Cancer_type	QTL_type	tag_SNP	LD	SNP	SNP_position	Alleles	Methylation_probe	Methylation_position	Probe_related_gene	Beta	t-stat	Correlation_coefficient (r)	p-value	Traits
CESC	cis	rs10208940	0.920	rs6724540	chr2:68779356	A/G	cg12452813	chr2:68675892	NA	0.52	5.16	0.3	4.88e-7	Urate levels in lean individuals;
CESC	cis	rs11122272	0.735	rs910823	chr1:231498766	G/T	cg06096015	chr1:231504339	EGLN1	0.43	6.26	0.36	1.57e-9	Hemoglobin concentration;
CESC	cis	rs2562152	0.706	rs216598	chr16:108585	T/C	cg02949481	chr16:131562	MPG	0.54	6.1	0.35	3.77e-9	Glioblastoma;
CESC	cis	rs1609391	0.543	rs7651085	chr3:136625339	C/G	cg15507776	chr3:136538369	TMEM22	0.82	11.97	0.59	1.08e-26	Neuroticism;
CESC	cis	rs9611565	0.559	rs132761	chr22:42004371	C/T	cg06634786	chr22:41940651	POLR3H	0.62	6.26	0.36	1.58e-9	Vitiligo;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg00306532	chr1:2323029	MORN1;RER1	-0.44	-6.99	-0.39	2.28e-11	Gambling;
CESC	trans	rs3942852	0.868	rs10769315	chr11:48110367	A/G	cg15704280	chr7:45808275	SEPT13	-0.63	-7.52	-0.42	8.6e-13	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs9325144	0.647	rs870431	chr12:38953073	T/C	cg26384229	chr12:38710491	ALG10B	-0.55	-7.83	-0.43	1.16e-13	Morning vs. evening chronotype;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg16003274	chr5:139944379	APBB3;SLC35A4	-0.46	-6.32	-0.36	1.11e-9	Fibrinogen levels;
CESC	cis	rs7818345	0.534	rs34221121	chr8:19319625	G/A	cg11303988	chr8:19266685	CSGALNACT1	0.34	5.37	0.31	1.71e-7	Language performance in older adults (adjusted for episodic memory);
CESC	cis	rs875971	1.000	rs778726	chr7:65828731	C/T	cg18876405	chr7:65276391	NA	0.5	6.64	0.38	1.75e-10	Aortic root size;
CESC	cis	rs4665809	0.590	rs2033317	chr2:26477650	G/A	cg25036284	chr2:26402008	FAM59B	0.88	9.99	0.52	3.79e-20	Gut microbiome composition (summer);
CESC	cis	rs12530845	0.830	rs73721678	chr7:135355710	T/G	cg23117316	chr7:135346802	PL-5283	-0.44	-5.2	-0.3	3.94e-7	Red blood cell traits;
CESC	cis	rs9926296	0.605	rs6500449	chr16:89856393	T/C	cg27121462	chr16:89883253	FANCA	0.74	10.59	0.55	4.54e-22	Vitiligo;
CESC	cis	rs35110281	0.840	rs2838331	chr21:45026728	A/G	cg01579765	chr21:45077557	HSF2BP	0.53	8.99	0.48	4.79e-17	Mean corpuscular volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24327389	chr8:11882982	NA	-0.69	-8.5	-0.46	1.38e-15	Gut microbiome composition (summer);
CESC	cis	rs854765	0.693	rs8079321	chr17:17760789	C/T	cg04398451	chr17:18023971	MYO15A	-0.65	-9.69	-0.51	3.35e-19	Total body bone mineral density;
CESC	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg06873352	chr17:61820015	STRADA	0.73	12.81	0.62	1.49e-29	Prudent dietary pattern;
CESC	cis	rs897984	0.806	rs8052245	chr16:30916430	C/G	cg00531865	chr16:30841666	NA	0.56	7.97	0.44	4.63e-14	Dementia with Lewy bodies;
CESC	cis	rs1355223	0.583	rs2941057	chr11:34882220	G/A	cg24088639	chr11:34937564	PDHX;APIP	-0.4	-5.12	-0.3	5.76e-7	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs3762637	0.941	rs9837149	chr3:122230845	G/C	cg24169773	chr3:122142474	KPNA1	-0.61	-7.18	-0.4	7.12e-12	LDL cholesterol levels;
CESC	cis	rs72901758	0.768	rs11659046	chr17:76245718	G/A	cg23302638	chr17:76210176	BIRC5	0.5	5.56	0.32	6.7e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
CESC	cis	rs7551222	0.789	rs4951408	chr1:204558984	C/G	cg20240347	chr1:204465584	NA	-0.28	-5.88	-0.34	1.24e-8	Schizophrenia;
CESC	cis	rs3857536	0.785	rs2157964	chr6:66938419	A/G	cg07460842	chr6:66804631	NA	-0.42	-5.34	-0.31	1.96e-7	Blood trace element (Cu levels);
CESC	cis	rs801193	1.000	rs13239306	chr7:66136017	T/G	cg11764359	chr7:65958608	NA	-0.66	-8.51	-0.46	1.32e-15	Aortic root size;
CESC	cis	rs1580019	0.587	rs7805311	chr7:32558302	A/G	cg07520158	chr7:32535189	LSM5;AVL9	-0.5	-6.26	-0.36	1.56e-9	Cognitive ability;
CESC	cis	rs875971	0.522	rs6960048	chr7:65408039	A/G	cg26939375	chr7:64535504	NA	0.77	11.14	0.56	6.67e-24	Aortic root size;
CESC	cis	rs4919687	0.550	rs12783444	chr10:104480659	G/A	cg04362960	chr10:104952993	NT5C2	0.49	5.63	0.33	4.64e-8	Colorectal cancer;
CESC	cis	rs854765	0.583	rs8065416	chr17:17851162	C/T	cg09796270	chr17:17721594	SREBF1	0.45	6.15	0.35	2.87e-9	Total body bone mineral density;
CESC	cis	rs7552404	0.727	rs6683437	chr1:76316619	G/A	cg10523679	chr1:76189770	ACADM	0.67	6.54	0.37	3.13e-10	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs7769051	1.000	rs7769051	chr6:133146796	G/T	cg22852734	chr6:133119734	C6orf192	0.91	9.84	0.52	1.14e-19	Type 2 diabetes nephropathy;
CESC	cis	rs17253792	0.822	rs17832371	chr14:56162302	C/A	cg01858014	chr14:56050164	KTN1	-0.97	-7.54	-0.42	7.36e-13	Putamen volume;
CESC	cis	rs11638352	1.000	rs2615288	chr15:44415886	T/A	cg27015174	chr15:43622946	ADAL;LCMT2	-0.61	-5.62	-0.33	4.75e-8	Lipoprotein phospholipase A2 activity in cardiovascular disease;
CESC	cis	rs9527	0.501	rs12244388	chr10:104640052	G/A	cg15744005	chr10:104629667	AS3MT	-0.38	-5.91	-0.34	1.06e-8	Arsenic metabolism;
CESC	cis	rs6063312	1.000	rs6063313	chr20:47343532	G/A	cg18078177	chr20:47281410	PREX1	0.56	5.49	0.32	9.32e-8	Tonometry;
CESC	trans	rs61931739	0.500	rs7308338	chr12:34553181	A/G	cg26384229	chr12:38710491	ALG10B	0.56	7.85	0.43	1.02e-13	Morning vs. evening chronotype;
CESC	cis	rs875971	0.965	rs9969301	chr7:65781655	G/A	cg18876405	chr7:65276391	NA	-0.52	-7.18	-0.4	6.89e-12	Aortic root size;
CESC	cis	rs7089973	0.872	rs3180654	chr10:116615045	T/C	cg23260525	chr10:116636907	FAM160B1	0.38	6.37	0.36	8.29e-10	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs397969	0.596	rs35315252	chr17:19905825	A/G	cg12073167	chr17:19770448	ULK2	-0.46	-5.28	-0.31	2.63e-7	Platelet count;
CESC	trans	rs3942852	0.774	rs10838813	chr11:48186969	C/A	cg15704280	chr7:45808275	SEPT13	-0.73	-8.25	-0.45	7.61e-15	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs7833790	0.963	rs28823280	chr8:82777716	G/A	cg07697082	chr8:82753677	SNX16	-0.41	-5.63	-0.33	4.47e-8	Diastolic blood pressure;
CESC	cis	rs1799949	1.000	rs8176212	chr17:41226601	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.67	9.12	0.49	1.92e-17	Menopause (age at onset);
CESC	trans	rs7672847	0.547	rs61516087	chr4:170367800	A/G	cg19308436	chr1:237949471	RYR2	0.6	6.27	0.36	1.46e-9	Subjective well-being;
CESC	cis	rs6540559	0.546	rs74991018	chr1:210033790	T/G	cg21951975	chr1:209979733	IRF6	0.58	6.23	0.36	1.85e-9	Cleft lip with or without cleft palate;
CESC	cis	rs7618915	0.570	rs2336145	chr3:52629750	A/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.38	6.68	0.38	1.37e-10	Bipolar disorder;
CESC	cis	rs2816062	0.813	rs2745314	chr1:18902851	T/A	cg18795169	chr1:18902165	NA	-0.93	-18.04	-0.74	5.1e-48	Urate levels in lean individuals;
CESC	cis	rs208520	0.690	rs207114	chr6:66791703	C/T	cg07460842	chr6:66804631	NA	-1.01	-13.21	-0.63	6.06e-31	Exhaled nitric oxide output;
CESC	cis	rs2762353	0.526	rs9461203	chr6:25710555	C/T	cg25753631	chr6:25732923	NA	0.26	5.14	0.3	5.41e-7	Blood metabolite levels;
CESC	cis	rs614226	0.935	rs2235222	chr12:120892193	G/C	cg01236616	chr12:121019343	POP5	-1.45	-16.8	-0.72	1.26e-43	Type 1 diabetes nephropathy;
CESC	cis	rs854765	0.693	rs9907287	chr17:17774118	C/T	cg04398451	chr17:18023971	MYO15A	0.68	10.1	0.53	1.73e-20	Total body bone mineral density;
CESC	cis	rs662064	0.852	rs616402	chr1:10566272	C/T	cg20482658	chr1:10539492	PEX14	0.37	7.4	0.41	1.79e-12	Asthma;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20925763	chr2:219879821	CCDC108	-0.55	-6.61	-0.38	2.15e-10	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05602567	chr22:32871203	FBXO7	-0.58	-6.61	-0.38	2.12e-10	Gut microbiome composition (summer);
CESC	cis	rs2439831	0.681	rs498837	chr15:43608024	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.82	12.34	0.6	5.9e-28	Lung cancer in ever smokers;
CESC	cis	rs7165102	0.930	rs7167657	chr15:65964479	C/T	cg11441148	chr15:65824328	PTPLAD1	0.3	5.06	0.3	7.69e-7	Mean corpuscular hemoglobin;
CESC	cis	rs1018836	0.923	rs13268594	chr8:91588545	G/T	cg16814680	chr8:91681699	NA	-0.69	-9.71	-0.51	2.89e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	trans	rs864643	0.773	rs11129837	chr3:39589963	A/G	cg00463507	chr1:36235431	CLSPN	0.51	6.45	0.37	5.2e-10	Attention deficit hyperactivity disorder;
CESC	cis	rs17125944	0.505	rs77690283	chr14:53233320	C/G	cg13660082	chr14:53194042	PSMC6	-0.65	-5.88	-0.34	1.23e-8	Alzheimer's disease (late onset);
CESC	cis	rs3820068	0.608	rs10927840	chr1:16045250	A/G	cg17385448	chr1:15911702	AGMAT	0.37	5.72	0.33	2.88e-8	Systolic blood pressure;
CESC	trans	rs7246760	1.000	rs67844335	chr19:9898039	G/A	cg02900749	chr2:68251473	NA	-0.83	-7.08	-0.4	1.3e-11	Pursuit maintenance gain;
CESC	cis	rs2985684	0.748	rs2985686	chr14:50100683	C/G	cg02151108	chr14:50098012	C14orf104	-0.44	-5.52	-0.32	7.91e-8	Carotid intima media thickness;
CESC	cis	rs4862750	0.872	rs9998173	chr4:187898778	T/A	cg07414643	chr4:187882934	NA	0.54	7.9	0.44	7.51e-14	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs14978	0.628	rs4721058	chr7:12267256	C/T	cg23422036	chr7:12250390	TMEM106B	0.38	5.17	0.3	4.7e-7	Response to amphetamines;
CESC	cis	rs10504229	0.906	rs2270609	chr8:58194684	G/A	cg22535103	chr8:58192502	C8orf71	-1.07	-13.39	-0.64	1.44e-31	Developmental language disorder (linguistic errors);
CESC	trans	rs11098499	0.644	rs6855918	chr4:120546299	C/T	cg25214090	chr10:38739885	LOC399744	0.63	8.89	0.48	9.62e-17	Corneal astigmatism;
CESC	cis	rs3806843	0.966	rs3756338	chr5:140180561	A/G	cg16179182	chr5:140090404	VTRNA1-1	-0.41	-5.25	-0.31	3.13e-7	Depressive symptoms (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20959894	chr7:27779871	TAX1BP1	0.57	6.44	0.37	5.52e-10	Gut microbiome composition (summer);
CESC	cis	rs2262909	0.962	rs409439	chr19:22227432	C/T	cg11619707	chr19:22235551	ZNF257	-0.32	-5.26	-0.31	2.94e-7	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
CESC	cis	rs11785400	0.793	rs12546978	chr8:143750205	T/A	cg24634471	chr8:143751801	JRK	-0.46	-5.64	-0.33	4.35e-8	Schizophrenia;
CESC	cis	rs7762018	0.941	rs4716384	chr6:170109184	T/A	cg13891659	chr6:170190454	C6orf122;C6orf208	0.55	5.63	0.33	4.55e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs873946	0.586	rs61862838	chr10:134572282	C/T	cg27286337	chr10:134555280	INPP5A	0.68	7.72	0.43	2.33e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs5758659	0.652	rs5751195	chr22:42380001	A/C	cg04733989	chr22:42467013	NAGA	0.47	6.23	0.36	1.8e-9	Cognitive function;
CESC	cis	rs4665809	0.887	rs2384324	chr2:26354239	A/G	cg25036284	chr2:26402008	FAM59B	-0.73	-8.34	-0.46	3.98e-15	Gut microbiome composition (summer);
CESC	cis	rs137699	1.000	rs2049986	chr22:39756854	C/G	cg05872129	chr22:39784769	NA	0.41	5.43	0.32	1.29e-7	IgG glycosylation;
CESC	cis	rs10540	0.818	rs12806089	chr11:501468	G/A	cg03934478	chr11:495069	RNH1	0.56	5.39	0.31	1.54e-7	Body mass index;
CESC	cis	rs6831352	0.959	rs6532795	chr4:100042221	C/T	cg12011299	chr4:100065546	ADH4	-0.72	-8.84	-0.48	1.4e-16	Alcohol dependence;
CESC	cis	rs4665809	1.000	rs4665821	chr2:26309949	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.7	-7.95	-0.44	5.54e-14	Gut microbiome composition (summer);
CESC	cis	rs7914558	0.966	rs56946876	chr10:104653545	T/C	cg15744005	chr10:104629667	AS3MT	-0.34	-5.49	-0.32	9.45e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs8028182	0.636	rs7166737	chr15:75682513	A/G	cg20655648	chr15:75932815	IMP3	0.46	5.82	0.34	1.69e-8	Sudden cardiac arrest;
CESC	cis	rs7726839	0.561	rs72703044	chr5:579737	G/A	cg09021430	chr5:549028	NA	-0.44	-5.96	-0.34	8.23e-9	Obesity-related traits;
CESC	cis	rs875971	1.000	rs2420591	chr7:65912381	T/C	cg10691866	chr7:65817282	TPST1	-0.34	-5.61	-0.33	5.14e-8	Aortic root size;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg13265914	chr8:21999630	REEP4	0.55	7.24	0.41	4.95e-12	Gut microbiota (bacterial taxa);
CESC	trans	rs35146811	0.695	rs858509	chr7:99821470	A/G	cg13215871	chr17:75784724	NA	-0.34	-6.33	-0.36	1.07e-9	Coronary artery disease;
CESC	cis	rs6964587	0.967	rs7801058	chr7:91784381	C/T	cg17063962	chr7:91808500	NA	0.51	6.93	0.39	3.25e-11	Breast cancer;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg01027365	chr2:191184571	HIBCH	0.44	6.13	0.35	3.21e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs7666738	0.830	rs2903152	chr4:99067992	A/G	cg03467027	chr4:99064603	C4orf37	0.48	5.96	0.34	7.81e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7829975	0.659	rs4382480	chr8:8721473	C/T	cg18904891	chr8:8559673	CLDN23	0.42	5.06	0.3	7.89e-7	Mood instability;
CESC	cis	rs881375	0.678	rs1930782	chr9:123687905	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.39	5.48	0.32	9.71e-8	Rheumatoid arthritis;
CESC	cis	rs56309584	0.673	rs7219471	chr17:8121594	G/T	cg06726167	chr17:8076949	TMEM107	-0.5	-5.1	-0.3	6.44e-7	Initial pursuit acceleration;
CESC	cis	rs2836974	0.931	rs2776309	chr21:40715791	A/G	cg11890956	chr21:40555474	PSMG1	1.05	15.72	0.69	8.58e-40	Cognitive function;
CESC	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg06873352	chr17:61820015	STRADA	0.73	12.94	0.62	5.33e-30	Prudent dietary pattern;
CESC	cis	rs13256369	0.851	rs11249890	chr8:8565245	G/T	cg18904891	chr8:8559673	CLDN23	0.73	8.15	0.45	1.43e-14	Obesity-related traits;
CESC	cis	rs2191566	0.761	rs446016	chr19:44501518	A/G	cg20607764	chr19:44506953	ZNF230	-0.53	-6.53	-0.37	3.38e-10	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs10861342	1.000	rs11112359	chr12:105471661	C/A	cg23923672	chr12:105501055	KIAA1033	0.69	5.09	0.3	6.84e-7	IgG glycosylation;
CESC	cis	rs2625529	0.938	rs4776579	chr15:72132608	C/T	cg16672083	chr15:72433130	SENP8	-0.43	-6.11	-0.35	3.54e-9	Red blood cell count;
CESC	cis	rs9837602	0.938	rs9823908	chr3:99795507	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.48	6.74	0.38	9.99e-11	Breast cancer;
CESC	cis	rs1005277	0.579	rs2008449	chr10:38414204	A/T	cg00409905	chr10:38381863	ZNF37A	0.5	6.82	0.39	6e-11	Extrinsic epigenetic age acceleration;
CESC	cis	rs8072100	0.748	rs9912592	chr17:45556945	G/A	cg08085267	chr17:45401833	C17orf57	-0.58	-7.67	-0.43	3.39e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs67460515	0.500	rs6806015	chr3:160724766	G/A	cg03342759	chr3:160939853	NMD3	-0.43	-5.44	-0.32	1.23e-7	Parkinson's disease;
CESC	cis	rs7084402	0.967	rs1658442	chr10:60318897	G/A	cg07615347	chr10:60278583	BICC1	0.63	10.12	0.53	1.48e-20	Refractive error;
CESC	cis	rs11608355	0.515	rs4766476	chr12:109934700	A/G	cg05360138	chr12:110035743	NA	0.82	8.85	0.48	1.27e-16	Neuroticism;
CESC	cis	rs3096299	0.748	rs2965822	chr16:89444677	A/T	cg00750074	chr16:89608354	SPG7	-0.37	-5.19	-0.3	4.1e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs8141529	0.732	rs5762784	chr22:29171298	C/T	cg15103426	chr22:29168792	CCDC117	0.7	9.95	0.52	5e-20	Lymphocyte counts;
CESC	cis	rs1865721	1.000	rs7236756	chr18:73175689	T/C	cg26385618	chr18:73139727	C18orf62	-0.48	-7.17	-0.4	7.58e-12	Intelligence;
CESC	cis	rs7845219	0.544	rs34293080	chr8:95908078	G/T	cg23172400	chr8:95962367	TP53INP1	-0.4	-7.52	-0.42	8.27e-13	Type 2 diabetes;
CESC	cis	rs72781680	0.898	rs72782117	chr2:24026921	G/A	cg20701182	chr2:24300061	SF3B14	0.78	6.7	0.38	1.22e-10	Lymphocyte counts;
CESC	cis	rs7927771	0.793	rs12803525	chr11:47413475	G/A	cg18512352	chr11:47633146	NA	-0.54	-8.02	-0.44	3.49e-14	Subjective well-being;
CESC	cis	rs9733	0.526	rs11204698	chr1:150659545	G/A	cg18016565	chr1:150552671	MCL1	0.33	5.09	0.3	6.65e-7	Tonsillectomy;
CESC	cis	rs7552404	0.924	rs1146574	chr1:76202671	A/G	cg22875332	chr1:76189707	ACADM	0.71	9.95	0.52	4.86e-20	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs10504229	0.683	rs16921808	chr8:58106049	C/T	cg24829409	chr8:58192753	C8orf71	-0.54	-6.6	-0.38	2.19e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs11786130	1.000	rs10956401	chr8:129002419	G/A	cg01765152	chr8:129005526	PVT1	-0.32	-5.12	-0.3	5.83e-7	Eosinophil counts;Sum eosinophil basophil counts;
CESC	cis	rs7103648	0.838	rs2293576	chr11:47434986	A/G	cg20307385	chr11:47447363	PSMC3	-0.89	-14.13	-0.66	3.62e-34	Diastolic blood pressure;Systolic blood pressure;
CESC	cis	rs6088580	0.634	rs2424992	chr20:33012060	C/T	cg24642439	chr20:33292090	TP53INP2	0.53	6.95	0.39	2.87e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs10242455	0.702	rs78680379	chr7:99198573	G/A	cg18809830	chr7:99032528	PTCD1	-0.89	-5.53	-0.32	7.8e-8	Blood metabolite levels;
CESC	cis	rs4474465	0.541	rs10736814	chr11:78286462	C/G	cg27205649	chr11:78285834	NARS2	0.45	5.7	0.33	3.2e-8	Alzheimer's disease (survival time);
CESC	cis	rs26868	0.742	rs26848	chr16:2263516	A/G	cg25665528	chr16:2260870	C16orf79	-0.33	-5.42	-0.32	1.36e-7	Height;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg13305165	chr3:25831802	NGLY1;OXSM	-0.44	-6.26	-0.36	1.55e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs7666738	0.830	rs7664169	chr4:99037859	C/T	cg17366294	chr4:99064904	C4orf37	-0.6	-8.67	-0.47	4.29e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs17253792	0.822	rs78261053	chr14:56061784	C/T	cg01858014	chr14:56050164	KTN1	-0.96	-7.13	-0.4	9.72e-12	Putamen volume;
CESC	cis	rs425277	1.000	rs262665	chr1:2083173	A/G	cg24578937	chr1:2090814	PRKCZ	0.55	9.54	0.51	9.57e-19	Height;
CESC	cis	rs910316	0.737	rs2098251	chr14:75492696	G/A	cg08847533	chr14:75593920	NEK9	0.92	16.29	0.71	8.22e-42	Height;
CESC	cis	rs10781543	0.839	rs7863766	chr9:139381314	T/G	cg14019695	chr9:139328340	INPP5E	0.38	5.67	0.33	3.72e-8	Monocyte percentage of white cells;
CESC	cis	rs524281	0.861	rs3862386	chr11:65894424	G/C	cg14036092	chr11:66035641	RAB1B	-0.61	-5.95	-0.34	8.3e-9	Electroencephalogram traits;
CESC	cis	rs734999	0.550	rs2985855	chr1:2531372	A/C	cg18854424	chr1:2615690	NA	-0.27	-5.14	-0.3	5.24e-7	Ulcerative colitis;
CESC	cis	rs72781680	0.898	rs7589440	chr2:24038595	G/A	cg20701182	chr2:24300061	SF3B14	0.63	5.65	0.33	4.21e-8	Lymphocyte counts;
CESC	cis	rs9611565	0.559	rs5758397	chr22:42019251	C/T	cg03806693	chr22:41940476	POLR3H	1.09	12.86	0.62	9.42e-30	Vitiligo;
CESC	cis	rs7208859	0.673	rs11658344	chr17:29207745	G/T	cg19761014	chr17:28927070	LRRC37B2	0.63	5.27	0.31	2.88e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs1862618	0.641	rs252893	chr5:56224714	T/C	cg18230493	chr5:56204884	C5orf35	-0.62	-8.35	-0.46	3.92e-15	Initial pursuit acceleration;
CESC	trans	rs9467711	0.790	rs72843784	chr6:26498758	G/T	cg06606381	chr12:133084897	FBRSL1	-1.11	-7.59	-0.42	5.41e-13	Autism spectrum disorder or schizophrenia;
CESC	cis	rs7799006	0.606	rs34417375	chr7:2315105	C/T	cg12745145	chr7:2261452	MAD1L1	-0.33	-5.19	-0.3	4.25e-7	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs7945705	0.840	rs10840136	chr11:8885024	C/T	cg09997546	chr11:8931473	C11orf17;ST5	-0.31	-5.12	-0.3	6e-7	Hemoglobin concentration;
CESC	cis	rs9486719	1.000	rs2472895	chr6:96870387	A/T	cg18709589	chr6:96969512	KIAA0776	0.53	5.81	0.34	1.75e-8	Migraine;Coronary artery disease;
CESC	cis	rs1008375	0.898	rs61047804	chr4:17593965	G/A	cg16339924	chr4:17578868	LAP3	0.73	9.5	0.5	1.31e-18	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs7927771	0.864	rs2868459	chr11:47454972	C/G	cg20307385	chr11:47447363	PSMC3	-0.64	-7.69	-0.43	2.97e-13	Subjective well-being;
CESC	cis	rs7949030	0.626	rs72927213	chr11:62351198	G/C	cg13298116	chr11:62369859	EML3;MTA2	0.64	9.42	0.5	2.35e-18	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs8114671	0.836	rs62213676	chr20:33612676	T/A	cg07148914	chr20:33460835	GGT7	-0.41	-5.31	-0.31	2.28e-7	Height;
CESC	trans	rs3749237	1.000	rs4768	chr3:49758764	A/G	cg21659725	chr3:3221576	CRBN	0.54	6.45	0.37	5.29e-10	Resting heart rate;
CESC	cis	rs6952809	0.561	rs1548598	chr7:2438912	T/C	cg23289794	chr7:2394357	EIF3B	-0.7	-6.79	-0.38	7.42e-11	Multiple sclerosis;
CESC	cis	rs754466	0.606	rs56402185	chr10:79585848	G/A	cg17075019	chr10:79541650	NA	-0.88	-14.17	-0.66	2.7e-34	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs868036	0.957	rs9920662	chr15:68104297	G/A	cg08079166	chr15:68083412	MAP2K5	0.43	6.92	0.39	3.35e-11	Restless legs syndrome;
CESC	cis	rs1707322	1.000	rs2458400	chr1:46530798	C/T	cg05343316	chr1:45956843	TESK2	-0.44	-5.26	-0.31	2.94e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs652260	1.000	rs590394	chr19:7902505	C/T	cg26014689	chr19:7917955	EVI5L	-0.44	-5.96	-0.34	8.05e-9	Menarche (age at onset);
CESC	cis	rs9916302	0.904	rs2303316	chr17:37704217	A/G	cg07936489	chr17:37558343	FBXL20	-0.82	-12.08	-0.6	4.62e-27	Glomerular filtration rate (creatinine);
CESC	cis	rs1545257	0.537	rs2702088	chr2:24642535	G/C	cg06627628	chr2:24431161	ITSN2	-0.48	-5.88	-0.34	1.21e-8	Sjögren's syndrome;
CESC	cis	rs9303401	0.614	rs34843288	chr17:57103140	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.97	11.03	0.56	1.59e-23	Cognitive test performance;
CESC	cis	rs12477438	0.765	rs1453564	chr2:99564428	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.65	-9.04	-0.49	3.51e-17	Chronic sinus infection;
CESC	cis	rs11098499	0.866	rs11098506	chr4:120284971	A/G	cg09307838	chr4:120376055	NA	0.88	11.94	0.59	1.41e-26	Corneal astigmatism;
CESC	cis	rs738322	1.000	rs738322	chr22:38569006	A/G	cg25457927	chr22:38595422	NA	-0.29	-5.52	-0.32	8.28e-8	Cutaneous nevi;
CESC	cis	rs796364	0.906	rs281789	chr2:200780698	T/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.87	8.44	0.46	2.14e-15	Schizophrenia;
CESC	cis	rs1707322	0.752	rs11488313	chr1:46224780	G/C	cg06784218	chr1:46089804	CCDC17	0.39	6.86	0.39	4.83e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs11122272	0.735	rs2486746	chr1:231497324	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.54	-7.45	-0.42	1.34e-12	Hemoglobin concentration;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg00162751	chr1:220921532	MOSC2	-0.44	-6.41	-0.37	6.49e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs4664308	0.691	rs1877196	chr2:160915150	G/T	cg03641300	chr2:160917029	PLA2R1	-0.63	-9.45	-0.5	1.84e-18	Idiopathic membranous nephropathy;
CESC	cis	rs847577	0.715	rs4729402	chr7:97707731	A/G	cg21770322	chr7:97807741	LMTK2	0.43	6.34	0.36	9.81e-10	Breast cancer;
CESC	cis	rs1949733	1.000	rs3103071	chr4:8508579	C/G	cg11789530	chr4:8429930	ACOX3	-0.73	-10.07	-0.53	2.01e-20	Response to antineoplastic agents;
CESC	cis	rs7589342	0.929	rs6725519	chr2:106445209	A/G	cg16077055	chr2:106428750	NCK2	-0.49	-7.04	-0.4	1.6e-11	Addiction;
CESC	cis	rs1784581	0.928	rs1789995	chr6:162396518	C/T	cg17173639	chr6:162384350	PARK2	-0.79	-12.86	-0.62	9.59e-30	Itch intensity from mosquito bite;
CESC	cis	rs6951245	0.706	rs28522260	chr7:1183964	C/A	cg18402987	chr7:1209562	NA	0.76	8.45	0.46	1.91e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs8180040	0.966	rs56351005	chr3:47430186	G/T	cg27129171	chr3:47204927	SETD2	-0.64	-9.82	-0.52	1.29e-19	Colorectal cancer;
CESC	cis	rs10256972	0.521	rs871019	chr7:1105230	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.36	-5.1	-0.3	6.5e-7	Longevity;Endometriosis;
CESC	cis	rs1005277	0.579	rs2505197	chr10:38393310	T/C	cg25517755	chr10:38738941	LOC399744	-0.47	-6.04	-0.35	5.12e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs12451471	0.637	rs12452616	chr17:78090081	A/G	cg06718696	chr17:78121285	EIF4A3	-0.86	-10.69	-0.55	2e-22	Plateletcrit;Mean corpuscular hemoglobin concentration;
CESC	cis	rs10256972	0.721	rs6975972	chr7:1070468	A/G	cg07308232	chr7:1071921	C7orf50	-0.61	-8.56	-0.47	9.45e-16	Longevity;Endometriosis;
CESC	cis	rs853679	0.550	rs1237875	chr6:28173010	A/G	cg12963246	chr6:28129442	ZNF389	-0.49	-6.56	-0.37	2.83e-10	Depression;
CESC	cis	rs8067354	0.540	rs12600680	chr17:58037374	T/C	cg02344993	chr17:57696989	CLTC	0.53	5.39	0.31	1.59e-7	Hemoglobin concentration;
CESC	cis	rs7918232	0.941	rs7096505	chr10:27326999	T/C	cg14240646	chr10:27532245	ACBD5	-0.57	-5.43	-0.32	1.26e-7	Breast cancer;
CESC	cis	rs1372520	0.684	rs2737010	chr4:90746466	G/A	cg15133208	chr4:90757351	SNCA	-0.39	-5.18	-0.3	4.45e-7	Neuroticism;
CESC	cis	rs4665809	0.838	rs7565843	chr2:26292912	G/C	cg25036284	chr2:26402008	FAM59B	-0.59	-6.9	-0.39	3.85e-11	Gut microbiome composition (summer);
CESC	cis	rs6701037	0.681	rs13374887	chr1:175131962	A/T	cg00321850	chr1:175162397	KIAA0040	0.44	6.4	0.37	7.2e-10	Alcohol dependence;
CESC	cis	rs7552404	0.727	rs1146653	chr1:76280438	A/G	cg22875332	chr1:76189707	ACADM	0.63	6.94	0.39	3.02e-11	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs11167764	0.895	rs9324865	chr5:141488792	T/C	cg08523384	chr5:141488047	NDFIP1	-0.37	-5.44	-0.32	1.23e-7	Crohn's disease;
CESC	cis	rs3091242	0.933	rs35497030	chr1:25783066	A/G	cg02931644	chr1:25747376	RHCE	-0.39	-6.5	-0.37	4.08e-10	Erythrocyte sedimentation rate;
CESC	cis	rs929354	1.000	rs1182410	chr7:157063837	C/T	cg05182265	chr7:156933206	UBE3C	0.44	6.05	0.35	4.86e-9	Body mass index;
CESC	cis	rs2710642	0.693	rs10168771	chr2:62903187	G/A	cg17519650	chr2:63277830	OTX1	0.57	6.72	0.38	1.14e-10	LDL cholesterol levels;LDL cholesterol;
CESC	cis	rs7662987	0.517	rs1453874	chr4:100022724	G/A	cg13256891	chr4:100009986	ADH5	0.75	8.03	0.44	3.21e-14	Smoking initiation;
CESC	cis	rs9398803	0.965	rs6919397	chr6:126659043	A/C	cg19875578	chr6:126661172	C6orf173	0.4	5.55	0.32	6.99e-8	Male-pattern baldness;
CESC	cis	rs477895	0.653	rs2875749	chr11:63903878	C/A	cg18225595	chr11:63971243	STIP1	0.52	5.13	0.3	5.55e-7	Mean platelet volume;
CESC	cis	rs5758659	0.714	rs2284087	chr22:42485671	T/C	cg19513890	chr22:42538836	CYP2D7P1	0.37	5.44	0.32	1.19e-7	Cognitive function;
CESC	cis	rs61931739	0.500	rs6488215	chr12:34434803	A/T	cg06521331	chr12:34319734	NA	-0.37	-5.12	-0.3	5.98e-7	Morning vs. evening chronotype;
CESC	cis	rs7084402	1.000	rs6481402	chr10:60268977	T/C	cg07615347	chr10:60278583	BICC1	-0.57	-8.72	-0.47	3.03e-16	Refractive error;
CESC	cis	rs1395	0.710	rs58965570	chr2:27481460	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.43	5.57	0.32	6.24e-8	Blood metabolite levels;
CESC	cis	rs1008375	0.966	rs12503517	chr4:17698725	G/A	cg02297831	chr4:17616191	MED28	0.44	5.33	0.31	2.07e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	trans	rs281302	0.621	rs373553	chr15:47749001	G/C	cg15377044	chr10:47688638	ANTXRL	-0.42	-6.01	-0.35	6.01e-9	Educational attainment (years of education);Cognitive ability (multi-trait analysis);
CESC	trans	rs899596	0.955	rs9903496	chr17:71736940	A/G	cg23413066	chr4:13548755	LOC285548	-0.38	-6.04	-0.35	5.14e-9	Glucose homeostasis traits;
CESC	cis	rs7827545	1.000	rs4909911	chr8:135565255	G/A	cg17885191	chr8:135476712	NA	0.48	6.28	0.36	1.39e-9	Hypertension (SNP x SNP interaction);
CESC	cis	rs589448	0.934	rs554591	chr12:69753847	T/C	cg14784868	chr12:69753453	YEATS4	0.92	14.57	0.67	1.05e-35	Cerebrospinal fluid biomarker levels;
CESC	cis	rs6570726	0.935	rs369214	chr6:145856709	G/A	cg23711669	chr6:146136114	FBXO30	0.8	11.74	0.58	6.58e-26	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs769267	0.566	rs9304962	chr19:19679992	G/C	cg03709012	chr19:19516395	GATAD2A	-0.68	-8.39	-0.46	2.84e-15	Tonsillectomy;
CESC	cis	rs3540	0.597	rs1978151	chr15:91037300	C/T	cg10434728	chr15:90938212	IQGAP1	0.42	7.36	0.41	2.28e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs60733400	0.667	rs4385650	chr1:2499898	G/A	cg20673091	chr1:2541236	MMEL1	0.39	6.32	0.36	1.13e-9	Multiple sclerosis;
CESC	cis	rs11785400	0.793	rs4736367	chr8:143742477	G/A	cg10596483	chr8:143751796	JRK	0.42	5.31	0.31	2.32e-7	Schizophrenia;
CESC	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	22.02	0.8	8.62e-62	Prudent dietary pattern;
CESC	cis	rs6088580	0.601	rs6059872	chr20:33082775	C/A	cg08999081	chr20:33150536	PIGU	0.66	11.6	0.58	2.04e-25	Glomerular filtration rate (creatinine);
CESC	cis	rs3820068	0.608	rs6668919	chr1:16049893	A/G	cg17385448	chr1:15911702	AGMAT	-0.4	-6.33	-0.36	1.05e-9	Systolic blood pressure;
CESC	cis	rs9322193	0.884	rs9688699	chr6:150054816	A/G	cg09699651	chr6:150184138	LRP11	0.43	5.6	0.33	5.25e-8	Lung cancer;
CESC	cis	rs28647808	0.881	rs28625799	chr9:136264557	C/T	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.84	5.73	0.33	2.7e-8	Blood protein levels;
CESC	cis	rs2832191	0.791	rs8134407	chr21:30476586	G/A	cg24692254	chr21:30365293	RNF160	0.78	12.05	0.59	5.98e-27	Dental caries;
CESC	cis	rs10791097	0.668	rs10791102	chr11:130744977	G/A	cg12179176	chr11:130786555	SNX19	0.64	9.87	0.52	8.97e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs853679	0.550	rs1150689	chr6:28165099	T/C	cg23161317	chr6:28129485	ZNF389	0.43	5.64	0.33	4.38e-8	Depression;
CESC	cis	rs13118159	0.651	rs4974599	chr4:1314430	A/C	cg19318889	chr4:1322082	MAEA	0.46	6.19	0.36	2.29e-9	Longevity;
CESC	cis	rs34779708	0.931	rs12261654	chr10:35322024	G/A	cg04310649	chr10:35416472	CREM	-0.51	-6.24	-0.36	1.76e-9	Inflammatory bowel disease;Crohn's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26247329	chr5:180670940	GNB2L1;SNORD95	-0.63	-7.0	-0.4	2.15e-11	Gut microbiome composition (summer);
CESC	cis	rs929354	0.772	rs6957939	chr7:156978485	T/C	cg05182265	chr7:156933206	UBE3C	-0.51	-7.5	-0.42	9.58e-13	Body mass index;
CESC	cis	rs2425143	0.818	rs11167280	chr20:34560526	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.79	-7.11	-0.4	1.1e-11	Blood protein levels;
CESC	cis	rs2953145	0.545	rs2975751	chr2:241521135	G/A	cg07929629	chr2:241523174	NA	0.63	8.28	0.45	6.17e-15	Bipolar disorder;
CESC	cis	rs17376456	0.741	rs7718842	chr5:93480568	G/A	cg21475434	chr5:93447410	FAM172A	0.91	7.66	0.43	3.51e-13	Diabetic retinopathy;
CESC	cis	rs17376456	0.825	rs12716453	chr5:93271697	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.65	5.32	0.31	2.26e-7	Diabetic retinopathy;
CESC	cis	rs2408955	0.522	rs6580650	chr12:48418556	G/T	cg24011408	chr12:48396354	COL2A1	-0.57	-8.65	-0.47	5.05e-16	Glycated hemoglobin levels;
CESC	cis	rs7084402	0.935	rs1658456	chr10:60304326	C/T	cg07615347	chr10:60278583	BICC1	0.58	9.11	0.49	2.1e-17	Refractive error;
CESC	cis	rs7666738	0.830	rs34070283	chr4:98893027	A/T	cg17366294	chr4:99064904	C4orf37	0.56	7.75	0.43	1.99e-13	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7267979	1.000	rs4815405	chr20:25317492	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.9	-18.66	-0.75	3.54e-50	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs6860806	0.531	rs270607	chr5:131649186	A/G	cg07395648	chr5:131743802	NA	-0.46	-6.16	-0.35	2.68e-9	Breast cancer;
CESC	cis	rs10504229	0.683	rs7459958	chr8:58111905	G/T	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs9487051	0.698	rs11153168	chr6:109629420	A/T	cg01475377	chr6:109611718	NA	-0.4	-5.62	-0.33	4.91e-8	Reticulocyte fraction of red cells;
CESC	cis	rs2404602	0.647	rs11072616	chr15:76985269	T/C	cg23625390	chr15:77176239	SCAPER	-0.47	-6.58	-0.37	2.44e-10	Blood metabolite levels;
CESC	trans	rs60843830	1.000	rs7566279	chr2:281178	C/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.66	8.23	0.45	8.6e-15	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs7824557	0.602	rs7833966	chr8:11206220	C/G	cg21775007	chr8:11205619	TDH	0.58	8.81	0.48	1.71e-16	Retinal vascular caliber;
CESC	cis	rs11792861	0.781	rs17729408	chr9:111740860	A/G	cg13535736	chr9:111863775	C9orf5	0.46	5.99	0.35	6.71e-9	Menarche (age at onset);
CESC	cis	rs1153858	1.000	rs1618874	chr15:45622786	A/G	cg21132104	chr15:45694354	SPATA5L1	0.78	10.44	0.54	1.35e-21	Homoarginine levels;
CESC	cis	rs6963495	0.818	rs73192122	chr7:105171471	G/A	cg02135003	chr7:105160482	PUS7	-0.46	-5.5	-0.32	9.1e-8	Bipolar disorder (body mass index interaction);
CESC	trans	rs10242455	0.717	rs2687134	chr7:99331042	T/G	cg09045935	chr12:6379348	NA	-0.58	-6.08	-0.35	4.15e-9	Blood metabolite levels;
CESC	cis	rs10924309	0.737	rs6701023	chr1:245854503	C/G	cg00036263	chr1:245852353	KIF26B	0.53	7.22	0.41	5.56e-12	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
CESC	cis	rs12497850	0.931	rs9311433	chr3:48863835	T/C	cg03060546	chr3:49711283	APEH	0.43	5.33	0.31	2.09e-7	Parkinson's disease;
CESC	cis	rs870825	0.616	rs28416641	chr4:185617999	C/T	cg04058563	chr4:185651563	MLF1IP	0.64	7.05	0.4	1.59e-11	Blood protein levels;
CESC	cis	rs146201400	1	rs146201400	chr1:26645955	G/GA	cg18121669	chr1:26560928	CCDC21	0.44	5.23	0.31	3.5e-7	Monocyte percentage of white cells;
CESC	cis	rs2637266	1.000	rs7098790	chr10:78361077	T/A	cg18941641	chr10:78392320	NA	0.41	7.89	0.44	7.84e-14	Pulmonary function;
CESC	cis	rs7918232	1.000	rs7918232	chr10:27369162	A/G	cg14240646	chr10:27532245	ACBD5	-0.55	-5.72	-0.33	2.88e-8	Breast cancer;
CESC	trans	rs6089829	0.925	rs6122086	chr20:61664528	T/C	cg23505145	chr19:12996616	KLF1	0.52	6.65	0.38	1.68e-10	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs79057730	0.639	rs6463933	chr7:793954	G/A	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.65	5.75	0.33	2.5e-8	Initial pursuit acceleration;
CESC	cis	rs7762018	1.000	rs6941766	chr6:170131653	A/G	cg05834625	chr6:170176447	C6orf70	0.66	7.84	0.43	1.07e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs11250464	0.804	rs11250463	chr10:1406228	T/C	cg08668359	chr10:1443807	ADARB2	0.56	6.76	0.38	8.99e-11	Radiation response;
CESC	cis	rs6831352	0.918	rs29001202	chr4:100053782	T/A	cg12011299	chr4:100065546	ADH4	-0.59	-6.49	-0.37	4.3e-10	Alcohol dependence;
CESC	cis	rs4654899	0.733	rs10799678	chr1:21322785	C/T	cg05370193	chr1:21551575	ECE1	0.38	5.88	0.34	1.26e-8	Superior frontal gyrus grey matter volume;
CESC	cis	rs17666538	0.585	rs336437	chr8:636251	A/C	cg13264159	chr8:625131	ERICH1	-0.78	-6.28	-0.36	1.37e-9	IgG glycosylation;
CESC	cis	rs7618915	0.501	rs767418	chr3:52767427	C/T	cg17372223	chr3:52568218	NT5DC2	0.43	6.42	0.37	6.1e-10	Bipolar disorder;
CESC	cis	rs17818399	0.926	rs13033177	chr2:46831062	C/A	cg02822958	chr2:46747628	ATP6V1E2	0.47	5.71	0.33	3.07e-8	Height;
CESC	cis	rs4555082	0.874	rs78923231	chr14:105754033	C/T	cg27165867	chr14:105738592	BRF1	-0.49	-5.15	-0.3	5.14e-7	Mean platelet volume;Platelet distribution width;
CESC	cis	rs7667	1.000	rs10917436	chr1:19708618	T/A	cg15026089	chr1:19640712	PQLC2	-0.31	-5.18	-0.3	4.43e-7	Crohn's disease and psoriasis;
CESC	cis	rs7666738	0.830	rs6811940	chr4:98777898	G/A	cg03467027	chr4:99064603	C4orf37	0.43	5.47	0.32	1.02e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11958404	0.932	rs7711898	chr5:157430688	A/G	cg05962755	chr5:157440814	NA	0.62	6.56	0.37	2.74e-10	IgG glycosylation;
CESC	cis	rs2836974	0.681	rs8128827	chr21:40710547	C/T	cg17971929	chr21:40555470	PSMG1	0.94	12.96	0.62	4.46e-30	Cognitive function;
CESC	cis	rs7605827	0.866	rs11678132	chr2:15533998	C/T	cg19274914	chr2:15703543	NA	0.36	6.59	0.38	2.3e-10	Educational attainment (years of education);
CESC	trans	rs17116334	1.000	rs17116334	chr11:113961762	C/T	cg26681847	chr11:120208749	ARHGEF12	0.37	6.22	0.36	1.89e-9	Conduct disorder (maternal expressed emotions interaction);
CESC	cis	rs2034088	0.833	rs9748016	chr17:410451	G/T	cg06217071	chr17:408420	NA	0.47	9.11	0.49	2.11e-17	Hip circumference adjusted for BMI;
CESC	cis	rs4595586	0.545	rs9668716	chr12:39378833	G/T	cg26384229	chr12:38710491	ALG10B	0.54	7.53	0.42	7.85e-13	Morning vs. evening chronotype;
CESC	cis	rs1862618	0.756	rs9292125	chr5:56107200	C/T	cg22800045	chr5:56110881	MAP3K1	0.81	10.13	0.53	1.33e-20	Initial pursuit acceleration;
CESC	cis	rs72901758	0.768	rs72901762	chr17:76244926	A/G	cg23302638	chr17:76210176	BIRC5	0.47	5.39	0.31	1.59e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
CESC	trans	rs9929218	1.000	rs12596061	chr16:68807828	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.63	-8.36	-0.46	3.68e-15	Colorectal cancer;
CESC	cis	rs2295359	1.000	rs11209007	chr1:67619345	C/G	cg03340356	chr1:67600835	NA	0.3	5.04	0.3	8.52e-7	Psoriasis;
CESC	cis	rs10504229	0.683	rs56408763	chr8:58137276	G/A	cg02725872	chr8:58115012	NA	-0.45	-7.05	-0.4	1.52e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs6582630	0.599	rs1851114	chr12:38424671	C/T	cg26384229	chr12:38710491	ALG10B	-0.44	-5.95	-0.34	8.28e-9	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs4148883	0.645	rs2851287	chr4:100014548	G/A	cg12011299	chr4:100065546	ADH4	0.68	9.84	0.52	1.15e-19	Alcohol dependence;
CESC	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg01238044	chr22:24384105	GSTT1	-0.52	-6.54	-0.37	3.15e-10	Liver enzyme levels (gamma-glutamyl transferase);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04872869	chr1:28908637	SNORA16A;SNHG12	0.49	6.15	0.35	2.87e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs61861422	0.543	rs34309159	chr10:134419166	C/T	cg26818010	chr10:134567672	INPP5A	-0.57	-5.42	-0.32	1.34e-7	Primary sclerosing cholangitis;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg10519709	chr1:204347359	NA	-0.51	-6.7	-0.38	1.25e-10	Ulcerative colitis;
CESC	cis	rs7845219	0.544	rs2945554	chr8:95939594	C/A	cg09323728	chr8:95962352	TP53INP1	-0.33	-6.35	-0.36	9.35e-10	Type 2 diabetes;
CESC	cis	rs116095464	0.558	rs61689490	chr5:224904	T/C	cg22857025	chr5:266934	NA	-1.27	-18.88	-0.76	5.63e-51	Breast cancer;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg21041514	chr17:40333411	KCNH4	-0.39	-6.0	-0.35	6.28e-9	Fibrinogen levels;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg23731836	chr8:29120779	KIF13B	0.48	6.64	0.38	1.78e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs111756027	0.593	rs9924848	chr16:77245971	G/A	cg01504555	chr16:77246968	SYCE1L	0.61	5.76	0.33	2.34e-8	Bone mineral density (Ward's triangle area);
CESC	cis	rs7264396	0.733	rs2425105	chr20:34312834	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.63	7.58	0.42	5.71e-13	Total cholesterol levels;
CESC	cis	rs909674	0.541	rs5757655	chr22:39797178	C/G	cg05872129	chr22:39784769	NA	0.83	11.61	0.58	1.8e-25	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs523522	0.923	rs1048830	chr12:120882217	G/T	cg12219531	chr12:120966889	COQ5	0.72	8.89	0.48	9.44e-17	High light scatter reticulocyte count;
CESC	cis	rs9660180	0.934	rs34849348	chr1:1762757	C/T	cg05132306	chr1:1846340	CALML6	-0.3	-6.37	-0.36	8.33e-10	Body mass index;
CESC	trans	rs9467711	0.606	rs9379900	chr6:26603811	A/C	cg06606381	chr12:133084897	FBRSL1	-0.78	-7.41	-0.41	1.7e-12	Autism spectrum disorder or schizophrenia;
CESC	cis	rs17711722	0.727	rs35850374	chr7:65357776	A/G	cg06456125	chr7:65229604	NA	0.44	5.71	0.33	3.09e-8	Calcium levels;
CESC	cis	rs6752107	1.000	rs2241878	chr2:234183718	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.49	6.7	0.38	1.27e-10	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs9916302	0.595	rs4795371	chr17:37636695	T/G	cg15445000	chr17:37608096	MED1	0.4	6.62	0.38	1.95e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs17376456	0.877	rs10040648	chr5:93490301	G/C	cg25358565	chr5:93447407	FAM172A	1.15	11.26	0.57	2.72e-24	Diabetic retinopathy;
CESC	cis	rs7927771	0.864	rs3781626	chr11:47442893	A/T	cg20307385	chr11:47447363	PSMC3	-0.64	-8.23	-0.45	8.82e-15	Subjective well-being;
CESC	cis	rs7582720	1.000	rs72926772	chr2:203804289	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.38	0.41	1.99e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs4808199	0.947	rs10404728	chr19:19595014	C/T	cg03709012	chr19:19516395	GATAD2A	1.13	13.2	0.63	6.29e-31	Nonalcoholic fatty liver disease;
CESC	cis	rs131777	0.575	rs131760	chr22:51011936	T/C	cg00083937	chr22:51039805	MAPK8IP2	0.38	5.43	0.32	1.27e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	cis	rs1550582	1.000	rs1550582	chr8:135542084	A/G	cg17885191	chr8:135476712	NA	-0.61	-7.37	-0.41	2.17e-12	Educational attainment;
CESC	cis	rs769267	1.000	rs7247309	chr19:19439631	A/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.62	-8.04	-0.44	2.94e-14	Tonsillectomy;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg02918483	chr4:84406202	FAM175A	-0.49	-6.49	-0.37	4.28e-10	Fibrinogen levels;
CESC	cis	rs709400	0.663	rs1028613	chr14:103888324	G/A	cg12935359	chr14:103987150	CKB	-0.56	-8.21	-0.45	9.64e-15	Body mass index;
CESC	cis	rs9926296	0.605	rs6500449	chr16:89856393	T/C	cg07648498	chr16:89883185	FANCA	0.43	5.3	0.31	2.43e-7	Vitiligo;
CESC	cis	rs12711979	0.509	rs10192699	chr2:3824297	A/G	cg17052675	chr2:3827356	NA	-0.66	-11.02	-0.56	1.71e-23	Itch intensity from mosquito bite adjusted by bite size;
CESC	cis	rs2985684	1.000	rs7142457	chr14:50097862	C/T	cg15316458	chr14:50087796	RPL36AL;MGAT2	0.45	5.15	0.3	4.99e-7	Carotid intima media thickness;
CESC	cis	rs6088580	0.524	rs2889855	chr20:33276853	A/G	cg07148914	chr20:33460835	GGT7	-0.4	-5.11	-0.3	6.05e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs11098499	0.865	rs1112817	chr4:120297800	T/C	cg24375607	chr4:120327624	NA	0.46	5.55	0.32	6.98e-8	Corneal astigmatism;
CESC	cis	rs5167	0.506	rs35193317	chr19:45470344	C/T	cg13119609	chr19:45449297	APOC2	-0.53	-8.28	-0.45	6.2e-15	Blood protein levels;
CESC	cis	rs208520	0.690	rs12198745	chr6:66722598	T/C	cg07460842	chr6:66804631	NA	0.94	12.59	0.61	8.06e-29	Exhaled nitric oxide output;
CESC	cis	rs4665809	0.887	rs6546716	chr2:26263836	A/G	cg27170947	chr2:26402098	FAM59B	-0.6	-7.11	-0.4	1.1e-11	Gut microbiome composition (summer);
CESC	cis	rs1545257	0.505	rs13016195	chr2:24634942	T/C	cg06627628	chr2:24431161	ITSN2	-0.47	-5.72	-0.33	2.84e-8	Sjögren's syndrome;
CESC	cis	rs1475911	1.000	rs12482477	chr21:43517233	T/A	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.43	-6.23	-0.36	1.82e-9	IgG glycosylation;
CESC	cis	rs362272	0.505	rs13104157	chr4:3366950	T/C	cg08886695	chr4:3369023	RGS12	-0.42	-5.82	-0.34	1.73e-8	Serum sulfate level;
CESC	cis	rs61008539	0.586	rs6959154	chr7:856320	C/T	cg00475322	chr7:917719	C7orf20	0.49	7.21	0.41	5.77e-12	Perceived unattractiveness to mosquitoes;
CESC	cis	rs6982240	0.514	rs10481414	chr8:142275326	T/C	cg00131261	chr8:142287264	NA	-0.54	-7.51	-0.42	8.94e-13	Tonsillectomy;
CESC	cis	rs7618915	0.501	rs7611731	chr3:52692721	T/C	cg07507251	chr3:52567010	NT5DC2	0.32	5.56	0.32	6.75e-8	Bipolar disorder;
CESC	cis	rs10504229	0.683	rs2005392	chr8:58106896	T/C	cg24829409	chr8:58192753	C8orf71	-0.56	-7.01	-0.4	1.97e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs2070488	0.745	rs9838792	chr3:38546726	G/A	cg24069376	chr3:38537580	EXOG	-0.33	-5.7	-0.33	3.19e-8	Electrocardiographic conduction measures;
CESC	trans	rs264943	0.703	rs264980	chr2:104269979	A/G	cg23260255	chr3:187871479	LPP	-0.51	-6.15	-0.35	2.91e-9	HIV-1 viral setpoint;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24472218	chr7:112579509	C7orf60	0.6	6.35	0.36	9.29e-10	Gut microbiome composition (summer);
CESC	cis	rs6582630	0.519	rs7294300	chr12:38277359	C/A	cg26384229	chr12:38710491	ALG10B	0.72	10.26	0.53	5.3e-21	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs7561273	0.586	rs12477718	chr2:24330539	A/G	cg01493198	chr2:24299560	SF3B14	0.41	5.05	0.3	8.11e-7	Quantitative traits;
CESC	cis	rs9486719	1.000	rs2472887	chr6:96865437	A/G	cg18709589	chr6:96969512	KIAA0776	0.53	5.81	0.34	1.75e-8	Migraine;Coronary artery disease;
CESC	cis	rs4713118	0.621	rs4713134	chr6:28034121	T/C	cg19592336	chr6:28129416	ZNF389	0.57	7.34	0.41	2.64e-12	Parkinson's disease;
CESC	trans	rs877282	0.583	rs11253428	chr10:823233	C/T	cg22713356	chr15:30763199	NA	1.03	9.37	0.5	3.32e-18	Uric acid levels;
CESC	trans	rs2727020	0.894	rs11040333	chr11:49346332	G/A	cg15704280	chr7:45808275	SEPT13	-0.76	-9.32	-0.5	4.9e-18	Coronary artery disease;
CESC	cis	rs6460942	0.915	rs62447639	chr7:12486803	T/C	cg20607287	chr7:12443886	VWDE	-0.77	-8.71	-0.47	3.35e-16	Coronary artery disease;
CESC	cis	rs35306767	0.953	rs12259801	chr10:959306	C/G	cg20503657	chr10:835505	NA	0.75	8.33	0.46	4.53e-15	Eosinophil percentage of granulocytes;
CESC	cis	rs12950390	0.853	rs66471233	chr17:45867086	C/T	cg00777063	chr17:45855553	NA	-0.38	-5.61	-0.33	5.08e-8	IgG glycosylation;
CESC	cis	rs4728302	0.869	rs6955707	chr7:133612188	G/A	cg10665199	chr7:133106180	EXOC4	0.41	5.72	0.33	2.92e-8	Intelligence;Intelligence (multi-trait analysis);
CESC	cis	rs3862435	0.518	rs2601169	chr15:90913890	T/C	cg22089800	chr15:90895588	ZNF774	0.49	5.14	0.3	5.36e-7	Response to exercise (triglyceride level interaction);
CESC	cis	rs9916302	0.904	rs11655531	chr17:37697959	T/C	cg00129232	chr17:37814104	STARD3	-0.6	-7.9	-0.44	7.51e-14	Glomerular filtration rate (creatinine);
CESC	cis	rs477895	0.653	rs11601577	chr11:63928574	C/T	cg18225595	chr11:63971243	STIP1	0.52	5.17	0.3	4.65e-7	Mean platelet volume;
CESC	cis	rs68170813	0.641	rs74524528	chr7:107090979	G/A	cg02696742	chr7:106810147	HBP1	-0.56	-5.19	-0.3	4.1e-7	Coronary artery disease;
CESC	cis	rs7223966	1.000	rs16947005	chr17:61702989	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.44	5.07	0.3	7.41e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs17209837	0.607	rs12539936	chr7:87110017	A/G	cg00919237	chr7:87102261	ABCB4	0.48	6.28	0.36	1.38e-9	Gallbladder cancer;
CESC	cis	rs4665809	1.000	rs4233709	chr2:26291493	C/T	cg27170947	chr2:26402098	FAM59B	0.55	6.55	0.37	2.97e-10	Gut microbiome composition (summer);
CESC	cis	rs477895	0.838	rs12798333	chr11:64012784	G/A	cg04317338	chr11:64019027	PLCB3	0.93	10.24	0.53	6.06e-21	Mean platelet volume;
CESC	cis	rs9611565	0.643	rs202634	chr22:41809623	A/G	cg06481639	chr22:41940642	POLR3H	0.63	6.47	0.37	4.71e-10	Vitiligo;
CESC	cis	rs9400271	0.632	rs4427037	chr6:109585612	G/C	cg01475377	chr6:109611718	NA	-0.44	-6.9	-0.39	3.76e-11	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
CESC	cis	rs17376456	1.000	rs34068652	chr5:93563319	G/A	cg25358565	chr5:93447407	FAM172A	1.17	11.32	0.57	1.64e-24	Diabetic retinopathy;
CESC	cis	rs208520	0.661	rs207090	chr6:66783963	T/A	cg07460842	chr6:66804631	NA	-1.0	-13.33	-0.63	2.21e-31	Exhaled nitric oxide output;
CESC	cis	rs2243480	1.000	rs1796228	chr7:66033084	G/A	cg18252515	chr7:66147081	NA	-1.4	-14.23	-0.66	1.55e-34	Diabetic kidney disease;
CESC	cis	rs11098499	0.954	rs7436506	chr4:120393769	T/C	cg09307838	chr4:120376055	NA	0.94	13.97	0.65	1.31e-33	Corneal astigmatism;
CESC	cis	rs977987	0.806	rs12599361	chr16:75434973	A/T	cg03315344	chr16:75512273	CHST6	0.39	5.52	0.32	8.14e-8	Dupuytren's disease;
CESC	cis	rs763121	0.853	rs5995610	chr22:39064681	C/T	cg21395723	chr22:39101663	GTPBP1	0.43	5.39	0.31	1.58e-7	Menopause (age at onset);
CESC	cis	rs6032067	0.852	rs17424751	chr20:43814622	T/C	cg11264863	chr20:43835661	SEMG1	0.49	5.32	0.31	2.21e-7	Blood protein levels;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg12413365	chr12:12510412	LOH12CR1;LOH12CR2	0.46	6.13	0.35	3.15e-9	Systemic lupus erythematosus;
CESC	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.51	6.82	0.39	6.15e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2898290	0.506	rs2736311	chr8:11252170	C/T	cg21775007	chr8:11205619	TDH	-0.41	-5.94	-0.34	8.91e-9	Systolic blood pressure;
CESC	cis	rs4664293	0.967	rs13020365	chr2:160476404	G/A	cg08347373	chr2:160653686	CD302	-0.32	-5.08	-0.3	7.08e-7	Monocyte percentage of white cells;
CESC	cis	rs9322193	0.962	rs2275046	chr6:150157001	A/G	cg04369109	chr6:150039330	LATS1	-0.42	-5.62	-0.33	4.9e-8	Lung cancer;
CESC	cis	rs1059312	0.966	rs35907548	chr12:129282180	T/C	cg09035930	chr12:129282057	SLC15A4	0.75	10.74	0.55	1.41e-22	Systemic lupus erythematosus;
CESC	cis	rs916888	0.687	rs199456	chr17:44797919	C/T	cg15921436	chr17:44337874	NA	0.75	7.9	0.44	7.36e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs1178968	0.748	rs10271751	chr7:72752062	T/C	cg25889504	chr7:72793014	NA	0.47	5.03	0.3	8.91e-7	Triglyceride levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11540416	chr15:72668720	HEXA;C15orf34	-0.56	-6.07	-0.35	4.37e-9	Gut microbiome composition (summer);
CESC	cis	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg13880726	chr7:1868755	MAD1L1	0.51	6.75	0.38	9.19e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs13191362	0.808	rs13217502	chr6:163231414	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.6	5.95	0.34	8.39e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	ch.17.48901521F	chr17:51546522	NA	-0.49	-6.06	-0.35	4.6e-9	Gut microbiome composition (summer);
CESC	cis	rs9858542	0.953	rs10640	chr3:49454277	G/A	cg07274523	chr3:49395745	GPX1	0.66	8.13	0.45	1.66e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs6502050	0.799	rs9675196	chr17:80096655	C/T	cg11859384	chr17:80120422	CCDC57	-0.37	-5.12	-0.3	5.89e-7	Life satisfaction;
CESC	cis	rs3809566	1.000	rs3809566	chr15:63333724	A/G	cg05507819	chr15:63340323	TPM1	0.51	6.11	0.35	3.45e-9	Platelet count;
CESC	cis	rs7927771	0.524	rs10838784	chr11:47882341	G/A	cg20307385	chr11:47447363	PSMC3	0.61	8.6	0.47	7.14e-16	Subjective well-being;
CESC	cis	rs7618915	0.547	rs11130317	chr3:52731483	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.5	7.23	0.41	5.15e-12	Bipolar disorder;
CESC	cis	rs11608355	0.515	rs4766606	chr12:109934390	C/G	cg05360138	chr12:110035743	NA	0.82	8.85	0.48	1.27e-16	Neuroticism;
CESC	cis	rs2228479	0.850	rs62054640	chr16:89823157	C/T	cg06558623	chr16:89946397	TCF25	1.16	9.28	0.5	6.08e-18	Skin colour saturation;
CESC	trans	rs875971	0.929	rs778692	chr7:65872449	A/G	cg26939375	chr7:64535504	NA	0.47	6.06	0.35	4.77e-9	Aortic root size;
CESC	cis	rs875971	0.862	rs1643375	chr7:65872677	T/C	cg11764359	chr7:65958608	NA	0.81	11.89	0.59	2.11e-26	Aortic root size;
CESC	cis	rs28489187	0.617	rs233068	chr1:85805355	G/A	cg16011679	chr1:85725395	C1orf52	0.45	5.33	0.31	2.12e-7	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	cis	rs4727027	0.645	rs12704072	chr7:148904888	G/A	cg23158103	chr7:148848205	ZNF398	-0.32	-5.09	-0.3	6.8e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs8067354	0.789	rs4622571	chr17:57884397	T/A	cg02344993	chr17:57696989	CLTC	0.47	6.17	0.35	2.48e-9	Hemoglobin concentration;
CESC	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg07167872	chr1:205819463	PM20D1	-0.68	-9.7	-0.51	3.01e-19	Menarche (age at onset);
CESC	cis	rs30380	0.632	rs26495	chr5:96137840	A/G	cg16492584	chr5:96139282	ERAP1	-0.48	-6.78	-0.38	7.83e-11	Cerebrospinal fluid biomarker levels;
CESC	trans	rs7937682	0.889	rs521155	chr11:111492563	G/A	cg18187862	chr3:45730750	SACM1L	0.48	6.01	0.35	6.26e-9	Primary sclerosing cholangitis;
CESC	cis	rs9322193	0.923	rs9322208	chr6:149979683	A/T	cg07701084	chr6:150067640	NUP43	0.47	6.62	0.38	1.97e-10	Lung cancer;
CESC	trans	rs7726839	0.540	rs7434	chr5:660804	A/G	cg25482853	chr8:67687455	SGK3	-0.97	-10.01	-0.52	3.3e-20	Obesity-related traits;
CESC	cis	rs4970988	0.640	rs7524734	chr1:150655686	C/T	cg17724175	chr1:150552817	MCL1	0.44	7.21	0.41	5.8e-12	Urate levels;
CESC	cis	rs7116495	0.609	rs2852365	chr11:71715218	T/C	cg10381502	chr11:71823885	C11orf51	-1.16	-7.97	-0.44	4.69e-14	Severe influenza A (H1N1) infection;
CESC	cis	rs35110281	0.667	rs2250773	chr21:45087786	T/C	cg21573476	chr21:45109991	RRP1B	-0.53	-8.02	-0.44	3.38e-14	Mean corpuscular volume;
CESC	cis	rs9309711	0.643	rs10188449	chr2:3480366	T/C	cg15506890	chr2:3487001	NA	-0.49	-6.19	-0.36	2.34e-9	Neurofibrillary tangles;
CESC	cis	rs9308433	0.529	rs904321	chr1:214506550	G/C	cg06198575	chr1:214491504	SMYD2	0.48	5.63	0.33	4.51e-8	IgG glycosylation;
CESC	trans	rs7672847	0.547	rs6829406	chr4:170394024	C/T	cg19308436	chr1:237949471	RYR2	0.6	6.48	0.37	4.45e-10	Subjective well-being;
CESC	cis	rs962856	0.897	rs7579304	chr2:67611250	G/A	cg09028215	chr2:67624308	ETAA1	-0.38	-5.06	-0.3	7.7e-7	Pancreatic cancer;
CESC	cis	rs425277	0.565	rs3128293	chr1:2065339	A/G	cg16545954	chr1:2118288	C1orf86	-0.35	-6.51	-0.37	3.82e-10	Height;
CESC	trans	rs7246657	0.882	rs6508719	chr19:37877419	A/G	cg24637308	chr11:6592297	DNHD1	0.53	6.16	0.35	2.67e-9	Coronary artery calcification;
CESC	cis	rs13118159	0.836	rs2293630	chr4:1342521	G/A	cg19318889	chr4:1322082	MAEA	0.39	5.07	0.3	7.4e-7	Longevity;
CESC	cis	rs875971	0.862	rs2420173	chr7:65645399	A/T	cg10691866	chr7:65817282	TPST1	0.31	5.24	0.31	3.34e-7	Aortic root size;
CESC	cis	rs2014572	0.510	rs8111661	chr19:57752326	C/G	cg24459738	chr19:57751996	ZNF805	0.55	8.06	0.44	2.62e-14	Hyperactive-impulsive symptoms;
CESC	trans	rs11098499	0.863	rs1552092	chr4:120488496	C/T	cg25214090	chr10:38739885	LOC399744	0.66	8.96	0.48	5.92e-17	Corneal astigmatism;
CESC	cis	rs920590	0.758	rs7010174	chr8:19661930	G/C	cg03894339	chr8:19674705	INTS10	0.63	7.26	0.41	4.24e-12	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs1552244	0.938	rs7647987	chr3:10140696	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	12.72	0.62	2.88e-29	Alzheimer's disease;
CESC	cis	rs27434	0.602	rs2927620	chr5:96181297	G/A	cg16492584	chr5:96139282	ERAP1	-0.53	-6.51	-0.37	3.69e-10	Ankylosing spondylitis;
CESC	trans	rs877282	0.945	rs10904556	chr10:789429	A/G	cg22713356	chr15:30763199	NA	1.31	13.31	0.63	2.78e-31	Uric acid levels;
CESC	cis	rs400736	0.894	rs172811	chr1:8039949	A/G	cg25007680	chr1:8021821	PARK7	0.71	10.28	0.53	4.35e-21	Response to antidepressants and depression;
CESC	cis	rs7552404	1.000	rs4646961	chr1:76217169	G/A	cg22875332	chr1:76189707	ACADM	0.64	7.7	0.43	2.76e-13	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs4713118	0.629	rs203888	chr6:28021589	C/T	cg23281280	chr6:28129359	ZNF389	0.48	6.57	0.37	2.58e-10	Parkinson's disease;
CESC	cis	rs4253772	0.591	rs6007740	chr22:46654323	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	-0.68	-8.24	-0.45	8.02e-15	LDL cholesterol;Cholesterol, total;
CESC	cis	rs7618915	0.571	rs67539070	chr3:52711974	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	7.02	0.4	1.82e-11	Bipolar disorder;
CESC	cis	rs854765	0.647	rs854767	chr17:18018263	A/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.62	-8.77	-0.47	2.27e-16	Total body bone mineral density;
CESC	cis	rs1862618	0.802	rs832560	chr5:56124423	T/A	cg12311346	chr5:56204834	C5orf35	-0.72	-8.86	-0.48	1.15e-16	Initial pursuit acceleration;
CESC	cis	rs12477438	0.520	rs6708576	chr2:99801308	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.86	15.09	0.68	1.43e-37	Chronic sinus infection;
CESC	cis	rs2625529	0.652	rs8040216	chr15:72255249	C/T	cg16672083	chr15:72433130	SENP8	0.39	5.89	0.34	1.17e-8	Red blood cell count;
CESC	cis	rs4975616	0.869	rs370348	chr5:1331219	A/G	cg07493874	chr5:1342172	CLPTM1L	-0.41	-7.93	-0.44	6.13e-14	Lung cancer;
CESC	cis	rs4803468	1.000	rs11670757	chr19:41913431	G/T	cg14132834	chr19:41945861	ATP5SL	-0.58	-7.23	-0.41	5.07e-12	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08631890	chr19:39902969	PLEKHG2	-0.6	-7.36	-0.41	2.32e-12	Gut microbiome composition (summer);
CESC	cis	rs4919694	0.901	rs113541728	chr10:104716771	A/T	cg04362960	chr10:104952993	NT5C2	0.78	6.79	0.38	7.53e-11	Arsenic metabolism;
CESC	cis	rs7208859	0.673	rs216424	chr17:28943064	T/G	cg17105886	chr17:28927953	LRRC37B2	0.65	5.64	0.33	4.37e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs6502050	0.765	rs55905076	chr17:80105441	G/A	cg11859384	chr17:80120422	CCDC57	-0.38	-5.15	-0.3	5.12e-7	Life satisfaction;
CESC	cis	rs10851478	0.872	rs17402115	chr15:49824761	C/T	cg08060515	chr15:49448048	GALK2;COPS2	0.42	5.19	0.3	4.12e-7	Oral cavity cancer;
CESC	cis	rs7917772	0.512	rs11594073	chr10:104308193	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.39	-5.34	-0.31	2.02e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs5769765	0.955	rs9616367	chr22:50303515	A/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.56	-5.92	-0.34	1.01e-8	Schizophrenia;
CESC	cis	rs10876993	0.928	rs10082911	chr12:58104104	C/A	cg18357645	chr12:58087776	OS9	0.63	10.47	0.54	1.11e-21	Celiac disease or Rheumatoid arthritis;
CESC	cis	rs2066819	0.786	rs116934693	chr12:56696545	T/G	cg26804944	chr12:56660921	COQ10A	-0.85	-5.19	-0.3	4.22e-7	Psoriasis vulgaris;
CESC	cis	rs6061231	0.544	rs2427314	chr20:60973666	C/T	cg22541963	chr20:60982533	CABLES2	0.54	6.71	0.38	1.21e-10	Colorectal cancer;
CESC	cis	rs1023500	0.505	rs134886	chr22:42673856	C/T	cg04733989	chr22:42467013	NAGA	-0.59	-8.82	-0.48	1.6e-16	Schizophrenia;
CESC	cis	rs892961	0.836	rs8071497	chr17:75414358	T/C	cg05865280	chr17:75406074	SEPT9	0.63	12.77	0.62	1.96e-29	Airflow obstruction;
CESC	cis	rs5750830	0.594	rs6001568	chr22:39775786	G/A	cg24399712	chr22:39784796	NA	-0.83	-11.45	-0.58	6.44e-25	Intelligence (multi-trait analysis);
CESC	cis	rs514406	0.929	rs557715	chr1:53321593	C/G	cg16325326	chr1:53192061	ZYG11B	0.82	13.08	0.63	1.64e-30	Monocyte count;
CESC	cis	rs11122272	0.705	rs2808599	chr1:231533482	T/C	cg06096015	chr1:231504339	EGLN1	0.43	6.15	0.35	2.9e-9	Hemoglobin concentration;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05147070	chr3:160283469	KPNA4	0.63	7.35	0.41	2.41e-12	Gut microbiome composition (summer);
CESC	cis	rs3008870	1.000	rs2755246	chr1:67488984	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.92	11.85	0.59	2.84e-26	Lymphocyte percentage of white cells;
CESC	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg03188948	chr7:1209495	NA	0.7	7.7	0.43	2.64e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs9291683	0.609	rs13141233	chr4:10028729	T/C	cg02734326	chr4:10020555	SLC2A9	0.47	6.52	0.37	3.47e-10	Bone mineral density;
CESC	cis	rs13720	0.722	rs163801	chr20:57578614	A/G	cg23907860	chr20:57583709	CTSZ	-0.47	-5.7	-0.33	3.11e-8	Platelet distribution width;
CESC	cis	rs4665809	1.000	rs1030730	chr2:26284143	T/C	cg04944784	chr2:26401820	FAM59B	-0.8	-8.93	-0.48	7.17e-17	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15537487	chr10:1043368	GTPBP4	-0.58	-6.82	-0.39	6e-11	Gut microbiome composition (summer);
CESC	cis	rs2303745	0.544	rs6512180	chr19:17399153	C/T	cg02221750	chr19:17393354	ANKLE1	-0.52	-6.29	-0.36	1.32e-9	Systemic lupus erythematosus;
CESC	cis	rs10504229	0.683	rs56196593	chr8:58141898	G/A	cg21724239	chr8:58056113	NA	0.56	5.78	0.33	2.13e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs14978	0.628	rs4721060	chr7:12267552	G/A	cg23422036	chr7:12250390	TMEM106B	0.38	5.13	0.3	5.58e-7	Response to amphetamines;
CESC	cis	rs6693567	0.545	rs2275246	chr1:150460168	A/G	cg09579323	chr1:150459698	TARS2	0.46	5.75	0.33	2.4e-8	Migraine;
CESC	cis	rs11252926	0.527	rs11252754	chr10:538637	G/A	cg16386425	chr10:429943	DIP2C	-0.45	-5.73	-0.33	2.66e-8	Psychosis in Alzheimer's disease;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg00903375	chr7:66460591	SBDS;TYW1	-0.47	-6.75	-0.38	9.03e-11	Gambling;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg22153931	chr7:43917675	URGCP	0.5	6.83	0.39	5.85e-11	Fibrinogen levels;
CESC	cis	rs6681460	0.966	rs10889644	chr1:67145322	C/A	cg02459107	chr1:67143332	SGIP1	0.37	5.09	0.3	6.76e-7	Presence of antiphospholipid antibodies;
CESC	trans	rs1728785	0.591	rs10775305	chr16:68656460	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	7.7	0.43	2.73e-13	Ulcerative colitis;
CESC	cis	rs4319547	0.737	rs7964138	chr12:122950375	A/G	cg23029597	chr12:123009494	RSRC2	-0.45	-5.15	-0.3	5.14e-7	Body mass index;
CESC	trans	rs6987853	0.830	rs12542919	chr8:42356035	C/T	cg27650678	chr11:66636318	PC	-0.46	-6.11	-0.35	3.45e-9	Mean corpuscular hemoglobin concentration;
CESC	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.71	9.97	0.52	4.3e-20	Prudent dietary pattern;
CESC	cis	rs2180341	0.782	rs4487601	chr6:127723521	A/G	cg24812749	chr6:127587940	RNF146	0.83	12.07	0.6	5.14e-27	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07241146	chr10:134145514	LRRC27	-0.54	-6.11	-0.35	3.56e-9	Gut microbiome composition (summer);
CESC	cis	rs7589728	0.563	rs79892776	chr2:88470593	G/A	cg14558114	chr2:88469736	THNSL2	0.58	5.53	0.32	7.83e-8	Plasma clusterin levels;
CESC	cis	rs7091068	0.671	rs604489	chr10:95405408	T/C	cg20715218	chr10:95462985	C10orf4	-0.51	-5.37	-0.31	1.76e-7	Urinary tract infection frequency;
CESC	cis	rs875971	0.862	rs57866200	chr7:65565392	A/G	cg12463550	chr7:65579703	CRCP	-0.54	-6.65	-0.38	1.65e-10	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01085995	chr3:47866817	DHX30	0.59	6.56	0.37	2.83e-10	Gut microbiome composition (summer);
CESC	cis	rs11958404	0.932	rs6884954	chr5:157436772	C/T	cg05962755	chr5:157440814	NA	0.6	6.38	0.36	7.98e-10	IgG glycosylation;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg26818010	chr10:134567672	INPP5A	0.56	7.32	0.41	3.05e-12	Fibrinogen levels;
CESC	cis	rs763121	0.853	rs7289855	chr22:39042221	G/T	cg14440974	chr22:39074834	NA	-0.42	-5.64	-0.33	4.24e-8	Menopause (age at onset);
CESC	cis	rs172166	0.611	rs203882	chr6:28078502	G/A	cg26335602	chr6:28129616	ZNF389	0.38	5.53	0.32	7.72e-8	Cardiac Troponin-T levels;
CESC	cis	rs1008375	1.000	rs555	chr4:17625658	A/G	cg04450456	chr4:17643702	FAM184B	0.37	5.32	0.31	2.26e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs7044106	0.762	rs966396	chr9:123453281	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.33	5.1	0.3	6.52e-7	Hip circumference adjusted for BMI;
CESC	cis	rs4237845	0.537	rs10877031	chr12:58266695	A/G	cg00677455	chr12:58241039	CTDSP2	0.8	10.71	0.55	1.76e-22	Intelligence (multi-trait analysis);
CESC	cis	rs11098499	0.866	rs6824111	chr4:120285968	T/A	cg09307838	chr4:120376055	NA	0.87	12.16	0.6	2.41e-27	Corneal astigmatism;
CESC	cis	rs1153858	0.668	rs63603561	chr15:45593323	T/A	cg21132104	chr15:45694354	SPATA5L1	-0.81	-10.19	-0.53	8.51e-21	Homoarginine levels;
CESC	cis	rs1728785	1.000	rs1099296	chr16:68588653	G/A	cg02972257	chr16:68554789	NA	-0.58	-6.68	-0.38	1.42e-10	Ulcerative colitis;
CESC	cis	rs12497850	0.864	rs6779394	chr3:49157771	G/A	cg02487422	chr3:49467188	NICN1	0.48	6.04	0.35	5.3300000000000004e-09	Parkinson's disease;
CESC	trans	rs4332037	0.539	rs56016347	chr7:2060126	C/T	cg11693508	chr17:37793320	STARD3	0.66	6.63	0.38	1.84e-10	Bipolar disorder;
CESC	cis	rs6693567	0.516	rs519126	chr1:150288859	T/G	cg09579323	chr1:150459698	TARS2	-0.46	-6.02	-0.35	5.85e-9	Migraine;
CESC	cis	rs35123781	0.654	rs356486	chr5:139085103	C/G	cg10513866	chr5:139070639	NA	-0.41	-5.61	-0.33	5.16e-8	Schizophrenia;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg10165071	chr2:217557160	IGFBP5	-0.45	-6.54	-0.37	3.11e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs7605827	0.930	rs3815597	chr2:15625404	T/C	cg19274914	chr2:15703543	NA	0.37	6.63	0.38	1.85e-10	Educational attainment (years of education);
CESC	cis	rs1538970	0.924	rs12046816	chr1:45891543	G/T	cg03146154	chr1:46216737	IPP	0.44	5.09	0.3	6.74e-7	Platelet count;
CESC	cis	rs4660306	1.000	rs10736426	chr1:45984353	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.52	6.79	0.39	7.22e-11	Homocysteine levels;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg04167064	chr1:46932305	NA	-0.48	-6.56	-0.37	2.77e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs644799	1.000	rs10831431	chr11:95510089	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.55	6.89	0.39	4.06e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs60871478	0.636	rs6976929	chr7:901382	C/T	cg13798912	chr7:905769	UNC84A	-0.56	-5.53	-0.32	7.82e-8	Cerebrospinal P-tau181p levels;
CESC	cis	rs796364	1.000	rs769950	chr2:200730028	A/G	cg23649088	chr2:200775458	C2orf69	0.54	5.1	0.3	6.38e-7	Schizophrenia;
CESC	cis	rs722599	0.748	rs20578	chr14:75367807	C/T	cg08847533	chr14:75593920	NEK9	-0.47	-5.62	-0.33	4.89e-8	IgG glycosylation;
CESC	cis	rs10504229	1.000	rs114486414	chr8:58185103	G/A	cg14926445	chr8:58193284	C8orf71	-0.51	-5.52	-0.32	8.28e-8	Developmental language disorder (linguistic errors);
CESC	trans	rs7824557	0.564	rs1435275	chr8:11235735	T/C	cg06636001	chr8:8085503	FLJ10661	-0.49	-6.15	-0.35	2.9e-9	Retinal vascular caliber;
CESC	trans	rs11098499	0.644	rs17517414	chr4:120262101	G/C	cg25214090	chr10:38739885	LOC399744	0.6	8.47	0.46	1.65e-15	Corneal astigmatism;
CESC	trans	rs11098499	1.000	rs28374891	chr4:120183550	G/A	cg25214090	chr10:38739885	LOC399744	0.64	8.57	0.47	8.75e-16	Corneal astigmatism;
CESC	cis	rs597539	0.652	rs478647	chr11:68700424	C/T	cg04772025	chr11:68637568	NA	0.5	6.17	0.35	2.5e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg15112475	chr7:1198522	ZFAND2A	-0.4	-6.23	-0.36	1.8e-9	Longevity;Endometriosis;
CESC	cis	rs9322193	1.000	rs9767077	chr6:150109615	T/A	cg04369109	chr6:150039330	LATS1	-0.4	-5.4	-0.31	1.48e-7	Lung cancer;
CESC	cis	rs6502050	0.761	rs11653003	chr17:80058795	G/T	cg23985595	chr17:80112537	CCDC57	0.42	6.25	0.36	1.64e-9	Life satisfaction;
CESC	cis	rs4253772	0.744	rs4253760	chr22:46622384	T/G	cg09491104	chr22:46646882	C22orf40	-0.6	-8.87	-0.48	1.14e-16	LDL cholesterol;Cholesterol, total;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23268322	chr19:50762551	MYH14	-0.56	-6.19	-0.36	2.3e-9	Gut microbiome composition (summer);
CESC	cis	rs826838	0.935	rs10875816	chr12:38955014	C/A	cg26384229	chr12:38710491	ALG10B	0.83	14.68	0.67	4.21e-36	Heart rate;
CESC	cis	rs1559088	0.842	rs12977993	chr19:33580453	T/A	cg27124370	chr19:33622961	WDR88	0.48	6.33	0.36	1.06e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs7589728	0.620	rs76687350	chr2:88473832	G/A	cg07952391	chr2:88470173	THNSL2	0.62	5.87	0.34	1.27e-8	Plasma clusterin levels;
CESC	cis	rs2072499	0.750	rs10159384	chr1:156160822	C/T	cg25208724	chr1:156163844	SLC25A44	1.01	12.84	0.62	1.13e-29	Testicular germ cell tumor;
CESC	trans	rs9858542	1.000	rs9822268	chr3:49719729	G/A	cg21659725	chr3:3221576	CRBN	-0.54	-6.71	-0.38	1.21e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs752010	0.714	rs6600384	chr1:42085141	A/G	cg06885757	chr1:42089581	HIVEP3	-0.51	-8.92	-0.48	8e-17	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs6598955	0.756	rs10902723	chr1:26568542	T/C	cg00852783	chr1:26633632	UBXN11	0.42	6.22	0.36	1.89e-9	Obesity-related traits;
CESC	trans	rs11039798	0.841	rs11500573	chr11:48713900	T/G	cg15704280	chr7:45808275	SEPT13	0.7	6.42	0.37	6.38e-10	Axial length;
CESC	cis	rs9914988	0.778	rs9907192	chr17:27122426	C/G	cg20469991	chr17:27169893	C17orf63	-0.48	-5.25	-0.31	3.18e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CESC	cis	rs11958404	0.932	rs72818104	chr5:157437632	T/C	cg05962755	chr5:157440814	NA	0.62	6.66	0.38	1.57e-10	IgG glycosylation;
CESC	cis	rs736408	0.609	rs1029871	chr3:52797634	G/C	cg17372223	chr3:52568218	NT5DC2	0.43	6.06	0.35	4.63e-9	Bipolar disorder;
CESC	cis	rs472402	0.623	rs8192130	chr5:6636450	G/A	cg10789808	chr5:6633262	NSUN2;SRD5A1	-0.53	-7.0	-0.4	2.06e-11	Response to amphetamines;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06110221	chr11:64257582	NA	0.42	6.0	0.35	6.59e-9	Gut microbiome composition (summer);
CESC	cis	rs2075371	0.933	rs1833474	chr7:133958240	A/G	cg11752832	chr7:134001865	SLC35B4	0.51	6.52	0.37	3.54e-10	Mean platelet volume;
CESC	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg07677032	chr17:61819896	STRADA	0.44	5.81	0.34	1.81e-8	Prudent dietary pattern;
CESC	cis	rs2011503	1.000	rs756999	chr19:19448200	A/G	cg11584989	chr19:19387371	SF4	-0.63	-7.55	-0.42	7.15e-13	Bipolar disorder;
CESC	cis	rs853679	0.517	rs9380062	chr6:28137569	G/A	cg22143856	chr6:28129313	ZNF389	0.46	5.83	0.34	1.58e-8	Depression;
CESC	cis	rs892961	0.899	rs72896163	chr17:75412525	C/T	cg05865280	chr17:75406074	SEPT9	0.62	12.67	0.61	4.57e-29	Airflow obstruction;
CESC	trans	rs5756813	0.754	rs11089854	chr22:38148882	G/A	cg19894588	chr14:64061835	NA	-0.66	-7.97	-0.44	4.62e-14	Optic cup area;Vertical cup-disc ratio;
CESC	cis	rs35110281	0.659	rs11909064	chr21:45092095	G/C	cg04455712	chr21:45112962	RRP1B	0.49	7.47	0.42	1.14e-12	Mean corpuscular volume;
CESC	cis	rs2243480	0.901	rs34807232	chr7:65965133	G/A	cg18252515	chr7:66147081	NA	-1.4	-14.3	-0.66	9.14e-35	Diabetic kidney disease;
CESC	cis	rs6662572	0.950	rs56093189	chr1:46234323	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.51	5.58	0.32	6e-8	Blood protein levels;
CESC	cis	rs7246657	0.943	rs6508711	chr19:37815134	G/T	cg23950597	chr19:37808831	NA	-0.55	-6.04	-0.35	5.24e-9	Coronary artery calcification;
CESC	cis	rs8027181	0.682	rs890354	chr15:73100924	C/G	cg25632853	chr15:73088954	NA	0.31	5.68	0.33	3.52e-8	Triglyceride levels;
CESC	cis	rs9611565	0.525	rs9611549	chr22:41705909	C/G	cg17376030	chr22:41985996	PMM1	0.48	5.38	0.31	1.6e-7	Vitiligo;
CESC	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	22.05	0.8	6.51e-62	Prudent dietary pattern;
CESC	cis	rs6964587	0.692	rs10227225	chr7:91571074	A/G	cg17063962	chr7:91808500	NA	-0.45	-6.32	-0.36	1.13e-9	Breast cancer;
CESC	cis	rs3733585	0.631	rs4697925	chr4:10124330	G/C	cg00071950	chr4:10020882	SLC2A9	-0.64	-9.63	-0.51	5.27e-19	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs853679	0.517	rs9393896	chr6:28127703	C/T	cg12963246	chr6:28129442	ZNF389	0.56	7.4	0.41	1.8e-12	Depression;
CESC	cis	rs12477438	0.798	rs13412764	chr2:99583733	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.7	-10.22	-0.53	6.79e-21	Chronic sinus infection;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09414045	chr1:110162465	AMPD2	0.56	6.43	0.37	6.08e-10	Gut microbiome composition (summer);
CESC	cis	rs6460942	0.778	rs74993124	chr7:12462917	A/G	cg10578991	chr7:12443926	VWDE	-0.49	-6.22	-0.36	1.91e-9	Coronary artery disease;
CESC	cis	rs2795502	0.882	rs2744087	chr10:43340270	A/C	cg27426351	chr10:43362370	NA	-0.45	-5.5	-0.32	8.91e-8	Blood protein levels;
CESC	cis	rs853679	0.517	rs9348796	chr6:28126202	A/G	cg19592336	chr6:28129416	ZNF389	0.61	8.03	0.44	3.13e-14	Depression;
CESC	cis	rs2625529	0.816	rs4777467	chr15:72138478	T/C	cg16672083	chr15:72433130	SENP8	-0.4	-5.18	-0.3	4.47e-7	Red blood cell count;
CESC	cis	rs7927592	0.626	rs11228279	chr11:68309680	C/T	cg20283391	chr11:68216788	NA	0.43	5.38	0.31	1.67e-7	Total body bone mineral density;
CESC	cis	rs965469	0.817	rs16988490	chr20:3335431	C/T	cg25506879	chr20:3388711	C20orf194	0.53	5.59	0.32	5.53e-8	IFN-related cytopenia;
CESC	cis	rs13191362	0.872	rs56404230	chr6:163252863	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.67	6.37	0.36	8.09e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs3806843	1.000	rs991918	chr5:140194858	C/T	cg16179182	chr5:140090404	VTRNA1-1	-0.41	-5.25	-0.31	3.19e-7	Depressive symptoms (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26020522	chr12:105629518	APPL2	0.56	6.02	0.35	5.66e-9	Gut microbiome composition (summer);
CESC	cis	rs8031584	0.958	rs8034856	chr15:31240957	T/C	cg08704250	chr15:31115839	NA	-0.63	-8.12	-0.45	1.8e-14	Huntington's disease progression;
CESC	trans	rs8026198	0.568	rs1678984	chr15:42616332	T/G	cg19625216	chr1:249132108	ZNF672	-0.72	-5.99	-0.35	6.68e-9	Fibrinogen levels;
CESC	cis	rs8031584	0.723	rs711224	chr15:31127921	G/C	cg08704250	chr15:31115839	NA	0.69	9.36	0.5	3.56e-18	Huntington's disease progression;
CESC	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg15383120	chr6:291909	DUSP22	-0.67	-8.63	-0.47	5.92e-16	Menopause (age at onset);
CESC	cis	rs1878931	0.501	rs42329	chr16:3425524	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.67	-8.42	-0.46	2.42e-15	Body mass index (adult);
CESC	cis	rs9733	0.566	rs72702554	chr1:150678234	A/G	cg09365446	chr1:150670422	GOLPH3L	0.42	5.87	0.34	1.27e-8	Tonsillectomy;
CESC	cis	rs2836633	0.965	rs2836621	chr21:40054149	C/T	cg05519781	chr21:40033154	ERG	0.6	9.25	0.49	7.96e-18	Coronary artery disease;
CESC	cis	rs6088580	0.634	rs6058073	chr20:33116483	T/C	cg08999081	chr20:33150536	PIGU	0.65	11.2	0.57	4.19e-24	Glomerular filtration rate (creatinine);
CESC	trans	rs74054849	0.850	rs72878850	chr1:16004612	A/G	cg06826283	chr7:600452	PRKAR1B	0.71	6.12	0.35	3.3e-9	Alcoholic chronic pancreatitis;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg24484856	chr12:69140014	SLC35E3	-0.49	-6.39	-0.37	7.27e-10	Asthma;
CESC	cis	rs1008375	1.000	rs6848360	chr4:17634442	G/T	cg15017067	chr4:17643749	FAM184B	0.38	5.45	0.32	1.16e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs4920343	0.890	rs4920531	chr1:19095746	A/G	cg19637330	chr1:19110922	NA	-0.37	-5.16	-0.3	4.82e-7	Knee osteoarthritis;
CESC	cis	rs2108622	0.958	rs56340170	chr19:15981877	G/C	cg13772218	chr19:15982569	NA	0.38	7.14	0.4	8.98e-12	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CESC	cis	rs780096	0.546	rs1647284	chr2:27608115	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.32	-5.95	-0.34	8.33e-9	Total body bone mineral density;
CESC	cis	rs2658782	0.789	rs2658775	chr11:93126799	C/T	cg15737290	chr11:93063684	CCDC67	0.49	6.14	0.35	3.01e-9	Pulmonary function decline;
CESC	cis	rs1059312	0.966	rs12368452	chr12:129277164	C/A	cg09035930	chr12:129282057	SLC15A4	0.75	10.45	0.54	1.28e-21	Systemic lupus erythematosus;
CESC	cis	rs4665809	0.652	rs4665832	chr2:26404775	A/G	cg27170947	chr2:26402098	FAM59B	-0.82	-9.69	-0.51	3.38e-19	Gut microbiome composition (summer);
CESC	cis	rs4862750	0.914	rs1863405	chr4:187874528	G/T	cg03647317	chr4:187891568	NA	0.36	5.26	0.31	3.03e-7	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2997447	0.688	rs17257100	chr1:26439586	C/T	cg24596570	chr1:26146463	FAM54B;LOC646471	0.62	5.33	0.31	2.07e-7	QRS complex (12-leadsum);
CESC	cis	rs7633857	0.532	rs1580254	chr3:160767278	C/T	cg03342759	chr3:160939853	NMD3	-0.44	-5.86	-0.34	1.4e-8	Educational attainment (years of education);
CESC	cis	rs1218582	0.772	rs2335408	chr1:154915977	G/A	cg24250549	chr1:154909240	PMVK	0.71	10.26	0.53	5.23e-21	Prostate cancer;
CESC	cis	rs4819052	0.851	rs2236445	chr21:46678453	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.77	10.33	0.54	3.13e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs2228479	0.702	rs62056100	chr16:89939753	C/T	cg04013166	chr16:89971882	TCF25	0.77	6.46	0.37	4.98e-10	Skin colour saturation;
CESC	cis	rs4654899	1.000	rs6689819	chr1:21472395	A/T	cg05370193	chr1:21551575	ECE1	0.41	6.2	0.36	2.2e-9	Superior frontal gyrus grey matter volume;
CESC	cis	rs875971	0.522	rs7784623	chr7:65395034	T/G	cg05332525	chr7:65337924	VKORC1L1	0.51	6.4	0.37	7.15e-10	Aortic root size;
CESC	cis	rs9733	0.818	rs4970926	chr1:150673684	T/C	cg04414720	chr1:150670196	GOLPH3L	-0.37	-5.19	-0.3	4.19e-7	Tonsillectomy;
CESC	cis	rs796364	0.806	rs11688168	chr2:200916004	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.85	-7.93	-0.44	6.07e-14	Schizophrenia;
CESC	cis	rs7582720	1.000	rs72934715	chr2:203713280	C/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.82	6.88	0.39	4.21e-11	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	trans	rs9858542	0.953	rs12330269	chr3:49513910	G/A	cg21659725	chr3:3221576	CRBN	-0.55	-6.49	-0.37	4.22e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs798554	0.836	rs13243214	chr7:2817455	G/T	cg04166393	chr7:2884313	GNA12	0.58	7.02	0.4	1.89e-11	Height;
CESC	cis	rs10129255	0.536	rs10142951	chr14:107190574	A/G	cg07958169	chr14:107095056	NA	-0.53	-8.25	-0.45	7.29e-15	Kawasaki disease;
CESC	cis	rs2073300	0.609	rs74273791	chr20:23418067	A/T	cg12062639	chr20:23401060	NAPB	1.04	8.1	0.45	1.97e-14	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs6831352	0.879	rs17218003	chr4:100054723	G/C	cg13256891	chr4:100009986	ADH5	-0.77	-8.45	-0.46	1.97e-15	Alcohol dependence;
CESC	cis	rs1568889	1.000	rs7937778	chr11:28104605	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.77	10.83	0.55	7.35e-23	Bipolar disorder;
CESC	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.63	7.15	0.4	8.37e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs6714710	0.603	rs6746768	chr2:98466647	C/T	cg26665480	chr2:98280029	ACTR1B	0.57	8.04	0.44	3.03e-14	Posterior cortical atrophy and Alzheimer's disease;
CESC	cis	rs6142102	0.625	rs6141432	chr20:32548597	A/G	cg08999081	chr20:33150536	PIGU	0.34	5.11	0.3	6.04e-7	Skin pigmentation;
CESC	cis	rs5758511	0.689	rs62240864	chr22:42563889	C/T	cg12850546	chr22:42539477	CYP2D7P1	-0.57	-5.12	-0.3	5.88e-7	Birth weight;
CESC	cis	rs921968	0.565	rs1541777	chr2:219587291	A/G	cg02176678	chr2:219576539	TTLL4	-0.43	-7.59	-0.42	5.51e-13	Mean corpuscular hemoglobin concentration;
CESC	cis	rs55883249	0.957	rs10495572	chr2:9734859	C/G	cg23886495	chr2:9695866	ADAM17	-0.52	-5.19	-0.3	4.13e-7	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
CESC	cis	rs10504229	1.000	rs73609762	chr8:58192695	A/G	cg22535103	chr8:58192502	C8orf71	-1.05	-13.08	-0.63	1.71e-30	Developmental language disorder (linguistic errors);
CESC	cis	rs13106227	0.550	rs1949137	chr4:77387997	C/G	cg20311846	chr4:77356250	SHROOM3	-0.32	-5.78	-0.33	2.12e-8	Eosinophilic esophagitis (pediatric);
CESC	cis	rs1124769	0.871	rs17646461	chr15:51158110	C/T	cg21246271	chr15:51200259	AP4E1	-0.54	-5.14	-0.3	5.29e-7	Cognitive performance;
CESC	cis	rs2576037	0.901	rs2060416	chr18:44576240	G/C	cg19077165	chr18:44547161	KATNAL2	0.55	8.0	0.44	4.02e-14	Personality dimensions;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16554516	chr1:206680868	RASSF5	0.52	6.13	0.35	3.11e-9	Gut microbiome composition (summer);
CESC	cis	rs4803468	1.000	rs3816037	chr19:41918009	C/T	cg14132834	chr19:41945861	ATP5SL	-0.58	-7.23	-0.41	5.22e-12	Height;
CESC	cis	rs4888262	0.564	rs8062404	chr16:74611675	T/C	cg01733217	chr16:74700730	RFWD3	0.83	11.46	0.58	5.96e-25	Testicular germ cell tumor;
CESC	cis	rs3820928	0.874	rs2177594	chr2:227836239	C/G	cg11843606	chr2:227700838	RHBDD1	-0.44	-5.69	-0.33	3.29e-8	Pulmonary function;
CESC	cis	rs35110281	0.744	rs162398	chr21:44949285	T/C	cg21573476	chr21:45109991	RRP1B	-0.37	-5.22	-0.31	3.65e-7	Mean corpuscular volume;
CESC	cis	rs765787	0.530	rs4775834	chr15:45537511	C/T	cg24006582	chr15:45444508	DUOX1	-0.59	-7.32	-0.41	3.04e-12	Uric acid levels;
CESC	cis	rs2835872	0.758	rs1709817	chr21:39036349	T/A	cg06728970	chr21:39037746	KCNJ6	0.3	5.53	0.32	7.57e-8	Electroencephalographic traits in alcoholism;
CESC	cis	rs67311347	0.911	rs9849224	chr3:40392562	T/C	cg09455208	chr3:40491958	NA	0.46	8.07	0.44	2.45e-14	Renal cell carcinoma;
CESC	cis	rs1570884	0.516	rs2094108	chr13:50171550	G/A	cg03651054	chr13:50194643	NA	0.31	5.08	0.3	7.07e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
CESC	trans	rs13398848	1.000	rs10496303	chr2:84210246	C/A	cg23262351	chr6:79576851	IRAK1BP1	-0.69	-6.08	-0.35	4.1e-9	Conduct disorder (symptom count);Conduct disorder;
CESC	cis	rs1799949	0.929	rs799905	chr17:41277187	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	6.93	0.39	3.16e-11	Menopause (age at onset);
CESC	cis	rs12930096	0.938	rs12444653	chr16:11677955	A/C	cg07439791	chr16:11680400	LITAF	0.63	5.76	0.33	2.31e-8	QT interval;
CESC	cis	rs2280018	1.000	rs2280018	chr16:15150833	A/C	cg07549590	chr16:15018862	NA	-0.49	-7.98	-0.44	4.41e-14	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	trans	rs12356475	0.710	rs10822686	chr10:67733250	C/T	cg26665246	chr5:179105570	CBY3	0.5	6.12	0.35	3.36e-9	Psoriatic arthritis;
CESC	cis	rs10927875	0.691	rs1048302	chr1:16340879	T/G	cg21385522	chr1:16154831	NA	0.59	7.09	0.4	1.24e-11	Dilated cardiomyopathy;
CESC	cis	rs228437	0.802	rs228441	chr6:134899931	C/T	cg24504307	chr6:134963096	NA	0.46	5.23	0.31	3.48e-7	Melanoma;
CESC	cis	rs2290159	0.800	rs11709504	chr3:12674199	T/C	cg23032965	chr3:12705835	RAF1	0.53	5.67	0.33	3.76e-8	Cholesterol, total;
CESC	cis	rs2066819	1.000	rs59811639	chr12:56695954	C/T	cg26714650	chr12:56694279	CS	-1.52	-10.39	-0.54	1.95e-21	Psoriasis vulgaris;
CESC	cis	rs7618915	0.501	rs3733039	chr3:52719088	C/T	cg07507251	chr3:52567010	NT5DC2	0.32	5.61	0.33	5.12e-8	Bipolar disorder;
CESC	cis	rs6724607	1.000	rs7598979	chr2:191453375	A/G	cg10560079	chr2:191398806	TMEM194B	0.48	6.93	0.39	3.2e-11	Pulse pressure;
CESC	cis	rs853679	0.517	rs9368558	chr6:28133306	A/G	cg23161317	chr6:28129485	ZNF389	0.52	6.48	0.37	4.37e-10	Depression;
CESC	cis	rs7264396	0.511	rs2425102	chr20:34312303	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.89	-10.75	-0.55	1.33e-22	Total cholesterol levels;
CESC	cis	rs4481887	0.893	rs11204632	chr1:248479532	G/A	cg00666640	chr1:248458726	OR2T12	0.34	5.32	0.31	2.18e-7	Common traits (Other);
CESC	cis	rs6587515	0.901	rs10788795	chr1:150758047	A/G	cg13175981	chr1:150552382	MCL1	0.62	5.23	0.31	3.48e-7	Pericardial adipose tissue adjusted for height and weight;
CESC	cis	rs1008375	0.966	rs4235392	chr4:17696422	A/G	cg16339924	chr4:17578868	LAP3	0.6	7.47	0.42	1.17e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs514406	0.825	rs497535	chr1:53284677	A/G	cg08859206	chr1:53392774	SCP2	0.56	7.3	0.41	3.27e-12	Monocyte count;
CESC	trans	rs7246760	1.000	rs28802413	chr19:9901617	T/C	cg02900749	chr2:68251473	NA	-0.74	-6.84	-0.39	5.62e-11	Pursuit maintenance gain;
CESC	cis	rs1050631	1.000	rs11873168	chr18:33707581	T/C	cg25426722	chr18:33708991	SLC39A6;ELP2	0.45	5.8	0.34	1.89e-8	Esophageal squamous cell cancer (length of survival);
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg08367703	chr9:139304491	SDCCAG3;PMPCA	0.49	6.46	0.37	5.1e-10	Systemic lupus erythematosus;
CESC	cis	rs7582720	1.000	rs72932573	chr2:203861113	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.36	0.41	2.34e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	trans	rs853679	0.546	rs200990	chr6:27815823	T/G	cg06606381	chr12:133084897	FBRSL1	-0.78	-7.42	-0.41	1.63e-12	Depression;
CESC	cis	rs7666738	0.830	rs6818045	chr4:99049374	G/A	cg05340658	chr4:99064831	C4orf37	0.82	12.78	0.62	1.87e-29	Colonoscopy-negative controls vs population controls;
CESC	trans	rs7819412	1.000	rs7819412	chr8:11045161	A/G	cg06636001	chr8:8085503	FLJ10661	0.51	6.46	0.37	5.11e-10	Triglycerides;
CESC	cis	rs3126085	0.673	rs3126089	chr1:152306187	T/A	cg03465714	chr1:152285911	FLG	0.43	5.22	0.31	3.62e-7	Atopic dermatitis;
CESC	cis	rs910316	1.000	rs4899546	chr14:75594946	G/C	cg08847533	chr14:75593920	NEK9	1.0	19.1	0.76	9.46e-52	Height;
CESC	cis	rs7586879	0.681	rs6545800	chr2:25118885	A/G	cg01884057	chr2:25150051	NA	-0.36	-6.99	-0.39	2.21e-11	Body mass index;
CESC	cis	rs1681630	0.545	rs12790666	chr11:47983477	G/A	cg18512352	chr11:47633146	NA	-0.37	-5.82	-0.34	1.68e-8	Height;
CESC	cis	rs2439831	0.850	rs12441984	chr15:44126285	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.63	5.58	0.32	5.87e-8	Lung cancer in ever smokers;
CESC	cis	rs9790314	0.846	rs4290817	chr3:160967354	G/A	cg03342759	chr3:160939853	NMD3	-0.51	-7.39	-0.41	1.96e-12	Morning vs. evening chronotype;
CESC	cis	rs7084402	0.967	rs1658489	chr10:60285924	A/G	cg07615347	chr10:60278583	BICC1	0.59	9.44	0.5	2.04e-18	Refractive error;
CESC	trans	rs116095464	0.558	rs9312979	chr5:222057	A/C	cg00938859	chr5:1591904	SDHAP3	0.66	6.24	0.36	1.72e-9	Breast cancer;
CESC	cis	rs763121	0.962	rs1980455	chr22:38925719	A/C	cg06022373	chr22:39101656	GTPBP1	0.77	12.05	0.59	5.87e-27	Menopause (age at onset);
CESC	cis	rs7666738	0.606	rs6852813	chr4:99084671	G/A	cg17366294	chr4:99064904	C4orf37	0.43	5.77	0.33	2.15e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs875971	0.862	rs1981799	chr7:65955559	T/C	cg11764359	chr7:65958608	NA	0.96	15.06	0.68	1.89e-37	Aortic root size;
CESC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg10243787	chr22:19419481	HIRA;MRPL40	-0.47	-6.15	-0.35	2.8e-9	Age-related hearing impairment (SNP x SNP interaction);
CESC	trans	rs673604	0.505	rs676614	chr1:36107510	G/T	cg05617927	chr15:83654886	FAM103A1	0.51	6.11	0.35	3.52e-9	Endometrial cancer;
CESC	trans	rs208520	0.731	rs12206488	chr6:66999917	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.86	8.87	0.48	1.11e-16	Exhaled nitric oxide output;
CESC	cis	rs1799949	1.000	rs8176120	chr17:41261233	C/T	cg25072359	chr17:41440525	NA	0.45	6.13	0.35	3.21e-9	Menopause (age at onset);
CESC	cis	rs9858542	0.953	rs34363169	chr3:49537712	G/A	cg03060546	chr3:49711283	APEH	-0.54	-6.12	-0.35	3.44e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs514406	0.755	rs10888754	chr1:53228751	C/G	cg24675658	chr1:53192096	ZYG11B	0.54	7.46	0.42	1.2e-12	Monocyte count;
CESC	trans	rs12599106	0.792	rs76039834	chr16:34598453	G/A	cg01516881	chr6:292596	DUSP22	-0.52	-6.81	-0.39	6.34e-11	Menopause (age at onset);
CESC	cis	rs13256369	0.755	rs11776987	chr8:8559401	C/G	cg18904891	chr8:8559673	CLDN23	0.72	7.96	0.44	4.94e-14	Obesity-related traits;
CESC	cis	rs2236918	1.000	rs2236919	chr1:242017731	A/G	cg17736920	chr1:242011382	EXO1	0.74	10.22	0.53	6.83e-21	Menopause (age at onset);
CESC	cis	rs4689388	0.727	rs1801213	chr4:6293696	C/G	cg00701064	chr4:6280414	WFS1	0.54	8.05	0.44	2.73e-14	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs703842	1.000	rs11172343	chr12:58188157	T/C	cg00677455	chr12:58241039	CTDSP2	0.52	6.55	0.37	3.04e-10	Multiple sclerosis;
CESC	cis	rs10242455	0.867	rs776742	chr7:99292755	C/T	cg07715041	chr7:99302981	CYP3A7	0.44	5.56	0.32	6.73e-8	Blood metabolite levels;
CESC	cis	rs561341	0.941	rs8081016	chr17:30331751	A/G	cg23018236	chr17:30244563	NA	-0.53	-5.14	-0.3	5.32e-7	Hip circumference adjusted for BMI;
CESC	trans	rs916888	0.773	rs199445	chr17:44817408	C/T	cg22968622	chr17:43663579	NA	1.3	18.06	0.74	4.28e-48	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs4555082	0.874	rs2142190	chr14:105719306	G/A	cg27165867	chr14:105738592	BRF1	-0.52	-5.57	-0.32	6.41e-8	Mean platelet volume;Platelet distribution width;
CESC	cis	rs3806843	1.000	rs3806845	chr5:140180737	C/T	cg26395211	chr5:140044315	WDR55	-0.41	-5.12	-0.3	5.95e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs11690935	1.000	rs6433311	chr2:172549248	A/G	cg13550731	chr2:172543902	DYNC1I2	1.0	16.64	0.71	4.76e-43	Schizophrenia;
CESC	cis	rs7520050	0.931	rs11211189	chr1:46261584	A/T	cg24296786	chr1:45957014	TESK2	0.44	5.54	0.32	7.17e-8	Red blood cell count;Reticulocyte count;
CESC	cis	rs12142240	1.000	rs12142240	chr1:46747301	T/C	cg00530320	chr1:46809349	NSUN4	0.55	6.87	0.39	4.56e-11	Menopause (age at onset);
CESC	cis	rs3768617	0.811	rs34721094	chr1:183051521	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.67	9.27	0.49	6.9e-18	Fuchs's corneal dystrophy;
CESC	cis	rs67478160	0.643	rs4906369	chr14:104242458	T/C	cg08213375	chr14:104286397	PPP1R13B	0.55	11.0	0.56	1.99e-23	Schizophrenia;
CESC	cis	rs875971	0.862	rs7783779	chr7:65796626	A/G	cg18252515	chr7:66147081	NA	0.45	5.97	0.34	7.65e-9	Aortic root size;
CESC	cis	rs7927771	0.524	rs10838758	chr11:47771476	T/C	cg20307385	chr11:47447363	PSMC3	0.61	8.59	0.47	7.41e-16	Subjective well-being;
CESC	cis	rs11785400	0.753	rs9773415	chr8:143731170	G/A	cg24634471	chr8:143751801	JRK	0.45	5.68	0.33	3.51e-8	Schizophrenia;
CESC	cis	rs67311347	1.000	rs9817142	chr3:40425774	C/A	cg09455208	chr3:40491958	NA	0.49	8.1	0.45	1.99e-14	Renal cell carcinoma;
CESC	cis	rs7666738	0.791	rs6828752	chr4:99063382	C/T	cg18180107	chr4:99064573	C4orf37	0.4	5.14	0.3	5.21e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11608355	0.515	rs61941631	chr12:109935475	C/T	cg05360138	chr12:110035743	NA	0.82	8.85	0.48	1.27e-16	Neuroticism;
CESC	cis	rs6933660	0.800	rs6931104	chr6:151786177	C/T	cg14262678	chr6:151773367	RMND1;C6orf211	0.68	10.01	0.52	3.25e-20	Menarche (age at onset);
CESC	cis	rs9393777	0.513	rs9368450	chr6:26652489	A/C	cg14345882	chr6:26364793	BTN3A2	0.43	5.14	0.3	5.39e-7	Intelligence (multi-trait analysis);
CESC	cis	rs727563	0.608	rs2076200	chr22:41985956	G/T	cg17376030	chr22:41985996	PMM1	0.81	8.45	0.46	1.98e-15	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs7772486	0.790	rs9497431	chr6:146248177	T/C	cg23711669	chr6:146136114	FBXO30	-0.93	-13.61	-0.64	2.34e-32	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs11098499	0.954	rs34858317	chr4:120387110	A/C	cg24375607	chr4:120327624	NA	0.44	5.48	0.32	9.91e-8	Corneal astigmatism;
CESC	cis	rs6952808	0.531	rs3779003	chr7:2184902	C/T	cg08027265	chr7:2291960	NA	-0.47	-7.24	-0.41	4.97e-12	Bipolar disorder and schizophrenia;
CESC	cis	rs13191362	1.000	rs67840803	chr6:163049048	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.89	9.95	0.52	4.99e-20	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs9311474	0.632	rs6445528	chr3:52572447	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.42	-6.25	-0.36	1.62e-9	Electroencephalogram traits;
CESC	cis	rs35306767	0.953	rs11253517	chr10:970524	A/G	cg26597838	chr10:835615	NA	-0.79	-8.98	-0.48	5.17e-17	Eosinophil percentage of granulocytes;
CESC	cis	rs7618915	0.547	rs35211965	chr3:52685305	C/G	cg18404041	chr3:52824283	ITIH1	-0.4	-6.69	-0.38	1.35e-10	Bipolar disorder;
CESC	cis	rs12682352	0.602	rs4841044	chr8:8664940	A/G	cg17143192	chr8:8559678	CLDN23	-0.43	-5.26	-0.31	3.01e-7	Neuroticism;
CESC	cis	rs8067354	0.645	rs72840522	chr17:57829992	G/A	cg13753209	chr17:57696993	CLTC	0.65	7.89	0.44	7.95e-14	Hemoglobin concentration;
CESC	cis	rs6089584	0.850	rs6142938	chr20:60627723	A/C	cg13770153	chr20:60521292	NA	-0.5	-6.53	-0.37	3.31e-10	Body mass index;
CESC	cis	rs2204008	0.837	rs11172728	chr12:38070042	C/A	cg13010199	chr12:38710504	ALG10B	0.47	5.79	0.34	2.01e-8	Bladder cancer;
CESC	cis	rs9399135	0.967	rs6923827	chr6:135335382	C/T	cg22676075	chr6:135203613	NA	0.5	7.08	0.4	1.31e-11	Red blood cell count;
CESC	cis	rs9300255	0.602	rs1727316	chr12:123618603	C/T	cg05973401	chr12:123451056	ABCB9	0.52	5.9	0.34	1.13e-8	Neutrophil percentage of white cells;
CESC	cis	rs3785574	0.638	rs2854182	chr17:61969062	G/A	cg11494091	chr17:61959527	GH2	0.37	5.09	0.3	6.71e-7	Height;
CESC	cis	rs76533333	0.564	rs114940891	chr13:113419784	A/T	cg08557188	chr13:113420371	ATP11A	-0.75	-5.1	-0.3	6.37e-7	Red cell distribution width;
CESC	cis	rs4253772	0.637	rs9627402	chr22:46702586	C/T	cg18190219	chr22:46762943	CELSR1	-0.58	-6.27	-0.36	1.49e-9	LDL cholesterol;Cholesterol, total;
CESC	cis	rs1048238	0.506	rs1262788	chr1:16215608	G/C	cg21385522	chr1:16154831	NA	-0.45	-5.79	-0.33	2.04e-8	Systolic blood pressure;
CESC	cis	rs4604732	0.589	rs78689516	chr1:247626274	C/T	cg12754571	chr1:247694271	LOC148824;OR2C3	0.44	5.44	0.32	1.21e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs4819052	0.851	rs28442024	chr21:46674475	C/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.74	10.06	0.53	2.28e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs6461049	0.765	rs10224497	chr7:2149967	A/G	cg21782813	chr7:2030301	MAD1L1	0.38	5.36	0.31	1.78e-7	Schizophrenia;
CESC	cis	rs11098499	0.955	rs6815725	chr4:120158410	C/A	cg24375607	chr4:120327624	NA	0.43	5.17	0.3	4.57e-7	Corneal astigmatism;
CESC	cis	rs27434	0.583	rs34760	chr5:96153491	T/C	cg16492584	chr5:96139282	ERAP1	-0.38	-5.54	-0.32	7.47e-8	Ankylosing spondylitis;
CESC	cis	rs7605827	0.930	rs7577512	chr2:15623218	G/T	cg19274914	chr2:15703543	NA	0.38	6.74	0.38	9.95e-11	Educational attainment (years of education);
CESC	cis	rs12541335	0.639	rs11135995	chr8:22200148	C/T	cg02788857	chr8:22132959	PIWIL2	-0.34	-6.13	-0.35	3.15e-9	Hypertriglyceridemia;
CESC	cis	rs56804039	1.000	rs58361948	chr8:8380995	C/T	cg15556689	chr8:8085844	FLJ10661	-0.49	-5.28	-0.31	2.66e-7	Cervical cancer;
CESC	cis	rs2243480	0.803	rs13224048	chr7:65993766	G/A	cg18252515	chr7:66147081	NA	-1.4	-14.3	-0.66	9.38e-35	Diabetic kidney disease;
CESC	cis	rs7412746	0.571	rs12402939	chr1:150615094	A/C	cg17724175	chr1:150552817	MCL1	0.41	6.39	0.37	7.27e-10	Melanoma;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg00905354	chr6:170059414	WDR27	0.45	6.33	0.36	1.03e-9	Fibrinogen levels;
CESC	cis	rs7937682	0.924	rs875257	chr11:111530453	A/G	cg22437258	chr11:111473054	SIK2	0.69	9.29	0.5	5.71e-18	Primary sclerosing cholangitis;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05606039	chr17:73511506	TSEN54;CASKIN2	0.48	6.6	0.38	2.2e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs3813567	0.759	rs7163204	chr15:78953740	G/A	cg05914723	chr15:78953907	NA	0.45	5.74	0.33	2.62e-8	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
CESC	cis	rs6933660	0.745	rs9371517	chr6:151739810	G/T	cg14262678	chr6:151773367	RMND1;C6orf211	0.66	9.4	0.5	2.72e-18	Menarche (age at onset);
CESC	cis	rs2124969	0.548	rs72979963	chr2:161014483	A/G	cg03641300	chr2:160917029	PLA2R1	-0.58	-6.01	-0.35	6.14e-9	Waist circumference adjusted for body mass index;
CESC	cis	rs7208859	0.623	rs56325146	chr17:29151024	T/C	cg13385521	chr17:29058706	SUZ12P	0.73	6.0	0.35	6.62e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs684232	0.602	rs331010	chr17:547124	G/A	cg12384639	chr17:618140	VPS53	0.41	5.31	0.31	2.36e-7	Prostate cancer;
CESC	cis	rs1729951	0.546	rs12054218	chr3:136677496	C/G	cg04103450	chr3:136751342	NA	0.4	5.4	0.31	1.47e-7	Neuroticism;
CESC	cis	rs72945132	0.882	rs7118156	chr11:70142922	T/C	cg00319359	chr11:70116639	PPFIA1	0.78	7.71	0.43	2.52e-13	Coronary artery disease;
CESC	cis	rs2204008	0.748	rs7312204	chr12:38334909	T/C	cg13010199	chr12:38710504	ALG10B	0.41	5.26	0.31	2.93e-7	Bladder cancer;
CESC	cis	rs801193	0.569	rs7800620	chr7:66223688	T/C	cg10691866	chr7:65817282	TPST1	-0.33	-5.63	-0.33	4.48e-8	Aortic root size;
CESC	cis	rs2440129	0.611	rs1042356	chr17:6902743	G/A	cg03407747	chr17:6899364	ALOX12	0.48	8.17	0.45	1.29e-14	Tonsillectomy;
CESC	cis	rs2070997	0.607	rs11244148	chr9:133677970	A/G	cg11464064	chr9:133710261	ABL1	0.62	6.72	0.38	1.14e-10	Response to amphetamines;
CESC	cis	rs4975616	0.839	rs2447853	chr5:1333077	A/G	cg07493874	chr5:1342172	CLPTM1L	-0.42	-7.9	-0.44	7.47e-14	Lung cancer;
CESC	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg18402987	chr7:1209562	NA	0.75	7.49	0.42	1.04e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7580658	0.637	rs4580338	chr2:127974937	T/C	cg10021288	chr2:128175891	PROC	-0.37	-5.72	-0.33	2.92e-8	Protein C levels;
CESC	cis	rs6032067	0.777	rs73907811	chr20:43801395	T/A	cg10761708	chr20:43804764	PI3	0.56	6.66	0.38	1.58e-10	Blood protein levels;
CESC	cis	rs6952808	0.609	rs6944877	chr7:1952582	T/G	cg20295408	chr7:1910781	MAD1L1	-0.4	-5.21	-0.3	3.89e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs2832191	0.740	rs13048618	chr21:30458684	A/G	cg24692254	chr21:30365293	RNF160	1.0	17.69	0.74	8.64e-47	Dental caries;
CESC	cis	rs897984	0.806	rs1458202	chr16:30953202	A/G	cg00531865	chr16:30841666	NA	-0.51	-7.14	-0.4	8.76e-12	Dementia with Lewy bodies;
CESC	cis	rs644799	1.000	rs546809	chr11:95579938	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.94	13.87	0.65	3.02e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs738322	0.967	rs4385	chr22:38573229	T/C	cg25457927	chr22:38595422	NA	-0.29	-5.35	-0.31	1.89e-7	Cutaneous nevi;
CESC	cis	rs60843830	0.508	rs300750	chr2:208794	T/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.47	6.01	0.35	6.07e-9	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs6032067	0.929	rs17424696	chr20:43810734	G/A	cg10761708	chr20:43804764	PI3	0.53	6.44	0.37	5.61e-10	Blood protein levels;
CESC	cis	rs2836974	0.932	rs56306759	chr21:40608106	G/A	cg17971929	chr21:40555470	PSMG1	1.05	15.99	0.7	9.33e-41	Cognitive function;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01144275	chr17:79478508	ACTG1	0.53	6.08	0.35	4.07e-9	Gut microbiome composition (summer);
CESC	cis	rs672059	1.000	rs566625	chr1:183161441	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.64	8.74	0.47	2.68e-16	Hypertriglyceridemia;
CESC	cis	rs10883723	0.810	rs12265877	chr10:104247247	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.54	7.48	0.42	1.09e-12	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs7666738	0.830	rs28594127	chr4:99001121	T/G	cg05340658	chr4:99064831	C4orf37	0.8	12.44	0.61	2.83e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6951245	0.872	rs11768895	chr7:1063691	T/C	cg03188948	chr7:1209495	NA	0.6	5.93	0.34	9.51e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs916888	0.647	rs199449	chr17:44808902	G/A	cg01570182	chr17:44337453	NA	0.63	8.66	0.47	4.84e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs6952808	0.965	rs4719318	chr7:1887930	G/A	cg21782813	chr7:2030301	MAD1L1	0.37	5.19	0.3	4.19e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs7818688	1.000	rs9297950	chr8:96025659	A/G	cg16049864	chr8:95962084	TP53INP1	0.61	5.74	0.33	2.62e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs2249625	1.000	rs2496522	chr6:72909076	A/G	cg18830697	chr6:72922368	RIMS1	-0.43	-6.24	-0.36	1.7e-9	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CESC	cis	rs847577	0.722	rs7790736	chr7:97713039	G/A	cg21770322	chr7:97807741	LMTK2	0.64	10.58	0.55	4.59e-22	Breast cancer;
CESC	cis	rs8038465	0.904	rs12594627	chr15:73986264	G/T	cg15420318	chr15:73925796	NPTN	0.41	5.65	0.33	4.21e-8	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs11098499	0.754	rs10212714	chr4:120254302	T/C	cg09307838	chr4:120376055	NA	0.79	10.52	0.54	7.35e-22	Corneal astigmatism;
CESC	cis	rs2718058	0.613	rs2718037	chr7:37777846	G/C	cg24998770	chr7:37888106	TXNDC3	0.36	5.42	0.32	1.34e-7	Alzheimer's disease (late onset);
CESC	cis	rs6088590	1.000	rs6088595	chr20:33358499	T/A	cg24642439	chr20:33292090	TP53INP2	0.84	11.14	0.56	6.84e-24	Coronary artery disease;
CESC	cis	rs7552404	0.545	rs12748741	chr1:76351193	A/G	cg10523679	chr1:76189770	ACADM	-0.59	-5.98	-0.34	7.31e-9	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs9309473	0.519	rs13017182	chr2:73891004	G/T	cg20560298	chr2:73613845	ALMS1	0.52	7.46	0.42	1.21e-12	Metabolite levels;
CESC	cis	rs8018808	0.935	rs17824316	chr14:77930407	G/A	cg20045696	chr14:77926864	AHSA1	0.43	5.9	0.34	1.13e-8	Myeloid white cell count;
CESC	cis	rs2230307	0.536	rs554742	chr1:100512568	G/A	cg24955406	chr1:100503596	HIAT1	0.53	5.08	0.3	7.04e-7	Carotid intima media thickness;
CESC	cis	rs2072499	0.931	rs1052053	chr1:156202173	A/G	cg25208724	chr1:156163844	SLC25A44	0.89	15.68	0.69	1.23e-39	Testicular germ cell tumor;
CESC	cis	rs9381040	0.674	rs3747742	chr6:41162518	C/T	cg20398880	chr6:41068722	NFYA;LOC221442	0.39	5.27	0.31	2.82e-7	Alzheimer's disease (late onset);
CESC	cis	rs1348850	0.567	rs4144276	chr2:178523420	T/C	cg23306229	chr2:178417860	TTC30B	0.52	6.28	0.36	1.36e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs3087591	0.959	rs2051505	chr17:29699859	C/G	cg24425628	chr17:29625626	OMG;NF1	-0.46	-5.86	-0.34	1.38e-8	Hip circumference;
CESC	cis	rs6545883	0.894	rs2694643	chr2:61604383	A/G	cg15711740	chr2:61764176	XPO1	-0.4	-5.11	-0.3	6.31e-7	Tuberculosis;
CESC	cis	rs6754311	0.731	rs687670	chr2:136740900	T/C	cg07169764	chr2:136633963	MCM6	0.69	8.52	0.46	1.22e-15	Mosquito bite size;
CESC	cis	rs1153858	0.943	rs1145079	chr15:45681761	T/C	cg21132104	chr15:45694354	SPATA5L1	0.77	10.24	0.53	5.77e-21	Homoarginine levels;
CESC	cis	rs2404602	0.647	rs10152247	chr15:76942252	T/G	cg23625390	chr15:77176239	SCAPER	-0.45	-6.27	-0.36	1.47e-9	Blood metabolite levels;
CESC	cis	rs2019216	0.521	rs2175657	chr17:21908494	T/G	cg22648282	chr17:21454238	C17orf51	-0.45	-5.89	-0.34	1.19e-8	Pelvic organ prolapse;
CESC	cis	rs4665809	1.000	rs2384321	chr2:26290054	A/G	cg22920501	chr2:26401640	FAM59B	-0.79	-9.3	-0.5	5.61e-18	Gut microbiome composition (summer);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg22281935	chr2:162934111	NA	-0.43	-6.33	-0.36	1.05e-9	Gut microbiota (bacterial taxa);
CESC	trans	rs561341	1.000	rs4795667	chr17:30244443	T/C	cg27661571	chr11:113659931	NA	-0.71	-7.13	-0.4	9.68e-12	Hip circumference adjusted for BMI;
CESC	cis	rs7078219	0.965	rs7081858	chr10:101274565	G/A	cg09788492	chr10:101292477	NKX2-3	0.29	5.29	0.31	2.62e-7	Dental caries;
CESC	cis	rs5753618	0.561	rs2078803	chr22:31652852	G/A	cg02404636	chr22:31891804	SFI1	-0.39	-5.09	-0.3	6.68e-7	Colorectal cancer;
CESC	cis	rs10774547	1.000	rs4766962	chr12:120863235	A/T	cg12219531	chr12:120966889	COQ5	0.43	5.46	0.32	1.09e-7	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
CESC	cis	rs694739	0.628	rs11606081	chr11:64137875	T/C	cg02228329	chr11:64053129	BAD;GPR137	0.62	7.67	0.43	3.25e-13	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CESC	cis	rs6952808	0.531	rs1107351	chr7:2177093	G/A	cg21782813	chr7:2030301	MAD1L1	0.49	6.94	0.39	2.98e-11	Bipolar disorder and schizophrenia;
CESC	trans	rs801193	1.000	rs7788576	chr7:66148302	G/A	cg26939375	chr7:64535504	NA	-0.64	-8.61	-0.47	6.84e-16	Aortic root size;
CESC	cis	rs2380220	0.541	rs72928283	chr6:96082490	A/C	cg04719120	chr6:96025338	MANEA	-0.64	-6.82	-0.39	6.23e-11	Behavioural disinhibition (generation interaction);
CESC	cis	rs11252926	0.545	rs1551508	chr10:555469	A/G	cg03684893	chr10:554711	DIP2C	-0.44	-6.88	-0.39	4.2e-11	Psychosis in Alzheimer's disease;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg09366861	chr1:211556286	C1orf97	0.49	6.33	0.36	1.04e-9	Systemic lupus erythematosus;
CESC	cis	rs3820068	0.608	rs12091750	chr1:16042766	T/C	cg17385448	chr1:15911702	AGMAT	0.38	6.08	0.35	4.28e-9	Systolic blood pressure;
CESC	cis	rs113835537	0.529	rs2298806	chr11:66282095	G/A	cg24851651	chr11:66362959	CCS	0.45	5.55	0.32	6.92e-8	Airway imaging phenotypes;
CESC	cis	rs8072100	0.840	rs9895746	chr17:45479099	C/A	cg08085267	chr17:45401833	C17orf57	-0.53	-7.1	-0.4	1.14e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs950169	0.881	rs150965	chr15:85080527	T/G	cg17507749	chr15:85114479	UBE2QP1	0.58	6.56	0.37	2.82e-10	Schizophrenia;
CESC	cis	rs1008375	1.000	rs6846238	chr4:17629939	A/G	cg16339924	chr4:17578868	LAP3	0.64	8.12	0.45	1.79e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs4604732	0.631	rs11490198	chr1:247625703	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.57	7.17	0.4	7.39e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs11867934	0.531	rs3803761	chr17:17116412	A/G	cg20098446	chr17:17120238	FLCN	0.38	5.99	0.35	6.78e-9	Diabetic retinopathy;
CESC	cis	rs6912958	0.728	rs7773906	chr6:88251869	T/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-6.55	-0.37	3.03e-10	Monocyte percentage of white cells;
CESC	cis	rs7949030	0.626	rs11231145	chr11:62328854	G/A	cg23462726	chr11:62437636	C11orf83;C11orf48	-0.39	-5.06	-0.3	7.68e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs7811142	0.830	rs73401450	chr7:99981859	G/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.08	10.92	0.56	3.59e-23	Platelet count;
CESC	cis	rs2842992	0.872	rs1570318	chr6:160111473	C/T	cg11366901	chr6:160182831	ACAT2	0.76	9.68	0.51	3.64e-19	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs7937682	0.855	rs11213985	chr11:111581521	C/A	cg22437258	chr11:111473054	SIK2	0.68	8.94	0.48	6.91e-17	Primary sclerosing cholangitis;
CESC	cis	rs1801251	0.752	rs709938	chr2:233746457	C/T	cg25237894	chr2:233734115	C2orf82	-0.49	-8.71	-0.47	3.36e-16	Coronary artery disease;
CESC	cis	rs1552244	1.000	rs34179822	chr3:10140017	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.85	-12.15	-0.6	2.74e-27	Alzheimer's disease;
CESC	cis	rs854765	0.547	rs2955370	chr17:17966945	C/T	cg09796270	chr17:17721594	SREBF1	-0.38	-5.16	-0.3	4.93e-7	Total body bone mineral density;
CESC	cis	rs11078597	0.671	rs62090058	chr17:1645624	G/C	cg18436246	chr17:1640651	WDR81	0.62	7.59	0.42	5.36e-13	Serum albumin level;
CESC	cis	rs9302635	0.513	rs9923575	chr16:72230112	C/T	cg01557791	chr16:72042693	DHODH	-0.63	-6.64	-0.38	1.76e-10	Blood protein levels;
CESC	cis	rs2228479	0.850	rs12597299	chr16:89822364	C/A	cg00800038	chr16:89945340	TCF25	-0.91	-7.54	-0.42	7.39e-13	Skin colour saturation;
CESC	trans	rs60843830	1.000	rs79716074	chr2:277003	A/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.68	8.6	0.47	7.3e-16	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs9399135	0.933	rs28384512	chr6:135376232	C/T	cg22676075	chr6:135203613	NA	0.5	7.07	0.4	1.34e-11	Red blood cell count;
CESC	cis	rs8067354	0.958	rs2777889	chr17:57848006	A/G	cg02344993	chr17:57696989	CLTC	0.48	6.21	0.36	2.06e-9	Hemoglobin concentration;
CESC	cis	rs1475911	0.708	rs56185023	chr21:43521538	T/C	cg19766460	chr21:43528205	UMODL1;C21orf128	0.95	13.13	0.63	1.17e-30	IgG glycosylation;
CESC	cis	rs7618915	0.501	rs34157897	chr3:52716937	T/C	cg05564831	chr3:52568323	NT5DC2	0.46	7.33	0.41	2.88e-12	Bipolar disorder;
CESC	cis	rs35995292	0.534	rs2392607	chr7:38930380	G/A	cg19327137	chr7:38886074	VPS41	0.66	10.9	0.56	4.24e-23	Subjective well-being (multi-trait analysis);
CESC	cis	rs7212590	0.581	rs57812342	chr17:57827154	A/G	cg20303301	chr17:57937339	TUBD1	-0.56	-5.06	-0.3	7.79e-7	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs7267979	1.000	rs2258769	chr20:25276680	G/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	18.72	0.75	2.09e-50	Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs3942852	0.688	rs10742834	chr11:48169717	G/A	cg15704280	chr7:45808275	SEPT13	-0.72	-8.13	-0.45	1.69e-14	Acute lymphoblastic leukemia (childhood);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg11472173	chr17:41624099	ETV4	-0.43	-6.08	-0.35	4.2e-9	Gambling;
CESC	cis	rs909002	0.749	rs10914462	chr1:32125943	A/G	cg13919466	chr1:32135498	COL16A1	0.41	7.14	0.4	9.18e-12	Intelligence (multi-trait analysis);
CESC	cis	rs4819052	0.851	rs7275874	chr21:46671223	C/T	cg11663144	chr21:46675770	NA	-0.64	-10.05	-0.53	2.34e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs3772130	0.527	rs2141614	chr3:121590173	G/A	cg20356878	chr3:121714668	ILDR1	0.43	6.31	0.36	1.19e-9	Cognitive performance;
CESC	trans	rs916888	0.531	rs183211	chr17:44788310	G/A	cg22433210	chr17:43662623	NA	0.58	7.2	0.4	6.19e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs6991838	0.557	rs7012578	chr8:66504827	A/C	cg13398993	chr8:66546079	ARMC1	-0.47	-5.59	-0.32	5.56e-8	Intelligence (multi-trait analysis);
CESC	cis	rs7727544	0.606	rs2631360	chr5:131707429	A/G	cg24060327	chr5:131705240	SLC22A5	-0.41	-5.04	-0.3	8.72e-7	Blood metabolite levels;
CESC	cis	rs7666738	0.791	rs34088022	chr4:99001508	G/T	cg18180107	chr4:99064573	C4orf37	0.4	5.23	0.31	3.41e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs854765	0.583	rs4925130	chr17:17807858	G/A	cg09796270	chr17:17721594	SREBF1	0.46	6.44	0.37	5.57e-10	Total body bone mineral density;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg20662616	chr2:30454643	LBH	-0.44	-6.67	-0.38	1.51e-10	Gambling;
CESC	cis	rs250677	1.000	rs28173	chr5:148423573	C/T	cg18129178	chr5:148520854	ABLIM3	-0.47	-5.52	-0.32	8.26e-8	Breast cancer;
CESC	cis	rs9660180	0.967	rs61422524	chr1:1767565	C/A	cg03396347	chr1:1875803	NA	-0.43	-6.75	-0.38	9.5e-11	Body mass index;
CESC	cis	rs6460942	0.908	rs78682952	chr7:12284886	C/A	cg20607287	chr7:12443886	VWDE	-0.57	-6.07	-0.35	4.48e-9	Coronary artery disease;
CESC	trans	rs4950322	0.580	rs72706428	chr1:146581801	G/A	cg04954894	chr8:38089920	DDHD2	-0.59	-6.42	-0.37	6.22e-10	Protein quantitative trait loci;
CESC	cis	rs1568889	1.000	rs12790932	chr11:28046189	G/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.76	10.49	0.54	9.55e-22	Bipolar disorder;
CESC	cis	rs6952808	0.792	rs12531315	chr7:1953650	C/G	cg21782813	chr7:2030301	MAD1L1	0.42	6.13	0.35	3.12e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs561341	1.000	rs508192	chr17:30315147	C/T	cg19193384	chr17:30244184	NA	0.64	5.9	0.34	1.11e-8	Hip circumference adjusted for BMI;
CESC	cis	rs1707322	0.963	rs34907901	chr1:46405214	T/G	cg06784218	chr1:46089804	CCDC17	0.35	6.1	0.35	3.78e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2708240	0.617	rs2710107	chr7:147593314	A/C	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.37	-6.2	-0.36	2.17e-9	QT interval (drug interaction);
CESC	cis	rs7592578	0.639	rs61709084	chr2:191287685	A/C	cg27211696	chr2:191398769	TMEM194B	-0.6	-6.15	-0.35	2.88e-9	Diastolic blood pressure;
CESC	cis	rs4072980	0.545	rs7528185	chr1:38452059	C/T	cg17077180	chr1:38461687	NA	-0.42	-5.84	-0.34	1.56e-8	Coronary artery disease;
CESC	cis	rs7618501	0.966	rs9882639	chr3:49799475	A/C	cg24308560	chr3:49941425	MST1R	-0.52	-7.18	-0.4	7.15e-12	Intelligence (multi-trait analysis);
CESC	cis	rs2180341	0.538	rs11556354	chr6:127664661	G/A	cg27446573	chr6:127587934	RNF146	0.53	7.24	0.41	4.9e-12	Breast cancer;
CESC	cis	rs7824557	0.592	rs920044	chr8:11224313	C/T	cg21775007	chr8:11205619	TDH	0.48	6.96	0.39	2.62e-11	Retinal vascular caliber;
CESC	cis	rs6460942	0.749	rs62448592	chr7:12435985	A/T	cg17427002	chr7:12443146	VWDE	-0.53	-5.18	-0.3	4.34e-7	Coronary artery disease;
CESC	cis	rs6502050	0.835	rs4789670	chr17:80151805	T/C	cg23985595	chr17:80112537	CCDC57	-0.4	-6.33	-0.36	1.03e-9	Life satisfaction;
CESC	cis	rs34779708	0.643	rs4275563	chr10:35545286	G/A	cg04310649	chr10:35416472	CREM	-0.45	-5.21	-0.3	3.84e-7	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs2180341	1.000	rs7453272	chr6:127633959	C/T	cg24812749	chr6:127587940	RNF146	-0.99	-13.09	-0.63	1.5e-30	Breast cancer;
CESC	cis	rs6502050	0.835	rs66531647	chr17:80089022	G/T	cg23985595	chr17:80112537	CCDC57	-0.42	-6.6	-0.38	2.18e-10	Life satisfaction;
CESC	cis	rs10504229	0.775	rs17805074	chr8:58161048	C/T	cg22535103	chr8:58192502	C8orf71	0.94	10.25	0.53	5.56e-21	Developmental language disorder (linguistic errors);
CESC	cis	rs763121	0.853	rs6001214	chr22:39149155	C/T	cg14440974	chr22:39074834	NA	-0.37	-5.09	-0.3	6.78e-7	Menopause (age at onset);
CESC	cis	rs1799949	1.000	rs8176220	chr17:41222462	A/G	cg06001716	chr17:41278141	BRCA1;NBR2	0.4	5.35	0.31	1.9e-7	Menopause (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04839274	chr20:30160903	NA	0.58	6.58	0.37	2.56e-10	Gut microbiome composition (summer);
CESC	cis	rs2361718	0.500	rs12451697	chr17:78100690	T/A	cg23534315	chr17:78082725	GAA	0.36	5.16	0.3	4.77e-7	Yeast infection;
CESC	cis	rs6066835	0.702	rs6095228	chr20:47279876	A/G	cg18078177	chr20:47281410	PREX1	-0.69	-5.58	-0.32	5.9e-8	Multiple myeloma;
CESC	cis	rs651907	0.557	rs3806653	chr3:101396972	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.47	6.02	0.35	5.82e-9	Colorectal cancer;
CESC	cis	rs7714584	1.000	rs1896708	chr5:150245076	A/T	cg22134413	chr5:150180641	NA	0.5	5.53	0.32	7.61e-8	Crohn's disease;
CESC	cis	rs7949030	0.596	rs11231137	chr11:62315699	G/A	cg11742103	chr11:62369870	EML3;MTA2	0.54	7.59	0.42	5.35e-13	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs9790314	0.934	rs462413	chr3:161101587	T/C	cg03342759	chr3:160939853	NMD3	-0.47	-6.07	-0.35	4.45e-9	Morning vs. evening chronotype;
CESC	cis	rs7662987	0.517	rs2851286	chr4:100014976	A/G	cg12011299	chr4:100065546	ADH4	-0.67	-7.18	-0.4	7.19e-12	Smoking initiation;
CESC	cis	rs10504229	0.728	rs72650852	chr8:58150463	G/A	cg24829409	chr8:58192753	C8orf71	-0.68	-8.19	-0.45	1.11e-14	Developmental language disorder (linguistic errors);
CESC	cis	rs826838	1.000	rs11609286	chr12:38875511	A/G	cg13010199	chr12:38710504	ALG10B	-0.6	-8.38	-0.46	3.22e-15	Heart rate;
CESC	cis	rs9487051	0.768	rs445796	chr6:109520145	T/C	cg01475377	chr6:109611718	NA	-0.45	-6.86	-0.39	4.74e-11	Reticulocyte fraction of red cells;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg25722142	chr6:139695762	CITED2	0.53	6.95	0.39	2.86e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs2228479	0.681	rs10153196	chr16:89967397	A/C	cg00800038	chr16:89945340	TCF25	-0.59	-6.29	-0.36	1.33e-9	Skin colour saturation;
CESC	cis	rs6502050	0.777	rs6502058	chr17:80082500	A/C	cg11859384	chr17:80120422	CCDC57	0.38	5.12	0.3	6.01e-7	Life satisfaction;
CESC	cis	rs1707322	1.000	rs6429580	chr1:46275648	A/G	cg05343316	chr1:45956843	TESK2	0.42	5.2	0.3	3.95e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs13064411	0.696	rs6768648	chr3:113234141	C/G	cg18753928	chr3:113234510	CCDC52	-0.51	-6.17	-0.35	2.52e-9	Response to simvastatin treatment (PCSK9 protein level change);
CESC	cis	rs12950390	0.893	rs4239166	chr17:45847329	A/G	cg00777063	chr17:45855553	NA	-0.41	-6.14	-0.35	3.03e-9	IgG glycosylation;
CESC	cis	rs763121	0.853	rs5757226	chr22:39070550	T/C	cg06544989	chr22:39130855	UNC84B	0.5	8.88	0.48	1.05e-16	Menopause (age at onset);
CESC	cis	rs116095464	1.000	rs56235400	chr5:312625	G/A	cg22857025	chr5:266934	NA	-1.19	-10.37	-0.54	2.3e-21	Breast cancer;
CESC	cis	rs17376456	0.569	rs2924374	chr5:93151141	T/C	cg21475434	chr5:93447410	FAM172A	-0.51	-5.18	-0.3	4.41e-7	Diabetic retinopathy;
CESC	cis	rs2295499	0.782	rs111559317	chr4:2719058	A/G	cg27239842	chr4:2403781	ZFYVE28	-0.31	-5.1	-0.3	6.51e-7	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
CESC	cis	rs7666738	0.830	rs4443293	chr4:99063120	G/A	cg05340658	chr4:99064831	C4orf37	0.84	13.04	0.63	2.35e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.55	-6.17	-0.35	2.48e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs9868809	0.772	rs12107418	chr3:48689787	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.64	-5.53	-0.32	7.69e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs9814567	1.000	rs62271514	chr3:134298554	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.44	6.0	0.35	6.44e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs7546094	1.000	rs10745330	chr1:113083439	C/T	cg22162597	chr1:113214053	CAPZA1	0.36	5.44	0.32	1.24e-7	Platelet distribution width;
CESC	cis	rs6587515	0.901	rs11204700	chr1:150660702	C/T	cg13175981	chr1:150552382	MCL1	0.62	5.65	0.33	4.23e-8	Pericardial adipose tissue adjusted for height and weight;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg08424427	chr5:180670815	SNORD95;GNB2L1	-0.44	-6.05	-0.35	4.86e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg02996269	chr4:106394692	PPA2	-0.46	-6.44	-0.37	5.54e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19846264	chr17:4125408	ANKFY1	-0.65	-7.69	-0.43	2.89e-13	Gut microbiome composition (summer);
CESC	cis	rs514406	0.893	rs476108	chr1:53317351	C/T	cg08859206	chr1:53392774	SCP2	-0.65	-8.93	-0.48	7.24e-17	Monocyte count;
CESC	cis	rs6951245	0.744	rs10275401	chr7:1213943	A/C	cg18402987	chr7:1209562	NA	0.78	8.65	0.47	4.88e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs798554	0.757	rs1182179	chr7:2873648	A/G	cg09658497	chr7:2847517	GNA12	-0.43	-6.11	-0.35	3.49e-9	Height;
CESC	cis	rs13191362	0.810	rs28360533	chr6:162996742	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.5	5.17	0.3	4.64e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs3008870	0.959	rs56707923	chr1:67388016	T/C	cg08660285	chr1:67390436	MIER1;WDR78	1.06	14.98	0.68	3.54e-37	Lymphocyte percentage of white cells;
CESC	cis	rs7267979	0.834	rs6115100	chr20:25225938	C/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.82	15.6	0.69	2.21e-39	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs10504229	1.000	rs114312649	chr8:58182539	C/G	cg22535103	chr8:58192502	C8orf71	-1.05	-13.08	-0.63	1.71e-30	Developmental language disorder (linguistic errors);
CESC	cis	rs2016266	0.787	rs4520636	chr12:53752133	G/T	cg26875137	chr12:53738046	NA	0.36	5.14	0.3	5.34e-7	Bone mineral density (spine);Bone mineral density;
CESC	cis	rs2569991	0.636	rs361225	chr3:12920171	G/T	cg22481960	chr3:13008800	IQSEC1	-0.52	-6.07	-0.35	4.51e-9	Periodontitis (DPAL);
CESC	cis	rs9513593	0.901	rs7335579	chr13:99939769	G/C	cg21788972	chr13:99853209	UBAC2	-0.56	-6.68	-0.38	1.36e-10	Psoriasis;
CESC	cis	rs7927771	0.965	rs12364432	chr11:47902883	G/A	cg20135002	chr11:47629003	NA	-0.4	-5.23	-0.31	3.37e-7	Subjective well-being;
CESC	cis	rs4665809	1.000	rs6546727	chr2:26275282	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.69	-7.63	-0.42	4.32e-13	Gut microbiome composition (summer);
CESC	cis	rs3858526	0.523	rs10769289	chr11:5886607	C/T	cg13902645	chr11:5959945	NA	-0.68	-10.46	-0.54	1.14e-21	DNA methylation (variation);
CESC	cis	rs910316	1.000	rs7156328	chr14:75532941	T/C	cg08847533	chr14:75593920	NEK9	1.0	18.9	0.76	5.02e-51	Height;
CESC	cis	rs9910055	0.664	rs433610	chr17:42197281	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.59	-7.64	-0.42	4e-13	Total body bone mineral density;
CESC	cis	rs9811920	0.609	rs793466	chr3:99609837	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.59	7.22	0.41	5.61e-12	Axial length;
CESC	cis	rs9291683	0.507	rs6845554	chr4:10013173	T/G	cg11266682	chr4:10021025	SLC2A9	0.68	13.13	0.63	1.11e-30	Bone mineral density;
CESC	cis	rs11673344	0.528	rs491326	chr19:37410939	G/A	cg27390819	chr19:37464633	NA	-0.35	-5.16	-0.3	4.77e-7	Obesity-related traits;
CESC	cis	rs1018836	0.923	rs11784529	chr8:91640956	C/A	cg16814680	chr8:91681699	NA	-0.75	-10.66	-0.55	2.51e-22	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs67478160	0.643	rs2024667	chr14:104211529	T/G	cg08213375	chr14:104286397	PPP1R13B	0.54	10.89	0.56	4.58e-23	Schizophrenia;
CESC	cis	rs35110281	0.693	rs2251253	chr21:45092257	T/A	cg01579765	chr21:45077557	HSF2BP	-0.52	-9.24	-0.49	8.14e-18	Mean corpuscular volume;
CESC	cis	rs13256369	1.000	rs10110591	chr8:8576608	G/T	cg17143192	chr8:8559678	CLDN23	-0.73	-9.0	-0.48	4.36e-17	Obesity-related traits;
CESC	cis	rs909674	0.524	rs5750821	chr22:39825492	A/T	cg11247378	chr22:39784982	NA	-0.64	-9.59	-0.51	7.09e-19	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs2439831	0.681	rs484846	chr15:43600803	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	13.21	0.63	6.03e-31	Lung cancer in ever smokers;
CESC	cis	rs854765	0.583	rs4925130	chr17:17807858	G/A	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.47	6.0	0.35	6.51e-9	Total body bone mineral density;
CESC	cis	rs2839186	0.681	rs13047198	chr21:47701835	T/C	cg02776659	chr21:47717406	C21orf57	-0.35	-5.2	-0.3	3.94e-7	Testicular germ cell tumor;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05721645	chr1:246729578	CNST;TFB2M	0.54	6.09	0.35	4.02e-9	Gut microbiome composition (summer);
CESC	cis	rs2645694	0.626	rs2645684	chr4:77819892	A/C	cg18351406	chr4:77819688	ANKRD56	0.54	6.79	0.38	7.56e-11	Emphysema distribution in smoking;
CESC	cis	rs13064411	0.696	rs2129434	chr3:113138763	A/C	cg18753928	chr3:113234510	CCDC52	-0.51	-6.14	-0.35	3.05e-9	Response to simvastatin treatment (PCSK9 protein level change);
CESC	cis	rs738322	0.967	rs133018	chr22:38572761	G/A	cg25457927	chr22:38595422	NA	-0.3	-5.46	-0.32	1.1e-7	Cutaneous nevi;
CESC	cis	rs1957429	0.901	rs1467569	chr14:65347986	T/C	cg23373153	chr14:65346875	NA	0.96	11.49	0.58	4.43e-25	Pediatric areal bone mineral density (radius);
CESC	cis	rs4713118	0.621	rs10484403	chr6:28033523	A/G	cg26335602	chr6:28129616	ZNF389	0.47	6.23	0.36	1.86e-9	Parkinson's disease;
CESC	cis	rs854765	0.619	rs6502636	chr17:17983817	A/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.46	5.82	0.34	1.7e-8	Total body bone mineral density;
CESC	trans	rs6964833	0.935	rs34762099	chr7:74050694	T/C	cg07504079	chr7:72649617	NCF1B	-0.55	-6.18	-0.35	2.43e-9	Menarche (age at onset);
CESC	cis	rs6732160	0.809	rs6728959	chr2:73383327	C/T	cg01422370	chr2:73384389	NA	0.44	7.59	0.42	5.4e-13	Intelligence (multi-trait analysis);
CESC	cis	rs4862750	0.872	rs13143414	chr4:187878213	G/A	cg03452623	chr4:187889614	NA	-0.94	-18.99	-0.76	2.42e-51	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4665809	1.000	rs4665308	chr2:26330514	C/A	cg25036284	chr2:26402008	FAM59B	-0.59	-6.88	-0.39	4.37e-11	Gut microbiome composition (summer);
CESC	cis	rs4523957	0.855	rs11078883	chr17:2138828	C/G	cg16513277	chr17:2031491	SMG6	-0.57	-7.69	-0.43	2.97e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs34779708	0.801	rs34592588	chr10:35540134	A/G	cg03585969	chr10:35415529	CREM	0.57	6.54	0.37	3.19e-10	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs1003719	0.788	rs60447195	chr21:38448600	A/T	cg10648535	chr21:38446584	PIGP;TTC3	0.62	8.64	0.47	5.56e-16	Eye color traits;
CESC	cis	rs643506	0.817	rs658373	chr11:111682991	T/C	cg17089665	chr11:111648010	NA	-0.36	-5.25	-0.31	3.11e-7	Breast cancer;
CESC	trans	rs11098499	0.731	rs10015579	chr4:120271802	T/C	cg25214090	chr10:38739885	LOC399744	0.6	8.36	0.46	3.68e-15	Corneal astigmatism;
CESC	cis	rs3126085	0.935	rs4845745	chr1:152185184	C/T	cg03465714	chr1:152285911	FLG	-0.43	-5.16	-0.3	4.81e-7	Atopic dermatitis;
CESC	cis	rs4713118	0.662	rs149900	chr6:28014597	C/T	cg19592336	chr6:28129416	ZNF389	0.53	6.51	0.37	3.7e-10	Parkinson's disease;
CESC	cis	rs1559088	0.546	rs11881543	chr19:33559372	T/G	cg17764715	chr19:33622953	WDR88	0.6	8.42	0.46	2.45e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs7809950	0.954	rs2520245	chr7:107137428	G/C	cg23024343	chr7:107201750	COG5	-0.44	-6.21	-0.36	2.03e-9	Coronary artery disease;
CESC	cis	rs1475911	1.000	rs2839467	chr21:43513200	A/G	cg24372256	chr21:43528868	UMODL1;C21orf128	0.43	6.17	0.35	2.55e-9	IgG glycosylation;
CESC	cis	rs2228479	0.850	rs17233448	chr16:89816424	G/T	cg19635926	chr16:89946313	TCF25	0.67	5.09	0.3	6.82e-7	Skin colour saturation;
CESC	trans	rs916888	0.773	rs199439	chr17:44793503	A/G	cg01341218	chr17:43662625	NA	0.92	10.98	0.56	2.25e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs34779708	0.966	rs7913615	chr10:35422957	T/G	cg03585969	chr10:35415529	CREM	0.76	9.94	0.52	5.31e-20	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs67478160	0.643	rs1535098	chr14:104216513	T/A	cg01849466	chr14:104193079	ZFYVE21	-0.5	-7.06	-0.4	1.45e-11	Schizophrenia;
CESC	cis	rs6502050	0.835	rs8078795	chr17:80126320	C/T	cg23985595	chr17:80112537	CCDC57	-0.41	-6.57	-0.37	2.61e-10	Life satisfaction;
CESC	cis	rs2637266	1.000	rs1907298	chr10:78329928	A/T	cg18941641	chr10:78392320	NA	0.41	7.45	0.42	1.3e-12	Pulmonary function;
CESC	cis	rs2361718	0.967	rs2361719	chr17:78103403	A/G	cg06718696	chr17:78121285	EIF4A3	-0.5	-6.75	-0.38	9.39e-11	Yeast infection;
CESC	cis	rs9926296	0.607	rs2079672	chr16:89884917	A/G	cg07648498	chr16:89883185	FANCA	-0.43	-5.23	-0.31	3.48e-7	Vitiligo;
CESC	cis	rs13191362	0.935	rs66635391	chr6:162964577	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.77	7.24	0.41	4.88e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs13082711	0.911	rs13075550	chr3:27427618	A/G	cg02860705	chr3:27208620	NA	0.56	6.89	0.39	4.13e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CESC	cis	rs1499614	0.803	rs1796229	chr7:66119661	G/A	cg18252515	chr7:66147081	NA	-1.42	-14.43	-0.66	3.04e-35	Gout;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09205801	chr11:34378956	ABTB2	0.56	6.38	0.36	7.83e-10	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17983724	chr7:72298804	TYW1B;SBDSP	0.61	6.93	0.39	3.24e-11	Gut microbiome composition (summer);
CESC	cis	rs4555082	0.874	rs11625098	chr14:105756891	A/G	cg27165867	chr14:105738592	BRF1	-0.51	-5.21	-0.31	3.72e-7	Mean platelet volume;Platelet distribution width;
CESC	cis	rs6860806	0.507	rs273901	chr5:131694360	G/T	cg24060327	chr5:131705240	SLC22A5	-0.75	-10.36	-0.54	2.45e-21	Breast cancer;
CESC	cis	rs4563143	0.634	rs113736470	chr19:29240125	G/A	cg04546413	chr19:29218101	NA	0.57	8.55	0.46	1.03e-15	Methadone dose in opioid dependence;
CESC	cis	rs6500395	1.000	rs12599744	chr16:48716729	G/A	cg04672837	chr16:48644449	N4BP1	-0.51	-6.51	-0.37	3.67e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs10129255	0.500	rs988132	chr14:107184997	C/T	cg23076370	chr14:107095027	NA	-0.63	-9.22	-0.49	9.9e-18	Kawasaki disease;
CESC	cis	rs6815814	0.950	rs5743560	chr4:38806200	G/T	cg02016764	chr4:38805732	TLR1	-0.63	-7.26	-0.41	4.22e-12	Breast cancer;
CESC	cis	rs72945132	0.882	rs7123602	chr11:70181489	C/T	cg14191688	chr11:70257035	CTTN	0.42	5.36	0.31	1.84e-7	Coronary artery disease;
CESC	cis	rs853679	0.769	rs7752448	chr6:28301099	A/G	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.75	6.65	0.38	1.65e-10	Depression;
CESC	cis	rs7561273	0.586	rs13418279	chr2:24349218	G/T	cg20701182	chr2:24300061	SF3B14	0.46	6.01	0.35	6.27e-9	Quantitative traits;
CESC	cis	rs8177253	0.901	rs9843728	chr3:133501407	C/T	cg11941060	chr3:133502564	NA	-0.41	-5.59	-0.32	5.66e-8	Iron status biomarkers;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20986608	chr11:65733627	SART1	-0.54	-6.26	-0.36	1.52e-9	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14806418	chr10:131904271	NA	-0.56	-6.43	-0.37	5.99e-10	Gut microbiome composition (summer);
CESC	cis	rs4766566	0.694	rs3843673	chr12:111746499	A/G	cg10833066	chr12:111807467	FAM109A	0.32	5.13	0.3	5.64e-7	Atrial fibrillation;Renal underexcretion gout;Gout;Renal overload gout;
CESC	cis	rs2228479	1.000	rs62052186	chr16:89969567	A/T	cg06558623	chr16:89946397	TCF25	1.14	8.82	0.48	1.55e-16	Skin colour saturation;
CESC	cis	rs896854	0.654	rs13281625	chr8:95972738	T/C	cg23172400	chr8:95962367	TP53INP1	-0.44	-9.04	-0.49	3.45e-17	Type 2 diabetes;
CESC	cis	rs12586317	0.547	rs78609489	chr14:35497285	T/C	cg16230307	chr14:35515116	FAM177A1	1.11	11.72	0.58	7.81e-26	Psoriasis;
CESC	cis	rs9467711	0.659	rs35555795	chr6:26509382	C/T	cg14345882	chr6:26364793	BTN3A2	0.62	5.11	0.3	6.12e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs3785574	0.962	rs62077512	chr17:61851435	C/T	cg07677032	chr17:61819896	STRADA	0.41	5.22	0.31	3.57e-7	Height;
CESC	cis	rs10791097	0.694	rs6590520	chr11:130747386	C/G	cg12179176	chr11:130786555	SNX19	0.64	9.92	0.52	6.17e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs7193541	0.550	rs28607667	chr16:74476015	C/T	cg01733217	chr16:74700730	RFWD3	-0.68	-9.31	-0.5	5.03e-18	Multiple myeloma;
CESC	cis	rs8141529	0.748	rs5762881	chr22:29289346	C/A	cg15103426	chr22:29168792	CCDC117	0.61	7.95	0.44	5.34e-14	Lymphocyte counts;
CESC	cis	rs9488822	0.676	rs12190737	chr6:116328128	C/A	cg05304507	chr6:116381966	FRK	0.25	6.53	0.37	3.39e-10	Cholesterol, total;LDL cholesterol;
CESC	cis	rs1799949	0.929	rs12937015	chr17:41307473	A/C	cg06001716	chr17:41278141	BRCA1;NBR2	0.37	5.07	0.3	7.62e-7	Menopause (age at onset);
CESC	cis	rs875971	0.862	rs7782704	chr7:65805366	G/A	cg12463550	chr7:65579703	CRCP	-0.47	-6.08	-0.35	4.28e-9	Aortic root size;
CESC	cis	rs1799949	1.000	rs16942	chr17:41244000	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.67	9.44	0.5	1.97e-18	Menopause (age at onset);
CESC	cis	rs78707713	0.511	rs28697194	chr10:71215483	T/C	cg12610070	chr10:71211762	TSPAN15	-0.3	-6.37	-0.36	8.41e-10	Venous thromboembolism;
CESC	cis	rs3749237	0.595	rs11130199	chr3:49538799	T/C	cg03060546	chr3:49711283	APEH	0.78	11.82	0.59	3.47e-26	Resting heart rate;
CESC	cis	rs9325144	0.505	rs901635	chr12:38646572	A/C	cg26384229	chr12:38710491	ALG10B	-0.66	-10.66	-0.55	2.65e-22	Morning vs. evening chronotype;
CESC	cis	rs6430585	0.646	rs1057031	chr2:136633962	G/A	cg07169764	chr2:136633963	MCM6	1.32	20.96	0.79	3.38e-58	Corneal structure;
CESC	cis	rs1348850	0.668	rs4893972	chr2:178496874	T/C	cg23306229	chr2:178417860	TTC30B	0.55	6.63	0.38	1.89e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	trans	rs916888	0.773	rs199445	chr17:44817408	C/T	cg04282206	chr17:62833786	PLEKHM1P	0.55	6.5	0.37	4.06e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs6952808	0.595	rs3800917	chr7:2167939	A/G	cg02951883	chr7:2050386	MAD1L1	0.49	6.26	0.36	1.52e-9	Bipolar disorder and schizophrenia;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg01399255	chr7:100271274	GNB2	-0.47	-6.1	-0.35	3.74e-9	Ulcerative colitis;
CESC	trans	rs7824557	0.564	rs7821459	chr8:11236681	T/G	cg06636001	chr8:8085503	FLJ10661	-0.49	-6.15	-0.35	2.9e-9	Retinal vascular caliber;
CESC	cis	rs6963495	0.818	rs73190155	chr7:105153535	T/A	cg13798780	chr7:105162888	PUS7	0.78	8.04	0.44	2.99e-14	Bipolar disorder (body mass index interaction);
CESC	cis	rs73001065	0.901	rs10401969	chr19:19407718	A/G	cg03709012	chr19:19516395	GATAD2A	0.95	6.27	0.36	1.47e-9	LDL cholesterol;
CESC	cis	rs116095464	0.558	rs9654453	chr5:299621	T/C	cg22857025	chr5:266934	NA	-1.31	-14.05	-0.65	7.02e-34	Breast cancer;
CESC	cis	rs7845219	0.544	rs2123647	chr8:95931782	A/G	cg09323728	chr8:95962352	TP53INP1	0.33	6.43	0.37	5.98e-10	Type 2 diabetes;
CESC	cis	rs12950390	0.853	rs12450733	chr17:45855404	A/G	cg00777063	chr17:45855553	NA	-0.4	-5.9	-0.34	1.12e-8	IgG glycosylation;
CESC	cis	rs7666738	0.716	rs35195511	chr4:98859660	G/A	cg17366294	chr4:99064904	C4orf37	0.55	7.73	0.43	2.21e-13	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1552244	0.935	rs2272124	chr3:10138189	T/C	cg08888203	chr3:10149979	C3orf24	0.46	6.05	0.35	4.97e-9	Alzheimer's disease;
CESC	cis	rs7666738	0.830	rs10470894	chr4:99039107	G/A	cg03676636	chr4:99064102	C4orf37	0.33	5.08	0.3	7.13e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3791556	0.504	rs1001285	chr2:240107814	A/G	cg03281426	chr2:240109471	HDAC4	0.68	10.78	0.55	1.05e-22	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs7116495	0.609	rs4945378	chr11:71668866	G/A	cg26138937	chr11:71823887	C11orf51	-1.23	-8.41	-0.46	2.56e-15	Severe influenza A (H1N1) infection;
CESC	cis	rs12887734	0.524	rs12588797	chr14:104300020	C/T	cg01849466	chr14:104193079	ZFYVE21	0.46	5.8	0.34	1.84e-8	Schizophrenia;Autism spectrum disorder or schizophrenia;
CESC	cis	rs6088590	1.000	rs28542147	chr20:33376323	G/A	cg06115741	chr20:33292138	TP53INP2	0.6	7.39	0.41	1.96e-12	Coronary artery disease;
CESC	cis	rs9910055	0.530	rs2269905	chr17:42294462	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.35	5.12	0.3	5.9e-7	Total body bone mineral density;
CESC	cis	rs769267	0.930	rs10282	chr19:19619317	T/C	cg03709012	chr19:19516395	GATAD2A	1.01	15.89	0.7	2.1e-40	Tonsillectomy;
CESC	cis	rs873946	0.648	rs3793673	chr10:134547732	A/C	cg26818010	chr10:134567672	INPP5A	-0.87	-10.83	-0.55	7.44e-23	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs7044106	0.791	rs4836829	chr9:123482747	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.73	10.84	0.55	6.59e-23	Hip circumference adjusted for BMI;
CESC	cis	rs6460942	0.597	rs7808537	chr7:12520913	G/C	cg06484146	chr7:12443880	VWDE	-0.71	-7.6	-0.42	5.22e-13	Coronary artery disease;
CESC	cis	rs2011503	0.941	rs7257875	chr19:19372150	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.53	5.53	0.32	7.55e-8	Bipolar disorder;
CESC	cis	rs12477438	0.765	rs17708262	chr2:99696313	T/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.62	-8.61	-0.47	6.82e-16	Chronic sinus infection;
CESC	cis	rs10927875	0.830	rs1763610	chr1:16335527	C/G	cg21214613	chr1:16344536	HSPB7	-0.35	-5.17	-0.3	4.62e-7	Dilated cardiomyopathy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06385459	chr4:82393184	RASGEF1B	0.53	6.03	0.35	5.38e-9	Gut microbiome composition (summer);
CESC	cis	rs17711722	0.701	rs781145	chr7:65440370	A/C	cg25985355	chr7:65971099	NA	-0.31	-5.03	-0.3	8.85e-7	Calcium levels;
CESC	cis	rs62432291	0.681	rs294913	chr6:159667227	G/A	cg14500486	chr6:159655392	FNDC1	-0.61	-5.93	-0.34	9.62e-9	Joint mobility (Beighton score);
CESC	cis	rs10992471	0.598	rs2031262	chr9:95170368	A/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.41	-5.27	-0.31	2.84e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CESC	cis	rs3820068	0.603	rs41270279	chr1:15988878	A/G	cg17385448	chr1:15911702	AGMAT	0.44	7.31	0.41	3.13e-12	Systolic blood pressure;
CESC	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg07677032	chr17:61819896	STRADA	0.47	6.28	0.36	1.35e-9	Prudent dietary pattern;
CESC	cis	rs15676	0.947	rs2805103	chr9:131598897	T/A	cg00228799	chr9:131580591	ENDOG	0.45	5.56	0.32	6.67e-8	Blood metabolite levels;
CESC	cis	rs7726839	0.561	rs3915384	chr5:573395	G/T	cg09021430	chr5:549028	NA	-0.41	-5.31	-0.31	2.37e-7	Obesity-related traits;
CESC	trans	rs1814175	0.645	rs1851849	chr11:50012164	G/A	cg03929089	chr4:120376271	NA	-0.91	-14.65	-0.67	5.08e-36	Height;
CESC	cis	rs9937943	0.667	rs35253850	chr16:74599103	T/C	cg01733217	chr16:74700730	RFWD3	0.62	5.6	0.33	5.33e-8	Neutrophil percentage of white cells;
CESC	cis	rs9815354	0.812	rs12108049	chr3:41958161	A/G	cg03022575	chr3:42003672	ULK4	0.67	6.1	0.35	3.77e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs875971	0.522	rs1968127	chr7:66056803	C/T	cg06456125	chr7:65229604	NA	-0.4	-5.24	-0.31	3.33e-7	Aortic root size;
CESC	cis	rs208520	0.608	rs3846803	chr6:66805743	C/A	cg07460842	chr6:66804631	NA	-1.0	-13.38	-0.63	1.55e-31	Exhaled nitric oxide output;
CESC	cis	rs7937682	0.883	rs631490	chr11:111452040	G/C	cg22437258	chr11:111473054	SIK2	0.68	9.04	0.49	3.43e-17	Primary sclerosing cholangitis;
CESC	cis	rs9916302	0.861	rs632202	chr17:37453294	C/A	cg20243544	chr17:37824526	PNMT	-0.45	-5.54	-0.32	7.43e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs4665809	1.000	rs6546726	chr2:26275116	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.71	-7.89	-0.44	8.2e-14	Gut microbiome composition (summer);
CESC	cis	rs1707322	0.686	rs2275085	chr1:46085852	C/T	cg05343316	chr1:45956843	TESK2	-0.53	-6.46	-0.37	4.92e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs7615952	0.512	rs4679430	chr3:125357893	T/C	cg00769240	chr8:12517080	NA	-0.44	-6.02	-0.35	5.7e-9	Blood pressure (smoking interaction);
CESC	cis	rs10504073	0.584	rs1511368	chr8:49949523	A/T	cg00325661	chr8:49890786	NA	0.56	8.53	0.46	1.16e-15	Blood metabolite ratios;
CESC	cis	rs9916302	0.800	rs9892675	chr17:37549200	C/T	cg20243544	chr17:37824526	PNMT	-0.48	-5.13	-0.3	5.59e-7	Glomerular filtration rate (creatinine);
CESC	trans	rs1814175	0.618	rs1851843	chr11:50021846	T/C	cg15704280	chr7:45808275	SEPT13	-1.0	-18.54	-0.75	9.01e-50	Height;
CESC	cis	rs644799	1.000	rs2508289	chr11:95624669	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.47	5.53	0.32	7.48e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs9814567	1.000	rs4367113	chr3:134287975	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.45	-6.1	-0.35	3.7e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs3771570	1.000	rs57196672	chr2:242235193	G/A	cg21155796	chr2:242212141	HDLBP	0.61	5.16	0.3	4.88e-7	Prostate cancer;
CESC	cis	rs6952809	0.504	rs1978169	chr7:2434522	G/A	cg23289794	chr7:2394357	EIF3B	-0.66	-6.69	-0.38	1.34e-10	Multiple sclerosis;
CESC	cis	rs453301	0.538	rs7830804	chr8:8970762	G/T	cg15556689	chr8:8085844	FLJ10661	-0.51	-6.48	-0.37	4.46e-10	Joint mobility (Beighton score);
CESC	cis	rs1707322	0.717	rs2253862	chr1:46081960	C/T	cg06784218	chr1:46089804	CCDC17	-0.41	-7.08	-0.4	1.31e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs965469	1.000	rs6051745	chr20:3307243	T/G	cg25506879	chr20:3388711	C20orf194	-0.57	-6.15	-0.35	2.79e-9	IFN-related cytopenia;
CESC	cis	rs6460942	0.591	rs62451465	chr7:12364585	A/G	cg06484146	chr7:12443880	VWDE	-0.62	-6.79	-0.39	7.18e-11	Coronary artery disease;
CESC	cis	rs919433	0.926	rs787996	chr2:198216805	A/G	cg20885578	chr2:198174922	NA	0.4	5.42	0.32	1.31e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs6121246	0.909	rs7354225	chr20:30296881	C/T	cg13852791	chr20:30311386	BCL2L1	0.79	7.29	0.41	3.64e-12	Mean corpuscular hemoglobin;
CESC	cis	rs9326248	0.530	rs10790172	chr11:116927740	G/T	cg01368799	chr11:117014884	PAFAH1B2	0.57	5.23	0.31	3.49e-7	Blood protein levels;
CESC	cis	rs35306767	0.903	rs35968821	chr10:910225	A/G	cg20503657	chr10:835505	NA	0.77	7.67	0.43	3.3e-13	Eosinophil percentage of granulocytes;
CESC	cis	rs35306767	0.807	rs34982663	chr10:852521	C/G	cg10556349	chr10:835070	NA	0.74	6.43	0.37	5.78e-10	Eosinophil percentage of granulocytes;
CESC	cis	rs2204008	0.774	rs11520237	chr12:38266978	G/A	cg13010199	chr12:38710504	ALG10B	0.48	6.04	0.35	5.23e-9	Bladder cancer;
CESC	cis	rs11583043	0.918	rs58029001	chr1:101393409	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.46	5.2	0.3	3.98e-7	Ulcerative colitis;Inflammatory bowel disease;
CESC	cis	rs2109514	0.902	rs6980387	chr7:116126882	A/G	cg12739419	chr7:116140593	CAV2	-0.38	-6.74	-0.38	9.73e-11	Prevalent atrial fibrillation;
CESC	cis	rs7264396	0.690	rs2425165	chr20:34438059	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.85	-11.51	-0.58	3.81e-25	Total cholesterol levels;
CESC	cis	rs7267979	0.966	rs4813557	chr20:25292545	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.85	-16.88	-0.72	6.68e-44	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs1799949	0.683	rs55737636	chr17:41264739	C/T	cg23758822	chr17:41437982	NA	0.99	16.8	0.72	1.23e-43	Menopause (age at onset);
CESC	cis	rs40363	0.720	rs4453493	chr16:3533881	T/C	cg05754148	chr16:3507555	NAT15	-0.48	-6.4	-0.37	6.86e-10	Tuberculosis;
CESC	cis	rs11252926	0.550	rs11252134	chr10:442599	G/A	cg16386425	chr10:429943	DIP2C	-0.56	-7.23	-0.41	5.26e-12	Psychosis in Alzheimer's disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg14337668	chr9:99883682	NA	0.46	6.4	0.37	7.01e-10	Fibrinogen levels;
CESC	cis	rs9549260	0.569	rs7328453	chr13:41334327	G/A	cg21288729	chr13:41239152	FOXO1	0.63	5.24	0.31	3.36e-7	Red blood cell count;
CESC	cis	rs7843479	0.509	rs899428	chr8:21770763	T/C	cg17168535	chr8:21777572	XPO7	0.65	9.76	0.51	1.95e-19	Mean corpuscular volume;
CESC	cis	rs60871478	0.947	rs4074610	chr7:791755	G/A	cg05535760	chr7:792225	HEATR2	0.86	10.52	0.54	7.3e-22	Cerebrospinal P-tau181p levels;
CESC	cis	rs11098499	0.754	rs28652763	chr4:120242312	C/T	cg09307838	chr4:120376055	NA	0.79	10.62	0.55	3.51e-22	Corneal astigmatism;
CESC	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg23978390	chr7:1156363	C7orf50	0.57	8.23	0.45	8.35e-15	Longevity;Endometriosis;
CESC	cis	rs66782572	1	rs66782572	chr3:52567617	A/G	cg07507251	chr3:52567010	NT5DC2	0.51	10.34	0.54	2.82e-21	Hemoglobin concentration;
CESC	cis	rs2952156	0.920	rs2517955	chr17:37843681	C/T	cg07936489	chr17:37558343	FBXL20	-0.6	-7.71	-0.43	2.57e-13	Asthma;
CESC	cis	rs35306767	0.903	rs12244355	chr10:944465	T/C	cg26597838	chr10:835615	NA	0.92	9.99	0.52	3.74e-20	Eosinophil percentage of granulocytes;
CESC	cis	rs9457247	0.663	rs2237277	chr6:167442107	G/A	cg25258033	chr6:167368657	RNASET2	0.37	5.4	0.31	1.51e-7	Crohn's disease;
CESC	cis	rs4900538	0.855	rs72698602	chr14:102880454	T/C	cg18135206	chr14:102964638	TECPR2	-0.73	-9.33	-0.5	4.35e-18	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	cis	rs2204008	0.744	rs11180504	chr12:38236313	C/T	cg26384229	chr12:38710491	ALG10B	0.69	9.8	0.52	1.51e-19	Bladder cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24029926	chr7:33102655	NT5C3	-0.73	-8.97	-0.48	5.37e-17	Gut microbiome composition (summer);
CESC	cis	rs668210	0.793	rs590531	chr11:65773939	C/A	cg02202077	chr11:65769826	EIF1AD;BANF1	-0.66	-6.59	-0.38	2.36e-10	Cerebrospinal fluid biomarker levels;
CESC	cis	rs7615952	0.599	rs67566088	chr3:125768973	C/A	cg04553112	chr3:125709451	NA	-0.52	-5.47	-0.32	1.05e-7	Blood pressure (smoking interaction);
CESC	cis	rs2836974	0.932	rs6517526	chr21:40581530	T/C	cg27266027	chr21:40555129	PSMG1	0.45	5.3	0.31	2.47e-7	Cognitive function;
CESC	cis	rs10911232	0.507	rs10911194	chr1:182993025	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.85	13.21	0.63	5.94e-31	Hypertriglyceridemia;
CESC	cis	rs712039	0.652	rs829160	chr17:35763091	T/A	cg16670864	chr17:35848621	DUSP14	0.48	6.12	0.35	3.37e-9	Tuberculosis;
CESC	cis	rs11122272	0.735	rs10489611	chr1:231517854	A/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.57	-7.82	-0.43	1.29e-13	Hemoglobin concentration;
CESC	cis	rs12142240	0.698	rs6697123	chr1:46811310	A/C	cg10495392	chr1:46806563	NSUN4	0.57	6.29	0.36	1.33e-9	Menopause (age at onset);
CESC	cis	rs9911578	0.900	rs7214335	chr17:57158840	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.39	5.13	0.3	5.63e-7	Intelligence (multi-trait analysis);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg16408394	chr9:137219075	RXRA	-0.46	-6.77	-0.38	8.4e-11	Gambling;
CESC	cis	rs116095464	0.558	rs7730700	chr5:264713	G/A	cg22857025	chr5:266934	NA	-1.3	-18.55	-0.75	8.05e-50	Breast cancer;
CESC	cis	rs514406	0.729	rs534070	chr1:53308858	T/G	cg24675658	chr1:53192096	ZYG11B	-0.67	-9.54	-0.51	9.7e-19	Monocyte count;
CESC	cis	rs9896933	0.778	rs80243549	chr17:80821485	G/T	cg15664640	chr17:80829946	TBCD	-0.52	-5.51	-0.32	8.68e-8	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
CESC	cis	rs3858526	0.920	rs11511938	chr11:5928793	A/G	cg13902645	chr11:5959945	NA	-0.61	-7.19	-0.4	6.77e-12	DNA methylation (variation);
CESC	cis	rs2180341	0.782	rs6912006	chr6:127722631	C/T	cg24812749	chr6:127587940	RNF146	0.74	9.83	0.52	1.18e-19	Breast cancer;
CESC	cis	rs875971	0.862	rs801209	chr7:66019390	G/T	cg12463550	chr7:65579703	CRCP	-0.5	-6.32	-0.36	1.08e-9	Aortic root size;
CESC	cis	rs2576037	0.796	rs6507718	chr18:44581284	G/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.61	-8.73	-0.47	2.97e-16	Personality dimensions;
CESC	trans	rs7618501	1.000	rs2271961	chr3:49878113	C/T	cg21659725	chr3:3221576	CRBN	-0.83	-13.84	-0.65	3.61e-33	Intelligence (multi-trait analysis);
CESC	cis	rs7918232	0.882	rs2149413	chr10:27430311	C/T	cg14442939	chr10:27389572	ANKRD26	-0.68	-6.52	-0.37	3.61e-10	Breast cancer;
CESC	cis	rs875971	1.000	rs937495	chr7:65779798	A/G	cg18876405	chr7:65276391	NA	-0.51	-7.03	-0.4	1.7e-11	Aortic root size;
CESC	cis	rs35146811	0.660	rs6465760	chr7:99591418	A/G	cg14163444	chr7:99595348	NA	0.39	5.2	0.3	4.07e-7	Coronary artery disease;
CESC	cis	rs1816752	0.935	rs3816219	chr13:25017133	C/T	cg02811702	chr13:24901961	NA	0.39	5.66	0.33	3.86e-8	Obesity-related traits;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg07155664	chr5:149829590	RPS14	-0.45	-6.32	-0.36	1.09e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs644799	0.965	rs565771	chr11:95644179	T/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.47	5.84	0.34	1.52e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs17401966	1.000	rs12734068	chr1:10376803	G/A	cg15208524	chr1:10270712	KIF1B	0.45	5.64	0.33	4.31e-8	Hepatocellular carcinoma;
CESC	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	22.27	0.81	1.17e-62	Prudent dietary pattern;
CESC	cis	rs3820068	0.581	rs72645895	chr1:15931709	G/A	cg17385448	chr1:15911702	AGMAT	0.41	6.69	0.38	1.33e-10	Systolic blood pressure;
CESC	cis	rs7666738	0.753	rs13137152	chr4:98938044	A/T	cg03467027	chr4:99064603	C4orf37	0.48	5.92	0.34	9.78e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs12477438	0.520	rs11123761	chr2:99705903	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.87	15.39	0.69	1.29e-38	Chronic sinus infection;
CESC	trans	rs2391518	0.639	rs2968997	chr4:130784669	A/C	cg04981619	chr2:43328122	NA	0.38	6.11	0.35	3.61e-9	Body mass index;
CESC	cis	rs34779708	0.931	rs4934721	chr10:35377715	A/G	cg04310649	chr10:35416472	CREM	-0.5	-5.88	-0.34	1.25e-8	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs514406	0.798	rs576650	chr1:53327207	C/T	cg16325326	chr1:53192061	ZYG11B	0.72	10.81	0.55	8.67e-23	Monocyte count;
CESC	cis	rs597539	0.652	rs507520	chr11:68666054	C/T	cg01988459	chr11:68622903	NA	-0.41	-5.53	-0.32	7.51e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs798554	0.642	rs2533871	chr7:2883006	C/G	cg19346786	chr7:2764209	NA	-0.36	-5.17	-0.3	4.71e-7	Height;
CESC	cis	rs2882667	0.964	rs12719517	chr5:138305502	C/T	cg04439458	chr5:138467593	SIL1	-0.37	-5.72	-0.33	2.87e-8	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs9300255	0.739	rs1980252	chr12:123745178	C/G	cg00376283	chr12:123451042	ABCB9	0.72	9.09	0.49	2.4e-17	Neutrophil percentage of white cells;
CESC	cis	rs8078723	0.714	rs12940405	chr17:38143768	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.35	5.05	0.3	8.15e-7	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CESC	cis	rs7223966	1.000	rs9903897	chr17:61716705	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	7.44	0.42	1.37e-12	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs861020	0.710	rs7516902	chr1:210022179	A/G	cg05527609	chr1:210001259	C1orf107	1.09	14.97	0.68	3.91e-37	Orofacial clefts;
CESC	cis	rs13191362	0.935	rs35100164	chr6:162963003	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.77	7.3	0.41	3.39e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs7412746	0.524	rs58304714	chr1:150831561	T/A	cg22823121	chr1:150693482	HORMAD1	0.43	5.86	0.34	1.4e-8	Melanoma;
CESC	cis	rs780096	0.546	rs1647284	chr2:27608115	C/T	cg22903471	chr2:27725779	GCKR	-0.5	-7.08	-0.4	1.27e-11	Total body bone mineral density;
CESC	cis	rs35110281	0.659	rs11909064	chr21:45092095	G/C	cg01579765	chr21:45077557	HSF2BP	-0.54	-8.98	-0.48	5.14e-17	Mean corpuscular volume;
CESC	cis	rs55882075	0.730	rs10794700	chr5:179148335	C/G	cg14593053	chr5:179126677	CANX	0.6	8.88	0.48	1.05e-16	Monocyte percentage of white cells;
CESC	cis	rs7264396	0.563	rs1970577	chr20:34336737	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.89	-10.73	-0.55	1.57e-22	Total cholesterol levels;
CESC	cis	rs7512552	0.803	rs9435997	chr1:150289496	G/A	cg15654264	chr1:150340011	RPRD2	-0.4	-5.18	-0.3	4.39e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CESC	trans	rs12960505	0.506	rs6508235	chr18:51053941	A/G	cg27659478	chr17:73891062	TRIM65	-0.46	-6.11	-0.35	3.58e-9	Intelligence (multi-trait analysis);
CESC	cis	rs870825	0.655	rs10013685	chr4:185617785	C/T	cg04058563	chr4:185651563	MLF1IP	0.64	7.05	0.4	1.59e-11	Blood protein levels;
CESC	cis	rs736408	0.522	rs11130310	chr3:52674667	C/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.31	5.64	0.33	4.27e-8	Bipolar disorder;
CESC	cis	rs9649213	0.593	rs2107716	chr7:97944744	G/A	cg21770322	chr7:97807741	LMTK2	0.54	8.17	0.45	1.31e-14	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs962856	0.575	rs7597266	chr2:67621641	G/A	cg09028215	chr2:67624308	ETAA1	-0.46	-5.69	-0.33	3.42e-8	Pancreatic cancer;
CESC	cis	rs644799	1.000	rs611020	chr11:95567905	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.94	13.74	0.64	8.5e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs8067354	0.645	rs9899611	chr17:57832190	A/G	cg02344993	chr17:57696989	CLTC	0.68	8.06	0.44	2.59e-14	Hemoglobin concentration;
CESC	cis	rs898097	0.812	rs72859941	chr17:80837459	G/A	cg05255149	chr17:80675120	FN3KRP	-0.46	-5.27	-0.31	2.76e-7	Breast cancer;
CESC	cis	rs644799	0.603	rs1255180	chr11:95472134	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.45	6.12	0.35	3.39e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs28374715	0.681	rs28712264	chr15:41588797	T/C	cg02330683	chr15:41787940	ITPKA	0.46	5.48	0.32	9.83e-8	Ulcerative colitis;
CESC	cis	rs9325144	0.581	rs6582564	chr12:38671282	G/A	cg13010199	chr12:38710504	ALG10B	-0.45	-6.1	-0.35	3.79e-9	Morning vs. evening chronotype;
CESC	cis	rs7666738	0.830	rs28887893	chr4:98963006	G/A	cg05340658	chr4:99064831	C4orf37	0.8	12.39	0.61	3.96e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs514406	0.505	rs269292	chr1:53187911	T/C	cg27535305	chr1:53392650	SCP2	-0.33	-5.38	-0.31	1.62e-7	Monocyte count;
CESC	cis	rs9311474	0.581	rs4687626	chr3:52569098	G/A	cg18404041	chr3:52824283	ITIH1	-0.38	-6.34	-0.36	9.76e-10	Electroencephalogram traits;
CESC	cis	rs892961	0.931	rs2411110	chr17:75400143	A/C	cg05865280	chr17:75406074	SEPT9	0.48	6.51	0.37	3.67e-10	Airflow obstruction;
CESC	cis	rs1348850	0.645	rs4893963	chr2:178430747	A/G	cg22681709	chr2:178499509	PDE11A	0.5	6.41	0.37	6.64e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs4604732	0.631	rs10754561	chr1:247622800	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.46	6.44	0.37	5.74e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs847577	0.630	rs6967926	chr7:97715088	C/T	cg24562669	chr7:97807699	LMTK2	0.8	13.78	0.65	5.96e-33	Breast cancer;
CESC	cis	rs4665809	0.887	rs6546716	chr2:26263836	A/G	cg04944784	chr2:26401820	FAM59B	-0.67	-7.61	-0.42	4.8e-13	Gut microbiome composition (summer);
CESC	cis	rs7959452	0.868	rs10784774	chr12:69737879	C/T	cg22834771	chr12:69754056	YEATS4	0.38	5.15	0.3	5.15e-7	Blood protein levels;
CESC	cis	rs8060686	0.641	rs111632263	chr16:68233122	T/A	cg26727032	chr16:67993705	SLC12A4	-0.51	-5.5	-0.32	8.83e-8	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs9649213	0.593	rs6949718	chr7:97924483	G/A	cg24562669	chr7:97807699	LMTK2	0.51	7.54	0.42	7.72e-13	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs881375	0.715	rs10818482	chr9:123648085	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.48	-6.84	-0.39	5.44e-11	Rheumatoid arthritis;
CESC	cis	rs8077889	0.672	rs3785810	chr17:41850689	C/G	cg26893861	chr17:41843967	DUSP3	1.01	18.7	0.75	2.58e-50	Triglycerides;
CESC	cis	rs12893668	0.616	rs58033365	chr14:104030901	T/C	cg24130564	chr14:104152367	KLC1	-0.48	-5.87	-0.34	1.31e-8	Reticulocyte count;
CESC	cis	rs1511802	0.501	rs7684025	chr4:187116227	C/T	cg24794857	chr4:187113578	CYP4V2	0.42	5.38	0.31	1.65e-7	Blood protein levels;
CESC	cis	rs5769765	0.955	rs4075330	chr22:50303249	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.5	-5.45	-0.32	1.15e-7	Schizophrenia;
CESC	cis	rs2011503	0.825	rs4808932	chr19:19358819	C/T	cg11584989	chr19:19387371	SF4	0.54	6.58	0.37	2.46e-10	Bipolar disorder;
CESC	cis	rs1552244	1.000	rs9881859	chr3:10072814	A/T	cg08888203	chr3:10149979	C3orf24	0.49	6.26	0.36	1.51e-9	Alzheimer's disease;
CESC	cis	rs56235845	0.694	rs12055081	chr5:176757191	C/T	cg17509989	chr5:176798049	RGS14	0.5	6.21	0.36	2.04e-9	Hemoglobin concentration;Hematocrit;
CESC	cis	rs8067354	0.957	rs9896742	chr17:57826530	T/G	cg13753209	chr17:57696993	CLTC	0.53	7.05	0.4	1.58e-11	Hemoglobin concentration;
CESC	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg11905131	chr22:24372483	LOC391322	-0.75	-10.92	-0.56	3.66e-23	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs9768139	0.935	rs7782393	chr7:158120486	G/A	cg25566285	chr7:158114605	PTPRN2	-0.51	-8.75	-0.47	2.59e-16	Calcium levels;
CESC	trans	rs459571	0.792	rs55923934	chr9:136888233	C/G	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.6	-7.76	-0.43	1.8e-13	Platelet distribution width;
CESC	cis	rs3011225	0.691	rs3791102	chr1:44366617	C/T	cg13606994	chr1:44402422	ARTN	-0.36	-5.61	-0.33	5.17e-8	Amyotrophic lateral sclerosis (age of onset);
CESC	cis	rs12458462	0.509	rs3786241	chr18:77494328	A/C	cg11879182	chr18:77439856	CTDP1	0.57	7.88	0.44	8.33e-14	Monocyte count;
CESC	cis	rs7618915	0.547	rs34173654	chr3:52634605	T/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.31	5.52	0.32	7.94e-8	Bipolar disorder;
CESC	cis	rs722599	0.683	rs11848876	chr14:75224626	C/G	cg11812906	chr14:75593930	NEK9	0.46	5.58	0.32	5.88e-8	IgG glycosylation;
CESC	cis	rs9611565	0.659	rs9607813	chr22:41941479	G/A	cg17376030	chr22:41985996	PMM1	0.68	7.43	0.42	1.46e-12	Vitiligo;
CESC	trans	rs804280	0.509	rs4841639	chr8:11796093	A/T	cg15556689	chr8:8085844	FLJ10661	0.51	6.32	0.36	1.1e-9	Myopia (pathological);
CESC	cis	rs936229	1.000	rs4886615	chr15:75131661	A/G	cg14664628	chr15:75095509	CSK	-0.86	-11.67	-0.58	1.12e-25	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CESC	cis	rs7666738	0.830	rs13144771	chr4:99026935	G/C	cg17366294	chr4:99064904	C4orf37	0.62	8.95	0.48	6.32e-17	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3096299	0.935	rs3114890	chr16:89449546	C/G	cg08822215	chr16:89438651	ANKRD11	-0.44	-6.68	-0.38	1.4e-10	Multiple myeloma (IgH translocation);
CESC	cis	rs13191362	1.000	rs34655790	chr6:163202739	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.96	9.4	0.5	2.62e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs1062746	0.834	rs9308347	chr16:87371752	C/T	cg02258303	chr16:87377426	FBXO31	-0.51	-6.51	-0.37	3.8e-10	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
CESC	cis	rs7584330	0.868	rs13386290	chr2:238393136	G/C	cg11271282	chr2:238384023	NA	0.51	5.76	0.33	2.28e-8	Prostate cancer;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg09580147	chr16:22431764	RRN3P3	0.4	6.19	0.36	2.33e-9	Fibrinogen levels;
CESC	trans	rs9393777	0.841	rs13191474	chr6:27413345	C/T	cg21479132	chr6:26055353	NA	0.84	6.15	0.35	2.82e-9	Intelligence (multi-trait analysis);
CESC	cis	rs9611565	0.694	rs202618	chr22:41822856	A/G	cg17376030	chr22:41985996	PMM1	-0.76	-8.01	-0.44	3.71e-14	Vitiligo;
CESC	cis	rs561341	1.000	rs550264	chr17:30317540	G/T	cg23018236	chr17:30244563	NA	-0.53	-5.21	-0.3	3.76e-7	Hip circumference adjusted for BMI;
CESC	cis	rs8177253	1.000	rs8177240	chr3:133477701	T/G	cg12373951	chr3:133503437	NA	0.43	6.16	0.35	2.67e-9	Iron status biomarkers;
CESC	cis	rs11690935	0.959	rs7355594	chr2:172639448	G/T	cg13550731	chr2:172543902	DYNC1I2	-1.01	-16.63	-0.71	5.07e-43	Schizophrenia;
CESC	cis	rs34779708	0.966	rs2505639	chr10:35474421	A/G	cg03585969	chr10:35415529	CREM	-0.71	-9.41	-0.5	2.52e-18	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs875971	0.862	rs4718383	chr7:66108409	T/C	cg18876405	chr7:65276391	NA	-0.47	-6.39	-0.37	7.56e-10	Aortic root size;
CESC	cis	rs3793683	0.520	rs12769959	chr10:134579026	A/C	cg18305652	chr10:134549665	INPP5A	0.5	7.32	0.41	2.93e-12	Migraine;
CESC	cis	rs8114671	0.967	rs6060285	chr20:33770487	G/T	cg24642439	chr20:33292090	TP53INP2	0.44	5.37	0.31	1.73e-7	Height;
CESC	cis	rs3857536	0.813	rs1029401	chr6:66952268	A/G	cg07460842	chr6:66804631	NA	-0.42	-5.11	-0.3	6.32e-7	Blood trace element (Cu levels);
CESC	cis	rs2228479	0.850	rs11639906	chr16:89798183	T/C	cg14709524	chr16:89940631	TCF25	0.78	5.43	0.32	1.3e-7	Skin colour saturation;
CESC	cis	rs9303401	1.000	rs7218362	chr17:56888299	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.73	9.42	0.5	2.35e-18	Cognitive test performance;
CESC	cis	rs4588572	0.537	rs7702000	chr5:77730556	A/G	cg11547950	chr5:77652471	NA	-0.38	-5.25	-0.31	3.12e-7	Triglycerides;
CESC	cis	rs11098499	0.615	rs28850368	chr4:120554313	G/A	cg24375607	chr4:120327624	NA	0.41	5.18	0.3	4.4e-7	Corneal astigmatism;
CESC	cis	rs727505	1.000	rs10230610	chr7:124425398	A/C	cg23710748	chr7:124431027	NA	-0.47	-7.56	-0.42	6.58e-13	Lewy body disease;
CESC	cis	rs9443645	0.901	rs9448584	chr6:79572799	G/T	cg05283184	chr6:79620031	NA	-0.42	-6.67	-0.38	1.47e-10	Intelligence (multi-trait analysis);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg05159949	chr15:81282184	MESDC2	-0.48	-6.15	-0.35	2.78e-9	Ulcerative colitis;
CESC	cis	rs8002861	0.664	rs895266	chr13:44461179	T/C	cg19180546	chr13:44453867	C13orf31;CCDC122	0.4	5.14	0.3	5.42e-7	Leprosy;
CESC	trans	rs3087243	0.755	rs231738	chr2:204693137	C/G	cg01841312	chr10:38069945	NA	0.38	6.37	0.36	8.32e-10	Rheumatoid arthritis;Hypothyroidism;Type 1 diabetes;
CESC	cis	rs2228479	0.557	rs62054639	chr16:89821489	C/T	cg04013166	chr16:89971882	TCF25	0.77	6.66	0.38	1.58e-10	Skin colour saturation;
CESC	cis	rs2046867	0.818	rs62249862	chr3:72867949	G/C	cg25664220	chr3:72788482	NA	-0.45	-6.56	-0.37	2.88e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CESC	cis	rs9926296	0.632	rs72807526	chr16:89775946	A/G	cg27121462	chr16:89883253	FANCA	-0.57	-7.16	-0.4	7.91e-12	Vitiligo;
CESC	cis	rs801193	0.844	rs2244022	chr7:66202430	A/G	cg18876405	chr7:65276391	NA	0.51	7.07	0.4	1.35e-11	Aortic root size;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg18262260	chr14:89029717	ZC3H14	-0.4	-6.2	-0.36	2.14e-9	Gambling;
CESC	cis	rs4629180	0.562	rs10198901	chr2:102127937	G/A	cg04415270	chr2:102091202	RFX8	-0.3	-5.31	-0.31	2.34e-7	Chronic rhinosinusitis with nasal polyps;
CESC	cis	rs11718455	0.960	rs17076254	chr3:44000361	C/T	cg08738300	chr3:44038990	NA	0.44	6.06	0.35	4.66e-9	Coronary artery disease;
CESC	cis	rs3820068	0.603	rs72645887	chr1:15929905	G/C	cg17385448	chr1:15911702	AGMAT	0.41	6.69	0.38	1.33e-10	Systolic blood pressure;
CESC	cis	rs13256369	0.950	rs13248096	chr8:8577476	C/T	cg17143192	chr8:8559678	CLDN23	0.74	8.94	0.48	6.99e-17	Obesity-related traits;
CESC	cis	rs9486719	0.948	rs11152953	chr6:96894305	C/T	cg06623918	chr6:96969491	KIAA0776	-0.81	-8.29	-0.45	5.61e-15	Migraine;Coronary artery disease;
CESC	cis	rs2836974	0.526	rs1888488	chr21:40686521	C/T	cg22974920	chr21:40686053	BRWD1	-0.44	-5.48	-0.32	9.81e-8	Cognitive function;
CESC	cis	rs3733585	0.699	rs7663097	chr4:9966791	T/C	cg11266682	chr4:10021025	SLC2A9	-0.58	-10.94	-0.56	3.08e-23	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs6460942	0.915	rs2216050	chr7:12304073	T/C	cg06484146	chr7:12443880	VWDE	-0.4	-5.63	-0.33	4.48e-8	Coronary artery disease;
CESC	cis	rs3126085	1.000	rs1858482	chr1:152306921	A/G	cg03465714	chr1:152285911	FLG	-0.42	-5.08	-0.3	7.09e-7	Atopic dermatitis;
CESC	cis	rs6502050	0.769	rs9898542	chr17:80119682	C/T	cg23985595	chr17:80112537	CCDC57	-0.41	-6.57	-0.37	2.6e-10	Life satisfaction;
CESC	cis	rs6693567	0.526	rs3818978	chr1:150266338	T/A	cg09579323	chr1:150459698	TARS2	-0.5	-6.36	-0.36	8.99e-10	Migraine;
CESC	cis	rs1707322	0.752	rs7529699	chr1:46134634	C/T	cg06784218	chr1:46089804	CCDC17	0.41	7.12	0.4	1.04e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs4129585	0.665	rs10098073	chr8:143309504	A/C	cg16886403	chr8:143471632	TSNARE1	0.41	5.18	0.3	4.35e-7	Schizophrenia;Autism spectrum disorder or schizophrenia;
CESC	trans	rs7937682	0.889	rs1789355	chr11:111499718	T/C	cg18187862	chr3:45730750	SACM1L	0.51	6.5	0.37	3.97e-10	Primary sclerosing cholangitis;
CESC	cis	rs3749237	0.964	rs11717463	chr3:49808981	C/T	cg03060546	chr3:49711283	APEH	0.65	7.21	0.41	5.74e-12	Resting heart rate;
CESC	cis	rs9916302	0.904	rs801420	chr17:37466103	C/G	cg00129232	chr17:37814104	STARD3	0.54	7.03	0.4	1.75e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs763014	0.966	rs4247097	chr16:654224	G/A	cg00908189	chr16:619842	PIGQ	0.65	9.18	0.49	1.26e-17	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26608221	chr2:74692293	MOGS	0.65	7.28	0.41	3.69e-12	Gut microbiome composition (summer);
CESC	cis	rs9300255	0.596	rs1727331	chr12:123718879	C/G	cg00376283	chr12:123451042	ABCB9	-0.66	-9.18	-0.49	1.29e-17	Neutrophil percentage of white cells;
CESC	cis	rs736408	0.812	rs1075653	chr3:52825528	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.56	7.29	0.41	3.66e-12	Bipolar disorder;
CESC	cis	rs7613875	0.600	rs2856238	chr3:50158191	C/T	cg24308560	chr3:49941425	MST1R	-0.52	-7.27	-0.41	4.16e-12	Body mass index;
CESC	cis	rs1372520	0.684	rs1442148	chr4:90748846	T/A	cg15133208	chr4:90757351	SNCA	-0.4	-5.34	-0.31	2.01e-7	Neuroticism;
CESC	cis	rs644799	1.000	rs566204	chr11:95580926	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.95	13.82	0.65	4.39e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs561341	1.000	rs72825740	chr17:30338356	A/G	cg00745463	chr17:30367425	LRRC37B	-0.88	-7.76	-0.43	1.9e-13	Hip circumference adjusted for BMI;
CESC	cis	rs1707322	0.752	rs10789467	chr1:46118745	C/G	cg06784218	chr1:46089804	CCDC17	0.43	7.48	0.42	1.07e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs12478296	0.685	rs12473450	chr2:242991746	C/T	cg06360820	chr2:242988706	NA	-0.71	-8.96	-0.48	5.82e-17	Obesity-related traits;
CESC	cis	rs7727544	0.594	rs10479000	chr5:131607402	T/C	cg14196790	chr5:131705035	SLC22A5	0.38	5.68	0.33	3.59e-8	Blood metabolite levels;
CESC	cis	rs7811142	0.830	rs3087502	chr7:99955364	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.13	11.76	0.59	5.69e-26	Platelet count;
CESC	cis	rs1707322	0.928	rs10732844	chr1:46372688	T/C	cg06784218	chr1:46089804	CCDC17	0.32	5.57	0.32	6.35e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7618915	0.571	rs7623199	chr3:52605974	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.38	6.72	0.38	1.13e-10	Bipolar disorder;
CESC	cis	rs10504229	0.683	rs7000349	chr8:58114569	C/A	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg23978390	chr7:1156363	C7orf50	0.6	8.72	0.47	3.01e-16	Longevity;Endometriosis;
CESC	cis	rs4819052	0.851	rs13047104	chr21:46673562	T/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.47	5.88	0.34	1.23e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs7666738	0.830	rs9995370	chr4:98732145	T/G	cg17366294	chr4:99064904	C4orf37	0.57	7.92	0.44	6.72e-14	Colonoscopy-negative controls vs population controls;
CESC	trans	rs801193	1.000	rs3800812	chr7:66223461	T/C	cg26939375	chr7:64535504	NA	0.67	9.16	0.49	1.49e-17	Aortic root size;
CESC	cis	rs8078723	1.000	rs4795412	chr17:38150604	C/T	cg17467752	chr17:38218738	THRA	0.68	10.14	0.53	1.24e-20	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CESC	cis	rs2235642	0.750	rs2974845	chr16:1648162	T/C	cg03715980	chr16:1756201	MAPK8IP3	0.4	5.25	0.31	3.08e-7	Coronary artery disease;
CESC	cis	rs875971	1.000	rs4718343	chr7:65874288	T/G	cg18876405	chr7:65276391	NA	0.5	6.68	0.38	1.43e-10	Aortic root size;
CESC	cis	rs116095464	0.558	rs113796397	chr5:246503	A/G	cg22496380	chr5:211416	CCDC127	-0.73	-7.94	-0.44	5.87e-14	Breast cancer;
CESC	trans	rs2115172	0.836	rs4835799	chr5:122762229	A/G	cg05935374	chr11:82782929	RAB30	0.45	6.23	0.36	1.79e-9	Weight;
CESC	cis	rs1950626	0.705	rs34991312	chr14:101435167	A/C	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.83	11.29	0.57	2.14e-24	Pelvic organ prolapse (moderate/severe);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg12934466	chr18:32820979	ZNF397	-0.45	-6.28	-0.36	1.35e-9	Fibrinogen levels;
CESC	cis	rs853679	0.550	rs9295762	chr6:28155418	C/T	cg12963246	chr6:28129442	ZNF389	-0.49	-6.88	-0.39	4.25e-11	Depression;
CESC	cis	rs637571	0.522	rs538954	chr11:65756808	A/G	cg04055107	chr11:65626734	MUS81;CFL1	0.42	5.2	0.3	4.08e-7	Eosinophil percentage of white cells;
CESC	cis	rs910316	1.000	rs11845639	chr14:75570293	C/T	cg11812906	chr14:75593930	NEK9	0.86	14.55	0.67	1.2e-35	Height;
CESC	cis	rs11650494	0.710	rs8066722	chr17:47475007	A/G	cg08112188	chr17:47440006	ZNF652	-0.84	-6.2	-0.36	2.12e-9	Prostate cancer;
CESC	trans	rs35110281	0.626	rs162368	chr21:44934767	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.44	6.06	0.35	4.67e-9	Mean corpuscular volume;
CESC	cis	rs7590368	0.673	rs56264212	chr2:10931435	A/C	cg15705551	chr2:10952987	PDIA6	0.55	5.26	0.31	2.96e-7	Educational attainment (years of education);
CESC	cis	rs11864453	0.793	rs7197453	chr16:72079127	G/C	cg23815491	chr16:72088622	HP	0.37	5.09	0.3	6.78e-7	Fibrinogen levels;
CESC	cis	rs977987	0.806	rs8054769	chr16:75401113	T/C	cg03315344	chr16:75512273	CHST6	0.4	5.73	0.33	2.73e-8	Dupuytren's disease;
CESC	cis	rs2637266	0.791	rs2395392	chr10:78359933	C/A	cg18941641	chr10:78392320	NA	0.41	7.64	0.42	3.93e-13	Pulmonary function;
CESC	cis	rs829883	0.966	rs249853	chr12:98864908	A/C	cg25150519	chr12:98850993	NA	0.61	7.9	0.44	7.44e-14	Colorectal adenoma (advanced);
CESC	cis	rs5498	0.869	rs892188	chr19:10409793	A/G	cg08845333	chr19:10403403	ICAM5	-0.38	-5.08	-0.3	7.07e-7	Lymphocyte counts;Soluble ICAM-1;Blood protein levels;
CESC	cis	rs61542988	0.570	rs62448267	chr7:22822501	T/C	cg13679077	chr7:22862647	TOMM7	0.6	6.55	0.37	2.94e-10	Fibrinogen levels;
CESC	cis	rs1448094	0.512	rs7134732	chr12:86241908	T/C	cg19622623	chr12:86230825	RASSF9	-0.47	-5.96	-0.34	8.09e-9	Major depressive disorder;
CESC	cis	rs9948	0.655	rs62156212	chr2:97399096	C/T	cg01990225	chr2:97406019	LMAN2L	-1.02	-7.77	-0.43	1.76e-13	Erectile dysfunction and prostate cancer treatment;
CESC	cis	rs1957429	0.808	rs4902327	chr14:65344803	C/T	cg23373153	chr14:65346875	NA	0.94	9.49	0.5	1.39e-18	Pediatric areal bone mineral density (radius);
CESC	cis	rs8180040	0.967	rs4858856	chr3:47565424	G/A	cg27129171	chr3:47204927	SETD2	0.6	8.5	0.46	1.36e-15	Colorectal cancer;
CESC	cis	rs7945705	0.902	rs10769980	chr11:9014180	G/A	cg12365402	chr11:9010492	NRIP3	0.43	7.08	0.4	1.29e-11	Hemoglobin concentration;
CESC	cis	rs2836974	0.897	rs35386515	chr21:40532047	C/T	cg27266027	chr21:40555129	PSMG1	0.46	5.59	0.32	5.74e-8	Cognitive function;
CESC	cis	rs2274273	0.870	rs7160523	chr14:55594560	G/T	cg04306507	chr14:55594613	LGALS3	0.29	5.71	0.33	3.08e-8	Protein biomarker;
CESC	cis	rs9372253	0.645	rs7753212	chr6:110700229	T/C	cg19196401	chr6:110721138	DDO	-0.39	-5.66	-0.33	3.99e-8	Platelet distribution width;
CESC	cis	rs10779751	0.734	rs2791649	chr1:11132561	A/G	cg08854313	chr1:11322531	MTOR	0.76	10.24	0.53	5.91e-21	Body mass index;
CESC	cis	rs4975616	0.686	rs37008	chr5:1351538	C/T	cg06550200	chr5:1325588	CLPTM1L	-0.61	-9.39	-0.5	2.89e-18	Lung cancer;
CESC	trans	rs9354308	0.866	rs2814092	chr6:66547346	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.6	6.62	0.38	1.93e-10	Metabolite levels;
CESC	cis	rs1862618	0.802	rs832560	chr5:56124423	T/A	cg24531977	chr5:56204891	C5orf35	-0.88	-11.52	-0.58	3.54e-25	Initial pursuit acceleration;
CESC	cis	rs11871801	0.560	rs8074296	chr17:40583421	A/G	cg21433558	chr17:40837037	CNTNAP1	0.46	5.96	0.34	8.13e-9	Crohn's disease;
CESC	cis	rs8031584	1.000	rs35607976	chr15:31277788	T/C	cg14829155	chr15:31115871	NA	-0.77	-9.8	-0.52	1.49e-19	Huntington's disease progression;
CESC	cis	rs9916302	0.904	rs588193	chr17:37440439	A/C	cg15445000	chr17:37608096	MED1	-0.39	-6.26	-0.36	1.53e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs72945132	0.714	rs57320340	chr11:70160010	G/C	cg14191688	chr11:70257035	CTTN	0.42	5.34	0.31	1.95e-7	Coronary artery disease;
CESC	cis	rs11997175	1.000	rs7464996	chr8:33770925	G/T	ch.8.33884649F	chr8:33765107	NA	0.64	8.33	0.46	4.36e-15	Body mass index;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg03970961	chr1:154292240	AQP10	-0.39	-6.28	-0.36	1.4e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs798554	0.634	rs6978692	chr7:2857411	C/T	cg09658497	chr7:2847517	GNA12	-0.34	-5.28	-0.31	2.73e-7	Height;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg00502555	chr19:1103806	GPX4	-0.4	-6.06	-0.35	4.7e-9	Gambling;
CESC	cis	rs11203032	0.831	rs2863216	chr10:90941937	C/T	cg16672925	chr10:90967113	CH25H	0.68	6.99	0.39	2.24e-11	Heart failure;
CESC	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg18402987	chr7:1209562	NA	0.76	7.79	0.43	1.5e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs9905704	0.918	rs304293	chr17:56823298	T/G	cg12560992	chr17:57184187	TRIM37	0.61	7.12	0.4	9.95e-12	Testicular germ cell tumor;
CESC	cis	rs4835473	0.808	rs4054643	chr4:144708482	A/G	cg25736465	chr4:144833511	NA	-0.35	-5.61	-0.33	5e-8	Immature fraction of reticulocytes;
CESC	cis	rs2228479	0.850	rs62054611	chr16:89817017	T/C	cg04013166	chr16:89971882	TCF25	0.77	6.66	0.38	1.58e-10	Skin colour saturation;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg26381048	chr12:132632420	NOC4L	0.54	7.88	0.44	8.62e-14	Fibrinogen levels;
CESC	cis	rs9649213	0.593	rs13246843	chr7:98002661	G/T	cg08684580	chr7:98029266	BAIAP2L1	-0.35	-5.8	-0.34	1.85e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7246657	0.882	rs8112610	chr19:37928730	C/A	cg23950597	chr19:37808831	NA	-0.54	-5.89	-0.34	1.17e-8	Coronary artery calcification;
CESC	cis	rs72781680	1.000	rs72781658	chr2:24220141	A/G	cg08917208	chr2:24149416	ATAD2B	1.13	9.89	0.52	7.76e-20	Lymphocyte counts;
CESC	trans	rs61931739	0.534	rs11053049	chr12:34164537	T/C	cg26384229	chr12:38710491	ALG10B	0.64	9.03	0.49	3.54e-17	Morning vs. evening chronotype;
CESC	cis	rs4862750	0.872	rs9998173	chr4:187898778	T/A	cg11301795	chr4:187892539	NA	-0.75	-12.51	-0.61	1.63e-28	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2239547	0.657	rs2072391	chr3:52862200	C/T	cg11645453	chr3:52864694	ITIH4	0.32	5.89	0.34	1.15e-8	Schizophrenia;
CESC	cis	rs7927771	1.000	rs4752797	chr11:47874364	C/T	cg18512352	chr11:47633146	NA	-0.55	-8.66	-0.47	4.6e-16	Subjective well-being;
CESC	cis	rs9916302	0.851	rs11870631	chr17:37645129	C/T	cg00129232	chr17:37814104	STARD3	-0.54	-7.14	-0.4	9.08e-12	Glomerular filtration rate (creatinine);
CESC	cis	rs2710642	0.721	rs6757128	chr2:62891752	C/T	cg17519650	chr2:63277830	OTX1	-0.56	-6.91	-0.39	3.59e-11	LDL cholesterol levels;LDL cholesterol;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01888129	chr15:64126210	HERC1	0.62	7.6	0.42	5.05e-13	Gut microbiome composition (summer);
CESC	cis	rs1799949	0.526	rs4352088	chr17:41414679	A/G	cg05368731	chr17:41323189	NBR1	0.78	10.63	0.55	3.32e-22	Menopause (age at onset);
CESC	cis	rs9649213	0.593	rs2394854	chr7:98027306	A/G	cg00277769	chr7:97922759	BAIAP2L1	-0.32	-5.21	-0.3	3.78e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs1799949	1.000	rs11653231	chr17:41331460	G/A	cg25072359	chr17:41440525	NA	0.48	6.46	0.37	4.98e-10	Menopause (age at onset);
CESC	cis	rs56046484	0.912	rs12914674	chr15:85663060	A/C	cg08123816	chr15:85640762	PDE8A	-0.5	-6.15	-0.35	2.81e-9	Testicular germ cell tumor;
CESC	cis	rs3820928	1.000	rs2163041	chr2:227772480	T/C	cg05526886	chr2:227700861	RHBDD1	-0.42	-5.54	-0.32	7.19e-8	Pulmonary function;
CESC	cis	rs9911578	0.874	rs302865	chr17:56756977	A/G	cg12560992	chr17:57184187	TRIM37	0.92	15.05	0.68	2.08e-37	Intelligence (multi-trait analysis);
CESC	cis	rs853679	0.517	rs9380056	chr6:28104476	C/T	cg26335602	chr6:28129616	ZNF389	0.54	7.3	0.41	3.37e-12	Depression;
CESC	cis	rs6430585	0.583	rs76097170	chr2:136593498	C/T	cg07169764	chr2:136633963	MCM6	1.28	19.03	0.76	1.69e-51	Corneal structure;
CESC	cis	rs116095464	0.558	rs7730700	chr5:264713	G/A	cg10591111	chr5:226296	SDHA	-0.52	-6.35	-0.36	9.51e-10	Breast cancer;
CESC	cis	rs9300255	0.782	rs12809602	chr12:123768916	T/G	cg00376283	chr12:123451042	ABCB9	-0.61	-6.35	-0.36	9.35e-10	Neutrophil percentage of white cells;
CESC	cis	rs959260	1.000	rs2053158	chr17:73393459	A/T	cg12999837	chr17:73267436	MIF4GD	0.46	5.34	0.31	1.98e-7	Systemic lupus erythematosus;
CESC	cis	rs6500602	0.627	rs9934267	chr16:4534366	G/C	cg08645402	chr16:4508243	NA	0.42	5.92	0.34	1.01e-8	Schizophrenia;
CESC	cis	rs2519796	0.562	rs2519112	chr9:136811747	A/G	cg13751417	chr9:136814406	VAV2	-0.42	-5.32	-0.31	2.2e-7	Hematocrit;Hemoglobin concentration;
CESC	cis	rs6952808	0.575	rs6950330	chr7:1953606	T/C	cg04267008	chr7:1944627	MAD1L1	-0.59	-7.47	-0.42	1.16e-12	Bipolar disorder and schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21101222	chr5:151138161	ATOX1	0.61	7.14	0.4	9.23e-12	Gut microbiome composition (summer);
CESC	cis	rs2276314	0.857	rs8097597	chr18:33619448	A/G	cg19628046	chr18:33552617	C18orf21	0.49	5.74	0.33	2.64e-8	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs4919694	1.000	rs4917986	chr10:104630181	T/C	cg04362960	chr10:104952993	NT5C2	0.73	6.43	0.37	5.81e-10	Arsenic metabolism;
CESC	cis	rs523522	0.926	rs10849766	chr12:121025894	G/A	cg27279351	chr12:120934652	DYNLL1	0.7	9.1	0.49	2.31e-17	High light scatter reticulocyte count;
CESC	cis	rs13108904	0.934	rs13124383	chr4:1299986	C/T	cg00684032	chr4:1343700	KIAA1530	0.39	5.44	0.32	1.19e-7	Obesity-related traits;
CESC	cis	rs2836974	0.545	rs3167757	chr21:40714478	C/T	cg17971929	chr21:40555470	PSMG1	0.59	7.62	0.42	4.4e-13	Cognitive function;
CESC	cis	rs826838	0.834	rs2387842	chr12:38736442	T/C	cg26384229	chr12:38710491	ALG10B	0.84	14.7	0.67	3.46e-36	Heart rate;
CESC	cis	rs1577917	0.958	rs11755642	chr6:86450066	A/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.56	-7.32	-0.41	2.99e-12	Response to antipsychotic treatment;
CESC	cis	rs425277	1.000	rs262667	chr1:2082722	T/C	cg16545954	chr1:2118288	C1orf86	0.33	5.58	0.32	5.82e-8	Height;
CESC	cis	rs6674176	0.628	rs3791116	chr1:44414156	T/A	cg12908607	chr1:44402522	ARTN	-0.45	-6.54	-0.37	3.07e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs6752107	1.000	rs3828309	chr2:234180410	C/T	cg23050873	chr2:234184376	ATG16L1;SCARNA5	-0.38	-5.62	-0.33	4.89e-8	Crohn's disease;Inflammatory bowel disease;
CESC	trans	rs11039798	0.588	rs11039807	chr11:48549391	T/A	cg15704280	chr7:45808275	SEPT13	0.65	6.75	0.38	9.47e-11	Axial length;
CESC	cis	rs7216064	1.000	rs12452511	chr17:65832576	A/G	cg12091567	chr17:66097778	LOC651250	-0.83	-8.29	-0.45	5.88e-15	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs62229266	0.835	rs998384	chr21:37445526	G/C	cg08632701	chr21:37451849	NA	-0.41	-5.65	-0.33	4.13e-8	Mitral valve prolapse;
CESC	trans	rs9929218	0.954	rs9929479	chr16:68821271	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.68	-8.65	-0.47	4.98e-16	Colorectal cancer;
CESC	cis	rs7618915	0.547	rs12486847	chr3:52691112	T/C	cg05564831	chr3:52568323	NT5DC2	0.44	6.76	0.38	9e-11	Bipolar disorder;
CESC	cis	rs1355223	1.000	rs2221720	chr11:34754921	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.42	5.53	0.32	7.58e-8	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg24101359	chr6:42928495	GNMT	-0.56	-8.09	-0.44	2.19e-14	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs977987	0.778	rs35415181	chr16:75403124	T/C	cg03315344	chr16:75512273	CHST6	0.4	5.74	0.33	2.54e-8	Dupuytren's disease;
CESC	cis	rs1707322	0.717	rs1972410	chr1:46080947	G/T	cg05343316	chr1:45956843	TESK2	0.47	5.74	0.33	2.6e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs10504229	0.906	rs2270609	chr8:58194684	G/A	cg24829409	chr8:58192753	C8orf71	-0.75	-9.61	-0.51	6.02e-19	Developmental language disorder (linguistic errors);
CESC	cis	rs12048904	0.541	rs6699536	chr1:101276544	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.79	10.18	0.53	9.36e-21	Multiple sclerosis;
CESC	cis	rs6938	0.534	rs7495739	chr15:75185670	C/T	cg14664628	chr15:75095509	CSK	0.55	7.56	0.42	6.62e-13	Breast cancer;
CESC	trans	rs650950	0.528	rs646660	chr11:35528452	C/T	cg08355568	chr6:7108248	RREB1	0.51	6.24	0.36	1.74e-9	Bronchopulmonary dysplasia;
CESC	cis	rs72781680	0.611	rs56326157	chr2:24312407	T/C	cg20701182	chr2:24300061	SF3B14	0.94	10.39	0.54	2.01e-21	Lymphocyte counts;
CESC	cis	rs60871478	0.730	rs62432226	chr7:792973	T/C	cg27478167	chr7:817139	HEATR2	-0.53	-5.67	-0.33	3.82e-8	Cerebrospinal P-tau181p levels;
CESC	cis	rs7395581	0.918	rs10838692	chr11:47345100	T/C	cg25783544	chr11:47291846	MADD	0.59	7.68	0.43	3.03e-13	HDL cholesterol;
CESC	cis	rs1799949	0.965	rs799916	chr17:41243190	G/T	cg05368731	chr17:41323189	NBR1	-0.57	-8.05	-0.44	2.88e-14	Menopause (age at onset);
CESC	cis	rs4919694	0.611	rs2271750	chr10:105174869	A/G	cg04362960	chr10:104952993	NT5C2	-0.62	-6.04	-0.35	5.26e-9	Arsenic metabolism;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07747791	chr7:27498134	NA	-0.51	-6.48	-0.37	4.42e-10	Gut microbiome composition (summer);
CESC	cis	rs7116495	0.609	rs2503	chr11:71719403	C/T	cg26138937	chr11:71823887	C11orf51	1.25	8.83	0.48	1.44e-16	Severe influenza A (H1N1) infection;
CESC	cis	rs1218582	0.600	rs72702224	chr1:154911689	G/A	cg24250549	chr1:154909240	PMVK	0.56	7.5	0.42	9.77e-13	Prostate cancer;
CESC	cis	rs8177253	0.761	rs12490148	chr3:133523973	C/T	cg12373951	chr3:133503437	NA	0.52	7.75	0.43	2.01e-13	Iron status biomarkers;
CESC	cis	rs1570884	0.516	rs2146144	chr13:50170245	C/T	cg08779649	chr13:50194554	NA	0.39	6.71	0.38	1.17e-10	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
CESC	cis	rs11190604	1.000	rs2495741	chr10:102331795	A/G	cg07080220	chr10:102295463	HIF1AN	0.58	5.64	0.33	4.47e-8	Palmitoleic acid (16:1n-7) levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27210852	chr21:46685308	POFUT2	-0.52	-6.11	-0.35	3.5e-9	Gut microbiome composition (summer);
CESC	cis	rs2274273	0.967	rs1009978	chr14:55603061	C/G	cg04306507	chr14:55594613	LGALS3	0.3	6.0	0.35	6.51e-9	Protein biomarker;
CESC	cis	rs9486719	1.000	rs12212614	chr6:97036466	T/G	cg18709589	chr6:96969512	KIAA0776	-0.5	-5.44	-0.32	1.21e-7	Migraine;Coronary artery disease;
CESC	trans	rs561341	0.941	rs2428341	chr17:30317295	C/T	cg27661571	chr11:113659931	NA	-0.56	-6.3	-0.36	1.24e-9	Hip circumference adjusted for BMI;
CESC	cis	rs2760061	0.626	rs591582	chr1:228117360	C/A	cg02753203	chr1:228287806	NA	-0.5	-7.24	-0.41	4.83e-12	Diastolic blood pressure;
CESC	cis	rs924607	0.966	rs1621827	chr5:635074	A/G	cg09021430	chr5:549028	NA	-0.39	-6.86	-0.39	4.95e-11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs7666738	0.830	rs11941844	chr4:99042722	A/T	cg05340658	chr4:99064831	C4orf37	0.82	12.88	0.62	8.44e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4665809	0.549	rs62130460	chr2:26472718	T/C	cg04944784	chr2:26401820	FAM59B	0.89	9.22	0.49	9.53e-18	Gut microbiome composition (summer);
CESC	cis	rs10242455	0.571	rs7805661	chr7:99171522	A/C	cg25640893	chr7:99214727	ZNF498	0.73	5.73	0.33	2.68e-8	Blood metabolite levels;
CESC	cis	rs1707322	1.000	rs11211222	chr1:46367757	T/C	cg05343316	chr1:45956843	TESK2	0.44	5.55	0.32	7.05e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7621025	0.675	rs34602896	chr3:136346385	A/G	cg15507776	chr3:136538369	TMEM22	-0.51	-5.48	-0.32	1.01e-7	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
CESC	cis	rs769267	1.000	rs7246748	chr19:19433105	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.62	-8.04	-0.44	2.94e-14	Tonsillectomy;
CESC	cis	rs733592	0.929	rs4760678	chr12:48461581	T/C	cg24011408	chr12:48396354	COL2A1	-0.51	-7.79	-0.43	1.55e-13	Plateletcrit;
CESC	cis	rs8114671	0.904	rs6060197	chr20:33654315	C/T	cg06115741	chr20:33292138	TP53INP2	-0.44	-5.31	-0.31	2.27e-7	Height;
CESC	cis	rs7714584	1.000	rs11749391	chr5:150229066	T/C	cg22134413	chr5:150180641	NA	0.53	5.84	0.34	1.49e-8	Crohn's disease;
CESC	cis	rs7917772	0.503	rs7902306	chr10:104290462	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.51	6.67	0.38	1.46e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg26354017	chr1:205819088	PM20D1	0.85	12.61	0.61	6.88e-29	Menarche (age at onset);
CESC	cis	rs7412746	0.658	rs10305714	chr1:150800655	C/T	cg04414720	chr1:150670196	GOLPH3L	-0.55	-7.46	-0.42	1.26e-12	Melanoma;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12503190	chr17:74733672	MIR636;SFRS2;MFSD11	0.59	6.62	0.38	1.98e-10	Gut microbiome composition (summer);
CESC	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.45	0.37	5.34e-10	Prudent dietary pattern;
CESC	cis	rs8050907	0.744	rs28629405	chr16:4525933	G/C	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.9	6.28	0.36	1.39e-9	Obesity-related traits;
CESC	cis	rs10504229	0.906	rs112793785	chr8:58190537	T/C	cg22535103	chr8:58192502	C8orf71	-1.04	-13.21	-0.63	5.76e-31	Developmental language disorder (linguistic errors);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg13327952	chr7:90032561	CLDN12	0.45	6.45	0.37	5.38e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs2742234	0.541	rs871763	chr10:43734188	C/T	cg07801480	chr10:43725741	RASGEF1A	-0.41	-5.3	-0.31	2.47e-7	Hirschsprung disease;
CESC	cis	rs2180341	0.920	rs1073932	chr6:127682009	G/T	cg24812749	chr6:127587940	RNF146	1.05	15.15	0.68	9.37e-38	Breast cancer;
CESC	cis	rs9322193	0.886	rs9485408	chr6:149940024	T/C	cg07701084	chr6:150067640	NUP43	0.46	6.45	0.37	5.26e-10	Lung cancer;
CESC	cis	rs7833986	0.501	rs2719227	chr8:57043794	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	-0.59	-7.45	-0.42	1.3e-12	Height;
CESC	cis	rs1552244	1.000	rs35198334	chr3:10104553	G/C	cg08888203	chr3:10149979	C3orf24	0.51	6.44	0.37	5.71e-10	Alzheimer's disease;
CESC	cis	rs35306767	0.903	rs12764024	chr10:922861	A/G	cg20503657	chr10:835505	NA	0.72	7.48	0.42	1.07e-12	Eosinophil percentage of granulocytes;
CESC	cis	rs2635047	0.967	rs3816125	chr18:44601611	C/T	cg19077165	chr18:44547161	KATNAL2	0.45	5.45	0.32	1.13e-7	Educational attainment;
CESC	cis	rs1355223	0.583	rs2941041	chr11:34874734	A/C	cg11058730	chr11:34937778	PDHX;APIP	0.84	12.9	0.62	6.88e-30	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs7772486	0.686	rs857880	chr6:145971115	T/C	cg05347473	chr6:146136440	FBXO30	-0.52	-6.77	-0.38	8.3e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2109514	1.000	rs7795510	chr7:116156961	T/C	cg12739419	chr7:116140593	CAV2	-0.36	-6.54	-0.37	3.15e-10	Prevalent atrial fibrillation;
CESC	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg24642844	chr7:1081250	C7orf50	-0.75	-8.99	-0.48	4.94e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7264396	0.635	rs6060681	chr20:34506147	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.78	-10.8	-0.55	8.73e-23	Total cholesterol levels;
CESC	trans	rs11098499	0.954	rs34858317	chr4:120387110	A/C	cg25214090	chr10:38739885	LOC399744	0.7	9.93	0.52	5.63e-20	Corneal astigmatism;
CESC	cis	rs9888739	0.800	rs1143678	chr16:31343005	C/T	cg15817542	chr16:31343056	ITGAM	-0.54	-7.68	-0.43	3.13e-13	Systemic lupus erythematosus;
CESC	cis	rs8180040	0.726	rs4234465	chr3:47026885	C/G	cg27129171	chr3:47204927	SETD2	0.61	8.52	0.46	1.24e-15	Colorectal cancer;
CESC	cis	rs9888739	1.000	rs12928810	chr16:31311715	G/A	cg15817542	chr16:31343056	ITGAM	-0.43	-5.54	-0.32	7.48e-8	Systemic lupus erythematosus;
CESC	cis	rs9611565	0.649	rs5758466	chr22:42176059	G/A	cg06634786	chr22:41940651	POLR3H	0.46	5.06	0.3	7.69e-7	Vitiligo;
CESC	cis	rs6991838	0.557	rs4737222	chr8:66500113	G/T	cg13398993	chr8:66546079	ARMC1	-0.48	-5.77	-0.33	2.26e-8	Intelligence (multi-trait analysis);
CESC	cis	rs1003719	0.788	rs2040341	chr21:38489753	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.63	8.7	0.47	3.66e-16	Eye color traits;
CESC	cis	rs9291683	0.546	rs7442336	chr4:10045783	G/A	cg00071950	chr4:10020882	SLC2A9	0.81	13.65	0.64	1.8e-32	Bone mineral density;
CESC	cis	rs11958404	0.932	rs72816564	chr5:157427484	T/C	cg05962755	chr5:157440814	NA	0.62	6.53	0.37	3.41e-10	IgG glycosylation;
CESC	cis	rs11098499	0.954	rs2892848	chr4:120381341	C/T	cg24375607	chr4:120327624	NA	0.45	5.54	0.32	7.19e-8	Corneal astigmatism;
CESC	cis	rs875971	0.660	rs10215132	chr7:66054406	C/A	cg14393609	chr7:65229607	NA	-0.46	-6.17	-0.35	2.6e-9	Aortic root size;
CESC	trans	rs2727020	0.575	rs10769587	chr11:49549849	C/G	cg15704280	chr7:45808275	SEPT13	-0.94	-16.08	-0.7	4.42e-41	Coronary artery disease;
CESC	cis	rs7178572	1.000	rs8024485	chr15:77718368	C/A	cg22256960	chr15:77711686	NA	-0.59	-7.96	-0.44	5e-14	Type 2 diabetes;
CESC	cis	rs35306767	0.855	rs11253465	chr10:897208	A/C	cg20503657	chr10:835505	NA	0.74	7.52	0.42	8.76e-13	Eosinophil percentage of granulocytes;
CESC	trans	rs10496702	0.818	rs17800749	chr2:134003754	C/T	cg01707976	chr16:4991230	NA	0.49	6.02	0.35	5.7e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs11864453	0.647	rs10492813	chr16:72122463	A/G	cg01557791	chr16:72042693	DHODH	0.43	5.63	0.33	4.58e-8	Fibrinogen levels;
CESC	cis	rs1499614	1.000	rs2141924	chr7:66186246	C/T	cg18252515	chr7:66147081	NA	-1.42	-14.62	-0.67	6.69e-36	Gout;
CESC	cis	rs2985684	0.895	rs3007033	chr14:50103816	T/C	cg15316458	chr14:50087796	RPL36AL;MGAT2	0.46	5.19	0.3	4.19e-7	Carotid intima media thickness;
CESC	cis	rs938554	0.571	rs7696092	chr4:10025320	C/A	cg11266682	chr4:10021025	SLC2A9	0.57	8.13	0.45	1.63e-14	Blood metabolite levels;
CESC	cis	rs7116495	0.609	rs567026	chr11:71769952	C/T	cg18441811	chr11:71824068	C11orf51	0.79	5.1	0.3	6.47e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs11997175	0.524	rs10954932	chr8:33650176	A/C	ch.8.33884649F	chr8:33765107	NA	0.65	8.33	0.46	4.44e-15	Body mass index;
CESC	cis	rs3820928	0.874	rs2396452	chr2:227838040	T/G	cg05526886	chr2:227700861	RHBDD1	-0.44	-5.53	-0.32	7.61e-8	Pulmonary function;
CESC	cis	rs1552244	1.000	rs4260416	chr3:10125283	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	12.84	0.62	1.18e-29	Alzheimer's disease;
CESC	cis	rs2839186	0.771	rs2280959	chr21:47641996	C/G	cg13126279	chr21:47581558	C21orf56	-0.48	-6.54	-0.37	3.1e-10	Testicular germ cell tumor;
CESC	cis	rs4699052	0.739	rs6836157	chr4:104242990	A/G	cg16532752	chr4:104119610	CENPE	-0.38	-5.35	-0.31	1.87e-7	Testicular germ cell tumor;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00814883	chr7:100076585	TSC22D4	0.62	7.27	0.41	4e-12	Gut microbiome composition (summer);
CESC	cis	rs7223966	1.000	rs8076717	chr17:61850301	C/T	cg11494091	chr17:61959527	GH2	-0.38	-5.1	-0.3	6.36e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs1348850	0.651	rs4893821	chr2:178229352	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.66	-9.11	-0.49	2.07e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs12586317	0.547	rs112510746	chr14:35491833	T/G	cg05294307	chr14:35346193	BAZ1A	-0.51	-5.4	-0.31	1.49e-7	Psoriasis;
CESC	trans	rs11098499	0.818	rs10008791	chr4:120431469	A/C	cg25214090	chr10:38739885	LOC399744	0.7	9.62	0.51	5.54e-19	Corneal astigmatism;
CESC	cis	rs910316	1.000	rs910316	chr14:75626042	A/C	cg11812906	chr14:75593930	NEK9	0.9	14.82	0.67	1.35e-36	Height;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg23814154	chr12:51611356	POU6F1	-0.5	-6.86	-0.39	4.87e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs1878931	0.582	rs27232	chr16:3436782	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.68	-8.23	-0.45	8.3e-15	Body mass index (adult);
CESC	cis	rs12545109	0.800	rs2221919	chr8:57412541	A/C	cg09654669	chr8:57350985	NA	-0.46	-6.28	-0.36	1.4e-9	Obesity-related traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18099850	chr8:22993352	TNFRSF10D	-0.54	-6.36	-0.36	8.79e-10	Gut microbiome composition (summer);
CESC	trans	rs916888	0.610	rs199530	chr17:44836653	C/T	cg22968622	chr17:43663579	NA	-0.73	-9.94	-0.52	5.42e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs17711722	0.727	rs2658585	chr7:65461941	A/T	cg11987759	chr7:65425863	GUSB	-0.47	-6.25	-0.36	1.62e-9	Calcium levels;
CESC	cis	rs911555	0.755	rs7147664	chr14:103963420	G/A	cg09975044	chr14:104007538	NA	0.43	5.31	0.31	2.33e-7	Intelligence (multi-trait analysis);
CESC	cis	rs3785574	0.621	rs1051684	chr17:62006497	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.82	-11.83	-0.59	3.34e-26	Height;
CESC	cis	rs1799949	0.965	rs799917	chr17:41244936	G/A	cg05368731	chr17:41323189	NBR1	0.52	7.34	0.41	2.56e-12	Menopause (age at onset);
CESC	cis	rs2635047	0.967	rs2571001	chr18:44665083	C/A	cg19077165	chr18:44547161	KATNAL2	-0.44	-5.81	-0.34	1.83e-8	Educational attainment;
CESC	cis	rs6496667	0.565	rs7162107	chr15:90889046	A/G	cg22089800	chr15:90895588	ZNF774	0.5	6.11	0.35	3.56e-9	Rheumatoid arthritis;
CESC	cis	rs9926296	0.593	rs6500456	chr16:89888341	T/C	cg03388025	chr16:89894329	SPIRE2	0.31	5.47	0.32	1.07e-7	Vitiligo;
CESC	cis	rs703842	0.616	rs4760332	chr12:58222672	A/C	cg00677455	chr12:58241039	CTDSP2	-0.74	-10.06	-0.53	2.31e-20	Multiple sclerosis;
CESC	cis	rs947211	0.948	rs12565968	chr1:205755046	A/G	cg14893161	chr1:205819251	PM20D1	-0.4	-5.34	-0.31	1.98e-7	Parkinson's disease;
CESC	trans	rs35851103	0.600	rs4841662	chr8:11843758	A/G	cg15556689	chr8:8085844	FLJ10661	-0.52	-6.45	-0.37	5.18e-10	Neuroticism;
CESC	cis	rs8114671	0.836	rs1885114	chr20:33577361	A/G	cg24642439	chr20:33292090	TP53INP2	-0.42	-5.04	-0.3	8.62e-7	Height;
CESC	cis	rs1215050	0.904	rs2903153	chr4:99057457	C/T	cg05340658	chr4:99064831	C4orf37	0.55	6.83	0.39	5.65e-11	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs7223966	1.000	rs73337598	chr17:61732576	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	7.4	0.41	1.86e-12	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs1707322	0.752	rs6658700	chr1:46160260	C/T	cg05343316	chr1:45956843	TESK2	0.51	6.32	0.36	1.09e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs12042938	0.935	rs1094653	chr1:231794794	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.47	6.5	0.37	3.89e-10	Neuranatomic and neurocognitive phenotypes;
CESC	cis	rs6831352	0.918	rs2851248	chr4:100045974	A/G	cg12011299	chr4:100065546	ADH4	0.57	6.49	0.37	4.09e-10	Alcohol dependence;
CESC	cis	rs3806843	0.868	rs2531352	chr5:140119534	A/G	cg26395211	chr5:140044315	WDR55	0.4	5.17	0.3	4.58e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs73206853	0.764	rs3026425	chr12:110688168	A/G	cg12870014	chr12:110450643	ANKRD13A	0.64	5.37	0.31	1.75e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.46	6.2	0.36	2.13e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.76	6.69	0.38	1.3e-10	Platelet count;
CESC	cis	rs11168351	0.864	rs10875743	chr12:48498413	C/T	cg24011408	chr12:48396354	COL2A1	-0.5	-7.63	-0.42	4.18e-13	Bipolar disorder and schizophrenia;
CESC	cis	rs17431357	1.000	rs73230318	chr12:120997937	T/C	cg25045489	chr12:120971538	RNF10	-0.93	-5.46	-0.32	1.1e-7	Insulin resistance/response;
CESC	cis	rs2236918	0.687	rs2797601	chr1:242029249	C/G	cg17736920	chr1:242011382	EXO1	0.55	6.97	0.39	2.5e-11	Menopause (age at onset);
CESC	cis	rs34638657	0.673	rs11645286	chr16:82201898	C/A	cg09439754	chr16:82129088	HSD17B2	-0.35	-6.28	-0.36	1.39e-9	Lung adenocarcinoma;
CESC	cis	rs4819052	0.851	rs7276103	chr21:46666078	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.73	9.92	0.52	6.12e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs950169	0.922	rs4842940	chr15:84831225	C/T	cg17507749	chr15:85114479	UBE2QP1	-0.55	-6.25	-0.36	1.66e-9	Schizophrenia;
CESC	cis	rs12586317	0.547	rs115019197	chr14:35503764	G/A	cg16230307	chr14:35515116	FAM177A1	0.99	10.61	0.55	3.72e-22	Psoriasis;
CESC	cis	rs16870629	0.541	rs2334955	chr5:1062444	A/G	cg00278107	chr5:1061253	SLC12A7	-0.69	-10.79	-0.55	9.44e-23	QT interval;
CESC	cis	rs6665290	0.904	rs6684821	chr1:227190233	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.21	-30.96	-0.89	5.21e-90	Myeloid white cell count;
CESC	cis	rs7772486	0.597	rs2246132	chr6:146182515	C/G	cg13319975	chr6:146136371	FBXO30	-0.42	-5.26	-0.31	3.01e-7	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg09800975	chr10:6130861	RBM17	0.46	6.19	0.36	2.32e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs4332037	0.539	rs11764590	chr7:2032803	C/T	cg11693508	chr17:37793320	STARD3	0.65	6.51	0.37	3.72e-10	Bipolar disorder;
CESC	cis	rs6938	0.534	rs4886636	chr15:75196176	G/A	cg14664628	chr15:75095509	CSK	-0.56	-7.58	-0.42	6e-13	Breast cancer;
CESC	cis	rs57083693	0.518	rs7975348	chr12:101701930	T/C	cg22051763	chr12:101673672	UTP20	-0.44	-5.5	-0.32	8.8e-8	Alcohol dependence (age at onset);
CESC	cis	rs2841277	0.646	rs3742935	chr14:105405599	G/C	cg21017887	chr14:105400489	NA	0.41	6.67	0.38	1.45e-10	Rheumatoid arthritis;
CESC	cis	rs6493487	0.512	rs11856129	chr15:51172604	T/C	cg02338191	chr15:51200825	AP4E1	0.6	5.58	0.32	5.79e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs67311347	1.000	rs11716675	chr3:40485280	G/T	cg24209194	chr3:40518798	ZNF619	0.46	5.99	0.35	6.78e-9	Renal cell carcinoma;
CESC	cis	rs763014	0.931	rs2071980	chr16:626346	A/C	cg00802000	chr16:706648	WDR90	-0.41	-6.09	-0.35	3.94e-9	Height;
CESC	cis	rs1559088	0.947	rs12461219	chr19:33550633	C/G	cg27124370	chr19:33622961	WDR88	0.42	5.34	0.31	1.99e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs11098499	0.866	rs12513310	chr4:120288039	T/A	cg09307838	chr4:120376055	NA	0.87	12.16	0.6	2.41e-27	Corneal astigmatism;
CESC	cis	rs2629540	0.824	rs1552345	chr10:126477406	A/G	cg08799069	chr10:126477246	METTL10	-0.69	-9.41	-0.5	2.51e-18	Cocaine dependence;
CESC	cis	rs801193	0.660	rs974239	chr7:66213491	G/A	cg10691866	chr7:65817282	TPST1	-0.36	-6.1	-0.35	3.77e-9	Aortic root size;
CESC	cis	rs1799949	1.000	rs8070085	chr17:41341984	C/T	cg01879757	chr17:41196368	BRCA1	0.37	5.17	0.3	4.61e-7	Menopause (age at onset);
CESC	cis	rs12579753	0.719	rs4418884	chr12:82277006	C/T	cg21193143	chr12:82153300	PPFIA2	-0.35	-5.35	-0.31	1.92e-7	Resting heart rate;
CESC	cis	rs9303401	0.614	rs34900851	chr17:56566399	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.99	12.07	0.6	4.86e-27	Cognitive test performance;
CESC	cis	rs4819052	0.679	rs4819053	chr21:46711357	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.85	-12.5	-0.61	1.71e-28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs2404602	0.692	rs10444858	chr15:76962504	T/C	cg26408565	chr15:76604113	ETFA	-0.39	-5.58	-0.32	5.8e-8	Blood metabolite levels;
CESC	trans	rs116095464	0.558	rs9688136	chr5:229348	T/C	cg00938859	chr5:1591904	SDHAP3	0.61	6.74	0.38	9.82e-11	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02607779	chr2:208030673	KLF7	0.54	6.33	0.36	1.05e-9	Gut microbiome composition (summer);
CESC	cis	rs3096299	0.967	rs2911256	chr16:89485096	G/C	cg08392591	chr16:89556376	ANKRD11	0.45	5.9	0.34	1.08e-8	Multiple myeloma (IgH translocation);
CESC	cis	rs863345	0.604	rs10797013	chr1:158465506	G/C	cg12129480	chr1:158549410	OR10X1	-0.35	-7.03	-0.4	1.78e-11	Pneumococcal bacteremia;
CESC	cis	rs6570726	0.934	rs9484995	chr6:145781114	T/A	cg23711669	chr6:146136114	FBXO30	-0.72	-10.53	-0.54	6.67e-22	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2425143	1.000	rs6058325	chr20:34388806	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.68	5.93	0.34	9.19e-9	Blood protein levels;
CESC	cis	rs2985684	1.000	rs17121651	chr14:50097172	T/C	cg02151108	chr14:50098012	C14orf104	-0.42	-5.65	-0.33	4.16e-8	Carotid intima media thickness;
CESC	cis	rs3105593	0.563	rs12909531	chr15:50964832	T/C	cg08437265	chr15:50716283	USP8	0.41	5.2	0.3	4e-7	QT interval;
CESC	cis	rs6662572	1.000	rs28584711	chr1:46212631	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.51	5.55	0.32	7.08e-8	Blood protein levels;
CESC	cis	rs6088590	0.813	rs1884668	chr20:33285514	A/G	cg08999081	chr20:33150536	PIGU	0.64	10.56	0.54	5.39e-22	Coronary artery disease;
CESC	cis	rs7618915	0.501	rs3755798	chr3:52741160	G/A	cg05564831	chr3:52568323	NT5DC2	0.46	7.17	0.4	7.29e-12	Bipolar disorder;
CESC	cis	rs1552244	0.515	rs67626468	chr3:10161518	C/A	cg00149659	chr3:10157352	C3orf10	1.01	12.05	0.59	5.88e-27	Alzheimer's disease;
CESC	cis	rs7666738	0.830	rs2865981	chr4:99031493	G/A	cg03676636	chr4:99064102	C4orf37	0.34	5.27	0.31	2.8e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9649465	1.000	rs6466881	chr7:123337734	G/C	cg04330084	chr7:123175371	IQUB	-0.38	-5.16	-0.3	4.75e-7	Migraine;
CESC	cis	rs11098499	0.863	rs3822191	chr4:120428101	A/T	cg24375607	chr4:120327624	NA	0.44	5.25	0.31	3.13e-7	Corneal astigmatism;
CESC	cis	rs72720396	0.694	rs6689362	chr1:91203251	T/A	cg13456504	chr1:91191583	NA	-0.36	-5.54	-0.32	7.18e-8	Morning vs. evening chronotype;Chronotype;
CESC	cis	rs4727027	0.651	rs12704068	chr7:148856153	T/C	cg23583168	chr7:148888333	NA	-0.73	-10.02	-0.52	2.91e-20	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs6570726	0.935	rs411641	chr6:145827532	G/A	cg05347473	chr6:146136440	FBXO30	0.49	6.69	0.38	1.36e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1144333	1.000	rs1144333	chr1:76275100	A/G	cg10523679	chr1:76189770	ACADM	-0.59	-5.59	-0.32	5.69e-8	Attention function in attention deficit hyperactive disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25008346	chr17:40118675	CNP	0.55	6.51	0.37	3.74e-10	Gut microbiome composition (summer);
CESC	cis	rs7188697	0.922	rs37056	chr16:58560877	G/A	cg02549819	chr16:58548995	SETD6	-0.41	-5.21	-0.3	3.79e-7	QT interval;
CESC	cis	rs7829975	0.658	rs907181	chr8:8702875	T/C	cg18904891	chr8:8559673	CLDN23	0.44	5.58	0.32	5.82e-8	Mood instability;
CESC	cis	rs10979	1.000	rs9390107	chr6:143892721	A/T	cg25407410	chr6:143891975	LOC285740	-0.61	-9.21	-0.49	1.01e-17	Hypospadias;
CESC	cis	rs1790761	0.692	rs614080	chr11:67347287	G/A	cg24690094	chr11:67383802	NA	0.38	6.26	0.36	1.55e-9	Mean corpuscular volume;
CESC	cis	rs3204270	1.000	rs3204270	chr17:79682051	C/T	cg18367735	chr17:79674897	NA	0.74	5.34	0.31	2.04e-7	Dental caries;
CESC	cis	rs9815354	1.000	rs10212536	chr3:41827026	A/G	cg03022575	chr3:42003672	ULK4	0.47	5.12	0.3	5.95e-7	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs861020	1.000	rs674433	chr1:209964875	A/C	cg05527609	chr1:210001259	C1orf107	-0.99	-12.29	-0.6	9.17e-28	Orofacial clefts;
CESC	cis	rs1003719	0.715	rs8128387	chr21:38556787	G/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.6	-8.13	-0.45	1.62e-14	Eye color traits;
CESC	cis	rs2710642	0.779	rs360807	chr2:62926859	C/T	cg17519650	chr2:63277830	OTX1	-0.6	-7.72	-0.43	2.43e-13	LDL cholesterol levels;LDL cholesterol;
CESC	cis	rs1799949	1.000	rs12950607	chr17:41299928	G/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.45	6.31	0.36	1.17e-9	Menopause (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25003565	chr1:150207434	ANP32E	0.65	7.21	0.4	5.69e-12	Gut microbiome composition (summer);
CESC	cis	rs7809950	0.678	rs12670688	chr7:106821016	A/G	cg23024343	chr7:107201750	COG5	0.6	6.84	0.39	5.58e-11	Coronary artery disease;
CESC	cis	rs6484504	0.532	rs12788257	chr11:31255045	T/C	cg14844989	chr11:31128820	NA	-0.41	-5.69	-0.33	3.28e-8	Red blood cell count;
CESC	cis	rs6547741	0.935	rs12615690	chr2:27851120	T/C	cg21248554	chr2:27665150	KRTCAP3	0.25	5.18	0.3	4.47e-7	Oral cavity cancer;
CESC	cis	rs72627509	0.857	rs2227901	chr4:57798189	A/G	cg26694713	chr4:57773883	REST	-0.58	-5.86	-0.34	1.37e-8	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CESC	cis	rs4819052	0.724	rs9753987	chr21:46661389	C/T	cg11663144	chr21:46675770	NA	-0.63	-10.02	-0.52	3.12e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs7726839	0.561	rs4957050	chr5:579066	A/C	cg16447950	chr5:562315	NA	-0.58	-6.74	-0.38	9.99e-11	Obesity-related traits;
CESC	cis	rs7267979	0.834	rs6115100	chr20:25225938	C/A	cg08601574	chr20:25228251	PYGB	0.44	6.36	0.36	8.57e-10	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs3741151	1.000	rs75912489	chr11:73073846	G/A	cg17517138	chr11:73019481	ARHGEF17	1.0	6.71	0.38	1.18e-10	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs6540559	0.611	rs61747285	chr1:210004332	G/A	cg21951975	chr1:209979733	IRF6	0.58	6.68	0.38	1.39e-10	Cleft lip with or without cleft palate;
CESC	cis	rs1008375	0.966	rs3775927	chr4:17599894	G/T	cg02297831	chr4:17616191	MED28	0.45	5.45	0.32	1.13e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs7762018	0.655	rs11966349	chr6:170162537	A/G	cg13891659	chr6:170190454	C6orf122;C6orf208	-0.51	-5.4	-0.31	1.49e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs77956314	0.515	rs60940473	chr12:117462582	C/T	cg02017074	chr12:117425053	FBXW8	-0.82	-8.44	-0.46	2.13e-15	Subcortical brain region volumes;Hippocampal volume;
CESC	cis	rs7927592	0.913	rs4084149	chr11:68288567	A/G	cg16797656	chr11:68205561	LRP5	0.37	5.04	0.3	8.47e-7	Total body bone mineral density;
CESC	cis	rs16867321	0.627	rs2042551	chr2:181579141	A/C	cg23363182	chr2:181467187	NA	0.44	6.53	0.37	3.28e-10	Obesity;
CESC	trans	rs7937682	0.883	rs11213941	chr11:111434094	T/C	cg18187862	chr3:45730750	SACM1L	-0.57	-6.74	-0.38	9.63e-11	Primary sclerosing cholangitis;
CESC	cis	rs2412819	0.599	rs2470120	chr15:43929070	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.47	7.15	0.4	8.67e-12	Lung cancer;
CESC	cis	rs10463316	0.862	rs59390562	chr5:150776092	A/G	cg03212797	chr5:150827313	SLC36A1	-0.45	-5.94	-0.34	9.07e-9	Metabolite levels (Pyroglutamine);
CESC	cis	rs2836974	0.932	rs2836953	chr21:40617483	G/A	cg17971929	chr21:40555470	PSMG1	1.06	16.47	0.71	1.87e-42	Cognitive function;
CESC	cis	rs7818345	0.967	rs12679712	chr8:19271032	C/G	cg11303988	chr8:19266685	CSGALNACT1	0.34	6.18	0.35	2.46e-9	Language performance in older adults (adjusted for episodic memory);
CESC	cis	rs2276314	1.000	rs2298716	chr18:33552598	C/T	cg05985134	chr18:33552581	C18orf21	0.66	7.82	0.43	1.28e-13	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs8077577	0.945	rs11656035	chr17:18086025	T/C	cg16794390	chr17:18148240	FLII	0.42	5.6	0.33	5.42e-8	Obesity-related traits;
CESC	cis	rs9796	0.689	rs28409432	chr15:41447454	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.46	-6.87	-0.39	4.48e-11	Menopause (age at onset);
CESC	cis	rs3820068	0.581	rs72645890	chr1:15930602	A/G	cg16988262	chr1:15930761	NA	0.35	5.65	0.33	4.18e-8	Systolic blood pressure;
CESC	cis	rs1023500	0.573	rs133377	chr22:42466950	C/T	cg04733989	chr22:42467013	NAGA	0.83	12.6	0.61	7.88e-29	Schizophrenia;
CESC	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.48	-6.08	-0.35	4.09e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2243480	1.000	rs778691	chr7:65873092	G/C	cg13147721	chr7:65941812	NA	-0.95	-8.95	-0.48	6.27e-17	Diabetic kidney disease;
CESC	cis	rs2657888	0.965	rs2657902	chr12:56933651	G/A	cg23002907	chr12:56915593	RBMS2	0.39	5.15	0.3	5.11e-7	Adiponectin levels;
CESC	cis	rs6088580	0.634	rs6120666	chr20:33090718	A/G	cg24642439	chr20:33292090	TP53INP2	0.5	6.54	0.37	3.24e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs1552244	0.882	rs66559400	chr3:10012551	G/A	cg08888203	chr3:10149979	C3orf24	0.48	5.96	0.34	7.91e-9	Alzheimer's disease;
CESC	cis	rs514406	0.644	rs7530078	chr1:53204861	G/T	cg27535305	chr1:53392650	SCP2	0.35	6.14	0.35	3.05e-9	Monocyte count;
CESC	cis	rs9902453	0.845	rs7501472	chr17:28010628	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.68	8.76	0.47	2.29e-16	Coffee consumption (cups per day);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12820191	chr3:186524311	RFC4	0.54	6.33	0.36	1.04e-9	Gut microbiome composition (summer);
CESC	cis	rs2882667	0.755	rs55650316	chr5:138467292	C/G	cg04439458	chr5:138467593	SIL1	-0.34	-5.29	-0.31	2.62e-7	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs798554	0.797	rs35957220	chr7:2812632	C/G	cg09658497	chr7:2847517	GNA12	-0.42	-5.82	-0.34	1.67e-8	Height;
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg17847749	chr12:116355168	NA	-0.46	-7.03	-0.4	1.78e-11	Vertical cup-disc ratio;
CESC	cis	rs7539409	0.764	rs4001465	chr1:84285304	T/C	cg10977910	chr1:84465055	TTLL7	0.69	5.75	0.33	2.5e-8	Alzheimer's disease;
CESC	cis	rs4889855	0.505	rs4890057	chr17:78591679	A/G	cg16591659	chr17:78472290	NA	-0.32	-5.17	-0.3	4.52e-7	Fractional excretion of uric acid;
CESC	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg16080015	chr7:5085479	RBAK	0.48	6.14	0.35	3.05e-9	Myopia (pathological);
CESC	cis	rs7666738	0.830	rs4699598	chr4:99019158	C/T	cg18180107	chr4:99064573	C4orf37	0.41	5.39	0.31	1.57e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs763014	0.966	rs7185390	chr16:666382	A/G	cg07343612	chr16:622815	PIGQ	-0.53	-7.71	-0.43	2.55e-13	Height;
CESC	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg11494091	chr17:61959527	GH2	-0.77	-12.9	-0.62	7.2e-30	Prudent dietary pattern;
CESC	cis	rs6594499	0.872	rs10059658	chr5:110452815	T/C	cg04022379	chr5:110408740	TSLP	0.33	5.7	0.33	3.24e-8	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs3806843	0.801	rs2531358	chr5:140117437	A/G	cg26395211	chr5:140044315	WDR55	0.45	5.69	0.33	3.28e-8	Depressive symptoms (multi-trait analysis);
CESC	cis	rs4654899	0.865	rs6426674	chr1:21483906	C/T	cg05370193	chr1:21551575	ECE1	0.46	7.08	0.4	1.28e-11	Superior frontal gyrus grey matter volume;
CESC	cis	rs397969	0.646	rs8079923	chr17:19869544	C/T	cg12073167	chr17:19770448	ULK2	-0.44	-5.11	-0.3	6.11e-7	Platelet count;
CESC	cis	rs6938	0.534	rs1127796	chr15:75193004	C/T	cg14664628	chr15:75095509	CSK	0.55	7.41	0.41	1.65e-12	Breast cancer;
CESC	trans	rs9325144	0.600	rs10785621	chr12:38744912	C/T	cg23762105	chr12:34175262	ALG10	-0.45	-6.02	-0.35	5.64e-9	Morning vs. evening chronotype;
CESC	cis	rs7666738	0.791	rs1115615	chr4:99006614	G/A	cg03467027	chr4:99064603	C4orf37	0.44	5.51	0.32	8.65e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4819052	1.000	rs733738	chr21:46666396	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	-0.59	-7.22	-0.41	5.53e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs4835473	0.663	rs4835115	chr4:144900461	G/T	cg25736465	chr4:144833511	NA	0.39	6.06	0.35	4.64e-9	Immature fraction of reticulocytes;
CESC	cis	rs11683229	0.704	rs13006926	chr2:63119967	T/C	cg17519650	chr2:63277830	OTX1	-0.7	-5.83	-0.34	1.64e-8	Protein quantitative trait loci;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg11887960	chr12:57824829	NA	-0.47	-6.25	-0.36	1.67e-9	Fibrinogen levels;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg10675120	chr10:75532504	FUT11	0.52	6.61	0.38	2.16e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs1580019	0.961	rs1610143	chr7:32498331	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.73	10.1	0.53	1.62e-20	Cognitive ability;
CESC	cis	rs6502050	0.835	rs66531647	chr17:80089022	G/T	cg11859384	chr17:80120422	CCDC57	-0.38	-5.14	-0.3	5.31e-7	Life satisfaction;
CESC	cis	rs6087990	0.735	rs2424906	chr20:31359109	A/G	cg13636640	chr20:31349939	DNMT3B	0.78	12.86	0.62	1.01e-29	Ulcerative colitis;
CESC	cis	rs2075371	0.965	rs1862049	chr7:133978344	A/T	cg11752832	chr7:134001865	SLC35B4	0.54	7.05	0.4	1.55e-11	Mean platelet volume;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg14394617	chr12:54674541	HNRNPA1;HNRPA1L-2;CBX5	-0.47	-6.75	-0.38	9.2e-11	Fibrinogen levels;
CESC	cis	rs17253792	0.822	rs17683728	chr14:56060389	C/T	cg01858014	chr14:56050164	KTN1	-0.87	-6.75	-0.38	9.11e-11	Putamen volume;
CESC	cis	rs56399783	0.614	rs11772508	chr7:2771504	A/C	cg19731401	chr7:2775893	GNA12	-0.64	-5.58	-0.32	5.9e-8	Childhood ear infection;
CESC	cis	rs889398	0.802	rs2291959	chr16:69873992	T/G	cg09409435	chr16:70099608	PDXDC2	0.42	5.3	0.31	2.47e-7	Body mass index;
CESC	cis	rs28829049	0.570	rs12060125	chr1:19391108	A/G	cg22333259	chr1:19394757	NA	-0.34	-5.86	-0.34	1.36e-8	QRS duration in Tripanosoma cruzi seropositivity;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg00983485	chr15:31284262	MTMR10	0.47	6.23	0.36	1.83e-9	Systemic lupus erythematosus;
CESC	cis	rs35306767	0.903	rs34270014	chr10:904666	T/C	cg26597838	chr10:835615	NA	0.85	8.88	0.48	1.02e-16	Eosinophil percentage of granulocytes;
CESC	cis	rs3026101	0.671	rs2301738	chr17:5308279	G/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.45	6.06	0.35	4.6e-9	Body mass index;
CESC	cis	rs6061231	0.724	rs1570027	chr20:60968596	A/G	cg22601191	chr20:60968625	CABLES2	0.53	6.24	0.36	1.73e-9	Colorectal cancer;
CESC	cis	rs35110281	0.574	rs1836856	chr21:44964638	A/T	cg21573476	chr21:45109991	RRP1B	-0.39	-5.41	-0.32	1.44e-7	Mean corpuscular volume;
CESC	cis	rs7605827	0.930	rs13033762	chr2:15592295	T/C	cg19274914	chr2:15703543	NA	0.32	5.67	0.33	3.73e-8	Educational attainment (years of education);
CESC	trans	rs4234798	0.546	rs4689667	chr4:7249188	A/T	cg24688926	chr19:6737877	GPR108	0.52	6.35	0.36	9.34e-10	Insulin-like growth factors;
CESC	cis	rs12579753	0.879	rs7971664	chr12:82264101	T/C	cg23701643	chr12:82153290	PPFIA2	-0.36	-5.21	-0.3	3.89e-7	Resting heart rate;
CESC	cis	rs10242455	0.702	rs73403247	chr7:99088730	G/A	cg25640893	chr7:99214727	ZNF498	0.69	5.12	0.3	5.75e-7	Blood metabolite levels;
CESC	cis	rs5763662	1.000	rs5753020	chr22:30524868	A/G	cg21388335	chr22:29999516	NF2	-0.74	-5.03	-0.3	9.22e-7	LDL cholesterol levels;LDL cholesterol;
CESC	cis	rs2652822	0.530	rs12595312	chr15:63494159	T/C	cg02713581	chr15:63449717	RPS27L	0.47	5.58	0.32	6.07e-8	Metabolic traits;
CESC	cis	rs7264396	1.000	rs224430	chr20:34153341	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.52	-6.44	-0.37	5.45e-10	Total cholesterol levels;
CESC	cis	rs9788682	0.747	rs28511883	chr15:78783683	C/T	cg24631222	chr15:78858424	CHRNA5	0.62	7.26	0.41	4.19e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs875971	0.895	rs10755833	chr7:65913917	A/G	cg11764359	chr7:65958608	NA	0.97	15.5	0.69	5.25e-39	Aortic root size;
CESC	cis	rs11792861	0.530	rs1772047	chr9:111679012	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	-0.38	-5.08	-0.3	7.12e-7	Menarche (age at onset);
CESC	cis	rs2836950	0.545	rs2836959	chr21:40623668	T/G	cg17971929	chr21:40555470	PSMG1	-0.6	-8.05	-0.44	2.83e-14	Menarche (age at onset);
CESC	cis	rs4901869	1.000	rs4901869	chr14:59334128	A/G	cg02291164	chr14:59296302	NA	0.45	7.73	0.43	2.21e-13	Panic disorder;
CESC	cis	rs1801251	0.778	rs809639	chr2:233731244	C/G	cg25237894	chr2:233734115	C2orf82	0.53	9.24	0.49	8.49e-18	Coronary artery disease;
CESC	cis	rs7264396	1.000	rs224434	chr20:34153856	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.5	-6.02	-0.35	5.88e-9	Total cholesterol levels;
CESC	cis	rs1862618	0.853	rs832583	chr5:56178217	A/C	cg24531977	chr5:56204891	C5orf35	-0.87	-10.95	-0.56	2.97e-23	Initial pursuit acceleration;
CESC	cis	rs3806843	0.676	rs2569159	chr5:140030710	C/T	cg26395211	chr5:140044315	WDR55	0.53	6.78	0.38	7.57e-11	Depressive symptoms (multi-trait analysis);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg14330119	chr7:73668867	RFC2	-0.39	-6.02	-0.35	5.83e-9	Gambling;
CESC	cis	rs7412746	0.634	rs3754212	chr1:150738200	A/G	cg09365446	chr1:150670422	GOLPH3L	0.39	5.11	0.3	6.21e-7	Melanoma;
CESC	cis	rs9660992	0.573	rs1172159	chr1:205207512	T/C	cg21643547	chr1:205240462	TMCC2	-0.38	-5.29	-0.31	2.51e-7	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs644799	1.000	rs518919	chr11:95623313	G/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.59	7.21	0.4	5.87e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs35955747	0.778	rs9609263	chr22:31745274	G/T	cg02404636	chr22:31891804	SFI1	-0.34	-5.04	-0.3	8.6e-7	Neutrophil count;Sum basophil neutrophil counts;
CESC	cis	rs4704187	0.687	rs67065524	chr5:74534309	A/G	cg03227963	chr5:74354835	NA	0.27	5.04	0.3	8.67e-7	Response to amphetamines;
CESC	cis	rs6952808	0.792	rs12536261	chr7:1953571	G/A	cg00106254	chr7:1943704	MAD1L1	-0.47	-5.93	-0.34	9.22e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs79839061	0.610	rs12651271	chr4:854071	C/T	cg07828340	chr4:882639	GAK	1.01	8.0	0.44	3.81e-14	Intelligence (multi-trait analysis);
CESC	cis	rs18122	0.632	rs12713595	chr2:67523685	A/G	cg09028215	chr2:67624308	ETAA1	0.42	5.28	0.31	2.68e-7	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs9868809	0.881	rs2276850	chr3:48669648	G/A	cg07636037	chr3:49044803	WDR6	-0.63	-5.15	-0.3	5.14e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs7408868	0.563	rs10404382	chr19:15301389	C/A	cg14696996	chr19:15285081	NOTCH3	0.96	9.76	0.51	1.98e-19	Pulse pressure;
CESC	cis	rs7084402	0.934	rs1579394	chr10:60294625	T/A	cg07615347	chr10:60278583	BICC1	0.6	9.42	0.5	2.35e-18	Refractive error;
CESC	trans	rs916888	0.821	rs199509	chr17:44858728	G/A	cg22968622	chr17:43663579	NA	-1.19	-16.28	-0.71	8.87e-42	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs752010	1.000	rs6664724	chr1:42093821	G/A	cg06885757	chr1:42089581	HIVEP3	0.5	8.15	0.45	1.49e-14	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs561341	1.000	rs501957	chr17:30314504	C/T	cg12193833	chr17:30244370	NA	-0.71	-6.63	-0.38	1.89e-10	Hip circumference adjusted for BMI;
CESC	cis	rs1461503	0.868	rs11602682	chr11:122842315	A/T	cg27398637	chr11:122830231	C11orf63	-0.53	-7.85	-0.43	1e-13	Menarche (age at onset);
CESC	cis	rs6922893	1.000	rs6922893	chr6:71660111	A/G	cg10766373	chr6:71666121	B3GAT2	-0.34	-5.47	-0.32	1.06e-7	Obesity-related traits;
CESC	cis	rs11696501	0.688	rs2281211	chr20:44312858	C/T	cg11783356	chr20:44313418	WFDC10B	-0.34	-5.25	-0.31	3.05e-7	Brain structure;
CESC	cis	rs10088262	0.629	rs12549683	chr8:124798276	G/C	cg02993010	chr8:124780839	FAM91A1	-0.67	-8.55	-0.46	1.01e-15	Pancreatic cancer;
CESC	cis	rs1023500	0.505	rs134878	chr22:42663874	A/G	cg15557168	chr22:42548783	NA	-0.41	-6.13	-0.35	3.17e-9	Schizophrenia;
CESC	cis	rs7520050	0.966	rs6677007	chr1:46400590	A/G	cg03146154	chr1:46216737	IPP	-0.47	-6.1	-0.35	3.66e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg07157834	chr1:205819609	PM20D1	0.71	11.02	0.56	1.73e-23	Menarche (age at onset);
CESC	cis	rs7107174	1.000	rs1399196	chr11:78071876	A/G	cg02023728	chr11:77925099	USP35	0.37	5.31	0.31	2.3e-7	Testicular germ cell tumor;
CESC	cis	rs9790314	0.846	rs1478568	chr3:161014276	C/T	cg04691961	chr3:161091175	C3orf57	-0.38	-5.07	-0.3	7.52e-7	Morning vs. evening chronotype;
CESC	cis	rs16866061	0.962	rs16825685	chr2:225434256	C/G	cg12698349	chr2:225449008	CUL3	0.75	11.58	0.58	2.29e-25	Acute graft versus host disease in bone marrow transplantation (recipient effect);
CESC	cis	rs4665809	0.590	rs11552518	chr2:26455127	G/A	cg22920501	chr2:26401640	FAM59B	0.91	10.38	0.54	2.08e-21	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20490900	chr1:1502606	SSU72	0.46	6.08	0.35	4.21e-9	Gut microbiome composition (summer);
CESC	cis	rs11250464	0.736	rs5015512	chr10:1411923	T/C	cg08668359	chr10:1443807	ADARB2	0.58	7.15	0.4	8.41e-12	Radiation response;
CESC	cis	rs9908102	0.740	rs55674356	chr17:12905574	T/A	cg26162695	chr17:12921313	ELAC2	0.5	5.49	0.32	9.61e-8	Schizophrenia;
CESC	cis	rs12474201	0.928	rs35825831	chr2:46932544	T/G	cg06386533	chr2:46925753	SOCS5	0.91	12.61	0.61	7.38e-29	Height;
CESC	cis	rs4862750	0.794	rs7672272	chr4:187896774	T/G	cg06074448	chr4:187884817	NA	-0.37	-5.45	-0.32	1.13e-7	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6582630	0.537	rs1829579	chr12:38420555	A/G	cg26384229	chr12:38710491	ALG10B	0.7	10.71	0.55	1.83e-22	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs7623687	0.786	rs73088161	chr3:49465162	C/T	cg07274523	chr3:49395745	GPX1	0.75	5.71	0.33	3e-8	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;
CESC	cis	rs11249608	0.548	rs7733072	chr5:178456007	A/G	cg01312482	chr5:178451176	ZNF879	-0.45	-6.36	-0.36	8.71e-10	Pubertal anthropometrics;
CESC	cis	rs72792276	1.000	rs3805603	chr5:127451581	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.66	5.2	0.3	3.93e-7	Red cell distribution width;
CESC	cis	rs1218582	0.661	rs4845695	chr1:154911798	A/G	cg03351412	chr1:154909251	PMVK	0.52	6.39	0.37	7.52e-10	Prostate cancer;
CESC	cis	rs62005083	1.000	rs62005154	chr14:74607008	G/A	cg05179529	chr14:74551516	LIN52;ALDH6A1	0.76	5.5	0.32	8.8e-8	Mean corpuscular volume;
CESC	cis	rs10979	1.000	rs9496681	chr6:143896964	G/A	cg25407410	chr6:143891975	LOC285740	-0.61	-9.2	-0.49	1.07e-17	Hypospadias;
CESC	cis	rs6714710	0.580	rs57804205	chr2:98454472	G/A	cg26665480	chr2:98280029	ACTR1B	0.57	7.91	0.44	7.03e-14	Posterior cortical atrophy and Alzheimer's disease;
CESC	cis	rs17376456	0.877	rs56373208	chr5:93491276	C/A	cg25358565	chr5:93447407	FAM172A	1.17	10.96	0.56	2.63e-23	Diabetic retinopathy;
CESC	cis	rs9894429	0.621	rs7502337	chr17:79588470	T/C	cg21984481	chr17:79567631	NPLOC4	-0.35	-5.5	-0.32	9.13e-8	Eye color traits;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg17757281	chr20:44604666	NA	-0.41	-6.16	-0.35	2.76e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs875971	0.964	rs12668936	chr7:65914404	C/T	cg11764359	chr7:65958608	NA	0.97	15.5	0.69	5.25e-39	Aortic root size;
CESC	cis	rs854765	0.693	rs9907246	chr17:17770965	T/C	cg16928487	chr17:17741425	SREBF1	0.6	10.79	0.55	9.76e-23	Total body bone mineral density;
CESC	cis	rs10242455	0.571	rs117370443	chr7:98975258	T/C	cg25640893	chr7:99214727	ZNF498	0.94	6.17	0.35	2.6e-9	Blood metabolite levels;
CESC	cis	rs644799	0.932	rs523934	chr11:95641775	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.79	11.35	0.57	1.33e-24	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs3862260	0.509	rs10802124	chr1:120164252	G/A	cg16322792	chr1:120165303	ZNF697	0.58	10.95	0.56	2.82e-23	Systemic lupus erythematosus;
CESC	cis	rs10504229	1.000	rs949848	chr8:58169125	A/G	cg24829409	chr8:58192753	C8orf71	-0.76	-10.0	-0.52	3.53e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs780096	0.526	rs1647276	chr2:27688601	C/T	cg02592271	chr2:27665507	KRTCAP3	-0.29	-5.79	-0.34	2e-8	Total body bone mineral density;
CESC	cis	rs4888262	0.564	rs8050850	chr16:74582597	C/A	cg01733217	chr16:74700730	RFWD3	0.81	11.45	0.58	6.4e-25	Testicular germ cell tumor;
CESC	cis	rs4253772	0.530	rs9615933	chr22:46677298	G/A	cg24881330	chr22:46731750	TRMU	0.78	5.81	0.34	1.81e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs9649213	0.593	rs7781916	chr7:97929738	A/G	cg00277769	chr7:97922759	BAIAP2L1	-0.34	-5.62	-0.33	4.89e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs875971	0.522	rs2949690	chr7:65483242	C/T	cg10691866	chr7:65817282	TPST1	0.33	5.24	0.31	3.31e-7	Aortic root size;
CESC	cis	rs11083475	0.692	rs755690	chr19:39167360	A/G	cg20002381	chr19:39279703	LGALS7B	-0.23	-5.09	-0.3	6.67e-7	Heart rate;
CESC	cis	rs1483121	0.609	rs34909049	chr11:48022512	C/T	cg20307385	chr11:47447363	PSMC3	0.7	6.37	0.36	8.22e-10	Fasting blood glucose (BMI interaction);Fasting blood glucose;
CESC	cis	rs8062405	0.723	rs12445744	chr16:28588395	A/C	cg01378222	chr16:28622494	SULT1A1	0.3	5.06	0.3	7.89e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs7927771	1.000	rs2290850	chr11:47807774	T/C	cg20307385	chr11:47447363	PSMC3	-0.5	-6.07	-0.35	4.49e-9	Subjective well-being;
CESC	cis	rs875971	0.660	rs6460308	chr7:66084740	T/C	cg18876405	chr7:65276391	NA	-0.56	-7.43	-0.42	1.46e-12	Aortic root size;
CESC	cis	rs654950	0.783	rs639298	chr1:42001530	A/G	cg06885757	chr1:42089581	HIVEP3	-0.48	-8.02	-0.44	3.38e-14	Airway imaging phenotypes;
CESC	cis	rs9611565	0.649	rs6002480	chr22:42176917	A/T	cg03806693	chr22:41940476	POLR3H	-0.76	-9.12	-0.49	2.01e-17	Vitiligo;
CESC	cis	rs6570726	0.791	rs11155426	chr6:145817130	T/C	cg05347473	chr6:146136440	FBXO30	0.59	7.59	0.42	5.36e-13	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs8070740	0.898	rs4239056	chr17:5324406	A/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.51	6.35	0.36	9.3e-10	Menopause (age at onset);
CESC	cis	rs4957048	0.577	rs56294732	chr5:568144	T/C	cg09021430	chr5:549028	NA	-0.48	-6.57	-0.37	2.6e-10	Ulcerative colitis;
CESC	cis	rs763121	0.853	rs2413546	chr22:39107001	G/A	cg06544989	chr22:39130855	UNC84B	0.51	8.87	0.48	1.07e-16	Menopause (age at onset);
CESC	cis	rs3106136	0.934	rs34145031	chr4:95167123	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.46	-6.94	-0.39	3.02e-11	Capecitabine sensitivity;
CESC	cis	rs7666738	0.800	rs13107586	chr4:99028788	G/C	cg03467027	chr4:99064603	C4orf37	0.49	6.18	0.35	2.44e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9837602	0.938	rs9828079	chr3:99806645	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.49	6.83	0.39	5.64e-11	Breast cancer;
CESC	trans	rs10411161	0.702	rs7251689	chr19:52389117	A/T	cg22319618	chr22:45562946	NUP50	-0.75	-7.56	-0.42	6.61e-13	Breast cancer;
CESC	cis	rs896854	0.654	rs4735339	chr8:95974373	C/T	cg16049864	chr8:95962084	TP53INP1	-0.65	-11.4	-0.57	9.17e-25	Type 2 diabetes;
CESC	cis	rs9815354	0.723	rs77572508	chr3:41938044	C/A	cg03022575	chr3:42003672	ULK4	0.71	6.44	0.37	5.46e-10	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs6582630	0.555	rs1969362	chr12:38514843	C/T	cg13010199	chr12:38710504	ALG10B	0.46	5.88	0.34	1.25e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs12497850	0.931	rs7643368	chr3:48992855	T/G	cg06212747	chr3:49208901	KLHDC8B	0.73	9.91	0.52	6.74e-20	Parkinson's disease;
CESC	cis	rs4727027	0.933	rs12667123	chr7:148850621	G/A	cg23158103	chr7:148848205	ZNF398	-0.42	-6.94	-0.39	3.1e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs34779708	0.931	rs67261877	chr10:35386340	T/A	cg04310649	chr10:35416472	CREM	-0.51	-6.06	-0.35	4.62e-9	Inflammatory bowel disease;Crohn's disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg05970768	chr5:171682616	UBTD2	0.45	6.44	0.37	5.67e-10	Fibrinogen levels;
CESC	trans	rs6818288	0.725	rs4286487	chr4:30077733	T/G	cg12528397	chr3:62933670	NA	0.42	6.13	0.35	3.2e-9	Obesity-related traits;
CESC	cis	rs7618915	0.501	rs3755798	chr3:52741160	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	7.99	0.44	4.17e-14	Bipolar disorder;
CESC	cis	rs2599510	0.811	rs2754520	chr2:32810293	G/A	cg02381751	chr2:32503542	YIPF4	0.43	5.3	0.31	2.45e-7	Interleukin-18 levels;
CESC	cis	rs10141207	0.531	rs1547213	chr14:32678646	C/A	cg23627301	chr14:32673368	NA	0.41	5.75	0.33	2.52e-8	Asthma;
CESC	cis	rs7219021	0.674	rs4793990	chr17:46960760	G/A	cg16584676	chr17:46985605	UBE2Z	0.63	7.71	0.43	2.52e-13	Schizophrenia or bipolar disorder;
CESC	cis	rs7927771	0.864	rs3781627	chr11:47441472	T/A	cg18512352	chr11:47633146	NA	0.45	6.31	0.36	1.19e-9	Subjective well-being;
CESC	cis	rs1878931	0.517	rs17685105	chr16:3413749	C/T	cg00484396	chr16:3507460	NAT15	0.34	5.09	0.3	6.64e-7	Body mass index (adult);
CESC	cis	rs7580658	0.545	rs12477559	chr2:127951797	C/T	cg10021288	chr2:128175891	PROC	-0.32	-5.07	-0.3	7.48e-7	Protein C levels;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg20615951	chr1:246730188	CNST;TFB2M	-0.46	-6.21	-0.36	2.02e-9	Height;
CESC	cis	rs412050	0.744	rs735244	chr22:22292099	C/T	cg17089214	chr22:22089827	YPEL1	0.67	5.77	0.33	2.2e-8	Attention deficit hyperactivity disorder;
CESC	cis	rs9913156	0.793	rs9436	chr17:4574751	T/A	cg19197139	chr17:4613644	ARRB2	0.94	10.64	0.55	2.94e-22	Lymphocyte counts;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg05312862	chr19:3699951	PIP5K1C	-0.49	-6.27	-0.36	1.44e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg10862848	chr6:42927986	GNMT	0.3	7.7	0.43	2.78e-13	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs7666738	0.830	rs1813251	chr4:98921170	A/G	cg03467027	chr4:99064603	C4orf37	0.43	5.32	0.31	2.17e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7267979	1.000	rs6083805	chr20:25317356	T/C	cg08601574	chr20:25228251	PYGB	-0.39	-5.58	-0.32	5.94e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs2979489	0.945	rs11988541	chr8:30334273	G/A	cg26383811	chr8:30366931	RBPMS	-0.84	-9.93	-0.52	5.8e-20	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CESC	cis	rs892961	0.867	rs1079354	chr17:75415713	C/T	cg05865280	chr17:75406074	SEPT9	0.58	11.17	0.57	5.43e-24	Airflow obstruction;
CESC	cis	rs10504229	0.906	rs56138544	chr8:58184558	A/C	cg05313129	chr8:58192883	C8orf71	-0.55	-6.29	-0.36	1.34e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs9916302	0.904	rs801420	chr17:37466103	C/G	cg15445000	chr17:37608096	MED1	-0.4	-6.54	-0.37	3.14e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs10242455	0.571	rs41279866	chr7:99315276	C/T	cg25640893	chr7:99214727	ZNF498	0.85	5.73	0.33	2.69e-8	Blood metabolite levels;
CESC	cis	rs193541	0.632	rs10037044	chr5:122123299	A/G	cg19412675	chr5:122181750	SNX24	-0.42	-5.04	-0.3	8.61e-7	Glucose homeostasis traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01806808	chr8:142011144	PTK2	0.67	7.36	0.41	2.36e-12	Gut microbiome composition (summer);
CESC	cis	rs6502050	0.712	rs8077079	chr17:80059011	C/T	cg23985595	chr17:80112537	CCDC57	0.39	5.9	0.34	1.13e-8	Life satisfaction;
CESC	cis	rs7833790	0.724	rs1054078	chr8:82712153	A/G	cg06027949	chr8:82754900	SNX16	-0.44	-5.23	-0.31	3.48e-7	Diastolic blood pressure;
CESC	cis	rs6540559	0.673	rs6540561	chr1:209982255	C/T	cg25204440	chr1:209979598	IRF6	0.65	6.63	0.38	1.83e-10	Cleft lip with or without cleft palate;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg09563240	chr3:47205630	SETD2	0.51	6.66	0.38	1.58e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs748404	0.697	rs524547	chr15:43551023	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.62	7.94	0.44	5.82e-14	Lung cancer;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg11642829	chr17:4607740	PELP1	0.48	6.77	0.38	8.28e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs4689592	0.546	rs2359012	chr4:7066053	A/C	cg19539972	chr4:7069911	GRPEL1	0.78	9.87	0.52	9.02e-20	Monocyte percentage of white cells;
CESC	cis	rs7666738	0.830	rs4292341	chr4:98959724	C/T	cg17366294	chr4:99064904	C4orf37	0.5	7.58	0.42	5.75e-13	Colonoscopy-negative controls vs population controls;
CESC	cis	rs477692	0.517	rs871026	chr10:131293145	A/G	cg05714579	chr10:131428358	MGMT	-0.42	-5.4	-0.31	1.46e-7	Response to temozolomide;
CESC	cis	rs9311474	0.607	rs34005367	chr3:52558904	A/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.68	0.38	1.41e-10	Electroencephalogram traits;
CESC	cis	rs6690583	0.623	rs61768853	chr1:85455707	T/C	cg22153463	chr1:85462885	MCOLN2	0.71	7.12	0.4	1.01e-11	Serum sulfate level;
CESC	cis	rs6502050	0.871	rs11870632	chr17:80075406	T/C	cg23985595	chr17:80112537	CCDC57	0.41	6.42	0.37	6.41e-10	Life satisfaction;
CESC	cis	rs6982240	0.514	rs10089212	chr8:142265380	T/A	cg27411547	chr8:142287226	NA	-0.52	-7.24	-0.41	5.01e-12	Tonsillectomy;
CESC	cis	rs863345	0.504	rs2482966	chr1:158563321	T/A	cg12129480	chr1:158549410	OR10X1	-0.3	-5.57	-0.32	6.31e-8	Pneumococcal bacteremia;
CESC	cis	rs6933660	0.745	rs3800272	chr6:151744283	A/G	cg02564969	chr6:151773285	C6orf211;RMND1	-0.59	-7.7	-0.43	2.79e-13	Menarche (age at onset);
CESC	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg11965913	chr1:205819406	PM20D1	0.91	16.7	0.72	2.84e-43	Menarche (age at onset);
CESC	cis	rs3096299	0.632	rs8051537	chr16:89544384	T/A	cg16743903	chr16:89593216	SPG7	-0.41	-5.37	-0.31	1.7e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs10540	1.000	rs61876339	chr11:495283	T/C	cg03352830	chr11:487213	PTDSS2	0.74	7.23	0.41	5.31e-12	Body mass index;
CESC	trans	rs35110281	0.591	rs86138	chr21:44932398	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.47	6.44	0.37	5.69e-10	Mean corpuscular volume;
CESC	cis	rs4555082	0.874	rs113291192	chr14:105738181	C/T	cg13114125	chr14:105738426	BRF1	-0.9	-11.13	-0.56	7.35e-24	Mean platelet volume;Platelet distribution width;
CESC	cis	rs317689	0.918	rs610192	chr12:69739941	T/C	cg20891283	chr12:69753455	YEATS4	0.61	6.91	0.39	3.68e-11	Response to diuretic therapy;
CESC	cis	rs7949030	0.591	rs12049914	chr11:62369436	C/G	cg22862634	chr11:62369728	EML3;MTA2	0.59	8.19	0.45	1.08e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs6963495	0.745	rs68153235	chr7:105184832	A/C	cg02135003	chr7:105160482	PUS7	-0.43	-5.94	-0.34	9.16e-9	Bipolar disorder (body mass index interaction);
CESC	cis	rs7904368	0.754	rs11254231	chr10:16870246	A/G	cg23933602	chr10:16859644	RSU1	0.57	5.09	0.3	6.65e-7	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
CESC	cis	rs10883723	0.668	rs12414479	chr10:104420902	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.59	6.93	0.39	3.27e-11	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs6987853	0.666	rs2923403	chr8:42447748	G/T	cg09913449	chr8:42400586	C8orf40	0.44	7.41	0.41	1.69e-12	Mean corpuscular hemoglobin concentration;
CESC	cis	rs9303401	0.614	rs56284918	chr17:57178838	A/G	cg25039879	chr17:56429692	SUPT4H1	0.5	5.29	0.31	2.58e-7	Cognitive test performance;
CESC	cis	rs13191362	0.507	rs2846535	chr6:163034019	T/C	cg21926612	chr6:163149169	PACRG;PARK2	-0.54	-6.89	-0.39	3.97e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs425277	0.539	rs3128337	chr1:2045882	A/G	cg13918804	chr1:2043761	PRKCZ	0.27	5.07	0.3	7.47e-7	Height;
CESC	cis	rs7659604	0.540	rs10004284	chr4:122699222	A/T	cg19748678	chr4:122722346	EXOSC9	-0.44	-5.59	-0.33	5.5e-8	Type 2 diabetes;
CESC	cis	rs2228479	0.850	rs2238532	chr16:89863672	T/C	cg00800038	chr16:89945340	TCF25	-0.88	-7.23	-0.41	5.07e-12	Skin colour saturation;
CESC	cis	rs977987	0.581	rs8056141	chr16:75497162	A/T	cg03315344	chr16:75512273	CHST6	0.48	6.72	0.38	1.12e-10	Dupuytren's disease;
CESC	cis	rs16910800	0.731	rs35725172	chr11:23185968	G/A	cg20040320	chr11:23191996	NA	-0.68	-6.61	-0.38	2.09e-10	Cancer;
CESC	cis	rs10479542	0.583	rs4131080	chr5:179044292	G/A	cg26516362	chr5:178986906	RUFY1	0.42	6.34	0.36	9.74e-10	Lung cancer;
CESC	cis	rs7551222	0.749	rs11240761	chr1:204566700	C/A	cg20240347	chr1:204465584	NA	-0.27	-5.61	-0.33	5.11e-8	Schizophrenia;
CESC	cis	rs2991971	0.967	rs937291	chr1:45957039	G/T	cg15605315	chr1:45957053	TESK2	0.5	6.63	0.38	1.83e-10	High light scatter reticulocyte count;
CESC	cis	rs7615952	0.576	rs2276729	chr3:125826214	G/A	cg02807482	chr3:125708958	NA	-0.41	-5.58	-0.32	6.02e-8	Blood pressure (smoking interaction);
CESC	cis	rs9905704	1.000	rs9905704	chr17:56632543	G/T	cg12560992	chr17:57184187	TRIM37	-0.61	-7.02	-0.4	1.8e-11	Testicular germ cell tumor;
CESC	cis	rs7666738	0.830	rs10516426	chr4:99035827	A/G	cg17366294	chr4:99064904	C4orf37	0.61	8.75	0.47	2.6e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7100689	0.784	rs10736341	chr10:82061206	C/G	cg00277334	chr10:82204260	NA	-0.58	-7.31	-0.41	3.1e-12	Post bronchodilator FEV1;
CESC	cis	rs1050631	0.592	rs1785930	chr18:33723718	A/G	cg25426722	chr18:33708991	SLC39A6;ELP2	0.53	7.16	0.4	7.87e-12	Esophageal squamous cell cancer (length of survival);
CESC	cis	rs2625529	0.818	rs16956241	chr15:72111688	G/T	cg16672083	chr15:72433130	SENP8	-0.43	-5.32	-0.31	2.26e-7	Red blood cell count;
CESC	cis	rs854765	0.663	rs3744115	chr17:17749822	G/A	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.4	-5.1	-0.3	6.59e-7	Total body bone mineral density;
CESC	cis	rs17253792	0.822	rs77599953	chr14:56058905	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.85	6.13	0.35	3.15e-9	Putamen volume;
CESC	cis	rs11785400	1.000	rs4736368	chr8:143748528	G/C	cg10596483	chr8:143751796	JRK	0.43	5.63	0.33	4.59e-8	Schizophrenia;
CESC	cis	rs875971	0.862	rs880166	chr7:65670762	T/C	cg18876405	chr7:65276391	NA	-0.55	-7.65	-0.43	3.65e-13	Aortic root size;
CESC	cis	rs6088580	0.634	rs6059890	chr20:33101653	G/C	cg24642439	chr20:33292090	TP53INP2	0.5	6.54	0.37	3.21e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs2243480	1.000	rs9769882	chr7:65642925	T/C	cg12463550	chr7:65579703	CRCP	-0.73	-5.66	-0.33	4.03e-8	Diabetic kidney disease;
CESC	cis	rs9611565	0.512	rs964899	chr22:42142386	G/A	cg17376030	chr22:41985996	PMM1	-0.8	-8.34	-0.46	3.99e-15	Vitiligo;
CESC	cis	rs853679	0.517	rs17774663	chr6:28120898	G/A	cg23281280	chr6:28129359	ZNF389	0.6	8.04	0.44	2.95e-14	Depression;
CESC	cis	rs561341	1.000	rs576985	chr17:30323323	C/T	cg19193384	chr17:30244184	NA	-0.7	-6.58	-0.37	2.49e-10	Hip circumference adjusted for BMI;
CESC	cis	rs7412746	0.658	rs6657388	chr1:150748786	A/G	cg04414720	chr1:150670196	GOLPH3L	0.58	7.57	0.42	6.3e-13	Melanoma;
CESC	cis	rs4803468	0.967	rs13345590	chr19:41886455	T/G	cg14132834	chr19:41945861	ATP5SL	-0.61	-7.79	-0.43	1.53e-13	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11759937	chr19:47729458	BBC3	0.59	6.42	0.37	6.1e-10	Gut microbiome composition (summer);
CESC	trans	rs1814175	0.618	rs1851843	chr11:50021846	T/C	cg03929089	chr4:120376271	NA	-0.91	-14.8	-0.67	1.58e-36	Height;
CESC	cis	rs637571	0.544	rs12361552	chr11:65701204	G/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.56	-6.88	-0.39	4.38e-11	Eosinophil percentage of white cells;
CESC	cis	rs6087990	0.735	rs4911261	chr20:31391360	A/G	cg13636640	chr20:31349939	DNMT3B	0.8	12.86	0.62	9.44e-30	Ulcerative colitis;
CESC	trans	rs330048	0.561	rs330088	chr8:9149746	T/C	cg06636001	chr8:8085503	FLJ10661	0.49	6.33	0.36	1.01e-9	Systemic lupus erythematosus;
CESC	cis	rs1801251	1.000	rs4517962	chr2:233578337	T/C	cg08000102	chr2:233561755	GIGYF2	0.66	9.02	0.48	3.87e-17	Coronary artery disease;
CESC	cis	rs9457247	1.000	rs376551	chr6:167384923	G/A	cg23791538	chr6:167370224	RNASET2	-0.6	-8.65	-0.47	5.12e-16	Crohn's disease;
CESC	cis	rs1008375	1.000	rs56974987	chr4:17627856	G/A	cg02297831	chr4:17616191	MED28	0.53	6.72	0.38	1.12e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs7662987	0.517	rs4235436	chr4:100039620	G/A	cg12011299	chr4:100065546	ADH4	0.6	6.56	0.37	2.83e-10	Smoking initiation;
CESC	cis	rs4718428	0.705	rs68168107	chr7:66255238	G/A	cg12165864	chr7:66369176	NA	-0.66	-7.44	-0.42	1.41e-12	Corneal structure;
CESC	cis	rs4819052	0.851	rs9974628	chr21:46672647	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.75	9.97	0.52	4.33e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs1059312	0.966	rs12370194	chr12:129277250	A/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.71	-9.86	-0.52	9.39e-20	Systemic lupus erythematosus;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20011974	chr14:75469661	EIF2B2	-0.61	-6.91	-0.39	3.66e-11	Gut microbiome composition (summer);
CESC	cis	rs3617	0.625	rs11922961	chr3:52868610	T/C	cg11645453	chr3:52864694	ITIH4	-0.26	-5.28	-0.31	2.65e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
CESC	trans	rs208520	0.754	rs7753158	chr6:66875633	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.92	-11.33	-0.57	1.55e-24	Exhaled nitric oxide output;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg03489495	chr6:33588875	ITPR3	-0.42	-6.04	-0.35	5.11e-9	Gambling;
CESC	cis	rs2070433	0.749	rs718496	chr21:47904585	A/C	cg12379764	chr21:47803548	PCNT	0.46	5.58	0.32	6.08e-8	Lymphocyte counts;
CESC	cis	rs1348850	0.846	rs4893962	chr2:178421106	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.69	9.44	0.5	2.04e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs10870270	1.000	rs4880250	chr10:133773919	G/A	cg26149184	chr10:133730230	NA	0.37	5.08	0.3	7.3e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg08204369	chr17:73150733	HN1	0.52	7.11	0.4	1.09e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs9457247	0.515	rs1951459	chr6:167402536	G/A	cg25258033	chr6:167368657	RNASET2	-0.37	-5.41	-0.32	1.42e-7	Crohn's disease;
CESC	cis	rs3892630	0.588	rs7260037	chr19:33242701	G/A	cg22980127	chr19:33182716	NUDT19	1.13	14.4	0.66	4.03e-35	Red blood cell traits;
CESC	cis	rs9926296	0.508	rs1558184	chr16:89842374	T/G	cg04287289	chr16:89883240	FANCA	0.94	16.82	0.72	1.1e-43	Vitiligo;
CESC	cis	rs71277158	0.624	rs16854848	chr3:169822201	T/C	cg04067573	chr3:169899625	PHC3	0.68	6.93	0.39	3.24e-11	Prostate cancer;
CESC	cis	rs12476592	0.602	rs11125978	chr2:63809602	C/T	cg17519650	chr2:63277830	OTX1	-0.48	-5.39	-0.31	1.52e-7	Childhood ear infection;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg08204369	chr17:73150733	HN1	0.5	6.97	0.39	2.48e-11	Systemic lupus erythematosus;
CESC	cis	rs1348850	0.914	rs7565022	chr2:178320222	A/T	cg22681709	chr2:178499509	PDE11A	-0.4	-5.98	-0.34	7.17e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs9916302	0.904	rs2061342	chr17:37405657	T/G	cg07936489	chr17:37558343	FBXL20	-0.79	-11.09	-0.56	9.87e-24	Glomerular filtration rate (creatinine);
CESC	cis	rs5750830	0.649	rs4821895	chr22:39823015	A/G	cg02038168	chr22:39784481	NA	-0.64	-8.08	-0.44	2.23e-14	Intelligence (multi-trait analysis);
CESC	cis	rs7561273	0.565	rs6545275	chr2:24331860	A/G	cg20701182	chr2:24300061	SF3B14	0.51	6.52	0.37	3.55e-10	Quantitative traits;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg02929209	chr4:53588595	NA	-0.47	-6.42	-0.37	6.31e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs2635047	0.934	rs11663321	chr18:44622704	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.51	6.94	0.39	3.07e-11	Educational attainment;
CESC	cis	rs6540559	0.546	rs57315825	chr1:210030197	C/T	cg22029157	chr1:209979665	IRF6	0.66	7.33	0.41	2.8e-12	Cleft lip with or without cleft palate;
CESC	cis	rs5750830	0.649	rs5750820	chr22:39825322	T/G	cg05872129	chr22:39784769	NA	-0.84	-11.23	-0.57	3.43e-24	Intelligence (multi-trait analysis);
CESC	trans	rs875971	0.964	rs6978721	chr7:65883204	A/G	cg26939375	chr7:64535504	NA	0.47	6.06	0.35	4.77e-9	Aortic root size;
CESC	cis	rs7793919	0.764	rs6944865	chr7:4766383	A/T	cg09789173	chr7:4769017	FOXK1	0.79	12.54	0.61	1.2e-28	Mosquito bite size;
CESC	cis	rs17376456	0.877	rs10078194	chr5:93364310	A/C	cg21475434	chr5:93447410	FAM172A	0.78	6.96	0.39	2.72e-11	Diabetic retinopathy;
CESC	cis	rs13394619	0.775	rs10200851	chr2:11722082	C/T	cg07314298	chr2:11723111	GREB1	-0.37	-5.2	-0.3	3.9e-7	Endometriosis;
CESC	cis	rs34172651	0.517	rs34172679	chr16:24840381	C/T	cg02428538	chr16:24856791	SLC5A11	-0.58	-6.03	-0.35	5.42e-9	Intelligence (multi-trait analysis);
CESC	cis	rs13118159	0.836	rs12647145	chr4:1338618	C/A	cg13395646	chr4:1353034	KIAA1530	-0.4	-5.35	-0.31	1.88e-7	Longevity;
CESC	cis	rs568617	1.000	rs641018	chr11:65655393	G/C	cg04055107	chr11:65626734	MUS81;CFL1	0.69	7.43	0.42	1.47e-12	Crohn's disease;
CESC	cis	rs7666738	0.830	rs17550735	chr4:99014076	T/G	cg05340658	chr4:99064831	C4orf37	0.8	12.51	0.61	1.52e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1401999	1.000	rs7620350	chr3:183710053	A/T	cg01324343	chr3:183735012	ABCC5	0.64	13.58	0.64	3.13e-32	Anterior chamber depth;
CESC	cis	rs2820292	0.678	rs4309038	chr1:201884647	C/G	cg11586189	chr1:201857591	SHISA4	-0.35	-5.84	-0.34	1.53e-8	Waist circumference;Body mass index (joint analysis main effects and smoking interaction);Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);
CESC	cis	rs3820068	0.705	rs4646072	chr1:15827711	G/A	cg18192808	chr1:15853278	DNAJC16	0.47	5.56	0.32	6.42e-8	Systolic blood pressure;
CESC	cis	rs12541635	0.966	rs12680670	chr8:107006811	T/G	cg10147462	chr8:107024639	NA	0.42	5.96	0.34	7.89e-9	Age of smoking initiation;
CESC	cis	rs60154123	0.505	rs1319435	chr1:210047618	C/T	cg22029157	chr1:209979665	IRF6	-0.71	-7.2	-0.4	6.19e-12	Coronary artery disease;
CESC	cis	rs79349575	0.783	rs58591767	chr17:47026076	G/A	cg16584676	chr17:46985605	UBE2Z	0.54	6.67	0.38	1.46e-10	Type 2 diabetes;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg06529459	chr11:67397595	NUDT8	-0.47	-6.13	-0.35	3.09e-9	Fibrinogen levels;
CESC	cis	rs6952808	1.000	rs4449693	chr7:1884630	G/C	cg05863683	chr7:1912471	MAD1L1	0.43	6.37	0.36	8.36e-10	Bipolar disorder and schizophrenia;
CESC	cis	rs6754311	0.608	rs3739020	chr2:136602491	T/G	cg07169764	chr2:136633963	MCM6	0.65	8.13	0.45	1.62e-14	Mosquito bite size;
CESC	cis	rs7666738	0.830	rs72882693	chr4:98960804	T/A	cg03676636	chr4:99064102	C4orf37	0.33	5.14	0.3	5.39e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6429082	0.749	rs3819974	chr1:235601958	G/T	cg26050004	chr1:235667680	B3GALNT2	-0.61	-7.76	-0.43	1.85e-13	Adiposity;
CESC	cis	rs1707322	0.717	rs12023439	chr1:46104636	C/T	cg05343316	chr1:45956843	TESK2	0.51	6.35	0.36	9.44e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7044106	0.791	rs747819	chr9:123488441	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.36	5.58	0.32	6.06e-8	Hip circumference adjusted for BMI;
CESC	cis	rs2066819	1.000	rs11575234	chr12:56744276	C/G	cg26714650	chr12:56694279	CS	-1.22	-14.58	-0.67	9.61e-36	Psoriasis vulgaris;
CESC	cis	rs11577318	0.853	rs11247913	chr1:26648551	G/C	cg00813993	chr1:26644493	UBXN11;CD52	-0.4	-6.47	-0.37	4.67e-10	Granulocyte percentage of myeloid white cells;
CESC	cis	rs35955747	0.902	rs739427	chr22:31659101	C/G	cg25791279	chr22:32026902	PISD	0.48	5.71	0.33	3.06e-8	Neutrophil count;Sum basophil neutrophil counts;
CESC	cis	rs875971	0.862	rs6947339	chr7:65888470	T/C	cg12463550	chr7:65579703	CRCP	0.51	6.41	0.37	6.58e-10	Aortic root size;
CESC	cis	rs61931739	0.500	rs6416261	chr12:34540377	T/C	cg06521331	chr12:34319734	NA	-0.36	-5.03	-0.3	9.01e-7	Morning vs. evening chronotype;
CESC	cis	rs6912958	0.559	rs446851	chr6:88043640	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.74	11.07	0.56	1.2e-23	Monocyte percentage of white cells;
CESC	cis	rs897984	0.542	rs7199949	chr16:31096164	G/C	cg00531865	chr16:30841666	NA	-0.39	-5.42	-0.32	1.33e-7	Dementia with Lewy bodies;
CESC	cis	rs36051895	0.632	rs1328919	chr9:5166548	C/T	cg02405213	chr9:5042618	JAK2	-0.46	-5.36	-0.31	1.77e-7	Pediatric autoimmune diseases;
CESC	cis	rs7666738	0.791	rs10017624	chr4:98984009	G/T	cg17366294	chr4:99064904	C4orf37	0.59	8.57	0.47	8.46e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10751667	0.600	rs4076915	chr11:1012464	C/G	cg20946044	chr11:1010712	AP2A2	-0.48	-6.33	-0.36	1.04e-9	Alzheimer's disease (late onset);
CESC	cis	rs12477438	0.520	rs13009147	chr2:99803998	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.86	14.96	0.68	4.16e-37	Chronic sinus infection;
CESC	cis	rs1670533	1.000	rs629261	chr4:1086763	A/C	cg27284194	chr4:1044797	NA	0.48	6.17	0.35	2.6e-9	Recombination rate (females);
CESC	cis	rs35995292	0.500	rs7776996	chr7:38919762	G/C	cg19327137	chr7:38886074	VPS41	0.66	10.86	0.55	5.69e-23	Subjective well-being (multi-trait analysis);
CESC	cis	rs3820068	0.581	rs16851855	chr1:15930869	G/A	cg13390004	chr1:15929781	NA	0.35	5.58	0.32	5.83e-8	Systolic blood pressure;
CESC	cis	rs6598955	0.640	rs6667826	chr1:26531408	T/C	cg04990556	chr1:26633338	UBXN11	-0.75	-10.53	-0.54	6.97e-22	Obesity-related traits;
CESC	cis	rs1799949	0.965	rs12947782	chr17:41279882	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.45	6.3	0.36	1.21e-9	Menopause (age at onset);
CESC	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg02018176	chr4:1364513	KIAA1530	0.6	7.62	0.42	4.61e-13	Longevity;
CESC	cis	rs941408	0.515	rs1640262	chr19:2779134	C/T	cg00079169	chr19:2811669	THOP1	-0.38	-5.17	-0.3	4.61e-7	Total cholesterol levels;
CESC	cis	rs9790314	0.905	rs6774276	chr3:160941318	C/T	cg03342759	chr3:160939853	NMD3	-0.48	-6.33	-0.36	1.04e-9	Morning vs. evening chronotype;
CESC	cis	rs6964587	0.934	rs6973792	chr7:91749798	C/A	cg17063962	chr7:91808500	NA	0.55	7.42	0.41	1.61e-12	Breast cancer;
CESC	cis	rs9463078	0.665	rs227849	chr6:44698708	C/T	cg25276700	chr6:44698697	NA	0.34	5.14	0.3	5.36e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CESC	cis	rs854765	0.583	rs9908832	chr17:17871068	C/T	cg04398451	chr17:18023971	MYO15A	-0.73	-10.6	-0.55	4.17e-22	Total body bone mineral density;
CESC	cis	rs208520	0.661	rs207079	chr6:66770462	C/T	cg07460842	chr6:66804631	NA	-1.0	-12.95	-0.62	4.78e-30	Exhaled nitric oxide output;
CESC	cis	rs4665809	1.000	rs1371553	chr2:26262948	G/A	cg27170947	chr2:26402098	FAM59B	-0.61	-7.16	-0.4	7.86e-12	Gut microbiome composition (summer);
CESC	cis	rs6088580	0.634	rs6059868	chr20:33079460	A/G	cg06115741	chr20:33292138	TP53INP2	0.45	5.75	0.33	2.5e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs6088590	0.561	rs764597	chr20:33161225	C/T	cg08999081	chr20:33150536	PIGU	0.67	11.74	0.59	6.51e-26	Coronary artery disease;
CESC	cis	rs9611565	0.765	rs202663	chr22:41812819	T/C	cg06634786	chr22:41940651	POLR3H	0.7	7.4	0.41	1.78e-12	Vitiligo;
CESC	cis	rs11190604	1.000	rs12358187	chr10:102284449	C/G	cg07080220	chr10:102295463	HIF1AN	0.7	6.48	0.37	4.34e-10	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs62229266	0.618	rs11088334	chr21:37466829	A/T	cg12218747	chr21:37451666	NA	-0.47	-6.46	-0.37	5.1e-10	Mitral valve prolapse;
CESC	cis	rs6546550	0.901	rs897119	chr2:70160658	T/C	cg02498382	chr2:70120550	SNRNP27	-0.4	-6.91	-0.39	3.62e-11	Prevalent atrial fibrillation;
CESC	cis	rs3767633	0.925	rs6427639	chr1:161866372	C/A	cg09175582	chr1:161736000	ATF6	0.85	6.91	0.39	3.53e-11	IgG glycosylation;
CESC	cis	rs6866344	0.697	rs17184344	chr5:178129281	A/G	cg03877680	chr5:178157825	ZNF354A	0.77	9.01	0.48	4.15e-17	Neutrophil percentage of white cells;
CESC	cis	rs1218582	0.772	rs12069356	chr1:154849771	C/T	cg06221963	chr1:154839813	KCNN3	-0.66	-11.48	-0.58	4.9e-25	Prostate cancer;
CESC	cis	rs10927875	0.929	rs4661674	chr1:16296039	A/G	cg21385522	chr1:16154831	NA	-0.77	-9.6	-0.51	6.35e-19	Dilated cardiomyopathy;
CESC	cis	rs2836974	0.644	rs7281853	chr21:40693490	A/G	cg22974920	chr21:40686053	BRWD1	-0.42	-5.09	-0.3	6.67e-7	Cognitive function;
CESC	trans	rs1908814	0.504	rs7830734	chr8:11795639	C/T	cg15556689	chr8:8085844	FLJ10661	0.53	6.46	0.37	4.89e-10	Neuroticism;
CESC	cis	rs10504229	0.906	rs7842482	chr8:58167720	A/T	cg24829409	chr8:58192753	C8orf71	-0.62	-8.39	-0.46	3.01e-15	Developmental language disorder (linguistic errors);
CESC	cis	rs6570726	0.935	rs384453	chr6:145815145	G/C	cg05347473	chr6:146136440	FBXO30	0.5	6.71	0.38	1.15e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9322193	0.884	rs11155689	chr6:150129606	T/C	cg05861140	chr6:150128134	PCMT1	-0.37	-5.34	-0.31	2.02e-7	Lung cancer;
CESC	cis	rs4853012	0.941	rs7571083	chr2:74342260	C/G	cg05776053	chr2:74358815	NA	0.42	5.23	0.31	3.47e-7	Gestational age at birth (maternal effect);
CESC	cis	rs68170813	0.559	rs78267892	chr7:106823734	C/T	cg02696742	chr7:106810147	HBP1	-0.55	-5.32	-0.31	2.24e-7	Coronary artery disease;
CESC	cis	rs1728785	1.000	rs12925177	chr16:68569645	A/G	cg02972257	chr16:68554789	NA	0.53	6.19	0.36	2.33e-9	Ulcerative colitis;
CESC	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg11301795	chr4:187892539	NA	-0.75	-12.33	-0.6	6.74e-28	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs728616	0.867	rs61860417	chr10:81734727	C/T	cg05935833	chr10:81318306	SFTPA2	-0.53	-5.37	-0.31	1.72e-7	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs1707322	1.000	rs10890350	chr1:46262378	G/A	cg03146154	chr1:46216737	IPP	0.71	9.81	0.52	1.43e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs1707322	0.686	rs61784833	chr1:46233772	T/C	cg03146154	chr1:46216737	IPP	0.81	11.48	0.58	4.89e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs35306767	0.951	rs12777021	chr10:967270	T/C	cg26597838	chr10:835615	NA	0.95	10.4	0.54	1.83e-21	Eosinophil percentage of granulocytes;
CESC	cis	rs12497850	0.931	rs9867373	chr3:48960938	A/T	cg03060546	chr3:49711283	APEH	0.45	5.62	0.33	4.84e-8	Parkinson's disease;
CESC	cis	rs7615952	0.641	rs66520539	chr3:125780374	G/A	cg15145296	chr3:125709740	NA	-0.52	-5.47	-0.32	1.06e-7	Blood pressure (smoking interaction);
CESC	cis	rs6860806	0.661	rs2136187	chr5:131577894	T/C	cg24060327	chr5:131705240	SLC22A5	-0.4	-5.12	-0.3	5.81e-7	Breast cancer;
CESC	cis	rs9549260	0.755	rs58919811	chr13:41226485	A/C	cg21288729	chr13:41239152	FOXO1	0.65	8.5	0.46	1.4e-15	Red blood cell count;
CESC	cis	rs7927771	1.000	rs34128973	chr11:47851376	C/T	cg05585544	chr11:47624801	NA	-0.5	-7.69	-0.43	2.81e-13	Subjective well-being;
CESC	cis	rs863345	0.604	rs1157524	chr1:158457298	T/C	cg12129480	chr1:158549410	OR10X1	-0.36	-7.15	-0.4	8.67e-12	Pneumococcal bacteremia;
CESC	cis	rs4970988	0.501	rs11204713	chr1:150694623	T/A	cg17724175	chr1:150552817	MCL1	0.43	7.13	0.4	9.75e-12	Urate levels;
CESC	cis	rs2839186	0.500	rs13049893	chr21:47707054	C/T	cg09417038	chr21:47716443	C21orf57	-0.43	-6.01	-0.35	6.09e-9	Testicular germ cell tumor;
CESC	cis	rs60871478	0.541	rs56964970	chr7:910791	G/C	cg05535760	chr7:792225	HEATR2	-0.8	-8.27	-0.45	6.55e-15	Cerebrospinal P-tau181p levels;
CESC	cis	rs4692589	1.000	rs4692783	chr4:170935407	G/A	cg19918862	chr4:170955249	NA	0.35	5.53	0.32	7.58e-8	Anxiety disorder;
CESC	cis	rs2404602	0.684	rs1603860	chr15:76849591	A/T	cg23625390	chr15:77176239	SCAPER	-0.44	-6.13	-0.35	3.14e-9	Blood metabolite levels;
CESC	cis	rs4969178	0.832	rs4969185	chr17:76398157	G/C	cg20026190	chr17:76395443	PGS1	0.49	7.79	0.43	1.51e-13	HDL cholesterol levels;
CESC	cis	rs6500602	0.609	rs7202910	chr16:4518948	T/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.42	5.85	0.34	1.45e-8	Schizophrenia;
CESC	cis	rs7116495	1.000	rs6592453	chr11:71683231	C/G	cg10381502	chr11:71823885	C11orf51	-0.66	-5.43	-0.32	1.3e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs3015497	0.789	rs3015502	chr14:51108427	T/C	cg09863266	chr14:51125203	SAV1	-0.35	-5.4	-0.31	1.48e-7	Mean platelet volume;
CESC	cis	rs4820539	0.611	rs28451783	chr22:23488569	G/T	cg14186256	chr22:23484241	RTDR1	0.7	10.34	0.54	2.79e-21	Bone mineral density;
CESC	cis	rs2404602	0.575	rs11072611	chr15:76947983	A/G	cg00316803	chr15:76480434	C15orf27	-0.38	-5.33	-0.31	2.13e-7	Blood metabolite levels;
CESC	cis	rs2299587	0.698	rs2283113	chr8:17880243	C/A	cg08627089	chr8:17753878	FGL1	-0.37	-5.21	-0.3	3.8e-7	Economic and political preferences;
CESC	cis	rs7851660	0.967	rs10046805	chr9:100613956	G/A	cg13688889	chr9:100608707	NA	-0.68	-10.54	-0.54	6.55e-22	Strep throat;
CESC	cis	rs2991971	0.967	rs7526665	chr1:46005832	G/T	cg03146154	chr1:46216737	IPP	-0.44	-5.58	-0.32	5.84e-8	High light scatter reticulocyte count;
CESC	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg06873352	chr17:61820015	STRADA	0.73	12.89	0.62	7.87e-30	Prudent dietary pattern;
CESC	cis	rs2204008	0.619	rs11178987	chr12:38201258	C/T	cg26384229	chr12:38710491	ALG10B	-0.43	-5.92	-0.34	9.92e-9	Bladder cancer;
CESC	cis	rs7178909	0.902	rs2043881	chr15:90439960	G/A	cg19708238	chr15:90437601	AP3S2	0.44	6.28	0.36	1.38e-9	Common traits (Other);
CESC	cis	rs7193541	0.662	rs8058133	chr16:74657485	A/T	cg05580060	chr16:74700937	RFWD3	-0.42	-5.36	-0.31	1.82e-7	Multiple myeloma;
CESC	cis	rs9811920	0.535	rs792835	chr3:99476295	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.33	-5.42	-0.32	1.37e-7	Axial length;
CESC	cis	rs2075371	0.830	rs12669960	chr7:133931782	A/G	cg20476274	chr7:133979776	SLC35B4	0.62	8.99	0.48	4.89e-17	Mean platelet volume;
CESC	cis	rs10979	1.000	rs13197332	chr6:143888095	T/A	cg25407410	chr6:143891975	LOC285740	-0.63	-9.51	-0.5	1.24e-18	Hypospadias;
CESC	trans	rs6499129	0.571	rs6499118	chr16:67265360	C/A	cg17013778	chr10:135130084	NA	-0.68	-6.02	-0.35	5.74e-9	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs61931739	0.517	rs10772139	chr12:34186178	A/T	cg19457237	chr12:34500585	NA	-0.39	-5.39	-0.31	1.53e-7	Morning vs. evening chronotype;
CESC	cis	rs1552244	1.000	rs17032396	chr3:10153559	A/G	cg00166722	chr3:10149974	C3orf24	-0.45	-5.57	-0.32	6.4e-8	Alzheimer's disease;
CESC	cis	rs36093924	0.646	rs5996094	chr22:42347060	A/G	cg15557168	chr22:42548783	NA	0.35	5.11	0.3	6.28e-7	Intelligence;
CESC	cis	rs10504229	1.000	rs66731170	chr8:58187895	C/G	cg14926445	chr8:58193284	C8orf71	-0.51	-5.52	-0.32	8.28e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs7618501	0.633	rs35065728	chr3:50009176	T/C	cg24110177	chr3:50126178	RBM5	-0.54	-7.41	-0.41	1.72e-12	Intelligence (multi-trait analysis);
CESC	cis	rs9487051	0.676	rs2222392	chr6:109602303	T/C	cg12927641	chr6:109611667	NA	-0.37	-5.52	-0.32	8.25e-8	Reticulocyte fraction of red cells;
CESC	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg06873352	chr17:61820015	STRADA	0.72	12.95	0.62	4.81e-30	Prudent dietary pattern;
CESC	cis	rs6089829	0.889	rs6122348	chr20:61663921	C/T	cg16240275	chr20:61666158	NCRNA00029	0.5	8.97	0.48	5.67e-17	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs858239	0.600	rs4628176	chr7:23142566	C/T	cg23682824	chr7:23144976	KLHL7	0.5	6.73	0.38	1.02e-10	Cerebrospinal fluid biomarker levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00905354	chr6:170059414	WDR27	-0.52	-6.05	-0.35	5e-9	Gut microbiome composition (summer);
CESC	cis	rs4434138	0.568	rs6414569	chr3:52708075	A/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.31	5.61	0.33	5.13e-8	Intelligence (multi-trait analysis);
CESC	cis	rs7772486	0.875	rs2748483	chr6:146335560	A/T	cg05347473	chr6:146136440	FBXO30	-0.51	-6.46	-0.37	5.08e-10	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg18146300	chr17:17184632	COPS3	0.47	6.55	0.37	2.91e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs9640161	0.783	rs1132261	chr7:150059987	G/A	cg10018233	chr7:150070692	REPIN1	0.37	5.68	0.33	3.62e-8	Blood protein levels;Circulating chemerin levels;
CESC	trans	rs61931739	0.534	rs1486886	chr12:34043619	C/T	cg26384229	chr12:38710491	ALG10B	0.53	7.22	0.41	5.44e-12	Morning vs. evening chronotype;
CESC	cis	rs2354432	0.556	rs4295925	chr1:146857335	T/C	cg25205988	chr1:146714368	CHD1L	1.03	9.11	0.49	2.04e-17	Mitochondrial DNA levels;
CESC	cis	rs2050392	0.624	rs303436	chr10:30731893	G/T	cg18806716	chr10:30721971	MAP3K8	-0.61	-9.12	-0.49	1.93e-17	Inflammatory bowel disease;
CESC	cis	rs5750830	0.594	rs9611165	chr22:39775250	A/G	cg05872129	chr22:39784769	NA	-0.75	-10.71	-0.55	1.76e-22	Intelligence (multi-trait analysis);
CESC	cis	rs13720	1.000	rs13720	chr20:57570568	G/A	cg23907860	chr20:57583709	CTSZ	-0.47	-5.66	-0.33	3.97e-8	Platelet distribution width;
CESC	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg06873352	chr17:61820015	STRADA	0.73	12.98	0.62	3.9e-30	Prudent dietary pattern;
CESC	cis	rs1879734	0.636	rs12043690	chr1:54175629	T/C	cg23596471	chr1:54105337	GLIS1	0.32	5.17	0.3	4.7e-7	Mitral valve prolapse;
CESC	cis	rs853679	0.517	rs56310871	chr6:28044482	A/G	cg22143856	chr6:28129313	ZNF389	0.49	6.3	0.36	1.2e-9	Depression;
CESC	cis	rs1348850	0.554	rs11679519	chr2:178432110	C/T	cg23306229	chr2:178417860	TTC30B	0.83	9.16	0.49	1.45e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs79149102	0.649	rs8039046	chr15:75096352	A/G	cg09165964	chr15:75287851	SCAMP5	-0.71	-5.26	-0.31	2.97e-7	Lung cancer;
CESC	cis	rs7666738	0.861	rs13139309	chr4:99020916	A/G	cg05340658	chr4:99064831	C4orf37	0.82	12.99	0.62	3.34e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs73072330	0.643	rs56298666	chr3:47667218	A/G	cg09665691	chr3:47563885	NA	0.93	5.68	0.33	3.57e-8	Stem cell growth factor beta levels;
CESC	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg26338869	chr17:61819248	STRADA	0.73	9.68	0.51	3.66e-19	Prudent dietary pattern;
CESC	cis	rs763014	0.898	rs1045277	chr16:633125	T/C	cg09263875	chr16:632152	PIGQ	0.67	11.24	0.57	3.15e-24	Height;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg05101135	chr3:179367500	NA	-0.36	-6.08	-0.35	4.13e-9	Gambling;
CESC	cis	rs8014204	0.806	rs11159104	chr14:75293374	A/G	cg08847533	chr14:75593920	NEK9	0.46	5.88	0.34	1.23e-8	Caffeine consumption;
CESC	cis	rs17826219	0.561	rs562840	chr17:28949390	G/T	cg14008862	chr17:28927542	LRRC37B2	0.63	6.04	0.35	5.13e-9	Body mass index;
CESC	cis	rs798554	0.660	rs798480	chr7:2805597	G/T	cg13628971	chr7:2884303	GNA12	0.4	5.13	0.3	5.47e-7	Height;
CESC	cis	rs3820068	0.581	rs72645861	chr1:15920314	A/G	cg16988262	chr1:15930761	NA	0.35	5.63	0.33	4.6e-8	Systolic blood pressure;
CESC	cis	rs10504229	0.871	rs10504227	chr8:58162005	G/A	cg02725872	chr8:58115012	NA	-0.34	-5.31	-0.31	2.34e-7	Developmental language disorder (linguistic errors);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20375947	chr15:25454579	SNORD115-15;SNORD115-21;SNORD115-22	-0.42	-6.21	-0.36	2.09e-9	Gut microbiome composition (summer);
CESC	cis	rs8072100	0.837	rs62074055	chr17:45771933	G/C	cg08085267	chr17:45401833	C17orf57	-0.39	-5.12	-0.3	6.01e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs7666738	0.753	rs2865957	chr4:99040725	G/A	cg17366294	chr4:99064904	C4orf37	0.6	8.51	0.46	1.33e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	13.66	0.64	1.57e-32	Prudent dietary pattern;
CESC	cis	rs2288912	0.838	rs7251503	chr19:45455715	C/G	cg09555818	chr19:45449301	APOC2	0.41	6.54	0.37	3.08e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs2273669	0.667	rs78550764	chr6:109312239	C/T	cg05315195	chr6:109294784	ARMC2	-0.66	-6.28	-0.36	1.36e-9	Prostate cancer;
CESC	cis	rs9790314	0.875	rs336582	chr3:161082659	C/T	cg03342759	chr3:160939853	NMD3	-0.41	-5.4	-0.31	1.5e-7	Morning vs. evening chronotype;
CESC	cis	rs924607	1.000	rs924607	chr5:610093	C/T	cg09021430	chr5:549028	NA	0.38	6.79	0.38	7.46e-11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg10668512	chr15:42565522	GANC;TMEM87A	-0.47	-6.95	-0.39	2.75e-11	Gambling;
CESC	cis	rs10504229	0.639	rs17331850	chr8:58113538	G/T	cg24829409	chr8:58192753	C8orf71	-0.59	-7.32	-0.41	2.94e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs7918232	0.830	rs10764672	chr10:27392541	A/C	cg14442939	chr10:27389572	ANKRD26	-0.66	-7.09	-0.4	1.21e-11	Breast cancer;
CESC	cis	rs780096	0.546	rs7563162	chr2:27631191	C/T	cg02592271	chr2:27665507	KRTCAP3	-0.28	-5.68	-0.33	3.5e-8	Total body bone mineral density;
CESC	cis	rs7116495	1.000	rs1573502	chr11:71747428	C/T	cg26138937	chr11:71823887	C11orf51	-0.82	-6.68	-0.38	1.39e-10	Severe influenza A (H1N1) infection;
CESC	cis	rs7927592	0.673	rs2510392	chr11:68394457	C/G	cg20283391	chr11:68216788	NA	-0.42	-5.09	-0.3	6.86e-7	Total body bone mineral density;
CESC	cis	rs68170813	0.559	rs3801958	chr7:106961139	C/T	cg02696742	chr7:106810147	HBP1	-0.56	-5.33	-0.31	2.08e-7	Coronary artery disease;
CESC	cis	rs59918340	0.692	rs6983780	chr8:142231944	G/A	cg23750338	chr8:142222470	SLC45A4	0.64	9.86	0.52	9.5e-20	Immature fraction of reticulocytes;
CESC	cis	rs10479542	0.549	rs4376229	chr5:179042971	A/G	cg26516362	chr5:178986906	RUFY1	0.37	5.48	0.32	9.9e-8	Lung cancer;
CESC	cis	rs72634258	0.945	rs34124834	chr1:8028930	T/G	cg00042356	chr1:8021962	PARK7	0.94	8.47	0.46	1.74e-15	Inflammatory bowel disease;
CESC	cis	rs67311347	1.000	rs6795475	chr3:40489281	A/G	cg24209194	chr3:40518798	ZNF619	0.46	5.9	0.34	1.12e-8	Renal cell carcinoma;
CESC	cis	rs10818894	0.571	rs4838068	chr9:126316354	G/A	cg16191174	chr9:126692580	DENND1A	0.5	5.68	0.33	3.59e-8	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
CESC	cis	rs2243480	1.000	rs35542501	chr7:65431215	T/C	cg18252515	chr7:66147081	NA	-1.06	-10.21	-0.53	7.51e-21	Diabetic kidney disease;
CESC	cis	rs963731	0.737	rs79756054	chr2:39338998	A/G	cg04010122	chr2:39346883	SOS1	0.68	5.53	0.32	7.68e-8	Corticobasal degeneration;
CESC	cis	rs1552244	1.000	rs6414438	chr3:10073824	G/C	cg00149659	chr3:10157352	C3orf10	0.76	9.49	0.5	1.4e-18	Alzheimer's disease;
CESC	cis	rs9457247	0.765	rs9457256	chr6:167436461	T/C	cg07741184	chr6:167504864	NA	0.35	6.29	0.36	1.31e-9	Crohn's disease;
CESC	cis	rs7412746	0.611	rs12085336	chr1:150775780	A/T	cg17724175	chr1:150552817	MCL1	0.4	6.08	0.35	4.25e-9	Melanoma;
CESC	cis	rs9649213	0.613	rs6961129	chr7:97975542	T/G	cg08684580	chr7:98029266	BAIAP2L1	-0.35	-5.8	-0.34	1.85e-8	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs7246760	0.867	rs55914342	chr19:9824447	A/T	cg02900749	chr2:68251473	NA	-0.81	-7.26	-0.41	4.4e-12	Pursuit maintenance gain;
CESC	cis	rs3892630	0.588	rs1976501	chr19:33208155	C/T	cg22980127	chr19:33182716	NUDT19	1.1	12.78	0.62	1.91e-29	Red blood cell traits;
CESC	cis	rs6460942	0.505	rs62448708	chr7:12328450	G/A	cg20607287	chr7:12443886	VWDE	-0.45	-5.29	-0.31	2.52e-7	Coronary artery disease;
CESC	cis	rs4665809	0.590	rs4665319	chr2:26424583	A/C	cg27170947	chr2:26402098	FAM59B	-0.7	-8.52	-0.46	1.24e-15	Gut microbiome composition (summer);
CESC	cis	rs854765	0.583	rs4257260	chr17:17857003	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.59	8.26	0.45	7.24e-15	Total body bone mineral density;
CESC	cis	rs7618915	0.547	rs10865973	chr3:52718154	A/T	cg07507251	chr3:52567010	NT5DC2	0.42	7.33	0.41	2.77e-12	Bipolar disorder;
CESC	cis	rs6088590	0.965	rs6058108	chr20:33288655	A/G	cg06115741	chr20:33292138	TP53INP2	0.52	6.42	0.37	6.3e-10	Coronary artery disease;
CESC	cis	rs6582630	0.638	rs11182428	chr12:38526387	T/C	cg26384229	chr12:38710491	ALG10B	-0.42	-5.59	-0.32	5.66e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs1799949	0.965	rs799910	chr17:41279561	G/C	cg05368731	chr17:41323189	NBR1	0.54	7.58	0.42	5.7e-13	Menopause (age at onset);
CESC	cis	rs2228479	0.850	rs12599473	chr16:89827435	A/C	cg04013166	chr16:89971882	TCF25	0.78	6.69	0.38	1.33e-10	Skin colour saturation;
CESC	cis	rs765787	0.530	rs11639403	chr15:45538350	A/G	cg24006582	chr15:45444508	DUOX1	-0.59	-7.32	-0.41	3.04e-12	Uric acid levels;
CESC	cis	rs8099014	0.906	rs4940692	chr18:56099715	A/G	cg19312305	chr18:56117016	MIR122	-0.3	-5.72	-0.33	2.82e-8	Platelet count;
CESC	cis	rs3820068	0.705	rs4645992	chr1:15849742	G/T	cg18192808	chr1:15853278	DNAJC16	0.46	5.2	0.3	3.99e-7	Systolic blood pressure;
CESC	cis	rs7666738	0.830	rs10022389	chr4:99022229	T/C	cg05340658	chr4:99064831	C4orf37	0.82	12.99	0.62	3.34e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs644799	0.710	rs564480	chr11:95561741	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.76	10.63	0.55	3.37e-22	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs1707322	0.686	rs3014239	chr1:46089801	G/A	cg03146154	chr1:46216737	IPP	-0.8	-11.05	-0.56	1.34e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs2099077	0.867	rs1428490	chr5:102798969	T/A	cg07434438	chr16:72961899	ZFHX3	0.5	6.76	0.38	8.6e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs11122272	0.735	rs2024878	chr1:231528415	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.55	7.77	0.43	1.73e-13	Hemoglobin concentration;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg23096297	chr20:61557774	DIDO1	-0.51	-6.59	-0.38	2.35e-10	Height;
CESC	trans	rs11098499	0.710	rs6851130	chr4:120133712	G/A	cg25214090	chr10:38739885	LOC399744	-0.54	-7.16	-0.4	7.81e-12	Corneal astigmatism;
CESC	cis	rs6570726	0.967	rs413880	chr6:145804822	G/A	cg05347473	chr6:146136440	FBXO30	0.42	5.6	0.33	5.29e-8	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1552244	1.000	rs722509	chr3:10102377	T/A	cg16606324	chr3:10149918	C3orf24	0.43	5.22	0.31	3.71e-7	Alzheimer's disease;
CESC	cis	rs3617	0.625	rs2245647	chr3:52862753	A/G	cg11645453	chr3:52864694	ITIH4	0.25	5.2	0.3	3.93e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
CESC	cis	rs9354308	0.933	rs2814134	chr6:66566658	C/G	cg07460842	chr6:66804631	NA	0.68	7.68	0.43	3.08e-13	Metabolite levels;
CESC	cis	rs853679	0.517	rs1947862	chr6:28105196	C/T	cg12963246	chr6:28129442	ZNF389	0.58	7.78	0.43	1.61e-13	Depression;
CESC	cis	rs10129255	0.957	rs11847726	chr14:107187355	T/C	cg23076370	chr14:107095027	NA	-0.44	-5.5	-0.32	9.06e-8	Kawasaki disease;
CESC	trans	rs148734725	1	rs148734725	chr3:49406708	G/A	cg21659725	chr3:3221576	CRBN	-0.55	-6.52	-0.37	3.62e-10	Educational attainment (college completion);
CESC	cis	rs7552404	0.731	rs1770885	chr1:76402212	C/T	cg22875332	chr1:76189707	ACADM	-0.57	-6.17	-0.35	2.5e-9	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs13106227	0.576	rs6532417	chr4:77405719	T/G	cg20311846	chr4:77356250	SHROOM3	-0.31	-6.04	-0.35	5.26e-9	Eosinophilic esophagitis (pediatric);
CESC	cis	rs853679	0.517	rs6922063	chr6:28094366	G/A	cg26335602	chr6:28129616	ZNF389	0.54	7.25	0.41	4.48e-12	Depression;
CESC	trans	rs7937682	0.924	rs513425	chr11:111504861	C/T	cg18187862	chr3:45730750	SACM1L	0.51	6.47	0.37	4.81e-10	Primary sclerosing cholangitis;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg09828310	chr1:2452844	PANK4	0.48	6.72	0.38	1.12e-10	Fibrinogen levels;
CESC	cis	rs7605827	0.930	rs1549015	chr2:15616458	T/C	cg19274914	chr2:15703543	NA	0.35	6.13	0.35	3.19e-9	Educational attainment (years of education);
CESC	cis	rs3733585	0.673	rs4235347	chr4:9951956	C/T	cg00071950	chr4:10020882	SLC2A9	-0.69	-11.34	-0.57	1.42e-24	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs875971	0.862	rs778707	chr7:65857027	G/A	cg12463550	chr7:65579703	CRCP	0.51	6.41	0.37	6.58e-10	Aortic root size;
CESC	cis	rs7264396	0.676	rs6060729	chr20:34557004	G/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.52	6.18	0.36	2.37e-9	Total cholesterol levels;
CESC	cis	rs7219021	0.518	rs6504584	chr17:46941419	G/T	cg16584676	chr17:46985605	UBE2Z	-0.41	-5.09	-0.3	6.71e-7	Schizophrenia or bipolar disorder;
CESC	trans	rs9467711	0.606	rs9379897	chr6:26601526	T/C	cg06606381	chr12:133084897	FBRSL1	-0.74	-7.14	-0.4	8.79e-12	Autism spectrum disorder or schizophrenia;
CESC	cis	rs7772486	0.712	rs1292335	chr6:145967877	G/T	cg23711669	chr6:146136114	FBXO30	0.66	9.76	0.51	2.02e-19	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4523957	0.928	rs216190	chr17:2187457	C/T	cg16513277	chr17:2031491	SMG6	0.59	8.02	0.44	3.49e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs2439831	0.850	rs694985	chr15:43813387	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.73	9.51	0.5	1.19e-18	Lung cancer in ever smokers;
CESC	cis	rs734999	0.545	rs10910111	chr1:2542653	A/G	cg20673091	chr1:2541236	MMEL1	0.44	7.65	0.43	3.63e-13	Ulcerative colitis;
CESC	cis	rs4665809	0.590	rs1122972	chr2:26418788	A/C	cg25036284	chr2:26402008	FAM59B	-0.83	-9.55	-0.51	9.32e-19	Gut microbiome composition (summer);
CESC	cis	rs7429990	0.965	rs35689209	chr3:48119763	A/G	cg11946769	chr3:48343235	NME6	-0.45	-5.53	-0.32	7.61e-8	Educational attainment (years of education);
CESC	cis	rs7618915	0.547	rs13085331	chr3:52627486	G/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	5.62	0.33	4.92e-8	Bipolar disorder;
CESC	trans	rs694739	0.595	rs11606015	chr11:64136877	C/G	cg01888411	chr11:34378293	ABTB2	0.4	6.01	0.35	6e-9	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CESC	cis	rs8114671	0.562	rs3818273	chr20:33509275	G/A	cg07148914	chr20:33460835	GGT7	0.46	6.13	0.35	3.19e-9	Height;
CESC	cis	rs4713118	0.587	rs9393899	chr6:28133528	G/C	cg23161317	chr6:28129485	ZNF389	0.52	6.48	0.37	4.37e-10	Parkinson's disease;
CESC	cis	rs6688613	0.685	rs742048	chr1:166910145	A/C	ch.1.3259774R	chr1:166827647	TADA1	-0.55	-5.22	-0.31	3.69e-7	Refractive astigmatism;
CESC	cis	rs6952808	0.723	rs60995052	chr7:2030007	G/C	cg23048001	chr7:2026167	MAD1L1	0.47	6.11	0.35	3.5e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs9929218	0.954	rs7199991	chr16:68818245	T/G	cg02972257	chr16:68554789	NA	0.47	5.63	0.33	4.49e-8	Colorectal cancer;
CESC	cis	rs1949733	0.877	rs940133	chr4:8473614	T/C	cg11789530	chr4:8429930	ACOX3	0.78	8.81	0.48	1.66e-16	Response to antineoplastic agents;
CESC	cis	rs34233420	1	rs34233420	chr17:38004929	GATTT/G	cg19468946	chr17:37922297	IKZF3	-0.42	-5.78	-0.33	2.08e-8	Lymphocyte counts;
CESC	cis	rs875971	0.658	rs432667	chr7:65514633	A/G	cg18876405	chr7:65276391	NA	0.56	7.47	0.42	1.15e-12	Aortic root size;
CESC	cis	rs1552244	1.000	rs112509186	chr3:10156533	A/G	cg00166722	chr3:10149974	C3orf24	0.45	5.65	0.33	4.12e-8	Alzheimer's disease;
CESC	cis	rs8141529	0.764	rs5752812	chr22:29225603	T/A	cg15103426	chr22:29168792	CCDC117	0.68	9.65	0.51	4.52e-19	Lymphocyte counts;
CESC	cis	rs9303401	0.614	rs34900851	chr17:56566399	G/A	cg12560992	chr17:57184187	TRIM37	0.52	5.05	0.3	8.23e-7	Cognitive test performance;
CESC	cis	rs10504229	1.000	rs77857677	chr8:58170131	G/A	cg24829409	chr8:58192753	C8orf71	-0.76	-9.92	-0.52	6.14e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs722599	0.683	rs10144845	chr14:75237770	C/T	cg08847533	chr14:75593920	NEK9	0.45	5.72	0.33	2.87e-8	IgG glycosylation;
CESC	cis	rs6460942	0.558	rs4330594	chr7:12278615	G/A	cg06484146	chr7:12443880	VWDE	-0.54	-5.77	-0.33	2.26e-8	Coronary artery disease;
CESC	cis	rs2354432	0.607	rs7545467	chr1:146746248	A/G	cg25205988	chr1:146714368	CHD1L	-0.94	-8.35	-0.46	3.88e-15	Mitochondrial DNA levels;
CESC	cis	rs8067354	0.574	rs1292050	chr17:57965169	T/C	cg13753209	chr17:57696993	CLTC	0.52	5.62	0.33	4.89e-8	Hemoglobin concentration;
CESC	cis	rs17125944	0.505	rs10483618	chr14:53203590	T/C	cg00686598	chr14:53173677	PSMC6	1.34	11.5	0.58	4.42e-25	Alzheimer's disease (late onset);
CESC	cis	rs6691722	0.506	rs1016209	chr1:24745615	A/G	cg18323236	chr1:24743029	NIPAL3	-0.48	-7.51	-0.42	8.94e-13	Response to interferon beta in multiple sclerosis;
CESC	cis	rs7811142	0.830	rs73401450	chr7:99981859	G/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.01	10.03	0.52	2.83e-20	Platelet count;
CESC	cis	rs2860975	0.666	rs1891073	chr10:96804911	G/A	cg09036531	chr10:96991505	NA	-0.37	-5.23	-0.31	3.42e-7	Immune response to smallpox vaccine (IL-6);
CESC	cis	rs7246657	0.943	rs3760825	chr19:37945601	C/T	cg23950597	chr19:37808831	NA	-0.55	-5.99	-0.35	6.69e-9	Coronary artery calcification;
CESC	cis	rs4843747	0.518	rs4072777	chr16:88107030	G/A	cg06374794	chr16:88002281	BANP	0.39	5.16	0.3	4.78e-7	Menopause (age at onset);
CESC	cis	rs2034088	0.965	rs4968070	chr17:446162	A/G	cg06217071	chr17:408420	NA	0.46	7.83	0.43	1.17e-13	Hip circumference adjusted for BMI;
CESC	cis	rs7568498	0.564	rs10490563	chr2:161914168	G/A	cg08807892	chr2:162101083	NA	-0.54	-5.97	-0.34	7.69e-9	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);
CESC	cis	rs3760982	0.585	rs8109812	chr19:44298494	C/A	cg11993925	chr19:44307056	LYPD5	0.33	5.56	0.32	6.54e-8	Breast cancer (estrogen-receptor negative);Breast cancer;
CESC	trans	rs2965280	0.793	rs8104344	chr19:34840228	C/T	cg05799317	chr6:165723796	C6orf118	0.81	6.0	0.35	6.45e-9	Colorectal cancer;
CESC	cis	rs367615	0.704	rs6889301	chr5:108835181	C/T	cg17395555	chr5:108820864	NA	0.62	11.06	0.56	1.27e-23	Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs7219021	0.961	rs67469980	chr17:46878250	C/G	cg16584676	chr17:46985605	UBE2Z	-0.59	-6.71	-0.38	1.2e-10	Schizophrenia or bipolar disorder;
CESC	cis	rs7973683	0.541	rs57078519	chr12:124388784	G/A	cg12597309	chr12:124393772	DNAH10	0.25	5.46	0.32	1.08e-7	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg11287903	chr10:115613834	DCLRE1A;NHLRC2	0.5	6.38	0.36	7.87e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs4808199	0.649	rs12983940	chr19:19516431	G/A	cg03709012	chr19:19516395	GATAD2A	1.13	13.56	0.64	3.46e-32	Nonalcoholic fatty liver disease;
CESC	cis	rs4665809	0.549	rs7577896	chr2:26524493	C/T	cg25036284	chr2:26402008	FAM59B	0.64	6.16	0.35	2.75e-9	Gut microbiome composition (summer);
CESC	cis	rs10504229	0.683	rs35244711	chr8:58117762	T/G	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs2180341	0.781	rs6913350	chr6:127570560	C/T	cg24812749	chr6:127587940	RNF146	0.84	11.9	0.59	1.98e-26	Breast cancer;
CESC	cis	rs847577	0.646	rs10270222	chr7:97781799	C/T	cg24562669	chr7:97807699	LMTK2	-0.57	-8.48	-0.46	1.6e-15	Breast cancer;
CESC	cis	rs1336900	0.641	rs6587756	chr1:150546865	A/T	cg09365446	chr1:150670422	GOLPH3L	-0.39	-5.07	-0.3	7.43e-7	Blood protein levels;
CESC	cis	rs17655565	1.000	rs76413558	chr12:52694156	A/G	cg08257133	chr12:52711352	KRT83	0.5	5.81	0.34	1.78e-8	Plasma amyloid beta peptide concentrations (ABx-42);
CESC	cis	rs4849845	0.812	rs7593660	chr2:121026652	T/A	cg24070213	chr2:121070622	NA	0.39	5.04	0.3	8.71e-7	Mean platelet volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03154536	chr11:107799237	RAB39	0.46	6.54	0.37	3.16e-10	Gut microbiome composition (summer);
CESC	cis	rs2228479	0.850	rs11640188	chr16:89807732	C/T	cg00800038	chr16:89945340	TCF25	-0.88	-7.38	-0.41	2.03e-12	Skin colour saturation;
CESC	cis	rs524281	0.773	rs2017969	chr11:66039032	G/A	cg14036092	chr11:66035641	RAB1B	-0.55	-5.38	-0.31	1.62e-7	Electroencephalogram traits;
CESC	cis	rs6933660	0.745	rs6912830	chr6:151743629	A/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.86	14.05	0.65	6.77e-34	Menarche (age at onset);
CESC	cis	rs11958404	0.546	rs10475647	chr5:157443489	A/G	cg05962755	chr5:157440814	NA	0.42	6.11	0.35	3.54e-9	IgG glycosylation;
CESC	cis	rs703842	0.642	rs73123375	chr12:58063664	C/T	cg18357645	chr12:58087776	OS9	-0.55	-7.33	-0.41	2.74e-12	Multiple sclerosis;
CESC	cis	rs35110281	0.805	rs2838318	chr21:44991825	G/A	cg04455712	chr21:45112962	RRP1B	0.37	5.59	0.32	5.67e-8	Mean corpuscular volume;
CESC	cis	rs5769765	0.819	rs9616379	chr22:50312035	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.58	-6.21	-0.36	2.01e-9	Schizophrenia;
CESC	cis	rs6951245	0.744	rs1133122	chr7:1192572	C/A	cg18402987	chr7:1209562	NA	0.76	8.5	0.46	1.38e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7666738	0.791	rs6840669	chr4:99016020	G/T	cg03676636	chr4:99064102	C4orf37	0.33	5.16	0.3	4.86e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs911555	0.755	rs10144051	chr14:103885931	A/C	cg09975044	chr14:104007538	NA	0.45	5.62	0.33	4.78e-8	Intelligence (multi-trait analysis);
CESC	cis	rs4523957	0.928	rs216220	chr17:2148821	G/T	cg16513277	chr17:2031491	SMG6	0.59	8.2	0.45	1.04e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	trans	rs35110281	0.837	rs12627667	chr21:45071396	A/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.53	7.01	0.4	1.99e-11	Mean corpuscular volume;
CESC	cis	rs2074585	0.713	rs2589941	chr15:90931457	C/T	cg22089800	chr15:90895588	ZNF774	0.68	9.5	0.5	1.35e-18	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
CESC	cis	rs1355223	0.583	rs2941043	chr11:34870994	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.8	-12.11	-0.6	3.65e-27	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs4072980	0.524	rs28477803	chr1:38398694	C/T	cg12658694	chr1:38397304	INPP5B	0.72	10.25	0.53	5.44e-21	Coronary artery disease;
CESC	cis	rs763121	0.853	rs138702	chr22:39132601	A/T	cg06544989	chr22:39130855	UNC84B	-0.49	-8.79	-0.48	1.95e-16	Menopause (age at onset);
CESC	cis	rs4948102	0.595	rs10255049	chr7:56121304	G/A	cg09872392	chr7:56161020	PHKG1	-0.42	-6.84	-0.39	5.32e-11	Plasma homocysteine levels (post-methionine load test);
CESC	cis	rs7524258	0.903	rs4908449	chr1:7292700	T/C	cg07173049	chr1:7289937	CAMTA1	0.47	7.14	0.4	9e-12	Tourette's syndrome or obsessive-compulsive disorder;
CESC	cis	rs1580019	0.587	rs7806941	chr7:32553319	G/T	cg06627557	chr7:32535165	LSM5;AVL9	1.06	18.98	0.76	2.51e-51	Cognitive ability;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24028381	chr8:145133668	EXOSC4	0.64	7.79	0.43	1.5e-13	Gut microbiome composition (summer);
CESC	trans	rs1814175	0.645	rs1722000	chr11:49917928	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.43	-6.36	-0.36	8.98e-10	Height;
CESC	cis	rs11583043	0.918	rs56402739	chr1:101397133	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.55	6.34	0.36	9.81e-10	Ulcerative colitis;Inflammatory bowel disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17951368	chr11:17298273	NUCB2	0.58	6.5	0.37	3.92e-10	Gut microbiome composition (summer);
CESC	cis	rs7818382	0.967	rs7812465	chr8:96050557	C/T	cg13393036	chr8:95962371	TP53INP1	0.41	8.55	0.46	9.96e-16	Alzheimer's disease (late onset);
CESC	cis	rs1832871	0.711	rs9457300	chr6:158714609	G/C	cg07165851	chr6:158734300	TULP4	0.6	6.59	0.38	2.33e-10	Height;
CESC	cis	rs2066819	1.000	rs2066818	chr12:56753822	C/A	cg26734620	chr12:56694298	CS	0.97	5.8	0.34	1.87e-8	Psoriasis vulgaris;
CESC	cis	rs1957429	0.572	rs3813421	chr14:65347239	G/A	cg23373153	chr14:65346875	NA	0.96	11.49	0.58	4.43e-25	Pediatric areal bone mineral density (radius);
CESC	cis	rs6088590	0.707	rs67159833	chr20:33488079	T/C	cg24642439	chr20:33292090	TP53INP2	0.85	11.05	0.56	1.34e-23	Coronary artery disease;
CESC	cis	rs344364	0.511	rs337286	chr16:1965719	C/T	cg26617929	chr16:1858877	NA	-0.53	-5.19	-0.3	4.17e-7	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs7771547	0.573	rs9470278	chr6:36399239	G/A	cg07856975	chr6:36356162	ETV7	-0.36	-5.38	-0.31	1.67e-7	Platelet distribution width;
CESC	cis	rs11098499	0.774	rs73842616	chr4:120290683	G/A	cg09307838	chr4:120376055	NA	0.87	12.16	0.6	2.41e-27	Corneal astigmatism;
CESC	cis	rs10905065	0.965	rs7078711	chr10:5744985	C/G	cg11519256	chr10:5708881	ASB13	0.43	5.82	0.34	1.68e-8	Menopause (age at onset);
CESC	cis	rs9811920	0.683	rs4928230	chr3:99661963	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.37	-6.16	-0.35	2.73e-9	Axial length;
CESC	cis	rs3785574	0.962	rs2955235	chr17:61966950	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.62	7.6	0.42	5.15e-13	Height;
CESC	cis	rs3540	0.597	rs4932346	chr15:91048991	T/C	cg10434728	chr15:90938212	IQGAP1	-0.4	-7.16	-0.4	8.07e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs1008375	0.800	rs28754811	chr4:17612312	C/T	cg16339924	chr4:17578868	LAP3	0.66	8.2	0.45	1.05e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs7264396	0.690	rs2425164	chr20:34434916	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.86	-11.33	-0.57	1.61e-24	Total cholesterol levels;
CESC	cis	rs7552404	0.691	rs5745449	chr1:76344711	A/T	cg10523679	chr1:76189770	ACADM	-0.61	-6.16	-0.35	2.75e-9	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs7000551	0.527	rs12677619	chr8:22243326	G/A	cg12081754	chr8:22256438	SLC39A14	0.92	12.12	0.6	3.45e-27	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CESC	cis	rs1862618	0.853	rs252921	chr5:56137787	G/A	cg03609598	chr5:56110824	MAP3K1	-0.51	-5.54	-0.32	7.13e-8	Initial pursuit acceleration;
CESC	cis	rs3741404	0.512	rs4980504	chr11:63873083	G/A	cg05555928	chr11:63887634	MACROD1	0.44	6.35	0.36	9.18e-10	Platelet count;
CESC	cis	rs1728785	1.000	rs1645935	chr16:68563791	A/C	cg02972257	chr16:68554789	NA	-0.55	-6.37	-0.36	8.21e-10	Ulcerative colitis;
CESC	cis	rs1707322	1.000	rs6429588	chr1:46454058	T/G	cg03146154	chr1:46216737	IPP	0.75	10.29	0.53	4.13e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs801193	0.904	rs4718403	chr7:66242729	C/G	cg18876405	chr7:65276391	NA	0.56	7.48	0.42	1.12e-12	Aortic root size;
CESC	cis	rs17666538	0.585	rs4333567	chr8:636611	C/T	cg13264159	chr8:625131	ERICH1	-0.81	-5.37	-0.31	1.76e-7	IgG glycosylation;
CESC	cis	rs8072100	0.666	rs9913014	chr17:45460189	C/T	cg08085267	chr17:45401833	C17orf57	-0.51	-6.49	-0.37	4.12e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs7833986	0.501	rs17815934	chr8:57038395	G/A	cg26371346	chr8:56986568	SNORD54;RPS20	0.56	5.04	0.3	8.57e-7	Height;
CESC	cis	rs7264396	0.561	rs6060741	chr20:34571484	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.61	6.94	0.39	2.96e-11	Total cholesterol levels;
CESC	cis	rs4820294	1.000	rs4820294	chr22:38071043	G/A	cg21798802	chr22:38057573	PDXP	0.46	7.94	0.44	5.92e-14	Fat distribution (HIV);
CESC	cis	rs11252926	0.624	rs7085214	chr10:468133	A/G	cg18196295	chr10:418757	DIP2C	0.52	7.1	0.4	1.12e-11	Psychosis in Alzheimer's disease;
CESC	cis	rs2250402	0.510	rs2291619	chr15:40329033	C/T	cg16127683	chr15:40268777	EIF2AK4	0.67	6.27	0.36	1.45e-9	Corneal curvature;
CESC	trans	rs2018683	0.707	rs4719961	chr7:28969513	C/T	cg19402173	chr7:128379420	CALU	-0.54	-7.32	-0.41	2.96e-12	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CESC	cis	rs1878931	0.580	rs8062722	chr16:3409161	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.94	14.22	0.66	1.67e-34	Body mass index (adult);
CESC	cis	rs28386778	0.700	rs11079515	chr17:62005645	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	-0.54	-6.67	-0.38	1.49e-10	Prudent dietary pattern;
CESC	cis	rs561341	1.000	rs55959993	chr17:30254771	C/G	cg12193833	chr17:30244370	NA	-0.76	-6.85	-0.39	5.14e-11	Hip circumference adjusted for BMI;
CESC	cis	rs5753618	0.504	rs9606848	chr22:31901867	G/A	cg02404636	chr22:31891804	SFI1	0.42	5.85	0.34	1.47e-8	Colorectal cancer;
CESC	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg27094323	chr7:1216898	NA	-0.37	-5.06	-0.3	7.7300000000000005e-07	Longevity;Endometriosis;
CESC	cis	rs7116495	1.000	rs7128317	chr11:71701367	C/T	cg10381502	chr11:71823885	C11orf51	0.63	5.49	0.32	9.25e-8	Severe influenza A (H1N1) infection;
CESC	cis	rs4253772	0.530	rs9615349	chr22:46732418	T/G	cg24881330	chr22:46731750	TRMU	0.81	5.76	0.33	2.32e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs5753618	0.561	rs2073857	chr22:31658281	A/G	cg13145458	chr22:31556086	RNF185	0.47	5.27	0.31	2.83e-7	Colorectal cancer;
CESC	cis	rs763121	0.853	rs138712	chr22:39141600	C/T	cg06022373	chr22:39101656	GTPBP1	0.92	15.99	0.7	9.42e-41	Menopause (age at onset);
CESC	trans	rs7937682	0.924	rs4630327	chr11:111539327	C/T	cg18187862	chr3:45730750	SACM1L	-0.48	-6.32	-0.36	1.13e-9	Primary sclerosing cholangitis;
CESC	cis	rs9902453	0.899	rs1979572	chr17:28511978	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	7.46	0.42	1.25e-12	Coffee consumption (cups per day);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg21989500	chr16:23607577	NDUFAB1	0.46	6.16	0.35	2.75e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs7666738	0.830	rs9884501	chr4:98893721	A/C	cg05340658	chr4:99064831	C4orf37	0.74	10.9	0.56	4.09e-23	Colonoscopy-negative controls vs population controls;
CESC	cis	rs875971	0.545	rs35459055	chr7:65944386	G/A	cg18876405	chr7:65276391	NA	0.5	5.88	0.34	1.2e-8	Aortic root size;
CESC	cis	rs36051895	0.623	rs1120679	chr9:5248073	C/G	cg02405213	chr9:5042618	JAK2	-0.54	-6.57	-0.37	2.65e-10	Pediatric autoimmune diseases;
CESC	cis	rs7089973	0.604	rs11196947	chr10:116601372	G/A	cg03647239	chr10:116582469	FAM160B1	0.43	5.35	0.31	1.94e-7	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs6968419	0.755	rs6967695	chr7:115896049	G/A	cg02561103	chr7:115862891	TES	-0.41	-5.35	-0.31	1.92e-7	Intraocular pressure;
CESC	cis	rs1801251	1.000	rs35085837	chr2:233624363	A/G	cg08000102	chr2:233561755	GIGYF2	0.67	9.48	0.5	1.53e-18	Coronary artery disease;
CESC	cis	rs34602589	0.535	rs7346579	chr20:43844722	A/G	cg10761708	chr20:43804764	PI3	0.48	5.61	0.33	5.1e-8	Parental longevity (mother's age at death);
CESC	trans	rs66573146	0.831	rs6851488	chr4:6987412	C/T	cg07817883	chr1:32538562	TMEM39B	0.96	6.93	0.39	3.23e-11	Granulocyte percentage of myeloid white cells;
CESC	cis	rs78132593	0.718	rs72702521	chr1:150650194	C/T	cg18945601	chr1:151320034	RFX5	-0.54	-5.07	-0.3	7.53e-7	High light scatter reticulocyte count;
CESC	cis	rs5758659	0.904	rs5758653	chr22:42613485	G/T	cg15557168	chr22:42548783	NA	-0.49	-7.7	-0.43	2.75e-13	Cognitive function;
CESC	cis	rs1348850	0.645	rs11889272	chr2:178432378	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.68	7.05	0.4	1.54e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs6545883	0.929	rs13413337	chr2:61747123	A/G	cg15711740	chr2:61764176	XPO1	-0.42	-5.2	-0.3	3.95e-7	Tuberculosis;
CESC	cis	rs9611565	0.512	rs4820446	chr22:42215684	C/T	cg06634786	chr22:41940651	POLR3H	-0.69	-6.79	-0.38	7.45e-11	Vitiligo;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg06119275	chr12:133384736	GOLGA3	0.43	6.08	0.35	4.19e-9	Fibrinogen levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04199396	chr11:118230165	UBE4A	-0.56	-6.11	-0.35	3.45e-9	Gut microbiome composition (summer);
CESC	cis	rs4930103	0.935	rs4930098	chr11:2020955	G/C	cg23202291	chr11:1979235	NA	0.35	5.04	0.3	8.79e-7	DNA methylation (parent-of-origin);DNA methylation (variation);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20618750	chr5:149380010	HMGXB3;TIGD6	-0.67	-7.83	-0.43	1.19e-13	Gut microbiome composition (summer);
CESC	cis	rs6967414	0.792	rs6954012	chr7:6755724	A/C	cg00387323	chr7:6746715	ZNF12	0.57	5.82	0.34	1.66e-8	Hematocrit;Hemoglobin concentration;
CESC	cis	rs7618915	0.547	rs11130311	chr3:52675005	T/C	cg07507251	chr3:52567010	NT5DC2	0.4	7.06	0.4	1.49e-11	Bipolar disorder;
CESC	cis	rs7945705	0.869	rs7925728	chr11:9013002	A/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.32	-5.57	-0.32	6.4e-8	Hemoglobin concentration;
CESC	cis	rs798554	0.959	rs798528	chr7:2772431	A/C	cg04166393	chr7:2884313	GNA12	0.55	7.0	0.4	2.04e-11	Height;
CESC	cis	rs7267979	0.844	rs8184820	chr20:25250577	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.69	-11.22	-0.57	3.72e-24	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs2286503	0.839	rs4722188	chr7:22860211	C/G	cg13679077	chr7:22862647	TOMM7	0.48	6.29	0.36	1.27e-9	Fibrinogen;
CESC	cis	rs10504229	0.679	rs10504217	chr8:58037522	A/G	cg24829409	chr8:58192753	C8orf71	-0.46	-5.84	-0.34	1.53e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs1065852	0.526	rs59993856	chr22:42403980	C/T	cg22189786	chr22:42395067	WBP2NL	0.41	5.18	0.3	4.48e-7	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04419871	chr3:197409435	KIAA0226	-0.62	-7.06	-0.4	1.45e-11	Gut microbiome composition (summer);
CESC	cis	rs2276314	0.857	rs62101376	chr18:33582955	T/C	cg05985134	chr18:33552581	C18orf21	0.59	6.71	0.38	1.18e-10	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs9457247	0.612	rs2237273	chr6:167443017	T/C	cg23791538	chr6:167370224	RNASET2	-0.56	-7.6	-0.42	5.05e-13	Crohn's disease;
CESC	cis	rs2204008	0.658	rs11181310	chr12:38315963	C/A	cg26384229	chr12:38710491	ALG10B	0.69	10.3	0.53	3.84e-21	Bladder cancer;
CESC	cis	rs637571	0.522	rs503524	chr11:65751764	C/T	cg02202077	chr11:65769826	EIF1AD;BANF1	0.45	5.99	0.35	6.81e-9	Eosinophil percentage of white cells;
CESC	cis	rs4665809	1.000	rs4665816	chr2:26305094	G/C	cg25036284	chr2:26402008	FAM59B	-0.57	-6.61	-0.38	2.09e-10	Gut microbiome composition (summer);
CESC	cis	rs6032067	0.929	rs6017511	chr20:43833132	C/T	cg11264863	chr20:43835661	SEMG1	0.48	5.29	0.31	2.56e-7	Blood protein levels;
CESC	cis	rs2637266	0.600	rs2395430	chr10:78465471	G/A	cg18941641	chr10:78392320	NA	0.41	7.43	0.41	1.54e-12	Pulmonary function;
CESC	cis	rs2239547	0.657	rs7638524	chr3:52874861	G/A	cg11645453	chr3:52864694	ITIH4	0.34	6.34	0.36	9.85e-10	Schizophrenia;
CESC	cis	rs6032067	0.929	rs13039213	chr20:43805712	A/C	cg11264863	chr20:43835661	SEMG1	0.51	5.56	0.32	6.5e-8	Blood protein levels;
CESC	cis	rs9457247	0.765	rs9459836	chr6:167419105	G/A	cg07741184	chr6:167504864	NA	0.35	6.48	0.37	4.36e-10	Crohn's disease;
CESC	cis	rs4889855	0.530	rs4890047	chr17:78549439	A/G	cg16591659	chr17:78472290	NA	-0.34	-5.88	-0.34	1.25e-8	Fractional excretion of uric acid;
CESC	cis	rs9811920	0.535	rs704577	chr3:99487375	T/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.34	-5.44	-0.32	1.18e-7	Axial length;
CESC	cis	rs5769765	0.913	rs8135071	chr22:50299587	T/C	cg26441486	chr22:50317300	CRELD2	0.39	5.33	0.31	2.11e-7	Schizophrenia;
CESC	cis	rs2795502	1.000	rs2795502	chr10:43340662	G/A	cg20628663	chr10:43360327	NA	-0.61	-7.24	-0.41	4.87e-12	Blood protein levels;
CESC	cis	rs6761276	0.649	rs3827763	chr2:113831289	C/T	cg12858261	chr2:113808755	IL1F8	-0.44	-5.48	-0.32	9.98e-8	Protein quantitative trait loci;
CESC	cis	rs524281	0.861	rs10896081	chr11:65880354	A/T	cg14036092	chr11:66035641	RAB1B	-0.56	-5.88	-0.34	1.2e-8	Electroencephalogram traits;
CESC	cis	rs7833790	1.000	rs7833384	chr8:82730915	T/C	cg02079420	chr8:82753780	SNX16	0.57	7.66	0.43	3.44e-13	Diastolic blood pressure;
CESC	cis	rs425277	1.000	rs196128	chr1:2078444	T/G	cg16545954	chr1:2118288	C1orf86	0.33	5.6	0.33	5.35e-8	Height;
CESC	cis	rs4665809	1.000	rs6546766	chr2:26328680	T/C	cg27170947	chr2:26402098	FAM59B	-0.6	-7.24	-0.41	4.78e-12	Gut microbiome composition (summer);
CESC	cis	rs2014572	0.933	rs8109882	chr19:57755618	C/G	cg12963866	chr19:57752005	ZNF805	-0.48	-6.47	-0.37	4.63e-10	Hyperactive-impulsive symptoms;
CESC	cis	rs6912958	0.559	rs395358	chr6:88057924	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.74	11.1	0.56	9.17e-24	Monocyte percentage of white cells;
CESC	cis	rs7412746	0.611	rs752376	chr1:150941381	C/T	cg04414720	chr1:150670196	GOLPH3L	0.45	5.96	0.34	8.16e-9	Melanoma;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg05669157	chr7:72742156	TRIM50;FKBP6	0.54	7.47	0.42	1.19e-12	Fibrinogen levels;
CESC	trans	rs10905099	0.708	rs12354420	chr10:7096717	A/G	cg05230642	chr15:25439252	SNORD115-14	-0.73	-6.17	-0.35	2.6e-9	Orofacial clefts;
CESC	trans	rs7615952	0.576	rs12497295	chr3:125818650	G/A	cg07211511	chr3:129823064	LOC729375	-0.57	-6.28	-0.36	1.38e-9	Blood pressure (smoking interaction);
CESC	cis	rs1153858	1.000	rs12593370	chr15:45617417	C/T	cg14582100	chr15:45693742	SPATA5L1	0.4	5.62	0.33	4.8e-8	Homoarginine levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03654279	chr20:62612439	PRPF6;SAMD10	0.74	8.06	0.44	2.58e-14	Gut microbiome composition (summer);
CESC	cis	rs2066819	0.818	rs703830	chr12:56701872	T/C	cg26316697	chr12:56727976	PAN2	-0.69	-6.58	-0.37	2.52e-10	Psoriasis vulgaris;
CESC	trans	rs7866350	0.604	rs1935389	chr9:100994470	A/G	cg09681335	chr6:74233510	NA	0.44	6.01	0.35	6.07e-9	Post-traumatic stress disorder;
CESC	cis	rs7618501	0.574	rs6765484	chr3:50041313	C/T	cg24110177	chr3:50126178	RBM5	0.53	7.36	0.41	2.28e-12	Intelligence (multi-trait analysis);
CESC	cis	rs1799949	0.965	rs12947782	chr17:41279882	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.67	9.34	0.5	3.98e-18	Menopause (age at onset);
CESC	cis	rs854765	0.663	rs4925120	chr17:17754633	C/T	cg09796270	chr17:17721594	SREBF1	-0.46	-6.71	-0.38	1.17e-10	Total body bone mineral density;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06757187	chr22:19110190	DGCR2	0.68	7.85	0.43	1.01e-13	Gut microbiome composition (summer);
CESC	cis	rs909674	0.731	rs4821897	chr22:39835587	A/G	cg01416388	chr22:39784598	NA	-0.67	-7.82	-0.43	1.24e-13	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs6912958	0.712	rs7772561	chr6:88331299	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.32	-5.26	-0.31	2.95e-7	Monocyte percentage of white cells;
CESC	cis	rs881375	0.692	rs2072438	chr9:123651301	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.49	6.99	0.39	2.27e-11	Rheumatoid arthritis;
CESC	cis	rs12765878	1.000	rs11191848	chr10:105650837	T/C	cg24587175	chr10:105670608	OBFC1	0.32	5.36	0.31	1.81e-7	Coronary artery disease;
CESC	cis	rs2576037	0.526	rs2571026	chr18:44561795	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.69	-10.89	-0.56	4.48e-23	Personality dimensions;
CESC	cis	rs9303401	0.659	rs7210700	chr17:56668186	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.03	12.7	0.62	3.56e-29	Cognitive test performance;
CESC	cis	rs13118159	0.872	rs4974605	chr4:1346389	C/G	cg16405210	chr4:1374714	KIAA1530	-0.53	-7.02	-0.4	1.86e-11	Longevity;
CESC	cis	rs8020095	0.571	rs2039055	chr14:67580793	A/C	cg19548862	chr14:67692701	FAM71D	-0.5	-6.18	-0.36	2.38e-9	Depression (quantitative trait);
CESC	cis	rs7762018	0.882	rs4716342	chr6:170137959	A/G	cg05834625	chr6:170176447	C6orf70	0.63	6.97	0.39	2.5e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs7927592	0.717	rs7126451	chr11:68257386	A/G	cg20283391	chr11:68216788	NA	0.44	5.62	0.33	4.9e-8	Total body bone mineral density;
CESC	trans	rs561341	0.700	rs886223	chr17:30229877	G/T	cg20587970	chr11:113659929	NA	-0.63	-8.23	-0.45	8.49e-15	Hip circumference adjusted for BMI;
CESC	cis	rs3820068	0.608	rs7516683	chr1:16020502	A/G	cg13390004	chr1:15929781	NA	-0.33	-5.3	-0.31	2.41e-7	Systolic blood pressure;
CESC	cis	rs8060686	0.641	rs3743735	chr16:68119555	G/A	cg26727032	chr16:67993705	SLC12A4	-0.54	-6.05	-0.35	4.92e-9	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs6835098	1.000	rs4561909	chr4:174086937	A/T	cg08422745	chr4:174089978	GALNT7	-0.74	-9.68	-0.51	3.55e-19	Dementia and core Alzheimer's disease neuropathologic changes;
CESC	cis	rs1348850	0.914	rs7587604	chr2:178309848	T/A	cg23306229	chr2:178417860	TTC30B	0.6	7.84	0.43	1.12e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs7412746	0.588	rs10305664	chr1:150839686	A/C	cg09365446	chr1:150670422	GOLPH3L	0.39	5.27	0.31	2.86e-7	Melanoma;
CESC	trans	rs7126679	0.544	rs672981	chr11:88623113	T/G	cg08270734	chr12:108951574	SART3	0.47	6.16	0.35	2.65e-9	Depressive symptoms;
CESC	cis	rs9309473	0.687	rs6710659	chr2:73607510	A/G	cg20560298	chr2:73613845	ALMS1	-0.47	-6.43	-0.37	5.85e-10	Metabolite levels;
CESC	cis	rs4727963	0.837	rs10258768	chr7:122799240	C/A	cg03640110	chr7:122635026	TAS2R16	0.33	5.07	0.3	7.45e-7	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
CESC	cis	rs6570726	0.791	rs446362	chr6:145878716	G/T	cg23711669	chr6:146136114	FBXO30	1.03	16.03	0.7	6.76e-41	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4589502	0.800	rs12595796	chr15:67202599	A/G	cg12317470	chr15:67143691	NA	-0.67	-7.8	-0.43	1.38e-13	Lung cancer (smoking interaction);
CESC	cis	rs7191439	0.858	rs2290902	chr16:88782676	A/G	cg02389323	chr16:88786976	FAM38A	0.88	7.33	0.41	2.71e-12	Plateletcrit;
CESC	cis	rs4889855	0.556	rs74003969	chr17:78526212	C/T	cg16591659	chr17:78472290	NA	0.39	6.35	0.36	9.31e-10	Fractional excretion of uric acid;
CESC	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg22535103	chr8:58192502	C8orf71	-0.94	-9.92	-0.52	6.46e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs7072216	0.763	rs2147901	chr10:100165496	A/C	cg26618903	chr10:100175079	PYROXD2	0.33	5.18	0.3	4.37e-7	Metabolite levels;
CESC	cis	rs7666738	0.861	rs10018654	chr4:99002226	A/G	cg18180107	chr4:99064573	C4orf37	0.4	5.21	0.31	3.72e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg04650786	chr6:108395545	OSTM1	-0.46	-6.0	-0.35	6.39e-9	Height;
CESC	cis	rs72781680	1.000	rs6751655	chr2:24155478	A/G	cg20701182	chr2:24300061	SF3B14	0.71	6.32	0.36	1.12e-9	Lymphocyte counts;
CESC	cis	rs12155623	0.504	rs10808736	chr8:49873039	C/A	cg22283653	chr8:49824208	NA	0.39	5.83	0.34	1.63e-8	Sudden cardiac arrest;
CESC	cis	rs941873	0.772	rs1316312	chr10:81110417	G/C	cg09469691	chr10:81107165	PPIF	0.53	7.03	0.4	1.8e-11	Height;
CESC	cis	rs7809950	0.798	rs10281535	chr7:107229618	T/G	cg23024343	chr7:107201750	COG5	0.41	5.68	0.33	3.5e-8	Coronary artery disease;
CESC	cis	rs1799949	1.000	rs11651341	chr17:41428061	T/C	cg23758822	chr17:41437982	NA	1.03	15.87	0.7	2.47e-40	Menopause (age at onset);
CESC	cis	rs780096	0.546	rs35073769	chr2:27731376	C/T	cg22903471	chr2:27725779	GCKR	-0.53	-7.16	-0.4	8.08e-12	Total body bone mineral density;
CESC	cis	rs7666738	0.830	rs1426663	chr4:98990092	T/G	cg18180107	chr4:99064573	C4orf37	0.4	5.21	0.31	3.72e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2985684	0.948	rs2883437	chr14:50031666	A/G	cg10008539	chr14:50087325	RPL36AL;MGAT2	-0.44	-5.29	-0.31	2.55e-7	Carotid intima media thickness;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg10156544	chr12:104324016	LOC253724;HSP90B1	-0.44	-6.05	-0.35	5.04e-9	Fibrinogen levels;
CESC	cis	rs9868809	0.881	rs2310996	chr3:48671834	T/C	cg06212747	chr3:49208901	KLHDC8B	-0.59	-5.15	-0.3	5.19e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs10463316	0.817	rs6879238	chr5:150820574	G/C	cg03212797	chr5:150827313	SLC36A1	-0.48	-6.32	-0.36	1.13e-9	Metabolite levels (Pyroglutamine);
CESC	cis	rs1218582	0.772	rs10796935	chr1:154891363	G/T	cg03351412	chr1:154909251	PMVK	0.7	9.52	0.5	1.11e-18	Prostate cancer;
CESC	cis	rs244293	0.695	rs9303360	chr17:53001456	T/C	cg19360675	chr17:53046073	COX11;STXBP4	-0.49	-6.6	-0.38	2.29e-10	Menarche (age at onset);
CESC	cis	rs748404	0.676	rs4401024	chr15:43650335	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.6	7.57	0.42	6.2e-13	Lung cancer;
CESC	cis	rs72634258	0.553	rs112697022	chr1:7949253	G/A	cg00042356	chr1:8021962	PARK7	0.56	5.11	0.3	6.03e-7	Inflammatory bowel disease;
CESC	cis	rs7267979	1.000	rs4813563	chr20:25365340	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.84	-16.5	-0.71	1.44e-42	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs796364	0.616	rs7589545	chr2:200676102	T/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.55	5.18	0.3	4.37e-7	Schizophrenia;
CESC	cis	rs2576037	0.523	rs4890705	chr18:44509758	A/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.34	5.38	0.31	1.6e-7	Personality dimensions;
CESC	cis	rs4319547	0.695	rs10734915	chr12:122873408	A/C	cg05707623	chr12:122985044	ZCCHC8	-0.52	-6.21	-0.36	2.05e-9	Body mass index;
CESC	cis	rs1568889	1.000	rs7934085	chr11:28369660	G/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.78	10.86	0.55	5.8e-23	Bipolar disorder;
CESC	cis	rs924607	0.931	rs1709556	chr5:637058	A/G	cg09021430	chr5:549028	NA	-0.39	-6.88	-0.39	4.32e-11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs2997447	0.748	rs2802346	chr1:26434354	G/A	cg24596570	chr1:26146463	FAM54B;LOC646471	0.57	5.04	0.3	8.68e-7	QRS complex (12-leadsum);
CESC	cis	rs703842	1.000	rs8181644	chr12:58173466	A/G	cg00677455	chr12:58241039	CTDSP2	0.54	7.01	0.4	1.93e-11	Multiple sclerosis;
CESC	cis	rs9815354	0.953	rs7631914	chr3:41813557	T/C	cg03022575	chr3:42003672	ULK4	0.46	5.04	0.3	8.45e-7	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs881375	0.678	rs2269060	chr9:123683569	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.4	5.75	0.33	2.45e-8	Rheumatoid arthritis;
CESC	cis	rs9894429	1.000	rs7209180	chr17:79581519	C/A	cg13777783	chr17:79615861	NA	-0.35	-5.79	-0.34	1.99e-8	Eye color traits;
CESC	trans	rs35883536	1.000	rs3904672	chr1:101136651	C/T	cg16931499	chr17:42786676	DBF4B	0.42	6.14	0.35	2.99e-9	Monocyte count;
CESC	cis	rs9790314	0.846	rs6441371	chr3:161008727	C/A	cg04691961	chr3:161091175	C3orf57	-0.41	-5.37	-0.31	1.7e-7	Morning vs. evening chronotype;
CESC	cis	rs14403	1.000	rs12406958	chr1:243662190	T/C	cg21452805	chr1:244014465	NA	0.49	5.75	0.33	2.48e-8	Schizophrenia;
CESC	cis	rs9311474	0.607	rs4234633	chr3:52557038	C/T	cg15147215	chr3:52552868	STAB1	-0.31	-5.26	-0.31	2.98e-7	Electroencephalogram traits;
CESC	cis	rs3736485	0.966	rs11070854	chr15:51808365	A/G	cg08986416	chr15:51914746	DMXL2	-0.4	-5.16	-0.3	4.85e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs7130144	0.541	rs1921573	chr11:130461493	A/T	cg26307797	chr11:130446613	NA	-0.74	-6.36	-0.36	8.72e-10	Urate levels in lean individuals;
CESC	cis	rs6964587	1.000	rs2299232	chr7:91626699	A/C	cg17063962	chr7:91808500	NA	0.55	7.43	0.42	1.53e-12	Breast cancer;
CESC	cis	rs8177253	1.000	rs8177272	chr3:133482870	C/T	cg01448562	chr3:133502909	NA	-0.45	-6.14	-0.35	2.96e-9	Iron status biomarkers;
CESC	cis	rs6701037	0.748	rs10912901	chr1:175138602	G/A	cg00321850	chr1:175162397	KIAA0040	-0.42	-6.04	-0.35	5.06e-9	Alcohol dependence;
CESC	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg10862848	chr6:42927986	GNMT	-0.3	-7.48	-0.42	1.13e-12	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs896854	0.902	rs726816	chr8:95968413	T/G	cg23172400	chr8:95962367	TP53INP1	-0.46	-9.39	-0.5	2.87e-18	Type 2 diabetes;
CESC	cis	rs73206853	0.764	rs55887805	chr12:110597246	T/C	cg12870014	chr12:110450643	ANKRD13A	0.65	5.62	0.33	4.79e-8	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs4566357	0.964	rs2396443	chr2:227921208	A/G	cg11843606	chr2:227700838	RHBDD1	-0.41	-5.29	-0.31	2.58e-7	Coronary artery disease;
CESC	cis	rs6032067	0.929	rs13038355	chr20:43805555	C/T	cg11264863	chr20:43835661	SEMG1	0.51	5.56	0.32	6.5e-8	Blood protein levels;
CESC	cis	rs66887589	0.807	rs7694483	chr4:120405929	T/A	cg09307838	chr4:120376055	NA	0.54	7.16	0.4	8.19e-12	Diastolic blood pressure;
CESC	cis	rs61931739	0.817	rs1705771	chr12:34174950	C/G	cg19457237	chr12:34500585	NA	-0.37	-5.2	-0.3	3.94e-7	Morning vs. evening chronotype;
CESC	cis	rs1552244	0.882	rs13074282	chr3:10024699	T/G	cg00166722	chr3:10149974	C3orf24	0.49	6.04	0.35	5.3e-9	Alzheimer's disease;
CESC	cis	rs2279817	0.863	rs12749985	chr1:18026004	C/T	cg21791023	chr1:18019539	ARHGEF10L	-0.55	-8.26	-0.45	6.78e-15	Neuroticism;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02050560	chr22:42486888	NDUFA6	0.56	6.54	0.37	3.14e-10	Gut microbiome composition (summer);
CESC	cis	rs2836974	0.666	rs4624474	chr21:40686327	T/C	cg11644478	chr21:40555479	PSMG1	-0.79	-11.66	-0.58	1.23e-25	Cognitive function;
CESC	trans	rs9388451	0.626	rs1935983	chr6:126068914	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.66	-9.31	-0.5	4.92e-18	Brugada syndrome;
CESC	cis	rs9660180	0.967	rs12044597	chr1:1708801	A/G	cg13866156	chr1:1669148	SLC35E2	-0.49	-6.54	-0.37	3.1e-10	Body mass index;
CESC	cis	rs4664293	0.967	rs6432548	chr2:160545537	T/C	cg08347373	chr2:160653686	CD302	-0.31	-5.1	-0.3	6.5e-7	Monocyte percentage of white cells;
CESC	cis	rs7818688	0.697	rs58314911	chr8:95985111	G/A	cg16049864	chr8:95962084	TP53INP1	0.57	5.73	0.33	2.68e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs4969178	0.965	rs16971107	chr17:76394042	C/T	cg20026190	chr17:76395443	PGS1	0.49	7.99	0.44	4.2e-14	HDL cholesterol levels;
CESC	cis	rs8180040	0.620	rs2305635	chr3:47043622	G/A	cg27129171	chr3:47204927	SETD2	-0.67	-9.72	-0.51	2.72e-19	Colorectal cancer;
CESC	cis	rs911555	0.692	rs7145753	chr14:103866100	G/A	cg24130564	chr14:104152367	KLC1	0.44	5.79	0.33	2.03e-8	Intelligence (multi-trait analysis);
CESC	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg26338869	chr17:61819248	STRADA	0.7	9.31	0.5	5.07e-18	Prudent dietary pattern;
CESC	cis	rs1371867	0.875	rs1788187	chr8:101336099	A/G	cg11906718	chr8:101322791	RNF19A	0.46	5.91	0.34	1.03e-8	Atrioventricular conduction;
CESC	cis	rs4819052	0.851	rs2838866	chr21:46713014	G/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.49	6.14	0.35	2.95e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs8072100	1.000	rs3809868	chr17:45750596	G/A	cg08085267	chr17:45401833	C17orf57	0.41	5.44	0.32	1.21e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs2952156	0.920	rs2941506	chr17:37833035	A/G	cg07936489	chr17:37558343	FBXL20	-0.58	-7.33	-0.41	2.84e-12	Asthma;
CESC	cis	rs10504229	0.595	rs76447299	chr8:58117395	A/G	cg02725872	chr8:58115012	NA	-0.45	-7.05	-0.4	1.52e-11	Developmental language disorder (linguistic errors);
CESC	trans	rs1105307	0.734	rs7025471	chr9:72159380	G/A	cg17994569	chr10:50821652	CHAT	-0.28	-6.06	-0.35	4.65e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs4665809	0.549	rs17527979	chr2:26428132	A/G	cg22920501	chr2:26401640	FAM59B	-0.8	-8.75	-0.47	2.48e-16	Gut microbiome composition (summer);
CESC	cis	rs2820292	0.804	rs2644120	chr1:201882277	C/G	cg06775570	chr1:201857621	SHISA4	0.33	5.57	0.32	6.15e-8	Waist circumference;Body mass index (joint analysis main effects and smoking interaction);Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);
CESC	cis	rs2239547	0.522	rs9846976	chr3:53007995	T/C	cg11645453	chr3:52864694	ITIH4	0.33	5.46	0.32	1.08e-7	Schizophrenia;
CESC	cis	rs12545109	0.959	rs12547974	chr8:57314785	G/T	cg09654669	chr8:57350985	NA	-0.58	-6.97	-0.39	2.44e-11	Obesity-related traits;
CESC	cis	rs11098499	0.697	rs10020027	chr4:120381879	G/C	cg09307838	chr4:120376055	NA	0.96	13.95	0.65	1.6e-33	Corneal astigmatism;
CESC	cis	rs1847505	0.559	rs2323133	chr13:61568946	G/A	cg25164009	chr13:61490935	NA	-0.41	-5.49	-0.32	9.53e-8	Polychlorinated biphenyl levels;
CESC	cis	rs941873	0.803	rs5015119	chr10:81101609	G/C	cg11057378	chr10:81107060	PPIF	0.37	5.86	0.34	1.36e-8	Height;
CESC	cis	rs7762018	1.000	rs7747645	chr6:170070291	G/C	cg05834625	chr6:170176447	C6orf70	0.62	7.46	0.42	1.25e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs13191362	1.000	rs13199223	chr6:163001083	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.83	8.39	0.46	3.02e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs8177179	0.967	rs4994581	chr3:133437563	T/C	cg16262614	chr3:133464971	TF	0.38	7.36	0.41	2.37e-12	Iron status biomarkers (transferrin levels);
CESC	cis	rs6547741	1.000	rs7604798	chr2:27824940	T/C	cg27432699	chr2:27873401	GPN1	0.49	6.94	0.39	3.02e-11	Oral cavity cancer;
CESC	cis	rs1552244	0.816	rs56271597	chr3:10042790	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.76	-9.68	-0.51	3.46e-19	Alzheimer's disease;
CESC	cis	rs3785574	0.638	rs2854182	chr17:61969062	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.6	7.28	0.41	3.77e-12	Height;
CESC	cis	rs35110281	0.626	rs162388	chr21:44936032	G/A	cg21573476	chr21:45109991	RRP1B	-0.35	-5.15	-0.3	5.01e-7	Mean corpuscular volume;
CESC	cis	rs3785574	0.743	rs2727334	chr17:61969063	A/T	cg11494091	chr17:61959527	GH2	0.37	5.09	0.3	6.71e-7	Height;
CESC	cis	rs6933660	0.646	rs9397410	chr6:151770503	C/T	cg14416726	chr6:151773293	C6orf211;RMND1	-0.54	-7.34	-0.41	2.59e-12	Menarche (age at onset);
CESC	cis	rs79349575	0.715	rs55724082	chr17:47017879	G/A	cg26022315	chr17:47021804	SNF8	0.39	5.15	0.3	5.01e-7	Type 2 diabetes;
CESC	trans	rs916888	0.821	rs199509	chr17:44858728	G/A	cg01341218	chr17:43662625	NA	-0.85	-10.53	-0.54	6.95e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs1797885	0.934	rs299654	chr3:12550078	A/G	cg26432171	chr3:12704882	RAF1	-0.45	-5.66	-0.33	3.94e-8	Immature fraction of reticulocytes;
CESC	cis	rs1862618	0.853	rs832551	chr5:56180112	T/G	cg24531977	chr5:56204891	C5orf35	-0.87	-10.87	-0.56	5.43e-23	Initial pursuit acceleration;
CESC	cis	rs12413816	0.963	rs12359348	chr10:13765950	C/T	cg16485048	chr10:13749193	FRMD4A	-0.48	-6.57	-0.37	2.69e-10	Red cell distribution width;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg09090048	chr11:134093731	VPS26B;NCAPD3	-0.43	-6.13	-0.35	3.17e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs9467711	0.606	rs9379901	chr6:26603866	T/C	cg14345882	chr6:26364793	BTN3A2	0.56	5.96	0.34	7.82e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs1448094	0.511	rs17280643	chr12:86210154	C/T	cg19622623	chr12:86230825	RASSF9	0.44	5.68	0.33	3.51e-8	Major depressive disorder;
CESC	cis	rs9443645	0.869	rs1507154	chr6:79503700	C/T	cg05283184	chr6:79620031	NA	-0.44	-6.79	-0.39	7.27e-11	Intelligence (multi-trait analysis);
CESC	trans	rs916888	0.610	rs199530	chr17:44836653	C/T	cg22433210	chr17:43662623	NA	-0.59	-7.81	-0.43	1.33e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs9916302	0.851	rs12947620	chr17:37605364	T/C	cg15445000	chr17:37608096	MED1	0.41	6.76	0.38	8.83e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs1448094	0.556	rs4897831	chr12:86168248	C/T	cg02569458	chr12:86230093	RASSF9	0.57	8.34	0.46	4.13e-15	Major depressive disorder;
CESC	cis	rs1577917	1.000	rs12207610	chr6:86688016	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.43	-5.57	-0.32	6.1e-8	Response to antipsychotic treatment;
CESC	cis	rs1552244	0.935	rs4441636	chr3:10083876	G/A	cg00166722	chr3:10149974	C3orf24	0.47	5.91	0.34	1.05e-8	Alzheimer's disease;
CESC	cis	rs2415984	0.622	rs61993301	chr14:46949667	C/T	cg14871534	chr14:47121158	RPL10L	-0.36	-5.37	-0.31	1.75e-7	Number of children ever born;
CESC	cis	rs597539	0.617	rs686348	chr11:68636996	A/G	cg01988459	chr11:68622903	NA	-0.39	-5.21	-0.3	3.76e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs7412746	0.611	rs2256355	chr1:150811794	A/G	cg22823121	chr1:150693482	HORMAD1	0.38	5.55	0.32	6.86e-8	Melanoma;
CESC	cis	rs1881797	0.872	rs12404733	chr1:247690417	A/C	cg18198730	chr1:247681584	NA	0.57	7.81	0.43	1.32e-13	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs208515	0.525	rs10944859	chr6:66665197	A/G	cg07460842	chr6:66804631	NA	0.83	10.33	0.54	3.09e-21	Exhaled nitric oxide levels;
CESC	cis	rs2236918	0.932	rs2488471	chr1:242019831	T/C	cg17736920	chr1:242011382	EXO1	0.72	9.08	0.49	2.55e-17	Menopause (age at onset);
CESC	trans	rs877282	0.945	rs71491303	chr10:772884	G/T	cg22713356	chr15:30763199	NA	1.12	11.31	0.57	1.87e-24	Uric acid levels;
CESC	cis	rs6089584	0.627	rs13045575	chr20:60565596	G/A	cg06108461	chr20:60628389	TAF4	-0.52	-6.87	-0.39	4.7e-11	Body mass index;
CESC	cis	rs2486288	0.656	rs2413774	chr15:45549423	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.54	-6.55	-0.37	3.03e-10	Glomerular filtration rate;
CESC	cis	rs863345	0.604	rs6674656	chr1:158495431	G/A	cg12129480	chr1:158549410	OR10X1	-0.35	-6.86	-0.39	4.87e-11	Pneumococcal bacteremia;
CESC	cis	rs7312933	0.558	rs4768402	chr12:42755576	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.48	-6.38	-0.36	7.99e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs898097	1.000	rs898098	chr17:80904564	G/A	cg15664640	chr17:80829946	TBCD	0.49	6.75	0.38	9.17e-11	Breast cancer;
CESC	cis	rs7914558	1.000	rs11191541	chr10:104824199	A/G	cg04362960	chr10:104952993	NT5C2	0.47	6.32	0.36	1.11e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs9581857	0.579	rs1759861	chr13:27996406	A/C	cg01674679	chr13:27998804	GTF3A	0.67	5.55	0.32	6.8e-8	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
CESC	cis	rs12142240	0.698	rs1135460	chr1:46815970	T/C	cg10495392	chr1:46806563	NSUN4	0.57	6.28	0.36	1.39e-9	Menopause (age at onset);
CESC	cis	rs9916302	0.595	rs4795371	chr17:37636695	T/G	cg07936489	chr17:37558343	FBXL20	-0.8	-11.83	-0.59	3.35e-26	Glomerular filtration rate (creatinine);
CESC	cis	rs6088590	1.000	rs6119530	chr20:33403930	A/G	cg24642439	chr20:33292090	TP53INP2	0.86	11.7	0.58	8.76e-26	Coronary artery disease;
CESC	cis	rs875971	0.862	rs7796162	chr7:65745758	T/C	cg12463550	chr7:65579703	CRCP	-0.47	-5.96	-0.34	7.88e-9	Aortic root size;
CESC	cis	rs1707322	0.865	rs785501	chr1:46579611	C/T	cg03146154	chr1:46216737	IPP	-0.69	-9.13	-0.49	1.84e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs523522	0.962	rs3759394	chr12:120933173	C/A	cg27279351	chr12:120934652	DYNLL1	0.69	9.11	0.49	2.02e-17	High light scatter reticulocyte count;
CESC	cis	rs7605378	0.528	rs1704191	chr2:200816393	C/A	cg17644776	chr2:200775616	C2orf69	0.54	6.56	0.37	2.76e-10	Osteoporosis;
CESC	cis	rs9911578	1.000	rs7223955	chr17:56917053	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.26	0.31	3.04e-7	Intelligence (multi-trait analysis);
CESC	cis	rs67460515	0.563	rs9883566	chr3:160770323	C/T	cg03342759	chr3:160939853	NMD3	0.56	7.17	0.4	7.34e-12	Parkinson's disease;
CESC	cis	rs910316	1.000	rs12589815	chr14:75544101	C/T	cg11812906	chr14:75593930	NEK9	0.89	15.06	0.68	1.89e-37	Height;
CESC	cis	rs875971	0.571	rs160641	chr7:65577346	G/A	cg25405998	chr7:65216604	CCT6P1	-0.49	-5.4	-0.31	1.48e-7	Aortic root size;
CESC	cis	rs1005277	0.540	rs289638	chr10:37923731	G/A	cg25427524	chr10:38739819	LOC399744	-0.62	-8.99	-0.48	4.74e-17	Extrinsic epigenetic age acceleration;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg14684917	chr11:62380363	EML3;ROM1	-0.5	-7.1	-0.4	1.13e-11	Fibrinogen levels;
CESC	cis	rs4727027	0.631	rs62507511	chr7:148796080	C/A	cg23583168	chr7:148888333	NA	-0.8	-12.01	-0.59	7.88e-27	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs17431357	1.000	rs73221382	chr12:120917765	T/A	cg25045489	chr12:120971538	RNF10	-0.93	-5.46	-0.32	1.1e-7	Insulin resistance/response;
CESC	cis	rs761746	0.960	rs5998035	chr22:31939612	G/A	cg25791279	chr22:32026902	PISD	0.49	5.59	0.32	5.55e-8	Intelligence;
CESC	cis	rs282587	0.530	rs406997	chr13:113417880	G/C	cg02820901	chr13:113351484	ATP11A	-0.64	-5.33	-0.31	2.09e-7	Glycated hemoglobin levels;
CESC	cis	rs6460942	1.000	rs75564554	chr7:12319362	A/C	cg02935154	chr7:12443704	VWDE	-0.59	-5.84	-0.34	1.5e-8	Coronary artery disease;
CESC	trans	rs9467711	0.559	rs6920256	chr6:26537801	G/A	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.72	6.21	0.36	2.06e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs2243480	0.803	rs403089	chr7:65517723	T/C	cg13147721	chr7:65941812	NA	-0.88	-8.52	-0.46	1.19e-15	Diabetic kidney disease;
CESC	cis	rs9916302	0.898	rs8072297	chr17:37478048	A/T	cg00129232	chr17:37814104	STARD3	0.5	6.23	0.36	1.8e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs7481584	0.624	rs449466	chr11:3047603	C/T	cg25174290	chr11:3078921	CARS	-0.46	-6.4	-0.37	6.86e-10	Calcium levels;
CESC	cis	rs6964587	0.967	rs6970743	chr7:91744311	C/G	cg17063962	chr7:91808500	NA	0.57	7.96	0.44	5.03e-14	Breast cancer;
CESC	cis	rs4853525	0.522	rs1860167	chr2:191582387	G/A	cg10560079	chr2:191398806	TMEM194B	-0.45	-5.54	-0.32	7.12e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
CESC	cis	rs2836974	0.932	rs56306759	chr21:40608106	G/A	cg11890956	chr21:40555474	PSMG1	1.16	21.17	0.79	6.55e-59	Cognitive function;
CESC	cis	rs4665809	0.590	rs35532350	chr2:26441605	T/C	cg08470875	chr2:26401718	FAM59B	-0.75	-7.79	-0.43	1.49e-13	Gut microbiome composition (summer);
CESC	cis	rs853679	0.517	rs9368556	chr6:28131153	T/C	cg08968635	chr6:28129556	ZNF389	0.4	5.22	0.31	3.69e-7	Depression;
CESC	cis	rs4144743	1.000	rs66738981	chr17:45325538	T/A	cg18085866	chr17:45331354	ITGB3	-0.61	-6.56	-0.37	2.75e-10	Body mass index;
CESC	cis	rs12136530	0.744	rs16862798	chr1:19777837	A/G	cg01832549	chr1:19774989	CAPZB	-0.46	-6.78	-0.38	8e-11	Lead levels in blood;
CESC	cis	rs4689388	0.856	rs1046314	chr4:6303955	A/G	cg00701064	chr4:6280414	WFS1	-0.71	-12.59	-0.61	8.45e-29	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs7618915	0.547	rs68021750	chr3:52624769	G/A	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.59	0.38	2.35e-10	Bipolar disorder;
CESC	cis	rs9902453	0.904	rs55633288	chr17:28368196	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.67	-8.69	-0.47	3.79e-16	Coffee consumption (cups per day);
CESC	cis	rs4450798	0.649	rs6782219	chr3:13779640	A/G	cg23332027	chr3:13681764	NA	0.4	5.58	0.32	5.95e-8	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs738322	0.839	rs133015	chr22:38572526	C/G	cg25457927	chr22:38595422	NA	-0.3	-5.46	-0.32	1.08e-7	Cutaneous nevi;
CESC	trans	rs916888	0.821	rs199506	chr17:44859031	A/G	cg22968622	chr17:43663579	NA	-1.2	-16.07	-0.7	4.83e-41	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs875971	0.862	rs11769079	chr7:65842128	G/A	cg11764359	chr7:65958608	NA	0.81	11.87	0.59	2.48e-26	Aortic root size;
CESC	cis	rs1401999	0.650	rs3792585	chr3:183646222	A/G	cg01324343	chr3:183735012	ABCC5	0.47	9.17	0.49	1.38e-17	Anterior chamber depth;
CESC	cis	rs5760092	0.572	rs738806	chr22:24234172	A/G	cg01238044	chr22:24384105	GSTT1	-0.55	-6.23	-0.36	1.8e-9	Urinary 1,3-butadiene metabolite levels in smokers;
CESC	cis	rs2839186	0.508	rs6518278	chr21:47640571	A/G	cg00815214	chr21:47717953	NA	0.47	6.34	0.36	9.9e-10	Testicular germ cell tumor;
CESC	cis	rs3820928	0.874	rs10933163	chr2:227815286	A/G	cg05526886	chr2:227700861	RHBDD1	-0.39	-5.04	-0.3	8.71e-7	Pulmonary function;
CESC	cis	rs950169	0.922	rs62021167	chr15:85118051	T/A	cg17507749	chr15:85114479	UBE2QP1	0.54	6.09	0.35	3.99e-9	Schizophrenia;
CESC	trans	rs11764590	0.724	rs62444917	chr7:2107262	A/C	cg11693508	chr17:37793320	STARD3	0.53	6.04	0.35	5.25e-9	Neuroticism;
CESC	cis	rs9796	0.558	rs11855102	chr15:41513257	T/C	cg20272979	chr15:41787780	ITPKA	0.34	5.25	0.31	3.18e-7	Menopause (age at onset);
CESC	cis	rs2865126	0.644	rs8098584	chr18:10736934	G/A	cg21165219	chr18:10698044	FAM38B	-0.53	-5.25	-0.31	3.15e-7	Metabolite levels (5-HIAA/ MHPG Ratio);
CESC	cis	rs10242455	0.557	rs73401516	chr7:99068351	C/A	cg18809830	chr7:99032528	PTCD1	-0.59	-5.03	-0.3	9.22e-7	Blood metabolite levels;
CESC	cis	rs698833	0.852	rs4953089	chr2:44565024	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.55	6.91	0.39	3.5e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs1552244	1.000	rs112847840	chr3:10101652	C/T	cg16606324	chr3:10149918	C3orf24	0.43	5.22	0.31	3.71e-7	Alzheimer's disease;
CESC	cis	rs2243480	0.708	rs13242216	chr7:65898277	T/C	cg13147721	chr7:65941812	NA	-0.94	-8.74	-0.47	2.71e-16	Diabetic kidney disease;
CESC	cis	rs7666738	0.830	rs13144771	chr4:99026935	G/C	cg18180107	chr4:99064573	C4orf37	0.42	5.43	0.32	1.29e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11871801	0.918	rs34460267	chr17:40615865	T/C	cg21433558	chr17:40837037	CNTNAP1	0.43	5.09	0.3	6.66e-7	Crohn's disease;
CESC	cis	rs12541335	0.639	rs11779277	chr8:22200683	C/T	cg02788857	chr8:22132959	PIWIL2	0.32	5.63	0.33	4.51e-8	Hypertriglyceridemia;
CESC	cis	rs7666738	0.800	rs7683737	chr4:99070880	A/T	cg17366294	chr4:99064904	C4orf37	0.62	8.59	0.47	7.53e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9322193	0.926	rs9689036	chr6:150101699	T/C	cg04369109	chr6:150039330	LATS1	-0.42	-5.95	-0.34	8.52e-9	Lung cancer;
CESC	trans	rs2109514	0.505	rs1633714	chr7:116022538	C/T	cg23019286	chr1:227728774	NA	-0.42	-6.04	-0.35	5.21e-9	Prevalent atrial fibrillation;
CESC	cis	rs7666738	0.791	rs4699324	chr4:98967496	G/A	cg17366294	chr4:99064904	C4orf37	0.59	8.46	0.46	1.8e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg20887711	chr4:1340912	KIAA1530	0.89	11.87	0.59	2.4e-26	Longevity;
CESC	trans	rs10411161	0.702	rs17778790	chr19:52399559	C/T	cg22319618	chr22:45562946	NUP50	-0.75	-7.3	-0.41	3.33e-12	Breast cancer;
CESC	cis	rs9733	0.569	rs11204691	chr1:150644339	A/T	cg09365446	chr1:150670422	GOLPH3L	0.42	5.91	0.34	1.03e-8	Tonsillectomy;
CESC	cis	rs9291683	0.546	rs13120348	chr4:10053155	C/G	cg11266682	chr4:10021025	SLC2A9	-0.65	-13.09	-0.63	1.61e-30	Bone mineral density;
CESC	trans	rs61931739	0.500	rs7489130	chr12:34539674	C/A	cg26384229	chr12:38710491	ALG10B	0.72	10.84	0.55	6.43e-23	Morning vs. evening chronotype;
CESC	cis	rs1215050	0.740	rs783916	chr4:99026264	A/C	cg17366294	chr4:99064904	C4orf37	-0.48	-6.47	-0.37	4.67e-10	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs6723226	0.804	rs17428810	chr2:32736043	T/C	cg02381751	chr2:32503542	YIPF4	-0.82	-11.07	-0.56	1.16e-23	Intelligence (multi-trait analysis);
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg17129466	chr19:1848747	REXO1	-0.45	-6.04	-0.35	5.28e-9	Asthma;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11692369	chr8:54755880	ATP6V1H	0.63	7.63	0.42	4.12e-13	Gut microbiome composition (summer);
CESC	cis	rs1862618	0.853	rs252915	chr5:56121754	C/T	cg12311346	chr5:56204834	C5orf35	0.73	8.93	0.48	7.24e-17	Initial pursuit acceleration;
CESC	cis	rs7648466	0.592	rs2087726	chr3:46208310	G/A	cg19145607	chr3:45983792	CXCR6;FYCO1	0.35	5.42	0.32	1.34e-7	Eotaxin levels;
CESC	cis	rs6032067	0.777	rs34343273	chr20:43795293	G/A	cg10761708	chr20:43804764	PI3	0.56	6.55	0.37	3.01e-10	Blood protein levels;
CESC	cis	rs12477438	0.765	rs12612688	chr2:99613091	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.64	-8.75	-0.47	2.51e-16	Chronic sinus infection;
CESC	cis	rs75804782	0.521	rs66477197	chr2:239403832	C/T	cg18131467	chr2:239335373	ASB1	-0.7	-5.57	-0.32	6.31e-8	Morning vs. evening chronotype;Chronotype;
CESC	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	-0.54	-6.73	-0.38	1.03e-10	Prudent dietary pattern;
CESC	cis	rs8031584	0.918	rs35396566	chr15:31263057	T/C	cg08704250	chr15:31115839	NA	-0.68	-8.4	-0.46	2.7e-15	Huntington's disease progression;
CESC	cis	rs875971	0.545	rs1796217	chr7:66085918	A/G	cg18876405	chr7:65276391	NA	-0.5	-5.7	-0.33	3.2e-8	Aortic root size;
CESC	cis	rs12497850	0.931	rs4974085	chr3:48924900	C/T	cg06212747	chr3:49208901	KLHDC8B	0.62	8.56	0.47	9.56e-16	Parkinson's disease;
CESC	cis	rs67311347	0.866	rs11712426	chr3:40330322	G/A	cg24209194	chr3:40518798	ZNF619	0.44	5.58	0.32	6.05e-8	Renal cell carcinoma;
CESC	cis	rs3785574	0.925	rs2727340	chr17:61970224	T/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.76	9.76	0.51	2.06e-19	Height;
CESC	cis	rs9815354	0.680	rs73075231	chr3:42051694	T/C	cg03022575	chr3:42003672	ULK4	0.78	6.65	0.38	1.67e-10	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs7662987	0.517	rs2602858	chr4:100030461	T/C	cg13256891	chr4:100009986	ADH5	0.75	8.03	0.44	3.29e-14	Smoking initiation;
CESC	trans	rs13160161	0.533	rs17364997	chr5:39054742	C/G	cg09550024	chr10:96698366	CYP2C9	-0.46	-6.22	-0.36	1.98e-9	Obesity-related traits;
CESC	cis	rs3026101	0.647	rs12603729	chr17:5320685	C/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.43	5.59	0.32	5.61e-8	Body mass index;
CESC	cis	rs6541297	0.715	rs4846840	chr1:230302521	A/C	cg20703242	chr1:230279135	GALNT2	0.37	5.74	0.33	2.52e-8	Coronary artery disease;
CESC	cis	rs9487051	0.676	rs7775206	chr6:109597222	A/G	cg21918786	chr6:109611834	NA	-0.38	-5.52	-0.32	8.19e-8	Reticulocyte fraction of red cells;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg19935506	chr2:242626874	DTYMK	0.46	6.41	0.37	6.66e-10	Systemic lupus erythematosus;
CESC	cis	rs7666738	0.830	rs1120708	chr4:98931260	G/C	cg17366294	chr4:99064904	C4orf37	0.6	8.22	0.45	9.04e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9815354	0.951	rs9850310	chr3:41891098	T/C	cg03022575	chr3:42003672	ULK4	0.58	5.94	0.34	9.04e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs10504229	0.906	rs111838497	chr8:58185620	A/C	cg22535103	chr8:58192502	C8orf71	-1.05	-13.08	-0.63	1.71e-30	Developmental language disorder (linguistic errors);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06474646	chr7:128864675	AHCYL2	0.55	6.14	0.35	2.94e-9	Gut microbiome composition (summer);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg03665832	chr7:98923565	ARPC1A	-0.47	-6.36	-0.36	9.05e-10	Ulcerative colitis;
CESC	cis	rs6912958	0.712	rs9444526	chr6:88326402	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.33	-5.41	-0.32	1.39e-7	Monocyte percentage of white cells;
CESC	cis	rs4253772	0.550	rs55926596	chr22:46682955	C/T	cg24881330	chr22:46731750	TRMU	0.82	6.07	0.35	4.41e-9	LDL cholesterol;Cholesterol, total;
CESC	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg22907277	chr7:1156413	C7orf50	0.45	6.43	0.37	6.07e-10	Longevity;Endometriosis;
CESC	cis	rs483180	0.531	rs662243	chr1:120209564	A/C	cg19096424	chr1:120255104	PHGDH	0.43	5.21	0.3	3.78e-7	Macular telangiectasia type 2;
CESC	cis	rs9790314	0.967	rs339101	chr3:161064193	A/T	cg03342759	chr3:160939853	NMD3	-0.45	-5.92	-0.34	1.02e-8	Morning vs. evening chronotype;
CESC	cis	rs754466	0.651	rs11002322	chr10:79649653	G/T	cg17075019	chr10:79541650	NA	-0.83	-12.12	-0.6	3.4e-27	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs2991971	1.000	rs622798	chr1:46015271	T/G	cg06784218	chr1:46089804	CCDC17	-0.3	-5.11	-0.3	6.3e-7	High light scatter reticulocyte count;
CESC	cis	rs1729951	0.575	rs10935214	chr3:136693485	G/A	cg03617693	chr3:136751559	NA	0.39	5.38	0.31	1.68e-7	Neuroticism;
CESC	cis	rs9314323	0.767	rs1865305	chr8:26233325	G/A	cg13160058	chr8:26243215	BNIP3L	-0.32	-5.14	-0.3	5.31e-7	Red cell distribution width;
CESC	cis	rs12142240	0.698	rs41293273	chr1:46806393	T/C	cg00530320	chr1:46809349	NSUN4	0.59	7.85	0.43	1.02e-13	Menopause (age at onset);
CESC	cis	rs6088580	0.634	rs6059860	chr20:33063830	A/C	cg06115741	chr20:33292138	TP53INP2	0.47	6.08	0.35	4.22e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs35306767	0.903	rs11253467	chr10:901244	A/G	cg10556349	chr10:835070	NA	0.52	5.03	0.3	9.17e-7	Eosinophil percentage of granulocytes;
CESC	trans	rs687914	0.710	rs938662	chr2:45864578	A/G	cg20104688	chr17:76183078	TK1;AFMID	0.62	6.2	0.36	2.17e-9	Diastolic blood pressure;
CESC	cis	rs4253772	0.550	rs6008598	chr22:46704243	C/T	cg18190219	chr22:46762943	CELSR1	-0.55	-6.14	-0.35	3.08e-9	LDL cholesterol;Cholesterol, total;
CESC	trans	rs459571	0.959	rs408307	chr9:136892523	A/G	cg09836344	chr4:1243392	C4orf42;CTBP1	0.55	7.32	0.41	3.04e-12	Platelet distribution width;
CESC	cis	rs1707322	1.000	rs10890355	chr1:46317348	G/A	cg03146154	chr1:46216737	IPP	0.71	9.86	0.52	9.69e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9902453	0.933	rs7221154	chr17:28505024	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.58	-7.33	-0.41	2.77e-12	Coffee consumption (cups per day);
CESC	cis	rs801193	0.935	rs3800820	chr7:66147178	C/T	cg14393609	chr7:65229607	NA	-0.47	-6.32	-0.36	1.08e-9	Aortic root size;
CESC	cis	rs9913156	0.707	rs9902000	chr17:4582426	A/C	cg19197139	chr17:4613644	ARRB2	-0.81	-9.47	-0.5	1.6e-18	Lymphocyte counts;
CESC	cis	rs1799949	1.000	rs11653069	chr17:41283377	C/T	cg23758822	chr17:41437982	NA	1.02	15.64	0.69	1.65e-39	Menopause (age at onset);
CESC	cis	rs8017423	0.967	rs12589808	chr14:90719236	C/T	cg14092571	chr14:90743983	NA	0.57	8.67	0.47	4.43e-16	Mortality in heart failure;
CESC	cis	rs2197308	0.765	rs68029712	chr12:37906585	T/G	cg13010199	chr12:38710504	ALG10B	0.53	6.75	0.38	9.06e-11	Morning vs. evening chronotype;
CESC	trans	rs17685	0.753	rs10952840	chr7:75772878	C/T	cg19862616	chr7:65841803	NCRNA00174	0.85	12.42	0.61	3.15e-28	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs9733	0.596	rs34600506	chr1:150687808	C/G	cg09365446	chr1:150670422	GOLPH3L	0.42	5.86	0.34	1.37e-8	Tonsillectomy;
CESC	cis	rs2191566	0.664	rs8105574	chr19:44589042	T/C	cg20607764	chr19:44506953	ZNF230	-0.4	-5.31	-0.31	2.33e-7	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs10242455	0.571	rs13438288	chr7:98916414	T/G	cg25640893	chr7:99214727	ZNF498	0.88	5.93	0.34	9.63e-9	Blood metabolite levels;
CESC	cis	rs763014	0.932	rs2269559	chr16:682297	T/C	cg07343612	chr16:622815	PIGQ	-0.54	-7.87	-0.44	9.33e-14	Height;
CESC	cis	rs2839186	0.708	rs17183123	chr21:47671961	G/C	cg11766577	chr21:47581405	C21orf56	-0.48	-6.58	-0.37	2.56e-10	Testicular germ cell tumor;
CESC	cis	rs10504073	0.584	rs55838473	chr8:49948281	C/A	cg00325661	chr8:49890786	NA	0.57	8.57	0.47	8.91e-16	Blood metabolite ratios;
CESC	cis	rs3091242	0.902	rs36003018	chr1:25784318	A/G	cg27572855	chr1:25598939	RHD	-0.43	-7.22	-0.41	5.47e-12	Erythrocyte sedimentation rate;
CESC	trans	rs9929218	0.953	rs9927329	chr16:68750331	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.79	-10.42	-0.54	1.52e-21	Colorectal cancer;
CESC	cis	rs1697139	0.583	rs6895853	chr5:66541427	T/C	cg11553311	chr5:66541588	NA	0.39	5.47	0.32	1.04e-7	Breast cancer;
CESC	cis	rs7605827	0.930	rs11896745	chr2:15515373	C/T	cg19274914	chr2:15703543	NA	0.32	5.7	0.33	3.17e-8	Educational attainment (years of education);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg15441230	chr15:44069583	ELL3	-0.48	-6.56	-0.37	2.76e-10	Fibrinogen levels;
CESC	cis	rs7254114	0.578	rs35248735	chr19:11312238	G/A	cg02815516	chr19:11306319	KANK2	-0.44	-7.18	-0.4	7.21e-12	Immature fraction of reticulocytes;
CESC	trans	rs561341	1.000	rs2470243	chr17:30290955	C/T	cg20587970	chr11:113659929	NA	-1.48	-19.48	-0.77	4.55e-53	Hip circumference adjusted for BMI;
CESC	cis	rs11785400	1.000	rs4736368	chr8:143748528	G/C	cg24634471	chr8:143751801	JRK	0.47	6.13	0.35	3.09e-9	Schizophrenia;
CESC	cis	rs2204008	0.837	rs11172728	chr12:38070042	C/A	cg26384229	chr12:38710491	ALG10B	0.67	9.33	0.5	4.5e-18	Bladder cancer;
CESC	cis	rs28374715	0.617	rs16971735	chr15:41563970	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.51	-7.35	-0.41	2.44e-12	Ulcerative colitis;
CESC	trans	rs2658782	0.756	rs3019223	chr11:93084182	G/A	cg03479527	chr8:145637966	SLC39A4	-0.41	-6.0	-0.35	6.35e-9	Pulmonary function decline;
CESC	cis	rs897984	0.806	rs4889571	chr16:30949047	A/G	cg00531865	chr16:30841666	NA	0.51	7.01	0.4	1.99e-11	Dementia with Lewy bodies;
CESC	cis	rs950027	0.620	rs1617634	chr15:45615578	A/G	cg21132104	chr15:45694354	SPATA5L1	0.66	8.52	0.46	1.22e-15	Response to fenofibrate (adiponectin levels);
CESC	cis	rs826838	0.804	rs6580755	chr12:39159190	C/T	cg26384229	chr12:38710491	ALG10B	0.79	13.41	0.64	1.19e-31	Heart rate;
CESC	cis	rs56104184	0.830	rs17272645	chr19:49342366	C/G	cg15549821	chr19:49342101	PLEKHA4	0.86	11.06	0.56	1.26e-23	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	cis	rs6775745	0.654	rs9840453	chr3:131777465	G/T	cg12213930	chr3:131751605	CPNE4	0.49	5.56	0.32	6.63e-8	Neutrophil count;
CESC	trans	rs6572548	0.504	rs1956082	chr14:49665496	A/C	cg24415082	chr16:74700811	RFWD3	-0.58	-6.4	-0.37	7.11e-10	Subjective well-being;
CESC	cis	rs6570726	0.599	rs426371	chr6:145886469	A/G	cg23711669	chr6:146136114	FBXO30	-0.89	-11.81	-0.59	3.86e-26	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1707322	0.821	rs11211182	chr1:46240170	G/A	cg06784218	chr1:46089804	CCDC17	0.37	6.24	0.36	1.73e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9905704	0.647	rs3809723	chr17:57061978	T/G	cg12560992	chr17:57184187	TRIM37	0.63	7.87	0.44	9.22e-14	Testicular germ cell tumor;
CESC	cis	rs35955747	0.689	rs5997988	chr22:31838085	G/A	cg25791279	chr22:32026902	PISD	-0.44	-5.21	-0.3	3.8e-7	Neutrophil count;Sum basophil neutrophil counts;
CESC	cis	rs1163251	0.869	rs487884	chr1:120217330	C/T	cg19096424	chr1:120255104	PHGDH	0.43	5.22	0.31	3.62e-7	Blood metabolite levels;
CESC	cis	rs10744422	1.000	rs937766	chr12:123331094	G/T	cg25930673	chr12:123319894	HIP1R	-0.72	-5.73	-0.33	2.79e-8	Schizophrenia;
CESC	cis	rs769267	0.965	rs2315025	chr19:19426609	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.42	5.26	0.31	3.02e-7	Tonsillectomy;
CESC	cis	rs4253772	0.745	rs78023664	chr22:46647844	G/A	cg18190219	chr22:46762943	CELSR1	-0.69	-6.19	-0.36	2.26e-9	LDL cholesterol;Cholesterol, total;
CESC	cis	rs4803455	0.565	rs1025497	chr19:41871254	A/G	cg09537434	chr19:41945824	ATP5SL	-0.69	-9.86	-0.52	9.56e-20	Migraine;Coronary artery disease;
CESC	cis	rs2243480	1.000	rs6966322	chr7:65646754	A/G	cg13147721	chr7:65941812	NA	0.97	9.16	0.49	1.47e-17	Diabetic kidney disease;
CESC	cis	rs35146811	0.555	rs2525539	chr7:99545309	A/G	cg22531904	chr7:99595276	NA	0.41	5.23	0.31	3.53e-7	Coronary artery disease;
CESC	cis	rs1448094	0.512	rs6539924	chr12:86236935	T/C	cg02569458	chr12:86230093	RASSF9	0.49	7.27	0.41	3.96e-12	Major depressive disorder;
CESC	cis	rs61931739	0.500	rs6488209	chr12:34319309	A/G	cg06521331	chr12:34319734	NA	-0.45	-6.26	-0.36	1.57e-9	Morning vs. evening chronotype;
CESC	cis	rs4665809	0.590	rs11897162	chr2:26503654	T/C	cg22920501	chr2:26401640	FAM59B	0.86	9.81	0.52	1.37e-19	Gut microbiome composition (summer);
CESC	cis	rs7772486	0.754	rs9497434	chr6:146260753	C/T	cg05347473	chr6:146136440	FBXO30	-0.57	-7.26	-0.41	4.32e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs13082711	0.834	rs2840088	chr3:27428371	G/A	cg02860705	chr3:27208620	NA	0.56	6.89	0.39	4.13e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CESC	cis	rs17125944	0.505	rs75296244	chr14:53233218	G/A	cg00686598	chr14:53173677	PSMC6	1.4	11.75	0.59	6.26e-26	Alzheimer's disease (late onset);
CESC	cis	rs5758659	0.652	rs133326	chr22:42406885	G/A	cg04733989	chr22:42467013	NAGA	0.44	5.86	0.34	1.35e-8	Cognitive function;
CESC	cis	rs1862618	0.853	rs832584	chr5:56179212	A/G	cg24531977	chr5:56204891	C5orf35	0.87	11.1	0.56	9.48e-24	Initial pursuit acceleration;
CESC	cis	rs17641971	0.684	rs1876717	chr8:49994968	T/G	cg00325661	chr8:49890786	NA	0.39	5.49	0.32	9.18e-8	Blood metabolite levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12149841	chr12:121124893	MLEC	-0.7	-8.46	-0.46	1.8e-15	Gut microbiome composition (summer);
CESC	cis	rs3096299	0.728	rs1011749	chr16:89510869	G/C	cg16743903	chr16:89593216	SPG7	-0.42	-5.5	-0.32	9.07e-8	Multiple myeloma (IgH translocation);
CESC	cis	rs863345	0.967	rs10797017	chr1:158468485	G/A	cg12129480	chr1:158549410	OR10X1	-0.31	-6.23	-0.36	1.78e-9	Pneumococcal bacteremia;
CESC	cis	rs9916302	0.904	rs4795384	chr17:37716771	C/G	cg07936489	chr17:37558343	FBXL20	-0.79	-10.78	-0.55	1.03e-22	Glomerular filtration rate (creatinine);
CESC	cis	rs73206853	0.764	rs12311093	chr12:110978032	A/G	cg12870014	chr12:110450643	ANKRD13A	-0.73	-7.62	-0.42	4.48e-13	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs9549367	0.713	rs11620600	chr13:113829090	G/A	cg00898013	chr13:113819073	PROZ	-0.56	-7.77	-0.43	1.77e-13	Platelet distribution width;
CESC	cis	rs7474896	0.515	rs2749582	chr10:38275284	A/G	cg00409905	chr10:38381863	ZNF37A	0.45	5.06	0.3	7.68e-7	Obesity (extreme);
CESC	cis	rs7264396	1.000	rs7264396	chr20:34154741	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.52	6.11	0.35	3.46e-9	Total cholesterol levels;
CESC	cis	rs854765	0.583	rs12452219	chr17:17829423	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.52	7.22	0.41	5.4e-12	Total body bone mineral density;
CESC	cis	rs13191362	1.000	rs34192365	chr6:163012382	T/G	cg21926612	chr6:163149169	PACRG;PARK2	0.87	8.98	0.48	5.33e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.88	13.54	0.64	4.12e-32	Prudent dietary pattern;
CESC	cis	rs4665809	0.590	rs62128455	chr2:26466530	G/A	cg22920501	chr2:26401640	FAM59B	0.91	10.33	0.54	3.07e-21	Gut microbiome composition (summer);
CESC	cis	rs4665809	1.000	rs4233709	chr2:26291493	C/T	cg22920501	chr2:26401640	FAM59B	0.64	7.7	0.43	2.68e-13	Gut microbiome composition (summer);
CESC	cis	rs9910055	0.530	rs2269906	chr17:42294337	G/T	cg19774624	chr17:42201019	HDAC5	0.61	8.75	0.47	2.55e-16	Total body bone mineral density;
CESC	cis	rs4563143	0.634	rs113736470	chr19:29240125	G/A	cg12756686	chr19:29218302	NA	0.53	7.09	0.4	1.18e-11	Methadone dose in opioid dependence;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg01517273	chr1:154599968	ADAR	-0.46	-6.01	-0.35	5.95e-9	Height;
CESC	cis	rs7927771	0.524	rs2290851	chr11:47753370	C/T	cg05585544	chr11:47624801	NA	-0.32	-5.11	-0.3	6.24e-7	Subjective well-being;
CESC	cis	rs9788682	0.694	rs10851906	chr15:78774676	A/G	cg24631222	chr15:78858424	CHRNA5	0.65	7.69	0.43	2.83e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs11719291	0.915	rs11557629	chr3:48732223	G/A	cg03060546	chr3:49711283	APEH	-0.61	-5.03	-0.3	9.02e-7	Cognitive function;
CESC	cis	rs959260	0.557	rs4788887	chr17:73323876	C/G	cg12999837	chr17:73267436	MIF4GD	-0.43	-5.16	-0.3	4.89e-7	Systemic lupus erythematosus;
CESC	cis	rs2304069	0.526	rs6863283	chr5:149402448	C/A	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.46	6.26	0.36	1.5e-9	HIV-1 control;
CESC	cis	rs3096299	0.933	rs2965938	chr16:89491336	C/T	cg08392591	chr16:89556376	ANKRD11	0.44	5.73	0.33	2.7e-8	Multiple myeloma (IgH translocation);
CESC	cis	rs72792276	0.818	rs57249773	chr5:127463166	C/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.66	5.26	0.31	3.04e-7	Red cell distribution width;
CESC	cis	rs4689388	0.926	rs11725494	chr4:6293855	C/T	cg14416269	chr4:6271139	WFS1	0.46	7.73	0.43	2.27e-13	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.69	9.72	0.51	2.72e-19	Prudent dietary pattern;
CESC	cis	rs4722166	0.645	rs1404006	chr7:22795077	T/C	cg05472934	chr7:22766657	IL6	0.64	8.44	0.46	2.08e-15	Lung cancer;
CESC	trans	rs11678036	1.000	rs11678036	chr2:186024735	A/G	cg21136544	chr6:3160547	NA	0.36	6.59	0.38	2.3e-10	IgG glycosylation;
CESC	cis	rs344364	0.511	rs1657132	chr16:1949924	C/T	cg26617929	chr16:1858877	NA	-0.49	-5.15	-0.3	5.09e-7	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs258892	0.895	rs2338793	chr5:72073172	T/G	cg21869765	chr5:72125136	TNPO1	-0.38	-5.2	-0.3	3.94e-7	Small cell lung carcinoma;
CESC	cis	rs7219021	0.961	rs3901705	chr17:46865760	T/C	cg16584676	chr17:46985605	UBE2Z	-0.73	-8.25	-0.45	7.64e-15	Schizophrenia or bipolar disorder;
CESC	cis	rs10206020	0.836	rs10202105	chr2:1553301	C/T	cg01028140	chr2:1542097	TPO	-0.43	-5.24	-0.31	3.2e-7	IgG glycosylation;
CESC	cis	rs4975616	0.869	rs465498	chr5:1325803	A/G	cg26373071	chr5:1325741	CLPTM1L	0.43	7.03	0.4	1.71e-11	Lung cancer;
CESC	cis	rs6460942	0.630	rs17670901	chr7:12386622	G/A	cg06484146	chr7:12443880	VWDE	-0.62	-6.76	-0.38	8.87e-11	Coronary artery disease;
CESC	cis	rs7143963	0.609	rs11846158	chr14:103292959	A/G	cg24154132	chr14:103367632	TRAF3	0.34	6.31	0.36	1.18e-9	Body mass index;
CESC	cis	rs875971	0.862	rs7783779	chr7:65796626	A/G	cg12463550	chr7:65579703	CRCP	-0.49	-6.27	-0.36	1.43e-9	Aortic root size;
CESC	cis	rs9583531	0.689	rs6492308	chr13:111377829	T/C	cg24331049	chr13:111365604	ING1	0.72	10.36	0.54	2.39e-21	Coronary artery disease;
CESC	cis	rs1580019	0.563	rs34319173	chr7:32585904	G/A	cg06627557	chr7:32535165	LSM5;AVL9	1.07	18.36	0.75	3.97e-49	Cognitive ability;
CESC	cis	rs35110281	0.782	rs9981790	chr21:45045052	G/C	cg01579765	chr21:45077557	HSF2BP	-0.57	-9.92	-0.52	6.23e-20	Mean corpuscular volume;
CESC	cis	rs425277	0.606	rs262664	chr1:2083537	G/C	cg16545954	chr1:2118288	C1orf86	0.35	6.55	0.37	2.95e-10	Height;
CESC	cis	rs10924309	0.737	rs4658797	chr1:245854862	G/A	cg00036263	chr1:245852353	KIF26B	-0.54	-7.18	-0.4	7.12e-12	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
CESC	cis	rs9858542	0.953	rs6803222	chr3:49665976	T/G	cg03060546	chr3:49711283	APEH	-0.57	-6.68	-0.38	1.42e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs6582630	0.555	rs10748382	chr12:38504529	C/T	cg26384229	chr12:38710491	ALG10B	0.68	10.17	0.53	1.02e-20	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs7647973	0.592	rs6774202	chr3:49687779	T/G	cg06212747	chr3:49208901	KLHDC8B	0.66	8.11	0.45	1.84e-14	Menarche (age at onset);
CESC	cis	rs3858526	0.916	rs11039551	chr11:5930773	C/T	cg02574844	chr11:5959923	NA	-0.41	-5.08	-0.3	6.96e-7	DNA methylation (variation);
CESC	cis	rs1003719	0.680	rs8130069	chr21:38552116	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.61	-8.29	-0.45	5.68e-15	Eye color traits;
CESC	cis	rs7666738	0.830	rs35433756	chr4:99070555	C/T	cg05340658	chr4:99064831	C4orf37	0.84	12.81	0.62	1.45e-29	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4803468	0.967	rs13345590	chr19:41886455	T/G	cg09537434	chr19:41945824	ATP5SL	-1.02	-18.22	-0.75	1.23e-48	Height;
CESC	trans	rs1814175	0.904	rs7924371	chr11:49620595	C/T	cg15704280	chr7:45808275	SEPT13	-1.0	-17.77	-0.74	4.61e-47	Height;
CESC	cis	rs12477438	0.572	rs10170063	chr2:99655639	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.62	-8.67	-0.47	4.43e-16	Chronic sinus infection;
CESC	trans	rs9951602	0.512	rs4799246	chr18:76653417	A/G	cg02800362	chr5:177631904	HNRNPAB	0.66	8.63	0.47	5.9e-16	Obesity-related traits;
CESC	cis	rs2933343	0.679	rs1091938	chr3:128637025	T/C	cg24203234	chr3:128598194	ACAD9	0.4	5.26	0.31	3.01e-7	IgG glycosylation;
CESC	cis	rs35110281	0.837	rs2838336	chr21:45071741	A/G	cg21573476	chr21:45109991	RRP1B	0.47	6.69	0.38	1.3100000000000001e-10	Mean corpuscular volume;
CESC	cis	rs473651	0.935	rs10170056	chr2:239339291	G/C	cg21699342	chr2:239360505	ASB1	0.41	5.72	0.33	2.92e-8	Multiple system atrophy;
CESC	cis	rs9322193	0.923	rs9689723	chr6:149977071	C/A	cg04369109	chr6:150039330	LATS1	-0.38	-5.29	-0.31	2.58e-7	Lung cancer;
CESC	cis	rs67072384	0.818	rs1872127	chr11:72465085	G/A	cg04827223	chr11:72435913	ARAP1	-0.7	-7.1	-0.4	1.16e-11	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
CESC	cis	rs113835537	0.877	rs57127845	chr11:66318325	C/T	cg24851651	chr11:66362959	CCS	0.61	5.48	0.32	9.88e-8	Airway imaging phenotypes;
CESC	cis	rs947211	0.750	rs5014255	chr1:205753870	C/A	cg26354017	chr1:205819088	PM20D1	0.41	5.14	0.3	5.41e-7	Parkinson's disease;
CESC	cis	rs9911578	0.692	rs411988	chr17:56709034	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.42	5.67	0.33	3.82e-8	Intelligence (multi-trait analysis);
CESC	cis	rs9660180	0.967	rs10907191	chr1:1774820	A/T	cg23982607	chr1:1823379	GNB1	-0.78	-12.63	-0.61	6.1e-29	Body mass index;
CESC	cis	rs6831352	0.879	rs56295995	chr4:100060899	C/T	cg13256891	chr4:100009986	ADH5	-0.75	-8.21	-0.45	9.89e-15	Alcohol dependence;
CESC	cis	rs2635047	0.967	rs7242978	chr18:44633424	G/T	cg19077165	chr18:44547161	KATNAL2	0.46	6.26	0.36	1.52e-9	Educational attainment;
CESC	cis	rs1949733	0.523	rs16842557	chr4:8543985	C/T	cg11789530	chr4:8429930	ACOX3	-0.58	-7.26	-0.41	4.33e-12	Response to antineoplastic agents;
CESC	cis	rs7917772	0.629	rs1475646	chr10:104522564	G/T	cg04362960	chr10:104952993	NT5C2	0.44	5.1	0.3	6.41e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs9733	0.744	rs3754211	chr1:150951857	G/A	cg13175981	chr1:150552382	MCL1	-0.42	-5.47	-0.32	1.06e-7	Tonsillectomy;
CESC	cis	rs7246865	0.510	rs11086051	chr19:17168590	A/G	cg16202187	chr19:17186497	HAUS8;MYO9B	0.51	6.72	0.38	1.13e-10	Reticulocyte fraction of red cells;
CESC	trans	rs17508449	0.819	rs17031795	chr1:114255828	T/C	cg23028848	chr11:57092561	TNKS1BP1	-0.76	-6.14	-0.35	2.99e-9	Leprosy;
CESC	cis	rs6938	0.618	rs2044157	chr15:75225808	G/C	cg09165964	chr15:75287851	SCAMP5	0.49	6.64	0.38	1.81e-10	Breast cancer;
CESC	trans	rs1116547	0.571	rs73242809	chr5:112898437	T/C	cg10115368	chr14:100435663	NA	0.5	6.1	0.35	3.72e-9	Cerebral amyloid angiopathy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08105951	chr7:5229733	WIPI2	0.52	6.02	0.35	5.67e-9	Gut microbiome composition (summer);
CESC	cis	rs2637266	0.818	rs7894799	chr10:78392012	T/C	cg18941641	chr10:78392320	NA	0.41	7.52	0.42	8.61e-13	Pulmonary function;
CESC	cis	rs9894429	0.690	rs12949956	chr17:79542813	C/T	cg21984481	chr17:79567631	NPLOC4	0.56	9.14	0.49	1.63e-17	Eye color traits;
CESC	cis	rs11098499	0.909	rs11723839	chr4:120299673	G/A	cg24375607	chr4:120327624	NA	0.46	5.58	0.32	5.79e-8	Corneal astigmatism;
CESC	cis	rs2243480	1.000	rs6974723	chr7:65637939	C/T	cg13147721	chr7:65941812	NA	0.97	9.19	0.49	1.2e-17	Diabetic kidney disease;
CESC	cis	rs9611565	0.765	rs132908	chr22:41801795	G/A	cg06634786	chr22:41940651	POLR3H	0.73	7.47	0.42	1.2e-12	Vitiligo;
CESC	cis	rs2273669	0.667	rs12196010	chr6:109302173	C/A	cg05315195	chr6:109294784	ARMC2	-0.65	-5.82	-0.34	1.71e-8	Prostate cancer;
CESC	cis	rs1552244	0.572	rs113406084	chr3:10170190	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.67	-7.6	-0.42	5.23e-13	Alzheimer's disease;
CESC	cis	rs6714710	0.603	rs58546246	chr2:98521823	C/A	cg26665480	chr2:98280029	ACTR1B	0.57	7.99	0.44	4.15e-14	Posterior cortical atrophy and Alzheimer's disease;
CESC	cis	rs2777491	0.915	rs7178777	chr15:41634588	C/A	cg18705301	chr15:41695430	NDUFAF1	-0.6	-9.0	-0.48	4.34e-17	Ulcerative colitis;
CESC	cis	rs1046896	0.627	rs7225515	chr17:80795783	C/T	cg05255149	chr17:80675120	FN3KRP	0.47	5.35	0.31	1.9e-7	Glycated hemoglobin levels;
CESC	cis	rs4074961	0.692	rs11264075	chr1:38083941	C/G	cg13401533	chr1:37979913	MEAF6	0.5	6.66	0.38	1.59e-10	Axial length;
CESC	cis	rs1862618	0.853	rs1559282	chr5:56099375	T/A	cg12311346	chr5:56204834	C5orf35	-0.64	-7.96	-0.44	4.98e-14	Initial pursuit acceleration;
CESC	cis	rs9900062	0.771	rs9909152	chr17:62719475	G/A	cg02598441	chr17:62777298	LOC146880	-0.67	-7.9	-0.44	7.57e-14	QT interval;
CESC	cis	rs6541297	0.699	rs12065546	chr1:230295245	C/T	cg20703242	chr1:230279135	GALNT2	0.6	6.81	0.39	6.49e-11	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04414295	chr14:102606318	WDR20;HSP90AA1	0.62	7.36	0.41	2.25e-12	Gut microbiome composition (summer);
CESC	trans	rs10489896	0.541	rs6693478	chr1:234593403	T/C	cg23817893	chr11:86085932	CCDC81	-0.45	-6.2	-0.36	2.14e-9	Cognitive test performance;
CESC	cis	rs55794721	0.509	rs12027110	chr1:25775682	A/T	cg02931644	chr1:25747376	RHCE	0.46	7.99	0.44	4.15e-14	Plateletcrit;Mean corpuscular volume;
CESC	cis	rs9372253	1.000	rs11153232	chr6:110716252	G/T	cg19196401	chr6:110721138	DDO	0.37	5.37	0.31	1.72e-7	Platelet distribution width;
CESC	cis	rs2243480	0.708	rs781141	chr7:65438553	A/G	cg12463550	chr7:65579703	CRCP	0.68	5.63	0.33	4.55e-8	Diabetic kidney disease;
CESC	cis	rs9300255	0.596	rs1568427	chr12:123738678	A/G	cg05973401	chr12:123451056	ABCB9	0.45	5.45	0.32	1.15e-7	Neutrophil percentage of white cells;
CESC	cis	rs763121	0.853	rs6519119	chr22:38989007	C/G	cg06022373	chr22:39101656	GTPBP1	0.84	12.27	0.6	1.07e-27	Menopause (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08058591	chr19:40708324	MAP3K10	-0.57	-6.72	-0.38	1.1e-10	Gut microbiome composition (summer);
CESC	cis	rs9807989	0.571	rs10208293	chr2:102966310	G/A	cg09003973	chr2:102972529	NA	0.53	5.32	0.31	2.25e-7	Asthma;
CESC	cis	rs2637266	0.935	rs12414653	chr10:78394071	C/G	cg18941641	chr10:78392320	NA	0.45	8.39	0.46	2.93e-15	Pulmonary function;
CESC	trans	rs1728785	1.000	rs698719	chr16:68560125	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.59	7.26	0.41	4.42e-12	Ulcerative colitis;
CESC	cis	rs4268898	0.552	rs6754391	chr2:24369019	C/T	cg20701182	chr2:24300061	SF3B14	0.4	5.48	0.32	1e-7	Asthma;
CESC	cis	rs875971	0.862	rs10261398	chr7:65750164	A/G	cg18876405	chr7:65276391	NA	-0.49	-6.83	-0.39	5.72e-11	Aortic root size;
CESC	cis	rs8114671	0.773	rs3746438	chr20:33584289	C/T	cg07148914	chr20:33460835	GGT7	-0.39	-5.12	-0.3	5.78e-7	Height;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg12640387	chr1:6694331	THAP3;DNAJC11	0.49	6.91	0.39	3.63e-11	Fibrinogen levels;
CESC	trans	rs7726839	0.574	rs11134148	chr5:637107	C/T	cg25482853	chr8:67687455	SGK3	1.01	10.03	0.52	2.86e-20	Obesity-related traits;
CESC	cis	rs7829975	0.502	rs7820738	chr8:8702607	C/G	cg18904891	chr8:8559673	CLDN23	-0.45	-5.49	-0.32	9.25e-8	Mood instability;
CESC	cis	rs9457247	1.000	rs422780	chr6:167406209	A/G	cg07741184	chr6:167504864	NA	0.29	5.31	0.31	2.32e-7	Crohn's disease;
CESC	cis	rs1448094	0.512	rs4540904	chr12:86235472	A/G	cg02569458	chr12:86230093	RASSF9	0.48	7.11	0.4	1.07e-11	Major depressive disorder;
CESC	cis	rs11997175	0.624	rs10435522	chr8:33698608	G/A	ch.8.33884649F	chr8:33765107	NA	0.5	6.27	0.36	1.46e-9	Body mass index;
CESC	cis	rs2842992	0.789	rs4235925	chr6:160202860	C/T	cg11366901	chr6:160182831	ACAT2	0.8	9.87	0.52	9.36e-20	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	22.54	0.81	1.53e-63	Prudent dietary pattern;
CESC	cis	rs7078219	0.505	rs7077040	chr10:101281014	C/G	cg09788492	chr10:101292477	NKX2-3	0.33	6.16	0.35	2.75e-9	Dental caries;
CESC	cis	rs7647973	0.626	rs9824435	chr3:49674343	A/G	cg03060546	chr3:49711283	APEH	-0.67	-7.26	-0.41	4.19e-12	Menarche (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04536951	chr19:9268775	ZNF317	-0.6	-6.48	-0.37	4.5e-10	Gut microbiome composition (summer);
CESC	cis	rs1624802	0.841	rs78426981	chr12:130497782	A/G	cg15444478	chr12:130494697	NA	-0.28	-5.16	-0.3	4.77e-7	Obesity-related traits;
CESC	cis	rs6736093	0.796	rs4848971	chr2:112790446	C/T	cg12686935	chr2:112915763	FBLN7	-0.41	-5.45	-0.32	1.13e-7	Coronary artery disease;
CESC	cis	rs1801251	0.727	rs6437071	chr2:233568793	G/A	cg25237894	chr2:233734115	C2orf82	0.38	6.5	0.37	3.93e-10	Coronary artery disease;
CESC	cis	rs6754311	0.551	rs10928545	chr2:136501840	A/G	cg07169764	chr2:136633963	MCM6	-0.74	-9.42	-0.5	2.37e-18	Mosquito bite size;
CESC	cis	rs10479542	0.892	rs7736163	chr5:178980316	G/C	cg00080972	chr5:178986291	RUFY1	0.44	6.98	0.39	2.35e-11	Lung cancer;
CESC	cis	rs2836950	0.520	rs8133928	chr21:40689963	G/A	cg17971929	chr21:40555470	PSMG1	-0.6	-7.91	-0.44	7.15e-14	Menarche (age at onset);
CESC	cis	rs965469	0.779	rs967366	chr20:3266935	T/G	cg25506879	chr20:3388711	C20orf194	-0.47	-5.23	-0.31	3.4e-7	IFN-related cytopenia;
CESC	cis	rs9311474	0.508	rs6788887	chr3:52605005	T/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	5.86	0.34	1.4e-8	Electroencephalogram traits;
CESC	cis	rs7605827	0.930	rs13002869	chr2:15674389	C/T	cg19274914	chr2:15703543	NA	0.38	6.79	0.38	7.31e-11	Educational attainment (years of education);
CESC	cis	rs17253792	0.749	rs17747301	chr14:56125030	C/G	cg01858014	chr14:56050164	KTN1	-0.98	-7.75	-0.43	1.97e-13	Putamen volume;
CESC	cis	rs66530629	0.874	rs4648878	chr1:25164113	A/G	cg22509179	chr1:25234806	RUNX3	-0.42	-5.58	-0.32	6.02e-8	Plateletcrit;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20448447	chr12:122255296	SETD1B	-0.5	-6.04	-0.35	5.3e-9	Gut microbiome composition (summer);
CESC	cis	rs4253772	0.550	rs6008729	chr22:46727428	C/G	cg18190219	chr22:46762943	CELSR1	0.47	6.1	0.35	3.77e-9	LDL cholesterol;Cholesterol, total;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07354253	chr5:131629923	SLC22A4	0.58	6.8	0.39	6.85e-11	Gut microbiome composition (summer);
CESC	cis	rs35306767	0.903	rs35968821	chr10:910225	A/G	cg26597838	chr10:835615	NA	0.86	8.99	0.48	4.68e-17	Eosinophil percentage of granulocytes;
CESC	cis	rs2882667	0.858	rs11959851	chr5:138421405	C/G	cg04439458	chr5:138467593	SIL1	-0.34	-5.24	-0.31	3.31e-7	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs4985726	0.702	rs12603708	chr17:16847113	C/T	cg22251401	chr17:16590232	NA	0.4	5.3	0.31	2.43e-7	Non-albumin protein levels;
CESC	cis	rs2749592	0.513	rs9417249	chr10:37837155	C/T	cg25427524	chr10:38739819	LOC399744	0.41	5.36	0.31	1.84e-7	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs4713118	0.586	rs6905522	chr6:28086479	A/C	cg20151795	chr6:28129481	ZNF389	0.45	5.87	0.34	1.29e-8	Parkinson's disease;
CESC	cis	rs10504229	0.953	rs57669205	chr8:58172253	T/C	cg14926445	chr8:58193284	C8orf71	-0.51	-5.49	-0.32	9.5e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs10779751	1.000	rs4845858	chr1:11304720	C/T	cg08854313	chr1:11322531	MTOR	0.92	14.42	0.66	3.5e-35	Body mass index;
CESC	cis	rs7927771	0.507	rs11039432	chr11:47873327	G/A	cg18512352	chr11:47633146	NA	0.34	5.23	0.31	3.39e-7	Subjective well-being;
CESC	cis	rs7044106	0.762	rs1324473	chr9:123404610	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.8	-12.62	-0.61	6.61e-29	Hip circumference adjusted for BMI;
CESC	cis	rs2228479	0.850	rs62052714	chr16:89857180	T/C	cg14709524	chr16:89940631	TCF25	0.94	7.06	0.4	1.5e-11	Skin colour saturation;
CESC	cis	rs17253792	0.545	rs34446601	chr14:56010586	A/G	cg01858014	chr14:56050164	KTN1	-0.87	-6.66	-0.38	1.56e-10	Putamen volume;
CESC	cis	rs7605827	0.930	rs11900088	chr2:15613994	T/C	cg19274914	chr2:15703543	NA	0.35	6.13	0.35	3.19e-9	Educational attainment (years of education);
CESC	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.89	13.61	0.64	2.42e-32	Prudent dietary pattern;
CESC	cis	rs8050907	0.744	rs7194436	chr16:4539832	G/C	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.89	6.22	0.36	1.94e-9	Obesity-related traits;
CESC	cis	rs12188164	0.965	rs56146525	chr5:442571	A/C	cg17553881	chr5:443987	EXOC3;C5orf55	-0.37	-5.99	-0.35	6.68e-9	Cystic fibrosis severity;
CESC	cis	rs72901758	0.696	rs72909029	chr17:76249451	A/G	cg25512537	chr17:76250053	NA	0.4	5.47	0.32	1.02e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
CESC	cis	rs875971	0.830	rs809025	chr7:65849819	C/G	cg18252515	chr7:66147081	NA	-0.43	-5.59	-0.32	5.73e-8	Aortic root size;
CESC	cis	rs6912958	0.781	rs3934838	chr6:88284699	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-6.58	-0.37	2.55e-10	Monocyte percentage of white cells;
CESC	cis	rs9311474	1.000	rs1060330	chr3:52288945	T/C	cg07507251	chr3:52567010	NT5DC2	0.33	5.78	0.33	2.14e-8	Electroencephalogram traits;
CESC	cis	rs113835537	0.529	rs11227514	chr11:66286627	G/A	cg22134325	chr11:66188745	NPAS4	0.35	5.59	0.32	5.52e-8	Airway imaging phenotypes;
CESC	cis	rs477895	0.838	rs11607007	chr11:64007976	C/T	cg18225595	chr11:63971243	STIP1	0.51	5.28	0.31	2.69e-7	Mean platelet volume;
CESC	cis	rs367943	1.000	rs348929	chr5:112814883	T/A	cg12552261	chr5:112820674	MCC	-0.62	-7.72	-0.43	2.34e-13	Type 2 diabetes;
CESC	cis	rs854765	0.693	rs9907246	chr17:17770965	T/C	cg09796270	chr17:17721594	SREBF1	-0.45	-6.36	-0.36	8.61e-10	Total body bone mineral density;
CESC	cis	rs7084402	0.967	rs1658422	chr10:60331758	G/T	cg07615347	chr10:60278583	BICC1	0.59	9.15	0.49	1.57e-17	Refractive error;
CESC	cis	rs514406	0.929	rs485631	chr1:53330245	A/G	cg24675658	chr1:53192096	ZYG11B	-0.57	-6.98	-0.39	2.37e-11	Monocyte count;
CESC	cis	rs71403859	0.502	rs75986475	chr16:71464058	C/G	cg08717414	chr16:71523259	ZNF19	-0.86	-8.17	-0.45	1.25e-14	Post bronchodilator FEV1;
CESC	cis	rs59698941	0.943	rs67422135	chr5:132222728	T/A	cg02081065	chr5:132209139	LEAP2	-0.52	-5.11	-0.3	6.08e-7	Apolipoprotein A-IV levels;
CESC	cis	rs7264396	0.836	rs961020	chr20:34182069	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-6.8	-0.39	7.02e-11	Total cholesterol levels;
CESC	cis	rs8072100	0.512	rs9674670	chr17:45386157	G/A	cg25173405	chr17:45401733	C17orf57	-0.41	-5.34	-0.31	2.04e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs9303280	0.776	rs9910826	chr17:38035648	A/G	cg20243544	chr17:37824526	PNMT	0.5	6.54	0.37	3.21e-10	Self-reported allergy;
CESC	cis	rs6991838	0.584	rs1533285	chr8:66549364	T/C	cg13398993	chr8:66546079	ARMC1	0.46	5.65	0.33	4.19e-8	Intelligence (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15550435	chr10:92979939	PCGF5	-0.52	-6.06	-0.35	4.62e-9	Gut microbiome composition (summer);
CESC	cis	rs4604732	0.631	rs34924545	chr1:247626892	G/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.56	6.94	0.39	2.97e-11	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs11098499	0.779	rs10011097	chr4:120310359	T/G	cg09307838	chr4:120376055	NA	0.92	12.66	0.61	4.96e-29	Corneal astigmatism;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14949694	chr7:66367000	NA	-0.6	-6.52	-0.37	3.54e-10	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16444294	chr16:28925790	RABEP2	-0.57	-6.73	-0.38	1.03e-10	Gut microbiome composition (summer);
CESC	cis	rs875971	1.000	rs1981798	chr7:65954903	G/T	cg10691866	chr7:65817282	TPST1	-0.36	-5.83	-0.34	1.58e-8	Aortic root size;
CESC	cis	rs9815354	0.680	rs73073239	chr3:42014597	G/C	cg03022575	chr3:42003672	ULK4	0.75	6.64	0.38	1.78e-10	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs826838	1.000	rs11168217	chr12:38884278	T/C	cg13010199	chr12:38710504	ALG10B	0.6	8.51	0.46	1.26e-15	Heart rate;
CESC	trans	rs459571	0.839	rs2519831	chr9:136886257	T/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.63	-8.08	-0.44	2.31e-14	Platelet distribution width;
CESC	cis	rs1499614	1.000	rs2141924	chr7:66186246	C/T	cg12463550	chr7:65579703	CRCP	0.73	5.73	0.33	2.78e-8	Gout;
CESC	cis	rs637571	0.726	rs669371	chr11:65674153	G/T	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.52	-6.38	-0.37	7.7e-10	Eosinophil percentage of white cells;
CESC	cis	rs9322193	0.962	rs9397357	chr6:150133601	G/A	cg09699651	chr6:150184138	LRP11	0.4	5.14	0.3	5.29e-7	Lung cancer;
CESC	cis	rs3785574	1.000	rs7223257	chr17:61787684	T/C	cg06420487	chr17:61919686	SMARCD2	0.46	5.53	0.32	7.65e-8	Height;
CESC	cis	rs2180341	0.924	rs6930849	chr6:127630963	A/T	cg27446573	chr6:127587934	RNF146	1.09	16.33	0.71	5.73e-42	Breast cancer;
CESC	cis	rs6582630	0.599	rs1589392	chr12:38418535	G/C	cg26384229	chr12:38710491	ALG10B	-0.45	-6.09	-0.35	4.05e-9	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs2842992	0.747	rs1547093	chr6:160205991	C/A	cg11366901	chr6:160182831	ACAT2	0.8	10.07	0.53	2.14e-20	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs12200560	0.505	rs211178	chr6:97074094	T/A	cg06623918	chr6:96969491	KIAA0776	0.52	6.65	0.38	1.71e-10	Coronary heart disease;
CESC	cis	rs3105593	0.933	rs2414059	chr15:50873344	T/A	cg08437265	chr15:50716283	USP8	0.42	5.47	0.32	1.05e-7	QT interval;
CESC	trans	rs9325144	0.647	rs61931899	chr12:38892422	A/G	cg10679878	chr6:156759499	NA	-0.34	-6.09	-0.35	4.04e-9	Morning vs. evening chronotype;
CESC	cis	rs1801251	1.000	rs7558609	chr2:233700379	C/T	cg25237894	chr2:233734115	C2orf82	0.45	7.76	0.43	1.9e-13	Coronary artery disease;
CESC	trans	rs17685	0.884	rs6978677	chr7:75636240	C/T	cg19862616	chr7:65841803	NCRNA00174	0.68	8.86	0.48	1.2e-16	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	22.65	0.81	6.31e-64	Prudent dietary pattern;
CESC	trans	rs4664304	0.620	rs2556086	chr2:160708446	G/T	cg03768106	chr11:111957237	TIMM8B;SDHD	0.43	6.09	0.35	4e-9	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs736408	0.509	rs3774349	chr3:52722335	A/C	cg17372223	chr3:52568218	NT5DC2	0.45	7.53	0.42	7.97e-13	Bipolar disorder;
CESC	cis	rs11123610	0.520	rs60644898	chr2:3718646	G/A	cg19052272	chr2:3704530	ALLC	-0.48	-5.85	-0.34	1.41e-8	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CESC	cis	rs79976124	0.842	rs7760550	chr6:66628788	T/C	cg07460842	chr6:66804631	NA	0.68	8.06	0.44	2.65e-14	Type 2 diabetes;
CESC	cis	rs634534	0.622	rs501353	chr11:65739549	T/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.64	8.87	0.48	1.12e-16	Sum eosinophil basophil counts;Eosinophil counts;
CESC	cis	rs4794106	0.792	rs847682	chr17:48208274	C/T	cg13127421	chr17:48202128	SAMD14	-0.53	-7.66	-0.43	3.6e-13	Temporomandibular joint disorder;
CESC	cis	rs4242434	0.672	rs2404654	chr8:22484949	T/C	cg03733263	chr8:22462867	KIAA1967	0.74	11.08	0.56	1.11e-23	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CESC	cis	rs5750830	0.569	rs5750809	chr22:39791491	T/G	cg02038168	chr22:39784481	NA	-0.63	-7.95	-0.44	5.4e-14	Intelligence (multi-trait analysis);
CESC	cis	rs1799949	0.550	rs2343818	chr17:41409774	G/A	cg05368731	chr17:41323189	NBR1	0.78	10.6	0.55	3.92e-22	Menopause (age at onset);
CESC	cis	rs11190604	1.000	rs2489035	chr10:102319395	C/T	cg07080220	chr10:102295463	HIF1AN	0.62	5.9	0.34	1.1e-8	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs28489187	0.667	rs233114	chr1:85786957	T/G	cg16011679	chr1:85725395	C1orf52	0.48	5.65	0.33	4.1e-8	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	cis	rs72781680	0.898	rs72782106	chr2:24022009	A/G	cg20701182	chr2:24300061	SF3B14	0.78	6.7	0.38	1.22e-10	Lymphocyte counts;
CESC	cis	rs4604732	0.631	rs12038880	chr1:247624603	A/G	cg12754571	chr1:247694271	LOC148824;OR2C3	0.4	5.34	0.31	2.05e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs4803468	1.000	rs284652	chr19:41928652	C/T	cg08639244	chr19:41945921	ATP5SL	-0.42	-5.11	-0.3	6.12e-7	Height;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg25094149	chr1:32253906	NA	-0.43	-6.07	-0.35	4.43e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs9457247	0.582	rs9459855	chr6:167466150	G/T	cg07741184	chr6:167504864	NA	0.37	6.49	0.37	4.2e-10	Crohn's disease;
CESC	trans	rs561341	0.882	rs2428337	chr17:30299467	C/T	cg27661571	chr11:113659931	NA	-0.83	-7.69	-0.43	2.82e-13	Hip circumference adjusted for BMI;
CESC	cis	rs875971	0.800	rs427557	chr7:65519250	A/G	cg10691866	chr7:65817282	TPST1	-0.34	-5.47	-0.32	1.03e-7	Aortic root size;
CESC	cis	rs2204008	0.577	rs11520050	chr12:38051839	G/A	cg13010199	chr12:38710504	ALG10B	0.54	6.69	0.38	1.28e-10	Bladder cancer;
CESC	cis	rs950173	1.000	rs950173	chr2:172570419	G/A	cg13550731	chr2:172543902	DYNC1I2	-0.85	-6.11	-0.35	3.55e-9	Hippocampal volume;
CESC	cis	rs9916302	0.904	rs10221223	chr17:37489100	T/G	cg00129232	chr17:37814104	STARD3	0.51	6.37	0.36	8.22e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs1670533	1.000	rs6827357	chr4:1059202	A/C	cg27284194	chr4:1044797	NA	0.46	5.32	0.31	2.2e-7	Recombination rate (females);
CESC	cis	rs8141529	0.711	rs5752797	chr22:29179998	C/T	cg15103426	chr22:29168792	CCDC117	0.48	5.15	0.3	5.19e-7	Lymphocyte counts;
CESC	trans	rs561341	0.941	rs72825746	chr17:30364610	G/A	cg20587970	chr11:113659929	NA	-1.51	-20.19	-0.78	1.54e-55	Hip circumference adjusted for BMI;
CESC	cis	rs2290159	0.800	rs55762590	chr3:12689451	C/T	cg23032965	chr3:12705835	RAF1	0.55	5.86	0.34	1.38e-8	Cholesterol, total;
CESC	cis	rs9951602	1.000	rs7232284	chr18:76667529	A/G	cg00806245	chr18:76673096	NA	-0.55	-6.83	-0.39	5.88e-11	Obesity-related traits;
CESC	cis	rs829883	0.932	rs249840	chr12:98871993	T/C	cg25150519	chr12:98850993	NA	0.68	9.14	0.49	1.7e-17	Colorectal adenoma (advanced);
CESC	cis	rs1801251	0.963	rs7562712	chr2:233606580	A/G	cg25237894	chr2:233734115	C2orf82	0.45	7.84	0.43	1.1e-13	Coronary artery disease;
CESC	cis	rs9611565	0.625	rs73178625	chr22:41928320	G/C	cg17376030	chr22:41985996	PMM1	0.67	7.47	0.42	1.14e-12	Vitiligo;
CESC	cis	rs34779708	0.966	rs35814343	chr10:35427714	G/T	cg04310649	chr10:35416472	CREM	-0.5	-6.04	-0.35	5.31e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs7618915	0.547	rs1561337	chr3:52659963	C/T	cg07507251	chr3:52567010	NT5DC2	0.4	6.92	0.39	3.39e-11	Bipolar disorder;
CESC	cis	rs4925325	0.876	rs6089560	chr20:60517325	T/G	cg18761221	chr20:60518478	NA	0.58	8.51	0.46	1.34e-15	Obesity-related traits;
CESC	cis	rs7833790	0.660	rs1451995	chr8:82746123	G/C	cg07697082	chr8:82753677	SNX16	-0.39	-6.08	-0.35	4.26e-9	Diastolic blood pressure;
CESC	cis	rs9768139	0.903	rs28503558	chr7:158119568	C/T	cg24154853	chr7:158122151	PTPRN2	-0.37	-5.82	-0.34	1.66e-8	Calcium levels;
CESC	cis	rs67311347	1.000	rs13073003	chr3:40504326	C/T	cg09455208	chr3:40491958	NA	-0.47	-8.03	-0.44	3.14e-14	Renal cell carcinoma;
CESC	cis	rs2243480	0.708	rs781141	chr7:65438553	A/G	cg13147721	chr7:65941812	NA	-0.86	-8.55	-0.47	9.73e-16	Diabetic kidney disease;
CESC	cis	rs6860806	0.695	rs6867282	chr5:131583120	G/C	cg09877947	chr5:131593287	PDLIM4	0.46	6.02	0.35	5.86e-9	Breast cancer;
CESC	cis	rs6430585	0.528	rs16832417	chr2:136744678	C/T	cg07169764	chr2:136633963	MCM6	1.28	17.38	0.73	1.11e-45	Corneal structure;
CESC	cis	rs1448094	0.512	rs12313775	chr12:86241197	G/A	cg19622623	chr12:86230825	RASSF9	-0.47	-6.05	-0.35	4.94e-9	Major depressive disorder;
CESC	trans	rs7618501	1.000	rs7649348	chr3:49772375	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.44	-6.01	-0.35	6.2e-9	Intelligence (multi-trait analysis);
CESC	cis	rs4722166	0.695	rs6946509	chr7:22809490	T/C	cg05472934	chr7:22766657	IL6	0.61	8.18	0.45	1.22e-14	Lung cancer;
CESC	cis	rs72781680	0.898	rs72781639	chr2:24204148	C/G	cg20701182	chr2:24300061	SF3B14	0.63	5.58	0.32	6.04e-8	Lymphocyte counts;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25308054	chr19:10676770	KRI1	0.59	6.85	0.39	5.02e-11	Gut microbiome composition (summer);
CESC	cis	rs2282802	0.651	rs13353827	chr5:139654537	T/C	cg26211634	chr5:139558579	C5orf32	0.51	7.37	0.41	2.24e-12	Intelligence (multi-trait analysis);
CESC	cis	rs4803468	0.967	rs3745290	chr19:41890003	C/T	cg14132834	chr19:41945861	ATP5SL	-0.55	-6.81	-0.39	6.37e-11	Height;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg26185531	chr11:75479825	DGAT2	-0.47	-6.51	-0.37	3.79e-10	Fibrinogen levels;
CESC	cis	rs763121	0.853	rs138716	chr22:39146527	C/T	cg21395723	chr22:39101663	GTPBP1	0.43	5.35	0.31	1.93e-7	Menopause (age at onset);
CESC	cis	rs4819052	0.851	rs13052344	chr21:46676101	C/T	cg11663144	chr21:46675770	NA	-0.63	-9.75	-0.51	2.19e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs7246657	0.882	rs6508716	chr19:37819010	T/C	cg24637308	chr11:6592297	DNHD1	0.53	6.24	0.36	1.74e-9	Coronary artery calcification;
CESC	cis	rs7811142	0.887	rs4074838	chr7:100032665	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.15	11.48	0.58	4.99e-25	Platelet count;
CESC	cis	rs1003719	0.715	rs13046581	chr21:38551985	G/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.6	-8.13	-0.45	1.62e-14	Eye color traits;
CESC	cis	rs873946	0.564	rs12263364	chr10:134555548	G/T	cg18305652	chr10:134549665	INPP5A	0.51	7.67	0.43	3.32e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg07092213	chr7:1199455	ZFAND2A	-0.51	-5.37	-0.31	1.7e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs478304	0.903	rs12293022	chr11:65531698	C/T	cg08755490	chr11:65554678	OVOL1	0.46	6.15	0.35	2.85e-9	Acne (severe);
CESC	cis	rs35306767	1.000	rs35306767	chr10:989437	A/T	cg25019033	chr10:957182	NA	-0.63	-7.03	-0.4	1.72e-11	Eosinophil percentage of granulocytes;
CESC	cis	rs7165102	1.000	rs352479	chr15:65803428	C/A	cg11441148	chr15:65824328	PTPLAD1	-0.32	-5.33	-0.31	2.07e-7	Mean corpuscular hemoglobin;
CESC	cis	rs6964587	0.869	rs405	chr7:91546327	G/C	cg01689657	chr7:91764605	CYP51A1	-0.28	-5.03	-0.3	9.02e-7	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27247569	chr16:88097866	BANP	-0.57	-6.14	-0.35	3.02e-9	Gut microbiome composition (summer);
CESC	cis	rs17376456	0.778	rs10440717	chr5:93424852	C/A	cg21475434	chr5:93447410	FAM172A	0.81	7.42	0.41	1.55e-12	Diabetic retinopathy;
CESC	cis	rs2070488	0.560	rs1381798	chr3:38437471	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.61	-7.61	-0.42	4.89e-13	Electrocardiographic conduction measures;
CESC	cis	rs561341	0.769	rs9899093	chr17:30191954	C/G	cg00745463	chr17:30367425	LRRC37B	-0.59	-5.53	-0.32	7.61e-8	Hip circumference adjusted for BMI;
CESC	cis	rs9649213	0.574	rs7802541	chr7:97933855	C/A	cg08684580	chr7:98029266	BAIAP2L1	-0.35	-5.49	-0.32	9.23e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs9303401	0.703	rs9909925	chr17:57210069	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.6	-7.73	-0.43	2.19e-13	Cognitive test performance;
CESC	cis	rs13191362	1.000	rs13199223	chr6:163001083	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.5	5.17	0.3	4.64e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs7208859	0.524	rs60114476	chr17:29097667	A/T	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.91e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs9948	0.786	rs72809850	chr2:97449762	A/C	cg01990225	chr2:97406019	LMAN2L	-0.92	-7.51	-0.42	9.04e-13	Erectile dysfunction and prostate cancer treatment;
CESC	cis	rs477692	0.583	rs12415589	chr10:131428336	C/G	cg05714579	chr10:131428358	MGMT	-0.75	-11.97	-0.59	1.08e-26	Response to temozolomide;
CESC	cis	rs7071206	0.947	rs1877998	chr10:79411740	C/T	cg23888215	chr10:79422304	NA	-0.53	-5.71	-0.33	2.96e-8	Bone mineral density;
CESC	cis	rs7208859	0.673	rs78799101	chr17:29215160	A/T	cg19761014	chr17:28927070	LRRC37B2	0.71	5.61	0.33	5.2100000000000003e-08	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs7666738	0.830	rs6532720	chr4:99043781	C/T	cg17366294	chr4:99064904	C4orf37	0.61	8.78	0.47	2.13e-16	Colonoscopy-negative controls vs population controls;
CESC	trans	rs7618501	0.966	rs2352974	chr3:49890613	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.58	8.19	0.45	1.15e-14	Intelligence (multi-trait analysis);
CESC	cis	rs10504229	1.000	rs17216957	chr8:58179893	C/T	cg05313129	chr8:58192883	C8orf71	-0.55	-6.37	-0.36	8.42e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs3820928	0.874	rs3769646	chr2:227896330	C/T	cg05526886	chr2:227700861	RHBDD1	-0.44	-5.69	-0.33	3.28e-8	Pulmonary function;
CESC	cis	rs7546094	0.967	rs351372	chr1:113059220	A/T	cg22162597	chr1:113214053	CAPZA1	0.38	5.86	0.34	1.39e-8	Platelet distribution width;
CESC	cis	rs7618915	0.621	rs6788993	chr3:52605136	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.59	8.42	0.46	2.37e-15	Bipolar disorder;
CESC	cis	rs12618769	0.597	rs3754893	chr2:99063149	T/A	cg10123293	chr2:99228465	UNC50	0.39	5.18	0.3	4.49e-7	Bipolar disorder;
CESC	cis	rs4332037	0.901	rs7791899	chr7:1935988	T/C	cg23422044	chr7:1970798	MAD1L1	-0.55	-5.65	-0.33	4.07e-8	Bipolar disorder;
CESC	cis	rs701145	0.556	rs355787	chr3:153994502	T/C	cg16511985	chr3:153974050	SGEF	0.43	5.88	0.34	1.22e-8	Coronary artery disease;
CESC	cis	rs5753618	0.504	rs9609303	chr22:31896309	C/T	cg13145458	chr22:31556086	RNF185	-0.53	-6.25	-0.36	1.63e-9	Colorectal cancer;
CESC	cis	rs10979	0.964	rs35205240	chr6:143898676	T/C	cg25407410	chr6:143891975	LOC285740	-0.61	-9.12	-0.49	1.91e-17	Hypospadias;
CESC	cis	rs17125944	0.505	rs80211268	chr14:53265483	C/G	cg13660082	chr14:53194042	PSMC6	-0.66	-5.81	-0.34	1.78e-8	Alzheimer's disease (late onset);
CESC	cis	rs13256369	0.802	rs11781257	chr8:8559663	A/T	cg18904891	chr8:8559673	CLDN23	0.72	7.98	0.44	4.42e-14	Obesity-related traits;
CESC	cis	rs11997175	0.545	rs4733458	chr8:33661542	G/T	ch.8.33884649F	chr8:33765107	NA	0.56	7.13	0.4	9.26e-12	Body mass index;
CESC	trans	rs673604	0.505	rs676614	chr1:36107510	G/T	ch.2.195648145F	chr2:195939902	NA	0.55	6.24	0.36	1.7e-9	Endometrial cancer;
CESC	cis	rs801193	0.967	rs2420827	chr7:66147101	G/A	cg11764359	chr7:65958608	NA	-0.64	-7.98	-0.44	4.42e-14	Aortic root size;
CESC	cis	rs2425143	1.000	rs6060591	chr20:34351476	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.8	-8.0	-0.44	3.85e-14	Blood protein levels;
CESC	cis	rs5750830	0.649	rs4337572	chr22:39800704	C/G	cg11247378	chr22:39784982	NA	-0.58	-7.88	-0.44	8.36e-14	Intelligence (multi-trait analysis);
CESC	cis	rs7618915	0.571	rs12632381	chr3:52607685	G/A	cg05564831	chr3:52568323	NT5DC2	0.46	6.93	0.39	3.15e-11	Bipolar disorder;
CESC	cis	rs1801251	1.000	rs6738386	chr2:233602028	T/C	cg25237894	chr2:233734115	C2orf82	0.44	7.55	0.42	7.05e-13	Coronary artery disease;
CESC	cis	rs12477438	0.798	rs4851179	chr2:99568774	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-10.4	-0.54	1.77e-21	Chronic sinus infection;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg10330885	chr16:88729968	MGC23284;MVD	0.44	6.32	0.36	1.1e-9	Fibrinogen levels;
CESC	cis	rs2635047	0.967	rs2668786	chr18:44708472	A/G	cg24371990	chr18:44770781	NA	0.34	5.33	0.31	2.11e-7	Educational attainment;
CESC	cis	rs72781680	0.898	rs72798064	chr2:23982832	T/C	cg20701182	chr2:24300061	SF3B14	0.63	5.54	0.32	7.13e-8	Lymphocyte counts;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24688926	chr19:6737877	GPR108	-0.63	-7.24	-0.41	4.86e-12	Gut microbiome composition (summer);
CESC	cis	rs7216064	0.684	rs8182243	chr17:66018505	T/C	cg12091567	chr17:66097778	LOC651250	0.86	11.3	0.57	1.95e-24	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	22.16	0.81	2.75e-62	Prudent dietary pattern;
CESC	cis	rs9814567	1.000	rs35718987	chr3:134272783	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.45	6.08	0.35	4.21e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00338893	chr7:140714614	MRPS33	-0.5	-6.22	-0.36	1.96e-9	Gut microbiome composition (summer);
CESC	cis	rs8070128	0.600	rs8071238	chr17:17900990	T/C	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.49	6.13	0.35	3.22e-9	Total body bone mineral density;
CESC	cis	rs7216064	1.000	rs11870068	chr17:65944515	A/C	cg07042672	chr17:66097459	LOC651250	-0.53	-5.67	-0.33	3.66e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs9926296	0.533	rs12102297	chr16:89812762	C/A	cg03388025	chr16:89894329	SPIRE2	0.39	7.42	0.41	1.63e-12	Vitiligo;
CESC	cis	rs9837602	0.592	rs1711557	chr3:99425669	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.39	-5.36	-0.31	1.77e-7	Breast cancer;
CESC	cis	rs7959452	0.535	rs4761228	chr12:69682327	G/A	cg20891283	chr12:69753455	YEATS4	0.75	10.8	0.55	8.98e-23	Blood protein levels;
CESC	cis	rs7618501	0.633	rs2008877	chr3:50162291	T/G	cg24308560	chr3:49941425	MST1R	0.57	8.07	0.44	2.42e-14	Intelligence (multi-trait analysis);
CESC	cis	rs7914558	0.966	rs10748836	chr10:104693917	G/A	cg08650961	chr10:104748594	CNNM2	0.32	5.16	0.3	4.94e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs6690583	0.562	rs6688354	chr1:85520854	A/G	cg11262906	chr1:85462892	MCOLN2	0.54	5.14	0.3	5.46e-7	Serum sulfate level;
CESC	cis	rs270601	0.770	rs61352298	chr5:131600589	G/C	cg24060327	chr5:131705240	SLC22A5	-0.47	-6.09	-0.35	4.03e-9	Acylcarnitine levels;
CESC	cis	rs780096	0.526	rs13391837	chr2:27649375	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.29	-5.87	-0.34	1.27e-8	Total body bone mineral density;
CESC	cis	rs2795502	0.882	rs2744087	chr10:43340270	A/C	cg20628663	chr10:43360327	NA	-0.63	-7.47	-0.42	1.16e-12	Blood protein levels;
CESC	cis	rs7872515	0.887	rs7856177	chr9:94839342	A/G	cg01248375	chr9:94877805	SPTLC1	0.53	5.94	0.34	8.91e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs8072100	1.000	rs7210738	chr17:45757598	G/A	cg08085267	chr17:45401833	C17orf57	0.41	5.44	0.32	1.21e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs7592578	0.771	rs1128723	chr2:191366707	A/G	cg27211696	chr2:191398769	TMEM194B	-0.61	-5.49	-0.32	9.37e-8	Diastolic blood pressure;
CESC	cis	rs2228479	0.850	rs62054610	chr16:89816920	G/A	cg04013166	chr16:89971882	TCF25	0.77	6.66	0.38	1.58e-10	Skin colour saturation;
CESC	cis	rs9303401	0.646	rs8067682	chr17:57219391	A/G	cg12560992	chr17:57184187	TRIM37	0.42	5.07	0.3	7.32e-7	Cognitive test performance;
CESC	cis	rs6460942	0.630	rs17671056	chr7:12390961	C/G	cg06484146	chr7:12443880	VWDE	-0.65	-7.09	-0.4	1.23e-11	Coronary artery disease;
CESC	cis	rs2991971	0.716	rs7532573	chr1:45915892	A/T	cg05343316	chr1:45956843	TESK2	0.59	8.4	0.46	2.75e-15	High light scatter reticulocyte count;
CESC	cis	rs11677370	0.561	rs10191326	chr2:3827524	G/C	cg17052675	chr2:3827356	NA	-0.43	-5.45	-0.32	1.14e-7	Type 2 diabetes;
CESC	trans	rs4424809	0.614	rs79094539	chr13:85572909	A/T	cg05918002	chr17:5019452	ZNF232	-0.63	-6.08	-0.35	4.29e-9	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs853679	0.517	rs9380049	chr6:28048535	A/G	cg26335602	chr6:28129616	ZNF389	0.53	7.05	0.4	1.55e-11	Depression;
CESC	trans	rs57221529	0.766	rs12518859	chr5:587432	C/T	cg25482853	chr8:67687455	SGK3	1.01	9.99	0.52	3.67e-20	Lung disease severity in cystic fibrosis;
CESC	cis	rs35110281	0.782	rs6518302	chr21:45018478	A/G	cg01579765	chr21:45077557	HSF2BP	-0.56	-9.42	-0.5	2.33e-18	Mean corpuscular volume;
CESC	cis	rs79976124	0.837	rs10944858	chr6:66646039	G/A	cg07460842	chr6:66804631	NA	0.71	8.33	0.46	4.36e-15	Type 2 diabetes;
CESC	cis	rs1538970	0.816	rs9727262	chr1:45998579	T/G	cg03146154	chr1:46216737	IPP	0.49	5.59	0.32	5.71e-8	Platelet count;
CESC	cis	rs754466	1.000	rs67059283	chr10:79683235	C/T	cg17075019	chr10:79541650	NA	-0.76	-9.65	-0.51	4.4e-19	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs12477438	0.520	rs4588238	chr2:99749350	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	15.46	0.69	7.45e-39	Chronic sinus infection;
CESC	cis	rs66887589	0.934	rs4834792	chr4:120555696	T/A	cg09307838	chr4:120376055	NA	-0.44	-5.85	-0.34	1.42e-8	Diastolic blood pressure;
CESC	cis	rs2760061	0.717	rs708117	chr1:228199902	G/A	cg02753203	chr1:228287806	NA	0.51	7.61	0.42	4.89e-13	Diastolic blood pressure;
CESC	cis	rs4975616	0.836	rs460073	chr5:1336459	T/C	cg07493874	chr5:1342172	CLPTM1L	-0.41	-7.85	-0.43	1.02e-13	Lung cancer;
CESC	cis	rs11098499	0.954	rs13133522	chr4:120324424	A/T	cg09307838	chr4:120376055	NA	0.94	13.7	0.64	1.18e-32	Corneal astigmatism;
CESC	cis	rs2243480	0.614	rs34032527	chr7:65565141	C/G	cg13147721	chr7:65941812	NA	-0.98	-9.11	-0.49	2.06e-17	Diabetic kidney disease;
CESC	cis	rs9467711	0.606	rs12174631	chr6:26373150	C/T	cg12826209	chr6:26865740	GUSBL1	0.61	5.28	0.31	2.72e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs9457247	0.534	rs12055488	chr6:167379570	A/G	cg23791538	chr6:167370224	RNASET2	0.65	9.17	0.49	1.33e-17	Crohn's disease;
CESC	cis	rs2832191	0.550	rs66484040	chr21:30511691	G/A	cg08807101	chr21:30365312	RNF160	-0.54	-6.29	-0.36	1.33e-9	Dental caries;
CESC	cis	rs9611565	0.694	rs202639	chr22:41856137	T/A	cg06634786	chr22:41940651	POLR3H	0.74	7.63	0.42	4.36e-13	Vitiligo;
CESC	cis	rs11792861	0.926	rs75128146	chr9:111833791	G/T	cg05043794	chr9:111880884	C9orf5	-0.4	-6.53	-0.37	3.36e-10	Menarche (age at onset);
CESC	cis	rs60871478	0.898	rs62432897	chr7:825429	A/G	cg27478167	chr7:817139	HEATR2	-0.48	-5.16	-0.3	4.93e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs2836974	0.666	rs4818015	chr21:40675493	A/C	cg17971929	chr21:40555470	PSMG1	0.87	12.55	0.61	1.18e-28	Cognitive function;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg13675319	chr9:31254329	NA	0.41	6.1	0.35	3.84e-9	Fibrinogen levels;
CESC	cis	rs7666738	0.830	rs13138063	chr4:99050438	A/C	cg05340658	chr4:99064831	C4orf37	0.82	12.75	0.62	2.34e-29	Colonoscopy-negative controls vs population controls;
CESC	cis	rs561341	1.000	rs55736640	chr17:30333848	G/A	cg12193833	chr17:30244370	NA	-0.72	-6.35	-0.36	9.13e-10	Hip circumference adjusted for BMI;
CESC	cis	rs1008375	0.932	rs11934968	chr4:17667766	A/G	cg16339924	chr4:17578868	LAP3	0.58	6.75	0.38	9.2e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs642803	0.591	rs620088	chr11:65508986	G/A	cg02870584	chr11:65547924	DKFZp761E198	0.53	6.69	0.38	1.36e-10	Urate levels;
CESC	cis	rs4601790	0.601	rs66864335	chr11:65390803	G/A	cg21033440	chr11:65409861	SIPA1	-0.58	-7.09	-0.4	1.25e-11	Blood pressure (age interaction);
CESC	cis	rs116095464	0.558	rs10057626	chr5:239720	T/G	cg20965017	chr5:231967	SDHA	-0.47	-5.3	-0.31	2.49e-7	Breast cancer;
CESC	trans	rs208520	0.754	rs1100989	chr6:66880532	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.99	-12.51	-0.61	1.58e-28	Exhaled nitric oxide output;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13795627	chr1:157015873	ARHGEF11	0.62	7.23	0.41	5.09e-12	Gut microbiome composition (summer);
CESC	cis	rs9811920	0.638	rs704581	chr3:99556160	A/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.47	-5.72	-0.33	2.8e-8	Axial length;
CESC	cis	rs7246657	0.943	rs10405064	chr19:37861861	C/T	cg23950597	chr19:37808831	NA	-0.61	-6.18	-0.35	2.39e-9	Coronary artery calcification;
CESC	cis	rs2573652	0.755	rs1469830	chr15:100517403	G/T	cg00587665	chr15:100533223	ADAMTS17	0.34	5.27	0.31	2.9e-7	Height;
CESC	cis	rs7666738	0.830	rs10034330	chr4:99064849	G/A	cg03676636	chr4:99064102	C4orf37	0.33	5.04	0.3	8.47e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2832191	0.791	rs2832199	chr21:30498501	G/A	cg24692254	chr21:30365293	RNF160	-0.8	-12.29	-0.6	9.16e-28	Dental caries;
CESC	cis	rs909002	0.800	rs1061770	chr1:32096265	A/G	cg13919466	chr1:32135498	COL16A1	-0.45	-8.04	-0.44	2.96e-14	Intelligence (multi-trait analysis);
CESC	cis	rs4862750	0.872	rs6830828	chr4:187897472	T/G	cg11301795	chr4:187892539	NA	-0.75	-12.37	-0.61	4.63e-28	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7613875	0.620	rs7624030	chr3:50071279	A/C	cg24308560	chr3:49941425	MST1R	0.57	8.16	0.45	1.32e-14	Body mass index;
CESC	cis	rs7546094	0.935	rs7554345	chr1:113122956	T/G	cg22162597	chr1:113214053	CAPZA1	0.37	5.67	0.33	3.64e-8	Platelet distribution width;
CESC	cis	rs11630290	0.592	rs12324556	chr15:64160951	G/A	cg12036633	chr15:63758958	NA	0.45	5.35	0.31	1.92e-7	Iris characteristics;
CESC	cis	rs7772486	0.846	rs2748499	chr6:146315002	T/C	cg05347473	chr6:146136440	FBXO30	0.52	6.88	0.39	4.32e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4566357	0.615	rs12328876	chr2:227918899	G/T	cg05526886	chr2:227700861	RHBDD1	-0.55	-6.97	-0.39	2.59e-11	Coronary artery disease;
CESC	cis	rs1153858	0.832	rs1145078	chr15:45682277	C/T	cg21132104	chr15:45694354	SPATA5L1	0.77	10.24	0.53	5.77e-21	Homoarginine levels;
CESC	cis	rs950027	0.620	rs2467862	chr15:45643843	T/G	cg21132104	chr15:45694354	SPATA5L1	0.66	8.52	0.46	1.22e-15	Response to fenofibrate (adiponectin levels);
CESC	cis	rs2180341	0.960	rs3756996	chr6:127664258	G/C	cg24812749	chr6:127587940	RNF146	1.07	15.08	0.68	1.65e-37	Breast cancer;
CESC	trans	rs7246760	1.000	rs58137206	chr19:9856624	G/A	cg02900749	chr2:68251473	NA	-0.77	-7.15	-0.4	8.22e-12	Pursuit maintenance gain;
CESC	cis	rs2836633	1.000	rs2836633	chr21:40067445	C/T	cg12884169	chr21:40033163	ERG	-0.33	-5.36	-0.31	1.84e-7	Coronary artery disease;
CESC	cis	rs9911578	1.000	rs304270	chr17:56802141	A/G	cg12560992	chr17:57184187	TRIM37	-0.91	-15.39	-0.69	1.32e-38	Intelligence (multi-trait analysis);
CESC	cis	rs7666738	0.830	rs7657982	chr4:99044015	G/A	cg03467027	chr4:99064603	C4orf37	0.47	5.9	0.34	1.12e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2576037	0.583	rs545344	chr18:44367079	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.5	-6.76	-0.38	8.8e-11	Personality dimensions;
CESC	cis	rs7267979	1.000	rs453329	chr20:25440593	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.85	16.7	0.72	2.9e-43	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs2730245	0.527	rs842693	chr7:158660491	C/T	cg24397884	chr7:158709396	WDR60	0.8	8.01	0.44	3.67e-14	Height;
CESC	cis	rs425277	0.583	rs3107151	chr1:2051513	T/G	cg04315214	chr1:2043799	PRKCZ	0.61	10.74	0.55	1.37e-22	Height;
CESC	cis	rs1799949	1.000	rs8176109	chr17:41265776	A/G	cg06001716	chr17:41278141	BRCA1;NBR2	0.39	5.35	0.31	1.89e-7	Menopause (age at onset);
CESC	cis	rs4713118	0.540	rs469227	chr6:27970705	A/C	cg26335602	chr6:28129616	ZNF389	0.41	5.43	0.32	1.25e-7	Parkinson's disease;
CESC	cis	rs2644899	0.594	rs11668644	chr19:41316746	G/C	cg24958765	chr19:41283667	RAB4B	-0.54	-5.89	-0.34	1.14e-8	Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs7085104	0.727	rs12773892	chr10:104631177	G/T	cg04362960	chr10:104952993	NT5C2	0.64	6.08	0.35	4.26e-9	Immature fraction of reticulocytes;Schizophrenia;
CESC	cis	rs992157	0.560	rs7605980	chr2:219100869	C/G	cg00012203	chr2:219082015	ARPC2	0.72	9.43	0.5	2.15e-18	Colorectal cancer;
CESC	cis	rs17401966	0.809	rs12406943	chr1:10308545	T/C	cg15208524	chr1:10270712	KIF1B	0.38	5.04	0.3	8.75e-7	Hepatocellular carcinoma;
CESC	cis	rs4423214	1.000	rs4944958	chr11:71168073	A/G	cg05163923	chr11:71159392	DHCR7	0.77	10.4	0.54	1.76e-21	Vitamin D levels;
CESC	cis	rs727505	1.000	rs66665074	chr7:124550526	C/T	cg23710748	chr7:124431027	NA	-0.47	-7.45	-0.42	1.35e-12	Lewy body disease;
CESC	cis	rs9486715	0.838	rs6928442	chr6:96870118	A/G	cg06623918	chr6:96969491	KIAA0776	0.91	14.05	0.65	6.83e-34	Headache;
CESC	cis	rs951366	0.903	rs708723	chr1:205739266	C/T	cg14159672	chr1:205819179	PM20D1	0.51	7.36	0.41	2.36e-12	Menarche (age at onset);
CESC	cis	rs2625529	0.824	rs7170461	chr15:72218599	C/A	cg16672083	chr15:72433130	SENP8	-0.39	-5.06	-0.3	7.68e-7	Red blood cell count;
CESC	cis	rs1545257	0.514	rs7581577	chr2:24638107	C/T	cg06627628	chr2:24431161	ITSN2	-0.48	-5.88	-0.34	1.21e-8	Sjögren's syndrome;
CESC	cis	rs854765	0.647	rs2974999	chr17:17997547	T/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.61	8.63	0.47	5.93e-16	Total body bone mineral density;
CESC	cis	rs763121	0.853	rs1043441	chr22:39130964	C/T	cg21395723	chr22:39101663	GTPBP1	0.47	6.12	0.35	3.37e-9	Menopause (age at onset);
CESC	cis	rs853679	0.517	rs9393895	chr6:28127621	T/C	cg12963246	chr6:28129442	ZNF389	0.56	7.38	0.41	1.99e-12	Depression;
CESC	cis	rs2408955	0.500	rs12816820	chr12:48558325	A/G	cg24011408	chr12:48396354	COL2A1	0.49	7.41	0.41	1.69e-12	Glycated hemoglobin levels;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg16263701	chr12:48213605	HDAC7	0.53	7.28	0.41	3.73e-12	Gut microbiota (bacterial taxa);
CESC	cis	rs34779708	0.702	rs35969476	chr10:35544318	G/A	cg03585969	chr10:35415529	CREM	0.56	6.54	0.37	3.22e-10	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs2302729	0.929	rs7136355	chr12:2783476	T/C	cg19945202	chr12:2788847	CACNA1C	-0.45	-5.22	-0.31	3.53e-7	Sleep quality;
CESC	cis	rs1799949	0.930	rs3092987	chr17:41222723	T/C	cg05368731	chr17:41323189	NBR1	0.78	10.41	0.54	1.66e-21	Menopause (age at onset);
CESC	cis	rs9583531	0.600	rs7984468	chr13:111362093	C/A	cg15841412	chr13:111365552	ING1	0.52	6.74	0.38	1.01e-10	Coronary artery disease;
CESC	cis	rs9443645	0.810	rs9448610	chr6:79739622	G/A	cg05283184	chr6:79620031	NA	-0.39	-6.05	-0.35	4.81e-9	Intelligence (multi-trait analysis);
CESC	cis	rs12142240	0.731	rs6681857	chr1:46850124	T/C	cg10495392	chr1:46806563	NSUN4	0.55	5.98	0.34	7.21e-9	Menopause (age at onset);
CESC	trans	rs11039798	0.588	rs11039855	chr11:48610091	A/G	cg15704280	chr7:45808275	SEPT13	0.61	6.29	0.36	1.32e-9	Axial length;
CESC	cis	rs6732160	0.691	rs13402225	chr2:73416906	T/G	cg01422370	chr2:73384389	NA	0.42	7.15	0.4	8.6e-12	Intelligence (multi-trait analysis);
CESC	cis	rs898097	0.607	rs2199111	chr17:80823203	A/G	cg15664640	chr17:80829946	TBCD	-0.4	-5.66	-0.33	4.01e-8	Breast cancer;
CESC	cis	rs61931739	0.500	rs56404399	chr12:34543101	A/G	cg19457237	chr12:34500585	NA	-0.37	-5.08	-0.3	6.97e-7	Morning vs. evening chronotype;
CESC	cis	rs1801251	1.000	rs283476	chr2:233650168	A/G	cg25237894	chr2:233734115	C2orf82	0.44	7.63	0.42	4.22e-13	Coronary artery disease;
CESC	cis	rs763121	0.853	rs5750622	chr22:38956464	C/G	cg06544989	chr22:39130855	UNC84B	0.49	8.18	0.45	1.16e-14	Menopause (age at onset);
CESC	cis	rs12135062	1.000	rs12135062	chr1:3103312	A/C	cg25382214	chr1:3105252	PRDM16	0.38	5.04	0.3	8.58e-7	Migraine;
CESC	cis	rs9303401	0.704	rs740605	chr17:56604811	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.56	7.53	0.42	8.06e-13	Cognitive test performance;
CESC	cis	rs9916302	0.904	rs13341996	chr17:37536862	C/T	cg00129232	chr17:37814104	STARD3	0.59	7.88	0.44	8.71e-14	Glomerular filtration rate (creatinine);
CESC	cis	rs6088590	0.930	rs6087618	chr20:33288407	C/T	cg24642439	chr20:33292090	TP53INP2	0.85	12.0	0.59	8.93e-27	Coronary artery disease;
CESC	cis	rs2075371	0.897	rs1643102	chr7:133999983	T/A	cg20476274	chr7:133979776	SLC35B4	0.65	9.4	0.5	2.76e-18	Mean platelet volume;
CESC	cis	rs4654899	0.758	rs6689852	chr1:21341051	T/C	cg05370193	chr1:21551575	ECE1	0.37	5.65	0.33	4.12e-8	Superior frontal gyrus grey matter volume;
CESC	cis	rs9300255	0.596	rs10734900	chr12:123743445	G/A	cg05973401	chr12:123451056	ABCB9	0.44	5.46	0.32	1.12e-7	Neutrophil percentage of white cells;
CESC	cis	rs6991838	0.584	rs57042777	chr8:66489090	T/A	cg13398993	chr8:66546079	ARMC1	-0.46	-5.54	-0.32	7.22e-8	Intelligence (multi-trait analysis);
CESC	cis	rs12477438	0.798	rs1580068	chr2:99649969	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-10.57	-0.54	5.22e-22	Chronic sinus infection;
CESC	cis	rs7904368	0.754	rs7076779	chr10:16852667	C/T	cg14835575	chr10:16859367	RSU1	0.47	5.04	0.3	8.69e-7	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
CESC	cis	rs208520	0.690	rs851468	chr6:66825875	G/A	cg07460842	chr6:66804631	NA	-1.01	-13.46	-0.64	8.19e-32	Exhaled nitric oxide output;
CESC	cis	rs10504229	0.596	rs7004566	chr8:58115602	G/C	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs4253772	0.513	rs9306512	chr22:46716603	T/C	cg09491104	chr22:46646882	C22orf40	-0.59	-8.98	-0.48	5.35e-17	LDL cholesterol;Cholesterol, total;
CESC	cis	rs748404	0.650	rs518234	chr15:43573421	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.59	7.76	0.43	1.84e-13	Lung cancer;
CESC	cis	rs9733	0.596	rs72702552	chr1:150677462	G/A	cg09365446	chr1:150670422	GOLPH3L	0.42	5.9	0.34	1.09e-8	Tonsillectomy;
CESC	cis	rs35146811	0.660	rs6465760	chr7:99591418	A/G	cg22531904	chr7:99595276	NA	0.38	5.1	0.3	6.46e-7	Coronary artery disease;
CESC	cis	rs9611565	0.659	rs12484175	chr22:41953739	A/C	cg17376030	chr22:41985996	PMM1	0.66	7.22	0.41	5.44e-12	Vitiligo;
CESC	cis	rs2836974	0.897	rs14194	chr21:40549466	T/C	cg17971929	chr21:40555470	PSMG1	1.03	15.89	0.7	2.13e-40	Cognitive function;
CESC	cis	rs9549328	0.885	rs3011546	chr13:113637009	T/A	cg18110590	chr13:113636679	MCF2L	0.53	6.79	0.38	7.35e-11	Systolic blood pressure;
CESC	cis	rs10540	1.000	rs67912009	chr11:495057	G/T	cg03934478	chr11:495069	RNH1	0.57	5.79	0.34	1.95e-8	Body mass index;
CESC	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	10.38	0.54	2.06e-21	Prudent dietary pattern;
CESC	cis	rs4722166	0.597	rs1554606	chr7:22768707	T/G	cg05472934	chr7:22766657	IL6	0.66	8.97	0.48	5.53e-17	Lung cancer;
CESC	cis	rs9768139	0.733	rs12698208	chr7:158117575	C/T	cg25566285	chr7:158114605	PTPRN2	0.46	7.72	0.43	2.46e-13	Calcium levels;
CESC	cis	rs35110281	0.667	rs914197	chr21:45117439	A/G	cg04455712	chr21:45112962	RRP1B	0.47	7.13	0.4	9.39e-12	Mean corpuscular volume;
CESC	cis	rs11190604	1.000	rs10883502	chr10:102238343	T/G	cg07080220	chr10:102295463	HIF1AN	0.56	5.59	0.32	5.61e-8	Palmitoleic acid (16:1n-7) levels;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg20646995	chr7:102105124	LRWD1;ALKBH4	-0.48	-6.35	-0.36	9.09e-10	Height;
CESC	cis	rs1348850	0.914	rs12693120	chr2:178283288	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.8	11.46	0.58	5.62e-25	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs4474465	0.850	rs4945287	chr11:78226521	C/T	cg27205649	chr11:78285834	NARS2	0.43	5.23	0.31	3.44e-7	Alzheimer's disease (survival time);
CESC	cis	rs7246657	0.943	rs4802136	chr19:37849811	T/A	cg23950597	chr19:37808831	NA	-0.57	-6.25	-0.36	1.67e-9	Coronary artery calcification;
CESC	cis	rs9399135	0.967	rs4388304	chr6:135309597	T/A	cg22676075	chr6:135203613	NA	0.52	7.21	0.4	5.95e-12	Red blood cell count;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg00304072	chr15:49338551	SECISBP2L	-0.48	-6.24	-0.36	1.72e-9	Ulcerative colitis;
CESC	trans	rs637571	0.544	rs55704213	chr11:65730002	C/A	cg17712092	chr4:129076599	LARP1B	0.75	10.36	0.54	2.43e-21	Eosinophil percentage of white cells;
CESC	cis	rs11146838	1	rs11146838	chr10:39149977	A/T	cg03665457	chr10:38645376	HSD17B7P2	-0.43	-5.31	-0.31	2.36e-7	Breast cancer;
CESC	cis	rs7851660	0.967	rs7043885	chr9:100596439	C/T	cg13688889	chr9:100608707	NA	-0.68	-10.65	-0.55	2.84e-22	Strep throat;
CESC	cis	rs7943191	0.768	rs34065644	chr11:62371938	C/T	cg02375832	chr11:62437615	C11orf48	-0.39	-5.46	-0.32	1.09e-7	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
CESC	cis	rs4253772	0.591	rs9615348	chr22:46729338	C/G	cg00784671	chr22:46762841	CELSR1	-0.62	-6.0	-0.35	6.33e-9	LDL cholesterol;Cholesterol, total;
CESC	cis	rs9309473	0.687	rs6747145	chr2:73609177	C/T	cg20560298	chr2:73613845	ALMS1	-0.48	-6.63	-0.38	1.92e-10	Metabolite levels;
CESC	cis	rs7084402	0.935	rs1427195	chr10:60278967	T/C	cg07615347	chr10:60278583	BICC1	-0.59	-9.45	-0.5	1.94e-18	Refractive error;
CESC	cis	rs9612	1.000	rs346527	chr19:44259361	A/G	cg08581076	chr19:44259116	C19orf61	0.52	6.14	0.35	2.96e-9	Exhaled nitric oxide output;
CESC	cis	rs11630290	0.806	rs72752906	chr15:64093465	G/T	cg12036633	chr15:63758958	NA	-0.56	-5.33	-0.31	2.06e-7	Iris characteristics;
CESC	cis	rs7945705	0.902	rs2012696	chr11:8995818	A/C	cg21881798	chr11:8931708	C11orf17;ST5	0.5	8.04	0.44	2.92e-14	Hemoglobin concentration;
CESC	cis	rs2073300	0.609	rs6137951	chr20:23429459	T/C	cg12062639	chr20:23401060	NAPB	0.93	6.51	0.37	3.78e-10	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs9611565	0.605	rs202638	chr22:41855458	A/G	cg17376030	chr22:41985996	PMM1	-0.56	-6.45	-0.37	5.19e-10	Vitiligo;
CESC	trans	rs11098499	0.954	rs17006190	chr4:120418838	C/G	cg25214090	chr10:38739885	LOC399744	0.71	10.02	0.52	3.04e-20	Corneal astigmatism;
CESC	cis	rs7927592	0.956	rs7124078	chr11:68298633	G/T	cg16797656	chr11:68205561	LRP5	0.39	5.46	0.32	1.09e-7	Total body bone mineral density;
CESC	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg05064044	chr6:292385	DUSP22	-0.68	-8.75	-0.47	2.48e-16	Menopause (age at onset);
CESC	cis	rs7615952	0.576	rs4646748	chr3:125826329	G/A	cg04553112	chr3:125709451	NA	-0.56	-5.99	-0.35	6.78e-9	Blood pressure (smoking interaction);
CESC	cis	rs2979489	0.891	rs3824107	chr8:30353412	A/G	cg26383811	chr8:30366931	RBPMS	0.72	8.86	0.48	1.16e-16	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CESC	cis	rs7481584	0.624	rs438384	chr11:3045651	A/G	cg08508325	chr11:3079039	CARS	0.31	5.1	0.3	6.52e-7	Calcium levels;
CESC	trans	rs1437396	0.586	rs2867175	chr2:55622549	T/A	cg07921503	chr7:2445843	CHST12	-0.24	-6.01	-0.35	6.16e-9	Alcohol dependence;
CESC	cis	rs17401966	0.931	rs61778401	chr1:10426474	G/A	cg15208524	chr1:10270712	KIF1B	0.4	5.12	0.3	6e-7	Hepatocellular carcinoma;
CESC	trans	rs12478296	0.685	rs12473450	chr2:242991746	C/T	cg18288967	chr1:45987694	PRDX1	0.61	6.98	0.39	2.38e-11	Obesity-related traits;
CESC	cis	rs9837602	0.810	rs35885423	chr3:99813218	C/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.49	6.83	0.39	5.64e-11	Breast cancer;
CESC	cis	rs7551222	0.752	rs12741351	chr1:204528256	G/A	cg20240347	chr1:204465584	NA	-0.28	-5.62	-0.33	4.73e-8	Schizophrenia;
CESC	cis	rs597539	0.652	rs673821	chr11:68678718	G/T	cg04772025	chr11:68637568	NA	0.52	6.23	0.36	1.87e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs8062405	1.000	rs8062405	chr16:28837906	C/T	cg08761264	chr16:28874980	SH2B1	0.47	5.93	0.34	9.27e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs72781680	0.566	rs6713865	chr2:23899807	A/G	cg08917208	chr2:24149416	ATAD2B	0.76	7.38	0.41	2.03e-12	Lymphocyte counts;
CESC	cis	rs13118159	0.836	rs12647145	chr4:1338618	C/A	cg02018176	chr4:1364513	KIAA1530	0.41	5.82	0.34	1.72e-8	Longevity;
CESC	cis	rs644799	0.601	rs7902	chr11:95565288	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.49	6.91	0.39	3.56e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs921968	0.643	rs539451	chr2:219426972	T/C	cg02176678	chr2:219576539	TTLL4	0.39	6.86	0.39	4.81e-11	Mean corpuscular hemoglobin concentration;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg18171715	chr4:852160	GAK	0.49	6.28	0.36	1.37e-9	Fibrinogen levels;
CESC	cis	rs13108904	0.517	rs13134568	chr4:1334289	G/A	cg22903657	chr4:1355424	KIAA1530	-0.4	-5.67	-0.33	3.82e-8	Obesity-related traits;
CESC	cis	rs8092503	0.536	rs12956375	chr18:52443203	G/C	cg12377874	chr18:52495404	RAB27B	0.34	5.14	0.3	5.36e-7	Childhood body mass index;
CESC	cis	rs7618915	0.547	rs13069481	chr3:52666866	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.5	0.37	3.95e-10	Bipolar disorder;
CESC	cis	rs9649213	0.614	rs12539761	chr7:98013839	C/T	cg09267113	chr7:98030324	BAIAP2L1	-0.43	-5.79	-0.34	1.95e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs13108904	0.901	rs1316394	chr4:1315820	G/A	cg00684032	chr4:1343700	KIAA1530	0.49	6.98	0.39	2.31e-11	Obesity-related traits;
CESC	cis	rs9291683	0.632	rs13137074	chr4:10042842	C/T	cg00071950	chr4:10020882	SLC2A9	0.83	14.41	0.66	3.63e-35	Bone mineral density;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg08698015	chr17:72744834	SLC9A3R1	-0.52	-6.96	-0.39	2.6e-11	Fibrinogen levels;
CESC	cis	rs12983728	1.000	rs12983728	chr19:58671267	G/A	cg08687515	chr19:58661962	ZNF329	0.52	5.07	0.3	7.41e-7	Cholesterol, total;
CESC	cis	rs514406	0.861	rs12038438	chr1:53230581	A/T	cg08736216	chr1:53307985	ZYG11A	0.41	6.99	0.39	2.22e-11	Monocyte count;
CESC	cis	rs4563143	0.675	rs112383987	chr19:29261081	C/T	cg12756686	chr19:29218302	NA	0.58	7.52	0.42	8.38e-13	Methadone dose in opioid dependence;
CESC	cis	rs9768139	0.733	rs13309363	chr7:158122179	C/A	cg24154853	chr7:158122151	PTPRN2	0.41	6.36	0.36	8.66e-10	Calcium levels;
CESC	cis	rs9457247	0.967	rs2769355	chr6:167380493	G/A	cg23791538	chr6:167370224	RNASET2	0.6	8.56	0.47	9.4e-16	Crohn's disease;
CESC	cis	rs832540	0.519	rs6450411	chr5:56265771	A/G	cg12311346	chr5:56204834	C5orf35	-0.44	-5.61	-0.33	5.07e-8	Coronary artery disease;
CESC	cis	rs1799949	0.965	rs11080034	chr17:41443014	T/C	cg07153921	chr17:41440717	NA	-0.4	-5.36	-0.31	1.79e-7	Menopause (age at onset);
CESC	trans	rs208520	0.526	rs9294682	chr6:66795159	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.09	-23.75	-0.82	1.36e-67	Exhaled nitric oxide output;
CESC	cis	rs7553864	0.614	rs4559475	chr1:87614236	T/C	cg17420885	chr1:87600446	LOC339524	-0.46	-6.31	-0.36	1.18e-9	Smoking behavior;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01800426	chr8:17659068	MTUS1	0.53	6.31	0.36	1.19e-9	Gut microbiome composition (summer);
CESC	cis	rs1348850	0.914	rs3813259	chr2:178257214	G/A	cg22681709	chr2:178499509	PDE11A	-0.43	-6.18	-0.36	2.34e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs9309473	0.904	rs79145598	chr2:73821382	T/A	cg20560298	chr2:73613845	ALMS1	-0.54	-6.85	-0.39	5.25e-11	Metabolite levels;
CESC	cis	rs7659604	0.540	rs67150579	chr4:122704331	T/A	cg19748678	chr4:122722346	EXOSC9	-0.42	-5.28	-0.31	2.64e-7	Type 2 diabetes;
CESC	trans	rs9329221	0.683	rs658385	chr8:9892177	C/T	cg06636001	chr8:8085503	FLJ10661	-0.54	-7.06	-0.4	1.45e-11	Neuroticism;
CESC	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg07308232	chr7:1071921	C7orf50	-0.6	-8.54	-0.46	1.04e-15	Longevity;Endometriosis;
CESC	cis	rs4849845	0.637	rs11688038	chr2:121026582	A/G	cg24070213	chr2:121070622	NA	0.44	6.52	0.37	3.44e-10	Mean platelet volume;
CESC	trans	rs7615952	0.576	rs1127717	chr3:125826059	T/C	cg07211511	chr3:129823064	LOC729375	-0.54	-6.07	-0.35	4.31e-9	Blood pressure (smoking interaction);
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg10156188	chr7:102006302	NA	-0.48	-6.0	-0.35	6.63e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg05313129	chr8:58192883	C8orf71	-0.49	-5.32	-0.31	2.23e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs9611565	0.649	rs126092	chr22:42178441	A/G	cg06634786	chr22:41940651	POLR3H	0.46	5.04	0.3	8.66e-7	Vitiligo;
CESC	cis	rs8177179	0.967	rs6439434	chr3:133450371	T/G	cg16262614	chr3:133464971	TF	0.43	8.64	0.47	5.58e-16	Iron status biomarkers (transferrin levels);
CESC	cis	rs1559088	0.901	rs12610053	chr19:33582606	A/G	cg17764715	chr19:33622953	WDR88	0.5	6.46	0.37	4.9e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00429477	chr12:6798907	ZNF384	0.6	6.31	0.36	1.19e-9	Gut microbiome composition (summer);
CESC	cis	rs1062177	1.000	rs2915869	chr5:151171509	C/T	cg12924095	chr5:151150029	G3BP1	0.49	6.44	0.37	5.67e-10	Preschool internalizing problems;
CESC	cis	rs3820068	0.581	rs59991988	chr1:15950552	T/A	cg13390004	chr1:15929781	NA	0.37	5.86	0.34	1.34e-8	Systolic blood pressure;
CESC	cis	rs61996546	0.622	rs11629779	chr15:26845126	T/A	cg15066197	chr15:26874202	GABRB3	-0.34	-5.09	-0.3	6.78e-7	Response to methotrexate in juvenile idiopathic arthritis;
CESC	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.44	5.88	0.34	1.2e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg08984405	chr17:685103	RNMTL1;GLOD4	0.48	6.56	0.37	2.84e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	13.74	0.64	8.59e-33	Prudent dietary pattern;
CESC	cis	rs3859192	0.577	rs2227333	chr17:38174167	C/G	cg17467752	chr17:38218738	THRA	-0.47	-6.16	-0.35	2.69e-9	White blood cell count;
CESC	trans	rs9467711	0.606	rs34104395	chr6:26478252	C/T	cg01620082	chr3:125678407	NA	-0.78	-6.1	-0.35	3.8e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs7116495	1.000	rs4944258	chr11:71743393	T/A	cg26138937	chr11:71823887	C11orf51	-0.82	-6.68	-0.38	1.39e-10	Severe influenza A (H1N1) infection;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg12153709	chr19:56196971	EPN1	0.5	6.37	0.36	8.13e-10	Fibrinogen levels;
CESC	cis	rs4727027	0.870	rs11524138	chr7:148799125	G/A	cg23158103	chr7:148848205	ZNF398	-0.42	-6.93	-0.39	3.25e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10224311	chr22:35817371	MCM5	-0.54	-6.75	-0.38	9.42e-11	Gut microbiome composition (summer);
CESC	cis	rs2404602	0.692	rs56193230	chr15:76934472	C/T	cg26408565	chr15:76604113	ETFA	-0.38	-5.44	-0.32	1.21e-7	Blood metabolite levels;
CESC	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.12	11.16	0.57	5.88e-24	Platelet count;
CESC	cis	rs12701220	0.522	rs868833	chr7:1054973	C/G	cg23978390	chr7:1156363	C7orf50	0.42	5.21	0.31	3.74e-7	Bronchopulmonary dysplasia;
CESC	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg06873352	chr17:61820015	STRADA	0.73	13.07	0.63	1.78e-30	Prudent dietary pattern;
CESC	cis	rs6669072	0.647	rs698274	chr1:91244177	A/G	cg08895590	chr1:91227319	NA	-0.32	-5.56	-0.32	6.53e-8	Cognitive function;
CESC	cis	rs3806843	1.000	rs3733710	chr5:140167463	C/T	cg26395211	chr5:140044315	WDR55	-0.42	-5.43	-0.32	1.28e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs2832191	0.671	rs73346699	chr21:30515529	C/T	cg24692254	chr21:30365293	RNF160	-0.63	-7.84	-0.43	1.13e-13	Dental caries;
CESC	cis	rs9346455	0.614	rs58732838	chr6:72000496	C/T	cg27238071	chr6:71998145	OGFRL1	0.63	6.1	0.35	3.77e-9	Antipsychotic drug-induced weight gain (time interaction);Antipsychotic drug-induced weight gain;
CESC	cis	rs926392	0.932	rs4812360	chr20:37689259	A/G	cg16355469	chr20:37678765	NA	0.4	5.08	0.3	7.06e-7	Dialysis-related mortality;
CESC	cis	rs36051895	0.672	rs12353218	chr9:5162828	T/C	cg02405213	chr9:5042618	JAK2	-0.54	-6.84	-0.39	5.41e-11	Pediatric autoimmune diseases;
CESC	cis	rs854765	0.547	rs8075189	chr17:17901946	C/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.54	7.23	0.41	5.11e-12	Total body bone mineral density;
CESC	cis	rs735396	0.770	rs1169314	chr12:121443116	A/G	cg15155738	chr12:121454335	C12orf43	0.44	5.11	0.3	6.1e-7	N-glycan levels;
CESC	cis	rs9443645	0.810	rs9448607	chr6:79715620	G/A	cg05283184	chr6:79620031	NA	-0.39	-6.17	-0.35	2.58e-9	Intelligence (multi-trait analysis);
CESC	cis	rs911555	0.755	rs12432803	chr14:103930032	C/T	cg12935359	chr14:103987150	CKB	0.65	9.46	0.5	1.73e-18	Intelligence (multi-trait analysis);
CESC	cis	rs4595586	0.545	rs11609541	chr12:39378331	T/C	cg26384229	chr12:38710491	ALG10B	0.54	7.53	0.42	7.85e-13	Morning vs. evening chronotype;
CESC	cis	rs80130819	0.793	rs2634674	chr12:48744897	T/C	cg05342945	chr12:48394962	COL2A1	-0.55	-5.83	-0.34	1.57e-8	Prostate cancer;
CESC	cis	rs10463316	0.894	rs12652733	chr5:150753999	G/A	cg03212797	chr5:150827313	SLC36A1	-0.42	-5.41	-0.32	1.41e-7	Metabolite levels (Pyroglutamine);
CESC	cis	rs9660180	0.967	rs6603803	chr1:1812688	A/G	cg20999797	chr1:1681921	NA	0.28	5.38	0.31	1.63e-7	Body mass index;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg17735320	chr10:135192001	PAOX	0.47	6.04	0.35	5.17e-9	Thyroid stimulating hormone;
CESC	cis	rs875971	0.862	rs1612452	chr7:65573896	T/A	cg11764359	chr7:65958608	NA	-0.78	-10.88	-0.56	4.83e-23	Aortic root size;
CESC	cis	rs7191700	0.644	rs918738	chr16:11439679	C/G	cg00044050	chr16:11439710	C16orf75	-0.49	-5.86	-0.34	1.36e-8	Multiple sclerosis;
CESC	cis	rs9611565	0.625	rs9611606	chr22:41931074	A/G	cg17376030	chr22:41985996	PMM1	0.68	7.35	0.41	2.5e-12	Vitiligo;
CESC	cis	rs3820068	0.580	rs36100011	chr1:16046920	C/T	cg17385448	chr1:15911702	AGMAT	0.37	5.75	0.33	2.45e-8	Systolic blood pressure;
CESC	cis	rs11031096	0.678	rs12223062	chr11:4180178	G/T	cg18678763	chr11:4115507	RRM1	-0.43	-5.95	-0.34	8.24e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	trans	rs7819412	0.703	rs2409713	chr8:11009797	C/T	cg15556689	chr8:8085844	FLJ10661	-0.52	-6.42	-0.37	6.21e-10	Triglycerides;
CESC	cis	rs60871478	1.000	rs4374882	chr7:821798	C/T	cg05535760	chr7:792225	HEATR2	0.83	10.11	0.53	1.53e-20	Cerebrospinal P-tau181p levels;
CESC	cis	rs2072499	0.898	rs2736609	chr1:156202640	C/T	cg25208724	chr1:156163844	SLC25A44	0.84	13.27	0.63	3.75e-31	Testicular germ cell tumor;
CESC	cis	rs478304	0.934	rs1193692	chr11:65504069	A/C	cg08755490	chr11:65554678	OVOL1	0.46	6.14	0.35	3.09e-9	Acne (severe);
CESC	cis	rs763014	0.932	rs2384972	chr16:674424	G/A	cg00908189	chr16:619842	PIGQ	0.64	8.94	0.48	6.68e-17	Height;
CESC	cis	rs17818399	0.547	rs7607633	chr2:46759427	T/C	cg02822958	chr2:46747628	ATP6V1E2	0.45	5.21	0.3	3.77e-7	Height;
CESC	cis	rs6500395	0.788	rs12446280	chr16:48651171	G/T	cg04672837	chr16:48644449	N4BP1	0.47	5.58	0.32	5.79e-8	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs61931739	0.500	rs7310237	chr12:34483435	G/A	cg06521331	chr12:34319734	NA	-0.37	-5.05	-0.3	8.21e-7	Morning vs. evening chronotype;
CESC	cis	rs2573652	0.722	rs11858932	chr15:100542763	G/A	cg09918751	chr15:100517450	ADAMTS17	-0.34	-6.26	-0.36	1.53e-9	Height;
CESC	cis	rs12530845	0.623	rs73721662	chr7:135341314	G/A	cg23117316	chr7:135346802	PL-5283	-0.58	-6.53	-0.37	3.25e-10	Red blood cell traits;
CESC	cis	rs2278034	0.578	rs881753	chr3:195606770	C/T	cg12923728	chr3:195709715	SDHAP1	0.39	5.42	0.32	1.32e-7	Bronchopulmonary dysplasia;
CESC	cis	rs7208859	0.673	rs56085216	chr17:29217234	T/C	cg19761014	chr17:28927070	LRRC37B2	0.64	5.35	0.31	1.95e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11074549	chr14:75642944	TMED10	0.65	7.33	0.41	2.76e-12	Gut microbiome composition (summer);
CESC	cis	rs116095464	0.558	rs9687898	chr5:253952	A/G	cg20965017	chr5:231967	SDHA	-0.47	-5.22	-0.31	3.61e-7	Breast cancer;
CESC	trans	rs853679	0.607	rs13203816	chr6:28079598	T/C	cg01620082	chr3:125678407	NA	-0.81	-6.34	-0.36	1.01e-9	Depression;
CESC	cis	rs12681366	0.663	rs1561648	chr8:95474437	C/T	cg13257157	chr8:95487014	RAD54B	0.39	5.34	0.31	2.04e-7	Nonsyndromic cleft lip with cleft palate;
CESC	cis	rs7666738	0.830	rs7662596	chr4:99019962	G/T	cg17366294	chr4:99064904	C4orf37	0.61	8.76	0.47	2.35e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10129255	0.500	rs4774189	chr14:107176517	G/T	cg07958169	chr14:107095056	NA	-0.51	-7.95	-0.44	5.56e-14	Kawasaki disease;
CESC	cis	rs4665809	0.590	rs35615763	chr2:26468778	C/G	cg25036284	chr2:26402008	FAM59B	0.86	9.4	0.5	2.74e-18	Gut microbiome composition (summer);
CESC	cis	rs1580019	0.563	rs896137	chr7:32579345	G/T	cg07520158	chr7:32535189	LSM5;AVL9	0.52	6.45	0.37	5.36e-10	Cognitive ability;
CESC	cis	rs67311347	0.866	rs56331709	chr3:40356558	A/C	cg09455208	chr3:40491958	NA	0.45	7.62	0.42	4.58e-13	Renal cell carcinoma;
CESC	cis	rs754466	0.830	rs61854186	chr10:79703255	G/A	cg17075019	chr10:79541650	NA	-0.68	-8.27	-0.45	6.72e-15	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs15676	0.947	rs2280842	chr9:131585808	C/G	cg00228799	chr9:131580591	ENDOG	0.45	5.66	0.33	4.03e-8	Blood metabolite levels;
CESC	cis	rs75477785	1.000	rs11119348	chr1:209989729	A/C	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.92	6.04	0.35	5.06e-9	Cleft lip with or without cleft palate;
CESC	cis	rs2404602	0.692	rs2120108	chr15:76869929	G/T	cg22467129	chr15:76604101	ETFA	0.35	5.21	0.3	3.84e-7	Blood metabolite levels;
CESC	cis	rs6088590	0.687	rs13044899	chr20:33287078	G/A	cg08999081	chr20:33150536	PIGU	0.6	9.38	0.5	3.17e-18	Coronary artery disease;
CESC	cis	rs965469	1.000	rs6133036	chr20:3349682	A/G	cg25506879	chr20:3388711	C20orf194	-0.57	-6.01	-0.35	5.96e-9	IFN-related cytopenia;
CESC	cis	rs501120	0.925	rs1657344	chr10:44781234	C/T	cg09554077	chr10:44749378	NA	0.61	5.51	0.32	8.67e-8	Coronary artery disease;Coronary heart disease;
CESC	cis	rs3785574	0.962	rs8066463	chr17:61818390	A/G	cg07677032	chr17:61819896	STRADA	0.42	5.27	0.31	2.83e-7	Height;
CESC	cis	rs12682352	0.602	rs4841044	chr8:8664940	A/G	cg06636001	chr8:8085503	FLJ10661	-0.41	-5.2	-0.3	4.05e-7	Neuroticism;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12401058	chr13:23423130	NA	-0.51	-6.25	-0.36	1.67e-9	Gut microbiome composition (summer);
CESC	cis	rs2440129	0.611	rs1126667	chr17:6902760	C/T	cg05657792	chr17:6899758	ALOX12	-0.39	-6.8	-0.39	7.06e-11	Tonsillectomy;
CESC	cis	rs17125944	0.505	rs17125746	chr14:53236079	C/T	cg13660082	chr14:53194042	PSMC6	-0.68	-6.17	-0.35	2.48e-9	Alzheimer's disease (late onset);
CESC	cis	rs748404	0.697	rs530683	chr15:43568999	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.52	-7.83	-0.43	1.19e-13	Lung cancer;
CESC	cis	rs7756236	0.521	rs6936993	chr6:36626322	C/T	cg08179530	chr6:36648295	CDKN1A	-0.37	-5.27	-0.31	2.85e-7	QRS duration;
CESC	cis	rs6582630	0.538	rs8189550	chr12:38333058	T/G	cg26384229	chr12:38710491	ALG10B	-0.46	-6.0	-0.35	6.62e-9	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs35110281	0.805	rs3788062	chr21:44991159	C/T	cg04455712	chr21:45112962	RRP1B	0.37	5.5	0.32	9.16e-8	Mean corpuscular volume;
CESC	cis	rs9916302	0.904	rs9898773	chr17:37532507	C/G	cg07936489	chr17:37558343	FBXL20	0.82	12.01	0.59	8.29e-27	Glomerular filtration rate (creatinine);
CESC	cis	rs2290720	0.804	rs1457564	chr12:101761867	G/T	cg22051763	chr12:101673672	UTP20	-0.46	-5.49	-0.32	9.26e-8	Brain structure (hippocampal volume);
CESC	cis	rs2404618	0.561	rs4242536	chr8:1477225	A/G	cg13402656	chr8:1511478	DLGAP2	-0.51	-7.22	-0.41	5.55e-12	Lung cancer;
CESC	cis	rs8114671	0.562	rs6088621	chr20:33418740	C/T	cg06115741	chr20:33292138	TP53INP2	0.5	5.98	0.34	7.07e-9	Height;
CESC	cis	rs6580649	0.941	rs7957764	chr12:48429701	C/T	cg05342945	chr12:48394962	COL2A1	0.54	6.22	0.36	1.96e-9	Lung cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23006133	chr5:10563856	ANKRD33B	0.53	6.1	0.35	3.84e-9	Gut microbiome composition (summer);
CESC	cis	rs4450798	0.793	rs60991429	chr3:13751113	G/A	cg23332027	chr3:13681764	NA	0.41	5.5	0.32	9.05e-8	Bipolar disorder with mood-incongruent psychosis;
CESC	trans	rs2085496	0.764	rs1596751	chr2:193807860	A/G	ch.15.1141100F	chr15:72509144	PKM2	0.46	6.17	0.35	2.53e-9	Neuroticism;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg24641125	chr21:40721130	HMGN1	0.45	6.11	0.35	3.48e-9	Fibrinogen levels;
CESC	cis	rs6433857	0.534	rs1157535	chr2:181361736	T/A	cg23363182	chr2:181467187	NA	-0.42	-5.82	-0.34	1.68e-8	Body mass index;
CESC	cis	rs5769765	1.000	rs4824112	chr22:50284345	A/G	cg03033257	chr22:50311977	ALG12;CRELD2	0.5	5.12	0.3	5.99e-7	Schizophrenia;
CESC	cis	rs662064	0.748	rs12375	chr1:10596341	C/T	cg20482658	chr1:10539492	PEX14	0.41	8.39	0.46	2.91e-15	Asthma;
CESC	cis	rs10504229	0.683	rs7827881	chr8:58132137	C/T	cg21724239	chr8:58056113	NA	0.58	5.95	0.34	8.37e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs35306767	0.855	rs56222464	chr10:867535	C/G	cg20503657	chr10:835505	NA	1.09	10.01	0.52	3.32e-20	Eosinophil percentage of granulocytes;
CESC	cis	rs11059919	1	rs11059919	chr12:129289190	G/A	cg09035930	chr12:129282057	SLC15A4	0.75	10.18	0.53	9.25e-21	Systemic lupus erythematosus;
CESC	cis	rs12497850	0.931	rs4974079	chr3:48906469	T/G	cg07636037	chr3:49044803	WDR6	1.03	18.76	0.76	1.49e-50	Parkinson's disease;
CESC	cis	rs4563143	0.647	rs117442062	chr19:29256823	A/T	cg14983838	chr19:29218262	NA	0.51	6.13	0.35	3.09e-9	Methadone dose in opioid dependence;
CESC	cis	rs853679	0.542	rs9380063	chr6:28137853	A/G	cg20151795	chr6:28129481	ZNF389	0.42	5.33	0.31	2.11e-7	Depression;
CESC	cis	rs7772486	0.754	rs9373475	chr6:146126419	C/T	cg05347473	chr6:146136440	FBXO30	0.56	7.19	0.4	6.72e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7959452	0.535	rs7135092	chr12:69658330	T/C	cg20891283	chr12:69753455	YEATS4	0.76	11.37	0.57	1.16e-24	Blood protein levels;
CESC	cis	rs10791323	0.720	rs2851117	chr11:133705905	A/G	cg15485101	chr11:133734466	NA	-0.36	-5.51	-0.32	8.43e-8	Childhood ear infection;
CESC	cis	rs3733585	0.699	rs11724510	chr4:9958583	C/T	cg00071950	chr4:10020882	SLC2A9	-0.73	-11.91	-0.59	1.82e-26	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs6598955	0.543	rs60433268	chr1:26548055	A/C	cg04990556	chr1:26633338	UBXN11	0.81	9.26	0.49	7.47e-18	Obesity-related traits;
CESC	cis	rs9915657	0.933	rs4793272	chr17:70139257	A/T	cg06234051	chr17:70120541	SOX9	-0.38	-5.72	-0.33	2.93e-8	Thyroid hormone levels;
CESC	cis	rs9926296	0.744	rs6860	chr16:89711120	C/T	cg27121462	chr16:89883253	FANCA	-0.49	-5.76	-0.33	2.38e-8	Vitiligo;
CESC	trans	rs3794271	0.706	rs9971816	chr12:20826911	C/T	cg06155833	chr10:135232936	MTG1	-0.4	-6.27	-0.36	1.5e-9	Response to TNF-alpha inhibitors in rheumatoid arthritis;
CESC	cis	rs3806843	0.648	rs2530233	chr5:140082876	A/G	cg26395211	chr5:140044315	WDR55	0.48	6.15	0.35	2.79e-9	Depressive symptoms (multi-trait analysis);
CESC	cis	rs722599	0.847	rs2058919	chr14:75310812	C/G	cg08847533	chr14:75593920	NEK9	-0.44	-5.87	-0.34	1.27e-8	IgG glycosylation;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg02949421	chr12:104359331	TDG	-0.46	-6.05	-0.35	4.85e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs7949030	0.590	rs12225213	chr11:62350248	T/A	cg22862634	chr11:62369728	EML3;MTA2	0.58	8.0	0.44	3.87e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs4835473	0.932	rs7670010	chr4:144742832	A/G	cg25736465	chr4:144833511	NA	0.43	6.62	0.38	1.99e-10	Immature fraction of reticulocytes;
CESC	cis	rs875971	0.508	rs10242423	chr7:66059175	A/G	cg19163074	chr7:65112434	INTS4L2	0.43	5.48	0.32	1.01e-7	Aortic root size;
CESC	cis	rs9926296	0.744	rs164749	chr16:89708224	A/C	cg03605463	chr16:89740564	NA	0.59	7.63	0.42	4.24e-13	Vitiligo;
CESC	cis	rs6963495	0.818	rs73192124	chr7:105171528	C/T	cg13798780	chr7:105162888	PUS7	0.77	7.87	0.44	9.18e-14	Bipolar disorder (body mass index interaction);
CESC	cis	rs1215050	0.669	rs783962	chr4:98884473	G/A	cg05340658	chr4:99064831	C4orf37	-0.45	-5.77	-0.33	2.19e-8	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs897984	0.806	rs1046276	chr16:30914626	A/G	cg02466173	chr16:30829666	NA	0.49	7.82	0.43	1.24e-13	Dementia with Lewy bodies;
CESC	cis	rs7599312	0.534	rs7355673	chr2:213404389	T/C	cg16329650	chr2:213403929	ERBB4	0.58	8.43	0.46	2.31e-15	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs909674	0.541	rs5750816	chr22:39810379	A/G	cg05872129	chr22:39784769	NA	0.82	11.4	0.57	9.25e-25	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs9486715	1.000	rs6902835	chr6:97063005	C/G	cg06623918	chr6:96969491	KIAA0776	-0.88	-13.13	-0.63	1.18e-30	Headache;
CESC	cis	rs643506	1.000	rs643506	chr11:111636627	T/G	cg09085632	chr11:111637200	PPP2R1B	0.53	6.83	0.39	5.7e-11	Breast cancer;
CESC	cis	rs5417	0.689	rs55868524	chr17:7170665	G/A	cg25256661	chr17:7137939	DVL2	-0.55	-7.3	-0.41	3.41e-12	Diastolic blood pressure;
CESC	cis	rs6460942	1.000	rs17668923	chr7:12302873	A/T	cg06484146	chr7:12443880	VWDE	-0.61	-6.96	-0.39	2.6e-11	Coronary artery disease;
CESC	cis	rs2354432	0.556	rs66501488	chr1:146853992	T/C	cg25205988	chr1:146714368	CHD1L	-1.03	-8.43	-0.46	2.28e-15	Mitochondrial DNA levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09305948	chr7:5254072	WIPI2	-0.53	-6.11	-0.35	3.47e-9	Gut microbiome composition (summer);
CESC	cis	rs2635047	0.542	rs2668768	chr18:44783447	A/T	cg24371990	chr18:44770781	NA	0.35	5.72	0.33	2.84e-8	Educational attainment;
CESC	cis	rs2463822	0.669	rs72919493	chr11:62049651	C/A	cg06239285	chr11:62104954	ASRGL1	-1.12	-8.86	-0.48	1.15e-16	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs559928	0.606	rs12419038	chr11:63912736	A/G	cg05555928	chr11:63887634	MACROD1	-0.5	-5.34	-0.31	1.98e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CESC	cis	rs9916302	0.904	rs6503506	chr17:37524653	C/A	cg07936489	chr17:37558343	FBXL20	0.79	11.58	0.58	2.25e-25	Glomerular filtration rate (creatinine);
CESC	cis	rs72781680	0.611	rs72797824	chr2:24356456	T/G	cg20701182	chr2:24300061	SF3B14	0.92	10.54	0.54	6.23e-22	Lymphocyte counts;
CESC	cis	rs863345	0.604	rs1342946	chr1:158453187	C/T	cg12129480	chr1:158549410	OR10X1	-0.36	-7.13	-0.4	9.28e-12	Pneumococcal bacteremia;
CESC	cis	rs12479064	0.703	rs28382977	chr2:100018304	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.58	-7.06	-0.4	1.42e-11	Chronic sinus infection;
CESC	cis	rs6963495	0.818	rs117845382	chr7:105152040	T/C	cg13798780	chr7:105162888	PUS7	0.76	7.77	0.43	1.79e-13	Bipolar disorder (body mass index interaction);
CESC	cis	rs4950322	0.570	rs72692917	chr1:146776087	A/T	cg16700924	chr1:146552102	NA	-0.41	-5.1	-0.3	6.37e-7	Protein quantitative trait loci;
CESC	cis	rs7254114	0.686	rs7249565	chr19:11302807	C/T	cg02815516	chr19:11306319	KANK2	-0.4	-6.67	-0.38	1.52e-10	Immature fraction of reticulocytes;
CESC	cis	rs1434579	0.572	rs926052	chr19:44952236	A/T	cg15540054	chr19:45004280	ZNF180	0.5	6.2	0.36	2.11e-9	Tuberculosis;
CESC	cis	rs2439831	0.850	rs3742982	chr15:44176681	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.57	5.13	0.3	5.52e-7	Lung cancer in ever smokers;
CESC	cis	rs3749237	0.595	rs3870337	chr3:49557095	G/T	cg03060546	chr3:49711283	APEH	0.76	11.77	0.59	5.42e-26	Resting heart rate;
CESC	cis	rs6424115	0.830	rs2502995	chr1:24199290	T/C	cg10978503	chr1:24200527	CNR2	0.33	6.63	0.38	1.85e-10	Immature fraction of reticulocytes;
CESC	cis	rs727505	0.954	rs28638102	chr7:124499480	A/C	cg23710748	chr7:124431027	NA	-0.48	-7.52	-0.42	8.73e-13	Lewy body disease;
CESC	cis	rs55871839	0.684	rs4738729	chr8:59808617	T/C	cg07426533	chr8:59803705	TOX	-0.44	-6.41	-0.37	6.57e-10	Pneumonia;
CESC	cis	rs71403859	0.730	rs35390364	chr16:71740049	A/G	cg08717414	chr16:71523259	ZNF19	-0.68	-5.42	-0.32	1.37e-7	Post bronchodilator FEV1;
CESC	cis	rs9911578	1.000	rs12453049	chr17:56611372	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.39	-5.16	-0.3	4.83e-7	Intelligence (multi-trait analysis);
CESC	cis	rs6502050	0.835	rs4247357	chr17:80166989	G/T	cg23985595	chr17:80112537	CCDC57	-0.39	-6.24	-0.36	1.76e-9	Life satisfaction;
CESC	cis	rs4819052	0.819	rs8134084	chr21:46693295	G/A	cg11663144	chr21:46675770	NA	-0.62	-9.82	-0.52	1.27e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs4665809	0.590	rs1049987	chr2:26413817	C/T	cg08470875	chr2:26401718	FAM59B	0.74	7.87	0.44	9.35e-14	Gut microbiome composition (summer);
CESC	cis	rs1030877	1.000	rs2576743	chr2:105901337	C/T	cg02079111	chr2:105885981	TGFBRAP1	0.67	10.23	0.53	6.49e-21	Obesity-related traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23203755	chr3:149182974	NA	-0.61	-7.32	-0.41	3e-12	Gut microbiome composition (summer);
CESC	cis	rs7949030	0.588	rs2428549	chr11:62312394	A/G	cg23462726	chr11:62437636	C11orf83;C11orf48	-0.39	-5.33	-0.31	2.12e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs2070488	0.574	rs57754356	chr3:38488706	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.79	12.46	0.61	2.36e-28	Electrocardiographic conduction measures;
CESC	cis	rs9560113	0.580	rs9560116	chr13:112193731	G/A	cg10483660	chr13:112241077	NA	0.4	6.56	0.37	2.74e-10	Menarche (age at onset);
CESC	cis	rs863345	0.967	rs4411130	chr1:158530665	C/T	cg12129480	chr1:158549410	OR10X1	0.35	7.22	0.41	5.45e-12	Pneumococcal bacteremia;
CESC	cis	rs875971	0.508	rs6947808	chr7:66045082	A/G	cg18876405	chr7:65276391	NA	-0.54	-7.59	-0.42	5.49e-13	Aortic root size;
CESC	cis	rs698813	0.703	rs2053457	chr2:44572164	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.53	6.19	0.36	2.28e-9	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
CESC	cis	rs2288912	0.872	rs9304646	chr19:45450408	T/C	cg09555818	chr19:45449301	APOC2	0.43	6.72	0.38	1.08e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs2412488	0.815	rs6843529	chr4:54355854	T/C	cg22241045	chr4:54363911	LNX1	-0.38	-5.32	-0.31	2.19e-7	DNA methylation (variation);
CESC	cis	rs1941023	0.584	rs2197236	chr11:60168859	T/C	cg08716584	chr11:60157161	MS4A7	-0.55	-9.03	-0.48	3.7e-17	Congenital heart disease (maternal effect);
CESC	cis	rs4665809	0.878	rs892448	chr2:26366205	A/G	cg26314531	chr2:26401878	FAM59B	-0.64	-7.3	-0.41	3.29e-12	Gut microbiome composition (summer);
CESC	cis	rs727505	0.721	rs56069273	chr7:124768604	G/A	cg23710748	chr7:124431027	NA	-0.34	-5.71	-0.33	3.05e-8	Lewy body disease;
CESC	cis	rs763121	0.853	rs3747174	chr22:39069181	T/C	cg06022373	chr22:39101656	GTPBP1	0.89	14.42	0.66	3.47e-35	Menopause (age at onset);
CESC	cis	rs4660261	0.561	rs11210934	chr1:44369435	G/A	cg23954153	chr1:44402353	ARTN	-0.35	-5.58	-0.32	6.05e-8	Intelligence (multi-trait analysis);
CESC	cis	rs360798	0.532	rs12994674	chr2:62996645	G/A	cg17519650	chr2:63277830	OTX1	-0.58	-7.33	-0.41	2.76e-12	Coronary artery disease;
CESC	cis	rs10504229	0.861	rs6990617	chr8:58182960	G/T	cg14926445	chr8:58193284	C8orf71	-0.51	-5.52	-0.32	8.28e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs5747327	0.771	rs5746453	chr22:18137274	C/T	cg19898043	chr22:18121309	BCL2L13	-0.4	-5.09	-0.3	6.74e-7	Myeloid white cell count;Granulocyte count;
CESC	cis	rs2115536	0.720	rs12916091	chr15:80222572	T/G	cg11839771	chr15:80205821	ST20	-0.35	-5.14	-0.3	5.45e-7	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CESC	cis	rs34779708	0.736	rs34195979	chr10:35549817	T/C	cg03585969	chr10:35415529	CREM	0.54	6.14	0.35	2.97e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs2243480	0.803	rs36004293	chr7:65416512	T/C	cg25894440	chr7:65020034	NA	-0.59	-5.23	-0.31	3.41e-7	Diabetic kidney disease;
CESC	cis	rs6952808	0.531	rs4721441	chr7:2184060	A/G	cg08027265	chr7:2291960	NA	-0.43	-6.82	-0.39	6.08e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs7607369	0.719	rs12613545	chr2:219623504	C/T	cg02176678	chr2:219576539	TTLL4	-0.44	-7.68	-0.43	3.02e-13	Red blood cell count;Amyotrophic lateral sclerosis;
CESC	cis	rs6032067	0.929	rs876835	chr20:43827241	T/C	cg11264863	chr20:43835661	SEMG1	0.48	5.29	0.31	2.53e-7	Blood protein levels;
CESC	cis	rs9486719	0.894	rs34826652	chr6:96899085	A/G	cg18709589	chr6:96969512	KIAA0776	-0.54	-5.87	-0.34	1.3e-8	Migraine;Coronary artery disease;
CESC	cis	rs12497850	0.644	rs11928552	chr3:48739883	T/C	cg03060546	chr3:49711283	APEH	0.44	5.22	0.31	3.54e-7	Parkinson's disease;
CESC	cis	rs7927771	0.965	rs4752845	chr11:47539697	T/C	cg05585544	chr11:47624801	NA	-0.53	-8.07	-0.44	2.41e-14	Subjective well-being;
CESC	cis	rs7223966	1.000	rs2854223	chr17:61939014	A/G	cg11494091	chr17:61959527	GH2	0.39	5.53	0.32	7.54e-8	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs875971	0.895	rs12531677	chr7:65769086	G/A	cg18252515	chr7:66147081	NA	0.43	5.73	0.33	2.76e-8	Aortic root size;
CESC	cis	rs1005277	0.505	rs13503	chr10:38239843	C/A	cg00409905	chr10:38381863	ZNF37A	0.57	8.02	0.44	3.33e-14	Extrinsic epigenetic age acceleration;
CESC	cis	rs636291	0.517	rs55935829	chr1:10540926	A/T	cg07384165	chr1:10488281	NA	-0.59	-8.64	-0.47	5.48e-16	Prostate cancer;
CESC	cis	rs9790314	1.000	rs336570	chr3:161072054	A/G	cg03342759	chr3:160939853	NMD3	0.53	7.01	0.4	1.97e-11	Morning vs. evening chronotype;
CESC	cis	rs2299587	0.500	rs7815785	chr8:17730338	T/C	cg08627089	chr8:17753878	FGL1	-0.39	-5.53	-0.32	7.86e-8	Economic and political preferences;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19238398	chr5:138775248	DNAJC18	0.61	7.4	0.41	1.79e-12	Gut microbiome composition (summer);
CESC	cis	rs9291683	0.588	rs6844329	chr4:10018544	T/C	cg02734326	chr4:10020555	SLC2A9	0.52	7.43	0.42	1.51e-12	Bone mineral density;
CESC	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg27532560	chr4:187881888	NA	-0.39	-6.0	-0.35	6.42e-9	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6732160	1.000	rs6732160	chr2:73387228	A/G	cg01422370	chr2:73384389	NA	0.5	8.63	0.47	5.72e-16	Intelligence (multi-trait analysis);
CESC	cis	rs9611565	0.694	rs5758368	chr22:41862288	C/T	cg06481639	chr22:41940642	POLR3H	-0.58	-6.4	-0.37	6.86e-10	Vitiligo;
CESC	cis	rs6964587	0.621	rs38799	chr7:92045139	C/T	cg17063962	chr7:91808500	NA	-0.53	-7.72	-0.43	2.34e-13	Breast cancer;
CESC	cis	rs2860975	0.580	rs11572120	chr10:96815303	A/C	cg09036531	chr10:96991505	NA	-0.37	-5.29	-0.31	2.56e-7	Immune response to smallpox vaccine (IL-6);
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg06488097	chr7:17921523	SNX13	0.39	6.5	0.37	3.9e-10	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs8067545	0.586	rs2526463	chr17:20078297	G/A	cg13482628	chr17:19912719	NA	-0.44	-5.83	-0.34	1.58e-8	Schizophrenia;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg06565220	chr1:112938731	CTTNBP2NL	0.5	6.28	0.36	1.4e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs4555082	0.834	rs2735817	chr14:105717796	A/G	cg06808227	chr14:105710500	BRF1	0.53	6.06	0.35	4.62e-9	Mean platelet volume;Platelet distribution width;
CESC	cis	rs3820928	0.839	rs13413292	chr2:227893747	G/C	cg05526886	chr2:227700861	RHBDD1	-0.45	-5.73	-0.33	2.68e-8	Pulmonary function;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20594519	chr1:145611013	POLR3C;RNF115	0.53	6.26	0.36	1.53e-9	Gut microbiome composition (summer);
CESC	cis	rs1218582	0.804	rs4845398	chr1:154859038	G/C	cg24250549	chr1:154909240	PMVK	0.72	10.85	0.55	6.34e-23	Prostate cancer;
CESC	cis	rs875971	0.619	rs2302918	chr7:66000932	A/G	cg25985355	chr7:65971099	NA	-0.31	-5.04	-0.3	8.76e-7	Aortic root size;
CESC	cis	rs7666738	0.791	rs13149968	chr4:99070262	G/T	cg18180107	chr4:99064573	C4orf37	0.4	5.03	0.3	9.17e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11098499	0.644	rs3806808	chr4:120551085	A/C	cg25214090	chr10:38739885	LOC399744	0.62	8.74	0.47	2.74e-16	Corneal astigmatism;
CESC	cis	rs9399135	0.967	rs4896119	chr6:135293391	C/T	cg24558204	chr6:135376177	HBS1L	0.51	6.77	0.38	8.17e-11	Red blood cell count;
CESC	cis	rs6456156	0.565	rs6456153	chr6:167472167	T/C	cg07741184	chr6:167504864	NA	0.36	6.21	0.36	2.01e-9	Primary biliary cholangitis;
CESC	cis	rs854765	0.547	rs9912096	chr17:17896673	A/C	cg04398451	chr17:18023971	MYO15A	-0.71	-10.4	-0.54	1.75e-21	Total body bone mineral density;
CESC	cis	rs926938	0.521	rs360649	chr1:115439668	G/C	cg12756093	chr1:115239321	AMPD1	0.45	6.13	0.35	3.25e-9	Autism;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg02760766	chr15:72668543	HEXA;C15orf34	-0.51	-6.05	-0.35	4.89e-9	Ulcerative colitis;
CESC	cis	rs5750830	0.595	rs4821892	chr22:39795683	G/C	cg02038168	chr22:39784481	NA	-0.61	-7.67	-0.43	3.23e-13	Intelligence (multi-trait analysis);
CESC	cis	rs6088590	0.582	rs6059909	chr20:33139691	C/A	cg24642439	chr20:33292090	TP53INP2	0.61	8.08	0.44	2.27e-14	Coronary artery disease;
CESC	cis	rs6032067	0.636	rs6104093	chr20:43908297	T/C	cg10761708	chr20:43804764	PI3	0.43	5.52	0.32	8.23e-8	Blood protein levels;
CESC	cis	rs1023500	0.573	rs133381	chr22:42470608	C/G	cg04733989	chr22:42467013	NAGA	0.82	12.06	0.6	5.34e-27	Schizophrenia;
CESC	cis	rs7089973	0.604	rs7923693	chr10:116619566	A/G	cg25233709	chr10:116636983	FAM160B1	0.4	6.61	0.38	2.08e-10	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs67311347	1.000	rs112619360	chr3:40432645	T/G	cg24209194	chr3:40518798	ZNF619	0.52	6.78	0.38	7.89e-11	Renal cell carcinoma;
CESC	cis	rs6424115	1.000	rs7514394	chr1:24100223	A/G	cg10978503	chr1:24200527	CNR2	-0.25	-5.03	-0.3	9.15e-7	Immature fraction of reticulocytes;
CESC	cis	rs7666738	0.830	rs13149404	chr4:99070236	A/G	cg17366294	chr4:99064904	C4orf37	0.61	8.5	0.46	1.36e-15	Colonoscopy-negative controls vs population controls;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg06514377	chr2:3320918	TSSC1	0.48	6.24	0.36	1.68e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs7824557	0.507	rs7010590	chr8:11062882	C/T	cg06636001	chr8:8085503	FLJ10661	0.57	7.47	0.42	1.18e-12	Retinal vascular caliber;
CESC	cis	rs7100689	0.577	rs2342813	chr10:82046302	T/G	cg00277334	chr10:82204260	NA	-0.53	-6.96	-0.39	2.64e-11	Post bronchodilator FEV1;
CESC	cis	rs10504229	0.906	rs66480865	chr8:58187100	C/T	cg14926445	chr8:58193284	C8orf71	-0.51	-5.52	-0.32	8.28e-8	Developmental language disorder (linguistic errors);
CESC	trans	rs66573146	1.000	rs7686168	chr4:6986057	C/A	cg07817883	chr1:32538562	TMEM39B	1.48	9.1	0.49	2.16e-17	Granulocyte percentage of myeloid white cells;
CESC	cis	rs1448094	0.511	rs17279261	chr12:86162714	C/T	cg06740227	chr12:86229804	RASSF9	0.37	5.05	0.3	8.19e-7	Major depressive disorder;
CESC	cis	rs757110	0.900	rs2074314	chr11:17411821	C/T	cg15432903	chr11:17409602	KCNJ11	0.67	9.5	0.5	1.32e-18	Type 2 diabetes;
CESC	cis	rs7927771	0.524	rs11039329	chr11:47684908	A/G	cg20307385	chr11:47447363	PSMC3	0.63	8.77	0.47	2.21e-16	Subjective well-being;
CESC	cis	rs7666738	0.680	rs11097613	chr4:99079991	G/T	cg05340658	chr4:99064831	C4orf37	0.75	10.87	0.56	5.36e-23	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3816788	0.774	rs11784816	chr8:21773500	C/T	cg17168535	chr8:21777572	XPO7	-0.65	-9.9	-0.52	7.47e-20	Lung cancer in ever smokers;
CESC	cis	rs9914988	0.943	rs2043031	chr17:27085564	A/G	cg20469991	chr17:27169893	C17orf63	-0.48	-5.29	-0.31	2.56e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CESC	cis	rs561341	0.941	rs2470236	chr17:30304940	G/C	cg00745463	chr17:30367425	LRRC37B	-0.66	-6.7	-0.38	1.25e-10	Hip circumference adjusted for BMI;
CESC	trans	rs526821	0.595	rs532278	chr11:55344983	A/G	cg15704280	chr7:45808275	SEPT13	-0.53	-6.57	-0.37	2.61e-10	Pediatric bone mineral density (spine);
CESC	cis	rs9611565	0.512	rs5758465	chr22:42175314	T/C	cg03806693	chr22:41940476	POLR3H	1.17	13.6	0.64	2.7e-32	Vitiligo;
CESC	cis	rs2836950	0.565	rs2836943	chr21:40592611	C/T	cg11890956	chr21:40555474	PSMG1	-0.62	-8.57	-0.47	8.5e-16	Menarche (age at onset);
CESC	cis	rs7296418	0.663	rs11057276	chr12:123820397	C/T	cg00376283	chr12:123451042	ABCB9	-0.55	-7.67	-0.43	3.2e-13	Platelet count;
CESC	cis	rs7191439	0.626	rs8059794	chr16:88787388	C/T	cg02389323	chr16:88786976	FAM38A	0.85	7.33	0.41	2.87e-12	Plateletcrit;
CESC	trans	rs11098499	1.000	rs10029750	chr4:120172543	A/G	cg25214090	chr10:38739885	LOC399744	0.64	8.53	0.46	1.16e-15	Corneal astigmatism;
CESC	trans	rs1545843	0.538	rs10779090	chr12:84759829	A/G	cg03015433	chr16:56623111	MT3	0.34	6.17	0.35	2.48e-9	Major depressive disorder;
CESC	cis	rs926938	0.563	rs360661	chr1:115455280	G/A	cg12756093	chr1:115239321	AMPD1	0.48	6.97	0.39	2.58e-11	Autism;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg13883984	chr15:83621779	HOMER2	0.45	6.33	0.36	1.04e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs6496667	0.533	rs2589949	chr15:90955015	C/T	cg10434728	chr15:90938212	IQGAP1	0.31	5.49	0.32	9.53e-8	Rheumatoid arthritis;
CESC	cis	rs61931739	0.500	rs10844846	chr12:34394611	C/G	cg23762105	chr12:34175262	ALG10	-0.39	-5.14	-0.3	5.26e-7	Morning vs. evening chronotype;
CESC	cis	rs5770917	0.522	rs8142477	chr22:51011376	G/C	cg25309564	chr22:51001381	C22orf41	0.55	6.15	0.35	2.79e-9	Narcolepsy;
CESC	cis	rs7605827	0.897	rs7572509	chr2:15597288	C/T	cg19274914	chr2:15703543	NA	0.32	5.6	0.33	5.41e-8	Educational attainment (years of education);
CESC	cis	rs1461503	0.966	rs1461502	chr11:122844927	C/G	cg27398637	chr11:122830231	C11orf63	-0.55	-8.32	-0.45	4.77e-15	Menarche (age at onset);
CESC	cis	rs7666738	0.830	rs13136930	chr4:98937933	A/T	cg17366294	chr4:99064904	C4orf37	0.61	8.56	0.47	9.36e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11601602	0.576	rs12576396	chr11:28555952	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.6	7.48	0.42	1.06e-12	Obesity-related traits;
CESC	cis	rs9660992	0.762	rs1172137	chr1:205246061	G/T	cg21643547	chr1:205240462	TMCC2	-0.47	-7.39	-0.41	1.96e-12	Mean corpuscular volume;Mean platelet volume;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg23731836	chr8:29120779	KIF13B	-0.53	-7.29	-0.41	3.65e-12	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	trans	rs853679	0.769	rs7752608	chr6:28301195	A/G	cg06606381	chr12:133084897	FBRSL1	-0.73	-6.67	-0.38	1.52e-10	Depression;
CESC	cis	rs11098499	0.909	rs28632018	chr4:120386730	T/C	cg09307838	chr4:120376055	NA	0.95	13.96	0.65	1.42e-33	Corneal astigmatism;
CESC	cis	rs2735413	0.958	rs11150034	chr16:78066369	G/A	cg04733911	chr16:78082701	NA	-0.49	-7.7	-0.43	2.75e-13	Systolic blood pressure (alcohol consumption interaction);
CESC	cis	rs7412746	0.658	rs6669855	chr1:150861229	C/T	cg22823121	chr1:150693482	HORMAD1	0.4	5.53	0.32	7.83e-8	Melanoma;
CESC	cis	rs1215050	0.791	rs11729826	chr4:98657190	G/T	cg05340658	chr4:99064831	C4orf37	-0.47	-6.04	-0.35	5.08e-9	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs1707322	0.927	rs11211194	chr1:46282084	C/T	cg05343316	chr1:45956843	TESK2	0.44	5.53	0.32	7.85e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs11122272	0.735	rs2491407	chr1:231518928	G/A	cg06096015	chr1:231504339	EGLN1	0.43	6.18	0.35	2.46e-9	Hemoglobin concentration;
CESC	cis	rs8114671	0.836	rs6142280	chr20:33622242	A/C	cg06115741	chr20:33292138	TP53INP2	-0.46	-5.57	-0.32	6.36e-8	Height;
CESC	cis	rs1878931	0.517	rs17685105	chr16:3413749	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.91	-13.09	-0.63	1.54e-30	Body mass index (adult);
CESC	cis	rs1559088	0.948	rs12460195	chr19:33584479	G/A	cg27124370	chr19:33622961	WDR88	0.45	6.0	0.35	6.49e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs17539620	0.624	rs111484697	chr6:154838903	A/G	cg20019720	chr6:154832845	CNKSR3	0.45	5.61	0.33	5.2100000000000003e-08	Lipoprotein (a) levels;
CESC	cis	rs3015497	0.603	rs1060197	chr14:51057727	A/G	cg26011998	chr14:51135199	SAV1	0.45	5.22	0.31	3.6e-7	Mean platelet volume;
CESC	cis	rs3785574	0.927	rs2727313	chr17:61961914	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.58	7.12	0.4	1.04e-11	Height;
CESC	cis	rs11871801	0.517	rs668799	chr17:40716235	C/T	cg14558262	chr17:40713999	COASY	0.5	5.84	0.34	1.53e-8	Crohn's disease;
CESC	cis	rs617791	0.530	rs7934543	chr11:65752508	G/T	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.43	-5.06	-0.3	8e-7	Breast cancer;
CESC	cis	rs2963155	0.518	rs9324918	chr5:142767160	T/C	cg17617527	chr5:142782415	NR3C1	0.82	7.43	0.42	1.48e-12	Breast cancer;
CESC	cis	rs6693567	0.565	rs834243	chr1:150339290	C/A	cg09579323	chr1:150459698	TARS2	0.46	6.05	0.35	4.93e-9	Migraine;
CESC	cis	rs7296418	0.630	rs11608305	chr12:123791165	C/G	cg00376283	chr12:123451042	ABCB9	0.59	8.18	0.45	1.19e-14	Platelet count;
CESC	cis	rs35160687	0.644	rs2113615	chr2:86517602	G/A	cg01119172	chr2:86362222	SNORD94;PTCD3	-0.38	-5.1	-0.3	6.57e-7	Night sleep phenotypes;
CESC	cis	rs2302190	0.882	rs6503869	chr17:56637461	C/G	cg25885038	chr17:56607967	SEPT4	-0.4	-5.43	-0.32	1.27e-7	Vitamin D levels;
CESC	cis	rs10911232	0.507	rs6660111	chr1:183014289	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.86	13.22	0.63	5.29e-31	Hypertriglyceridemia;
CESC	cis	rs1862618	0.671	rs2591968	chr5:56233541	A/G	cg22800045	chr5:56110881	MAP3K1	0.59	7.78	0.43	1.58e-13	Initial pursuit acceleration;
CESC	cis	rs853679	0.517	rs4713144	chr6:28106790	C/G	cg20151795	chr6:28129481	ZNF389	0.45	5.92	0.34	9.77e-9	Depression;
CESC	cis	rs9733	0.791	rs11800059	chr1:150651175	C/T	cg04414720	chr1:150670196	GOLPH3L	-0.37	-5.19	-0.3	4.14e-7	Tonsillectomy;
CESC	cis	rs6570726	0.846	rs397311	chr6:145806701	C/T	cg05347473	chr6:146136440	FBXO30	-0.49	-6.5	-0.37	3.9e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs5769707	0.609	rs135861	chr22:49998118	A/G	cg20744362	chr22:50050164	C22orf34	0.37	5.44	0.32	1.18e-7	Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs9925964	0.933	rs9939417	chr16:31053467	C/T	cg02466173	chr16:30829666	NA	0.34	5.24	0.31	3.3e-7	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs7246657	0.943	rs10407084	chr19:37907792	T/C	cg23950597	chr19:37808831	NA	-0.61	-6.23	-0.36	1.81e-9	Coronary artery calcification;
CESC	cis	rs780096	0.565	rs8179252	chr2:27746832	A/C	cg21248554	chr2:27665150	KRTCAP3	-0.35	-7.12	-0.4	1.05e-11	Total body bone mineral density;
CESC	cis	rs4665809	0.590	rs2289019	chr2:26420809	G/C	cg04944784	chr2:26401820	FAM59B	-0.93	-10.74	-0.55	1.38e-22	Gut microbiome composition (summer);
CESC	cis	rs62458065	0.513	rs702831	chr7:32579715	C/T	cg20159608	chr7:32802032	NA	-0.55	-6.15	-0.35	2.89e-9	Metabolite levels (HVA/MHPG ratio);
CESC	cis	rs8027181	1.000	rs2162269	chr15:73090262	C/T	cg25632853	chr15:73088954	NA	0.36	6.45	0.37	5.23e-10	Triglyceride levels;
CESC	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.89	13.57	0.64	3.26e-32	Prudent dietary pattern;
CESC	trans	rs1814175	0.791	rs7395713	chr11:49877887	A/G	cg03929089	chr4:120376271	NA	-0.91	-15.43	-0.69	9.49e-39	Height;
CESC	cis	rs1595825	0.891	rs77946222	chr2:198533251	C/T	cg00982548	chr2:198649783	BOLL	-0.48	-5.14	-0.3	5.44e-7	Ulcerative colitis;
CESC	cis	rs561341	1.000	rs111454793	chr17:30319267	T/C	cg19193384	chr17:30244184	NA	-0.69	-6.51	-0.37	3.73e-10	Hip circumference adjusted for BMI;
CESC	cis	rs1707322	0.717	rs2991989	chr1:46082965	C/T	cg05343316	chr1:45956843	TESK2	-0.53	-6.5	-0.37	3.98e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs28374715	0.532	rs11070328	chr15:41651569	T/C	cg18705301	chr15:41695430	NDUFAF1	-1.04	-16.61	-0.71	6.09e-43	Ulcerative colitis;
CESC	cis	rs6964587	0.626	rs10266424	chr7:91503228	C/T	cg17063962	chr7:91808500	NA	-0.46	-6.39	-0.37	7.32e-10	Breast cancer;
CESC	cis	rs829883	0.659	rs10860342	chr12:98941223	C/T	cg25150519	chr12:98850993	NA	0.63	7.37	0.41	2.11e-12	Colorectal adenoma (advanced);
CESC	cis	rs2749592	0.550	rs10764135	chr10:37866845	C/T	cg25427524	chr10:38739819	LOC399744	0.55	7.63	0.42	4.22e-13	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs13108904	0.560	rs11247994	chr4:1343720	G/A	cg00684032	chr4:1343700	KIAA1530	0.61	9.14	0.49	1.66e-17	Obesity-related traits;
CESC	cis	rs1707322	0.716	rs28375469	chr1:46195375	T/C	cg03146154	chr1:46216737	IPP	0.82	11.53	0.58	3.39e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs793571	0.544	rs11638244	chr15:58907151	A/T	cg05156742	chr15:59063176	FAM63B	0.81	11.73	0.58	7.22e-26	Schizophrenia;
CESC	cis	rs6866344	0.697	rs62392823	chr5:178126968	T/C	cg03877680	chr5:178157825	ZNF354A	0.75	8.48	0.46	1.59e-15	Neutrophil percentage of white cells;
CESC	cis	rs1552244	0.882	rs68153882	chr3:10013110	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.85	10.98	0.56	2.23e-23	Alzheimer's disease;
CESC	cis	rs9649213	0.593	rs6949214	chr7:97960233	G/A	cg24562669	chr7:97807699	LMTK2	0.51	7.57	0.42	6.13e-13	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs965513	1.000	rs7847663	chr9:100544868	C/T	cg13688889	chr9:100608707	NA	-0.61	-8.54	-0.46	1.06e-15	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
CESC	cis	rs5769765	0.955	rs9616368	chr22:50303533	C/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.54	-5.73	-0.33	2.72e-8	Schizophrenia;
CESC	cis	rs10489525	0.599	rs34710929	chr1:115606608	G/A	cg01522456	chr1:115632236	TSPAN2	0.48	5.82	0.34	1.7e-8	Autism;
CESC	cis	rs6866344	0.697	rs11739893	chr5:178127837	G/A	cg10224037	chr5:178157518	ZNF354A	0.68	7.46	0.42	1.24e-12	Neutrophil percentage of white cells;
CESC	cis	rs7160336	0.515	rs7152352	chr14:74611271	A/G	cg05179529	chr14:74551516	LIN52;ALDH6A1	-0.43	-5.26	-0.31	2.93e-7	Blood protein levels;
CESC	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg06873352	chr17:61820015	STRADA	0.72	12.67	0.61	4.43e-29	Prudent dietary pattern;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19069963	chr22:29663643	EWSR1;RHBDD3	0.64	7.46	0.42	1.25e-12	Gut microbiome composition (summer);
CESC	cis	rs514406	0.861	rs562182	chr1:53270010	C/T	cg08736216	chr1:53307985	ZYG11A	-0.42	-7.06	-0.4	1.46e-11	Monocyte count;
CESC	cis	rs9581857	0.579	rs3759434	chr13:27997700	A/C	cg22138327	chr13:27999177	GTF3A	0.73	7.68	0.43	3.08e-13	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
CESC	cis	rs2228479	0.850	rs62054601	chr16:89811751	C/G	cg00800038	chr16:89945340	TCF25	-0.88	-7.27	-0.41	4e-12	Skin colour saturation;
CESC	cis	rs7618501	0.633	rs2856234	chr3:50139142	A/G	cg24110177	chr3:50126178	RBM5	0.52	7.29	0.41	3.61e-12	Intelligence (multi-trait analysis);
CESC	cis	rs17253792	0.822	rs10150498	chr14:56064124	G/T	cg01858014	chr14:56050164	KTN1	-0.85	-6.79	-0.38	7.45e-11	Putamen volume;
CESC	cis	rs11209002	0.524	rs2815386	chr1:67541996	A/G	cg02640540	chr1:67518911	SLC35D1	0.47	5.39	0.31	1.52e-7	Crohn's disease;
CESC	cis	rs7917772	0.582	rs4917973	chr10:104333700	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.41	5.61	0.33	5.05e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	trans	rs10065369	0.544	rs4476711	chr5:113554595	G/A	cg04850370	chr1:32573395	KPNA6	0.71	6.15	0.35	2.85e-9	Night sleep phenotypes;
CESC	cis	rs7656342	0.636	rs1914874	chr4:9839490	C/A	cg11266682	chr4:10021025	SLC2A9	-0.34	-5.17	-0.3	4.7e-7	Gut microbiota (bacterial taxa);
CESC	cis	rs72781680	1.000	rs72781653	chr2:24215633	T/C	cg08917208	chr2:24149416	ATAD2B	0.94	8.45	0.46	1.99e-15	Lymphocyte counts;
CESC	cis	rs644799	0.965	rs2508713	chr11:95547927	T/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	9.13	0.49	1.83e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs6728642	0.803	rs11891457	chr2:97632449	G/T	cg26665480	chr2:98280029	ACTR1B	-0.72	-7.76	-0.43	1.9e-13	Bipolar disorder lithium response (continuous) or schizophrenia;
CESC	cis	rs7586879	0.616	rs876186	chr2:25125585	C/T	cg01884057	chr2:25150051	NA	0.36	7.01	0.4	2.02e-11	Body mass index;
CESC	cis	rs2070488	0.965	rs2300668	chr3:38540541	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.89	-16.32	-0.71	6.19e-42	Electrocardiographic conduction measures;
CESC	cis	rs2075671	0.903	rs11983334	chr7:100302434	C/T	cg16850897	chr7:100343110	ZAN	-0.7	-8.84	-0.48	1.38e-16	Other erythrocyte phenotypes;
CESC	cis	rs7829975	0.714	rs6994038	chr8:8660538	C/A	cg15556689	chr8:8085844	FLJ10661	0.49	6.27	0.36	1.49e-9	Mood instability;
CESC	cis	rs10789491	0.767	rs1595898	chr1:47193577	G/A	cg15501359	chr1:47185051	KIAA0494	0.76	7.41	0.41	1.65e-12	Response to hepatitis C treatment;
CESC	cis	rs3733585	0.775	rs13124007	chr4:10043931	G/C	cg02734326	chr4:10020555	SLC2A9	0.45	6.19	0.36	2.29e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	trans	rs7618501	0.902	rs7645061	chr3:49868842	C/T	cg21659725	chr3:3221576	CRBN	0.84	13.68	0.64	1.39e-32	Intelligence (multi-trait analysis);
CESC	cis	rs1185460	0.967	rs1786141	chr11:118938315	C/T	cg23280166	chr11:118938394	VPS11	0.6	8.45	0.46	1.92e-15	Coronary artery disease;
CESC	cis	rs7949030	0.588	rs2509982	chr11:62312318	C/T	cg22862634	chr11:62369728	EML3;MTA2	0.49	6.89	0.39	4.13e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	trans	rs523522	0.923	rs1048830	chr12:120882217	G/T	cg02849695	chr1:159869960	CCDC19	0.35	6.19	0.36	2.24e-9	High light scatter reticulocyte count;
CESC	cis	rs9916302	0.706	rs439537	chr17:37734482	T/C	cg20243544	chr17:37824526	PNMT	0.56	5.47	0.32	1.03e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs62432291	0.681	rs423533	chr6:159664516	G/T	cg14500486	chr6:159655392	FNDC1	-0.57	-5.58	-0.32	5.94e-8	Joint mobility (Beighton score);
CESC	cis	rs3931020	0.530	rs12125889	chr1:75241971	A/G	cg10128416	chr1:75198403	TYW3;CRYZ	0.5	6.84	0.39	5.44e-11	Resistin levels;
CESC	cis	rs1552244	1.000	rs67134728	chr3:10151431	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.89	12.23	0.6	1.42e-27	Alzheimer's disease;
CESC	cis	rs13102973	0.931	rs4608864	chr4:135883488	G/A	cg14419869	chr4:135874104	NA	0.33	5.1	0.3	6.39e-7	Subjective well-being;
CESC	cis	rs60843830	1.000	rs6709534	chr2:217334	G/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.85	11.18	0.57	5.09e-24	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg10295955	chr4:187884368	NA	-1.08	-23.01	-0.82	4.07e-65	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7811142	0.775	rs1059129	chr7:99926522	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.92	10.15	0.53	1.19e-20	Platelet count;
CESC	cis	rs9814567	0.896	rs6763188	chr3:134349995	G/A	cg15484384	chr3:134203672	ANAPC13;CEP63	0.32	5.11	0.3	6.06e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs7843479	0.965	rs1484162	chr8:21831385	A/G	cg17168535	chr8:21777572	XPO7	0.52	7.31	0.41	3.25e-12	Mean corpuscular volume;
CESC	cis	rs7949030	0.626	rs11231145	chr11:62328854	G/A	cg22862634	chr11:62369728	EML3;MTA2	0.6	8.48	0.46	1.55e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs11688816	0.967	rs6714241	chr2:63069112	G/T	cg17519650	chr2:63277830	OTX1	0.42	5.95	0.34	8.43e-9	Body mass index;
CESC	cis	rs854765	0.520	rs9899355	chr17:17898243	C/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.53	7.02	0.4	1.82e-11	Total body bone mineral density;
CESC	cis	rs6541297	0.703	rs598203	chr1:230322122	C/G	cg20703242	chr1:230279135	GALNT2	0.37	5.05	0.3	8.38e-7	Coronary artery disease;
CESC	cis	rs3096299	0.967	rs28689480	chr16:89460093	T/C	cg16743903	chr16:89593216	SPG7	-0.43	-5.4	-0.32	1.45e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs12410462	0.748	rs1495853	chr1:227657336	A/G	cg23173402	chr1:227635558	NA	-0.56	-5.75	-0.33	2.44e-8	Major depressive disorder;
CESC	cis	rs3008870	0.727	rs2862729	chr1:67500828	T/C	cg02640540	chr1:67518911	SLC35D1	0.45	5.43	0.32	1.26e-7	Lymphocyte percentage of white cells;
CESC	cis	rs1552244	0.882	rs68080705	chr3:10025743	C/T	cg08888203	chr3:10149979	C3orf24	0.5	6.25	0.36	1.62e-9	Alzheimer's disease;
CESC	cis	rs654950	1.000	rs679449	chr1:41988634	G/T	cg06885757	chr1:42089581	HIVEP3	-0.56	-8.44	-0.46	2.06e-15	Airway imaging phenotypes;
CESC	cis	rs7666738	0.791	rs11735105	chr4:98937357	C/T	cg05340658	chr4:99064831	C4orf37	0.82	12.54	0.61	1.29e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2294693	0.945	rs9369260	chr6:41010368	C/G	cg14769373	chr6:40998127	UNC5CL	0.48	5.83	0.34	1.63e-8	Gastric cancer;Non-cardia gastric cancer;
CESC	cis	rs2120019	1.000	rs2083731	chr15:75368538	A/C	cg09165964	chr15:75287851	SCAMP5	-0.66	-7.99	-0.44	4.25e-14	Blood trace element (Zn levels);
CESC	cis	rs9916302	0.904	rs35335692	chr17:37710006	A/G	cg07936489	chr17:37558343	FBXL20	-0.79	-11.2	-0.57	4.43e-24	Glomerular filtration rate (creatinine);
CESC	cis	rs6502050	0.835	rs9646397	chr17:80083534	G/A	cg23985595	chr17:80112537	CCDC57	0.42	6.52	0.37	3.56e-10	Life satisfaction;
CESC	trans	rs2764766	0.789	rs151885	chr5:127169836	A/G	cg15764593	chr10:829463	NA	0.4	6.33	0.36	1.06e-9	Schizophrenia;
CESC	cis	rs72634258	0.945	rs397349	chr1:8074872	A/C	cg00042356	chr1:8021962	PARK7	0.45	5.11	0.3	6.21e-7	Inflammatory bowel disease;
CESC	cis	rs2576037	0.796	rs2576034	chr18:44588548	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.62	-8.9	-0.48	8.87e-17	Personality dimensions;
CESC	cis	rs1862618	0.853	rs1833896	chr5:56097669	C/A	cg12311346	chr5:56204834	C5orf35	-0.64	-7.96	-0.44	4.98e-14	Initial pursuit acceleration;
CESC	cis	rs752010	0.543	rs1570355	chr1:42042317	C/T	cg06885757	chr1:42089581	HIVEP3	0.45	7.27	0.41	3.99e-12	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs9902453	0.765	rs3102555	chr17:28044101	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.76	10.3	0.53	3.92e-21	Coffee consumption (cups per day);
CESC	cis	rs881375	0.715	rs10760119	chr9:123646060	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.48	6.99	0.39	2.29e-11	Rheumatoid arthritis;
CESC	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	7.83	0.43	1.17e-13	Prudent dietary pattern;
CESC	cis	rs2997447	0.761	rs17257120	chr1:26450101	A/G	cg24596570	chr1:26146463	FAM54B;LOC646471	0.59	5.16	0.3	4.74e-7	QRS complex (12-leadsum);
CESC	cis	rs798554	0.796	rs2533884	chr7:2836848	T/G	cg04166393	chr7:2884313	GNA12	0.62	7.66	0.43	3.44e-13	Height;
CESC	cis	rs644799	1.000	rs500054	chr11:95593806	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	12.34	0.6	6.1e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs5750830	0.594	rs9611169	chr22:39783027	C/T	cg05872129	chr22:39784769	NA	-0.81	-11.37	-0.57	1.19e-24	Intelligence (multi-trait analysis);
CESC	cis	rs6460942	0.915	rs7802454	chr7:12454508	A/G	cg06484146	chr7:12443880	VWDE	-0.78	-9.14	-0.49	1.68e-17	Coronary artery disease;
CESC	cis	rs10504229	1.000	rs60231757	chr8:58169937	T/C	cg22535103	chr8:58192502	C8orf71	-1.05	-13.27	-0.63	3.63e-31	Developmental language disorder (linguistic errors);
CESC	cis	rs7772486	0.764	rs2265468	chr6:146218346	A/C	cg05347473	chr6:146136440	FBXO30	0.56	7.13	0.4	9.67e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6696846	0.749	rs7515178	chr1:205084120	G/A	cg00857998	chr1:205179979	DSTYK	0.5	6.85	0.39	5.06e-11	Red blood cell count;
CESC	cis	rs9796	0.727	rs12101934	chr15:41353079	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.4	-5.83	-0.34	1.58e-8	Menopause (age at onset);
CESC	trans	rs4689592	0.503	rs11937667	chr4:7057037	C/G	cg07817883	chr1:32538562	TMEM39B	0.67	6.36	0.36	8.92e-10	Monocyte percentage of white cells;
CESC	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg05313129	chr8:58192883	C8orf71	-0.48	-5.27	-0.31	2.89e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs1055129	0.655	rs7223416	chr17:73836162	C/G	cg02397686	chr17:73851076	WBP2	0.35	5.12	0.3	5.96e-7	White matter hyperintensity burden;
CESC	cis	rs7188697	0.922	rs28479997	chr16:58614877	G/A	cg21335942	chr16:58549945	SETD6	-0.45	-5.24	-0.31	3.34e-7	QT interval;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14095983	chr9:71737204	TJP2	0.65	7.66	0.43	3.59e-13	Gut microbiome composition (summer);
CESC	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg07677032	chr17:61819896	STRADA	0.45	6.05	0.35	4.97e-9	Prudent dietary pattern;
CESC	cis	rs7666738	0.830	rs62318472	chr4:98926030	G/A	cg17366294	chr4:99064904	C4orf37	0.58	8.03	0.44	3.26e-14	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7617773	0.963	rs9822496	chr3:48181333	T/C	cg11946769	chr3:48343235	NME6	0.61	8.11	0.45	1.84e-14	Coronary artery disease;
CESC	cis	rs5769765	1.000	rs2319458	chr22:50236306	G/A	cg26441486	chr22:50317300	CRELD2	0.4	5.4	0.31	1.46e-7	Schizophrenia;
CESC	cis	rs11252926	0.563	rs10795103	chr10:451849	C/A	cg03684893	chr10:554711	DIP2C	-0.35	-5.12	-0.3	5.9e-7	Psychosis in Alzheimer's disease;
CESC	cis	rs6570726	0.791	rs408443	chr6:145874643	T/C	cg05347473	chr6:146136440	FBXO30	0.57	7.21	0.4	5.99e-12	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs11039571	0.588	rs10734564	chr11:48160429	A/G	cg15704280	chr7:45808275	SEPT13	-0.64	-6.35	-0.36	9.56e-10	D-dimer levels;
CESC	cis	rs7552404	0.824	rs1251079	chr1:76189445	C/T	cg03433033	chr1:76189801	ACADM	0.8	12.71	0.62	3.18e-29	Blood metabolite levels;Acylcarnitine levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12564526	chr7:66767603	PMS2L4;STAG3L4	0.62	7.54	0.42	7.65e-13	Gut microbiome composition (summer);
CESC	cis	rs8177179	0.904	rs1130459	chr3:133465283	A/G	cg24879335	chr3:133465180	TF	0.44	8.37	0.46	3.38e-15	Iron status biomarkers (transferrin levels);
CESC	cis	rs12188164	1.000	rs55842567	chr5:437586	G/A	cg15813090	chr5:442598	EXOC3;C5orf55	0.41	6.22	0.36	1.89e-9	Cystic fibrosis severity;
CESC	cis	rs7772486	0.790	rs9403749	chr6:146162239	A/G	cg05347473	chr6:146136440	FBXO30	0.56	7.25	0.41	4.62e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9768139	0.708	rs896780	chr7:158113972	C/T	cg25566285	chr7:158114605	PTPRN2	0.54	9.06	0.49	2.99e-17	Calcium levels;
CESC	cis	rs17376456	0.825	rs10051878	chr5:93064164	T/G	cg25358565	chr5:93447407	FAM172A	1.11	10.66	0.55	2.6e-22	Diabetic retinopathy;
CESC	cis	rs7772486	0.790	rs6923545	chr6:146244743	A/G	cg05347473	chr6:146136440	FBXO30	-0.57	-7.31	-0.41	3.07e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs10858047	0.883	rs6701427	chr1:115216886	C/T	cg12756093	chr1:115239321	AMPD1	-0.5	-5.14	-0.3	5.34e-7	Autism;
CESC	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.56	-6.24	-0.36	1.77e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs5758659	1.000	rs5758659	chr22:42622003	C/T	cg04733989	chr22:42467013	NAGA	0.42	5.83	0.34	1.57e-8	Cognitive function;
CESC	trans	rs35110281	0.782	rs1454650	chr21:45012353	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.53	7.08	0.4	1.29e-11	Mean corpuscular volume;
CESC	cis	rs7811142	1.000	rs6975514	chr7:100056220	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.14	11.43	0.57	7.11e-25	Platelet count;
CESC	trans	rs2727020	0.553	rs3907576	chr11:49536639	A/C	cg03929089	chr4:120376271	NA	-0.81	-12.24	-0.6	1.37e-27	Coronary artery disease;
CESC	cis	rs4819052	0.851	rs2838834	chr21:46665208	C/T	cg11663144	chr21:46675770	NA	-0.65	-10.06	-0.53	2.22e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs2839186	0.558	rs2968	chr21:47608580	C/T	cg10351095	chr21:47802916	PCNT	0.42	5.37	0.31	1.74e-7	Testicular germ cell tumor;
CESC	cis	rs7116495	1.000	rs607446	chr11:71789252	G/A	cg10381502	chr11:71823885	C11orf51	-0.68	-5.48	-0.32	9.68e-8	Severe influenza A (H1N1) infection;
CESC	cis	rs72781680	0.611	rs56113233	chr2:24341085	A/C	cg20701182	chr2:24300061	SF3B14	0.93	10.39	0.54	2.03e-21	Lymphocyte counts;
CESC	cis	rs763014	0.931	rs10903017	chr16:627920	T/C	cg09263875	chr16:632152	PIGQ	0.67	11.07	0.56	1.14e-23	Height;
CESC	cis	rs9303401	0.573	rs62081879	chr17:57181524	C/T	cg25039879	chr17:56429692	SUPT4H1	0.5	5.13	0.3	5.66e-7	Cognitive test performance;
CESC	cis	rs10504229	0.815	rs16921955	chr8:58164553	C/T	cg22535103	chr8:58192502	C8orf71	-0.94	-11.93	-0.59	1.55e-26	Developmental language disorder (linguistic errors);
CESC	cis	rs3857536	0.813	rs9354404	chr6:66948408	C/T	cg07460842	chr6:66804631	NA	-0.42	-5.29	-0.31	2.55e-7	Blood trace element (Cu levels);
CESC	cis	rs644799	1.000	rs10831431	chr11:95510089	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	14.67	0.67	4.56e-36	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs60871478	0.898	rs4725241	chr7:796883	C/T	cg27478167	chr7:817139	HEATR2	-0.51	-6.03	-0.35	5.54e-9	Cerebrospinal P-tau181p levels;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg18634782	chr6:136610989	BCLAF1	-0.49	-6.38	-0.36	7.97e-10	Fibrinogen levels;
CESC	cis	rs9549367	0.662	rs3818334	chr13:113825174	C/G	cg18105134	chr13:113819100	PROZ	-0.68	-8.1	-0.45	2.04e-14	Platelet distribution width;
CESC	cis	rs10883723	0.773	rs715439	chr10:104257809	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.54	7.43	0.42	1.49e-12	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs873946	0.564	rs12772704	chr10:134557318	G/A	cg26818010	chr10:134567672	INPP5A	-0.9	-10.88	-0.56	4.78e-23	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs1018836	0.886	rs10112242	chr8:91642631	G/C	cg16814680	chr8:91681699	NA	-0.72	-11.03	-0.56	1.55e-23	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg10424330	chr16:71894309	ZNF821;ATXN1L	0.49	6.22	0.36	1.94e-9	Fibrinogen levels;
CESC	cis	rs6752107	1.000	rs6708373	chr2:234172846	A/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.48	6.71	0.38	1.19e-10	Crohn's disease;Inflammatory bowel disease;
CESC	trans	rs10463316	0.894	rs12153347	chr5:150765471	C/T	cg24389359	chr12:111284228	CCDC63	-0.34	-6.08	-0.35	4.19e-9	Metabolite levels (Pyroglutamine);
CESC	cis	rs8044868	0.586	rs7190994	chr16:72099241	T/A	cg16558253	chr16:72132732	DHX38	-0.41	-6.44	-0.37	5.61e-10	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CESC	cis	rs7772486	0.720	rs7752286	chr6:146072662	C/T	cg23711669	chr6:146136114	FBXO30	-0.96	-14.87	-0.67	8.61e-37	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4819052	0.620	rs421619	chr21:46546115	C/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.54	5.76	0.33	2.34e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs8141529	0.748	rs132531	chr22:29297365	C/T	cg15103426	chr22:29168792	CCDC117	-0.61	-7.9	-0.44	7.26e-14	Lymphocyte counts;
CESC	cis	rs1729951	0.546	rs12054219	chr3:136677472	G/A	cg04103450	chr3:136751342	NA	0.39	5.2	0.3	4.01e-7	Neuroticism;
CESC	cis	rs12681288	0.676	rs2600514	chr8:994175	G/A	cg15309053	chr8:964076	NA	0.41	7.06	0.4	1.44e-11	Schizophrenia;
CESC	cis	rs524023	1.000	rs524023	chr11:64358265	C/T	cg07220939	chr11:64358617	SLC22A12	0.36	5.54	0.32	7.2e-8	Urate levels in obese individuals;
CESC	cis	rs2952156	0.883	rs1495100	chr17:37832279	C/T	cg20243544	chr17:37824526	PNMT	0.63	8.15	0.45	1.48e-14	Asthma;
CESC	cis	rs6912958	0.559	rs242279	chr6:88048191	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.44	7.8	0.43	1.47e-13	Monocyte percentage of white cells;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg03229959	chr8:38089560	DDHD2	0.47	6.19	0.36	2.22e-9	Systemic lupus erythematosus;
CESC	cis	rs9403521	1.000	rs6901659	chr6:143985106	T/C	cg21026257	chr6:143998961	PHACTR2	0.46	5.03	0.3	8.88e-7	Obesity-related traits;
CESC	cis	rs977987	0.835	rs4888380	chr16:75347690	T/C	cg03315344	chr16:75512273	CHST6	0.39	5.59	0.32	5.55e-8	Dupuytren's disease;
CESC	cis	rs9487051	0.676	rs1608042	chr6:109595631	G/A	cg01475377	chr6:109611718	NA	-0.45	-7.04	-0.4	1.6e-11	Reticulocyte fraction of red cells;
CESC	cis	rs2836974	0.653	rs8130556	chr21:40516872	C/T	cg17971929	chr21:40555470	PSMG1	0.98	14.09	0.65	4.83e-34	Cognitive function;
CESC	cis	rs2404602	0.618	rs12442266	chr15:76567142	T/C	cg22467129	chr15:76604101	ETFA	-0.38	-5.8	-0.34	1.89e-8	Blood metabolite levels;
CESC	cis	rs2074038	1.000	rs2074038	chr11:44087989	G/T	cg17479956	chr11:44115929	EXT2	0.81	7.07	0.4	1.34e-11	IgA nephropathy;
CESC	cis	rs875971	0.540	rs736270	chr7:65428822	T/C	cg11764359	chr7:65958608	NA	0.68	8.7	0.47	3.55e-16	Aortic root size;
CESC	cis	rs17253792	0.822	rs10149408	chr14:56046075	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.81	5.95	0.34	8.68e-9	Putamen volume;
CESC	trans	rs11088226	0.681	rs11700670	chr21:33938615	T/C	cg09050820	chr6:167586206	TCP10L2	0.83	7.75	0.43	2.01e-13	Gastritis;
CESC	cis	rs10927875	0.632	rs7535248	chr1:16129598	C/T	cg18973939	chr1:16164122	FLJ37453	0.37	5.58	0.32	6.01e-8	Dilated cardiomyopathy;
CESC	cis	rs1178968	0.901	rs799306	chr7:72801939	C/T	cg25889504	chr7:72793014	NA	0.56	5.32	0.31	2.17e-7	Triglyceride levels;
CESC	cis	rs4662945	0.504	rs35568023	chr2:130251812	A/T	cg05962382	chr2:130345044	NA	-0.46	-6.82	-0.39	6.19e-11	Response to cytidine analogues (gemcitabine);
CESC	cis	rs4727963	0.777	rs4262262	chr7:122701364	A/G	cg03640110	chr7:122635026	TAS2R16	-0.37	-5.7	-0.33	3.11e-8	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
CESC	cis	rs9486719	1.000	rs12208884	chr6:96885572	G/A	cg06623918	chr6:96969491	KIAA0776	-0.81	-8.29	-0.45	5.61e-15	Migraine;Coronary artery disease;
CESC	cis	rs1862618	0.620	rs2591967	chr5:56233551	C/G	cg18230493	chr5:56204884	C5orf35	0.6	8.15	0.45	1.43e-14	Initial pursuit acceleration;
CESC	cis	rs9322193	0.884	rs9688794	chr6:149953257	C/T	cg07701084	chr6:150067640	NUP43	0.43	6.0	0.35	6.52e-9	Lung cancer;
CESC	trans	rs6089829	1.000	rs6089828	chr20:61668998	C/T	cg23505145	chr19:12996616	KLF1	0.54	6.97	0.39	2.49e-11	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs875971	1.000	rs778726	chr7:65828731	C/T	cg11764359	chr7:65958608	NA	0.98	15.78	0.7	5.36e-40	Aortic root size;
CESC	cis	rs7582720	1.000	rs6435169	chr2:203753016	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.39	0.41	1.96e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs9487051	0.802	rs6568558	chr6:109592701	A/T	cg01475377	chr6:109611718	NA	-0.51	-8.56	-0.47	9.09e-16	Reticulocyte fraction of red cells;
CESC	cis	rs9388451	0.839	rs980014	chr6:126068001	T/G	cg10911889	chr6:126070802	HEY2	0.42	5.8	0.34	1.86e-8	Brugada syndrome;
CESC	cis	rs4906332	1.000	rs12885234	chr14:103889181	A/G	cg09975044	chr14:104007538	NA	0.46	6.38	0.36	7.81e-10	Coronary artery disease;
CESC	cis	rs11809207	0.501	rs3762460	chr1:26495550	A/G	cg00300879	chr1:26503847	CNKSR1	0.26	5.06	0.3	7.88e-7	Height;
CESC	cis	rs7917772	0.503	rs7096072	chr10:104299976	C/T	cg22532475	chr10:104410764	TRIM8	-0.35	-5.97	-0.34	7.47e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs1401999	1.000	rs2872249	chr3:183636273	T/A	cg01324343	chr3:183735012	ABCC5	0.64	13.47	0.64	7.66e-32	Anterior chamber depth;
CESC	cis	rs7772486	0.651	rs1292338	chr6:145967471	A/C	cg23711669	chr6:146136114	FBXO30	-0.86	-12.69	-0.61	3.91e-29	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs854765	0.583	rs7222480	chr17:17818817	G/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.52	7.22	0.41	5.4e-12	Total body bone mineral density;
CESC	cis	rs9926296	0.548	rs12447465	chr16:89829895	C/T	cg27121462	chr16:89883253	FANCA	0.75	11.1	0.56	9.55e-24	Vitiligo;
CESC	trans	rs35110281	0.627	rs1836855	chr21:44965414	C/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.53	7.05	0.4	1.57e-11	Mean corpuscular volume;
CESC	cis	rs881375	0.678	rs10760128	chr9:123696325	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.51	7.48	0.42	1.08e-12	Rheumatoid arthritis;
CESC	cis	rs9649213	0.574	rs12873	chr7:97922773	T/C	cg24562669	chr7:97807699	LMTK2	0.47	6.71	0.38	1.15e-10	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs10129255	0.957	rs8009073	chr14:107185517	G/T	cg23076370	chr14:107095027	NA	-0.45	-5.59	-0.32	5.68e-8	Kawasaki disease;
CESC	cis	rs611744	0.647	rs11785776	chr8:109264933	C/T	cg21045802	chr8:109455806	TTC35	0.5	6.25	0.36	1.6e-9	Dupuytren's disease;
CESC	cis	rs1799949	0.894	rs71367985	chr17:41374463	G/A	cg23758822	chr17:41437982	NA	1.03	17.57	0.73	2.4e-46	Menopause (age at onset);
CESC	cis	rs56235845	0.694	rs11748912	chr5:176765395	G/A	cg16006841	chr5:176797999	RGS14	0.46	5.71	0.33	2.96e-8	Hemoglobin concentration;Hematocrit;
CESC	cis	rs4925166	1	rs4925166	chr17:18210810	T/G	cg04261877	chr17:18218829	SMCR8;TOP3A	0.59	6.9	0.39	3.9e-11	Multiple sclerosis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02045845	chr11:65338336	FAM89B;SSSCA1	0.58	6.84	0.39	5.46e-11	Gut microbiome composition (summer);
CESC	cis	rs8038465	1.000	rs8041523	chr15:73982556	C/T	cg15420318	chr15:73925796	NPTN	0.43	6.0	0.35	6.44e-9	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs5769765	1.000	rs5769764	chr22:50270784	G/A	cg02269571	chr22:50332266	NA	0.46	6.28	0.36	1.39e-9	Schizophrenia;
CESC	cis	rs9733	0.744	rs2089081	chr1:150800117	T/C	cg22823121	chr1:150693482	HORMAD1	-0.39	-5.93	-0.34	9.24e-9	Tonsillectomy;
CESC	cis	rs6866344	0.697	rs62392832	chr5:178134395	T/C	cg03877680	chr5:178157825	ZNF354A	0.68	7.84	0.43	1.09e-13	Neutrophil percentage of white cells;
CESC	cis	rs801193	1.000	rs1553609	chr7:66197139	T/C	cg14393609	chr7:65229607	NA	0.48	6.5	0.37	4e-10	Aortic root size;
CESC	cis	rs6662572	0.737	rs7555458	chr1:46554142	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.47	5.17	0.3	4.73e-7	Blood protein levels;
CESC	trans	rs2207136	0.835	rs571503	chr6:50904692	G/A	cg06522515	chr3:184090630	THPO	-0.36	-6.26	-0.36	1.56e-9	Myopia;
CESC	cis	rs7666738	0.830	rs10034330	chr4:99064849	G/A	cg05340658	chr4:99064831	C4orf37	0.84	13.04	0.63	2.35e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs798554	1.000	rs798536	chr7:2766383	G/A	cg04166393	chr7:2884313	GNA12	0.55	6.9	0.39	3.83e-11	Height;
CESC	cis	rs208520	0.690	rs10455594	chr6:66737894	C/G	cg07460842	chr6:66804631	NA	0.96	12.87	0.62	8.96e-30	Exhaled nitric oxide output;
CESC	cis	rs10788972	0.903	rs7537946	chr1:54538700	A/G	cg25741118	chr1:54482237	LDLRAD1	-0.22	-5.24	-0.31	3.35e-7	Parkinson disease and lewy body pathology;
CESC	cis	rs7945705	0.935	rs11042102	chr11:8882164	C/T	cg12365402	chr11:9010492	NRIP3	0.36	5.54	0.32	7.27e-8	Hemoglobin concentration;
CESC	cis	rs10848704	1.000	rs10848704	chr12:2882544	A/G	cg19995117	chr12:2880862	NA	-0.54	-7.87	-0.44	9.09e-14	Quantitative traits;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg03028685	chr10:99078963	FRAT1	-0.48	-6.22	-0.36	1.89e-9	Ulcerative colitis;
CESC	cis	rs2842992	0.830	rs2273819	chr6:160183325	G/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.69	8.61	0.47	6.66e-16	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs7017914	0.967	rs7014012	chr8:71672743	G/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.2	-0.3	4.01e-7	Bone mineral density;
CESC	cis	rs12079745	0.793	rs3766064	chr1:169157919	A/G	cg09363564	chr1:169337483	NME7;BLZF1	1.01	6.03	0.35	5.5e-9	QT interval;
CESC	cis	rs875971	0.638	rs10249404	chr7:66046724	G/A	cg11764359	chr7:65958608	NA	-0.72	-9.54	-0.51	9.49e-19	Aortic root size;
CESC	cis	rs10504229	0.679	rs72649109	chr8:58031274	A/T	cg24829409	chr8:58192753	C8orf71	-0.66	-7.28	-0.41	3.87e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs7949030	0.523	rs12223627	chr11:62368557	G/C	cg22862634	chr11:62369728	EML3;MTA2	0.48	6.38	0.36	7.82e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs6493487	0.512	rs2306333	chr15:51217674	A/G	cg02338191	chr15:51200825	AP4E1	0.6	5.57	0.32	6.13e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs9300255	0.739	rs4759371	chr12:123742563	T/C	cg00376283	chr12:123451042	ABCB9	0.7	8.63	0.47	5.59e-16	Neutrophil percentage of white cells;
CESC	cis	rs6951245	0.744	rs1133122	chr7:1192572	C/A	cg23708337	chr7:1209742	NA	0.49	5.31	0.31	2.35e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs67478160	0.643	rs12434686	chr14:104316033	C/T	cg08213375	chr14:104286397	PPP1R13B	-0.54	-10.51	-0.54	8.25e-22	Schizophrenia;
CESC	cis	rs7103648	1.000	rs11039225	chr11:47430599	G/A	cg20307385	chr11:47447363	PSMC3	0.97	16.84	0.72	9.04e-44	Diastolic blood pressure;Systolic blood pressure;
CESC	cis	rs962856	0.619	rs1601530	chr2:67594916	G/A	cg09028215	chr2:67624308	ETAA1	-0.44	-5.28	-0.31	2.66e-7	Pancreatic cancer;
CESC	cis	rs11690935	0.632	rs2292816	chr2:172586714	G/C	cg13550731	chr2:172543902	DYNC1I2	0.6	8.4	0.46	2.73e-15	Schizophrenia;
CESC	cis	rs921968	0.612	rs832810	chr2:219322430	T/C	cg02176678	chr2:219576539	TTLL4	0.38	6.67	0.38	1.48e-10	Mean corpuscular hemoglobin concentration;
CESC	cis	rs1580019	0.961	rs6949851	chr7:32493807	T/G	cg06627557	chr7:32535165	LSM5;AVL9	0.77	10.77	0.55	1.1e-22	Cognitive ability;
CESC	cis	rs13256369	0.802	rs13255789	chr8:8562791	T/C	cg17143192	chr8:8559678	CLDN23	0.77	8.79	0.48	1.94e-16	Obesity-related traits;
CESC	trans	rs2727020	0.563	rs10769582	chr11:49474040	T/C	cg15704280	chr7:45808275	SEPT13	-0.91	-15.68	-0.69	1.17e-39	Coronary artery disease;
CESC	cis	rs1729951	0.575	rs1682356	chr3:136692037	T/C	cg03617693	chr3:136751559	NA	0.39	5.48	0.32	9.84e-8	Neuroticism;
CESC	cis	rs727505	0.607	rs67680878	chr7:124787381	G/A	cg23710748	chr7:124431027	NA	-0.4	-6.24	-0.36	1.73e-9	Lewy body disease;
CESC	cis	rs473651	0.506	rs561264	chr2:239329979	G/T	cg21699342	chr2:239360505	ASB1	0.43	5.63	0.33	4.67e-8	Multiple system atrophy;
CESC	cis	rs1950626	0.827	rs35829821	chr14:101409763	A/G	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.79	10.67	0.55	2.42e-22	Pelvic organ prolapse (moderate/severe);
CESC	cis	rs11264213	0.786	rs72659701	chr1:36317380	C/T	cg27506609	chr1:36549197	TEKT2	0.66	5.51	0.32	8.52e-8	Schizophrenia;
CESC	cis	rs929354	0.772	rs3802118	chr7:156986814	T/C	cg05182265	chr7:156933206	UBE3C	-0.51	-7.5	-0.42	9.58e-13	Body mass index;
CESC	cis	rs7552404	0.731	rs7523573	chr1:76372020	G/T	cg10523679	chr1:76189770	ACADM	0.65	6.11	0.35	3.62e-9	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs4819052	0.808	rs11909411	chr21:46676556	A/C	cg11663144	chr21:46675770	NA	-0.63	-9.75	-0.51	2.19e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs4727027	0.704	rs12535154	chr7:148895304	G/A	cg23583168	chr7:148888333	NA	-0.95	-17.1	-0.72	1.08e-44	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs854765	0.547	rs2955385	chr17:17939247	C/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.51	6.59	0.38	2.32e-10	Total body bone mineral density;
CESC	cis	rs798554	0.679	rs2527677	chr7:2882621	A/G	cg04166393	chr7:2884313	GNA12	0.62	8.46	0.46	1.85e-15	Height;
CESC	cis	rs1048238	0.506	rs7552077	chr1:16196759	A/G	cg22431228	chr1:16359049	CLCNKA	-0.36	-6.53	-0.37	3.43e-10	Systolic blood pressure;
CESC	cis	rs7264396	0.790	rs6060519	chr20:34217383	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.65	7.72	0.43	2.42e-13	Total cholesterol levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05668043	chr16:84733982	USP10	0.58	7.09	0.4	1.25e-11	Gut microbiome composition (summer);
CESC	cis	rs798554	1.000	rs798559	chr7:2758341	T/C	cg13628971	chr7:2884303	GNA12	0.57	7.4	0.41	1.83e-12	Height;
CESC	cis	rs7937682	0.889	rs1784786	chr11:111486043	A/G	cg22437258	chr11:111473054	SIK2	-0.69	-9.02	-0.48	3.96e-17	Primary sclerosing cholangitis;
CESC	cis	rs2479724	0.935	rs2025951	chr6:41827193	C/T	cg17623882	chr6:41773611	USP49	0.4	5.88	0.34	1.2e-8	Menarche (age at onset);
CESC	cis	rs7818688	0.697	rs11783985	chr8:95979886	A/G	cg16049864	chr8:95962084	TP53INP1	0.55	5.55	0.32	6.92e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs7666738	0.830	rs13118892	chr4:98968497	T/C	cg17366294	chr4:99064904	C4orf37	0.59	8.43	0.46	2.22e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6087990	0.965	rs6058869	chr20:31348750	C/T	cg13636640	chr20:31349939	DNMT3B	0.9	16.32	0.71	6.41e-42	Ulcerative colitis;
CESC	cis	rs17376456	0.825	rs36042718	chr5:93180997	C/T	cg25358565	chr5:93447407	FAM172A	1.11	10.79	0.55	9.8e-23	Diabetic retinopathy;
CESC	cis	rs4665809	0.590	rs7588328	chr2:26469788	G/A	cg08470875	chr2:26401718	FAM59B	0.75	7.78	0.43	1.63e-13	Gut microbiome composition (summer);
CESC	cis	rs763121	0.853	rs6001214	chr22:39149155	C/T	cg21395723	chr22:39101663	GTPBP1	0.46	5.96	0.34	7.99e-9	Menopause (age at onset);
CESC	cis	rs6951245	0.507	rs11763865	chr7:1194274	G/A	cg03188948	chr7:1209495	NA	0.47	5.32	0.31	2.2e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs9393777	0.920	rs34150729	chr6:27388754	T/C	cg06606381	chr12:133084897	FBRSL1	-1.12	-8.38	-0.46	3.2e-15	Intelligence (multi-trait analysis);
CESC	cis	rs875971	0.825	rs28480509	chr7:66099224	A/G	cg11764359	chr7:65958608	NA	-0.74	-10.41	-0.54	1.72e-21	Aortic root size;
CESC	trans	rs3741489	1.000	rs4758915	chr12:133477147	A/G	cg24132527	chr5:140019269	TMCO6	1.05	7.12	0.4	1.01e-11	Cognitive function;
CESC	cis	rs290268	0.874	rs290994	chr9:93559515	T/A	cg02608019	chr9:93564028	SYK	0.67	10.21	0.53	7.53e-21	Platelet count;
CESC	trans	rs916888	0.773	rs169201	chr17:44790203	A/G	cg10053473	chr17:62856997	LRRC37A3	-0.72	-7.56	-0.42	6.69e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01464969	chr4:1768943	NA	0.56	6.35	0.36	9.52e-10	Gut microbiome composition (summer);
CESC	cis	rs62432291	0.681	rs2932988	chr6:159655402	A/G	cg14500486	chr6:159655392	FNDC1	-0.62	-6.21	-0.36	2.04e-9	Joint mobility (Beighton score);
CESC	cis	rs921968	0.643	rs559722	chr2:219398159	A/G	cg02176678	chr2:219576539	TTLL4	0.42	7.44	0.42	1.43e-12	Mean corpuscular hemoglobin concentration;
CESC	cis	rs1218582	0.804	rs869506	chr1:154859581	A/C	cg09359103	chr1:154839909	KCNN3	-0.65	-12.4	-0.61	3.83e-28	Prostate cancer;
CESC	cis	rs9611565	0.512	rs5758465	chr22:42175314	T/C	cg06634786	chr22:41940651	POLR3H	0.67	6.62	0.38	1.93e-10	Vitiligo;
CESC	cis	rs9303401	0.614	rs34678056	chr17:57177549	G/A	cg12560992	chr17:57184187	TRIM37	0.5	5.21	0.3	3.78e-7	Cognitive test performance;
CESC	cis	rs4481887	0.800	rs10888342	chr1:248441999	A/G	cg00666640	chr1:248458726	OR2T12	0.33	5.71	0.33	3.05e-8	Common traits (Other);
CESC	cis	rs7666738	0.716	rs28792413	chr4:99083707	G/A	cg17366294	chr4:99064904	C4orf37	0.54	7.24	0.41	5.01e-12	Colonoscopy-negative controls vs population controls;
CESC	cis	rs12824058	0.831	rs4759655	chr12:130815740	A/G	cg24838063	chr12:130822603	PIWIL1	-0.64	-8.83	-0.48	1.51e-16	Menopause (age at onset);
CESC	cis	rs7959452	0.535	rs7135092	chr12:69658330	T/C	cg14784868	chr12:69753453	YEATS4	0.74	10.82	0.55	7.97e-23	Blood protein levels;
CESC	cis	rs10504229	1.000	rs17816781	chr8:58186161	A/T	cg22535103	chr8:58192502	C8orf71	-1.05	-13.08	-0.63	1.71e-30	Developmental language disorder (linguistic errors);
CESC	cis	rs10540	1.000	rs35255804	chr11:492617	G/A	cg03352830	chr11:487213	PTDSS2	0.74	7.2	0.4	6.29e-12	Body mass index;
CESC	cis	rs616402	0.527	rs2274985	chr1:10573867	G/A	cg17425144	chr1:10567563	PEX14	0.38	6.12	0.35	3.27e-9	Breast size;
CESC	cis	rs10751667	0.666	rs7105477	chr11:964271	C/G	cg20946044	chr11:1010712	AP2A2	-0.4	-5.53	-0.32	7.72e-8	Alzheimer's disease (late onset);
CESC	cis	rs344364	0.511	rs2982433	chr16:1954508	A/G	cg03013636	chr16:1946785	NA	0.44	5.98	0.34	7.22e-9	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs3091242	0.933	rs28530483	chr1:25740847	A/C	cg27572855	chr1:25598939	RHD	0.44	7.17	0.4	7.61e-12	Erythrocyte sedimentation rate;
CESC	cis	rs7762018	0.607	rs7759404	chr6:170135728	A/G	cg13891659	chr6:170190454	C6orf122;C6orf208	0.62	6.19	0.36	2.3e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs13034020	0.522	rs72809436	chr2:61251145	C/T	cg18625361	chr2:61244694	PEX13;PUS10	0.66	5.9	0.34	1.13e-8	Hodgkin's lymphoma;
CESC	cis	rs72781680	0.678	rs872169	chr2:24259188	C/G	cg20701182	chr2:24300061	SF3B14	0.93	10.38	0.54	2.17e-21	Lymphocyte counts;
CESC	cis	rs769267	0.899	rs3934667	chr19:19431423	T/G	cg15052019	chr19:19431593	KIAA0892;SF4	-0.42	-5.36	-0.31	1.77e-7	Tonsillectomy;
CESC	cis	rs1552244	0.882	rs3732967	chr3:10015437	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.87	11.29	0.57	2.21e-24	Alzheimer's disease;
CESC	cis	rs2842992	0.830	rs2758312	chr6:160153452	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.71	9.33	0.5	4.3e-18	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs1577917	0.876	rs1582126	chr6:86697205	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-6.09	-0.35	3.92e-9	Response to antipsychotic treatment;
CESC	cis	rs1499614	0.803	rs1922723	chr7:66175063	C/T	cg12463550	chr7:65579703	CRCP	0.73	5.73	0.33	2.78e-8	Gout;
CESC	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg01238044	chr22:24384105	GSTT1	-0.47	-6.0	-0.35	6.35e-9	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs1799949	1.000	rs2070834	chr17:41242285	T/G	cg25072359	chr17:41440525	NA	0.43	5.95	0.34	8.39e-9	Menopause (age at onset);
CESC	cis	rs9733	0.519	rs11204717	chr1:150709129	T/A	cg18016565	chr1:150552671	MCL1	0.34	5.23	0.31	3.36e-7	Tonsillectomy;
CESC	cis	rs10504229	0.683	rs35840293	chr8:58117634	C/T	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs4665809	0.887	rs28699126	chr2:26357294	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.68	-7.76	-0.43	1.83e-13	Gut microbiome composition (summer);
CESC	cis	rs4746818	0.901	rs10740317	chr10:70937566	G/A	cg04149295	chr10:70884716	VPS26A	0.58	5.08	0.3	7.06e-7	Left atrial antero-posterior diameter;
CESC	cis	rs10883723	0.773	rs2296587	chr10:104245588	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.57	6.95	0.39	2.86e-11	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs9486719	0.843	rs2499797	chr6:96848669	C/T	cg18709589	chr6:96969512	KIAA0776	0.55	5.4	0.31	1.47e-7	Migraine;Coronary artery disease;
CESC	cis	rs708547	0.874	rs1713984	chr4:57886493	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.69	7.7	0.43	2.7e-13	Response to bleomycin (chromatid breaks);
CESC	cis	rs875971	0.522	rs2008188	chr7:65429013	G/C	cg26939375	chr7:64535504	NA	0.76	10.85	0.55	6e-23	Aortic root size;
CESC	cis	rs9814567	1.000	rs9289471	chr3:134230811	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.46	-6.24	-0.36	1.69e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	trans	rs61931739	0.534	rs12831685	chr12:34038392	C/T	cg26384229	chr12:38710491	ALG10B	0.5	6.74	0.38	9.74e-11	Morning vs. evening chronotype;
CESC	cis	rs798554	0.660	rs2283783	chr7:2855326	G/A	cg09658497	chr7:2847517	GNA12	-0.35	-5.27	-0.31	2.85e-7	Height;
CESC	cis	rs9487051	0.621	rs396635	chr6:109523508	A/G	cg01475377	chr6:109611718	NA	-0.39	-5.15	-0.3	5.18e-7	Reticulocyte fraction of red cells;
CESC	cis	rs28374715	0.681	rs7163989	chr15:41614621	A/G	cg02330683	chr15:41787940	ITPKA	0.47	6.26	0.36	1.58e-9	Ulcerative colitis;
CESC	cis	rs9309473	1.000	rs56154726	chr2:73721767	C/T	cg20560298	chr2:73613845	ALMS1	-0.55	-7.15	-0.4	8.23e-12	Metabolite levels;
CESC	trans	rs9929218	1.000	rs8045022	chr16:68807087	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.61	-8.03	-0.44	3.1e-14	Colorectal cancer;
CESC	cis	rs12541635	0.677	rs6469026	chr8:107006356	T/C	cg10147462	chr8:107024639	NA	0.43	6.37	0.36	8.26e-10	Age of smoking initiation;
CESC	cis	rs1348850	0.537	rs3770010	chr2:178537796	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.54	7.24	0.41	4.92e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs7772486	0.754	rs6932863	chr6:146021255	A/T	cg05347473	chr6:146136440	FBXO30	-0.55	-6.66	-0.38	1.6e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs801193	0.527	rs2707837	chr7:66181073	G/C	cg12463550	chr7:65579703	CRCP	0.49	6.35	0.36	9.51e-10	Aortic root size;
CESC	cis	rs1620921	0.505	rs12526591	chr6:161204311	T/A	cg01280913	chr6:161186852	NA	-0.36	-5.27	-0.31	2.81e-7	Lipoprotein (a) - cholesterol levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27209265	chr16:790912	NARFL	0.56	6.79	0.38	7.37e-11	Gut microbiome composition (summer);
CESC	cis	rs1552244	1.000	rs76041173	chr3:10078695	G/T	cg08888203	chr3:10149979	C3orf24	0.47	6.21	0.36	2.03e-9	Alzheimer's disease;
CESC	cis	rs4481887	0.893	rs6702113	chr1:248486151	T/C	cg00666640	chr1:248458726	OR2T12	0.35	5.98	0.35	7.04e-9	Common traits (Other);
CESC	cis	rs12188164	0.965	rs11743639	chr5:450710	C/T	cg15813090	chr5:442598	EXOC3;C5orf55	0.42	6.26	0.36	1.51e-9	Cystic fibrosis severity;
CESC	cis	rs4969178	0.965	rs938350	chr17:76399552	C/T	cg05887092	chr17:76393375	PGS1	0.58	9.19	0.49	1.15e-17	HDL cholesterol levels;
CESC	cis	rs2836950	0.565	rs7276046	chr21:40581293	T/C	cg11644478	chr21:40555479	PSMG1	-0.55	-7.6	-0.42	5.07e-13	Menarche (age at onset);
CESC	cis	rs8031584	0.541	rs2955797	chr15:31210981	A/G	cg19680485	chr15:31195859	MTMR15	0.48	5.86	0.34	1.35e-8	Huntington's disease progression;
CESC	cis	rs2011503	1.000	rs2916072	chr19:19525712	G/A	cg11584989	chr19:19387371	SF4	0.65	7.59	0.42	5.44e-13	Bipolar disorder;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg27365485	chr11:64126452	RPS6KA4	-0.39	-6.29	-0.36	1.3e-9	Gambling;
CESC	trans	rs11098499	0.955	rs11931312	chr4:120159023	T/C	cg25214090	chr10:38739885	LOC399744	0.64	8.6	0.47	7.03e-16	Corneal astigmatism;
CESC	cis	rs477692	0.905	rs485579	chr10:131425492	T/G	cg05714579	chr10:131428358	MGMT	0.58	8.4	0.46	2.67e-15	Response to temozolomide;
CESC	cis	rs72627123	0.867	rs73303113	chr14:74481068	A/G	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.79	5.81	0.34	1.8e-8	Morning vs. evening chronotype;
CESC	cis	rs9611565	0.659	rs56319767	chr22:41933837	G/A	cg06634786	chr22:41940651	POLR3H	-0.69	-7.12	-0.4	1.01e-11	Vitiligo;
CESC	cis	rs3105593	0.555	rs3131560	chr15:50775562	T/C	cg08437265	chr15:50716283	USP8	0.48	6.32	0.36	1.09e-9	QT interval;
CESC	cis	rs736408	0.609	rs13095332	chr3:52787242	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.48	6.71	0.38	1.14e-10	Bipolar disorder;
CESC	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg11494091	chr17:61959527	GH2	0.72	12.22	0.6	1.56e-27	Prudent dietary pattern;
CESC	cis	rs7808935	0.628	rs12666442	chr7:27937203	C/T	cg05786569	chr7:27702416	HIBADH	0.53	5.87	0.34	1.28e-8	Prostate cancer;
CESC	cis	rs8077577	0.945	rs34474249	chr17:18074525	T/C	cg16794390	chr17:18148240	FLII	0.42	5.64	0.33	4.41e-8	Obesity-related traits;
CESC	cis	rs722599	0.715	rs2080086	chr14:75338408	G/A	cg08847533	chr14:75593920	NEK9	-0.45	-5.71	-0.33	3.01e-8	IgG glycosylation;
CESC	cis	rs10479542	0.766	rs7733389	chr5:178974997	C/T	cg19626725	chr5:178986131	RUFY1	0.33	5.1	0.3	6.5e-7	Lung cancer;
CESC	cis	rs933688	1.000	rs889213	chr5:90682151	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.11	12.36	0.6	5.17e-28	Smoking behavior;
CESC	cis	rs208346	0.612	rs208356	chr7:2775825	A/T	cg19717773	chr7:2847554	GNA12	0.68	11.21	0.57	3.86e-24	Loneliness (linear analysis);
CESC	cis	rs7618915	1.000	rs3852063	chr3:52349204	A/G	cg18404041	chr3:52824283	ITIH1	-0.39	-5.62	-0.33	4.89e-8	Bipolar disorder;
CESC	cis	rs796364	0.951	rs769952	chr2:200734368	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.85	8.19	0.45	1.12e-14	Schizophrenia;
CESC	cis	rs4481887	1.000	rs4244182	chr1:248471174	A/G	cg00666640	chr1:248458726	OR2T12	0.4	6.57	0.37	2.7e-10	Common traits (Other);
CESC	cis	rs10992471	0.756	rs7043152	chr9:95138499	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.45	-5.68	-0.33	3.52e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CESC	cis	rs6540559	0.740	rs2064163	chr1:210048819	G/T	cg22029157	chr1:209979665	IRF6	0.6	8.91	0.48	8.14e-17	Cleft lip with or without cleft palate;
CESC	cis	rs9300255	0.602	rs1616131	chr12:123619838	G/A	cg05973401	chr12:123451056	ABCB9	0.53	5.92	0.34	9.71e-9	Neutrophil percentage of white cells;
CESC	cis	rs55788414	0.932	rs8059559	chr16:81185684	G/A	cg06400318	chr16:81190750	PKD1L2	0.59	6.83	0.39	5.74e-11	Left ventricular obstructive tract defect (maternal effect);
CESC	cis	rs4704187	0.687	rs6860441	chr5:74389799	G/A	cg03227963	chr5:74354835	NA	0.32	5.92	0.34	9.97e-9	Response to amphetamines;
CESC	cis	rs10256972	0.967	rs1881122	chr7:1040946	A/T	cg23978390	chr7:1156363	C7orf50	0.45	6.04	0.35	5.3e-9	Longevity;Endometriosis;
CESC	cis	rs6088580	0.634	rs6120650	chr20:33039973	G/A	cg24642439	chr20:33292090	TP53INP2	0.52	6.82	0.39	6.28e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs1799949	1.000	rs33918839	chr17:41329172	T/C	cg25072359	chr17:41440525	NA	0.48	6.52	0.37	3.45e-10	Menopause (age at onset);
CESC	cis	rs7927592	0.763	rs1193699	chr11:68249480	C/G	cg16797656	chr11:68205561	LRP5	0.48	7.43	0.42	1.48e-12	Total body bone mineral density;
CESC	cis	rs2842992	0.915	rs1967802	chr6:160097791	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.65	7.45	0.42	1.31e-12	Age-related macular degeneration (geographic atrophy);
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg09251995	chr19:18392994	JUND	-0.48	-6.31	-0.36	1.18e-9	Asthma;
CESC	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg22907277	chr7:1156413	C7orf50	0.42	5.91	0.34	1.05e-8	Longevity;Endometriosis;
CESC	cis	rs4409675	0.576	rs7356	chr1:28218100	T/C	cg23691781	chr1:28212827	C1orf38	0.3	5.92	0.34	1.02e-8	Corneal astigmatism;
CESC	cis	rs12136530	0.554	rs4912093	chr1:19762321	T/C	cg01832549	chr1:19774989	CAPZB	-0.47	-6.48	-0.37	4.5e-10	Lead levels in blood;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg23031969	chr7:5014415	RNF216L	-0.46	-6.94	-0.39	2.93e-11	Fibrinogen levels;
CESC	cis	rs10949834	0.504	rs150862	chr7:73524207	C/T	cg07137043	chr7:73588983	EIF4H	0.64	7.58	0.42	5.84e-13	Verbal memory performance (residualized delayed recall change);
CESC	cis	rs4660261	0.526	rs810680	chr1:44347856	C/T	cg13606994	chr1:44402422	ARTN	-0.38	-5.78	-0.33	2.14e-8	Intelligence (multi-trait analysis);
CESC	cis	rs9488822	0.676	rs13194714	chr6:116394819	T/A	cg15226275	chr6:116381976	FRK	0.25	6.32	0.36	1.08e-9	Cholesterol, total;LDL cholesterol;
CESC	cis	rs875971	0.825	rs10281499	chr7:66048966	A/G	cg10691866	chr7:65817282	TPST1	0.33	5.47	0.32	1.02e-7	Aortic root size;
CESC	cis	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg18337363	chr3:52569053	NT5DC2	-0.31	-5.17	-0.3	4.69e-7	Bipolar disorder;
CESC	cis	rs3105593	0.635	rs3131567	chr15:50757930	A/T	cg08437265	chr15:50716283	USP8	0.46	6.17	0.35	2.48e-9	QT interval;
CESC	cis	rs7249142	0.549	rs12975253	chr19:19279745	A/C	cg27384695	chr19:19271486	LOC729991-MEF2B;MEF2B	0.29	5.22	0.31	3.57e-7	IgG glycosylation;
CESC	cis	rs875971	0.862	rs778724	chr7:65829291	T/C	cg18876405	chr7:65276391	NA	0.51	6.94	0.39	3e-11	Aortic root size;
CESC	cis	rs2985684	0.948	rs11623263	chr14:50083295	A/G	cg10008539	chr14:50087325	RPL36AL;MGAT2	-0.47	-5.6	-0.33	5.45e-8	Carotid intima media thickness;
CESC	cis	rs748404	0.560	rs570933	chr15:43824030	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.49	7.55	0.42	7.09e-13	Lung cancer;
CESC	cis	rs3768617	0.565	rs7542277	chr1:183063527	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.84	13.13	0.63	1.16e-30	Fuchs's corneal dystrophy;
CESC	cis	rs7395581	0.918	rs12575456	chr11:47326073	G/A	cg25783544	chr11:47291846	MADD	0.61	7.92	0.44	6.78e-14	HDL cholesterol;
CESC	cis	rs9660992	0.674	rs56198325	chr1:205265450	G/A	cg21643547	chr1:205240462	TMCC2	-0.49	-6.52	-0.37	3.5e-10	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs853679	0.517	rs9295759	chr6:28124469	C/T	cg26335602	chr6:28129616	ZNF389	0.53	6.74	0.38	9.91e-11	Depression;
CESC	cis	rs10911232	0.507	rs4652772	chr1:183023696	C/G	ch.1.3577855R	chr1:183094577	LAMC1	-0.84	-12.89	-0.62	7.57e-30	Hypertriglyceridemia;
CESC	trans	rs1814175	0.616	rs1794139	chr11:49910855	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.43	-6.3	-0.36	1.26e-9	Height;
CESC	cis	rs10489525	1.000	rs10489525	chr1:115263685	A/G	cg01522456	chr1:115632236	TSPAN2	-0.45	-5.36	-0.31	1.82e-7	Autism;
CESC	trans	rs877282	0.842	rs12357963	chr10:757562	C/T	cg22713356	chr15:30763199	NA	1.05	9.16	0.49	1.45e-17	Uric acid levels;
CESC	cis	rs7666738	0.830	rs1534318	chr4:98965058	C/T	cg05340658	chr4:99064831	C4orf37	0.78	11.83	0.59	3.34e-26	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7208859	0.573	rs73267873	chr17:29068457	C/T	cg13385521	chr17:29058706	SUZ12P	0.74	6.21	0.36	2.01e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs7178909	0.872	rs57715404	chr15:90433958	T/C	cg19708238	chr15:90437601	AP3S2	0.42	5.83	0.34	1.57e-8	Common traits (Other);
CESC	cis	rs2880765	0.835	rs4842884	chr15:86035174	T/C	cg10818794	chr15:86012489	AKAP13	-0.35	-5.42	-0.32	1.34e-7	Coronary artery disease;
CESC	cis	rs11098499	0.954	rs11098524	chr4:120390032	A/G	cg24375607	chr4:120327624	NA	0.49	5.88	0.34	1.24e-8	Corneal astigmatism;
CESC	cis	rs854765	0.547	rs6502633	chr17:17941037	G/C	cg16928487	chr17:17741425	SREBF1	-0.54	-8.97	-0.48	5.44e-17	Total body bone mineral density;
CESC	cis	rs34779708	0.733	rs4298846	chr10:35547380	A/G	cg03585969	chr10:35415529	CREM	0.55	6.37	0.36	8.28e-10	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs7772486	0.875	rs2814875	chr6:146305810	G/A	cg05347473	chr6:146136440	FBXO30	0.56	7.37	0.41	2.14e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs3820928	0.869	rs2396436	chr2:227795464	G/A	cg05526886	chr2:227700861	RHBDD1	-0.4	-5.1	-0.3	6.58e-7	Pulmonary function;
CESC	cis	rs2629540	0.924	rs1545910	chr10:126428145	G/C	cg08799069	chr10:126477246	METTL10	-0.68	-9.05	-0.49	3.16e-17	Cocaine dependence;
CESC	cis	rs5750830	0.594	rs5757647	chr22:39775047	C/A	cg24399712	chr22:39784796	NA	-0.77	-11.05	-0.56	1.34e-23	Intelligence (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10514093	chr5:156277587	PPP1R2P3	-0.56	-6.91	-0.39	3.7e-11	Gut microbiome composition (summer);
CESC	cis	rs780096	0.565	rs13022659	chr2:27743630	C/T	cg02592271	chr2:27665507	KRTCAP3	-0.3	-6.02	-0.35	5.73e-9	Total body bone mineral density;
CESC	cis	rs11676348	0.783	rs4674252	chr2:218984478	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.46	-6.03	-0.35	5.51e-9	Ulcerative colitis;
CESC	cis	rs6502050	0.835	rs11658335	chr17:80084821	C/T	cg11859384	chr17:80120422	CCDC57	0.38	5.12	0.3	6.01e-7	Life satisfaction;
CESC	cis	rs739401	0.611	rs417957	chr11:3046231	A/G	cg08508325	chr11:3079039	CARS	-0.53	-10.56	-0.54	5.43e-22	Longevity;
CESC	cis	rs7274811	0.744	rs3213183	chr20:32262962	C/T	cg21523528	chr20:32077966	CBFA2T2	0.56	6.51	0.37	3.8e-10	Height;
CESC	cis	rs6663390	0.831	rs3754172	chr1:208086878	G/T	cg00387621	chr1:208086895	NA	0.41	5.04	0.3	8.57e-7	Facial morphology (factor 18);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg07513383	chr19:52552126	ZNF432	-0.46	-6.03	-0.35	5.45e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs7618915	0.501	rs2164885	chr3:52731269	T/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.76	0.38	8.98e-11	Bipolar disorder;
CESC	cis	rs60843830	1.000	rs17713396	chr2:227201	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.88	11.44	0.57	6.88e-25	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs832540	0.931	rs832536	chr5:56212595	C/T	cg12311346	chr5:56204834	C5orf35	-0.42	-5.21	-0.3	3.88e-7	Coronary artery disease;
CESC	cis	rs2901656	1.000	rs6699095	chr1:172429245	T/C	cg03748243	chr1:172413542	C1orf105;PIGC	0.4	6.19	0.36	2.33e-9	Red cell distribution width;Platelet distribution width;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16681977	chr1:11332969	UBIAD1	0.55	6.21	0.36	1.98e-9	Gut microbiome composition (summer);
CESC	cis	rs10883723	0.668	rs12414407	chr10:104387019	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.54	-7.5	-0.42	9.48e-13	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs684232	0.666	rs838371	chr17:609275	T/C	cg12384639	chr17:618140	VPS53	0.4	5.19	0.3	4.22e-7	Prostate cancer;
CESC	cis	rs72781680	1.000	rs11125372	chr2:24257582	A/T	cg08917208	chr2:24149416	ATAD2B	-0.8	-7.51	-0.42	8.95e-13	Lymphocyte counts;
CESC	cis	rs9291683	0.588	rs13133766	chr4:10019732	C/T	cg11266682	chr4:10021025	SLC2A9	0.72	14.87	0.67	8.73e-37	Bone mineral density;
CESC	cis	rs12188164	0.965	rs11744539	chr5:451425	C/T	cg26850624	chr5:429559	AHRR	-0.5	-6.76	-0.38	8.87e-11	Cystic fibrosis severity;
CESC	cis	rs9462846	0.959	rs9471960	chr6:42884750	A/C	cg05552183	chr6:42928497	GNMT	0.44	5.24	0.31	3.22e-7	Blood protein levels;
CESC	cis	rs116095464	0.558	rs6878087	chr5:223117	C/T	cg22496380	chr5:211416	CCDC127	0.66	7.87	0.44	9.06e-14	Breast cancer;
CESC	cis	rs9811920	0.770	rs4928237	chr3:99731330	A/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.39	-5.04	-0.3	8.68e-7	Axial length;
CESC	cis	rs9300255	0.679	rs10846507	chr12:123786492	G/T	cg00376283	chr12:123451042	ABCB9	0.58	6.88	0.39	4.38e-11	Neutrophil percentage of white cells;
CESC	cis	rs798554	0.757	rs2533879	chr7:2859847	G/A	cg13628971	chr7:2884303	GNA12	0.63	8.01	0.44	3.58e-14	Height;
CESC	cis	rs7084402	0.967	rs1658494	chr10:60280323	C/T	cg07615347	chr10:60278583	BICC1	-0.59	-9.45	-0.5	1.94e-18	Refractive error;
CESC	cis	rs1348850	0.626	rs1901825	chr2:178225331	A/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.76	10.83	0.55	7.38e-23	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs2991971	0.810	rs998199	chr1:45912898	A/C	cg15605315	chr1:45957053	TESK2	-0.39	-5.31	-0.31	2.27e-7	High light scatter reticulocyte count;
CESC	cis	rs7258465	1.000	rs28572537	chr19:18552208	C/T	cg25828334	chr19:18545568	ISYNA1	-0.32	-5.15	-0.3	5.19e-7	Breast cancer;
CESC	cis	rs8014204	1.000	rs10483863	chr14:75322327	A/G	cg08847533	chr14:75593920	NEK9	-0.43	-5.64	-0.33	4.38e-8	Caffeine consumption;
CESC	cis	rs9612	0.718	rs346522	chr19:44262545	C/T	cg08581076	chr19:44259116	C19orf61	-0.47	-5.87	-0.34	1.33e-8	Exhaled nitric oxide output;
CESC	cis	rs12477438	0.798	rs2045057	chr2:99684929	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.75	-10.87	-0.56	5.17e-23	Chronic sinus infection;
CESC	cis	rs7259376	0.936	rs59598661	chr19:22537029	T/A	cg02657401	chr19:22469223	NA	-0.26	-5.19	-0.3	4.17e-7	Menopause (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04607442	chr13:21872219	NA	0.64	6.93	0.39	3.14e-11	Gut microbiome composition (summer);
CESC	cis	rs4835473	0.900	rs13137885	chr4:144655365	T/C	cg25736465	chr4:144833511	NA	-0.32	-5.04	-0.3	8.48e-7	Immature fraction of reticulocytes;
CESC	cis	rs875971	1.000	rs4718344	chr7:65874381	C/A	cg18876405	chr7:65276391	NA	0.52	6.87	0.39	4.49e-11	Aortic root size;
CESC	cis	rs35306767	1.000	rs35306767	chr10:989437	A/T	cg20503657	chr10:835505	NA	0.75	7.7	0.43	2.63e-13	Eosinophil percentage of granulocytes;
CESC	cis	rs7945705	0.935	rs11042102	chr11:8882164	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.48	7.56	0.42	6.46e-13	Hemoglobin concentration;
CESC	cis	rs2576037	0.526	rs4890707	chr18:44497724	C/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.44	7.45	0.42	1.29e-12	Personality dimensions;
CESC	cis	rs992157	0.661	rs10171839	chr2:219051314	C/T	cg00012203	chr2:219082015	ARPC2	0.75	10.91	0.56	4.02e-23	Colorectal cancer;
CESC	cis	rs9467711	0.606	rs72836482	chr6:26359241	A/T	cg12826209	chr6:26865740	GUSBL1	0.61	5.17	0.3	4.52e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs4450798	0.793	rs62234798	chr3:13753974	T/C	cg23332027	chr3:13681764	NA	0.41	5.46	0.32	1.11e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs7412746	0.658	rs12068264	chr1:150727329	C/T	cg17724175	chr1:150552817	MCL1	0.43	6.53	0.37	3.35e-10	Melanoma;
CESC	cis	rs6963495	0.818	rs6943132	chr7:105166776	C/T	cg19920283	chr7:105172520	RINT1	0.72	5.52	0.32	8.03e-8	Bipolar disorder (body mass index interaction);
CESC	cis	rs11920090	0.789	rs11711206	chr3:170732945	A/G	cg09710316	chr3:170744871	SLC2A2	0.51	5.77	0.33	2.25e-8	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
CESC	cis	rs9926296	0.546	rs9935541	chr16:89905925	G/C	cg27121462	chr16:89883253	FANCA	0.57	6.76	0.38	8.51e-11	Vitiligo;
CESC	cis	rs9640161	0.789	rs11767409	chr7:150058043	C/T	cg17279839	chr7:150038598	RARRES2	0.46	5.51	0.32	8.38e-8	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs2074585	0.713	rs2589941	chr15:90931457	C/T	cg10434728	chr15:90938212	IQGAP1	0.42	7.69	0.43	2.9e-13	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
CESC	cis	rs801193	0.636	rs10233806	chr7:66118248	G/C	cg11764359	chr7:65958608	NA	-0.89	-13.68	-0.64	1.31e-32	Aortic root size;
CESC	cis	rs67478160	0.634	rs7141928	chr14:104219949	C/T	cg08213375	chr14:104286397	PPP1R13B	0.47	9.32	0.5	4.86e-18	Schizophrenia;
CESC	cis	rs9287719	0.967	rs759402	chr2:10729554	A/T	cg00105475	chr2:10696890	NA	0.39	5.69	0.33	3.35e-8	Prostate cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11409060	chr12:14518540	ATF7IP	-0.57	-6.83	-0.39	5.89e-11	Gut microbiome composition (summer);
CESC	trans	rs8073060	0.544	rs225252	chr17:33952401	G/A	cg19694781	chr19:47549865	TMEM160	-0.73	-7.03	-0.4	1.79e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	cis	rs13108904	0.557	rs1680033	chr4:1243404	C/T	cg05025164	chr4:1340916	KIAA1530	-0.67	-9.17	-0.49	1.41e-17	Obesity-related traits;
CESC	cis	rs4718428	0.662	rs34577323	chr7:66310041	G/C	cg12165864	chr7:66369176	NA	-0.65	-7.39	-0.41	1.88e-12	Corneal structure;
CESC	cis	rs35110281	0.622	rs9977258	chr21:44976485	G/T	cg01579765	chr21:45077557	HSF2BP	-0.51	-8.21	-0.45	9.73e-15	Mean corpuscular volume;
CESC	cis	rs644799	0.931	rs496305	chr11:95567035	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	13.72	0.64	9.86e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs7091068	0.754	rs6583903	chr10:95422174	T/C	cg20715218	chr10:95462985	C10orf4	0.59	6.16	0.35	2.73e-9	Urinary tract infection frequency;
CESC	cis	rs1950626	0.750	rs34228453	chr14:101440321	A/C	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.83	11.29	0.57	2.14e-24	Pelvic organ prolapse (moderate/severe);
CESC	cis	rs3096299	0.685	rs12446145	chr16:89542695	C/T	cg16743903	chr16:89593216	SPG7	-0.43	-5.59	-0.32	5.7e-8	Multiple myeloma (IgH translocation);
CESC	cis	rs3741151	1.000	rs78433080	chr11:73067565	G/A	cg17517138	chr11:73019481	ARHGEF17	1.02	6.93	0.39	3.11e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs1552244	1.000	rs6807846	chr3:10134491	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	12.4	0.61	3.79e-28	Alzheimer's disease;
CESC	cis	rs9486719	0.843	rs1009597	chr6:96843540	A/T	cg06623918	chr6:96969491	KIAA0776	0.78	7.39	0.41	1.89e-12	Migraine;Coronary artery disease;
CESC	cis	rs1957429	0.901	rs2884308	chr14:65350406	A/T	cg23373153	chr14:65346875	NA	-0.93	-10.8	-0.55	8.96e-23	Pediatric areal bone mineral density (radius);
CESC	cis	rs4851870	1.000	rs4851871	chr2:106439218	A/G	cg16077055	chr2:106428750	NCK2	-0.4	-5.14	-0.3	5.23e-7	Addiction;
CESC	cis	rs875971	0.929	rs12673810	chr7:65923853	T/A	cg10691866	chr7:65817282	TPST1	-0.34	-5.62	-0.33	4.93e-8	Aortic root size;
CESC	cis	rs963731	0.649	rs10186762	chr2:39219361	A/G	cg04010122	chr2:39346883	SOS1	-0.76	-5.58	-0.32	5.98e-8	Corticobasal degeneration;
CESC	cis	rs965513	1.000	rs7020976	chr9:100547972	T/C	cg13688889	chr9:100608707	NA	-0.6	-8.62	-0.47	6.27e-16	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
CESC	cis	rs1799949	1.000	rs2037076	chr17:41305883	G/A	cg06001716	chr17:41278141	BRCA1;NBR2	0.38	5.2	0.3	3.96e-7	Menopause (age at onset);
CESC	cis	rs17376456	0.825	rs12188163	chr5:93250608	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.65	-5.5	-0.32	8.97e-8	Diabetic retinopathy;
CESC	cis	rs4727027	0.933	rs6961605	chr7:148870108	G/A	cg23158103	chr7:148848205	ZNF398	-0.41	-6.61	-0.38	2.09e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs3820068	0.580	rs12082523	chr1:16005792	A/G	cg13390004	chr1:15929781	NA	-0.33	-5.25	-0.31	3.19e-7	Systolic blood pressure;
CESC	cis	rs367615	0.552	rs2115511	chr5:108725403	A/T	cg17395555	chr5:108820864	NA	-0.44	-7.4	-0.41	1.8e-12	Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs4665809	0.590	rs3806515	chr2:26466975	C/T	cg22920501	chr2:26401640	FAM59B	0.91	10.33	0.54	3.07e-21	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.830	rs114722517	chr4:99042061	G/A	cg18180107	chr4:99064573	C4orf37	0.41	5.29	0.31	2.51e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23071962	chr2:12856964	TRIB2	0.63	7.62	0.42	4.56e-13	Gut microbiome composition (summer);
CESC	cis	rs3105593	1.000	rs12439744	chr15:50899211	C/T	cg08437265	chr15:50716283	USP8	0.41	5.37	0.31	1.76e-7	QT interval;
CESC	cis	rs2243480	1.000	rs6970243	chr7:65388490	C/A	cg13147721	chr7:65941812	NA	-0.85	-8.1	-0.45	2e-14	Diabetic kidney disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16116313	chr12:122255002	SETD1B	-0.63	-7.22	-0.41	5.4e-12	Gut microbiome composition (summer);
CESC	cis	rs7089973	0.604	rs10885618	chr10:116617718	A/G	cg25233709	chr10:116636983	FAM160B1	0.4	6.61	0.38	2.08e-10	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs13108904	0.518	rs4974602	chr4:1342391	C/T	cg22903657	chr4:1355424	KIAA1530	-0.38	-5.11	-0.3	6.12e-7	Obesity-related traits;
CESC	cis	rs9733	0.596	rs72702580	chr1:150691285	A/T	cg18016565	chr1:150552671	MCL1	0.35	5.36	0.31	1.86e-7	Tonsillectomy;
CESC	cis	rs801193	1.000	rs7789184	chr7:66210195	A/T	cg18876405	chr7:65276391	NA	0.54	7.28	0.41	3.88e-12	Aortic root size;
CESC	trans	rs1814175	0.645	rs1818895	chr11:50031523	G/T	cg15704280	chr7:45808275	SEPT13	-1.01	-18.5	-0.75	1.25e-49	Height;
CESC	cis	rs644799	0.710	rs1852535	chr11:95501241	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.78	11.71	0.58	8.64e-26	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs4803468	1.000	rs2569754	chr19:41936734	A/G	cg08639244	chr19:41945921	ATP5SL	-0.43	-5.32	-0.31	2.24e-7	Height;
CESC	cis	rs769267	0.965	rs2965191	chr19:19453521	T/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.64	-8.23	-0.45	8.51e-15	Tonsillectomy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13751645	chr22:17513505	NA	-0.47	-6.22	-0.36	1.89e-9	Gut microbiome composition (summer);
CESC	cis	rs875971	1.000	rs6460296	chr7:65895139	C/T	cg10691866	chr7:65817282	TPST1	-0.34	-5.67	-0.33	3.76e-8	Aortic root size;
CESC	cis	rs362272	0.545	rs2749782	chr4:3339761	A/G	cg08886695	chr4:3369023	RGS12	-0.4	-5.43	-0.32	1.29e-7	Serum sulfate level;
CESC	cis	rs12497850	0.931	rs4974082	chr3:48999323	G/A	cg06212747	chr3:49208901	KLHDC8B	0.73	10.02	0.52	3.02e-20	Parkinson's disease;
CESC	cis	rs7582720	1.000	rs72926781	chr2:203808835	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.36	0.41	2.34e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs8141529	0.956	rs132539	chr22:29304253	C/T	cg02153584	chr22:29168773	CCDC117	0.45	5.38	0.31	1.65e-7	Lymphocyte counts;
CESC	cis	rs4819052	0.851	rs2838864	chr21:46711474	A/T	cg20896738	chr21:46707857	POFUT2;LOC642852	-0.44	-5.61	-0.33	5.1e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs17001868	0.527	rs73167009	chr22:40734249	T/C	cg07138101	chr22:40742427	ADSL	0.54	5.18	0.3	4.49e-7	Mammographic density (dense area);
CESC	cis	rs1620921	0.505	rs34797199	chr6:161203769	C/T	cg01280913	chr6:161186852	NA	-0.36	-5.27	-0.31	2.81e-7	Lipoprotein (a) - cholesterol levels;
CESC	cis	rs801193	1.000	rs3778909	chr7:66255646	G/C	cg11764359	chr7:65958608	NA	0.67	8.85	0.48	1.28e-16	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20118422	chr15:64455210	PPIB	0.63	7.5	0.42	9.57e-13	Gut microbiome composition (summer);
CESC	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg06877462	chr1:205807181	PM20D1	0.37	5.41	0.32	1.41e-7	Menarche (age at onset);
CESC	cis	rs2637266	0.703	rs2395435	chr10:78476163	G/C	cg18941641	chr10:78392320	NA	0.39	7.38	0.41	2.05e-12	Pulmonary function;
CESC	cis	rs8180040	0.726	rs6785790	chr3:47146932	C/T	cg27129171	chr3:47204927	SETD2	0.7	10.5	0.54	8.74e-22	Colorectal cancer;
CESC	cis	rs1008375	0.966	rs6837664	chr4:17697835	G/C	cg02297831	chr4:17616191	MED28	0.44	5.4	0.31	1.46e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs7264396	0.790	rs6060526	chr20:34225302	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.84	10.38	0.54	2.06e-21	Total cholesterol levels;
CESC	cis	rs4689388	0.926	rs10010131	chr4:6292915	A/G	cg14416269	chr4:6271139	WFS1	0.47	8.04	0.44	3.08e-14	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs2836974	0.568	rs414850	chr21:40543337	A/C	cg27266027	chr21:40555129	PSMG1	0.4	5.12	0.3	5.9e-7	Cognitive function;
CESC	cis	rs317689	0.513	rs317659	chr12:69686132	T/A	cg14784868	chr12:69753453	YEATS4	0.53	6.55	0.37	2.96e-10	Response to diuretic therapy;
CESC	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg24829409	chr8:58192753	C8orf71	-0.66	-7.93	-0.44	6.14e-14	Developmental language disorder (linguistic errors);
CESC	cis	rs6570726	0.791	rs13202312	chr6:145913093	T/G	cg05347473	chr6:146136440	FBXO30	0.57	7.24	0.41	4.72e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2070488	0.689	rs6809352	chr3:38544349	G/A	cg24069376	chr3:38537580	EXOG	-0.33	-5.75	-0.33	2.45e-8	Electrocardiographic conduction measures;
CESC	cis	rs1707322	1.000	rs12097761	chr1:46291162	T/C	cg06784218	chr1:46089804	CCDC17	0.34	5.77	0.33	2.17e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs3820928	1.000	rs10204368	chr2:227774244	G/C	cg05526886	chr2:227700861	RHBDD1	-0.42	-5.54	-0.32	7.19e-8	Pulmonary function;
CESC	cis	rs2506889	0.553	rs11580264	chr1:10605796	C/A	cg17425144	chr1:10567563	PEX14	0.34	5.27	0.31	2.79e-7	Breast cancer;
CESC	cis	rs6089829	0.925	rs3746748	chr20:61667526	C/T	cg03213289	chr20:61660250	NA	0.39	6.06	0.35	4.6e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs12464559	0.522	rs4300824	chr2:152581866	T/C	cg01189475	chr2:152685088	ARL5A	0.65	6.14	0.35	3.04e-9	Response to cognitive-behavioural therapy in anxiety disorder;
CESC	cis	rs67478160	0.619	rs10083370	chr14:104314182	G/A	cg01849466	chr14:104193079	ZFYVE21	0.5	6.84	0.39	5.43e-11	Schizophrenia;
CESC	cis	rs4713118	0.662	rs9468277	chr6:28028390	C/A	cg18032046	chr6:28092343	ZSCAN16	-0.54	-6.2	-0.36	2.21e-9	Parkinson's disease;
CESC	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.91	13.75	0.65	7.71e-33	Prudent dietary pattern;
CESC	cis	rs8031584	0.652	rs2691683	chr15:31135060	A/G	cg08704250	chr15:31115839	NA	0.69	9.23	0.49	8.87e-18	Huntington's disease progression;
CESC	cis	rs9467711	0.538	rs35942482	chr6:26444938	T/A	cg12826209	chr6:26865740	GUSBL1	0.67	5.15	0.3	5.15e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs6952809	0.590	rs1468337	chr7:2432211	C/T	cg23289794	chr7:2394357	EIF3B	-0.72	-6.86	-0.39	4.82e-11	Multiple sclerosis;
CESC	trans	rs7922314	0.571	rs16917985	chr10:64732314	T/C	cg06935979	chr1:232941706	KIAA1383	-0.66	-6.0	-0.35	6.47e-9	Cutaneous psoriasis;
CESC	cis	rs854765	0.575	rs7207821	chr17:17891781	A/G	cg04398451	chr17:18023971	MYO15A	-0.71	-10.17	-0.53	1.03e-20	Total body bone mineral density;
CESC	cis	rs7666738	0.830	rs1896154	chr4:99021161	T/C	cg17366294	chr4:99064904	C4orf37	0.6	8.67	0.47	4.29e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2070488	0.636	rs2284817	chr3:38510388	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.68	8.88	0.48	1.01e-16	Electrocardiographic conduction measures;
CESC	cis	rs9894429	0.966	rs7405901	chr17:79587813	T/C	cg13777783	chr17:79615861	NA	-0.35	-5.79	-0.34	1.99e-8	Eye color traits;
CESC	cis	rs9300255	0.602	rs2510885	chr12:123614813	G/C	cg19016782	chr12:123741754	C12orf65	-0.4	-5.62	-0.33	4.74e-8	Neutrophil percentage of white cells;
CESC	cis	rs597539	0.652	rs602805	chr11:68662076	A/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.8	10.48	0.54	9.64e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs7188697	0.922	rs7199856	chr16:58584772	A/C	cg02549819	chr16:58548995	SETD6	-0.42	-5.42	-0.32	1.36e-7	QT interval;
CESC	cis	rs4132509	1.000	rs9287269	chr1:243954551	G/A	cg21452805	chr1:244014465	NA	0.45	5.67	0.33	3.65e-8	RR interval (heart rate);
CESC	cis	rs6582630	0.555	rs11181053	chr12:38271364	T/C	cg26384229	chr12:38710491	ALG10B	-0.45	-5.97	-0.34	7.79e-9	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs6429082	0.791	rs291394	chr1:235651682	A/G	cg26050004	chr1:235667680	B3GALNT2	0.63	7.82	0.43	1.24e-13	Adiposity;
CESC	cis	rs9768139	0.733	rs13221388	chr7:158119270	G/A	cg06219351	chr7:158114137	PTPRN2	-0.5	-7.84	-0.43	1.1e-13	Calcium levels;
CESC	cis	rs12900413	0.687	rs35562959	chr15:90310537	C/T	cg24249390	chr15:90295951	MESP1	-0.4	-5.5	-0.32	9.05e-8	Coronary artery aneurysm in Kawasaki disease;
CESC	cis	rs12134245	0.747	rs11164929	chr1:92012836	G/C	cg07090678	chr1:91966139	CDC7	0.38	5.37	0.31	1.74e-7	Breast cancer;
CESC	cis	rs13242816	1.000	rs55803834	chr7:116103141	C/T	cg04696780	chr7:116139425	CAV2	-0.62	-5.69	-0.33	3.31e-8	P wave duration;
CESC	cis	rs1348850	0.526	rs10803912	chr2:178407176	A/C	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.64	-5.94	-0.34	8.78e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs1881797	0.872	rs2141544	chr1:247690800	A/G	cg21399703	chr1:247681439	NA	0.5	7.59	0.42	5.3e-13	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs7617773	0.539	rs12486935	chr3:48390164	C/T	cg11946769	chr3:48343235	NME6	0.66	8.41	0.46	2.55e-15	Coronary artery disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg05712126	chr22:29601860	EMID1	-0.47	-6.12	-0.35	3.44e-9	Fibrinogen levels;
CESC	cis	rs7666738	0.830	rs17027198	chr4:98991085	G/C	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.62e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1048238	0.846	rs945422	chr1:16345619	T/C	cg22431228	chr1:16359049	CLCNKA	-0.55	-11.23	-0.57	3.4e-24	Systolic blood pressure;
CESC	cis	rs6032067	1.000	rs13038434	chr20:43888106	G/A	cg11264863	chr20:43835661	SEMG1	0.48	5.05	0.3	8.23e-7	Blood protein levels;
CESC	cis	rs10789491	0.953	rs1866770	chr1:47182468	G/T	cg15501359	chr1:47185051	KIAA0494	0.8	8.75	0.47	2.51e-16	Response to hepatitis C treatment;
CESC	cis	rs9486719	1.000	rs2273622	chr6:97058567	A/G	cg06623918	chr6:96969491	KIAA0776	-0.82	-8.57	-0.47	8.91e-16	Migraine;Coronary artery disease;
CESC	cis	rs4629710	0.592	rs13195700	chr6:131585299	C/T	cg12606694	chr6:131520996	AKAP7	0.46	5.74	0.33	2.56e-8	Multiple myeloma (IgH translocation);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26052635	chr2:29339307	CLIP4	-0.53	-6.52	-0.37	3.64e-10	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24376286	chr2:198245629	NA	-0.6	-6.82	-0.39	6.17e-11	Gut microbiome composition (summer);
CESC	cis	rs6076065	0.925	rs6083106	chr20:23368809	A/C	cg11657817	chr20:23433608	CST11	0.36	5.35	0.31	1.92e-7	Facial morphology (factor 15, philtrum width);
CESC	cis	rs2273669	0.667	rs11755471	chr6:109342169	T/C	cg05315195	chr6:109294784	ARMC2	-0.67	-6.32	-0.36	1.13e-9	Prostate cancer;
CESC	cis	rs9457247	1.000	rs389946	chr6:167407268	T/C	cg25258033	chr6:167368657	RNASET2	0.39	5.89	0.34	1.15e-8	Crohn's disease;
CESC	cis	rs9303280	0.628	rs12939565	chr17:38038389	A/T	cg19468946	chr17:37922297	IKZF3	-0.43	-5.82	-0.34	1.71e-8	Self-reported allergy;
CESC	cis	rs77216612	0.877	rs7956514	chr12:12879254	T/G	cg04607235	chr12:12878440	APOLD1	-1.04	-16.29	-0.71	8.18e-42	Lymphocyte counts;
CESC	cis	rs9303280	0.806	rs2305480	chr17:38062196	G/A	cg19468946	chr17:37922297	IKZF3	-0.39	-5.2	-0.3	4.07e-7	Self-reported allergy;
CESC	cis	rs6951245	0.810	rs117800627	chr7:1081075	G/C	cg03188948	chr7:1209495	NA	0.68	6.6	0.38	2.23e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7660520	0.524	rs4862100	chr4:183732709	G/T	cg12483801	chr4:183727862	NA	0.76	6.92	0.39	3.38e-11	Pediatric autoimmune diseases;
CESC	cis	rs870825	0.616	rs6852082	chr4:185645783	T/C	cg04058563	chr4:185651563	MLF1IP	0.63	6.96	0.39	2.59e-11	Blood protein levels;
CESC	cis	rs4727027	0.866	rs2373437	chr7:148779032	T/C	cg23158103	chr7:148848205	ZNF398	-0.4	-6.44	-0.37	5.45e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs12541335	0.639	rs4871994	chr8:22206038	G/A	cg02788857	chr8:22132959	PIWIL2	0.31	5.42	0.32	1.33e-7	Hypertriglyceridemia;
CESC	cis	rs1707322	1.000	rs11211217	chr1:46348229	C/G	cg05343316	chr1:45956843	TESK2	0.44	5.55	0.32	7.05e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13507888	chr9:132199983	NA	0.55	6.06	0.35	4.57e-9	Gut microbiome composition (summer);
CESC	trans	rs561341	0.714	rs547473	chr17:30297560	T/G	cg27661571	chr11:113659931	NA	-0.72	-7.36	-0.41	2.36e-12	Hip circumference adjusted for BMI;
CESC	cis	rs1642645	0.793	rs4083557	chr1:42478177	C/T	cg16685388	chr1:42384056	HIVEP3	0.38	5.68	0.33	3.57e-8	Left ventricular obstructive tract defect (maternal effect);
CESC	trans	rs1994135	0.617	rs12821909	chr12:33723466	T/C	cg26384229	chr12:38710491	ALG10B	0.58	7.82	0.43	1.26e-13	Resting heart rate;
CESC	cis	rs17253792	0.822	rs79398217	chr14:56067350	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.82	5.73	0.33	2.69e-8	Putamen volume;
CESC	cis	rs853679	0.517	rs4713145	chr6:28106827	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.54	-6.33	-0.36	1.05e-9	Depression;
CESC	cis	rs17209837	1.000	rs45607141	chr7:87087025	A/G	cg00919237	chr7:87102261	ABCB4	-0.5	-5.83	-0.34	1.6e-8	Gallbladder cancer;
CESC	cis	rs2439831	0.867	rs6493085	chr15:43654182	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.84	12.1	0.6	4.05e-27	Lung cancer in ever smokers;
CESC	cis	rs4523957	0.583	rs2760739	chr17:2024217	C/T	cg16513277	chr17:2031491	SMG6	-0.71	-10.1	-0.53	1.62e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs7937682	0.562	rs630002	chr11:111377758	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.65	-8.61	-0.47	6.62e-16	Primary sclerosing cholangitis;
CESC	cis	rs6540559	1.000	rs4844895	chr1:209958580	T/C	cg22442454	chr1:209979470	IRF6	0.43	5.03	0.3	8.93e-7	Cleft lip with or without cleft palate;
CESC	cis	rs3813567	0.759	rs12148319	chr15:78956192	A/G	cg05914723	chr15:78953907	NA	0.44	5.66	0.33	4e-8	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
CESC	cis	rs7216064	1.000	rs58551145	chr17:65837235	A/G	cg07042672	chr17:66097459	LOC651250	-0.51	-5.23	-0.31	3.46e-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs12701220	0.655	rs10215292	chr7:1135263	A/G	cg26769984	chr7:1090371	C7orf50	0.65	7.22	0.41	5.64e-12	Bronchopulmonary dysplasia;
CESC	cis	rs950776	0.593	rs481134	chr15:78877563	C/T	cg24631222	chr15:78858424	CHRNA5	-0.4	-5.12	-0.3	5.74e-7	Sudden cardiac arrest;
CESC	cis	rs853679	0.517	rs9368557	chr6:28131537	T/C	cg20151795	chr6:28129481	ZNF389	0.44	5.55	0.32	6.85e-8	Depression;
CESC	cis	rs3785574	0.927	rs2854183	chr17:61968002	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.58	7.18	0.4	7.24e-12	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15010184	chr1:23543591	NA	0.54	6.12	0.35	3.28e-9	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.830	rs1813642	chr4:98852225	G/A	cg17366294	chr4:99064904	C4orf37	0.55	7.58	0.42	5.91e-13	Colonoscopy-negative controls vs population controls;
CESC	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.58	7.79	0.43	1.51e-13	Prudent dietary pattern;
CESC	cis	rs73019876	0.901	rs1849001	chr19:22130763	C/G	cg11619707	chr19:22235551	ZNF257	-0.27	-5.12	-0.3	5.8e-7	Testicular germ cell tumor;
CESC	cis	rs56104184	0.887	rs4801778	chr19:49370609	G/T	cg15549821	chr19:49342101	PLEKHA4	-0.56	-6.57	-0.37	2.68e-10	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	cis	rs7552404	1.000	rs11161510	chr1:76210289	A/G	cg22875332	chr1:76189707	ACADM	-0.62	-7.23	-0.41	5.23e-12	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs4253772	0.591	rs6007727	chr22:46650959	G/A	cg09491104	chr22:46646882	C22orf40	-0.59	-9.15	-0.49	1.58e-17	LDL cholesterol;Cholesterol, total;
CESC	trans	rs208520	0.690	rs207096	chr6:66797287	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.99	-12.82	-0.62	1.32e-29	Exhaled nitric oxide output;
CESC	cis	rs2832191	0.632	rs2246777	chr21:30309586	T/C	cg24692254	chr21:30365293	RNF160	-0.97	-16.5	-0.71	1.45e-42	Dental caries;
CESC	cis	rs847577	0.630	rs6969384	chr7:97732842	C/T	cg24562669	chr7:97807699	LMTK2	0.81	13.36	0.63	1.77e-31	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01110955	chr16:1706924	CRAMP1L	-0.63	-7.18	-0.4	7.06e-12	Gut microbiome composition (summer);
CESC	cis	rs42648	0.869	rs10234301	chr7:89918278	T/C	cg23697855	chr7:89950296	NA	0.28	5.37	0.31	1.7e-7	Homocysteine levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04880506	chr22:22337034	TOP3B	0.58	6.0	0.35	6.33e-9	Gut microbiome composition (summer);
CESC	cis	rs7659604	0.846	rs60340409	chr4:122666355	G/C	cg19671926	chr4:122722719	EXOSC9	-0.49	-5.94	-0.34	9.04e-9	Type 2 diabetes;
CESC	cis	rs2228479	0.850	rs117880578	chr16:89910230	C/G	cg06558623	chr16:89946397	TCF25	1.12	8.22	0.45	9.28e-15	Skin colour saturation;
CESC	cis	rs868036	0.958	rs4261478	chr15:68074084	G/A	cg08079166	chr15:68083412	MAP2K5	0.44	6.98	0.39	2.39e-11	Restless legs syndrome;
CESC	cis	rs950169	0.920	rs17300048	chr15:84749477	C/T	cg17507749	chr15:85114479	UBE2QP1	0.64	7.1	0.4	1.17e-11	Schizophrenia;
CESC	trans	rs12356475	0.710	rs10822686	chr10:67733250	C/T	cg09538139	chr9:127532208	NR6A1	-0.51	-6.21	-0.36	1.99e-9	Psoriatic arthritis;
CESC	cis	rs4555082	0.874	rs4677	chr14:105717279	T/C	cg13114125	chr14:105738426	BRF1	-0.81	-10.1	-0.53	1.72e-20	Mean platelet volume;Platelet distribution width;
CESC	cis	rs17253792	0.822	rs74609892	chr14:56053002	G/A	cg01858014	chr14:56050164	KTN1	-0.94	-6.94	-0.39	3.01e-11	Putamen volume;
CESC	cis	rs733175	0.855	rs9291641	chr4:10007259	C/T	cg11266682	chr4:10021025	SLC2A9	0.39	5.33	0.31	2.1e-7	Psychosis and Alzheimer's disease;
CESC	cis	rs9486715	1.000	rs6905737	chr6:97066659	A/T	cg18709589	chr6:96969512	KIAA0776	-0.47	-6.62	-0.38	1.98e-10	Headache;
CESC	cis	rs7666738	0.830	rs36028444	chr4:98968635	G/T	cg05340658	chr4:99064831	C4orf37	0.79	12.28	0.6	9.45e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs12422267	0.623	rs11246919	chr12:132569493	G/T	cg09764611	chr12:132620959	NA	-0.67	-5.15	-0.3	5.05e-7	Plasma amyloid beta peptide concentrations (ABx-40);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18202577	chr15:65809771	DPP8	0.56	6.11	0.35	3.61e-9	Gut microbiome composition (summer);
CESC	cis	rs875971	0.862	rs801206	chr7:66021966	C/G	cg18252515	chr7:66147081	NA	0.46	5.96	0.34	8.08e-9	Aortic root size;
CESC	cis	rs4654899	0.965	rs61779124	chr1:21513306	C/T	cg05370193	chr1:21551575	ECE1	0.41	6.25	0.36	1.61e-9	Superior frontal gyrus grey matter volume;
CESC	trans	rs10411161	0.721	rs1433082	chr19:52390726	A/C	cg22319618	chr22:45562946	NUP50	0.7	7.31	0.41	3.17e-12	Breast cancer;
CESC	cis	rs12928939	0.517	rs8050058	chr16:71981374	T/G	cg03805757	chr16:71968109	PKD1L3	-0.56	-6.33	-0.36	1.04e-9	Post bronchodilator FEV1;
CESC	cis	rs4665809	0.531	rs3892649	chr2:26457267	T/G	cg27170947	chr2:26402098	FAM59B	0.87	9.85	0.52	1.01e-19	Gut microbiome composition (summer);
CESC	cis	rs1008375	0.966	rs3775923	chr4:17585625	T/C	cg27347728	chr4:17578864	LAP3	0.5	5.75	0.33	2.49e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs3806843	1.000	rs7701755	chr5:140182101	G/T	cg16179182	chr5:140090404	VTRNA1-1	-0.41	-5.24	-0.31	3.26e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs332507	0.789	rs11928787	chr3:124408149	C/T	cg05980111	chr3:124395277	KALRN	0.36	5.13	0.3	5.56e-7	Plateletcrit;
CESC	cis	rs4853012	1.000	rs2280643	chr2:74358286	T/C	cg01017244	chr2:74357527	NA	0.68	9.44	0.5	1.95e-18	Gestational age at birth (maternal effect);
CESC	cis	rs16854884	0.609	rs9872126	chr3:143683851	G/A	cg01302019	chr3:143689584	C3orf58	-0.38	-5.95	-0.34	8.45e-9	Economic and political preferences (feminism/equality);
CESC	cis	rs2573652	0.722	rs12908133	chr15:100544405	G/A	cg00587665	chr15:100533223	ADAMTS17	-0.4	-6.48	-0.37	4.5e-10	Height;
CESC	cis	rs2439831	0.681	rs11858152	chr15:43634196	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.91	11.07	0.56	1.12e-23	Lung cancer in ever smokers;
CESC	cis	rs561341	1.000	rs4795669	chr17:30244701	C/T	cg19193384	chr17:30244184	NA	-0.67	-6.96	-0.39	2.6e-11	Hip circumference adjusted for BMI;
CESC	cis	rs7945705	0.818	rs2653613	chr11:8879105	C/T	cg09997546	chr11:8931473	C11orf17;ST5	-0.31	-5.14	-0.3	5.27e-7	Hemoglobin concentration;
CESC	cis	rs250677	1.000	rs190378	chr5:148434275	G/T	cg18129178	chr5:148520854	ABLIM3	-0.5	-5.74	-0.33	2.6e-8	Breast cancer;
CESC	cis	rs9322193	0.926	rs952166	chr6:150119910	A/T	cg04369109	chr6:150039330	LATS1	-0.39	-5.35	-0.31	1.93e-7	Lung cancer;
CESC	cis	rs1707322	0.752	rs28890893	chr1:46186576	T/G	cg05343316	chr1:45956843	TESK2	0.51	6.32	0.36	1.09e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs9929218	0.953	rs12920562	chr16:68737512	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.77	-9.51	-0.5	1.24e-18	Colorectal cancer;
CESC	cis	rs9287719	0.967	rs2287062	chr2:10743191	G/A	cg02196655	chr2:10830764	NOL10	-0.38	-5.83	-0.34	1.61e-8	Prostate cancer;
CESC	cis	rs7772486	0.875	rs1331639	chr6:146431869	A/G	cg05347473	chr6:146136440	FBXO30	-0.48	-6.42	-0.37	6.4e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7590368	0.673	rs17365181	chr2:10937980	T/C	cg15705551	chr2:10952987	PDIA6	0.54	5.17	0.3	4.51e-7	Educational attainment (years of education);
CESC	cis	rs2294693	0.945	rs9349175	chr6:40982401	T/C	cg14418226	chr6:40996092	UNC5CL	0.53	6.06	0.35	4.63e-9	Gastric cancer;Non-cardia gastric cancer;
CESC	cis	rs7085104	0.700	rs10786712	chr10:104596396	A/G	cg15744005	chr10:104629667	AS3MT	0.33	5.09	0.3	6.89e-7	Immature fraction of reticulocytes;Schizophrenia;
CESC	cis	rs6089829	0.889	rs6090206	chr20:61668363	G/A	cg16240275	chr20:61666158	NCRNA00029	0.5	8.89	0.48	9.54e-17	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs116095464	0.558	rs73031482	chr5:227594	G/A	cg22857025	chr5:266934	NA	-1.26	-18.2	-0.75	1.38e-48	Breast cancer;
CESC	cis	rs67478160	0.643	rs8004408	chr14:104203938	G/A	cg08213375	chr14:104286397	PPP1R13B	0.55	11.03	0.56	1.54e-23	Schizophrenia;
CESC	cis	rs6163	0.727	rs284862	chr10:104572081	C/T	cg04362960	chr10:104952993	NT5C2	-0.5	-6.85	-0.39	5.11e-11	Waist circumference;Hip circumference;
CESC	cis	rs6732160	0.588	rs10192654	chr2:73370882	A/T	cg01422370	chr2:73384389	NA	-0.53	-8.49	-0.46	1.51e-15	Intelligence (multi-trait analysis);
CESC	cis	rs10791323	0.604	rs2723605	chr11:133711241	C/G	cg15485101	chr11:133734466	NA	0.4	6.48	0.37	4.47e-10	Childhood ear infection;
CESC	cis	rs597539	0.552	rs6591361	chr11:68719284	T/C	cg04772025	chr11:68637568	NA	0.5	5.73	0.33	2.73e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs854765	0.583	rs7214536	chr17:17852446	G/A	cg16928487	chr17:17741425	SREBF1	-0.57	-9.57	-0.51	7.66e-19	Total body bone mineral density;
CESC	cis	rs6736093	0.830	rs11680463	chr2:112775611	T/A	cg12686935	chr2:112915763	FBLN7	-0.42	-5.34	-0.31	2.03e-7	Coronary artery disease;
CESC	cis	rs3820068	0.603	rs3766163	chr1:15986547	T/C	cg17385448	chr1:15911702	AGMAT	0.43	7.2	0.4	6.19e-12	Systolic blood pressure;
CESC	cis	rs7618915	0.501	rs3733045	chr3:52643307	A/G	cg07507251	chr3:52567010	NT5DC2	0.31	5.42	0.32	1.33e-7	Bipolar disorder;
CESC	cis	rs4481887	1.000	rs4244176	chr1:248468231	G/A	cg00666640	chr1:248458726	OR2T12	0.39	6.36	0.36	8.71e-10	Common traits (Other);
CESC	cis	rs35110281	0.627	rs7283362	chr21:44973667	C/G	cg01579765	chr21:45077557	HSF2BP	-0.51	-8.45	-0.46	1.98e-15	Mean corpuscular volume;
CESC	cis	rs7927771	0.770	rs11039203	chr11:47384597	A/G	cg05585544	chr11:47624801	NA	-0.49	-7.25	-0.41	4.56e-12	Subjective well-being;
CESC	cis	rs4332037	0.539	rs11764590	chr7:2032803	C/T	cg23422044	chr7:1970798	MAD1L1	-0.48	-5.16	-0.3	4.97e-7	Bipolar disorder;
CESC	cis	rs7692995	1.000	rs7692995	chr4:17936634	T/C	cg08925142	chr4:18023851	LCORL	-0.46	-5.31	-0.31	2.29e-7	Height;
CESC	cis	rs2072499	0.833	rs2251847	chr1:156204047	G/A	cg24450063	chr1:156163899	SLC25A44	0.82	12.61	0.61	7.21e-29	Testicular germ cell tumor;
CESC	cis	rs868036	0.915	rs4489954	chr15:68072075	A/C	cg08079166	chr15:68083412	MAP2K5	-0.46	-7.32	-0.41	3.03e-12	Restless legs syndrome;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09373211	chr1:154193749	C1orf43;UBAP2L	0.74	8.23	0.45	8.28e-15	Gut microbiome composition (summer);
CESC	cis	rs1538970	0.924	rs4660858	chr1:45936351	G/A	cg06784218	chr1:46089804	CCDC17	0.35	5.64	0.33	4.31e-8	Platelet count;
CESC	cis	rs13191362	1.000	rs35126854	chr6:163012443	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.78	8.14	0.45	1.51e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs7615952	0.599	rs60847438	chr3:125746005	T/C	cg15145296	chr3:125709740	NA	-0.51	-5.4	-0.31	1.5e-7	Blood pressure (smoking interaction);
CESC	cis	rs483180	0.511	rs496198	chr1:120207177	A/G	cg19096424	chr1:120255104	PHGDH	-0.42	-5.08	-0.3	7.2e-7	Macular telangiectasia type 2;
CESC	cis	rs9309711	0.643	rs4535074	chr2:3481637	A/G	cg15541040	chr2:3486749	NA	-0.45	-5.82	-0.34	1.67e-8	Neurofibrillary tangles;
CESC	cis	rs4713118	0.662	rs9393881	chr6:28023751	C/G	cg26335602	chr6:28129616	ZNF389	0.44	5.65	0.33	4.17e-8	Parkinson's disease;
CESC	cis	rs7666738	0.830	rs13149404	chr4:99070236	A/G	cg18180107	chr4:99064573	C4orf37	0.4	5.03	0.3	9.17e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs6600671	1.000	rs10903161	chr1:121178741	A/T	cg17023122	chr1:144479586	NA	0.45	6.27	0.36	1.49e-9	Hip geometry;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06943682	chr22:46692606	GTSE1;CN5H6.4	0.55	6.26	0.36	1.58e-9	Gut microbiome composition (summer);
CESC	cis	rs6674176	1.000	rs6674176	chr1:44379957	G/A	cg12908607	chr1:44402522	ARTN	-0.47	-6.51	-0.37	3.82e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg15763497	chr22:18256852	BID	0.42	6.16	0.35	2.64e-9	Vertical cup-disc ratio;
CESC	cis	rs1348850	0.914	rs8941	chr2:178406481	C/T	cg23306229	chr2:178417860	TTC30B	0.65	8.14	0.45	1.57e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs55823223	0.648	rs936394	chr17:73852008	C/A	cg23806715	chr17:73775811	H3F3B	0.61	6.68	0.38	1.37e-10	Psoriasis;
CESC	cis	rs853679	0.517	rs17711801	chr6:28092307	C/G	cg23161317	chr6:28129485	ZNF389	0.51	6.5	0.37	3.98e-10	Depression;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg09623457	chr3:183735666	ABCC5	0.43	6.15	0.35	2.88e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs7772486	0.875	rs9403764	chr6:146360582	G/A	cg23711669	chr6:146136114	FBXO30	0.85	12.56	0.61	1.02e-28	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1005277	0.579	rs2505194	chr10:38393881	C/T	cg00409905	chr10:38381863	ZNF37A	-0.45	-5.87	-0.34	1.28e-8	Extrinsic epigenetic age acceleration;
CESC	cis	rs4665809	0.887	rs6546716	chr2:26263836	A/G	cg26314531	chr2:26401878	FAM59B	-0.62	-6.88	-0.39	4.38e-11	Gut microbiome composition (summer);
CESC	trans	rs9329221	0.741	rs534523	chr8:9884999	C/G	cg15556689	chr8:8085844	FLJ10661	-0.54	-6.84	-0.39	5.51e-11	Neuroticism;
CESC	cis	rs6867032	1.000	rs4074914	chr5:2020274	C/T	cg26168224	chr5:2018326	NA	0.97	19.12	0.76	8.34e-52	Gut microbiome composition (winter);
CESC	cis	rs3736485	0.966	rs7161973	chr15:51854163	T/C	cg08986416	chr15:51914746	DMXL2	-0.4	-5.13	-0.3	5.5e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg10150615	chr22:24372951	LOC391322	0.56	7.73	0.43	2.18e-13	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs3820928	0.845	rs10165767	chr2:227781863	G/A	cg05526886	chr2:227700861	RHBDD1	-0.46	-5.9	-0.34	1.1e-8	Pulmonary function;
CESC	cis	rs11098499	0.710	rs4145952	chr4:120155806	C/A	cg09307838	chr4:120376055	NA	0.63	7.8	0.43	1.4e-13	Corneal astigmatism;
CESC	cis	rs1153858	1.000	rs7163720	chr15:45639374	G/A	cg21132104	chr15:45694354	SPATA5L1	0.82	11.02	0.56	1.72e-23	Homoarginine levels;
CESC	cis	rs4862750	0.872	rs6852907	chr4:187897094	A/C	cg07414643	chr4:187882934	NA	0.55	7.99	0.44	4.15e-14	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9926296	0.605	rs3743859	chr16:89846050	A/G	cg27121462	chr16:89883253	FANCA	-0.75	-10.99	-0.56	2.17e-23	Vitiligo;
CESC	cis	rs12325245	0.536	rs35832551	chr16:58591444	G/T	cg01152986	chr16:58549298	SETD6	0.89	5.4	0.32	1.45e-7	Schizophrenia;
CESC	cis	rs10751667	0.666	rs11246358	chr11:967349	G/A	cg06064525	chr11:970664	AP2A2	-0.5	-9.7	-0.51	3.17e-19	Alzheimer's disease (late onset);
CESC	cis	rs9733	0.596	rs2275236	chr1:150669952	A/G	cg22823121	chr1:150693482	HORMAD1	-0.5	-7.45	-0.42	1.36e-12	Tonsillectomy;
CESC	cis	rs10870270	1.000	rs10159746	chr10:133742677	C/T	cg26149184	chr10:133730230	NA	0.38	5.15	0.3	5.07e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg25789201	chr7:72395803	POM121	-0.51	-7.52	-0.42	8.45e-13	Gambling;
CESC	cis	rs10791323	0.569	rs10791328	chr11:133713730	A/G	cg06766960	chr11:133703094	NA	-0.39	-5.49	-0.32	9.51e-8	Childhood ear infection;
CESC	cis	rs1003719	0.788	rs2835578	chr21:38457671	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.62	8.67	0.47	4.41e-16	Eye color traits;
CESC	trans	rs864643	0.773	rs11129837	chr3:39589963	A/G	cg17274400	chr12:8234945	NECAP1	0.47	6.0	0.35	6.45e-9	Attention deficit hyperactivity disorder;
CESC	cis	rs2204008	0.837	rs11519926	chr12:38348992	G/A	cg13010199	chr12:38710504	ALG10B	0.53	6.62	0.38	2.03e-10	Bladder cancer;
CESC	cis	rs4722166	0.508	rs2069832	chr7:22767433	A/G	cg13104385	chr7:22767384	IL6	0.42	5.83	0.34	1.59e-8	Lung cancer;
CESC	trans	rs1814175	0.645	rs1608632	chr11:49967148	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.43	-6.26	-0.36	1.53e-9	Height;
CESC	cis	rs72634258	0.945	rs12735338	chr1:8078569	T/C	cg00042356	chr1:8021962	PARK7	0.82	7.53	0.42	7.8e-13	Inflammatory bowel disease;
CESC	cis	rs57221529	0.766	rs4081846	chr5:574019	G/A	cg16447950	chr5:562315	NA	-0.64	-6.86	-0.39	4.95e-11	Lung disease severity in cystic fibrosis;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg25845374	chr2:119981187	STEAP3	-0.45	-6.3	-0.36	1.25e-9	Ulcerative colitis;
CESC	cis	rs7098414	0.531	rs3844126	chr10:82019997	T/G	cg00277334	chr10:82204260	NA	-0.45	-5.85	-0.34	1.46e-8	Post bronchodilator FEV1;
CESC	cis	rs514406	0.861	rs554760	chr1:53266749	G/A	cg08736216	chr1:53307985	ZYG11A	0.43	7.13	0.4	9.53e-12	Monocyte count;
CESC	cis	rs9814567	1.000	rs9850015	chr3:134269541	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.47	-6.35	-0.36	9.53e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15921587	chr2:73144353	EMX1	0.66	8.08	0.44	2.28e-14	Gut microbiome composition (summer);
CESC	cis	rs2658782	0.789	rs2605580	chr11:93147054	C/T	cg15737290	chr11:93063684	CCDC67	0.39	5.03	0.3	9.19e-7	Pulmonary function decline;
CESC	cis	rs3796352	1.000	rs13072457	chr3:53102389	G/A	cg15956490	chr3:53032818	SFMBT1	0.63	5.15	0.3	5.18e-7	Immune reponse to smallpox (secreted IL-2);
CESC	cis	rs9399135	0.622	rs3817776	chr6:135256756	C/T	cg22676075	chr6:135203613	NA	-0.56	-8.44	-0.46	2.16e-15	Red blood cell count;
CESC	cis	rs6540556	0.769	rs6665715	chr1:209931353	A/C	cg05527609	chr1:210001259	C1orf107	0.49	6.09	0.35	3.9e-9	Red blood cell count;
CESC	cis	rs11148252	0.595	rs4885117	chr13:53153027	T/C	cg00495681	chr13:53174319	NA	0.61	8.44	0.46	2.05e-15	Lewy body disease;
CESC	cis	rs6540559	1.000	rs7522250	chr1:209962539	T/C	cg25204440	chr1:209979598	IRF6	0.63	8.01	0.44	3.76e-14	Cleft lip with or without cleft palate;
CESC	cis	rs11252926	0.966	rs11252923	chr10:566195	G/A	cg18196295	chr10:418757	DIP2C	-0.49	-5.78	-0.33	2.06e-8	Psychosis in Alzheimer's disease;
CESC	cis	rs2290159	0.800	rs73132351	chr3:12688284	A/G	cg23032965	chr3:12705835	RAF1	0.5	5.2	0.3	3.9e-7	Cholesterol, total;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg12791010	chr2:190305806	WDR75	-0.47	-6.27	-0.36	1.44e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs35306767	0.903	rs1341741	chr10:888073	A/G	cg25019033	chr10:957182	NA	-0.62	-6.76	-0.38	8.97e-11	Eosinophil percentage of granulocytes;
CESC	cis	rs30380	0.632	rs26496	chr5:96137882	A/G	cg16492584	chr5:96139282	ERAP1	-0.48	-6.78	-0.38	7.83e-11	Cerebrospinal fluid biomarker levels;
CESC	cis	rs9682041	0.696	rs11917147	chr3:170088448	C/T	cg11886554	chr3:170076028	SKIL	0.7	6.49	0.37	4.1e-10	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CESC	cis	rs1552244	0.882	rs13063098	chr3:10009919	G/A	cg00166722	chr3:10149974	C3orf24	0.46	5.67	0.33	3.7e-8	Alzheimer's disease;
CESC	cis	rs11920090	0.860	rs7646014	chr3:170740071	G/C	cg09710316	chr3:170744871	SLC2A2	0.4	5.03	0.3	9.13e-7	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
CESC	cis	rs4253772	0.515	rs77797820	chr22:46771270	C/T	cg18190219	chr22:46762943	CELSR1	-0.78	-6.33	-0.36	1.06e-9	LDL cholesterol;Cholesterol, total;
CESC	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg09177884	chr7:1199841	ZFAND2A	-0.59	-6.53	-0.37	3.28e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs11792861	0.888	rs72607168	chr9:111832192	G/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.42	5.26	0.31	3.04e-7	Menarche (age at onset);
CESC	cis	rs12701220	0.522	rs12701455	chr7:1055409	A/G	cg04025307	chr7:1156635	C7orf50	0.36	5.34	0.31	1.96e-7	Bronchopulmonary dysplasia;
CESC	cis	rs7809950	1.000	rs2712200	chr7:107142435	G/T	cg23024343	chr7:107201750	COG5	-0.43	-5.99	-0.35	6.99e-9	Coronary artery disease;
CESC	cis	rs8067545	1.000	rs8067545	chr17:19912710	T/C	cg13482628	chr17:19912719	NA	0.46	6.17	0.35	2.55e-9	Schizophrenia;
CESC	cis	rs12971120	0.891	rs12608037	chr18:72169395	A/G	cg26446133	chr18:72167187	CNDP2	-0.77	-9.41	-0.5	2.5e-18	Refractive error;
CESC	cis	rs9303280	0.840	rs12939457	chr17:38032188	T/C	cg20243544	chr17:37824526	PNMT	0.5	6.45	0.37	5.25e-10	Self-reported allergy;
CESC	cis	rs1801251	0.964	rs13007783	chr2:233566679	G/A	cg25237894	chr2:233734115	C2orf82	0.5	8.64	0.47	5.54e-16	Coronary artery disease;
CESC	trans	rs1814175	0.645	rs1851869	chr11:49960552	T/C	cg03929089	chr4:120376271	NA	-0.92	-15.24	-0.68	4.49e-38	Height;
CESC	cis	rs870825	0.616	rs6419939	chr4:185642869	C/T	cg04058563	chr4:185651563	MLF1IP	0.64	7.1	0.4	1.15e-11	Blood protein levels;
CESC	cis	rs6430585	0.528	rs111682961	chr2:136653848	C/T	cg07169764	chr2:136633963	MCM6	1.25	16.8	0.72	1.28e-43	Corneal structure;
CESC	cis	rs7647973	1.000	rs6783003	chr3:49524778	G/C	cg06212747	chr3:49208901	KLHDC8B	-0.56	-6.93	-0.39	3.22e-11	Menarche (age at onset);
CESC	cis	rs35306767	0.953	rs1106064	chr10:957211	G/A	cg10556349	chr10:835070	NA	0.57	5.98	0.34	7.08e-9	Eosinophil percentage of granulocytes;
CESC	cis	rs1874326	0.545	rs6964218	chr7:138112861	A/G	cg18008034	chr7:138118925	NA	-0.4	-5.16	-0.3	4.79e-7	Quantitative traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04760117	chr10:75900017	AP3M1	-0.58	-6.65	-0.38	1.72e-10	Gut microbiome composition (summer);
CESC	cis	rs10088262	0.629	rs7833650	chr8:124822969	C/T	cg20713898	chr8:124780851	FAM91A1	-0.67	-8.75	-0.47	2.52e-16	Pancreatic cancer;
CESC	cis	rs4908760	0.773	rs301805	chr1:8481016	T/G	cg00120948	chr1:8484417	RERE	-0.37	-5.9	-0.34	1.09e-8	Vitiligo;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg17895080	chr13:114096090	ADPRHL1	-0.44	-6.11	-0.35	3.61e-9	Systemic lupus erythematosus;
CESC	cis	rs4295623	0.559	rs4841600	chr8:11688148	T/C	cg00262122	chr8:11665843	FDFT1	0.51	6.36	0.36	8.71e-10	Morning vs. evening chronotype;
CESC	cis	rs7412746	0.658	rs6656535	chr1:150940357	G/T	cg22823121	chr1:150693482	HORMAD1	0.39	5.35	0.31	1.93e-7	Melanoma;
CESC	cis	rs9815354	0.812	rs73073233	chr3:42010550	A/G	cg03022575	chr3:42003672	ULK4	0.69	6.24	0.36	1.72e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs34779708	0.966	rs12769484	chr10:35465746	G/A	cg03585969	chr10:35415529	CREM	0.77	10.34	0.54	2.94e-21	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs614226	1.000	rs12310837	chr12:120880572	C/T	cg01236616	chr12:121019343	POP5	1.41	16.05	0.7	5.8e-41	Type 1 diabetes nephropathy;
CESC	cis	rs9911578	1.000	rs172565	chr17:56808996	A/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.38	5.15	0.3	5.07e-7	Intelligence (multi-trait analysis);
CESC	cis	rs1008375	1.000	rs1008375	chr4:17682834	T/C	cg02297831	chr4:17616191	MED28	0.46	5.83	0.34	1.63e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg06873352	chr17:61820015	STRADA	0.72	12.87	0.62	9.11e-30	Prudent dietary pattern;
CESC	cis	rs896854	0.715	rs12548874	chr8:95935164	A/C	cg09323728	chr8:95962352	TP53INP1	0.35	7.42	0.41	1.63e-12	Type 2 diabetes;
CESC	cis	rs12762955	0.561	rs10752022	chr10:1043798	C/T	cg06753689	chr10:1034030	GTPBP4	0.5	5.05	0.3	8.33e-7	Response to angiotensin II receptor blocker therapy;
CESC	cis	rs228437	1.000	rs1535118	chr6:134912447	C/T	cg24504307	chr6:134963096	NA	0.58	6.13	0.35	3.17e-9	Melanoma;
CESC	trans	rs7618501	0.933	rs3811695	chr3:49761613	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.59	-8.48	-0.46	1.65e-15	Intelligence (multi-trait analysis);
CESC	cis	rs1862618	0.853	rs863840	chr5:56128999	C/G	cg24549020	chr5:56110836	MAP3K1	0.57	6.52	0.37	3.61e-10	Initial pursuit acceleration;
CESC	cis	rs4665809	0.590	rs6716858	chr2:26423414	G/A	cg26314531	chr2:26401878	FAM59B	-0.73	-8.61	-0.47	6.76e-16	Gut microbiome composition (summer);
CESC	cis	rs2742234	0.541	rs61845684	chr10:43744983	T/C	cg07801480	chr10:43725741	RASGEF1A	-0.41	-5.22	-0.31	3.61e-7	Hirschsprung disease;
CESC	cis	rs7786877	0.583	rs41303510	chr7:100226129	C/T	cg27028030	chr7:100209634	MOSPD3	0.58	5.49	0.32	9.24e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	trans	rs2877832	0.778	rs73603735	chr14:27822378	A/G	cg13449535	chr1:1101348	MIR200B	0.55	6.65	0.38	1.67e-10	Diabetes related insulin traits;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg09435674	chr3:46933864	PTH1R	-0.5	-6.38	-0.36	7.82e-10	Ulcerative colitis;
CESC	cis	rs9916302	0.800	rs8069451	chr17:37504933	C/T	cg00129232	chr17:37814104	STARD3	-0.57	-7.34	-0.41	2.64e-12	Glomerular filtration rate (creatinine);
CESC	cis	rs1904096	0.506	rs8336	chr4:95211610	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.6	-9.53	-0.51	1.04e-18	Type 2 diabetes;
CESC	cis	rs7412746	0.658	rs2089082	chr1:150800090	T/G	cg04414720	chr1:150670196	GOLPH3L	0.56	7.46	0.42	1.21e-12	Melanoma;
CESC	cis	rs9611519	0.732	rs1883826	chr22:41703428	G/A	cg17376030	chr22:41985996	PMM1	0.48	5.38	0.31	1.6e-7	Neuroticism;
CESC	cis	rs929596	0.561	rs7564935	chr2:234645186	G/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.53	-6.33	-0.36	1.02e-9	Total bilirubin levels in HIV-1 infection;
CESC	trans	rs11098499	1.000	rs3749591	chr4:120214030	T/G	cg25214090	chr10:38739885	LOC399744	0.67	8.98	0.48	5.1e-17	Corneal astigmatism;
CESC	cis	rs10788264	0.569	rs7089468	chr10:124019052	T/C	cg09507567	chr10:124027408	NA	0.37	5.55	0.32	6.84e-8	Total body bone mineral density;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg00846248	chr7:86849067	C7orf23	-0.45	-6.42	-0.37	6.4e-10	Fibrinogen levels;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg04860312	chr1:209786644	CAMK1G	0.44	6.49	0.37	4.16e-10	Fibrinogen levels;
CESC	cis	rs55692411	0.537	rs35012435	chr3:50031840	C/T	cg03060546	chr3:49711283	APEH	-0.46	-5.24	-0.31	3.32e-7	Intelligence (multi-trait analysis);
CESC	trans	rs864643	0.773	rs11129837	chr3:39589963	A/G	cg15933527	chr12:51632360	DAZAP2	0.49	6.27	0.36	1.43e-9	Attention deficit hyperactivity disorder;
CESC	cis	rs1499614	1.000	rs60326618	chr7:66166358	G/A	cg12463550	chr7:65579703	CRCP	0.73	5.73	0.33	2.78e-8	Gout;
CESC	cis	rs9788333	0.962	rs34853044	chr13:21883784	C/T	cg21970626	chr13:21893289	NA	-0.44	-6.7	-0.38	1.24e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs9399135	0.967	rs2297340	chr6:135376058	T/C	cg24558204	chr6:135376177	HBS1L	0.53	7.22	0.41	5.36e-12	Red blood cell count;
CESC	cis	rs2242116	1.000	rs2168443	chr3:46947087	A/T	cg02527881	chr3:46936655	PTH1R	0.54	8.25	0.45	7.6e-15	Birth weight;
CESC	cis	rs7666738	0.962	rs1527515	chr4:99025733	C/A	cg17366294	chr4:99064904	C4orf37	0.58	7.75	0.43	1.91e-13	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10838687	0.736	rs4647726	chr11:47245494	A/T	cg25783544	chr11:47291846	MADD	0.57	6.54	0.37	3.15e-10	Proinsulin levels;
CESC	cis	rs1008375	0.931	rs1860592	chr4:17577028	C/G	cg02297831	chr4:17616191	MED28	0.5	6.15	0.35	2.82e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs875971	0.545	rs6950988	chr7:65976415	C/T	cg25405998	chr7:65216604	CCT6P1	0.45	5.11	0.3	6.25e-7	Aortic root size;
CESC	cis	rs2749592	0.588	rs2504144	chr10:38383525	C/T	cg25427524	chr10:38739819	LOC399744	-0.66	-8.75	-0.47	2.46e-16	Age-related hearing impairment (SNP x SNP interaction);
CESC	trans	rs66573146	1.000	rs6838250	chr4:6973184	C/G	cg07817883	chr1:32538562	TMEM39B	1.43	8.97	0.48	5.56e-17	Granulocyte percentage of myeloid white cells;
CESC	cis	rs7212590	0.748	rs8074843	chr17:57935935	C/G	cg20303301	chr17:57937339	TUBD1	-0.53	-5.24	-0.31	3.3e-7	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs1552244	1.000	rs12374115	chr3:10134766	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.85	-12.29	-0.6	9.22e-28	Alzheimer's disease;
CESC	cis	rs7811142	1.000	rs11763511	chr7:100081944	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.12	12.88	0.62	8.6e-30	Platelet count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10573763	chr19:19030094	COPE;DDX49	-0.62	-6.85	-0.39	5.01e-11	Gut microbiome composition (summer);
CESC	cis	rs9815354	0.680	rs73071354	chr3:41829186	C/A	cg03022575	chr3:42003672	ULK4	0.7	6.04	0.35	5.26e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs863345	0.967	rs1491196	chr1:158505506	T/A	cg12129480	chr1:158549410	OR10X1	-0.32	-6.3	-0.36	1.23e-9	Pneumococcal bacteremia;
CESC	cis	rs36051895	0.623	rs12720	chr9:5231712	T/A	cg02405213	chr9:5042618	JAK2	-0.57	-6.98	-0.39	2.31e-11	Pediatric autoimmune diseases;
CESC	cis	rs1552244	0.752	rs9867091	chr3:10043429	T/C	cg00149659	chr3:10157352	C3orf10	0.69	8.14	0.45	1.54e-14	Alzheimer's disease;
CESC	cis	rs116095464	1.000	rs7736	chr5:314935	T/C	cg10591111	chr5:226296	SDHA	-0.63	-5.89	-0.34	1.16e-8	Breast cancer;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg05644321	chr20:20693493	RALGAPA2	0.46	6.68	0.38	1.42e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs8064299	0.597	rs6501737	chr17:72780830	C/T	cg25054828	chr17:72772726	NAT9;TMEM104	-0.79	-13.48	-0.64	7.09e-32	Monocyte count;
CESC	cis	rs2050392	0.799	rs303429	chr10:30708441	C/T	cg25182066	chr10:30743637	MAP3K8	-0.39	-5.23	-0.31	3.5e-7	Inflammatory bowel disease;
CESC	cis	rs7208859	0.524	rs28760584	chr17:29141017	G/A	cg14008862	chr17:28927542	LRRC37B2	0.65	5.14	0.3	5.34e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs3820928	0.874	rs7562776	chr2:227806550	G/A	cg05526886	chr2:227700861	RHBDD1	-0.39	-5.04	-0.3	8.54e-7	Pulmonary function;
CESC	cis	rs1707322	1.000	rs6429588	chr1:46454058	T/G	cg05343316	chr1:45956843	TESK2	0.45	5.54	0.32	7.24e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs4851870	1.000	rs12997253	chr2:106444416	T/C	cg16077055	chr2:106428750	NCK2	-0.4	-5.13	-0.3	5.61e-7	Addiction;
CESC	cis	rs10504229	0.683	rs7835498	chr8:58129780	A/C	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs3857067	0.806	rs12505596	chr4:95109600	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.54	-7.94	-0.44	5.83e-14	QT interval;
CESC	cis	rs10887741	0.624	rs9633742	chr10:89432286	A/G	cg13926569	chr10:89418898	PAPSS2	0.46	6.98	0.39	2.36e-11	Exercise (leisure time);
CESC	cis	rs9911578	0.835	rs1990008	chr17:56459408	C/G	cg12560992	chr17:57184187	TRIM37	-0.89	-14.57	-0.67	1.04e-35	Intelligence (multi-trait analysis);
CESC	cis	rs911555	0.504	rs8006526	chr14:104075015	T/C	cg24130564	chr14:104152367	KLC1	-0.81	-13.18	-0.63	7.32e-31	Intelligence (multi-trait analysis);
CESC	cis	rs11098499	0.738	rs10026493	chr4:120384194	C/G	cg09307838	chr4:120376055	NA	0.95	13.79	0.65	5.71e-33	Corneal astigmatism;
CESC	trans	rs7615952	0.932	rs6438948	chr3:125650045	A/T	cg07211511	chr3:129823064	LOC729375	1.04	13.77	0.65	6.46e-33	Blood pressure (smoking interaction);
CESC	cis	rs10883723	0.775	rs7917158	chr10:104246471	C/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.55	7.56	0.42	6.55e-13	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs9948	0.655	rs57582887	chr2:97406354	A/C	cg01990225	chr2:97406019	LMAN2L	-1.02	-7.77	-0.43	1.76e-13	Erectile dysfunction and prostate cancer treatment;
CESC	cis	rs6088580	0.609	rs945674	chr20:32964247	G/C	cg24642439	chr20:33292090	TP53INP2	-0.53	-6.99	-0.39	2.17e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs11645898	0.935	rs35370634	chr16:72184566	C/T	cg14768367	chr16:72042858	DHODH	-0.76	-6.49	-0.37	4.28e-10	Blood protein levels;
CESC	cis	rs2354432	0.556	rs2353975	chr1:146837703	C/A	cg25205988	chr1:146714368	CHD1L	1.01	8.86	0.48	1.18e-16	Mitochondrial DNA levels;
CESC	cis	rs2717559	0.542	rs11774823	chr8:143887568	G/T	cg17252645	chr8:143867129	LY6D	-0.32	-5.47	-0.32	1.02e-7	Urinary tract infection frequency;
CESC	cis	rs7264396	0.790	rs6058293	chr20:34248891	T/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.64	7.77	0.43	1.78e-13	Total cholesterol levels;
CESC	cis	rs1878931	0.520	rs2015640	chr16:3465018	G/C	cg22508957	chr16:3507546	NAT15	0.44	5.81	0.34	1.82e-8	Body mass index (adult);
CESC	cis	rs10870270	1.000	rs10159943	chr10:133744744	T/C	cg08754478	chr10:133766260	PPP2R2D	-0.61	-7.93	-0.44	6.3e-14	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs651907	0.557	rs1056579	chr3:101397877	T/G	cg12386194	chr3:101231763	SENP7	0.45	5.53	0.32	7.8e-8	Colorectal cancer;
CESC	cis	rs9309473	0.607	rs7586361	chr2:73601606	G/A	cg20560298	chr2:73613845	ALMS1	-0.52	-7.4	-0.41	1.82e-12	Metabolite levels;
CESC	cis	rs6772849	0.805	rs61159406	chr3:128336009	G/A	cg16766828	chr3:128327626	NA	-0.31	-5.19	-0.3	4.14e-7	Monocyte percentage of white cells;Monocyte count;
CESC	cis	rs9291683	0.632	rs13101785	chr4:10042915	T/A	cg11266682	chr4:10021025	SLC2A9	0.67	13.02	0.62	2.72e-30	Bone mineral density;
CESC	cis	rs116095464	0.558	rs62347677	chr5:227453	A/G	cg20965017	chr5:231967	SDHA	-0.46	-5.26	-0.31	2.96e-7	Breast cancer;
CESC	cis	rs4819052	0.807	rs28715237	chr21:46673768	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.95	14.15	0.66	3.14e-34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs8060686	0.641	rs73612208	chr16:68206844	G/A	cg26727032	chr16:67993705	SLC12A4	-0.51	-6.18	-0.36	2.35e-9	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs12681288	0.723	rs12545453	chr8:970582	C/T	cg04851639	chr8:1020857	NA	-0.34	-6.88	-0.39	4.39e-11	Schizophrenia;
CESC	cis	rs4949448	1.000	rs4949448	chr1:32062066	A/C	cg13919466	chr1:32135498	COL16A1	0.46	8.13	0.45	1.68e-14	Intelligence (multi-trait analysis);
CESC	trans	rs3942852	0.568	rs7479361	chr11:48109793	C/T	cg03929089	chr4:120376271	NA	-0.69	-8.48	-0.46	1.62e-15	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs3820928	1.000	rs3820928	chr2:227773466	A/G	cg11843606	chr2:227700838	RHBDD1	-0.4	-5.41	-0.32	1.4e-7	Pulmonary function;
CESC	cis	rs17376456	0.825	rs12716453	chr5:93271697	T/C	cg21475434	chr5:93447410	FAM172A	0.74	6.16	0.35	2.67e-9	Diabetic retinopathy;
CESC	cis	rs1348850	0.768	rs57681892	chr2:178357645	G/C	cg23306229	chr2:178417860	TTC30B	0.66	8.49	0.46	1.49e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs2932538	0.744	rs6537742	chr1:113085197	G/T	cg22162597	chr1:113214053	CAPZA1	0.48	5.82	0.34	1.66e-8	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CESC	cis	rs736801	0.808	rs72797303	chr5:131796163	T/C	cg21138405	chr5:131827807	IRF1	-0.38	-5.64	-0.33	4.36e-8	Breast cancer;Mosquito bite size;
CESC	cis	rs10899021	0.920	rs11236181	chr11:74345823	A/C	cg12569118	chr11:74394623	NA	-0.55	-5.36	-0.31	1.79e-7	Response to metformin (IC50);
CESC	cis	rs12900413	0.687	rs8035472	chr15:90313432	T/C	cg24249390	chr15:90295951	MESP1	-0.41	-5.73	-0.33	2.78e-8	Coronary artery aneurysm in Kawasaki disease;
CESC	cis	rs6540556	0.608	rs3817821	chr1:209918503	A/T	cg05527609	chr1:210001259	C1orf107	-0.42	-5.16	-0.3	4.87e-7	Red blood cell count;
CESC	cis	rs798554	0.718	rs1636247	chr7:2881917	A/G	cg18446336	chr7:2847575	GNA12	-0.38	-5.91	-0.34	1.02e-8	Height;
CESC	cis	rs4722166	0.603	rs7801406	chr7:22788274	A/G	cg05472934	chr7:22766657	IL6	0.85	10.73	0.55	1.49e-22	Lung cancer;
CESC	cis	rs2204008	0.837	rs12366727	chr12:38365748	A/C	cg13010199	chr12:38710504	ALG10B	0.53	6.62	0.38	2.03e-10	Bladder cancer;
CESC	cis	rs561341	1.000	rs117979353	chr17:30272866	A/G	cg19193384	chr17:30244184	NA	-0.74	-6.9	-0.39	3.78e-11	Hip circumference adjusted for BMI;
CESC	cis	rs1348850	0.526	rs2141157	chr2:178374112	C/T	cg23306229	chr2:178417860	TTC30B	0.8	7.39	0.41	1.96e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs11112613	0.713	rs11112590	chr12:105951376	C/G	cg03607813	chr12:105948248	NA	-0.57	-6.79	-0.39	7.23e-11	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CESC	cis	rs977987	0.771	rs4888387	chr16:75389755	T/G	cg03315344	chr16:75512273	CHST6	0.39	5.6	0.33	5.36e-8	Dupuytren's disease;
CESC	cis	rs2011503	1.000	rs4808205	chr19:19645493	T/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.53	5.18	0.3	4.31e-7	Bipolar disorder;
CESC	cis	rs727563	0.635	rs5751149	chr22:42139501	A/G	cg03806693	chr22:41940476	POLR3H	1.16	13.59	0.64	2.85e-32	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs6460942	1.000	rs62448568	chr7:12407445	A/G	cg20607287	chr7:12443886	VWDE	-0.8	-9.05	-0.49	3.2e-17	Coronary artery disease;
CESC	cis	rs9611565	0.729	rs4822027	chr22:41786227	G/A	cg17376030	chr22:41985996	PMM1	0.7	7.6	0.42	5.18e-13	Vitiligo;
CESC	cis	rs2455799	0.634	rs62243671	chr3:15921098	C/T	cg16303742	chr3:15540471	COLQ	-0.37	-5.65	-0.33	4.12e-8	Mean platelet volume;
CESC	cis	rs9790314	0.586	rs16832246	chr3:161109916	A/G	cg03342759	chr3:160939853	NMD3	0.41	5.09	0.3	6.8e-7	Morning vs. evening chronotype;
CESC	cis	rs897080	0.515	rs1067337	chr2:44624859	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	5.91	0.34	1.07e-8	Height;
CESC	cis	rs7666738	0.830	rs11938686	chr4:98964470	A/G	cg17366294	chr4:99064904	C4orf37	0.59	8.35	0.46	3.96e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7666738	0.830	rs62318471	chr4:98925848	G/A	cg03467027	chr4:99064603	C4orf37	0.46	5.59	0.32	5.78e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9902453	0.967	rs9900911	chr17:28330280	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.62	-7.83	-0.43	1.15e-13	Coffee consumption (cups per day);
CESC	cis	rs736408	0.716	rs2239549	chr3:52823126	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.39	-5.11	-0.3	6.29e-7	Bipolar disorder;
CESC	cis	rs7927771	0.864	rs112060627	chr11:47426956	G/A	cg20307385	chr11:47447363	PSMC3	-0.63	-7.66	-0.43	3.58e-13	Subjective well-being;
CESC	cis	rs875971	0.965	rs9969301	chr7:65781655	G/A	cg10691866	chr7:65817282	TPST1	0.33	5.52	0.32	8.21e-8	Aortic root size;
CESC	cis	rs3020736	0.500	rs6002614	chr22:42501802	G/A	cg04733989	chr22:42467013	NAGA	-0.78	-11.9	-0.59	1.87e-26	Autism spectrum disorder or schizophrenia;
CESC	cis	rs72781680	0.848	rs6748727	chr2:24041058	G/A	cg20701182	chr2:24300061	SF3B14	0.63	5.65	0.33	4.21e-8	Lymphocyte counts;
CESC	trans	rs7819412	0.668	rs2409714	chr8:11010118	A/G	cg15556689	chr8:8085844	FLJ10661	-0.53	-6.68	-0.38	1.37e-10	Triglycerides;
CESC	cis	rs9905704	0.552	rs8071623	chr17:56621286	G/T	cg12560992	chr17:57184187	TRIM37	-0.63	-6.02	-0.35	5.95e-9	Testicular germ cell tumor;
CESC	cis	rs853679	0.517	rs9295758	chr6:28120663	C/G	cg08968635	chr6:28129556	ZNF389	0.41	5.28	0.31	2.7e-7	Depression;
CESC	cis	rs12701220	0.655	rs6955290	chr7:1151066	A/G	cg04025307	chr7:1156635	C7orf50	-0.45	-5.48	-0.32	9.86e-8	Bronchopulmonary dysplasia;
CESC	cis	rs754466	0.651	rs11002317	chr10:79617648	G/A	cg17075019	chr10:79541650	NA	-0.87	-13.72	-0.64	1.01e-32	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs7666738	0.761	rs13136913	chr4:98998031	C/T	cg18180107	chr4:99064573	C4orf37	0.4	5.23	0.31	3.41e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs963731	0.649	rs212322	chr2:39305928	C/T	cg04010122	chr2:39346883	SOS1	-0.65	-5.31	-0.31	2.3e-7	Corticobasal degeneration;
CESC	cis	rs9291683	0.509	rs6849717	chr4:9958719	T/C	cg00071950	chr4:10020882	SLC2A9	-0.8	-14.7	-0.67	3.54e-36	Bone mineral density;
CESC	cis	rs10870270	1.000	rs10870270	chr10:133754334	G/A	cg26149184	chr10:133730230	NA	0.38	5.22	0.31	3.7e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs727505	1.000	rs10271646	chr7:124549573	T/C	cg23710748	chr7:124431027	NA	-0.4	-6.39	-0.37	7.51e-10	Lewy body disease;
CESC	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-6.21	-0.36	2.01e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs9611565	0.802	rs2234058	chr22:41777883	G/A	cg03806693	chr22:41940476	POLR3H	-1.12	-13.95	-0.65	1.55e-33	Vitiligo;
CESC	cis	rs2637266	0.756	rs846623	chr10:78542819	C/T	cg18941641	chr10:78392320	NA	0.41	7.79	0.43	1.56e-13	Pulmonary function;
CESC	cis	rs1499614	0.803	rs1922723	chr7:66175063	C/T	cg18252515	chr7:66147081	NA	-1.42	-14.62	-0.67	6.69e-36	Gout;
CESC	cis	rs35110281	0.782	rs2246602	chr21:45064296	C/A	cg01579765	chr21:45077557	HSF2BP	-0.59	-10.14	-0.53	1.28e-20	Mean corpuscular volume;
CESC	cis	rs926392	0.547	rs8118808	chr20:37674996	C/G	cg16355469	chr20:37678765	NA	0.51	6.2	0.36	2.17e-9	Dialysis-related mortality;
CESC	cis	rs10958542	0.638	rs10958540	chr8:39081821	A/G	cg04904469	chr8:38845670	HTRA4	-0.32	-5.15	-0.3	4.97e-7	Interleukin-12p70 levels;
CESC	cis	rs2228479	1.000	rs62052213	chr16:89991963	C/T	cg14709524	chr16:89940631	TCF25	0.85	6.04	0.35	5.29e-9	Skin colour saturation;
CESC	cis	rs4665809	0.877	rs35224700	chr2:26298037	T/C	cg04944784	chr2:26401820	FAM59B	0.75	8.12	0.45	1.72e-14	Gut microbiome composition (summer);
CESC	cis	rs2235642	0.750	rs763152	chr16:1658056	T/C	cg03715980	chr16:1756201	MAPK8IP3	0.42	5.61	0.33	5.02e-8	Coronary artery disease;
CESC	cis	rs1461503	0.966	rs11218910	chr11:122842861	G/A	cg27398637	chr11:122830231	C11orf63	-0.55	-8.32	-0.45	4.77e-15	Menarche (age at onset);
CESC	cis	rs9911578	0.935	rs34523895	chr17:57034095	T/C	cg05425664	chr17:57184151	TRIM37	-0.4	-5.47	-0.32	1.04e-7	Intelligence (multi-trait analysis);
CESC	cis	rs933688	0.938	rs6869048	chr5:90664322	G/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.96	12.92	0.62	6.09e-30	Smoking behavior;
CESC	cis	rs8170	0.603	rs1544940	chr19:17414843	A/T	cg04749549	chr19:17459798	NA	-0.35	-5.61	-0.33	5.01e-8	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
CESC	cis	rs1552244	0.938	rs7625049	chr3:10115619	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	12.09	0.6	4.37e-27	Alzheimer's disease;
CESC	cis	rs12477438	0.765	rs13390672	chr2:99589829	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.64	-8.73	-0.47	2.94e-16	Chronic sinus infection;
CESC	cis	rs4888262	0.545	rs4588013	chr16:74703388	C/T	cg01733217	chr16:74700730	RFWD3	0.88	12.23	0.6	1.47e-27	Testicular germ cell tumor;
CESC	cis	rs7618501	0.602	rs10049087	chr3:50123417	A/G	cg24110177	chr3:50126178	RBM5	0.51	6.95	0.39	2.76e-11	Intelligence (multi-trait analysis);
CESC	cis	rs9614461	0.702	rs16993867	chr22:45733199	A/G	cg23503501	chr22:45809793	SMC1B;RIBC2	0.61	6.6	0.38	2.23e-10	Tonsillectomy;
CESC	cis	rs9611519	0.732	rs1883826	chr22:41703428	G/A	cg06481639	chr22:41940642	POLR3H	-0.52	-5.74	-0.33	2.57e-8	Neuroticism;
CESC	cis	rs597539	0.616	rs10896386	chr11:68722694	C/T	cg04772025	chr11:68637568	NA	0.56	6.47	0.37	4.68e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs6580649	0.941	rs72644843	chr12:48465061	A/G	cg05342945	chr12:48394962	COL2A1	0.51	5.91	0.34	1.07e-8	Lung cancer;
CESC	cis	rs13108904	0.837	rs4591539	chr4:1279938	G/C	cg00684032	chr4:1343700	KIAA1530	0.39	5.43	0.32	1.27e-7	Obesity-related traits;
CESC	cis	rs73001065	1.000	rs56255430	chr19:19477877	A/C	cg03709012	chr19:19516395	GATAD2A	0.95	5.91	0.34	1.07e-8	LDL cholesterol;
CESC	cis	rs9399137	0.507	rs11754021	chr6:135308375	A/G	cg24558204	chr6:135376177	HBS1L	0.7	9.61	0.51	5.93e-19	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	ch.2.3422646F	chr2:169470259	LASS6	-0.55	-6.38	-0.36	7.91e-10	Gut microbiome composition (summer);
CESC	cis	rs1832871	0.672	rs56326208	chr6:158762944	C/T	cg07165851	chr6:158734300	TULP4	0.58	6.19	0.36	2.31e-9	Height;
CESC	cis	rs11792861	0.781	rs72607159	chr9:111764270	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.53	6.83	0.39	5.63e-11	Menarche (age at onset);
CESC	cis	rs35110281	0.548	rs7276316	chr21:45029333	A/T	cg21573476	chr21:45109991	RRP1B	-0.49	-6.9	-0.39	3.77e-11	Mean corpuscular volume;
CESC	cis	rs8014204	0.836	rs7150254	chr14:75299101	G/A	cg08847533	chr14:75593920	NEK9	0.47	6.01	0.35	6.18e-9	Caffeine consumption;
CESC	cis	rs2760061	0.626	rs1636192	chr1:228124688	A/G	cg01973587	chr1:228161476	NA	0.38	5.84	0.34	1.49e-8	Diastolic blood pressure;
CESC	cis	rs7560272	0.723	rs1083919	chr2:73713863	C/G	cg20560298	chr2:73613845	ALMS1	0.51	7.22	0.41	5.48e-12	Schizophrenia;
CESC	cis	rs6463523	0.864	rs73047957	chr7:759373	A/T	cg11064039	chr7:766100	PRKAR1B;HEATR2	1.0	15.85	0.7	3.03e-40	Subjective well-being;
CESC	cis	rs4919694	0.808	rs4918001	chr10:105013147	G/T	cg04362960	chr10:104952993	NT5C2	-0.8	-6.85	-0.39	5.28e-11	Arsenic metabolism;
CESC	cis	rs3815700	1.000	rs8104726	chr19:33094675	G/A	cg02997394	chr19:33096574	ANKRD27	0.71	7.07	0.4	1.39e-11	Eosinophilic esophagitis;
CESC	cis	rs12477438	0.700	rs10190421	chr2:99670711	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-10.57	-0.54	5.22e-22	Chronic sinus infection;
CESC	cis	rs6686643	0.630	rs7554034	chr1:165610464	G/A	cg19407955	chr1:165599744	MGST3	-0.52	-5.24	-0.31	3.33e-7	Total ventricular volume;
CESC	cis	rs1552244	0.882	rs13099507	chr3:10031603	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.83	10.05	0.53	2.43e-20	Alzheimer's disease;
CESC	cis	rs1559088	1.000	rs7260051	chr19:33550111	C/A	cg17764715	chr19:33622953	WDR88	0.45	5.67	0.33	3.76e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	trans	rs9987353	0.840	rs329994	chr8:9123233	A/G	cg11939075	chr4:83956728	COPS4	0.52	6.77	0.38	8.29e-11	Recombination measurement;
CESC	cis	rs11098499	0.779	rs7356491	chr4:120381974	C/T	cg24375607	chr4:120327624	NA	0.44	5.51	0.32	8.65e-8	Corneal astigmatism;
CESC	cis	rs57506017	0.585	rs4721059	chr7:12267495	C/G	cg23422036	chr7:12250390	TMEM106B	-0.39	-5.29	-0.31	2.51e-7	Neuroticism;
CESC	cis	rs736408	0.609	rs13061423	chr3:52790213	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.48	6.72	0.38	1.09e-10	Bipolar disorder;
CESC	cis	rs11608355	0.515	rs3742018	chr12:109949134	C/T	cg05360138	chr12:110035743	NA	0.8	8.72	0.47	3.14e-16	Neuroticism;
CESC	cis	rs514406	0.929	rs554301	chr1:53321948	A/T	cg16325326	chr1:53192061	ZYG11B	-0.81	-12.88	-0.62	8.6e-30	Monocyte count;
CESC	cis	rs2836633	0.929	rs62217519	chr21:40034390	G/A	cg05519781	chr21:40033154	ERG	0.79	13.58	0.64	3e-32	Coronary artery disease;
CESC	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg26338869	chr17:61819248	STRADA	0.7	9.28	0.5	6.1e-18	Prudent dietary pattern;
CESC	cis	rs2742234	0.541	rs10793427	chr10:43747443	G/A	cg07801480	chr10:43725741	RASGEF1A	-0.41	-5.28	-0.31	2.75e-7	Hirschsprung disease;
CESC	cis	rs3858526	0.883	rs11039686	chr11:5948725	T/C	cg02574844	chr11:5959923	NA	-0.46	-5.73	-0.33	2.76e-8	DNA methylation (variation);
CESC	cis	rs10504229	0.906	rs7003276	chr8:58173089	A/T	cg22535103	chr8:58192502	C8orf71	-1.03	-12.84	-0.62	1.16e-29	Developmental language disorder (linguistic errors);
CESC	cis	rs514406	0.565	rs897732	chr1:53382816	A/C	cg25767906	chr1:53392781	SCP2	-0.52	-7.16	-0.4	7.76e-12	Monocyte count;
CESC	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg22535103	chr8:58192502	C8orf71	-0.92	-9.62	-0.51	5.68e-19	Developmental language disorder (linguistic errors);
CESC	cis	rs4665809	0.627	rs13032756	chr2:26489730	A/T	cg25036284	chr2:26402008	FAM59B	0.89	9.95	0.52	5.09e-20	Gut microbiome composition (summer);
CESC	cis	rs10504229	0.683	rs7820559	chr8:58142662	C/T	cg24829409	chr8:58192753	C8orf71	-0.55	-6.96	-0.39	2.66e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs10791111	1	rs10791111	chr11:130856099	T/G	cg14779329	chr11:130786720	SNX19	0.33	5.06	0.3	7.68e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs362296	0.511	rs2857861	chr4:3323767	C/T	cg08886695	chr4:3369023	RGS12	-0.47	-6.78	-0.38	7.57e-11	Parental longevity (mother's age at death);
CESC	cis	rs7267979	1.000	rs6050564	chr20:25344231	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.88	-18.07	-0.74	3.95e-48	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs4237845	0.742	rs3751330	chr12:58290226	T/C	cg02175503	chr12:58329896	NA	0.63	9.07	0.49	2.83e-17	Intelligence (multi-trait analysis);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg01472951	chr12:5603816	NTF3	0.45	6.02	0.35	5.77e-9	Fibrinogen levels;
CESC	cis	rs9660180	0.967	rs12044597	chr1:1708801	A/G	cg03396347	chr1:1875803	NA	-0.42	-6.52	-0.37	3.62e-10	Body mass index;
CESC	cis	rs7084402	0.935	rs12263522	chr10:60343527	C/A	cg07615347	chr10:60278583	BICC1	0.56	8.67	0.47	4.26e-16	Refractive error;
CESC	cis	rs7605827	0.930	rs9287660	chr2:15595767	C/A	cg19274914	chr2:15703543	NA	0.34	6.12	0.35	3.4e-9	Educational attainment (years of education);
CESC	cis	rs8112211	0.911	rs8106895	chr19:38848861	C/G	cg14299480	chr19:38876666	GGN	-0.41	-5.05	-0.3	8.09e-7	Blood protein levels;
CESC	cis	rs3126085	0.935	rs4845745	chr1:152185184	C/T	cg26876637	chr1:152193138	HRNR	0.48	5.44	0.32	1.21e-7	Atopic dermatitis;
CESC	cis	rs6502050	0.871	rs7226049	chr17:80071049	A/G	cg23985595	chr17:80112537	CCDC57	0.38	5.99	0.35	6.82e-9	Life satisfaction;
CESC	cis	rs6121246	0.609	rs6060627	chr20:30262159	C/T	cg13852791	chr20:30311386	BCL2L1	0.78	9.96	0.52	4.55e-20	Mean corpuscular hemoglobin;
CESC	trans	rs116095464	0.558	rs61689490	chr5:224904	T/C	cg00938859	chr5:1591904	SDHAP3	0.61	6.78	0.38	7.58e-11	Breast cancer;
CESC	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	10.23	0.53	6.6e-21	Prudent dietary pattern;
CESC	cis	rs10254118	0.730	rs6961517	chr7:133130940	G/T	cg10665199	chr7:133106180	EXOC4	0.55	7.4	0.41	1.78e-12	Intelligence (multi-trait analysis);
CESC	cis	rs34779708	0.897	rs4934529	chr10:35302376	T/A	cg03585969	chr10:35415529	CREM	0.76	10.03	0.52	2.79e-20	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs11098499	0.754	rs938056	chr4:120237453	C/T	cg09307838	chr4:120376055	NA	0.81	10.89	0.56	4.41e-23	Corneal astigmatism;
CESC	cis	rs2072499	0.966	rs6427304	chr1:156156789	A/G	cg24450063	chr1:156163899	SLC25A44	1.07	21.09	0.79	1.23e-58	Testicular germ cell tumor;
CESC	cis	rs9611565	0.592	rs12484254	chr22:41962003	T/A	cg06481639	chr22:41940642	POLR3H	-0.57	-6.38	-0.36	7.88e-10	Vitiligo;
CESC	cis	rs9916302	0.861	rs12150493	chr17:37586154	T/C	cg20243544	chr17:37824526	PNMT	0.51	6.5	0.37	4.03e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs1904096	0.506	rs4693378	chr4:95168552	A/T	cg11021082	chr4:95130006	SMARCAD1	-0.68	-11.1	-0.56	9.37e-24	Type 2 diabetes;
CESC	cis	rs7264396	0.563	rs2425119	chr20:34324216	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.88	-10.7	-0.55	1.88e-22	Total cholesterol levels;
CESC	cis	rs9291683	0.588	rs12507330	chr4:10002195	G/A	cg11266682	chr4:10021025	SLC2A9	0.64	12.68	0.61	4.08e-29	Bone mineral density;
CESC	cis	rs6500395	1.000	rs36077931	chr16:48594221	A/G	cg04672837	chr16:48644449	N4BP1	0.5	6.23	0.36	1.78e-9	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs6714710	0.535	rs3192177	chr2:98354511	G/A	cg26665480	chr2:98280029	ACTR1B	0.59	7.59	0.42	5.34e-13	Posterior cortical atrophy and Alzheimer's disease;
CESC	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.48	-5.04	-0.3	8.58e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs6952808	0.609	rs4721190	chr7:1954732	A/G	cg05863683	chr7:1912471	MAD1L1	-0.4	-6.02	-0.35	5.94e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs11690935	0.959	rs10207085	chr2:172585885	T/G	cg13550731	chr2:172543902	DYNC1I2	-0.97	-14.97	-0.68	4e-37	Schizophrenia;
CESC	cis	rs6460942	0.591	rs6942551	chr7:12338356	C/T	cg20607287	chr7:12443886	VWDE	-0.59	-6.5	-0.37	4.02e-10	Coronary artery disease;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg12205742	chr18:68097929	NA	-0.48	-6.66	-0.38	1.58e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs9556958	0.527	rs9517313	chr13:99105892	C/G	cg07423050	chr13:99094983	FARP1	0.28	5.29	0.31	2.52e-7	Educational attainment (years of education);
CESC	cis	rs1552244	1.000	rs6442146	chr3:10073544	C/T	cg00149659	chr3:10157352	C3orf10	0.75	9.34	0.5	4.04e-18	Alzheimer's disease;
CESC	cis	rs60154123	0.615	rs701943	chr1:210425727	A/G	cg21951975	chr1:209979733	IRF6	-0.48	-6.65	-0.38	1.67e-10	Coronary artery disease;
CESC	trans	rs11098499	0.754	rs2964	chr4:120240131	T/C	cg25214090	chr10:38739885	LOC399744	0.61	8.51	0.46	1.33e-15	Corneal astigmatism;
CESC	cis	rs533123	0.816	rs569356	chr1:29136686	A/G	cg08366446	chr1:29138936	OPRD1	-0.51	-5.03	-0.3	8.87e-7	Schizophrenia;
CESC	cis	rs17253792	0.822	rs10483645	chr14:56103766	G/T	cg01858014	chr14:56050164	KTN1	-0.96	-7.52	-0.42	8.3e-13	Putamen volume;
CESC	cis	rs17711722	0.510	rs11767457	chr7:65290615	C/T	cg06456125	chr7:65229604	NA	0.41	5.27	0.31	2.8e-7	Calcium levels;
CESC	cis	rs2276314	1.000	rs9304153	chr18:33562150	T/C	cg05985134	chr18:33552581	C18orf21	0.63	7.17	0.4	7.56e-12	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs9640161	0.750	rs1983440	chr7:150023941	G/C	cg13722127	chr7:150037890	RARRES2	0.34	5.12	0.3	6e-7	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs4909189	1.000	rs62493651	chr7:158135592	T/C	cg25566285	chr7:158114605	PTPRN2	0.44	5.97	0.34	7.51e-9	Response to amphetamines;
CESC	cis	rs57244997	0.725	rs73030431	chr6:162439575	G/A	cg17173639	chr6:162384350	PARK2	-0.45	-5.19	-0.3	4.15e-7	Mosquito bite size;
CESC	cis	rs1799949	0.930	rs4584865	chr17:41424919	C/G	cg23758822	chr17:41437982	NA	1.05	16.08	0.7	4.39e-41	Menopause (age at onset);
CESC	cis	rs10751667	0.961	rs7395928	chr11:952605	T/G	cg20946044	chr11:1010712	AP2A2	-0.41	-5.5	-0.32	8.87e-8	Alzheimer's disease (late onset);
CESC	cis	rs853679	0.517	rs11552219	chr6:28126834	C/T	cg23281280	chr6:28129359	ZNF389	0.59	7.9	0.44	7.47e-14	Depression;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg12882762	chr14:53196687	STYX	-0.5	-6.36	-0.36	8.94e-10	Fibrinogen levels;
CESC	cis	rs2204008	0.745	rs8189516	chr12:38239084	C/T	cg26384229	chr12:38710491	ALG10B	0.69	9.8	0.52	1.51e-19	Bladder cancer;
CESC	cis	rs4819052	0.851	rs13048789	chr21:46660714	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.46	5.79	0.34	2e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs7552404	1.000	rs12123977	chr1:76209754	A/G	cg22875332	chr1:76189707	ACADM	-0.61	-6.43	-0.37	6.02e-10	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs2000999	0.515	rs2854956	chr16:72115238	A/T	cg16558253	chr16:72132732	DHX38	-0.6	-9.28	-0.5	6.21e-18	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
CESC	cis	rs8141529	0.632	rs5762803	chr22:29193638	G/C	cg02153584	chr22:29168773	CCDC117	0.68	9.39	0.5	2.95e-18	Lymphocyte counts;
CESC	trans	rs61931739	0.500	rs11053271	chr12:34545407	C/A	cg13010199	chr12:38710504	ALG10B	0.51	6.58	0.37	2.47e-10	Morning vs. evening chronotype;
CESC	cis	rs4523957	0.651	rs9906968	chr17:2077493	G/C	cg16513277	chr17:2031491	SMG6	-0.71	-10.17	-0.53	1.04e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs2836974	0.897	rs8132295	chr21:40527774	A/G	cg27266027	chr21:40555129	PSMG1	-0.48	-5.96	-0.34	7.94e-9	Cognitive function;
CESC	cis	rs684232	0.602	rs10521107	chr17:511156	G/A	cg15660573	chr17:549704	VPS53	-0.82	-11.93	-0.59	1.53e-26	Prostate cancer;
CESC	cis	rs9322193	0.962	rs9689242	chr6:150109106	T/C	cg07701084	chr6:150067640	NUP43	0.43	5.85	0.34	1.45e-8	Lung cancer;
CESC	cis	rs6754311	0.510	rs1374329	chr2:136421323	A/G	cg15123519	chr2:136567270	LCT	-0.32	-5.18	-0.3	4.41e-7	Mosquito bite size;
CESC	cis	rs6991838	0.584	rs7836349	chr8:66503563	A/G	cg13398993	chr8:66546079	ARMC1	-0.48	-5.85	-0.34	1.45e-8	Intelligence (multi-trait analysis);
CESC	cis	rs12586317	0.553	rs78124218	chr14:35570606	G/A	cg16230307	chr14:35515116	FAM177A1	0.92	9.84	0.52	1.12e-19	Psoriasis;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03734322	chr17:1532856	SLC43A2	0.5	6.62	0.38	2.04e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg16132339	chr22:24313637	DDTL;DDT	0.42	6.34	0.36	9.7e-10	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs698813	0.756	rs2592196	chr2:44605522	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.45	5.44	0.32	1.18e-7	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
CESC	cis	rs6089584	0.850	rs881993	chr20:60623862	A/G	cg24733560	chr20:60626293	TAF4	0.47	6.75	0.38	9.09e-11	Body mass index;
CESC	cis	rs875971	0.862	rs10250544	chr7:65766561	A/G	cg18252515	chr7:66147081	NA	0.43	5.73	0.33	2.67e-8	Aortic root size;
CESC	cis	rs736408	0.507	rs6445531	chr3:52717282	T/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	5.93	0.34	9.38e-9	Bipolar disorder;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg13808088	chr2:74334539	TET3	0.43	6.44	0.37	5.57e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs72781680	0.898	rs72786286	chr2:24074659	T/A	cg08917208	chr2:24149416	ATAD2B	0.93	8.48	0.46	1.57e-15	Lymphocyte counts;
CESC	trans	rs1814175	0.781	rs11040681	chr11:49981654	G/T	cg15704280	chr7:45808275	SEPT13	-1.03	-20.41	-0.78	2.75e-56	Height;
CESC	trans	rs3749237	0.964	rs11714957	chr3:49776178	C/T	cg21659725	chr3:3221576	CRBN	0.54	6.48	0.37	4.54e-10	Resting heart rate;
CESC	cis	rs6785206	0.892	rs2712429	chr3:128336221	A/C	cg16766828	chr3:128327626	NA	-0.63	-6.46	-0.37	4.93e-10	Lymphocyte percentage of white cells;
CESC	cis	rs11048434	0.673	rs1124402	chr12:9062606	C/T	cg23795048	chr12:9217529	LOC144571	0.36	5.68	0.33	3.52e-8	Sjögren's syndrome;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg06746101	chr15:79603771	TMED3	-0.42	-6.01	-0.35	5.99e-9	Gambling;
CESC	cis	rs76419734	0.510	rs2216516	chr4:106749857	G/C	cg24545054	chr4:106630052	GSTCD;INTS12	-0.63	-6.38	-0.36	7.88e-10	Post bronchodilator FEV1;
CESC	cis	rs3845702	1.000	rs9989852	chr2:180839707	G/A	cg01881094	chr2:180872142	CWC22	-0.68	-7.29	-0.41	3.63e-12	Schizophrenia;
CESC	cis	rs6750795	0.569	rs1667305	chr2:232403829	A/G	cg19187155	chr2:232395269	NMUR1	0.64	11.51	0.58	3.87e-25	Height;
CESC	cis	rs10927875	0.632	rs1122068	chr1:16127480	G/C	cg21385522	chr1:16154831	NA	-1.03	-16.84	-0.72	9.42e-44	Dilated cardiomyopathy;
CESC	cis	rs35110281	0.774	rs141521	chr21:44963686	G/A	cg21573476	chr21:45109991	RRP1B	-0.41	-5.69	-0.33	3.34e-8	Mean corpuscular volume;
CESC	cis	rs965469	1.000	rs6051808	chr20:3350697	A/T	cg25506879	chr20:3388711	C20orf194	-0.57	-6.12	-0.35	3.41e-9	IFN-related cytopenia;
CESC	cis	rs7584330	0.737	rs6431540	chr2:238360966	T/C	cg14458575	chr2:238380390	NA	0.58	8.09	0.45	2.14e-14	Prostate cancer;
CESC	trans	rs804280	0.509	rs13268030	chr8:11783073	C/T	cg15556689	chr8:8085844	FLJ10661	0.5	6.14	0.35	2.93e-9	Myopia (pathological);
CESC	cis	rs9303401	0.573	rs34717648	chr17:56886624	T/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.01	12.43	0.61	2.98e-28	Cognitive test performance;
CESC	cis	rs1975974	1.000	rs7224508	chr17:21722352	T/A	cg18423549	chr17:21743878	NA	-0.56	-8.08	-0.44	2.36e-14	Psoriasis;
CESC	cis	rs6460942	0.597	rs12699388	chr7:12536336	T/C	cg20607287	chr7:12443886	VWDE	-0.72	-7.71	-0.43	2.51e-13	Coronary artery disease;
CESC	cis	rs6679073	1.000	rs6679073	chr1:205756484	A/C	cg11965913	chr1:205819406	PM20D1	0.43	6.15	0.35	2.9e-9	Prostate-specific antigen levels;
CESC	cis	rs910316	0.935	rs175448	chr14:75591071	G/A	cg11812906	chr14:75593930	NEK9	-0.87	-15.0	-0.68	3.17e-37	Height;
CESC	cis	rs453301	0.653	rs7016139	chr8:8895470	A/G	cg15556689	chr8:8085844	FLJ10661	-0.5	-6.3	-0.36	1.22e-9	Joint mobility (Beighton score);
CESC	cis	rs4692589	1.000	rs4692785	chr4:170938593	C/T	cg19918862	chr4:170955249	NA	0.35	5.49	0.32	9.23e-8	Anxiety disorder;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg15238519	chr22:50683529	TUBGCP6	-0.39	-6.07	-0.35	4.41e-9	Gambling;
CESC	cis	rs6541297	0.645	rs666718	chr1:230313662	A/G	cg20703242	chr1:230279135	GALNT2	-0.43	-5.6	-0.33	5.46e-8	Coronary artery disease;
CESC	cis	rs6540559	1.000	rs6696825	chr1:209982372	A/G	cg21951975	chr1:209979733	IRF6	0.58	9.08	0.49	2.56e-17	Cleft lip with or without cleft palate;
CESC	cis	rs1348850	0.567	rs12994392	chr2:178536640	A/G	cg22681709	chr2:178499509	PDE11A	-0.48	-7.68	-0.43	3e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs1691799	0.867	rs1027401	chr12:66760892	C/G	cg16791601	chr12:66731901	HELB	-0.77	-13.33	-0.63	2.24e-31	White blood cell count (basophil);
CESC	cis	rs7666738	0.830	rs28485415	chr4:99060340	G/A	cg17366294	chr4:99064904	C4orf37	0.62	8.89	0.48	9.9e-17	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3820928	1.000	rs7592387	chr2:227777095	A/G	cg05526886	chr2:227700861	RHBDD1	-0.44	-5.75	-0.33	2.45e-8	Pulmonary function;
CESC	cis	rs6835098	0.924	rs12639929	chr4:174156538	C/T	cg08422745	chr4:174089978	GALNT7	-0.76	-10.21	-0.53	7.67e-21	Dementia and core Alzheimer's disease neuropathologic changes;
CESC	cis	rs7116495	0.609	rs11235444	chr11:71831859	G/A	cg07596299	chr11:71824057	C11orf51	0.84	5.26	0.31	2.9e-7	Severe influenza A (H1N1) infection;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg17400366	chr19:10420311	ZGLP1	0.41	6.07	0.35	4.52e-9	Fibrinogen levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18045461	chr22:29601862	EMID1	0.57	6.21	0.36	2.09e-9	Gut microbiome composition (summer);
CESC	cis	rs7523050	0.730	rs7519107	chr1:109399367	A/C	cg08274380	chr1:109419600	GPSM2	0.83	5.58	0.32	5.89e-8	Fat distribution (HIV);
CESC	cis	rs300703	0.935	rs7568664	chr2:280939	A/G	cg21211680	chr2:198530	NA	0.86	7.32	0.41	2.89e-12	Blood protein levels;
CESC	cis	rs2842992	0.789	rs2277072	chr6:160182845	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.69	8.61	0.47	6.66e-16	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs7589728	1.000	rs12473740	chr2:88527647	A/G	cg04511125	chr2:88470314	THNSL2	0.53	5.31	0.31	2.37e-7	Plasma clusterin levels;
CESC	cis	rs1552244	0.882	rs36006511	chr3:10054191	C/T	cg00149659	chr3:10157352	C3orf10	0.69	8.03	0.44	3.14e-14	Alzheimer's disease;
CESC	trans	rs116095464	0.510	rs7714944	chr5:231765	C/T	cg00938859	chr5:1591904	SDHAP3	0.66	7.22	0.41	5.41e-12	Breast cancer;
CESC	cis	rs17253792	0.822	rs10143002	chr14:56074278	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.79	5.9	0.34	1.12e-8	Putamen volume;
CESC	cis	rs752010	0.684	rs10789402	chr1:42084649	A/G	cg06885757	chr1:42089581	HIVEP3	0.51	8.84	0.48	1.38e-16	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs9399135	0.622	rs3817776	chr6:135256756	C/T	cg24558204	chr6:135376177	HBS1L	-0.51	-7.15	-0.4	8.26e-12	Red blood cell count;
CESC	cis	rs826838	0.935	rs11168761	chr12:38997211	C/A	cg13010199	chr12:38710504	ALG10B	0.6	8.42	0.46	2.45e-15	Heart rate;
CESC	cis	rs12478296	0.685	rs67829386	chr2:242992276	T/A	cg06360820	chr2:242988706	NA	-0.81	-9.49	-0.5	1.36e-18	Obesity-related traits;
CESC	cis	rs2243480	1.000	rs1796228	chr7:66033084	G/A	cg12463550	chr7:65579703	CRCP	0.72	5.62	0.33	4.87e-8	Diabetic kidney disease;
CESC	cis	rs4713118	0.662	rs9468278	chr6:28028482	C/T	cg23281280	chr6:28129359	ZNF389	0.5	6.56	0.37	2.75e-10	Parkinson's disease;
CESC	cis	rs3857536	0.740	rs7756519	chr6:66892275	A/G	cg07460842	chr6:66804631	NA	-0.4	-5.23	-0.31	3.47e-7	Blood trace element (Cu levels);
CESC	cis	rs736408	0.509	rs13083798	chr3:52649748	A/G	cg05564831	chr3:52568323	NT5DC2	0.47	7.98	0.44	4.48e-14	Bipolar disorder;
CESC	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.44	-5.84	-0.34	1.49e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs1218582	0.804	rs4845398	chr1:154859038	G/C	cg09359103	chr1:154839909	KCNN3	-0.65	-12.4	-0.61	3.83e-28	Prostate cancer;
CESC	cis	rs2576037	0.899	rs2571034	chr18:44578565	A/G	cg19077165	chr18:44547161	KATNAL2	0.49	6.72	0.38	1.12e-10	Personality dimensions;
CESC	cis	rs2486288	0.656	rs7165039	chr15:45570413	C/G	cg09092052	chr15:45571596	NA	0.45	5.33	0.31	2.14e-7	Glomerular filtration rate;
CESC	cis	rs7618915	0.547	rs62253703	chr3:52632357	T/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.38	6.65	0.38	1.63e-10	Bipolar disorder;
CESC	cis	rs854765	0.583	rs5002487	chr17:17832460	A/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.5	6.6	0.38	2.21e-10	Total body bone mineral density;
CESC	cis	rs9649465	0.561	rs603060	chr7:123427568	A/G	cg03229431	chr7:123269106	ASB15	-0.43	-5.77	-0.33	2.15e-8	Migraine;
CESC	cis	rs7927771	0.524	rs7929014	chr11:47776283	C/T	cg18512352	chr11:47633146	NA	0.34	5.24	0.31	3.22e-7	Subjective well-being;
CESC	cis	rs769267	1.000	rs1009136	chr19:19440428	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	-0.45	-5.6	-0.33	5.33e-8	Tonsillectomy;
CESC	cis	rs35110281	0.686	rs162399	chr21:44950020	G/A	cg21573476	chr21:45109991	RRP1B	-0.41	-5.69	-0.33	3.38e-8	Mean corpuscular volume;
CESC	cis	rs10129255	0.500	rs59939897	chr14:107191651	A/G	cg07958169	chr14:107095056	NA	-0.54	-8.28	-0.45	5.93e-15	Kawasaki disease;
CESC	trans	rs1728785	1.000	rs1645938	chr16:68595197	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.65	7.84	0.43	1.09e-13	Ulcerative colitis;
CESC	cis	rs4253772	0.720	rs4253778	chr22:46630634	C/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.55	6.4	0.37	7.06e-10	LDL cholesterol;Cholesterol, total;
CESC	cis	rs1799949	0.965	rs8176322	chr17:41195773	A/G	cg23758822	chr17:41437982	NA	1.0	14.9	0.68	6.88e-37	Menopause (age at onset);
CESC	cis	rs7246657	0.882	rs28623164	chr19:37913453	G/A	cg23950597	chr19:37808831	NA	-0.55	-5.99	-0.35	6.69e-9	Coronary artery calcification;
CESC	cis	rs317689	0.513	rs529268	chr12:69687051	G/A	cg20891283	chr12:69753455	YEATS4	0.58	7.3	0.41	3.39e-12	Response to diuretic therapy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24853765	chr1:109584962	WDR47	0.66	7.87	0.44	8.86e-14	Gut microbiome composition (summer);
CESC	cis	rs2425143	1.000	rs2425141	chr20:34350123	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.8	-7.96	-0.44	5.07e-14	Blood protein levels;
CESC	cis	rs17376456	0.825	rs13155452	chr5:93164449	C/T	cg21475434	chr5:93447410	FAM172A	-0.76	-6.99	-0.39	2.19e-11	Diabetic retinopathy;
CESC	cis	rs13242816	1.000	rs56250718	chr7:116103303	A/G	cg04696780	chr7:116139425	CAV2	-0.62	-5.69	-0.33	3.31e-8	P wave duration;
CESC	cis	rs4654899	0.865	rs3856173	chr1:21114833	C/T	cg05370193	chr1:21551575	ECE1	0.35	5.28	0.31	2.74e-7	Superior frontal gyrus grey matter volume;
CESC	cis	rs262150	0.574	rs2730273	chr7:158797754	A/C	cg09640425	chr7:158790006	NA	-0.38	-5.89	-0.34	1.18e-8	Facial morphology (factor 20);
CESC	cis	rs2298450	0.717	rs2835330	chr21:37631173	G/A	cg02919814	chr21:37666008	DOPEY2	-0.38	-5.03	-0.3	9.06e-7	Schizophrenia;
CESC	cis	rs1059312	0.808	rs10847694	chr12:129292457	C/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.82	-12.11	-0.6	3.74e-27	Systemic lupus erythematosus;
CESC	cis	rs9300255	0.568	rs1790090	chr12:123633424	G/A	cg00376283	chr12:123451042	ABCB9	0.71	8.76	0.47	2.38e-16	Neutrophil percentage of white cells;
CESC	cis	rs7193541	0.965	rs4402594	chr16:74701360	C/T	cg01733217	chr16:74700730	RFWD3	0.89	13.1	0.63	1.44e-30	Multiple myeloma;
CESC	cis	rs9911578	0.967	rs4076229	chr17:56937256	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.26	0.31	3.04e-7	Intelligence (multi-trait analysis);
CESC	cis	rs7772486	0.790	rs7742333	chr6:146159029	A/G	cg05347473	chr6:146136440	FBXO30	-0.51	-6.36	-0.36	8.94e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs80130819	0.748	rs2130096	chr12:48742489	A/G	cg05342945	chr12:48394962	COL2A1	-0.53	-5.67	-0.33	3.64e-8	Prostate cancer;
CESC	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg03188948	chr7:1209495	NA	0.73	7.02	0.4	1.85e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs3857536	0.813	rs9363554	chr6:66930183	A/G	cg07460842	chr6:66804631	NA	-0.41	-5.19	-0.3	4.18e-7	Blood trace element (Cu levels);
CESC	cis	rs9815354	0.812	rs73828283	chr3:41835099	T/C	cg03022575	chr3:42003672	ULK4	0.7	6.04	0.35	5.26e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs6570726	0.935	rs436212	chr6:145849400	G/A	cg23711669	chr6:146136114	FBXO30	0.8	11.89	0.59	2e-26	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7789940	1.000	rs11765693	chr7:75985373	A/G	cg10167463	chr7:75959203	YWHAG	-0.56	-7.09	-0.4	1.23e-11	Multiple sclerosis;
CESC	cis	rs644799	0.544	rs1150360	chr11:95512060	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.61	8.27	0.45	6.69e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	trans	rs2727020	0.634	rs11040331	chr11:49345726	T/C	cg03929089	chr4:120376271	NA	-0.64	-6.89	-0.39	3.95e-11	Coronary artery disease;
CESC	cis	rs875971	0.830	rs4718358	chr7:65973668	T/C	cg18876405	chr7:65276391	NA	0.47	6.22	0.36	1.88e-9	Aortic root size;
CESC	cis	rs1401999	1.000	rs4148571	chr3:183720576	A/C	cg01324343	chr3:183735012	ABCC5	0.65	13.72	0.64	1e-32	Anterior chamber depth;
CESC	cis	rs2952156	0.920	rs2934956	chr17:37830447	T/A	cg00129232	chr17:37814104	STARD3	-0.79	-11.45	-0.58	6.45e-25	Asthma;
CESC	cis	rs4319547	0.695	rs4758643	chr12:122924819	A/T	cg05707623	chr12:122985044	ZCCHC8	-0.54	-6.14	-0.35	2.93e-9	Body mass index;
CESC	cis	rs367943	0.871	rs348938	chr5:112825032	C/A	cg12552261	chr5:112820674	MCC	-0.59	-7.57	-0.42	6.04e-13	Type 2 diabetes;
CESC	cis	rs7772486	0.754	rs13214277	chr6:146136125	G/T	cg05347473	chr6:146136440	FBXO30	0.57	7.31	0.41	3.12e-12	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg01786151	chr1:41347977	NA	-0.51	-7.11	-0.4	1.11e-11	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs28489187	0.706	rs233058	chr1:85798865	G/T	cg16011679	chr1:85725395	C1orf52	0.48	5.68	0.33	3.58e-8	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg21227347	chr9:117374170	C9orf91	-0.43	-6.1	-0.35	3.82e-9	Gambling;
CESC	cis	rs4148883	0.675	rs34511427	chr4:100105405	G/T	cg13256891	chr4:100009986	ADH5	0.53	6.95	0.39	2.8e-11	Alcohol dependence;
CESC	cis	rs9787249	0.957	rs6670841	chr1:40220284	C/G	cg19912559	chr1:40204330	PPIE	0.41	6.19	0.36	2.22e-9	Blood protein levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02099053	chr1:110880516	RBM15	-0.57	-6.73	-0.38	1.05e-10	Gut microbiome composition (summer);
CESC	cis	rs9660992	0.542	rs17345153	chr1:205179997	A/G	cg00857998	chr1:205179979	DSTYK	0.56	7.12	0.4	1.02e-11	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs9611565	0.729	rs2413646	chr22:41906325	C/T	cg03806693	chr22:41940476	POLR3H	-1.2	-14.88	-0.67	7.9e-37	Vitiligo;
CESC	cis	rs7927771	0.965	rs4752845	chr11:47539697	T/C	cg20307385	chr11:47447363	PSMC3	-0.52	-6.29	-0.36	1.32e-9	Subjective well-being;
CESC	cis	rs7818688	0.697	rs11784140	chr8:95987480	G/T	cg16049864	chr8:95962084	TP53INP1	0.55	5.6	0.33	5.32e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs6088580	0.634	rs6058041	chr20:33018008	A/G	cg08999081	chr20:33150536	PIGU	0.65	11.48	0.58	4.87e-25	Glomerular filtration rate (creatinine);
CESC	cis	rs2635047	0.935	rs2576031	chr18:44658146	A/G	cg19077165	chr18:44547161	KATNAL2	-0.5	-6.9	-0.39	3.81e-11	Educational attainment;
CESC	cis	rs9311474	0.607	rs28661185	chr3:52567188	G/T	cg07507251	chr3:52567010	NT5DC2	0.47	8.72	0.47	3.18e-16	Electroencephalogram traits;
CESC	cis	rs3784262	1.000	rs3204689	chr15:58246802	G/C	cg12031962	chr15:58353849	ALDH1A2	-0.32	-5.32	-0.31	2.2e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
CESC	cis	rs425277	0.917	rs78395918	chr1:2045876	G/A	cg04315214	chr1:2043799	PRKCZ	-0.43	-6.01	-0.35	6.26e-9	Height;
CESC	cis	rs10504229	1.000	rs76023408	chr8:58193345	A/G	cg22535103	chr8:58192502	C8orf71	-1.02	-12.7	-0.62	3.45e-29	Developmental language disorder (linguistic errors);
CESC	trans	rs11039798	0.920	rs11039940	chr11:48716316	C/T	cg15704280	chr7:45808275	SEPT13	0.7	6.42	0.37	6.38e-10	Axial length;
CESC	trans	rs10065369	0.545	rs11747036	chr5:113503402	A/T	cg04850370	chr1:32573395	KPNA6	0.61	6.04	0.35	5.31e-9	Night sleep phenotypes;
CESC	trans	rs11971186	0.824	rs1204516	chr7:126503252	A/C	cg10894441	chr11:111169905	C11orf92;C11orf93	0.48	6.09	0.35	3.99e-9	Chemerin levels;
CESC	cis	rs12497850	0.897	rs7373778	chr3:48836392	C/G	cg02487422	chr3:49467188	NICN1	0.4	5.08	0.3	6.97e-7	Parkinson's disease;
CESC	trans	rs11098499	0.909	rs79704848	chr4:120309351	T/A	cg25214090	chr10:38739885	LOC399744	0.68	9.2	0.49	1.14e-17	Corneal astigmatism;
CESC	cis	rs317689	0.690	rs570256	chr12:69662929	A/T	cg14784868	chr12:69753453	YEATS4	0.5	5.41	0.32	1.38e-7	Response to diuretic therapy;
CESC	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg08132940	chr7:1081526	C7orf50	-0.47	-5.05	-0.3	8.21e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs8073060	0.586	rs9303690	chr17:34005513	C/T	cg19694781	chr19:47549865	TMEM160	-0.72	-6.82	-0.39	6.11e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	cis	rs12824058	0.831	rs11616174	chr12:130814503	A/G	cg24838063	chr12:130822603	PIWIL1	0.62	8.55	0.47	9.78e-16	Menopause (age at onset);
CESC	cis	rs4803468	0.967	rs67047091	chr19:41938684	C/T	cg14132834	chr19:41945861	ATP5SL	0.69	8.52	0.46	1.24e-15	Height;
CESC	cis	rs977987	0.806	rs4887823	chr16:75433074	T/A	cg03315344	chr16:75512273	CHST6	0.4	5.71	0.33	3e-8	Dupuytren's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13866129	chr11:62623438	SNORD27;SLC3A2;SNORD28;SNORD25;SNORD26;SNHG1	0.57	6.93	0.39	3.19e-11	Gut microbiome composition (summer);
CESC	cis	rs11148252	0.574	rs2038826	chr13:53280013	G/A	cg00495681	chr13:53174319	NA	0.59	8.24	0.45	8.2e-15	Lewy body disease;
CESC	cis	rs60871478	0.636	rs10245785	chr7:894422	T/C	cg13798912	chr7:905769	UNC84A	-0.56	-5.52	-0.32	8.27e-8	Cerebrospinal P-tau181p levels;
CESC	trans	rs7937682	0.924	rs499750	chr11:111513645	T/G	cg18187862	chr3:45730750	SACM1L	0.5	6.44	0.37	5.46e-10	Primary sclerosing cholangitis;
CESC	cis	rs7772486	0.686	rs857883	chr6:145969214	G/T	cg05347473	chr6:146136440	FBXO30	-0.55	-7.1	-0.4	1.12e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs780096	0.546	rs2911712	chr2:27626945	A/T	cg17158414	chr2:27665306	KRTCAP3	-0.32	-5.98	-0.35	7.04e-9	Total body bone mineral density;
CESC	cis	rs2836974	0.800	rs73221174	chr21:40540939	T/C	cg11890956	chr21:40555474	PSMG1	1.13	20.04	0.78	5.19e-55	Cognitive function;
CESC	cis	rs7666738	0.752	rs62318905	chr4:99036103	T/G	cg24818145	chr4:99064322	C4orf37	0.38	5.04	0.3	8.81e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs8141529	0.687	rs6005867	chr22:29165120	T/C	cg02153584	chr22:29168773	CCDC117	0.72	10.16	0.53	1.11e-20	Lymphocyte counts;
CESC	cis	rs10504229	0.679	rs17193048	chr8:58055392	G/A	cg24829409	chr8:58192753	C8orf71	-0.6	-6.57	-0.37	2.71e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs1153858	1.000	rs1613559	chr15:45622116	A/G	cg21132104	chr15:45694354	SPATA5L1	0.78	10.44	0.54	1.35e-21	Homoarginine levels;
CESC	cis	rs6088580	0.634	rs4911151	chr20:32932273	T/C	cg08999081	chr20:33150536	PIGU	-0.64	-11.02	-0.56	1.76e-23	Glomerular filtration rate (creatinine);
CESC	cis	rs7680126	0.596	rs11722185	chr4:10317482	C/G	cg00071950	chr4:10020882	SLC2A9	-0.51	-5.74	-0.33	2.6e-8	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	cis	rs801193	0.660	rs2659897	chr7:66187715	A/G	cg13147721	chr7:65941812	NA	0.37	5.13	0.3	5.57e-7	Aortic root size;
CESC	cis	rs172166	0.694	rs203876	chr6:28046673	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.46	-5.96	-0.34	8.05e-9	Cardiac Troponin-T levels;
CESC	cis	rs13118159	0.641	rs4974598	chr4:1313220	C/T	cg16405210	chr4:1374714	KIAA1530	-0.62	-8.36	-0.46	3.58e-15	Longevity;
CESC	cis	rs1707322	1.000	rs946527	chr1:46485970	C/T	cg03146154	chr1:46216737	IPP	0.71	9.76	0.51	2.08e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg26737766	chr1:24127303	GALE	-0.45	-6.21	-0.36	2.01e-9	Asthma;
CESC	cis	rs965469	0.895	rs6051839	chr20:3391191	C/T	cg25506879	chr20:3388711	C20orf194	0.58	6.17	0.35	2.56e-9	IFN-related cytopenia;
CESC	cis	rs7917772	0.503	rs7915589	chr10:104299264	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.54	7.49	0.42	9.98e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs854765	0.647	rs854767	chr17:18018263	A/C	cg04398451	chr17:18023971	MYO15A	0.76	11.35	0.57	1.31e-24	Total body bone mineral density;
CESC	cis	rs7208859	0.623	rs7503335	chr17:29073962	G/A	cg14008862	chr17:28927542	LRRC37B2	0.65	5.14	0.3	5.34e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs1552244	0.572	rs17032440	chr3:10169819	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.79	-8.57	-0.47	8.91e-16	Alzheimer's disease;
CESC	trans	rs11088226	0.645	rs78172258	chr21:33936539	T/G	cg09050820	chr6:167586206	TCP10L2	0.83	7.75	0.43	2.01e-13	Gastritis;
CESC	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg07167872	chr1:205819463	PM20D1	0.77	12.56	0.61	1.05e-28	Menarche (age at onset);
CESC	cis	rs4713118	0.586	rs6905516	chr6:28086478	A/G	cg19592336	chr6:28129416	ZNF389	0.6	7.98	0.44	4.4e-14	Parkinson's disease;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03398387	chr6:160114178	SOD2	0.46	6.09	0.35	3.92e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs62064224	0.791	rs11653160	chr17:30717222	A/G	cg18200150	chr17:30822561	MYO1D	0.68	10.48	0.54	9.68e-22	Schizophrenia;
CESC	cis	rs6089584	0.566	rs6061963	chr20:60607480	C/G	cg06108461	chr20:60628389	TAF4	-0.58	-7.67	-0.43	3.26e-13	Body mass index;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23504092	chr20:13201342	ISM1	0.5	6.17	0.35	2.55e-9	Gut microbiome composition (summer);
CESC	trans	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg22433210	chr17:43662623	NA	0.99	11.0	0.56	1.96e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs7618915	0.547	rs2164884	chr3:52629633	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.59	0.38	2.35e-10	Bipolar disorder;
CESC	cis	rs992157	0.710	rs10169718	chr2:219103580	C/T	cg00012203	chr2:219082015	ARPC2	-0.85	-12.53	-0.61	1.3e-28	Colorectal cancer;
CESC	cis	rs3785574	0.962	rs2584633	chr17:61879501	T/C	cg07677032	chr17:61819896	STRADA	0.41	5.17	0.3	4.59e-7	Height;
CESC	cis	rs10832963	1.000	rs7943121	chr11:18656062	G/C	cg09201001	chr11:18656081	SPTY2D1	0.82	12.42	0.61	3.32e-28	Breast cancer;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg15003434	chr9:136202985	SURF6	-0.45	-6.57	-0.37	2.72e-10	Fibrinogen levels;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg04259979	chr5:44808944	MRPS30	0.49	6.1	0.35	3.7e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs13256369	1.000	rs12547721	chr8:8570671	C/T	cg18904891	chr8:8559673	CLDN23	0.68	7.92	0.44	6.49e-14	Obesity-related traits;
CESC	cis	rs2841277	0.770	rs10149193	chr14:105403474	C/T	cg21017887	chr14:105400489	NA	0.41	6.67	0.38	1.45e-10	Rheumatoid arthritis;
CESC	cis	rs2777491	0.915	rs16971767	chr15:41623308	T/C	cg02330683	chr15:41787940	ITPKA	0.43	6.27	0.36	1.43e-9	Ulcerative colitis;
CESC	cis	rs67460515	0.563	rs68166680	chr3:160829735	T/A	cg03342759	chr3:160939853	NMD3	-0.54	-6.86	-0.39	4.9e-11	Parkinson's disease;
CESC	cis	rs1003719	0.751	rs2835585	chr21:38460488	T/A	cg10648535	chr21:38446584	PIGP;TTC3	0.62	8.67	0.47	4.41e-16	Eye color traits;
CESC	cis	rs9733	0.596	rs2867300	chr1:150666990	C/G	cg04414720	chr1:150670196	GOLPH3L	0.61	8.64	0.47	5.42e-16	Tonsillectomy;
CESC	cis	rs2952156	0.920	rs732084	chr17:37834357	A/C	cg19468946	chr17:37922297	IKZF3	-0.39	-5.1	-0.3	6.37e-7	Asthma;
CESC	cis	rs1799949	1.000	rs11653069	chr17:41283377	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.67	9.36	0.5	3.44e-18	Menopause (age at onset);
CESC	cis	rs1577917	0.958	rs7747897	chr6:86647349	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.45	-5.87	-0.34	1.31e-8	Response to antipsychotic treatment;
CESC	cis	rs9611565	0.512	rs7291736	chr22:42124874	C/A	cg06634786	chr22:41940651	POLR3H	0.65	6.57	0.37	2.6200000000000003e-10	Vitiligo;
CESC	cis	rs748404	0.723	rs560134	chr15:43555699	A/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.61	8.03	0.44	3.2e-14	Lung cancer;
CESC	cis	rs7666738	0.830	rs991169	chr4:98928567	C/A	cg03467027	chr4:99064603	C4orf37	0.46	5.59	0.32	5.78e-8	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04276370	chr6:160390055	IGF2R	0.59	6.72	0.38	1.14e-10	Gut microbiome composition (summer);
CESC	cis	rs3741404	0.672	rs4980524	chr11:63959259	A/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.73	10.61	0.55	3.86e-22	Platelet count;
CESC	cis	rs1862618	0.671	rs2591970	chr5:56232595	T/C	cg22800045	chr5:56110881	MAP3K1	-0.59	-7.8	-0.43	1.43e-13	Initial pursuit acceleration;
CESC	cis	rs2929278	0.589	rs7174732	chr15:44038463	C/A	cg02155558	chr15:43621948	ADAL;LCMT2	-0.47	-7.42	-0.41	1.6e-12	Schizophrenia;
CESC	cis	rs3106136	1.000	rs3106136	chr4:95153349	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.48	-7.41	-0.41	1.65e-12	Capecitabine sensitivity;
CESC	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg03188948	chr7:1209495	NA	0.73	7.02	0.4	1.85e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs1448094	0.512	rs11117057	chr12:86248546	C/T	cg02569458	chr12:86230093	RASSF9	0.49	7.27	0.41	3.98e-12	Major depressive disorder;
CESC	cis	rs7666738	0.830	rs6532723	chr4:99052147	A/T	cg03467027	chr4:99064603	C4orf37	0.47	5.98	0.34	7.19e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1059312	1.000	rs2291350	chr12:129283711	G/A	cg09035930	chr12:129282057	SLC15A4	0.76	10.86	0.55	5.73e-23	Systemic lupus erythematosus;
CESC	cis	rs35306767	0.903	rs11253494	chr10:937047	C/T	cg25019033	chr10:957182	NA	-0.52	-5.56	-0.32	6.58e-8	Eosinophil percentage of granulocytes;
CESC	cis	rs13118159	0.714	rs6843025	chr4:1334418	C/G	cg16405210	chr4:1374714	KIAA1530	-0.6	-8.29	-0.45	5.79e-15	Longevity;
CESC	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg24829409	chr8:58192753	C8orf71	-0.67	-8.18	-0.45	1.19e-14	Developmental language disorder (linguistic errors);
CESC	cis	rs4625783	0.583	rs11077974	chr17:80095193	A/G	cg23985595	chr17:80112537	CCDC57	-0.42	-6.6	-0.38	2.18e-10	Blood metabolite levels;
CESC	cis	rs832540	0.931	rs33319	chr5:56206675	C/A	cg14703610	chr5:56206110	C5orf35	0.52	6.9	0.39	3.86e-11	Coronary artery disease;
CESC	cis	rs10504229	0.861	rs116964504	chr8:58185354	A/C	cg22535103	chr8:58192502	C8orf71	-1.05	-13.08	-0.63	1.71e-30	Developmental language disorder (linguistic errors);
CESC	cis	rs6456156	0.586	rs720325	chr6:167467349	G/T	cg07741184	chr6:167504864	NA	0.37	6.25	0.36	1.62e-9	Primary biliary cholangitis;
CESC	cis	rs2120019	0.938	rs8040169	chr15:75370958	C/A	cg09165964	chr15:75287851	SCAMP5	-0.67	-8.12	-0.45	1.76e-14	Blood trace element (Zn levels);
CESC	cis	rs11098499	0.789	rs12498994	chr4:120250818	A/C	cg09307838	chr4:120376055	NA	0.77	10.49	0.54	9.15e-22	Corneal astigmatism;
CESC	cis	rs925228	0.504	rs7568272	chr2:24313785	T/C	cg01493198	chr2:24299560	SF3B14	0.68	5.91	0.34	1.04e-8	Reticulocyte fraction of red cells;Reticulocyte count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07817097	chr1:179851575	TOR1AIP1	0.58	7.03	0.4	1.75e-11	Gut microbiome composition (summer);
CESC	cis	rs2932538	0.922	rs6673930	chr1:113104887	A/G	cg22162597	chr1:113214053	CAPZA1	0.54	6.94	0.39	2.97e-11	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CESC	cis	rs7666738	0.830	rs1813642	chr4:98852225	G/A	cg03467027	chr4:99064603	C4orf37	0.42	5.17	0.3	4.66e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs5771242	0.518	rs6010216	chr22:50679471	C/T	cg16473166	chr22:50639996	SELO	0.6	7.15	0.4	8.47e-12	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
CESC	cis	rs425277	0.565	rs61775448	chr1:2045376	A/G	cg23803603	chr1:2058230	PRKCZ	-0.35	-6.12	-0.35	3.38e-9	Height;
CESC	cis	rs2710642	0.962	rs7567923	chr2:63085848	C/T	cg17519650	chr2:63277830	OTX1	-0.55	-7.28	-0.41	3.78e-12	LDL cholesterol levels;LDL cholesterol;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg26335430	chr17:73780571	UNK	0.45	6.47	0.37	4.63e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs637571	0.522	rs1786175	chr11:65754808	G/A	cg17712092	chr4:129076599	LARP1B	0.75	10.7	0.55	1.89e-22	Eosinophil percentage of white cells;
CESC	cis	rs6121246	0.609	rs6060983	chr20:30420924	T/C	cg13852791	chr20:30311386	BCL2L1	0.8	10.12	0.53	1.39e-20	Mean corpuscular hemoglobin;
CESC	cis	rs11864453	1.000	rs7201491	chr16:72034312	G/A	cg01557791	chr16:72042693	DHODH	-0.67	-9.11	-0.49	2.07e-17	Fibrinogen levels;
CESC	cis	rs7809950	1.000	rs2395883	chr7:107089670	T/C	cg23024343	chr7:107201750	COG5	-0.41	-5.81	-0.34	1.75e-8	Coronary artery disease;
CESC	cis	rs7191700	0.673	rs12325495	chr16:11418328	C/T	cg00044050	chr16:11439710	C16orf75	0.46	5.71	0.33	3.07e-8	Multiple sclerosis;
CESC	cis	rs9399135	0.967	rs12527707	chr6:135324511	G/A	cg22676075	chr6:135203613	NA	0.51	7.23	0.41	5.22e-12	Red blood cell count;
CESC	cis	rs6690583	0.623	rs74761855	chr1:85432947	A/C	cg22153463	chr1:85462885	MCOLN2	0.78	7.42	0.41	1.57e-12	Serum sulfate level;
CESC	cis	rs7267979	0.903	rs2474766	chr20:25246153	A/G	cg08601574	chr20:25228251	PYGB	0.43	6.32	0.36	1.1e-9	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs9296736	0.890	rs9382280	chr6:53912613	C/T	cg04374786	chr6:53939321	C6orf142	0.35	5.31	0.31	2.38e-7	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs9457247	0.508	rs6941355	chr6:167506238	A/G	cg23791538	chr6:167370224	RNASET2	-0.45	-5.77	-0.33	2.2e-8	Crohn's disease;
CESC	cis	rs6540559	0.546	rs59435160	chr1:210030730	C/A	cg22029157	chr1:209979665	IRF6	0.67	7.21	0.41	5.69e-12	Cleft lip with or without cleft palate;
CESC	cis	rs4665809	0.556	rs4665314	chr2:26415912	T/C	cg27170947	chr2:26402098	FAM59B	-0.84	-9.99	-0.52	3.83e-20	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10165071	chr2:217557160	IGFBP5	-0.61	-7.56	-0.42	6.44e-13	Gut microbiome composition (summer);
CESC	trans	rs11098499	0.954	rs12508504	chr4:120410607	A/C	cg25214090	chr10:38739885	LOC399744	0.72	10.56	0.54	5.46e-22	Corneal astigmatism;
CESC	cis	rs17376456	0.825	rs6898842	chr5:93213221	T/C	cg21475434	chr5:93447410	FAM172A	0.83	7.21	0.41	5.8e-12	Diabetic retinopathy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09571404	chr2:241500448	DUSP28	0.62	6.98	0.39	2.32e-11	Gut microbiome composition (summer);
CESC	cis	rs11098499	0.820	rs28535956	chr4:120536858	C/T	cg24375607	chr4:120327624	NA	-0.45	-5.59	-0.32	5.71e-8	Corneal astigmatism;
CESC	cis	rs3785574	0.962	rs2584621	chr17:61912436	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.79	10.49	0.54	9.34e-22	Height;
CESC	cis	rs9287719	0.967	rs7608498	chr2:10738428	G/A	cg02196655	chr2:10830764	NOL10	-0.37	-5.72	-0.33	2.87e-8	Prostate cancer;
CESC	trans	rs9467711	0.659	rs35433030	chr6:26529890	G/A	cg06606381	chr12:133084897	FBRSL1	-0.93	-7.16	-0.4	8.07e-12	Autism spectrum disorder or schizophrenia;
CESC	cis	rs3820928	1.000	rs59904960	chr2:227761269	T/C	cg11843606	chr2:227700838	RHBDD1	-0.44	-5.84	-0.34	1.52e-8	Pulmonary function;
CESC	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg07092213	chr7:1199455	ZFAND2A	-0.48	-5.67	-0.33	3.71e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2115536	0.606	rs8024713	chr15:80206958	C/G	cg02196730	chr15:80188777	MTHFS	0.45	5.74	0.33	2.58e-8	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CESC	trans	rs9929218	0.954	rs4485355	chr16:68754730	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.76	-9.95	-0.52	5.04e-20	Colorectal cancer;
CESC	cis	rs3820068	0.554	rs60233444	chr1:15921330	A/C	cg17385448	chr1:15911702	AGMAT	0.42	6.72	0.38	1.13e-10	Systolic blood pressure;
CESC	cis	rs6973256	0.568	rs7783019	chr7:133347347	A/G	cg10665199	chr7:133106180	EXOC4	-0.46	-6.26	-0.36	1.55e-9	Intelligence (multi-trait analysis);
CESC	cis	rs9633740	1.000	rs1902660	chr10:82263683	G/C	cg00277334	chr10:82204260	NA	-0.58	-5.83	-0.34	1.62e-8	Post bronchodilator FEV1;
CESC	cis	rs10479542	0.892	rs7736163	chr5:178980316	G/C	cg09060608	chr5:178986726	RUFY1	0.51	7.79	0.43	1.5700000000000001e-13	Lung cancer;
CESC	cis	rs12824058	0.831	rs12320318	chr12:130812335	T/C	cg24838063	chr12:130822603	PIWIL1	0.62	8.55	0.47	9.78e-16	Menopause (age at onset);
CESC	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg07677032	chr17:61819896	STRADA	0.45	5.92	0.34	1.01e-8	Prudent dietary pattern;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg19024381	chr2:242626441	DTYMK	-0.57	-6.82	-0.39	6.3e-11	Ulcerative colitis;
CESC	cis	rs9486719	1.000	rs67996804	chr6:96884387	C/T	cg06623918	chr6:96969491	KIAA0776	-0.81	-8.29	-0.45	5.61e-15	Migraine;Coronary artery disease;
CESC	cis	rs950776	0.752	rs62010327	chr15:78892784	G/A	cg06917634	chr15:78832804	PSMA4	0.63	7.42	0.41	1.6e-12	Sudden cardiac arrest;
CESC	cis	rs5753618	0.554	rs5753648	chr22:31879465	A/G	cg00478049	chr22:31556069	RNF185	-0.48	-5.44	-0.32	1.23e-7	Colorectal cancer;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg23469188	chr7:108166441	PNPLA8	-0.48	-6.32	-0.36	1.13e-9	Fibrinogen levels;
CESC	cis	rs6952808	0.717	rs12534679	chr7:1926745	G/A	cg20295408	chr7:1910781	MAD1L1	-0.42	-5.4	-0.31	1.51e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs9300255	0.537	rs2682429	chr12:123642955	C/G	cg00376283	chr12:123451042	ABCB9	0.7	8.86	0.48	1.16e-16	Neutrophil percentage of white cells;
CESC	cis	rs9393777	0.513	rs9393737	chr6:26617306	A/G	cg11502198	chr6:26597334	ABT1	-0.5	-5.29	-0.31	2.61e-7	Intelligence (multi-trait analysis);
CESC	cis	rs2652822	0.530	rs1017545	chr15:63553994	A/G	cg02713581	chr15:63449717	RPS27L	0.41	5.07	0.3	7.51e-7	Metabolic traits;
CESC	cis	rs4835473	0.864	rs7682096	chr4:144630045	A/T	cg25736465	chr4:144833511	NA	0.4	6.17	0.35	2.59e-9	Immature fraction of reticulocytes;
CESC	cis	rs28830936	1.000	rs12440747	chr15:42036690	G/A	cg11010575	chr15:42129464	JMJD7-PLA2G4B;JMJD7	-0.37	-5.43	-0.32	1.25e-7	Diastolic blood pressure;
CESC	cis	rs6540559	0.611	rs76766079	chr1:209997731	C/T	cg22029157	chr1:209979665	IRF6	0.72	7.72	0.43	2.32e-13	Cleft lip with or without cleft palate;
CESC	cis	rs7385804	0.633	rs221795	chr7:100283261	C/T	cg16850897	chr7:100343110	ZAN	0.52	7.39	0.41	1.9e-12	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
CESC	trans	rs877282	0.891	rs12767043	chr10:797943	C/T	cg22713356	chr15:30763199	NA	1.35	13.42	0.64	1.08e-31	Uric acid levels;
CESC	cis	rs2439831	1.000	rs2467743	chr15:43750346	T/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.89	10.57	0.54	5.08e-22	Lung cancer in ever smokers;
CESC	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg07092213	chr7:1199455	ZFAND2A	-0.4	-5.45	-0.32	1.13e-7	Longevity;Endometriosis;
CESC	cis	rs830124	0.602	rs1375655	chr12:122385690	A/G	cg22168489	chr12:122356033	WDR66	0.38	5.12	0.3	5.85e-7	Urinary metabolites;
CESC	cis	rs910316	1.000	rs12588240	chr14:75612083	C/A	cg11812906	chr14:75593930	NEK9	0.91	15.77	0.7	5.67e-40	Height;
CESC	cis	rs9486715	0.830	rs2475023	chr6:96996833	G/A	cg18709589	chr6:96969512	KIAA0776	-0.46	-6.49	-0.37	4.3e-10	Headache;
CESC	cis	rs73001065	0.591	rs11668386	chr19:19531910	A/G	cg03709012	chr19:19516395	GATAD2A	0.92	7.09	0.4	1.19e-11	LDL cholesterol;
CESC	cis	rs2576037	0.526	rs2051292	chr18:44484372	C/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.46	7.39	0.41	1.86e-12	Personality dimensions;
CESC	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg18402987	chr7:1209562	NA	0.74	8.07	0.44	2.5e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs1008375	0.932	rs4698627	chr4:17605959	T/C	cg16339924	chr4:17578868	LAP3	0.63	8.08	0.44	2.34e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs7666738	0.753	rs11097607	chr4:99011640	C/T	cg03467027	chr4:99064603	C4orf37	0.44	5.53	0.32	7.6e-8	Colonoscopy-negative controls vs population controls;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg02671806	chr15:65477420	CLPX	-0.43	-6.06	-0.35	4.53e-9	Gambling;
CESC	cis	rs4728302	0.869	rs12707128	chr7:133589796	A/G	cg10665199	chr7:133106180	EXOC4	0.4	5.41	0.32	1.44e-7	Intelligence;Intelligence (multi-trait analysis);
CESC	cis	rs2439831	1.000	rs690263	chr15:43704465	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.8	11.73	0.58	7.16e-26	Lung cancer in ever smokers;
CESC	cis	rs13385	0.769	rs34675890	chr5:139622272	T/C	cg26211634	chr5:139558579	C5orf32	0.49	5.32	0.31	2.2e-7	Atrial fibrillation;
CESC	cis	rs7208859	0.562	rs216408	chr17:28907757	C/G	cg19761014	chr17:28927070	LRRC37B2	-0.81	-7.73	-0.43	2.29e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs10752881	0.935	rs12082051	chr1:183051614	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.85	13.7	0.64	1.21e-32	Colorectal cancer;
CESC	cis	rs7666738	0.830	rs7687958	chr4:99014495	T/C	cg17366294	chr4:99064904	C4orf37	0.6	8.62	0.47	6.37e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4077515	0.934	rs78428995	chr9:139281847	T/C	cg14169450	chr9:139327907	INPP5E	0.39	5.59	0.32	5.58e-8	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs2070488	0.775	rs1073505	chr3:38566722	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.78	-12.87	-0.62	9.13e-30	Electrocardiographic conduction measures;
CESC	cis	rs7296418	0.816	rs1790096	chr12:123710364	C/T	cg05973401	chr12:123451056	ABCB9	0.51	6.63	0.38	1.88e-10	Platelet count;
CESC	cis	rs75064307	0.798	rs2290601	chr3:108112760	C/T	cg03329597	chr3:108125523	MYH15	0.52	5.86	0.34	1.4e-8	Intelligence (multi-trait analysis);
CESC	cis	rs1665050	0.534	rs4775106	chr15:59238261	A/G	cg05156742	chr15:59063176	FAM63B	0.5	6.42	0.37	6.18e-10	Atopic dermatitis;
CESC	cis	rs2576037	0.583	rs8098948	chr18:44512332	C/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.5	-6.75	-0.38	9.12e-11	Personality dimensions;
CESC	trans	rs6921919	0.562	rs13198809	chr6:28323702	G/A	cg06606381	chr12:133084897	FBRSL1	-1.1	-8.38	-0.46	3.13e-15	Autism spectrum disorder or schizophrenia;
CESC	cis	rs9311474	0.607	rs13076398	chr3:52573096	G/A	cg18099408	chr3:52552593	STAB1	-0.35	-6.11	-0.35	3.63e-9	Electroencephalogram traits;
CESC	cis	rs739401	0.572	rs12276060	chr11:3015572	A/T	cg25174290	chr11:3078921	CARS	0.51	6.94	0.39	3.06e-11	Longevity;
CESC	cis	rs870825	0.698	rs72703549	chr4:185623963	T/C	cg04058563	chr4:185651563	MLF1IP	0.64	7.05	0.4	1.59e-11	Blood protein levels;
CESC	cis	rs863345	0.604	rs7544134	chr1:158475421	G/T	cg12129480	chr1:158549410	OR10X1	-0.35	-6.97	-0.39	2.58e-11	Pneumococcal bacteremia;
CESC	cis	rs514406	0.698	rs511599	chr1:53362818	T/C	cg16325326	chr1:53192061	ZYG11B	0.53	7.5	0.42	9.67e-13	Monocyte count;
CESC	cis	rs6762	0.748	rs7936838	chr11:839093	G/C	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.67	-8.57	-0.47	8.66e-16	Mean platelet volume;
CESC	cis	rs6500395	1.000	rs7194570	chr16:48672986	A/G	cg04672837	chr16:48644449	N4BP1	-0.49	-6.14	-0.35	2.97e-9	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs780096	0.506	rs72819512	chr2:27614449	G/A	cg17158414	chr2:27665306	KRTCAP3	-0.29	-5.34	-0.31	2.04e-7	Total body bone mineral density;
CESC	cis	rs2267137	0.868	rs5763178	chr22:29773869	A/G	cg07256473	chr22:29710276	RASL10A	0.41	6.16	0.35	2.76e-9	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	cis	rs2180341	0.920	rs9398836	chr6:127576497	T/G	cg24812749	chr6:127587940	RNF146	1.08	15.45	0.69	7.93e-39	Breast cancer;
CESC	cis	rs35955747	1.000	rs35955747	chr22:31813058	A/T	cg25791279	chr22:32026902	PISD	-0.43	-5.13	-0.3	5.7e-7	Neutrophil count;Sum basophil neutrophil counts;
CESC	cis	rs8114671	0.562	rs6058137	chr20:33475074	G/A	cg07148914	chr20:33460835	GGT7	0.52	6.78	0.38	7.94e-11	Height;
CESC	cis	rs9660992	0.789	rs1768584	chr1:205240145	A/G	cg21643547	chr1:205240462	TMCC2	-0.47	-6.93	-0.39	3.13e-11	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs11264213	0.786	rs72659686	chr1:36275767	G/T	cg27506609	chr1:36549197	TEKT2	0.65	5.34	0.31	1.97e-7	Schizophrenia;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg24333206	chr3:140660642	SLC25A36	-0.45	-6.11	-0.35	3.54e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs11723261	0.621	rs57013142	chr4:135738	T/A	cg12746427	chr4:53362	ZNF718;ZNF595	0.43	5.08	0.3	7.2e-7	Immune response to smallpox vaccine (IL-6);
CESC	cis	rs2502731	0.539	rs3003615	chr9:130997892	C/T	cg09976142	chr9:130955436	CIZ1	0.39	6.29	0.36	1.33e-9	Attention deficit hyperactivity disorder;
CESC	cis	rs7666738	0.830	rs28729647	chr4:99059552	T/C	cg03467027	chr4:99064603	C4orf37	0.47	5.9	0.34	1.11e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs752010	0.875	rs11210502	chr1:42093712	A/C	cg06885757	chr1:42089581	HIVEP3	0.53	8.91	0.48	8.68e-17	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs71636778	0.509	rs71636795	chr1:27241025	A/G	cg12203394	chr1:27248618	NUDC	0.66	5.55	0.32	6.85e-8	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
CESC	cis	rs2425143	0.514	rs8114246	chr20:34581979	T/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.52	5.05	0.3	8.09e-7	Blood protein levels;
CESC	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg22535103	chr8:58192502	C8orf71	-0.92	-10.22	-0.53	6.79e-21	Developmental language disorder (linguistic errors);
CESC	cis	rs10504229	1.000	rs57186557	chr8:58177277	A/G	cg05313129	chr8:58192883	C8orf71	-0.55	-6.37	-0.36	8.42e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs7618501	0.633	rs6772095	chr3:49978069	C/T	cg24308560	chr3:49941425	MST1R	-0.64	-9.19	-0.49	1.17e-17	Intelligence (multi-trait analysis);
CESC	cis	rs9733	0.519	rs7521898	chr1:150707596	G/A	cg09365446	chr1:150670422	GOLPH3L	0.4	5.68	0.33	3.53e-8	Tonsillectomy;
CESC	cis	rs3096299	0.967	rs2911257	chr16:89484134	C/G	cg02187348	chr16:89574699	SPG7	0.56	7.73	0.43	2.25e-13	Multiple myeloma (IgH translocation);
CESC	cis	rs7666738	0.830	rs28516388	chr4:98987449	A/G	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.67e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3785574	0.962	rs4968660	chr17:61792221	G/A	cg06873352	chr17:61820015	STRADA	0.49	7.31	0.41	3.09e-12	Height;
CESC	trans	rs16845107	0.826	rs16861032	chr3:113187675	C/G	cg14157042	chr20:58515396	C20orf177;PPP1R3D	-0.84	-6.08	-0.35	4.27e-9	Colorectal cancer;
CESC	cis	rs826838	1.000	rs851934	chr12:39104453	G/T	cg26384229	chr12:38710491	ALG10B	-0.63	-9.99	-0.52	3.63e-20	Heart rate;
CESC	cis	rs524281	0.684	rs7946447	chr11:65864338	T/C	cg14036092	chr11:66035641	RAB1B	-0.56	-5.92	-0.34	1.01e-8	Electroencephalogram traits;
CESC	cis	rs7818688	0.697	rs11780130	chr8:95976083	A/G	cg16049864	chr8:95962084	TP53INP1	0.57	5.73	0.33	2.79e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs11583043	0.918	rs11581062	chr1:101407519	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.44	-5.08	-0.3	7.1e-7	Ulcerative colitis;Inflammatory bowel disease;
CESC	cis	rs2046867	0.818	rs2208	chr3:72871773	A/G	cg25664220	chr3:72788482	NA	0.43	6.27	0.36	1.46e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CESC	cis	rs4481887	0.893	rs1339991	chr1:248509363	C/T	cg00666640	chr1:248458726	OR2T12	0.35	6.02	0.35	5.85e-9	Common traits (Other);
CESC	cis	rs713587	0.520	rs488817	chr2:25332696	C/T	cg01884057	chr2:25150051	NA	-0.3	-5.17	-0.3	4.65e-7	Body mass index in non-asthmatics;
CESC	cis	rs7833790	0.724	rs6473310	chr8:82707981	A/G	cg06027949	chr8:82754900	SNX16	-0.41	-5.03	-0.3	8.94e-7	Diastolic blood pressure;
CESC	cis	rs9814567	0.929	rs2241556	chr3:134183312	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.37	5.15	0.3	5.14e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs4803468	0.934	rs2317131	chr19:41885151	C/T	cg09537434	chr19:41945824	ATP5SL	-1.02	-18.01	-0.74	6.8e-48	Height;
CESC	cis	rs9611565	0.765	rs132915	chr22:41805782	T/C	cg03806693	chr22:41940476	POLR3H	1.04	12.37	0.61	4.76e-28	Vitiligo;
CESC	cis	rs7666738	0.830	rs4699595	chr4:99012827	A/G	cg03467027	chr4:99064603	C4orf37	0.44	5.63	0.33	4.57e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs780096	0.506	rs1728922	chr2:27644464	A/C	cg17158414	chr2:27665306	KRTCAP3	-0.32	-5.96	-0.34	8.13e-9	Total body bone mineral density;
CESC	cis	rs7267979	1.000	rs4815421	chr20:25386509	G/A	cg08601574	chr20:25228251	PYGB	-0.38	-5.55	-0.32	6.85e-8	Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs12681287	0.517	rs68008113	chr8:87520894	C/A	cg27317242	chr8:23145699	R3HCC1	-0.51	-6.08	-0.35	4.09e-9	Caudate activity during reward;
CESC	cis	rs7264396	0.790	rs11697903	chr20:34272224	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.65	7.81	0.43	1.36e-13	Total cholesterol levels;
CESC	cis	rs3857536	0.813	rs6455083	chr6:66935406	T/C	cg07460842	chr6:66804631	NA	-0.42	-5.34	-0.31	1.96e-7	Blood trace element (Cu levels);
CESC	cis	rs8017423	0.935	rs2104704	chr14:90696609	A/G	cg14092571	chr14:90743983	NA	0.54	7.9	0.44	7.42e-14	Mortality in heart failure;
CESC	trans	rs875971	0.964	rs6945019	chr7:65922458	C/G	cg26939375	chr7:64535504	NA	0.47	6.07	0.35	4.41e-9	Aortic root size;
CESC	cis	rs66887589	0.967	rs1155577	chr4:120449810	C/T	cg09307838	chr4:120376055	NA	-0.51	-6.94	-0.39	3.03e-11	Diastolic blood pressure;
CESC	cis	rs8070740	0.838	rs1050456	chr17:5336188	A/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.58	6.7	0.38	1.27e-10	Menopause (age at onset);
CESC	cis	rs10911251	0.508	rs2296297	chr1:183105324	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.85	13.35	0.63	1.89e-31	Colorectal cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20227886	chr18:48405353	ME2	0.62	7.14	0.4	8.8e-12	Gut microbiome composition (summer);
CESC	trans	rs7615952	0.512	rs11921452	chr3:125359750	A/G	cg00769240	chr8:12517080	NA	-0.44	-6.02	-0.35	5.7e-9	Blood pressure (smoking interaction);
CESC	trans	rs7980799	0.935	rs4931717	chr12:33521151	A/G	cg26384229	chr12:38710491	ALG10B	0.52	7.23	0.41	5.14e-12	Heart rate;Heart rate variability traits (RMSSD);
CESC	cis	rs62432291	0.614	rs420339	chr6:159657195	G/T	cg14500486	chr6:159655392	FNDC1	-0.62	-6.34	-0.36	9.83e-10	Joint mobility (Beighton score);
CESC	cis	rs9902453	0.967	rs4294864	chr17:28440138	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	7.99	0.44	4.2e-14	Coffee consumption (cups per day);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14851770	chr14:50065970	PPIL5	0.6	6.89	0.39	4.05e-11	Gut microbiome composition (summer);
CESC	cis	rs3096299	0.781	rs2965819	chr16:89501030	G/T	cg00750074	chr16:89608354	SPG7	0.39	5.64	0.33	4.31e-8	Multiple myeloma (IgH translocation);
CESC	cis	rs25645	0.744	rs66826786	chr17:38206092	T/C	cg17344932	chr17:38183730	MED24;SNORD124	0.55	7.58	0.42	5.86e-13	Myeloid white cell count;
CESC	cis	rs7267979	1.000	rs2500436	chr20:25406366	G/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.84	-16.42	-0.71	2.87e-42	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs3960554	0.709	rs73138006	chr7:75769990	T/C	cg17325771	chr7:75508891	RHBDD2	-0.35	-5.21	-0.3	3.82e-7	Eotaxin levels;
CESC	cis	rs9329289	0.510	rs11251283	chr10:2555784	C/G	cg15501526	chr10:2543763	NA	0.47	7.39	0.41	1.92e-12	Age-related hearing impairment;
CESC	cis	rs763014	0.931	rs3752567	chr16:628130	A/G	cg07343612	chr16:622815	PIGQ	-0.58	-8.36	-0.46	3.61e-15	Height;
CESC	cis	rs8053891	0.502	rs34679758	chr16:71995427	A/G	cg04254540	chr16:71951199	KIAA0174	-0.88	-8.04	-0.44	2.94e-14	Coronary artery disease;
CESC	cis	rs796364	0.806	rs11691873	chr2:200966337	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.74	-6.39	-0.37	7.31e-10	Schizophrenia;
CESC	cis	rs6964587	0.967	rs10953063	chr7:91576958	A/G	cg17063962	chr7:91808500	NA	-0.57	-7.68	-0.43	3.06e-13	Breast cancer;
CESC	cis	rs13191362	1.000	rs13215491	chr6:163010325	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.5	5.17	0.3	4.63e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs13191362	1.000	rs35103567	chr6:163183400	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.95	8.9	0.48	8.88e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs1018836	0.786	rs10956736	chr8:91602067	C/T	cg16814680	chr8:91681699	NA	-0.72	-10.75	-0.55	1.31e-22	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.43	5.82	0.34	1.68e-8	Lymphocyte counts;
CESC	cis	rs782590	0.902	rs782600	chr2:55848040	T/C	cg18811423	chr2:55921094	PNPT1	0.79	12.15	0.6	2.79e-27	Metabolic syndrome;
CESC	cis	rs2832191	0.740	rs13048618	chr21:30458684	A/G	cg08807101	chr21:30365312	RNF160	0.94	14.38	0.66	4.69e-35	Dental caries;
CESC	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg16132339	chr22:24313637	DDTL;DDT	0.37	5.55	0.32	7.05e-8	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs6736093	0.769	rs56361454	chr2:112774105	C/T	cg07905836	chr2:113190072	RGPD8;RGPD5	-0.45	-5.2	-0.3	3.92e-7	Coronary artery disease;
CESC	cis	rs360798	0.512	rs17027429	chr2:63079983	C/T	cg17519650	chr2:63277830	OTX1	0.51	6.65	0.38	1.64e-10	Coronary artery disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg09527731	chr5:132097228	SEPT8	0.47	6.65	0.38	1.67e-10	Fibrinogen levels;
CESC	cis	rs9303280	0.806	rs35736272	chr17:38032680	T/C	cg19468946	chr17:37922297	IKZF3	-0.41	-5.49	-0.32	9.59e-8	Self-reported allergy;
CESC	cis	rs10465746	0.780	rs10874423	chr1:84374071	C/T	cg10977910	chr1:84465055	TTLL7	0.51	7.01	0.4	2.02e-11	Obesity-related traits;
CESC	cis	rs13118159	0.836	rs2276903	chr4:1343405	A/G	cg20887711	chr4:1340912	KIAA1530	0.6	8.34	0.46	4.03e-15	Longevity;
CESC	cis	rs1552244	0.882	rs55962400	chr3:10044457	C/T	cg00166722	chr3:10149974	C3orf24	0.51	6.06	0.35	4.6e-9	Alzheimer's disease;
CESC	cis	rs875971	0.642	rs35526611	chr7:66094008	C/T	cg18876405	chr7:65276391	NA	-0.55	-7.15	-0.4	8.45e-12	Aortic root size;
CESC	cis	rs2477686	0.526	rs12042427	chr1:2398107	C/T	cg02275930	chr1:2372054	NA	-0.53	-8.5	-0.46	1.44e-15	Non-obstructive azoospermia;
CESC	cis	rs8031584	0.697	rs798080	chr15:31122169	T/C	cg14829155	chr15:31115871	NA	0.76	10.65	0.55	2.8e-22	Huntington's disease progression;
CESC	cis	rs2011503	0.941	rs11670775	chr19:19649636	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.5	5.05	0.3	8.31e-7	Bipolar disorder;
CESC	cis	rs3096299	0.719	rs12934708	chr16:89523790	C/T	cg08392591	chr16:89556376	ANKRD11	0.61	8.31	0.45	5.13e-15	Multiple myeloma (IgH translocation);
CESC	cis	rs2235642	0.750	rs2859310	chr16:1656765	C/T	cg03771183	chr16:1608904	IFT140	-0.39	-5.63	-0.33	4.55e-8	Coronary artery disease;
CESC	cis	rs6980507	0.524	rs4568607	chr8:42364354	T/C	cg09913449	chr8:42400586	C8orf40	-0.36	-5.66	-0.33	3.98e-8	Glycated hemoglobin levels;
CESC	cis	rs3768617	0.510	rs3768619	chr1:183092404	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.89	14.39	0.66	4.39e-35	Fuchs's corneal dystrophy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07050647	chr2:122287957	CLASP1;RNU4ATAC	0.58	6.5	0.37	4.08e-10	Gut microbiome composition (summer);
CESC	cis	rs1832871	0.672	rs56075516	chr6:158745752	G/A	cg07165851	chr6:158734300	TULP4	0.59	6.41	0.37	6.63e-10	Height;
CESC	cis	rs7216064	0.734	rs12942774	chr17:65967562	A/G	cg07042672	chr17:66097459	LOC651250	0.5	6.95	0.39	2.92e-11	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs2243480	1.000	rs160637	chr7:65584318	C/T	cg12463550	chr7:65579703	CRCP	0.74	5.77	0.33	2.23e-8	Diabetic kidney disease;
CESC	cis	rs854765	0.547	rs2955372	chr17:17970229	T/C	cg04398451	chr17:18023971	MYO15A	0.73	10.47	0.54	1.1e-21	Total body bone mineral density;
CESC	cis	rs7124681	0.584	rs10769285	chr11:47709212	C/T	cg20307385	chr11:47447363	PSMC3	0.61	8.46	0.46	1.87e-15	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
CESC	cis	rs11638352	1.000	rs2412850	chr15:44278161	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.53	-5.46	-0.32	1.09e-7	Lipoprotein phospholipase A2 activity in cardiovascular disease;
CESC	cis	rs9815354	0.767	rs73079325	chr3:41864565	G/A	cg03022575	chr3:42003672	ULK4	0.49	5.52	0.32	7.99e-8	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs2573652	1.000	rs2581362	chr15:100513524	T/C	cg00587665	chr15:100533223	ADAMTS17	-0.34	-5.45	-0.32	1.13e-7	Height;
CESC	cis	rs1050631	0.564	rs1785929	chr18:33725165	C/T	cg25426722	chr18:33708991	SLC39A6;ELP2	0.59	8.05	0.44	2.82e-14	Esophageal squamous cell cancer (length of survival);
CESC	cis	rs7631605	0.647	rs59594366	chr3:37173774	A/C	cg22985146	chr3:37219077	LRRFIP2	-0.33	-5.23	-0.31	3.44e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs4718428	0.705	rs12698547	chr7:66278258	T/C	cg12165864	chr7:66369176	NA	-0.62	-6.97	-0.39	2.47e-11	Corneal structure;
CESC	cis	rs7647973	0.696	rs7100	chr3:49053219	A/G	cg07636037	chr3:49044803	WDR6	0.85	11.19	0.57	4.69e-24	Menarche (age at onset);
CESC	cis	rs12042107	0.818	rs12568187	chr1:91193691	T/C	cg13456504	chr1:91191583	NA	0.37	6.42	0.37	6.31e-10	Educational attainment;
CESC	cis	rs9814567	1.000	rs7356093	chr3:134238753	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.47	-6.44	-0.37	5.64e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs17253792	0.822	rs79398217	chr14:56067350	C/T	cg01858014	chr14:56050164	KTN1	-0.95	-7.43	-0.42	1.54e-12	Putamen volume;
CESC	cis	rs7552404	0.731	rs61770552	chr1:76373050	T/C	cg22875332	chr1:76189707	ACADM	0.59	5.73	0.33	2.74e-8	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs11122272	0.525	rs2749713	chr1:231537921	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.55	-7.48	-0.42	1.11e-12	Hemoglobin concentration;
CESC	cis	rs9300255	0.568	rs1727300	chr12:123664205	C/T	cg05973401	chr12:123451056	ABCB9	0.5	5.74	0.33	2.53e-8	Neutrophil percentage of white cells;
CESC	cis	rs7666738	0.830	rs60007031	chr4:98824753	G/C	cg05340658	chr4:99064831	C4orf37	0.73	10.47	0.54	1.07e-21	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9430161	0.611	rs2095920	chr1:11033457	T/A	cg02454025	chr1:11042201	C1orf127	0.99	16.1	0.7	3.84e-41	Ewing sarcoma;
CESC	cis	rs763121	0.853	rs4821798	chr22:39021165	T/C	cg06022373	chr22:39101656	GTPBP1	0.96	17.24	0.73	3.58e-45	Menopause (age at onset);
CESC	cis	rs2742234	0.541	rs2742235	chr10:43616325	A/G	cg15436174	chr10:43711423	RASGEF1A	-0.46	-5.38	-0.31	1.6e-7	Hirschsprung disease;
CESC	cis	rs826838	0.967	rs1684415	chr12:39130099	T/C	cg26384229	chr12:38710491	ALG10B	-0.67	-11.01	-0.56	1.82e-23	Heart rate;
CESC	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg15112475	chr7:1198522	ZFAND2A	-0.39	-6.11	-0.35	3.53e-9	Longevity;Endometriosis;
CESC	cis	rs1167827	1.000	rs1167827	chr7:75163169	A/G	cg09988129	chr7:74988866	PMS2L2;STAG3L1	0.57	8.11	0.45	1.87e-14	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs2549003	0.966	rs2706385	chr5:131831766	T/G	cg02551604	chr5:131831745	NA	0.42	5.99	0.35	6.98e-9	Asthma (sex interaction);
CESC	cis	rs7927771	0.965	rs34958982	chr11:47547046	T/C	cg18512352	chr11:47633146	NA	-0.6	-9.23	-0.49	8.67e-18	Subjective well-being;
CESC	cis	rs1552244	1.000	rs7622963	chr3:10139825	C/T	cg08888203	chr3:10149979	C3orf24	0.46	6.01	0.35	6.24e-9	Alzheimer's disease;
CESC	cis	rs11098499	0.909	rs2127821	chr4:120394535	T/C	cg24375607	chr4:120327624	NA	0.45	5.72	0.33	2.9e-8	Corneal astigmatism;
CESC	cis	rs7666738	0.830	rs7680909	chr4:98934604	A/G	cg05340658	chr4:99064831	C4orf37	0.82	12.54	0.61	1.29e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4072980	0.524	rs28477803	chr1:38398694	C/T	cg04673462	chr1:38461896	NA	0.37	5.32	0.31	2.19e-7	Coronary artery disease;
CESC	cis	rs1008375	0.932	rs6857678	chr4:17696964	A/T	cg16339924	chr4:17578868	LAP3	0.59	7.4	0.41	1.83e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs10979	1.000	rs12191231	chr6:143891114	A/C	cg25407410	chr6:143891975	LOC285740	-0.61	-9.14	-0.49	1.72e-17	Hypospadias;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg15422050	chr6:88412138	NCRNA00120;AKIRIN2	-0.49	-6.37	-0.36	8.24e-10	Fibrinogen levels;
CESC	cis	rs28374715	0.532	rs28477406	chr15:41642036	C/G	cg18705301	chr15:41695430	NDUFAF1	-1.07	-16.73	-0.72	2.18e-43	Ulcerative colitis;
CESC	cis	rs72945132	0.882	rs4261311	chr11:70132902	C/T	cg00319359	chr11:70116639	PPFIA1	0.78	7.78	0.43	1.6e-13	Coronary artery disease;
CESC	cis	rs7582720	1.000	rs114527590	chr2:203787405	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.38	0.41	1.99e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs4969178	0.965	rs11077364	chr17:76400337	C/A	cg20026190	chr17:76395443	PGS1	0.46	7.35	0.41	2.41e-12	HDL cholesterol levels;
CESC	cis	rs597539	0.652	rs602805	chr11:68662076	A/T	cg04772025	chr11:68637568	NA	0.5	6.07	0.35	4.44e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs9910055	0.639	rs7217858	chr17:42254527	T/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.5	7.5	0.42	9.57e-13	Total body bone mineral density;
CESC	trans	rs629535	0.862	rs2178955	chr8:70045303	C/T	cg21567404	chr3:27674614	NA	0.93	11.25	0.57	2.83e-24	Dupuytren's disease;
CESC	cis	rs11031096	0.655	rs10835695	chr11:4178962	G/T	cg18678763	chr11:4115507	RRM1	-0.43	-5.95	-0.34	8.38e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	cis	rs3768617	0.624	rs34105373	chr1:183098387	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.65	9.12	0.49	1.89e-17	Fuchs's corneal dystrophy;
CESC	cis	rs10504229	1.000	rs17805656	chr8:58180318	T/C	cg14926445	chr8:58193284	C8orf71	-0.51	-5.47	-0.32	1.03e-7	Developmental language disorder (linguistic errors);
CESC	trans	rs3942852	0.806	rs4752893	chr11:48118604	C/T	cg15704280	chr7:45808275	SEPT13	-0.63	-7.45	-0.42	1.3e-12	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs1461503	0.966	rs11218907	chr11:122841562	A/G	cg27398637	chr11:122830231	C11orf63	-0.55	-8.32	-0.45	4.77e-15	Menarche (age at onset);
CESC	cis	rs1878931	0.696	rs35984213	chr16:3451030	G/A	cg00484396	chr16:3507460	NAT15	-0.39	-6.03	-0.35	5.63e-9	Body mass index (adult);
CESC	cis	rs7615952	0.932	rs13086087	chr3:125646281	A/C	cg05084668	chr3:125655381	ALG1L	-0.51	-5.94	-0.34	8.98e-9	Blood pressure (smoking interaction);
CESC	cis	rs727505	0.754	rs55723877	chr7:124780899	T/A	cg23710748	chr7:124431027	NA	-0.38	-6.2	-0.36	2.14e-9	Lewy body disease;
CESC	cis	rs1775715	0.678	rs7096139	chr10:32217404	A/C	cg18675610	chr10:32216311	ARHGAP12	0.36	5.51	0.32	8.56e-8	Bipolar disorder with mood-incongruent psychosis;
CESC	trans	rs650950	0.528	rs646660	chr11:35528452	C/T	cg06634887	chr4:967541	DGKQ	0.49	6.47	0.37	4.6e-10	Bronchopulmonary dysplasia;
CESC	cis	rs9487051	0.714	rs7757347	chr6:109633815	G/A	cg21918786	chr6:109611834	NA	-0.39	-5.62	-0.33	4.72e-8	Reticulocyte fraction of red cells;
CESC	cis	rs3003334	1	rs3003334	chr1:24199869	G/A	cg10978503	chr1:24200527	CNR2	0.33	6.52	0.37	3.61e-10	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;
CESC	cis	rs3785574	0.962	rs2727332	chr17:61878584	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.1	19.47	0.77	5.16e-53	Height;
CESC	trans	rs9388451	0.626	rs1268074	chr6:126107791	G/C	cg05039488	chr6:79577232	IRAK1BP1	-0.56	-7.28	-0.41	3.8e-12	Brugada syndrome;
CESC	cis	rs1218582	0.772	rs4845690	chr1:154886817	C/T	cg16680214	chr1:154839983	KCNN3	0.45	6.79	0.39	7.29e-11	Prostate cancer;
CESC	cis	rs6087990	0.735	rs1003522	chr20:31368560	T/C	cg13636640	chr20:31349939	DNMT3B	0.77	12.54	0.61	1.27e-28	Ulcerative colitis;
CESC	cis	rs11650494	0.710	rs57030023	chr17:47468546	T/A	cg08112188	chr17:47440006	ZNF652	0.84	6.39	0.37	7.58e-10	Prostate cancer;
CESC	cis	rs10504229	0.953	rs66676208	chr8:58173866	C/T	cg24829409	chr8:58192753	C8orf71	-0.76	-10.0	-0.52	3.53e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs798554	0.797	rs798493	chr7:2798731	A/G	cg18446336	chr7:2847575	GNA12	-0.39	-5.84	-0.34	1.49e-8	Height;
CESC	cis	rs873946	0.504	rs3793681	chr10:134564451	T/C	cg27297192	chr10:134578999	INPP5A	0.4	5.46	0.32	1.08e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs1506636	1.000	rs666266	chr7:123417759	A/G	cg03229431	chr7:123269106	ASB15	0.49	6.59	0.38	2.41e-10	Plateletcrit;Platelet count;
CESC	trans	rs61931739	0.534	rs4931783	chr12:34115322	G/A	cg26384229	chr12:38710491	ALG10B	0.6	8.41	0.46	2.52e-15	Morning vs. evening chronotype;
CESC	cis	rs1552244	0.510	rs13075308	chr3:10034925	G/C	cg08888203	chr3:10149979	C3orf24	0.48	6.06	0.35	4.71e-9	Alzheimer's disease;
CESC	cis	rs17253792	0.915	rs28537145	chr14:56179119	G/A	cg01858014	chr14:56050164	KTN1	-0.91	-7.03	-0.4	1.8e-11	Putamen volume;
CESC	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg10150615	chr22:24372951	LOC391322	0.56	7.51	0.42	8.92e-13	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs9914988	0.887	rs8078402	chr17:27145124	T/A	cg20469991	chr17:27169893	C17orf63	-0.48	-5.25	-0.31	3.18e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CESC	cis	rs6736093	0.966	rs3761699	chr2:112705290	G/A	cg12686935	chr2:112915763	FBLN7	-0.42	-5.46	-0.32	1.1e-7	Coronary artery disease;
CESC	trans	rs7107217	1.000	rs1873872	chr11:129473993	A/T	cg15741583	chr11:6461908	HPX	-0.35	-6.15	-0.35	2.91e-9	Breast cancer;Type 2 diabetes;
CESC	cis	rs9322193	0.886	rs17672976	chr6:150097343	T/A	cg07701084	chr6:150067640	NUP43	0.43	5.8	0.34	1.91e-8	Lung cancer;
CESC	cis	rs684232	0.602	rs384628	chr17:554912	G/A	cg12384639	chr17:618140	VPS53	0.41	5.31	0.31	2.36e-7	Prostate cancer;
CESC	cis	rs6952808	0.691	rs2398709	chr7:2112548	C/T	cg05863683	chr7:1912471	MAD1L1	0.37	5.5	0.32	8.93e-8	Bipolar disorder and schizophrenia;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg12468273	chr17:46620917	HOXB2	-0.45	-6.27	-0.36	1.45e-9	Fibrinogen levels;
CESC	cis	rs11190604	0.943	rs9420792	chr10:102258439	C/T	cg07080220	chr10:102295463	HIF1AN	0.68	6.68	0.38	1.42e-10	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs2836950	0.565	rs2836930	chr21:40545656	A/G	cg11890956	chr21:40555474	PSMG1	-0.69	-9.97	-0.52	4.48e-20	Menarche (age at onset);
CESC	cis	rs7095944	0.613	rs11245366	chr10:126482849	C/T	cg08799069	chr10:126477246	METTL10	-0.4	-5.63	-0.33	4.52e-8	Asthma;
CESC	cis	rs78456975	0.943	rs13391932	chr2:1577679	T/C	cg26248373	chr2:1572462	NA	-0.52	-5.11	-0.3	6.08e-7	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs7666738	0.830	rs11721726	chr4:98996314	T/C	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.62e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs12325245	0.536	rs12924708	chr16:58567643	G/A	cg05725404	chr16:58534157	NDRG4	-0.61	-5.24	-0.31	3.21e-7	Schizophrenia;
CESC	cis	rs875971	0.862	rs10256544	chr7:65675128	A/G	cg12463550	chr7:65579703	CRCP	0.49	6.15	0.35	2.86e-9	Aortic root size;
CESC	cis	rs138341189	1	rs138341189	chr11:68224411	GATTGTGCCAAT/G	cg20283391	chr11:68216788	NA	-0.66	-5.76	-0.33	2.35e-8	Monobrow;
CESC	cis	rs1878931	0.726	rs3843728	chr16:3448251	T/C	cg26668626	chr16:3451006	ZNF174;ZNF434	1.11	19.51	0.77	3.49e-53	Body mass index (adult);
CESC	cis	rs3096299	0.719	rs2965818	chr16:89510494	A/G	cg08392591	chr16:89556376	ANKRD11	0.57	7.8	0.43	1.44e-13	Multiple myeloma (IgH translocation);
CESC	cis	rs2074585	0.708	rs2601190	chr15:90932966	A/C	cg22089800	chr15:90895588	ZNF774	0.67	9.33	0.5	4.5e-18	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
CESC	cis	rs12220238	0.908	rs73284278	chr10:76011751	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.63	5.75	0.33	2.5e-8	Soluble interleukin-2 receptor subunit alpha;
CESC	cis	rs8180040	0.701	rs34103310	chr3:47073266	C/T	cg27129171	chr3:47204927	SETD2	0.69	10.35	0.54	2.56e-21	Colorectal cancer;
CESC	cis	rs3820068	0.655	rs72645823	chr1:15887442	C/T	cg17385448	chr1:15911702	AGMAT	0.37	5.81	0.34	1.8e-8	Systolic blood pressure;
CESC	cis	rs6728642	0.908	rs13400545	chr2:97871626	A/G	cg26665480	chr2:98280029	ACTR1B	-0.86	-7.51	-0.42	9.04e-13	Bipolar disorder lithium response (continuous) or schizophrenia;
CESC	cis	rs1218582	0.682	rs12144978	chr1:154850445	G/A	cg09359103	chr1:154839909	KCNN3	-0.64	-11.39	-0.57	9.95e-25	Prostate cancer;
CESC	cis	rs9359856	0.564	rs17292768	chr6:90379311	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.65	-6.38	-0.36	7.94e-10	Bipolar disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13790909	chr19:36391442	NFKBID	0.58	6.77	0.38	8.39e-11	Gut microbiome composition (summer);
CESC	cis	rs2075671	0.857	rs11772849	chr7:100308412	G/A	cg16850897	chr7:100343110	ZAN	-0.66	-8.3	-0.45	5.29e-15	Other erythrocyte phenotypes;
CESC	trans	rs948562	0.690	rs11229425	chr11:58178587	C/T	cg24637035	chr12:120445227	CCDC64	0.49	6.06	0.35	4.73e-9	Lymphoma;
CESC	cis	rs7666738	0.830	rs7679961	chr4:99000202	C/T	cg05340658	chr4:99064831	C4orf37	0.8	12.44	0.61	2.83e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4595586	0.525	rs4768531	chr12:39417754	T/A	cg26384229	chr12:38710491	ALG10B	0.59	7.99	0.44	4.26e-14	Morning vs. evening chronotype;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01811378	chr1:120611586	NOTCH2	0.66	7.97	0.44	4.81e-14	Gut microbiome composition (summer);
CESC	cis	rs9902453	0.845	rs7221516	chr17:28232506	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.68	8.87	0.48	1.08e-16	Coffee consumption (cups per day);
CESC	cis	rs7086627	0.515	rs7077373	chr10:82211615	C/T	cg03267442	chr10:82210566	NA	-0.34	-5.66	-0.33	3.98e-8	Post bronchodilator FEV1;
CESC	cis	rs875971	1.000	rs6460296	chr7:65895139	C/T	cg18876405	chr7:65276391	NA	0.52	7.03	0.4	1.8e-11	Aortic root size;
CESC	cis	rs9611565	0.649	rs202614	chr22:41822150	A/C	cg06481639	chr22:41940642	POLR3H	0.64	6.41	0.37	6.73e-10	Vitiligo;
CESC	cis	rs9457247	0.534	rs9355610	chr6:167383075	G/A	cg23791538	chr6:167370224	RNASET2	0.66	9.43	0.5	2.19e-18	Crohn's disease;
CESC	cis	rs12765878	1.000	rs7100920	chr10:105640978	A/G	cg11005552	chr10:105648138	OBFC1	-0.36	-5.21	-0.3	3.76e-7	Coronary artery disease;
CESC	cis	rs113835537	0.529	rs2276406	chr11:66283257	C/T	cg22134325	chr11:66188745	NPAS4	0.37	5.81	0.34	1.77e-8	Airway imaging phenotypes;
CESC	trans	rs1493916	0.655	rs4534926	chr18:31349072	G/C	cg27147174	chr7:100797783	AP1S1	-0.47	-6.15	-0.35	2.9e-9	Life satisfaction;
CESC	cis	rs6952808	0.594	rs3778965	chr7:2138296	G/A	cg05863683	chr7:1912471	MAD1L1	0.37	5.42	0.32	1.35e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs4891159	0.527	rs34956524	chr18:74130480	A/G	cg24786174	chr18:74118243	ZNF516	0.83	15.82	0.7	3.9e-40	Longevity;
CESC	cis	rs6484504	0.576	rs208071	chr11:31144996	C/T	cg14844989	chr11:31128820	NA	-0.4	-5.68	-0.33	3.62e-8	Red blood cell count;
CESC	cis	rs2249694	0.919	rs11101867	chr10:135400250	C/T	cg20169779	chr10:135381914	SYCE1	-0.38	-5.48	-0.32	9.69e-8	Obesity-related traits;
CESC	cis	rs35306767	0.761	rs11253538	chr10:1011166	C/T	cg26597838	chr10:835615	NA	0.76	7.38	0.41	2.08e-12	Eosinophil percentage of granulocytes;
CESC	cis	rs2243480	1.000	rs56016656	chr7:65383481	C/T	cg18252515	chr7:66147081	NA	-1.18	-10.88	-0.56	5.02e-23	Diabetic kidney disease;
CESC	cis	rs1580019	0.922	rs34545272	chr7:32460630	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.81	11.17	0.57	5.36e-24	Cognitive ability;
CESC	cis	rs4727027	0.804	rs13231262	chr7:148886058	C/T	cg23158103	chr7:148848205	ZNF398	-0.4	-6.19	-0.36	2.26e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs15676	0.947	rs2977999	chr9:131579807	G/A	cg00228799	chr9:131580591	ENDOG	0.44	5.47	0.32	1.06e-7	Blood metabolite levels;
CESC	cis	rs4629710	0.563	rs9483238	chr6:131567196	A/T	cg12606694	chr6:131520996	AKAP7	0.48	5.95	0.34	8.26e-9	Multiple myeloma (IgH translocation);
CESC	cis	rs2302729	0.860	rs7138079	chr12:2781304	G/A	cg19945202	chr12:2788847	CACNA1C	-0.42	-5.47	-0.32	1.02e-7	Sleep quality;
CESC	cis	rs1799949	0.930	rs4445938	chr17:41337900	A/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.41	5.57	0.32	6.16e-8	Menopause (age at onset);
CESC	cis	rs4862750	0.872	rs6852907	chr4:187897094	A/C	cg03452623	chr4:187889614	NA	-0.88	-16.15	-0.7	2.59e-41	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4819052	0.851	rs7279011	chr21:46655995	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.74	9.47	0.5	1.6e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs10870270	0.956	rs11146425	chr10:133734261	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.86	-12.69	-0.61	3.83e-29	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs13253111	0.624	rs7012030	chr8:28096346	C/T	cg26534493	chr8:28060551	NA	0.48	7.52	0.42	8.73e-13	Childhood body mass index;
CESC	cis	rs8017423	0.874	rs4900029	chr14:90686257	T/A	cg14092571	chr14:90743983	NA	-0.57	-8.5	-0.46	1.4e-15	Mortality in heart failure;
CESC	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg18765753	chr7:1198926	ZFAND2A	-0.5	-7.43	-0.42	1.47e-12	Longevity;Endometriosis;
CESC	cis	rs4975709	0.589	rs1466606	chr5:1865055	C/T	cg15595755	chr5:1867978	NA	0.52	8.55	0.47	9.75e-16	Cardiovascular disease risk factors;
CESC	cis	rs9322193	0.962	rs62441335	chr6:150113794	G/A	cg05861140	chr6:150128134	PCMT1	-0.37	-5.3	-0.31	2.42e-7	Lung cancer;
CESC	cis	rs933688	0.938	rs10942634	chr5:90658392	A/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.92	12.49	0.61	1.78e-28	Smoking behavior;
CESC	cis	rs6540559	0.605	rs3753518	chr1:209977964	G/C	cg22029157	chr1:209979665	IRF6	0.77	8.93	0.48	7.41e-17	Cleft lip with or without cleft palate;
CESC	cis	rs1018836	0.859	rs10808614	chr8:91569677	C/G	cg16814680	chr8:91681699	NA	-0.63	-9.25	-0.49	7.74e-18	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs9649213	0.555	rs6968193	chr7:97915902	C/T	cg24562669	chr7:97807699	LMTK2	0.47	6.72	0.38	1.08e-10	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs17508449	0.736	rs76038270	chr1:114238920	C/G	cg23028848	chr11:57092561	TNKS1BP1	-0.79	-6.23	-0.36	1.86e-9	Leprosy;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg12566780	chr7:92157604	PEX1;C7orf64	-0.43	-6.08	-0.35	4.23e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg03188948	chr7:1209495	NA	0.7	6.71	0.38	1.2e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs35146811	0.586	rs10267212	chr7:99595422	T/C	cg22906224	chr7:99728672	NA	0.45	5.36	0.31	1.79e-7	Coronary artery disease;
CESC	cis	rs910316	0.692	rs7156586	chr14:75506230	A/T	cg08847533	chr14:75593920	NEK9	0.77	11.17	0.57	5.38e-24	Height;
CESC	cis	rs4604732	0.631	rs12031694	chr1:247623653	C/T	cg12758973	chr1:247694275	LOC148824;OR2C3	0.46	6.08	0.35	4.15e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs1799949	1.000	rs1824889	chr17:41421876	C/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.64	8.68	0.47	4.11e-16	Menopause (age at onset);
CESC	cis	rs8067354	0.681	rs9907923	chr17:57824927	C/T	cg13753209	chr17:57696993	CLTC	0.65	7.95	0.44	5.28e-14	Hemoglobin concentration;
CESC	cis	rs7481584	1.000	rs4758623	chr11:3014953	T/C	cg25174290	chr11:3078921	CARS	-0.45	-5.61	-0.33	4.97e-8	Calcium levels;
CESC	cis	rs300703	0.604	rs373375	chr2:203350	C/A	cg21211680	chr2:198530	NA	0.95	10.44	0.54	1.33e-21	Blood protein levels;
CESC	cis	rs7267979	1.000	rs6050602	chr20:25401203	A/G	cg08601574	chr20:25228251	PYGB	-0.37	-5.36	-0.31	1.77e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs9926296	0.572	rs2376878	chr16:89885161	G/A	cg04287289	chr16:89883240	FANCA	0.63	8.77	0.47	2.22e-16	Vitiligo;
CESC	cis	rs6502050	0.835	rs34199331	chr17:80134487	C/T	cg11859384	chr17:80120422	CCDC57	-0.41	-5.71	-0.33	3.06e-8	Life satisfaction;
CESC	cis	rs9787249	0.915	rs58589165	chr1:40213670	A/T	cg24920358	chr1:40204285	PPIE	0.43	6.4	0.37	7.07e-10	Blood protein levels;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg18827097	chr2:3522506	ADI1	-0.46	-6.18	-0.35	2.47e-9	Height;
CESC	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg04234412	chr22:24373322	LOC391322	-0.53	-7.54	-0.42	7.35e-13	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs2455799	0.613	rs11713820	chr3:15866590	A/G	cg16303742	chr3:15540471	COLQ	0.35	5.39	0.31	1.53e-7	Mean platelet volume;
CESC	cis	rs2072499	1.000	rs2241107	chr1:156182710	C/T	cg25208724	chr1:156163844	SLC25A44	-0.91	-16.91	-0.72	5.25e-44	Testicular germ cell tumor;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22511408	chr5:6378790	MED10	0.58	6.44	0.37	5.73e-10	Gut microbiome composition (summer);
CESC	cis	rs597539	0.652	rs496616	chr11:68672800	G/C	cg04772025	chr11:68637568	NA	0.51	6.02	0.35	5.83e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs9837602	0.938	rs9873709	chr3:99711687	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.48	6.78	0.38	7.72e-11	Breast cancer;
CESC	trans	rs11098499	0.780	rs10013652	chr4:120292256	A/G	cg25214090	chr10:38739885	LOC399744	0.66	9.1	0.49	2.19e-17	Corneal astigmatism;
CESC	cis	rs3096299	0.933	rs2965934	chr16:89481229	C/G	cg02187348	chr16:89574699	SPG7	0.56	7.66	0.43	3.52e-13	Multiple myeloma (IgH translocation);
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg26708280	chr2:190649305	PMS1;ORMDL1	-0.5	-6.3	-0.36	1.24e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs2637266	0.905	rs11001834	chr10:78360494	T/C	cg18941641	chr10:78392320	NA	0.4	7.45	0.42	1.35e-12	Pulmonary function;
CESC	cis	rs1707322	0.686	rs3014239	chr1:46089801	G/A	cg06784218	chr1:46089804	CCDC17	-0.42	-7.37	-0.41	2.13e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2228479	0.717	rs2074904	chr16:89811546	A/G	cg19635926	chr16:89946313	TCF25	0.68	5.17	0.3	4.67e-7	Skin colour saturation;
CESC	cis	rs858239	0.600	rs10235786	chr7:23139940	T/C	cg23682824	chr7:23144976	KLHL7	0.52	7.1	0.4	1.16e-11	Cerebrospinal fluid biomarker levels;
CESC	cis	rs10504229	0.683	rs55807014	chr8:58131801	T/C	cg24829409	chr8:58192753	C8orf71	-0.58	-7.2	-0.4	6.31e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs2522056	1.000	rs2706395	chr5:131796803	A/T	cg24060327	chr5:131705240	SLC22A5	0.59	6.63	0.38	1.85e-10	Lymphocyte counts;Fibrinogen;
CESC	cis	rs9443189	0.762	rs2647417	chr6:76435943	A/G	cg01950844	chr6:76311363	SENP6	-0.69	-7.55	-0.42	7.2e-13	Prostate cancer;
CESC	cis	rs861020	0.606	rs627459	chr1:210004682	C/G	cg05527609	chr1:210001259	C1orf107	0.74	9.71	0.51	2.88e-19	Orofacial clefts;
CESC	cis	rs9733	0.544	rs72700902	chr1:150633347	C/T	cg04414720	chr1:150670196	GOLPH3L	0.63	9.04	0.49	3.4e-17	Tonsillectomy;
CESC	cis	rs796364	0.951	rs281776	chr2:200834282	T/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.85	8.38	0.46	3.1e-15	Schizophrenia;
CESC	trans	rs916888	0.821	rs415430	chr17:44859144	C/T	cg22968622	chr17:43663579	NA	-1.19	-16.22	-0.71	1.43e-41	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs643506	0.817	rs1940392	chr11:111776846	G/A	cg17089665	chr11:111648010	NA	-0.38	-5.45	-0.32	1.17e-7	Breast cancer;
CESC	cis	rs7818345	0.935	rs7016259	chr8:19277530	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.32	5.84	0.34	1.56e-8	Language performance in older adults (adjusted for episodic memory);
CESC	cis	rs4969178	0.930	rs2292644	chr17:76394449	C/T	cg05887092	chr17:76393375	PGS1	0.57	9.02	0.48	3.94e-17	HDL cholesterol levels;
CESC	trans	rs78049276	0.736	rs6842241	chr4:148400819	C/A	cg13149281	chr14:23389818	RBM23;PRMT5	-0.74	-9.02	-0.48	4.04e-17	Pulse pressure;
CESC	cis	rs1568889	1.000	rs11604085	chr11:28141002	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.75	9.44	0.5	2.08e-18	Bipolar disorder;
CESC	cis	rs11122272	0.735	rs2790883	chr1:231532726	A/G	cg06096015	chr1:231504339	EGLN1	0.44	6.37	0.36	8.28e-10	Hemoglobin concentration;
CESC	trans	rs1814175	0.669	rs12364577	chr11:49707361	A/C	cg03929089	chr4:120376271	NA	-0.72	-9.28	-0.5	6.08e-18	Height;
CESC	cis	rs6582630	0.555	rs10880602	chr12:38505660	T/C	cg26384229	chr12:38710491	ALG10B	0.65	9.78	0.51	1.78e-19	Drug-induced liver injury (flucloxacillin);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg06324094	chr1:153950482	JTB	-0.42	-6.2	-0.36	2.14e-9	Gambling;
CESC	cis	rs35110281	0.805	rs2838318	chr21:44991825	G/A	cg01579765	chr21:45077557	HSF2BP	-0.51	-8.76	-0.47	2.32e-16	Mean corpuscular volume;
CESC	cis	rs2963155	0.518	rs2963151	chr5:142734151	T/C	cg17617527	chr5:142782415	NR3C1	0.84	7.96	0.44	5.19e-14	Breast cancer;
CESC	cis	rs7301826	0.934	rs10773826	chr12:131321174	C/G	cg11011512	chr12:131303247	STX2	0.44	5.54	0.32	7.24e-8	Plasma plasminogen activator levels;
CESC	cis	rs6741892	0.536	rs6761563	chr2:38891406	A/T	cg19391498	chr2:38892846	GALM	-0.54	-7.06	-0.4	1.48e-11	5-HTT brain serotonin transporter levels;
CESC	cis	rs10256972	0.967	rs4723338	chr7:1036241	A/G	cg07308232	chr7:1071921	C7orf50	-0.45	-6.25	-0.36	1.67e-9	Longevity;Endometriosis;
CESC	cis	rs748404	0.690	rs2467737	chr15:43737188	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.57	7.6	0.42	5e-13	Lung cancer;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg03973167	chr4:185394988	IRF2	-0.42	-6.03	-0.35	5.44e-9	Gambling;
CESC	cis	rs2952156	1.000	rs1565923	chr17:37858678	A/G	cg20243544	chr17:37824526	PNMT	0.62	7.53	0.42	7.8e-13	Asthma;
CESC	cis	rs7666738	0.830	rs11932887	chr4:99072965	C/G	cg17366294	chr4:99064904	C4orf37	0.63	8.7	0.47	3.53e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9303401	0.632	rs9915267	chr17:57244907	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.55	7.12	0.4	1.02e-11	Cognitive test performance;
CESC	cis	rs1008375	0.966	rs12509962	chr4:17680292	G/A	cg16339924	chr4:17578868	LAP3	0.5	6.44	0.37	5.52e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs2836974	0.602	rs2836987	chr21:40706594	C/T	cg17971929	chr21:40555470	PSMG1	-0.86	-12.63	-0.61	6.31e-29	Cognitive function;
CESC	cis	rs7666738	0.546	rs7679681	chr4:98882221	A/G	cg05340658	chr4:99064831	C4orf37	0.58	7.31	0.41	3.1e-12	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11025559	0.796	rs11603462	chr11:20412180	C/A	cg19653624	chr11:20408972	PRMT3	-0.46	-5.43	-0.32	1.27e-7	Pursuit maintenance gain;
CESC	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg18402987	chr7:1209562	NA	0.75	7.57	0.42	6.17e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2228479	0.681	rs7199685	chr16:89959805	G/C	cg00800038	chr16:89945340	TCF25	-0.61	-6.76	-0.38	8.84e-11	Skin colour saturation;
CESC	cis	rs5167	0.586	rs4803774	chr19:45450872	A/G	cg20090143	chr19:45452003	APOC2	0.38	6.49	0.37	4.3e-10	Blood protein levels;
CESC	cis	rs7843479	0.601	rs10109521	chr8:21829948	G/A	cg17168535	chr8:21777572	XPO7	0.75	11.75	0.59	6.18e-26	Mean corpuscular volume;
CESC	cis	rs7829975	0.624	rs7823056	chr8:8382705	A/G	cg15556689	chr8:8085844	FLJ10661	0.61	7.26	0.41	4.35e-12	Mood instability;
CESC	cis	rs2115630	1.000	rs58581703	chr15:85276935	C/T	cg12501888	chr15:85177176	SCAND2	-0.39	-5.05	-0.3	8.2e-7	P wave terminal force;
CESC	cis	rs4722166	0.630	rs4722168	chr7:22779002	G/A	cg05265849	chr7:22767390	IL6	0.57	7.11	0.4	1.06e-11	Lung cancer;
CESC	cis	rs7312933	0.584	rs6582391	chr12:42634686	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.46	6.03	0.35	5.34e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs13108904	0.901	rs12642410	chr4:1308409	A/G	cg00684032	chr4:1343700	KIAA1530	0.43	6.08	0.35	4.16e-9	Obesity-related traits;
CESC	cis	rs6032067	0.777	rs13037087	chr20:43834313	T/C	cg10761708	chr20:43804764	PI3	0.52	6.32	0.36	1.07e-9	Blood protein levels;
CESC	cis	rs921968	0.544	rs58827325	chr2:219415166	A/T	cg02176678	chr2:219576539	TTLL4	0.5	9.06	0.49	3.06e-17	Mean corpuscular hemoglobin concentration;
CESC	cis	rs6540559	0.673	rs17317411	chr1:209961314	C/T	cg22029157	chr1:209979665	IRF6	-0.71	-7.56	-0.42	6.67e-13	Cleft lip with or without cleft palate;
CESC	cis	rs9916302	0.904	rs11655531	chr17:37697959	T/C	cg20243544	chr17:37824526	PNMT	0.5	6.23	0.36	1.8e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs2708240	0.967	rs1922892	chr7:147576411	C/T	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.35	-5.78	-0.33	2.12e-8	QT interval (drug interaction);
CESC	cis	rs1862618	0.671	rs252897	chr5:56223000	G/A	cg12311346	chr5:56204834	C5orf35	-0.66	-8.8	-0.48	1.74e-16	Initial pursuit acceleration;
CESC	cis	rs1865721	0.728	rs7232269	chr18:73219023	G/A	cg26385618	chr18:73139727	C18orf62	-0.53	-7.75	-0.43	2.02e-13	Intelligence;
CESC	cis	rs12136530	0.593	rs12136926	chr1:19710794	G/A	cg15026089	chr1:19640712	PQLC2	0.33	5.08	0.3	7.13e-7	Lead levels in blood;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg19917744	chr2:208890468	PLEKHM3	-0.43	-6.16	-0.35	2.65e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs9300255	0.602	rs1616181	chr12:123619856	T/A	cg00376283	chr12:123451042	ABCB9	0.71	8.71	0.47	3.37e-16	Neutrophil percentage of white cells;
CESC	cis	rs6540559	0.673	rs114467813	chr1:210017785	G/A	cg22029157	chr1:209979665	IRF6	0.73	7.62	0.42	4.41e-13	Cleft lip with or without cleft palate;
CESC	cis	rs1448094	0.512	rs7302741	chr12:86237127	C/T	cg02569458	chr12:86230093	RASSF9	0.52	7.66	0.43	3.46e-13	Major depressive disorder;
CESC	cis	rs9814567	0.712	rs4245905	chr3:134328864	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.4	-5.09	-0.3	6.84e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs2204008	0.744	rs8186814	chr12:38335169	C/T	cg26384229	chr12:38710491	ALG10B	0.73	10.9	0.56	4.29e-23	Bladder cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02365862	chr6:7541556	DSP	0.6	6.52	0.37	3.55e-10	Gut microbiome composition (summer);
CESC	cis	rs1707322	0.681	rs12048866	chr1:46117492	T/G	cg06784218	chr1:46089804	CCDC17	0.41	7.12	0.4	1.04e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2439831	0.850	rs9944216	chr15:44160773	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.63	-5.52	-0.32	8.04e-8	Lung cancer in ever smokers;
CESC	cis	rs367615	0.842	rs2578484	chr5:108950808	G/A	cg17395555	chr5:108820864	NA	-0.5	-7.06	-0.4	1.49e-11	Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs12249377	0.519	rs7906960	chr10:92586205	A/G	cg14313238	chr10:92632228	RPP30	0.43	5.26	0.31	2.92e-7	White matter microstructure (global fractional anisotropy);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg14843989	chr17:10600751	C17orf48;SCO1	-0.46	-6.03	-0.35	5.34e-9	Ulcerative colitis;
CESC	cis	rs7949030	0.591	rs11231156	chr11:62366454	G/A	cg22862634	chr11:62369728	EML3;MTA2	0.6	8.25	0.45	7.24e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs514406	0.505	rs269292	chr1:53187911	T/C	cg08859206	chr1:53392774	SCP2	-0.58	-7.73	-0.43	2.26e-13	Monocyte count;
CESC	cis	rs78456975	1.000	rs13414537	chr2:1556330	C/T	cg01028140	chr2:1542097	TPO	-0.58	-5.9	-0.34	1.1e-8	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs6089584	1.000	rs6089591	chr20:60570548	A/C	cg13770153	chr20:60521292	NA	-0.46	-6.23	-0.36	1.87e-9	Body mass index;
CESC	cis	rs7208859	0.673	rs423151	chr17:28952286	A/G	cg17105886	chr17:28927953	LRRC37B2	0.62	5.49	0.32	9.21e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	trans	rs9987353	0.840	rs329994	chr8:9123233	A/G	cg00745731	chr19:929724	ARID3A	0.47	6.26	0.36	1.55e-9	Recombination measurement;
CESC	cis	rs9815354	0.857	rs13087502	chr3:42015110	A/G	cg03022575	chr3:42003672	ULK4	0.47	5.24	0.31	3.26e-7	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs2243480	0.803	rs34804747	chr7:65412942	G/C	cg12463550	chr7:65579703	CRCP	0.69	5.62	0.33	4.79e-8	Diabetic kidney disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17181325	chr17:1613831	TLCD2	0.58	6.91	0.39	3.51e-11	Gut microbiome composition (summer);
CESC	cis	rs2303759	0.676	rs10426452	chr19:49907690	G/A	cg22307029	chr19:49891270	CCDC155	0.62	7.43	0.42	1.52e-12	Multiple sclerosis;
CESC	cis	rs3820068	0.608	rs12091750	chr1:16042766	T/C	cg13390004	chr1:15929781	NA	0.33	5.13	0.3	5.64e-7	Systolic blood pressure;
CESC	cis	rs9611565	0.512	rs9607841	chr22:42186838	G/A	cg06481639	chr22:41940642	POLR3H	-0.58	-5.73	-0.33	2.78e-8	Vitiligo;
CESC	cis	rs7044106	0.762	rs3903886	chr9:123383646	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	-0.34	-5.62	-0.33	4.77e-8	Hip circumference adjusted for BMI;
CESC	trans	rs1945213	0.694	rs34828123	chr11:55837868	T/A	cg15704280	chr7:45808275	SEPT13	0.76	7.31	0.41	3.15e-12	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs12413816	0.824	rs1571008	chr10:13760776	T/C	cg16485048	chr10:13749193	FRMD4A	0.57	7.73	0.43	2.28e-13	Red cell distribution width;
CESC	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	21.15	0.79	7.49e-59	Prudent dietary pattern;
CESC	cis	rs2404602	0.679	rs12900494	chr15:76912504	A/G	cg26408565	chr15:76604113	ETFA	-0.39	-5.49	-0.32	9.6e-8	Blood metabolite levels;
CESC	cis	rs7772486	0.754	rs4896839	chr6:146019689	T/G	cg23711669	chr6:146136114	FBXO30	-1.04	-15.13	-0.68	1.04e-37	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1691799	0.899	rs1168308	chr12:66742183	A/G	cg16791601	chr12:66731901	HELB	-0.75	-12.9	-0.62	7.25e-30	White blood cell count (basophil);
CESC	cis	rs12220238	1.000	rs11000905	chr10:75925532	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.63	6.1	0.35	3.78e-9	Soluble interleukin-2 receptor subunit alpha;
CESC	cis	rs875971	0.964	rs12668936	chr7:65914404	C/T	cg18876405	chr7:65276391	NA	0.51	6.82	0.39	6.05e-11	Aortic root size;
CESC	cis	rs637571	0.557	rs1204649	chr11:65702776	A/C	cg17985854	chr11:65770987	BANF1;EIF1AD	0.41	5.89	0.34	1.19e-8	Eosinophil percentage of white cells;
CESC	trans	rs1814175	0.817	rs6486044	chr11:49982718	C/T	cg15704280	chr7:45808275	SEPT13	-1.03	-20.41	-0.78	2.75e-56	Height;
CESC	cis	rs1008375	1.000	rs917665	chr4:17668504	A/C	cg16339924	chr4:17578868	LAP3	-0.45	-5.53	-0.32	7.65e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs6570726	0.791	rs1280275	chr6:145892402	C/T	cg05347473	chr6:146136440	FBXO30	0.59	7.63	0.42	4.24e-13	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs861020	1.000	rs595918	chr1:209966843	A/G	cg05527609	chr1:210001259	C1orf107	0.99	12.22	0.6	1.57e-27	Orofacial clefts;
CESC	cis	rs36229146	1	rs36229146	chr7:22784486	TTATATATAAATATATATATATATATA/T	cg13104385	chr7:22767384	IL6	0.47	6.08	0.35	4.1e-9	Eosinophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;
CESC	trans	rs1814175	0.817	rs11040474	chr11:49708441	G/A	cg03929089	chr4:120376271	NA	-0.91	-14.83	-0.67	1.26e-36	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22428961	chr1:2344426	PEX10	0.61	7.12	0.4	1e-11	Gut microbiome composition (summer);
CESC	cis	rs9399135	0.935	rs6908681	chr6:135337733	A/G	cg22676075	chr6:135203613	NA	0.52	7.42	0.41	1.61e-12	Red blood cell count;
CESC	cis	rs10540	1.000	rs35068485	chr11:466032	A/T	cg03352830	chr11:487213	PTDSS2	0.71	7.25	0.41	4.71e-12	Body mass index;
CESC	cis	rs3762637	0.823	rs59569049	chr3:122238788	A/T	cg24169773	chr3:122142474	KPNA1	-0.59	-6.88	-0.39	4.42e-11	LDL cholesterol levels;
CESC	cis	rs1577917	0.958	rs67024565	chr6:86553997	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.52	-6.57	-0.37	2.64e-10	Response to antipsychotic treatment;
CESC	cis	rs736408	0.609	rs13087772	chr3:52782274	T/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	6.71	0.38	1.18e-10	Bipolar disorder;
CESC	cis	rs425277	0.958	rs262660	chr1:2086757	A/G	cg16545954	chr1:2118288	C1orf86	0.33	5.59	0.32	5.57e-8	Height;
CESC	cis	rs7666738	0.747	rs2865955	chr4:99040518	A/C	cg05340658	chr4:99064831	C4orf37	0.82	12.88	0.62	8.44e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9900062	0.546	rs2428352	chr17:62694738	C/T	cg02097616	chr17:62675921	NA	-0.43	-5.38	-0.31	1.63e-7	QT interval;
CESC	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg15112475	chr7:1198522	ZFAND2A	-0.36	-5.81	-0.34	1.78e-8	Longevity;Endometriosis;
CESC	cis	rs4843747	0.641	rs11117353	chr16:88090895	A/G	cg17633681	chr16:88106987	BANP	0.68	8.95	0.48	6.21e-17	Menopause (age at onset);
CESC	cis	rs853679	0.713	rs200991	chr6:27815494	A/C	cg26587870	chr6:27730563	NA	0.48	5.21	0.3	3.76e-7	Depression;
CESC	cis	rs1957429	0.901	rs1957434	chr14:65349909	C/T	cg23373153	chr14:65346875	NA	0.96	11.49	0.58	4.43e-25	Pediatric areal bone mineral density (radius);
CESC	cis	rs875971	0.545	rs7787063	chr7:65628999	G/A	cg25405998	chr7:65216604	CCT6P1	0.45	5.06	0.3	7.71e-7	Aortic root size;
CESC	cis	rs7917772	0.636	rs7897384	chr10:104529042	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.45	-5.32	-0.31	2.2e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	trans	rs4245128	0.930	rs4245127	chr11:112791864	T/C	cg10894232	chr8:11772343	NA	0.37	6.1	0.35	3.78e-9	Life satisfaction;
CESC	cis	rs2439831	0.681	rs11858152	chr15:43634196	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.85	12.88	0.62	8.26e-30	Lung cancer in ever smokers;
CESC	cis	rs9902453	0.904	rs7213076	chr17:28419428	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.7	-9.02	-0.48	3.81e-17	Coffee consumption (cups per day);
CESC	cis	rs34779708	0.966	rs12774834	chr10:35400070	A/T	cg04310649	chr10:35416472	CREM	-0.52	-6.25	-0.36	1.62e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs4604732	0.588	rs9943231	chr1:247629829	C/T	cg12758973	chr1:247694275	LOC148824;OR2C3	0.47	5.82	0.34	1.73e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs6598955	0.724	rs884533	chr1:26585657	G/T	cg04990556	chr1:26633338	UBXN11	-0.79	-11.43	-0.57	7.15e-25	Obesity-related traits;
CESC	cis	rs7666738	0.830	rs11941961	chr4:99065654	G/T	cg18180107	chr4:99064573	C4orf37	0.4	5.07	0.3	7.34e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs651907	0.535	rs35810977	chr3:101531380	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.46	5.99	0.35	6.92e-9	Colorectal cancer;
CESC	cis	rs6754311	0.731	rs218174	chr2:136658345	C/T	cg07169764	chr2:136633963	MCM6	-0.69	-8.58	-0.47	8.13e-16	Mosquito bite size;
CESC	cis	rs6570726	0.764	rs376257	chr6:145862949	G/A	cg23711669	chr6:146136114	FBXO30	1.02	15.62	0.69	2.01e-39	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs875971	1.000	rs12533997	chr7:65965377	A/G	cg10691866	chr7:65817282	TPST1	-0.34	-5.64	-0.33	4.29e-8	Aortic root size;
CESC	cis	rs17345786	0.906	rs11710016	chr3:101120030	A/C	cg11279151	chr3:101281821	RG9MTD1	0.51	5.61	0.33	5.07e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6688613	0.649	rs2294195	chr1:166838281	T/C	cg07049167	chr1:166818506	POGK	0.44	5.07	0.3	7.39e-7	Refractive astigmatism;
CESC	cis	rs4409675	0.556	rs2064710	chr1:28231154	G/A	cg23691781	chr1:28212827	C1orf38	0.28	5.64	0.33	4.46e-8	Corneal astigmatism;
CESC	cis	rs6430585	0.528	rs660002	chr2:136723504	C/T	cg07169764	chr2:136633963	MCM6	1.1	16.89	0.72	6.1e-44	Corneal structure;
CESC	cis	rs6088580	0.634	rs4911153	chr20:32961547	C/T	cg08999081	chr20:33150536	PIGU	-0.64	-11.05	-0.56	1.38e-23	Glomerular filtration rate (creatinine);
CESC	cis	rs5758659	0.653	rs133383	chr22:42473603	C/T	cg19513890	chr22:42538836	CYP2D7P1	-0.38	-5.62	-0.33	4.73e-8	Cognitive function;
CESC	cis	rs7552404	0.727	rs1159214	chr1:76317910	G/T	cg22875332	chr1:76189707	ACADM	-0.63	-6.66	-0.38	1.6e-10	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs7927771	0.864	rs4752999	chr11:47428565	C/T	cg05585544	chr11:47624801	NA	-0.46	-6.74	-0.38	9.81e-11	Subjective well-being;
CESC	cis	rs9596863	1.000	rs9568939	chr13:54411497	A/C	ch.13.53330881F	chr13:54432880	NA	0.66	5.25	0.31	3.08e-7	Epilepsy and lamotrigine-induced maculopapular eruptions;
CESC	cis	rs11229555	0.834	rs7925560	chr11:58263036	G/A	cg15696309	chr11:58395628	NA	-0.42	-5.2	-0.3	3.98e-7	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs1862618	0.853	rs866222	chr5:56184444	T/C	cg03609598	chr5:56110824	MAP3K1	-0.51	-5.32	-0.31	2.22e-7	Initial pursuit acceleration;
CESC	cis	rs7666738	0.830	rs34412187	chr4:99010454	A/G	cg17366294	chr4:99064904	C4orf37	0.6	8.62	0.47	6.37e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs853679	0.517	rs9393901	chr6:28136797	A/G	cg26335602	chr6:28129616	ZNF389	0.52	6.84	0.39	5.58e-11	Depression;
CESC	cis	rs6570726	1.000	rs1935617	chr6:145943326	C/T	cg23711669	chr6:146136114	FBXO30	0.7	10.28	0.53	4.29e-21	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1552244	1.000	rs56394721	chr3:10150795	A/G	cg00166722	chr3:10149974	C3orf24	0.5	6.35	0.36	9.36e-10	Alzheimer's disease;
CESC	cis	rs897984	0.542	rs11864839	chr16:31095251	G/C	cg00531865	chr16:30841666	NA	-0.4	-5.54	-0.32	7.3900000000000007e-08	Dementia with Lewy bodies;
CESC	cis	rs9916302	0.904	rs4794807	chr17:37531718	T/A	cg20243544	chr17:37824526	PNMT	-0.48	-6.1	-0.35	3.8e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs11690935	0.959	rs67204065	chr2:172672624	G/A	cg13550731	chr2:172543902	DYNC1I2	-0.92	-13.72	-0.64	1.02e-32	Schizophrenia;
CESC	cis	rs4713118	0.621	rs4713133	chr6:28034041	T/C	cg22143856	chr6:28129313	ZNF389	0.44	5.49	0.32	9.24e-8	Parkinson's disease;
CESC	trans	rs11764590	0.671	rs17734969	chr7:2110517	T/C	cg11693508	chr17:37793320	STARD3	0.66	7.13	0.4	9.32e-12	Neuroticism;
CESC	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg18402987	chr7:1209562	NA	0.76	7.58	0.42	5.85e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7824557	0.564	rs2736294	chr8:11234626	T/C	cg21775007	chr8:11205619	TDH	-0.54	-8.08	-0.44	2.28e-14	Retinal vascular caliber;
CESC	cis	rs9300255	0.602	rs2851438	chr12:123643689	T/C	cg19016782	chr12:123741754	C12orf65	-0.4	-5.77	-0.33	2.27e-8	Neutrophil percentage of white cells;
CESC	cis	rs853679	0.546	rs200953	chr6:27837267	T/C	cg02228804	chr6:27775720	HIST1H2AI;HIST1H2BL	0.64	5.51	0.32	8.38e-8	Depression;
CESC	cis	rs57244997	0.725	rs73028496	chr6:162422243	A/G	cg17173639	chr6:162384350	PARK2	-0.49	-5.66	-0.33	3.98e-8	Mosquito bite size;
CESC	cis	rs4665809	1.000	rs11126375	chr2:26344787	G/A	cg08470875	chr2:26401718	FAM59B	-0.47	-5.24	-0.31	3.31e-7	Gut microbiome composition (summer);
CESC	cis	rs28647808	0.881	rs7042326	chr9:136266636	T/C	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.84	5.73	0.33	2.7e-8	Blood protein levels;
CESC	cis	rs9644630	0.897	rs6984644	chr8:19363425	C/T	cg01280390	chr8:19363452	CSGALNACT1	0.34	5.22	0.31	3.6e-7	Oropharynx cancer;
CESC	cis	rs6860806	0.507	rs582490	chr5:131710095	G/A	cg24060327	chr5:131705240	SLC22A5	0.76	10.65	0.55	2.72e-22	Breast cancer;
CESC	cis	rs9527	0.614	rs11191589	chr10:104930382	T/C	cg04362960	chr10:104952993	NT5C2	0.42	5.25	0.31	3.11e-7	Arsenic metabolism;
CESC	cis	rs35306767	0.903	rs10904577	chr10:922077	A/G	cg25019033	chr10:957182	NA	-0.59	-6.33	-0.36	1.02e-9	Eosinophil percentage of granulocytes;
CESC	trans	rs561341	1.000	rs561341	chr17:30316385	T/G	cg20587970	chr11:113659929	NA	-1.41	-18.23	-0.75	1.08e-48	Hip circumference adjusted for BMI;
CESC	cis	rs79149102	0.649	rs75725543	chr15:75097737	T/C	cg09165964	chr15:75287851	SCAMP5	-0.71	-5.26	-0.31	2.97e-7	Lung cancer;
CESC	cis	rs4713118	0.662	rs9468274	chr6:28026077	G/T	cg12963246	chr6:28129442	ZNF389	0.5	6.4	0.37	6.93e-10	Parkinson's disease;
CESC	cis	rs12586317	0.547	rs10130773	chr14:35445299	G/A	cg05294307	chr14:35346193	BAZ1A	-0.49	-5.37	-0.31	1.75e-7	Psoriasis;
CESC	cis	rs3126085	0.935	rs1496050	chr1:152163549	T/C	cg26876637	chr1:152193138	HRNR	0.44	5.12	0.3	5.85e-7	Atopic dermatitis;
CESC	cis	rs1552244	1.000	rs9820598	chr3:10117912	C/G	cg08888203	chr3:10149979	C3orf24	0.55	7.2	0.4	6.16e-12	Alzheimer's disease;
CESC	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg07092213	chr7:1199455	ZFAND2A	-0.51	-5.99	-0.35	6.78e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2485892	0.553	rs2494191	chr1:210346053	G/C	cg21951975	chr1:209979733	IRF6	0.47	5.82	0.34	1.66e-8	Manic episodes in bipolar disorder;
CESC	cis	rs654950	0.875	rs2759248	chr1:41990795	T/C	cg06885757	chr1:42089581	HIVEP3	-0.43	-6.7	-0.38	1.27e-10	Airway imaging phenotypes;
CESC	cis	rs2576037	0.583	rs12386118	chr18:44540376	C/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.32	5.03	0.3	9.21e-7	Personality dimensions;
CESC	cis	rs28374715	0.578	rs7165914	chr15:41632451	C/T	cg02330683	chr15:41787940	ITPKA	0.49	5.72	0.33	2.93e-8	Ulcerative colitis;
CESC	cis	rs8031584	0.958	rs61997079	chr15:31238271	G/C	cg08109568	chr15:31115862	NA	-0.71	-9.44	-0.5	2.03e-18	Huntington's disease progression;
CESC	cis	rs752010	0.715	rs4083592	chr1:42099522	A/G	cg06885757	chr1:42089581	HIVEP3	0.7	10.86	0.56	5.6e-23	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs561341	1.000	rs8070262	chr17:30262467	A/G	cg00745463	chr17:30367425	LRRC37B	-0.49	-5.29	-0.31	2.57e-7	Hip circumference adjusted for BMI;
CESC	cis	rs1144713	1.000	rs1144713	chr12:32261239	A/G	cg01321189	chr12:32259338	BICD1	0.39	6.17	0.35	2.53e-9	Obesity-related traits;
CESC	cis	rs11785400	0.701	rs9297968	chr8:143723009	A/G	cg24634471	chr8:143751801	JRK	0.43	5.57	0.32	6.39e-8	Schizophrenia;
CESC	cis	rs853679	0.546	rs200953	chr6:27837267	T/C	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.88	7.6	0.42	5.11e-13	Depression;
CESC	cis	rs7296418	0.961	rs12425850	chr12:123501972	T/C	cg00376283	chr12:123451042	ABCB9	0.75	10.88	0.56	4.77e-23	Platelet count;
CESC	cis	rs1595825	0.891	rs59938443	chr2:198497105	C/T	cg10820045	chr2:198174542	NA	0.4	5.07	0.3	7.53e-7	Ulcerative colitis;
CESC	cis	rs950027	0.620	rs1153862	chr15:45631868	A/G	cg21132104	chr15:45694354	SPATA5L1	0.67	8.72	0.47	3.16e-16	Response to fenofibrate (adiponectin levels);
CESC	cis	rs1371867	0.875	rs1962901	chr8:101326428	A/G	cg11906718	chr8:101322791	RNF19A	0.46	5.92	0.34	1.02e-8	Atrioventricular conduction;
CESC	cis	rs9929218	0.508	rs1559366	chr16:68799611	A/G	cg02972257	chr16:68554789	NA	-0.42	-5.3	-0.31	2.41e-7	Colorectal cancer;
CESC	cis	rs3750965	0.920	rs4930644	chr11:68819097	C/T	cg01403660	chr11:68851641	TPCN2	0.44	5.6	0.33	5.45e-8	Hair color;
CESC	trans	rs6572548	0.504	rs1956082	chr14:49665496	A/C	cg04726876	chr9:2017576	SMARCA2	-0.52	-6.33	-0.36	1.06e-9	Subjective well-being;
CESC	cis	rs7100689	0.577	rs1340385	chr10:82058851	G/A	cg09936400	chr10:82049201	MAT1A	0.41	6.06	0.35	4.57e-9	Post bronchodilator FEV1;
CESC	trans	rs2797160	0.875	rs12527010	chr6:125991507	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.45	6.16	0.35	2.76e-9	Endometrial cancer;
CESC	cis	rs798554	0.679	rs7784066	chr7:2819727	T/A	cg18446336	chr7:2847575	GNA12	-0.4	-6.02	-0.35	5.71e-9	Height;
CESC	cis	rs1065852	0.526	rs12166549	chr22:42410419	T/C	cg22189786	chr22:42395067	WBP2NL	0.41	5.22	0.31	3.55e-7	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
CESC	cis	rs477692	0.789	rs507900	chr10:131398144	A/G	cg05714579	chr10:131428358	MGMT	-0.45	-5.9	-0.34	1.1e-8	Response to temozolomide;
CESC	cis	rs853679	0.517	rs9368554	chr6:28082711	T/C	cg22143856	chr6:28129313	ZNF389	0.52	6.71	0.38	1.21e-10	Depression;
CESC	cis	rs7296418	0.663	rs11057284	chr12:123830692	G/C	cg00376283	chr12:123451042	ABCB9	0.56	7.79	0.43	1.53e-13	Platelet count;
CESC	cis	rs9916302	0.904	rs4794807	chr17:37531718	T/A	cg07936489	chr17:37558343	FBXL20	0.8	11.67	0.58	1.17e-25	Glomerular filtration rate (creatinine);
CESC	cis	rs9649213	0.593	rs3801263	chr7:97965016	A/G	cg00277769	chr7:97922759	BAIAP2L1	-0.34	-5.62	-0.33	4.84e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs10504229	0.683	rs56208052	chr8:58130207	A/T	cg21724239	chr8:58056113	NA	0.58	5.95	0.34	8.29e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs11098499	0.863	rs17050695	chr4:120489527	G/T	cg24375607	chr4:120327624	NA	0.48	5.89	0.34	1.16e-8	Corneal astigmatism;
CESC	cis	rs7666738	0.830	rs11944855	chr4:99068258	G/A	cg05340658	chr4:99064831	C4orf37	0.83	12.82	0.62	1.36e-29	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6938	0.597	rs11856413	chr15:75199892	A/G	cg09165964	chr15:75287851	SCAMP5	0.46	6.28	0.36	1.36e-9	Breast cancer;
CESC	cis	rs1008375	0.863	rs10003291	chr4:17600728	A/C	cg27347728	chr4:17578864	LAP3	0.48	5.57	0.32	6.36e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs9399401	0.667	rs6900233	chr6:142717283	C/G	cg04461802	chr6:142623433	GPR126	0.42	6.04	0.35	5.13e-9	Chronic obstructive pulmonary disease;
CESC	cis	rs9611519	0.603	rs8142276	chr22:41471447	T/C	cg03806693	chr22:41940476	POLR3H	-0.43	-5.22	-0.31	3.67e-7	Neuroticism;
CESC	cis	rs9487051	0.676	rs9398196	chr6:109601554	A/G	cg12927641	chr6:109611667	NA	-0.37	-5.51	-0.32	8.39e-8	Reticulocyte fraction of red cells;
CESC	cis	rs798554	0.797	rs798494	chr7:2798294	C/A	cg19717773	chr7:2847554	GNA12	-0.57	-8.18	-0.45	1.18e-14	Height;
CESC	cis	rs9393777	0.623	rs9358948	chr6:26483806	G/A	cg14345882	chr6:26364793	BTN3A2	0.43	5.34	0.31	2.01e-7	Intelligence (multi-trait analysis);
CESC	cis	rs13256369	0.802	rs11995449	chr8:8559898	G/A	cg18904891	chr8:8559673	CLDN23	0.72	7.86	0.43	9.45e-14	Obesity-related traits;
CESC	cis	rs9733	0.791	rs11800059	chr1:150651175	C/T	cg22823121	chr1:150693482	HORMAD1	-0.41	-6.29	-0.36	1.29e-9	Tonsillectomy;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg00653609	chr6:39082964	C6orf64	0.5	6.33	0.36	1.02e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs9467711	0.523	rs9379853	chr6:26357635	A/G	cg12826209	chr6:26865740	GUSBL1	0.61	5.17	0.3	4.52e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg24829409	chr8:58192753	C8orf71	-0.61	-7.02	-0.4	1.9e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs7528419	0.927	rs660240	chr1:109817838	T/C	cg00908766	chr1:109817496	CELSR2	0.47	6.73	0.38	1.05e-10	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
CESC	cis	rs10129255	0.500	rs11628999	chr14:107208446	C/T	cg23076370	chr14:107095027	NA	-0.64	-9.31	-0.5	5.13e-18	Kawasaki disease;
CESC	cis	rs704795	0.805	rs1728926	chr2:27612937	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.34	-6.98	-0.39	2.43e-11	Menopause (age at onset);
CESC	cis	rs3768617	0.811	rs6424883	chr1:183037695	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.66	9.15	0.49	1.56e-17	Fuchs's corneal dystrophy;
CESC	cis	rs7927771	1.000	rs10838747	chr11:47716324	G/C	cg20307385	chr11:47447363	PSMC3	-0.5	-6.11	-0.35	3.6e-9	Subjective well-being;
CESC	cis	rs11792861	0.926	rs72607173	chr9:111879398	T/G	cg05043794	chr9:111880884	C9orf5	-0.4	-6.68	-0.38	1.44e-10	Menarche (age at onset);
CESC	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg24829409	chr8:58192753	C8orf71	-0.69	-7.68	-0.43	3.13e-13	Developmental language disorder (linguistic errors);
CESC	cis	rs4566357	0.615	rs4675139	chr2:227908527	G/A	cg11843606	chr2:227700838	RHBDD1	-0.48	-6.54	-0.37	3.12e-10	Coronary artery disease;
CESC	cis	rs137699	0.959	rs5757631	chr22:39755953	T/C	cg05872129	chr22:39784769	NA	-0.41	-5.3	-0.31	2.45e-7	IgG glycosylation;
CESC	cis	rs6570726	0.935	rs454370	chr6:145846729	T/G	cg05347473	chr6:146136440	FBXO30	0.49	6.62	0.38	1.96e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1538970	0.924	rs7528573	chr1:45913860	T/C	cg03146154	chr1:46216737	IPP	0.46	5.34	0.31	1.97e-7	Platelet count;
CESC	cis	rs1865721	1.000	rs7244787	chr18:73195162	T/C	cg26385618	chr18:73139727	C18orf62	-0.51	-7.56	-0.42	6.81e-13	Intelligence;
CESC	cis	rs12474201	0.928	rs34186074	chr2:46965010	T/C	cg06386533	chr2:46925753	SOCS5	0.91	12.78	0.62	1.92e-29	Height;
CESC	cis	rs7666738	0.609	rs35214820	chr4:98864692	G/A	cg17366294	chr4:99064904	C4orf37	0.47	5.73	0.33	2.67e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2204008	0.526	rs2320448	chr12:38224180	G/A	cg26384229	chr12:38710491	ALG10B	-0.46	-6.06	-0.35	4.66e-9	Bladder cancer;
CESC	cis	rs9818941	1.000	rs4507209	chr3:157710946	T/A	cg08654915	chr3:157813417	NA	-0.46	-7.77	-0.43	1.72e-13	Height;
CESC	cis	rs2576037	0.526	rs509647	chr18:44383675	G/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.44	7.15	0.4	8.31e-12	Personality dimensions;
CESC	cis	rs7605827	0.930	rs11692624	chr2:15499127	C/T	cg19274914	chr2:15703543	NA	0.32	5.76	0.33	2.35e-8	Educational attainment (years of education);
CESC	cis	rs6460942	0.558	rs4330594	chr7:12278615	G/A	cg20607287	chr7:12443886	VWDE	-0.55	-5.86	-0.34	1.38e-8	Coronary artery disease;
CESC	cis	rs9300255	0.602	rs884548	chr12:123634122	A/G	cg19016782	chr12:123741754	C12orf65	-0.37	-5.04	-0.3	8.55e-7	Neutrophil percentage of white cells;
CESC	cis	rs3540	0.514	rs2601194	chr15:90937051	T/A	cg10434728	chr15:90938212	IQGAP1	0.43	7.7	0.43	2.72e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs7582720	1.000	rs72932554	chr2:203845828	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.36	0.41	2.34e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs854765	0.654	rs9911281	chr17:17762457	G/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.6	-8.95	-0.48	6.29e-17	Total body bone mineral density;
CESC	cis	rs7412746	0.634	rs3754212	chr1:150738200	A/G	cg22823121	chr1:150693482	HORMAD1	0.47	6.51	0.37	3.7e-10	Melanoma;
CESC	cis	rs477895	0.713	rs11600867	chr11:63972052	T/A	cg04317338	chr11:64019027	PLCB3	0.89	9.33	0.5	4.45e-18	Mean platelet volume;
CESC	cis	rs16858210	0.874	rs11918588	chr3:183601715	C/A	cg25686905	chr3:183603175	PARL	-0.33	-5.98	-0.35	7.05e-9	Menopause (age at onset);
CESC	cis	rs57221529	0.713	rs56328416	chr5:591138	G/A	cg16447950	chr5:562315	NA	-0.59	-6.06	-0.35	4.53e-9	Lung disease severity in cystic fibrosis;
CESC	cis	rs6496667	0.509	rs2657948	chr15:90948617	G/A	cg10434728	chr15:90938212	IQGAP1	0.32	5.65	0.33	4.22e-8	Rheumatoid arthritis;
CESC	cis	rs9649213	0.586	rs11768599	chr7:97974555	C/T	cg09267113	chr7:98030324	BAIAP2L1	-0.44	-5.98	-0.34	7.33e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs8038465	0.571	rs7176654	chr15:73999006	C/T	cg15420318	chr15:73925796	NPTN	-0.4	-5.95	-0.34	8.37e-9	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs4132509	0.779	rs3006940	chr1:243683001	A/G	cg21452805	chr1:244014465	NA	0.41	5.12	0.3	5.8e-7	RR interval (heart rate);
CESC	cis	rs10924309	0.737	rs6700721	chr1:245854173	C/T	cg00036263	chr1:245852353	KIF26B	-0.55	-7.28	-0.41	3.71e-12	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
CESC	cis	rs7772486	0.623	rs9485021	chr6:146068797	A/G	cg23711669	chr6:146136114	FBXO30	-0.87	-12.87	-0.62	8.94e-30	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs3749237	0.555	rs2117939	chr3:49415179	C/A	cg02487422	chr3:49467188	NICN1	0.53	7.7	0.43	2.74e-13	Resting heart rate;
CESC	cis	rs3015497	0.549	rs10133807	chr14:51151522	G/A	cg26011998	chr14:51135199	SAV1	-0.6	-6.65	-0.38	1.65e-10	Mean platelet volume;
CESC	cis	rs7666738	0.791	rs7678564	chr4:99057341	A/G	cg17366294	chr4:99064904	C4orf37	0.61	8.6	0.47	7.18e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1707322	0.717	rs28752166	chr1:46213309	G/A	cg03146154	chr1:46216737	IPP	0.82	11.53	0.58	3.39e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs694739	0.541	rs61886926	chr11:64133552	C/T	cg02228329	chr11:64053129	BAD;GPR137	0.61	7.58	0.42	5.67e-13	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CESC	cis	rs7134594	0.677	rs1866066	chr12:109858264	A/T	cg19025524	chr12:109796872	NA	-0.42	-6.15	-0.35	2.8e-9	HDL cholesterol;
CESC	cis	rs10129255	0.500	rs988133	chr14:107184963	A/G	cg23076370	chr14:107095027	NA	-0.66	-9.85	-0.52	1.01e-19	Kawasaki disease;
CESC	cis	rs7412746	0.611	rs2228099	chr1:150808889	C/G	cg04414720	chr1:150670196	GOLPH3L	0.45	6.31	0.36	1.16e-9	Melanoma;
CESC	cis	rs10979	0.931	rs9484770	chr6:143896758	A/G	cg25407410	chr6:143891975	LOC285740	-0.61	-9.2	-0.49	1.13e-17	Hypospadias;
CESC	cis	rs7666738	0.791	rs10033211	chr4:98995624	T/A	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.62e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7178572	0.633	rs4886875	chr15:77838419	C/T	cg22256960	chr15:77711686	NA	0.53	6.99	0.39	2.18e-11	Type 2 diabetes;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg16548348	chr22:19842481	GNB1L;C22orf29	-0.45	-6.67	-0.38	1.48e-10	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs1552244	0.938	rs56274701	chr3:10167790	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.82	-11.61	-0.58	1.83e-25	Alzheimer's disease;
CESC	cis	rs801193	0.660	rs2659914	chr7:66156914	C/T	cg12463550	chr7:65579703	CRCP	0.54	6.92	0.39	3.34e-11	Aortic root size;
CESC	cis	rs769267	0.896	rs7253807	chr19:19631444	A/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.43	5.38	0.31	1.65e-7	Tonsillectomy;
CESC	cis	rs9910055	0.821	rs4473241	chr17:42281282	G/T	cg08499158	chr17:42289980	UBTF	-0.47	-5.66	-0.33	4.02e-8	Total body bone mineral density;
CESC	cis	rs2243480	1.000	rs2177703	chr7:65391717	C/A	cg13147721	chr7:65941812	NA	-0.83	-7.92	-0.44	6.77e-14	Diabetic kidney disease;
CESC	cis	rs7107174	1.000	rs901104	chr11:77930499	C/T	cg02023728	chr11:77925099	USP35	0.52	6.5	0.37	4.01e-10	Testicular germ cell tumor;
CESC	trans	rs7615952	0.932	rs3811679	chr3:125648283	A/G	cg07211511	chr3:129823064	LOC729375	-1.13	-15.25	-0.68	4.15e-38	Blood pressure (smoking interaction);
CESC	cis	rs3768617	0.510	rs10911254	chr1:183088627	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.89	14.36	0.66	5.49e-35	Fuchs's corneal dystrophy;
CESC	cis	rs2857078	0.745	rs4793085	chr17:42320732	A/C	cg08499158	chr17:42289980	UBTF	0.42	5.22	0.31	3.57e-7	Red cell distribution width;Reticulocyte count;
CESC	cis	rs7666738	0.791	rs1115615	chr4:99006614	G/A	cg17366294	chr4:99064904	C4orf37	0.6	8.61	0.47	6.47e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6800768	0.633	rs12498129	chr3:24120454	A/G	cg10674438	chr3:24145617	LOC152024	-0.46	-6.3	-0.36	1.24e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs7552404	1.000	rs437298	chr1:76113770	T/C	cg22875332	chr1:76189707	ACADM	-0.59	-6.73	-0.38	1.04e-10	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs7219021	0.705	rs28635466	chr17:46983820	G/A	cg16584676	chr17:46985605	UBE2Z	-0.63	-7.84	-0.43	1.14e-13	Schizophrenia or bipolar disorder;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg21150049	chr12:50677498	LIMA1	-0.44	-6.25	-0.36	1.65e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs6598955	0.671	rs12088858	chr1:26643708	C/A	cg19743891	chr1:26644573	UBXN11;CD52	0.35	5.09	0.3	6.68e-7	Obesity-related traits;
CESC	cis	rs365132	1.000	rs35977534	chr5:176335231	T/C	cg16309518	chr5:176445507	NA	-0.41	-6.02	-0.35	5.68e-9	Menarche and menopause (age at onset);Menopause (age at onset);
CESC	cis	rs1050631	0.564	rs1785931	chr18:33722107	T/C	cg25426722	chr18:33708991	SLC39A6;ELP2	0.59	8.21	0.45	9.51e-15	Esophageal squamous cell cancer (length of survival);
CESC	cis	rs425277	0.958	rs262652	chr1:2090816	T/C	cg16545954	chr1:2118288	C1orf86	0.33	5.59	0.32	5.57e-8	Height;
CESC	cis	rs6502050	0.835	rs8065037	chr17:80158966	T/G	cg23985595	chr17:80112537	CCDC57	-0.4	-6.37	-0.36	8.38e-10	Life satisfaction;
CESC	cis	rs1008375	1.000	rs56974987	chr4:17627856	G/A	cg16339924	chr4:17578868	LAP3	0.59	7.47	0.42	1.15e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs9916302	0.851	rs12936646	chr17:37647450	A/T	cg20243544	chr17:37824526	PNMT	0.49	6.23	0.36	1.85e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs854765	0.583	rs4925129	chr17:17807186	A/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.47	5.97	0.34	7.54e-9	Total body bone mineral density;
CESC	cis	rs9486719	1.000	rs2499809	chr6:96870110	C/T	cg06623918	chr6:96969491	KIAA0776	0.81	8.29	0.45	5.61e-15	Migraine;Coronary artery disease;
CESC	cis	rs7666738	0.830	rs17550630	chr4:99008332	G/T	cg03467027	chr4:99064603	C4orf37	0.44	5.51	0.32	8.65e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9457247	1.000	rs2757047	chr6:167374489	C/T	cg23791538	chr6:167370224	RNASET2	0.6	8.47	0.46	1.73e-15	Crohn's disease;
CESC	cis	rs4629710	0.592	rs4310080	chr6:131538377	T/G	cg12606694	chr6:131520996	AKAP7	0.45	5.55	0.32	6.81e-8	Multiple myeloma (IgH translocation);
CESC	cis	rs4925386	0.765	rs6142737	chr20:60919800	C/G	cg24112000	chr20:60950667	NA	-0.44	-5.4	-0.31	1.5e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg24846343	chr22:24311635	DDTL	0.71	12.77	0.62	2.06e-29	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs7586879	0.964	rs6545795	chr2:25116783	C/T	cg01884057	chr2:25150051	NA	0.28	5.12	0.3	5.86e-7	Body mass index;
CESC	cis	rs4474465	0.646	rs7936011	chr11:78275931	G/T	cg27205649	chr11:78285834	NARS2	0.46	6.07	0.35	4.44e-9	Alzheimer's disease (survival time);
CESC	cis	rs950169	0.763	rs35372971	chr15:84941795	G/A	cg17507749	chr15:85114479	UBE2QP1	0.59	6.52	0.37	3.46e-10	Schizophrenia;
CESC	cis	rs68170813	0.599	rs12532849	chr7:106959226	A/C	cg02696742	chr7:106810147	HBP1	-0.53	-5.04	-0.3	8.64e-7	Coronary artery disease;
CESC	trans	rs11148252	0.574	rs3742297	chr13:53278067	T/C	cg18335740	chr13:41363409	SLC25A15	0.53	7.16	0.4	7.78e-12	Lewy body disease;
CESC	cis	rs10504229	0.610	rs6999661	chr8:58127391	C/G	cg22535103	chr8:58192502	C8orf71	-0.84	-9.44	-0.5	2.04e-18	Developmental language disorder (linguistic errors);
CESC	cis	rs2880765	0.545	rs17553734	chr15:86013059	C/G	cg19183879	chr15:85880815	NA	0.32	5.93	0.34	9.5e-9	Coronary artery disease;
CESC	cis	rs2294693	0.945	rs9394755	chr6:41006680	C/T	cg14769373	chr6:40998127	UNC5CL	0.39	5.43	0.32	1.27e-7	Gastric cancer;Non-cardia gastric cancer;
CESC	cis	rs1882538	0.503	rs1345938	chr7:133137867	C/T	cg10665199	chr7:133106180	EXOC4	-0.54	-7.42	-0.41	1.57e-12	Intelligence (multi-trait analysis);
CESC	cis	rs5771242	0.776	rs6010198	chr22:50610628	A/G	cg08875078	chr22:50639485	SELO	-0.51	-5.94	-0.34	8.72e-9	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
CESC	cis	rs7903847	0.642	rs11817875	chr10:99158414	G/A	cg20016023	chr10:99160130	RRP12	-0.3	-5.16	-0.3	4.81e-7	Granulocyte percentage of myeloid white cells;
CESC	cis	rs6952808	0.531	rs1107351	chr7:2177093	G/A	cg05863683	chr7:1912471	MAD1L1	0.39	5.64	0.33	4.45e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs2836950	0.509	rs4816618	chr21:40599529	G/A	cg11890956	chr21:40555474	PSMG1	-0.6	-8.25	-0.45	7.41e-15	Menarche (age at onset);
CESC	cis	rs9908102	0.740	rs7211501	chr17:12917479	A/G	cg26162695	chr17:12921313	ELAC2	0.55	5.9	0.34	1.12e-8	Schizophrenia;
CESC	cis	rs8072100	0.640	rs3851808	chr17:45425144	C/T	cg08085267	chr17:45401833	C17orf57	-0.53	-6.65	-0.38	1.65e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs9488822	0.636	rs12524932	chr6:116330266	G/A	cg05304507	chr6:116381966	FRK	0.25	6.49	0.37	4.22e-10	Cholesterol, total;LDL cholesterol;
CESC	cis	rs9815354	0.812	rs73069240	chr3:41950973	A/T	cg03022575	chr3:42003672	ULK4	0.68	5.92	0.34	9.9e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs7618915	0.501	rs35526119	chr3:52749334	C/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	5.84	0.34	1.51e-8	Bipolar disorder;
CESC	cis	rs1062177	1.000	rs2915877	chr5:151150601	C/G	cg00977110	chr5:151150581	G3BP1	0.67	7.15	0.4	8.3e-12	Preschool internalizing problems;
CESC	cis	rs10905065	0.804	rs2380203	chr10:5810897	A/G	cg11519256	chr10:5708881	ASB13	0.4	5.27	0.31	2.84e-7	Menopause (age at onset);
CESC	cis	rs1577917	0.958	rs12203457	chr6:86689277	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.43	-5.57	-0.32	6.1e-8	Response to antipsychotic treatment;
CESC	cis	rs9611565	0.840	rs9607799	chr22:41777558	A/G	cg06481639	chr22:41940642	POLR3H	-0.6	-6.44	-0.37	5.59e-10	Vitiligo;
CESC	cis	rs11209002	0.567	rs983110	chr1:67539215	A/T	cg02640540	chr1:67518911	SLC35D1	0.47	5.39	0.31	1.52e-7	Crohn's disease;
CESC	cis	rs7647973	1.000	rs74471041	chr3:49542543	T/G	cg02487422	chr3:49467188	NICN1	-0.41	-5.36	-0.31	1.81e-7	Menarche (age at onset);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg02615117	chr20:36034986	NA	0.41	6.11	0.35	3.51e-9	Fibrinogen levels;
CESC	cis	rs5750830	0.594	rs9611169	chr22:39783027	C/T	cg24399712	chr22:39784796	NA	-0.8	-11.16	-0.57	6.02e-24	Intelligence (multi-trait analysis);
CESC	cis	rs6740322	0.643	rs13390381	chr2:43534414	C/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.5	-5.07	-0.3	7.57e-7	Coronary artery disease;
CESC	cis	rs261532	0.953	rs446588	chr5:138987756	G/C	cg10513866	chr5:139070639	NA	0.33	5.17	0.3	4.52e-7	Immune reponse to smallpox (secreted IFN-alpha);
CESC	cis	rs2243480	1.000	rs13310597	chr7:65598540	A/G	cg18252515	chr7:66147081	NA	-1.41	-14.36	-0.66	5.44e-35	Diabetic kidney disease;
CESC	cis	rs4664293	0.967	rs7597482	chr2:160547091	T/A	cg08347373	chr2:160653686	CD302	-0.31	-5.09	-0.3	6.83e-7	Monocyte percentage of white cells;
CESC	cis	rs6598955	0.724	rs869683	chr1:26570993	T/A	cg00852783	chr1:26633632	UBXN11	0.42	6.29	0.36	1.34e-9	Obesity-related traits;
CESC	cis	rs8031584	0.918	rs61997138	chr15:31270776	C/T	cg14298792	chr15:30685198	CHRFAM7A	-0.46	-5.44	-0.32	1.19e-7	Huntington's disease progression;
CESC	cis	rs7666738	0.830	rs11731478	chr4:99001686	A/G	cg17366294	chr4:99064904	C4orf37	0.6	8.61	0.47	6.47e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2645424	0.671	rs2294138	chr8:11705139	C/T	cg21281001	chr8:11725306	CTSB	0.5	6.2	0.36	2.18e-9	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);
CESC	cis	rs1552244	0.808	rs7615088	chr3:10035896	A/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.85	11.02	0.56	1.64e-23	Alzheimer's disease;
CESC	cis	rs7959452	0.562	rs10878975	chr12:69782044	G/C	cg22834771	chr12:69754056	YEATS4	-0.48	-6.46	-0.37	4.87e-10	Blood protein levels;
CESC	cis	rs9611565	0.659	rs12483786	chr22:41938536	A/G	cg06634786	chr22:41940651	POLR3H	-0.68	-7.02	-0.4	1.86e-11	Vitiligo;
CESC	cis	rs950169	0.887	rs220333	chr15:85091133	C/T	cg17507749	chr15:85114479	UBE2QP1	0.58	6.47	0.37	4.82e-10	Schizophrenia;
CESC	cis	rs116095464	0.542	rs28650039	chr5:273954	C/A	cg12570787	chr5:219185	SDHA;CCDC127	0.52	5.37	0.31	1.76e-7	Breast cancer;
CESC	cis	rs9894429	0.789	rs8074989	chr17:79598728	G/C	cg13777783	chr17:79615861	NA	-0.33	-5.23	-0.31	3.45e-7	Eye color traits;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg10612046	chr4:39640456	C4orf34	-0.48	-6.3	-0.36	1.26e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs7666738	0.830	rs11097598	chr4:98946057	T/C	cg18180107	chr4:99064573	C4orf37	0.41	5.27	0.31	2.88e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs12048904	0.505	rs11166511	chr1:101240686	G/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.75	-9.3	-0.5	5.56e-18	Multiple sclerosis;
CESC	cis	rs7771547	0.573	rs664370	chr6:36393816	A/G	cg04289385	chr6:36355825	ETV7	0.39	5.75	0.33	2.44e-8	Platelet distribution width;
CESC	cis	rs10876993	0.890	rs1689584	chr12:58081478	G/A	cg18357645	chr12:58087776	OS9	0.63	10.59	0.55	4.28e-22	Celiac disease or Rheumatoid arthritis;
CESC	cis	rs1799949	0.965	rs8176140	chr17:41251646	T/A	cg06001716	chr17:41278141	BRCA1;NBR2	0.39	5.4	0.31	1.51e-7	Menopause (age at onset);
CESC	cis	rs4919694	0.667	rs75890466	chr10:105076383	C/T	cg04362960	chr10:104952993	NT5C2	0.72	5.71	0.33	2.99e-8	Arsenic metabolism;
CESC	cis	rs1348850	0.567	rs7605493	chr2:178534983	C/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.55	6.95	0.39	2.92e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	trans	rs17764205	0.568	rs72987040	chr19:3251116	C/A	cg03776506	chr16:30581384	ZNF688	-0.78	-6.02	-0.35	5.68e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs8170	0.603	rs7249329	chr19:17423373	G/T	cg04749549	chr19:17459798	NA	-0.34	-5.31	-0.31	2.31e-7	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
CESC	cis	rs61931739	0.500	rs10844789	chr12:34202279	C/G	cg19457237	chr12:34500585	NA	-0.38	-5.33	-0.31	2.12e-7	Morning vs. evening chronotype;
CESC	cis	rs10504229	0.683	rs1495865	chr8:58141160	T/G	cg02725872	chr8:58115012	NA	-0.45	-7.12	-0.4	1.02e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs1552244	0.882	rs56332224	chr3:10037321	G/A	cg08888203	chr3:10149979	C3orf24	0.48	6.09	0.35	3.99e-9	Alzheimer's disease;
CESC	cis	rs896854	0.654	rs10104909	chr8:95977973	C/T	cg13393036	chr8:95962371	TP53INP1	-0.5	-10.81	-0.55	8.28e-23	Type 2 diabetes;
CESC	cis	rs3785574	0.962	rs2665799	chr17:61919723	A/G	cg06420487	chr17:61919686	SMARCD2	0.46	5.49	0.32	9.46e-8	Height;
CESC	cis	rs67311347	0.544	rs9864664	chr3:40336226	T/C	cg09455208	chr3:40491958	NA	0.37	6.51	0.37	3.82e-10	Renal cell carcinoma;
CESC	cis	rs936229	0.813	rs8033381	chr15:75080685	G/A	cg14664628	chr15:75095509	CSK	-0.95	-14.32	-0.66	8.02e-35	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CESC	cis	rs854765	0.583	rs6502619	chr17:17779704	C/G	cg16928487	chr17:17741425	SREBF1	0.61	10.65	0.55	2.81e-22	Total body bone mineral density;
CESC	cis	rs2637266	1.000	rs2395384	chr10:78335329	G/A	cg18941641	chr10:78392320	NA	0.43	7.93	0.44	6.22e-14	Pulmonary function;
CESC	cis	rs4665809	0.590	rs962217	chr2:26438276	T/C	cg04944784	chr2:26401820	FAM59B	-0.96	-10.43	-0.54	1.41e-21	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24810594	chr8:23104082	CHMP7	0.57	6.62	0.38	2.03e-10	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.783	rs10028584	chr4:98962404	C/T	cg03467027	chr4:99064603	C4orf37	0.44	5.45	0.32	1.17e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11487532	chr11:44586968	CD82	0.62	7.6	0.42	5.22e-13	Gut microbiome composition (summer);
CESC	cis	rs514406	0.893	rs1242326	chr1:53399104	C/A	cg08736216	chr1:53307985	ZYG11A	-0.41	-6.6	-0.38	2.25e-10	Monocyte count;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg17675882	chr20:35374068	NDRG3	0.52	6.71	0.38	1.17e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs7212590	0.655	rs56198517	chr17:57976582	G/T	cg20303301	chr17:57937339	TUBD1	-0.55	-5.46	-0.32	1.08e-7	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs2777491	1.000	rs316605	chr15:41771591	G/A	cg20272979	chr15:41787780	ITPKA	0.43	6.44	0.37	5.63e-10	Ulcerative colitis;
CESC	cis	rs1506636	1.000	rs12706545	chr7:123348744	C/T	cg03229431	chr7:123269106	ASB15	-0.5	-6.79	-0.39	7.28e-11	Plateletcrit;Platelet count;
CESC	cis	rs3126085	0.866	rs3126066	chr1:152276871	A/G	cg03465714	chr1:152285911	FLG	0.42	5.09	0.3	6.7e-7	Atopic dermatitis;
CESC	cis	rs8060686	0.516	rs8048365	chr16:68253326	T/A	cg26727032	chr16:67993705	SLC12A4	-0.59	-8.5	-0.46	1.38e-15	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs7666738	0.791	rs2865953	chr4:99040319	C/T	cg05340658	chr4:99064831	C4orf37	0.82	12.91	0.62	6.41e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9911578	1.000	rs302840	chr17:56673079	C/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.23	0.31	3.51e-7	Intelligence (multi-trait analysis);
CESC	cis	rs10504229	0.683	rs61364624	chr8:58134339	T/A	cg02725872	chr8:58115012	NA	-0.45	-7.05	-0.4	1.52e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs7100689	0.646	rs7098045	chr10:82123856	G/C	cg00277334	chr10:82204260	NA	-0.58	-7.76	-0.43	1.84e-13	Post bronchodilator FEV1;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05998639	chr12:1639527	NA	0.54	6.02	0.35	5.64e-9	Gut microbiome composition (summer);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg12680326	chr20:2821316	VPS16;FAM113A	-0.45	-6.14	-0.35	3.02e-9	Fibrinogen levels;
CESC	cis	rs10927875	0.632	rs10927864	chr1:16165661	C/G	cg18973939	chr1:16164122	FLJ37453	0.36	5.38	0.31	1.6e-7	Dilated cardiomyopathy;
CESC	cis	rs8077889	1.000	rs113919636	chr17:41877740	A/C	cg26893861	chr17:41843967	DUSP3	0.69	8.2	0.45	1.08e-14	Triglycerides;
CESC	cis	rs34779708	0.733	rs12243593	chr10:35549045	C/T	cg04310649	chr10:35416472	CREM	-0.45	-5.14	-0.3	5.34e-7	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs963731	0.649	rs297141	chr2:39319382	T/C	cg04010122	chr2:39346883	SOS1	-0.74	-5.39	-0.31	1.54e-7	Corticobasal degeneration;
CESC	cis	rs1577917	1.000	rs10455449	chr6:86592226	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-6.23	-0.36	1.83e-9	Response to antipsychotic treatment;
CESC	cis	rs868036	1.000	rs868036	chr15:68055013	T/A	cg08079166	chr15:68083412	MAP2K5	-0.42	-6.51	-0.37	3.73e-10	Restless legs syndrome;
CESC	cis	rs9916302	0.851	rs7220650	chr17:37487168	A/G	cg20243544	chr17:37824526	PNMT	-0.48	-6.07	-0.35	4.4e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs6938	0.534	rs1133322	chr15:75212357	A/G	cg09165964	chr15:75287851	SCAMP5	0.46	6.31	0.36	1.17e-9	Breast cancer;
CESC	cis	rs12477438	0.765	rs6542846	chr2:99563654	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.65	-8.75	-0.47	2.56e-16	Chronic sinus infection;
CESC	cis	rs75477785	0.590	rs2298930	chr1:209896212	A/G	cg02304930	chr1:210405566	SERTAD4;C1orf133	-0.86	-5.44	-0.32	1.22e-7	Cleft lip with or without cleft palate;
CESC	cis	rs7772486	0.875	rs9399573	chr6:146403255	A/T	cg05347473	chr6:146136440	FBXO30	0.49	6.62	0.38	1.99e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7103648	0.630	rs7120548	chr11:47662932	A/G	cg10504702	chr11:47789108	FNBP4	0.43	5.48	0.32	9.91e-8	Diastolic blood pressure;Systolic blood pressure;
CESC	cis	rs116095464	0.558	rs9687621	chr5:229194	C/T	cg22496380	chr5:211416	CCDC127	-1.0	-10.33	-0.54	3.05e-21	Breast cancer;
CESC	cis	rs11608355	0.545	rs11615336	chr12:109914802	C/A	cg05360138	chr12:110035743	NA	0.81	8.75	0.47	2.52e-16	Neuroticism;
CESC	cis	rs55728055	1.000	rs55728055	chr22:32093268	G/C	cg01338084	chr22:32026380	PISD	1.25	8.16	0.45	1.39e-14	Age-related hearing impairment;
CESC	cis	rs921968	0.613	rs1427445	chr2:219555573	C/A	cg02176678	chr2:219576539	TTLL4	-0.45	-8.04	-0.44	2.96e-14	Mean corpuscular hemoglobin concentration;
CESC	cis	rs9815354	0.597	rs73075211	chr3:42033424	G/T	cg03022575	chr3:42003672	ULK4	0.75	6.64	0.38	1.72e-10	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs9399135	0.967	rs12526055	chr6:135325918	C/T	cg22676075	chr6:135203613	NA	0.49	6.77	0.38	8.23e-11	Red blood cell count;
CESC	cis	rs2651899	0.934	rs10909887	chr1:3087373	A/T	cg22674798	chr1:3096360	PRDM16	-0.39	-7.48	-0.42	1.08e-12	Migraine;
CESC	trans	rs2115172	0.836	rs4835799	chr5:122762229	A/G	cg09068198	chr2:65357064	RAB1A	0.45	6.03	0.35	5.39e-9	Weight;
CESC	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg11494091	chr17:61959527	GH2	0.73	12.57	0.61	9.63e-29	Prudent dietary pattern;
CESC	cis	rs34779708	0.966	rs17591781	chr10:35498538	G/A	cg03585969	chr10:35415529	CREM	0.75	9.88	0.52	8.37e-20	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs1348850	0.750	rs13031008	chr2:178477114	G/A	cg23306229	chr2:178417860	TTC30B	0.52	6.49	0.37	4.2e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs6963495	0.745	rs73192151	chr7:105211876	A/G	cg13798780	chr7:105162888	PUS7	0.77	7.56	0.42	6.63e-13	Bipolar disorder (body mass index interaction);
CESC	cis	rs35306767	0.951	rs61833265	chr10:990143	C/T	cg26597838	chr10:835615	NA	0.81	8.56	0.47	9.03e-16	Eosinophil percentage of granulocytes;
CESC	cis	rs7914558	0.966	rs7085598	chr10:104650128	T/C	cg15744005	chr10:104629667	AS3MT	-0.34	-5.49	-0.32	9.45e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs7116495	0.609	rs2852365	chr11:71715218	T/C	cg07596299	chr11:71824057	C11orf51	-0.8	-5.4	-0.31	1.49e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs9287719	0.967	rs6432118	chr2:10749441	C/T	cg00105475	chr2:10696890	NA	0.38	5.57	0.32	6.34e-8	Prostate cancer;
CESC	cis	rs1799949	1.000	rs915945	chr17:41179864	C/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.39	5.04	0.3	8.47e-7	Menopause (age at onset);
CESC	cis	rs7666738	0.716	rs13108535	chr4:99046324	A/G	cg18180107	chr4:99064573	C4orf37	0.41	5.29	0.31	2.51e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs1545843	0.593	rs9669281	chr12:84791458	C/T	cg03015433	chr16:56623111	MT3	-0.33	-6.01	-0.35	6.11e-9	Major depressive disorder;
CESC	cis	rs2836974	0.966	rs7283420	chr21:40666865	T/C	cg11890956	chr21:40555474	PSMG1	1.11	17.6	0.73	1.91e-46	Cognitive function;
CESC	cis	rs4665809	1.000	rs4233710	chr2:26291565	G/A	cg25036284	chr2:26402008	FAM59B	-0.73	-8.35	-0.46	3.78e-15	Gut microbiome composition (summer);
CESC	trans	rs10848704	0.525	rs4765709	chr12:2883637	C/T	cg02057211	chr3:31803876	OSBPL10	-0.35	-6.22	-0.36	1.98e-9	Quantitative traits;
CESC	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.6	-9.21	-0.49	1.01e-17	Longevity;Endometriosis;
CESC	cis	rs7212590	0.748	rs62081818	chr17:57890629	C/T	cg20303301	chr17:57937339	TUBD1	-0.59	-5.56	-0.32	6.49e-8	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs6952808	1.000	rs6953693	chr7:1886388	C/G	cg05863683	chr7:1912471	MAD1L1	0.37	5.52	0.32	8.19e-8	Bipolar disorder and schizophrenia;
CESC	trans	rs11098499	0.657	rs9996569	chr4:120299004	G/C	cg25214090	chr10:38739885	LOC399744	0.68	9.2	0.49	1.14e-17	Corneal astigmatism;
CESC	cis	rs796364	0.813	rs7565417	chr2:201057491	G/A	cg23649088	chr2:200775458	C2orf69	0.51	5.24	0.31	3.21e-7	Schizophrenia;
CESC	cis	rs7843479	0.562	rs6988010	chr8:21859084	G/A	cg17168535	chr8:21777572	XPO7	0.73	11.4	0.57	9.24e-25	Mean corpuscular volume;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg25706861	chr2:220404357	CHPF	0.44	6.07	0.35	4.37e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs4835473	0.801	rs999049	chr4:144636593	T/C	cg25736465	chr4:144833511	NA	-0.45	-6.81	-0.39	6.71e-11	Immature fraction of reticulocytes;
CESC	cis	rs1401999	1.000	rs1402002	chr3:183642794	A/G	cg01324343	chr3:183735012	ABCC5	0.63	13.49	0.64	6.17e-32	Anterior chamber depth;
CESC	cis	rs2073300	1.000	rs17830565	chr20:23444805	G/A	cg12062639	chr20:23401060	NAPB	0.91	6.41	0.37	6.71e-10	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs67311347	0.955	rs60554147	chr3:40472503	T/C	cg01475735	chr3:40494733	NA	-0.4	-5.06	-0.3	8.01e-7	Renal cell carcinoma;
CESC	cis	rs7429990	0.965	rs7627645	chr3:48093133	A/T	cg11946769	chr3:48343235	NME6	-0.44	-5.37	-0.31	1.69e-7	Educational attainment (years of education);
CESC	cis	rs4319547	0.915	rs3803005	chr12:123110654	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.59	-7.04	-0.4	1.69e-11	Body mass index;
CESC	cis	rs3733585	0.673	rs4467563	chr4:9953460	A/T	cg00071950	chr4:10020882	SLC2A9	-0.69	-11.34	-0.57	1.42e-24	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs1355223	0.902	rs34751755	chr11:34694243	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.46	-5.97	-0.34	7.73e-9	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs9790314	0.905	rs7633186	chr3:161003124	A/G	cg04691961	chr3:161091175	C3orf57	-0.41	-5.34	-0.31	2e-7	Morning vs. evening chronotype;
CESC	cis	rs4523957	0.893	rs11078018	chr17:2162119	A/G	cg16513277	chr17:2031491	SMG6	-0.6	-8.18	-0.45	1.22e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs4843747	0.671	rs8062855	chr16:88106941	T/C	cg17633681	chr16:88106987	BANP	0.76	10.51	0.54	8.01e-22	Menopause (age at onset);
CESC	cis	rs1129187	0.837	rs3763236	chr6:42902508	C/T	cg10862848	chr6:42927986	GNMT	0.26	6.77	0.38	8.38e-11	Alzheimer's disease in APOE e4+ carriers;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07996992	chr1:85040343	CTBS	0.65	7.87	0.44	9.03e-14	Gut microbiome composition (summer);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg11843188	chr11:102322558	TMEM123	-0.45	-6.27	-0.36	1.49e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs6933660	0.800	rs3800273	chr6:151759035	G/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.67	9.63	0.51	5.06e-19	Menarche (age at onset);
CESC	cis	rs34734847	0.842	rs556001	chr12:121152967	A/G	cg21892295	chr12:121157589	UNC119B	-0.4	-6.43	-0.37	5.96e-10	Mean corpuscular volume;
CESC	cis	rs6502050	0.835	rs10163482	chr17:80110394	C/A	cg11859384	chr17:80120422	CCDC57	-0.39	-5.31	-0.31	2.34e-7	Life satisfaction;
CESC	cis	rs7584330	0.554	rs11892169	chr2:238432809	G/A	cg14458575	chr2:238380390	NA	0.48	5.31	0.31	2.37e-7	Prostate cancer;
CESC	cis	rs4665809	1.000	rs3910272	chr2:26287842	T/A	cg26314531	chr2:26401878	FAM59B	-0.77	-8.56	-0.47	9.38e-16	Gut microbiome composition (summer);
CESC	cis	rs2880765	0.835	rs900573	chr15:86037993	G/T	cg19183879	chr15:85880815	NA	0.25	5.11	0.3	6.1e-7	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25292628	chr9:6758853	KDM4C	-0.58	-6.71	-0.38	1.19e-10	Gut microbiome composition (summer);
CESC	cis	rs10832963	0.924	rs10500834	chr11:18638712	A/T	cg09201001	chr11:18656081	SPTY2D1	0.82	12.36	0.6	5.21e-28	Breast cancer;
CESC	cis	rs7264396	0.635	rs3827030	chr20:34474947	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.85	10.99	0.56	2.06e-23	Total cholesterol levels;
CESC	cis	rs3126085	0.877	rs7543541	chr1:152230878	T/C	cg03465714	chr1:152285911	FLG	-0.44	-5.52	-0.32	8.23e-8	Atopic dermatitis;
CESC	cis	rs7772486	0.875	rs6938972	chr6:146410608	G/A	cg23711669	chr6:146136114	FBXO30	0.86	12.72	0.62	2.98e-29	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs17253792	0.822	rs78323463	chr14:56045451	T/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.85	5.74	0.33	2.53e-8	Putamen volume;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg13468249	chr17:7154818	DULLARD;C17orf81	-0.44	-6.14	-0.35	3.06e-9	Ulcerative colitis;
CESC	cis	rs9467711	0.591	rs17586553	chr6:25928775	C/T	cg08501292	chr6:25962987	TRIM38	0.83	8.12	0.45	1.73e-14	Autism spectrum disorder or schizophrenia;
CESC	cis	rs7084402	0.967	rs7098326	chr10:60276906	C/T	cg07615347	chr10:60278583	BICC1	-0.59	-9.42	-0.5	2.24e-18	Refractive error;
CESC	cis	rs568617	0.903	rs601863	chr11:65646557	C/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.69	-7.4	-0.41	1.81e-12	Crohn's disease;
CESC	cis	rs6089584	0.819	rs1467593	chr20:60601432	T/G	cg06108461	chr20:60628389	TAF4	0.83	11.48	0.58	4.88e-25	Body mass index;
CESC	cis	rs801193	1.000	rs2659889	chr7:66217112	A/G	cg14393609	chr7:65229607	NA	0.48	6.47	0.37	4.72e-10	Aortic root size;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg27343303	chr11:34380546	NA	-0.46	-6.8	-0.39	7.07e-11	Gambling;
CESC	cis	rs3733585	0.673	rs7376505	chr4:9952744	C/A	cg11266682	chr4:10021025	SLC2A9	-0.57	-10.99	-0.56	2.07e-23	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.45	-6.65	-0.38	1.65e-10	Longevity;Endometriosis;
CESC	cis	rs11122272	0.735	rs2808591	chr1:231523421	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.57	-7.82	-0.43	1.29e-13	Hemoglobin concentration;
CESC	cis	rs4665809	0.878	rs892448	chr2:26366205	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.74	-8.58	-0.47	7.96e-16	Gut microbiome composition (summer);
CESC	cis	rs4319547	1.000	rs10998	chr12:122989412	G/A	cg23029597	chr12:123009494	RSRC2	-0.49	-5.35	-0.31	1.93e-7	Body mass index;
CESC	cis	rs4595586	0.545	rs2388179	chr12:39364036	T/A	cg26384229	chr12:38710491	ALG10B	0.54	7.54	0.42	7.28e-13	Morning vs. evening chronotype;
CESC	cis	rs7552167	0.925	rs78312791	chr1:24513613	C/A	cg01960748	chr1:24522592	NA	0.45	5.59	0.32	5.57e-8	Psoriasis vulgaris;
CESC	cis	rs11760633	0.615	rs11767667	chr7:1840557	C/T	cg23422044	chr7:1970798	MAD1L1	-0.48	-5.67	-0.33	3.67e-8	Coronary artery disease;
CESC	cis	rs7923609	0.934	rs10761756	chr10:65172328	C/T	cg01631684	chr10:65280961	REEP3	-0.43	-5.32	-0.31	2.25e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7089973	0.604	rs11196952	chr10:116607592	G/A	cg23260525	chr10:116636907	FAM160B1	0.4	7.2	0.4	6.31e-12	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs10883723	0.810	rs7917525	chr10:104246755	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.55	7.56	0.42	6.55e-13	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs734999	0.545	rs3890745	chr1:2553624	C/T	cg20673091	chr1:2541236	MMEL1	-0.47	-7.89	-0.44	8.09e-14	Ulcerative colitis;
CESC	cis	rs597539	0.690	rs647661	chr11:68625875	T/C	cg01988459	chr11:68622903	NA	-0.4	-5.3	-0.31	2.4e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs4523957	0.854	rs404392	chr17:2191000	G/A	cg16513277	chr17:2031491	SMG6	0.59	8.07	0.44	2.51e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs228437	1.000	rs985122	chr6:134931300	A/G	cg24504307	chr6:134963096	NA	0.55	5.93	0.34	9.31e-9	Melanoma;
CESC	cis	rs35849525	0.633	rs62263602	chr3:50152491	C/T	cg24308560	chr3:49941425	MST1R	-0.54	-6.41	-0.37	6.64e-10	Intelligence (multi-trait analysis);
CESC	cis	rs6456156	0.586	rs9459853	chr6:167465774	C/A	cg23791538	chr6:167370224	RNASET2	-0.52	-6.7	-0.38	1.23e-10	Primary biliary cholangitis;
CESC	cis	rs7772486	0.875	rs1412081	chr6:146409733	A/G	cg05347473	chr6:146136440	FBXO30	0.48	6.51	0.37	3.83e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7072216	0.763	rs6584204	chr10:100173580	C/G	cg26618903	chr10:100175079	PYROXD2	-0.38	-5.87	-0.34	1.32e-8	Metabolite levels;
CESC	cis	rs9815354	1.000	rs1717031	chr3:41905791	G/T	cg03022575	chr3:42003672	ULK4	0.44	5.16	0.3	4.85e-7	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs801193	0.636	rs2659895	chr7:66196471	C/A	cg18876405	chr7:65276391	NA	0.46	6.19	0.36	2.27e-9	Aortic root size;
CESC	cis	rs875971	1.000	rs6460292	chr7:65810075	G/A	cg10691866	chr7:65817282	TPST1	0.34	5.61	0.33	5.03e-8	Aortic root size;
CESC	cis	rs4713118	0.513	rs1225591	chr6:28148752	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.47	-5.96	-0.34	8.09e-9	Parkinson's disease;
CESC	cis	rs1552244	1.000	rs55822690	chr3:10128003	A/G	cg00166722	chr3:10149974	C3orf24	0.49	6.31	0.36	1.18e-9	Alzheimer's disease;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg18220030	chr1:110090737	GNAI3	-0.47	-6.79	-0.38	7.13e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	trans	rs1945213	0.694	rs7116741	chr11:55862620	C/T	cg15704280	chr7:45808275	SEPT13	0.76	7.34	0.41	2.57e-12	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs7666738	0.927	rs6832373	chr4:99051967	A/G	cg03676636	chr4:99064102	C4orf37	0.34	5.18	0.3	4.39e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4713118	0.621	rs10484403	chr6:28033523	A/G	cg22143856	chr6:28129313	ZNF389	0.45	5.78	0.33	2.12e-8	Parkinson's disease;
CESC	cis	rs17253792	0.822	rs77761669	chr14:56034216	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.8	5.87	0.34	1.27e-8	Putamen volume;
CESC	cis	rs4665809	0.941	rs1470096	chr2:26311482	T/C	cg26314531	chr2:26401878	FAM59B	-0.76	-8.49	-0.46	1.47e-15	Gut microbiome composition (summer);
CESC	cis	rs10129255	0.556	rs9324093	chr14:107139910	C/T	cg07958169	chr14:107095056	NA	-0.45	-6.75	-0.38	9.52e-11	Kawasaki disease;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg02262025	chr16:75657287	ADAT1	-0.48	-6.26	-0.36	1.57e-9	Ulcerative colitis;
CESC	cis	rs11677416	1.000	rs6542093	chr2:113528536	G/A	cg27083787	chr2:113543245	IL1A	0.41	5.16	0.3	4.75e-7	Response to antipsychotic treatment in schizophrenia (working memory);
CESC	cis	rs6543140	0.964	rs62154972	chr2:103048738	G/A	cg04239558	chr2:103089729	SLC9A4	0.48	6.04	0.35	5.06e-9	Blood protein levels;
CESC	cis	rs35079168	0.923	rs12115573	chr9:137288782	G/A	cg00753924	chr9:137298813	RXRA	-0.36	-5.52	-0.32	7.94e-8	Intelligence;
CESC	cis	rs7264396	0.790	rs6121026	chr20:34266883	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.87	-11.88	-0.59	2.18e-26	Total cholesterol levels;
CESC	cis	rs1401999	1.000	rs6443927	chr3:183718864	A/G	cg01324343	chr3:183735012	ABCC5	0.65	13.75	0.65	8.04e-33	Anterior chamber depth;
CESC	cis	rs77972916	0.561	rs13411629	chr2:43566990	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.58	-5.11	-0.3	6.3e-7	Granulocyte percentage of myeloid white cells;
CESC	cis	rs9894429	1.000	rs11652797	chr17:79574124	A/G	cg18240062	chr17:79603768	NPLOC4	0.72	10.3	0.53	3.89e-21	Eye color traits;
CESC	cis	rs6963495	0.818	rs17343556	chr7:105151272	C/T	cg02135003	chr7:105160482	PUS7	-0.47	-5.63	-0.33	4.47e-8	Bipolar disorder (body mass index interaction);
CESC	cis	rs863345	0.535	rs12068285	chr1:158499632	G/A	cg12129480	chr1:158549410	OR10X1	-0.32	-6.15	-0.35	2.82e-9	Pneumococcal bacteremia;
CESC	cis	rs10504229	0.906	rs113745779	chr8:58191301	C/G	cg14926445	chr8:58193284	C8orf71	-0.51	-5.52	-0.32	8.28e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs4819052	1.000	rs4818769	chr21:46667451	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.83	10.53	0.54	7.1e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs4974559	1.000	rs4974559	chr4:1380848	C/T	cg20887711	chr4:1340912	KIAA1530	-0.45	-5.37	-0.31	1.76e-7	Systolic blood pressure;
CESC	cis	rs11252926	0.528	rs11252090	chr10:436547	C/T	cg18196295	chr10:418757	DIP2C	-0.55	-7.6	-0.42	5.07e-13	Psychosis in Alzheimer's disease;
CESC	cis	rs7666738	0.830	rs60411337	chr4:99046617	T/C	cg05340658	chr4:99064831	C4orf37	0.82	12.88	0.62	8.44e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4604732	0.642	rs10925047	chr1:247640143	A/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.4	5.89	0.34	1.19e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs6691722	0.503	rs3765431	chr1:24706410	T/C	cg18323236	chr1:24743029	NIPAL3	0.37	5.61	0.33	5.09e-8	Response to interferon beta in multiple sclerosis;
CESC	cis	rs4481887	0.927	rs10749646	chr1:248429719	A/G	cg00666640	chr1:248458726	OR2T12	-0.4	-6.93	-0.39	3.15e-11	Common traits (Other);
CESC	cis	rs875971	0.928	rs6970357	chr7:65968878	T/C	cg11764359	chr7:65958608	NA	0.96	15.25	0.68	3.95e-38	Aortic root size;
CESC	cis	rs8005677	0.962	rs34917191	chr14:23387628	T/C	cg01529538	chr14:23388837	RBM23	0.51	6.87	0.39	4.64e-11	Cognitive ability (multi-trait analysis);
CESC	cis	rs2952156	0.959	rs2952151	chr17:37828496	T/C	cg07936489	chr17:37558343	FBXL20	-0.53	-6.33	-0.36	1.07e-9	Asthma;
CESC	cis	rs1062177	1.000	rs12518722	chr5:151231460	A/G	cg12924095	chr5:151150029	G3BP1	0.49	6.42	0.37	6.23e-10	Preschool internalizing problems;
CESC	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.8	-11.18	-0.57	4.95e-24	Prudent dietary pattern;
CESC	cis	rs7777484	0.517	rs2644306	chr7:2831602	A/G	cg09658497	chr7:2847517	GNA12	-0.43	-6.86	-0.39	4.85e-11	Height;
CESC	cis	rs798554	0.680	rs1713912	chr7:2895784	C/A	cg04166393	chr7:2884313	GNA12	0.59	7.63	0.42	4.18e-13	Height;
CESC	cis	rs425277	1.000	rs262647	chr1:2095699	C/T	cg24578937	chr1:2090814	PRKCZ	0.55	9.67	0.51	3.78e-19	Height;
CESC	cis	rs2180341	0.855	rs4308584	chr6:127714874	A/G	cg24812749	chr6:127587940	RNF146	0.81	11.3	0.57	1.96e-24	Breast cancer;
CESC	cis	rs7208859	0.623	rs73269916	chr17:29096326	A/G	cg19761014	chr17:28927070	LRRC37B2	0.77	6.36	0.36	8.68e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	trans	rs208520	0.837	rs208509	chr6:66941706	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.8	-9.45	-0.5	1.91e-18	Exhaled nitric oxide output;
CESC	cis	rs7914558	1.000	rs11191542	chr10:104824324	T/A	cg15744005	chr10:104629667	AS3MT	-0.34	-5.58	-0.32	5.99e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs875971	0.508	rs10258739	chr7:66062935	A/T	cg18876405	chr7:65276391	NA	-0.52	-7.37	-0.41	2.11e-12	Aortic root size;
CESC	cis	rs7100689	0.646	rs10466235	chr10:82149655	C/T	cg00277334	chr10:82204260	NA	0.47	6.57	0.37	2.63e-10	Post bronchodilator FEV1;
CESC	cis	rs2797160	1.000	rs78602343	chr6:126019768	T/C	cg05901451	chr6:126070800	HEY2	0.46	6.54	0.37	3.08e-10	Endometrial cancer;
CESC	cis	rs61931739	0.500	rs4436630	chr12:34394200	C/T	cg23762105	chr12:34175262	ALG10	-0.39	-5.14	-0.3	5.26e-7	Morning vs. evening chronotype;
CESC	cis	rs6580649	0.941	rs7959755	chr12:48446318	T/A	cg05342945	chr12:48394962	COL2A1	0.5	5.85	0.34	1.47e-8	Lung cancer;
CESC	cis	rs763014	0.898	rs35666389	chr16:629458	A/G	cg00908189	chr16:619842	PIGQ	0.67	9.38	0.5	3.07e-18	Height;
CESC	trans	rs11039798	0.557	rs4441015	chr11:49027070	A/G	cg03929089	chr4:120376271	NA	0.62	6.14	0.35	2.96e-9	Axial length;
CESC	cis	rs9393777	0.546	rs9366673	chr6:26893329	C/G	cg12292205	chr6:26970375	C6orf41	-0.63	-7.3	-0.41	3.46e-12	Intelligence (multi-trait analysis);
CESC	trans	rs61931739	0.500	rs28624237	chr12:34457171	G/T	cg26384229	chr12:38710491	ALG10B	0.69	10.44	0.54	1.34e-21	Morning vs. evening chronotype;
CESC	cis	rs2522056	0.808	rs17771891	chr5:131744202	A/G	cg24060327	chr5:131705240	SLC22A5	-0.66	-7.14	-0.4	8.97e-12	Lymphocyte counts;Fibrinogen;
CESC	cis	rs9929218	0.953	rs3114411	chr16:68734591	G/T	cg02972257	chr16:68554789	NA	-0.57	-6.67	-0.38	1.47e-10	Colorectal cancer;
CESC	cis	rs3617	0.573	rs12492391	chr3:52912296	C/A	cg17372223	chr3:52568218	NT5DC2	0.36	5.07	0.3	7.49e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
CESC	cis	rs7937682	0.575	rs11604704	chr11:111764396	G/A	cg22437258	chr11:111473054	SIK2	-0.48	-5.3	-0.31	2.39e-7	Primary sclerosing cholangitis;
CESC	cis	rs9910055	0.659	rs112114764	chr17:42201041	G/T	cg08499158	chr17:42289980	UBTF	0.5	6.33	0.36	1.07e-9	Total body bone mineral density;
CESC	cis	rs12586317	0.511	rs11540758	chr14:35498485	C/T	cg16230307	chr14:35515116	FAM177A1	0.99	10.61	0.55	3.72e-22	Psoriasis;
CESC	cis	rs9430161	0.579	rs7542164	chr1:11040223	G/A	cg27631724	chr1:11040367	C1orf127	0.44	7.63	0.42	4.18e-13	Ewing sarcoma;
CESC	cis	rs11677416	1.000	rs61381693	chr2:113525912	C/A	cg27083787	chr2:113543245	IL1A	0.59	7.36	0.41	2.33e-12	Response to antipsychotic treatment in schizophrenia (working memory);
CESC	cis	rs7927771	0.524	rs7114813	chr11:47801101	A/G	cg18512352	chr11:47633146	NA	0.33	5.17	0.3	4.51e-7	Subjective well-being;
CESC	cis	rs9796	0.621	rs691702	chr15:41474399	C/G	cg20272979	chr15:41787780	ITPKA	0.33	5.07	0.3	7.6e-7	Menopause (age at onset);
CESC	cis	rs7666738	0.830	rs28416660	chr4:98899525	C/G	cg05340658	chr4:99064831	C4orf37	0.76	11.13	0.56	7.59e-24	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4727027	0.865	rs62505077	chr7:148849656	T/A	cg23158103	chr7:148848205	ZNF398	-0.42	-6.94	-0.39	3.1e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs6502050	0.835	rs62080004	chr17:80079079	C/T	cg11859384	chr17:80120422	CCDC57	0.38	5.15	0.3	5.1e-7	Life satisfaction;
CESC	cis	rs4423214	1.000	rs4944957	chr11:71168035	C/T	cg05163923	chr11:71159392	DHCR7	-0.76	-10.07	-0.53	2.02e-20	Vitamin D levels;
CESC	cis	rs2625529	0.938	rs2625530	chr15:72126034	G/A	cg16672083	chr15:72433130	SENP8	-0.42	-5.29	-0.31	2.54e-7	Red blood cell count;
CESC	trans	rs11098499	0.908	rs9995234	chr4:120321827	A/G	cg25214090	chr10:38739885	LOC399744	0.71	9.49	0.5	1.41e-18	Corneal astigmatism;
CESC	cis	rs7666738	0.830	rs11940273	chr4:98979965	T/A	cg18180107	chr4:99064573	C4orf37	0.39	5.1	0.3	6.45e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs728616	0.867	rs12412257	chr10:81729603	C/T	cg05935833	chr10:81318306	SFTPA2	-0.51	-5.04	-0.3	8.51e-7	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs60154123	0.505	rs76426571	chr1:210041634	C/T	cg25204440	chr1:209979598	IRF6	0.67	6.11	0.35	3.54e-9	Coronary artery disease;
CESC	cis	rs12971120	0.891	rs12605820	chr18:72167802	G/A	cg26446133	chr18:72167187	CNDP2	-0.76	-9.63	-0.51	5.13e-19	Refractive error;
CESC	cis	rs13315871	0.858	rs13090428	chr3:58314412	A/G	cg20936604	chr3:58311152	NA	-0.51	-5.17	-0.3	4.65e-7	Cholesterol, total;
CESC	cis	rs9815354	1.000	rs1564716	chr3:41862613	A/G	cg03022575	chr3:42003672	ULK4	0.48	5.38	0.31	1.68e-7	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs2576037	0.526	rs571181	chr18:44376399	T/C	cg19077165	chr18:44547161	KATNAL2	-0.52	-7.63	-0.42	4.14e-13	Personality dimensions;
CESC	cis	rs933688	0.526	rs9293565	chr5:90609736	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.62	7.19	0.4	6.76e-12	Smoking behavior;
CESC	cis	rs172166	0.611	rs203882	chr6:28078502	G/A	cg23161317	chr6:28129485	ZNF389	0.4	5.69	0.33	3.29e-8	Cardiac Troponin-T levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25307277	chr6:26124601	HIST1H2AC;HIST1H2BC	0.52	6.12	0.35	3.34e-9	Gut microbiome composition (summer);
CESC	cis	rs4665809	0.652	rs12611790	chr2:26404221	C/T	cg04944784	chr2:26401820	FAM59B	-0.92	-10.23	-0.53	6.32e-21	Gut microbiome composition (summer);
CESC	cis	rs2120019	0.938	rs5020842	chr15:75322310	T/C	cg17294928	chr15:75287854	SCAMP5	-0.8	-9.5	-0.5	1.29e-18	Blood trace element (Zn levels);
CESC	cis	rs9291683	0.588	rs6857693	chr4:10018435	G/A	cg00071950	chr4:10020882	SLC2A9	0.91	17.5	0.73	4.14e-46	Bone mineral density;
CESC	trans	rs11601239	0.593	rs1954761	chr11:105596885	T/C	cg15315312	chr2:176867285	KIAA1715	-0.47	-6.3	-0.36	1.25e-9	Refractive error;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25910466	chr20:21283998	XRN2	0.57	6.17	0.35	2.54e-9	Gut microbiome composition (summer);
CESC	trans	rs2727020	0.513	rs10839307	chr11:49609843	A/C	cg15704280	chr7:45808275	SEPT13	-0.95	-16.87	-0.72	7.12e-44	Coronary artery disease;
CESC	cis	rs2573652	0.698	rs12916269	chr15:100530216	A/T	cg09918751	chr15:100517450	ADAMTS17	0.33	6.08	0.35	4.28e-9	Height;
CESC	cis	rs6815814	1.000	rs11722836	chr4:38811529	T/A	cg02016764	chr4:38805732	TLR1	-0.62	-7.43	-0.42	1.5e-12	Breast cancer;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg02955369	chr1:173837185	SNORD76;SNORD74;SNORD75;GAS5;ZBTB37	-0.51	-6.63	-0.38	1.9e-10	Height;
CESC	cis	rs7809950	0.678	rs17154040	chr7:107005246	C/T	cg23024343	chr7:107201750	COG5	0.54	7.01	0.4	1.99e-11	Coronary artery disease;
CESC	cis	rs7192380	0.639	rs7186296	chr16:69808998	A/G	cg00738113	chr16:70207722	CLEC18C	0.32	5.26	0.31	3.04e-7	Sjögren's syndrome;
CESC	cis	rs7618915	0.501	rs9917834	chr3:52634619	A/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	5.83	0.34	1.59e-8	Bipolar disorder;
CESC	trans	rs116095464	0.558	rs6555052	chr5:224268	G/A	cg00938859	chr5:1591904	SDHAP3	0.61	6.78	0.38	7.58e-11	Breast cancer;
CESC	cis	rs7937682	0.883	rs553632	chr11:111462897	C/T	cg22437258	chr11:111473054	SIK2	0.71	9.19	0.49	1.16e-17	Primary sclerosing cholangitis;
CESC	cis	rs2191566	0.576	rs419839	chr19:44495598	C/T	cg20607764	chr19:44506953	ZNF230	0.45	5.69	0.33	3.38e-8	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs12220238	1.000	rs3812638	chr10:75896072	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.65	5.84	0.34	1.49e-8	Soluble interleukin-2 receptor subunit alpha;
CESC	cis	rs3793917	0.901	rs36212732	chr10:124215198	A/G	cg24884230	chr10:124216658	ARMS2	0.31	5.15	0.3	5.08e-7	Age-related macular degeneration;
CESC	cis	rs6991838	0.584	rs6997959	chr8:66540482	T/C	cg13398993	chr8:66546079	ARMC1	0.46	5.65	0.33	4.19e-8	Intelligence (multi-trait analysis);
CESC	cis	rs1018836	0.631	rs61276517	chr8:91474406	A/G	cg16814680	chr8:91681699	NA	-0.55	-7.3	-0.41	3.26e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs9311474	1.000	rs7629072	chr3:52305633	C/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.33	6.09	0.35	3.9e-9	Electroencephalogram traits;
CESC	cis	rs3762637	0.941	rs79493664	chr3:122109546	T/A	cg24169773	chr3:122142474	KPNA1	-0.53	-6.13	-0.35	3.13e-9	LDL cholesterol levels;
CESC	trans	rs11088226	0.681	rs2833897	chr21:33931792	T/C	cg09050820	chr6:167586206	TCP10L2	0.82	7.68	0.43	3.12e-13	Gastritis;
CESC	cis	rs7927771	1.000	rs10838748	chr11:47716381	T/G	cg05585544	chr11:47624801	NA	-0.5	-7.84	-0.43	1.14e-13	Subjective well-being;
CESC	cis	rs801193	1.000	rs62466794	chr7:66191579	G/A	cg06456125	chr7:65229604	NA	0.39	5.05	0.3	8.06e-7	Aortic root size;
CESC	cis	rs4132509	0.947	rs320339	chr1:243870910	G/T	cg21452805	chr1:244014465	NA	0.42	5.19	0.3	4.1e-7	RR interval (heart rate);
CESC	cis	rs10927875	0.830	rs1763610	chr1:16335527	C/G	cg22431228	chr1:16359049	CLCNKA	0.46	7.84	0.43	1.1e-13	Dilated cardiomyopathy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00543632	chr16:19098067	NA	-0.62	-7.41	-0.41	1.67e-12	Gut microbiome composition (summer);
CESC	cis	rs2882667	0.788	rs11959691	chr5:138481088	C/T	cg04439458	chr5:138467593	SIL1	-0.38	-5.66	-0.33	3.95e-8	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs17601876	0.814	rs11636639	chr15:51563092	T/G	cg19946085	chr15:51559439	CYP19A1	-0.33	-5.38	-0.31	1.64e-7	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
CESC	cis	rs524281	0.817	rs7115081	chr11:65853541	A/G	cg14036092	chr11:66035641	RAB1B	-0.62	-6.39	-0.37	7.55e-10	Electroencephalogram traits;
CESC	cis	rs35306767	0.903	rs12254002	chr10:929133	A/G	cg20503657	chr10:835505	NA	-0.74	-7.9	-0.44	7.56e-14	Eosinophil percentage of granulocytes;
CESC	cis	rs7208859	0.623	rs216436	chr17:28922900	G/A	cg13385521	chr17:29058706	SUZ12P	0.73	5.32	0.31	2.23e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs3820068	0.581	rs72645881	chr1:15928203	C/T	cg17385448	chr1:15911702	AGMAT	0.41	6.69	0.38	1.33e-10	Systolic blood pressure;
CESC	cis	rs208520	0.690	rs10455194	chr6:66743356	A/G	cg07460842	chr6:66804631	NA	0.97	12.84	0.62	1.11e-29	Exhaled nitric oxide output;
CESC	cis	rs2380220	0.606	rs9488080	chr6:96006973	A/G	cg23517279	chr6:96025343	MANEA	0.52	5.65	0.33	4.17e-8	Behavioural disinhibition (generation interaction);
CESC	cis	rs3793683	0.825	rs3793674	chr10:134555773	C/T	cg27286337	chr10:134555280	INPP5A	-0.91	-14.42	-0.66	3.47e-35	Migraine;
CESC	trans	rs3942852	0.774	rs10838812	chr11:48186924	T/C	cg03929089	chr4:120376271	NA	-0.65	-7.1	-0.4	1.15e-11	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs3781663	0.581	rs10793018	chr11:70004396	G/A	cg06393558	chr11:69982916	ANO1	-0.34	-5.86	-0.34	1.39e-8	Survival in rectal cancer;
CESC	cis	rs2439831	0.867	rs3213991	chr15:43670280	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.92	11.23	0.57	3.34e-24	Lung cancer in ever smokers;
CESC	cis	rs2635047	0.638	rs55730206	chr18:44608230	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.44	6.13	0.35	3.18e-9	Educational attainment;
CESC	cis	rs796364	0.760	rs56225698	chr2:200910653	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.85	-7.93	-0.44	6.07e-14	Schizophrenia;
CESC	cis	rs853679	0.517	rs11552219	chr6:28126834	C/T	cg12963246	chr6:28129442	ZNF389	0.56	7.38	0.41	1.99e-12	Depression;
CESC	cis	rs7666738	0.791	rs1593571	chr4:98963763	T/C	cg03467027	chr4:99064603	C4orf37	0.44	5.57	0.32	6.09e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7296418	0.961	rs4148862	chr12:123568619	A/C	cg00376283	chr12:123451042	ABCB9	0.73	10.1	0.53	1.68e-20	Platelet count;
CESC	cis	rs5758511	0.680	rs5758652	chr22:42612408	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.59	8.71	0.47	3.36e-16	Birth weight;
CESC	cis	rs870825	0.616	rs67409049	chr4:185623989	G/A	cg04058563	chr4:185651563	MLF1IP	0.64	7.05	0.4	1.59e-11	Blood protein levels;
CESC	cis	rs10045504	0.502	rs17456635	chr5:38745456	G/A	cg15396434	chr5:38725168	NA	-0.73	-6.82	-0.39	6.32e-11	Night sleep phenotypes;
CESC	cis	rs9556958	0.708	rs9513435	chr13:99160334	C/G	cg20750642	chr13:99100586	FARP1	0.37	5.98	0.34	7.19e-9	Educational attainment (years of education);
CESC	cis	rs7618915	0.570	rs4687633	chr3:52630548	G/A	cg07507251	chr3:52567010	NT5DC2	0.41	7.11	0.4	1.05e-11	Bipolar disorder;
CESC	cis	rs7512552	0.780	rs55823828	chr1:150467296	G/C	cg15654264	chr1:150340011	RPRD2	0.39	5.15	0.3	5.07e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs798554	0.836	rs13243214	chr7:2817455	G/T	cg19346786	chr7:2764209	NA	-0.52	-7.23	-0.41	5.12e-12	Height;
CESC	trans	rs7246760	0.867	rs10410379	chr19:9902197	G/A	cg02900749	chr2:68251473	NA	-0.74	-6.81	-0.39	6.68e-11	Pursuit maintenance gain;
CESC	cis	rs10896135	0.526	rs484262	chr11:66399681	C/T	cg15964523	chr11:66469143	SPTBN2	0.41	5.43	0.32	1.29e-7	Bipolar disorder;
CESC	cis	rs6964587	0.934	rs4512319	chr7:91733829	G/A	cg17063962	chr7:91808500	NA	0.47	5.72	0.33	2.82e-8	Breast cancer;
CESC	cis	rs4713118	0.527	rs35949862	chr6:28115367	A/G	cg19592336	chr6:28129416	ZNF389	0.62	8.12	0.45	1.77e-14	Parkinson's disease;
CESC	cis	rs1559088	0.948	rs12608825	chr19:33581219	C/T	cg27124370	chr19:33622961	WDR88	-0.48	-6.29	-0.36	1.27e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs2594989	0.943	rs2606748	chr3:11373989	T/C	cg00170343	chr3:11313890	ATG7	0.56	5.11	0.3	6.27e-7	Circulating chemerin levels;
CESC	cis	rs637571	0.544	rs617791	chr11:65702523	C/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.41	5.89	0.34	1.2e-8	Eosinophil percentage of white cells;
CESC	cis	rs9911578	1.000	rs2270097	chr17:56572070	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	-0.42	-5.69	-0.33	3.29e-8	Intelligence (multi-trait analysis);
CESC	cis	rs8014204	0.544	rs2286913	chr14:75386576	G/A	cg11812906	chr14:75593930	NEK9	0.54	6.59	0.38	2.31e-10	Caffeine consumption;
CESC	cis	rs7937682	1.000	rs11213973	chr11:111538903	A/T	cg22437258	chr11:111473054	SIK2	0.68	9.07	0.49	2.8e-17	Primary sclerosing cholangitis;
CESC	cis	rs16895831	0.549	rs12198323	chr6:42611872	A/G	cg10605015	chr6:42532144	UBR2	-0.5	-5.52	-0.32	8.27e-8	Granulocyte percentage of myeloid white cells;Neutrophil percentage of white cells;Eosinophil percentage of white cells;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Neutrophil count;Sum basophil neutrophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
CESC	cis	rs1559088	0.847	rs8110181	chr19:33605939	G/A	cg17764715	chr19:33622953	WDR88	0.46	5.94	0.34	8.75e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs12541635	0.677	rs13439705	chr8:106967268	T/C	cg10147462	chr8:107024639	NA	0.43	6.32	0.36	1.08e-9	Age of smoking initiation;
CESC	trans	rs4740619	0.556	rs2987010	chr9:15966278	C/G	cg02108068	chr19:56826442	NA	-0.44	-6.35	-0.36	9.18e-10	Body mass index;
CESC	cis	rs1144333	1.000	rs5745343	chr1:76273805	A/G	cg22875332	chr1:76189707	ACADM	-0.57	-6.05	-0.35	4.96e-9	Attention function in attention deficit hyperactive disorder;
CESC	cis	rs2228479	0.702	rs17233441	chr16:89817998	C/G	cg06558623	chr16:89946397	TCF25	1.16	9.28	0.5	6.08e-18	Skin colour saturation;
CESC	cis	rs826838	1.000	rs12366971	chr12:38737687	T/G	cg13010199	chr12:38710504	ALG10B	0.61	8.81	0.48	1.68e-16	Heart rate;
CESC	cis	rs17376456	0.569	rs10057664	chr5:93182274	C/T	cg21475434	chr5:93447410	FAM172A	-0.5	-5.14	-0.3	5.34e-7	Diabetic retinopathy;
CESC	cis	rs8005677	0.828	rs12437151	chr14:23372913	G/A	cg01529538	chr14:23388837	RBM23	0.42	5.57	0.32	6.3e-8	Cognitive ability (multi-trait analysis);
CESC	cis	rs67311347	0.955	rs9821036	chr3:40379007	A/G	cg09455208	chr3:40491958	NA	0.48	8.34	0.46	4.1e-15	Renal cell carcinoma;
CESC	cis	rs15300	0.661	rs9505461	chr6:8495128	C/G	cg07606381	chr6:8435919	SLC35B3	0.89	5.44	0.32	1.23e-7	Pursuit maintenance gain;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg06178104	chr17:43246560	HEXIM2	0.45	6.19	0.36	2.34e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs3820068	0.581	rs111699992	chr1:15927158	G/A	cg13390004	chr1:15929781	NA	0.35	5.58	0.32	5.83e-8	Systolic blood pressure;
CESC	cis	rs7618915	0.501	rs13060048	chr3:52598608	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.57	7.93	0.44	6.13e-14	Bipolar disorder;
CESC	trans	rs650950	0.528	rs646660	chr11:35528452	C/T	cg19507727	chr1:233086292	C1orf57	0.49	6.08	0.35	4.25e-9	Bronchopulmonary dysplasia;
CESC	cis	rs8062405	0.723	rs4788079	chr16:28559363	C/A	cg01378222	chr16:28622494	SULT1A1	0.31	5.16	0.3	4.87e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs1218582	0.740	rs1977879	chr1:154879743	G/A	cg16680214	chr1:154839983	KCNN3	-0.44	-6.69	-0.38	1.28e-10	Prostate cancer;
CESC	cis	rs7618501	0.902	rs7645061	chr3:49868842	C/T	cg24308560	chr3:49941425	MST1R	-0.52	-6.97	-0.39	2.55e-11	Intelligence (multi-trait analysis);
CESC	cis	rs6831352	0.879	rs1230154	chr4:99988659	C/T	cg12011299	chr4:100065546	ADH4	0.62	7.95	0.44	5.44e-14	Alcohol dependence;
CESC	cis	rs3733585	0.736	rs4543113	chr4:10008305	G/A	cg00071950	chr4:10020882	SLC2A9	0.79	12.78	0.62	1.78e-29	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs17253792	0.822	rs79538158	chr14:56051365	G/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.84	5.66	0.33	3.95e-8	Putamen volume;
CESC	cis	rs1577917	1.000	rs955196	chr6:86729951	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.4	5.04	0.3	8.45e-7	Response to antipsychotic treatment;
CESC	cis	rs9527	0.545	rs12247514	chr10:104958066	C/A	cg04362960	chr10:104952993	NT5C2	0.43	5.44	0.32	1.2e-7	Arsenic metabolism;
CESC	cis	rs514406	0.793	rs12081018	chr1:53217542	C/A	cg25767906	chr1:53392781	SCP2	0.44	6.13	0.35	3.09e-9	Monocyte count;
CESC	cis	rs736408	0.527	rs2577831	chr3:52628056	C/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	6.73	0.38	1.07e-10	Bipolar disorder;
CESC	cis	rs9487051	0.652	rs6568559	chr6:109592751	C/T	cg21918786	chr6:109611834	NA	-0.37	-5.41	-0.32	1.39e-7	Reticulocyte fraction of red cells;
CESC	cis	rs2842992	0.714	rs2475564	chr6:160123673	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.73	9.12	0.49	2e-17	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs1799949	0.965	rs9646418	chr17:41425901	A/G	cg05368731	chr17:41323189	NBR1	0.59	8.38	0.46	3.14e-15	Menopause (age at onset);
CESC	cis	rs13102973	0.932	rs4130840	chr4:135869598	T/G	cg14419869	chr4:135874104	NA	-0.4	-6.29	-0.36	1.32e-9	Subjective well-being;
CESC	cis	rs4713118	0.621	rs4713132	chr6:28034035	A/G	cg12963246	chr6:28129442	ZNF389	0.53	6.91	0.39	3.61e-11	Parkinson's disease;
CESC	cis	rs72781680	0.898	rs72782126	chr2:24039901	A/C	cg08917208	chr2:24149416	ATAD2B	0.95	8.71	0.47	3.45e-16	Lymphocyte counts;
CESC	cis	rs751837	0.591	rs8007077	chr14:103413454	T/C	cg10087771	chr14:103399429	CDC42BPB	0.72	6.21	0.36	2.06e-9	Large B-cell lymphoma;
CESC	cis	rs2559856	1.000	rs2559860	chr12:102087636	C/T	cg15068132	chr12:102092402	CHPT1	-0.39	-5.19	-0.3	4.21e-7	Blood protein levels;
CESC	cis	rs6952808	0.825	rs34296663	chr7:1935245	C/T	cg08027265	chr7:2291960	NA	-0.34	-5.13	-0.3	5.48e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs7191439	0.728	rs4238687	chr16:88788903	T/G	cg27087555	chr16:88793112	FAM38A	-1.43	-12.29	-0.6	9.2e-28	Plateletcrit;
CESC	cis	rs6815814	0.847	rs11725309	chr4:38783848	T/C	cg02016764	chr4:38805732	TLR1	-0.69	-8.4	-0.46	2.75e-15	Breast cancer;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg07870854	chr16:791252	NARFL	-0.48	-6.49	-0.37	4.13e-10	Fibrinogen levels;
CESC	cis	rs7666738	0.830	rs4345191	chr4:98945408	A/G	cg03676636	chr4:99064102	C4orf37	0.34	5.11	0.3	6.15e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9399137	0.507	rs56164974	chr6:135288716	C/T	cg22676075	chr6:135203613	NA	0.54	7.12	0.4	9.9e-12	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	cis	rs854765	0.583	rs11871899	chr17:17826748	C/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.53	7.31	0.41	3.19e-12	Total body bone mineral density;
CESC	cis	rs11098499	0.955	rs6815725	chr4:120158410	C/A	cg09307838	chr4:120376055	NA	0.87	11.52	0.58	3.6e-25	Corneal astigmatism;
CESC	cis	rs1775715	0.737	rs2799012	chr10:32103077	C/T	cg18675610	chr10:32216311	ARHGAP12	0.34	5.27	0.31	2.85e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs7107174	1.000	rs10793309	chr11:78093799	G/A	cg02023728	chr11:77925099	USP35	0.38	5.2	0.3	3.96e-7	Testicular germ cell tumor;
CESC	cis	rs798554	0.679	rs1636250	chr7:2884433	T/C	cg04166393	chr7:2884313	GNA12	0.61	8.24	0.45	8.02e-15	Height;
CESC	cis	rs67478160	0.643	rs12880167	chr14:104300829	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.51	-7.16	-0.4	8.15e-12	Schizophrenia;
CESC	trans	rs10776614	0.799	rs7085183	chr10:49764029	G/C	cg19218067	chr2:181235115	NA	0.5	6.1	0.35	3.7e-9	Self-employment;
CESC	cis	rs10504229	0.683	rs16921807	chr8:58105967	C/T	cg24829409	chr8:58192753	C8orf71	-0.56	-7.01	-0.4	1.97e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs4629710	0.592	rs11759926	chr6:131571269	G/T	cg12606694	chr6:131520996	AKAP7	0.5	6.05	0.35	4.84e-9	Multiple myeloma (IgH translocation);
CESC	cis	rs7259376	0.902	rs10414591	chr19:22600122	G/A	cg02657401	chr19:22469223	NA	0.26	5.12	0.3	5.79e-7	Menopause (age at onset);
CESC	cis	rs4853012	0.941	rs7571083	chr2:74342260	C/G	cg05890377	chr2:74357713	NA	0.59	7.22	0.41	5.5e-12	Gestational age at birth (maternal effect);
CESC	trans	rs561341	0.941	rs17780086	chr17:30343282	G/A	cg20587970	chr11:113659929	NA	-1.5	-18.59	-0.75	5.81e-50	Hip circumference adjusted for BMI;
CESC	cis	rs4665809	0.838	rs6546780	chr2:26352857	T/C	cg25036284	chr2:26402008	FAM59B	-0.59	-6.76	-0.38	8.61e-11	Gut microbiome composition (summer);
CESC	cis	rs748404	0.646	rs2253268	chr15:43800968	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.61	7.84	0.43	1.11e-13	Lung cancer;
CESC	cis	rs1552244	0.882	rs28366039	chr3:10028988	C/A	cg00166722	chr3:10149974	C3orf24	0.53	6.19	0.36	2.32e-9	Alzheimer's disease;
CESC	cis	rs12900413	0.687	rs10152954	chr15:90307442	T/C	cg24249390	chr15:90295951	MESP1	-0.41	-5.65	-0.33	4.04e-8	Coronary artery aneurysm in Kawasaki disease;
CESC	cis	rs6460942	0.597	rs4719315	chr7:12528634	A/G	cg10578991	chr7:12443926	VWDE	-0.49	-5.08	-0.3	7.1e-7	Coronary artery disease;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg12788078	chr18:43546845	KIAA1632	-0.51	-6.75	-0.38	9.36e-11	Height;
CESC	cis	rs7116495	1.000	rs7937582	chr11:71744613	C/T	cg10381502	chr11:71823885	C11orf51	-0.65	-5.29	-0.31	2.62e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs6831352	0.918	rs6813415	chr4:100048509	T/C	cg13256891	chr4:100009986	ADH5	-0.77	-8.43	-0.46	2.27e-15	Alcohol dependence;
CESC	cis	rs10754283	0.870	rs2390764	chr1:90112827	T/G	cg21401794	chr1:90099060	LRRC8C	0.69	9.34	0.5	4.06e-18	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs9486719	1.000	rs2064947	chr6:97052754	C/T	cg06623918	chr6:96969491	KIAA0776	-0.83	-8.8	-0.48	1.81e-16	Migraine;Coronary artery disease;
CESC	cis	rs4072980	0.545	rs10890285	chr1:38453576	A/C	cg26528311	chr1:38462546	FHL3	-0.37	-5.67	-0.33	3.78e-8	Coronary artery disease;
CESC	cis	rs2228479	0.850	rs62056103	chr16:89942781	G/A	cg04013166	chr16:89971882	TCF25	0.75	6.39	0.37	7.38e-10	Skin colour saturation;
CESC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg06691214	chr2:208394839	CREB1	0.58	6.13	0.35	3.26e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs721399	0.614	rs4646246	chr8:18248661	A/G	cg18736775	chr8:18248649	NAT2	-0.5	-5.3	-0.31	2.42e-7	Blood metabolite levels;
CESC	cis	rs12681288	0.862	rs7814231	chr8:1021103	A/G	cg04851639	chr8:1020857	NA	-0.38	-8.57	-0.47	8.49e-16	Schizophrenia;
CESC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg06001652	chr11:2951578	PHLDA2	0.48	6.69	0.38	1.36e-10	Tetralogy of Fallot;
CESC	cis	rs2836950	0.585	rs1029004	chr21:40615343	A/G	cg11890956	chr21:40555474	PSMG1	-0.6	-8.28	-0.45	6.25e-15	Menarche (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04429812	chr17:37814043	STARD3	-0.57	-6.03	-0.35	5.36e-9	Gut microbiome composition (summer);
CESC	cis	rs801193	0.660	rs974239	chr7:66213491	G/A	cg18876405	chr7:65276391	NA	0.46	6.09	0.35	3.86e-9	Aortic root size;
CESC	trans	rs61931739	0.517	rs11053067	chr12:34191391	T/C	cg26384229	chr12:38710491	ALG10B	0.65	9.11	0.49	2.1e-17	Morning vs. evening chronotype;
CESC	cis	rs9815354	0.812	rs73073226	chr3:42005838	T/C	cg03022575	chr3:42003672	ULK4	0.64	5.78	0.33	2.07e-8	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs6500602	0.727	rs1477123	chr16:4560627	T/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.4	5.9	0.34	1.08e-8	Schizophrenia;
CESC	cis	rs225245	0.817	rs12150359	chr17:34024584	C/T	cg05299278	chr17:33885742	SLFN14	0.39	5.65	0.33	4.16e-8	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
CESC	cis	rs703842	1.000	rs6581155	chr12:58178162	A/G	cg18357645	chr12:58087776	OS9	-0.38	-5.36	-0.31	1.82e-7	Multiple sclerosis;
CESC	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg22105103	chr4:187893119	NA	0.51	7.69	0.43	2.88e-13	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9549367	0.826	rs35306827	chr13:113869045	G/A	cg18105134	chr13:113819100	PROZ	-0.7	-8.83	-0.48	1.47e-16	Platelet distribution width;
CESC	cis	rs8020095	0.528	rs2064489	chr14:67476497	C/G	cg19548862	chr14:67692701	FAM71D	-0.49	-6.09	-0.35	3.92e-9	Depression (quantitative trait);
CESC	cis	rs769267	0.930	rs2315022	chr19:19413381	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	7.59	0.42	5.31e-13	Tonsillectomy;
CESC	cis	rs694739	0.628	rs538147	chr11:64129722	G/A	cg23796481	chr11:64053134	BAD;GPR137	0.56	6.92	0.39	3.4e-11	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CESC	cis	rs3820068	0.581	rs16849152	chr1:15921774	A/C	cg17385448	chr1:15911702	AGMAT	0.41	6.58	0.37	2.54e-10	Systolic blood pressure;
CESC	cis	rs56235845	0.694	rs11738681	chr5:176761535	A/G	cg16006841	chr5:176797999	RGS14	0.46	5.78	0.33	2.09e-8	Hemoglobin concentration;Hematocrit;
CESC	cis	rs1538970	1.000	rs1538970	chr1:45847562	G/A	cg03146154	chr1:46216737	IPP	0.46	5.59	0.33	5.5e-8	Platelet count;
CESC	cis	rs7727544	0.684	rs272893	chr5:131663062	T/C	cg24060327	chr5:131705240	SLC22A5	-0.62	-8.06	-0.44	2.55e-14	Blood metabolite levels;
CESC	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	10.12	0.53	1.44e-20	Prudent dietary pattern;
CESC	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg04025307	chr7:1156635	C7orf50	0.45	6.15	0.35	2.8e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16668394	chr11:64578521	MEN1	-0.63	-7.6	-0.42	5.29e-13	Gut microbiome composition (summer);
CESC	cis	rs4888262	0.526	rs12921903	chr16:74625575	C/T	cg01733217	chr16:74700730	RFWD3	0.85	11.4	0.57	9.25e-25	Testicular germ cell tumor;
CESC	cis	rs11098499	0.657	rs4463052	chr4:120313258	T/C	cg09307838	chr4:120376055	NA	0.92	12.66	0.61	4.96e-29	Corneal astigmatism;
CESC	cis	rs11190604	1.000	rs2295776	chr10:102295629	G/T	cg07080220	chr10:102295463	HIF1AN	0.7	6.5	0.37	3.99e-10	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs2842992	0.672	rs4708845	chr6:160219601	T/G	cg26839252	chr6:160211577	TCP1;MRPL18	0.44	5.03	0.3	9.06e-7	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs2522056	0.935	rs757104	chr5:131795229	T/C	cg24060327	chr5:131705240	SLC22A5	0.59	6.61	0.38	2.07e-10	Lymphocyte counts;Fibrinogen;
CESC	cis	rs7084402	0.934	rs1649089	chr10:60289695	T/C	cg07615347	chr10:60278583	BICC1	0.6	9.41	0.5	2.54e-18	Refractive error;
CESC	trans	rs7980799	0.682	rs1601006	chr12:33629519	C/T	cg26384229	chr12:38710491	ALG10B	-0.6	-8.38	-0.46	3.05e-15	Heart rate;Heart rate variability traits (RMSSD);
CESC	cis	rs2836950	0.565	rs8131132	chr21:40538256	T/C	cg11644478	chr21:40555479	PSMG1	-0.53	-7.28	-0.41	3.78e-12	Menarche (age at onset);
CESC	cis	rs11098499	0.708	rs10005237	chr4:120237897	T/C	cg09307838	chr4:120376055	NA	0.79	10.77	0.55	1.17e-22	Corneal astigmatism;
CESC	cis	rs9640161	0.830	rs3757425	chr7:150067640	A/C	cg21361702	chr7:150065534	REPIN1	0.57	7.54	0.42	7.72e-13	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs1218582	0.772	rs6656435	chr1:154876869	G/A	cg24250549	chr1:154909240	PMVK	0.74	11.09	0.56	1.01e-23	Prostate cancer;
CESC	cis	rs11190604	1.000	rs10883512	chr10:102308516	A/G	cg07080220	chr10:102295463	HIF1AN	0.66	6.04	0.35	5.08e-9	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs1552244	1.000	rs6764068	chr3:10153842	A/G	cg00166722	chr3:10149974	C3orf24	0.45	5.65	0.33	4.12e-8	Alzheimer's disease;
CESC	cis	rs892961	0.932	rs12452788	chr17:75406866	T/C	cg05865280	chr17:75406074	SEPT9	0.65	13.12	0.63	1.19e-30	Airflow obstruction;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07052513	chr2:86668451	KDM3A	0.57	6.26	0.36	1.58e-9	Gut microbiome composition (summer);
CESC	cis	rs11734570	0.581	rs4401459	chr4:38585268	G/T	cg18361445	chr4:38666374	KLF3;FLJ13197	-0.62	-7.39	-0.41	1.94e-12	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs1443512	0.812	rs4759058	chr12:54339052	C/A	cg12374095	chr12:54320830	NA	-0.44	-5.99	-0.35	6.65e-9	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
CESC	cis	rs7937682	0.961	rs17113227	chr11:111620491	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.03	-15.9	-0.7	1.98e-40	Primary sclerosing cholangitis;
CESC	cis	rs7799006	0.527	rs73039284	chr7:2221583	C/G	cg21782813	chr7:2030301	MAD1L1	0.51	7.09	0.4	1.23e-11	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs4253772	0.591	rs113101219	chr22:46659186	C/A	cg10541313	chr22:46663664	TTC38	0.72	5.84	0.34	1.54e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs10504229	0.871	rs10504226	chr8:58159283	A/G	cg22535103	chr8:58192502	C8orf71	-0.92	-11.38	-0.57	1.11e-24	Developmental language disorder (linguistic errors);
CESC	cis	rs3806843	1.000	rs10053586	chr5:140210760	T/C	cg26395211	chr5:140044315	WDR55	-0.44	-5.5	-0.32	9.16e-8	Depressive symptoms (multi-trait analysis);
CESC	cis	rs11098499	0.954	rs67265404	chr4:120359270	C/T	cg09307838	chr4:120376055	NA	0.92	12.73	0.62	2.79e-29	Corneal astigmatism;
CESC	cis	rs17253792	0.822	rs7150841	chr14:56088986	T/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.76	5.39	0.31	1.56e-7	Putamen volume;
CESC	cis	rs11864453	0.647	rs9941346	chr16:72135707	C/G	cg16558253	chr16:72132732	DHX38	-0.54	-8.44	-0.46	2.04e-15	Fibrinogen levels;
CESC	cis	rs6732160	0.774	rs11890053	chr2:73373448	G/A	cg01422370	chr2:73384389	NA	0.43	7.45	0.42	1.31e-12	Intelligence (multi-trait analysis);
CESC	cis	rs7772486	0.597	rs2485631	chr6:146190077	G/C	cg05347473	chr6:146136440	FBXO30	0.75	9.54	0.51	9.85e-19	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22199410	chr12:51985016	SCN8A	0.52	6.42	0.37	6.22e-10	Gut microbiome composition (summer);
CESC	cis	rs9560113	0.597	rs947170	chr13:112241062	G/A	cg10483660	chr13:112241077	NA	-0.45	-7.66	-0.43	3.6e-13	Menarche (age at onset);
CESC	cis	rs7660520	0.524	rs12643521	chr4:183728242	C/G	cg03209412	chr4:183728196	NA	0.57	5.2	0.3	3.97e-7	Pediatric autoimmune diseases;
CESC	cis	rs9660992	0.626	rs1172113	chr1:205226288	T/C	cg21643547	chr1:205240462	TMCC2	-0.42	-6.05	-0.35	4.94e-9	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs3858526	0.727	rs10769353	chr11:5954809	C/T	cg05234568	chr11:5960015	NA	0.73	11.53	0.58	3.47e-25	DNA methylation (variation);
CESC	cis	rs34779708	0.966	rs4294520	chr10:35422506	C/T	cg03585969	chr10:35415529	CREM	0.76	9.95	0.52	4.98e-20	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs763121	0.853	rs138702	chr22:39132601	A/T	cg06022373	chr22:39101656	GTPBP1	-0.93	-16.41	-0.71	3.14e-42	Menopause (age at onset);
CESC	cis	rs1153858	1.000	rs56850226	chr15:45633118	T/C	cg21132104	chr15:45694354	SPATA5L1	0.83	11.2	0.57	4.45e-24	Homoarginine levels;
CESC	cis	rs7666738	0.830	rs28522896	chr4:99008243	C/T	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.62e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs3780486	0.522	rs7029897	chr9:33124042	T/C	cg20290983	chr6:43655470	MRPS18A	0.76	12.21	0.6	1.63e-27	IgG glycosylation;
CESC	trans	rs11098499	0.779	rs7674500	chr4:120303593	C/T	cg25214090	chr10:38739885	LOC399744	0.68	9.2	0.49	1.14e-17	Corneal astigmatism;
CESC	cis	rs1448094	0.511	rs7959372	chr12:86160680	T/C	cg00310523	chr12:86230176	RASSF9	0.33	5.29	0.31	2.53e-7	Major depressive disorder;
CESC	cis	rs9322193	0.923	rs1934534	chr6:150033032	A/G	cg13206674	chr6:150067644	NUP43	0.46	6.67	0.38	1.46e-10	Lung cancer;
CESC	cis	rs875971	0.862	rs801206	chr7:66021966	C/G	cg11764359	chr7:65958608	NA	-0.78	-11.22	-0.57	3.73e-24	Aortic root size;
CESC	cis	rs7666738	0.830	rs7667796	chr4:99071415	G/T	cg18180107	chr4:99064573	C4orf37	-0.41	-5.18	-0.3	4.5e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs34779708	0.931	rs11593858	chr10:35381373	G/A	cg03585969	chr10:35415529	CREM	0.77	10.07	0.53	2.06e-20	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs5769765	0.818	rs8140681	chr22:50292081	C/A	cg26441486	chr22:50317300	CRELD2	0.39	5.37	0.31	1.76e-7	Schizophrenia;
CESC	cis	rs7666738	0.830	rs7663924	chr4:99037679	A/G	cg03467027	chr4:99064603	C4orf37	-0.47	-5.76	-0.33	2.35e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs17384381	0.953	rs11161599	chr1:85795965	A/G	cg16011679	chr1:85725395	C1orf52	-0.77	-8.08	-0.44	2.31e-14	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1190552	0.739	rs1998421	chr14:102979644	C/T	cg18135206	chr14:102964638	TECPR2	0.43	5.45	0.32	1.14e-7	Blood protein levels;
CESC	cis	rs2718058	0.630	rs2722292	chr7:37824581	A/G	cg24998770	chr7:37888106	TXNDC3	0.34	5.17	0.3	4.67e-7	Alzheimer's disease (late onset);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg20818191	chr4:866154	GAK	0.53	7.12	0.4	1.03e-11	Fibrinogen levels;
CESC	cis	rs11031096	0.678	rs4606468	chr11:4183643	G/T	cg18678763	chr11:4115507	RRM1	-0.47	-6.52	-0.37	3.57e-10	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	cis	rs7100689	0.646	rs9804233	chr10:82134667	T/C	cg00277334	chr10:82204260	NA	-0.57	-7.51	-0.42	9.08e-13	Post bronchodilator FEV1;
CESC	cis	rs780096	0.506	rs1647286	chr2:27714517	A/T	cg22903471	chr2:27725779	GCKR	-0.51	-7.16	-0.4	7.71e-12	Total body bone mineral density;
CESC	cis	rs1552244	0.882	rs2030564	chr3:10039044	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.85	11.03	0.56	1.62e-23	Alzheimer's disease;
CESC	cis	rs1008375	0.797	rs6843530	chr4:17593605	G/T	cg16339924	chr4:17578868	LAP3	0.69	8.95	0.48	6.16e-17	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs6424115	0.830	rs2501423	chr1:24199026	A/C	cg10978503	chr1:24200527	CNR2	0.32	6.24	0.36	1.74e-9	Immature fraction of reticulocytes;
CESC	cis	rs9322193	0.923	rs9688350	chr6:150052113	A/T	cg07701084	chr6:150067640	NUP43	0.46	6.25	0.36	1.64e-9	Lung cancer;
CESC	cis	rs9911578	0.692	rs411988	chr17:56709034	G/A	cg05425664	chr17:57184151	TRIM37	-0.4	-5.47	-0.32	1.05e-7	Intelligence (multi-trait analysis);
CESC	cis	rs698833	0.892	rs1067363	chr2:44658401	G/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.47	5.97	0.34	7.62e-9	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs7539624	1.000	rs7539624	chr1:223906827	G/A	cg10100437	chr1:223903862	CAPN2	-0.35	-5.19	-0.3	4.12e-7	Schizophrenia;
CESC	cis	rs654950	0.840	rs2810551	chr1:41995402	G/A	cg06885757	chr1:42089581	HIVEP3	-0.44	-6.82	-0.39	6.21e-11	Airway imaging phenotypes;
CESC	cis	rs4888262	0.545	rs4072450	chr16:74666634	G/C	cg01733217	chr16:74700730	RFWD3	0.92	12.31	0.6	7.71e-28	Testicular germ cell tumor;
CESC	cis	rs72781680	0.851	rs12612830	chr2:24134599	C/T	cg08917208	chr2:24149416	ATAD2B	0.93	8.42	0.46	2.35e-15	Lymphocyte counts;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12581730	chr6:170599861	DLL1	-0.65	-7.6	-0.42	4.98e-13	Gut microbiome composition (summer);
CESC	cis	rs1448094	0.510	rs1993806	chr12:86147151	T/C	cg02569458	chr12:86230093	RASSF9	-0.42	-6.44	-0.37	5.67e-10	Major depressive disorder;
CESC	trans	rs116095464	0.510	rs73016876	chr5:244475	T/C	cg00938859	chr5:1591904	SDHAP3	0.68	7.38	0.41	2.02e-12	Breast cancer;
CESC	cis	rs425277	0.628	rs3107147	chr1:2048729	G/A	cg16545954	chr1:2118288	C1orf86	-0.33	-6.12	-0.35	3.4e-9	Height;
CESC	cis	rs7296418	0.961	rs10848428	chr12:123572495	C/T	cg05973401	chr12:123451056	ABCB9	0.6	7.84	0.43	1.11e-13	Platelet count;
CESC	trans	rs7943203	0.962	rs2118308	chr11:108315463	C/G	cg01416241	chr5:148737479	PCYOX1L	-0.48	-6.07	-0.35	4.35e-9	Red blood cell count;Mean corpuscular volume;
CESC	cis	rs4563143	0.514	rs112540771	chr19:29316100	C/T	cg14983838	chr19:29218262	NA	0.5	5.79	0.33	2.02e-8	Methadone dose in opioid dependence;
CESC	cis	rs9399137	0.507	rs6569986	chr6:135311641	T/C	cg22676075	chr6:135203613	NA	0.53	7.09	0.4	1.22e-11	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	cis	rs709400	0.894	rs56017123	chr14:104075277	G/A	cg12935359	chr14:103987150	CKB	-0.47	-5.94	-0.34	8.91e-9	Body mass index;
CESC	cis	rs798554	0.683	rs1636264	chr7:2864586	G/T	cg19346786	chr7:2764209	NA	-0.45	-6.59	-0.38	2.32e-10	Height;
CESC	cis	rs9905704	0.681	rs4277402	chr17:56581651	C/G	cg12560992	chr17:57184187	TRIM37	-0.65	-5.99	-0.35	6.78e-9	Testicular germ cell tumor;
CESC	cis	rs6580649	0.882	rs2286022	chr12:48436647	G/A	cg24011408	chr12:48396354	COL2A1	-0.44	-5.35	-0.31	1.86e-7	Lung cancer;
CESC	cis	rs989128	0.600	rs9913430	chr17:48628470	A/T	cg24438145	chr17:48624694	SPATA20	0.45	5.42	0.32	1.37e-7	Type 2 diabetes;
CESC	cis	rs10504229	0.683	rs11785258	chr8:58132893	A/G	cg24829409	chr8:58192753	C8orf71	-0.58	-7.2	-0.4	6.31e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs12142240	0.692	rs7532149	chr1:46824932	A/C	cg10495392	chr1:46806563	NSUN4	0.58	6.32	0.36	1.09e-9	Menopause (age at onset);
CESC	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.55	-6.1	-0.35	3.69e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs9916302	0.784	rs4795361	chr17:37573446	G/A	cg07936489	chr17:37558343	FBXL20	-0.81	-11.75	-0.59	6.21e-26	Glomerular filtration rate (creatinine);
CESC	cis	rs4595586	0.525	rs4450203	chr12:39381493	T/G	cg26384229	chr12:38710491	ALG10B	0.54	7.53	0.42	7.85e-13	Morning vs. evening chronotype;
CESC	cis	rs13191362	1.000	rs13210756	chr6:163009030	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.78	8.21	0.45	9.97e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs9322193	0.926	rs2342860	chr6:150098777	T/C	cg13206674	chr6:150067644	NUP43	0.41	5.68	0.33	3.47e-8	Lung cancer;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg13220357	chr22:25202163	SGSM1	-0.47	-6.14	-0.35	3.05e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs1878931	0.615	rs4786412	chr16:3440390	C/T	cg00484396	chr16:3507460	NAT15	-0.4	-6.23	-0.36	1.82e-9	Body mass index (adult);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11159084	chr1:236767889	HEATR1	0.61	6.55	0.37	3.04e-10	Gut microbiome composition (summer);
CESC	cis	rs769267	0.896	rs7250893	chr19:19625547	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.48	6.05	0.35	4.88e-9	Tonsillectomy;
CESC	cis	rs6502050	0.835	rs56095560	chr17:80151304	C/T	cg23985595	chr17:80112537	CCDC57	-0.42	-6.57	-0.37	2.59e-10	Life satisfaction;
CESC	cis	rs1552244	1.000	rs12152512	chr3:10143770	C/T	cg24633833	chr3:10029261	TMEM111	0.44	5.11	0.3	6.19e-7	Alzheimer's disease;
CESC	cis	rs1348850	0.651	rs4893931	chr2:178228212	T/C	cg22681709	chr2:178499509	PDE11A	-0.34	-5.26	-0.31	3.02e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs4930103	0.619	rs739905	chr11:1980360	G/C	cg23202291	chr11:1979235	NA	0.4	5.6	0.33	5.5e-8	DNA methylation (parent-of-origin);DNA methylation (variation);
CESC	cis	rs875971	0.862	rs778684	chr7:65836403	A/T	cg18252515	chr7:66147081	NA	-0.43	-5.62	-0.33	4.86e-8	Aortic root size;
CESC	trans	rs12599106	0.625	rs12923277	chr16:34896261	G/A	cg15383120	chr6:291909	DUSP22	-0.65	-8.2	-0.45	1.07e-14	Menopause (age at onset);
CESC	cis	rs7944584	0.511	rs10838731	chr11:47607135	C/T	cg20307385	chr11:47447363	PSMC3	0.83	12.25	0.6	1.27e-27	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CESC	cis	rs708547	0.874	rs1713978	chr4:57875879	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.68	7.91	0.44	6.86e-14	Response to bleomycin (chromatid breaks);
CESC	cis	rs3008870	0.755	rs2815362	chr1:67496803	C/T	cg02640540	chr1:67518911	SLC35D1	0.45	5.55	0.32	6.76e-8	Lymphocyte percentage of white cells;
CESC	cis	rs9814567	1.000	rs2887797	chr3:134202506	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.47	-6.37	-0.36	8.13e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs2576037	0.526	rs2571027	chr18:44561516	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.69	-10.89	-0.56	4.48e-23	Personality dimensions;
CESC	cis	rs13256369	1.000	rs10095733	chr8:8574646	A/G	cg17143192	chr8:8559678	CLDN23	0.71	8.49	0.46	1.46e-15	Obesity-related traits;
CESC	trans	rs7819412	0.668	rs2409715	chr8:11010136	A/T	cg15556689	chr8:8085844	FLJ10661	-0.54	-6.71	-0.38	1.16e-10	Triglycerides;
CESC	cis	rs9300255	0.602	rs1790098	chr12:123655481	A/C	cg00376283	chr12:123451042	ABCB9	0.7	8.57	0.47	8.55e-16	Neutrophil percentage of white cells;
CESC	cis	rs1878931	0.668	rs11643983	chr16:3438865	G/A	cg00484396	chr16:3507460	NAT15	-0.39	-6.2	-0.36	2.18e-9	Body mass index (adult);
CESC	cis	rs728616	0.867	rs61860412	chr10:81728486	G/A	cg05935833	chr10:81318306	SFTPA2	-0.51	-5.04	-0.3	8.51e-7	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs644799	0.965	rs11021310	chr11:95502106	A/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.95	15.06	0.68	1.9e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs947211	0.898	rs1775146	chr1:205756168	A/G	cg14159672	chr1:205819179	PM20D1	0.4	5.15	0.3	4.99e-7	Parkinson's disease;
CESC	cis	rs7520050	0.801	rs6703960	chr1:46232723	C/T	cg24296786	chr1:45957014	TESK2	0.46	5.99	0.35	6.97e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs6933660	0.800	rs963193	chr6:151789355	G/T	cg14416726	chr6:151773293	C6orf211;RMND1	0.54	7.3	0.41	3.26e-12	Menarche (age at onset);
CESC	cis	rs9916302	0.808	rs12943928	chr17:37611330	G/A	cg00129232	chr17:37814104	STARD3	-0.54	-7.14	-0.4	9.08e-12	Glomerular filtration rate (creatinine);
CESC	cis	rs11645898	0.810	rs72787046	chr16:72079342	A/G	cg14768367	chr16:72042858	DHODH	-0.84	-6.92	-0.39	3.43e-11	Blood protein levels;
CESC	cis	rs5758659	0.679	rs134870	chr22:42652317	T/C	cg15557168	chr22:42548783	NA	-0.34	-5.2	-0.3	4e-7	Cognitive function;
CESC	cis	rs7259376	0.875	rs10409520	chr19:22512477	C/T	cg02657401	chr19:22469223	NA	-0.26	-5.35	-0.31	1.86e-7	Menopause (age at onset);
CESC	cis	rs910316	1.000	rs10142865	chr14:75555624	G/A	cg08847533	chr14:75593920	NEK9	1.02	20.11	0.78	2.88e-55	Height;
CESC	cis	rs1045714	0.895	rs17833498	chr7:2647007	A/G	cg20813462	chr7:2646259	IQCE	-0.62	-5.41	-0.32	1.43e-7	Urate levels in lean individuals;
CESC	trans	rs4245128	0.930	rs4936212	chr11:112794836	C/T	cg10894232	chr8:11772343	NA	0.37	6.1	0.35	3.78e-9	Life satisfaction;
CESC	cis	rs8014204	0.804	rs34956813	chr14:75254167	G/A	cg08847533	chr14:75593920	NEK9	0.47	5.97	0.34	7.75e-9	Caffeine consumption;
CESC	cis	rs9858542	0.953	rs7622302	chr3:49547561	T/C	cg07274523	chr3:49395745	GPX1	0.65	7.92	0.44	6.77e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs7855088	1.000	rs879275	chr9:100781720	G/C	cg13688889	chr9:100608707	NA	-0.38	-5.7	-0.33	3.13e-8	Serum thyroid-stimulating hormone levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15929228	chr2:240323491	HDAC4	0.57	6.69	0.38	1.33e-10	Gut microbiome composition (summer);
CESC	cis	rs79057730	0.599	rs35928068	chr7:805363	G/C	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.92	8.05	0.44	2.75e-14	Initial pursuit acceleration;
CESC	cis	rs6540559	0.673	rs2357230	chr1:210019498	G/A	cg23283495	chr1:209979779	IRF6	0.48	5.59	0.32	5.57e-8	Cleft lip with or without cleft palate;
CESC	cis	rs1215050	0.716	rs356549	chr4:98699344	A/G	cg05340658	chr4:99064831	C4orf37	0.5	6.36	0.36	8.61e-10	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs7811142	1.000	rs2406255	chr7:100053690	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.1	10.23	0.53	6.23e-21	Platelet count;
CESC	cis	rs5750830	0.649	rs5750811	chr22:39793066	G/T	cg02038168	chr22:39784481	NA	0.57	6.94	0.39	3e-11	Intelligence (multi-trait analysis);
CESC	cis	rs4481887	0.927	rs4390208	chr1:248472211	C/T	cg00666640	chr1:248458726	OR2T12	0.33	5.64	0.33	4.25e-8	Common traits (Other);
CESC	cis	rs2072732	0.861	rs34408665	chr1:2950067	A/G	cg15211996	chr1:2936768	ACTRT2	0.36	6.33	0.36	1.02e-9	Plateletcrit;
CESC	cis	rs1670533	1.000	rs10084889	chr4:1053815	G/A	cg27284194	chr4:1044797	NA	0.46	5.86	0.34	1.35e-8	Recombination rate (females);
CESC	cis	rs10197940	0.624	rs10497082	chr2:152355258	T/C	cg19508488	chr2:152266495	RIF1	0.51	5.45	0.32	1.17e-7	Lung cancer;
CESC	cis	rs11098499	0.564	rs11098507	chr4:120288286	G/A	cg09307838	chr4:120376055	NA	0.87	12.13	0.6	3.13e-27	Corneal astigmatism;
CESC	trans	rs747782	0.528	rs624348	chr11:48400795	G/A	cg15704280	chr7:45808275	SEPT13	-0.68	-6.25	-0.36	1.61e-9	Intraocular pressure;
CESC	cis	rs9911578	1.000	rs9892062	chr17:56976981	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.39	5.05	0.3	8.26e-7	Intelligence (multi-trait analysis);
CESC	cis	rs727563	0.594	rs5758408	chr22:42077737	A/C	cg06634786	chr22:41940651	POLR3H	0.62	6.25	0.36	1.67e-9	Crohn's disease;Inflammatory bowel disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06788172	chr15:51915087	DMXL2	0.59	6.72	0.38	1.14e-10	Gut microbiome composition (summer);
CESC	cis	rs9911578	1.000	rs3744108	chr17:56585872	G/C	cg12560992	chr17:57184187	TRIM37	-0.91	-15.19	-0.68	6.51e-38	Intelligence (multi-trait analysis);
CESC	cis	rs853679	0.517	rs9348794	chr6:28117757	T/A	cg20151795	chr6:28129481	ZNF389	0.46	5.83	0.34	1.65e-8	Depression;
CESC	cis	rs67311347	0.594	rs12629111	chr3:40285351	T/C	cg09455208	chr3:40491958	NA	0.32	5.32	0.31	2.17e-7	Renal cell carcinoma;
CESC	cis	rs910316	0.810	rs77939209	chr14:75670070	A/G	cg11812906	chr14:75593930	NEK9	-0.84	-13.59	-0.64	2.87e-32	Height;
CESC	trans	rs877282	0.898	rs11253356	chr10:768604	G/A	cg22713356	chr15:30763199	NA	0.9	9.35	0.5	3.78e-18	Uric acid levels;
CESC	cis	rs1707322	0.752	rs28550303	chr1:46188914	G/T	cg03146154	chr1:46216737	IPP	0.83	11.68	0.58	1.09e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs853679	0.517	rs9295758	chr6:28120663	C/G	cg22143856	chr6:28129313	ZNF389	0.53	6.73	0.38	1.06e-10	Depression;
CESC	cis	rs5758659	0.652	rs5758537	chr22:42397042	G/T	cg15557168	chr22:42548783	NA	-0.43	-6.35	-0.36	9.55e-10	Cognitive function;
CESC	cis	rs597539	0.654	rs7107137	chr11:68623712	A/G	cg21963583	chr11:68658836	MRPL21	0.4	5.42	0.32	1.37e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs1218582	0.741	rs883718	chr1:154846274	C/T	cg06221963	chr1:154839813	KCNN3	-0.69	-12.3	-0.6	8.47e-28	Prostate cancer;
CESC	cis	rs9584850	0.834	rs7339274	chr13:99120272	A/G	cg20750642	chr13:99100586	FARP1	0.38	5.93	0.34	9.48e-9	Neuroticism;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg22754179	chr19:42901115	NA	0.45	6.22	0.36	1.89e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs12926788	0.546	rs200537	chr16:24747787	G/C	cg02428538	chr16:24856791	SLC5A11	0.48	5.07	0.3	7.62e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs9811920	0.609	rs6440938	chr3:99652092	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.64	-10.11	-0.53	1.53e-20	Axial length;
CESC	cis	rs425277	0.606	rs424079	chr1:2071340	C/A	cg12718519	chr1:2058417	PRKCZ	-0.25	-5.25	-0.31	3.18e-7	Height;
CESC	cis	rs9614461	0.702	rs3788648	chr22:45727180	G/A	cg13318129	chr22:45737514	FAM118A	0.49	5.12	0.3	5.79e-7	Tonsillectomy;
CESC	cis	rs1707322	1.000	rs785465	chr1:46522577	G/T	cg05343316	chr1:45956843	TESK2	0.45	5.58	0.32	5.89e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2637266	1.000	rs7900616	chr10:78367075	C/T	cg18941641	chr10:78392320	NA	0.42	7.87	0.44	8.96e-14	Pulmonary function;
CESC	cis	rs4927850	1.000	rs7625570	chr3:195747398	A/G	cg12923728	chr3:195709715	SDHAP1	-0.66	-8.75	-0.47	2.61e-16	Pancreatic cancer;
CESC	cis	rs12950390	0.814	rs11659069	chr17:45834275	G/T	cg00777063	chr17:45855553	NA	-0.41	-6.11	-0.35	3.53e-9	IgG glycosylation;
CESC	cis	rs9906944	0.707	rs4794020	chr17:47111399	C/T	cg09029085	chr17:47094198	IGF2BP1	0.25	5.06	0.3	7.94e-7	Intelligence (multi-trait analysis);Body fat percentage;
CESC	cis	rs2070433	0.752	rs11700468	chr21:47776391	C/T	cg12379764	chr21:47803548	PCNT	0.67	7.43	0.42	1.52e-12	Lymphocyte counts;
CESC	cis	rs7408868	0.764	rs12610803	chr19:15260682	A/C	cg14696996	chr19:15285081	NOTCH3	1.11	11.21	0.57	3.98e-24	Pulse pressure;
CESC	cis	rs9902453	0.967	rs61014003	chr17:28485233	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	8.09	0.44	2.2e-14	Coffee consumption (cups per day);
CESC	cis	rs4975709	0.610	rs4975706	chr5:1860365	G/T	cg11168104	chr5:1857477	NA	-0.38	-5.67	-0.33	3.63e-8	Cardiovascular disease risk factors;
CESC	cis	rs748404	0.650	rs556851	chr15:43571219	A/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.51	8.03	0.44	3.27e-14	Lung cancer;
CESC	cis	rs7845219	0.525	rs7820818	chr8:95919231	G/A	cg23172400	chr8:95962367	TP53INP1	-0.4	-7.29	-0.41	3.51e-12	Type 2 diabetes;
CESC	cis	rs7666738	0.830	rs6854919	chr4:98947326	C/T	cg17366294	chr4:99064904	C4orf37	0.56	7.55	0.42	6.85e-13	Colonoscopy-negative controls vs population controls;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg18598152	chr14:24020957	NA	0.44	6.23	0.36	1.85e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs763121	0.853	rs6001182	chr22:39047443	A/G	cg21395723	chr22:39101663	GTPBP1	0.43	5.33	0.31	2.09e-7	Menopause (age at onset);
CESC	cis	rs4665809	0.627	rs7562192	chr2:26469457	C/G	cg26119090	chr2:26468346	HADHA;HADHB	1.06	12.34	0.6	5.85e-28	Gut microbiome composition (summer);
CESC	cis	rs2820292	0.595	rs10800793	chr1:201825750	A/G	cg11586189	chr1:201857591	SHISA4	-0.36	-5.85	-0.34	1.43e-8	Waist circumference;Body mass index (joint analysis main effects and smoking interaction);Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);
CESC	cis	rs6951245	0.608	rs10252234	chr7:1114381	C/T	cg04025307	chr7:1156635	C7orf50	0.39	5.27	0.31	2.77e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg18402987	chr7:1209562	NA	0.76	7.57	0.42	6.04e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7851660	0.967	rs6478437	chr9:100607497	A/G	cg13688889	chr9:100608707	NA	-0.68	-10.61	-0.55	3.8e-22	Strep throat;
CESC	cis	rs60843830	0.661	rs7588043	chr2:104979	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.51	6.08	0.35	4.11e-9	Spherical equivalent (joint analysis main effects and education interaction);
CESC	trans	rs9325144	0.723	rs11169535	chr12:39183494	C/T	cg23762105	chr12:34175262	ALG10	0.45	6.14	0.35	3.01e-9	Morning vs. evening chronotype;
CESC	cis	rs9362426	0.503	rs34977536	chr6:88112368	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.44	-5.36	-0.31	1.79e-7	Depressive episodes in bipolar disorder;
CESC	cis	rs116095464	0.558	rs10065584	chr5:253997	G/A	cg22857025	chr5:266934	NA	-1.31	-13.97	-0.65	1.35e-33	Breast cancer;
CESC	cis	rs116095464	0.558	rs9312977	chr5:221916	G/C	cg12570787	chr5:219185	SDHA;CCDC127	0.53	5.74	0.33	2.63e-8	Breast cancer;
CESC	cis	rs933688	1.000	rs10059163	chr5:90742444	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.11	14.08	0.65	5.45e-34	Smoking behavior;
CESC	cis	rs3213545	0.659	rs2259693	chr12:121457995	G/A	cg02403541	chr12:121454288	C12orf43	0.74	10.68	0.55	2.25e-22	Subjective well-being;Cardiovascular disease risk factors;
CESC	cis	rs3785574	0.962	rs114027117	chr17:61939935	T/A	cg06873352	chr17:61820015	STRADA	0.46	6.8	0.39	6.85e-11	Height;
CESC	cis	rs4927850	0.957	rs4927851	chr3:195751853	A/G	cg01181863	chr3:195395398	SDHAP2	-0.5	-5.85	-0.34	1.47e-8	Pancreatic cancer;
CESC	cis	rs4862750	0.872	rs7679956	chr4:187900229	C/T	cg27532560	chr4:187881888	NA	-0.4	-6.2	-0.36	2.12e-9	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs2530545	0.851	rs10246319	chr7:34692257	G/A	cg14080982	chr15:71736038	THSD4	-0.48	-6.27	-0.36	1.43e-9	IgG glycosylation;
CESC	trans	rs9951602	0.512	rs12607612	chr18:76651799	G/A	cg02800362	chr5:177631904	HNRNPAB	0.66	8.64	0.47	5.41e-16	Obesity-related traits;
CESC	cis	rs2836974	0.897	rs4817996	chr21:40525759	G/C	cg11890956	chr21:40555474	PSMG1	1.18	23.84	0.83	6.88e-68	Cognitive function;
CESC	cis	rs2635047	0.967	rs2576056	chr18:44675462	G/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.49	6.59	0.38	2.33e-10	Educational attainment;
CESC	cis	rs6752107	1.000	rs6752107	chr2:234161448	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.49	6.91	0.39	3.61e-11	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs7772486	0.806	rs2265477	chr6:146212338	T/C	cg23711669	chr6:146136114	FBXO30	0.77	10.91	0.56	3.81e-23	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs8177253	0.931	rs8177256	chr3:133480276	G/T	cg11941060	chr3:133502564	NA	-0.48	-6.65	-0.38	1.67e-10	Iron status biomarkers;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18487609	chr19:18392554	JUND	0.68	7.83	0.43	1.21e-13	Gut microbiome composition (summer);
CESC	cis	rs7914558	0.966	rs10786727	chr10:104698523	G/A	cg08650961	chr10:104748594	CNNM2	0.32	5.16	0.3	4.94e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs11764590	0.694	rs55860148	chr7:2105594	G/A	cg12017631	chr7:1980892	MAD1L1	-0.42	-5.17	-0.3	4.71e-7	Neuroticism;
CESC	cis	rs6088580	0.524	rs6088565	chr20:33254986	A/C	cg07148914	chr20:33460835	GGT7	-0.44	-5.42	-0.32	1.34e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs712039	0.652	rs712038	chr17:35762557	G/A	cg16670864	chr17:35848621	DUSP14	0.48	6.12	0.35	3.37e-9	Tuberculosis;
CESC	cis	rs1552244	0.882	rs55962400	chr3:10044457	C/T	cg08888203	chr3:10149979	C3orf24	0.5	6.02	0.35	5.84e-9	Alzheimer's disease;
CESC	cis	rs9926296	0.509	rs2159113	chr16:89832083	C/T	cg04287289	chr16:89883240	FANCA	0.72	10.49	0.54	9.56e-22	Vitiligo;
CESC	cis	rs1153858	0.887	rs28569043	chr15:45730926	A/T	cg21132104	chr15:45694354	SPATA5L1	0.73	8.89	0.48	9.73e-17	Homoarginine levels;
CESC	cis	rs2842992	0.709	rs1853257	chr6:160212710	C/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.73	9.53	0.51	1.08e-18	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs6582630	0.555	rs56228141	chr12:38518652	T/G	cg13010199	chr12:38710504	ALG10B	0.49	6.43	0.37	6.06e-10	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs9640161	0.830	rs3757424	chr7:150067679	C/A	cg21361702	chr7:150065534	REPIN1	0.57	7.54	0.42	7.72e-13	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs7953508	0.619	rs11107114	chr12:93972927	G/A	cg18151635	chr12:93972918	NA	-0.48	-6.68	-0.38	1.4e-10	Pubertal anthropometrics;
CESC	cis	rs2839186	0.770	rs2330353	chr21:47669648	T/A	cg05896524	chr21:47604654	C21orf56	0.43	5.6	0.33	5.28e-8	Testicular germ cell tumor;
CESC	cis	rs11650494	0.908	rs8076023	chr17:47399633	C/G	cg08112188	chr17:47440006	ZNF652	0.98	7.01	0.4	1.95e-11	Prostate cancer;
CESC	cis	rs2404602	0.735	rs437131	chr15:76781051	C/T	cg23625390	chr15:77176239	SCAPER	0.38	5.52	0.32	8.13e-8	Blood metabolite levels;
CESC	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.51	0.37	3.65e-10	Prudent dietary pattern;
CESC	cis	rs559928	0.606	rs76653616	chr11:63936139	T/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.66	5.84	0.34	1.55e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CESC	cis	rs7208859	0.673	rs11653955	chr17:29033292	C/A	cg14008862	chr17:28927542	LRRC37B2	0.67	5.18	0.3	4.41e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs34779708	0.966	rs1213392	chr10:35430285	C/T	cg03585969	chr10:35415529	CREM	0.67	8.81	0.48	1.66e-16	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs6502050	0.835	rs67106357	chr17:80116826	T/G	cg11859384	chr17:80120422	CCDC57	-0.38	-5.17	-0.3	4.51e-7	Life satisfaction;
CESC	cis	rs7394190	0.748	rs4082339	chr10:75539812	C/T	cg07699608	chr10:75541558	CHCHD1	-0.59	-5.21	-0.3	3.74e-7	Incident atrial fibrillation;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg11438737	chr11:43918796	LOC729799;ALKBH3	-0.5	-6.59	-0.38	2.31e-10	Systemic lupus erythematosus;
CESC	cis	rs6460942	0.915	rs7802454	chr7:12454508	A/G	cg10578991	chr7:12443926	VWDE	-0.5	-5.52	-0.32	7.93e-8	Coronary artery disease;
CESC	cis	rs7208859	0.673	rs8077116	chr17:29140162	A/G	cg14008862	chr17:28927542	LRRC37B2	0.65	5.14	0.3	5.34e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs896854	0.540	rs2011567	chr8:95971920	G/A	cg09323728	chr8:95962352	TP53INP1	-0.38	-8.08	-0.44	2.35e-14	Type 2 diabetes;
CESC	cis	rs1799949	1.000	rs4340367	chr17:41307772	G/A	cg23758822	chr17:41437982	NA	1.03	16.08	0.7	4.57e-41	Menopause (age at onset);
CESC	cis	rs853679	0.517	rs3757185	chr6:28107776	T/A	cg19592336	chr6:28129416	ZNF389	0.62	8.32	0.46	4.64e-15	Depression;
CESC	cis	rs7666738	0.680	rs34267968	chr4:99002574	A/T	cg18180107	chr4:99064573	C4orf37	0.4	5.23	0.31	3.41e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4889855	0.614	rs7221663	chr17:78484166	T/C	cg16591659	chr17:78472290	NA	-0.51	-7.57	-0.42	6.27e-13	Fractional excretion of uric acid;
CESC	cis	rs4566357	0.576	rs10187255	chr2:227913442	T/A	cg05526886	chr2:227700861	RHBDD1	-0.47	-6.27	-0.36	1.45e-9	Coronary artery disease;
CESC	cis	rs7843479	0.582	rs7009693	chr8:21775314	C/T	cg17168535	chr8:21777572	XPO7	0.74	11.9	0.59	1.86e-26	Mean corpuscular volume;
CESC	trans	rs13098911	0.540	rs13069079	chr3:46000870	G/A	cg10236987	chr1:228114221	WNT9A	0.57	6.07	0.35	4.38e-9	Celiac disease;
CESC	cis	rs1005277	0.579	rs1780146	chr10:38517874	C/A	cg00409905	chr10:38381863	ZNF37A	-0.51	-6.79	-0.38	7.54e-11	Extrinsic epigenetic age acceleration;
CESC	cis	rs4481887	0.830	rs9662041	chr1:248484701	A/T	cg00666640	chr1:248458726	OR2T12	0.36	6.17	0.35	2.56e-9	Common traits (Other);
CESC	cis	rs9929218	0.859	rs9936682	chr16:68748223	A/G	cg02972257	chr16:68554789	NA	0.57	6.39	0.37	7.31e-10	Colorectal cancer;
CESC	cis	rs938554	0.784	rs13102218	chr4:9976113	G/T	cg00071950	chr4:10020882	SLC2A9	0.48	5.68	0.33	3.49e-8	Blood metabolite levels;
CESC	cis	rs1322639	0.618	rs9505942	chr6:169591793	T/C	cg04662567	chr6:169592167	NA	-0.48	-5.17	-0.3	4.61e-7	Pulse pressure;
CESC	trans	rs61931739	0.500	rs6488209	chr12:34319309	A/G	cg26384229	chr12:38710491	ALG10B	0.47	6.29	0.36	1.29e-9	Morning vs. evening chronotype;
CESC	trans	rs9951602	0.541	rs56882694	chr18:76647010	C/T	cg02800362	chr5:177631904	HNRNPAB	0.62	8.14	0.45	1.57e-14	Obesity-related traits;
CESC	cis	rs6752107	0.935	rs10199278	chr2:234160669	C/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.49	6.91	0.39	3.59e-11	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs875971	0.862	rs2420173	chr7:65645399	A/T	cg18876405	chr7:65276391	NA	-0.53	-7.38	-0.41	2.09e-12	Aortic root size;
CESC	cis	rs1348850	0.526	rs7607073	chr2:178375065	C/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.69	6.19	0.36	2.22e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs9926296	0.508	rs1558184	chr16:89842374	T/G	cg07648498	chr16:89883185	FANCA	0.5	6.28	0.36	1.41e-9	Vitiligo;
CESC	cis	rs7937682	0.883	rs1611989	chr11:111456299	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.93	-13.47	-0.64	7.49e-32	Primary sclerosing cholangitis;
CESC	cis	rs712039	0.652	rs853200	chr17:35804114	G/A	cg16670864	chr17:35848621	DUSP14	0.44	5.38	0.31	1.63e-7	Tuberculosis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04244056	chr16:28835698	ATXN2L	0.59	6.5	0.37	3.99e-10	Gut microbiome composition (summer);
CESC	cis	rs9611565	0.592	rs5751129	chr22:42015765	C/T	cg17376030	chr22:41985996	PMM1	-0.53	-5.98	-0.34	7.19e-9	Vitiligo;
CESC	cis	rs6121246	0.738	rs6121242	chr20:30410877	T/C	cg13852791	chr20:30311386	BCL2L1	0.81	8.16	0.45	1.33e-14	Mean corpuscular hemoglobin;
CESC	cis	rs1552244	0.935	rs7621551	chr3:10114205	C/T	cg00166722	chr3:10149974	C3orf24	0.53	6.65	0.38	1.64e-10	Alzheimer's disease;
CESC	cis	rs8031584	0.918	rs34331396	chr15:31248736	C/G	cg08109568	chr15:31115862	NA	-0.71	-9.55	-0.51	9.27e-19	Huntington's disease progression;
CESC	cis	rs2880765	0.835	rs12324277	chr15:86041735	G/A	cg19183879	chr15:85880815	NA	-0.25	-5.09	-0.3	6.82e-7	Coronary artery disease;
CESC	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg07092213	chr7:1199455	ZFAND2A	-0.46	-6.35	-0.36	9.42e-10	Longevity;Endometriosis;
CESC	cis	rs798554	1.000	rs798560	chr7:2758309	A/G	cg19717773	chr7:2847554	GNA12	-0.52	-7.46	-0.42	1.23e-12	Height;
CESC	cis	rs1129187	0.837	rs3763236	chr6:42902508	C/T	cg27588902	chr6:42928151	GNMT	0.26	5.25	0.31	3.08e-7	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs9486719	0.947	rs12194971	chr6:96911073	T/C	cg06623918	chr6:96969491	KIAA0776	-0.81	-8.3	-0.45	5.45e-15	Migraine;Coronary artery disease;
CESC	cis	rs1506636	1.000	rs60689684	chr7:123370403	C/T	cg03229431	chr7:123269106	ASB15	0.52	6.69	0.38	1.33e-10	Plateletcrit;Platelet count;
CESC	cis	rs7666738	0.830	rs11097582	chr4:98772201	G/A	cg17366294	chr4:99064904	C4orf37	0.58	8.3	0.45	5.45e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1799949	1.000	rs11659028	chr17:41195025	T/A	cg23758822	chr17:41437982	NA	1.02	14.33	0.66	7.2e-35	Menopause (age at onset);
CESC	cis	rs7917772	0.582	rs12411442	chr10:104349531	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.41	5.64	0.33	4.41e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs7666738	0.830	rs13139024	chr4:99020700	C/T	cg05340658	chr4:99064831	C4orf37	0.82	12.99	0.62	3.34e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2072732	0.821	rs12038530	chr1:2946726	T/A	cg03976712	chr1:2946727	NA	0.32	5.35	0.31	1.9e-7	Plateletcrit;
CESC	trans	rs11148252	0.595	rs9526968	chr13:53240183	T/C	cg18335740	chr13:41363409	SLC25A15	0.51	6.99	0.39	2.17e-11	Lewy body disease;
CESC	cis	rs870825	0.616	rs28445002	chr4:185648977	C/T	cg04058563	chr4:185651563	MLF1IP	0.63	6.96	0.39	2.59e-11	Blood protein levels;
CESC	trans	rs10242455	0.557	rs77997620	chr7:99070415	G/T	cg09045935	chr12:6379348	NA	0.89	7.37	0.41	2.14e-12	Blood metabolite levels;
CESC	cis	rs2228479	0.850	rs17233664	chr16:89810628	C/T	cg06558623	chr16:89946397	TCF25	1.17	9.44	0.5	1.96e-18	Skin colour saturation;
CESC	cis	rs7845219	0.544	rs7001535	chr8:95921090	C/G	cg23172400	chr8:95962367	TP53INP1	-0.37	-6.78	-0.38	7.89e-11	Type 2 diabetes;
CESC	cis	rs1801251	1.000	rs13008942	chr2:233594875	G/A	cg08000102	chr2:233561755	GIGYF2	0.68	9.52	0.5	1.13e-18	Coronary artery disease;
CESC	cis	rs4808199	0.948	rs7259434	chr19:19428805	A/T	cg03709012	chr19:19516395	GATAD2A	1.03	11.72	0.58	7.52e-26	Nonalcoholic fatty liver disease;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg25942178	chr2:85829833	TMEM150A	-0.48	-6.07	-0.35	4.34e-9	Ulcerative colitis;
CESC	cis	rs853679	0.550	rs1233704	chr6:28166923	A/G	cg22143856	chr6:28129313	ZNF389	-0.44	-5.91	-0.34	1.05e-8	Depression;
CESC	cis	rs12701220	0.689	rs12536282	chr7:1115650	C/T	cg26769984	chr7:1090371	C7orf50	0.55	5.73	0.33	2.66e-8	Bronchopulmonary dysplasia;
CESC	cis	rs11696501	0.688	rs6124727	chr20:44325623	T/C	cg11783356	chr20:44313418	WFDC10B	-0.31	-5.09	-0.3	6.94e-7	Brain structure;
CESC	cis	rs142518269	1	rs142518269	chr2:24087095	G/A	cg08917208	chr2:24149416	ATAD2B	1.11	10.18	0.53	9.57e-21	Mean corpuscular hemoglobin;
CESC	cis	rs55823223	0.564	rs936391	chr17:73847799	A/G	cg08125733	chr17:73851984	WBP2	-0.79	-10.7	-0.55	1.88e-22	Psoriasis;
CESC	cis	rs62229266	0.835	rs998384	chr21:37445526	G/C	cg12218747	chr21:37451666	NA	-0.46	-6.35	-0.36	9.06e-10	Mitral valve prolapse;
CESC	cis	rs7552404	1.000	rs7552404	chr1:76135946	A/G	cg03433033	chr1:76189801	ACADM	0.69	8.23	0.45	8.78e-15	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs832540	0.966	rs252923	chr5:56205662	T/G	cg14703610	chr5:56206110	C5orf35	0.5	6.49	0.37	4.31e-10	Coronary artery disease;
CESC	cis	rs9894429	0.682	rs7406360	chr17:79591545	G/A	cg21984481	chr17:79567631	NPLOC4	-0.56	-8.99	-0.48	4.98e-17	Eye color traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21932983	chr1:6321378	GPR153	0.54	6.61	0.38	2.1e-10	Gut microbiome composition (summer);
CESC	trans	rs916888	0.610	rs199530	chr17:44836653	C/T	cg01341218	chr17:43662625	NA	-0.53	-7.32	-0.41	3.05e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs1534166	0.602	rs3817524	chr3:133526403	C/T	cg27366882	chr3:133540807	NA	-0.28	-5.1	-0.3	6.43e-7	Alcohol consumption (transferrin glycosylation);
CESC	cis	rs9682041	0.696	rs10936626	chr3:170095019	G/A	cg11886554	chr3:170076028	SKIL	0.7	6.5	0.37	3.93e-10	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CESC	cis	rs6540559	1.000	rs742215	chr1:209961023	A/T	cg22442454	chr1:209979470	IRF6	0.43	5.13	0.3	5.62e-7	Cleft lip with or without cleft palate;
CESC	cis	rs2842992	0.789	rs2146163	chr6:160224346	T/C	cg11366901	chr6:160182831	ACAT2	0.76	9.16	0.49	1.45e-17	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs698833	0.926	rs1085485	chr2:44616728	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.46	5.74	0.33	2.54e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs1552244	0.572	rs58862481	chr3:10164308	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.68	-7.37	-0.41	2.18e-12	Alzheimer's disease;
CESC	cis	rs6430585	0.528	rs12476127	chr2:136763242	A/G	cg07169764	chr2:136633963	MCM6	1.3	19.87	0.77	2.02e-54	Corneal structure;
CESC	cis	rs6062302	0.545	rs2297430	chr20:62229244	T/C	cg09650180	chr20:62225654	GMEB2	-0.81	-9.23	-0.49	8.68e-18	Glioblastoma;
CESC	cis	rs1020064	0.636	rs1529974	chr2:105927996	T/C	cg02079111	chr2:105885981	TGFBRAP1	0.37	5.13	0.3	5.61e-7	AIDS;
CESC	cis	rs561341	0.609	rs9906443	chr17:30185565	C/T	cg13647721	chr17:30228624	UTP6	-0.72	-8.19	-0.45	1.13e-14	Hip circumference adjusted for BMI;
CESC	cis	rs6964587	0.967	rs10953065	chr7:91808915	A/G	cg17063962	chr7:91808500	NA	-0.58	-8.04	-0.44	2.92e-14	Breast cancer;
CESC	cis	rs7267979	0.966	rs6050567	chr20:25354561	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.88	-18.13	-0.74	2.42e-48	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs9389248	0.737	rs56358308	chr6:135306980	A/T	cg24558204	chr6:135376177	HBS1L	0.7	9.61	0.51	5.93e-19	High light scatter reticulocyte percentage of red cells;
CESC	cis	rs7959452	0.557	rs7980883	chr12:69778914	C/T	cg20891283	chr12:69753455	YEATS4	0.91	15.03	0.68	2.41e-37	Blood protein levels;
CESC	cis	rs36051895	0.632	rs11793886	chr9:5125469	A/G	cg02405213	chr9:5042618	JAK2	-0.5	-5.91	-0.34	1.05e-8	Pediatric autoimmune diseases;
CESC	cis	rs7659604	0.517	rs56311153	chr4:122729685	T/C	cg20573242	chr4:122745356	CCNA2	0.62	7.47	0.42	1.14e-12	Type 2 diabetes;
CESC	cis	rs6087990	0.769	rs17123658	chr20:31390840	C/A	cg13636640	chr20:31349939	DNMT3B	0.76	11.67	0.58	1.11e-25	Ulcerative colitis;
CESC	cis	rs6570726	0.791	rs1280275	chr6:145892402	C/T	cg23711669	chr6:146136114	FBXO30	0.97	14.77	0.67	2.05e-36	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4975709	0.589	rs4975746	chr5:1861069	G/A	cg07747251	chr5:1868357	NA	0.32	5.26	0.31	2.94e-7	Cardiovascular disease risk factors;
CESC	cis	rs9815354	1.000	rs56121764	chr3:41883975	T/C	cg03022575	chr3:42003672	ULK4	0.58	6.01	0.35	5.96e-9	Pulse pressure;Diastolic blood pressure;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04593571	chr2:85361052	TCF7L1	0.52	6.12	0.35	3.38e-9	Gut microbiome composition (summer);
CESC	cis	rs4253772	0.591	rs6519993	chr22:46656479	A/G	cg09491104	chr22:46646882	C22orf40	-0.6	-9.2	-0.49	1.09e-17	LDL cholesterol;Cholesterol, total;
CESC	cis	rs2072732	0.656	rs113272167	chr1:2954051	C/T	cg15211996	chr1:2936768	ACTRT2	0.34	5.78	0.33	2.08e-8	Plateletcrit;
CESC	cis	rs7208859	0.623	rs3794796	chr17:29130880	G/C	cg14008862	chr17:28927542	LRRC37B2	0.69	5.36	0.31	1.79e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs6693567	0.565	rs471657	chr1:150276461	G/A	cg09579323	chr1:150459698	TARS2	-0.45	-5.85	-0.34	1.46e-8	Migraine;
CESC	cis	rs4595586	0.545	rs3911798	chr12:39389901	A/G	cg26384229	chr12:38710491	ALG10B	0.54	7.57	0.42	6.13e-13	Morning vs. evening chronotype;
CESC	cis	rs3540	0.597	rs3539	chr15:91045419	G/T	cg22089800	chr15:90895588	ZNF774	-0.65	-8.98	-0.48	5.06e-17	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs3747547	0.685	rs72726094	chr9:38126746	G/T	cg13774184	chr9:37916125	SHB	-0.63	-5.21	-0.3	3.86e-7	Metabolite levels (Dihydroxy docosatrienoic acid);
CESC	cis	rs637571	0.607	rs589253	chr11:65693080	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.41	5.75	0.33	2.42e-8	Eosinophil percentage of white cells;
CESC	cis	rs6121246	0.559	rs6087782	chr20:30391580	C/T	cg13852791	chr20:30311386	BCL2L1	0.83	10.8	0.55	8.95e-23	Mean corpuscular hemoglobin;
CESC	cis	rs1552244	0.706	rs279545	chr3:9972493	A/G	cg16606324	chr3:10149918	C3orf24	0.43	5.97	0.34	7.65e-9	Alzheimer's disease;
CESC	cis	rs10078	0.515	rs6872510	chr5:481610	T/C	cg08916839	chr5:415575	AHRR	0.6	6.92	0.39	3.35e-11	Fat distribution (HIV);
CESC	cis	rs8017423	0.967	rs55894943	chr14:90714799	A/G	cg14092571	chr14:90743983	NA	-0.58	-8.71	-0.47	3.33e-16	Mortality in heart failure;
CESC	cis	rs11792861	0.888	rs11794648	chr9:111829792	C/T	cg05043794	chr9:111880884	C9orf5	-0.38	-6.43	-0.37	5.83e-10	Menarche (age at onset);
CESC	cis	rs1348850	0.567	rs3770005	chr2:178528874	A/G	cg23306229	chr2:178417860	TTC30B	0.53	6.93	0.39	3.18e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs807669	0.548	rs723414	chr22:19185736	G/A	cg02655711	chr22:19163373	SLC25A1	0.7	10.53	0.54	6.71e-22	Metabolite levels;
CESC	cis	rs17345786	0.906	rs12638137	chr3:101150964	C/T	cg12386194	chr3:101231763	SENP7	0.61	6.47	0.37	4.81e-10	Colonoscopy-negative controls vs population controls;
CESC	cis	rs57506017	0.585	rs1468804	chr7:12275508	A/G	cg23422036	chr7:12250390	TMEM106B	0.39	5.41	0.32	1.41e-7	Neuroticism;
CESC	cis	rs17209837	0.920	rs4148817	chr7:87087397	C/G	cg00919237	chr7:87102261	ABCB4	-0.5	-5.83	-0.34	1.6e-8	Gallbladder cancer;
CESC	cis	rs4843747	0.671	rs72818576	chr16:88111019	C/G	cg03395651	chr16:88107091	BANP	0.47	5.43	0.32	1.26e-7	Menopause (age at onset);
CESC	cis	rs2228479	0.850	rs117285117	chr16:89910250	T/G	cg04013166	chr16:89971882	TCF25	0.72	5.75	0.33	2.41e-8	Skin colour saturation;
CESC	cis	rs2180341	0.680	rs9388554	chr6:127576234	C/G	cg27446573	chr6:127587934	RNF146	0.83	11.71	0.58	8.67e-26	Breast cancer;
CESC	cis	rs6736093	0.763	rs4848973	chr2:112790562	G/A	cg12686935	chr2:112915763	FBLN7	-0.41	-5.45	-0.32	1.13e-7	Coronary artery disease;
CESC	cis	rs4819052	1.000	rs733739	chr21:46666210	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.58	7.02	0.4	1.87e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs8077577	0.708	rs3829590	chr17:18134265	C/A	cg16794390	chr17:18148240	FLII	-0.44	-6.58	-0.37	2.46e-10	Obesity-related traits;
CESC	cis	rs1808579	0.935	rs4800162	chr18:21117419	G/T	cg14672496	chr18:21087552	C18orf8	0.39	6.05	0.35	5.03e-9	Hip circumference;Body mass index;BMI (adjusted for smoking behaviour);
CESC	cis	rs6460942	1.000	rs79659770	chr7:12326371	T/C	cg20607287	chr7:12443886	VWDE	-0.8	-8.57	-0.47	8.66e-16	Coronary artery disease;
CESC	cis	rs6087990	0.806	rs4911257	chr20:31359574	T/C	cg13636640	chr20:31349939	DNMT3B	0.79	12.0	0.59	8.62e-27	Ulcerative colitis;
CESC	cis	rs7412746	0.658	rs17660092	chr1:150797748	T/C	cg04414720	chr1:150670196	GOLPH3L	0.55	7.44	0.42	1.44e-12	Melanoma;
CESC	cis	rs7078219	1.000	rs6584278	chr10:101278099	C/T	cg09788492	chr10:101292477	NKX2-3	0.28	5.16	0.3	4.74e-7	Dental caries;
CESC	cis	rs7089973	0.549	rs7094440	chr10:116745408	T/C	cg23260525	chr10:116636907	FAM160B1	0.3	5.24	0.31	3.21e-7	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs10911363	0.592	rs2702182	chr1:183516440	C/T	cg09173681	chr1:183549694	NCF2	0.51	7.56	0.42	6.81e-13	Systemic lupus erythematosus;
CESC	cis	rs523522	0.962	rs2168319	chr12:120933217	C/T	cg12219531	chr12:120966889	COQ5	0.75	9.79	0.52	1.59e-19	High light scatter reticulocyte count;
CESC	cis	rs13064411	0.696	rs6808394	chr3:113122524	T/G	cg18753928	chr3:113234510	CCDC52	-0.5	-5.51	-0.32	8.64e-8	Response to simvastatin treatment (PCSK9 protein level change);
CESC	cis	rs7959452	0.718	rs10878963	chr12:69717166	T/G	cg20891283	chr12:69753455	YEATS4	0.55	7.32	0.41	2.96e-12	Blood protein levels;
CESC	cis	rs7560272	0.723	rs7566315	chr2:73791808	C/T	cg20560298	chr2:73613845	ALMS1	-0.5	-7.19	-0.4	6.73e-12	Schizophrenia;
CESC	cis	rs208520	0.955	rs208538	chr6:66964492	C/G	cg07460842	chr6:66804631	NA	-0.8	-9.14	-0.49	1.64e-17	Exhaled nitric oxide output;
CESC	cis	rs262150	0.842	rs2657398	chr7:158784911	T/C	cg09640425	chr7:158790006	NA	-0.38	-5.92	-0.34	9.68e-9	Facial morphology (factor 20);
CESC	cis	rs3820928	0.904	rs2894623	chr2:227766112	T/C	cg05526886	chr2:227700861	RHBDD1	-0.44	-5.65	-0.33	4.24e-8	Pulmonary function;
CESC	cis	rs3540	0.512	rs11633872	chr15:91080512	G/A	cg22089800	chr15:90895588	ZNF774	-0.6	-7.73	-0.43	2.22e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs4713118	0.662	rs149947	chr6:27972433	A/T	cg19592336	chr6:28129416	ZNF389	0.53	7.02	0.4	1.85e-11	Parkinson's disease;
CESC	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg13877285	chr8:26148873	PPP2R2A	0.5	6.26	0.36	1.52e-9	Myopia (pathological);
CESC	trans	rs7070678	0.905	rs10826650	chr10:29814284	T/C	cg06477056	chr5:175110609	HRH2	0.35	6.61	0.38	2.15e-10	Platelet thrombus formation;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg05463257	chr3:182782445	MCCC1	0.45	6.27	0.36	1.45e-9	Fibrinogen levels;
CESC	cis	rs2303759	0.709	rs7256363	chr19:49827804	C/T	cg22307029	chr19:49891270	CCDC155	0.55	6.0	0.35	6.6e-9	Multiple sclerosis;
CESC	cis	rs7254114	0.578	rs6511727	chr19:11315817	G/T	cg02815516	chr19:11306319	KANK2	-0.4	-6.42	-0.37	6.31e-10	Immature fraction of reticulocytes;
CESC	cis	rs10504229	0.679	rs16921677	chr8:58052431	T/C	cg24829409	chr8:58192753	C8orf71	-0.5	-6.25	-0.36	1.62e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs7560272	0.538	rs7599453	chr2:73937901	T/G	cg20560298	chr2:73613845	ALMS1	0.42	5.84	0.34	1.56e-8	Schizophrenia;
CESC	cis	rs924607	0.898	rs1697990	chr5:626278	A/G	cg09021430	chr5:549028	NA	0.36	7.06	0.4	1.49e-11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs1557765	0.527	rs10832782	chr11:17397273	G/C	cg15432903	chr11:17409602	KCNJ11	0.42	6.07	0.35	4.32e-9	Body mass index;Social communication problems;
CESC	cis	rs4563143	0.514	rs112540771	chr19:29316100	C/T	cg04546413	chr19:29218101	NA	0.48	6.08	0.35	4.28e-9	Methadone dose in opioid dependence;
CESC	cis	rs7666738	0.570	rs11097612	chr4:99079772	T/C	cg24818145	chr4:99064322	C4orf37	0.39	5.13	0.3	5.73e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs12142240	0.698	rs72677587	chr1:46813982	G/A	cg00530320	chr1:46809349	NSUN4	0.58	7.89	0.44	8.17e-14	Menopause (age at onset);
CESC	cis	rs4631830	0.900	rs10763588	chr10:51539762	G/T	cg16070123	chr10:51489643	NA	-0.34	-5.03	-0.3	9.19e-7	Prostate-specific antigen levels;
CESC	cis	rs13064411	0.696	rs9836396	chr3:113184282	T/C	cg18753928	chr3:113234510	CCDC52	-0.46	-5.49	-0.32	9.43e-8	Response to simvastatin treatment (PCSK9 protein level change);
CESC	cis	rs796364	0.625	rs1369843	chr2:201088171	A/G	cg23649088	chr2:200775458	C2orf69	0.51	5.78	0.33	2.1e-8	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05732876	chr22:22337374	TOP3B	-0.51	-6.03	-0.35	5.62e-9	Gut microbiome composition (summer);
CESC	cis	rs7592578	0.713	rs60915953	chr2:191331304	G/C	cg10560079	chr2:191398806	TMEM194B	-0.65	-5.65	-0.33	4.11e-8	Diastolic blood pressure;
CESC	cis	rs798554	0.679	rs2533877	chr7:2882421	G/A	cg19346786	chr7:2764209	NA	-0.36	-5.17	-0.3	4.71e-7	Height;
CESC	cis	rs9649213	0.593	rs13246942	chr7:97915021	C/T	cg21770322	chr7:97807741	LMTK2	0.58	8.64	0.47	5.26e-16	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs1355223	0.506	rs12294339	chr11:34860199	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.44	-5.39	-0.31	1.53e-7	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs9354308	0.867	rs2802051	chr6:66536403	C/T	cg07460842	chr6:66804631	NA	0.58	6.6	0.38	2.28e-10	Metabolite levels;
CESC	cis	rs7829975	0.871	rs7829826	chr8:8578120	T/A	cg15556689	chr8:8085844	FLJ10661	-0.45	-5.59	-0.33	5.5e-8	Mood instability;
CESC	cis	rs959260	0.748	rs4789178	chr17:73368242	C/G	cg20590849	chr17:73267439	MIF4GD	-0.54	-6.32	-0.36	1.13e-9	Systemic lupus erythematosus;
CESC	cis	rs2235642	0.701	rs2281230	chr16:1601767	T/C	cg09080909	chr16:1797204	MAPK8IP3	-0.42	-5.82	-0.34	1.69e-8	Coronary artery disease;
CESC	cis	rs6088590	0.931	rs12625149	chr20:33425812	A/C	cg06115741	chr20:33292138	TP53INP2	-0.57	-7.1	-0.4	1.12e-11	Coronary artery disease;
CESC	cis	rs9611565	0.559	rs132765	chr22:42008068	A/G	cg06634786	chr22:41940651	POLR3H	0.61	6.03	0.35	5.57e-9	Vitiligo;
CESC	cis	rs12497850	0.931	rs62262517	chr3:49134914	T/G	cg06212747	chr3:49208901	KLHDC8B	0.7	9.15	0.49	1.59e-17	Parkinson's disease;
CESC	cis	rs875971	0.895	rs6460300	chr7:65952924	A/G	cg18876405	chr7:65276391	NA	0.5	6.5	0.37	3.98e-10	Aortic root size;
CESC	cis	rs2573652	1.000	rs2581346	chr15:100514178	T/G	cg09918751	chr15:100517450	ADAMTS17	-0.39	-7.61	-0.42	4.66e-13	Height;
CESC	cis	rs2075371	0.932	rs2544215	chr7:133987896	T/C	cg11752832	chr7:134001865	SLC35B4	0.55	7.19	0.4	6.74e-12	Mean platelet volume;
CESC	cis	rs13382862	0.895	rs13385499	chr2:20882413	A/G	cg10553204	chr2:20871195	GDF7	-0.37	-5.18	-0.3	4.43e-7	Abdominal aortic aneurysm;
CESC	cis	rs12122100	0.526	rs12122534	chr1:146504399	A/G	cg03526459	chr1:146549940	NA	0.36	5.71	0.33	3e-8	HIV-1 control;
CESC	cis	rs17376456	0.825	rs10038831	chr5:93124115	C/T	cg25358565	chr5:93447407	FAM172A	1.1	10.84	0.55	6.88e-23	Diabetic retinopathy;
CESC	cis	rs6456156	0.742	rs6456157	chr6:167527818	C/A	cg07741184	chr6:167504864	NA	-0.31	-5.18	-0.3	4.44e-7	Primary biliary cholangitis;
CESC	cis	rs853679	0.517	rs9393886	chr6:28050039	T/G	cg23161317	chr6:28129485	ZNF389	0.5	6.31	0.36	1.19e-9	Depression;
CESC	cis	rs9287719	0.839	rs11683335	chr2:10756665	C/G	cg00105475	chr2:10696890	NA	0.37	5.33	0.31	2.11e-7	Prostate cancer;
CESC	cis	rs477692	1.000	rs516704	chr10:131419879	G/A	cg05714579	chr10:131428358	MGMT	0.46	6.16	0.35	2.67e-9	Response to temozolomide;
CESC	cis	rs644799	1.000	rs494829	chr11:95571750	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.69	8.63	0.47	5.73e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs7590368	0.673	rs56140102	chr2:10943256	T/C	cg15705551	chr2:10952987	PDIA6	0.54	5.2	0.3	4.09e-7	Educational attainment (years of education);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg09941266	chr16:3285496	ZNF200	0.5	6.54	0.37	3.11e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs1941023	0.503	rs4939348	chr11:60135871	A/C	cg08716584	chr11:60157161	MS4A7	-0.54	-8.74	-0.47	2.67e-16	Congenital heart disease (maternal effect);
CESC	cis	rs559928	0.606	rs11231710	chr11:63925743	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.66	5.92	0.34	9.68e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CESC	cis	rs2841277	0.708	rs10083490	chr14:105402418	A/G	cg17340268	chr14:105411764	AHNAK2	0.5	6.7	0.38	1.25e-10	Rheumatoid arthritis;
CESC	cis	rs9811920	0.638	rs2452321	chr3:99638836	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.4	-5.38	-0.31	1.67e-7	Axial length;
CESC	trans	rs853679	0.546	rs34371502	chr6:28081758	T/C	cg06606381	chr12:133084897	FBRSL1	-1.1	-8.36	-0.46	3.51e-15	Depression;
CESC	cis	rs10751667	0.600	rs14346	chr11:1011829	T/C	cg20946044	chr11:1010712	AP2A2	-0.48	-6.33	-0.36	1.04e-9	Alzheimer's disease (late onset);
CESC	cis	rs6582630	0.555	rs2090785	chr12:38424342	G/A	cg13010199	chr12:38710504	ALG10B	0.46	6.0	0.35	6.56e-9	Drug-induced liver injury (flucloxacillin);
CESC	trans	rs11098499	0.657	rs71614442	chr4:120379346	C/T	cg25214090	chr10:38739885	LOC399744	0.7	9.86	0.52	9.48e-20	Corneal astigmatism;
CESC	cis	rs1003719	0.788	rs9977602	chr21:38450650	G/T	cg10648535	chr21:38446584	PIGP;TTC3	0.62	8.64	0.47	5.56e-16	Eye color traits;
CESC	cis	rs6547741	0.904	rs2384628	chr2:27774702	T/G	cg21248554	chr2:27665150	KRTCAP3	0.25	5.16	0.3	4.77e-7	Oral cavity cancer;
CESC	cis	rs7208859	0.524	rs28760584	chr17:29141017	G/A	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.1e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs6982240	0.514	rs1865247	chr8:142274654	A/T	cg00131261	chr8:142287264	NA	-0.53	-7.28	-0.41	3.72e-12	Tonsillectomy;
CESC	cis	rs6964587	1.000	rs36021614	chr7:91717490	C/G	cg01689657	chr7:91764605	CYP51A1	0.28	5.12	0.3	5.88e-7	Breast cancer;
CESC	cis	rs1692580	0.774	rs10797416	chr1:2182342	T/C	cg04315214	chr1:2043799	PRKCZ	-0.36	-5.09	-0.3	6.87e-7	Coronary artery disease;
CESC	cis	rs875971	0.505	rs2462573	chr7:65507392	C/T	cg25985355	chr7:65971099	NA	0.32	5.26	0.31	2.95e-7	Aortic root size;
CESC	trans	rs79976124	0.760	rs74295030	chr6:66654441	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.76	8.75	0.47	2.61e-16	Type 2 diabetes;
CESC	cis	rs595982	0.527	rs12151238	chr19:49368613	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.71	-7.97	-0.44	4.79e-14	Red cell distribution width;
CESC	cis	rs763014	0.898	rs1981484	chr16:630710	A/G	cg09263875	chr16:632152	PIGQ	0.67	11.14	0.56	6.6e-24	Height;
CESC	cis	rs6952808	1.000	rs12540579	chr7:1882227	C/A	cg05863683	chr7:1912471	MAD1L1	0.36	5.35	0.31	1.86e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs1865721	0.771	rs724764	chr18:73139742	C/T	cg26385618	chr18:73139727	C18orf62	-0.53	-8.6	-0.47	7.15e-16	Intelligence;
CESC	cis	rs2075371	0.579	rs11766422	chr7:134018160	T/C	cg20476274	chr7:133979776	SLC35B4	0.58	7.78	0.43	1.64e-13	Mean platelet volume;
CESC	cis	rs344364	0.511	rs2906912	chr16:1953151	G/A	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.53	-5.94	-0.34	9.01e-9	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs2991971	0.967	rs60608374	chr1:46008913	G/A	cg05343316	chr1:45956843	TESK2	-0.5	-6.41	-0.37	6.55e-10	High light scatter reticulocyte count;
CESC	cis	rs1448094	0.512	rs11832503	chr12:86240797	A/G	cg02569458	chr12:86230093	RASSF9	0.5	7.53	0.42	7.91e-13	Major depressive disorder;
CESC	cis	rs1046896	0.514	rs67735447	chr17:80823042	G/T	cg19046167	chr17:80928561	B3GNTL1	0.46	5.58	0.32	5.84e-8	Glycated hemoglobin levels;
CESC	cis	rs9486719	1.000	rs9373978	chr6:97056255	T/C	cg06623918	chr6:96969491	KIAA0776	-0.82	-8.4	-0.46	2.77e-15	Migraine;Coronary artery disease;
CESC	cis	rs12497850	0.966	rs6792510	chr3:48723302	G/C	cg06212747	chr3:49208901	KLHDC8B	0.61	7.79	0.43	1.48e-13	Parkinson's disease;
CESC	cis	rs1008375	0.966	rs11722132	chr4:17697217	T/C	cg16339924	chr4:17578868	LAP3	0.59	7.4	0.41	1.83e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs1050631	0.657	rs1789551	chr18:33716092	G/A	cg25426722	chr18:33708991	SLC39A6;ELP2	0.59	8.21	0.45	9.51e-15	Esophageal squamous cell cancer (length of survival);
CESC	cis	rs1448094	0.512	rs11117060	chr12:86250788	G/T	cg19622623	chr12:86230825	RASSF9	0.47	6.01	0.35	6.16e-9	Major depressive disorder;
CESC	cis	rs7666738	0.830	rs28687737	chr4:99009226	G/A	cg03467027	chr4:99064603	C4orf37	0.44	5.63	0.33	4.57e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7640424	0.929	rs17828045	chr3:107821546	A/C	cg09227934	chr3:107805635	CD47	-0.42	-5.68	-0.33	3.6e-8	Body mass index;
CESC	cis	rs2228479	0.850	rs11076624	chr16:89855749	T/C	cg19635926	chr16:89946313	TCF25	0.67	5.08	0.3	7.19e-7	Skin colour saturation;
CESC	cis	rs6089584	1.000	rs6142910	chr20:60562181	C/A	cg24733560	chr20:60626293	TAF4	0.4	5.77	0.33	2.15e-8	Body mass index;
CESC	cis	rs7927771	0.524	rs11039431	chr11:47872012	G/T	cg20307385	chr11:47447363	PSMC3	0.62	8.75	0.47	2.56e-16	Subjective well-being;
CESC	cis	rs10504229	0.906	rs72650894	chr8:58179734	C/T	cg22535103	chr8:58192502	C8orf71	-1.06	-13.3	-0.63	2.88e-31	Developmental language disorder (linguistic errors);
CESC	cis	rs68170813	0.599	rs11769901	chr7:106958505	G/A	cg02696742	chr7:106810147	HBP1	-0.53	-5.04	-0.3	8.64e-7	Coronary artery disease;
CESC	cis	rs1008375	1.000	rs6449319	chr4:17640283	T/A	cg15017067	chr4:17643749	FAM184B	0.39	5.46	0.32	1.07e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs933688	1.000	rs60513756	chr5:90727692	A/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.12	12.34	0.6	6.14e-28	Smoking behavior;
CESC	cis	rs2239547	0.657	rs13072536	chr3:52861211	A/T	cg11645453	chr3:52864694	ITIH4	0.32	5.89	0.34	1.15e-8	Schizophrenia;
CESC	cis	rs7520050	0.966	rs61783200	chr1:46297403	T/C	cg24296786	chr1:45957014	TESK2	0.42	5.39	0.31	1.6e-7	Red blood cell count;Reticulocyte count;
CESC	cis	rs17854409	0.803	rs3210314	chr20:61472117	C/A	cg05147244	chr20:61493195	TCFL5	0.97	6.5	0.37	4e-10	Obesity-related traits;
CESC	cis	rs1799949	1.000	rs8176202	chr17:41230228	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.64	8.68	0.47	4.07e-16	Menopause (age at onset);
CESC	cis	rs116095464	0.558	rs9312978	chr5:221930	C/G	cg22496380	chr5:211416	CCDC127	-0.96	-10.08	-0.53	1.95e-20	Breast cancer;
CESC	cis	rs6741892	0.536	rs13024840	chr2:38895920	T/A	cg05604112	chr2:38893237	GALM	-0.53	-6.98	-0.39	2.36e-11	5-HTT brain serotonin transporter levels;
CESC	cis	rs3785574	0.743	rs2727334	chr17:61969063	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	7.37	0.41	2.17e-12	Height;
CESC	cis	rs6089829	0.962	rs6062776	chr20:61663736	A/G	cg16240275	chr20:61666158	NCRNA00029	0.5	8.97	0.48	5.67e-17	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg01021483	chr22:35820284	MCM5	0.45	6.43	0.37	6.07e-10	Fibrinogen levels;
CESC	cis	rs2235544	0.579	rs1537323	chr1:54482523	G/T	cg09175620	chr1:54484536	LDLRAD1	0.29	5.17	0.3	4.53e-7	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
CESC	cis	rs34779708	0.966	rs34605125	chr10:35411246	A/G	cg04310649	chr10:35416472	CREM	-0.52	-6.23	-0.36	1.85e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs739401	0.572	rs739399	chr11:3016452	A/G	cg08508325	chr11:3079039	CARS	-0.54	-10.51	-0.54	7.98e-22	Longevity;
CESC	cis	rs7552404	0.731	rs11161836	chr1:76354333	C/T	cg03433033	chr1:76189801	ACADM	0.59	5.67	0.33	3.67e-8	Blood metabolite levels;Acylcarnitine levels;
CESC	trans	rs1728785	0.818	rs1814299	chr16:68581332	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.61	7.49	0.42	1.04e-12	Ulcerative colitis;
CESC	cis	rs7772486	0.719	rs4391282	chr6:146276780	A/T	cg05347473	chr6:146136440	FBXO30	-0.52	-6.75	-0.38	9.24e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7394190	0.748	rs12573448	chr10:75504512	T/G	cg07699608	chr10:75541558	CHCHD1	0.64	5.21	0.3	3.8e-7	Incident atrial fibrillation;
CESC	cis	rs7130144	0.541	rs7936388	chr11:130462511	T/C	cg26307797	chr11:130446613	NA	-0.76	-6.78	-0.38	7.92e-11	Urate levels in lean individuals;
CESC	cis	rs11608355	0.521	rs7972346	chr12:109808771	C/G	cg19025524	chr12:109796872	NA	0.5	7.3	0.41	3.27e-12	Neuroticism;
CESC	cis	rs3617	0.625	rs3774364	chr3:52863605	G/A	cg07507251	chr3:52567010	NT5DC2	0.33	5.79	0.34	1.96e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
CESC	cis	rs1986734	0.576	rs4493564	chr4:77420407	A/G	cg20311846	chr4:77356250	SHROOM3	-0.28	-5.68	-0.33	3.62e-8	Eosinophilic esophagitis (pediatric);Metabolite levels (small molecules and protein measures);
CESC	cis	rs7188697	0.922	rs9923491	chr16:58603176	T/G	cg02549819	chr16:58548995	SETD6	0.43	5.4	0.31	1.51e-7	QT interval;
CESC	cis	rs6430585	0.583	rs12373779	chr2:136586840	A/C	cg07169764	chr2:136633963	MCM6	1.26	18.12	0.74	2.76e-48	Corneal structure;
CESC	cis	rs4253772	0.513	rs9306512	chr22:46716603	T/C	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.77	9.33	0.5	4.27e-18	LDL cholesterol;Cholesterol, total;
CESC	cis	rs4665809	0.590	rs6730317	chr2:26419482	C/T	cg04944784	chr2:26401820	FAM59B	-0.9	-10.54	-0.54	6.5e-22	Gut microbiome composition (summer);
CESC	cis	rs2404602	0.552	rs11630185	chr15:76959783	A/T	cg06336613	chr15:77223807	RCN2	0.44	5.42	0.32	1.37e-7	Blood metabolite levels;
CESC	cis	rs1862618	0.853	rs43184	chr5:56141777	G/C	cg12311346	chr5:56204834	C5orf35	-0.74	-8.76	-0.47	2.43e-16	Initial pursuit acceleration;
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg26708280	chr2:190649305	PMS1;ORMDL1	-0.51	-7.39	-0.41	1.98e-12	Vertical cup-disc ratio;
CESC	cis	rs13108904	0.539	rs11247997	chr4:1361057	T/C	cg24496475	chr4:1400189	NA	0.33	5.05	0.3	8.4e-7	Obesity-related traits;
CESC	cis	rs9487051	0.836	rs9487036	chr6:109607449	C/T	cg12927641	chr6:109611667	NA	-0.43	-6.7	-0.38	1.22e-10	Reticulocyte fraction of red cells;
CESC	cis	rs4253772	0.591	rs11703245	chr22:46684890	A/G	cg18190219	chr22:46762943	CELSR1	-0.58	-5.33	-0.31	2.14e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs897984	0.762	rs4889604	chr16:30985994	G/T	cg02466173	chr16:30829666	NA	0.48	7.99	0.44	4.09e-14	Dementia with Lewy bodies;
CESC	cis	rs35306767	0.761	rs11253540	chr10:1011958	C/T	cg26597838	chr10:835615	NA	-0.75	-7.28	-0.41	3.88e-12	Eosinophil percentage of granulocytes;
CESC	cis	rs5769765	0.773	rs9616208	chr22:50313359	G/A	cg02269571	chr22:50332266	NA	-0.58	-7.2	-0.4	6.05e-12	Schizophrenia;
CESC	cis	rs6963495	0.745	rs56239334	chr7:105165351	G/A	cg13798780	chr7:105162888	PUS7	0.78	8.06	0.44	2.68e-14	Bipolar disorder (body mass index interaction);
CESC	cis	rs1003719	0.751	rs10154032	chr21:38453459	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.62	8.67	0.47	4.41e-16	Eye color traits;
CESC	cis	rs644799	0.511	rs1016030	chr11:95472693	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.46	5.88	0.34	1.25e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs2836950	0.565	rs2150414	chr21:40614988	A/G	cg11644478	chr21:40555479	PSMG1	-0.55	-7.38	-0.41	2.08e-12	Menarche (age at onset);
CESC	cis	rs55794721	0.509	rs2375313	chr1:25748235	G/A	cg12412775	chr1:25698385	RHCE	-0.29	-5.21	-0.3	3.87e-7	Plateletcrit;Mean corpuscular volume;
CESC	cis	rs9611565	0.802	rs73176692	chr22:41785735	G/A	cg06634786	chr22:41940651	POLR3H	-0.72	-7.51	-0.42	9.19e-13	Vitiligo;
CESC	cis	rs1552244	0.935	rs66493421	chr3:10092569	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.75	-8.3	-0.45	5.44e-15	Alzheimer's disease;
CESC	cis	rs360071	0.528	rs360097	chr1:226065755	C/A	cg17950169	chr1:226067900	TMEM63A	0.4	6.06	0.35	4.65e-9	Response to radiotherapy in prostate cancer (toxicity, rectal bleeding);
CESC	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg05457628	chr5:178986728	RUFY1	-0.55	-8.4	-0.46	2.75e-15	Lung cancer;
CESC	cis	rs801193	1.000	rs62466793	chr7:66191517	G/A	cg06456125	chr7:65229604	NA	0.4	5.23	0.31	3.51e-7	Aortic root size;
CESC	cis	rs9611565	0.512	rs5751147	chr22:42139054	G/A	cg03806693	chr22:41940476	POLR3H	1.16	13.59	0.64	2.85e-32	Vitiligo;
CESC	cis	rs2456568	0.548	rs10466334	chr11:93663512	A/G	cg26875233	chr11:93583750	C11orf90	-0.32	-5.81	-0.34	1.77e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
CESC	cis	rs4555082	0.874	rs760270	chr14:105737785	A/G	cg13114125	chr14:105738426	BRF1	-0.9	-11.23	-0.57	3.37e-24	Mean platelet volume;Platelet distribution width;
CESC	cis	rs1218582	0.774	rs11264284	chr1:154875793	C/T	cg16680214	chr1:154839983	KCNN3	-0.52	-8.09	-0.45	2.12e-14	Prostate cancer;
CESC	cis	rs4713118	0.662	rs149946	chr6:27970031	A/C	cg26335602	chr6:28129616	ZNF389	-0.47	-6.02	-0.35	5.75e-9	Parkinson's disease;
CESC	cis	rs1218582	0.772	rs10908445	chr1:154849590	A/G	cg06221963	chr1:154839813	KCNN3	0.66	11.67	0.58	1.11e-25	Prostate cancer;
CESC	cis	rs10214930	0.697	rs7806169	chr7:27907593	A/G	cg05786569	chr7:27702416	HIBADH	-0.44	-5.3	-0.31	2.42e-7	Hypospadias;
CESC	cis	rs12950390	0.853	rs4793647	chr17:45854090	G/C	cg00777063	chr17:45855553	NA	-0.39	-5.74	-0.33	2.62e-8	IgG glycosylation;
CESC	cis	rs2066819	0.818	rs773652	chr12:56674766	G/A	cg26734620	chr12:56694298	CS	-0.93	-9.55	-0.51	9.4e-19	Psoriasis vulgaris;
CESC	cis	rs17711722	0.640	rs13237956	chr7:65318029	G/A	cg18876405	chr7:65276391	NA	0.7	9.83	0.52	1.18e-19	Calcium levels;
CESC	cis	rs3749237	0.555	rs7637665	chr3:49552295	T/C	cg07636037	chr3:49044803	WDR6	0.6	8.77	0.47	2.16e-16	Resting heart rate;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22068044	chr9:140095070	C9orf75	0.6	7.31	0.41	3.23e-12	Gut microbiome composition (summer);
CESC	cis	rs514406	0.861	rs2477741	chr1:53265278	A/G	cg24675658	chr1:53192096	ZYG11B	0.56	6.99	0.39	2.2e-11	Monocyte count;
CESC	cis	rs4654899	0.758	rs6694455	chr1:21352185	C/T	cg05370193	chr1:21551575	ECE1	0.37	5.65	0.33	4.12e-8	Superior frontal gyrus grey matter volume;
CESC	cis	rs926938	0.765	rs2268701	chr1:115233046	C/T	cg12756093	chr1:115239321	AMPD1	-0.59	-8.98	-0.48	5.08e-17	Autism;
CESC	cis	rs2760061	0.626	rs1636192	chr1:228124688	A/G	cg02753203	chr1:228287806	NA	-0.5	-7.22	-0.41	5.36e-12	Diastolic blood pressure;
CESC	cis	rs7296418	0.663	rs11057276	chr12:123820397	C/T	cg05973401	chr12:123451056	ABCB9	-0.4	-5.19	-0.3	4.2e-7	Platelet count;
CESC	cis	rs3749237	0.595	rs4855877	chr3:49448527	T/C	cg02487422	chr3:49467188	NICN1	0.54	7.77	0.43	1.74e-13	Resting heart rate;
CESC	trans	rs10435719	0.809	rs77601743	chr8:11790569	G/A	cg15556689	chr8:8085844	FLJ10661	0.52	6.36	0.36	8.63e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
CESC	cis	rs9467711	0.606	rs9393715	chr6:26375645	G/A	cg14345882	chr6:26364793	BTN3A2	0.61	6.06	0.35	4.73e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs71403859	0.502	rs12927006	chr16:71549911	A/G	cg08717414	chr16:71523259	ZNF19	-1.04	-9.94	-0.52	5.46e-20	Post bronchodilator FEV1;
CESC	cis	rs3785574	0.962	rs2665842	chr17:61878535	G/A	cg06420487	chr17:61919686	SMARCD2	0.45	5.36	0.31	1.82e-7	Height;
CESC	cis	rs10504229	0.683	rs72649188	chr8:58108829	A/G	cg02725872	chr8:58115012	NA	-0.43	-6.81	-0.39	6.39e-11	Developmental language disorder (linguistic errors);
CESC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg23147149	chr17:2304328	MNT	0.48	6.0	0.35	6.51e-9	Tetralogy of Fallot;
CESC	cis	rs1045714	1.000	rs1045713	chr7:2653579	G/A	cg20813462	chr7:2646259	IQCE	0.71	5.79	0.34	1.98e-8	Urate levels in lean individuals;
CESC	cis	rs1665050	0.625	rs8028764	chr15:59304635	C/T	cg05156742	chr15:59063176	FAM63B	0.41	5.14	0.3	5.4e-7	Atopic dermatitis;
CESC	cis	rs2180341	0.781	rs6913350	chr6:127570560	C/T	cg27446573	chr6:127587934	RNF146	0.82	11.68	0.58	1.09e-25	Breast cancer;
CESC	cis	rs1348850	0.958	rs1405713	chr2:178461560	G/C	cg23306229	chr2:178417860	TTC30B	0.57	7.52	0.42	8.3e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs4665809	0.590	rs5001914	chr2:26415429	A/G	cg25036284	chr2:26402008	FAM59B	-0.83	-9.55	-0.51	8.86e-19	Gut microbiome composition (summer);
CESC	cis	rs8067545	0.611	rs2703775	chr17:20134466	A/G	cg13482628	chr17:19912719	NA	-0.42	-5.64	-0.33	4.25e-8	Schizophrenia;
CESC	cis	rs7927592	0.956	rs7944870	chr11:68309108	C/G	cg20283391	chr11:68216788	NA	-0.53	-6.36	-0.36	8.74e-10	Total body bone mineral density;
CESC	cis	rs8114671	0.869	rs2145559	chr20:33651725	G/A	cg06115741	chr20:33292138	TP53INP2	-0.46	-5.46	-0.32	1.08e-7	Height;
CESC	cis	rs2197308	0.765	rs11182434	chr12:37923968	C/A	cg13010199	chr12:38710504	ALG10B	0.53	6.76	0.38	8.79e-11	Morning vs. evening chronotype;
CESC	cis	rs829883	0.659	rs4762495	chr12:98934105	C/T	cg25150519	chr12:98850993	NA	-0.64	-7.87	-0.44	8.8e-14	Colorectal adenoma (advanced);
CESC	cis	rs4566357	0.595	rs10201538	chr2:227914449	A/G	cg11843606	chr2:227700838	RHBDD1	-0.46	-6.28	-0.36	1.38e-9	Coronary artery disease;
CESC	cis	rs801193	1.000	rs7782320	chr7:66177098	C/T	cg14393609	chr7:65229607	NA	0.47	6.33	0.36	1.01e-9	Aortic root size;
CESC	trans	rs12659622	0.703	rs74655962	chr5:15680745	G/A	cg08701621	chr19:58570419	ZNF135	-0.55	-6.1	-0.35	3.65e-9	Obesity-related traits;
CESC	trans	rs79976124	0.800	rs12194767	chr6:66639599	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.69	8.08	0.44	2.23e-14	Type 2 diabetes;
CESC	cis	rs12155623	0.619	rs11775403	chr8:49877323	A/T	cg00325661	chr8:49890786	NA	0.41	5.64	0.33	4.34e-8	Sudden cardiac arrest;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg12044889	chr6:3000430	NQO2	-0.45	-6.48	-0.37	4.57e-10	Gambling;
CESC	cis	rs10791097	0.629	rs11222361	chr11:130731424	T/G	cg12179176	chr11:130786555	SNX19	0.56	8.16	0.45	1.36e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08660999	chr19:1592898	MBD3	0.55	6.47	0.37	4.66e-10	Gut microbiome composition (summer);
CESC	cis	rs738322	0.718	rs2899297	chr22:38594668	A/G	cg17652424	chr22:38574118	PLA2G6	-0.32	-5.53	-0.32	7.64e-8	Cutaneous nevi;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg22568695	chr18:59888119	KIAA1468	0.4	6.34	0.36	9.91e-10	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs57024841	0.562	rs7862602	chr9:139840471	G/T	cg00693599	chr9:139836323	FBXW5	0.46	6.74	0.38	1e-10	Beta-trace protein levels;
CESC	cis	rs4853525	0.522	rs62179717	chr2:191590813	T/G	cg10560079	chr2:191398806	TMEM194B	-0.47	-5.91	-0.34	1.08e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
CESC	cis	rs2573652	0.963	rs2573649	chr15:100514040	C/G	cg00587665	chr15:100533223	ADAMTS17	-0.32	-5.15	-0.3	5.13e-7	Height;
CESC	cis	rs734999	0.588	rs876938	chr1:2523212	G/C	cg20673091	chr1:2541236	MMEL1	0.43	6.85	0.39	5.3e-11	Ulcerative colitis;
CESC	cis	rs1348850	0.651	rs1901826	chr2:178225266	G/A	cg22681709	chr2:178499509	PDE11A	-0.36	-5.42	-0.32	1.31e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs8038465	0.592	rs899981	chr15:73935329	G/A	cg15420318	chr15:73925796	NPTN	0.49	7.03	0.4	1.77e-11	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs13102973	0.965	rs11731021	chr4:135850391	G/T	cg14419869	chr4:135874104	NA	0.33	5.19	0.3	4.29e-7	Subjective well-being;
CESC	cis	rs7666738	0.830	rs1813972	chr4:98886828	C/A	cg05340658	chr4:99064831	C4orf37	0.73	10.55	0.54	5.89e-22	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10465746	0.780	rs1871924	chr1:84398466	T/A	cg10977910	chr1:84465055	TTLL7	0.52	7.14	0.4	9.05e-12	Obesity-related traits;
CESC	cis	rs7116495	1.000	rs12283462	chr11:71835406	T/G	cg10381502	chr11:71823885	C11orf51	0.72	5.91	0.34	1.05e-8	Severe influenza A (H1N1) infection;
CESC	cis	rs11098499	0.863	rs9997631	chr4:120469995	C/G	cg09307838	chr4:120376055	NA	0.9	12.5	0.61	1.67e-28	Corneal astigmatism;
CESC	cis	rs72781680	0.611	rs72783636	chr2:24328706	C/T	cg06627628	chr2:24431161	ITSN2	-0.68	-6.58	-0.37	2.44e-10	Lymphocyte counts;
CESC	cis	rs12971120	0.947	rs34676212	chr18:72170006	A/G	cg26446133	chr18:72167187	CNDP2	-0.77	-11.45	-0.58	6.12e-25	Refractive error;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27633877	chr2:109329328	NA	-0.53	-6.25	-0.36	1.6e-9	Gut microbiome composition (summer);
CESC	cis	rs2370759	1.000	rs2370759	chr10:32634972	G/A	cg01819863	chr10:32635814	EPC1	1.16	12.73	0.62	2.71e-29	Sexual dysfunction (female);
CESC	cis	rs2011503	1.000	rs77616520	chr19:19652776	G/A	cg11584989	chr19:19387371	SF4	0.58	6.67	0.38	1.52e-10	Bipolar disorder;
CESC	cis	rs8180040	0.934	rs12630641	chr3:47534836	G/T	cg27129171	chr3:47204927	SETD2	0.6	8.92	0.48	7.91e-17	Colorectal cancer;
CESC	cis	rs3812762	0.783	rs34524863	chr11:8777408	T/C	cg03980550	chr11:8754370	ST5	-0.41	-5.65	-0.33	4.08e-8	Hypospadias;
CESC	cis	rs7552404	1.000	rs441109	chr1:76120430	T/G	cg03433033	chr1:76189801	ACADM	-0.65	-7.61	-0.42	4.81e-13	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs9905704	0.881	rs302846	chr17:56687536	T/A	cg12560992	chr17:57184187	TRIM37	0.62	7.73	0.43	2.17e-13	Testicular germ cell tumor;
CESC	cis	rs796364	0.806	rs55985986	chr2:201120987	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.71	-6.44	-0.37	5.68e-10	Schizophrenia;
CESC	cis	rs4660306	1.000	rs2356561	chr1:45980862	T/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.51	-6.58	-0.37	2.54e-10	Homocysteine levels;
CESC	trans	rs7582180	0.700	rs1437971	chr2:100986964	A/C	cg03343534	chr8:117778609	UTP23	0.63	6.39	0.37	7.44e-10	Intelligence (multi-trait analysis);
CESC	cis	rs10751667	0.643	rs10794350	chr11:946070	A/G	cg20946044	chr11:1010712	AP2A2	-0.42	-5.72	-0.33	2.9e-8	Alzheimer's disease (late onset);
CESC	cis	rs7953249	0.618	rs7954331	chr12:121398657	G/T	cg25281562	chr12:121454272	C12orf43	-0.46	-5.7	-0.33	3.12e-8	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
CESC	cis	rs4665809	0.590	rs4665840	chr2:26444962	C/T	cg27170947	chr2:26402098	FAM59B	-0.87	-9.89	-0.52	7.6e-20	Gut microbiome composition (summer);
CESC	cis	rs763121	0.626	rs5750643	chr22:39009017	A/G	cg06544989	chr22:39130855	UNC84B	0.51	9.26	0.49	7.17e-18	Menopause (age at onset);
CESC	cis	rs7818345	0.967	rs7015440	chr8:19276991	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.32	5.85	0.34	1.45e-8	Language performance in older adults (adjusted for episodic memory);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20982311	chr1:9489248	NA	0.64	7.23	0.41	5.18e-12	Gut microbiome composition (summer);
CESC	cis	rs7927592	0.913	rs7107622	chr11:68374183	T/C	cg20283391	chr11:68216788	NA	-0.47	-5.7	-0.33	3.12e-8	Total body bone mineral density;
CESC	cis	rs12618769	0.543	rs56357378	chr2:99032455	T/G	cg10123293	chr2:99228465	UNC50	0.4	5.32	0.31	2.21e-7	Bipolar disorder;
CESC	cis	rs6831352	0.918	rs17218602	chr4:100061073	A/G	cg13256891	chr4:100009986	ADH5	-0.75	-8.21	-0.45	9.89e-15	Alcohol dependence;
CESC	trans	rs875971	0.660	rs801193	chr7:66030612	A/C	cg26939375	chr7:64535504	NA	-0.67	-9.27	-0.49	6.86e-18	Aortic root size;
CESC	cis	rs10754283	0.901	rs10922684	chr1:90117934	T/C	cg21401794	chr1:90099060	LRRC8C	0.67	9.08	0.49	2.59e-17	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs4242434	0.927	rs3736147	chr8:22471824	A/G	cg03733263	chr8:22462867	KIAA1967	-0.92	-14.09	-0.65	5.02e-34	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CESC	cis	rs514406	0.767	rs551591	chr1:53301876	A/G	cg08736216	chr1:53307985	ZYG11A	-0.44	-7.61	-0.42	4.91e-13	Monocyte count;
CESC	cis	rs13191362	0.810	rs66921603	chr6:162996982	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.5	5.17	0.3	4.64e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg24642844	chr7:1081250	C7orf50	-0.73	-8.84	-0.48	1.36e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs9325144	0.560	rs2013804	chr12:38631079	C/T	cg13010199	chr12:38710504	ALG10B	-0.44	-6.05	-0.35	4.95e-9	Morning vs. evening chronotype;
CESC	cis	rs832540	0.519	rs6895442	chr5:56260998	T/C	cg14703610	chr5:56206110	C5orf35	0.5	6.54	0.37	3.21e-10	Coronary artery disease;
CESC	cis	rs425277	0.606	rs2257182	chr1:2082566	C/T	cg16545954	chr1:2118288	C1orf86	-0.36	-7.21	-0.4	5.92e-12	Height;
CESC	cis	rs2439831	0.850	rs2439832	chr15:43779686	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.9	10.47	0.54	1.1e-21	Lung cancer in ever smokers;
CESC	cis	rs736408	0.562	rs2072390	chr3:52780509	A/T	cg05564831	chr3:52568323	NT5DC2	0.48	7.58	0.42	5.66e-13	Bipolar disorder;
CESC	cis	rs61542988	0.797	rs4329182	chr7:22882621	C/T	cg11367502	chr7:22862612	TOMM7	0.48	5.98	0.34	7.09e-9	Fibrinogen levels;
CESC	cis	rs10203711	0.966	rs907105	chr2:239565052	A/G	cg14580085	chr2:239553406	NA	0.34	5.16	0.3	4.74e-7	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6866344	0.570	rs1132338	chr5:178139442	T/G	cg10224037	chr5:178157518	ZNF354A	0.73	8.63	0.47	5.77e-16	Neutrophil percentage of white cells;
CESC	cis	rs73019876	0.869	rs812673	chr19:22122335	C/T	cg11619707	chr19:22235551	ZNF257	-0.29	-5.37	-0.31	1.72e-7	Testicular germ cell tumor;
CESC	cis	rs4835473	0.932	rs1849113	chr4:144883665	C/T	cg25736465	chr4:144833511	NA	-0.41	-5.65	-0.33	4.08e-8	Immature fraction of reticulocytes;
CESC	cis	rs7000551	0.751	rs2449329	chr8:22374794	G/T	cg12081754	chr8:22256438	SLC39A14	0.4	5.39	0.31	1.55e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg19089314	chr22:50919938	ADM2	-0.5	-6.35	-0.36	9.18e-10	Ulcerative colitis;
CESC	cis	rs12931792	0.712	rs4787495	chr16:30165725	C/T	cg17640201	chr16:30407289	ZNF48	-0.56	-7.75	-0.43	1.98e-13	Tonsillectomy;
CESC	cis	rs9916302	0.595	rs4795371	chr17:37636695	T/G	cg20243544	chr17:37824526	PNMT	0.51	6.5	0.37	3.97e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs9911578	0.813	rs8066773	chr17:56601552	A/G	cg12560992	chr17:57184187	TRIM37	0.87	12.6	0.61	7.81e-29	Intelligence (multi-trait analysis);
CESC	cis	rs11638352	0.661	rs1426657	chr15:44434529	A/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.56	-5.29	-0.31	2.53e-7	Lipoprotein phospholipase A2 activity in cardiovascular disease;
CESC	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg19626725	chr5:178986131	RUFY1	-0.4	-6.52	-0.37	3.57e-10	Lung cancer;
CESC	cis	rs6460942	0.591	rs10262667	chr7:12385391	C/T	cg20607287	chr7:12443886	VWDE	-0.55	-7.85	-0.43	1.05e-13	Coronary artery disease;
CESC	cis	rs4975709	0.569	rs1684965	chr5:1865248	A/G	cg14773178	chr5:1868261	NA	0.32	5.76	0.33	2.31e-8	Cardiovascular disease risk factors;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg21881364	chr11:72438004	ARAP1	0.45	6.01	0.35	6.2e-9	Fibrinogen levels;
CESC	cis	rs7635838	0.650	rs1375206	chr3:11339117	C/G	cg00170343	chr3:11313890	ATG7	0.54	7.77	0.43	1.71e-13	HDL cholesterol;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg20696051	chr7:158649028	WDR60	-0.45	-6.02	-0.35	5.81e-9	Height;
CESC	cis	rs3820928	0.845	rs13419076	chr2:227873028	A/G	cg11843606	chr2:227700838	RHBDD1	-0.47	-6.05	-0.35	4.92e-9	Pulmonary function;
CESC	cis	rs8180040	0.966	rs11925823	chr3:47443065	C/G	cg27129171	chr3:47204927	SETD2	0.63	9.65	0.51	4.34e-19	Colorectal cancer;
CESC	trans	rs7618501	0.966	rs7372966	chr3:49788969	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.6	-8.49	-0.46	1.55e-15	Intelligence (multi-trait analysis);
CESC	trans	rs35110281	0.627	rs56369437	chr21:44970275	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.52	7.03	0.4	1.8e-11	Mean corpuscular volume;
CESC	cis	rs7937682	0.889	rs567859	chr11:111486738	A/G	cg22437258	chr11:111473054	SIK2	0.72	9.66	0.51	4.24e-19	Primary sclerosing cholangitis;
CESC	cis	rs7666738	0.830	rs28522896	chr4:99008243	C/T	cg17366294	chr4:99064904	C4orf37	0.6	8.61	0.47	6.47e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs854765	0.619	rs1101727	chr17:18016148	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.62	8.59	0.47	7.7e-16	Total body bone mineral density;
CESC	cis	rs9596863	1.000	rs9596860	chr13:54431215	G/A	ch.13.53330881F	chr13:54432880	NA	0.66	5.25	0.31	3.08e-7	Epilepsy and lamotrigine-induced maculopapular eruptions;
CESC	cis	rs1801251	0.778	rs2592115	chr2:233736349	C/T	cg08000102	chr2:233561755	GIGYF2	-0.61	-8.67	-0.47	4.44e-16	Coronary artery disease;
CESC	cis	rs780096	0.506	rs1262430	chr2:27673798	T/C	cg02592271	chr2:27665507	KRTCAP3	-0.29	-5.8	-0.34	1.84e-8	Total body bone mineral density;
CESC	cis	rs9287719	0.934	rs6710033	chr2:10757677	C/T	cg02196655	chr2:10830764	NOL10	-0.37	-5.67	-0.33	3.73e-8	Prostate cancer;
CESC	cis	rs1218582	0.803	rs7531728	chr1:154840516	C/A	cg24250549	chr1:154909240	PMVK	0.62	8.37	0.46	3.3e-15	Prostate cancer;
CESC	cis	rs6691722	0.503	rs2274168	chr1:24707211	G/T	cg02336364	chr1:24764700	NIPAL3	0.32	6.58	0.37	2.48e-10	Response to interferon beta in multiple sclerosis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20249169	chr2:64881356	SERTAD2	-0.7	-8.02	-0.44	3.39e-14	Gut microbiome composition (summer);
CESC	cis	rs17711722	0.675	rs6947132	chr7:65273495	G/A	cg11987759	chr7:65425863	GUSB	0.48	6.51	0.37	3.76e-10	Calcium levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17973565	chr1:153606594	C1orf77;S100A13	0.58	6.44	0.37	5.64e-10	Gut microbiome composition (summer);
CESC	cis	rs7617773	0.817	rs6791930	chr3:48329900	A/G	cg11946769	chr3:48343235	NME6	0.81	10.91	0.56	3.86e-23	Coronary artery disease;
CESC	cis	rs11190604	1.000	rs10883503	chr10:102275504	C/A	cg07080220	chr10:102295463	HIF1AN	0.67	6.12	0.35	3.3e-9	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs2032447	0.517	rs7767546	chr6:25904067	T/C	cg03264133	chr6:25882463	NA	-0.62	-9.43	-0.5	2.14e-18	Intelligence (multi-trait analysis);
CESC	cis	rs8064299	0.560	rs11077763	chr17:72786029	T/C	cg25054828	chr17:72772726	NAT9;TMEM104	0.82	13.87	0.65	3e-33	Monocyte count;
CESC	trans	rs1814175	0.645	rs6486022	chr11:49776137	A/G	cg03929089	chr4:120376271	NA	-0.89	-13.67	-0.64	1.51e-32	Height;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg02290708	chr21:35747831	FAM165B	-0.44	-6.14	-0.35	2.99e-9	Asthma;
CESC	cis	rs71403859	0.667	rs12920890	chr16:71787588	G/A	cg08717414	chr16:71523259	ZNF19	-0.69	-5.77	-0.33	2.24e-8	Post bronchodilator FEV1;
CESC	cis	rs35110281	0.748	rs162403	chr21:44963365	C/G	cg04455712	chr21:45112962	RRP1B	0.37	5.42	0.32	1.35e-7	Mean corpuscular volume;
CESC	cis	rs9987353	0.620	rs34455383	chr8:9066458	C/T	cg06636001	chr8:8085503	FLJ10661	-0.59	-6.58	-0.37	2.47e-10	Recombination measurement;
CESC	cis	rs9488822	0.676	rs13210143	chr6:116389636	G/A	cg18764771	chr6:116381957	FRK	0.24	6.01	0.35	6.14e-9	Cholesterol, total;LDL cholesterol;
CESC	trans	rs61931739	0.534	rs1608912	chr12:34008574	C/T	cg26384229	chr12:38710491	ALG10B	0.46	6.31	0.36	1.17e-9	Morning vs. evening chronotype;
CESC	trans	rs9693444	0.898	rs4732697	chr8:29519861	A/G	cg10169971	chr6:83902988	RWDD2A;PGM3	-0.44	-6.31	-0.36	1.14e-9	Breast cancer;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg12457035	chr5:180688144	TRIM52	-0.44	-6.24	-0.36	1.71e-9	Fibrinogen levels;
CESC	cis	rs1030877	1.000	rs1030877	chr2:105910513	G/A	cg02079111	chr2:105885981	TGFBRAP1	0.63	9.92	0.52	6.12e-20	Obesity-related traits;
CESC	cis	rs12478296	0.534	rs67092377	chr2:243002171	T/G	cg06360820	chr2:242988706	NA	-0.58	-7.58	-0.42	5.89e-13	Obesity-related traits;
CESC	cis	rs7824557	0.767	rs1897950	chr8:11169551	C/A	cg21775007	chr8:11205619	TDH	0.48	6.95	0.39	2.89e-11	Retinal vascular caliber;
CESC	cis	rs7678296	0.730	rs1435385	chr4:37228506	C/G	cg06805348	chr4:37245195	KIAA1239	0.42	5.05	0.3	8.22e-7	3-hydroxypropylmercapturic acid levels in smokers;
CESC	cis	rs7208859	0.623	rs57486336	chr17:29085731	G/T	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.17e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs6679073	1.000	rs6679073	chr1:205756484	A/C	cg17178900	chr1:205818956	PM20D1	0.38	5.25	0.31	3.19e-7	Prostate-specific antigen levels;
CESC	cis	rs892961	0.932	rs3987887	chr17:75414862	T/C	cg05865280	chr17:75406074	SEPT9	0.62	12.42	0.61	3.19e-28	Airflow obstruction;
CESC	cis	rs7267979	0.816	rs404775	chr20:25481117	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.78	14.71	0.67	3.22e-36	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs262150	0.522	rs2527182	chr7:158813812	A/G	cg19418458	chr7:158789849	NA	-0.41	-6.23	-0.36	1.81e-9	Facial morphology (factor 20);
CESC	cis	rs35306767	0.953	rs11253517	chr10:970524	A/G	cg25019033	chr10:957182	NA	0.68	8.27	0.45	6.77e-15	Eosinophil percentage of granulocytes;
CESC	cis	rs7584330	0.554	rs76408976	chr2:238384784	C/T	cg14458575	chr2:238380390	NA	0.69	5.73	0.33	2.65e-8	Prostate cancer;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg19155557	chr3:41240643	CTNNB1	0.39	6.02	0.35	5.74e-9	Gambling;
CESC	cis	rs6831352	0.734	rs12502237	chr4:100015675	G/A	cg12011299	chr4:100065546	ADH4	0.57	6.92	0.39	3.46e-11	Alcohol dependence;
CESC	cis	rs17253792	0.822	rs10483645	chr14:56103766	G/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.8	5.65	0.33	4.2e-8	Putamen volume;
CESC	cis	rs2204008	0.870	rs12369578	chr12:38444227	C/T	cg13010199	chr12:38710504	ALG10B	0.46	5.9	0.34	1.1e-8	Bladder cancer;
CESC	cis	rs9457247	1.000	rs10946198	chr6:167404432	C/T	cg07741184	chr6:167504864	NA	0.28	5.1	0.3	6.54e-7	Crohn's disease;
CESC	cis	rs250677	0.958	rs10056942	chr5:148416114	C/A	cg18129178	chr5:148520854	ABLIM3	-0.52	-5.78	-0.33	2.05e-8	Breast cancer;
CESC	cis	rs6582630	0.519	rs8189599	chr12:38280748	A/G	cg26384229	chr12:38710491	ALG10B	0.69	9.96	0.52	4.57e-20	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs2289328	0.943	rs3803360	chr15:40662669	C/T	cg13931752	chr15:40660718	DISP2	0.47	5.86	0.34	1.33e-8	Intelligence (multi-trait analysis);Cognitive ability;Cognitive ability (multi-trait analysis);
CESC	cis	rs2072732	0.821	rs60287244	chr1:2943668	A/G	cg03976712	chr1:2946727	NA	0.34	5.35	0.31	1.9e-7	Plateletcrit;
CESC	trans	rs78049276	0.688	rs73855809	chr4:148380348	G/T	cg13149281	chr14:23389818	RBM23;PRMT5	-0.63	-6.69	-0.38	1.33e-10	Pulse pressure;
CESC	cis	rs708547	0.874	rs1630798	chr4:57883558	T/C	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.56	-5.78	-0.33	2.06e-8	Response to bleomycin (chromatid breaks);
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg10864883	chr7:75943751	NA	-0.49	-6.21	-0.36	2.07e-9	Asthma;
CESC	cis	rs769267	0.930	rs7256149	chr19:19566255	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.47	5.87	0.34	1.28e-8	Tonsillectomy;
CESC	trans	rs2727020	0.615	rs4980435	chr11:49591576	G/A	cg15704280	chr7:45808275	SEPT13	-0.96	-17.09	-0.72	1.22e-44	Coronary artery disease;
CESC	cis	rs4595586	0.566	rs11615585	chr12:39409351	C/T	cg26384229	chr12:38710491	ALG10B	0.54	7.64	0.42	3.96e-13	Morning vs. evening chronotype;
CESC	cis	rs7829975	0.514	rs2976926	chr8:8261624	T/C	cg06636001	chr8:8085503	FLJ10661	0.53	6.97	0.39	2.48e-11	Mood instability;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14029580	chr4:1363708	KIAA1530	-0.54	-6.18	-0.35	2.36e-9	Gut microbiome composition (summer);
CESC	cis	rs2235642	0.891	rs2281231	chr16:1601879	A/G	cg09080909	chr16:1797204	MAPK8IP3	-0.42	-6.01	-0.35	6.2e-9	Coronary artery disease;
CESC	cis	rs2836974	0.831	rs6517521	chr21:40551588	A/G	cg11644478	chr21:40555479	PSMG1	1.01	16.84	0.72	9.25e-44	Cognitive function;
CESC	cis	rs796364	0.806	rs6435041	chr2:200867144	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.87	7.76	0.43	1.81e-13	Schizophrenia;
CESC	cis	rs7726839	0.561	rs72703058	chr5:584519	G/A	cg16447950	chr5:562315	NA	-0.55	-6.19	-0.36	2.29e-9	Obesity-related traits;
CESC	cis	rs1580019	0.844	rs1037322	chr7:32501857	C/T	cg07520158	chr7:32535189	LSM5;AVL9	0.42	5.08	0.3	6.98e-7	Cognitive ability;
CESC	cis	rs3741404	0.825	rs11603538	chr11:63986713	C/A	cg04317338	chr11:64019027	PLCB3	0.48	5.7	0.33	3.25e-8	Platelet count;
CESC	cis	rs9837602	0.507	rs6803204	chr3:99680874	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.64	-10.1	-0.53	1.62e-20	Breast cancer;
CESC	cis	rs636291	0.517	rs673254	chr1:10550352	C/T	cg07384165	chr1:10488281	NA	-0.58	-8.62	-0.47	6.26e-16	Prostate cancer;
CESC	cis	rs524281	0.861	rs2293121	chr11:65961347	T/G	cg14036092	chr11:66035641	RAB1B	-0.61	-6.46	-0.37	5.06e-10	Electroencephalogram traits;
CESC	cis	rs4948102	0.731	rs10229446	chr7:56064262	A/G	cg09872392	chr7:56161020	PHKG1	0.46	7.35	0.41	2.42e-12	Plasma homocysteine levels (post-methionine load test);
CESC	trans	rs61931739	0.500	rs10844846	chr12:34394611	C/G	cg26384229	chr12:38710491	ALG10B	0.54	7.75	0.43	2.01e-13	Morning vs. evening chronotype;
CESC	cis	rs17818399	0.926	rs35682608	chr2:46836542	A/T	cg06386533	chr2:46925753	SOCS5	0.47	5.19	0.3	4.11e-7	Height;
CESC	cis	rs13256369	0.789	rs13282500	chr8:8568489	A/T	cg18904891	chr8:8559673	CLDN23	0.52	6.03	0.35	5.45e-9	Obesity-related traits;
CESC	cis	rs11098499	0.954	rs10518328	chr4:120401779	G/A	cg09307838	chr4:120376055	NA	0.93	13.07	0.63	1.85e-30	Corneal astigmatism;
CESC	cis	rs12142240	0.698	rs68083747	chr1:46807416	T/G	cg00530320	chr1:46809349	NSUN4	0.6	7.98	0.44	4.48e-14	Menopause (age at onset);
CESC	cis	rs1538970	0.884	rs61788261	chr1:45899114	G/A	cg06784218	chr1:46089804	CCDC17	0.33	5.45	0.32	1.14e-7	Platelet count;
CESC	cis	rs7666738	0.830	rs4440224	chr4:99044924	G/A	cg24818145	chr4:99064322	C4orf37	0.38	5.04	0.3	8.49e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs875971	0.862	rs801206	chr7:66021966	C/G	cg19163074	chr7:65112434	INTS4L2	0.42	5.25	0.31	3.18e-7	Aortic root size;
CESC	cis	rs1322639	0.697	rs12661910	chr6:169584388	A/G	cg03254818	chr6:169586852	NA	0.53	6.02	0.35	5.72e-9	Pulse pressure;
CESC	trans	rs11039798	0.588	rs10160381	chr11:48599491	A/G	cg15704280	chr7:45808275	SEPT13	0.6	6.24	0.36	1.69e-9	Axial length;
CESC	cis	rs2228479	0.618	rs34689166	chr16:89860697	C/T	cg04013166	chr16:89971882	TCF25	0.77	6.61	0.38	2.05e-10	Skin colour saturation;
CESC	cis	rs8062405	1.000	rs8055982	chr16:28881202	A/C	cg08761264	chr16:28874980	SH2B1	-0.47	-5.85	-0.34	1.42e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs61931739	0.749	rs7315233	chr12:34271975	G/T	cg19457237	chr12:34500585	NA	-0.41	-5.61	-0.33	5.17e-8	Morning vs. evening chronotype;
CESC	cis	rs7671266	0.668	rs10002562	chr4:10159736	C/G	cg11266682	chr4:10021025	SLC2A9	-0.48	-6.0	-0.35	6.29e-9	Cardiovascular disease risk factors;
CESC	cis	rs2034088	0.897	rs11652657	chr17:439124	A/G	cg06217071	chr17:408420	NA	0.5	9.67	0.51	3.82e-19	Hip circumference adjusted for BMI;
CESC	cis	rs1552244	1.000	rs6807846	chr3:10134491	G/T	cg00166722	chr3:10149974	C3orf24	0.48	6.15	0.35	2.78e-9	Alzheimer's disease;
CESC	cis	rs1707322	0.682	rs12041197	chr1:46104464	T/C	cg03146154	chr1:46216737	IPP	0.81	11.48	0.58	5.05e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs763121	0.853	rs6001191	chr22:39074452	T/C	cg21395723	chr22:39101663	GTPBP1	0.42	5.32	0.31	2.17e-7	Menopause (age at onset);
CESC	cis	rs5753618	0.583	rs9606843	chr22:31853371	A/C	cg00478049	chr22:31556069	RNF185	-0.43	-5.12	-0.3	5.93e-7	Colorectal cancer;
CESC	cis	rs1707322	0.647	rs6686944	chr1:46156308	G/T	cg06784218	chr1:46089804	CCDC17	0.43	7.53	0.42	7.83e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs898097	0.841	rs4986122	chr17:80825500	C/T	cg20271620	chr17:80763330	TBCD	0.43	5.12	0.3	5.78e-7	Breast cancer;
CESC	cis	rs9583531	0.600	rs3809344	chr13:111358705	G/A	cg24331049	chr13:111365604	ING1	0.75	10.98	0.56	2.28e-23	Coronary artery disease;
CESC	cis	rs2742234	0.955	rs2503849	chr10:43672776	G/A	cg07801480	chr10:43725741	RASGEF1A	0.38	5.35	0.31	1.86e-7	Hirschsprung disease;
CESC	cis	rs6499255	0.951	rs11075728	chr16:69611582	A/G	cg15192750	chr16:69999425	NA	0.53	6.19	0.36	2.31e-9	IgE levels;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg20526303	chr3:197676828	RPL35A;IQCG	-0.47	-6.22	-0.36	1.89e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs9649213	0.593	rs62478233	chr7:98023092	T/C	cg21770322	chr7:97807741	LMTK2	0.55	8.28	0.45	5.99e-15	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs963731	0.649	rs1470915	chr2:39247336	G/A	cg04010122	chr2:39346883	SOS1	-0.73	-5.39	-0.31	1.54e-7	Corticobasal degeneration;
CESC	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg15112475	chr7:1198522	ZFAND2A	-0.39	-6.2	-0.36	2.18e-9	Longevity;Endometriosis;
CESC	cis	rs13118159	0.742	rs7679860	chr4:1333987	C/T	cg02018176	chr4:1364513	KIAA1530	0.41	5.47	0.32	1.06e-7	Longevity;
CESC	trans	rs3780486	0.846	rs10124479	chr9:33136233	T/G	cg04842962	chr6:43655489	MRPS18A	1.0	19.15	0.76	6.75e-52	IgG glycosylation;
CESC	cis	rs637571	0.522	rs7105628	chr11:65763067	C/T	cg04055107	chr11:65626734	MUS81;CFL1	0.44	5.4	0.32	1.45e-7	Eosinophil percentage of white cells;
CESC	cis	rs35306767	0.953	rs12762973	chr10:960761	C/G	cg26597838	chr10:835615	NA	0.86	9.62	0.51	5.72e-19	Eosinophil percentage of granulocytes;
CESC	cis	rs7618915	0.547	rs13064064	chr3:52657002	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	6.88	0.39	4.18e-11	Bipolar disorder;
CESC	cis	rs7264396	0.676	rs6058383	chr20:34556005	T/C	cg17201900	chr20:34330562	RBM39	0.5	5.22	0.31	3.71e-7	Total cholesterol levels;
CESC	cis	rs16854884	0.657	rs2099543	chr3:143742164	C/T	cg06585982	chr3:143692056	C3orf58	0.5	6.71	0.38	1.18e-10	Economic and political preferences (feminism/equality);
CESC	cis	rs875971	0.862	rs4149461	chr7:65744732	T/C	cg11764359	chr7:65958608	NA	-0.8	-12.02	-0.59	7.52e-27	Aortic root size;
CESC	cis	rs1395	0.778	rs2580761	chr2:27426362	G/A	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.44	5.85	0.34	1.44e-8	Blood metabolite levels;
CESC	cis	rs9325144	0.560	rs7971313	chr12:38653413	A/G	cg13010199	chr12:38710504	ALG10B	-0.45	-6.1	-0.35	3.79e-9	Morning vs. evening chronotype;
CESC	cis	rs7429990	0.965	rs4858880	chr3:48104449	C/A	cg11946769	chr3:48343235	NME6	-0.44	-5.36	-0.31	1.8e-7	Educational attainment (years of education);
CESC	cis	rs9549260	0.755	rs1413482	chr13:41218451	C/T	cg21288729	chr13:41239152	FOXO1	0.67	8.78	0.47	2.01e-16	Red blood cell count;
CESC	cis	rs736408	0.812	rs1075653	chr3:52825528	T/C	cg17372223	chr3:52568218	NT5DC2	0.41	5.69	0.33	3.28e-8	Bipolar disorder;
CESC	cis	rs17376456	0.877	rs13156865	chr5:93390908	C/A	cg21475434	chr5:93447410	FAM172A	0.77	6.96	0.39	2.61e-11	Diabetic retinopathy;
CESC	cis	rs40363	0.723	rs2736	chr16:3536872	G/A	cg00484396	chr16:3507460	NAT15	-0.58	-6.29	-0.36	1.32e-9	Tuberculosis;
CESC	cis	rs4819052	0.851	rs13048789	chr21:46660714	A/G	cg11663144	chr21:46675770	NA	-0.63	-10.02	-0.52	3.12e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs12681288	0.823	rs2701908	chr8:1003250	T/C	cg04851639	chr8:1020857	NA	-0.35	-7.79	-0.43	1.54e-13	Schizophrenia;
CESC	cis	rs2425143	0.908	rs75331436	chr20:34391052	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.79	-7.16	-0.4	7.72e-12	Blood protein levels;
CESC	cis	rs807669	0.548	rs762522	chr22:19180575	C/T	cg02655711	chr22:19163373	SLC25A1	0.75	11.77	0.59	5.32e-26	Metabolite levels;
CESC	cis	rs1707322	0.716	rs28375469	chr1:46195375	T/C	cg06784218	chr1:46089804	CCDC17	0.41	7.21	0.41	5.75e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs12497850	0.765	rs12487580	chr3:49182932	G/A	cg06212747	chr3:49208901	KLHDC8B	0.76	10.35	0.54	2.7e-21	Parkinson's disease;
CESC	trans	rs7107217	1.000	rs1873872	chr11:129473993	A/T	cg25263898	chr1:36774223	C1orf113	-0.49	-6.51	-0.37	3.76e-10	Breast cancer;Type 2 diabetes;
CESC	cis	rs7666738	1.000	rs13116475	chr4:99054843	C/T	cg17366294	chr4:99064904	C4orf37	-0.59	-7.69	-0.43	2.81e-13	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4704187	0.649	rs58999738	chr5:74545798	A/G	cg03227963	chr5:74354835	NA	0.28	5.27	0.31	2.86e-7	Response to amphetamines;
CESC	cis	rs2658782	0.756	rs2658777	chr11:93148423	C/T	cg15737290	chr11:93063684	CCDC67	0.49	5.94	0.34	8.92e-9	Pulmonary function decline;
CESC	cis	rs1023500	0.551	rs2859438	chr22:42466980	A/T	cg15557168	chr22:42548783	NA	-0.44	-6.12	-0.35	3.35e-9	Schizophrenia;
CESC	cis	rs2731664	0.792	rs337374	chr5:176890416	A/G	cg23176889	chr5:176863531	GRK6	0.64	11.63	0.58	1.59e-25	Intelligence (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21810621	chr11:1331345	LOC255512;TOLLIP	0.6	7.05	0.4	1.56e-11	Gut microbiome composition (summer);
CESC	cis	rs611744	0.839	rs638238	chr8:109169152	A/G	cg21045802	chr8:109455806	TTC35	0.46	5.56	0.32	6.54e-8	Dupuytren's disease;
CESC	cis	rs1707322	0.963	rs4459051	chr1:46451203	A/G	cg03146154	chr1:46216737	IPP	0.72	9.82	0.52	1.31e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7267979	0.565	rs958075	chr20:25595123	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.72	-12.01	-0.59	8.11e-27	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs12824058	0.831	rs11608406	chr12:130805866	G/C	cg23887609	chr12:130822674	PIWIL1	0.43	5.49	0.32	9.43e-8	Menopause (age at onset);
CESC	cis	rs11031096	0.711	rs11031156	chr11:4179021	C/T	cg18678763	chr11:4115507	RRM1	-0.43	-5.95	-0.34	8.38e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	cis	rs10088262	0.629	rs7828192	chr8:124804669	C/T	cg15047889	chr8:124780837	FAM91A1	-0.51	-6.37	-0.36	8.14e-10	Pancreatic cancer;
CESC	cis	rs3617	0.625	rs11715347	chr3:52883070	C/T	cg07507251	chr3:52567010	NT5DC2	-0.32	-5.47	-0.32	1.03e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
CESC	cis	rs6439153	0.901	rs2630263	chr3:128688318	A/G	cg25356066	chr3:128598488	ACAD9	0.53	6.93	0.39	3.19e-11	Pneumococcal bacteremia;
CESC	cis	rs798554	0.680	rs1713912	chr7:2895784	C/A	cg09658497	chr7:2847517	GNA12	-0.37	-5.22	-0.31	3.56e-7	Height;
CESC	cis	rs875971	0.505	rs1167386	chr7:65513096	G/A	cg11987759	chr7:65425863	GUSB	0.45	6.07	0.35	4.35e-9	Aortic root size;
CESC	cis	rs1878931	0.726	rs3843728	chr16:3448251	T/C	cg21433313	chr16:3507492	NAT15	-0.38	-5.64	-0.33	4.25e-8	Body mass index (adult);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10624161	chr6:107349251	C6orf203	0.55	6.73	0.38	1.02e-10	Gut microbiome composition (summer);
CESC	cis	rs13082711	0.595	rs6778612	chr3:27370789	T/C	cg02860705	chr3:27208620	NA	-0.63	-7.86	-0.43	9.88e-14	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CESC	cis	rs7412746	0.611	rs6660084	chr1:150748803	T/C	cg09365446	chr1:150670422	GOLPH3L	0.4	5.26	0.31	3.02e-7	Melanoma;
CESC	cis	rs7178909	0.872	rs28865973	chr15:90435178	T/G	cg19708238	chr15:90437601	AP3S2	0.43	6.13	0.35	3.11e-9	Common traits (Other);
CESC	cis	rs751728	0.638	rs4607416	chr6:33784998	G/C	cg25922239	chr6:33757077	LEMD2	0.41	5.21	0.3	3.88e-7	Crohn's disease;
CESC	cis	rs3741489	1.000	rs2062161	chr12:133428032	G/A	cg01499426	chr12:133417423	CHFR	0.9	5.59	0.32	5.77e-8	Cognitive function;
CESC	cis	rs7020830	0.898	rs12555207	chr9:37315476	C/T	cg14294708	chr9:37120828	ZCCHC7	1.1	18.59	0.75	6.22e-50	Schizophrenia;
CESC	cis	rs8067545	0.611	rs2703781	chr17:20144714	A/G	cg13482628	chr17:19912719	NA	-0.41	-5.51	-0.32	8.66e-8	Schizophrenia;
CESC	cis	rs2404602	0.536	rs11072599	chr15:76774508	T/C	cg26408565	chr15:76604113	ETFA	-0.43	-6.4	-0.37	7.01e-10	Blood metabolite levels;
CESC	cis	rs7412746	0.621	rs11204749	chr1:150929563	G/A	cg04414720	chr1:150670196	GOLPH3L	0.45	6.02	0.35	5.91e-9	Melanoma;
CESC	cis	rs7666738	0.830	rs13138051	chr4:99050367	C/T	cg05340658	chr4:99064831	C4orf37	0.82	12.88	0.62	8.44e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4862750	0.872	rs6811837	chr4:187898162	G/A	cg07414643	chr4:187882934	NA	0.54	7.9	0.44	7.51e-14	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7618915	0.501	rs2164885	chr3:52731269	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.53	8.0	0.44	3.86e-14	Bipolar disorder;
CESC	cis	rs6938	0.618	rs12912839	chr15:75221245	C/T	cg09165964	chr15:75287851	SCAMP5	0.47	6.32	0.36	1.12e-9	Breast cancer;
CESC	cis	rs3617	0.573	rs56383738	chr3:52908398	T/C	cg11645453	chr3:52864694	ITIH4	-0.27	-5.31	-0.31	2.33e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
CESC	cis	rs4835473	0.831	rs7689322	chr4:144894914	A/G	cg25736465	chr4:144833511	NA	0.39	5.97	0.34	7.43e-9	Immature fraction of reticulocytes;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg04141250	chr12:120729794	NA	0.46	6.2	0.36	2.12e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs1552244	0.882	rs13064570	chr3:9997545	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.81	10.7	0.55	1.86e-22	Alzheimer's disease;
CESC	cis	rs1218582	0.772	rs4845400	chr1:154872523	C/T	cg16680214	chr1:154839983	KCNN3	-0.44	-6.76	-0.38	8.73e-11	Prostate cancer;
CESC	cis	rs10479542	0.784	rs7702303	chr5:178986436	G/A	cg00080972	chr5:178986291	RUFY1	0.48	7.76	0.43	1.86e-13	Lung cancer;
CESC	cis	rs1348850	0.526	rs4243389	chr2:178379783	G/C	cg22681709	chr2:178499509	PDE11A	-0.5	-5.26	-0.31	2.97e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs2033711	0.870	rs3764534	chr19:58929136	G/A	cg13877915	chr19:58951672	ZNF132	0.39	5.81	0.34	1.83e-8	Uric acid clearance;
CESC	cis	rs6582630	0.593	rs7299329	chr12:38447943	G/C	cg26384229	chr12:38710491	ALG10B	0.69	10.55	0.54	5.83e-22	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs10504229	0.683	rs949856	chr8:58144496	G/A	cg21724239	chr8:58056113	NA	0.56	5.96	0.34	8.22e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs9640161	0.789	rs34495356	chr7:150057791	A/G	cg21361702	chr7:150065534	REPIN1	0.6	6.57	0.37	2.63e-10	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs701145	0.529	rs355746	chr3:153961627	C/G	cg16511985	chr3:153974050	SGEF	0.46	6.25	0.36	1.66e-9	Coronary artery disease;
CESC	cis	rs7259376	0.846	rs4024624	chr19:22568264	C/T	cg02657401	chr19:22469223	NA	-0.25	-5.1	-0.3	6.58e-7	Menopause (age at onset);
CESC	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg07167872	chr1:205819463	PM20D1	0.43	6.62	0.38	1.98e-10	Menarche (age at onset);
CESC	cis	rs796364	0.806	rs10931890	chr2:201102055	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.76	-6.61	-0.38	2.14e-10	Schizophrenia;
CESC	cis	rs116095464	1.000	rs56075848	chr5:308352	T/C	cg10591111	chr5:226296	SDHA	-0.63	-5.72	-0.33	2.8e-8	Breast cancer;
CESC	trans	rs9467711	0.606	rs72841536	chr6:26378288	T/A	cg06606381	chr12:133084897	FBRSL1	-0.73	-6.26	-0.36	1.53e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs597539	0.689	rs596874	chr11:68630874	C/T	cg21963583	chr11:68658836	MRPL21	-0.36	-5.18	-0.3	4.48e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs6598955	0.671	rs7550997	chr1:26596080	G/A	cg19743891	chr1:26644573	UBXN11;CD52	0.36	5.09	0.3	6.7e-7	Obesity-related traits;
CESC	cis	rs7772486	0.641	rs2253757	chr6:146199686	C/T	cg23711669	chr6:146136114	FBXO30	0.95	12.49	0.61	1.83e-28	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.55	7.27	0.41	4.05e-12	Lymphocyte counts;
CESC	cis	rs9473147	0.543	rs9296558	chr6:47451883	C/T	cg20196966	chr6:47445060	CD2AP	0.41	5.35	0.31	1.91e-7	Platelet distribution width;Mean platelet volume;
CESC	cis	rs8180040	0.932	rs62248599	chr3:47516728	G/A	cg27129171	chr3:47204927	SETD2	-0.63	-9.49	-0.5	1.44e-18	Colorectal cancer;
CESC	trans	rs9951602	0.512	rs6506868	chr18:76642559	C/G	cg02800362	chr5:177631904	HNRNPAB	0.62	8.1	0.45	1.96e-14	Obesity-related traits;
CESC	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg21548813	chr6:291882	DUSP22	-0.76	-10.45	-0.54	1.28e-21	Menopause (age at onset);
CESC	cis	rs1218582	0.772	rs2335408	chr1:154915977	G/A	cg09359103	chr1:154839909	KCNN3	-0.67	-12.45	-0.61	2.6e-28	Prostate cancer;
CESC	cis	rs7587476	0.822	rs6726763	chr2:215681580	T/G	cg04004882	chr2:215674386	BARD1	0.53	5.89	0.34	1.16e-8	Neuroblastoma;
CESC	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.52	-7.97	-0.44	4.59e-14	Longevity;Endometriosis;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg24877558	chr1:42801138	FOXJ3	-0.46	-6.05	-0.35	4.98e-9	Fibrinogen levels;
CESC	cis	rs875971	0.505	rs2462573	chr7:65507392	C/T	cg11987759	chr7:65425863	GUSB	0.45	6.06	0.35	4.53e-9	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17966709	chr11:57435952	ZDHHC5	0.59	6.86	0.39	4.94e-11	Gut microbiome composition (summer);
CESC	cis	rs9858542	1.000	rs34762726	chr3:49689210	G/A	cg07274523	chr3:49395745	GPX1	0.67	8.54	0.46	1.03e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs17209837	0.607	rs4148810	chr7:87102251	C/T	cg00919237	chr7:87102261	ABCB4	-0.51	-6.51	-0.37	3.66e-10	Gallbladder cancer;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg02331450	chr3:33155354	CRTAP	-0.42	-6.06	-0.35	4.72e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs4076764	0.914	rs12123378	chr1:163377846	C/T	cg06092702	chr1:163392909	NA	-0.42	-6.15	-0.35	2.8e-9	Motion sickness;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg22118131	chr15:78369834	TBC1D2B	-0.44	-6.48	-0.37	4.52e-10	Gambling;
CESC	cis	rs17428076	0.514	rs3821095	chr2:172684006	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.56	-7.75	-0.43	1.99e-13	Myopia;
CESC	cis	rs13191362	0.872	rs13196631	chr6:163001588	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.83	8.39	0.46	3.02e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs4975616	0.686	rs37011	chr5:1348798	A/T	cg26373071	chr5:1325741	CLPTM1L	0.45	7.29	0.41	3.58e-12	Lung cancer;
CESC	cis	rs736408	0.507	rs6445531	chr3:52717282	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.61	8.82	0.48	1.53e-16	Bipolar disorder;
CESC	cis	rs11690935	0.571	rs1008151	chr2:172912098	G/A	cg13550731	chr2:172543902	DYNC1I2	0.48	6.36	0.36	8.59e-10	Schizophrenia;
CESC	trans	rs7824557	0.583	rs2263512	chr8:11233419	T/G	cg06636001	chr8:8085503	FLJ10661	-0.5	-6.31	-0.36	1.14e-9	Retinal vascular caliber;
CESC	cis	rs854765	0.693	rs4924823	chr17:17764502	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.6	-8.85	-0.48	1.24e-16	Total body bone mineral density;
CESC	cis	rs34779708	0.931	rs12240347	chr10:35359475	A/G	cg03585969	chr10:35415529	CREM	0.76	9.94	0.52	5.37e-20	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs2742234	0.578	rs2742241	chr10:43625223	G/A	cg07801480	chr10:43725741	RASGEF1A	0.41	5.3	0.31	2.44e-7	Hirschsprung disease;
CESC	cis	rs875971	0.522	rs2949690	chr7:65483242	C/T	cg26939375	chr7:64535504	NA	-0.75	-10.83	-0.55	7.3e-23	Aortic root size;
CESC	trans	rs7246760	1.000	rs10418248	chr19:9938214	T/A	cg02900749	chr2:68251473	NA	-0.74	-6.81	-0.39	6.57e-11	Pursuit maintenance gain;
CESC	cis	rs9486715	0.830	rs2475023	chr6:96996833	G/A	cg06623918	chr6:96969491	KIAA0776	-0.95	-15.19	-0.68	6.54e-38	Headache;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27022678	chr5:140563942	PCDHB16	-0.57	-7.09	-0.4	1.25e-11	Gut microbiome composition (summer);
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg19244826	chr22:19466934	UFD1L;CDC45L	-0.45	-6.15	-0.35	2.77e-9	Asthma;
CESC	cis	rs12477438	0.798	rs896886	chr2:99652713	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.72	10.53	0.54	6.66e-22	Chronic sinus infection;
CESC	cis	rs2243480	1.000	rs2243480	chr7:65599196	C/T	cg18252515	chr7:66147081	NA	-1.18	-11.21	-0.57	3.97e-24	Diabetic kidney disease;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg04903157	chr22:35795952	MCM5	0.49	6.1	0.35	3.69e-9	Thyroid stimulating hormone;
CESC	cis	rs2243480	1.000	rs1267820	chr7:66050295	C/G	cg18252515	chr7:66147081	NA	-1.4	-14.23	-0.66	1.55e-34	Diabetic kidney disease;
CESC	cis	rs9308433	0.529	rs4655336	chr1:214499667	A/C	cg06198575	chr1:214491504	SMYD2	0.49	5.98	0.34	7.22e-9	IgG glycosylation;
CESC	trans	rs1557351	0.723	rs1942344	chr18:54720778	A/G	cg11433624	chr6:7146702	RREB1	0.39	6.27	0.36	1.48e-9	Multiple sclerosis (age of onset);
CESC	cis	rs113835537	0.866	rs59320108	chr11:66365996	A/T	cg24851651	chr11:66362959	CCS	0.61	5.46	0.32	1.11e-7	Airway imaging phenotypes;
CESC	cis	rs4132509	1.000	rs2291410	chr1:243716654	A/C	cg21452805	chr1:244014465	NA	-0.43	-5.31	-0.31	2.36e-7	RR interval (heart rate);
CESC	cis	rs9916302	0.904	rs4357971	chr17:37717280	C/T	cg20243544	chr17:37824526	PNMT	0.51	6.5	0.37	3.97e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs2576037	0.796	rs2571018	chr18:44585344	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.61	-8.76	-0.47	2.43e-16	Personality dimensions;
CESC	cis	rs698813	0.604	rs7565928	chr2:44489956	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	5.51	0.32	8.66e-8	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
CESC	cis	rs2354432	0.556	rs11239964	chr1:146753902	G/C	cg25205988	chr1:146714368	CHD1L	-0.92	-7.89	-0.44	7.91e-14	Mitochondrial DNA levels;
CESC	cis	rs11098499	0.863	rs59732491	chr4:120489588	G/C	cg09307838	chr4:120376055	NA	0.91	12.59	0.61	8.49e-29	Corneal astigmatism;
CESC	cis	rs11608355	0.515	rs7971160	chr12:109946751	T/A	cg05360138	chr12:110035743	NA	0.82	8.85	0.48	1.27e-16	Neuroticism;
CESC	cis	rs7714584	0.793	rs7709721	chr5:150246858	A/G	cg22134413	chr5:150180641	NA	0.5	5.76	0.33	2.3e-8	Crohn's disease;
CESC	cis	rs698833	0.886	rs2289463	chr2:44565447	A/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.53	6.74	0.38	9.88e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs853679	0.550	rs1233704	chr6:28166923	A/G	cg20151795	chr6:28129481	ZNF389	-0.4	-5.49	-0.32	9.54e-8	Depression;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg02656959	chr1:21786446	NBPF3	0.46	6.28	0.36	1.39e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs634534	0.622	rs624273	chr11:65712413	A/G	cg17712092	chr4:129076599	LARP1B	0.55	6.8	0.39	7.08e-11	Sum eosinophil basophil counts;Eosinophil counts;
CESC	trans	rs61931739	0.817	rs1705771	chr12:34174950	C/G	cg26384229	chr12:38710491	ALG10B	0.48	6.57	0.37	2.6200000000000003e-10	Morning vs. evening chronotype;
CESC	cis	rs4889855	0.614	rs9898443	chr17:78469357	C/T	cg16591659	chr17:78472290	NA	0.52	7.92	0.44	6.49e-14	Fractional excretion of uric acid;
CESC	cis	rs6828523	0.698	rs80082041	chr4:175855409	A/G	cg14561282	chr4:175839468	ADAM29	0.44	5.15	0.3	5.09e-7	Breast cancer;
CESC	cis	rs6942756	1.000	rs6467235	chr7:128939150	A/G	cg02491457	chr7:128862824	NA	0.74	8.22	0.45	9.29e-15	White matter hyperintensity burden;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05654483	chr10:122610929	WDR11	0.52	6.12	0.35	3.36e-9	Gut microbiome composition (summer);
CESC	cis	rs13394619	0.655	rs7578132	chr2:11718858	C/T	cg07314298	chr2:11723111	GREB1	-0.46	-6.32	-0.36	1.09e-9	Endometriosis;
CESC	cis	rs10504229	0.679	rs72649115	chr8:58037631	T/G	cg14926445	chr8:58193284	C8orf71	-0.54	-5.21	-0.31	3.73e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs15676	0.947	rs2997913	chr9:131589033	C/T	cg00228799	chr9:131580591	ENDOG	0.44	5.54	0.32	7.2e-8	Blood metabolite levels;
CESC	cis	rs7312933	0.558	rs4768399	chr12:42742696	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.48	-6.43	-0.37	5.79e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg21271961	chr1:95285780	SLC44A3	-0.44	-6.37	-0.36	8.51e-10	Gambling;
CESC	cis	rs72781680	1.000	rs55773155	chr2:24255081	A/G	cg20701182	chr2:24300061	SF3B14	0.97	8.24	0.45	7.96e-15	Lymphocyte counts;
CESC	cis	rs6540556	0.769	rs10157973	chr1:209924425	C/T	cg23920097	chr1:209922102	NA	-0.38	-5.31	-0.31	2.27e-7	Red blood cell count;
CESC	cis	rs73206853	0.841	rs56017652	chr12:110931054	C/T	cg12870014	chr12:110450643	ANKRD13A	0.63	5.22	0.31	3.56e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs7618915	0.547	rs12487591	chr3:52642936	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	6.17	0.35	2.56e-9	Bipolar disorder;
CESC	cis	rs1559088	0.948	rs10408093	chr19:33597816	T/C	cg17764715	chr19:33622953	WDR88	0.48	6.31	0.36	1.17e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs11122272	0.735	rs2244986	chr1:231537452	C/T	cg06096015	chr1:231504339	EGLN1	0.42	6.13	0.35	3.17e-9	Hemoglobin concentration;
CESC	cis	rs8077577	0.895	rs62073615	chr17:18080329	T/A	cg16794390	chr17:18148240	FLII	0.46	5.78	0.33	2.13e-8	Obesity-related traits;
CESC	cis	rs920590	0.758	rs1817836	chr8:19664852	T/C	cg17834443	chr8:19674713	INTS10	0.58	6.75	0.38	9.22e-11	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs10751667	0.666	rs10902241	chr11:949129	G/A	cg06064525	chr11:970664	AP2A2	-0.48	-9.45	-0.5	1.86e-18	Alzheimer's disease (late onset);
CESC	cis	rs1799949	0.965	rs2236762	chr17:41226675	A/T	cg23758822	chr17:41437982	NA	0.99	16.59	0.71	6.91e-43	Menopause (age at onset);
CESC	cis	rs317689	0.513	rs317678	chr12:69692166	C/G	cg14784868	chr12:69753453	YEATS4	0.52	6.49	0.37	4.29e-10	Response to diuretic therapy;
CESC	cis	rs35110281	0.659	rs73367822	chr21:45024252	C/T	cg21573476	chr21:45109991	RRP1B	-0.47	-6.55	-0.37	3.01e-10	Mean corpuscular volume;
CESC	cis	rs826838	1.000	rs10506122	chr12:38699232	A/G	cg13010199	chr12:38710504	ALG10B	0.62	8.96	0.48	6.04e-17	Heart rate;
CESC	trans	rs61931739	0.500	rs11053236	chr12:34507962	C/G	cg26384229	chr12:38710491	ALG10B	0.71	10.63	0.55	3.31e-22	Morning vs. evening chronotype;
CESC	cis	rs2075671	0.903	rs62482252	chr7:100274063	C/A	cg16850897	chr7:100343110	ZAN	-0.69	-8.36	-0.46	3.62e-15	Other erythrocyte phenotypes;
CESC	trans	rs801193	1.000	rs4279493	chr7:66226620	C/T	cg26939375	chr7:64535504	NA	0.67	9.16	0.49	1.49e-17	Aortic root size;
CESC	cis	rs796364	0.616	rs7589545	chr2:200676102	T/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.54	5.09	0.3	6.86e-7	Schizophrenia;
CESC	cis	rs2228479	0.850	rs11641552	chr16:89838700	C/A	cg04013166	chr16:89971882	TCF25	0.78	6.69	0.38	1.3e-10	Skin colour saturation;
CESC	cis	rs2742234	0.541	rs11238479	chr10:43717423	C/T	cg07801480	chr10:43725741	RASGEF1A	-0.4	-5.24	-0.31	3.22e-7	Hirschsprung disease;
CESC	cis	rs10504229	1.000	rs112284078	chr8:58191640	A/G	cg22535103	chr8:58192502	C8orf71	-1.07	-13.22	-0.63	5.72e-31	Developmental language disorder (linguistic errors);
CESC	cis	rs5758659	0.652	rs133347	chr22:42423645	A/T	cg19513890	chr22:42538836	CYP2D7P1	-0.39	-5.82	-0.34	1.69e-8	Cognitive function;
CESC	cis	rs9916302	0.904	rs1077715	chr17:37683548	A/T	cg00129232	chr17:37814104	STARD3	-0.6	-7.99	-0.44	4.15e-14	Glomerular filtration rate (creatinine);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00888876	chr4:74124772	ANKRD17	0.6	6.74	0.38	9.62e-11	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02708898	chr8:54755848	ATP6V1H	0.57	6.14	0.35	3e-9	Gut microbiome composition (summer);
CESC	cis	rs6456156	0.792	rs9366089	chr6:167512896	A/G	cg07741184	chr6:167504864	NA	0.37	6.61	0.38	2.1e-10	Primary biliary cholangitis;
CESC	cis	rs6502050	0.799	rs8066370	chr17:80102105	T/C	cg11859384	chr17:80120422	CCDC57	-0.38	-5.11	-0.3	6.21e-7	Life satisfaction;
CESC	cis	rs3733585	0.673	rs7375587	chr4:9954758	A/T	cg02734326	chr4:10020555	SLC2A9	0.41	5.92	0.34	9.96e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs7639513	0.545	rs13061104	chr3:12717321	G/T	cg23032965	chr3:12705835	RAF1	0.68	7.42	0.41	1.58e-12	Itch intensity from mosquito bite;
CESC	cis	rs6582630	0.502	rs4309219	chr12:38293584	A/G	cg13010199	chr12:38710504	ALG10B	0.4	5.14	0.3	5.25e-7	Drug-induced liver injury (flucloxacillin);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg08330117	chr8:90770456	RIPK2	0.48	6.44	0.37	5.5e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs79839061	0.732	rs11734742	chr4:821565	C/T	cg07828340	chr4:882639	GAK	0.83	6.03	0.35	5.37e-9	Intelligence (multi-trait analysis);
CESC	cis	rs662064	0.962	rs596537	chr1:10554709	G/T	cg20482658	chr1:10539492	PEX14	-0.36	-7.27	-0.41	4.01e-12	Asthma;
CESC	trans	rs10506458	0.915	rs12423078	chr12:63397529	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.34	-18.94	-0.76	3.59e-51	Hemostatic factors and hematological phenotypes;
CESC	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.6	0.38	2.17e-10	Prudent dietary pattern;
CESC	cis	rs9911578	1.000	rs8079774	chr17:56908188	A/G	cg12560992	chr17:57184187	TRIM37	0.94	15.75	0.7	6.57e-40	Intelligence (multi-trait analysis);
CESC	cis	rs10751667	0.643	rs11246348	chr11:939476	G/C	cg20946044	chr11:1010712	AP2A2	-0.41	-5.64	-0.33	4.31e-8	Alzheimer's disease (late onset);
CESC	cis	rs3785574	0.962	rs2584633	chr17:61879501	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.58	7.15	0.4	8.48e-12	Height;
CESC	cis	rs9596863	1.000	rs9568941	chr13:54419426	A/G	ch.13.53330881F	chr13:54432880	NA	0.66	5.25	0.31	3.08e-7	Epilepsy and lamotrigine-induced maculopapular eruptions;
CESC	cis	rs2204008	0.774	rs2387811	chr12:38369794	C/A	cg26384229	chr12:38710491	ALG10B	0.74	10.65	0.55	2.8e-22	Bladder cancer;
CESC	cis	rs66573146	0.572	rs67922134	chr4:6955772	G/A	cg26116260	chr4:7069785	GRPEL1	-0.79	-5.16	-0.3	4.78e-7	Granulocyte percentage of myeloid white cells;
CESC	cis	rs4808199	0.843	rs10402308	chr19:19657500	G/A	cg03709012	chr19:19516395	GATAD2A	1.04	12.91	0.62	6.34e-30	Nonalcoholic fatty liver disease;
CESC	cis	rs854765	0.647	rs2974998	chr17:17995619	A/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.47	5.9	0.34	1.1e-8	Total body bone mineral density;
CESC	cis	rs13102973	0.965	rs7656631	chr4:135869921	C/T	cg14419869	chr4:135874104	NA	-0.4	-6.29	-0.36	1.32e-9	Subjective well-being;
CESC	cis	rs13382862	0.862	rs340595	chr2:20889714	A/G	cg14780466	chr2:20870812	GDF7	-0.47	-7.77	-0.43	1.73e-13	Abdominal aortic aneurysm;
CESC	cis	rs965469	1.000	rs6037554	chr20:3315613	G/A	cg25506879	chr20:3388711	C20orf194	-0.53	-5.81	-0.34	1.78e-8	IFN-related cytopenia;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg04109349	chr1:245317172	KIF26B	-0.41	-6.14	-0.35	3.07e-9	Gambling;
CESC	cis	rs660498	0.526	rs610451	chr10:27705152	A/G	cg11203244	chr10:27609286	NA	-0.36	-5.17	-0.3	4.58e-7	Asthma (childhood onset);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04237075	chr9:34637949	SIGMAR1	0.48	6.11	0.35	3.58e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs4834770	1.000	rs1397613	chr4:120242929	G/T	cg09307838	chr4:120376055	NA	0.45	5.37	0.31	1.74e-7	Blood protein levels;
CESC	cis	rs10504229	0.683	rs35889486	chr8:58117749	T/A	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs1707322	0.686	rs2991977	chr1:46053683	G/A	cg03146154	chr1:46216737	IPP	-0.75	-10.01	-0.52	3.19e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7914558	0.966	rs10883817	chr10:104755431	C/T	cg15744005	chr10:104629667	AS3MT	-0.34	-5.49	-0.32	9.51e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs875971	0.756	rs4718328	chr7:65693337	A/G	cg10691866	chr7:65817282	TPST1	0.31	5.26	0.31	2.97e-7	Aortic root size;
CESC	cis	rs1707322	0.827	rs6683274	chr1:46241638	T/G	cg05343316	chr1:45956843	TESK2	0.5	5.98	0.34	7.2e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs875971	1.000	rs9986696	chr7:65704576	C/A	cg11764359	chr7:65958608	NA	-0.91	-14.71	-0.67	3.26e-36	Aortic root size;
CESC	cis	rs7208859	0.623	rs3752019	chr17:29151705	C/T	cg19761014	chr17:28927070	LRRC37B2	0.74	6.03	0.35	5.43e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs7843479	0.601	rs12056476	chr8:21854188	T/A	cg17168535	chr8:21777572	XPO7	0.71	11.2	0.57	4.39e-24	Mean corpuscular volume;
CESC	cis	rs7577696	0.711	rs385076	chr2:32489851	T/C	cg02381751	chr2:32503542	YIPF4	0.42	5.27	0.31	2.85e-7	Inflammatory biomarkers;
CESC	cis	rs10861342	1.000	rs10861360	chr12:105570041	A/G	cg23923672	chr12:105501055	KIAA1033	-0.8	-7.21	-0.4	5.91e-12	IgG glycosylation;
CESC	cis	rs11122272	0.701	rs2790894	chr1:231505587	T/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-7.15	-0.4	8.55e-12	Hemoglobin concentration;
CESC	cis	rs4853012	0.838	rs72915068	chr2:74356185	G/A	cg20891558	chr2:74357851	NA	0.87	12.53	0.61	1.39e-28	Gestational age at birth (maternal effect);
CESC	cis	rs2635047	0.682	rs4534948	chr18:44793419	G/A	cg24371990	chr18:44770781	NA	0.39	6.26	0.36	1.5e-9	Educational attainment;
CESC	cis	rs2985684	0.948	rs2985685	chr14:50101370	G/A	cg02151108	chr14:50098012	C14orf104	-0.42	-5.48	-0.32	9.97e-8	Carotid intima media thickness;
CESC	cis	rs9611565	0.765	rs132906	chr22:41799767	G/C	cg06481639	chr22:41940642	POLR3H	0.45	5.36	0.31	1.85e-7	Vitiligo;
CESC	cis	rs11785693	0.862	rs11782343	chr8:5001642	C/G	cg26367366	chr8:4980734	NA	0.52	5.23	0.31	3.43e-7	Neuroticism (multi-trait analysis);Neuroticism;
CESC	cis	rs13256369	0.802	rs11249887	chr8:8562184	T/C	cg17143192	chr8:8559678	CLDN23	0.77	9.05	0.49	3.19e-17	Obesity-related traits;
CESC	trans	rs12063142	0.673	rs72651812	chr1:19141142	C/G	cg08487374	chr7:100076562	TSC22D4	0.74	6.37	0.36	8.2e-10	Parkinson's disease;
CESC	cis	rs13256369	0.802	rs4840350	chr8:8561442	A/G	cg00074818	chr8:8560427	CLDN23	0.36	5.24	0.31	3.32e-7	Obesity-related traits;
CESC	cis	rs367615	0.704	rs4286723	chr5:108835959	G/A	cg17395555	chr5:108820864	NA	0.62	11.06	0.56	1.27e-23	Colorectal cancer (SNP x SNP interaction);
CESC	trans	rs7615952	0.641	rs60839048	chr3:125807938	G/A	cg07211511	chr3:129823064	LOC729375	-0.56	-6.22	-0.36	1.92e-9	Blood pressure (smoking interaction);
CESC	cis	rs72945132	0.882	rs3781648	chr11:70190058	T/C	cg00319359	chr11:70116639	PPFIA1	0.72	6.84	0.39	5.42e-11	Coronary artery disease;
CESC	cis	rs2880765	0.835	rs12910373	chr15:86046802	G/C	cg19183879	chr15:85880815	NA	-0.26	-5.29	-0.31	2.52e-7	Coronary artery disease;
CESC	cis	rs9788682	0.747	rs2938674	chr15:78757913	C/A	cg24631222	chr15:78858424	CHRNA5	0.62	7.24	0.41	4.83e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg07959380	chr16:89894648	SPIRE2	-0.42	-6.0	-0.35	6.34e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs8033133	1.000	rs8033133	chr15:25350474	A/G	cg14481604	chr15:25334117	SNORD116-22	-0.37	-5.41	-0.32	1.42e-7	Blood osmolality (transformed sodium);
CESC	cis	rs1707322	0.686	rs2991987	chr1:46081422	C/G	cg06784218	chr1:46089804	CCDC17	-0.43	-7.52	-0.42	8.27e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs4803455	0.565	rs1800470	chr19:41858921	G/A	cg08477640	chr19:41863820	B9D2	0.5	6.94	0.39	3.03e-11	Migraine;Coronary artery disease;
CESC	cis	rs7552404	0.961	rs211710	chr1:76109038	G/A	cg10523679	chr1:76189770	ACADM	-0.64	-7.13	-0.4	9.27e-12	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs2302190	0.882	rs7221205	chr17:56485799	G/A	cg25885038	chr17:56607967	SEPT4	-0.4	-5.41	-0.32	1.42e-7	Vitamin D levels;
CESC	cis	rs524281	0.861	rs10896095	chr11:65962560	A/G	cg14036092	chr11:66035641	RAB1B	-0.52	-5.7	-0.33	3.17e-8	Electroencephalogram traits;
CESC	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg03188948	chr7:1209495	NA	0.68	6.53	0.37	3.35e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs11098499	0.955	rs11944880	chr4:120159334	A/G	cg09307838	chr4:120376055	NA	-0.86	-11.3	-0.57	2.01e-24	Corneal astigmatism;
CESC	cis	rs7618915	0.547	rs13065019	chr3:52685244	T/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.31	5.61	0.33	5.12e-8	Bipolar disorder;
CESC	cis	rs9916302	0.861	rs4795376	chr17:37669043	T/C	cg15445000	chr17:37608096	MED1	0.4	6.56	0.37	2.85e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs853679	0.574	rs1233705	chr6:28166447	C/G	cg22143856	chr6:28129313	ZNF389	0.44	5.84	0.34	1.49e-8	Depression;
CESC	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg26516362	chr5:178986906	RUFY1	0.48	7.75	0.43	1.93e-13	Lung cancer;
CESC	cis	rs1707322	0.691	rs28495425	chr1:46187320	T/G	cg03146154	chr1:46216737	IPP	0.82	11.54	0.58	3.18e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg15358743	chr18:56807035	SEC11C	0.45	6.19	0.36	2.33e-9	Systemic lupus erythematosus;
CESC	cis	rs9768139	0.733	rs35016950	chr7:158118710	C/A	cg27057461	chr7:158136379	PTPRN2	-0.34	-5.3	-0.31	2.46e-7	Calcium levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08125682	chr16:11038455	CLEC16A	0.62	7.3	0.41	3.37e-12	Gut microbiome composition (summer);
CESC	cis	rs1577917	1.000	rs12205548	chr6:86759770	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.47	-6.14	-0.35	3.04e-9	Response to antipsychotic treatment;
CESC	cis	rs7020830	0.867	rs55845273	chr9:37362219	C/T	cg14294708	chr9:37120828	ZCCHC7	1.11	19.1	0.76	9.61e-52	Schizophrenia;
CESC	cis	rs950169	1.000	rs35648189	chr15:84740748	T/C	cg17507749	chr15:85114479	UBE2QP1	0.64	7.1	0.4	1.17e-11	Schizophrenia;
CESC	trans	rs35110281	0.744	rs162395	chr21:44945759	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.49	6.66	0.38	1.59e-10	Mean corpuscular volume;
CESC	cis	rs11608355	0.545	rs35018715	chr12:109893134	T/C	cg05360138	chr12:110035743	NA	0.82	8.92	0.48	7.93e-17	Neuroticism;
CESC	cis	rs10751667	0.961	rs6597951	chr11:991530	C/T	cg06064525	chr11:970664	AP2A2	-0.41	-6.99	-0.39	2.22e-11	Alzheimer's disease (late onset);
CESC	cis	rs3741404	0.825	rs11603384	chr11:63949095	G/A	cg18225595	chr11:63971243	STIP1	0.7	9.36	0.5	3.65e-18	Platelet count;
CESC	cis	rs6163	0.588	rs11191392	chr10:104526951	C/A	cg04362960	chr10:104952993	NT5C2	0.39	5.28	0.31	2.74e-7	Waist circumference;Hip circumference;
CESC	trans	rs116095464	0.558	rs10055354	chr5:243794	G/A	cg00938859	chr5:1591904	SDHAP3	0.64	6.98	0.39	2.36e-11	Breast cancer;
CESC	cis	rs9894429	0.816	rs9747093	chr17:79584280	G/A	cg21984481	chr17:79567631	NPLOC4	-0.46	-7.64	-0.42	3.95e-13	Eye color traits;
CESC	cis	rs853679	0.517	rs9380050	chr6:28048538	A/G	cg20151795	chr6:28129481	ZNF389	0.44	5.59	0.33	5.5e-8	Depression;
CESC	cis	rs5753037	0.653	rs140129	chr22:30150549	C/T	cg01021169	chr22:30184971	ASCC2	-0.44	-6.08	-0.35	4.19e-9	Type 1 diabetes;
CESC	cis	rs2735413	0.918	rs12918409	chr16:78082681	G/A	cg04733911	chr16:78082701	NA	-0.53	-8.89	-0.48	9.44e-17	Systolic blood pressure (alcohol consumption interaction);
CESC	cis	rs7223966	1.000	rs73337598	chr17:61732576	T/C	cg11494091	chr17:61959527	GH2	0.39	5.53	0.32	7.67e-8	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs4819052	0.851	rs2838864	chr21:46711474	A/T	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.86	-12.8	-0.62	1.61e-29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs2382817	0.580	rs6756265	chr2:219095554	G/A	cg00012203	chr2:219082015	ARPC2	-0.74	-9.9	-0.52	7.06e-20	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs7552404	0.924	rs12136754	chr1:76230232	C/A	cg22875332	chr1:76189707	ACADM	0.7	9.6	0.51	6.53e-19	Blood metabolite levels;Acylcarnitine levels;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg12177922	chr1:154245232	HAX1	-0.43	-6.16	-0.35	2.72e-9	Ulcerative colitis;
CESC	cis	rs10256972	0.528	rs7784607	chr7:1178694	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.45	-6.53	-0.37	3.38e-10	Longevity;Endometriosis;
CESC	cis	rs2652822	0.509	rs4774478	chr15:63434763	A/G	cg02713581	chr15:63449717	RPS27L	0.46	5.43	0.32	1.27e-7	Metabolic traits;
CESC	cis	rs11864453	0.647	rs2550035	chr16:72113416	C/G	cg01557791	chr16:72042693	DHODH	-0.45	-5.96	-0.34	8.06e-9	Fibrinogen levels;
CESC	cis	rs7107174	0.892	rs11237450	chr11:78023356	C/A	cg02023728	chr11:77925099	USP35	0.47	6.16	0.35	2.7e-9	Testicular germ cell tumor;
CESC	cis	rs10870270	0.913	rs4550	chr10:133781798	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.59	-7.6	-0.42	5.25e-13	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs9611565	0.765	rs767593	chr22:41779971	G/T	cg17376030	chr22:41985996	PMM1	0.67	7.28	0.41	3.82e-12	Vitiligo;
CESC	cis	rs7666738	0.546	rs10026181	chr4:98814118	C/T	cg05340658	chr4:99064831	C4orf37	-0.55	-6.56	-0.37	2.87e-10	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1178968	0.901	rs1178958	chr7:72777384	G/A	cg25889504	chr7:72793014	NA	0.51	5.42	0.32	1.36e-7	Triglyceride levels;
CESC	cis	rs73206853	0.698	rs871922	chr12:111114942	T/C	cg12870014	chr12:110450643	ANKRD13A	0.66	5.48	0.32	9.67e-8	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs5769707	0.837	rs5770599	chr22:50019981	C/G	cg20744362	chr22:50050164	C22orf34	0.44	7.22	0.41	5.51e-12	Monocyte count;Monocyte percentage of white cells;
CESC	trans	rs9987353	0.840	rs329994	chr8:9123233	A/G	cg01249180	chr5:95997867	CAST	-0.45	-6.04	-0.35	5.2e-9	Recombination measurement;
CESC	cis	rs3741151	0.773	rs73542938	chr11:73103012	G/C	cg17517138	chr11:73019481	ARHGEF17	0.98	7.14	0.4	8.86e-12	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs7666738	0.657	rs13102002	chr4:98617794	T/C	cg17366294	chr4:99064904	C4orf37	0.51	5.29	0.31	2.53e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs10411161	0.657	rs67462252	chr19:52382851	T/C	cg22319618	chr22:45562946	NUP50	-0.69	-6.52	-0.37	3.48e-10	Breast cancer;
CESC	cis	rs36051895	0.659	rs67006981	chr9:5070401	A/G	cg02405213	chr9:5042618	JAK2	-0.51	-6.24	-0.36	1.72e-9	Pediatric autoimmune diseases;
CESC	cis	rs10242455	0.867	rs2687139	chr7:99323074	A/C	cg07715041	chr7:99302981	CYP3A7	-0.43	-5.42	-0.32	1.36e-7	Blood metabolite levels;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg07869135	chr8:123794843	ZHX2	0.49	6.26	0.36	1.58e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs79387448	0.655	rs79144324	chr2:102932814	G/A	cg09003973	chr2:102972529	NA	1.04	8.15	0.45	1.46e-14	Gut microbiota (bacterial taxa);
CESC	cis	rs965513	1.000	rs7027030	chr9:100550455	A/C	cg13688889	chr9:100608707	NA	-0.6	-8.46	-0.46	1.88e-15	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
CESC	cis	rs12824058	0.831	rs4759653	chr12:130812604	T/C	cg26677194	chr12:130822605	PIWIL1	0.52	6.81	0.39	6.58e-11	Menopause (age at onset);
CESC	cis	rs11122272	0.735	rs2749714	chr1:231538634	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.55	-7.47	-0.42	1.14e-12	Hemoglobin concentration;
CESC	cis	rs8017423	0.904	rs4603489	chr14:90760607	A/G	cg14092571	chr14:90743983	NA	0.55	8.28	0.45	6.32e-15	Mortality in heart failure;
CESC	trans	rs116095464	0.510	rs55750776	chr5:230467	T/C	cg00938859	chr5:1591904	SDHAP3	0.61	6.74	0.38	9.82e-11	Breast cancer;
CESC	cis	rs5760092	0.755	rs915589	chr22:24261004	C/T	cg10150615	chr22:24372951	LOC391322	0.58	6.71	0.38	1.16e-10	Urinary 1,3-butadiene metabolite levels in smokers;
CESC	cis	rs238295	0.881	rs6116869	chr20:5594432	G/T	cg24001556	chr20:5591874	RP5-1022P6.2	0.53	5.91	0.34	1.04e-8	Occipital cortical area (total cortical area interaction);
CESC	cis	rs9322193	0.962	rs9505974	chr6:150100430	C/T	cg05861140	chr6:150128134	PCMT1	-0.35	-5.07	-0.3	7.45e-7	Lung cancer;
CESC	cis	rs1552244	0.882	rs2130813	chr3:10038706	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.76	-9.68	-0.51	3.46e-19	Alzheimer's disease;
CESC	cis	rs1707322	0.655	rs3014240	chr1:46089225	C/G	cg05343316	chr1:45956843	TESK2	-0.52	-6.53	-0.37	3.41e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs3857067	0.806	rs1876918	chr4:95099424	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.6	-9.01	-0.48	4.22e-17	QT interval;
CESC	cis	rs17253792	0.915	rs28663681	chr14:56178820	A/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.74	5.1	0.3	6.53e-7	Putamen volume;
CESC	cis	rs425277	0.958	rs262660	chr1:2086757	A/G	cg04315214	chr1:2043799	PRKCZ	-0.38	-5.31	-0.31	2.35e-7	Height;
CESC	cis	rs9443645	0.901	rs7742431	chr6:79679577	A/G	cg05283184	chr6:79620031	NA	-0.41	-6.42	-0.37	6.26e-10	Intelligence (multi-trait analysis);
CESC	cis	rs4911259	0.593	rs6058924	chr20:31464467	G/A	cg13636640	chr20:31349939	DNMT3B	-0.54	-7.47	-0.42	1.16e-12	Inflammatory bowel disease;
CESC	cis	rs6484504	0.576	rs16922084	chr11:31371109	C/T	cg14844989	chr11:31128820	NA	0.39	5.25	0.31	3.13e-7	Red blood cell count;
CESC	cis	rs6951245	0.706	rs1133116	chr7:1195215	A/C	cg03188948	chr7:1209495	NA	0.73	7.85	0.43	1.04e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2274273	0.806	rs7146752	chr14:55738907	A/G	cg04306507	chr14:55594613	LGALS3	0.29	5.65	0.33	4.17e-8	Protein biomarker;
CESC	cis	rs270601	0.633	rs733300	chr5:131572243	A/G	cg18758796	chr5:131593413	PDLIM4	0.42	5.61	0.33	5.09e-8	Acylcarnitine levels;
CESC	cis	rs72820985	0.504	rs8055721	chr16:80803117	G/T	cg05451730	chr16:80358022	NA	0.42	5.09	0.3	6.65e-7	Breast cancer;
CESC	cis	rs4555082	0.834	rs2735822	chr14:105712734	C/T	cg27165867	chr14:105738592	BRF1	-0.51	-5.42	-0.32	1.31e-7	Mean platelet volume;Platelet distribution width;
CESC	cis	rs1620921	0.756	rs783163	chr6:161182401	A/T	cg01280913	chr6:161186852	NA	-0.43	-6.41	-0.37	6.63e-10	Lipoprotein (a) - cholesterol levels;
CESC	trans	rs1223629	1.000	rs11187805	chr10:95944685	T/A	cg16346422	chr11:2920819	SLC22A18;SLC22A18AS	0.67	6.05	0.35	4.83e-9	Glucose homeostasis traits;
CESC	cis	rs9300255	0.699	rs11057204	chr12:123725827	T/C	cg19016782	chr12:123741754	C12orf65	-0.48	-6.72	-0.38	1.12e-10	Neutrophil percentage of white cells;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg08949862	chr2:63277672	OTX1	0.49	6.31	0.36	1.16e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs17711722	0.565	rs73372653	chr7:65442795	A/T	cg26939375	chr7:64535504	NA	0.63	8.55	0.47	9.86e-16	Calcium levels;
CESC	trans	rs864643	0.773	rs11129837	chr3:39589963	A/G	cg04067598	chr5:70751409	BDP1	0.44	6.18	0.35	2.47e-9	Attention deficit hyperactivity disorder;
CESC	trans	rs79976124	0.877	rs79507557	chr6:66640908	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.73	8.24	0.45	7.76e-15	Type 2 diabetes;
CESC	cis	rs11577318	0.853	rs4471263	chr1:26622700	C/T	cg00852783	chr1:26633632	UBXN11	0.52	7.09	0.4	1.23e-11	Granulocyte percentage of myeloid white cells;
CESC	cis	rs7130144	0.541	rs7949893	chr11:130462408	G/A	cg26307797	chr11:130446613	NA	-0.76	-6.78	-0.38	7.92e-11	Urate levels in lean individuals;
CESC	cis	rs2477686	0.526	rs12042427	chr1:2398107	C/T	cg11214544	chr1:2391121	NA	-0.46	-7.07	-0.4	1.35e-11	Non-obstructive azoospermia;
CESC	trans	rs916888	0.821	rs70602	chr17:44859715	T/C	cg27125505	chr17:43679177	LOC644172	-0.48	-6.62	-0.38	2.01e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs9910055	0.762	rs6503489	chr17:42246289	G/A	cg08499158	chr17:42289980	UBTF	-0.56	-7.2	-0.4	6.2e-12	Total body bone mineral density;
CESC	cis	rs793571	0.744	rs11630265	chr15:59159826	C/T	cg05156742	chr15:59063176	FAM63B	-0.47	-6.15	-0.35	2.78e-9	Schizophrenia;
CESC	cis	rs6665290	0.935	rs12409755	chr1:227196949	A/T	cg10327440	chr1:227177885	CDC42BPA	-1.23	-33.54	-0.9	2.34e-97	Myeloid white cell count;
CESC	cis	rs3015497	0.561	rs3015469	chr14:51157160	C/T	cg26011998	chr14:51135199	SAV1	-0.54	-6.17	-0.35	2.55e-9	Mean platelet volume;
CESC	cis	rs722599	0.683	rs8011071	chr14:75286705	T/C	cg08847533	chr14:75593920	NEK9	0.48	6.0	0.35	6.61e-9	IgG glycosylation;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03638180	chr17:65373763	PITPNC1	0.61	6.64	0.38	1.76e-10	Gut microbiome composition (summer);
CESC	cis	rs9916302	0.904	rs12452509	chr17:37574722	G/A	cg00129232	chr17:37814104	STARD3	-0.56	-7.35	-0.41	2.4e-12	Glomerular filtration rate (creatinine);
CESC	trans	rs7726839	0.574	rs12522955	chr5:639231	C/A	cg25482853	chr8:67687455	SGK3	1.01	10.03	0.52	2.8e-20	Obesity-related traits;
CESC	cis	rs9911578	1.000	rs4793952	chr17:56608465	C/T	cg05425664	chr17:57184151	TRIM37	0.51	7.09	0.4	1.2e-11	Intelligence (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06111305	chr13:98086784	RAP2A	-0.55	-6.14	-0.35	3.02e-9	Gut microbiome composition (summer);
CESC	cis	rs9916302	0.808	rs12947281	chr17:37652210	G/T	cg07936489	chr17:37558343	FBXL20	-0.81	-11.96	-0.59	1.17e-26	Glomerular filtration rate (creatinine);
CESC	cis	rs6089829	0.890	rs6062775	chr20:61663650	T/C	cg08564027	chr20:61660810	NA	0.9	15.42	0.69	9.97e-39	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs9486719	1.000	rs2499807	chr6:96864053	T/G	cg06623918	chr6:96969491	KIAA0776	0.82	8.4	0.46	2.72e-15	Migraine;Coronary artery disease;
CESC	cis	rs2404602	0.552	rs11072613	chr15:76961526	A/C	cg00316803	chr15:76480434	C15orf27	0.38	5.08	0.3	7.29e-7	Blood metabolite levels;
CESC	cis	rs7615952	0.551	rs12695470	chr3:125635718	C/A	cg05084668	chr3:125655381	ALG1L	-0.49	-5.52	-0.32	8e-8	Blood pressure (smoking interaction);
CESC	cis	rs7084402	1.000	rs7910442	chr10:60270260	T/G	cg07615347	chr10:60278583	BICC1	-0.57	-8.71	-0.47	3.43e-16	Refractive error;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg01571169	chr16:87367721	FBXO31	0.52	6.82	0.39	6.1e-11	Fibrinogen levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05007375	chr14:92588364	NDUFB1;CPSF2	0.59	7.17	0.4	7.64e-12	Gut microbiome composition (summer);
CESC	cis	rs3785574	0.962	rs7215915	chr17:61828385	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.81	10.74	0.55	1.39e-22	Height;
CESC	cis	rs1448094	0.512	rs4362214	chr12:86245145	C/T	cg00310523	chr12:86230176	RASSF9	0.35	5.46	0.32	1.1e-7	Major depressive disorder;
CESC	cis	rs9911578	0.900	rs4793593	chr17:56892699	C/G	cg02118635	chr17:56770003	RAD51C;TEX14	-0.37	-5.04	-0.3	8.47e-7	Intelligence (multi-trait analysis);
CESC	cis	rs7208859	0.573	rs60724269	chr17:29113273	G/T	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.1e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs6121246	0.559	rs10439608	chr20:30258814	T/C	cg13852791	chr20:30311386	BCL2L1	0.81	10.53	0.54	6.68e-22	Mean corpuscular hemoglobin;
CESC	cis	rs7843479	0.601	rs10866837	chr8:21861663	G/C	cg17168535	chr8:21777572	XPO7	0.7	10.73	0.55	1.59e-22	Mean corpuscular volume;
CESC	cis	rs10504229	0.635	rs72649130	chr8:58053810	G/T	cg22535103	chr8:58192502	C8orf71	-0.94	-9.35	-0.5	3.78e-18	Developmental language disorder (linguistic errors);
CESC	cis	rs193541	0.555	rs2438151	chr5:122199197	A/G	cg19412675	chr5:122181750	SNX24	0.48	5.69	0.33	3.28e-8	Glucose homeostasis traits;
CESC	cis	rs1865721	1.000	rs1865721	chr18:73192446	C/T	cg26385618	chr18:73139727	C18orf62	-0.51	-7.5	-0.42	9.85e-13	Intelligence;
CESC	cis	rs853679	0.607	rs201002	chr6:27808192	A/G	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.75	7.05	0.4	1.55e-11	Depression;
CESC	cis	rs3936840	0.964	rs10150698	chr14:102977876	A/G	cg18135206	chr14:102964638	TECPR2	0.48	6.49	0.37	4.12e-10	Plateletcrit;
CESC	cis	rs6952808	0.608	rs6461049	chr7:2017445	C/T	cg23048001	chr7:2026167	MAD1L1	-0.48	-6.27	-0.36	1.45e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs4253772	0.530	rs55653327	chr22:46682976	C/T	cg00784671	chr22:46762841	CELSR1	-0.62	-6.02	-0.35	5.64e-9	LDL cholesterol;Cholesterol, total;
CESC	cis	rs72781680	1.000	rs6751655	chr2:24155478	A/G	cg08917208	chr2:24149416	ATAD2B	1.04	9.49	0.5	1.4e-18	Lymphocyte counts;
CESC	cis	rs7618501	0.633	rs12485600	chr3:50025530	A/G	cg24308560	chr3:49941425	MST1R	-0.63	-9.02	-0.48	3.81e-17	Intelligence (multi-trait analysis);
CESC	cis	rs9796	0.775	rs57393155	chr15:41426251	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.43	-6.27	-0.36	1.5e-9	Menopause (age at onset);
CESC	cis	rs4654899	0.812	rs7539512	chr1:21410791	A/G	cg05370193	chr1:21551575	ECE1	0.37	5.57	0.32	6.34e-8	Superior frontal gyrus grey matter volume;
CESC	cis	rs10256972	0.616	rs7806746	chr7:1075573	A/C	cg07308232	chr7:1071921	C7orf50	-0.54	-7.34	-0.41	2.67e-12	Longevity;Endometriosis;
CESC	cis	rs2976388	0.566	rs2585141	chr8:143806343	G/A	cg10596483	chr8:143751796	JRK	-0.42	-5.06	-0.3	7.93e-7	Urinary tract infection frequency;
CESC	cis	rs1799949	1.000	rs12944430	chr17:41330820	C/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.59	7.71	0.43	2.62e-13	Menopause (age at onset);
CESC	cis	rs6736093	0.966	rs34087685	chr2:112693010	G/C	cg12686935	chr2:112915763	FBLN7	-0.44	-5.72	-0.33	2.86e-8	Coronary artery disease;
CESC	cis	rs10504229	0.683	rs67077711	chr8:58139769	G/T	cg02725872	chr8:58115012	NA	-0.45	-7.12	-0.4	1.02e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs698833	0.508	rs698765	chr2:44573671	G/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.47	5.66	0.33	3.83e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs11122272	0.668	rs2808616	chr1:231554993	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.51	6.9	0.39	3.81e-11	Hemoglobin concentration;
CESC	trans	rs687914	0.710	rs938662	chr2:45864578	A/G	cg03274021	chr8:130952480	FAM49B	0.62	6.08	0.35	4.13e-9	Diastolic blood pressure;
CESC	cis	rs1707322	0.663	rs3935296	chr1:46180470	T/C	cg05343316	chr1:45956843	TESK2	-0.51	-6.2	-0.36	2.19e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9788682	1.000	rs7181447	chr15:78814567	A/G	cg24631222	chr15:78858424	CHRNA5	0.73	9.27	0.49	6.82e-18	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs34421088	0.678	rs35928010	chr8:11591876	C/T	cg12395012	chr8:11607386	GATA4	0.4	5.9	0.34	1.1e-8	Neuroticism;
CESC	trans	rs9850225	0.719	rs4856616	chr3:80466481	A/C	cg24448245	chr7:66461718	SBDS;TYW1	0.42	6.0	0.35	6.39e-9	Erectile dysfunction in type 1 diabetes;
CESC	cis	rs2929278	0.588	rs688009	chr15:44156302	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.46	7.2	0.4	6.29e-12	Schizophrenia;
CESC	cis	rs12136530	0.651	rs12141760	chr1:19717901	C/T	cg01832549	chr1:19774989	CAPZB	-0.41	-5.75	-0.33	2.41e-8	Lead levels in blood;
CESC	trans	rs9833726	0.799	rs35614120	chr3:86138618	T/C	cg10416071	chr15:75628863	COMMD4	0.59	6.12	0.35	3.37e-9	Breast cancer;
CESC	cis	rs10504229	0.683	rs11784908	chr8:58131472	T/C	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg06873352	chr17:61820015	STRADA	0.71	12.47	0.61	2.23e-28	Prudent dietary pattern;
CESC	cis	rs4950322	0.748	rs56392137	chr1:146824196	A/G	cg22381352	chr1:146742008	CHD1L	-0.49	-5.27	-0.31	2.89e-7	Protein quantitative trait loci;
CESC	trans	rs9987353	0.840	rs329994	chr8:9123233	A/G	cg03252340	chr4:83293766	HNRNPD	0.47	6.35	0.36	9.56e-10	Recombination measurement;
CESC	trans	rs9937837	1.000	rs34594027	chr16:31318314	T/C	cg04903759	chr3:167238645	WDR49	0.52	6.5	0.37	3.93e-10	Systemic lupus erythematosus;
CESC	cis	rs3806843	0.966	rs2563263	chr5:140137644	A/G	cg16179182	chr5:140090404	VTRNA1-1	-0.43	-5.56	-0.32	6.51e-8	Depressive symptoms (multi-trait analysis);
CESC	cis	rs8092503	1.000	rs7236320	chr18:52475051	C/T	cg12377874	chr18:52495404	RAB27B	0.37	5.97	0.34	7.65e-9	Childhood body mass index;
CESC	cis	rs11098499	0.954	rs10006706	chr4:120409152	A/G	cg24375607	chr4:120327624	NA	0.45	5.56	0.32	6.68e-8	Corneal astigmatism;
CESC	cis	rs853679	0.517	rs9380049	chr6:28048535	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.53	-6.09	-0.35	3.91e-9	Depression;
CESC	cis	rs7940866	0.845	rs1991899	chr11:130801649	C/T	cg12179176	chr11:130786555	SNX19	-0.56	-7.88	-0.44	8.74e-14	Schizophrenia;
CESC	cis	rs77741769	0.571	rs61946382	chr12:121344574	A/T	cg02419362	chr12:121203948	SPPL3	0.35	5.6	0.33	5.35e-8	Mean corpuscular volume;
CESC	cis	rs9796	0.866	rs692155	chr15:41407061	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.4	-5.91	-0.34	1.04e-8	Menopause (age at onset);
CESC	cis	rs1552244	1.000	rs113153120	chr3:10156398	G/A	cg00149659	chr3:10157352	C3orf10	0.7	8.47	0.46	1.68e-15	Alzheimer's disease;
CESC	cis	rs2274273	0.773	rs8012380	chr14:55735010	T/G	cg04306507	chr14:55594613	LGALS3	0.29	5.59	0.33	5.51e-8	Protein biomarker;
CESC	cis	rs4654899	0.733	rs6698440	chr1:21258712	C/T	cg05370193	chr1:21551575	ECE1	0.4	6.19	0.36	2.24e-9	Superior frontal gyrus grey matter volume;
CESC	cis	rs9815354	1.000	rs1615543	chr3:41906404	C/T	cg03022575	chr3:42003672	ULK4	0.44	5.16	0.3	4.85e-7	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs4654899	0.772	rs12145203	chr1:21086127	C/T	cg05370193	chr1:21551575	ECE1	0.34	5.05	0.3	8.26e-7	Superior frontal gyrus grey matter volume;
CESC	cis	rs703842	1.000	rs10747783	chr12:58176614	T/C	cg00677455	chr12:58241039	CTDSP2	0.54	7.02	0.4	1.9e-11	Multiple sclerosis;
CESC	cis	rs72901758	0.768	rs72901762	chr17:76244926	A/G	cg26068271	chr17:76253126	NA	0.48	7.33	0.41	2.85e-12	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg19828298	chr1:3713105	LRRC47	0.46	6.58	0.37	2.48e-10	Systemic lupus erythematosus;
CESC	cis	rs344364	0.511	rs337284	chr16:1954799	A/C	cg03013636	chr16:1946785	NA	0.45	6.15	0.35	2.83e-9	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs6674176	0.597	rs4031031	chr1:44393533	C/T	cg12908607	chr1:44402522	ARTN	-0.5	-7.66	-0.43	3.54e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg26338869	chr17:61819248	STRADA	0.68	8.87	0.48	1.08e-16	Prudent dietary pattern;
CESC	cis	rs6964587	0.869	rs10278155	chr7:91532456	T/G	cg17063962	chr7:91808500	NA	-0.54	-7.19	-0.4	6.56e-12	Breast cancer;
CESC	cis	rs9611519	0.780	rs2235850	chr22:41657626	C/T	cg03806693	chr22:41940476	POLR3H	-0.57	-6.51	-0.37	3.71e-10	Neuroticism;
CESC	cis	rs3768617	0.510	rs3765521	chr1:183077615	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.83	13.2	0.63	6.62e-31	Fuchs's corneal dystrophy;
CESC	cis	rs4074961	0.586	rs10908360	chr1:38058693	T/C	cg13401533	chr1:37979913	MEAF6	0.53	7.05	0.4	1.6e-11	Axial length;
CESC	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg14893161	chr1:205819251	PM20D1	1.02	19.9	0.77	1.57e-54	Menarche (age at onset);
CESC	cis	rs1552244	1.000	rs6442147	chr3:10078247	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.79	-10.7	-0.55	1.91e-22	Alzheimer's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16635483	chr3:96338407	NA	-0.67	-7.77	-0.43	1.73e-13	Gut microbiome composition (summer);
CESC	cis	rs67311347	1.000	rs17078813	chr3:40434162	C/T	cg24209194	chr3:40518798	ZNF619	0.51	6.45	0.37	5.32e-10	Renal cell carcinoma;
CESC	cis	rs4423214	0.879	rs1790345	chr11:71145941	G/A	cg05163923	chr11:71159392	DHCR7	-0.61	-7.17	-0.4	7.67e-12	Vitamin D levels;
CESC	cis	rs8072100	0.875	rs7208530	chr17:45544107	C/T	cg25173405	chr17:45401733	C17orf57	-0.46	-6.03	-0.35	5.59e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs11638352	1.000	rs958485	chr15:44350065	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.49	-5.35	-0.31	1.95e-7	Lipoprotein phospholipase A2 activity in cardiovascular disease;
CESC	cis	rs1801251	1.000	rs3817311	chr2:233612557	C/T	cg08000102	chr2:233561755	GIGYF2	0.66	9.34	0.5	4.05e-18	Coronary artery disease;
CESC	cis	rs35306767	0.903	rs12249634	chr10:872744	G/A	cg25019033	chr10:957182	NA	-0.6	-6.22	-0.36	1.96e-9	Eosinophil percentage of granulocytes;
CESC	cis	rs4819052	0.851	rs4819042	chr21:46660072	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.46	5.79	0.34	2e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs6088580	0.634	rs6142159	chr20:32993035	G/A	cg06115741	chr20:33292138	TP53INP2	-0.47	-6.08	-0.35	4.22e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs853679	0.599	rs149943	chr6:28002388	G/A	cg20933634	chr6:27740509	NA	0.58	5.16	0.3	4.82e-7	Depression;
CESC	cis	rs1797885	0.902	rs1699346	chr3:12504295	C/A	cg26432171	chr3:12704882	RAF1	-0.5	-6.43	-0.37	5.83e-10	Immature fraction of reticulocytes;
CESC	cis	rs4803468	1.000	rs284657	chr19:41929915	G/C	cg14132834	chr19:41945861	ATP5SL	-0.58	-7.17	-0.4	7.5e-12	Height;
CESC	cis	rs2235544	0.565	rs928444	chr1:54473548	C/G	cg25741118	chr1:54482237	LDLRAD1	0.25	6.28	0.36	1.41e-9	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
CESC	cis	rs654950	0.841	rs676383	chr1:41993753	C/T	cg06885757	chr1:42089581	HIVEP3	-0.46	-7.21	-0.4	5.83e-12	Airway imaging phenotypes;
CESC	cis	rs172166	0.637	rs1233708	chr6:28173219	C/T	cg17221315	chr6:27791827	HIST1H4J	0.4	5.07	0.3	7.46e-7	Cardiac Troponin-T levels;
CESC	cis	rs4919694	1.000	rs3740394	chr10:104634474	A/G	cg04362960	chr10:104952993	NT5C2	0.82	6.94	0.39	2.97e-11	Arsenic metabolism;
CESC	cis	rs10463316	0.604	rs28744577	chr5:150768983	A/T	cg03212797	chr5:150827313	SLC36A1	-0.45	-5.88	-0.34	1.24e-8	Metabolite levels (Pyroglutamine);
CESC	cis	rs1799949	0.859	rs11657004	chr17:41442751	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.52	7.61	0.42	4.8e-13	Menopause (age at onset);
CESC	trans	rs208520	0.874	rs208456	chr6:66907942	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.85	-9.69	-0.51	3.38e-19	Exhaled nitric oxide output;
CESC	cis	rs4925325	0.741	rs6142886	chr20:60511190	A/G	cg23262073	chr20:60523788	NA	0.49	6.87	0.39	4.59e-11	Obesity-related traits;
CESC	trans	rs1223629	1.000	rs11187804	chr10:95944627	G/A	cg16346422	chr11:2920819	SLC22A18;SLC22A18AS	0.67	6.05	0.35	4.83e-9	Glucose homeostasis traits;
CESC	cis	rs875971	0.545	rs67775320	chr7:65658779	T/C	cg18876405	chr7:65276391	NA	0.51	5.96	0.34	8.21e-9	Aortic root size;
CESC	cis	rs10751667	0.643	rs6597970	chr11:928669	C/A	cg06064525	chr11:970664	AP2A2	-0.5	-9.87	-0.52	9.15e-20	Alzheimer's disease (late onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00746083	chr14:21905454	CHD8	-0.6	-6.54	-0.37	3.09e-10	Gut microbiome composition (summer);
CESC	cis	rs9916302	0.904	rs2338800	chr17:37498149	C/G	cg00129232	chr17:37814104	STARD3	0.52	6.79	0.38	7.52e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs6460942	0.908	rs59410610	chr7:12282847	A/G	cg06484146	chr7:12443880	VWDE	-0.54	-5.77	-0.33	2.26e-8	Coronary artery disease;
CESC	cis	rs2197308	0.626	rs6581156	chr12:37858731	C/A	cg26384229	chr12:38710491	ALG10B	-0.56	-8.06	-0.44	2.59e-14	Morning vs. evening chronotype;
CESC	trans	rs4950322	0.563	rs61838944	chr1:146581857	C/T	cg04954894	chr8:38089920	DDHD2	-0.59	-6.42	-0.37	6.22e-10	Protein quantitative trait loci;
CESC	trans	rs673604	0.505	rs676614	chr1:36107510	G/T	cg18632102	chr5:154238496	CNOT8	0.55	6.36	0.36	8.57e-10	Endometrial cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20554397	chr5:303564	PDCD6;AHRR	-0.7	-8.16	-0.45	1.38e-14	Gut microbiome composition (summer);
CESC	cis	rs9287719	0.904	rs55738250	chr2:10757132	G/A	cg00105475	chr2:10696890	NA	0.37	5.4	0.31	1.52e-7	Prostate cancer;
CESC	cis	rs425277	1.000	rs262672	chr1:2080813	G/T	cg04315214	chr1:2043799	PRKCZ	-0.38	-5.3	-0.31	2.42e-7	Height;
CESC	cis	rs2797160	0.967	rs1739368	chr6:126011079	C/T	cg05901451	chr6:126070800	HEY2	0.45	6.62	0.38	2e-10	Endometrial cancer;
CESC	cis	rs2228479	0.718	rs11645376	chr16:89912281	G/C	cg00800038	chr16:89945340	TCF25	-0.89	-6.89	-0.39	4.13e-11	Skin colour saturation;
CESC	cis	rs4849845	0.637	rs4849851	chr2:121055910	A/C	cg24070213	chr2:121070622	NA	0.42	6.1	0.35	3.78e-9	Mean platelet volume;
CESC	cis	rs8141529	0.644	rs5752795	chr22:29178820	T/C	cg02153584	chr22:29168773	CCDC117	0.69	9.9	0.52	7.13e-20	Lymphocyte counts;
CESC	cis	rs763014	0.593	rs28455838	chr16:681966	T/C	cg07256732	chr16:621771	PIGQ	-0.32	-5.66	-0.33	4e-8	Height;
CESC	cis	rs17711722	0.565	rs4717276	chr7:65294741	G/T	cg18876405	chr7:65276391	NA	0.43	5.6	0.33	5.38e-8	Calcium levels;
CESC	cis	rs1799949	1.000	rs8176233	chr17:41219804	T/C	cg05368731	chr17:41323189	NBR1	0.79	11.1	0.56	8.99e-24	Menopause (age at onset);
CESC	cis	rs9611565	0.580	rs5758449	chr22:42140160	C/T	cg06481639	chr22:41940642	POLR3H	0.5	5.81	0.34	1.78e-8	Vitiligo;
CESC	cis	rs9916302	0.706	rs594794	chr17:37453485	T/C	cg07936489	chr17:37558343	FBXL20	0.92	10.37	0.54	2.23e-21	Glomerular filtration rate (creatinine);
CESC	cis	rs6963495	0.519	rs3892297	chr7:105152173	G/A	cg19920283	chr7:105172520	RINT1	0.68	6.43	0.37	6.01e-10	Bipolar disorder (body mass index interaction);
CESC	cis	rs67072384	0.818	rs2291291	chr11:72466897	T/C	cg04827223	chr11:72435913	ARAP1	-0.7	-7.1	-0.4	1.16e-11	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg15554505	chr19:22123728	NA	0.38	6.1	0.35	3.76e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs6951245	0.744	rs1133122	chr7:1192572	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.48	-5.74	-0.33	2.54e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs514406	0.584	rs11205997	chr1:53195271	G/C	cg24675658	chr1:53192096	ZYG11B	0.64	7.98	0.44	4.39e-14	Monocyte count;
CESC	cis	rs6570726	0.791	rs6570692	chr6:145904401	T/A	cg23711669	chr6:146136114	FBXO30	0.97	14.59	0.67	8.43e-36	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs11148252	0.624	rs6561682	chr13:53266297	A/G	cg12121983	chr17:1387582	MYO1C	-0.4	-6.05	-0.35	4.94e-9	Lewy body disease;
CESC	cis	rs10851478	0.872	rs1911612	chr15:49830708	G/A	cg08060515	chr15:49448048	GALK2;COPS2	0.42	5.19	0.3	4.12e-7	Oral cavity cancer;
CESC	cis	rs425277	0.561	rs11584491	chr1:2042543	A/G	cg04315214	chr1:2043799	PRKCZ	0.53	9.14	0.49	1.72e-17	Height;
CESC	cis	rs1941023	0.584	rs10750937	chr11:60172087	C/T	cg08716584	chr11:60157161	MS4A7	-0.55	-9.03	-0.48	3.7e-17	Congenital heart disease (maternal effect);
CESC	cis	rs9329289	0.510	rs2029604	chr10:2554700	T/C	cg15501526	chr10:2543763	NA	0.47	7.49	0.42	1e-12	Age-related hearing impairment;
CESC	cis	rs2075371	0.933	rs2244548	chr7:133986234	A/G	cg00033643	chr7:134001901	SLC35B4	0.44	5.71	0.33	3.05e-8	Mean platelet volume;
CESC	cis	rs6968419	0.788	rs72603592	chr7:115831195	C/T	cg02561103	chr7:115862891	TES	-0.39	-5.26	-0.31	3.04e-7	Intraocular pressure;
CESC	cis	rs651907	0.535	rs17412601	chr3:101499275	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.45	6.04	0.35	5.25e-9	Colorectal cancer;
CESC	cis	rs9914578	1.000	rs62067978	chr17:2013058	G/A	cg22021934	chr17:1358234	CRK	0.34	5.31	0.31	2.29e-7	Body mass index;
CESC	cis	rs2228479	0.850	rs2238531	chr16:89856217	C/G	cg19635926	chr16:89946313	TCF25	0.67	5.08	0.3	7.19e-7	Skin colour saturation;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg01160766	chr17:72199871	RPL38	-0.49	-6.66	-0.38	1.57e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs6088580	0.524	rs6088560	chr20:33228549	T/C	cg08999081	chr20:33150536	PIGU	-0.44	-6.19	-0.36	2.33e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs875971	0.862	rs1167399	chr7:65561877	G/A	cg11764359	chr7:65958608	NA	-0.78	-10.74	-0.55	1.44e-22	Aortic root size;
CESC	trans	rs561341	1.000	rs554078	chr17:30330109	A/C	cg20587970	chr11:113659929	NA	-1.48	-19.5	-0.77	4.04e-53	Hip circumference adjusted for BMI;
CESC	cis	rs9430161	0.644	rs34365965	chr1:11034442	G/A	cg02454025	chr1:11042201	C1orf127	0.99	16.16	0.7	2.35e-41	Ewing sarcoma;
CESC	cis	rs875971	0.862	rs1981799	chr7:65955559	T/C	cg10691866	chr7:65817282	TPST1	-0.35	-5.62	-0.33	4.9e-8	Aortic root size;
CESC	cis	rs4853525	0.522	rs10490538	chr2:191590066	C/T	cg10560079	chr2:191398806	TMEM194B	0.42	5.36	0.31	1.78e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
CESC	cis	rs2228479	0.850	rs17226519	chr16:89839854	T/C	cg00800038	chr16:89945340	TCF25	-0.92	-7.64	-0.42	4.02e-13	Skin colour saturation;
CESC	cis	rs9896933	0.887	rs78483419	chr17:80870884	T/C	cg20578329	chr17:80767326	TBCD	-0.72	-7.3	-0.41	3.42e-12	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
CESC	cis	rs858239	0.730	rs858290	chr7:23248036	A/G	cg23682824	chr7:23144976	KLHL7	0.42	5.54	0.32	7.17e-8	Cerebrospinal fluid biomarker levels;
CESC	cis	rs6732160	0.967	rs6760964	chr2:73387386	C/G	cg01422370	chr2:73384389	NA	0.52	9.06	0.49	2.88e-17	Intelligence (multi-trait analysis);
CESC	cis	rs854765	0.583	rs5002487	chr17:17832460	A/G	cg04398451	chr17:18023971	MYO15A	-0.62	-8.86	-0.48	1.16e-16	Total body bone mineral density;
CESC	cis	rs897984	0.762	rs1870293	chr16:30970941	T/C	cg00531865	chr16:30841666	NA	0.48	6.31	0.36	1.16e-9	Dementia with Lewy bodies;
CESC	cis	rs4803468	1.000	rs2241706	chr19:41912807	A/G	cg09537434	chr19:41945824	ATP5SL	-1.09	-19.79	-0.77	3.84e-54	Height;
CESC	cis	rs875971	1.000	rs6979382	chr7:65886375	C/T	cg18876405	chr7:65276391	NA	0.49	6.42	0.37	6.43e-10	Aortic root size;
CESC	cis	rs7555523	0.887	rs6696454	chr1:165707923	T/C	cg24409356	chr1:165738333	TMCO1	0.97	8.67	0.47	4.48e-16	Intraocular pressure;Glaucoma (high intraocular pressure);
CESC	cis	rs4853012	0.793	rs6723185	chr2:74344884	T/A	cg20891558	chr2:74357851	NA	0.84	12.26	0.6	1.12e-27	Gestational age at birth (maternal effect);
CESC	trans	rs7107217	1.000	rs1873872	chr11:129473993	A/T	cg16998327	chr1:184020984	TSEN15	0.48	6.21	0.36	2.01e-9	Breast cancer;Type 2 diabetes;
CESC	cis	rs2124969	0.548	rs7586751	chr2:160958145	T/C	cg03641300	chr2:160917029	PLA2R1	-0.57	-5.72	-0.33	2.87e-8	Waist circumference adjusted for body mass index;
CESC	trans	rs2623325	0.874	rs11711371	chr3:99109345	G/C	cg19595760	chr1:25948511	MAN1C1	-0.48	-6.34	-0.36	9.63e-10	Optic cup area;Vertical cup-disc ratio;
CESC	cis	rs4253772	0.591	rs7291444	chr22:46656246	T/G	cg09491104	chr22:46646882	C22orf40	-0.57	-8.75	-0.47	2.58e-16	LDL cholesterol;Cholesterol, total;
CESC	cis	rs72781680	1.000	rs72798417	chr2:24188656	C/T	cg20701182	chr2:24300061	SF3B14	0.64	5.74	0.33	2.56e-8	Lymphocyte counts;
CESC	cis	rs2841277	0.708	rs11623422	chr14:105407031	A/G	cg14403583	chr14:105418241	AHNAK2	-0.57	-7.86	-0.43	9.9e-14	Rheumatoid arthritis;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg20503117	chr3:5164013	ARL8B	-0.44	-6.22	-0.36	1.98e-9	Gambling;
CESC	cis	rs9303401	0.646	rs7217845	chr17:57236900	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.56	7.32	0.41	2.93e-12	Cognitive test performance;
CESC	cis	rs2050392	0.799	rs303429	chr10:30708441	C/T	cg18806716	chr10:30721971	MAP3K8	-0.42	-5.98	-0.35	7.05e-9	Inflammatory bowel disease;
CESC	cis	rs10200850	0.881	rs950225	chr2:240258244	C/T	cg26975040	chr2:240205772	HDAC4	-0.65	-5.19	-0.3	4.26e-7	Perioperative myocardial infarction in coronary artery bypass surgery;
CESC	cis	rs9399401	0.601	rs171891	chr6:142850612	G/A	cg04461802	chr6:142623433	GPR126	0.4	5.58	0.32	5.87e-8	Chronic obstructive pulmonary disease;
CESC	cis	rs7666738	0.791	rs13128640	chr4:99003918	A/C	cg03467027	chr4:99064603	C4orf37	0.44	5.51	0.32	8.65e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6788895	1.000	rs76801042	chr3:150482720	A/C	cg07663535	chr3:150480033	SIAH2	0.72	5.09	0.3	6.94e-7	Breast cancer;
CESC	cis	rs2346177	0.576	rs1530621	chr2:46688688	T/C	cg02822958	chr2:46747628	ATP6V1E2	0.44	5.47	0.32	1.03e-7	HDL cholesterol;
CESC	cis	rs1023500	0.551	rs2859438	chr22:42466980	A/T	cg04733989	chr22:42467013	NAGA	0.83	12.62	0.61	6.7e-29	Schizophrenia;
CESC	cis	rs10504229	0.906	rs7003285	chr8:58173108	A/G	cg14926445	chr8:58193284	C8orf71	-0.51	-5.47	-0.32	1.03e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs17711722	0.653	rs2460421	chr7:65491123	A/T	cg11987759	chr7:65425863	GUSB	0.42	5.8	0.34	1.84e-8	Calcium levels;
CESC	cis	rs798554	0.797	rs2107964	chr7:2863574	G/A	cg19346786	chr7:2764209	NA	-0.51	-7.14	-0.4	8.86e-12	Height;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg04619800	chr15:83654972	FAM103A1	-0.48	-6.38	-0.36	8.07e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs7647973	0.516	rs4308307	chr3:49193216	C/T	cg02487422	chr3:49467188	NICN1	0.39	5.27	0.31	2.78e-7	Menarche (age at onset);
CESC	cis	rs2243480	0.901	rs57126451	chr7:65416306	T/C	cg12463550	chr7:65579703	CRCP	0.68	5.63	0.33	4.48e-8	Diabetic kidney disease;
CESC	cis	rs8072100	0.713	rs9899859	chr17:45513049	A/G	cg08085267	chr17:45401833	C17orf57	-0.52	-6.6	-0.38	2.28e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs7927771	0.839	rs7124681	chr11:47529947	C/A	cg20307385	chr11:47447363	PSMC3	-0.4	-5.04	-0.3	8.81e-7	Subjective well-being;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21156815	chr8:22526736	BIN3	0.63	7.37	0.41	2.11e-12	Gut microbiome composition (summer);
CESC	cis	rs11229555	0.645	rs12226725	chr11:58246332	G/A	cg15696309	chr11:58395628	NA	-0.44	-5.27	-0.31	2.88e-7	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs7772486	0.686	rs4896827	chr6:145953338	T/A	cg05347473	chr6:146136440	FBXO30	0.57	7.4	0.41	1.83e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1153858	1.000	rs2668747	chr15:45617216	T/C	cg21132104	chr15:45694354	SPATA5L1	0.77	10.36	0.54	2.41e-21	Homoarginine levels;
CESC	cis	rs60154123	0.772	rs701944	chr1:210417098	G/A	cg22029157	chr1:209979665	IRF6	0.51	5.7	0.33	3.12e-8	Coronary artery disease;
CESC	cis	rs7914558	0.966	rs10786727	chr10:104698523	G/A	cg04362960	chr10:104952993	NT5C2	0.43	5.53	0.32	7.76e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs1881797	1.000	rs10925069	chr1:247681313	C/T	cg18198730	chr1:247681584	NA	-0.65	-8.7	-0.47	3.67e-16	Acute lymphoblastic leukemia (childhood);
CESC	trans	rs958685	0.766	rs7561997	chr2:70716048	C/T	cg20996124	chr1:1144203	NA	-0.4	-6.03	-0.35	5.58e-9	Hand grip strength;
CESC	cis	rs13106227	0.550	rs4859673	chr4:77364799	A/G	cg20311846	chr4:77356250	SHROOM3	-0.32	-6.07	-0.35	4.3e-9	Eosinophilic esophagitis (pediatric);
CESC	cis	rs10504229	0.683	rs16921937	chr8:58145010	A/G	cg21724239	chr8:58056113	NA	0.57	5.94	0.34	9.1e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs116095464	0.558	rs62346508	chr5:203668	T/C	cg22496380	chr5:211416	CCDC127	-0.95	-9.99	-0.52	3.65e-20	Breast cancer;
CESC	cis	rs59918340	0.728	rs59172574	chr8:142231945	C/G	cg23750338	chr8:142222470	SLC45A4	0.64	9.86	0.52	9.5e-20	Immature fraction of reticulocytes;
CESC	cis	rs12497850	0.805	rs6446198	chr3:49007638	T/A	cg06212747	chr3:49208901	KLHDC8B	0.71	9.31	0.5	5.11e-18	Parkinson's disease;
CESC	cis	rs2243480	1.000	rs10950032	chr7:65738591	C/A	cg18252515	chr7:66147081	NA	1.41	14.3	0.66	9.43e-35	Diabetic kidney disease;
CESC	cis	rs11229555	0.645	rs11229489	chr11:58244917	A/G	cg15696309	chr11:58395628	NA	-0.44	-5.23	-0.31	3.47e-7	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs7267979	1.000	rs6050599	chr20:25400240	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.87	-18.03	-0.74	5.66e-48	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs10883723	0.810	rs1884929	chr10:104275418	C/T	cg22532475	chr10:104410764	TRIM8	-0.33	-5.68	-0.33	3.5e-8	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs7666738	0.710	rs7674407	chr4:98838522	A/G	cg05340658	chr4:99064831	C4orf37	0.7	9.73	0.51	2.46e-19	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01145475	chr6:7313460	SSR1	0.57	6.16	0.35	2.62e-9	Gut microbiome composition (summer);
CESC	cis	rs6540556	0.736	rs2076152	chr1:209936060	A/G	cg05527609	chr1:210001259	C1orf107	-0.42	-5.32	-0.31	2.18e-7	Red blood cell count;
CESC	cis	rs2425143	1.000	rs113203744	chr20:34253656	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.83	-7.54	-0.42	7.65e-13	Blood protein levels;
CESC	cis	rs7666738	0.830	rs9998682	chr4:98939009	T/C	cg03467027	chr4:99064603	C4orf37	0.48	5.91	0.34	1.03e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs780096	0.506	rs2303369	chr2:27715416	C/T	cg21248554	chr2:27665150	KRTCAP3	-0.33	-6.7	-0.38	1.27e-10	Total body bone mineral density;
CESC	trans	rs10411161	0.702	rs7247017	chr19:52391769	T/C	cg22319618	chr22:45562946	NUP50	-0.74	-7.44	-0.42	1.37e-12	Breast cancer;
CESC	cis	rs748404	0.560	rs689797	chr15:43826557	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.53	6.76	0.38	8.53e-11	Lung cancer;
CESC	cis	rs2573652	0.723	rs2727201	chr15:100515311	A/G	cg00587665	chr15:100533223	ADAMTS17	-0.34	-5.39	-0.31	1.58e-7	Height;
CESC	cis	rs780096	0.587	rs6743819	chr2:27567407	G/T	cg22903471	chr2:27725779	GCKR	-0.45	-6.26	-0.36	1.53e-9	Total body bone mineral density;
CESC	cis	rs6748734	0.901	rs6720357	chr2:241830296	A/C	cg15164180	chr2:241846931	NA	-0.35	-5.16	-0.3	4.87e-7	Urinary metabolites;
CESC	cis	rs926938	0.552	rs360613	chr1:115394864	C/G	cg12756093	chr1:115239321	AMPD1	0.51	7.18	0.4	7.17e-12	Autism;
CESC	cis	rs1775715	0.737	rs55859032	chr10:32213239	C/T	cg26784012	chr10:32216390	ARHGAP12	0.39	5.11	0.3	6.18e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg01577865	chr5:176854009	GRK6	0.44	6.27	0.36	1.48e-9	Myopia (pathological);
CESC	cis	rs4728302	0.838	rs7798804	chr7:133584085	C/T	cg10665199	chr7:133106180	EXOC4	0.4	5.5	0.32	8.86e-8	Intelligence;Intelligence (multi-trait analysis);
CESC	cis	rs12824058	0.831	rs12320318	chr12:130812335	T/C	cg23887609	chr12:130822674	PIWIL1	0.45	5.82	0.34	1.69e-8	Menopause (age at onset);
CESC	cis	rs10992471	0.651	rs13296623	chr9:95301627	T/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.41	-5.16	-0.3	4.93e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CESC	cis	rs13256369	0.851	rs13256611	chr8:8564341	G/A	cg00074818	chr8:8560427	CLDN23	0.37	5.45	0.32	1.16e-7	Obesity-related traits;
CESC	cis	rs2991971	0.933	rs666720	chr1:46020795	T/C	cg05343316	chr1:45956843	TESK2	-0.5	-6.46	-0.37	5.09e-10	High light scatter reticulocyte count;
CESC	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	10.31	0.54	3.43e-21	Prudent dietary pattern;
CESC	cis	rs7267979	0.966	rs7270835	chr20:25435067	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.84	16.15	0.7	2.53e-41	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs9388451	0.626	rs3799712	chr6:126075103	A/G	cg05901451	chr6:126070800	HEY2	-0.62	-9.32	-0.5	4.81e-18	Brugada syndrome;
CESC	cis	rs2839186	0.900	rs2839196	chr21:47708037	G/A	cg13012494	chr21:47604986	C21orf56	0.41	5.43	0.32	1.3e-7	Testicular germ cell tumor;
CESC	cis	rs12142240	0.698	rs55670684	chr1:46835139	C/T	cg10495392	chr1:46806563	NSUN4	0.58	6.07	0.35	4.34e-9	Menopause (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00155844	chr15:28394612	HERC2	-0.66	-7.64	-0.42	4.08e-13	Gut microbiome composition (summer);
CESC	cis	rs10504229	1.000	rs68112919	chr8:58188247	G/A	cg14926445	chr8:58193284	C8orf71	-0.51	-5.41	-0.32	1.43e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs909674	0.865	rs5757683	chr22:39850174	G/A	cg02038168	chr22:39784481	NA	-0.65	-7.99	-0.44	4.22e-14	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs9796	0.663	rs11853192	chr15:41368515	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.47	-6.94	-0.39	3.09e-11	Menopause (age at onset);
CESC	cis	rs9811920	0.809	rs793476	chr3:99541747	G/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.44	-7.27	-0.41	3.99e-12	Axial length;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg18727501	chr4:89513542	HERC3	-0.45	-6.15	-0.35	2.79e-9	Ulcerative colitis;
CESC	cis	rs9811920	0.609	rs793462	chr3:99616461	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.64	10.11	0.53	1.53e-20	Axial length;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17655527	chr19:56128027	NA	-0.62	-6.64	-0.38	1.77e-10	Gut microbiome composition (summer);
CESC	cis	rs7312933	0.558	rs11181466	chr12:42765181	A/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.5	6.34	0.36	9.95e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs9840812	0.728	rs12630999	chr3:136300927	G/A	cg15507776	chr3:136538369	TMEM22	0.43	5.25	0.31	3.18e-7	Fibrinogen levels;
CESC	cis	rs28489187	0.683	rs233093	chr1:85823120	C/T	cg16011679	chr1:85725395	C1orf52	0.47	5.43	0.32	1.27e-7	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	cis	rs4555082	0.874	rs2816626	chr14:105735425	G/A	cg06808227	chr14:105710500	BRF1	-0.6	-6.91	-0.39	3.55e-11	Mean platelet volume;Platelet distribution width;
CESC	cis	rs11792861	0.589	rs2176692	chr9:111927723	G/A	cg05043794	chr9:111880884	C9orf5	-0.44	-7.16	-0.4	7.81e-12	Menarche (age at onset);
CESC	cis	rs2730245	0.528	rs1188954	chr7:158691417	G/A	cg14689365	chr7:158441557	NCAPG2	0.41	5.11	0.3	6.07e-7	Height;
CESC	cis	rs10504229	1.000	rs58947041	chr8:58188934	G/A	cg22535103	chr8:58192502	C8orf71	-1.05	-13.08	-0.63	1.71e-30	Developmental language disorder (linguistic errors);
CESC	cis	rs9300255	0.512	rs2851436	chr12:123667354	G/T	cg00376283	chr12:123451042	ABCB9	0.71	8.71	0.47	3.27e-16	Neutrophil percentage of white cells;
CESC	cis	rs11167764	0.945	rs891991	chr5:141484977	A/T	cg08523384	chr5:141488047	NDFIP1	-0.37	-5.49	-0.32	9.48e-8	Crohn's disease;
CESC	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	13.83	0.65	4.07e-33	Prudent dietary pattern;
CESC	cis	rs7666738	0.830	rs28867388	chr4:98962794	A/T	cg18180107	chr4:99064573	C4orf37	0.4	5.14	0.3	5.26e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7666738	0.830	rs34671152	chr4:98978177	C/T	cg17366294	chr4:99064904	C4orf37	0.59	8.43	0.46	2.31e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3125734	0.653	rs1007976	chr10:63970144	C/T	cg09941381	chr10:64027924	RTKN2	0.31	5.11	0.3	6.14e-7	Rheumatoid arthritis;
CESC	trans	rs9325144	0.647	rs12227834	chr12:38849246	G/C	cg10679878	chr6:156759499	NA	-0.33	-6.0	-0.35	6.61e-9	Morning vs. evening chronotype;
CESC	cis	rs425277	0.958	rs7546523	chr1:2043792	G/A	cg24578937	chr1:2090814	PRKCZ	0.54	8.93	0.48	7.07e-17	Height;
CESC	trans	rs6011002	1.000	rs6010614	chr20:62300906	G/C	cg02961472	chr15:70340064	NA	0.57	6.16	0.35	2.68e-9	Dental caries;
CESC	cis	rs7772486	0.846	rs1854901	chr6:146325685	T/C	cg23711669	chr6:146136114	FBXO30	0.79	11.12	0.56	7.65e-24	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs11677416	1.000	rs1878318	chr2:113545185	A/G	cg27083787	chr2:113543245	IL1A	0.61	7.53	0.42	7.75e-13	Response to antipsychotic treatment in schizophrenia (working memory);
CESC	cis	rs2019216	0.542	rs1987424	chr17:21874036	G/A	cg22648282	chr17:21454238	C17orf51	-0.41	-5.29	-0.31	2.61e-7	Pelvic organ prolapse;
CESC	cis	rs9733	0.519	rs1336900	chr1:150679033	C/T	cg04414720	chr1:150670196	GOLPH3L	0.54	7.58	0.42	5.66e-13	Tonsillectomy;
CESC	cis	rs7615952	0.641	rs4490307	chr3:125712676	T/G	cg15145296	chr3:125709740	NA	-0.5	-5.65	-0.33	4.04e-8	Blood pressure (smoking interaction);
CESC	cis	rs11098499	0.866	rs3756156	chr4:120524841	G/A	cg09307838	chr4:120376055	NA	0.88	12.11	0.6	3.6e-27	Corneal astigmatism;
CESC	cis	rs898097	0.812	rs7406011	chr17:80829980	C/T	cg05483915	chr17:80145575	CCDC57	0.45	5.38	0.31	1.63e-7	Breast cancer;
CESC	cis	rs7605378	0.567	rs717915	chr2:200714766	C/T	cg17644776	chr2:200775616	C2orf69	0.55	6.65	0.38	1.65e-10	Osteoporosis;
CESC	cis	rs4835473	0.932	rs35947648	chr4:144656245	G/A	cg25736465	chr4:144833511	NA	-0.33	-5.3	-0.31	2.48e-7	Immature fraction of reticulocytes;
CESC	cis	rs12497850	0.931	rs62262517	chr3:49134914	T/G	cg02487422	chr3:49467188	NICN1	0.47	5.85	0.34	1.42e-8	Parkinson's disease;
CESC	cis	rs2404602	0.716	rs12907805	chr15:76690606	C/T	cg26408565	chr15:76604113	ETFA	-0.42	-6.21	-0.36	2e-9	Blood metabolite levels;
CESC	trans	rs11098499	0.588	rs6534149	chr4:120559292	T/G	cg25214090	chr10:38739885	LOC399744	-0.57	-8.11	-0.45	1.87e-14	Corneal astigmatism;
CESC	cis	rs2777491	0.574	rs28700583	chr15:41714072	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.08	-17.44	-0.73	7.01e-46	Ulcerative colitis;
CESC	cis	rs1218582	0.774	rs4845683	chr1:154877407	T/C	cg06221963	chr1:154839813	KCNN3	-0.71	-12.38	-0.61	4.56e-28	Prostate cancer;
CESC	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg14159672	chr1:205819179	PM20D1	0.79	12.1	0.6	4.05e-27	Menarche (age at onset);
CESC	cis	rs10504073	0.647	rs11997959	chr8:50014044	C/T	cg00325661	chr8:49890786	NA	0.52	7.95	0.44	5.53e-14	Blood metabolite ratios;
CESC	cis	rs698813	0.774	rs786625	chr2:44604156	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.45	5.41	0.32	1.43e-7	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
CESC	cis	rs9287719	0.601	rs759401	chr2:10709922	G/A	cg00105475	chr2:10696890	NA	0.41	5.65	0.33	4.24e-8	Prostate cancer;
CESC	cis	rs2228479	0.850	rs45567439	chr16:89814604	G/A	cg04013166	chr16:89971882	TCF25	0.77	6.66	0.38	1.58e-10	Skin colour saturation;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16714616	chr20:40247229	CHD6	-0.62	-7.33	-0.41	2.87e-12	Gut microbiome composition (summer);
CESC	cis	rs2562152	0.530	rs216604	chr16:112513	T/C	cg02949481	chr16:131562	MPG	0.63	6.36	0.36	8.71e-10	Glioblastoma;
CESC	cis	rs6754311	0.731	rs1470457	chr2:136581848	A/G	cg07169764	chr2:136633963	MCM6	0.65	8.16	0.45	1.39e-14	Mosquito bite size;
CESC	cis	rs8099014	0.861	rs6566969	chr18:56118999	A/G	cg19312305	chr18:56117016	MIR122	-0.27	-5.4	-0.31	1.5e-7	Platelet count;
CESC	cis	rs9733	0.596	rs6587516	chr1:150623221	C/T	cg22823121	chr1:150693482	HORMAD1	0.48	7.12	0.4	1.03e-11	Tonsillectomy;
CESC	cis	rs9473147	0.543	rs9367279	chr6:47448336	A/G	cg20196966	chr6:47445060	CD2AP	0.4	5.1	0.3	6.36e-7	Platelet distribution width;Mean platelet volume;
CESC	cis	rs7216064	0.953	rs11868959	chr17:65840810	T/C	cg12091567	chr17:66097778	LOC651250	-0.86	-8.83	-0.48	1.49e-16	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs2361718	0.603	rs12951255	chr17:78085597	A/G	cg20811857	chr17:78079795	GAA	-0.38	-5.86	-0.34	1.36e-8	Yeast infection;
CESC	cis	rs4523957	0.855	rs9893573	chr17:2126003	A/G	cg16513277	chr17:2031491	SMG6	-0.6	-8.12	-0.45	1.72e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08089031	chr6:139456240	HECA	0.62	7.34	0.41	2.65e-12	Gut microbiome composition (summer);
CESC	trans	rs9325144	0.534	rs4882350	chr12:38686979	A/G	cg23762105	chr12:34175262	ALG10	-0.46	-6.15	-0.35	2.77e-9	Morning vs. evening chronotype;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg22571926	chr5:56112222	MAP3K1	-0.48	-6.56	-0.37	2.8e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs523522	0.673	rs643372	chr12:121022640	C/G	cg27279351	chr12:120934652	DYNLL1	0.7	9.06	0.49	2.86e-17	High light scatter reticulocyte count;
CESC	cis	rs7666738	0.822	rs17484018	chr4:98988960	G/A	cg18180107	chr4:99064573	C4orf37	0.4	5.2	0.3	3.92e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4561483	0.551	rs1126889	chr16:12061910	C/G	cg08843971	chr16:11963173	GSPT1	-0.39	-5.32	-0.31	2.25e-7	Testicular germ cell tumor;
CESC	cis	rs6546550	0.901	rs10496174	chr2:70153436	T/G	cg02498382	chr2:70120550	SNRNP27	-0.4	-6.88	-0.39	4.23e-11	Prevalent atrial fibrillation;
CESC	cis	rs7412746	0.658	rs4970982	chr1:150865084	G/C	cg22823121	chr1:150693482	HORMAD1	0.4	5.68	0.33	3.61e-8	Melanoma;
CESC	cis	rs1862618	0.620	rs2591967	chr5:56233551	C/G	cg14703610	chr5:56206110	C5orf35	-0.4	-5.2	-0.3	4.08e-7	Initial pursuit acceleration;
CESC	cis	rs7639513	0.737	rs13070228	chr3:12706914	G/A	cg23032965	chr3:12705835	RAF1	0.76	10.8	0.55	8.99e-23	Itch intensity from mosquito bite;
CESC	cis	rs67311347	1.000	rs11714032	chr3:40431605	G/A	cg09455208	chr3:40491958	NA	0.51	8.27	0.45	6.59e-15	Renal cell carcinoma;
CESC	cis	rs698833	0.521	rs35627501	chr2:44506971	G/C	cg04920474	chr2:44395004	PPM1B	0.48	6.8	0.39	6.87e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs7208859	0.673	rs8077116	chr17:29140162	A/G	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.79e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs10479542	0.892	rs7723230	chr5:178980474	T/C	cg19723775	chr5:179050963	HNRNPH1	0.41	5.46	0.32	1.08e-7	Lung cancer;
CESC	cis	rs4665809	1.000	rs10202478	chr2:26276049	T/C	cg08470875	chr2:26401718	FAM59B	-0.55	-6.0	-0.35	6.49e-9	Gut microbiome composition (summer);
CESC	cis	rs9916302	0.904	rs602688	chr17:37439496	C/T	cg15445000	chr17:37608096	MED1	0.39	6.53	0.37	3.36e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs7666738	0.830	rs13133619	chr4:99067312	C/G	cg24818145	chr4:99064322	C4orf37	-0.4	-5.19	-0.3	4.29e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3858526	0.584	rs10734560	chr11:5864503	G/T	cg13902645	chr11:5959945	NA	-0.67	-9.43	-0.5	2.19e-18	DNA methylation (variation);
CESC	cis	rs6570726	0.935	rs387965	chr6:145869366	A/G	cg05347473	chr6:146136440	FBXO30	0.45	5.98	0.34	7.1e-9	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg23209459	chr19:56652545	ZNF444	-0.46	-6.02	-0.35	5.69e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs9649213	0.593	rs10953257	chr7:97960664	A/G	cg08684580	chr7:98029266	BAIAP2L1	0.35	5.78	0.33	2.08e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs875971	0.862	rs10240949	chr7:65804417	A/G	cg18252515	chr7:66147081	NA	0.39	5.08	0.3	7.05e-7	Aortic root size;
CESC	trans	rs10463316	0.894	rs7729438	chr5:150762197	G/A	cg24389359	chr12:111284228	CCDC63	-0.33	-6.02	-0.35	5.68e-9	Metabolite levels (Pyroglutamine);
CESC	cis	rs7945705	0.869	rs2742471	chr11:9003953	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.48	-8.16	-0.45	1.33e-14	Hemoglobin concentration;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg18663499	chr3:118959852	B4GALT4	-0.43	-6.68	-0.38	1.42e-10	Gambling;
CESC	cis	rs2933343	0.729	rs6790091	chr3:128608751	G/C	cg25356066	chr3:128598488	ACAD9	0.66	9.18	0.49	1.27e-17	IgG glycosylation;
CESC	cis	rs597539	0.616	rs513476	chr11:68698996	C/T	cg18350739	chr11:68623251	NA	-0.44	-6.73	-0.38	1.02e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs7666738	0.822	rs6815312	chr4:99058220	T/C	cg17366294	chr4:99064904	C4orf37	0.62	8.88	0.48	1.03e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6582630	0.555	rs1829583	chr12:38423161	T/C	cg13010199	chr12:38710504	ALG10B	-0.42	-5.52	-0.32	8.07e-8	Drug-induced liver injury (flucloxacillin);
CESC	trans	rs9987353	0.840	rs329994	chr8:9123233	A/G	cg17986463	chr6:150326316	RAET1K	-0.49	-6.32	-0.36	1.12e-9	Recombination measurement;
CESC	cis	rs1218582	0.772	rs12069356	chr1:154849771	C/T	cg16680214	chr1:154839983	KCNN3	-0.47	-7.4	-0.41	1.82e-12	Prostate cancer;
CESC	cis	rs8070624	0.543	rs7219320	chr17:17880877	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.59	8.06	0.44	2.64e-14	Total body bone mineral density;
CESC	cis	rs1448094	0.549	rs7297996	chr12:86235899	C/T	cg19622623	chr12:86230825	RASSF9	-0.42	-5.13	-0.3	5.64e-7	Major depressive disorder;
CESC	cis	rs1552244	0.572	rs3894322	chr3:10168965	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.78	8.84	0.48	1.4e-16	Alzheimer's disease;
CESC	cis	rs7666738	0.830	rs6833312	chr4:98951356	A/T	cg03467027	chr4:99064603	C4orf37	0.45	5.67	0.33	3.69e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9399137	0.507	rs4896129	chr6:135349845	C/T	cg24558204	chr6:135376177	HBS1L	0.71	10.05	0.53	2.38e-20	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	cis	rs897080	0.515	rs786401	chr2:44712069	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.47	5.24	0.31	3.34e-7	Height;
CESC	cis	rs7851660	0.874	rs10122541	chr9:100628268	G/A	cg13688889	chr9:100608707	NA	-0.63	-8.87	-0.48	1.09e-16	Strep throat;
CESC	cis	rs7851660	0.809	rs7037324	chr9:100658318	A/G	cg13688889	chr9:100608707	NA	-0.61	-8.64	-0.47	5.47e-16	Strep throat;
CESC	cis	rs11997175	0.625	rs7018213	chr8:33625770	T/C	ch.8.33884649F	chr8:33765107	NA	0.54	6.82	0.39	6.18e-11	Body mass index;
CESC	trans	rs2832077	0.527	rs2776210	chr21:30268558	A/G	cg14791747	chr16:20752902	THUMPD1	-0.48	-6.6	-0.38	2.18e-10	Cognitive test performance;
CESC	cis	rs898097	0.841	rs9896263	chr17:80902741	A/G	cg15664640	chr17:80829946	TBCD	0.56	8.42	0.46	2.37e-15	Breast cancer;
CESC	cis	rs7666738	0.753	rs28463863	chr4:98844444	T/C	cg17366294	chr4:99064904	C4orf37	0.54	7.19	0.4	6.68e-12	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6570726	0.935	rs366308	chr6:145814532	T/A	cg05347473	chr6:146136440	FBXO30	0.5	6.71	0.38	1.15e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2576037	0.526	rs4258717	chr18:44456954	T/C	cg19077165	chr18:44547161	KATNAL2	-0.54	-7.93	-0.44	6.27e-14	Personality dimensions;
CESC	trans	rs10463316	0.894	rs12652733	chr5:150753999	G/A	cg24389359	chr12:111284228	CCDC63	-0.35	-6.17	-0.35	2.52e-9	Metabolite levels (Pyroglutamine);
CESC	cis	rs769267	0.930	rs1054930	chr19:19648346	G/C	cg03709012	chr19:19516395	GATAD2A	1.01	15.33	0.69	2.07e-38	Tonsillectomy;
CESC	cis	rs17666538	0.792	rs1703912	chr8:600643	A/G	cg23958373	chr8:599963	NA	0.77	6.19	0.36	2.33e-9	IgG glycosylation;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19981660	chr12:132434166	EP400	0.66	7.95	0.44	5.56e-14	Gut microbiome composition (summer);
CESC	cis	rs1957429	0.901	rs1467571	chr14:65347682	C/T	cg23373153	chr14:65346875	NA	0.96	11.49	0.58	4.43e-25	Pediatric areal bone mineral density (radius);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07277190	chr12:48723631	H1FNT	-0.58	-6.37	-0.36	8.28e-10	Gut microbiome composition (summer);
CESC	cis	rs1957429	0.520	rs66511472	chr14:65330330	C/A	cg23373153	chr14:65346875	NA	-0.74	-5.87	-0.34	1.33e-8	Pediatric areal bone mineral density (radius);
CESC	cis	rs79349575	0.716	rs46522	chr17:46988597	C/T	cg16584676	chr17:46985605	UBE2Z	0.5	5.8	0.34	1.88e-8	Type 2 diabetes;
CESC	cis	rs10791097	0.694	rs1893018	chr11:130756632	T/C	cg12179176	chr11:130786555	SNX19	0.65	10.22	0.53	6.73e-21	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs798554	1.000	rs798536	chr7:2766383	G/A	cg13628971	chr7:2884303	GNA12	0.59	7.61	0.42	4.77e-13	Height;
CESC	cis	rs6840258	1.000	rs72667759	chr4:87952199	C/G	cg08197287	chr4:87952173	AFF1	-0.4	-5.37	-0.31	1.7e-7	Mean corpuscular volume;Basophil percentage of granulocytes;
CESC	cis	rs3020736	0.500	rs7292241	chr22:42492063	G/A	cg15557168	chr22:42548783	NA	0.44	6.1	0.35	3.82e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs561341	0.883	rs1034626	chr17:30219500	C/G	cg19193384	chr17:30244184	NA	0.53	5.68	0.33	3.55e-8	Hip circumference adjusted for BMI;
CESC	cis	rs2239547	0.522	rs2581779	chr3:53056199	T/C	cg11645453	chr3:52864694	ITIH4	-0.32	-5.11	-0.3	6.21e-7	Schizophrenia;
CESC	cis	rs965469	1.000	rs6037583	chr20:3360632	G/A	cg25506879	chr20:3388711	C20orf194	-0.58	-6.15	-0.35	2.83e-9	IFN-related cytopenia;
CESC	cis	rs1371867	0.764	rs1020171	chr8:101288610	T/C	cg11906718	chr8:101322791	RNF19A	0.5	6.41	0.37	6.67e-10	Atrioventricular conduction;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12454419	chr4:77135195	SCARB2	0.57	7.04	0.4	1.62e-11	Gut microbiome composition (summer);
CESC	cis	rs7615952	0.641	rs7618515	chr3:125790578	C/T	cg04553112	chr3:125709451	NA	-0.54	-5.75	-0.33	2.4e-8	Blood pressure (smoking interaction);
CESC	cis	rs16854884	0.586	rs6795008	chr3:143738421	A/G	cg01302019	chr3:143689584	C3orf58	-0.32	-5.07	-0.3	7.32e-7	Economic and political preferences (feminism/equality);
CESC	cis	rs4713118	0.662	rs9468271	chr6:28024570	A/G	cg26335602	chr6:28129616	ZNF389	0.44	5.7	0.33	3.25e-8	Parkinson's disease;
CESC	cis	rs4268898	0.662	rs2303292	chr2:24432138	C/T	cg06627628	chr2:24431161	ITSN2	-1.02	-11.2	-0.57	4.2e-24	Asthma;
CESC	cis	rs514406	0.505	rs269289	chr1:53167151	A/C	cg16325326	chr1:53192061	ZYG11B	0.8	13.36	0.63	1.79e-31	Monocyte count;
CESC	cis	rs7666738	0.962	rs2865991	chr4:99067369	C/A	cg18180107	chr4:99064573	C4orf37	0.41	5.07	0.3	7.43e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3096299	0.629	rs12929744	chr16:89493580	G/C	cg00750074	chr16:89608354	SPG7	-0.42	-5.56	-0.32	6.53e-8	Multiple myeloma (IgH translocation);
CESC	cis	rs5498	0.869	rs892188	chr19:10409793	A/G	cg21994045	chr19:10403936	ICAM5	-0.43	-6.08	-0.35	4.17e-9	Lymphocyte counts;Soluble ICAM-1;Blood protein levels;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg26865258	chr19:47551991	TMEM160	0.49	6.18	0.35	2.43e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg26726589	chr20:306364	SOX12	0.47	6.59	0.38	2.34e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs9487051	0.735	rs1260594	chr6:109519891	A/C	cg01475377	chr6:109611718	NA	-0.37	-5.55	-0.32	6.99e-8	Reticulocyte fraction of red cells;
CESC	cis	rs6088580	0.524	rs6087612	chr20:33230822	T/G	cg07148914	chr20:33460835	GGT7	-0.4	-5.06	-0.3	7.78e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs3105593	0.563	rs7178070	chr15:50974496	C/T	cg08437265	chr15:50716283	USP8	0.4	5.15	0.3	5e-7	QT interval;
CESC	cis	rs7615952	0.673	rs9841194	chr3:125635739	C/T	cg05084668	chr3:125655381	ALG1L	-0.77	-7.77	-0.43	1.75e-13	Blood pressure (smoking interaction);
CESC	cis	rs2228479	1.000	rs62052186	chr16:89969567	A/T	cg14709524	chr16:89940631	TCF25	0.86	6.25	0.36	1.66e-9	Skin colour saturation;
CESC	cis	rs6942756	0.806	rs2566877	chr7:128897317	G/A	cg02491457	chr7:128862824	NA	0.65	9.72	0.51	2.71e-19	White matter hyperintensity burden;
CESC	cis	rs8031584	0.560	rs7171208	chr15:31198929	A/G	cg14829155	chr15:31115871	NA	0.7	10.22	0.53	7.16e-21	Huntington's disease progression;
CESC	cis	rs929354	0.772	rs4716460	chr7:156970054	T/C	cg05182265	chr7:156933206	UBE3C	-0.5	-7.3	-0.41	3.28e-12	Body mass index;
CESC	cis	rs736801	0.836	rs2522052	chr5:131798487	C/T	cg00255919	chr5:131827918	IRF1	0.35	5.17	0.3	4.69e-7	Breast cancer;Mosquito bite size;
CESC	cis	rs9929218	0.551	rs2296405	chr16:68721470	C/T	cg02972257	chr16:68554789	NA	0.42	5.13	0.3	5.5e-7	Colorectal cancer;
CESC	cis	rs3820068	0.581	rs6666373	chr1:15939884	A/T	cg16988262	chr1:15930761	NA	0.34	5.52	0.32	7.98e-8	Systolic blood pressure;
CESC	cis	rs1707322	1.000	rs4660318	chr1:46334876	A/G	cg03146154	chr1:46216737	IPP	0.71	9.86	0.52	9.69e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7000551	0.751	rs2100291	chr8:22374551	C/T	cg12081754	chr8:22256438	SLC39A14	0.42	5.6	0.33	5.45e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CESC	cis	rs172166	0.694	rs203876	chr6:28046673	T/C	cg26335602	chr6:28129616	ZNF389	0.38	5.52	0.32	7.89e-8	Cardiac Troponin-T levels;
CESC	cis	rs2463822	1.000	rs2513076	chr11:62103711	A/G	cg06239285	chr11:62104954	ASRGL1	0.89	8.97	0.48	5.69e-17	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs12142240	0.698	rs66516678	chr1:46810112	G/T	cg00530320	chr1:46809349	NSUN4	0.6	7.98	0.44	4.48e-14	Menopause (age at onset);
CESC	cis	rs16867321	0.639	rs12466770	chr2:181441312	C/G	cg23363182	chr2:181467187	NA	0.49	7.26	0.41	4.25e-12	Obesity;
CESC	cis	rs2204008	0.616	rs1607852	chr12:38398125	G/A	cg13010199	chr12:38710504	ALG10B	0.54	6.68	0.38	1.41e-10	Bladder cancer;
CESC	cis	rs7408868	0.764	rs62113791	chr19:15277009	C/T	cg14696996	chr19:15285081	NOTCH3	1.11	11.51	0.58	3.92e-25	Pulse pressure;
CESC	cis	rs6665290	0.904	rs12409428	chr1:227189969	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.22	-32.58	-0.89	1.11e-94	Myeloid white cell count;
CESC	cis	rs6762	0.719	rs28620453	chr11:836971	G/C	cg23754390	chr11:835074	CD151	0.32	5.77	0.33	2.24e-8	Mean platelet volume;
CESC	cis	rs10504229	1.000	rs1390411	chr8:58194146	C/A	cg02725872	chr8:58115012	NA	-0.34	-5.09	-0.3	6.69e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs17655565	0.636	rs73311144	chr12:52717544	G/A	cg08257133	chr12:52711352	KRT83	0.37	5.22	0.31	3.58e-7	Plasma amyloid beta peptide concentrations (ABx-42);
CESC	cis	rs11785400	0.793	rs4736362	chr8:143741381	G/A	cg10596483	chr8:143751796	JRK	0.41	5.26	0.31	3.03e-7	Schizophrenia;
CESC	cis	rs295140	0.546	rs295134	chr2:201110223	A/G	cg23649088	chr2:200775458	C2orf69	-0.42	-5.48	-0.32	9.82e-8	QT interval;
CESC	cis	rs6964587	0.967	rs10279210	chr7:91616891	G/A	cg17063962	chr7:91808500	NA	0.56	7.66	0.43	3.61e-13	Breast cancer;
CESC	cis	rs7178572	0.568	rs12901739	chr15:77395491	C/T	cg22256960	chr15:77711686	NA	-0.54	-6.86	-0.39	4.85e-11	Type 2 diabetes;
CESC	cis	rs1790761	0.505	rs17593068	chr11:67350932	G/T	cg00290607	chr11:67383545	NA	-0.36	-5.33	-0.31	2.14e-7	Mean corpuscular volume;
CESC	cis	rs10504229	1.000	rs57941207	chr8:58169821	A/G	cg24829409	chr8:58192753	C8orf71	-0.75	-9.71	-0.51	2.88e-19	Developmental language disorder (linguistic errors);
CESC	cis	rs4613509	1	rs4613509	chr3:160728059	T/C	cg04691961	chr3:161091175	C3orf57	-0.39	-5.2	-0.3	3.97e-7	Morning vs. evening chronotype;
CESC	cis	rs2797160	0.904	rs2326292	chr6:125999674	G/A	cg05901451	chr6:126070800	HEY2	-0.48	-7.04	-0.4	1.6e-11	Endometrial cancer;
CESC	cis	rs4803468	1.000	rs4803463	chr19:41911040	C/G	cg14132834	chr19:41945861	ATP5SL	-0.63	-7.89	-0.44	8.04e-14	Height;
CESC	cis	rs7772486	0.875	rs2748485	chr6:146332421	T/C	cg23711669	chr6:146136114	FBXO30	0.81	11.57	0.58	2.49e-25	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs10953454	1.000	rs10272668	chr7:104494565	A/C	cg04245439	chr3:142607978	PCOLCE2	-0.76	-6.14	-0.35	2.96e-9	Obesity;
CESC	cis	rs4268898	0.662	rs2891382	chr2:24511491	C/G	cg20701182	chr2:24300061	SF3B14	0.62	6.85	0.39	5.2e-11	Asthma;
CESC	cis	rs4253772	0.513	rs6008597	chr22:46703904	A/C	cg10541313	chr22:46663664	TTC38	0.67	5.9	0.34	1.1e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs2839186	0.596	rs4819217	chr21:47644092	G/T	cg00815214	chr21:47717953	NA	-0.37	-5.51	-0.32	8.6e-8	Testicular germ cell tumor;
CESC	cis	rs6460942	0.778	rs76030612	chr7:12462937	C/A	cg17427002	chr7:12443146	VWDE	-0.44	-5.04	-0.3	8.59e-7	Coronary artery disease;
CESC	cis	rs425277	1.000	rs421992	chr1:2077260	C/T	cg16545954	chr1:2118288	C1orf86	0.33	5.62	0.33	4.82e-8	Height;
CESC	cis	rs4474465	0.850	rs10793323	chr11:78244170	C/T	cg27205649	chr11:78285834	NARS2	0.43	5.28	0.31	2.65e-7	Alzheimer's disease (survival time);
CESC	cis	rs12541635	0.966	rs16873989	chr8:106966381	C/T	cg10147462	chr8:107024639	NA	0.39	5.34	0.31	2.02e-7	Age of smoking initiation;
CESC	cis	rs6800768	0.663	rs7428009	chr3:24094151	A/C	cg10674438	chr3:24145617	LOC152024	-0.43	-5.84	-0.34	1.5e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs6912958	0.712	rs2754260	chr6:88397666	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.35	-5.61	-0.33	5.2e-8	Monocyte percentage of white cells;
CESC	cis	rs3785574	0.962	rs2584632	chr17:61880641	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.58	7.15	0.4	8.48e-12	Height;
CESC	cis	rs763014	0.966	rs35642938	chr16:642249	T/C	cg00908189	chr16:619842	PIGQ	0.64	9.06	0.49	2.94e-17	Height;
CESC	cis	rs34172651	0.502	rs12930727	chr16:24838497	G/T	cg04756594	chr16:24857601	SLC5A11	-0.38	-5.16	-0.3	4.83e-7	Intelligence (multi-trait analysis);
CESC	cis	rs7829975	0.714	rs60315134	chr8:8670599	A/G	cg06636001	chr8:8085503	FLJ10661	0.42	5.5	0.32	9.11e-8	Mood instability;
CESC	cis	rs9488822	0.676	rs10456902	chr6:116333742	C/G	cg05304507	chr6:116381966	FRK	-0.26	-6.68	-0.38	1.44e-10	Cholesterol, total;LDL cholesterol;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg03604796	chr7:134896227	WDR91	-0.51	-6.94	-0.39	3.04e-11	Fibrinogen levels;
CESC	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.47	7.42	0.41	1.59e-12	Bipolar disorder;
CESC	cis	rs7618915	0.501	rs12635140	chr3:52738165	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.6	-8.57	-0.47	8.76e-16	Bipolar disorder;
CESC	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.65	7.41	0.41	1.72e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs12188164	0.543	rs890972	chr5:462465	C/A	cg16584290	chr5:462447	EXOC3	0.47	7.09	0.4	1.19e-11	Cystic fibrosis severity;
CESC	cis	rs4423214	0.879	rs4945008	chr11:71221248	A/G	cg05163923	chr11:71159392	DHCR7	0.79	10.87	0.56	5.22e-23	Vitamin D levels;
CESC	cis	rs9457247	0.566	rs10946207	chr6:167456036	C/T	cg07741184	chr6:167504864	NA	0.37	6.3	0.36	1.24e-9	Crohn's disease;
CESC	cis	rs9457247	0.935	rs1044059	chr6:167369897	C/A	cg23791538	chr6:167370224	RNASET2	0.59	8.29	0.45	5.92e-15	Crohn's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14259716	chr8:145623015	CPSF1	-0.53	-6.24	-0.36	1.7e-9	Gut microbiome composition (summer);
CESC	cis	rs933688	1.000	rs7715402	chr5:90679504	T/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.16	16.64	0.71	4.87e-43	Smoking behavior;
CESC	cis	rs875971	0.798	rs6460304	chr7:65964728	G/A	cg12463550	chr7:65579703	CRCP	0.49	6.11	0.35	3.61e-9	Aortic root size;
CESC	cis	rs853679	0.517	rs9380065	chr6:28144751	A/G	cg17949981	chr6:28129498	ZNF389	0.42	5.23	0.31	3.39e-7	Depression;
CESC	cis	rs6582630	0.537	rs6582500	chr12:38534206	G/A	cg26384229	chr12:38710491	ALG10B	0.74	11.16	0.57	6e-24	Drug-induced liver injury (flucloxacillin);
CESC	trans	rs916888	0.821	rs199506	chr17:44859031	A/G	cg27125505	chr17:43679177	LOC644172	-0.47	-6.4	-0.37	6.98e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs79976124	0.879	rs12214239	chr6:66636059	A/G	cg07460842	chr6:66804631	NA	0.72	8.31	0.45	5.13e-15	Type 2 diabetes;
CESC	cis	rs12220238	0.554	rs11001029	chr10:76154777	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.56	5.16	0.3	4.9e-7	Soluble interleukin-2 receptor subunit alpha;
CESC	cis	rs4689592	0.503	rs10516184	chr4:7060959	C/T	cg19539972	chr4:7069911	GRPEL1	0.71	7.39	0.41	1.89e-12	Monocyte percentage of white cells;
CESC	cis	rs1395	0.778	rs4665960	chr2:27467598	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.45	5.84	0.34	1.53e-8	Blood metabolite levels;
CESC	cis	rs8092503	1.000	rs12970682	chr18:52481635	G/A	cg12377874	chr18:52495404	RAB27B	0.38	6.2	0.36	2.13e-9	Childhood body mass index;
CESC	cis	rs7296418	0.961	rs1727307	chr12:123575742	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.33	-5.05	-0.3	8.33e-7	Platelet count;
CESC	cis	rs8031584	0.651	rs28664821	chr15:31172323	G/A	cg08704250	chr15:31115839	NA	0.74	10.56	0.54	5.53e-22	Huntington's disease progression;
CESC	cis	rs11690935	0.589	rs6729945	chr2:172864695	C/G	cg13550731	chr2:172543902	DYNC1I2	0.48	6.63	0.38	1.83e-10	Schizophrenia;
CESC	cis	rs7618915	0.501	rs2109634	chr3:52752075	T/G	cg17372223	chr3:52568218	NT5DC2	0.44	6.64	0.38	1.8e-10	Bipolar disorder;
CESC	cis	rs9596863	1.000	rs9568943	chr13:54423065	G/T	ch.13.53330881F	chr13:54432880	NA	0.66	5.25	0.31	3.08e-7	Epilepsy and lamotrigine-induced maculopapular eruptions;
CESC	cis	rs1475911	1.000	rs2839467	chr21:43513200	A/G	cg19766460	chr21:43528205	UMODL1;C21orf128	-0.61	-6.87	-0.39	4.55e-11	IgG glycosylation;
CESC	cis	rs12464483	0.591	rs4952170	chr2:30885429	G/A	cg07150166	chr2:30669952	LCLAT1	0.52	5.03	0.3	8.86e-7	Pre-treatment pain in head and neck squamous cell carcinoma;
CESC	trans	rs875971	0.638	rs3898855	chr7:66036398	G/C	cg26939375	chr7:64535504	NA	-0.64	-8.7	-0.47	3.62e-16	Aortic root size;
CESC	cis	rs1559088	0.948	rs12610266	chr19:33581237	C/G	cg27124370	chr19:33622961	WDR88	-0.48	-6.37	-0.36	8.14e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs2718058	0.613	rs2718037	chr7:37777846	G/C	cg15028436	chr7:37888078	TXNDC3	0.44	5.99	0.35	6.68e-9	Alzheimer's disease (late onset);
CESC	cis	rs9612	1.000	rs346534	chr19:44250831	A/G	cg08581076	chr19:44259116	C19orf61	0.5	5.9	0.34	1.1e-8	Exhaled nitric oxide output;
CESC	cis	rs6089829	0.925	rs6122086	chr20:61664528	T/C	cg08564027	chr20:61660810	NA	0.9	15.14	0.68	9.71e-38	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7520050	0.966	rs12409773	chr1:46358831	A/G	cg03146154	chr1:46216737	IPP	-0.45	-5.71	-0.33	2.99e-8	Red blood cell count;Reticulocyte count;
CESC	cis	rs9926296	0.565	rs8055825	chr16:89832848	C/T	cg27121462	chr16:89883253	FANCA	0.76	10.69	0.55	2.04e-22	Vitiligo;
CESC	cis	rs10479542	0.766	rs7733389	chr5:178974997	C/T	cg05457628	chr5:178986728	RUFY1	0.43	6.07	0.35	4.45e-9	Lung cancer;
CESC	cis	rs9309473	0.519	rs2178154	chr2:73661738	C/T	cg20560298	chr2:73613845	ALMS1	0.49	7.01	0.4	1.92e-11	Metabolite levels;
CESC	cis	rs7605827	0.930	rs11681344	chr2:15711885	C/A	cg19274914	chr2:15703543	NA	0.3	5.23	0.31	3.38e-7	Educational attainment (years of education);
CESC	cis	rs1050631	0.592	rs948417	chr18:33711274	A/G	cg25426722	chr18:33708991	SLC39A6;ELP2	0.52	7.14	0.4	9.15e-12	Esophageal squamous cell cancer (length of survival);
CESC	cis	rs703842	1.000	rs11172335	chr12:58175201	C/T	cg00677455	chr12:58241039	CTDSP2	0.51	6.46	0.37	5.06e-10	Multiple sclerosis;
CESC	cis	rs9291683	0.552	rs11736410	chr4:10017241	G/A	cg11266682	chr4:10021025	SLC2A9	0.72	14.87	0.67	9.06e-37	Bone mineral density;
CESC	cis	rs6088580	0.634	rs6059880	chr20:33088669	G/A	cg06115741	chr20:33292138	TP53INP2	0.46	5.82	0.34	1.68e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs2197308	0.765	rs11182481	chr12:37926019	T/C	cg13010199	chr12:38710504	ALG10B	0.49	6.14	0.35	3.06e-9	Morning vs. evening chronotype;
CESC	cis	rs3008870	0.920	rs3008860	chr1:67391003	G/C	cg08660285	chr1:67390436	MIER1;WDR78	1.06	15.03	0.68	2.49e-37	Lymphocyte percentage of white cells;
CESC	trans	rs6572548	0.504	rs1956082	chr14:49665496	A/C	cg12477297	chr1:150336859	RPRD2	-0.55	-6.17	-0.35	2.57e-9	Subjective well-being;
CESC	cis	rs10504229	1.000	rs67188507	chr8:58187492	A/T	cg24829409	chr8:58192753	C8orf71	-0.76	-9.9	-0.52	7.25e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs11155671	0.530	rs7742993	chr6:150205095	G/A	cg09699651	chr6:150184138	LRP11	0.55	7.62	0.42	4.45e-13	Testicular germ cell tumor;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg24881159	chr15:31284219	MTMR10	0.49	6.28	0.36	1.39e-9	Systemic lupus erythematosus;
CESC	cis	rs763121	0.853	rs9610986	chr22:39025277	T/C	cg14440974	chr22:39074834	NA	-0.41	-5.48	-0.32	9.71e-8	Menopause (age at onset);
CESC	cis	rs3862260	0.509	rs2281493	chr1:120162787	T/C	cg11530693	chr1:120165357	ZNF697	0.69	10.68	0.55	2.17e-22	Systemic lupus erythematosus;
CESC	cis	rs9322193	0.923	rs12174716	chr6:149965623	C/T	cg07701084	chr6:150067640	NUP43	0.44	6.03	0.35	5.38e-9	Lung cancer;
CESC	cis	rs875971	0.505	rs1167385	chr7:65513308	G/A	cg05332525	chr7:65337924	VKORC1L1	-0.49	-6.05	-0.35	5.03e-9	Aortic root size;
CESC	cis	rs35306767	0.855	rs35666723	chr10:867346	A/G	cg26597838	chr10:835615	NA	1.18	11.49	0.58	4.57e-25	Eosinophil percentage of granulocytes;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg05611218	chr5:43121586	ZNF131	-0.56	-7.17	-0.4	7.5e-12	Ulcerative colitis;
CESC	cis	rs7264396	0.635	rs6088971	chr20:34535373	A/G	cg17201900	chr20:34330562	RBM39	0.49	5.11	0.3	6.14e-7	Total cholesterol levels;
CESC	cis	rs1784581	0.894	rs1784594	chr6:162382734	A/G	cg17173639	chr6:162384350	PARK2	-0.82	-13.71	-0.64	1.1e-32	Itch intensity from mosquito bite;
CESC	cis	rs4728302	0.869	rs10156088	chr7:133592544	G/A	cg10665199	chr7:133106180	EXOC4	0.38	5.33	0.31	2.05e-7	Intelligence;Intelligence (multi-trait analysis);
CESC	cis	rs6691722	0.503	rs1142057	chr1:24706292	C/T	cg02336364	chr1:24764700	NIPAL3	-0.32	-6.79	-0.38	7.45e-11	Response to interferon beta in multiple sclerosis;
CESC	cis	rs116095464	0.558	rs10057492	chr5:239503	T/C	cg20965017	chr5:231967	SDHA	-0.47	-5.3	-0.31	2.49e-7	Breast cancer;
CESC	cis	rs1577917	0.959	rs12201739	chr6:86720739	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.49	-6.37	-0.36	8.3e-10	Response to antipsychotic treatment;
CESC	cis	rs1538970	0.816	rs11211123	chr1:45957609	G/A	cg03146154	chr1:46216737	IPP	0.49	5.57	0.32	6.31e-8	Platelet count;
CESC	cis	rs6089584	0.816	rs4925336	chr20:60627180	A/G	cg24733560	chr20:60626293	TAF4	0.49	7.13	0.4	9.83e-12	Body mass index;
CESC	cis	rs1270639	0.778	rs1638021	chr7:157438037	A/G	cg13357408	chr7:157437802	PTPRN2	0.56	6.42	0.37	6.42e-10	Colorectal cancer;
CESC	cis	rs11792861	0.926	rs11787878	chr9:111866749	C/T	cg05043794	chr9:111880884	C9orf5	-0.42	-6.93	-0.39	3.22e-11	Menarche (age at onset);
CESC	cis	rs2652822	0.901	rs4775622	chr15:63408179	A/C	cg02713581	chr15:63449717	RPS27L	0.53	6.88	0.39	4.24e-11	Metabolic traits;
CESC	trans	rs7618501	0.602	rs9311446	chr3:50092226	G/A	cg21659725	chr3:3221576	CRBN	-0.53	-7.42	-0.41	1.59e-12	Intelligence (multi-trait analysis);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg02599068	chr2:25195213	DNAJC27	0.45	6.13	0.35	3.16e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs9815354	0.812	rs73073229	chr3:42007850	T/C	cg03022575	chr3:42003672	ULK4	0.69	6.24	0.36	1.72e-9	Pulse pressure;Diastolic blood pressure;
CESC	trans	rs9987353	0.840	rs329994	chr8:9123233	A/G	cg21694044	chr22:41215540	SLC25A17	-0.47	-6.06	-0.35	4.75e-9	Recombination measurement;
CESC	cis	rs4555082	0.957	rs3825762	chr14:105752404	T/C	cg06808227	chr14:105710500	BRF1	-0.53	-6.54	-0.37	3.14e-10	Mean platelet volume;Platelet distribution width;
CESC	cis	rs660498	0.507	rs765700	chr10:27734885	G/A	cg08398567	chr10:27609333	NA	0.39	5.36	0.31	1.79e-7	Asthma (childhood onset);
CESC	cis	rs2243480	0.803	rs403089	chr7:65517723	T/C	cg18252515	chr7:66147081	NA	-1.25	-12.55	-0.61	1.18e-28	Diabetic kidney disease;
CESC	cis	rs6831352	0.879	rs2602888	chr4:100041706	C/T	cg13256891	chr4:100009986	ADH5	0.74	7.89	0.44	7.94e-14	Alcohol dependence;
CESC	cis	rs72781680	0.716	rs72788206	chr2:24084989	T/C	cg08917208	chr2:24149416	ATAD2B	0.58	5.81	0.34	1.82e-8	Lymphocyte counts;
CESC	cis	rs6665290	0.669	rs3738725	chr1:227174210	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.14	-25.39	-0.84	6.16e-73	Myeloid white cell count;
CESC	cis	rs208520	0.909	rs58958359	chr6:67021381	A/C	cg07460842	chr6:66804631	NA	0.84	8.13	0.45	1.67e-14	Exhaled nitric oxide output;
CESC	cis	rs75804782	0.690	rs56198112	chr2:239348887	A/G	cg18131467	chr2:239335373	ASB1	-0.66	-5.83	-0.34	1.58e-8	Morning vs. evening chronotype;Chronotype;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg17411103	chr17:65241599	HELZ	0.48	6.14	0.35	3.04e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs9457247	1.000	rs429083	chr6:167383972	T/C	cg07741184	chr6:167504864	NA	0.31	5.53	0.32	7.76e-8	Crohn's disease;
CESC	cis	rs722599	0.748	rs3742783	chr14:75377008	C/T	cg11812906	chr14:75593930	NEK9	-0.47	-5.63	-0.33	4.7e-8	IgG glycosylation;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05703344	chr12:111051745	TCTN1	-0.57	-6.67	-0.38	1.51e-10	Gut microbiome composition (summer);
CESC	cis	rs1348850	0.574	rs11889488	chr2:178426793	A/G	cg23306229	chr2:178417860	TTC30B	-0.7	-6.03	-0.35	5.46e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs7216064	1.000	rs9912770	chr17:65868233	C/T	cg12091567	chr17:66097778	LOC651250	-0.8	-9.03	-0.49	3.62e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs2806561	0.796	rs1738467	chr1:23506521	C/T	cg12483005	chr1:23474871	LUZP1	0.39	6.15	0.35	2.86e-9	Height;
CESC	cis	rs712039	0.652	rs853224	chr17:35791328	A/T	cg16670864	chr17:35848621	DUSP14	0.44	5.38	0.31	1.63e-7	Tuberculosis;
CESC	cis	rs1665050	0.534	rs12911441	chr15:59236540	T/A	cg05156742	chr15:59063176	FAM63B	0.5	6.42	0.37	6.18e-10	Atopic dermatitis;
CESC	cis	rs7772486	0.875	rs2814872	chr6:146310234	T/C	cg23711669	chr6:146136114	FBXO30	0.9	13.1	0.63	1.45e-30	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2066819	1.000	rs773664	chr12:56702176	C/T	cg26316697	chr12:56727976	PAN2	-0.69	-6.58	-0.37	2.52e-10	Psoriasis vulgaris;
CESC	cis	rs6964587	1.000	rs6950470	chr7:91680641	G/A	cg17063962	chr7:91808500	NA	0.56	7.79	0.43	1.53e-13	Breast cancer;
CESC	cis	rs9815354	0.812	rs74947509	chr3:42006323	T/C	cg03022575	chr3:42003672	ULK4	0.67	6.27	0.36	1.43e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs916888	0.821	rs199513	chr17:44856932	A/G	cg01570182	chr17:44337453	NA	-0.84	-10.02	-0.52	3.09e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs113835537	0.529	rs11227509	chr11:66281194	T/C	cg24851651	chr11:66362959	CCS	0.45	5.55	0.32	6.92e-8	Airway imaging phenotypes;
CESC	cis	rs9287719	0.781	rs6732671	chr2:10759149	T/G	cg02196655	chr2:10830764	NOL10	-0.36	-5.59	-0.32	5.58e-8	Prostate cancer;
CESC	cis	rs9486719	1.000	rs2263192	chr6:96873037	C/G	cg06623918	chr6:96969491	KIAA0776	0.81	8.29	0.45	5.61e-15	Migraine;Coronary artery disease;
CESC	cis	rs2749592	0.725	rs9417245	chr10:37826322	C/T	cg25427524	chr10:38739819	LOC399744	0.41	5.09	0.3	6.81e-7	Age-related hearing impairment (SNP x SNP interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01187952	chr3:63850081	THOC7;ATXN7	0.65	8.15	0.45	1.42e-14	Gut microbiome composition (summer);
CESC	cis	rs10504229	0.871	rs56372514	chr8:58157166	A/G	cg22535103	chr8:58192502	C8orf71	-0.92	-11.42	-0.57	7.99e-25	Developmental language disorder (linguistic errors);
CESC	cis	rs796364	0.616	rs769955	chr2:200692595	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.55	5.44	0.32	1.24e-7	Schizophrenia;
CESC	cis	rs77972916	0.536	rs59362315	chr2:43594931	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.53	-5.39	-0.31	1.57e-7	Granulocyte percentage of myeloid white cells;
CESC	cis	rs9393777	0.513	rs13210025	chr6:26654817	A/C	cg12826209	chr6:26865740	GUSBL1	0.73	7.92	0.44	6.48e-14	Intelligence (multi-trait analysis);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg02153299	chr16:30968484	SETD1A	-0.47	-6.41	-0.37	6.48e-10	Fibrinogen levels;
CESC	cis	rs3749237	0.595	rs1464567	chr3:49459252	C/G	cg07636037	chr3:49044803	WDR6	-0.6	-8.62	-0.47	6.31e-16	Resting heart rate;
CESC	cis	rs262150	0.842	rs2657398	chr7:158784911	T/C	cg10570241	chr7:158785291	NA	0.31	5.31	0.31	2.32e-7	Facial morphology (factor 20);
CESC	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg26354017	chr1:205819088	PM20D1	0.85	13.22	0.63	5.7e-31	Menarche (age at onset);
CESC	cis	rs1957429	0.808	rs8009510	chr14:65351338	T/G	cg23373153	chr14:65346875	NA	0.96	11.49	0.58	4.43e-25	Pediatric areal bone mineral density (radius);
CESC	cis	rs6460942	0.597	rs12699381	chr7:12527026	G/A	cg10578991	chr7:12443926	VWDE	-0.49	-5.08	-0.3	7.1e-7	Coronary artery disease;
CESC	cis	rs13191362	0.872	rs56404230	chr6:163252863	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.5	5.15	0.3	5.01e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs736408	0.609	rs2230535	chr3:52800284	T/C	cg17372223	chr3:52568218	NT5DC2	0.43	6.19	0.36	2.25e-9	Bipolar disorder;
CESC	cis	rs977987	0.806	rs34996006	chr16:75479434	A/G	cg03315344	chr16:75512273	CHST6	0.43	6.15	0.35	2.85e-9	Dupuytren's disease;
CESC	cis	rs11098499	0.908	rs12504149	chr4:120318577	G/A	cg09307838	chr4:120376055	NA	0.92	12.53	0.61	1.29e-28	Corneal astigmatism;
CESC	cis	rs1448094	0.791	rs61929395	chr12:86331584	A/T	cg02569458	chr12:86230093	RASSF9	0.45	6.43	0.37	5.79e-10	Major depressive disorder;
CESC	cis	rs7131987	0.903	rs10843373	chr12:29420608	A/T	cg09582351	chr12:29534625	ERGIC2	-0.33	-5.58	-0.32	6.03e-8	QT interval;
CESC	cis	rs765787	0.530	rs4775832	chr15:45534828	A/G	cg24006582	chr15:45444508	DUOX1	-0.59	-7.23	-0.41	5.15e-12	Uric acid levels;
CESC	cis	rs854765	0.547	rs4925135	chr17:17952868	T/C	cg16928487	chr17:17741425	SREBF1	0.55	9.13	0.49	1.86e-17	Total body bone mineral density;
CESC	cis	rs7336332	0.598	rs1885988	chr13:28010262	C/T	cg22138327	chr13:27999177	GTF3A	-0.61	-5.93	-0.34	9.33e-9	Weight;
CESC	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg23708337	chr7:1209742	NA	0.55	5.41	0.32	1.44e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2455799	0.634	rs11128764	chr3:15902836	G/C	cg16303742	chr3:15540471	COLQ	-0.38	-5.93	-0.34	9.55e-9	Mean platelet volume;
CESC	cis	rs1707322	0.721	rs10789471	chr1:46215619	G/A	cg05343316	chr1:45956843	TESK2	0.51	6.32	0.36	1.09e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg07899956	chr17:74261249	FAM100B	-0.42	-6.14	-0.35	3.08e-9	Fibrinogen levels;
CESC	cis	rs1538970	0.962	rs3219489	chr1:45797505	C/G	cg05343316	chr1:45956843	TESK2	0.85	10.73	0.55	1.58e-22	Platelet count;
CESC	cis	rs1372520	0.577	rs2737028	chr4:90717016	A/G	cg15133208	chr4:90757351	SNCA	-0.43	-5.74	-0.33	2.63e-8	Neuroticism;
CESC	cis	rs28830936	0.625	rs8038764	chr15:41907905	A/C	cg11010575	chr15:42129464	JMJD7-PLA2G4B;JMJD7	0.33	5.13	0.3	5.61e-7	Diastolic blood pressure;
CESC	cis	rs1218582	0.772	rs11264290	chr1:154912300	C/T	cg03351412	chr1:154909251	PMVK	0.69	9.21	0.49	1.02e-17	Prostate cancer;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg27140474	chr11:82868555	PCF11	-0.48	-6.86	-0.39	4.89e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs2425143	1.000	rs7273174	chr20:34350306	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.67	5.85	0.34	1.42e-8	Blood protein levels;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg06633615	chr10:131592944	NA	-0.43	-6.09	-0.35	3.92e-9	Systemic lupus erythematosus;
CESC	cis	rs1055129	0.537	rs1135640	chr17:73949540	C/G	cg02678768	chr17:74002944	EVPL	-0.4	-5.49	-0.32	9.61e-8	White matter hyperintensity burden;
CESC	cis	rs12200560	0.505	rs60879781	chr6:97075466	A/T	cg06623918	chr6:96969491	KIAA0776	0.5	6.49	0.37	4.13e-10	Coronary heart disease;
CESC	trans	rs561341	1.000	rs546519	chr17:30297682	T/G	cg20587970	chr11:113659929	NA	-1.12	-14.24	-0.66	1.49e-34	Hip circumference adjusted for BMI;
CESC	cis	rs4975709	0.589	rs1466607	chr5:1864856	A/G	cg14773178	chr5:1868261	NA	0.29	5.09	0.3	6.89e-7	Cardiovascular disease risk factors;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg19732566	chr8:145911660	NA	-0.37	-6.02	-0.35	5.76e-9	Height;
CESC	cis	rs875971	1.000	rs6956179	chr7:65806659	C/T	cg18876405	chr7:65276391	NA	-0.56	-7.56	-0.42	6.66e-13	Aortic root size;
CESC	cis	rs10927875	0.722	rs1763605	chr1:16338925	T/G	cg21214613	chr1:16344536	HSPB7	0.37	5.42	0.32	1.31e-7	Dilated cardiomyopathy;
CESC	cis	rs453301	0.624	rs2288671	chr8:8860894	T/C	cg06636001	chr8:8085503	FLJ10661	0.43	5.51	0.32	8.57e-8	Joint mobility (Beighton score);
CESC	cis	rs854765	0.505	rs2955358	chr17:17946623	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.57	-8.11	-0.45	1.84e-14	Total body bone mineral density;
CESC	cis	rs7666738	0.830	rs6855393	chr4:99056534	T/C	cg18180107	chr4:99064573	C4orf37	0.42	5.36	0.31	1.79e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6460942	0.915	rs62448599	chr7:12453764	C/T	cg10578991	chr7:12443926	VWDE	-0.5	-5.34	-0.31	2.03e-7	Coronary artery disease;
CESC	cis	rs950776	0.647	rs495956	chr15:78869930	C/T	cg06917634	chr15:78832804	PSMA4	-0.5	-6.19	-0.36	2.26e-9	Sudden cardiac arrest;
CESC	cis	rs12586317	0.547	rs112138868	chr14:35444385	C/T	cg05294307	chr14:35346193	BAZ1A	-0.49	-5.37	-0.31	1.75e-7	Psoriasis;
CESC	cis	rs7552404	0.731	rs11161836	chr1:76354333	C/T	cg22875332	chr1:76189707	ACADM	0.59	5.66	0.33	3.89e-8	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs7786808	0.712	rs2335167	chr7:158213948	A/C	cg01191920	chr7:158217561	PTPRN2	-0.36	-6.07	-0.35	4.41e-9	Obesity-related traits;
CESC	cis	rs7618915	0.547	rs11130323	chr3:52770277	T/C	cg18404041	chr3:52824283	ITIH1	-0.41	-6.75	-0.38	9.55e-11	Bipolar disorder;
CESC	trans	rs2755237	0.519	rs11616662	chr13:41119466	A/G	cg16029875	chr1:204320179	PLEKHA6	0.57	6.05	0.35	4.91e-9	Central corneal thickness;
CESC	cis	rs9291683	0.588	rs12647117	chr4:10022059	T/C	cg00071950	chr4:10020882	SLC2A9	0.9	17.26	0.73	2.98e-45	Bone mineral density;
CESC	cis	rs7772486	0.790	rs3924498	chr6:146233338	A/T	cg05347473	chr6:146136440	FBXO30	-0.57	-7.31	-0.41	3.07e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2456568	0.867	rs7935801	chr11:93658000	G/A	cg26875233	chr11:93583750	C11orf90	-0.32	-5.56	-0.32	6.54e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
CESC	cis	rs12701220	0.655	rs7799656	chr7:1140515	C/T	cg23978390	chr7:1156363	C7orf50	0.64	6.33	0.36	1.03e-9	Bronchopulmonary dysplasia;
CESC	cis	rs13256369	0.851	rs13258283	chr8:8563630	T/C	cg00074818	chr8:8560427	CLDN23	0.38	5.41	0.32	1.39e-7	Obesity-related traits;
CESC	trans	rs1814175	0.519	rs3913237	chr11:49551828	G/A	cg15704280	chr7:45808275	SEPT13	0.82	9.9	0.52	7.22e-20	Height;
CESC	cis	rs11577318	0.853	rs11803933	chr1:26629465	G/C	cg19743891	chr1:26644573	UBXN11;CD52	-0.28	-5.11	-0.3	6.05e-7	Granulocyte percentage of myeloid white cells;
CESC	trans	rs60380162	0.963	rs4111582	chr1:87736382	G/A	cg20163645	chr8:1900353	ARHGEF10	-0.43	-6.04	-0.35	5.32e-9	Loneliness (linear analysis);
CESC	cis	rs11871801	1.000	rs6503703	chr17:40592207	A/T	cg21433558	chr17:40837037	CNTNAP1	0.45	5.06	0.3	7.79e-7	Crohn's disease;
CESC	cis	rs78456975	1.000	rs13413096	chr2:1553588	G/A	cg26248373	chr2:1572462	NA	-0.57	-5.31	-0.31	2.29e-7	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs477692	0.905	rs508360	chr10:131424969	A/G	cg05714579	chr10:131428358	MGMT	0.58	8.4	0.46	2.66e-15	Response to temozolomide;
CESC	cis	rs208520	0.690	rs1351867	chr6:66760995	A/G	cg07460842	chr6:66804631	NA	0.96	12.67	0.61	4.52e-29	Exhaled nitric oxide output;
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg07822143	chr4:146019674	ABCE1;ANAPC10	-0.4	-6.16	-0.35	2.7e-9	Vertical cup-disc ratio;
CESC	cis	rs875971	0.789	rs10260426	chr7:65736042	G/T	cg12463550	chr7:65579703	CRCP	-0.46	-5.81	-0.34	1.76e-8	Aortic root size;
CESC	cis	rs7618915	0.501	rs3733045	chr3:52643307	A/G	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	5.84	0.34	1.51e-8	Bipolar disorder;
CESC	cis	rs854765	0.583	rs11650890	chr17:17790882	C/T	cg04398451	chr17:18023971	MYO15A	0.64	8.99	0.48	4.76e-17	Total body bone mineral density;
CESC	cis	rs514406	0.679	rs960570	chr1:53237763	A/G	cg24675658	chr1:53192096	ZYG11B	0.77	11.82	0.59	3.51e-26	Monocyte count;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg24397552	chr15:40226086	EIF2AK4	0.44	6.21	0.36	2.06e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11421459	chr7:91763989	CYP51A1	-0.57	-6.33	-0.36	1.04e-9	Gut microbiome composition (summer);
CESC	cis	rs9420	0.961	rs499188	chr11:57434122	C/A	cg23127183	chr11:57508653	C11orf31	-0.43	-5.05	-0.3	8.37e-7	Schizophrenia;
CESC	cis	rs7208859	0.623	rs56378576	chr17:29010120	C/T	cg13385521	chr17:29058706	SUZ12P	0.72	5.63	0.33	4.63e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs9486715	0.867	rs9480700	chr6:96965056	A/G	cg18709589	chr6:96969512	KIAA0776	0.47	6.57	0.37	2.6200000000000003e-10	Headache;
CESC	cis	rs7210086	0.808	rs6501558	chr17:70639488	T/C	cg04206342	chr17:70636940	NA	-0.33	-6.09	-0.35	3.92e-9	Ulcerative colitis;
CESC	cis	rs2842992	0.830	rs1535475	chr6:160148935	T/C	cg11366901	chr6:160182831	ACAT2	0.77	9.96	0.52	4.68e-20	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs9814567	0.752	rs1534030	chr3:134330083	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.4	-5.09	-0.3	6.84e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg18765753	chr7:1198926	ZFAND2A	-0.58	-8.93	-0.48	7.49e-17	Longevity;Endometriosis;
CESC	cis	rs9863	0.828	rs34114498	chr12:124480373	G/C	cg17562584	chr12:124393655	DNAH10	0.32	5.5	0.32	8.94e-8	White blood cell count;
CESC	cis	rs7520050	0.933	rs12045165	chr1:46256022	C/A	cg06784218	chr1:46089804	CCDC17	-0.29	-5.15	-0.3	5.07e-7	Red blood cell count;Reticulocyte count;
CESC	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg12419862	chr22:24373484	LOC391322	0.68	9.49	0.5	1.42e-18	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs9902453	0.900	rs9910970	chr17:28478329	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.65	8.35	0.46	3.91e-15	Coffee consumption (cups per day);
CESC	cis	rs3820068	0.655	rs72645826	chr1:15889741	A/G	cg17385448	chr1:15911702	AGMAT	0.37	5.81	0.34	1.8e-8	Systolic blood pressure;
CESC	cis	rs1862618	0.853	rs832568	chr5:56153776	G/A	cg24549020	chr5:56110836	MAP3K1	0.68	7.64	0.43	3.9e-13	Initial pursuit acceleration;
CESC	cis	rs853679	0.517	rs35227624	chr6:28132726	A/G	cg12963246	chr6:28129442	ZNF389	0.56	7.38	0.41	1.99e-12	Depression;
CESC	cis	rs1003719	0.680	rs2835629	chr21:38521660	A/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.59	-8.03	-0.44	3.23e-14	Eye color traits;
CESC	cis	rs7809950	0.954	rs12673675	chr7:107113220	T/C	cg23024343	chr7:107201750	COG5	-0.43	-6.11	-0.35	3.58e-9	Coronary artery disease;
CESC	cis	rs9611565	0.765	rs767593	chr22:41779971	G/T	cg06634786	chr22:41940651	POLR3H	-0.72	-7.55	-0.42	7.14e-13	Vitiligo;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12538597	chr11:85906334	NA	-0.69	-8.49	-0.46	1.51e-15	Gut microbiome composition (summer);
CESC	cis	rs1797081	1.000	rs1797081	chr10:16874565	A/G	cg23933602	chr10:16859644	RSU1	1.12	24.3	0.83	2.17e-69	Platelet distribution width;
CESC	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.59	6.64	0.38	1.78e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs6963495	0.556	rs818474	chr7:105155243	A/T	cg19920283	chr7:105172520	RINT1	0.54	6.28	0.36	1.41e-9	Bipolar disorder (body mass index interaction);
CESC	cis	rs79349575	0.721	rs3744608	chr17:46993233	C/G	cg16584676	chr17:46985605	UBE2Z	0.53	6.6	0.38	2.25e-10	Type 2 diabetes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12275661	chr10:33247232	ITGB1	0.68	7.68	0.43	3.06e-13	Gut microbiome composition (summer);
CESC	cis	rs7762018	0.660	rs78181018	chr6:170096652	A/C	cg19338460	chr6:170058176	WDR27	-1.06	-8.47	-0.46	1.73e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs965469	1.000	rs6037556	chr20:3317890	G/C	cg25506879	chr20:3388711	C20orf194	-0.53	-5.81	-0.34	1.78e-8	IFN-related cytopenia;
CESC	cis	rs6502050	0.805	rs9898507	chr17:80119628	C/T	cg23985595	chr17:80112537	CCDC57	-0.41	-6.57	-0.37	2.6e-10	Life satisfaction;
CESC	cis	rs72781680	0.611	rs55983206	chr2:24333995	A/C	cg06627628	chr2:24431161	ITSN2	-0.66	-6.22	-0.36	1.98e-9	Lymphocyte counts;
CESC	cis	rs6938	0.596	rs11630918	chr15:75155896	C/T	cg14664628	chr15:75095509	CSK	-0.53	-7.01	-0.4	1.96e-11	Breast cancer;
CESC	cis	rs11630290	0.649	rs1036910	chr15:64157015	T/C	cg12036633	chr15:63758958	NA	0.44	5.28	0.31	2.74e-7	Iris characteristics;
CESC	cis	rs7100689	0.646	rs1934696	chr10:82124966	T/C	cg00277334	chr10:82204260	NA	-0.58	-7.76	-0.43	1.84e-13	Post bronchodilator FEV1;
CESC	cis	rs9902453	0.904	rs12936302	chr17:28349476	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.72	-9.33	-0.5	4.29e-18	Coffee consumption (cups per day);
CESC	cis	rs35146811	0.622	rs6946204	chr7:99589125	T/C	cg22531904	chr7:99595276	NA	-0.39	-5.15	-0.3	5.12e-7	Coronary artery disease;
CESC	cis	rs6026584	1.000	rs15754	chr20:57469227	C/G	cg11480267	chr20:57463503	GNAS	0.47	5.69	0.33	3.44e-8	Renal function-related traits (BUN);
CESC	cis	rs637571	0.558	rs10896064	chr11:65641033	G/C	cg26695010	chr11:65641043	EFEMP2	0.63	8.0	0.44	3.86e-14	Eosinophil percentage of white cells;
CESC	cis	rs8114671	0.527	rs2253484	chr20:33405263	A/T	cg08999081	chr20:33150536	PIGU	-0.38	-5.42	-0.32	1.32e-7	Height;
CESC	cis	rs863345	0.967	rs7517254	chr1:158469882	A/G	cg12129480	chr1:158549410	OR10X1	-0.31	-6.19	-0.36	2.34e-9	Pneumococcal bacteremia;
CESC	cis	rs7552404	0.924	rs1251075	chr1:76190569	C/G	cg03433033	chr1:76189801	ACADM	0.71	9.69	0.51	3.31e-19	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs7662987	0.517	rs2851263	chr4:100030354	A/G	cg12011299	chr4:100065546	ADH4	0.6	6.52	0.37	3.48e-10	Smoking initiation;
CESC	cis	rs6121246	0.567	rs6058189	chr20:30192389	A/G	cg13852791	chr20:30311386	BCL2L1	0.67	6.71	0.38	1.2e-10	Mean corpuscular hemoglobin;
CESC	cis	rs4665809	1.000	rs4665809	chr2:26251361	C/T	cg04944784	chr2:26401820	FAM59B	0.67	7.58	0.42	5.95e-13	Gut microbiome composition (summer);
CESC	trans	rs73568641	0.583	rs73572625	chr6:154089464	T/C	cg08374472	chr16:87445639	ZCCHC14	-0.46	-6.15	-0.35	2.82e-9	Methadone dose in opioid dependence;
CESC	trans	rs709082	0.573	rs709088	chr3:191461155	C/T	cg25305879	chr2:106814630	NA	0.41	6.45	0.37	5.29e-10	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7904368	0.806	rs6602161	chr10:16862280	A/G	cg23933602	chr10:16859644	RSU1	0.64	6.02	0.35	5.67e-9	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
CESC	trans	rs561341	0.824	rs1978115	chr17:30220776	A/C	cg20587970	chr11:113659929	NA	-1.03	-12.71	-0.62	3.33e-29	Hip circumference adjusted for BMI;
CESC	cis	rs9517313	0.615	rs4772079	chr13:99090837	C/G	cg07423050	chr13:99094983	FARP1	-0.32	-5.61	-0.33	5.12e-8	Neuroticism;
CESC	cis	rs7618915	0.547	rs4130905	chr3:52709831	A/T	cg17372223	chr3:52568218	NT5DC2	0.44	6.54	0.37	3.13e-10	Bipolar disorder;
CESC	cis	rs4919694	1.000	rs12241091	chr10:104808997	G/A	cg04362960	chr10:104952993	NT5C2	0.79	7.08	0.4	1.27e-11	Arsenic metabolism;
CESC	cis	rs6499129	0.558	rs28711261	chr16:67617186	A/G	cg26727032	chr16:67993705	SLC12A4	-0.57	-6.12	-0.35	3.41e-9	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs611744	0.647	rs10106246	chr8:109268710	T/C	cg21045802	chr8:109455806	TTC35	0.48	5.99	0.35	6.98e-9	Dupuytren's disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg00252696	chr1:31769601	ZCCHC17;SNRNP40	-0.41	-6.03	-0.35	5.53e-9	Fibrinogen levels;
CESC	trans	rs9858542	0.953	rs11715915	chr3:49455330	A/G	cg21659725	chr3:3221576	CRBN	0.58	6.65	0.38	1.66e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs8141529	0.509	rs5762864	chr22:29253364	T/C	cg02153584	chr22:29168773	CCDC117	0.6	8.06	0.44	2.66e-14	Lymphocyte counts;
CESC	cis	rs875971	0.540	rs736270	chr7:65428822	T/C	cg11987759	chr7:65425863	GUSB	-0.46	-6.09	-0.35	4.02e-9	Aortic root size;
CESC	cis	rs6076065	0.748	rs6137933	chr20:23383103	A/T	cg11657817	chr20:23433608	CST11	0.4	6.1	0.35	3.7e-9	Facial morphology (factor 15, philtrum width);
CESC	cis	rs6540556	0.682	rs11119332	chr1:209892960	C/T	cg05527609	chr1:210001259	C1orf107	-0.66	-7.34	-0.41	2.56e-12	Red blood cell count;
CESC	cis	rs11190604	1.000	rs2495743	chr10:102329739	G/C	cg07080220	chr10:102295463	HIF1AN	0.64	5.85	0.34	1.46e-8	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs10504229	0.636	rs77691549	chr8:58055126	G/T	cg21724239	chr8:58056113	NA	0.53	5.04	0.3	8.64e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg04025307	chr7:1156635	C7orf50	0.41	6.61	0.38	2.11e-10	Longevity;Endometriosis;
CESC	cis	rs7666738	0.791	rs10856934	chr4:99010844	A/G	cg03676636	chr4:99064102	C4orf37	-0.34	-5.23	-0.31	3.46e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs2797160	0.904	rs1418637	chr6:125992553	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.49	-6.67	-0.38	1.48e-10	Endometrial cancer;
CESC	cis	rs4474465	1.000	rs7933612	chr11:78209366	G/T	cg02023728	chr11:77925099	USP35	-0.38	-5.31	-0.31	2.35e-7	Alzheimer's disease (survival time);
CESC	cis	rs9649213	0.593	rs6949718	chr7:97924483	G/A	cg21770322	chr7:97807741	LMTK2	0.57	8.78	0.47	2.12e-16	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs11792861	0.816	rs7027263	chr9:111699569	G/A	cg05043794	chr9:111880884	C9orf5	-0.39	-6.41	-0.37	6.44e-10	Menarche (age at onset);
CESC	cis	rs34172651	0.517	rs189919	chr16:24737741	G/A	cg06505273	chr16:24850292	NA	-0.52	-5.93	-0.34	9.48e-9	Intelligence (multi-trait analysis);
CESC	cis	rs4253772	0.513	rs9615345	chr22:46713631	C/T	cg07012999	chr22:46692446	CN5H6.4;GTSE1	0.55	5.6	0.33	5.26e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs8060686	0.516	rs255052	chr16:68024995	C/T	cg26727032	chr16:67993705	SLC12A4	-0.53	-6.43	-0.37	5.99e-10	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs9311474	0.508	rs6786919	chr3:52599789	A/G	cg18099408	chr3:52552593	STAB1	-0.36	-6.1	-0.35	3.74e-9	Electroencephalogram traits;
CESC	cis	rs2274273	0.624	rs67795323	chr14:55797833	G/A	cg04306507	chr14:55594613	LGALS3	0.29	5.11	0.3	6.15e-7	Protein biomarker;
CESC	cis	rs10129255	0.500	rs8004923	chr14:107194164	A/G	cg23076370	chr14:107095027	NA	-0.64	-9.33	-0.5	4.36e-18	Kawasaki disease;
CESC	cis	rs7202877	0.706	rs11149812	chr16:75323645	T/C	cg04384234	chr16:75411784	CFDP1	-0.45	-5.19	-0.3	4.24e-7	Type 2 diabetes;Type 1 diabetes;
CESC	cis	rs2075371	0.863	rs34231360	chr7:133944988	A/C	cg20476274	chr7:133979776	SLC35B4	0.63	9.07	0.49	2.72e-17	Mean platelet volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07319014	chr16:89777268	C16orf7	-0.59	-6.73	-0.38	1.05e-10	Gut microbiome composition (summer);
CESC	cis	rs1003719	0.688	rs2835660	chr21:38568882	G/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.61	-8.29	-0.45	5.58e-15	Eye color traits;
CESC	cis	rs477895	1.000	rs7938380	chr11:64034866	G/A	cg04317338	chr11:64019027	PLCB3	0.7	5.96	0.34	8.22e-9	Mean platelet volume;
CESC	cis	rs8044868	0.530	rs2287999	chr16:72059149	A/G	cg01557791	chr16:72042693	DHODH	-0.46	-6.36	-0.36	8.8e-10	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CESC	cis	rs11252926	0.565	rs60553947	chr10:474284	T/C	cg03684893	chr10:554711	DIP2C	0.37	5.42	0.32	1.35e-7	Psychosis in Alzheimer's disease;
CESC	cis	rs9287719	0.967	rs6709466	chr2:10748257	T/C	cg00105475	chr2:10696890	NA	0.38	5.57	0.32	6.34e-8	Prostate cancer;
CESC	cis	rs9322193	0.607	rs9322229	chr6:150230085	A/G	cg01145232	chr6:150245071	RAET1G	0.45	5.93	0.34	9.65e-9	Lung cancer;
CESC	cis	rs11048434	0.636	rs11047953	chr12:9064923	A/C	cg23795048	chr12:9217529	LOC144571	0.36	5.68	0.33	3.46e-8	Sjögren's syndrome;
CESC	cis	rs6693567	0.565	rs578353	chr1:150287884	C/G	cg09579323	chr1:150459698	TARS2	0.44	5.93	0.34	9.45e-9	Migraine;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg19455322	chr3:46735335	ALS2CL	-0.43	-6.65	-0.38	1.67e-10	Gambling;
CESC	cis	rs2236918	1.000	rs1776137	chr1:242027045	A/G	cg17736920	chr1:242011382	EXO1	0.72	9.16	0.49	1.5e-17	Menopause (age at onset);
CESC	cis	rs12142240	0.698	rs1475390	chr1:46816340	A/G	cg00530320	chr1:46809349	NSUN4	0.58	7.89	0.44	8.17e-14	Menopause (age at onset);
CESC	cis	rs6942756	0.955	rs9641849	chr7:128899238	C/T	cg02491457	chr7:128862824	NA	-0.7	-9.93	-0.52	5.71e-20	White matter hyperintensity burden;
CESC	cis	rs10504229	0.953	rs57669205	chr8:58172253	T/C	cg05313129	chr8:58192883	C8orf71	-0.54	-6.23	-0.36	1.82e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs8062405	1.000	rs8055138	chr16:28891465	C/T	cg08761264	chr16:28874980	SH2B1	-0.47	-5.85	-0.34	1.42e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs4654899	1.000	rs7554770	chr1:21481361	A/T	cg05370193	chr1:21551575	ECE1	0.41	6.22	0.36	1.96e-9	Superior frontal gyrus grey matter volume;
CESC	cis	rs3820068	0.603	rs72647138	chr1:15980929	C/T	cg13390004	chr1:15929781	NA	0.36	5.69	0.33	3.37e-8	Systolic blood pressure;
CESC	cis	rs6893300	0.961	rs3797776	chr5:179193598	C/T	cg14593053	chr5:179126677	CANX	-0.52	-5.77	-0.33	2.19e-8	Resting heart rate;
CESC	cis	rs7605827	0.897	rs6431715	chr2:15717917	C/A	cg19274914	chr2:15703543	NA	0.35	6.39	0.37	7.23e-10	Educational attainment (years of education);
CESC	cis	rs16854884	0.657	rs1867609	chr3:143752916	A/G	cg06585982	chr3:143692056	C3orf58	0.5	6.71	0.38	1.18e-10	Economic and political preferences (feminism/equality);
CESC	cis	rs13191362	1.000	rs34725898	chr6:163127302	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.09	11.08	0.56	1.09e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs3204270	0.639	rs62080213	chr17:79642531	C/T	cg26965718	chr17:79658957	HGS	-0.75	-5.53	-0.32	7.54e-8	Dental caries;
CESC	cis	rs2933343	0.729	rs789224	chr3:128598231	A/C	cg25356066	chr3:128598488	ACAD9	0.63	8.94	0.48	6.95e-17	IgG glycosylation;
CESC	cis	rs10504229	0.683	rs72649187	chr8:58108320	A/G	cg21724239	chr8:58056113	NA	0.57	5.9	0.34	1.08e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs9858542	0.953	rs1801143	chr3:49570200	C/T	cg03060546	chr3:49711283	APEH	-0.52	-5.99	-0.35	6.8e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs10845606	1.000	rs11055013	chr12:12829037	T/C	cg04607235	chr12:12878440	APOLD1	-0.7	-7.84	-0.43	1.12e-13	Systemic lupus erythematosus;
CESC	cis	rs2243480	1.000	rs35432774	chr7:65393019	G/C	cg12463550	chr7:65579703	CRCP	0.7	5.7	0.33	3.21e-8	Diabetic kidney disease;
CESC	cis	rs72634258	0.554	rs13306061	chr1:7913445	C/T	cg26816564	chr1:7831052	VAMP3	0.49	5.16	0.3	4.91e-7	Inflammatory bowel disease;
CESC	cis	rs2991971	0.810	rs998199	chr1:45912898	A/C	cg24296786	chr1:45957014	TESK2	-0.62	-8.77	-0.47	2.21e-16	High light scatter reticulocyte count;
CESC	cis	rs6748734	1.000	rs6748734	chr2:241837452	A/G	cg07537917	chr2:241836409	C2orf54	-0.25	-5.4	-0.31	1.49e-7	Urinary metabolites;
CESC	cis	rs1801251	1.000	rs283469	chr2:233656997	G/T	cg25237894	chr2:233734115	C2orf82	0.44	7.81	0.43	1.34e-13	Coronary artery disease;
CESC	cis	rs798554	0.796	rs2533884	chr7:2836848	T/G	cg19717773	chr7:2847554	GNA12	-0.56	-7.68	-0.43	3.17e-13	Height;
CESC	cis	rs10949834	0.504	rs13238778	chr7:73567709	G/A	cg07137043	chr7:73588983	EIF4H	-0.63	-7.03	-0.4	1.8e-11	Verbal memory performance (residualized delayed recall change);
CESC	cis	rs2836950	0.545	rs11700449	chr21:40522419	A/T	cg17971929	chr21:40555470	PSMG1	-0.56	-7.35	-0.41	2.48e-12	Menarche (age at onset);
CESC	cis	rs1799949	0.930	rs4445938	chr17:41337900	A/C	cg25072359	chr17:41440525	NA	0.48	6.46	0.37	4.98e-10	Menopause (age at onset);
CESC	cis	rs17345786	0.906	rs58835747	chr3:101243634	T/C	cg12386194	chr3:101231763	SENP7	0.6	6.53	0.37	3.28e-10	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1348850	0.526	rs6723063	chr2:178491398	C/T	cg23306229	chr2:178417860	TTC30B	0.7	6.1	0.35	3.73e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs7824557	0.591	rs2572452	chr8:11228254	C/T	cg21775007	chr8:11205619	TDH	-0.54	-8.59	-0.47	7.7e-16	Retinal vascular caliber;
CESC	cis	rs2228479	0.764	rs35518096	chr16:89961140	C/A	cg00800038	chr16:89945340	TCF25	-0.7	-6.79	-0.38	7.4e-11	Skin colour saturation;
CESC	cis	rs734999	0.505	rs4648659	chr1:2560903	T/G	cg18854424	chr1:2615690	NA	-0.3	-5.83	-0.34	1.62e-8	Ulcerative colitis;
CESC	cis	rs4629710	0.592	rs3777476	chr6:131533821	A/C	cg12606694	chr6:131520996	AKAP7	0.45	5.6	0.33	5.38e-8	Multiple myeloma (IgH translocation);
CESC	cis	rs6912958	1.000	rs2207144	chr6:88150816	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.56	-7.57	-0.42	6.29e-13	Monocyte percentage of white cells;
CESC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg00983485	chr15:31284262	MTMR10	0.5	6.36	0.36	8.92e-10	Tetralogy of Fallot;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01930679	chr17:79514274	C17orf70	-0.52	-6.42	-0.37	6.21e-10	Gut microbiome composition (summer);
CESC	cis	rs71403859	0.730	rs12922775	chr16:71584354	C/T	cg08717414	chr16:71523259	ZNF19	-0.86	-7.78	-0.43	1.66e-13	Post bronchodilator FEV1;
CESC	cis	rs9322193	0.923	rs12174349	chr6:150039148	G/A	cg07701084	chr6:150067640	NUP43	0.48	6.85	0.39	5.03e-11	Lung cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22466620	chr6:138187852	TNFAIP3	0.59	6.62	0.38	2.03e-10	Gut microbiome composition (summer);
CESC	cis	rs4253772	0.530	rs55653327	chr22:46682976	C/T	cg24881330	chr22:46731750	TRMU	0.82	6.02	0.35	5.78e-9	LDL cholesterol;Cholesterol, total;
CESC	cis	rs8067354	0.645	rs9910518	chr17:57812067	T/C	cg13753209	chr17:57696993	CLTC	0.65	7.89	0.44	7.95e-14	Hemoglobin concentration;
CESC	cis	rs3091242	0.967	rs3091240	chr1:25676935	G/T	cg12412775	chr1:25698385	RHCE	-0.31	-5.49	-0.32	9.57e-8	Erythrocyte sedimentation rate;
CESC	cis	rs853679	0.550	rs1150692	chr6:28173957	A/G	cg17949981	chr6:28129498	ZNF389	0.44	5.68	0.33	3.47e-8	Depression;
CESC	cis	rs1348850	0.874	rs2166558	chr2:178373652	G/T	cg22681709	chr2:178499509	PDE11A	-0.41	-5.88	-0.34	1.24e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs13242816	1.000	rs13226307	chr7:116137485	A/T	cg04696780	chr7:116139425	CAV2	0.57	5.22	0.31	3.61e-7	P wave duration;
CESC	cis	rs1707322	1.000	rs6693336	chr1:46354595	C/T	cg03146154	chr1:46216737	IPP	0.71	9.86	0.52	9.69e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs561341	0.883	rs4450460	chr17:30201309	C/T	cg19193384	chr17:30244184	NA	0.49	5.11	0.3	6.2e-7	Hip circumference adjusted for BMI;
CESC	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.71	9.82	0.52	1.29e-19	Prudent dietary pattern;
CESC	cis	rs11785400	0.762	rs7007349	chr8:143722673	T/C	cg24634471	chr8:143751801	JRK	0.45	5.74	0.33	2.53e-8	Schizophrenia;
CESC	cis	rs4713118	0.513	rs149954	chr6:28035246	G/A	cg23161317	chr6:28129485	ZNF389	0.38	5.24	0.31	3.26e-7	Parkinson's disease;
CESC	cis	rs8017423	0.967	rs4900030	chr14:90689813	T/A	cg14092571	chr14:90743983	NA	-0.57	-8.28	-0.45	6.11e-15	Mortality in heart failure;
CESC	cis	rs9649213	0.593	rs10808107	chr7:97951671	T/C	cg08684580	chr7:98029266	BAIAP2L1	-0.35	-5.69	-0.33	3.38e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs2777491	0.574	rs28700583	chr15:41714072	C/T	cg02330683	chr15:41787940	ITPKA	0.42	5.09	0.3	6.82e-7	Ulcerative colitis;
CESC	cis	rs853679	0.550	rs1233699	chr6:28169158	A/T	cg22143856	chr6:28129313	ZNF389	0.44	5.93	0.34	9.34e-9	Depression;
CESC	cis	rs2228479	0.850	rs11076623	chr16:89844120	G/T	cg00800038	chr16:89945340	TCF25	-0.91	-7.58	-0.42	5.75e-13	Skin colour saturation;
CESC	trans	rs561341	0.769	rs559228	chr17:30294527	T/C	cg27661571	chr11:113659931	NA	-0.83	-7.69	-0.43	2.82e-13	Hip circumference adjusted for BMI;
CESC	cis	rs412050	0.947	rs239914	chr22:22317337	C/T	cg17089214	chr22:22089827	YPEL1	0.66	6.14	0.35	3.02e-9	Attention deficit hyperactivity disorder;
CESC	cis	rs3862435	0.518	rs2601166	chr15:90911179	G/A	cg22089800	chr15:90895588	ZNF774	0.53	5.63	0.33	4.66e-8	Response to exercise (triglyceride level interaction);
CESC	cis	rs6540559	1.000	rs1044516	chr1:209959614	G/T	cg21951975	chr1:209979733	IRF6	0.58	8.78	0.47	2.03e-16	Cleft lip with or without cleft palate;
CESC	cis	rs9816226	0.645	rs16860471	chr3:185847441	G/T	cg00760338	chr3:185826511	ETV5	-0.62	-6.61	-0.38	2.06e-10	Obesity;Body mass index;
CESC	cis	rs3857536	0.505	rs208459	chr6:66911055	C/T	cg07460842	chr6:66804631	NA	-0.63	-7.73	-0.43	2.29e-13	Blood trace element (Cu levels);
CESC	cis	rs736408	0.546	rs3733046	chr3:52621627	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.78	0.38	7.7e-11	Bipolar disorder;
CESC	cis	rs8092503	1.000	rs12964118	chr18:52495506	A/G	cg12377874	chr18:52495404	RAB27B	0.37	6.14	0.35	3.02e-9	Childhood body mass index;
CESC	cis	rs10788972	0.779	rs7516791	chr1:54551875	G/T	cg25741118	chr1:54482237	LDLRAD1	-0.22	-5.25	-0.31	3.19e-7	Parkinson disease and lewy body pathology;
CESC	cis	rs4704187	0.687	rs10805893	chr5:74507390	C/A	cg03227963	chr5:74354835	NA	0.28	5.19	0.3	4.21e-7	Response to amphetamines;
CESC	cis	rs2455799	0.613	rs11128760	chr3:15873407	A/G	cg16303742	chr3:15540471	COLQ	-0.38	-5.78	-0.33	2.06e-8	Mean platelet volume;
CESC	cis	rs10088262	0.629	rs12549683	chr8:124798276	G/C	cg20713898	chr8:124780851	FAM91A1	-0.67	-9.11	-0.49	2.02e-17	Pancreatic cancer;
CESC	cis	rs3733585	0.638	rs6449155	chr4:9956547	T/G	cg11266682	chr4:10021025	SLC2A9	-0.59	-11.16	-0.57	5.9e-24	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs7772486	0.681	rs9390343	chr6:146010527	A/T	cg05347473	chr6:146136440	FBXO30	-0.49	-6.25	-0.36	1.65e-9	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs561341	0.505	rs28708703	chr17:30386845	C/G	cg12193833	chr17:30244370	NA	-0.52	-5.12	-0.3	5.9e-7	Hip circumference adjusted for BMI;
CESC	cis	rs9486715	0.793	rs2499777	chr6:97013814	T/C	cg18709589	chr6:96969512	KIAA0776	-0.47	-6.59	-0.38	2.36e-10	Headache;
CESC	cis	rs4812048	0.846	rs151361	chr20:57614002	A/G	cg14073986	chr20:57617431	SLMO2	0.54	5.96	0.34	8.01e-9	Mean platelet volume;
CESC	cis	rs8017423	0.900	rs11625870	chr14:90693396	C/T	cg14092571	chr14:90743983	NA	0.54	7.96	0.44	5.07e-14	Mortality in heart failure;
CESC	cis	rs9894429	1.000	rs11651264	chr17:79576394	A/G	cg13777783	chr17:79615861	NA	0.35	5.79	0.34	1.99e-8	Eye color traits;
CESC	cis	rs1559088	0.600	rs58173463	chr19:33596749	C/T	cg17764715	chr19:33622953	WDR88	0.58	8.2	0.45	1.02e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs739401	0.572	rs384490	chr11:3078885	A/C	cg25174290	chr11:3078921	CARS	0.66	9.27	0.49	6.74e-18	Longevity;
CESC	cis	rs1218582	0.772	rs10796934	chr1:154849479	C/G	cg06221963	chr1:154839813	KCNN3	-0.66	-11.56	-0.58	2.63e-25	Prostate cancer;
CESC	cis	rs1008375	1.000	rs12507142	chr4:17656103	A/G	cg15017067	chr4:17643749	FAM184B	0.39	5.47	0.32	1.02e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs9467711	0.606	rs9393706	chr6:26361500	G/A	cg14345882	chr6:26364793	BTN3A2	0.59	6.08	0.35	4.27e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs9309473	0.500	rs10865398	chr2:73741497	A/C	cg20560298	chr2:73613845	ALMS1	0.47	6.77	0.38	8.28e-11	Metabolite levels;
CESC	cis	rs3820068	0.637	rs4646080	chr1:15826627	A/T	cg17385448	chr1:15911702	AGMAT	0.39	6.18	0.35	2.44e-9	Systolic blood pressure;
CESC	cis	rs9649213	0.574	rs34830366	chr7:97899535	G/T	cg00277769	chr7:97922759	BAIAP2L1	-0.32	-5.1	-0.3	6.4e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs11718455	1.000	rs9858826	chr3:44031412	C/T	cg08738300	chr3:44038990	NA	-0.43	-6.05	-0.35	4.87e-9	Coronary artery disease;
CESC	cis	rs4808199	0.847	rs34647936	chr19:19548239	T/G	cg03709012	chr19:19516395	GATAD2A	1.15	13.67	0.64	1.53e-32	Nonalcoholic fatty liver disease;
CESC	cis	rs9733	0.744	rs12758227	chr1:150844583	C/A	cg18016565	chr1:150552671	MCL1	-0.35	-5.74	-0.33	2.55e-8	Tonsillectomy;
CESC	cis	rs1594829	0.553	rs6996531	chr8:26153455	C/A	cg11498726	chr8:26250323	BNIP3L	-0.4	-6.06	-0.35	4.68e-9	Height;
CESC	cis	rs1707322	1.000	rs1768817	chr1:46514534	C/G	cg03146154	chr1:46216737	IPP	-0.72	-9.73	-0.51	2.49e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs7582180	0.700	rs1437971	chr2:100986964	A/C	cg07601672	chr11:27384696	CCDC34	0.59	6.07	0.35	4.44e-9	Intelligence (multi-trait analysis);
CESC	cis	rs35306767	0.714	rs12767171	chr10:1084491	A/G	cg26597838	chr10:835615	NA	0.49	5.34	0.31	1.96e-7	Eosinophil percentage of granulocytes;
CESC	cis	rs10504229	0.636	rs114725691	chr8:58054292	C/T	cg22535103	chr8:58192502	C8orf71	-0.65	-7.2	-0.4	6.27e-12	Developmental language disorder (linguistic errors);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08556938	chr17:58512855	NA	-0.6	-6.48	-0.37	4.48e-10	Gut microbiome composition (summer);
CESC	cis	rs9814567	1.000	rs9828815	chr3:134265749	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.45	-6.15	-0.35	2.87e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs7246657	0.765	rs10402455	chr19:37728707	G/A	cg23950597	chr19:37808831	NA	-0.6	-5.89	-0.34	1.16e-8	Coronary artery calcification;
CESC	trans	rs2235573	0.527	rs139866	chr22:38354684	C/T	cg19894588	chr14:64061835	NA	0.63	8.4	0.46	2.72e-15	Glioblastoma;Glioma;
CESC	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg23708337	chr7:1209742	NA	0.52	5.16	0.3	4.88e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs9660992	0.710	rs55671824	chr1:205249814	G/A	cg00857998	chr1:205179979	DSTYK	0.46	5.21	0.3	3.77e-7	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs13126513	0.519	rs12641768	chr4:100558594	C/A	cg05468953	chr4:100565104	NA	0.34	5.26	0.31	2.98e-7	Metabolite levels (MHPG);
CESC	cis	rs193541	0.593	rs154499	chr5:122219666	A/C	cg19412675	chr5:122181750	SNX24	0.46	5.38	0.31	1.64e-7	Glucose homeostasis traits;
CESC	cis	rs9308433	0.529	rs9430131	chr1:214481121	C/A	cg06198575	chr1:214491504	SMYD2	0.5	6.09	0.35	3.86e-9	IgG glycosylation;
CESC	cis	rs262150	0.788	rs2657408	chr7:158782275	A/G	cg19418458	chr7:158789849	NA	-0.5	-7.69	-0.43	2.81e-13	Facial morphology (factor 20);
CESC	cis	rs2439831	0.867	rs2412778	chr15:43660982	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	12.96	0.62	4.52e-30	Lung cancer in ever smokers;
CESC	cis	rs11077998	0.901	rs3794723	chr17:80529495	G/A	cg10255544	chr17:80519551	FOXK2	0.55	8.73	0.47	2.83e-16	Reticulocyte fraction of red cells;
CESC	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg26338869	chr17:61819248	STRADA	-0.67	-8.94	-0.48	6.62e-17	Prudent dietary pattern;
CESC	cis	rs7680126	0.609	rs11723742	chr4:10111572	A/G	cg11266682	chr4:10021025	SLC2A9	-0.47	-6.53	-0.37	3.39e-10	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	cis	rs898097	0.578	rs6502021	chr17:80907728	T/C	cg19046167	chr17:80928561	B3GNTL1	0.4	5.39	0.31	1.56e-7	Breast cancer;
CESC	cis	rs10504229	0.593	rs17192845	chr8:58053339	C/T	cg14926445	chr8:58193284	C8orf71	-0.54	-5.1	-0.3	6.45e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs4665809	0.590	rs35615763	chr2:26468778	C/G	cg08470875	chr2:26401718	FAM59B	0.75	7.79	0.43	1.49e-13	Gut microbiome composition (summer);
CESC	cis	rs10949834	0.517	rs810536	chr7:73504233	G/A	cg07137043	chr7:73588983	EIF4H	0.63	7.37	0.41	2.2e-12	Verbal memory performance (residualized delayed recall change);
CESC	cis	rs748404	0.697	rs473016	chr15:43558823	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	7.84	0.43	1.08e-13	Lung cancer;
CESC	cis	rs17401966	0.898	rs12757288	chr1:10323921	T/C	cg15208524	chr1:10270712	KIF1B	0.39	5.07	0.3	7.62e-7	Hepatocellular carcinoma;
CESC	cis	rs801193	0.569	rs2707824	chr7:66189243	A/G	cg10691866	chr7:65817282	TPST1	-0.32	-5.44	-0.32	1.19e-7	Aortic root size;
CESC	trans	rs10242455	0.702	rs45448997	chr7:99041598	G/C	cg09045935	chr12:6379348	NA	0.91	7.41	0.41	1.73e-12	Blood metabolite levels;
CESC	cis	rs12476592	0.602	rs262478	chr2:63872386	T/C	cg17519650	chr2:63277830	OTX1	-0.45	-5.04	-0.3	8.82e-7	Childhood ear infection;
CESC	cis	rs7829975	0.871	rs777709	chr8:8583872	T/C	cg15556689	chr8:8085844	FLJ10661	-0.43	-5.28	-0.31	2.74e-7	Mood instability;
CESC	cis	rs853679	0.542	rs9380063	chr6:28137853	A/G	cg22143856	chr6:28129313	ZNF389	0.47	5.89	0.34	1.16e-8	Depression;
CESC	cis	rs514406	0.793	rs4500255	chr1:53213279	A/G	cg08859206	chr1:53392774	SCP2	0.61	9.07	0.49	2.75e-17	Monocyte count;
CESC	cis	rs2243480	1.000	rs462853	chr7:65558167	G/C	cg12463550	chr7:65579703	CRCP	0.74	5.71	0.33	3.02e-8	Diabetic kidney disease;
CESC	cis	rs1707322	1.000	rs10890359	chr1:46336635	A/G	cg06784218	chr1:46089804	CCDC17	0.32	5.52	0.32	8.1e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7809950	1.000	rs2066735	chr7:107188719	G/T	cg23024343	chr7:107201750	COG5	-0.42	-5.76	-0.33	2.3e-8	Coronary artery disease;
CESC	cis	rs7223966	1.000	rs7220821	chr17:61704147	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.45	-5.38	-0.31	1.61e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs2228479	0.702	rs2074903	chr16:89811663	T/C	cg06558623	chr16:89946397	TCF25	1.19	9.55	0.51	8.99e-19	Skin colour saturation;
CESC	cis	rs11718455	0.767	rs11708363	chr3:43966585	G/A	cg08738300	chr3:44038990	NA	0.46	6.14	0.35	2.95e-9	Coronary artery disease;
CESC	cis	rs6500395	1.000	rs1115758	chr16:48599609	T/C	cg04672837	chr16:48644449	N4BP1	0.5	6.23	0.36	1.78e-9	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs6669072	0.647	rs814543	chr1:91241709	C/T	cg08895590	chr1:91227319	NA	0.33	5.71	0.33	2.98e-8	Cognitive function;
CESC	cis	rs875971	0.522	rs9530	chr7:65425894	A/G	cg18876405	chr7:65276391	NA	0.68	9.02	0.48	3.98e-17	Aortic root size;
CESC	cis	rs67311347	1.000	rs28707772	chr3:40504666	G/A	cg24209194	chr3:40518798	ZNF619	0.52	6.27	0.36	1.43e-9	Renal cell carcinoma;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg11450001	chr12:10365596	GABARAPL1	-0.46	-6.29	-0.36	1.31e-9	Fibrinogen levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11295902	chr11:64546368	SF1	-0.68	-8.43	-0.46	2.25e-15	Gut microbiome composition (summer);
CESC	cis	rs7917772	0.503	rs7896841	chr10:104294665	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.53	7.24	0.41	4.83e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs2836950	0.502	rs12627205	chr21:40630027	C/T	cg11644478	chr21:40555479	PSMG1	-0.53	-7.08	-0.4	1.28e-11	Menarche (age at onset);
CESC	cis	rs853679	0.517	rs1947862	chr6:28105196	C/T	cg08968635	chr6:28129556	ZNF389	0.43	5.76	0.33	2.31e-8	Depression;
CESC	cis	rs12956009	0.583	rs12960952	chr18:44857476	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.5	6.52	0.37	3.49e-10	Educational attainment (years of education);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg26343667	chr3:156391915	TIPARP;LOC100287227	-0.4	-6.18	-0.35	2.4e-9	Gambling;
CESC	cis	rs2243480	1.000	rs6460274	chr7:65628484	T/A	cg18252515	chr7:66147081	NA	1.36	13.62	0.64	2.25e-32	Diabetic kidney disease;
CESC	cis	rs3785574	0.962	rs9944483	chr17:61783553	G/T	cg06420487	chr17:61919686	SMARCD2	-0.46	-5.62	-0.33	4.78e-8	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23440816	chr1:223948910	CAPN2	-0.53	-6.22	-0.36	1.91e-9	Gut microbiome composition (summer);
CESC	cis	rs6570726	0.526	rs7755237	chr6:145731852	T/C	cg23711669	chr6:146136114	FBXO30	-0.62	-8.2	-0.45	1.02e-14	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs12136530	0.744	rs66932922	chr1:19776143	G/A	cg01832549	chr1:19774989	CAPZB	-0.47	-6.86	-0.39	4.99e-11	Lead levels in blood;
CESC	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg26338869	chr17:61819248	STRADA	0.68	8.97	0.48	5.62e-17	Prudent dietary pattern;
CESC	cis	rs12586317	0.547	rs10145723	chr14:35460954	G/A	cg16230307	chr14:35515116	FAM177A1	0.99	10.61	0.55	3.76e-22	Psoriasis;
CESC	trans	rs9467711	0.559	rs13208916	chr6:26601940	G/A	cg06606381	chr12:133084897	FBRSL1	-0.74	-7.14	-0.4	8.79e-12	Autism spectrum disorder or schizophrenia;
CESC	cis	rs9457247	0.565	rs2038580	chr6:167456490	A/T	cg07741184	chr6:167504864	NA	0.36	6.21	0.36	2.05e-9	Crohn's disease;
CESC	cis	rs7666738	0.830	rs35531558	chr4:98938217	A/G	cg17366294	chr4:99064904	C4orf37	0.61	8.56	0.47	9.36e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9309711	0.698	rs9750503	chr2:3491772	A/G	cg10845886	chr2:3471009	TTC15	0.8	10.75	0.55	1.33e-22	Neurofibrillary tangles;
CESC	cis	rs769267	0.930	rs4808203	chr19:19568659	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.45	5.59	0.32	5.78e-8	Tonsillectomy;
CESC	cis	rs7772486	0.846	rs1474871	chr6:146406294	G/A	cg23711669	chr6:146136114	FBXO30	0.76	11.08	0.56	1.11e-23	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9660180	0.967	rs6603802	chr1:1812521	C/T	cg13866156	chr1:1669148	SLC35E2	-0.48	-6.33	-0.36	1.04e-9	Body mass index;
CESC	cis	rs1348850	0.668	rs13034886	chr2:178493301	G/T	cg22681709	chr2:178499509	PDE11A	-0.43	-6.02	-0.35	5.77e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs6952808	0.564	rs73038441	chr7:2139286	T/C	cg08027265	chr7:2291960	NA	-0.46	-6.99	-0.39	2.19e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs2629540	1.000	rs2629540	chr10:126426148	G/C	cg08799069	chr10:126477246	METTL10	0.69	8.33	0.46	4.5e-15	Cocaine dependence;
CESC	cis	rs12618769	0.597	rs72821908	chr2:99085359	A/G	cg10123293	chr2:99228465	UNC50	0.4	5.38	0.31	1.64e-7	Bipolar disorder;
CESC	cis	rs17125944	0.505	rs77949716	chr14:53204234	G/A	cg00686598	chr14:53173677	PSMC6	1.4	11.75	0.59	6.26e-26	Alzheimer's disease (late onset);
CESC	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.45	-6.35	-0.36	9.46e-10	Longevity;Endometriosis;
CESC	cis	rs7131987	0.868	rs7958210	chr12:29395181	G/C	cg09582351	chr12:29534625	ERGIC2	-0.33	-5.24	-0.31	3.32e-7	QT interval;
CESC	cis	rs7666738	0.716	rs11721453	chr4:99045485	G/T	cg05340658	chr4:99064831	C4orf37	0.82	12.88	0.62	8.44e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs947211	0.846	rs823155	chr1:205762946	T/C	cg24503407	chr1:205819492	PM20D1	0.42	5.61	0.33	5.13e-8	Parkinson's disease;
CESC	cis	rs11671005	0.695	rs8106061	chr19:58917990	G/C	cg11952622	chr19:58962976	ZNF324B	0.75	10.84	0.55	6.74e-23	Mean platelet volume;
CESC	cis	rs7937682	0.961	rs7106104	chr11:111635655	T/C	cg09085632	chr11:111637200	PPP2R1B	1.1	15.49	0.69	5.53e-39	Primary sclerosing cholangitis;
CESC	cis	rs2439831	0.850	rs3759790	chr15:44121030	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.66	6.03	0.35	5.4e-9	Lung cancer in ever smokers;
CESC	cis	rs1008375	0.872	rs6831115	chr4:17640463	A/G	cg16339924	chr4:17578868	LAP3	0.58	7.25	0.41	4.56e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs9902453	0.967	rs9913074	chr17:28481199	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	7.67	0.43	3.29e-13	Coffee consumption (cups per day);
CESC	cis	rs3796352	1.000	rs750474	chr3:53085280	A/C	cg07884673	chr3:53033167	SFMBT1	0.55	5.41	0.32	1.4e-7	Immune reponse to smallpox (secreted IL-2);
CESC	cis	rs1707322	0.721	rs10749856	chr1:46164846	A/T	cg05343316	chr1:45956843	TESK2	0.51	6.2	0.36	2.19e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2011503	0.943	rs4239639	chr19:19435876	G/A	cg11584989	chr19:19387371	SF4	-0.64	-7.79	-0.43	1.51e-13	Bipolar disorder;
CESC	cis	rs3857067	0.806	rs6858342	chr4:95112318	G/C	cg11021082	chr4:95130006	SMARCAD1	-0.6	-9.12	-0.49	1.97e-17	QT interval;
CESC	trans	rs7618501	0.633	rs4688755	chr3:50064424	G/A	cg21659725	chr3:3221576	CRBN	-0.53	-7.47	-0.42	1.15e-12	Intelligence (multi-trait analysis);
CESC	cis	rs2486288	0.656	rs12911861	chr15:45566718	T/C	cg09092052	chr15:45571596	NA	0.45	5.24	0.31	3.23e-7	Glomerular filtration rate;
CESC	cis	rs11055008	0.620	rs10845608	chr12:12836088	C/T	cg04607235	chr12:12878440	APOLD1	0.52	6.9	0.39	3.79e-11	Pulse pressure;
CESC	cis	rs7044106	0.791	rs10984994	chr9:123478769	A/T	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.76	-11.18	-0.57	5.08e-24	Hip circumference adjusted for BMI;
CESC	cis	rs8060686	0.641	rs8044014	chr16:68209872	T/C	cg26727032	chr16:67993705	SLC12A4	-0.51	-6.18	-0.36	2.35e-9	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs11864453	0.612	rs12924413	chr16:72129745	T/C	cg16558253	chr16:72132732	DHX38	-0.54	-8.47	-0.46	1.7e-15	Fibrinogen levels;
CESC	cis	rs753778	0.570	rs4961335	chr8:142209142	A/G	cg18755752	chr8:142205143	DENND3	-0.63	-9.27	-0.49	6.94e-18	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	cis	rs7811142	1.000	rs11763511	chr7:100081944	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.83	8.2	0.45	1.06e-14	Platelet count;
CESC	cis	rs11077998	0.967	rs60488670	chr17:80522667	T/C	cg10255544	chr17:80519551	FOXK2	0.55	8.78	0.47	2.02e-16	Reticulocyte fraction of red cells;
CESC	cis	rs1799949	0.536	rs4793227	chr17:41412250	A/C	cg07153921	chr17:41440717	NA	-0.4	-5.24	-0.31	3.33e-7	Menopause (age at onset);
CESC	cis	rs2204008	0.694	rs10880262	chr12:38328696	C/T	cg26384229	chr12:38710491	ALG10B	0.53	7.76	0.43	1.86e-13	Bladder cancer;
CESC	cis	rs514406	0.861	rs2065477	chr1:53250213	C/T	cg16325326	chr1:53192061	ZYG11B	0.85	13.86	0.65	3.32e-33	Monocyte count;
CESC	cis	rs8027181	0.839	rs2304597	chr15:73052431	A/G	cg25632853	chr15:73088954	NA	0.3	5.31	0.31	2.29e-7	Triglyceride levels;
CESC	cis	rs9733	0.596	rs17606613	chr1:150683015	C/T	cg22823121	chr1:150693482	HORMAD1	0.48	7.11	0.4	1.11e-11	Tonsillectomy;
CESC	cis	rs4727027	0.933	rs1468369	chr7:148839840	G/C	cg23158103	chr7:148848205	ZNF398	-0.4	-6.51	-0.37	3.67e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs9905704	0.609	rs72828712	chr17:56897404	A/T	cg12560992	chr17:57184187	TRIM37	0.63	5.8	0.34	1.84e-8	Testicular germ cell tumor;
CESC	cis	rs4629710	0.592	rs4424112	chr6:131563788	C/T	cg12606694	chr6:131520996	AKAP7	0.49	5.96	0.34	8.04e-9	Multiple myeloma (IgH translocation);
CESC	cis	rs7259376	0.936	rs8111665	chr19:22588559	C/T	cg02657401	chr19:22469223	NA	0.26	5.12	0.3	5.76e-7	Menopause (age at onset);
CESC	cis	rs9916302	0.821	rs1966915	chr17:37425262	A/C	cg00129232	chr17:37814104	STARD3	-0.53	-6.89	-0.39	4.12e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs1609391	0.567	rs835633	chr3:136676496	T/C	cg25687071	chr3:136751404	NA	0.38	5.11	0.3	6.21e-7	Neuroticism;
CESC	cis	rs6540556	0.723	rs11487866	chr1:209892046	G/A	cg05527609	chr1:210001259	C1orf107	-0.67	-7.35	-0.41	2.43e-12	Red blood cell count;
CESC	cis	rs1843834	0.611	rs1058360	chr2:225449242	A/T	cg22455342	chr2:225449267	CUL3	0.71	9.63	0.51	5.19e-19	IgE levels in asthmatics (D.p. specific);
CESC	cis	rs832540	1.000	rs832540	chr5:56199202	G/A	cg14703610	chr5:56206110	C5orf35	0.54	7.22	0.41	5.35e-12	Coronary artery disease;
CESC	cis	rs1506636	0.962	rs10273985	chr7:123309538	A/T	cg03229431	chr7:123269106	ASB15	-0.51	-6.63	-0.38	1.88e-10	Plateletcrit;Platelet count;
CESC	cis	rs13118159	0.934	rs4974608	chr4:1356780	C/T	cg05025164	chr4:1340916	KIAA1530	0.38	5.24	0.31	3.21e-7	Longevity;
CESC	cis	rs9814567	1.000	rs9826496	chr3:134224437	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.43	-5.82	-0.34	1.68e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs3806843	1.000	rs3733707	chr5:140181892	T/C	cg26395211	chr5:140044315	WDR55	-0.41	-5.12	-0.3	5.95e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs7223966	1.000	rs8067431	chr17:61817048	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.53	6.23	0.36	1.8e-9	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs10504229	1.000	rs115548028	chr8:58170672	T/C	cg22535103	chr8:58192502	C8orf71	-1.05	-13.08	-0.63	1.64e-30	Developmental language disorder (linguistic errors);
CESC	cis	rs858239	0.600	rs10241208	chr7:23144914	G/C	cg23682824	chr7:23144976	KLHL7	0.51	6.82	0.39	6.16e-11	Cerebrospinal fluid biomarker levels;
CESC	cis	rs28374715	0.578	rs17730589	chr15:41600878	T/C	cg20272979	chr15:41787780	ITPKA	0.45	5.14	0.3	5.32e-7	Ulcerative colitis;
CESC	cis	rs8031584	0.781	rs4779498	chr15:31177476	C/T	cg14298792	chr15:30685198	CHRFAM7A	-0.46	-5.7	-0.33	3.13e-8	Huntington's disease progression;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg10011647	chr11:58892585	FAM111B	-0.45	-6.08	-0.35	4.24e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs6741892	0.536	rs11688977	chr2:38896631	C/T	cg05275752	chr2:38892887	GALM	-0.48	-6.52	-0.37	3.61e-10	5-HTT brain serotonin transporter levels;
CESC	cis	rs4713118	0.629	rs203889	chr6:28021775	T/G	cg23161317	chr6:28129485	ZNF389	0.49	6.14	0.35	2.99e-9	Parkinson's disease;
CESC	cis	rs597539	0.652	rs613128	chr11:68638058	G/T	cg21963583	chr11:68658836	MRPL21	0.4	5.52	0.32	8.06e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs6460942	0.915	rs2216050	chr7:12304073	T/C	cg02935154	chr7:12443704	VWDE	-0.4	-5.54	-0.32	7.3e-8	Coronary artery disease;
CESC	cis	rs858239	0.541	rs4624924	chr7:23168843	A/C	cg23682824	chr7:23144976	KLHL7	0.54	7.41	0.41	1.69e-12	Cerebrospinal fluid biomarker levels;
CESC	cis	rs4555082	0.794	rs2735829	chr14:105708472	C/T	cg06808227	chr14:105710500	BRF1	-0.51	-5.78	-0.33	2.13e-8	Mean platelet volume;Platelet distribution width;
CESC	trans	rs7174755	0.558	rs11071975	chr15:68329444	A/C	cg00239025	chr2:96937097	CIAO1	0.54	6.6	0.38	2.2e-10	Major depressive disorder;
CESC	cis	rs7259376	0.936	rs17391718	chr19:22554154	A/G	cg02657401	chr19:22469223	NA	-0.25	-5.05	-0.3	8.34e-7	Menopause (age at onset);
CESC	cis	rs17401966	0.931	rs2276100	chr1:10394536	C/G	cg15208524	chr1:10270712	KIF1B	0.43	5.5	0.32	9.01e-8	Hepatocellular carcinoma;
CESC	cis	rs863345	0.901	rs10752625	chr1:158468626	G/A	cg12129480	chr1:158549410	OR10X1	-0.31	-6.23	-0.36	1.78e-9	Pneumococcal bacteremia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15880211	chr22:50250494	ZBED4	-0.52	-6.57	-0.37	2.61e-10	Gut microbiome composition (summer);
CESC	cis	rs13242816	1.000	rs62468976	chr7:116126891	C/G	cg04696780	chr7:116139425	CAV2	-0.62	-5.68	-0.33	3.58e-8	P wave duration;
CESC	cis	rs2228479	0.850	rs74251568	chr16:89903416	A/C	cg04013166	chr16:89971882	TCF25	0.72	5.75	0.33	2.41e-8	Skin colour saturation;
CESC	cis	rs6439153	0.839	rs2624901	chr3:128677188	C/T	cg25356066	chr3:128598488	ACAD9	-0.41	-5.36	-0.31	1.81e-7	Pneumococcal bacteremia;
CESC	cis	rs2860975	0.905	rs10882516	chr10:96791217	A/C	cg09036531	chr10:96991505	NA	-0.35	-5.13	-0.3	5.74e-7	Immune response to smallpox vaccine (IL-6);
CESC	cis	rs7811142	1.000	rs11764818	chr7:100043055	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.07	10.45	0.54	1.23e-21	Platelet count;
CESC	cis	rs8058578	0.775	rs8046391	chr16:30836648	G/C	cg00531865	chr16:30841666	NA	-0.41	-5.31	-0.31	2.32e-7	Multiple myeloma;
CESC	cis	rs3820068	0.580	rs36100011	chr1:16046920	C/T	cg13390004	chr1:15929781	NA	0.34	5.21	0.3	3.79e-7	Systolic blood pressure;
CESC	cis	rs2204008	0.837	rs11495548	chr12:38076756	C/T	cg13010199	chr12:38710504	ALG10B	0.54	6.69	0.38	1.28e-10	Bladder cancer;
CESC	cis	rs11252926	0.673	rs10795161	chr10:497748	G/T	cg18196295	chr10:418757	DIP2C	0.49	6.94	0.39	2.96e-11	Psychosis in Alzheimer's disease;
CESC	cis	rs2180341	0.618	rs11154398	chr6:127654281	C/A	cg24812749	chr6:127587940	RNF146	0.6	8.02	0.44	3.42e-14	Breast cancer;
CESC	cis	rs1198430	0.568	rs1119439	chr1:23828904	A/T	cg22040403	chr1:23858016	E2F2	0.61	5.62	0.33	4.79e-8	Total cholesterol levels;
CESC	trans	rs62103177	0.714	rs7227962	chr18:77603283	T/G	cg05926928	chr17:57297772	GDPD1	0.75	7.99	0.44	4.26e-14	Opioid sensitivity;
CESC	cis	rs2637266	0.729	rs860166	chr10:78549111	C/T	cg18941641	chr10:78392320	NA	0.4	7.63	0.42	4.22e-13	Pulmonary function;
CESC	cis	rs7917772	0.503	rs7100753	chr10:104300979	C/T	ch.10.2196322F	chr10:104248062	ACTR1A	0.42	5.19	0.3	4.1e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs7296418	0.961	rs1790121	chr12:123604492	G/A	cg05973401	chr12:123451056	ABCB9	0.56	7.25	0.41	4.58e-12	Platelet count;
CESC	cis	rs9926296	0.605	rs12599180	chr16:89839306	C/T	cg03388025	chr16:89894329	SPIRE2	-0.31	-5.95	-0.34	8.44e-9	Vitiligo;
CESC	cis	rs4689388	0.926	rs10937717	chr4:6295087	T/A	cg00701064	chr4:6280414	WFS1	0.69	11.92	0.59	1.61e-26	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg09344629	chr2:128471493	WDR33	0.47	6.56	0.37	2.77e-10	Fibrinogen levels;
CESC	cis	rs6582630	0.533	rs4103689	chr12:38702980	A/C	cg26384229	chr12:38710491	ALG10B	0.59	8.5	0.46	1.37e-15	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs5769765	0.819	rs9616379	chr22:50312035	C/T	cg02269571	chr22:50332266	NA	-0.57	-6.99	-0.39	2.29e-11	Schizophrenia;
CESC	cis	rs4460629	0.742	rs7365544	chr1:155068748	C/A	cg01019262	chr1:155095195	NA	-0.3	-5.05	-0.3	8.13e-7	Serum magnesium levels;
CESC	cis	rs34172651	0.517	rs11862923	chr16:24767303	G/T	cg02428538	chr16:24856791	SLC5A11	-0.47	-5.03	-0.3	9.12e-7	Intelligence (multi-trait analysis);
CESC	cis	rs7666738	0.830	rs10022331	chr4:98960392	C/A	cg17366294	chr4:99064904	C4orf37	0.6	8.52	0.46	1.2e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7666738	0.861	rs28829607	chr4:98964325	G/C	cg18180107	chr4:99064573	C4orf37	0.4	5.14	0.3	5.26e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9911578	1.000	rs4636974	chr17:56965373	C/G	cg12560992	chr17:57184187	TRIM37	0.93	15.52	0.69	4.53e-39	Intelligence (multi-trait analysis);
CESC	cis	rs12079745	0.590	rs74317850	chr1:169169924	T/G	cg09363564	chr1:169337483	NME7;BLZF1	-1.11	-6.52	-0.37	3.5e-10	QT interval;
CESC	cis	rs3812831	0.599	rs428636	chr13:114927133	T/C	cg08824895	chr13:115047677	UPF3A	0.41	5.37	0.31	1.76e-7	Schizophrenia;
CESC	cis	rs9346455	0.881	rs16881116	chr6:72031488	C/A	cg27238071	chr6:71998145	OGFRL1	0.6	5.13	0.3	5.48e-7	Antipsychotic drug-induced weight gain (time interaction);Antipsychotic drug-induced weight gain;
CESC	cis	rs4253772	0.720	rs4253778	chr22:46630634	C/G	cg09491104	chr22:46646882	C22orf40	-0.57	-8.83	-0.48	1.5e-16	LDL cholesterol;Cholesterol, total;
CESC	cis	rs7851660	0.805	rs4255258	chr9:100647545	A/G	cg13688889	chr9:100608707	NA	-0.65	-9.02	-0.48	3.79e-17	Strep throat;
CESC	cis	rs2072499	0.750	rs72708291	chr1:156177285	A/T	cg24450063	chr1:156163899	SLC25A44	0.9	11.26	0.57	2.62e-24	Testicular germ cell tumor;
CESC	cis	rs7264396	0.635	rs6060719	chr20:34546013	A/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.57	6.83	0.39	5.63e-11	Total cholesterol levels;
CESC	cis	rs6598955	0.614	rs1134584	chr1:26608828	G/A	cg00852783	chr1:26633632	UBXN11	0.37	5.44	0.32	1.18e-7	Obesity-related traits;
CESC	cis	rs113835537	0.597	rs4576	chr11:66331000	A/G	cg24851651	chr11:66362959	CCS	0.48	5.89	0.34	1.16e-8	Airway imaging phenotypes;
CESC	trans	rs17764205	0.777	rs17696630	chr19:3261995	A/G	cg18335933	chr6:2765945	WRNIP1	-0.77	-6.2	-0.36	2.15e-9	Bipolar disorder and schizophrenia;
CESC	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg16041123	chr14:71373980	PCNX	0.49	6.07	0.35	4.33e-9	DNA methylation (variation);
CESC	cis	rs61935443	0.562	rs11107791	chr12:95316374	G/A	cg21533806	chr12:95267307	NA	0.5	5.41	0.32	1.4e-7	Schizophrenia;
CESC	cis	rs10465746	0.752	rs10874426	chr1:84451820	A/G	cg10977910	chr1:84465055	TTLL7	0.52	7.22	0.41	5.38e-12	Obesity-related traits;
CESC	cis	rs116095464	0.614	rs10067482	chr5:219328	T/G	cg10591111	chr5:226296	SDHA	-0.51	-6.35	-0.36	9.22e-10	Breast cancer;
CESC	cis	rs61931739	0.500	rs10844863	chr12:34532284	C/T	cg06521331	chr12:34319734	NA	-0.37	-5.15	-0.3	5.19e-7	Morning vs. evening chronotype;
CESC	cis	rs919433	0.783	rs3097383	chr2:198236887	A/G	cg20885578	chr2:198174922	NA	0.41	5.36	0.31	1.79e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs7666738	0.830	rs13138438	chr4:99050545	C/A	cg17366294	chr4:99064904	C4orf37	0.61	8.78	0.47	2.13e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7618915	0.501	rs1866268	chr3:52719398	C/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.61	8.82	0.48	1.53e-16	Bipolar disorder;
CESC	cis	rs28386778	0.799	rs12450683	chr17:61984299	C/G	cg00945038	chr17:61921165	SMARCD2	0.35	5.11	0.3	6.22e-7	Prudent dietary pattern;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg26012578	chr2:122125185	CLASP1	0.53	7.41	0.41	1.68e-12	Fibrinogen levels;
CESC	cis	rs4891159	0.790	rs8098821	chr18:74140345	T/C	cg24786174	chr18:74118243	ZNF516	-0.73	-10.73	-0.55	1.55e-22	Longevity;
CESC	cis	rs2066819	1.000	rs57870697	chr12:56752874	A/G	cg26714650	chr12:56694279	CS	-1.39	-9.05	-0.49	3.19e-17	Psoriasis vulgaris;
CESC	cis	rs4604732	0.578	rs7525209	chr1:247627404	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.57	7.17	0.4	7.39e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs2841277	0.676	rs4264326	chr14:105411700	A/G	cg19901468	chr14:105411992	AHNAK2	-0.6	-8.78	-0.47	2.03e-16	Rheumatoid arthritis;
CESC	cis	rs9457247	0.967	rs2149084	chr6:167370988	G/C	cg23791538	chr6:167370224	RNASET2	0.61	8.62	0.47	6.14e-16	Crohn's disease;
CESC	cis	rs9790314	0.723	rs10936223	chr3:160884313	C/A	cg03342759	chr3:160939853	NMD3	-0.36	-5.05	-0.3	8.4e-7	Morning vs. evening chronotype;
CESC	cis	rs6952808	0.692	rs6950627	chr7:2086672	C/T	cg05863683	chr7:1912471	MAD1L1	0.38	5.52	0.32	7.99e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs17362650	0.653	rs35968355	chr2:9551713	G/A	cg12832956	chr2:9616023	IAH1	-0.56	-6.47	-0.37	4.74e-10	Alcohol dependence (age at onset);
CESC	cis	rs9902453	0.904	rs4598962	chr17:28293948	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	8.71	0.47	3.26e-16	Coffee consumption (cups per day);
CESC	cis	rs12142240	0.698	rs4372193	chr1:46853233	G/T	cg00530320	chr1:46809349	NSUN4	0.6	8.3	0.45	5.19e-15	Menopause (age at onset);
CESC	cis	rs9649213	0.555	rs7785612	chr7:97933867	T/A	cg00277769	chr7:97922759	BAIAP2L1	-0.33	-5.25	-0.31	3.09e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs763121	0.819	rs6001205	chr22:39100264	T/A	cg06544989	chr22:39130855	UNC84B	0.52	9.04	0.49	3.39e-17	Menopause (age at onset);
CESC	cis	rs875971	0.965	rs28682868	chr7:65689809	C/T	cg10691866	chr7:65817282	TPST1	0.33	5.42	0.32	1.33e-7	Aortic root size;
CESC	cis	rs4588572	0.606	rs6859161	chr5:77742776	A/G	cg11547950	chr5:77652471	NA	-0.4	-5.46	-0.32	1.12e-7	Triglycerides;
CESC	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg22963979	chr7:1858916	MAD1L1	-0.43	-5.89	-0.34	1.2e-8	Bipolar disorder and schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09388058	chr16:47494735	PHKB;ITFG1	0.68	7.84	0.43	1.12e-13	Gut microbiome composition (summer);
CESC	cis	rs4689388	0.750	rs12642481	chr4:6301058	G/A	cg14416269	chr4:6271139	WFS1	0.39	5.89	0.34	1.19e-8	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs644799	1.000	rs1784135	chr11:95531748	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.92	13.87	0.65	2.93e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs7666738	0.830	rs62321570	chr4:98984276	G/A	cg03467027	chr4:99064603	C4orf37	0.44	5.54	0.32	7.12e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9837602	1.000	rs793472	chr3:99546110	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.52	-7.0	-0.4	2.06e-11	Breast cancer;
CESC	cis	rs597539	0.652	rs686877	chr11:68637169	G/A	cg01988459	chr11:68622903	NA	-0.39	-5.21	-0.3	3.76e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs9311474	0.597	rs6778735	chr3:52565100	T/C	cg18337363	chr3:52569053	NT5DC2	0.31	5.95	0.34	8.63e-9	Electroencephalogram traits;
CESC	cis	rs698813	0.604	rs7606004	chr2:44479983	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.48	5.38	0.31	1.62e-7	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg15461550	chr8:4644719	CSMD1	-0.5	-7.74	-0.43	2.16e-13	Gut microbiota (bacterial taxa);
CESC	trans	rs78049276	0.736	rs6841581	chr4:148401190	C/T	cg13149281	chr14:23389818	RBM23;PRMT5	-0.68	-7.17	-0.4	7.54e-12	Pulse pressure;
CESC	cis	rs433852	0.904	rs8102492	chr19:49140809	A/C	cg06677660	chr19:49140777	SEC1;DBP	0.58	7.27	0.41	4.07e-12	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;
CESC	cis	rs2760061	0.545	rs1636196	chr1:228204030	A/G	cg02753203	chr1:228287806	NA	0.79	11.24	0.57	3.22e-24	Diastolic blood pressure;
CESC	cis	rs12893668	0.603	rs61637848	chr14:104096031	C/T	cg24130564	chr14:104152367	KLC1	-0.49	-6.43	-0.37	5.96e-10	Reticulocyte count;
CESC	cis	rs1552244	0.935	rs2272124	chr3:10138189	T/C	cg00149659	chr3:10157352	C3orf10	0.72	8.99	0.48	4.93e-17	Alzheimer's disease;
CESC	cis	rs17711722	0.675	rs6947132	chr7:65273495	G/A	cg26939375	chr7:64535504	NA	-0.76	-10.82	-0.55	7.64e-23	Calcium levels;
CESC	cis	rs727505	0.754	rs55905546	chr7:124783064	A/C	cg23710748	chr7:124431027	NA	-0.38	-6.2	-0.36	2.14e-9	Lewy body disease;
CESC	cis	rs6952808	0.895	rs12669518	chr7:1921429	G/C	cg05863683	chr7:1912471	MAD1L1	0.49	7.56	0.42	6.59e-13	Bipolar disorder and schizophrenia;
CESC	cis	rs6430585	0.583	rs73957037	chr2:136588031	C/A	cg07169764	chr2:136633963	MCM6	1.21	18.18	0.74	1.72e-48	Corneal structure;
CESC	cis	rs801193	0.569	rs35070132	chr7:66238083	C/T	cg18876405	chr7:65276391	NA	0.47	6.36	0.36	8.96e-10	Aortic root size;
CESC	cis	rs2070488	0.775	rs13072731	chr3:38533335	A/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.83	13.6	0.64	2.69e-32	Electrocardiographic conduction measures;
CESC	trans	rs629535	0.862	rs654604	chr8:70048939	C/A	cg21567404	chr3:27674614	NA	0.93	11.25	0.57	2.83e-24	Dupuytren's disease;
CESC	cis	rs875971	0.929	rs10950041	chr7:65973875	T/C	cg11764359	chr7:65958608	NA	0.94	14.73	0.67	2.83e-36	Aortic root size;
CESC	cis	rs7615952	0.599	rs67575510	chr3:125742355	C/G	cg02807482	chr3:125708958	NA	-0.4	-5.14	-0.3	5.45e-7	Blood pressure (smoking interaction);
CESC	cis	rs7772486	0.754	rs6570703	chr6:145957052	C/T	cg23711669	chr6:146136114	FBXO30	0.89	13.03	0.62	2.53e-30	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs9325144	0.647	rs34963631	chr12:38912260	T/A	cg23762105	chr12:34175262	ALG10	0.47	6.12	0.35	3.3e-9	Morning vs. evening chronotype;
CESC	cis	rs9322193	0.923	rs62441303	chr6:150088683	A/G	cg05861140	chr6:150128134	PCMT1	-0.38	-5.43	-0.32	1.29e-7	Lung cancer;
CESC	cis	rs1552244	0.572	rs3774208	chr3:10164722	T/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.79	8.79	0.47	1.98e-16	Alzheimer's disease;
CESC	trans	rs9467711	0.606	rs9357006	chr6:26364628	A/C	cg06606381	chr12:133084897	FBRSL1	-0.76	-7.01	-0.4	1.97e-11	Autism spectrum disorder or schizophrenia;
CESC	cis	rs9303401	0.659	rs36109237	chr17:56653834	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	1.03	12.7	0.62	3.56e-29	Cognitive test performance;
CESC	trans	rs4942242	1.000	rs7331003	chr13:44230253	C/T	cg19169023	chr15:41853346	TYRO3	-0.44	-6.36	-0.36	8.92e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs9926296	0.715	rs467035	chr16:89740285	C/G	cg03605463	chr16:89740564	NA	-0.6	-7.58	-0.42	5.85e-13	Vitiligo;
CESC	cis	rs6665290	0.901	rs7535826	chr1:227213968	A/C	cg10327440	chr1:227177885	CDC42BPA	1.08	20.93	0.79	4.28e-58	Myeloid white cell count;
CESC	cis	rs10791323	0.521	rs10894756	chr11:133745852	G/A	cg15485101	chr11:133734466	NA	0.3	5.13	0.3	5.52e-7	Childhood ear infection;
CESC	cis	rs4423214	0.559	rs7949129	chr11:71193135	G/C	cg05163923	chr11:71159392	DHCR7	-0.61	-6.16	-0.35	2.66e-9	Vitamin D levels;
CESC	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg10295955	chr4:187884368	NA	-1.04	-20.81	-0.79	1.12e-57	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs8067354	0.645	rs2645489	chr17:57883371	T/G	cg13753209	chr17:57696993	CLTC	0.66	8.26	0.45	7.21e-15	Hemoglobin concentration;
CESC	cis	rs12530845	0.943	rs58577912	chr7:135329269	T/G	cg23117316	chr7:135346802	PL-5283	-0.45	-5.58	-0.32	6.05e-8	Red blood cell traits;
CESC	cis	rs2239547	0.618	rs13083728	chr3:52868445	G/A	cg11645453	chr3:52864694	ITIH4	0.36	6.5	0.37	3.98e-10	Schizophrenia;
CESC	cis	rs9517302	0.847	rs9517300	chr13:99095057	T/C	cg22223119	chr13:99095684	FARP1	-0.56	-8.54	-0.46	1.06e-15	Obesity-related traits;
CESC	cis	rs4481887	0.760	rs4559544	chr1:248412507	T/G	cg00666640	chr1:248458726	OR2T12	0.33	5.55	0.32	6.83e-8	Common traits (Other);
CESC	cis	rs1008375	0.931	rs6813374	chr4:17649494	T/C	cg15017067	chr4:17643749	FAM184B	0.38	5.35	0.31	1.86e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs9322193	0.886	rs10872652	chr6:150096439	C/T	cg05861140	chr6:150128134	PCMT1	-0.37	-5.24	-0.31	3.23e-7	Lung cancer;
CESC	cis	rs897984	0.762	rs12931046	chr16:30987144	G/A	cg02466173	chr16:30829666	NA	0.48	7.99	0.44	4.09e-14	Dementia with Lewy bodies;
CESC	cis	rs7845219	0.544	rs9643350	chr8:95917276	C/A	cg13393036	chr8:95962371	TP53INP1	-0.41	-7.76	-0.43	1.86e-13	Type 2 diabetes;
CESC	cis	rs6582630	0.502	rs11520261	chr12:38332019	T/G	cg26384229	chr12:38710491	ALG10B	0.64	9.46	0.5	1.69e-18	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs7116495	1.000	rs2511076	chr11:71783827	A/G	cg10381502	chr11:71823885	C11orf51	-0.68	-5.48	-0.32	9.68e-8	Severe influenza A (H1N1) infection;
CESC	cis	rs6460942	0.591	rs62448728	chr7:12332915	A/T	cg06484146	chr7:12443880	VWDE	-0.66	-7.27	-0.41	4.01e-12	Coronary artery disease;
CESC	cis	rs7666738	0.822	rs17484018	chr4:98988960	G/A	cg03467027	chr4:99064603	C4orf37	0.44	5.56	0.32	6.57e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9287719	0.934	rs6706763	chr2:10751407	C/T	cg02196655	chr2:10830764	NOL10	-0.38	-5.79	-0.34	1.96e-8	Prostate cancer;
CESC	cis	rs6812193	0.518	rs28498588	chr4:77188766	A/T	cg20311846	chr4:77356250	SHROOM3	0.28	5.14	0.3	5.41e-7	Parkinson's disease;
CESC	cis	rs734999	0.588	rs745367	chr1:2524457	T/C	cg18854424	chr1:2615690	NA	0.28	5.48	0.32	1.01e-7	Ulcerative colitis;
CESC	cis	rs7927592	0.956	rs12281742	chr11:68303629	C/T	cg16797656	chr11:68205561	LRP5	-0.41	-6.19	-0.36	2.34e-9	Total body bone mineral density;
CESC	cis	rs11718455	0.960	rs3843372	chr3:43997666	C/T	cg08738300	chr3:44038990	NA	0.44	5.73	0.33	2.75e-8	Coronary artery disease;
CESC	cis	rs17750015	0.733	rs7506986	chr18:54404558	C/T	cg18434998	chr18:54306185	TXNL1	-0.4	-5.18	-0.3	4.4e-7	Depression and alcohol dependence;
CESC	cis	rs7824557	0.688	rs2572397	chr8:11176403	G/A	cg21775007	chr8:11205619	TDH	0.41	5.71	0.33	3.09e-8	Retinal vascular caliber;
CESC	cis	rs7208859	0.623	rs73269913	chr17:29092183	T/C	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.91e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs1008375	1.000	rs1121091	chr4:17676386	A/C	cg16339924	chr4:17578868	LAP3	0.51	6.44	0.37	5.73e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs4595586	0.545	rs12809435	chr12:39404341	C/T	cg26384229	chr12:38710491	ALG10B	-0.55	-7.72	-0.43	2.41e-13	Morning vs. evening chronotype;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg04421424	chr19:57791681	ZNF460	-0.46	-6.69	-0.38	1.3e-10	Gambling;
CESC	cis	rs941873	0.900	rs4979862	chr10:81131599	G/A	cg09469691	chr10:81107165	PPIF	0.55	7.49	0.42	1.06e-12	Height;
CESC	cis	rs2425143	0.730	rs6060624	chr20:34413663	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.79	-7.17	-0.4	7.27e-12	Blood protein levels;
CESC	cis	rs911555	0.755	rs2756132	chr14:103967820	C/G	cg12935359	chr14:103987150	CKB	0.6	8.86	0.48	1.16e-16	Intelligence (multi-trait analysis);
CESC	cis	rs7618915	0.571	rs6805539	chr3:52609710	T/A	cg18099408	chr3:52552593	STAB1	-0.31	-5.16	-0.3	4.79e-7	Bipolar disorder;
CESC	cis	rs7811142	0.775	rs6946768	chr7:99954393	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.09	10.29	0.53	4.06e-21	Platelet count;
CESC	cis	rs514406	0.929	rs12410420	chr1:53323754	T/C	cg24675658	chr1:53192096	ZYG11B	-0.6	-7.61	-0.42	4.78e-13	Monocyte count;
CESC	cis	rs875971	0.638	rs10249404	chr7:66046724	G/A	cg06456125	chr7:65229604	NA	-0.4	-5.24	-0.31	3.32e-7	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13396246	chr19:54619133	PRPF31;TFPT	0.59	6.88	0.39	4.19e-11	Gut microbiome composition (summer);
CESC	cis	rs5167	0.506	rs7257916	chr19:45482884	T/C	cg13119609	chr19:45449297	APOC2	-0.52	-7.96	-0.44	4.96e-14	Blood protein levels;
CESC	cis	rs6968419	0.714	rs3807980	chr7:115893647	A/G	cg02561103	chr7:115862891	TES	-0.39	-5.14	-0.3	5.44e-7	Intraocular pressure;
CESC	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.73	-12.04	-0.59	6.62e-27	Longevity;Endometriosis;
CESC	cis	rs8017423	0.967	rs4904658	chr14:90721640	C/T	cg14092571	chr14:90743983	NA	-0.55	-8.25	-0.45	7.71e-15	Mortality in heart failure;
CESC	cis	rs10129255	0.500	rs34326748	chr14:107190760	G/C	cg23076370	chr14:107095027	NA	-0.65	-9.64	-0.51	4.66e-19	Kawasaki disease;
CESC	cis	rs7845219	0.544	rs2945554	chr8:95939594	C/A	cg16049864	chr8:95962084	TP53INP1	-0.47	-6.9	-0.39	3.92e-11	Type 2 diabetes;
CESC	cis	rs2455799	0.613	rs13060772	chr3:15896795	C/T	cg16303742	chr3:15540471	COLQ	-0.37	-5.53	-0.32	7.49e-8	Mean platelet volume;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg07556218	chr8:144623533	ZC3H3	-0.51	-6.51	-0.37	3.68e-10	Fibrinogen levels;
CESC	cis	rs7937682	0.889	rs521155	chr11:111492563	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.95	-14.6	-0.67	8.26e-36	Primary sclerosing cholangitis;
CESC	cis	rs6951245	0.744	rs10275401	chr7:1213943	A/C	cg16145915	chr7:1198662	ZFAND2A	-0.5	-5.58	-0.32	5.95e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs1862618	0.756	rs9292125	chr5:56107200	C/T	cg03609598	chr5:56110824	MAP3K1	-0.49	-5.32	-0.31	2.16e-7	Initial pursuit acceleration;
CESC	cis	rs2991971	0.967	rs644915	chr1:46007002	T/C	cg15605315	chr1:45957053	TESK2	0.43	5.48	0.32	1.01e-7	High light scatter reticulocyte count;
CESC	cis	rs4919044	0.756	rs835257	chr10:94779801	T/A	cg00487187	chr10:94451625	HHEX	-0.45	-5.05	-0.3	8.21e-7	Coronary artery disease;
CESC	cis	rs8114671	0.562	rs6087649	chr20:33510662	A/G	cg06115741	chr20:33292138	TP53INP2	0.46	5.58	0.32	6.06e-8	Height;
CESC	cis	rs965469	0.625	rs1043159	chr20:3232031	C/T	cg25506879	chr20:3388711	C20orf194	-0.55	-6.62	-0.38	1.99e-10	IFN-related cytopenia;
CESC	cis	rs9291683	0.525	rs12506455	chr4:10031569	T/A	cg00071950	chr4:10020882	SLC2A9	0.88	16.15	0.7	2.65e-41	Bone mineral density;
CESC	cis	rs7412746	0.658	rs12068264	chr1:150727329	C/T	cg04414720	chr1:150670196	GOLPH3L	0.56	7.36	0.41	2.26e-12	Melanoma;
CESC	trans	rs7715474	0.738	rs7728749	chr5:120097929	C/T	cg12384126	chr1:185285600	IVNS1ABP	-0.46	-6.02	-0.35	5.66e-9	Post bronchodilator FEV1/FVC ratio;
CESC	trans	rs916888	0.821	rs199507	chr17:44858855	A/G	cg27125505	chr17:43679177	LOC644172	-0.48	-6.74	-0.38	1.01e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs8005677	1.000	rs1956881	chr14:23394069	A/C	cg01529538	chr14:23388837	RBM23	0.51	6.91	0.39	3.52e-11	Cognitive ability (multi-trait analysis);
CESC	cis	rs10540	0.915	rs12419209	chr11:494510	T/C	cg03352830	chr11:487213	PTDSS2	0.74	7.23	0.41	5.09e-12	Body mass index;
CESC	cis	rs6060717	0.654	rs6060686	chr20:34512606	C/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.63	6.84	0.39	5.4e-11	Hip circumference adjusted for BMI;
CESC	cis	rs11264213	0.901	rs72661644	chr1:36453894	G/A	cg27506609	chr1:36549197	TEKT2	0.66	5.6	0.33	5.44e-8	Schizophrenia;
CESC	cis	rs17384381	0.953	rs12130145	chr1:85828970	G/C	cg16011679	chr1:85725395	C1orf52	0.79	7.92	0.44	6.43e-14	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs858239	0.602	rs6953996	chr7:23175946	A/G	cg23682824	chr7:23144976	KLHL7	0.49	6.37	0.36	8.51e-10	Cerebrospinal fluid biomarker levels;
CESC	cis	rs6582630	0.555	rs11180986	chr12:38264486	G/A	cg26384229	chr12:38710491	ALG10B	-0.46	-6.03	-0.35	5.38e-9	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs7264396	0.508	rs6060739	chr20:34567592	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.49	5.7	0.33	3.15e-8	Total cholesterol levels;
CESC	trans	rs877282	0.945	rs12776447	chr10:790625	A/G	cg22713356	chr15:30763199	NA	1.32	13.44	0.64	9.25e-32	Uric acid levels;
CESC	cis	rs7680126	0.632	rs78030862	chr4:10150412	G/A	cg00071950	chr4:10020882	SLC2A9	-0.6	-6.48	-0.37	4.33e-10	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	cis	rs3747547	0.539	rs72726090	chr9:38124186	T/C	cg13774184	chr9:37916125	SHB	-0.67	-6.03	-0.35	5.38e-9	Metabolite levels (Dihydroxy docosatrienoic acid);
CESC	cis	rs7116495	0.609	rs10736783	chr11:71654143	G/A	cg07596299	chr11:71824057	C11orf51	-0.76	-5.21	-0.3	3.77e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs644799	0.965	rs602512	chr11:95561682	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.55	6.78	0.38	7.87e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs10089	1.000	rs1864922	chr5:127420700	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.78	10.48	0.54	9.74e-22	Ileal carcinoids;
CESC	cis	rs10504073	0.584	rs62507177	chr8:49937306	C/A	cg00325661	chr8:49890786	NA	0.58	8.62	0.47	6.03e-16	Blood metabolite ratios;
CESC	cis	rs9916302	0.904	rs12452509	chr17:37574722	G/A	cg20243544	chr17:37824526	PNMT	0.51	6.5	0.37	4.03e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs8062405	0.721	rs151181	chr16:28490517	A/G	cg05966235	chr16:28915196	ATP2A1	0.36	5.23	0.31	3.48e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs60871478	1.000	rs62432252	chr7:802886	C/G	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.53	5.21	0.31	3.73e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs854765	0.583	rs8070128	chr17:17804725	C/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.46	-5.91	-0.34	1.02e-8	Total body bone mineral density;
CESC	cis	rs12137294	0.866	rs896318	chr1:205205784	A/G	cg21643547	chr1:205240462	TMCC2	-0.35	-5.65	-0.33	4.24e-8	Red cell distribution width;
CESC	cis	rs9311474	1.000	rs6445358	chr3:52308845	C/G	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.33	6.25	0.36	1.59e-9	Electroencephalogram traits;
CESC	cis	rs4568518	0.740	rs12699924	chr7:18010391	A/G	cg03009463	chr7:17980271	SNX13	0.47	6.15	0.35	2.9e-9	Measles;
CESC	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.07	10.75	0.55	1.35e-22	Platelet count;
CESC	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg23978390	chr7:1156363	C7orf50	0.53	7.11	0.4	1.08e-11	Longevity;Endometriosis;
CESC	cis	rs2072732	0.861	rs56398543	chr1:2950237	G/A	cg03976712	chr1:2946727	NA	0.33	5.5	0.32	8.8e-8	Plateletcrit;
CESC	cis	rs2228479	0.850	rs1800344	chr16:89816367	T/G	cg00800038	chr16:89945340	TCF25	-0.91	-7.54	-0.42	7.39e-13	Skin colour saturation;
CESC	cis	rs2243480	1.000	rs34933526	chr7:65383199	A/G	cg25894440	chr7:65020034	NA	-0.59	-5.07	-0.3	7.57e-7	Diabetic kidney disease;
CESC	cis	rs7927771	0.800	rs12146565	chr11:47398963	G/A	cg20307385	chr11:47447363	PSMC3	-0.63	-7.46	-0.42	1.24e-12	Subjective well-being;
CESC	cis	rs2806561	0.765	rs1612905	chr1:23510023	G/T	cg12483005	chr1:23474871	LUZP1	0.38	6.01	0.35	6.04e-9	Height;
CESC	cis	rs1580019	0.961	rs4255041	chr7:32496383	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.73	10.15	0.53	1.14e-20	Cognitive ability;
CESC	cis	rs4722166	0.532	rs6963591	chr7:22757270	G/T	cg05472934	chr7:22766657	IL6	-0.49	-6.4	-0.37	6.84e-10	Lung cancer;
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg13709765	chr18:3451484	TGIF1	-0.41	-6.07	-0.35	4.44e-9	Vertical cup-disc ratio;
CESC	cis	rs4713118	0.662	rs149970	chr6:27980220	C/T	cg23161317	chr6:28129485	ZNF389	0.46	6.26	0.36	1.54e-9	Parkinson's disease;
CESC	cis	rs8180040	0.764	rs11708451	chr3:47198826	G/A	cg27129171	chr3:47204927	SETD2	0.69	10.44	0.54	1.33e-21	Colorectal cancer;
CESC	cis	rs2294693	0.679	rs12200923	chr6:40970092	T/G	cg14769373	chr6:40998127	UNC5CL	-0.42	-5.14	-0.3	5.46e-7	Gastric cancer;Non-cardia gastric cancer;
CESC	cis	rs1322639	0.592	rs7743597	chr6:169591678	T/C	cg03254818	chr6:169586852	NA	0.43	6.23	0.36	1.77e-9	Pulse pressure;
CESC	cis	rs919433	0.927	rs3843857	chr2:198195965	T/C	cg03934865	chr2:198174659	NA	-0.48	-6.9	-0.39	3.77e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs11030122	0.673	rs4910869	chr11:4006438	C/T	cg18678763	chr11:4115507	RRM1	-0.47	-6.22	-0.36	1.95e-9	Mean platelet volume;Platelet distribution width;
CESC	cis	rs7666738	0.830	rs13101352	chr4:98957544	C/T	cg17366294	chr4:99064904	C4orf37	0.6	8.47	0.46	1.72e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6952808	0.792	rs13224989	chr7:1953766	C/G	cg05863683	chr7:1912471	MAD1L1	0.44	6.8	0.39	6.97e-11	Bipolar disorder and schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24972080	chr11:65154083	FRMD8	0.6	6.98	0.39	2.39e-11	Gut microbiome composition (summer);
CESC	cis	rs2463822	0.920	rs72923207	chr11:62117959	A/G	cg06239285	chr11:62104954	ASRGL1	-1.04	-8.88	-0.48	1.02e-16	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs7618915	0.501	rs34157897	chr3:52716937	T/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	5.93	0.34	9.38e-9	Bipolar disorder;
CESC	cis	rs6570726	0.846	rs973856	chr6:145781916	C/T	cg23711669	chr6:146136114	FBXO30	-0.83	-12.39	-0.61	4.12e-28	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7511006	1.000	rs7290710	chr22:50677454	C/T	cg16473166	chr22:50639996	SELO	0.5	6.26	0.36	1.54e-9	Obesity-related traits;
CESC	cis	rs10911251	0.508	rs729672	chr1:183109236	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.82	12.85	0.62	1.02e-29	Colorectal cancer;
CESC	cis	rs6690583	0.623	rs12042845	chr1:85429801	A/G	cg22153463	chr1:85462885	MCOLN2	0.76	7.47	0.42	1.14e-12	Serum sulfate level;
CESC	cis	rs3820068	0.532	rs6701009	chr1:15935614	T/C	cg17385448	chr1:15911702	AGMAT	0.43	7.11	0.4	1.11e-11	Systolic blood pressure;
CESC	cis	rs1005277	0.579	rs2983343	chr10:38383332	A/G	cg00409905	chr10:38381863	ZNF37A	-0.45	-6.0	-0.35	6.61e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs7618915	0.547	rs1561337	chr3:52659963	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.39	7.01	0.4	1.97e-11	Bipolar disorder;
CESC	trans	rs7656342	0.808	rs10003216	chr4:9766749	A/G	cg05243909	chr16:2097910	NTHL1;TSC2	-0.52	-6.03	-0.35	5.52e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs6693567	0.545	rs5011187	chr1:150422761	T/C	cg09579323	chr1:150459698	TARS2	0.48	6.0	0.35	6.34e-9	Migraine;
CESC	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.54	6.63	0.38	1.87e-10	Prudent dietary pattern;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg04529868	chr14:65381343	CHURC1	-0.45	-6.61	-0.38	2.09e-10	Gambling;
CESC	trans	rs5756813	0.754	rs8136757	chr22:38185971	A/G	cg19894588	chr14:64061835	NA	-0.64	-8.24	-0.45	7.83e-15	Optic cup area;Vertical cup-disc ratio;
CESC	cis	rs3806843	0.735	rs2530240	chr5:140060547	T/C	cg26395211	chr5:140044315	WDR55	0.47	6.03	0.35	5.51e-9	Depressive symptoms (multi-trait analysis);
CESC	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg11494091	chr17:61959527	GH2	0.71	12.02	0.59	7.35e-27	Prudent dietary pattern;
CESC	cis	rs1559088	1.000	rs1974783	chr19:33551507	C/G	cg27124370	chr19:33622961	WDR88	0.42	5.34	0.31	1.98e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs7267979	1.000	rs2257982	chr20:25269630	A/G	cg08601574	chr20:25228251	PYGB	0.39	5.65	0.33	4.08e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs796364	0.806	rs10931887	chr2:200968905	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.74	-6.39	-0.37	7.31e-10	Schizophrenia;
CESC	cis	rs9649213	0.593	rs7787858	chr7:98009914	T/C	cg08684580	chr7:98029266	BAIAP2L1	-0.35	-5.67	-0.33	3.8e-8	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs61148964	0.826	rs73156281	chr22:37234612	C/T	cg14267671	chr19:45572412	SFRS16	0.67	6.22	0.36	1.95e-9	Scarlet fever;
CESC	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	10.35	0.54	2.67e-21	Prudent dietary pattern;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg03828693	chr10:63661686	ARID5B	0.5	7.26	0.41	4.38e-12	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg18404041	chr3:52824283	ITIH1	-0.38	-6.74	-0.38	9.93e-11	Electroencephalogram traits;
CESC	cis	rs4722166	0.630	rs12537614	chr7:22789551	C/G	cg05472934	chr7:22766657	IL6	0.8	10.05	0.53	2.41e-20	Lung cancer;
CESC	cis	rs11723261	0.582	rs3747693	chr4:124375	T/G	cg12746427	chr4:53362	ZNF718;ZNF595	0.5	6.45	0.37	5.22e-10	Immune response to smallpox vaccine (IL-6);
CESC	cis	rs1538970	0.924	rs4660858	chr1:45936351	G/A	cg03146154	chr1:46216737	IPP	0.46	5.28	0.31	2.65e-7	Platelet count;
CESC	cis	rs561341	1.000	rs117029332	chr17:30266085	C/G	cg19193384	chr17:30244184	NA	-0.66	-6.21	-0.36	2.01e-9	Hip circumference adjusted for BMI;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01905589	chr1:26856408	RPS6KA1	0.59	7.02	0.4	1.91e-11	Gut microbiome composition (summer);
CESC	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	22.16	0.81	2.75e-62	Prudent dietary pattern;
CESC	cis	rs2832191	1.000	rs8131214	chr21:30483386	T/G	cg08807101	chr21:30365312	RNF160	-0.66	-8.93	-0.48	7.14e-17	Dental caries;
CESC	cis	rs6540559	0.611	rs17015226	chr1:209970096	C/G	cg09509183	chr1:209979624	IRF6	0.51	5.33	0.31	2.07e-7	Cleft lip with or without cleft palate;
CESC	cis	rs5753618	0.561	rs4820043	chr22:31647094	A/G	cg13145458	chr22:31556086	RNF185	0.48	5.37	0.31	1.71e-7	Colorectal cancer;
CESC	cis	rs7945705	0.935	rs2568062	chr11:8887945	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.48	-8.14	-0.45	1.51e-14	Hemoglobin concentration;
CESC	cis	rs10493773	0.674	rs414618	chr1:86220418	G/A	cg17807903	chr1:86174739	ZNHIT6	0.41	5.92	0.34	1.02e-8	Urate levels in overweight individuals;
CESC	cis	rs854765	0.893	rs712265	chr17:18008447	G/A	cg16928487	chr17:17741425	SREBF1	0.56	9.12	0.49	1.93e-17	Total body bone mineral density;
CESC	cis	rs7959452	0.562	rs10878975	chr12:69782044	G/C	cg20891283	chr12:69753455	YEATS4	0.91	15.03	0.68	2.41e-37	Blood protein levels;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg00697668	chr14:105617575	JAG2	-0.47	-6.23	-0.36	1.86e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs3091242	0.904	rs6661533	chr1:25771715	A/G	cg02931644	chr1:25747376	RHCE	0.47	8.04	0.44	3.09e-14	Erythrocyte sedimentation rate;
CESC	cis	rs1218582	0.772	rs10908448	chr1:154882544	A/G	cg06221963	chr1:154839813	KCNN3	0.66	11.63	0.58	1.58e-25	Prostate cancer;
CESC	cis	rs3793917	0.948	rs3750848	chr10:124215315	A/C	cg24884230	chr10:124216658	ARMS2	0.31	5.12	0.3	5.94e-7	Age-related macular degeneration;
CESC	cis	rs2549003	1.000	rs7734334	chr5:131815004	C/A	cg00255919	chr5:131827918	IRF1	0.51	8.71	0.47	3.26e-16	Asthma (sex interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	ch.2.747167F	chr2:30383352	YPEL5	-0.57	-7.15	-0.4	8.41e-12	Gut microbiome composition (summer);
CESC	cis	rs644799	1.000	rs527899	chr11:95529242	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	9.15	0.49	1.61e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs17376456	0.877	rs10065056	chr5:93380123	G/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.6	5.18	0.3	4.41e-7	Diabetic retinopathy;
CESC	cis	rs3806843	0.735	rs2563335	chr5:140044292	A/C	cg16179182	chr5:140090404	VTRNA1-1	-0.42	-5.3	-0.31	2.4e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs7296418	0.961	rs11608811	chr12:123529056	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.32	-5.04	-0.3	8.54e-7	Platelet count;
CESC	cis	rs1559088	0.522	rs7254912	chr19:33554151	A/G	cg03563238	chr19:33554763	RHPN2	-0.32	-5.78	-0.33	2.08e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs2559856	0.935	rs2695287	chr12:102088361	T/C	cg15068132	chr12:102092402	CHPT1	-0.42	-5.59	-0.32	5.57e-8	Blood protein levels;
CESC	cis	rs4555082	0.834	rs2735816	chr14:105721603	C/G	cg13114125	chr14:105738426	BRF1	0.79	9.33	0.5	4.29e-18	Mean platelet volume;Platelet distribution width;
CESC	cis	rs7772486	0.743	rs9376955	chr6:145949404	T/A	cg23711669	chr6:146136114	FBXO30	0.82	11.91	0.59	1.77e-26	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9715521	0.677	rs6822690	chr4:59853530	A/G	cg11281224	chr4:60001000	NA	-0.52	-7.18	-0.4	7.11e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs9611565	0.921	rs3927	chr22:41722864	A/G	cg06634786	chr22:41940651	POLR3H	-0.6	-6.29	-0.36	1.27e-9	Vitiligo;
CESC	cis	rs736408	0.511	rs12637632	chr3:52708073	A/T	cg18337363	chr3:52569053	NT5DC2	0.28	5.05	0.3	8.38e-7	Bipolar disorder;
CESC	cis	rs7191439	0.584	rs8048897	chr16:88744470	T/G	cg27087555	chr16:88793112	FAM38A	-1.13	-6.74	-0.38	9.85e-11	Plateletcrit;
CESC	cis	rs4563143	0.675	rs73029042	chr19:29267979	A/T	cg04546413	chr19:29218101	NA	0.56	7.91	0.44	6.84e-14	Methadone dose in opioid dependence;
CESC	trans	rs7246760	0.867	rs1115825	chr19:9786121	C/G	cg02900749	chr2:68251473	NA	-0.85	-7.53	-0.42	8.04e-13	Pursuit maintenance gain;
CESC	cis	rs2415984	0.540	rs1494095	chr14:46960671	T/C	cg14871534	chr14:47121158	RPL10L	0.35	5.32	0.31	2.24e-7	Number of children ever born;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg13883939	chr12:118541731	VSIG10	0.38	6.09	0.35	3.9e-9	Gambling;
CESC	cis	rs12701220	0.522	rs12334290	chr7:1054517	A/G	cg04025307	chr7:1156635	C7orf50	0.37	5.57	0.32	6.18e-8	Bronchopulmonary dysplasia;
CESC	cis	rs933688	1.000	rs9293568	chr5:90737845	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.09	12.09	0.6	4.37e-27	Smoking behavior;
CESC	cis	rs4654899	0.865	rs10493006	chr1:21375904	G/A	cg05370193	chr1:21551575	ECE1	0.42	6.15	0.35	2.79e-9	Superior frontal gyrus grey matter volume;
CESC	cis	rs9322193	0.962	rs3805753	chr6:150116798	C/T	cg07701084	chr6:150067640	NUP43	0.42	5.63	0.33	4.6e-8	Lung cancer;
CESC	cis	rs875971	0.767	rs12668005	chr7:65909021	T/C	cg18876405	chr7:65276391	NA	0.54	7.36	0.41	2.37e-12	Aortic root size;
CESC	cis	rs853679	0.517	rs9468292	chr6:28095355	G/A	cg12963246	chr6:28129442	ZNF389	0.56	7.62	0.42	4.43e-13	Depression;
CESC	cis	rs6461049	0.519	rs3778992	chr7:2175313	C/G	cg23048001	chr7:2026167	MAD1L1	0.4	5.24	0.31	3.21e-7	Schizophrenia;
CESC	cis	rs977987	0.843	rs28558946	chr16:75489322	G/T	cg03315344	chr16:75512273	CHST6	0.46	6.73	0.38	1.02e-10	Dupuytren's disease;
CESC	cis	rs875971	0.502	rs11769702	chr7:65720516	A/C	cg18876405	chr7:65276391	NA	0.45	5.04	0.3	8.75e-7	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01623343	chr16:354374	AXIN1	-0.64	-7.46	-0.42	1.23e-12	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.791	rs10017624	chr4:98984009	G/T	cg03467027	chr4:99064603	C4orf37	0.44	5.54	0.32	7.12e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2688608	0.592	rs10824031	chr10:75509273	C/T	cg23231163	chr10:75533350	FUT11	-0.38	-5.85	-0.34	1.42e-8	Inflammatory bowel disease;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg22505778	chr3:113822317	NA	-0.45	-6.01	-0.35	6.17e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs2929278	0.617	rs533143	chr15:44188854	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.44	5.72	0.33	2.87e-8	Schizophrenia;
CESC	cis	rs1003719	0.715	rs8129942	chr21:38552070	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.61	-8.41	-0.46	2.54e-15	Eye color traits;
CESC	cis	rs8058578	1.000	rs6565201	chr16:30747191	C/T	cg00531865	chr16:30841666	NA	-0.46	-6.26	-0.36	1.51e-9	Multiple myeloma;
CESC	cis	rs1799949	1.000	rs1799966	chr17:41223094	T/C	cg25072359	chr17:41440525	NA	0.46	6.14	0.35	2.95e-9	Menopause (age at onset);
CESC	cis	rs6500602	0.727	rs3761681	chr16:4566857	C/T	cg08645402	chr16:4508243	NA	0.55	8.94	0.48	6.61e-17	Schizophrenia;
CESC	cis	rs1124376	0.832	rs6793985	chr3:20136485	T/C	cg05072819	chr3:20081367	KAT2B	0.47	5.41	0.32	1.39e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs868036	0.681	rs3784718	chr15:68098004	C/T	cg08079166	chr15:68083412	MAP2K5	0.35	5.07	0.3	7.5e-7	Restless legs syndrome;
CESC	cis	rs7666738	0.791	rs6828752	chr4:99063382	C/T	cg17366294	chr4:99064904	C4orf37	0.62	8.8	0.48	1.82e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4862750	0.872	rs13101408	chr4:187894777	G/A	cg03647317	chr4:187891568	NA	-0.39	-5.76	-0.33	2.34e-8	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs11690935	0.959	rs10204502	chr2:172588866	C/G	cg13550731	chr2:172543902	DYNC1I2	-0.97	-14.97	-0.68	4e-37	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17379558	chr17:41322482	NBR1	-0.6	-7.32	-0.41	2.88e-12	Gut microbiome composition (summer);
CESC	trans	rs1814175	0.791	rs10769625	chr11:49869887	G/A	cg03929089	chr4:120376271	NA	-0.91	-15.43	-0.69	9.49e-39	Height;
CESC	cis	rs13256369	0.802	rs12680019	chr8:8561698	A/G	cg17143192	chr8:8559678	CLDN23	0.77	8.74	0.47	2.64e-16	Obesity-related traits;
CESC	cis	rs1707322	1.000	rs11211236	chr1:46443767	C/A	cg05343316	chr1:45956843	TESK2	0.44	5.42	0.32	1.36e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9583531	0.689	rs9515273	chr13:111383427	G/C	cg24331049	chr13:111365604	ING1	0.78	10.45	0.54	1.26e-21	Coronary artery disease;
CESC	cis	rs17433780	0.523	rs6701673	chr1:89525812	C/G	cg09516651	chr1:89888402	LOC400759	0.72	10.78	0.55	1.07e-22	Carotid intima media thickness;
CESC	cis	rs10489202	1.000	rs1846416	chr1:167905411	G/A	cg24449463	chr1:168025552	DCAF6	-0.46	-5.27	-0.31	2.87e-7	Schizophrenia;
CESC	cis	rs35306767	0.903	rs4522091	chr10:874116	G/T	cg10556349	chr10:835070	NA	0.62	5.93	0.34	9.61e-9	Eosinophil percentage of granulocytes;
CESC	cis	rs7833790	0.654	rs6415652	chr8:82702257	G/A	cg06027949	chr8:82754900	SNX16	-0.43	-5.22	-0.31	3.66e-7	Diastolic blood pressure;
CESC	cis	rs11997175	0.646	rs4733177	chr8:33691754	A/G	ch.8.33884649F	chr8:33765107	NA	0.56	7.33	0.41	2.73e-12	Body mass index;
CESC	cis	rs4666360	1.000	rs4666361	chr2:20336215	G/C	cg23291376	chr2:20336282	NA	-0.36	-6.07	-0.35	4.5e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel);
CESC	cis	rs3091242	0.967	rs665372	chr1:25719235	A/C	cg02931644	chr1:25747376	RHCE	0.4	6.67	0.38	1.45e-10	Erythrocyte sedimentation rate;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20769334	chr22:50913335	SBF1	0.55	6.8	0.39	6.98e-11	Gut microbiome composition (summer);
CESC	cis	rs9322193	0.923	rs9766004	chr6:150075499	C/T	cg13206674	chr6:150067644	NUP43	0.44	6.35	0.36	9.51e-10	Lung cancer;
CESC	cis	rs796364	0.806	rs203767	chr2:200902411	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.83	-7.74	-0.43	2.09e-13	Schizophrenia;
CESC	cis	rs4072980	0.524	rs28442147	chr1:38395410	T/A	cg04673462	chr1:38461896	NA	0.36	5.21	0.31	3.72e-7	Coronary artery disease;
CESC	cis	rs7408868	1.000	rs7408868	chr19:15285679	G/C	cg14696996	chr19:15285081	NOTCH3	1.04	11.2	0.57	4.4e-24	Pulse pressure;
CESC	cis	rs34779708	0.966	rs35079558	chr10:35479886	A/G	cg03585969	chr10:35415529	CREM	0.74	9.5	0.5	1.28e-18	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs8180040	0.764	rs13061071	chr3:47138708	G/A	cg27129171	chr3:47204927	SETD2	0.7	10.54	0.54	6.41e-22	Colorectal cancer;
CESC	cis	rs8040855	0.627	rs17540307	chr15:85633845	A/G	cg08123816	chr15:85640762	PDE8A	-0.4	-5.89	-0.34	1.18e-8	Bulimia nervosa;
CESC	cis	rs4563143	0.663	rs5025682	chr19:29238670	A/C	cg12756686	chr19:29218302	NA	0.52	6.87	0.39	4.69e-11	Methadone dose in opioid dependence;
CESC	cis	rs4862750	0.914	rs1863405	chr4:187874528	G/T	cg10295955	chr4:187884368	NA	0.97	17.32	0.73	1.78e-45	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs62244186	0.566	rs3762636	chr3:44854563	A/G	cg15225532	chr3:44803084	KIF15;KIAA1143	0.44	5.75	0.33	2.42e-8	Depressive symptoms;
CESC	cis	rs10504229	1.000	rs77857677	chr8:58170131	G/A	cg22535103	chr8:58192502	C8orf71	-1.05	-12.98	-0.62	3.88e-30	Developmental language disorder (linguistic errors);
CESC	cis	rs7833790	0.963	rs7836040	chr8:82698328	G/A	cg17211192	chr8:82754475	SNX16	-0.67	-8.05	-0.44	2.84e-14	Diastolic blood pressure;
CESC	cis	rs7223966	1.000	rs8064261	chr17:61705212	G/A	cg11494091	chr17:61959527	GH2	0.38	5.09	0.3	6.73e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs4594175	0.926	rs11851960	chr14:51598610	A/G	cg23942311	chr14:51606299	NA	0.4	5.94	0.34	9.07e-9	Cancer;
CESC	cis	rs4665809	1.000	rs6546726	chr2:26275116	A/G	cg26314531	chr2:26401878	FAM59B	-0.62	-6.87	-0.39	4.62e-11	Gut microbiome composition (summer);
CESC	cis	rs2228479	0.850	rs12600051	chr16:89992072	G/T	cg14709524	chr16:89940631	TCF25	0.85	6.04	0.35	5.29e-9	Skin colour saturation;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg07758428	chr11:68193549	LRP5	0.47	6.37	0.36	8.12e-10	Fibrinogen levels;
CESC	cis	rs6460942	0.915	rs62448593	chr7:12436845	G/C	cg06484146	chr7:12443880	VWDE	-0.78	-9.1	-0.49	2.28e-17	Coronary artery disease;
CESC	cis	rs35306767	0.715	rs1871622	chr10:1049309	T/G	cg26597838	chr10:835615	NA	0.7	6.53	0.37	3.31e-10	Eosinophil percentage of granulocytes;
CESC	cis	rs6456156	0.565	rs2181058	chr6:167465330	A/T	cg07741184	chr6:167504864	NA	0.35	6.08	0.35	4.1e-9	Primary biliary cholangitis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08597319	chr8:103876573	AZIN1	0.66	7.76	0.43	1.85e-13	Gut microbiome composition (summer);
CESC	cis	rs1448094	0.511	rs17280643	chr12:86210154	C/T	cg00310523	chr12:86230176	RASSF9	-0.34	-5.45	-0.32	1.17e-7	Major depressive disorder;
CESC	cis	rs7818688	0.697	rs10504939	chr8:95983354	C/G	cg16049864	chr8:95962084	TP53INP1	0.55	5.55	0.32	6.92e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs4689388	0.856	rs3200	chr4:6304878	C/T	cg00701064	chr4:6280414	WFS1	0.69	11.71	0.58	8.28e-26	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs662064	0.962	rs622623	chr1:10555257	C/T	cg20482658	chr1:10539492	PEX14	-0.35	-6.92	-0.39	3.39e-11	Asthma;
CESC	cis	rs6952808	0.594	rs3778964	chr7:2138109	C/T	cg02951883	chr7:2050386	MAD1L1	-0.46	-5.98	-0.34	7.07e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs10197940	0.624	rs17270233	chr2:152372420	A/G	cg06191203	chr2:152266755	RIF1	-0.45	-5.15	-0.3	5.05e-7	Lung cancer;
CESC	cis	rs7666738	0.830	rs2865977	chr4:99017916	C/T	cg03676636	chr4:99064102	C4orf37	0.33	5.15	0.3	5.05e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg10150615	chr22:24372951	LOC391322	-0.47	-6.21	-0.36	2.07e-9	Liver enzyme levels (gamma-glutamyl transferase);
CESC	trans	rs10489896	0.541	rs66638830	chr1:234591064	T/G	cg10395685	chr11:86085715	CCDC81	-0.43	-6.15	-0.35	2.9e-9	Cognitive test performance;
CESC	cis	rs2635047	0.811	rs10502880	chr18:44770746	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.46	6.05	0.35	4.8e-9	Educational attainment;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg14666473	chr12:27091463	FGFR1OP2;C12orf11	0.41	6.32	0.36	1.08e-9	Gut microbiota (bacterial taxa);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg11142944	chr22:35653622	HMGXB4	-0.48	-6.62	-0.38	2.03e-10	Fibrinogen levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03757398	chr1:28920491	RAB42	-0.54	-6.79	-0.38	7.28e-11	Gut microbiome composition (summer);
CESC	cis	rs7605827	0.930	rs6431699	chr2:15540281	A/G	cg19274914	chr2:15703543	NA	0.36	6.55	0.37	2.91e-10	Educational attainment (years of education);
CESC	cis	rs10242455	0.717	rs2687133	chr7:99332083	C/T	cg07715041	chr7:99302981	CYP3A7	-0.49	-5.86	-0.34	1.34e-8	Blood metabolite levels;
CESC	cis	rs875971	1.000	rs1144895	chr7:65541307	C/G	cg11764359	chr7:65958608	NA	-0.93	-13.63	-0.64	2.02e-32	Aortic root size;
CESC	cis	rs73036520	0.560	rs346750	chr19:45737218	G/T	cg01416317	chr19:45737208	EXOC3L2	-0.5	-8.22	-0.45	9.21e-15	Monocyte percentage of white cells;
CESC	cis	rs67072384	1.000	rs72964185	chr11:72443177	G/A	cg04827223	chr11:72435913	ARAP1	-0.65	-5.96	-0.34	7.94e-9	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
CESC	cis	rs7666738	0.830	rs34313689	chr4:99013689	T/C	cg18180107	chr4:99064573	C4orf37	0.4	5.26	0.31	3.05e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4713118	0.621	rs4713132	chr6:28034035	A/G	cg22143856	chr6:28129313	ZNF389	0.44	5.49	0.32	9.24e-8	Parkinson's disease;
CESC	cis	rs9649213	0.555	rs12667634	chr7:97965442	A/G	cg00277769	chr7:97922759	BAIAP2L1	-0.34	-5.62	-0.33	4.84e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs2243480	1.000	rs35820085	chr7:65442758	C/T	cg13147721	chr7:65941812	NA	-0.9	-8.65	-0.47	4.98e-16	Diabetic kidney disease;
CESC	cis	rs6568686	0.577	rs174400	chr6:111922979	A/G	cg22127309	chr6:111907043	TRAF3IP2	0.55	5.25	0.31	3.18e-7	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
CESC	cis	rs916888	0.531	rs183211	chr17:44788310	G/A	cg01570182	chr17:44337453	NA	0.67	9.05	0.49	3.12e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs12579753	0.810	rs10862355	chr12:82162698	C/T	cg24719984	chr12:82153464	PPFIA2	-0.33	-5.22	-0.31	3.55e-7	Resting heart rate;
CESC	cis	rs5750830	0.649	rs5750813	chr22:39795228	G/C	cg01416388	chr22:39784598	NA	-0.57	-7.1	-0.4	1.14e-11	Intelligence (multi-trait analysis);
CESC	cis	rs4727027	0.835	rs11767810	chr7:148774433	T/A	cg23583168	chr7:148888333	NA	-0.78	-11.73	-0.58	7.14e-26	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25887236	chr18:74844781	MBP	0.52	6.17	0.35	2.49e-9	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05492845	chr11:64002298	VEGFB	0.51	6.29	0.36	1.3e-9	Gut microbiome composition (summer);
CESC	cis	rs8020095	0.528	rs8004488	chr14:67667402	C/G	cg19548862	chr14:67692701	FAM71D	0.45	5.58	0.32	6.05e-8	Depression (quantitative trait);
CESC	cis	rs854765	0.647	rs721669	chr17:18005073	A/G	cg04398451	chr17:18023971	MYO15A	-0.76	-11.07	-0.56	1.15e-23	Total body bone mineral density;
CESC	cis	rs7666738	0.618	rs10856932	chr4:98819992	C/T	cg17366294	chr4:99064904	C4orf37	0.55	7.51	0.42	9.06e-13	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7607369	0.536	rs6436090	chr2:219669002	A/G	cg02176678	chr2:219576539	TTLL4	-0.36	-6.37	-0.36	8.16e-10	Red blood cell count;Amyotrophic lateral sclerosis;
CESC	cis	rs6088590	0.561	rs6059926	chr20:33164804	C/T	cg08999081	chr20:33150536	PIGU	0.69	12.25	0.6	1.2100000000000001e-27	Coronary artery disease;
CESC	cis	rs7618915	0.571	rs67539070	chr3:52711974	T/C	cg05564831	chr3:52568323	NT5DC2	0.43	6.65	0.38	1.71e-10	Bipolar disorder;
CESC	cis	rs875971	0.508	rs10258739	chr7:66062935	A/T	cg18252515	chr7:66147081	NA	0.39	5.26	0.31	2.97e-7	Aortic root size;
CESC	cis	rs896854	0.654	rs28591375	chr8:95973637	C/G	cg26343298	chr8:95960752	TP53INP1	0.36	5.98	0.34	7.06e-9	Type 2 diabetes;
CESC	cis	rs8014204	0.836	rs12888998	chr14:75292662	G/T	cg08847533	chr14:75593920	NEK9	0.46	5.88	0.34	1.23e-8	Caffeine consumption;
CESC	cis	rs921968	0.643	rs832799	chr2:219490111	C/A	cg02176678	chr2:219576539	TTLL4	0.37	6.33	0.36	1.07e-9	Mean corpuscular hemoglobin concentration;
CESC	trans	rs1814175	0.645	rs28538913	chr11:50040718	C/T	cg03929089	chr4:120376271	NA	-0.91	-14.92	-0.68	5.78e-37	Height;
CESC	cis	rs711245	0.573	rs11899523	chr2:36800918	T/C	cg15105969	chr2:36825350	FEZ2	0.46	5.19	0.3	4.27e-7	Height;
CESC	cis	rs8072100	0.905	rs9895274	chr17:45539117	C/T	cg08085267	chr17:45401833	C17orf57	-0.53	-7.22	-0.41	5.36e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs6570726	0.791	rs392612	chr6:145881586	C/G	cg23711669	chr6:146136114	FBXO30	-0.97	-14.96	-0.68	4.14e-37	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs916888	0.773	rs199445	chr17:44817408	C/T	cg01341218	chr17:43662625	NA	0.92	11.17	0.57	5.26e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs10870270	1.000	rs10870232	chr10:133738537	T/G	cg08754478	chr10:133766260	PPP2R2D	-0.61	-7.97	-0.44	4.75e-14	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	trans	rs9929218	0.954	rs9925923	chr16:68819614	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.65	-8.6	-0.47	6.87e-16	Colorectal cancer;
CESC	cis	rs7847628	0.550	rs12343516	chr9:123603469	A/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.93	17.08	0.72	1.34e-44	Birth weight;
CESC	cis	rs1153858	0.723	rs1719238	chr15:45594766	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.8	-10.19	-0.53	8.67e-21	Homoarginine levels;
CESC	trans	rs2797160	0.967	rs1343120	chr6:125992810	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.45	-6.01	-0.35	6.16e-9	Endometrial cancer;
CESC	cis	rs9611565	0.643	rs202634	chr22:41809623	A/G	cg17376030	chr22:41985996	PMM1	-0.68	-7.16	-0.4	7.99e-12	Vitiligo;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07012189	chr14:93408043	ITPK1	-0.52	-6.0	-0.35	6.45e-9	Gut microbiome composition (summer);
CESC	cis	rs9926296	0.656	rs2376884	chr16:89826922	C/T	cg04287289	chr16:89883240	FANCA	0.57	7.62	0.42	4.55e-13	Vitiligo;
CESC	trans	rs9693444	0.898	rs4732697	chr8:29519861	A/G	cg01509141	chr13:44453359	CCDC122;C13orf31	-0.4	-6.26	-0.36	1.54e-9	Breast cancer;
CESC	cis	rs208346	1.000	rs208346	chr7:2799686	G/T	cg18446336	chr7:2847575	GNA12	0.41	7.08	0.4	1.26e-11	Loneliness (linear analysis);
CESC	cis	rs57221529	0.664	rs72704802	chr5:554211	C/T	cg16447950	chr5:562315	NA	-0.8	-7.49	-0.42	1.01e-12	Lung disease severity in cystic fibrosis;
CESC	cis	rs832540	0.519	rs10039338	chr5:56260363	C/T	cg24531977	chr5:56204891	C5orf35	0.42	5.47	0.32	1.06e-7	Coronary artery disease;
CESC	cis	rs2985684	0.948	rs2985685	chr14:50101370	G/A	cg15316458	chr14:50087796	RPL36AL;MGAT2	0.45	5.15	0.3	4.99e-7	Carotid intima media thickness;
CESC	cis	rs1322639	1.000	rs9689079	chr6:169587148	A/G	cg03254818	chr6:169586852	NA	-0.53	-7.27	-0.41	4.15e-12	Pulse pressure;
CESC	cis	rs7216064	0.953	rs4791048	chr17:65848994	G/A	cg07042672	chr17:66097459	LOC651250	-0.62	-7.37	-0.41	2.23e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs10504229	0.953	rs72652908	chr8:58191324	G/A	cg05313129	chr8:58192883	C8orf71	-0.55	-6.29	-0.36	1.34e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs854765	0.552	rs6502624	chr17:17847936	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.59	8.26	0.45	7.24e-15	Total body bone mineral density;
CESC	cis	rs7520050	0.807	rs3013594	chr1:46138000	T/C	cg03146154	chr1:46216737	IPP	0.52	6.76	0.38	8.52e-11	Red blood cell count;Reticulocyte count;
CESC	cis	rs3741404	0.665	rs12418535	chr11:63910980	A/G	cg04317338	chr11:64019027	PLCB3	0.47	5.62	0.33	4.95e-8	Platelet count;
CESC	cis	rs4253772	0.513	rs9306512	chr22:46716603	T/C	cg18190219	chr22:46762943	CELSR1	-0.44	-5.8	-0.34	1.84e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs9814567	1.000	rs9869981	chr3:134248801	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.45	-6.08	-0.35	4.19e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs10242455	0.702	rs917152	chr7:99004497	T/C	cg25640893	chr7:99214727	ZNF498	1.03	6.4	0.37	7.13e-10	Blood metabolite levels;
CESC	cis	rs875971	0.767	rs61348003	chr7:66005934	C/T	cg18876405	chr7:65276391	NA	0.53	7.28	0.41	3.9e-12	Aortic root size;
CESC	cis	rs7833790	0.777	rs1005850	chr8:82692255	G/A	cg02079420	chr8:82753780	SNX16	0.5	6.87	0.39	4.45e-11	Diastolic blood pressure;
CESC	cis	rs2204008	0.640	rs2320744	chr12:38162389	A/G	cg13010199	chr12:38710504	ALG10B	0.55	6.84	0.39	5.39e-11	Bladder cancer;
CESC	trans	rs11039798	1.000	rs10769383	chr11:48592510	C/G	cg15704280	chr7:45808275	SEPT13	0.7	6.68	0.38	1.41e-10	Axial length;
CESC	cis	rs62432291	0.681	rs365045	chr6:159632250	A/G	cg14500486	chr6:159655392	FNDC1	0.52	5.67	0.33	3.65e-8	Joint mobility (Beighton score);
CESC	cis	rs791888	1.000	rs2762521	chr10:89414923	T/A	cg13926569	chr10:89418898	PAPSS2	-0.44	-6.28	-0.36	1.36e-9	Magnesium levels;
CESC	cis	rs1552244	0.882	rs13088350	chr3:10044626	T/C	cg00166722	chr3:10149974	C3orf24	0.47	5.86	0.34	1.38e-8	Alzheimer's disease;
CESC	cis	rs6815814	0.851	rs11466645	chr4:38778203	A/T	cg02016764	chr4:38805732	TLR1	-0.68	-8.12	-0.45	1.73e-14	Breast cancer;
CESC	cis	rs35110281	0.641	rs9983670	chr21:45083425	A/G	cg21573476	chr21:45109991	RRP1B	-0.59	-8.81	-0.48	1.63e-16	Mean corpuscular volume;
CESC	cis	rs6740322	0.748	rs6732337	chr2:43462822	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.76	8.71	0.47	3.24e-16	Coronary artery disease;
CESC	cis	rs6964587	0.692	rs10271430	chr7:91710466	G/C	cg17063962	chr7:91808500	NA	0.45	6.46	0.37	5.12e-10	Breast cancer;
CESC	cis	rs666930	0.519	rs477992	chr1:120257576	A/G	cg19096424	chr1:120255104	PHGDH	0.69	8.71	0.47	3.35e-16	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14156148	chr15:102502487	WASH3P	-0.59	-6.75	-0.38	9.55e-11	Gut microbiome composition (summer);
CESC	cis	rs4919694	1.000	rs12245779	chr10:104645944	C/A	cg04362960	chr10:104952993	NT5C2	0.78	6.59	0.38	2.31e-10	Arsenic metabolism;
CESC	cis	rs2204008	0.818	rs7313608	chr12:38383428	C/A	cg13010199	chr12:38710504	ALG10B	-0.44	-5.7	-0.33	3.24e-8	Bladder cancer;
CESC	cis	rs73206853	0.764	rs7312139	chr12:110985442	C/A	cg12870014	chr12:110450643	ANKRD13A	0.67	5.85	0.34	1.42e-8	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05610740	chr12:96794311	CDK17	0.58	6.2	0.36	2.1e-9	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07777156	chr17:22022000	NA	-0.54	-6.07	-0.35	4.47e-9	Gut microbiome composition (summer);
CESC	cis	rs2625529	0.652	rs2929513	chr15:72229180	G/A	cg16672083	chr15:72433130	SENP8	0.4	5.95	0.34	8.49e-9	Red blood cell count;
CESC	cis	rs208520	0.954	rs12190073	chr6:66983740	T/C	cg07460842	chr6:66804631	NA	0.88	10.14	0.53	1.22e-20	Exhaled nitric oxide output;
CESC	cis	rs10504229	0.683	rs11786074	chr8:58133532	A/G	cg02725872	chr8:58115012	NA	-0.45	-7.05	-0.4	1.52e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs11209002	0.567	rs2755268	chr1:67539881	T/C	cg02640540	chr1:67518911	SLC35D1	0.47	5.39	0.31	1.52e-7	Crohn's disease;
CESC	cis	rs854765	0.583	rs4925125	chr17:17794444	T/C	cg04398451	chr17:18023971	MYO15A	0.69	10.07	0.53	2.12e-20	Total body bone mineral density;
CESC	cis	rs9359856	0.564	rs11962292	chr6:90476788	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.64	-6.06	-0.35	4.56e-9	Bipolar disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27276079	chr15:42211520	EHD4	-0.61	-6.58	-0.37	2.5e-10	Gut microbiome composition (summer);
CESC	cis	rs6032067	0.929	rs13043296	chr20:43805688	T/C	cg10761708	chr20:43804764	PI3	0.53	6.33	0.36	1.04e-9	Blood protein levels;
CESC	trans	rs1545843	0.593	rs7310247	chr12:84799396	C/T	cg03015433	chr16:56623111	MT3	-0.34	-6.14	-0.35	3.04e-9	Major depressive disorder;
CESC	cis	rs2204008	0.542	rs34770471	chr12:38009613	C/T	cg13010199	chr12:38710504	ALG10B	0.54	6.71	0.38	1.15e-10	Bladder cancer;
CESC	trans	rs4904167	0.841	rs10149675	chr14:84679322	G/T	cg06870609	chr15:89787223	FANCI	0.46	6.01	0.35	6.03e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs769267	0.965	rs12977937	chr19:19429975	C/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.42	5.2	0.3	3.98e-7	Tonsillectomy;
CESC	cis	rs2180341	0.618	rs4502958	chr6:127593113	G/A	cg24812749	chr6:127587940	RNF146	0.59	8.02	0.44	3.42e-14	Breast cancer;
CESC	cis	rs36051895	0.589	rs7848312	chr9:5237442	T/C	cg02405213	chr9:5042618	JAK2	-0.56	-6.63	-0.38	1.9e-10	Pediatric autoimmune diseases;
CESC	cis	rs875971	0.545	rs1796226	chr7:66087710	C/T	cg18876405	chr7:65276391	NA	0.49	5.81	0.34	1.83e-8	Aortic root size;
CESC	trans	rs4670302	1.000	rs4670302	chr2:34068392	A/C	cg12382846	chr20:60892121	LAMA5	-0.48	-6.21	-0.36	2e-9	Gut microbiota (beta diversity);
CESC	cis	rs28595532	0.748	rs67928655	chr4:119336525	C/A	cg21605333	chr4:119757512	SEC24D	0.95	5.97	0.34	7.39e-9	Cannabis dependence symptom count;
CESC	cis	rs28374715	0.635	rs28557159	chr15:41657353	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.8	-12.15	-0.6	2.72e-27	Ulcerative colitis;
CESC	cis	rs780096	0.506	rs1728922	chr2:27644464	A/C	cg12648201	chr2:27665141	KRTCAP3	-0.34	-6.28	-0.36	1.34e-9	Total body bone mineral density;
CESC	cis	rs2274273	0.870	rs13379169	chr14:55741287	C/T	cg04306507	chr14:55594613	LGALS3	0.29	5.6	0.33	5.29e-8	Protein biomarker;
CESC	trans	rs4424809	0.614	rs74484132	chr13:85572870	A/G	cg05918002	chr17:5019452	ZNF232	-0.63	-6.08	-0.35	4.29e-9	Age-related hearing impairment (SNP x SNP interaction);
CESC	trans	rs748404	0.578	rs478028	chr15:43610772	C/T	cg24053811	chr14:70265306	SLC10A1	0.41	6.0	0.35	6.61e-9	Lung cancer;
CESC	cis	rs7000551	0.505	rs73227818	chr8:22243325	T/C	cg12081754	chr8:22256438	SLC39A14	0.84	11.21	0.57	3.99e-24	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CESC	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg24642844	chr7:1081250	C7orf50	-0.77	-9.3	-0.5	5.54e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs6426558	0.537	rs694740	chr1:227293451	A/G	cg10327440	chr1:227177885	CDC42BPA	0.45	5.56	0.32	6.54e-8	Neutrophil percentage of white cells;
CESC	cis	rs4665809	1.000	rs11126364	chr2:26314515	A/G	cg26314531	chr2:26401878	FAM59B	-0.62	-7.07	-0.4	1.37e-11	Gut microbiome composition (summer);
CESC	cis	rs10206020	0.921	rs2280127	chr2:1546531	C/T	cg01028140	chr2:1542097	TPO	-0.48	-6.04	-0.35	5.2e-9	IgG glycosylation;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg22438603	chr5:127418940	SLC12A2;FLJ33630	0.45	6.18	0.35	2.38e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs4253772	0.551	rs9615936	chr22:46686328	C/G	cg03036452	chr22:46663545	TTC38	0.62	5.22	0.31	3.6e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs9811920	0.555	rs68092024	chr3:99691522	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.49	-7.69	-0.43	2.89e-13	Axial length;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01584448	chr16:50099761	HEATR3	0.55	6.52	0.37	3.59e-10	Gut microbiome composition (summer);
CESC	cis	rs6665290	0.669	rs34267809	chr1:227176162	C/G	cg10327440	chr1:227177885	CDC42BPA	-1.14	-25.45	-0.84	3.87e-73	Myeloid white cell count;
CESC	cis	rs8114671	0.804	rs3803936	chr20:33632775	T/C	cg24642439	chr20:33292090	TP53INP2	-0.45	-5.44	-0.32	1.19e-7	Height;
CESC	cis	rs11971779	0.941	rs1127424	chr7:139107660	A/G	cg07862535	chr7:139043722	LUC7L2	0.56	5.68	0.33	3.53e-8	Diisocyanate-induced asthma;
CESC	cis	rs9300255	0.739	rs1969354	chr12:123741776	T/C	cg00376283	chr12:123451042	ABCB9	0.7	8.63	0.47	5.59e-16	Neutrophil percentage of white cells;
CESC	cis	rs2050392	0.630	rs303427	chr10:30739780	G/A	cg25182066	chr10:30743637	MAP3K8	-0.47	-6.61	-0.38	2.11e-10	Inflammatory bowel disease;
CESC	cis	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg07157506	chr18:12883603	PTPN2	-0.47	-6.31	-0.36	1.17e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs11098499	0.954	rs12499324	chr4:120393786	C/T	cg24375607	chr4:120327624	NA	0.46	5.7	0.33	3.25e-8	Corneal astigmatism;
CESC	cis	rs7089973	0.872	rs11818115	chr10:116634891	G/A	cg23260525	chr10:116636907	FAM160B1	0.37	6.15	0.35	2.84e-9	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs9399137	0.507	rs7745289	chr6:135380327	A/G	cg24558204	chr6:135376177	HBS1L	0.69	9.52	0.5	1.12e-18	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	cis	rs4699052	0.893	rs4699058	chr4:104171321	T/A	cg16532752	chr4:104119610	CENPE	-0.43	-5.89	-0.34	1.15e-8	Testicular germ cell tumor;
CESC	cis	rs6502050	0.699	rs9901808	chr17:80107814	C/T	cg23985595	chr17:80112537	CCDC57	-0.42	-6.56	-0.37	2.74e-10	Life satisfaction;
CESC	cis	rs763121	0.853	rs2413544	chr22:39059404	A/C	cg06022373	chr22:39101656	GTPBP1	0.88	13.88	0.65	2.66e-33	Menopause (age at onset);
CESC	cis	rs2361718	0.500	rs4889818	chr17:78085228	A/G	cg23534315	chr17:78082725	GAA	0.39	5.39	0.31	1.55e-7	Yeast infection;
CESC	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	22.35	0.81	6.51e-63	Prudent dietary pattern;
CESC	cis	rs4268898	0.662	rs72793208	chr2:24510284	C/T	cg08917208	chr2:24149416	ATAD2B	0.53	5.32	0.31	2.24e-7	Asthma;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg02501984	chr12:133263946	POLE;PXMP2	-0.47	-6.23	-0.36	1.87e-9	Ulcerative colitis;
CESC	cis	rs7552404	0.731	rs2029683	chr1:76341643	T/G	cg10523679	chr1:76189770	ACADM	-0.63	-6.33	-0.36	1.02e-9	Blood metabolite levels;Acylcarnitine levels;
CESC	trans	rs2115172	0.836	rs4835799	chr5:122762229	A/G	cg25722142	chr6:139695762	CITED2	0.46	6.22	0.36	1.96e-9	Weight;
CESC	cis	rs4692589	1.000	rs4321597	chr4:170934424	C/T	cg19918862	chr4:170955249	NA	0.37	5.83	0.34	1.59e-8	Anxiety disorder;
CESC	cis	rs60871478	1.000	rs4719314	chr7:822523	A/G	cg00475322	chr7:917719	C7orf20	-0.47	-5.08	-0.3	7.01e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs4969178	0.965	rs8077859	chr17:76386335	C/T	cg20026190	chr17:76395443	PGS1	0.44	6.81	0.39	6.46e-11	HDL cholesterol levels;
CESC	cis	rs3820068	0.705	rs4646075	chr1:15827461	T/C	cg17385448	chr1:15911702	AGMAT	0.39	6.18	0.35	2.44e-9	Systolic blood pressure;
CESC	cis	rs4595586	0.525	rs35046524	chr12:39414535	A/G	cg13010199	chr12:38710504	ALG10B	0.43	5.33	0.31	2.13e-7	Morning vs. evening chronotype;
CESC	cis	rs67460515	0.892	rs34016896	chr3:160992864	C/T	cg03342759	chr3:160939853	NMD3	-0.53	-7.28	-0.41	3.89e-12	Parkinson's disease;
CESC	cis	rs4253772	0.550	rs6007779	chr22:46678615	A/C	cg24881330	chr22:46731750	TRMU	0.92	10.31	0.53	3.68e-21	LDL cholesterol;Cholesterol, total;
CESC	cis	rs1348850	0.846	rs4893962	chr2:178421106	A/G	cg23306229	chr2:178417860	TTC30B	0.58	7.45	0.42	1.3e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs34734847	1.000	rs3752531	chr12:121157851	A/G	cg21892295	chr12:121157589	UNC119B	-0.41	-6.51	-0.37	3.79e-10	Mean corpuscular volume;
CESC	cis	rs1799949	1.000	rs1973646	chr17:41310495	T/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.4	5.44	0.32	1.2e-7	Menopause (age at onset);
CESC	cis	rs6541297	0.703	rs585361	chr1:230314954	G/A	cg20703242	chr1:230279135	GALNT2	-0.43	-5.62	-0.33	4.84e-8	Coronary artery disease;
CESC	cis	rs4654899	0.865	rs4654891	chr1:21286391	T/C	cg05370193	chr1:21551575	ECE1	0.41	6.2	0.36	2.21e-9	Superior frontal gyrus grey matter volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00804338	chr13:114239234	TFDP1	0.57	7.33	0.41	2.82e-12	Gut microbiome composition (summer);
CESC	cis	rs2251381	0.778	rs722013	chr21:30549245	G/T	cg08807101	chr21:30365312	RNF160	0.67	8.23	0.45	8.77e-15	Selective IgA deficiency;
CESC	cis	rs10851478	0.872	rs1395901	chr15:49849674	C/T	cg08060515	chr15:49448048	GALK2;COPS2	0.42	5.18	0.3	4.41e-7	Oral cavity cancer;
CESC	cis	rs7666738	0.800	rs2839836	chr4:98970512	A/G	cg03467027	chr4:99064603	C4orf37	0.43	5.42	0.32	1.34e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1348850	0.750	rs55792594	chr2:178496468	C/T	cg23306229	chr2:178417860	TTC30B	0.55	7.02	0.4	1.91e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs2519796	0.531	rs2519802	chr9:136805853	A/G	cg13751417	chr9:136814406	VAV2	-0.44	-5.85	-0.34	1.43e-8	Hematocrit;Hemoglobin concentration;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05110787	chr11:61447839	DAGLA	0.57	6.83	0.39	5.68e-11	Gut microbiome composition (summer);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg25697769	chr22:39097335	JOSD1	-0.49	-6.4	-0.37	7.15e-10	Ulcerative colitis;
CESC	cis	rs9322193	0.847	rs12210605	chr6:150138403	A/G	cg04369109	chr6:150039330	LATS1	-0.48	-6.6	-0.38	2.26e-10	Lung cancer;
CESC	cis	rs7618915	0.501	rs3733045	chr3:52643307	A/G	cg18404041	chr3:52824283	ITIH1	-0.35	-5.92	-0.34	9.85e-9	Bipolar disorder;
CESC	cis	rs7811142	0.779	rs111312383	chr7:99905325	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.12	10.62	0.55	3.59e-22	Platelet count;
CESC	cis	rs1008375	1.000	rs10939742	chr4:17659936	G/T	cg02297831	chr4:17616191	MED28	0.54	6.79	0.39	7.22e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs853679	0.517	rs9468297	chr6:28118874	G/T	cg19592336	chr6:28129416	ZNF389	0.62	8.12	0.45	1.77e-14	Depression;
CESC	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.64	7.45	0.42	1.33e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs9911578	1.000	rs9892795	chr17:57023054	G/C	cg05425664	chr17:57184151	TRIM37	-0.5	-6.92	-0.39	3.41e-11	Intelligence (multi-trait analysis);
CESC	cis	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg08027265	chr7:2291960	NA	-0.4	-5.97	-0.34	7.43e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs1799949	0.930	rs56729776	chr17:41422131	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.61	8.07	0.44	2.51e-14	Menopause (age at onset);
CESC	trans	rs1814175	0.616	rs847641	chr11:49919261	T/C	cg03929089	chr4:120376271	NA	-0.92	-15.2	-0.68	6e-38	Height;
CESC	cis	rs2274273	0.686	rs66782529	chr14:55587867	C/T	cg04306507	chr14:55594613	LGALS3	0.33	5.86	0.34	1.37e-8	Protein biomarker;
CESC	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg11494091	chr17:61959527	GH2	0.73	12.55	0.61	1.13e-28	Prudent dietary pattern;
CESC	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	10.25	0.53	5.63e-21	Prudent dietary pattern;
CESC	cis	rs2573652	1.000	rs2581362	chr15:100513524	T/C	cg09918751	chr15:100517450	ADAMTS17	-0.39	-7.61	-0.42	4.79e-13	Height;
CESC	cis	rs4466137	1.000	rs1154888	chr5:82977410	C/A	cg16102102	chr5:83017553	HAPLN1	-0.42	-6.27	-0.36	1.49e-9	Prostate cancer;
CESC	cis	rs67311347	1.000	rs4571217	chr3:40521973	A/G	cg09455208	chr3:40491958	NA	0.49	8.24	0.45	7.86e-15	Renal cell carcinoma;
CESC	cis	rs9970334	0.596	rs709209	chr1:6278414	A/G	cg02892189	chr1:6321676	GPR153	-0.41	-6.1	-0.35	3.74e-9	Resting heart rate;
CESC	cis	rs1879734	0.731	rs12082358	chr1:54156624	A/C	cg23596471	chr1:54105337	GLIS1	0.34	5.47	0.32	1.03e-7	Mitral valve prolapse;
CESC	cis	rs1030877	0.960	rs3792047	chr2:105901553	A/G	cg02079111	chr2:105885981	TGFBRAP1	-0.66	-10.14	-0.53	1.28e-20	Obesity-related traits;
CESC	cis	rs1059312	0.771	rs11059922	chr12:129290418	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.82	-12.11	-0.6	3.74e-27	Systemic lupus erythematosus;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg18816107	chr1:151227233	PSMD4	-0.42	-6.08	-0.35	4.21e-9	Gambling;
CESC	cis	rs1008375	0.966	rs4515155	chr4:17696477	G/T	cg04450456	chr4:17643702	FAM184B	0.36	5.16	0.3	4.93e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09544279	chr5:179921349	CNOT6	0.57	6.88	0.39	4.24e-11	Gut microbiome composition (summer);
CESC	cis	rs921968	0.541	rs526897	chr2:219433597	C/T	cg02176678	chr2:219576539	TTLL4	0.52	8.72	0.47	3.12e-16	Mean corpuscular hemoglobin concentration;
CESC	cis	rs8020095	0.528	rs2296561	chr14:67849139	A/T	cg19548862	chr14:67692701	FAM71D	-0.45	-5.3	-0.31	2.41e-7	Depression (quantitative trait);
CESC	cis	rs12476592	0.602	rs6732791	chr2:63788901	C/A	cg17519650	chr2:63277830	OTX1	-0.48	-5.45	-0.32	1.15e-7	Childhood ear infection;
CESC	cis	rs7412746	0.658	rs12097963	chr1:150870450	T/C	cg04414720	chr1:150670196	GOLPH3L	0.51	6.78	0.38	7.88e-11	Melanoma;
CESC	cis	rs4889609	0.834	rs72785520	chr16:31070778	C/T	cg02466173	chr16:30829666	NA	-0.42	-7.33	-0.41	2.8e-12	Response to metformin (IC50);
CESC	cis	rs11227306	0.934	rs2303384	chr11:65640204	C/T	cg00576331	chr11:65640516	EFEMP2	0.48	6.18	0.36	2.38e-9	DNA methylation (variation);
CESC	cis	rs861020	0.606	rs689210	chr1:210013723	A/C	cg05527609	chr1:210001259	C1orf107	0.75	10.05	0.53	2.48e-20	Orofacial clefts;
CESC	cis	rs709400	0.894	rs61996721	chr14:104061352	G/A	cg24130564	chr14:104152367	KLC1	-0.42	-5.07	-0.3	7.49e-7	Body mass index;
CESC	cis	rs11155671	0.530	rs7768626	chr6:150207962	G/T	cg09699651	chr6:150184138	LRP11	0.55	7.65	0.43	3.82e-13	Testicular germ cell tumor;
CESC	cis	rs6951245	0.507	rs11763865	chr7:1194274	G/A	cg18402987	chr7:1209562	NA	0.52	6.21	0.36	2.06e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs11098499	0.954	rs6849561	chr4:120409694	C/G	cg09307838	chr4:120376055	NA	-0.93	-13.17	-0.63	8.4e-31	Corneal astigmatism;
CESC	trans	rs1814175	0.715	rs10839409	chr11:49884647	G/T	cg03929089	chr4:120376271	NA	-0.91	-15.47	-0.69	6.82e-39	Height;
CESC	cis	rs1153858	1.000	rs4775911	chr15:45649787	G/T	cg14582100	chr15:45693742	SPATA5L1	-0.42	-6.05	-0.35	4.98e-9	Homoarginine levels;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg27006547	chr11:62606509	WDR74	0.44	6.23	0.36	1.84e-9	Systemic lupus erythematosus;
CESC	cis	rs904251	0.861	rs1757183	chr6:37484790	C/T	cg01843034	chr6:37503916	NA	0.28	5.36	0.31	1.85e-7	Cognitive performance;
CESC	trans	rs11039798	0.588	rs7946443	chr11:48545504	G/A	cg15704280	chr7:45808275	SEPT13	0.66	6.67	0.38	1.46e-10	Axial length;
CESC	cis	rs3784262	1.000	rs4646622	chr15:58257199	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.31	-5.07	-0.3	7.58e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
CESC	cis	rs3796619	1.000	rs1453605	chr4:1075771	C/T	cg27284194	chr4:1044797	NA	0.36	5.5	0.32	8.88e-8	Recombination rate (males);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14455541	chr20:49203350	FAM65C	-0.58	-6.63	-0.38	1.86e-10	Gut microbiome composition (summer);
CESC	cis	rs7684253	0.587	rs4339274	chr4:57747634	A/G	cg21154227	chr4:57904332	IGFBP7	-0.35	-5.16	-0.3	4.83e-7	Migraine;
CESC	cis	rs7618915	0.547	rs8906	chr3:52739520	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	6.69	0.38	1.3100000000000001e-10	Bipolar disorder;
CESC	cis	rs7095944	0.584	rs4962691	chr10:126424137	C/T	cg08799069	chr10:126477246	METTL10	-0.4	-5.89	-0.34	1.19e-8	Asthma;
CESC	cis	rs4065321	0.609	rs8075668	chr17:38137623	C/T	cg17467752	chr17:38218738	THRA	-0.5	-7.19	-0.4	6.59e-12	White blood cell count (basophil);White blood cell count;
CESC	cis	rs72945132	0.941	rs66803755	chr11:70117473	G/A	cg14191688	chr11:70257035	CTTN	0.41	5.15	0.3	5.15e-7	Coronary artery disease;
CESC	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg07677032	chr17:61819896	STRADA	0.47	6.18	0.35	2.41e-9	Prudent dietary pattern;
CESC	cis	rs9549328	0.800	rs9549619	chr13:113632620	C/G	cg22951483	chr13:113628068	MCF2L	-0.35	-5.05	-0.3	8.1e-7	Systolic blood pressure;
CESC	cis	rs7249142	0.573	rs2238668	chr19:19282597	A/G	cg27384695	chr19:19271486	LOC729991-MEF2B;MEF2B	0.29	5.21	0.3	3.75e-7	IgG glycosylation;
CESC	cis	rs1729951	0.546	rs835632	chr3:136676525	A/T	cg03617693	chr3:136751559	NA	0.37	5.26	0.31	2.9e-7	Neuroticism;
CESC	cis	rs425277	0.583	rs925905	chr1:2044037	T/C	cg24578937	chr1:2090814	PRKCZ	-0.32	-5.51	-0.32	8.51e-8	Height;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg02203922	chr6:657011	HUS1B;EXOC2	0.49	6.35	0.36	9.15e-10	Fibrinogen levels;
CESC	cis	rs2243480	1.000	rs34577383	chr7:65385726	C/T	cg12463550	chr7:65579703	CRCP	0.7	5.7	0.33	3.21e-8	Diabetic kidney disease;
CESC	cis	rs12497850	0.931	rs11705888	chr3:48817289	T/C	cg06212747	chr3:49208901	KLHDC8B	0.64	8.49	0.46	1.49e-15	Parkinson's disease;
CESC	cis	rs17428076	0.793	rs72881938	chr2:172628752	C/G	cg13550731	chr2:172543902	DYNC1I2	0.47	5.25	0.31	3.08e-7	Myopia;
CESC	cis	rs12291225	0.679	rs11023172	chr11:14295367	C/G	cg19336497	chr11:14380999	RRAS2	-0.37	-5.27	-0.31	2.76e-7	Sense of smell;
CESC	cis	rs965469	0.843	rs6051698	chr20:3248983	T/C	cg25506879	chr20:3388711	C20orf194	-0.51	-5.6	-0.33	5.48e-8	IFN-related cytopenia;
CESC	cis	rs11696501	0.688	rs6073854	chr20:44309605	A/G	cg11783356	chr20:44313418	WFDC10B	-0.32	-5.12	-0.3	5.77e-7	Brain structure;
CESC	cis	rs1005277	0.577	rs4934906	chr10:38015028	C/T	cg25427524	chr10:38739819	LOC399744	-0.62	-8.7	-0.47	3.56e-16	Extrinsic epigenetic age acceleration;
CESC	cis	rs208520	0.690	rs12192710	chr6:66718137	C/T	cg07460842	chr6:66804631	NA	0.95	12.62	0.61	6.69e-29	Exhaled nitric oxide output;
CESC	cis	rs7824557	0.505	rs2736313	chr8:11086942	C/T	cg14752069	chr8:11977206	FAM66D	0.32	5.36	0.31	1.82e-7	Retinal vascular caliber;
CESC	cis	rs17376456	1.000	rs9968691	chr5:93509756	C/G	cg21475434	chr5:93447410	FAM172A	0.88	7.77	0.43	1.71e-13	Diabetic retinopathy;
CESC	cis	rs4319547	0.915	rs1473553	chr12:122985057	G/T	cg05707623	chr12:122985044	ZCCHC8	-0.66	-7.6	-0.42	5.09e-13	Body mass index;
CESC	cis	rs11098499	0.863	rs1552095	chr4:120460306	A/G	cg24375607	chr4:120327624	NA	0.46	5.43	0.32	1.29e-7	Corneal astigmatism;
CESC	cis	rs3892630	0.817	rs12609866	chr19:33184412	C/T	cg22980127	chr19:33182716	NUDT19	1.02	11.67	0.58	1.15e-25	Red blood cell traits;
CESC	cis	rs10256972	0.933	rs35696159	chr7:1047194	A/G	cg04025307	chr7:1156635	C7orf50	0.4	6.45	0.37	5.38e-10	Longevity;Endometriosis;
CESC	cis	rs514406	0.861	rs503015	chr1:53254456	T/C	cg08859206	chr1:53392774	SCP2	0.54	7.13	0.4	9.54e-12	Monocyte count;
CESC	cis	rs7772486	0.875	rs10457793	chr6:146415403	A/G	cg23711669	chr6:146136114	FBXO30	0.86	12.72	0.62	2.98e-29	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg04429812	chr17:37814043	STARD3	0.52	6.9	0.39	3.81e-11	Fibrinogen levels;
CESC	cis	rs6502050	0.799	rs8066370	chr17:80102105	T/C	cg23985595	chr17:80112537	CCDC57	-0.42	-6.57	-0.37	2.72e-10	Life satisfaction;
CESC	cis	rs643506	0.874	rs673679	chr11:111686800	C/T	cg17089665	chr11:111648010	NA	-0.36	-5.29	-0.31	2.53e-7	Breast cancer;
CESC	cis	rs6430585	0.527	rs62168830	chr2:136443900	A/T	cg07169764	chr2:136633963	MCM6	1.09	12.56	0.61	1.07e-28	Corneal structure;
CESC	cis	rs12541635	0.677	rs55639043	chr8:107055993	C/T	cg10147462	chr8:107024639	NA	0.48	7.18	0.4	6.9e-12	Age of smoking initiation;
CESC	cis	rs10089	1.000	rs3805606	chr5:127470813	A/C	cg19767477	chr5:127420684	SLC12A2	0.42	5.64	0.33	4.32e-8	Ileal carcinoids;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05784314	chr1:153747728	SLC27A3	0.61	6.6	0.38	2.28e-10	Gut microbiome composition (summer);
CESC	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg24739457	chr1:205821442	NA	0.46	6.03	0.35	5.48e-9	Menarche (age at onset);
CESC	cis	rs7666738	0.830	rs13145011	chr4:98993410	G/A	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.62e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs17666538	0.585	rs4735812	chr8:607766	C/G	cg07234876	chr8:600039	NA	0.82	5.79	0.34	1.95e-8	IgG glycosylation;
CESC	cis	rs6032067	0.929	rs13043503	chr20:43805835	T/C	cg11264863	chr20:43835661	SEMG1	0.51	5.56	0.32	6.5e-8	Blood protein levels;
CESC	cis	rs1348850	0.789	rs13027959	chr2:178275887	G/A	cg23306229	chr2:178417860	TTC30B	0.62	8.13	0.45	1.71e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs6840258	1.000	rs72667765	chr4:87965942	G/A	cg08197287	chr4:87952173	AFF1	-0.39	-5.33	-0.31	2.11e-7	Mean corpuscular volume;Basophil percentage of granulocytes;
CESC	cis	rs9926296	0.581	rs2108838	chr16:89904426	A/G	cg27121462	chr16:89883253	FANCA	0.62	7.5	0.42	9.46e-13	Vitiligo;
CESC	cis	rs2840044	0.534	rs167691	chr17:33885826	G/A	cg05299278	chr17:33885742	SLFN14	0.42	6.13	0.35	3.14e-9	Response to radiotherapy in cancer (late toxicity);
CESC	cis	rs2952156	0.920	rs903502	chr17:37829604	C/T	cg20243544	chr17:37824526	PNMT	0.63	8.15	0.45	1.47e-14	Asthma;
CESC	cis	rs7692995	1.000	rs6842114	chr4:18008199	A/C	cg08925142	chr4:18023851	LCORL	-0.44	-5.1	-0.3	6.35e-7	Height;
CESC	cis	rs7772486	0.764	rs2265471	chr6:146220250	G/A	cg05347473	chr6:146136440	FBXO30	0.53	6.86	0.39	4.96e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs35306767	0.855	rs55708963	chr10:925712	C/A	cg26597838	chr10:835615	NA	1.15	11.56	0.58	2.63e-25	Eosinophil percentage of granulocytes;
CESC	cis	rs9894429	0.646	rs7405937	chr17:79597811	G/A	cg18240062	chr17:79603768	NPLOC4	0.54	7.12	0.4	1.04e-11	Eye color traits;
CESC	cis	rs4523957	0.928	rs375245	chr17:2199754	G/A	cg16513277	chr17:2031491	SMG6	0.63	8.49	0.46	1.48e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs9916302	0.851	rs9909064	chr17:37500434	G/T	cg19468946	chr17:37922297	IKZF3	0.4	5.22	0.31	3.56e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs116095464	0.558	rs10079760	chr5:230778	A/G	cg22857025	chr5:266934	NA	-1.26	-18.31	-0.75	5.63e-49	Breast cancer;
CESC	cis	rs6500395	1.000	rs9938308	chr16:48607229	A/G	cg04672837	chr16:48644449	N4BP1	0.52	6.51	0.37	3.68e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs2070997	0.592	rs7858778	chr9:133679656	A/G	cg11464064	chr9:133710261	ABL1	0.58	6.42	0.37	6.27e-10	Response to amphetamines;
CESC	cis	rs1552244	0.882	rs55808392	chr3:10054681	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.85	11.05	0.56	1.38e-23	Alzheimer's disease;
CESC	cis	rs7103648	0.897	rs35032070	chr11:47408592	G/A	cg20307385	chr11:47447363	PSMC3	0.94	14.65	0.67	5.08e-36	Diastolic blood pressure;Systolic blood pressure;
CESC	cis	rs3785574	0.962	rs2955235	chr17:61966950	A/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.75	9.45	0.5	1.89e-18	Height;
CESC	cis	rs7917772	0.536	rs12357172	chr10:104388549	C/T	cg22532475	chr10:104410764	TRIM8	-0.44	-6.77	-0.38	8.33e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs7560272	0.723	rs780391	chr2:73703904	C/T	cg20560298	chr2:73613845	ALMS1	0.5	7.15	0.4	8.3e-12	Schizophrenia;
CESC	cis	rs9733	0.818	rs10888388	chr1:150687296	C/T	cg22823121	chr1:150693482	HORMAD1	-0.41	-6.39	-0.37	7.49e-10	Tonsillectomy;
CESC	cis	rs1385374	0.858	rs11059933	chr12:129303593	T/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.6	5.22	0.31	3.61e-7	Systemic lupus erythematosus;
CESC	cis	rs514406	0.505	rs395169	chr1:53174071	G/A	cg24675658	chr1:53192096	ZYG11B	-0.52	-6.44	-0.37	5.68e-10	Monocyte count;
CESC	cis	rs9486719	1.000	rs2472882	chr6:96863474	C/T	cg06623918	chr6:96969491	KIAA0776	0.82	8.4	0.46	2.72e-15	Migraine;Coronary artery disease;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg01700524	chr14:24803014	ADCY4	-0.48	-6.2	-0.36	2.17e-9	Ulcerative colitis;
CESC	cis	rs1843834	1.000	rs4624372	chr2:225553128	A/G	cg22455342	chr2:225449267	CUL3	0.53	6.56	0.37	2.86e-10	IgE levels in asthmatics (D.p. specific);
CESC	cis	rs6502050	0.769	rs9916231	chr17:80119645	A/G	cg23985595	chr17:80112537	CCDC57	-0.4	-6.32	-0.36	1.1e-9	Life satisfaction;
CESC	cis	rs1552244	0.882	rs67895180	chr3:10026079	T/C	cg00149659	chr3:10157352	C3orf10	0.71	8.4	0.46	2.72e-15	Alzheimer's disease;
CESC	cis	rs875971	0.862	rs1083554	chr7:65852341	T/C	cg10691866	chr7:65817282	TPST1	-0.33	-5.43	-0.32	1.3e-7	Aortic root size;
CESC	trans	rs561341	0.700	rs6505266	chr17:30225813	G/A	cg20587970	chr11:113659929	NA	-0.6	-7.99	-0.44	4.15e-14	Hip circumference adjusted for BMI;
CESC	cis	rs1559088	0.948	rs12608825	chr19:33581219	C/T	cg17764715	chr19:33622953	WDR88	-0.53	-6.91	-0.39	3.66e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs1953600	0.870	rs2789695	chr10:81946840	C/T	cg00277334	chr10:82204260	NA	0.45	6.28	0.36	1.4e-9	Sarcoidosis;
CESC	cis	rs947211	0.846	rs823155	chr1:205762946	T/C	cg14893161	chr1:205819251	PM20D1	0.44	5.83	0.34	1.63e-8	Parkinson's disease;
CESC	trans	rs11098499	0.954	rs2306455	chr4:120421969	G/A	cg25214090	chr10:38739885	LOC399744	0.7	9.78	0.51	1.7e-19	Corneal astigmatism;
CESC	cis	rs916888	0.821	rs70602	chr17:44859715	T/C	cg14517863	chr17:44321492	NA	-0.4	-5.16	-0.3	4.79e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs7178572	0.568	rs8037561	chr15:77680462	A/G	cg22256960	chr15:77711686	NA	-0.54	-6.95	-0.39	2.9e-11	Type 2 diabetes;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg11239145	chr4:26320844	RBPJ	-0.45	-6.01	-0.35	6.18e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs7267979	1.000	rs6115159	chr20:25350944	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.88	-18.14	-0.74	2.23e-48	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs6938	0.534	rs11072512	chr15:75204026	C/T	cg17294928	chr15:75287854	SCAMP5	0.47	6.23	0.36	1.81e-9	Breast cancer;
CESC	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg18765753	chr7:1198926	ZFAND2A	-0.47	-5.86	-0.34	1.38e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17240275	chr15:75500943	C15orf39	-0.52	-6.03	-0.35	5.34e-9	Gut microbiome composition (summer);
CESC	cis	rs4666360	1.000	rs4666295	chr2:20337144	C/T	cg23291376	chr2:20336282	NA	0.36	6.04	0.35	5.14e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel);
CESC	cis	rs7666738	1.000	rs13144055	chr4:99026849	A/G	cg03676636	chr4:99064102	C4orf37	0.37	5.41	0.32	1.39e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7618501	0.571	rs2240329	chr3:50107512	G/A	cg24308560	chr3:49941425	MST1R	0.63	9.38	0.5	3.2e-18	Intelligence (multi-trait analysis);
CESC	cis	rs9517302	0.847	rs9517297	chr13:99094961	A/C	cg22223119	chr13:99095684	FARP1	-0.56	-8.64	-0.47	5.26e-16	Obesity-related traits;
CESC	cis	rs7666738	0.830	rs13138059	chr4:99050430	A/G	cg03467027	chr4:99064603	C4orf37	0.47	5.89	0.34	1.2e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7582720	1.000	rs4675310	chr2:203880834	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	-0.86	-6.93	-0.39	3.28e-11	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs10504229	0.728	rs72650852	chr8:58150463	G/A	cg22535103	chr8:58192502	C8orf71	-0.92	-10.13	-0.53	1.34e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs4589502	0.512	rs7183242	chr15:67096658	A/G	cg12317470	chr15:67143691	NA	0.51	6.51	0.37	3.67e-10	Lung cancer (smoking interaction);
CESC	cis	rs11650494	0.710	rs16948078	chr17:47474800	C/T	cg08112188	chr17:47440006	ZNF652	-0.77	-5.8	-0.34	1.87e-8	Prostate cancer;
CESC	cis	rs7089973	0.872	rs17092542	chr10:116630289	G/A	cg25233709	chr10:116636983	FAM160B1	0.35	5.09	0.3	6.77e-7	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg15228606	chr17:1812096	NA	-0.52	-7.06	-0.4	1.46e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs7829975	0.502	rs7820738	chr8:8702607	C/G	cg15556689	chr8:8085844	FLJ10661	-0.44	-5.38	-0.31	1.6e-7	Mood instability;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg10311315	chr2:101889706	SNORD89	0.44	6.24	0.36	1.74e-9	Fibrinogen levels;
CESC	trans	rs724568	0.681	rs4671842	chr2:67945371	T/C	cg19718508	chr5:176831858	F12	-0.44	-6.01	-0.35	6.26e-9	Major depressive disorder (broad);
CESC	cis	rs6459788	0.693	rs35146559	chr7:157238557	G/A	cg06271696	chr7:157225062	NA	-0.39	-5.35	-0.31	1.89e-7	Epstein-Barr virus copy number in lymphoblastoid cell lines;
CESC	cis	rs11997175	0.624	rs4733179	chr8:33692223	T/G	ch.8.33884649F	chr8:33765107	NA	0.55	7.18	0.4	6.97e-12	Body mass index;
CESC	cis	rs7223966	1.000	rs9903903	chr17:61762044	A/G	cg11494091	chr17:61959527	GH2	0.38	5.35	0.31	1.93e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs8031584	0.918	rs35396566	chr15:31263057	T/C	cg08109568	chr15:31115862	NA	-0.74	-9.38	-0.5	3.17e-18	Huntington's disease progression;
CESC	cis	rs7208859	0.623	rs9911173	chr17:29154750	C/T	cg19761014	chr17:28927070	LRRC37B2	0.72	5.91	0.34	1.03e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs763014	0.898	rs8060585	chr16:635794	C/G	cg09781414	chr16:715207	WDR90	-0.33	-5.04	-0.3	8.57e-7	Height;
CESC	cis	rs7264396	0.635	rs6060681	chr20:34506147	A/G	cg17201900	chr20:34330562	RBM39	0.48	5.12	0.3	5.97e-7	Total cholesterol levels;
CESC	cis	rs7607369	0.536	rs4674344	chr2:219669875	A/T	cg02176678	chr2:219576539	TTLL4	-0.36	-6.22	-0.36	1.94e-9	Red blood cell count;Amyotrophic lateral sclerosis;
CESC	cis	rs7666738	0.800	rs10028921	chr4:98962630	G/T	cg18180107	chr4:99064573	C4orf37	0.4	5.14	0.3	5.27e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10089	1.000	rs4836363	chr5:127462737	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.76	10.07	0.53	2.04e-20	Ileal carcinoids;
CESC	cis	rs1355223	0.902	rs7130325	chr11:34750959	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.47	-6.13	-0.35	3.23e-9	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs6963495	0.818	rs55740553	chr7:105159551	A/G	cg02135003	chr7:105160482	PUS7	-0.46	-5.55	-0.32	6.92e-8	Bipolar disorder (body mass index interaction);
CESC	cis	rs938554	0.736	rs4475146	chr4:9946656	C/A	cg11266682	chr4:10021025	SLC2A9	-0.39	-5.29	-0.31	2.53e-7	Blood metabolite levels;
CESC	cis	rs2836974	0.897	rs2836932	chr21:40546717	G/A	cg11644478	chr21:40555479	PSMG1	1.03	16.69	0.72	3.03e-43	Cognitive function;
CESC	cis	rs17021463	0.902	rs62320439	chr4:95248721	G/C	cg11021082	chr4:95130006	SMARCAD1	0.52	7.84	0.43	1.1e-13	Testicular germ cell tumor;
CESC	cis	rs13256369	0.851	rs13254997	chr8:8563753	G/C	cg17143192	chr8:8559678	CLDN23	0.77	8.87	0.48	1.09e-16	Obesity-related traits;
CESC	cis	rs933688	0.532	rs2367292	chr5:90556785	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	-0.45	-5.09	-0.3	6.76e-7	Smoking behavior;
CESC	cis	rs1712517	0.545	rs3740381	chr10:105046689	G/C	cg04362960	chr10:104952993	NT5C2	-0.45	-5.42	-0.32	1.37e-7	Migraine;
CESC	cis	rs801193	1.000	rs7783924	chr7:66209057	A/C	cg06456125	chr7:65229604	NA	0.4	5.23	0.31	3.51e-7	Aortic root size;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg21767207	chr19:36236454	PSENEN;U2AF1L4	-0.44	-6.07	-0.35	4.51e-9	Fibrinogen levels;
CESC	cis	rs2953174	0.938	rs2975758	chr2:241530750	G/A	cg07929629	chr2:241523174	NA	0.57	5.33	0.31	2.15e-7	Bipolar disorder;
CESC	cis	rs1707322	1.000	rs4134387	chr1:46395158	A/T	cg03146154	chr1:46216737	IPP	0.78	10.77	0.55	1.17e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs853679	0.517	rs9368553	chr6:28082265	T/C	cg08968635	chr6:28129556	ZNF389	0.4	5.36	0.31	1.84e-7	Depression;
CESC	cis	rs7666738	0.830	rs10025174	chr4:98914172	A/G	cg03467027	chr4:99064603	C4orf37	0.43	5.22	0.31	3.57e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19226866	chr11:63993875	NUDT22;TRPT1	-0.59	-6.3	-0.36	1.21e-9	Gut microbiome composition (summer);
CESC	cis	rs1707322	0.835	rs946525	chr1:46487277	A/T	cg03146154	chr1:46216737	IPP	-0.72	-9.88	-0.52	8.55e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs3096299	0.509	rs4785691	chr16:89597221	A/G	cg02034447	chr16:89574710	SPG7	0.55	7.09	0.4	1.24e-11	Multiple myeloma (IgH translocation);
CESC	cis	rs137699	1.000	rs5757632	chr22:39756097	A/C	cg24399712	chr22:39784796	NA	-0.4	-5.24	-0.31	3.22e-7	IgG glycosylation;
CESC	cis	rs6499255	0.904	rs7190652	chr16:69616292	C/G	cg15192750	chr16:69999425	NA	0.53	6.19	0.36	2.33e-9	IgE levels;
CESC	cis	rs5758659	1.000	rs5758659	chr22:42622003	C/T	cg15557168	chr22:42548783	NA	-0.49	-7.77	-0.43	1.73e-13	Cognitive function;
CESC	cis	rs7666738	0.830	rs13133619	chr4:99067312	C/G	cg05340658	chr4:99064831	C4orf37	-0.83	-12.91	-0.62	6.34e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2836974	0.830	rs2735309	chr21:40715313	C/T	cg17971929	chr21:40555470	PSMG1	0.92	12.31	0.6	7.68e-28	Cognitive function;
CESC	cis	rs10504073	0.647	rs10504072	chr8:49993083	G/A	cg00325661	chr8:49890786	NA	0.55	8.17	0.45	1.29e-14	Blood metabolite ratios;
CESC	cis	rs4604732	0.631	rs12036460	chr1:247626928	A/G	cg12754571	chr1:247694271	LOC148824;OR2C3	0.44	5.44	0.32	1.21e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs6432018	0.927	rs6432023	chr2:9736874	C/T	cg23886495	chr2:9695866	ADAM17	0.43	5.06	0.3	7.74e-7	Heart rate variability traits;
CESC	cis	rs501120	0.810	rs541483	chr10:44746395	A/G	cg09554077	chr10:44749378	NA	0.5	6.29	0.36	1.34e-9	Coronary artery disease;Coronary heart disease;
CESC	cis	rs832540	0.898	rs331498	chr5:56249842	C/G	cg12311346	chr5:56204834	C5orf35	0.42	5.06	0.3	7.84e-7	Coronary artery disease;
CESC	cis	rs5753618	0.504	rs9606848	chr22:31901867	G/A	cg00478049	chr22:31556069	RNF185	-0.46	-5.53	-0.32	7.55e-8	Colorectal cancer;
CESC	cis	rs3749237	0.557	rs7631908	chr3:49425707	T/G	cg06212747	chr3:49208901	KLHDC8B	0.53	7.2	0.4	6.14e-12	Resting heart rate;
CESC	cis	rs1348850	0.519	rs13034781	chr2:178523550	C/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.57	7.04	0.4	1.67e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27248073	chr17:6347727	FAM64A	0.55	6.62	0.38	2e-10	Gut microbiome composition (summer);
CESC	cis	rs7659604	0.502	rs13106764	chr4:122699630	C/G	cg19671926	chr4:122722719	EXOSC9	0.65	8.58	0.47	7.87e-16	Type 2 diabetes;
CESC	cis	rs6939532	0.522	rs6933583	chr6:26355283	A/C	cg14345882	chr6:26364793	BTN3A2	0.4	6.24	0.36	1.7e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs2486288	0.656	rs8039352	chr15:45551790	A/G	cg09092052	chr15:45571596	NA	0.45	5.37	0.31	1.72e-7	Glomerular filtration rate;
CESC	cis	rs963731	0.649	rs10166801	chr2:39250771	C/T	cg04010122	chr2:39346883	SOS1	-0.77	-5.69	-0.33	3.29e-8	Corticobasal degeneration;
CESC	cis	rs7809950	0.834	rs3801946	chr7:107242995	T/A	cg23024343	chr7:107201750	COG5	0.46	6.24	0.36	1.76e-9	Coronary artery disease;
CESC	cis	rs4969178	0.645	rs4490057	chr17:76375095	C/T	cg05887092	chr17:76393375	PGS1	-0.6	-9.38	-0.5	3.08e-18	HDL cholesterol levels;
CESC	cis	rs12291225	0.585	rs12270374	chr11:14375079	T/C	cg19336497	chr11:14380999	RRAS2	-0.45	-6.59	-0.38	2.32e-10	Sense of smell;
CESC	cis	rs3008870	1.000	rs7511948	chr1:67430427	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.06	15.19	0.68	6.65e-38	Lymphocyte percentage of white cells;
CESC	cis	rs6547741	0.935	rs4666005	chr2:27855239	A/G	cg21248554	chr2:27665150	KRTCAP3	0.27	5.7	0.33	3.16e-8	Oral cavity cancer;
CESC	trans	rs6089829	0.925	rs6062396	chr20:61667949	T/C	cg23505145	chr19:12996616	KLF1	0.51	6.68	0.38	1.37e-10	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs324780	0.544	rs401687	chr12:83924986	G/C	cg22140261	chr22:42466895	NAGA	-0.48	-6.12	-0.35	3.34e-9	Vertical cup-disc ratio;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg27294288	chr5:170750725	NA	0.45	6.16	0.35	2.65e-9	Fibrinogen levels;
CESC	cis	rs17376456	1.000	rs9968749	chr5:93509559	A/G	cg25358565	chr5:93447407	FAM172A	1.14	11.21	0.57	4.02e-24	Diabetic retinopathy;
CESC	cis	rs4665809	1.000	rs10048648	chr2:26320315	T/C	cg27170947	chr2:26402098	FAM59B	-0.57	-6.76	-0.38	8.73e-11	Gut microbiome composition (summer);
CESC	cis	rs894734	0.535	rs7301643	chr12:54325796	G/T	cg17410650	chr12:54324560	NA	-0.46	-8.26	-0.45	6.82e-15	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
CESC	cis	rs4891159	0.790	rs72975929	chr18:74144630	G/C	cg24786174	chr18:74118243	ZNF516	-0.73	-11.05	-0.56	1.39e-23	Longevity;
CESC	cis	rs2249625	0.844	rs2463749	chr6:72918148	C/G	cg18830697	chr6:72922368	RIMS1	0.38	5.35	0.31	1.92e-7	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CESC	cis	rs2733201	1.000	rs11635948	chr15:44286094	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.59	-5.37	-0.31	1.7e-7	Lipoprotein phospholipase A2 activity in cardiovascular disease;
CESC	cis	rs6570726	0.738	rs4495284	chr6:145916617	T/A	cg05347473	chr6:146136440	FBXO30	0.55	7.01	0.4	2.02e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs727563	0.569	rs73178647	chr22:41964168	G/A	cg06481639	chr22:41940642	POLR3H	-0.66	-6.62	-0.38	2e-10	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs6964587	0.967	rs6974827	chr7:91772945	C/T	cg17063962	chr7:91808500	NA	0.59	8.22	0.45	8.94e-15	Breast cancer;
CESC	cis	rs30380	1.000	rs151964	chr5:96123666	G/T	cg16492584	chr5:96139282	ERAP1	-0.35	-5.35	-0.31	1.95e-7	Cerebrospinal fluid biomarker levels;
CESC	cis	rs34779708	0.931	rs11596502	chr10:35387187	A/C	cg03585969	chr10:35415529	CREM	0.75	9.77	0.51	1.82e-19	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs7666738	0.830	rs13108705	chr4:99044438	T/C	cg17366294	chr4:99064904	C4orf37	0.61	8.78	0.47	2.13e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10479542	0.892	rs7723230	chr5:178980474	T/C	cg00080972	chr5:178986291	RUFY1	0.44	6.98	0.39	2.35e-11	Lung cancer;
CESC	cis	rs9486719	0.857	rs4839833	chr6:96882069	T/C	cg06623918	chr6:96969491	KIAA0776	0.89	10.34	0.54	2.9e-21	Migraine;Coronary artery disease;
CESC	cis	rs473651	1.000	rs473651	chr2:239335401	A/C	cg21699342	chr2:239360505	ASB1	0.53	8.62	0.47	6.06e-16	Multiple system atrophy;
CESC	cis	rs4843747	0.519	rs12599755	chr16:88107006	A/G	cg06374794	chr16:88002281	BANP	0.4	5.13	0.3	5.56e-7	Menopause (age at onset);
CESC	cis	rs7223966	1.000	rs11079509	chr17:61762148	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.48	5.05	0.3	8.31e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs7589342	0.899	rs11885225	chr2:106486548	T/C	cg14210321	chr2:106509881	NCK2	-0.47	-5.35	-0.31	1.88e-7	Addiction;
CESC	cis	rs4862750	0.832	rs6836076	chr4:187899660	A/C	cg06074448	chr4:187884817	NA	-0.37	-5.43	-0.32	1.27e-7	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs10493773	0.609	rs3753789	chr1:86174814	T/C	cg17807903	chr1:86174739	ZNHIT6	-0.44	-6.5	-0.37	3.91e-10	Urate levels in overweight individuals;
CESC	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg17178900	chr1:205818956	PM20D1	0.85	14.81	0.67	1.47e-36	Menarche (age at onset);
CESC	cis	rs9549367	0.789	rs9549695	chr13:113874814	A/G	cg18105134	chr13:113819100	PROZ	0.59	7.24	0.41	4.73e-12	Platelet distribution width;
CESC	cis	rs30380	1.000	rs30380	chr5:96122281	A/C	cg16492584	chr5:96139282	ERAP1	-0.35	-5.35	-0.31	1.89e-7	Cerebrospinal fluid biomarker levels;
CESC	cis	rs8031584	1.000	rs1474380	chr15:31269235	T/C	cg14829155	chr15:31115871	NA	-0.71	-9.41	-0.5	2.57e-18	Huntington's disease progression;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg23672752	chr16:66785618	DYNC1LI2	-0.42	-6.0	-0.35	6.59e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs9611565	0.512	rs139573	chr22:42214785	G/A	cg03806693	chr22:41940476	POLR3H	-1.14	-13.25	-0.63	4.18e-31	Vitiligo;
CESC	cis	rs7617480	0.648	rs6766238	chr3:48801929	G/A	cg06212747	chr3:49208901	KLHDC8B	0.46	5.39	0.31	1.59e-7	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CESC	cis	rs9660992	0.649	rs12128254	chr1:205268097	C/T	cg21643547	chr1:205240462	TMCC2	-0.47	-6.19	-0.36	2.23e-9	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg22907277	chr7:1156413	C7orf50	0.46	5.4	0.32	1.45e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs896854	0.654	rs10104909	chr8:95977973	C/T	cg23172400	chr8:95962367	TP53INP1	-0.44	-9.18	-0.49	1.3e-17	Type 2 diabetes;
CESC	trans	rs4471313	0.956	rs3119904	chr1:170352054	T/G	cg14876685	chr7:99177937	NA	-0.4	-6.15	-0.35	2.85e-9	Waist-hip ratio;
CESC	cis	rs13095912	0.785	rs34619288	chr3:185331678	G/C	cg11274856	chr3:185301563	NA	0.36	5.19	0.3	4.28e-7	Systolic blood pressure;
CESC	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg16145915	chr7:1198662	ZFAND2A	-0.82	-15.27	-0.68	3.45e-38	Longevity;Endometriosis;
CESC	cis	rs3733585	0.699	rs7683283	chr4:9969974	T/C	cg02734326	chr4:10020555	SLC2A9	-0.39	-5.6	-0.33	5.49e-8	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs4665809	0.590	rs7579504	chr2:26439995	T/C	cg25036284	chr2:26402008	FAM59B	-0.86	-9.4	-0.5	2.74e-18	Gut microbiome composition (summer);
CESC	cis	rs1691799	0.899	rs1168321	chr12:66744517	C/G	cg16791601	chr12:66731901	HELB	0.79	14.58	0.67	9.12e-36	White blood cell count (basophil);
CESC	cis	rs10089	0.953	rs17164427	chr5:127361736	C/G	cg19767477	chr5:127420684	SLC12A2	0.4	5.43	0.32	1.26e-7	Ileal carcinoids;
CESC	cis	rs11785693	0.862	rs11782556	chr8:5002389	C/G	cg26367366	chr8:4980734	NA	0.79	7.5	0.42	9.6e-13	Neuroticism (multi-trait analysis);Neuroticism;
CESC	cis	rs798554	0.679	rs1636253	chr7:2885123	A/G	cg19717773	chr7:2847554	GNA12	-0.47	-6.75	-0.38	9.38e-11	Height;
CESC	cis	rs1707322	1.000	rs10890372	chr1:46391020	T/G	cg05343316	chr1:45956843	TESK2	0.44	5.42	0.32	1.36e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7586879	0.575	rs6744205	chr2:25133148	T/C	cg01884057	chr2:25150051	NA	0.36	7.03	0.4	1.8e-11	Body mass index;
CESC	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	7.56	0.42	6.72e-13	Prudent dietary pattern;
CESC	cis	rs2985684	1.000	rs11157696	chr14:50105746	C/G	cg02151108	chr14:50098012	C14orf104	0.4	5.21	0.3	3.85e-7	Carotid intima media thickness;
CESC	cis	rs10504229	1.000	rs72650900	chr8:58185675	T/A	cg24829409	chr8:58192753	C8orf71	-0.76	-9.93	-0.52	5.87e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.48	-5.11	-0.3	6.3e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs1348850	0.958	rs11684320	chr2:178456346	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.61	8.32	0.46	4.74e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs2011503	1.000	rs7252453	chr19:19654117	G/C	cg03709012	chr19:19516395	GATAD2A	0.53	5.47	0.32	1.03e-7	Bipolar disorder;
CESC	cis	rs1552244	0.935	rs6805869	chr3:10119917	T/C	cg13047869	chr3:10149882	C3orf24	0.4	5.03	0.3	8.89e-7	Alzheimer's disease;
CESC	cis	rs1044573	0.514	rs2268879	chr20:25177805	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.37	-5.32	-0.31	2.18e-7	Allergic rhinitis;
CESC	trans	rs2018683	0.707	rs2391718	chr7:28974988	T/C	cg19402173	chr7:128379420	CALU	-0.49	-6.5	-0.37	3.95e-10	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CESC	cis	rs763014	0.932	rs2269559	chr16:682297	T/C	cg00802000	chr16:706648	WDR90	-0.39	-5.94	-0.34	9.01e-9	Height;
CESC	cis	rs8017423	0.647	rs1958345	chr14:90823770	T/C	cg14092571	chr14:90743983	NA	0.44	6.77	0.38	8.12e-11	Mortality in heart failure;
CESC	cis	rs801193	0.569	rs2013908	chr7:66121069	A/T	cg18876405	chr7:65276391	NA	-0.45	-6.21	-0.36	2e-9	Aortic root size;
CESC	cis	rs6582630	0.519	rs10880194	chr12:38302836	G/A	cg26384229	chr12:38710491	ALG10B	0.7	10.34	0.54	2.92e-21	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs7618915	0.547	rs11714419	chr3:52628816	A/G	cg17372223	chr3:52568218	NT5DC2	0.46	6.92	0.39	3.4e-11	Bipolar disorder;
CESC	cis	rs2806561	0.765	rs1738470	chr1:23511911	G/A	cg12483005	chr1:23474871	LUZP1	0.39	6.15	0.35	2.78e-9	Height;
CESC	cis	rs7914558	1.000	rs10883837	chr10:104896486	G/A	cg04362960	chr10:104952993	NT5C2	0.46	5.92	0.34	9.98e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03260790	chr12:56211718	ORMDL2;SARNP	-0.57	-6.26	-0.36	1.56e-9	Gut microbiome composition (summer);
CESC	cis	rs7635838	0.654	rs4684766	chr3:11285474	G/A	cg00170343	chr3:11313890	ATG7	0.53	7.31	0.41	3.13e-12	HDL cholesterol;
CESC	cis	rs2985684	0.901	rs7146248	chr14:50112067	C/T	cg02151108	chr14:50098012	C14orf104	-0.4	-5.13	-0.3	5.53e-7	Carotid intima media thickness;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21872608	chr12:54121322	CALCOCO1	0.69	7.44	0.42	1.43e-12	Gut microbiome composition (summer);
CESC	cis	rs2576037	0.583	rs504668	chr18:44410749	T/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.33	5.29	0.31	2.52e-7	Personality dimensions;
CESC	cis	rs709400	1.000	rs861538	chr14:104166733	C/T	cg12935359	chr14:103987150	CKB	-0.46	-6.22	-0.36	1.91e-9	Body mass index;
CESC	cis	rs4604732	0.536	rs12058821	chr1:247649651	G/T	cg12758973	chr1:247694275	LOC148824;OR2C3	0.46	5.85	0.34	1.41e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs1552244	1.000	rs7615646	chr3:10089773	A/C	cg00149659	chr3:10157352	C3orf10	0.74	8.69	0.47	3.76e-16	Alzheimer's disease;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg01812826	chr8:123793836	ZHX2	-0.43	-6.0	-0.35	6.6e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs1707322	0.721	rs10890333	chr1:46100322	T/C	cg05343316	chr1:45956843	TESK2	0.51	6.26	0.36	1.51e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs6088580	0.634	rs6059829	chr20:33017074	G/A	cg06115741	chr20:33292138	TP53INP2	0.48	6.14	0.35	3e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs7236492	0.683	rs78250476	chr18:77198934	G/A	cg15644404	chr18:77186268	NFATC1	-0.69	-5.4	-0.31	1.49e-7	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs6752107	1.000	rs6752107	chr2:234161448	C/T	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.38	5.94	0.34	9.06e-9	Crohn's disease;Inflammatory bowel disease;
CESC	trans	rs2727020	0.681	rs1976901	chr11:49378697	T/C	cg03929089	chr4:120376271	NA	-0.79	-11.92	-0.59	1.64e-26	Coronary artery disease;
CESC	cis	rs7618915	0.547	rs10780035	chr3:52764624	C/T	cg18099408	chr3:52552593	STAB1	-0.32	-5.17	-0.3	4.69e-7	Bipolar disorder;
CESC	cis	rs713587	0.525	rs11675457	chr2:25079770	C/T	cg01884057	chr2:25150051	NA	0.35	6.73	0.38	1.06e-10	Body mass index in non-asthmatics;
CESC	cis	rs17384381	0.859	rs35761966	chr1:85918357	G/A	cg16011679	chr1:85725395	C1orf52	0.69	6.85	0.39	5.08e-11	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg00436174	chr2:128051630	ERCC3	-0.45	-6.14	-0.35	3.01e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs763121	0.853	rs926299	chr22:39095698	C/G	cg21395723	chr22:39101663	GTPBP1	0.49	6.67	0.38	1.5e-10	Menopause (age at onset);
CESC	cis	rs10883723	0.738	rs715438	chr10:104258303	C/T	cg22532475	chr10:104410764	TRIM8	-0.35	-5.94	-0.34	8.94e-9	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs2760061	0.626	rs672907	chr1:228120345	G/A	cg02753203	chr1:228287806	NA	-0.51	-7.43	-0.42	1.5e-12	Diastolic blood pressure;
CESC	cis	rs1348850	0.526	rs7582179	chr2:178370631	A/G	cg22681709	chr2:178499509	PDE11A	-0.5	-5.32	-0.31	2.2e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs7618915	0.547	rs4130905	chr3:52709831	A/T	cg05564831	chr3:52568323	NT5DC2	0.44	6.72	0.38	1.1e-10	Bipolar disorder;
CESC	cis	rs74181299	0.784	rs2723085	chr2:65297359	C/G	cg05010058	chr2:65284262	CEP68	0.34	5.74	0.33	2.58e-8	Pulse pressure;
CESC	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.89	13.55	0.64	3.99e-32	Prudent dietary pattern;
CESC	cis	rs1728785	0.901	rs1170420	chr16:68635877	G/C	cg02972257	chr16:68554789	NA	-0.63	-7.01	-0.4	1.94e-11	Ulcerative colitis;
CESC	trans	rs3733585	0.660	rs13122290	chr4:9933832	A/G	cg26043149	chr18:55253948	FECH	-0.43	-6.04	-0.35	5.22e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs7666738	0.830	rs2865979	chr4:99027137	T/C	cg18180107	chr4:99064573	C4orf37	0.42	5.43	0.32	1.29e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs35110281	0.782	rs6518309	chr21:45047992	C/A	cg01579765	chr21:45077557	HSF2BP	-0.56	-8.51	-0.46	1.34e-15	Mean corpuscular volume;
CESC	cis	rs7264396	0.635	rs6058346	chr20:34481043	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.85	-11.19	-0.57	4.57e-24	Total cholesterol levels;
CESC	cis	rs2243480	1.000	rs2420171	chr7:65637760	T/C	cg13147721	chr7:65941812	NA	0.97	9.19	0.49	1.2e-17	Diabetic kidney disease;
CESC	cis	rs10504229	1.000	rs115548028	chr8:58170672	T/C	cg14926445	chr8:58193284	C8orf71	-0.51	-5.48	-0.32	1.01e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs8067354	0.574	rs1291947	chr17:57996336	G/T	cg02344993	chr17:57696989	CLTC	0.52	5.61	0.33	5.15e-8	Hemoglobin concentration;
CESC	cis	rs11098499	0.863	rs10004484	chr4:120442428	C/T	cg09307838	chr4:120376055	NA	0.91	12.35	0.6	5.59e-28	Corneal astigmatism;
CESC	cis	rs1008375	0.966	rs3775925	chr4:17588437	A/G	cg02297831	chr4:17616191	MED28	0.5	6.12	0.35	3.36e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs916888	0.821	rs199507	chr17:44858855	A/G	cg17911788	chr17:44343683	NA	0.53	7.2	0.4	6.14e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	trans	rs2121875	0.667	rs4637558	chr5:44224783	G/A	cg09056876	chr6:156718398	NA	-0.48	-6.13	-0.35	3.09e-9	Prostate cancer;
CESC	cis	rs9660992	0.573	rs1172147	chr1:205225457	G/A	cg00857998	chr1:205179979	DSTYK	0.55	6.76	0.38	8.73e-11	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs589448	0.902	rs315113	chr12:69786543	G/T	cg22834771	chr12:69754056	YEATS4	0.52	7.21	0.4	5.89e-12	Cerebrospinal fluid biomarker levels;
CESC	cis	rs2243480	1.000	rs4718309	chr7:65627764	G/C	cg18252515	chr7:66147081	NA	1.36	13.62	0.64	2.25e-32	Diabetic kidney disease;
CESC	cis	rs12048904	1.000	rs12048904	chr1:101331536	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.52	-6.83	-0.39	5.72e-11	Multiple sclerosis;
CESC	cis	rs3096299	0.685	rs12446145	chr16:89542695	C/T	cg02034447	chr16:89574710	SPG7	0.48	6.17	0.35	2.48e-9	Multiple myeloma (IgH translocation);
CESC	cis	rs16870629	0.541	rs2334955	chr5:1062444	A/G	cg18655438	chr5:1077845	SLC12A7	-0.36	-5.24	-0.31	3.36e-7	QT interval;
CESC	cis	rs2235642	0.893	rs2143285	chr16:1593171	A/G	cg03771183	chr16:1608904	IFT140	0.41	5.88	0.34	1.26e-8	Coronary artery disease;
CESC	cis	rs3106136	0.872	rs2059606	chr4:95255278	C/T	cg11021082	chr4:95130006	SMARCAD1	0.36	5.2	0.3	3.99e-7	Capecitabine sensitivity;
CESC	cis	rs1267303	0.642	rs116078607	chr1:46999238	G/A	cg25110126	chr1:46999211	NA	1.07	12.0	0.59	8.98e-27	Monobrow;
CESC	cis	rs9311474	0.508	rs11720243	chr3:52618018	T/C	cg07507251	chr3:52567010	NT5DC2	0.33	5.73	0.33	2.76e-8	Electroencephalogram traits;
CESC	cis	rs17376456	1.000	rs34756085	chr5:93556294	A/G	cg25358565	chr5:93447407	FAM172A	1.2	10.72	0.55	1.67e-22	Diabetic retinopathy;
CESC	cis	rs425277	1.000	rs262667	chr1:2082722	T/C	cg04315214	chr1:2043799	PRKCZ	-0.38	-5.36	-0.31	1.82e-7	Height;
CESC	cis	rs11190604	1.000	rs2495737	chr10:102338344	T/C	cg07080220	chr10:102295463	HIF1AN	0.6	5.52	0.32	7.97e-8	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs1843834	0.755	rs10197382	chr2:225574650	T/C	cg22455342	chr2:225449267	CUL3	0.45	5.69	0.33	3.28e-8	IgE levels in asthmatics (D.p. specific);
CESC	cis	rs7666738	0.712	rs34043080	chr4:99008748	G/C	cg05340658	chr4:99064831	C4orf37	0.78	11.87	0.59	2.5e-26	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1950626	0.750	rs35683125	chr14:101454750	T/C	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.81	11.0	0.56	2.01e-23	Pelvic organ prolapse (moderate/severe);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg01110846	chr16:29937190	KCTD13	0.49	6.5	0.37	3.89e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs35110281	0.774	rs1378080	chr21:45011315	T/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.55	7.31	0.41	3.21e-12	Mean corpuscular volume;
CESC	cis	rs9916302	0.904	rs4511574	chr17:37532916	A/G	cg00129232	chr17:37814104	STARD3	-0.48	-6.01	-0.35	5.96e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs9916302	0.861	rs4795377	chr17:37669056	C/T	cg20243544	chr17:37824526	PNMT	0.51	6.5	0.37	3.88e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs9768139	0.733	rs10156158	chr7:158122287	G/T	cg24154853	chr7:158122151	PTPRN2	0.38	5.79	0.34	1.94e-8	Calcium levels;
CESC	cis	rs7552404	0.924	rs2153126	chr1:76199345	C/G	cg03433033	chr1:76189801	ACADM	0.75	10.58	0.54	4.7e-22	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs782590	0.764	rs2586969	chr2:55829392	G/C	cg18811423	chr2:55921094	PNPT1	0.77	12.1	0.6	4.01e-27	Metabolic syndrome;
CESC	cis	rs1552244	0.882	rs6443279	chr3:10053599	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.87	11.45	0.58	6.38e-25	Alzheimer's disease;
CESC	cis	rs6088580	0.634	rs4911421	chr20:32998948	T/C	cg06115741	chr20:33292138	TP53INP2	-0.46	-5.98	-0.34	7.28e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs72781680	1.000	rs72796337	chr2:24142957	G/A	cg20701182	chr2:24300061	SF3B14	0.63	5.67	0.33	3.79e-8	Lymphocyte counts;
CESC	cis	rs7267979	0.966	rs6083817	chr20:25343998	G/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.88	-18.07	-0.74	3.95e-48	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs10504229	1.000	rs111915672	chr8:58191665	T/C	cg22535103	chr8:58192502	C8orf71	-1.06	-13.14	-0.63	1.04e-30	Developmental language disorder (linguistic errors);
CESC	trans	rs459571	0.839	rs10993895	chr9:136887726	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	0.58	7.52	0.42	8.32e-13	Platelet distribution width;
CESC	cis	rs854765	0.583	rs12452254	chr17:17829434	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.53	7.31	0.41	3.19e-12	Total body bone mineral density;
CESC	cis	rs7618915	0.571	rs33964154	chr3:52596914	A/G	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.38	6.72	0.38	1.13e-10	Bipolar disorder;
CESC	cis	rs10206020	0.921	rs11884956	chr2:1566426	A/G	cg26248373	chr2:1572462	NA	-0.56	-6.78	-0.38	7.98e-11	IgG glycosylation;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg15096432	chr1:202162128	LGR6	-0.45	-6.48	-0.37	4.49e-10	Gambling;
CESC	cis	rs10504229	0.679	rs72649132	chr8:58054615	G/A	cg24829409	chr8:58192753	C8orf71	-0.58	-6.75	-0.38	9.05e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs6987853	0.966	rs2923428	chr8:42388301	T/C	cg09913449	chr8:42400586	C8orf40	0.39	6.13	0.35	3.15e-9	Mean corpuscular hemoglobin concentration;
CESC	cis	rs1983170	1.000	rs483532	chr1:91980447	A/G	cg21854759	chr1:92012499	NA	-0.48	-5.19	-0.3	4.12e-7	Eosinophil percentage of white cells;
CESC	cis	rs13272623	0.502	rs268628	chr8:71560505	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.5	-6.33	-0.36	1.05e-9	IgG glycosylation;
CESC	cis	rs9899728	0.539	rs11077772	chr17:73035698	C/T	cg27626185	chr17:73056755	KCTD2	-1.06	-9.21	-0.49	1.05e-17	Alzheimer's disease or small vessel stroke;
CESC	cis	rs4253772	0.530	rs9615961	chr22:46754993	T/C	cg10541313	chr22:46663664	TTC38	0.75	5.27	0.31	2.83e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs703842	1.000	rs10783847	chr12:58196447	G/A	cg18357645	chr12:58087776	OS9	-0.39	-5.51	-0.32	8.5e-8	Multiple sclerosis;
CESC	cis	rs3015497	0.603	rs12891820	chr14:51016774	G/C	cg26011998	chr14:51135199	SAV1	0.49	5.44	0.32	1.22e-7	Mean platelet volume;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg21751787	chr5:176778504	LMAN2	0.5	6.27	0.36	1.47e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs67072384	1.000	rs11235577	chr11:72451380	C/T	cg04827223	chr11:72435913	ARAP1	-0.7	-6.74	-0.38	9.93e-11	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
CESC	cis	rs5769765	0.825	rs7511620	chr22:50307932	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.58	-6.22	-0.36	1.88e-9	Schizophrenia;
CESC	cis	rs950169	0.579	rs881983	chr15:84647308	C/T	cg17507749	chr15:85114479	UBE2QP1	0.62	6.02	0.35	5.73e-9	Schizophrenia;
CESC	cis	rs10465746	0.570	rs11163884	chr1:84472760	A/G	cg10977910	chr1:84465055	TTLL7	0.44	5.54	0.32	7.2e-8	Obesity-related traits;
CESC	cis	rs6665290	0.904	rs1045290	chr1:227178700	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.23	-34.55	-0.9	3.8e-100	Myeloid white cell count;
CESC	cis	rs4268898	1.000	rs2303294	chr2:24432620	A/G	cg06627628	chr2:24431161	ITSN2	0.63	7.39	0.41	1.89e-12	Asthma;
CESC	cis	rs798554	0.757	rs2533882	chr7:2846894	G/T	cg18446336	chr7:2847575	GNA12	-0.38	-5.58	-0.32	5.92e-8	Height;
CESC	cis	rs258892	0.895	rs2338790	chr5:72055184	A/T	cg21869765	chr5:72125136	TNPO1	-0.42	-5.32	-0.31	2.2e-7	Small cell lung carcinoma;
CESC	cis	rs2070488	0.804	rs6764551	chr3:38460305	A/G	cg24069376	chr3:38537580	EXOG	0.33	5.6	0.33	5.27e-8	Electrocardiographic conduction measures;
CESC	cis	rs6088580	0.634	rs6059835	chr20:33020141	A/G	cg08999081	chr20:33150536	PIGU	0.65	11.36	0.57	1.22e-24	Glomerular filtration rate (creatinine);
CESC	cis	rs7772486	0.686	rs2179323	chr6:145982786	T/G	cg05347473	chr6:146136440	FBXO30	-0.53	-7.03	-0.4	1.8e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs68092024	0.731	rs793480	chr3:99488364	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.43	-6.78	-0.38	7.81e-11	Cleft lip with or without cleft palate;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22272508	chr17:34961264	MRM1	-0.66	-7.78	-0.43	1.6e-13	Gut microbiome composition (summer);
CESC	cis	rs2191566	0.555	rs60744406	chr19:44492164	A/G	cg20607764	chr19:44506953	ZNF230	-0.44	-5.51	-0.32	8.47e-8	Acute lymphoblastic leukemia (childhood);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg11015833	chr12:83079681	TMTC2	0.45	6.35	0.36	9.15e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs9369898	0.963	rs9381787	chr6:49413244	G/C	cg15934674	chr1:150266645	MRPS21	-0.37	-6.03	-0.35	5.37e-9	Homocysteine levels;
CESC	cis	rs3091242	0.900	rs4649086	chr1:25778967	T/A	cg02931644	chr1:25747376	RHCE	0.39	6.56	0.37	2.88e-10	Erythrocyte sedimentation rate;
CESC	cis	rs9868809	0.772	rs9877501	chr3:48718390	C/G	cg07636037	chr3:49044803	WDR6	-0.61	-5.36	-0.31	1.8e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs561341	0.714	rs111760509	chr17:30304320	A/G	cg00745463	chr17:30367425	LRRC37B	-0.79	-7.2	-0.4	6.19e-12	Hip circumference adjusted for BMI;
CESC	cis	rs9329289	0.926	rs9329290	chr10:2542751	G/T	cg18171855	chr10:2543474	NA	0.36	5.61	0.33	4.99e-8	Age-related hearing impairment;
CESC	cis	rs7607369	0.536	rs12623007	chr2:219665335	T/C	cg02176678	chr2:219576539	TTLL4	-0.36	-6.37	-0.36	8.16e-10	Red blood cell count;Amyotrophic lateral sclerosis;
CESC	cis	rs6977955	1.000	rs11495981	chr7:28177301	A/G	cg23620719	chr7:28220237	JAZF1	-0.48	-5.41	-0.32	1.39e-7	Allergic disease (asthma, hay fever or eczema);
CESC	trans	rs11098499	0.954	rs11734241	chr4:120416872	A/G	cg25214090	chr10:38739885	LOC399744	0.72	10.09	0.53	1.85e-20	Corneal astigmatism;
CESC	cis	rs7666738	0.830	rs10470893	chr4:99038756	C/T	cg05340658	chr4:99064831	C4orf37	0.82	12.88	0.62	8.44e-30	Colonoscopy-negative controls vs population controls;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg16248618	chr11:65819774	SF3B2	-0.47	-6.19	-0.36	2.34e-9	Fibrinogen levels;
CESC	cis	rs3733585	0.725	rs6449201	chr4:9973894	C/T	cg02734326	chr4:10020555	SLC2A9	-0.4	-5.69	-0.33	3.43e-8	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs6424115	0.729	rs586173	chr1:24055718	A/G	cg15997130	chr1:24165203	NA	-0.41	-5.48	-0.32	9.71e-8	Immature fraction of reticulocytes;
CESC	cis	rs1448094	0.544	rs56330110	chr12:86166666	A/G	cg02569458	chr12:86230093	RASSF9	0.53	7.64	0.42	4.03e-13	Major depressive disorder;
CESC	cis	rs7255436	0.965	rs7249624	chr19:8446135	G/A	cg16745616	chr19:8428856	ANGPTL4	-0.37	-5.67	-0.33	3.75e-8	HDL cholesterol;
CESC	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.41	7.89	0.44	8.18e-14	Electroencephalogram traits;
CESC	cis	rs9916302	0.768	rs11078900	chr17:37614641	C/T	cg00129232	chr17:37814104	STARD3	-0.57	-7.57	-0.42	6.31e-13	Glomerular filtration rate (creatinine);
CESC	trans	rs6759922	1.000	rs4416248	chr2:22455521	C/T	cg21162304	chr4:80247171	NAA11	0.4	6.52	0.37	3.48e-10	Subjective well-being (multi-trait analysis);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg08084737	chr7:43965691	URGCP;UBE2D4	-0.48	-6.88	-0.39	4.4e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs858239	0.601	rs1981665	chr7:23167969	T/C	cg23682824	chr7:23144976	KLHL7	0.55	7.73	0.43	2.27e-13	Cerebrospinal fluid biomarker levels;
CESC	cis	rs6088590	0.582	rs6059909	chr20:33139691	C/A	cg08999081	chr20:33150536	PIGU	0.68	11.84	0.59	3.15e-26	Coronary artery disease;
CESC	cis	rs561341	0.941	rs7215147	chr17:30266711	G/A	cg00745463	chr17:30367425	LRRC37B	-0.49	-5.41	-0.32	1.38e-7	Hip circumference adjusted for BMI;
CESC	cis	rs1847202	0.762	rs62249896	chr3:72949857	C/G	cg25664220	chr3:72788482	NA	-0.38	-5.55	-0.32	7.03e-8	Motion sickness;
CESC	cis	rs17362650	0.694	rs62118851	chr2:9566878	C/T	cg12832956	chr2:9616023	IAH1	-0.59	-6.63	-0.38	1.89e-10	Alcohol dependence (age at onset);
CESC	cis	rs7605827	0.930	rs10179765	chr2:15541249	C/T	cg19274914	chr2:15703543	NA	0.36	6.55	0.37	2.91e-10	Educational attainment (years of education);
CESC	cis	rs6835098	0.692	rs7657374	chr4:174065756	A/T	cg08422745	chr4:174089978	GALNT7	-0.62	-8.25	-0.45	7.29e-15	Dementia and core Alzheimer's disease neuropathologic changes;
CESC	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg02353165	chr6:42928485	GNMT	0.88	15.25	0.68	4e-38	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	13.6	0.64	2.58e-32	Prudent dietary pattern;
CESC	trans	rs637571	0.522	rs649000	chr11:65742933	T/C	cg17712092	chr4:129076599	LARP1B	0.77	10.89	0.56	4.7e-23	Eosinophil percentage of white cells;
CESC	cis	rs6120849	0.663	rs11698868	chr20:33549946	C/T	cg24642439	chr20:33292090	TP53INP2	0.69	6.9	0.39	3.78e-11	Protein C levels;
CESC	cis	rs6032067	0.561	rs6032104	chr20:43932412	G/A	cg10761708	chr20:43804764	PI3	0.44	5.48	0.32	9.84e-8	Blood protein levels;
CESC	cis	rs60871478	1.000	rs34761279	chr7:794471	A/G	cg13798912	chr7:905769	UNC84A	0.54	5.31	0.31	2.31e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs28386778	0.863	rs3760252	chr17:61852186	G/C	cg07677032	chr17:61819896	STRADA	0.45	5.94	0.34	8.78e-9	Prudent dietary pattern;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg02983885	chr19:42772892	NA	0.5	6.44	0.37	5.65e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs853679	0.513	rs9468296	chr6:28113730	A/G	cg08968635	chr6:28129556	ZNF389	0.4	5.25	0.31	3.15e-7	Depression;
CESC	cis	rs7561273	0.586	rs11896092	chr2:24317827	G/A	cg06627628	chr2:24431161	ITSN2	-0.48	-5.71	-0.33	3.03e-8	Quantitative traits;
CESC	cis	rs1799949	1.000	rs11657053	chr17:41191129	G/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.39	5.12	0.3	5.78e-7	Menopause (age at onset);
CESC	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg06873352	chr17:61820015	STRADA	0.71	12.09	0.6	4.24e-27	Prudent dietary pattern;
CESC	cis	rs7553864	0.614	rs10493796	chr1:87614175	A/G	cg17420885	chr1:87600446	LOC339524	0.45	6.21	0.36	2.01e-9	Smoking behavior;
CESC	cis	rs6120849	0.901	rs6088737	chr20:33745938	A/G	cg24642439	chr20:33292090	TP53INP2	0.6	6.4	0.37	7.09e-10	Protein C levels;
CESC	cis	rs8177253	0.965	rs8177260	chr3:133480458	T/A	cg11941060	chr3:133502564	NA	-0.5	-6.96	-0.39	2.7e-11	Iron status biomarkers;
CESC	cis	rs7666738	0.715	rs3857216	chr4:99032129	G/T	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.58e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs763121	0.853	rs5757196	chr22:39039855	G/C	cg06022373	chr22:39101656	GTPBP1	0.88	13.79	0.65	5.43e-33	Menopause (age at onset);
CESC	cis	rs9291683	0.546	rs10939672	chr4:10052136	A/G	cg02734326	chr4:10020555	SLC2A9	0.45	6.34	0.36	9.85e-10	Bone mineral density;
CESC	cis	rs7084402	0.875	rs1593671	chr10:60295969	A/T	cg07615347	chr10:60278583	BICC1	0.6	9.42	0.5	2.35e-18	Refractive error;
CESC	cis	rs6831352	0.734	rs2851259	chr4:100033986	C/T	cg13256891	chr4:100009986	ADH5	0.69	8.13	0.45	1.61e-14	Alcohol dependence;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg02100365	chr1:92762956	GLMN	0.44	7.07	0.4	1.4e-11	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs2997447	0.802	rs61776621	chr1:26459058	C/G	cg24596570	chr1:26146463	FAM54B;LOC646471	0.59	5.16	0.3	4.76e-7	QRS complex (12-leadsum);
CESC	cis	rs76525880	0.568	rs9905793	chr17:46635649	A/G	cg06593406	chr17:46696139	NA	-0.65	-5.57	-0.32	6.19e-8	Colorectal or endometrial cancer;
CESC	cis	rs3785574	0.962	rs8079161	chr17:61808561	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.57	7.05	0.4	1.58e-11	Height;
CESC	cis	rs7666738	0.830	rs13149346	chr4:99009933	C/T	cg17366294	chr4:99064904	C4orf37	0.6	8.62	0.47	6.37e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9322193	0.926	rs9689036	chr6:150101699	T/C	cg07701084	chr6:150067640	NUP43	0.4	5.48	0.32	9.87e-8	Lung cancer;
CESC	cis	rs3026101	0.671	rs8067917	chr17:5278307	G/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.42	5.64	0.33	4.35e-8	Body mass index;
CESC	cis	rs6582630	0.502	rs11181230	chr12:38300085	A/G	cg13010199	chr12:38710504	ALG10B	0.45	5.65	0.33	4.06e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs4727027	0.933	rs10277119	chr7:148849942	T/C	cg23583168	chr7:148888333	NA	-0.77	-11.36	-0.57	1.24e-24	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs17253792	0.822	rs75763956	chr14:56071176	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.79	5.91	0.34	1.06e-8	Putamen volume;
CESC	cis	rs2249694	0.959	rs2987799	chr10:135380499	T/G	cg20169779	chr10:135381914	SYCE1	0.39	5.47	0.32	1.06e-7	Obesity-related traits;
CESC	cis	rs4919694	1.000	rs10509758	chr10:104681710	T/C	cg04362960	chr10:104952993	NT5C2	0.74	6.45	0.37	5.42e-10	Arsenic metabolism;
CESC	cis	rs7666738	0.830	rs1426666	chr4:99030887	A/G	cg03467027	chr4:99064603	C4orf37	0.49	6.18	0.35	2.44e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs12042052	1.000	rs6686747	chr1:232912743	T/C	cg00951395	chr1:232941775	KIAA1383	0.7	6.94	0.39	3.02e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CESC	cis	rs2637266	0.846	rs2637263	chr10:78322442	G/A	cg18941641	chr10:78392320	NA	0.38	6.9	0.39	3.72e-11	Pulmonary function;
CESC	trans	rs916888	0.779	rs430685	chr17:44859148	T/C	cg01341218	chr17:43662625	NA	-0.86	-10.6	-0.55	3.99e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs9399135	0.967	rs9376075	chr6:135296963	A/G	cg22676075	chr6:135203613	NA	0.52	7.21	0.4	5.94e-12	Red blood cell count;
CESC	cis	rs2576037	0.501	rs7227700	chr18:44537102	T/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.43	7.0	0.4	2.07e-11	Personality dimensions;
CESC	cis	rs3815700	1.000	rs2287670	chr19:33095057	G/A	cg24916020	chr19:33096688	ANKRD27	0.59	5.75	0.33	2.5e-8	Eosinophilic esophagitis;
CESC	cis	rs2228479	1.000	rs12596492	chr16:89957169	T/G	cg06558623	chr16:89946397	TCF25	1.17	9.37	0.5	3.29e-18	Skin colour saturation;
CESC	cis	rs7552404	1.000	rs11161515	chr1:76212559	C/T	cg22875332	chr1:76189707	ACADM	0.59	6.89	0.39	4.15e-11	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs9512730	0.527	rs11619784	chr13:27999643	A/G	cg04070771	chr13:27998621	GTF3A	0.54	5.79	0.34	1.98e-8	Schizophrenia;
CESC	cis	rs1878931	0.582	rs10048083	chr16:3417465	A/C	cg02880119	chr16:3481970	NA	-0.39	-5.11	-0.3	6.21e-7	Body mass index (adult);
CESC	cis	rs1577917	1.000	rs7771342	chr6:86631936	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.44	-5.78	-0.33	2.14e-8	Response to antipsychotic treatment;
CESC	cis	rs4481887	0.741	rs7417519	chr1:248550370	C/T	cg26353448	chr1:248524236	OR2T4	0.37	5.2	0.3	4e-7	Common traits (Other);
CESC	cis	rs9733	0.536	rs10888385	chr1:150574302	T/C	cg18016565	chr1:150552671	MCL1	-0.42	-6.87	-0.39	4.59e-11	Tonsillectomy;
CESC	cis	rs10751667	0.666	rs10794354	chr11:954615	A/T	cg06064525	chr11:970664	AP2A2	-0.48	-9.52	-0.5	1.15e-18	Alzheimer's disease (late onset);
CESC	cis	rs933688	1.000	rs60513756	chr5:90727692	A/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.97	11.16	0.57	5.75e-24	Smoking behavior;
CESC	cis	rs2576037	0.583	rs501062	chr18:44411135	C/T	cg19077165	chr18:44547161	KATNAL2	-0.61	-9.1	-0.49	2.28e-17	Personality dimensions;
CESC	trans	rs208520	0.661	rs207090	chr6:66783963	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.0	-12.83	-0.62	1.2e-29	Exhaled nitric oxide output;
CESC	cis	rs116095464	0.558	rs6962	chr5:256509	G/A	cg22496380	chr5:211416	CCDC127	-0.79	-8.37	-0.46	3.28e-15	Breast cancer;
CESC	cis	rs13031619	0.605	rs4849972	chr2:3698846	C/A	cg19052272	chr2:3704530	ALLC	0.69	7.67	0.43	3.32e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg05732646	chr13:41706942	KBTBD6	-0.39	-6.38	-0.36	7.94e-10	Gambling;
CESC	cis	rs763014	0.898	rs2017567	chr16:637212	T/C	cg00802000	chr16:706648	WDR90	-0.41	-6.33	-0.36	1.05e-9	Height;
CESC	cis	rs2841277	0.645	rs28380382	chr14:105410827	C/T	cg14403583	chr14:105418241	AHNAK2	-0.58	-8.06	-0.44	2.55e-14	Rheumatoid arthritis;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg09339876	chr11:64564812	MAP4K2	0.45	6.63	0.38	1.87e-10	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs1364705	1.000	rs12677951	chr8:120226900	C/G	cg09273054	chr8:120220131	MAL2	0.61	6.75	0.38	9.08e-11	Hippocampal atrophy;
CESC	cis	rs3749237	0.595	rs4955412	chr3:49418168	A/C	cg03060546	chr3:49711283	APEH	0.75	11.31	0.57	1.91e-24	Resting heart rate;
CESC	cis	rs5769707	0.967	rs9616327	chr22:50010891	G/A	cg20744362	chr22:50050164	C22orf34	0.46	8.0	0.44	3.89e-14	Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs4423214	0.959	rs11233747	chr11:71171642	G/A	cg05163923	chr11:71159392	DHCR7	0.78	10.34	0.54	2.91e-21	Vitamin D levels;
CESC	cis	rs9325144	1.000	rs9325144	chr12:39018673	C/T	cg26384229	chr12:38710491	ALG10B	-0.47	-5.8	-0.34	1.87e-8	Morning vs. evening chronotype;
CESC	cis	rs12497850	0.897	rs7432989	chr3:49105136	A/G	cg06212747	chr3:49208901	KLHDC8B	0.69	9.04	0.49	3.3e-17	Parkinson's disease;
CESC	cis	rs780096	0.545	rs2280737	chr2:27589810	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.32	-6.15	-0.35	2.82e-9	Total body bone mineral density;
CESC	cis	rs898097	0.841	rs8074284	chr17:80909967	G/A	cg10494973	chr17:80897199	TBCD	-0.5	-5.77	-0.33	2.26e-8	Breast cancer;
CESC	cis	rs477895	0.713	rs7952318	chr11:63961242	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.77	8.42	0.46	2.43e-15	Mean platelet volume;
CESC	cis	rs8040855	0.627	rs11634975	chr15:85606478	T/C	cg08123816	chr15:85640762	PDE8A	-0.38	-5.74	-0.33	2.54e-8	Bulimia nervosa;
CESC	cis	rs3859192	0.561	rs34453912	chr17:38180352	T/A	cg17467752	chr17:38218738	THRA	-0.45	-5.9	-0.34	1.13e-8	White blood cell count;
CESC	cis	rs12477438	0.520	rs7572660	chr2:99788582	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	15.34	0.69	1.93e-38	Chronic sinus infection;
CESC	cis	rs4819052	0.851	rs4819039	chr21:46659458	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.91	13.24	0.63	4.51e-31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs66573146	0.572	rs66734745	chr4:6948765	T/C	cg07817883	chr1:32538562	TMEM39B	1.19	8.24	0.45	7.79e-15	Granulocyte percentage of myeloid white cells;
CESC	cis	rs2455799	0.573	rs2455829	chr3:15746937	G/A	cg09340198	chr3:15902540	ANKRD28	-0.33	-5.14	-0.3	5.37e-7	Mean platelet volume;
CESC	cis	rs962856	0.619	rs11890682	chr2:67589585	A/G	cg09028215	chr2:67624308	ETAA1	-0.44	-5.3	-0.31	2.43e-7	Pancreatic cancer;
CESC	cis	rs1799949	1.000	rs8176297	chr17:41203325	T/A	cg23758822	chr17:41437982	NA	1.0	14.95	0.68	4.7e-37	Menopause (age at onset);
CESC	cis	rs7828089	0.582	rs13282084	chr8:22266280	T/C	cg13512537	chr8:22265999	SLC39A14	-0.36	-5.1	-0.3	6.53e-7	Verbal declarative memory;
CESC	trans	rs1814175	0.817	rs10769598	chr11:49669326	C/G	cg15704280	chr7:45808275	SEPT13	-1.04	-20.38	-0.78	3.56e-56	Height;
CESC	cis	rs7246657	0.943	rs4803460	chr19:37885228	T/C	cg23950597	chr19:37808831	NA	-0.54	-5.9	-0.34	1.11e-8	Coronary artery calcification;
CESC	cis	rs4132509	0.744	rs10803146	chr1:243709454	T/G	cg21452805	chr1:244014465	NA	0.59	6.33	0.36	1.05e-9	RR interval (heart rate);
CESC	cis	rs748404	0.697	rs579651	chr15:43558376	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.61	7.77	0.43	1.69e-13	Lung cancer;
CESC	cis	rs9649213	0.593	rs6970990	chr7:97925382	T/G	cg24562669	chr7:97807699	LMTK2	0.51	7.54	0.42	7.27e-13	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs11764590	0.694	rs4721359	chr7:2104951	A/G	cg21782813	chr7:2030301	MAD1L1	-0.42	-5.41	-0.32	1.42e-7	Neuroticism;
CESC	cis	rs599083	0.530	rs667126	chr11:68177728	C/T	cg16797656	chr11:68205561	LRP5	-0.4	-5.38	-0.31	1.6e-7	Bone mineral density (spine);
CESC	cis	rs4282054	0.631	rs13081155	chr3:52732429	A/G	cg05564831	chr3:52568323	NT5DC2	0.48	8.08	0.44	2.36e-14	Cognitive function;
CESC	cis	rs13095912	1.000	rs7374856	chr3:185311964	A/C	cg11274856	chr3:185301563	NA	0.36	5.87	0.34	1.3e-8	Systolic blood pressure;
CESC	cis	rs8017423	0.740	rs7152196	chr14:90703900	G/T	cg14092571	chr14:90743983	NA	-0.56	-8.3	-0.45	5.2e-15	Mortality in heart failure;
CESC	cis	rs12142240	0.698	rs6695043	chr1:46844530	A/G	cg00530320	chr1:46809349	NSUN4	-0.58	-7.98	-0.44	4.42e-14	Menopause (age at onset);
CESC	cis	rs7089973	0.624	rs1359080	chr10:116582419	C/A	cg23260525	chr10:116636907	FAM160B1	0.38	6.81	0.39	6.44e-11	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs9549367	0.713	rs9549357	chr13:113860121	C/T	cg00898013	chr13:113819073	PROZ	-0.49	-7.07	-0.4	1.41e-11	Platelet distribution width;
CESC	cis	rs7000551	0.715	rs7839577	chr8:22307325	T/A	cg12081754	chr8:22256438	SLC39A14	0.44	5.91	0.34	1.08e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CESC	cis	rs60843830	1.000	rs114976176	chr2:264621	A/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.88	11.92	0.59	1.67e-26	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs7651736	1.000	rs7651736	chr3:136760598	A/G	cg03617693	chr3:136751559	NA	0.39	6.37	0.36	8.11e-10	Neuroticism;
CESC	cis	rs2836974	0.644	rs4818017	chr21:40690561	G/T	cg22974920	chr21:40686053	BRWD1	-0.46	-5.73	-0.33	2.77e-8	Cognitive function;
CESC	cis	rs780096	0.546	rs2293572	chr2:27728777	C/G	cg02592271	chr2:27665507	KRTCAP3	0.29	5.66	0.33	3.85e-8	Total body bone mineral density;
CESC	cis	rs2197308	0.692	rs67352173	chr12:37906912	A/T	cg26384229	chr12:38710491	ALG10B	0.67	9.69	0.51	3.43e-19	Morning vs. evening chronotype;
CESC	cis	rs897984	0.806	rs9319588	chr16:30930983	C/T	cg00531865	chr16:30841666	NA	0.51	7.12	0.4	1.01e-11	Dementia with Lewy bodies;
CESC	cis	rs3768617	0.706	rs11588675	chr1:182988052	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.69	9.8	0.52	1.51e-19	Fuchs's corneal dystrophy;
CESC	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	7.61	0.42	4.95e-13	Prudent dietary pattern;
CESC	cis	rs9911578	0.935	rs6503878	chr17:56884581	T/G	cg05425664	chr17:57184151	TRIM37	-0.49	-6.87	-0.39	4.62e-11	Intelligence (multi-trait analysis);
CESC	cis	rs4474742	1	rs4474742	chr17:28065578	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-10.22	-0.53	6.81e-21	Monocyte count;
CESC	cis	rs7949030	0.596	rs11231137	chr11:62315699	G/A	cg13298116	chr11:62369859	EML3;MTA2	0.51	7.03	0.4	1.72e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs6740322	0.748	rs6544635	chr2:43486704	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.77	-8.25	-0.45	7.31e-15	Coronary artery disease;
CESC	cis	rs2932538	0.885	rs7516421	chr1:113089696	T/C	cg22162597	chr1:113214053	CAPZA1	0.46	6.1	0.35	3.73e-9	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CESC	cis	rs6951245	0.706	rs28522260	chr7:1183964	C/A	cg16145915	chr7:1198662	ZFAND2A	-0.49	-5.47	-0.32	1.02e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs4853012	0.838	rs6715351	chr2:74346119	G/A	cg20891558	chr2:74357851	NA	0.82	12.12	0.6	3.38e-27	Gestational age at birth (maternal effect);
CESC	cis	rs7264396	0.790	rs2425097	chr20:34308926	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.62	7.32	0.41	2.93e-12	Total cholesterol levels;
CESC	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg07677032	chr17:61819896	STRADA	0.41	5.33	0.31	2.15e-7	Prudent dietary pattern;
CESC	cis	rs875971	0.825	rs1129531	chr7:65619104	C/T	cg11764359	chr7:65958608	NA	-0.79	-11.64	-0.58	1.44e-25	Aortic root size;
CESC	cis	rs75477785	0.590	rs10863809	chr1:210253684	G/T	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.95	6.41	0.37	6.82e-10	Cleft lip with or without cleft palate;
CESC	cis	rs1577917	1.000	rs12204365	chr6:86700532	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.45	-5.82	-0.34	1.67e-8	Response to antipsychotic treatment;
CESC	cis	rs3820068	0.603	rs16851884	chr1:15961871	A/G	cg13390004	chr1:15929781	NA	0.37	5.9	0.34	1.11e-8	Systolic blood pressure;
CESC	cis	rs2635047	0.566	rs8092050	chr18:44796323	C/T	cg24371990	chr18:44770781	NA	0.39	6.27	0.36	1.48e-9	Educational attainment;
CESC	cis	rs7264396	0.563	rs2425122	chr20:34328848	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.88	-10.7	-0.55	1.88e-22	Total cholesterol levels;
CESC	cis	rs1153858	1.000	rs61365925	chr15:45650311	T/C	cg21132104	chr15:45694354	SPATA5L1	0.84	11.41	0.57	8.8e-25	Homoarginine levels;
CESC	cis	rs875971	0.545	rs316305	chr7:65617971	G/A	cg19163074	chr7:65112434	INTS4L2	0.46	5.05	0.3	8.07e-7	Aortic root size;
CESC	cis	rs17376456	0.825	rs67328989	chr5:93243133	T/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.65	5.24	0.31	3.28e-7	Diabetic retinopathy;
CESC	cis	rs10504229	1.000	rs79561699	chr8:58170601	A/G	cg14926445	chr8:58193284	C8orf71	-0.49	-5.28	-0.31	2.73e-7	Developmental language disorder (linguistic errors);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15277511	chr18:43678182	ATP5A1	0.62	6.81	0.39	6.39e-11	Gut microbiome composition (summer);
CESC	cis	rs2742234	0.590	rs2505553	chr10:43681251	G/T	cg07801480	chr10:43725741	RASGEF1A	0.41	5.28	0.31	2.72e-7	Hirschsprung disease;
CESC	cis	rs2239547	0.563	rs9839035	chr3:52909877	C/T	cg11645453	chr3:52864694	ITIH4	0.35	5.97	0.34	7.68e-9	Schizophrenia;
CESC	cis	rs11264213	0.786	rs79674501	chr1:36270589	G/A	cg27506609	chr1:36549197	TEKT2	0.61	5.04	0.3	8.54e-7	Schizophrenia;
CESC	cis	rs5769707	1.000	rs5769707	chr22:50013402	G/T	cg20744362	chr22:50050164	C22orf34	0.47	8.17	0.45	1.26e-14	Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs6087990	0.735	rs2889703	chr20:31379184	C/A	cg13636640	chr20:31349939	DNMT3B	0.75	11.68	0.58	1.04e-25	Ulcerative colitis;
CESC	cis	rs920590	0.876	rs3907477	chr8:19657744	C/T	cg17834443	chr8:19674713	INTS10	0.49	5.78	0.33	2.13e-8	Acute lymphoblastic leukemia (childhood);
CESC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg00275962	chr6:43484808	POLR1C;YIPF3	0.48	6.57	0.37	2.69e-10	Intelligence (multi-trait analysis);
CESC	cis	rs6089829	0.962	rs6062780	chr20:61666648	T/C	cg16240275	chr20:61666158	NCRNA00029	0.5	8.96	0.48	6.1e-17	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs9291683	0.609	rs55959894	chr4:10026580	G/A	cg02734326	chr4:10020555	SLC2A9	0.47	6.52	0.37	3.47e-10	Bone mineral density;
CESC	cis	rs412000	0.560	rs4793583	chr17:56451407	A/C	cg05425664	chr17:57184151	TRIM37	0.4	5.5	0.32	8.94e-8	Primary tooth development (time to first tooth eruption);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg16092991	chr4:15004611	CPEB2	0.48	6.2	0.36	2.2e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs8062405	0.929	rs11864750	chr16:28875204	A/T	cg08761264	chr16:28874980	SH2B1	-0.47	-5.85	-0.34	1.42e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs10791323	0.569	rs2257004	chr11:133712473	C/T	cg15485101	chr11:133734466	NA	0.41	6.66	0.38	1.57e-10	Childhood ear infection;
CESC	cis	rs12887734	0.524	rs4906364	chr14:104214342	C/G	cg08213375	chr14:104286397	PPP1R13B	0.42	7.06	0.4	1.46e-11	Schizophrenia;Autism spectrum disorder or schizophrenia;
CESC	cis	rs9611565	0.571	rs2050032	chr22:42152429	C/T	cg03806693	chr22:41940476	POLR3H	0.85	10.66	0.55	2.56e-22	Vitiligo;
CESC	cis	rs769267	0.896	rs11882123	chr19:19386339	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	7.34	0.41	2.56e-12	Tonsillectomy;
CESC	cis	rs1799949	1.000	rs12936831	chr17:41331816	C/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.38	5.04	0.3	8.73e-7	Menopause (age at onset);
CESC	cis	rs7917772	0.582	rs10883736	chr10:104320029	G/T	ch.10.2196322F	chr10:104248062	ACTR1A	0.41	5.19	0.3	4.27e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs8082590	1	rs8082590	chr17:17958402	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.6	-8.42	-0.46	2.43e-15	Schizophrenia;
CESC	cis	rs2637266	0.967	rs4979898	chr10:78355672	G/A	cg18941641	chr10:78392320	NA	0.42	7.79	0.43	1.49e-13	Pulmonary function;
CESC	cis	rs875971	0.522	rs4718285	chr7:65292005	A/G	cg14393609	chr7:65229607	NA	0.52	7.08	0.4	1.33e-11	Aortic root size;
CESC	cis	rs684232	0.623	rs417171	chr17:576941	A/G	cg15660573	chr17:549704	VPS53	-0.65	-8.94	-0.48	6.83e-17	Prostate cancer;
CESC	cis	rs12079745	1.000	rs74967728	chr1:169202731	C/T	cg09363564	chr1:169337483	NME7;BLZF1	-1.03	-6.33	-0.36	1.04e-9	QT interval;
CESC	cis	rs875971	1.000	rs1544549	chr7:66090663	T/A	cg11764359	chr7:65958608	NA	-0.91	-13.85	-0.65	3.33e-33	Aortic root size;
CESC	cis	rs2011503	0.882	rs4808933	chr19:19363812	T/A	cg11584989	chr19:19387371	SF4	0.53	6.41	0.37	6.52e-10	Bipolar disorder;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg04769705	chr14:69262517	C14orf181	-0.49	-6.34	-0.36	9.73e-10	Thyroid stimulating hormone;
CESC	cis	rs11690935	1.000	rs312924	chr2:172564021	A/T	cg13550731	chr2:172543902	DYNC1I2	0.92	13.68	0.64	1.4e-32	Schizophrenia;
CESC	cis	rs9322193	0.923	rs62439840	chr6:149995775	G/A	cg13206674	chr6:150067644	NUP43	0.4	5.43	0.32	1.25e-7	Lung cancer;
CESC	cis	rs736408	0.648	rs3774354	chr3:52817675	G/A	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.33	5.59	0.32	5.66e-8	Bipolar disorder;
CESC	cis	rs7647973	0.587	rs10452032	chr3:49680973	G/A	cg13072238	chr3:49761600	GMPPB	-0.45	-5.47	-0.32	1.04e-7	Menarche (age at onset);
CESC	cis	rs9818941	0.956	rs4317052	chr3:157721994	C/T	cg08654915	chr3:157813417	NA	0.4	7.48	0.42	1.06e-12	Height;
CESC	cis	rs1552244	1.000	rs6442148	chr3:10078289	G/C	cg08888203	chr3:10149979	C3orf24	0.47	6.03	0.35	5.45e-9	Alzheimer's disease;
CESC	cis	rs6912958	0.703	rs9359748	chr6:88095500	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.46	7.73	0.43	2.2e-13	Monocyte percentage of white cells;
CESC	cis	rs12586317	0.547	rs12435454	chr14:35466997	A/G	cg05294307	chr14:35346193	BAZ1A	-0.51	-5.45	-0.32	1.16e-7	Psoriasis;
CESC	cis	rs12824058	0.831	rs4759451	chr12:130812739	G/A	cg23887609	chr12:130822674	PIWIL1	0.44	5.7	0.33	3.2e-8	Menopause (age at onset);
CESC	cis	rs11828289	0.607	rs78341320	chr11:23188865	C/T	cg20040320	chr11:23191996	NA	-0.68	-5.87	-0.34	1.31e-8	Cancer;
CESC	cis	rs17125944	0.505	rs75661138	chr14:53259262	G/A	cg00686598	chr14:53173677	PSMC6	1.42	11.79	0.59	4.37e-26	Alzheimer's disease (late onset);
CESC	cis	rs3820068	0.637	rs4646080	chr1:15826627	A/T	cg18192808	chr1:15853278	DNAJC16	0.47	5.78	0.33	2.05e-8	Systolic blood pressure;
CESC	cis	rs9308731	0.966	rs6753785	chr2:111923630	T/G	cg04202892	chr2:111875749	ACOXL	0.36	5.21	0.31	3.73e-7	Chronic lymphocytic leukemia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21400344	chr1:25870172	LDLRAP1	0.57	6.26	0.36	1.55e-9	Gut microbiome composition (summer);
CESC	cis	rs12500824	0.564	rs62300857	chr4:77284421	G/T	cg20311846	chr4:77356250	SHROOM3	0.37	6.88	0.39	4.32e-11	Coronary artery disease;
CESC	trans	rs17685	0.725	rs6467993	chr7:75719350	G/A	cg19862616	chr7:65841803	NCRNA00174	0.83	11.96	0.59	1.23e-26	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs8067545	0.611	rs4925090	chr17:20066631	C/T	cg13482628	chr17:19912719	NA	0.43	5.74	0.33	2.65e-8	Schizophrenia;
CESC	cis	rs12545109	0.876	rs1992120	chr8:57337112	G/A	cg09654669	chr8:57350985	NA	-0.6	-7.06	-0.4	1.48e-11	Obesity-related traits;
CESC	cis	rs36051895	0.623	rs11506292	chr9:5257048	C/A	cg02405213	chr9:5042618	JAK2	-0.54	-6.37	-0.36	8.41e-10	Pediatric autoimmune diseases;
CESC	cis	rs9908102	0.740	rs56369392	chr17:12904928	C/T	cg26162695	chr17:12921313	ELAC2	0.5	5.49	0.32	9.61e-8	Schizophrenia;
CESC	cis	rs12926788	0.640	rs73551577	chr16:24845143	G/A	cg00339695	chr16:24857497	SLC5A11	0.51	6.71	0.38	1.19e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs7618501	0.966	rs13085679	chr3:49869631	G/A	cg24308560	chr3:49941425	MST1R	-0.53	-7.28	-0.41	3.78e-12	Intelligence (multi-trait analysis);
CESC	cis	rs7656342	0.622	rs10009838	chr4:9833882	G/A	cg11266682	chr4:10021025	SLC2A9	0.32	5.15	0.3	5.17e-7	Gut microbiota (bacterial taxa);
CESC	cis	rs3733585	0.699	rs7677710	chr4:9969517	T/G	cg00071950	chr4:10020882	SLC2A9	-0.69	-11.47	-0.58	5.42e-25	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs2439831	0.867	rs8041132	chr15:43635136	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.88	10.46	0.54	1.19e-21	Lung cancer in ever smokers;
CESC	cis	rs67311347	0.955	rs4973999	chr3:40460383	G/A	cg01475735	chr3:40494733	NA	-0.4	-5.1	-0.3	6.47e-7	Renal cell carcinoma;
CESC	cis	rs11252926	0.537	rs4554800	chr10:458477	G/T	cg18196295	chr10:418757	DIP2C	-0.55	-7.62	-0.42	4.6e-13	Psychosis in Alzheimer's disease;
CESC	cis	rs694739	0.726	rs17857342	chr11:64138905	T/G	cg02228329	chr11:64053129	BAD;GPR137	0.62	7.62	0.42	4.42e-13	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CESC	cis	rs11792861	0.926	rs7470160	chr9:111844246	C/A	cg05043794	chr9:111880884	C9orf5	-0.41	-6.74	-0.38	9.83e-11	Menarche (age at onset);
CESC	cis	rs597539	0.690	rs7129960	chr11:68622456	A/G	cg04772025	chr11:68637568	NA	0.53	5.93	0.34	9.67e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs8072100	0.871	rs7206971	chr17:45425115	A/G	cg25173405	chr17:45401733	C17orf57	0.45	6.08	0.35	4.21e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs9926296	0.656	rs2376884	chr16:89826922	C/T	cg27121462	chr16:89883253	FANCA	0.54	6.79	0.39	7.27e-11	Vitiligo;
CESC	cis	rs10504229	0.683	rs7817188	chr8:58129549	C/T	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs3733585	0.746	rs4318650	chr4:10016868	T/C	cg02734326	chr4:10020555	SLC2A9	0.42	5.76	0.33	2.3e-8	Cleft plate (environmental tobacco smoke interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19451435	chr6:158402916	SYNJ2	0.68	8.12	0.45	1.8e-14	Gut microbiome composition (summer);
CESC	cis	rs10504229	0.683	rs34859456	chr8:58117722	A/C	cg21724239	chr8:58056113	NA	0.58	5.95	0.34	8.29e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs4807542	1.000	rs4807542	chr19:1104078	G/A	cg09432775	chr19:1117453	SBNO2	0.38	5.15	0.3	5.09e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
CESC	cis	rs3858526	0.523	rs10769287	chr11:5884845	T/C	cg02574844	chr11:5959923	NA	-0.46	-7.02	-0.4	1.9e-11	DNA methylation (variation);
CESC	cis	rs10754283	0.967	rs6663363	chr1:90116854	A/G	cg21401794	chr1:90099060	LRRC8C	0.67	8.97	0.48	5.53e-17	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs8002861	0.905	rs11617551	chr13:44443977	T/C	cg14210620	chr13:44453864	C13orf31;CCDC122	-0.44	-5.65	-0.33	4.21e-8	Leprosy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14428669	chr9:114659192	UGCG	0.61	7.33	0.41	2.87e-12	Gut microbiome composition (summer);
CESC	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg03452623	chr4:187889614	NA	-0.89	-14.8	-0.67	1.53e-36	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1552244	0.938	rs7647987	chr3:10140696	A/G	cg00166722	chr3:10149974	C3orf24	0.46	5.89	0.34	1.18e-8	Alzheimer's disease;
CESC	cis	rs7666738	0.830	rs4401456	chr4:98959902	C/T	cg03676636	chr4:99064102	C4orf37	0.33	5.14	0.3	5.39e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4819052	0.851	rs4819049	chr21:46673086	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.95	14.08	0.65	5.33e-34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs12479064	0.724	rs28369945	chr2:100080928	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.6	-6.72	-0.38	1.14e-10	Chronic sinus infection;
CESC	cis	rs992157	0.798	rs1017698	chr2:219170525	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.66	-9.07	-0.49	2.81e-17	Colorectal cancer;
CESC	cis	rs7662987	1.000	rs28730640	chr4:99994053	C/T	cg13256891	chr4:100009986	ADH5	-0.81	-6.09	-0.35	4.04e-9	Smoking initiation;
CESC	cis	rs1003719	0.715	rs2835613	chr21:38496883	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.64	-8.74	-0.47	2.66e-16	Eye color traits;
CESC	cis	rs3126085	0.935	rs1496050	chr1:152163549	T/C	cg03465714	chr1:152285911	FLG	-0.44	-5.33	-0.31	2.06e-7	Atopic dermatitis;
CESC	cis	rs7149242	0.796	rs12588718	chr14:101149605	G/C	cg18089426	chr14:101175970	NA	-0.39	-5.95	-0.34	8.68e-9	Platelet count;
CESC	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg07677032	chr17:61819896	STRADA	0.44	5.85	0.34	1.44e-8	Prudent dietary pattern;
CESC	cis	rs3096299	0.934	rs9927904	chr16:89462847	G/A	cg08822215	chr16:89438651	ANKRD11	-0.43	-6.59	-0.38	2.31e-10	Multiple myeloma (IgH translocation);
CESC	cis	rs9951602	0.703	rs2959407	chr18:76682915	A/G	cg00806245	chr18:76673096	NA	-0.48	-5.86	-0.34	1.35e-8	Obesity-related traits;
CESC	cis	rs2243480	1.000	rs464895	chr7:65527106	A/G	cg12463550	chr7:65579703	CRCP	0.65	5.26	0.31	3.04e-7	Diabetic kidney disease;
CESC	cis	rs853679	0.517	rs9393901	chr6:28136797	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.57	-6.59	-0.38	2.36e-10	Depression;
CESC	cis	rs6144337	1	rs6144337	chr11:47284302	TCCATGTGCCTCA/T	cg25783544	chr11:47291846	MADD	0.58	6.57	0.37	2.6200000000000003e-10	Lymphocyte percentage of white cells;
CESC	cis	rs3806843	0.966	rs1030163	chr5:140185132	G/A	cg16179182	chr5:140090404	VTRNA1-1	-0.41	-5.26	-0.31	2.95e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs11608355	0.545	rs4766475	chr12:109908373	G/A	cg05360138	chr12:110035743	NA	0.81	8.75	0.47	2.52e-16	Neuroticism;
CESC	cis	rs12368653	0.591	rs1552842	chr12:58012163	A/G	cg18357645	chr12:58087776	OS9	-0.38	-5.36	-0.31	1.83e-7	Multiple sclerosis;
CESC	cis	rs4523957	0.855	rs7217226	chr17:2136065	A/C	cg16513277	chr17:2031491	SMG6	-0.63	-8.97	-0.48	5.52e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	trans	rs1493916	0.870	rs7235698	chr18:31382486	A/G	cg27147174	chr7:100797783	AP1S1	-0.51	-7.06	-0.4	1.48e-11	Life satisfaction;
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg16773294	chr8:55048378	MRPL15	-0.4	-6.14	-0.35	2.92e-9	Vertical cup-disc ratio;
CESC	cis	rs8062405	1.000	rs12443881	chr16:28841777	C/T	cg08761264	chr16:28874980	SH2B1	-0.42	-5.25	-0.31	3.11e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs2228479	0.702	rs78331410	chr16:89917775	C/T	cg14709524	chr16:89940631	TCF25	0.88	6.04	0.35	5.27e-9	Skin colour saturation;
CESC	cis	rs4665809	0.590	rs35727620	chr2:26458364	G/A	cg08470875	chr2:26401718	FAM59B	0.75	7.79	0.43	1.49e-13	Gut microbiome composition (summer);
CESC	cis	rs13118159	0.725	rs71614967	chr4:1341291	A/G	cg02018176	chr4:1364513	KIAA1530	0.46	6.59	0.38	2.41e-10	Longevity;
CESC	cis	rs6088580	0.602	rs6059834	chr20:33019299	A/G	cg24642439	chr20:33292090	TP53INP2	0.52	6.79	0.39	7.18e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs1707322	0.721	rs10430124	chr1:46221617	C/T	cg05343316	chr1:45956843	TESK2	0.51	6.36	0.36	8.88e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs2270927	1.000	rs31243	chr5:75594360	A/G	cg13563193	chr19:33072644	PDCD5	0.72	6.35	0.36	9.45e-10	Mean corpuscular volume;
CESC	cis	rs61008539	0.893	rs4719460	chr7:859610	C/T	cg15782153	chr7:917662	C7orf20	-0.48	-7.18	-0.4	7.25e-12	Perceived unattractiveness to mosquitoes;
CESC	cis	rs1005277	0.579	rs2472175	chr10:38382901	T/G	cg25517755	chr10:38738941	LOC399744	-0.48	-6.22	-0.36	1.95e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs7824557	0.510	rs2736297	chr8:11234885	C/G	cg21775007	chr8:11205619	TDH	-0.54	-8.13	-0.45	1.67e-14	Retinal vascular caliber;
CESC	cis	rs1799949	1.000	rs4534897	chr17:41431808	A/G	cg05368731	chr17:41323189	NBR1	0.77	10.67	0.55	2.44e-22	Menopause (age at onset);
CESC	cis	rs1881797	1.000	rs66845073	chr1:247688010	C/T	cg18198730	chr1:247681584	NA	0.59	7.76	0.43	1.84e-13	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs1799949	0.965	rs8176161	chr17:41241390	C/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.65	9.25	0.49	7.64e-18	Menopause (age at onset);
CESC	cis	rs7618915	0.547	rs34537256	chr3:52657472	A/G	cg18404041	chr3:52824283	ITIH1	-0.39	-6.54	-0.37	3.08e-10	Bipolar disorder;
CESC	cis	rs9837602	0.529	rs1688774	chr3:99521108	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.62	-9.72	-0.51	2.66e-19	Breast cancer;
CESC	cis	rs1843834	0.539	rs2068244	chr2:225440011	A/G	cg12698349	chr2:225449008	CUL3	-0.65	-8.33	-0.46	4.48e-15	IgE levels in asthmatics (D.p. specific);
CESC	cis	rs523522	0.962	rs7488320	chr12:120981630	G/T	cg12219531	chr12:120966889	COQ5	0.75	9.99	0.52	3.7e-20	High light scatter reticulocyte count;
CESC	cis	rs889398	0.802	rs8051168	chr16:69887274	T/A	cg09409435	chr16:70099608	PDXDC2	0.41	5.05	0.3	8.37e-7	Body mass index;
CESC	trans	rs9836484	0.778	rs12636817	chr3:78065901	C/T	cg04871336	chr15:75202037	NA	-0.38	-6.08	-0.35	4.11e-9	Brain imaging in schizophrenia (dorsolateral prefrontal cortex interaction);
CESC	cis	rs12464483	0.591	rs67686878	chr2:30895044	C/T	cg12454169	chr2:30669597	LCLAT1	0.58	5.96	0.34	8.18e-9	Pre-treatment pain in head and neck squamous cell carcinoma;
CESC	cis	rs4975709	1.000	rs2279588	chr5:1878021	G/A	cg12288994	chr5:1860383	NA	0.4	6.36	0.36	8.55e-10	Cardiovascular disease risk factors;
CESC	cis	rs2242116	0.796	rs7623898	chr3:46974172	C/T	cg27129171	chr3:47204927	SETD2	-0.56	-7.18	-0.4	6.9e-12	Birth weight;
CESC	cis	rs4595586	0.525	rs11612680	chr12:39344443	A/G	cg26384229	chr12:38710491	ALG10B	0.63	8.79	0.48	1.9e-16	Morning vs. evening chronotype;
CESC	trans	rs9467711	0.606	rs9379854	chr6:26362854	T/C	cg06606381	chr12:133084897	FBRSL1	-0.76	-7.01	-0.4	1.97e-11	Autism spectrum disorder or schizophrenia;
CESC	cis	rs801193	0.591	rs2707839	chr7:66193084	A/G	cg13147721	chr7:65941812	NA	-0.36	-5.05	-0.3	8.35e-7	Aortic root size;
CESC	cis	rs875971	0.862	rs778705	chr7:65861115	G/A	cg11764359	chr7:65958608	NA	0.78	11.31	0.57	1.86e-24	Aortic root size;
CESC	cis	rs910316	0.726	rs175040	chr14:75469555	A/G	cg11812906	chr14:75593930	NEK9	-0.81	-13.3	-0.63	2.89e-31	Height;
CESC	cis	rs6493487	0.512	rs35134521	chr15:51317759	C/G	cg02338191	chr15:51200825	AP4E1	0.58	5.42	0.32	1.34e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09158336	chr17:76338205	NA	0.56	6.73	0.38	1.06e-10	Gut microbiome composition (summer);
CESC	trans	rs9987353	0.840	rs329994	chr8:9123233	A/G	cg15437133	chr10:77160907	ZNF503;C10orf41	-0.46	-6.08	-0.35	4.2e-9	Recombination measurement;
CESC	cis	rs1008375	1.000	rs12507142	chr4:17656103	A/G	cg02297831	chr4:17616191	MED28	0.6	7.51	0.42	9.14e-13	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg16456906	chr16:69373271	NIP7;COG8	-0.51	-6.36	-0.36	8.97e-10	Ulcerative colitis;
CESC	cis	rs896854	0.812	rs12546365	chr8:95911477	T/C	cg13393036	chr8:95962371	TP53INP1	-0.51	-11.08	-0.56	1.08e-23	Type 2 diabetes;
CESC	cis	rs7927771	0.839	rs11039308	chr11:47622412	G/A	cg18512352	chr11:47633146	NA	-0.46	-7.02	-0.4	1.91e-11	Subjective well-being;
CESC	cis	rs7618915	0.571	rs33964154	chr3:52596914	A/G	cg07507251	chr3:52567010	NT5DC2	0.41	7.13	0.4	9.51e-12	Bipolar disorder;
CESC	trans	rs57221529	0.825	rs72703051	chr5:582997	G/A	cg25482853	chr8:67687455	SGK3	1.14	10.23	0.53	6.39e-21	Lung disease severity in cystic fibrosis;
CESC	cis	rs826838	1.000	rs11169031	chr12:39056738	T/C	cg13010199	chr12:38710504	ALG10B	0.58	8.03	0.44	3.13e-14	Heart rate;
CESC	cis	rs9640161	0.702	rs3735175	chr7:150020457	C/T	cg21361702	chr7:150065534	REPIN1	0.54	6.23	0.36	1.84e-9	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs7618915	0.570	rs11714088	chr3:52758942	A/C	cg18404041	chr3:52824283	ITIH1	-0.41	-6.75	-0.38	9.55e-11	Bipolar disorder;
CESC	trans	rs9792269	0.735	rs72724706	chr8:129244551	C/G	cg07707498	chr16:46865555	C16orf87	-0.57	-6.04	-0.35	5.08e-9	Celiac disease;
CESC	cis	rs1005224	0.926	rs7143743	chr14:76127805	G/C	cg25116370	chr14:76127843	TTLL5;C14orf1	-0.47	-6.44	-0.37	5.53e-10	Large artery stroke;
CESC	cis	rs6545883	0.929	rs6707830	chr2:61749472	G/A	cg15711740	chr2:61764176	XPO1	-0.42	-5.22	-0.31	3.65e-7	Tuberculosis;
CESC	cis	rs2806561	0.765	rs641808	chr1:23514123	T/G	cg12483005	chr1:23474871	LUZP1	0.38	6.0	0.35	6.44e-9	Height;
CESC	cis	rs4662945	0.762	rs2406822	chr2:130218178	C/T	cg05962382	chr2:130345044	NA	-0.37	-5.07	-0.3	7.65e-7	Response to cytidine analogues (gemcitabine);
CESC	cis	rs9611565	0.729	rs202654	chr22:41841034	G/A	cg17376030	chr22:41985996	PMM1	-0.42	-5.11	-0.3	6.27e-7	Vitiligo;
CESC	cis	rs4889855	0.530	rs4889872	chr17:78621306	G/A	cg16591659	chr17:78472290	NA	0.32	5.24	0.31	3.22e-7	Fractional excretion of uric acid;
CESC	cis	rs1552244	0.935	rs66493421	chr3:10092569	G/A	cg00149659	chr3:10157352	C3orf10	0.7	7.32	0.41	2.88e-12	Alzheimer's disease;
CESC	cis	rs9815354	1.000	rs1994157	chr3:41897482	G/A	cg03022575	chr3:42003672	ULK4	0.58	5.94	0.34	9.04e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs9902453	0.817	rs2617880	chr17:28106118	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.66	-8.47	-0.46	1.74e-15	Coffee consumption (cups per day);
CESC	cis	rs9486719	0.843	rs2499796	chr6:96848364	A/G	cg18709589	chr6:96969512	KIAA0776	0.53	5.5	0.32	8.99e-8	Migraine;Coronary artery disease;
CESC	cis	rs9354308	1.000	rs9342503	chr6:66565436	A/G	cg07460842	chr6:66804631	NA	-0.51	-6.34	-0.36	1.01e-9	Metabolite levels;
CESC	cis	rs1008375	1.000	rs7697889	chr4:17617961	G/T	cg15017067	chr4:17643749	FAM184B	0.42	6.03	0.35	5.39e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs877282	0.947	rs7475589	chr10:767479	C/G	cg17470449	chr10:769945	NA	0.47	5.21	0.3	3.74e-7	Uric acid levels;
CESC	cis	rs7552404	1.000	rs12126607	chr1:76217097	G/A	cg03433033	chr1:76189801	ACADM	0.68	8.23	0.45	8.33e-15	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs8070128	0.688	rs59304093	chr17:17875407	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.6	8.13	0.45	1.68e-14	Total body bone mineral density;
CESC	cis	rs977987	0.806	rs1030262	chr16:75491327	C/A	cg03315344	chr16:75512273	CHST6	0.44	6.4	0.37	6.95e-10	Dupuytren's disease;
CESC	cis	rs8005677	1.000	rs8005677	chr14:23376678	T/C	cg25600027	chr14:23388339	RBM23	-0.41	-5.04	-0.3	8.45e-7	Cognitive ability (multi-trait analysis);
CESC	cis	rs6732160	0.588	rs3891890	chr2:73378049	A/G	cg01422370	chr2:73384389	NA	0.57	9.07	0.49	2.79e-17	Intelligence (multi-trait analysis);
CESC	cis	rs9322193	0.923	rs9371199	chr6:150138662	A/T	cg13206674	chr6:150067644	NUP43	0.41	5.61	0.33	5.2100000000000003e-08	Lung cancer;
CESC	cis	rs589448	0.535	rs12423794	chr12:69713018	G/A	cg20891283	chr12:69753455	YEATS4	0.79	11.48	0.58	5.05e-25	Cerebrospinal fluid biomarker levels;
CESC	cis	rs7216064	1.000	rs56393562	chr17:65933918	C/T	cg12091567	chr17:66097778	LOC651250	-0.71	-7.28	-0.41	3.82e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs9733	0.628	rs11807409	chr1:150683423	C/T	cg09365446	chr1:150670422	GOLPH3L	0.42	5.86	0.34	1.37e-8	Tonsillectomy;
CESC	cis	rs875971	1.000	rs811880	chr7:65818646	T/C	cg18876405	chr7:65276391	NA	0.51	6.92	0.39	3.39e-11	Aortic root size;
CESC	cis	rs35110281	0.805	rs4818843	chr21:45006607	C/T	cg04455712	chr21:45112962	RRP1B	0.36	5.23	0.31	3.41e-7	Mean corpuscular volume;
CESC	cis	rs476633	0.691	rs28735224	chr15:41537539	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.5	-7.27	-0.41	3.93e-12	Glomerular filtration rate (creatinine);
CESC	cis	rs17711722	0.523	rs313812	chr7:65505043	T/C	cg04775059	chr7:64541387	NA	-0.44	-5.46	-0.32	1.12e-7	Calcium levels;
CESC	cis	rs2737618	0.674	rs2821332	chr1:200085714	A/T	cg21825944	chr1:200113062	NR5A2	-0.47	-7.28	-0.41	3.77e-12	Uric acid levels;
CESC	cis	rs5753618	0.561	rs5749265	chr22:31796897	A/C	cg13145458	chr22:31556086	RNF185	-0.5	-5.96	-0.34	7.96e-9	Colorectal cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24024291	chr19:6740123	TRIP10	0.61	7.08	0.4	1.27e-11	Gut microbiome composition (summer);
CESC	cis	rs6598955	0.724	rs10902737	chr1:26635716	G/A	cg04990556	chr1:26633338	UBXN11	-0.78	-10.94	-0.56	3.11e-23	Obesity-related traits;
CESC	cis	rs7666738	0.830	rs7662218	chr4:98983126	T/G	cg03467027	chr4:99064603	C4orf37	0.45	5.61	0.33	5.13e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9486719	1.000	rs11153018	chr6:96956137	G/A	cg18709589	chr6:96969512	KIAA0776	-0.57	-6.26	-0.36	1.53e-9	Migraine;Coronary artery disease;
CESC	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg24503407	chr1:205819492	PM20D1	0.96	17.97	0.74	8.92e-48	Menarche (age at onset);
CESC	cis	rs4862750	0.872	rs56389997	chr4:187894796	A/C	cg22105103	chr4:187893119	NA	0.5	7.27	0.41	4.07e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs3092073	0.624	rs3848714	chr20:44547176	T/C	cg00125455	chr20:44574271	PCIF1	0.37	5.87	0.34	1.28e-8	Intelligence (multi-trait analysis);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg15020732	chr15:85144228	ZSCAN2	-0.47	-6.16	-0.35	2.62e-9	Fibrinogen levels;
CESC	trans	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg22968622	chr17:43663579	NA	1.23	17.24	0.73	3.49e-45	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs7843479	0.601	rs10453141	chr8:21847235	T/C	cg17168535	chr8:21777572	XPO7	0.73	11.44	0.57	6.96e-25	Mean corpuscular volume;
CESC	cis	rs1218582	0.772	rs6656435	chr1:154876869	G/A	cg16680214	chr1:154839983	KCNN3	-0.44	-6.76	-0.38	8.73e-11	Prostate cancer;
CESC	cis	rs4604732	0.527	rs7539082	chr1:247627260	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.57	7.2	0.4	6.34e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs6088580	0.634	rs6088498	chr20:33020446	A/G	cg06115741	chr20:33292138	TP53INP2	0.48	6.47	0.37	4.84e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs950169	0.922	rs4842941	chr15:84831312	G/C	cg17507749	chr15:85114479	UBE2QP1	-0.55	-6.25	-0.36	1.66e-9	Schizophrenia;
CESC	cis	rs911555	0.755	rs55742283	chr14:103942965	A/G	cg12935359	chr14:103987150	CKB	0.67	9.78	0.52	1.73e-19	Intelligence (multi-trait analysis);
CESC	cis	rs11190604	1.000	rs4917901	chr10:102201773	A/C	cg07080220	chr10:102295463	HIF1AN	0.55	5.56	0.32	6.43e-8	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs372883	0.600	rs1312254	chr21:30695401	A/G	cg24692254	chr21:30365293	RNF160	-0.58	-7.27	-0.41	4.04e-12	Pancreatic cancer;
CESC	cis	rs6582630	0.599	rs11181807	chr12:38403763	G/A	cg26384229	chr12:38710491	ALG10B	-0.46	-6.2	-0.36	2.14e-9	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs853679	0.513	rs9468296	chr6:28113730	A/G	cg23281280	chr6:28129359	ZNF389	0.59	7.96	0.44	5.16e-14	Depression;
CESC	cis	rs870825	0.616	rs41278579	chr4:185622402	A/G	cg04058563	chr4:185651563	MLF1IP	0.64	6.48	0.37	4.51e-10	Blood protein levels;
CESC	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg26338869	chr17:61819248	STRADA	0.69	9.1	0.49	2.2e-17	Prudent dietary pattern;
CESC	cis	rs919433	0.854	rs787994	chr2:198223121	T/C	cg03934865	chr2:198174659	NA	0.43	6.37	0.36	8.42e-10	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs35110281	0.782	rs2329442	chr21:45041790	T/C	cg21573476	chr21:45109991	RRP1B	-0.5	-6.86	-0.39	4.89e-11	Mean corpuscular volume;
CESC	cis	rs113835537	0.529	rs17580784	chr11:66214859	T/A	cg22134325	chr11:66188745	NPAS4	0.42	6.35	0.36	9.18e-10	Airway imaging phenotypes;
CESC	cis	rs10504229	0.906	rs58559296	chr8:58171714	T/C	cg14926445	chr8:58193284	C8orf71	-0.51	-5.47	-0.32	1.03e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs9322193	0.962	rs9688809	chr6:150109056	C/T	cg04369109	chr6:150039330	LATS1	-0.4	-5.4	-0.31	1.48e-7	Lung cancer;
CESC	cis	rs769267	0.930	rs10402451	chr19:19608537	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.46	5.93	0.34	9.24e-9	Tonsillectomy;
CESC	cis	rs7267979	0.868	rs6138546	chr20:25216534	G/A	cg08601574	chr20:25228251	PYGB	0.45	6.5	0.37	4.01e-10	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs4764124	0.646	rs11610238	chr12:14975721	C/T	cg19759883	chr12:14956454	WBP11;C12orf60	0.58	8.74	0.47	2.79e-16	Pubertal anthropometrics;
CESC	trans	rs650950	0.528	rs646660	chr11:35528452	C/T	cg01062786	chr14:20929651	TMEM55B	0.47	6.65	0.38	1.63e-10	Bronchopulmonary dysplasia;
CESC	cis	rs1882538	0.564	rs12707090	chr7:133115163	G/A	cg10665199	chr7:133106180	EXOC4	0.58	7.77	0.43	1.75e-13	Intelligence (multi-trait analysis);
CESC	cis	rs1062177	0.901	rs1549622	chr5:151266049	A/G	cg12924095	chr5:151150029	G3BP1	0.5	6.6	0.38	2.21e-10	Preschool internalizing problems;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg15876657	chr6:144416565	SF3B5	-0.52	-6.46	-0.37	5.01e-10	Ulcerative colitis;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg11078198	chr14:21572134	ZNF219	0.5	6.32	0.36	1.08e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs4819052	0.807	rs1075788	chr21:46666564	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.88	12.95	0.62	4.58e-30	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs1941023	0.503	rs2233238	chr11:60145441	G/C	cg08716584	chr11:60157161	MS4A7	-0.56	-9.41	-0.5	2.55e-18	Congenital heart disease (maternal effect);
CESC	cis	rs4853012	0.838	rs72915068	chr2:74356185	G/A	cg05890377	chr2:74357713	NA	0.79	10.23	0.53	6.62e-21	Gestational age at birth (maternal effect);
CESC	cis	rs7666738	0.606	rs4637413	chr4:99088151	A/G	cg24818145	chr4:99064322	C4orf37	0.39	5.13	0.3	5.73e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs13256369	0.851	rs13249700	chr8:8563637	C/T	cg00074818	chr8:8560427	CLDN23	0.38	5.41	0.32	1.39e-7	Obesity-related traits;
CESC	cis	rs7615952	0.599	rs1875683	chr3:125732481	C/G	cg15145296	chr3:125709740	NA	-0.5	-5.37	-0.31	1.74e-7	Blood pressure (smoking interaction);
CESC	cis	rs11098499	0.866	rs12510451	chr4:120289143	C/T	cg24375607	chr4:120327624	NA	0.42	5.19	0.3	4.19e-7	Corneal astigmatism;
CESC	cis	rs2204008	0.571	rs8175738	chr12:38311234	C/T	cg26384229	chr12:38710491	ALG10B	-0.46	-6.03	-0.35	5.42e-9	Bladder cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16749093	chr11:65352605	EHBP1L1	-0.55	-6.05	-0.35	4.82e-9	Gut microbiome composition (summer);
CESC	trans	rs875971	1.000	rs6460295	chr7:65882728	T/C	cg26939375	chr7:64535504	NA	0.47	6.06	0.35	4.77e-9	Aortic root size;
CESC	cis	rs55788414	0.932	rs9940095	chr16:81182108	A/G	cg06400318	chr16:81190750	PKD1L2	-0.59	-7.04	-0.4	1.62e-11	Left ventricular obstructive tract defect (maternal effect);
CESC	cis	rs6502050	0.799	rs6502089	chr17:80169523	G/A	cg23985595	chr17:80112537	CCDC57	-0.42	-6.7	-0.38	1.24e-10	Life satisfaction;
CESC	cis	rs11148252	0.553	rs9536236	chr13:53255012	T/A	cg00495681	chr13:53174319	NA	0.59	8.05	0.44	2.84e-14	Lewy body disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg10822418	chr8:61430157	RAB2A	-0.49	-6.4	-0.37	7.17e-10	Fibrinogen levels;
CESC	cis	rs7827545	1.000	rs1372659	chr8:135566779	T/A	cg17885191	chr8:135476712	NA	0.48	6.28	0.36	1.35e-9	Hypertension (SNP x SNP interaction);
CESC	cis	rs793571	0.566	rs1648532	chr15:59076778	G/C	cg05156742	chr15:59063176	FAM63B	0.63	8.3	0.45	5.26e-15	Schizophrenia;
CESC	cis	rs6977955	0.627	rs1513275	chr7:28259233	C/T	cg23620719	chr7:28220237	JAZF1	-0.49	-5.53	-0.32	7.67e-8	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs9814567	0.762	rs13075332	chr3:134329836	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.47	5.7	0.33	3.21e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs6088590	0.523	rs6058084	chr20:33183804	C/T	cg06115741	chr20:33292138	TP53INP2	0.52	6.6	0.38	2.21e-10	Coronary artery disease;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg04856952	chr22:29664439	EWSR1;RHBDD3	-0.49	-6.13	-0.35	3.11e-9	Asthma;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09161758	chr1:205720516	NUCKS1	-0.56	-6.39	-0.37	7.55e-10	Gut microbiome composition (summer);
CESC	cis	rs4665809	0.759	rs62128394	chr2:26364026	T/G	cg04944784	chr2:26401820	FAM59B	0.83	9.32	0.5	4.83e-18	Gut microbiome composition (summer);
CESC	cis	rs10927875	0.578	rs10927859	chr1:16141862	C/T	cg05821634	chr1:16164109	FLJ37453	0.34	5.04	0.3	8.45e-7	Dilated cardiomyopathy;
CESC	cis	rs3733585	0.699	rs6449202	chr4:9974043	T/C	cg11266682	chr4:10021025	SLC2A9	-0.58	-10.92	-0.56	3.75e-23	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs7818688	0.697	rs11787303	chr8:95972864	C/T	cg16049864	chr8:95962084	TP53INP1	0.59	5.82	0.34	1.68e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs79057730	0.527	rs35316052	chr7:802954	C/T	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.89	7.76	0.43	1.79e-13	Initial pursuit acceleration;
CESC	cis	rs2404602	0.735	rs2957614	chr15:76696635	C/T	cg00316803	chr15:76480434	C15orf27	-0.34	-5.05	-0.3	8.18e-7	Blood metabolite levels;
CESC	cis	rs117623576	0.941	rs7912584	chr10:32416623	C/T	cg03047570	chr10:32398778	NA	-0.82	-8.41	-0.46	2.48e-15	Anti-saccade response;
CESC	cis	rs6540559	1.000	rs2073485	chr1:209962794	G/A	cg12034118	chr1:209979487	IRF6	0.47	5.8	0.34	1.91e-8	Cleft lip with or without cleft palate;
CESC	cis	rs9908102	0.770	rs73300518	chr17:12914795	G/C	cg26162695	chr17:12921313	ELAC2	0.53	5.73	0.33	2.68e-8	Schizophrenia;
CESC	cis	rs6484504	0.576	rs208072	chr11:31141288	A/G	cg14844989	chr11:31128820	NA	0.4	5.3	0.31	2.45e-7	Red blood cell count;
CESC	cis	rs11098499	0.690	rs34818745	chr4:120257055	T/C	cg09307838	chr4:120376055	NA	0.91	12.45	0.61	2.44e-28	Corneal astigmatism;
CESC	cis	rs1050631	1.000	rs1789504	chr18:33696772	A/C	cg25426722	chr18:33708991	SLC39A6;ELP2	0.44	5.65	0.33	4.2e-8	Esophageal squamous cell cancer (length of survival);
CESC	cis	rs7582720	0.511	rs116219813	chr2:204081675	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.18	0.4	7.05e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06102153	chr16:4674926	MGRN1	0.56	6.34	0.36	1.01e-9	Gut microbiome composition (summer);
CESC	cis	rs6860806	0.531	rs274556	chr5:131722075	A/G	cg07395648	chr5:131743802	NA	0.43	5.66	0.33	3.92e-8	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10164987	chr2:63816052	MDH1;C2orf86	0.54	6.75	0.38	9.53e-11	Gut microbiome composition (summer);
CESC	cis	rs763121	0.853	rs2072794	chr22:39150543	G/T	cg06544989	chr22:39130855	UNC84B	0.5	8.78	0.47	2.12e-16	Menopause (age at onset);
CESC	cis	rs9611565	0.527	rs73178638	chr22:41942904	T/C	cg03806693	chr22:41940476	POLR3H	-1.22	-14.63	-0.67	5.98e-36	Vitiligo;
CESC	cis	rs10504229	0.906	rs61638902	chr8:58193511	A/C	cg14926445	chr8:58193284	C8orf71	-0.48	-5.3	-0.31	2.39e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs1008375	1.000	rs2286771	chr4:17643848	G/A	cg02297831	chr4:17616191	MED28	0.53	6.71	0.38	1.2e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs2290720	0.896	rs7980431	chr12:101707067	A/G	cg22051763	chr12:101673672	UTP20	-0.45	-5.35	-0.31	1.95e-7	Brain structure (hippocampal volume);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07956857	chr9:106761676	NA	-0.52	-6.28	-0.36	1.36e-9	Gut microbiome composition (summer);
CESC	cis	rs71277158	0.688	rs59249820	chr3:169755545	C/T	cg04067573	chr3:169899625	PHC3	0.53	5.4	0.31	1.48e-7	Prostate cancer;
CESC	cis	rs801193	0.569	rs2659907	chr7:66164032	G/A	cg10691866	chr7:65817282	TPST1	-0.32	-5.45	-0.32	1.13e-7	Aortic root size;
CESC	cis	rs9467711	0.606	rs9358935	chr6:26369587	A/G	cg12826209	chr6:26865740	GUSBL1	0.62	5.22	0.31	3.66e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs926938	0.527	rs6680112	chr1:115548915	G/C	cg12756093	chr1:115239321	AMPD1	0.44	6.11	0.35	3.53e-9	Autism;
CESC	cis	rs9487051	0.698	rs35757653	chr6:109644599	A/C	cg01475377	chr6:109611718	NA	-0.4	-5.39	-0.31	1.54e-7	Reticulocyte fraction of red cells;
CESC	cis	rs4604732	0.812	rs6663238	chr1:247624971	C/T	cg12758973	chr1:247694275	LOC148824;OR2C3	-0.35	-5.05	-0.3	8.4e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs3091242	0.933	rs34933589	chr1:25788198	T/C	cg03538708	chr1:25844672	NA	0.37	5.6	0.33	5.26e-8	Erythrocyte sedimentation rate;
CESC	cis	rs7811142	0.830	rs11768967	chr7:99967644	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.74	7.77	0.43	1.75e-13	Platelet count;
CESC	cis	rs10779751	1.000	rs11121698	chr1:11267283	C/T	cg08854313	chr1:11322531	MTOR	0.91	14.23	0.66	1.56e-34	Body mass index;
CESC	cis	rs10242455	0.702	rs41385645	chr7:98974038	A/T	cg18809830	chr7:99032528	PTCD1	-0.68	-5.08	-0.3	7.02e-7	Blood metabolite levels;
CESC	cis	rs3096299	0.869	rs748941	chr16:89440754	T/A	cg08392591	chr16:89556376	ANKRD11	0.41	5.23	0.31	3.42e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs11920090	0.872	rs5400	chr3:170732300	G/A	cg09710316	chr3:170744871	SLC2A2	0.45	5.4	0.32	1.46e-7	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
CESC	cis	rs9303401	0.659	rs17222691	chr17:56771096	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.04	11.66	0.58	1.27e-25	Cognitive test performance;
CESC	cis	rs11098499	0.691	rs28396837	chr4:120271541	G/A	cg09307838	chr4:120376055	NA	0.77	10.19	0.53	8.72e-21	Corneal astigmatism;
CESC	cis	rs12618769	0.597	rs3769727	chr2:99103318	C/T	cg10123293	chr2:99228465	UNC50	0.4	5.38	0.31	1.64e-7	Bipolar disorder;
CESC	cis	rs6542838	0.609	rs13028500	chr2:99528296	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.4	-5.19	-0.3	4.16e-7	Fear of minor pain;
CESC	cis	rs7264396	0.887	rs224360	chr20:34059675	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.41	5.08	0.3	7.15e-7	Total cholesterol levels;
CESC	cis	rs875971	0.638	rs35986979	chr7:66088990	G/A	cg25985355	chr7:65971099	NA	0.31	5.09	0.3	6.82e-7	Aortic root size;
CESC	cis	rs6499255	0.904	rs12447883	chr16:69722797	T/C	cg15192750	chr16:69999425	NA	0.53	6.13	0.35	3.24e-9	IgE levels;
CESC	cis	rs2932538	0.961	rs4240534	chr1:113175429	T/A	cg22162597	chr1:113214053	CAPZA1	-0.58	-7.45	-0.42	1.3e-12	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CESC	cis	rs7666738	0.830	rs2903154	chr4:99048151	A/G	cg03467027	chr4:99064603	C4orf37	0.47	5.96	0.34	8.08e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11166629	1.000	rs1036820	chr8:135646571	C/T	cg27224718	chr8:135614730	ZFAT	-0.5	-6.55	-0.37	2.93e-10	Smoking quantity;
CESC	cis	rs7084402	1.000	rs6481400	chr10:60268783	T/C	cg07615347	chr10:60278583	BICC1	-0.57	-8.72	-0.47	3.03e-16	Refractive error;
CESC	cis	rs6570726	0.791	rs387376	chr6:145822565	T/C	cg23711669	chr6:146136114	FBXO30	1.02	16.0	0.7	8.93e-41	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2440129	0.611	rs11571335	chr17:6904263	C/T	cg09737314	chr17:6899359	ALOX12	0.46	7.9	0.44	7.33e-14	Tonsillectomy;
CESC	cis	rs72781680	1.000	rs72781680	chr2:24238928	C/T	cg20701182	chr2:24300061	SF3B14	0.82	6.96	0.39	2.66e-11	Lymphocyte counts;
CESC	cis	rs6964587	0.610	rs4729008	chr7:91457054	G/T	cg17063962	chr7:91808500	NA	0.42	5.77	0.33	2.22e-8	Breast cancer;
CESC	cis	rs7267979	1.000	rs2259926	chr20:25281733	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	18.72	0.75	2.09e-50	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs2625529	0.730	rs982752	chr15:72145937	C/T	cg16672083	chr15:72433130	SENP8	-0.45	-6.55	-0.37	2.91e-10	Red blood cell count;
CESC	cis	rs28374715	0.580	rs8030228	chr15:41636867	A/G	cg20272979	chr15:41787780	ITPKA	0.4	5.07	0.3	7.38e-7	Ulcerative colitis;
CESC	trans	rs9388451	0.626	rs1343115	chr6:126069817	C/G	cg05039488	chr6:79577232	IRAK1BP1	-0.66	-9.31	-0.5	4.92e-18	Brugada syndrome;
CESC	cis	rs7223966	1.000	rs8077265	chr17:61732727	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.45	-5.56	-0.32	6.64e-8	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs1505368	0.567	rs972491	chr2:213316573	A/G	cg16329650	chr2:213403929	ERBB4	-0.49	-7.48	-0.42	1.11e-12	Symmetrical dimethylarginine levels;
CESC	cis	rs9914544	1.000	rs28436199	chr17:18751730	C/T	cg26378065	chr17:18585709	ZNF286B	0.44	5.46	0.32	1.07e-7	Educational attainment (years of education);
CESC	cis	rs7100689	0.646	rs1340374	chr10:82129114	C/T	cg00277334	chr10:82204260	NA	-0.58	-7.6	-0.42	5.01e-13	Post bronchodilator FEV1;
CESC	cis	rs6977660	0.652	rs58559474	chr7:19751569	C/T	cg05791153	chr7:19748676	TWISTNB	0.83	7.38	0.41	2.1e-12	Thyroid stimulating hormone;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03936012	chr13:37633916	FAM48A	0.57	6.06	0.35	4.63e-9	Gut microbiome composition (summer);
CESC	cis	rs10899021	0.920	rs11236171	chr11:74317518	C/T	cg25880958	chr11:74394337	NA	-0.78	-8.14	-0.45	1.53e-14	Response to metformin (IC50);
CESC	cis	rs4713118	0.540	rs469227	chr6:27970705	A/C	cg23161317	chr6:28129485	ZNF389	0.46	6.04	0.35	5.25e-9	Parkinson's disease;
CESC	cis	rs73206853	0.697	rs56084592	chr12:110577910	T/A	cg12870014	chr12:110450643	ANKRD13A	0.65	5.58	0.32	5.95e-8	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs12956009	0.518	rs4574017	chr18:44891703	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.52	6.81	0.39	6.63e-11	Educational attainment (years of education);
CESC	cis	rs2249694	0.960	rs6537613	chr10:135412414	T/G	cg19469447	chr10:135341870	CYP2E1	0.36	5.07	0.3	7.39e-7	Obesity-related traits;
CESC	cis	rs12477438	0.748	rs6712773	chr2:99585781	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.75	-10.87	-0.56	5.17e-23	Chronic sinus infection;
CESC	cis	rs4243830	0.850	rs12030607	chr1:6601007	T/A	cg22792644	chr1:6614718	TAS1R1;NOL9	0.97	9.8	0.52	1.46e-19	Body mass index;
CESC	cis	rs7666738	0.830	rs13111977	chr4:98953813	G/A	cg03467027	chr4:99064603	C4orf37	0.45	5.61	0.33	4.97e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7312774	0.618	rs7304621	chr12:107325888	C/T	cg16260113	chr12:107380972	MTERFD3	0.78	7.11	0.4	1.05e-11	Severe influenza A (H1N1) infection;
CESC	cis	rs12410462	0.681	rs76191945	chr1:227673919	A/G	cg23173402	chr1:227635558	NA	0.7	6.02	0.35	5.94e-9	Major depressive disorder;
CESC	cis	rs853679	0.517	rs12174753	chr6:28042465	C/G	cg12963246	chr6:28129442	ZNF389	0.55	7.35	0.41	2.46e-12	Depression;
CESC	cis	rs10504229	1.000	rs77120900	chr8:58170368	C/T	cg05313129	chr8:58192883	C8orf71	-0.55	-6.29	-0.36	1.31e-9	Developmental language disorder (linguistic errors);
CESC	trans	rs1814175	0.817	rs28544182	chr11:50049577	G/T	cg15704280	chr7:45808275	SEPT13	-1.05	-21.42	-0.8	9.36e-60	Height;
CESC	trans	rs11098499	0.954	rs7656252	chr4:120404268	T/C	cg25214090	chr10:38739885	LOC399744	0.72	10.18	0.53	9.16e-21	Corneal astigmatism;
CESC	cis	rs11792861	0.962	rs3750454	chr9:111801325	C/G	cg13535736	chr9:111863775	C9orf5	0.49	6.47	0.37	4.84e-10	Menarche (age at onset);
CESC	cis	rs1797885	0.934	rs1797874	chr3:12529592	C/A	cg26432171	chr3:12704882	RAF1	-0.48	-5.97	-0.34	7.75e-9	Immature fraction of reticulocytes;
CESC	cis	rs7589342	0.501	rs7602971	chr2:106440675	G/A	cg16077055	chr2:106428750	NCK2	0.4	6.28	0.36	1.35e-9	Addiction;
CESC	cis	rs1801251	0.896	rs921054	chr2:233694673	G/A	cg08000102	chr2:233561755	GIGYF2	-0.72	-11.37	-0.57	1.16e-24	Coronary artery disease;
CESC	cis	rs7659604	0.521	rs4833234	chr4:122694799	T/C	cg19748678	chr4:122722346	EXOSC9	-0.45	-5.77	-0.33	2.15e-8	Type 2 diabetes;
CESC	cis	rs3617	0.591	rs2276823	chr3:52869263	C/A	cg07507251	chr3:52567010	NT5DC2	-0.32	-5.43	-0.32	1.31e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
CESC	cis	rs5760092	0.572	rs738806	chr22:24234172	A/G	cg10150615	chr22:24372951	LOC391322	-0.44	-5.05	-0.3	8.22e-7	Urinary 1,3-butadiene metabolite levels in smokers;
CESC	cis	rs17253792	0.822	rs77197405	chr14:56159662	T/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.82	5.73	0.33	2.74e-8	Putamen volume;
CESC	trans	rs12356475	0.710	rs10822686	chr10:67733250	C/T	cg01263691	chr6:52535928	TMEM14A	0.51	6.23	0.36	1.83e-9	Psoriatic arthritis;
CESC	cis	rs6977660	0.507	rs72591450	chr7:19775480	A/G	cg07541023	chr7:19748670	TWISTNB	0.8	7.2	0.4	6.34e-12	Thyroid stimulating hormone;
CESC	cis	rs4665809	0.525	rs10865402	chr2:26535383	A/G	cg04944784	chr2:26401820	FAM59B	-0.5	-5.82	-0.34	1.66e-8	Gut microbiome composition (summer);
CESC	cis	rs561341	0.700	rs6505266	chr17:30225813	G/A	cg13647721	chr17:30228624	UTP6	0.82	10.56	0.54	5.47e-22	Hip circumference adjusted for BMI;
CESC	cis	rs10504229	0.683	rs7822631	chr8:58130916	C/G	cg24829409	chr8:58192753	C8orf71	-0.58	-7.2	-0.4	6.31e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	10.35	0.54	2.67e-21	Prudent dietary pattern;
CESC	cis	rs2425143	1.000	rs6060572	chr20:34294015	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.66	6.01	0.35	6.17e-9	Blood protein levels;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg14788749	chr22:35937309	RASD2	-0.48	-6.2	-0.36	2.2e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs8009147	1	rs8009147	chr14:104264662	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.51	-7.09	-0.4	1.2e-11	Autism spectrum disorder or schizophrenia;
CESC	cis	rs4722166	0.597	rs1554606	chr7:22768707	T/G	cg13104385	chr7:22767384	IL6	0.36	5.33	0.31	2.11e-7	Lung cancer;
CESC	cis	rs9527	0.590	rs10883839	chr10:104920341	A/G	cg04362960	chr10:104952993	NT5C2	0.46	5.36	0.31	1.79e-7	Arsenic metabolism;
CESC	cis	rs7246657	0.943	rs10403613	chr19:37844306	C/T	cg23950597	chr19:37808831	NA	-0.62	-6.3	-0.36	1.26e-9	Coronary artery calcification;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16561543	chr14:105714843	BRF1;BTBD6	0.55	6.64	0.38	1.74e-10	Gut microbiome composition (summer);
CESC	cis	rs2346177	0.542	rs6718875	chr2:46687982	G/T	cg02822958	chr2:46747628	ATP6V1E2	0.44	5.47	0.32	1.03e-7	HDL cholesterol;
CESC	cis	rs950169	0.649	rs12911612	chr15:84691014	T/C	cg17507749	chr15:85114479	UBE2QP1	0.58	5.77	0.33	2.21e-8	Schizophrenia;
CESC	cis	rs4242434	0.698	rs10104039	chr8:22538384	A/G	cg03733263	chr8:22462867	KIAA1967	-0.76	-11.82	-0.59	3.46e-26	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CESC	trans	rs10463316	0.894	rs6579865	chr5:150762335	A/C	cg24389359	chr12:111284228	CCDC63	-0.33	-6.02	-0.35	5.68e-9	Metabolite levels (Pyroglutamine);
CESC	trans	rs10506458	0.915	rs2013042	chr12:63394211	A/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.24	-15.9	-0.7	2.02e-40	Hemostatic factors and hematological phenotypes;
CESC	cis	rs875971	0.862	rs908915	chr7:65614651	G/T	cg18876405	chr7:65276391	NA	-0.52	-7.15	-0.4	8.38e-12	Aortic root size;
CESC	cis	rs425277	0.565	rs3128293	chr1:2065339	A/G	cg23803603	chr1:2058230	PRKCZ	-0.31	-5.08	-0.3	7.14e-7	Height;
CESC	cis	rs1707322	1.000	rs785519	chr1:46568562	C/T	cg06784218	chr1:46089804	CCDC17	-0.33	-5.63	-0.33	4.67e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs5769765	0.908	rs9616396	chr22:50317825	T/C	cg02269571	chr22:50332266	NA	-0.57	-6.6	-0.38	2.28e-10	Schizophrenia;
CESC	cis	rs6502050	0.637	rs74765203	chr17:80118223	A/G	cg23985595	chr17:80112537	CCDC57	-0.42	-6.59	-0.38	2.31e-10	Life satisfaction;
CESC	cis	rs9596863	1.000	rs1155438	chr13:54460544	G/T	ch.13.53330881F	chr13:54432880	NA	-0.67	-5.68	-0.33	3.5e-8	Epilepsy and lamotrigine-induced maculopapular eruptions;
CESC	cis	rs12220238	0.915	rs11001014	chr10:76128832	A/G	cg19889307	chr10:75911429	ADK;AP3M1	-0.55	-5.25	-0.31	3.05e-7	Soluble interleukin-2 receptor subunit alpha;
CESC	cis	rs4727027	0.866	rs1405124	chr7:148779618	C/T	cg23158103	chr7:148848205	ZNF398	-0.41	-6.62	-0.38	1.97e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs7772486	0.790	rs6926076	chr6:146232804	C/T	cg05347473	chr6:146136440	FBXO30	-0.55	-7.05	-0.4	1.57e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs896543	1.000	rs896543	chr2:237509207	A/G	cg25295825	chr2:237489920	CXCR7	-0.56	-7.45	-0.42	1.33e-12	Alcohol dependence (age at onset);
CESC	cis	rs7923609	0.812	rs10761753	chr10:65161903	G/A	cg01631684	chr10:65280961	REEP3	-0.44	-5.46	-0.32	1.09e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg03664139	chr6:101329504	ASCC3	-0.47	-6.72	-0.38	1.11e-10	Gambling;
CESC	cis	rs7914558	0.966	rs1890185	chr10:104748718	A/G	cg04362960	chr10:104952993	NT5C2	0.46	6.04	0.35	5.22e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs546131	0.890	rs496558	chr11:34826425	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.49	6.25	0.36	1.64e-9	Lung disease severity in cystic fibrosis;
CESC	cis	rs1865721	0.771	rs62092763	chr18:73128623	T/G	cg26385618	chr18:73139727	C18orf62	-0.52	-8.29	-0.45	5.91e-15	Intelligence;
CESC	cis	rs4132509	0.625	rs1417121	chr1:243669350	G/C	cg21452805	chr1:244014465	NA	0.4	5.09	0.3	6.74e-7	RR interval (heart rate);
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg20999565	chr14:68265668	ZFYVE26	-0.51	-6.37	-0.36	8.15e-10	Asthma;
CESC	cis	rs5758659	0.845	rs5758645	chr22:42598951	T/G	cg15557168	chr22:42548783	NA	-0.49	-7.65	-0.43	3.71e-13	Cognitive function;
CESC	cis	rs875971	1.000	rs778706	chr7:65860424	A/G	cg10691866	chr7:65817282	TPST1	-0.34	-5.47	-0.32	1.06e-7	Aortic root size;
CESC	cis	rs12148488	0.738	rs4886417	chr15:75330159	T/G	cg17294928	chr15:75287854	SCAMP5	0.56	7.04	0.4	1.67e-11	Caffeine consumption;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04426326	chr15:59499030	LDHAL6B;MYO1E	-0.57	-6.31	-0.36	1.14e-9	Gut microbiome composition (summer);
CESC	cis	rs6088590	1.000	rs2378256	chr20:33292127	G/C	cg24642439	chr20:33292090	TP53INP2	0.87	12.01	0.59	8.2e-27	Coronary artery disease;
CESC	cis	rs1448094	0.556	rs11610627	chr12:86167752	C/T	cg02569458	chr12:86230093	RASSF9	0.57	8.34	0.46	4.13e-15	Major depressive disorder;
CESC	cis	rs710216	0.843	rs10890232	chr1:43416514	C/T	cg07803811	chr1:43423981	SLC2A1	0.46	5.2	0.3	3.94e-7	Red cell distribution width;
CESC	cis	rs7665939	1.000	rs72709217	chr4:190113079	C/T	cg09826759	chr4:190284978	NA	-0.71	-7.06	-0.4	1.46e-11	Amyotrophic lateral sclerosis;
CESC	cis	rs60871478	1.000	rs62432251	chr7:801855	T/G	cg27478167	chr7:817139	HEATR2	-0.51	-5.54	-0.32	7.4e-8	Cerebrospinal P-tau181p levels;
CESC	cis	rs3733585	0.699	rs7683283	chr4:9969974	T/C	cg00071950	chr4:10020882	SLC2A9	-0.69	-11.44	-0.57	6.98e-25	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs8103278	1.000	rs8108590	chr19:46301620	A/G	cg14061069	chr19:46274453	DMPK	-0.37	-5.07	-0.3	7.38e-7	Coronary artery disease;
CESC	cis	rs854765	0.583	rs4925129	chr17:17807186	A/G	cg04398451	chr17:18023971	MYO15A	-0.64	-8.72	-0.47	3.17e-16	Total body bone mineral density;
CESC	cis	rs4819052	0.851	rs2838848	chr21:46671017	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.75	9.89	0.52	7.53e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs6840258	1.000	rs114701347	chr4:87965001	C/T	cg08197287	chr4:87952173	AFF1	-0.39	-5.34	-0.31	1.96e-7	Mean corpuscular volume;Basophil percentage of granulocytes;
CESC	cis	rs2072499	0.931	rs1052053	chr1:156202173	A/G	cg24450063	chr1:156163899	SLC25A44	0.94	17.22	0.73	4.18e-45	Testicular germ cell tumor;
CESC	cis	rs9840812	0.728	rs12635723	chr3:136300732	A/G	cg15507776	chr3:136538369	TMEM22	0.44	5.32	0.31	2.21e-7	Fibrinogen levels;
CESC	cis	rs3784262	0.900	rs12911071	chr15:58314848	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.31	-5.05	-0.3	8.08e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
CESC	cis	rs3015497	0.603	rs1845416	chr14:51071600	A/G	cg26011998	chr14:51135199	SAV1	-0.47	-5.31	-0.31	2.36e-7	Mean platelet volume;
CESC	cis	rs7998202	0.614	rs282573	chr13:113362105	G/A	cg02820901	chr13:113351484	ATP11A	0.65	5.53	0.32	7.54e-8	Glycated hemoglobin levels;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg23901904	chr1:10855062	CASZ1	-0.47	-6.21	-0.36	2.07e-9	Height;
CESC	cis	rs6831352	0.838	rs2851250	chr4:100044113	G/C	cg12011299	chr4:100065546	ADH4	0.59	6.66	0.38	1.56e-10	Alcohol dependence;
CESC	cis	rs3859192	0.539	rs2302774	chr17:38183090	G/T	cg17467752	chr17:38218738	THRA	-0.45	-5.91	-0.34	1.07e-8	White blood cell count;
CESC	trans	rs459571	0.804	rs448918	chr9:136885979	G/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.64	-8.09	-0.45	2.13e-14	Platelet distribution width;
CESC	cis	rs6951245	0.507	rs10227709	chr7:1180515	T/G	cg24642844	chr7:1081250	C7orf50	-0.45	-6.35	-0.36	9.5e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs3816587	0.839	rs6840730	chr4:25422976	G/A	cg01822600	chr1:245751692	KIF26B	0.41	6.04	0.35	5.19e-9	Rheumatoid arthritis;
CESC	cis	rs367943	0.966	rs451425	chr5:112808637	A/G	cg12552261	chr5:112820674	MCC	-0.62	-7.85	-0.43	1.05e-13	Type 2 diabetes;
CESC	cis	rs12474201	0.862	rs7562173	chr2:46976217	C/G	cg06386533	chr2:46925753	SOCS5	-0.83	-11.22	-0.57	3.72e-24	Height;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg17677112	chr7:77428730	PHTF2;TMEM60	0.45	6.04	0.35	5.23e-9	Systemic lupus erythematosus;
CESC	cis	rs72781680	0.898	rs6712175	chr2:24023431	T/G	cg08917208	chr2:24149416	ATAD2B	0.95	8.71	0.47	3.45e-16	Lymphocyte counts;
CESC	cis	rs7707921	0.602	rs10514231	chr5:81307412	C/T	cg15871215	chr5:81402204	ATG10	0.47	6.61	0.38	2.12e-10	Breast cancer;
CESC	cis	rs10504229	0.773	rs1874373	chr8:58194423	T/C	cg24829409	chr8:58192753	C8orf71	-0.74	-9.68	-0.51	3.6e-19	Developmental language disorder (linguistic errors);
CESC	cis	rs864537	0.590	rs1214596	chr1:167427170	A/T	cg22356347	chr1:167427500	CD247	0.41	8.36	0.46	3.52e-15	Celiac disease or Rheumatoid arthritis;Celiac disease;
CESC	trans	rs7615952	0.599	rs7652883	chr3:125707977	T/G	cg07211511	chr3:129823064	LOC729375	-0.55	-6.35	-0.36	9.41e-10	Blood pressure (smoking interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26048388	chr10:7829683	ATP5C1;KIN	0.55	6.32	0.36	1.1e-9	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06239170	chr6:657134	HUS1B;EXOC2	-0.69	-7.76	-0.43	1.83e-13	Gut microbiome composition (summer);
CESC	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg03188948	chr7:1209495	NA	0.57	6.61	0.38	2.06e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7586879	0.609	rs7608976	chr2:25075281	G/A	cg01884057	chr2:25150051	NA	0.37	7.18	0.4	7.06e-12	Body mass index;
CESC	cis	rs4423214	0.840	rs1792235	chr11:71181473	C/T	cg05163923	chr11:71159392	DHCR7	-0.65	-7.77	-0.43	1.71e-13	Vitamin D levels;
CESC	cis	rs6866344	0.568	rs10516147	chr5:178094484	A/G	cg10224037	chr5:178157518	ZNF354A	0.54	5.96	0.34	8.1e-9	Neutrophil percentage of white cells;
CESC	cis	rs8135665	0.600	rs8139025	chr22:38450881	G/C	cg13116946	chr22:38479732	SLC16A8	0.43	5.26	0.31	2.92e-7	Advanced age-related macular degeneration;Age-related macular degeneration;
CESC	cis	rs1552244	0.832	rs3732968	chr3:10013273	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.88	11.52	0.58	3.61e-25	Alzheimer's disease;
CESC	cis	rs10129255	0.646	rs55995061	chr14:107207547	A/G	cg07958169	chr14:107095056	NA	-0.51	-7.43	-0.42	1.49e-12	Kawasaki disease;
CESC	cis	rs258892	0.895	rs34658	chr5:72148496	A/G	cg21869765	chr5:72125136	TNPO1	0.44	5.55	0.32	6.92e-8	Small cell lung carcinoma;
CESC	cis	rs8114671	0.562	rs4911449	chr20:33512236	T/G	cg06115741	chr20:33292138	TP53INP2	0.46	5.58	0.32	6.06e-8	Height;
CESC	cis	rs10129255	0.957	rs6576233	chr14:107195477	G/A	cg07958169	chr14:107095056	NA	-0.46	-6.31	-0.36	1.19e-9	Kawasaki disease;
CESC	cis	rs7640424	0.649	rs13082569	chr3:107870835	A/C	cg09227934	chr3:107805635	CD47	0.43	5.59	0.32	5.69e-8	Body mass index;
CESC	cis	rs875971	0.522	rs1880556	chr7:65432544	T/C	cg06456125	chr7:65229604	NA	0.46	5.83	0.34	1.6e-8	Aortic root size;
CESC	cis	rs4555082	0.957	rs2816629	chr14:105737261	G/A	cg06808227	chr14:105710500	BRF1	-0.62	-7.91	-0.44	7.23e-14	Mean platelet volume;Platelet distribution width;
CESC	cis	rs4862750	0.872	rs56389997	chr4:187894796	A/C	cg03647317	chr4:187891568	NA	-0.39	-5.72	-0.33	2.84e-8	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs11758351	0.660	rs16891455	chr6:26230485	G/A	cg01420254	chr6:26195488	NA	0.77	8.49	0.46	1.48e-15	Gout;Renal underexcretion gout;
CESC	cis	rs34421088	0.585	rs1390950	chr8:11595829	C/T	cg13293535	chr8:11597251	GATA4	0.27	5.1	0.3	6.54e-7	Neuroticism;
CESC	trans	rs7156960	0.866	rs935331	chr14:76699532	A/G	cg18786782	chr3:13936527	NA	-0.43	-6.32	-0.36	1.1e-9	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs2991971	0.967	rs2275276	chr1:45973928	C/T	cg06784218	chr1:46089804	CCDC17	-0.28	-5.09	-0.3	6.71e-7	High light scatter reticulocyte count;
CESC	cis	rs2991971	0.810	rs781058	chr1:45935056	C/G	cg15605315	chr1:45957053	TESK2	-0.38	-5.27	-0.31	2.82e-7	High light scatter reticulocyte count;
CESC	cis	rs6582630	0.621	rs10880656	chr12:38571220	A/C	cg26384229	chr12:38710491	ALG10B	-0.42	-5.58	-0.32	5.84e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs4820539	0.932	rs3788349	chr22:23467950	A/G	cg14186256	chr22:23484241	RTDR1	0.82	14.59	0.67	8.64e-36	Bone mineral density;
CESC	cis	rs7503807	0.688	rs12952285	chr17:78596158	C/G	cg09596252	chr17:78655493	RPTOR	-0.37	-5.22	-0.31	3.62e-7	Obesity;
CESC	trans	rs6073597	1.000	rs6031980	chr20:43714384	C/T	cg16406212	chr2:24163862	UBXN2A	0.45	6.31	0.36	1.15e-9	Positive affect;
CESC	cis	rs7608623	0.804	rs11675585	chr2:24237180	T/C	cg08917208	chr2:24149416	ATAD2B	-0.44	-5.49	-0.32	9.22e-8	Obesity-related traits;
CESC	cis	rs2243480	1.000	rs316331	chr7:65604622	A/G	cg12463550	chr7:65579703	CRCP	-0.66	-5.15	-0.3	5.09e-7	Diabetic kidney disease;
CESC	trans	rs3780486	0.846	rs10813960	chr9:33180362	C/T	cg04842962	chr6:43655489	MRPS18A	0.84	12.22	0.6	1.58e-27	IgG glycosylation;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg00615915	chr18:61637299	SERPINB8	0.45	6.23	0.36	1.87e-9	Systemic lupus erythematosus;
CESC	cis	rs7615952	0.576	rs6780025	chr3:125815624	A/C	cg04553112	chr3:125709451	NA	-0.55	-5.85	-0.34	1.44e-8	Blood pressure (smoking interaction);
CESC	cis	rs11098499	0.954	rs1022145	chr4:120230979	A/G	cg24375607	chr4:120327624	NA	0.46	5.56	0.32	6.43e-8	Corneal astigmatism;
CESC	cis	rs116095464	1.000	rs6555159	chr5:311562	G/A	cg10591111	chr5:226296	SDHA	-0.59	-5.43	-0.32	1.3e-7	Breast cancer;
CESC	cis	rs9913156	0.793	rs55682338	chr17:4582183	G/A	cg19197139	chr17:4613644	ARRB2	0.92	10.4	0.54	1.85e-21	Lymphocyte counts;
CESC	cis	rs704795	0.867	rs7566052	chr2:27628635	A/G	cg22903471	chr2:27725779	GCKR	-0.5	-7.15	-0.4	8.25e-12	Menopause (age at onset);
CESC	cis	rs72627509	0.904	rs17081933	chr4:57822869	T/A	cg26694713	chr4:57773883	REST	0.54	5.26	0.31	3e-7	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CESC	cis	rs9649213	0.593	rs11766808	chr7:97915376	A/G	cg21770322	chr7:97807741	LMTK2	0.55	8.08	0.44	2.32e-14	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs17655565	0.581	rs17657609	chr12:52763601	C/T	cg00777198	chr12:52828273	KRT75	0.35	5.07	0.3	7.59e-7	Plasma amyloid beta peptide concentrations (ABx-42);
CESC	cis	rs1153858	1.000	rs1153858	chr15:45652703	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.75	-9.89	-0.52	8.06e-20	Homoarginine levels;
CESC	trans	rs1814175	0.650	rs6486000	chr11:49659090	T/A	cg03929089	chr4:120376271	NA	-0.85	-11.91	-0.59	1.78e-26	Height;
CESC	cis	rs798554	0.704	rs709282	chr7:2769921	G/A	cg13628971	chr7:2884303	GNA12	0.41	5.41	0.32	1.42e-7	Height;
CESC	cis	rs11098499	0.954	rs10034623	chr4:120397829	G/A	cg09307838	chr4:120376055	NA	0.94	14.09	0.65	4.83e-34	Corneal astigmatism;
CESC	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg09177884	chr7:1199841	ZFAND2A	-0.59	-7.61	-0.42	4.93e-13	Longevity;Endometriosis;
CESC	cis	rs9527	0.615	rs7899622	chr10:104727333	C/T	cg04362960	chr10:104952993	NT5C2	0.43	5.34	0.31	1.97e-7	Arsenic metabolism;
CESC	cis	rs9300255	0.602	rs10846486	chr12:123709927	G/A	cg19016782	chr12:123741754	C12orf65	-0.45	-6.55	-0.37	2.97e-10	Neutrophil percentage of white cells;
CESC	cis	rs7618915	0.547	rs34215106	chr3:52659124	T/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.29	5.18	0.3	4.42e-7	Bipolar disorder;
CESC	cis	rs10870270	1.000	rs10159943	chr10:133744744	T/C	cg17892150	chr10:133769511	PPP2R2D	-0.86	-12.61	-0.61	6.93e-29	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs9916302	0.652	rs9903269	chr17:37742383	A/T	cg00129232	chr17:37814104	STARD3	-0.55	-5.22	-0.31	3.64e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs2066819	0.892	rs2066807	chr12:56740682	C/G	cg26734620	chr12:56694298	CS	0.98	5.95	0.34	8.45e-9	Psoriasis vulgaris;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg19452060	chr12:57914632	DDIT3	-0.47	-6.27	-0.36	1.48e-9	Ulcerative colitis;
CESC	cis	rs9733	0.569	rs11204691	chr1:150644339	A/T	cg04414720	chr1:150670196	GOLPH3L	0.63	9.02	0.48	3.87e-17	Tonsillectomy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27382058	chr22:43506933	BIK	0.54	6.98	0.39	2.39e-11	Gut microbiome composition (summer);
CESC	cis	rs7786877	0.626	rs11767547	chr7:100221635	C/T	cg20848291	chr7:100343083	ZAN	-0.67	-6.94	-0.39	2.94e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs9549260	0.564	rs4941990	chr13:41299857	A/C	cg21288729	chr13:41239152	FOXO1	0.59	7.63	0.42	4.25e-13	Red blood cell count;
CESC	trans	rs11098499	0.954	rs59394118	chr4:120295551	A/G	cg25214090	chr10:38739885	LOC399744	0.68	9.23	0.49	8.9e-18	Corneal astigmatism;
CESC	cis	rs6582630	0.560	rs4882325	chr12:38510037	C/T	cg26384229	chr12:38710491	ALG10B	-0.45	-5.99	-0.35	6.96e-9	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs7562790	0.535	rs28705335	chr2:36655721	T/C	cg09467607	chr2:36825704	FEZ2	0.33	5.2	0.3	3.98e-7	QRS duration;QRS complex (Cornell);
CESC	cis	rs921665	0.584	rs5019161	chr2:3174761	A/G	cg02624386	chr2:3182749	NA	0.5	5.13	0.3	5.69e-7	World class endurance athleticism;
CESC	cis	rs4268898	0.662	rs74470633	chr2:24438712	A/G	cg06627628	chr2:24431161	ITSN2	-1.02	-11.2	-0.57	4.2e-24	Asthma;
CESC	cis	rs7208859	0.623	rs11652533	chr17:29060601	A/C	cg19761014	chr17:28927070	LRRC37B2	0.76	6.25	0.36	1.66e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs4665809	0.627	rs13032756	chr2:26489730	A/T	cg22920501	chr2:26401640	FAM59B	0.94	11.01	0.56	1.85e-23	Gut microbiome composition (summer);
CESC	cis	rs7918232	0.941	rs4749230	chr10:27441218	C/T	cg14442939	chr10:27389572	ANKRD26	0.67	6.72	0.38	1.09e-10	Breast cancer;
CESC	cis	rs28374715	0.532	rs28897479	chr15:41690851	T/G	cg18705301	chr15:41695430	NDUFAF1	-1.08	-16.89	-0.72	6.07e-44	Ulcerative colitis;
CESC	cis	rs561341	0.941	rs2428338	chr17:30299629	T/C	cg12193833	chr17:30244370	NA	-0.58	-5.85	-0.34	1.41e-8	Hip circumference adjusted for BMI;
CESC	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.72	-10.4	-0.54	1.76e-21	Prudent dietary pattern;
CESC	cis	rs4243830	0.737	rs6692747	chr1:6610049	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	0.76	5.87	0.34	1.29e-8	Body mass index;
CESC	cis	rs1559088	0.947	rs7256182	chr19:33558591	G/A	cg27124370	chr19:33622961	WDR88	0.43	5.41	0.32	1.41e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs6893300	0.857	rs6860716	chr5:179162840	T/C	cg14593053	chr5:179126677	CANX	-0.45	-5.03	-0.3	9.11e-7	Resting heart rate;
CESC	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg15112475	chr7:1198522	ZFAND2A	-0.38	-5.93	-0.34	9.19e-9	Longevity;Endometriosis;
CESC	cis	rs6429082	0.521	rs704711	chr1:235629802	G/A	cg26050004	chr1:235667680	B3GALNT2	0.82	12.83	0.62	1.26e-29	Adiposity;
CESC	cis	rs4268898	0.552	rs12620938	chr2:24367122	C/A	cg20701182	chr2:24300061	SF3B14	-0.39	-5.47	-0.32	1.03e-7	Asthma;
CESC	cis	rs4665809	0.590	rs10179959	chr2:26426403	G/A	cg27170947	chr2:26402098	FAM59B	-0.85	-9.9	-0.52	7.08e-20	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20756454	chr17:28951397	LRRC37B2	-0.6	-6.3	-0.36	1.23e-9	Gut microbiome composition (summer);
CESC	cis	rs896854	0.812	rs4582532	chr8:95969257	G/A	cg26343298	chr8:95960752	TP53INP1	0.37	6.22	0.36	1.96e-9	Type 2 diabetes;
CESC	cis	rs7833986	0.534	rs17813240	chr8:56925791	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.6	7.3	0.41	3.36e-12	Height;
CESC	cis	rs992157	1.000	rs13429408	chr2:219142860	C/A	cg20019365	chr2:219134978	PNKD;AAMP	0.75	10.39	0.54	1.89e-21	Colorectal cancer;
CESC	cis	rs7666738	0.830	rs4699600	chr4:99019429	C/G	cg18180107	chr4:99064573	C4orf37	0.41	5.39	0.31	1.57e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7666738	0.753	rs7698541	chr4:98986351	T/A	cg18180107	chr4:99064573	C4orf37	0.4	5.19	0.3	4.29e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7613875	0.600	rs2856237	chr3:50158774	A/G	cg24308560	chr3:49941425	MST1R	0.55	7.82	0.43	1.28e-13	Body mass index;
CESC	cis	rs5750830	0.594	rs9611166	chr22:39775268	T/C	cg01416388	chr22:39784598	NA	-0.54	-7.15	-0.4	8.7e-12	Intelligence (multi-trait analysis);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg14461963	chr10:12111049	DHTKD1	0.51	6.53	0.37	3.34e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs1953600	0.521	rs7067644	chr10:81924245	A/G	cg00277334	chr10:82204260	NA	-0.49	-6.76	-0.38	8.9e-11	Sarcoidosis;
CESC	cis	rs11030122	0.702	rs10835403	chr11:3990941	A/C	cg18678763	chr11:4115507	RRM1	0.43	5.03	0.3	8.95e-7	Mean platelet volume;Platelet distribution width;
CESC	cis	rs9527	0.640	rs6584541	chr10:104929124	A/G	cg04362960	chr10:104952993	NT5C2	0.42	5.26	0.31	3.03e-7	Arsenic metabolism;
CESC	cis	rs9911578	0.740	rs368243	chr17:56708979	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.41	5.31	0.31	2.34e-7	Intelligence (multi-trait analysis);
CESC	cis	rs8028182	0.636	rs11637586	chr15:75791112	G/C	cg20655648	chr15:75932815	IMP3	0.47	5.87	0.34	1.33e-8	Sudden cardiac arrest;
CESC	cis	rs1395	0.778	rs17005956	chr2:27451099	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.42	5.49	0.32	9.35e-8	Blood metabolite levels;
CESC	cis	rs1862618	0.671	rs2591957	chr5:56243146	A/T	cg22800045	chr5:56110881	MAP3K1	-0.6	-7.71	-0.43	2.55e-13	Initial pursuit acceleration;
CESC	cis	rs9837602	1.000	rs7616988	chr3:99701134	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.48	-6.78	-0.38	7.72e-11	Breast cancer;
CESC	trans	rs57221529	0.713	rs12522724	chr5:590742	T/C	cg25482853	chr8:67687455	SGK3	1.0	10.02	0.52	2.99e-20	Lung disease severity in cystic fibrosis;
CESC	cis	rs870825	0.581	rs7675106	chr4:185652388	C/G	cg04058563	chr4:185651563	MLF1IP	-0.6	-6.93	-0.39	3.28e-11	Blood protein levels;
CESC	cis	rs35306767	0.903	rs17159970	chr10:935601	T/C	cg25019033	chr10:957182	NA	-0.56	-5.92	-0.34	9.7e-9	Eosinophil percentage of granulocytes;
CESC	cis	rs17253792	0.545	rs34136598	chr14:56013238	C/T	cg01858014	chr14:56050164	KTN1	-0.79	-5.58	-0.32	5.93e-8	Putamen volume;
CESC	trans	rs561341	1.000	rs72823789	chr17:30284084	G/A	cg27661571	chr11:113659931	NA	-0.87	-8.06	-0.44	2.57e-14	Hip circumference adjusted for BMI;
CESC	cis	rs561341	0.883	rs1034627	chr17:30219569	C/T	cg12193833	chr17:30244370	NA	-0.49	-5.21	-0.3	3.78e-7	Hip circumference adjusted for BMI;
CESC	cis	rs4604732	0.588	rs74154678	chr1:247626202	A/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.57	7.17	0.4	7.39e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs2836950	0.545	rs8132143	chr21:40584258	A/T	cg11644478	chr21:40555479	PSMG1	-0.55	-7.55	-0.42	7.19e-13	Menarche (age at onset);
CESC	cis	rs7714584	1.000	rs10065172	chr5:150227998	C/T	cg22134413	chr5:150180641	NA	0.52	5.64	0.33	4.31e-8	Crohn's disease;
CESC	cis	rs6089829	0.855	rs4809459	chr20:61661345	C/T	cg03213289	chr20:61660250	NA	0.39	6.06	0.35	4.64e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs6460942	1.000	rs112996286	chr7:12315741	G/C	cg02935154	chr7:12443704	VWDE	-0.59	-5.84	-0.34	1.5e-8	Coronary artery disease;
CESC	cis	rs9611565	0.569	rs188057	chr22:41822305	T/G	cg06634786	chr22:41940651	POLR3H	0.71	7.17	0.4	7.6e-12	Vitiligo;
CESC	cis	rs7666738	0.830	rs4440224	chr4:99044924	G/A	cg17366294	chr4:99064904	C4orf37	0.61	8.78	0.47	2.13e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11098499	0.754	rs10213554	chr4:120260785	A/G	cg09307838	chr4:120376055	NA	-0.78	-10.45	-0.54	1.28e-21	Corneal astigmatism;
CESC	cis	rs13191362	1.000	rs13213408	chr6:162998049	A/T	cg06582575	chr6:163149167	PACRG;PARK2	0.8	8.16	0.45	1.33e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs4835473	0.897	rs13145976	chr4:144656863	T/A	cg25736465	chr4:144833511	NA	-0.36	-5.54	-0.32	7.38e-8	Immature fraction of reticulocytes;
CESC	cis	rs7089973	0.604	rs7895830	chr10:116625776	A/G	cg25233709	chr10:116636983	FAM160B1	0.4	6.61	0.38	2.08e-10	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs7312774	0.618	rs4964500	chr12:107320788	T/C	cg16260113	chr12:107380972	MTERFD3	0.79	6.85	0.39	5.21e-11	Severe influenza A (H1N1) infection;
CESC	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.64	7.2	0.4	6.35e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs6496667	1.000	rs8042825	chr15:90897885	C/G	cg22089800	chr15:90895588	ZNF774	-0.55	-5.61	-0.33	5.11e-8	Rheumatoid arthritis;
CESC	cis	rs1799949	0.965	rs11654051	chr17:41419656	C/T	cg23758822	chr17:41437982	NA	1.05	15.68	0.69	1.15e-39	Menopause (age at onset);
CESC	cis	rs9291683	0.692	rs1558489	chr4:10325489	T/A	cg00071950	chr4:10020882	SLC2A9	-0.52	-7.72	-0.43	2.32e-13	Bone mineral density;
CESC	cis	rs2213920	0.516	rs2188042	chr9:118159740	C/T	cg13918206	chr9:118159781	DEC1	-0.7	-5.54	-0.32	7.42e-8	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00490421	chr12:69326528	CPM	-0.53	-6.14	-0.35	2.93e-9	Gut microbiome composition (summer);
CESC	cis	rs8067545	0.611	rs2703795	chr17:20077141	C/A	cg13482628	chr17:19912719	NA	-0.43	-5.75	-0.33	2.45e-8	Schizophrenia;
CESC	cis	rs17655565	1.000	rs17655565	chr12:52691958	T/C	cg08257133	chr12:52711352	KRT83	0.45	5.09	0.3	6.86e-7	Plasma amyloid beta peptide concentrations (ABx-42);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg18827097	chr2:3522506	ADI1	0.49	6.37	0.36	8.28e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs30380	0.586	rs28119	chr5:96131733	G/A	cg16492584	chr5:96139282	ERAP1	-0.49	-6.65	-0.38	1.7e-10	Cerebrospinal fluid biomarker levels;
CESC	cis	rs2070997	0.667	rs72765063	chr9:133717391	G/A	cg11464064	chr9:133710261	ABL1	0.69	7.38	0.41	2.11e-12	Response to amphetamines;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04334422	chr4:8398880	ACOX3	-0.61	-6.65	-0.38	1.68e-10	Gut microbiome composition (summer);
CESC	cis	rs863345	0.604	rs11265007	chr1:158498522	C/T	cg12129480	chr1:158549410	OR10X1	0.33	6.54	0.37	3.11e-10	Pneumococcal bacteremia;
CESC	cis	rs72781680	0.611	rs2303287	chr2:24302246	A/G	cg20701182	chr2:24300061	SF3B14	-0.91	-10.15	-0.53	1.13e-20	Lymphocyte counts;
CESC	cis	rs4919087	0.810	rs10736115	chr10:99031685	A/G	cg25902810	chr10:99078978	FRAT1	0.67	9.43	0.5	2.24e-18	Monocyte count;
CESC	cis	rs3820928	0.874	rs6717168	chr2:227901342	C/T	cg05526886	chr2:227700861	RHBDD1	-0.43	-5.53	-0.32	7.56e-8	Pulmonary function;
CESC	cis	rs9915657	0.773	rs9894696	chr17:70099487	C/T	cg06234051	chr17:70120541	SOX9	-0.33	-5.1	-0.3	6.48e-7	Thyroid hormone levels;
CESC	cis	rs6987853	0.563	rs10958723	chr8:42448188	T/C	cg09913449	chr8:42400586	C8orf40	0.33	5.25	0.31	3.17e-7	Mean corpuscular hemoglobin concentration;
CESC	cis	rs35110281	0.548	rs2838350	chr21:45109972	T/C	cg04455712	chr21:45112962	RRP1B	0.5	7.72	0.43	2.45e-13	Mean corpuscular volume;
CESC	cis	rs116095464	1.000	rs1567956	chr5:315616	C/A	cg22857025	chr5:266934	NA	-1.21	-10.53	-0.54	7.01e-22	Breast cancer;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg25355226	chr3:150320980	SELT	-0.53	-6.98	-0.39	2.34e-11	Height;
CESC	cis	rs7089973	0.604	rs17095662	chr10:116596071	A/C	cg03647239	chr10:116582469	FAM160B1	0.41	5.08	0.3	7.3e-7	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs3087591	1.000	rs2854331	chr17:29711728	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.43	-5.21	-0.31	3.71e-7	Hip circumference;
CESC	cis	rs9733	0.596	rs6686525	chr1:150635811	C/T	cg18016565	chr1:150552671	MCL1	0.33	5.15	0.3	5.13e-7	Tonsillectomy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18126572	chr7:43909213	MRPS24	0.58	6.57	0.37	2.72e-10	Gut microbiome composition (summer);
CESC	cis	rs780096	0.506	rs56076827	chr2:27676287	A/T	cg21248554	chr2:27665150	KRTCAP3	-0.33	-6.7	-0.38	1.27e-10	Total body bone mineral density;
CESC	cis	rs28647808	1.000	rs28729896	chr9:136277796	C/T	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.88	5.66	0.33	3.88e-8	Blood protein levels;
CESC	cis	rs7216064	1.000	rs9912084	chr17:65868035	A/C	cg12091567	chr17:66097778	LOC651250	-0.8	-9.03	-0.49	3.62e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg07483432	chr12:72079704	TMEM19	-0.47	-6.5	-0.37	4.08e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs703842	1.000	rs3782130	chr12:58161898	G/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.73	9.34	0.5	4.23e-18	Multiple sclerosis;
CESC	cis	rs4665809	1.000	rs4665821	chr2:26309949	A/C	cg08470875	chr2:26401718	FAM59B	-0.48	-5.27	-0.31	2.84e-7	Gut microbiome composition (summer);
CESC	cis	rs2455799	0.574	rs2455800	chr3:15701589	T/G	cg16303742	chr3:15540471	COLQ	-0.38	-6.13	-0.35	3.19e-9	Mean platelet volume;
CESC	cis	rs34779708	0.931	rs67976880	chr10:35372261	G/C	cg04310649	chr10:35416472	CREM	-0.51	-6.06	-0.35	4.62e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs7811142	0.830	rs11768967	chr7:99967644	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.08	13.51	0.64	5.48e-32	Platelet count;
CESC	cis	rs864537	0.646	rs2995091	chr1:167434277	T/C	cg22356347	chr1:167427500	CD247	-0.4	-8.17	-0.45	1.31e-14	Celiac disease or Rheumatoid arthritis;Celiac disease;
CESC	cis	rs2404602	0.692	rs35170561	chr15:77130695	C/T	cg22467129	chr15:76604101	ETFA	-0.34	-5.07	-0.3	7.56e-7	Blood metabolite levels;
CESC	cis	rs1788820	0.917	rs1652349	chr18:21142734	A/T	cg14672496	chr18:21087552	C18orf8	0.55	7.43	0.42	1.5e-12	Body mass index;
CESC	trans	rs12681287	0.547	rs7459877	chr8:87505660	G/A	cg27317242	chr8:23145699	R3HCC1	-0.53	-6.35	-0.36	9.05e-10	Caudate activity during reward;
CESC	trans	rs9447700	1.000	rs2872785	chr6:77141238	A/G	cg17508591	chr5:140214138	PCDHA6;PCDHA2;PCDHA1;PCDHA7;PCDHA5;PCDHA3;PCDHA4	-0.37	-6.02	-0.35	5.87e-9	Menarche (age at onset);
CESC	cis	rs17376456	0.877	rs10476597	chr5:93367172	C/T	cg21475434	chr5:93447410	FAM172A	-0.85	-7.34	-0.41	2.7e-12	Diabetic retinopathy;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg06070291	chr15:44828899	EIF3J	-0.47	-6.34	-0.36	9.58e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs9479482	0.935	rs9479507	chr6:150366514	T/G	cg03788504	chr6:150331562	NA	-0.34	-6.36	-0.36	8.57e-10	Alopecia areata;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg24088293	chr10:13141924	OPTN	-0.4	-6.37	-0.36	8.46e-10	Gambling;
CESC	cis	rs10871290	0.650	rs28484753	chr16:74489395	G/C	cg01733217	chr16:74700730	RFWD3	0.75	9.85	0.52	1.08e-19	Breast cancer;
CESC	cis	rs736408	0.812	rs2270197	chr3:52824095	T/G	cg05564831	chr3:52568323	NT5DC2	0.45	6.39	0.37	7.51e-10	Bipolar disorder;
CESC	cis	rs9837602	1.000	rs1038294	chr3:99503728	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.52	-7.18	-0.4	7.08e-12	Breast cancer;
CESC	cis	rs1801251	1.000	rs6761324	chr2:233582793	T/G	cg08000102	chr2:233561755	GIGYF2	0.69	9.31	0.5	4.9e-18	Coronary artery disease;
CESC	cis	rs2688608	0.617	rs6480709	chr10:75479125	T/C	cg23231163	chr10:75533350	FUT11	-0.37	-5.67	-0.33	3.78e-8	Inflammatory bowel disease;
CESC	cis	rs12142240	0.698	rs17361915	chr1:46847321	C/T	cg00530320	chr1:46809349	NSUN4	0.6	8.3	0.45	5.19e-15	Menopause (age at onset);
CESC	cis	rs372883	0.600	rs1153277	chr21:30666867	A/T	cg08807101	chr21:30365312	RNF160	-0.48	-5.71	-0.33	2.96e-8	Pancreatic cancer;
CESC	cis	rs798554	0.757	rs1182171	chr7:2878510	A/G	cg04166393	chr7:2884313	GNA12	0.6	7.7	0.43	2.66e-13	Height;
CESC	cis	rs2243480	1.000	rs906134	chr7:65444288	G/C	cg12463550	chr7:65579703	CRCP	0.69	5.5	0.32	9.16e-8	Diabetic kidney disease;
CESC	cis	rs1005224	0.853	rs12898082	chr14:76306359	A/C	cg25116370	chr14:76127843	TTLL5;C14orf1	0.41	5.44	0.32	1.21e-7	Large artery stroke;
CESC	cis	rs3820928	0.709	rs2894627	chr2:227910171	A/G	cg11843606	chr2:227700838	RHBDD1	-0.45	-5.47	-0.32	1.03e-7	Pulmonary function;
CESC	cis	rs950169	0.922	rs11633075	chr15:85113972	C/A	cg17507749	chr15:85114479	UBE2QP1	0.54	6.11	0.35	3.61e-9	Schizophrenia;
CESC	cis	rs1008375	0.931	rs2109519	chr4:17695453	A/G	cg04450456	chr4:17643702	FAM184B	0.38	5.35	0.31	1.95e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs9831754	0.704	rs9836909	chr3:78451594	A/G	cg06138941	chr3:78371609	NA	-0.49	-6.07	-0.35	4.35e-9	Calcium levels;
CESC	cis	rs9911578	0.935	rs12948039	chr17:57045184	C/T	cg12560992	chr17:57184187	TRIM37	0.82	12.96	0.62	4.31e-30	Intelligence (multi-trait analysis);
CESC	cis	rs2836974	0.931	rs2836968	chr21:40642386	A/G	cg27266027	chr21:40555129	PSMG1	0.45	5.34	0.31	2.05e-7	Cognitive function;
CESC	cis	rs6456156	0.586	rs6909180	chr6:167460537	A/G	cg07741184	chr6:167504864	NA	0.35	6.0	0.35	6.57e-9	Primary biliary cholangitis;
CESC	cis	rs6424115	1.000	rs12031592	chr1:24127864	A/C	cg15997130	chr1:24165203	NA	0.44	6.15	0.35	2.78e-9	Immature fraction of reticulocytes;
CESC	cis	rs2075371	0.830	rs2077671	chr7:133951204	C/T	cg20476274	chr7:133979776	SLC35B4	0.68	9.88	0.52	8.59e-20	Mean platelet volume;
CESC	trans	rs11098499	0.754	rs7689729	chr4:120256192	A/G	cg25214090	chr10:38739885	LOC399744	0.64	9.04	0.49	3.46e-17	Corneal astigmatism;
CESC	cis	rs703842	0.575	rs701006	chr12:58106836	C/T	cg18357645	chr12:58087776	OS9	-0.56	-9.31	-0.5	5.06e-18	Multiple sclerosis;
CESC	cis	rs34779708	0.931	rs12248333	chr10:35362977	A/G	cg04310649	chr10:35416472	CREM	-0.54	-6.39	-0.37	7.6e-10	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs9660180	0.967	rs9660106	chr1:1797947	A/G	cg13866156	chr1:1669148	SLC35E2	-0.5	-6.53	-0.37	3.26e-10	Body mass index;
CESC	cis	rs9796	0.576	rs13329511	chr15:41299121	T/C	cg02330683	chr15:41787940	ITPKA	0.37	5.05	0.3	8.14e-7	Menopause (age at onset);
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg20873039	chr2:180871638	CWC22	-0.51	-7.35	-0.41	2.53e-12	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs6912958	0.525	rs586771	chr6:88064971	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.47	8.42	0.46	2.42e-15	Monocyte percentage of white cells;
CESC	cis	rs7727544	0.709	rs441969	chr5:131702120	G/A	cg07395648	chr5:131743802	NA	-0.42	-5.33	-0.31	2.09e-7	Blood metabolite levels;
CESC	cis	rs616402	0.527	rs589151	chr1:10567711	C/T	cg07384165	chr1:10488281	NA	-0.58	-8.63	-0.47	5.96e-16	Breast size;
CESC	cis	rs727505	0.954	rs67146030	chr7:124561790	T/G	cg23710748	chr7:124431027	NA	-0.48	-7.43	-0.42	1.48e-12	Lewy body disease;
CESC	cis	rs832540	0.931	rs832399	chr5:56222358	A/T	cg24531977	chr5:56204891	C5orf35	-0.43	-5.45	-0.32	1.15e-7	Coronary artery disease;
CESC	cis	rs7772486	0.875	rs863820	chr6:146347402	C/T	cg05347473	chr6:146136440	FBXO30	-0.5	-6.6	-0.38	2.28e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs875971	0.862	rs13226170	chr7:65999298	G/A	cg10691866	chr7:65817282	TPST1	-0.33	-5.39	-0.31	1.58e-7	Aortic root size;
CESC	trans	rs561341	0.883	rs1034626	chr17:30219500	C/G	cg27661571	chr11:113659931	NA	0.62	6.52	0.37	3.64e-10	Hip circumference adjusted for BMI;
CESC	cis	rs9486719	1.000	rs926276	chr6:96868735	C/T	cg06623918	chr6:96969491	KIAA0776	0.89	10.0	0.52	3.56e-20	Migraine;Coronary artery disease;
CESC	cis	rs7520050	0.966	rs4660319	chr1:46341623	C/T	cg24296786	chr1:45957014	TESK2	0.42	5.37	0.31	1.69e-7	Red blood cell count;Reticulocyte count;
CESC	cis	rs4692589	0.965	rs2291167	chr4:170950887	G/A	cg19918862	chr4:170955249	NA	0.38	6.04	0.35	5.16e-9	Anxiety disorder;
CESC	cis	rs6783573	0.683	rs3806702	chr3:46617502	T/C	cg21489266	chr3:46619131	LRRC2;TDGF1	-0.54	-7.79	-0.43	1.48e-13	Cerebrospinal fluid biomarker levels;
CESC	cis	rs7474896	0.559	rs1208560	chr10:38221618	A/T	cg25427524	chr10:38739819	LOC399744	0.48	5.49	0.32	9.28e-8	Obesity (extreme);
CESC	cis	rs3749237	0.595	rs4855839	chr3:49507847	G/A	cg02487422	chr3:49467188	NICN1	0.58	8.37	0.46	3.39e-15	Resting heart rate;
CESC	cis	rs6546550	0.900	rs897122	chr2:70140271	C/T	cg02498382	chr2:70120550	SNRNP27	-0.4	-7.03	-0.4	1.71e-11	Prevalent atrial fibrillation;
CESC	cis	rs12477438	0.765	rs7591794	chr2:99567514	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.64	-8.87	-0.48	1.09e-16	Chronic sinus infection;
CESC	cis	rs1005277	0.579	rs932538	chr10:38381314	T/C	cg00409905	chr10:38381863	ZNF37A	-0.52	-7.09	-0.4	1.22e-11	Extrinsic epigenetic age acceleration;
CESC	cis	rs2204008	0.837	rs11180821	chr12:38242843	A/G	cg13010199	chr12:38710504	ALG10B	0.45	5.52	0.32	7.92e-8	Bladder cancer;
CESC	cis	rs17376456	0.825	rs13165400	chr5:93091427	G/A	cg21475434	chr5:93447410	FAM172A	0.83	7.31	0.41	3.16e-12	Diabetic retinopathy;
CESC	cis	rs9948	0.655	rs17119562	chr2:97381844	G/C	cg01990225	chr2:97406019	LMAN2L	-0.99	-7.31	-0.41	3.23e-12	Erectile dysfunction and prostate cancer treatment;
CESC	trans	rs853679	0.546	rs35353359	chr6:28324378	C/T	cg01620082	chr3:125678407	NA	-0.83	-6.55	-0.37	2.93e-10	Depression;
CESC	cis	rs4523957	0.614	rs2641439	chr17:2017561	C/G	cg16513277	chr17:2031491	SMG6	-0.71	-10.1	-0.53	1.62e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs5758659	0.652	rs133349	chr22:42428727	A/T	cg05082376	chr22:42548792	NA	-0.38	-5.59	-0.32	5.52e-8	Cognitive function;
CESC	cis	rs2404602	0.716	rs7169394	chr15:76913274	G/A	cg22467129	chr15:76604101	ETFA	-0.36	-5.31	-0.31	2.34e-7	Blood metabolite levels;
CESC	cis	rs7165102	1.000	rs6494521	chr15:65739928	A/T	cg11441148	chr15:65824328	PTPLAD1	0.31	5.18	0.3	4.29e-7	Mean corpuscular hemoglobin;
CESC	cis	rs8114671	0.562	rs6087643	chr20:33474462	C/T	cg06115741	chr20:33292138	TP53INP2	0.48	5.8	0.34	1.91e-8	Height;
CESC	cis	rs763121	0.853	rs138702	chr22:39132601	A/T	cg21395723	chr22:39101663	GTPBP1	-0.48	-6.37	-0.36	8.53e-10	Menopause (age at onset);
CESC	cis	rs9314323	0.964	rs3808579	chr8:26250682	C/T	cg13160058	chr8:26243215	BNIP3L	-0.32	-5.14	-0.3	5.26e-7	Red cell distribution width;
CESC	cis	rs11696501	0.637	rs6104298	chr20:44327774	A/G	cg11783356	chr20:44313418	WFDC10B	-0.31	-5.08	-0.3	7.02e-7	Brain structure;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27003951	chr16:11350045	SOCS1	0.6	6.95	0.39	2.8e-11	Gut microbiome composition (summer);
CESC	cis	rs11608355	0.515	rs4766605	chr12:109895636	C/A	cg05360138	chr12:110035743	NA	0.82	8.92	0.48	7.93e-17	Neuroticism;
CESC	cis	rs3087591	1.000	rs8068801	chr17:29570587	G/T	cg24425628	chr17:29625626	OMG;NF1	-0.45	-5.63	-0.33	4.56e-8	Hip circumference;
CESC	cis	rs72781680	1.000	rs12620594	chr2:24194490	G/A	cg08917208	chr2:24149416	ATAD2B	0.94	8.54	0.46	1.09e-15	Lymphocyte counts;
CESC	cis	rs1915146	0.546	rs2454055	chr10:126859832	T/C	cg17191109	chr10:126851326	NA	0.42	6.68	0.38	1.36e-10	Menarche (age at onset);
CESC	cis	rs8005677	1.000	rs7155857	chr14:23400059	C/A	cg01529538	chr14:23388837	RBM23	0.5	6.72	0.38	1.14e-10	Cognitive ability (multi-trait analysis);
CESC	cis	rs9611565	0.512	rs6519289	chr22:42170432	A/C	cg06481639	chr22:41940642	POLR3H	0.6	5.9	0.34	1.13e-8	Vitiligo;
CESC	cis	rs854765	0.624	rs9899634	chr17:17727943	A/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.42	-5.48	-0.32	9.81e-8	Total body bone mineral density;
CESC	cis	rs12291225	0.679	rs1043237	chr11:14289053	A/T	cg19336497	chr11:14380999	RRAS2	-0.36	-5.31	-0.31	2.27e-7	Sense of smell;
CESC	cis	rs1552244	0.935	rs7649243	chr3:10089470	T/A	cg00149659	chr3:10157352	C3orf10	0.74	8.69	0.47	3.76e-16	Alzheimer's disease;
CESC	trans	rs7819412	0.654	rs34741518	chr8:10776860	A/C	cg06636001	chr8:8085503	FLJ10661	-0.58	-7.43	-0.42	1.54e-12	Triglycerides;
CESC	cis	rs12500824	0.564	rs72657826	chr4:77293574	G/A	cg20311846	chr4:77356250	SHROOM3	0.37	6.68	0.38	1.41e-10	Coronary artery disease;
CESC	cis	rs11098499	0.954	rs71614438	chr4:120371252	G/A	cg24375607	chr4:120327624	NA	0.47	5.89	0.34	1.14e-8	Corneal astigmatism;
CESC	cis	rs9436747	0.626	rs7516763	chr1:65972550	C/A	cg14976592	chr1:65886160	LEPROT;LEPR	-0.43	-5.23	-0.31	3.38e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
CESC	cis	rs7520050	0.966	rs12144263	chr1:46352446	G/A	cg03146154	chr1:46216737	IPP	-0.48	-6.22	-0.36	1.94e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs79976124	0.800	rs6918860	chr6:66637741	G/C	cg07460842	chr6:66804631	NA	0.69	8.03	0.44	3.13e-14	Type 2 diabetes;
CESC	cis	rs9921222	0.500	rs8046256	chr16:393948	C/T	cg08923669	chr16:420230	MRPL28	-0.5	-5.54	-0.32	7.37e-8	Bone mineral density (spine);Bone mineral density;
CESC	cis	rs7267979	0.903	rs2474766	chr20:25246153	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.82	15.62	0.69	2.01e-39	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs9915657	0.933	rs8075603	chr17:70136833	G/T	cg09344028	chr17:70110421	NA	0.32	5.93	0.34	9.32e-9	Thyroid hormone levels;
CESC	cis	rs79349575	0.783	rs11079844	chr17:47028334	G/A	cg26022315	chr17:47021804	SNF8	0.39	5.16	0.3	4.94e-7	Type 2 diabetes;
CESC	cis	rs7772486	0.875	rs1331637	chr6:146337087	T/C	cg05347473	chr6:146136440	FBXO30	0.52	6.71	0.38	1.17e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg24642844	chr7:1081250	C7orf50	-0.38	-5.05	-0.3	8.17e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg20375947	chr15:25454579	SNORD115-15;SNORD115-21;SNORD115-22	0.34	6.2	0.36	2.21e-9	Fibrinogen levels;
CESC	cis	rs10883723	0.810	rs10748824	chr10:104274466	T/C	cg22532475	chr10:104410764	TRIM8	-0.33	-5.68	-0.33	3.5e-8	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs72945132	0.882	rs11235739	chr11:70132780	C/T	cg00319359	chr11:70116639	PPFIA1	0.76	7.74	0.43	2.05e-13	Coronary artery disease;
CESC	cis	rs7833986	0.501	rs2976044	chr8:56986737	A/G	cg26371346	chr8:56986568	SNORD54;RPS20	0.61	6.0	0.35	6.52e-9	Height;
CESC	cis	rs9487051	0.676	rs6568568	chr6:109597048	C/T	cg12927641	chr6:109611667	NA	-0.37	-5.5	-0.32	8.91e-8	Reticulocyte fraction of red cells;
CESC	cis	rs344364	0.511	rs1742395	chr16:1955965	G/A	cg26617929	chr16:1858877	NA	-0.52	-5.45	-0.32	1.13e-7	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs2880765	0.835	rs900573	chr15:86037993	G/T	cg10818794	chr15:86012489	AKAP13	0.34	5.29	0.31	2.61e-7	Coronary artery disease;
CESC	cis	rs2032447	0.802	rs199755	chr6:25990367	G/A	cg03264133	chr6:25882463	NA	-0.47	-6.47	-0.37	4.71e-10	Intelligence (multi-trait analysis);
CESC	cis	rs72720396	0.789	rs12048450	chr1:91199660	G/A	cg13456504	chr1:91191583	NA	0.49	7.07	0.4	1.38e-11	Morning vs. evening chronotype;Chronotype;
CESC	cis	rs9393777	0.588	rs9467772	chr6:26496578	A/T	cg12826209	chr6:26865740	GUSBL1	0.59	6.84	0.39	5.36e-11	Intelligence (multi-trait analysis);
CESC	cis	rs73206853	0.698	rs1018133	chr12:111121302	G/C	cg12870014	chr12:110450643	ANKRD13A	0.68	5.79	0.33	2.02e-8	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs9911578	1.000	rs302840	chr17:56673079	C/G	cg05425664	chr17:57184151	TRIM37	-0.49	-6.83	-0.39	5.7e-11	Intelligence (multi-trait analysis);
CESC	cis	rs6952808	0.624	rs60137119	chr7:2083664	A/G	cg21782813	chr7:2030301	MAD1L1	0.52	7.43	0.42	1.49e-12	Bipolar disorder and schizophrenia;
CESC	cis	rs977987	0.806	rs4888416	chr16:75449176	C/G	cg03315344	chr16:75512273	CHST6	0.41	5.81	0.34	1.79e-8	Dupuytren's disease;
CESC	cis	rs190217029	1	rs190217029	chr11:111092986	C/G	cg08450021	chr11:111101517	NA	-0.42	-5.22	-0.31	3.57e-7	Carotid plaque burden;
CESC	cis	rs9311474	0.569	rs7614981	chr3:52566914	G/T	cg18404041	chr3:52824283	ITIH1	-0.37	-6.59	-0.38	2.32e-10	Electroencephalogram traits;
CESC	cis	rs4555082	0.874	rs2142190	chr14:105719306	G/A	cg13114125	chr14:105738426	BRF1	-0.89	-10.86	-0.55	5.82e-23	Mean platelet volume;Platelet distribution width;
CESC	cis	rs7927771	0.864	rs3781625	chr11:47443080	T/C	cg05585544	chr11:47624801	NA	-0.47	-6.94	-0.39	3e-11	Subjective well-being;
CESC	cis	rs916888	0.773	rs538628	chr17:44787313	G/C	cg17911788	chr17:44343683	NA	-0.62	-8.15	-0.45	1.43e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs6500602	0.701	rs4785968	chr16:4535307	T/A	cg08645402	chr16:4508243	NA	0.42	6.49	0.37	4.13e-10	Schizophrenia;
CESC	cis	rs873946	0.504	rs4880275	chr10:134576552	C/T	cg18305652	chr10:134549665	INPP5A	0.49	7.11	0.4	1.1e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs9487051	0.872	rs6924776	chr6:109612276	A/G	cg21918786	chr6:109611834	NA	-0.4	-6.1	-0.35	3.81e-9	Reticulocyte fraction of red cells;
CESC	cis	rs1799949	0.965	rs799917	chr17:41244936	G/A	cg25072359	chr17:41440525	NA	0.48	7.35	0.41	2.44e-12	Menopause (age at onset);
CESC	cis	rs6088813	0.857	rs6142378	chr20:33997291	T/A	cg14752227	chr20:34000481	UQCC	-0.4	-5.08	-0.3	7.17e-7	Height;
CESC	cis	rs1620921	0.505	rs13199812	chr6:161201960	T/C	cg01280913	chr6:161186852	NA	-0.36	-5.27	-0.31	2.81e-7	Lipoprotein (a) - cholesterol levels;
CESC	trans	rs7089973	0.523	rs61869297	chr10:116779005	G/C	cg17463145	chr7:79084011	MAGI2	0.3	6.06	0.35	4.75e-9	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs7020830	0.823	rs13285624	chr9:37129496	T/G	cg14294708	chr9:37120828	ZCCHC7	1.25	24.2	0.83	4.65e-69	Schizophrenia;
CESC	cis	rs8072100	0.701	rs4794053	chr17:45769551	G/A	cg08085267	chr17:45401833	C17orf57	-0.43	-5.43	-0.32	1.27e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs3785574	0.962	rs8066463	chr17:61818390	A/G	cg06420487	chr17:61919686	SMARCD2	0.45	5.42	0.32	1.33e-7	Height;
CESC	cis	rs2075371	0.932	rs11766132	chr7:133993062	T/C	cg11752832	chr7:134001865	SLC35B4	0.53	6.89	0.39	3.97e-11	Mean platelet volume;
CESC	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-6.21	-0.36	2.01e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs6831352	0.918	rs13143133	chr4:100054970	A/G	cg12011299	chr4:100065546	ADH4	-0.6	-6.62	-0.38	2.04e-10	Alcohol dependence;
CESC	cis	rs911555	0.755	rs6575988	chr14:103900827	G/T	cg09975044	chr14:104007538	NA	-0.41	-5.22	-0.31	3.71e-7	Intelligence (multi-trait analysis);
CESC	cis	rs10504229	0.565	rs7010503	chr8:58147127	G/A	cg22535103	chr8:58192502	C8orf71	-0.74	-8.78	-0.47	2.09e-16	Developmental language disorder (linguistic errors);
CESC	cis	rs6546537	1.000	rs2048256	chr2:69847357	G/C	cg10773587	chr2:69614142	GFPT1	-0.52	-6.41	-0.37	6.57e-10	Serum thyroid-stimulating hormone levels;
CESC	cis	rs11122272	0.735	rs2244994	chr1:231537127	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.57	-7.73	-0.43	2.29e-13	Hemoglobin concentration;
CESC	cis	rs9910055	0.530	rs7222349	chr17:42304644	C/T	cg08499158	chr17:42289980	UBTF	-0.41	-5.24	-0.31	3.34e-7	Total body bone mineral density;
CESC	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	21.97	0.8	1.29e-61	Prudent dietary pattern;
CESC	cis	rs17253792	0.822	rs76267907	chr14:56066969	C/A	cg01858014	chr14:56050164	KTN1	-0.87	-6.75	-0.38	9.11e-11	Putamen volume;
CESC	cis	rs797680	0.586	rs2281525	chr1:93595306	G/C	cg15093775	chr1:93646470	TMED5;CCDC18	-0.38	-5.79	-0.34	1.97e-8	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
CESC	cis	rs1707322	0.721	rs28442079	chr1:46172001	A/G	cg06784218	chr1:46089804	CCDC17	0.43	7.58	0.42	5.65e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs722599	0.748	rs59112602	chr14:75358817	C/G	cg00095594	chr1:236228625	NID1	-0.4	-6.11	-0.35	3.53e-9	IgG glycosylation;
CESC	cis	rs6582630	0.555	rs12372536	chr12:38400864	C/G	cg26384229	chr12:38710491	ALG10B	0.72	10.94	0.56	3.12e-23	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs34638657	0.732	rs62045964	chr16:82200920	T/C	cg09439754	chr16:82129088	HSD17B2	-0.36	-6.24	-0.36	1.71e-9	Lung adenocarcinoma;
CESC	cis	rs875971	0.862	rs778705	chr7:65861115	G/A	cg12463550	chr7:65579703	CRCP	0.51	6.41	0.37	6.58e-10	Aortic root size;
CESC	cis	rs921968	0.565	rs6436082	chr2:219639430	A/G	cg02176678	chr2:219576539	TTLL4	-0.44	-7.74	-0.43	2.15e-13	Mean corpuscular hemoglobin concentration;
CESC	cis	rs4654899	0.865	rs6658526	chr1:21391314	A/G	cg05370193	chr1:21551575	ECE1	-0.42	-6.19	-0.36	2.25e-9	Superior frontal gyrus grey matter volume;
CESC	cis	rs933688	0.938	rs12110065	chr5:90718474	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.97	12.5	0.61	1.77e-28	Smoking behavior;
CESC	cis	rs7542091	0.669	rs11119357	chr1:210042382	C/T	cg23283495	chr1:209979779	IRF6	0.33	5.25	0.31	3.06e-7	Monobrow;
CESC	cis	rs35306767	0.953	rs35693858	chr10:979813	C/T	cg26597838	chr10:835615	NA	0.72	8.01	0.44	3.58e-14	Eosinophil percentage of granulocytes;
CESC	cis	rs2455799	0.613	rs3924773	chr3:15796853	G/A	cg16303742	chr3:15540471	COLQ	-0.39	-6.14	-0.35	3.01e-9	Mean platelet volume;
CESC	cis	rs4434138	0.664	rs62255364	chr3:52701502	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.71	0.38	1.17e-10	Intelligence (multi-trait analysis);
CESC	cis	rs10242455	0.702	rs57832867	chr7:98966396	C/T	cg18809830	chr7:99032528	PTCD1	-0.7	-5.07	-0.3	7.34e-7	Blood metabolite levels;
CESC	cis	rs11792861	0.926	rs75128146	chr9:111833791	G/T	cg13535736	chr9:111863775	C9orf5	-0.52	-6.9	-0.39	3.71e-11	Menarche (age at onset);
CESC	cis	rs559928	0.606	rs7941773	chr11:63952759	C/T	cg18225595	chr11:63971243	STIP1	0.69	6.2	0.36	2.17e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CESC	cis	rs73019876	0.901	rs1848998	chr19:22135280	A/G	cg11619707	chr19:22235551	ZNF257	-0.27	-5.12	-0.3	5.8e-7	Testicular germ cell tumor;
CESC	trans	rs4950322	0.580	rs17355474	chr1:146592123	C/T	cg04954894	chr8:38089920	DDHD2	-0.59	-6.39	-0.37	7.54e-10	Protein quantitative trait loci;
CESC	cis	rs7666738	0.830	rs6532721	chr4:99048015	G/A	cg17366294	chr4:99064904	C4orf37	0.61	8.78	0.47	2.13e-16	Colonoscopy-negative controls vs population controls;
CESC	trans	rs9929218	1.000	rs7200690	chr16:68778457	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.75	-9.71	-0.51	2.91e-19	Colorectal cancer;
CESC	cis	rs13191362	1.000	rs55822577	chr6:163069710	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.94	8.93	0.48	7.5e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs2479106	0.889	rs7026674	chr9:126452936	C/T	cg16191174	chr9:126692580	DENND1A	0.47	6.17	0.35	2.5e-9	Polycystic ovary syndrome;
CESC	cis	rs11122272	0.735	rs2808584	chr1:231512925	A/G	cg06096015	chr1:231504339	EGLN1	0.43	6.18	0.35	2.46e-9	Hemoglobin concentration;
CESC	cis	rs875971	0.545	rs221986	chr7:65570310	T/C	cg18876405	chr7:65276391	NA	-0.56	-6.11	-0.35	3.54e-9	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15133313	chr6:53213956	ELOVL5	0.51	6.11	0.35	3.56e-9	Gut microbiome composition (summer);
CESC	cis	rs459571	1.000	rs2810489	chr9:136922700	C/T	cg13789015	chr9:136890014	NCRNA00094	0.55	7.79	0.43	1.53e-13	Platelet distribution width;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg19542841	chr11:64073530	ESRRA	-0.46	-6.42	-0.37	6.38e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs826838	0.754	rs2387920	chr12:38626351	A/G	cg26384229	chr12:38710491	ALG10B	0.74	11.21	0.57	3.91e-24	Heart rate;
CESC	cis	rs9815354	1.000	rs6768128	chr3:41865080	G/A	cg03022575	chr3:42003672	ULK4	0.47	5.24	0.31	3.33e-7	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs13253111	0.603	rs17058753	chr8:28090914	T/C	cg26534493	chr8:28060551	NA	0.52	8.02	0.44	3.36e-14	Childhood body mass index;
CESC	cis	rs11122272	0.766	rs2024879	chr1:231528638	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.56	-7.66	-0.43	3.45e-13	Hemoglobin concentration;
CESC	cis	rs875971	1.000	rs6958271	chr7:65979331	A/C	cg11764359	chr7:65958608	NA	0.94	14.51	0.67	1.69e-35	Aortic root size;
CESC	cis	rs1775715	0.870	rs7912121	chr10:32228995	T/G	cg18675610	chr10:32216311	ARHGAP12	0.37	5.53	0.32	7.74e-8	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs1018836	0.884	rs7823461	chr8:91581075	T/C	cg16814680	chr8:91681699	NA	-0.72	-10.29	-0.53	4.15e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs9291683	0.575	rs3756223	chr4:10105797	C/T	cg11266682	chr4:10021025	SLC2A9	0.48	8.49	0.46	1.45e-15	Bone mineral density;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08836144	chr11:66886918	KDM2A	-0.57	-6.02	-0.35	5.77e-9	Gut microbiome composition (summer);
CESC	cis	rs7726839	0.540	rs28364691	chr5:664084	G/A	cg09021430	chr5:549028	NA	-0.42	-5.16	-0.3	4.75e-7	Obesity-related traits;
CESC	cis	rs1707322	0.650	rs4553239	chr1:46150486	C/A	cg05343316	chr1:45956843	TESK2	0.49	6.02	0.35	5.64e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs950776	0.593	rs555018	chr15:78879242	G/A	cg24631222	chr15:78858424	CHRNA5	0.44	5.51	0.32	8.68e-8	Sudden cardiac arrest;
CESC	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg06873352	chr17:61820015	STRADA	-0.72	-12.84	-0.62	1.11e-29	Prudent dietary pattern;
CESC	cis	rs2795502	1.000	rs2795508	chr10:43353555	G/T	cg27426351	chr10:43362370	NA	0.4	5.16	0.3	4.74e-7	Blood protein levels;
CESC	cis	rs11098499	0.954	rs9685777	chr4:120365965	C/A	cg09307838	chr4:120376055	NA	0.94	13.7	0.64	1.18e-32	Corneal astigmatism;
CESC	cis	rs853679	0.517	rs1947863	chr6:28099344	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.55	-6.39	-0.37	7.41e-10	Depression;
CESC	cis	rs7186908	0.761	rs34714490	chr16:72177099	G/T	cg01557791	chr16:72042693	DHODH	-0.63	-7.02	-0.4	1.83e-11	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs863345	0.535	rs12064570	chr1:158499631	T/C	cg12129480	chr1:158549410	OR10X1	-0.32	-6.15	-0.35	2.82e-9	Pneumococcal bacteremia;
CESC	cis	rs9911578	1.000	rs12449365	chr17:56600660	C/G	cg10487724	chr17:56770010	TEX14;RAD51C	-0.39	-5.16	-0.3	4.83e-7	Intelligence (multi-trait analysis);
CESC	cis	rs769267	0.895	rs1000237	chr19:19518316	T/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.57	7.48	0.42	1.09e-12	Tonsillectomy;
CESC	cis	rs7116495	0.609	rs1892920	chr11:71702431	A/G	cg07596299	chr11:71824057	C11orf51	-0.8	-5.3	-0.31	2.47e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs1862618	0.853	rs6450409	chr5:56101399	A/G	cg24531977	chr5:56204891	C5orf35	-0.83	-11.11	-0.56	8.79e-24	Initial pursuit acceleration;
CESC	cis	rs72781680	0.752	rs72796116	chr2:23913769	C/T	cg08917208	chr2:24149416	ATAD2B	1.13	10.2	0.53	7.92e-21	Lymphocyte counts;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg23661306	chr3:57541993	PDE12	-0.49	-6.29	-0.36	1.28e-9	Fibrinogen levels;
CESC	cis	rs7666738	0.830	rs2903154	chr4:99048151	A/G	cg17366294	chr4:99064904	C4orf37	0.6	8.51	0.46	1.33e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10504229	0.593	rs12155520	chr8:58014318	C/T	cg05313129	chr8:58192883	C8orf71	-0.5	-5.05	-0.3	8.06e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs9291683	0.704	rs11726271	chr4:10098192	G/A	cg11266682	chr4:10021025	SLC2A9	-0.49	-8.85	-0.48	1.31e-16	Bone mineral density;
CESC	cis	rs1862618	0.853	rs252898	chr5:56188931	T/C	cg12311346	chr5:56204834	C5orf35	-0.76	-9.27	-0.49	6.68e-18	Initial pursuit acceleration;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg08757289	chr5:179107813	CBY3	-0.37	-6.08	-0.35	4.15e-9	Gambling;
CESC	cis	rs3749237	0.537	rs4459909	chr3:49469217	T/C	cg03060546	chr3:49711283	APEH	0.77	11.7	0.58	8.99e-26	Resting heart rate;
CESC	trans	rs4664293	0.625	rs6722715	chr2:160525026	T/C	cg00243281	chr11:2597838	KCNQ1	-0.35	-6.0	-0.35	6.35e-9	Monocyte percentage of white cells;
CESC	cis	rs7618915	0.547	rs11130315	chr3:52697163	A/G	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	5.7	0.33	3.27e-8	Bipolar disorder;
CESC	cis	rs736408	0.812	rs1075653	chr3:52825528	T/C	cg18337363	chr3:52569053	NT5DC2	0.32	5.42	0.32	1.37e-7	Bipolar disorder;
CESC	cis	rs11252926	0.537	rs4881274	chr10:459940	G/A	cg16386425	chr10:429943	DIP2C	-0.58	-7.56	-0.42	6.78e-13	Psychosis in Alzheimer's disease;
CESC	cis	rs921968	0.541	rs4674308	chr2:219310483	A/C	cg02176678	chr2:219576539	TTLL4	0.47	8.3	0.45	5.36e-15	Mean corpuscular hemoglobin concentration;
CESC	cis	rs2952156	0.920	rs1018246	chr17:37835240	C/T	cg20243544	chr17:37824526	PNMT	0.62	8.35	0.46	3.8e-15	Asthma;
CESC	cis	rs17253792	0.822	rs78432811	chr14:56051545	T/C	cg01858014	chr14:56050164	KTN1	-0.98	-7.15	-0.4	8.47e-12	Putamen volume;
CESC	cis	rs8114671	0.967	rs4911472	chr20:33775377	T/A	cg24642439	chr20:33292090	TP53INP2	0.44	5.29	0.31	2.55e-7	Height;
CESC	cis	rs7809950	0.815	rs62482495	chr7:106965009	A/G	cg23024343	chr7:107201750	COG5	-0.56	-7.18	-0.4	6.84e-12	Coronary artery disease;
CESC	cis	rs72781680	1.000	rs12616250	chr2:24211550	T/C	cg08917208	chr2:24149416	ATAD2B	0.92	8.28	0.45	6.31e-15	Lymphocyte counts;
CESC	cis	rs12711979	0.692	rs6751947	chr2:3820739	G/A	cg17052675	chr2:3827356	NA	-0.41	-6.47	-0.37	4.74e-10	Itch intensity from mosquito bite adjusted by bite size;
CESC	trans	rs875971	0.508	rs10258739	chr7:66062935	A/T	cg26939375	chr7:64535504	NA	-0.5	-6.96	-0.39	2.63e-11	Aortic root size;
CESC	cis	rs2050392	0.517	rs602966	chr10:30755853	C/T	cg25182066	chr10:30743637	MAP3K8	-0.51	-7.24	-0.41	4.76e-12	Inflammatory bowel disease;
CESC	cis	rs67311347	1.000	rs9822909	chr3:40457084	G/T	cg24209194	chr3:40518798	ZNF619	0.45	5.18	0.3	4.49e-7	Renal cell carcinoma;
CESC	cis	rs3126085	0.935	rs7533529	chr1:152176871	T/C	cg26876637	chr1:152193138	HRNR	0.47	5.34	0.31	1.99e-7	Atopic dermatitis;
CESC	cis	rs4594175	0.926	rs12323654	chr14:51630894	G/T	cg23942311	chr14:51606299	NA	0.37	5.53	0.32	7.79e-8	Cancer;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg18604876	chr3:5164258	ARL8B	0.47	6.74	0.38	1e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs2439831	0.867	rs2920781	chr15:43924682	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.7	8.59	0.47	7.81e-16	Lung cancer in ever smokers;
CESC	cis	rs9322193	0.923	rs10782314	chr6:150056663	C/T	cg09699651	chr6:150184138	LRP11	0.44	5.63	0.33	4.66e-8	Lung cancer;
CESC	cis	rs1983891	1.000	rs9296365	chr6:41535379	A/G	cg20194872	chr6:41519635	FOXP4	0.55	7.85	0.43	1.06e-13	Prostate cancer;
CESC	cis	rs2637266	0.626	rs846617	chr10:78546881	A/G	cg18941641	chr10:78392320	NA	0.41	7.77	0.43	1.68e-13	Pulmonary function;
CESC	cis	rs2359239	0.519	rs8007145	chr14:75185748	T/A	cg11812906	chr14:75593930	NEK9	0.46	5.54	0.32	7.3900000000000007e-08	Neuroticism (multi-trait analysis);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg26343667	chr3:156391915	TIPARP;LOC100287227	-0.45	-6.49	-0.37	4.15e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs4629180	0.675	rs13388183	chr2:102111912	A/G	cg21388029	chr2:102003306	CREG2	0.32	5.17	0.3	4.65e-7	Chronic rhinosinusitis with nasal polyps;
CESC	cis	rs4718428	1.000	rs4718428	chr7:66421446	T/G	cg25985355	chr7:65971099	NA	-0.32	-5.2	-0.3	4.08e-7	Corneal structure;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00023492	chr1:19970710	NBL1	0.55	6.09	0.35	3.95e-9	Gut microbiome composition (summer);
CESC	cis	rs17376456	0.825	rs34967135	chr5:93221785	G/A	cg25358565	chr5:93447407	FAM172A	1.09	10.69	0.55	2.14e-22	Diabetic retinopathy;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg12296079	chr11:61849674	NA	-0.43	-6.06	-0.35	4.77e-9	Gambling;
CESC	cis	rs12325245	0.536	rs12924708	chr16:58567643	G/A	cg02549819	chr16:58548995	SETD6	0.96	6.42	0.37	6.42e-10	Schizophrenia;
CESC	cis	rs3862260	0.509	rs2281493	chr1:120162787	T/C	cg16322792	chr1:120165303	ZNF697	0.59	11.23	0.57	3.44e-24	Systemic lupus erythematosus;
CESC	cis	rs1707322	1.000	rs12403666	chr1:46431621	G/A	cg05343316	chr1:45956843	TESK2	0.45	5.54	0.32	7.24e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs16937	0.597	rs3862949	chr1:205103070	A/T	cg00857998	chr1:205179979	DSTYK	0.39	5.26	0.31	2.94e-7	Schizophrenia;
CESC	cis	rs897984	0.760	rs11076	chr16:30995528	A/G	cg02466173	chr16:30829666	NA	0.49	8.16	0.45	1.32e-14	Dementia with Lewy bodies;
CESC	cis	rs1712517	0.566	rs7076274	chr10:105046007	G/A	cg04362960	chr10:104952993	NT5C2	-0.45	-5.42	-0.32	1.37e-7	Migraine;
CESC	cis	rs7618915	0.547	rs62255362	chr3:52699741	C/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.5	7.23	0.41	5.08e-12	Bipolar disorder;
CESC	cis	rs4308124	0.679	rs7600458	chr2:111963590	G/C	cg04571233	chr2:111982156	NA	-0.63	-6.97	-0.39	2.48e-11	Vitiligo;
CESC	cis	rs12530845	0.945	rs7799891	chr7:135322853	T/C	cg23117316	chr7:135346802	PL-5283	-0.43	-5.43	-0.32	1.26e-7	Red blood cell traits;
CESC	cis	rs7100689	0.577	rs1417219	chr10:82041409	C/T	cg00277334	chr10:82204260	NA	-0.53	-6.89	-0.39	3.94e-11	Post bronchodilator FEV1;
CESC	trans	rs11039798	0.588	rs11039818	chr11:48562120	C/T	cg15704280	chr7:45808275	SEPT13	0.65	6.87	0.39	4.53e-11	Axial length;
CESC	cis	rs10744422	1.000	rs3852536	chr12:123333824	C/T	cg25930673	chr12:123319894	HIP1R	-0.72	-5.72	-0.33	2.83e-8	Schizophrenia;
CESC	cis	rs6502050	0.835	rs35070385	chr17:80128447	G/A	cg23985595	chr17:80112537	CCDC57	-0.41	-6.57	-0.37	2.61e-10	Life satisfaction;
CESC	cis	rs4148883	0.645	rs2851264	chr4:100029715	C/T	cg12011299	chr4:100065546	ADH4	0.69	10.44	0.54	1.38e-21	Alcohol dependence;
CESC	cis	rs796364	0.951	rs12613687	chr2:200999256	C/T	cg23649088	chr2:200775458	C2orf69	-0.52	-5.09	-0.3	6.77e-7	Schizophrenia;
CESC	cis	rs1799949	0.965	rs6503727	chr17:41312859	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.48	6.74	0.38	9.67e-11	Menopause (age at onset);
CESC	cis	rs6866344	0.697	rs62392831	chr5:178134365	A/G	cg03877680	chr5:178157825	ZNF354A	0.76	8.58	0.47	8.33e-16	Neutrophil percentage of white cells;
CESC	cis	rs9611565	0.694	rs5758365	chr22:41858657	A/G	cg03806693	chr22:41940476	POLR3H	1.2	14.94	0.68	5.18e-37	Vitiligo;
CESC	cis	rs853679	0.517	rs1340004	chr6:28103691	C/T	cg26335602	chr6:28129616	ZNF389	0.47	5.71	0.33	2.95e-8	Depression;
CESC	cis	rs727563	0.635	rs713988	chr22:42159072	A/G	cg17376030	chr22:41985996	PMM1	-0.77	-8.07	-0.44	2.39e-14	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs853679	0.517	rs9380050	chr6:28048538	A/G	cg19592336	chr6:28129416	ZNF389	0.6	7.97	0.44	4.69e-14	Depression;
CESC	cis	rs4595586	0.525	rs7968458	chr12:39377139	C/A	cg26384229	chr12:38710491	ALG10B	0.54	7.53	0.42	7.85e-13	Morning vs. evening chronotype;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg16349277	chr4:83323642	NA	0.47	6.63	0.38	1.93e-10	Fibrinogen levels;
CESC	cis	rs7552404	0.628	rs5745442	chr1:76342858	T/G	cg10523679	chr1:76189770	ACADM	0.65	6.17	0.35	2.56e-9	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs6089584	0.566	rs2146852	chr20:60616492	T/G	cg23463467	chr20:60627584	TAF4	0.35	5.1	0.3	6.6e-7	Body mass index;
CESC	cis	rs2262909	0.924	rs11085509	chr19:22204573	T/C	cg11619707	chr19:22235551	ZNF257	-0.35	-5.7	-0.33	3.19e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20443613	chr6:52769353	GSTA3	-0.56	-6.41	-0.37	6.52e-10	Gut microbiome composition (summer);
CESC	cis	rs11864453	0.826	rs12325142	chr16:72138112	G/T	cg01557791	chr16:72042693	DHODH	-0.51	-6.73	-0.38	1.02e-10	Fibrinogen levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07139317	chr1:11333383	UBIAD1	0.52	6.19	0.36	2.33e-9	Gut microbiome composition (summer);
CESC	cis	rs752010	0.746	rs10749837	chr1:42089471	T/C	cg06885757	chr1:42089581	HIVEP3	0.53	9.13	0.49	1.84e-17	Lupus nephritis in systemic lupus erythematosus;
CESC	trans	rs79976124	0.879	rs10944856	chr6:66636960	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.73	8.2	0.45	1.02e-14	Type 2 diabetes;
CESC	cis	rs854765	0.547	rs9894138	chr17:17964345	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.6	-8.3	-0.45	5.22e-15	Total body bone mineral density;
CESC	cis	rs113835537	0.502	rs7104378	chr11:66216675	A/G	cg24851651	chr11:66362959	CCS	0.46	5.99	0.35	6.96e-9	Airway imaging phenotypes;
CESC	cis	rs16854884	0.586	rs7642551	chr3:143732167	C/T	cg06585982	chr3:143692056	C3orf58	0.52	7.16	0.4	7.74e-12	Economic and political preferences (feminism/equality);
CESC	trans	rs7824557	0.527	rs2572446	chr8:11239565	C/T	cg06636001	chr8:8085503	FLJ10661	-0.48	-6.07	-0.35	4.35e-9	Retinal vascular caliber;
CESC	trans	rs650950	0.528	rs646660	chr11:35528452	C/T	cg16693872	chr5:176882643	PRR7	0.44	6.0	0.35	6.3e-9	Bronchopulmonary dysplasia;
CESC	cis	rs4077515	0.504	rs7628	chr9:139318071	A/G	cg14169450	chr9:139327907	INPP5E	0.48	7.18	0.4	6.92e-12	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
CESC	trans	rs7246657	1.000	rs7246657	chr19:37747108	C/T	cg01833234	chr11:6592585	DNHD1	-0.52	-6.08	-0.35	4.23e-9	Coronary artery calcification;
CESC	cis	rs6831352	0.879	rs29001196	chr4:100054116	C/T	cg13256891	chr4:100009986	ADH5	-0.77	-8.45	-0.46	1.97e-15	Alcohol dependence;
CESC	cis	rs1215050	0.740	rs783936	chr4:98928628	G/T	cg05340658	chr4:99064831	C4orf37	-0.54	-7.23	-0.41	5.23e-12	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs2228479	0.850	rs2190808	chr16:89840856	C/T	cg06558623	chr16:89946397	TCF25	1.17	9.29	0.5	5.84e-18	Skin colour saturation;
CESC	cis	rs6076065	0.963	rs999072	chr20:23347553	C/T	cg11657817	chr20:23433608	CST11	0.35	5.2	0.3	4.04e-7	Facial morphology (factor 15, philtrum width);
CESC	cis	rs910316	0.763	rs175042	chr14:75470833	A/T	cg08847533	chr14:75593920	NEK9	-0.87	-14.71	-0.67	3.14e-36	Height;
CESC	cis	rs1799949	1.000	rs35330014	chr17:41212547	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.64	8.68	0.47	4.22e-16	Menopause (age at onset);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg25798982	chr7:129251645	NRF1	-0.5	-6.36	-0.36	8.56e-10	Fibrinogen levels;
CESC	cis	rs6582630	0.555	rs2387598	chr12:38510472	G/A	cg26384229	chr12:38710491	ALG10B	-0.64	-9.42	-0.5	2.36e-18	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs16895831	0.519	rs12210135	chr6:42570156	G/T	cg10605015	chr6:42532144	UBR2	-0.52	-5.96	-0.34	7.96e-9	Granulocyte percentage of myeloid white cells;Neutrophil percentage of white cells;Eosinophil percentage of white cells;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Neutrophil count;Sum basophil neutrophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
CESC	cis	rs9322193	0.847	rs880246	chr6:150167108	G/A	cg04369109	chr6:150039330	LATS1	-0.4	-5.16	-0.3	4.88e-7	Lung cancer;
CESC	cis	rs1862618	0.671	rs2034244	chr5:56242774	T/C	cg18230493	chr5:56204884	C5orf35	0.61	8.02	0.44	3.4e-14	Initial pursuit acceleration;
CESC	cis	rs12711979	0.509	rs12711972	chr2:3823786	T/C	cg17052675	chr2:3827356	NA	-0.66	-11.01	-0.56	1.79e-23	Itch intensity from mosquito bite adjusted by bite size;
CESC	cis	rs7666738	0.830	rs34313689	chr4:99013689	T/C	cg03467027	chr4:99064603	C4orf37	0.45	5.69	0.33	3.29e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2882667	0.858	rs13174479	chr5:138444170	G/A	cg04439458	chr5:138467593	SIL1	-0.38	-5.94	-0.34	9.16e-9	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs7666738	0.783	rs10028584	chr4:98962404	C/T	cg03676636	chr4:99064102	C4orf37	0.34	5.2	0.3	4.01e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4746818	0.892	rs2394505	chr10:70871598	A/G	cg04149295	chr10:70884716	VPS26A	-0.54	-5.13	-0.3	5.58e-7	Left atrial antero-posterior diameter;
CESC	cis	rs9858542	0.953	rs3811697	chr3:49590770	C/T	cg03060546	chr3:49711283	APEH	-0.5	-5.89	-0.34	1.15e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs832540	0.656	rs832573	chr5:56159578	T/C	cg12311346	chr5:56204834	C5orf35	-0.42	-5.17	-0.3	4.53e-7	Coronary artery disease;
CESC	cis	rs17376456	0.696	rs6860390	chr5:93494731	G/T	cg25358565	chr5:93447407	FAM172A	-0.51	-5.93	-0.34	9.64e-9	Diabetic retinopathy;
CESC	cis	rs2070488	0.775	rs2300669	chr3:38541318	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.79	-12.83	-0.62	1.24e-29	Electrocardiographic conduction measures;
CESC	cis	rs11098499	0.754	rs10212714	chr4:120254302	T/C	cg24375607	chr4:120327624	NA	0.41	5.07	0.3	7.59e-7	Corneal astigmatism;
CESC	cis	rs853679	0.513	rs13437444	chr6:28070998	C/T	cg26335602	chr6:28129616	ZNF389	0.52	5.75	0.33	2.39e-8	Depression;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23492582	chr20:55926133	RAE1	-0.56	-6.28	-0.36	1.36e-9	Gut microbiome composition (summer);
CESC	cis	rs6061231	0.624	rs8668	chr20:60964064	C/T	cg22633769	chr20:60982531	CABLES2	-0.67	-8.62	-0.47	6.22e-16	Colorectal cancer;
CESC	cis	rs796364	0.906	rs281789	chr2:200780698	T/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.89	8.76	0.47	2.43e-16	Schizophrenia;
CESC	cis	rs1018836	0.923	rs13255452	chr8:91582988	A/G	cg16814680	chr8:91681699	NA	-0.7	-9.8	-0.52	1.52e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs1552244	0.572	rs6442154	chr3:10168785	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.66	-7.28	-0.41	3.86e-12	Alzheimer's disease;
CESC	cis	rs4481887	0.861	rs1339989	chr1:248511624	C/G	cg00666640	chr1:248458726	OR2T12	0.36	6.15	0.35	2.91e-9	Common traits (Other);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09372928	chr1:6845395	CAMTA1	0.56	6.71	0.38	1.21e-10	Gut microbiome composition (summer);
CESC	cis	rs9467160	1.000	rs9461012	chr6:24441844	A/G	cg20631270	chr6:24437470	GPLD1	-0.46	-5.78	-0.33	2.06e-8	Liver enzyme levels;
CESC	cis	rs3858526	0.883	rs10769320	chr11:5932831	G/C	cg13902645	chr11:5959945	NA	-0.63	-7.53	-0.42	8.16e-13	DNA methylation (variation);
CESC	cis	rs1371867	0.846	rs1660317	chr8:101333252	G/T	cg11906718	chr8:101322791	RNF19A	0.53	6.86	0.39	4.86e-11	Atrioventricular conduction;
CESC	cis	rs1008375	0.932	rs10009933	chr4:17670107	A/C	cg16339924	chr4:17578868	LAP3	0.59	7.08	0.4	1.27e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs12995491	0.569	rs6724281	chr2:88529531	T/G	cg04169830	chr2:88471460	THNSL2	0.42	6.06	0.35	4.69e-9	Response to metformin (IC50);
CESC	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg07677032	chr17:61819896	STRADA	0.44	5.77	0.33	2.15e-8	Prudent dietary pattern;
CESC	cis	rs6587515	0.748	rs7520511	chr1:150659692	C/A	cg13175981	chr1:150552382	MCL1	0.62	5.65	0.33	4.23e-8	Pericardial adipose tissue adjusted for height and weight;
CESC	cis	rs7116495	0.609	rs577435	chr11:71794681	C/T	cg10381502	chr11:71823885	C11orf51	-1.0	-6.24	-0.36	1.74e-9	Severe influenza A (H1N1) infection;
CESC	cis	rs7714584	1.000	rs73282234	chr5:150195924	G/C	cg22134413	chr5:150180641	NA	0.6	5.56	0.32	6.61e-8	Crohn's disease;
CESC	cis	rs1465370	0.720	rs3823579	chr7:130017374	T/C	cg04743876	chr7:130013617	NA	0.31	5.86	0.34	1.38e-8	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
CESC	cis	rs1862618	0.853	rs860580	chr5:56149429	G/T	cg18230493	chr5:56204884	C5orf35	0.7	8.79	0.48	1.89e-16	Initial pursuit acceleration;
CESC	trans	rs61931739	0.500	rs11053242	chr12:34511625	A/G	cg26384229	chr12:38710491	ALG10B	0.54	7.55	0.42	7.05e-13	Morning vs. evening chronotype;
CESC	cis	rs17095355	0.901	rs61881586	chr10:111758419	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.48	-5.6	-0.33	5.27e-8	Biliary atresia;
CESC	cis	rs4319547	0.695	rs4758645	chr12:122946487	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.48	-6.03	-0.35	5.46e-9	Body mass index;
CESC	cis	rs1008375	0.933	rs6449324	chr4:17694880	G/C	cg16339924	chr4:17578868	LAP3	0.57	7.2	0.4	6.15e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs5750830	0.594	rs5757647	chr22:39775047	C/A	cg01416388	chr22:39784598	NA	-0.54	-7.15	-0.4	8.7e-12	Intelligence (multi-trait analysis);
CESC	cis	rs3820068	0.705	rs72643683	chr1:15824905	C/A	cg18192808	chr1:15853278	DNAJC16	0.47	5.66	0.33	3.93e-8	Systolic blood pressure;
CESC	cis	rs7432375	0.580	rs4678442	chr3:136532971	A/G	cg15507776	chr3:136538369	TMEM22	0.61	7.75	0.43	1.96e-13	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
CESC	cis	rs3733585	0.699	rs7657340	chr4:9966772	A/T	cg02734326	chr4:10020555	SLC2A9	-0.39	-5.58	-0.32	5.91e-8	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs3126085	0.935	rs7531094	chr1:152176850	A/G	cg03465714	chr1:152285911	FLG	-0.44	-5.34	-0.31	2.04e-7	Atopic dermatitis;
CESC	cis	rs9549260	0.755	rs2701869	chr13:41157372	G/A	cg21288729	chr13:41239152	FOXO1	0.61	7.57	0.42	6.17e-13	Red blood cell count;
CESC	cis	rs6430585	0.583	rs58116536	chr2:136585323	C/T	cg07169764	chr2:136633963	MCM6	1.34	19.43	0.77	6.67e-53	Corneal structure;
CESC	trans	rs875971	0.965	rs7794930	chr7:65778546	A/C	cg26939375	chr7:64535504	NA	-0.45	-6.03	-0.35	5.37e-9	Aortic root size;
CESC	cis	rs6460942	0.630	rs17671056	chr7:12390961	C/G	cg02935154	chr7:12443704	VWDE	-0.52	-5.31	-0.31	2.29e-7	Coronary artery disease;
CESC	cis	rs2066819	1.000	rs77131854	chr12:56664231	C/T	cg26714650	chr12:56694279	CS	-1.41	-9.99	-0.52	3.69e-20	Psoriasis vulgaris;
CESC	cis	rs6502050	0.865	rs8079388	chr17:80162798	C/A	cg11859384	chr17:80120422	CCDC57	-0.37	-5.15	-0.3	4.98e-7	Life satisfaction;
CESC	cis	rs1862618	0.853	rs832553	chr5:56114786	A/G	cg03609598	chr5:56110824	MAP3K1	-0.49	-5.36	-0.31	1.8e-7	Initial pursuit acceleration;
CESC	cis	rs9311474	0.597	rs6778735	chr3:52565100	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.35	-5.05	-0.3	8.43e-7	Electroencephalogram traits;
CESC	cis	rs9393777	0.513	rs6936555	chr6:26640886	C/T	cg14345882	chr6:26364793	BTN3A2	0.41	5.38	0.31	1.68e-7	Intelligence (multi-trait analysis);
CESC	trans	rs3087243	0.755	rs231791	chr2:204701865	C/A	cg01841312	chr10:38069945	NA	0.39	6.38	0.36	7.87e-10	Rheumatoid arthritis;Hypothyroidism;Type 1 diabetes;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg22817718	chr3:128880473	ISY1	-0.46	-6.4	-0.37	6.99e-10	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs10392	0.543	rs62204117	chr20:37565335	T/C	cg27552599	chr20:37590471	DHX35	0.38	5.82	0.34	1.68e-8	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
CESC	cis	rs6466055	0.720	rs10227302	chr7:105021829	C/G	cg04380332	chr7:105027541	SRPK2	-0.42	-5.37	-0.31	1.74e-7	Schizophrenia;
CESC	cis	rs4919087	1.000	rs7067835	chr10:99074649	T/C	cg25902810	chr10:99078978	FRAT1	0.71	10.31	0.54	3.48e-21	Monocyte count;
CESC	cis	rs7937682	1.000	rs10789843	chr11:111576158	C/T	cg22437258	chr11:111473054	SIK2	-0.68	-7.99	-0.44	4.13e-14	Primary sclerosing cholangitis;
CESC	cis	rs12478296	0.818	rs57194240	chr2:243011545	A/G	cg06360820	chr2:242988706	NA	-0.72	-9.21	-0.49	1.06e-17	Obesity-related traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02462761	chr5:139937169	SRA1	0.57	6.63	0.38	1.86e-10	Gut microbiome composition (summer);
CESC	cis	rs7216064	1.000	rs62084249	chr17:65874998	A/G	cg12091567	chr17:66097778	LOC651250	-0.86	-8.82	-0.48	1.55e-16	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	trans	rs17685	0.712	rs10235086	chr7:75833138	G/T	cg19862616	chr7:65841803	NCRNA00174	0.8	11.31	0.57	1.78e-24	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs1790761	0.505	rs7941395	chr11:67347417	A/G	cg00290607	chr11:67383545	NA	-0.36	-5.33	-0.31	2.14e-7	Mean corpuscular volume;
CESC	cis	rs4233366	0.585	rs3924264	chr1:161178684	C/T	cg13853198	chr1:161185092	FCER1G	-0.32	-5.06	-0.3	7.78e-7	Asthma;
CESC	cis	rs2299587	0.689	rs2299588	chr8:17801725	A/G	cg08627089	chr8:17753878	FGL1	-0.39	-5.07	-0.3	7.32e-7	Economic and political preferences;
CESC	cis	rs1511802	0.666	rs4862663	chr4:187119228	T/A	cg24794857	chr4:187113578	CYP4V2	0.46	5.99	0.35	6.77e-9	Blood protein levels;
CESC	trans	rs1814175	0.645	rs11040661	chr11:49952146	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.41	-6.15	-0.35	2.82e-9	Height;
CESC	cis	rs929596	0.518	rs13401281	chr2:234628679	T/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.55	-6.93	-0.39	3.12e-11	Total bilirubin levels in HIV-1 infection;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg06692641	chr19:40030326	EID2	-0.49	-6.29	-0.36	1.32e-9	Ulcerative colitis;
CESC	cis	rs10876993	0.672	rs2640611	chr12:58037757	T/A	cg18357645	chr12:58087776	OS9	0.59	9.08	0.49	2.55e-17	Celiac disease or Rheumatoid arthritis;
CESC	cis	rs1552244	1.000	rs55882090	chr3:10139082	C/T	cg08888203	chr3:10149979	C3orf24	0.46	6.01	0.35	6.24e-9	Alzheimer's disease;
CESC	cis	rs1799949	1.000	rs4340367	chr17:41307772	G/A	cg05368731	chr17:41323189	NBR1	0.79	11.16	0.57	5.74e-24	Menopause (age at onset);
CESC	cis	rs4523957	0.583	rs7212589	chr17:2042393	A/G	cg16513277	chr17:2031491	SMG6	-0.79	-11.73	-0.58	6.95e-26	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs77972916	0.505	rs6756575	chr2:43528519	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-6.02	-0.35	5.74e-9	Granulocyte percentage of myeloid white cells;
CESC	cis	rs7267979	0.727	rs2474765	chr20:25245950	G/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.78	14.09	0.65	4.79e-34	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs2842992	0.714	rs2475564	chr6:160123673	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.75	8.83	0.48	1.45e-16	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs72781680	1.000	rs72796328	chr2:24141343	A/G	cg08917208	chr2:24149416	ATAD2B	1.1	9.84	0.52	1.09e-19	Lymphocyte counts;
CESC	cis	rs6736093	0.796	rs13024271	chr2:112814326	G/A	cg12686935	chr2:112915763	FBLN7	-0.42	-5.63	-0.33	4.68e-8	Coronary artery disease;
CESC	cis	rs853679	0.542	rs9380063	chr6:28137853	A/G	cg08968635	chr6:28129556	ZNF389	0.38	5.04	0.3	8.58e-7	Depression;
CESC	cis	rs7223966	1.000	rs6504171	chr17:61710010	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.46	-5.66	-0.33	3.84e-8	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs9303280	0.806	rs2305480	chr17:38062196	G/A	cg20243544	chr17:37824526	PNMT	0.53	6.87	0.39	4.54e-11	Self-reported allergy;
CESC	cis	rs2952156	0.920	rs907090	chr17:37833632	T/C	cg07936489	chr17:37558343	FBXL20	-0.62	-8.15	-0.45	1.42e-14	Asthma;
CESC	cis	rs7666738	0.830	rs6846739	chr4:99016647	G/A	cg17366294	chr4:99064904	C4orf37	0.61	8.77	0.47	2.15e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2180341	0.722	rs9388555	chr6:127576363	G/A	cg24812749	chr6:127587940	RNF146	0.85	11.86	0.59	2.68e-26	Breast cancer;
CESC	cis	rs425277	1.000	rs262651	chr1:2091397	A/G	cg24578937	chr1:2090814	PRKCZ	0.55	9.48	0.5	1.47e-18	Height;
CESC	cis	rs9649213	0.593	rs6465672	chr7:97963717	C/T	cg21770322	chr7:97807741	LMTK2	-0.55	-8.34	-0.46	4e-15	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs9788333	0.888	rs35880230	chr13:21885972	A/G	cg25811766	chr13:21894605	NA	0.76	10.27	0.53	4.91e-21	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs4332037	0.624	rs58169303	chr7:1883274	T/C	cg13880726	chr7:1868755	MAD1L1	-0.5	-5.25	-0.31	3.06e-7	Bipolar disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07867325	chr3:73159953	NA	-0.62	-7.43	-0.42	1.45e-12	Gut microbiome composition (summer);
CESC	cis	rs728616	0.867	rs61860400	chr10:81723427	T/C	cg05935833	chr10:81318306	SFTPA2	-0.51	-5.04	-0.3	8.51e-7	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs9911578	0.967	rs7222789	chr17:56819853	C/G	cg05425664	chr17:57184151	TRIM37	-0.49	-6.72	-0.38	1.11e-10	Intelligence (multi-trait analysis);
CESC	cis	rs397969	0.502	rs62066352	chr17:19902002	A/G	cg12073167	chr17:19770448	ULK2	-0.45	-5.08	-0.3	7.05e-7	Platelet count;
CESC	cis	rs9916302	0.904	rs2024073	chr17:37471330	T/G	cg15445000	chr17:37608096	MED1	-0.4	-6.54	-0.37	3.06e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg04234412	chr22:24373322	LOC391322	-0.49	-6.87	-0.39	4.6e-11	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs2985684	0.802	rs10150823	chr14:50051751	C/T	cg10008539	chr14:50087325	RPL36AL;MGAT2	-0.43	-5.25	-0.31	3.09e-7	Carotid intima media thickness;
CESC	cis	rs62064224	0.533	rs11657826	chr17:30790386	T/A	cg24550644	chr17:30846204	MYO1D	-0.34	-5.04	-0.3	8.63e-7	Schizophrenia;
CESC	cis	rs7520050	0.751	rs592214	chr1:46024505	G/A	cg24296786	chr1:45957014	TESK2	0.5	6.23	0.36	1.83e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs4819052	0.724	rs9753962	chr21:46661384	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.75	9.98	0.52	4.1e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs7267979	0.816	rs405822	chr20:25501314	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.79	14.8	0.67	1.56e-36	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs963731	0.522	rs13031871	chr2:39252851	T/G	cg04010122	chr2:39346883	SOS1	-0.58	-5.11	-0.3	6.03e-7	Corticobasal degeneration;
CESC	cis	rs11958404	0.932	rs112683473	chr5:157437819	T/C	cg05962755	chr5:157440814	NA	0.59	6.52	0.37	3.45e-10	IgG glycosylation;
CESC	cis	rs77741769	0.571	rs989986	chr12:121274178	A/C	cg02419362	chr12:121203948	SPPL3	0.34	5.5	0.32	8.97e-8	Mean corpuscular volume;
CESC	cis	rs1348850	0.914	rs7573763	chr2:178249808	C/T	cg22681709	chr2:178499509	PDE11A	-0.41	-5.88	-0.34	1.24e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs17376456	0.569	rs7735009	chr5:93260865	T/C	cg25358565	chr5:93447407	FAM172A	-0.47	-5.46	-0.32	1.09e-7	Diabetic retinopathy;
CESC	cis	rs863345	0.604	rs11265003	chr1:158490631	C/T	cg12129480	chr1:158549410	OR10X1	-0.34	-6.85	-0.39	5.17e-11	Pneumococcal bacteremia;
CESC	trans	rs1814175	0.647	rs2903409	chr11:49953612	C/G	cg03929089	chr4:120376271	NA	-0.73	-9.48	-0.5	1.52e-18	Height;
CESC	trans	rs804280	0.543	rs13261205	chr8:11791216	A/G	cg15556689	chr8:8085844	FLJ10661	0.52	6.41	0.37	6.53e-10	Myopia (pathological);
CESC	cis	rs10465746	0.780	rs11163872	chr1:84421969	G/T	cg10977910	chr1:84465055	TTLL7	0.52	7.13	0.4	9.81e-12	Obesity-related traits;
CESC	cis	rs17711722	0.701	rs55773927	chr7:65337902	T/C	cg05332525	chr7:65337924	VKORC1L1	0.52	6.39	0.37	7.52e-10	Calcium levels;
CESC	cis	rs17407555	0.821	rs4292329	chr4:10144459	C/G	cg11266682	chr4:10021025	SLC2A9	-0.52	-6.07	-0.35	4.35e-9	Schizophrenia (age at onset);
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg13859216	chr5:137910711	HSPA9	-0.44	-6.37	-0.36	8.42e-10	Vertical cup-disc ratio;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg19960880	chr10:97050830	PDLIM1	-0.5	-6.75	-0.38	9.45e-11	Fibrinogen levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00076353	chr20:442752	TBC1D20	0.55	6.11	0.35	3.52e-9	Gut microbiome composition (summer);
CESC	cis	rs8044868	0.586	rs2070937	chr16:72089740	A/G	cg01557791	chr16:72042693	DHODH	-0.42	-5.69	-0.33	3.29e-8	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CESC	cis	rs6088580	0.634	rs6088488	chr20:32992631	T/C	cg06115741	chr20:33292138	TP53INP2	-0.46	-5.96	-0.34	7.8e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs11583043	0.708	rs915405	chr1:101574145	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.51	5.56	0.32	6.53e-8	Ulcerative colitis;Inflammatory bowel disease;
CESC	cis	rs11203032	0.831	rs12217507	chr10:90922828	G/A	cg16672925	chr10:90967113	CH25H	0.74	6.99	0.39	2.26e-11	Heart failure;
CESC	cis	rs3858526	0.883	rs7481923	chr11:5933342	T/C	cg05234568	chr11:5960015	NA	-0.57	-6.71	-0.38	1.15e-10	DNA methylation (variation);
CESC	cis	rs1048238	0.846	rs945420	chr1:16345208	G/A	cg22431228	chr1:16359049	CLCNKA	-0.55	-11.0	-0.56	1.96e-23	Systolic blood pressure;
CESC	cis	rs2652834	0.851	rs16946416	chr15:63356721	A/T	cg05507819	chr15:63340323	TPM1	-0.62	-6.08	-0.35	4.22e-9	HDL cholesterol;
CESC	cis	rs71718386	1	rs71718386	chr13:41224287	CTATA/C	cg21288729	chr13:41239152	FOXO1	0.66	8.55	0.47	9.85e-16	Eosinophil counts;
CESC	cis	rs10791097	0.667	rs2155358	chr11:130740357	T/C	cg12179176	chr11:130786555	SNX19	0.64	10.04	0.52	2.69e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	trans	rs1850744	0.510	rs4697905	chr4:9889042	T/C	cg06372015	chr11:43602000	MIR129-2	0.59	6.19	0.36	2.26e-9	Economic and political preferences;
CESC	cis	rs12701220	0.655	rs7784403	chr7:1153077	G/A	cg00990874	chr7:1149470	C7orf50	-0.47	-5.06	-0.3	7.67e-7	Bronchopulmonary dysplasia;
CESC	trans	rs875971	0.660	rs10281080	chr7:66042441	T/C	cg26939375	chr7:64535504	NA	-0.64	-8.62	-0.47	6.05e-16	Aortic root size;
CESC	cis	rs8044868	0.530	rs3890860	chr16:72103409	A/G	cg16558253	chr16:72132732	DHX38	-0.39	-6.0	-0.35	6.38e-9	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11141692	chr4:111866916	NA	-0.55	-6.5	-0.37	3.96e-10	Gut microbiome composition (summer);
CESC	trans	rs9929218	0.954	rs60302411	chr16:68824220	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.62	-8.14	-0.45	1.51e-14	Colorectal cancer;
CESC	cis	rs7598759	0.548	rs11686485	chr2:232360697	C/T	cg19187155	chr2:232395269	NMUR1	0.61	10.22	0.53	7.11e-21	Noise-induced hearing loss;
CESC	cis	rs1707322	1.000	rs4660332	chr1:46461418	T/A	cg03146154	chr1:46216737	IPP	0.78	10.77	0.55	1.17e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs864537	0.618	rs2995089	chr1:167431193	G/A	cg22356347	chr1:167427500	CD247	-0.4	-8.24	-0.45	8.17e-15	Celiac disease or Rheumatoid arthritis;Celiac disease;
CESC	cis	rs2842992	0.768	rs2273824	chr6:160211445	C/T	cg11366901	chr6:160182831	ACAT2	0.64	8.17	0.45	1.24e-14	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs13191362	1.000	rs2156257	chr6:163100710	G/T	cg14584255	chr6:163149320	PACRG;PARK2	0.68	6.93	0.39	3.14e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs6456156	0.586	rs6456154	chr6:167472256	C/T	cg07741184	chr6:167504864	NA	0.36	6.21	0.36	2.01e-9	Primary biliary cholangitis;
CESC	cis	rs11098499	0.779	rs28495013	chr4:120375831	A/C	cg09307838	chr4:120376055	NA	0.94	13.7	0.64	1.18e-32	Corneal astigmatism;
CESC	cis	rs7762018	1.000	rs6912959	chr6:170126224	G/A	cg13891659	chr6:170190454	C6orf122;C6orf208	0.57	5.76	0.33	2.27e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02562419	chr6:159049626	TMEM181	-0.6	-7.18	-0.4	6.98e-12	Gut microbiome composition (summer);
CESC	cis	rs9584850	0.834	rs8481	chr13:99105395	G/A	cg22223119	chr13:99095684	FARP1	-0.36	-5.21	-0.31	3.73e-7	Neuroticism;
CESC	cis	rs514406	0.792	rs481440	chr1:53344976	C/T	cg16325326	chr1:53192061	ZYG11B	0.61	9.08	0.49	2.55e-17	Monocyte count;
CESC	cis	rs792448	0.743	rs351378	chr1:212425196	T/C	cg01059126	chr1:212459029	PPP2R5A	-0.42	-5.19	-0.3	4.19e-7	White blood cell count (basophil);
CESC	cis	rs873946	0.564	rs12772704	chr10:134557318	G/A	cg27286337	chr10:134555280	INPP5A	0.68	7.64	0.42	4.05e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg07677032	chr17:61819896	STRADA	0.45	6.06	0.35	4.7e-9	Prudent dietary pattern;
CESC	cis	rs4862750	0.872	rs6821507	chr4:187876829	G/T	cg22105103	chr4:187893119	NA	-0.49	-7.08	-0.4	1.32e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs12477438	0.501	rs12992218	chr2:99753834	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	15.46	0.69	7.45e-39	Chronic sinus infection;
CESC	cis	rs12476592	0.571	rs2176415	chr2:63636568	A/C	cg17519650	chr2:63277830	OTX1	-0.5	-5.31	-0.31	2.36e-7	Childhood ear infection;
CESC	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg11965913	chr1:205819406	PM20D1	0.81	13.52	0.64	5.03e-32	Menarche (age at onset);
CESC	cis	rs116095464	0.510	rs55750776	chr5:230467	T/C	cg22496380	chr5:211416	CCDC127	-0.74	-8.65	-0.47	5.2e-16	Breast cancer;
CESC	cis	rs9814567	1.000	rs9863786	chr3:134247203	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.45	-6.15	-0.35	2.87e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs7116495	1.000	rs7930721	chr11:71737481	C/A	cg26138937	chr11:71823887	C11orf51	-0.77	-6.19	-0.36	2.3e-9	Severe influenza A (H1N1) infection;
CESC	trans	rs748404	0.578	rs507178	chr15:43610135	A/G	cg24053811	chr14:70265306	SLC10A1	0.41	6.0	0.35	6.61e-9	Lung cancer;
CESC	cis	rs4077515	0.935	rs3812565	chr9:139272502	T/C	cg14019695	chr9:139328340	INPP5E	0.36	5.45	0.32	1.16e-7	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs7223966	0.960	rs7212379	chr17:61706122	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.47	-5.57	-0.32	6.28e-8	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs2637266	0.678	rs846580	chr10:78498184	G/A	cg18941641	chr10:78392320	NA	0.39	7.49	0.42	9.97e-13	Pulmonary function;
CESC	cis	rs35110281	0.776	rs9306159	chr21:45061839	G/T	cg21573476	chr21:45109991	RRP1B	-0.5	-6.84	-0.39	5.38e-11	Mean corpuscular volume;
CESC	cis	rs853679	0.517	rs9283884	chr6:28135660	C/G	cg20151795	chr6:28129481	ZNF389	-0.43	-5.51	-0.32	8.59e-8	Depression;
CESC	trans	rs17685	0.697	rs28689051	chr7:75763624	G/A	cg19862616	chr7:65841803	NCRNA00174	0.79	10.91	0.56	3.92e-23	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs6032067	0.929	rs56131549	chr20:43842014	A/T	cg10761708	chr20:43804764	PI3	0.5	5.94	0.34	8.83e-9	Blood protein levels;
CESC	trans	rs208520	0.526	rs9351542	chr6:66788571	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.1	-24.71	-0.84	9.81e-71	Exhaled nitric oxide output;
CESC	trans	rs6137287	0.924	rs6047279	chr20:21142353	C/T	cg18379495	chr8:37553668	ZNF703	-0.45	-6.35	-0.36	9.48e-10	Height;
CESC	cis	rs910316	1.000	rs1047418	chr14:75605792	A/G	cg08847533	chr14:75593920	NEK9	0.99	18.94	0.76	3.66e-51	Height;
CESC	cis	rs854765	0.604	rs12948749	chr17:17949802	G/A	cg09796270	chr17:17721594	SREBF1	-0.43	-6.04	-0.35	5.09e-9	Total body bone mineral density;
CESC	cis	rs4975616	0.804	rs456366	chr5:1337070	T/C	cg07493874	chr5:1342172	CLPTM1L	-0.42	-7.77	-0.43	1.68e-13	Lung cancer;
CESC	cis	rs7666738	0.822	rs13110418	chr4:99046963	G/A	cg05340658	chr4:99064831	C4orf37	0.82	12.88	0.62	8.44e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs801193	0.967	rs2707849	chr7:66152712	T/C	cg18876405	chr7:65276391	NA	0.54	7.28	0.41	3.88e-12	Aortic root size;
CESC	cis	rs2836974	0.897	rs2836933	chr21:40564202	C/G	cg11890956	chr21:40555474	PSMG1	1.19	22.54	0.81	1.51e-63	Cognitive function;
CESC	cis	rs8072100	0.667	rs1912485	chr17:45515678	T/G	cg08085267	chr17:45401833	C17orf57	-0.52	-6.6	-0.38	2.28e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg07491357	chr18:9914943	VAPA	0.45	6.06	0.35	4.73e-9	Systemic lupus erythematosus;
CESC	cis	rs780096	0.526	rs11127013	chr2:27692973	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.27	-5.32	-0.31	2.21e-7	Total body bone mineral density;
CESC	cis	rs116095464	0.558	rs73031482	chr5:227594	G/A	cg12570787	chr5:219185	SDHA;CCDC127	0.51	5.44	0.32	1.19e-7	Breast cancer;
CESC	trans	rs2115172	0.836	rs4835799	chr5:122762229	A/G	cg09379601	chr19:12992224	DNASE2	0.49	6.59	0.38	2.35e-10	Weight;
CESC	cis	rs7666738	0.830	rs3911282	chr4:99037602	T/A	cg05340658	chr4:99064831	C4orf37	0.82	12.87	0.62	9.38e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2228479	0.850	rs11639788	chr16:89807543	G/A	cg04013166	chr16:89971882	TCF25	0.76	6.51	0.37	3.75e-10	Skin colour saturation;
CESC	cis	rs2842992	0.789	rs2342446	chr6:160220687	A/G	cg11366901	chr6:160182831	ACAT2	0.76	9.31	0.5	4.95e-18	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs10927875	0.929	rs4661674	chr1:16296039	A/G	cg22431228	chr1:16359049	CLCNKA	0.38	5.86	0.34	1.41e-8	Dilated cardiomyopathy;
CESC	cis	rs10097731	0.908	rs28550260	chr8:82025584	T/C	cg25230327	chr8:82042993	NA	-0.61	-7.28	-0.41	3.86e-12	Serum total protein level;
CESC	cis	rs6448317	0.906	rs4053966	chr4:24901466	A/G	cg21108841	chr4:24914750	CCDC149	-0.51	-6.45	-0.37	5.39e-10	Heschl's gyrus morphology;
CESC	cis	rs875971	0.516	rs6945322	chr7:65336056	T/C	cg05332525	chr7:65337924	VKORC1L1	0.52	6.37	0.36	8.18e-10	Aortic root size;
CESC	cis	rs939658	0.776	rs68147688	chr15:79443848	G/A	cg17916960	chr15:79447300	NA	-0.36	-5.87	-0.34	1.28e-8	Refractive error;
CESC	cis	rs6963495	0.818	rs6956249	chr7:105149743	A/T	cg13798780	chr7:105162888	PUS7	0.76	7.8	0.43	1.47e-13	Bipolar disorder (body mass index interaction);
CESC	cis	rs67311347	1.000	rs6762251	chr3:40531136	A/G	cg01475735	chr3:40494733	NA	0.42	5.33	0.31	2.06e-7	Renal cell carcinoma;
CESC	cis	rs7833790	0.927	rs61020899	chr8:82757090	C/T	cg02079420	chr8:82753780	SNX16	-0.57	-7.71	-0.43	2.52e-13	Diastolic blood pressure;
CESC	cis	rs2980439	0.870	rs2945230	chr8:8109936	A/G	cg06636001	chr8:8085503	FLJ10661	0.57	7.08	0.4	1.28e-11	Neuroticism;
CESC	cis	rs2070488	0.775	rs2051213	chr3:38560254	C/T	cg24069376	chr3:38537580	EXOG	0.34	5.93	0.34	9.56e-9	Electrocardiographic conduction measures;
CESC	cis	rs9733	0.650	rs11204680	chr1:150587140	T/G	cg13175981	chr1:150552382	MCL1	0.72	10.82	0.55	7.62e-23	Tonsillectomy;
CESC	cis	rs4595586	0.525	rs1400279	chr12:39343825	T/A	cg26384229	chr12:38710491	ALG10B	0.63	8.79	0.48	1.9e-16	Morning vs. evening chronotype;
CESC	cis	rs11122272	0.735	rs2474631	chr1:231541341	T/A	cg06096015	chr1:231504339	EGLN1	0.41	5.67	0.33	3.75e-8	Hemoglobin concentration;
CESC	cis	rs9640161	0.789	rs2373751	chr7:150021599	G/C	cg10018233	chr7:150070692	REPIN1	0.4	5.47	0.32	1.06e-7	Blood protein levels;Circulating chemerin levels;
CESC	trans	rs1814175	0.645	rs28634872	chr11:50042175	T/A	cg15704280	chr7:45808275	SEPT13	-1.0	-18.7	-0.75	2.39e-50	Height;
CESC	cis	rs7553864	0.667	rs4656143	chr1:87605208	G/A	cg17420885	chr1:87600446	LOC339524	-0.42	-5.67	-0.33	3.7e-8	Smoking behavior;
CESC	cis	rs12900413	0.687	rs8034777	chr15:90313057	C/T	cg24249390	chr15:90295951	MESP1	0.4	5.62	0.33	4.75e-8	Coronary artery aneurysm in Kawasaki disease;
CESC	cis	rs8141529	1.000	rs8141529	chr22:29269692	A/G	cg02153584	chr22:29168773	CCDC117	0.46	5.73	0.33	2.72e-8	Lymphocyte counts;
CESC	cis	rs13095912	0.962	rs34505819	chr3:185340721	C/T	cg11274856	chr3:185301563	NA	0.34	5.49	0.32	9.19e-8	Systolic blood pressure;
CESC	cis	rs10504229	0.953	rs6985942	chr8:58173412	T/C	cg24829409	chr8:58192753	C8orf71	-0.62	-8.61	-0.47	6.73e-16	Developmental language disorder (linguistic errors);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg07379344	chr16:70147964	PDPR	-0.52	-6.27	-0.36	1.44e-9	Ulcerative colitis;
CESC	cis	rs7843479	0.601	rs2002941	chr8:21834366	A/C	cg17168535	chr8:21777572	XPO7	0.73	11.8	0.59	4.28e-26	Mean corpuscular volume;
CESC	cis	rs3820068	0.705	rs4646103	chr1:15819827	T/A	cg18192808	chr1:15853278	DNAJC16	0.48	5.81	0.34	1.77e-8	Systolic blood pressure;
CESC	cis	rs763121	0.925	rs17032	chr22:39130843	C/G	cg06022373	chr22:39101656	GTPBP1	0.88	15.38	0.69	1.34e-38	Menopause (age at onset);
CESC	cis	rs1218582	0.772	rs4845689	chr1:154885524	A/G	cg16680214	chr1:154839983	KCNN3	-0.44	-6.72	-0.38	1.1e-10	Prostate cancer;
CESC	cis	rs10504229	0.595	rs79077737	chr8:58117520	G/A	cg24829409	chr8:58192753	C8orf71	-0.58	-7.21	-0.41	5.76e-12	Developmental language disorder (linguistic errors);
CESC	trans	rs11088226	1.000	rs2833890	chr21:33927886	A/G	cg09050820	chr6:167586206	TCP10L2	-0.62	-6.58	-0.37	2.44e-10	Gastritis;
CESC	cis	rs11785693	0.862	rs62489554	chr8:4960685	T/C	cg26367366	chr8:4980734	NA	0.67	6.32	0.36	1.09e-9	Neuroticism (multi-trait analysis);Neuroticism;
CESC	cis	rs17666538	0.585	rs6559065	chr8:623156	G/C	cg02524346	chr8:600233	NA	0.84	5.97	0.34	7.53e-9	IgG glycosylation;
CESC	cis	rs2180341	0.889	rs2000909	chr6:127711173	G/A	cg24812749	chr6:127587940	RNF146	0.81	11.3	0.57	1.96e-24	Breast cancer;
CESC	cis	rs2760061	0.626	rs594916	chr1:228133544	C/A	cg02753203	chr1:228287806	NA	-0.5	-7.22	-0.41	5.51e-12	Diastolic blood pressure;
CESC	cis	rs9790314	0.846	rs7627528	chr3:160990878	A/G	cg03342759	chr3:160939853	NMD3	-0.5	-7.13	-0.4	9.71e-12	Morning vs. evening chronotype;
CESC	cis	rs4853012	1.000	rs2280643	chr2:74358286	T/C	cg05776053	chr2:74358815	NA	0.42	5.17	0.3	4.65e-7	Gestational age at birth (maternal effect);
CESC	trans	rs11098499	0.615	rs59867181	chr4:120556467	C/T	cg25214090	chr10:38739885	LOC399744	-0.56	-7.97	-0.44	4.84e-14	Corneal astigmatism;
CESC	cis	rs1559088	0.948	rs2019603	chr19:33577367	C/T	cg27124370	chr19:33622961	WDR88	-0.48	-6.43	-0.37	6.02e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg04370807	chr17:29248951	ADAP2	-0.42	-6.02	-0.35	5.93e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs9611565	0.559	rs132765	chr22:42008068	A/G	cg03806693	chr22:41940476	POLR3H	1.1	12.65	0.61	5.01e-29	Vitiligo;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04324509	chr3:101295624	PCNP	-0.55	-6.49	-0.37	4.3e-10	Gut microbiome composition (summer);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg05809890	chr11:1491432	HCCA2	0.53	7.6	0.42	5.05e-13	Fibrinogen levels;
CESC	cis	rs2404602	0.692	rs4886503	chr15:77108874	C/T	cg26408565	chr15:76604113	ETFA	0.4	5.76	0.33	2.32e-8	Blood metabolite levels;
CESC	cis	rs1862618	0.802	rs7733041	chr5:56107377	A/C	cg18230493	chr5:56204884	C5orf35	-0.65	-7.83	-0.43	1.19e-13	Initial pursuit acceleration;
CESC	cis	rs7264396	0.836	rs4911183	chr20:34181553	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	0.62	7.74	0.43	2.06e-13	Total cholesterol levels;
CESC	cis	rs5769765	0.837	rs8142737	chr22:50291889	T/C	cg02269571	chr22:50332266	NA	-0.46	-6.1	-0.35	3.76e-9	Schizophrenia;
CESC	cis	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg23048001	chr7:2026167	MAD1L1	0.43	5.76	0.33	2.39e-8	Bipolar disorder and schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09235138	chr15:40987404	RAD51	0.59	6.92	0.39	3.31e-11	Gut microbiome composition (summer);
CESC	cis	rs1865721	1.000	rs62089507	chr18:73179019	C/T	cg26385618	chr18:73139727	C18orf62	-0.52	-7.51	-0.42	8.78e-13	Intelligence;
CESC	cis	rs2836974	0.796	rs77153312	chr21:40695499	G/A	cg22974920	chr21:40686053	BRWD1	0.46	5.33	0.31	2.07e-7	Cognitive function;
CESC	cis	rs4523957	0.928	rs177567	chr17:2197637	A/G	cg16513277	chr17:2031491	SMG6	-0.6	-8.33	-0.46	4.51e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs4523957	0.620	rs9912385	chr17:2062591	T/G	cg16513277	chr17:2031491	SMG6	-0.72	-10.2	-0.53	8.12e-21	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs1018836	0.886	rs12545351	chr8:91636668	C/T	cg16814680	chr8:91681699	NA	-0.73	-11.15	-0.57	6.08e-24	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs7666738	0.830	rs7684646	chr4:99071062	C/T	cg03676636	chr4:99064102	C4orf37	0.33	5.05	0.3	8.23e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs13191362	0.935	rs34934114	chr6:163082480	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.95	9.59	0.51	7e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs9815354	1.000	rs73081364	chr3:41913616	G/C	cg03022575	chr3:42003672	ULK4	0.57	5.88	0.34	1.2e-8	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs9323205	1.000	rs7149022	chr14:51613980	A/C	cg23942311	chr14:51606299	NA	-0.45	-5.75	-0.33	2.5e-8	Cancer;
CESC	cis	rs873946	0.648	rs1543593	chr10:134553185	A/T	cg26818010	chr10:134567672	INPP5A	-0.87	-10.51	-0.54	8.06e-22	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs1552244	0.882	rs2030564	chr3:10039044	A/G	cg00149659	chr3:10157352	C3orf10	0.7	8.27	0.45	6.42e-15	Alzheimer's disease;
CESC	cis	rs703842	0.616	rs10783851	chr12:58231155	A/G	cg02175503	chr12:58329896	NA	-0.48	-5.76	-0.33	2.29e-8	Multiple sclerosis;
CESC	cis	rs9811920	0.599	rs1688758	chr3:99539890	A/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.4	5.4	0.31	1.48e-7	Axial length;
CESC	cis	rs829883	0.659	rs11109521	chr12:98930809	C/A	cg25150519	chr12:98850993	NA	-0.64	-7.87	-0.44	8.8e-14	Colorectal adenoma (advanced);
CESC	cis	rs9300255	0.516	rs6488868	chr12:123799974	A/G	cg00376283	chr12:123451042	ABCB9	0.55	6.6	0.38	2.19e-10	Neutrophil percentage of white cells;
CESC	cis	rs3820928	0.874	rs1917125	chr2:227798981	G/A	cg11843606	chr2:227700838	RHBDD1	-0.43	-5.75	-0.33	2.45e-8	Pulmonary function;
CESC	cis	rs597539	0.617	rs672853	chr11:68636362	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.78	9.33	0.5	4.32e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	trans	rs561341	0.714	rs473535	chr17:30312365	A/G	cg20587970	chr11:113659929	NA	-1.36	-16.67	-0.72	3.75e-43	Hip circumference adjusted for BMI;
CESC	cis	rs780094	0.585	rs7586601	chr2:27584666	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.26	-5.39	-0.31	1.57e-7	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
CESC	cis	rs4689388	0.890	rs6838400	chr4:6295427	C/G	cg14416269	chr4:6271139	WFS1	0.46	7.76	0.43	1.79e-13	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs6500602	0.702	rs9929475	chr16:4540885	C/T	cg08645402	chr16:4508243	NA	-0.52	-8.01	-0.44	3.72e-14	Schizophrenia;
CESC	cis	rs10752881	1.000	rs12403189	chr1:182983832	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.83	13.25	0.63	4.18e-31	Colorectal cancer;
CESC	cis	rs4820539	0.708	rs5751591	chr22:23489042	G/A	cg14186256	chr22:23484241	RTDR1	0.66	9.66	0.51	4.22e-19	Bone mineral density;
CESC	cis	rs963731	0.522	rs7607509	chr2:39285372	A/G	cg04010122	chr2:39346883	SOS1	-0.57	-5.14	-0.3	5.26e-7	Corticobasal degeneration;
CESC	cis	rs854765	0.583	rs6502627	chr17:17849671	C/T	cg09796270	chr17:17721594	SREBF1	0.45	6.15	0.35	2.87e-9	Total body bone mineral density;
CESC	cis	rs910316	0.934	rs4903278	chr14:75535019	C/A	cg08847533	chr14:75593920	NEK9	1.0	18.93	0.76	3.73e-51	Height;
CESC	cis	rs2404602	0.647	rs4886837	chr15:77156417	A/G	cg23625390	chr15:77176239	SCAPER	-0.45	-6.35	-0.36	9.29e-10	Blood metabolite levels;
CESC	cis	rs34779708	0.931	rs10437420	chr10:35335044	A/C	cg04310649	chr10:35416472	CREM	0.54	6.54	0.37	3.09e-10	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs7680126	0.633	rs74469609	chr4:10294424	G/A	cg00071950	chr4:10020882	SLC2A9	-0.53	-5.89	-0.34	1.19e-8	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	cis	rs7772486	0.776	rs4316025	chr6:146238032	C/T	cg23711669	chr6:146136114	FBXO30	-0.77	-10.91	-0.56	3.81e-23	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs300703	0.935	rs417829	chr2:206851	A/G	cg21211680	chr2:198530	NA	0.8	7.84	0.43	1.1e-13	Blood protein levels;
CESC	cis	rs2576037	0.583	rs8096263	chr18:44515216	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.49	-6.6	-0.38	2.28e-10	Personality dimensions;
CESC	cis	rs2066819	1.000	rs2629447	chr12:56700809	G/A	cg26734620	chr12:56694298	CS	-0.92	-9.33	-0.5	4.31e-18	Psoriasis vulgaris;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01040181	chr8:146278358	C8orf33	0.54	6.4	0.37	6.89e-10	Gut microbiome composition (summer);
CESC	cis	rs12410462	1.000	rs75198003	chr1:227623853	C/A	cg23173402	chr1:227635558	NA	0.57	5.92	0.34	9.9e-9	Major depressive disorder;
CESC	cis	rs798554	0.704	rs798531	chr7:2770067	G/C	cg19717773	chr7:2847554	GNA12	-0.56	-8.81	-0.48	1.66e-16	Height;
CESC	cis	rs5753618	0.561	rs737684	chr22:31659827	C/G	cg13145458	chr22:31556086	RNF185	0.46	5.24	0.31	3.26e-7	Colorectal cancer;
CESC	cis	rs5758659	0.714	rs6002607	chr22:42496506	C/T	cg05082376	chr22:42548792	NA	0.36	5.23	0.31	3.46e-7	Cognitive function;
CESC	cis	rs919433	0.889	rs788004	chr2:198219032	C/T	cg10820045	chr2:198174542	NA	0.39	5.78	0.33	2.05e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs4973397	0.643	rs2034413	chr2:232288149	C/T	cg09339159	chr2:232260559	B3GNT7	0.51	6.25	0.36	1.59e-9	Anti-saccade response;
CESC	cis	rs4555082	0.834	rs28489970	chr14:105748862	T/C	cg13114125	chr14:105738426	BRF1	-0.86	-10.36	-0.54	2.37e-21	Mean platelet volume;Platelet distribution width;
CESC	cis	rs2836974	0.897	rs34035316	chr21:40594023	T/C	cg11644478	chr21:40555479	PSMG1	1.05	17.06	0.72	1.55e-44	Cognitive function;
CESC	cis	rs778371	0.915	rs938569	chr2:233759695	C/G	cg08000102	chr2:233561755	GIGYF2	0.76	11.65	0.58	1.32e-25	Schizophrenia;
CESC	cis	rs7666738	0.830	rs10050008	chr4:99025313	T/G	cg18180107	chr4:99064573	C4orf37	0.42	5.43	0.32	1.29e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg07414643	chr4:187882934	NA	0.57	8.41	0.46	2.53e-15	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1552244	0.935	rs2272124	chr3:10138189	T/C	cg00166722	chr3:10149974	C3orf24	0.46	5.95	0.34	8.35e-9	Alzheimer's disease;
CESC	cis	rs1018836	0.608	rs10094978	chr8:91509054	C/T	cg16814680	chr8:91681699	NA	-0.55	-7.74	-0.43	2.15e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs67460515	0.500	rs9860537	chr3:160660500	G/T	cg03342759	chr3:160939853	NMD3	0.45	5.45	0.32	1.17e-7	Parkinson's disease;
CESC	cis	rs7590368	0.673	rs17365209	chr2:10939117	C/T	cg15705551	chr2:10952987	PDIA6	0.54	5.2	0.3	4.08e-7	Educational attainment (years of education);
CESC	cis	rs9733	0.596	rs11204704	chr1:150671630	T/C	cg22823121	chr1:150693482	HORMAD1	0.48	7.06	0.4	1.48e-11	Tonsillectomy;
CESC	cis	rs875971	0.862	rs778734	chr7:65814849	C/G	cg18252515	chr7:66147081	NA	-0.39	-5.12	-0.3	5.92e-7	Aortic root size;
CESC	cis	rs4253772	0.550	rs6008601	chr22:46705326	C/G	cg18190219	chr22:46762943	CELSR1	-0.61	-6.68	-0.38	1.37e-10	LDL cholesterol;Cholesterol, total;
CESC	cis	rs4665809	0.556	rs6730311	chr2:26419474	C/T	cg22920501	chr2:26401640	FAM59B	-0.92	-11.65	-0.58	1.33e-25	Gut microbiome composition (summer);
CESC	trans	rs11098499	1.000	rs7659194	chr4:120207147	T/G	cg25214090	chr10:38739885	LOC399744	0.67	9.18	0.49	1.26e-17	Corneal astigmatism;
CESC	cis	rs8018967	0.622	rs2041073	chr14:73972535	C/T	cg09844916	chr14:74004424	HEATR4;ACOT1	-0.44	-5.48	-0.32	1.01e-7	Blood metabolite ratios;
CESC	cis	rs941873	0.868	rs2233718	chr10:81108956	A/G	cg08514558	chr10:81106712	PPIF	0.32	5.49	0.32	9.19e-8	Height;
CESC	cis	rs4975616	0.804	rs462608	chr5:1336626	T/A	cg07493874	chr5:1342172	CLPTM1L	-0.4	-7.5	-0.42	9.41e-13	Lung cancer;
CESC	cis	rs6696846	0.791	rs7520752	chr1:205054114	C/T	cg00857998	chr1:205179979	DSTYK	-0.53	-6.98	-0.39	2.42e-11	Red blood cell count;
CESC	cis	rs10129255	0.500	rs6576225	chr14:107186359	G/C	cg07958169	chr14:107095056	NA	-0.54	-8.49	-0.46	1.51e-15	Kawasaki disease;
CESC	cis	rs9303401	0.580	rs2013166	chr17:56637630	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.03	12.7	0.62	3.56e-29	Cognitive test performance;
CESC	cis	rs1799949	0.930	rs34210004	chr17:41370337	A/T	cg05368731	chr17:41323189	NBR1	0.58	7.83	0.43	1.18e-13	Menopause (age at onset);
CESC	cis	rs6424115	0.867	rs34902309	chr1:24192200	A/G	cg10978503	chr1:24200527	CNR2	-0.29	-5.67	-0.33	3.78e-8	Immature fraction of reticulocytes;
CESC	cis	rs1552244	1.000	rs111392584	chr3:10075991	A/G	cg00166722	chr3:10149974	C3orf24	0.47	5.95	0.34	8.68e-9	Alzheimer's disease;
CESC	cis	rs7223966	1.000	rs8081612	chr17:61724695	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.46	5.56	0.32	6.44e-8	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs4561483	0.603	rs7202065	chr16:11951045	C/T	cg08843971	chr16:11963173	GSPT1	0.47	6.49	0.37	4.25e-10	Testicular germ cell tumor;
CESC	cis	rs780096	0.546	rs2293571	chr2:27729480	C/T	cg21248554	chr2:27665150	KRTCAP3	-0.36	-7.38	-0.41	2.05e-12	Total body bone mineral density;
CESC	trans	rs208520	0.690	rs1885100	chr6:66871047	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.99	-13.06	-0.63	1.94e-30	Exhaled nitric oxide output;
CESC	cis	rs9811920	0.638	rs10936008	chr3:99686665	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.57	9.11	0.49	2.08e-17	Axial length;
CESC	cis	rs35110281	0.715	rs969060	chr21:45080852	T/G	cg21573476	chr21:45109991	RRP1B	-0.55	-7.58	-0.42	6.01e-13	Mean corpuscular volume;
CESC	cis	rs728616	0.614	rs61859191	chr10:82091027	T/C	cg05935833	chr10:81318306	SFTPA2	-0.47	-5.98	-0.34	7.22e-9	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs9916302	0.904	rs7208274	chr17:37513796	C/T	cg00129232	chr17:37814104	STARD3	0.57	7.44	0.42	1.38e-12	Glomerular filtration rate (creatinine);
CESC	cis	rs1862618	0.853	rs1423620	chr5:56100996	G/T	cg12311346	chr5:56204834	C5orf35	-0.6	-7.41	-0.41	1.73e-12	Initial pursuit acceleration;
CESC	cis	rs514406	0.505	rs437954	chr1:53173321	C/G	cg24675658	chr1:53192096	ZYG11B	-0.54	-6.64	-0.38	1.78e-10	Monocyte count;
CESC	cis	rs35995292	0.500	rs2392606	chr7:38926955	C/A	cg19327137	chr7:38886074	VPS41	0.67	11.08	0.56	1.1e-23	Subjective well-being (multi-trait analysis);
CESC	cis	rs9733	0.596	rs11803569	chr1:150664077	C/T	cg09365446	chr1:150670422	GOLPH3L	0.42	5.91	0.34	1.03e-8	Tonsillectomy;
CESC	cis	rs2404602	0.716	rs4079681	chr15:76695230	G/A	cg22467129	chr15:76604101	ETFA	-0.38	-5.67	-0.33	3.78e-8	Blood metabolite levels;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg00873521	chr9:95056130	IARS;SNORA84	-0.47	-6.11	-0.35	3.51e-9	Height;
CESC	cis	rs644799	1.000	rs1944074	chr11:95511445	C/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.55	6.89	0.39	4e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs6088590	1.000	rs6088607	chr20:33378733	C/T	cg24642439	chr20:33292090	TP53INP2	0.84	11.75	0.59	6.33e-26	Coronary artery disease;
CESC	cis	rs6499188	0.522	rs10153230	chr16:68671741	C/G	cg02972257	chr16:68554789	NA	-0.61	-7.18	-0.4	7.07e-12	Ulcerative colitis;
CESC	cis	rs7959452	0.530	rs12811632	chr12:69755003	G/A	cg22834771	chr12:69754056	YEATS4	-0.46	-6.11	-0.35	3.64e-9	Blood protein levels;
CESC	cis	rs16867321	0.901	rs768116	chr2:181511012	A/G	cg23363182	chr2:181467187	NA	-0.45	-5.65	-0.33	4.19e-8	Obesity;
CESC	cis	rs4665809	0.590	rs34728554	chr2:26481959	C/G	cg26119090	chr2:26468346	HADHA;HADHB	1.1	12.71	0.62	3.31e-29	Gut microbiome composition (summer);
CESC	cis	rs10779751	1.000	rs1135172	chr1:11301714	C/T	cg08854313	chr1:11322531	MTOR	-0.83	-11.94	-0.59	1.38e-26	Body mass index;
CESC	cis	rs870825	0.721	rs72703528	chr4:185607311	A/G	cg04058563	chr4:185651563	MLF1IP	0.6	5.43	0.32	1.28e-7	Blood protein levels;
CESC	cis	rs1003719	0.680	rs1034357	chr21:38571482	G/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.61	-8.29	-0.45	5.58e-15	Eye color traits;
CESC	cis	rs950169	0.840	rs2896002	chr15:84945121	A/G	cg17507749	chr15:85114479	UBE2QP1	0.6	6.65	0.38	1.66e-10	Schizophrenia;
CESC	cis	rs709400	1.000	rs861536	chr14:104167564	A/G	cg12935359	chr14:103987150	CKB	-0.47	-6.25	-0.36	1.59e-9	Body mass index;
CESC	cis	rs11577318	0.853	rs12743998	chr1:26629882	G/A	cg00852783	chr1:26633632	UBXN11	0.5	6.99	0.39	2.17e-11	Granulocyte percentage of myeloid white cells;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04346366	chr12:117257441	RNFT2	0.57	6.11	0.35	3.54e-9	Gut microbiome composition (summer);
CESC	trans	rs1814175	0.645	rs1818895	chr11:50031523	G/T	cg03929089	chr4:120376271	NA	-0.91	-14.76	-0.67	2.17e-36	Height;
CESC	cis	rs1048238	0.545	rs848199	chr1:16292742	C/T	cg21385522	chr1:16154831	NA	-0.46	-5.94	-0.34	9.13e-9	Systolic blood pressure;
CESC	cis	rs9488822	0.676	rs12202181	chr6:116327102	A/G	cg18764771	chr6:116381957	FRK	0.22	5.42	0.32	1.35e-7	Cholesterol, total;LDL cholesterol;
CESC	cis	rs2180341	0.782	rs6569490	chr6:127729615	C/T	cg27446573	chr6:127587934	RNF146	0.83	12.03	0.59	6.99e-27	Breast cancer;
CESC	cis	rs8060686	0.516	rs7197756	chr16:68275516	A/C	cg26727032	chr16:67993705	SLC12A4	-0.6	-8.67	-0.47	4.34e-16	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs1691799	0.899	rs1177555	chr12:66727568	A/G	cg16791601	chr12:66731901	HELB	-0.73	-12.46	-0.61	2.25e-28	White blood cell count (basophil);
CESC	cis	rs9322193	0.926	rs9766562	chr6:150109845	C/G	cg04369109	chr6:150039330	LATS1	-0.4	-5.39	-0.31	1.58e-7	Lung cancer;
CESC	cis	rs6693567	0.565	rs698914	chr1:150298750	A/G	cg09579323	chr1:150459698	TARS2	0.5	6.24	0.36	1.75e-9	Migraine;
CESC	cis	rs4665809	1.000	rs10182857	chr2:26344411	C/T	cg04944784	chr2:26401820	FAM59B	-0.66	-7.62	-0.42	4.62e-13	Gut microbiome composition (summer);
CESC	cis	rs780094	0.585	rs3739095	chr2:27556721	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.27	-5.43	-0.32	1.3e-7	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
CESC	cis	rs8017423	0.967	rs4904662	chr14:90729427	G/A	cg14092571	chr14:90743983	NA	-0.56	-8.38	-0.46	3.07e-15	Mortality in heart failure;
CESC	trans	rs11088226	0.846	rs13047501	chr21:33924660	G/A	cg09050820	chr6:167586206	TCP10L2	0.63	6.85	0.39	5.21e-11	Gastritis;
CESC	cis	rs7633770	0.841	rs11709020	chr3:46680063	A/G	cg11219411	chr3:46661640	NA	-0.37	-5.2	-0.3	4.04e-7	Coronary artery disease;
CESC	cis	rs3796352	1.000	rs11718538	chr3:52975987	C/G	cg12962167	chr3:53033115	SFMBT1	0.6	5.09	0.3	6.95e-7	Immune reponse to smallpox (secreted IL-2);
CESC	cis	rs4472734	1.000	rs11120326	chr1:214626321	T/C	cg00063699	chr1:214624242	PTPN14	-0.33	-5.11	-0.3	6.06e-7	Height;
CESC	cis	rs35306767	0.903	rs12249634	chr10:872744	G/A	cg10556349	chr10:835070	NA	0.59	5.46	0.32	1.11e-7	Eosinophil percentage of granulocytes;
CESC	cis	rs7666738	0.830	rs13138438	chr4:99050545	C/A	cg03676636	chr4:99064102	C4orf37	0.33	5.12	0.3	5.93e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01923523	chr1:3712654	LRRC47	0.57	6.68	0.38	1.41e-10	Gut microbiome composition (summer);
CESC	cis	rs72945132	0.823	rs12292240	chr11:70152612	T/C	cg00319359	chr11:70116639	PPFIA1	0.78	7.71	0.43	2.52e-13	Coronary artery disease;
CESC	cis	rs748404	0.660	rs690367	chr15:43748304	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.58	-7.46	-0.42	1.24e-12	Lung cancer;
CESC	cis	rs3858526	0.523	rs10769287	chr11:5884845	T/C	cg13902645	chr11:5959945	NA	-0.67	-9.87	-0.52	8.74e-20	DNA methylation (variation);
CESC	cis	rs561341	0.941	rs17780086	chr17:30343282	G/A	cg23018236	chr17:30244563	NA	-0.54	-5.08	-0.3	7.28e-7	Hip circumference adjusted for BMI;
CESC	cis	rs2637266	0.538	rs11001850	chr10:78425431	C/T	cg18941641	chr10:78392320	NA	-0.32	-5.12	-0.3	5.81e-7	Pulmonary function;
CESC	cis	rs208520	0.690	rs207082	chr6:66773796	G/A	cg07460842	chr6:66804631	NA	-0.98	-12.95	-0.62	4.75e-30	Exhaled nitric oxide output;
CESC	cis	rs1552244	0.882	rs3732967	chr3:10015437	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.76	-9.64	-0.51	4.86e-19	Alzheimer's disease;
CESC	cis	rs9346455	0.614	rs9354989	chr6:72022171	T/C	cg27238071	chr6:71998145	OGFRL1	0.56	5.34	0.31	2e-7	Antipsychotic drug-induced weight gain (time interaction);Antipsychotic drug-induced weight gain;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02530705	chr16:2518497	NA	0.6	7.15	0.4	8.53e-12	Gut microbiome composition (summer);
CESC	cis	rs28647808	0.881	rs41297211	chr9:136260721	G/A	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.85	5.74	0.33	2.59e-8	Blood protein levels;
CESC	cis	rs7809950	1.000	rs6976607	chr7:107223401	A/C	cg23024343	chr7:107201750	COG5	0.44	5.95	0.34	8.24e-9	Coronary artery disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg24601517	chr6:5004202	RPP40	-0.52	-7.37	-0.41	2.18e-12	Fibrinogen levels;
CESC	cis	rs3096299	0.685	rs3803682	chr16:89544636	C/T	cg00750074	chr16:89608354	SPG7	-0.41	-6.02	-0.35	5.8e-9	Multiple myeloma (IgH translocation);
CESC	cis	rs597539	0.690	rs552517	chr11:68625286	T/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.81	9.87	0.52	8.87e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs10870270	0.956	rs4131689	chr10:133744328	A/C	cg17892150	chr10:133769511	PPP2R2D	0.85	12.55	0.61	1.17e-28	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs3092073	0.617	rs3893276	chr20:44591089	G/C	cg27529037	chr20:44575021	PCIF1	-0.39	-5.15	-0.3	5.03e-7	Intelligence (multi-trait analysis);
CESC	cis	rs7296418	0.630	rs11057238	chr12:123767971	C/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.33	-5.2	-0.3	3.9e-7	Platelet count;
CESC	cis	rs7520050	0.966	rs2275426	chr1:46487552	G/A	cg03146154	chr1:46216737	IPP	-0.47	-6.03	-0.35	5.46e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs4819052	0.851	rs1056100	chr21:46678711	A/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.81	11.01	0.56	1.89e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs853679	0.517	rs9295761	chr6:28147987	A/G	cg17949981	chr6:28129498	ZNF389	0.42	5.24	0.31	3.34e-7	Depression;
CESC	cis	rs4713118	0.662	rs149969	chr6:27977737	A/G	cg20151795	chr6:28129481	ZNF389	0.4	5.43	0.32	1.29e-7	Parkinson's disease;
CESC	cis	rs12142240	0.698	rs1135459	chr1:46815930	C/T	cg00530320	chr1:46809349	NSUN4	0.58	7.89	0.44	8.17e-14	Menopause (age at onset);
CESC	cis	rs11792861	0.816	rs11788336	chr9:111688387	T/C	cg13535736	chr9:111863775	C9orf5	-0.46	-6.08	-0.35	4.18e-9	Menarche (age at onset);
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg21601059	chr12:56122983	CD63	0.49	6.62	0.38	2.04e-10	Thyroid stimulating hormone;
CESC	cis	rs910316	0.763	rs4556	chr14:75476071	G/C	cg11812906	chr14:75593930	NEK9	0.78	12.34	0.6	6.0500000000000004e-28	Height;
CESC	cis	rs2576037	0.623	rs2576042	chr18:44577461	T/C	cg19077165	chr18:44547161	KATNAL2	0.59	8.87	0.48	1.09e-16	Personality dimensions;
CESC	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg26338869	chr17:61819248	STRADA	-0.79	-10.55	-0.54	5.75e-22	Prudent dietary pattern;
CESC	trans	rs9987353	0.840	rs329994	chr8:9123233	A/G	cg16698583	chr5:138534147	SIL1	-0.48	-6.23	-0.36	1.82e-9	Recombination measurement;
CESC	cis	rs2880765	0.835	rs28874135	chr15:86031503	G/A	cg19183879	chr15:85880815	NA	-0.25	-5.26	-0.31	3.03e-7	Coronary artery disease;
CESC	cis	rs3733346	0.553	rs6813110	chr4:942660	C/T	cg23939001	chr4:940644	TMEM175	0.47	7.33	0.41	2.85e-12	Sjögren's syndrome;
CESC	trans	rs1814175	0.781	rs28681334	chr11:50051177	C/T	cg15704280	chr7:45808275	SEPT13	-1.05	-21.04	-0.79	1.87e-58	Height;
CESC	trans	rs6027005	1.000	rs7261037	chr20:58196703	A/C	cg19657214	chr8:6794872	DEFA4	0.87	6.01	0.35	6.02e-9	Intelligence (multi-trait analysis);
CESC	cis	rs42648	0.837	rs10262603	chr7:89909442	G/A	cg23697855	chr7:89950296	NA	0.27	5.14	0.3	5.43e-7	Homocysteine levels;
CESC	cis	rs853679	0.882	rs9461432	chr6:28086883	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.73	-6.54	-0.37	3.21e-10	Depression;
CESC	cis	rs6089829	0.962	rs6122352	chr20:61668284	T/C	cg03213289	chr20:61660250	NA	0.39	6.06	0.35	4.6e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7772486	0.875	rs2814866	chr6:146339414	C/A	cg23711669	chr6:146136114	FBXO30	0.77	11.07	0.56	1.17e-23	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2230307	0.536	rs834277	chr1:100510855	T/G	cg24955406	chr1:100503596	HIAT1	0.56	5.47	0.32	1.06e-7	Carotid intima media thickness;
CESC	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg03452623	chr4:187889614	NA	-0.88	-15.96	-0.7	1.25e-40	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2839186	0.504	rs4347941	chr21:47938239	T/C	cg12379764	chr21:47803548	PCNT	0.64	8.84	0.48	1.34e-16	Testicular germ cell tumor;
CESC	cis	rs7772486	0.875	rs9403765	chr6:146368041	C/T	cg05347473	chr6:146136440	FBXO30	-0.5	-6.46	-0.37	5.12e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4242434	0.819	rs7843128	chr8:22473465	T/C	cg03733263	chr8:22462867	KIAA1967	0.87	14.35	0.66	6.02e-35	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CESC	cis	rs7210086	0.799	rs58953467	chr17:70636980	T/A	cg04206342	chr17:70636940	NA	-0.31	-5.48	-0.32	9.7e-8	Ulcerative colitis;
CESC	cis	rs9790314	0.934	rs9290074	chr3:160997823	T/C	cg03342759	chr3:160939853	NMD3	-0.45	-5.9	-0.34	1.08e-8	Morning vs. evening chronotype;
CESC	cis	rs12135062	0.687	rs6685614	chr1:3108517	C/T	cg21609526	chr1:3105151	PRDM16	0.35	5.56	0.32	6.49e-8	Migraine;
CESC	cis	rs10744422	1.000	rs10744422	chr12:123336789	T/C	cg25930673	chr12:123319894	HIP1R	-0.83	-6.31	-0.36	1.15e-9	Schizophrenia;
CESC	cis	rs7474896	0.583	rs10740950	chr10:38003496	C/T	cg00409905	chr10:38381863	ZNF37A	-0.46	-5.36	-0.31	1.85e-7	Obesity (extreme);
CESC	cis	rs9303401	0.538	rs12603174	chr17:56489279	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.9	10.65	0.55	2.76e-22	Cognitive test performance;
CESC	trans	rs3780486	0.505	rs10217267	chr9:33146528	T/C	cg20290983	chr6:43655470	MRPS18A	0.73	11.27	0.57	2.6e-24	IgG glycosylation;
CESC	cis	rs1371867	0.875	rs1619759	chr8:101337560	T/C	cg11906718	chr8:101322791	RNF19A	0.54	6.86	0.39	4.86e-11	Atrioventricular conduction;
CESC	cis	rs6963495	0.719	rs73190174	chr7:105161216	T/G	cg02135003	chr7:105160482	PUS7	-0.46	-5.55	-0.32	6.92e-8	Bipolar disorder (body mass index interaction);
CESC	cis	rs7267979	0.546	rs8115804	chr20:25438783	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.67	-10.32	-0.54	3.3e-21	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs12410462	0.581	rs7547204	chr1:227560909	C/T	cg04117972	chr1:227635322	NA	0.68	5.8	0.34	1.89e-8	Major depressive disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24149930	chr19:33182641	NUDT19	0.64	7.71	0.43	2.51e-13	Gut microbiome composition (summer);
CESC	cis	rs208520	0.526	rs2881644	chr6:66803535	A/C	cg07460842	chr6:66804631	NA	1.09	25.81	0.85	2.83e-74	Exhaled nitric oxide output;
CESC	cis	rs7520050	0.966	rs4134386	chr1:46395089	G/A	cg24296786	chr1:45957014	TESK2	0.44	5.49	0.32	9.64e-8	Red blood cell count;Reticulocyte count;
CESC	cis	rs853679	0.599	rs156743	chr6:27967089	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.72	-5.75	-0.33	2.48e-8	Depression;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg23868848	chr8:128806661	PVT1	-0.51	-6.26	-0.36	1.55e-9	Ulcerative colitis;
CESC	cis	rs2836974	0.568	rs371625	chr21:40535271	A/G	cg11644478	chr21:40555479	PSMG1	-0.83	-12.81	-0.62	1.5e-29	Cognitive function;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26468205	chr20:62886904	PCMTD2	0.56	6.45	0.37	5.36e-10	Gut microbiome composition (summer);
CESC	cis	rs1322639	0.614	rs6925188	chr6:169563337	T/C	cg04662567	chr6:169592167	NA	-0.49	-5.12	-0.3	5.81e-7	Pulse pressure;
CESC	trans	rs7824557	0.564	rs2736294	chr8:11234626	T/C	cg06636001	chr8:8085503	FLJ10661	-0.48	-6.0	-0.35	6.44e-9	Retinal vascular caliber;
CESC	cis	rs7582720	1.000	rs72932553	chr2:203842661	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.36	0.41	2.34e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs6502050	0.805	rs4789721	chr17:80157453	T/C	cg23985595	chr17:80112537	CCDC57	-0.4	-6.37	-0.36	8.38e-10	Life satisfaction;
CESC	cis	rs2439831	1.000	rs2251538	chr15:43767209	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.82	11.93	0.59	1.53e-26	Lung cancer in ever smokers;
CESC	cis	rs2836974	0.831	rs34294410	chr21:40555160	C/G	cg17971929	chr21:40555470	PSMG1	1.07	16.52	0.71	1.23e-42	Cognitive function;
CESC	cis	rs739401	0.572	rs7111857	chr11:3068106	A/G	cg08508325	chr11:3079039	CARS	0.52	10.03	0.52	2.78e-20	Longevity;
CESC	cis	rs35110281	0.774	rs1003280	chr21:44997322	A/G	cg01579765	chr21:45077557	HSF2BP	-0.57	-9.92	-0.52	6.26e-20	Mean corpuscular volume;
CESC	cis	rs8177179	0.967	rs4287912	chr3:133437778	A/G	cg24879335	chr3:133465180	TF	0.4	7.63	0.42	4.26e-13	Iron status biomarkers (transferrin levels);
CESC	cis	rs9911578	0.740	rs368243	chr17:56708979	T/C	cg12560992	chr17:57184187	TRIM37	0.82	12.27	0.6	1.02e-27	Intelligence (multi-trait analysis);
CESC	cis	rs4253772	0.591	rs10854854	chr22:46684706	C/G	cg24881330	chr22:46731750	TRMU	0.68	5.79	0.34	1.96e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs7914558	0.966	rs10786721	chr10:104654383	C/A	cg04362960	chr10:104952993	NT5C2	0.46	5.99	0.35	6.65e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs1348850	0.567	rs7605493	chr2:178534983	C/G	cg23306229	chr2:178417860	TTC30B	0.53	6.37	0.36	8.45e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs7246657	0.943	rs9917081	chr19:37876616	T/C	cg23950597	chr19:37808831	NA	-0.62	-6.3	-0.36	1.26e-9	Coronary artery calcification;
CESC	cis	rs909674	0.775	rs8138462	chr22:39839670	G/C	cg24399712	chr22:39784796	NA	-0.81	-11.18	-0.57	5.03e-24	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs3096299	0.591	rs748940	chr16:89440757	T/A	cg16743903	chr16:89593216	SPG7	-0.43	-5.35	-0.31	1.9e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs1865721	0.771	rs7235563	chr18:73139335	C/G	cg26385618	chr18:73139727	C18orf62	-0.49	-8.09	-0.44	2.19e-14	Intelligence;
CESC	cis	rs3812762	0.879	rs10743089	chr11:8788168	A/T	cg03980550	chr11:8754370	ST5	-0.35	-5.22	-0.31	3.64e-7	Hypospadias;
CESC	cis	rs9487051	0.802	rs6910696	chr6:109592329	A/T	cg12927641	chr6:109611667	NA	-0.4	-6.27	-0.36	1.44e-9	Reticulocyte fraction of red cells;
CESC	cis	rs17376456	0.877	rs10060462	chr5:93455073	C/T	cg25358565	chr5:93447407	FAM172A	1.19	11.28	0.57	2.31e-24	Diabetic retinopathy;
CESC	cis	rs7666738	0.861	rs28821920	chr4:98962743	T/C	cg03676636	chr4:99064102	C4orf37	0.33	5.14	0.3	5.39e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs8018808	0.935	rs11625365	chr14:77908588	A/G	cg20045696	chr14:77926864	AHSA1	0.42	5.79	0.33	2.03e-8	Myeloid white cell count;
CESC	cis	rs8141529	0.748	rs132531	chr22:29297365	C/T	cg02153584	chr22:29168773	CCDC117	-0.56	-7.38	-0.41	2.07e-12	Lymphocyte counts;
CESC	cis	rs1348850	0.914	rs9789582	chr2:178330173	C/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.89	12.61	0.61	6.89e-29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs6540559	1.000	rs2235372	chr1:209960436	A/G	cg21951975	chr1:209979733	IRF6	-0.61	-9.24	-0.49	8.52e-18	Cleft lip with or without cleft palate;
CESC	cis	rs11764590	0.694	rs4721321	chr7:2068470	A/G	cg21782813	chr7:2030301	MAD1L1	-0.41	-5.48	-0.32	9.8e-8	Neuroticism;
CESC	cis	rs1552244	0.882	rs67762674	chr3:10014485	C/T	cg08888203	chr3:10149979	C3orf24	0.48	6.0	0.35	6.3e-9	Alzheimer's disease;
CESC	cis	rs7903847	0.642	rs11817852	chr10:99158426	C/T	cg20016023	chr10:99160130	RRP12	-0.3	-5.16	-0.3	4.81e-7	Granulocyte percentage of myeloid white cells;
CESC	cis	rs1971256	0.500	rs80285688	chr6:151818830	G/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.65	6.05	0.35	4.8e-9	Endometriosis;
CESC	cis	rs10484885	0.878	rs72921916	chr6:90555990	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.76	-7.22	-0.41	5.66e-12	QRS interval (sulfonylurea treatment interaction);
CESC	cis	rs10504229	0.683	rs2318148	chr8:58114955	G/A	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	trans	rs308403	0.506	rs309365	chr4:123659343	C/T	cg18677716	chr21:47865349	PCNT	-0.48	-6.03	-0.35	5.56e-9	Blood protein levels;
CESC	cis	rs17711722	0.565	rs4717276	chr7:65294741	G/T	cg11764359	chr7:65958608	NA	0.47	5.87	0.34	1.33e-8	Calcium levels;
CESC	cis	rs7296418	0.699	rs11057254	chr12:123794581	A/C	cg05973401	chr12:123451056	ABCB9	0.43	5.44	0.32	1.2e-7	Platelet count;
CESC	cis	rs6723226	0.638	rs6543657	chr2:32705085	T/C	cg02381751	chr2:32503542	YIPF4	0.66	8.54	0.46	1.07e-15	Intelligence (multi-trait analysis);
CESC	cis	rs11677416	1.000	rs1040193	chr2:113530099	C/T	cg27083787	chr2:113543245	IL1A	0.58	7.26	0.41	4.23e-12	Response to antipsychotic treatment in schizophrenia (working memory);
CESC	cis	rs1218582	0.772	rs906593	chr1:154885255	G/A	cg24250549	chr1:154909240	PMVK	0.75	11.2	0.57	4.32e-24	Prostate cancer;
CESC	cis	rs3858526	0.796	rs9645652	chr11:5944264	C/T	cg13902645	chr11:5959945	NA	-0.67	-8.03	-0.44	3.21e-14	DNA methylation (variation);
CESC	cis	rs1707322	0.964	rs785516	chr1:46564758	T/G	cg05343316	chr1:45956843	TESK2	-0.47	-5.52	-0.32	7.97e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs10751667	0.643	rs10794350	chr11:946070	A/G	cg06064525	chr11:970664	AP2A2	-0.54	-10.79	-0.55	9.5e-23	Alzheimer's disease (late onset);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg03016991	chr12:109124380	CORO1C	0.44	6.21	0.36	2e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs1707322	0.721	rs11211166	chr1:46157942	G/A	cg05343316	chr1:45956843	TESK2	0.51	6.22	0.36	1.96e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26973045	chr18:77711805	PQLC1	0.54	6.19	0.36	2.25e-9	Gut microbiome composition (summer);
CESC	cis	rs763121	0.853	rs5750677	chr22:39147715	C/T	cg06544989	chr22:39130855	UNC84B	0.5	8.92	0.48	7.59e-17	Menopause (age at onset);
CESC	cis	rs4268898	0.931	rs7603997	chr2:24524958	C/T	cg06627628	chr2:24431161	ITSN2	-0.71	-8.6	-0.47	7.33e-16	Asthma;
CESC	cis	rs853679	0.882	rs9468300	chr6:28126840	C/T	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.79	6.93	0.39	3.13e-11	Depression;
CESC	cis	rs12477438	0.520	rs6542870	chr2:99796638	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.86	15.21	0.68	5.36e-38	Chronic sinus infection;
CESC	cis	rs698833	0.813	rs3768919	chr2:44512971	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.57	7.26	0.41	4.19e-12	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	trans	rs9693444	0.898	rs4732697	chr8:29519861	A/G	cg21407906	chr20:61427925	C20orf20	-0.41	-6.11	-0.35	3.51e-9	Breast cancer;
CESC	cis	rs9905704	0.633	rs757484	chr17:56457097	C/G	cg12560992	chr17:57184187	TRIM37	-0.61	-5.75	-0.33	2.49e-8	Testicular germ cell tumor;
CESC	trans	rs7726839	0.540	rs4957081	chr5:646418	G/C	cg25482853	chr8:67687455	SGK3	0.92	9.68	0.51	3.5e-19	Obesity-related traits;
CESC	cis	rs2382817	0.580	rs6756265	chr2:219095554	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.57	-7.45	-0.42	1.29e-12	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg07546262	chr12:54753490	NA	-0.52	-6.66	-0.38	1.56e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs9311474	0.508	rs6805156	chr3:52609362	T/C	cg05564831	chr3:52568323	NT5DC2	0.48	7.76	0.43	1.85e-13	Electroencephalogram traits;
CESC	cis	rs1580019	0.547	rs56981934	chr7:32535202	C/G	cg07520158	chr7:32535189	LSM5;AVL9	0.51	6.55	0.37	3e-10	Cognitive ability;
CESC	cis	rs2996428	0.667	rs10492942	chr1:3764216	C/T	cg13057898	chr1:3703894	LRRC47	0.43	5.92	0.34	1.01e-8	Red cell distribution width;
CESC	cis	rs11577318	0.853	rs4471263	chr1:26622700	C/T	cg00813993	chr1:26644493	UBXN11;CD52	-0.4	-6.3	-0.36	1.21e-9	Granulocyte percentage of myeloid white cells;
CESC	cis	rs875971	0.862	rs2088653	chr7:65808608	G/A	cg18876405	chr7:65276391	NA	-0.53	-7.27	-0.41	4.11e-12	Aortic root size;
CESC	cis	rs2991971	0.967	rs6661321	chr1:45954599	C/G	cg24296786	chr1:45957014	TESK2	0.68	9.36	0.5	3.55e-18	High light scatter reticulocyte count;
CESC	cis	rs1348850	0.793	rs6734528	chr2:178493731	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.52	6.72	0.38	1.12e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg05141709	chr3:53857445	CHDH	0.49	6.13	0.35	3.23e-9	Fibrinogen levels;
CESC	cis	rs763121	0.853	rs4821809	chr22:39065743	G/C	cg14440974	chr22:39074834	NA	-0.41	-5.59	-0.32	5.61e-8	Menopause (age at onset);
CESC	cis	rs780096	0.546	rs1060525	chr2:27635582	A/G	cg22903471	chr2:27725779	GCKR	-0.52	-7.37	-0.41	2.21e-12	Total body bone mineral density;
CESC	cis	rs7267979	0.899	rs2179459	chr20:25456141	C/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.73	12.55	0.61	1.1e-28	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs736408	0.688	rs2239551	chr3:52818579	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.51	-6.69	-0.38	1.32e-10	Bipolar disorder;
CESC	cis	rs7216064	1.000	rs4318247	chr17:65882172	A/G	cg07042672	chr17:66097459	LOC651250	-0.52	-5.4	-0.31	1.5e-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs752010	0.695	rs10789408	chr1:42106579	T/C	cg06885757	chr1:42089581	HIVEP3	0.49	7.81	0.43	1.37e-13	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs12912251	0.947	rs7165988	chr15:38988815	C/G	cg01338139	chr15:38987640	C15orf53	-0.47	-5.43	-0.32	1.26e-7	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
CESC	cis	rs10504229	0.679	rs73681882	chr8:58030038	A/G	cg22535103	chr8:58192502	C8orf71	-0.61	-6.86	-0.39	4.87e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs854765	0.547	rs7209003	chr17:17907393	T/A	cg16928487	chr17:17741425	SREBF1	-0.58	-10.22	-0.53	6.92e-21	Total body bone mineral density;
CESC	cis	rs2370759	1.000	rs16933177	chr10:32565705	G/A	cg01819863	chr10:32635814	EPC1	1.17	12.5	0.61	1.7e-28	Sexual dysfunction (female);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25793785	chr19:38281423	NA	-0.57	-6.73	-0.38	1.04e-10	Gut microbiome composition (summer);
CESC	cis	rs9911578	0.835	rs1476596	chr17:56485358	C/T	cg12560992	chr17:57184187	TRIM37	0.87	14.1	0.65	4.75e-34	Intelligence (multi-trait analysis);
CESC	cis	rs3785574	0.745	rs2854162	chr17:61975610	T/C	cg06420487	chr17:61919686	SMARCD2	-0.43	-5.14	-0.3	5.37e-7	Height;
CESC	cis	rs8018808	0.935	rs8018513	chr14:77928288	T/C	cg20045696	chr14:77926864	AHSA1	0.42	5.71	0.33	3.08e-8	Myeloid white cell count;
CESC	cis	rs244293	0.931	rs2787484	chr17:53210120	C/T	cg19360675	chr17:53046073	COX11;STXBP4	-0.4	-5.11	-0.3	6.03e-7	Menarche (age at onset);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg21209604	chr6:26032199	HIST1H3B	-0.46	-6.56	-0.37	2.84e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs7843479	0.524	rs1031884	chr8:21788984	C/T	cg17168535	chr8:21777572	XPO7	0.8	13.33	0.63	2.25e-31	Mean corpuscular volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17974674	chr2:241451567	ANKMY1	-0.64	-7.85	-0.43	1.02e-13	Gut microbiome composition (summer);
CESC	cis	rs27434	0.607	rs26654	chr5:96140367	C/T	cg16492584	chr5:96139282	ERAP1	-0.37	-5.33	-0.31	2.07e-7	Ankylosing spondylitis;
CESC	cis	rs7412746	0.611	rs2271076	chr1:150916657	C/T	cg17724175	chr1:150552817	MCL1	0.33	5.08	0.3	7.16e-7	Melanoma;
CESC	cis	rs1152591	0.543	rs1152594	chr14:64675044	C/T	cg21174375	chr14:64681225	SYNE2	-0.63	-9.1	-0.49	2.21e-17	Atrial fibrillation;
CESC	cis	rs9303401	0.614	rs2240719	chr17:56582477	G/C	cg12560992	chr17:57184187	TRIM37	0.52	5.08	0.3	7.01e-7	Cognitive test performance;
CESC	cis	rs6587515	0.892	rs11204665	chr1:150536349	A/G	cg13175981	chr1:150552382	MCL1	-0.69	-5.05	-0.3	8.31e-7	Pericardial adipose tissue adjusted for height and weight;
CESC	cis	rs873946	0.586	rs36084869	chr10:134566069	G/A	cg27286337	chr10:134555280	INPP5A	0.68	7.69	0.43	2.81e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	trans	rs7649739	0.894	rs9849333	chr3:65396182	C/T	cg19002941	chr8:641497	ERICH1	-0.48	-6.03	-0.35	5.57e-9	IgG glycosylation;
CESC	cis	rs4808199	0.947	rs1465695	chr19:19588546	A/C	cg03709012	chr19:19516395	GATAD2A	1.13	13.2	0.63	6.29e-31	Nonalcoholic fatty liver disease;
CESC	cis	rs897080	0.515	rs1067334	chr2:44626633	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	5.91	0.34	1.07e-8	Height;
CESC	cis	rs2303759	0.918	rs1054770	chr19:49878115	G/A	cg22133161	chr19:49891603	CCDC155	0.44	5.08	0.3	7.08e-7	Multiple sclerosis;
CESC	cis	rs7216064	1.000	rs12451707	chr17:65871598	G/A	cg12091567	chr17:66097778	LOC651250	-0.84	-8.57	-0.47	8.53e-16	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs2625529	0.586	rs2306489	chr15:72227471	G/A	cg16672083	chr15:72433130	SENP8	0.42	6.37	0.36	8.12e-10	Red blood cell count;
CESC	cis	rs4423214	0.592	rs10898223	chr11:71219264	G/A	cg05163923	chr11:71159392	DHCR7	-0.62	-6.5	-0.37	3.88e-10	Vitamin D levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07058132	chr16:1755945	MAPK8IP3	0.53	6.48	0.37	4.45e-10	Gut microbiome composition (summer);
CESC	cis	rs1878047	0.665	rs10408324	chr19:51774806	C/T	cg14884932	chr19:51774451	NA	-0.37	-5.16	-0.3	4.87e-7	Body mass index;
CESC	trans	rs7937682	0.855	rs539553	chr11:111477333	C/T	cg18187862	chr3:45730750	SACM1L	0.48	6.13	0.35	3.12e-9	Primary sclerosing cholangitis;
CESC	cis	rs4665809	0.590	rs4665319	chr2:26424583	A/C	cg25036284	chr2:26402008	FAM59B	-0.7	-8.12	-0.45	1.83e-14	Gut microbiome composition (summer);
CESC	cis	rs12824058	0.831	rs4759658	chr12:130815872	C/T	cg24838063	chr12:130822603	PIWIL1	0.63	8.58	0.47	7.91e-16	Menopause (age at onset);
CESC	cis	rs7216064	1.000	rs1976054	chr17:65833224	T/G	cg07042672	chr17:66097459	LOC651250	-0.57	-6.66	-0.38	1.59e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs11122272	0.735	rs2486736	chr1:231521478	A/G	cg06096015	chr1:231504339	EGLN1	-0.38	-5.43	-0.32	1.26e-7	Hemoglobin concentration;
CESC	cis	rs7631605	0.905	rs7651903	chr3:37006686	T/C	cg22985146	chr3:37219077	LRRFIP2	-0.34	-5.36	-0.31	1.82e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs2286503	0.839	rs1054471	chr7:22852643	T/A	cg13679077	chr7:22862647	TOMM7	0.45	5.77	0.33	2.2e-8	Fibrinogen;
CESC	cis	rs3741151	0.686	rs1002127	chr11:73103835	G/C	cg17517138	chr11:73019481	ARHGEF17	0.84	6.47	0.37	4.77e-10	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs7818345	0.763	rs4431609	chr8:19293565	A/C	cg11303988	chr8:19266685	CSGALNACT1	-0.32	-5.43	-0.32	1.3e-7	Language performance in older adults (adjusted for episodic memory);
CESC	cis	rs6540559	1.000	rs6659367	chr1:209982408	G/T	cg21951975	chr1:209979733	IRF6	0.6	9.51	0.5	1.18e-18	Cleft lip with or without cleft palate;
CESC	trans	rs6951245	0.706	rs28522260	chr7:1183964	C/A	cg13565492	chr6:43139072	SRF	-0.6	-6.21	-0.36	2.06e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs1799949	0.931	rs9912203	chr17:41445145	A/G	cg05368731	chr17:41323189	NBR1	-0.58	-8.27	-0.45	6.71e-15	Menopause (age at onset);
CESC	cis	rs875971	0.502	rs11769702	chr7:65720516	A/C	cg25405998	chr7:65216604	CCT6P1	0.5	5.52	0.32	8.16e-8	Aortic root size;
CESC	cis	rs6496667	0.533	rs2074583	chr15:91009192	T/C	cg22089800	chr15:90895588	ZNF774	0.45	5.86	0.34	1.35e-8	Rheumatoid arthritis;
CESC	cis	rs13223928	0.631	rs12531881	chr7:3156842	C/T	cg19214707	chr7:3157722	NA	-0.43	-5.88	-0.34	1.26e-8	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
CESC	cis	rs2228479	0.850	rs11649100	chr16:89798179	A/G	cg04013166	chr16:89971882	TCF25	0.67	5.38	0.31	1.65e-7	Skin colour saturation;
CESC	cis	rs4253772	0.550	rs6007818	chr22:46703776	C/T	cg00784671	chr22:46762841	CELSR1	-0.47	-5.56	-0.32	6.45e-8	LDL cholesterol;Cholesterol, total;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14837817	chr8:144692253	PYCRL	-0.54	-6.05	-0.35	4.95e-9	Gut microbiome composition (summer);
CESC	cis	rs9926296	0.632	rs7184315	chr16:89799373	C/G	cg27121462	chr16:89883253	FANCA	-0.63	-7.94	-0.44	5.8e-14	Vitiligo;
CESC	cis	rs2243480	1.000	rs1979823	chr7:65704613	G/A	cg13147721	chr7:65941812	NA	0.98	9.24	0.49	8.25e-18	Diabetic kidney disease;
CESC	trans	rs6700559	0.810	rs2809344	chr1:200596606	C/A	cg13401811	chr12:52345646	ACVR1B	-0.47	-6.01	-0.35	6.03e-9	Coronary artery disease;
CESC	cis	rs55665837	0.559	rs11023209	chr11:14422600	T/C	cg19336497	chr11:14380999	RRAS2	-0.35	-5.23	-0.31	3.49e-7	Vitamin D levels;
CESC	cis	rs116095464	0.558	rs73024831	chr5:257192	A/G	cg22857025	chr5:266934	NA	-1.29	-18.21	-0.75	1.29e-48	Breast cancer;
CESC	cis	rs4835473	0.897	rs34425128	chr4:144646344	T/A	cg25736465	chr4:144833511	NA	-0.44	-6.5	-0.37	3.98e-10	Immature fraction of reticulocytes;
CESC	cis	rs17209837	0.607	rs1558375	chr7:87079069	T/C	cg00919237	chr7:87102261	ABCB4	-0.52	-6.67	-0.38	1.45e-10	Gallbladder cancer;
CESC	cis	rs6580649	1.000	rs3825404	chr12:48399931	A/G	cg05342945	chr12:48394962	COL2A1	-0.56	-6.73	-0.38	1.04e-10	Lung cancer;
CESC	cis	rs9303401	0.614	rs3803753	chr17:56540110	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.99	12.3	0.6	8.24e-28	Cognitive test performance;
CESC	cis	rs6570726	1.000	rs405622	chr6:145871897	G/T	cg05347473	chr6:146136440	FBXO30	0.43	5.83	0.34	1.63e-8	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1552244	1.000	rs6786638	chr3:10118075	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	11.97	0.59	1.11e-26	Alzheimer's disease;
CESC	cis	rs34779708	0.931	rs1926556	chr10:35344907	T/C	cg03585969	chr10:35415529	CREM	0.75	9.67	0.51	3.92e-19	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs1443512	0.796	rs1822437	chr12:54340077	A/G	cg12374095	chr12:54320830	NA	0.44	5.88	0.34	1.24e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
CESC	cis	rs4974559	0.895	rs28493051	chr4:1331030	A/C	cg02980000	chr4:1222292	CTBP1	0.64	7.46	0.42	1.21e-12	Systolic blood pressure;
CESC	cis	rs1215050	0.740	rs783929	chr4:98972495	T/A	cg05340658	chr4:99064831	C4orf37	-0.54	-7.33	-0.41	2.75e-12	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs4654899	0.802	rs7519685	chr1:21192623	G/A	cg05370193	chr1:21551575	ECE1	0.39	5.65	0.33	4.12e-8	Superior frontal gyrus grey matter volume;
CESC	cis	rs2380220	0.606	rs7747776	chr6:96005852	C/T	cg15832292	chr6:96025679	MANEA	0.59	6.94	0.39	2.97e-11	Behavioural disinhibition (generation interaction);
CESC	cis	rs15676	0.783	rs2280843	chr9:131585069	A/G	cg00228799	chr9:131580591	ENDOG	0.55	7.13	0.4	9.74e-12	Blood metabolite levels;
CESC	cis	rs7089973	0.604	rs2181563	chr10:116604344	T/C	cg03647239	chr10:116582469	FAM160B1	0.46	6.1	0.35	3.77e-9	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs3093024	0.839	rs968334	chr6:167526096	T/C	cg23791538	chr6:167370224	RNASET2	0.45	5.63	0.33	4.49e-8	Rheumatoid arthritis;
CESC	cis	rs1580019	0.563	rs34201720	chr7:32568935	G/A	cg06627557	chr7:32535165	LSM5;AVL9	1.06	18.97	0.76	2.73e-51	Cognitive ability;
CESC	cis	rs4689388	0.824	rs6446482	chr4:6295693	C/G	cg00701064	chr4:6280414	WFS1	0.69	11.68	0.58	1.03e-25	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs10857712	0.950	rs10857711	chr10:135224059	G/A	cg01444801	chr10:135216882	MTG1	-0.46	-5.6	-0.33	5.48e-8	Systemic lupus erythematosus;
CESC	trans	rs9393777	0.920	rs35869525	chr6:26946687	C/T	cg01620082	chr3:125678407	NA	-0.81	-6.76	-0.38	8.96e-11	Intelligence (multi-trait analysis);
CESC	cis	rs801193	0.839	rs6968619	chr7:66068867	T/C	cg06456125	chr7:65229604	NA	-0.4	-5.58	-0.32	5.97e-8	Aortic root size;
CESC	cis	rs9302635	0.513	rs35460163	chr16:72177060	C/T	cg16558253	chr16:72132732	DHX38	-0.42	-5.15	-0.3	5.18e-7	Blood protein levels;
CESC	cis	rs6582630	0.555	rs7305352	chr12:38473800	T/C	cg13010199	chr12:38710504	ALG10B	0.53	6.74	0.38	9.64e-11	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs2463822	1.000	rs2513749	chr11:62105391	C/T	cg06239285	chr11:62104954	ASRGL1	0.85	8.6	0.47	7.06e-16	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs7216064	0.953	rs4791046	chr17:65851973	G/A	cg12091567	chr17:66097778	LOC651250	-0.77	-8.39	-0.46	2.89e-15	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs9611519	0.566	rs4821981	chr22:41415644	A/C	cg03806693	chr22:41940476	POLR3H	0.51	6.02	0.35	5.76e-9	Neuroticism;
CESC	cis	rs7267979	0.966	rs2257712	chr20:25264910	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	18.61	0.75	5.02e-50	Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs10242455	0.571	rs7805661	chr7:99171522	A/C	cg09045935	chr12:6379348	NA	0.83	7.16	0.4	7.87e-12	Blood metabolite levels;
CESC	cis	rs2288073	0.930	rs7604097	chr2:24401805	G/C	cg06627628	chr2:24431161	ITSN2	-0.73	-8.63	-0.47	5.71e-16	Venous thromboembolism (SNP x SNP interaction);
CESC	trans	rs11822910	0.871	rs2581928	chr11:57202790	A/G	cg06103642	chr6:108496716	NR2E1	0.51	6.33	0.36	1.05e-9	Platelet distribution width;
CESC	cis	rs1018836	0.923	rs34126139	chr8:91572045	T/G	cg16814680	chr8:91681699	NA	-0.66	-9.17	-0.49	1.33e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs8180040	0.966	rs60369822	chr3:47479735	A/C	cg27129171	chr3:47204927	SETD2	-0.63	-9.48	-0.5	1.49e-18	Colorectal cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03689120	chr13:20767179	GJB2	0.56	6.33	0.36	1.06e-9	Gut microbiome composition (summer);
CESC	cis	rs5760092	0.618	rs4461358	chr22:24260106	T/C	cg04234412	chr22:24373322	LOC391322	0.66	9.02	0.48	3.88e-17	Urinary 1,3-butadiene metabolite levels in smokers;
CESC	cis	rs6430585	0.527	rs62168836	chr2:136463117	G/A	cg07169764	chr2:136633963	MCM6	1.09	12.63	0.61	6.06e-29	Corneal structure;
CESC	cis	rs1008375	1.000	rs2872959	chr4:17677163	G/A	cg16339924	chr4:17578868	LAP3	-0.59	-7.06	-0.4	1.48e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	ch.7.1147807F	chr7:49473528	NA	-0.57	-6.83	-0.39	5.91e-11	Gut microbiome composition (summer);
CESC	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg09858108	chr8:58055024	NA	0.37	5.33	0.31	2.15e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs2836974	0.836	rs8129355	chr21:40579869	A/G	cg17971929	chr21:40555470	PSMG1	1.07	16.35	0.71	4.96e-42	Cognitive function;
CESC	cis	rs7666738	0.830	rs2865981	chr4:99031493	G/A	cg17366294	chr4:99064904	C4orf37	0.62	8.89	0.48	9.33e-17	Colonoscopy-negative controls vs population controls;
CESC	cis	rs796364	0.664	rs3106089	chr2:200884615	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.83	7.54	0.42	7.3e-13	Schizophrenia;
CESC	trans	rs9929218	1.000	rs8056538	chr16:68802282	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.63	-8.46	-0.46	1.84e-15	Colorectal cancer;
CESC	cis	rs875971	0.825	rs6951503	chr7:65718936	T/G	cg11764359	chr7:65958608	NA	-0.8	-11.72	-0.58	7.64e-26	Aortic root size;
CESC	cis	rs9300255	0.602	rs1716168	chr12:123651966	C/G	cg19016782	chr12:123741754	C12orf65	0.4	5.69	0.33	3.29e-8	Neutrophil percentage of white cells;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg03383661	chr6:42714115	TBCC	-0.47	-6.82	-0.39	6.1e-11	Gambling;
CESC	cis	rs769267	0.930	rs6909	chr19:19619542	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.48	6.05	0.35	4.83e-9	Tonsillectomy;
CESC	cis	rs4808199	0.895	rs10419672	chr19:19471241	T/C	cg03709012	chr19:19516395	GATAD2A	1.09	12.15	0.6	2.63e-27	Nonalcoholic fatty liver disease;
CESC	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg07308232	chr7:1071921	C7orf50	-0.39	-5.2	-0.3	3.9e-7	Longevity;Endometriosis;
CESC	cis	rs2032447	0.670	rs198834	chr6:26114372	G/A	cg03264133	chr6:25882463	NA	0.45	6.63	0.38	1.86e-10	Intelligence (multi-trait analysis);
CESC	cis	rs7267979	1.000	rs1047171	chr20:25428786	T/C	cg08601574	chr20:25228251	PYGB	0.38	5.64	0.33	4.4e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs77303550	1.000	rs217181	chr16:72114002	A/G	cg01557791	chr16:72042693	DHODH	-0.59	-6.15	-0.35	2.86e-9	Metabolite levels (small molecules and protein measures);
CESC	cis	rs17401966	0.928	rs11121531	chr1:10277357	G/A	cg15208524	chr1:10270712	KIF1B	0.53	6.89	0.39	3.99e-11	Hepatocellular carcinoma;
CESC	cis	rs13191362	1.000	rs34637087	chr6:163004064	T/G	cg06582575	chr6:163149167	PACRG;PARK2	0.83	8.39	0.46	3.02e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs9549260	0.755	rs7335520	chr13:41196407	C/T	cg21288729	chr13:41239152	FOXO1	0.6	7.67	0.43	3.27e-13	Red blood cell count;
CESC	trans	rs7178375	1.000	rs10163148	chr15:31212684	C/G	cg04373760	chr16:53404718	NA	0.56	6.87	0.39	4.69e-11	Hypertriglyceridemia;
CESC	cis	rs7084402	0.967	rs1658469	chr10:60292402	C/T	cg07615347	chr10:60278583	BICC1	-0.62	-9.96	-0.52	4.59e-20	Refractive error;
CESC	cis	rs10504229	0.683	rs7463453	chr8:58112053	A/G	cg02725872	chr8:58115012	NA	-0.45	-7.04	-0.4	1.66e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs10782582	0.545	rs12138018	chr1:76186794	T/C	cg22875332	chr1:76189707	ACADM	-0.44	-5.3	-0.31	2.41e-7	Daytime sleep phenotypes;
CESC	cis	rs2637266	0.678	rs846604	chr10:78569223	A/G	cg18941641	chr10:78392320	NA	0.39	7.54	0.42	7.31e-13	Pulmonary function;
CESC	cis	rs12477438	0.520	rs2516835	chr2:99779131	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.79	12.62	0.61	6.6e-29	Chronic sinus infection;
CESC	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg07677032	chr17:61819896	STRADA	0.45	6.0	0.35	6.49e-9	Prudent dietary pattern;
CESC	cis	rs2204008	0.805	rs10881112	chr12:37956611	G/A	cg26384229	chr12:38710491	ALG10B	-0.53	-7.46	-0.42	1.26e-12	Bladder cancer;
CESC	cis	rs7264396	0.635	rs6058375	chr20:34531997	T/A	cg17201900	chr20:34330562	RBM39	0.51	5.4	0.31	1.5e-7	Total cholesterol levels;
CESC	cis	rs4664308	0.935	rs4665148	chr2:160917901	A/G	cg03641300	chr2:160917029	PLA2R1	-0.67	-10.08	-0.53	1.88e-20	Idiopathic membranous nephropathy;
CESC	cis	rs7188697	0.769	rs9932944	chr16:58616165	C/T	cg21335942	chr16:58549945	SETD6	-0.45	-5.17	-0.3	4.73e-7	QT interval;
CESC	cis	rs60843830	0.661	rs62116682	chr2:104618	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.51	6.08	0.35	4.11e-9	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs6088580	0.634	rs6059880	chr20:33088669	G/A	cg24642439	chr20:33292090	TP53INP2	0.49	6.4	0.37	7.03e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs7589728	0.514	rs74426843	chr2:88459388	C/T	cg04511125	chr2:88470314	THNSL2	0.68	6.66	0.38	1.61e-10	Plasma clusterin levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12528016	chr1:27998711	IFI6	0.57	6.13	0.35	3.2e-9	Gut microbiome composition (summer);
CESC	cis	rs2075371	0.933	rs432336	chr7:133949064	A/G	cg20476274	chr7:133979776	SLC35B4	0.68	9.87	0.52	8.91e-20	Mean platelet volume;
CESC	cis	rs10504229	1.000	rs67705655	chr8:58177688	G/A	cg14926445	chr8:58193284	C8orf71	-0.51	-5.47	-0.32	1.03e-7	Developmental language disorder (linguistic errors);
CESC	trans	rs7819412	0.668	rs2409715	chr8:11010136	A/T	cg06636001	chr8:8085503	FLJ10661	-0.48	-6.01	-0.35	6.2e-9	Triglycerides;
CESC	cis	rs4665809	0.590	rs13006973	chr2:26454707	C/T	cg22920501	chr2:26401640	FAM59B	0.91	10.33	0.54	3.07e-21	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07852735	chr8:63951642	GGH	0.59	6.58	0.37	2.53e-10	Gut microbiome composition (summer);
CESC	trans	rs8026198	0.568	rs1659218	chr15:42616073	A/T	cg11538410	chr8:142141455	DENND3	0.61	6.02	0.35	5.66e-9	Fibrinogen levels;
CESC	cis	rs548181	0.673	rs12288034	chr11:125570941	A/T	cg03464685	chr11:125439445	EI24	-0.73	-6.24	-0.36	1.76e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	trans	rs208520	0.526	rs2881644	chr6:66803535	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.07	23.24	0.82	6.96e-66	Exhaled nitric oxide output;
CESC	cis	rs9309473	0.848	rs9750915	chr2:73811880	T/C	cg20560298	chr2:73613845	ALMS1	-0.54	-7.04	-0.4	1.64e-11	Metabolite levels;
CESC	cis	rs11098499	0.954	rs7654587	chr4:120388406	C/T	cg24375607	chr4:120327624	NA	0.44	5.48	0.32	9.91e-8	Corneal astigmatism;
CESC	cis	rs2952156	0.920	rs12150298	chr17:37834541	T/C	cg19468946	chr17:37922297	IKZF3	-0.4	-5.28	-0.31	2.75e-7	Asthma;
CESC	cis	rs7666738	0.830	rs6819177	chr4:99040907	T/C	cg24818145	chr4:99064322	C4orf37	0.38	5.04	0.3	8.49e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs12478296	1.000	rs55758933	chr2:243040289	T/C	cg06360820	chr2:242988706	NA	-0.66	-7.52	-0.42	8.51e-13	Obesity-related traits;
CESC	cis	rs7666738	0.830	rs7682991	chr4:98982595	C/A	cg17366294	chr4:99064904	C4orf37	0.59	8.57	0.47	8.46e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs13064411	0.696	rs6769516	chr3:113219905	T/C	cg18753928	chr3:113234510	CCDC52	-0.51	-6.22	-0.36	1.9e-9	Response to simvastatin treatment (PCSK9 protein level change);
CESC	cis	rs4595586	0.545	rs6580896	chr12:39372223	C/T	cg26384229	chr12:38710491	ALG10B	0.54	7.53	0.42	7.85e-13	Morning vs. evening chronotype;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07079059	chr17:33569328	SLFN5	-0.58	-6.68	-0.38	1.39e-10	Gut microbiome composition (summer);
CESC	cis	rs727505	1.000	rs7801661	chr7:124483222	C/T	cg23710748	chr7:124431027	NA	0.48	7.65	0.43	3.62e-13	Lewy body disease;
CESC	cis	rs7107174	1.000	rs10899475	chr11:78051610	T/C	cg02023728	chr11:77925099	USP35	0.38	5.39	0.31	1.57e-7	Testicular germ cell tumor;
CESC	cis	rs1538970	0.924	rs4660855	chr1:45899795	A/G	cg06784218	chr1:46089804	CCDC17	0.33	5.46	0.32	1.11e-7	Platelet count;
CESC	cis	rs111326718	1	rs111326718	chr10:104771211	A/AAAAAT	cg04362960	chr10:104952993	NT5C2	0.44	5.82	0.34	1.67e-8	Reticulocyte count;
CESC	cis	rs1003719	0.715	rs2156077	chr21:38539357	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.59	-7.98	-0.44	4.49e-14	Eye color traits;
CESC	cis	rs17253792	0.822	rs112374071	chr14:56061919	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.88	5.69	0.33	3.38e-8	Putamen volume;
CESC	cis	rs6987853	0.865	rs2923445	chr8:42400743	C/A	cg09913449	chr8:42400586	C8orf40	0.4	6.34	0.36	9.76e-10	Mean corpuscular hemoglobin concentration;
CESC	cis	rs8031584	0.958	rs35256769	chr15:31237776	G/A	cg14829155	chr15:31115871	NA	-0.7	-9.48	-0.5	1.52e-18	Huntington's disease progression;
CESC	cis	rs950776	0.518	rs12906846	chr15:78825295	G/A	cg24631222	chr15:78858424	CHRNA5	-0.42	-5.33	-0.31	2.09e-7	Sudden cardiac arrest;
CESC	cis	rs6963495	0.818	rs6943132	chr7:105166776	C/T	cg13798780	chr7:105162888	PUS7	0.8	6.56	0.37	2.76e-10	Bipolar disorder (body mass index interaction);
CESC	cis	rs7659604	1.000	rs6846232	chr4:122664805	A/G	cg19671926	chr4:122722719	EXOSC9	-0.44	-5.3	-0.31	2.49e-7	Type 2 diabetes;
CESC	trans	rs1814175	0.817	rs1319547	chr11:49916705	C/T	cg15704280	chr7:45808275	SEPT13	-1.03	-20.27	-0.78	8.31e-56	Height;
CESC	cis	rs6545883	0.859	rs2600661	chr2:61543081	T/C	cg15711740	chr2:61764176	XPO1	0.41	5.12	0.3	5.78e-7	Tuberculosis;
CESC	cis	rs9549260	0.755	rs9549241	chr13:41210041	G/A	cg21288729	chr13:41239152	FOXO1	0.63	8.41	0.46	2.55e-15	Red blood cell count;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg14275457	chr9:132934675	FREQ	-0.41	-6.18	-0.35	2.43e-9	Gambling;
CESC	cis	rs9309473	1.000	rs10193972	chr2:73717656	A/G	cg20560298	chr2:73613845	ALMS1	-0.47	-6.29	-0.36	1.28e-9	Metabolite levels;
CESC	cis	rs10129255	0.500	rs6576229	chr14:107186773	G/A	cg07958169	chr14:107095056	NA	-0.55	-8.65	-0.47	4.94e-16	Kawasaki disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21705506	chr17:33842181	SLFN12L	-0.55	-6.51	-0.37	3.72e-10	Gut microbiome composition (summer);
CESC	cis	rs2637266	0.703	rs2920792	chr10:78532842	A/T	cg18941641	chr10:78392320	NA	-0.39	-7.6	-0.42	5.12e-13	Pulmonary function;
CESC	cis	rs644148	0.693	rs2686772	chr19:44999729	T/C	cg15540054	chr19:45004280	ZNF180	-0.63	-6.74	-0.38	9.58e-11	Personality dimensions;
CESC	cis	rs6691722	0.544	rs7551707	chr1:24696892	G/A	cg18323236	chr1:24743029	NIPAL3	0.36	5.38	0.31	1.62e-7	Response to interferon beta in multiple sclerosis;
CESC	trans	rs11039798	0.588	rs10838923	chr11:48534864	C/G	cg15704280	chr7:45808275	SEPT13	0.67	7.17	0.4	7.54e-12	Axial length;
CESC	cis	rs2014572	0.967	rs10411941	chr19:57762886	C/T	cg24459738	chr19:57751996	ZNF805	-0.53	-7.54	-0.42	7.48e-13	Hyperactive-impulsive symptoms;
CESC	trans	rs11039798	0.920	rs11040015	chr11:48783130	G/T	cg15704280	chr7:45808275	SEPT13	0.7	6.51	0.37	3.81e-10	Axial length;
CESC	cis	rs3859192	0.599	rs2227321	chr17:38171294	G/C	cg17467752	chr17:38218738	THRA	-0.45	-5.88	-0.34	1.2e-8	White blood cell count;
CESC	cis	rs11098499	0.738	rs34566984	chr4:120361270	G/A	cg09307838	chr4:120376055	NA	0.94	13.7	0.64	1.18e-32	Corneal astigmatism;
CESC	cis	rs9486719	1.000	rs2472897	chr6:96870569	G/T	cg06623918	chr6:96969491	KIAA0776	0.78	7.96	0.44	5.01e-14	Migraine;Coronary artery disease;
CESC	cis	rs10504229	1.000	rs17816781	chr8:58186161	A/T	cg24829409	chr8:58192753	C8orf71	-0.76	-9.93	-0.52	5.87e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs62229266	0.693	rs2835264	chr21:37435965	C/T	cg12218747	chr21:37451666	NA	-0.39	-5.41	-0.32	1.4e-7	Mitral valve prolapse;
CESC	cis	rs875971	0.862	rs7798630	chr7:65771479	G/C	cg11764359	chr7:65958608	NA	-0.78	-11.61	-0.58	1.78e-25	Aortic root size;
CESC	cis	rs1799949	1.000	rs33918839	chr17:41329172	T/C	cg23758822	chr17:41437982	NA	1.05	16.2	0.71	1.69e-41	Menopause (age at onset);
CESC	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	22.75	0.81	2.95e-64	Prudent dietary pattern;
CESC	cis	rs7666738	0.830	rs28810677	chr4:99043193	C/T	cg03676636	chr4:99064102	C4orf37	0.33	5.12	0.3	5.93e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs5769765	0.778	rs8137331	chr22:50313358	G/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.51	-5.58	-0.32	5.93e-8	Schizophrenia;
CESC	trans	rs11039798	0.688	rs12277029	chr11:48852833	G/T	cg15704280	chr7:45808275	SEPT13	0.71	6.44	0.37	5.59e-10	Axial length;
CESC	cis	rs826838	0.651	rs12367384	chr12:38618460	G/T	cg26384229	chr12:38710491	ALG10B	0.57	8.25	0.45	7.66e-15	Heart rate;
CESC	cis	rs4664304	0.966	rs7601374	chr2:160754050	T/C	cg03641300	chr2:160917029	PLA2R1	-0.48	-6.89	-0.39	3.99e-11	Crohn's disease;Inflammatory bowel disease;
CESC	trans	rs2488856	0.689	rs1954400	chr14:43602205	C/T	cg14326805	chr9:71737756	TJP2	0.37	6.14	0.35	2.93e-9	Osteoprotegerin levels;
CESC	cis	rs9399401	0.633	rs1329705	chr6:142753338	G/A	cg04461802	chr6:142623433	GPR126	0.39	5.63	0.33	4.67e-8	Chronic obstructive pulmonary disease;
CESC	cis	rs9467711	0.606	rs9379855	chr6:26364930	C/T	cg14345882	chr6:26364793	BTN3A2	-0.56	-6.16	-0.35	2.67e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs4604732	0.536	rs4925674	chr1:247636906	C/T	cg12758973	chr1:247694275	LOC148824;OR2C3	0.46	6.18	0.35	2.47e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	trans	rs9467711	0.659	rs3823158	chr6:26463271	T/A	cg01620082	chr3:125678407	NA	-0.74	-6.02	-0.35	5.74e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs7615952	0.576	rs2276729	chr3:125826214	G/A	cg18479299	chr3:125709523	NA	-0.49	-5.44	-0.32	1.23e-7	Blood pressure (smoking interaction);
CESC	cis	rs2479724	0.905	rs2251274	chr6:41839438	T/G	cg08135965	chr6:41755394	TOMM6	0.4	5.55	0.32	6.92e-8	Menarche (age at onset);
CESC	cis	rs72945132	0.882	rs12294540	chr11:70118973	A/T	cg14191688	chr11:70257035	CTTN	0.4	5.06	0.3	8.03e-7	Coronary artery disease;
CESC	cis	rs873946	0.517	rs2803990	chr10:134560340	A/G	cg18305652	chr10:134549665	INPP5A	0.48	7.63	0.42	4.11e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs4555082	1.000	rs7146643	chr14:105757392	A/G	cg27165867	chr14:105738592	BRF1	-0.48	-5.73	-0.33	2.72e-8	Mean platelet volume;Platelet distribution width;
CESC	cis	rs7772486	0.654	rs1011597	chr6:146075672	A/C	cg23711669	chr6:146136114	FBXO30	-0.9	-13.43	-0.64	1e-31	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs832540	0.556	rs4146565	chr5:56093825	T/C	cg14703610	chr5:56206110	C5orf35	0.42	5.07	0.3	7.54e-7	Coronary artery disease;
CESC	cis	rs9457247	1.000	rs439237	chr6:167391392	A/G	cg23791538	chr6:167370224	RNASET2	-0.6	-8.65	-0.47	4.96e-16	Crohn's disease;
CESC	cis	rs2625529	0.586	rs7175197	chr15:72461648	G/A	cg16672083	chr15:72433130	SENP8	0.5	7.48	0.42	1.11e-12	Red blood cell count;
CESC	cis	rs863345	0.625	rs6663286	chr1:158473725	C/A	cg12129480	chr1:158549410	OR10X1	-0.35	-6.97	-0.39	2.58e-11	Pneumococcal bacteremia;
CESC	cis	rs7918232	0.830	rs7087033	chr10:27392522	A/G	cg14240646	chr10:27532245	ACBD5	-0.66	-6.25	-0.36	1.64e-9	Breast cancer;
CESC	cis	rs7727544	0.606	rs2631360	chr5:131707429	A/G	cg14196790	chr5:131705035	SLC22A5	0.43	6.97	0.39	2.53e-11	Blood metabolite levels;
CESC	cis	rs5769765	0.908	rs9616211	chr22:50317676	G/A	cg26441486	chr22:50317300	CRELD2	0.48	5.75	0.33	2.44e-8	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11885407	chr3:193310886	OPA1	0.59	6.46	0.37	5.09e-10	Gut microbiome composition (summer);
CESC	cis	rs6963495	0.818	rs55794529	chr7:105165747	T/C	cg02135003	chr7:105160482	PUS7	-0.47	-5.59	-0.33	5.51e-8	Bipolar disorder (body mass index interaction);
CESC	cis	rs6570726	0.935	rs414222	chr6:145850482	C/T	cg23711669	chr6:146136114	FBXO30	0.8	11.89	0.59	2e-26	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9916302	0.904	rs8066704	chr17:37477218	C/T	cg00129232	chr17:37814104	STARD3	0.55	7.1	0.4	1.14e-11	Glomerular filtration rate (creatinine);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg00450571	chr11:10716455	MRVI1	0.41	6.08	0.35	4.22e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs6860806	0.603	rs112300250	chr5:131583292	G/A	cg18301423	chr5:131593218	PDLIM4	0.38	5.43	0.32	1.29e-7	Breast cancer;
CESC	cis	rs9527	0.590	rs7894959	chr10:104756182	C/T	cg04362960	chr10:104952993	NT5C2	0.44	5.36	0.31	1.81e-7	Arsenic metabolism;
CESC	cis	rs9303401	0.703	rs8072182	chr17:57211213	G/A	cg12560992	chr17:57184187	TRIM37	0.47	5.73	0.33	2.71e-8	Cognitive test performance;
CESC	trans	rs208520	0.526	rs9363522	chr6:66816642	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.07	-23.26	-0.82	6.02e-66	Exhaled nitric oxide output;
CESC	cis	rs6088590	0.931	rs6088617	chr20:33408036	G/A	cg24642439	chr20:33292090	TP53INP2	0.84	11.62	0.58	1.67e-25	Coronary artery disease;
CESC	cis	rs7772486	0.790	rs6917482	chr6:146243581	C/T	cg23711669	chr6:146136114	FBXO30	-0.92	-13.36	-0.63	1.78e-31	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1506636	1.000	rs1506636	chr7:123317140	C/T	cg03229431	chr7:123269106	ASB15	0.49	6.41	0.37	6.76e-10	Plateletcrit;Platelet count;
CESC	cis	rs11785400	1.000	rs10099892	chr8:143734608	C/T	cg24634471	chr8:143751801	JRK	0.46	6.14	0.35	3.02e-9	Schizophrenia;
CESC	cis	rs748404	0.631	rs1133395	chr15:43650384	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.6	7.65	0.43	3.83e-13	Lung cancer;
CESC	cis	rs9303401	0.614	rs34678056	chr17:57177549	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.88	11.1	0.56	8.94e-24	Cognitive test performance;
CESC	cis	rs7116495	0.588	rs547208	chr11:71779668	A/G	cg26138937	chr11:71823887	C11orf51	-0.84	-6.68	-0.38	1.39e-10	Severe influenza A (H1N1) infection;
CESC	cis	rs708547	0.874	rs1401190	chr4:57885174	T/C	cg16868167	chr4:57843880	C4orf14;POLR2B	0.68	7.93	0.44	5.96e-14	Response to bleomycin (chromatid breaks);
CESC	cis	rs9300255	0.568	rs1727300	chr12:123664205	C/T	cg19016782	chr12:123741754	C12orf65	-0.45	-6.4	-0.37	6.92e-10	Neutrophil percentage of white cells;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg17565094	chr4:124036420	SPATA5	0.49	6.85	0.39	5.14e-11	Fibrinogen levels;
CESC	cis	rs6665290	0.669	rs7552783	chr1:227174145	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.11	-22.82	-0.81	1.74e-64	Myeloid white cell count;
CESC	cis	rs10832963	1.000	rs4757676	chr11:18640477	C/T	cg20219074	chr11:18656078	SPTY2D1	0.8	11.77	0.59	5.17e-26	Breast cancer;
CESC	cis	rs8070624	0.543	rs11078409	chr17:17876296	C/G	cg16928487	chr17:17741425	SREBF1	-0.54	-8.64	-0.47	5.35e-16	Total body bone mineral density;
CESC	cis	rs514406	0.607	rs11206000	chr1:53205923	A/C	cg08859206	chr1:53392774	SCP2	0.64	9.36	0.5	3.66e-18	Monocyte count;
CESC	cis	rs9908102	0.740	rs58578352	chr17:12907095	G/C	cg26162695	chr17:12921313	ELAC2	0.51	5.64	0.33	4.33e-8	Schizophrenia;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg08597319	chr8:103876573	AZIN1	-0.47	-6.56	-0.37	2.81e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06862150	chr5:151150984	G3BP1	0.56	6.29	0.36	1.32e-9	Gut microbiome composition (summer);
CESC	cis	rs9311474	0.507	rs6787154	chr3:52784416	C/T	cg18404041	chr3:52824283	ITIH1	-0.39	-6.7	-0.38	1.28e-10	Electroencephalogram traits;
CESC	cis	rs9467160	0.734	rs10946702	chr6:24462672	A/G	cg20631270	chr6:24437470	GPLD1	-0.44	-5.49	-0.32	9.63e-8	Liver enzyme levels;
CESC	cis	rs9611565	0.802	rs2234058	chr22:41777883	G/A	cg06634786	chr22:41940651	POLR3H	-0.7	-7.4	-0.41	1.85e-12	Vitiligo;
CESC	trans	rs1437396	0.657	rs3111404	chr2:55593010	T/A	cg07921503	chr7:2445843	CHST12	-0.24	-6.19	-0.36	2.29e-9	Alcohol dependence;
CESC	cis	rs17826219	0.636	rs8080829	chr17:29058730	C/T	cg14008862	chr17:28927542	LRRC37B2	0.65	5.12	0.3	5.86e-7	Body mass index;
CESC	cis	rs7385804	0.761	rs504141	chr7:100309125	G/A	cg20848291	chr7:100343083	ZAN	0.48	6.46	0.37	5.08e-10	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
CESC	cis	rs11077998	0.844	rs8064433	chr17:80501046	A/T	cg10255544	chr17:80519551	FOXK2	0.54	8.77	0.47	2.16e-16	Reticulocyte fraction of red cells;
CESC	cis	rs7666738	0.830	rs34628820	chr4:99004764	C/T	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.62e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10751667	0.666	rs7396509	chr11:956761	G/A	cg01483505	chr11:975446	AP2A2	0.37	5.05	0.3	8.3e-7	Alzheimer's disease (late onset);
CESC	cis	rs472402	0.623	rs8192133	chr5:6636645	A/G	cg10789808	chr5:6633262	NSUN2;SRD5A1	-0.46	-6.13	-0.35	3.2e-9	Response to amphetamines;
CESC	cis	rs9660180	0.967	rs12044597	chr1:1708801	A/G	cg23982607	chr1:1823379	GNB1	-0.75	-11.94	-0.59	1.41e-26	Body mass index;
CESC	cis	rs10504229	0.679	rs16921676	chr8:58052386	G/T	cg24829409	chr8:58192753	C8orf71	-0.51	-6.16	-0.35	2.75e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs5750830	0.621	rs5750810	chr22:39792943	A/G	cg24399712	chr22:39784796	NA	-0.79	-11.26	-0.57	2.67e-24	Intelligence (multi-trait analysis);
CESC	cis	rs2439831	0.867	rs2614811	chr15:43913487	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.67	8.22	0.45	9.07e-15	Lung cancer in ever smokers;
CESC	cis	rs7666738	0.791	rs34437628	chr4:99029232	C/G	cg18180107	chr4:99064573	C4orf37	0.42	5.43	0.32	1.29e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2921036	0.529	rs2979192	chr8:8338147	C/T	cg06636001	chr8:8085503	FLJ10661	0.49	6.09	0.35	3.94e-9	Neuroticism;
CESC	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg06873352	chr17:61820015	STRADA	0.72	12.71	0.62	3.11e-29	Prudent dietary pattern;
CESC	cis	rs9486719	1.000	rs2472884	chr6:96863965	C/T	cg06623918	chr6:96969491	KIAA0776	0.82	8.4	0.46	2.72e-15	Migraine;Coronary artery disease;
CESC	cis	rs2197308	0.659	rs11181327	chr12:37903171	C/T	cg26384229	chr12:38710491	ALG10B	-0.54	-7.66	-0.43	3.57e-13	Morning vs. evening chronotype;
CESC	cis	rs9311474	0.581	rs13621	chr3:52558133	T/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.3	5.52	0.32	7.89e-8	Electroencephalogram traits;
CESC	cis	rs6500602	0.673	rs1861652	chr16:4505331	C/T	cg08645402	chr16:4508243	NA	0.49	7.27	0.41	3.98e-12	Schizophrenia;
CESC	cis	rs72634258	0.945	rs225132	chr1:8095500	A/C	cg00042356	chr1:8021962	PARK7	0.53	6.06	0.35	4.64e-9	Inflammatory bowel disease;
CESC	cis	rs6546550	0.935	rs6747542	chr2:70106832	T/C	cg02498382	chr2:70120550	SNRNP27	-0.36	-6.23	-0.36	1.86e-9	Prevalent atrial fibrillation;
CESC	cis	rs72945132	0.882	rs7129843	chr11:70180381	G/A	cg14191688	chr11:70257035	CTTN	0.42	5.38	0.31	1.61e-7	Coronary artery disease;
CESC	cis	rs870825	0.616	rs7660939	chr4:185640792	T/C	cg04058563	chr4:185651563	MLF1IP	0.64	7.1	0.4	1.15e-11	Blood protein levels;
CESC	cis	rs3733585	0.673	rs4447861	chr4:9953940	C/T	cg11266682	chr4:10021025	SLC2A9	-0.58	-11.0	-0.56	2.04e-23	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs651907	0.557	rs3806653	chr3:101396972	T/C	cg12386194	chr3:101231763	SENP7	0.44	5.5	0.32	9.14e-8	Colorectal cancer;
CESC	cis	rs4243830	0.850	rs7540913	chr1:6581877	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.78	-8.68	-0.47	4.15e-16	Body mass index;
CESC	cis	rs9467711	0.606	rs9366656	chr6:26434630	T/C	cg14345882	chr6:26364793	BTN3A2	0.61	5.84	0.34	1.56e-8	Autism spectrum disorder or schizophrenia;
CESC	cis	rs2657888	0.965	rs2657905	chr12:56935402	T/A	cg23002907	chr12:56915593	RBMS2	0.39	5.15	0.3	5.11e-7	Adiponectin levels;
CESC	cis	rs10504229	0.906	rs7842855	chr8:58167718	G/C	cg24829409	chr8:58192753	C8orf71	-0.62	-8.39	-0.46	3.01e-15	Developmental language disorder (linguistic errors);
CESC	cis	rs28374715	0.532	rs1899	chr15:41689232	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.03	-16.22	-0.71	1.51e-41	Ulcerative colitis;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg09356014	chr16:87380193	FBXO31	0.53	7.01	0.4	1.92e-11	Fibrinogen levels;
CESC	cis	rs1559088	0.847	rs2287680	chr19:33608566	A/G	cg27124370	chr19:33622961	WDR88	-0.49	-6.49	-0.37	4.22e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs4555082	0.874	rs1882846	chr14:105717448	G/C	cg27165867	chr14:105738592	BRF1	-0.5	-5.46	-0.32	1.09e-7	Mean platelet volume;Platelet distribution width;
CESC	cis	rs832540	0.656	rs832567	chr5:56152416	C/A	cg22800045	chr5:56110881	MAP3K1	0.49	5.83	0.34	1.63e-8	Coronary artery disease;
CESC	cis	rs6964587	1.000	rs6956431	chr7:91750016	T/C	cg17063962	chr7:91808500	NA	0.57	7.87	0.44	9.34e-14	Breast cancer;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg13908518	chr1:104096517	RNPC3;AMY2B	0.38	6.35	0.36	9.12e-10	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs11264213	0.786	rs72659695	chr1:36311143	T/G	cg27506609	chr1:36549197	TEKT2	0.65	5.49	0.32	9.31e-8	Schizophrenia;
CESC	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg14893161	chr1:205819251	PM20D1	0.51	7.67	0.43	3.23e-13	Menarche (age at onset);
CESC	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg03188948	chr7:1209495	NA	0.73	7.05	0.4	1.54e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs11098499	0.863	rs1480940	chr4:120457682	T/C	cg25214090	chr10:38739885	LOC399744	0.7	9.7	0.51	3e-19	Corneal astigmatism;
CESC	cis	rs258892	0.895	rs13182583	chr5:72051575	C/T	cg21869765	chr5:72125136	TNPO1	-0.4	-5.26	-0.31	2.97e-7	Small cell lung carcinoma;
CESC	trans	rs61931739	0.500	rs11053278	chr12:34555955	T/C	cg26384229	chr12:38710491	ALG10B	0.53	7.41	0.41	1.74e-12	Morning vs. evening chronotype;
CESC	cis	rs34172651	0.517	rs7204288	chr16:24784531	A/G	cg06505273	chr16:24850292	NA	0.53	6.51	0.37	3.7e-10	Intelligence (multi-trait analysis);
CESC	cis	rs10882165	0.547	rs10882179	chr10:94952199	C/T	cg00992348	chr10:94926053	NA	-0.31	-5.39	-0.31	1.57e-7	Refractive error;
CESC	cis	rs9916302	0.904	rs801419	chr17:37466327	A/G	cg07936489	chr17:37558343	FBXL20	0.73	9.81	0.52	1.43e-19	Glomerular filtration rate (creatinine);
CESC	cis	rs920590	0.684	rs3899017	chr8:19669198	A/T	cg03894339	chr8:19674705	INTS10	0.67	7.56	0.42	6.62e-13	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs3825932	0.961	rs10400877	chr15:79234378	A/T	cg25744700	chr15:79237217	CTSH	0.48	6.52	0.37	3.62e-10	Type 1 diabetes;
CESC	cis	rs1953600	0.818	rs2152546	chr10:81906384	G/T	cg04850286	chr10:81895943	PLAC9	-0.3	-5.15	-0.3	5.01e-7	Sarcoidosis;
CESC	cis	rs7666738	0.830	rs10017557	chr4:98983969	G/A	cg17366294	chr4:99064904	C4orf37	0.59	8.57	0.47	8.46e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3540	0.597	rs3743409	chr15:91045539	T/A	cg22089800	chr15:90895588	ZNF774	-0.65	-8.98	-0.48	5.06e-17	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs7208859	0.673	rs9915139	chr17:29158515	A/G	cg19761014	chr17:28927070	LRRC37B2	0.78	6.29	0.36	1.31e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs3126085	0.935	rs11204951	chr1:152224404	A/G	cg03465714	chr1:152285911	FLG	-0.46	-5.75	-0.33	2.47e-8	Atopic dermatitis;
CESC	cis	rs72945132	0.882	rs17160039	chr11:70145489	A/G	cg00319359	chr11:70116639	PPFIA1	0.78	7.71	0.43	2.52e-13	Coronary artery disease;
CESC	cis	rs12541635	0.966	rs4734128	chr8:107026913	G/A	cg10147462	chr8:107024639	NA	0.41	5.77	0.33	2.26e-8	Age of smoking initiation;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18439323	chr14:23755769	HOMEZ	-0.57	-7.07	-0.4	1.38e-11	Gut microbiome composition (summer);
CESC	cis	rs7568458	0.684	rs6731700	chr2:85760991	C/G	cg02493740	chr2:85810744	VAMP5	-0.57	-8.29	-0.45	5.86e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CESC	cis	rs2273669	0.667	rs17070139	chr6:109358345	C/G	cg05315195	chr6:109294784	ARMC2	-0.67	-6.06	-0.35	4.74e-9	Prostate cancer;
CESC	trans	rs1814175	0.817	rs1818890	chr11:49856882	T/C	cg15704280	chr7:45808275	SEPT13	-1.02	-19.98	-0.78	8.73e-55	Height;
CESC	trans	rs61931739	0.500	rs7488438	chr12:34531359	G/T	cg26384229	chr12:38710491	ALG10B	0.73	10.87	0.56	5.18e-23	Morning vs. evening chronotype;
CESC	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg06877462	chr1:205807181	PM20D1	0.46	7.03	0.4	1.76e-11	Menarche (age at onset);
CESC	cis	rs9308731	0.591	rs13398360	chr2:111937940	C/T	cg04202892	chr2:111875749	ACOXL	0.37	5.18	0.3	4.34e-7	Chronic lymphocytic leukemia;
CESC	cis	rs818427	0.548	rs373059	chr5:112188437	G/A	cg07820702	chr5:112228657	REEP5	0.4	5.3	0.31	2.46e-7	Total body bone mineral density;
CESC	cis	rs2204008	0.557	rs11520191	chr12:38197057	T/A	cg26384229	chr12:38710491	ALG10B	0.71	10.3	0.53	3.96e-21	Bladder cancer;
CESC	cis	rs7666738	0.830	rs10001479	chr4:98918764	A/G	cg05340658	chr4:99064831	C4orf37	-0.66	-8.88	-0.48	1.01e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg11494091	chr17:61959527	GH2	0.72	12.16	0.6	2.58e-27	Prudent dietary pattern;
CESC	cis	rs73001065	0.792	rs17216525	chr19:19662220	C/T	cg03709012	chr19:19516395	GATAD2A	0.99	6.13	0.35	3.1e-9	LDL cholesterol;
CESC	cis	rs6754459	0.502	rs34759180	chr2:3707394	C/T	cg25251562	chr2:3704773	ALLC	-0.63	-6.57	-0.37	2.73e-10	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CESC	cis	rs922182	0.607	rs8030264	chr15:64271496	C/T	cg24729988	chr15:64271149	DAPK2	-0.48	-6.84	-0.39	5.34e-11	Blood protein levels;
CESC	cis	rs9325144	0.560	rs10785562	chr12:38637419	A/C	cg26384229	chr12:38710491	ALG10B	-0.58	-8.27	-0.45	6.69e-15	Morning vs. evening chronotype;
CESC	cis	rs9788682	0.748	rs667282	chr15:78863472	T/C	cg24631222	chr15:78858424	CHRNA5	0.8	10.3	0.53	3.7e-21	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs4253772	0.550	rs12165597	chr22:46705584	A/G	cg00784671	chr22:46762841	CELSR1	-0.49	-5.67	-0.33	3.76e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs478304	0.934	rs1193496	chr11:65537556	C/T	cg08755490	chr11:65554678	OVOL1	-0.46	-6.06	-0.35	4.6e-9	Acne (severe);
CESC	cis	rs875971	0.545	rs1796219	chr7:66110964	A/G	cg11764359	chr7:65958608	NA	-0.81	-8.99	-0.48	4.92e-17	Aortic root size;
CESC	cis	rs11864453	0.826	rs12708928	chr16:72137227	C/A	cg16558253	chr16:72132732	DHX38	-0.6	-9.59	-0.51	6.97e-19	Fibrinogen levels;
CESC	cis	rs9916302	0.861	rs10491129	chr17:37461643	T/G	cg15445000	chr17:37608096	MED1	-0.4	-6.48	-0.37	4.55e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs7312774	0.618	rs2888892	chr12:107328071	C/T	cg16260113	chr12:107380972	MTERFD3	0.84	7.16	0.4	8.13e-12	Severe influenza A (H1N1) infection;
CESC	cis	rs344364	0.511	rs1742468	chr16:1950243	C/G	cg03013636	chr16:1946785	NA	0.48	6.62	0.38	2.02e-10	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs61776719	0.520	rs17465651	chr1:38418496	C/T	cg18451016	chr1:38461880	NA	0.42	6.24	0.36	1.68e-9	Coronary artery disease;
CESC	cis	rs2760061	0.626	rs672977	chr1:228120288	A/C	cg01973587	chr1:228161476	NA	0.38	5.93	0.34	9.18e-9	Diastolic blood pressure;
CESC	cis	rs2645694	0.626	rs2645704	chr4:77830805	T/C	cg10057126	chr4:77819792	ANKRD56	0.6	8.56	0.47	9.47e-16	Emphysema distribution in smoking;
CESC	cis	rs4629180	0.675	rs10183203	chr2:102095080	C/T	cg01388757	chr2:102091195	RFX8	0.31	5.07	0.3	7.59e-7	Chronic rhinosinusitis with nasal polyps;
CESC	trans	rs2391518	0.639	rs2968998	chr4:130784655	A/G	cg24601559	chr2:43328536	NA	0.35	6.1	0.35	3.83e-9	Body mass index;
CESC	cis	rs12477438	1.000	rs12053372	chr2:99810055	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.72	-8.36	-0.46	3.54e-15	Chronic sinus infection;
CESC	cis	rs3793683	0.520	rs12769959	chr10:134579026	A/C	cg27286337	chr10:134555280	INPP5A	0.66	7.7	0.43	2.68e-13	Migraine;
CESC	cis	rs736408	0.677	rs1042779	chr3:52821011	A/G	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.38	6.5	0.37	3.97e-10	Bipolar disorder;
CESC	cis	rs796364	0.806	rs188102	chr2:200903189	T/A	cg23649088	chr2:200775458	C2orf69	-0.57	-5.24	-0.31	3.23e-7	Schizophrenia;
CESC	cis	rs4073582	0.595	rs10896104	chr11:66001869	C/T	cg14036092	chr11:66035641	RAB1B	0.55	7.65	0.43	3.82e-13	Gout;
CESC	cis	rs7615952	0.576	rs6780025	chr3:125815624	A/C	cg18479299	chr3:125709523	NA	-0.47	-5.05	-0.3	8.2e-7	Blood pressure (smoking interaction);
CESC	trans	rs61931739	1.000	rs12298806	chr12:34036528	C/G	cg26384229	chr12:38710491	ALG10B	-0.46	-6.16	-0.35	2.75e-9	Morning vs. evening chronotype;
CESC	trans	rs3942852	0.545	rs7395231	chr11:48091689	T/C	cg03929089	chr4:120376271	NA	-0.64	-7.91	-0.44	6.85e-14	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs6460942	0.915	rs62448623	chr7:12464122	A/G	cg02935154	chr7:12443704	VWDE	-0.58	-6.16	-0.35	2.73e-9	Coronary artery disease;
CESC	cis	rs7582720	1.000	rs79539678	chr2:203740938	G/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.32	0.41	3.04e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs9948	0.655	rs6751132	chr2:97405866	T/C	cg01990225	chr2:97406019	LMAN2L	-0.88	-7.35	-0.41	2.53e-12	Erectile dysfunction and prostate cancer treatment;
CESC	cis	rs801193	1.000	rs2659915	chr7:66153101	A/G	cg18876405	chr7:65276391	NA	0.51	6.74	0.38	9.86e-11	Aortic root size;
CESC	cis	rs2732480	0.557	rs923397	chr12:48720392	G/A	cg04545296	chr12:48745243	ZNF641	0.36	6.27	0.36	1.49e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs2033711	0.654	rs734380	chr19:58898963	A/C	cg11952622	chr19:58962976	ZNF324B	0.39	5.3	0.31	2.49e-7	Uric acid clearance;
CESC	cis	rs514406	0.893	rs2897561	chr1:53388747	C/A	cg08736216	chr1:53307985	ZYG11A	-0.41	-6.68	-0.38	1.42e-10	Monocyte count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00524296	chr16:88928681	PABPN1L	-0.56	-6.99	-0.39	2.2e-11	Gut microbiome composition (summer);
CESC	trans	rs3780486	0.874	rs10813955	chr9:33141791	C/T	cg20290983	chr6:43655470	MRPS18A	0.98	17.7	0.74	8.37e-47	IgG glycosylation;
CESC	cis	rs9733	0.621	rs12746899	chr1:150579678	A/T	cg17724175	chr1:150552817	MCL1	-0.32	-5.21	-0.3	3.77e-7	Tonsillectomy;
CESC	cis	rs7818688	0.697	rs77805255	chr8:95983566	G/A	cg16049864	chr8:95962084	TP53INP1	0.55	5.55	0.32	6.92e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs1799949	1.000	rs4793197	chr17:41231902	C/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.43	5.81	0.34	1.81e-8	Menopause (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04565464	chr8:145669602	NFKBIL2	0.57	6.45	0.37	5.34e-10	Gut microbiome composition (summer);
CESC	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg24642844	chr7:1081250	C7orf50	-0.76	-9.26	-0.49	7.23e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs9926296	0.529	rs7195906	chr16:89806347	A/T	cg21285383	chr16:89894308	SPIRE2	0.3	5.4	0.31	1.5e-7	Vitiligo;
CESC	trans	rs3780486	0.846	rs10813950	chr9:33127640	A/G	cg20290983	chr6:43655470	MRPS18A	-0.92	-15.5	-0.69	5.15e-39	IgG glycosylation;
CESC	cis	rs172166	0.611	rs203883	chr6:28078356	A/G	cg19592336	chr6:28129416	ZNF389	0.47	6.96	0.39	2.68e-11	Cardiac Troponin-T levels;
CESC	cis	rs875971	1.000	rs778699	chr7:65868290	G/A	cg10691866	chr7:65817282	TPST1	-0.34	-5.47	-0.32	1.06e-7	Aortic root size;
CESC	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg23708337	chr7:1209742	NA	0.55	5.41	0.32	1.41e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs9916302	0.904	rs6503503	chr17:37514373	G/A	cg15445000	chr17:37608096	MED1	-0.41	-6.6	-0.38	2.18e-10	Glomerular filtration rate (creatinine);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06756931	chr17:78820893	RPTOR	-0.53	-6.06	-0.35	4.78e-9	Gut microbiome composition (summer);
CESC	trans	rs71636778	0.509	rs17162311	chr1:27174966	C/T	cg21878188	chr8:67089887	CRH	0.73	6.05	0.35	5.05e-9	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
CESC	cis	rs6545883	0.929	rs778154	chr2:61646631	T/C	cg15711740	chr2:61764176	XPO1	0.39	5.04	0.3	8.79e-7	Tuberculosis;
CESC	cis	rs2303745	0.589	rs10401700	chr19:17397700	A/C	cg22549504	chr19:17448937	GTPBP3	0.48	5.4	0.31	1.52e-7	Systemic lupus erythematosus;
CESC	cis	rs9640161	0.659	rs77354576	chr7:150013300	A/C	cg21361702	chr7:150065534	REPIN1	0.51	5.89	0.34	1.19e-8	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs644799	1.000	rs481630	chr11:95582447	G/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.55	6.62	0.38	1.95e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs372883	0.600	rs1236460	chr21:30615513	G/A	cg24692254	chr21:30365293	RNF160	-0.6	-7.74	-0.43	2.16e-13	Pancreatic cancer;
CESC	cis	rs6541297	0.887	rs6541295	chr1:230281698	A/G	cg20703242	chr1:230279135	GALNT2	0.75	8.08	0.44	2.34e-14	Coronary artery disease;
CESC	cis	rs977987	0.806	rs11641587	chr16:75464419	G/T	cg03315344	chr16:75512273	CHST6	0.41	5.91	0.34	1.07e-8	Dupuytren's disease;
CESC	cis	rs8060686	0.641	rs11075665	chr16:68070774	C/T	cg26727032	chr16:67993705	SLC12A4	-0.55	-6.23	-0.36	1.81e-9	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs3806843	1.000	rs6579987	chr5:140183659	T/C	cg26395211	chr5:140044315	WDR55	-0.42	-5.33	-0.31	2.07e-7	Depressive symptoms (multi-trait analysis);
CESC	trans	rs916888	0.687	rs199456	chr17:44797919	C/T	cg10053473	chr17:62856997	LRRC37A3	-0.72	-7.62	-0.42	4.44e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs7408868	1.000	rs7254269	chr19:15277429	A/T	cg14696996	chr19:15285081	NOTCH3	-1.08	-11.77	-0.59	5.18e-26	Pulse pressure;
CESC	cis	rs9926296	0.529	rs7195906	chr16:89806347	A/T	cg27121462	chr16:89883253	FANCA	0.8	11.85	0.59	2.9e-26	Vitiligo;
CESC	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	7.37	0.41	2.2e-12	Prudent dietary pattern;
CESC	cis	rs2839186	0.770	rs2280956	chr21:47642323	C/G	cg13012494	chr21:47604986	C21orf56	-0.44	-5.82	-0.34	1.72e-8	Testicular germ cell tumor;
CESC	cis	rs6860806	0.695	rs11952099	chr5:131576772	A/G	cg24060327	chr5:131705240	SLC22A5	-0.4	-5.12	-0.3	5.81e-7	Breast cancer;
CESC	cis	rs2637266	1.000	rs7475638	chr10:78358586	G/T	cg18941641	chr10:78392320	NA	-0.41	-7.58	-0.42	5.8e-13	Pulmonary function;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14058584	chr2:130939451	SMPD4;FAM128B	0.55	6.12	0.35	3.43e-9	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09067967	chr4:39529342	UGDH	0.56	6.99	0.39	2.17e-11	Gut microbiome composition (summer);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg10494282	chr1:44440945	ATP6V0B	-0.44	-6.07	-0.35	4.42e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs7666738	0.830	rs11727235	chr4:98946331	T/C	cg05340658	chr4:99064831	C4orf37	0.82	12.66	0.61	4.8e-29	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10927875	0.691	rs1048261	chr1:16340951	A/T	cg22431228	chr1:16359049	CLCNKA	-0.48	-7.88	-0.44	8.75e-14	Dilated cardiomyopathy;
CESC	cis	rs72781680	0.898	rs72782113	chr2:24024952	G/C	cg20701182	chr2:24300061	SF3B14	0.63	5.65	0.33	4.21e-8	Lymphocyte counts;
CESC	cis	rs72781680	1.000	rs72781643	chr2:24208746	G/A	cg20701182	chr2:24300061	SF3B14	0.63	5.58	0.32	5.96e-8	Lymphocyte counts;
CESC	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.89	13.67	0.64	1.49e-32	Prudent dietary pattern;
CESC	trans	rs10751667	1.000	rs6597972	chr11:928402	C/T	cg27162705	chr10:114713024	TCF7L2	-0.4	-6.1	-0.35	3.66e-9	Alzheimer's disease (late onset);
CESC	cis	rs2576037	0.526	rs642897	chr18:44396917	T/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.58	-8.09	-0.45	2.1e-14	Personality dimensions;
CESC	cis	rs7917772	0.503	rs10748825	chr10:104293609	A/G	ch.10.2196322F	chr10:104248062	ACTR1A	0.42	5.17	0.3	4.66e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs11997175	0.624	rs6996590	chr8:33680486	A/G	ch.8.33884649F	chr8:33765107	NA	0.58	7.4	0.41	1.85e-12	Body mass index;
CESC	cis	rs7546094	1.000	rs6666579	chr1:113132393	A/G	cg22162597	chr1:113214053	CAPZA1	0.36	5.6	0.33	5.45e-8	Platelet distribution width;
CESC	cis	rs7945705	0.837	rs10769981	chr11:9024460	T/C	cg21881798	chr11:8931708	C11orf17;ST5	0.46	7.56	0.42	6.62e-13	Hemoglobin concentration;
CESC	cis	rs4629180	0.675	rs6707298	chr2:102089738	A/G	cg04415270	chr2:102091202	RFX8	0.32	5.61	0.33	5.01e-8	Chronic rhinosinusitis with nasal polyps;
CESC	cis	rs7851660	0.870	rs1867278	chr9:100615949	C/A	cg13688889	chr9:100608707	NA	-0.69	-10.57	-0.54	4.92e-22	Strep throat;
CESC	cis	rs13191362	1.000	rs66789102	chr6:163104432	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.67	6.9	0.39	3.79e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs59918340	0.523	rs4961255	chr8:142208248	T/C	cg23750338	chr8:142222470	SLC45A4	0.46	6.52	0.37	3.44e-10	Immature fraction of reticulocytes;
CESC	cis	rs2625529	0.617	rs11633167	chr15:72179178	C/A	cg16672083	chr15:72433130	SENP8	0.37	5.47	0.32	1.06e-7	Red blood cell count;
CESC	cis	rs1801251	1.000	rs6745879	chr2:233590007	A/G	cg08000102	chr2:233561755	GIGYF2	0.69	9.56	0.51	8.52e-19	Coronary artery disease;
CESC	cis	rs6540556	0.723	rs3765240	chr1:209918151	G/A	cg23920097	chr1:209922102	NA	-0.41	-6.03	-0.35	5.56e-9	Red blood cell count;
CESC	cis	rs10883723	0.810	rs10786671	chr10:104271303	G/A	ch.10.2196322F	chr10:104248062	ACTR1A	0.42	5.16	0.3	4.76e-7	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs853679	0.517	rs9393895	chr6:28127621	T/C	cg08968635	chr6:28129556	ZNF389	0.4	5.22	0.31	3.69e-7	Depression;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg19818298	chr14:21905552	CHD8	0.39	6.2	0.36	2.1e-9	Gambling;
CESC	cis	rs9486719	1.000	rs13207333	chr6:96882254	T/C	cg18709589	chr6:96969512	KIAA0776	-0.53	-5.81	-0.34	1.75e-8	Migraine;Coronary artery disease;
CESC	cis	rs7618915	0.571	rs17264436	chr3:52610651	T/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	6.78	0.38	7.75e-11	Bipolar disorder;
CESC	trans	rs4843747	0.671	rs4072871	chr16:88106614	C/T	cg26811252	chr16:29126840	RRN3P2	0.68	9.51	0.5	1.18e-18	Menopause (age at onset);
CESC	cis	rs798554	0.610	rs2527696	chr7:2858315	T/C	cg19717773	chr7:2847554	GNA12	-0.52	-8.16	-0.45	1.32e-14	Height;
CESC	cis	rs1568889	0.838	rs11030187	chr11:28044391	A/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.8	13.73	0.64	9.4e-33	Bipolar disorder;
CESC	cis	rs4722166	0.695	rs7793125	chr7:22809160	A/G	cg05265849	chr7:22767390	IL6	0.44	6.2	0.36	2.19e-9	Lung cancer;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg13904199	chr9:86594091	HNRNPK	0.47	6.04	0.35	5.17e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs6831352	0.877	rs29001183	chr4:100056539	C/T	cg12011299	chr4:100065546	ADH4	-0.6	-6.62	-0.38	2.04e-10	Alcohol dependence;
CESC	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg00730857	chr4:1994281	WHSC2	0.4	5.07	0.3	7.45e-7	Longevity;
CESC	trans	rs9936075	0.519	rs13334398	chr16:7411518	G/A	cg24715815	chr2:183642235	DNAJC10	0.55	6.49	0.37	4.19e-10	Platelet-derived growth factor BB levels;
CESC	cis	rs7833790	0.553	rs9693128	chr8:82706128	A/G	cg02079420	chr8:82753780	SNX16	0.37	5.36	0.31	1.82e-7	Diastolic blood pressure;
CESC	cis	rs748404	0.697	rs546722	chr15:43580819	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.59	7.77	0.43	1.69e-13	Lung cancer;
CESC	cis	rs3092073	0.624	rs3848719	chr20:44596545	G/A	cg17986701	chr20:44574422	PCIF1	0.35	5.11	0.3	6.03e-7	Intelligence (multi-trait analysis);
CESC	cis	rs10779751	1.000	rs11121703	chr1:11293792	G/T	cg08854313	chr1:11322531	MTOR	-0.84	-12.07	-0.6	5.2e-27	Body mass index;
CESC	cis	rs1707322	0.964	rs7512395	chr1:46361177	G/A	cg03146154	chr1:46216737	IPP	0.78	10.75	0.55	1.29e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07706515	chr7:4830907	KIAA0415	-0.57	-6.3	-0.36	1.24e-9	Gut microbiome composition (summer);
CESC	cis	rs13102973	0.932	rs11099305	chr4:135895569	C/G	cg14419869	chr4:135874104	NA	0.34	5.33	0.31	2.13e-7	Subjective well-being;
CESC	cis	rs3858526	0.834	rs10839160	chr11:6002113	T/C	cg13902645	chr11:5959945	NA	-0.51	-6.02	-0.35	5.95e-9	DNA methylation (variation);
CESC	cis	rs1552244	1.000	rs68067759	chr3:10150535	T/C	cg08888203	chr3:10149979	C3orf24	0.46	5.84	0.34	1.5e-8	Alzheimer's disease;
CESC	cis	rs7264396	0.790	rs4519606	chr20:34324648	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.56	7.19	0.4	6.71e-12	Total cholesterol levels;
CESC	cis	rs11683229	0.704	rs4671453	chr2:63102012	G/A	cg17519650	chr2:63277830	OTX1	-0.68	-5.46	-0.32	1.11e-7	Protein quantitative trait loci;
CESC	cis	rs561341	0.739	rs9906455	chr17:30215669	G/A	cg13647721	chr17:30228624	UTP6	-0.76	-9.32	-0.5	4.59e-18	Hip circumference adjusted for BMI;
CESC	cis	rs1862618	0.641	rs170733	chr5:56249251	A/G	cg22800045	chr5:56110881	MAP3K1	-0.61	-7.65	-0.43	3.63e-13	Initial pursuit acceleration;
CESC	cis	rs9733	0.593	rs10888384	chr1:150574256	C/T	cg22823121	chr1:150693482	HORMAD1	-0.36	-5.3	-0.31	2.47e-7	Tonsillectomy;
CESC	cis	rs8017423	0.586	rs2896134	chr14:90831293	G/A	cg14092571	chr14:90743983	NA	0.43	6.42	0.37	6.16e-10	Mortality in heart failure;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg22085380	chr3:120174428	NA	0.45	6.1	0.35	3.71e-9	Thyroid stimulating hormone;
CESC	cis	rs7666738	0.830	rs2865990	chr4:99067399	C/A	cg18180107	chr4:99064573	C4orf37	0.4	5.12	0.3	5.82e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs8141529	0.732	rs2269577	chr22:29196757	G/C	cg15103426	chr22:29168792	CCDC117	0.7	9.94	0.52	5.59e-20	Lymphocyte counts;
CESC	cis	rs1799949	1.000	rs67060599	chr17:41255102	A/G	cg05368731	chr17:41323189	NBR1	0.77	10.75	0.55	1.27e-22	Menopause (age at onset);
CESC	cis	rs9303401	0.614	rs3087762	chr17:56568680	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.0	12.06	0.6	5.33e-27	Cognitive test performance;
CESC	cis	rs2576037	0.796	rs6507718	chr18:44581284	G/C	cg19077165	chr18:44547161	KATNAL2	0.51	7.13	0.4	9.52e-12	Personality dimensions;
CESC	cis	rs11645898	0.748	rs11641424	chr16:72066879	C/T	cg14768367	chr16:72042858	DHODH	-0.84	-6.92	-0.39	3.43e-11	Blood protein levels;
CESC	cis	rs4253772	0.530	rs8140573	chr22:46800363	G/C	cg00784671	chr22:46762841	CELSR1	-0.48	-5.1	-0.3	6.39e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs6669072	0.647	rs2954561	chr1:91240853	G/A	cg08895590	chr1:91227319	NA	-0.33	-5.73	-0.33	2.75e-8	Cognitive function;
CESC	trans	rs5756813	0.700	rs1894525	chr22:38186400	G/A	cg19894588	chr14:64061835	NA	-0.63	-7.98	-0.44	4.47e-14	Optic cup area;Vertical cup-disc ratio;
CESC	cis	rs514406	0.861	rs7526275	chr1:53245849	C/T	cg08859206	chr1:53392774	SCP2	0.54	7.15	0.4	8.22e-12	Monocyte count;
CESC	cis	rs2440129	0.611	rs11571335	chr17:6904263	C/T	cg22741997	chr17:6900356	ALOX12	0.43	6.86	0.39	4.74e-11	Tonsillectomy;
CESC	trans	rs650950	0.528	rs646660	chr11:35528452	C/T	cg02260482	chr12:104359603	TDG	0.46	6.07	0.35	4.37e-9	Bronchopulmonary dysplasia;
CESC	cis	rs9815354	1.000	rs17063584	chr3:41861463	A/G	cg03022575	chr3:42003672	ULK4	0.47	5.22	0.31	3.69e-7	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs9916302	0.904	rs634365	chr17:37436966	C/T	cg07936489	chr17:37558343	FBXL20	-0.74	-10.22	-0.53	6.77e-21	Glomerular filtration rate (creatinine);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21587637	chr13:25861355	MTMR6	0.62	6.78	0.38	7.9e-11	Gut microbiome composition (summer);
CESC	cis	rs2797685	1.000	rs707467	chr1:7861684	A/C	cg04725166	chr1:7887271	PER3	-0.44	-5.99	-0.35	6.84e-9	Crohn's disease;
CESC	cis	rs2836974	0.604	rs2854727	chr21:40713787	A/G	cg17971929	chr21:40555470	PSMG1	0.58	7.57	0.42	6.1e-13	Cognitive function;
CESC	cis	rs72781680	0.848	rs55725028	chr2:23966447	A/G	cg20701182	chr2:24300061	SF3B14	0.76	6.71	0.38	1.15e-10	Lymphocyte counts;
CESC	cis	rs9916302	0.851	rs4390625	chr17:37620347	A/G	cg15445000	chr17:37608096	MED1	0.41	6.76	0.38	8.83e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs4474465	0.850	rs4285892	chr11:78243134	C/A	cg27205649	chr11:78285834	NARS2	0.44	5.34	0.31	1.96e-7	Alzheimer's disease (survival time);
CESC	cis	rs920590	0.721	rs61180388	chr8:19670214	G/C	cg01411142	chr8:19674711	INTS10	0.55	6.02	0.35	5.68e-9	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs514406	0.861	rs2477741	chr1:53265278	A/G	cg08859206	chr1:53392774	SCP2	0.56	7.29	0.41	3.54e-12	Monocyte count;
CESC	cis	rs12541335	0.639	rs11779277	chr8:22200683	C/T	cg26039829	chr8:22132926	PIWIL2	0.38	5.89	0.34	1.19e-8	Hypertriglyceridemia;
CESC	cis	rs9733	0.519	rs1336899	chr1:150678910	T/C	cg18016565	chr1:150552671	MCL1	0.34	5.25	0.31	3.08e-7	Tonsillectomy;
CESC	cis	rs3857067	0.509	rs11729256	chr4:95027272	A/G	cg11021082	chr4:95130006	SMARCAD1	0.42	5.31	0.31	2.36e-7	QT interval;
CESC	cis	rs1577917	0.958	rs10944147	chr6:86550786	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-6.14	-0.35	2.93e-9	Response to antipsychotic treatment;
CESC	cis	rs6540556	0.634	rs11485195	chr1:209891738	T/C	cg05527609	chr1:210001259	C1orf107	-0.67	-7.35	-0.41	2.43e-12	Red blood cell count;
CESC	cis	rs3020736	0.500	rs9620026	chr22:42498578	C/T	cg04733989	chr22:42467013	NAGA	-0.79	-12.03	-0.59	6.75e-27	Autism spectrum disorder or schizophrenia;
CESC	cis	rs11249608	0.548	rs7709054	chr5:178462757	C/T	cg01312482	chr5:178451176	ZNF879	-0.45	-6.05	-0.35	4.95e-9	Pubertal anthropometrics;
CESC	cis	rs12950390	0.853	rs11079791	chr17:45859099	C/T	cg00777063	chr17:45855553	NA	-0.38	-5.78	-0.33	2.08e-8	IgG glycosylation;
CESC	trans	rs10028773	0.556	rs4473640	chr4:120260437	G/A	cg25214090	chr10:38739885	LOC399744	0.61	8.64	0.47	5.49e-16	Educational attainment;
CESC	cis	rs826838	0.967	rs7970069	chr12:38810631	T/C	cg13010199	chr12:38710504	ALG10B	0.6	8.53	0.46	1.18e-15	Heart rate;
CESC	trans	rs7824557	0.505	rs2736313	chr8:11086942	C/T	cg06636001	chr8:8085503	FLJ10661	0.52	6.68	0.38	1.41e-10	Retinal vascular caliber;
CESC	cis	rs2730245	1.000	rs6965685	chr7:158726462	C/T	cg24397884	chr7:158709396	WDR60	0.85	12.94	0.62	5.12e-30	Height;
CESC	cis	rs9311474	1.000	rs2276834	chr3:52325759	A/G	cg18337363	chr3:52569053	NT5DC2	0.34	6.4	0.37	7e-10	Electroencephalogram traits;
CESC	cis	rs2760061	0.583	rs708124	chr1:228220771	A/T	cg02753203	chr1:228287806	NA	0.83	13.13	0.63	1.09e-30	Diastolic blood pressure;
CESC	cis	rs6087990	0.842	rs4911253	chr20:31352585	A/G	cg13636640	chr20:31349939	DNMT3B	0.79	12.8	0.62	1.58e-29	Ulcerative colitis;
CESC	cis	rs1055129	0.560	rs56248937	chr17:73915153	T/A	cg02678768	chr17:74002944	EVPL	0.42	5.91	0.34	1.02e-8	White matter hyperintensity burden;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21483906	chr3:33758870	CLASP2	0.54	6.09	0.35	3.94e-9	Gut microbiome composition (summer);
CESC	cis	rs4975709	0.589	rs4975747	chr5:1862836	G/A	cg07747251	chr5:1868357	NA	0.32	5.39	0.31	1.54e-7	Cardiovascular disease risk factors;
CESC	cis	rs9487051	0.872	rs9386794	chr6:109611521	A/C	cg01475377	chr6:109611718	NA	-0.49	-8.21	-0.45	9.56e-15	Reticulocyte fraction of red cells;
CESC	cis	rs6598955	0.670	rs4659366	chr1:26542572	G/A	cg00852783	chr1:26633632	UBXN11	0.4	5.83	0.34	1.57e-8	Obesity-related traits;
CESC	cis	rs763014	0.931	rs3752567	chr16:628130	A/G	cg00802000	chr16:706648	WDR90	-0.42	-6.22	-0.36	1.96e-9	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22254299	chr17:77772001	CBX8	0.6	6.57	0.37	2.65e-10	Gut microbiome composition (summer);
CESC	cis	rs7811142	1.000	rs1073	chr7:100031612	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.0	9.63	0.51	5.12e-19	Platelet count;
CESC	cis	rs2932538	0.922	rs6663922	chr1:113095948	T/C	cg22162597	chr1:113214053	CAPZA1	0.47	6.21	0.36	2.05e-9	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CESC	cis	rs2836974	0.568	rs7282604	chr21:40536910	C/T	cg17971929	chr21:40555470	PSMG1	-0.86	-12.83	-0.62	1.24e-29	Cognitive function;
CESC	cis	rs7666738	0.753	rs35146453	chr4:98902278	A/G	cg17366294	chr4:99064904	C4orf37	0.57	7.73	0.43	2.3e-13	Colonoscopy-negative controls vs population controls;
CESC	cis	rs56235845	0.694	rs11949401	chr5:176765989	A/G	cg17509989	chr5:176798049	RGS14	0.5	6.27	0.36	1.47e-9	Hemoglobin concentration;Hematocrit;
CESC	cis	rs12618769	0.652	rs76525766	chr2:99221088	A/G	cg10123293	chr2:99228465	UNC50	0.4	5.32	0.31	2.2e-7	Bipolar disorder;
CESC	cis	rs2243480	0.808	rs12698508	chr7:65411958	A/T	cg13147721	chr7:65941812	NA	-0.88	-8.15	-0.45	1.5e-14	Diabetic kidney disease;
CESC	cis	rs8064299	0.655	rs895691	chr17:72766300	G/T	cg25054828	chr17:72772726	NAT9;TMEM104	0.48	6.51	0.37	3.79e-10	Monocyte count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04198107	chr10:125852011	NA	-0.63	-7.28	-0.41	3.86e-12	Gut microbiome composition (summer);
CESC	cis	rs7412746	0.611	rs7556661	chr1:150892009	C/T	cg17724175	chr1:150552817	MCL1	0.38	5.9	0.34	1.11e-8	Melanoma;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10729317	chr20:2821390	FAM113A;VPS16	0.6	7.51	0.42	8.99e-13	Gut microbiome composition (summer);
CESC	cis	rs909674	0.865	rs5757683	chr22:39850174	G/A	cg24399712	chr22:39784796	NA	-0.81	-10.59	-0.55	4.37e-22	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs7091068	0.616	rs7084701	chr10:95482249	A/G	cg20715218	chr10:95462985	C10orf4	0.52	5.37	0.31	1.69e-7	Urinary tract infection frequency;
CESC	cis	rs2404602	0.536	rs17364330	chr15:76765385	A/T	cg22467129	chr15:76604101	ETFA	-0.4	-6.27	-0.36	1.48e-9	Blood metabolite levels;
CESC	cis	rs2425143	1.000	rs117010355	chr20:34343442	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.65	5.44	0.32	1.2e-7	Blood protein levels;
CESC	cis	rs938554	0.513	rs3775947	chr4:9995240	C/T	cg11266682	chr4:10021025	SLC2A9	0.5	7.25	0.41	4.69e-12	Blood metabolite levels;
CESC	trans	rs2018683	0.707	rs7799357	chr7:28970118	A/G	cg19402173	chr7:128379420	CALU	-0.53	-7.1	-0.4	1.13e-11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CESC	cis	rs2228479	0.867	rs62052189	chr16:89975555	G/C	cg06558623	chr16:89946397	TCF25	0.9	7.89	0.44	7.95e-14	Skin colour saturation;
CESC	cis	rs4722166	0.630	rs4722168	chr7:22779002	G/A	cg26061582	chr7:22766209	IL6	0.51	5.55	0.32	6.82e-8	Lung cancer;
CESC	cis	rs4374383	0.532	rs4525701	chr2:112787827	A/G	cg07905836	chr2:113190072	RGPD8;RGPD5	0.56	5.83	0.34	1.59e-8	Hepatitis C induced liver fibrosis;
CESC	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg26354017	chr1:205819088	PM20D1	0.91	15.59	0.69	2.45e-39	Menarche (age at onset);
CESC	cis	rs4330281	0.715	rs7427588	chr3:17806424	A/G	cg20981856	chr3:17787350	NA	0.37	5.17	0.3	4.61e-7	Schizophrenia;
CESC	cis	rs11098499	0.739	rs9884728	chr4:120127079	C/T	cg09307838	chr4:120376055	NA	-0.67	-8.34	-0.46	4e-15	Corneal astigmatism;
CESC	cis	rs3733585	0.806	rs11723382	chr4:9954660	T/C	cg11266682	chr4:10021025	SLC2A9	-0.61	-12.75	-0.62	2.35e-29	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs4555082	1.000	rs7146683	chr14:105759385	A/G	cg27165867	chr14:105738592	BRF1	-0.47	-5.52	-0.32	7.94e-8	Mean platelet volume;Platelet distribution width;
CESC	cis	rs1387259	0.929	rs2956703	chr12:48670294	C/T	cg24011408	chr12:48396354	COL2A1	0.43	6.07	0.35	4.46e-9	Obstructive sleep apnea trait (apnea hypopnea index);
CESC	cis	rs9309473	0.687	rs10165862	chr2:73610743	C/T	cg20560298	chr2:73613845	ALMS1	-0.45	-6.4	-0.37	7.04e-10	Metabolite levels;
CESC	cis	rs4665809	1.000	rs6546768	chr2:26328800	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.66	-7.37	-0.41	2.12e-12	Gut microbiome composition (summer);
CESC	cis	rs13118159	0.771	rs13117476	chr4:1334721	A/G	cg16405210	chr4:1374714	KIAA1530	-0.6	-8.28	-0.45	6.07e-15	Longevity;
CESC	cis	rs2276314	1.000	rs58054756	chr18:33554053	G/C	cg05985134	chr18:33552581	C18orf21	0.65	7.57	0.42	6.14e-13	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs61996546	0.622	rs61998698	chr15:26868306	G/C	cg14859324	chr15:26874363	GABRB3	-0.38	-5.27	-0.31	2.81e-7	Response to methotrexate in juvenile idiopathic arthritis;
CESC	cis	rs4665809	1.000	rs6546726	chr2:26275116	A/G	cg22920501	chr2:26401640	FAM59B	-0.7	-8.35	-0.46	3.85e-15	Gut microbiome composition (summer);
CESC	cis	rs6580649	0.941	rs7310579	chr12:48427523	G/A	cg05342945	chr12:48394962	COL2A1	0.53	6.07	0.35	4.33e-9	Lung cancer;
CESC	cis	rs11696501	0.688	rs6073848	chr20:44298550	G/A	cg11783356	chr20:44313418	WFDC10B	-0.34	-5.3	-0.31	2.4e-7	Brain structure;
CESC	cis	rs9487051	0.676	rs7773775	chr6:109600339	T/C	cg01475377	chr6:109611718	NA	-0.43	-6.82	-0.39	6.19e-11	Reticulocyte fraction of red cells;
CESC	cis	rs12042107	0.740	rs2166171	chr1:91208451	T/C	cg13456504	chr1:91191583	NA	-0.34	-5.79	-0.34	1.97e-8	Educational attainment;
CESC	cis	rs4481887	0.893	rs1934543	chr1:248505602	C/G	cg00666640	chr1:248458726	OR2T12	0.35	6.04	0.35	5.14e-9	Common traits (Other);
CESC	cis	rs1008375	1.000	rs3815413	chr4:17654648	T/C	cg02297831	chr4:17616191	MED28	0.61	7.82	0.43	1.23e-13	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs6598955	0.671	rs17163868	chr1:26648381	A/G	cg19743891	chr1:26644573	UBXN11;CD52	-0.36	-5.27	-0.31	2.84e-7	Obesity-related traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25166340	chr7:39605883	C7orf36	0.58	6.85	0.39	5e-11	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16235531	chr5:66459345	MAST4	-0.57	-6.56	-0.37	2.77e-10	Gut microbiome composition (summer);
CESC	cis	rs4853012	0.887	rs77148265	chr2:74339519	C/T	cg20891558	chr2:74357851	NA	0.75	9.91	0.52	6.63e-20	Gestational age at birth (maternal effect);
CESC	cis	rs769267	0.965	rs7254230	chr19:19434350	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.62	-8.04	-0.44	2.94e-14	Tonsillectomy;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg12780433	chr3:159481918	SCHIP1	-0.44	-6.26	-0.36	1.58e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs1348850	0.567	rs880897	chr2:178532503	C/T	cg22681709	chr2:178499509	PDE11A	-0.49	-7.27	-0.41	4.12e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs6754311	0.731	rs7579771	chr2:136580260	T/A	cg07169764	chr2:136633963	MCM6	0.64	7.7	0.43	2.68e-13	Mosquito bite size;
CESC	trans	rs7746199	0.736	rs58616630	chr6:27474715	A/G	cg21479132	chr6:26055353	NA	0.84	6.06	0.35	4.64e-9	Gait speed in old age;Autism spectrum disorder or schizophrenia;
CESC	cis	rs6121246	0.954	rs6058470	chr20:30416827	A/T	cg13852791	chr20:30311386	BCL2L1	0.82	8.33	0.46	4.24e-15	Mean corpuscular hemoglobin;
CESC	cis	rs2710642	0.576	rs6545968	chr2:62871184	C/A	cg17519650	chr2:63277830	OTX1	0.51	5.98	0.34	7.08e-9	LDL cholesterol levels;LDL cholesterol;
CESC	cis	rs3026101	0.624	rs55970234	chr17:5316765	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.4	5.17	0.3	4.63e-7	Body mass index;
CESC	cis	rs7223966	0.655	rs9906882	chr17:61634382	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.47	5.26	0.31	3.03e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs12541335	0.639	rs11135995	chr8:22200148	C/T	cg02463440	chr8:22132932	PIWIL2	-0.4	-6.21	-0.36	2.03e-9	Hypertriglyceridemia;
CESC	cis	rs9612	1.000	rs12611034	chr19:44268678	C/T	cg08581076	chr19:44259116	C19orf61	0.49	5.76	0.33	2.35e-8	Exhaled nitric oxide output;
CESC	cis	rs6456156	0.792	rs4710178	chr6:167513532	G/A	cg07741184	chr6:167504864	NA	0.38	6.89	0.39	4.14e-11	Primary biliary cholangitis;
CESC	cis	rs9916302	0.904	rs801426	chr17:37441109	C/T	cg15445000	chr17:37608096	MED1	-0.41	-6.73	-0.38	1.03e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs7044106	0.791	rs4836830	chr9:123483668	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.7	10.15	0.53	1.13e-20	Hip circumference adjusted for BMI;
CESC	cis	rs2439831	0.850	rs558656	chr15:43723514	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.87	10.44	0.54	1.39e-21	Lung cancer in ever smokers;
CESC	cis	rs62432291	0.681	rs425906	chr6:159657575	C/T	cg14500486	chr6:159655392	FNDC1	-0.62	-6.34	-0.36	9.83e-10	Joint mobility (Beighton score);
CESC	cis	rs425277	0.606	rs3128339	chr1:2046938	G/T	cg24578937	chr1:2090814	PRKCZ	-0.35	-6.06	-0.35	4.65e-9	Height;
CESC	cis	rs7615952	0.799	rs13315434	chr3:125641394	T/G	cg05084668	chr3:125655381	ALG1L	-0.45	-5.44	-0.32	1.21e-7	Blood pressure (smoking interaction);
CESC	cis	rs4423214	0.570	rs7118246	chr11:71231124	G/C	cg05163923	chr11:71159392	DHCR7	0.74	9.16	0.49	1.44e-17	Vitamin D levels;
CESC	cis	rs10870270	1.000	rs10870271	chr10:133754807	A/G	cg17892150	chr10:133769511	PPP2R2D	0.84	12.0	0.59	8.42e-27	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs7937682	0.632	rs11214028	chr11:111761149	T/C	cg22437258	chr11:111473054	SIK2	-0.5	-5.53	-0.32	7.78e-8	Primary sclerosing cholangitis;
CESC	cis	rs514406	0.505	rs269287	chr1:53168842	T/C	cg27535305	chr1:53392650	SCP2	-0.33	-5.47	-0.32	1.03e-7	Monocyte count;
CESC	cis	rs6121246	0.909	rs3203770	chr20:30382315	A/G	cg13852791	chr20:30311386	BCL2L1	0.81	8.61	0.47	6.48e-16	Mean corpuscular hemoglobin;
CESC	cis	rs7520050	0.966	rs7540325	chr1:46338217	A/T	cg03146154	chr1:46216737	IPP	-0.48	-6.22	-0.36	1.98e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs7100689	0.556	rs10788541	chr10:82016530	T/G	cg00277334	chr10:82204260	NA	-0.48	-6.1	-0.35	3.69e-9	Post bronchodilator FEV1;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27360527	chr16:85722694	GINS2	0.59	6.71	0.38	1.19e-10	Gut microbiome composition (summer);
CESC	cis	rs801193	1.000	rs7788576	chr7:66148302	G/A	cg25985355	chr7:65971099	NA	0.31	5.08	0.3	7.18e-7	Aortic root size;
CESC	cis	rs7618915	0.547	rs34017441	chr3:52742413	T/C	cg07507251	chr3:52567010	NT5DC2	0.39	6.87	0.39	4.68e-11	Bipolar disorder;
CESC	cis	rs4268898	0.662	rs55661701	chr2:24400769	A/C	cg06627628	chr2:24431161	ITSN2	-0.98	-9.85	-0.52	1.06e-19	Asthma;
CESC	cis	rs854765	1.000	rs854765	chr17:18012730	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.48	-6.25	-0.36	1.61e-9	Total body bone mineral density;
CESC	cis	rs6500602	0.789	rs2404546	chr16:4479734	C/G	cg08645402	chr16:4508243	NA	0.43	6.65	0.38	1.67e-10	Schizophrenia;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg21150049	chr12:50677498	LIMA1	-0.5	-6.68	-0.38	1.39e-10	Ulcerative colitis;
CESC	cis	rs10504229	0.593	rs12216730	chr8:58003894	C/T	cg24829409	chr8:58192753	C8orf71	-0.47	-5.83	-0.34	1.63e-8	Developmental language disorder (linguistic errors);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg13823188	chr17:80039244	FASN	0.46	6.41	0.37	6.63e-10	Fibrinogen levels;
CESC	cis	rs4268898	0.931	rs34504814	chr2:24503766	C/T	cg08917208	chr2:24149416	ATAD2B	0.46	5.29	0.31	2.59e-7	Asthma;
CESC	cis	rs7666738	0.927	rs11736876	chr4:98987206	A/G	cg03676636	chr4:99064102	C4orf37	0.36	5.36	0.31	1.78e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2576037	0.544	rs629097	chr18:44378097	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.51	-7.03	-0.4	1.73e-11	Personality dimensions;
CESC	cis	rs3768617	0.528	rs6672093	chr1:183079853	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.83	13.05	0.63	2.08e-30	Fuchs's corneal dystrophy;
CESC	cis	rs5758659	0.652	rs133330	chr22:42409456	G/A	cg04733989	chr22:42467013	NAGA	0.44	5.85	0.34	1.41e-8	Cognitive function;
CESC	cis	rs875971	0.545	rs4718348	chr7:65906576	A/G	cg25405998	chr7:65216604	CCT6P1	0.47	5.3	0.31	2.38e-7	Aortic root size;
CESC	cis	rs7584330	0.638	rs13429533	chr2:238448712	A/G	cg06639874	chr2:238417703	MLPH	-0.37	-5.56	-0.32	6.73e-8	Prostate cancer;
CESC	cis	rs4268898	0.931	rs60716082	chr2:24526265	T/A	cg08917208	chr2:24149416	ATAD2B	0.47	5.37	0.31	1.73e-7	Asthma;
CESC	cis	rs56804039	1.000	rs56804039	chr8:8381029	C/G	cg15556689	chr8:8085844	FLJ10661	-0.49	-5.28	-0.31	2.66e-7	Cervical cancer;
CESC	cis	rs2075371	0.933	rs2544201	chr7:133963561	C/G	cg00033643	chr7:134001901	SLC35B4	0.4	5.1	0.3	6.45e-7	Mean platelet volume;
CESC	cis	rs796364	0.806	rs12616905	chr2:201007764	C/G	cg23649088	chr2:200775458	C2orf69	-0.55	-5.04	-0.3	8.69e-7	Schizophrenia;
CESC	cis	rs7264396	0.563	rs2425114	chr20:34322346	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.88	-10.7	-0.55	1.88e-22	Total cholesterol levels;
CESC	cis	rs4737010	0.501	rs34342524	chr8:41633857	G/A	cg08923054	chr8:41654455	ANK1	-0.47	-5.83	-0.34	1.59e-8	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
CESC	cis	rs4969178	0.965	rs8075131	chr17:76394595	T/G	cg05887092	chr17:76393375	PGS1	0.57	9.02	0.48	3.94e-17	HDL cholesterol levels;
CESC	trans	rs561341	0.941	rs8066558	chr17:30272879	G/T	cg20587970	chr11:113659929	NA	-1.14	-14.26	-0.66	1.22e-34	Hip circumference adjusted for BMI;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07853084	chr13:73632891	KLF5	0.56	6.52	0.37	3.57e-10	Gut microbiome composition (summer);
CESC	cis	rs80130819	0.748	rs901963	chr12:48734609	A/G	cg05342945	chr12:48394962	COL2A1	-0.5	-5.32	-0.31	2.21e-7	Prostate cancer;
CESC	cis	rs7834588	0.523	rs1902237	chr8:63820239	C/G	cg20602954	chr8:63776762	NKAIN3	0.3	5.1	0.3	6.36e-7	Response to Vitamin E supplementation;
CESC	cis	rs3741151	0.773	rs73542976	chr11:73127471	A/G	cg17517138	chr11:73019481	ARHGEF17	0.94	6.86	0.39	4.87e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs7811142	1.000	rs7783159	chr7:100017454	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.01	10.51	0.54	8.06e-22	Platelet count;
CESC	cis	rs12497850	0.897	rs9681717	chr3:48872998	A/G	cg03060546	chr3:49711283	APEH	0.46	5.45	0.32	1.13e-7	Parkinson's disease;
CESC	cis	rs9814567	0.865	rs9834981	chr3:134282279	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.46	-6.17	-0.35	2.48e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs933688	0.532	rs10072084	chr5:90539203	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.44	5.63	0.33	4.61e-8	Smoking behavior;
CESC	cis	rs7264396	0.563	rs2225950	chr20:34333015	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.89	-10.73	-0.55	1.57e-22	Total cholesterol levels;
CESC	cis	rs7208859	0.623	rs7503335	chr17:29073962	G/A	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.1e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	trans	rs208520	0.802	rs208499	chr6:66932146	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.81	-9.62	-0.51	5.57e-19	Exhaled nitric oxide output;
CESC	cis	rs28386778	0.965	rs2854154	chr17:61981696	C/A	cg06601766	chr17:61851465	DDX42;CCDC47	-0.46	-5.56	-0.32	6.5e-8	Prudent dietary pattern;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10824722	chr1:206506826	NA	-0.62	-7.9	-0.44	7.61e-14	Gut microbiome composition (summer);
CESC	cis	rs10504229	0.953	rs6985942	chr8:58173412	T/C	cg05313129	chr8:58192883	C8orf71	-0.46	-5.73	-0.33	2.74e-8	Developmental language disorder (linguistic errors);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg20095338	chr12:76478402	NAP1L1	-0.42	-6.29	-0.36	1.32e-9	Gambling;
CESC	cis	rs12188164	0.965	rs11744539	chr5:451425	C/T	cg17553881	chr5:443987	EXOC3;C5orf55	-0.39	-6.25	-0.36	1.67e-9	Cystic fibrosis severity;
CESC	cis	rs9788682	0.747	rs8043009	chr15:78908154	G/C	cg24631222	chr15:78858424	CHRNA5	0.79	9.71	0.51	2.93e-19	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs7666738	0.830	rs10034619	chr4:98970067	G/C	cg05340658	chr4:99064831	C4orf37	0.77	11.73	0.58	7.21e-26	Colonoscopy-negative controls vs population controls;
CESC	cis	rs28374715	0.681	rs7168307	chr15:41620534	A/G	cg20272979	chr15:41787780	ITPKA	0.43	5.79	0.33	2.02e-8	Ulcerative colitis;
CESC	cis	rs6089829	0.889	rs6122348	chr20:61663921	C/T	cg03213289	chr20:61660250	NA	0.39	6.07	0.35	4.42e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs17102884	0.506	rs11845397	chr14:75404587	G/A	cg11812906	chr14:75593930	NEK9	-0.44	-5.41	-0.32	1.44e-7	Neuroticism;
CESC	cis	rs3126085	1.000	rs3126095	chr1:152309683	G/A	cg03465714	chr1:152285911	FLG	0.43	5.22	0.31	3.62e-7	Atopic dermatitis;
CESC	cis	rs9916302	0.808	rs12948906	chr17:37644854	C/T	cg00129232	chr17:37814104	STARD3	-0.57	-7.57	-0.42	6.31e-13	Glomerular filtration rate (creatinine);
CESC	cis	rs9549367	0.713	rs9549682	chr13:113830181	C/T	cg00898013	chr13:113819073	PROZ	-0.57	-7.72	-0.43	2.32e-13	Platelet distribution width;
CESC	cis	rs6540559	0.673	rs17015218	chr1:209967915	A/G	cg09509183	chr1:209979624	IRF6	0.54	5.74	0.33	2.59e-8	Cleft lip with or without cleft palate;
CESC	cis	rs62408225	1.000	rs55881869	chr6:90968025	C/A	cg06866423	chr6:90926672	BACH2	0.46	5.5	0.32	9.01e-8	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs2836950	0.501	rs2836980	chr21:40687618	G/T	cg11644478	chr21:40555479	PSMG1	-0.55	-7.57	-0.42	6.38e-13	Menarche (age at onset);
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg04818274	chr16:69420026	TERF2	-0.49	-6.44	-0.37	5.53e-10	Asthma;
CESC	cis	rs853679	0.517	rs9368556	chr6:28131153	T/C	cg20151795	chr6:28129481	ZNF389	0.44	5.55	0.32	6.85e-8	Depression;
CESC	cis	rs599083	0.530	rs546803	chr11:68186392	C/T	cg01657329	chr11:68192670	LRP5	0.44	5.07	0.3	7.55e-7	Bone mineral density (spine);
CESC	cis	rs3015497	0.904	rs3015501	chr14:51108524	C/T	cg26011998	chr14:51135199	SAV1	-0.41	-5.18	-0.3	4.36e-7	Mean platelet volume;
CESC	cis	rs1691799	0.899	rs903589	chr12:66745835	C/T	cg16791601	chr12:66731901	HELB	-0.62	-10.33	-0.54	2.96e-21	White blood cell count (basophil);
CESC	cis	rs13256369	0.802	rs12681326	chr8:8566389	G/A	cg17143192	chr8:8559678	CLDN23	0.74	8.34	0.46	4.15e-15	Obesity-related traits;
CESC	cis	rs3015497	0.575	rs8023035	chr14:51162419	A/G	cg09863266	chr14:51125203	SAV1	-0.33	-5.07	-0.3	7.64e-7	Mean platelet volume;
CESC	cis	rs2251381	0.565	rs2832279	chr21:30613466	G/T	cg24692254	chr21:30365293	RNF160	0.59	7.41	0.41	1.71e-12	Selective IgA deficiency;
CESC	cis	rs17666538	0.585	rs6559063	chr8:623051	C/T	cg23958373	chr8:599963	NA	0.81	5.63	0.33	4.61e-8	IgG glycosylation;
CESC	cis	rs7116495	0.881	rs7930142	chr11:71737016	C/T	cg10381502	chr11:71823885	C11orf51	-0.64	-5.21	-0.3	3.81e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs4718428	0.705	rs4717331	chr7:66378886	C/T	cg12165864	chr7:66369176	NA	-0.68	-7.98	-0.44	4.53e-14	Corneal structure;
CESC	cis	rs2455799	0.573	rs2455836	chr3:15754538	A/G	cg16303742	chr3:15540471	COLQ	-0.39	-6.19	-0.36	2.34e-9	Mean platelet volume;
CESC	cis	rs2262909	1.000	rs431328	chr19:22222236	A/G	cg11619707	chr19:22235551	ZNF257	-0.37	-6.28	-0.36	1.34e-9	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
CESC	cis	rs9420	0.961	rs7938083	chr11:57493622	C/A	cg19752551	chr11:57585705	CTNND1	-0.38	-5.1	-0.3	6.6e-7	Schizophrenia;
CESC	cis	rs17376456	0.877	rs28633397	chr5:93447048	A/G	cg21475434	chr5:93447410	FAM172A	0.82	7.56	0.42	6.81e-13	Diabetic retinopathy;
CESC	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg17178900	chr1:205818956	PM20D1	-0.66	-10.82	-0.55	7.95e-23	Monocyte percentage of white cells;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02927949	chr13:103426033	C13orf27	0.58	6.28	0.36	1.42e-9	Gut microbiome composition (summer);
CESC	cis	rs4911259	0.552	rs11697394	chr20:31460076	G/A	cg13636640	chr20:31349939	DNMT3B	-0.56	-7.85	-0.43	1e-13	Inflammatory bowel disease;
CESC	cis	rs17376456	0.877	rs10070390	chr5:93452345	G/A	cg25358565	chr5:93447407	FAM172A	1.15	11.8	0.59	4.11e-26	Diabetic retinopathy;
CESC	cis	rs7833790	0.724	rs6473309	chr8:82707880	A/G	cg07697082	chr8:82753677	SNX16	0.38	5.79	0.33	2.02e-8	Diastolic blood pressure;
CESC	trans	rs916888	0.821	rs199512	chr17:44857352	T/C	cg22968622	chr17:43663579	NA	-1.19	-16.28	-0.71	8.87e-42	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs8077577	1.000	rs8077577	chr17:18064730	C/T	cg16794390	chr17:18148240	FLII	0.43	5.87	0.34	1.27e-8	Obesity-related traits;
CESC	cis	rs11690935	0.959	rs10497374	chr2:172640623	A/G	cg13550731	chr2:172543902	DYNC1I2	-1.01	-16.56	-0.71	9.29e-43	Schizophrenia;
CESC	cis	rs7833986	0.501	rs72653967	chr8:56999432	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.62	7.54	0.42	7.58e-13	Height;
CESC	cis	rs7666738	0.546	rs10025064	chr4:98914060	A/G	cg17366294	chr4:99064904	C4orf37	0.52	6.57	0.37	2.65e-10	Colonoscopy-negative controls vs population controls;
CESC	cis	rs12545109	0.800	rs1348082	chr8:57415016	A/G	cg09654669	chr8:57350985	NA	-0.46	-6.25	-0.36	1.67e-9	Obesity-related traits;
CESC	cis	rs2439831	0.618	rs8023508	chr15:44176103	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.67	-6.88	-0.39	4.24e-11	Lung cancer in ever smokers;
CESC	cis	rs1799949	0.965	rs8176193	chr17:41231516	C/T	cg25072359	chr17:41440525	NA	0.45	6.17	0.35	2.49e-9	Menopause (age at onset);
CESC	cis	rs3858526	0.514	rs1530973	chr11:5861449	C/T	cg13902645	chr11:5959945	NA	-0.66	-9.03	-0.49	3.62e-17	DNA methylation (variation);
CESC	trans	rs11098499	0.754	rs7672372	chr4:120248406	A/G	cg25214090	chr10:38739885	LOC399744	0.62	8.69	0.47	3.79e-16	Corneal astigmatism;
CESC	cis	rs898097	0.756	rs11655103	chr17:80813467	T/C	cg10494973	chr17:80897199	TBCD	0.49	5.66	0.33	3.89e-8	Breast cancer;
CESC	trans	rs11039798	0.588	rs6485857	chr11:48556511	C/A	cg15704280	chr7:45808275	SEPT13	0.66	6.67	0.38	1.46e-10	Axial length;
CESC	cis	rs7647973	0.580	rs12629759	chr3:49237394	T/C	cg03060546	chr3:49711283	APEH	0.5	6.76	0.38	8.72e-11	Menarche (age at onset);
CESC	cis	rs9733	0.596	rs34140753	chr1:150642583	T/C	cg18016565	chr1:150552671	MCL1	0.33	5.16	0.3	4.96e-7	Tonsillectomy;
CESC	cis	rs7843479	0.965	rs11135763	chr8:21813962	A/G	cg17168535	chr8:21777572	XPO7	0.5	6.94	0.39	3.07e-11	Mean corpuscular volume;
CESC	cis	rs6942756	0.774	rs66479871	chr7:129009687	T/C	cg02491457	chr7:128862824	NA	-0.53	-7.28	-0.41	3.77e-12	White matter hyperintensity burden;
CESC	cis	rs11864453	0.647	rs10492814	chr16:72126514	G/A	cg01557791	chr16:72042693	DHODH	-0.43	-5.57	-0.32	6.39e-8	Fibrinogen levels;
CESC	cis	rs2228479	0.717	rs11644967	chr16:89806614	T/A	cg04287289	chr16:89883240	FANCA	0.65	5.67	0.33	3.67e-8	Skin colour saturation;
CESC	cis	rs72781680	0.848	rs72798057	chr2:23976731	T/C	cg08917208	chr2:24149416	ATAD2B	0.96	8.7	0.47	3.55e-16	Lymphocyte counts;
CESC	cis	rs9916302	0.706	rs903507	chr17:37726423	A/G	cg00129232	chr17:37814104	STARD3	-0.57	-5.84	-0.34	1.51e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs801193	1.000	rs3857688	chr7:66127806	G/A	cg14393609	chr7:65229607	NA	-0.45	-6.02	-0.35	5.91e-9	Aortic root size;
CESC	cis	rs9948	0.655	rs7568206	chr2:97393108	A/C	cg01990225	chr2:97406019	LMAN2L	-0.87	-7.29	-0.41	3.59e-12	Erectile dysfunction and prostate cancer treatment;
CESC	cis	rs6860806	0.632	rs4330455	chr5:131586349	T/C	cg22638593	chr5:131593259	PDLIM4	0.42	5.41	0.32	1.44e-7	Breast cancer;
CESC	cis	rs7660520	0.557	rs76004373	chr4:183731011	C/G	cg09197432	chr4:183729176	NA	0.58	5.65	0.33	4.07e-8	Pediatric autoimmune diseases;
CESC	cis	rs10504229	0.683	rs55645894	chr8:58116145	A/G	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs6089829	0.962	rs2277769	chr20:61666805	C/T	cg08564027	chr20:61660810	NA	0.9	15.86	0.7	2.68e-40	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13453304	chr18:77493499	CTDP1	-0.6	-6.22	-0.36	1.88e-9	Gut microbiome composition (summer);
CESC	cis	rs6831352	0.918	rs2851253	chr4:100043505	G/T	cg12011299	chr4:100065546	ADH4	-0.58	-6.71	-0.38	1.21e-10	Alcohol dependence;
CESC	cis	rs2842992	0.715	rs2277073	chr6:160182749	G/A	cg26839252	chr6:160211577	TCP1;MRPL18	0.45	5.23	0.31	3.4e-7	Age-related macular degeneration (geographic atrophy);
CESC	trans	rs4973517	0.833	rs998985	chr2:233071691	A/C	cg20998127	chr7:158859224	VIPR2	0.39	6.03	0.35	5.58e-9	Hip circumference adjusted for BMI;
CESC	cis	rs72615157	0.561	rs113401658	chr7:99858505	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.64	6.01	0.35	6.2e-9	Lung function (FEV1/FVC);
CESC	cis	rs10883723	0.810	rs7069356	chr10:104254359	G/C	ch.10.2196322F	chr10:104248062	ACTR1A	0.42	5.08	0.3	6.99e-7	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs11098499	0.863	rs3775854	chr4:120471971	C/T	cg09307838	chr4:120376055	NA	0.91	12.56	0.61	1.08e-28	Corneal astigmatism;
CESC	cis	rs3820068	0.577	rs9728986	chr1:16040603	G/A	cg13390004	chr1:15929781	NA	0.33	5.13	0.3	5.64e-7	Systolic blood pressure;
CESC	cis	rs1552244	1.000	rs6768102	chr3:10149380	A/G	cg08888203	chr3:10149979	C3orf24	0.45	5.6	0.33	5.47e-8	Alzheimer's disease;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg03586379	chr3:140660603	SLC25A36	-0.56	-6.95	-0.39	2.9100000000000002e-11	Ulcerative colitis;
CESC	cis	rs10504229	0.683	rs2088217	chr8:58113124	C/T	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs962856	0.619	rs7564335	chr2:67579967	A/G	cg09028215	chr2:67624308	ETAA1	-0.44	-5.32	-0.31	2.2e-7	Pancreatic cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06466203	chr10:89623360	PTEN;KILLIN	0.59	7.05	0.4	1.56e-11	Gut microbiome composition (summer);
CESC	cis	rs8077577	0.747	rs12451698	chr17:18237116	A/G	cg16794390	chr17:18148240	FLII	0.4	6.29	0.36	1.31e-9	Obesity-related traits;
CESC	cis	rs8077577	0.708	rs4925151	chr17:18130132	G/C	cg16794390	chr17:18148240	FLII	-0.43	-6.33	-0.36	1.04e-9	Obesity-related traits;
CESC	cis	rs7216064	1.000	rs7223930	chr17:65842186	G/A	cg07042672	chr17:66097459	LOC651250	-0.57	-6.64	-0.38	1.72e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	trans	rs10506458	0.915	rs56321182	chr12:63392023	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.33	-17.99	-0.74	7.53e-48	Hemostatic factors and hematological phenotypes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23913400	chr17:73717552	ITGB4	0.66	7.37	0.41	2.13e-12	Gut microbiome composition (summer);
CESC	cis	rs9467711	0.606	rs9348726	chr6:26605206	G/A	cg14345882	chr6:26364793	BTN3A2	0.56	5.97	0.34	7.78e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs2953174	0.786	rs2953146	chr2:241515252	A/G	cg07929629	chr2:241523174	NA	-0.48	-5.83	-0.34	1.63e-8	Bipolar disorder;
CESC	cis	rs892961	0.932	rs55661113	chr17:75408386	A/C	cg05865280	chr17:75406074	SEPT9	0.57	11.18	0.57	5.1900000000000004e-24	Airflow obstruction;
CESC	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	7.75	0.43	1.94e-13	Prudent dietary pattern;
CESC	cis	rs9549260	0.564	rs4943805	chr13:41270080	A/G	cg21288729	chr13:41239152	FOXO1	0.57	6.92	0.39	3.39e-11	Red blood cell count;
CESC	cis	rs9322193	0.923	rs7767622	chr6:150002902	T/C	cg04369109	chr6:150039330	LATS1	-0.41	-5.75	-0.33	2.48e-8	Lung cancer;
CESC	cis	rs7937682	0.575	rs1940391	chr11:111776891	G/A	cg09085632	chr11:111637200	PPP2R1B	0.94	13.08	0.63	1.67e-30	Primary sclerosing cholangitis;
CESC	cis	rs67478160	0.619	rs11628481	chr14:104241499	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.51	-7.15	-0.4	8.55e-12	Schizophrenia;
CESC	cis	rs7520050	0.778	rs3013597	chr1:46128356	C/A	cg03146154	chr1:46216737	IPP	0.52	6.97	0.39	2.55e-11	Red blood cell count;Reticulocyte count;
CESC	cis	rs1045714	0.895	rs4719602	chr7:2647800	G/A	cg20813462	chr7:2646259	IQCE	0.65	5.63	0.33	4.68e-8	Urate levels in lean individuals;
CESC	cis	rs4481887	0.861	rs10888345	chr1:248447533	A/G	cg00666640	chr1:248458726	OR2T12	0.39	6.67	0.38	1.47e-10	Common traits (Other);
CESC	cis	rs3947	0.855	rs1293327	chr8:11694986	G/A	cg00262122	chr8:11665843	FDFT1	-0.51	-5.37	-0.31	1.69e-7	Blood protein levels;
CESC	cis	rs863345	0.967	rs1857251	chr1:158512801	G/A	cg12129480	chr1:158549410	OR10X1	-0.32	-6.5	-0.37	4e-10	Pneumococcal bacteremia;
CESC	cis	rs2710642	0.525	rs1386401	chr2:62889906	C/G	cg17519650	chr2:63277830	OTX1	0.54	7.08	0.4	1.33e-11	LDL cholesterol levels;LDL cholesterol;
CESC	cis	rs2836950	0.565	rs2836934	chr21:40564885	A/C	cg17971929	chr21:40555470	PSMG1	-0.53	-6.95	-0.39	2.89e-11	Menarche (age at onset);
CESC	cis	rs10504229	0.639	rs72650811	chr8:58115661	G/A	cg24829409	chr8:58192753	C8orf71	-0.58	-7.2	-0.4	6.31e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs6964587	0.934	rs2961019	chr7:91572749	T/G	cg17063962	chr7:91808500	NA	-0.46	-5.28	-0.31	2.7e-7	Breast cancer;
CESC	cis	rs6089584	0.546	rs6061978	chr20:60615604	C/T	cg24733560	chr20:60626293	TAF4	0.44	6.56	0.37	2.84e-10	Body mass index;
CESC	cis	rs4474465	0.790	rs7932315	chr11:78214878	G/A	cg27205649	chr11:78285834	NARS2	0.42	5.1	0.3	6.45e-7	Alzheimer's disease (survival time);
CESC	cis	rs117623576	0.941	rs7098334	chr10:32418501	G/T	cg03047570	chr10:32398778	NA	-0.84	-8.64	-0.47	5.28e-16	Anti-saccade response;
CESC	trans	rs11638815	0.871	rs8033106	chr15:83299461	C/T	cg25333056	chr10:135107159	TUBGCP2	0.48	6.28	0.36	1.35e-9	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;
CESC	cis	rs9925964	0.744	rs12716979	chr16:31011821	T/G	cg02466173	chr16:30829666	NA	0.34	5.54	0.32	7.45e-8	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs2880765	0.835	rs6497206	chr15:86029225	A/G	cg19183879	chr15:85880815	NA	-0.24	-5.09	-0.3	6.65e-7	Coronary artery disease;
CESC	cis	rs6089584	0.925	rs35683654	chr20:60625401	G/T	cg13770153	chr20:60521292	NA	0.56	7.23	0.41	5.3e-12	Body mass index;
CESC	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg16132339	chr22:24313637	DDTL;DDT	-0.41	-6.32	-0.36	1.08e-9	Liver enzyme levels (gamma-glutamyl transferase);
CESC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg03930357	chr16:84150069	MBTPS1	0.48	6.16	0.35	2.76e-9	Tetralogy of Fallot;
CESC	cis	rs7247513	0.797	rs3815914	chr19:12760664	T/C	cg01871581	chr19:12707946	ZNF490	-0.72	-10.47	-0.54	1.09e-21	Bipolar disorder;
CESC	cis	rs7937682	0.889	rs490199	chr11:111487890	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.94	-14.45	-0.66	2.76e-35	Primary sclerosing cholangitis;
CESC	cis	rs10504229	0.683	rs1495865	chr8:58141160	T/G	cg24829409	chr8:58192753	C8orf71	-0.59	-7.31	-0.41	3.16e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs8062405	1.000	rs7498665	chr16:28883241	A/G	cg08761264	chr16:28874980	SH2B1	-0.47	-5.85	-0.34	1.42e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs7659604	0.539	rs3217753	chr4:122746325	A/G	cg19748678	chr4:122722346	EXOSC9	0.76	10.32	0.54	3.3e-21	Type 2 diabetes;
CESC	trans	rs11039798	0.920	rs12279378	chr11:48571030	A/C	cg15704280	chr7:45808275	SEPT13	0.7	6.69	0.38	1.3100000000000001e-10	Axial length;
CESC	cis	rs9549367	0.789	rs9549705	chr13:113888425	T/C	cg00898013	chr13:113819073	PROZ	-0.54	-7.39	-0.41	1.93e-12	Platelet distribution width;
CESC	cis	rs3733585	0.673	rs4235347	chr4:9951956	C/T	cg11266682	chr4:10021025	SLC2A9	-0.58	-11.0	-0.56	2.04e-23	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs868036	0.958	rs12593813	chr15:68036852	C/T	cg08079166	chr15:68083412	MAP2K5	0.39	6.19	0.36	2.26e-9	Restless legs syndrome;
CESC	cis	rs561341	1.000	rs72821971	chr17:30269343	T/G	cg00745463	chr17:30367425	LRRC37B	-0.83	-7.62	-0.42	4.42e-13	Hip circumference adjusted for BMI;
CESC	cis	rs2075371	0.932	rs34664116	chr7:133984878	G/A	cg00033643	chr7:134001901	SLC35B4	0.43	5.48	0.32	1.01e-7	Mean platelet volume;
CESC	cis	rs514406	0.661	rs550561	chr1:53375134	C/T	cg08736216	chr1:53307985	ZYG11A	-0.38	-6.48	-0.37	4.45e-10	Monocyte count;
CESC	cis	rs7937682	0.883	rs512669	chr11:111467893	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.9	-12.87	-0.62	9.33e-30	Primary sclerosing cholangitis;
CESC	cis	rs5769765	0.908	rs9627800	chr22:50319351	T/C	cg26441486	chr22:50317300	CRELD2	0.48	5.78	0.33	2.08e-8	Schizophrenia;
CESC	cis	rs1348850	0.914	rs4341974	chr2:178324879	A/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.73	10.16	0.53	1.07e-20	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs853679	0.517	rs9368550	chr6:28051803	T/A	cg08968635	chr6:28129556	ZNF389	0.39	5.22	0.31	3.64e-7	Depression;
CESC	cis	rs10540	1.000	rs71487292	chr11:486076	G/A	cg03934478	chr11:495069	RNH1	0.56	5.18	0.3	4.45e-7	Body mass index;
CESC	cis	rs2836974	0.931	rs7283569	chr21:40644062	T/G	cg11644478	chr21:40555479	PSMG1	1.05	16.84	0.72	9.02e-44	Cognitive function;
CESC	cis	rs11792861	0.564	rs3816237	chr9:111718348	T/A	cg13535736	chr9:111863775	C9orf5	-0.39	-5.74	-0.33	2.58e-8	Menarche (age at onset);
CESC	cis	rs2066819	1.000	rs79101914	chr12:56729739	A/G	cg26714650	chr12:56694279	CS	-1.39	-9.17	-0.49	1.33e-17	Psoriasis vulgaris;
CESC	cis	rs4901869	0.864	rs12891575	chr14:59334342	T/A	cg02291164	chr14:59296302	NA	0.45	7.59	0.42	5.56e-13	Panic disorder;
CESC	cis	rs3815700	1.000	rs8101356	chr19:33093402	C/T	cg24916020	chr19:33096688	ANKRD27	0.6	5.84	0.34	1.56e-8	Eosinophilic esophagitis;
CESC	cis	rs2072499	0.966	rs2253677	chr1:156171296	C/G	cg24450063	chr1:156163899	SLC25A44	-1.12	-24.35	-0.83	1.43e-69	Testicular germ cell tumor;
CESC	cis	rs4665809	0.590	rs6730310	chr2:26419470	C/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.09	-13.48	-0.64	6.79e-32	Gut microbiome composition (summer);
CESC	cis	rs798554	0.836	rs798490	chr7:2801542	C/T	cg19717773	chr7:2847554	GNA12	-0.55	-7.83	-0.43	1.15e-13	Height;
CESC	cis	rs854765	0.547	rs9896837	chr17:17924868	A/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.47	6.06	0.35	4.68e-9	Total body bone mineral density;
CESC	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg03188948	chr7:1209495	NA	0.7	6.71	0.38	1.2e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs10927875	0.501	rs61782229	chr1:16220118	G/A	cg21385522	chr1:16154831	NA	-0.9	-10.32	-0.54	3.37e-21	Dilated cardiomyopathy;
CESC	cis	rs67311347	1.000	rs4571217	chr3:40521973	A/G	cg24209194	chr3:40518798	ZNF619	0.49	6.32	0.36	1.12e-9	Renal cell carcinoma;
CESC	cis	rs684232	0.666	rs838372	chr17:566428	C/T	cg15660573	chr17:549704	VPS53	-0.63	-8.69	-0.47	3.83e-16	Prostate cancer;
CESC	cis	rs13102973	0.932	rs4130841	chr4:135869673	T/C	cg14419869	chr4:135874104	NA	-0.4	-6.29	-0.36	1.32e-9	Subjective well-being;
CESC	cis	rs12887734	0.546	rs66676135	chr14:104271504	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.44	-5.62	-0.33	4.85e-8	Schizophrenia;Autism spectrum disorder or schizophrenia;
CESC	trans	rs11039798	0.528	rs10839208	chr11:49030456	C/T	cg03929089	chr4:120376271	NA	0.62	6.47	0.37	4.6e-10	Axial length;
CESC	cis	rs2072732	0.821	rs1005471	chr1:2952614	T/C	cg15211996	chr1:2936768	ACTRT2	0.32	5.93	0.34	9.43e-9	Plateletcrit;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg23508591	chr15:75871807	PTPN9	0.48	6.31	0.36	1.15e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs28595532	0.748	rs66615663	chr4:119336701	C/T	cg21605333	chr4:119757512	SEC24D	0.93	5.92	0.34	1.02e-8	Cannabis dependence symptom count;
CESC	cis	rs2842992	0.724	rs2273827	chr6:160211339	C/A	cg11366901	chr6:160182831	ACAT2	0.64	8.17	0.45	1.24e-14	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs7618915	0.501	rs7622694	chr3:52663882	G/A	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.31	5.63	0.33	4.49e-8	Bipolar disorder;
CESC	trans	rs7090925	0.853	rs2892582	chr10:8482310	C/T	cg22997768	chr12:11092816	TAS2R14;PRR4;PRH1	-0.47	-6.17	-0.35	2.53e-9	Systemic lupus erythematosus;
CESC	cis	rs6912958	0.559	rs1201409	chr6:88055264	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.72	10.73	0.55	1.55e-22	Monocyte percentage of white cells;
CESC	cis	rs7666738	0.830	rs11097600	chr4:98959564	T/G	cg05340658	chr4:99064831	C4orf37	0.78	11.79	0.59	4.44e-26	Colonoscopy-negative controls vs population controls;
CESC	cis	rs820218	0.926	rs820135	chr17:73674977	T/C	cg01592526	chr17:73663357	RECQL5;SAP30BP	0.47	6.12	0.35	3.28e-9	Rotator cuff tears;
CESC	cis	rs4713118	0.629	rs203887	chr6:28021269	C/T	cg12963246	chr6:28129442	ZNF389	0.48	5.85	0.34	1.48e-8	Parkinson's disease;
CESC	cis	rs2688608	0.592	rs10762560	chr10:75495405	T/G	cg23231163	chr10:75533350	FUT11	-0.35	-5.28	-0.31	2.63e-7	Inflammatory bowel disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11397033	chr7:83379104	NA	-0.54	-6.38	-0.36	8.02e-10	Gut microbiome composition (summer);
CESC	cis	rs6500602	0.702	rs2304634	chr16:4500544	C/T	cg08645402	chr16:4508243	NA	0.55	8.78	0.47	2.02e-16	Schizophrenia;
CESC	cis	rs6991838	0.530	rs35038843	chr8:66522498	T/A	cg13398993	chr8:66546079	ARMC1	-0.46	-5.65	-0.33	4.19e-8	Intelligence (multi-trait analysis);
CESC	cis	rs4665809	1.000	rs6546726	chr2:26275116	A/G	cg27170947	chr2:26402098	FAM59B	-0.61	-7.15	-0.4	8.59e-12	Gut microbiome composition (summer);
CESC	cis	rs4563143	0.704	rs16961809	chr19:29226299	C/T	cg04546413	chr19:29218101	NA	0.45	6.61	0.38	2.11e-10	Methadone dose in opioid dependence;
CESC	trans	rs9951602	0.512	rs9952372	chr18:76656295	A/G	cg02800362	chr5:177631904	HNRNPAB	0.64	8.35	0.46	3.86e-15	Obesity-related traits;
CESC	cis	rs7618915	0.547	rs12496634	chr3:52709259	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.5	7.26	0.41	4.39e-12	Bipolar disorder;
CESC	cis	rs2439831	0.557	rs13329084	chr15:44151063	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.63	-5.07	-0.3	7.5e-7	Lung cancer in ever smokers;
CESC	cis	rs2070488	0.804	rs13085153	chr3:38461279	A/G	cg24069376	chr3:38537580	EXOG	0.36	6.26	0.36	1.51e-9	Electrocardiographic conduction measures;
CESC	cis	rs4654899	0.802	rs2290381	chr1:21213271	C/A	cg05370193	chr1:21551575	ECE1	0.38	5.64	0.33	4.32e-8	Superior frontal gyrus grey matter volume;
CESC	cis	rs7044106	0.708	rs991121	chr9:123370345	C/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.36	5.75	0.33	2.46e-8	Hip circumference adjusted for BMI;
CESC	cis	rs5769765	1.000	rs2295408	chr22:50261051	A/G	cg26441486	chr22:50317300	CRELD2	-0.39	-5.4	-0.32	1.45e-7	Schizophrenia;
CESC	cis	rs2635047	0.682	rs9960932	chr18:44792445	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.39	5.09	0.3	6.89e-7	Educational attainment;
CESC	cis	rs7666738	0.830	rs13137859	chr4:99050319	A/G	cg05340658	chr4:99064831	C4orf37	0.82	12.88	0.62	8.44e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9457247	1.000	rs376551	chr6:167384923	G/A	cg25258033	chr6:167368657	RNASET2	0.39	5.87	0.34	1.27e-8	Crohn's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23666278	chr2:171785822	GORASP2	0.55	6.03	0.35	5.56e-9	Gut microbiome composition (summer);
CESC	cis	rs2279817	0.735	rs11580813	chr1:17981913	C/T	cg21791023	chr1:18019539	ARHGEF10L	0.58	7.25	0.41	4.61e-12	Neuroticism;
CESC	cis	rs9837602	1.000	rs1688766	chr3:99647850	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.54	7.42	0.41	1.61e-12	Breast cancer;
CESC	cis	rs35306767	0.761	rs1871621	chr10:1049596	C/T	cg20503657	chr10:835505	NA	0.69	6.31	0.36	1.19e-9	Eosinophil percentage of granulocytes;
CESC	trans	rs60843830	1.000	rs62114501	chr2:231741	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.67	8.18	0.45	1.17e-14	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs17818399	0.788	rs17818315	chr2:46818992	C/T	cg02822958	chr2:46747628	ATP6V1E2	0.43	5.21	0.3	3.87e-7	Height;
CESC	cis	rs8067354	0.645	rs2645486	chr17:57885901	T/A	cg02344993	chr17:57696989	CLTC	0.67	8.16	0.45	1.33e-14	Hemoglobin concentration;
CESC	cis	rs10504229	0.679	rs16921688	chr8:58054659	T/C	cg21724239	chr8:58056113	NA	0.52	5.05	0.3	8.08e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs1005277	0.579	rs2472173	chr10:38374638	G/A	cg00409905	chr10:38381863	ZNF37A	-0.45	-6.04	-0.35	5.25e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs2180341	1.000	rs6903878	chr6:127638600	C/G	cg24812749	chr6:127587940	RNF146	1.07	15.48	0.69	6.31e-39	Breast cancer;
CESC	cis	rs2073300	1.000	rs6137983	chr20:23469465	C/A	cg12062639	chr20:23401060	NAPB	0.94	6.04	0.35	5.14e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs9527	0.590	rs2066322	chr10:104909339	T/G	cg04362960	chr10:104952993	NT5C2	0.42	5.28	0.31	2.71e-7	Arsenic metabolism;
CESC	cis	rs7772486	0.790	rs9497424	chr6:146225271	C/A	cg05347473	chr6:146136440	FBXO30	-0.52	-6.82	-0.39	6.28e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1215050	0.765	rs1530905	chr4:98805705	A/G	cg05340658	chr4:99064831	C4orf37	0.52	6.88	0.39	4.36e-11	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs10751667	0.643	rs11246348	chr11:939476	G/C	cg06064525	chr11:970664	AP2A2	-0.52	-10.43	-0.54	1.43e-21	Alzheimer's disease (late onset);
CESC	cis	rs950776	0.616	rs647041	chr15:78880481	T/C	cg06917634	chr15:78832804	PSMA4	-0.6	-7.84	-0.43	1.08e-13	Sudden cardiac arrest;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg26421448	chr1:224622516	WDR26	-0.48	-6.2	-0.36	2.15e-9	Height;
CESC	cis	rs1670533	0.872	rs10017931	chr4:1060747	G/A	cg04106633	chr4:1044584	NA	0.39	5.04	0.3	8.74e-7	Recombination rate (females);
CESC	cis	rs11758351	0.660	rs55643278	chr6:26222888	C/A	cg23601095	chr6:26197514	HIST1H3D	0.92	9.82	0.52	1.28e-19	Gout;Renal underexcretion gout;
CESC	cis	rs12666575	0.504	rs10226475	chr7:2226162	A/G	cg05863683	chr7:1912471	MAD1L1	0.36	5.35	0.31	1.88e-7	Schizophrenia;
CESC	cis	rs1163251	0.902	rs627707	chr1:120217133	C/G	cg19096424	chr1:120255104	PHGDH	0.43	5.22	0.31	3.62e-7	Blood metabolite levels;
CESC	cis	rs933688	0.502	rs4916858	chr5:90601290	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.47	-6.23	-0.36	1.87e-9	Smoking behavior;
CESC	cis	rs10411262	0.935	rs2312289	chr19:47175615	G/C	cg13467550	chr19:47212573	PRKD2	0.35	5.77	0.33	2.16e-8	Tonsillectomy;
CESC	cis	rs763121	0.853	rs2267395	chr22:39113903	C/T	cg06544989	chr22:39130855	UNC84B	0.5	9.6	0.51	6.59e-19	Menopause (age at onset);
CESC	cis	rs62064224	0.765	rs62065463	chr17:30732405	G/T	cg09324608	chr17:30823087	MYO1D	0.51	7.72	0.43	2.35e-13	Schizophrenia;
CESC	cis	rs10256972	0.524	rs6945202	chr7:1116558	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.49	-7.28	-0.41	3.84e-12	Longevity;Endometriosis;
CESC	cis	rs3820068	0.580	rs7556473	chr1:15996858	C/T	cg16988262	chr1:15930761	NA	-0.33	-5.06	-0.3	7.7e-7	Systolic blood pressure;
CESC	cis	rs2549003	1.000	rs10214312	chr5:131821866	T/G	cg21138405	chr5:131827807	IRF1	0.54	9.32	0.5	4.74e-18	Asthma (sex interaction);
CESC	cis	rs9790314	0.936	rs7629987	chr3:161002023	A/C	cg04691961	chr3:161091175	C3orf57	-0.4	-5.18	-0.3	4.39e-7	Morning vs. evening chronotype;
CESC	cis	rs3820928	0.874	rs55959848	chr2:227805426	C/A	cg11843606	chr2:227700838	RHBDD1	-0.43	-5.66	-0.33	3.83e-8	Pulmonary function;
CESC	cis	rs11718455	0.629	rs4082418	chr3:43908243	C/T	cg08738300	chr3:44038990	NA	-0.37	-5.16	-0.3	4.77e-7	Coronary artery disease;
CESC	cis	rs7089973	0.668	rs7077148	chr10:116644896	A/G	cg25233709	chr10:116636983	FAM160B1	0.41	6.56	0.37	2.89e-10	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg20095674	chr2:210673274	UNC80	0.43	6.2	0.36	2.14e-9	Fibrinogen levels;
CESC	cis	rs1509123	0.609	rs118144554	chr17:6721816	C/A	cg12642237	chr17:6703447	TEKT1	-0.6	-5.06	-0.3	7.77e-7	Blood metabolite levels;
CESC	cis	rs9584850	0.540	rs17574536	chr13:99171040	G/A	cg20750642	chr13:99100586	FARP1	-0.4	-5.75	-0.33	2.4e-8	Neuroticism;
CESC	cis	rs9911578	0.935	rs12948039	chr17:57045184	C/T	cg05425664	chr17:57184151	TRIM37	-0.4	-5.54	-0.32	7.36e-8	Intelligence (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16532752	chr4:104119610	CENPE	0.57	6.29	0.36	1.34e-9	Gut microbiome composition (summer);
CESC	cis	rs34779708	0.966	rs10508816	chr10:35459976	G/A	cg04310649	chr10:35416472	CREM	-0.54	-6.54	-0.37	3.16e-10	Inflammatory bowel disease;Crohn's disease;
CESC	trans	rs11971186	0.793	rs1204523	chr7:126508102	T/C	cg10894441	chr11:111169905	C11orf92;C11orf93	-0.51	-6.55	-0.37	2.9e-10	Chemerin levels;
CESC	cis	rs708547	0.647	rs12621	chr4:57897570	G/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.51	7.01	0.4	1.96e-11	Response to bleomycin (chromatid breaks);
CESC	cis	rs7809950	0.678	rs79902674	chr7:106866498	A/C	cg23024343	chr7:107201750	COG5	-0.56	-6.76	-0.38	8.76e-11	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01764079	chr8:144718741	ZNF623	-0.64	-7.6	-0.42	5.26e-13	Gut microbiome composition (summer);
CESC	trans	rs11039798	1.000	rs8188963	chr11:48685693	C/A	cg15704280	chr7:45808275	SEPT13	0.7	6.42	0.37	6.38e-10	Axial length;
CESC	cis	rs7188697	0.882	rs9921370	chr16:58611935	C/A	cg02549819	chr16:58548995	SETD6	0.43	5.4	0.31	1.51e-7	QT interval;
CESC	cis	rs2576037	0.526	rs2010834	chr18:44560875	C/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.55	7.6	0.42	5.28e-13	Personality dimensions;
CESC	cis	rs763121	0.853	rs2267393	chr22:39101619	G/C	cg21395723	chr22:39101663	GTPBP1	0.49	6.76	0.38	8.89e-11	Menopause (age at onset);
CESC	cis	rs7100689	0.598	rs2342815	chr10:82086532	T/C	cg00277334	chr10:82204260	NA	-0.6	-7.96	-0.44	4.91e-14	Post bronchodilator FEV1;
CESC	cis	rs2832191	0.692	rs2245517	chr21:30357968	C/T	cg08807101	chr21:30365312	RNF160	0.91	14.18	0.66	2.38e-34	Dental caries;
CESC	cis	rs7824557	0.602	rs7834139	chr8:11206363	C/G	cg21775007	chr8:11205619	TDH	0.58	8.81	0.48	1.71e-16	Retinal vascular caliber;
CESC	cis	rs2191566	0.691	rs55676341	chr19:44587689	G/C	cg20607764	chr19:44506953	ZNF230	-0.39	-5.07	-0.3	7.54e-7	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs9457247	1.000	rs408040	chr6:167398903	A/T	cg25258033	chr6:167368657	RNASET2	0.4	6.12	0.35	3.43e-9	Crohn's disease;
CESC	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.56	-6.36	-0.36	8.99e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs10927875	0.632	rs10927864	chr1:16165661	C/G	cg21385522	chr1:16154831	NA	-1.02	-17.08	-0.72	1.28e-44	Dilated cardiomyopathy;
CESC	cis	rs9287719	0.967	rs10929682	chr2:10732189	C/A	cg00105475	chr2:10696890	NA	0.39	5.69	0.33	3.35e-8	Prostate cancer;
CESC	cis	rs66573146	0.656	rs56094305	chr4:6956086	C/T	cg26116260	chr4:7069785	GRPEL1	-0.79	-5.16	-0.3	4.78e-7	Granulocyte percentage of myeloid white cells;
CESC	cis	rs362296	0.698	rs362283	chr4:3259558	T/C	cg08886695	chr4:3369023	RGS12	0.41	5.46	0.32	1.07e-7	Parental longevity (mother's age at death);
CESC	cis	rs9787249	0.957	rs56064244	chr1:40213890	C/T	cg02773041	chr1:40204384	PPIE	0.53	7.56	0.42	6.49e-13	Blood protein levels;
CESC	cis	rs1062177	1.000	rs62377945	chr5:151208004	C/G	cg12924095	chr5:151150029	G3BP1	0.5	6.48	0.37	4.55e-10	Preschool internalizing problems;
CESC	cis	rs2228479	0.850	rs17227057	chr16:89816333	C/T	cg00800038	chr16:89945340	TCF25	-0.91	-7.54	-0.42	7.39e-13	Skin colour saturation;
CESC	cis	rs2777491	0.915	rs9302109	chr15:41612180	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.6	-8.84	-0.48	1.39e-16	Ulcerative colitis;
CESC	cis	rs873946	0.586	rs3829130	chr10:134563122	C/T	cg27286337	chr10:134555280	INPP5A	0.67	7.62	0.42	4.43e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs965469	0.779	rs6037581	chr20:3351595	C/T	cg25506879	chr20:3388711	C20orf194	-0.49	-5.24	-0.31	3.22e-7	IFN-related cytopenia;
CESC	cis	rs425277	0.565	rs61775448	chr1:2045376	A/G	cg19257562	chr1:2043853	PRKCZ	0.38	6.38	0.37	7.7e-10	Height;
CESC	cis	rs7666738	0.830	rs10049627	chr4:99025272	A/C	cg05340658	chr4:99064831	C4orf37	0.83	13.1	0.63	1.43e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs35110281	0.807	rs6518301	chr21:45016818	T/C	cg01579765	chr21:45077557	HSF2BP	-0.57	-9.91	-0.52	6.75e-20	Mean corpuscular volume;
CESC	cis	rs916888	0.610	rs199444	chr17:44818276	T/C	cg15921436	chr17:44337874	NA	0.44	5.55	0.32	7.08e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs9486719	0.895	rs3734238	chr6:96996228	A/T	cg18709589	chr6:96969512	KIAA0776	-0.52	-5.69	-0.33	3.43e-8	Migraine;Coronary artery disease;
CESC	cis	rs9611519	0.894	rs9611486	chr22:41458784	C/G	cg03806693	chr22:41940476	POLR3H	-0.56	-5.86	-0.34	1.38e-8	Neuroticism;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg15979344	chr10:99496871	ZFYVE27	-0.46	-6.12	-0.35	3.31e-9	Ulcerative colitis;
CESC	cis	rs67478160	0.643	rs11624184	chr14:104240998	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.45	-6.5	-0.37	4.04e-10	Schizophrenia;
CESC	cis	rs2204008	0.577	rs11520050	chr12:38051839	G/A	cg26384229	chr12:38710491	ALG10B	0.74	10.7	0.55	1.96e-22	Bladder cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06622468	chr19:10491460	TYK2	0.63	7.62	0.42	4.61e-13	Gut microbiome composition (summer);
CESC	cis	rs1799949	1.000	rs12936831	chr17:41331816	C/T	cg25072359	chr17:41440525	NA	0.5	6.77	0.38	8.41e-11	Menopause (age at onset);
CESC	cis	rs10504229	0.683	rs903702	chr8:58128557	T/C	cg02725872	chr8:58115012	NA	-0.45	-7.05	-0.4	1.52e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs9308731	0.591	rs9308742	chr2:111943621	G/A	cg04202892	chr2:111875749	ACOXL	0.37	5.17	0.3	4.61e-7	Chronic lymphocytic leukemia;
CESC	cis	rs12579753	0.719	rs11115060	chr12:82269624	C/T	cg21193143	chr12:82153300	PPFIA2	-0.34	-5.16	-0.3	4.75e-7	Resting heart rate;
CESC	cis	rs7647973	0.580	rs2117938	chr3:49263850	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.71	-10.82	-0.55	7.92e-23	Menarche (age at onset);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg18356743	chr13:30408050	UBL3	-0.37	-6.25	-0.36	1.61e-9	Gambling;
CESC	cis	rs7208859	0.562	rs8078897	chr17:29106257	T/G	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.91e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs1775715	0.870	rs10827001	chr10:32229734	C/T	cg18675610	chr10:32216311	ARHGAP12	0.35	5.36	0.31	1.85e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs8062405	0.755	rs62034358	chr16:28587597	G/T	cg07382826	chr16:28625726	SULT1A1	0.4	6.52	0.37	3.49e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs10129255	0.518	rs10136903	chr14:107187105	T/C	cg23076370	chr14:107095027	NA	-0.66	-10.01	-0.52	3.13e-20	Kawasaki disease;
CESC	cis	rs2841277	0.708	rs10083490	chr14:105402418	A/G	cg19901468	chr14:105411992	AHNAK2	0.61	8.92	0.48	7.7e-17	Rheumatoid arthritis;
CESC	trans	rs4824093	0.610	rs56810176	chr22:50303149	G/C	cg09872104	chr7:134855509	C7orf49	-0.87	-6.16	-0.35	2.76e-9	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs9768139	0.733	rs13309408	chr7:158122261	C/T	cg27057461	chr7:158136379	PTPRN2	-0.37	-5.76	-0.33	2.36e-8	Calcium levels;
CESC	cis	rs6963495	0.818	rs56268110	chr7:105166712	T/C	cg19920283	chr7:105172520	RINT1	0.7	6.68	0.38	1.39e-10	Bipolar disorder (body mass index interaction);
CESC	cis	rs7666738	1.000	rs13144055	chr4:99026849	A/G	cg17366294	chr4:99064904	C4orf37	0.58	7.76	0.43	1.85e-13	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10504229	0.861	rs59873610	chr8:58172290	T/A	cg14926445	chr8:58193284	C8orf71	-0.5	-5.41	-0.32	1.44e-7	Developmental language disorder (linguistic errors);
CESC	trans	rs561341	0.941	rs8081016	chr17:30331751	A/G	cg20587970	chr11:113659929	NA	-1.43	-18.64	-0.75	3.98e-50	Hip circumference adjusted for BMI;
CESC	cis	rs2228479	0.850	rs12598276	chr16:89829196	G/C	cg04013166	chr16:89971882	TCF25	0.77	6.55	0.37	3.05e-10	Skin colour saturation;
CESC	cis	rs826838	1.000	rs10506122	chr12:38699232	A/G	cg26384229	chr12:38710491	ALG10B	0.84	15.37	0.69	1.45e-38	Heart rate;
CESC	cis	rs1400745	0.756	rs10136352	chr14:35334555	C/T	cg16230307	chr14:35515116	FAM177A1	0.45	5.47	0.32	1.06e-7	Monocyte count;
CESC	cis	rs8103278	1.000	rs9807819	chr19:46239598	C/T	cg11657440	chr19:46296263	DMWD	-0.59	-7.73	-0.43	2.24e-13	Coronary artery disease;
CESC	trans	rs1814175	0.817	rs1390676	chr11:50056778	C/T	cg03929089	chr4:120376271	NA	-0.94	-15.72	-0.69	8.37e-40	Height;
CESC	cis	rs801193	0.569	rs6951302	chr7:66132512	T/C	cg12463550	chr7:65579703	CRCP	-0.5	-6.43	-0.37	5.9e-10	Aortic root size;
CESC	cis	rs2050392	0.590	rs17547917	chr10:30718303	G/A	cg02070205	chr10:30722105	MAP3K8	-0.46	-5.42	-0.32	1.33e-7	Inflammatory bowel disease;
CESC	cis	rs3796352	1.000	rs71299622	chr3:52917038	G/A	cg12962167	chr3:53033115	SFMBT1	0.64	5.12	0.3	5.99e-7	Immune reponse to smallpox (secreted IL-2);
CESC	cis	rs17376456	0.877	rs12153501	chr5:93360866	T/G	cg25358565	chr5:93447407	FAM172A	1.1	10.93	0.56	3.31e-23	Diabetic retinopathy;
CESC	cis	rs2228479	0.718	rs62054253	chr16:89896932	T/C	cg06558623	chr16:89946397	TCF25	1.06	7.64	0.42	4.04e-13	Skin colour saturation;
CESC	cis	rs2236918	1.000	rs2526699	chr1:242022130	T/C	cg17736920	chr1:242011382	EXO1	0.73	9.16	0.49	1.46e-17	Menopause (age at onset);
CESC	cis	rs4654899	0.865	rs6664532	chr1:21515800	G/A	cg05370193	chr1:21551575	ECE1	0.46	7.14	0.4	8.84e-12	Superior frontal gyrus grey matter volume;
CESC	cis	rs17253792	0.822	rs77544029	chr14:56087917	T/C	cg01858014	chr14:56050164	KTN1	-0.83	-7.03	-0.4	1.7e-11	Putamen volume;
CESC	cis	rs7412746	0.646	rs10399947	chr1:150861960	G/A	cg18016565	chr1:150552671	MCL1	0.34	5.12	0.3	6e-7	Melanoma;
CESC	cis	rs6460942	1.000	rs6460936	chr7:12404913	T/C	cg06484146	chr7:12443880	VWDE	-0.79	-8.75	-0.47	2.47e-16	Coronary artery disease;
CESC	cis	rs1552244	1.000	rs722509	chr3:10102377	T/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.8	-10.46	-0.54	1.15e-21	Alzheimer's disease;
CESC	cis	rs9790314	0.846	rs6441371	chr3:161008727	C/A	cg03342759	chr3:160939853	NMD3	-0.46	-6.12	-0.35	3.41e-9	Morning vs. evening chronotype;
CESC	cis	rs1256061	0.624	rs1256046	chr14:64729356	A/C	cg23250157	chr14:64679961	SYNE2	0.53	7.64	0.42	4.09e-13	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs2952156	0.883	rs8077172	chr17:37834977	G/T	cg00129232	chr17:37814104	STARD3	-0.73	-10.6	-0.55	4.07e-22	Asthma;
CESC	cis	rs11792861	0.962	rs72607161	chr9:111792640	T/C	cg05043794	chr9:111880884	C9orf5	-0.42	-6.93	-0.39	3.25e-11	Menarche (age at onset);
CESC	cis	rs35306767	0.903	rs12769873	chr10:936526	G/T	cg26597838	chr10:835615	NA	0.9	9.85	0.52	1.01e-19	Eosinophil percentage of granulocytes;
CESC	cis	rs7301826	0.557	rs7953184	chr12:131284852	T/G	cg11011512	chr12:131303247	STX2	-0.48	-5.89	-0.34	1.18e-8	Plasma plasminogen activator levels;
CESC	cis	rs1832871	0.672	rs9456285	chr6:158732819	T/G	cg07165851	chr6:158734300	TULP4	0.6	6.55	0.37	2.92e-10	Height;
CESC	cis	rs9916302	0.660	rs4795379	chr17:37674683	T/G	cg07936489	chr17:37558343	FBXL20	-0.95	-10.64	-0.55	3e-22	Glomerular filtration rate (creatinine);
CESC	cis	rs72781680	0.851	rs72796397	chr2:24178211	T/A	cg20701182	chr2:24300061	SF3B14	0.64	5.74	0.33	2.63e-8	Lymphocyte counts;
CESC	cis	rs901683	1.000	rs35424022	chr10:45976540	T/C	cg16031567	chr10:46195673	NA	-0.75	-5.04	-0.3	8.78e-7	Red blood cell traits;Mean corpuscular volume;
CESC	cis	rs7666738	0.791	rs1559860	chr4:99024422	C/T	cg03467027	chr4:99064603	C4orf37	0.49	6.18	0.35	2.44e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3780486	0.801	rs6476398	chr9:33119241	C/T	cg13443165	chr9:33130375	B4GALT1	0.44	6.19	0.36	2.27e-9	IgG glycosylation;
CESC	cis	rs1799949	1.000	rs8176109	chr17:41265776	A/G	cg23758822	chr17:41437982	NA	1.02	15.58	0.69	2.64e-39	Menopause (age at onset);
CESC	cis	rs58688157	0.880	rs12272314	chr11:590648	A/G	cg17005319	chr11:655579	DEAF1	0.46	5.18	0.3	4.3e-7	Systemic lupus erythematosus;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05404161	chr11:62446492	UBXN1	0.61	6.87	0.39	4.57e-11	Gut microbiome composition (summer);
CESC	cis	rs17666538	0.591	rs2878547	chr8:603416	G/A	cg23958373	chr8:599963	NA	0.75	6.32	0.36	1.1e-9	IgG glycosylation;
CESC	cis	rs11958404	0.932	rs72818108	chr5:157437883	A/T	cg05962755	chr5:157440814	NA	0.62	6.66	0.38	1.57e-10	IgG glycosylation;
CESC	cis	rs11997175	0.545	rs7839592	chr8:33666662	T/C	ch.8.33884649F	chr8:33765107	NA	0.55	6.85	0.39	5.18e-11	Body mass index;
CESC	cis	rs9467711	0.606	rs9379871	chr6:26375854	C/G	cg12826209	chr6:26865740	GUSBL1	0.66	5.47	0.32	1.02e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs4728302	0.583	rs58955798	chr7:133158420	C/T	cg10665199	chr7:133106180	EXOC4	0.53	7.37	0.41	2.16e-12	Intelligence;Intelligence (multi-trait analysis);
CESC	cis	rs11122272	0.701	rs971533	chr1:231522097	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.57	-7.82	-0.43	1.29e-13	Hemoglobin concentration;
CESC	cis	rs854765	0.616	rs8070624	chr17:17843396	G/A	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.42	5.1	0.3	6.42e-7	Total body bone mineral density;
CESC	cis	rs60843830	0.928	rs62114494	chr2:211317	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.84	10.88	0.56	4.99e-23	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs992157	0.735	rs13388024	chr2:219097773	A/G	cg00012203	chr2:219082015	ARPC2	0.84	12.14	0.6	2.8e-27	Colorectal cancer;
CESC	cis	rs3105593	0.965	rs3109891	chr15:50874964	T/C	cg08437265	chr15:50716283	USP8	0.41	5.29	0.31	2.61e-7	QT interval;
CESC	cis	rs1218582	0.774	rs1007170	chr1:154881461	G/A	cg03351412	chr1:154909251	PMVK	0.59	7.51	0.42	8.91e-13	Prostate cancer;
CESC	cis	rs13095912	1.000	rs13072759	chr3:185326391	G/A	cg11274856	chr3:185301563	NA	0.35	5.5	0.32	8.96e-8	Systolic blood pressure;
CESC	cis	rs910316	0.763	rs13712	chr14:75483812	T/C	cg16144293	chr14:75469539	EIF2B2	-0.4	-5.3	-0.31	2.47e-7	Height;
CESC	cis	rs2180341	1.000	rs2144742	chr6:127595786	C/A	cg24812749	chr6:127587940	RNF146	1.06	15.23	0.68	4.52e-38	Breast cancer;
CESC	cis	rs977987	0.778	rs4888400	chr16:75425596	G/C	cg03315344	chr16:75512273	CHST6	0.4	5.79	0.34	1.99e-8	Dupuytren's disease;
CESC	cis	rs9649213	0.593	rs6465682	chr7:98016417	C/A	cg08684580	chr7:98029266	BAIAP2L1	-0.35	-5.72	-0.33	2.93e-8	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs9329221	0.683	rs3105738	chr8:9889914	A/T	cg15556689	chr8:8085844	FLJ10661	-0.54	-7.2	-0.4	6.29e-12	Neuroticism;
CESC	cis	rs2243480	1.000	rs34815098	chr7:65292254	A/C	cg13147721	chr7:65941812	NA	-0.84	-8.42	-0.46	2.36e-15	Diabetic kidney disease;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg13673779	chr18:48723081	MEX3C	-0.45	-6.2	-0.36	2.14e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs1904096	0.506	rs4693381	chr4:95206855	A/T	cg11021082	chr4:95130006	SMARCAD1	0.69	11.54	0.58	3.07e-25	Type 2 diabetes;
CESC	cis	rs6963495	0.745	rs2392749	chr7:105182605	A/G	cg19920283	chr7:105172520	RINT1	0.73	8.19	0.45	1.09e-14	Bipolar disorder (body mass index interaction);
CESC	cis	rs875971	0.660	rs1860470	chr7:66103694	G/C	cg14393609	chr7:65229607	NA	-0.42	-5.59	-0.32	5.63e-8	Aortic root size;
CESC	cis	rs897984	0.806	rs10782002	chr16:30946506	A/G	cg02466173	chr16:30829666	NA	0.47	7.87	0.44	9.26e-14	Dementia with Lewy bodies;
CESC	cis	rs2243480	1.000	rs55895244	chr7:65387678	C/G	cg12463550	chr7:65579703	CRCP	0.7	5.7	0.33	3.21e-8	Diabetic kidney disease;
CESC	cis	rs4746818	1.000	rs906217	chr10:70954661	T/C	cg04149295	chr10:70884716	VPS26A	0.58	5.07	0.3	7.44e-7	Left atrial antero-posterior diameter;
CESC	cis	rs7084402	0.902	rs1649017	chr10:60288531	T/C	cg07615347	chr10:60278583	BICC1	0.59	9.2	0.49	1.13e-17	Refractive error;
CESC	trans	rs561341	0.943	rs508566	chr17:30289861	G/C	cg27661571	chr11:113659931	NA	-0.83	-7.45	-0.42	1.3e-12	Hip circumference adjusted for BMI;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10780495	chr1:8939136	ENO1	0.55	6.15	0.35	2.78e-9	Gut microbiome composition (summer);
CESC	cis	rs3820928	0.874	rs10178731	chr2:227874232	C/T	cg11843606	chr2:227700838	RHBDD1	-0.42	-5.25	-0.31	3.06e-7	Pulmonary function;
CESC	cis	rs35079168	0.923	rs11103473	chr9:137287629	A/T	cg00753924	chr9:137298813	RXRA	0.35	5.45	0.32	1.18e-7	Intelligence;
CESC	cis	rs7659604	0.605	rs67772833	chr4:122723106	G/A	cg20573242	chr4:122745356	CCNA2	0.61	8.01	0.44	3.57e-14	Type 2 diabetes;
CESC	cis	rs9811920	0.809	rs796976	chr3:99621002	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.44	5.82	0.34	1.7e-8	Axial length;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg01809819	chr1:31192165	MATN1	-0.46	-6.36	-0.36	8.89e-10	Height;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg09273779	chr9:35605990	TESK1	-0.47	-6.29	-0.36	1.29e-9	Height;
CESC	cis	rs67478160	0.619	rs1040813	chr14:104306696	T/C	cg08213375	chr14:104286397	PPP1R13B	0.53	10.41	0.54	1.75e-21	Schizophrenia;
CESC	trans	rs1814175	0.817	rs4881645	chr11:49791168	G/A	cg03929089	chr4:120376271	NA	-0.9	-14.97	-0.68	4.06e-37	Height;
CESC	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg22535103	chr8:58192502	C8orf71	-0.93	-10.36	-0.54	2.49e-21	Developmental language disorder (linguistic errors);
CESC	cis	rs4727027	0.866	rs3735311	chr7:148877737	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.43	5.38	0.31	1.62e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs4819052	0.918	rs2330013	chr21:46658662	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.87	11.34	0.57	1.42e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.54	6.73	0.38	1.03e-10	Prudent dietary pattern;
CESC	cis	rs3766606	0.505	rs72633047	chr1:7935440	G/A	cg00042356	chr1:8021962	PARK7	0.58	5.51	0.32	8.57e-8	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs6466055	0.692	rs13226540	chr7:104999901	G/A	cg04380332	chr7:105027541	SRPK2	-0.43	-5.61	-0.33	5.18e-8	Schizophrenia;
CESC	trans	rs9467711	0.606	rs9393707	chr6:26362486	T/C	cg06606381	chr12:133084897	FBRSL1	-0.76	-7.08	-0.4	1.28e-11	Autism spectrum disorder or schizophrenia;
CESC	cis	rs6541297	0.703	rs638097	chr1:230310728	C/T	cg20703242	chr1:230279135	GALNT2	-0.43	-5.56	-0.32	6.46e-8	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09685104	chr18:13726506	C18orf19;RNMT	0.55	6.59	0.38	2.39e-10	Gut microbiome composition (summer);
CESC	cis	rs7618915	0.524	rs10433615	chr3:52638482	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	6.77	0.38	8.38e-11	Bipolar disorder;
CESC	trans	rs7615952	0.599	rs1044215	chr3:125725559	C/G	cg07211511	chr3:129823064	LOC729375	-0.59	-7.29	-0.41	3.66e-12	Blood pressure (smoking interaction);
CESC	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	13.67	0.64	1.44e-32	Prudent dietary pattern;
CESC	cis	rs3733585	0.781	rs13103690	chr4:9972778	T/G	cg00071950	chr4:10020882	SLC2A9	-0.77	-13.79	-0.65	5.54e-33	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs7267979	1.000	rs6115182	chr20:25410259	G/A	cg08601574	chr20:25228251	PYGB	-0.38	-5.59	-0.32	5.69e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs12477438	0.520	rs10865029	chr2:99718298	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.88	15.61	0.69	2.15e-39	Chronic sinus infection;
CESC	cis	rs2901656	0.934	rs2285170	chr1:172425529	C/G	cg03748243	chr1:172413542	C1orf105;PIGC	0.41	5.98	0.34	7.33e-9	Red cell distribution width;Platelet distribution width;
CESC	cis	rs1348850	0.958	rs4893941	chr2:178269531	A/T	cg23306229	chr2:178417860	TTC30B	0.64	7.98	0.44	4.35e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs1552244	0.882	rs28366039	chr3:10028988	C/A	cg00149659	chr3:10157352	C3orf10	0.6	6.3	0.36	1.27e-9	Alzheimer's disease;
CESC	cis	rs13064411	0.696	rs6438156	chr3:113206929	C/A	cg18753928	chr3:113234510	CCDC52	-0.5	-5.9	-0.34	1.11e-8	Response to simvastatin treatment (PCSK9 protein level change);
CESC	cis	rs8114671	0.836	rs6142284	chr20:33641367	G/A	cg07148914	chr20:33460835	GGT7	-0.41	-5.31	-0.31	2.28e-7	Height;
CESC	trans	rs7246760	1.000	rs113915533	chr19:9881379	A/C	cg02900749	chr2:68251473	NA	-0.78	-6.71	-0.38	1.2e-10	Pursuit maintenance gain;
CESC	trans	rs7902708	0.920	rs7095383	chr10:54425601	G/T	cg26219051	chr22:43739629	SCUBE1	-0.48	-6.19	-0.36	2.25e-9	Bone properties (heel);
CESC	cis	rs7647973	0.580	rs11130184	chr3:49229930	C/T	cg03060546	chr3:49711283	APEH	0.5	6.8	0.39	6.79e-11	Menarche (age at onset);
CESC	cis	rs901683	0.867	rs17157885	chr10:46020094	G/A	cg16031567	chr10:46195673	NA	-0.77	-5.04	-0.3	8.57e-7	Red blood cell traits;Mean corpuscular volume;
CESC	cis	rs4450131	0.522	rs11245327	chr10:126358174	T/C	cg20435097	chr10:126320824	FAM53B	0.29	5.18	0.3	4.31e-7	White blood cell count (basophil);
CESC	cis	rs7552404	0.727	rs5745427	chr1:76332637	C/A	cg10523679	chr1:76189770	ACADM	-0.65	-6.61	-0.38	2.12e-10	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs9649213	0.593	rs7458551	chr7:97952167	G/C	cg08684580	chr7:98029266	BAIAP2L1	-0.35	-5.7	-0.33	3.23e-8	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs9329221	0.655	rs656319	chr8:9814411	A/G	cg06636001	chr8:8085503	FLJ10661	-0.49	-6.58	-0.37	2.48e-10	Neuroticism;
CESC	cis	rs2760061	0.624	rs10442629	chr1:228191070	T/A	cg02753203	chr1:228287806	NA	0.78	11.66	0.58	1.19e-25	Diastolic blood pressure;
CESC	cis	rs1707322	0.721	rs10430124	chr1:46221617	C/T	cg06784218	chr1:46089804	CCDC17	0.43	7.54	0.42	7.28e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs4713118	0.587	rs61471148	chr6:28037032	T/A	cg19592336	chr6:28129416	ZNF389	0.58	7.25	0.41	4.65e-12	Parkinson's disease;
CESC	cis	rs72781680	1.000	rs111229211	chr2:24167417	T/G	cg20701182	chr2:24300061	SF3B14	0.62	5.13	0.3	5.5e-7	Lymphocyte counts;
CESC	cis	rs1401999	0.966	rs2037379	chr3:183650330	T/C	cg01324343	chr3:183735012	ABCC5	0.65	13.56	0.64	3.53e-32	Anterior chamber depth;
CESC	trans	rs2085496	0.764	rs1596751	chr2:193807860	A/G	cg26248645	chr2:64370690	PELI1	0.48	6.46	0.37	4.97e-10	Neuroticism;
CESC	cis	rs561341	1.000	rs501957	chr17:30314504	C/T	cg19193384	chr17:30244184	NA	-0.69	-6.53	-0.37	3.32e-10	Hip circumference adjusted for BMI;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg01519164	chr14:69619846	DCAF5	0.49	6.18	0.35	2.35e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs35110281	0.693	rs2838344	chr21:45089877	C/T	cg01579765	chr21:45077557	HSF2BP	-0.52	-9.12	-0.49	1.96e-17	Mean corpuscular volume;
CESC	cis	rs2576037	0.526	rs998819	chr18:44564181	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.54	7.54	0.42	7.31e-13	Personality dimensions;
CESC	cis	rs3820068	0.608	rs7514858	chr1:16035246	G/A	cg13390004	chr1:15929781	NA	0.33	5.13	0.3	5.64e-7	Systolic blood pressure;
CESC	cis	rs1461503	0.966	rs10790546	chr11:122838426	C/A	cg27398637	chr11:122830231	C11orf63	-0.56	-8.42	-0.46	2.35e-15	Menarche (age at onset);
CESC	cis	rs7116495	0.881	rs7930722	chr11:71737484	C/G	cg10381502	chr11:71823885	C11orf51	-0.64	-5.21	-0.3	3.81e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs875971	1.000	rs35149210	chr7:65929925	T/C	cg11764359	chr7:65958608	NA	0.97	15.5	0.69	5.25e-39	Aortic root size;
CESC	cis	rs4660261	0.526	rs2040950	chr1:44315113	G/C	cg12908607	chr1:44402522	ARTN	-0.46	-6.6	-0.38	2.29e-10	Intelligence (multi-trait analysis);
CESC	cis	rs10504229	0.683	rs56204590	chr8:58131642	T/G	cg02725872	chr8:58115012	NA	-0.45	-7.05	-0.4	1.52e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs9311474	0.508	rs12629701	chr3:52619836	T/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	5.75	0.33	2.45e-8	Electroencephalogram traits;
CESC	cis	rs10206020	0.885	rs13388254	chr2:1577209	A/G	cg12573674	chr2:1569213	NA	-0.46	-5.2	-0.3	3.96e-7	IgG glycosylation;
CESC	cis	rs1371867	0.513	rs1542812	chr8:101207064	G/A	cg06002616	chr8:101225028	SPAG1	0.31	5.15	0.3	4.98e-7	Atrioventricular conduction;
CESC	cis	rs10191773	0.535	rs12477879	chr2:112969865	C/T	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.64	-6.47	-0.37	4.77e-10	Yeast infection;
CESC	cis	rs55728055	1.000	rs16989427	chr22:32108475	C/T	cg01338084	chr22:32026380	PISD	1.21	7.95	0.44	5.53e-14	Age-related hearing impairment;
CESC	trans	rs877282	0.583	rs12356155	chr10:823940	C/T	cg22713356	chr15:30763199	NA	1.02	9.67	0.51	3.88e-19	Uric acid levels;
CESC	cis	rs4843747	0.636	rs11117358	chr16:88105053	T/A	cg17633681	chr16:88106987	BANP	0.76	10.4	0.54	1.88e-21	Menopause (age at onset);
CESC	cis	rs11249608	0.548	rs12152869	chr5:178462520	A/G	cg01312482	chr5:178451176	ZNF879	-0.45	-6.07	-0.35	4.31e-9	Pubertal anthropometrics;
CESC	cis	rs9486719	1.000	rs12190508	chr6:96898269	T/C	cg18709589	chr6:96969512	KIAA0776	-0.54	-5.87	-0.34	1.3e-8	Migraine;Coronary artery disease;
CESC	cis	rs6467136	0.765	rs11767380	chr7:127209302	T/C	cg25922125	chr7:127225783	GCC1	-0.37	-5.15	-0.3	5.11e-7	Type 2 diabetes;
CESC	cis	rs897984	0.647	rs8060857	chr16:31002720	G/A	cg00531865	chr16:30841666	NA	0.49	6.53	0.37	3.31e-10	Dementia with Lewy bodies;
CESC	cis	rs1580019	0.922	rs1376289	chr7:32486980	C/G	cg06627557	chr7:32535165	LSM5;AVL9	-0.87	-11.67	-0.58	1.14e-25	Cognitive ability;
CESC	cis	rs9611565	0.694	rs9607816	chr22:41950897	G/A	cg06481639	chr22:41940642	POLR3H	-0.61	-6.47	-0.37	4.81e-10	Vitiligo;
CESC	trans	rs853679	0.546	rs200950	chr6:27835772	A/G	cg06606381	chr12:133084897	FBRSL1	-0.83	-7.8	-0.43	1.44e-13	Depression;
CESC	cis	rs875971	0.862	rs7782704	chr7:65805366	G/A	cg18876405	chr7:65276391	NA	-0.51	-7.03	-0.4	1.8e-11	Aortic root size;
CESC	cis	rs6952808	0.689	rs2008263	chr7:2048335	A/G	cg23048001	chr7:2026167	MAD1L1	0.48	6.29	0.36	1.33e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs2836974	0.666	rs4624474	chr21:40686327	T/C	cg11890956	chr21:40555474	PSMG1	-0.92	-14.5	-0.67	1.81e-35	Cognitive function;
CESC	cis	rs7520050	0.966	rs12049588	chr1:46472422	G/A	cg03146154	chr1:46216737	IPP	-0.46	-5.87	-0.34	1.31e-8	Red blood cell count;Reticulocyte count;
CESC	cis	rs7259376	0.875	rs4932755	chr19:22494816	A/G	cg02657401	chr19:22469223	NA	-0.26	-5.32	-0.31	2.22e-7	Menopause (age at onset);
CESC	cis	rs9818758	0.607	rs9311439	chr3:49310408	A/G	cg00383909	chr3:49044727	WDR6	0.81	6.16	0.35	2.63e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CESC	trans	rs11115322	1.000	rs11115323	chr12:83019495	C/T	cg02020882	chr3:128336728	NA	-0.95	-6.48	-0.37	4.39e-10	Immune response to smallpox vaccine (IL-6);
CESC	cis	rs921968	0.643	rs645796	chr2:219389236	A/G	cg02176678	chr2:219576539	TTLL4	0.43	7.75	0.43	2.03e-13	Mean corpuscular hemoglobin concentration;
CESC	cis	rs902774	0.515	rs2363635	chr12:53354622	T/C	cg16329197	chr12:53359506	NA	-0.62	-8.76	-0.47	2.34e-16	Prostate cancer;
CESC	cis	rs7618915	0.547	rs62253703	chr3:52632357	T/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	5.66	0.33	3.97e-8	Bipolar disorder;
CESC	cis	rs9291683	0.566	rs13122689	chr4:10044648	A/G	cg11266682	chr4:10021025	SLC2A9	0.65	12.28	0.6	9.55e-28	Bone mineral density;
CESC	cis	rs7188697	0.922	rs37040	chr16:58578262	T/C	cg02549819	chr16:58548995	SETD6	-0.42	-5.29	-0.31	2.55e-7	QT interval;
CESC	cis	rs929596	0.597	rs10173355	chr2:234597321	A/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.48	-6.01	-0.35	6.26e-9	Total bilirubin levels in HIV-1 infection;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg16749093	chr11:65352605	EHBP1L1	0.47	6.33	0.36	1.06e-9	Fibrinogen levels;
CESC	cis	rs6570726	0.791	rs1509213	chr6:145783360	G/A	cg23711669	chr6:146136114	FBXO30	-1.0	-15.6	-0.69	2.23e-39	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6429082	0.791	rs61836205	chr1:235638753	C/G	cg26050004	chr1:235667680	B3GALNT2	0.62	7.86	0.43	9.85e-14	Adiposity;
CESC	cis	rs854765	0.619	rs6502636	chr17:17983817	A/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.62	8.84	0.48	1.38e-16	Total body bone mineral density;
CESC	cis	rs10911251	0.528	rs4652779	chr1:183104552	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.85	13.46	0.64	8.11e-32	Colorectal cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13012899	chr14:105685616	BRF1	-0.6	-6.89	-0.39	4.14e-11	Gut microbiome composition (summer);
CESC	cis	rs2836974	0.863	rs8128026	chr21:40533702	T/C	cg17971929	chr21:40555470	PSMG1	1.06	16.44	0.71	2.32e-42	Cognitive function;
CESC	cis	rs9311474	0.508	rs2878628	chr3:52584715	C/T	cg18337363	chr3:52569053	NT5DC2	-0.29	-5.22	-0.31	3.67e-7	Electroencephalogram traits;
CESC	cis	rs1023500	0.573	rs133382	chr22:42471774	C/T	cg15557168	chr22:42548783	NA	-0.45	-6.5	-0.37	3.87e-10	Schizophrenia;
CESC	cis	rs1799949	0.965	rs8176322	chr17:41195773	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	8.59	0.47	7.39e-16	Menopause (age at onset);
CESC	cis	rs7666738	0.753	rs28390295	chr4:99028497	C/A	cg18180107	chr4:99064573	C4orf37	0.42	5.43	0.32	1.29e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs8031584	0.918	rs34095794	chr15:31269691	C/T	cg14298792	chr15:30685198	CHRFAM7A	-0.44	-5.14	-0.3	5.38e-7	Huntington's disease progression;
CESC	cis	rs7568458	0.636	rs11126995	chr2:85792408	A/T	cg02493740	chr2:85810744	VAMP5	-0.55	-8.24	-0.45	7.91e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CESC	cis	rs3820068	0.705	rs4646075	chr1:15827461	T/C	cg18192808	chr1:15853278	DNAJC16	0.47	5.78	0.33	2.05e-8	Systolic blood pressure;
CESC	cis	rs55794721	0.509	rs2375313	chr1:25748235	G/A	cg02931644	chr1:25747376	RHCE	0.46	7.85	0.43	1.06e-13	Plateletcrit;Mean corpuscular volume;
CESC	trans	rs853679	0.546	rs200996	chr6:27811828	G/A	cg06606381	chr12:133084897	FBRSL1	-0.73	-6.99	-0.39	2.21e-11	Depression;
CESC	cis	rs854765	0.587	rs4077828	chr17:17833644	A/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.55	7.29	0.41	3.65e-12	Total body bone mineral density;
CESC	cis	rs7607369	0.714	rs4674334	chr2:219622811	T/C	cg02176678	chr2:219576539	TTLL4	-0.5	-8.62	-0.47	6.1e-16	Red blood cell count;Amyotrophic lateral sclerosis;
CESC	cis	rs3733585	0.699	rs7658170	chr4:9966593	C/T	cg02734326	chr4:10020555	SLC2A9	0.39	5.54	0.32	7.3900000000000007e-08	Cleft plate (environmental tobacco smoke interaction);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg08355568	chr6:7108248	RREB1	-0.47	-6.01	-0.35	6.12e-9	Fibrinogen levels;
CESC	cis	rs6831352	0.819	rs1230155	chr4:99989259	C/T	cg21548116	chr4:100009993	ADH5	0.46	5.06	0.3	7.96e-7	Alcohol dependence;
CESC	cis	rs9908102	0.740	rs60713770	chr17:12912385	A/G	cg26162695	chr17:12921313	ELAC2	0.52	5.71	0.33	3.04e-8	Schizophrenia;
CESC	cis	rs3008870	1.000	rs3008858	chr1:67390416	G/C	cg02640540	chr1:67518911	SLC35D1	0.49	5.29	0.31	2.6e-7	Lymphocyte percentage of white cells;
CESC	cis	rs7100689	0.646	rs11202724	chr10:82136190	T/C	cg00277334	chr10:82204260	NA	-0.57	-7.51	-0.42	9.08e-13	Post bronchodilator FEV1;
CESC	cis	rs7149337	0.805	rs2999354	chr14:51607179	C/G	cg23942311	chr14:51606299	NA	0.48	8.36	0.46	3.56e-15	Cancer;
CESC	trans	rs747782	0.639	rs61649224	chr11:48057640	G/A	cg15704280	chr7:45808275	SEPT13	0.67	6.02	0.35	5.74e-9	Intraocular pressure;
CESC	cis	rs250677	0.687	rs250664	chr5:148453823	C/T	cg18129178	chr5:148520854	ABLIM3	-0.51	-5.91	-0.34	1.05e-8	Breast cancer;
CESC	cis	rs9811920	0.555	rs68092024	chr3:99691522	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.44	-5.49	-0.32	9.63e-8	Axial length;
CESC	cis	rs9287719	0.601	rs13427815	chr2:10707985	C/T	cg00105475	chr2:10696890	NA	0.41	5.59	0.32	5.74e-8	Prostate cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24947615	chr21:44515479	U2AF1	-0.77	-8.58	-0.47	8.32e-16	Gut microbiome composition (summer);
CESC	cis	rs564309	0.681	rs11581974	chr1:228617063	A/G	cg13771378	chr1:228613100	HIST3H3	-0.59	-6.26	-0.36	1.55e-9	Hip circumference (psychosocial stress interaction);
CESC	cis	rs9888739	0.800	rs7200615	chr16:31337155	G/A	cg15817542	chr16:31343056	ITGAM	-0.51	-6.83	-0.39	5.73e-11	Systemic lupus erythematosus;
CESC	cis	rs4889855	0.530	rs11654265	chr17:78602697	G/A	cg16591659	chr17:78472290	NA	0.34	5.33	0.31	2.11e-7	Fractional excretion of uric acid;
CESC	cis	rs2250402	0.510	rs2898984	chr15:40324075	G/C	cg20255370	chr15:40268687	EIF2AK4	-0.57	-5.25	-0.31	3.15e-7	Corneal curvature;
CESC	cis	rs12530845	0.623	rs73721673	chr7:135349573	A/T	cg23117316	chr7:135346802	PL-5283	-0.59	-6.35	-0.36	9.48e-10	Red blood cell traits;
CESC	cis	rs6933660	0.646	rs3736176	chr6:151773320	T/A	cg02564969	chr6:151773285	C6orf211;RMND1	0.66	9.47	0.5	1.61e-18	Menarche (age at onset);
CESC	cis	rs10979	1.000	rs9373394	chr6:143890776	A/G	cg25407410	chr6:143891975	LOC285740	-0.61	-9.14	-0.49	1.72e-17	Hypospadias;
CESC	cis	rs7618915	0.501	rs1866268	chr3:52719398	C/A	cg18404041	chr3:52824283	ITIH1	-0.38	-6.53	-0.37	3.29e-10	Bipolar disorder;
CESC	cis	rs7824557	0.564	rs35009431	chr8:11232788	G/A	cg21775007	chr8:11205619	TDH	-0.53	-7.4	-0.41	1.84e-12	Retinal vascular caliber;
CESC	cis	rs9311474	0.629	rs13081028	chr3:52555316	G/A	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.42	8.04	0.44	3.05e-14	Electroencephalogram traits;
CESC	cis	rs9902453	0.967	rs4493117	chr17:28489770	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.65	8.43	0.46	2.29e-15	Coffee consumption (cups per day);
CESC	cis	rs2425143	1.000	rs12479473	chr20:34398628	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.68	5.88	0.34	1.24e-8	Blood protein levels;
CESC	cis	rs3820068	0.603	rs1122387	chr1:15947282	T/C	cg16988262	chr1:15930761	NA	0.34	5.45	0.32	1.13e-7	Systolic blood pressure;
CESC	cis	rs4975709	1.000	rs2279588	chr5:1878021	G/A	cg15595755	chr5:1867978	NA	0.47	7.25	0.41	4.67e-12	Cardiovascular disease risk factors;
CESC	cis	rs2070433	0.539	rs2839312	chr21:47958225	T/C	cg12379764	chr21:47803548	PCNT	0.62	8.18	0.45	1.17e-14	Lymphocyte counts;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg05433637	chr1:1510598	SSU72	0.48	6.88	0.39	4.42e-11	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs10504229	0.636	rs72649133	chr8:58054681	G/A	cg22535103	chr8:58192502	C8orf71	-0.94	-9.35	-0.5	3.78e-18	Developmental language disorder (linguistic errors);
CESC	cis	rs314370	0.570	rs314314	chr7:100423841	C/T	cg10426581	chr7:100472382	SRRT	0.49	5.46	0.32	1.09e-7	Resting heart rate;
CESC	cis	rs7223966	1.000	rs9903903	chr17:61762044	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.46	-5.6	-0.33	5.23e-8	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs1878931	1.000	rs1878931	chr16:3450907	G/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.92	12.96	0.62	4.47e-30	Body mass index (adult);
CESC	cis	rs921968	0.643	rs483172	chr2:219428299	A/G	cg02176678	chr2:219576539	TTLL4	0.42	7.32	0.41	2.96e-12	Mean corpuscular hemoglobin concentration;
CESC	cis	rs1018836	0.923	rs756569	chr8:91610957	G/A	cg16814680	chr8:91681699	NA	-0.74	-10.57	-0.54	5.17e-22	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.89	13.38	0.63	1.56e-31	Prudent dietary pattern;
CESC	cis	rs9649213	0.593	rs34129434	chr7:97926464	C/T	cg24562669	chr7:97807699	LMTK2	0.48	6.92	0.39	3.3e-11	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs1862618	0.627	rs744023	chr5:56197078	C/T	cg22800045	chr5:56110881	MAP3K1	0.81	9.16	0.49	1.47e-17	Initial pursuit acceleration;
CESC	cis	rs4665809	0.590	rs1865324	chr2:26417533	C/A	cg27170947	chr2:26402098	FAM59B	-0.84	-10.0	-0.52	3.41e-20	Gut microbiome composition (summer);
CESC	cis	rs929596	0.755	rs6742078	chr2:234672639	A/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.67	9.16	0.49	1.45e-17	Total bilirubin levels in HIV-1 infection;
CESC	cis	rs2204008	0.807	rs4123933	chr12:37973539	G/A	cg13010199	chr12:38710504	ALG10B	0.53	6.61	0.38	2.1e-10	Bladder cancer;
CESC	cis	rs12142240	0.698	rs72885198	chr1:46812888	C/T	cg10495392	chr1:46806563	NSUN4	0.57	6.29	0.36	1.33e-9	Menopause (age at onset);
CESC	cis	rs752010	0.934	rs11210503	chr1:42101134	A/G	cg06885757	chr1:42089581	HIVEP3	0.49	7.96	0.44	5e-14	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs748404	0.631	rs28702649	chr15:43648629	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.59	7.38	0.41	2.04e-12	Lung cancer;
CESC	cis	rs514406	0.798	rs4351588	chr1:53263826	A/T	cg08859206	chr1:53392774	SCP2	0.67	10.03	0.52	2.87e-20	Monocyte count;
CESC	cis	rs8017423	1.000	rs8015379	chr14:90679432	C/T	cg14092571	chr14:90743983	NA	-0.58	-8.73	-0.47	2.97e-16	Mortality in heart failure;
CESC	cis	rs7582720	1.000	rs116382857	chr2:203751932	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.39	0.41	1.96e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	trans	rs7726839	0.540	rs12517638	chr5:645484	C/T	cg25482853	chr8:67687455	SGK3	0.92	9.68	0.51	3.5e-19	Obesity-related traits;
CESC	cis	rs7084402	0.967	rs11815274	chr10:60328891	A/G	cg07615347	chr10:60278583	BICC1	-0.58	-9.01	-0.48	4.24e-17	Refractive error;
CESC	cis	rs4665809	1.000	rs12475854	chr2:26267375	G/A	cg22920501	chr2:26401640	FAM59B	-0.66	-7.92	-0.44	6.58e-14	Gut microbiome composition (summer);
CESC	cis	rs17253792	0.822	rs74720318	chr14:56099828	G/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.79	5.91	0.34	1.06e-8	Putamen volume;
CESC	cis	rs514406	0.548	rs6670871	chr1:53212082	A/C	cg24675658	chr1:53192096	ZYG11B	0.6	7.55	0.42	7.08e-13	Monocyte count;
CESC	trans	rs877282	1.000	rs71491304	chr10:772982	C/T	cg22713356	chr15:30763199	NA	1.12	11.31	0.57	1.87e-24	Uric acid levels;
CESC	cis	rs77106637	0.932	rs3814730	chr11:72555553	G/A	cg04827223	chr11:72435913	ARAP1	-0.5	-5.18	-0.3	4.39e-7	Type 2 diabetes;
CESC	cis	rs7542091	0.669	rs11119357	chr1:210042382	C/T	cg21951975	chr1:209979733	IRF6	0.45	7.76	0.43	1.82e-13	Monobrow;
CESC	cis	rs2838344	0.776	rs2298561	chr21:45085234	A/G	cg01579765	chr21:45077557	HSF2BP	-0.53	-8.77	-0.47	2.15e-16	Coronary artery disease;
CESC	cis	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg18200150	chr17:30822561	MYO1D	-0.56	-8.4	-0.46	2.67e-15	Schizophrenia;
CESC	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg27532560	chr4:187881888	NA	0.41	6.47	0.37	4.65e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7833790	0.700	rs7834483	chr8:82704828	A/G	cg27398817	chr8:82754497	SNX16	-0.44	-5.61	-0.33	5.08e-8	Diastolic blood pressure;
CESC	trans	rs61931739	0.517	rs11052980	chr12:34036036	T/C	cg26384229	chr12:38710491	ALG10B	0.5	6.78	0.38	7.87e-11	Morning vs. evening chronotype;
CESC	cis	rs7618915	0.547	rs2164884	chr3:52629633	C/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	5.62	0.33	4.92e-8	Bipolar disorder;
CESC	cis	rs55728055	0.661	rs5753700	chr22:31971258	C/T	cg01338084	chr22:32026380	PISD	0.92	6.54	0.37	3.09e-10	Age-related hearing impairment;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg22110492	chr9:136283026	ADAMTS13;REXO4	-0.48	-6.06	-0.35	4.58e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs3105593	0.933	rs874665	chr15:50877992	C/T	cg08437265	chr15:50716283	USP8	0.41	5.24	0.31	3.23e-7	QT interval;
CESC	cis	rs7044106	0.718	rs1981021	chr9:123388393	T/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.68	9.89	0.52	7.73e-20	Hip circumference adjusted for BMI;
CESC	cis	rs17711722	0.727	rs2658585	chr7:65461941	A/T	cg05332525	chr7:65337924	VKORC1L1	0.51	6.23	0.36	1.85e-9	Calcium levels;
CESC	cis	rs13256369	0.789	rs13282500	chr8:8568489	A/T	cg17143192	chr8:8559678	CLDN23	0.54	6.32	0.36	1.09e-9	Obesity-related traits;
CESC	cis	rs7818345	1.000	rs4392915	chr8:19308938	T/G	cg11303988	chr8:19266685	CSGALNACT1	0.36	6.33	0.36	1.06e-9	Language performance in older adults (adjusted for episodic memory);
CESC	cis	rs6500395	1.000	rs1486412	chr16:48651750	A/T	cg04672837	chr16:48644449	N4BP1	0.51	6.21	0.36	2.08e-9	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs4975709	0.610	rs4975704	chr5:1859807	C/A	cg12288994	chr5:1860383	NA	0.41	6.78	0.38	7.8e-11	Cardiovascular disease risk factors;
CESC	cis	rs5753618	0.529	rs5749298	chr22:31941032	C/T	cg02404636	chr22:31891804	SFI1	0.44	5.99	0.35	6.95e-9	Colorectal cancer;
CESC	cis	rs454510	0.857	rs838990	chr1:120193252	A/G	cg11530693	chr1:120165357	ZNF697	0.43	5.58	0.32	6.07e-8	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
CESC	cis	rs1862618	0.713	rs832549	chr5:56183542	C/T	cg18230493	chr5:56204884	C5orf35	-0.73	-8.65	-0.47	5.17e-16	Initial pursuit acceleration;
CESC	cis	rs4555082	0.834	rs2816653	chr14:105713973	A/G	cg06808227	chr14:105710500	BRF1	-0.58	-6.88	-0.39	4.31e-11	Mean platelet volume;Platelet distribution width;
CESC	cis	rs367615	0.552	rs2963024	chr5:108730773	C/T	cg17395555	chr5:108820864	NA	-0.42	-7.05	-0.4	1.6e-11	Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs1577917	0.958	rs10944168	chr6:86680156	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.47	-6.08	-0.35	4.29e-9	Response to antipsychotic treatment;
CESC	cis	rs875971	0.862	rs6460293	chr7:65810192	C/A	cg12463550	chr7:65579703	CRCP	-0.48	-6.17	-0.35	2.6e-9	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02751449	chr3:142443340	TRPC1	0.56	6.29	0.36	1.33e-9	Gut microbiome composition (summer);
CESC	trans	rs12599106	0.707	rs2163977	chr16:34916134	A/G	cg03395511	chr6:291903	DUSP22	-0.66	-8.18	-0.45	1.21e-14	Menopause (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02423323	chr4:146100633	OTUD4	-0.55	-6.51	-0.37	3.78e-10	Gut microbiome composition (summer);
CESC	cis	rs2279817	0.863	rs35871295	chr1:17984468	A/T	cg21791023	chr1:18019539	ARHGEF10L	-0.66	-7.97	-0.44	4.73e-14	Neuroticism;
CESC	cis	rs11098499	0.780	rs10013652	chr4:120292256	A/G	cg09307838	chr4:120376055	NA	0.86	11.74	0.58	6.58e-26	Corneal astigmatism;
CESC	cis	rs7927592	0.763	rs10896327	chr11:68235275	G/C	cg20283391	chr11:68216788	NA	-0.45	-5.58	-0.32	5.81e-8	Total body bone mineral density;
CESC	cis	rs7100689	0.646	rs1934692	chr10:82125734	C/A	cg00277334	chr10:82204260	NA	-0.58	-7.76	-0.43	1.84e-13	Post bronchodilator FEV1;
CESC	cis	rs910316	0.763	rs175450	chr14:75590340	G/A	cg11812906	chr14:75593930	NEK9	-0.82	-13.14	-0.63	1.07e-30	Height;
CESC	cis	rs73206853	0.563	rs16940992	chr12:111207515	C/T	cg12870014	chr12:110450643	ANKRD13A	-0.69	-7.23	-0.41	5.18e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs4911253	0.509	rs66499347	chr20:31448696	C/T	cg13636640	chr20:31349939	DNMT3B	-0.67	-9.39	-0.5	2.83e-18	Lymphocyte counts;
CESC	cis	rs4555082	0.834	rs4412909	chr14:105759226	T/C	cg27165867	chr14:105738592	BRF1	-0.52	-5.55	-0.32	6.93e-8	Mean platelet volume;Platelet distribution width;
CESC	cis	rs6121246	0.909	rs1994250	chr20:30287494	A/G	cg13852791	chr20:30311386	BCL2L1	0.79	8.3	0.45	5.47e-15	Mean corpuscular hemoglobin;
CESC	cis	rs875971	0.660	rs3764903	chr7:66098482	G/A	cg11764359	chr7:65958608	NA	-0.66	-8.67	-0.47	4.31e-16	Aortic root size;
CESC	cis	rs7937682	0.924	rs4630327	chr11:111539327	C/T	cg09085632	chr11:111637200	PPP2R1B	0.97	16.43	0.71	2.69e-42	Primary sclerosing cholangitis;
CESC	cis	rs2832077	0.943	rs11701445	chr21:30160807	C/T	cg03476357	chr21:30257390	N6AMT1	-0.51	-5.54	-0.32	7.32e-8	Cognitive test performance;
CESC	cis	rs9486715	0.867	rs4131519	chr6:96964939	G/A	cg06623918	chr6:96969491	KIAA0776	0.81	11.56	0.58	2.67e-25	Headache;
CESC	cis	rs7666738	0.830	rs11097609	chr4:99011707	C/T	cg18180107	chr4:99064573	C4orf37	0.4	5.3	0.31	2.48e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9911578	0.967	rs1267542	chr17:56654690	T/C	cg05425664	chr17:57184151	TRIM37	0.49	6.71	0.38	1.18e-10	Intelligence (multi-trait analysis);
CESC	cis	rs1461503	0.932	rs6589962	chr11:122843535	G/A	cg27398637	chr11:122830231	C11orf63	-0.55	-8.32	-0.45	4.77e-15	Menarche (age at onset);
CESC	cis	rs523522	0.962	rs9788155	chr12:120938408	G/A	cg27279351	chr12:120934652	DYNLL1	0.69	9.11	0.49	2.02e-17	High light scatter reticulocyte count;
CESC	cis	rs9682041	0.660	rs34158232	chr3:170115360	T/C	cg11886554	chr3:170076028	SKIL	0.75	6.6	0.38	2.23e-10	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CESC	cis	rs1729951	0.575	rs361244	chr3:136697506	C/T	cg15507776	chr3:136538369	TMEM22	0.4	5.06	0.3	8.02e-7	Neuroticism;
CESC	cis	rs514406	0.763	rs9988539	chr1:53213884	T/C	cg16325326	chr1:53192061	ZYG11B	-0.89	-15.22	-0.68	5.28e-38	Monocyte count;
CESC	cis	rs3540	0.512	rs8033818	chr15:91075535	C/T	cg10434728	chr15:90938212	IQGAP1	-0.42	-7.22	-0.41	5.4e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs11792861	0.962	rs72607161	chr9:111792640	T/C	cg13535736	chr9:111863775	C9orf5	-0.51	-6.69	-0.38	1.32e-10	Menarche (age at onset);
CESC	cis	rs9910055	0.529	rs190144	chr17:42164584	A/G	cg13607699	chr17:42295918	UBTF	-0.46	-5.79	-0.34	1.95e-8	Total body bone mineral density;
CESC	cis	rs55692468	0.520	rs62180799	chr2:153302108	G/A	cg04681845	chr2:153283485	FMNL2	0.29	5.91	0.34	1.06e-8	Intraocular pressure;
CESC	cis	rs2243480	1.000	rs4718333	chr7:65772758	T/C	cg12463550	chr7:65579703	CRCP	-0.74	-5.73	-0.33	2.74e-8	Diabetic kidney disease;
CESC	cis	rs17376456	0.877	rs10044066	chr5:93437580	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.6	5.27	0.31	2.85e-7	Diabetic retinopathy;
CESC	cis	rs694739	0.894	rs887314	chr11:64053157	T/G	cg02228329	chr11:64053129	BAD;GPR137	0.67	8.56	0.47	9.07e-16	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CESC	cis	rs3126085	0.935	rs1552995	chr1:152171427	A/G	cg03465714	chr1:152285911	FLG	-0.45	-5.51	-0.32	8.46e-8	Atopic dermatitis;
CESC	cis	rs34375054	0.738	rs3751181	chr12:125626535	A/G	cg06287003	chr12:125626642	AACS	-0.34	-5.35	-0.31	1.87e-7	Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs7843479	0.965	rs17616085	chr8:21857267	C/T	cg17168535	chr8:21777572	XPO7	0.48	6.65	0.38	1.62e-10	Mean corpuscular volume;
CESC	cis	rs2404602	0.692	rs8043474	chr15:76974723	T/C	cg26408565	chr15:76604113	ETFA	-0.39	-5.72	-0.33	2.94e-8	Blood metabolite levels;
CESC	cis	rs12477438	1.000	rs6732980	chr2:99921613	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.68	-7.84	-0.43	1.13e-13	Chronic sinus infection;
CESC	cis	rs16867321	0.694	rs11889207	chr2:181424527	A/C	cg23363182	chr2:181467187	NA	-0.5	-7.15	-0.4	8.5e-12	Obesity;
CESC	cis	rs7917772	0.619	rs2251772	chr10:104470918	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.51	5.75	0.33	2.45e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs6502050	0.805	rs7225560	chr17:80160884	C/G	cg23985595	chr17:80112537	CCDC57	-0.41	-6.55	-0.37	3.05e-10	Life satisfaction;
CESC	cis	rs10504229	0.953	rs57131327	chr8:58171895	T/C	cg14926445	chr8:58193284	C8orf71	-0.51	-5.47	-0.32	1.03e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs8072100	0.840	rs2136751	chr17:45456093	A/G	cg08085267	chr17:45401833	C17orf57	-0.54	-7.23	-0.41	5.16e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs1059312	0.966	rs12368452	chr12:129277164	C/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.71	-9.86	-0.52	9.39e-20	Systemic lupus erythematosus;
CESC	cis	rs4727027	0.727	rs1568944	chr7:148873497	A/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.49	5.76	0.33	2.3e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	trans	rs875971	0.898	rs6977501	chr7:65693342	T/C	cg26939375	chr7:64535504	NA	-0.47	-6.22	-0.36	1.89e-9	Aortic root size;
CESC	trans	rs17307778	1.000	rs4437989	chr11:25358786	T/C	cg22888484	chr20:37075185	SNHG11	-0.62	-6.11	-0.35	3.51e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs892961	0.932	rs6501954	chr17:75414398	G/C	cg05865280	chr17:75406074	SEPT9	0.63	12.77	0.62	1.96e-29	Airflow obstruction;
CESC	cis	rs6752107	1.000	rs35300242	chr2:234168790	G/A	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.39	5.94	0.34	9.02e-9	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs9322193	0.923	rs1572229	chr6:150064977	T/A	cg04369109	chr6:150039330	LATS1	-0.43	-5.91	-0.34	1.05e-8	Lung cancer;
CESC	cis	rs16854884	0.586	rs11914731	chr3:143725594	A/G	cg01302019	chr3:143689584	C3orf58	-0.33	-5.2	-0.3	4.05e-7	Economic and political preferences (feminism/equality);
CESC	cis	rs892961	0.899	rs35217221	chr17:75412385	G/A	cg05865280	chr17:75406074	SEPT9	0.62	12.43	0.61	2.89e-28	Airflow obstruction;
CESC	cis	rs11190604	0.943	rs3750631	chr10:102279294	A/G	cg07080220	chr10:102295463	HIF1AN	0.68	6.29	0.36	1.31e-9	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs11587400	0.679	rs6537834	chr1:115108870	T/C	cg12756093	chr1:115239321	AMPD1	0.43	5.76	0.33	2.27e-8	Autism;
CESC	cis	rs2836633	1.000	rs2836634	chr21:40068230	T/A	cg12884169	chr21:40033163	ERG	0.33	5.3	0.31	2.46e-7	Coronary artery disease;
CESC	cis	rs10779751	0.610	rs2486921	chr1:11124943	G/A	cg08854313	chr1:11322531	MTOR	0.77	10.41	0.54	1.73e-21	Body mass index;
CESC	trans	rs6828577	0.862	rs298995	chr4:119625273	G/A	cg05098011	chr1:151736092	OAZ3;MRPL9	0.48	6.01	0.35	6e-9	Perioperative myocardial infarction in coronary artery bypass surgery;
CESC	cis	rs684232	0.666	rs366151	chr17:598311	A/C	cg15660573	chr17:549704	VPS53	-0.66	-9.31	-0.5	5.09e-18	Prostate cancer;
CESC	cis	rs4689388	0.890	rs11732208	chr4:6292716	G/C	cg25554036	chr4:6271136	WFS1	0.52	8.47	0.46	1.68e-15	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs10504229	1.000	rs67630725	chr8:58185580	G/A	cg05313129	chr8:58192883	C8orf71	-0.55	-6.29	-0.36	1.34e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs644799	0.710	rs3748253	chr11:95519506	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	11.8	0.59	4.17e-26	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs7408868	0.520	rs10417567	chr19:15308068	C/T	cg14696996	chr19:15285081	NOTCH3	-0.96	-9.34	-0.5	4.13e-18	Pulse pressure;
CESC	cis	rs6430585	0.528	rs75524146	chr2:136725459	C/T	cg07169764	chr2:136633963	MCM6	1.29	17.68	0.74	9.44e-47	Corneal structure;
CESC	cis	rs7647973	0.621	rs3774800	chr3:49334768	A/G	cg07636037	chr3:49044803	WDR6	-0.85	-13.2	-0.63	6.28e-31	Menarche (age at onset);
CESC	cis	rs1862618	0.853	rs860580	chr5:56149429	G/T	cg24531977	chr5:56204891	C5orf35	0.84	11.2	0.57	4.3e-24	Initial pursuit acceleration;
CESC	cis	rs763014	0.931	rs62030903	chr16:638323	T/A	cg07343612	chr16:622815	PIGQ	-0.51	-6.95	-0.39	2.81e-11	Height;
CESC	cis	rs9916302	0.861	rs644173	chr17:37430519	T/C	cg15445000	chr17:37608096	MED1	0.39	6.31	0.36	1.17e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs7590368	0.673	rs17456162	chr2:10948090	C/T	cg15705551	chr2:10952987	PDIA6	-0.52	-5.08	-0.3	7.2e-7	Educational attainment (years of education);
CESC	cis	rs17376456	0.877	rs10514380	chr5:93409370	C/T	cg25358565	chr5:93447407	FAM172A	1.13	11.34	0.57	1.45e-24	Diabetic retinopathy;
CESC	cis	rs2991971	0.810	rs12738318	chr1:45929589	A/G	cg06784218	chr1:46089804	CCDC17	0.27	5.12	0.3	5.94e-7	High light scatter reticulocyte count;
CESC	cis	rs4803468	0.967	rs11083619	chr19:41913267	A/C	cg09537434	chr19:41945824	ATP5SL	-1.09	-19.79	-0.77	3.84e-54	Height;
CESC	cis	rs1799949	0.501	rs2343819	chr17:41409653	T/G	cg23758822	chr17:41437982	NA	1.05	16.25	0.71	1.17e-41	Menopause (age at onset);
CESC	cis	rs7618915	0.547	rs34537256	chr3:52657472	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	6.79	0.39	7.29e-11	Bipolar disorder;
CESC	cis	rs644799	0.542	rs10831418	chr11:95468828	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.48	6.11	0.35	3.58e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs9296092	0.538	rs9469491	chr6:33521545	A/G	cg13560919	chr6:33536144	NA	0.67	10.9	0.56	4.32e-23	Age at smoking initiation in chronic obstructive pulmonary disease;
CESC	cis	rs10242455	0.702	rs28753399	chr7:98997259	C/T	cg18809830	chr7:99032528	PTCD1	-0.91	-6.3	-0.36	1.22e-9	Blood metabolite levels;
CESC	cis	rs116095464	1.000	rs7736	chr5:314935	T/C	cg22857025	chr5:266934	NA	-1.2	-10.6	-0.55	4.2e-22	Breast cancer;
CESC	cis	rs929354	1.000	rs929354	chr7:157045557	C/T	cg05182265	chr7:156933206	UBE3C	0.41	5.77	0.33	2.21e-8	Body mass index;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg18778933	chr5:52760204	NA	0.42	6.08	0.35	4.26e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs6540559	1.000	rs742215	chr1:209961023	A/T	cg25204440	chr1:209979598	IRF6	0.63	7.97	0.44	4.79e-14	Cleft lip with or without cleft palate;
CESC	cis	rs559928	0.606	rs55970968	chr11:63961433	C/T	cg18225595	chr11:63971243	STIP1	0.69	6.2	0.36	2.17e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CESC	cis	rs6951245	0.810	rs117800627	chr7:1081075	G/C	cg24642844	chr7:1081250	C7orf50	-0.76	-9.37	-0.5	3.35e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs9443645	0.869	rs9343827	chr6:79501036	A/G	cg05283184	chr6:79620031	NA	-0.43	-6.75	-0.38	9.12e-11	Intelligence (multi-trait analysis);
CESC	cis	rs7666738	0.830	rs17027225	chr4:99028564	C/T	cg03467027	chr4:99064603	C4orf37	0.49	6.18	0.35	2.44e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs425277	1.000	rs1401138	chr1:2063149	C/T	cg24578937	chr1:2090814	PRKCZ	0.54	8.96	0.48	5.82e-17	Height;
CESC	cis	rs7829975	0.511	rs2980426	chr8:8145609	T/C	cg06636001	chr8:8085503	FLJ10661	0.62	7.94	0.44	5.75e-14	Mood instability;
CESC	cis	rs7474896	0.515	rs675628	chr10:38305331	C/G	cg00409905	chr10:38381863	ZNF37A	0.46	5.07	0.3	7.48e-7	Obesity (extreme);
CESC	trans	rs3780486	0.757	rs10813949	chr9:33123464	G/A	cg20290983	chr6:43655470	MRPS18A	0.99	18.2	0.75	1.39e-48	IgG glycosylation;
CESC	cis	rs897080	0.552	rs1067405	chr2:44674861	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.46	5.31	0.31	2.35e-7	Height;
CESC	trans	rs62103177	0.810	rs62103194	chr18:77629482	G/A	cg05926928	chr17:57297772	GDPD1	1.18	10.14	0.53	1.27e-20	Opioid sensitivity;
CESC	cis	rs62064224	0.593	rs916663	chr17:30835833	A/C	cg18200150	chr17:30822561	MYO1D	-0.6	-8.95	-0.48	6.27e-17	Schizophrenia;
CESC	cis	rs3767633	0.858	rs10753645	chr1:161815364	T/C	cg09175582	chr1:161736000	ATF6	0.86	6.85	0.39	5.21e-11	IgG glycosylation;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg02072376	chr1:153606637	C1orf77;S100A13	-0.48	-6.59	-0.38	2.37e-10	Thyroid stimulating hormone;
CESC	cis	rs295140	0.506	rs4673855	chr2:201136143	A/G	cg23649088	chr2:200775458	C2orf69	-0.46	-6.16	-0.35	2.67e-9	QT interval;
CESC	cis	rs2486288	0.656	rs8024620	chr15:45574329	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.6	-7.31	-0.41	3.23e-12	Glomerular filtration rate;
CESC	cis	rs897080	0.515	rs1085450	chr2:44650698	A/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	5.93	0.34	9.59e-9	Height;
CESC	cis	rs9322193	0.962	rs9688750	chr6:149978769	T/C	cg13206674	chr6:150067644	NUP43	0.41	5.8	0.34	1.87e-8	Lung cancer;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg10757852	chr3:141319363	RASA2	0.47	6.33	0.36	1.03e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs709400	0.597	rs1013650	chr14:103909203	G/A	cg12935359	chr14:103987150	CKB	-0.51	-7.49	-0.42	1.06e-12	Body mass index;
CESC	cis	rs60871478	0.898	rs62432897	chr7:825429	A/G	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.59	5.81	0.34	1.82e-8	Cerebrospinal P-tau181p levels;
CESC	cis	rs1153858	1.000	rs1365610	chr15:45694610	C/T	cg21132104	chr15:45694354	SPATA5L1	0.86	11.67	0.58	1.14e-25	Homoarginine levels;
CESC	cis	rs5769765	0.908	rs9616376	chr22:50310829	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.58	-6.21	-0.36	2.01e-9	Schizophrenia;
CESC	cis	rs71403859	0.730	rs12931191	chr16:71621373	A/T	cg08717414	chr16:71523259	ZNF19	0.78	7.19	0.4	6.64e-12	Post bronchodilator FEV1;
CESC	cis	rs8017423	0.935	rs11628906	chr14:90738002	C/T	cg14092571	chr14:90743983	NA	0.54	8.28	0.45	5.95e-15	Mortality in heart failure;
CESC	cis	rs8077577	0.945	rs62072496	chr17:18124743	G/A	cg16794390	chr17:18148240	FLII	0.47	6.09	0.35	4.05e-9	Obesity-related traits;
CESC	trans	rs7319358	0.844	rs7337382	chr13:79550458	A/G	cg11055926	chr10:111683227	XPNPEP1	-0.41	-6.02	-0.35	5.68e-9	Ulcerative colitis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22370370	chr17:47439802	ZNF652	0.55	6.06	0.35	4.65e-9	Gut microbiome composition (summer);
CESC	cis	rs6456156	0.846	rs9364891	chr6:167516319	C/T	cg07741184	chr6:167504864	NA	-0.34	-5.83	-0.34	1.58e-8	Primary biliary cholangitis;
CESC	cis	rs4713118	0.621	rs9368548	chr6:28034737	A/G	cg23281280	chr6:28129359	ZNF389	0.54	7.05	0.4	1.53e-11	Parkinson's disease;
CESC	cis	rs2120019	1.000	rs2120019	chr15:75334184	T/C	cg17294928	chr15:75287854	SCAMP5	-0.74	-8.31	-0.45	5.03e-15	Blood trace element (Zn levels);
CESC	cis	rs10743315	0.599	rs11044451	chr12:19365798	C/T	cg02471346	chr12:19282374	PLEKHA5	-0.6	-6.37	-0.36	8.52e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs3747547	0.539	rs75396486	chr9:38123834	A/T	cg13774184	chr9:37916125	SHB	-0.67	-6.03	-0.35	5.38e-9	Metabolite levels (Dihydroxy docosatrienoic acid);
CESC	cis	rs7552167	0.925	rs7546025	chr1:24510252	T/C	cg01960748	chr1:24522592	NA	-0.42	-5.23	-0.31	3.44e-7	Psoriasis vulgaris;
CESC	cis	rs7071206	0.947	rs1877998	chr10:79411740	C/T	cg07817648	chr10:79422355	NA	-0.86	-10.92	-0.56	3.71e-23	Bone mineral density;
CESC	cis	rs2292884	0.505	rs77856818	chr2:238402830	G/A	cg14458575	chr2:238380390	NA	0.71	6.11	0.35	3.63e-9	Prostate cancer;
CESC	cis	rs8031584	0.678	rs798127	chr15:31117403	T/C	cg14298792	chr15:30685198	CHRFAM7A	0.46	5.56	0.32	6.72e-8	Huntington's disease progression;
CESC	cis	rs9039	1.000	rs17652208	chr16:9196463	C/T	cg08831531	chr16:9218945	NA	-0.58	-7.35	-0.41	2.46e-12	Menopause (age at onset);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg09379601	chr19:12992224	DNASE2	-0.45	-6.52	-0.37	3.5e-10	Gambling;
CESC	cis	rs2228479	0.850	rs1800355	chr16:89813194	C/T	cg19635926	chr16:89946313	TCF25	0.67	5.04	0.3	8.66e-7	Skin colour saturation;
CESC	cis	rs875971	0.964	rs11765965	chr7:65842221	A/G	cg10691866	chr7:65817282	TPST1	-0.34	-5.46	-0.32	1.08e-7	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07728084	chr10:21683123	NA	-0.62	-6.83	-0.39	5.9e-11	Gut microbiome composition (summer);
CESC	cis	rs1670533	1.000	rs10007978	chr4:1060984	A/T	cg27284194	chr4:1044797	NA	0.47	6.07	0.35	4.4e-9	Recombination rate (females);
CESC	cis	rs7845219	0.539	rs13271644	chr8:95853948	A/G	cg13393036	chr8:95962371	TP53INP1	-0.34	-6.43	-0.37	5.88e-10	Type 2 diabetes;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg09479758	chr16:11890209	NA	-0.5	-6.18	-0.35	2.41e-9	Ulcerative colitis;
CESC	cis	rs4835473	0.831	rs10428468	chr4:144895257	C/T	cg25736465	chr4:144833511	NA	0.39	5.97	0.34	7.43e-9	Immature fraction of reticulocytes;
CESC	cis	rs2816062	0.786	rs735946	chr1:18901323	T/C	cg18795169	chr1:18902165	NA	-0.93	-17.75	-0.74	5.32e-47	Urate levels in lean individuals;
CESC	trans	rs7893279	0.543	rs11597737	chr10:18959091	A/C	cg23539753	chr2:231280698	SP100	0.45	6.0	0.35	6.31e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs514406	0.798	rs4351588	chr1:53263826	A/T	cg24675658	chr1:53192096	ZYG11B	0.69	9.98	0.52	3.91e-20	Monocyte count;
CESC	trans	rs916888	0.610	rs199438	chr17:44791643	G/A	cg22968622	chr17:43663579	NA	0.79	10.59	0.55	4.29e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs2228479	0.850	rs62054599	chr16:89808850	C/G	cg14709524	chr16:89940631	TCF25	0.94	7.08	0.4	1.27e-11	Skin colour saturation;
CESC	trans	rs208520	0.874	rs208473	chr6:66917265	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.85	-10.02	-0.52	3.11e-20	Exhaled nitric oxide output;
CESC	cis	rs11785693	0.862	rs11774126	chr8:4979583	A/C	cg26367366	chr8:4980734	NA	0.9	8.27	0.45	6.5e-15	Neuroticism (multi-trait analysis);Neuroticism;
CESC	cis	rs7666738	0.822	rs28512427	chr4:98919029	G/A	cg03676636	chr4:99064102	C4orf37	0.34	5.05	0.3	8.1e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg07870213	chr5:140052090	DND1	0.65	6.78	0.38	7.75e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs12995491	0.731	rs17435433	chr2:88509616	A/G	cg07952391	chr2:88470173	THNSL2	-0.53	-7.79	-0.43	1.53e-13	Response to metformin (IC50);
CESC	cis	rs2262909	1.000	rs765527	chr19:22129555	A/G	cg11619707	chr19:22235551	ZNF257	0.33	5.48	0.32	9.82e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
CESC	cis	rs7666738	0.830	rs11947027	chr4:99005941	T/C	cg17366294	chr4:99064904	C4orf37	0.6	8.61	0.47	6.47e-16	Colonoscopy-negative controls vs population controls;
CESC	trans	rs3942852	0.774	rs1039481	chr11:48182237	G/A	cg03929089	chr4:120376271	NA	-0.66	-7.24	-0.41	4.83e-12	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs10256972	0.786	rs3735686	chr7:1062527	G/A	cg09177884	chr7:1199841	ZFAND2A	-0.49	-6.25	-0.36	1.67e-9	Longevity;Endometriosis;
CESC	cis	rs7223966	1.000	rs9903897	chr17:61716705	T/A	cg11494091	chr17:61959527	GH2	0.38	5.44	0.32	1.24e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs2075371	1.000	rs2544211	chr7:133973230	A/G	cg11752832	chr7:134001865	SLC35B4	0.53	6.78	0.38	7.76e-11	Mean platelet volume;
CESC	cis	rs7772486	0.875	rs854146	chr6:146341033	A/G	cg23711669	chr6:146136114	FBXO30	0.88	12.86	0.62	9.55e-30	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs67478160	0.643	rs2024667	chr14:104211529	T/G	cg01849466	chr14:104193079	ZFYVE21	-0.5	-7.06	-0.4	1.45e-11	Schizophrenia;
CESC	cis	rs8072100	0.764	rs2644349	chr17:45641743	G/A	cg08085267	chr17:45401833	C17orf57	0.41	5.3	0.31	2.46e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs4253772	0.550	rs6007819	chr22:46704916	C/G	cg09491104	chr22:46646882	C22orf40	-0.51	-6.16	-0.35	2.69e-9	LDL cholesterol;Cholesterol, total;
CESC	cis	rs1005277	0.505	rs200936	chr10:38134935	T/C	cg25427524	chr10:38739819	LOC399744	-0.68	-10.02	-0.52	3.01e-20	Extrinsic epigenetic age acceleration;
CESC	cis	rs116095464	1.000	rs56095714	chr5:311256	C/T	cg22857025	chr5:266934	NA	-1.25	-7.68	-0.43	3e-13	Breast cancer;
CESC	cis	rs9916302	0.904	rs8070695	chr17:37478062	C/T	cg00129232	chr17:37814104	STARD3	0.59	7.59	0.42	5.46e-13	Glomerular filtration rate (creatinine);
CESC	cis	rs2243480	0.908	rs4718273	chr7:65216099	G/A	cg25894440	chr7:65020034	NA	0.63	5.26	0.31	2.92e-7	Diabetic kidney disease;
CESC	cis	rs7618915	0.547	rs11714419	chr3:52628816	A/G	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.35	6.22	0.36	1.88e-9	Bipolar disorder;
CESC	cis	rs1552244	1.000	rs6786638	chr3:10118075	G/C	cg08888203	chr3:10149979	C3orf24	0.52	6.65	0.38	1.63e-10	Alzheimer's disease;
CESC	cis	rs8016982	0.633	rs7141288	chr14:81710232	C/A	cg01989461	chr14:81687754	GTF2A1	0.72	11.21	0.57	3.87e-24	Schizophrenia;
CESC	cis	rs7618915	0.547	rs13069481	chr3:52666866	C/T	cg05564831	chr3:52568323	NT5DC2	0.45	6.89	0.39	4.03e-11	Bipolar disorder;
CESC	trans	rs4308128	0.657	rs272051	chr2:116619655	A/G	cg17910586	chr3:52479098	SEMA3G	-0.43	-6.12	-0.35	3.43e-9	Suicide attempts in major depressive disorder;
CESC	cis	rs7772486	0.641	rs9390370	chr6:146357569	C/T	cg23711669	chr6:146136114	FBXO30	0.84	11.04	0.56	1.43e-23	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs10751667	0.666	rs7395267	chr11:962326	C/A	cg01483505	chr11:975446	AP2A2	0.36	5.05	0.3	8.13e-7	Alzheimer's disease (late onset);
CESC	trans	rs208520	0.690	rs864314	chr6:66814830	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.11	-25.02	-0.84	9.4e-72	Exhaled nitric oxide output;
CESC	trans	rs35110281	0.782	rs7282933	chr21:45046988	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.54	7.02	0.4	1.88e-11	Mean corpuscular volume;
CESC	trans	rs11098499	0.722	rs17595727	chr4:120262074	C/T	cg25214090	chr10:38739885	LOC399744	-0.62	-8.63	-0.47	5.96e-16	Corneal astigmatism;
CESC	cis	rs71636778	0.543	rs36109400	chr1:27247822	G/A	cg12203394	chr1:27248618	NUDC	0.66	5.55	0.32	6.85e-8	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
CESC	cis	rs9948	0.786	rs56797569	chr2:97413555	G/T	cg01990225	chr2:97406019	LMAN2L	-0.96	-7.6	-0.42	5.16e-13	Erectile dysfunction and prostate cancer treatment;
CESC	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.58	7.48	0.42	1.1e-12	Prudent dietary pattern;
CESC	cis	rs9457247	1.000	rs2149090	chr6:167372764	T/C	cg07741184	chr6:167504864	NA	-0.3	-5.39	-0.31	1.6e-7	Crohn's disease;
CESC	cis	rs7223966	1.000	rs7209435	chr17:61712964	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	7.44	0.42	1.37e-12	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg03188948	chr7:1209495	NA	0.73	7.02	0.4	1.85e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs1005277	0.579	rs2749616	chr10:38510993	A/T	cg25427524	chr10:38739819	LOC399744	-0.71	-10.4	-0.54	1.84e-21	Extrinsic epigenetic age acceleration;
CESC	cis	rs2282802	0.677	rs9686454	chr5:139627813	T/C	cg26211634	chr5:139558579	C5orf32	0.51	7.39	0.41	1.93e-12	Intelligence (multi-trait analysis);
CESC	trans	rs4950322	0.563	rs6686480	chr1:146583568	G/A	cg04954894	chr8:38089920	DDHD2	-0.58	-6.36	-0.36	8.8e-10	Protein quantitative trait loci;
CESC	cis	rs7089973	0.872	rs7074729	chr10:116632257	C/G	cg25233709	chr10:116636983	FAM160B1	0.34	5.03	0.3	9.07e-7	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs12464483	0.591	rs72800120	chr2:30897122	G/A	cg17749961	chr2:30669863	LCLAT1	0.66	6.84	0.39	5.49e-11	Pre-treatment pain in head and neck squamous cell carcinoma;
CESC	cis	rs2425143	1.000	rs13038622	chr20:34319343	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.8	-7.49	-0.42	1.03e-12	Blood protein levels;
CESC	cis	rs6831352	0.734	rs2602857	chr4:100030318	G/A	cg13256891	chr4:100009986	ADH5	0.68	7.84	0.43	1.07e-13	Alcohol dependence;
CESC	cis	rs3820928	0.933	rs1429267	chr2:227767593	G/C	cg05526886	chr2:227700861	RHBDD1	-0.43	-5.63	-0.33	4.53e-8	Pulmonary function;
CESC	cis	rs12682352	0.579	rs7006589	chr8:8668486	A/G	cg06636001	chr8:8085503	FLJ10661	0.41	5.03	0.3	9.1e-7	Neuroticism;
CESC	cis	rs7580658	0.926	rs79789049	chr2:128145472	G/A	cg10021288	chr2:128175891	PROC	-0.42	-6.47	-0.37	4.69e-10	Protein C levels;
CESC	cis	rs7666738	0.830	rs28451101	chr4:99001190	T/C	cg03467027	chr4:99064603	C4orf37	0.44	5.51	0.32	8.65e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2573652	0.928	rs2581348	chr15:100514063	C/T	cg09918751	chr15:100517450	ADAMTS17	-0.37	-7.21	-0.41	5.75e-12	Height;
CESC	cis	rs1218582	0.774	rs1007170	chr1:154881461	G/A	cg24250549	chr1:154909240	PMVK	0.61	8.44	0.46	2.07e-15	Prostate cancer;
CESC	cis	rs1048238	0.506	rs56352596	chr1:16297592	G/A	cg21385522	chr1:16154831	NA	0.47	6.03	0.35	5.38e-9	Systolic blood pressure;
CESC	cis	rs875971	0.502	rs2465121	chr7:65621004	A/G	cg18876405	chr7:65276391	NA	-0.49	-5.33	-0.31	2.12e-7	Aortic root size;
CESC	cis	rs7130144	0.541	rs7941653	chr11:130460365	C/A	cg26307797	chr11:130446613	NA	-0.8	-6.53	-0.37	3.43e-10	Urate levels in lean individuals;
CESC	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.43	-5.8	-0.34	1.93e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs4604732	0.631	rs75320597	chr1:247626751	T/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.57	7.17	0.4	7.39e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs7116495	1.000	rs3018302	chr11:71790942	A/C	cg10381502	chr11:71823885	C11orf51	-0.66	-5.33	-0.31	2.12e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs4713118	0.597	rs172166	chr6:28020820	C/G	cg23281280	chr6:28129359	ZNF389	0.49	6.37	0.36	8.34e-10	Parkinson's disease;
CESC	cis	rs4595586	1.000	rs4384412	chr12:39218113	T/C	cg26384229	chr12:38710491	ALG10B	-0.37	-5.21	-0.3	3.81e-7	Morning vs. evening chronotype;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg06074314	chr2:70475575	TIA1	-0.45	-6.45	-0.37	5.38e-10	Gambling;
CESC	cis	rs7089973	0.872	rs35628210	chr10:116630031	G/A	cg23260525	chr10:116636907	FAM160B1	0.37	6.24	0.36	1.68e-9	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs3733585	0.664	rs17245436	chr4:9958169	A/G	cg02734326	chr4:10020555	SLC2A9	-0.43	-5.93	-0.34	9.22e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs9733	0.519	rs2184833	chr1:150675483	C/T	cg17724175	chr1:150552817	MCL1	0.45	7.31	0.41	3.13e-12	Tonsillectomy;
CESC	cis	rs7091068	0.566	rs7098349	chr10:95514907	A/C	cg20715218	chr10:95462985	C10orf4	0.56	5.37	0.31	1.74e-7	Urinary tract infection frequency;
CESC	cis	rs62064224	0.720	rs8078837	chr17:30763537	A/G	cg24550644	chr17:30846204	MYO1D	-0.35	-5.14	-0.3	5.24e-7	Schizophrenia;
CESC	cis	rs7584330	0.554	rs13390883	chr2:238432619	A/T	cg14458575	chr2:238380390	NA	0.48	5.34	0.31	2.03e-7	Prostate cancer;
CESC	cis	rs4665809	0.590	rs11552518	chr2:26455127	G/A	cg26314531	chr2:26401878	FAM59B	0.85	9.04	0.49	3.46e-17	Gut microbiome composition (summer);
CESC	cis	rs27434	0.607	rs695965	chr5:96148366	C/T	cg16492584	chr5:96139282	ERAP1	-0.41	-5.97	-0.34	7.62e-9	Ankylosing spondylitis;
CESC	cis	rs3859192	0.599	rs34933056	chr17:38162983	G/A	cg17467752	chr17:38218738	THRA	-0.44	-5.86	-0.34	1.37e-8	White blood cell count;
CESC	cis	rs8002861	0.967	rs7994883	chr13:44478805	A/G	cg14210620	chr13:44453864	C13orf31;CCDC122	-0.4	-5.17	-0.3	4.68e-7	Leprosy;
CESC	cis	rs2708240	0.577	rs851715	chr7:147526906	C/T	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.38	-5.88	-0.34	1.22e-8	QT interval (drug interaction);
CESC	cis	rs9649213	0.593	rs1859482	chr7:97983774	C/T	cg08684580	chr7:98029266	BAIAP2L1	-0.35	-5.8	-0.34	1.85e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs734999	0.588	rs6701238	chr1:2520500	G/A	cg20673091	chr1:2541236	MMEL1	0.43	7.14	0.4	9.15e-12	Ulcerative colitis;
CESC	cis	rs875971	0.540	rs35510581	chr7:65578777	G/A	cg18876405	chr7:65276391	NA	-0.66	-9.04	-0.49	3.46e-17	Aortic root size;
CESC	cis	rs1799949	0.894	rs71367985	chr17:41374463	G/A	cg25072359	chr17:41440525	NA	0.51	7.49	0.42	1.05e-12	Menopause (age at onset);
CESC	cis	rs9527	1.000	rs12416687	chr10:104629011	T/C	cg04362960	chr10:104952993	NT5C2	0.5	5.42	0.32	1.32e-7	Arsenic metabolism;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg17130815	chr7:2558891	LFNG	-0.45	-6.6	-0.38	2.18e-10	Gambling;
CESC	trans	rs1814175	0.645	rs28447324	chr11:50046629	C/A	cg03929089	chr4:120376271	NA	-0.93	-15.32	-0.69	2.24e-38	Height;
CESC	cis	rs875971	0.522	rs1917563	chr7:65415647	C/T	cg11764359	chr7:65958608	NA	-0.64	-8.27	-0.45	6.39e-15	Aortic root size;
CESC	cis	rs17826219	0.636	rs7221463	chr17:29080551	A/C	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.91e-10	Body mass index;
CESC	cis	rs62344088	0.590	rs6889904	chr5:177264	A/C	cg02160872	chr5:212506	CCDC127	-0.67	-5.22	-0.31	3.61e-7	Asthma (childhood onset);
CESC	trans	rs11098499	0.789	rs10212719	chr4:120254437	T/C	cg25214090	chr10:38739885	LOC399744	0.64	8.96	0.48	5.98e-17	Corneal astigmatism;
CESC	cis	rs9815354	0.951	rs1716674	chr3:41902972	G/C	cg03022575	chr3:42003672	ULK4	0.45	5.23	0.31	3.46e-7	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs6460942	0.915	rs6966791	chr7:12439714	T/C	cg02935154	chr7:12443704	VWDE	-0.59	-6.31	-0.36	1.14e-9	Coronary artery disease;
CESC	trans	rs4650994	0.525	rs2761463	chr1:178557137	T/C	cg05059571	chr16:84539110	KIAA1609	0.39	6.02	0.35	5.7e-9	HDL cholesterol levels;HDL cholesterol;
CESC	cis	rs7959452	0.590	rs6581889	chr12:69757429	T/C	cg14784868	chr12:69753453	YEATS4	0.83	12.94	0.62	5.29e-30	Blood protein levels;
CESC	cis	rs677665	0.722	rs10746487	chr1:9338689	T/C	cg25755851	chr1:9335794	NA	-0.63	-7.52	-0.42	8.31e-13	Eosinophil percentage of white cells;
CESC	cis	rs72945132	0.882	rs10466703	chr11:70218548	C/T	cg00319359	chr11:70116639	PPFIA1	0.71	6.78	0.38	7.58e-11	Coronary artery disease;
CESC	cis	rs2439831	1.000	rs690002	chr15:43729349	C/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.82	11.89	0.59	2.04e-26	Lung cancer in ever smokers;
CESC	cis	rs9309473	1.000	rs11903916	chr2:73815328	G/A	cg20560298	chr2:73613845	ALMS1	-0.48	-6.49	-0.37	4.23e-10	Metabolite levels;
CESC	cis	rs9614461	0.609	rs9614653	chr22:45767391	A/G	cg23503501	chr22:45809793	SMC1B;RIBC2	-0.65	-6.74	-0.38	1.01e-10	Tonsillectomy;
CESC	cis	rs9768139	0.611	rs12698211	chr7:158119623	G/A	cg24154853	chr7:158122151	PTPRN2	0.43	6.78	0.38	7.65e-11	Calcium levels;
CESC	cis	rs6558174	0.965	rs6558172	chr8:22492052	C/T	cg03733263	chr8:22462867	KIAA1967	0.49	6.38	0.37	7.71e-10	Breast cancer;
CESC	cis	rs6879260	1.000	rs888922	chr5:179731635	C/G	cg23221052	chr5:179740743	GFPT2	-0.66	-8.72	-0.47	3.06e-16	Height;
CESC	cis	rs7659604	1.000	rs28618203	chr4:122663935	T/C	cg19671926	chr4:122722719	EXOSC9	-0.44	-5.23	-0.31	3.46e-7	Type 2 diabetes;
CESC	cis	rs727505	0.954	rs59673207	chr7:124596982	G/C	cg23710748	chr7:124431027	NA	-0.45	-7.08	-0.4	1.27e-11	Lewy body disease;
CESC	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.14	21.25	0.79	3.66e-59	Prudent dietary pattern;
CESC	cis	rs13118159	0.778	rs12640984	chr4:1338834	G/A	cg05025164	chr4:1340916	KIAA1530	0.42	5.65	0.33	4.21e-8	Longevity;
CESC	trans	rs10489896	0.541	rs16843133	chr1:234564255	A/G	cg23817893	chr11:86085932	CCDC81	0.43	6.04	0.35	5.15e-9	Cognitive test performance;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27182915	chr1:150241589	APH1A	0.62	6.68	0.38	1.42e-10	Gut microbiome composition (summer);
CESC	cis	rs116095464	0.558	rs12173244	chr5:269524	G/A	cg22857025	chr5:266934	NA	-1.3	-18.8	-0.76	1.12e-50	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02930615	chr19:18966003	UPF1	-0.59	-6.88	-0.39	4.32e-11	Gut microbiome composition (summer);
CESC	cis	rs6460942	0.555	rs7803268	chr7:12306793	G/A	cg20607287	chr7:12443886	VWDE	-0.76	-8.16	-0.45	1.34e-14	Coronary artery disease;
CESC	cis	rs1983891	0.874	rs3747744	chr6:41516351	A/G	cg20194872	chr6:41519635	FOXP4	0.57	8.19	0.45	1.1e-14	Prostate cancer;
CESC	cis	rs1957429	0.520	rs230715	chr14:65320549	G/C	cg23373153	chr14:65346875	NA	-0.74	-5.8	-0.34	1.86e-8	Pediatric areal bone mineral density (radius);
CESC	cis	rs79839061	0.610	rs1564282	chr4:852313	C/T	cg07828340	chr4:882639	GAK	0.98	7.46	0.42	1.27e-12	Intelligence (multi-trait analysis);
CESC	cis	rs8031584	0.678	rs4779497	chr15:31151365	T/A	cg14298792	chr15:30685198	CHRFAM7A	-0.46	-5.51	-0.32	8.35e-8	Huntington's disease progression;
CESC	cis	rs2637266	0.626	rs846616	chr10:78547311	A/G	cg18941641	chr10:78392320	NA	0.41	7.84	0.43	1.12e-13	Pulmonary function;
CESC	cis	rs11098499	0.954	rs28572238	chr4:120316686	T/G	cg09307838	chr4:120376055	NA	0.92	12.46	0.61	2.41e-28	Corneal astigmatism;
CESC	cis	rs1065656	0.571	rs12149777	chr16:1834724	A/G	cg19030554	chr16:1822289	NME3;MRPS34;EME2	-0.43	-6.12	-0.35	3.44e-9	Insulin-like growth factors;
CESC	cis	rs7937682	0.575	rs1346180	chr11:111715570	G/C	cg22437258	chr11:111473054	SIK2	-0.47	-5.35	-0.31	1.86e-7	Primary sclerosing cholangitis;
CESC	cis	rs2742417	0.624	rs2673029	chr3:45758867	A/G	cg04837898	chr3:45731254	SACM1L	-0.48	-6.55	-0.37	2.96e-10	Response to anti-depressant treatment in major depressive disorder;
CESC	cis	rs763121	0.853	rs5757193	chr22:39034867	A/G	cg06544989	chr22:39130855	UNC84B	-0.48	-7.79	-0.43	1.52e-13	Menopause (age at onset);
CESC	cis	rs62344088	0.590	rs62345236	chr5:283519	G/A	cg22857025	chr5:266934	NA	-1.22	-9.0	-0.48	4.49e-17	Asthma (childhood onset);
CESC	cis	rs7937682	1.000	rs11213973	chr11:111538903	A/T	cg09085632	chr11:111637200	PPP2R1B	-0.95	-15.2	-0.68	6.01e-38	Primary sclerosing cholangitis;
CESC	cis	rs5747327	0.874	rs2401164	chr22:18131226	C/T	cg19898043	chr22:18121309	BCL2L13	-0.41	-5.16	-0.3	4.8e-7	Myeloid white cell count;Granulocyte count;
CESC	cis	rs13191362	0.935	rs34009353	chr6:163007668	T/G	cg21926612	chr6:163149169	PACRG;PARK2	0.82	8.75	0.47	2.56e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs2573652	0.722	rs12914180	chr15:100544416	T/C	cg00587665	chr15:100533223	ADAMTS17	-0.39	-6.41	-0.37	6.47e-10	Height;
CESC	trans	rs2727020	0.576	rs61885308	chr11:49343363	G/A	cg15704280	chr7:45808275	SEPT13	-0.69	-9.12	-0.49	1.95e-17	Coronary artery disease;
CESC	trans	rs11098499	0.863	rs7678400	chr4:120461957	G/A	cg25214090	chr10:38739885	LOC399744	0.67	9.24	0.49	8.09e-18	Corneal astigmatism;
CESC	cis	rs6662572	0.737	rs4434876	chr1:46270129	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.45	-5.11	-0.3	6.16e-7	Blood protein levels;
CESC	cis	rs2303745	0.589	rs10401700	chr19:17397700	A/C	cg02221750	chr19:17393354	ANKLE1	-0.51	-6.23	-0.36	1.79e-9	Systemic lupus erythematosus;
CESC	cis	rs10540	1.000	rs10540	chr11:494662	G/A	cg03352830	chr11:487213	PTDSS2	0.74	7.24	0.41	4.78e-12	Body mass index;
CESC	cis	rs5753037	0.543	rs140122	chr22:30138908	C/G	cg01021169	chr22:30184971	ASCC2	-0.55	-7.87	-0.44	9.3e-14	Type 1 diabetes;
CESC	cis	rs1953600	0.818	rs2152546	chr10:81906384	G/T	cg00277334	chr10:82204260	NA	-0.48	-6.84	-0.39	5.43e-11	Sarcoidosis;
CESC	trans	rs8014252	0.667	rs10148586	chr14:70807623	G/A	cg03123320	chr1:229394665	NA	-0.49	-6.27	-0.36	1.45e-9	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
CESC	cis	rs2228479	0.850	rs11641147	chr16:89813589	C/T	cg19635926	chr16:89946313	TCF25	0.68	5.17	0.3	4.67e-7	Skin colour saturation;
CESC	cis	rs1707322	1.000	rs10890382	chr1:46469674	A/G	cg05343316	chr1:45956843	TESK2	0.49	5.83	0.34	1.61e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs10504229	0.953	rs75545548	chr8:58172816	T/C	cg14926445	chr8:58193284	C8orf71	-0.51	-5.47	-0.32	1.03e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs60871478	0.730	rs62432226	chr7:792973	T/C	cg13798912	chr7:905769	UNC84A	0.6	5.98	0.34	7.1e-9	Cerebrospinal P-tau181p levels;
CESC	cis	rs17253792	0.822	rs77544029	chr14:56087917	T/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.77	5.98	0.34	7.23e-9	Putamen volume;
CESC	cis	rs7072216	0.763	rs7910014	chr10:100172110	C/T	cg26618903	chr10:100175079	PYROXD2	-0.38	-5.86	-0.34	1.38e-8	Metabolite levels;
CESC	trans	rs9467711	0.790	rs66488313	chr6:26631568	G/T	cg06606381	chr12:133084897	FBRSL1	-1.07	-7.69	-0.43	2.98e-13	Autism spectrum disorder or schizophrenia;
CESC	cis	rs7647973	0.848	rs4292260	chr3:49148890	T/C	cg07636037	chr3:49044803	WDR6	0.9	12.49	0.61	1.87e-28	Menarche (age at onset);
CESC	cis	rs28489187	0.706	rs233057	chr1:85798855	T/C	cg16011679	chr1:85725395	C1orf52	0.48	5.68	0.33	3.58e-8	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	cis	rs7613875	0.641	rs6446194	chr3:50067298	T/A	cg24308560	chr3:49941425	MST1R	0.59	8.47	0.46	1.76e-15	Body mass index;
CESC	cis	rs8020095	0.571	rs10138850	chr14:67606768	A/G	cg19548862	chr14:67692701	FAM71D	0.47	5.6	0.33	5.47e-8	Depression (quantitative trait);
CESC	cis	rs4919694	1.000	rs17881215	chr10:104629236	G/C	cg04362960	chr10:104952993	NT5C2	0.69	6.56	0.37	2.84e-10	Arsenic metabolism;
CESC	cis	rs4919087	1.000	rs10786327	chr10:99071408	C/T	cg25902810	chr10:99078978	FRAT1	0.72	10.73	0.55	1.48e-22	Monocyte count;
CESC	trans	rs9467711	0.606	rs12174631	chr6:26373150	C/T	cg06606381	chr12:133084897	FBRSL1	-0.76	-7.04	-0.4	1.64e-11	Autism spectrum disorder or schizophrenia;
CESC	cis	rs7660520	0.524	rs4862101	chr4:183733177	T/C	cg12483801	chr4:183727862	NA	0.76	6.97	0.39	2.47e-11	Pediatric autoimmune diseases;
CESC	cis	rs6831352	0.879	rs67311928	chr4:100048999	A/G	cg13256891	chr4:100009986	ADH5	-0.77	-8.43	-0.46	2.27e-15	Alcohol dependence;
CESC	trans	rs2963826	0.589	rs298091	chr5:58996603	A/T	cg19828298	chr1:3713105	LRRC47	0.44	6.02	0.35	5.66e-9	Obesity-related traits;
CESC	cis	rs2997447	0.761	rs61776620	chr1:26457980	T/C	cg24596570	chr1:26146463	FAM54B;LOC646471	0.62	5.41	0.32	1.44e-7	QRS complex (12-leadsum);
CESC	cis	rs7520050	0.751	rs2991975	chr1:46024526	A/G	cg06784218	chr1:46089804	CCDC17	-0.33	-5.79	-0.33	2.01e-8	Red blood cell count;Reticulocyte count;
CESC	cis	rs7845219	0.544	rs7015841	chr8:95920193	A/C	cg16049864	chr8:95962084	TP53INP1	-0.5	-7.48	-0.42	1.06e-12	Type 2 diabetes;
CESC	cis	rs17253792	0.822	rs75897560	chr14:56090965	C/T	cg01858014	chr14:56050164	KTN1	-0.85	-6.99	-0.39	2.22e-11	Putamen volume;
CESC	cis	rs17253792	0.822	rs113649689	chr14:56088065	G/A	cg01858014	chr14:56050164	KTN1	-0.93	-7.33	-0.41	2.71e-12	Putamen volume;
CESC	cis	rs13256369	0.755	rs12550057	chr8:8562268	G/A	cg17143192	chr8:8559678	CLDN23	0.77	9.05	0.49	3.19e-17	Obesity-related traits;
CESC	cis	rs6912958	0.712	rs6454640	chr6:88370352	G/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.35	5.77	0.33	2.22e-8	Monocyte percentage of white cells;
CESC	cis	rs7666738	0.791	rs1405766	chr4:98965389	T/C	cg03467027	chr4:99064603	C4orf37	0.44	5.57	0.32	6.41e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9487051	0.698	rs13202939	chr6:109649655	A/G	cg01475377	chr6:109611718	NA	-0.4	-5.47	-0.32	1.03e-7	Reticulocyte fraction of red cells;
CESC	cis	rs72781680	0.898	rs12622290	chr2:23979894	C/G	cg08917208	chr2:24149416	ATAD2B	0.96	8.7	0.47	3.55e-16	Lymphocyte counts;
CESC	cis	rs597539	0.652	rs516425	chr11:68715675	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.79	10.06	0.53	2.23e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg23708337	chr7:1209742	NA	0.52	5.16	0.3	4.88e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs35306767	0.671	rs11253473	chr10:906826	A/G	cg10556349	chr10:835070	NA	0.58	5.48	0.32	9.7e-8	Eosinophil percentage of granulocytes;
CESC	cis	rs875971	0.862	rs57866200	chr7:65565392	A/G	cg11764359	chr7:65958608	NA	-0.78	-10.74	-0.55	1.44e-22	Aortic root size;
CESC	cis	rs9487051	0.676	rs13195816	chr6:109598624	T/C	cg21918786	chr6:109611834	NA	-0.38	-5.65	-0.33	4.23e-8	Reticulocyte fraction of red cells;
CESC	cis	rs4604732	0.536	rs61184655	chr1:247651342	T/C	cg12758973	chr1:247694275	LOC148824;OR2C3	0.44	5.64	0.33	4.36e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs4665809	1.000	rs1550382	chr2:26266877	T/G	cg22920501	chr2:26401640	FAM59B	-0.69	-8.19	-0.45	1.1e-14	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27445169	chr11:65769623	BANF1;EIF1AD	0.58	6.24	0.36	1.74e-9	Gut microbiome composition (summer);
CESC	trans	rs916888	0.531	rs183211	chr17:44788310	G/A	cg10053473	chr17:62856997	LRRC37A3	-0.66	-8.86	-0.48	1.17e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs644799	0.710	rs10831427	chr11:95508383	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.78	11.68	0.58	1.03e-25	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs9311474	0.508	rs11714565	chr3:52606292	C/T	cg18337363	chr3:52569053	NT5DC2	0.29	5.26	0.31	3.02e-7	Electroencephalogram traits;
CESC	cis	rs853679	0.517	rs9368558	chr6:28133306	A/G	cg23281280	chr6:28129359	ZNF389	0.59	7.9	0.44	7.47e-14	Depression;
CESC	cis	rs6694270	0.529	rs35417699	chr1:19105105	C/T	cg19637330	chr1:19110922	NA	-0.48	-5.93	-0.34	9.65e-9	Drug-induced liver injury (nitrofurantoin);
CESC	cis	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg24642844	chr7:1081250	C7orf50	-0.65	-8.26	-0.45	7.08e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2404602	0.716	rs7164060	chr15:76707694	T/C	cg26408565	chr15:76604113	ETFA	-0.42	-6.08	-0.35	4.19e-9	Blood metabolite levels;
CESC	cis	rs4727027	0.704	rs2888600	chr7:148908562	C/T	cg23583168	chr7:148888333	NA	-0.92	-16.22	-0.71	1.45e-41	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs2637266	1.000	rs7082587	chr10:78386328	C/T	cg18941641	chr10:78392320	NA	0.43	8.35	0.46	3.96e-15	Pulmonary function;
CESC	cis	rs250677	0.522	rs1432798	chr5:148383345	C/G	cg18129178	chr5:148520854	ABLIM3	-0.43	-5.49	-0.32	9.64e-8	Breast cancer;
CESC	cis	rs13191362	1.000	rs34653853	chr6:163114362	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.07	11.07	0.56	1.14e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs6952808	0.792	rs12536261	chr7:1953571	G/A	cg05863683	chr7:1912471	MAD1L1	0.44	6.8	0.39	6.93e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs3749237	0.595	rs885592	chr3:49497883	T/G	cg06212747	chr3:49208901	KLHDC8B	0.49	6.65	0.38	1.64e-10	Resting heart rate;
CESC	cis	rs873946	0.586	rs3793682	chr10:134564563	C/T	cg27297192	chr10:134578999	INPP5A	0.4	5.13	0.3	5.54e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs55879323	1	rs55879323	chr1:152168740	C/T	cg17718321	chr1:152188247	HRNR	-0.54	-8.85	-0.48	1.26e-16	Inflammatory skin disease;
CESC	cis	rs875971	0.522	rs56028712	chr7:65466565	C/T	cg26939375	chr7:64535504	NA	0.75	10.64	0.55	3.11e-22	Aortic root size;
CESC	cis	rs11650494	0.901	rs74659133	chr17:47336931	C/T	cg08112188	chr17:47440006	ZNF652	0.99	6.28	0.36	1.36e-9	Prostate cancer;
CESC	cis	rs6575793	0.553	rs61993004	chr14:101030579	G/A	cg18516195	chr14:101012996	BEGAIN	0.43	5.22	0.31	3.56e-7	Menarche (age at onset);
CESC	cis	rs7945705	0.902	rs7930026	chr11:9013639	T/C	cg12365402	chr11:9010492	NRIP3	0.43	7.0	0.39	2.14e-11	Hemoglobin concentration;
CESC	cis	rs8077889	0.956	rs6503476	chr17:41850163	C/T	cg26893861	chr17:41843967	DUSP3	0.86	10.56	0.54	5.49e-22	Triglycerides;
CESC	cis	rs6964587	1.000	rs13224513	chr7:91601465	G/A	cg17063962	chr7:91808500	NA	0.57	7.84	0.43	1.14e-13	Breast cancer;
CESC	trans	rs11098499	0.955	rs11944880	chr4:120159334	A/G	cg25214090	chr10:38739885	LOC399744	-0.63	-8.44	-0.46	2.05e-15	Corneal astigmatism;
CESC	cis	rs11250098	0.574	rs4240672	chr8:10767917	G/A	cg27411982	chr8:10470053	RP1L1	-0.41	-5.1	-0.3	6.47e-7	Morning vs. evening chronotype;
CESC	cis	rs3091242	0.933	rs61775174	chr1:25787313	G/A	cg03538708	chr1:25844672	NA	0.39	5.86	0.34	1.38e-8	Erythrocyte sedimentation rate;
CESC	cis	rs2576037	0.526	rs2571024	chr18:44557877	G/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.42	-6.95	-0.39	2.78e-11	Personality dimensions;
CESC	cis	rs7917772	0.536	rs12357172	chr10:104388549	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.59	7.14	0.4	9.11e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25560965	chr12:12510064	LOH12CR1;LOH12CR2	0.56	6.68	0.38	1.38e-10	Gut microbiome composition (summer);
CESC	cis	rs9287719	0.870	rs10167676	chr2:10753140	G/A	cg02196655	chr2:10830764	NOL10	-0.37	-5.69	-0.33	3.39e-8	Prostate cancer;
CESC	cis	rs738322	0.753	rs5756968	chr22:38595240	C/T	cg25457927	chr22:38595422	NA	0.38	7.2	0.4	6.37e-12	Cutaneous nevi;
CESC	cis	rs13191362	0.935	rs73023493	chr6:162952769	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.79	7.44	0.42	1.36e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs35520189	0.806	rs11123151	chr2:113668005	T/G	cg06156847	chr2:113672199	IL1F7	0.38	5.66	0.33	3.86e-8	Obstructive sleep apnea trait (apnea hypopnea index);
CESC	cis	rs28595532	0.748	rs72670249	chr4:119336823	G/T	cg21605333	chr4:119757512	SEC24D	1.01	5.58	0.32	5.98e-8	Cannabis dependence symptom count;
CESC	cis	rs17125944	0.505	rs74642116	chr14:53213507	A/G	cg00686598	chr14:53173677	PSMC6	1.36	11.65	0.58	1.34e-25	Alzheimer's disease (late onset);
CESC	cis	rs853679	0.517	rs9393898	chr6:28130376	G/T	cg12963246	chr6:28129442	ZNF389	0.58	7.72	0.43	2.41e-13	Depression;
CESC	cis	rs854765	0.647	rs9303144	chr17:17977355	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.62	8.74	0.47	2.8e-16	Total body bone mineral density;
CESC	cis	rs10256972	0.521	rs871019	chr7:1105230	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.49	-7.11	-0.4	1.11e-11	Longevity;Endometriosis;
CESC	cis	rs4819052	0.851	rs13047598	chr21:46660777	G/T	cg11663144	chr21:46675770	NA	-0.63	-10.02	-0.52	3.12e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs7412746	0.658	rs6656535	chr1:150940357	G/T	cg04414720	chr1:150670196	GOLPH3L	0.5	6.49	0.37	4.21e-10	Melanoma;
CESC	cis	rs477692	0.612	rs58103386	chr10:131319958	C/A	cg24747557	chr10:131355152	MGMT	-0.37	-5.09	-0.3	6.87e-7	Response to temozolomide;
CESC	cis	rs35110281	0.774	rs1003280	chr21:44997322	A/G	cg04455712	chr21:45112962	RRP1B	0.39	5.81	0.34	1.81e-8	Mean corpuscular volume;
CESC	cis	rs9303280	0.806	rs12936409	chr17:38043649	C/T	cg20243544	chr17:37824526	PNMT	0.53	6.97	0.39	2.49e-11	Self-reported allergy;
CESC	cis	rs7845219	0.597	rs7002058	chr8:95873993	G/C	cg16049864	chr8:95962084	TP53INP1	-0.51	-7.82	-0.43	1.22e-13	Type 2 diabetes;
CESC	cis	rs710216	0.536	rs710222	chr1:43413653	A/G	cg03128534	chr1:43423976	SLC2A1	0.69	10.39	0.54	1.92e-21	Red cell distribution width;
CESC	cis	rs6831352	0.959	rs6532796	chr4:100042242	C/T	cg13256891	chr4:100009986	ADH5	-0.73	-8.42	-0.46	2.39e-15	Alcohol dependence;
CESC	cis	rs17039065	0.920	rs7688259	chr4:109435575	A/G	cg16022748	chr4:109541635	LOC285456;RPL34	0.68	6.32	0.36	1.11e-9	Gut microbiome composition (summer);
CESC	cis	rs644799	0.965	rs11021313	chr11:95506907	G/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	14.66	0.67	4.91e-36	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs7267979	1.000	rs4815421	chr20:25386509	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.88	-18.14	-0.74	2.39e-48	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs6662572	0.737	rs9429179	chr1:46514198	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.46	5.2	0.3	4.03e-7	Blood protein levels;
CESC	cis	rs2991971	0.967	rs60608374	chr1:46008913	G/A	cg15605315	chr1:45957053	TESK2	0.48	6.24	0.36	1.75e-9	High light scatter reticulocyte count;
CESC	cis	rs4073582	0.595	rs2508657	chr11:66043898	G/A	cg14036092	chr11:66035641	RAB1B	0.56	7.87	0.44	9.14e-14	Gout;
CESC	cis	rs514406	0.893	rs1242326	chr1:53399104	C/A	cg06600287	chr1:53387719	ECHDC2	-0.29	-5.04	-0.3	8.48e-7	Monocyte count;
CESC	cis	rs6121246	0.529	rs6058152	chr20:30178107	G/A	cg13852791	chr20:30311386	BCL2L1	0.57	5.5	0.32	9.14e-8	Mean corpuscular hemoglobin;
CESC	cis	rs7223966	0.921	rs2854207	chr17:61947107	C/G	cg11494091	chr17:61959527	GH2	0.41	5.62	0.33	4.78e-8	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs34172651	0.517	rs11862923	chr16:24767303	G/T	cg06028605	chr16:24865363	SLC5A11	0.54	8.07	0.44	2.39e-14	Intelligence (multi-trait analysis);
CESC	cis	rs36051895	0.632	rs62543560	chr9:5175938	C/T	cg02405213	chr9:5042618	JAK2	-0.47	-5.36	-0.31	1.79e-7	Pediatric autoimmune diseases;
CESC	cis	rs10465746	0.775	rs4907186	chr1:84340753	G/T	cg10977910	chr1:84465055	TTLL7	0.56	7.74	0.43	2.09e-13	Obesity-related traits;
CESC	cis	rs763121	0.853	rs7289577	chr22:39042214	C/G	cg06544989	chr22:39130855	UNC84B	0.5	8.66	0.47	4.63e-16	Menopause (age at onset);
CESC	cis	rs853679	0.517	rs9393884	chr6:28046789	A/G	cg20151795	chr6:28129481	ZNF389	0.48	6.27	0.36	1.47e-9	Depression;
CESC	trans	rs916888	0.773	rs199445	chr17:44817408	C/T	cg07870213	chr5:140052090	DND1	0.62	6.7	0.38	1.21e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs734999	0.588	rs10910098	chr1:2533250	C/A	cg20673091	chr1:2541236	MMEL1	0.44	7.36	0.41	2.28e-12	Ulcerative colitis;
CESC	cis	rs7618915	0.547	rs11130323	chr3:52770277	T/C	cg05564831	chr3:52568323	NT5DC2	0.44	6.58	0.37	2.57e-10	Bipolar disorder;
CESC	cis	rs7666738	0.830	rs6827516	chr4:98971740	T/C	cg03676636	chr4:99064102	C4orf37	0.34	5.2	0.3	3.93e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2415984	0.579	rs61993337	chr14:46965297	C/T	cg14871534	chr14:47121158	RPL10L	-0.35	-5.22	-0.31	3.7e-7	Number of children ever born;
CESC	cis	rs9311474	0.508	rs3796353	chr3:52593230	C/T	cg17372223	chr3:52568218	NT5DC2	0.39	5.84	0.34	1.53e-8	Electroencephalogram traits;
CESC	trans	rs921968	0.541	rs561570	chr2:219379348	T/A	cg15547669	chr20:2781122	CPXM1	0.36	6.03	0.35	5.54e-9	Mean corpuscular hemoglobin concentration;
CESC	cis	rs9583531	0.689	rs4773244	chr13:111383937	A/T	cg24331049	chr13:111365604	ING1	-0.8	-11.65	-0.58	1.37e-25	Coronary artery disease;
CESC	cis	rs2836974	0.897	rs2836925	chr21:40532353	T/C	cg11644478	chr21:40555479	PSMG1	1.02	16.76	0.72	1.74e-43	Cognitive function;
CESC	trans	rs1994135	0.586	rs7308214	chr12:33713834	T/A	cg26384229	chr12:38710491	ALG10B	0.54	7.54	0.42	7.26e-13	Resting heart rate;
CESC	cis	rs1552244	1.000	rs6764168	chr3:10123805	A/G	cg00149659	chr3:10157352	C3orf10	0.73	8.73	0.47	2.9e-16	Alzheimer's disease;
CESC	cis	rs2072499	0.778	rs41265025	chr1:156163906	C/T	cg24450063	chr1:156163899	SLC25A44	0.96	12.08	0.6	4.83e-27	Testicular germ cell tumor;
CESC	cis	rs4604732	0.678	rs74154674	chr1:247625685	C/T	cg12758973	chr1:247694275	LOC148824;OR2C3	0.51	6.36	0.36	8.65e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs12477438	0.561	rs2084988	chr2:99655755	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.62	-8.67	-0.47	4.43e-16	Chronic sinus infection;
CESC	cis	rs6540559	0.673	rs41305104	chr1:209950848	G/A	cg25204440	chr1:209979598	IRF6	0.59	5.8	0.34	1.9e-8	Cleft lip with or without cleft palate;
CESC	cis	rs13031619	0.605	rs4849972	chr2:3698846	C/A	cg10645314	chr2:3704589	ALLC	0.53	5.18	0.3	4.46e-7	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CESC	cis	rs6582630	0.562	rs35080195	chr12:38310866	G/A	cg26384229	chr12:38710491	ALG10B	-0.45	-5.83	-0.34	1.64e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs9303401	0.614	rs28687626	chr17:57191904	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.99	11.34	0.57	1.49e-24	Cognitive test performance;
CESC	cis	rs1538970	0.961	rs4660854	chr1:45854087	A/T	cg06784218	chr1:46089804	CCDC17	0.31	5.33	0.31	2.13e-7	Platelet count;
CESC	cis	rs7224314	1.000	rs7224314	chr17:65386214	A/C	cg01507342	chr17:65387096	PITPNC1	-0.49	-5.91	-0.34	1.05e-8	Diisocyanate-induced asthma;
CESC	cis	rs5769765	0.671	rs138833	chr22:50178917	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.47	-5.26	-0.31	2.98e-7	Schizophrenia;
CESC	cis	rs344364	0.511	rs2982455	chr16:1950498	T/G	cg26617929	chr16:1858877	NA	-0.49	-5.15	-0.3	5.09e-7	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs9611565	0.649	rs5758466	chr22:42176059	G/A	cg03806693	chr22:41940476	POLR3H	0.79	9.47	0.5	1.59e-18	Vitiligo;
CESC	cis	rs2425143	0.915	rs6060597	chr20:34370100	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	0.8	7.75	0.43	1.96e-13	Blood protein levels;
CESC	cis	rs1448094	0.511	rs10506920	chr12:86165212	A/T	cg02569458	chr12:86230093	RASSF9	0.5	7.74	0.43	2.06e-13	Major depressive disorder;
CESC	cis	rs9733	0.818	rs10888388	chr1:150687296	C/T	cg04414720	chr1:150670196	GOLPH3L	-0.37	-5.26	-0.31	3.03e-7	Tonsillectomy;
CESC	cis	rs1348850	0.757	rs4893969	chr2:178478476	T/A	cg22681709	chr2:178499509	PDE11A	-0.42	-6.35	-0.36	9.34e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs798554	0.757	rs1182181	chr7:2873247	C/G	cg19717773	chr7:2847554	GNA12	-0.56	-8.27	-0.45	6.44e-15	Height;
CESC	cis	rs514406	0.584	rs7524702	chr1:53197830	G/A	cg08736216	chr1:53307985	ZYG11A	0.4	6.48	0.37	4.57e-10	Monocyte count;
CESC	cis	rs1559088	0.947	rs7256182	chr19:33558591	G/A	cg17764715	chr19:33622953	WDR88	0.46	5.66	0.33	3.86e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs8012	0.537	rs741702	chr19:13024250	A/C	cg23899408	chr19:12877188	HOOK2	0.43	5.17	0.3	4.71e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;Blood metabolite levels;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg19374457	chr1:44412380	IPO13	-0.4	-6.21	-0.36	2.02e-9	Gambling;
CESC	cis	rs9322193	0.923	rs9505826	chr6:149955048	A/G	cg13206674	chr6:150067644	NUP43	0.43	6.18	0.35	2.39e-9	Lung cancer;
CESC	cis	rs6502050	0.769	rs9898292	chr17:80100345	A/T	cg23985595	chr17:80112537	CCDC57	-0.42	-6.57	-0.37	2.72e-10	Life satisfaction;
CESC	cis	rs28386778	0.863	rs3760252	chr17:61852186	G/C	cg11494091	chr17:61959527	GH2	0.71	11.9	0.59	1.84e-26	Prudent dietary pattern;
CESC	cis	rs796364	0.951	rs11680258	chr2:200996976	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.63	-6.26	-0.36	1.57e-9	Schizophrenia;
CESC	cis	rs1801251	1.000	rs10933412	chr2:233707226	G/C	cg08000102	chr2:233561755	GIGYF2	-0.69	-9.93	-0.52	5.71e-20	Coronary artery disease;
CESC	cis	rs2011503	1.000	rs8110171	chr19:19560063	C/T	cg11584989	chr19:19387371	SF4	0.62	7.22	0.41	5.51e-12	Bipolar disorder;
CESC	cis	rs17490626	0.568	rs12413523	chr10:71211664	C/G	cg12610070	chr10:71211762	TSPAN15	-0.32	-6.91	-0.39	3.55e-11	Thrombosis;
CESC	cis	rs6732160	0.613	rs62151837	chr2:73390396	G/T	cg01422370	chr2:73384389	NA	0.56	9.02	0.48	3.8e-17	Intelligence (multi-trait analysis);
CESC	trans	rs1218282	0.655	rs17771893	chr13:79466495	C/T	cg07274194	chr6:43423442	DLK2	0.74	6.24	0.36	1.69e-9	Response to statin therapy;
CESC	trans	rs11098499	0.954	rs878373	chr4:120237484	A/T	cg25214090	chr10:38739885	LOC399744	0.69	9.59	0.51	6.82e-19	Corneal astigmatism;
CESC	cis	rs2014572	0.967	rs7259978	chr19:57756129	C/T	cg12963866	chr19:57752005	ZNF805	-0.49	-6.53	-0.37	3.32e-10	Hyperactive-impulsive symptoms;
CESC	trans	rs208520	0.690	rs10455194	chr6:66743356	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.96	12.2	0.6	1.84e-27	Exhaled nitric oxide output;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13648682	chr9:136933664	BRD3	0.51	6.17	0.35	2.57e-9	Gut microbiome composition (summer);
CESC	cis	rs561341	1.000	rs72825740	chr17:30338356	A/G	cg19193384	chr17:30244184	NA	-0.68	-6.12	-0.35	3.42e-9	Hip circumference adjusted for BMI;
CESC	cis	rs72781680	0.898	rs72790310	chr2:24116716	C/T	cg08917208	chr2:24149416	ATAD2B	0.93	8.42	0.46	2.35e-15	Lymphocyte counts;
CESC	cis	rs1801251	1.000	rs4973053	chr2:233670099	G/A	cg25237894	chr2:233734115	C2orf82	-0.46	-8.17	-0.45	1.27e-14	Coronary artery disease;
CESC	cis	rs514406	0.825	rs1242328	chr1:53396869	A/G	cg16325326	chr1:53192061	ZYG11B	0.9	14.85	0.67	1.06e-36	Monocyte count;
CESC	cis	rs6500395	1.000	rs4785535	chr16:48707659	A/G	cg04672837	chr16:48644449	N4BP1	-0.51	-6.53	-0.37	3.33e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs739401	0.967	rs451041	chr11:3060725	C/T	cg25174290	chr11:3078921	CARS	0.48	6.75	0.38	9.5e-11	Longevity;
CESC	cis	rs17711722	0.701	rs781143	chr7:65439879	G/C	cg26939375	chr7:64535504	NA	0.76	10.8	0.55	8.95e-23	Calcium levels;
CESC	cis	rs2243480	1.000	rs2420171	chr7:65637760	T/C	cg18252515	chr7:66147081	NA	1.36	13.62	0.64	2.25e-32	Diabetic kidney disease;
CESC	cis	rs9487051	0.872	rs9487033	chr6:109605388	C/G	cg12927641	chr6:109611667	NA	0.44	6.87	0.39	4.65e-11	Reticulocyte fraction of red cells;
CESC	cis	rs7592578	0.679	rs59929070	chr2:191327852	A/G	cg10560079	chr2:191398806	TMEM194B	-0.6	-5.84	-0.34	1.56e-8	Diastolic blood pressure;
CESC	cis	rs875971	0.862	rs7809814	chr7:65615397	G/A	cg10691866	chr7:65817282	TPST1	0.31	5.18	0.3	4.5e-7	Aortic root size;
CESC	cis	rs2066819	1.000	rs78495928	chr12:56635080	G/C	cg26714650	chr12:56694279	CS	-1.42	-10.04	-0.53	2.52e-20	Psoriasis vulgaris;
CESC	cis	rs36051895	0.623	rs57707737	chr9:5062844	A/T	cg02405213	chr9:5042618	JAK2	-0.49	-5.94	-0.34	8.82e-9	Pediatric autoimmune diseases;
CESC	cis	rs62244186	0.545	rs725866	chr3:44765533	A/G	cg15225532	chr3:44803084	KIF15;KIAA1143	0.48	6.18	0.35	2.43e-9	Depressive symptoms;
CESC	cis	rs4727963	0.840	rs1464876	chr7:122729235	C/G	cg03640110	chr7:122635026	TAS2R16	-0.37	-5.6	-0.33	5.48e-8	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
CESC	cis	rs7824557	0.527	rs2736296	chr8:11234844	G/A	cg21775007	chr8:11205619	TDH	-0.54	-8.08	-0.44	2.33e-14	Retinal vascular caliber;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06077405	chr7:2313805	SNX8	-0.57	-6.54	-0.37	3.11e-10	Gut microbiome composition (summer);
CESC	cis	rs644799	0.509	rs580181	chr11:95643040	G/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.55	7.29	0.41	3.58e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs1707322	0.721	rs11211158	chr1:46132850	C/G	cg03146154	chr1:46216737	IPP	0.82	11.52	0.58	3.64e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs11031096	0.678	rs11031220	chr11:4197638	G/A	cg18678763	chr11:4115507	RRM1	-0.4	-5.18	-0.3	4.46e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	cis	rs2404602	0.622	rs11632670	chr15:76974055	A/G	cg23625390	chr15:77176239	SCAPER	-0.46	-6.32	-0.36	1.12e-9	Blood metabolite levels;
CESC	cis	rs4481887	1.000	rs4508046	chr1:248488988	T/C	cg00666640	chr1:248458726	OR2T12	0.41	6.74	0.38	9.64e-11	Common traits (Other);
CESC	cis	rs9916302	0.904	rs12452509	chr17:37574722	G/A	cg15445000	chr17:37608096	MED1	0.41	6.74	0.38	9.67e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs9394152	0.845	rs7747216	chr6:33476718	A/G	cg13560919	chr6:33536144	NA	-0.47	-7.27	-0.41	4.05e-12	Age at smoking initiation in chronic obstructive pulmonary disease;
CESC	cis	rs959260	1.000	rs2033609	chr17:73367021	C/T	cg12999837	chr17:73267436	MIF4GD	-0.47	-5.46	-0.32	1.1e-7	Systemic lupus erythematosus;
CESC	cis	rs11785400	1.000	rs4736365	chr8:143742197	A/G	cg10596483	chr8:143751796	JRK	0.43	5.63	0.33	4.56e-8	Schizophrenia;
CESC	cis	rs854765	0.547	rs4584886	chr17:17896205	C/T	cg04398451	chr17:18023971	MYO15A	-0.65	-9.27	-0.49	6.65e-18	Total body bone mineral density;
CESC	cis	rs992157	0.835	rs12987219	chr2:219144149	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.68	-8.81	-0.48	1.66e-16	Colorectal cancer;
CESC	cis	rs9894429	0.608	rs7406382	chr17:79597786	T/C	cg18240062	chr17:79603768	NPLOC4	0.54	7.12	0.4	1.04e-11	Eye color traits;
CESC	cis	rs1862618	0.802	rs4389648	chr5:56103602	A/G	cg12311346	chr5:56204834	C5orf35	-0.73	-8.78	-0.47	2.14e-16	Initial pursuit acceleration;
CESC	cis	rs12681288	0.550	rs4637864	chr8:959761	C/T	cg04851639	chr8:1020857	NA	-0.28	-5.59	-0.32	5.55e-8	Schizophrenia;
CESC	cis	rs6087990	0.735	rs2424907	chr20:31359819	C/T	cg13636640	chr20:31349939	DNMT3B	0.79	12.88	0.62	8.47e-30	Ulcerative colitis;
CESC	cis	rs7312933	0.558	rs1796382	chr12:42840955	C/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.5	-6.6	-0.38	2.29e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs10927875	0.688	rs2009371	chr1:16348083	A/T	cg22431228	chr1:16359049	CLCNKA	-0.51	-8.37	-0.46	3.39e-15	Dilated cardiomyopathy;
CESC	cis	rs79387448	0.638	rs6759588	chr2:103040159	A/G	cg09003973	chr2:102972529	NA	1.18	8.9	0.48	9.32e-17	Gut microbiota (bacterial taxa);
CESC	cis	rs6582630	0.555	rs34730221	chr12:38405140	C/T	cg26384229	chr12:38710491	ALG10B	-0.66	-9.89	-0.52	7.72e-20	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs1799949	0.602	rs4600503	chr17:41414324	C/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.41	5.64	0.33	4.45e-8	Menopause (age at onset);
CESC	cis	rs1707322	1.000	rs11211222	chr1:46367757	T/C	cg03146154	chr1:46216737	IPP	0.71	9.86	0.52	9.69e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2346177	0.554	rs34854267	chr2:46708542	T/C	cg02822958	chr2:46747628	ATP6V1E2	0.44	5.47	0.32	1.02e-7	HDL cholesterol;
CESC	cis	rs55728055	0.661	rs62237796	chr22:31976578	T/G	cg01338084	chr22:32026380	PISD	1.22	8.02	0.44	3.48e-14	Age-related hearing impairment;
CESC	cis	rs9487051	0.844	rs9386792	chr6:109609975	G/A	cg12927641	chr6:109611667	NA	-0.44	-6.78	-0.38	7.73e-11	Reticulocyte fraction of red cells;
CESC	trans	rs864643	0.773	rs11129837	chr3:39589963	A/G	cg05409276	chr17:73400549	GRB2	0.47	6.03	0.35	5.53e-9	Attention deficit hyperactivity disorder;
CESC	cis	rs2832077	0.943	rs2832084	chr21:30154798	A/G	cg03476357	chr21:30257390	N6AMT1	-0.49	-5.2	-0.3	3.91e-7	Cognitive test performance;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23115219	chr1:150459717	TARS2	0.6	6.76	0.38	8.76e-11	Gut microbiome composition (summer);
CESC	cis	rs1580019	0.563	rs10486509	chr7:32585443	C/G	cg06627557	chr7:32535165	LSM5;AVL9	-1.07	-18.17	-0.74	1.83e-48	Cognitive ability;
CESC	cis	rs5753618	0.583	rs5753615	chr22:31828027	T/C	cg00478049	chr22:31556069	RNF185	-0.43	-5.12	-0.3	5.75e-7	Colorectal cancer;
CESC	cis	rs72945132	0.607	rs67767222	chr11:70121610	T/A	cg00319359	chr11:70116639	PPFIA1	0.78	7.78	0.43	1.6e-13	Coronary artery disease;
CESC	cis	rs9581857	0.685	rs11839899	chr13:28041780	G/A	cg01674679	chr13:27998804	GTF3A	-0.69	-5.52	-0.32	8.1e-8	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
CESC	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg21548813	chr6:291882	DUSP22	-0.75	-10.21	-0.53	7.25e-21	Menopause (age at onset);
CESC	trans	rs12681287	0.547	rs4961197	chr8:87512436	T/C	cg27317242	chr8:23145699	R3HCC1	-0.53	-6.34	-0.36	9.67e-10	Caudate activity during reward;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03066081	chr17:77784036	NA	0.47	6.08	0.35	4.28e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs9457247	0.646	rs4710160	chr6:167409241	T/A	cg07741184	chr6:167504864	NA	0.3	5.52	0.32	8.06e-8	Crohn's disease;
CESC	cis	rs7666738	0.830	rs11727653	chr4:99001774	T/C	cg03467027	chr4:99064603	C4orf37	0.44	5.51	0.32	8.65e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9430161	0.579	rs6696575	chr1:11037136	G/A	cg02454025	chr1:11042201	C1orf127	0.93	14.49	0.66	1.93e-35	Ewing sarcoma;
CESC	cis	rs1862618	0.802	rs42769	chr5:56144152	G/A	cg24549020	chr5:56110836	MAP3K1	0.65	7.56	0.42	6.72e-13	Initial pursuit acceleration;
CESC	cis	rs7264396	0.676	rs6058383	chr20:34556005	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.77	-10.35	-0.54	2.7e-21	Total cholesterol levels;
CESC	cis	rs597539	0.652	rs10792001	chr11:68637737	G/C	cg21963583	chr11:68658836	MRPL21	0.4	5.52	0.32	8.06e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs909341	0.710	rs2297433	chr20:62293460	T/C	cg03999872	chr20:62272968	STMN3	0.56	5.43	0.32	1.27e-7	Atopic dermatitis;
CESC	cis	rs1448094	0.511	rs7968059	chr12:86163606	A/G	cg00310523	chr12:86230176	RASSF9	0.35	5.61	0.33	5.01e-8	Major depressive disorder;
CESC	trans	rs9987353	0.840	rs329994	chr8:9123233	A/G	cg15459695	chr2:236403016	AGAP1	-0.48	-6.62	-0.38	2.02e-10	Recombination measurement;
CESC	cis	rs9300255	0.510	rs1790133	chr12:123698518	T/G	cg00376283	chr12:123451042	ABCB9	0.71	8.97	0.48	5.68e-17	Neutrophil percentage of white cells;
CESC	cis	rs4891159	0.790	rs7241485	chr18:74122325	C/T	cg24786174	chr18:74118243	ZNF516	-0.72	-11.28	-0.57	2.31e-24	Longevity;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg22515636	chr2:109150313	NA	0.49	6.29	0.36	1.28e-9	Gut microbiota (bacterial taxa);
CESC	trans	rs35110281	0.592	rs6417729	chr21:44967202	A/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.58	7.91	0.44	6.95e-14	Mean corpuscular volume;
CESC	cis	rs6831352	1.000	rs6822348	chr4:100053894	A/T	cg21548116	chr4:100009993	ADH5	0.48	5.08	0.3	7.18e-7	Alcohol dependence;
CESC	cis	rs7474896	0.561	rs2474603	chr10:38445682	C/T	cg25427524	chr10:38739819	LOC399744	-0.52	-5.11	-0.3	6.12e-7	Obesity (extreme);
CESC	cis	rs752010	0.644	rs7541348	chr1:42113215	T/G	cg06885757	chr1:42089581	HIVEP3	0.5	8.0	0.44	3.85e-14	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs597539	0.652	rs627731	chr11:68698663	A/C	cg01988459	chr11:68622903	NA	-0.44	-5.96	-0.34	8.1e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs4665809	0.549	rs7577896	chr2:26524493	C/T	cg08470875	chr2:26401718	FAM59B	0.55	5.12	0.3	6.02e-7	Gut microbiome composition (summer);
CESC	trans	rs11098499	0.588	rs2389874	chr4:120554991	A/G	cg25214090	chr10:38739885	LOC399744	-0.54	-7.62	-0.42	4.53e-13	Corneal astigmatism;
CESC	cis	rs3096299	0.658	rs34590044	chr16:89543157	A/C	cg00750074	chr16:89608354	SPG7	-0.42	-6.26	-0.36	1.55e-9	Multiple myeloma (IgH translocation);
CESC	cis	rs734999	0.545	rs10797441	chr1:2551660	T/G	cg20673091	chr1:2541236	MMEL1	0.48	8.03	0.44	3.11e-14	Ulcerative colitis;
CESC	trans	rs916888	0.773	rs199533	chr17:44828931	G/A	cg22433210	chr17:43662623	NA	0.97	10.98	0.56	2.25e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs711245	0.670	rs7560321	chr2:36822318	C/G	cg01206211	chr2:36825736	FEZ2	-0.34	-5.88	-0.34	1.25e-8	Height;
CESC	cis	rs1949733	0.675	rs2688219	chr4:8444631	T/C	cg11789530	chr4:8429930	ACOX3	0.75	10.87	0.56	5.27e-23	Response to antineoplastic agents;
CESC	cis	rs4148883	0.504	rs2000864	chr4:100123776	A/C	cg13256891	chr4:100009986	ADH5	0.48	6.16	0.35	2.76e-9	Alcohol dependence;
CESC	cis	rs2075371	0.966	rs1619682	chr7:133996703	T/G	cg11752832	chr7:134001865	SLC35B4	0.54	7.01	0.4	1.96e-11	Mean platelet volume;
CESC	cis	rs780096	0.527	rs11127044	chr2:27740404	C/G	cg12648201	chr2:27665141	KRTCAP3	-0.31	-5.56	-0.32	6.74e-8	Total body bone mineral density;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26104816	chr1:42922390	ZMYND12;PPCS	0.58	6.49	0.37	4.17e-10	Gut microbiome composition (summer);
CESC	cis	rs2404602	0.669	rs12441484	chr15:77109875	G/A	cg22467129	chr15:76604101	ETFA	-0.34	-5.16	-0.3	4.84e-7	Blood metabolite levels;
CESC	cis	rs6582630	0.638	rs12831496	chr12:38552604	G/A	cg26384229	chr12:38710491	ALG10B	-0.42	-5.67	-0.33	3.67e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs7539624	0.588	rs2186006	chr1:223901545	T/C	cg10100437	chr1:223903862	CAPN2	0.43	5.54	0.32	7.26e-8	Schizophrenia;
CESC	cis	rs4979906	1.000	rs11002244	chr10:79446207	T/C	cg00983440	chr10:79422392	NA	-0.48	-5.12	-0.3	5.86e-7	Mortality in heart failure;
CESC	cis	rs9787249	1.000	rs9787249	chr1:40212878	G/A	cg02773041	chr1:40204384	PPIE	0.53	7.59	0.42	5.32e-13	Blood protein levels;
CESC	cis	rs7772486	0.875	rs2748485	chr6:146332421	T/C	cg05347473	chr6:146136440	FBXO30	0.51	6.72	0.38	1.12e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9814567	0.896	rs6794258	chr3:134344505	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.42	-5.67	-0.33	3.63e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs9910055	0.718	rs7212854	chr17:42254417	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.63	8.4	0.46	2.81e-15	Total body bone mineral density;
CESC	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg22907277	chr7:1156413	C7orf50	0.44	6.41	0.37	6.75e-10	Longevity;Endometriosis;
CESC	cis	rs12911832	1.000	rs12911961	chr15:58985867	C/T	cg05156742	chr15:59063176	FAM63B	0.58	7.41	0.41	1.69e-12	Schizophrenia;
CESC	cis	rs2274273	0.870	rs28716725	chr14:55816610	T/C	cg04306507	chr14:55594613	LGALS3	0.32	6.31	0.36	1.19e-9	Protein biomarker;
CESC	cis	rs3008870	0.755	rs2755251	chr1:67496425	G/T	cg08660285	chr1:67390436	MIER1;WDR78	0.58	7.57	0.42	6.16e-13	Lymphocyte percentage of white cells;
CESC	cis	rs5769765	0.955	rs5769767	chr22:50276909	G/A	cg02269571	chr22:50332266	NA	0.46	6.28	0.36	1.39e-9	Schizophrenia;
CESC	cis	rs11098499	0.909	rs9759478	chr4:120367998	G/A	cg24375607	chr4:120327624	NA	0.48	5.93	0.34	9.24e-9	Corneal astigmatism;
CESC	trans	rs9929218	1.000	rs4783570	chr16:68806539	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.61	-8.03	-0.44	3.1e-14	Colorectal cancer;
CESC	cis	rs2070488	0.689	rs6809352	chr3:38544349	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.78	-12.67	-0.61	4.27e-29	Electrocardiographic conduction measures;
CESC	cis	rs17023223	0.537	rs10923759	chr1:119692194	A/G	cg05756136	chr1:119680316	WARS2	0.49	5.91	0.34	1.06e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CESC	cis	rs2066819	1.000	rs1802236	chr12:56679751	A/G	cg26734620	chr12:56694298	CS	1.07	6.58	0.37	2.56e-10	Psoriasis vulgaris;
CESC	trans	rs650950	0.528	rs646660	chr11:35528452	C/T	cg02352107	chr15:76603736	ETFA	0.45	6.04	0.35	5.3e-9	Bronchopulmonary dysplasia;
CESC	cis	rs6952808	0.531	rs3778998	chr7:2180753	C/A	cg21782813	chr7:2030301	MAD1L1	0.45	6.45	0.37	5.4e-10	Bipolar disorder and schizophrenia;
CESC	trans	rs7178375	1.000	rs1474382	chr15:31214649	A/G	cg04373760	chr16:53404718	NA	0.53	6.88	0.39	4.35e-11	Hypertriglyceridemia;
CESC	cis	rs10504229	0.638	rs6981055	chr8:58113941	T/C	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs10242455	0.764	rs2037497	chr7:99315904	G/A	cg07715041	chr7:99302981	CYP3A7	-0.43	-5.42	-0.32	1.36e-7	Blood metabolite levels;
CESC	cis	rs10504229	0.861	rs116923397	chr8:58185162	T/G	cg14926445	chr8:58193284	C8orf71	-0.51	-5.52	-0.32	8.28e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs7811142	0.943	rs73403312	chr7:100024153	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.08	10.67	0.55	2.41e-22	Platelet count;
CESC	cis	rs7633857	0.532	rs9873705	chr3:160768818	A/T	cg03342759	chr3:160939853	NMD3	-0.44	-5.85	-0.34	1.45e-8	Educational attainment (years of education);
CESC	cis	rs9815354	0.812	rs10510729	chr3:41831998	G/A	cg03022575	chr3:42003672	ULK4	0.7	6.04	0.35	5.26e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs9467711	0.606	rs9393705	chr6:26361011	G/A	cg14345882	chr6:26364793	BTN3A2	0.59	6.06	0.35	4.66e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs7071206	0.947	rs4979905	chr10:79416367	C/T	cg23888215	chr10:79422304	NA	-0.52	-5.64	-0.33	4.3e-8	Bone mineral density;
CESC	cis	rs754466	0.580	rs11002289	chr10:79532580	G/A	cg17075019	chr10:79541650	NA	-0.89	-13.8	-0.65	5.03e-33	Liver enzyme levels (gamma-glutamyl transferase);
CESC	trans	rs11098499	0.863	rs3775845	chr4:120432447	T/C	cg25214090	chr10:38739885	LOC399744	0.71	9.72	0.51	2.71e-19	Corneal astigmatism;
CESC	cis	rs597539	0.652	rs514296	chr11:68654182	G/T	cg01988459	chr11:68622903	NA	-0.39	-5.5	-0.32	8.79e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs6977940	0.512	rs6461600	chr7:2816537	C/T	cg19731401	chr7:2775893	GNA12	0.59	5.69	0.33	3.34e-8	White matter integrity;
CESC	cis	rs6460942	0.524	rs6948366	chr7:12369905	A/G	cg06484146	chr7:12443880	VWDE	-0.55	-7.79	-0.43	1.56e-13	Coronary artery disease;
CESC	cis	rs10876993	0.928	rs2169988	chr12:58071165	G/A	cg18357645	chr12:58087776	OS9	0.63	10.45	0.54	1.28e-21	Celiac disease or Rheumatoid arthritis;
CESC	cis	rs35146811	0.806	rs1534310	chr7:99699169	A/T	cg22906224	chr7:99728672	NA	0.43	5.03	0.3	8.85e-7	Coronary artery disease;
CESC	cis	rs13118159	0.872	rs4974605	chr4:1346389	C/G	cg02018176	chr4:1364513	KIAA1530	0.46	6.47	0.37	4.84e-10	Longevity;
CESC	cis	rs7927592	0.956	rs948315	chr11:68309140	T/C	cg20283391	chr11:68216788	NA	-0.51	-6.11	-0.35	3.48e-9	Total body bone mineral density;
CESC	cis	rs7020830	0.867	rs1472169	chr9:37209396	C/T	cg14294708	chr9:37120828	ZCCHC7	1.24	23.66	0.82	2.8e-67	Schizophrenia;
CESC	cis	rs7635838	0.617	rs347590	chr3:11289561	G/A	cg00170343	chr3:11313890	ATG7	0.58	8.56	0.47	9.36e-16	HDL cholesterol;
CESC	trans	rs2727020	0.729	rs1917325	chr11:49370004	G/A	cg15704280	chr7:45808275	SEPT13	-0.87	-14.54	-0.67	1.28e-35	Coronary artery disease;
CESC	cis	rs9581857	0.685	rs78595793	chr13:28031881	C/T	cg01674679	chr13:27998804	GTF3A	-0.68	-5.42	-0.32	1.35e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
CESC	cis	rs4835473	0.897	rs4835333	chr4:144624327	A/C	cg25736465	chr4:144833511	NA	-0.36	-5.53	-0.32	7.69e-8	Immature fraction of reticulocytes;
CESC	trans	rs12479064	0.724	rs3087403	chr2:100058870	C/T	cg20598333	chr11:3663511	ART5	0.5	6.09	0.35	4.03e-9	Chronic sinus infection;
CESC	cis	rs977987	0.843	rs35737321	chr16:75439185	A/T	cg03315344	chr16:75512273	CHST6	0.4	5.77	0.33	2.24e-8	Dupuytren's disease;
CESC	cis	rs501120	1.000	rs573141	chr10:44758587	G/A	cg09554077	chr10:44749378	NA	0.52	6.91	0.39	3.59e-11	Coronary artery disease;Coronary heart disease;
CESC	cis	rs4253772	0.637	rs41279831	chr22:46651623	T/C	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.59	5.16	0.3	4.74e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs1062177	0.950	rs59580263	chr5:151269577	T/A	cg00977110	chr5:151150581	G3BP1	0.62	6.42	0.37	6.18e-10	Preschool internalizing problems;
CESC	cis	rs6546550	0.901	rs6750488	chr2:70146125	C/T	cg02498382	chr2:70120550	SNRNP27	-0.41	-7.36	-0.41	2.35e-12	Prevalent atrial fibrillation;
CESC	cis	rs2839186	0.771	rs13049175	chr21:47641326	G/A	cg13126279	chr21:47581558	C21orf56	0.48	6.53	0.37	3.3e-10	Testicular germ cell tumor;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg26313233	chr2:114415511	NA	-0.48	-6.04	-0.35	5.21e-9	Asthma;
CESC	cis	rs801193	1.000	rs2055682	chr7:66260289	A/G	cg18876405	chr7:65276391	NA	0.63	8.43	0.46	2.23e-15	Aortic root size;
CESC	cis	rs2832191	0.729	rs2832201	chr21:30499841	A/G	cg08807101	chr21:30365312	RNF160	-0.84	-11.67	-0.58	1.12e-25	Dental caries;
CESC	cis	rs34779708	0.966	rs4934536	chr10:35441169	A/G	cg03585969	chr10:35415529	CREM	0.76	10.0	0.52	3.56e-20	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs853679	0.760	rs9468317	chr6:28198456	A/G	cg26335602	chr6:28129616	ZNF389	0.41	5.45	0.32	1.18e-7	Depression;
CESC	cis	rs9399401	0.626	rs1928528	chr6:142779109	T/G	cg03128060	chr6:142623767	GPR126	0.3	5.03	0.3	8.92e-7	Chronic obstructive pulmonary disease;
CESC	cis	rs1865760	0.566	rs4529296	chr6:26083135	C/G	cg16482183	chr6:26056742	HIST1H1C	0.38	5.11	0.3	6.19e-7	Height;
CESC	cis	rs1559088	0.576	rs4805852	chr19:33609441	C/T	cg03563238	chr19:33554763	RHPN2	-0.29	-5.35	-0.31	1.94e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs10242455	0.702	rs116671616	chr7:98954558	C/T	cg25640893	chr7:99214727	ZNF498	0.85	5.73	0.33	2.69e-8	Blood metabolite levels;
CESC	cis	rs113835537	0.529	rs4930379	chr11:66255674	G/A	cg24851651	chr11:66362959	CCS	0.45	5.62	0.33	4.87e-8	Airway imaging phenotypes;
CESC	cis	rs523522	0.962	rs10849757	chr12:120964014	G/A	cg27279351	chr12:120934652	DYNLL1	0.69	9.11	0.49	2.02e-17	High light scatter reticulocyte count;
CESC	cis	rs4930103	1.000	rs4930103	chr11:2024544	G/A	cg23202291	chr11:1979235	NA	0.4	6.03	0.35	5.48e-9	DNA methylation (parent-of-origin);DNA methylation (variation);
CESC	cis	rs4319547	0.695	rs6489002	chr12:122929822	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.5	-5.78	-0.33	2.14e-8	Body mass index;
CESC	cis	rs17407555	0.821	rs4533775	chr4:10141404	G/C	cg11266682	chr4:10021025	SLC2A9	-0.49	-5.18	-0.3	4.33e-7	Schizophrenia (age at onset);
CESC	cis	rs7927771	0.524	rs7942074	chr11:47720509	T/C	cg18512352	chr11:47633146	NA	0.35	5.36	0.31	1.82e-7	Subjective well-being;
CESC	cis	rs1218582	0.772	rs4240874	chr1:154885779	C/T	cg24250549	chr1:154909240	PMVK	0.74	10.98	0.56	2.38e-23	Prostate cancer;
CESC	cis	rs11764590	0.724	rs1533829	chr7:2082841	A/G	cg21782813	chr7:2030301	MAD1L1	-0.41	-5.68	-0.33	3.57e-8	Neuroticism;
CESC	cis	rs1348850	0.668	rs6705405	chr2:178493713	A/G	cg23306229	chr2:178417860	TTC30B	0.56	6.75	0.38	9.5e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs35110281	0.782	rs4818856	chr21:45043495	A/G	cg21573476	chr21:45109991	RRP1B	-0.5	-6.86	-0.39	4.89e-11	Mean corpuscular volume;
CESC	cis	rs2440129	0.611	rs11571335	chr17:6904263	C/T	cg21237687	chr17:6899380	ALOX12	0.5	8.64	0.47	5.34e-16	Tonsillectomy;
CESC	cis	rs9300255	0.602	rs1727306	chr12:123665695	A/G	cg19016782	chr12:123741754	C12orf65	-0.45	-6.21	-0.36	2.01e-9	Neutrophil percentage of white cells;
CESC	cis	rs3820068	0.705	rs4646085	chr1:15825411	A/T	cg18192808	chr1:15853278	DNAJC16	0.48	5.83	0.34	1.58e-8	Systolic blood pressure;
CESC	cis	rs7296418	0.630	rs28419092	chr12:123812629	G/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.32	-5.11	-0.3	6.23e-7	Platelet count;
CESC	cis	rs634534	0.622	rs1308733	chr11:65720841	T/C	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.44	-6.39	-0.37	7.53e-10	Sum eosinophil basophil counts;Eosinophil counts;
CESC	cis	rs7777484	0.517	rs2644306	chr7:2831602	A/G	cg19717773	chr7:2847554	GNA12	-0.65	-11.24	-0.57	3.1e-24	Height;
CESC	cis	rs7618915	0.571	rs34954168	chr3:52612159	C/T	cg18404041	chr3:52824283	ITIH1	-0.4	-6.63	-0.38	1.92e-10	Bipolar disorder;
CESC	cis	rs6866344	0.570	rs11740283	chr5:178136440	T/C	cg10224037	chr5:178157518	ZNF354A	0.71	8.39	0.46	2.99e-15	Neutrophil percentage of white cells;
CESC	trans	rs7615952	0.576	rs4646748	chr3:125826329	G/A	cg07211511	chr3:129823064	LOC729375	-0.58	-6.44	-0.37	5.64e-10	Blood pressure (smoking interaction);
CESC	cis	rs643506	1.000	rs1788955	chr11:111630998	C/G	cg09085632	chr11:111637200	PPP2R1B	0.52	6.79	0.39	7.17e-11	Breast cancer;
CESC	cis	rs7191439	0.674	rs4782430	chr16:88792047	A/G	cg27087555	chr16:88793112	FAM38A	-1.38	-13.51	-0.64	5.47e-32	Plateletcrit;
CESC	cis	rs4843747	0.671	rs74729706	chr16:88104159	C/T	cg03395651	chr16:88107091	BANP	0.46	5.34	0.31	2.01e-7	Menopause (age at onset);
CESC	cis	rs514406	0.929	rs12410420	chr1:53323754	T/C	cg08736216	chr1:53307985	ZYG11A	-0.42	-7.0	-0.4	2.05e-11	Monocyte count;
CESC	cis	rs72781680	1.000	rs72788278	chr2:24095285	A/C	cg20701182	chr2:24300061	SF3B14	0.62	5.68	0.33	3.54e-8	Lymphocyte counts;
CESC	cis	rs7216064	0.861	rs12449312	chr17:65829358	A/C	cg07042672	chr17:66097459	LOC651250	-0.53	-5.9	-0.34	1.09e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	trans	rs11098499	0.738	rs72918577	chr4:120326701	G/A	cg25214090	chr10:38739885	LOC399744	0.7	9.97	0.52	4.42e-20	Corneal astigmatism;
CESC	cis	rs10771431	0.817	rs10843149	chr12:9362067	G/A	cg08997352	chr12:9597637	DDX12	-0.75	-10.16	-0.53	1.1e-20	Breast size;
CESC	trans	rs724568	0.643	rs4671196	chr2:67927432	A/C	cg19718508	chr5:176831858	F12	-0.45	-6.32	-0.36	1.12e-9	Major depressive disorder (broad);
CESC	cis	rs2242194	0.816	rs6671688	chr1:154994265	T/C	cg06221963	chr1:154839813	KCNN3	-0.38	-5.68	-0.33	3.51e-8	Schizophrenia;
CESC	cis	rs9911578	0.933	rs2531726	chr17:56522533	C/T	cg12560992	chr17:57184187	TRIM37	-0.91	-15.38	-0.69	1.41e-38	Intelligence (multi-trait analysis);
CESC	cis	rs9660992	0.674	rs72745219	chr1:205262271	G/A	cg21643547	chr1:205240462	TMCC2	-0.47	-6.25	-0.36	1.6e-9	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs12900413	0.687	rs12913409	chr15:90319251	T/A	cg24249390	chr15:90295951	MESP1	-0.42	-5.81	-0.34	1.78e-8	Coronary artery aneurysm in Kawasaki disease;
CESC	cis	rs9527	0.615	rs11191489	chr10:104740568	C/A	cg04362960	chr10:104952993	NT5C2	0.42	5.2	0.3	4.06e-7	Arsenic metabolism;
CESC	cis	rs7772486	0.686	rs2142983	chr6:146069701	G/C	cg05347473	chr6:146136440	FBXO30	-0.53	-6.96	-0.39	2.69e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9911578	1.000	rs302854	chr17:56683612	G/A	cg12560992	chr17:57184187	TRIM37	0.93	15.58	0.69	2.6e-39	Intelligence (multi-trait analysis);
CESC	cis	rs637571	0.780	rs677029	chr11:65683531	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.62	7.9	0.44	7.51e-14	Eosinophil percentage of white cells;
CESC	cis	rs1577917	1.000	rs12203924	chr6:86776412	A/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-6.01	-0.35	6.11e-9	Response to antipsychotic treatment;
CESC	cis	rs7267979	1.000	rs7019	chr20:25278278	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.86	16.82	0.72	1.06e-43	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs6429082	0.585	rs7524848	chr1:235711688	G/C	cg26050004	chr1:235667680	B3GALNT2	-0.45	-5.03	-0.3	9.23e-7	Adiposity;
CESC	cis	rs11608355	0.506	rs11066471	chr12:109828039	T/C	cg19025524	chr12:109796872	NA	-0.5	-6.34	-0.36	9.63e-10	Neuroticism;
CESC	cis	rs2380220	0.516	rs7748108	chr6:96008082	T/C	cg15832292	chr6:96025679	MANEA	0.65	7.31	0.41	3.09e-12	Behavioural disinhibition (generation interaction);
CESC	cis	rs7089973	0.872	rs7918253	chr10:116614501	T/C	cg23260525	chr10:116636907	FAM160B1	0.38	6.37	0.36	8.29e-10	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs4243830	0.737	rs925744	chr1:6615695	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.8	-7.85	-0.43	1.01e-13	Body mass index;
CESC	cis	rs950169	0.881	rs72750843	chr15:85135783	C/T	cg17507749	chr15:85114479	UBE2QP1	0.54	6.17	0.35	2.56e-9	Schizophrenia;
CESC	cis	rs6724607	1.000	rs11680758	chr2:191446268	T/G	cg27211696	chr2:191398769	TMEM194B	0.49	7.29	0.41	3.51e-12	Pulse pressure;
CESC	cis	rs4665809	1.000	rs11126375	chr2:26344787	G/A	cg26314531	chr2:26401878	FAM59B	-0.62	-6.99	-0.39	2.29e-11	Gut microbiome composition (summer);
CESC	cis	rs34638657	0.529	rs2059276	chr16:82223123	A/T	cg09439754	chr16:82129088	HSD17B2	-0.29	-5.09	-0.3	6.69e-7	Lung adenocarcinoma;
CESC	cis	rs7666738	0.791	rs10856934	chr4:99010844	A/G	cg05340658	chr4:99064831	C4orf37	-0.8	-12.65	-0.61	5.04e-29	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2204008	0.660	rs2320745	chr12:38239101	T/C	cg13010199	chr12:38710504	ALG10B	0.46	5.7	0.33	3.26e-8	Bladder cancer;
CESC	cis	rs2228479	0.850	rs17233664	chr16:89810628	C/T	cg00800038	chr16:89945340	TCF25	-0.88	-7.36	-0.41	2.3e-12	Skin colour saturation;
CESC	cis	rs4423214	1.000	rs11233746	chr11:71171440	A/G	cg05163923	chr11:71159392	DHCR7	0.88	11.67	0.58	1.18e-25	Vitamin D levels;
CESC	cis	rs763121	0.853	rs9607566	chr22:39075434	C/G	cg21395723	chr22:39101663	GTPBP1	0.43	5.28	0.31	2.76e-7	Menopause (age at onset);
CESC	cis	rs2228479	0.850	rs11648433	chr16:89965055	G/A	cg06558623	chr16:89946397	TCF25	1.14	8.82	0.48	1.55e-16	Skin colour saturation;
CESC	cis	rs4727027	0.835	rs6959224	chr7:148784495	A/G	cg23158103	chr7:148848205	ZNF398	-0.39	-6.12	-0.35	3.28e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg13880726	chr7:1868755	MAD1L1	0.51	6.72	0.38	1.11e-10	Bipolar disorder and schizophrenia;
CESC	cis	rs9913156	0.793	rs72835644	chr17:4573667	G/A	cg19197139	chr17:4613644	ARRB2	0.95	10.62	0.55	3.4e-22	Lymphocyte counts;
CESC	cis	rs12479064	0.694	rs4341989	chr2:100046783	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.6	-7.13	-0.4	9.27e-12	Chronic sinus infection;
CESC	cis	rs412050	0.501	rs2876980	chr22:22106535	C/T	cg17089214	chr22:22089827	YPEL1	-0.66	-5.65	-0.33	4.24e-8	Attention deficit hyperactivity disorder;
CESC	cis	rs10504229	0.683	rs11786843	chr8:58133629	T/C	cg21724239	chr8:58056113	NA	0.57	5.87	0.34	1.3e-8	Developmental language disorder (linguistic errors);
CESC	trans	rs12681287	0.547	rs9942792	chr8:87509046	C/T	cg27317242	chr8:23145699	R3HCC1	-0.53	-6.35	-0.36	9.05e-10	Caudate activity during reward;
CESC	cis	rs1580019	0.562	rs4720064	chr7:32559638	G/A	cg06627557	chr7:32535165	LSM5;AVL9	1.06	19.17	0.76	5.81e-52	Cognitive ability;
CESC	cis	rs17601876	0.778	rs4774584	chr15:51562007	G/A	cg19946085	chr15:51559439	CYP19A1	-0.32	-5.12	-0.3	5.89e-7	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
CESC	cis	rs6430585	0.591	rs61187091	chr2:136468238	G/A	cg07169764	chr2:136633963	MCM6	1.19	13.73	0.64	9.04e-33	Corneal structure;
CESC	cis	rs6460942	0.778	rs76030612	chr7:12462937	C/A	cg02935154	chr7:12443704	VWDE	-0.53	-6.73	-0.38	1.07e-10	Coronary artery disease;
CESC	cis	rs6951245	0.706	rs28522260	chr7:1183964	C/A	cg07092213	chr7:1199455	ZFAND2A	-0.48	-5.11	-0.3	6.12e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg17164693	chr10:124913828	BUB3	-0.51	-7.48	-0.42	1.13e-12	Gambling;
CESC	cis	rs7089973	0.872	rs12773943	chr10:116631184	G/A	cg23260525	chr10:116636907	FAM160B1	0.37	6.31	0.36	1.15e-9	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs7296418	0.518	rs28825193	chr12:123878262	T/C	cg05973401	chr12:123451056	ABCB9	0.44	5.48	0.32	9.68e-8	Platelet count;
CESC	cis	rs1670533	1.000	rs28562028	chr4:1055115	G/A	cg27284194	chr4:1044797	NA	0.48	6.06	0.35	4.7e-9	Recombination rate (females);
CESC	cis	rs7949030	1.000	rs7949030	chr11:62394881	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.5	7.81	0.43	1.32e-13	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg11494091	chr17:61959527	GH2	0.73	12.53	0.61	1.31e-28	Prudent dietary pattern;
CESC	cis	rs9910055	0.762	rs2526021	chr17:42213347	G/A	cg08499158	chr17:42289980	UBTF	-0.56	-7.32	-0.41	2.94e-12	Total body bone mineral density;
CESC	trans	rs9354308	0.933	rs2802063	chr6:66564148	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.7	7.85	0.43	1.02e-13	Metabolite levels;
CESC	cis	rs16866061	1.000	rs11686590	chr2:225334070	A/G	cg12698349	chr2:225449008	CUL3	0.71	10.56	0.54	5.29e-22	Acute graft versus host disease in bone marrow transplantation (recipient effect);
CESC	cis	rs9399135	0.967	rs4896125	chr6:135342569	C/T	cg22676075	chr6:135203613	NA	0.51	7.36	0.41	2.34e-12	Red blood cell count;
CESC	cis	rs9948	0.786	rs62156233	chr2:97434061	C/G	cg01990225	chr2:97406019	LMAN2L	-0.86	-7.56	-0.42	6.72e-13	Erectile dysfunction and prostate cancer treatment;
CESC	cis	rs977987	0.800	rs12935787	chr16:75332335	C/T	cg03315344	chr16:75512273	CHST6	0.38	5.47	0.32	1.06e-7	Dupuytren's disease;
CESC	cis	rs546131	0.928	rs535719	chr11:34853382	A/G	cg06937548	chr11:34938143	PDHX;APIP	0.54	6.88	0.39	4.21e-11	Lung disease severity in cystic fibrosis;
CESC	cis	rs3820928	0.874	rs7594505	chr2:227878562	C/G	cg05526886	chr2:227700861	RHBDD1	-0.45	-5.6	-0.33	5.33e-8	Pulmonary function;
CESC	cis	rs6504663	1.000	rs6504661	chr17:48580126	A/T	cg03611598	chr17:48586076	MYCBPAP	-0.53	-6.96	-0.39	2.66e-11	Visceral fat;
CESC	cis	rs9311474	0.659	rs7638808	chr3:52572056	C/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	-0.32	-6.23	-0.36	1.83e-9	Electroencephalogram traits;
CESC	cis	rs7843479	0.601	rs10866827	chr8:21801141	G/A	cg17168535	chr8:21777572	XPO7	0.73	11.81	0.59	3.82e-26	Mean corpuscular volume;
CESC	cis	rs6439153	0.743	rs71331685	chr3:128711425	T/A	cg25356066	chr3:128598488	ACAD9	0.53	6.89	0.39	4.17e-11	Pneumococcal bacteremia;
CESC	cis	rs896854	0.967	rs1320164	chr8:95960767	G/A	cg23172400	chr8:95962367	TP53INP1	-0.5	-10.43	-0.54	1.43e-21	Type 2 diabetes;
CESC	cis	rs8114671	0.836	rs734308	chr20:33572096	A/G	cg07148914	chr20:33460835	GGT7	-0.43	-5.5	-0.32	9.05e-8	Height;
CESC	cis	rs9517313	0.897	rs4772087	chr13:99115041	A/G	cg20750642	chr13:99100586	FARP1	-0.36	-5.79	-0.34	1.98e-8	Neuroticism;
CESC	cis	rs7945705	0.935	rs2568061	chr11:8886260	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.47	-7.86	-0.43	9.42e-14	Hemoglobin concentration;
CESC	cis	rs4664308	0.810	rs62175552	chr2:160937220	T/G	cg03641300	chr2:160917029	PLA2R1	-0.67	-9.84	-0.52	1.11e-19	Idiopathic membranous nephropathy;
CESC	cis	rs875971	0.830	rs778711	chr7:65851657	G/A	cg18876405	chr7:65276391	NA	0.53	7.32	0.41	3.01e-12	Aortic root size;
CESC	cis	rs36051895	0.632	rs11788963	chr9:5120157	C/A	cg02405213	chr9:5042618	JAK2	-0.53	-6.36	-0.36	8.65e-10	Pediatric autoimmune diseases;
CESC	cis	rs1552244	1.000	rs67569278	chr3:10149893	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.8	-10.08	-0.53	2.01e-20	Alzheimer's disease;
CESC	cis	rs35306767	0.953	rs1539174	chr10:974870	C/G	cg20503657	chr10:835505	NA	0.64	7.17	0.4	7.7e-12	Eosinophil percentage of granulocytes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19977241	chr2:74692637	MOGS	0.56	6.05	0.35	4.86e-9	Gut microbiome composition (summer);
CESC	cis	rs4704187	0.625	rs11947996	chr5:74545548	A/T	cg03227963	chr5:74354835	NA	0.28	5.27	0.31	2.86e-7	Response to amphetamines;
CESC	cis	rs7811142	0.943	rs111493473	chr7:100049742	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.13	13.28	0.63	3.38e-31	Platelet count;
CESC	cis	rs8177253	0.665	rs12639304	chr3:133441594	A/T	cg24879335	chr3:133465180	TF	0.36	6.36	0.36	8.76e-10	Iron status biomarkers;
CESC	cis	rs5763662	1.000	rs5753028	chr22:30556845	A/G	cg21388335	chr22:29999516	NF2	-0.76	-5.22	-0.31	3.63e-7	LDL cholesterol levels;LDL cholesterol;
CESC	cis	rs9611565	0.559	rs5758412	chr22:42080803	T/A	cg06481639	chr22:41940642	POLR3H	0.57	5.74	0.33	2.58e-8	Vitiligo;
CESC	cis	rs9815354	0.812	rs113772069	chr3:41933389	T/C	cg03022575	chr3:42003672	ULK4	0.71	6.44	0.37	5.46e-10	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs7666738	0.753	rs6826709	chr4:98714553	C/G	cg03676636	chr4:99064102	C4orf37	0.34	5.08	0.3	7.25e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs921968	0.565	rs3770220	chr2:219619550	C/T	cg02176678	chr2:219576539	TTLL4	-0.44	-7.67	-0.43	3.29e-13	Mean corpuscular hemoglobin concentration;
CESC	cis	rs317689	0.718	rs315122	chr12:69771073	G/T	cg20891283	chr12:69753455	YEATS4	0.64	7.56	0.42	6.68e-13	Response to diuretic therapy;
CESC	cis	rs12701220	0.553	rs9639882	chr7:1133731	G/A	cg23978390	chr7:1156363	C7orf50	0.65	6.39	0.37	7.5e-10	Bronchopulmonary dysplasia;
CESC	cis	rs12765878	1.000	rs10883942	chr10:105651386	A/G	cg24587175	chr10:105670608	OBFC1	0.33	5.61	0.33	5.02e-8	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18604876	chr3:5164258	ARL8B	0.54	6.5	0.37	4.01e-10	Gut microbiome composition (summer);
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg21409833	chr1:63062724	DOCK7;ANGPTL3	0.37	6.01	0.35	6.06e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg25130390	chr15:65810150	DPP8	-0.46	-6.41	-0.37	6.69e-10	Fibrinogen levels;
CESC	cis	rs6502050	0.805	rs9915071	chr17:80119138	T/C	cg11859384	chr17:80120422	CCDC57	-0.39	-5.34	-0.31	1.98e-7	Life satisfaction;
CESC	cis	rs11231629	1	rs11231629	chr11:63648573	C/T	cg04362095	chr11:63592001	C11orf84	-0.41	-5.26	-0.31	2.93e-7	Schizophrenia;
CESC	cis	rs9660992	0.573	rs1172139	chr1:205213962	G/A	cg00857998	chr1:205179979	DSTYK	0.56	6.86	0.39	4.73e-11	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs769267	0.965	rs2965191	chr19:19453521	T/G	cg15052019	chr19:19431593	KIAA0892;SF4	-0.41	-5.2	-0.3	3.93e-7	Tonsillectomy;
CESC	cis	rs1799949	1.000	rs4792981	chr17:41308274	A/G	cg25072359	chr17:41440525	NA	0.43	5.82	0.34	1.72e-8	Menopause (age at onset);
CESC	cis	rs4555082	0.830	rs2735812	chr14:105727575	A/G	cg10792982	chr14:105748885	BRF1	0.42	5.55	0.32	6.75e-8	Mean platelet volume;Platelet distribution width;
CESC	cis	rs4423214	0.879	rs1790324	chr11:71150520	A/C	cg05163923	chr11:71159392	DHCR7	-0.62	-7.59	-0.42	5.42e-13	Vitamin D levels;
CESC	cis	rs7647973	1.000	rs13096474	chr3:49443081	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.61	-8.02	-0.44	3.43e-14	Menarche (age at onset);
CESC	cis	rs1018836	0.651	rs2339175	chr8:91565805	A/T	cg16814680	chr8:91681699	NA	-0.73	-10.01	-0.52	3.27e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs16866061	1.000	rs11688397	chr2:225393173	C/T	cg12698349	chr2:225449008	CUL3	0.75	11.61	0.58	1.89e-25	Acute graft versus host disease in bone marrow transplantation (recipient effect);
CESC	cis	rs2273669	0.667	rs12153822	chr6:109315115	T/C	cg05315195	chr6:109294784	ARMC2	-0.66	-6.28	-0.36	1.36e-9	Prostate cancer;
CESC	cis	rs854765	0.583	rs8070722	chr17:17813562	C/T	cg16928487	chr17:17741425	SREBF1	-0.56	-9.71	-0.51	2.83e-19	Total body bone mineral density;
CESC	cis	rs6582630	0.519	rs4294627	chr12:38293982	C/T	cg26384229	chr12:38710491	ALG10B	0.7	10.34	0.54	2.92e-21	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs7666738	0.791	rs13111960	chr4:98976851	C/T	cg03676636	chr4:99064102	C4orf37	0.33	5.12	0.3	5.91e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9486719	0.947	rs2472908	chr6:96875998	A/T	cg06623918	chr6:96969491	KIAA0776	0.81	8.29	0.45	5.61e-15	Migraine;Coronary artery disease;
CESC	cis	rs8103278	1.000	rs17571725	chr19:46290822	C/T	cg12641515	chr19:46296257	DMWD	-0.51	-5.83	-0.34	1.6e-8	Coronary artery disease;
CESC	cis	rs9943753	0.508	rs7138357	chr12:109832303	A/G	cg19025524	chr12:109796872	NA	-0.47	-6.66	-0.38	1.61e-10	HDL cholesterol;
CESC	cis	rs11190604	1.000	rs2295779	chr10:102296061	A/G	cg07080220	chr10:102295463	HIF1AN	0.68	6.33	0.36	1.02e-9	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs3096299	0.503	rs9940093	chr16:89558705	G/A	cg02034447	chr16:89574710	SPG7	0.46	5.67	0.33	3.77e-8	Multiple myeloma (IgH translocation);
CESC	cis	rs7811142	1.000	rs74460138	chr7:100027339	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.15	11.48	0.58	4.99e-25	Platelet count;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg06975592	chr1:165796857	UCK2	-0.45	-6.34	-0.36	9.6e-10	Gambling;
CESC	cis	rs7833790	0.963	rs6473312	chr8:82732515	C/A	cg27398817	chr8:82754497	SNX16	-0.56	-6.59	-0.38	2.39e-10	Diastolic blood pressure;
CESC	cis	rs6032067	0.777	rs34085254	chr20:43786170	T/G	cg10761708	chr20:43804764	PI3	0.57	6.65	0.38	1.64e-10	Blood protein levels;
CESC	cis	rs820218	0.926	rs820204	chr17:73639951	G/C	cg01592526	chr17:73663357	RECQL5;SAP30BP	0.4	5.36	0.31	1.79e-7	Rotator cuff tears;
CESC	cis	rs35146811	0.807	rs10228764	chr7:99608029	A/G	cg13334819	chr7:99746414	C7orf59	-0.43	-5.12	-0.3	5.86e-7	Coronary artery disease;
CESC	cis	rs9837602	0.935	rs17392948	chr3:99754498	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.45	5.85	0.34	1.48e-8	Breast cancer;
CESC	cis	rs4409675	0.527	rs12067053	chr1:28227122	T/G	cg23691781	chr1:28212827	C1orf38	0.28	5.53	0.32	7.57e-8	Corneal astigmatism;
CESC	cis	rs2295359	1.000	rs12043240	chr1:67624304	C/T	cg17031739	chr1:67600172	NA	0.4	5.23	0.31	3.44e-7	Psoriasis;
CESC	cis	rs40363	0.723	rs757269	chr16:3538003	A/G	cg21433313	chr16:3507492	NAT15	-0.59	-6.54	-0.37	3.24e-10	Tuberculosis;
CESC	cis	rs17166499	0.803	rs17166479	chr7:12915193	T/C	cg12945054	chr7:12841881	NA	0.5	5.08	0.3	7.05e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs2439831	0.867	rs12443102	chr15:43932103	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.7	8.4	0.46	2.73e-15	Lung cancer in ever smokers;
CESC	cis	rs941764	0.965	rs747159	chr14:91841030	A/C	cg10511902	chr14:91842949	CCDC88C	-0.53	-8.54	-0.46	1.08e-15	Breast cancer;
CESC	trans	rs1728785	1.000	rs698716	chr16:68560296	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.62	7.2	0.4	6.15e-12	Ulcerative colitis;
CESC	cis	rs1801251	0.752	rs2675966	chr2:233735543	T/C	cg08000102	chr2:233561755	GIGYF2	-0.58	-7.8	-0.43	1.4e-13	Coronary artery disease;
CESC	cis	rs6543140	0.964	rs6761350	chr2:103030776	A/G	cg04239558	chr2:103089729	SLC9A4	0.45	5.76	0.33	2.28e-8	Blood protein levels;
CESC	cis	rs7833986	0.501	rs2976038	chr8:57028864	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.57	7.28	0.41	3.83e-12	Height;
CESC	cis	rs67072384	0.818	rs6592483	chr11:72463974	A/G	cg04827223	chr11:72435913	ARAP1	-0.67	-6.09	-0.35	3.94e-9	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
CESC	cis	rs4665809	0.878	rs35709953	chr2:26334997	G/A	cg26119090	chr2:26468346	HADHA;HADHB	0.81	8.68	0.47	4e-16	Gut microbiome composition (summer);
CESC	cis	rs6942756	0.956	rs7792317	chr7:128963971	G/A	cg02491457	chr7:128862824	NA	-0.66	-8.95	-0.48	6.38e-17	White matter hyperintensity burden;
CESC	cis	rs7605827	0.897	rs7425203	chr2:15697410	A/G	cg19274914	chr2:15703543	NA	0.37	6.48	0.37	4.42e-10	Educational attainment (years of education);
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg04578738	chr17:34136331	TAF15	0.48	6.49	0.37	4.12e-10	Systemic lupus erythematosus;
CESC	cis	rs7516138	1.000	rs4240896	chr1:9713500	A/G	cg26573321	chr1:9711663	PIK3CD	-0.6	-9.5	-0.5	1.31e-18	Monocyte count;
CESC	cis	rs7666738	0.830	rs1896154	chr4:99021161	T/C	cg03676636	chr4:99064102	C4orf37	0.33	5.12	0.3	5.88e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	22.21	0.81	1.96e-62	Prudent dietary pattern;
CESC	cis	rs2777491	0.507	rs11854081	chr15:41646398	C/T	cg02330683	chr15:41787940	ITPKA	0.41	5.03	0.3	9.07e-7	Ulcerative colitis;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg13577194	chr9:95378173	IPPK	0.49	6.05	0.35	5.05e-9	Ulcerative colitis;
CESC	trans	rs11098499	0.954	rs12505469	chr4:120249585	C/T	cg25214090	chr10:38739885	LOC399744	0.7	9.87	0.52	8.97e-20	Corneal astigmatism;
CESC	cis	rs9916302	0.904	rs10491128	chr17:37551988	G/A	cg07936489	chr17:37558343	FBXL20	0.78	10.65	0.55	2.75e-22	Glomerular filtration rate (creatinine);
CESC	cis	rs4665809	0.549	rs62130460	chr2:26472718	T/C	cg22920501	chr2:26401640	FAM59B	0.83	8.85	0.48	1.25e-16	Gut microbiome composition (summer);
CESC	cis	rs12048904	0.505	rs6577209	chr1:101255080	A/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.6	7.52	0.42	8.77e-13	Multiple sclerosis;
CESC	cis	rs7607369	0.580	rs17573724	chr2:219652141	T/A	cg02176678	chr2:219576539	TTLL4	-0.48	-8.58	-0.47	8.14e-16	Red blood cell count;Amyotrophic lateral sclerosis;
CESC	cis	rs4665809	0.887	rs6546716	chr2:26263836	A/G	cg22920501	chr2:26401640	FAM59B	-0.7	-8.39	-0.46	2.85e-15	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20259401	chr15:66995639	SMAD6	0.56	6.32	0.36	1.09e-9	Gut microbiome composition (summer);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg02116590	chr2:3207260	TSSC1	0.51	7.03	0.4	1.78e-11	Fibrinogen levels;
CESC	cis	rs4434138	0.683	rs13063160	chr3:52602274	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.5	7.4	0.41	1.83e-12	Intelligence (multi-trait analysis);
CESC	cis	rs5769765	1.000	rs2092982	chr22:50282204	C/A	cg26441486	chr22:50317300	CRELD2	-0.39	-5.5	-0.32	8.72e-8	Schizophrenia;
CESC	cis	rs9487051	0.872	rs9487038	chr6:109610152	T/C	cg21918786	chr6:109611834	NA	-0.4	-6.01	-0.35	6.17e-9	Reticulocyte fraction of red cells;
CESC	cis	rs9733	0.596	rs17658705	chr1:150678071	A/C	cg18016565	chr1:150552671	MCL1	-0.34	-5.15	-0.3	4.99e-7	Tonsillectomy;
CESC	cis	rs2477686	0.526	rs12042427	chr1:2398107	C/T	cg07700843	chr1:2391317	NA	-0.42	-6.95	-0.39	2.84e-11	Non-obstructive azoospermia;
CESC	cis	rs2839186	0.632	rs2839184	chr21:47689013	G/A	cg09417038	chr21:47716443	C21orf57	-0.45	-6.38	-0.36	7.77e-10	Testicular germ cell tumor;
CESC	cis	rs9457247	1.000	rs439553	chr6:167391212	A/G	cg23791538	chr6:167370224	RNASET2	-0.58	-8.26	-0.45	7.22e-15	Crohn's disease;
CESC	cis	rs6748734	1.000	rs11893118	chr2:241828308	C/G	cg07537917	chr2:241836409	C2orf54	-0.25	-5.38	-0.31	1.64e-7	Urinary metabolites;
CESC	cis	rs875971	0.862	rs6460306	chr7:66060793	T/C	cg18876405	chr7:65276391	NA	-0.53	-7.37	-0.41	2.19e-12	Aortic root size;
CESC	cis	rs637571	0.522	rs7105628	chr11:65763067	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.72	10.11	0.53	1.52e-20	Eosinophil percentage of white cells;
CESC	cis	rs9815354	0.812	rs73071212	chr3:41981856	C/A	cg03022575	chr3:42003672	ULK4	0.67	5.95	0.34	8.63e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs853679	0.517	rs9393898	chr6:28130376	G/T	cg22143856	chr6:28129313	ZNF389	0.49	6.22	0.36	1.9e-9	Depression;
CESC	cis	rs3858526	0.883	rs7481923	chr11:5933342	T/C	cg02574844	chr11:5959923	NA	-0.42	-5.36	-0.31	1.83e-7	DNA methylation (variation);
CESC	cis	rs7551222	0.752	rs4245737	chr1:204486242	A/G	cg20240347	chr1:204465584	NA	-0.28	-5.63	-0.33	4.7e-8	Schizophrenia;
CESC	cis	rs7000551	0.505	rs13258195	chr8:22227271	A/G	cg12081754	chr8:22256438	SLC39A14	-0.91	-11.74	-0.58	6.61e-26	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CESC	cis	rs55823223	0.564	rs936391	chr17:73847799	A/G	cg10935138	chr17:73851978	WBP2	-0.79	-9.83	-0.52	1.17e-19	Psoriasis;
CESC	cis	rs11122272	0.735	rs2790876	chr1:231536033	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.57	-7.73	-0.43	2.29e-13	Hemoglobin concentration;
CESC	cis	rs17253792	0.822	rs17832365	chr14:56153531	C/G	cg01858014	chr14:56050164	KTN1	-0.97	-7.59	-0.42	5.34e-13	Putamen volume;
CESC	cis	rs1008375	1.000	rs11727312	chr4:17669185	C/T	cg02297831	chr4:17616191	MED28	0.48	5.93	0.34	9.5e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs34779708	0.677	rs112355105	chr10:35550294	A/T	cg04310649	chr10:35416472	CREM	-0.46	-5.21	-0.3	3.75e-7	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs17601876	0.814	rs35939475	chr15:51554710	C/A	cg19946085	chr15:51559439	CYP19A1	-0.33	-5.28	-0.31	2.69e-7	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
CESC	cis	rs4722166	0.630	rs7781534	chr7:22778592	A/C	cg26061582	chr7:22766209	IL6	0.51	5.55	0.32	6.82e-8	Lung cancer;
CESC	cis	rs3785574	0.621	rs1051684	chr17:62006497	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	-0.61	-7.78	-0.43	1.5700000000000001e-13	Height;
CESC	cis	rs30380	0.632	rs26497	chr5:96138767	T/C	cg16492584	chr5:96139282	ERAP1	-0.49	-6.59	-0.38	2.37e-10	Cerebrospinal fluid biomarker levels;
CESC	cis	rs3859192	0.537	rs12309	chr17:38175462	C/T	cg17467752	chr17:38218738	THRA	-0.44	-5.8	-0.34	1.93e-8	White blood cell count;
CESC	cis	rs1008375	0.932	rs11938710	chr4:17670664	G/C	cg16339924	chr4:17578868	LAP3	-0.63	-7.36	-0.41	2.26e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	trans	rs650950	0.528	rs646660	chr11:35528452	C/T	cg09388058	chr16:47494735	PHKB;ITFG1	0.47	6.03	0.35	5.39e-9	Bronchopulmonary dysplasia;
CESC	cis	rs12950390	0.893	rs11079789	chr17:45849715	A/G	cg00777063	chr17:45855553	NA	-0.41	-6.12	-0.35	3.4e-9	IgG glycosylation;
CESC	cis	rs35306767	0.761	rs11253537	chr10:1010735	G/A	cg20503657	chr10:835505	NA	0.71	6.72	0.38	1.12e-10	Eosinophil percentage of granulocytes;
CESC	cis	rs67257959	0.708	rs13343952	chr19:17197064	G/C	cg16202187	chr19:17186497	HAUS8;MYO9B	0.45	5.4	0.31	1.52e-7	Selective IgA deficiency;
CESC	cis	rs35306767	0.903	rs12240651	chr10:943656	A/G	cg20503657	chr10:835505	NA	0.83	8.5	0.46	1.4e-15	Eosinophil percentage of granulocytes;
CESC	cis	rs10751667	0.666	rs7395402	chr11:950293	A/G	cg20946044	chr11:1010712	AP2A2	0.4	5.59	0.32	5.65e-8	Alzheimer's disease (late onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02390588	chr12:53722253	SP7	-0.46	-6.0	-0.35	6.51e-9	Gut microbiome composition (summer);
CESC	cis	rs425277	0.583	rs4648807	chr1:2040898	A/G	cg12718519	chr1:2058417	PRKCZ	-0.25	-5.53	-0.32	7.59e-8	Height;
CESC	cis	rs78132593	0.723	rs34593358	chr1:150686633	A/T	cg22823121	chr1:150693482	HORMAD1	-0.43	-5.33	-0.31	2.13e-7	High light scatter reticulocyte count;
CESC	cis	rs7811142	0.943	rs11769886	chr7:99998607	G/A	cg11814155	chr7:99998594	ZCWPW1	0.53	5.14	0.3	5.31e-7	Platelet count;
CESC	cis	rs9818758	0.607	rs34784192	chr3:49274823	G/T	cg00383909	chr3:49044727	WDR6	0.75	5.99	0.35	6.72e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CESC	cis	rs875971	1.000	rs2220626	chr7:65546062	C/T	cg12463550	chr7:65579703	CRCP	-0.61	-7.62	-0.42	4.56e-13	Aortic root size;
CESC	cis	rs1387259	0.931	rs11168474	chr12:48621384	A/C	cg04545296	chr12:48745243	ZNF641	0.39	6.56	0.37	2.76e-10	Obstructive sleep apnea trait (apnea hypopnea index);
CESC	cis	rs9911578	1.000	rs4793950	chr17:56593111	T/C	cg12560992	chr17:57184187	TRIM37	-0.93	-15.56	-0.69	3.26e-39	Intelligence (multi-trait analysis);
CESC	cis	rs2637266	1.000	rs7098929	chr10:78361194	T/G	cg18941641	chr10:78392320	NA	0.41	7.87	0.44	9.17e-14	Pulmonary function;
CESC	cis	rs10463316	0.894	rs6891272	chr5:150762842	G/T	cg03212797	chr5:150827313	SLC36A1	-0.46	-6.02	-0.35	5.83e-9	Metabolite levels (Pyroglutamine);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg00093900	chr1:204381012	PPP1R15B	0.46	6.68	0.38	1.44e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs7412746	0.658	rs6669855	chr1:150861229	C/T	cg17724175	chr1:150552817	MCL1	0.4	6.06	0.35	4.56e-9	Melanoma;
CESC	cis	rs6598955	0.724	rs12754536	chr1:26639605	T/C	cg04990556	chr1:26633338	UBXN11	-0.74	-10.4	-0.54	1.88e-21	Obesity-related traits;
CESC	cis	rs7917772	0.565	rs1043450	chr10:104434209	A/G	ch.10.2196322F	chr10:104248062	ACTR1A	0.53	5.78	0.33	2.14e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	trans	rs61931739	0.534	rs11052974	chr12:34029877	T/G	cg26384229	chr12:38710491	ALG10B	0.59	8.27	0.45	6.34e-15	Morning vs. evening chronotype;
CESC	cis	rs7223966	1.000	rs7223966	chr17:61893398	G/A	cg11494091	chr17:61959527	GH2	0.38	5.19	0.3	4.25e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs4665809	0.590	rs10179959	chr2:26426403	G/A	cg08470875	chr2:26401718	FAM59B	-0.74	-7.92	-0.44	6.42e-14	Gut microbiome composition (summer);
CESC	cis	rs4835473	0.932	rs4835120	chr4:144903523	C/A	cg25736465	chr4:144833511	NA	0.41	6.25	0.36	1.64e-9	Immature fraction of reticulocytes;
CESC	trans	rs7615952	0.599	rs2279821	chr3:125734308	G/A	cg07211511	chr3:129823064	LOC729375	-0.6	-6.74	-0.38	9.88e-11	Blood pressure (smoking interaction);
CESC	cis	rs2576037	0.583	rs680018	chr18:44409167	T/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.33	5.29	0.31	2.63e-7	Personality dimensions;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg24031277	chr7:33102336	NT5C3	-0.46	-6.02	-0.35	5.64e-9	Ulcerative colitis;
CESC	cis	rs10899021	0.790	rs10899019	chr11:74335162	A/G	cg25880958	chr11:74394337	NA	-0.74	-7.95	-0.44	5.44e-14	Response to metformin (IC50);
CESC	cis	rs9611565	0.559	rs1006407	chr22:41972032	T/C	cg03806693	chr22:41940476	POLR3H	-1.16	-13.02	-0.62	2.74e-30	Vitiligo;
CESC	cis	rs727505	1.000	rs9655845	chr7:124513355	G/C	cg23710748	chr7:124431027	NA	-0.46	-7.26	-0.41	4.25e-12	Lewy body disease;
CESC	cis	rs7818688	0.697	rs11783878	chr8:95979261	C/T	cg16049864	chr8:95962084	TP53INP1	-0.55	-5.58	-0.32	6.03e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs4664304	0.900	rs62176692	chr2:160743463	C/T	cg03641300	chr2:160917029	PLA2R1	-0.46	-6.56	-0.37	2.88e-10	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs7659604	0.539	rs3217771	chr4:122739483	G/A	cg19748678	chr4:122722346	EXOSC9	0.79	9.99	0.52	3.82e-20	Type 2 diabetes;
CESC	cis	rs826838	0.967	rs826856	chr12:39115434	G/A	cg13010199	chr12:38710504	ALG10B	-0.46	-6.44	-0.37	5.5e-10	Heart rate;
CESC	cis	rs3785574	0.582	rs62072238	chr17:61948841	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.63	7.99	0.44	4.28e-14	Height;
CESC	cis	rs7577696	0.512	rs212691	chr2:32438075	G/A	cg02381751	chr2:32503542	YIPF4	0.46	5.16	0.3	4.77e-7	Inflammatory biomarkers;
CESC	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg03188948	chr7:1209495	NA	0.73	7.02	0.4	1.85e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs9911578	0.835	rs1476596	chr17:56485358	C/T	cg05425664	chr17:57184151	TRIM37	-0.45	-6.23	-0.36	1.83e-9	Intelligence (multi-trait analysis);
CESC	cis	rs514406	0.644	rs7529978	chr1:53204705	G/A	cg27535305	chr1:53392650	SCP2	0.35	6.14	0.35	3.05e-9	Monocyte count;
CESC	cis	rs853679	0.517	rs35512245	chr6:28079953	T/C	cg12963246	chr6:28129442	ZNF389	0.56	7.63	0.42	4.26e-13	Depression;
CESC	cis	rs3733585	0.673	rs116046986	chr4:9957794	A/G	cg00071950	chr4:10020882	SLC2A9	-0.71	-11.5	-0.58	4.32e-25	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs5769765	0.671	rs138841	chr22:50181960	C/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.46	-5.14	-0.3	5.34e-7	Schizophrenia;
CESC	cis	rs919433	0.680	rs7582536	chr2:198436103	C/T	cg20885578	chr2:198174922	NA	-0.4	-5.08	-0.3	7.2e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs765787	0.530	rs55771002	chr15:45541566	T/C	cg24006582	chr15:45444508	DUOX1	-0.59	-7.32	-0.41	3.04e-12	Uric acid levels;
CESC	cis	rs9457247	0.967	rs425039	chr6:167410527	C/T	cg07741184	chr6:167504864	NA	0.3	5.52	0.32	8.06e-8	Crohn's disease;
CESC	cis	rs35110281	0.744	rs230644	chr21:44917183	C/T	cg04455712	chr21:45112962	RRP1B	-0.36	-5.35	-0.31	1.89e-7	Mean corpuscular volume;
CESC	cis	rs11252926	0.545	rs10466270	chr10:556129	A/G	cg03684893	chr10:554711	DIP2C	-0.44	-6.92	-0.39	3.4e-11	Psychosis in Alzheimer's disease;
CESC	cis	rs9611565	0.659	rs12484694	chr22:41919330	A/G	cg03806693	chr22:41940476	POLR3H	-1.26	-16.9	-0.72	5.59e-44	Vitiligo;
CESC	cis	rs60871478	0.578	rs62432900	chr7:826794	G/C	cg00934597	chr7:893267	UNC84A	0.53	5.41	0.32	1.43e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs7772486	0.875	rs2748490	chr6:146329681	G/T	cg23711669	chr6:146136114	FBXO30	0.75	10.74	0.55	1.4e-22	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2304069	0.817	rs216132	chr5:149431259	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.74	-9.35	-0.5	3.69e-18	HIV-1 control;
CESC	cis	rs9906944	0.933	rs35051752	chr17:47089908	G/A	cg09029085	chr17:47094198	IGF2BP1	0.26	5.14	0.3	5.4e-7	Intelligence (multi-trait analysis);Body fat percentage;
CESC	cis	rs6973256	0.605	rs12707114	chr7:133345207	C/G	cg10665199	chr7:133106180	EXOC4	0.46	6.18	0.35	2.44e-9	Intelligence (multi-trait analysis);
CESC	cis	rs3733346	0.553	rs6813110	chr4:942660	C/T	cg20814179	chr4:940893	TMEM175	0.36	5.39	0.31	1.54e-7	Sjögren's syndrome;
CESC	cis	rs9916302	0.904	rs4794813	chr17:37670994	A/T	cg20243544	chr17:37824526	PNMT	0.48	5.94	0.34	8.96e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs2243480	1.000	rs3885839	chr7:65290403	G/T	cg25894440	chr7:65020034	NA	-0.64	-5.53	-0.32	7.69e-8	Diabetic kidney disease;
CESC	cis	rs11048434	0.736	rs12823100	chr12:9108908	C/A	cg23795048	chr12:9217529	LOC144571	0.35	5.35	0.31	1.9e-7	Sjögren's syndrome;
CESC	cis	rs818427	0.865	rs1093611	chr5:112218476	A/T	cg07820702	chr5:112228657	REEP5	0.41	5.36	0.31	1.84e-7	Total body bone mineral density;
CESC	cis	rs2952156	0.920	rs732084	chr17:37834357	A/C	cg20243544	chr17:37824526	PNMT	0.63	8.38	0.46	3.08e-15	Asthma;
CESC	cis	rs6912958	0.712	rs2246113	chr6:88410050	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.33	-5.13	-0.3	5.52e-7	Monocyte percentage of white cells;
CESC	cis	rs10751667	0.580	rs11246363	chr11:971667	T/C	cg11406765	chr11:980039	AP2A2	-0.36	-5.07	-0.3	7.42e-7	Alzheimer's disease (late onset);
CESC	cis	rs60843830	1.000	rs7605824	chr2:280819	A/G	cg00108164	chr2:264199	ACP1;SH3YL1	-0.8	-10.46	-0.54	1.16e-21	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs7666738	0.830	rs13149404	chr4:99070236	A/G	cg03467027	chr4:99064603	C4orf37	0.48	5.9	0.34	1.11e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs5769765	0.773	rs138861	chr22:50202276	A/G	cg02269571	chr22:50332266	NA	-0.44	-5.52	-0.32	8.24e-8	Schizophrenia;
CESC	cis	rs7274811	0.681	rs210074	chr20:31949756	A/T	cg21523528	chr20:32077966	CBFA2T2	-0.46	-5.47	-0.32	1.04e-7	Height;
CESC	cis	rs6089584	0.962	rs6142913	chr20:60566950	A/G	cg13770153	chr20:60521292	NA	-0.4	-5.19	-0.3	4.14e-7	Body mass index;
CESC	cis	rs3768617	0.510	rs3768618	chr1:183092491	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.89	14.39	0.66	4.39e-35	Fuchs's corneal dystrophy;
CESC	cis	rs10206020	0.885	rs13388254	chr2:1577209	A/G	cg26248373	chr2:1572462	NA	-0.59	-6.93	-0.39	3.22e-11	IgG glycosylation;
CESC	cis	rs4664308	1.000	rs2175416	chr2:160904021	G/A	cg03641300	chr2:160917029	PLA2R1	-0.67	-10.16	-0.53	1.05e-20	Idiopathic membranous nephropathy;
CESC	trans	rs7615952	0.733	rs13314847	chr3:125644788	C/T	cg07211511	chr3:129823064	LOC729375	-1.13	-15.5	-0.69	5.37e-39	Blood pressure (smoking interaction);
CESC	cis	rs921968	0.541	rs12617603	chr2:219369288	A/G	cg02176678	chr2:219576539	TTLL4	-0.55	-9.83	-0.52	1.17e-19	Mean corpuscular hemoglobin concentration;
CESC	cis	rs9291683	0.551	rs2276961	chr4:10022981	C/T	cg11266682	chr4:10021025	SLC2A9	0.71	14.78	0.67	1.77e-36	Bone mineral density;
CESC	cis	rs12824058	0.831	rs4759450	chr12:130812732	G/A	cg24838063	chr12:130822603	PIWIL1	0.61	8.41	0.46	2.59e-15	Menopause (age at onset);
CESC	cis	rs8092503	1.000	rs12606265	chr18:52492470	T/C	cg12377874	chr18:52495404	RAB27B	0.37	6.13	0.35	3.13e-9	Childhood body mass index;
CESC	cis	rs9926296	0.643	rs12596429	chr16:89841374	T/C	cg27121462	chr16:89883253	FANCA	0.54	6.76	0.38	8.55e-11	Vitiligo;
CESC	cis	rs1182196	0.533	rs2527521	chr7:2904928	A/G	cg19717773	chr7:2847554	GNA12	0.52	8.25	0.45	7.55e-15	Plateletcrit;
CESC	trans	rs7837860	0.588	rs7821897	chr8:89330431	C/G	cg04391754	chr17:18022714	MYO15A	-0.5	-6.01	-0.35	6.16e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs9916302	0.904	rs11078915	chr17:37715426	T/C	cg07936489	chr17:37558343	FBXL20	-0.81	-11.66	-0.58	1.24e-25	Glomerular filtration rate (creatinine);
CESC	cis	rs854765	0.547	rs12150369	chr17:17911014	G/A	cg04398451	chr17:18023971	MYO15A	-0.69	-10.33	-0.54	3.02e-21	Total body bone mineral density;
CESC	cis	rs75477785	1.000	rs79384526	chr1:209988274	A/G	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.92	6.04	0.35	5.06e-9	Cleft lip with or without cleft palate;
CESC	cis	rs4665809	0.590	rs962217	chr2:26438276	T/C	cg25036284	chr2:26402008	FAM59B	-0.86	-9.28	-0.5	6.28e-18	Gut microbiome composition (summer);
CESC	cis	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg01570182	chr17:44337453	NA	0.82	9.7	0.51	3.02e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs9796	0.553	rs2925343	chr15:41306493	T/C	cg18705301	chr15:41695430	NDUFAF1	0.49	6.93	0.39	3.1e-11	Menopause (age at onset);
CESC	trans	rs7937682	1.000	rs10789843	chr11:111576158	C/T	cg18187862	chr3:45730750	SACM1L	-0.57	-6.57	-0.37	2.59e-10	Primary sclerosing cholangitis;
CESC	cis	rs977987	0.806	rs7185640	chr16:75394399	A/G	cg03315344	chr16:75512273	CHST6	0.39	5.64	0.33	4.3e-8	Dupuytren's disease;
CESC	cis	rs2479106	0.591	rs6415840	chr9:126415689	A/G	cg16191174	chr9:126692580	DENND1A	0.41	5.72	0.33	2.89e-8	Polycystic ovary syndrome;
CESC	cis	rs1499614	1.000	rs2707832	chr7:66136549	C/T	cg12463550	chr7:65579703	CRCP	0.77	5.93	0.34	9.26e-9	Gout;
CESC	cis	rs7618915	0.501	rs13060048	chr3:52598608	G/A	cg18404041	chr3:52824283	ITIH1	-0.38	-6.5	-0.37	4e-10	Bipolar disorder;
CESC	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg01238044	chr22:24384105	GSTT1	-0.44	-5.47	-0.32	1.02e-7	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs9287719	0.578	rs62127189	chr2:10761326	T/C	cg00105475	chr2:10696890	NA	0.37	5.03	0.3	9.03e-7	Prostate cancer;
CESC	cis	rs9583531	0.600	rs7986286	chr13:111357207	A/G	cg24331049	chr13:111365604	ING1	0.73	10.7	0.55	1.9e-22	Coronary artery disease;
CESC	cis	rs2120019	1.000	rs12324912	chr15:75361006	G/A	cg09165964	chr15:75287851	SCAMP5	-0.74	-8.85	-0.48	1.3e-16	Blood trace element (Zn levels);
CESC	cis	rs7523875	0.516	rs6682599	chr1:211522427	G/A	cg25617285	chr1:211431773	RCOR3	0.39	5.44	0.32	1.22e-7	Mean corpuscular volume;
CESC	cis	rs6076065	0.748	rs1016628	chr20:23398738	C/G	cg11657817	chr20:23433608	CST11	-0.41	-6.29	-0.36	1.3e-9	Facial morphology (factor 15, philtrum width);
CESC	cis	rs2072732	0.861	rs72629494	chr1:2951349	T/C	cg03976712	chr1:2946727	NA	0.33	5.45	0.32	1.17e-7	Plateletcrit;
CESC	cis	rs10911232	0.524	rs4487994	chr1:182982173	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.83	13.31	0.63	2.65e-31	Hypertriglyceridemia;
CESC	cis	rs10779751	0.690	rs910661	chr1:11130116	C/A	cg08854313	chr1:11322531	MTOR	0.76	10.26	0.53	4.97e-21	Body mass index;
CESC	cis	rs9815354	0.680	rs73073242	chr3:42015335	G/A	cg03022575	chr3:42003672	ULK4	0.74	6.64	0.38	1.79e-10	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs8112211	0.834	rs4312417	chr19:38797189	A/G	cg14299480	chr19:38876666	GGN	-0.41	-5.69	-0.33	3.28e-8	Blood protein levels;
CESC	cis	rs5750830	0.649	rs5750808	chr22:39790987	G/A	cg24399712	chr22:39784796	NA	-0.84	-11.77	-0.59	5.08e-26	Intelligence (multi-trait analysis);
CESC	cis	rs35110281	0.626	rs162368	chr21:44934767	G/A	cg01579765	chr21:45077557	HSF2BP	-0.49	-8.75	-0.47	2.54e-16	Mean corpuscular volume;
CESC	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg26354017	chr1:205819088	PM20D1	0.84	12.93	0.62	5.49e-30	Menarche (age at onset);
CESC	cis	rs9811920	0.809	rs4928153	chr3:99808445	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.46	-7.53	-0.42	8.23e-13	Axial length;
CESC	cis	rs8028182	0.636	rs4545784	chr15:75755651	A/G	cg20655648	chr15:75932815	IMP3	0.49	6.33	0.36	1.05e-9	Sudden cardiac arrest;
CESC	cis	rs9457247	0.935	rs401260	chr6:167405888	T/C	cg23791538	chr6:167370224	RNASET2	-0.59	-8.54	-0.46	1.09e-15	Crohn's disease;
CESC	cis	rs875971	1.000	rs2087647	chr7:65593188	C/A	cg12463550	chr7:65579703	CRCP	-0.56	-7.23	-0.41	5.19e-12	Aortic root size;
CESC	cis	rs2576037	0.526	rs8095373	chr18:44527895	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.54	-7.5	-0.42	9.68e-13	Personality dimensions;
CESC	cis	rs7953249	0.502	rs1169294	chr12:121426594	G/A	cg02403541	chr12:121454288	C12orf43	0.63	8.23	0.45	8.41e-15	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
CESC	cis	rs4665809	0.590	rs6730317	chr2:26419482	C/T	cg25036284	chr2:26402008	FAM59B	-0.85	-10.07	-0.53	2.12e-20	Gut microbiome composition (summer);
CESC	cis	rs13108904	0.870	rs1960426	chr4:1274365	C/T	cg00684032	chr4:1343700	KIAA1530	0.43	6.37	0.36	8.23e-10	Obesity-related traits;
CESC	cis	rs2845885	0.793	rs57779243	chr11:63882363	G/T	cg26318627	chr11:63887540	MACROD1	-0.46	-5.46	-0.32	1.1e-7	Body mass index;
CESC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg04674357	chr15:31745729	NA	-0.42	-6.13	-0.35	3.09e-9	Intelligence (multi-trait analysis);
CESC	cis	rs7223966	1.000	rs8064261	chr17:61705212	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.56	6.64	0.38	1.8e-10	Hip circumference adjusted for BMI;Body mass index;
CESC	trans	rs10435719	0.902	rs4840599	chr8:11805380	C/T	cg15556689	chr8:8085844	FLJ10661	-0.53	-6.64	-0.38	1.75e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
CESC	cis	rs11676348	0.818	rs1126579	chr2:219000734	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.46	-6.08	-0.35	4.18e-9	Ulcerative colitis;
CESC	cis	rs9733	0.596	rs72702536	chr1:150662574	C/T	cg22823121	chr1:150693482	HORMAD1	0.48	7.12	0.4	1.04e-11	Tonsillectomy;
CESC	cis	rs12765878	1.000	rs11191848	chr10:105650837	T/C	cg11005552	chr10:105648138	OBFC1	0.34	5.05	0.3	8.35e-7	Coronary artery disease;
CESC	cis	rs17021463	0.643	rs6841656	chr4:95300532	A/G	cg11021082	chr4:95130006	SMARCAD1	0.51	7.12	0.4	1.03e-11	Testicular germ cell tumor;
CESC	cis	rs6951245	0.507	rs11976805	chr7:1138716	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.43	-6.04	-0.35	5.25e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs10504229	0.575	rs78075335	chr8:57997243	A/C	cg24829409	chr8:58192753	C8orf71	-0.42	-5.5	-0.32	8.75e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs17209837	0.607	rs2072384	chr7:87082868	A/T	cg00919237	chr7:87102261	ABCB4	-0.51	-6.58	-0.37	2.45e-10	Gallbladder cancer;
CESC	cis	rs7613875	0.663	rs6762477	chr3:50093209	G/A	cg24308560	chr3:49941425	MST1R	0.58	8.37	0.46	3.27e-15	Body mass index;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg10501177	chr8:17435088	PDGFRL	0.44	6.08	0.35	4.15e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs3740540	0.507	rs897292	chr10:126290035	A/G	cg04949429	chr10:126290192	LHPP	0.39	5.49	0.32	9.29e-8	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
CESC	cis	rs9325144	0.723	rs11169518	chr12:39177237	C/A	cg26384229	chr12:38710491	ALG10B	-0.52	-7.43	-0.42	1.46e-12	Morning vs. evening chronotype;
CESC	cis	rs7618915	0.571	rs34954168	chr3:52612159	C/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.33	5.8	0.34	1.87e-8	Bipolar disorder;
CESC	cis	rs8058578	1.000	rs8058578	chr16:30726248	C/T	cg02466173	chr16:30829666	NA	-0.46	-7.36	-0.41	2.28e-12	Multiple myeloma;
CESC	cis	rs798766	0.779	rs55895920	chr4:1735930	C/T	cg10756475	chr4:1757242	NA	0.47	6.1	0.35	3.81e-9	Bladder cancer;Urinary bladder cancer;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg10883266	chr13:100741297	PCCA	-0.41	-6.25	-0.36	1.65e-9	Gambling;
CESC	cis	rs3736485	0.873	rs12441759	chr15:51755033	C/A	cg08986416	chr15:51914746	DMXL2	-0.41	-5.23	-0.31	3.37e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15163040	chr3:167813423	GOLIM4	0.53	6.03	0.35	5.63e-9	Gut microbiome composition (summer);
CESC	cis	rs992157	0.698	rs6746089	chr2:219170377	A/G	cg00012203	chr2:219082015	ARPC2	0.74	9.77	0.51	1.94e-19	Colorectal cancer;
CESC	cis	rs7927771	0.832	rs55677087	chr11:47397714	C/G	cg05585544	chr11:47624801	NA	-0.48	-7.06	-0.4	1.47e-11	Subjective well-being;
CESC	cis	rs2274273	0.901	rs10140801	chr14:55730404	C/T	cg04306507	chr14:55594613	LGALS3	0.3	5.93	0.34	9.63e-9	Protein biomarker;
CESC	cis	rs17253792	0.822	rs10129890	chr14:56040413	A/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.81	6.32	0.36	1.08e-9	Putamen volume;
CESC	cis	rs11098499	0.863	rs11723090	chr4:120490592	T/C	cg09307838	chr4:120376055	NA	0.91	12.59	0.61	8.49e-29	Corneal astigmatism;
CESC	cis	rs12681288	0.676	rs7459467	chr8:999359	C/T	cg04851639	chr8:1020857	NA	-0.33	-7.03	-0.4	1.76e-11	Schizophrenia;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg22146484	chr8:57123862	CHCHD7;PLAG1	-0.47	-6.17	-0.35	2.58e-9	Height;
CESC	trans	rs7246657	0.943	rs1373991	chr19:37838911	T/C	cg24637308	chr11:6592297	DNHD1	0.53	6.17	0.35	2.55e-9	Coronary artery calcification;
CESC	cis	rs9796	0.870	rs4923890	chr15:41258990	T/C	cg18705301	chr15:41695430	NDUFAF1	0.4	6.03	0.35	5.36e-9	Menopause (age at onset);
CESC	cis	rs733175	0.855	rs10022499	chr4:10006537	C/A	cg11266682	chr4:10021025	SLC2A9	0.39	5.26	0.31	2.93e-7	Psychosis and Alzheimer's disease;
CESC	cis	rs9487051	0.676	rs6568567	chr6:109596993	A/G	cg21918786	chr6:109611834	NA	-0.38	-5.52	-0.32	8.19e-8	Reticulocyte fraction of red cells;
CESC	cis	rs7084402	0.967	rs10763551	chr10:60273898	G/A	cg07615347	chr10:60278583	BICC1	-0.58	-9.07	-0.49	2.75e-17	Refractive error;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg20770540	chr3:123304003	PTPLB	-0.47	-6.16	-0.35	2.68e-9	Fibrinogen levels;
CESC	cis	rs1552244	0.882	rs13099136	chr3:10031431	G/A	cg00149659	chr3:10157352	C3orf10	0.71	8.45	0.46	2.01e-15	Alzheimer's disease;
CESC	cis	rs4722166	0.630	rs12700390	chr7:22777129	G/T	cg05265849	chr7:22767390	IL6	0.57	7.11	0.4	1.06e-11	Lung cancer;
CESC	cis	rs7412746	0.611	rs36008098	chr1:150856806	G/A	cg22823121	chr1:150693482	HORMAD1	0.39	5.47	0.32	1.05e-7	Melanoma;
CESC	cis	rs10504229	0.683	rs16921810	chr8:58106067	A/G	cg22535103	chr8:58192502	C8orf71	-0.77	-8.76	-0.47	2.37e-16	Developmental language disorder (linguistic errors);
CESC	cis	rs4819052	1.000	rs28628220	chr21:46663741	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.87	11.36	0.57	1.21e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs10504229	1.000	rs73609760	chr8:58192170	A/G	cg05313129	chr8:58192883	C8orf71	-0.53	-6.02	-0.35	5.63e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs17376456	0.877	rs17083455	chr5:93446380	A/C	cg21475434	chr5:93447410	FAM172A	0.81	7.64	0.42	3.93e-13	Diabetic retinopathy;
CESC	trans	rs1728785	1.000	rs3203684	chr16:68600440	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.63	-7.67	-0.43	3.32e-13	Ulcerative colitis;
CESC	trans	rs1814175	0.935	rs11040465	chr11:49689323	C/T	cg15704280	chr7:45808275	SEPT13	-1.0	-17.52	-0.73	3.71e-46	Height;
CESC	cis	rs9649465	0.967	rs12537072	chr7:123377213	A/G	cg04330084	chr7:123175371	IQUB	-0.38	-5.18	-0.3	4.46e-7	Migraine;
CESC	cis	rs9649213	0.593	rs7796611	chr7:97908223	A/G	cg21770322	chr7:97807741	LMTK2	0.55	8.18	0.45	1.16e-14	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs3091242	0.933	rs28633797	chr1:25741629	C/A	cg12412775	chr1:25698385	RHCE	-0.3	-5.37	-0.31	1.7e-7	Erythrocyte sedimentation rate;
CESC	cis	rs4862750	0.872	rs13143414	chr4:187878213	G/A	cg22105103	chr4:187893119	NA	0.45	6.61	0.38	2.05e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4474465	0.688	rs4277140	chr11:78285096	G/T	cg27205649	chr11:78285834	NARS2	-0.48	-6.2	-0.36	2.21e-9	Alzheimer's disease (survival time);
CESC	cis	rs6088590	0.561	rs6059934	chr20:33178324	G/T	cg08999081	chr20:33150536	PIGU	0.7	12.48	0.61	1.97e-28	Coronary artery disease;
CESC	cis	rs11638352	1.000	rs2733203	chr15:44415602	G/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.61	-5.62	-0.33	4.75e-8	Lipoprotein phospholipase A2 activity in cardiovascular disease;
CESC	cis	rs9467711	0.606	rs28360517	chr6:26602453	A/G	cg14345882	chr6:26364793	BTN3A2	0.56	6.06	0.35	4.58e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs425277	1.000	rs55826501	chr1:2059143	G/A	cg16545954	chr1:2118288	C1orf86	0.33	5.53	0.32	7.52e-8	Height;
CESC	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg24846343	chr22:24311635	DDTL	0.64	10.95	0.56	2.8e-23	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	22.16	0.81	2.75e-62	Prudent dietary pattern;
CESC	cis	rs4243830	0.850	rs7552196	chr1:6590502	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.81	-8.27	-0.45	6.59e-15	Body mass index;
CESC	cis	rs1448094	0.511	rs10735486	chr12:86154352	T/A	cg02569458	chr12:86230093	RASSF9	-0.42	-6.46	-0.37	4.89e-10	Major depressive disorder;
CESC	trans	rs561341	0.941	rs4525554	chr17:30312819	T/C	cg20587970	chr11:113659929	NA	-1.41	-18.23	-0.75	1.08e-48	Hip circumference adjusted for BMI;
CESC	cis	rs6991838	0.584	rs7459944	chr8:66478275	T/C	cg13398993	chr8:66546079	ARMC1	-0.44	-5.37	-0.31	1.75e-7	Intelligence (multi-trait analysis);
CESC	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg07677032	chr17:61819896	STRADA	0.45	6.05	0.35	5.02e-9	Prudent dietary pattern;
CESC	cis	rs763121	0.853	rs6001173	chr22:39015302	A/G	cg06022373	chr22:39101656	GTPBP1	0.94	16.75	0.72	1.86e-43	Menopause (age at onset);
CESC	cis	rs7944584	0.545	rs7118178	chr11:47659135	G/A	cg03711944	chr11:47377212	SPI1	-0.34	-5.33	-0.31	2.09e-7	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CESC	cis	rs2839186	0.771	rs13049175	chr21:47641326	G/A	cg10351095	chr21:47802916	PCNT	0.46	6.35	0.36	9.45e-10	Testicular germ cell tumor;
CESC	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg23708337	chr7:1209742	NA	0.55	5.41	0.32	1.41e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs7726839	0.540	rs72705097	chr5:655067	G/A	cg25482853	chr8:67687455	SGK3	0.92	9.68	0.51	3.5e-19	Obesity-related traits;
CESC	trans	rs1728785	1.000	rs889561	chr16:68605741	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.71	8.47	0.46	1.69e-15	Ulcerative colitis;
CESC	cis	rs6987853	0.966	rs2974349	chr8:42404040	A/G	cg09913449	chr8:42400586	C8orf40	-0.4	-5.91	-0.34	1.08e-8	Mean corpuscular hemoglobin concentration;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg25810927	chr2:84686638	SUCLG1	0.51	6.77	0.38	8.09e-11	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs9399137	0.507	rs6923512	chr6:135335268	A/G	cg24558204	chr6:135376177	HBS1L	-0.7	-9.52	-0.5	1.12e-18	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	cis	rs9811920	0.570	rs1021102	chr3:99603780	T/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.59	7.22	0.41	5.61e-12	Axial length;
CESC	cis	rs9322193	0.923	rs7769101	chr6:150169904	C/A	cg07701084	chr6:150067640	NUP43	0.47	6.12	0.35	3.44e-9	Lung cancer;
CESC	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg23034840	chr1:205782522	SLC41A1	0.66	7.9	0.44	7.59e-14	Menarche (age at onset);
CESC	cis	rs7818345	0.595	rs58551730	chr8:19316627	T/A	cg11303988	chr8:19266685	CSGALNACT1	0.35	5.34	0.31	2.02e-7	Language performance in older adults (adjusted for episodic memory);
CESC	cis	rs9611565	0.659	rs169361	chr22:41877989	A/G	cg06481639	chr22:41940642	POLR3H	0.64	6.51	0.37	3.83e-10	Vitiligo;
CESC	cis	rs116095464	0.558	rs10055993	chr5:264296	A/C	cg22857025	chr5:266934	NA	-1.32	-13.72	-0.64	9.72e-33	Breast cancer;
CESC	cis	rs9926296	0.585	rs6500450	chr16:89858024	A/G	cg04287289	chr16:89883240	FANCA	0.88	14.67	0.67	4.58e-36	Vitiligo;
CESC	cis	rs2439831	0.867	rs4075674	chr15:43650230	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.84	12.1	0.6	4.05e-27	Lung cancer in ever smokers;
CESC	cis	rs6540559	0.673	rs17015218	chr1:209967915	A/G	cg10074409	chr1:209979377	IRF6	0.4	5.47	0.32	1.02e-7	Cleft lip with or without cleft palate;
CESC	cis	rs1568889	0.838	rs716366	chr11:28121536	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.79	13.26	0.63	3.98e-31	Bipolar disorder;
CESC	cis	rs2839186	0.814	rs13052376	chr21:47707403	G/C	cg10351095	chr21:47802916	PCNT	-0.5	-6.8	-0.39	7.02e-11	Testicular germ cell tumor;
CESC	cis	rs7927771	0.965	rs17788930	chr11:47752775	A/G	cg20307385	chr11:47447363	PSMC3	-0.5	-6.18	-0.35	2.41e-9	Subjective well-being;
CESC	cis	rs4843747	0.708	rs11866437	chr16:88072279	A/G	cg09044154	chr16:88155775	NA	0.44	5.27	0.31	2.87e-7	Menopause (age at onset);
CESC	cis	rs3126085	0.935	rs11583524	chr1:152161657	T/C	cg03465714	chr1:152285911	FLG	0.46	5.38	0.31	1.61e-7	Atopic dermatitis;
CESC	cis	rs1552244	1.000	rs6786638	chr3:10118075	G/C	cg00149659	chr3:10157352	C3orf10	0.73	8.73	0.47	2.9e-16	Alzheimer's disease;
CESC	cis	rs7666738	0.830	rs114722517	chr4:99042061	G/A	cg17366294	chr4:99064904	C4orf37	0.61	8.78	0.47	2.13e-16	Colonoscopy-negative controls vs population controls;
CESC	trans	rs526821	0.574	rs11230156	chr11:55334809	A/G	cg15704280	chr7:45808275	SEPT13	-0.51	-6.3	-0.36	1.2e-9	Pediatric bone mineral density (spine);
CESC	cis	rs748404	0.560	rs2255663	chr15:43829008	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.52	-6.72	-0.38	1.1e-10	Lung cancer;
CESC	cis	rs4819052	0.851	rs28501512	chr21:46676702	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.95	14.1	0.65	4.6e-34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs1707322	0.963	rs11211229	chr1:46400517	A/C	cg03146154	chr1:46216737	IPP	0.72	9.82	0.52	1.31e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs1559088	0.576	rs11084707	chr19:33612873	C/T	cg17764715	chr19:33622953	WDR88	0.59	8.43	0.46	2.31e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs4588572	0.643	rs10044028	chr5:77794750	C/T	cg11547950	chr5:77652471	NA	0.43	5.48	0.32	1.01e-7	Triglycerides;
CESC	cis	rs10979	0.964	rs9496682	chr6:143898805	A/G	cg25407410	chr6:143891975	LOC285740	-0.6	-9.01	-0.48	4.13e-17	Hypospadias;
CESC	cis	rs9611565	0.649	rs139540	chr22:42178040	C/T	cg06481639	chr22:41940642	POLR3H	-0.47	-5.36	-0.31	1.8e-7	Vitiligo;
CESC	cis	rs2742234	0.614	rs3026750	chr10:43607756	G/A	cg07801480	chr10:43725741	RASGEF1A	0.37	5.22	0.31	3.7e-7	Hirschsprung disease;
CESC	cis	rs1538970	0.816	rs3790583	chr1:45956828	C/G	cg03146154	chr1:46216737	IPP	0.49	5.57	0.32	6.31e-8	Platelet count;
CESC	cis	rs7824557	0.628	rs11991153	chr8:11203107	A/T	cg21775007	chr8:11205619	TDH	0.58	8.95	0.48	6.5e-17	Retinal vascular caliber;
CESC	cis	rs7660520	0.524	rs4862100	chr4:183732709	G/T	cg03209412	chr4:183728196	NA	0.58	5.16	0.3	4.83e-7	Pediatric autoimmune diseases;
CESC	cis	rs6460942	0.687	rs74753576	chr7:12463926	G/A	cg17427002	chr7:12443146	VWDE	-0.48	-5.33	-0.31	2.06e-7	Coronary artery disease;
CESC	cis	rs9660992	0.710	rs1172138	chr1:205246019	G/A	cg00857998	chr1:205179979	DSTYK	0.47	5.41	0.32	1.41e-7	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs561341	0.941	rs7215147	chr17:30266711	G/A	cg12193833	chr17:30244370	NA	-0.51	-5.75	-0.33	2.4e-8	Hip circumference adjusted for BMI;
CESC	cis	rs9640161	0.673	rs34489187	chr7:150044379	G/A	cg10018233	chr7:150070692	REPIN1	0.38	5.3	0.31	2.39e-7	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs524281	0.954	rs549187	chr11:65898631	C/T	cg14036092	chr11:66035641	RAB1B	-0.52	-6.11	-0.35	3.61e-9	Electroencephalogram traits;
CESC	cis	rs4665809	1.000	rs11126364	chr2:26314515	A/G	cg25036284	chr2:26402008	FAM59B	-0.61	-7.08	-0.4	1.31e-11	Gut microbiome composition (summer);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg05980726	chr4:1138767	NA	0.45	6.17	0.35	2.6e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs7998202	0.668	rs2774422	chr13:113352392	C/T	cg02820901	chr13:113351484	ATP11A	0.63	5.85	0.34	1.41e-8	Glycated hemoglobin levels;
CESC	cis	rs35306767	0.903	rs35567307	chr10:915804	G/C	cg26597838	chr10:835615	NA	0.87	9.15	0.49	1.55e-17	Eosinophil percentage of granulocytes;
CESC	cis	rs7618915	0.547	rs11130315	chr3:52697163	A/G	cg07507251	chr3:52567010	NT5DC2	0.4	7.1	0.4	1.15e-11	Bipolar disorder;
CESC	cis	rs9291683	0.588	rs34501273	chr4:9996996	C/T	cg00071950	chr4:10020882	SLC2A9	0.82	15.01	0.68	2.81e-37	Bone mineral density;
CESC	cis	rs10256972	0.684	rs2363279	chr7:1096143	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.48	-6.02	-0.35	5.87e-9	Longevity;Endometriosis;
CESC	cis	rs10504229	0.679	rs11783963	chr8:58130496	T/A	cg02725872	chr8:58115012	NA	-0.45	-7.05	-0.4	1.52e-11	Developmental language disorder (linguistic errors);
CESC	trans	rs9325144	0.555	rs6582607	chr12:38717678	T/C	cg23762105	chr12:34175262	ALG10	0.49	6.24	0.36	1.76e-9	Morning vs. evening chronotype;
CESC	cis	rs1211375	0.606	rs1203977	chr16:256278	A/C	cg00126636	chr16:237282	NA	0.41	6.22	0.36	1.92e-9	Hematology traits;Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	cis	rs6582630	0.555	rs11182202	chr12:38476451	C/G	cg13010199	chr12:38710504	ALG10B	0.47	6.11	0.35	3.63e-9	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs2070433	0.756	rs2839295	chr21:47917871	A/T	cg12379764	chr21:47803548	PCNT	0.51	6.19	0.36	2.33e-9	Lymphocyte counts;
CESC	cis	rs13095912	0.889	rs34765114	chr3:185335156	T/A	cg11274856	chr3:185301563	NA	0.34	5.35	0.31	1.94e-7	Systolic blood pressure;
CESC	cis	rs7208859	0.623	rs8082537	chr17:29015932	T/C	cg14008862	chr17:28927542	LRRC37B2	0.59	5.1	0.3	6.35e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs4862750	0.872	rs6830828	chr4:187897472	T/G	cg03647317	chr4:187891568	NA	-0.39	-5.8	-0.34	1.88e-8	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs172166	0.611	rs203883	chr6:28078356	A/G	cg12963246	chr6:28129442	ZNF389	0.43	6.31	0.36	1.15e-9	Cardiac Troponin-T levels;
CESC	cis	rs4689388	0.926	rs4689391	chr4:6280449	G/A	cg14416269	chr4:6271139	WFS1	0.48	7.99	0.44	4.16e-14	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs7089973	0.604	rs7904188	chr10:116610271	G/C	cg23260525	chr10:116636907	FAM160B1	0.4	7.2	0.4	6.31e-12	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs4665809	0.556	rs1560869	chr2:26417095	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.08	-13.24	-0.63	4.53e-31	Gut microbiome composition (summer);
CESC	cis	rs10504229	0.679	rs17800895	chr8:58050085	A/G	cg24829409	chr8:58192753	C8orf71	-0.68	-7.53	-0.42	7.94e-13	Developmental language disorder (linguistic errors);
CESC	cis	rs3020736	0.519	rs5996116	chr22:42517492	G/A	cg15557168	chr22:42548783	NA	0.45	6.51	0.37	3.78e-10	Autism spectrum disorder or schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26162020	chr7:48964031	CDC14C	-0.55	-6.38	-0.36	7.98e-10	Gut microbiome composition (summer);
CESC	cis	rs9733	0.596	rs12089989	chr1:150715782	G/A	cg13175981	chr1:150552382	MCL1	-0.4	-5.1	-0.3	6.53e-7	Tonsillectomy;
CESC	cis	rs11191270	0.554	rs11191275	chr10:104142800	C/T	cg15320455	chr10:103880129	LDB1	0.58	5.25	0.31	3.11e-7	Intelligence (multi-trait analysis);
CESC	cis	rs853679	0.517	rs9380055	chr6:28081629	A/G	cg19592336	chr6:28129416	ZNF389	0.6	7.98	0.44	4.4e-14	Depression;
CESC	cis	rs4654899	0.965	rs61781115	chr1:21322860	C/T	cg05370193	chr1:21551575	ECE1	0.41	6.3	0.36	1.21e-9	Superior frontal gyrus grey matter volume;
CESC	cis	rs12530845	1.000	rs12540688	chr7:135329690	T/C	cg23117316	chr7:135346802	PL-5283	-0.41	-5.29	-0.31	2.52e-7	Red blood cell traits;
CESC	cis	rs6691722	0.503	rs6656485	chr1:24707685	A/G	cg02336364	chr1:24764700	NIPAL3	0.32	6.58	0.37	2.56e-10	Response to interferon beta in multiple sclerosis;
CESC	cis	rs9486719	1.000	rs13208422	chr6:96892119	C/T	cg18709589	chr6:96969512	KIAA0776	-0.53	-5.81	-0.34	1.75e-8	Migraine;Coronary artery disease;
CESC	cis	rs9811920	0.809	rs793443	chr3:99573547	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.38	-5.09	-0.3	6.84e-7	Axial length;
CESC	cis	rs9902453	0.967	rs4356528	chr17:28489670	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	7.74	0.43	2.08e-13	Coffee consumption (cups per day);
CESC	cis	rs875971	0.660	rs7807944	chr7:66087195	C/G	cg11764359	chr7:65958608	NA	-0.72	-9.54	-0.51	1e-18	Aortic root size;
CESC	cis	rs4891159	0.790	rs689885	chr18:74110563	T/G	cg24786174	chr18:74118243	ZNF516	0.75	11.79	0.59	4.61e-26	Longevity;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27331401	chr3:37035207	MLH1;EPM2AIP1	0.55	6.39	0.37	7.61e-10	Gut microbiome composition (summer);
CESC	cis	rs55728055	0.661	rs16989760	chr22:31951808	A/G	cg01338084	chr22:32026380	PISD	1.26	8.09	0.44	2.21e-14	Age-related hearing impairment;
CESC	cis	rs9896933	0.623	rs77166830	chr17:80833525	T/C	cg19500275	chr17:80737654	TBCD	0.62	5.88	0.34	1.23e-8	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
CESC	cis	rs7143963	0.666	rs8008502	chr14:103359492	G/A	cg24154132	chr14:103367632	TRAF3	0.36	6.22	0.36	1.88e-9	Body mass index;
CESC	cis	rs7107174	0.892	rs4291702	chr11:78001248	C/T	cg02023728	chr11:77925099	USP35	0.42	6.22	0.36	1.88e-9	Testicular germ cell tumor;
CESC	cis	rs4654899	0.644	rs6669077	chr1:21290520	A/C	cg05370193	chr1:21551575	ECE1	0.36	5.4	0.31	1.49e-7	Superior frontal gyrus grey matter volume;
CESC	cis	rs9311474	0.967	rs11717383	chr3:52287468	G/T	cg05564831	chr3:52568323	NT5DC2	0.43	6.94	0.39	3.05e-11	Electroencephalogram traits;
CESC	cis	rs7552404	0.961	rs211710	chr1:76109038	G/A	cg03433033	chr1:76189801	ACADM	-0.6	-6.89	-0.39	4.03e-11	Blood metabolite levels;Acylcarnitine levels;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg18976797	chr7:56434617	NA	-0.34	-6.2	-0.36	2.14e-9	Asthma;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03357160	chr6:42531879	UBR2	0.6	7.34	0.41	2.69e-12	Gut microbiome composition (summer);
CESC	cis	rs9916302	0.718	rs10445306	chr17:37591422	A/G	cg07936489	chr17:37558343	FBXL20	-0.8	-11.5	-0.58	4.29e-25	Glomerular filtration rate (creatinine);
CESC	cis	rs67478160	0.571	rs1155751	chr14:104286547	C/G	cg08213375	chr14:104286397	PPP1R13B	0.53	10.58	0.55	4.57e-22	Schizophrenia;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg13647821	chr6:148852503	SASH1	0.41	6.12	0.35	3.31e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs875971	1.000	rs6945843	chr7:65734783	G/A	cg18876405	chr7:65276391	NA	-0.53	-7.29	-0.41	3.66e-12	Aortic root size;
CESC	cis	rs36051895	0.623	rs6476956	chr9:5261238	A/G	cg02405213	chr9:5042618	JAK2	-0.51	-6.28	-0.36	1.41e-9	Pediatric autoimmune diseases;
CESC	cis	rs1448094	0.511	rs17279464	chr12:86164473	C/T	cg00310523	chr12:86230176	RASSF9	0.35	5.7	0.33	3.22e-8	Major depressive disorder;
CESC	cis	rs12479064	0.671	rs4851207	chr2:100105775	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.65	-7.42	-0.41	1.6e-12	Chronic sinus infection;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12184120	chr19:38188083	ZNF607	-0.45	-5.99	-0.35	6.67e-9	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08886844	chr19:8373286	CD320	0.58	6.27	0.36	1.43e-9	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01676552	chr8:146156633	ZNF16	-0.6	-6.59	-0.38	2.3e-10	Gut microbiome composition (summer);
CESC	cis	rs7772486	0.875	rs1125461	chr6:146417653	C/T	cg23711669	chr6:146136114	FBXO30	0.84	12.04	0.59	6.45e-27	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs300703	0.872	rs428697	chr2:213302	G/A	cg21211680	chr2:198530	NA	0.98	8.48	0.46	1.64e-15	Blood protein levels;
CESC	cis	rs9291683	0.551	rs2240720	chr4:10020480	C/T	cg11266682	chr4:10021025	SLC2A9	0.72	14.84	0.67	1.1e-36	Bone mineral density;
CESC	cis	rs8016982	0.634	rs1035948	chr14:81682392	C/T	cg01989461	chr14:81687754	GTF2A1	0.74	11.59	0.58	2.12e-25	Schizophrenia;
CESC	cis	rs2073300	1.000	rs34449811	chr20:23443771	T/C	cg12062639	chr20:23401060	NAPB	0.91	6.41	0.37	6.71e-10	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs10870270	0.956	rs7904594	chr10:133734671	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.62	-8.06	-0.44	2.63e-14	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs5769707	0.935	rs5770594	chr22:50018497	G/A	cg20744362	chr22:50050164	C22orf34	0.46	8.08	0.44	2.23e-14	Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs864537	0.676	rs3108155	chr1:167422057	C/G	cg09179987	chr1:167433047	CD247	0.5	7.56	0.42	6.54e-13	Celiac disease or Rheumatoid arthritis;Celiac disease;
CESC	cis	rs17401966	0.894	rs11587309	chr1:10446596	G/T	cg15208524	chr1:10270712	KIF1B	0.41	5.29	0.31	2.61e-7	Hepatocellular carcinoma;
CESC	cis	rs11785400	1.000	rs6997771	chr8:143747752	T/G	cg10596483	chr8:143751796	JRK	0.43	5.63	0.33	4.59e-8	Schizophrenia;
CESC	cis	rs9649465	0.522	rs662705	chr7:123431594	A/C	cg03229431	chr7:123269106	ASB15	0.4	5.52	0.32	8.08e-8	Migraine;
CESC	cis	rs1506636	1.000	rs2215553	chr7:123318478	G/T	cg03229431	chr7:123269106	ASB15	-0.51	-6.74	-0.38	9.6e-11	Plateletcrit;Platelet count;
CESC	cis	rs2243480	1.000	rs2460422	chr7:65601505	C/T	cg13147721	chr7:65941812	NA	-0.98	-9.24	-0.49	8.33e-18	Diabetic kidney disease;
CESC	cis	rs2880765	0.835	rs2170736	chr15:86043398	A/G	cg19183879	chr15:85880815	NA	-0.25	-5.18	-0.3	4.31e-7	Coronary artery disease;
CESC	cis	rs7605827	0.930	rs10929366	chr2:15531754	C/T	cg19274914	chr2:15703543	NA	0.35	6.36	0.36	8.62e-10	Educational attainment (years of education);
CESC	cis	rs6541297	0.703	rs653523	chr1:230318402	C/T	cg20703242	chr1:230279135	GALNT2	-0.44	-5.77	-0.33	2.27e-8	Coronary artery disease;
CESC	cis	rs9868809	0.772	rs9841602	chr3:48713570	A/G	cg07636037	chr3:49044803	WDR6	-0.56	-5.17	-0.3	4.72e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs2549003	1.000	rs6894655	chr5:131818649	T/C	cg21138405	chr5:131827807	IRF1	0.54	9.25	0.49	8e-18	Asthma (sex interaction);
CESC	cis	rs2637266	1.000	rs2395388	chr10:78357203	C/T	cg18941641	chr10:78392320	NA	0.42	7.79	0.43	1.49e-13	Pulmonary function;
CESC	cis	rs796364	0.806	rs11688194	chr2:200916239	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.85	-7.93	-0.44	6.07e-14	Schizophrenia;
CESC	cis	rs6547741	1.000	rs1919126	chr2:27801418	C/A	cg27432699	chr2:27873401	GPN1	0.5	7.01	0.4	2.01e-11	Oral cavity cancer;
CESC	cis	rs1355223	1.000	rs11601923	chr11:34764354	C/G	cg11058730	chr11:34937778	PDHX;APIP	-0.46	-5.99	-0.35	6.91e-9	Systemic lupus erythematosus and Systemic sclerosis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09166770	chr16:30941758	FBXL19	-0.61	-6.7	-0.38	1.25e-10	Gut microbiome composition (summer);
CESC	cis	rs6701037	1.000	rs6681020	chr1:175125264	G/A	cg00321850	chr1:175162397	KIAA0040	-0.42	-5.88	-0.34	1.22e-8	Alcohol dependence;
CESC	cis	rs1008375	1.000	rs11737138	chr4:17657986	G/A	cg16339924	chr4:17578868	LAP3	0.55	6.93	0.39	3.22e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs4566357	0.615	rs2396445	chr2:227917726	C/G	cg05526886	chr2:227700861	RHBDD1	-0.54	-6.89	-0.39	4.01e-11	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27583038	chr1:234735904	NA	0.59	6.42	0.37	6.41e-10	Gut microbiome composition (summer);
CESC	cis	rs2721195	0.967	rs10108150	chr8:145687475	A/G	cg15320075	chr8:145703422	NA	-0.41	-5.74	-0.33	2.55e-8	Age at first birth;
CESC	cis	rs6461049	0.734	rs1558465	chr7:2151398	G/C	cg04267008	chr7:1944627	MAD1L1	-0.48	-5.52	-0.32	8.26e-8	Schizophrenia;
CESC	cis	rs3809566	0.963	rs12148057	chr15:63331509	A/T	cg05507819	chr15:63340323	TPM1	0.52	6.37	0.36	8.15e-10	Platelet count;
CESC	cis	rs10206020	0.885	rs11886082	chr2:1576683	T/C	cg26248373	chr2:1572462	NA	-0.6	-6.73	-0.38	1.02e-10	IgG glycosylation;
CESC	trans	rs4950322	0.515	rs11239954	chr1:146717699	C/T	cg04954894	chr8:38089920	DDHD2	-0.51	-6.03	-0.35	5.49e-9	Protein quantitative trait loci;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23416307	chr4:858299	GAK	-0.56	-6.03	-0.35	5.63e-9	Gut microbiome composition (summer);
CESC	cis	rs9611565	0.512	rs5751153	chr22:42156561	T/C	cg06634786	chr22:41940651	POLR3H	0.7	7.03	0.4	1.8e-11	Vitiligo;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg19695842	chr20:19997930	NAA20	-0.49	-7.0	-0.4	2.14e-11	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs561341	0.882	rs563539	chr17:30307958	A/G	cg00745463	chr17:30367425	LRRC37B	-0.64	-6.4	-0.37	7.07e-10	Hip circumference adjusted for BMI;
CESC	cis	rs7811142	1.000	rs67471932	chr7:100009985	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.0	9.62	0.51	5.54e-19	Platelet count;
CESC	cis	rs6736093	0.966	rs13027171	chr2:112686988	G/A	cg12686935	chr2:112915763	FBLN7	-0.43	-5.56	-0.32	6.75e-8	Coronary artery disease;
CESC	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.48	-5.55	-0.32	7.08e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg11494091	chr17:61959527	GH2	0.71	12.04	0.59	6.33e-27	Prudent dietary pattern;
CESC	cis	rs4555082	0.874	rs2816626	chr14:105735425	G/A	cg13114125	chr14:105738426	BRF1	-0.91	-11.41	-0.57	8.44e-25	Mean platelet volume;Platelet distribution width;
CESC	cis	rs7666738	0.791	rs13120773	chr4:98972589	C/T	cg03676636	chr4:99064102	C4orf37	0.34	5.2	0.3	3.93e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1552244	0.872	rs7646073	chr3:10097405	G/A	cg00149659	chr3:10157352	C3orf10	0.7	8.38	0.46	3.2e-15	Alzheimer's disease;
CESC	cis	rs6951245	0.706	rs28522260	chr7:1183964	C/A	cg24642844	chr7:1081250	C7orf50	-0.64	-8.34	-0.46	4.05e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7833986	0.501	rs2667978	chr8:56897951	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.56	6.88	0.39	4.32e-11	Height;
CESC	cis	rs2204008	0.575	rs10444564	chr12:38043782	T/C	cg26384229	chr12:38710491	ALG10B	0.75	10.72	0.55	1.61e-22	Bladder cancer;
CESC	cis	rs11098499	0.955	rs13129661	chr4:120152909	C/G	cg09307838	chr4:120376055	NA	0.87	11.39	0.57	1.02e-24	Corneal astigmatism;
CESC	cis	rs765787	0.530	rs11636395	chr15:45535684	G/C	cg24006582	chr15:45444508	DUOX1	-0.54	-6.63	-0.38	1.84e-10	Uric acid levels;
CESC	cis	rs67311347	1.000	rs2276870	chr3:40499182	C/T	cg01475735	chr3:40494733	NA	0.45	5.51	0.32	8.33e-8	Renal cell carcinoma;
CESC	trans	rs12310956	0.532	rs7306007	chr12:33975209	C/G	cg26384229	chr12:38710491	ALG10B	0.5	6.82	0.39	5.98e-11	Morning vs. evening chronotype;
CESC	cis	rs9611565	0.546	rs739132	chr22:42123099	A/T	cg06481639	chr22:41940642	POLR3H	0.59	5.91	0.34	1.07e-8	Vitiligo;
CESC	cis	rs6540556	0.954	rs7548219	chr1:209936466	A/G	cg23920097	chr1:209922102	NA	-0.36	-5.35	-0.31	1.93e-7	Red blood cell count;
CESC	cis	rs2836974	0.931	rs2735306	chr21:40713134	A/G	cg27266027	chr21:40555129	PSMG1	-0.44	-5.22	-0.31	3.55e-7	Cognitive function;
CESC	cis	rs8002861	0.870	rs12865116	chr13:44440441	C/G	cg19180546	chr13:44453867	C13orf31;CCDC122	-0.43	-5.45	-0.32	1.14e-7	Leprosy;
CESC	cis	rs2361718	0.521	rs2361724	chr17:78099114	G/A	cg20811857	chr17:78079795	GAA	-0.43	-6.25	-0.36	1.63e-9	Yeast infection;
CESC	cis	rs3892630	0.824	rs35700505	chr19:33325006	C/T	cg22980127	chr19:33182716	NUDT19	1.03	11.5	0.58	4.17e-25	Red blood cell traits;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg25951811	chr14:96858416	AK7	-0.44	-6.0	-0.35	6.46e-9	Fibrinogen levels;
CESC	cis	rs9300255	0.739	rs4759417	chr12:123746510	C/T	cg00376283	chr12:123451042	ABCB9	0.71	8.92	0.48	7.64e-17	Neutrophil percentage of white cells;
CESC	cis	rs2522056	0.808	rs2706373	chr5:131804256	C/T	cg24060327	chr5:131705240	SLC22A5	0.61	6.89	0.39	4.17e-11	Lymphocyte counts;Fibrinogen;
CESC	cis	rs868036	1.000	rs6494694	chr15:68057142	A/C	cg08079166	chr15:68083412	MAP2K5	-0.44	-6.83	-0.39	5.7e-11	Restless legs syndrome;
CESC	cis	rs992157	0.835	rs2271543	chr2:219142491	C/T	cg00012203	chr2:219082015	ARPC2	-0.76	-9.55	-0.51	9.45e-19	Colorectal cancer;
CESC	cis	rs425277	0.585	rs2222217	chr1:2063164	G/A	cg19257562	chr1:2043853	PRKCZ	0.41	6.53	0.37	3.33e-10	Height;
CESC	cis	rs317689	0.718	rs645026	chr12:69757931	G/A	cg14784868	chr12:69753453	YEATS4	0.64	7.46	0.42	1.21e-12	Response to diuretic therapy;
CESC	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.55	7.27	0.41	4.11e-12	Lymphocyte counts;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg00450475	chr10:75118604	TTC18	-0.51	-6.15	-0.35	2.92e-9	Ulcerative colitis;
CESC	cis	rs796364	1.000	rs281771	chr2:200812202	A/C	cg23649088	chr2:200775458	C2orf69	-0.52	-5.33	-0.31	2.12e-7	Schizophrenia;
CESC	cis	rs6460942	0.659	rs28366613	chr7:12512167	C/T	cg20607287	chr7:12443886	VWDE	-0.66	-7.1	-0.4	1.16e-11	Coronary artery disease;
CESC	cis	rs780096	0.506	rs72819512	chr2:27614449	G/A	cg24768116	chr2:27665128	KRTCAP3	-0.29	-5.3	-0.31	2.42e-7	Total body bone mineral density;
CESC	cis	rs2486288	0.554	rs1719235	chr15:45576108	A/G	cg09092052	chr15:45571596	NA	0.47	5.65	0.33	4.16e-8	Glomerular filtration rate;
CESC	cis	rs7618915	0.571	rs7623199	chr3:52605974	C/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	5.67	0.33	3.7e-8	Bipolar disorder;
CESC	cis	rs1008375	1.000	rs10012335	chr4:17628630	C/G	cg04450456	chr4:17643702	FAM184B	0.41	5.79	0.33	2.03e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs1577917	1.000	rs12661204	chr6:86678586	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.49	-6.29	-0.36	1.32e-9	Response to antipsychotic treatment;
CESC	cis	rs2836974	0.829	rs34227163	chr21:40551943	A/G	cg11644478	chr21:40555479	PSMG1	1.01	16.79	0.72	1.35e-43	Cognitive function;
CESC	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg02071572	chr4:1403502	NA	0.39	5.64	0.33	4.28e-8	Longevity;
CESC	cis	rs7666738	0.830	rs17027090	chr4:98897923	G/T	cg17366294	chr4:99064904	C4orf37	0.57	7.86	0.43	9.47e-14	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2535633	0.631	rs2245424	chr3:53003021	G/C	cg11645453	chr3:52864694	ITIH4	-0.28	-5.34	-0.31	1.95e-7	Body mass index;
CESC	cis	rs6445797	0.632	rs2054988	chr3:56593170	G/A	cg13792233	chr3:56591045	CCDC66	0.38	5.04	0.3	8.76e-7	Gastritis;
CESC	trans	rs9987353	0.840	rs329994	chr8:9123233	A/G	cg09395855	chr10:120967408	GRK5	-0.48	-6.24	-0.36	1.73e-9	Recombination measurement;
CESC	cis	rs7811142	0.830	rs11761426	chr7:99956893	A/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.04	10.52	0.54	7.52e-22	Platelet count;
CESC	cis	rs1624802	1.000	rs1624802	chr12:130497472	C/T	cg15444478	chr12:130494697	NA	0.27	5.34	0.31	2.04e-7	Obesity-related traits;
CESC	cis	rs763121	0.853	rs5750668	chr22:39079964	T/C	cg06022373	chr22:39101656	GTPBP1	0.9	14.22	0.66	1.8e-34	Menopause (age at onset);
CESC	cis	rs2573652	0.674	rs11630583	chr15:100543355	G/A	cg09918751	chr15:100517450	ADAMTS17	-0.3	-5.57	-0.32	6.12e-8	Height;
CESC	cis	rs763121	0.853	rs2413544	chr22:39059404	A/C	cg06544989	chr22:39130855	UNC84B	0.49	8.49	0.46	1.53e-15	Menopause (age at onset);
CESC	cis	rs9296736	0.890	rs1359561	chr6:53899341	C/T	cg04374786	chr6:53939321	C6orf142	0.39	6.02	0.35	5.83e-9	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs477895	1.000	rs477895	chr11:64048912	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.56	-5.62	-0.33	4.9e-8	Mean platelet volume;
CESC	cis	rs6964587	0.869	rs406	chr7:91546526	C/A	cg17063962	chr7:91808500	NA	-0.52	-6.87	-0.39	4.7e-11	Breast cancer;
CESC	cis	rs59918340	0.764	rs10107024	chr8:142227592	T/C	cg23750338	chr8:142222470	SLC45A4	0.62	9.36	0.5	3.58e-18	Immature fraction of reticulocytes;
CESC	cis	rs7666738	0.830	rs6825211	chr4:98807698	A/T	cg03467027	chr4:99064603	C4orf37	0.43	5.47	0.32	1.02e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4722166	0.532	rs4719713	chr7:22758811	G/A	cg05472934	chr7:22766657	IL6	0.5	6.52	0.37	3.59e-10	Lung cancer;
CESC	cis	rs637571	0.522	rs12797319	chr11:65735672	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.42	6.16	0.35	2.75e-9	Eosinophil percentage of white cells;
CESC	cis	rs10504229	0.636	rs10958525	chr8:58051528	C/A	cg02725872	chr8:58115012	NA	-0.34	-5.2	-0.3	3.99e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs13191362	1.000	rs35449999	chr6:163023465	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.5	5.18	0.3	4.34e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs4665809	0.590	rs66477033	chr2:26472497	T/C	cg04944784	chr2:26401820	FAM59B	0.96	10.5	0.54	8.76e-22	Gut microbiome composition (summer);
CESC	cis	rs763121	0.853	rs2064088	chr22:39053382	A/G	cg06022373	chr22:39101656	GTPBP1	0.88	13.91	0.65	2.06e-33	Menopause (age at onset);
CESC	cis	rs1552244	1.000	rs2272123	chr3:10140115	G/A	cg16606324	chr3:10149918	C3orf24	0.41	5.09	0.3	6.8e-7	Alzheimer's disease;
CESC	cis	rs7618915	0.547	rs33967311	chr3:52683864	G/T	cg07507251	chr3:52567010	NT5DC2	0.36	6.46	0.37	5.02e-10	Bipolar disorder;
CESC	cis	rs9831754	0.756	rs2872626	chr3:78435049	A/T	cg06138941	chr3:78371609	NA	-0.48	-6.0	-0.35	6.33e-9	Calcium levels;
CESC	cis	rs769267	1.000	rs2074090	chr19:19449686	G/T	cg17414380	chr19:19431394	KIAA0892;SF4	-0.49	-6.06	-0.35	4.66e-9	Tonsillectomy;
CESC	cis	rs863345	0.604	rs12041350	chr1:158482048	A/G	cg12129480	chr1:158549410	OR10X1	-0.34	-6.74	-0.38	9.86e-11	Pneumococcal bacteremia;
CESC	cis	rs5769765	0.955	rs2295406	chr22:50260169	G/A	cg02269571	chr22:50332266	NA	0.47	6.29	0.36	1.3e-9	Schizophrenia;
CESC	cis	rs72949976	0.898	rs6732233	chr2:214022834	C/T	cg08319019	chr2:214017104	IKZF2	-0.42	-5.07	-0.3	7.37e-7	Lung cancer;Squamous cell lung carcinoma;
CESC	cis	rs1023500	0.505	rs2143139	chr22:42614401	G/C	cg15557168	chr22:42548783	NA	-0.41	-6.02	-0.35	5.69e-9	Schizophrenia;
CESC	cis	rs4253772	0.591	rs6008361	chr22:46652372	A/G	cg09491104	chr22:46646882	C22orf40	0.64	10.02	0.52	3.12e-20	LDL cholesterol;Cholesterol, total;
CESC	cis	rs4835473	0.897	rs6846984	chr4:144904251	G/C	cg25736465	chr4:144833511	NA	0.41	6.16	0.35	2.72e-9	Immature fraction of reticulocytes;
CESC	cis	rs68092024	0.704	rs704576	chr3:99487154	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.43	-6.77	-0.38	8.4e-11	Cleft lip with or without cleft palate;
CESC	cis	rs2635047	0.967	rs2247784	chr18:44746997	G/A	cg19077165	chr18:44547161	KATNAL2	-0.45	-6.0	-0.35	6.38e-9	Educational attainment;
CESC	cis	rs10883723	0.810	rs17782574	chr10:104279394	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.54	7.42	0.41	1.57e-12	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs1707322	0.682	rs28490344	chr1:46197948	C/T	cg06784218	chr1:46089804	CCDC17	0.43	7.58	0.42	5.65e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs763121	0.853	rs9622833	chr22:39000397	G/A	cg06022373	chr22:39101656	GTPBP1	0.84	12.31	0.6	7.77e-28	Menopause (age at onset);
CESC	cis	rs713587	0.624	rs1550110	chr2:25124563	T/C	cg01884057	chr2:25150051	NA	0.36	6.98	0.39	2.32e-11	Body mass index in non-asthmatics;
CESC	cis	rs4268898	0.717	rs2543662	chr2:24443271	G/T	cg20701182	chr2:24300061	SF3B14	-0.49	-5.72	-0.33	2.94e-8	Asthma;
CESC	cis	rs9811920	0.638	rs793503	chr3:99588070	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.55	6.72	0.38	1.1e-10	Axial length;
CESC	cis	rs514406	0.825	rs6588441	chr1:53223494	G/A	cg08859206	chr1:53392774	SCP2	0.53	7.09	0.4	1.19e-11	Monocyte count;
CESC	cis	rs6740322	0.901	rs2163228	chr2:43549246	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.6	-5.89	-0.34	1.19e-8	Coronary artery disease;
CESC	cis	rs2243480	1.000	rs1964692	chr7:65454183	G/A	cg25894440	chr7:65020034	NA	-0.65	-5.63	-0.33	4.5e-8	Diabetic kidney disease;
CESC	cis	rs7264396	0.790	rs2295355	chr20:34252654	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.66	7.92	0.44	6.7e-14	Total cholesterol levels;
CESC	cis	rs11122272	0.735	rs2486728	chr1:231535883	T/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.57	-7.73	-0.43	2.29e-13	Hemoglobin concentration;
CESC	cis	rs12926788	0.542	rs6497759	chr16:24801737	G/A	cg04756594	chr16:24857601	SLC5A11	0.45	5.53	0.32	7.79e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	trans	rs9833726	0.727	rs71318644	chr3:86129349	A/G	cg10416071	chr15:75628863	COMMD4	0.59	6.12	0.35	3.37e-9	Breast cancer;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg23967809	chr8:141647658	NA	-0.41	-6.14	-0.35	3.06e-9	Gambling;
CESC	cis	rs8060686	0.565	rs75735284	chr16:68126635	C/A	cg26727032	chr16:67993705	SLC12A4	-0.54	-6.05	-0.35	4.92e-9	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs2637266	1.000	rs3923670	chr10:78375001	C/G	cg18941641	chr10:78392320	NA	0.43	8.26	0.45	6.94e-15	Pulmonary function;
CESC	cis	rs10927875	1.000	rs3979179	chr1:16306846	A/G	cg21385522	chr1:16154831	NA	0.82	10.47	0.54	1.09e-21	Dilated cardiomyopathy;
CESC	cis	rs1904096	0.513	rs2632405	chr4:95152215	T/G	cg11021082	chr4:95130006	SMARCAD1	-0.7	-11.56	-0.58	2.74e-25	Type 2 diabetes;
CESC	cis	rs34375054	0.738	rs10846834	chr12:125625570	A/G	cg25124228	chr12:125621409	AACS	-0.54	-7.2	-0.4	6.37e-12	Post bronchodilator FEV1/FVC ratio;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01305483	chr7:935436	C7orf20	-0.55	-6.15	-0.35	2.85e-9	Gut microbiome composition (summer);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg15739904	chr8:125313885	NA	0.51	7.06	0.4	1.46e-11	Fibrinogen levels;
CESC	cis	rs853679	0.550	rs1225598	chr6:28160799	T/G	cg12963246	chr6:28129442	ZNF389	0.5	6.76	0.38	8.57e-11	Depression;
CESC	cis	rs17253792	0.822	rs10151664	chr14:56029533	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.73	5.52	0.32	8.19e-8	Putamen volume;
CESC	cis	rs769267	0.965	rs4808200	chr19:19554803	C/T	cg03709012	chr19:19516395	GATAD2A	1.01	14.94	0.68	5.1e-37	Tonsillectomy;
CESC	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.45	-5.61	-0.33	5.1e-8	Longevity;Endometriosis;
CESC	cis	rs7666738	0.753	rs34164013	chr4:98976333	A/G	cg05340658	chr4:99064831	C4orf37	0.79	12.26	0.6	1.12e-27	Colonoscopy-negative controls vs population controls;
CESC	cis	rs12497850	0.931	rs11924597	chr3:48937790	T/C	cg03060546	chr3:49711283	APEH	0.44	5.48	0.32	9.71e-8	Parkinson's disease;
CESC	cis	rs2033711	0.870	rs7409473	chr19:58939165	A/G	cg13877915	chr19:58951672	ZNF132	0.39	5.8	0.34	1.93e-8	Uric acid clearance;
CESC	cis	rs28374715	0.681	rs7162231	chr15:41591859	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.0	-14.55	-0.67	1.24e-35	Ulcerative colitis;
CESC	trans	rs35110281	0.776	rs9983763	chr21:44990578	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.56	-7.23	-0.41	5.32e-12	Mean corpuscular volume;
CESC	cis	rs909674	0.662	rs2899318	chr22:39837625	A/G	cg02038168	chr22:39784481	NA	-0.69	-8.61	-0.47	6.42e-16	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs7772486	0.651	rs1292338	chr6:145967471	A/C	cg05347473	chr6:146136440	FBXO30	-0.52	-6.83	-0.39	5.76e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7927771	0.524	rs2290851	chr11:47753370	C/T	cg18512352	chr11:47633146	NA	-0.36	-5.64	-0.33	4.36e-8	Subjective well-being;
CESC	cis	rs6582630	0.638	rs7963994	chr12:38555535	G/A	cg26384229	chr12:38710491	ALG10B	-0.39	-5.19	-0.3	4.24e-7	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs36051895	0.632	rs7040806	chr9:5174782	C/T	cg02405213	chr9:5042618	JAK2	-0.52	-6.65	-0.38	1.72e-10	Pediatric autoimmune diseases;
CESC	cis	rs875971	0.838	rs2173570	chr7:65762963	T/A	cg12463550	chr7:65579703	CRCP	-0.51	-6.51	-0.37	3.74e-10	Aortic root size;
CESC	cis	rs875971	0.895	rs1833495	chr7:65921595	T/C	cg10691866	chr7:65817282	TPST1	-0.34	-5.62	-0.33	4.93e-8	Aortic root size;
CESC	cis	rs2637266	0.739	rs2395404	chr10:78380513	G/T	cg18941641	chr10:78392320	NA	0.43	8.11	0.45	1.88e-14	Pulmonary function;
CESC	cis	rs704795	0.867	rs7566052	chr2:27628635	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.31	-5.93	-0.34	9.59e-9	Menopause (age at onset);
CESC	cis	rs3096299	0.967	rs2911257	chr16:89484134	C/G	cg08822215	chr16:89438651	ANKRD11	-0.36	-5.52	-0.32	8.06e-8	Multiple myeloma (IgH translocation);
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg27429832	chr16:1398627	BAIAP3	0.43	6.83	0.39	5.78e-11	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs4862750	0.872	rs6553030	chr4:187899234	T/C	cg10295955	chr4:187884368	NA	-1.08	-23.15	-0.82	1.38e-65	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs3931020	0.508	rs28568334	chr1:75199299	C/G	cg10128416	chr1:75198403	TYW3;CRYZ	0.46	5.53	0.32	7.52e-8	Resistin levels;
CESC	cis	rs13256369	0.950	rs13270006	chr8:8574197	C/A	cg18904891	chr8:8559673	CLDN23	0.68	8.07	0.44	2.45e-14	Obesity-related traits;
CESC	cis	rs4141404	0.604	rs5753625	chr22:31854846	C/T	cg00478049	chr22:31556069	RNF185	0.4	5.03	0.3	9.08e-7	Paclitaxel-induced neuropathy;
CESC	cis	rs2243480	1.000	rs1723267	chr7:65473314	G/A	cg13147721	chr7:65941812	NA	-0.89	-8.55	-0.47	9.65e-16	Diabetic kidney disease;
CESC	cis	rs1059312	0.932	rs4760592	chr12:129287149	G/C	cg09035930	chr12:129282057	SLC15A4	0.78	10.94	0.56	3.13e-23	Systemic lupus erythematosus;
CESC	cis	rs2282802	0.651	rs10060071	chr5:139599097	T/C	cg26211634	chr5:139558579	C5orf32	0.5	7.38	0.41	2.03e-12	Intelligence (multi-trait analysis);
CESC	cis	rs17376456	0.877	rs12716460	chr5:93416733	A/G	cg25358565	chr5:93447407	FAM172A	1.14	11.27	0.57	2.51e-24	Diabetic retinopathy;
CESC	cis	rs7945705	0.902	rs7479407	chr11:9023421	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.45	7.61	0.42	4.9e-13	Hemoglobin concentration;
CESC	cis	rs1348850	0.831	rs7606235	chr2:178401288	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.83	11.32	0.57	1.71e-24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs6502050	0.799	rs7501461	chr17:80109806	C/T	cg23985595	chr17:80112537	CCDC57	-0.42	-6.57	-0.37	2.72e-10	Life satisfaction;
CESC	cis	rs13427251	0.903	rs6746402	chr2:100150443	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.54	-7.12	-0.4	9.92e-12	Chronic sinus infection;
CESC	cis	rs4595586	0.545	rs12828790	chr12:39401043	G/A	cg13010199	chr12:38710504	ALG10B	0.44	5.6	0.33	5.42e-8	Morning vs. evening chronotype;
CESC	cis	rs2841277	0.708	rs10083374	chr14:105402994	T/C	cg21017887	chr14:105400489	NA	0.41	6.68	0.38	1.42e-10	Rheumatoid arthritis;
CESC	cis	rs10504229	1.000	rs59275611	chr8:58195191	G/A	cg14926445	chr8:58193284	C8orf71	-0.56	-5.86	-0.34	1.38e-8	Developmental language disorder (linguistic errors);
CESC	trans	rs79976124	1.000	rs79976124	chr6:66618657	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.75	8.32	0.46	4.83e-15	Type 2 diabetes;
CESC	cis	rs722599	1.000	rs722599	chr14:75327443	T/C	cg11812906	chr14:75593930	NEK9	-0.4	-5.08	-0.3	7.29e-7	IgG glycosylation;
CESC	cis	rs4665809	0.878	rs4143538	chr2:26290178	A/C	cg22920501	chr2:26401640	FAM59B	-0.78	-9.1	-0.49	2.17e-17	Gut microbiome composition (summer);
CESC	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg15112475	chr7:1198522	ZFAND2A	-0.44	-6.99	-0.39	2.18e-11	Longevity;Endometriosis;
CESC	cis	rs2463822	0.748	rs2513038	chr11:62081329	A/C	cg06239285	chr11:62104954	ASRGL1	0.94	8.8	0.48	1.75e-16	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs514406	0.644	rs1855127	chr1:53199594	A/G	cg16325326	chr1:53192061	ZYG11B	-0.69	-10.87	-0.56	5.49e-23	Monocyte count;
CESC	cis	rs6502050	0.871	rs8082577	chr17:80070581	T/C	cg23985595	chr17:80112537	CCDC57	0.41	6.34	0.36	9.63e-10	Life satisfaction;
CESC	cis	rs7267979	0.789	rs62213729	chr20:25363426	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.71	-11.87	-0.59	2.34e-26	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs193541	0.632	rs154504	chr5:122204086	A/T	cg19412675	chr5:122181750	SNX24	0.48	5.65	0.33	4.11e-8	Glucose homeostasis traits;
CESC	cis	rs10751667	0.666	rs4072741	chr11:976565	T/C	cg20946044	chr11:1010712	AP2A2	-0.39	-5.33	-0.31	2.08e-7	Alzheimer's disease (late onset);
CESC	cis	rs6446731	0.517	rs2798221	chr4:3270488	T/C	cg08886695	chr4:3369023	RGS12	0.39	5.77	0.33	2.21e-8	Mean platelet volume;
CESC	cis	rs6499255	0.904	rs2161631	chr16:69556948	C/A	cg15192750	chr16:69999425	NA	0.51	5.85	0.34	1.47e-8	IgE levels;
CESC	cis	rs2657888	0.593	rs2638319	chr12:56857057	A/G	cg23002907	chr12:56915593	RBMS2	-0.38	-5.09	-0.3	6.66e-7	Adiponectin levels;
CESC	cis	rs73206853	0.640	rs3825390	chr12:110976409	A/C	cg12870014	chr12:110450643	ANKRD13A	0.77	7.25	0.41	4.5e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg20887711	chr4:1340912	KIAA1530	0.92	12.09	0.6	4.36e-27	Longevity;
CESC	cis	rs4654899	1.000	rs885363	chr1:21325360	C/A	cg05370193	chr1:21551575	ECE1	0.41	6.3	0.36	1.21e-9	Superior frontal gyrus grey matter volume;
CESC	cis	rs60871478	1.000	rs34761279	chr7:794471	A/G	cg27478167	chr7:817139	HEATR2	-0.54	-5.74	-0.33	2.58e-8	Cerebrospinal P-tau181p levels;
CESC	cis	rs4481887	1.000	rs6671789	chr1:248482931	G/A	cg00666640	chr1:248458726	OR2T12	0.41	6.64	0.38	1.75e-10	Common traits (Other);
CESC	cis	rs287982	0.935	rs1119632	chr2:9967664	C/A	cg10881225	chr2:9984929	TAF1B	0.42	5.31	0.31	2.27e-7	Nonsyndromic cleft lip with cleft palate;
CESC	cis	rs7605378	0.528	rs812760	chr2:200724372	C/T	cg17644776	chr2:200775616	C2orf69	0.55	6.72	0.38	1.13e-10	Osteoporosis;
CESC	cis	rs9911578	1.000	rs11869828	chr17:56609525	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	-0.39	-5.16	-0.3	4.83e-7	Intelligence (multi-trait analysis);
CESC	cis	rs9467773	0.620	rs2504567	chr6:26662920	C/G	cg11502198	chr6:26597334	ABT1	0.53	7.62	0.42	4.39e-13	Intelligence (multi-trait analysis);
CESC	cis	rs72627509	0.904	rs7687767	chr4:57824932	C/T	cg26694713	chr4:57773883	REST	-0.54	-5.34	-0.31	1.99e-7	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CESC	cis	rs9733	0.818	rs11204702	chr1:150663507	C/A	cg04414720	chr1:150670196	GOLPH3L	-0.37	-5.14	-0.3	5.41e-7	Tonsillectomy;
CESC	cis	rs2882667	0.858	rs2043271	chr5:138459108	A/G	cg04439458	chr5:138467593	SIL1	-0.34	-5.29	-0.31	2.52e-7	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs10779751	0.734	rs910660	chr1:11130643	C/T	cg08854313	chr1:11322531	MTOR	-0.76	-10.12	-0.53	1.49e-20	Body mass index;
CESC	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg09177884	chr7:1199841	ZFAND2A	-0.58	-7.99	-0.44	4.11e-14	Longevity;Endometriosis;
CESC	cis	rs2635047	0.507	rs2668767	chr18:44785302	T/C	cg24371990	chr18:44770781	NA	0.36	5.73	0.33	2.73e-8	Educational attainment;
CESC	cis	rs27434	0.583	rs34761	chr5:96153624	C/T	cg16492584	chr5:96139282	ERAP1	-0.4	-5.66	-0.33	3.92e-8	Ankylosing spondylitis;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg24001719	chr20:25388278	GINS1	-0.49	-6.39	-0.37	7.22e-10	Asthma;
CESC	cis	rs17826219	0.636	rs79565452	chr17:29142841	T/C	cg13385521	chr17:29058706	SUZ12P	0.81	6.55	0.37	2.94e-10	Body mass index;
CESC	cis	rs372883	0.600	rs2832298	chr21:30743863	C/G	cg08807101	chr21:30365312	RNF160	0.44	5.16	0.3	4.78e-7	Pancreatic cancer;
CESC	cis	rs1953600	0.668	rs11201879	chr10:81908573	A/C	cg04850286	chr10:81895943	PLAC9	0.31	5.28	0.31	2.74e-7	Sarcoidosis;
CESC	cis	rs1882538	0.564	rs10488164	chr7:133106199	A/G	cg10665199	chr7:133106180	EXOC4	0.61	8.34	0.46	4.02e-15	Intelligence (multi-trait analysis);
CESC	trans	rs629535	0.773	rs72654090	chr8:70118666	G/A	cg21567404	chr3:27674614	NA	-0.87	-10.2	-0.53	8.16e-21	Dupuytren's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04203450	chr20:36028737	SRC	-0.52	-6.06	-0.35	4.59e-9	Gut microbiome composition (summer);
CESC	cis	rs763121	1.000	rs763121	chr22:38879940	C/T	cg06544989	chr22:39130855	UNC84B	-0.38	-6.47	-0.37	4.65e-10	Menopause (age at onset);
CESC	cis	rs17384381	1.000	rs36110608	chr1:85852936	A/C	cg16011679	chr1:85725395	C1orf52	0.79	8.08	0.44	2.34e-14	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg23598054	chr2:201754268	NIF3L1;PPIL3	-0.44	-6.72	-0.38	1.14e-10	Gambling;
CESC	cis	rs1670533	1.000	rs688785	chr4:1082707	G/C	cg04106633	chr4:1044584	NA	0.4	5.1	0.3	6.33e-7	Recombination rate (females);
CESC	cis	rs6063312	0.935	rs6095256	chr20:47340806	C/T	cg18078177	chr20:47281410	PREX1	0.57	5.69	0.33	3.28e-8	Tonometry;
CESC	cis	rs7098414	0.511	rs7898787	chr10:82156042	G/A	cg00277334	chr10:82204260	NA	-0.5	-7.47	-0.42	1.17e-12	Post bronchodilator FEV1;
CESC	cis	rs780096	0.565	rs11681351	chr2:27743423	G/A	cg22903471	chr2:27725779	GCKR	-0.56	-7.84	-0.43	1.09e-13	Total body bone mineral density;
CESC	cis	rs9393777	0.513	rs11967852	chr6:26612870	G/T	cg12826209	chr6:26865740	GUSBL1	0.73	8.53	0.46	1.14e-15	Intelligence (multi-trait analysis);
CESC	cis	rs1538970	0.924	rs4660851	chr1:45843810	A/T	cg05343316	chr1:45956843	TESK2	0.81	11.55	0.58	2.79e-25	Platelet count;
CESC	cis	rs875971	0.862	rs4368860	chr7:65608482	C/G	cg18876405	chr7:65276391	NA	-0.53	-7.3	-0.41	3.31e-12	Aortic root size;
CESC	cis	rs1707322	1.000	rs7526369	chr1:46390560	G/C	cg06784218	chr1:46089804	CCDC17	0.33	5.63	0.33	4.7e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs4555082	0.874	rs760270	chr14:105737785	A/G	cg10792982	chr14:105748885	BRF1	0.42	5.37	0.31	1.75e-7	Mean platelet volume;Platelet distribution width;
CESC	cis	rs7828089	0.875	rs6998575	chr8:22254499	C/T	cg12081754	chr8:22256438	SLC39A14	0.51	7.39	0.41	1.9e-12	Verbal declarative memory;
CESC	cis	rs7772486	0.754	rs4566902	chr6:146244128	A/G	cg23711669	chr6:146136114	FBXO30	-0.92	-13.36	-0.63	1.78e-31	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2439831	0.867	rs933941	chr15:43632226	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.86	12.53	0.61	1.34e-28	Lung cancer in ever smokers;
CESC	cis	rs2742417	1.000	rs2673056	chr3:45737802	C/T	cg10512202	chr3:45649293	LIMD1	0.36	5.16	0.3	4.9e-7	Response to anti-depressant treatment in major depressive disorder;
CESC	cis	rs752010	0.902	rs60743712	chr1:42076629	G/A	cg06885757	chr1:42089581	HIVEP3	0.52	8.42	0.46	2.44e-15	Lupus nephritis in systemic lupus erythematosus;
CESC	trans	rs4332037	0.539	rs11762545	chr7:2060775	C/T	cg11693508	chr17:37793320	STARD3	0.66	6.63	0.38	1.84e-10	Bipolar disorder;
CESC	cis	rs7851660	0.844	rs10759975	chr9:100625193	C/T	cg13688889	chr9:100608707	NA	0.63	8.84	0.48	1.41e-16	Strep throat;
CESC	cis	rs11122272	0.735	rs2739507	chr1:231527329	T/C	cg06096015	chr1:231504339	EGLN1	0.4	5.77	0.33	2.23e-8	Hemoglobin concentration;
CESC	trans	rs1814175	0.645	rs10444311	chr11:49986906	A/G	cg03929089	chr4:120376271	NA	-0.92	-15.24	-0.68	4.38e-38	Height;
CESC	cis	rs9549367	0.662	rs3818334	chr13:113825174	C/G	cg00898013	chr13:113819073	PROZ	-0.54	-7.27	-0.41	4.12e-12	Platelet distribution width;
CESC	cis	rs894734	0.535	rs2366144	chr12:54324069	G/T	cg17410650	chr12:54324560	NA	-0.47	-8.91	-0.48	8.57e-17	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
CESC	cis	rs1538970	0.962	rs2298018	chr1:45813441	T/C	cg05343316	chr1:45956843	TESK2	0.77	10.75	0.55	1.34e-22	Platelet count;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg13680954	chr1:1850738	TMEM52	0.39	6.08	0.35	4.25e-9	Gambling;
CESC	cis	rs7666738	0.791	rs1593571	chr4:98963763	T/C	cg17366294	chr4:99064904	C4orf37	0.6	8.53	0.46	1.16e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1008375	1.000	rs2159583	chr4:17658838	T/C	cg02297831	chr4:17616191	MED28	0.54	6.87	0.39	4.6e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs892961	1.000	rs1110638	chr17:75400690	T/C	cg05865280	chr17:75406074	SEPT9	0.63	12.07	0.6	5.13e-27	Airflow obstruction;
CESC	cis	rs1545257	0.505	rs7595372	chr2:24632122	A/C	cg06627628	chr2:24431161	ITSN2	-0.48	-5.85	-0.34	1.41e-8	Sjögren's syndrome;
CESC	cis	rs1448094	0.556	rs4897831	chr12:86168248	C/T	cg00310523	chr12:86230176	RASSF9	0.41	6.23	0.36	1.85e-9	Major depressive disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04547554	chr19:41860013	TGFB1	0.53	6.15	0.35	2.82e-9	Gut microbiome composition (summer);
CESC	cis	rs11608355	0.521	rs11066503	chr12:109842434	A/G	cg19025524	chr12:109796872	NA	-0.53	-7.28	-0.41	3.84e-12	Neuroticism;
CESC	cis	rs9487051	0.714	rs6903695	chr6:109631422	C/G	cg12927641	chr6:109611667	NA	0.35	5.22	0.31	3.66e-7	Reticulocyte fraction of red cells;
CESC	trans	rs11098499	0.863	rs3736115	chr4:120488703	A/G	cg25214090	chr10:38739885	LOC399744	-0.65	-8.43	-0.46	2.28e-15	Corneal astigmatism;
CESC	cis	rs736408	0.527	rs2577831	chr3:52628056	C/A	cg15147215	chr3:52552868	STAB1	-0.33	-5.96	-0.34	7.82e-9	Bipolar disorder;
CESC	cis	rs4727027	0.870	rs1105261	chr7:148794442	T/G	cg23583168	chr7:148888333	NA	-0.73	-10.45	-0.54	1.28e-21	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs3617	0.539	rs4687689	chr3:52948674	A/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	-0.32	-5.27	-0.31	2.8e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
CESC	cis	rs10504229	1.000	rs68112919	chr8:58188247	G/A	cg05313129	chr8:58192883	C8orf71	-0.54	-6.13	-0.35	3.13e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs9611565	0.802	rs73176694	chr22:41786788	C/T	cg17376030	chr22:41985996	PMM1	0.67	7.19	0.4	6.44e-12	Vitiligo;
CESC	cis	rs11997175	0.646	rs4463379	chr8:33692719	G/A	ch.8.33884649F	chr8:33765107	NA	0.57	7.42	0.41	1.61e-12	Body mass index;
CESC	cis	rs801193	1.000	rs7788576	chr7:66148302	G/A	cg18876405	chr7:65276391	NA	-0.53	-6.94	-0.39	2.96e-11	Aortic root size;
CESC	cis	rs6582630	0.638	rs12425379	chr12:38523705	G/A	cg26384229	chr12:38710491	ALG10B	-0.45	-6.06	-0.35	4.57e-9	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs7659604	0.605	rs1396080	chr4:122740454	T/G	cg19748678	chr4:122722346	EXOSC9	0.72	9.27	0.49	6.93e-18	Type 2 diabetes;
CESC	trans	rs7246657	0.941	rs12982333	chr19:37794724	A/G	cg01833234	chr11:6592585	DNHD1	0.54	6.13	0.35	3.19e-9	Coronary artery calcification;
CESC	cis	rs225245	0.755	rs226432	chr17:34043825	G/A	cg05299278	chr17:33885742	SLFN14	-0.38	-5.36	-0.31	1.82e-7	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
CESC	cis	rs8177253	0.514	rs6790668	chr3:133442481	T/A	cg18769074	chr3:133464867	TF	0.27	5.23	0.31	3.37e-7	Iron status biomarkers;
CESC	cis	rs10089	1.000	rs73337363	chr5:127483597	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.78	10.51	0.54	8.08e-22	Ileal carcinoids;
CESC	cis	rs1005224	0.963	rs12887886	chr14:76167846	C/T	cg25116370	chr14:76127843	TTLL5;C14orf1	-0.41	-5.76	-0.33	2.39e-8	Large artery stroke;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14178837	chr14:39639234	TRAPPC6B	-0.56	-6.15	-0.35	2.84e-9	Gut microbiome composition (summer);
CESC	cis	rs4819052	0.851	rs2877019	chr21:46658647	G/A	cg11663144	chr21:46675770	NA	-0.64	-10.07	-0.53	2.16e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs10225163	1.000	rs10225163	chr7:27925645	C/G	cg05786569	chr7:27702416	HIBADH	-0.4	-5.23	-0.31	3.48e-7	Gout;
CESC	cis	rs7914558	1.000	rs943038	chr10:104826261	T/C	cg04362960	chr10:104952993	NT5C2	0.47	6.32	0.36	1.11e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs7659604	1.000	rs6814995	chr4:122664963	A/T	cg19671926	chr4:122722719	EXOSC9	0.45	5.3	0.31	2.43e-7	Type 2 diabetes;
CESC	cis	rs7481584	1.000	rs12786344	chr11:3021392	G/A	cg25174290	chr11:3078921	CARS	-0.43	-5.36	-0.31	1.78e-7	Calcium levels;
CESC	cis	rs7666738	0.830	rs1967979	chr4:98966201	G/T	cg05340658	chr4:99064831	C4orf37	0.8	12.39	0.61	3.96e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1580019	0.885	rs3801331	chr7:32497039	A/G	cg06627557	chr7:32535165	LSM5;AVL9	-0.88	-12.35	-0.6	5.45e-28	Cognitive ability;
CESC	cis	rs1729951	0.575	rs361241	chr3:136699561	C/A	cg04103450	chr3:136751342	NA	0.38	5.07	0.3	7.54e-7	Neuroticism;
CESC	cis	rs13256369	0.802	rs11249885	chr8:8562008	C/T	cg18904891	chr8:8559673	CLDN23	0.69	8.59	0.47	7.39e-16	Obesity-related traits;
CESC	cis	rs3026101	0.599	rs1058381	chr17:5288018	G/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.44	5.89	0.34	1.19e-8	Body mass index;
CESC	cis	rs9649465	0.561	rs688242	chr7:123420442	C/A	cg03229431	chr7:123269106	ASB15	0.42	5.65	0.33	4.24e-8	Migraine;
CESC	cis	rs2842992	0.724	rs9365097	chr6:160211259	G/A	cg11366901	chr6:160182831	ACAT2	0.65	8.27	0.45	6.51e-15	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs1801251	0.928	rs737028	chr2:233640750	T/C	cg08000102	chr2:233561755	GIGYF2	0.66	9.35	0.5	3.83e-18	Coronary artery disease;
CESC	cis	rs9322193	0.962	rs7745915	chr6:150155247	C/T	cg04369109	chr6:150039330	LATS1	-0.42	-5.69	-0.33	3.41e-8	Lung cancer;
CESC	cis	rs1878931	0.624	rs1149492	chr16:3445239	A/G	cg22508957	chr16:3507546	NAT15	0.4	5.42	0.32	1.33e-7	Body mass index (adult);
CESC	trans	rs916888	0.687	rs199456	chr17:44797919	C/T	cg22433210	chr17:43662623	NA	0.99	11.09	0.56	9.69e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs4819052	0.765	rs2838854	chr21:46680364	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.93	13.94	0.65	1.73e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs8062405	0.756	rs151301	chr16:28497059	T/A	cg05966235	chr16:28915196	ATP2A1	0.37	5.17	0.3	4.62e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs11098499	0.863	rs34308924	chr4:120481431	T/C	cg09307838	chr4:120376055	NA	0.9	12.45	0.61	2.6e-28	Corneal astigmatism;
CESC	trans	rs11039798	1.000	rs12225599	chr11:48755868	T/C	cg15704280	chr7:45808275	SEPT13	0.69	6.29	0.36	1.33e-9	Axial length;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg03610000	chr11:128392383	ETS1	-0.43	-6.01	-0.35	5.99e-9	Fibrinogen levels;
CESC	cis	rs4975709	0.589	rs1466606	chr5:1865055	C/T	cg07747251	chr5:1868357	NA	0.34	5.7	0.33	3.17e-8	Cardiovascular disease risk factors;
CESC	cis	rs7795096	0.806	rs1109277	chr7:151540959	C/G	cg17008978	chr7:151542804	PRKAG2	-0.4	-7.54	-0.42	7.6e-13	Bipolar disorder (age of onset and psychotic symptoms);
CESC	cis	rs863345	0.967	rs12133354	chr1:158526537	T/C	cg12129480	chr1:158549410	OR10X1	-0.32	-6.54	-0.37	3.13e-10	Pneumococcal bacteremia;
CESC	cis	rs1799949	1.000	rs1799966	chr17:41223094	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.67	9.17	0.49	1.32e-17	Menopause (age at onset);
CESC	cis	rs4555082	0.834	rs1473672	chr14:105721981	G/T	cg13114125	chr14:105738426	BRF1	-0.85	-10.46	-0.54	1.18e-21	Mean platelet volume;Platelet distribution width;
CESC	cis	rs7520050	0.966	rs6700597	chr1:46284246	G/A	cg03146154	chr1:46216737	IPP	-0.47	-6.19	-0.36	2.34e-9	Red blood cell count;Reticulocyte count;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg19840540	chr4:159593380	ETFDH;C4orf46	-0.47	-6.93	-0.39	3.1e-11	Gambling;
CESC	cis	rs2742234	0.590	rs2435337	chr10:43661836	G/C	cg15436174	chr10:43711423	RASGEF1A	-0.51	-5.84	-0.34	1.54e-8	Hirschsprung disease;
CESC	cis	rs2952156	0.920	rs2934951	chr17:37833328	A/G	cg20243544	chr17:37824526	PNMT	0.63	7.97	0.44	4.89e-14	Asthma;
CESC	cis	rs1552244	1.000	rs113153120	chr3:10156398	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.88	12.09	0.6	4.15e-27	Alzheimer's disease;
CESC	cis	rs965469	1.000	rs6139064	chr20:3277050	G/T	cg25506879	chr20:3388711	C20orf194	-0.54	-5.88	-0.34	1.24e-8	IFN-related cytopenia;
CESC	cis	rs896854	0.812	rs4582532	chr8:95969257	G/A	cg09323728	chr8:95962352	TP53INP1	-0.41	-9.06	-0.49	2.87e-17	Type 2 diabetes;
CESC	cis	rs2996428	0.561	rs72640913	chr1:3747023	C/G	cg10555106	chr1:3691387	LOC388588	0.37	5.4	0.31	1.48e-7	Red cell distribution width;
CESC	cis	rs6061231	0.761	rs2427312	chr20:60970591	C/T	cg24112000	chr20:60950667	NA	-0.69	-6.84	-0.39	5.46e-11	Colorectal cancer;
CESC	cis	rs425277	0.628	rs3128340	chr1:2047496	C/G	cg16545954	chr1:2118288	C1orf86	-0.31	-5.64	-0.33	4.43e-8	Height;
CESC	cis	rs12142240	0.698	rs10158130	chr1:46822600	T/C	cg00530320	chr1:46809349	NSUN4	0.6	8.04	0.44	2.96e-14	Menopause (age at onset);
CESC	cis	rs11785400	0.963	rs9771845	chr8:143726577	C/G	cg10596483	chr8:143751796	JRK	0.42	5.47	0.32	1.05e-7	Schizophrenia;
CESC	cis	rs4253772	0.638	rs6007845	chr22:46718417	A/T	cg24881330	chr22:46731750	TRMU	-0.88	-10.27	-0.53	4.84e-21	LDL cholesterol;Cholesterol, total;
CESC	cis	rs853679	0.882	rs9468287	chr6:28079741	G/T	cg18032046	chr6:28092343	ZSCAN16	-0.71	-6.29	-0.36	1.27e-9	Depression;
CESC	cis	rs12477438	0.834	rs1563106	chr2:99701381	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.7	-10.07	-0.53	2.12e-20	Chronic sinus infection;
CESC	cis	rs6582630	0.502	rs11181214	chr12:38298313	C/A	cg26384229	chr12:38710491	ALG10B	0.71	10.63	0.55	3.23e-22	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs858239	0.600	rs6960001	chr7:23130876	T/C	cg23682824	chr7:23144976	KLHL7	0.55	7.67	0.43	3.39e-13	Cerebrospinal fluid biomarker levels;
CESC	cis	rs611744	0.647	rs2859813	chr8:109263497	G/A	cg21045802	chr8:109455806	TTC35	0.46	5.69	0.33	3.37e-8	Dupuytren's disease;
CESC	cis	rs863345	0.565	rs12403685	chr1:158452399	C/T	cg12129480	chr1:158549410	OR10X1	0.3	6.18	0.35	2.41e-9	Pneumococcal bacteremia;
CESC	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	10.16	0.53	1.09e-20	Prudent dietary pattern;
CESC	cis	rs3026101	0.723	rs1806247	chr17:5310409	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.42	5.6	0.33	5.31e-8	Body mass index;
CESC	cis	rs9399401	0.601	rs171891	chr6:142850612	G/A	cg03128060	chr6:142623767	GPR126	0.41	6.68	0.38	1.42e-10	Chronic obstructive pulmonary disease;
CESC	cis	rs9814567	0.964	rs9833753	chr3:134213665	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.44	-5.99	-0.35	6.9e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	trans	rs637571	0.544	rs56239996	chr11:65730003	A/T	cg17712092	chr4:129076599	LARP1B	0.75	10.36	0.54	2.43e-21	Eosinophil percentage of white cells;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg05695311	chr8:37887949	EIF4EBP1	-0.5	-6.27	-0.36	1.48e-9	Ulcerative colitis;
CESC	cis	rs17401966	0.965	rs12751375	chr1:10291874	C/G	cg15208524	chr1:10270712	KIF1B	0.5	6.55	0.37	2.97e-10	Hepatocellular carcinoma;
CESC	cis	rs561341	0.800	rs7209766	chr17:30234848	T/A	cg13647721	chr17:30228624	UTP6	0.79	9.4	0.5	2.71e-18	Hip circumference adjusted for BMI;
CESC	cis	rs1552244	0.882	rs28366039	chr3:10028988	C/A	cg08888203	chr3:10149979	C3orf24	0.52	6.09	0.35	3.95e-9	Alzheimer's disease;
CESC	cis	rs80130819	0.515	rs1635536	chr12:48385945	A/G	cg05342945	chr12:48394962	COL2A1	-0.54	-6.43	-0.37	5.94e-10	Prostate cancer;
CESC	cis	rs6582630	0.519	rs10880629	chr12:38533611	T/G	cg26384229	chr12:38710491	ALG10B	0.71	10.89	0.56	4.51e-23	Drug-induced liver injury (flucloxacillin);
CESC	trans	rs9929218	0.954	rs7186333	chr16:68815838	T/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.65	-8.88	-0.48	1.05e-16	Colorectal cancer;
CESC	cis	rs4862750	0.872	rs6553030	chr4:187899234	T/C	cg03452623	chr4:187889614	NA	-0.88	-16.46	-0.71	2.04e-42	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9400467	0.506	rs12203093	chr6:111585382	T/C	cg15721981	chr6:111408429	SLC16A10	0.52	5.03	0.3	8.93e-7	Blood metabolite levels;Amino acid levels;
CESC	cis	rs7520050	0.807	rs28647556	chr1:46206399	G/A	cg03146154	chr1:46216737	IPP	0.5	6.71	0.38	1.16e-10	Red blood cell count;Reticulocyte count;
CESC	cis	rs8114671	0.562	rs6088622	chr20:33419977	C/A	cg07148914	chr20:33460835	GGT7	0.41	5.28	0.31	2.71e-7	Height;
CESC	cis	rs2034088	0.965	rs11651340	chr17:425099	A/C	cg06217071	chr17:408420	NA	-0.42	-7.19	-0.4	6.62e-12	Hip circumference adjusted for BMI;
CESC	cis	rs2933343	0.700	rs789240	chr3:128630635	T/C	cg25356066	chr3:128598488	ACAD9	0.58	7.92	0.44	6.51e-14	IgG glycosylation;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg05207834	chr17:49199381	SPAG9	-0.41	-6.06	-0.35	4.6e-9	Gambling;
CESC	cis	rs7618915	0.501	rs13060048	chr3:52598608	G/A	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	5.86	0.34	1.4e-8	Bipolar disorder;
CESC	cis	rs12477438	0.798	rs2045057	chr2:99684929	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-10.57	-0.54	5.22e-22	Chronic sinus infection;
CESC	cis	rs2516839	0.652	rs2516841	chr1:161010774	A/G	cg00945666	chr1:160990265	F11R	-0.34	-5.45	-0.32	1.16e-7	Granulocyte percentage of myeloid white cells;
CESC	cis	rs17401966	1.000	rs12755094	chr1:10305711	T/C	cg15208524	chr1:10270712	KIF1B	0.43	5.77	0.33	2.16e-8	Hepatocellular carcinoma;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg16739247	chr1:76252438	SNORD45C;SNORD45A;RABGGTB	0.54	7.29	0.41	3.66e-12	Systemic lupus erythematosus;
CESC	cis	rs2243480	0.908	rs313822	chr7:65573939	G/A	cg18252515	chr7:66147081	NA	-1.38	-13.61	-0.64	2.47e-32	Diabetic kidney disease;
CESC	cis	rs7223966	0.960	rs2854222	chr17:61939015	C/T	cg11494091	chr17:61959527	GH2	0.39	5.53	0.32	7.54e-8	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs1799949	1.000	rs35668327	chr17:41273095	G/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.45	6.21	0.36	2e-9	Menopause (age at onset);
CESC	cis	rs2842992	0.750	rs2758354	chr6:160125854	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.71	9.11	0.49	2.04e-17	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs1879734	0.636	rs17109178	chr1:54173551	C/G	cg23596471	chr1:54105337	GLIS1	0.31	5.03	0.3	8.88e-7	Mitral valve prolapse;
CESC	cis	rs7666738	0.830	rs7680909	chr4:98934604	A/G	cg03467027	chr4:99064603	C4orf37	0.48	5.91	0.34	1.03e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2836974	0.932	rs73221193	chr21:40554693	C/T	cg11890956	chr21:40555474	PSMG1	1.16	21.78	0.8	5.46e-61	Cognitive function;
CESC	cis	rs1707322	1.000	rs4660331	chr1:46458783	A/C	cg06784218	chr1:46089804	CCDC17	0.33	5.74	0.33	2.64e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13588715	chr4:164415922	C4orf43	-0.55	-6.37	-0.36	8.47e-10	Gut microbiome composition (summer);
CESC	cis	rs7580658	0.963	rs12622436	chr2:128081682	C/A	cg10021288	chr2:128175891	PROC	-0.41	-6.49	-0.37	4.24e-10	Protein C levels;
CESC	cis	rs2243480	1.000	rs34702770	chr7:65344823	T/C	cg25894440	chr7:65020034	NA	-0.6	-5.32	-0.31	2.19e-7	Diabetic kidney disease;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg05520288	chr5:34929958	DNAJC21	-0.48	-6.1	-0.35	3.69e-9	Asthma;
CESC	cis	rs597539	0.690	rs647661	chr11:68625875	T/C	cg06028808	chr11:68637592	NA	0.48	5.68	0.33	3.55e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs7949030	0.626	rs61296092	chr11:62320838	T/C	cg22862634	chr11:62369728	EML3;MTA2	0.61	8.53	0.46	1.11e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs7618915	0.547	rs2118540	chr3:52629386	T/C	cg17372223	chr3:52568218	NT5DC2	0.43	6.37	0.36	8.35e-10	Bipolar disorder;
CESC	cis	rs9640161	0.711	rs3800781	chr7:150027324	T/A	cg10018233	chr7:150070692	REPIN1	0.47	6.94	0.39	3.01e-11	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs9733	0.818	rs6694531	chr1:150683512	C/A	cg04414720	chr1:150670196	GOLPH3L	-0.37	-5.26	-0.31	3.03e-7	Tonsillectomy;
CESC	cis	rs2073300	1.000	rs6048803	chr20:23438889	A/G	cg12062639	chr20:23401060	NAPB	0.67	5.15	0.3	5.15e-7	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs7894051	1.000	rs7074435	chr10:135190570	G/T	cg24905316	chr10:135186343	ECHS1	0.69	5.87	0.34	1.31e-8	Lifespan;
CESC	cis	rs1707322	0.890	rs2297883	chr1:46511487	G/C	cg03146154	chr1:46216737	IPP	-0.72	-9.73	-0.51	2.49e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs6674176	0.660	rs11210936	chr1:44391438	A/T	cg12908607	chr1:44402522	ARTN	-0.51	-7.54	-0.42	7.68e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03909097	chr20:30555528	XKR7	-0.64	-7.56	-0.42	6.69e-13	Gut microbiome composition (summer);
CESC	cis	rs1577917	1.000	rs12203493	chr6:86758642	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-6.01	-0.35	5.96e-9	Response to antipsychotic treatment;
CESC	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg03647317	chr4:187891568	NA	0.45	7.07	0.4	1.34e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1986734	0.597	rs4859684	chr4:77419107	C/T	cg20311846	chr4:77356250	SHROOM3	-0.27	-5.39	-0.31	1.53e-7	Eosinophilic esophagitis (pediatric);Metabolite levels (small molecules and protein measures);
CESC	cis	rs854765	0.724	rs2955371	chr17:17967397	G/A	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.46	-5.96	-0.34	8.06e-9	Total body bone mineral density;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg24748448	chr17:3493352	TRPV1	-0.43	-6.01	-0.35	6.15e-9	Asthma;
CESC	cis	rs9584850	0.834	rs12869627	chr13:99120452	G/A	cg20750642	chr13:99100586	FARP1	-0.37	-5.56	-0.32	6.44e-8	Neuroticism;
CESC	cis	rs6594713	0.717	rs13174075	chr5:112795352	A/T	cg12552261	chr5:112820674	MCC	0.53	5.13	0.3	5.64e-7	Brain cytoarchitecture;
CESC	cis	rs1124376	1.000	rs9857135	chr3:20147790	G/A	cg05072819	chr3:20081367	KAT2B	0.47	5.14	0.3	5.39e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs736408	0.648	rs3774354	chr3:52817675	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	5.97	0.34	7.42e-9	Bipolar disorder;
CESC	cis	rs72901758	0.768	rs72901766	chr17:76245203	G/C	cg26068271	chr17:76253126	NA	0.51	7.68	0.43	3.15e-13	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
CESC	cis	rs2408955	0.522	rs4760679	chr12:48461635	G/T	cg04545296	chr12:48745243	ZNF641	-0.36	-6.23	-0.36	1.86e-9	Glycated hemoglobin levels;
CESC	cis	rs9457247	0.508	rs6918286	chr6:167505829	C/T	cg07741184	chr6:167504864	NA	0.33	5.73	0.33	2.76e-8	Crohn's disease;
CESC	cis	rs8067545	0.611	rs2703776	chr17:20137709	C/A	cg13482628	chr17:19912719	NA	-0.42	-5.63	-0.33	4.63e-8	Schizophrenia;
CESC	cis	rs28374715	0.528	rs7181982	chr15:41623020	C/G	cg02330683	chr15:41787940	ITPKA	0.49	5.81	0.34	1.77e-8	Ulcerative colitis;
CESC	cis	rs4629180	1.000	rs6744495	chr2:102099956	T/C	cg01388757	chr2:102091195	RFX8	-0.44	-6.78	-0.38	7.91e-11	Chronic rhinosinusitis with nasal polyps;
CESC	cis	rs1801251	0.778	rs778340	chr2:233734083	C/T	cg25237894	chr2:233734115	C2orf82	-0.52	-9.37	-0.5	3.4e-18	Coronary artery disease;
CESC	cis	rs3768617	0.510	rs6424885	chr1:183066254	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.88	14.24	0.66	1.45e-34	Fuchs's corneal dystrophy;
CESC	cis	rs7552404	0.731	rs10873787	chr1:76367797	G/A	cg22875332	chr1:76189707	ACADM	0.58	5.72	0.33	2.83e-8	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs875971	0.522	rs781144	chr7:65440344	C/G	cg14393609	chr7:65229607	NA	0.51	6.63	0.38	1.82e-10	Aortic root size;
CESC	cis	rs911555	0.755	rs7148567	chr14:103882234	C/T	cg09975044	chr14:104007538	NA	0.45	5.62	0.33	4.78e-8	Intelligence (multi-trait analysis);
CESC	cis	rs7618915	0.547	rs35211965	chr3:52685305	C/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	7.03	0.4	1.71e-11	Bipolar disorder;
CESC	trans	rs61931739	0.517	rs1197562	chr12:34122037	G/A	cg26384229	chr12:38710491	ALG10B	0.49	6.66	0.38	1.55e-10	Morning vs. evening chronotype;
CESC	cis	rs875971	0.545	rs2173571	chr7:65770379	G/A	cg11764359	chr7:65958608	NA	0.82	9.71	0.51	2.93e-19	Aortic root size;
CESC	cis	rs6545883	0.894	rs2694642	chr2:61596180	A/G	cg15711740	chr2:61764176	XPO1	0.4	5.07	0.3	7.63e-7	Tuberculosis;
CESC	cis	rs7107174	1.000	rs10899451	chr11:77991222	A/C	cg02023728	chr11:77925099	USP35	0.48	6.39	0.37	7.22e-10	Testicular germ cell tumor;
CESC	cis	rs765787	0.530	rs2413775	chr15:45544288	T/A	cg24006582	chr15:45444508	DUOX1	-0.59	-7.12	-0.4	9.9e-12	Uric acid levels;
CESC	trans	rs7937682	0.855	rs7934922	chr11:111500026	T/C	cg18187862	chr3:45730750	SACM1L	0.51	6.5	0.37	3.97e-10	Primary sclerosing cholangitis;
CESC	cis	rs754133	0.507	rs10876531	chr12:54443718	A/C	cg10005224	chr12:54424964	HOXC4;HOXC5	0.33	5.56	0.32	6.65e-8	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;
CESC	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg26338869	chr17:61819248	STRADA	0.67	8.77	0.47	2.24e-16	Prudent dietary pattern;
CESC	cis	rs9929218	0.954	rs35444713	chr16:68824492	C/T	cg02972257	chr16:68554789	NA	0.5	5.67	0.33	3.64e-8	Colorectal cancer;
CESC	cis	rs1267303	0.563	rs2486163	chr1:47004680	T/C	cg25110126	chr1:46999211	NA	0.86	10.82	0.55	7.89e-23	Monobrow;
CESC	cis	rs3126085	0.515	rs10788835	chr1:152330945	T/C	cg03465714	chr1:152285911	FLG	0.4	5.15	0.3	5.16e-7	Atopic dermatitis;
CESC	cis	rs858239	0.601	rs10239760	chr7:23149950	C/T	cg23682824	chr7:23144976	KLHL7	0.46	6.0	0.35	6.55e-9	Cerebrospinal fluid biomarker levels;
CESC	cis	rs780096	0.526	rs1647267	chr2:27651054	A/T	cg21248554	chr2:27665150	KRTCAP3	-0.36	-7.38	-0.41	2.02e-12	Total body bone mineral density;
CESC	cis	rs8031584	0.918	rs35784593	chr15:31254588	G/A	cg14829155	chr15:31115871	NA	-0.72	-9.75	-0.51	2.15e-19	Huntington's disease progression;
CESC	cis	rs7666738	0.830	rs4699592	chr4:98974202	A/C	cg17366294	chr4:99064904	C4orf37	0.59	8.43	0.46	2.31e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7605827	0.930	rs6720900	chr2:15688281	T/C	cg19274914	chr2:15703543	NA	0.36	6.39	0.37	7.29e-10	Educational attainment (years of education);
CESC	cis	rs11785400	0.701	rs9297967	chr8:143723002	A/C	cg24634471	chr8:143751801	JRK	0.43	5.57	0.32	6.39e-8	Schizophrenia;
CESC	cis	rs10751667	0.643	rs10902237	chr11:944801	C/A	cg20946044	chr11:1010712	AP2A2	-0.39	-5.32	-0.31	2.22e-7	Alzheimer's disease (late onset);
CESC	cis	rs13108904	0.840	rs3915420	chr4:1260337	T/C	cg00684032	chr4:1343700	KIAA1530	0.42	5.93	0.34	9.41e-9	Obesity-related traits;
CESC	cis	rs763121	0.853	rs2072795	chr22:39064209	A/G	cg06022373	chr22:39101656	GTPBP1	-0.88	-14.01	-0.65	9.39e-34	Menopause (age at onset);
CESC	trans	rs9325144	0.560	rs11183189	chr12:38683770	T/A	cg23762105	chr12:34175262	ALG10	-0.46	-6.24	-0.36	1.69e-9	Morning vs. evening chronotype;
CESC	cis	rs1499972	0.618	rs56255439	chr3:117651366	C/A	cg07612923	chr3:117604196	NA	0.68	6.16	0.35	2.74e-9	Schizophrenia;
CESC	trans	rs916888	0.773	rs199448	chr17:44809001	A/G	cg27125505	chr17:43679177	LOC644172	0.5	6.82	0.39	6.04e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.54	-6.79	-0.38	7.32e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7811142	0.830	rs76798830	chr7:99952828	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.02	9.43	0.5	2.11e-18	Platelet count;
CESC	cis	rs11690935	0.550	rs7584187	chr2:172866105	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.46	-6.35	-0.36	9.19e-10	Schizophrenia;
CESC	cis	rs2576037	0.566	rs2437854	chr18:44557613	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.32	-5.07	-0.3	7.5e-7	Personality dimensions;
CESC	cis	rs2299587	0.554	rs7815429	chr8:17737357	T/C	cg08627089	chr8:17753878	FGL1	-0.39	-5.63	-0.33	4.49e-8	Economic and political preferences;
CESC	cis	rs258892	0.895	rs34653	chr5:72146480	A/G	cg21869765	chr5:72125136	TNPO1	0.43	5.5	0.32	9.01e-8	Small cell lung carcinoma;
CESC	cis	rs3785574	0.962	rs4480868	chr17:61788859	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.6	7.48	0.42	1.07e-12	Height;
CESC	cis	rs13102973	0.965	rs13129208	chr4:135858263	A/G	cg14419869	chr4:135874104	NA	0.33	5.14	0.3	5.24e-7	Subjective well-being;
CESC	cis	rs875971	1.000	rs4718344	chr7:65874381	C/A	cg10691866	chr7:65817282	TPST1	-0.34	-5.51	-0.32	8.3e-8	Aortic root size;
CESC	cis	rs9788682	1.000	rs12441426	chr15:78812329	T/C	cg24631222	chr15:78858424	CHRNA5	0.76	9.52	0.5	1.13e-18	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11450715	chr2:171627404	NA	0.66	8.03	0.44	3.17e-14	Gut microbiome composition (summer);
CESC	cis	rs782590	0.967	rs62165173	chr2:55741666	T/C	cg18811423	chr2:55921094	PNPT1	0.79	12.44	0.61	2.79e-28	Metabolic syndrome;
CESC	cis	rs116095464	0.558	rs1812843	chr5:267658	A/G	cg10591111	chr5:226296	SDHA	-0.52	-6.35	-0.36	9.51e-10	Breast cancer;
CESC	cis	rs2273669	0.667	rs4527738	chr6:109309150	T/C	cg05315195	chr6:109294784	ARMC2	-0.65	-6.08	-0.35	4.15e-9	Prostate cancer;
CESC	cis	rs11958404	0.615	rs10053795	chr5:157449185	T/C	cg05962755	chr5:157440814	NA	0.38	5.47	0.32	1.05e-7	IgG glycosylation;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg25936770	chr7:122321411	CADPS2	-0.51	-7.2	-0.4	6.28e-12	Gut microbiota (bacterial taxa);
CESC	cis	rs2652822	0.525	rs17828874	chr15:63516266	C/G	cg02713581	chr15:63449717	RPS27L	-0.48	-6.24	-0.36	1.73e-9	Metabolic traits;
CESC	cis	rs2952156	0.920	rs12150298	chr17:37834541	T/C	cg00129232	chr17:37814104	STARD3	-0.73	-10.54	-0.54	6.53e-22	Asthma;
CESC	cis	rs6570726	0.791	rs400329	chr6:145879442	A/T	cg05347473	chr6:146136440	FBXO30	0.55	7.06	0.4	1.45e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs11098499	0.657	rs4463052	chr4:120313258	T/C	cg24375607	chr4:120327624	NA	0.46	5.55	0.32	6.98e-8	Corneal astigmatism;
CESC	trans	rs2109514	0.505	rs1633714	chr7:116022538	C/T	cg01396998	chr7:76181996	LOC100133091	0.42	6.17	0.35	2.57e-9	Prevalent atrial fibrillation;
CESC	cis	rs11030122	0.592	rs4910880	chr11:4084630	C/G	cg18678763	chr11:4115507	RRM1	-0.45	-6.19	-0.36	2.26e-9	Mean platelet volume;Platelet distribution width;
CESC	trans	rs7615952	0.609	rs13088451	chr3:125553499	G/C	cg07211511	chr3:129823064	LOC729375	-0.92	-10.87	-0.56	5.45e-23	Blood pressure (smoking interaction);
CESC	cis	rs28647808	1.000	rs7032021	chr9:136276601	T/C	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.9	5.73	0.33	2.75e-8	Blood protein levels;
CESC	cis	rs2487048	0.804	rs2472496	chr9:107695353	C/T	cg14470647	chr9:107690075	ABCA1	-0.44	-5.21	-0.31	3.71e-7	Intraocular pressure;
CESC	cis	rs1552244	0.608	rs3732962	chr3:10048951	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.56	-7.27	-0.41	4.1e-12	Alzheimer's disease;
CESC	cis	rs3008870	1.000	rs3008888	chr1:67368965	C/T	cg02640540	chr1:67518911	SLC35D1	0.49	5.31	0.31	2.33e-7	Lymphocyte percentage of white cells;
CESC	cis	rs7633770	0.710	rs4683259	chr3:46698538	A/G	cg11219411	chr3:46661640	NA	-0.32	-5.03	-0.3	9.14e-7	Coronary artery disease;
CESC	cis	rs7582720	1.000	rs72934505	chr2:203916487	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.84	7.1	0.4	1.13e-11	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs13102973	0.931	rs13103718	chr4:135843990	C/T	cg14419869	chr4:135874104	NA	0.34	5.25	0.31	3.11e-7	Subjective well-being;
CESC	cis	rs6500395	0.775	rs7191225	chr16:48662675	C/G	cg04672837	chr16:48644449	N4BP1	0.5	6.49	0.37	4.09e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs10870270	1.000	rs72636963	chr10:133771271	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.6	-7.65	-0.43	3.77e-13	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs6088580	0.634	rs2378133	chr20:32919505	C/G	cg24642439	chr20:33292090	TP53INP2	-0.51	-6.65	-0.38	1.63e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs13191362	0.507	rs13207363	chr6:163201285	C/G	cg06582575	chr6:163149167	PACRG;PARK2	-0.5	-5.79	-0.33	2.03e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs4237845	0.513	rs7134797	chr12:58263852	C/T	cg00677455	chr12:58241039	CTDSP2	0.79	10.41	0.54	1.66e-21	Intelligence (multi-trait analysis);
CESC	cis	rs736408	0.505	rs2083180	chr3:52668119	G/T	cg07507251	chr3:52567010	NT5DC2	0.32	5.58	0.32	5.93e-8	Bipolar disorder;
CESC	cis	rs875971	0.862	rs1167408	chr7:65556108	G/A	cg12463550	chr7:65579703	CRCP	-0.54	-6.65	-0.38	1.65e-10	Aortic root size;
CESC	cis	rs2836974	0.899	rs68004583	chr21:40659587	T/C	cg11890956	chr21:40555474	PSMG1	1.21	23.76	0.82	1.3e-67	Cognitive function;
CESC	cis	rs35110281	0.755	rs4819270	chr21:45020919	G/A	cg21573476	chr21:45109991	RRP1B	-0.48	-6.71	-0.38	1.19e-10	Mean corpuscular volume;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg14903685	chr15:70391316	TLE3	-0.46	-6.16	-0.35	2.72e-9	Fibrinogen levels;
CESC	cis	rs920590	0.758	rs17091534	chr8:19670651	C/T	cg03894339	chr8:19674705	INTS10	0.64	7.38	0.41	2.01e-12	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs67478160	0.704	rs12894254	chr14:104290949	G/C	cg01849466	chr14:104193079	ZFYVE21	-0.51	-7.13	-0.4	9.71e-12	Schizophrenia;
CESC	cis	rs6088580	0.524	rs4911437	chr20:33266149	G/T	cg08999081	chr20:33150536	PIGU	-0.37	-5.03	-0.3	8.96e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs2204008	0.627	rs10878488	chr12:38148666	G/A	cg13010199	chr12:38710504	ALG10B	0.54	6.67	0.38	1.48e-10	Bladder cancer;
CESC	cis	rs875971	0.522	rs9530	chr7:65425894	A/G	cg14393609	chr7:65229607	NA	0.5	6.46	0.37	4.93e-10	Aortic root size;
CESC	cis	rs838147	0.537	rs632111	chr19:49208978	A/G	cg21064579	chr19:49206444	FUT2	0.51	7.21	0.4	5.87e-12	Dietary macronutrient intake;
CESC	cis	rs9916302	0.821	rs11078916	chr17:37746307	T/C	cg07936489	chr17:37558343	FBXL20	-0.76	-10.1	-0.53	1.65e-20	Glomerular filtration rate (creatinine);
CESC	cis	rs11711311	0.824	rs9876528	chr3:113357196	G/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.62	8.05	0.44	2.87e-14	IgG glycosylation;
CESC	cis	rs6587515	0.901	rs7520516	chr1:150659695	C/G	cg13175981	chr1:150552382	MCL1	0.62	5.65	0.33	4.23e-8	Pericardial adipose tissue adjusted for height and weight;
CESC	cis	rs4132509	0.947	rs10927039	chr1:243721726	C/T	cg21452805	chr1:244014465	NA	-0.45	-5.69	-0.33	3.37e-8	RR interval (heart rate);
CESC	cis	rs9894429	0.624	rs9910935	chr17:79613949	T/C	cg18240062	chr17:79603768	NPLOC4	0.8	10.72	0.55	1.6e-22	Eye color traits;
CESC	cis	rs2066819	0.786	rs111580405	chr12:56739557	A/G	cg26734620	chr12:56694298	CS	0.98	5.95	0.34	8.45e-9	Psoriasis vulgaris;
CESC	cis	rs6952808	0.594	rs3778964	chr7:2138109	C/T	cg05863683	chr7:1912471	MAD1L1	0.38	5.45	0.32	1.16e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs1178968	0.901	rs2528705	chr7:72791238	A/G	cg25889504	chr7:72793014	NA	0.52	5.58	0.32	5.95e-8	Triglyceride levels;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg00717482	chr1:112531938	KCND3	-0.46	-6.06	-0.35	4.65e-9	Fibrinogen levels;
CESC	cis	rs6540559	0.611	rs17015226	chr1:209970096	C/G	cg23283495	chr1:209979779	IRF6	0.48	5.73	0.33	2.78e-8	Cleft lip with or without cleft palate;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg14147105	chr19:17531148	FAM125A	0.49	6.46	0.37	5.07e-10	Systemic lupus erythematosus;
CESC	cis	rs6089584	0.830	rs4925331	chr20:60580174	T/C	cg13770153	chr20:60521292	NA	-0.44	-5.71	-0.33	3.02e-8	Body mass index;
CESC	cis	rs2243480	0.901	rs35823062	chr7:65965821	A/G	cg18252515	chr7:66147081	NA	-1.4	-14.33	-0.66	7.01e-35	Diabetic kidney disease;
CESC	cis	rs10504229	0.679	rs16921687	chr8:58053514	T/C	cg02725872	chr8:58115012	NA	-0.33	-5.04	-0.3	8.84e-7	Developmental language disorder (linguistic errors);
CESC	trans	rs5756813	0.754	rs11705616	chr22:38180487	G/T	cg19894588	chr14:64061835	NA	-0.65	-8.27	-0.45	6.52e-15	Optic cup area;Vertical cup-disc ratio;
CESC	cis	rs8114671	0.562	rs6120763	chr20:33506400	C/G	cg06115741	chr20:33292138	TP53INP2	0.46	5.58	0.32	6.06e-8	Height;
CESC	cis	rs7580658	0.895	rs4662722	chr2:128102569	T/C	cg10021288	chr2:128175891	PROC	-0.41	-6.46	-0.37	5.11e-10	Protein C levels;
CESC	trans	rs916888	0.610	rs199452	chr17:44801340	C/T	cg22968622	chr17:43663579	NA	0.77	10.69	0.55	2.1e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs875971	0.522	rs34973832	chr7:65396204	A/G	cg18876405	chr7:65276391	NA	0.69	9.64	0.51	4.96e-19	Aortic root size;
CESC	cis	rs4689592	0.503	rs4689064	chr4:7055603	A/G	cg19539972	chr4:7069911	GRPEL1	-0.67	-7.05	-0.4	1.59e-11	Monocyte percentage of white cells;
CESC	cis	rs796364	0.951	rs12463436	chr2:201061962	C/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.61	6.36	0.36	8.55e-10	Schizophrenia;
CESC	cis	rs9790314	0.580	rs960212	chr3:161047974	C/T	cg03342759	chr3:160939853	NMD3	-0.45	-6.57	-0.37	2.59e-10	Morning vs. evening chronotype;
CESC	cis	rs117623576	0.618	rs211416	chr10:32397591	T/A	cg03047570	chr10:32398778	NA	0.66	7.29	0.41	3.65e-12	Anti-saccade response;
CESC	cis	rs4665809	1.000	rs4665809	chr2:26251361	C/T	cg26119090	chr2:26468346	HADHA;HADHB	0.7	7.96	0.44	4.98e-14	Gut microbiome composition (summer);
CESC	cis	rs2797160	1.000	rs1739376	chr6:126012084	C/G	cg05901451	chr6:126070800	HEY2	0.47	6.36	0.36	8.56e-10	Endometrial cancer;
CESC	cis	rs7274811	0.625	rs293725	chr20:31929643	C/G	cg21523528	chr20:32077966	CBFA2T2	-0.46	-5.16	-0.3	4.87e-7	Height;
CESC	cis	rs1185460	0.967	rs1784460	chr11:118938371	A/T	cg01677386	chr11:118938358	VPS11	0.46	6.18	0.35	2.46e-9	Coronary artery disease;
CESC	cis	rs55728055	0.661	rs55648708	chr22:32032062	G/A	cg01338084	chr22:32026380	PISD	1.12	7.87	0.44	9.3e-14	Age-related hearing impairment;
CESC	cis	rs801193	1.000	rs2659889	chr7:66217112	A/G	cg11764359	chr7:65958608	NA	0.7	9.23	0.49	8.79e-18	Aortic root size;
CESC	cis	rs4664308	1.000	rs10929965	chr2:160906931	C/T	cg03641300	chr2:160917029	PLA2R1	0.66	10.16	0.53	1.1e-20	Idiopathic membranous nephropathy;
CESC	cis	rs10883723	0.810	rs7093028	chr10:104259417	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.54	7.43	0.42	1.49e-12	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs7091068	0.518	rs9633674	chr10:95455431	C/T	cg20715218	chr10:95462985	C10orf4	0.5	6.41	0.37	6.46e-10	Urinary tract infection frequency;
CESC	cis	rs6582630	0.555	rs11181684	chr12:38388000	T/C	cg13010199	chr12:38710504	ALG10B	0.45	5.88	0.34	1.23e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs7617773	0.780	rs35411187	chr3:48360017	C/G	cg11946769	chr3:48343235	NME6	0.89	12.34	0.6	5.98e-28	Coronary artery disease;
CESC	cis	rs3858526	0.584	rs10769276	chr11:5868020	G/T	cg13902645	chr11:5959945	NA	-0.64	-9.09	-0.49	2.36e-17	DNA methylation (variation);
CESC	cis	rs11098499	0.863	rs3822194	chr4:120471648	A/G	cg24375607	chr4:120327624	NA	0.43	5.32	0.31	2.16e-7	Corneal astigmatism;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg18510056	chr10:77163383	C10orf41	0.39	6.23	0.36	1.82e-9	Gambling;
CESC	cis	rs7527798	0.592	rs12025522	chr1:207854355	A/C	cg21110645	chr1:207815933	NA	0.32	5.81	0.34	1.83e-8	Erythrocyte sedimentation rate;
CESC	cis	rs477895	0.653	rs2875749	chr11:63903878	C/A	cg04317338	chr11:64019027	PLCB3	0.87	9.06	0.49	3.04e-17	Mean platelet volume;
CESC	cis	rs6912958	1.000	rs2223880	chr6:88167897	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.6	-8.41	-0.46	2.5e-15	Monocyte percentage of white cells;
CESC	cis	rs2522056	1.000	rs2522062	chr5:131805416	A/G	cg24060327	chr5:131705240	SLC22A5	0.61	6.93	0.39	3.22e-11	Lymphocyte counts;Fibrinogen;
CESC	cis	rs11252926	0.545	rs11252693	chr10:532139	A/G	cg16386425	chr10:429943	DIP2C	-0.43	-5.63	-0.33	4.65e-8	Psychosis in Alzheimer's disease;
CESC	cis	rs1568889	0.838	rs4614434	chr11:28302234	C/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.8	13.99	0.65	1.11e-33	Bipolar disorder;
CESC	cis	rs875971	1.000	rs2036264	chr7:65799904	G/A	cg10691866	chr7:65817282	TPST1	0.35	5.78	0.33	2.13e-8	Aortic root size;
CESC	cis	rs2072499	0.868	rs2758600	chr1:156195205	C/T	cg24450063	chr1:156163899	SLC25A44	0.93	14.21	0.66	1.84e-34	Testicular germ cell tumor;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg25179170	chr1:93427589	FAM69A	-0.44	-6.25	-0.36	1.62e-9	Gambling;
CESC	cis	rs637571	0.522	rs491973	chr11:65727301	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.74	10.78	0.55	1.01e-22	Eosinophil percentage of white cells;
CESC	cis	rs2950393	0.857	rs9989034	chr12:57068292	C/T	cg05584118	chr12:57595605	LRP1	-0.37	-5.25	-0.31	3.16e-7	Platelet distribution width;
CESC	cis	rs6089584	0.888	rs6089623	chr20:60615759	A/G	cg06108461	chr20:60628389	TAF4	-0.94	-14.7	-0.67	3.53e-36	Body mass index;
CESC	cis	rs7843479	0.601	rs9969551	chr8:21860007	T/C	cg17168535	chr8:21777572	XPO7	0.73	11.4	0.57	9.24e-25	Mean corpuscular volume;
CESC	cis	rs727505	1.000	rs10233596	chr7:124556659	A/G	cg23710748	chr7:124431027	NA	-0.48	-7.46	-0.42	1.27e-12	Lewy body disease;
CESC	cis	rs875971	0.862	rs11984115	chr7:65773859	C/T	cg18252515	chr7:66147081	NA	0.43	5.66	0.33	3.97e-8	Aortic root size;
CESC	cis	rs1595825	0.891	rs60582020	chr2:198520555	A/C	cg10820045	chr2:198174542	NA	0.41	5.21	0.3	3.79e-7	Ulcerative colitis;
CESC	cis	rs1144333	0.655	rs1144337	chr1:76278877	A/G	cg10523679	chr1:76189770	ACADM	-0.57	-5.48	-0.32	9.94e-8	Attention function in attention deficit hyperactive disorder;
CESC	cis	rs3749237	0.537	rs4459909	chr3:49469217	T/C	cg07636037	chr3:49044803	WDR6	0.64	9.27	0.49	6.68e-18	Resting heart rate;
CESC	cis	rs1707322	1.000	rs1707322	chr1:46505147	C/T	cg03146154	chr1:46216737	IPP	0.75	10.34	0.54	2.93e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9291683	0.609	rs36084205	chr4:10028678	A/C	cg00071950	chr4:10020882	SLC2A9	0.89	16.34	0.71	5.39e-42	Bone mineral density;
CESC	cis	rs8067354	0.645	rs2645467	chr17:57854783	C/T	cg13753209	chr17:57696993	CLTC	0.65	8.23	0.45	8.42e-15	Hemoglobin concentration;
CESC	cis	rs875971	1.000	rs2420168	chr7:65630631	C/G	cg11764359	chr7:65958608	NA	-0.92	-14.72	-0.67	2.89e-36	Aortic root size;
CESC	cis	rs6460942	0.915	rs62448596	chr7:12446869	C/T	cg13733410	chr7:12443478	VWDE	-0.53	-5.45	-0.32	1.17e-7	Coronary artery disease;
CESC	cis	rs4819052	0.819	rs34818688	chr21:46672416	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.75	9.92	0.52	6.18e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs1552244	1.000	rs9811771	chr3:10133949	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.87	11.55	0.58	2.95e-25	Alzheimer's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07396495	chr16:53468716	RBL2	0.63	8.08	0.44	2.37e-14	Gut microbiome composition (summer);
CESC	cis	rs9393777	0.513	rs9379895	chr6:26592707	A/G	cg11502198	chr6:26597334	ABT1	0.49	5.18	0.3	4.47e-7	Intelligence (multi-trait analysis);
CESC	cis	rs698833	0.892	rs698796	chr2:44689669	C/A	cg04920474	chr2:44395004	PPM1B	0.36	5.08	0.3	6.98e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs8031584	0.723	rs711224	chr15:31127921	G/C	cg14298792	chr15:30685198	CHRFAM7A	0.47	5.61	0.33	5.13e-8	Huntington's disease progression;
CESC	cis	rs2032447	0.839	rs199750	chr6:26016462	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.68	-9.39	-0.5	2.89e-18	Intelligence (multi-trait analysis);
CESC	cis	rs12136530	0.806	rs10917451	chr1:19769323	G/C	cg01832549	chr1:19774989	CAPZB	-0.48	-6.66	-0.38	1.6e-10	Lead levels in blood;
CESC	trans	rs451417	1.000	rs384578	chr20:5981476	A/G	cg17614506	chr7:47803072	NA	0.57	6.03	0.35	5.6e-9	Menopause (age at onset);
CESC	cis	rs6430585	0.528	rs56064699	chr2:136595706	G/A	cg07169764	chr2:136633963	MCM6	1.34	18.28	0.75	7.53e-49	Corneal structure;
CESC	cis	rs7927592	0.913	rs7102898	chr11:68328870	G/A	cg20283391	chr11:68216788	NA	-0.61	-7.36	-0.41	2.26e-12	Total body bone mineral density;
CESC	cis	rs116095464	0.558	rs7730700	chr5:264713	G/A	cg20965017	chr5:231967	SDHA	-0.48	-5.43	-0.32	1.25e-7	Breast cancer;
CESC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg13030908	chr1:11741533	MAD2L2	0.47	6.14	0.35	2.93e-9	Tetralogy of Fallot;
CESC	cis	rs6088580	0.634	rs4911151	chr20:32932273	T/C	cg24642439	chr20:33292090	TP53INP2	-0.52	-6.78	-0.38	7.99e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs72945132	0.882	rs11235953	chr11:70184937	C/T	cg00319359	chr11:70116639	PPFIA1	0.71	6.92	0.39	3.49e-11	Coronary artery disease;
CESC	cis	rs9916302	0.706	rs8182252	chr17:37727950	T/C	cg20243544	chr17:37824526	PNMT	-0.53	-5.88	-0.34	1.22e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs644148	0.730	rs2571044	chr19:44985573	G/A	cg15540054	chr19:45004280	ZNF180	-0.59	-6.38	-0.37	7.68e-10	Personality dimensions;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19393587	chr2:70106252	GMCL1	-0.54	-6.41	-0.37	6.46e-10	Gut microbiome composition (summer);
CESC	cis	rs7824557	1.000	rs7824557	chr8:11104111	C/T	cg21775007	chr8:11205619	TDH	-0.42	-6.23	-0.36	1.86e-9	Retinal vascular caliber;
CESC	cis	rs7666738	0.830	rs28618180	chr4:98912184	A/C	cg03676636	chr4:99064102	C4orf37	0.34	5.09	0.3	6.84e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg13880726	chr7:1868755	MAD1L1	0.51	6.72	0.38	1.11e-10	Bipolar disorder and schizophrenia;
CESC	cis	rs853679	0.550	rs1237875	chr6:28173010	A/G	cg23281280	chr6:28129359	ZNF389	-0.46	-6.22	-0.36	1.9e-9	Depression;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01737507	chr5:122372093	PPIC	0.54	6.56	0.37	2.88e-10	Gut microbiome composition (summer);
CESC	cis	rs7267979	0.868	rs6138550	chr20:25223430	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.82	15.6	0.69	2.21e-39	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.89	13.68	0.64	1.42e-32	Prudent dietary pattern;
CESC	cis	rs634534	0.622	rs531612	chr11:65705432	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.4	-5.72	-0.33	2.87e-8	Sum eosinophil basophil counts;Eosinophil counts;
CESC	cis	rs72945132	0.882	rs56176527	chr11:70162513	A/G	cg14191688	chr11:70257035	CTTN	0.42	5.34	0.31	1.95e-7	Coronary artery disease;
CESC	cis	rs7618915	0.547	rs62253733	chr3:52653414	A/G	cg05564831	chr3:52568323	NT5DC2	0.45	6.8	0.39	6.82e-11	Bipolar disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07911682	chr1:51425659	FAF1	0.62	7.65	0.43	3.71e-13	Gut microbiome composition (summer);
CESC	cis	rs3857536	0.740	rs7763555	chr6:66889930	C/T	cg07460842	chr6:66804631	NA	-0.42	-5.39	-0.31	1.56e-7	Blood trace element (Cu levels);
CESC	cis	rs9311474	0.581	rs13621	chr3:52558133	T/C	cg18099408	chr3:52552593	STAB1	-0.32	-5.51	-0.32	8.55e-8	Electroencephalogram traits;
CESC	cis	rs950776	0.518	rs12910289	chr15:78822065	T/G	cg24631222	chr15:78858424	CHRNA5	-0.42	-5.33	-0.31	2.09e-7	Sudden cardiac arrest;
CESC	cis	rs524281	0.861	rs7937281	chr11:65950074	T/C	cg14036092	chr11:66035641	RAB1B	-0.48	-5.17	-0.3	4.61e-7	Electroencephalogram traits;
CESC	cis	rs425277	1.000	rs425277	chr1:2069172	C/T	cg04315214	chr1:2043799	PRKCZ	-0.41	-5.81	-0.34	1.82e-8	Height;
CESC	cis	rs79057730	0.528	rs4719313	chr7:822501	C/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.82	6.91	0.39	3.58e-11	Initial pursuit acceleration;
CESC	cis	rs6582630	0.519	rs1607868	chr12:38385512	G/T	cg26384229	chr12:38710491	ALG10B	0.71	10.82	0.55	7.95e-23	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs853679	0.517	rs12332979	chr6:28141548	T/G	cg12963246	chr6:28129442	ZNF389	0.54	7.18	0.4	6.92e-12	Depression;
CESC	cis	rs4253772	0.513	rs9615345	chr22:46713631	C/T	cg00784671	chr22:46762841	CELSR1	-0.39	-5.07	-0.3	7.53e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs7267979	0.903	rs6115109	chr20:25239667	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.82	15.09	0.68	1.41e-37	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs6662572	0.806	rs12047498	chr1:45954632	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.53	5.74	0.33	2.56e-8	Blood protein levels;
CESC	cis	rs2250402	0.510	rs2291621	chr15:40324837	C/T	cg16127683	chr15:40268777	EIF2AK4	-0.61	-5.42	-0.32	1.32e-7	Corneal curvature;
CESC	cis	rs736801	0.569	rs11748193	chr5:131725329	A/T	cg07395648	chr5:131743802	NA	-0.44	-5.64	-0.33	4.32e-8	Breast cancer;Mosquito bite size;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg11905814	chr11:46639029	KIAA0652;HARBI1	-0.5	-6.17	-0.35	2.57e-9	Ulcerative colitis;
CESC	cis	rs7602441	0.521	rs77940955	chr2:14767411	T/C	cg06545361	chr2:14773388	FAM84A	0.69	6.69	0.38	1.34e-10	Visceral adipose tissue adjusted for BMI;
CESC	cis	rs72781680	0.652	rs12618900	chr2:23910775	C/T	cg08917208	chr2:24149416	ATAD2B	1.22	10.51	0.54	8.13e-22	Lymphocyte counts;
CESC	cis	rs7178572	0.568	rs7177533	chr15:77387923	C/T	cg22256960	chr15:77711686	NA	-0.5	-6.14	-0.35	2.96e-9	Type 2 diabetes;
CESC	cis	rs3091242	0.933	rs11249251	chr1:25770188	C/G	cg02931644	chr1:25747376	RHCE	0.39	6.6	0.38	2.19e-10	Erythrocyte sedimentation rate;
CESC	cis	rs9527	0.544	rs11191549	chr10:104846797	C/T	cg04362960	chr10:104952993	NT5C2	0.44	5.61	0.33	4.97e-8	Arsenic metabolism;
CESC	cis	rs919433	0.927	rs1429418	chr2:198158151	G/C	cg10820045	chr2:198174542	NA	-0.37	-5.13	-0.3	5.73e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs2294693	0.679	rs4317403	chr6:40971173	C/T	cg14769373	chr6:40998127	UNC5CL	-0.43	-5.27	-0.31	2.84e-7	Gastric cancer;Non-cardia gastric cancer;
CESC	cis	rs4819052	0.679	rs2838860	chr21:46684904	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.44	5.68	0.33	3.45e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs6963495	0.651	rs3892298	chr7:105152187	A/G	cg02135003	chr7:105160482	PUS7	-0.46	-5.46	-0.32	1.08e-7	Bipolar disorder (body mass index interaction);
CESC	cis	rs990171	0.571	rs3771202	chr2:102772669	C/G	cg22835712	chr2:102737379	NA	0.43	5.83	0.34	1.64e-8	Lymphocyte counts;
CESC	trans	rs12339966	0.689	rs3001252	chr9:11680323	G/A	cg03904639	chr13:37677730	CSNK1A1L	0.39	5.99	0.35	6.65e-9	Systolic blood pressure;
CESC	cis	rs17854409	0.881	rs1046784	chr20:61472808	G/C	cg05147244	chr20:61493195	TCFL5	0.97	6.63	0.38	1.88e-10	Obesity-related traits;
CESC	trans	rs61931739	0.534	rs11053072	chr12:34202399	A/C	cg26384229	chr12:38710491	ALG10B	0.64	9.15	0.49	1.59e-17	Morning vs. evening chronotype;
CESC	cis	rs9611565	0.568	rs5758441	chr22:42132888	C/A	cg06634786	chr22:41940651	POLR3H	0.49	5.5	0.32	8.83e-8	Vitiligo;
CESC	cis	rs4728302	0.869	rs6963032	chr7:133599527	T/C	cg10665199	chr7:133106180	EXOC4	0.42	5.93	0.34	9.21e-9	Intelligence;Intelligence (multi-trait analysis);
CESC	cis	rs7100689	0.646	rs10736356	chr10:82148325	A/G	cg00277334	chr10:82204260	NA	-0.59	-7.69	-0.43	2.82e-13	Post bronchodilator FEV1;
CESC	cis	rs910316	0.712	rs175037	chr14:75465038	T/C	cg11812906	chr14:75593930	NEK9	-0.81	-13.34	-0.63	2.05e-31	Height;
CESC	cis	rs4665809	0.877	rs34536218	chr2:26287376	T/A	cg04944784	chr2:26401820	FAM59B	0.75	8.12	0.45	1.79e-14	Gut microbiome composition (summer);
CESC	cis	rs7618915	1.000	rs59565798	chr3:52307169	G/A	cg07507251	chr3:52567010	NT5DC2	0.38	6.04	0.35	5.06e-9	Bipolar disorder;
CESC	cis	rs1862618	0.853	rs832583	chr5:56178217	A/C	cg24549020	chr5:56110836	MAP3K1	0.66	7.46	0.42	1.23e-12	Initial pursuit acceleration;
CESC	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	7.7	0.43	2.77e-13	Prudent dietary pattern;
CESC	cis	rs6088590	0.965	rs910869	chr20:33292777	C/T	cg24642439	chr20:33292090	TP53INP2	0.87	12.04	0.59	6.42e-27	Coronary artery disease;
CESC	cis	rs1552244	1.000	rs9879080	chr3:10084224	C/T	cg08888203	chr3:10149979	C3orf24	0.48	6.16	0.35	2.73e-9	Alzheimer's disease;
CESC	cis	rs9894429	0.789	rs7502346	chr17:79603741	T/C	cg21984481	chr17:79567631	NPLOC4	-0.57	-9.11	-0.49	2.03e-17	Eye color traits;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg26512142	chr11:2554198	KCNQ1	0.48	6.83	0.39	5.92e-11	Systemic lupus erythematosus;
CESC	cis	rs2204008	0.805	rs12146846	chr12:37985847	C/T	cg26384229	chr12:38710491	ALG10B	0.74	10.92	0.56	3.59e-23	Bladder cancer;
CESC	cis	rs7845219	0.544	rs10956930	chr8:95919786	C/G	cg09323728	chr8:95962352	TP53INP1	-0.32	-6.23	-0.36	1.8e-9	Type 2 diabetes;
CESC	cis	rs832540	0.593	rs252912	chr5:56195792	C/T	cg14703610	chr5:56206110	C5orf35	0.46	5.75	0.33	2.42e-8	Coronary artery disease;
CESC	cis	rs9929218	0.559	rs55907909	chr16:68805805	C/T	cg02972257	chr16:68554789	NA	-0.42	-5.25	-0.31	3.17e-7	Colorectal cancer;
CESC	cis	rs769267	0.965	rs4808937	chr19:19398005	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.43	5.27	0.31	2.88e-7	Tonsillectomy;
CESC	cis	rs751837	0.591	rs2285013	chr14:103429825	A/G	cg10087771	chr14:103399429	CDC42BPB	0.61	5.67	0.33	3.66e-8	Large B-cell lymphoma;
CESC	cis	rs514406	0.679	rs12563825	chr1:53238324	G/T	cg06600287	chr1:53387719	ECHDC2	0.27	5.16	0.3	4.92e-7	Monocyte count;
CESC	cis	rs17655565	0.636	rs17119838	chr12:52716596	C/T	cg08257133	chr12:52711352	KRT83	0.37	5.22	0.31	3.58e-7	Plasma amyloid beta peptide concentrations (ABx-42);
CESC	cis	rs902774	0.515	rs2363635	chr12:53354622	T/C	cg25025879	chr12:53359317	NA	-0.53	-6.91	-0.39	3.59e-11	Prostate cancer;
CESC	cis	rs5753618	0.583	rs8138596	chr22:31786961	T/A	cg00478049	chr22:31556069	RNF185	-0.43	-5.04	-0.3	8.52e-7	Colorectal cancer;
CESC	cis	rs258892	0.895	rs394274	chr5:72135955	C/T	cg21869765	chr5:72125136	TNPO1	0.44	5.68	0.33	3.61e-8	Small cell lung carcinoma;
CESC	cis	rs35955747	0.633	rs5998012	chr22:31889844	G/A	cg25791279	chr22:32026902	PISD	-0.44	-5.14	-0.3	5.38e-7	Neutrophil count;Sum basophil neutrophil counts;
CESC	cis	rs4253772	0.591	rs7286155	chr22:46714735	A/G	cg18190219	chr22:46762943	CELSR1	-0.59	-6.57	-0.37	2.66e-10	LDL cholesterol;Cholesterol, total;
CESC	cis	rs2361718	0.500	rs8064429	chr17:78096187	A/C	cg23534315	chr17:78082725	GAA	0.37	5.27	0.31	2.88e-7	Yeast infection;
CESC	cis	rs35306767	0.807	rs72778228	chr10:938435	A/G	cg10556349	chr10:835070	NA	0.72	6.12	0.35	3.39e-9	Eosinophil percentage of granulocytes;
CESC	cis	rs722599	0.683	rs2058918	chr14:75288518	A/G	cg11812906	chr14:75593930	NEK9	0.45	5.41	0.32	1.39e-7	IgG glycosylation;
CESC	cis	rs2735413	0.918	rs12598024	chr16:78079114	G/A	cg04733911	chr16:78082701	NA	-0.53	-9.01	-0.48	4.08e-17	Systolic blood pressure (alcohol consumption interaction);
CESC	cis	rs798554	0.679	rs2527681	chr7:2892384	A/T	cg18446336	chr7:2847575	GNA12	-0.34	-5.15	-0.3	5.13e-7	Height;
CESC	cis	rs4713118	0.616	rs9348789	chr6:28025486	C/T	cg12963246	chr6:28129442	ZNF389	0.5	6.4	0.37	6.93e-10	Parkinson's disease;
CESC	cis	rs7586673	0.866	rs747003	chr2:161916409	C/T	cg08807892	chr2:162101083	NA	-0.46	-6.24	-0.36	1.75e-9	Intelligence (multi-trait analysis);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg16435601	chr17:65822392	BPTF	-0.47	-6.28	-0.36	1.35e-9	Fibrinogen levels;
CESC	cis	rs35306767	0.903	rs34847097	chr10:902252	A/T	cg20503657	chr10:835505	NA	0.78	7.72	0.43	2.41e-13	Eosinophil percentage of granulocytes;
CESC	cis	rs6580649	0.943	rs9651993	chr12:48404692	G/A	cg05342945	chr12:48394962	COL2A1	-0.57	-6.62	-0.38	1.95e-10	Lung cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05236446	chr14:73524740	RBM25	-0.52	-6.04	-0.35	5.25e-9	Gut microbiome composition (summer);
CESC	cis	rs7605827	0.930	rs1996517	chr2:15517330	T/C	cg19274914	chr2:15703543	NA	0.35	6.27	0.36	1.43e-9	Educational attainment (years of education);
CESC	cis	rs1986734	0.555	rs12500824	chr4:77416627	A/G	cg20311846	chr4:77356250	SHROOM3	-0.29	-5.8	-0.34	1.84e-8	Eosinophilic esophagitis (pediatric);Metabolite levels (small molecules and protein measures);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg00903375	chr7:66460591	SBDS;TYW1	0.51	6.68	0.38	1.41e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs10788972	0.815	rs9651202	chr1:54553207	T/C	cg25741118	chr1:54482237	LDLRAD1	-0.22	-5.25	-0.31	3.19e-7	Parkinson disease and lewy body pathology;
CESC	cis	rs1448094	0.617	rs4842569	chr12:86468609	T/G	cg02569458	chr12:86230093	RASSF9	-0.35	-5.17	-0.3	4.66e-7	Major depressive disorder;
CESC	cis	rs8060686	0.920	rs111315946	chr16:67889793	G/C	cg26727032	chr16:67993705	SLC12A4	-0.57	-6.11	-0.35	3.47e-9	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs662064	0.748	rs2506889	chr1:10596022	C/T	cg20482658	chr1:10539492	PEX14	0.41	8.38	0.46	3.21e-15	Asthma;
CESC	cis	rs7618915	0.571	rs6798246	chr3:52599922	G/A	cg17372223	chr3:52568218	NT5DC2	0.43	6.36	0.36	9.03e-10	Bipolar disorder;
CESC	cis	rs34779708	0.931	rs11010083	chr10:35351531	C/G	cg03585969	chr10:35415529	CREM	0.76	9.88	0.52	8.46e-20	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs1005277	0.579	rs1780139	chr10:38503018	C/T	cg25517755	chr10:38738941	LOC399744	-0.44	-5.7	-0.33	3.12e-8	Extrinsic epigenetic age acceleration;
CESC	cis	rs12893668	0.572	rs4906350	chr14:104111794	C/T	cg08213375	chr14:104286397	PPP1R13B	0.33	5.38	0.31	1.62e-7	Reticulocyte count;
CESC	cis	rs2050392	1.000	rs2480280	chr10:30696092	A/G	cg18806716	chr10:30721971	MAP3K8	-0.4	-5.83	-0.34	1.58e-8	Inflammatory bowel disease;
CESC	cis	rs2228479	0.850	rs62054257	chr16:89900195	G/A	cg04013166	chr16:89971882	TCF25	0.72	5.75	0.33	2.41e-8	Skin colour saturation;
CESC	cis	rs9393777	0.513	rs9379895	chr6:26592707	A/G	cg12826209	chr6:26865740	GUSBL1	0.77	9.33	0.5	4.38e-18	Intelligence (multi-trait analysis);
CESC	cis	rs9911578	1.000	rs8071916	chr17:56660279	A/G	cg12560992	chr17:57184187	TRIM37	0.93	15.87	0.7	2.55e-40	Intelligence (multi-trait analysis);
CESC	cis	rs1670533	0.932	rs3796620	chr4:1095079	A/G	cg04106633	chr4:1044584	NA	-0.4	-5.16	-0.3	4.94e-7	Recombination rate (females);
CESC	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	10.19	0.53	8.59e-21	Prudent dietary pattern;
CESC	cis	rs2737618	0.551	rs2816989	chr1:200070765	G/T	cg21825944	chr1:200113062	NR5A2	0.39	5.57	0.32	6.12e-8	Uric acid levels;
CESC	cis	rs7923452	1.000	rs7923452	chr10:30751171	T/C	cg25182066	chr10:30743637	MAP3K8	0.5	5.57	0.32	6.34e-8	Itch intensity from mosquito bite;
CESC	cis	rs7599312	0.534	rs6735626	chr2:213403972	G/A	cg16329650	chr2:213403929	ERBB4	0.58	8.43	0.46	2.31e-15	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs2502731	0.561	rs3003606	chr9:130982416	C/T	cg09976142	chr9:130955436	CIZ1	0.39	6.34	0.36	9.84e-10	Attention deficit hyperactivity disorder;
CESC	cis	rs6456156	0.586	rs12525855	chr6:167480013	T/G	cg23791538	chr6:167370224	RNASET2	-0.53	-6.91	-0.39	3.59e-11	Primary biliary cholangitis;
CESC	cis	rs17270561	0.583	rs12662869	chr6:25784481	A/C	cg25753631	chr6:25732923	NA	0.28	5.47	0.32	1.02e-7	Iron status biomarkers;
CESC	cis	rs11997175	0.646	rs6468197	chr8:33734894	G/T	ch.8.33884649F	chr8:33765107	NA	0.56	7.05	0.4	1.58e-11	Body mass index;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11321298	chr22:40766510	SGSM3	-0.56	-6.38	-0.36	7.83e-10	Gut microbiome composition (summer);
CESC	cis	rs7089973	0.604	rs7903663	chr10:116609904	G/A	cg03647239	chr10:116582469	FAM160B1	0.41	5.15	0.3	5.11e-7	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs832540	1.000	rs252914	chr5:56198150	A/C	cg14703610	chr5:56206110	C5orf35	0.53	6.97	0.39	2.54e-11	Coronary artery disease;
CESC	cis	rs9640161	0.742	rs11767726	chr7:150018096	A/C	cg21361702	chr7:150065534	REPIN1	-0.57	-6.82	-0.39	6.27e-11	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs854765	0.583	rs11871899	chr17:17826748	C/G	cg04398451	chr17:18023971	MYO15A	-0.65	-9.23	-0.49	9.1e-18	Total body bone mineral density;
CESC	trans	rs7839040	0.698	rs7836783	chr8:82928934	C/A	cg14472086	chr9:107730925	NA	-0.47	-6.33	-0.36	1.02e-9	Response to methotrexate in juvenile idiopathic arthritis;
CESC	cis	rs3733585	0.699	rs7699609	chr4:9961059	A/G	cg11266682	chr4:10021025	SLC2A9	-0.6	-11.2	-0.57	4.42e-24	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs28374715	0.617	rs28626792	chr15:41562218	A/G	cg02330683	chr15:41787940	ITPKA	0.36	5.04	0.3	8.78e-7	Ulcerative colitis;
CESC	cis	rs801193	0.839	rs12534943	chr7:66070520	A/G	cg14393609	chr7:65229607	NA	-0.42	-5.86	-0.34	1.35e-8	Aortic root size;
CESC	cis	rs2235642	0.533	rs2667679	chr16:1654946	G/A	cg03650551	chr16:1797383	MAPK8IP3	-0.38	-5.29	-0.31	2.57e-7	Coronary artery disease;
CESC	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg06873352	chr17:61820015	STRADA	0.73	12.86	0.62	9.85e-30	Prudent dietary pattern;
CESC	cis	rs11252926	0.598	rs4881256	chr10:453831	T/A	cg16386425	chr10:429943	DIP2C	-0.57	-7.3	-0.41	3.29e-12	Psychosis in Alzheimer's disease;
CESC	cis	rs533123	0.818	rs204051	chr1:29166578	A/G	cg08366446	chr1:29138936	OPRD1	0.55	5.62	0.33	4.85e-8	Schizophrenia;
CESC	cis	rs2050392	0.687	rs608693	chr10:30734971	G/A	cg18806716	chr10:30721971	MAP3K8	-0.47	-6.64	-0.38	1.78e-10	Inflammatory bowel disease;
CESC	cis	rs10883723	0.810	rs7090034	chr10:104281155	C/G	ch.10.2196322F	chr10:104248062	ACTR1A	0.42	5.18	0.3	4.34e-7	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs854765	0.583	rs4925123	chr17:17784374	A/G	cg09796270	chr17:17721594	SREBF1	-0.45	-6.35	-0.36	9.24e-10	Total body bone mineral density;
CESC	cis	rs7809799	1.000	rs6975245	chr7:98755272	G/T	cg05967295	chr7:98741636	SMURF1	-0.75	-5.19	-0.3	4.14e-7	Ulcerative colitis;
CESC	cis	rs9393777	0.513	rs7759969	chr6:26663096	T/A	cg14345882	chr6:26364793	BTN3A2	0.42	5.29	0.31	2.59e-7	Intelligence (multi-trait analysis);
CESC	cis	rs9894429	0.966	rs7405901	chr17:79587813	T/C	cg21984481	chr17:79567631	NPLOC4	-0.49	-8.04	-0.44	2.97e-14	Eye color traits;
CESC	cis	rs2635047	0.530	rs4986228	chr18:44595259	C/T	cg19077165	chr18:44547161	KATNAL2	-0.43	-5.67	-0.33	3.79e-8	Educational attainment;
CESC	cis	rs2180341	0.597	rs11154397	chr6:127646649	G/C	cg27446573	chr6:127587934	RNF146	0.63	8.54	0.46	1.09e-15	Breast cancer;
CESC	cis	rs7703051	0.901	rs4704227	chr5:74826735	G/A	cg03227963	chr5:74354835	NA	0.29	5.21	0.31	3.73e-7	LDL cholesterol;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
CESC	cis	rs7618915	0.501	rs10865974	chr3:52718280	A/C	cg07507251	chr3:52567010	NT5DC2	-0.29	-5.09	-0.3	6.64e-7	Bipolar disorder;
CESC	cis	rs7811142	1.000	rs6972167	chr7:100080013	G/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.88	9.12	0.49	1.99e-17	Platelet count;
CESC	cis	rs9435341	0.965	rs3108680	chr1:107572997	T/C	cg09367891	chr1:107599246	PRMT6	0.59	7.19	0.4	6.63e-12	Facial morphology (factor 21, depth of nasal alae);
CESC	cis	rs1538970	0.816	rs10789464	chr1:45959102	C/T	cg06784218	chr1:46089804	CCDC17	0.37	5.84	0.34	1.53e-8	Platelet count;
CESC	cis	rs7520050	0.966	rs11211199	chr1:46287869	T/C	cg24296786	chr1:45957014	TESK2	0.43	5.42	0.32	1.32e-7	Red blood cell count;Reticulocyte count;
CESC	cis	rs1348850	0.958	rs4528793	chr2:178464271	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.62	8.62	0.47	6.11e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs9467711	0.606	rs9357006	chr6:26364628	A/C	cg12826209	chr6:26865740	GUSBL1	0.62	5.31	0.31	2.27e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs11252926	0.650	rs4880678	chr10:490472	G/A	cg03684893	chr10:554711	DIP2C	-0.42	-6.39	-0.37	7.23e-10	Psychosis in Alzheimer's disease;
CESC	cis	rs933688	1.000	rs12188467	chr5:90765632	A/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.82	10.4	0.54	1.78e-21	Smoking behavior;
CESC	cis	rs4665809	0.590	rs1469523	chr2:26474631	T/A	cg22920501	chr2:26401640	FAM59B	0.91	10.38	0.54	2.08e-21	Gut microbiome composition (summer);
CESC	cis	rs9291683	0.609	rs36084205	chr4:10028678	A/C	cg11266682	chr4:10021025	SLC2A9	0.7	14.15	0.66	2.99e-34	Bone mineral density;
CESC	cis	rs12479064	0.671	rs62155807	chr2:100076579	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.64	-7.28	-0.41	3.69e-12	Chronic sinus infection;
CESC	trans	rs1814175	0.817	rs28544182	chr11:50049577	G/T	cg03929089	chr4:120376271	NA	-0.94	-16.17	-0.7	2.25e-41	Height;
CESC	cis	rs1003719	1.000	rs2154536	chr21:38492147	G/C	cg10648535	chr21:38446584	PIGP;TTC3	0.63	8.62	0.47	6.04e-16	Eye color traits;
CESC	cis	rs3741404	0.825	rs11603538	chr11:63986713	C/A	cg18225595	chr11:63971243	STIP1	0.72	9.79	0.52	1.64e-19	Platelet count;
CESC	cis	rs1707322	0.717	rs2991988	chr1:46082431	C/A	cg05343316	chr1:45956843	TESK2	-0.53	-6.5	-0.37	3.98e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7666738	0.791	rs6853608	chr4:99047916	A/G	cg03467027	chr4:99064603	C4orf37	0.47	5.98	0.34	7.19e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs897984	0.542	rs73530203	chr16:31099859	G/A	cg02466173	chr16:30829666	NA	-0.44	-7.27	-0.41	4e-12	Dementia with Lewy bodies;
CESC	cis	rs853679	0.517	rs9393893	chr6:28109262	T/C	cg20151795	chr6:28129481	ZNF389	0.45	5.84	0.34	1.5e-8	Depression;
CESC	cis	rs7811142	0.830	rs705866	chr7:99965285	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.07	10.49	0.54	9.53e-22	Platelet count;
CESC	cis	rs9287719	0.967	rs6727768	chr2:10757479	T/C	cg00105475	chr2:10696890	NA	0.37	5.4	0.31	1.52e-7	Prostate cancer;
CESC	cis	rs8177253	0.574	rs6775042	chr3:133442245	G/T	cg18769074	chr3:133464867	TF	0.32	5.91	0.34	1.06e-8	Iron status biomarkers;
CESC	cis	rs7264396	0.563	rs2425111	chr20:34319765	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.87	-10.68	-0.55	2.2e-22	Total cholesterol levels;
CESC	cis	rs1348850	0.526	rs10803912	chr2:178407176	A/C	cg23306229	chr2:178417860	TTC30B	-0.78	-7.35	-0.41	2.52e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs1691799	0.867	rs1495497	chr12:66770020	A/T	cg16791601	chr12:66731901	HELB	-0.75	-12.92	-0.62	5.97e-30	White blood cell count (basophil);
CESC	cis	rs67311347	0.955	rs6782746	chr3:40510592	A/G	cg24209194	chr3:40518798	ZNF619	-0.53	-6.88	-0.39	4.25e-11	Renal cell carcinoma;
CESC	cis	rs1215050	0.791	rs7688192	chr4:98900798	G/T	cg05340658	chr4:99064831	C4orf37	-0.53	-6.94	-0.39	2.96e-11	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs910316	0.737	rs175048	chr14:75479894	A/T	cg08847533	chr14:75593920	NEK9	-0.88	-15.45	-0.69	7.88e-39	Height;
CESC	cis	rs6693567	0.565	rs1776273	chr1:150270209	C/T	cg09579323	chr1:150459698	TARS2	0.42	5.56	0.32	6.46e-8	Migraine;
CESC	cis	rs17433780	0.836	rs17434342	chr1:89505742	C/G	cg09516651	chr1:89888402	LOC400759	-0.6	-9.04	-0.49	3.29e-17	Carotid intima media thickness;
CESC	cis	rs72799341	1.000	rs72799341	chr16:30936743	G/A	cg02466173	chr16:30829666	NA	-0.41	-5.35	-0.31	1.86e-7	Diastolic blood pressure;
CESC	cis	rs6570726	0.935	rs12663205	chr6:145818378	G/A	cg23711669	chr6:146136114	FBXO30	0.81	12.04	0.59	6.44e-27	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs116095464	0.558	rs59284383	chr5:284525	C/G	cg20965017	chr5:231967	SDHA	-0.46	-5.2	-0.3	4.02e-7	Breast cancer;
CESC	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.97	9.29	0.5	5.68e-18	Platelet count;
CESC	cis	rs763121	0.626	rs5757236	chr22:39073824	T/C	cg14440974	chr22:39074834	NA	-0.42	-5.89	-0.34	1.14e-8	Menopause (age at onset);
CESC	cis	rs7542091	0.748	rs2357231	chr1:210028454	A/C	cg23283495	chr1:209979779	IRF6	-0.33	-5.37	-0.31	1.74e-7	Monobrow;
CESC	cis	rs72772090	0.539	rs72773932	chr5:96118148	T/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.57	-5.21	-0.3	3.74e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs7959452	0.562	rs11177630	chr12:69767963	G/C	cg20891283	chr12:69753455	YEATS4	0.91	15.06	0.68	1.86e-37	Blood protein levels;
CESC	cis	rs875971	0.862	rs2909688	chr7:65841612	C/A	cg10691866	chr7:65817282	TPST1	-0.33	-5.44	-0.32	1.21e-7	Aortic root size;
CESC	cis	rs7727544	0.548	rs4705938	chr5:131694077	A/G	cg14196790	chr5:131705035	SLC22A5	0.37	5.77	0.33	2.19e-8	Blood metabolite levels;
CESC	cis	rs9811920	0.683	rs793439	chr3:99637783	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.39	6.49	0.37	4.22e-10	Axial length;
CESC	cis	rs2228479	0.764	rs7191836	chr16:89961597	T/C	cg06558623	chr16:89946397	TCF25	0.68	5.89	0.34	1.17e-8	Skin colour saturation;
CESC	cis	rs11723261	0.582	rs61792238	chr4:112283	G/A	cg12746427	chr4:53362	ZNF718;ZNF595	0.45	5.33	0.31	2.12e-7	Immune response to smallpox vaccine (IL-6);
CESC	cis	rs35146811	0.586	rs10267212	chr7:99595422	T/C	cg14163444	chr7:99595348	NA	-0.39	-5.11	-0.3	6.28e-7	Coronary artery disease;
CESC	cis	rs2439831	0.681	rs484029	chr15:43619560	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.9	10.75	0.55	1.33e-22	Lung cancer in ever smokers;
CESC	cis	rs8070128	0.601	rs8080602	chr17:17954728	G/C	cg16928487	chr17:17741425	SREBF1	0.55	9.13	0.49	1.86e-17	Total body bone mineral density;
CESC	cis	rs11098499	0.909	rs9759478	chr4:120367998	G/A	cg09307838	chr4:120376055	NA	0.92	12.77	0.62	2.08e-29	Corneal astigmatism;
CESC	cis	rs16854884	0.586	rs2011080	chr3:143756149	T/G	cg06585982	chr3:143692056	C3orf58	0.49	6.63	0.38	1.89e-10	Economic and political preferences (feminism/equality);
CESC	cis	rs2439831	0.850	rs10438303	chr15:44016417	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.71	6.76	0.38	8.96e-11	Lung cancer in ever smokers;
CESC	cis	rs9322193	0.923	rs4870529	chr6:150037572	A/G	cg07701084	chr6:150067640	NUP43	0.48	6.69	0.38	1.35e-10	Lung cancer;
CESC	cis	rs10465746	0.967	rs11576870	chr1:84333301	G/A	cg10977910	chr1:84465055	TTLL7	0.48	6.52	0.37	3.64e-10	Obesity-related traits;
CESC	cis	rs3820068	0.580	rs7512308	chr1:16006604	C/A	cg18133145	chr1:16060689	PLEKHM2	-0.43	-5.32	-0.31	2.19e-7	Systolic blood pressure;
CESC	cis	rs9616064	0.531	rs9616086	chr22:47050744	G/A	cg25730555	chr22:47059586	GRAMD4	0.46	5.73	0.33	2.71e-8	Urate levels in obese individuals;
CESC	cis	rs6964587	0.732	rs12539523	chr7:91710836	G/A	cg01689657	chr7:91764605	CYP51A1	0.28	5.13	0.3	5.67e-7	Breast cancer;
CESC	cis	rs3858526	0.523	rs10838749	chr11:5884246	A/G	cg02574844	chr11:5959923	NA	-0.44	-6.54	-0.37	3.17e-10	DNA methylation (variation);
CESC	cis	rs9916302	0.861	rs10491129	chr17:37461643	T/G	cg00129232	chr17:37814104	STARD3	0.56	7.41	0.41	1.72e-12	Glomerular filtration rate (creatinine);
CESC	cis	rs875971	0.577	rs35072105	chr7:65609817	A/G	cg11764359	chr7:65958608	NA	-0.63	-8.13	-0.45	1.66e-14	Aortic root size;
CESC	cis	rs2985684	1.000	rs2147712	chr14:50091684	G/A	cg10008539	chr14:50087325	RPL36AL;MGAT2	-0.48	-5.66	-0.33	3.83e-8	Carotid intima media thickness;
CESC	cis	rs2836974	0.568	rs4816620	chr21:40613786	A/G	cg11644478	chr21:40555479	PSMG1	-0.81	-12.21	-0.6	1.68e-27	Cognitive function;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11015833	chr12:83079681	TMTC2	-0.65	-7.92	-0.44	6.61e-14	Gut microbiome composition (summer);
CESC	cis	rs6089584	0.526	rs6089619	chr20:60610916	C/T	cg24733560	chr20:60626293	TAF4	0.45	6.75	0.38	9.16e-11	Body mass index;
CESC	cis	rs2522056	1.000	rs2522054	chr5:131799526	G/T	cg24060327	chr5:131705240	SLC22A5	0.6	6.66	0.38	1.61e-10	Lymphocyte counts;Fibrinogen;
CESC	cis	rs898097	0.841	rs4986122	chr17:80825500	C/T	cg15664640	chr17:80829946	TBCD	-0.64	-9.4	-0.5	2.63e-18	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15563237	chr1:47799827	CMPK1	0.57	6.32	0.36	1.1e-9	Gut microbiome composition (summer);
CESC	cis	rs863345	0.564	rs4614256	chr1:158464611	T/G	cg12129480	chr1:158549410	OR10X1	-0.35	-6.97	-0.39	2.46e-11	Pneumococcal bacteremia;
CESC	cis	rs9911578	0.867	rs4793941	chr17:56472366	G/A	cg05425664	chr17:57184151	TRIM37	0.45	6.32	0.36	1.09e-9	Intelligence (multi-trait analysis);
CESC	cis	rs11718455	0.883	rs4682926	chr3:44006170	C/T	cg08738300	chr3:44038990	NA	0.46	6.12	0.35	3.33e-9	Coronary artery disease;
CESC	cis	rs9828933	0.766	rs704361	chr3:63883671	T/G	cg16258503	chr3:63850278	ATXN7;THOC7	0.8	7.84	0.43	1.12e-13	Type 2 diabetes;
CESC	trans	rs2693676	0.504	rs870827	chr14:99604585	A/G	cg17465227	chr4:47427752	GABRB1	0.6	6.63	0.38	1.84e-10	Corneal curvature;
CESC	cis	rs853679	0.517	rs12174753	chr6:28042465	C/G	cg17949981	chr6:28129498	ZNF389	0.45	5.62	0.33	4.9e-8	Depression;
CESC	cis	rs11190604	0.943	rs11190574	chr10:102234331	T/C	cg07080220	chr10:102295463	HIF1AN	0.51	5.15	0.3	5.13e-7	Palmitoleic acid (16:1n-7) levels;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg07934232	chr19:36619082	NA	-0.43	-6.34	-0.36	9.6e-10	Gambling;
CESC	cis	rs660498	0.507	rs34773871	chr10:27727645	G/A	cg25705717	chr10:27608719	NA	0.49	5.75	0.33	2.45e-8	Asthma (childhood onset);
CESC	cis	rs7697216	0.668	rs7666569	chr4:175840903	T/C	cg14561282	chr4:175839468	ADAM29	0.49	5.6	0.33	5.35e-8	Breast cancer;
CESC	cis	rs3008870	0.755	rs2815365	chr1:67499628	C/T	cg02640540	chr1:67518911	SLC35D1	0.46	5.64	0.33	4.33e-8	Lymphocyte percentage of white cells;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg03227570	chr1:17766306	RCC2	-0.45	-6.25	-0.36	1.65e-9	Fibrinogen levels;
CESC	cis	rs72781680	0.566	rs72796106	chr2:23901362	A/C	cg08917208	chr2:24149416	ATAD2B	0.84	8.23	0.45	8.63e-15	Lymphocyte counts;
CESC	cis	rs7312933	0.966	rs7977365	chr12:42513127	G/A	cg01256987	chr12:42539512	GXYLT1	-0.34	-5.23	-0.31	3.46e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs7949030	0.626	rs71490390	chr11:62329185	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.6	8.51	0.46	1.32e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg19318889	chr4:1322082	MAEA	0.56	6.79	0.39	7.23e-11	Longevity;
CESC	cis	rs6582630	0.585	rs12422588	chr12:38478675	C/T	cg26384229	chr12:38710491	ALG10B	-0.41	-5.41	-0.32	1.42e-7	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs6088580	0.524	rs6088567	chr20:33263872	A/T	cg24642439	chr20:33292090	TP53INP2	-0.47	-5.48	-0.32	9.79e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs2842992	0.673	rs6930904	chr6:160217433	T/A	cg26839252	chr6:160211577	TCP1;MRPL18	0.44	5.03	0.3	9.06e-7	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs9916302	0.800	rs8069451	chr17:37504933	C/T	cg15445000	chr17:37608096	MED1	0.39	6.15	0.35	2.85e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs9910055	0.659	rs8079310	chr17:42270291	A/G	cg19774624	chr17:42201019	HDAC5	-0.88	-14.17	-0.66	2.58e-34	Total body bone mineral density;
CESC	trans	rs916888	0.821	rs199512	chr17:44857352	T/C	cg27125505	chr17:43679177	LOC644172	-0.48	-6.74	-0.38	1.01e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs35955747	0.902	rs11703927	chr22:31644964	G/A	cg25791279	chr22:32026902	PISD	-0.5	-5.98	-0.35	7.04e-9	Neutrophil count;Sum basophil neutrophil counts;
CESC	cis	rs962856	1.000	rs6722203	chr2:67569193	G/A	cg09028215	chr2:67624308	ETAA1	-0.43	-5.5	-0.32	8.95e-8	Pancreatic cancer;
CESC	cis	rs13191362	1.000	rs34052221	chr6:163160803	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.68	6.7	0.38	1.25e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs10461617	0.535	rs7709874	chr5:56047451	C/T	cg24531977	chr5:56204891	C5orf35	-0.64	-8.16	-0.45	1.33e-14	Type 2 diabetes;
CESC	cis	rs6963495	0.818	rs115609508	chr7:105163716	C/A	cg19920283	chr7:105172520	RINT1	0.7	6.66	0.38	1.58e-10	Bipolar disorder (body mass index interaction);
CESC	cis	rs854765	0.822	rs1889014	chr17:17767165	C/T	cg16928487	chr17:17741425	SREBF1	0.58	10.01	0.52	3.32e-20	Total body bone mineral density;
CESC	cis	rs1152591	1.000	rs1152591	chr14:64680848	A/G	cg23250157	chr14:64679961	SYNE2	0.56	8.2	0.45	1.04e-14	Atrial fibrillation;
CESC	cis	rs2204008	0.623	rs1607878	chr12:38376000	A/G	cg13010199	chr12:38710504	ALG10B	0.43	5.45	0.32	1.15e-7	Bladder cancer;
CESC	cis	rs6785206	0.772	rs6439134	chr3:128323504	C/T	cg16766828	chr3:128327626	NA	-0.64	-6.53	-0.37	3.38e-10	Lymphocyte percentage of white cells;
CESC	cis	rs9910055	0.762	rs4239142	chr17:42205876	A/G	cg13607699	chr17:42295918	UBTF	-0.58	-7.57	-0.42	6.06e-13	Total body bone mineral density;
CESC	cis	rs703842	1.000	rs2072052	chr12:58146719	A/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.7	8.91	0.48	8.33e-17	Multiple sclerosis;
CESC	cis	rs1185460	1.000	rs1799993	chr11:118958127	A/C	cg23280166	chr11:118938394	VPS11	-0.45	-6.28	-0.36	1.35e-9	Coronary artery disease;
CESC	cis	rs2806561	0.729	rs35919647	chr1:23326072	C/T	cg12483005	chr1:23474871	LUZP1	-0.32	-5.06	-0.3	7.9e-7	Height;
CESC	cis	rs9322193	0.923	rs9688350	chr6:150052113	A/T	cg00933542	chr6:150070202	PCMT1	0.3	5.11	0.3	6.15e-7	Lung cancer;
CESC	trans	rs57221529	0.825	rs7443550	chr5:578404	G/T	cg25482853	chr8:67687455	SGK3	1.01	10.17	0.53	9.74e-21	Lung disease severity in cystic fibrosis;
CESC	cis	rs35306767	0.903	rs12254002	chr10:929133	A/G	cg26597838	chr10:835615	NA	-0.84	-9.38	-0.5	3.01e-18	Eosinophil percentage of granulocytes;
CESC	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg26338869	chr17:61819248	STRADA	0.69	9.24	0.49	8.57e-18	Prudent dietary pattern;
CESC	cis	rs7618915	0.547	rs68021750	chr3:52624769	G/A	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	5.62	0.33	4.92e-8	Bipolar disorder;
CESC	cis	rs4642101	0.737	rs4299468	chr3:12825559	G/A	cg05775895	chr3:12838266	CAND2	0.39	5.99	0.35	6.95e-9	QRS complex (12-leadsum);
CESC	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg26304593	chr6:42947056	PEX6	0.44	5.66	0.33	3.87e-8	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs8062405	0.754	rs3859172	chr16:28566158	G/T	cg07382826	chr16:28625726	SULT1A1	0.31	5.12	0.3	5.91e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	trans	rs916888	0.687	rs199456	chr17:44797919	C/T	cg04282206	chr17:62833786	PLEKHM1P	0.57	6.57	0.37	2.6e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs4953318	0.619	rs35744969	chr2:46353140	C/A	cg12428440	chr2:46370979	PRKCE	0.44	5.75	0.33	2.52e-8	Red blood cell count;Hematocrit;Red blood cell traits;
CESC	cis	rs1843834	0.721	rs6436507	chr2:225598242	T/A	cg22455342	chr2:225449267	CUL3	0.41	5.24	0.31	3.2e-7	IgE levels in asthmatics (D.p. specific);
CESC	cis	rs8031584	0.918	rs3817498	chr15:31268781	T/C	cg14298792	chr15:30685198	CHRFAM7A	-0.42	-5.09	-0.3	6.89e-7	Huntington's disease progression;
CESC	cis	rs4665809	0.590	rs11552518	chr2:26455127	G/A	cg25036284	chr2:26402008	FAM59B	0.86	9.36	0.5	3.44e-18	Gut microbiome composition (summer);
CESC	cis	rs2180341	0.574	rs13192350	chr6:127677762	G/T	cg27446573	chr6:127587934	RNF146	0.6	8.18	0.45	1.18e-14	Breast cancer;
CESC	cis	rs116095464	0.867	rs10074958	chr5:230828	C/T	cg22496380	chr5:211416	CCDC127	-0.75	-8.7	-0.47	3.54e-16	Breast cancer;
CESC	cis	rs61841072	0.922	rs2344124	chr1:243127644	A/G	cg02356786	chr1:243265016	LOC731275	0.4	5.03	0.3	9.1e-7	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03104356	chr8:30013879	DCTN6	0.58	6.35	0.36	9.43e-10	Gut microbiome composition (summer);
CESC	cis	rs36051895	0.659	rs58345215	chr9:5043767	A/T	cg02405213	chr9:5042618	JAK2	-0.49	-5.84	-0.34	1.55e-8	Pediatric autoimmune diseases;
CESC	cis	rs854765	0.547	rs2955356	chr17:17964717	G/A	cg09796270	chr17:17721594	SREBF1	-0.38	-5.12	-0.3	5.97e-7	Total body bone mineral density;
CESC	cis	rs12477438	0.798	rs4324365	chr2:99623845	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.75	-10.87	-0.56	5.17e-23	Chronic sinus infection;
CESC	cis	rs873946	0.504	rs3793681	chr10:134564451	T/C	cg26818010	chr10:134567672	INPP5A	-0.86	-10.61	-0.55	3.67e-22	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs4665809	0.531	rs12987980	chr2:26462093	A/T	cg26119090	chr2:26468346	HADHA;HADHB	1.1	12.71	0.62	3.31e-29	Gut microbiome composition (summer);
CESC	cis	rs9325144	0.534	rs1973293	chr12:38679575	C/T	cg13010199	chr12:38710504	ALG10B	0.42	5.76	0.33	2.31e-8	Morning vs. evening chronotype;
CESC	cis	rs2262909	0.849	rs2666447	chr19:22132868	T/A	cg11619707	chr19:22235551	ZNF257	-0.32	-5.15	-0.3	5.02e-7	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
CESC	cis	rs4820539	1.000	rs916583	chr22:23469267	C/T	cg14186256	chr22:23484241	RTDR1	0.81	14.45	0.66	2.68e-35	Bone mineral density;
CESC	cis	rs7666738	0.830	rs1559859	chr4:99024325	C/T	cg03467027	chr4:99064603	C4orf37	0.49	6.24	0.36	1.75e-9	Colonoscopy-negative controls vs population controls;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg08679808	chr17:79886116	LOC92659;MAFG	-0.5	-7.06	-0.4	1.43e-11	Fibrinogen levels;
CESC	cis	rs12369635	1.000	rs12369635	chr12:129561356	C/T	cg01909103	chr12:129572610	TMEM132D	-0.75	-6.44	-0.37	5.48e-10	Schizophrenia (inflammation and infection response interaction);
CESC	cis	rs2569991	0.588	rs62240725	chr3:12929360	A/G	cg22481960	chr3:13008800	IQSEC1	0.55	6.58	0.37	2.47e-10	Periodontitis (DPAL);
CESC	cis	rs4919087	0.962	rs10882891	chr10:99059645	C/A	cg25902810	chr10:99078978	FRAT1	0.74	10.75	0.55	1.34e-22	Monocyte count;
CESC	cis	rs3793683	0.597	rs12767469	chr10:134587261	C/G	cg18305652	chr10:134549665	INPP5A	0.48	6.85	0.39	5.07e-11	Migraine;
CESC	cis	rs7605378	0.528	rs1704190	chr2:200760629	G/A	cg17644776	chr2:200775616	C2orf69	0.56	6.81	0.39	6.4e-11	Osteoporosis;
CESC	cis	rs2243480	1.000	rs464895	chr7:65527106	A/G	cg18252515	chr7:66147081	NA	-1.23	-12.45	-0.61	2.44e-28	Diabetic kidney disease;
CESC	trans	rs7656342	0.808	rs10003216	chr4:9766749	A/G	cg20553782	chr10:104403435	TRIM8	-0.51	-6.33	-0.36	1.04e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs6089829	0.962	rs11086151	chr20:61664644	C/T	cg16240275	chr20:61666158	NCRNA00029	0.5	8.97	0.48	5.67e-17	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg12939298	chr14:75643618	TMED10	0.46	6.08	0.35	4.19e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg07216194	chr8:27182965	PTK2B	-0.43	-6.25	-0.36	1.64e-9	Vertical cup-disc ratio;
CESC	cis	rs1215050	0.791	rs155019	chr4:98759126	G/A	cg05340658	chr4:99064831	C4orf37	0.51	6.65	0.38	1.63e-10	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs1559088	0.847	rs2287679	chr19:33600764	T/C	cg17764715	chr19:33622953	WDR88	0.48	6.2	0.36	2.2e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs2573652	0.755	rs6598286	chr15:100515985	G/T	cg00587665	chr15:100533223	ADAMTS17	-0.39	-6.25	-0.36	1.61e-9	Height;
CESC	cis	rs6951245	0.744	rs10275401	chr7:1213943	A/C	cg24642844	chr7:1081250	C7orf50	-0.58	-7.25	-0.41	4.71e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs12681366	0.623	rs10106494	chr8:95483454	A/G	cg13257157	chr8:95487014	RAD54B	0.47	5.68	0.33	3.47e-8	Nonsyndromic cleft lip with cleft palate;
CESC	cis	rs17345786	0.906	rs72940399	chr3:101122575	A/T	cg12386194	chr3:101231763	SENP7	0.58	6.19	0.36	2.33e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9611565	0.694	rs202618	chr22:41822856	A/G	cg03806693	chr22:41940476	POLR3H	1.2	14.5	0.67	1.86e-35	Vitiligo;
CESC	cis	rs8033133	0.706	rs12594112	chr15:25350127	A/C	cg14481604	chr15:25334117	SNORD116-22	-0.35	-5.43	-0.32	1.27e-7	Blood osmolality (transformed sodium);
CESC	cis	rs7615952	1.000	rs9289275	chr3:125648659	A/T	cg05084668	chr3:125655381	ALG1L	-0.5	-5.86	-0.34	1.36e-8	Blood pressure (smoking interaction);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg11688874	chr10:28822482	WAC	-0.41	-6.23	-0.36	1.83e-9	Gambling;
CESC	cis	rs6570726	0.846	rs7762536	chr6:145923145	T/C	cg23711669	chr6:146136114	FBXO30	0.85	12.48	0.61	2.03e-28	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9303401	0.659	rs62081315	chr17:56781468	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.03	12.82	0.62	1.31e-29	Cognitive test performance;
CESC	cis	rs4727963	0.869	rs2402634	chr7:122797119	C/T	cg03640110	chr7:122635026	TAS2R16	0.33	5.11	0.3	6.14e-7	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
CESC	cis	rs2404602	0.583	rs3759853	chr15:76587777	C/T	cg26408565	chr15:76604113	ETFA	-0.4	-5.93	-0.34	9.58e-9	Blood metabolite levels;
CESC	cis	rs12477438	0.765	rs2278895	chr2:99613484	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.62	-8.67	-0.47	4.43e-16	Chronic sinus infection;
CESC	cis	rs7197653	0.748	rs61460037	chr16:68336125	A/C	cg26727032	chr16:67993705	SLC12A4	-0.53	-5.15	-0.3	4.98e-7	Magnesium levels;
CESC	cis	rs4665809	0.590	rs72809668	chr2:26467653	C/T	cg26314531	chr2:26401878	FAM59B	0.85	9.04	0.49	3.44e-17	Gut microbiome composition (summer);
CESC	cis	rs34779708	0.750	rs35032841	chr10:35312687	G/A	cg03585969	chr10:35415529	CREM	0.76	9.89	0.52	7.54e-20	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs73206853	0.563	rs16940992	chr12:111207515	C/T	cg04375036	chr12:111181819	PPP1CC	0.47	5.19	0.3	4.11e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs7666738	0.830	rs34892904	chr4:98938097	T/C	cg05340658	chr4:99064831	C4orf37	0.82	12.54	0.61	1.29e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2404602	0.536	rs1587381	chr15:76769620	G/A	cg22467129	chr15:76604101	ETFA	-0.38	-5.82	-0.34	1.69e-8	Blood metabolite levels;
CESC	trans	rs916888	0.821	rs199504	chr17:44861003	C/T	cg22433210	chr17:43662623	NA	-0.93	-10.71	-0.55	1.77e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg19545348	chr1:211434133	RCOR3	0.51	6.83	0.39	5.68e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs9929218	0.551	rs1886697	chr16:68716179	T/C	cg02972257	chr16:68554789	NA	-0.42	-5.18	-0.3	4.34e-7	Colorectal cancer;
CESC	cis	rs2228479	0.850	rs11639788	chr16:89807543	G/A	cg19635926	chr16:89946313	TCF25	0.68	5.15	0.3	4.99e-7	Skin colour saturation;
CESC	cis	rs763121	0.853	rs3747170	chr22:39067331	G/A	cg14440974	chr22:39074834	NA	-0.42	-5.81	-0.34	1.75e-8	Menopause (age at onset);
CESC	cis	rs72781680	0.898	rs17509001	chr2:24021231	T/C	cg20701182	chr2:24300061	SF3B14	0.63	5.65	0.33	4.21e-8	Lymphocyte counts;
CESC	cis	rs6594499	0.872	rs6594498	chr5:110458351	G/A	cg04022379	chr5:110408740	TSLP	0.33	5.94	0.34	8.75e-9	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs1691799	0.899	rs1168294	chr12:66733988	T/C	cg16791601	chr12:66731901	HELB	-0.75	-13.03	-0.62	2.51e-30	White blood cell count (basophil);
CESC	cis	rs9896933	0.832	rs77512810	chr17:80804589	C/T	cg19500275	chr17:80737654	TBCD	0.63	6.1	0.35	3.82e-9	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
CESC	cis	rs11167764	1.000	rs7730511	chr5:141480418	T/C	cg08523384	chr5:141488047	NDFIP1	-0.38	-5.62	-0.33	4.87e-8	Crohn's disease;
CESC	cis	rs7811142	0.830	rs75636500	chr7:99947657	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.94	8.59	0.47	7.33e-16	Platelet count;
CESC	cis	rs6938	0.534	rs1127796	chr15:75193004	C/T	cg17294928	chr15:75287854	SCAMP5	-0.47	-6.19	-0.36	2.26e-9	Breast cancer;
CESC	cis	rs6912958	0.516	rs242278	chr6:88047059	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.71	10.75	0.55	1.35e-22	Monocyte percentage of white cells;
CESC	cis	rs1729951	0.575	rs361245	chr3:136695706	A/G	cg03617693	chr3:136751559	NA	0.38	5.34	0.31	2e-7	Neuroticism;
CESC	cis	rs2243480	1.000	rs58669269	chr7:65951953	T/C	cg12463550	chr7:65579703	CRCP	0.71	5.46	0.32	1.08e-7	Diabetic kidney disease;
CESC	cis	rs11098499	0.866	rs72676074	chr4:120359841	A/C	cg09307838	chr4:120376055	NA	0.97	14.07	0.65	5.69e-34	Corneal astigmatism;
CESC	cis	rs2952156	0.920	rs2517953	chr17:37841211	G/C	cg20243544	chr17:37824526	PNMT	0.63	8.1	0.45	1.99e-14	Asthma;
CESC	cis	rs870825	0.616	rs1401360	chr4:185643571	T/C	cg04058563	chr4:185651563	MLF1IP	0.64	7.1	0.4	1.15e-11	Blood protein levels;
CESC	cis	rs9790314	0.747	rs1599386	chr3:160856314	C/T	cg03342759	chr3:160939853	NMD3	0.41	5.19	0.3	4.11e-7	Morning vs. evening chronotype;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg18141532	chr1:104068301	RNPC3	0.5	6.68	0.38	1.38e-10	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7666738	0.830	rs11935588	chr4:98979862	A/G	cg18180107	chr4:99064573	C4orf37	-0.4	-5.3	-0.31	2.43e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1348850	0.634	rs1534304	chr2:178489264	C/T	cg22681709	chr2:178499509	PDE11A	-0.48	-6.49	-0.37	4.17e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs7618501	0.633	rs7621026	chr3:49975334	A/G	cg24110177	chr3:50126178	RBM5	-0.54	-7.55	-0.42	7.06e-13	Intelligence (multi-trait analysis);
CESC	cis	rs727505	0.954	rs58618031	chr7:124583896	T/C	cg23710748	chr7:124431027	NA	-0.39	-6.27	-0.36	1.46e-9	Lewy body disease;
CESC	cis	rs1044826	0.597	rs1017468	chr3:139145778	A/G	cg00490450	chr3:139108681	COPB2	0.41	5.09	0.3	6.9e-7	Obesity-related traits;
CESC	cis	rs6570726	0.846	rs6899900	chr6:145883873	T/G	cg23711669	chr6:146136114	FBXO30	0.87	12.96	0.62	4.33e-30	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7666738	0.830	rs6829567	chr4:99047340	T/C	cg24818145	chr4:99064322	C4orf37	0.38	5.04	0.3	8.49e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2637266	1.000	rs1907319	chr10:78337049	A/G	cg18941641	chr10:78392320	NA	-0.37	-6.69	-0.38	1.34e-10	Pulmonary function;
CESC	cis	rs9894429	0.683	rs112612275	chr17:79552604	C/A	cg18240062	chr17:79603768	NPLOC4	-0.87	-12.62	-0.61	6.39e-29	Eye color traits;
CESC	cis	rs7666738	0.830	rs3846445	chr4:99032939	T/A	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.58e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs931812	0.825	rs35515344	chr8:101896769	C/G	cg20993868	chr7:22813445	NA	0.56	7.84	0.43	1.13e-13	Attention deficit hyperactivity disorder and conduct disorder;
CESC	cis	rs10504229	0.775	rs55734109	chr8:58162322	G/A	cg22535103	chr8:58192502	C8orf71	-0.91	-9.94	-0.52	5.5e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs72634258	0.503	rs71637401	chr1:7837012	G/A	cg26816564	chr1:7831052	VAMP3	0.67	6.0	0.35	6.63e-9	Inflammatory bowel disease;
CESC	cis	rs568617	1.000	rs568617	chr11:65653242	C/T	cg19792802	chr11:65647270	CTSW	0.36	5.44	0.32	1.24e-7	Crohn's disease;
CESC	cis	rs7267979	0.808	rs84816	chr20:25459919	G/A	cg08601574	chr20:25228251	PYGB	0.36	5.23	0.31	3.44e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs2836974	0.897	rs2836927	chr21:40543216	T/C	cg11644478	chr21:40555479	PSMG1	1.03	16.81	0.72	1.2e-43	Cognitive function;
CESC	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg02475777	chr4:1388615	CRIPAK	0.74	9.29	0.5	5.92e-18	Longevity;
CESC	cis	rs10242455	0.702	rs3528	chr7:99055940	T/C	cg13560068	chr7:99070416	ZNF789	0.67	5.14	0.3	5.4e-7	Blood metabolite levels;
CESC	cis	rs6754311	0.509	rs10188066	chr2:136539513	G/A	cg15123519	chr2:136567270	LCT	0.3	5.22	0.31	3.69e-7	Mosquito bite size;
CESC	cis	rs4889855	0.505	rs8077626	chr17:78600552	G/C	cg16591659	chr17:78472290	NA	-0.33	-5.25	-0.31	3.08e-7	Fractional excretion of uric acid;
CESC	cis	rs919433	0.963	rs4850429	chr2:198178409	A/G	cg03934865	chr2:198174659	NA	0.41	5.66	0.33	4e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs4822044	0.561	rs132781	chr22:42046122	T/G	cg17376030	chr22:41985996	PMM1	-0.79	-8.79	-0.48	1.94e-16	Cannabis dependence symptom count;
CESC	cis	rs7615952	0.599	rs1875683	chr3:125732481	C/G	cg04553112	chr3:125709451	NA	-0.51	-5.58	-0.32	5.83e-8	Blood pressure (smoking interaction);
CESC	cis	rs6570726	0.791	rs6902410	chr6:145905261	G/A	cg23711669	chr6:146136114	FBXO30	0.97	14.56	0.67	1.09e-35	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1163251	0.837	rs517533	chr1:120229170	T/G	cg19096424	chr1:120255104	PHGDH	0.5	6.22	0.36	1.95e-9	Blood metabolite levels;
CESC	cis	rs5758659	0.679	rs134870	chr22:42652317	T/C	cg00645731	chr22:42541494	CYP2D7P1	-0.31	-5.35	-0.31	1.9e-7	Cognitive function;
CESC	cis	rs2354432	0.607	rs72692962	chr1:146802674	C/A	cg25205988	chr1:146714368	CHD1L	-1.03	-9.0	-0.48	4.56e-17	Mitochondrial DNA levels;
CESC	cis	rs3785574	0.962	rs62077512	chr17:61851435	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.81	10.73	0.55	1.51e-22	Height;
CESC	cis	rs9287719	0.781	rs6714413	chr2:10758859	C/T	cg00105475	chr2:10696890	NA	0.35	5.07	0.3	7.65e-7	Prostate cancer;
CESC	cis	rs651907	0.557	rs59596156	chr3:101394217	C/T	cg12386194	chr3:101231763	SENP7	0.45	5.61	0.33	5.02e-8	Colorectal cancer;
CESC	trans	rs10074525	0.885	rs35299092	chr5:90276745	A/G	cg22855255	chr17:50237267	CA10	-0.34	-6.01	-0.35	5.96e-9	Obesity-related traits;
CESC	cis	rs7927592	0.913	rs7116994	chr11:68254627	C/T	cg16797656	chr11:68205561	LRP5	0.4	5.68	0.33	3.52e-8	Total body bone mineral density;
CESC	cis	rs12926788	0.689	rs1862450	chr16:24856775	A/G	cg04756594	chr16:24857601	SLC5A11	-0.45	-5.19	-0.3	4.09e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs7264396	0.528	rs7273880	chr20:34551507	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.77	-10.35	-0.54	2.7e-21	Total cholesterol levels;
CESC	cis	rs7845219	0.525	rs6471501	chr8:95922491	A/G	cg16049864	chr8:95962084	TP53INP1	-0.5	-7.41	-0.41	1.67e-12	Type 2 diabetes;
CESC	cis	rs1153858	1.000	rs4775911	chr15:45649787	G/T	cg10760299	chr15:45669010	GATM	-0.38	-5.15	-0.3	5.09e-7	Homoarginine levels;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg16779626	chr15:41709933	RTF1	0.5	6.29	0.36	1.32e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs13242816	1.000	rs55977427	chr7:116110768	C/T	cg04696780	chr7:116139425	CAV2	-0.59	-5.28	-0.31	2.65e-7	P wave duration;
CESC	cis	rs6933660	0.745	rs6557138	chr6:151732017	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.87	14.29	0.66	1e-34	Menarche (age at onset);
CESC	cis	rs611744	0.647	rs2594358	chr8:109256018	A/G	cg21045802	chr8:109455806	TTC35	0.52	6.64	0.38	1.77e-10	Dupuytren's disease;
CESC	cis	rs8078723	0.668	rs4239225	chr17:38127112	G/A	cg17467752	chr17:38218738	THRA	0.55	8.04	0.44	2.91e-14	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CESC	cis	rs5753037	0.653	rs140123	chr22:30143206	A/G	cg01021169	chr22:30184971	ASCC2	0.45	6.29	0.36	1.28e-9	Type 1 diabetes;
CESC	cis	rs9399135	0.967	rs9399129	chr6:135285148	C/A	cg24558204	chr6:135376177	HBS1L	0.5	6.64	0.38	1.73e-10	Red blood cell count;
CESC	cis	rs10504229	0.817	rs35207430	chr8:58167614	G/A	cg24829409	chr8:58192753	C8orf71	-0.7	-9.37	-0.5	3.27e-18	Developmental language disorder (linguistic errors);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05317605	chr19:4558499	SEMA6B	0.54	6.82	0.39	6.06e-11	Gut microbiome composition (summer);
CESC	cis	rs9527	0.614	rs4919691	chr10:104624475	A/C	cg04362960	chr10:104952993	NT5C2	0.46	5.79	0.34	1.97e-8	Arsenic metabolism;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg27576415	chr15:41709087	RTF1	0.5	6.42	0.37	6.09e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs34779708	0.931	rs35997236	chr10:35376690	C/T	cg03585969	chr10:35415529	CREM	0.77	10.07	0.53	2.06e-20	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs9649213	0.614	rs4729432	chr7:97947055	G/C	cg09267113	chr7:98030324	BAIAP2L1	-0.44	-5.92	-0.34	1.01e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs1564271	0.528	rs1980756	chr10:26979371	G/C	cg13837822	chr10:26931731	LOC731789	0.43	6.59	0.38	2.37e-10	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;
CESC	cis	rs3741798	1.000	rs61922027	chr12:12486444	C/T	cg08615371	chr12:12503544	MANSC1	0.87	6.35	0.36	9.19e-10	Cerebrospinal fluid biomarker levels;
CESC	cis	rs9649213	0.593	rs7781916	chr7:97929738	A/G	cg08684580	chr7:98029266	BAIAP2L1	-0.35	-5.68	-0.33	3.49e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7635838	0.718	rs2249051	chr3:11403234	G/A	cg00170343	chr3:11313890	ATG7	0.5	7.05	0.4	1.57e-11	HDL cholesterol;
CESC	cis	rs17384381	1.000	rs12758768	chr1:85835206	C/T	cg16011679	chr1:85725395	C1orf52	0.81	8.16	0.45	1.33e-14	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg13012494	chr21:47604986	C21orf56	-0.44	-5.9	-0.34	1.11e-8	Testicular germ cell tumor;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02994162	chr1:159915569	IGSF9	0.55	6.18	0.35	2.42e-9	Gut microbiome composition (summer);
CESC	cis	rs6570726	0.935	rs454370	chr6:145846729	T/G	cg23711669	chr6:146136114	FBXO30	0.8	11.89	0.59	2e-26	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6540559	0.673	rs926346	chr1:209962204	A/T	cg25204440	chr1:209979598	IRF6	0.65	6.71	0.38	1.21e-10	Cleft lip with or without cleft palate;
CESC	cis	rs2204008	0.744	rs11495519	chr12:38060546	C/A	cg13010199	chr12:38710504	ALG10B	0.54	6.69	0.38	1.28e-10	Bladder cancer;
CESC	cis	rs9916302	0.904	rs4239222	chr17:37696235	A/C	cg20243544	chr17:37824526	PNMT	-0.51	-6.22	-0.36	1.89e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs4727027	0.834	rs7811446	chr7:148773226	G/T	cg23158103	chr7:148848205	ZNF398	-0.41	-6.53	-0.37	3.38e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs250677	0.958	rs43147	chr5:148417103	C/G	cg18129178	chr5:148520854	ABLIM3	0.48	5.5	0.32	9.07e-8	Breast cancer;
CESC	cis	rs1862618	0.671	rs173763	chr5:56225418	G/A	cg18230493	chr5:56204884	C5orf35	-0.62	-8.3	-0.45	5.39e-15	Initial pursuit acceleration;
CESC	cis	rs9768139	0.733	rs13225172	chr7:158120334	G/A	cg24154853	chr7:158122151	PTPRN2	0.43	6.53	0.37	3.36e-10	Calcium levels;
CESC	cis	rs147649347	1	rs147649347	chr2:24210076	GATAA/G	cg08917208	chr2:24149416	ATAD2B	1.01	9.08	0.49	2.55e-17	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	trans	rs61931739	0.500	rs4436630	chr12:34394200	C/T	cg26384229	chr12:38710491	ALG10B	0.54	7.75	0.43	2.01e-13	Morning vs. evening chronotype;
CESC	cis	rs6570726	0.837	rs419991	chr6:145864212	C/T	cg23711669	chr6:146136114	FBXO30	0.8	11.78	0.59	4.84e-26	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg26338869	chr17:61819248	STRADA	0.69	9.11	0.49	2.04e-17	Prudent dietary pattern;
CESC	cis	rs2072732	0.861	rs4576609	chr1:2938265	C/T	cg15211996	chr1:2936768	ACTRT2	0.35	5.75	0.33	2.47e-8	Plateletcrit;
CESC	cis	rs4665809	0.590	rs2303894	chr2:26508187	A/G	cg08470875	chr2:26401718	FAM59B	0.66	6.44	0.37	5.58e-10	Gut microbiome composition (summer);
CESC	cis	rs7129220	0.623	rs35815123	chr11:10119764	G/A	cg01453529	chr11:10209919	SBF2	-0.48	-5.35	-0.31	1.86e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CESC	cis	rs62064224	0.748	rs72813015	chr17:30693331	T/C	cg12855166	chr17:30846586	MYO1D	0.41	5.21	0.3	3.74e-7	Schizophrenia;
CESC	cis	rs4595586	0.545	rs2197940	chr12:39401937	C/T	cg26384229	chr12:38710491	ALG10B	0.54	7.64	0.42	3.96e-13	Morning vs. evening chronotype;
CESC	cis	rs1595825	0.891	rs16825786	chr2:198794681	G/T	cg10820045	chr2:198174542	NA	0.4	5.07	0.3	7.32e-7	Ulcerative colitis;
CESC	cis	rs68170813	0.641	rs12534124	chr7:107119047	G/A	cg02696742	chr7:106810147	HBP1	-0.56	-5.26	-0.31	3.03e-7	Coronary artery disease;
CESC	cis	rs7335046	0.505	rs6491493	chr13:99900420	C/G	cg21788972	chr13:99853209	UBAC2	-0.4	-5.07	-0.3	7.64e-7	Basal cell carcinoma;
CESC	cis	rs698833	0.962	rs698829	chr2:44730846	G/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.46	5.33	0.31	2.09e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs561341	0.941	rs72825746	chr17:30364610	G/A	cg19193384	chr17:30244184	NA	-0.69	-6.44	-0.37	5.6e-10	Hip circumference adjusted for BMI;
CESC	cis	rs7666738	0.830	rs13111977	chr4:98953813	G/A	cg03676636	chr4:99064102	C4orf37	0.33	5.11	0.3	6.05e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs17060993	0.618	rs17056484	chr8:26848328	C/T	cg26814335	chr8:6584320	AGPAT5	-0.66	-6.29	-0.36	1.33e-9	Musician's dystonia;
CESC	cis	rs7666738	0.830	rs4323111	chr4:98952276	A/G	cg17366294	chr4:99064904	C4orf37	0.58	8.28	0.45	6.04e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2066819	1.000	rs17118403	chr12:56630067	C/T	cg26714650	chr12:56694279	CS	-1.42	-10.04	-0.53	2.52e-20	Psoriasis vulgaris;
CESC	cis	rs28374715	0.681	rs7163989	chr15:41614621	A/G	cg20272979	chr15:41787780	ITPKA	0.39	5.16	0.3	4.86e-7	Ulcerative colitis;
CESC	cis	rs1707322	0.752	rs4660313	chr1:46110841	A/G	cg03146154	chr1:46216737	IPP	-0.8	-11.24	-0.57	3.12e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9660992	0.710	rs1768587	chr1:205236432	C/T	cg00857998	chr1:205179979	DSTYK	0.47	5.35	0.31	1.87e-7	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs1050631	0.556	rs4267398	chr18:33767749	C/T	cg25426722	chr18:33708991	SLC39A6;ELP2	0.52	6.59	0.38	2.35e-10	Esophageal squamous cell cancer (length of survival);
CESC	cis	rs1964356	0.967	rs17701675	chr8:8850633	A/G	cg15556689	chr8:8085844	FLJ10661	-0.43	-5.68	-0.33	3.58e-8	Mean corpuscular volume;
CESC	cis	rs7829975	0.807	rs519019	chr8:8595104	A/T	cg18904891	chr8:8559673	CLDN23	-0.42	-5.26	-0.31	3e-7	Mood instability;
CESC	cis	rs7618501	0.602	rs2526754	chr3:50125996	G/A	cg24308560	chr3:49941425	MST1R	0.61	8.83	0.48	1.46e-16	Intelligence (multi-trait analysis);
CESC	cis	rs1448094	0.512	rs61930864	chr12:86246740	G/A	cg19622623	chr12:86230825	RASSF9	-0.47	-5.96	-0.34	7.92e-9	Major depressive disorder;
CESC	cis	rs2635047	0.713	rs9304344	chr18:44758665	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.43	-5.75	-0.33	2.41e-8	Educational attainment;
CESC	cis	rs7666738	0.791	rs2903142	chr4:99040071	C/T	cg24818145	chr4:99064322	C4orf37	0.38	5.04	0.3	8.49e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs889312	0.500	rs702688	chr5:56190986	A/G	cg14703610	chr5:56206110	C5orf35	0.46	5.89	0.34	1.19e-8	Breast cancer;Breast cancer (early onset);
CESC	cis	rs123509	0.687	rs17238972	chr3:42819975	C/G	cg12982090	chr3:42733453	KBTBD5	-0.64	-7.27	-0.41	4.03e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs116095464	1.000	rs10475185	chr5:306981	C/T	cg22496380	chr5:211416	CCDC127	-0.89	-5.62	-0.33	4.78e-8	Breast cancer;
CESC	cis	rs10752881	0.839	rs6692207	chr1:183085304	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.89	14.36	0.66	5.49e-35	Colorectal cancer;
CESC	cis	rs514406	0.570	rs1332776	chr1:53189816	C/T	cg16325326	chr1:53192061	ZYG11B	0.71	11.36	0.57	1.26e-24	Monocyte count;
CESC	cis	rs7216064	1.000	rs8067892	chr17:65837983	A/G	cg07042672	chr17:66097459	LOC651250	-0.57	-6.69	-0.38	1.32e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs6964587	1.000	rs10488512	chr7:91753579	C/T	cg17063962	chr7:91808500	NA	0.58	7.95	0.44	5.44e-14	Breast cancer;
CESC	cis	rs1707322	1.000	rs4298677	chr1:46306619	G/A	cg06784218	chr1:46089804	CCDC17	0.32	5.49	0.32	9.45e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2425143	0.730	rs7263640	chr20:34314725	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.61	5.2	0.3	4.03e-7	Blood protein levels;
CESC	cis	rs1729951	0.575	rs1682333	chr3:136688618	G/A	cg25687071	chr3:136751404	NA	0.39	5.17	0.3	4.67e-7	Neuroticism;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg10423227	chr2:64752200	AFTPH	-0.44	-6.43	-0.37	5.76e-10	Gambling;
CESC	cis	rs9303401	0.704	rs7359501	chr17:56641200	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.52	6.8	0.39	6.98e-11	Cognitive test performance;
CESC	cis	rs2625529	0.617	rs6494973	chr15:72145728	A/T	cg16672083	chr15:72433130	SENP8	0.38	5.58	0.32	5.89e-8	Red blood cell count;
CESC	cis	rs7429990	0.965	rs1060407	chr3:47958037	G/T	cg11946769	chr3:48343235	NME6	0.45	5.55	0.32	6.93e-8	Educational attainment (years of education);
CESC	cis	rs7605827	0.930	rs11688071	chr2:15612626	T/G	cg19274914	chr2:15703543	NA	0.33	5.96	0.34	8.22e-9	Educational attainment (years of education);
CESC	cis	rs10791323	0.627	rs2723614	chr11:133705871	T/G	cg06766960	chr11:133703094	NA	-0.4	-5.69	-0.33	3.37e-8	Childhood ear infection;
CESC	cis	rs7264396	0.563	rs2425116	chr20:34323553	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.88	-10.7	-0.55	1.88e-22	Total cholesterol levels;
CESC	cis	rs854765	0.647	rs741782	chr17:18019712	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.6	8.47	0.46	1.74e-15	Total body bone mineral density;
CESC	cis	rs3733585	0.725	rs6449201	chr4:9973894	C/T	cg11266682	chr4:10021025	SLC2A9	-0.58	-10.87	-0.56	5.22e-23	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs727563	0.636	rs2187795	chr22:42092225	C/A	cg03806693	chr22:41940476	POLR3H	1.13	13.07	0.63	1.86e-30	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs7562790	0.624	rs68111949	chr2:36655465	A/G	cg09467607	chr2:36825704	FEZ2	0.32	5.14	0.3	5.26e-7	QRS duration;QRS complex (Cornell);
CESC	cis	rs2576037	0.562	rs612519	chr18:44379490	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.76	12.54	0.61	1.26e-28	Personality dimensions;
CESC	cis	rs1670533	1.000	rs10003009	chr4:1050849	G/A	cg04106633	chr4:1044584	NA	0.41	5.12	0.3	5.87e-7	Recombination rate (females);
CESC	cis	rs1707322	1.000	rs10890377	chr1:46406594	G/A	cg06784218	chr1:46089804	CCDC17	0.33	5.63	0.33	4.7e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs1707322	0.964	rs1707339	chr1:46513179	A/G	cg05343316	chr1:45956843	TESK2	-0.44	-5.44	-0.32	1.2e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs6541297	0.703	rs611841	chr1:230309481	C/A	cg20703242	chr1:230279135	GALNT2	-0.43	-5.59	-0.33	5.51e-8	Coronary artery disease;
CESC	cis	rs11650494	0.908	rs74830554	chr17:47431950	G/A	cg08112188	chr17:47440006	ZNF652	1.28	8.43	0.46	2.19e-15	Prostate cancer;
CESC	trans	rs6499188	1.000	rs6499188	chr16:68674788	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.63	7.6	0.42	5.1e-13	Ulcerative colitis;
CESC	cis	rs2415984	0.579	rs2642103	chr14:46963280	C/T	cg14871534	chr14:47121158	RPL10L	0.35	5.32	0.31	2.21e-7	Number of children ever born;
CESC	cis	rs10751667	0.600	rs7950955	chr11:1011490	G/A	cg06064525	chr11:970664	AP2A2	-0.33	-5.63	-0.33	4.64e-8	Alzheimer's disease (late onset);
CESC	cis	rs10411936	0.712	rs8100755	chr19:16593415	G/A	cg10248733	chr19:16607483	C19orf44;CALR3	0.57	6.81	0.39	6.51e-11	White blood cell count;Multiple sclerosis;
CESC	cis	rs8031584	0.958	rs34294266	chr15:31246840	A/G	cg14298792	chr15:30685198	CHRFAM7A	-0.48	-5.66	-0.33	4.02e-8	Huntington's disease progression;
CESC	cis	rs4481887	0.893	rs10736379	chr1:248455876	A/T	cg00666640	chr1:248458726	OR2T12	0.37	6.1	0.35	3.72e-9	Common traits (Other);
CESC	cis	rs17376456	0.877	rs10052428	chr5:93476530	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.63	5.33	0.31	2.11e-7	Diabetic retinopathy;
CESC	cis	rs9611565	0.765	rs132905	chr22:41799106	C/A	cg17376030	chr22:41985996	PMM1	-0.58	-6.19	-0.36	2.22e-9	Vitiligo;
CESC	cis	rs11997175	0.740	rs6991071	chr8:33814103	G/A	ch.8.33884649F	chr8:33765107	NA	0.66	9.06	0.49	3.03e-17	Body mass index;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03003689	chr1:156674970	CRABP2	0.54	6.18	0.35	2.35e-9	Gut microbiome composition (summer);
CESC	cis	rs10504229	0.683	rs59679713	chr8:58134370	G/C	cg21724239	chr8:58056113	NA	0.58	5.98	0.34	7.26e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs2370759	1.000	rs7910776	chr10:32639093	C/T	cg18270830	chr10:32634957	EPC1	0.73	6.71	0.38	1.2e-10	Sexual dysfunction (female);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg16534196	chr19:56089807	ZNF579	0.5	6.68	0.38	1.39e-10	Fibrinogen levels;
CESC	cis	rs854765	0.964	rs12950562	chr17:17995166	C/T	cg04398451	chr17:18023971	MYO15A	0.67	9.39	0.5	2.97e-18	Total body bone mineral density;
CESC	cis	rs10256972	0.527	rs28671326	chr7:1174973	G/A	cg23978390	chr7:1156363	C7orf50	0.65	9.4	0.5	2.64e-18	Longevity;Endometriosis;
CESC	cis	rs34172651	0.517	rs11647120	chr16:24819806	A/G	cg02428538	chr16:24856791	SLC5A11	-0.49	-5.2	-0.3	3.98e-7	Intelligence (multi-trait analysis);
CESC	cis	rs11623869	0.772	rs12587310	chr14:103907286	G/A	cg12935359	chr14:103987150	CKB	0.58	9.02	0.48	3.89e-17	Bone mineral density;
CESC	trans	rs561341	0.714	rs474455	chr17:30312465	A/T	cg27661571	chr11:113659931	NA	-0.71	-7.4	-0.41	1.86e-12	Hip circumference adjusted for BMI;
CESC	cis	rs6088765	0.606	rs2425024	chr20:33844938	G/T	cg24642439	chr20:33292090	TP53INP2	-0.44	-5.42	-0.32	1.37e-7	Ulcerative colitis;
CESC	cis	rs78456975	1.000	rs10208340	chr2:1563100	G/A	cg26248373	chr2:1572462	NA	-0.59	-5.66	-0.33	3.87e-8	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs9595066	0.941	rs9533777	chr13:44708720	C/T	cg04068111	chr13:44716778	NA	0.46	6.82	0.39	6.26e-11	Schizophrenia;
CESC	cis	rs9733	0.635	rs486836	chr1:150875967	A/T	cg22823121	chr1:150693482	HORMAD1	-0.35	-5.11	-0.3	6.31e-7	Tonsillectomy;
CESC	cis	rs1062177	1.000	rs2915882	chr5:151145436	T/C	cg12924095	chr5:151150029	G3BP1	0.48	6.2	0.36	2.21e-9	Preschool internalizing problems;
CESC	cis	rs7560272	0.538	rs17434655	chr2:73923089	C/T	cg20560298	chr2:73613845	ALMS1	-0.48	-6.91	-0.39	3.57e-11	Schizophrenia;
CESC	cis	rs561341	0.505	rs28708703	chr17:30386845	C/G	cg19193384	chr17:30244184	NA	-0.52	-5.35	-0.31	1.88e-7	Hip circumference adjusted for BMI;
CESC	cis	rs748404	0.560	rs1060939	chr15:43816917	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.57	7.15	0.4	8.33e-12	Lung cancer;
CESC	cis	rs72781680	0.800	rs56398785	chr2:24091515	T/A	cg08917208	chr2:24149416	ATAD2B	1.11	10.15	0.53	1.13e-20	Lymphocyte counts;
CESC	cis	rs1775715	0.870	rs7912121	chr10:32228995	T/G	cg04359828	chr10:32216031	ARHGAP12	0.37	5.11	0.3	6.2e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs28489187	0.643	rs2011825	chr1:85844671	T/C	cg16011679	chr1:85725395	C1orf52	0.47	5.64	0.33	4.25e-8	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	cis	rs7618915	0.547	rs2878726	chr3:52748271	C/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	6.63	0.38	1.84e-10	Bipolar disorder;
CESC	cis	rs1552244	1.000	rs9845756	chr3:10067548	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-10.79	-0.55	9.49e-23	Alzheimer's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09926380	chr3:10052611	LOC401052	0.48	6.08	0.35	4.25e-9	Gut microbiome composition (summer);
CESC	cis	rs425277	0.585	rs3128294	chr1:2065343	G/C	cg16545954	chr1:2118288	C1orf86	-0.35	-6.51	-0.37	3.82e-10	Height;
CESC	cis	rs539096	0.500	rs2527776	chr1:44345292	G/A	cg23954153	chr1:44402353	ARTN	-0.35	-5.49	-0.32	9.27e-8	Intelligence (multi-trait analysis);
CESC	cis	rs9916302	0.904	rs9898773	chr17:37532507	C/G	cg19468946	chr17:37922297	IKZF3	0.39	5.07	0.3	7.46e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs61996546	0.622	rs34916314	chr15:26833559	A/G	cg15066197	chr15:26874202	GABRB3	-0.35	-5.09	-0.3	6.95e-7	Response to methotrexate in juvenile idiopathic arthritis;
CESC	cis	rs9322193	0.887	rs11155662	chr6:149913867	T/G	cg13206674	chr6:150067644	NUP43	0.39	5.4	0.31	1.47e-7	Lung cancer;
CESC	cis	rs698833	0.892	rs1085483	chr2:44616047	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.51	6.54	0.37	3.23e-10	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs2841277	0.708	rs9671643	chr14:105408030	A/G	cg21017887	chr14:105400489	NA	0.41	6.8	0.39	7.06e-11	Rheumatoid arthritis;
CESC	cis	rs11690935	0.688	rs7600835	chr2:172521827	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.54	-7.14	-0.4	8.9e-12	Schizophrenia;
CESC	cis	rs66573146	0.808	rs73202120	chr4:7005588	A/G	cg26116260	chr4:7069785	GRPEL1	-0.72	-5.52	-0.32	8.05e-8	Granulocyte percentage of myeloid white cells;
CESC	cis	rs4889855	0.556	rs4506961	chr17:78543182	G/A	cg16591659	chr17:78472290	NA	0.41	6.82	0.39	6.04e-11	Fractional excretion of uric acid;
CESC	cis	rs854765	0.547	rs9912096	chr17:17896673	A/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.57	8.19	0.45	1.14e-14	Total body bone mineral density;
CESC	cis	rs2730245	0.527	rs842707	chr7:158656012	C/T	cg24397884	chr7:158709396	WDR60	0.83	8.47	0.46	1.71e-15	Height;
CESC	cis	rs9875589	0.509	rs2731330	chr3:14111588	C/G	cg19554555	chr3:13937349	NA	-0.45	-5.84	-0.34	1.54e-8	Ovarian reserve;
CESC	cis	rs9911578	1.000	rs4398153	chr17:56968181	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	-0.39	-5.22	-0.31	3.67e-7	Intelligence (multi-trait analysis);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04904834	chr1:179851103	TOR1AIP1	0.51	6.45	0.37	5.41e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs1215050	0.740	rs11097580	chr4:98767255	C/A	cg05340658	chr4:99064831	C4orf37	0.53	6.85	0.39	5.29e-11	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs9858542	0.953	rs7622302	chr3:49547561	T/C	cg03060546	chr3:49711283	APEH	-0.53	-6.04	-0.35	5.21e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs17854409	0.881	rs68066790	chr20:61487150	T/A	cg07645718	chr20:61493192	TCFL5	0.79	5.44	0.32	1.22e-7	Obesity-related traits;
CESC	cis	rs6502050	0.835	rs7406220	chr17:80077850	T/C	cg11859384	chr17:80120422	CCDC57	0.38	5.15	0.3	5.1e-7	Life satisfaction;
CESC	cis	rs6938	0.618	rs12901190	chr15:75231452	T/C	cg14664628	chr15:75095509	CSK	-0.51	-6.6	-0.38	2.2e-10	Breast cancer;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14595275	chr17:62075755	C17orf72	0.5	6.37	0.36	8.24e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg18402987	chr7:1209562	NA	0.75	7.49	0.42	1.04e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs1552244	1.000	rs9820598	chr3:10117912	C/G	cg16606324	chr3:10149918	C3orf24	0.43	5.36	0.31	1.81e-7	Alzheimer's disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg02976575	chr7:97835841	LMTK2	0.49	6.67	0.38	1.51e-10	Fibrinogen levels;
CESC	cis	rs3026101	0.671	rs886361	chr17:5292762	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.43	5.77	0.33	2.16e-8	Body mass index;
CESC	trans	rs4716602	0.596	rs10253193	chr7:156157801	C/T	cg07175507	chr18:77160758	NFATC1	-0.46	-6.28	-0.36	1.42e-9	Anti-saccade response;
CESC	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg18765753	chr7:1198926	ZFAND2A	-0.41	-5.15	-0.3	5.19e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs9916302	0.706	rs4488484	chr17:37717377	A/T	cg07936489	chr17:37558343	FBXL20	0.97	11.39	0.57	1.03e-24	Glomerular filtration rate (creatinine);
CESC	cis	rs344364	0.511	rs1657134	chr16:1953127	A/G	cg03013636	chr16:1946785	NA	0.47	6.41	0.37	6.45e-10	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs6831352	0.734	rs3100630	chr4:100031715	T/A	cg12011299	chr4:100065546	ADH4	0.57	6.88	0.39	4.34e-11	Alcohol dependence;
CESC	cis	rs10779751	1.000	rs1010447	chr1:11269796	A/G	cg08854313	chr1:11322531	MTOR	0.76	9.88	0.52	8.71e-20	Body mass index;
CESC	cis	rs4588572	0.643	rs10474555	chr5:77799193	A/G	cg11547950	chr5:77652471	NA	0.44	5.76	0.33	2.3e-8	Triglycerides;
CESC	cis	rs1707322	0.717	rs3014245	chr1:46086913	C/T	cg03146154	chr1:46216737	IPP	-0.79	-10.83	-0.55	7.06e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs11785693	0.862	rs62491191	chr8:4993460	G/A	cg26367366	chr8:4980734	NA	0.85	8.09	0.44	2.18e-14	Neuroticism (multi-trait analysis);Neuroticism;
CESC	cis	rs28830936	0.510	rs7175346	chr15:42100674	G/A	cg17847044	chr15:42102381	MAPKBP1	-0.44	-7.69	-0.43	2.84e-13	Diastolic blood pressure;
CESC	cis	rs2559856	0.967	rs2695290	chr12:102087844	A/G	cg15068132	chr12:102092402	CHPT1	0.39	5.23	0.31	3.43e-7	Blood protein levels;
CESC	cis	rs916888	0.821	rs199525	chr17:44847834	T/G	cg01570182	chr17:44337453	NA	0.93	10.7	0.55	1.93e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs1799949	0.930	rs8176194	chr17:41231221	A/C	cg23758822	chr17:41437982	NA	1.01	15.35	0.69	1.71e-38	Menopause (age at onset);
CESC	cis	rs8112211	1.000	rs73043010	chr19:38823202	T/G	cg14299480	chr19:38876666	GGN	-0.42	-5.64	-0.33	4.29e-8	Blood protein levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06773604	chr16:18995157	TMC7	-0.55	-6.15	-0.35	2.92e-9	Gut microbiome composition (summer);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg00357593	chr19:14530417	DDX39	-0.46	-6.04	-0.35	5.15e-9	Ulcerative colitis;
CESC	cis	rs9287719	0.578	rs10168852	chr2:10746323	C/A	cg00105475	chr2:10696890	NA	0.38	5.11	0.3	6.03e-7	Prostate cancer;
CESC	cis	rs780096	0.546	rs8179225	chr2:27737181	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.37	-7.33	-0.41	2.81e-12	Total body bone mineral density;
CESC	cis	rs11997175	0.549	rs4357253	chr8:33652458	G/A	ch.8.33884649F	chr8:33765107	NA	0.66	8.38	0.46	3.14e-15	Body mass index;
CESC	cis	rs9611519	0.761	rs35445172	chr22:41660301	G/A	cg03806693	chr22:41940476	POLR3H	-0.57	-6.62	-0.38	2.01e-10	Neuroticism;
CESC	cis	rs3785574	0.962	rs16947051	chr17:61790917	G/C	cg07677032	chr17:61819896	STRADA	0.43	5.44	0.32	1.21e-7	Height;
CESC	cis	rs11167764	0.638	rs7729747	chr5:141478055	C/A	cg08523384	chr5:141488047	NDFIP1	-0.37	-5.19	-0.3	4.28e-7	Crohn's disease;
CESC	cis	rs3087591	0.919	rs2012581	chr17:29560800	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.44	-5.43	-0.32	1.24e-7	Hip circumference;
CESC	cis	rs3008870	1.000	rs3008894	chr1:67377739	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.03	13.7	0.64	1.14e-32	Lymphocyte percentage of white cells;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg05323904	chr16:691677	FAM195A	-0.43	-6.03	-0.35	5.61e-9	Gambling;
CESC	cis	rs3096299	0.679	rs3102338	chr16:89442250	C/G	cg02187348	chr16:89574699	SPG7	0.49	6.5	0.37	4.04e-10	Multiple myeloma (IgH translocation);
CESC	cis	rs7044106	0.791	rs4837792	chr9:123483559	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.34	5.55	0.32	7.02e-8	Hip circumference adjusted for BMI;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg10384294	chr12:57636980	NA	-0.45	-6.34	-0.36	9.59e-10	Asthma;
CESC	trans	rs1728785	1.000	rs1645981	chr16:68571648	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.61	7.44	0.42	1.41e-12	Ulcerative colitis;
CESC	cis	rs1799949	0.683	rs55737636	chr17:41264739	C/T	cg05368731	chr17:41323189	NBR1	0.6	8.29	0.45	5.67e-15	Menopause (age at onset);
CESC	cis	rs7829975	0.807	rs519019	chr8:8595104	A/T	cg15556689	chr8:8085844	FLJ10661	-0.44	-5.61	-0.33	5.06e-8	Mood instability;
CESC	cis	rs9300255	0.596	rs7304782	chr12:123719444	A/G	cg00376283	chr12:123451042	ABCB9	-0.67	-8.93	-0.48	7.11e-17	Neutrophil percentage of white cells;
CESC	cis	rs6674176	0.932	rs7412307	chr1:44433864	C/G	cg13606994	chr1:44402422	ARTN	0.4	5.71	0.33	3.05e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs2439831	0.867	rs28415933	chr15:43635800	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.84	12.56	0.61	1.02e-28	Lung cancer in ever smokers;
CESC	cis	rs7513165	0.935	rs4951316	chr1:204161490	C/T	cg23788856	chr1:204159729	KISS1	0.37	5.04	0.3	8.81e-7	Psychosis proneness (hypomanic personality scale);Psychosis proneness (hypomanic personality scale and perceptual aberration scale);Psychosis proneness (hypomanic personality scale and revised social anhedonia scale);Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale);
CESC	cis	rs13108904	0.901	rs4516656	chr4:1279860	A/G	cg22903657	chr4:1355424	KIAA1530	-0.38	-5.18	-0.3	4.5e-7	Obesity-related traits;
CESC	cis	rs11190604	1.000	rs11190607	chr10:102303614	C/T	cg07080220	chr10:102295463	HIF1AN	0.66	6.04	0.35	5.08e-9	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs7903847	0.596	rs11189203	chr10:99159096	C/A	cg20016023	chr10:99160130	RRP12	-0.3	-5.22	-0.31	3.56e-7	Granulocyte percentage of myeloid white cells;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg10071186	chr14:71194292	NA	-0.37	-6.1	-0.35	3.8e-9	Gambling;
CESC	cis	rs778371	0.723	rs1078323	chr2:233681512	T/G	cg08000102	chr2:233561755	GIGYF2	-0.78	-11.63	-0.58	1.61e-25	Schizophrenia;
CESC	cis	rs13253111	0.624	rs7357359	chr8:28094835	T/C	cg26534493	chr8:28060551	NA	0.48	7.52	0.42	8.73e-13	Childhood body mass index;
CESC	cis	rs1152591	0.543	rs1152594	chr14:64675044	C/T	cg23250157	chr14:64679961	SYNE2	-0.44	-6.34	-0.36	1.01e-9	Atrial fibrillation;
CESC	cis	rs2439831	0.850	rs3816792	chr15:44116986	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.69	-7.62	-0.42	4.41e-13	Lung cancer in ever smokers;
CESC	cis	rs4819052	0.851	rs34101026	chr21:46662200	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.75	9.94	0.52	5.31e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs4665809	0.938	rs6742226	chr2:26342537	A/G	cg27170947	chr2:26402098	FAM59B	-0.57	-6.75	-0.38	9.52e-11	Gut microbiome composition (summer);
CESC	trans	rs731565	1.000	rs731565	chr7:147406262	C/T	cg13413955	chr9:842914	DMRT1	-0.55	-6.06	-0.35	4.71e-9	Diabetic kidney disease;
CESC	cis	rs7580658	0.929	rs4662575	chr2:128022215	C/T	cg10021288	chr2:128175891	PROC	-0.41	-6.45	-0.37	5.16e-10	Protein C levels;
CESC	cis	rs780096	0.526	rs1260341	chr2:27663215	T/A	cg17158414	chr2:27665306	KRTCAP3	-0.32	-5.97	-0.34	7.45e-9	Total body bone mineral density;
CESC	cis	rs7412746	0.587	rs11204722	chr1:150730184	A/C	cg04414720	chr1:150670196	GOLPH3L	-0.57	-7.52	-0.42	8.27e-13	Melanoma;
CESC	cis	rs6982240	0.514	rs7002268	chr8:142277340	A/G	cg27411547	chr8:142287226	NA	-0.53	-7.26	-0.41	4.22e-12	Tonsillectomy;
CESC	cis	rs1707322	0.717	rs3014249	chr1:46079493	A/G	cg05343316	chr1:45956843	TESK2	-0.52	-6.44	-0.37	5.59e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs208520	0.874	rs208485	chr6:66925654	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.85	-10.02	-0.52	3.11e-20	Exhaled nitric oxide output;
CESC	cis	rs9379850	0.730	rs9393738	chr6:26620658	G/A	cg12292205	chr6:26970375	C6orf41	-0.49	-5.44	-0.32	1.24e-7	Intelligence (multi-trait analysis);
CESC	cis	rs6912958	0.702	rs6906769	chr6:88235949	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.51	-6.82	-0.39	6.1e-11	Monocyte percentage of white cells;
CESC	cis	rs7560272	0.538	rs4241257	chr2:73938607	T/C	cg20560298	chr2:73613845	ALMS1	0.4	5.38	0.31	1.62e-7	Schizophrenia;
CESC	cis	rs4819052	0.788	rs13049700	chr21:46701909	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.79	10.4	0.54	1.76e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs72781680	0.950	rs72796402	chr2:24180104	A/G	cg20701182	chr2:24300061	SF3B14	0.78	6.82	0.39	5.98e-11	Lymphocyte counts;
CESC	cis	rs4819052	0.851	rs1006779	chr21:46670752	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.89	13.15	0.63	1e-30	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs3008870	0.727	rs2755270	chr1:67474503	C/T	cg02640540	chr1:67518911	SLC35D1	0.45	5.43	0.32	1.25e-7	Lymphocyte percentage of white cells;
CESC	cis	rs3096299	0.967	rs7205785	chr16:89458984	A/G	cg00750074	chr16:89608354	SPG7	-0.37	-5.24	-0.31	3.22e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs12997796	0.556	rs13004867	chr2:86982504	C/G	cg25203885	chr2:87302643	LOC285074	-0.63	-5.12	-0.3	6e-7	Schizophrenia;
CESC	cis	rs57221529	0.766	rs28563961	chr5:554498	C/G	cg16447950	chr5:562315	NA	-0.75	-7.74	-0.43	2.06e-13	Lung disease severity in cystic fibrosis;
CESC	cis	rs3820068	0.532	rs1547034	chr1:15919049	T/A	cg17385448	chr1:15911702	AGMAT	0.44	7.37	0.41	2.12e-12	Systolic blood pressure;
CESC	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg10150615	chr22:24372951	LOC391322	-0.58	-7.91	-0.44	6.93e-14	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs12142240	0.698	rs72677600	chr1:46834449	G/A	cg10495392	chr1:46806563	NSUN4	0.58	6.07	0.35	4.34e-9	Menopause (age at onset);
CESC	cis	rs2243480	1.000	rs316331	chr7:65604622	A/G	cg13147721	chr7:65941812	NA	0.93	8.9	0.48	9.27e-17	Diabetic kidney disease;
CESC	cis	rs9400271	0.632	rs9384704	chr6:109587209	C/T	cg01475377	chr6:109611718	NA	-0.47	-7.47	-0.42	1.15e-12	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
CESC	cis	rs9929218	0.954	rs72785165	chr16:68755635	T/A	cg02972257	chr16:68554789	NA	0.54	6.26	0.36	1.52e-9	Colorectal cancer;
CESC	cis	rs9611565	0.512	rs2050031	chr22:42152266	A/G	cg06634786	chr22:41940651	POLR3H	0.71	7.03	0.4	1.75e-11	Vitiligo;
CESC	cis	rs6089584	0.888	rs2386555	chr20:60612373	C/T	cg13770153	chr20:60521292	NA	-0.46	-5.88	-0.34	1.25e-8	Body mass index;
CESC	cis	rs9354352	0.967	rs9354351	chr6:66696271	G/A	cg07460842	chr6:66804631	NA	0.66	9.67	0.51	3.82e-19	Initial pursuit acceleration in psychotic disorders;
CESC	cis	rs1030877	0.521	rs2576747	chr2:105978676	A/T	cg02079111	chr2:105885981	TGFBRAP1	0.46	6.72	0.38	1.11e-10	Obesity-related traits;
CESC	cis	rs561341	0.714	rs111760509	chr17:30304320	A/G	cg12193833	chr17:30244370	NA	-0.68	-6.3	-0.36	1.24e-9	Hip circumference adjusted for BMI;
CESC	cis	rs9814567	0.806	rs6799543	chr3:134216139	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.44	-5.99	-0.35	6.73e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg13413755	chr9:94186957	NFIL3	-0.45	-6.03	-0.35	5.42e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs2952156	0.920	rs2247862	chr17:37829129	A/G	cg20243544	chr17:37824526	PNMT	0.58	7.13	0.4	9.71e-12	Asthma;
CESC	cis	rs78456975	1.000	rs13400784	chr2:1564473	T/A	cg26248373	chr2:1572462	NA	-0.54	-5.25	-0.31	3.13e-7	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs7210086	0.808	rs3935122	chr17:70641315	C/T	cg04206342	chr17:70636940	NA	-0.35	-6.4	-0.37	7.01e-10	Ulcerative colitis;
CESC	cis	rs7474896	0.526	rs1208716	chr10:38089273	T/A	cg25427524	chr10:38739819	LOC399744	-0.48	-5.16	-0.3	4.76e-7	Obesity (extreme);
CESC	cis	rs1552244	0.810	rs7612908	chr3:10089148	A/G	cg00166722	chr3:10149974	C3orf24	0.52	6.38	0.36	7.91e-10	Alzheimer's disease;
CESC	cis	rs1413885	0.516	rs3818449	chr1:65844963	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.5	6.43	0.37	5.97e-10	Anticoagulant levels;
CESC	cis	rs7618915	0.547	rs35211965	chr3:52685305	C/G	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.31	5.52	0.32	8.19e-8	Bipolar disorder;
CESC	cis	rs3096299	0.933	rs3114848	chr16:89452771	G/A	cg08392591	chr16:89556376	ANKRD11	0.4	5.1	0.3	6.45e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs9837602	0.592	rs629120	chr3:99425767	A/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.41	-5.5	-0.32	8.72e-8	Breast cancer;
CESC	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg04025307	chr7:1156635	C7orf50	0.41	5.62	0.33	4.93e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs1348850	0.651	rs1901824	chr2:178225466	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.69	9.83	0.52	1.2e-19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs8058578	1.000	rs8051050	chr16:30687909	A/G	cg02466173	chr16:30829666	NA	-0.45	-7.25	-0.41	4.68e-12	Multiple myeloma;
CESC	cis	rs9811920	0.609	rs809415	chr3:99582242	G/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.53	-6.44	-0.37	5.6e-10	Axial length;
CESC	cis	rs35306767	0.761	rs12770173	chr10:1027108	A/C	cg25019033	chr10:957182	NA	-0.65	-6.53	-0.37	3.28e-10	Eosinophil percentage of granulocytes;
CESC	cis	rs9443189	0.762	rs2748944	chr6:76436106	A/G	cg01950844	chr6:76311363	SENP6	0.69	7.86	0.43	9.43e-14	Prostate cancer;
CESC	cis	rs9457247	0.967	rs2757054	chr6:167380501	A/G	cg07741184	chr6:167504864	NA	-0.3	-5.38	-0.31	1.65e-7	Crohn's disease;
CESC	cis	rs2991971	0.967	rs12743512	chr1:45954033	A/G	cg15605315	chr1:45957053	TESK2	-0.47	-6.2	-0.36	2.12e-9	High light scatter reticulocyte count;
CESC	cis	rs4819052	0.765	rs2838852	chr21:46677037	C/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.95	14.06	0.65	6.32e-34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs2516839	0.652	rs2774276	chr1:161011716	G/C	cg00945666	chr1:160990265	F11R	-0.34	-5.45	-0.32	1.16e-7	Granulocyte percentage of myeloid white cells;
CESC	trans	rs208520	1.000	rs12195505	chr6:66986279	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.84	9.34	0.5	4.23e-18	Exhaled nitric oxide output;
CESC	cis	rs2836974	0.899	rs35774464	chr21:40580169	G/A	cg27266027	chr21:40555129	PSMG1	0.45	5.19	0.3	4.26e-7	Cognitive function;
CESC	cis	rs7666738	0.830	rs10031190	chr4:98908683	C/A	cg05340658	chr4:99064831	C4orf37	0.76	11.21	0.57	4.1e-24	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7193541	0.825	rs4411525	chr16:74595502	A/C	cg01733217	chr16:74700730	RFWD3	0.89	13.44	0.64	9.36e-32	Multiple myeloma;
CESC	cis	rs642803	0.613	rs489574	chr11:65542739	C/T	cg08755490	chr11:65554678	OVOL1	0.44	5.7	0.33	3.23e-8	Urate levels;
CESC	cis	rs7666738	0.791	rs2865958	chr4:99040732	G/T	cg17366294	chr4:99064904	C4orf37	0.61	8.78	0.47	2.13e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4849845	0.598	rs11690576	chr2:121019800	A/G	cg24070213	chr2:121070622	NA	-0.46	-6.84	-0.39	5.36e-11	Mean platelet volume;
CESC	cis	rs9796	0.689	rs692195	chr15:41444894	G/C	cg12426344	chr15:41135900	SPINT1	-0.25	-5.48	-0.32	1e-7	Menopause (age at onset);
CESC	cis	rs4654899	0.758	rs3820326	chr1:21277141	G/A	cg05370193	chr1:21551575	ECE1	0.37	5.62	0.33	4.75e-8	Superior frontal gyrus grey matter volume;
CESC	cis	rs864537	0.676	rs1773561	chr1:167421951	C/T	cg09179987	chr1:167433047	CD247	0.51	7.67	0.43	3.24e-13	Celiac disease or Rheumatoid arthritis;Celiac disease;
CESC	cis	rs1009170	0.794	rs3088123	chr14:92628952	A/C	cg10324096	chr14:92587714	CPSF2;NDUFB1	0.52	5.03	0.3	9.19e-7	Dialysis-related mortality;
CESC	cis	rs6963495	0.818	rs73190189	chr7:105164452	G/A	cg02135003	chr7:105160482	PUS7	-0.46	-5.54	-0.32	7.17e-8	Bipolar disorder (body mass index interaction);
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg18509826	chr3:52017385	ACY1	0.51	6.77	0.38	8.23e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs7937682	0.883	rs549143	chr11:111463779	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.9	-12.87	-0.62	9.33e-30	Primary sclerosing cholangitis;
CESC	cis	rs6952808	0.756	rs12537348	chr7:1948172	C/G	cg00106254	chr7:1943704	MAD1L1	-0.48	-6.03	-0.35	5.49e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs2836633	0.929	rs4143428	chr21:40030582	G/T	cg12884169	chr21:40033163	ERG	0.38	5.99	0.35	6.69e-9	Coronary artery disease;
CESC	cis	rs9467711	0.538	rs35942482	chr6:26444938	T/A	cg14345882	chr6:26364793	BTN3A2	0.63	5.85	0.34	1.42e-8	Autism spectrum disorder or schizophrenia;
CESC	cis	rs6815814	0.898	rs73236646	chr4:38871385	T/C	cg02016764	chr4:38805732	TLR1	-0.59	-6.68	-0.38	1.39e-10	Breast cancer;
CESC	cis	rs2832191	0.720	rs2832194	chr21:30494250	T/C	cg24692254	chr21:30365293	RNF160	-0.79	-12.11	-0.6	3.54e-27	Dental caries;
CESC	cis	rs7618915	0.571	rs33964154	chr3:52596914	A/G	cg18404041	chr3:52824283	ITIH1	-0.4	-6.62	-0.38	1.98e-10	Bipolar disorder;
CESC	cis	rs2425143	1.000	rs56904633	chr20:34400757	T/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.68	5.88	0.34	1.24e-8	Blood protein levels;
CESC	cis	rs9322193	0.923	rs4870509	chr6:150023348	C/G	cg07701084	chr6:150067640	NUP43	0.43	5.84	0.34	1.56e-8	Lung cancer;
CESC	cis	rs909674	0.690	rs5750823	chr22:39829973	C/T	cg24399712	chr22:39784796	NA	-0.76	-10.43	-0.54	1.46e-21	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs910316	0.967	rs4903293	chr14:75656568	A/G	cg16144293	chr14:75469539	EIF2B2	0.4	5.17	0.3	4.71e-7	Height;
CESC	cis	rs2797160	1.000	rs9491471	chr6:125991715	C/T	cg05901451	chr6:126070800	HEY2	-0.45	-6.58	-0.37	2.52e-10	Endometrial cancer;
CESC	cis	rs736408	0.609	rs13087772	chr3:52782274	T/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.48	6.83	0.39	5.76e-11	Bipolar disorder;
CESC	trans	rs12356475	0.710	rs10822686	chr10:67733250	C/T	cg15070096	chr1:156470876	MEF2D	0.49	6.25	0.36	1.68e-9	Psoriatic arthritis;
CESC	cis	rs8067545	0.611	rs10491107	chr17:20188174	C/T	cg13482628	chr17:19912719	NA	0.45	6.14	0.35	2.94e-9	Schizophrenia;
CESC	cis	rs67478160	0.529	rs12880413	chr14:104267407	A/G	cg08213375	chr14:104286397	PPP1R13B	0.54	10.79	0.55	9.69e-23	Schizophrenia;
CESC	cis	rs6952808	0.823	rs58222895	chr7:1885064	G/A	cg22963979	chr7:1858916	MAD1L1	-0.38	-5.19	-0.3	4.18e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs78456975	1.000	rs11884854	chr2:1566154	A/G	cg26248373	chr2:1572462	NA	-0.51	-5.16	-0.3	4.92e-7	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs10927875	0.632	rs6677321	chr1:16149301	A/C	cg21385522	chr1:16154831	NA	-1.02	-16.41	-0.71	2.97e-42	Dilated cardiomyopathy;
CESC	cis	rs7412746	0.611	rs11204748	chr1:150927369	G/T	cg17724175	chr1:150552817	MCL1	0.33	5.09	0.3	6.88e-7	Melanoma;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg05876094	chr1:174968893	CACYBP	-0.4	-6.02	-0.35	5.8e-9	Gambling;
CESC	cis	rs4925325	0.741	rs6142886	chr20:60511190	A/G	cg13770153	chr20:60521292	NA	0.76	11.17	0.57	5.53e-24	Obesity-related traits;
CESC	cis	rs1862618	0.802	rs7733041	chr5:56107377	A/C	cg22800045	chr5:56110881	MAP3K1	0.69	8.16	0.45	1.36e-14	Initial pursuit acceleration;
CESC	trans	rs7824557	0.505	rs2736313	chr8:11086942	C/T	cg15556689	chr8:8085844	FLJ10661	0.51	6.47	0.37	4.69e-10	Retinal vascular caliber;
CESC	cis	rs17125944	0.656	rs74825460	chr14:53390015	C/T	cg00686598	chr14:53173677	PSMC6	0.91	6.17	0.35	2.5e-9	Alzheimer's disease (late onset);
CESC	cis	rs1348850	0.567	rs2222711	chr2:178534110	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.6	7.37	0.41	2.24e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs7914558	0.966	rs7085598	chr10:104650128	T/C	cg08650961	chr10:104748594	CNNM2	0.33	5.37	0.31	1.75e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg15977278	chr12:104234975	NT5DC3	0.51	6.69	0.38	1.3100000000000001e-10	Tetralogy of Fallot;
CESC	trans	rs11088226	0.645	rs7281844	chr21:33932435	T/C	cg09050820	chr6:167586206	TCP10L2	0.88	8.47	0.46	1.72e-15	Gastritis;
CESC	cis	rs477692	1.000	rs477692	chr10:131426022	T/C	cg05714579	chr10:131428358	MGMT	0.53	7.22	0.41	5.66e-12	Response to temozolomide;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11464464	chr5:68513891	MRPS36	-0.67	-7.2	-0.4	6.3e-12	Gut microbiome composition (summer);
CESC	trans	rs9987353	0.840	rs329994	chr8:9123233	A/G	cg10229899	chr1:49364797	AGBL4	0.45	6.13	0.35	3.18e-9	Recombination measurement;
CESC	cis	rs2836974	0.526	rs418359	chr21:40536734	T/C	cg11890956	chr21:40555474	PSMG1	-0.97	-16.62	-0.71	5.65e-43	Cognitive function;
CESC	cis	rs2997447	0.706	rs55657303	chr1:26421012	A/G	cg24596570	chr1:26146463	FAM54B;LOC646471	0.67	5.55	0.32	6.83e-8	QRS complex (12-leadsum);
CESC	cis	rs796364	1.000	rs281783	chr2:200751582	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.9	8.79	0.48	1.87e-16	Schizophrenia;
CESC	cis	rs13082711	0.911	rs34307140	chr3:27467875	A/C	cg02860705	chr3:27208620	NA	0.53	6.8	0.39	7.04e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CESC	cis	rs3733585	0.699	rs6852441	chr4:9973744	C/T	cg11266682	chr4:10021025	SLC2A9	-0.58	-10.87	-0.56	5.22e-23	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs3820068	0.608	rs58140482	chr1:16043979	A/G	cg13390004	chr1:15929781	NA	0.33	5.13	0.3	5.64e-7	Systolic blood pressure;
CESC	cis	rs1832871	0.672	rs9457343	chr6:158740567	A/G	cg07165851	chr6:158734300	TULP4	0.59	6.41	0.37	6.63e-10	Height;
CESC	cis	rs9457247	1.000	rs389956	chr6:167407254	T/G	cg07741184	chr6:167504864	NA	0.29	5.31	0.31	2.32e-7	Crohn's disease;
CESC	cis	rs9916302	0.904	rs6503519	chr17:37706578	A/G	cg15445000	chr17:37608096	MED1	0.4	6.5	0.37	3.95e-10	Glomerular filtration rate (creatinine);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18905668	chr11:18388147	GTF2H1	-0.55	-6.75	-0.38	9.41e-11	Gut microbiome composition (summer);
CESC	cis	rs4969178	0.965	rs16971107	chr17:76394042	C/T	cg05887092	chr17:76393375	PGS1	0.56	8.87	0.48	1.1e-16	HDL cholesterol levels;
CESC	cis	rs4947534	1	rs4947534	chr7:56079094	T/C	cg09872392	chr7:56161020	PHKG1	-0.42	-6.07	-0.35	4.49e-9	Amino acid levels;Blood metabolite levels;
CESC	cis	rs9863	0.828	rs12303671	chr12:124492610	T/G	cg17562584	chr12:124393655	DNAH10	0.31	5.39	0.31	1.58e-7	White blood cell count;
CESC	cis	rs780096	0.546	rs1528533	chr2:27595756	G/C	cg22903471	chr2:27725779	GCKR	-0.5	-7.17	-0.4	7.52e-12	Total body bone mineral density;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02603784	chr3:52294457	WDR82	-0.58	-7.22	-0.41	5.58e-12	Gut microbiome composition (summer);
CESC	cis	rs10504229	0.815	rs72650879	chr8:58164648	A/G	cg05313129	chr8:58192883	C8orf71	-0.48	-5.18	-0.3	4.41e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs67311347	1.000	rs1004655	chr3:40490009	G/A	cg24209194	chr3:40518798	ZNF619	0.51	6.16	0.35	2.74e-9	Renal cell carcinoma;
CESC	cis	rs6121246	0.567	rs6058203	chr20:30198979	C/T	cg13852791	chr20:30311386	BCL2L1	0.55	5.13	0.3	5.66e-7	Mean corpuscular hemoglobin;
CESC	cis	rs55728055	0.661	rs62237775	chr22:31965401	A/G	cg01338084	chr22:32026380	PISD	1.15	8.06	0.44	2.64e-14	Age-related hearing impairment;
CESC	cis	rs7089973	0.628	rs11196953	chr10:116607707	A/G	cg25233709	chr10:116636983	FAM160B1	0.38	6.08	0.35	4.13e-9	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs2243480	1.000	rs709607	chr7:65449541	C/G	cg18252515	chr7:66147081	NA	0.93	8.62	0.47	6.08e-16	Diabetic kidney disease;
CESC	cis	rs10464366	0.544	rs2280667	chr7:39172228	A/C	cg18850127	chr7:39170497	POU6F2	0.35	5.08	0.3	7.19e-7	IgG glycosylation;
CESC	cis	rs1008375	0.897	rs1006723	chr4:17618524	G/A	cg16339924	chr4:17578868	LAP3	0.63	8.09	0.45	2.13e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs1862618	0.853	rs10461617	chr5:56104308	A/G	cg18230493	chr5:56204884	C5orf35	-0.71	-8.72	-0.47	3.23e-16	Initial pursuit acceleration;
CESC	cis	rs853679	0.542	rs6934769	chr6:28090931	A/G	cg19592336	chr6:28129416	ZNF389	0.6	8.08	0.44	2.36e-14	Depression;
CESC	cis	rs9611565	0.729	rs4822027	chr22:41786227	G/A	cg03806693	chr22:41940476	POLR3H	-1.18	-14.76	-0.67	2.13e-36	Vitiligo;
CESC	cis	rs9796	0.689	rs561301	chr15:41444723	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.42	-6.21	-0.36	2.03e-9	Menopause (age at onset);
CESC	cis	rs514406	0.607	rs6665324	chr1:53201610	G/A	cg16325326	chr1:53192061	ZYG11B	-0.69	-10.97	-0.56	2.48e-23	Monocyte count;
CESC	cis	rs7811142	0.779	rs28680963	chr7:99905475	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.14	10.97	0.56	2.56e-23	Platelet count;
CESC	cis	rs6121246	0.697	rs6088856	chr20:30226543	C/G	cg13852791	chr20:30311386	BCL2L1	0.71	7.29	0.41	3.62e-12	Mean corpuscular hemoglobin;
CESC	cis	rs722599	0.715	rs12147629	chr14:75307588	A/G	cg11812906	chr14:75593930	NEK9	-0.46	-5.54	-0.32	7.17e-8	IgG glycosylation;
CESC	cis	rs1448094	0.512	rs6539928	chr12:86244920	G/A	cg00310523	chr12:86230176	RASSF9	0.35	5.46	0.32	1.1e-7	Major depressive disorder;
CESC	cis	rs644799	0.623	rs17207890	chr11:95490754	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.61	7.58	0.42	5.7e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs2204008	0.627	rs10878488	chr12:38148666	G/A	cg26384229	chr12:38710491	ALG10B	0.74	10.58	0.55	4.66e-22	Bladder cancer;
CESC	cis	rs7208859	0.623	rs75136574	chr17:28934549	C/A	cg19761014	chr17:28927070	LRRC37B2	0.82	6.21	0.36	2.01e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs3931020	0.530	rs6668736	chr1:75234550	C/T	cg00121533	chr1:75199117	CRYZ;TYW3	0.49	6.75	0.38	9.48e-11	Resistin levels;
CESC	cis	rs12711979	0.765	rs7559345	chr2:3818523	G/A	cg17052675	chr2:3827356	NA	-0.42	-6.45	-0.37	5.34e-10	Itch intensity from mosquito bite adjusted by bite size;
CESC	cis	rs7666738	0.830	rs10856936	chr4:99011319	T/C	cg05340658	chr4:99064831	C4orf37	0.78	11.94	0.59	1.39e-26	Colonoscopy-negative controls vs population controls;
CESC	cis	rs870825	0.616	rs28636679	chr4:185627481	C/T	cg04058563	chr4:185651563	MLF1IP	0.64	7.05	0.4	1.59e-11	Blood protein levels;
CESC	cis	rs2276314	1.000	rs1540042	chr18:33555236	C/T	cg05985134	chr18:33552581	C18orf21	0.64	7.58	0.42	5.71e-13	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs10411262	0.935	rs2871987	chr19:47175528	A/G	cg13467550	chr19:47212573	PRKD2	0.33	5.38	0.31	1.66e-7	Tonsillectomy;
CESC	trans	rs1994135	0.617	rs10844642	chr12:33730368	A/C	cg26384229	chr12:38710491	ALG10B	0.47	6.35	0.36	9.33e-10	Resting heart rate;
CESC	cis	rs4820539	0.902	rs4822359	chr22:23474972	A/G	cg14186256	chr22:23484241	RTDR1	0.82	14.46	0.66	2.45e-35	Bone mineral density;
CESC	cis	rs72781680	1.000	rs72796329	chr2:24141912	G/A	cg08917208	chr2:24149416	ATAD2B	0.93	8.42	0.46	2.35e-15	Lymphocyte counts;
CESC	cis	rs763121	0.853	rs2072795	chr22:39064209	A/G	cg14440974	chr22:39074834	NA	0.43	5.92	0.34	9.84e-9	Menopause (age at onset);
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg25940728	chr20:48429179	SLC9A8	-0.5	-6.28	-0.36	1.37e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs1046896	0.586	rs9897951	chr17:80810662	T/C	cg19046167	chr17:80928561	B3GNTL1	0.45	5.33	0.31	2.1e-7	Glycated hemoglobin levels;
CESC	cis	rs6736093	0.933	rs4848238	chr2:112754720	A/C	cg12686935	chr2:112915763	FBLN7	-0.43	-5.65	-0.33	4.18e-8	Coronary artery disease;
CESC	cis	rs6089829	0.925	rs13041507	chr20:61666180	T/C	cg08564027	chr20:61660810	NA	0.9	15.37	0.69	1.54e-38	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs17854409	1.000	rs6011427	chr20:61496680	C/T	cg05147244	chr20:61493195	TCFL5	0.87	6.24	0.36	1.76e-9	Obesity-related traits;
CESC	cis	rs780096	0.546	rs1104	chr2:27599875	T/G	cg21248554	chr2:27665150	KRTCAP3	-0.35	-7.11	-0.4	1.06e-11	Total body bone mineral density;
CESC	cis	rs832540	0.656	rs2408597	chr5:56098632	G/A	cg14703610	chr5:56206110	C5orf35	0.41	5.2	0.3	3.95e-7	Coronary artery disease;
CESC	trans	rs916888	0.773	rs538628	chr17:44787313	G/C	cg27125505	chr17:43679177	LOC644172	0.49	6.53	0.37	3.43e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs1862618	0.853	rs2548665	chr5:56131805	T/A	cg18230493	chr5:56204884	C5orf35	-0.75	-8.9	-0.48	9.02e-17	Initial pursuit acceleration;
CESC	cis	rs738322	0.935	rs4384	chr22:38572440	G/C	cg17652424	chr22:38574118	PLA2G6	-0.33	-5.86	-0.34	1.35e-8	Cutaneous nevi;
CESC	cis	rs3106136	0.527	rs10016806	chr4:95158495	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.7	-11.59	-0.58	2.09e-25	Capecitabine sensitivity;
CESC	cis	rs4899554	0.640	rs72719935	chr14:75724345	C/T	cg18117039	chr14:75741733	NA	0.44	5.79	0.34	1.95e-8	Inflammatory bowel disease;
CESC	cis	rs13191362	1.000	rs13195226	chr6:163006421	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.78	8.21	0.45	9.97e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs10089	0.953	rs1432614	chr5:127416919	A/G	cg19767477	chr5:127420684	SLC12A2	-0.39	-5.06	-0.3	7.71e-7	Ileal carcinoids;
CESC	cis	rs1799949	0.965	rs1842147	chr17:41435192	C/T	cg05368731	chr17:41323189	NBR1	0.75	10.1	0.53	1.66e-20	Menopause (age at onset);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg02182185	chr11:47600575	NDUFS3;KBTBD4	-0.48	-6.64	-0.38	1.72e-10	Fibrinogen levels;
CESC	cis	rs10791097	0.694	rs7107595	chr11:130758556	C/T	cg12179176	chr11:130786555	SNX19	0.65	10.05	0.53	2.46e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs80130819	0.591	rs17122651	chr12:48496660	C/T	cg05342945	chr12:48394962	COL2A1	0.51	5.92	0.34	9.78e-9	Prostate cancer;
CESC	cis	rs2425143	1.000	rs7264414	chr20:34446826	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.65	5.62	0.33	4.72e-8	Blood protein levels;
CESC	cis	rs921968	0.509	rs7571743	chr2:219352572	C/T	cg02176678	chr2:219576539	TTLL4	0.5	8.96	0.48	5.83e-17	Mean corpuscular hemoglobin concentration;
CESC	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.46	-6.75	-0.38	9.04e-11	Longevity;Endometriosis;
CESC	cis	rs959260	0.688	rs9302989	chr17:73359270	G/A	cg20590849	chr17:73267439	MIF4GD	-0.56	-6.17	-0.35	2.61e-9	Systemic lupus erythematosus;
CESC	cis	rs7680126	0.500	rs4697935	chr4:10149593	C/T	cg00071950	chr4:10020882	SLC2A9	-0.6	-6.6	-0.38	2.26e-10	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.77	10.87	0.56	5.23e-23	Prudent dietary pattern;
CESC	cis	rs6540556	0.954	rs10863786	chr1:209937764	A/G	cg05527609	chr1:210001259	C1orf107	-0.52	-6.49	-0.37	4.21e-10	Red blood cell count;
CESC	cis	rs780096	0.565	rs13022659	chr2:27743630	C/T	cg22903471	chr2:27725779	GCKR	-0.56	-7.88	-0.44	8.25e-14	Total body bone mineral density;
CESC	cis	rs9399137	0.507	rs12663810	chr6:135289782	G/C	cg22676075	chr6:135203613	NA	0.55	7.25	0.41	4.69e-12	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	cis	rs801193	0.839	rs6968619	chr7:66068867	T/C	cg18876405	chr7:65276391	NA	-0.54	-7.57	-0.42	6.06e-13	Aortic root size;
CESC	cis	rs7618915	0.501	rs2336149	chr3:52692124	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	7.86	0.43	9.89e-14	Bipolar disorder;
CESC	cis	rs2439831	0.867	rs4075674	chr15:43650230	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.9	10.46	0.54	1.12e-21	Lung cancer in ever smokers;
CESC	cis	rs2204008	0.747	rs11514040	chr12:38201040	G/A	cg13010199	chr12:38710504	ALG10B	0.54	6.69	0.38	1.28e-10	Bladder cancer;
CESC	trans	rs9467711	0.606	rs9379871	chr6:26375854	C/G	cg06606381	chr12:133084897	FBRSL1	-0.74	-6.44	-0.37	5.71e-10	Autism spectrum disorder or schizophrenia;
CESC	cis	rs208520	0.661	rs1776361	chr6:66822270	G/A	cg07460842	chr6:66804631	NA	-1.0	-13.52	-0.64	5.1e-32	Exhaled nitric oxide output;
CESC	cis	rs7786808	0.741	rs62479982	chr7:158227546	A/G	cg01191920	chr7:158217561	PTPRN2	-0.45	-7.99	-0.44	4.29e-14	Obesity-related traits;
CESC	cis	rs11190604	1.000	rs10883508	chr10:102294413	G/A	cg07080220	chr10:102295463	HIF1AN	0.68	6.43	0.37	5.89e-10	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs801193	0.935	rs2659916	chr7:66151352	C/G	cg18876405	chr7:65276391	NA	0.54	7.18	0.4	6.97e-12	Aortic root size;
CESC	cis	rs752092	0.855	rs7171515	chr15:101769618	C/T	cg19997662	chr15:101784653	CHSY1	-0.41	-5.48	-0.32	9.66e-8	Corneal structure;
CESC	cis	rs798766	1.000	rs1665362	chr4:1726367	T/A	cg10756475	chr4:1757242	NA	0.46	6.26	0.36	1.57e-9	Bladder cancer;Urinary bladder cancer;
CESC	cis	rs1633360	1	rs1633360	chr12:58108052	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	-0.42	-5.51	-0.32	8.55e-8	Rheumatoid arthritis;
CESC	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-6.21	-0.36	2.01e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs4654899	0.714	rs12401630	chr1:21495049	G/A	cg05370193	chr1:21551575	ECE1	0.46	7.14	0.4	8.89e-12	Superior frontal gyrus grey matter volume;
CESC	trans	rs7945705	0.875	rs2653616	chr11:8885892	A/G	cg10637292	chr12:52960529	KRT74	0.36	6.19	0.36	2.27e-9	Hemoglobin concentration;
CESC	cis	rs11696845	0.649	rs6031782	chr20:43383832	A/G	cg25301532	chr20:43378953	KCNK15	-0.33	-5.33	-0.31	2.15e-7	Obesity-related traits;
CESC	cis	rs4722166	0.695	rs35779989	chr7:22800314	A/C	cg13104385	chr7:22767384	IL6	0.39	5.67	0.33	3.78e-8	Lung cancer;
CESC	cis	rs10504229	1.000	rs67236942	chr8:58176525	T/C	cg24829409	chr8:58192753	C8orf71	-0.76	-10.0	-0.52	3.53e-20	Developmental language disorder (linguistic errors);
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg15813570	chr14:64854563	MTHFD1	-0.48	-6.57	-0.37	2.6e-10	Height;
CESC	cis	rs9818758	0.607	rs55873331	chr3:49597055	C/T	cg00383909	chr3:49044727	WDR6	0.82	5.13	0.3	5.59e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CESC	cis	rs72781680	0.898	rs72786286	chr2:24074659	T/A	cg20701182	chr2:24300061	SF3B14	0.62	5.6	0.33	5.24e-8	Lymphocyte counts;
CESC	cis	rs72945132	0.882	rs947812	chr11:70209169	C/T	cg14191688	chr11:70257035	CTTN	0.43	5.22	0.31	3.62e-7	Coronary artery disease;
CESC	cis	rs7267979	1.000	rs4815418	chr20:25382211	T/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.88	-18.14	-0.74	2.39e-48	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs12220238	1.000	rs10824130	chr10:76008931	T/A	cg19889307	chr10:75911429	ADK;AP3M1	0.6	5.68	0.33	3.61e-8	Soluble interleukin-2 receptor subunit alpha;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24869748	chr6:86303744	SNX14	0.55	6.26	0.36	1.51e-9	Gut microbiome composition (summer);
CESC	cis	rs61931739	0.517	rs7958755	chr12:34294699	T/C	cg19457237	chr12:34500585	NA	-0.38	-5.19	-0.3	4.19e-7	Morning vs. evening chronotype;
CESC	cis	rs6582630	0.502	rs1607867	chr12:38385463	C/T	cg13010199	chr12:38710504	ALG10B	0.48	6.23	0.36	1.87e-9	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs8177253	1.000	rs6762719	chr3:133480817	A/G	cg12373951	chr3:133503437	NA	0.43	6.39	0.37	7.3e-10	Iron status biomarkers;
CESC	cis	rs2836950	0.520	rs1980407	chr21:40543961	T/C	cg11644478	chr21:40555479	PSMG1	-0.57	-7.9	-0.44	7.71e-14	Menarche (age at onset);
CESC	cis	rs9916302	0.561	rs12453198	chr17:37741879	T/C	cg20243544	chr17:37824526	PNMT	0.56	5.14	0.3	5.26e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs4662945	0.603	rs2406981	chr2:130305487	A/G	cg05962382	chr2:130345044	NA	-0.48	-6.85	-0.39	5.15e-11	Response to cytidine analogues (gemcitabine);
CESC	cis	rs853679	0.517	rs34716816	chr6:28046169	C/A	cg26335602	chr6:28129616	ZNF389	0.53	7.05	0.4	1.55e-11	Depression;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07898632	chr15:73345666	NEO1	0.65	7.21	0.4	5.75e-12	Gut microbiome composition (summer);
CESC	cis	rs35995292	0.534	rs2008199	chr7:38939678	T/C	cg19327137	chr7:38886074	VPS41	0.66	10.91	0.56	3.88e-23	Subjective well-being (multi-trait analysis);
CESC	cis	rs875971	1.000	rs778706	chr7:65860424	A/G	cg18876405	chr7:65276391	NA	0.5	6.68	0.38	1.43e-10	Aortic root size;
CESC	cis	rs3796352	1.000	rs34979715	chr3:53048960	G/A	cg12962167	chr3:53033115	SFMBT1	0.67	5.32	0.31	2.17e-7	Immune reponse to smallpox (secreted IL-2);
CESC	cis	rs9910055	0.659	rs7207464	chr17:42245033	C/T	cg13607699	chr17:42295918	UBTF	0.58	7.66	0.43	3.44e-13	Total body bone mineral density;
CESC	cis	rs748404	0.660	rs2602141	chr15:43724646	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	8.25	0.45	7.39e-15	Lung cancer;
CESC	cis	rs7000551	0.642	rs2449328	chr8:22375043	A/G	cg12081754	chr8:22256438	SLC39A14	0.42	5.56	0.32	6.44e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CESC	cis	rs7927771	0.524	rs3816605	chr11:47857253	T/C	cg20307385	chr11:47447363	PSMC3	0.62	8.68	0.47	4.02e-16	Subjective well-being;
CESC	cis	rs9916302	0.904	rs11654018	chr17:37703740	C/T	cg00129232	chr17:37814104	STARD3	0.57	7.44	0.42	1.39e-12	Glomerular filtration rate (creatinine);
CESC	cis	rs2070488	0.775	rs6599211	chr3:38558830	A/G	cg24069376	chr3:38537580	EXOG	-0.34	-5.89	-0.34	1.18e-8	Electrocardiographic conduction measures;
CESC	cis	rs7772486	0.719	rs2206141	chr6:146086192	A/G	cg23711669	chr6:146136114	FBXO30	-0.99	-15.26	-0.68	3.83e-38	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7607369	0.536	rs13033409	chr2:219666509	T/G	cg02176678	chr2:219576539	TTLL4	-0.36	-6.35	-0.36	9.45e-10	Red blood cell count;Amyotrophic lateral sclerosis;
CESC	cis	rs9911578	0.803	rs8069033	chr17:57131581	T/A	cg02118635	chr17:56770003	RAD51C;TEX14	-0.4	-5.19	-0.3	4.23e-7	Intelligence (multi-trait analysis);
CESC	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg02146966	chr17:18967117	NA	0.42	6.04	0.35	5.14e-9	Myopia;
CESC	cis	rs10504229	0.683	rs6999351	chr8:58127227	C/T	cg21724239	chr8:58056113	NA	0.57	5.76	0.33	2.29e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs9611565	0.659	rs4822037	chr22:41945113	G/T	cg03806693	chr22:41940476	POLR3H	-1.2	-15.25	-0.68	4.12e-38	Vitiligo;
CESC	cis	rs11098499	1.000	rs12506395	chr4:120185094	C/T	cg09307838	chr4:120376055	NA	0.88	11.63	0.58	1.52e-25	Corneal astigmatism;
CESC	cis	rs9309473	1.000	rs10496193	chr2:73773503	G/A	cg20560298	chr2:73613845	ALMS1	-0.48	-6.51	-0.37	3.74e-10	Metabolite levels;
CESC	cis	rs9611565	0.592	rs28750375	chr22:41990644	A/C	cg06481639	chr22:41940642	POLR3H	-0.57	-6.4	-0.37	7.18e-10	Vitiligo;
CESC	cis	rs597539	0.652	rs584108	chr11:68630282	A/T	cg04772025	chr11:68637568	NA	-0.52	-6.14	-0.35	3.06e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs3820068	0.581	rs3940061	chr1:15941276	C/T	cg13390004	chr1:15929781	NA	0.37	5.96	0.34	8.08e-9	Systolic blood pressure;
CESC	cis	rs12682352	0.602	rs6993494	chr8:8667444	C/T	cg06636001	chr8:8085503	FLJ10661	0.43	5.32	0.31	2.17e-7	Neuroticism;
CESC	cis	rs644799	1.000	rs568668	chr11:95528209	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.69	8.94	0.48	6.65e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs2991971	0.810	rs12738318	chr1:45929589	A/G	cg05343316	chr1:45956843	TESK2	0.56	7.94	0.44	5.63e-14	High light scatter reticulocyte count;
CESC	cis	rs7590368	0.673	rs2306922	chr2:10942520	C/T	cg15705551	chr2:10952987	PDIA6	0.54	5.23	0.31	3.48e-7	Educational attainment (years of education);
CESC	cis	rs3026101	0.671	rs739766	chr17:5290599	G/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.43	5.69	0.33	3.32e-8	Body mass index;
CESC	cis	rs875971	0.545	rs73142265	chr7:65699497	G/A	cg11764359	chr7:65958608	NA	0.78	8.89	0.48	9.36e-17	Aortic root size;
CESC	cis	rs2153904	0.793	rs12564209	chr1:205720212	C/G	cg23034840	chr1:205782522	SLC41A1	-0.62	-5.97	-0.34	7.48e-9	Prostate-specific antigen levels;
CESC	trans	rs1814175	0.817	rs4881627	chr11:49953955	C/A	cg03929089	chr4:120376271	NA	-0.93	-15.75	-0.7	6.66e-40	Height;
CESC	cis	rs7408868	0.908	rs62113794	chr19:15277337	C/A	cg14696996	chr19:15285081	NOTCH3	1.11	11.3	0.57	2.05e-24	Pulse pressure;
CESC	cis	rs17401966	0.931	rs3737155	chr1:10459779	G/A	cg15208524	chr1:10270712	KIF1B	0.41	5.12	0.3	5.94e-7	Hepatocellular carcinoma;
CESC	cis	rs12155623	0.592	rs12682003	chr8:49865454	G/T	cg00325661	chr8:49890786	NA	0.41	5.67	0.33	3.69e-8	Sudden cardiac arrest;
CESC	trans	rs561341	1.000	rs15654	chr17:30326360	A/C	cg27661571	chr11:113659931	NA	-0.82	-7.63	-0.42	4.18e-13	Hip circumference adjusted for BMI;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09417937	chr11:1298918	TOLLIP	-0.51	-6.1	-0.35	3.81e-9	Gut microbiome composition (summer);
CESC	cis	rs4237845	0.551	rs116263297	chr12:58273445	A/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.52	5.77	0.33	2.18e-8	Intelligence (multi-trait analysis);
CESC	cis	rs6570726	0.526	rs9403699	chr6:145730685	G/T	cg23711669	chr6:146136114	FBXO30	0.59	7.62	0.42	4.61e-13	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs12134245	0.776	rs12125947	chr1:91990487	T/C	cg02896835	chr1:92012615	NA	-0.51	-6.63	-0.38	1.84e-10	Breast cancer;
CESC	cis	rs763121	0.853	rs5757204	chr22:39046700	A/C	cg06022373	chr22:39101656	GTPBP1	0.88	13.79	0.65	5.43e-33	Menopause (age at onset);
CESC	cis	rs10949834	0.878	rs2855727	chr7:73517852	T/G	cg07137043	chr7:73588983	EIF4H	-0.66	-5.7	-0.33	3.2e-8	Verbal memory performance (residualized delayed recall change);
CESC	cis	rs1348850	0.526	rs2293475	chr2:178407897	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.61	-5.54	-0.32	7.18e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs7666738	0.753	rs13137152	chr4:98938044	A/T	cg17366294	chr4:99064904	C4orf37	0.6	8.34	0.46	4.08e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs634534	0.561	rs613924	chr11:65769295	C/T	cg02202077	chr11:65769826	EIF1AD;BANF1	0.47	6.31	0.36	1.14e-9	Sum eosinophil basophil counts;Eosinophil counts;
CESC	cis	rs798554	0.679	rs2644281	chr7:2886748	A/G	cg18446336	chr7:2847575	GNA12	-0.34	-5.4	-0.31	1.49e-7	Height;
CESC	cis	rs11098499	0.909	rs9994810	chr4:120381590	A/G	cg24375607	chr4:120327624	NA	0.44	5.51	0.32	8.65e-8	Corneal astigmatism;
CESC	cis	rs7044106	0.791	rs2416798	chr9:123480603	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.64	8.83	0.48	1.43e-16	Hip circumference adjusted for BMI;
CESC	cis	rs2836974	0.666	rs12626405	chr21:40663121	G/T	cg17971929	chr21:40555470	PSMG1	-0.87	-12.58	-0.61	8.68e-29	Cognitive function;
CESC	cis	rs34779708	0.966	rs1478463	chr10:35473035	G/A	cg04310649	chr10:35416472	CREM	-0.54	-6.78	-0.38	7.74e-11	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs9649213	0.574	rs13238610	chr7:97909277	T/C	cg08684580	chr7:98029266	BAIAP2L1	-0.33	-5.27	-0.31	2.82e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs9811920	0.625	rs7631174	chr3:99913902	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.36	5.38	0.31	1.61e-7	Axial length;
CESC	cis	rs7680126	0.596	rs10939835	chr4:10313750	A/G	cg11266682	chr4:10021025	SLC2A9	-0.43	-5.29	-0.31	2.54e-7	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	cis	rs10504229	1.000	rs17216620	chr8:58169412	A/G	cg14926445	chr8:58193284	C8orf71	-0.51	-5.47	-0.32	1.03e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs10206020	0.921	rs6605278	chr2:1547230	C/T	cg26248373	chr2:1572462	NA	-0.58	-6.59	-0.38	2.38e-10	IgG glycosylation;
CESC	cis	rs9815354	0.904	rs73081347	chr3:41903582	T/C	cg03022575	chr3:42003672	ULK4	0.7	6.18	0.36	2.38e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs10504229	0.906	rs7842855	chr8:58167718	G/C	cg22535103	chr8:58192502	C8orf71	-0.93	-12.03	-0.59	6.97e-27	Developmental language disorder (linguistic errors);
CESC	cis	rs5013026	1	rs5013026	chr22:18171650	C/T	cg19898043	chr22:18121309	BCL2L13	-0.42	-5.32	-0.31	2.17e-7	Neutrophil count;
CESC	cis	rs1670533	1.000	rs2014318	chr4:1068778	C/T	cg27284194	chr4:1044797	NA	-0.44	-5.59	-0.32	5.56e-8	Recombination rate (females);
CESC	cis	rs7089973	0.624	rs10885614	chr10:116609098	C/T	cg25233709	chr10:116636983	FAM160B1	0.38	6.08	0.35	4.13e-9	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs9916302	0.652	rs9903269	chr17:37742383	A/T	cg20243544	chr17:37824526	PNMT	0.56	5.14	0.3	5.26e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs9486715	0.867	rs9373833	chr6:96904998	A/G	cg18709589	chr6:96969512	KIAA0776	-0.49	-6.91	-0.39	3.7e-11	Headache;
CESC	cis	rs597539	0.654	rs7107137	chr11:68623712	A/G	cg18350739	chr11:68623251	NA	-0.46	-6.64	-0.38	1.73e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs853679	0.517	rs7755442	chr6:28039015	T/C	cg26335602	chr6:28129616	ZNF389	0.53	7.05	0.4	1.55e-11	Depression;
CESC	cis	rs9457247	1.000	rs1819333	chr6:167373547	G/T	cg23791538	chr6:167370224	RNASET2	-0.59	-8.39	-0.46	3.02e-15	Crohn's disease;
CESC	cis	rs10504229	0.683	rs7817188	chr8:58129549	C/T	cg02725872	chr8:58115012	NA	-0.45	-7.05	-0.4	1.52e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs2286503	1.000	rs2286503	chr7:22856606	C/T	cg13679077	chr7:22862647	TOMM7	0.39	5.03	0.3	9.17e-7	Fibrinogen;
CESC	cis	rs1552244	0.935	rs35515831	chr3:10071362	G/A	cg00166722	chr3:10149974	C3orf24	0.5	6.31	0.36	1.19e-9	Alzheimer's disease;
CESC	cis	rs9329289	0.550	rs11251294	chr10:2562328	C/T	cg05625103	chr10:2543513	NA	-0.45	-6.1	-0.35	3.71e-9	Age-related hearing impairment;
CESC	trans	rs35110281	0.755	rs4819270	chr21:45020919	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.53	6.99	0.39	2.2e-11	Mean corpuscular volume;
CESC	cis	rs858239	0.932	rs1624451	chr7:23262435	A/T	cg23682824	chr7:23144976	KLHL7	-0.44	-5.86	-0.34	1.37e-8	Cerebrospinal fluid biomarker levels;
CESC	cis	rs7666738	0.830	rs13136930	chr4:98937933	A/T	cg05340658	chr4:99064831	C4orf37	0.82	12.54	0.61	1.29e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs936229	0.813	rs2168519	chr15:75080872	T/C	cg14664628	chr15:75095509	CSK	-0.9	-13.32	-0.63	2.53e-31	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CESC	cis	rs6598955	0.502	rs6683157	chr1:26545865	G/A	cg04990556	chr1:26633338	UBXN11	0.81	9.2	0.49	1.08e-17	Obesity-related traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17749735	chr1:155051360	EFNA3	0.58	6.45	0.37	5.22e-10	Gut microbiome composition (summer);
CESC	cis	rs4974559	0.501	rs1250093	chr4:1240911	G/A	cg02980000	chr4:1222292	CTBP1	-0.75	-7.67	-0.43	3.18e-13	Systolic blood pressure;
CESC	cis	rs796364	1.000	rs1658807	chr2:200767512	C/T	cg23649088	chr2:200775458	C2orf69	0.54	5.13	0.3	5.74e-7	Schizophrenia;
CESC	cis	rs6693567	0.565	rs12731296	chr1:150411787	A/G	cg09579323	chr1:150459698	TARS2	0.48	6.0	0.35	6.34e-9	Migraine;
CESC	trans	rs116095464	0.558	rs57335027	chr5:262907	A/G	cg00938859	chr5:1591904	SDHAP3	0.63	6.77	0.38	8.38e-11	Breast cancer;
CESC	cis	rs11048434	0.736	rs11048344	chr12:9122609	G/C	cg23795048	chr12:9217529	LOC144571	0.33	5.03	0.3	9.05e-7	Sjögren's syndrome;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23625236	chr1:214776790	CENPF	0.61	7.09	0.4	1.21e-11	Gut microbiome composition (summer);
CESC	cis	rs2120019	1.000	rs7168680	chr15:75369212	G/A	cg17294928	chr15:75287854	SCAMP5	-0.59	-6.61	-0.38	2.16e-10	Blood trace element (Zn levels);
CESC	cis	rs12134245	0.747	rs11164912	chr1:92005191	A/T	cg07090678	chr1:91966139	CDC7	0.41	5.6	0.33	5.37e-8	Breast cancer;
CESC	cis	rs1552244	1.000	rs6442150	chr3:10122575	T/C	cg08888203	chr3:10149979	C3orf24	0.52	6.65	0.38	1.63e-10	Alzheimer's disease;
CESC	cis	rs7267979	0.966	rs2261747	chr20:25261784	G/A	cg08601574	chr20:25228251	PYGB	0.39	5.61	0.33	5e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs2282802	0.660	rs4463213	chr5:139545748	G/A	cg26211634	chr5:139558579	C5orf32	-0.46	-6.63	-0.38	1.88e-10	Intelligence (multi-trait analysis);
CESC	cis	rs6772849	1.000	rs9839508	chr3:128310794	A/T	cg16766828	chr3:128327626	NA	0.32	5.17	0.3	4.7e-7	Monocyte percentage of white cells;Monocyte count;
CESC	cis	rs2933343	0.729	rs1683780	chr3:128640239	C/T	cg25356066	chr3:128598488	ACAD9	0.65	8.91	0.48	8.67e-17	IgG glycosylation;
CESC	cis	rs9916302	0.904	rs8079303	chr17:37530755	G/C	cg00129232	chr17:37814104	STARD3	0.57	7.44	0.42	1.38e-12	Glomerular filtration rate (creatinine);
CESC	trans	rs9354308	0.901	rs2814096	chr6:66566131	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.71	7.98	0.44	4.55e-14	Metabolite levels;
CESC	cis	rs911555	0.755	rs10148970	chr14:103892000	G/A	cg12935359	chr14:103987150	CKB	-0.56	-8.03	-0.44	3.16e-14	Intelligence (multi-trait analysis);
CESC	cis	rs6426558	0.537	rs7523167	chr1:227365304	G/A	cg10327440	chr1:227177885	CDC42BPA	-0.46	-5.7	-0.33	3.19e-8	Neutrophil percentage of white cells;
CESC	cis	rs6546550	0.901	rs6741449	chr2:70156589	A/G	cg02498382	chr2:70120550	SNRNP27	-0.41	-7.13	-0.4	9.44e-12	Prevalent atrial fibrillation;
CESC	cis	rs662064	0.962	rs620405	chr1:10554794	T/C	cg20482658	chr1:10539492	PEX14	-0.37	-7.43	-0.42	1.51e-12	Asthma;
CESC	cis	rs854765	0.583	rs8078138	chr17:17811251	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.52	7.22	0.41	5.44e-12	Total body bone mineral density;
CESC	cis	rs6087990	0.871	rs4911252	chr20:31330115	A/G	cg13636640	chr20:31349939	DNMT3B	-0.83	-14.66	-0.67	4.77e-36	Ulcerative colitis;
CESC	cis	rs8180040	0.966	rs9683033	chr3:47489820	C/T	cg27129171	chr3:47204927	SETD2	0.62	9.25	0.49	7.87e-18	Colorectal cancer;
CESC	cis	rs8180040	0.966	rs11711824	chr3:47468261	C/T	cg27129171	chr3:47204927	SETD2	0.63	9.46	0.5	1.81e-18	Colorectal cancer;
CESC	cis	rs2635047	0.638	rs2668758	chr18:44685679	A/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.32	5.03	0.3	9.22e-7	Educational attainment;
CESC	cis	rs501120	1.000	rs605445	chr10:44756779	C/T	cg09554077	chr10:44749378	NA	0.52	6.91	0.39	3.59e-11	Coronary artery disease;Coronary heart disease;
CESC	cis	rs7267979	0.966	rs6050532	chr20:25308793	A/T	cg08601574	chr20:25228251	PYGB	-0.39	-5.61	-0.33	4.99e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs3747547	0.892	rs17516973	chr9:37968915	C/T	cg13774184	chr9:37916125	SHB	-0.72	-6.13	-0.35	3.15e-9	Metabolite levels (Dihydroxy docosatrienoic acid);
CESC	cis	rs11105298	0.891	rs11105314	chr12:89924559	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.5	-5.24	-0.31	3.25e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CESC	cis	rs2549003	1.000	rs2548999	chr5:131831058	G/T	cg00255919	chr5:131827918	IRF1	-0.56	-9.46	-0.5	1.72e-18	Asthma (sex interaction);
CESC	cis	rs7811142	0.830	rs11769057	chr7:99964661	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.89	8.82	0.48	1.51e-16	Platelet count;
CESC	cis	rs7267979	0.966	rs2261747	chr20:25261784	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.86	16.87	0.72	7.12e-44	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs1904096	0.506	rs6532476	chr4:95192461	C/A	cg11021082	chr4:95130006	SMARCAD1	-0.68	-11.15	-0.57	6.32e-24	Type 2 diabetes;
CESC	cis	rs73206853	0.686	rs7974047	chr12:111119631	C/T	cg12870014	chr12:110450643	ANKRD13A	0.64	5.21	0.3	3.87e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs11098499	0.738	rs72918577	chr4:120326701	G/A	cg24375607	chr4:120327624	NA	0.47	5.91	0.34	1.03e-8	Corneal astigmatism;
CESC	trans	rs561341	0.609	rs7209493	chr17:30197323	A/G	cg20587970	chr11:113659929	NA	0.56	6.75	0.38	9.08e-11	Hip circumference adjusted for BMI;
CESC	cis	rs17095355	1.000	rs9630102	chr10:111738662	A/T	cg00817464	chr10:111662876	XPNPEP1	-0.44	-5.2	-0.3	3.98e-7	Biliary atresia;
CESC	cis	rs2455799	0.613	rs2654654	chr3:15789242	C/T	cg16303742	chr3:15540471	COLQ	-0.39	-6.14	-0.35	3.01e-9	Mean platelet volume;
CESC	cis	rs3741151	0.686	rs11828904	chr11:73139116	T/C	cg17517138	chr11:73019481	ARHGEF17	0.62	5.31	0.31	2.31e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs9322193	0.962	rs4380763	chr6:149999222	A/G	cg04369109	chr6:150039330	LATS1	-0.39	-5.4	-0.32	1.45e-7	Lung cancer;
CESC	cis	rs921968	0.565	rs7594046	chr2:219624170	A/G	cg02176678	chr2:219576539	TTLL4	0.41	7.12	0.4	1e-11	Mean corpuscular hemoglobin concentration;
CESC	cis	rs796364	1.000	rs281762	chr2:200799201	C/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.9	9.29	0.5	5.66e-18	Schizophrenia;
CESC	cis	rs6460942	1.000	rs7791634	chr7:12401482	A/T	cg20607287	chr7:12443886	VWDE	-0.68	-7.81	-0.43	1.33e-13	Coronary artery disease;
CESC	cis	rs7949030	0.588	rs2509982	chr11:62312318	C/T	cg23462726	chr11:62437636	C11orf83;C11orf48	-0.4	-5.42	-0.32	1.37e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs1008375	0.966	rs10939735	chr4:17578891	A/G	cg02297831	chr4:17616191	MED28	0.52	6.02	0.35	5.93e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg10446143	chr21:44394730	PKNOX1	-0.45	-6.55	-0.37	2.95e-10	Gambling;
CESC	cis	rs6860806	0.661	rs4705929	chr5:131584178	G/T	cg11843238	chr5:131593191	PDLIM4	0.37	5.39	0.31	1.53e-7	Breast cancer;
CESC	cis	rs7258465	0.931	rs271626	chr19:18627067	C/T	cg11102782	chr19:18549136	ISYNA1	0.37	5.13	0.3	5.54e-7	Breast cancer;
CESC	cis	rs7843479	0.544	rs11135735	chr8:21791557	C/T	cg17168535	chr8:21777572	XPO7	0.71	11.57	0.58	2.48e-25	Mean corpuscular volume;
CESC	cis	rs875971	0.862	rs2420611	chr7:65999320	A/G	cg18876405	chr7:65276391	NA	0.53	7.28	0.41	3.9e-12	Aortic root size;
CESC	cis	rs4654899	1.000	rs72865329	chr1:21517567	G/A	cg05370193	chr1:21551575	ECE1	0.41	6.27	0.36	1.44e-9	Superior frontal gyrus grey matter volume;
CESC	cis	rs4835473	0.800	rs1849122	chr4:144899852	A/G	cg25736465	chr4:144833511	NA	0.39	5.99	0.35	6.88e-9	Immature fraction of reticulocytes;
CESC	cis	rs7811142	0.830	rs10085549	chr7:99983135	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.84	8.97	0.48	5.64e-17	Platelet count;
CESC	cis	rs2576037	0.501	rs557661	chr18:44365657	A/G	cg19077165	chr18:44547161	KATNAL2	-0.51	-7.44	-0.42	1.4e-12	Personality dimensions;
CESC	cis	rs477895	0.568	rs12418035	chr11:63871558	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.87	9.57	0.51	7.96e-19	Mean platelet volume;
CESC	cis	rs116095464	0.867	rs10074958	chr5:230828	C/T	cg22857025	chr5:266934	NA	-1.29	-18.71	-0.75	2.22e-50	Breast cancer;
CESC	trans	rs931812	0.757	rs34988706	chr8:101907062	C/T	cg20993868	chr7:22813445	NA	0.42	6.33	0.36	1.04e-9	Attention deficit hyperactivity disorder and conduct disorder;
CESC	cis	rs1153858	0.621	rs1706824	chr15:45579948	C/T	cg21132104	chr15:45694354	SPATA5L1	0.75	8.97	0.48	5.5e-17	Homoarginine levels;
CESC	cis	rs2228479	0.764	rs7191836	chr16:89961597	T/C	cg04013166	chr16:89971882	TCF25	0.69	7.12	0.4	1.04e-11	Skin colour saturation;
CESC	cis	rs9303401	0.580	rs12946396	chr17:57164195	T/A	cg25039879	chr17:56429692	SUPT4H1	0.5	5.13	0.3	5.66e-7	Cognitive test performance;
CESC	cis	rs9733	0.596	rs2065900	chr1:150652202	A/G	cg18016565	chr1:150552671	MCL1	0.33	5.14	0.3	5.34e-7	Tonsillectomy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19230575	chr3:179041494	ZNF639	0.58	6.96	0.39	2.71e-11	Gut microbiome composition (summer);
CESC	cis	rs796364	0.951	rs769952	chr2:200734368	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.89	8.76	0.47	2.4e-16	Schizophrenia;
CESC	cis	rs76878669	0.538	rs1546358	chr11:66175261	G/C	cg18002602	chr11:66138449	SLC29A2	0.37	5.94	0.34	8.8e-9	Educational attainment (years of education);
CESC	cis	rs2290159	0.800	rs9817675	chr3:12676113	C/T	cg23032965	chr3:12705835	RAF1	0.53	5.67	0.33	3.76e-8	Cholesterol, total;
CESC	cis	rs2777491	0.874	rs7161772	chr15:41611066	A/T	cg18705301	chr15:41695430	NDUFAF1	-0.6	-8.98	-0.48	5.23e-17	Ulcerative colitis;
CESC	cis	rs9911578	0.935	rs7216698	chr17:57007495	G/A	cg05425664	chr17:57184151	TRIM37	-0.4	-5.47	-0.32	1.05e-7	Intelligence (multi-trait analysis);
CESC	cis	rs10089	1.000	rs1842006	chr5:127508687	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.75	10.07	0.53	2.04e-20	Ileal carcinoids;
CESC	cis	rs7666738	0.830	rs11932942	chr4:98998939	T/C	cg18180107	chr4:99064573	C4orf37	0.4	5.23	0.31	3.41e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs854765	0.583	rs9912895	chr17:17826020	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.55	-7.74	-0.43	2.04e-13	Total body bone mineral density;
CESC	cis	rs10870270	0.913	rs115236491	chr10:133766855	T/G	cg17892150	chr10:133769511	PPP2R2D	-0.87	-12.67	-0.61	4.28e-29	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs11792861	0.619	rs2289481	chr9:111712924	G/C	cg05043794	chr9:111880884	C9orf5	-0.31	-5.64	-0.33	4.4e-8	Menarche (age at onset);
CESC	cis	rs13256369	1.000	rs4841016	chr8:8572561	C/T	cg18904891	chr8:8559673	CLDN23	0.71	8.39	0.46	2.99e-15	Obesity-related traits;
CESC	cis	rs6912958	0.514	rs1980792	chr6:87889917	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.49	-8.37	-0.46	3.39e-15	Monocyte percentage of white cells;
CESC	cis	rs9399137	0.507	rs28384513	chr6:135376209	T/G	cg24558204	chr6:135376177	HBS1L	0.69	9.54	0.51	9.81e-19	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	cis	rs7116495	0.609	rs7115513	chr11:71664495	T/A	cg10381502	chr11:71823885	C11orf51	-1.09	-7.58	-0.42	5.83e-13	Severe influenza A (H1N1) infection;
CESC	cis	rs9796	0.558	rs8043253	chr15:41503730	C/T	cg20272979	chr15:41787780	ITPKA	0.34	5.05	0.3	8.32e-7	Menopause (age at onset);
CESC	cis	rs4268898	0.662	rs2288074	chr2:24413595	C/T	cg08917208	chr2:24149416	ATAD2B	0.62	5.79	0.34	1.95e-8	Asthma;
CESC	cis	rs10504229	1.000	rs78953746	chr8:58170608	A/G	cg24829409	chr8:58192753	C8orf71	-0.76	-9.82	-0.52	1.29e-19	Developmental language disorder (linguistic errors);
CESC	cis	rs8031584	0.918	rs34095794	chr15:31269691	C/T	cg14829155	chr15:31115871	NA	-0.7	-9.23	-0.49	9.02e-18	Huntington's disease progression;
CESC	cis	rs769267	0.930	rs892022	chr19:19613381	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.46	5.81	0.34	1.77e-8	Tonsillectomy;
CESC	cis	rs57244997	1.000	rs57244997	chr6:162397506	G/A	cg17173639	chr6:162384350	PARK2	-0.82	-8.02	-0.44	3.46e-14	Mosquito bite size;
CESC	cis	rs7130144	0.609	rs7928982	chr11:130432459	A/G	cg26307797	chr11:130446613	NA	-0.69	-6.6	-0.38	2.19e-10	Urate levels in lean individuals;
CESC	cis	rs896854	0.654	rs6982393	chr8:95980708	T/C	cg26343298	chr8:95960752	TP53INP1	0.36	5.95	0.34	8.55e-9	Type 2 diabetes;
CESC	cis	rs10848704	0.956	rs10848703	chr12:2882250	C/T	cg19995117	chr12:2880862	NA	0.56	9.06	0.49	3.01e-17	Quantitative traits;
CESC	cis	rs2836974	0.932	rs2836953	chr21:40617483	G/A	cg11644478	chr21:40555479	PSMG1	1.03	16.91	0.72	5.38e-44	Cognitive function;
CESC	cis	rs7811142	0.830	rs6945952	chr7:99981775	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.89	8.51	0.46	1.27e-15	Platelet count;
CESC	cis	rs75477785	0.590	rs2282740	chr1:209900307	C/A	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.85	5.21	0.3	3.82e-7	Cleft lip with or without cleft palate;
CESC	cis	rs7656342	0.622	rs2102872	chr4:9831358	T/C	cg00071950	chr4:10020882	SLC2A9	0.4	5.41	0.32	1.4e-7	Gut microbiota (bacterial taxa);
CESC	cis	rs6546537	0.550	rs6546531	chr2:69779963	C/A	cg10773587	chr2:69614142	GFPT1	-0.43	-5.49	-0.32	9.29e-8	Serum thyroid-stimulating hormone levels;
CESC	cis	rs2115630	0.967	rs8028490	chr15:85277888	G/A	cg12501888	chr15:85177176	SCAND2	-0.39	-5.07	-0.3	7.37e-7	P wave terminal force;
CESC	cis	rs35306767	0.855	rs61830900	chr10:871481	C/G	cg10556349	chr10:835070	NA	0.76	6.39	0.37	7.22e-10	Eosinophil percentage of granulocytes;
CESC	cis	rs13040088	1.000	rs10854167	chr20:61533039	G/C	cg23096297	chr20:61557774	DIDO1	0.97	10.76	0.55	1.19e-22	Menopause (age at onset);
CESC	cis	rs6484504	0.532	rs2150212	chr11:31255935	G/A	cg14844989	chr11:31128820	NA	-0.41	-5.79	-0.34	1.96e-8	Red blood cell count;
CESC	cis	rs7095944	0.584	rs10901814	chr10:126431281	G/C	cg08799069	chr10:126477246	METTL10	-0.38	-5.34	-0.31	2.02e-7	Asthma;
CESC	trans	rs1285495	0.627	rs10912059	chr1:187354887	C/T	cg12869820	chr12:125478231	BRI3BP	-0.42	-6.23	-0.36	1.86e-9	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
CESC	cis	rs61931739	0.534	rs10844828	chr12:34303109	C/T	cg19457237	chr12:34500585	NA	-0.37	-5.23	-0.31	3.45e-7	Morning vs. evening chronotype;
CESC	cis	rs7165102	1.000	rs7178584	chr15:65795200	T/G	cg11441148	chr15:65824328	PTPLAD1	-0.32	-5.32	-0.31	2.2e-7	Mean corpuscular hemoglobin;
CESC	cis	rs208520	1.000	rs12193077	chr6:66989548	C/T	cg07460842	chr6:66804631	NA	0.89	10.18	0.53	9.11e-21	Exhaled nitric oxide output;
CESC	cis	rs6500395	0.962	rs989070	chr16:48602243	G/A	cg04672837	chr16:48644449	N4BP1	0.47	5.8	0.34	1.9e-8	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs79057730	0.528	rs6965219	chr7:821807	C/G	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.68	6.26	0.36	1.5e-9	Initial pursuit acceleration;
CESC	cis	rs4563143	0.514	rs73029076	chr19:29292032	G/T	cg04546413	chr19:29218101	NA	0.49	6.08	0.35	4.2e-9	Methadone dose in opioid dependence;
CESC	cis	rs1729951	0.575	rs1654923	chr3:136692620	A/T	cg03617693	chr3:136751559	NA	0.39	5.38	0.31	1.68e-7	Neuroticism;
CESC	cis	rs4689388	0.926	rs28420833	chr4:6279504	G/A	cg14416269	chr4:6271139	WFS1	0.48	8.17	0.45	1.25e-14	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	trans	rs875971	0.964	rs55748098	chr7:65763618	T/C	cg26939375	chr7:64535504	NA	-0.46	-6.07	-0.35	4.31e-9	Aortic root size;
CESC	cis	rs1003719	0.751	rs7280371	chr21:38450008	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.62	8.64	0.47	5.56e-16	Eye color traits;
CESC	cis	rs34172651	0.517	rs12920774	chr16:24830750	T/C	cg06028605	chr16:24865363	SLC5A11	0.54	7.43	0.42	1.49e-12	Intelligence (multi-trait analysis);
CESC	cis	rs6088590	1.000	rs6087632	chr20:33407704	A/C	cg06115741	chr20:33292138	TP53INP2	0.61	7.59	0.42	5.47e-13	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19237607	chr20:36156146	BLCAP	0.56	6.12	0.35	3.3e-9	Gut microbiome composition (summer);
CESC	cis	rs4253772	0.688	rs113928699	chr22:46649344	G/A	cg24881330	chr22:46731750	TRMU	0.77	6.19	0.36	2.26e-9	LDL cholesterol;Cholesterol, total;
CESC	cis	rs9457247	0.602	rs17615336	chr6:167506734	A/G	cg07741184	chr6:167504864	NA	0.39	6.65	0.38	1.7e-10	Crohn's disease;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg13099106	chr12:120525172	CCDC64	-0.47	-6.1	-0.35	3.7e-9	Height;
CESC	cis	rs3813567	0.759	rs7163204	chr15:78953740	G/A	cg24631222	chr15:78858424	CHRNA5	0.48	5.25	0.31	3.13e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
CESC	cis	rs1775715	0.870	rs1775735	chr10:32255846	A/G	cg04359828	chr10:32216031	ARHGAP12	0.35	5.17	0.3	4.72e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs4665809	0.887	rs2384324	chr2:26354239	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.82	-9.14	-0.49	1.66e-17	Gut microbiome composition (summer);
CESC	cis	rs35160687	0.644	rs4832272	chr2:86516211	A/G	cg01119172	chr2:86362222	SNORD94;PTCD3	-0.39	-5.17	-0.3	4.72e-7	Night sleep phenotypes;
CESC	cis	rs6952808	0.723	rs4721295	chr7:2036669	G/T	cg08027265	chr7:2291960	NA	0.35	5.32	0.31	2.2e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs9611565	0.559	rs5758428	chr22:42106216	G/A	cg03806693	chr22:41940476	POLR3H	1.15	13.6	0.64	2.54e-32	Vitiligo;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07310536	chr10:103892743	PPRC1	0.62	6.57	0.37	2.6200000000000003e-10	Gut microbiome composition (summer);
CESC	cis	rs12579753	0.879	rs12829053	chr12:82161926	T/A	cg24719984	chr12:82153464	PPFIA2	-0.36	-5.33	-0.31	2.11e-7	Resting heart rate;
CESC	cis	rs7100689	0.599	rs6585968	chr10:82139807	T/C	cg00277334	chr10:82204260	NA	-0.59	-7.8	-0.43	1.4e-13	Post bronchodilator FEV1;
CESC	cis	rs1862618	0.853	rs6450409	chr5:56101399	A/G	cg24549020	chr5:56110836	MAP3K1	0.59	6.95	0.39	2.75e-11	Initial pursuit acceleration;
CESC	cis	rs10924970	0.649	rs6697580	chr1:235484609	T/A	cg26050004	chr1:235667680	B3GALNT2	0.44	5.11	0.3	6.16e-7	Asthma;
CESC	cis	rs6933660	0.646	rs9397410	chr6:151770503	C/T	cg02564969	chr6:151773285	C6orf211;RMND1	0.66	9.47	0.5	1.67e-18	Menarche (age at onset);
CESC	cis	rs853679	0.517	rs6922063	chr6:28094366	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.53	-6.19	-0.36	2.27e-9	Depression;
CESC	cis	rs7666738	0.830	rs13115356	chr4:98933171	T/C	cg05340658	chr4:99064831	C4orf37	0.82	12.17	0.6	2.24e-27	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7208859	0.673	rs17826219	chr17:29161845	G/A	cg19761014	chr17:28927070	LRRC37B2	0.72	5.68	0.33	3.48e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs9300255	0.544	rs10772995	chr12:123671761	T/C	cg19016782	chr12:123741754	C12orf65	-0.45	-6.21	-0.36	2.01e-9	Neutrophil percentage of white cells;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09832218	chr12:56694334	CS	-0.62	-6.85	-0.39	5.24e-11	Gut microbiome composition (summer);
CESC	cis	rs7552404	0.924	rs7535991	chr1:76162624	C/T	cg03433033	chr1:76189801	ACADM	0.7	9.38	0.5	2.99e-18	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs2841277	0.708	rs4465542	chr14:105407798	A/G	cg21017887	chr14:105400489	NA	0.41	6.64	0.38	1.81e-10	Rheumatoid arthritis;
CESC	cis	rs55788414	0.932	rs12102691	chr16:81181460	G/T	cg06400318	chr16:81190750	PKD1L2	-0.6	-7.07	-0.4	1.38e-11	Left ventricular obstructive tract defect (maternal effect);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15420785	chr6:34216928	C6orf1	0.56	6.91	0.39	3.58e-11	Gut microbiome composition (summer);
CESC	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg24739457	chr1:205821442	NA	0.39	5.35	0.31	1.88e-7	Monocyte percentage of white cells;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27104117	chr17:27276789	PHF12	0.6	7.24	0.41	4.75e-12	Gut microbiome composition (summer);
CESC	cis	rs13108904	0.905	rs1732108	chr4:1276550	C/T	cg00684032	chr4:1343700	KIAA1530	-0.37	-5.18	-0.3	4.37e-7	Obesity-related traits;
CESC	cis	rs1707322	0.963	rs6666763	chr1:46436451	C/A	cg03146154	chr1:46216737	IPP	0.72	9.82	0.52	1.31e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs6951245	0.810	rs117800627	chr7:1081075	G/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.47	-5.05	-0.3	8.15e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs6542838	0.554	rs4311103	chr2:99538362	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.43	-5.57	-0.32	6.3e-8	Fear of minor pain;
CESC	cis	rs12541635	0.677	rs34872724	chr8:107033071	C/T	cg10147462	chr8:107024639	NA	-0.47	-7.07	-0.4	1.39e-11	Age of smoking initiation;
CESC	cis	rs7412746	0.658	rs897815	chr1:150879101	C/T	cg17724175	chr1:150552817	MCL1	-0.39	-6.08	-0.35	4.07e-9	Melanoma;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg09829838	chr6:42952307	PPP2R5D	-0.39	-6.09	-0.35	4.06e-9	Gambling;
CESC	cis	rs7091068	0.518	rs4144098	chr10:95432600	C/T	cg20715218	chr10:95462985	C10orf4	0.47	6.07	0.35	4.47e-9	Urinary tract infection frequency;
CESC	cis	rs6598955	0.694	rs4659416	chr1:26580937	T/G	cg04990556	chr1:26633338	UBXN11	-0.75	-10.68	-0.55	2.29e-22	Obesity-related traits;
CESC	trans	rs6582630	0.533	rs4103689	chr12:38702980	A/C	cg23762105	chr12:34175262	ALG10	-0.49	-6.58	-0.37	2.46e-10	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs6714710	0.580	rs35564270	chr2:98602165	A/G	cg26665480	chr2:98280029	ACTR1B	0.54	7.28	0.41	3.85e-12	Posterior cortical atrophy and Alzheimer's disease;
CESC	cis	rs72945132	0.825	rs57871058	chr11:70192344	T/C	cg00319359	chr11:70116639	PPFIA1	0.72	6.94	0.39	3.1e-11	Coronary artery disease;
CESC	cis	rs1448094	0.512	rs12297441	chr12:86233980	C/T	cg02569458	chr12:86230093	RASSF9	0.48	6.97	0.39	2.56e-11	Major depressive disorder;
CESC	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg22535103	chr8:58192502	C8orf71	-0.99	-10.43	-0.54	1.42e-21	Developmental language disorder (linguistic errors);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg03348573	chr5:133304316	C5orf15	-0.49	-6.43	-0.37	5.98e-10	Ulcerative colitis;
CESC	cis	rs12478296	1.000	rs6739247	chr2:243039189	C/A	cg06360820	chr2:242988706	NA	-0.66	-7.53	-0.42	8.09e-13	Obesity-related traits;
CESC	cis	rs798554	0.704	rs709282	chr7:2769921	G/A	cg19717773	chr7:2847554	GNA12	-0.56	-8.77	-0.47	2.25e-16	Height;
CESC	cis	rs7666738	0.830	rs13108871	chr4:98803872	T/C	cg17366294	chr4:99064904	C4orf37	0.58	8.36	0.46	3.62e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1322639	0.806	rs1322640	chr6:169586887	T/C	cg03254818	chr6:169586852	NA	-0.53	-7.21	-0.41	5.71e-12	Pulse pressure;
CESC	cis	rs4665809	0.531	rs34081866	chr2:26475940	C/T	cg08470875	chr2:26401718	FAM59B	0.76	8.06	0.44	2.69e-14	Gut microbiome composition (summer);
CESC	cis	rs4975616	0.869	rs401681	chr5:1322087	C/T	cg26373071	chr5:1325741	CLPTM1L	0.42	6.73	0.38	1.05e-10	Lung cancer;
CESC	cis	rs10754283	0.901	rs10047070	chr1:90098715	G/C	cg21401794	chr1:90099060	LRRC8C	0.69	9.16	0.49	1.45e-17	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs55728055	0.661	rs73162106	chr22:32034875	A/G	cg01338084	chr22:32026380	PISD	1.21	8.55	0.47	9.91e-16	Age-related hearing impairment;
CESC	cis	rs2456568	0.548	rs4402256	chr11:93660803	T/C	cg26875233	chr11:93583750	C11orf90	-0.32	-5.55	-0.32	7.1e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
CESC	trans	rs11722228	0.522	rs7681250	chr4:10133013	G/T	cg26043149	chr18:55253948	FECH	1.0	12.65	0.61	5.33e-29	Gout;Urate levels;Serum uric acid levels;
CESC	cis	rs62229266	0.804	rs2835231	chr21:37390598	C/T	cg08632701	chr21:37451849	NA	-0.37	-5.12	-0.3	6.01e-7	Mitral valve prolapse;
CESC	cis	rs10504229	0.683	rs7827881	chr8:58132137	C/T	cg22535103	chr8:58192502	C8orf71	-0.8	-9.09	-0.49	2.46e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs2011503	0.941	rs6511027	chr19:19391851	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.49	5.12	0.3	6.01e-7	Bipolar disorder;
CESC	trans	rs10435719	0.899	rs9693925	chr8:11789963	A/G	cg15556689	chr8:8085844	FLJ10661	0.52	6.48	0.37	4.4e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
CESC	cis	rs11168351	0.927	rs10875716	chr12:48389023	C/T	cg04545296	chr12:48745243	ZNF641	0.35	5.94	0.34	8.72e-9	Bipolar disorder and schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09664812	chr18:9475361	RALBP1	-0.67	-7.91	-0.44	7.03e-14	Gut microbiome composition (summer);
CESC	cis	rs9303401	0.659	rs12946852	chr17:57013337	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.98	12.19	0.6	1.93e-27	Cognitive test performance;
CESC	cis	rs425277	0.606	rs451061	chr1:2075068	C/G	cg16545954	chr1:2118288	C1orf86	0.37	7.24	0.41	4.83e-12	Height;
CESC	cis	rs6866344	0.568	rs10516147	chr5:178094484	A/G	cg03877680	chr5:178157825	ZNF354A	0.6	6.74	0.38	9.93e-11	Neutrophil percentage of white cells;
CESC	cis	rs4692589	0.965	rs733672	chr4:170950243	C/A	cg19918862	chr4:170955249	NA	0.38	6.04	0.35	5.16e-9	Anxiety disorder;
CESC	cis	rs2242116	0.734	rs4683294	chr3:46979013	C/G	cg27129171	chr3:47204927	SETD2	-0.48	-6.49	-0.37	4.24e-10	Birth weight;
CESC	cis	rs2735413	0.958	rs7192416	chr16:78063143	C/T	cg04733911	chr16:78082701	NA	-0.48	-7.75	-0.43	2.03e-13	Systolic blood pressure (alcohol consumption interaction);
CESC	cis	rs1538970	1.000	rs61791368	chr1:45867944	T/C	cg05343316	chr1:45956843	TESK2	0.85	11.62	0.58	1.69e-25	Platelet count;
CESC	cis	rs8114671	0.562	rs6120746	chr20:33448496	A/G	cg07148914	chr20:33460835	GGT7	0.48	6.36	0.36	8.83e-10	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11490987	chr7:149535717	ZNF862	0.52	6.07	0.35	4.43e-9	Gut microbiome composition (summer);
CESC	cis	rs6460942	0.731	rs75994414	chr7:12307992	C/A	cg20607287	chr7:12443886	VWDE	-0.76	-8.16	-0.45	1.34e-14	Coronary artery disease;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg24117104	chr4:149366997	NA	-0.46	-6.59	-0.38	2.36e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs3540	0.533	rs2352601	chr15:91053125	G/A	cg10434728	chr15:90938212	IQGAP1	-0.41	-7.26	-0.41	4.36e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg26714410	chr13:45150072	TSC22D1	-0.44	-6.2	-0.36	2.14e-9	Gambling;
CESC	cis	rs6598955	0.671	rs10493030	chr1:26561856	T/C	cg19743891	chr1:26644573	UBXN11;CD52	0.38	5.44	0.32	1.21e-7	Obesity-related traits;
CESC	cis	rs1707322	0.721	rs28501477	chr1:46199084	A/G	cg03146154	chr1:46216737	IPP	0.82	11.54	0.58	3.18e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs8014252	0.667	rs12588623	chr14:70817914	C/T	cg03123320	chr1:229394665	NA	-0.49	-6.27	-0.36	1.45e-9	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
CESC	cis	rs9902453	0.845	rs12452201	chr17:28214173	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.65	8.12	0.45	1.77e-14	Coffee consumption (cups per day);
CESC	cis	rs7666738	0.830	rs10012271	chr4:99065154	A/C	cg17366294	chr4:99064904	C4orf37	0.62	8.8	0.48	1.82e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4523957	0.583	rs2641438	chr17:2017786	C/G	cg16513277	chr17:2031491	SMG6	-0.71	-10.1	-0.53	1.62e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs9905704	0.633	rs8068455	chr17:56589381	C/T	cg12560992	chr17:57184187	TRIM37	-0.64	-6.04	-0.35	5.11e-9	Testicular germ cell tumor;
CESC	cis	rs13385	0.769	rs7703595	chr5:139611190	A/C	cg26211634	chr5:139558579	C5orf32	0.46	5.22	0.31	3.67e-7	Atrial fibrillation;
CESC	cis	rs1059312	1.000	rs7135987	chr12:129280117	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.73	-10.24	-0.53	6.08e-21	Systemic lupus erythematosus;
CESC	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg10150615	chr22:24372951	LOC391322	-0.54	-7.23	-0.41	5.19e-12	Liver enzyme levels (gamma-glutamyl transferase);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10955642	chr7:99699603	MCM7;AP4M1	0.64	7.43	0.42	1.49e-12	Gut microbiome composition (summer);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg01691987	chr17:7789028	CHD3	0.46	6.14	0.35	3e-9	Fibrinogen levels;
CESC	cis	rs832540	0.966	rs33321	chr5:56206073	G/T	cg14703610	chr5:56206110	C5orf35	0.52	6.75	0.38	9.51e-11	Coronary artery disease;
CESC	cis	rs10779751	0.959	rs2300091	chr1:11266711	C/T	cg08854313	chr1:11322531	MTOR	0.91	14.23	0.66	1.56e-34	Body mass index;
CESC	cis	rs1348850	0.526	rs7607073	chr2:178375065	C/A	cg22681709	chr2:178499509	PDE11A	-0.5	-5.16	-0.3	4.97e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs7659604	0.540	rs4240264	chr4:122683818	A/G	cg19671926	chr4:122722719	EXOSC9	0.6	7.69	0.43	2.87e-13	Type 2 diabetes;
CESC	cis	rs644799	1.000	rs557079	chr11:95530125	C/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.52	6.29	0.36	1.32e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs2637266	1.000	rs12251862	chr10:78367929	A/G	cg18941641	chr10:78392320	NA	0.42	8.09	0.44	2.18e-14	Pulmonary function;
CESC	cis	rs8077577	0.895	rs11871491	chr17:18105656	T/C	cg16794390	chr17:18148240	FLII	0.41	5.59	0.32	5.53e-8	Obesity-related traits;
CESC	cis	rs2070488	0.965	rs2284820	chr3:38562579	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.9	-16.54	-0.71	1.1e-42	Electrocardiographic conduction measures;
CESC	cis	rs7605827	0.930	rs3792579	chr2:15534723	A/G	cg19274914	chr2:15703543	NA	0.36	6.59	0.38	2.3e-10	Educational attainment (years of education);
CESC	cis	rs17253792	0.822	rs113692713	chr14:56087424	C/T	cg01858014	chr14:56050164	KTN1	-0.93	-7.33	-0.41	2.71e-12	Putamen volume;
CESC	cis	rs4319547	0.760	rs61954973	chr12:123074168	T/C	cg23029597	chr12:123009494	RSRC2	-0.49	-5.41	-0.32	1.41e-7	Body mass index;
CESC	cis	rs2073300	1.000	rs6048810	chr20:23446429	G/A	cg12062639	chr20:23401060	NAPB	0.74	5.43	0.32	1.3e-7	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs1577917	1.000	rs34581302	chr6:86705948	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-6.34	-0.36	9.79e-10	Response to antipsychotic treatment;
CESC	cis	rs17209837	1.000	rs60123540	chr7:87085182	T/C	cg00919237	chr7:87102261	ABCB4	-0.5	-5.83	-0.34	1.6e-8	Gallbladder cancer;
CESC	cis	rs950776	0.518	rs1979907	chr15:78842239	T/C	cg24631222	chr15:78858424	CHRNA5	0.39	5.06	0.3	7.77e-7	Sudden cardiac arrest;
CESC	cis	rs1538970	0.924	rs1006216	chr1:45909994	A/G	cg05343316	chr1:45956843	TESK2	0.89	12.04	0.59	6.22e-27	Platelet count;
CESC	cis	rs11122272	0.735	rs2295420	chr1:231485640	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.56	-7.74	-0.43	2.14e-13	Hemoglobin concentration;
CESC	cis	rs7949030	0.626	rs35587183	chr11:62318656	C/T	cg11742103	chr11:62369870	EML3;MTA2	0.56	8.09	0.45	2.1e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs3087591	1.000	rs1800845	chr17:29703438	C/G	cg24425628	chr17:29625626	OMG;NF1	-0.44	-5.48	-0.32	1e-7	Hip circumference;
CESC	cis	rs12291225	0.546	rs12795545	chr11:14355564	G/A	cg19336497	chr11:14380999	RRAS2	-0.44	-6.6	-0.38	2.28e-10	Sense of smell;
CESC	cis	rs2836950	0.565	rs7279497	chr21:40531306	A/G	cg11644478	chr21:40555479	PSMG1	0.51	7.05	0.4	1.59e-11	Menarche (age at onset);
CESC	cis	rs1124376	1.000	rs61457790	chr3:20136186	G/A	cg05072819	chr3:20081367	KAT2B	0.54	5.89	0.34	1.14e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs10752881	1.000	rs8179283	chr1:182974602	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.83	13.12	0.63	1.19e-30	Colorectal cancer;
CESC	cis	rs920590	0.758	rs35280191	chr8:19665214	A/C	cg03894339	chr8:19674705	INTS10	0.67	7.83	0.43	1.15e-13	Acute lymphoblastic leukemia (childhood);
CESC	trans	rs7866350	0.604	rs1935389	chr9:100994470	A/G	cg08984023	chr10:64133896	ZNF365	0.38	6.11	0.35	3.6e-9	Post-traumatic stress disorder;
CESC	cis	rs4665809	0.590	rs13006973	chr2:26454707	C/T	cg25036284	chr2:26402008	FAM59B	0.86	9.4	0.5	2.74e-18	Gut microbiome composition (summer);
CESC	cis	rs9611565	0.694	rs5758411	chr22:42079734	G/A	cg03806693	chr22:41940476	POLR3H	0.75	9.02	0.48	3.84e-17	Vitiligo;
CESC	trans	rs4756846	1.000	rs55820833	chr11:16400359	A/T	cg05579622	chr5:10618622	ANKRD33B	0.76	6.93	0.39	3.14e-11	Obesity and osteoporosis;
CESC	cis	rs9649213	0.593	rs6465682	chr7:98016417	C/A	cg00277769	chr7:97922759	BAIAP2L1	-0.31	-5.08	-0.3	6.96e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs8014204	0.901	rs6574200	chr14:75364451	C/T	cg08847533	chr14:75593920	NEK9	-0.43	-5.38	-0.31	1.64e-7	Caffeine consumption;
CESC	cis	rs13102973	0.932	rs28801464	chr4:135876630	A/G	cg14419869	chr4:135874104	NA	-0.37	-5.7	-0.33	3.19e-8	Subjective well-being;
CESC	cis	rs1799949	1.000	rs8176145	chr17:41249094	A/G	cg05368731	chr17:41323189	NBR1	0.78	11.02	0.56	1.73e-23	Menopause (age at onset);
CESC	trans	rs637571	0.522	rs538954	chr11:65756808	A/G	cg17712092	chr4:129076599	LARP1B	0.74	10.42	0.54	1.61e-21	Eosinophil percentage of white cells;
CESC	trans	rs2727020	0.731	rs10450572	chr11:49281073	T/C	cg15704280	chr7:45808275	SEPT13	0.88	14.46	0.66	2.45e-35	Coronary artery disease;
CESC	cis	rs1385374	0.858	rs12321643	chr12:129302867	A/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.6	5.22	0.31	3.61e-7	Systemic lupus erythematosus;
CESC	cis	rs2985684	1.000	rs2985697	chr14:50092902	A/G	cg10008539	chr14:50087325	RPL36AL;MGAT2	-0.47	-5.45	-0.32	1.13e-7	Carotid intima media thickness;
CESC	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg11905131	chr22:24372483	LOC391322	-0.75	-10.81	-0.55	8.09e-23	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs1538970	1.000	rs2050884	chr1:45830824	A/G	cg06784218	chr1:46089804	CCDC17	0.31	5.29	0.31	2.62e-7	Platelet count;
CESC	cis	rs832540	0.931	rs1445996	chr5:56235548	C/T	cg14703610	chr5:56206110	C5orf35	-0.57	-7.67	-0.43	3.26e-13	Coronary artery disease;
CESC	cis	rs9788682	1.000	rs61204066	chr15:78815298	G/A	cg06917634	chr15:78832804	PSMA4	-0.55	-6.37	-0.36	8.16e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs3809863	0.602	rs7225700	chr17:45391804	T/C	cg25173405	chr17:45401733	C17orf57	-0.53	-6.89	-0.39	4e-11	Glaucoma (primary open-angle);
CESC	cis	rs40363	0.951	rs72778117	chr16:3531827	T/C	cg05754148	chr16:3507555	NAT15	0.69	7.62	0.42	4.56e-13	Tuberculosis;
CESC	cis	rs12476592	0.602	rs6736411	chr2:63674060	G/A	cg17519650	chr2:63277830	OTX1	-0.46	-5.3	-0.31	2.47e-7	Childhood ear infection;
CESC	cis	rs801193	0.569	rs2659892	chr7:66200305	A/G	cg18876405	chr7:65276391	NA	0.45	6.09	0.35	3.92e-9	Aortic root size;
CESC	cis	rs6933660	0.745	rs9371517	chr6:151739810	G/T	cg02564969	chr6:151773285	C6orf211;RMND1	0.63	8.72	0.47	3.15e-16	Menarche (age at onset);
CESC	cis	rs9300255	0.543	rs1617156	chr12:123590165	T/C	cg05973401	chr12:123451056	ABCB9	0.58	6.33	0.36	1.07e-9	Neutrophil percentage of white cells;
CESC	trans	rs352242	0.686	rs9317800	chr13:69850652	A/C	cg15456293	chr8:2044148	MYOM2	-0.35	-6.03	-0.35	5.55e-9	Life satisfaction;
CESC	cis	rs798554	0.757	rs1182176	chr7:2874601	A/G	cg04166393	chr7:2884313	GNA12	0.57	7.6	0.42	5.03e-13	Height;
CESC	trans	rs6073597	1.000	rs6031980	chr20:43714384	C/T	cg03497419	chr3:37034654	EPM2AIP1;MLH1	0.45	6.49	0.37	4.19e-10	Positive affect;
CESC	cis	rs7666738	0.822	rs6815312	chr4:99058220	T/C	cg03467027	chr4:99064603	C4orf37	0.48	5.98	0.35	7.02e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs55883249	1.000	rs11676903	chr2:9763201	G/C	cg23886495	chr2:9695866	ADAM17	0.61	5.41	0.32	1.4e-7	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
CESC	cis	rs7618915	1.000	rs34569561	chr3:52287293	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.42	5.11	0.3	6.17e-7	Bipolar disorder;
CESC	cis	rs854765	0.583	rs11650890	chr17:17790882	C/T	cg09796270	chr17:17721594	SREBF1	-0.46	-6.46	-0.37	5.04e-10	Total body bone mineral density;
CESC	cis	rs2404602	0.679	rs12908421	chr15:76881794	T/G	cg26408565	chr15:76604113	ETFA	-0.4	-5.71	-0.33	3.03e-8	Blood metabolite levels;
CESC	cis	rs6991838	0.584	rs2048650	chr8:66537899	A/G	cg13398993	chr8:66546079	ARMC1	0.46	5.65	0.33	4.19e-8	Intelligence (multi-trait analysis);
CESC	trans	rs8057939	0.593	rs1345473	chr16:49405649	T/C	cg15532236	chr6:170188124	NA	0.55	6.43	0.37	5.91e-10	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7216064	0.954	rs9907491	chr17:65949993	G/A	cg12091567	chr17:66097778	LOC651250	0.72	8.17	0.45	1.3e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg11060661	chr22:24314208	DDT;DDTL	0.32	5.12	0.3	5.92e-7	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs597539	0.690	rs552517	chr11:68625286	T/G	cg01988459	chr11:68622903	NA	-0.4	-5.3	-0.31	2.45e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	trans	rs916888	0.773	rs199533	chr17:44828931	G/A	cg22968622	chr17:43663579	NA	1.3	17.9	0.74	1.66e-47	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs5760092	0.755	rs4585126	chr22:24270005	T/C	cg24846343	chr22:24311635	DDTL	-0.4	-5.75	-0.33	2.4e-8	Urinary 1,3-butadiene metabolite levels in smokers;
CESC	cis	rs4481887	1.000	rs4244178	chr1:248468441	A/G	cg00666640	chr1:248458726	OR2T12	0.4	6.57	0.37	2.7e-10	Common traits (Other);
CESC	cis	rs2228479	0.850	rs17227263	chr16:89810598	G/A	cg00800038	chr16:89945340	TCF25	-0.88	-7.36	-0.41	2.3e-12	Skin colour saturation;
CESC	cis	rs1023500	0.552	rs133368	chr22:42463689	T/C	cg04733989	chr22:42467013	NAGA	0.78	11.67	0.58	1.18e-25	Schizophrenia;
CESC	cis	rs9300255	0.679	rs12829456	chr12:123725395	C/T	cg00376283	chr12:123451042	ABCB9	-0.63	-6.57	-0.37	2.66e-10	Neutrophil percentage of white cells;
CESC	cis	rs9303401	0.659	rs62083525	chr17:56658088	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	1.02	12.93	0.62	5.59e-30	Cognitive test performance;
CESC	cis	rs2228479	0.850	rs12598276	chr16:89829196	G/C	cg00800038	chr16:89945340	TCF25	-0.89	-7.33	-0.41	2.79e-12	Skin colour saturation;
CESC	cis	rs6540559	1.000	rs7522250	chr1:209962539	T/C	cg23283495	chr1:209979779	IRF6	0.52	7.59	0.42	5.58e-13	Cleft lip with or without cleft palate;
CESC	cis	rs8180040	0.764	rs11716539	chr3:47186503	G/T	cg27129171	chr3:47204927	SETD2	0.72	11.24	0.57	3.23e-24	Colorectal cancer;
CESC	cis	rs7927771	0.864	rs755553	chr11:47432303	G/A	cg20307385	chr11:47447363	PSMC3	0.69	8.97	0.48	5.36e-17	Subjective well-being;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01745522	chr6:26217416	HIST1H2BG;HIST1H2AE	0.59	6.79	0.38	7.38e-11	Gut microbiome composition (summer);
CESC	cis	rs7165102	0.770	rs635728	chr15:65789389	G/A	cg11441148	chr15:65824328	PTPLAD1	-0.32	-5.32	-0.31	2.2e-7	Mean corpuscular hemoglobin;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg19716462	chr2:62115576	CCT4	-0.49	-6.13	-0.35	3.14e-9	Asthma;
CESC	cis	rs6424115	0.830	rs1130321	chr1:24200524	C/T	cg10978503	chr1:24200527	CNR2	0.33	6.63	0.38	1.85e-10	Immature fraction of reticulocytes;
CESC	cis	rs477895	0.653	rs11231701	chr11:63893702	G/A	cg04317338	chr11:64019027	PLCB3	0.86	8.94	0.48	6.64e-17	Mean platelet volume;
CESC	cis	rs798554	0.679	rs2644300	chr7:2883071	G/A	cg04166393	chr7:2884313	GNA12	0.62	8.56	0.47	9.25e-16	Height;
CESC	cis	rs708547	0.836	rs1277287	chr4:57853147	C/G	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.61	-6.86	-0.39	4.91e-11	Response to bleomycin (chromatid breaks);
CESC	cis	rs826838	0.967	rs826855	chr12:39114888	T/C	cg13010199	chr12:38710504	ALG10B	-0.46	-6.44	-0.37	5.5e-10	Heart rate;
CESC	cis	rs16866061	1.000	rs11694987	chr2:225397409	C/G	cg12698349	chr2:225449008	CUL3	0.66	9.82	0.52	1.33e-19	Acute graft versus host disease in bone marrow transplantation (recipient effect);
CESC	cis	rs921968	0.643	rs3932856	chr2:219320207	C/A	cg02176678	chr2:219576539	TTLL4	0.43	7.65	0.43	3.82e-13	Mean corpuscular hemoglobin concentration;
CESC	cis	rs13095912	0.819	rs11918734	chr3:185296602	T/C	cg11274856	chr3:185301563	NA	0.37	5.5	0.32	8.96e-8	Systolic blood pressure;
CESC	cis	rs6460942	1.000	rs2053381	chr7:12400710	C/A	cg02935154	chr7:12443704	VWDE	-0.56	-6.09	-0.35	3.85e-9	Coronary artery disease;
CESC	cis	rs1707322	0.686	rs3014236	chr1:46091305	T/C	cg03146154	chr1:46216737	IPP	-0.8	-11.05	-0.56	1.34e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2576037	0.562	rs9959877	chr18:44522293	T/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.32	5.09	0.3	6.92e-7	Personality dimensions;
CESC	cis	rs57506017	0.585	rs5011439	chr7:12268811	G/C	cg23422036	chr7:12250390	TMEM106B	0.38	5.13	0.3	5.62e-7	Neuroticism;
CESC	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg23708337	chr7:1209742	NA	0.55	5.41	0.32	1.41e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs17742757	0.522	rs899364	chr8:11329544	G/T	cg03403963	chr8:11986501	LOC392196;FAM66D	-0.4	-5.14	-0.3	5.45e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs2797160	1.000	rs1777195	chr6:126006861	A/C	cg05901451	chr6:126070800	HEY2	0.45	6.49	0.37	4.24e-10	Endometrial cancer;
CESC	cis	rs9649465	0.967	rs13230230	chr7:123329603	G/A	cg04330084	chr7:123175371	IQUB	-0.38	-5.16	-0.3	4.75e-7	Migraine;
CESC	cis	rs477692	0.673	rs556253	chr10:131355781	G/A	cg05714579	chr10:131428358	MGMT	0.39	5.06	0.3	7.71e-7	Response to temozolomide;
CESC	cis	rs853679	0.517	rs9380065	chr6:28144751	A/G	cg23281280	chr6:28129359	ZNF389	0.56	7.61	0.42	4.91e-13	Depression;
CESC	cis	rs2486288	0.656	rs8039354	chr15:45551756	A/G	cg21132104	chr15:45694354	SPATA5L1	0.54	6.59	0.38	2.36e-10	Glomerular filtration rate;
CESC	cis	rs67311347	1.000	rs12634013	chr3:40452388	T/C	cg24209194	chr3:40518798	ZNF619	0.5	6.11	0.35	3.62e-9	Renal cell carcinoma;
CESC	cis	rs4862750	0.758	rs2375915	chr4:187896255	A/C	cg03647317	chr4:187891568	NA	-0.44	-6.42	-0.37	6.16e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2576037	0.501	rs557661	chr18:44365657	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.43	7.17	0.4	7.31e-12	Personality dimensions;
CESC	cis	rs10838687	0.736	rs2242261	chr11:47266808	T/G	cg25783544	chr11:47291846	MADD	0.57	6.63	0.38	1.91e-10	Proinsulin levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09124081	chr1:224370616	DEGS1	0.57	6.05	0.35	4.96e-9	Gut microbiome composition (summer);
CESC	cis	rs8141529	0.636	rs5762813	chr22:29203314	C/T	cg15103426	chr22:29168792	CCDC117	0.49	5.29	0.31	2.58e-7	Lymphocyte counts;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07431748	chr10:99094531	FRAT2	0.6	7.09	0.4	1.2e-11	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.791	rs4699329	chr4:99056212	G/A	cg17366294	chr4:99064904	C4orf37	0.62	8.85	0.48	1.3e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1348850	0.750	rs55792594	chr2:178496468	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.51	6.59	0.38	2.42e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs798554	0.679	rs7784066	chr7:2819727	T/A	cg13628971	chr7:2884303	GNA12	0.64	8.37	0.46	3.33e-15	Height;
CESC	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	10.58	0.55	4.6e-22	Prudent dietary pattern;
CESC	cis	rs698833	0.518	rs7560807	chr2:44557089	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.51	5.38	0.31	1.61e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs40363	0.645	rs250631	chr16:3523215	G/C	cg00484396	chr16:3507460	NAT15	0.43	6.91	0.39	3.71e-11	Tuberculosis;
CESC	cis	rs6426558	0.537	rs10799381	chr1:227239746	G/T	cg10327440	chr1:227177885	CDC42BPA	0.48	6.0	0.35	6.39e-9	Neutrophil percentage of white cells;
CESC	cis	rs2180341	0.814	rs9401958	chr6:127736357	T/G	cg27446573	chr6:127587934	RNF146	0.83	12.03	0.59	6.99e-27	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20332866	chr1:100678932	DBT	-0.64	-6.71	-0.38	1.16e-10	Gut microbiome composition (summer);
CESC	cis	rs6952808	0.595	rs3778983	chr7:2166319	T/G	cg08027265	chr7:2291960	NA	-0.41	-6.32	-0.36	1.1e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs6089584	1.000	rs6089580	chr20:60558976	G/A	cg13770153	chr20:60521292	NA	-0.45	-5.9	-0.34	1.12e-8	Body mass index;
CESC	cis	rs9894429	0.546	rs55917554	chr17:79608776	T/C	cg13777783	chr17:79615861	NA	-0.36	-5.79	-0.34	1.94e-8	Eye color traits;
CESC	cis	rs7264396	0.563	rs59064961	chr20:34307950	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.89	-10.65	-0.55	2.79e-22	Total cholesterol levels;
CESC	cis	rs798554	0.797	rs798488	chr7:2802522	T/C	cg13628971	chr7:2884303	GNA12	0.64	8.23	0.45	8.41e-15	Height;
CESC	cis	rs7520050	0.807	rs6429576	chr1:46216575	T/C	cg24296786	chr1:45957014	TESK2	-0.48	-6.19	-0.36	2.27e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs6933660	0.800	rs9383900	chr6:151782816	A/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.83	13.36	0.63	1.78e-31	Menarche (age at onset);
CESC	cis	rs9929218	0.911	rs1075959	chr16:68832750	A/G	cg02972257	chr16:68554789	NA	0.5	5.83	0.34	1.64e-8	Colorectal cancer;
CESC	cis	rs854765	0.583	rs11656840	chr17:17837354	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.57	8.17	0.45	1.3e-14	Total body bone mineral density;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg12931157	chr6:41040265	C6orf130;NFYA	-0.47	-6.7	-0.38	1.25e-10	Fibrinogen levels;
CESC	cis	rs12497850	0.931	rs7621015	chr3:49016056	A/G	cg07636037	chr3:49044803	WDR6	1.07	19.9	0.77	1.54e-54	Parkinson's disease;
CESC	cis	rs240764	0.725	rs11155477	chr6:100935505	T/A	cg21058520	chr6:100914733	NA	0.39	6.05	0.35	5.04e-9	Neuroticism;
CESC	cis	rs300703	0.542	rs189762	chr2:180079	A/T	cg21211680	chr2:198530	NA	-0.86	-9.41	-0.5	2.5e-18	Blood protein levels;
CESC	cis	rs11718455	1.000	rs9854785	chr3:44031295	A/G	cg08738300	chr3:44038990	NA	0.45	6.1	0.35	3.68e-9	Coronary artery disease;
CESC	cis	rs10927875	0.722	rs1763605	chr1:16338925	T/G	cg22431228	chr1:16359049	CLCNKA	-0.48	-7.83	-0.43	1.15e-13	Dilated cardiomyopathy;
CESC	cis	rs3733585	0.673	rs10000983	chr4:9951606	T/C	cg02734326	chr4:10020555	SLC2A9	-0.41	-5.76	-0.33	2.34e-8	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs875971	0.660	rs10272357	chr7:66063074	G/A	cg11764359	chr7:65958608	NA	-0.7	-9.25	-0.49	7.64e-18	Aortic root size;
CESC	cis	rs17376456	0.877	rs9314095	chr5:93425495	T/C	cg25358565	chr5:93447407	FAM172A	1.14	11.29	0.57	2.12e-24	Diabetic retinopathy;
CESC	trans	rs6845865	1.000	rs6845865	chr4:148974602	A/G	cg10775173	chr7:151534032	PRKAG2	-0.42	-6.1	-0.35	3.74e-9	QT interval;Resting heart rate;
CESC	cis	rs9733	0.527	rs11204694	chr1:150653391	G/A	cg13175981	chr1:150552382	MCL1	-0.4	-5.04	-0.3	8.56e-7	Tonsillectomy;
CESC	cis	rs1552244	1.000	rs9824585	chr3:10114802	T/C	cg00166722	chr3:10149974	C3orf24	0.54	6.89	0.39	4.08e-11	Alzheimer's disease;
CESC	trans	rs1814175	0.645	rs1851845	chr11:49982396	C/T	cg03929089	chr4:120376271	NA	-0.92	-15.24	-0.68	4.38e-38	Height;
CESC	cis	rs643506	0.874	rs613292	chr11:111668805	C/T	cg17089665	chr11:111648010	NA	-0.38	-5.55	-0.32	7.03e-8	Breast cancer;
CESC	cis	rs748404	0.697	rs531910	chr15:43560607	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.61	7.77	0.43	1.69e-13	Lung cancer;
CESC	trans	rs17685	0.712	rs9800948	chr7:75810473	A/G	cg19862616	chr7:65841803	NCRNA00174	0.81	11.17	0.57	5.3e-24	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs2228479	0.850	rs11648689	chr16:89806732	G/A	cg19635926	chr16:89946313	TCF25	0.68	5.06	0.3	7.81e-7	Skin colour saturation;
CESC	cis	rs34779708	0.931	rs10466072	chr10:35402756	C/T	cg03585969	chr10:35415529	CREM	0.79	10.48	0.54	1.04e-21	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs853679	0.517	rs9357061	chr6:28051772	A/G	cg26335602	chr6:28129616	ZNF389	0.53	7.05	0.4	1.55e-11	Depression;
CESC	cis	rs6088580	0.543	rs13042351	chr20:33238573	G/A	cg08999081	chr20:33150536	PIGU	-0.44	-6.27	-0.36	1.48e-9	Glomerular filtration rate (creatinine);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg17838705	chr1:112298602	DDX20;C1orf183	0.42	6.02	0.35	5.89e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs62103177	0.733	rs62096748	chr18:77619699	T/C	cg12964065	chr18:77638022	KCNG2	0.57	5.63	0.33	4.7e-8	Opioid sensitivity;
CESC	cis	rs9399135	0.933	rs9389262	chr6:135376409	G/T	cg24558204	chr6:135376177	HBS1L	0.52	7.19	0.4	6.44e-12	Red blood cell count;
CESC	cis	rs875971	0.964	rs6945019	chr7:65922458	C/G	cg12463550	chr7:65579703	CRCP	0.56	7.07	0.4	1.33e-11	Aortic root size;
CESC	cis	rs7923609	0.818	rs10822159	chr10:65096250	C/T	cg01631684	chr10:65280961	REEP3	-0.43	-5.38	-0.31	1.66e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs73568641	0.546	rs6899940	chr6:154085465	A/C	cg08374472	chr16:87445639	ZCCHC14	-0.46	-6.2	-0.36	2.14e-9	Methadone dose in opioid dependence;
CESC	trans	rs3857536	0.605	rs36040831	chr6:66876588	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.72	-10.18	-0.53	9.34e-21	Blood trace element (Cu levels);
CESC	cis	rs17384381	0.859	rs12130591	chr1:85904985	C/T	cg16011679	chr1:85725395	C1orf52	0.65	6.8	0.39	7.11e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9811920	0.695	rs793497	chr3:99505610	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.45	-7.26	-0.41	4.26e-12	Axial length;
CESC	trans	rs7866350	0.604	rs1935389	chr9:100994470	A/G	cg00508498	chr11:34378805	ABTB2	0.43	6.37	0.36	8.48e-10	Post-traumatic stress disorder;
CESC	trans	rs650950	0.528	rs646660	chr11:35528452	C/T	cg19900852	chr14:35451793	SRP54	0.45	6.02	0.35	5.7e-9	Bronchopulmonary dysplasia;
CESC	cis	rs10225163	0.590	rs10266923	chr7:27918229	C/T	cg05786569	chr7:27702416	HIBADH	-0.4	-5.03	-0.3	9.21e-7	Gout;
CESC	cis	rs9915657	0.660	rs12602039	chr17:70089384	A/G	cg09344028	chr17:70110421	NA	0.38	6.83	0.39	5.84e-11	Thyroid hormone levels;
CESC	cis	rs10479542	0.766	rs6894980	chr5:178974592	C/T	cg21226059	chr5:178986404	RUFY1	0.38	5.33	0.31	2.12e-7	Lung cancer;
CESC	cis	rs9300255	0.739	rs2337934	chr12:123745359	A/G	cg00376283	chr12:123451042	ABCB9	0.71	8.91	0.48	8.4e-17	Neutrophil percentage of white cells;
CESC	cis	rs9303401	0.659	rs7224276	chr17:56897827	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.01	12.5	0.61	1.71e-28	Cognitive test performance;
CESC	cis	rs7617773	0.817	rs17647717	chr3:48305456	C/T	cg11946769	chr3:48343235	NME6	0.86	11.22	0.57	3.67e-24	Coronary artery disease;
CESC	cis	rs1348850	0.608	rs10176632	chr2:178225934	G/T	cg23306229	chr2:178417860	TTC30B	0.48	6.0	0.35	6.62e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs4481887	1.000	rs4244172	chr1:248466838	A/G	cg00666640	chr1:248458726	OR2T12	0.39	6.49	0.37	4.25e-10	Common traits (Other);
CESC	cis	rs568617	1.000	rs694994	chr11:65653309	A/G	cg00576331	chr11:65640516	EFEMP2	-0.46	-5.45	-0.32	1.15e-7	Crohn's disease;
CESC	cis	rs1465370	0.682	rs7811409	chr7:130024701	G/C	cg04743876	chr7:130013617	NA	0.3	5.66	0.33	3.97e-8	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
CESC	cis	rs3126085	0.935	rs1858480	chr1:152301735	A/G	cg03465714	chr1:152285911	FLG	0.43	5.46	0.32	1.11e-7	Atopic dermatitis;
CESC	cis	rs1348850	0.914	rs7573763	chr2:178249808	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.9	13.2	0.63	6.71e-31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs4665809	0.680	rs3955310	chr2:26290828	T/G	cg26314531	chr2:26401878	FAM59B	-0.59	-6.67	-0.38	1.5e-10	Gut microbiome composition (summer);
CESC	cis	rs736408	0.609	rs13061423	chr3:52790213	T/C	cg07507251	chr3:52567010	NT5DC2	0.43	7.33	0.41	2.79e-12	Bipolar disorder;
CESC	cis	rs9916302	0.861	rs3889368	chr17:37683231	C/T	cg07936489	chr17:37558343	FBXL20	-0.8	-11.56	-0.58	2.74e-25	Glomerular filtration rate (creatinine);
CESC	cis	rs4689592	0.546	rs10937782	chr4:7057106	G/C	cg26116260	chr4:7069785	GRPEL1	0.98	14.65	0.67	5.14e-36	Monocyte percentage of white cells;
CESC	cis	rs2839186	0.504	rs11702278	chr21:47936295	T/G	cg10657630	chr21:48055338	PRMT2	0.45	5.69	0.33	3.38e-8	Testicular germ cell tumor;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17505757	chr17:5323140	RPAIN;NUP88	-0.56	-6.28	-0.36	1.42e-9	Gut microbiome composition (summer);
CESC	cis	rs7520050	0.966	rs1707336	chr1:46493460	T/G	cg03146154	chr1:46216737	IPP	-0.47	-6.08	-0.35	4.25e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs6598955	0.543	rs60676610	chr1:26543421	G/C	cg04990556	chr1:26633338	UBXN11	0.82	9.16	0.49	1.45e-17	Obesity-related traits;
CESC	cis	rs933688	0.877	rs1477349	chr5:90707773	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.18	14.23	0.66	1.63e-34	Smoking behavior;
CESC	cis	rs10883723	0.810	rs10883728	chr10:104269301	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.56	-7.81	-0.43	1.33e-13	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs7216064	1.000	rs58122682	chr17:65876915	T/C	cg12091567	chr17:66097778	LOC651250	-0.86	-8.82	-0.48	1.55e-16	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs10883723	0.810	rs7074343	chr10:104283165	G/A	ch.10.2196322F	chr10:104248062	ACTR1A	0.42	5.18	0.3	4.34e-7	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs3015497	0.562	rs8011264	chr14:51091499	A/T	cg26011998	chr14:51135199	SAV1	-0.51	-5.63	-0.33	4.48e-8	Mean platelet volume;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg11563264	chr4:190862026	FRG1	-0.48	-6.2	-0.36	2.18e-9	Ulcerative colitis;
CESC	cis	rs7086627	0.515	rs7088877	chr10:82208860	C/G	cg03267442	chr10:82210566	NA	-0.34	-5.6	-0.33	5.45e-8	Post bronchodilator FEV1;
CESC	trans	rs7615952	0.673	rs16834637	chr3:125605471	C/T	cg07211511	chr3:129823064	LOC729375	-0.86	-8.99	-0.48	4.82e-17	Blood pressure (smoking interaction);
CESC	cis	rs736408	0.546	rs3733046	chr3:52621627	C/T	cg07507251	chr3:52567010	NT5DC2	0.33	5.65	0.33	4.12e-8	Bipolar disorder;
CESC	cis	rs1865721	1.000	rs8094181	chr18:73193976	T/A	cg26385618	chr18:73139727	C18orf62	-0.51	-7.56	-0.42	6.81e-13	Intelligence;
CESC	cis	rs7618915	0.547	rs1561337	chr3:52659963	C/T	cg18099408	chr3:52552593	STAB1	-0.31	-5.08	-0.3	7.05e-7	Bipolar disorder;
CESC	cis	rs10465746	0.935	rs11580836	chr1:84333310	C/T	cg10977910	chr1:84465055	TTLL7	0.48	6.52	0.37	3.64e-10	Obesity-related traits;
CESC	cis	rs12368653	1.000	rs12371356	chr12:58135420	T/C	cg02175503	chr12:58329896	NA	-0.39	-5.11	-0.3	6.28e-7	Multiple sclerosis;
CESC	cis	rs13191362	1.000	rs35044651	chr6:163004142	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.88	9.11	0.49	2.15e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs4700695	0.719	rs27587	chr5:65444163	C/T	cg21114390	chr5:65439923	SFRS12	-0.51	-6.17	-0.35	2.52e-9	Facial morphology (factor 19);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03288803	chr16:88690881	ZC3H18	-0.53	-6.47	-0.37	4.79e-10	Gut microbiome composition (summer);
CESC	cis	rs2769264	0.602	rs11204777	chr1:151072049	G/A	cg03258749	chr1:151040405	MLLT11	-0.55	-6.97	-0.39	2.49e-11	Blood trace element (Cu levels);
CESC	cis	rs8103278	0.507	rs3745802	chr19:46271177	G/T	cg11657440	chr19:46296263	DMWD	0.79	12.35	0.6	5.72e-28	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12178287	chr19:17631836	PGLS	-0.58	-6.24	-0.36	1.73e-9	Gut microbiome composition (summer);
CESC	trans	rs1853207	1.000	rs74154119	chr10:96632871	C/T	cg02968918	chr4:184908541	STOX2	0.61	6.23	0.36	1.8e-9	Blood metabolite levels;
CESC	cis	rs7193541	0.859	rs12598791	chr16:74500745	A/C	cg01733217	chr16:74700730	RFWD3	0.78	10.64	0.55	3.06e-22	Multiple myeloma;
CESC	trans	rs4671386	0.901	rs6708756	chr2:60521398	G/C	cg24386296	chr4:1723849	TMEM129;TACC3	0.49	6.17	0.35	2.54e-9	Acne (severe);
CESC	cis	rs748404	0.697	rs493444	chr15:43566470	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.59	7.87	0.44	9.34e-14	Lung cancer;
CESC	cis	rs287982	0.932	rs9973654	chr2:9962568	C/A	cg10881225	chr2:9984929	TAF1B	0.4	5.13	0.3	5.69e-7	Nonsyndromic cleft lip with cleft palate;
CESC	cis	rs10206020	0.842	rs7590900	chr2:1574902	A/G	cg26248373	chr2:1572462	NA	-0.59	-6.93	-0.39	3.22e-11	IgG glycosylation;
CESC	cis	rs5758659	0.845	rs5758645	chr22:42598951	T/G	cg04733989	chr22:42467013	NAGA	0.41	5.62	0.33	4.79e-8	Cognitive function;
CESC	cis	rs7918232	0.941	rs1755399	chr10:27394958	A/G	cg14240646	chr10:27532245	ACBD5	-0.68	-6.35	-0.36	9.2e-10	Breast cancer;
CESC	cis	rs1008375	1.000	rs4642241	chr4:17617111	T/C	cg16339924	chr4:17578868	LAP3	0.54	6.76	0.38	8.56e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg03654001	chr7:100812981	NA	0.42	6.39	0.37	7.32e-10	Systemic lupus erythematosus;
CESC	cis	rs9309473	0.500	rs4852952	chr2:73869907	T/C	cg20560298	chr2:73613845	ALMS1	0.46	6.36	0.36	8.78e-10	Metabolite levels;
CESC	cis	rs1355223	1.000	rs1396883	chr11:34757447	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.46	-5.95	-0.34	8.52e-9	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs561341	1.000	rs560132	chr17:30320019	C/T	cg00745463	chr17:30367425	LRRC37B	-0.86	-7.83	-0.43	1.21e-13	Hip circumference adjusted for BMI;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg19531713	chr17:41277059	BRCA1;NBR2	0.5	6.49	0.37	4.22e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs4843747	0.749	rs12102841	chr16:88072574	C/G	cg03395651	chr16:88107091	BANP	-0.42	-5.03	-0.3	9.2e-7	Menopause (age at onset);
CESC	cis	rs7582720	0.943	rs72936839	chr2:203773237	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.39	0.41	1.96e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs6496667	0.509	rs2253419	chr15:90945875	A/G	cg22089800	chr15:90895588	ZNF774	0.48	6.19	0.36	2.29e-9	Rheumatoid arthritis;
CESC	cis	rs6831352	0.918	rs2602894	chr4:100045647	A/G	cg13256891	chr4:100009986	ADH5	0.74	8.13	0.45	1.63e-14	Alcohol dependence;
CESC	cis	rs514406	0.668	rs1672911	chr1:53340320	T/C	cg24675658	chr1:53192096	ZYG11B	-0.66	-9.16	-0.49	1.46e-17	Monocyte count;
CESC	cis	rs17293817	0.617	rs12764264	chr10:1411526	A/G	cg04271617	chr10:1416546	ADARB2	0.34	5.27	0.31	2.76e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs6860806	0.661	rs1588263	chr5:131577158	T/C	cg12564285	chr5:131593104	PDLIM4	0.39	5.98	0.34	7.2e-9	Breast cancer;
CESC	cis	rs9322193	0.923	rs9767309	chr6:150037943	A/G	cg13206674	chr6:150067644	NUP43	0.45	6.53	0.37	3.37e-10	Lung cancer;
CESC	cis	rs644799	0.932	rs572015	chr11:95637416	T/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.47	5.86	0.34	1.38e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs6539267	0.741	rs7314289	chr12:106686260	A/C	cg02476566	chr12:106696527	TCP11L2	0.59	6.88	0.39	4.41e-11	Tourette syndrome;
CESC	cis	rs3858526	0.628	rs4237762	chr11:5956626	A/C	cg13902645	chr11:5959945	NA	-0.67	-8.81	-0.48	1.73e-16	DNA methylation (variation);
CESC	cis	rs7618915	0.571	rs6762457	chr3:52609157	G/A	cg18099408	chr3:52552593	STAB1	-0.32	-5.17	-0.3	4.55e-7	Bipolar disorder;
CESC	cis	rs7618501	1.000	rs2234391	chr3:49842625	A/G	cg24308560	chr3:49941425	MST1R	-0.5	-6.74	-0.38	9.71e-11	Intelligence (multi-trait analysis);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg21400344	chr1:25870172	LDLRAP1	-0.45	-6.03	-0.35	5.36e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26353328	chr8:42010408	AP3M2	0.57	6.49	0.37	4.16e-10	Gut microbiome composition (summer);
CESC	cis	rs858239	0.712	rs199650	chr7:23367189	C/T	cg23682824	chr7:23144976	KLHL7	-0.41	-5.43	-0.32	1.28e-7	Cerebrospinal fluid biomarker levels;
CESC	cis	rs1387259	0.929	rs11168460	chr12:48597365	A/G	cg24011408	chr12:48396354	COL2A1	0.43	6.11	0.35	3.5e-9	Obstructive sleep apnea trait (apnea hypopnea index);
CESC	cis	rs9322193	0.962	rs6914319	chr6:150127440	G/A	cg07701084	chr6:150067640	NUP43	0.44	5.97	0.34	7.65e-9	Lung cancer;
CESC	cis	rs13191362	1.000	rs13199223	chr6:163001083	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.88	9.16	0.49	1.46e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs7818688	1.000	rs28406132	chr8:96030377	C/T	cg16049864	chr8:95962084	TP53INP1	0.61	5.78	0.33	2.13e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs9487051	0.714	rs1546722	chr6:109625797	A/G	cg21918786	chr6:109611834	NA	-0.36	-5.29	-0.31	2.58e-7	Reticulocyte fraction of red cells;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11971027	chr1:153651147	NPR1	0.6	6.65	0.38	1.7e-10	Gut microbiome composition (summer);
CESC	cis	rs524281	0.861	rs7931544	chr11:65917034	C/T	cg14036092	chr11:66035641	RAB1B	-0.58	-5.86	-0.34	1.35e-8	Electroencephalogram traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06414596	chr16:58232216	CSNK2A2	0.55	6.13	0.35	3.2e-9	Gut microbiome composition (summer);
CESC	cis	rs4654899	0.758	rs6702331	chr1:21516107	A/T	cg05370193	chr1:21551575	ECE1	0.39	6.08	0.35	4.23e-9	Superior frontal gyrus grey matter volume;
CESC	cis	rs151349	1.000	rs108727	chr20:57584890	C/T	cg23907860	chr20:57583709	CTSZ	0.41	6.59	0.38	2.34e-10	Platelet distribution width;
CESC	cis	rs4727027	0.901	rs34201592	chr7:148842403	C/G	cg23158103	chr7:148848205	ZNF398	-0.41	-6.57	-0.37	2.65e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs6912958	0.582	rs242285	chr6:88070743	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.77	11.65	0.58	1.33e-25	Monocyte percentage of white cells;
CESC	cis	rs10504229	1.000	rs66796009	chr8:58174529	G/A	cg05313129	chr8:58192883	C8orf71	-0.55	-6.37	-0.36	8.42e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs10504229	0.906	rs112793785	chr8:58190537	T/C	cg14926445	chr8:58193284	C8orf71	-0.5	-5.4	-0.31	1.49e-7	Developmental language disorder (linguistic errors);
CESC	trans	rs9467711	0.606	rs34550936	chr6:26361985	A/G	cg06606381	chr12:133084897	FBRSL1	-0.76	-7.08	-0.4	1.28e-11	Autism spectrum disorder or schizophrenia;
CESC	cis	rs6032067	0.632	rs35361894	chr20:43794403	G/A	cg11264863	chr20:43835661	SEMG1	0.5	5.35	0.31	1.86e-7	Blood protein levels;
CESC	cis	rs763121	0.925	rs9835	chr22:39130971	A/G	cg06022373	chr22:39101656	GTPBP1	0.72	11.48	0.58	5.11e-25	Menopause (age at onset);
CESC	cis	rs6952808	0.825	rs11761818	chr7:1935273	C/T	cg21782813	chr7:2030301	MAD1L1	0.39	5.49	0.32	9.33e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs6541297	0.645	rs4846919	chr1:230301451	A/G	cg20703242	chr1:230279135	GALNT2	0.56	6.6	0.38	2.29e-10	Coronary artery disease;
CESC	cis	rs1005277	0.579	rs1548255	chr10:38417193	T/C	cg25517755	chr10:38738941	LOC399744	-0.46	-5.98	-0.34	7.38e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs6570726	0.870	rs370653	chr6:145823642	G/A	cg23711669	chr6:146136114	FBXO30	0.81	12.04	0.59	6.44e-27	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22561380	chr8:42829775	HOOK3	-0.66	-8.0	-0.44	3.98e-14	Gut microbiome composition (summer);
CESC	cis	rs2599510	0.811	rs176413	chr2:32646847	G/A	cg02381751	chr2:32503542	YIPF4	-0.5	-6.39	-0.37	7.35e-10	Interleukin-18 levels;
CESC	cis	rs9790314	0.967	rs9821201	chr3:160996155	G/C	cg04691961	chr3:161091175	C3orf57	-0.41	-5.27	-0.31	2.87e-7	Morning vs. evening chronotype;
CESC	cis	rs6582630	0.512	rs11181007	chr12:38266700	C/T	cg26384229	chr12:38710491	ALG10B	-0.43	-5.56	-0.32	6.46e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs514406	0.667	rs10788942	chr1:53210521	A/T	cg16325326	chr1:53192061	ZYG11B	-0.7	-11.23	-0.57	3.43e-24	Monocyte count;
CESC	cis	rs7264396	0.690	rs2425178	chr20:34446395	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.85	-11.57	-0.58	2.56e-25	Total cholesterol levels;
CESC	cis	rs6446731	0.593	rs2858083	chr4:3272331	T/A	cg08886695	chr4:3369023	RGS12	-0.37	-5.32	-0.31	2.23e-7	Mean platelet volume;
CESC	cis	rs11098499	0.604	rs2389882	chr4:120566733	A/C	cg24375607	chr4:120327624	NA	0.46	5.73	0.33	2.76e-8	Corneal astigmatism;
CESC	cis	rs769267	1.000	rs3764567	chr19:19440066	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.57	-7.23	-0.41	5.33e-12	Tonsillectomy;
CESC	trans	rs11658311	0.850	rs60149982	chr17:17667240	A/G	cg01883427	chr16:15242839	NA	0.55	6.22	0.36	1.96e-9	Obsessive-compulsive symptoms;
CESC	cis	rs798554	1.000	rs798554	chr7:2759795	C/T	cg09658497	chr7:2847517	GNA12	-0.37	-5.28	-0.31	2.72e-7	Height;
CESC	cis	rs737337	0.623	rs4804155	chr19:11334295	C/G	cg00586551	chr19:11347513	LOC55908;DOCK6	0.51	6.22	0.36	1.97e-9	HDL cholesterol;HDL cholesterol levels;
CESC	cis	rs2836974	0.829	rs34227163	chr21:40551943	A/G	cg17971929	chr21:40555470	PSMG1	1.03	15.86	0.7	2.81e-40	Cognitive function;
CESC	cis	rs921968	0.565	rs4674330	chr2:219595710	T/C	cg02176678	chr2:219576539	TTLL4	-0.43	-7.55	-0.42	7.04e-13	Mean corpuscular hemoglobin concentration;
CESC	cis	rs853679	0.517	rs4713141	chr6:28101678	G/C	cg23281280	chr6:28129359	ZNF389	0.59	8.18	0.45	1.15e-14	Depression;
CESC	cis	rs10882165	0.547	rs12264655	chr10:94951798	A/G	cg00992348	chr10:94926053	NA	-0.31	-5.39	-0.31	1.57e-7	Refractive error;
CESC	cis	rs6088580	0.634	rs6120650	chr20:33039973	G/A	cg08999081	chr20:33150536	PIGU	0.65	11.42	0.57	7.86e-25	Glomerular filtration rate (creatinine);
CESC	cis	rs7208859	0.673	rs9912122	chr17:29140716	C/A	cg13385521	chr17:29058706	SUZ12P	0.59	5.49	0.32	9.51e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs7116495	0.609	rs2276384	chr11:71701523	A/G	cg10381502	chr11:71823885	C11orf51	1.01	6.97	0.39	2.46e-11	Severe influenza A (H1N1) infection;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg15583012	chr2:204103676	CYP20A1	-0.48	-6.66	-0.38	1.58e-10	Fibrinogen levels;
CESC	cis	rs12476592	0.602	rs4671508	chr2:63654140	C/T	cg17519650	chr2:63277830	OTX1	-0.47	-5.26	-0.31	2.93e-7	Childhood ear infection;
CESC	cis	rs2320614	0.679	rs72631678	chr4:164102715	G/A	cg15586945	chr4:164088095	NAF1	-0.58	-7.56	-0.42	6.75e-13	Lung adenocarcinoma;
CESC	cis	rs5753618	0.583	rs5753632	chr22:31863097	C/T	cg02404636	chr22:31891804	SFI1	0.43	6.04	0.35	5.21e-9	Colorectal cancer;
CESC	cis	rs2075371	1.000	rs1868783	chr7:133975087	A/G	cg20476274	chr7:133979776	SLC35B4	0.68	10.07	0.53	2.09e-20	Mean platelet volume;
CESC	cis	rs7618915	0.570	rs11714088	chr3:52758942	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	6.83	0.39	5.96e-11	Bipolar disorder;
CESC	cis	rs7666738	0.830	rs113999196	chr4:99041961	C/T	cg17366294	chr4:99064904	C4orf37	0.61	8.78	0.47	2.13e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs42648	0.935	rs42659	chr7:89981958	A/G	cg23697855	chr7:89950296	NA	0.28	5.3	0.31	2.42e-7	Homocysteine levels;
CESC	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	13.76	0.65	7.11e-33	Prudent dietary pattern;
CESC	cis	rs7618915	0.547	rs13065019	chr3:52685244	T/C	cg17372223	chr3:52568218	NT5DC2	0.43	6.5	0.37	4.04e-10	Bipolar disorder;
CESC	cis	rs875971	0.545	rs13311962	chr7:66068129	C/T	cg11764359	chr7:65958608	NA	-0.83	-10.16	-0.53	1.05e-20	Aortic root size;
CESC	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	7.61	0.42	4.95e-13	Prudent dietary pattern;
CESC	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg07677032	chr17:61819896	STRADA	-0.44	-5.75	-0.33	2.48e-8	Prudent dietary pattern;
CESC	cis	rs1218582	0.741	rs4339857	chr1:154888962	A/G	cg16680214	chr1:154839983	KCNN3	-0.44	-6.71	-0.38	1.14e-10	Prostate cancer;
CESC	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	10.12	0.53	1.44e-20	Prudent dietary pattern;
CESC	cis	rs9814567	1.000	rs6801596	chr3:134252114	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.43	-5.82	-0.34	1.69e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs17253792	0.822	rs13379340	chr14:56050346	C/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.81	5.86	0.34	1.36e-8	Putamen volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16260977	chr19:3761708	MRPL54;APBA3	0.62	7.22	0.41	5.36e-12	Gut microbiome composition (summer);
CESC	cis	rs117623576	0.941	rs60146023	chr10:32411515	G/A	cg03047570	chr10:32398778	NA	-0.73	-7.72	-0.43	2.44e-13	Anti-saccade response;
CESC	cis	rs10479542	0.721	rs6894113	chr5:178974789	G/C	cg00080972	chr5:178986291	RUFY1	0.39	5.86	0.34	1.35e-8	Lung cancer;
CESC	cis	rs7666738	0.830	rs13328042	chr4:99055406	A/G	cg03467027	chr4:99064603	C4orf37	0.47	5.87	0.34	1.32e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6547741	0.904	rs2384659	chr2:27856793	G/A	cg27432699	chr2:27873401	GPN1	0.46	6.37	0.36	8.38e-10	Oral cavity cancer;
CESC	cis	rs2797685	0.898	rs2071987	chr1:7834026	G/A	cg04725166	chr1:7887271	PER3	-0.41	-5.59	-0.32	5.54e-8	Crohn's disease;
CESC	cis	rs9488822	0.597	rs12214881	chr6:116342187	G/T	cg26893134	chr6:116381904	FRK	0.25	6.14	0.35	3.03e-9	Cholesterol, total;LDL cholesterol;
CESC	cis	rs7959452	0.684	rs11177615	chr12:69754189	G/A	cg20891283	chr12:69753455	YEATS4	0.88	13.97	0.65	1.29e-33	Blood protein levels;
CESC	cis	rs780096	0.526	rs3845687	chr2:27689899	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.31	-5.67	-0.33	3.74e-8	Total body bone mineral density;
CESC	cis	rs4555082	0.874	rs2816626	chr14:105735425	G/A	cg27165867	chr14:105738592	BRF1	-0.55	-5.89	-0.34	1.14e-8	Mean platelet volume;Platelet distribution width;
CESC	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.52	6.51	0.37	3.8e-10	Prudent dietary pattern;
CESC	cis	rs769267	0.965	rs7254230	chr19:19434350	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.42	-5.4	-0.31	1.51e-7	Tonsillectomy;
CESC	trans	rs11722228	0.508	rs2241473	chr4:10085949	G/A	cg26043149	chr18:55253948	FECH	0.9	11.07	0.56	1.19e-23	Gout;Urate levels;Serum uric acid levels;
CESC	cis	rs853679	0.517	rs11552219	chr6:28126834	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.57	-6.49	-0.37	4.32e-10	Depression;
CESC	cis	rs96067	0.528	rs274131	chr1:36582925	C/T	cg27506609	chr1:36549197	TEKT2	-0.42	-6.15	-0.35	2.77e-9	Corneal structure;
CESC	cis	rs1348850	0.632	rs11678875	chr2:178509068	A/G	cg22681709	chr2:178499509	PDE11A	-0.57	-8.97	-0.48	5.43e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs113835537	0.529	rs57691879	chr11:66236604	C/T	cg22134325	chr11:66188745	NPAS4	0.33	5.08	0.3	7.01e-7	Airway imaging phenotypes;
CESC	cis	rs3785574	0.962	rs2727331	chr17:61926990	G/T	cg06420487	chr17:61919686	SMARCD2	0.46	5.51	0.32	8.47e-8	Height;
CESC	cis	rs3105593	1.000	rs11070800	chr15:50907347	C/T	cg08437265	chr15:50716283	USP8	0.4	5.13	0.3	5.69e-7	QT interval;
CESC	cis	rs875971	0.830	rs427575	chr7:65519219	A/G	cg10691866	chr7:65817282	TPST1	-0.33	-5.28	-0.31	2.74e-7	Aortic root size;
CESC	cis	rs9303280	0.747	rs1453559	chr17:38020419	T/C	cg20243544	chr17:37824526	PNMT	0.49	6.6	0.38	2.22e-10	Self-reported allergy;
CESC	cis	rs853679	0.517	rs4713141	chr6:28101678	G/C	cg18032046	chr6:28092343	ZSCAN16	-0.55	-6.41	-0.37	6.51e-10	Depression;
CESC	cis	rs11098499	0.863	rs36040693	chr4:120477616	A/G	cg24375607	chr4:120327624	NA	0.45	5.54	0.32	7.33e-8	Corneal astigmatism;
CESC	cis	rs765787	0.530	rs4775822	chr15:45527127	A/G	cg24006582	chr15:45444508	DUOX1	-0.59	-7.23	-0.41	5.15e-12	Uric acid levels;
CESC	cis	rs12477438	0.798	rs4851179	chr2:99568774	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.73	-10.82	-0.55	7.58e-23	Chronic sinus infection;
CESC	cis	rs7208859	0.524	rs8065744	chr17:29099449	C/T	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.17e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs9914988	0.832	rs11650788	chr17:27174523	T/A	cg20469991	chr17:27169893	C17orf63	-0.44	-5.24	-0.31	3.2e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CESC	trans	rs10776614	0.799	rs1345110	chr10:49765168	G/A	cg19218067	chr2:181235115	NA	0.49	6.0	0.35	6.35e-9	Self-employment;
CESC	cis	rs13191362	0.507	rs13197051	chr6:163201728	A/T	cg21926612	chr6:163149169	PACRG;PARK2	0.5	5.93	0.34	9.18e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs1483890	0.723	rs12631128	chr3:69411416	G/T	cg22125112	chr3:69402811	FRMD4B	0.39	5.15	0.3	5.15e-7	Resting heart rate;
CESC	cis	rs7814319	0.966	rs10112328	chr8:97254372	C/T	cg20787634	chr8:97240163	UQCRB	0.53	6.94	0.39	3.08e-11	Lung function (FVC);
CESC	cis	rs875971	0.862	rs6971059	chr7:66067032	A/G	cg10691866	chr7:65817282	TPST1	0.33	5.53	0.32	7.81e-8	Aortic root size;
CESC	cis	rs2243480	1.000	rs34136756	chr7:65381256	A/G	cg13147721	chr7:65941812	NA	-0.85	-8.1	-0.45	2e-14	Diabetic kidney disease;
CESC	cis	rs9649213	0.555	rs6948346	chr7:97959956	A/G	cg21770322	chr7:97807741	LMTK2	0.55	8.3	0.45	5.53e-15	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7666738	0.830	rs28465658	chr4:99035866	T/C	cg05340658	chr4:99064831	C4orf37	0.82	12.87	0.62	9.38e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7666738	0.830	rs890470	chr4:98923435	A/C	cg17366294	chr4:99064904	C4orf37	0.6	8.23	0.45	8.65e-15	Colonoscopy-negative controls vs population controls;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg22217807	chr16:8768618	ABAT	-0.49	-6.49	-0.37	4.26e-10	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23121547	chr11:1593657	HCCA2;LOC338651;DUSP8	0.59	7.35	0.41	2.53e-12	Gut microbiome composition (summer);
CESC	cis	rs4665809	0.590	rs2303894	chr2:26508187	A/G	cg22920501	chr2:26401640	FAM59B	0.89	9.73	0.51	2.53e-19	Gut microbiome composition (summer);
CESC	cis	rs9300255	0.569	rs1790115	chr12:123620270	C/G	cg05973401	chr12:123451056	ABCB9	0.53	5.91	0.34	1.04e-8	Neutrophil percentage of white cells;
CESC	cis	rs9733	0.596	rs12077833	chr1:150674333	C/T	cg04414720	chr1:150670196	GOLPH3L	0.63	9.02	0.48	3.87e-17	Tonsillectomy;
CESC	cis	rs10754283	0.967	rs7546410	chr1:90109815	C/T	cg21401794	chr1:90099060	LRRC8C	0.69	9.34	0.5	4.06e-18	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs7666738	0.830	rs6830124	chr4:99054872	C/T	cg17366294	chr4:99064904	C4orf37	-0.61	-8.62	-0.47	5.98e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6665290	0.935	rs6693535	chr1:227197685	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.22	-33.0	-0.9	7.42e-96	Myeloid white cell count;
CESC	cis	rs4665809	0.590	rs62128455	chr2:26466530	G/A	cg26314531	chr2:26401878	FAM59B	0.85	9.04	0.49	3.44e-17	Gut microbiome composition (summer);
CESC	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.7	9.85	0.52	1.04e-19	Prudent dietary pattern;
CESC	cis	rs7647973	0.626	rs2329021	chr3:49679072	G/A	cg06212747	chr3:49208901	KLHDC8B	0.64	7.75	0.43	1.94e-13	Menarche (age at onset);
CESC	cis	rs8031584	0.560	rs1056118	chr15:31203786	G/A	cg14829155	chr15:31115871	NA	0.72	10.44	0.54	1.32e-21	Huntington's disease progression;
CESC	cis	rs992157	0.835	rs12987180	chr2:219144089	G/A	cg00012203	chr2:219082015	ARPC2	-0.76	-9.55	-0.51	9.45e-19	Colorectal cancer;
CESC	cis	rs1881797	1.000	rs1881796	chr1:247688931	G/A	cg18198730	chr1:247681584	NA	0.59	7.77	0.43	1.76e-13	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs724767	1.000	rs73065951	chr3:193721651	T/A	cg01524723	chr3:193718032	NA	-0.67	-6.84	-0.39	5.45e-11	Estradiol plasma levels (breast cancer);
CESC	cis	rs7618915	0.547	rs2590846	chr3:52692359	C/G	cg18404041	chr3:52824283	ITIH1	-0.39	-6.54	-0.37	3.18e-10	Bipolar disorder;
CESC	cis	rs2075371	0.933	rs2244548	chr7:133986234	A/G	cg11752832	chr7:134001865	SLC35B4	0.55	7.23	0.41	5.27e-12	Mean platelet volume;
CESC	trans	rs7690543	0.681	rs6552068	chr4:67994467	A/G	cg05505961	chr17:66375071	ARSG	-0.52	-6.13	-0.35	3.13e-9	Glucose homeostasis traits;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg11574758	chr20:21107113	PLK1S1	-0.44	-6.31	-0.36	1.15e-9	Gambling;
CESC	cis	rs7811142	1.000	rs66632384	chr7:100018904	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.16	11.71	0.58	8.43e-26	Platelet count;
CESC	cis	rs6120849	0.901	rs13037296	chr20:33749228	T/A	cg24642439	chr20:33292090	TP53INP2	0.6	6.42	0.37	6.21e-10	Protein C levels;
CESC	cis	rs780096	0.526	rs1647266	chr2:27693485	T/C	cg02592271	chr2:27665507	KRTCAP3	-0.29	-5.79	-0.34	2e-8	Total body bone mineral density;
CESC	cis	rs1801251	1.000	rs36007169	chr2:233621834	A/G	cg25237894	chr2:233734115	C2orf82	0.45	7.9	0.44	7.6e-14	Coronary artery disease;
CESC	cis	rs3740713	1.000	rs16935424	chr11:18456737	A/T	cg23797887	chr11:18477753	LDHAL6A	-0.53	-5.27	-0.31	2.89e-7	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs793571	0.715	rs11071399	chr15:59139255	A/G	cg05156742	chr15:59063176	FAM63B	-0.52	-6.34	-0.36	9.64e-10	Schizophrenia;
CESC	cis	rs3015497	0.603	rs2934684	chr14:51058234	G/T	cg26011998	chr14:51135199	SAV1	-0.48	-5.44	-0.32	1.2e-7	Mean platelet volume;
CESC	cis	rs854765	0.547	rs2955370	chr17:17966945	C/T	cg16928487	chr17:17741425	SREBF1	0.55	9.21	0.49	9.96e-18	Total body bone mineral density;
CESC	cis	rs7412746	0.611	rs11803940	chr1:150685835	A/G	cg22823121	chr1:150693482	HORMAD1	0.47	7.03	0.4	1.73e-11	Melanoma;
CESC	cis	rs12188164	0.515	rs11744936	chr5:412112	C/T	cg26850624	chr5:429559	AHRR	-0.45	-5.94	-0.34	8.72e-9	Cystic fibrosis severity;
CESC	cis	rs939658	0.805	rs35291410	chr15:79438660	C/T	cg17916960	chr15:79447300	NA	-0.37	-6.15	-0.35	2.8e-9	Refractive error;
CESC	cis	rs875971	0.830	rs7799834	chr7:65880694	A/C	cg10691866	chr7:65817282	TPST1	-0.34	-5.51	-0.32	8.3e-8	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22887498	chr19:39401301	NA	-0.53	-6.18	-0.35	2.34e-9	Gut microbiome composition (summer);
CESC	cis	rs7520050	0.966	rs11810993	chr1:46478793	A/G	cg24296786	chr1:45957014	TESK2	0.44	5.49	0.32	9.23e-8	Red blood cell count;Reticulocyte count;
CESC	cis	rs360798	0.553	rs11682530	chr2:63073194	C/T	cg17519650	chr2:63277830	OTX1	-0.6	-7.71	-0.43	2.52e-13	Coronary artery disease;
CESC	cis	rs9486715	0.838	rs9320127	chr6:96865358	G/A	cg06623918	chr6:96969491	KIAA0776	0.92	14.42	0.66	3.55e-35	Headache;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26534993	chr2:3291401	TSSC1	-0.61	-6.69	-0.38	1.3100000000000001e-10	Gut microbiome composition (summer);
CESC	cis	rs9858542	0.953	rs9827708	chr3:49649989	C/G	cg07274523	chr3:49395745	GPX1	0.66	8.59	0.47	7.45e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs11123610	0.520	rs7576701	chr2:3718227	T/C	cg10645314	chr2:3704589	ALLC	-0.47	-5.34	-0.31	2.02e-7	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CESC	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg27094323	chr7:1216898	NA	-0.38	-5.23	-0.31	3.4e-7	Longevity;Endometriosis;
CESC	cis	rs863345	0.967	rs4477267	chr1:158470644	C/T	cg12129480	chr1:158549410	OR10X1	-0.31	-6.19	-0.36	2.34e-9	Pneumococcal bacteremia;
CESC	cis	rs72781680	0.821	rs12623521	chr2:24181670	C/T	cg08917208	chr2:24149416	ATAD2B	0.66	6.5	0.37	3.98e-10	Lymphocyte counts;
CESC	cis	rs1799949	0.965	rs8176140	chr17:41251646	T/A	cg05368731	chr17:41323189	NBR1	0.78	11.02	0.56	1.73e-23	Menopause (age at onset);
CESC	cis	rs854765	0.547	rs4643387	chr17:17972973	C/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.53	6.82	0.39	6.26e-11	Total body bone mineral density;
CESC	cis	rs9715521	0.867	rs7437815	chr4:59826005	T/C	cg11281224	chr4:60001000	NA	-0.5	-6.53	-0.37	3.38e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs6502050	0.835	rs56095560	chr17:80151304	C/T	cg11859384	chr17:80120422	CCDC57	-0.38	-5.17	-0.3	4.56e-7	Life satisfaction;
CESC	trans	rs17613427	1.000	rs16846186	chr2:142242486	G/C	cg16810031	chr17:38024146	ZPBP2	-0.9	-6.22	-0.36	1.89e-9	Left  ventricle systolic dysfunction;
CESC	cis	rs8177253	0.965	rs4854761	chr3:133498789	A/G	cg12373951	chr3:133503437	NA	-0.38	-5.59	-0.32	5.53e-8	Iron status biomarkers;
CESC	trans	rs11098499	0.644	rs10050092	chr4:120532085	T/C	cg25214090	chr10:38739885	LOC399744	0.62	8.88	0.48	1.06e-16	Corneal astigmatism;
CESC	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg22442454	chr1:209979470	IRF6	0.61	9.24	0.49	8.25e-18	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
CESC	cis	rs6502050	0.871	rs62079998	chr17:80077245	A/C	cg23985595	chr17:80112537	CCDC57	0.4	6.33	0.36	1.05e-9	Life satisfaction;
CESC	cis	rs748404	0.697	rs491804	chr15:43560825	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	7.8	0.43	1.47e-13	Lung cancer;
CESC	cis	rs9300255	0.602	rs1716164	chr12:123663660	G/A	cg05973401	chr12:123451056	ABCB9	0.5	5.74	0.33	2.53e-8	Neutrophil percentage of white cells;
CESC	cis	rs3785574	0.962	rs2727324	chr17:61922102	G/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.45	5.68	0.33	3.55e-8	Height;
CESC	trans	rs1814175	0.817	rs6486046	chr11:49997017	T/C	cg03929089	chr4:120376271	NA	-0.94	-16.03	-0.7	7.02e-41	Height;
CESC	cis	rs7666738	0.830	rs2865979	chr4:99027137	T/C	cg17366294	chr4:99064904	C4orf37	0.62	8.95	0.48	6.32e-17	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4601790	0.601	rs4930295	chr11:65390554	C/G	cg21033440	chr11:65409861	SIPA1	-0.59	-7.18	-0.4	7.19e-12	Blood pressure (age interaction);
CESC	cis	rs2816062	0.775	rs2745315	chr1:18897118	G/A	cg18795169	chr1:18902165	NA	-0.91	-17.81	-0.74	3.44e-47	Urate levels in lean individuals;
CESC	cis	rs2075371	0.637	rs2544165	chr7:133920443	A/G	cg11752832	chr7:134001865	SLC35B4	-0.51	-6.56	-0.37	2.82e-10	Mean platelet volume;
CESC	cis	rs12477438	0.520	rs13031919	chr2:99848932	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.71	10.11	0.53	1.57e-20	Chronic sinus infection;
CESC	cis	rs2839186	0.867	rs13050387	chr21:47701423	C/T	cg10351095	chr21:47802916	PCNT	-0.5	-6.8	-0.39	6.74e-11	Testicular germ cell tumor;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg24849267	chr2:172374169	NA	-0.52	-7.12	-0.4	1.04e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs9322193	0.923	rs10782315	chr6:150064229	T/C	cg04369109	chr6:150039330	LATS1	-0.45	-6.4	-0.37	6.93e-10	Lung cancer;
CESC	cis	rs9911578	0.900	rs8067264	chr17:57182793	G/C	cg12560992	chr17:57184187	TRIM37	1.01	17.89	0.74	1.77e-47	Intelligence (multi-trait analysis);
CESC	cis	rs1799949	0.894	rs36062488	chr17:41337472	C/T	cg05368731	chr17:41323189	NBR1	-0.6	-8.11	-0.45	1.85e-14	Menopause (age at onset);
CESC	cis	rs739401	0.572	rs410820	chr11:3080102	G/A	cg08508325	chr11:3079039	CARS	-0.59	-11.16	-0.57	5.74e-24	Longevity;
CESC	cis	rs796364	0.951	rs12996313	chr2:200997916	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.69	-6.64	-0.38	1.77e-10	Schizophrenia;
CESC	cis	rs672059	0.934	rs6703054	chr1:183155778	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.54	7.06	0.4	1.49e-11	Hypertriglyceridemia;
CESC	cis	rs3008870	0.959	rs2985826	chr1:67412918	G/C	cg02640540	chr1:67518911	SLC35D1	0.51	5.58	0.32	5.89e-8	Lymphocyte percentage of white cells;
CESC	cis	rs9487051	0.621	rs830552	chr6:109549914	A/G	cg01475377	chr6:109611718	NA	-0.38	-5.12	-0.3	5.74e-7	Reticulocyte fraction of red cells;
CESC	cis	rs11191270	0.554	rs11191265	chr10:104102118	G/A	cg15320455	chr10:103880129	LDB1	0.61	5.82	0.34	1.67e-8	Intelligence (multi-trait analysis);
CESC	cis	rs897984	0.762	rs2305880	chr16:30999462	T/C	cg02466173	chr16:30829666	NA	0.48	8.16	0.45	1.32e-14	Dementia with Lewy bodies;
CESC	cis	rs796364	1.000	rs11895190	chr2:200838613	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.83	-8.25	-0.45	7.41e-15	Schizophrenia;
CESC	cis	rs35146811	0.844	rs4729576	chr7:99692594	G/A	cg22906224	chr7:99728672	NA	0.45	5.17	0.3	4.66e-7	Coronary artery disease;
CESC	cis	rs4891159	0.790	rs77878087	chr18:74116337	G/A	cg24786174	chr18:74118243	ZNF516	-0.72	-11.21	-0.57	3.84e-24	Longevity;
CESC	cis	rs7666738	0.830	rs6851253	chr4:99029980	A/G	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.58e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9487051	0.676	rs1521905	chr6:109594515	T/C	cg12927641	chr6:109611667	NA	-0.37	-5.56	-0.32	6.55e-8	Reticulocyte fraction of red cells;
CESC	cis	rs6121246	0.559	rs6060944	chr20:30372114	G/A	cg13852791	chr20:30311386	BCL2L1	0.85	11.17	0.57	5.35e-24	Mean corpuscular hemoglobin;
CESC	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg27094323	chr7:1216898	NA	-0.36	-5.17	-0.3	4.72e-7	Longevity;Endometriosis;
CESC	cis	rs4862750	0.872	rs6821507	chr4:187876829	G/T	cg11301795	chr4:187892539	NA	0.75	12.13	0.6	3.12e-27	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2645424	1.000	rs7009302	chr8:11685981	C/G	cg21281001	chr8:11725306	CTSB	0.43	5.19	0.3	4.27e-7	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);
CESC	cis	rs910316	0.967	rs10142770	chr14:75525449	G/A	cg11812906	chr14:75593930	NEK9	0.92	15.44	0.69	8.57e-39	Height;
CESC	cis	rs7824557	0.751	rs2099456	chr8:11127001	A/C	cg21775007	chr8:11205619	TDH	0.4	6.12	0.35	3.41e-9	Retinal vascular caliber;
CESC	cis	rs7592578	0.766	rs62182865	chr2:191434180	T/C	cg10560079	chr2:191398806	TMEM194B	-0.65	-5.46	-0.32	1.07e-7	Diastolic blood pressure;
CESC	cis	rs6089584	0.527	rs927589	chr20:60606363	A/G	cg24733560	chr20:60626293	TAF4	0.49	7.28	0.41	3.85e-12	Body mass index;
CESC	cis	rs853679	0.517	rs9295761	chr6:28147987	A/G	cg22143856	chr6:28129313	ZNF389	0.46	5.81	0.34	1.76e-8	Depression;
CESC	cis	rs9322193	0.923	rs2297928	chr6:150039720	G/C	cg04369109	chr6:150039330	LATS1	-0.41	-5.81	-0.34	1.82e-8	Lung cancer;
CESC	cis	rs4642101	0.640	rs9877049	chr3:12821231	A/G	cg24848339	chr3:12840334	CAND2	0.38	6.07	0.35	4.5e-9	QRS complex (12-leadsum);
CESC	trans	rs3780486	0.846	rs3824458	chr9:33144809	C/T	cg20290983	chr6:43655470	MRPS18A	0.97	17.29	0.73	2.29e-45	IgG glycosylation;
CESC	cis	rs875971	0.638	rs6960778	chr7:66071597	C/T	cg11764359	chr7:65958608	NA	-0.71	-9.33	-0.5	4.52e-18	Aortic root size;
CESC	cis	rs2032447	0.869	rs199752	chr6:26012875	C/T	cg02841227	chr6:26021843	HIST1H4A	0.43	5.29	0.31	2.59e-7	Intelligence (multi-trait analysis);
CESC	cis	rs4132509	1.000	rs10754807	chr1:243804158	G/A	cg21452805	chr1:244014465	NA	0.43	5.08	0.3	7.3e-7	RR interval (heart rate);
CESC	cis	rs9911578	0.704	rs72628393	chr17:56585314	A/T	cg12560992	chr17:57184187	TRIM37	-0.9	-14.75	-0.67	2.37e-36	Intelligence (multi-trait analysis);
CESC	cis	rs2228479	0.850	rs11640188	chr16:89807732	C/T	cg14709524	chr16:89940631	TCF25	0.92	6.97	0.39	2.55e-11	Skin colour saturation;
CESC	cis	rs6088590	1.000	rs12626122	chr20:33425800	A/G	cg24642439	chr20:33292090	TP53INP2	0.84	11.08	0.56	1.04e-23	Coronary artery disease;
CESC	cis	rs17253792	0.822	rs8009239	chr14:56062490	A/G	cg01858014	chr14:56050164	KTN1	-0.96	-7.13	-0.4	9.72e-12	Putamen volume;
CESC	cis	rs1448094	0.791	rs61929394	chr12:86331541	C/A	cg02569458	chr12:86230093	RASSF9	0.45	6.43	0.37	5.79e-10	Major depressive disorder;
CESC	cis	rs7605827	0.930	rs11687986	chr2:15591308	G/T	cg19274914	chr2:15703543	NA	0.34	6.07	0.35	4.38e-9	Educational attainment (years of education);
CESC	cis	rs17209837	0.667	rs45605032	chr7:87090301	C/T	cg00919237	chr7:87102261	ABCB4	-0.5	-5.83	-0.34	1.6e-8	Gallbladder cancer;
CESC	cis	rs17384381	1.000	rs12129502	chr1:85900727	T/C	cg16011679	chr1:85725395	C1orf52	0.74	7.57	0.42	6.02e-13	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9457247	0.902	rs366938	chr6:167403538	T/C	cg25258033	chr6:167368657	RNASET2	0.39	5.83	0.34	1.58e-8	Crohn's disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg05425294	chr16:1644664	IFT140	0.5	6.47	0.37	4.83e-10	Fibrinogen levels;
CESC	cis	rs17021463	0.676	rs12512832	chr4:95310216	G/T	cg11021082	chr4:95130006	SMARCAD1	0.52	7.14	0.4	9.2e-12	Testicular germ cell tumor;
CESC	cis	rs6732160	0.593	rs2288630	chr2:73457552	C/T	cg01422370	chr2:73384389	NA	0.41	6.83	0.39	5.93e-11	Intelligence (multi-trait analysis);
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg20662616	chr2:30454643	LBH	-0.43	-6.04	-0.35	5.13e-9	Height;
CESC	cis	rs1862618	0.671	rs2591965	chr5:56236176	T/C	cg18230493	chr5:56204884	C5orf35	0.61	7.97	0.44	4.6e-14	Initial pursuit acceleration;
CESC	cis	rs72634258	0.554	rs34305100	chr1:7913029	A/G	cg00042356	chr1:8021962	PARK7	0.59	5.66	0.33	3.99e-8	Inflammatory bowel disease;
CESC	cis	rs34779708	0.966	rs2505639	chr10:35474421	A/G	cg04310649	chr10:35416472	CREM	0.53	6.65	0.38	1.63e-10	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs11166927	0.901	rs7014257	chr8:140802694	G/T	cg16909799	chr8:140841666	TRAPPC9	0.58	8.59	0.47	7.53e-16	Pediatric non-alcoholic fatty liver disease activity score;
CESC	cis	rs684232	0.623	rs365118	chr17:580543	G/A	cg12384639	chr17:618140	VPS53	0.42	5.41	0.32	1.4e-7	Prostate cancer;
CESC	cis	rs9916302	0.821	rs12938268	chr17:37572139	G/A	cg20243544	chr17:37824526	PNMT	0.49	5.92	0.34	9.98e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs425277	0.585	rs3107156	chr1:2060630	T/C	cg23803603	chr1:2058230	PRKCZ	-0.34	-5.83	-0.34	1.57e-8	Height;
CESC	cis	rs67478160	0.619	rs2368560	chr14:104273311	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.5	-7.0	-0.4	2.04e-11	Schizophrenia;
CESC	cis	rs1008375	0.932	rs13127157	chr4:17618049	A/G	cg15017067	chr4:17643749	FAM184B	-0.4	-5.4	-0.32	1.45e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs79349575	0.749	rs2546491	chr17:46977916	A/G	cg16584676	chr17:46985605	UBE2Z	0.53	6.58	0.37	2.57e-10	Type 2 diabetes;
CESC	cis	rs7618915	0.798	rs353547	chr3:52268866	A/G	cg05315796	chr3:52349193	DNAH1	-0.39	-6.78	-0.38	7.82e-11	Bipolar disorder;
CESC	cis	rs7772486	0.875	rs10457793	chr6:146415403	A/G	cg05347473	chr6:146136440	FBXO30	0.51	6.68	0.38	1.37e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs113835537	0.935	rs79496339	chr11:66467769	T/A	cg24851651	chr11:66362959	CCS	0.66	5.87	0.34	1.27e-8	Airway imaging phenotypes;
CESC	cis	rs782590	0.967	rs62165172	chr2:55736237	A/G	cg18811423	chr2:55921094	PNPT1	0.79	12.47	0.61	2.15e-28	Metabolic syndrome;
CESC	cis	rs7412746	0.503	rs72704639	chr1:150798335	A/C	cg22823121	chr1:150693482	HORMAD1	0.39	5.6	0.33	5.33e-8	Melanoma;
CESC	cis	rs6433857	0.536	rs4625864	chr2:181353942	G/C	cg23363182	chr2:181467187	NA	-0.41	-5.79	-0.34	1.97e-8	Body mass index;
CESC	cis	rs752010	0.574	rs10890161	chr1:42121623	T/C	cg06885757	chr1:42089581	HIVEP3	0.47	7.64	0.43	3.89e-13	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs853679	0.517	rs7755442	chr6:28039015	T/C	cg08968635	chr6:28129556	ZNF389	0.39	5.22	0.31	3.64e-7	Depression;
CESC	cis	rs875971	0.895	rs6460300	chr7:65952924	A/G	cg10691866	chr7:65817282	TPST1	-0.35	-5.6	-0.33	5.33e-8	Aortic root size;
CESC	cis	rs10504229	0.683	rs11781690	chr8:58132931	C/G	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs875971	0.508	rs10242423	chr7:66059175	A/G	cg14393609	chr7:65229607	NA	-0.41	-5.78	-0.33	2.1e-8	Aortic root size;
CESC	cis	rs8078723	0.901	rs709591	chr17:38175561	T/A	cg17467752	chr17:38218738	THRA	0.66	9.91	0.52	6.68e-20	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CESC	cis	rs9911578	1.000	rs302859	chr17:56693132	C/T	cg12560992	chr17:57184187	TRIM37	0.93	15.58	0.69	2.6e-39	Intelligence (multi-trait analysis);
CESC	cis	rs4319547	0.656	rs28730465	chr12:122863864	A/C	cg05707623	chr12:122985044	ZCCHC8	0.56	6.3	0.36	1.22e-9	Body mass index;
CESC	cis	rs7666738	0.830	rs7661264	chr4:98961574	G/A	cg05340658	chr4:99064831	C4orf37	0.8	12.39	0.61	3.96e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7267979	0.844	rs1555330	chr20:25232097	A/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.72	11.88	0.59	2.28e-26	Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs1728785	0.818	rs1069289	chr16:68585317	C/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.64	7.49	0.42	1.03e-12	Ulcerative colitis;
CESC	cis	rs2415984	0.541	rs12433740	chr14:46933240	G/T	cg14871534	chr14:47121158	RPL10L	0.39	5.69	0.33	3.39e-8	Number of children ever born;
CESC	cis	rs397969	0.596	rs17605101	chr17:19877634	T/C	cg12073167	chr17:19770448	ULK2	-0.51	-5.78	-0.33	2.05e-8	Platelet count;
CESC	trans	rs916888	0.773	rs199447	chr17:44812188	C/T	cg10053473	chr17:62856997	LRRC37A3	-0.73	-7.85	-0.43	1.05e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs9811920	0.809	rs1384062	chr3:99597928	A/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.44	5.82	0.34	1.7e-8	Axial length;
CESC	cis	rs4243830	0.737	rs11122088	chr1:6603677	T/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.85	-7.32	-0.41	3.05e-12	Body mass index;
CESC	trans	rs2727020	0.563	rs10769582	chr11:49474040	T/C	cg03929089	chr4:120376271	NA	-0.81	-12.71	-0.62	3.17e-29	Coronary artery disease;
CESC	cis	rs1153858	1.000	rs10519021	chr15:45631795	G/A	cg21132104	chr15:45694354	SPATA5L1	0.84	11.38	0.57	1.09e-24	Homoarginine levels;
CESC	cis	rs10504229	1.000	rs57624567	chr8:58176995	T/C	cg22535103	chr8:58192502	C8orf71	-1.05	-13.27	-0.63	3.63e-31	Developmental language disorder (linguistic errors);
CESC	cis	rs9649213	0.593	rs6465667	chr7:97957885	G/A	cg21770322	chr7:97807741	LMTK2	0.56	8.61	0.47	6.55e-16	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs6460942	0.597	rs7808537	chr7:12520913	G/C	cg02935154	chr7:12443704	VWDE	-0.54	-5.44	-0.32	1.23e-7	Coronary artery disease;
CESC	cis	rs2760061	0.659	rs708107	chr1:228189495	C/T	cg01973587	chr1:228161476	NA	-0.36	-5.46	-0.32	1.1e-7	Diastolic blood pressure;
CESC	cis	rs67311347	0.824	rs59922539	chr3:40337110	G/A	cg09455208	chr3:40491958	NA	0.43	7.06	0.4	1.49e-11	Renal cell carcinoma;
CESC	cis	rs854765	0.718	rs7224815	chr17:17845800	A/T	cg04398451	chr17:18023971	MYO15A	-0.64	-8.64	-0.47	5.33e-16	Total body bone mineral density;
CESC	cis	rs9467773	1.000	rs9467783	chr6:26542894	C/T	cg11502198	chr6:26597334	ABT1	0.38	5.32	0.31	2.16e-7	Intelligence (multi-trait analysis);
CESC	cis	rs2011503	0.941	rs4808934	chr19:19370917	C/T	cg11584989	chr19:19387371	SF4	0.53	6.32	0.36	1.09e-9	Bipolar disorder;
CESC	cis	rs2228479	0.850	rs17233664	chr16:89810628	C/T	cg14709524	chr16:89940631	TCF25	0.94	7.08	0.4	1.27e-11	Skin colour saturation;
CESC	cis	rs10504229	0.683	rs6980540	chr8:58127022	A/G	cg24829409	chr8:58192753	C8orf71	-0.59	-7.24	-0.41	4.79e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs698833	0.828	rs3738984	chr2:44531484	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	-0.5	-6.35	-0.36	9.45e-10	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs875971	1.000	rs2420591	chr7:65912381	T/C	cg11764359	chr7:65958608	NA	0.97	15.5	0.69	5.24e-39	Aortic root size;
CESC	cis	rs60871478	0.636	rs12532761	chr7:905229	C/T	cg13798912	chr7:905769	UNC84A	-0.6	-5.85	-0.34	1.44e-8	Cerebrospinal P-tau181p levels;
CESC	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg22764044	chr5:178986830	RUFY1	0.48	7.22	0.41	5.45e-12	Lung cancer;
CESC	cis	rs7666738	0.546	rs10010088	chr4:98655945	C/T	cg17366294	chr4:99064904	C4orf37	0.48	5.84	0.34	1.52e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3820068	0.603	rs56032936	chr1:15970953	T/C	cg16988262	chr1:15930761	NA	0.33	5.41	0.32	1.44e-7	Systolic blood pressure;
CESC	cis	rs7666738	0.752	rs35436270	chr4:99088280	G/A	cg05340658	chr4:99064831	C4orf37	0.61	7.1	0.4	1.17e-11	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11864453	0.611	rs9926927	chr16:72130556	G/T	cg01557791	chr16:72042693	DHODH	-0.43	-5.63	-0.33	4.52e-8	Fibrinogen levels;
CESC	cis	rs13191362	1.000	rs13204439	chr6:163015358	A/C	cg06582575	chr6:163149167	PACRG;PARK2	-0.78	-8.41	-0.46	2.51e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs412050	0.547	rs79111189	chr22:22164597	T/G	cg17089214	chr22:22089827	YPEL1	0.68	5.74	0.33	2.53e-8	Attention deficit hyperactivity disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11711062	chr6:132102214	NA	-0.48	-6.15	-0.35	2.78e-9	Gut microbiome composition (summer);
CESC	cis	rs748404	0.723	rs512431	chr15:43541939	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.61	-8.23	-0.45	8.6e-15	Lung cancer;
CESC	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.53	-5.81	-0.34	1.79e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs9916302	0.861	rs593480	chr17:37453780	A/C	cg07936489	chr17:37558343	FBXL20	0.75	10.39	0.54	1.96e-21	Glomerular filtration rate (creatinine);
CESC	cis	rs698833	0.886	rs8886	chr2:44547909	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	-0.49	-6.22	-0.36	1.98e-9	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs875971	0.660	rs1860468	chr7:66107252	T/C	cg11764359	chr7:65958608	NA	-0.57	-7.49	-0.42	1.04e-12	Aortic root size;
CESC	cis	rs875971	0.545	rs75840613	chr7:65841386	G/A	cg11764359	chr7:65958608	NA	0.81	9.84	0.52	1.15e-19	Aortic root size;
CESC	cis	rs4835473	0.932	rs4260486	chr4:144908709	C/T	cg25736465	chr4:144833511	NA	0.42	6.43	0.37	6.02e-10	Immature fraction of reticulocytes;
CESC	cis	rs2243480	1.000	rs4718270	chr7:65202407	A/G	cg25894440	chr7:65020034	NA	-0.64	-5.33	-0.31	2.1e-7	Diabetic kidney disease;
CESC	cis	rs11190604	1.000	rs12354411	chr10:102294537	G/A	cg07080220	chr10:102295463	HIF1AN	0.7	6.5	0.37	3.99e-10	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs6963495	0.818	rs73190166	chr7:105159955	G/A	cg02135003	chr7:105160482	PUS7	-0.46	-5.38	-0.31	1.64e-7	Bipolar disorder (body mass index interaction);
CESC	cis	rs7666738	0.830	rs3852122	chr4:98697400	T/C	cg03467027	chr4:99064603	C4orf37	0.43	5.31	0.31	2.33e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7799006	0.964	rs3757440	chr7:2272936	A/G	cg08027265	chr7:2291960	NA	-0.44	-6.79	-0.38	7.4e-11	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs10242455	0.702	rs59574285	chr7:99236151	C/T	cg25640893	chr7:99214727	ZNF498	0.78	5.22	0.31	3.66e-7	Blood metabolite levels;
CESC	cis	rs9790314	0.846	rs13083229	chr3:161008125	G/A	cg03342759	chr3:160939853	NMD3	-0.51	-7.26	-0.41	4.27e-12	Morning vs. evening chronotype;
CESC	cis	rs2839186	0.771	rs2280957	chr21:47642272	A/G	cg11766577	chr21:47581405	C21orf56	0.49	6.77	0.38	8.44e-11	Testicular germ cell tumor;
CESC	cis	rs1552244	0.938	rs66915020	chr3:10110174	A/G	cg00166722	chr3:10149974	C3orf24	0.54	6.89	0.39	4.08e-11	Alzheimer's disease;
CESC	cis	rs6690583	0.562	rs6688354	chr1:85520854	A/G	cg22153463	chr1:85462885	MCOLN2	0.78	7.62	0.42	4.59e-13	Serum sulfate level;
CESC	cis	rs2985684	0.789	rs1957979	chr14:50063332	A/G	cg10008539	chr14:50087325	RPL36AL;MGAT2	-0.46	-5.58	-0.32	6.08e-8	Carotid intima media thickness;
CESC	cis	rs79057730	0.599	rs79272827	chr7:807015	C/G	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.92	7.99	0.44	4.08e-14	Initial pursuit acceleration;
CESC	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg24503407	chr1:205819492	PM20D1	0.79	12.71	0.62	3.22e-29	Menarche (age at onset);
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	ch.2.1420302F	chr2:62093097	NA	-0.39	-6.19	-0.36	2.22e-9	Vertical cup-disc ratio;
CESC	cis	rs7618915	0.501	rs35526119	chr3:52749334	C/T	cg18337363	chr3:52569053	NT5DC2	0.29	5.32	0.31	2.23e-7	Bipolar disorder;
CESC	cis	rs4689388	0.853	rs6446479	chr4:6291737	G/C	cg14416269	chr4:6271139	WFS1	0.44	7.14	0.4	8.83e-12	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs1707322	0.752	rs11211169	chr1:46166709	A/G	cg06784218	chr1:46089804	CCDC17	0.41	7.21	0.41	5.75e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2034088	0.833	rs4968120	chr17:431364	T/G	cg13332499	chr17:408570	NA	0.49	8.61	0.47	6.72e-16	Hip circumference adjusted for BMI;
CESC	cis	rs3096299	0.802	rs3102336	chr16:89442006	C/T	cg08392591	chr16:89556376	ANKRD11	0.39	5.06	0.3	7.98e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs4835473	0.897	rs4054616	chr4:144758625	T/A	cg25736465	chr4:144833511	NA	0.45	6.65	0.38	1.67e-10	Immature fraction of reticulocytes;
CESC	cis	rs7824557	0.564	rs2572392	chr8:11235605	T/G	cg21775007	chr8:11205619	TDH	-0.54	-8.07	-0.44	2.43e-14	Retinal vascular caliber;
CESC	cis	rs2243480	0.901	rs3813708	chr7:65305632	C/A	cg13147721	chr7:65941812	NA	-0.91	-8.71	-0.47	3.41e-16	Diabetic kidney disease;
CESC	cis	rs7116495	0.609	rs4477459	chr11:71720616	T/C	cg18441811	chr11:71824068	C11orf51	-0.81	-5.37	-0.31	1.74e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs561341	0.709	rs8068049	chr17:30183857	T/C	cg00745463	chr17:30367425	LRRC37B	0.69	6.15	0.35	2.82e-9	Hip circumference adjusted for BMI;
CESC	cis	rs7089973	0.604	rs1359079	chr10:116582502	A/G	cg23260525	chr10:116636907	FAM160B1	0.38	6.86	0.39	4.82e-11	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs2070488	1.000	rs1002676	chr3:38444932	A/C	cg24069376	chr3:38537580	EXOG	-0.45	-8.06	-0.44	2.58e-14	Electrocardiographic conduction measures;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10561472	chr19:4066818	ZBTB7A	-0.57	-6.33	-0.36	1.07e-9	Gut microbiome composition (summer);
CESC	cis	rs4970988	0.556	rs2280078	chr1:150600181	C/T	cg17724175	chr1:150552817	MCL1	-0.48	-7.67	-0.43	3.31e-13	Urate levels;
CESC	trans	rs9354308	0.933	rs12194424	chr6:66574007	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.7	7.79	0.43	1.56e-13	Metabolite levels;
CESC	cis	rs892961	0.932	rs747481	chr17:75412143	A/G	cg05865280	chr17:75406074	SEPT9	0.62	12.7	0.62	3.53e-29	Airflow obstruction;
CESC	cis	rs13191362	1.000	rs4489133	chr6:163137793	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.09	11.08	0.56	1.09e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs1799949	0.965	rs12950779	chr17:41306523	C/T	cg23758822	chr17:41437982	NA	1.03	16.04	0.7	6.23e-41	Menopause (age at onset);
CESC	cis	rs34779708	0.966	rs4934536	chr10:35441169	A/G	cg04310649	chr10:35416472	CREM	-0.51	-6.21	-0.36	2.08e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs1008375	0.932	rs1008894	chr4:17704667	C/T	cg02297831	chr4:17616191	MED28	-0.53	-6.31	-0.36	1.18e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs6500395	1.000	rs1004909	chr16:48725580	C/G	cg04672837	chr16:48644449	N4BP1	-0.51	-6.32	-0.36	1.13e-9	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs10504229	0.683	rs903706	chr8:58128134	T/G	cg02725872	chr8:58115012	NA	-0.45	-7.05	-0.4	1.52e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs2380220	0.720	rs9398251	chr6:95984709	C/T	cg04719120	chr6:96025338	MANEA	0.45	5.06	0.3	7.88e-7	Behavioural disinhibition (generation interaction);
CESC	cis	rs7953508	0.506	rs3782415	chr12:93967755	T/C	cg18151635	chr12:93972918	NA	-0.44	-5.87	-0.34	1.31e-8	Pubertal anthropometrics;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg04570540	chr13:113383816	ATP11A	-0.48	-6.41	-0.37	6.82e-10	Systemic lupus erythematosus;
CESC	cis	rs2839186	0.967	rs17176131	chr21:47705237	T/C	cg10351095	chr21:47802916	PCNT	-0.49	-6.68	-0.38	1.42e-10	Testicular germ cell tumor;
CESC	cis	rs10540	1.000	rs12788729	chr11:502371	G/A	cg03934478	chr11:495069	RNH1	0.56	5.39	0.31	1.54e-7	Body mass index;
CESC	cis	rs7851660	0.654	rs2120264	chr9:100645728	A/G	cg13688889	chr9:100608707	NA	-0.61	-8.66	-0.47	4.59e-16	Strep throat;
CESC	trans	rs1977584	0.673	rs17416363	chr10:45392198	C/T	cg09262100	chr14:103416268	CDC42BPB	0.61	6.1	0.35	3.67e-9	Selective IgA deficiency;
CESC	cis	rs2243480	1.000	rs1546059	chr7:65654709	C/A	cg13147721	chr7:65941812	NA	0.97	9.16	0.49	1.47e-17	Diabetic kidney disease;
CESC	cis	rs910316	0.763	rs175057	chr14:75489632	C/T	cg08847533	chr14:75593920	NEK9	-0.89	-14.97	-0.68	3.77e-37	Height;
CESC	cis	rs1348850	0.540	rs6737342	chr2:178419117	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.7	6.81	0.39	6.62e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs71636778	0.543	rs17162330	chr1:27236212	A/G	cg12203394	chr1:27248618	NUDC	0.64	5.55	0.32	6.82e-8	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
CESC	cis	rs1862618	0.853	rs2113078	chr5:56087190	C/T	cg22800045	chr5:56110881	MAP3K1	0.79	9.22	0.49	9.3e-18	Initial pursuit acceleration;
CESC	cis	rs7107174	1.000	rs2512533	chr11:77968674	A/C	cg02023728	chr11:77925099	USP35	0.48	6.34	0.36	9.87e-10	Testicular germ cell tumor;
CESC	cis	rs2228479	0.557	rs11641726	chr16:89891619	G/A	cg14709524	chr16:89940631	TCF25	0.87	6.05	0.35	4.99e-9	Skin colour saturation;
CESC	cis	rs7223966	1.000	rs9895920	chr17:61852719	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	7.36	0.41	2.28e-12	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs4862750	0.872	rs6836781	chr4:187899701	G/A	cg07414643	chr4:187882934	NA	0.56	8.14	0.45	1.53e-14	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs826838	0.967	rs826876	chr12:39123843	T/C	cg26384229	chr12:38710491	ALG10B	-0.67	-11.02	-0.56	1.72e-23	Heart rate;
CESC	trans	rs66887589	0.807	rs7694483	chr4:120405929	T/A	cg25214090	chr10:38739885	LOC399744	0.43	6.09	0.35	3.92e-9	Diastolic blood pressure;
CESC	cis	rs11051970	0.625	rs2728709	chr12:32567716	C/T	cg24626660	chr12:32551988	NA	0.32	5.04	0.3	8.57e-7	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs1775715	0.870	rs3847414	chr10:32219176	A/G	cg18675610	chr10:32216311	ARHGAP12	0.35	5.25	0.31	3.1e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs7923609	0.967	rs3740331	chr10:65192288	G/A	cg01631684	chr10:65280961	REEP3	-0.44	-5.48	-0.32	9.84e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs6540559	0.546	rs57315825	chr1:210030197	C/T	cg25204440	chr1:209979598	IRF6	0.56	5.51	0.32	8.42e-8	Cleft lip with or without cleft palate;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23845400	chr6:36343668	ETV7	-0.56	-6.21	-0.36	2.02e-9	Gut microbiome composition (summer);
CESC	cis	rs243505	0.528	rs740951	chr7:148470160	C/A	cg09806900	chr7:148480153	CUL1	0.44	5.24	0.31	3.3e-7	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs2033732	0.826	rs2196617	chr8:85089394	G/A	cg05716166	chr8:85095498	RALYL	0.32	5.09	0.3	6.67e-7	Body mass index;
CESC	cis	rs9322193	0.923	rs9371199	chr6:150138662	A/T	cg04369109	chr6:150039330	LATS1	-0.48	-6.6	-0.38	2.26e-10	Lung cancer;
CESC	trans	rs6089829	0.962	rs6062393	chr20:61663230	G/A	cg23505145	chr19:12996616	KLF1	0.52	6.74	0.38	1e-10	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg23332732	chr12:26986274	ITPR2	-0.46	-6.01	-0.35	6.19e-9	Fibrinogen levels;
CESC	cis	rs4654899	0.758	rs6426665	chr1:21382205	T/C	cg05370193	chr1:21551575	ECE1	0.35	5.33	0.31	2.07e-7	Superior frontal gyrus grey matter volume;
CESC	cis	rs9322193	0.847	rs880246	chr6:150167108	G/A	cg07701084	chr6:150067640	NUP43	0.43	5.54	0.32	7.12e-8	Lung cancer;
CESC	cis	rs9549367	0.789	rs3764125	chr13:113897648	A/G	cg00898013	chr13:113819073	PROZ	0.58	7.67	0.43	3.26e-13	Platelet distribution width;
CESC	cis	rs8177253	0.665	rs11921527	chr3:133441167	G/A	cg18769074	chr3:133464867	TF	0.32	5.97	0.34	7.63e-9	Iron status biomarkers;
CESC	trans	rs116095464	0.558	rs10076655	chr5:239464	G/C	cg00938859	chr5:1591904	SDHAP3	0.63	6.92	0.39	3.43e-11	Breast cancer;
CESC	cis	rs3820068	0.532	rs72645862	chr1:15920366	A/G	cg16988262	chr1:15930761	NA	0.36	5.67	0.33	3.63e-8	Systolic blood pressure;
CESC	cis	rs13108904	0.837	rs4519749	chr4:1280102	A/G	cg00684032	chr4:1343700	KIAA1530	0.39	5.43	0.32	1.27e-7	Obesity-related traits;
CESC	cis	rs4835473	0.897	rs61611095	chr4:144879955	C/A	cg25736465	chr4:144833511	NA	0.41	6.11	0.35	3.59e-9	Immature fraction of reticulocytes;
CESC	cis	rs9303280	0.685	rs9916765	chr17:38005595	T/C	cg20243544	chr17:37824526	PNMT	0.5	6.88	0.39	4.34e-11	Self-reported allergy;
CESC	cis	rs941873	0.805	rs876678	chr10:81111036	G/T	cg08514558	chr10:81106712	PPIF	0.3	5.23	0.31	3.5e-7	Height;
CESC	cis	rs761746	0.607	rs5753715	chr22:31991001	G/A	cg25791279	chr22:32026902	PISD	0.57	5.71	0.33	2.96e-8	Intelligence;
CESC	cis	rs690037	0.551	rs690522	chr3:16377067	C/T	cg23474789	chr3:16306055	DPH3;OXNAD1	-0.46	-6.06	-0.35	4.56e-9	Optic nerve measurement (cup-to-disc ratio);Optic nerve measurement (cup area);
CESC	cis	rs7520050	0.966	rs785492	chr1:46583607	G/A	cg24296786	chr1:45957014	TESK2	0.41	5.17	0.3	4.55e-7	Red blood cell count;Reticulocyte count;
CESC	cis	rs977987	0.735	rs166013	chr16:75434146	C/T	cg03315344	chr16:75512273	CHST6	-0.44	-6.11	-0.35	3.46e-9	Dupuytren's disease;
CESC	cis	rs36051895	0.664	rs11793659	chr9:5109707	A/G	cg02405213	chr9:5042618	JAK2	-0.53	-6.13	-0.35	3.25e-9	Pediatric autoimmune diseases;
CESC	cis	rs262150	0.659	rs2527236	chr7:158796644	C/T	cg19418458	chr7:158789849	NA	-0.5	-8.26	-0.45	6.78e-15	Facial morphology (factor 20);
CESC	cis	rs4555082	0.874	rs28785556	chr14:105745388	A/T	cg06808227	chr14:105710500	BRF1	-0.52	-5.53	-0.32	7.68e-8	Mean platelet volume;Platelet distribution width;
CESC	cis	rs4727963	0.846	rs10258817	chr7:122738914	G/A	cg03640110	chr7:122635026	TAS2R16	0.37	5.76	0.33	2.32e-8	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
CESC	cis	rs7336332	0.598	rs10220056	chr13:28003781	T/G	cg22138327	chr13:27999177	GTF3A	0.64	5.96	0.34	8.09e-9	Weight;
CESC	cis	rs1559088	0.600	rs7259117	chr19:33550113	G/T	cg17764715	chr19:33622953	WDR88	0.59	8.28	0.45	6.31e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs7103648	0.553	rs12803857	chr11:47890172	G/A	cg03711944	chr11:47377212	SPI1	-0.34	-5.15	-0.3	5.02e-7	Diastolic blood pressure;Systolic blood pressure;
CESC	cis	rs6939532	0.522	rs2073528	chr6:26375143	G/C	cg14345882	chr6:26364793	BTN3A2	0.38	6.03	0.35	5.54e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs1707322	0.752	rs28812624	chr1:46203736	T/A	cg03146154	chr1:46216737	IPP	0.82	11.53	0.58	3.39e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs34172651	0.517	rs3803716	chr16:24802325	C/T	cg00339695	chr16:24857497	SLC5A11	0.5	6.53	0.37	3.25e-10	Intelligence (multi-trait analysis);
CESC	cis	rs3213545	0.659	rs2259693	chr12:121457995	G/A	cg15155738	chr12:121454335	C12orf43	0.5	6.07	0.35	4.35e-9	Subjective well-being;Cardiovascular disease risk factors;
CESC	cis	rs8031584	0.958	rs8034856	chr15:31240957	T/C	cg14829155	chr15:31115871	NA	-0.72	-9.72	-0.51	2.73e-19	Huntington's disease progression;
CESC	cis	rs651907	0.557	rs34624546	chr3:101374226	T/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.48	6.2	0.36	2.21e-9	Colorectal cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15623359	chr2:73441816	SMYD5	-0.68	-7.96	-0.44	5.01e-14	Gut microbiome composition (summer);
CESC	cis	rs12586317	0.547	rs28577270	chr14:35498443	G/A	cg05294307	chr14:35346193	BAZ1A	-0.51	-5.4	-0.31	1.49e-7	Psoriasis;
CESC	cis	rs8062405	1.000	rs1987472	chr16:28825777	C/T	cg08761264	chr16:28874980	SH2B1	-0.45	-5.7	-0.33	3.19e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs1044826	0.642	rs407958	chr3:139213632	T/C	cg00490450	chr3:139108681	COPB2	0.42	5.09	0.3	6.87e-7	Obesity-related traits;
CESC	cis	rs13253111	0.583	rs6993376	chr8:28096300	A/C	cg26534493	chr8:28060551	NA	0.48	7.52	0.42	8.73e-13	Childhood body mass index;
CESC	cis	rs4746818	1.000	rs7893492	chr10:70960448	C/T	cg11621586	chr10:70884670	VPS26A	-0.8	-8.11	-0.45	1.9e-14	Left atrial antero-posterior diameter;
CESC	cis	rs2857078	0.720	rs9901595	chr17:42305699	G/A	cg08499158	chr17:42289980	UBTF	-0.41	-5.1	-0.3	6.39e-7	Red cell distribution width;Reticulocyte count;
CESC	cis	rs11264213	0.786	rs72659690	chr1:36291750	G/A	cg27506609	chr1:36549197	TEKT2	0.61	5.04	0.3	8.54e-7	Schizophrenia;
CESC	cis	rs780096	0.565	rs8179252	chr2:27746832	A/C	cg17158414	chr2:27665306	KRTCAP3	-0.28	-5.12	-0.3	5.87e-7	Total body bone mineral density;
CESC	cis	rs2204008	0.536	rs12368354	chr12:38042798	G/A	cg13010199	chr12:38710504	ALG10B	0.54	6.63	0.38	1.87e-10	Bladder cancer;
CESC	cis	rs2644899	0.750	rs2249835	chr19:41269766	G/A	cg24958765	chr19:41283667	RAB4B	-0.57	-6.63	-0.38	1.93e-10	Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs858239	0.699	rs1881200	chr7:23201637	T/C	cg23682824	chr7:23144976	KLHL7	-0.38	-5.14	-0.3	5.4e-7	Cerebrospinal fluid biomarker levels;
CESC	cis	rs9902453	0.740	rs2628189	chr17:28088813	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-10.42	-0.54	1.51e-21	Coffee consumption (cups per day);
CESC	cis	rs10504229	0.774	rs72650880	chr8:58164727	C/T	cg24829409	chr8:58192753	C8orf71	-0.72	-8.48	-0.46	1.65e-15	Developmental language disorder (linguistic errors);
CESC	cis	rs11122272	0.735	rs2739509	chr1:231526765	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.56	-7.69	-0.43	2.97e-13	Hemoglobin concentration;
CESC	trans	rs11250098	0.574	rs4554431	chr8:10771638	T/A	cg06636001	chr8:8085503	FLJ10661	-0.5	-6.23	-0.36	1.82e-9	Morning vs. evening chronotype;
CESC	cis	rs4253772	0.591	rs9615343	chr22:46690824	C/G	cg18190219	chr22:46762943	CELSR1	-0.59	-5.45	-0.32	1.14e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs3617	0.573	rs6795646	chr3:52922621	C/T	cg07507251	chr3:52567010	NT5DC2	-0.33	-5.54	-0.32	7.48e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
CESC	cis	rs72781680	0.898	rs72788218	chr2:24090435	C/T	cg20701182	chr2:24300061	SF3B14	0.59	5.44	0.32	1.23e-7	Lymphocyte counts;
CESC	cis	rs2404602	0.735	rs3765115	chr15:76673716	T/C	cg23625390	chr15:77176239	SCAPER	-0.43	-5.93	-0.34	9.52e-9	Blood metabolite levels;
CESC	cis	rs13191362	0.935	rs34141091	chr6:162953893	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.77	7.22	0.41	5.52e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27109030	chr19:2702898	GNG7	0.43	6.14	0.35	3.05e-9	Gut microbiome composition (summer);
CESC	cis	rs2243480	1.000	rs35391607	chr7:65360829	G/A	cg13147721	chr7:65941812	NA	-0.83	-7.97	-0.44	4.85e-14	Diabetic kidney disease;
CESC	cis	rs9868809	0.772	rs9812200	chr3:48695667	A/G	cg07636037	chr3:49044803	WDR6	0.59	5.24	0.31	3.34e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs7605827	0.930	rs9287661	chr2:15595901	G/A	cg19274914	chr2:15703543	NA	0.33	5.97	0.34	7.72e-9	Educational attainment (years of education);
CESC	cis	rs1707322	0.686	rs2152078	chr1:46055600	C/T	cg05343316	chr1:45956843	TESK2	-0.53	-6.5	-0.37	3.87e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7551222	0.752	rs2369244	chr1:204515299	C/G	cg20240347	chr1:204465584	NA	0.26	5.35	0.31	1.95e-7	Schizophrenia;
CESC	cis	rs4642101	0.793	rs6763619	chr3:12822147	T/G	cg05775895	chr3:12838266	CAND2	0.39	5.93	0.34	9.32e-9	QRS complex (12-leadsum);
CESC	cis	rs9322193	0.962	rs4869966	chr6:150084850	A/G	cg04369109	chr6:150039330	LATS1	-0.39	-5.27	-0.31	2.82e-7	Lung cancer;
CESC	cis	rs7811142	0.830	rs6979910	chr7:99940630	A/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.85	9.37	0.5	3.24e-18	Platelet count;
CESC	cis	rs939574	0.790	rs72955452	chr2:220101783	C/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.87	7.33	0.41	2.86e-12	Platelet distribution width;
CESC	cis	rs7772486	0.686	rs4895684	chr6:146114023	A/C	cg05347473	chr6:146136440	FBXO30	-0.51	-6.72	-0.38	1.1e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg24829409	chr8:58192753	C8orf71	-0.67	-8.09	-0.44	2.23e-14	Developmental language disorder (linguistic errors);
CESC	cis	rs2625529	0.730	rs4777485	chr15:72389384	G/C	cg16672083	chr15:72433130	SENP8	-0.43	-6.09	-0.35	3.93e-9	Red blood cell count;
CESC	cis	rs3820068	0.608	rs7552400	chr1:16035892	A/G	cg17385448	chr1:15911702	AGMAT	0.38	6.08	0.35	4.28e-9	Systolic blood pressure;
CESC	cis	rs780096	0.526	rs12476704	chr2:27613031	C/A	cg12648201	chr2:27665141	KRTCAP3	-0.3	-5.33	-0.31	2.13e-7	Total body bone mineral density;
CESC	cis	rs7829975	0.840	rs572366	chr8:8578794	A/T	cg06636001	chr8:8085503	FLJ10661	0.41	5.28	0.31	2.74e-7	Mood instability;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18033235	chr19:16989681	SIN3B	-0.65	-7.49	-0.42	1.05e-12	Gut microbiome composition (summer);
CESC	cis	rs71403859	0.614	rs12447033	chr16:71583655	G/T	cg08717414	chr16:71523259	ZNF19	-0.83	-7.59	-0.42	5.57e-13	Post bronchodilator FEV1;
CESC	cis	rs2836974	0.899	rs68004583	chr21:40659587	T/C	cg17971929	chr21:40555470	PSMG1	1.07	16.52	0.71	1.29e-42	Cognitive function;
CESC	cis	rs13191362	0.935	rs13205279	chr6:162945030	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.68	5.9	0.34	1.1e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs4819052	0.918	rs34886433	chr21:46680538	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.9	11.37	0.57	1.16e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs4665809	0.590	rs10179959	chr2:26426403	G/A	cg04944784	chr2:26401820	FAM59B	-0.94	-10.63	-0.55	3.14e-22	Gut microbiome composition (summer);
CESC	cis	rs8177253	0.828	rs8177259	chr3:133480388	T/C	cg12373951	chr3:133503437	NA	0.43	6.3	0.36	1.24e-9	Iron status biomarkers;
CESC	cis	rs748404	0.660	rs693510	chr15:43714625	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	8.37	0.46	3.47e-15	Lung cancer;
CESC	cis	rs12477438	0.798	rs10198293	chr2:99602929	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.75	-10.87	-0.56	5.17e-23	Chronic sinus infection;
CESC	cis	rs7219021	0.705	rs67174000	chr17:46982380	G/A	cg16584676	chr17:46985605	UBE2Z	-0.63	-7.84	-0.43	1.14e-13	Schizophrenia or bipolar disorder;
CESC	cis	rs9911578	0.935	rs7218105	chr17:57041119	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.38	5.08	0.3	7.21e-7	Intelligence (multi-trait analysis);
CESC	cis	rs7772486	0.790	rs2247429	chr6:146217769	T/C	cg23711669	chr6:146136114	FBXO30	0.94	13.73	0.64	9.31e-33	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs909674	0.865	rs5757682	chr22:39848259	T/G	cg01416388	chr22:39784598	NA	-0.59	-6.82	-0.39	6.08e-11	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs4242434	0.927	rs57594397	chr8:22475657	T/C	cg03733263	chr8:22462867	KIAA1967	0.94	12.79	0.62	1.7e-29	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CESC	trans	rs9929218	0.953	rs3118227	chr16:68734855	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.76	-9.55	-0.51	9.37e-19	Colorectal cancer;
CESC	trans	rs931812	0.825	rs55818461	chr8:101899229	T/C	cg20993868	chr7:22813445	NA	0.55	7.74	0.43	2.04e-13	Attention deficit hyperactivity disorder and conduct disorder;
CESC	cis	rs1790761	0.692	rs1148883	chr11:67304686	A/G	cg08355456	chr11:67383691	NA	0.34	5.32	0.31	2.2e-7	Mean corpuscular volume;
CESC	cis	rs10791323	0.569	rs11223609	chr11:133741766	C/T	cg15485101	chr11:133734466	NA	0.3	5.12	0.3	5.99e-7	Childhood ear infection;
CESC	cis	rs9649213	0.574	rs13238610	chr7:97909277	T/C	cg00277769	chr7:97922759	BAIAP2L1	-0.36	-5.89	-0.34	1.2e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs60871478	0.730	rs13222476	chr7:826630	T/C	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.57	5.61	0.33	4.98e-8	Cerebrospinal P-tau181p levels;
CESC	cis	rs13255475	0.772	rs7824600	chr8:121506382	C/T	cg05978010	chr8:121408224	MRPL13	-0.33	-5.12	-0.3	5.88e-7	Cerebrospinal T-tau levels;Cerebrospinal P-tau181p levels;
CESC	cis	rs9322193	0.923	rs9372044	chr6:150102003	G/A	cg04369109	chr6:150039330	LATS1	-0.39	-5.35	-0.31	1.93e-7	Lung cancer;
CESC	cis	rs11711311	0.712	rs3773683	chr3:113341007	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.54	7.09	0.4	1.24e-11	IgG glycosylation;
CESC	cis	rs7923609	0.846	rs10761731	chr10:65027610	A/T	cg01631684	chr10:65280961	REEP3	-0.44	-5.4	-0.31	1.51e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs11741688	0.557	rs10043579	chr5:178330174	C/T	cg20935368	chr5:178288625	ZNF354B	0.34	5.4	0.32	1.45e-7	Sleep duration;
CESC	cis	rs4243830	0.850	rs12029123	chr1:6607142	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	0.95	9.41	0.5	2.46e-18	Body mass index;
CESC	cis	rs748404	0.631	rs12905772	chr15:43648444	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.55	8.42	0.46	2.44e-15	Lung cancer;
CESC	cis	rs35110281	0.591	rs162390	chr21:44936826	C/T	cg01579765	chr21:45077557	HSF2BP	-0.48	-8.29	-0.45	5.8e-15	Mean corpuscular volume;
CESC	cis	rs3096299	0.728	rs1011749	chr16:89510869	G/C	cg08392591	chr16:89556376	ANKRD11	0.57	7.71	0.43	2.51e-13	Multiple myeloma (IgH translocation);
CESC	cis	rs4689388	0.824	rs114669221	chr4:6301459	G/A	cg00701064	chr4:6280414	WFS1	0.68	11.88	0.59	2.27e-26	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs959260	1.000	rs4789189	chr17:73397985	C/G	cg20590849	chr17:73267439	MIF4GD	-0.57	-6.49	-0.37	4.3e-10	Systemic lupus erythematosus;
CESC	cis	rs1862618	0.573	rs2034245	chr5:56243685	T/C	cg22800045	chr5:56110881	MAP3K1	-0.76	-8.63	-0.47	5.76e-16	Initial pursuit acceleration;
CESC	cis	rs561341	1.000	rs473356	chr17:30321762	G/C	cg00745463	chr17:30367425	LRRC37B	-0.82	-7.51	-0.42	9.09e-13	Hip circumference adjusted for BMI;
CESC	cis	rs10197940	0.710	rs4500942	chr2:152334580	A/G	cg19508488	chr2:152266495	RIF1	0.49	5.82	0.34	1.68e-8	Lung cancer;
CESC	cis	rs7845219	0.506	rs12548999	chr8:95929843	C/T	cg16049864	chr8:95962084	TP53INP1	-0.46	-6.68	-0.38	1.43e-10	Type 2 diabetes;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg25449970	chr10:5550506	NA	0.44	6.19	0.36	2.26e-9	Fibrinogen levels;
CESC	cis	rs898097	0.812	rs72859941	chr17:80837459	G/A	cg15369054	chr17:80825471	TBCD	0.53	7.21	0.4	5.94e-12	Breast cancer;
CESC	cis	rs11098499	0.863	rs2306457	chr4:120472839	T/A	cg24375607	chr4:120327624	NA	0.45	5.52	0.32	8.02e-8	Corneal astigmatism;
CESC	cis	rs12079745	0.793	rs3753298	chr1:169176899	G/A	cg09363564	chr1:169337483	NME7;BLZF1	-1.1	-6.5	-0.37	3.95e-10	QT interval;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23094080	chr8:145550361	DGAT1	0.54	6.29	0.36	1.34e-9	Gut microbiome composition (summer);
CESC	trans	rs916888	0.773	rs199533	chr17:44828931	G/A	cg04282206	chr17:62833786	PLEKHM1P	0.55	6.41	0.37	6.71e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs9733	0.525	rs11584184	chr1:150695689	A/T	cg09365446	chr1:150670422	GOLPH3L	0.42	5.84	0.34	1.55e-8	Tonsillectomy;
CESC	cis	rs3126085	0.877	rs3126045	chr1:152256794	A/G	cg03465714	chr1:152285911	FLG	-0.45	-5.54	-0.32	7.12e-8	Atopic dermatitis;
CESC	cis	rs6598955	0.671	rs12085416	chr1:26627835	T/C	cg19743891	chr1:26644573	UBXN11;CD52	0.37	5.45	0.32	1.18e-7	Obesity-related traits;
CESC	cis	rs4843747	0.518	rs4072777	chr16:88107030	G/A	cg06915872	chr16:87998081	BANP	0.44	5.24	0.31	3.36e-7	Menopause (age at onset);
CESC	cis	rs9911578	1.000	rs437732	chr17:56675861	A/C	cg05425664	chr17:57184151	TRIM37	-0.51	-7.21	-0.4	6.03e-12	Intelligence (multi-trait analysis);
CESC	trans	rs801193	1.000	rs6958520	chr7:66151453	T/C	cg26939375	chr7:64535504	NA	0.64	8.81	0.48	1.69e-16	Aortic root size;
CESC	cis	rs10479542	0.766	rs7733389	chr5:178974997	C/T	cg26516362	chr5:178986906	RUFY1	0.36	5.46	0.32	1.11e-7	Lung cancer;
CESC	cis	rs1348850	0.793	rs6734528	chr2:178493731	G/A	cg23306229	chr2:178417860	TTC30B	0.56	7.14	0.4	9.13e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs3740713	1.000	rs1848048	chr11:18468996	T/C	cg23797887	chr11:18477753	LDHAL6A	-0.54	-5.21	-0.31	3.72e-7	Amyotrophic lateral sclerosis (sporadic);
CESC	trans	rs7937682	1.000	rs505372	chr11:111507189	A/C	cg18187862	chr3:45730750	SACM1L	0.48	6.04	0.35	5.1e-9	Primary sclerosing cholangitis;
CESC	cis	rs6424115	0.830	rs6680132	chr1:24198804	T/C	cg10978503	chr1:24200527	CNR2	0.33	6.63	0.38	1.85e-10	Immature fraction of reticulocytes;
CESC	cis	rs7107174	1.000	rs2510041	chr11:77945284	G/A	cg02023728	chr11:77925099	USP35	0.44	6.19	0.36	2.3e-9	Testicular germ cell tumor;
CESC	cis	rs1801251	0.928	rs737028	chr2:233640750	T/C	cg25237894	chr2:233734115	C2orf82	0.45	7.98	0.44	4.53e-14	Coronary artery disease;
CESC	cis	rs7552404	1.000	rs11163924	chr1:76132070	A/C	cg10523679	chr1:76189770	ACADM	-0.7	-8.01	-0.44	3.6e-14	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs7666738	0.830	rs6532720	chr4:99043781	C/T	cg03467027	chr4:99064603	C4orf37	0.47	5.98	0.34	7.19e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9488822	0.676	rs11153594	chr6:116354591	A/G	cg18764771	chr6:116381957	FRK	-0.24	-6.03	-0.35	5.58e-9	Cholesterol, total;LDL cholesterol;
CESC	cis	rs7552404	0.727	rs2172507	chr1:76331320	A/G	cg03433033	chr1:76189801	ACADM	-0.62	-6.47	-0.37	4.68e-10	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs6460942	0.915	rs17541464	chr7:12462675	A/G	cg17427002	chr7:12443146	VWDE	-0.48	-5.42	-0.32	1.35e-7	Coronary artery disease;
CESC	cis	rs763121	0.744	rs5757140	chr22:38957013	T/C	cg14440974	chr22:39074834	NA	-0.4	-5.25	-0.31	3.08e-7	Menopause (age at onset);
CESC	cis	rs9611565	0.729	rs203319	chr22:41914593	C/T	cg17376030	chr22:41985996	PMM1	0.48	5.71	0.33	3.04e-8	Vitiligo;
CESC	cis	rs13256369	0.802	rs11249883	chr8:8561537	G/A	cg18904891	chr8:8559673	CLDN23	0.7	7.82	0.43	1.26e-13	Obesity-related traits;
CESC	cis	rs56104184	0.775	rs73063505	chr19:49402765	T/C	cg21252483	chr19:49399788	TULP2	-0.52	-5.69	-0.33	3.36e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	cis	rs9487051	0.676	rs6933326	chr6:109601333	C/T	cg21918786	chr6:109611834	NA	-0.39	-5.74	-0.33	2.65e-8	Reticulocyte fraction of red cells;
CESC	cis	rs7923609	0.902	rs10822158	chr10:65094383	A/G	cg01631684	chr10:65280961	REEP3	-0.42	-5.26	-0.31	3.04e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs9787249	0.957	rs12086750	chr1:40210468	G/C	cg24920358	chr1:40204285	PPIE	0.42	6.37	0.36	8.16e-10	Blood protein levels;
CESC	cis	rs4523957	0.614	rs7208638	chr17:2061334	G/C	cg16513277	chr17:2031491	SMG6	-0.72	-10.2	-0.53	8.12e-21	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs11828289	0.660	rs28825707	chr11:23224075	G/A	cg20040320	chr11:23191996	NA	-0.7	-5.78	-0.33	2.11e-8	Cancer;
CESC	cis	rs1018836	0.663	rs56784954	chr8:91505094	C/T	cg16814680	chr8:91681699	NA	-0.58	-7.68	-0.43	3e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs2842992	0.789	rs4709370	chr6:160210061	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.78	9.51	0.5	1.25e-18	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs1670533	1.000	rs28562028	chr4:1055115	G/A	cg04106633	chr4:1044584	NA	0.41	5.19	0.3	4.11e-7	Recombination rate (females);
CESC	cis	rs2370759	1.000	rs2370759	chr10:32634972	G/A	cg18270830	chr10:32634957	EPC1	0.71	6.87	0.39	4.58e-11	Sexual dysfunction (female);
CESC	cis	rs7666738	0.606	rs28625338	chr4:99076996	A/G	cg05340658	chr4:99064831	C4orf37	0.65	9.19	0.49	1.17e-17	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3820928	0.804	rs4144327	chr2:227790262	C/T	cg05526886	chr2:227700861	RHBDD1	-0.4	-5.2	-0.3	3.93e-7	Pulmonary function;
CESC	cis	rs7618915	0.501	rs10865974	chr3:52718280	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	-0.5	-7.63	-0.42	4.19e-13	Bipolar disorder;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg02222454	chr3:141762828	NA	0.48	6.28	0.36	1.36e-9	Fibrinogen levels;
CESC	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.58	7.49	0.42	1.01e-12	Prudent dietary pattern;
CESC	cis	rs589448	0.535	rs12423794	chr12:69713018	G/A	cg22834771	chr12:69754056	YEATS4	-0.43	-5.5	-0.32	8.86e-8	Cerebrospinal fluid biomarker levels;
CESC	trans	rs916888	0.779	rs199498	chr17:44865603	A/G	cg22968622	chr17:43663579	NA	0.8	9.85	0.52	1.06e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs7503807	0.967	rs9915162	chr17:78614326	T/C	cg09596252	chr17:78655493	RPTOR	0.52	7.73	0.43	2.3e-13	Obesity;
CESC	cis	rs780096	0.526	rs7594812	chr2:27611469	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.28	-5.67	-0.33	3.77e-8	Total body bone mineral density;
CESC	cis	rs2463822	0.583	rs72919477	chr11:62042403	G/C	cg06239285	chr11:62104954	ASRGL1	-1.09	-8.77	-0.47	2.15e-16	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs4919694	1.000	rs12257935	chr10:104803062	C/A	cg04362960	chr10:104952993	NT5C2	0.79	7.08	0.4	1.27e-11	Arsenic metabolism;
CESC	cis	rs7811142	1.000	rs66632384	chr7:100018904	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.78	6.87	0.39	4.46e-11	Platelet count;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg22146484	chr8:57123862	CHCHD7;PLAG1	0.48	6.15	0.35	2.8e-9	Gut microbiota (bacterial taxa);
CESC	trans	rs61931739	0.500	rs7307583	chr12:34521711	T/C	cg26384229	chr12:38710491	ALG10B	0.54	7.55	0.42	7.05e-13	Morning vs. evening chronotype;
CESC	cis	rs11122272	0.735	rs2808611	chr1:231548480	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.52	6.98	0.39	2.42e-11	Hemoglobin concentration;
CESC	cis	rs6429082	0.811	rs291348	chr1:235667690	A/G	cg26050004	chr1:235667680	B3GALNT2	0.83	12.89	0.62	7.78e-30	Adiposity;
CESC	cis	rs9303280	0.901	rs7359623	chr17:38049589	C/T	cg20243544	chr17:37824526	PNMT	0.5	6.5	0.37	3.94e-10	Self-reported allergy;
CESC	trans	rs13401620	0.843	rs3101945	chr2:120591657	A/G	cg01115923	chr16:57793728	KIFC3	0.33	6.05	0.35	5e-9	Breast size;
CESC	cis	rs853679	1.000	rs7740487	chr6:28216486	C/G	cg12740337	chr6:28058973	ZSCAN12L1	0.32	5.06	0.3	7.74e-7	Depression;
CESC	cis	rs9640161	0.750	rs11765644	chr7:150026339	C/G	cg21361702	chr7:150065534	REPIN1	0.49	5.39	0.31	1.54e-7	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs9322193	0.923	rs9322214	chr6:150025122	C/T	cg07701084	chr6:150067640	NUP43	0.43	5.86	0.34	1.4e-8	Lung cancer;
CESC	cis	rs1348850	0.668	rs4893971	chr2:178495743	T/C	cg22681709	chr2:178499509	PDE11A	-0.41	-5.9	-0.34	1.09e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	trans	rs11098499	0.863	rs2306457	chr4:120472839	T/A	cg25214090	chr10:38739885	LOC399744	0.65	8.96	0.48	5.89e-17	Corneal astigmatism;
CESC	cis	rs3087591	0.959	rs9893872	chr17:29571195	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.45	-5.63	-0.33	4.56e-8	Hip circumference;
CESC	cis	rs6582630	0.555	rs7133706	chr12:38475465	G/A	cg13010199	chr12:38710504	ALG10B	-0.43	-5.5	-0.32	9.15e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs896854	0.552	rs2515236	chr8:95934907	A/G	cg13393036	chr8:95962371	TP53INP1	0.48	8.25	0.45	7.5e-15	Type 2 diabetes;
CESC	cis	rs7520050	0.966	rs10890354	chr1:46305347	G/A	cg03146154	chr1:46216737	IPP	-0.48	-6.24	-0.36	1.68e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs7301826	0.651	rs4514465	chr12:131313669	T/A	cg11011512	chr12:131303247	STX2	0.45	5.58	0.32	5.98e-8	Plasma plasminogen activator levels;
CESC	cis	rs55794721	0.509	rs2982358	chr1:25745204	G/T	cg27572855	chr1:25598939	RHD	0.44	7.3	0.41	3.32e-12	Plateletcrit;Mean corpuscular volume;
CESC	cis	rs753778	0.570	rs6985866	chr8:142210336	C/T	cg18755752	chr8:142205143	DENND3	0.51	7.4	0.41	1.82e-12	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	trans	rs9850225	0.719	rs4856616	chr3:80466481	A/C	cg03650674	chr8:102505986	GRHL2	-0.35	-6.13	-0.35	3.26e-9	Erectile dysfunction in type 1 diabetes;
CESC	cis	rs4243830	0.826	rs12565181	chr1:6620545	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	0.94	9.09	0.49	2.34e-17	Body mass index;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg01830674	chr2:219433148	RQCD1;USP37	-0.48	-6.63	-0.38	1.86e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs3087243	0.755	rs231792	chr2:204702249	A/G	cg01841312	chr10:38069945	NA	0.39	6.38	0.36	7.83e-10	Rheumatoid arthritis;Hypothyroidism;Type 1 diabetes;
CESC	trans	rs11098499	0.954	rs10008392	chr4:120318839	G/A	cg25214090	chr10:38739885	LOC399744	0.7	9.55	0.51	9.27e-19	Corneal astigmatism;
CESC	cis	rs1153858	1.000	rs4775937	chr15:45678614	C/A	cg21132104	chr15:45694354	SPATA5L1	0.86	11.62	0.58	1.67e-25	Homoarginine levels;
CESC	cis	rs2115536	0.692	rs8036559	chr15:80170563	C/T	cg00225070	chr15:80189496	MTHFS	0.41	5.45	0.32	1.15e-7	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CESC	cis	rs561341	1.000	rs4795668	chr17:30244554	G/A	cg19193384	chr17:30244184	NA	-0.67	-6.96	-0.39	2.6e-11	Hip circumference adjusted for BMI;
CESC	cis	rs34779708	0.966	rs4934725	chr10:35398236	T/C	cg04310649	chr10:35416472	CREM	-0.52	-6.25	-0.36	1.62e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs9287719	0.967	rs7600587	chr2:10739851	A/G	cg00105475	chr2:10696890	NA	0.39	5.61	0.33	4.96e-8	Prostate cancer;
CESC	cis	rs782590	0.935	rs782568	chr2:55881538	T/C	cg18811423	chr2:55921094	PNPT1	0.78	12.63	0.61	6.09e-29	Metabolic syndrome;
CESC	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg05313129	chr8:58192883	C8orf71	-0.48	-5.27	-0.31	2.89e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs7474896	0.583	rs10827817	chr10:37997974	A/G	cg25427524	chr10:38739819	LOC399744	-0.44	-5.05	-0.3	8.37e-7	Obesity (extreme);
CESC	cis	rs2228479	0.557	rs62056064	chr16:89903843	G/A	cg14709524	chr16:89940631	TCF25	0.88	6.1	0.35	3.82e-9	Skin colour saturation;
CESC	trans	rs9467711	0.675	rs58825580	chr6:26365679	T/G	cg06606381	chr12:133084897	FBRSL1	-0.68	-6.26	-0.36	1.5e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs10461617	0.541	rs7715822	chr5:56043600	G/T	cg24531977	chr5:56204891	C5orf35	-0.72	-6.67	-0.38	1.44e-10	Type 2 diabetes;
CESC	cis	rs2204008	0.811	rs2139752	chr12:38370398	C/T	cg26384229	chr12:38710491	ALG10B	0.73	11.2	0.57	4.34e-24	Bladder cancer;
CESC	cis	rs7598759	0.712	rs10933372	chr2:232332325	G/A	cg19187155	chr2:232395269	NMUR1	0.39	6.12	0.35	3.36e-9	Noise-induced hearing loss;
CESC	cis	rs5769765	0.954	rs5770739	chr22:50268014	C/G	cg02269571	chr22:50332266	NA	0.46	6.28	0.36	1.39e-9	Schizophrenia;
CESC	cis	rs8114671	0.967	rs6058202	chr20:33777983	A/G	cg24642439	chr20:33292090	TP53INP2	0.42	5.04	0.3	8.77e-7	Height;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg27123106	chr10:855660	LARP4B	-0.54	-6.87	-0.39	4.51e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs6545883	0.965	rs1562308	chr2:61768421	A/C	cg15711740	chr2:61764176	XPO1	-0.44	-5.34	-0.31	1.98e-7	Tuberculosis;
CESC	cis	rs1577917	0.771	rs2484355	chr6:86394403	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.54	-7.72	-0.43	2.33e-13	Response to antipsychotic treatment;
CESC	cis	rs10504229	0.906	rs113823909	chr8:58170635	A/G	cg24829409	chr8:58192753	C8orf71	-0.76	-10.0	-0.52	3.39e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs10754283	0.967	rs4658302	chr1:90103336	A/G	cg21401794	chr1:90099060	LRRC8C	0.7	9.42	0.5	2.27e-18	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs7647973	0.600	rs35174559	chr3:49287759	T/C	cg03060546	chr3:49711283	APEH	0.51	6.99	0.39	2.25e-11	Menarche (age at onset);
CESC	cis	rs1355223	0.872	rs12785367	chr11:34715269	G/T	cg11058730	chr11:34937778	PDHX;APIP	-0.48	-6.43	-0.37	6.04e-10	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs7044106	0.791	rs10984995	chr9:123479210	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.69	10.21	0.53	7.21e-21	Hip circumference adjusted for BMI;
CESC	cis	rs875971	0.928	rs2036263	chr7:65800197	C/T	cg18252515	chr7:66147081	NA	0.39	5.08	0.3	7.05e-7	Aortic root size;
CESC	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	13.67	0.64	1.44e-32	Prudent dietary pattern;
CESC	cis	rs6570726	0.935	rs447247	chr6:145812678	G/T	cg05347473	chr6:146136440	FBXO30	0.49	6.49	0.37	4.31e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2204008	0.777	rs6582664	chr12:37947022	A/G	cg26384229	chr12:38710491	ALG10B	-0.53	-7.59	-0.42	5.46e-13	Bladder cancer;
CESC	cis	rs2230307	0.536	rs7518943	chr1:100463422	G/T	cg24955406	chr1:100503596	HIAT1	0.52	5.15	0.3	5.2e-7	Carotid intima media thickness;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg07596845	chr6:82957841	IBTK	0.48	6.36	0.36	8.58e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs7833790	0.654	rs6415652	chr8:82702257	G/A	cg02079420	chr8:82753780	SNX16	0.5	7.56	0.42	6.82e-13	Diastolic blood pressure;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11439475	chr15:52821378	MYO5A	0.53	6.08	0.35	4.26e-9	Gut microbiome composition (summer);
CESC	cis	rs225245	0.791	rs7216391	chr17:34024706	G/A	cg05299278	chr17:33885742	SLFN14	0.38	5.51	0.32	8.62e-8	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
CESC	cis	rs9902453	0.740	rs2254414	chr17:28061130	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.75	-9.91	-0.52	6.74e-20	Coffee consumption (cups per day);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg15649193	chr19:14640403	TECR;MIR639	-0.43	-6.22	-0.36	1.92e-9	Fibrinogen levels;
CESC	cis	rs7560272	0.723	rs12995433	chr2:73641326	C/T	cg20560298	chr2:73613845	ALMS1	0.5	7.17	0.4	7.57e-12	Schizophrenia;
CESC	cis	rs2276314	1.000	rs2276314	chr18:33557466	C/T	cg05985134	chr18:33552581	C18orf21	-0.66	-7.95	-0.44	5.32e-14	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs72781680	0.898	rs56179550	chr2:23934867	C/T	cg20701182	chr2:24300061	SF3B14	0.78	6.91	0.39	3.5e-11	Lymphocyte counts;
CESC	cis	rs2836950	0.545	rs8132424	chr21:40584412	A/T	cg11644478	chr21:40555479	PSMG1	0.53	7.27	0.41	4.04e-12	Menarche (age at onset);
CESC	cis	rs7552404	1.000	rs7524467	chr1:76194054	C/G	cg03433033	chr1:76189801	ACADM	0.67	7.96	0.44	5.11e-14	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs4474465	0.915	rs12272791	chr11:78159426	G/A	cg02023728	chr11:77925099	USP35	0.39	5.04	0.3	8.78e-7	Alzheimer's disease (survival time);
CESC	cis	rs11718455	1.000	rs17076273	chr3:44020113	A/G	cg08738300	chr3:44038990	NA	0.48	6.1	0.35	3.81e-9	Coronary artery disease;
CESC	cis	rs3766606	0.505	rs60057745	chr1:7946819	G/A	cg00042356	chr1:8021962	PARK7	0.57	5.22	0.31	3.56e-7	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg24434368	chr7:116593263	ST7;ST7OT4;ST7OT1	-0.44	-6.19	-0.36	2.31e-9	Asthma;
CESC	cis	rs57221529	0.766	rs12518859	chr5:587432	C/T	cg16447950	chr5:562315	NA	-0.62	-6.52	-0.37	3.51e-10	Lung disease severity in cystic fibrosis;
CESC	cis	rs34638657	0.833	rs4889479	chr16:82201474	T/C	cg09439754	chr16:82129088	HSD17B2	-0.34	-5.62	-0.33	4.8e-8	Lung adenocarcinoma;
CESC	cis	rs2836950	0.565	rs4816617	chr21:40540690	T/C	cg11890956	chr21:40555474	PSMG1	-0.63	-8.76	-0.47	2.33e-16	Menarche (age at onset);
CESC	cis	rs12188164	0.965	rs11739543	chr5:443676	G/A	cg15813090	chr5:442598	EXOC3;C5orf55	0.42	6.26	0.36	1.51e-9	Cystic fibrosis severity;
CESC	cis	rs1707322	1.000	rs946524	chr1:46487560	A/G	cg05343316	chr1:45956843	TESK2	-0.45	-5.54	-0.32	7.32e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs1538970	0.924	rs1826691	chr1:45881262	A/G	cg06784218	chr1:46089804	CCDC17	-0.33	-5.52	-0.32	8.23e-8	Platelet count;
CESC	cis	rs2228479	0.764	rs7184960	chr16:89961661	C/T	cg00800038	chr16:89945340	TCF25	-0.69	-6.65	-0.38	1.66e-10	Skin colour saturation;
CESC	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg18402987	chr7:1209562	NA	0.76	7.55	0.42	7.26e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2769264	0.602	rs11204777	chr1:151072049	G/A	cg11822372	chr1:151115635	SEMA6C	0.51	6.14	0.35	3.07e-9	Blood trace element (Cu levels);
CESC	cis	rs9596863	0.847	rs9316667	chr13:54399759	C/T	ch.13.53330881F	chr13:54432880	NA	0.66	5.28	0.31	2.7e-7	Epilepsy and lamotrigine-induced maculopapular eruptions;
CESC	trans	rs7726839	0.794	rs6883536	chr5:599274	G/A	cg25482853	chr8:67687455	SGK3	0.62	6.36	0.36	8.59e-10	Obesity-related traits;
CESC	cis	rs853679	0.517	rs9348797	chr6:28137533	G/C	cg17949981	chr6:28129498	ZNF389	0.42	5.24	0.31	3.27e-7	Depression;
CESC	cis	rs6963495	0.818	rs56165465	chr7:105180384	C/T	cg13798780	chr7:105162888	PUS7	0.75	8.34	0.46	4.18e-15	Bipolar disorder (body mass index interaction);
CESC	cis	rs13108904	0.557	rs1680041	chr4:1238521	C/T	cg20887711	chr4:1340912	KIAA1530	-0.62	-8.34	-0.46	4.1e-15	Obesity-related traits;
CESC	trans	rs7618501	1.000	rs7648987	chr3:49868455	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.56	7.84	0.43	1.07e-13	Intelligence (multi-trait analysis);
CESC	cis	rs863345	0.564	rs7515245	chr1:158494110	A/G	cg12129480	chr1:158549410	OR10X1	-0.35	-6.86	-0.39	4.75e-11	Pneumococcal bacteremia;
CESC	trans	rs116095464	0.558	rs6881920	chr5:222411	T/C	cg00938859	chr5:1591904	SDHAP3	0.6	6.66	0.38	1.55e-10	Breast cancer;
CESC	cis	rs7100689	0.577	rs756208	chr10:82041751	A/G	cg00277334	chr10:82204260	NA	-0.54	-7.05	-0.4	1.53e-11	Post bronchodilator FEV1;
CESC	cis	rs7666738	0.753	rs1830230	chr4:99026186	G/C	cg03467027	chr4:99064603	C4orf37	0.49	6.18	0.35	2.44e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1594829	0.553	rs11135933	chr8:26162364	A/G	cg11498726	chr8:26250323	BNIP3L	-0.4	-6.06	-0.35	4.68e-9	Height;
CESC	cis	rs2549003	1.000	rs2070722	chr5:131824486	A/C	cg02551604	chr5:131831745	NA	-0.35	-5.1	-0.3	6.59e-7	Asthma (sex interaction);
CESC	cis	rs7635838	0.785	rs2594972	chr3:11397417	A/G	cg00170343	chr3:11313890	ATG7	0.44	6.27	0.36	1.43e-9	HDL cholesterol;
CESC	cis	rs6582630	0.555	rs34730221	chr12:38405140	C/T	cg13010199	chr12:38710504	ALG10B	-0.45	-5.79	-0.34	2e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs71403859	0.730	rs12446333	chr16:71752157	T/C	cg08717414	chr16:71523259	ZNF19	-0.68	-5.42	-0.32	1.37e-7	Post bronchodilator FEV1;
CESC	cis	rs2404602	0.669	rs12595313	chr15:76978370	A/G	cg22467129	chr15:76604101	ETFA	-0.34	-5.15	-0.3	5.13e-7	Blood metabolite levels;
CESC	cis	rs5769707	0.749	rs7286706	chr22:50058346	G/C	cg20744362	chr22:50050164	C22orf34	0.41	7.16	0.4	8.13e-12	Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs478304	0.903	rs1151502	chr11:65503485	G/C	cg08755490	chr11:65554678	OVOL1	0.47	6.21	0.36	2.06e-9	Acne (severe);
CESC	cis	rs1270639	0.778	rs2952650	chr7:157450939	C/T	cg13357408	chr7:157437802	PTPRN2	0.62	6.81	0.39	6.37e-11	Colorectal cancer;
CESC	cis	rs7264396	0.563	rs6060569	chr20:34290731	C/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.64	6.86	0.39	4.8e-11	Total cholesterol levels;
CESC	cis	rs9322193	0.923	rs10747275	chr6:149943918	C/T	cg13206674	chr6:150067644	NUP43	0.41	5.77	0.33	2.21e-8	Lung cancer;
CESC	cis	rs10504229	0.906	rs114810777	chr8:58185298	A/G	cg14926445	chr8:58193284	C8orf71	-0.51	-5.41	-0.32	1.39e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs826838	0.933	rs980573	chr12:39127811	T/C	cg26384229	chr12:38710491	ALG10B	-0.67	-11.01	-0.56	1.82e-23	Heart rate;
CESC	cis	rs8020095	0.571	rs1955606	chr14:67477647	A/G	cg19548862	chr14:67692701	FAM71D	-0.49	-6.09	-0.35	3.92e-9	Depression (quantitative trait);
CESC	cis	rs17345786	0.861	rs74768235	chr3:101142821	T/C	cg12386194	chr3:101231763	SENP7	0.62	6.69	0.38	1.3100000000000001e-10	Colonoscopy-negative controls vs population controls;
CESC	cis	rs514406	0.505	rs12726160	chr1:53175099	A/G	cg08859206	chr1:53392774	SCP2	-0.57	-7.77	-0.43	1.78e-13	Monocyte count;
CESC	cis	rs28489187	0.706	rs761601	chr1:85797298	A/G	cg16011679	chr1:85725395	C1orf52	0.56	6.48	0.37	4.45e-10	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	cis	rs73206853	0.841	rs3026483	chr12:110780905	A/G	cg12870014	chr12:110450643	ANKRD13A	0.66	5.42	0.32	1.36e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs3617	0.573	rs2336668	chr3:52919096	G/T	cg17372223	chr3:52568218	NT5DC2	-0.36	-5.16	-0.3	4.95e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
CESC	cis	rs9291683	0.609	rs4622999	chr4:10003395	C/G	cg00071950	chr4:10020882	SLC2A9	0.83	14.91	0.68	6.47e-37	Bone mineral density;
CESC	cis	rs6835098	0.924	rs7672108	chr4:174165126	A/G	cg08422745	chr4:174089978	GALNT7	0.73	10.76	0.55	1.26e-22	Dementia and core Alzheimer's disease neuropathologic changes;
CESC	cis	rs62005083	1.000	rs62005115	chr14:74528952	G/C	cg05179529	chr14:74551516	LIN52;ALDH6A1	0.62	5.07	0.3	7.61e-7	Mean corpuscular volume;
CESC	cis	rs17539620	0.624	rs62432738	chr6:154835674	T/C	cg20019720	chr6:154832845	CNKSR3	0.46	6.13	0.35	3.22e-9	Lipoprotein (a) levels;
CESC	cis	rs3126085	0.935	rs4845421	chr1:152173259	G/T	cg26876637	chr1:152193138	HRNR	0.45	5.11	0.3	6.05e-7	Atopic dermatitis;
CESC	cis	rs8017423	0.967	rs4900033	chr14:90701963	C/A	cg14092571	chr14:90743983	NA	-0.57	-8.35	-0.46	3.87e-15	Mortality in heart failure;
CESC	cis	rs1005277	0.579	rs1740742	chr10:38518860	C/T	cg25517755	chr10:38738941	LOC399744	-0.44	-5.72	-0.33	2.85e-8	Extrinsic epigenetic age acceleration;
CESC	cis	rs7208859	0.623	rs216434	chr17:28922335	G/C	cg13385521	chr17:29058706	SUZ12P	0.75	5.52	0.32	7.98e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs6952808	0.543	rs4719436	chr7:2141239	G/A	cg02951883	chr7:2050386	MAD1L1	-0.46	-6.0	-0.35	6.38e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs2180341	0.814	rs6914131	chr6:127737489	T/C	cg27446573	chr6:127587934	RNF146	0.82	11.65	0.58	1.38e-25	Breast cancer;
CESC	cis	rs8062405	0.721	rs151181	chr16:28490517	A/G	cg08761264	chr16:28874980	SH2B1	-0.45	-5.44	-0.32	1.23e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs4834770	1.000	rs4834771	chr4:120242772	C/A	cg09307838	chr4:120376055	NA	0.45	5.37	0.31	1.74e-7	Blood protein levels;
CESC	cis	rs2625529	0.730	rs6494990	chr15:72401074	T/A	cg16672083	chr15:72433130	SENP8	0.44	6.72	0.38	1.09e-10	Red blood cell count;
CESC	cis	rs1862618	0.671	rs2591964	chr5:56236900	T/G	cg24549020	chr5:56110836	MAP3K1	-0.51	-6.31	-0.36	1.18e-9	Initial pursuit acceleration;
CESC	cis	rs875971	0.520	rs2420597	chr7:65915986	A/G	cg10691866	chr7:65817282	TPST1	-0.31	-5.16	-0.3	4.78e-7	Aortic root size;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg05124756	chr4:2263820	MXD4	0.44	6.03	0.35	5.56e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs7520050	0.966	rs785492	chr1:46583607	G/A	cg03146154	chr1:46216737	IPP	-0.43	-5.52	-0.32	8.2e-8	Red blood cell count;Reticulocyte count;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg14431266	chr11:67057003	ANKRD13D	0.5	6.67	0.38	1.5e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs1729951	0.575	rs361243	chr3:136697786	C/T	cg15507776	chr3:136538369	TMEM22	0.4	5.06	0.3	8.02e-7	Neuroticism;
CESC	cis	rs6504249	0.893	rs2521827	chr17:62692728	T/G	cg02097616	chr17:62675921	NA	0.42	5.1	0.3	6.39e-7	Joint mobility (Beighton score);
CESC	trans	rs3936060	0.551	rs6872503	chr5:124374180	A/G	cg23072383	chr22:31031044	SLC35E4	-0.39	-6.22	-0.36	1.89e-9	Body mass index;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg26574964	chr11:117049906	SIDT2	-0.5	-6.46	-0.37	5.12e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs3087591	1.000	rs2905877	chr17:29543269	A/C	cg24425628	chr17:29625626	OMG;NF1	-0.43	-5.22	-0.31	3.57e-7	Hip circumference;
CESC	cis	rs5769765	0.773	rs9616206	chr22:50310847	G/T	cg02269571	chr22:50332266	NA	-0.57	-6.98	-0.39	2.33e-11	Schizophrenia;
CESC	cis	rs733175	0.855	rs6853437	chr4:10005435	A/G	cg00071950	chr4:10020882	SLC2A9	-0.56	-6.74	-0.38	9.61e-11	Psychosis and Alzheimer's disease;
CESC	cis	rs7833986	0.501	rs2953898	chr8:56980803	C/T	cg26371346	chr8:56986568	SNORD54;RPS20	0.57	5.16	0.3	4.9e-7	Height;
CESC	cis	rs2249625	0.874	rs1852704	chr6:72880088	C/T	cg18830697	chr6:72922368	RIMS1	-0.39	-5.53	-0.32	7.83e-8	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CESC	cis	rs7811142	0.943	rs28660238	chr7:100023308	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.01	11.77	0.59	5.45e-26	Platelet count;
CESC	cis	rs9790314	0.875	rs336568	chr3:161072763	G/C	cg03342759	chr3:160939853	NMD3	-0.42	-5.75	-0.33	2.43e-8	Morning vs. evening chronotype;
CESC	cis	rs10911363	0.592	rs2702180	chr1:183517971	T/C	cg09173681	chr1:183549694	NCF2	0.53	8.02	0.44	3.49e-14	Systemic lupus erythematosus;
CESC	cis	rs4604732	0.642	rs10925048	chr1:247640736	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.45	6.54	0.37	3.08e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs7243790	0.846	rs56053948	chr18:51960665	C/A	cg04730925	chr18:51795821	POLI	-0.42	-5.54	-0.32	7.14e-8	Diastolic blood pressure;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg08162257	chr15:90777190	CIB1;C15orf58	-0.49	-6.1	-0.35	3.74e-9	Ulcerative colitis;
CESC	cis	rs11583043	1.000	rs7541397	chr1:101322866	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.46	-5.37	-0.31	1.73e-7	Ulcerative colitis;Inflammatory bowel disease;
CESC	cis	rs2841277	0.676	rs4264326	chr14:105411700	A/G	cg21017887	chr14:105400489	NA	0.41	6.6	0.38	2.17e-10	Rheumatoid arthritis;
CESC	cis	rs6912958	0.712	rs4706294	chr6:88317675	G/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.32	-5.25	-0.31	3.18e-7	Monocyte percentage of white cells;
CESC	cis	rs4919087	0.962	rs3814164	chr10:98982749	G/A	cg25902810	chr10:99078978	FRAT1	0.71	10.32	0.54	3.25e-21	Monocyte count;
CESC	cis	rs2303759	0.918	rs9749416	chr19:49885005	G/A	cg22590775	chr19:49891494	CCDC155	0.54	6.45	0.37	5.19e-10	Multiple sclerosis;
CESC	cis	rs6500395	1.000	rs11647048	chr16:48623227	T/G	cg04672837	chr16:48644449	N4BP1	0.47	5.82	0.34	1.72e-8	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs854765	0.654	rs11078400	chr17:17757728	A/G	cg04398451	chr17:18023971	MYO15A	0.67	10.08	0.53	1.98e-20	Total body bone mineral density;
CESC	cis	rs10504229	0.569	rs75466737	chr8:58055034	A/G	cg21724239	chr8:58056113	NA	0.59	5.24	0.31	3.36e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs7202877	0.610	rs4536500	chr16:75343197	C/G	cg04384234	chr16:75411784	CFDP1	0.43	5.16	0.3	4.75e-7	Type 2 diabetes;Type 1 diabetes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06999776	chr2:74881146	SEMA4F	-0.55	-6.46	-0.37	4.99e-10	Gut microbiome composition (summer);
CESC	cis	rs2806561	0.765	rs2806557	chr1:23503372	T/A	cg12483005	chr1:23474871	LUZP1	0.39	6.18	0.36	2.37e-9	Height;
CESC	cis	rs4849845	0.886	rs13412677	chr2:121029517	C/G	cg24070213	chr2:121070622	NA	0.39	5.04	0.3	8.71e-7	Mean platelet volume;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg10557320	chr6:12012551	HIVEP1	0.42	6.03	0.35	5.62e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs7937682	0.564	rs1944116	chr11:111366792	A/C	cg09085632	chr11:111637200	PPP2R1B	0.47	5.46	0.32	1.1e-7	Primary sclerosing cholangitis;
CESC	trans	rs7618501	1.000	rs11716575	chr3:49744890	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.58	-8.44	-0.46	2.11e-15	Intelligence (multi-trait analysis);
CESC	cis	rs1552244	0.572	rs59132826	chr3:10169725	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.77	8.79	0.48	1.96e-16	Alzheimer's disease;
CESC	cis	rs853679	0.882	rs9380069	chr6:28203300	A/G	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.68	6.32	0.36	1.08e-9	Depression;
CESC	cis	rs2228479	0.850	rs17226519	chr16:89839854	T/C	cg14709524	chr16:89940631	TCF25	0.91	6.74	0.38	1e-10	Skin colour saturation;
CESC	cis	rs4434138	0.664	rs62255364	chr3:52701502	C/T	cg17372223	chr3:52568218	NT5DC2	0.44	6.63	0.38	1.86e-10	Intelligence (multi-trait analysis);
CESC	cis	rs11785400	0.793	rs6996760	chr8:143722386	G/A	cg24634471	chr8:143751801	JRK	0.43	5.57	0.32	6.39e-8	Schizophrenia;
CESC	cis	rs1799949	0.965	rs4239149	chr17:41328095	A/G	cg23758822	chr17:41437982	NA	-1.02	-17.99	-0.74	7.99e-48	Menopause (age at onset);
CESC	cis	rs763014	0.966	rs7185390	chr16:666382	A/G	cg00908189	chr16:619842	PIGQ	0.61	8.38	0.46	3.17e-15	Height;
CESC	cis	rs9733	0.596	rs12403255	chr1:150660412	C/T	cg17724175	chr1:150552817	MCL1	0.43	7.02	0.4	1.87e-11	Tonsillectomy;
CESC	cis	rs6460942	1.000	rs2053382	chr7:12400587	A/G	cg20607287	chr7:12443886	VWDE	-0.67	-7.69	-0.43	2.8e-13	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05919122	chr15:20104494	NA	-0.51	-6.47	-0.37	4.7e-10	Gut microbiome composition (summer);
CESC	cis	rs780096	0.587	rs1049817	chr2:27550967	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.34	-6.45	-0.37	5.42e-10	Total body bone mineral density;
CESC	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.5	-7.38	-0.41	2.04e-12	Longevity;Endometriosis;
CESC	cis	rs7100689	0.577	rs10749551	chr10:82054001	A/C	cg00277334	chr10:82204260	NA	-0.53	-6.92	-0.39	3.3e-11	Post bronchodilator FEV1;
CESC	cis	rs7312774	0.881	rs60941459	chr12:107318583	T/C	cg16260113	chr12:107380972	MTERFD3	0.68	6.37	0.36	8.12e-10	Severe influenza A (H1N1) infection;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00214056	chr18:46478384	SMAD7	0.69	8.29	0.45	5.89e-15	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04524321	chr12:57916344	MBD6	0.58	6.38	0.36	7.7e-10	Gut microbiome composition (summer);
CESC	cis	rs60843830	1.000	rs55946380	chr2:268293	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.88	11.83	0.59	3.33e-26	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs28374715	0.532	rs28703570	chr15:41679492	G/A	cg20272979	chr15:41787780	ITPKA	0.41	5.05	0.3	8.42e-7	Ulcerative colitis;
CESC	cis	rs6460942	0.908	rs73301032	chr7:12256799	C/G	cg20607287	chr7:12443886	VWDE	-0.55	-5.69	-0.33	3.34e-8	Coronary artery disease;
CESC	cis	rs1153858	1.000	rs4774577	chr15:45644685	A/C	cg21132104	chr15:45694354	SPATA5L1	0.84	11.4	0.57	9.5e-25	Homoarginine levels;
CESC	cis	rs684232	0.805	rs2360737	chr17:506163	C/T	cg15660573	chr17:549704	VPS53	-0.42	-5.63	-0.33	4.65e-8	Prostate cancer;
CESC	cis	rs7618915	0.547	rs2590846	chr3:52692359	C/G	cg17372223	chr3:52568218	NT5DC2	0.43	6.5	0.37	4.04e-10	Bipolar disorder;
CESC	cis	rs4665809	0.590	rs7579504	chr2:26439995	T/C	cg22920501	chr2:26401640	FAM59B	-0.91	-10.33	-0.54	3.07e-21	Gut microbiome composition (summer);
CESC	cis	rs4233802	1.000	rs4425095	chr2:151139757	C/T	cg25300694	chr2:151184358	NA	0.88	7.6	0.42	5.07e-13	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
CESC	trans	rs5756813	0.688	rs34891095	chr22:38126582	C/T	cg19894588	chr14:64061835	NA	-0.65	-7.41	-0.41	1.7e-12	Optic cup area;Vertical cup-disc ratio;
CESC	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg03188948	chr7:1209495	NA	0.7	6.71	0.38	1.2e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7618501	0.699	rs9821675	chr3:49902544	A/G	cg24110177	chr3:50126178	RBM5	-0.45	-5.95	-0.34	8.26e-9	Intelligence (multi-trait analysis);
CESC	cis	rs9393777	0.623	rs9358945	chr6:26472114	C/T	cg14345882	chr6:26364793	BTN3A2	-0.41	-5.07	-0.3	7.46e-7	Intelligence (multi-trait analysis);
CESC	cis	rs2836974	1.000	rs28360661	chr21:40681972	G/C	cg17971929	chr21:40555470	PSMG1	0.98	13.06	0.63	2.04e-30	Cognitive function;
CESC	cis	rs875971	0.660	rs10950044	chr7:66042976	A/G	cg18876405	chr7:65276391	NA	-0.59	-7.9	-0.44	7.25e-14	Aortic root size;
CESC	cis	rs1707322	1.000	rs1768818	chr1:46514286	G/C	cg03146154	chr1:46216737	IPP	-0.72	-9.73	-0.51	2.49e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11636714	chr8:42128950	IKBKB	0.6	7.23	0.41	5.33e-12	Gut microbiome composition (summer);
CESC	cis	rs10779751	0.734	rs7533211	chr1:11132965	G/C	cg08854313	chr1:11322531	MTOR	0.79	11.17	0.57	5.4e-24	Body mass index;
CESC	cis	rs2243480	1.000	rs36068983	chr7:65408991	C/T	cg13147721	chr7:65941812	NA	-0.85	-8.1	-0.45	2e-14	Diabetic kidney disease;
CESC	cis	rs9929218	0.953	rs12930910	chr16:68762520	A/G	cg02972257	chr16:68554789	NA	0.55	6.37	0.36	8.53e-10	Colorectal cancer;
CESC	cis	rs6964587	0.934	rs12531561	chr7:91707780	A/G	cg17063962	chr7:91808500	NA	0.59	8.09	0.45	2.1e-14	Breast cancer;
CESC	cis	rs2075371	0.829	rs727202	chr7:133947942	A/G	cg00033643	chr7:134001901	SLC35B4	0.4	5.14	0.3	5.46e-7	Mean platelet volume;
CESC	cis	rs1878931	0.545	rs28603	chr16:3449479	A/G	cg05754148	chr16:3507555	NAT15	0.44	5.22	0.31	3.63e-7	Body mass index (adult);
CESC	cis	rs4692589	0.540	rs1904823	chr4:170956772	C/T	cg19918862	chr4:170955249	NA	0.42	5.43	0.32	1.26e-7	Anxiety disorder;
CESC	cis	rs643506	0.874	rs687152	chr11:111721673	T/C	cg09085632	chr11:111637200	PPP2R1B	0.4	5.21	0.31	3.71e-7	Breast cancer;
CESC	cis	rs1538970	0.810	rs12067642	chr1:45927517	G/T	cg24296786	chr1:45957014	TESK2	-0.44	-5.18	-0.3	4.5e-7	Platelet count;
CESC	cis	rs17384381	0.861	rs2300640	chr1:85823795	C/G	cg16011679	chr1:85725395	C1orf52	0.8	8.18	0.45	1.16e-14	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg10509185	chr10:134504666	INPP5A	0.51	6.73	0.38	1.06e-10	Fibrinogen levels;
CESC	cis	rs4713118	0.824	rs742046	chr6:27739254	A/G	cg20933634	chr6:27740509	NA	0.4	5.45	0.32	1.18e-7	Parkinson's disease;
CESC	cis	rs9388451	0.536	rs34725880	chr6:126155237	A/G	cg05901451	chr6:126070800	HEY2	-0.43	-5.87	-0.34	1.33e-8	Brugada syndrome;
CESC	cis	rs4727027	0.933	rs12667123	chr7:148850621	G/A	cg23583168	chr7:148888333	NA	-0.81	-12.69	-0.61	3.68e-29	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs3741404	0.609	rs592271	chr11:63872029	G/T	cg18225595	chr11:63971243	STIP1	0.5	6.59	0.38	2.39e-10	Platelet count;
CESC	cis	rs7845219	0.544	rs4735331	chr8:95917958	C/T	cg09323728	chr8:95962352	TP53INP1	-0.34	-6.59	-0.38	2.41e-10	Type 2 diabetes;
CESC	cis	rs4474465	0.790	rs10899554	chr11:78265667	T/G	cg27205649	chr11:78285834	NARS2	0.45	5.57	0.32	6.11e-8	Alzheimer's disease (survival time);
CESC	cis	rs7552404	1.000	rs441109	chr1:76120430	T/G	cg10523679	chr1:76189770	ACADM	-0.68	-7.79	-0.43	1.56e-13	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs7605827	0.930	rs2111453	chr2:15673248	C/T	cg19274914	chr2:15703543	NA	0.38	6.8	0.39	7.12e-11	Educational attainment (years of education);
CESC	cis	rs763121	0.925	rs4821797	chr22:39016182	T/C	cg21395723	chr22:39101663	GTPBP1	0.46	5.97	0.34	7.61e-9	Menopause (age at onset);
CESC	cis	rs9393777	0.513	rs9348728	chr6:26634436	G/A	cg12292205	chr6:26970375	C6orf41	-0.5	-5.67	-0.33	3.8e-8	Intelligence (multi-trait analysis);
CESC	cis	rs9926296	0.605	rs12709094	chr16:89853017	A/G	cg27121462	chr16:89883253	FANCA	0.75	10.57	0.54	5.18e-22	Vitiligo;
CESC	cis	rs1707322	0.963	rs4630155	chr1:46257110	G/C	cg03146154	chr1:46216737	IPP	0.8	11.02	0.56	1.72e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs939658	0.805	rs939661	chr15:79431063	A/G	cg17916960	chr15:79447300	NA	-0.38	-6.18	-0.35	2.43e-9	Refractive error;
CESC	cis	rs2243480	0.901	rs13237344	chr7:66022256	T/A	cg18252515	chr7:66147081	NA	-1.4	-14.27	-0.66	1.16e-34	Diabetic kidney disease;
CESC	cis	rs9733	0.596	rs72702504	chr1:150635374	G/C	cg09365446	chr1:150670422	GOLPH3L	0.42	5.93	0.34	9.63e-9	Tonsillectomy;
CESC	cis	rs11958404	0.615	rs6884132	chr5:157437035	G/A	cg05962755	chr5:157440814	NA	0.42	6.13	0.35	3.1e-9	IgG glycosylation;
CESC	cis	rs11718455	0.960	rs13059547	chr3:44004492	G/A	cg08738300	chr3:44038990	NA	0.46	6.12	0.35	3.34e-9	Coronary artery disease;
CESC	cis	rs9311474	0.502	rs4687624	chr3:52563572	C/T	cg18404041	chr3:52824283	ITIH1	-0.38	-6.43	-0.37	5.89e-10	Electroencephalogram traits;
CESC	cis	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22466171	chr4:99850251	EIF4E	-0.45	-5.12	-0.3	6.01e-7	Gut microbiome composition (summer);
CESC	cis	rs769267	0.930	rs10414830	chr19:19562332	C/T	cg03709012	chr19:19516395	GATAD2A	1.01	15.7	0.69	1.02e-39	Tonsillectomy;
CESC	trans	rs4950322	0.515	rs72691016	chr1:146717027	T/C	cg04954894	chr8:38089920	DDHD2	-0.55	-6.07	-0.35	4.3e-9	Protein quantitative trait loci;
CESC	cis	rs7666738	0.830	rs11725477	chr4:98803266	G/T	cg03467027	chr4:99064603	C4orf37	0.44	5.43	0.32	1.26e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs116095464	0.558	rs6879656	chr5:264428	T/C	cg22496380	chr5:211416	CCDC127	-0.85	-9.0	-0.48	4.59e-17	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10658516	chr2:98612531	TMEM131	0.59	6.58	0.37	2.53e-10	Gut microbiome composition (summer);
CESC	cis	rs9929218	1.000	rs12596061	chr16:68807828	A/G	cg02972257	chr16:68554789	NA	0.48	5.73	0.33	2.71e-8	Colorectal cancer;
CESC	cis	rs9905704	0.723	rs71372848	chr17:56736598	G/C	cg12560992	chr17:57184187	TRIM37	0.59	6.95	0.39	2.9e-11	Testicular germ cell tumor;
CESC	cis	rs6089829	0.888	rs4809468	chr20:61673566	T/C	cg16240275	chr20:61666158	NCRNA00029	0.49	8.3	0.45	5.23e-15	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs875971	0.767	rs1695815	chr7:65831344	A/G	cg11764359	chr7:65958608	NA	0.98	15.78	0.7	5.36e-40	Aortic root size;
CESC	cis	rs7772486	0.738	rs75288066	chr6:146319386	C/A	cg05347473	chr6:146136440	FBXO30	0.5	6.47	0.37	4.8e-10	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs11098499	0.909	rs28884220	chr4:120307211	A/G	cg25214090	chr10:38739885	LOC399744	0.68	9.2	0.49	1.14e-17	Corneal astigmatism;
CESC	cis	rs8060686	0.623	rs6499162	chr16:68239460	T/C	cg26727032	chr16:67993705	SLC12A4	-0.59	-8.17	-0.45	1.3e-14	HDL cholesterol;Metabolic syndrome;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26561082	chr10:410363	DIP2C	-0.65	-7.28	-0.41	3.83e-12	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.791	rs1559860	chr4:99024422	C/T	cg05340658	chr4:99064831	C4orf37	0.83	13.1	0.63	1.43e-30	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14761318	chr5:68788469	OCLN	0.56	6.56	0.37	2.75e-10	Gut microbiome composition (summer);
CESC	cis	rs9596863	0.756	rs9316652	chr13:54279802	T/C	ch.13.53330881F	chr13:54432880	NA	0.62	5.08	0.3	6.99e-7	Epilepsy and lamotrigine-induced maculopapular eruptions;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg23987549	chr20:56285728	PMEPA1	0.39	6.25	0.36	1.64e-9	Gambling;
CESC	cis	rs3785574	0.962	rs2727324	chr17:61922102	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.99	16.42	0.71	2.9e-42	Height;
CESC	cis	rs818427	0.896	rs430665	chr5:112228667	G/A	cg07820702	chr5:112228657	REEP5	-0.41	-5.15	-0.3	4.99e-7	Total body bone mineral density;
CESC	cis	rs3126085	0.935	rs10888466	chr1:152166223	A/C	cg26876637	chr1:152193138	HRNR	-0.46	-5.35	-0.31	1.91e-7	Atopic dermatitis;
CESC	cis	rs9487051	1.000	rs6568570	chr6:109613241	T/G	cg21918786	chr6:109611834	NA	-0.35	-5.03	-0.3	8.9e-7	Reticulocyte fraction of red cells;
CESC	cis	rs6496667	0.586	rs7162687	chr15:90889323	C/T	cg22089800	chr15:90895588	ZNF774	-0.48	-5.84	-0.34	1.52e-8	Rheumatoid arthritis;
CESC	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg23131131	chr22:24373011	LOC391322	0.64	8.64	0.47	5.25e-16	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs2075371	1.000	rs7486	chr7:133975183	A/G	cg11752832	chr7:134001865	SLC35B4	0.54	7.09	0.4	1.19e-11	Mean platelet volume;
CESC	cis	rs9486719	1.000	rs11752584	chr6:96884952	C/A	cg18709589	chr6:96969512	KIAA0776	-0.53	-5.81	-0.34	1.75e-8	Migraine;Coronary artery disease;
CESC	cis	rs9815354	0.767	rs79323474	chr3:42000973	C/T	cg03022575	chr3:42003672	ULK4	0.66	5.77	0.33	2.17e-8	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs919433	0.889	rs10931782	chr2:198211579	G/A	cg03934865	chr2:198174659	NA	-0.45	-6.47	-0.37	4.63e-10	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	trans	rs2433610	1	rs2433610	chr15:45686091	C/T	cg18489146	chr19:39759357	IL28A	0.89	6.25	0.36	1.66e-9	Serum metabolite levels;
CESC	cis	rs1552244	1.000	rs6768102	chr3:10149380	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.82	-10.93	-0.56	3.49e-23	Alzheimer's disease;
CESC	cis	rs2072499	0.932	rs3001790	chr1:156165290	T/G	cg06970220	chr1:156163860	SLC25A44	0.39	5.19	0.3	4.29e-7	Testicular germ cell tumor;
CESC	cis	rs10504229	0.636	rs77753517	chr8:58115897	C/T	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs10851478	0.836	rs11070706	chr15:49845296	T/C	cg08060515	chr15:49448048	GALK2;COPS2	0.42	5.19	0.3	4.12e-7	Oral cavity cancer;
CESC	cis	rs34779708	0.931	rs34815241	chr10:35296676	T/C	cg04310649	chr10:35416472	CREM	-0.49	-5.93	-0.34	9.63e-9	Inflammatory bowel disease;Crohn's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16004202	chr4:159689901	FNIP2	0.63	6.98	0.39	2.39e-11	Gut microbiome composition (summer);
CESC	cis	rs13392177	0.672	rs1877715	chr2:219052546	C/T	cg00012203	chr2:219082015	ARPC2	0.73	9.48	0.5	1.53e-18	Pyoderma gangrenosum in inflammatory bowel disease;
CESC	cis	rs10504229	0.683	rs16921829	chr8:58110950	A/G	cg24829409	chr8:58192753	C8orf71	-0.59	-7.32	-0.41	2.94e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs7937682	0.889	rs493865	chr11:111495178	A/C	cg09085632	chr11:111637200	PPP2R1B	-0.94	-14.68	-0.67	4.23e-36	Primary sclerosing cholangitis;
CESC	cis	rs7829975	0.711	rs4841051	chr8:8685646	C/T	cg15556689	chr8:8085844	FLJ10661	-0.5	-6.41	-0.37	6.46e-10	Mood instability;
CESC	trans	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg13565492	chr6:43139072	SRF	-0.72	-8.53	-0.46	1.17e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs4819052	0.851	rs13047104	chr21:46673562	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.77	10.14	0.53	1.23e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs2576037	0.561	rs513775	chr18:44396334	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.52	-7.02	-0.4	1.82e-11	Personality dimensions;
CESC	cis	rs6089584	0.893	rs6089306	chr20:60574868	G/A	cg06108461	chr20:60628389	TAF4	-0.79	-11.4	-0.57	8.95e-25	Body mass index;
CESC	cis	rs6121246	0.559	rs6060952	chr20:30382108	T/G	cg13852791	chr20:30311386	BCL2L1	0.82	10.47	0.54	1.07e-21	Mean corpuscular hemoglobin;
CESC	cis	rs7680126	0.596	rs35782983	chr4:10117728	G/A	cg00071950	chr4:10020882	SLC2A9	-0.6	-6.78	-0.38	7.84e-11	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	cis	rs1784581	0.588	rs9295180	chr6:162420579	T/C	cg17173639	chr6:162384350	PARK2	0.56	8.62	0.47	6.34e-16	Itch intensity from mosquito bite;
CESC	cis	rs2841277	0.676	rs10438247	chr14:105411781	G/A	cg15352829	chr14:105391018	PLD4	-0.61	-10.84	-0.55	6.85e-23	Rheumatoid arthritis;
CESC	trans	rs1814175	0.645	rs1963215	chr11:49931486	G/A	cg03929089	chr4:120376271	NA	-0.92	-15.2	-0.68	6e-38	Height;
CESC	cis	rs7552404	0.696	rs12140121	chr1:76455001	A/G	cg03433033	chr1:76189801	ACADM	0.6	6.04	0.35	5.3e-9	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs1552244	1.000	rs7615764	chr3:10082592	C/T	cg08888203	chr3:10149979	C3orf24	0.46	5.94	0.34	9.02e-9	Alzheimer's disease;
CESC	cis	rs2072499	1.000	rs2072499	chr1:156169610	A/G	cg24450063	chr1:156163899	SLC25A44	1.08	22.52	0.81	1.8e-63	Testicular germ cell tumor;
CESC	cis	rs208520	0.545	rs6899712	chr6:66749670	T/C	cg07460842	chr6:66804631	NA	1.0	19.81	0.77	3.24e-54	Exhaled nitric oxide output;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21517865	chr17:4046969	ZZEF1;CYB5D2	0.59	6.73	0.38	1.03e-10	Gut microbiome composition (summer);
CESC	cis	rs854765	0.663	rs16960744	chr17:17755259	A/G	cg04398451	chr17:18023971	MYO15A	0.63	9.18	0.49	1.25e-17	Total body bone mineral density;
CESC	cis	rs561341	1.000	rs72821971	chr17:30269343	T/G	cg19193384	chr17:30244184	NA	-0.66	-6.21	-0.36	2.01e-9	Hip circumference adjusted for BMI;
CESC	cis	rs2836974	0.932	rs2836955	chr21:40619887	G/A	cg17971929	chr21:40555470	PSMG1	1.01	14.05	0.65	6.8e-34	Cognitive function;
CESC	cis	rs769267	0.965	rs8101938	chr19:19390497	G/A	cg03709012	chr19:19516395	GATAD2A	0.96	14.18	0.66	2.35e-34	Tonsillectomy;
CESC	cis	rs1062177	1.000	rs12518722	chr5:151231460	A/G	cg00977110	chr5:151150581	G3BP1	0.63	6.75	0.38	9.5e-11	Preschool internalizing problems;
CESC	trans	rs916888	0.779	rs430685	chr17:44859148	T/C	cg23590916	chr17:43697445	MGC57346	-0.61	-6.5	-0.37	3.94e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs12500824	0.535	rs17001890	chr4:77305346	A/G	cg20311846	chr4:77356250	SHROOM3	0.37	7.27	0.41	4.03e-12	Coronary artery disease;
CESC	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.62	8.14	0.45	1.52e-14	Prudent dietary pattern;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00215801	chr6:34855797	TAF11;ANKS1A	0.63	7.34	0.41	2.56e-12	Gut microbiome composition (summer);
CESC	cis	rs9549367	0.789	rs3850451	chr13:113905812	C/G	cg18105134	chr13:113819100	PROZ	-0.72	-8.77	-0.47	2.21e-16	Platelet distribution width;
CESC	cis	rs9303280	0.936	rs12950209	chr17:38049102	T/C	cg19468946	chr17:37922297	IKZF3	-0.42	-5.6	-0.33	5.39e-8	Self-reported allergy;
CESC	cis	rs2953174	0.786	rs8662	chr2:241517770	G/A	cg07929629	chr2:241523174	NA	0.55	6.18	0.35	2.47e-9	Bipolar disorder;
CESC	cis	rs4713118	0.629	rs172165	chr6:28020814	T/G	cg19592336	chr6:28129416	ZNF389	0.52	6.71	0.38	1.18e-10	Parkinson's disease;
CESC	cis	rs11122272	0.735	rs722302	chr1:231480152	A/C	cg06096015	chr1:231504339	EGLN1	0.43	6.41	0.37	6.78e-10	Hemoglobin concentration;
CESC	cis	rs875971	0.862	rs4236208	chr7:65749078	C/T	cg10691866	chr7:65817282	TPST1	0.31	5.27	0.31	2.76e-7	Aortic root size;
CESC	cis	rs9303401	0.659	rs62081316	chr17:56781499	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.03	12.82	0.62	1.31e-29	Cognitive test performance;
CESC	trans	rs13395018	0.892	rs10084272	chr2:170947923	G/A	cg09813610	chr5:3601357	IRX1	-0.56	-6.01	-0.35	6.23e-9	Pulse pressure;
CESC	cis	rs2243480	0.522	rs12698511	chr7:65474919	G/T	cg05590025	chr7:65112418	INTS4L2	-0.75	-5.21	-0.31	3.73e-7	Diabetic kidney disease;
CESC	cis	rs2820292	0.595	rs4950796	chr1:201835409	G/A	cg06775570	chr1:201857621	SHISA4	-0.33	-5.16	-0.3	4.78e-7	Waist circumference;Body mass index (joint analysis main effects and smoking interaction);Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg07494914	chr16:46461571	NA	0.43	6.07	0.35	4.39e-9	Fibrinogen levels;
CESC	cis	rs360798	0.512	rs4461246	chr2:63027671	C/T	cg17519650	chr2:63277830	OTX1	-0.57	-7.41	-0.41	1.71e-12	Coronary artery disease;
CESC	trans	rs11039798	0.588	rs12278284	chr11:48612063	G/C	cg15704280	chr7:45808275	SEPT13	0.62	6.57	0.37	2.63e-10	Axial length;
CESC	cis	rs1790761	0.692	rs614080	chr11:67347287	G/A	cg00290607	chr11:67383545	NA	0.45	6.35	0.36	9.22e-10	Mean corpuscular volume;
CESC	cis	rs1461503	0.966	rs10892938	chr11:122841921	A/C	cg27398637	chr11:122830231	C11orf63	-0.55	-8.32	-0.45	4.77e-15	Menarche (age at onset);
CESC	cis	rs4253772	0.530	rs9615362	chr22:46795141	A/C	cg24881330	chr22:46731750	TRMU	-0.67	-6.53	-0.37	3.41e-10	LDL cholesterol;Cholesterol, total;
CESC	cis	rs8067354	0.574	rs1292035	chr17:57989557	G/A	cg02344993	chr17:57696989	CLTC	0.53	5.48	0.32	9.75e-8	Hemoglobin concentration;
CESC	cis	rs17711722	0.727	rs35850374	chr7:65357776	A/G	cg11987759	chr7:65425863	GUSB	-0.47	-6.44	-0.37	5.7e-10	Calcium levels;
CESC	cis	rs7312933	0.558	rs2178753	chr12:42732804	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.49	-6.37	-0.36	8.12e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs853679	0.517	rs9380049	chr6:28048535	A/G	cg08968635	chr6:28129556	ZNF389	0.39	5.22	0.31	3.64e-7	Depression;
CESC	cis	rs736408	0.609	rs62255396	chr3:52782839	C/T	cg05564831	chr3:52568323	NT5DC2	0.44	6.62	0.38	1.94e-10	Bipolar disorder;
CESC	cis	rs7267979	0.528	rs34485039	chr20:25583763	G/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.69	-11.13	-0.56	7.53e-24	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs9929218	0.906	rs4783571	chr16:68806778	C/T	cg02972257	chr16:68554789	NA	0.43	5.12	0.3	5.89e-7	Colorectal cancer;
CESC	cis	rs3785574	0.925	rs2727340	chr17:61970224	T/A	cg06420487	chr17:61919686	SMARCD2	0.43	5.13	0.3	5.59e-7	Height;
CESC	cis	rs7945705	0.875	rs2568065	chr11:8889648	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.5	-8.52	-0.46	1.24e-15	Hemoglobin concentration;
CESC	cis	rs7666738	0.830	rs9995386	chr4:98907826	T/C	cg03467027	chr4:99064603	C4orf37	0.43	5.31	0.31	2.3e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs763121	0.813	rs4821807	chr22:39065582	A/G	cg14440974	chr22:39074834	NA	-0.42	-5.65	-0.33	4.24e-8	Menopause (age at onset);
CESC	cis	rs4566357	0.615	rs2272202	chr2:227914625	C/T	cg05526886	chr2:227700861	RHBDD1	0.45	5.89	0.34	1.16e-8	Coronary artery disease;
CESC	cis	rs7208859	0.623	rs9912440	chr17:29148772	A/G	cg13385521	chr17:29058706	SUZ12P	0.8	6.7	0.38	1.22e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs6693567	0.565	rs3754217	chr1:150480373	G/T	cg09579323	chr1:150459698	TARS2	0.47	5.73	0.33	2.76e-8	Migraine;
CESC	cis	rs9611565	0.649	rs2064189	chr22:42127999	A/G	cg03806693	chr22:41940476	POLR3H	0.74	9.02	0.48	3.81e-17	Vitiligo;
CESC	cis	rs2806561	0.514	rs7414010	chr1:23543929	T/C	cg19743168	chr1:23544995	NA	0.38	5.79	0.33	2.03e-8	Height;
CESC	cis	rs2204008	0.774	rs8189620	chr12:38241621	A/G	cg26384229	chr12:38710491	ALG10B	0.72	10.15	0.53	1.19e-20	Bladder cancer;
CESC	cis	rs10504229	0.683	rs1495866	chr8:58141128	T/C	cg02725872	chr8:58115012	NA	-0.45	-7.12	-0.4	1.02e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs367615	0.552	rs2963025	chr5:108733256	A/C	cg17395555	chr5:108820864	NA	-0.45	-7.49	-0.42	1.03e-12	Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs7666738	0.830	rs2903150	chr4:99027184	T/C	cg24818145	chr4:99064322	C4orf37	0.39	5.09	0.3	6.95e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6460942	1.000	rs112794590	chr7:12319426	G/A	cg20607287	chr7:12443886	VWDE	-0.79	-8.51	-0.46	1.32e-15	Coronary artery disease;
CESC	cis	rs3806843	1.000	rs3756339	chr5:140180537	A/G	cg26395211	chr5:140044315	WDR55	-0.42	-5.35	-0.31	1.9e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs2228479	0.681	rs2270461	chr16:89972345	C/T	cg06558623	chr16:89946397	TCF25	-0.55	-5.51	-0.32	8.65e-8	Skin colour saturation;
CESC	cis	rs66887589	0.934	rs7672519	chr4:120544112	C/T	cg09307838	chr4:120376055	NA	-0.46	-6.27	-0.36	1.5e-9	Diastolic blood pressure;
CESC	cis	rs4555082	0.874	rs2245329	chr14:105719181	T/C	cg27165867	chr14:105738592	BRF1	-0.55	-6.16	-0.35	2.66e-9	Mean platelet volume;Platelet distribution width;
CESC	trans	rs9929218	0.551	rs2281850	chr16:68718750	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.96	-16.72	-0.72	2.37e-43	Colorectal cancer;
CESC	cis	rs447735	0.587	rs258335	chr16:89720944	G/A	cg03605463	chr16:89740564	NA	0.42	5.23	0.31	3.4e-7	Hemoglobin concentration;
CESC	cis	rs2408955	0.522	rs2051851	chr12:48485940	G/C	cg04545296	chr12:48745243	ZNF641	-0.35	-6.11	-0.35	3.47e-9	Glycated hemoglobin levels;
CESC	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg18765753	chr7:1198926	ZFAND2A	-0.45	-6.54	-0.37	3.23e-10	Longevity;Endometriosis;
CESC	cis	rs6831352	0.918	rs29001216	chr4:100051556	A/T	cg12011299	chr4:100065546	ADH4	-0.59	-6.52	-0.37	3.62e-10	Alcohol dependence;
CESC	cis	rs1799949	1.000	rs35668327	chr17:41273095	G/A	cg05368731	chr17:41323189	NBR1	0.8	11.39	0.57	9.99e-25	Menopause (age at onset);
CESC	cis	rs1552244	0.808	rs17032306	chr3:10091399	C/G	cg00149659	chr3:10157352	C3orf10	0.72	8.45	0.46	1.95e-15	Alzheimer's disease;
CESC	cis	rs2204008	0.540	rs1283306	chr12:38153778	C/A	cg26384229	chr12:38710491	ALG10B	-0.42	-5.74	-0.33	2.61e-8	Bladder cancer;
CESC	cis	rs9611565	0.729	rs132902	chr22:41797758	A/G	cg03806693	chr22:41940476	POLR3H	-1.12	-15.13	-0.68	1.07e-37	Vitiligo;
CESC	cis	rs9837602	1.000	rs4571265	chr3:99705111	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.53	-7.24	-0.41	4.82e-12	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08142232	chr20:32399298	CHMP4B	0.55	5.99	0.35	6.71e-9	Gut microbiome composition (summer);
CESC	cis	rs8177253	1.000	rs8177247	chr3:133479499	T/G	cg11941060	chr3:133502564	NA	-0.48	-6.53	-0.37	3.39e-10	Iron status biomarkers;
CESC	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.53	-6.5	-0.37	4.07e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs6032067	0.929	rs1997892	chr20:43810961	A/T	cg11264863	chr20:43835661	SEMG1	0.47	5.24	0.31	3.3e-7	Blood protein levels;
CESC	cis	rs2576037	0.526	rs7234570	chr18:44459656	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.72	11.53	0.58	3.49e-25	Personality dimensions;
CESC	cis	rs9457247	0.935	rs2757046	chr6:167374353	C/T	cg25258033	chr6:167368657	RNASET2	-0.42	-6.29	-0.36	1.31e-9	Crohn's disease;
CESC	cis	rs10242455	0.702	rs17161726	chr7:99008395	C/G	cg25640893	chr7:99214727	ZNF498	0.96	6.28	0.36	1.41e-9	Blood metabolite levels;
CESC	cis	rs3096299	0.900	rs4785666	chr16:89462771	C/G	cg16743903	chr16:89593216	SPG7	-0.39	-5.03	-0.3	9.17e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs10733682	0.659	rs1887970	chr9:129464827	C/T	cg00232160	chr9:129468157	NA	0.4	6.38	0.36	7.99e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs11785693	0.909	rs11784246	chr8:4970497	A/G	cg26367366	chr8:4980734	NA	0.81	7.25	0.41	4.53e-12	Neuroticism (multi-trait analysis);Neuroticism;
CESC	cis	rs459571	0.920	rs433402	chr9:136898627	A/G	cg13789015	chr9:136890014	NCRNA00094	0.55	7.69	0.43	2.94e-13	Platelet distribution width;
CESC	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.58	-8.86	-0.48	1.18e-16	Longevity;Endometriosis;
CESC	cis	rs1348850	0.872	rs2084233	chr2:178331206	G/A	cg22681709	chr2:178499509	PDE11A	-0.42	-5.99	-0.35	6.97e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs8062405	1.000	rs55719896	chr16:28846866	G/A	cg08761264	chr16:28874980	SH2B1	-0.46	-5.77	-0.33	2.26e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	trans	rs7937682	0.855	rs7109592	chr11:111533105	C/A	cg18187862	chr3:45730750	SACM1L	0.47	6.04	0.35	5.2e-9	Primary sclerosing cholangitis;
CESC	cis	rs6693567	0.545	rs35705743	chr1:150451832	G/A	cg09579323	chr1:150459698	TARS2	0.48	6.02	0.35	5.7e-9	Migraine;
CESC	cis	rs7078219	0.505	rs10883365	chr10:101287764	C/T	cg09788492	chr10:101292477	NKX2-3	0.33	6.19	0.36	2.28e-9	Dental caries;
CESC	cis	rs7296418	0.961	rs949143	chr12:123595163	G/A	cg05973401	chr12:123451056	ABCB9	0.58	7.68	0.43	3.16e-13	Platelet count;
CESC	cis	rs4964805	0.710	rs1866296	chr12:104187092	G/A	cg02344784	chr12:104178138	NT5DC3	0.46	6.57	0.37	2.73e-10	Attention deficit hyperactivity disorder;
CESC	cis	rs1008375	1.000	rs7436403	chr4:17692685	T/G	cg16339924	chr4:17578868	LAP3	-0.66	-7.98	-0.44	4.41e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs13382862	0.895	rs13385499	chr2:20882413	A/G	cg07755735	chr2:20870362	GDF7	-0.47	-7.07	-0.4	1.35e-11	Abdominal aortic aneurysm;
CESC	cis	rs1348850	0.574	rs13431105	chr2:178434674	A/G	cg22681709	chr2:178499509	PDE11A	-0.52	-5.2	-0.3	3.95e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	trans	rs17780086	0.527	rs72827711	chr17:30537920	T/A	cg20587970	chr11:113659929	NA	-1.24	-11.04	-0.56	1.46e-23	Height;
CESC	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg06873352	chr17:61820015	STRADA	0.65	11.05	0.56	1.35e-23	Prudent dietary pattern;
CESC	cis	rs1799949	0.931	rs9912203	chr17:41445145	A/G	cg23758822	chr17:41437982	NA	-0.98	-17.21	-0.73	4.39e-45	Menopause (age at onset);
CESC	cis	rs10743315	0.778	rs9805106	chr12:19372357	A/G	cg02471346	chr12:19282374	PLEKHA5	-0.48	-5.2	-0.3	4.07e-7	Gut microbiota (bacterial taxa);
CESC	cis	rs6582630	0.638	rs10880644	chr12:38554959	G/A	cg26384229	chr12:38710491	ALG10B	0.45	6.3	0.36	1.22e-9	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs3738443	0.645	rs11811599	chr1:247366435	C/A	cg07706540	chr1:247373924	NA	-0.41	-5.09	-0.3	6.82e-7	Alcohol dependence;
CESC	trans	rs9929218	0.911	rs4783686	chr16:68834156	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.64	-8.03	-0.44	3.13e-14	Colorectal cancer;
CESC	cis	rs4148883	0.504	rs4585310	chr4:100120233	T/C	cg12011299	chr4:100065546	ADH4	-0.52	-7.3	-0.41	3.3e-12	Alcohol dependence;
CESC	cis	rs7666738	0.719	rs35184673	chr4:99050945	T/C	cg17366294	chr4:99064904	C4orf37	0.57	6.06	0.35	4.58e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9581857	0.615	rs3759435	chr13:27996813	T/G	cg22138327	chr13:27999177	GTF3A	0.8	8.32	0.46	4.65e-15	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
CESC	cis	rs9314323	0.558	rs7828560	chr8:26188998	G/A	cg11498726	chr8:26250323	BNIP3L	-0.43	-6.08	-0.35	4.16e-9	Red cell distribution width;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg15380588	chr6:144606480	NA	-0.45	-6.01	-0.35	6.17e-9	Fibrinogen levels;
CESC	cis	rs2635047	0.638	rs2317324	chr18:44628687	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.42	-5.36	-0.31	1.78e-7	Educational attainment;
CESC	cis	rs1448094	0.512	rs11832992	chr12:86240790	T/C	cg19622623	chr12:86230825	RASSF9	-0.47	-6.07	-0.35	4.34e-9	Major depressive disorder;
CESC	cis	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg13636640	chr20:31349939	DNMT3B	0.84	13.53	0.64	4.51e-32	Ulcerative colitis;
CESC	cis	rs7100689	0.646	rs11202721	chr10:82135762	G/A	cg00277334	chr10:82204260	NA	-0.57	-7.51	-0.42	9.08e-13	Post bronchodilator FEV1;
CESC	cis	rs2836974	0.966	rs7283516	chr21:40690537	A/G	cg27266027	chr21:40555129	PSMG1	0.44	5.24	0.31	3.26e-7	Cognitive function;
CESC	cis	rs910316	0.726	rs61979167	chr14:75663610	C/T	cg16144293	chr14:75469539	EIF2B2	0.42	5.57	0.32	6.39e-8	Height;
CESC	cis	rs9611565	0.592	rs5758405	chr22:42076381	C/A	cg06634786	chr22:41940651	POLR3H	0.58	6.02	0.35	5.72e-9	Vitiligo;
CESC	cis	rs2991971	0.810	rs781058	chr1:45935056	C/G	cg05343316	chr1:45956843	TESK2	0.58	8.44	0.46	2.06e-15	High light scatter reticulocyte count;
CESC	cis	rs763014	0.865	rs2018789	chr16:632051	T/C	cg00908189	chr16:619842	PIGQ	0.67	9.34	0.5	4.24e-18	Height;
CESC	cis	rs71277158	0.630	rs73879159	chr3:169753747	G/T	cg04067573	chr3:169899625	PHC3	0.57	5.71	0.33	2.95e-8	Prostate cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15203618	chr11:85646125	NA	-0.59	-6.82	-0.39	6.23e-11	Gut microbiome composition (summer);
CESC	cis	rs4665809	0.590	rs1056389	chr2:26502875	T/C	cg22920501	chr2:26401640	FAM59B	0.92	10.12	0.53	1.47e-20	Gut microbiome composition (summer);
CESC	cis	rs2228479	0.867	rs57492102	chr16:89975572	A/G	cg00800038	chr16:89945340	TCF25	-0.75	-7.05	-0.4	1.54e-11	Skin colour saturation;
CESC	cis	rs829883	0.646	rs4762494	chr12:98933834	T/G	cg25150519	chr12:98850993	NA	-0.64	-7.87	-0.44	8.8e-14	Colorectal adenoma (advanced);
CESC	cis	rs9303401	0.614	rs3803752	chr17:56540267	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.95	10.53	0.54	7.11e-22	Cognitive test performance;
CESC	cis	rs9611565	0.512	rs4512	chr22:42206084	G/C	cg06634786	chr22:41940651	POLR3H	-0.66	-6.31	-0.36	1.15e-9	Vitiligo;
CESC	cis	rs4466137	0.868	rs4703962	chr5:82999808	A/G	cg16102102	chr5:83017553	HAPLN1	-0.47	-6.74	-0.38	9.88e-11	Prostate cancer;
CESC	cis	rs2404602	0.716	rs7174953	chr15:76906847	A/C	cg26408565	chr15:76604113	ETFA	-0.4	-5.73	-0.33	2.73e-8	Blood metabolite levels;
CESC	cis	rs7584330	0.554	rs880931	chr2:238396741	G/A	cg14458575	chr2:238380390	NA	0.68	5.98	0.34	7.17e-9	Prostate cancer;
CESC	trans	rs11148252	0.532	rs9536190	chr13:53181044	T/C	cg18335740	chr13:41363409	SLC25A15	0.57	7.6	0.42	5.06e-13	Lewy body disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg18447950	chr17:79073781	BAIAP2	0.51	6.95	0.39	2.89e-11	Fibrinogen levels;
CESC	cis	rs2637266	0.521	rs4587671	chr10:78398879	A/G	cg18941641	chr10:78392320	NA	-0.35	-5.58	-0.32	6.05e-8	Pulmonary function;
CESC	cis	rs1040555	0.516	rs242547	chr20:31418581	T/C	cg13636640	chr20:31349939	DNMT3B	0.68	9.79	0.52	1.66e-19	Lymphocyte percentage of white cells;
CESC	cis	rs1728785	0.792	rs1111502	chr16:68581209	A/G	cg02972257	chr16:68554789	NA	-0.55	-6.31	-0.36	1.17e-9	Ulcerative colitis;
CESC	cis	rs9612	0.718	rs346536	chr19:44251470	A/T	cg08581076	chr19:44259116	C19orf61	0.43	5.24	0.31	3.2e-7	Exhaled nitric oxide output;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg24701985	chr7:149535383	ZNF862	-0.45	-6.41	-0.37	6.6e-10	Gambling;
CESC	cis	rs7666738	0.962	rs2865985	chr4:99068009	T/C	cg18180107	chr4:99064573	C4orf37	0.41	5.07	0.3	7.43e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs35110281	0.607	rs4819212	chr21:44977455	G/A	cg21573476	chr21:45109991	RRP1B	-0.4	-5.4	-0.32	1.46e-7	Mean corpuscular volume;
CESC	cis	rs2777491	0.957	rs1757454	chr15:41777934	A/G	cg20272979	chr15:41787780	ITPKA	0.42	6.19	0.36	2.29e-9	Ulcerative colitis;
CESC	cis	rs6747952	0.866	rs4663854	chr2:239083167	C/T	cg17459225	chr2:239074497	NA	-0.32	-5.04	-0.3	8.55e-7	Mean corpuscular hemoglobin concentration;
CESC	cis	rs36051895	0.664	rs3780374	chr9:5099677	G/A	cg02405213	chr9:5042618	JAK2	-0.51	-6.17	-0.35	2.61e-9	Pediatric autoimmune diseases;
CESC	cis	rs8017423	0.967	rs4904656	chr14:90721442	G/T	cg14092571	chr14:90743983	NA	-0.55	-8.25	-0.45	7.71e-15	Mortality in heart failure;
CESC	cis	rs9388451	0.872	rs2008027	chr6:126052359	A/G	cg05901451	chr6:126070800	HEY2	-0.63	-9.12	-0.49	2.01e-17	Brugada syndrome;
CESC	cis	rs9910055	0.762	rs2631299	chr17:42219773	G/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.61	8.0	0.44	3.92e-14	Total body bone mineral density;
CESC	cis	rs7845219	0.544	rs9643352	chr8:95918288	C/T	cg13393036	chr8:95962371	TP53INP1	-0.42	-7.77	-0.43	1.69e-13	Type 2 diabetes;
CESC	cis	rs722599	0.715	rs2080086	chr14:75338408	G/A	cg11812906	chr14:75593930	NEK9	-0.44	-5.51	-0.32	8.58e-8	IgG glycosylation;
CESC	cis	rs2842992	0.872	rs2758328	chr6:160090731	T/A	cg11366901	chr6:160182831	ACAT2	0.77	9.45	0.5	1.88e-18	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs60871478	0.588	rs56205589	chr7:910419	G/A	cg13798912	chr7:905769	UNC84A	-0.58	-5.66	-0.33	3.86e-8	Cerebrospinal P-tau181p levels;
CESC	cis	rs8067354	1.000	rs8067354	chr17:57821430	G/A	cg13753209	chr17:57696993	CLTC	0.53	7.05	0.4	1.58e-11	Hemoglobin concentration;
CESC	cis	rs2070677	0.935	rs4384343	chr10:135422545	G/C	cg20169779	chr10:135381914	SYCE1	-0.74	-9.88	-0.52	8.58e-20	Gout;
CESC	cis	rs951366	1.000	rs951366	chr1:205685352	C/T	cg17178900	chr1:205818956	PM20D1	0.46	6.59	0.38	2.3e-10	Menarche (age at onset);
CESC	cis	rs11997175	0.603	rs12234894	chr8:33699275	G/C	ch.8.33884649F	chr8:33765107	NA	0.56	7.34	0.41	2.56e-12	Body mass index;
CESC	trans	rs17685	0.725	rs4728548	chr7:75654632	A/T	cg19862616	chr7:65841803	NCRNA00174	-0.7	-9.33	-0.5	4.53e-18	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs13392177	0.684	rs11695527	chr2:219068103	A/G	cg00012203	chr2:219082015	ARPC2	0.64	8.13	0.45	1.7e-14	Pyoderma gangrenosum in inflammatory bowel disease;
CESC	cis	rs9325144	0.681	rs7957376	chr12:39096518	C/T	cg26384229	chr12:38710491	ALG10B	0.45	5.19	0.3	4.26e-7	Morning vs. evening chronotype;
CESC	cis	rs2486288	0.656	rs11632724	chr15:45550791	G/A	cg21132104	chr15:45694354	SPATA5L1	-0.54	-6.55	-0.37	3.03e-10	Glomerular filtration rate;
CESC	cis	rs4523957	0.690	rs28505924	chr17:2088838	G/C	cg16513277	chr17:2031491	SMG6	-0.7	-9.59	-0.51	6.78e-19	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs1799949	1.000	rs11651341	chr17:41428061	T/C	cg05368731	chr17:41323189	NBR1	0.77	10.67	0.55	2.44e-22	Menopause (age at onset);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg01102197	chr9:135753538	C9orf98;C9orf9	-0.42	-6.04	-0.35	5.14e-9	Gambling;
CESC	cis	rs875971	0.825	rs66981195	chr7:66079035	C/A	cg19163074	chr7:65112434	INTS4L2	0.42	5.28	0.31	2.63e-7	Aortic root size;
CESC	cis	rs13191362	0.935	rs13193473	chr6:162966852	C/A	cg21926612	chr6:163149169	PACRG;PARK2	0.81	7.42	0.41	1.58e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01288993	chr7:99631485	ZKSCAN1	-0.73	-8.15	-0.45	1.49e-14	Gut microbiome composition (summer);
CESC	cis	rs684232	0.602	rs384628	chr17:554912	G/A	cg15660573	chr17:549704	VPS53	-0.8	-11.67	-0.58	1.16e-25	Prostate cancer;
CESC	cis	rs4563143	0.675	rs55849754	chr19:29279665	G/A	cg12756686	chr19:29218302	NA	0.58	7.36	0.41	2.38e-12	Methadone dose in opioid dependence;
CESC	cis	rs9916302	0.904	rs12452880	chr17:37591149	G/C	cg00129232	chr17:37814104	STARD3	-0.59	-7.8	-0.43	1.45e-13	Glomerular filtration rate (creatinine);
CESC	cis	rs1862618	0.802	rs986049	chr5:56110233	G/A	cg24531977	chr5:56204891	C5orf35	-0.87	-11.43	-0.57	7.1e-25	Initial pursuit acceleration;
CESC	cis	rs7605827	0.930	rs3805105	chr2:15535312	T/A	cg19274914	chr2:15703543	NA	0.37	6.74	0.38	9.98e-11	Educational attainment (years of education);
CESC	cis	rs7044106	0.791	rs10985008	chr9:123492960	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.75	11.04	0.56	1.49e-23	Hip circumference adjusted for BMI;
CESC	cis	rs7223966	1.000	rs9899491	chr17:61934384	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.44	-5.16	-0.3	4.76e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs1008375	0.931	rs10019482	chr4:17578079	G/A	cg16339924	chr4:17578868	LAP3	0.74	9.68	0.51	3.59e-19	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	trans	rs1994135	0.565	rs11052767	chr12:33731194	A/G	cg26384229	chr12:38710491	ALG10B	0.48	6.52	0.37	3.62e-10	Resting heart rate;
CESC	cis	rs4665809	1.000	rs6749855	chr2:26255263	A/G	cg27170947	chr2:26402098	FAM59B	-0.63	-7.23	-0.41	5.09e-12	Gut microbiome composition (summer);
CESC	cis	rs11166927	1.000	rs11166929	chr8:140801430	G/A	cg16909799	chr8:140841666	TRAPPC9	0.57	8.49	0.46	1.52e-15	Pediatric non-alcoholic fatty liver disease activity score;
CESC	cis	rs4727027	0.865	rs62505077	chr7:148849656	T/A	cg23583168	chr7:148888333	NA	-0.81	-12.69	-0.61	3.68e-29	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg09504196	chr7:148823235	ZNF425;ZNF398	-0.43	-6.16	-0.35	2.74e-9	Gambling;
CESC	cis	rs7552404	0.727	rs1159214	chr1:76317910	G/T	cg03433033	chr1:76189801	ACADM	-0.62	-6.54	-0.37	3.12e-10	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs7072216	0.763	rs733345	chr10:100164215	G/T	cg26618903	chr10:100175079	PYROXD2	-0.35	-5.33	-0.31	2.15e-7	Metabolite levels;
CESC	cis	rs2836974	0.644	rs9978775	chr21:40694526	A/G	cg11644478	chr21:40555479	PSMG1	-0.76	-10.97	-0.56	2.48e-23	Cognitive function;
CESC	cis	rs9649213	0.593	rs1468338	chr7:97951118	T/C	cg21770322	chr7:97807741	LMTK2	0.54	8.15	0.45	1.45e-14	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs4704187	0.687	rs4295370	chr5:74528858	G/T	cg03227963	chr5:74354835	NA	0.28	5.17	0.3	4.61e-7	Response to amphetamines;
CESC	cis	rs3091242	1.000	rs3091242	chr1:25674785	C/T	cg12412775	chr1:25698385	RHCE	-0.31	-5.49	-0.32	9.57e-8	Erythrocyte sedimentation rate;
CESC	cis	rs1707322	1.000	rs10890377	chr1:46406594	G/A	cg05343316	chr1:45956843	TESK2	0.44	5.42	0.32	1.36e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg01745726	chr22:24129337	SMARCB1	-0.51	-6.65	-0.38	1.67e-10	Fibrinogen levels;
CESC	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg11494091	chr17:61959527	GH2	0.73	12.75	0.62	2.36e-29	Prudent dietary pattern;
CESC	cis	rs9457247	0.905	rs377232	chr6:167409638	C/A	cg07741184	chr6:167504864	NA	0.32	5.7	0.33	3.12e-8	Crohn's disease;
CESC	cis	rs13082711	0.863	rs13062327	chr3:27495573	G/A	cg02860705	chr3:27208620	NA	0.51	6.33	0.36	1.06e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CESC	cis	rs7259376	0.936	rs12608491	chr19:22541627	A/G	cg02657401	chr19:22469223	NA	-0.25	-5.08	-0.3	7.12e-7	Menopause (age at onset);
CESC	cis	rs733175	0.599	rs6856396	chr4:10031163	A/T	cg00071950	chr4:10020882	SLC2A9	0.54	5.09	0.3	6.82e-7	Psychosis and Alzheimer's disease;
CESC	cis	rs763121	0.853	rs9610986	chr22:39025277	T/C	cg06022373	chr22:39101656	GTPBP1	0.88	13.7	0.64	1.21e-32	Menopause (age at onset);
CESC	cis	rs3741151	0.687	rs724111	chr11:73238645	G/A	cg17517138	chr11:73019481	ARHGEF17	1.05	7.72	0.43	2.46e-13	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs4141404	0.923	rs2413035	chr22:31600460	A/G	cg13145458	chr22:31556086	RNF185	0.47	5.11	0.3	6.03e-7	Paclitaxel-induced neuropathy;
CESC	cis	rs763014	0.932	rs2269559	chr16:682297	T/C	cg09263875	chr16:632152	PIGQ	0.68	11.59	0.58	2.18e-25	Height;
CESC	cis	rs1862618	0.802	rs252900	chr5:56185281	T/A	cg24549020	chr5:56110836	MAP3K1	0.66	7.45	0.42	1.29e-12	Initial pursuit acceleration;
CESC	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	22.16	0.81	2.84e-62	Prudent dietary pattern;
CESC	cis	rs2033711	0.654	rs734380	chr19:58898963	A/C	cg26874164	chr19:58962979	ZNF324B	0.38	5.21	0.3	3.77e-7	Uric acid clearance;
CESC	cis	rs9787249	0.957	rs11809515	chr1:40205326	C/A	cg19912559	chr1:40204330	PPIE	0.43	6.57	0.37	2.68e-10	Blood protein levels;
CESC	trans	rs1728785	1.000	rs8058314	chr16:68584151	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.61	7.48	0.42	1.11e-12	Ulcerative colitis;
CESC	cis	rs4713118	0.516	rs6931858	chr6:28078411	A/T	cg23281280	chr6:28129359	ZNF389	0.55	7.09	0.4	1.21e-11	Parkinson's disease;
CESC	cis	rs7680126	0.596	rs17198547	chr4:10141419	A/G	cg11266682	chr4:10021025	SLC2A9	0.38	5.44	0.32	1.19e-7	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	cis	rs798554	0.679	rs2533868	chr7:2886559	G/A	cg18446336	chr7:2847575	GNA12	-0.35	-5.53	-0.32	7.65e-8	Height;
CESC	cis	rs7605827	0.860	rs13425097	chr2:15528920	C/G	cg19274914	chr2:15703543	NA	0.35	6.24	0.36	1.73e-9	Educational attainment (years of education);
CESC	cis	rs2273669	0.667	rs75675305	chr6:109324353	T/C	cg05315195	chr6:109294784	ARMC2	-0.66	-6.28	-0.36	1.36e-9	Prostate cancer;
CESC	cis	rs11252926	0.603	rs17293419	chr10:537014	G/A	cg03684893	chr10:554711	DIP2C	0.44	6.64	0.38	1.77e-10	Psychosis in Alzheimer's disease;
CESC	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg16132339	chr22:24313637	DDTL;DDT	-0.38	-5.89	-0.34	1.19e-8	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs733592	0.560	rs2158515	chr12:48507668	T/C	cg24011408	chr12:48396354	COL2A1	-0.51	-8.44	-0.46	2.09e-15	Plateletcrit;
CESC	cis	rs7937682	1.000	rs7128353	chr11:111538875	A/G	cg22437258	chr11:111473054	SIK2	0.66	8.68	0.47	4.2e-16	Primary sclerosing cholangitis;
CESC	cis	rs2304069	0.826	rs2244195	chr5:149403528	C/A	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.88	11.3	0.57	1.98e-24	HIV-1 control;
CESC	cis	rs116095464	0.558	rs10057626	chr5:239720	T/G	cg10591111	chr5:226296	SDHA	-0.52	-6.32	-0.36	1.1e-9	Breast cancer;
CESC	cis	rs7659604	0.539	rs7686084	chr4:122764725	A/C	cg20573242	chr4:122745356	CCNA2	0.65	8.05	0.44	2.81e-14	Type 2 diabetes;
CESC	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg26354017	chr1:205819088	PM20D1	0.84	13.62	0.64	2.19e-32	Menarche (age at onset);
CESC	cis	rs1552244	1.000	rs7619340	chr3:10108178	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	11.94	0.59	1.43e-26	Alzheimer's disease;
CESC	cis	rs1008375	0.800	rs10008598	chr4:17607323	T/C	cg27347728	chr4:17578864	LAP3	0.45	5.49	0.32	9.26e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs1448094	0.648	rs10863093	chr12:86285792	T/G	cg02569458	chr12:86230093	RASSF9	0.39	5.76	0.33	2.31e-8	Major depressive disorder;
CESC	cis	rs853679	0.517	rs17711344	chr6:28077602	A/G	cg22143856	chr6:28129313	ZNF389	-0.44	-5.57	-0.32	6.34e-8	Depression;
CESC	trans	rs11098499	0.863	rs58452170	chr4:120459674	A/T	cg25214090	chr10:38739885	LOC399744	0.69	9.51	0.5	1.19e-18	Corneal astigmatism;
CESC	cis	rs2839186	0.588	rs2839140	chr21:47616080	G/A	cg00612595	chr21:47717864	NA	0.42	5.69	0.33	3.43e-8	Testicular germ cell tumor;
CESC	cis	rs11792861	1.000	rs11792861	chr9:111809295	A/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.47	5.94	0.34	8.73e-9	Menarche (age at onset);
CESC	cis	rs7666738	0.830	rs62321587	chr4:98997958	T/C	cg18180107	chr4:99064573	C4orf37	0.4	5.12	0.3	5.92e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs73001065	0.536	rs10408596	chr19:19512657	A/T	cg03709012	chr19:19516395	GATAD2A	0.93	7.68	0.43	3.03e-13	LDL cholesterol;
CESC	cis	rs477692	0.597	rs574831	chr10:131379190	C/T	cg05714579	chr10:131428358	MGMT	-0.46	-6.26	-0.36	1.53e-9	Response to temozolomide;
CESC	cis	rs72945132	0.714	rs115143889	chr11:70150122	G/T	cg00319359	chr11:70116639	PPFIA1	0.82	7.48	0.42	1.07e-12	Coronary artery disease;
CESC	cis	rs17818399	0.645	rs35870739	chr2:46784231	A/C	cg02822958	chr2:46747628	ATP6V1E2	0.47	5.56	0.32	6.69e-8	Height;
CESC	cis	rs854765	0.547	rs9897761	chr17:17912011	A/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.54	7.72	0.43	2.32e-13	Total body bone mineral density;
CESC	cis	rs2479106	0.591	rs10760295	chr9:126441397	A/G	cg16191174	chr9:126692580	DENND1A	-0.4	-5.62	-0.33	4.77e-8	Polycystic ovary syndrome;
CESC	cis	rs7786808	0.712	rs12671981	chr7:158202971	G/A	cg01191920	chr7:158217561	PTPRN2	-0.36	-5.91	-0.34	1.04e-8	Obesity-related traits;
CESC	cis	rs2635047	0.638	rs2635051	chr18:44645029	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.41	5.56	0.32	6.6e-8	Educational attainment;
CESC	cis	rs8031584	0.678	rs8035703	chr15:31168472	T/C	cg08109568	chr15:31115862	NA	-0.72	-9.88	-0.52	8.33e-20	Huntington's disease progression;
CESC	cis	rs4566357	0.576	rs6750845	chr2:227911037	T/G	cg05526886	chr2:227700861	RHBDD1	-0.45	-5.99	-0.35	6.98e-9	Coronary artery disease;
CESC	cis	rs4975616	0.714	rs27069	chr5:1347128	C/T	cg26373071	chr5:1325741	CLPTM1L	0.46	7.36	0.41	2.36e-12	Lung cancer;
CESC	cis	rs12497850	1.000	rs4858798	chr3:48727112	C/T	cg03060546	chr3:49711283	APEH	0.4	5.17	0.3	4.72e-7	Parkinson's disease;
CESC	cis	rs13256369	0.756	rs13280759	chr8:8562995	G/T	cg18904891	chr8:8559673	CLDN23	0.73	8.12	0.45	1.74e-14	Obesity-related traits;
CESC	cis	rs7927771	0.524	rs11039402	chr11:47826090	A/C	cg20307385	chr11:47447363	PSMC3	0.62	8.62	0.47	6.37e-16	Subjective well-being;
CESC	cis	rs10256972	0.758	rs4723649	chr7:1071905	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.5	-6.21	-0.36	2.01e-9	Longevity;Endometriosis;
CESC	cis	rs4722166	0.508	rs1474347	chr7:22768124	A/C	cg05472934	chr7:22766657	IL6	-0.68	-8.88	-0.48	1.05e-16	Lung cancer;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg23620433	chr14:58894395	KIAA0586;TIMM9	-0.43	-6.33	-0.36	1.05e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs400736	0.637	rs2300428	chr1:7996894	A/G	cg25007680	chr1:8021821	PARK7	-0.57	-8.03	-0.44	3.2e-14	Response to antidepressants and depression;
CESC	cis	rs9916302	0.706	rs1877030	chr17:37740161	T/C	cg00129232	chr17:37814104	STARD3	-0.56	-5.25	-0.31	3.08e-7	Glomerular filtration rate (creatinine);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg13898697	chr1:36641773	MAP7D1	0.51	7.02	0.4	1.9e-11	Fibrinogen levels;
CESC	trans	rs8135828	0.770	rs5763303	chr22:29929744	A/G	cg17961835	chr3:126195582	ZXDC	-0.45	-6.03	-0.35	5.5e-9	Lipid traits;
CESC	cis	rs2463822	0.592	rs72919486	chr11:62043501	G/C	cg06239285	chr11:62104954	ASRGL1	-1.13	-9.21	-0.49	1.05e-17	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs780096	0.546	rs7563162	chr2:27631191	C/T	cg21248554	chr2:27665150	KRTCAP3	-0.35	-7.21	-0.41	5.68e-12	Total body bone mineral density;
CESC	cis	rs2070997	0.527	rs3847192	chr9:133724916	T/G	cg11464064	chr9:133710261	ABL1	0.59	5.93	0.34	9.31e-9	Response to amphetamines;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03043663	chr1:2344561	PEX10	0.62	7.4	0.41	1.77e-12	Gut microbiome composition (summer);
CESC	cis	rs6570726	0.846	rs409553	chr6:145886963	C/T	cg05347473	chr6:146136440	FBXO30	0.49	6.59	0.38	2.33e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs11785400	0.701	rs9721143	chr8:143727511	A/T	cg10596483	chr8:143751796	JRK	0.42	5.36	0.31	1.77e-7	Schizophrenia;
CESC	cis	rs9790314	1.000	rs1993891	chr3:161047467	A/G	cg03342759	chr3:160939853	NMD3	-0.47	-6.11	-0.35	3.61e-9	Morning vs. evening chronotype;
CESC	cis	rs9487051	0.714	rs13209277	chr6:109624963	T/A	cg21918786	chr6:109611834	NA	-0.36	-5.26	-0.31	3.03e-7	Reticulocyte fraction of red cells;
CESC	cis	rs2075371	0.796	rs1646645	chr7:134012232	G/T	cg11752832	chr7:134001865	SLC35B4	-0.44	-5.51	-0.32	8.64e-8	Mean platelet volume;
CESC	cis	rs7072216	0.691	rs7910973	chr10:100166732	G/A	cg26618903	chr10:100175079	PYROXD2	-0.36	-5.38	-0.31	1.65e-7	Metabolite levels;
CESC	cis	rs780096	0.565	rs13022659	chr2:27743630	C/T	cg12648201	chr2:27665141	KRTCAP3	-0.32	-5.67	-0.33	3.75e-8	Total body bone mineral density;
CESC	cis	rs6952808	0.692	rs12666575	chr7:2004421	C/T	cg04267008	chr7:1944627	MAD1L1	-0.63	-7.63	-0.42	4.34e-13	Bipolar disorder and schizophrenia;
CESC	cis	rs6545883	0.929	rs7561229	chr2:61737990	A/T	cg15711740	chr2:61764176	XPO1	-0.43	-5.21	-0.3	3.86e-7	Tuberculosis;
CESC	cis	rs644799	0.965	rs687529	chr11:95545587	T/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.53	6.41	0.37	6.77e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs2075371	0.796	rs10954440	chr7:134005657	C/T	cg00033643	chr7:134001901	SLC35B4	0.43	5.48	0.32	9.9e-8	Mean platelet volume;
CESC	cis	rs9457247	0.663	rs9457257	chr6:167440736	G/A	cg23791538	chr6:167370224	RNASET2	-0.57	-7.71	-0.43	2.6e-13	Crohn's disease;
CESC	cis	rs9815354	1.000	rs17064124	chr3:41890803	A/G	cg03022575	chr3:42003672	ULK4	0.45	5.2	0.3	3.99e-7	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs523522	0.962	rs4766966	chr12:120942911	G/C	cg27279351	chr12:120934652	DYNLL1	0.69	8.94	0.48	6.79e-17	High light scatter reticulocyte count;
CESC	cis	rs2075371	0.897	rs1643033	chr7:134004662	T/C	cg20476274	chr7:133979776	SLC35B4	0.55	7.8	0.43	1.45e-13	Mean platelet volume;
CESC	cis	rs8077577	0.689	rs62072515	chr17:18213435	T/G	cg16794390	chr17:18148240	FLII	0.4	6.16	0.35	2.74e-9	Obesity-related traits;
CESC	cis	rs2479724	0.811	rs8393	chr6:41757836	C/A	cg08135965	chr6:41755394	TOMM6	-0.41	-5.26	-0.31	3e-7	Menarche (age at onset);
CESC	cis	rs2279817	0.818	rs883379	chr1:17983789	G/A	cg21791023	chr1:18019539	ARHGEF10L	-0.55	-7.37	-0.41	2.21e-12	Neuroticism;
CESC	cis	rs9457247	1.000	rs2769352	chr6:167378619	A/G	cg23791538	chr6:167370224	RNASET2	0.58	8.26	0.45	7.1e-15	Crohn's disease;
CESC	cis	rs7640424	0.784	rs68044584	chr3:107845395	A/G	cg09227934	chr3:107805635	CD47	-0.46	-5.87	-0.34	1.28e-8	Body mass index;
CESC	cis	rs9486719	0.947	rs12210834	chr6:96890407	A/T	cg18709589	chr6:96969512	KIAA0776	-0.53	-5.81	-0.34	1.75e-8	Migraine;Coronary artery disease;
CESC	cis	rs7666738	0.830	rs13138920	chr4:99020786	A/G	cg18180107	chr4:99064573	C4orf37	0.41	5.39	0.31	1.57e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7851660	0.809	rs7034648	chr9:100654093	C/A	cg13688889	chr9:100608707	NA	-0.63	-8.96	-0.48	5.96e-17	Strep throat;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg01936430	chr1:204380496	PPP1R15B	-0.44	-6.26	-0.36	1.53e-9	Fibrinogen levels;
CESC	cis	rs1046896	0.594	rs9914570	chr17:80783721	C/T	cg19500275	chr17:80737654	TBCD	0.5	5.56	0.32	6.55e-8	Glycated hemoglobin levels;
CESC	cis	rs9948	0.500	rs62152903	chr2:97570377	T/C	cg26665480	chr2:98280029	ACTR1B	-0.58	-5.22	-0.31	3.69e-7	Erectile dysfunction and prostate cancer treatment;
CESC	cis	rs7927592	0.546	rs638076	chr11:68202580	A/G	cg16797656	chr11:68205561	LRP5	0.63	9.89	0.52	7.78e-20	Total body bone mineral density;
CESC	cis	rs13191362	1.000	rs67487119	chr6:163102657	A/C	cg14584255	chr6:163149320	PACRG;PARK2	0.68	6.93	0.39	3.14e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs28489187	0.756	rs233047	chr1:85830570	G/A	cg16011679	chr1:85725395	C1orf52	0.5	5.67	0.33	3.81e-8	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	cis	rs3096299	0.582	rs12935119	chr16:89542874	A/T	cg00750074	chr16:89608354	SPG7	-0.41	-6.01	-0.35	6.05e-9	Multiple myeloma (IgH translocation);
CESC	cis	rs2439831	1.000	rs2584725	chr15:43793135	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.83	12.17	0.6	2.26e-27	Lung cancer in ever smokers;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg26650539	chr6:34664812	C6orf106	0.38	6.12	0.35	3.28e-9	Gambling;
CESC	cis	rs2836974	0.863	rs8132333	chr21:40527900	A/G	cg11644478	chr21:40555479	PSMG1	1.03	17.22	0.73	4.12e-45	Cognitive function;
CESC	cis	rs6540559	0.740	rs2064163	chr1:210048819	G/T	cg25204440	chr1:209979598	IRF6	0.54	7.28	0.41	3.71e-12	Cleft lip with or without cleft palate;
CESC	cis	rs1957429	0.614	rs73279834	chr14:65352544	G/A	cg23373153	chr14:65346875	NA	-0.92	-6.68	-0.38	1.43e-10	Pediatric areal bone mineral density (radius);
CESC	trans	rs61931739	0.500	rs11519398	chr12:34473553	C/T	cg13010199	chr12:38710504	ALG10B	0.49	6.21	0.36	2.09e-9	Morning vs. evening chronotype;
CESC	cis	rs9900062	0.519	rs2676293	chr17:62710461	T/C	cg02097616	chr17:62675921	NA	0.42	5.09	0.3	6.69e-7	QT interval;
CESC	cis	rs7084402	0.870	rs4948525	chr10:60361270	G/A	cg07615347	chr10:60278583	BICC1	0.57	8.73	0.47	2.99e-16	Refractive error;
CESC	trans	rs1814175	0.645	rs10742953	chr11:49807491	C/G	cg15704280	chr7:45808275	SEPT13	0.96	15.84	0.7	3.3e-40	Height;
CESC	cis	rs4481887	1.000	rs7553333	chr1:248493956	C/G	cg00666640	chr1:248458726	OR2T12	0.41	6.71	0.38	1.17e-10	Common traits (Other);
CESC	cis	rs7223966	1.000	rs8081541	chr17:61812483	C/T	cg11494091	chr17:61959527	GH2	0.38	5.15	0.3	5.2e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs4908760	0.783	rs301799	chr1:8489302	C/T	cg00120948	chr1:8484417	RERE	-0.41	-6.49	-0.37	4.19e-10	Vitiligo;
CESC	cis	rs854765	0.583	rs11656840	chr17:17837354	C/T	cg04398451	chr17:18023971	MYO15A	-0.67	-9.61	-0.51	5.88e-19	Total body bone mineral density;
CESC	cis	rs7618915	0.571	rs2251219	chr3:52584787	C/T	cg07507251	chr3:52567010	NT5DC2	-0.44	-7.2	-0.4	6.11e-12	Bipolar disorder;
CESC	cis	rs3741404	0.895	rs2429455	chr11:63995302	C/G	cg18225595	chr11:63971243	STIP1	0.67	9.29	0.5	5.92e-18	Platelet count;
CESC	cis	rs4481887	1.000	rs4916125	chr1:248466583	A/T	cg00666640	chr1:248458726	OR2T12	0.39	6.37	0.36	8.47e-10	Common traits (Other);
CESC	cis	rs7618915	0.533	rs35107891	chr3:52613656	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.47	6.55	0.37	2.89e-10	Bipolar disorder;
CESC	cis	rs9733	0.596	rs11582840	chr1:150688487	A/G	cg09365446	chr1:150670422	GOLPH3L	0.42	5.86	0.34	1.37e-8	Tonsillectomy;
CESC	cis	rs748404	0.660	rs493377	chr15:43773467	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.57	7.42	0.41	1.57e-12	Lung cancer;
CESC	cis	rs1879734	0.689	rs11206191	chr1:54158102	A/G	cg23596471	chr1:54105337	GLIS1	-0.33	-5.39	-0.31	1.58e-7	Mitral valve prolapse;
CESC	cis	rs10089	0.953	rs4836358	chr5:127376869	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.78	10.15	0.53	1.14e-20	Ileal carcinoids;
CESC	cis	rs4141404	0.561	rs5994376	chr22:31563555	A/C	cg25791279	chr22:32026902	PISD	-0.42	-5.04	-0.3	8.61e-7	Paclitaxel-induced neuropathy;
CESC	cis	rs10779751	0.686	rs2791656	chr1:11128329	A/G	cg08854313	chr1:11322531	MTOR	0.76	9.57	0.51	8.15e-19	Body mass index;
CESC	cis	rs9911578	0.765	rs66954617	chr17:56999427	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.39	5.04	0.3	8.51e-7	Intelligence (multi-trait analysis);
CESC	cis	rs10504229	1.000	rs67705655	chr8:58177688	G/A	cg24829409	chr8:58192753	C8orf71	-0.76	-10.0	-0.52	3.53e-20	Developmental language disorder (linguistic errors);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg14729071	chr8:117886537	RAD21	-0.44	-6.08	-0.35	4.08e-9	Gambling;
CESC	cis	rs10504229	0.683	rs56235637	chr8:58106008	T/C	cg02725872	chr8:58115012	NA	-0.4	-6.25	-0.36	1.67e-9	Developmental language disorder (linguistic errors);
CESC	trans	rs2273788	1.000	rs2273788	chr9:114348617	C/T	cg05983323	chr4:166249203	SC4MOL	-0.61	-6.15	-0.35	2.86e-9	Monocyte count;
CESC	cis	rs12477438	0.520	rs6542864	chr2:99725223	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.89	15.87	0.7	2.44e-40	Chronic sinus infection;
CESC	cis	rs10838687	0.736	rs11039144	chr11:47264044	G/A	cg25783544	chr11:47291846	MADD	0.56	6.5	0.37	4.04e-10	Proinsulin levels;
CESC	cis	rs2228479	0.850	rs62054609	chr16:89816569	C/A	cg00800038	chr16:89945340	TCF25	-0.91	-7.54	-0.42	7.39e-13	Skin colour saturation;
CESC	cis	rs3026401	0.562	rs2863231	chr11:31796560	C/T	cg14844989	chr11:31128820	NA	-0.53	-6.68	-0.38	1.4e-10	Body mass index;
CESC	cis	rs5769765	1.000	rs4597652	chr22:50270570	A/G	cg02269571	chr22:50332266	NA	0.46	6.28	0.36	1.39e-9	Schizophrenia;
CESC	trans	rs7836436	0.686	rs61519992	chr8:120954517	A/C	cg22699279	chr15:79383890	RASGRF1	-0.7	-6.72	-0.38	1.12e-10	HIV-1 viral setpoint;
CESC	cis	rs4423214	1.000	rs7928249	chr11:71161063	A/G	cg24826892	chr11:71159390	DHCR7	0.45	5.38	0.31	1.68e-7	Vitamin D levels;
CESC	cis	rs17376456	0.757	rs6859757	chr5:93206042	C/T	cg25358565	chr5:93447407	FAM172A	1.13	10.54	0.54	6.44e-22	Diabetic retinopathy;
CESC	cis	rs7520050	0.966	rs1707336	chr1:46493460	T/G	cg24296786	chr1:45957014	TESK2	0.43	5.42	0.32	1.33e-7	Red blood cell count;Reticulocyte count;
CESC	cis	rs67478160	0.595	rs2295146	chr14:104199356	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.53	-7.32	-0.41	2.97e-12	Schizophrenia;
CESC	cis	rs9487051	0.676	rs9372208	chr6:109596168	A/G	cg01475377	chr6:109611718	NA	-0.45	-7.04	-0.4	1.6e-11	Reticulocyte fraction of red cells;
CESC	cis	rs4727027	0.870	rs1568945	chr7:148874112	T/G	cg23158103	chr7:148848205	ZNF398	-0.4	-6.29	-0.36	1.31e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs35306767	0.761	rs34480046	chr10:1027440	A/G	cg20503657	chr10:835505	NA	0.74	6.75	0.38	9.51e-11	Eosinophil percentage of granulocytes;
CESC	cis	rs6546537	0.869	rs13035491	chr2:69827456	G/A	cg10773587	chr2:69614142	GFPT1	-0.55	-6.86	-0.39	4.72e-11	Serum thyroid-stimulating hormone levels;
CESC	trans	rs116095464	0.558	rs6962	chr5:256509	G/A	cg00938859	chr5:1591904	SDHAP3	0.69	6.93	0.39	3.2e-11	Breast cancer;
CESC	cis	rs7546094	0.509	rs7415988	chr1:113159730	G/T	cg22162597	chr1:113214053	CAPZA1	-0.62	-7.57	-0.42	6.29e-13	Platelet distribution width;
CESC	cis	rs7937682	0.855	rs521947	chr11:111492616	A/G	cg22437258	chr11:111473054	SIK2	0.72	9.66	0.51	4.24e-19	Primary sclerosing cholangitis;
CESC	cis	rs8060686	0.920	rs1124324	chr16:67897487	C/T	cg26727032	chr16:67993705	SLC12A4	-0.48	-5.62	-0.33	4.79e-8	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs3096299	0.685	rs3803681	chr16:89544756	C/T	cg02034447	chr16:89574710	SPG7	0.46	5.92	0.34	9.77e-9	Multiple myeloma (IgH translocation);
CESC	cis	rs727563	0.635	rs5758444	chr22:42133921	T/A	cg03806693	chr22:41940476	POLR3H	1.09	12.68	0.61	4.08e-29	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs61996546	0.622	rs34660647	chr15:26841524	T/C	cg14859324	chr15:26874363	GABRB3	-0.37	-5.05	-0.3	8.05e-7	Response to methotrexate in juvenile idiopathic arthritis;
CESC	cis	rs35955747	0.902	rs12166373	chr22:31700508	A/G	cg25791279	chr22:32026902	PISD	-0.48	-5.88	-0.34	1.25e-8	Neutrophil count;Sum basophil neutrophil counts;
CESC	cis	rs60871478	0.853	rs62432864	chr7:808405	T/G	cg05535760	chr7:792225	HEATR2	0.89	10.55	0.54	6.14e-22	Cerebrospinal P-tau181p levels;
CESC	trans	rs561341	1.000	rs530209	chr17:30315287	A/G	cg27661571	chr11:113659931	NA	-0.83	-7.76	-0.43	1.9e-13	Hip circumference adjusted for BMI;
CESC	cis	rs2735413	0.918	rs56397244	chr16:78081366	A/T	cg04733911	chr16:78082701	NA	-0.53	-9.01	-0.48	4.08e-17	Systolic blood pressure (alcohol consumption interaction);
CESC	cis	rs7542091	0.635	rs7550733	chr1:210044968	G/A	cg21951975	chr1:209979733	IRF6	0.47	8.25	0.45	7.51e-15	Monobrow;
CESC	cis	rs4699052	0.662	rs6828151	chr4:104284756	C/G	cg16532752	chr4:104119610	CENPE	-0.37	-5.3	-0.31	2.46e-7	Testicular germ cell tumor;
CESC	cis	rs962856	0.619	rs6546302	chr2:67605733	G/T	cg09028215	chr2:67624308	ETAA1	-0.43	-5.25	-0.31	3.17e-7	Pancreatic cancer;
CESC	cis	rs763121	0.853	rs5757211	chr22:39051705	C/T	cg06544989	chr22:39130855	UNC84B	0.5	8.66	0.47	4.63e-16	Menopause (age at onset);
CESC	cis	rs8028182	0.636	rs4462560	chr15:75647964	G/C	cg20655648	chr15:75932815	IMP3	-0.44	-5.6	-0.33	5.29e-8	Sudden cardiac arrest;
CESC	cis	rs9788682	0.747	rs2568485	chr15:78752114	C/T	cg24631222	chr15:78858424	CHRNA5	-0.64	-7.55	-0.42	7.09e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs3096299	0.933	rs3096297	chr16:89453155	T/G	cg16743903	chr16:89593216	SPG7	-0.44	-5.55	-0.32	6.77e-8	Multiple myeloma (IgH translocation);
CESC	cis	rs13102973	0.899	rs4479760	chr4:135867474	T/C	cg14419869	chr4:135874104	NA	0.36	5.81	0.34	1.8e-8	Subjective well-being;
CESC	cis	rs1577917	1.000	rs34281561	chr6:86701872	T/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.47	-5.97	-0.34	7.47e-9	Response to antipsychotic treatment;
CESC	cis	rs55871839	0.708	rs13263261	chr8:59814688	T/G	cg07426533	chr8:59803705	TOX	-0.51	-7.41	-0.41	1.71e-12	Pneumonia;
CESC	cis	rs1371867	0.846	rs1660330	chr8:101305015	T/A	cg11906718	chr8:101322791	RNF19A	0.54	6.93	0.39	3.24e-11	Atrioventricular conduction;
CESC	cis	rs8027181	0.839	rs7167076	chr15:73028873	G/A	cg25632853	chr15:73088954	NA	-0.31	-5.4	-0.31	1.51e-7	Triglyceride levels;
CESC	cis	rs7208859	0.623	rs8079891	chr17:29058863	G/A	cg13385521	chr17:29058706	SUZ12P	0.81	6.53	0.37	3.28e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs2228479	0.850	rs17227263	chr16:89810598	G/A	cg04013166	chr16:89971882	TCF25	0.77	6.69	0.38	1.32e-10	Skin colour saturation;
CESC	cis	rs3749237	1.000	rs11130214	chr3:49735746	C/G	cg03060546	chr3:49711283	APEH	-0.64	-7.66	-0.43	3.42e-13	Resting heart rate;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg00377757	chr17:76921538	TIMP2	-0.43	-6.1	-0.35	3.76e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs7635838	0.822	rs9861633	chr3:11473437	C/G	cg00170343	chr3:11313890	ATG7	0.43	5.71	0.33	3.03e-8	HDL cholesterol;
CESC	cis	rs13031619	0.605	rs4849972	chr2:3698846	C/A	cg25251562	chr2:3704773	ALLC	0.54	5.28	0.31	2.64e-7	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CESC	cis	rs7818688	1.000	rs28363725	chr8:96027108	T/C	cg16049864	chr8:95962084	TP53INP1	0.6	5.77	0.33	2.25e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	trans	rs931812	0.895	rs4236763	chr8:101913022	G/A	cg20993868	chr7:22813445	NA	0.5	6.99	0.39	2.23e-11	Attention deficit hyperactivity disorder and conduct disorder;
CESC	cis	rs3768617	0.565	rs4233194	chr1:183060917	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.84	13.13	0.63	1.12e-30	Fuchs's corneal dystrophy;
CESC	cis	rs16866061	1.000	rs72974219	chr2:225423784	G/C	cg12698349	chr2:225449008	CUL3	0.75	11.51	0.58	4.07e-25	Acute graft versus host disease in bone marrow transplantation (recipient effect);
CESC	cis	rs910316	0.967	rs10142770	chr14:75525449	G/A	cg08847533	chr14:75593920	NEK9	1.01	18.87	0.76	6.3e-51	Height;
CESC	cis	rs7940866	1.000	rs7940866	chr11:130817579	A/T	cg12179176	chr11:130786555	SNX19	-0.56	-7.71	-0.43	2.57e-13	Schizophrenia;
CESC	cis	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg05863683	chr7:1912471	MAD1L1	0.42	6.21	0.36	2.02e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs514406	0.505	rs7543239	chr1:53162416	A/G	cg16325326	chr1:53192061	ZYG11B	0.9	15.66	0.69	1.42e-39	Monocyte count;
CESC	cis	rs4975709	0.569	rs1684965	chr5:1865248	A/G	cg07747251	chr5:1868357	NA	0.36	6.13	0.35	3.19e-9	Cardiovascular disease risk factors;
CESC	cis	rs3820928	1.000	rs978909	chr2:227771389	A/C	cg11843606	chr2:227700838	RHBDD1	-0.44	-5.8	-0.34	1.87e-8	Pulmonary function;
CESC	cis	rs1953600	1.000	rs2573346	chr10:81918041	G/A	cg00277334	chr10:82204260	NA	-0.48	-6.82	-0.39	6.16e-11	Sarcoidosis;
CESC	trans	rs2727020	0.729	rs7924782	chr11:49267249	A/G	cg15704280	chr7:45808275	SEPT13	-0.86	-13.88	-0.65	2.73e-33	Coronary artery disease;
CESC	cis	rs6598955	0.670	rs10902734	chr1:26617923	G/T	cg04990556	chr1:26633338	UBXN11	0.76	10.7	0.55	1.85e-22	Obesity-related traits;
CESC	cis	rs6088590	1.000	rs6088595	chr20:33358499	T/A	cg08999081	chr20:33150536	PIGU	0.59	8.69	0.47	3.73e-16	Coronary artery disease;
CESC	cis	rs7937682	0.921	rs688354	chr11:111438762	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.91	-13.02	-0.62	2.75e-30	Primary sclerosing cholangitis;
CESC	cis	rs2011503	0.882	rs8108777	chr19:19359058	C/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.53	5.56	0.32	6.43e-8	Bipolar disorder;
CESC	cis	rs9517313	0.707	rs9517298	chr13:99095003	C/T	cg07423050	chr13:99094983	FARP1	-0.34	-6.23	-0.36	1.86e-9	Neuroticism;
CESC	cis	rs13082711	0.911	rs4973772	chr3:27450234	G/T	cg02860705	chr3:27208620	NA	0.59	7.39	0.41	1.94e-12	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CESC	cis	rs62229266	0.804	rs62230788	chr21:37380337	A/T	cg12218747	chr21:37451666	NA	-0.41	-5.63	-0.33	4.55e-8	Mitral valve prolapse;
CESC	cis	rs3749237	0.595	rs4855877	chr3:49448527	T/C	cg06212747	chr3:49208901	KLHDC8B	0.53	7.21	0.4	5.87e-12	Resting heart rate;
CESC	cis	rs727505	1.000	rs1541418	chr7:124448672	A/G	cg23710748	chr7:124431027	NA	-0.49	-7.84	-0.43	1.12e-13	Lewy body disease;
CESC	cis	rs9487051	0.676	rs1829694	chr6:109593860	G/T	cg21918786	chr6:109611834	NA	-0.37	-5.41	-0.32	1.39e-7	Reticulocyte fraction of red cells;
CESC	cis	rs2652822	0.935	rs12594313	chr15:63436662	A/G	cg02713581	chr15:63449717	RPS27L	0.57	7.39	0.41	1.95e-12	Metabolic traits;
CESC	cis	rs6964587	0.677	rs62467839	chr7:91967371	A/G	cg17063962	chr7:91808500	NA	0.52	6.45	0.37	5.28e-10	Breast cancer;
CESC	cis	rs1950626	0.577	rs61991118	chr14:101441974	C/T	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.69	9.23	0.49	8.76e-18	Pelvic organ prolapse (moderate/severe);
CESC	cis	rs992157	0.835	rs6707559	chr2:219142773	C/T	cg00012203	chr2:219082015	ARPC2	0.78	10.25	0.53	5.43e-21	Colorectal cancer;
CESC	cis	rs854765	0.693	rs12941039	chr17:17765655	C/T	cg04398451	chr17:18023971	MYO15A	0.63	9.0	0.48	4.56e-17	Total body bone mineral density;
CESC	cis	rs1729951	0.575	rs10935213	chr3:136693459	A/G	cg03617693	chr3:136751559	NA	0.39	5.45	0.32	1.13e-7	Neuroticism;
CESC	cis	rs2842992	0.724	rs2273823	chr6:160211485	T/C	cg26839252	chr6:160211577	TCP1;MRPL18	0.49	6.15	0.35	2.83e-9	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs11871801	0.517	rs60929812	chr17:40759448	G/A	cg16308533	chr17:40838983	CNTNAP1	0.39	5.12	0.3	5.95e-7	Crohn's disease;
CESC	cis	rs9322193	0.962	rs9397022	chr6:150133188	C/T	cg05861140	chr6:150128134	PCMT1	-0.34	-5.04	-0.3	8.49e-7	Lung cancer;
CESC	cis	rs11098499	0.754	rs17595608	chr4:120250506	C/T	cg09307838	chr4:120376055	NA	0.77	10.45	0.54	1.22e-21	Corneal astigmatism;
CESC	cis	rs7586879	0.616	rs6726199	chr2:25126328	G/C	cg01884057	chr2:25150051	NA	0.36	7.01	0.4	2.02e-11	Body mass index;
CESC	cis	rs7100689	0.784	rs1870142	chr10:82182296	G/A	cg00277334	chr10:82204260	NA	-0.61	-7.47	-0.42	1.19e-12	Post bronchodilator FEV1;
CESC	cis	rs2576037	0.899	rs2571034	chr18:44578565	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.49	6.36	0.36	8.73e-10	Personality dimensions;
CESC	cis	rs769267	1.000	rs12985655	chr19:19442434	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	-0.47	-5.87	-0.34	1.33e-8	Tonsillectomy;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg13762774	chr10:32048991	NA	0.48	6.28	0.36	1.38e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs9467711	0.606	rs12173854	chr6:26371679	A/G	cg12826209	chr6:26865740	GUSBL1	0.62	5.24	0.31	3.25e-7	Autism spectrum disorder or schizophrenia;
CESC	trans	rs561341	0.769	rs8074383	chr17:30178793	C/T	cg20587970	chr11:113659929	NA	1.02	10.75	0.55	1.29e-22	Hip circumference adjusted for BMI;
CESC	cis	rs7223966	1.000	rs11657306	chr17:61704822	G/A	cg11494091	chr17:61959527	GH2	0.41	5.7	0.33	3.18e-8	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs7618915	0.547	rs12496634	chr3:52709259	A/C	cg05564831	chr3:52568323	NT5DC2	0.44	6.69	0.38	1.3e-10	Bipolar disorder;
CESC	cis	rs2404602	0.692	rs2137307	chr15:77149020	T/A	cg26408565	chr15:76604113	ETFA	-0.39	-5.68	-0.33	3.63e-8	Blood metabolite levels;
CESC	cis	rs4665809	0.838	rs6546749	chr2:26306288	T/C	cg27170947	chr2:26402098	FAM59B	-0.72	-8.31	-0.45	5.18e-15	Gut microbiome composition (summer);
CESC	cis	rs6800768	0.633	rs826372	chr3:24163705	T/C	cg10674438	chr3:24145617	LOC152024	-0.46	-6.73	-0.38	1.03e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09654908	chr15:62989952	TLN2	-0.56	-6.45	-0.37	5.19e-10	Gut microbiome composition (summer);
CESC	cis	rs7833790	0.927	rs61020899	chr8:82757090	C/T	cg27398817	chr8:82754497	SNX16	0.55	6.41	0.37	6.45e-10	Diastolic blood pressure;
CESC	cis	rs12422267	0.536	rs58521339	chr12:132609486	T/C	cg05134918	chr12:132603531	EP400NL	-0.48	-5.08	-0.3	7.1e-7	Plasma amyloid beta peptide concentrations (ABx-40);
CESC	cis	rs965469	1.000	rs6051724	chr20:3279338	T/C	cg25506879	chr20:3388711	C20orf194	-0.54	-5.88	-0.34	1.24e-8	IFN-related cytopenia;
CESC	cis	rs7552404	0.921	rs10873685	chr1:76218818	A/C	cg22875332	chr1:76189707	ACADM	0.66	7.84	0.43	1.1e-13	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs3096299	0.658	rs12443705	chr16:89547054	C/G	cg02187348	chr16:89574699	SPG7	0.64	8.83	0.48	1.48e-16	Multiple myeloma (IgH translocation);
CESC	cis	rs7666738	0.830	rs10007261	chr4:98926155	C/T	cg05340658	chr4:99064831	C4orf37	0.82	12.2	0.6	1.81e-27	Colonoscopy-negative controls vs population controls;
CESC	cis	rs780096	0.546	rs8179225	chr2:27737181	A/G	cg22903471	chr2:27725779	GCKR	-0.55	-7.55	-0.42	6.9e-13	Total body bone mineral density;
CESC	cis	rs9815354	0.761	rs57638657	chr3:41809238	G/C	cg03022575	chr3:42003672	ULK4	0.68	6.06	0.35	4.7e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs4072980	0.524	rs28477803	chr1:38398694	C/T	cg17077180	chr1:38461687	NA	0.43	6.18	0.36	2.38e-9	Coronary artery disease;
CESC	cis	rs798554	0.679	rs13230995	chr7:2887284	G/A	cg18446336	chr7:2847575	GNA12	-0.34	-5.4	-0.31	1.49e-7	Height;
CESC	cis	rs67072384	1.000	rs72964198	chr11:72446464	C/T	cg04827223	chr11:72435913	ARAP1	-0.71	-6.88	-0.39	4.23e-11	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
CESC	cis	rs6088580	0.634	rs1205345	chr20:32914699	A/G	cg24642439	chr20:33292090	TP53INP2	-0.5	-6.58	-0.37	2.48e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs12497850	1.000	rs10865952	chr3:48744484	A/G	cg03060546	chr3:49711283	APEH	0.43	5.35	0.31	1.91e-7	Parkinson's disease;
CESC	cis	rs7078219	0.505	rs10883367	chr10:101287990	A/G	cg09788492	chr10:101292477	NKX2-3	0.33	6.39	0.37	7.59e-10	Dental caries;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04902851	chr8:59572557	NSMAF	-0.7	-8.47	-0.46	1.67e-15	Gut microbiome composition (summer);
CESC	cis	rs9359856	0.623	rs7742602	chr6:90327385	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.55	-6.37	-0.36	8.29e-10	Bipolar disorder;
CESC	cis	rs9660180	1.000	rs3737628	chr1:1722932	C/T	cg23982607	chr1:1823379	GNB1	-0.79	-12.31	-0.6	7.86e-28	Body mass index;
CESC	cis	rs854765	0.927	rs12943914	chr17:17980671	A/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.4	5.08	0.3	7.27e-7	Total body bone mineral density;
CESC	cis	rs798554	0.679	rs11973498	chr7:2886873	C/A	cg13628971	chr7:2884303	GNA12	0.63	8.76	0.47	2.41e-16	Height;
CESC	cis	rs453301	0.686	rs6601281	chr8:8911004	A/G	cg06636001	chr8:8085503	FLJ10661	-0.42	-5.06	-0.3	7.94e-7	Joint mobility (Beighton score);
CESC	cis	rs3105593	1.000	rs56069965	chr15:50966973	G/A	cg08437265	chr15:50716283	USP8	0.46	6.07	0.35	4.49e-9	QT interval;
CESC	cis	rs4132509	0.895	rs12045787	chr1:244011843	T/A	cg21452805	chr1:244014465	NA	0.53	6.39	0.37	7.3e-10	RR interval (heart rate);
CESC	cis	rs9811920	0.809	rs4928235	chr3:99706870	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.43	-5.49	-0.32	9.48e-8	Axial length;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg08945467	chr1:58522070	DAB1	0.45	6.27	0.36	1.44e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs796364	0.806	rs10445791	chr2:201078307	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.75	-6.26	-0.36	1.58e-9	Schizophrenia;
CESC	cis	rs7851660	0.967	rs7049054	chr9:100599969	T/G	cg13688889	chr9:100608707	NA	-0.68	-10.61	-0.55	3.8e-22	Strep throat;
CESC	cis	rs6598955	0.670	rs3795685	chr1:26601385	A/G	cg04990556	chr1:26633338	UBXN11	0.79	11.49	0.58	4.54e-25	Obesity-related traits;
CESC	cis	rs1059312	0.772	rs11609637	chr12:129300202	T/G	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.83	-12.15	-0.6	2.78e-27	Systemic lupus erythematosus;
CESC	cis	rs34330	0.562	rs12229100	chr12:12865836	A/G	cg04607235	chr12:12878440	APOLD1	0.83	9.25	0.49	7.77e-18	Systemic lupus erythematosus;
CESC	cis	rs67311347	1.000	rs13095055	chr3:40505666	G/T	cg09455208	chr3:40491958	NA	-0.47	-8.04	-0.44	2.9e-14	Renal cell carcinoma;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg13995169	chr10:72142516	LRRC20	0.53	6.88	0.39	4.4e-11	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs2530545	0.851	rs58859869	chr7:34692177	G/A	cg14080982	chr15:71736038	THSD4	-0.48	-6.26	-0.36	1.53e-9	IgG glycosylation;
CESC	cis	rs4819052	0.724	rs9753987	chr21:46661389	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.91	13.24	0.63	4.51e-31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs736801	0.704	rs56399423	chr5:131672657	T/C	cg21138405	chr5:131827807	IRF1	-0.36	-5.15	-0.3	5.07e-7	Breast cancer;Mosquito bite size;
CESC	cis	rs769267	0.895	rs2965183	chr19:19545696	G/A	cg03709012	chr19:19516395	GATAD2A	1.01	16.06	0.7	5.36e-41	Tonsillectomy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04714248	chr16:27561727	GTF3C1;KIAA0556	-0.58	-6.87	-0.39	4.61e-11	Gut microbiome composition (summer);
CESC	cis	rs738322	0.967	rs4383	chr22:38570927	C/G	cg17652424	chr22:38574118	PLA2G6	-0.34	-6.04	-0.35	5.08e-9	Cutaneous nevi;
CESC	cis	rs7520050	0.751	rs2230657	chr1:46073489	G/A	cg06784218	chr1:46089804	CCDC17	-0.34	-6.06	-0.35	4.6e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs7552404	0.696	rs1417405	chr1:76457797	T/C	cg03433033	chr1:76189801	ACADM	0.62	6.17	0.35	2.5e-9	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs9916302	0.571	rs28799952	chr17:37533056	C/T	cg07936489	chr17:37558343	FBXL20	0.9	9.82	0.52	1.27e-19	Glomerular filtration rate (creatinine);
CESC	cis	rs11583043	0.918	rs17525451	chr1:101422409	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.55	6.12	0.35	3.39e-9	Ulcerative colitis;Inflammatory bowel disease;
CESC	cis	rs2303745	0.622	rs1864113	chr19:17393504	G/C	cg04248312	chr19:17393744	ANKLE1	-0.93	-15.26	-0.68	3.79e-38	Systemic lupus erythematosus;
CESC	cis	rs6456156	0.586	rs9459862	chr6:167487011	A/G	cg23791538	chr6:167370224	RNASET2	0.5	6.66	0.38	1.59e-10	Primary biliary cholangitis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16693212	chr11:108093249	ATM;NPAT	-0.53	-6.29	-0.36	1.32e-9	Gut microbiome composition (summer);
CESC	cis	rs6499255	1.000	rs55863174	chr16:69819996	G/C	cg15192750	chr16:69999425	NA	0.46	5.64	0.33	4.46e-8	IgE levels;
CESC	cis	rs3747547	0.534	rs11794104	chr9:38091723	T/C	cg13774184	chr9:37916125	SHB	-0.57	-5.1	-0.3	6.41e-7	Metabolite levels (Dihydroxy docosatrienoic acid);
CESC	cis	rs6957923	0.655	rs7781714	chr7:23593479	A/G	cg20265043	chr7:23510089	IGF2BP3	0.41	5.11	0.3	6.03e-7	Height;
CESC	cis	rs7408868	1.000	rs7245814	chr19:15274503	A/G	cg14696996	chr19:15285081	NOTCH3	1.11	11.47	0.58	5.57e-25	Pulse pressure;
CESC	cis	rs9768139	0.935	rs116290351	chr7:158119712	T/A	cg06219351	chr7:158114137	PTPRN2	0.47	7.27	0.41	4.07e-12	Calcium levels;
CESC	cis	rs7833986	0.501	rs2953901	chr8:56981824	C/A	cg26371346	chr8:56986568	SNORD54;RPS20	0.57	5.16	0.3	4.9e-7	Height;
CESC	cis	rs7666738	0.830	rs1967980	chr4:98966426	C/G	cg05340658	chr4:99064831	C4orf37	0.79	12.12	0.6	3.52e-27	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10463316	0.744	rs6579869	chr5:150763621	G/A	cg03212797	chr5:150827313	SLC36A1	-0.46	-6.02	-0.35	5.83e-9	Metabolite levels (Pyroglutamine);
CESC	trans	rs208520	1.000	rs28773210	chr6:66993566	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.84	9.14	0.49	1.65e-17	Exhaled nitric oxide output;
CESC	cis	rs1832871	0.672	rs9456289	chr6:158740347	G/A	cg07165851	chr6:158734300	TULP4	0.59	6.4	0.37	7.02e-10	Height;
CESC	trans	rs61931739	0.517	rs7313663	chr12:34417058	T/C	cg26384229	chr12:38710491	ALG10B	0.53	7.41	0.41	1.75e-12	Morning vs. evening chronotype;
CESC	cis	rs7639513	0.767	rs9861472	chr3:12707776	A/T	cg23032965	chr3:12705835	RAF1	-0.8	-11.46	-0.58	6.01e-25	Itch intensity from mosquito bite;
CESC	cis	rs7940866	0.903	rs1820353	chr11:130870765	A/G	cg12179176	chr11:130786555	SNX19	0.64	9.2	0.49	1.13e-17	Schizophrenia;
CESC	cis	rs7520050	0.966	rs6675946	chr1:46371774	G/T	cg03146154	chr1:46216737	IPP	-0.48	-6.19	-0.36	2.33e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs6426558	0.537	rs56219094	chr1:227340191	T/C	cg10327440	chr1:227177885	CDC42BPA	-0.47	-5.85	-0.34	1.48e-8	Neutrophil percentage of white cells;
CESC	cis	rs7552404	0.731	rs61770556	chr1:76421902	T/C	cg03433033	chr1:76189801	ACADM	0.62	5.93	0.34	9.18e-9	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs651907	0.557	rs12629658	chr3:101356535	A/G	cg12386194	chr3:101231763	SENP7	0.44	5.4	0.31	1.51e-7	Colorectal cancer;
CESC	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg02475777	chr4:1388615	CRIPAK	0.74	9.22	0.49	9.67e-18	Longevity;
CESC	trans	rs9650657	0.562	rs10090444	chr8:10745469	C/G	cg15556689	chr8:8085844	FLJ10661	0.59	7.33	0.41	2.73e-12	Neuroticism;
CESC	cis	rs735396	0.595	rs2258287	chr12:121454313	G/T	cg25281562	chr12:121454272	C12orf43	0.53	6.95	0.39	2.9e-11	N-glycan levels;
CESC	cis	rs6860806	0.531	rs270607	chr5:131649186	A/G	cg04518342	chr5:131593106	PDLIM4	0.35	5.06	0.3	7.79e-7	Breast cancer;
CESC	cis	rs7115242	0.800	rs10736487	chr11:116950232	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.67	5.82	0.34	1.71e-8	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
CESC	cis	rs3796352	1.000	rs71301814	chr3:53117663	G/A	cg12962167	chr3:53033115	SFMBT1	0.67	5.87	0.34	1.29e-8	Immune reponse to smallpox (secreted IL-2);
CESC	cis	rs873946	0.504	rs4880275	chr10:134576552	C/T	cg27297192	chr10:134578999	INPP5A	0.42	5.75	0.33	2.39e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs4862750	0.832	rs10007858	chr4:187877492	A/G	cg22105103	chr4:187893119	NA	0.48	6.91	0.39	3.67e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs3820068	0.603	rs67349836	chr1:15966176	T/C	cg16988262	chr1:15930761	NA	0.32	5.13	0.3	5.66e-7	Systolic blood pressure;
CESC	cis	rs4835473	0.932	rs17694797	chr4:144699965	T/C	cg25736465	chr4:144833511	NA	-0.33	-5.23	-0.31	3.48e-7	Immature fraction of reticulocytes;
CESC	cis	rs2279817	0.735	rs12067869	chr1:17989765	G/T	cg21791023	chr1:18019539	ARHGEF10L	-0.56	-7.36	-0.41	2.38e-12	Neuroticism;
CESC	cis	rs2842992	0.662	rs2273825	chr6:160211424	A/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.77	11.06	0.56	1.26e-23	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs10949834	0.529	rs150861	chr7:73524901	T/C	cg07137043	chr7:73588983	EIF4H	0.64	7.58	0.42	5.84e-13	Verbal memory performance (residualized delayed recall change);
CESC	cis	rs589448	0.902	rs642786	chr12:69758462	T/C	cg20891283	chr12:69753455	YEATS4	0.98	16.88	0.72	6.73e-44	Cerebrospinal fluid biomarker levels;
CESC	cis	rs17826219	0.714	rs11650821	chr17:28968150	T/C	cg19761014	chr17:28927070	LRRC37B2	0.86	6.49	0.37	4.09e-10	Body mass index;
CESC	trans	rs11039798	0.841	rs7950737	chr11:48590678	T/G	cg15704280	chr7:45808275	SEPT13	0.66	6.21	0.36	2.01e-9	Axial length;
CESC	cis	rs9902453	0.780	rs62068621	chr17:28170382	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	8.39	0.46	2.99e-15	Coffee consumption (cups per day);
CESC	cis	rs736408	0.540	rs4687637	chr3:52634092	C/T	cg18099408	chr3:52552593	STAB1	-0.34	-5.77	-0.33	2.17e-8	Bipolar disorder;
CESC	cis	rs611744	0.647	rs674391	chr8:109242803	A/T	cg21045802	chr8:109455806	TTC35	0.46	5.67	0.33	3.66e-8	Dupuytren's disease;
CESC	cis	rs9916302	0.904	rs11867312	chr17:37597748	C/T	cg15445000	chr17:37608096	MED1	0.41	6.74	0.38	9.67e-11	Glomerular filtration rate (creatinine);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg27613860	chr2:30369571	YPEL5	0.46	6.39	0.37	7.53e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs365132	0.934	rs251844	chr5:176476605	T/A	cg16309518	chr5:176445507	NA	-0.43	-6.3	-0.36	1.24e-9	Menarche and menopause (age at onset);Menopause (age at onset);
CESC	cis	rs7772486	0.790	rs7753833	chr6:146161432	C/A	cg23711669	chr6:146136114	FBXO30	0.89	13.01	0.62	2.86e-30	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2880765	0.835	rs6496027	chr15:86049988	C/T	cg10818794	chr15:86012489	AKAP13	-0.34	-5.19	-0.3	4.25e-7	Coronary artery disease;
CESC	cis	rs4604732	0.631	rs34443739	chr1:247626913	A/G	cg12754571	chr1:247694271	LOC148824;OR2C3	0.44	5.45	0.32	1.17e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs7945705	0.875	rs2568065	chr11:8889648	C/T	cg12365402	chr11:9010492	NRIP3	-0.32	-5.26	-0.31	3e-7	Hemoglobin concentration;
CESC	trans	rs61931739	0.500	rs56056630	chr12:34543465	T/C	cg26384229	chr12:38710491	ALG10B	0.53	7.41	0.41	1.74e-12	Morning vs. evening chronotype;
CESC	cis	rs801193	1.000	rs6958520	chr7:66151453	T/C	cg18876405	chr7:65276391	NA	0.54	7.18	0.4	6.97e-12	Aortic root size;
CESC	cis	rs7666738	0.830	rs17486413	chr4:99060544	G/T	cg05340658	chr4:99064831	C4orf37	0.82	12.2	0.6	1.84e-27	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4474465	0.850	rs7942371	chr11:78219975	A/G	cg27205649	chr11:78285834	NARS2	0.44	5.28	0.31	2.69e-7	Alzheimer's disease (survival time);
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg15065069	chr1:154974120	ZBTB7B	0.5	6.06	0.35	4.69e-9	Thyroid stimulating hormone;
CESC	cis	rs654950	0.806	rs7550496	chr1:42043834	G/A	cg06885757	chr1:42089581	HIVEP3	0.63	10.21	0.53	7.69e-21	Airway imaging phenotypes;
CESC	cis	rs1153858	0.725	rs74572151	chr15:45647526	T/G	cg14582100	chr15:45693742	SPATA5L1	0.44	6.25	0.36	1.61e-9	Homoarginine levels;
CESC	cis	rs9311474	1.000	rs7614727	chr3:52295895	C/T	cg18099408	chr3:52552593	STAB1	-0.31	-5.54	-0.32	7.14e-8	Electroencephalogram traits;
CESC	cis	rs7584330	0.657	rs10211024	chr2:238353776	A/T	cg14458575	chr2:238380390	NA	0.57	8.15	0.45	1.42e-14	Prostate cancer;
CESC	cis	rs10463316	0.894	rs1876619	chr5:150744773	G/C	cg03212797	chr5:150827313	SLC36A1	-0.51	-6.64	-0.38	1.79e-10	Metabolite levels (Pyroglutamine);
CESC	cis	rs35110281	0.837	rs2838343	chr21:45078035	C/T	cg01579765	chr21:45077557	HSF2BP	-0.56	-9.55	-0.51	9.17e-19	Mean corpuscular volume;
CESC	cis	rs7089973	0.604	rs11196941	chr10:116596258	A/G	cg23260525	chr10:116636907	FAM160B1	0.4	7.38	0.41	2.02e-12	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs10504229	0.593	rs17794451	chr8:58019217	C/T	cg05313129	chr8:58192883	C8orf71	-0.5	-5.05	-0.3	8.06e-7	Developmental language disorder (linguistic errors);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg13530817	chr7:72951610	BCL7B	0.47	6.59	0.38	2.3e-10	Fibrinogen levels;
CESC	cis	rs7520050	0.933	rs6666743	chr1:46311275	C/T	cg24296786	chr1:45957014	TESK2	0.42	5.42	0.32	1.33e-7	Red blood cell count;Reticulocyte count;
CESC	cis	rs710216	0.917	rs1681859	chr1:43411829	G/A	cg03128534	chr1:43423976	SLC2A1	0.56	6.28	0.36	1.38e-9	Red cell distribution width;
CESC	cis	rs3008870	0.755	rs1535365	chr1:67497613	T/C	cg02640540	chr1:67518911	SLC35D1	0.44	5.36	0.31	1.84e-7	Lymphocyte percentage of white cells;
CESC	cis	rs1215050	0.791	rs7434393	chr4:98768576	T/C	cg05340658	chr4:99064831	C4orf37	0.53	7.03	0.4	1.75e-11	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs644799	1.000	rs487609	chr11:95588102	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.68	8.41	0.46	2.59e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs9457247	1.000	rs4710147	chr6:167374239	G/A	cg23791538	chr6:167370224	RNASET2	0.6	8.47	0.46	1.73e-15	Crohn's disease;
CESC	cis	rs1801251	1.000	rs6717841	chr2:233590255	C/T	cg08000102	chr2:233561755	GIGYF2	0.69	9.56	0.51	8.52e-19	Coronary artery disease;
CESC	cis	rs1008375	0.966	rs10939755	chr4:17693755	T/C	cg15017067	chr4:17643749	FAM184B	0.36	5.05	0.3	8.11e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs17253792	0.822	rs79262019	chr14:56092704	A/G	cg01858014	chr14:56050164	KTN1	-0.83	-7.03	-0.4	1.7e-11	Putamen volume;
CESC	cis	rs4144743	0.759	rs34251886	chr17:45320299	G/T	cg18085866	chr17:45331354	ITGB3	-0.62	-5.53	-0.32	7.54e-8	Body mass index;
CESC	cis	rs34638657	0.732	rs12597171	chr16:82200119	A/G	cg09439754	chr16:82129088	HSD17B2	0.38	6.42	0.37	6.11e-10	Lung adenocarcinoma;
CESC	cis	rs10256972	0.967	rs4723338	chr7:1036241	A/G	cg07930192	chr7:1003750	NA	0.42	5.79	0.34	1.96e-8	Longevity;Endometriosis;
CESC	cis	rs1448094	0.512	rs11117057	chr12:86248546	C/T	cg00310523	chr12:86230176	RASSF9	0.35	5.46	0.32	1.1e-7	Major depressive disorder;
CESC	cis	rs11098499	0.865	rs28845498	chr4:120405186	G/A	cg24375607	chr4:120327624	NA	0.45	5.52	0.32	8.1e-8	Corneal astigmatism;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg13481374	chr9:34318769	KIF24	-0.42	-6.07	-0.35	4.38e-9	Systemic lupus erythematosus;
CESC	cis	rs4523957	0.928	rs11657644	chr17:2175210	C/G	cg16513277	chr17:2031491	SMG6	-0.58	-7.64	-0.42	3.93e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs7000551	0.689	rs2122878	chr8:22311916	T/C	cg12081754	chr8:22256438	SLC39A14	0.4	5.15	0.3	5.07e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CESC	cis	rs1552244	1.000	rs9879080	chr3:10084224	C/T	cg00149659	chr3:10157352	C3orf10	0.74	9.17	0.49	1.36e-17	Alzheimer's disease;
CESC	cis	rs7552404	0.960	rs4949877	chr1:76201668	C/G	cg22875332	chr1:76189707	ACADM	0.66	7.95	0.44	5.45e-14	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs6120849	0.663	rs11698868	chr20:33549946	C/T	cg06115741	chr20:33292138	TP53INP2	0.53	5.04	0.3	8.81e-7	Protein C levels;
CESC	cis	rs7772486	0.875	rs854148	chr6:146310979	G/C	cg05347473	chr6:146136440	FBXO30	0.56	7.37	0.41	2.14e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2576037	0.796	rs2571020	chr18:44584189	A/T	cg19077165	chr18:44547161	KATNAL2	0.53	7.36	0.41	2.29e-12	Personality dimensions;
CESC	cis	rs1568889	0.838	rs7131379	chr11:28085789	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.8	13.5	0.64	5.83e-32	Bipolar disorder;
CESC	cis	rs3768617	0.510	rs6424888	chr1:183085696	C/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.81	-12.68	-0.61	4e-29	Fuchs's corneal dystrophy;
CESC	cis	rs9611565	0.659	rs28530678	chr22:41934961	G/C	cg03806693	chr22:41940476	POLR3H	-1.23	-14.8	-0.67	1.54e-36	Vitiligo;
CESC	cis	rs2425143	1.000	rs6060643	chr20:34449851	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.66	5.69	0.33	3.4e-8	Blood protein levels;
CESC	cis	rs1800469	1.000	rs2241714	chr19:41869392	C/T	cg09537434	chr19:41945824	ATP5SL	0.63	7.74	0.43	2.12e-13	Colorectal cancer;
CESC	cis	rs17641971	0.599	rs818555	chr8:49999211	A/G	cg00325661	chr8:49890786	NA	-0.48	-6.81	-0.39	6.59e-11	Blood metabolite levels;
CESC	cis	rs854765	0.718	rs7224815	chr17:17845800	A/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.42	5.17	0.3	4.66e-7	Total body bone mineral density;
CESC	cis	rs6502050	0.830	rs7219036	chr17:80161119	T/C	cg23985595	chr17:80112537	CCDC57	-0.41	-6.53	-0.37	3.39e-10	Life satisfaction;
CESC	cis	rs10504229	1.000	rs66936919	chr8:58172868	C/G	cg14926445	chr8:58193284	C8orf71	-0.49	-5.29	-0.31	2.6e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs796364	0.806	rs1509832	chr2:200874443	G/T	cg23649088	chr2:200775458	C2orf69	0.6	5.44	0.32	1.23e-7	Schizophrenia;
CESC	cis	rs561341	1.000	rs521919	chr17:30298039	G/T	cg00745463	chr17:30367425	LRRC37B	-0.68	-6.71	-0.38	1.19e-10	Hip circumference adjusted for BMI;
CESC	cis	rs12618769	0.625	rs72819982	chr2:99043337	A/G	cg10123293	chr2:99228465	UNC50	0.38	5.04	0.3	8.52e-7	Bipolar disorder;
CESC	cis	rs7809950	1.000	rs10251808	chr7:107120453	G/A	cg23024343	chr7:107201750	COG5	-0.44	-6.2	-0.36	2.11e-9	Coronary artery disease;
CESC	cis	rs7666738	0.830	rs10031190	chr4:98908683	C/A	cg17366294	chr4:99064904	C4orf37	0.57	7.93	0.44	6.16e-14	Colonoscopy-negative controls vs population controls;
CESC	cis	rs16854884	0.710	rs1867607	chr3:143809274	T/C	cg06585982	chr3:143692056	C3orf58	0.47	6.15	0.35	2.83e-9	Economic and political preferences (feminism/equality);
CESC	trans	rs4942242	0.663	rs9525816	chr13:44223898	A/G	cg19169023	chr15:41853346	TYRO3	-0.59	-7.22	-0.41	5.54e-12	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs8177179	1.000	rs8177179	chr3:133463457	G/A	cg18769074	chr3:133464867	TF	0.3	5.75	0.33	2.42e-8	Iron status biomarkers (transferrin levels);
CESC	cis	rs4555082	0.834	rs2816653	chr14:105713973	A/G	cg27165867	chr14:105738592	BRF1	-0.55	-6.17	-0.35	2.55e-9	Mean platelet volume;Platelet distribution width;
CESC	cis	rs4819052	0.851	rs58644915	chr21:46669912	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.92	13.63	0.64	2.09e-32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs7666738	0.830	rs3846444	chr4:99032888	T/C	cg24818145	chr4:99064322	C4orf37	0.39	5.09	0.3	6.95e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9467773	0.620	rs3800303	chr6:26598188	A/G	cg24633756	chr6:26577808	NA	0.38	5.76	0.33	2.33e-8	Intelligence (multi-trait analysis);
CESC	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg26354017	chr1:205819088	PM20D1	-0.75	-10.0	-0.52	3.59e-20	Menarche (age at onset);
CESC	cis	rs75477785	0.590	rs72649913	chr1:210077087	G/A	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.96	6.81	0.39	6.53e-11	Cleft lip with or without cleft palate;
CESC	cis	rs7179456	0.544	rs2555357	chr15:59087115	A/G	cg05156742	chr15:59063176	FAM63B	0.78	11.22	0.57	3.54e-24	Asperger disorder;
CESC	cis	rs116095464	0.510	rs7723883	chr5:270798	T/C	cg22496380	chr5:211416	CCDC127	-0.73	-8.42	-0.46	2.47e-15	Breast cancer;
CESC	cis	rs172166	0.694	rs1631552	chr6:28089699	C/A	cg19592336	chr6:28129416	ZNF389	0.48	7.09	0.4	1.19e-11	Cardiac Troponin-T levels;
CESC	cis	rs9467711	0.606	rs67509210	chr6:26354100	G/T	cg12826209	chr6:26865740	GUSBL1	0.62	5.31	0.31	2.36e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs17253792	0.730	rs77079997	chr14:56155250	A/G	cg01858014	chr14:56050164	KTN1	-0.82	-6.79	-0.39	7.15e-11	Putamen volume;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg10821925	chr12:29533733	ERGIC2	-0.46	-6.09	-0.35	3.89e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs3617	0.539	rs9880619	chr3:52953055	G/A	cg13284614	chr3:52569169	NT5DC2;LOC440957	-0.32	-5.29	-0.31	2.55e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
CESC	cis	rs875971	0.929	rs34406470	chr7:65929956	A/G	cg12463550	chr7:65579703	CRCP	0.56	6.93	0.39	3.29e-11	Aortic root size;
CESC	cis	rs10504229	1.000	rs73609764	chr8:58192971	G/A	cg24829409	chr8:58192753	C8orf71	-0.76	-9.93	-0.52	5.87e-20	Developmental language disorder (linguistic errors);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07067085	chr12:120638762	RPLP0	0.57	6.68	0.38	1.37e-10	Gut microbiome composition (summer);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg16109817	chr1:16162209	FLJ37453	-0.45	-6.35	-0.36	9.42e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs2425143	1.000	rs2425078	chr20:34298163	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.65	5.95	0.34	8.42e-9	Blood protein levels;
CESC	cis	rs10504229	0.728	rs56180705	chr8:58149734	T/C	cg22535103	chr8:58192502	C8orf71	-0.92	-10.13	-0.53	1.3e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs2204008	0.807	rs12816136	chr12:38456037	A/G	cg13010199	chr12:38710504	ALG10B	-0.43	-5.57	-0.32	6.22e-8	Bladder cancer;
CESC	cis	rs7264396	0.563	rs2050729	chr20:34294409	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.89	10.7	0.55	1.88e-22	Total cholesterol levels;
CESC	cis	rs941408	0.515	rs4624312	chr19:2774460	T/C	cg06609049	chr19:2785107	THOP1	0.96	14.86	0.67	9.75e-37	Total cholesterol levels;
CESC	cis	rs7224737	1.000	rs11079034	chr17:40288890	G/A	cg20291162	chr17:40259547	DHX58	-0.41	-5.57	-0.32	6.12e-8	Fibrinogen levels;
CESC	trans	rs7902708	0.920	rs12268596	chr10:54421876	G/A	cg26219051	chr22:43739629	SCUBE1	-0.48	-6.08	-0.35	4.13e-9	Bone properties (heel);
CESC	cis	rs9479482	1.000	rs9478354	chr6:150334366	G/A	cg03788504	chr6:150331562	NA	-0.4	-7.64	-0.42	4.07e-13	Alopecia areata;
CESC	cis	rs6570726	0.846	rs870491	chr6:145933390	T/G	cg05347473	chr6:146136440	FBXO30	0.5	6.57	0.37	2.6e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs992157	0.835	rs4674282	chr2:219144230	A/T	cg00012203	chr2:219082015	ARPC2	-0.73	-9.38	-0.5	3.16e-18	Colorectal cancer;
CESC	cis	rs7267979	0.789	rs6083810	chr20:25329759	T/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.7	-11.59	-0.58	2.18e-25	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs9649213	0.593	rs34129434	chr7:97926464	C/T	cg21770322	chr7:97807741	LMTK2	0.54	8.13	0.45	1.67e-14	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs801193	1.000	rs3857688	chr7:66127806	G/A	cg11764359	chr7:65958608	NA	-0.68	-8.81	-0.48	1.68e-16	Aortic root size;
CESC	cis	rs2011503	0.769	rs72999059	chr19:19378245	A/C	cg11584989	chr19:19387371	SF4	0.63	7.58	0.42	5.75e-13	Bipolar disorder;
CESC	cis	rs4803468	1.000	rs10853751	chr19:41903220	G/A	cg14132834	chr19:41945861	ATP5SL	-0.65	-8.13	-0.45	1.69e-14	Height;
CESC	cis	rs13256369	0.802	rs11249883	chr8:8561537	G/A	cg00074818	chr8:8560427	CLDN23	0.36	5.24	0.31	3.32e-7	Obesity-related traits;
CESC	cis	rs901683	1.000	rs35750365	chr10:46013143	A/G	cg16031567	chr10:46195673	NA	-0.81	-5.4	-0.32	1.45e-7	Red blood cell traits;Mean corpuscular volume;
CESC	cis	rs5753618	0.583	rs5749279	chr22:31854209	A/G	cg00478049	chr22:31556069	RNF185	-0.41	-5.21	-0.3	3.82e-7	Colorectal cancer;
CESC	cis	rs3126085	0.935	rs11204952	chr1:152227321	G/A	cg03465714	chr1:152285911	FLG	-0.42	-5.19	-0.3	4.2e-7	Atopic dermatitis;
CESC	cis	rs9549367	0.789	rs57747440	chr13:113894750	C/A	cg18105134	chr13:113819100	PROZ	-0.66	-7.97	-0.44	4.85e-14	Platelet distribution width;
CESC	cis	rs1538970	0.962	rs4660849	chr1:45819872	A/G	cg03146154	chr1:46216737	IPP	-0.45	-5.39	-0.31	1.54e-7	Platelet count;
CESC	cis	rs9815354	0.812	rs73071358	chr3:41830487	G/A	cg03022575	chr3:42003672	ULK4	0.7	6.04	0.35	5.26e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs1552244	0.938	rs34750074	chr3:10091740	G/A	cg00166722	chr3:10149974	C3orf24	0.49	6.08	0.35	4.1e-9	Alzheimer's disease;
CESC	cis	rs1344694	0.566	rs13029765	chr2:216894976	A/T	cg25588852	chr2:216877276	MREG	-0.35	-5.69	-0.33	3.33e-8	Alcohol dependence;
CESC	cis	rs10733682	0.524	rs10987418	chr9:129462563	A/G	cg00232160	chr9:129468157	NA	0.41	6.58	0.37	2.45e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs780096	0.546	rs1104	chr2:27599875	T/G	cg24768116	chr2:27665128	KRTCAP3	-0.29	-5.44	-0.32	1.24e-7	Total body bone mineral density;
CESC	trans	rs958685	0.716	rs765871	chr2:70708357	T/C	cg20996124	chr1:1144203	NA	-0.41	-6.07	-0.35	4.5e-9	Hand grip strength;
CESC	cis	rs2576037	0.526	rs538221	chr18:44375111	G/A	cg19077165	chr18:44547161	KATNAL2	-0.52	-7.67	-0.43	3.35e-13	Personality dimensions;
CESC	cis	rs6500602	0.727	rs10451135	chr16:4580214	T/C	cg08645402	chr16:4508243	NA	0.51	8.34	0.46	4.21e-15	Schizophrenia;
CESC	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.61	6.89	0.39	3.99e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7130144	0.686	rs7936714	chr11:130434295	T/C	cg26307797	chr11:130446613	NA	-0.59	-5.42	-0.32	1.31e-7	Urate levels in lean individuals;
CESC	cis	rs9951602	0.920	rs3859334	chr18:76684193	G/A	cg00806245	chr18:76673096	NA	-0.53	-6.11	-0.35	3.58e-9	Obesity-related traits;
CESC	cis	rs10781543	0.839	rs6560632	chr9:139371786	A/C	cg14019695	chr9:139328340	INPP5E	0.38	5.77	0.33	2.19e-8	Monocyte percentage of white cells;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12683467	chr3:197686956	IQCG;LMLN	0.59	6.18	0.35	2.36e-9	Gut microbiome composition (summer);
CESC	cis	rs1153858	1.000	rs66714503	chr15:45648038	G/C	cg21132104	chr15:45694354	SPATA5L1	0.84	11.4	0.57	9.5e-25	Homoarginine levels;
CESC	cis	rs9300255	0.679	rs28583837	chr12:123863620	G/A	cg00376283	chr12:123451042	ABCB9	-0.58	-5.97	-0.34	7.65e-9	Neutrophil percentage of white cells;
CESC	cis	rs769267	0.930	rs4808957	chr19:19567248	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	7.45	0.42	1.34e-12	Tonsillectomy;
CESC	cis	rs854765	0.724	rs2955371	chr17:17967397	G/A	cg04398451	chr17:18023971	MYO15A	0.69	9.97	0.52	4.48e-20	Total body bone mineral density;
CESC	cis	rs5758659	1.000	rs134873	chr22:42657566	T/G	cg04733989	chr22:42467013	NAGA	0.42	5.74	0.33	2.52e-8	Cognitive function;
CESC	cis	rs6500602	0.627	rs1641866	chr16:4593040	A/C	cg08645402	chr16:4508243	NA	0.46	6.87	0.39	4.45e-11	Schizophrenia;
CESC	cis	rs4481887	0.927	rs6587445	chr1:248440915	A/G	cg00666640	chr1:248458726	OR2T12	0.39	6.6	0.38	2.23e-10	Common traits (Other);
CESC	cis	rs4865169	0.783	rs7668814	chr4:57825190	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.53	7.59	0.42	5.47e-13	Breast cancer;
CESC	cis	rs9915657	0.870	rs759499	chr17:70133177	C/T	cg09344028	chr17:70110421	NA	0.33	5.85	0.34	1.41e-8	Thyroid hormone levels;
CESC	cis	rs597539	0.616	rs473997	chr11:68639481	C/T	cg21963583	chr11:68658836	MRPL21	0.43	5.85	0.34	1.43e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs9875589	0.957	rs62234598	chr3:13964610	G/A	cg19554555	chr3:13937349	NA	0.53	6.68	0.38	1.36e-10	Ovarian reserve;
CESC	cis	rs2721195	0.719	rs4925812	chr8:145808035	C/T	cg26752003	chr8:145688521	CYHR1	-0.43	-5.5	-0.32	8.8e-8	Age at first birth;
CESC	cis	rs1799949	1.000	rs2271574	chr17:41327648	T/C	cg23758822	chr17:41437982	NA	1.05	16.21	0.71	1.53e-41	Menopause (age at onset);
CESC	cis	rs769267	0.931	rs2965197	chr19:19470910	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.43	-5.38	-0.31	1.64e-7	Tonsillectomy;
CESC	trans	rs7827545	0.545	rs1867062	chr8:135559079	G/A	cg24633756	chr6:26577808	NA	-0.53	-6.05	-0.35	5e-9	Hypertension (SNP x SNP interaction);
CESC	cis	rs1552244	1.000	rs17032414	chr3:10158302	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.87	12.2	0.6	1.79e-27	Alzheimer's disease;
CESC	cis	rs12410462	0.582	rs2872251	chr1:227647723	G/A	cg04117972	chr1:227635322	NA	0.62	6.0	0.35	6.56e-9	Major depressive disorder;
CESC	cis	rs7188697	0.922	rs37034	chr16:58551360	C/G	cg21335942	chr16:58549945	SETD6	0.46	5.41	0.32	1.44e-7	QT interval;
CESC	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg23708337	chr7:1209742	NA	0.54	5.38	0.31	1.61e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg07092213	chr7:1199455	ZFAND2A	-0.5	-5.71	-0.33	3.07e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs4727027	0.901	rs4727019	chr7:148822266	A/G	cg23583168	chr7:148888333	NA	-0.74	-10.66	-0.55	2.51e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs6032067	0.777	rs80323300	chr20:43785287	T/C	cg10761708	chr20:43804764	PI3	0.56	6.55	0.37	3.01e-10	Blood protein levels;
CESC	cis	rs853679	0.546	rs200989	chr6:27816442	A/G	cg02228804	chr6:27775720	HIST1H2AI;HIST1H2BL	0.64	5.48	0.32	9.84e-8	Depression;
CESC	cis	rs6460942	1.000	rs117657017	chr7:12318891	T/C	cg06484146	chr7:12443880	VWDE	-0.81	-8.78	-0.47	2.13e-16	Coronary artery disease;
CESC	cis	rs853679	0.517	rs9380047	chr6:28037893	G/T	cg17949981	chr6:28129498	ZNF389	0.44	5.49	0.32	9.34e-8	Depression;
CESC	cis	rs2952156	1.000	rs2952156	chr17:37876835	A/G	cg00129232	chr17:37814104	STARD3	-0.68	-8.52	-0.46	1.25e-15	Asthma;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27026005	chr19:50380748	TBC1D17;AKT1S1	0.55	6.3	0.36	1.26e-9	Gut microbiome composition (summer);
CESC	cis	rs56104184	1.000	rs56104184	chr19:49370310	C/T	cg15549821	chr19:49342101	PLEKHA4	-0.56	-6.57	-0.37	2.68e-10	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	cis	rs5769765	0.825	rs9616780	chr22:50292763	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.45	-5.2	-0.3	4.01e-7	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09256617	chr11:44587148	CD82	0.57	6.62	0.38	1.99e-10	Gut microbiome composition (summer);
CESC	trans	rs453301	0.571	rs330054	chr8:9088291	G/A	cg06636001	chr8:8085503	FLJ10661	-0.53	-6.82	-0.39	6.1e-11	Joint mobility (Beighton score);
CESC	cis	rs9611565	1.000	rs5751086	chr22:41768862	C/T	cg17376030	chr22:41985996	PMM1	0.5	6.17	0.35	2.52e-9	Vitiligo;
CESC	cis	rs11252926	0.537	rs61836851	chr10:447231	T/C	cg18196295	chr10:418757	DIP2C	0.52	7.01	0.4	2.01e-11	Psychosis in Alzheimer's disease;
CESC	cis	rs6089584	0.850	rs6089634	chr20:60632566	T/C	cg06108461	chr20:60628389	TAF4	-0.92	-14.01	-0.65	9.73e-34	Body mass index;
CESC	cis	rs10861342	1.000	rs10861357	chr12:105544254	C/T	cg23923672	chr12:105501055	KIAA1033	0.73	5.51	0.32	8.58e-8	IgG glycosylation;
CESC	cis	rs826838	0.935	rs1684406	chr12:39127265	A/G	cg26384229	chr12:38710491	ALG10B	-0.67	-10.95	-0.56	2.81e-23	Heart rate;
CESC	cis	rs10504229	1.000	rs67895971	chr8:58177994	A/G	cg22535103	chr8:58192502	C8orf71	-1.05	-13.27	-0.63	3.63e-31	Developmental language disorder (linguistic errors);
CESC	cis	rs4689388	0.926	rs11725500	chr4:6293919	C/G	cg25554036	chr4:6271136	WFS1	0.51	8.37	0.46	3.31e-15	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs4722166	0.630	rs1581497	chr7:22779503	C/A	cg26061582	chr7:22766209	IL6	0.51	5.55	0.32	6.82e-8	Lung cancer;
CESC	cis	rs11098499	0.754	rs1511017	chr4:120250805	G/A	cg09307838	chr4:120376055	NA	0.77	10.49	0.54	9.15e-22	Corneal astigmatism;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23506964	chr4:56413211	CLOCK	0.55	6.1	0.35	3.7e-9	Gut microbiome composition (summer);
CESC	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg10295955	chr4:187884368	NA	-1.04	-21.25	-0.79	3.44e-59	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6499129	0.558	rs13334205	chr16:67581883	A/G	cg26727032	chr16:67993705	SLC12A4	-0.61	-7.42	-0.41	1.56e-12	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs116095464	0.558	rs61689490	chr5:224904	T/C	cg12570787	chr5:219185	SDHA;CCDC127	0.52	5.65	0.33	4.24e-8	Breast cancer;
CESC	cis	rs7512552	0.839	rs11581351	chr1:150440200	G/C	cg15654264	chr1:150340011	RPRD2	0.39	5.1	0.3	6.55e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs6952808	0.656	rs11764212	chr7:2067593	C/A	cg21782813	chr7:2030301	MAD1L1	0.53	7.68	0.43	2.99e-13	Bipolar disorder and schizophrenia;
CESC	cis	rs67311347	1.000	rs954589	chr3:40444545	C/T	cg09455208	chr3:40491958	NA	0.5	8.28	0.45	6.1e-15	Renal cell carcinoma;
CESC	cis	rs617219	0.889	rs1664551	chr5:78440096	C/T	cg22188827	chr5:78429774	NA	-0.42	-5.05	-0.3	8.28e-7	Betaine levels in individuals undergoing cardiac evaluation;
CESC	cis	rs12136530	0.625	rs61334679	chr1:19754993	G/A	cg01832549	chr1:19774989	CAPZB	-0.5	-6.59	-0.38	2.39e-10	Lead levels in blood;
CESC	cis	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08180459	chr4:100870737	LOC256880;H2AFZ	-0.58	-6.51	-0.37	3.77e-10	Gut microbiome composition (summer);
CESC	cis	rs9660180	0.935	rs9786942	chr1:1759213	A/G	cg05132306	chr1:1846340	CALML6	-0.3	-6.37	-0.36	8.4e-10	Body mass index;
CESC	cis	rs4835473	0.897	rs11727223	chr4:144628243	C/T	cg25736465	chr4:144833511	NA	0.43	6.62	0.38	1.95e-10	Immature fraction of reticulocytes;
CESC	cis	rs6062302	0.549	rs4809586	chr20:62249402	C/T	cg09650180	chr20:62225654	GMEB2	-0.82	-9.32	-0.5	4.63e-18	Glioblastoma;
CESC	cis	rs12930096	0.878	rs12917676	chr16:11680268	A/G	cg07439791	chr16:11680400	LITAF	0.66	6.06	0.35	4.76e-9	QT interval;
CESC	cis	rs9649213	0.574	rs7802560	chr7:97903806	A/G	cg24562669	chr7:97807699	LMTK2	-0.49	-7.06	-0.4	1.49e-11	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs4555082	0.874	rs2816621	chr14:105732762	A/T	cg10792982	chr14:105748885	BRF1	0.42	5.33	0.31	2.11e-7	Mean platelet volume;Platelet distribution width;
CESC	cis	rs7599312	0.532	rs1531788	chr2:213394320	C/T	cg20637307	chr2:213403960	ERBB4	0.39	5.42	0.32	1.34e-7	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs10504229	0.595	rs76447299	chr8:58117395	A/G	cg24829409	chr8:58192753	C8orf71	-0.58	-7.2	-0.4	6.31e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs7264396	0.580	rs6119655	chr20:34412049	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.62	7.28	0.41	3.81e-12	Total cholesterol levels;
CESC	cis	rs533581	0.866	rs2968474	chr16:88970566	A/G	cg16701003	chr16:89028210	CBFA2T3	-0.49	-6.7	-0.38	1.23e-10	Social autistic-like traits;
CESC	cis	rs12476592	0.602	rs1255	chr2:63825934	T/C	cg17519650	chr2:63277830	OTX1	-0.45	-5.12	-0.3	5.75e-7	Childhood ear infection;
CESC	cis	rs854765	0.547	rs9913277	chr17:17919749	G/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.57	7.61	0.42	4.9e-13	Total body bone mineral density;
CESC	cis	rs7949030	0.626	rs11231141	chr11:62326265	T/C	cg13298116	chr11:62369859	EML3;MTA2	0.66	9.93	0.52	5.83e-20	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs7216064	0.954	rs4790974	chr17:65951107	A/T	cg07042672	chr17:66097459	LOC651250	0.62	7.67	0.43	3.21e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs7828089	0.582	rs7825938	chr8:22266866	G/A	cg23129673	chr8:22266227	SLC39A14	0.36	5.39	0.31	1.56e-7	Verbal declarative memory;
CESC	cis	rs9309473	1.000	rs6756987	chr2:73687077	G/T	cg20560298	chr2:73613845	ALMS1	-0.46	-6.18	-0.36	2.36e-9	Metabolite levels;
CESC	cis	rs780096	0.545	rs6716894	chr2:27583273	A/G	cg22903471	chr2:27725779	GCKR	-0.52	-7.3	-0.41	3.33e-12	Total body bone mineral density;
CESC	cis	rs920590	0.721	rs61180388	chr8:19670214	G/C	cg03894339	chr8:19674705	INTS10	0.68	7.77	0.43	1.72e-13	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs752010	0.619	rs7539238	chr1:42113572	A/C	cg06885757	chr1:42089581	HIVEP3	0.62	9.75	0.51	2.22e-19	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs7959452	0.868	rs10878967	chr12:69740869	T/C	cg14784868	chr12:69753453	YEATS4	0.6	8.56	0.47	9.5e-16	Blood protein levels;
CESC	cis	rs3008870	0.755	rs10789219	chr1:67417742	A/C	cg08660285	chr1:67390436	MIER1;WDR78	0.63	8.38	0.46	3.04e-15	Lymphocyte percentage of white cells;
CESC	cis	rs9623117	0.915	rs7290587	chr22:40482752	G/A	cg05033341	chr22:40419857	FAM83F	-0.47	-5.28	-0.31	2.67e-7	Prostate cancer (SNP x SNP interaction);Prostate cancer;
CESC	cis	rs561341	1.000	rs56903735	chr17:30254393	T/A	cg12193833	chr17:30244370	NA	-0.61	-6.12	-0.35	3.31e-9	Hip circumference adjusted for BMI;
CESC	cis	rs1799949	1.000	rs8176296	chr17:41203591	T/C	cg23758822	chr17:41437982	NA	1.0	14.95	0.68	4.7e-37	Menopause (age at onset);
CESC	cis	rs4812048	0.793	rs6070693	chr20:57589516	C/T	cg14073986	chr20:57617431	SLMO2	0.73	5.8	0.34	1.92e-8	Mean platelet volume;
CESC	cis	rs977987	0.778	rs11858992	chr16:75411445	A/C	cg03315344	chr16:75512273	CHST6	0.4	5.74	0.33	2.65e-8	Dupuytren's disease;
CESC	cis	rs2075371	1.000	rs1862047	chr7:133978078	G/C	cg11752832	chr7:134001865	SLC35B4	0.54	7.09	0.4	1.19e-11	Mean platelet volume;
CESC	cis	rs7914558	0.966	rs2065977	chr10:104729415	C/T	cg08650961	chr10:104748594	CNNM2	0.31	5.05	0.3	8.15e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs1144333	1.000	rs76192904	chr1:76359995	C/T	cg10523679	chr1:76189770	ACADM	0.62	5.93	0.34	9.62e-9	Attention function in attention deficit hyperactive disorder;
CESC	cis	rs35110281	0.667	rs4819285	chr21:45118970	C/T	cg21573476	chr21:45109991	RRP1B	0.53	7.91	0.44	7.05e-14	Mean corpuscular volume;
CESC	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg24642844	chr7:1081250	C7orf50	-0.77	-9.41	-0.5	2.48e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs208520	0.526	rs6455072	chr6:66797215	A/G	cg07460842	chr6:66804631	NA	-1.11	-27.05	-0.86	3.36e-78	Exhaled nitric oxide output;
CESC	cis	rs40363	0.720	rs4453493	chr16:3533881	T/C	cg22508957	chr16:3507546	NAT15	-0.53	-7.83	-0.43	1.17e-13	Tuberculosis;
CESC	cis	rs79349575	0.721	rs4794004	chr17:47038471	C/T	cg16584676	chr17:46985605	UBE2Z	0.47	5.88	0.34	1.26e-8	Type 2 diabetes;
CESC	cis	rs589448	0.902	rs2603089	chr12:69776800	C/T	cg22834771	chr12:69754056	YEATS4	0.55	7.38	0.41	2.08e-12	Cerebrospinal fluid biomarker levels;
CESC	trans	rs9393777	0.920	rs13191227	chr6:27390115	G/C	cg06606381	chr12:133084897	FBRSL1	-1.12	-8.34	-0.46	4.21e-15	Intelligence (multi-trait analysis);
CESC	cis	rs9443189	0.703	rs2748950	chr6:76442985	A/G	cg01950844	chr6:76311363	SENP6	-0.61	-6.83	-0.39	5.64e-11	Prostate cancer;
CESC	cis	rs3820928	0.874	rs10166456	chr2:227900113	G/A	cg05526886	chr2:227700861	RHBDD1	-0.44	-5.59	-0.32	5.74e-8	Pulmonary function;
CESC	cis	rs8062405	0.754	rs149299	chr16:28485141	T/C	cg08761264	chr16:28874980	SH2B1	-0.44	-5.22	-0.31	3.59e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg06751603	chr19:11152063	SMARCA4	0.51	6.69	0.38	1.29e-10	Fibrinogen levels;
CESC	cis	rs2243480	1.000	rs313799	chr7:65494330	A/G	cg12463550	chr7:65579703	CRCP	0.72	5.92	0.34	9.68e-9	Diabetic kidney disease;
CESC	cis	rs4141404	0.787	rs11913992	chr22:31585220	G/A	cg13145458	chr22:31556086	RNF185	0.48	6.03	0.35	5.34e-9	Paclitaxel-induced neuropathy;
CESC	cis	rs8077577	0.895	rs16960996	chr17:18110559	A/G	cg16794390	chr17:18148240	FLII	0.41	5.64	0.33	4.37e-8	Obesity-related traits;
CESC	cis	rs9814567	1.000	rs6769885	chr3:134286913	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.45	-6.1	-0.35	3.7e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs1511802	0.666	rs6835646	chr4:187123519	T/C	cg24794857	chr4:187113578	CYP4V2	0.47	5.87	0.34	1.32e-8	Blood protein levels;
CESC	cis	rs116095464	1.000	rs7723693	chr5:306032	G/A	cg22857025	chr5:266934	NA	-1.15	-9.5	-0.5	1.31e-18	Breast cancer;
CESC	trans	rs1908814	0.516	rs11250178	chr8:11800234	A/C	cg15556689	chr8:8085844	FLJ10661	0.52	6.52	0.37	3.57e-10	Neuroticism;
CESC	cis	rs7811142	0.830	rs75636500	chr7:99947657	C/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.72	5.99	0.35	6.66e-9	Platelet count;
CESC	cis	rs4819052	0.851	rs4819042	chr21:46660072	A/G	cg11663144	chr21:46675770	NA	-0.63	-10.02	-0.52	3.12e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs1728785	0.901	rs698711	chr16:68561955	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.59	7.23	0.41	5.24e-12	Ulcerative colitis;
CESC	cis	rs6582630	0.555	rs11181657	chr12:38381858	T/C	cg13010199	chr12:38710504	ALG10B	-0.46	-5.95	-0.34	8.29e-9	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs4555082	0.874	rs2142190	chr14:105719306	G/A	cg06808227	chr14:105710500	BRF1	-0.54	-6.05	-0.35	4.99e-9	Mean platelet volume;Platelet distribution width;
CESC	cis	rs8111998	0.625	rs57665772	chr19:22764877	A/G	cg19914732	chr19:22715077	NA	-0.37	-5.09	-0.3	6.68e-7	Corneal structure;
CESC	cis	rs7618915	0.571	rs6798246	chr3:52599922	G/A	cg18337363	chr3:52569053	NT5DC2	0.29	5.03	0.3	8.89e-7	Bipolar disorder;
CESC	trans	rs7839040	0.698	rs13282879	chr8:82928431	A/G	cg14472086	chr9:107730925	NA	-0.47	-6.33	-0.36	1.02e-9	Response to methotrexate in juvenile idiopathic arthritis;
CESC	cis	rs477895	0.653	rs34113693	chr11:63900123	G/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.93	10.18	0.53	9.01e-21	Mean platelet volume;
CESC	cis	rs2070677	0.668	rs7899159	chr10:135431451	C/T	cg20169779	chr10:135381914	SYCE1	-0.75	-8.81	-0.48	1.65e-16	Gout;
CESC	cis	rs7000551	0.751	rs2469755	chr8:22360212	G/A	cg12081754	chr8:22256438	SLC39A14	0.39	5.22	0.31	3.7e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CESC	cis	rs6089584	0.528	rs881994	chr20:60623931	G/A	cg24733560	chr20:60626293	TAF4	0.48	7.12	0.4	1.01e-11	Body mass index;
CESC	cis	rs3816788	0.620	rs11783414	chr8:21773384	A/G	cg17168535	chr8:21777572	XPO7	-0.6	-9.18	-0.49	1.29e-17	Lung cancer in ever smokers;
CESC	cis	rs28374715	0.609	rs8043237	chr15:41514298	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.81	-10.3	-0.53	3.78e-21	Ulcerative colitis;
CESC	cis	rs3096299	0.692	rs4785565	chr16:89515759	T/C	cg02034447	chr16:89574710	SPG7	0.46	5.81	0.34	1.79e-8	Multiple myeloma (IgH translocation);
CESC	cis	rs9486719	0.843	rs2499787	chr6:96841762	G/C	cg06623918	chr6:96969491	KIAA0776	0.81	7.49	0.42	9.97e-13	Migraine;Coronary artery disease;
CESC	cis	rs7666738	0.800	rs13107586	chr4:99028788	G/C	cg24818145	chr4:99064322	C4orf37	0.39	5.09	0.3	6.95e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6088590	1.000	rs6119512	chr20:33306904	T/C	cg24642439	chr20:33292090	TP53INP2	0.85	11.75	0.59	5.97e-26	Coronary artery disease;
CESC	cis	rs6460942	0.908	rs78374554	chr7:12242285	G/A	cg06484146	chr7:12443880	VWDE	-0.67	-6.56	-0.37	2.76e-10	Coronary artery disease;
CESC	cis	rs2749592	0.918	rs1208653	chr10:38253826	C/G	cg25427524	chr10:38739819	LOC399744	0.5	6.48	0.37	4.4e-10	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs11098499	0.691	rs9307471	chr4:120261262	G/A	cg09307838	chr4:120376055	NA	0.76	10.31	0.54	3.54e-21	Corneal astigmatism;
CESC	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg26338869	chr17:61819248	STRADA	0.65	8.51	0.46	1.28e-15	Prudent dietary pattern;
CESC	cis	rs12497850	0.931	rs7636057	chr3:48992582	C/T	cg02487422	chr3:49467188	NICN1	0.44	5.57	0.32	6.38e-8	Parkinson's disease;
CESC	cis	rs78707713	0.512	rs12772559	chr10:71184356	C/G	cg12610070	chr10:71211762	TSPAN15	-0.33	-7.09	-0.4	1.21e-11	Venous thromboembolism;
CESC	cis	rs2425143	0.730	rs2095819	chr20:34353278	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.72	6.67	0.38	1.52e-10	Blood protein levels;
CESC	cis	rs2228479	0.702	rs62053702	chr16:89860688	G/T	cg04013166	chr16:89971882	TCF25	0.77	6.61	0.38	2.05e-10	Skin colour saturation;
CESC	cis	rs2408955	0.521	rs10875749	chr12:48531917	T/A	cg24011408	chr12:48396354	COL2A1	-0.5	-7.61	-0.42	4.79e-13	Glycated hemoglobin levels;
CESC	cis	rs10484885	0.775	rs17584945	chr6:90512776	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.75	-7.12	-0.4	1.02e-11	QRS interval (sulfonylurea treatment interaction);
CESC	trans	rs61931739	0.500	rs11053277	chr12:34553835	T/A	cg26384229	chr12:38710491	ALG10B	0.53	7.41	0.41	1.74e-12	Morning vs. evening chronotype;
CESC	trans	rs3942852	0.696	rs4597030	chr11:48176573	G/A	cg15704280	chr7:45808275	SEPT13	-0.75	-8.67	-0.47	4.34e-16	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs7833790	0.632	rs6473308	chr8:82707708	G/A	cg07697082	chr8:82753677	SNX16	0.38	5.74	0.33	2.55e-8	Diastolic blood pressure;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16584020	chr19:3573832	HMG20B	0.54	5.99	0.35	6.7e-9	Gut microbiome composition (summer);
CESC	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.54	-6.8	-0.39	6.8e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7605827	0.866	rs6752546	chr2:15630729	T/C	cg19274914	chr2:15703543	NA	0.38	6.74	0.38	9.95e-11	Educational attainment (years of education);
CESC	cis	rs7191439	0.858	rs6500489	chr16:88772046	T/C	cg27087555	chr16:88793112	FAM38A	-1.25	-8.68	-0.47	4.03e-16	Plateletcrit;
CESC	trans	rs7927771	1.000	rs11039255	chr11:47495746	G/T	cg22986597	chr11:65341001	FAM89B	-0.41	-6.18	-0.35	2.46e-9	Subjective well-being;
CESC	cis	rs1538970	0.924	rs7528573	chr1:45913860	T/C	cg05343316	chr1:45956843	TESK2	0.89	12.04	0.59	6.22e-27	Platelet count;
CESC	cis	rs5750830	0.594	rs6001568	chr22:39775786	G/A	cg05872129	chr22:39784769	NA	-0.84	-11.47	-0.58	5.43e-25	Intelligence (multi-trait analysis);
CESC	cis	rs9911578	0.813	rs8066773	chr17:56601552	A/G	cg05425664	chr17:57184151	TRIM37	-0.44	-5.61	-0.33	5.2100000000000003e-08	Intelligence (multi-trait analysis);
CESC	cis	rs589448	0.967	rs2617835	chr12:69753420	C/A	cg14784868	chr12:69753453	YEATS4	0.92	14.62	0.67	7.03e-36	Cerebrospinal fluid biomarker levels;
CESC	cis	rs35306767	0.953	rs1539174	chr10:974870	C/G	cg25019033	chr10:957182	NA	-0.65	-8.4	-0.46	2.8e-15	Eosinophil percentage of granulocytes;
CESC	cis	rs7259376	0.936	rs6511344	chr19:22535673	C/T	cg02657401	chr19:22469223	NA	-0.26	-5.05	-0.3	8.29e-7	Menopause (age at onset);
CESC	cis	rs854765	0.583	rs2350977	chr17:17802779	A/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.47	5.87	0.34	1.32e-8	Total body bone mineral density;
CESC	cis	rs7084402	0.967	rs1658421	chr10:60331928	A/T	cg07615347	chr10:60278583	BICC1	0.59	9.15	0.49	1.57e-17	Refractive error;
CESC	cis	rs8180040	0.966	rs922957	chr3:47422152	G/C	cg27129171	chr3:47204927	SETD2	-0.63	-9.81	-0.52	1.42e-19	Colorectal cancer;
CESC	cis	rs3857067	0.736	rs2865333	chr4:95019964	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.52	-8.04	-0.44	3.04e-14	QT interval;
CESC	cis	rs9929218	0.953	rs3118227	chr16:68734855	G/A	cg02972257	chr16:68554789	NA	0.59	6.7	0.38	1.24e-10	Colorectal cancer;
CESC	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg09033563	chr22:24373618	LOC391322	-0.45	-5.82	-0.34	1.68e-8	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs6570726	0.577	rs441982	chr6:145842848	A/G	cg23711669	chr6:146136114	FBXO30	0.93	12.36	0.6	5.18e-28	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs853679	0.517	rs3173443	chr6:28137027	T/G	cg23161317	chr6:28129485	ZNF389	0.47	5.89	0.34	1.18e-8	Depression;
CESC	cis	rs780096	0.546	rs12473776	chr2:27636474	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.34	-6.28	-0.36	1.34e-9	Total body bone mineral density;
CESC	cis	rs921968	0.541	rs3770214	chr2:219508988	C/T	cg02176678	chr2:219576539	TTLL4	-0.53	-8.74	-0.47	2.76e-16	Mean corpuscular hemoglobin concentration;
CESC	cis	rs2997447	0.761	rs17184891	chr1:26447557	A/T	cg24596570	chr1:26146463	FAM54B;LOC646471	0.59	5.17	0.3	4.68e-7	QRS complex (12-leadsum);
CESC	cis	rs28386778	0.734	rs12946669	chr17:62006007	A/G	cg26338869	chr17:61819248	STRADA	0.62	7.74	0.43	2.06e-13	Prudent dietary pattern;
CESC	cis	rs12995491	0.569	rs6724281	chr2:88529531	T/G	cg24977027	chr2:88469347	THNSL2	-0.45	-6.09	-0.35	3.93e-9	Response to metformin (IC50);
CESC	cis	rs35110281	0.748	rs2838324	chr21:44999820	T/C	cg01579765	chr21:45077557	HSF2BP	-0.54	-9.07	-0.49	2.67e-17	Mean corpuscular volume;
CESC	cis	rs9486719	0.843	rs2499793	chr6:96846402	A/C	cg06623918	chr6:96969491	KIAA0776	0.78	7.39	0.41	1.89e-12	Migraine;Coronary artery disease;
CESC	cis	rs6502050	0.835	rs4789724	chr17:80150546	G/A	cg23985595	chr17:80112537	CCDC57	-0.41	-6.48	-0.37	4.56e-10	Life satisfaction;
CESC	cis	rs514406	0.893	rs2897561	chr1:53388747	C/A	cg06600287	chr1:53387719	ECHDC2	-0.29	-5.06	-0.3	7.72e-7	Monocyte count;
CESC	cis	rs11252926	0.673	rs10795161	chr10:497748	G/T	cg03684893	chr10:554711	DIP2C	-0.37	-5.75	-0.33	2.4e-8	Psychosis in Alzheimer's disease;
CESC	cis	rs977987	0.806	rs7204984	chr16:75475520	G/C	cg03315344	chr16:75512273	CHST6	0.43	6.11	0.35	3.53e-9	Dupuytren's disease;
CESC	cis	rs3096299	0.685	rs8050512	chr16:89552320	C/G	cg00750074	chr16:89608354	SPG7	-0.42	-6.18	-0.35	2.41e-9	Multiple myeloma (IgH translocation);
CESC	cis	rs1941023	0.584	rs4938941	chr11:60173360	C/T	cg08716584	chr11:60157161	MS4A7	0.53	8.54	0.46	1.09e-15	Congenital heart disease (maternal effect);
CESC	cis	rs548181	0.736	rs540723	chr11:125489621	A/G	cg03464685	chr11:125439445	EI24	0.91	8.01	0.44	3.76e-14	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg00399650	chr7:141402322	KIAA1147	0.46	6.28	0.36	1.42e-9	Systemic lupus erythematosus;
CESC	cis	rs4718428	0.705	rs12536410	chr7:66254290	G/A	cg12165864	chr7:66369176	NA	-0.65	-7.35	-0.41	2.52e-12	Corneal structure;
CESC	cis	rs9322193	0.923	rs9688350	chr6:150052113	A/T	cg13206674	chr6:150067644	NUP43	0.43	6.05	0.35	4.94e-9	Lung cancer;
CESC	cis	rs7584330	0.518	rs7585975	chr2:238439089	G/A	cg14458575	chr2:238380390	NA	0.6	5.91	0.34	1.07e-8	Prostate cancer;
CESC	cis	rs8060686	0.545	rs117751972	chr16:68171968	C/T	cg26727032	chr16:67993705	SLC12A4	-0.5	-5.45	-0.32	1.16e-7	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs7412746	0.658	rs10305704	chr1:150804429	A/C	cg17724175	chr1:150552817	MCL1	0.4	6.28	0.36	1.4e-9	Melanoma;
CESC	cis	rs2073300	0.793	rs75758241	chr20:23434696	A/G	cg12062639	chr20:23401060	NAPB	0.64	5.07	0.3	7.46e-7	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs13256369	0.755	rs12550057	chr8:8562268	G/A	cg18904891	chr8:8559673	CLDN23	0.73	8.39	0.46	2.86e-15	Obesity-related traits;
CESC	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg22535103	chr8:58192502	C8orf71	-0.92	-10.19	-0.53	8.81e-21	Developmental language disorder (linguistic errors);
CESC	cis	rs6963495	0.556	rs711427	chr7:105161755	T/G	cg19920283	chr7:105172520	RINT1	0.54	6.28	0.36	1.35e-9	Bipolar disorder (body mass index interaction);
CESC	cis	rs113835537	0.627	rs11227534	chr11:66336171	C/A	cg22134325	chr11:66188745	NPAS4	0.37	5.52	0.32	7.98e-8	Airway imaging phenotypes;
CESC	cis	rs10540	1.000	rs35811812	chr11:498442	G/A	cg03352830	chr11:487213	PTDSS2	0.67	6.75	0.38	9.33e-11	Body mass index;
CESC	cis	rs561341	0.883	rs72821942	chr17:30234460	C/T	cg00745463	chr17:30367425	LRRC37B	-0.63	-6.18	-0.36	2.36e-9	Hip circumference adjusted for BMI;
CESC	cis	rs2835872	0.758	rs1709821	chr21:39035622	T/C	cg06728970	chr21:39037746	KCNJ6	0.3	5.51	0.32	8.67e-8	Electroencephalographic traits in alcoholism;
CESC	cis	rs7666738	0.830	rs13111977	chr4:98953813	G/A	cg05340658	chr4:99064831	C4orf37	0.8	12.4	0.61	3.76e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3106136	0.527	rs2632410	chr4:95149507	A/T	cg11021082	chr4:95130006	SMARCAD1	-0.7	-11.56	-0.58	2.74e-25	Capecitabine sensitivity;
CESC	cis	rs7845219	0.544	rs34208552	chr8:95908067	C/G	cg16049864	chr8:95962084	TP53INP1	-0.5	-7.32	-0.41	3.04e-12	Type 2 diabetes;
CESC	cis	rs763121	0.853	rs5757208	chr22:39049230	A/C	cg21395723	chr22:39101663	GTPBP1	0.43	5.39	0.31	1.54e-7	Menopause (age at onset);
CESC	cis	rs12497850	0.931	rs7430198	chr3:48988760	T/C	cg02487422	chr3:49467188	NICN1	0.46	5.81	0.34	1.82e-8	Parkinson's disease;
CESC	cis	rs3785574	0.962	rs2665835	chr17:61903258	C/T	cg06873352	chr17:61820015	STRADA	0.47	6.81	0.39	6.42e-11	Height;
CESC	cis	rs6088590	0.523	rs6058084	chr20:33183804	C/T	cg08999081	chr20:33150536	PIGU	0.7	12.11	0.6	3.66e-27	Coronary artery disease;
CESC	cis	rs7927771	0.524	rs10838746	chr11:47706291	A/G	cg20307385	chr11:47447363	PSMC3	0.61	8.46	0.46	1.87e-15	Subjective well-being;
CESC	cis	rs4665809	0.590	rs2303894	chr2:26508187	A/G	cg25036284	chr2:26402008	FAM59B	0.82	8.54	0.46	1.06e-15	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04637597	chr2:201754183	NIF3L1;PPIL3	0.6	6.32	0.36	1.08e-9	Gut microbiome composition (summer);
CESC	cis	rs2236918	0.710	rs2488470	chr1:242019580	A/G	cg17736920	chr1:242011382	EXO1	0.55	6.92	0.39	3.37e-11	Menopause (age at onset);
CESC	cis	rs4808199	0.895	rs2163805	chr19:19575945	G/A	cg03709012	chr19:19516395	GATAD2A	1.17	13.38	0.63	1.53e-31	Nonalcoholic fatty liver disease;
CESC	cis	rs1023500	0.505	rs134886	chr22:42673856	C/T	cg05082376	chr22:42548792	NA	0.38	5.69	0.33	3.41e-8	Schizophrenia;
CESC	cis	rs7666738	0.791	rs13111960	chr4:98976851	C/T	cg03467027	chr4:99064603	C4orf37	0.42	5.29	0.31	2.5e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1538970	0.816	rs34673142	chr1:45985561	G/A	cg06784218	chr1:46089804	CCDC17	0.36	5.7	0.33	3.12e-8	Platelet count;
CESC	cis	rs67478160	0.643	rs11624184	chr14:104240998	A/G	cg08213375	chr14:104286397	PPP1R13B	0.45	9.04	0.49	3.46e-17	Schizophrenia;
CESC	cis	rs62283056	0.512	rs752854	chr4:6281961	C/T	cg14416269	chr4:6271139	WFS1	0.43	6.11	0.35	3.59e-9	Cisplatin-induced ototoxicity;
CESC	cis	rs12497850	0.865	rs13072911	chr3:48962128	T/G	cg03060546	chr3:49711283	APEH	0.45	5.63	0.33	4.66e-8	Parkinson's disease;
CESC	cis	rs798766	0.779	rs3134866	chr4:1723265	A/G	cg07041428	chr4:1763019	NA	-0.39	-5.56	-0.32	6.66e-8	Bladder cancer;Urinary bladder cancer;
CESC	cis	rs4253772	0.701	rs9627280	chr22:46643964	T/C	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.57	6.67	0.38	1.45e-10	LDL cholesterol;Cholesterol, total;
CESC	cis	rs798554	0.836	rs798490	chr7:2801542	C/T	cg13628971	chr7:2884303	GNA12	0.64	8.46	0.46	1.82e-15	Height;
CESC	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg11235426	chr6:292522	DUSP22	-0.73	-9.79	-0.52	1.62e-19	Menopause (age at onset);
CESC	cis	rs763121	0.785	rs6001203	chr22:39099602	T/C	cg21395723	chr22:39101663	GTPBP1	0.49	6.67	0.38	1.5e-10	Menopause (age at onset);
CESC	cis	rs2991971	0.933	rs666720	chr1:46020795	T/C	cg15605315	chr1:45957053	TESK2	0.42	5.38	0.31	1.67e-7	High light scatter reticulocyte count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19064601	chr11:68142605	LRP5	-0.55	-6.33	-0.36	1.06e-9	Gut microbiome composition (summer);
CESC	cis	rs7000551	0.779	rs2443507	chr8:22373231	G/A	cg12081754	chr8:22256438	SLC39A14	0.45	6.1	0.35	3.71e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CESC	cis	rs718433	0.584	rs1569292	chr14:22216993	G/A	cg02257791	chr14:22217085	NA	-0.33	-5.13	-0.3	5.64e-7	Intraocular pressure;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06831761	chr7:104885108	SRPK2	-0.64	-7.55	-0.42	7.23e-13	Gut microbiome composition (summer);
CESC	cis	rs7116495	0.609	rs7113520	chr11:71691946	G/A	cg18441811	chr11:71824068	C11orf51	-0.82	-5.21	-0.31	3.71e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs801193	1.000	rs3800812	chr7:66223461	T/C	cg11764359	chr7:65958608	NA	0.67	8.72	0.47	3.12e-16	Aortic root size;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg27261837	chr1:146714163	CHD1L	0.53	7.01	0.4	1.93e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs11203032	0.901	rs4074851	chr10:90958618	A/G	cg16672925	chr10:90967113	CH25H	-0.66	-6.72	-0.38	1.12e-10	Heart failure;
CESC	cis	rs3820928	0.839	rs58580037	chr2:227876274	G/T	cg11843606	chr2:227700838	RHBDD1	-0.48	-6.13	-0.35	3.13e-9	Pulmonary function;
CESC	cis	rs10504229	0.683	rs16921829	chr8:58110950	A/G	cg21724239	chr8:58056113	NA	0.58	5.93	0.34	9.45e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs2710642	0.566	rs2710651	chr2:63166379	G/A	cg17519650	chr2:63277830	OTX1	0.58	8.01	0.44	3.55e-14	LDL cholesterol levels;LDL cholesterol;
CESC	cis	rs4665809	1.000	rs6709595	chr2:26259885	A/G	cg22920501	chr2:26401640	FAM59B	-0.66	-7.9	-0.44	7.42e-14	Gut microbiome composition (summer);
CESC	cis	rs7520050	0.966	rs4660321	chr1:46366760	A/G	cg24296786	chr1:45957014	TESK2	0.44	5.55	0.32	7.05e-8	Red blood cell count;Reticulocyte count;
CESC	cis	rs10489202	0.657	rs201541	chr1:167992344	T/A	cg24449463	chr1:168025552	DCAF6	-0.42	-5.3	-0.31	2.4e-7	Schizophrenia;
CESC	cis	rs13108904	0.557	rs1680030	chr4:1245500	A/T	cg16405210	chr4:1374714	KIAA1530	0.77	10.47	0.54	1.04e-21	Obesity-related traits;
CESC	cis	rs2795502	0.882	rs2744091	chr10:43339441	A/G	cg27426351	chr10:43362370	NA	-0.44	-5.48	-0.32	9.96e-8	Blood protein levels;
CESC	cis	rs116095464	0.558	rs62347677	chr5:227453	A/G	cg10591111	chr5:226296	SDHA	-0.55	-6.84	-0.39	5.44e-11	Breast cancer;
CESC	cis	rs4862750	0.872	rs56389997	chr4:187894796	A/C	cg03452623	chr4:187889614	NA	-0.89	-16.06	-0.7	5.23e-41	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs476633	0.691	rs6492997	chr15:41541171	G/A	cg20272979	chr15:41787780	ITPKA	0.38	5.64	0.33	4.37e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs7103648	0.695	rs12223593	chr11:47789082	T/G	cg20307385	chr11:47447363	PSMC3	0.8	12.17	0.6	2.22e-27	Diastolic blood pressure;Systolic blood pressure;
CESC	cis	rs7811142	0.943	rs28578163	chr7:100044754	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.14	13.13	0.63	1.15e-30	Platelet count;
CESC	cis	rs12478296	1.000	rs7603984	chr2:243047294	A/G	cg06360820	chr2:242988706	NA	-0.92	-9.02	-0.48	3.81e-17	Obesity-related traits;
CESC	trans	rs11039798	1.000	rs10160423	chr11:48457227	G/T	cg15704280	chr7:45808275	SEPT13	0.69	6.58	0.37	2.56e-10	Axial length;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg08309023	chr2:148839265	NA	0.42	6.4	0.37	7.09e-10	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs425277	0.585	rs3107143	chr1:2045372	G/C	cg19257562	chr1:2043853	PRKCZ	0.38	6.38	0.37	7.7e-10	Height;
CESC	cis	rs4568518	0.740	rs12699927	chr7:18011752	A/T	cg03009463	chr7:17980271	SNX13	0.44	5.9	0.34	1.08e-8	Measles;
CESC	cis	rs3806843	0.771	rs2563336	chr5:140107199	A/G	cg16179182	chr5:140090404	VTRNA1-1	0.42	5.51	0.32	8.6e-8	Depressive symptoms (multi-trait analysis);
CESC	cis	rs6860806	0.661	rs1588263	chr5:131577158	T/C	cg11843238	chr5:131593191	PDLIM4	0.36	5.18	0.3	4.41e-7	Breast cancer;
CESC	cis	rs10504229	0.679	rs72649115	chr8:58037631	T/G	cg22535103	chr8:58192502	C8orf71	-0.9	-8.99	-0.48	4.95e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs9926296	0.585	rs4785595	chr16:89835521	C/T	cg21285383	chr16:89894308	SPIRE2	-0.35	-6.28	-0.36	1.35e-9	Vitiligo;
CESC	cis	rs60871478	0.636	rs4719520	chr7:875216	C/G	cg15782153	chr7:917662	C7orf20	0.51	5.58	0.32	6.04e-8	Cerebrospinal P-tau181p levels;
CESC	cis	rs9790314	1.000	rs7647327	chr3:161016421	T/C	cg04691961	chr3:161091175	C3orf57	-0.44	-5.73	-0.33	2.74e-8	Morning vs. evening chronotype;
CESC	cis	rs9611565	0.559	rs4822049	chr22:41993496	G/A	cg06634786	chr22:41940651	POLR3H	-0.67	-6.46	-0.37	4.85e-10	Vitiligo;
CESC	trans	rs2727020	0.734	rs1164663	chr11:49294723	A/T	cg03929089	chr4:120376271	NA	0.69	8.55	0.46	9.62e-16	Coronary artery disease;
CESC	cis	rs10979	1.000	rs1416206	chr6:143889385	T/C	cg25407410	chr6:143891975	LOC285740	-0.61	-9.14	-0.49	1.72e-17	Hypospadias;
CESC	cis	rs9902453	0.933	rs9898353	chr17:28451865	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	7.6	0.42	5.23e-13	Coffee consumption (cups per day);
CESC	cis	rs4629710	0.534	rs6916881	chr6:131565153	C/T	cg12606694	chr6:131520996	AKAP7	0.48	5.83	0.34	1.62e-8	Multiple myeloma (IgH translocation);
CESC	cis	rs2777491	0.957	rs2015781	chr15:41648967	C/G	cg02330683	chr15:41787940	ITPKA	0.43	6.32	0.36	1.08e-9	Ulcerative colitis;
CESC	cis	rs6964587	0.869	rs6979024	chr7:91481512	T/C	cg17063962	chr7:91808500	NA	-0.5	-6.6	-0.38	2.22e-10	Breast cancer;
CESC	cis	rs977987	0.771	rs12929673	chr16:75470295	C/T	cg03315344	chr16:75512273	CHST6	0.42	6.12	0.35	3.38e-9	Dupuytren's disease;
CESC	cis	rs11997175	1.000	rs7838577	chr8:33760802	A/G	ch.8.33884649F	chr8:33765107	NA	0.67	8.59	0.47	7.79e-16	Body mass index;
CESC	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg17178900	chr1:205818956	PM20D1	0.79	12.63	0.61	6.05e-29	Menarche (age at onset);
CESC	cis	rs2012796	0.785	rs61986597	chr14:81853107	T/C	cg02996355	chr14:81879375	NA	0.66	8.38	0.46	3.05e-15	Night sleep phenotypes;
CESC	cis	rs1552244	0.882	rs55840655	chr3:10042690	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.85	11.01	0.56	1.86e-23	Alzheimer's disease;
CESC	cis	rs1843834	0.539	rs3912999	chr2:225390089	C/T	cg22455342	chr2:225449267	CUL3	0.69	8.96	0.48	5.92e-17	IgE levels in asthmatics (D.p. specific);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg06096994	chr13:41635664	WBP4	-0.42	-6.08	-0.35	4.24e-9	Fibrinogen levels;
CESC	cis	rs2066819	1.000	rs111885088	chr12:56657216	A/C	cg26714650	chr12:56694279	CS	-1.43	-10.45	-0.54	1.24e-21	Psoriasis vulgaris;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg18195498	chr7:100281506	GIGYF1	0.56	8.04	0.44	2.95e-14	Fibrinogen levels;
CESC	cis	rs10129255	0.500	rs8022547	chr14:107190222	A/T	cg23076370	chr14:107095027	NA	-0.65	-9.79	-0.52	1.6e-19	Kawasaki disease;
CESC	cis	rs853679	0.517	rs9393886	chr6:28050039	T/G	cg26335602	chr6:28129616	ZNF389	0.53	7.05	0.4	1.55e-11	Depression;
CESC	cis	rs7481584	0.624	rs377765	chr11:3046298	C/T	cg25174290	chr11:3078921	CARS	-0.45	-6.3	-0.36	1.21e-9	Calcium levels;
CESC	cis	rs6502050	0.835	rs6502077	chr17:80122966	G/C	cg11859384	chr17:80120422	CCDC57	-0.39	-5.34	-0.31	1.98e-7	Life satisfaction;
CESC	cis	rs6694270	0.529	rs12041777	chr1:19109193	T/C	cg19637330	chr1:19110922	NA	-0.53	-6.39	-0.37	7.37e-10	Drug-induced liver injury (nitrofurantoin);
CESC	cis	rs1475718	0.563	rs1041608	chr9:137116205	C/T	cg21243944	chr9:137118148	NA	-0.35	-5.1	-0.3	6.45e-7	Immature fraction of reticulocytes;Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
CESC	cis	rs7666738	0.680	rs11726233	chr4:99079773	G/A	cg17366294	chr4:99064904	C4orf37	0.55	7.47	0.42	1.15e-12	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3785574	0.962	rs4968660	chr17:61792221	G/A	cg07677032	chr17:61819896	STRADA	0.43	5.46	0.32	1.09e-7	Height;
CESC	cis	rs4803468	1.000	rs284655	chr19:41928765	C/T	cg09537434	chr19:41945824	ATP5SL	-1.1	-20.31	-0.78	5.82e-56	Height;
CESC	cis	rs4648845	0.777	rs2477686	chr1:2392648	C/G	cg07700843	chr1:2391317	NA	-0.49	-9.44	-0.5	2.08e-18	Schizophrenia;
CESC	cis	rs17376456	0.877	rs28539612	chr5:93499099	C/T	cg25358565	chr5:93447407	FAM172A	1.17	10.95	0.56	2.93e-23	Diabetic retinopathy;
CESC	cis	rs734999	0.545	rs10797436	chr1:2538349	G/A	cg20673091	chr1:2541236	MMEL1	0.45	7.53	0.42	8.1e-13	Ulcerative colitis;
CESC	cis	rs13392177	0.660	rs62185964	chr2:219073745	A/G	cg00012203	chr2:219082015	ARPC2	-0.66	-8.2	-0.45	1.01e-14	Pyoderma gangrenosum in inflammatory bowel disease;
CESC	cis	rs875971	0.862	rs10274883	chr7:66116091	C/T	cg11764359	chr7:65958608	NA	-0.73	-10.48	-0.54	1.01e-21	Aortic root size;
CESC	cis	rs1348850	0.561	rs57986285	chr2:178468663	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.57	5.32	0.31	2.19e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs26868	0.766	rs30995	chr16:2248017	C/T	cg07587117	chr16:2239488	CASKIN1	-0.32	-5.23	-0.31	3.41e-7	Height;
CESC	cis	rs2797160	1.000	rs1832980	chr6:125997444	T/G	cg05901451	chr6:126070800	HEY2	-0.45	-6.66	-0.38	1.55e-10	Endometrial cancer;
CESC	cis	rs11048434	0.736	rs11048190	chr12:9104939	C/T	cg23795048	chr12:9217529	LOC144571	0.37	5.76	0.33	2.38e-8	Sjögren's syndrome;
CESC	cis	rs2247341	1.000	rs34049648	chr4:1697337	G/A	cg07465881	chr4:1713556	SLBP	-0.53	-6.83	-0.39	5.78e-11	Hip circumference adjusted for BMI;Height;
CESC	cis	rs9888739	1.000	rs9940397	chr16:31303201	T/C	cg15817542	chr16:31343056	ITGAM	-0.45	-5.39	-0.31	1.56e-7	Systemic lupus erythematosus;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19274820	chr6:41863130	USP49	0.54	6.08	0.35	4.14e-9	Gut microbiome composition (summer);
CESC	cis	rs763121	0.853	rs5750671	chr22:39094619	A/C	cg06022373	chr22:39101656	GTPBP1	0.94	17.4	0.73	9.39e-46	Menopause (age at onset);
CESC	trans	rs9354308	0.899	rs2802057	chr6:66548093	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.6	6.62	0.38	1.93e-10	Metabolite levels;
CESC	trans	rs28735056	0.609	rs4799099	chr18:77639585	A/G	cg05926928	chr17:57297772	GDPD1	0.61	7.61	0.42	4.91e-13	Schizophrenia;
CESC	cis	rs1153858	0.621	rs1719237	chr15:45579822	G/A	cg14582100	chr15:45693742	SPATA5L1	0.4	5.37	0.31	1.72e-7	Homoarginine levels;
CESC	cis	rs2024825	1	rs2024825	chr1:67597977	T/C	cg17031739	chr1:67600172	NA	0.55	6.1	0.35	3.68e-9	Leprosy;
CESC	cis	rs9640161	0.830	rs36069544	chr7:150061538	G/A	cg17279839	chr7:150038598	RARRES2	0.44	5.57	0.32	6.27e-8	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs10504229	0.683	rs61241336	chr8:58106585	A/G	cg02725872	chr8:58115012	NA	-0.43	-6.81	-0.39	6.53e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs34779708	0.966	rs1545757	chr10:35445588	A/T	cg03585969	chr10:35415529	CREM	0.77	10.24	0.53	6.08e-21	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs9309473	0.950	rs17009149	chr2:73790368	T/C	cg20560298	chr2:73613845	ALMS1	-0.53	-6.86	-0.39	4.91e-11	Metabolite levels;
CESC	cis	rs514406	0.760	rs475969	chr1:53292607	T/A	cg25767906	chr1:53392781	SCP2	-0.51	-7.09	-0.4	1.22e-11	Monocyte count;
CESC	cis	rs16867335	0.625	rs7573877	chr2:181478111	A/G	cg23363182	chr2:181467187	NA	-0.4	-6.11	-0.35	3.49e-9	Survival in rectal cancer;
CESC	cis	rs7474896	0.515	rs662928	chr10:38316216	G/T	cg00409905	chr10:38381863	ZNF37A	0.46	5.15	0.3	5.06e-7	Obesity (extreme);
CESC	cis	rs6121246	0.909	rs1994251	chr20:30287328	T/G	cg13852791	chr20:30311386	BCL2L1	0.78	8.17	0.45	1.24e-14	Mean corpuscular hemoglobin;
CESC	cis	rs9834373	0.821	rs13314576	chr3:78485637	T/C	cg06138941	chr3:78371609	NA	-0.42	-5.14	-0.3	5.43e-7	Protein quantitative trait loci;
CESC	cis	rs8111998	0.826	rs59838183	chr19:22766434	G/A	cg19914732	chr19:22715077	NA	-0.37	-5.18	-0.3	4.45e-7	Corneal structure;
CESC	cis	rs4662945	0.525	rs10174479	chr2:130296287	A/C	cg05962382	chr2:130345044	NA	-0.5	-7.68	-0.43	3.16e-13	Response to cytidine analogues (gemcitabine);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05373286	chr10:76969678	VDAC2	0.46	6.24	0.36	1.73e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs4268898	0.722	rs4665253	chr2:24382546	G/A	cg06627628	chr2:24431161	ITSN2	0.52	6.77	0.38	8.5e-11	Asthma;
CESC	cis	rs6460942	0.597	rs13232817	chr7:12551909	C/A	cg20607287	chr7:12443886	VWDE	-0.72	-7.3	-0.41	3.43e-12	Coronary artery disease;
CESC	cis	rs8077889	0.917	rs72836545	chr17:41892602	A/G	cg26893861	chr17:41843967	DUSP3	0.82	9.8	0.52	1.55e-19	Triglycerides;
CESC	cis	rs11098499	0.954	rs6846442	chr4:120326323	G/A	cg09307838	chr4:120376055	NA	0.94	13.7	0.64	1.18e-32	Corneal astigmatism;
CESC	cis	rs7666738	0.830	rs921523	chr4:98841659	C/T	cg05340658	chr4:99064831	C4orf37	0.7	9.96	0.52	4.58e-20	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7085104	0.572	rs284857	chr10:104574063	C/T	cg23093090	chr10:104574429	C10orf26	0.34	5.39	0.31	1.53e-7	Immature fraction of reticulocytes;Schizophrenia;
CESC	cis	rs11997175	0.624	rs4733460	chr8:33675169	T/C	ch.8.33884649F	chr8:33765107	NA	0.57	7.31	0.41	3.1e-12	Body mass index;
CESC	cis	rs7666738	0.830	rs28465658	chr4:99035866	T/C	cg18180107	chr4:99064573	C4orf37	0.41	5.29	0.31	2.52e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs8067545	0.611	rs7222984	chr17:20019694	A/C	cg13482628	chr17:19912719	NA	0.4	5.29	0.31	2.52e-7	Schizophrenia;
CESC	cis	rs796364	0.664	rs3106089	chr2:200884615	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	0.84	7.64	0.42	3.96e-13	Schizophrenia;
CESC	cis	rs73206853	0.619	rs112148402	chr12:111171493	T/C	cg04375036	chr12:111181819	PPP1CC	-0.64	-5.11	-0.3	6.21e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs763121	0.853	rs4821809	chr22:39065743	G/C	cg21395723	chr22:39101663	GTPBP1	0.42	5.27	0.31	2.86e-7	Menopause (age at onset);
CESC	cis	rs66561647	1.000	rs66561647	chr8:128971861	C/T	cg05480350	chr8:128972681	MIR1205;PVT1	0.58	8.12	0.45	1.77e-14	Hemoglobin concentration;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02352107	chr15:76603736	ETFA	0.62	7.47	0.42	1.17e-12	Gut microbiome composition (summer);
CESC	cis	rs672059	1.000	rs672119	chr1:183162506	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.55	7.16	0.4	7.77e-12	Hypertriglyceridemia;
CESC	cis	rs9649213	0.613	rs10953256	chr7:97951886	G/C	cg00277769	chr7:97922759	BAIAP2L1	-0.34	-5.61	-0.33	4.97e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs6938	0.618	rs1133323	chr15:75212225	C/T	cg14664628	chr15:75095509	CSK	-0.53	-6.96	-0.39	2.6e-11	Breast cancer;
CESC	cis	rs34779708	0.931	rs11010082	chr10:35351155	A/G	cg03585969	chr10:35415529	CREM	0.78	10.17	0.53	1.03e-20	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs72945132	0.714	rs115143889	chr11:70150122	G/T	cg14191688	chr11:70257035	CTTN	0.47	5.65	0.33	4.1e-8	Coronary artery disease;
CESC	cis	rs1185460	0.967	rs1784459	chr11:118938388	C/A	cg23280166	chr11:118938394	VPS11	0.58	8.12	0.45	1.77e-14	Coronary artery disease;
CESC	cis	rs3008870	0.755	rs1024229	chr1:67512903	G/T	cg02640540	chr1:67518911	SLC35D1	0.71	9.16	0.49	1.46e-17	Lymphocyte percentage of white cells;
CESC	cis	rs12586317	0.576	rs6571696	chr14:35630175	A/G	cg16230307	chr14:35515116	FAM177A1	0.41	5.15	0.3	5.03e-7	Psoriasis;
CESC	cis	rs9916302	0.904	rs4795355	chr17:37427382	C/T	cg20243544	chr17:37824526	PNMT	0.46	5.75	0.33	2.52e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs3820068	0.705	rs927206	chr1:15893338	C/T	cg17385448	chr1:15911702	AGMAT	0.36	5.55	0.32	6.93e-8	Systolic blood pressure;
CESC	cis	rs7666738	0.546	rs17546687	chr4:98769266	T/A	cg17366294	chr4:99064904	C4orf37	0.5	6.16	0.35	2.71e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9902453	1.000	rs60967688	chr17:28437052	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	7.73	0.43	2.28e-13	Coffee consumption (cups per day);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18052984	chr12:51158439	ATF1	0.6	7.24	0.41	4.81e-12	Gut microbiome composition (summer);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg06622468	chr19:10491460	TYK2	-0.44	-6.22	-0.36	1.93e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs9902453	0.899	rs8067580	chr17:28471248	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.62	8.02	0.44	3.41e-14	Coffee consumption (cups per day);
CESC	trans	rs4671386	0.901	rs7578291	chr2:60522662	T/C	cg24386296	chr4:1723849	TMEM129;TACC3	0.51	6.52	0.37	3.54e-10	Acne (severe);
CESC	cis	rs7267979	0.718	rs2983489	chr20:25244120	C/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.78	14.08	0.65	5.37e-34	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs4253772	0.591	rs11705624	chr22:46685380	C/T	cg24881330	chr22:46731750	TRMU	0.75	5.43	0.32	1.25e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs12476592	0.602	rs989527	chr2:63726791	G/T	cg17519650	chr2:63277830	OTX1	-0.47	-5.4	-0.31	1.46e-7	Childhood ear infection;
CESC	trans	rs1814175	0.645	rs11040661	chr11:49952146	G/T	cg03929089	chr4:120376271	NA	-0.89	-14.87	-0.67	8.52e-37	Height;
CESC	cis	rs9457247	0.967	rs387733	chr6:167409771	C/T	cg25258033	chr6:167368657	RNASET2	-0.4	-5.92	-0.34	9.71e-9	Crohn's disease;
CESC	cis	rs6502050	0.835	rs28481866	chr17:80105160	G/A	cg11859384	chr17:80120422	CCDC57	-0.38	-5.11	-0.3	6.21e-7	Life satisfaction;
CESC	cis	rs10911232	0.507	rs4575047	chr1:182976028	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.83	13.29	0.63	3.24e-31	Hypertriglyceridemia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05926606	chr21:40685342	BRWD1	0.63	7.15	0.4	8.21e-12	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24385632	chr11:16838615	PLEKHA7	-0.56	-6.11	-0.35	3.53e-9	Gut microbiome composition (summer);
CESC	cis	rs4853012	0.941	rs60291089	chr2:74344890	T/G	cg01017244	chr2:74357527	NA	0.67	9.66	0.51	4.19e-19	Gestational age at birth (maternal effect);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03311339	chr17:64299562	PRKCA	0.58	6.56	0.37	2.73e-10	Gut microbiome composition (summer);
CESC	cis	rs36051895	0.622	rs10974952	chr9:5079828	A/T	cg02405213	chr9:5042618	JAK2	-0.5	-6.01	-0.35	5.99e-9	Pediatric autoimmune diseases;
CESC	cis	rs561341	0.769	rs7217004	chr17:30178092	A/G	cg12193833	chr17:30244370	NA	0.62	5.74	0.33	2.58e-8	Hip circumference adjusted for BMI;
CESC	cis	rs6460942	1.000	rs73053527	chr7:12313008	C/A	cg06484146	chr7:12443880	VWDE	-0.81	-8.78	-0.47	2.13e-16	Coronary artery disease;
CESC	cis	rs12477438	0.748	rs4851185	chr2:99666497	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.62	-8.67	-0.47	4.43e-16	Chronic sinus infection;
CESC	cis	rs916888	0.821	rs415430	chr17:44859144	C/T	cg15921436	chr17:44337874	NA	-0.71	-8.07	-0.44	2.47e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs12135062	0.851	rs2651927	chr1:3101762	A/C	cg00254258	chr1:3105189	PRDM16	-0.35	-5.21	-0.3	3.76e-7	Migraine;
CESC	cis	rs9291683	0.679	rs13137795	chr4:10051506	G/A	cg00071950	chr4:10020882	SLC2A9	0.81	14.28	0.66	1.04e-34	Bone mineral density;
CESC	cis	rs4629180	0.593	rs6707517	chr2:102089878	C/T	cg01388757	chr2:102091195	RFX8	-0.44	-6.74	-0.38	9.61e-11	Chronic rhinosinusitis with nasal polyps;
CESC	cis	rs9527	0.545	rs10883847	chr10:104958284	C/T	cg04362960	chr10:104952993	NT5C2	0.44	5.56	0.32	6.74e-8	Arsenic metabolism;
CESC	cis	rs258892	0.895	rs34670	chr5:72162863	T/C	cg21869765	chr5:72125136	TNPO1	0.44	5.55	0.32	6.92e-8	Small cell lung carcinoma;
CESC	cis	rs7100689	0.784	rs10736342	chr10:82130005	A/G	cg00277334	chr10:82204260	NA	-0.59	-7.35	-0.41	2.39e-12	Post bronchodilator FEV1;
CESC	cis	rs4853012	0.941	rs2421752	chr2:74341615	A/G	cg05890377	chr2:74357713	NA	0.68	8.24	0.45	8.21e-15	Gestational age at birth (maternal effect);
CESC	cis	rs7250872	0.647	rs2304613	chr19:1817943	G/C	cg10370574	chr19:1840461	REXO1	-0.43	-6.02	-0.35	5.82e-9	Bipolar disorder;
CESC	cis	rs9913156	0.707	rs9902000	chr17:4582426	A/C	cg00122941	chr17:4613640	ARRB2	-0.74	-8.99	-0.48	4.81e-17	Lymphocyte counts;
CESC	cis	rs3741151	1.000	rs74346863	chr11:73054772	C/T	cg17517138	chr11:73019481	ARHGEF17	1.04	7.13	0.4	9.44e-12	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs5758511	0.680	rs5758686	chr22:42655377	G/T	cg00645731	chr22:42541494	CYP2D7P1	0.58	8.74	0.47	2.75e-16	Birth weight;
CESC	cis	rs67311347	1.000	rs11706148	chr3:40407243	A/C	cg09455208	chr3:40491958	NA	0.52	8.6	0.47	7.3e-16	Renal cell carcinoma;
CESC	cis	rs4665809	0.525	rs10865402	chr2:26535383	A/G	cg25036284	chr2:26402008	FAM59B	-0.47	-5.64	-0.33	4.43e-8	Gut microbiome composition (summer);
CESC	cis	rs2842992	0.789	rs9365093	chr6:160175819	C/G	cg11366901	chr6:160182831	ACAT2	0.81	10.47	0.54	1.08e-21	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs2637266	1.000	rs11001829	chr10:78343387	A/T	cg18941641	chr10:78392320	NA	0.41	7.78	0.43	1.65e-13	Pulmonary function;
CESC	cis	rs763121	0.925	rs9611008	chr22:39098787	T/C	cg14440974	chr22:39074834	NA	-0.36	-5.18	-0.3	4.31e-7	Menopause (age at onset);
CESC	cis	rs910316	1.000	rs10143132	chr14:75525850	G/A	cg08847533	chr14:75593920	NEK9	0.99	18.49	0.75	1.4e-49	Height;
CESC	cis	rs56399783	0.614	rs116929101	chr7:2760325	G/A	cg19731401	chr7:2775893	GNA12	0.59	5.16	0.3	4.95e-7	Childhood ear infection;
CESC	cis	rs6088580	0.634	rs6059868	chr20:33079460	A/G	cg24642439	chr20:33292090	TP53INP2	0.51	6.64	0.38	1.8e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs4689388	0.926	rs4416547	chr4:6293967	G/A	cg25554036	chr4:6271136	WFS1	0.51	8.37	0.46	3.31e-15	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs1670533	1.000	rs4690213	chr4:1054868	C/T	cg27284194	chr4:1044797	NA	0.47	5.99	0.35	6.72e-9	Recombination rate (females);
CESC	cis	rs11229555	0.645	rs36019763	chr11:58232283	G/T	cg15696309	chr11:58395628	NA	-0.45	-5.22	-0.31	3.63e-7	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs6570726	0.846	rs409553	chr6:145886963	C/T	cg23711669	chr6:146136114	FBXO30	0.85	12.88	0.62	8.09e-30	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs5753037	0.630	rs140111	chr22:30131570	A/G	cg01021169	chr22:30184971	ASCC2	-0.47	-6.6	-0.38	2.29e-10	Type 1 diabetes;
CESC	cis	rs1256061	0.603	rs1152579	chr14:64695087	A/G	cg23250157	chr14:64679961	SYNE2	0.53	7.52	0.42	8.32e-13	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs6762	0.719	rs1130698	chr11:838542	C/T	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.76	-10.21	-0.53	7.68e-21	Mean platelet volume;
CESC	cis	rs6088580	0.634	rs13041646	chr20:33082881	T/A	cg24642439	chr20:33292090	TP53INP2	0.51	6.67	0.38	1.46e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs801193	0.569	rs7782587	chr7:66166472	C/T	cg10691866	chr7:65817282	TPST1	-0.32	-5.38	-0.31	1.61e-7	Aortic root size;
CESC	cis	rs10461617	0.541	rs832575	chr5:56161787	C/T	cg12311346	chr5:56204834	C5orf35	-0.67	-6.69	-0.38	1.3100000000000001e-10	Type 2 diabetes;
CESC	cis	rs6570726	0.967	rs413880	chr6:145804822	G/A	cg23711669	chr6:146136114	FBXO30	0.72	10.46	0.54	1.16e-21	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs10744422	0.858	rs2292136	chr12:123339344	A/G	cg25930673	chr12:123319894	HIP1R	-0.76	-5.88	-0.34	1.26e-8	Schizophrenia;
CESC	cis	rs12620999	0.774	rs6711726	chr2:238101795	C/T	cg23555395	chr2:238036564	NA	-0.4	-5.34	-0.31	1.97e-7	Systemic lupus erythematosus;
CESC	cis	rs2637266	0.678	rs864027	chr10:78532061	G/A	cg18941641	chr10:78392320	NA	0.39	7.71	0.43	2.5e-13	Pulmonary function;
CESC	cis	rs7605827	0.930	rs1024870	chr2:15625846	T/C	cg19274914	chr2:15703543	NA	0.36	6.49	0.37	4.08e-10	Educational attainment (years of education);
CESC	trans	rs9329221	0.510	rs4841282	chr8:9975604	C/A	cg06636001	chr8:8085503	FLJ10661	0.51	6.61	0.38	2.12e-10	Neuroticism;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg01334186	chr1:151372572	PSMB4	0.48	6.31	0.36	1.2e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs728616	0.558	rs2880599	chr10:82164435	A/G	cg05935833	chr10:81318306	SFTPA2	-0.46	-5.68	-0.33	3.5e-8	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs1801251	0.778	rs2592116	chr2:233735709	G/A	cg08000102	chr2:233561755	GIGYF2	-0.58	-7.82	-0.43	1.22e-13	Coronary artery disease;
CESC	cis	rs7953249	0.807	rs7310409	chr12:121424861	A/G	cg02403541	chr12:121454288	C12orf43	-0.48	-6.38	-0.37	7.75e-10	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
CESC	cis	rs2708240	0.599	rs1613285	chr7:147520530	A/C	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.34	-5.09	-0.3	6.68e-7	QT interval (drug interaction);
CESC	cis	rs2549003	0.870	rs61175929	chr5:131821548	C/G	cg00255919	chr5:131827918	IRF1	0.51	8.68	0.47	4.19e-16	Asthma (sex interaction);
CESC	cis	rs2635047	1.000	rs2684841	chr18:44724262	C/T	cg19077165	chr18:44547161	KATNAL2	-0.43	-5.97	-0.34	7.4e-9	Educational attainment;
CESC	cis	rs853679	0.517	rs9380056	chr6:28104476	C/T	cg22143856	chr6:28129313	ZNF389	0.52	6.77	0.38	8.31e-11	Depression;
CESC	trans	rs9329221	0.521	rs17693945	chr8:10106010	C/T	cg15556689	chr8:8085844	FLJ10661	-0.53	-6.21	-0.36	2.07e-9	Neuroticism;
CESC	cis	rs9487051	0.735	rs352837	chr6:109521806	C/T	cg01475377	chr6:109611718	NA	0.38	5.67	0.33	3.76e-8	Reticulocyte fraction of red cells;
CESC	cis	rs7845219	0.544	rs9643350	chr8:95917276	C/A	cg23172400	chr8:95962367	TP53INP1	-0.37	-6.83	-0.39	5.67e-11	Type 2 diabetes;
CESC	cis	rs6741892	0.536	rs11688977	chr2:38896631	C/T	cg23643435	chr2:38893251	GALM	-0.65	-8.9	-0.48	8.72e-17	5-HTT brain serotonin transporter levels;
CESC	cis	rs3733585	0.699	rs57574512	chr4:9960182	T/C	cg00071950	chr4:10020882	SLC2A9	-0.73	-11.79	-0.59	4.58e-26	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs17253792	0.822	rs10147380	chr14:56054354	T/C	cg01858014	chr14:56050164	KTN1	-0.82	-6.45	-0.37	5.37e-10	Putamen volume;
CESC	cis	rs116095464	0.558	rs62344300	chr5:246336	A/G	cg20965017	chr5:231967	SDHA	-0.47	-5.38	-0.31	1.65e-7	Breast cancer;
CESC	cis	rs6430585	0.528	rs3098102	chr2:136654833	C/T	cg07169764	chr2:136633963	MCM6	1.04	15.27	0.68	3.34e-38	Corneal structure;
CESC	cis	rs1707322	0.721	rs11211181	chr1:46236800	C/T	cg05343316	chr1:45956843	TESK2	0.48	6.11	0.35	3.51e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7666738	0.791	rs6833691	chr4:98951508	A/G	cg03467027	chr4:99064603	C4orf37	0.45	5.62	0.33	4.95e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs5769765	0.817	rs9616212	chr22:50317687	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.63	-6.44	-0.37	5.53e-10	Schizophrenia;
CESC	cis	rs11931598	0.513	rs3857170	chr4:7003366	A/T	cg26116260	chr4:7069785	GRPEL1	0.43	6.03	0.35	5.47e-9	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
CESC	cis	rs4665809	0.590	rs4665837	chr2:26434022	C/A	cg04944784	chr2:26401820	FAM59B	-0.95	-10.38	-0.54	2.13e-21	Gut microbiome composition (summer);
CESC	cis	rs763014	0.931	rs2071980	chr16:626346	A/C	cg07256732	chr16:621771	PIGQ	-0.3	-5.14	-0.3	5.25e-7	Height;
CESC	cis	rs10129255	0.500	rs8006888	chr14:107190456	A/C	cg07958169	chr14:107095056	NA	-0.53	-8.28	-0.45	6.23e-15	Kawasaki disease;
CESC	cis	rs7552404	1.000	rs6593585	chr1:76140273	G/A	cg03433033	chr1:76189801	ACADM	0.68	8.11	0.45	1.9e-14	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs4704187	0.663	rs6889760	chr5:74503704	A/C	cg03227963	chr5:74354835	NA	0.28	5.18	0.3	4.33e-7	Response to amphetamines;
CESC	cis	rs9287719	0.967	rs10206225	chr2:10758657	A/G	cg02196655	chr2:10830764	NOL10	-0.36	-5.62	-0.33	4.93e-8	Prostate cancer;
CESC	cis	rs7552404	0.727	rs7547508	chr1:76327958	A/G	cg22875332	chr1:76189707	ACADM	-0.62	-6.57	-0.37	2.73e-10	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs7666738	0.830	rs10010223	chr4:99021758	G/A	cg03467027	chr4:99064603	C4orf37	0.46	5.81	0.34	1.8e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs116095464	0.558	rs6875291	chr5:264192	T/C	cg22857025	chr5:266934	NA	-1.3	-18.55	-0.75	8.05e-50	Breast cancer;
CESC	cis	rs896854	0.548	rs574183	chr8:95973816	A/G	cg16049864	chr8:95962084	TP53INP1	0.62	9.17	0.49	1.37e-17	Type 2 diabetes;
CESC	cis	rs6570726	0.791	rs12208812	chr6:145900924	T/G	cg05347473	chr6:146136440	FBXO30	0.58	7.57	0.42	6.18e-13	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9948	0.655	rs62152771	chr2:97447121	C/G	cg01990225	chr2:97406019	LMAN2L	-0.98	-7.25	-0.41	4.67e-12	Erectile dysfunction and prostate cancer treatment;
CESC	cis	rs4563143	0.514	rs73030738	chr19:29312328	G/A	cg14983838	chr19:29218262	NA	0.52	5.99	0.35	6.65e-9	Methadone dose in opioid dependence;
CESC	cis	rs10504229	0.639	rs2318145	chr8:58114867	A/G	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs2273669	0.667	rs11153148	chr6:109304084	C/T	cg05315195	chr6:109294784	ARMC2	-0.67	-6.07	-0.35	4.34e-9	Prostate cancer;
CESC	trans	rs2797160	0.904	rs1612274	chr6:126014907	C/A	cg05039488	chr6:79577232	IRAK1BP1	0.48	6.31	0.36	1.18e-9	Endometrial cancer;
CESC	cis	rs3845702	0.866	rs818659	chr2:180870893	G/A	cg01881094	chr2:180872142	CWC22	0.65	6.71	0.38	1.16e-10	Schizophrenia;
CESC	cis	rs1983891	0.706	rs745548	chr6:41557117	G/T	cg20194872	chr6:41519635	FOXP4	-0.45	-6.34	-0.36	9.98e-10	Prostate cancer;
CESC	cis	rs7666738	0.830	rs35938349	chr4:98974998	T/C	cg17366294	chr4:99064904	C4orf37	0.59	8.43	0.46	2.31e-15	Colonoscopy-negative controls vs population controls;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg09645772	chr5:180688272	TRIM52	0.47	6.18	0.35	2.43e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs769267	0.930	rs892022	chr19:19613381	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.51	6.37	0.36	8.35e-10	Tonsillectomy;
CESC	cis	rs10540	1.000	rs61876336	chr11:489537	C/T	cg03352830	chr11:487213	PTDSS2	0.7	6.74	0.38	1.01e-10	Body mass index;
CESC	cis	rs12900413	0.687	rs6496601	chr15:90317694	C/T	cg24249390	chr15:90295951	MESP1	-0.4	-5.63	-0.33	4.62e-8	Coronary artery aneurysm in Kawasaki disease;
CESC	cis	rs950027	0.620	rs2453533	chr15:45641225	C/A	cg21132104	chr15:45694354	SPATA5L1	0.67	8.55	0.46	1.01e-15	Response to fenofibrate (adiponectin levels);
CESC	cis	rs6502050	0.835	rs4789754	chr17:80091941	C/T	cg23985595	chr17:80112537	CCDC57	-0.41	-6.41	-0.37	6.57e-10	Life satisfaction;
CESC	cis	rs1448094	0.512	rs7313278	chr12:86250263	C/T	cg02569458	chr12:86230093	RASSF9	0.48	7.19	0.4	6.74e-12	Major depressive disorder;
CESC	cis	rs870825	0.616	rs9631782	chr4:185626379	A/G	cg04058563	chr4:185651563	MLF1IP	0.64	7.05	0.4	1.59e-11	Blood protein levels;
CESC	cis	rs7590368	0.706	rs56268818	chr2:10956011	C/T	cg15705551	chr2:10952987	PDIA6	0.52	5.12	0.3	5.91e-7	Educational attainment (years of education);
CESC	cis	rs6545977	0.531	rs2539981	chr2:63104904	T/C	cg17519650	chr2:63277830	OTX1	0.66	9.29	0.5	5.78e-18	Prostate cancer;
CESC	trans	rs11098499	0.954	rs12502423	chr4:120424172	A/C	cg25214090	chr10:38739885	LOC399744	0.7	9.73	0.51	2.51e-19	Corneal astigmatism;
CESC	cis	rs6429082	0.764	rs2481095	chr1:235695756	T/C	cg26050004	chr1:235667680	B3GALNT2	-0.57	-6.84	-0.39	5.54e-11	Adiposity;
CESC	cis	rs7208859	0.673	rs11652370	chr17:29097223	G/A	cg04154034	chr17:28927549	LRRC37B2	0.55	5.23	0.31	3.39e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs9790314	1.000	rs6441373	chr3:161026717	T/G	cg03342759	chr3:160939853	NMD3	-0.44	-5.77	-0.33	2.15e-8	Morning vs. evening chronotype;
CESC	cis	rs9457247	0.967	rs2769346	chr6:167370999	A/G	cg07741184	chr6:167504864	NA	-0.3	-5.28	-0.31	2.64e-7	Crohn's disease;
CESC	cis	rs10129255	0.530	rs11624912	chr14:107129907	A/G	cg23076370	chr14:107095027	NA	-0.62	-9.35	-0.5	3.79e-18	Kawasaki disease;
CESC	cis	rs17384381	0.861	rs34561661	chr1:85777250	C/T	cg16011679	chr1:85725395	C1orf52	0.88	9.06	0.49	3.04e-17	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs10256972	0.869	rs13236369	chr7:1033799	G/T	cg07930192	chr7:1003750	NA	0.4	5.4	0.31	1.51e-7	Longevity;Endometriosis;
CESC	cis	rs72781680	0.533	rs56009471	chr2:23890084	A/C	cg20701182	chr2:24300061	SF3B14	0.68	6.37	0.36	8.46e-10	Lymphocyte counts;
CESC	cis	rs2075371	0.897	rs1646743	chr7:134003451	C/A	cg20476274	chr7:133979776	SLC35B4	0.57	7.95	0.44	5.42e-14	Mean platelet volume;
CESC	cis	rs9611565	0.512	rs139571	chr22:42214238	G/A	cg06481639	chr22:41940642	POLR3H	-0.58	-5.72	-0.33	2.87e-8	Vitiligo;
CESC	cis	rs9908102	0.740	rs7215565	chr17:12900517	G/A	cg26162695	chr17:12921313	ELAC2	0.52	5.72	0.33	2.91e-8	Schizophrenia;
CESC	cis	rs4790333	0.715	rs2447110	chr17:2261677	A/G	cg02569219	chr17:2266849	SGSM2	0.43	5.92	0.34	9.78e-9	Proinsulin levels;
CESC	cis	rs1355223	0.506	rs1509659	chr11:34865133	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.54	-6.72	-0.38	1.12e-10	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs6088580	0.634	rs6059890	chr20:33101653	G/C	cg06115741	chr20:33292138	TP53INP2	0.44	5.69	0.33	3.38e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs9840812	0.623	rs6794351	chr3:136292279	C/T	cg15507776	chr3:136538369	TMEM22	0.43	5.19	0.3	4.27e-7	Fibrinogen levels;
CESC	cis	rs7613875	0.578	rs4688753	chr3:50074773	A/G	cg24308560	chr3:49941425	MST1R	0.6	8.72	0.47	3.17e-16	Body mass index;
CESC	cis	rs7659604	0.967	rs10008348	chr4:122666987	A/C	cg19671926	chr4:122722719	EXOSC9	-0.49	-5.98	-0.35	7.01e-9	Type 2 diabetes;
CESC	cis	rs6499255	0.951	rs60472033	chr16:69677709	A/G	cg15192750	chr16:69999425	NA	0.47	5.54	0.32	7.28e-8	IgE levels;
CESC	cis	rs7617773	0.817	rs9847953	chr3:48282695	A/G	cg11946769	chr3:48343235	NME6	0.79	10.88	0.56	4.99e-23	Coronary artery disease;
CESC	cis	rs6831352	0.837	rs2924583	chr4:100044640	T/C	cg13256891	chr4:100009986	ADH5	0.74	8.21	0.45	9.57e-15	Alcohol dependence;
CESC	cis	rs9649465	1.000	rs7803287	chr7:123354807	T/C	cg04330084	chr7:123175371	IQUB	-0.39	-5.23	-0.31	3.47e-7	Migraine;
CESC	trans	rs2727020	0.576	rs1917321	chr11:49377760	A/C	cg00717180	chr2:96193071	NA	-0.44	-6.25	-0.36	1.63e-9	Coronary artery disease;
CESC	trans	rs10463316	0.894	rs13361298	chr5:150765549	T/C	cg24389359	chr12:111284228	CCDC63	-0.34	-6.08	-0.35	4.19e-9	Metabolite levels (Pyroglutamine);
CESC	cis	rs10504073	0.584	rs60449482	chr8:49974865	G/A	cg00325661	chr8:49890786	NA	0.59	8.9	0.48	9.3e-17	Blood metabolite ratios;
CESC	cis	rs9611565	0.685	rs169363	chr22:41853117	G/T	cg06634786	chr22:41940651	POLR3H	0.68	7.08	0.4	1.33e-11	Vitiligo;
CESC	cis	rs28830936	0.528	rs11630242	chr15:42124643	T/C	cg11010575	chr15:42129464	JMJD7-PLA2G4B;JMJD7	-0.38	-5.91	-0.34	1.04e-8	Diastolic blood pressure;
CESC	cis	rs875971	0.528	rs801213	chr7:66014918	C/T	cg11764359	chr7:65958608	NA	-0.81	-9.98	-0.52	4.19e-20	Aortic root size;
CESC	cis	rs10504229	0.679	rs16921623	chr8:58039473	G/C	cg22535103	chr8:58192502	C8orf71	-0.64	-7.12	-0.4	1.02e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs9916302	0.904	rs8070695	chr17:37478062	C/T	cg20243544	chr17:37824526	PNMT	-0.45	-5.39	-0.31	1.59e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs1448094	0.511	rs61930590	chr12:86159959	T/A	cg02569458	chr12:86230093	RASSF9	0.48	7.58	0.42	5.99e-13	Major depressive disorder;
CESC	cis	rs116095464	0.558	rs10058428	chr5:235608	A/G	cg10591111	chr5:226296	SDHA	-0.51	-6.29	-0.36	1.32e-9	Breast cancer;
CESC	cis	rs10504229	0.815	rs72650877	chr8:58164510	T/C	cg22535103	chr8:58192502	C8orf71	-0.95	-10.54	-0.54	6.39e-22	Developmental language disorder (linguistic errors);
CESC	cis	rs561341	1.000	rs535151	chr17:30317405	C/T	cg23018236	chr17:30244563	NA	-0.45	-5.55	-0.32	6.83e-8	Hip circumference adjusted for BMI;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02284982	chr2:128145269	NA	0.57	6.91	0.39	3.63e-11	Gut microbiome composition (summer);
CESC	cis	rs34375054	0.738	rs3751181	chr12:125626535	A/G	cg25124228	chr12:125621409	AACS	-0.61	-8.29	-0.45	5.58e-15	Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs12497850	0.829	rs12636030	chr3:49182237	A/G	cg02487422	chr3:49467188	NICN1	0.5	6.35	0.36	9.14e-10	Parkinson's disease;
CESC	cis	rs10242455	0.702	rs1045012	chr7:98984354	G/C	cg25640893	chr7:99214727	ZNF498	1.04	6.35	0.36	9.57e-10	Blood metabolite levels;
CESC	cis	rs7772486	0.686	rs9497396	chr6:146014963	C/A	cg23711669	chr6:146136114	FBXO30	-0.88	-12.63	-0.61	6.23e-29	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2576037	0.796	rs2576034	chr18:44588548	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.45	5.75	0.33	2.48e-8	Personality dimensions;
CESC	cis	rs9393777	0.513	rs9368451	chr6:26654333	A/G	cg12292205	chr6:26970375	C6orf41	-0.53	-5.76	-0.33	2.33e-8	Intelligence (multi-trait analysis);
CESC	cis	rs1799949	1.000	rs11655505	chr17:41278377	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.67	9.34	0.5	3.98e-18	Menopause (age at onset);
CESC	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg18402987	chr7:1209562	NA	0.76	7.58	0.42	5.85e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs6831352	0.918	rs17218141	chr4:100055908	T/C	cg12011299	chr4:100065546	ADH4	-0.6	-6.62	-0.38	2.04e-10	Alcohol dependence;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg21564803	chr22:43485544	TTLL1	-0.44	-6.46	-0.37	4.94e-10	Gambling;
CESC	cis	rs9303401	0.704	rs740605	chr17:56604811	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.53	6.92	0.39	3.33e-11	Cognitive test performance;
CESC	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg11494091	chr17:61959527	GH2	-0.72	-12.61	-0.61	7.13e-29	Prudent dietary pattern;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25215298	chr1:860022	SAMD11	0.63	7.84	0.43	1.13e-13	Gut microbiome composition (summer);
CESC	cis	rs12497850	0.931	rs7627404	chr3:48819668	A/C	cg03060546	chr3:49711283	APEH	0.44	5.44	0.32	1.18e-7	Parkinson's disease;
CESC	cis	rs12497850	0.931	rs4974080	chr3:49030828	A/C	cg03060546	chr3:49711283	APEH	0.51	6.16	0.35	2.66e-9	Parkinson's disease;
CESC	cis	rs6835098	0.961	rs28709762	chr4:174099149	T/C	cg08422745	chr4:174089978	GALNT7	-0.72	-9.42	-0.5	2.37e-18	Dementia and core Alzheimer's disease neuropathologic changes;
CESC	trans	rs629535	0.814	rs55873935	chr8:70081646	G/A	cg21567404	chr3:27674614	NA	-0.88	-10.3	-0.53	3.7e-21	Dupuytren's disease;
CESC	cis	rs9811920	0.965	rs9849632	chr3:99867211	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.45	7.37	0.41	2.19e-12	Axial length;
CESC	cis	rs9733	0.818	rs12130363	chr1:150688596	T/C	cg22823121	chr1:150693482	HORMAD1	-0.41	-6.39	-0.37	7.49e-10	Tonsillectomy;
CESC	cis	rs13108904	0.840	rs13106092	chr4:1257290	T/A	cg00684032	chr4:1343700	KIAA1530	0.42	6.02	0.35	5.68e-9	Obesity-related traits;
CESC	cis	rs7592578	0.639	rs61709084	chr2:191287685	A/C	cg10560079	chr2:191398806	TMEM194B	-0.6	-5.99	-0.35	6.83e-9	Diastolic blood pressure;
CESC	cis	rs11642862	0.792	rs75586365	chr16:30996363	C/T	cg02466173	chr16:30829666	NA	-0.57	-5.21	-0.3	3.81e-7	Tonsillectomy;
CESC	cis	rs1218582	0.772	rs6699043	chr1:154913021	T/C	cg03351412	chr1:154909251	PMVK	0.68	9.09	0.49	2.32e-17	Prostate cancer;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg00031476	chr2:28114244	BRE;RBKS;LOC100302650	0.39	6.05	0.35	4.83e-9	Gambling;
CESC	cis	rs4727027	0.933	rs12704063	chr7:148827909	T/C	cg23583168	chr7:148888333	NA	-0.79	-12.21	-0.6	1.63e-27	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs9303280	0.901	rs2313430	chr17:37929816	T/C	cg19468946	chr17:37922297	IKZF3	0.37	5.1	0.3	6.46e-7	Self-reported allergy;
CESC	cis	rs9837602	0.507	rs793452	chr3:99529523	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.58	8.89	0.48	9.9e-17	Breast cancer;
CESC	cis	rs10751667	1.000	rs7395632	chr11:958789	C/T	cg20946044	chr11:1010712	AP2A2	0.4	5.42	0.32	1.34e-7	Alzheimer's disease (late onset);
CESC	cis	rs9815354	0.812	rs4264702	chr3:41952539	T/A	cg03022575	chr3:42003672	ULK4	0.68	5.92	0.34	9.9e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs6580649	0.769	rs60629297	chr12:48438290	T/A	cg05342945	chr12:48394962	COL2A1	0.5	5.67	0.33	3.69e-8	Lung cancer;
CESC	cis	rs2228479	0.702	rs11649501	chr16:89850957	A/T	cg19635926	chr16:89946313	TCF25	0.67	5.08	0.3	7.08e-7	Skin colour saturation;
CESC	cis	rs4803468	0.967	rs4803462	chr19:41908936	T/A	cg14132834	chr19:41945861	ATP5SL	-0.65	-8.1	-0.45	2.05e-14	Height;
CESC	cis	rs60871478	0.786	rs62432898	chr7:826102	G/A	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.58	5.69	0.33	3.43e-8	Cerebrospinal P-tau181p levels;
CESC	cis	rs2070997	0.667	rs13295907	chr9:133718242	G/T	cg11464064	chr9:133710261	ABL1	0.66	7.38	0.41	1.99e-12	Response to amphetamines;
CESC	cis	rs7727544	0.660	rs2631361	chr5:131707380	C/A	cg07395648	chr5:131743802	NA	0.39	5.14	0.3	5.25e-7	Blood metabolite levels;
CESC	cis	rs7107174	0.792	rs12291726	chr11:78088210	A/G	cg02023728	chr11:77925099	USP35	0.46	6.08	0.35	4.14e-9	Testicular germ cell tumor;
CESC	cis	rs10752881	0.875	rs10752894	chr1:183050610	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.85	13.7	0.64	1.21e-32	Colorectal cancer;
CESC	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.64	7.45	0.42	1.33e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg26894841	chr16:90016551	DEF8	0.33	6.0	0.35	6.52e-9	Electrocardiographic conduction measures;
CESC	cis	rs17376456	0.877	rs10059230	chr5:93450347	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.62	5.44	0.32	1.23e-7	Diabetic retinopathy;
CESC	cis	rs6121246	0.529	rs6060145	chr20:30178631	T/C	cg13852791	chr20:30311386	BCL2L1	0.61	5.83	0.34	1.62e-8	Mean corpuscular hemoglobin;
CESC	cis	rs4148883	0.504	rs28720150	chr4:100132790	T/G	cg13256891	chr4:100009986	ADH5	-0.5	-6.6	-0.38	2.2e-10	Alcohol dependence;
CESC	cis	rs13082711	0.911	rs2172298	chr3:27425611	T/C	cg02860705	chr3:27208620	NA	0.52	6.57	0.37	2.64e-10	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CESC	cis	rs11155671	0.530	rs7756850	chr6:150212596	G/C	cg09699651	chr6:150184138	LRP11	0.54	7.4	0.41	1.79e-12	Testicular germ cell tumor;
CESC	cis	rs941408	1.000	rs2260416	chr19:2796355	G/A	cg00079169	chr19:2811669	THOP1	0.45	6.44	0.37	5.69e-10	Total cholesterol levels;
CESC	trans	rs7246657	0.943	rs2891699	chr19:37920237	A/G	cg24637308	chr11:6592297	DNHD1	0.54	6.34	0.36	1.01e-9	Coronary artery calcification;
CESC	cis	rs9901225	1	rs9901225	chr17:40755811	C/T	cg11629889	chr17:40839022	CNTNAP1	0.54	8.62	0.47	6.23e-16	Colorectal or endometrial cancer;
CESC	trans	rs7668874	0.779	rs7697741	chr4:116805075	A/G	cg05356848	chr7:140098092	SLC37A3	0.64	6.34	0.36	1e-9	Response to platinum-based chemotherapy (carboplatin);
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg13917004	chr19:42462874	RABAC1	-0.52	-6.6	-0.38	2.19e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs9309473	1.000	rs11689392	chr2:73622026	T/C	cg20560298	chr2:73613845	ALMS1	-0.47	-6.34	-0.36	9.83e-10	Metabolite levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04422277	chr15:30918065	ARHGAP11B	-0.58	-6.84	-0.39	5.38e-11	Gut microbiome composition (summer);
CESC	cis	rs1451375	0.617	rs1376524	chr7:50563582	G/A	cg14593290	chr7:50529359	DDC	-0.5	-6.26	-0.36	1.59e-9	Malaria;
CESC	cis	rs950776	0.616	rs56276142	chr15:78889795	T/C	cg24631222	chr15:78858424	CHRNA5	-0.43	-5.43	-0.32	1.25e-7	Sudden cardiac arrest;
CESC	cis	rs7851660	0.805	rs10759981	chr9:100635780	A/G	cg13688889	chr9:100608707	NA	-0.62	-8.62	-0.47	6.13e-16	Strep throat;
CESC	cis	rs853679	0.517	rs3757187	chr6:28107654	T/C	cg22143856	chr6:28129313	ZNF389	0.53	6.86	0.39	4.9e-11	Depression;
CESC	cis	rs2066819	1.000	rs78149779	chr12:56694817	A/G	cg26714650	chr12:56694279	CS	-1.52	-10.39	-0.54	1.95e-21	Psoriasis vulgaris;
CESC	cis	rs12477438	0.520	rs2632277	chr2:99778985	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.85	15.95	0.7	1.29e-40	Chronic sinus infection;
CESC	cis	rs4319547	0.626	rs10744210	chr12:122931793	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.5	-5.77	-0.33	2.19e-8	Body mass index;
CESC	cis	rs13191362	0.935	rs13219926	chr6:163004213	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.88	9.16	0.49	1.46e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs2303745	0.589	rs6512182	chr19:17399476	G/T	cg02221750	chr19:17393354	ANKLE1	-0.51	-6.24	-0.36	1.71e-9	Systemic lupus erythematosus;
CESC	cis	rs116095464	0.558	rs28635197	chr5:279071	T/C	cg22857025	chr5:266934	NA	-1.29	-18.38	-0.75	3.21e-49	Breast cancer;
CESC	cis	rs67311347	1.000	rs2305522	chr3:40429358	A/G	cg24209194	chr3:40518798	ZNF619	0.47	6.07	0.35	4.32e-9	Renal cell carcinoma;
CESC	cis	rs116095464	0.558	rs7356696	chr5:284251	A/G	cg20965017	chr5:231967	SDHA	-0.46	-5.2	-0.3	4.02e-7	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14714711	chr20:13619694	TASP1	0.6	6.23	0.36	1.82e-9	Gut microbiome composition (summer);
CESC	cis	rs1832871	0.711	rs6906854	chr6:158695000	C/T	cg07165851	chr6:158734300	TULP4	0.57	5.97	0.34	7.78e-9	Height;
CESC	cis	rs6032067	0.777	rs56063128	chr20:43783210	G/A	cg10761708	chr20:43804764	PI3	0.54	6.43	0.37	5.89e-10	Blood protein levels;
CESC	cis	rs875971	0.540	rs4717275	chr7:65265180	C/T	cg11987759	chr7:65425863	GUSB	0.46	6.14	0.35	2.94e-9	Aortic root size;
CESC	cis	rs7107174	1.000	rs2450122	chr11:77930345	T/C	cg02023728	chr11:77925099	USP35	0.46	5.86	0.34	1.35e-8	Testicular germ cell tumor;
CESC	cis	rs2859741	0.528	rs2359647	chr1:37483054	A/T	cg09363841	chr1:37513479	NA	-0.5	-7.19	-0.4	6.5e-12	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
CESC	cis	rs9309473	0.607	rs6546824	chr2:73587331	G/A	cg20560298	chr2:73613845	ALMS1	-0.46	-6.2	-0.36	2.14e-9	Metabolite levels;
CESC	cis	rs12142240	0.698	rs7525309	chr1:46809025	G/T	cg00530320	chr1:46809349	NSUN4	0.6	7.98	0.44	4.48e-14	Menopause (age at onset);
CESC	trans	rs208520	0.954	rs72884027	chr6:66995044	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.84	9.14	0.49	1.65e-17	Exhaled nitric oxide output;
CESC	cis	rs4455778	0.565	rs7809432	chr7:49014472	C/T	cg26309511	chr7:48887640	NA	-0.35	-5.1	-0.3	6.4e-7	Lung cancer in never smokers;
CESC	cis	rs9527	0.590	rs10883830	chr10:104851285	G/A	cg04362960	chr10:104952993	NT5C2	0.44	5.6	0.33	5.49e-8	Arsenic metabolism;
CESC	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg18402987	chr7:1209562	NA	0.4	5.16	0.3	4.94e-7	Longevity;Endometriosis;
CESC	cis	rs7618915	0.547	rs62253733	chr3:52653414	A/G	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.36	6.26	0.36	1.52e-9	Bipolar disorder;
CESC	cis	rs11764590	0.694	rs10235664	chr7:2086814	T/C	cg21782813	chr7:2030301	MAD1L1	-0.4	-5.35	-0.31	1.91e-7	Neuroticism;
CESC	cis	rs1799949	0.931	rs34474989	chr17:41445410	A/T	cg05368731	chr17:41323189	NBR1	0.58	8.27	0.45	6.71e-15	Menopause (age at onset);
CESC	cis	rs7727544	0.735	rs272875	chr5:131674888	T/C	cg07395648	chr5:131743802	NA	-0.47	-6.3	-0.36	1.25e-9	Blood metabolite levels;
CESC	cis	rs2228479	0.867	rs11645970	chr16:89958118	G/A	cg06558623	chr16:89946397	TCF25	1.08	9.18	0.49	1.3e-17	Skin colour saturation;
CESC	cis	rs8028182	0.636	rs28783769	chr15:75849009	C/A	cg20655648	chr15:75932815	IMP3	0.49	5.95	0.34	8.55e-9	Sudden cardiac arrest;
CESC	cis	rs826838	0.967	rs1719858	chr12:39124505	C/T	cg26384229	chr12:38710491	ALG10B	-0.67	-11.02	-0.56	1.72e-23	Heart rate;
CESC	trans	rs61931739	0.500	rs7309931	chr12:34483471	A/C	cg26384229	chr12:38710491	ALG10B	0.55	7.58	0.42	5.66e-13	Morning vs. evening chronotype;
CESC	cis	rs9649213	0.593	rs6969731	chr7:97924571	T/G	cg00277769	chr7:97922759	BAIAP2L1	-0.34	-5.52	-0.32	7.98e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs12579753	0.719	rs4384447	chr12:82268069	G/C	cg23701643	chr12:82153290	PPFIA2	-0.36	-5.27	-0.31	2.81e-7	Resting heart rate;
CESC	cis	rs7772486	0.686	rs702305	chr6:145973840	A/G	cg23711669	chr6:146136114	FBXO30	-0.91	-13.72	-0.64	9.83e-33	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9911578	0.967	rs6503883	chr17:56917543	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.26	0.31	3.04e-7	Intelligence (multi-trait analysis);
CESC	cis	rs875971	0.798	rs57739047	chr7:65972566	A/T	cg18252515	chr7:66147081	NA	-0.43	-5.62	-0.33	4.9e-8	Aortic root size;
CESC	cis	rs9916302	0.904	rs35285898	chr17:37555872	A/C	cg07936489	chr17:37558343	FBXL20	0.8	11.5	0.58	4.2e-25	Glomerular filtration rate (creatinine);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16001793	chr1:161369711	NA	0.57	6.5	0.37	3.94e-10	Gut microbiome composition (summer);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg04334422	chr4:8398880	ACOX3	0.47	6.11	0.35	3.45e-9	Fibrinogen levels;
CESC	cis	rs2204008	0.744	rs67889662	chr12:38327042	T/A	cg13010199	chr12:38710504	ALG10B	0.53	6.54	0.37	3.12e-10	Bladder cancer;
CESC	cis	rs9300255	0.508	rs1716176	chr12:123655467	T/G	cg05973401	chr12:123451056	ABCB9	0.54	6.04	0.35	5.31e-9	Neutrophil percentage of white cells;
CESC	cis	rs501120	0.810	rs684196	chr10:44745950	A/T	cg09554077	chr10:44749378	NA	0.5	6.64	0.38	1.74e-10	Coronary artery disease;Coronary heart disease;
CESC	cis	rs644799	1.000	rs627568	chr11:95569253	A/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.55	6.53	0.37	3.43e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs7927592	0.673	rs498782	chr11:68275851	A/G	cg20283391	chr11:68216788	NA	-0.45	-5.64	-0.33	4.39e-8	Total body bone mineral density;
CESC	cis	rs2288073	0.619	rs6713263	chr2:24375463	A/G	cg06627628	chr2:24431161	ITSN2	-0.5	-6.54	-0.37	3.24e-10	Venous thromboembolism (SNP x SNP interaction);
CESC	cis	rs9443189	1.000	rs3822957	chr6:76607280	A/G	cg01950844	chr6:76311363	SENP6	-0.61	-6.31	-0.36	1.18e-9	Prostate cancer;
CESC	cis	rs2243480	1.000	rs4149468	chr7:65825690	T/C	cg18252515	chr7:66147081	NA	-1.39	-14.0	-0.65	1.04e-33	Diabetic kidney disease;
CESC	cis	rs3087591	1.000	rs6505235	chr17:29688603	C/A	cg24425628	chr17:29625626	OMG;NF1	-0.48	-5.99	-0.35	6.66e-9	Hip circumference;
CESC	cis	rs798554	0.524	rs2283784	chr7:2855337	T/C	cg13628971	chr7:2884303	GNA12	0.43	5.76	0.33	2.35e-8	Height;
CESC	cis	rs7385804	0.633	rs221795	chr7:100283261	C/T	cg20848291	chr7:100343083	ZAN	0.56	7.72	0.43	2.32e-13	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
CESC	cis	rs7927771	0.864	rs3781625	chr11:47443080	T/C	cg18512352	chr11:47633146	NA	-0.51	-7.24	-0.41	4.87e-12	Subjective well-being;
CESC	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg06873352	chr17:61820015	STRADA	0.72	12.6	0.61	7.87e-29	Prudent dietary pattern;
CESC	cis	rs9611519	0.894	rs9611488	chr22:41462592	G/T	cg03806693	chr22:41940476	POLR3H	-0.57	-5.94	-0.34	8.9e-9	Neuroticism;
CESC	cis	rs4699052	0.662	rs1400363	chr4:104250722	A/C	cg16532752	chr4:104119610	CENPE	-0.44	-6.49	-0.37	4.12e-10	Testicular germ cell tumor;
CESC	cis	rs7520050	0.966	rs809775	chr1:46538040	A/T	cg03146154	chr1:46216737	IPP	-0.44	-5.73	-0.33	2.78e-8	Red blood cell count;Reticulocyte count;
CESC	cis	rs6748734	1.000	rs7604393	chr2:241825034	T/G	cg04034577	chr2:241836375	C2orf54	-0.48	-8.06	-0.44	2.66e-14	Urinary metabolites;
CESC	cis	rs909674	0.818	rs8137426	chr22:39844350	T/G	cg24399712	chr22:39784796	NA	-0.83	-10.33	-0.54	2.97e-21	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs6570726	0.764	rs9403731	chr6:145907937	G/A	cg23711669	chr6:146136114	FBXO30	0.9	13.39	0.64	1.41e-31	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs3733585	0.699	rs10017674	chr4:9967053	T/C	cg00071950	chr4:10020882	SLC2A9	-0.7	-11.44	-0.58	6.69e-25	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs6912958	0.781	rs9444522	chr6:88309705	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-6.69	-0.38	1.35e-10	Monocyte percentage of white cells;
CESC	cis	rs2735413	0.632	rs4436790	chr16:78097252	G/A	cg04733911	chr16:78082701	NA	0.47	7.32	0.41	3.04e-12	Systolic blood pressure (alcohol consumption interaction);
CESC	cis	rs12824058	0.831	rs55726136	chr12:130810312	G/A	cg26677194	chr12:130822605	PIWIL1	0.52	6.81	0.39	6.58e-11	Menopause (age at onset);
CESC	cis	rs2070488	0.965	rs6805386	chr3:38557921	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.91	-16.76	-0.72	1.69e-43	Electrocardiographic conduction measures;
CESC	cis	rs9916302	0.904	rs8065879	chr17:37515978	G/A	cg00129232	chr17:37814104	STARD3	0.57	7.44	0.42	1.38e-12	Glomerular filtration rate (creatinine);
CESC	cis	rs10242455	0.702	rs74552228	chr7:98977046	C/T	cg25640893	chr7:99214727	ZNF498	0.94	5.73	0.33	2.71e-8	Blood metabolite levels;
CESC	cis	rs3806843	0.808	rs6893708	chr5:140125922	T/C	cg26395211	chr5:140044315	WDR55	0.39	5.13	0.3	5.55e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs13191362	1.000	rs73035023	chr6:163000927	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.83	8.39	0.46	3.02e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs9611565	0.649	rs202645	chr22:41798520	A/G	cg06481639	chr22:41940642	POLR3H	0.64	6.58	0.37	2.51e-10	Vitiligo;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg01382281	chr19:56104340	FIZ1	0.46	6.05	0.35	4.99e-9	Fibrinogen levels;
CESC	cis	rs5750830	0.649	rs4337572	chr22:39800704	C/G	cg05872129	chr22:39784769	NA	-0.75	-9.12	-0.49	2e-17	Intelligence (multi-trait analysis);
CESC	trans	rs877282	0.583	rs10904566	chr10:821662	C/G	cg22713356	chr15:30763199	NA	1.07	9.68	0.51	3.6e-19	Uric acid levels;
CESC	cis	rs2014572	0.967	rs8100154	chr19:57765432	A/G	cg12963866	chr19:57752005	ZNF805	-0.48	-6.47	-0.37	4.61e-10	Hyperactive-impulsive symptoms;
CESC	cis	rs6762	0.748	rs28735718	chr11:839629	A/G	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.75	-9.89	-0.52	7.59e-20	Mean platelet volume;
CESC	cis	rs11676348	0.755	rs1008562	chr2:219026972	G/C	cg00012203	chr2:219082015	ARPC2	0.59	7.61	0.42	4.8e-13	Ulcerative colitis;
CESC	cis	rs1609391	0.567	rs835633	chr3:136676496	T/C	cg03617693	chr3:136751559	NA	0.37	5.29	0.31	2.62e-7	Neuroticism;
CESC	cis	rs9796	0.621	rs12324159	chr15:41462468	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.5	-7.42	-0.41	1.62e-12	Menopause (age at onset);
CESC	cis	rs6032067	0.852	rs17333103	chr20:43803613	C/T	cg10761708	chr20:43804764	PI3	0.55	6.55	0.37	2.91e-10	Blood protein levels;
CESC	cis	rs6952808	0.529	rs73038442	chr7:2139457	C/T	cg23048001	chr7:2026167	MAD1L1	0.45	5.74	0.33	2.61e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs2120019	1.000	rs2415255	chr15:75332412	A/G	cg17294928	chr15:75287854	SCAMP5	-0.73	-8.22	-0.45	8.88e-15	Blood trace element (Zn levels);
CESC	trans	rs55704346	0.566	rs908056	chr4:25394531	G/A	cg01822600	chr1:245751692	KIF26B	0.42	6.17	0.35	2.58e-9	Tonsillectomy;
CESC	cis	rs6754311	0.509	rs3820794	chr2:136505546	C/T	cg15123519	chr2:136567270	LCT	0.29	5.09	0.3	6.68e-7	Mosquito bite size;
CESC	cis	rs7927771	0.524	rs1563820	chr11:47833398	A/T	cg18512352	chr11:47633146	NA	-0.36	-5.55	-0.32	6.84e-8	Subjective well-being;
CESC	cis	rs116095464	0.558	rs7730700	chr5:264713	G/A	cg12570787	chr5:219185	SDHA;CCDC127	0.53	5.49	0.32	9.44e-8	Breast cancer;
CESC	cis	rs6540559	1.000	rs4844895	chr1:209958580	T/C	cg25204440	chr1:209979598	IRF6	0.63	7.82	0.43	1.22e-13	Cleft lip with or without cleft palate;
CESC	cis	rs514406	0.793	rs4500255	chr1:53213279	A/G	cg08736216	chr1:53307985	ZYG11A	0.32	5.61	0.33	4.96e-8	Monocyte count;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg01655781	chr12:102513797	NUP37;C12orf48	-0.48	-6.28	-0.36	1.35e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs8072100	0.713	rs8075058	chr17:45482857	A/G	cg08085267	chr17:45401833	C17orf57	-0.52	-6.64	-0.38	1.81e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs9486719	1.000	rs2092096	chr6:96870919	A/G	cg18709589	chr6:96969512	KIAA0776	0.56	6.1	0.35	3.8e-9	Migraine;Coronary artery disease;
CESC	cis	rs7223966	1.000	rs9899788	chr17:61756384	G/A	cg11494091	chr17:61959527	GH2	0.38	5.35	0.31	1.93e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs2836974	0.568	rs371625	chr21:40535271	A/G	cg17971929	chr21:40555470	PSMG1	-0.87	-12.83	-0.62	1.2e-29	Cognitive function;
CESC	cis	rs35306767	0.761	rs1871621	chr10:1049596	C/T	cg26597838	chr10:835615	NA	0.7	6.53	0.37	3.31e-10	Eosinophil percentage of granulocytes;
CESC	cis	rs9487051	0.676	rs6910119	chr6:109599263	A/G	cg12927641	chr6:109611667	NA	-0.36	-5.43	-0.32	1.28e-7	Reticulocyte fraction of red cells;
CESC	cis	rs854765	0.547	rs7223696	chr17:17915791	G/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.53	7.66	0.43	3.59e-13	Total body bone mineral density;
CESC	cis	rs854765	0.583	rs62064158	chr17:17826935	T/C	cg09796270	chr17:17721594	SREBF1	0.43	6.05	0.35	4.93e-9	Total body bone mineral density;
CESC	cis	rs10465746	0.657	rs67045520	chr1:84414998	G/T	cg10977910	chr1:84465055	TTLL7	0.49	6.45	0.37	5.15e-10	Obesity-related traits;
CESC	cis	rs853679	0.517	rs1904840	chr6:28108232	C/T	cg22143856	chr6:28129313	ZNF389	0.51	6.55	0.37	3e-10	Depression;
CESC	cis	rs4843747	0.671	rs4075998	chr16:88106776	G/A	cg17633681	chr16:88106987	BANP	0.76	10.51	0.54	8.01e-22	Menopause (age at onset);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg07638871	chr5:56247860	MIER3	-0.51	-6.48	-0.37	4.39e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs172166	0.694	rs1770131	chr6:28086413	C/T	cg23161317	chr6:28129485	ZNF389	0.4	5.69	0.33	3.29e-8	Cardiac Troponin-T levels;
CESC	cis	rs2404602	0.692	rs7174673	chr15:77071998	T/C	cg26408565	chr15:76604113	ETFA	-0.38	-5.52	-0.32	8.03e-8	Blood metabolite levels;
CESC	cis	rs1862618	0.853	rs1862619	chr5:56098256	T/A	cg24549020	chr5:56110836	MAP3K1	0.59	6.95	0.39	2.75e-11	Initial pursuit acceleration;
CESC	trans	rs916888	0.821	rs199512	chr17:44857352	T/C	cg01341218	chr17:43662625	NA	-0.85	-10.53	-0.54	6.95e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	trans	rs9693444	0.898	rs4732697	chr8:29519861	A/G	cg23640300	chr22:24059086	LOC91316	-0.45	-6.46	-0.37	4.93e-10	Breast cancer;
CESC	cis	rs3916	0.955	rs35525135	chr12:121140064	T/C	cg21892295	chr12:121157589	UNC119B	-0.35	-5.12	-0.3	5.93e-7	Urinary metabolites (H-NMR features);
CESC	cis	rs3020736	0.500	rs7292241	chr22:42492063	G/A	cg12850546	chr22:42539477	CYP2D7P1	0.45	5.3	0.31	2.4e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs8014204	0.748	rs12889277	chr14:75229376	A/T	cg08847533	chr14:75593920	NEK9	0.46	5.85	0.34	1.45e-8	Caffeine consumption;
CESC	cis	rs7824557	0.606	rs1435277	chr8:11196970	C/T	cg21775007	chr8:11205619	TDH	0.53	7.78	0.43	1.59e-13	Retinal vascular caliber;
CESC	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.58	-9.25	-0.49	7.81e-18	Longevity;Endometriosis;
CESC	cis	rs2250402	0.510	rs7535	chr15:40328575	G/C	cg01081584	chr15:40268610	EIF2AK4	-0.56	-5.26	-0.31	3.01e-7	Corneal curvature;
CESC	trans	rs7395662	0.500	rs10838984	chr11:48640485	C/T	cg15704280	chr7:45808275	SEPT13	-0.58	-6.87	-0.39	4.44e-11	HDL cholesterol;
CESC	cis	rs11190604	1.000	rs2489045	chr10:102344754	C/T	cg07080220	chr10:102295463	HIF1AN	0.65	5.97	0.34	7.75e-9	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs6582630	0.555	rs11503799	chr12:38294578	G/A	cg26384229	chr12:38710491	ALG10B	-0.43	-5.63	-0.33	4.55e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs4665809	1.000	rs1550382	chr2:26266877	T/G	cg26314531	chr2:26401878	FAM59B	-0.62	-6.91	-0.39	3.56e-11	Gut microbiome composition (summer);
CESC	cis	rs4481887	0.636	rs4397683	chr1:248411089	C/T	cg00666640	chr1:248458726	OR2T12	0.34	5.43	0.32	1.26e-7	Common traits (Other);
CESC	cis	rs826838	0.967	rs7299170	chr12:38789536	G/A	cg26384229	chr12:38710491	ALG10B	0.83	14.61	0.67	7.23e-36	Heart rate;
CESC	cis	rs7945705	0.967	rs10769970	chr11:8917937	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.51	8.16	0.45	1.39e-14	Hemoglobin concentration;
CESC	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-6.15	-0.35	2.85e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs751728	0.687	rs4711355	chr6:33759906	G/T	cg25922239	chr6:33757077	LEMD2	0.44	6.16	0.35	2.7e-9	Crohn's disease;
CESC	cis	rs79839061	0.667	rs73207777	chr4:836046	A/G	cg07828340	chr4:882639	GAK	0.81	5.74	0.33	2.62e-8	Intelligence (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08172461	chr2:200820611	C2orf60;C2orf47	0.57	6.52	0.37	3.47e-10	Gut microbiome composition (summer);
CESC	cis	rs35110281	0.667	rs7282405	chr21:45123611	C/G	cg04455712	chr21:45112962	RRP1B	0.49	7.91	0.44	7.1e-14	Mean corpuscular volume;
CESC	cis	rs12579753	0.719	rs12369450	chr12:82266940	A/G	cg23701643	chr12:82153290	PPFIA2	-0.35	-5.19	-0.3	4.11e-7	Resting heart rate;
CESC	cis	rs854765	0.583	rs67253360	chr17:17828973	T/C	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.55	7.28	0.41	3.9e-12	Total body bone mineral density;
CESC	cis	rs8067545	0.611	rs12938355	chr17:20195217	A/G	cg13482628	chr17:19912719	NA	-0.42	-5.61	-0.33	5.2e-8	Schizophrenia;
CESC	cis	rs10504229	1.000	rs56740825	chr8:58175617	A/G	cg24829409	chr8:58192753	C8orf71	-0.76	-10.0	-0.52	3.53e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs2204008	0.623	rs1663281	chr12:38120936	A/G	cg26384229	chr12:38710491	ALG10B	-0.43	-5.92	-0.34	9.92e-9	Bladder cancer;
CESC	cis	rs3892630	0.824	rs12976069	chr19:33280084	G/A	cg13157960	chr19:33183277	NUDT19	0.55	5.29	0.31	2.55e-7	Red blood cell traits;
CESC	cis	rs4908760	0.965	rs10864354	chr1:8549741	C/T	cg00120948	chr1:8484417	RERE	-0.33	-5.15	-0.3	5.07e-7	Vitiligo;
CESC	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg06873352	chr17:61820015	STRADA	0.72	12.61	0.61	7.18e-29	Prudent dietary pattern;
CESC	cis	rs4595586	0.545	rs2197941	chr12:39402223	G/A	cg26384229	chr12:38710491	ALG10B	0.54	7.64	0.42	3.96e-13	Morning vs. evening chronotype;
CESC	cis	rs2075371	1.000	rs2241336	chr7:133979578	A/G	cg20476274	chr7:133979776	SLC35B4	0.63	9.19	0.49	1.17e-17	Mean platelet volume;
CESC	cis	rs3741404	0.825	rs11604782	chr11:63946650	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.98	15.28	0.68	3.16e-38	Platelet count;
CESC	cis	rs9322193	0.962	rs4552	chr6:150132319	A/T	cg05861140	chr6:150128134	PCMT1	-0.37	-5.33	-0.31	2.07e-7	Lung cancer;
CESC	cis	rs2594989	0.708	rs2594997	chr3:11365739	A/T	cg00170343	chr3:11313890	ATG7	0.56	5.04	0.3	8.52e-7	Circulating chemerin levels;
CESC	cis	rs4076764	0.958	rs10917748	chr1:163400377	T/C	cg24596788	chr1:163392923	NA	-0.5	-7.17	-0.4	7.57e-12	Motion sickness;
CESC	cis	rs9908102	0.740	rs4792308	chr17:12899726	A/G	cg26162695	chr17:12921313	ELAC2	0.52	5.65	0.33	4.11e-8	Schizophrenia;
CESC	cis	rs7107174	1.000	rs2511190	chr11:77988310	T/C	cg02023728	chr11:77925099	USP35	0.47	6.49	0.37	4.19e-10	Testicular germ cell tumor;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00300090	chr3:4345167	SETMAR	0.57	6.46	0.37	4.86e-10	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00045303	chr21:37432620	SETD4	0.6	6.35	0.36	9.44e-10	Gut microbiome composition (summer);
CESC	cis	rs4713118	0.586	rs6905516	chr6:28086478	A/G	cg23281280	chr6:28129359	ZNF389	0.58	7.93	0.44	6.31e-14	Parkinson's disease;
CESC	cis	rs7208859	0.623	rs11657777	chr17:29091785	T/C	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.91e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs10845606	1.000	rs10845607	chr12:12835228	C/T	cg09462578	chr12:12878428	APOLD1	-0.66	-7.21	-0.41	5.73e-12	Systemic lupus erythematosus;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26634121	chr16:88897219	GALNS	-0.63	-7.14	-0.4	9.21e-12	Gut microbiome composition (summer);
CESC	cis	rs875971	0.660	rs3857686	chr7:66036191	C/T	cg14393609	chr7:65229607	NA	-0.45	-6.13	-0.35	3.17e-9	Aortic root size;
CESC	cis	rs13256369	0.851	rs13267036	chr8:8566685	G/A	cg17143192	chr8:8559678	CLDN23	0.74	8.11	0.45	1.85e-14	Obesity-related traits;
CESC	cis	rs1218582	0.628	rs12130132	chr1:154880386	C/T	cg24250549	chr1:154909240	PMVK	0.54	7.21	0.41	5.82e-12	Prostate cancer;
CESC	trans	rs7618501	0.633	rs11130228	chr3:50003246	C/T	cg21659725	chr3:3221576	CRBN	0.49	6.79	0.38	7.26e-11	Intelligence (multi-trait analysis);
CESC	cis	rs6952808	0.692	rs59619245	chr7:2068630	C/T	cg08027265	chr7:2291960	NA	-0.4	-6.14	-0.35	3.02e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs9649465	1.000	rs627689	chr7:123400543	C/T	cg04330084	chr7:123175371	IQUB	-0.38	-5.04	-0.3	8.78e-7	Migraine;
CESC	cis	rs10751667	0.666	rs10794347	chr11:939863	G/A	cg01483505	chr11:975446	AP2A2	0.38	5.18	0.3	4.33e-7	Alzheimer's disease (late onset);
CESC	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.88	13.25	0.63	4.33e-31	Prudent dietary pattern;
CESC	cis	rs4925325	1.000	rs4925325	chr20:60514224	G/A	cg18761221	chr20:60518478	NA	-0.54	-7.45	-0.42	1.35e-12	Obesity-related traits;
CESC	cis	rs7666738	0.830	rs28417577	chr4:99053007	T/C	cg03467027	chr4:99064603	C4orf37	0.47	5.98	0.34	7.19e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3806843	1.000	rs10038174	chr5:140210616	G/A	cg16179182	chr5:140090404	VTRNA1-1	-0.41	-5.25	-0.31	3.08e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs7727544	0.735	rs272860	chr5:131684175	C/G	cg24060327	chr5:131705240	SLC22A5	-0.65	-8.62	-0.47	6.22e-16	Blood metabolite levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13704678	chr3:10362667	SEC13	0.6	6.86	0.39	4.74e-11	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.830	rs7662199	chr4:99019766	G/A	cg03467027	chr4:99064603	C4orf37	0.45	5.72	0.33	2.89e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs96067	0.772	rs1033891	chr1:36608402	A/G	cg24686825	chr1:36642396	MAP7D1	-0.45	-5.15	-0.3	5e-7	Corneal structure;
CESC	cis	rs1559088	0.948	rs7257858	chr19:33591231	T/C	cg17764715	chr19:33622953	WDR88	0.49	6.32	0.36	1.11e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs514406	0.698	rs522259	chr1:53365481	A/G	cg16325326	chr1:53192061	ZYG11B	0.53	7.56	0.42	6.47e-13	Monocyte count;
CESC	cis	rs7927592	0.731	rs2156463	chr11:68386311	T/C	cg16797656	chr11:68205561	LRP5	0.48	7.16	0.4	8.17e-12	Total body bone mineral density;
CESC	cis	rs611744	0.647	rs615233	chr8:109254262	C/T	cg21045802	chr8:109455806	TTC35	0.49	6.06	0.35	4.71e-9	Dupuytren's disease;
CESC	cis	rs11645898	0.872	rs34832584	chr16:72162966	G/T	cg14768367	chr16:72042858	DHODH	-0.76	-6.45	-0.37	5.39e-10	Blood protein levels;
CESC	cis	rs116095464	0.542	rs28650039	chr5:273954	C/A	cg10591111	chr5:226296	SDHA	-0.52	-6.2	-0.36	2.12e-9	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05949034	chr4:83295361	HNRNPD	0.58	6.41	0.37	6.51e-10	Gut microbiome composition (summer);
CESC	cis	rs6484504	0.576	rs208090	chr11:31190992	T/C	cg14844989	chr11:31128820	NA	-0.42	-6.01	-0.35	6.07e-9	Red blood cell count;
CESC	cis	rs1707322	0.721	rs10890336	chr1:46111056	C/T	cg05343316	chr1:45956843	TESK2	0.5	6.05	0.35	4.9e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7666738	0.830	rs13101352	chr4:98957544	C/T	cg05340658	chr4:99064831	C4orf37	0.8	12.4	0.61	3.76e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4713118	0.527	rs4713151	chr6:28136356	G/A	cg20151795	chr6:28129481	ZNF389	0.41	5.3	0.31	2.46e-7	Parkinson's disease;
CESC	cis	rs2228479	0.850	rs11644526	chr16:89898660	C/T	cg04013166	chr16:89971882	TCF25	0.72	5.75	0.33	2.41e-8	Skin colour saturation;
CESC	cis	rs2836974	0.932	rs56306759	chr21:40608106	G/A	cg27266027	chr21:40555129	PSMG1	0.44	5.2	0.3	4.05e-7	Cognitive function;
CESC	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg21548813	chr6:291882	DUSP22	-0.75	-10.35	-0.54	2.55e-21	Menopause (age at onset);
CESC	cis	rs2050392	0.517	rs619864	chr10:30750950	A/G	cg25182066	chr10:30743637	MAP3K8	0.51	7.41	0.41	1.72e-12	Inflammatory bowel disease;
CESC	cis	rs13242816	1.000	rs987791	chr7:116134701	A/G	cg04696780	chr7:116139425	CAV2	-0.61	-5.51	-0.32	8.44e-8	P wave duration;
CESC	cis	rs9309473	0.607	rs1522927	chr2:73556155	T/G	cg20560298	chr2:73613845	ALMS1	-0.48	-6.47	-0.37	4.65e-10	Metabolite levels;
CESC	cis	rs9926296	0.682	rs645019	chr16:89716883	C/T	cg03605463	chr16:89740564	NA	0.65	7.77	0.43	1.77e-13	Vitiligo;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19602773	chr3:52007747	ABHD14B;ABHD14A	0.55	6.18	0.35	2.42e-9	Gut microbiome composition (summer);
CESC	cis	rs6963495	0.745	rs73192153	chr7:105212418	A/T	cg13798780	chr7:105162888	PUS7	0.77	7.56	0.42	6.63e-13	Bipolar disorder (body mass index interaction);
CESC	cis	rs4319547	0.656	rs3817011	chr12:122819566	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.5	-5.93	-0.34	9.57e-9	Body mass index;
CESC	cis	rs4665809	0.652	rs12611790	chr2:26404221	C/T	cg27170947	chr2:26402098	FAM59B	-0.82	-9.38	-0.5	3.02e-18	Gut microbiome composition (summer);
CESC	cis	rs7909791	0.632	rs11191853	chr10:105657363	C/G	cg24587175	chr10:105670608	OBFC1	0.43	5.6	0.33	5.36e-8	White matter hyperintensity burden;
CESC	cis	rs735396	0.770	rs1169301	chr12:121431300	C/T	cg02403541	chr12:121454288	C12orf43	0.72	9.79	0.52	1.56e-19	N-glycan levels;
CESC	cis	rs834811	0.829	rs10252049	chr7:135903178	G/A	cg01726295	chr7:135938950	NA	-0.38	-6.37	-0.36	8.4e-10	Post-traumatic stress disorder;
CESC	cis	rs9303401	0.614	rs3887355	chr17:56538639	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.99	12.3	0.6	8.24e-28	Cognitive test performance;
CESC	cis	rs736408	0.511	rs12637632	chr3:52708073	A/T	cg18404041	chr3:52824283	ITIH1	-0.39	-6.52	-0.37	3.49e-10	Bipolar disorder;
CESC	cis	rs1153858	1.000	rs10444821	chr15:45647236	C/T	cg14582100	chr15:45693742	SPATA5L1	0.42	5.95	0.34	8.45e-9	Homoarginine levels;
CESC	cis	rs10504229	1.000	rs66672857	chr8:58179817	G/C	cg14926445	chr8:58193284	C8orf71	-0.51	-5.47	-0.32	1.03e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs796364	0.806	rs10931889	chr2:201101900	G/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.77	-6.46	-0.37	5.11e-10	Schizophrenia;
CESC	cis	rs3015497	0.527	rs3015473	chr14:51154010	A/G	cg26011998	chr14:51135199	SAV1	-0.56	-6.25	-0.36	1.66e-9	Mean platelet volume;
CESC	cis	rs4604732	0.631	rs10925043	chr1:247627001	G/A	cg12758973	chr1:247694275	LOC148824;OR2C3	0.51	6.36	0.36	8.65e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs4065321	0.522	rs11078930	chr17:38141955	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.61	8.98	0.48	5.1e-17	White blood cell count (basophil);White blood cell count;
CESC	cis	rs8114671	0.836	rs1885114	chr20:33577361	A/G	cg06115741	chr20:33292138	TP53INP2	-0.42	-5.04	-0.3	8.75e-7	Height;
CESC	cis	rs7666738	0.830	rs1593569	chr4:99017485	C/G	cg03467027	chr4:99064603	C4orf37	0.45	5.74	0.33	2.58e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2857078	0.654	rs4793083	chr17:42312973	C/T	cg13607699	chr17:42295918	UBTF	-0.76	-10.52	-0.54	7.64e-22	Red cell distribution width;Reticulocyte count;
CESC	cis	rs8062405	0.754	rs149299	chr16:28485141	T/C	cg05966235	chr16:28915196	ATP2A1	0.37	5.2	0.3	3.94e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01769284	chr22:24665573	CYTSA	-0.44	-6.45	-0.37	5.4e-10	Gut microbiome composition (summer);
CESC	cis	rs6570726	0.837	rs419991	chr6:145864212	C/T	cg05347473	chr6:146136440	FBXO30	0.48	6.45	0.37	5.27e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4555082	0.834	rs2735826	chr14:105710866	G/A	cg06808227	chr14:105710500	BRF1	-0.51	-5.81	-0.34	1.77e-8	Mean platelet volume;Platelet distribution width;
CESC	cis	rs7191700	1.000	rs7191700	chr16:11406803	C/T	cg00044050	chr16:11439710	C16orf75	0.47	5.46	0.32	1.07e-7	Multiple sclerosis;
CESC	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg21280719	chr6:42927975	GNMT	-0.3	-6.81	-0.39	6.46e-11	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs1218582	0.772	rs6683557	chr1:154852307	C/G	cg03351412	chr1:154909251	PMVK	0.68	9.11	0.49	2.15e-17	Prostate cancer;
CESC	cis	rs9457247	1.000	rs430293	chr6:167404958	A/G	cg23791538	chr6:167370224	RNASET2	-0.59	-8.42	-0.46	2.44e-15	Crohn's disease;
CESC	cis	rs13256369	0.802	rs12681925	chr8:8561649	G/A	cg00074818	chr8:8560427	CLDN23	0.36	5.17	0.3	4.63e-7	Obesity-related traits;
CESC	cis	rs1348850	0.874	rs952746	chr2:178306584	A/G	cg22681709	chr2:178499509	PDE11A	-0.4	-5.94	-0.34	9.14e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs2180341	0.842	rs6569476	chr6:127553539	G/A	cg27446573	chr6:127587934	RNF146	0.94	11.52	0.58	3.72e-25	Breast cancer;
CESC	cis	rs3015497	0.527	rs2934668	chr14:51153525	C/T	cg26011998	chr14:51135199	SAV1	-0.57	-6.43	-0.37	5.8e-10	Mean platelet volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12746790	chr22:50683553	TUBGCP6	0.56	6.2	0.36	2.2e-9	Gut microbiome composition (summer);
CESC	cis	rs9640161	0.659	rs7806429	chr7:150013393	A/G	cg21361702	chr7:150065534	REPIN1	0.5	5.79	0.34	1.99e-8	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs6496667	0.557	rs2601201	chr15:90958000	C/T	cg22089800	chr15:90895588	ZNF774	0.5	6.38	0.36	8.03e-10	Rheumatoid arthritis;
CESC	cis	rs4906332	1.000	rs78316803	chr14:103942863	A/G	cg09975044	chr14:104007538	NA	0.47	6.39	0.37	7.49e-10	Coronary artery disease;
CESC	cis	rs11997175	0.583	rs4386938	chr8:33673156	A/G	ch.8.33884649F	chr8:33765107	NA	0.59	8.05	0.44	2.87e-14	Body mass index;
CESC	cis	rs7666738	0.579	rs7672718	chr4:98645122	A/G	cg05340658	chr4:99064831	C4orf37	0.61	7.53	0.42	7.79e-13	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2898681	0.528	rs73814883	chr4:53728054	G/C	cg00791764	chr4:53727839	RASL11B	0.53	5.36	0.31	1.78e-7	Optic nerve measurement (cup area);
CESC	cis	rs10129255	0.518	rs8010020	chr14:107186255	A/G	cg07958169	chr14:107095056	NA	-0.54	-8.51	-0.46	1.3e-15	Kawasaki disease;
CESC	cis	rs3093024	1.000	rs3093024	chr6:167532793	C/T	cg23791538	chr6:167370224	RNASET2	-0.4	-5.17	-0.3	4.63e-7	Rheumatoid arthritis;
CESC	cis	rs2463822	1.000	rs72921498	chr11:62113090	C/T	cg06239285	chr11:62104954	ASRGL1	-0.92	-8.83	-0.48	1.43e-16	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs4727027	0.933	rs4727028	chr7:148874666	A/G	cg23158103	chr7:148848205	ZNF398	0.42	6.76	0.38	8.7e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs7264396	1.000	rs224440	chr20:34159447	C/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.43	5.26	0.31	2.93e-7	Total cholesterol levels;
CESC	cis	rs11758351	0.660	rs55643278	chr6:26222888	C/A	cg01420254	chr6:26195488	NA	0.77	8.34	0.46	4.12e-15	Gout;Renal underexcretion gout;
CESC	cis	rs8068544	0.818	rs7209012	chr17:40161323	C/T	cg26502583	chr17:39992600	KLHL10;NT5C3L	-0.76	-6.07	-0.35	4.34e-9	Reticulocyte fraction of red cells;Reticulocyte count;
CESC	cis	rs9308731	0.591	rs10199020	chr2:111946456	T/A	cg04202892	chr2:111875749	ACOXL	0.41	5.74	0.33	2.53e-8	Chronic lymphocytic leukemia;
CESC	cis	rs2066819	1.000	rs74673257	chr12:56638077	T/C	cg26714650	chr12:56694279	CS	-1.42	-10.05	-0.53	2.39e-20	Psoriasis vulgaris;
CESC	trans	rs11039571	0.544	rs7947811	chr11:48167738	C/T	cg15704280	chr7:45808275	SEPT13	-0.68	-6.68	-0.38	1.38e-10	D-dimer levels;
CESC	cis	rs832540	0.931	rs832534	chr5:56213672	G/A	cg24531977	chr5:56204891	C5orf35	-0.44	-5.49	-0.32	9.32e-8	Coronary artery disease;
CESC	trans	rs11098499	0.644	rs34835603	chr4:120553428	C/T	cg25214090	chr10:38739885	LOC399744	0.61	8.57	0.47	8.89e-16	Corneal astigmatism;
CESC	cis	rs7267979	0.816	rs8115257	chr20:25207931	A/G	cg08601574	chr20:25228251	PYGB	0.36	5.32	0.31	2.23e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs9400271	0.632	rs6930844	chr6:109590286	C/A	cg01475377	chr6:109611718	NA	-0.45	-7.01	-0.4	1.99e-11	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
CESC	cis	rs9611565	0.571	rs7364123	chr22:42216326	A/G	cg06481639	chr22:41940642	POLR3H	-0.46	-5.35	-0.31	1.91e-7	Vitiligo;
CESC	cis	rs10779751	1.000	rs11121710	chr1:11313244	T/C	cg08854313	chr1:11322531	MTOR	0.78	10.28	0.53	4.36e-21	Body mass index;
CESC	cis	rs933688	1.000	rs985434	chr5:90744509	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.1	12.13	0.6	3.17e-27	Smoking behavior;
CESC	cis	rs2836974	0.627	rs9981301	chr21:40686078	G/C	cg11644478	chr21:40555479	PSMG1	-0.79	-11.66	-0.58	1.23e-25	Cognitive function;
CESC	cis	rs10504229	0.610	rs7840469	chr8:58146992	C/T	cg02725872	chr8:58115012	NA	-0.37	-6.03	-0.35	5.44e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs8177179	0.904	rs1130459	chr3:133465283	A/G	cg16262614	chr3:133464971	TF	0.38	7.59	0.42	5.42e-13	Iron status biomarkers (transferrin levels);
CESC	cis	rs72945132	0.769	rs3781644	chr11:70190375	G/A	cg14191688	chr11:70257035	CTTN	0.41	5.13	0.3	5.6e-7	Coronary artery disease;
CESC	trans	rs877282	0.838	rs11253408	chr10:796374	T/C	cg22713356	chr15:30763199	NA	1.32	13.47	0.64	7.47e-32	Uric acid levels;
CESC	cis	rs9322193	0.847	rs868375	chr6:150166041	T/A	cg09699651	chr6:150184138	LRP11	0.45	5.63	0.33	4.49e-8	Lung cancer;
CESC	cis	rs34779708	0.931	rs12240347	chr10:35359475	A/G	cg04310649	chr10:35416472	CREM	-0.53	-6.43	-0.37	5.94e-10	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs11711311	0.712	rs2271498	chr3:113334752	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.48	6.48	0.37	4.51e-10	IgG glycosylation;
CESC	cis	rs959260	1.000	rs7221050	chr17:73393949	A/T	cg12999837	chr17:73267436	MIF4GD	-0.48	-5.65	-0.33	4.03e-8	Systemic lupus erythematosus;
CESC	cis	rs10504229	0.817	rs58957714	chr8:58195864	G/A	cg24829409	chr8:58192753	C8orf71	-0.75	-8.27	-0.45	6.38e-15	Developmental language disorder (linguistic errors);
CESC	cis	rs832540	0.519	rs6450411	chr5:56265771	A/G	cg24531977	chr5:56204891	C5orf35	-0.42	-5.25	-0.31	3.05e-7	Coronary artery disease;
CESC	cis	rs35306767	0.903	rs11253458	chr10:882843	T/C	cg20503657	chr10:835505	NA	0.79	7.91	0.44	7.09e-14	Eosinophil percentage of granulocytes;
CESC	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg12419862	chr22:24373484	LOC391322	-0.92	-14.27	-0.66	1.19e-34	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs3096299	0.685	rs4785675	chr16:89539974	T/C	cg02034447	chr16:89574710	SPG7	0.51	6.56	0.37	2.88e-10	Multiple myeloma (IgH translocation);
CESC	cis	rs3096299	0.566	rs4129126	chr16:89561475	A/C	cg02034447	chr16:89574710	SPG7	0.49	5.96	0.34	7.85e-9	Multiple myeloma (IgH translocation);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10519709	chr1:204347359	NA	0.56	6.56	0.37	2.87e-10	Gut microbiome composition (summer);
CESC	cis	rs1552244	0.572	rs6797536	chr3:10168802	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.79	-8.68	-0.47	4.11e-16	Alzheimer's disease;
CESC	cis	rs10540	1.000	rs79808876	chr11:465763	C/A	cg03576123	chr11:487126	PTDSS2	-1.06	-10.99	-0.56	2.1e-23	Body mass index;
CESC	cis	rs12497850	0.864	rs4955410	chr3:49181218	A/G	cg07636037	chr3:49044803	WDR6	1.01	17.95	0.74	1.05e-47	Parkinson's disease;
CESC	cis	rs7552404	1.000	rs2133134	chr1:76179587	G/A	cg22875332	chr1:76189707	ACADM	0.63	7.42	0.41	1.59e-12	Blood metabolite levels;Acylcarnitine levels;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg23152667	chr5:77072348	TBCA	0.45	6.09	0.35	3.93e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs8017423	0.967	rs2149655	chr14:90707246	T/C	cg14092571	chr14:90743983	NA	-0.58	-8.54	-0.46	1.04e-15	Mortality in heart failure;
CESC	cis	rs6089584	0.527	rs927589	chr20:60606363	A/G	cg06108461	chr20:60628389	TAF4	-0.62	-8.19	-0.45	1.14e-14	Body mass index;
CESC	cis	rs4713118	0.662	rs9468278	chr6:28028482	C/T	cg22143856	chr6:28129313	ZNF389	0.42	5.26	0.31	2.91e-7	Parkinson's disease;
CESC	cis	rs28386778	0.669	rs12603821	chr17:62006432	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.95	-15.09	-0.68	1.47e-37	Prudent dietary pattern;
CESC	cis	rs80130819	0.688	rs2054902	chr12:48724778	A/C	cg05342945	chr12:48394962	COL2A1	-0.5	-5.35	-0.31	1.9e-7	Prostate cancer;
CESC	trans	rs1814175	0.765	rs1721990	chr11:49912154	G/C	cg15704280	chr7:45808275	SEPT13	-1.03	-21.21	-0.79	4.77e-59	Height;
CESC	cis	rs7666738	0.830	rs7662114	chr4:99019985	A/G	cg17366294	chr4:99064904	C4orf37	0.61	8.76	0.47	2.35e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2204008	0.558	rs66545149	chr12:38204694	A/G	cg26384229	chr12:38710491	ALG10B	0.73	10.16	0.53	1.08e-20	Bladder cancer;
CESC	cis	rs17539620	0.624	rs62432740	chr6:154836054	C/T	cg17771515	chr6:154831774	CNKSR3	0.59	5.81	0.34	1.8e-8	Lipoprotein (a) levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01973725	chr5:80608537	RNU5E;RNU5D;ZCCHC9	-0.55	-6.36	-0.36	8.7e-10	Gut microbiome composition (summer);
CESC	cis	rs1577917	1.000	rs1962716	chr6:86648436	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.44	-5.9	-0.34	1.14e-8	Response to antipsychotic treatment;
CESC	cis	rs7914558	0.966	rs10786724	chr10:104668942	A/G	cg04362960	chr10:104952993	NT5C2	0.43	5.56	0.32	6.69e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs447	1.000	rs6977099	chr7:83762428	C/A	cg22846510	chr7:83753280	SEMA3A	-0.47	-5.76	-0.33	2.37e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs10771431	1.000	rs11611670	chr12:9385535	C/T	cg00504896	chr12:9437009	LOC642846	-0.41	-5.49	-0.32	9.47e-8	Breast size;
CESC	cis	rs112591243	0.570	rs2839340	chr21:47989804	C/T	cg26904215	chr21:47823096	PCNT	-0.8	-5.08	-0.3	7.13e-7	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg18300819	chr6:88299852	ORC3L;RARS2	-0.47	-6.03	-0.35	5.58e-9	Ulcerative colitis;
CESC	cis	rs9733	0.596	rs34600506	chr1:150687808	C/G	cg04414720	chr1:150670196	GOLPH3L	0.62	8.86	0.48	1.21e-16	Tonsillectomy;
CESC	cis	rs7618915	0.547	rs2164884	chr3:52629633	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	6.77	0.38	8.38e-11	Bipolar disorder;
CESC	cis	rs2302190	0.882	rs9911609	chr17:56673087	T/C	cg25885038	chr17:56607967	SEPT4	-0.4	-5.43	-0.32	1.27e-7	Vitamin D levels;
CESC	cis	rs17253792	0.749	rs45458197	chr14:56145018	A/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.81	5.68	0.33	3.46e-8	Putamen volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10304803	chr17:80771384	TBCD	-0.59	-6.45	-0.37	5.19e-10	Gut microbiome composition (summer);
CESC	cis	rs10129255	0.642	rs11624918	chr14:107120688	T/C	cg07958169	chr14:107095056	NA	-0.46	-6.52	-0.37	3.46e-10	Kawasaki disease;
CESC	cis	rs16854884	0.580	rs6778791	chr3:143846398	C/T	cg06585982	chr3:143692056	C3orf58	0.42	5.3	0.31	2.42e-7	Economic and political preferences (feminism/equality);
CESC	cis	rs3747547	0.818	rs11790550	chr9:37935319	C/T	cg13774184	chr9:37916125	SHB	-0.54	-5.44	-0.32	1.21e-7	Metabolite levels (Dihydroxy docosatrienoic acid);
CESC	trans	rs7618501	0.602	rs2071206	chr3:50160109	G/A	cg21659725	chr3:3221576	CRBN	-0.47	-6.53	-0.37	3.4e-10	Intelligence (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14649924	chr1:10535034	PEX14	0.56	6.17	0.35	2.53e-9	Gut microbiome composition (summer);
CESC	cis	rs916888	0.821	rs199512	chr17:44857352	T/C	cg01570182	chr17:44337453	NA	-0.87	-10.59	-0.55	4.47e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs5753618	0.554	rs5753648	chr22:31879465	A/G	cg02404636	chr22:31891804	SFI1	0.41	5.28	0.31	2.73e-7	Colorectal cancer;
CESC	cis	rs1461503	0.932	rs10790542	chr11:122838243	C/T	cg27398637	chr11:122830231	C11orf63	-0.57	-8.68	-0.47	4.17e-16	Menarche (age at onset);
CESC	cis	rs67478160	0.643	rs2223937	chr14:104286380	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.51	-7.14	-0.4	8.85e-12	Schizophrenia;
CESC	cis	rs16867321	0.507	rs2013577	chr2:181370505	C/T	cg23363182	chr2:181467187	NA	-0.42	-5.92	-0.34	9.91e-9	Obesity;
CESC	cis	rs6570726	0.599	rs9376951	chr6:145898911	C/T	cg05347473	chr6:146136440	FBXO30	0.72	9.12	0.49	1.9e-17	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs5758659	0.819	rs134871	chr22:42652716	A/G	cg00645731	chr22:42541494	CYP2D7P1	-0.3	-5.28	-0.31	2.71e-7	Cognitive function;
CESC	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg16132339	chr22:24313637	DDTL;DDT	0.4	5.99	0.35	6.79e-9	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs8062405	1.000	rs62036624	chr16:28839930	G/T	cg08761264	chr16:28874980	SH2B1	-0.47	-5.83	-0.34	1.64e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	trans	rs11039798	0.920	rs8186465	chr11:48796771	T/C	cg15704280	chr7:45808275	SEPT13	0.71	6.44	0.37	5.59e-10	Axial length;
CESC	cis	rs3126085	0.935	rs4595369	chr1:152248193	G/A	cg03465714	chr1:152285911	FLG	-0.46	-5.75	-0.33	2.42e-8	Atopic dermatitis;
CESC	cis	rs7553864	0.574	rs6576867	chr1:87615796	A/T	cg17420885	chr1:87600446	LOC339524	-0.53	-7.22	-0.41	5.44e-12	Smoking behavior;
CESC	cis	rs10129255	0.500	rs8011115	chr14:107194530	T/C	cg23076370	chr14:107095027	NA	-0.61	-8.76	-0.47	2.31e-16	Kawasaki disease;
CESC	cis	rs2730245	0.550	rs2657364	chr7:158683825	T/C	cg14689365	chr7:158441557	NCAPG2	0.42	5.22	0.31	3.7e-7	Height;
CESC	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg18402987	chr7:1209562	NA	0.76	7.61	0.42	4.74e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2262909	0.745	rs1989120	chr19:22205528	T/C	cg11619707	chr19:22235551	ZNF257	-0.32	-5.36	-0.31	1.8e-7	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10341310	chr8:66582206	MTFR1	-0.63	-7.52	-0.42	8.4e-13	Gut microbiome composition (summer);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg02677328	chr6:52267982	PAQR8	-0.41	-6.64	-0.38	1.74e-10	Gambling;
CESC	cis	rs13108904	0.870	rs12506095	chr4:1262233	T/C	cg00684032	chr4:1343700	KIAA1530	0.41	5.83	0.34	1.58e-8	Obesity-related traits;
CESC	cis	rs6089584	0.816	rs4134440	chr20:60624296	A/G	cg13770153	chr20:60521292	NA	-0.51	-6.61	-0.38	2.08e-10	Body mass index;
CESC	cis	rs7666738	0.830	rs7662218	chr4:98983126	T/G	cg05340658	chr4:99064831	C4orf37	0.8	12.25	0.6	1.2e-27	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg07414643	chr4:187882934	NA	0.49	7.0	0.39	2.16e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2075371	0.796	rs35440439	chr7:134006094	C/T	cg11752832	chr7:134001865	SLC35B4	0.5	6.33	0.36	1.03e-9	Mean platelet volume;
CESC	cis	rs7539624	0.588	rs1892076	chr1:223899417	T/A	cg10100437	chr1:223903862	CAPN2	0.45	5.94	0.34	8.77e-9	Schizophrenia;
CESC	cis	rs6879260	1.000	rs7725605	chr5:179732678	T/G	cg23221052	chr5:179740743	GFPT2	-0.67	-9.14	-0.49	1.66e-17	Height;
CESC	cis	rs9486715	0.838	rs9320127	chr6:96865358	G/A	cg18709589	chr6:96969512	KIAA0776	0.44	6.26	0.36	1.59e-9	Headache;
CESC	cis	rs7772486	0.790	rs2256998	chr6:146207657	A/C	cg05347473	chr6:146136440	FBXO30	0.55	7.05	0.4	1.52e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs713587	0.646	rs34697209	chr2:25127394	A/G	cg01884057	chr2:25150051	NA	0.33	6.34	0.36	9.84e-10	Body mass index in non-asthmatics;
CESC	cis	rs12824058	0.831	rs4759451	chr12:130812739	G/A	cg26677194	chr12:130822605	PIWIL1	0.51	6.72	0.38	1.13e-10	Menopause (age at onset);
CESC	cis	rs4665809	1.000	rs6750681	chr2:26329677	C/T	cg25036284	chr2:26402008	FAM59B	-0.57	-6.53	-0.37	3.25e-10	Gut microbiome composition (summer);
CESC	cis	rs9837602	0.935	rs9875640	chr3:99729091	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.54	7.78	0.43	1.62e-13	Breast cancer;
CESC	cis	rs10870270	1.000	rs4880246	chr10:133764064	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.6	-7.71	-0.43	2.59e-13	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs782590	0.967	rs4290693	chr2:55799991	C/G	cg18811423	chr2:55921094	PNPT1	0.75	11.91	0.59	1.8e-26	Metabolic syndrome;
CESC	cis	rs7615952	0.866	rs1976459	chr3:125647486	A/T	cg05084668	chr3:125655381	ALG1L	-0.51	-5.95	-0.34	8.56e-9	Blood pressure (smoking interaction);
CESC	cis	rs9733	0.596	rs6686525	chr1:150635811	C/T	cg04414720	chr1:150670196	GOLPH3L	0.63	9.02	0.48	3.86e-17	Tonsillectomy;
CESC	trans	rs2727020	0.619	rs1164665	chr11:49295630	T/C	cg03929089	chr4:120376271	NA	0.68	8.49	0.46	1.48e-15	Coronary artery disease;
CESC	cis	rs2011503	0.882	rs751857	chr19:19602873	G/T	cg11584989	chr19:19387371	SF4	0.62	7.13	0.4	9.66e-12	Bipolar disorder;
CESC	cis	rs7623687	0.892	rs73088122	chr3:49432404	C/T	cg19401529	chr3:49056140	DALRD3	0.61	5.39	0.31	1.53e-7	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;
CESC	trans	rs3008870	0.583	rs17497947	chr1:67457199	G/T	cg19754094	chr2:74055942	STAMBP	-0.62	-6.0	-0.35	6.49e-9	Lymphocyte percentage of white cells;
CESC	cis	rs1552244	0.816	rs56271597	chr3:10042790	C/T	cg00166722	chr3:10149974	C3orf24	0.48	5.95	0.34	8.39e-9	Alzheimer's disease;
CESC	cis	rs763121	0.853	rs5750677	chr22:39147715	C/T	cg21395723	chr22:39101663	GTPBP1	0.46	5.97	0.34	7.51e-9	Menopause (age at onset);
CESC	cis	rs12681288	0.823	rs2701905	chr8:1003482	T/C	cg04851639	chr8:1020857	NA	-0.34	-7.65	-0.43	3.67e-13	Schizophrenia;
CESC	cis	rs3960554	0.808	rs78811105	chr7:75702795	G/A	cg17325771	chr7:75508891	RHBDD2	-0.36	-5.37	-0.31	1.72e-7	Eotaxin levels;
CESC	cis	rs524281	0.692	rs10896076	chr11:65840668	A/G	cg14036092	chr11:66035641	RAB1B	-0.6	-6.44	-0.37	5.56e-10	Electroencephalogram traits;
CESC	cis	rs425277	0.585	rs3107156	chr1:2060630	T/C	cg04315214	chr1:2043799	PRKCZ	0.63	11.01	0.56	1.78e-23	Height;
CESC	cis	rs3809863	0.782	rs7220606	chr17:45374795	A/G	cg25173405	chr17:45401733	C17orf57	-0.47	-6.19	-0.36	2.25e-9	Glaucoma (primary open-angle);
CESC	cis	rs7267979	1.000	rs4815426	chr20:25405186	A/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.87	-18.09	-0.74	3.57e-48	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs4523957	0.620	rs9892754	chr17:2084565	G/T	cg16513277	chr17:2031491	SMG6	-0.71	-10.17	-0.53	1.04e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg17177017	chr17:74668252	NA	-0.4	-6.12	-0.35	3.27e-9	Gambling;
CESC	cis	rs9611565	0.512	rs2050033	chr22:42159229	G/T	cg06481639	chr22:41940642	POLR3H	0.6	5.97	0.34	7.49e-9	Vitiligo;
CESC	cis	rs938554	0.542	rs7678287	chr4:10000501	A/G	cg00071950	chr4:10020882	SLC2A9	0.61	7.08	0.4	1.28e-11	Blood metabolite levels;
CESC	cis	rs6541297	1.000	rs6686054	chr1:230282853	C/T	cg20703242	chr1:230279135	GALNT2	0.68	10.93	0.56	3.41e-23	Coronary artery disease;
CESC	cis	rs11122272	0.735	rs2749699	chr1:231520279	A/C	cg06096015	chr1:231504339	EGLN1	0.43	6.18	0.35	2.46e-9	Hemoglobin concentration;
CESC	cis	rs9549260	0.564	rs9646110	chr13:41308301	A/T	cg21288729	chr13:41239152	FOXO1	-0.59	-7.29	-0.41	3.5e-12	Red blood cell count;
CESC	cis	rs2404602	0.647	rs12904149	chr15:77043652	A/C	cg23625390	chr15:77176239	SCAPER	-0.4	-5.2	-0.3	4e-7	Blood metabolite levels;
CESC	cis	rs853679	0.517	rs3757187	chr6:28107654	T/C	cg12963246	chr6:28129442	ZNF389	0.58	7.86	0.43	9.67e-14	Depression;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20263942	chr9:88714961	GOLM1	-0.53	-6.01	-0.35	6.22e-9	Gut microbiome composition (summer);
CESC	cis	rs67311347	0.955	rs11711994	chr3:40391086	T/C	cg09455208	chr3:40491958	NA	0.53	8.84	0.48	1.32e-16	Renal cell carcinoma;
CESC	cis	rs1355223	0.583	rs2941044	chr11:34867444	A/C	cg11058730	chr11:34937778	PDHX;APIP	0.83	12.78	0.62	1.78e-29	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs975210	0.556	rs2291986	chr15:70368432	C/T	cg01666796	chr15:70364327	TLE3	0.41	5.11	0.3	6.22e-7	Height;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
CESC	cis	rs1799949	1.000	rs4793215	chr17:41318932	G/A	cg25072359	chr17:41440525	NA	0.49	6.51	0.37	3.66e-10	Menopause (age at onset);
CESC	cis	rs1949733	0.598	rs869602	chr4:8535371	G/T	cg11789530	chr4:8429930	ACOX3	-0.62	-8.01	-0.44	3.62e-14	Response to antineoplastic agents;
CESC	cis	rs2180341	1.000	rs9385419	chr6:127597591	A/G	cg27446573	chr6:127587934	RNF146	1.07	15.98	0.7	1e-40	Breast cancer;
CESC	cis	rs6912958	0.754	rs4707374	chr6:88255438	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.48	-6.5	-0.37	3.97e-10	Monocyte percentage of white cells;
CESC	cis	rs9733	0.818	rs12403609	chr1:150676485	T/C	cg18016565	chr1:150552671	MCL1	-0.35	-5.82	-0.34	1.67e-8	Tonsillectomy;
CESC	trans	rs11098499	0.909	rs9759478	chr4:120367998	G/A	cg25214090	chr10:38739885	LOC399744	0.71	9.8	0.52	1.46e-19	Corneal astigmatism;
CESC	cis	rs2303745	0.544	rs6512180	chr19:17399153	C/T	cg22549504	chr19:17448937	GTPBP3	0.52	5.82	0.34	1.7e-8	Systemic lupus erythematosus;
CESC	cis	rs7267979	1.000	rs4815405	chr20:25317492	T/C	cg08601574	chr20:25228251	PYGB	-0.39	-5.52	-0.32	8.07e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs3741404	0.609	rs651855	chr11:63870810	T/C	cg18225595	chr11:63971243	STIP1	0.52	6.77	0.38	8.2e-11	Platelet count;
CESC	cis	rs4268898	0.662	rs72793213	chr2:24524725	A/G	cg20701182	chr2:24300061	SF3B14	0.63	6.88	0.39	4.32e-11	Asthma;
CESC	cis	rs12142240	0.698	rs72886911	chr1:46814352	G/A	cg00530320	chr1:46809349	NSUN4	0.58	7.89	0.44	8.17e-14	Menopause (age at onset);
CESC	cis	rs2777491	0.915	rs7180418	chr15:41629502	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.61	-9.27	-0.49	6.62e-18	Ulcerative colitis;
CESC	cis	rs9948	0.655	rs62156221	chr2:97410850	A/G	cg01990225	chr2:97406019	LMAN2L	-1.02	-7.83	-0.43	1.17e-13	Erectile dysfunction and prostate cancer treatment;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06748078	chr4:1004703	FGFRL1	-0.6	-7.24	-0.41	4.86e-12	Gut microbiome composition (summer);
CESC	cis	rs10838687	1.000	rs4752979	chr11:47339180	A/G	cg25783544	chr11:47291846	MADD	0.58	7.22	0.41	5.57e-12	Proinsulin levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18268492	chr10:99185986	PGAM1	0.6	6.73	0.38	1.07e-10	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12129209	chr14:102276033	PPP2R5C	-0.6	-7.09	-0.4	1.25e-11	Gut microbiome composition (summer);
CESC	cis	rs1799949	1.000	rs1973646	chr17:41310495	T/C	cg25072359	chr17:41440525	NA	0.48	6.51	0.37	3.85e-10	Menopause (age at onset);
CESC	cis	rs514406	0.929	rs483073	chr1:53314084	T/C	cg16325326	chr1:53192061	ZYG11B	0.89	14.76	0.67	2.21e-36	Monocyte count;
CESC	trans	rs61931739	0.534	rs2636072	chr12:34062386	C/T	cg26384229	chr12:38710491	ALG10B	0.52	6.96	0.39	2.64e-11	Morning vs. evening chronotype;
CESC	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg22535103	chr8:58192502	C8orf71	-0.94	-9.92	-0.52	6.46e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs367943	0.712	rs26969	chr5:112742436	A/G	cg12552261	chr5:112820674	MCC	0.4	5.35	0.31	1.89e-7	Type 2 diabetes;
CESC	cis	rs2243480	1.000	rs313803	chr7:65514731	G/A	cg25894440	chr7:65020034	NA	-0.61	-5.3	-0.31	2.42e-7	Diabetic kidney disease;
CESC	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg04025307	chr7:1156635	C7orf50	0.54	9.5	0.5	1.35e-18	Longevity;Endometriosis;
CESC	cis	rs67311347	0.784	rs13326389	chr3:40459724	A/G	cg09455208	chr3:40491958	NA	0.49	8.17	0.45	1.3e-14	Renal cell carcinoma;
CESC	trans	rs1814175	0.529	rs1988417	chr11:49932430	A/G	cg15704280	chr7:45808275	SEPT13	-0.9	-13.12	-0.63	1.2e-30	Height;
CESC	cis	rs2839186	0.814	rs12482209	chr21:47664275	C/G	cg10351095	chr21:47802916	PCNT	0.49	6.82	0.39	6.08e-11	Testicular germ cell tumor;
CESC	cis	rs34779708	1.000	rs12769189	chr10:35399668	A/G	cg03585969	chr10:35415529	CREM	0.77	10.08	0.53	1.97e-20	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs9467711	0.659	rs13195509	chr6:26463660	C/T	cg21479132	chr6:26055353	NA	0.74	5.69	0.33	3.43e-8	Autism spectrum disorder or schizophrenia;
CESC	cis	rs4481887	0.927	rs4581306	chr1:248476158	C/A	cg00666640	chr1:248458726	OR2T12	0.35	5.93	0.34	9.43e-9	Common traits (Other);
CESC	cis	rs3740540	0.530	rs2362506	chr10:126290751	C/G	cg04949429	chr10:126290192	LHPP	0.4	5.6	0.33	5.33e-8	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
CESC	cis	rs9311474	0.597	rs6778735	chr3:52565100	T/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	6.14	0.35	3e-9	Electroencephalogram traits;
CESC	cis	rs4727963	0.846	rs1404838	chr7:122696223	C/T	cg03640110	chr7:122635026	TAS2R16	0.38	5.82	0.34	1.68e-8	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
CESC	cis	rs3008870	0.755	rs2815364	chr1:67498384	C/T	cg02640540	chr1:67518911	SLC35D1	0.46	5.64	0.33	4.33e-8	Lymphocyte percentage of white cells;
CESC	cis	rs3733585	0.699	rs7686538	chr4:9948077	C/T	cg00071950	chr4:10020882	SLC2A9	-0.73	-11.96	-0.59	1.23e-26	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs4253772	0.550	rs6007819	chr22:46704916	C/G	cg10541313	chr22:46663664	TTC38	0.61	5.23	0.31	3.38e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs9611565	0.840	rs2234059	chr22:41777913	T/C	cg06481639	chr22:41940642	POLR3H	-0.61	-6.49	-0.37	4.09e-10	Vitiligo;
CESC	cis	rs2839186	0.770	rs2839984	chr21:47671690	A/G	cg11766577	chr21:47581405	C21orf56	-0.46	-6.3	-0.36	1.21e-9	Testicular germ cell tumor;
CESC	cis	rs644799	0.710	rs666398	chr11:95551136	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.77	10.82	0.55	8.02e-23	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs2594989	0.943	rs2244617	chr3:11503097	T/C	cg00170343	chr3:11313890	ATG7	0.56	5.1	0.3	6.55e-7	Circulating chemerin levels;
CESC	cis	rs9611565	0.694	rs202641	chr22:41833116	C/T	cg03806693	chr22:41940476	POLR3H	1.08	14.48	0.66	2.06e-35	Vitiligo;
CESC	cis	rs910316	0.789	rs175444	chr14:75601782	G/C	cg16144293	chr14:75469539	EIF2B2	0.41	5.35	0.31	1.88e-7	Height;
CESC	cis	rs7923609	0.967	rs10761758	chr10:65172747	A/T	cg01631684	chr10:65280961	REEP3	-0.43	-5.32	-0.31	2.25e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs2439831	0.702	rs9989313	chr15:44152817	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.63	5.6	0.33	5.26e-8	Lung cancer in ever smokers;
CESC	cis	rs1552244	0.882	rs13075842	chr3:10055813	A/C	cg08888203	chr3:10149979	C3orf24	0.48	6.08	0.35	4.18e-9	Alzheimer's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27223663	chr16:2983543	FLYWCH1	-0.61	-7.32	-0.41	2.92e-12	Gut microbiome composition (summer);
CESC	cis	rs9733	0.596	rs2867301	chr1:150653795	C/T	cg22823121	chr1:150693482	HORMAD1	0.48	7.09	0.4	1.21e-11	Tonsillectomy;
CESC	cis	rs1048238	0.935	rs761760	chr1:16342419	A/G	cg22431228	chr1:16359049	CLCNKA	-0.52	-9.9	-0.52	7.22e-20	Systolic blood pressure;
CESC	cis	rs9486715	0.867	rs9384585	chr6:96875664	C/T	cg06623918	chr6:96969491	KIAA0776	0.91	14.05	0.65	6.83e-34	Headache;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg02767759	chr16:30366751	CD2BP2	0.47	5.99	0.35	6.65e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs4481887	0.893	rs1339992	chr1:248509182	G/A	cg00666640	chr1:248458726	OR2T12	0.35	6.02	0.35	5.85e-9	Common traits (Other);
CESC	cis	rs8002861	0.875	rs11616803	chr13:44457109	A/G	cg19180546	chr13:44453867	C13orf31;CCDC122	-0.47	-6.02	-0.35	5.84e-9	Leprosy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22829908	chr10:21814466	C10orf140	-0.59	-6.78	-0.38	7.65e-11	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24489813	chr12:53574330	ZNF740;CSAD	0.55	6.43	0.37	5.75e-10	Gut microbiome composition (summer);
CESC	cis	rs7618501	0.633	rs6792892	chr3:49995518	T/C	cg24308560	chr3:49941425	MST1R	-0.64	-9.19	-0.49	1.17e-17	Intelligence (multi-trait analysis);
CESC	cis	rs6570726	0.935	rs384806	chr6:145814889	C/G	cg05347473	chr6:146136440	FBXO30	0.5	6.71	0.38	1.15e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4819052	0.851	rs4819038	chr21:46659393	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.91	13.24	0.63	4.51e-31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs3942852	0.774	rs2279823	chr11:48146092	T/C	cg03929089	chr4:120376271	NA	-0.57	-6.12	-0.35	3.4e-9	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs7412746	0.611	rs10888391	chr1:150729983	G/A	cg04414720	chr1:150670196	GOLPH3L	0.56	7.34	0.41	2.56e-12	Melanoma;
CESC	cis	rs4819052	1.000	rs9984901	chr21:46663952	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.56	6.6	0.38	2.27e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs6121246	0.909	rs6058460	chr20:30363071	G/A	cg13852791	chr20:30311386	BCL2L1	0.81	8.65	0.47	5.15e-16	Mean corpuscular hemoglobin;
CESC	trans	rs7618501	0.633	rs4688689	chr3:50035542	C/T	cg21659725	chr3:3221576	CRBN	0.5	6.96	0.39	2.63e-11	Intelligence (multi-trait analysis);
CESC	cis	rs258892	0.895	rs9293450	chr5:72068476	G/A	cg21869765	chr5:72125136	TNPO1	-0.42	-5.08	-0.3	7.12e-7	Small cell lung carcinoma;
CESC	cis	rs629922	1.000	rs629922	chr11:114064825	C/T	cg25009965	chr11:114031120	ZBTB16	-0.41	-5.33	-0.31	2.13e-7	Paneth cell defects in Crohn's disease;
CESC	cis	rs6714710	0.603	rs17489454	chr2:98407350	C/T	cg10020592	chr2:97779784	ANKRD36	-0.38	-5.12	-0.3	5.96e-7	Posterior cortical atrophy and Alzheimer's disease;
CESC	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg07677032	chr17:61819896	STRADA	0.45	5.96	0.34	8.19e-9	Prudent dietary pattern;
CESC	cis	rs6690583	0.943	rs1837329	chr1:85469614	G/A	cg11262906	chr1:85462892	MCOLN2	-0.53	-5.9	-0.34	1.11e-8	Serum sulfate level;
CESC	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg21280719	chr6:42927975	GNMT	-0.3	-7.07	-0.4	1.4e-11	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs7772486	0.875	rs7766463	chr6:146364453	A/G	cg23711669	chr6:146136114	FBXO30	0.83	12.17	0.6	2.39e-27	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs3785574	0.924	rs2584641	chr17:61862889	A/G	cg06420487	chr17:61919686	SMARCD2	0.46	5.53	0.32	7.63e-8	Height;
CESC	cis	rs7568458	0.709	rs762684	chr2:85782023	G/A	cg02493740	chr2:85810744	VAMP5	-0.57	-8.42	-0.46	2.41e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CESC	cis	rs2952156	0.920	rs1565920	chr17:37831613	G/A	cg07936489	chr17:37558343	FBXL20	-0.58	-7.43	-0.42	1.48e-12	Asthma;
CESC	cis	rs3814231	0.531	rs12773054	chr10:115476042	C/T	cg24846397	chr10:115438155	CASP7	-0.32	-5.26	-0.31	2.96e-7	Vitiligo;
CESC	cis	rs2635047	1.000	rs9304341	chr18:44670263	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.47	6.54	0.37	3.23e-10	Educational attainment;
CESC	cis	rs858239	0.932	rs1637190	chr7:23269065	A/G	cg23682824	chr7:23144976	KLHL7	0.44	5.84	0.34	1.51e-8	Cerebrospinal fluid biomarker levels;
CESC	cis	rs4148883	0.898	rs4699726	chr4:100099513	T/C	cg12011299	chr4:100065546	ADH4	0.41	5.76	0.33	2.39e-8	Alcohol dependence;
CESC	trans	rs6572548	0.504	rs1956082	chr14:49665496	A/C	cg13547551	chr9:133455399	LOC100272217;FUBP3	-0.59	-6.93	-0.39	3.18e-11	Subjective well-being;
CESC	cis	rs76419734	0.510	rs2553456	chr4:106751028	T/C	cg24545054	chr4:106630052	GSTCD;INTS12	-0.59	-5.96	-0.34	7.85e-9	Post bronchodilator FEV1;
CESC	cis	rs2836974	0.897	rs11911112	chr21:40528346	A/C	cg11644478	chr21:40555479	PSMG1	1.04	17.66	0.74	1.16e-46	Cognitive function;
CESC	cis	rs1862618	0.526	rs2591963	chr5:56237135	T/A	cg22800045	chr5:56110881	MAP3K1	-0.76	-8.67	-0.47	4.42e-16	Initial pursuit acceleration;
CESC	cis	rs2267137	0.574	rs5752910	chr22:29803493	A/G	cg07256473	chr22:29710276	RASL10A	0.38	5.5	0.32	9.13e-8	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	trans	rs3780486	0.846	rs3780487	chr9:33139237	T/C	cg20290983	chr6:43655470	MRPS18A	0.99	18.43	0.75	2.16e-49	IgG glycosylation;
CESC	cis	rs875971	0.862	rs4236208	chr7:65749078	C/T	cg12463550	chr7:65579703	CRCP	-0.45	-5.77	-0.33	2.19e-8	Aortic root size;
CESC	cis	rs9914988	0.943	rs4795467	chr17:27180784	C/T	cg20469991	chr17:27169893	C17orf63	-0.51	-5.12	-0.3	5.81e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CESC	cis	rs10276381	0.786	rs10255700	chr7:28220228	C/T	cg23620719	chr7:28220237	JAZF1	0.83	9.02	0.48	3.88e-17	Crohn's disease;
CESC	cis	rs6546537	0.824	rs55864699	chr2:69803650	C/T	cg10773587	chr2:69614142	GFPT1	-0.61	-7.44	-0.42	1.4e-12	Serum thyroid-stimulating hormone levels;
CESC	cis	rs55728055	0.661	rs62239169	chr22:32042514	G/A	cg01338084	chr22:32026380	PISD	1.26	8.24	0.45	8.13e-15	Age-related hearing impairment;
CESC	cis	rs7084402	0.902	rs1346300	chr10:60287635	G/C	cg07615347	chr10:60278583	BICC1	0.6	9.41	0.5	2.54e-18	Refractive error;
CESC	cis	rs11718455	0.961	rs3846068	chr3:44029835	G/A	cg08738300	chr3:44038990	NA	0.47	6.3	0.36	1.22e-9	Coronary artery disease;
CESC	cis	rs35306767	0.715	rs17293580	chr10:1034895	T/C	cg26597838	chr10:835615	NA	0.75	6.88	0.39	4.43e-11	Eosinophil percentage of granulocytes;
CESC	cis	rs7801375	0.504	rs2058969	chr7:131560764	C/A	cg26572488	chr7:132299669	PLXNA4	-0.46	-5.32	-0.31	2.17e-7	Schizophrenia;Autism spectrum disorder or schizophrenia;
CESC	cis	rs4853012	0.838	rs6707729	chr2:74344685	G/A	cg20891558	chr2:74357851	NA	0.81	11.98	0.59	1.05e-26	Gestational age at birth (maternal effect);
CESC	cis	rs1691799	0.867	rs1168348	chr12:66757168	G/A	cg16791601	chr12:66731901	HELB	-0.78	-13.77	-0.65	6.86e-33	White blood cell count (basophil);
CESC	cis	rs2742417	0.603	rs2531755	chr3:45772742	T/C	cg04837898	chr3:45731254	SACM1L	-0.47	-6.17	-0.35	2.54e-9	Response to anti-depressant treatment in major depressive disorder;
CESC	cis	rs11098499	0.863	rs9997631	chr4:120469995	C/G	cg24375607	chr4:120327624	NA	0.42	5.16	0.3	4.82e-7	Corneal astigmatism;
CESC	cis	rs7520050	0.966	rs11211208	chr1:46334256	A/C	cg03146154	chr1:46216737	IPP	-0.48	-6.18	-0.36	2.39e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs17711722	0.523	rs365896	chr7:65510697	A/G	cg14393609	chr7:65229607	NA	-0.47	-6.56	-0.37	2.83e-10	Calcium levels;
CESC	cis	rs67311347	1.000	rs2305522	chr3:40429358	A/G	cg01475735	chr3:40494733	NA	-0.41	-5.22	-0.31	3.64e-7	Renal cell carcinoma;
CESC	cis	rs1185460	0.967	rs1177562	chr11:118949331	C/T	cg01677386	chr11:118938358	VPS11	-0.43	-5.15	-0.3	5.05e-7	Coronary artery disease;
CESC	cis	rs2380220	0.640	rs9320386	chr6:95994955	T/C	cg15832292	chr6:96025679	MANEA	0.7	6.74	0.38	9.99e-11	Behavioural disinhibition (generation interaction);
CESC	cis	rs4148883	0.675	rs116265877	chr4:100096896	G/A	cg12011299	chr4:100065546	ADH4	0.66	9.76	0.51	1.98e-19	Alcohol dependence;
CESC	trans	rs4424809	0.614	rs17078993	chr13:85572180	C/T	cg05918002	chr17:5019452	ZNF232	-0.64	-6.06	-0.35	4.77e-9	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs4253772	0.678	rs9627281	chr22:46644168	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.57	6.67	0.38	1.45e-10	LDL cholesterol;Cholesterol, total;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg01870456	chr13:111267991	CARKD	-0.44	-6.52	-0.37	3.44e-10	Gambling;
CESC	cis	rs12477438	0.520	rs11123764	chr2:99750677	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.87	15.48	0.69	6.26e-39	Chronic sinus infection;
CESC	cis	rs2576037	0.583	rs541634	chr18:44420271	C/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.35	5.6	0.33	5.46e-8	Personality dimensions;
CESC	trans	rs687914	0.710	rs938662	chr2:45864578	A/G	cg00371891	chr19:4723959	DPP9	0.58	6.02	0.35	5.69e-9	Diastolic blood pressure;
CESC	cis	rs10504229	0.593	rs79615400	chr8:57988740	C/T	cg22535103	chr8:58192502	C8orf71	-0.92	-9.13	-0.49	1.84e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs6424115	0.800	rs6665733	chr1:24200158	T/C	cg10978503	chr1:24200527	CNR2	0.33	6.63	0.38	1.85e-10	Immature fraction of reticulocytes;
CESC	cis	rs801193	0.660	rs1962050	chr7:66240008	C/T	cg11764359	chr7:65958608	NA	-0.84	-12.8	-0.62	1.53e-29	Aortic root size;
CESC	cis	rs9300255	0.510	rs1790086	chr12:123672518	A/G	cg05973401	chr12:123451056	ABCB9	0.51	5.75	0.33	2.51e-8	Neutrophil percentage of white cells;
CESC	cis	rs7605827	0.930	rs13029846	chr2:15674686	T/C	cg19274914	chr2:15703543	NA	0.33	5.76	0.33	2.28e-8	Educational attainment (years of education);
CESC	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg24829409	chr8:58192753	C8orf71	-0.65	-7.84	-0.43	1.13e-13	Developmental language disorder (linguistic errors);
CESC	cis	rs11098499	0.954	rs13113483	chr4:120309039	C/T	cg24375607	chr4:120327624	NA	0.46	5.55	0.32	6.98e-8	Corneal astigmatism;
CESC	cis	rs6963495	0.818	rs6943132	chr7:105166776	C/T	cg02135003	chr7:105160482	PUS7	-0.55	-5.38	-0.31	1.62e-7	Bipolar disorder (body mass index interaction);
CESC	cis	rs992157	0.710	rs6719789	chr2:219057810	G/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.61	-8.31	-0.45	5.16e-15	Colorectal cancer;
CESC	cis	rs853679	0.517	rs9348796	chr6:28126202	A/G	cg12963246	chr6:28129442	ZNF389	0.56	7.38	0.41	1.99e-12	Depression;
CESC	cis	rs12477438	0.520	rs2309581	chr2:99784292	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.97	-17.47	-0.73	5.51e-46	Chronic sinus infection;
CESC	cis	rs1005277	0.579	rs9418322	chr10:38377296	G/T	cg25517755	chr10:38738941	LOC399744	-0.48	-6.22	-0.36	1.94e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs5498	0.809	rs2228615	chr19:10403368	G/A	cg10604476	chr19:10403908	ICAM5	0.45	6.36	0.36	8.97e-10	Lymphocyte counts;Soluble ICAM-1;Blood protein levels;
CESC	cis	rs12477438	1.000	rs12477438	chr2:99841085	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.77	-9.03	-0.48	3.7e-17	Chronic sinus infection;
CESC	cis	rs75477785	1.000	rs12405750	chr1:209977844	C/T	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.88	5.74	0.33	2.62e-8	Cleft lip with or without cleft palate;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27498211	chr16:4588826	C16orf5	0.58	6.35	0.36	9.34e-10	Gut microbiome composition (summer);
CESC	cis	rs2933343	0.630	rs75824035	chr3:128652985	T/C	cg25356066	chr3:128598488	ACAD9	0.65	9.06	0.49	2.95e-17	IgG glycosylation;
CESC	cis	rs9527	0.521	rs12259163	chr10:104961477	A/G	cg04362960	chr10:104952993	NT5C2	0.44	5.44	0.32	1.24e-7	Arsenic metabolism;
CESC	cis	rs3815700	0.920	rs10424732	chr19:33096487	C/T	cg02997394	chr19:33096574	ANKRD27	0.75	7.44	0.42	1.44e-12	Eosinophilic esophagitis;
CESC	cis	rs4332037	0.707	rs10268797	chr7:1873756	C/G	cg23422044	chr7:1970798	MAD1L1	0.52	5.45	0.32	1.15e-7	Bipolar disorder;
CESC	cis	rs853679	0.517	rs12174753	chr6:28042465	C/G	cg23161317	chr6:28129485	ZNF389	0.5	6.31	0.36	1.19e-9	Depression;
CESC	cis	rs2404602	0.735	rs283789	chr15:76777577	G/A	cg23625390	chr15:77176239	SCAPER	0.41	5.86	0.34	1.35e-8	Blood metabolite levels;
CESC	cis	rs873946	0.504	rs12254034	chr10:134571007	T/C	cg27286337	chr10:134555280	INPP5A	0.63	7.37	0.41	2.23e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs651907	0.557	rs17411983	chr3:101399126	A/G	cg12386194	chr3:101231763	SENP7	-0.45	-5.53	-0.32	7.54e-8	Colorectal cancer;
CESC	cis	rs711245	0.573	rs7570763	chr2:36800589	A/C	cg01206211	chr2:36825736	FEZ2	-0.33	-5.3	-0.31	2.41e-7	Height;
CESC	trans	rs9325144	0.671	rs7486919	chr12:38767997	A/G	cg23762105	chr12:34175262	ALG10	0.48	6.27	0.36	1.49e-9	Morning vs. evening chronotype;
CESC	cis	rs6460942	1.000	rs17274870	chr7:12406221	G/T	cg10578991	chr7:12443926	VWDE	-0.55	-5.84	-0.34	1.53e-8	Coronary artery disease;
CESC	cis	rs13191362	1.000	rs36007635	chr6:163009335	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.87	9.04	0.49	3.35e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs77956314	0.515	rs10850733	chr12:117380961	G/A	cg25972092	chr12:117363249	FBXW8	0.55	6.19	0.36	2.28e-9	Subcortical brain region volumes;Hippocampal volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06494227	chr22:30752758	CCDC157;SF3A1	0.63	6.9	0.39	3.83e-11	Gut microbiome composition (summer);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg15394763	chr10:77054788	NA	-0.45	-6.36	-0.36	8.85e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs10463316	0.894	rs954341	chr5:150751855	G/A	cg03212797	chr5:150827313	SLC36A1	-0.52	-6.83	-0.39	5.78e-11	Metabolite levels (Pyroglutamine);
CESC	cis	rs910316	1.000	rs4903275	chr14:75512509	C/T	cg08847533	chr14:75593920	NEK9	0.99	18.02	0.74	6.08e-48	Height;
CESC	cis	rs3762637	1.000	rs7626861	chr3:122155196	T/C	cg24169773	chr3:122142474	KPNA1	-0.54	-6.31	-0.36	1.2e-9	LDL cholesterol levels;
CESC	cis	rs7089973	0.604	rs765174	chr10:116601888	C/T	cg03647239	chr10:116582469	FAM160B1	0.43	5.35	0.31	1.94e-7	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs4862750	0.832	rs6836076	chr4:187899660	A/C	cg07414643	chr4:187882934	NA	0.56	8.14	0.45	1.53e-14	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2075371	1.000	rs1862047	chr7:133978078	G/C	cg20476274	chr7:133979776	SLC35B4	0.68	10.07	0.53	2.09e-20	Mean platelet volume;
CESC	cis	rs9916302	0.821	rs12938268	chr17:37572139	G/A	cg15445000	chr17:37608096	MED1	0.4	6.35	0.36	9.2e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs798554	0.757	rs1182178	chr7:2873763	G/A	cg09658497	chr7:2847517	GNA12	-0.42	-6.07	-0.35	4.38e-9	Height;
CESC	cis	rs35306767	0.903	rs12254002	chr10:929133	A/G	cg10556349	chr10:835070	NA	-0.52	-5.25	-0.31	3.17e-7	Eosinophil percentage of granulocytes;
CESC	cis	rs798554	0.679	rs2527677	chr7:2882621	A/G	cg13628971	chr7:2884303	GNA12	0.64	8.77	0.47	2.21e-16	Height;
CESC	cis	rs524281	1.000	rs527897	chr11:65900777	C/T	cg14036092	chr11:66035641	RAB1B	-0.51	-5.81	-0.34	1.75e-8	Electroencephalogram traits;
CESC	trans	rs7618501	1.000	rs60205400	chr3:49800272	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.59	8.5	0.46	1.36e-15	Intelligence (multi-trait analysis);
CESC	cis	rs4654899	0.758	rs12137408	chr1:21282945	A/G	cg05370193	chr1:21551575	ECE1	0.37	5.62	0.33	4.75e-8	Superior frontal gyrus grey matter volume;
CESC	cis	rs9858542	1.000	rs11718165	chr3:49696797	A/G	cg03060546	chr3:49711283	APEH	-0.57	-6.65	-0.38	1.66e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs3749237	0.929	rs62260715	chr3:49829326	G/A	cg03060546	chr3:49711283	APEH	0.66	7.27	0.41	3.99e-12	Resting heart rate;
CESC	cis	rs2637266	0.846	rs2583051	chr10:78403542	T/C	cg18941641	chr10:78392320	NA	0.41	7.58	0.42	5.75e-13	Pulmonary function;
CESC	cis	rs2645694	0.533	rs2645681	chr4:77820949	G/A	cg18351406	chr4:77819688	ANKRD56	0.55	6.89	0.39	4.12e-11	Emphysema distribution in smoking;
CESC	cis	rs1008375	0.931	rs10939734	chr4:17570709	C/T	cg02297831	chr4:17616191	MED28	0.5	6.1	0.35	3.84e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs752010	0.571	rs10890135	chr1:42054084	G/A	cg06885757	chr1:42089581	HIVEP3	0.48	7.75	0.43	1.96e-13	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs1552244	1.000	rs2160869	chr3:10079255	G/A	cg00166722	chr3:10149974	C3orf24	0.48	6.13	0.35	3.09e-9	Alzheimer's disease;
CESC	trans	rs61931739	0.517	rs1844525	chr12:34103183	T/A	cg26384229	chr12:38710491	ALG10B	0.59	8.18	0.45	1.17e-14	Morning vs. evening chronotype;
CESC	cis	rs7147624	1.000	rs11848209	chr14:66022832	T/A	cg03016385	chr14:66212404	NA	-0.49	-5.09	-0.3	6.8e-7	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs7953249	0.618	rs7954331	chr12:121398657	G/T	cg02403541	chr12:121454288	C12orf43	-0.53	-6.9	-0.39	3.77e-11	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
CESC	cis	rs7072216	0.727	rs942807	chr10:100168219	G/A	cg26618903	chr10:100175079	PYROXD2	-0.36	-5.45	-0.32	1.14e-7	Metabolite levels;
CESC	trans	rs2963826	0.589	rs298091	chr5:58996603	A/T	cg12427896	chr2:111880694	BCL2L11	0.48	6.39	0.37	7.45e-10	Obesity-related traits;
CESC	cis	rs73206853	0.841	rs16940933	chr12:111102574	C/A	cg12870014	chr12:110450643	ANKRD13A	0.63	5.12	0.3	5.79e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs9325144	0.534	rs1973293	chr12:38679575	C/T	cg26384229	chr12:38710491	ALG10B	0.6	9.3	0.5	5.38e-18	Morning vs. evening chronotype;
CESC	cis	rs6061231	0.556	rs6121571	chr20:60977323	T/G	cg22633769	chr20:60982531	CABLES2	0.67	8.4	0.46	2.65e-15	Colorectal cancer;
CESC	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.5	-5.79	-0.33	2.02e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs10465746	0.780	rs1952065	chr1:84464205	T/C	cg10977910	chr1:84465055	TTLL7	0.53	7.18	0.4	7.12e-12	Obesity-related traits;
CESC	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg11494091	chr17:61959527	GH2	0.74	13.06	0.63	1.94e-30	Prudent dietary pattern;
CESC	cis	rs1030877	0.557	rs2278501	chr2:105979506	C/T	cg02079111	chr2:105885981	TGFBRAP1	-0.43	-6.38	-0.36	7.9e-10	Obesity-related traits;
CESC	cis	rs2440129	0.611	rs434473	chr17:6904934	A/G	cg05215272	chr17:6899095	ALOX12	-0.39	-7.01	-0.4	1.95e-11	Tonsillectomy;
CESC	cis	rs17376456	0.877	rs17316137	chr5:93456577	C/T	cg21475434	chr5:93447410	FAM172A	0.81	7.47	0.42	1.14e-12	Diabetic retinopathy;
CESC	cis	rs780096	0.545	rs2280737	chr2:27589810	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.27	-5.13	-0.3	5.7e-7	Total body bone mineral density;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25754926	chr6:7986689	MGC26597	-0.52	-6.09	-0.35	3.9e-9	Gut microbiome composition (summer);
CESC	cis	rs7103648	0.695	rs6485758	chr11:47530024	G/A	cg10504702	chr11:47789108	FNBP4	0.43	5.31	0.31	2.34e-7	Diastolic blood pressure;Systolic blood pressure;
CESC	cis	rs11825685	0.790	rs56657264	chr11:134543459	C/T	cg06603561	chr11:134479413	NA	-0.64	-5.39	-0.31	1.59e-7	IgG glycosylation;
CESC	cis	rs7084402	0.967	rs1658443	chr10:60316926	G/T	cg07615347	chr10:60278583	BICC1	0.61	9.59	0.51	7.04e-19	Refractive error;
CESC	cis	rs2072732	0.861	rs6661908	chr1:2950334	C/T	cg15211996	chr1:2936768	ACTRT2	0.33	5.88	0.34	1.23e-8	Plateletcrit;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg10436540	chr17:4047319	ZZEF1;CYB5D2	0.5	6.64	0.38	1.75e-10	Systemic lupus erythematosus;
CESC	trans	rs7980799	0.935	rs2389194	chr12:33529164	A/G	cg26384229	chr12:38710491	ALG10B	-0.48	-6.51	-0.37	3.68e-10	Heart rate;Heart rate variability traits (RMSSD);
CESC	cis	rs787274	1.000	rs9409123	chr9:115507165	G/A	cg13803584	chr9:115635662	SNX30	0.65	5.5	0.32	8.78e-8	Age-related hearing impairment (SNP x SNP interaction);
CESC	trans	rs11039798	0.588	rs1847640	chr11:49004025	C/T	cg03929089	chr4:120376271	NA	0.63	6.06	0.35	4.74e-9	Axial length;
CESC	cis	rs3106136	0.609	rs11097406	chr4:95146042	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.47	-6.49	-0.37	4.28e-10	Capecitabine sensitivity;
CESC	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg24642844	chr7:1081250	C7orf50	-0.77	-9.41	-0.5	2.48e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs11764590	0.671	rs3800872	chr7:2110272	C/G	cg11693508	chr17:37793320	STARD3	0.67	7.21	0.4	5.73e-12	Neuroticism;
CESC	cis	rs9399135	0.967	rs6919862	chr6:135352443	C/A	cg22676075	chr6:135203613	NA	0.51	7.27	0.41	4.07e-12	Red blood cell count;
CESC	cis	rs9911578	1.000	rs10401050	chr17:56953786	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.16	0.3	4.87e-7	Intelligence (multi-trait analysis);
CESC	cis	rs2836974	0.644	rs2410123	chr21:40700093	C/T	cg11644478	chr21:40555479	PSMG1	-0.8	-12.02	-0.59	7.25e-27	Cognitive function;
CESC	cis	rs2882667	0.858	rs66839813	chr5:138442322	A/T	cg04439458	chr5:138467593	SIL1	-0.39	-6.09	-0.35	3.9e-9	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs7615952	0.641	rs4422257	chr3:125774363	A/G	cg02807482	chr3:125708958	NA	-0.41	-5.39	-0.31	1.58e-7	Blood pressure (smoking interaction);
CESC	cis	rs1707322	0.721	rs28641748	chr1:46212836	A/G	cg05343316	chr1:45956843	TESK2	0.51	6.2	0.36	2.19e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs6089829	0.889	rs6062773	chr20:61663262	G/C	cg08564027	chr20:61660810	NA	0.9	15.42	0.69	9.97e-39	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs561341	1.000	rs4795668	chr17:30244554	G/A	cg27661571	chr11:113659931	NA	-0.69	-6.95	-0.39	2.88e-11	Hip circumference adjusted for BMI;
CESC	trans	rs7615952	0.576	rs6780025	chr3:125815624	A/C	cg07211511	chr3:129823064	LOC729375	-0.57	-6.31	-0.36	1.15e-9	Blood pressure (smoking interaction);
CESC	cis	rs11838776	0.522	rs7318424	chr13:111021623	C/G	cg06243866	chr13:111019493	COL4A2	0.34	5.09	0.3	6.65e-7	Coronary artery disease;
CESC	trans	rs687914	0.710	rs938662	chr2:45864578	A/G	cg16265552	chr3:113667068	ZDHHC23	0.59	6.11	0.35	3.47e-9	Diastolic blood pressure;
CESC	cis	rs748404	0.697	rs572959	chr15:43550502	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.61	8.13	0.45	1.62e-14	Lung cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25377475	chr1:236030556	LYST	0.55	6.77	0.38	8.4e-11	Gut microbiome composition (summer);
CESC	cis	rs7809950	0.773	rs62483722	chr7:107186349	C/T	cg23024343	chr7:107201750	COG5	-0.41	-5.65	-0.33	4.03e-8	Coronary artery disease;
CESC	cis	rs9359856	0.510	rs4235839	chr6:90472410	A/G	cg13799429	chr6:90582589	CASP8AP2	0.7	7.91	0.44	6.85e-14	Bipolar disorder;
CESC	trans	rs1814175	0.684	rs1827015	chr11:49585241	A/G	cg15704280	chr7:45808275	SEPT13	-0.95	-14.94	-0.68	5.15e-37	Height;
CESC	trans	rs7911712	0.515	rs2487504	chr10:45254830	C/T	cg12743970	chr17:64536520	PRKCA	0.63	6.12	0.35	3.36e-9	Emphysema-related traits;
CESC	cis	rs72634258	0.796	rs4369247	chr1:8168993	C/T	cg00042356	chr1:8021962	PARK7	-0.48	-5.27	-0.31	2.88e-7	Inflammatory bowel disease;
CESC	cis	rs73019876	0.869	rs2158107	chr19:22151345	T/G	cg11619707	chr19:22235551	ZNF257	-0.28	-5.14	-0.3	5.26e-7	Testicular germ cell tumor;
CESC	trans	rs7107217	1.000	rs1873872	chr11:129473993	A/T	cg03148428	chr7:156433416	C7orf13;RNF32	0.42	6.03	0.35	5.49e-9	Breast cancer;Type 2 diabetes;
CESC	cis	rs3026101	0.624	rs1806219	chr17:5288073	A/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.44	5.89	0.34	1.19e-8	Body mass index;
CESC	cis	rs7618915	0.547	rs2268026	chr3:52778347	T/C	cg05564831	chr3:52568323	NT5DC2	0.44	6.58	0.37	2.57e-10	Bipolar disorder;
CESC	cis	rs7264396	0.563	rs2066066	chr20:34329359	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.63	6.86	0.39	4.77e-11	Total cholesterol levels;
CESC	cis	rs2415984	0.579	rs61993339	chr14:46969266	G/A	cg14871534	chr14:47121158	RPL10L	-0.35	-5.23	-0.31	3.52e-7	Number of children ever born;
CESC	cis	rs7122539	0.506	rs7944999	chr11:66687863	A/G	cg24851651	chr11:66362959	CCS	0.4	5.78	0.33	2.08e-8	HIV-1 susceptibility;
CESC	cis	rs10045504	0.502	rs72746031	chr5:38743161	G/A	cg15396434	chr5:38725168	NA	-0.73	-6.85	-0.39	5.24e-11	Night sleep phenotypes;
CESC	cis	rs9581857	0.547	rs9579086	chr13:28058537	T/A	cg01674679	chr13:27998804	GTF3A	-0.62	-5.1	-0.3	6.52e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
CESC	cis	rs561341	0.714	rs473535	chr17:30312365	A/G	cg00745463	chr17:30367425	LRRC37B	-0.77	-6.94	-0.39	2.98e-11	Hip circumference adjusted for BMI;
CESC	cis	rs9916302	0.861	rs10491129	chr17:37461643	T/G	cg19468946	chr17:37922297	IKZF3	0.41	5.36	0.31	1.81e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs7264396	0.563	rs2066066	chr20:34329359	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.88	-10.7	-0.55	1.88e-22	Total cholesterol levels;
CESC	cis	rs2303759	0.874	rs10411630	chr19:49891314	C/A	cg22133161	chr19:49891603	CCDC155	0.45	5.04	0.3	8.8e-7	Multiple sclerosis;
CESC	cis	rs4555082	0.957	rs2816609	chr14:105720803	A/C	cg27165867	chr14:105738592	BRF1	-0.46	-5.56	-0.32	6.6e-8	Mean platelet volume;Platelet distribution width;
CESC	cis	rs2228479	0.717	rs1061647	chr16:89806063	G/C	cg14709524	chr16:89940631	TCF25	0.9	6.47	0.37	4.72e-10	Skin colour saturation;
CESC	cis	rs7811142	0.775	rs6946768	chr7:99954393	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.74	6.19	0.36	2.23e-9	Platelet count;
CESC	cis	rs9630089	0.746	rs10882873	chr10:98966485	A/G	cg25902810	chr10:99078978	FRAT1	-0.53	-7.45	-0.42	1.29e-12	Neutrophil percentage of white cells;
CESC	cis	rs60871478	0.947	rs62432255	chr7:804219	G/A	cg05535760	chr7:792225	HEATR2	0.85	10.63	0.55	3.21e-22	Cerebrospinal P-tau181p levels;
CESC	cis	rs9311474	0.508	rs1570	chr3:52586682	T/A	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.31	5.54	0.32	7.15e-8	Electroencephalogram traits;
CESC	cis	rs17401966	0.838	rs1013952	chr1:10319247	G/A	cg15208524	chr1:10270712	KIF1B	0.39	5.13	0.3	5.5e-7	Hepatocellular carcinoma;
CESC	cis	rs875971	0.800	rs427557	chr7:65519250	A/G	cg18876405	chr7:65276391	NA	0.55	7.39	0.41	1.98e-12	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09115837	chr10:79541592	NA	-0.73	-8.15	-0.45	1.48e-14	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26422153	chr6:47277743	TNFRSF21	0.6	7.07	0.4	1.39e-11	Gut microbiome composition (summer);
CESC	cis	rs7528419	1.000	rs12740374	chr1:109817590	G/T	cg00908766	chr1:109817496	CELSR2	-0.46	-6.25	-0.36	1.63e-9	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg09796886	chr4:39640558	C4orf34	-0.43	-6.02	-0.35	5.88e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs11098499	0.863	rs3775848	chr4:120447724	C/T	cg24375607	chr4:120327624	NA	0.43	5.22	0.31	3.68e-7	Corneal astigmatism;
CESC	cis	rs6754311	0.517	rs1469996	chr2:136542560	A/G	cg07169764	chr2:136633963	MCM6	0.99	12.59	0.61	8.12e-29	Mosquito bite size;
CESC	cis	rs7927592	0.913	rs67947146	chr11:68314980	C/T	cg20283391	chr11:68216788	NA	-0.61	-7.36	-0.41	2.26e-12	Total body bone mineral density;
CESC	cis	rs916888	0.779	rs430685	chr17:44859148	T/C	cg17911788	chr17:44343683	NA	0.53	7.17	0.4	7.3e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs4930103	0.935	rs2071094	chr11:2021164	G/T	cg23202291	chr11:1979235	NA	0.35	5.04	0.3	8.44e-7	DNA methylation (parent-of-origin);DNA methylation (variation);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg26035463	chr12:117627651	FBXO21	-0.45	-6.26	-0.36	1.57e-9	Gambling;
CESC	cis	rs1799949	1.000	rs8176133	chr17:41257458	A/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.42	5.78	0.33	2.09e-8	Menopause (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10047026	chr17:4613992	ARRB2	0.55	6.19	0.36	2.3e-9	Gut microbiome composition (summer);
CESC	cis	rs2408955	0.521	rs7301003	chr12:48550227	A/G	cg04545296	chr12:48745243	ZNF641	0.34	5.81	0.34	1.76e-8	Glycated hemoglobin levels;
CESC	trans	rs9987353	0.840	rs329994	chr8:9123233	A/G	cg02510453	chr4:152020490	RPS3A	0.48	6.27	0.36	1.43e-9	Recombination measurement;
CESC	cis	rs10751667	0.666	rs10902248	chr11:957742	A/G	cg01483505	chr11:975446	AP2A2	0.37	5.05	0.3	8.3e-7	Alzheimer's disease (late onset);
CESC	cis	rs3768617	0.510	rs10752896	chr1:183068516	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.89	14.23	0.66	1.55e-34	Fuchs's corneal dystrophy;
CESC	cis	rs3204270	0.684	rs62080212	chr17:79642500	G/A	cg26965718	chr17:79658957	HGS	-0.73	-5.61	-0.33	5.17e-8	Dental caries;
CESC	cis	rs742320	0.756	rs4984925	chr16:839996	T/C	cg03433313	chr16:819064	MIR662	-0.48	-6.19	-0.36	2.27e-9	Mean corpuscular volume;
CESC	cis	rs4563143	0.514	rs73029079	chr19:29294903	A/G	cg14983838	chr19:29218262	NA	0.5	5.52	0.32	8.22e-8	Methadone dose in opioid dependence;
CESC	cis	rs2576037	0.583	rs530205	chr18:44385150	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.36	5.81	0.34	1.81e-8	Personality dimensions;
CESC	cis	rs710216	0.917	rs2297977	chr1:43415288	G/T	cg22176566	chr1:43424700	SLC2A1	0.51	5.69	0.33	3.29e-8	Red cell distribution width;
CESC	cis	rs2276314	0.857	rs8087539	chr18:33631537	C/T	cg19628046	chr18:33552617	C18orf21	0.53	5.97	0.34	7.5e-9	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs524023	0.874	rs519090	chr11:64456240	G/C	cg19131476	chr11:64387923	NRXN2	-0.33	-5.05	-0.3	8.13e-7	Urate levels in obese individuals;
CESC	cis	rs6942756	1.000	rs6942756	chr7:128886821	T/G	cg02491457	chr7:128862824	NA	-0.68	-9.81	-0.52	1.35e-19	White matter hyperintensity burden;
CESC	cis	rs2439831	0.850	rs8032649	chr15:44134922	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.67	-7.47	-0.42	1.15e-12	Lung cancer in ever smokers;
CESC	cis	rs875971	0.862	rs57866200	chr7:65565392	A/G	cg19163074	chr7:65112434	INTS4L2	0.46	5.57	0.32	6.37e-8	Aortic root size;
CESC	cis	rs7927592	0.956	rs7102273	chr11:68385579	T/C	cg16797656	chr11:68205561	LRP5	0.38	5.33	0.31	2.12e-7	Total body bone mineral density;
CESC	cis	rs9322193	0.962	rs7745915	chr6:150155247	C/T	cg07701084	chr6:150067640	NUP43	0.45	6.1	0.35	3.75e-9	Lung cancer;
CESC	cis	rs9948	0.867	rs62152860	chr2:97516818	C/A	cg01990225	chr2:97406019	LMAN2L	-0.76	-5.41	-0.32	1.44e-7	Erectile dysfunction and prostate cancer treatment;
CESC	cis	rs933688	1.000	rs933688	chr5:90762748	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.01	12.83	0.62	1.25e-29	Smoking behavior;
CESC	cis	rs2288073	0.965	rs10192600	chr2:24396680	A/G	cg06627628	chr2:24431161	ITSN2	-0.73	-8.37	-0.46	3.41e-15	Venous thromboembolism (SNP x SNP interaction);
CESC	cis	rs4713118	0.513	rs1225591	chr6:28148752	G/A	cg23161317	chr6:28129485	ZNF389	0.4	5.55	0.32	7.03e-8	Parkinson's disease;
CESC	trans	rs12681287	0.511	rs7839601	chr8:87503839	G/C	cg27317242	chr8:23145699	R3HCC1	-0.53	-6.35	-0.36	9.05e-10	Caudate activity during reward;
CESC	cis	rs6500602	0.963	rs7201012	chr16:4480682	C/G	cg08645402	chr16:4508243	NA	0.42	6.43	0.37	6.09e-10	Schizophrenia;
CESC	cis	rs7605378	0.688	rs769961	chr2:200712141	C/A	cg23649088	chr2:200775458	C2orf69	0.58	7.08	0.4	1.32e-11	Osteoporosis;
CESC	cis	rs4975709	0.838	rs4975753	chr5:1880865	T/C	cg15595755	chr5:1867978	NA	0.46	7.15	0.4	8.29e-12	Cardiovascular disease risk factors;
CESC	cis	rs11190604	1.000	rs3793706	chr10:102269085	A/C	cg07080220	chr10:102295463	HIF1AN	-0.67	-6.28	-0.36	1.38e-9	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs4423214	0.921	rs11603330	chr11:71153459	C/A	cg05163923	chr11:71159392	DHCR7	0.82	11.52	0.58	3.73e-25	Vitamin D levels;
CESC	cis	rs6912958	0.712	rs2787927	chr6:88412786	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.48	-5.98	-0.34	7.17e-9	Monocyte percentage of white cells;
CESC	cis	rs9399135	0.967	rs59329760	chr6:135342437	G/A	cg22676075	chr6:135203613	NA	0.51	7.35	0.41	2.44e-12	Red blood cell count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12534480	chr22:43582739	TTLL12	0.59	6.76	0.38	8.74e-11	Gut microbiome composition (summer);
CESC	cis	rs763121	0.853	rs4821809	chr22:39065743	G/C	cg06544989	chr22:39130855	UNC84B	0.49	8.38	0.46	3.04e-15	Menopause (age at onset);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg27161463	chr11:118123074	MPZL3	-0.45	-6.2	-0.36	2.1e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs2315504	0.509	rs2240076	chr17:39035615	C/T	cg05063374	chr17:38953512	KRT28	-0.39	-5.67	-0.33	3.69e-8	Height;
CESC	cis	rs3820928	0.709	rs10178202	chr2:227914561	C/T	cg11843606	chr2:227700838	RHBDD1	-0.49	-5.84	-0.34	1.51e-8	Pulmonary function;
CESC	cis	rs7568458	0.684	rs1048739	chr2:85764968	T/G	cg02493740	chr2:85810744	VAMP5	-0.57	-8.34	-0.46	4.23e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CESC	cis	rs6754311	0.517	rs1865452	chr2:136539330	C/T	cg07169764	chr2:136633963	MCM6	0.98	12.46	0.61	2.27e-28	Mosquito bite size;
CESC	cis	rs10504229	0.906	rs6990615	chr8:58182956	G/A	cg22535103	chr8:58192502	C8orf71	-1.05	-13.08	-0.63	1.71e-30	Developmental language disorder (linguistic errors);
CESC	cis	rs8103278	0.507	rs522769	chr19:46284520	G/A	cg06577658	chr19:46296270	DMWD	0.43	5.2	0.3	4.02e-7	Coronary artery disease;
CESC	cis	rs2279817	1.000	rs2279815	chr1:18022066	G/T	cg21791023	chr1:18019539	ARHGEF10L	0.59	8.48	0.46	1.57e-15	Neuroticism;
CESC	cis	rs561341	0.660	rs7406043	chr17:30220152	C/G	cg13647721	chr17:30228624	UTP6	0.61	5.73	0.33	2.74e-8	Hip circumference adjusted for BMI;
CESC	cis	rs4969178	0.965	rs8077859	chr17:76386335	C/T	cg05887092	chr17:76393375	PGS1	0.57	8.87	0.48	1.08e-16	HDL cholesterol levels;
CESC	cis	rs6866344	0.697	rs11743893	chr5:178125194	C/T	cg10224037	chr5:178157518	ZNF354A	0.59	6.79	0.38	7.51e-11	Neutrophil percentage of white cells;
CESC	cis	rs763121	0.962	rs2071887	chr22:38879010	A/T	cg06544989	chr22:39130855	UNC84B	0.41	6.98	0.39	2.41e-11	Menopause (age at onset);
CESC	cis	rs9443189	0.901	rs2038625	chr6:76560968	G/A	cg01950844	chr6:76311363	SENP6	-0.59	-6.22	-0.36	1.88e-9	Prostate cancer;
CESC	cis	rs11098499	0.954	rs10031483	chr4:120422636	T/C	cg09307838	chr4:120376055	NA	0.93	13.08	0.63	1.67e-30	Corneal astigmatism;
CESC	cis	rs28489187	0.597	rs10489513	chr1:85855622	C/T	cg16011679	chr1:85725395	C1orf52	-0.42	-5.11	-0.3	6.15e-7	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	cis	rs6502050	0.805	rs8082653	chr17:80162382	G/A	cg23985595	chr17:80112537	CCDC57	-0.4	-6.48	-0.37	4.35e-10	Life satisfaction;
CESC	cis	rs10191773	0.535	rs56048537	chr2:113078467	G/T	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.62	-6.8	-0.39	7.11e-11	Yeast infection;
CESC	cis	rs6665290	0.935	rs1929862	chr1:227199718	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.22	-32.32	-0.89	6.28e-94	Myeloid white cell count;
CESC	cis	rs6835098	0.828	rs28612521	chr4:174085294	G/A	cg08422745	chr4:174089978	GALNT7	-0.84	-12.18	-0.6	2.12e-27	Dementia and core Alzheimer's disease neuropathologic changes;
CESC	cis	rs2576037	0.501	rs7245049	chr18:44528213	G/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.32	5.05	0.3	8.14e-7	Personality dimensions;
CESC	cis	rs6500602	0.701	rs4786500	chr16:4525265	A/G	cg08645402	chr16:4508243	NA	-0.36	-5.29	-0.31	2.53e-7	Schizophrenia;
CESC	cis	rs4243830	0.522	rs10864614	chr1:6596008	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.98	-9.97	-0.52	4.22e-20	Body mass index;
CESC	cis	rs2299587	0.662	rs6586671	chr8:17776084	T/C	cg08627089	chr8:17753878	FGL1	-0.39	-5.2	-0.3	3.96e-7	Economic and political preferences;
CESC	cis	rs6500602	0.893	rs4786489	chr16:4485527	G/A	cg08645402	chr16:4508243	NA	0.37	5.29	0.31	2.56e-7	Schizophrenia;
CESC	cis	rs4974559	0.947	rs28540746	chr4:1352954	G/A	cg02980000	chr4:1222292	CTBP1	0.73	6.79	0.38	7.37e-11	Systolic blood pressure;
CESC	cis	rs2180341	0.855	rs9385422	chr6:127716457	C/T	cg24812749	chr6:127587940	RNF146	0.83	11.75	0.59	6.25e-26	Breast cancer;
CESC	cis	rs7561273	0.586	rs7589717	chr2:24357463	G/A	cg20701182	chr2:24300061	SF3B14	0.46	6.01	0.35	6.27e-9	Quantitative traits;
CESC	cis	rs6460942	0.630	rs62451487	chr7:12390464	G/A	cg20607287	chr7:12443886	VWDE	-0.61	-6.64	-0.38	1.82e-10	Coronary artery disease;
CESC	cis	rs826838	1.000	rs1719830	chr12:39096992	T/G	cg26384229	chr12:38710491	ALG10B	-0.62	-9.94	-0.52	5.53e-20	Heart rate;
CESC	cis	rs10504073	0.647	rs28685207	chr8:50003484	A/G	cg00325661	chr8:49890786	NA	0.51	7.78	0.43	1.65e-13	Blood metabolite ratios;
CESC	cis	rs7424096	0.613	rs72873859	chr2:37246738	T/G	cg14987922	chr2:37194071	STRN	0.48	5.2	0.3	4e-7	High light scatter reticulocyte percentage of red cells;
CESC	cis	rs9457247	0.624	rs9457260	chr6:167466665	C/T	cg23791538	chr6:167370224	RNASET2	-0.52	-6.87	-0.39	4.45e-11	Crohn's disease;
CESC	cis	rs2842992	0.789	rs7765490	chr6:160204326	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.74	9.35	0.5	3.84e-18	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs7772486	0.790	rs3923579	chr6:146230232	C/G	cg23711669	chr6:146136114	FBXO30	-0.94	-13.73	-0.64	9.31e-33	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2880765	0.835	rs4340287	chr15:86043737	A/G	cg19183879	chr15:85880815	NA	-0.25	-5.18	-0.3	4.31e-7	Coronary artery disease;
CESC	cis	rs6942756	0.531	rs7811141	chr7:128908273	C/G	cg02491457	chr7:128862824	NA	0.48	6.85	0.39	5.14e-11	White matter hyperintensity burden;
CESC	cis	rs7680126	0.596	rs12511337	chr4:10311972	A/G	cg11266682	chr4:10021025	SLC2A9	0.41	5.34	0.31	2.05e-7	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	cis	rs1005277	0.563	rs2505215	chr10:38481273	A/G	cg00409905	chr10:38381863	ZNF37A	-0.47	-6.33	-0.36	1.04e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs367943	0.673	rs7708084	chr5:112732692	G/T	cg12552261	chr5:112820674	MCC	0.38	5.14	0.3	5.32e-7	Type 2 diabetes;
CESC	cis	rs6461049	0.765	rs4719432	chr7:2140330	A/G	cg08027265	chr7:2291960	NA	-0.34	-5.23	-0.31	3.44e-7	Schizophrenia;
CESC	trans	rs7246657	0.943	rs7255407	chr19:37933936	G/A	cg01833234	chr11:6592585	DNHD1	0.52	6.0	0.35	6.5e-9	Coronary artery calcification;
CESC	cis	rs7582720	1.000	rs72936862	chr2:203786812	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.38	0.41	1.99e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	trans	rs1814175	0.904	rs1846289	chr11:49620253	G/A	cg03929089	chr4:120376271	NA	-0.88	-13.63	-0.64	2.05e-32	Height;
CESC	cis	rs7274811	0.711	rs184110	chr20:31981432	G/A	cg21523528	chr20:32077966	CBFA2T2	-0.43	-5.07	-0.3	7.53e-7	Height;
CESC	cis	rs4713118	0.527	rs35949862	chr6:28115367	A/G	cg23161317	chr6:28129485	ZNF389	0.52	6.48	0.37	4.48e-10	Parkinson's disease;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg17378273	chr11:45169082	PRDM11	0.39	6.0	0.35	6.39e-9	Gambling;
CESC	cis	rs875971	0.862	rs6460307	chr7:66060871	A/G	cg12463550	chr7:65579703	CRCP	0.5	6.42	0.37	6.17e-10	Aortic root size;
CESC	cis	rs6912958	0.712	rs9444525	chr6:88324142	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.34	-5.57	-0.32	6.14e-8	Monocyte percentage of white cells;
CESC	cis	rs5753618	0.504	rs9609297	chr22:31893731	G/T	cg13145458	chr22:31556086	RNF185	-0.46	-5.25	-0.31	3.09e-7	Colorectal cancer;
CESC	cis	rs2832191	0.646	rs2832210	chr21:30508723	T/G	cg24692254	chr21:30365293	RNF160	-0.61	-7.72	-0.43	2.35e-13	Dental caries;
CESC	cis	rs3749237	1.000	rs11710675	chr3:49751900	C/A	cg03060546	chr3:49711283	APEH	0.64	7.48	0.42	1.09e-12	Resting heart rate;
CESC	cis	rs7267979	0.744	rs6050464	chr20:25209299	C/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.72	12.0	0.59	8.92e-27	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs2228479	0.702	rs62053702	chr16:89860688	G/T	cg06558623	chr16:89946397	TCF25	1.18	9.47	0.5	1.65e-18	Skin colour saturation;
CESC	cis	rs10504229	0.610	rs6999661	chr8:58127391	C/G	cg24829409	chr8:58192753	C8orf71	-0.59	-7.24	-0.41	4.79e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs10882165	0.547	rs2104631	chr10:94955827	G/C	cg00992348	chr10:94926053	NA	-0.31	-5.47	-0.32	1.04e-7	Refractive error;
CESC	cis	rs4665809	0.652	rs2241739	chr2:26411894	C/T	cg22920501	chr2:26401640	FAM59B	-0.86	-10.87	-0.56	5.47e-23	Gut microbiome composition (summer);
CESC	cis	rs701145	0.617	rs7426835	chr3:154049539	C/T	cg16511985	chr3:153974050	SGEF	0.36	5.14	0.3	5.33e-7	Coronary artery disease;
CESC	cis	rs1843834	0.539	rs6739735	chr2:225405253	A/G	cg12698349	chr2:225449008	CUL3	-0.62	-8.93	-0.48	7.53e-17	IgE levels in asthmatics (D.p. specific);
CESC	cis	rs5758659	0.653	rs133383	chr22:42473603	C/T	cg15557168	chr22:42548783	NA	-0.48	-7.52	-0.42	8.34e-13	Cognitive function;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg22478328	chr22:32340140	C22orf24;YWHAH	0.49	6.4	0.37	7.09e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs2243480	1.000	rs4718309	chr7:65627764	G/C	cg13147721	chr7:65941812	NA	0.97	9.19	0.49	1.2e-17	Diabetic kidney disease;
CESC	cis	rs7945705	0.902	rs7930026	chr11:9013639	T/C	cg21881798	chr11:8931708	C11orf17;ST5	0.46	7.55	0.42	6.89e-13	Hemoglobin concentration;
CESC	cis	rs4566357	0.615	rs12474622	chr2:227912793	A/G	cg05526886	chr2:227700861	RHBDD1	-0.47	-6.28	-0.36	1.35e-9	Coronary artery disease;
CESC	cis	rs2033711	0.728	rs4801586	chr19:58934528	A/G	cg11952622	chr19:58962976	ZNF324B	0.46	6.13	0.35	3.11e-9	Uric acid clearance;
CESC	cis	rs2243480	0.831	rs7806717	chr7:65393174	A/G	cg13147721	chr7:65941812	NA	0.85	8.1	0.45	2e-14	Diabetic kidney disease;
CESC	cis	rs963731	0.649	rs10153761	chr2:39262068	C/T	cg04010122	chr2:39346883	SOS1	-0.74	-5.44	-0.32	1.19e-7	Corticobasal degeneration;
CESC	cis	rs9291683	0.679	rs2241483	chr4:10099831	A/G	cg00071950	chr4:10020882	SLC2A9	-0.57	-9.11	-0.49	2.11e-17	Bone mineral density;
CESC	cis	rs738322	0.935	rs2413503	chr22:38568944	A/T	cg25457927	chr22:38595422	NA	-0.29	-5.52	-0.32	8.22e-8	Cutaneous nevi;
CESC	cis	rs10504229	0.569	rs75466737	chr8:58055034	A/G	cg02725872	chr8:58115012	NA	-0.41	-5.49	-0.32	9.22e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs2839186	0.709	rs2839176	chr21:47678173	A/G	cg10351095	chr21:47802916	PCNT	-0.5	-6.82	-0.39	6.04e-11	Testicular germ cell tumor;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27657525	chr19:30432971	C19orf2	0.53	6.55	0.37	3.04e-10	Gut microbiome composition (summer);
CESC	cis	rs9649213	0.593	rs6465664	chr7:97921834	A/G	cg00277769	chr7:97922759	BAIAP2L1	-0.34	-5.57	-0.32	6.1e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs116095464	0.558	rs10057299	chr5:242135	C/T	cg10591111	chr5:226296	SDHA	-0.52	-6.38	-0.36	7.94e-10	Breast cancer;
CESC	cis	rs9457247	0.663	rs9457257	chr6:167440736	G/A	cg07741184	chr6:167504864	NA	0.34	6.01	0.35	6.21e-9	Crohn's disease;
CESC	cis	rs2576037	0.583	rs593340	chr18:44418346	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.35	5.6	0.33	5.46e-8	Personality dimensions;
CESC	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg24642844	chr7:1081250	C7orf50	-0.75	-8.99	-0.48	4.94e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs780096	0.546	rs2293571	chr2:27729480	C/T	cg24768116	chr2:27665128	KRTCAP3	-0.34	-6.45	-0.37	5.39e-10	Total body bone mineral density;
CESC	cis	rs2075371	0.611	rs12531769	chr7:134016899	C/G	cg20476274	chr7:133979776	SLC35B4	0.58	7.82	0.43	1.23e-13	Mean platelet volume;
CESC	trans	rs9325144	0.560	rs11183046	chr12:38655270	A/T	cg23762105	chr12:34175262	ALG10	0.48	6.31	0.36	1.15e-9	Morning vs. evening chronotype;
CESC	cis	rs77741769	0.507	rs11065264	chr12:121218380	T/G	cg02419362	chr12:121203948	SPPL3	0.35	5.61	0.33	5e-8	Mean corpuscular volume;
CESC	cis	rs1218582	0.772	rs12095061	chr1:154912968	A/T	cg09359103	chr1:154839909	KCNN3	-0.66	-12.34	-0.6	5.93e-28	Prostate cancer;
CESC	cis	rs2760061	0.626	rs672907	chr1:228120345	G/A	cg01973587	chr1:228161476	NA	0.38	5.93	0.34	9.18e-9	Diastolic blood pressure;
CESC	cis	rs9640161	0.789	rs1464751	chr7:150021282	C/T	cg21361702	chr7:150065534	REPIN1	0.47	5.54	0.32	7.34e-8	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs735860	0.726	rs209518	chr6:53208016	C/A	cg10236188	chr6:53219634	NA	0.35	5.27	0.31	2.79e-7	Glaucoma;
CESC	cis	rs9584850	0.609	rs7983408	chr13:99155593	G/C	cg20750642	chr13:99100586	FARP1	-0.37	-5.24	-0.31	3.29e-7	Neuroticism;
CESC	cis	rs35955747	0.633	rs7287937	chr22:32020745	G/A	cg25791279	chr22:32026902	PISD	-0.49	-5.95	-0.34	8.57e-9	Neutrophil count;Sum basophil neutrophil counts;
CESC	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.49	-6.2	-0.36	2.12e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs1483890	0.642	rs1010315	chr3:69402165	C/T	cg22125112	chr3:69402811	FRMD4B	0.38	5.1	0.3	6.48e-7	Resting heart rate;
CESC	cis	rs8016982	0.674	rs11850714	chr14:81662993	C/G	cg01989461	chr14:81687754	GTF2A1	0.75	11.64	0.58	1.4e-25	Schizophrenia;
CESC	cis	rs10754283	0.557	rs1215511	chr1:90087543	C/A	cg21401794	chr1:90099060	LRRC8C	0.56	7.81	0.43	1.31e-13	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs12130219	0.500	rs1552991	chr1:152165878	C/T	cg17718321	chr1:152188247	HRNR	-0.54	-8.84	-0.48	1.39e-16	Inflammatory skin disease;
CESC	cis	rs1799949	1.000	rs11655505	chr17:41278377	G/A	cg06001716	chr17:41278141	BRCA1;NBR2	0.39	5.28	0.31	2.75e-7	Menopause (age at onset);
CESC	cis	rs2688608	0.588	rs10128205	chr10:75469648	C/G	cg23231163	chr10:75533350	FUT11	-0.36	-5.43	-0.32	1.28e-7	Inflammatory bowel disease;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg09366641	chr1:153643528	ILF2	-0.46	-6.62	-0.38	1.93e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs4803468	1.000	rs10409485	chr19:41920765	C/T	cg14132834	chr19:41945861	ATP5SL	0.63	7.78	0.43	1.58e-13	Height;
CESC	cis	rs1008375	0.606	rs6828925	chr4:17561139	C/T	cg16339924	chr4:17578868	LAP3	0.55	7.0	0.4	2.09e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs1008375	1.000	rs56974987	chr4:17627856	G/A	cg04450456	chr4:17643702	FAM184B	0.39	5.56	0.32	6.7e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs2455799	0.613	rs1976479	chr3:15729714	C/G	cg16303742	chr3:15540471	COLQ	-0.38	-5.8	-0.34	1.88e-8	Mean platelet volume;
CESC	cis	rs1348850	0.567	rs3821006	chr2:178537694	G/A	cg23306229	chr2:178417860	TTC30B	0.53	6.97	0.39	2.55e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs57506017	0.606	rs7785087	chr7:12257549	A/G	cg23422036	chr7:12250390	TMEM106B	0.38	5.11	0.3	6.06e-7	Neuroticism;
CESC	cis	rs9309711	0.689	rs4535075	chr2:3481716	T/C	cg15506890	chr2:3487001	NA	-0.48	-6.12	-0.35	3.33e-9	Neurofibrillary tangles;
CESC	cis	rs10861342	0.892	rs10459207	chr12:105531072	C/T	cg23923672	chr12:105501055	KIAA1033	0.71	5.98	0.34	7.09e-9	IgG glycosylation;
CESC	cis	rs9834373	0.811	rs9837213	chr3:78481884	A/G	cg06138941	chr3:78371609	NA	-0.42	-5.15	-0.3	5.18e-7	Protein quantitative trait loci;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg19189310	chr6:34393779	RPS10	-0.48	-6.5	-0.37	4.07e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs796364	0.806	rs74771155	chr2:200913743	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.85	-7.93	-0.44	6.07e-14	Schizophrenia;
CESC	cis	rs2576037	0.526	rs4890703	chr18:44522037	A/G	cg19077165	chr18:44547161	KATNAL2	-0.51	-7.09	-0.4	1.21e-11	Personality dimensions;
CESC	cis	rs1008375	0.872	rs2315552	chr4:17627294	A/G	cg15017067	chr4:17643749	FAM184B	0.39	5.53	0.32	7.68e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs8060686	0.545	rs12596883	chr16:68172416	A/T	cg26727032	chr16:67993705	SLC12A4	-0.5	-5.45	-0.32	1.16e-7	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs854765	0.583	rs4257260	chr17:17857003	A/G	cg04398451	chr17:18023971	MYO15A	-0.69	-9.72	-0.51	2.77e-19	Total body bone mineral density;
CESC	cis	rs7615952	0.641	rs60839048	chr3:125807938	G/A	cg02807482	chr3:125708958	NA	-0.39	-5.07	-0.3	7.59e-7	Blood pressure (smoking interaction);
CESC	cis	rs4654899	0.865	rs6700459	chr1:21279396	T/C	cg05370193	chr1:21551575	ECE1	0.41	6.2	0.36	2.21e-9	Superior frontal gyrus grey matter volume;
CESC	cis	rs12545109	0.800	rs1837614	chr8:57414497	T/A	cg09654669	chr8:57350985	NA	-0.46	-6.25	-0.36	1.67e-9	Obesity-related traits;
CESC	cis	rs17376456	0.542	rs35672980	chr5:93284877	A/T	cg25358565	chr5:93447407	FAM172A	-0.45	-5.29	-0.31	2.62e-7	Diabetic retinopathy;
CESC	cis	rs7789940	1.000	rs2072435	chr7:75959188	G/A	cg10167463	chr7:75959203	YWHAG	-0.56	-7.09	-0.4	1.23e-11	Multiple sclerosis;
CESC	cis	rs637571	0.522	rs679581	chr11:65746653	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.76	11.08	0.56	1.05e-23	Eosinophil percentage of white cells;
CESC	cis	rs317689	0.718	rs645026	chr12:69757931	G/A	cg20891283	chr12:69753455	YEATS4	0.63	7.35	0.41	2.45e-12	Response to diuretic therapy;
CESC	cis	rs10463316	0.894	rs7703283	chr5:150764904	C/T	cg03212797	chr5:150827313	SLC36A1	-0.46	-6.02	-0.35	5.83e-9	Metabolite levels (Pyroglutamine);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg14080940	chr6:79944542	HMGN3	-0.43	-6.7	-0.38	1.21e-10	Gambling;
CESC	cis	rs2066819	1.000	rs74673257	chr12:56638077	T/C	cg26734620	chr12:56694298	CS	1.04	6.73	0.38	1.06e-10	Psoriasis vulgaris;
CESC	cis	rs2243480	1.000	rs1039664	chr7:65449716	T/G	cg18252515	chr7:66147081	NA	-1.13	-10.9	-0.56	4.18e-23	Diabetic kidney disease;
CESC	cis	rs10088262	0.629	rs12541177	chr8:124800273	G/T	cg15047889	chr8:124780837	FAM91A1	-0.52	-6.58	-0.37	2.57e-10	Pancreatic cancer;
CESC	cis	rs8072100	0.840	rs4968319	chr17:45464967	A/G	cg08085267	chr17:45401833	C17orf57	-0.52	-6.92	-0.39	3.47e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs13242816	1.000	rs6979182	chr7:116119345	T/G	cg04696780	chr7:116139425	CAV2	-0.59	-5.23	-0.31	3.42e-7	P wave duration;
CESC	cis	rs9611565	0.659	rs12484175	chr22:41953739	A/C	cg06481639	chr22:41940642	POLR3H	-0.62	-6.57	-0.37	2.66e-10	Vitiligo;
CESC	trans	rs1545843	0.564	rs2611292	chr12:84891790	C/T	cg03015433	chr16:56623111	MT3	0.33	6.1	0.35	3.76e-9	Major depressive disorder;
CESC	cis	rs889398	0.802	rs12925700	chr16:69793463	C/A	cg09409435	chr16:70099608	PDXDC2	-0.42	-5.2	-0.3	3.96e-7	Body mass index;
CESC	cis	rs4654899	0.758	rs6668370	chr1:21369568	C/T	cg05370193	chr1:21551575	ECE1	0.35	5.28	0.31	2.63e-7	Superior frontal gyrus grey matter volume;
CESC	cis	rs9309711	0.666	rs6723126	chr2:3484500	T/C	cg15541040	chr2:3486749	NA	-0.43	-5.38	-0.31	1.64e-7	Neurofibrillary tangles;
CESC	cis	rs7267979	0.586	rs6050439	chr20:25192331	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.67	11.21	0.57	4.12e-24	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs2836974	0.965	rs6517538	chr21:40656242	C/T	cg11890956	chr21:40555474	PSMG1	1.16	21.11	0.79	1.03e-58	Cognitive function;
CESC	trans	rs2963826	0.589	rs298091	chr5:58996603	A/T	cg21871735	chr16:2015157	SNHG9;RPS2;SNORA78	0.48	6.3	0.36	1.27e-9	Obesity-related traits;
CESC	cis	rs78456975	1.000	rs6708604	chr2:1556887	C/T	cg26248373	chr2:1572462	NA	-0.58	-5.22	-0.31	3.67e-7	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs3820068	0.580	rs34426856	chr1:16006315	C/T	cg17385448	chr1:15911702	AGMAT	0.4	6.26	0.36	1.55e-9	Systolic blood pressure;
CESC	cis	rs3733585	0.699	rs6844787	chr4:9959233	A/G	cg11266682	chr4:10021025	SLC2A9	-0.6	-11.2	-0.57	4.42e-24	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs7618915	0.547	rs12496634	chr3:52709259	A/C	cg07507251	chr3:52567010	NT5DC2	0.4	7.07	0.4	1.34e-11	Bipolar disorder;
CESC	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg23708337	chr7:1209742	NA	0.53	5.34	0.31	1.98e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs9649213	0.593	rs1076272	chr7:98031005	C/G	cg21770322	chr7:97807741	LMTK2	0.58	8.75	0.47	2.54e-16	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs2228479	0.850	rs11648433	chr16:89965055	G/A	cg00800038	chr16:89945340	TCF25	-0.91	-7.41	-0.41	1.71e-12	Skin colour saturation;
CESC	cis	rs8077577	0.747	rs3829956	chr17:18219835	A/G	cg16794390	chr17:18148240	FLII	0.4	6.34	0.36	9.74e-10	Obesity-related traits;
CESC	trans	rs2727020	0.681	rs2866362	chr11:49379316	A/G	cg03929089	chr4:120376271	NA	-0.79	-11.94	-0.59	1.39e-26	Coronary artery disease;
CESC	cis	rs4689388	0.926	rs10010131	chr4:6292915	A/G	cg00701064	chr4:6280414	WFS1	0.7	12.17	0.6	2.37e-27	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs1552244	0.626	rs2886396	chr3:10037670	C/T	cg08888203	chr3:10149979	C3orf24	0.48	6.06	0.35	4.71e-9	Alzheimer's disease;
CESC	cis	rs75804782	0.521	rs60779166	chr2:239433943	G/A	cg18131467	chr2:239335373	ASB1	-0.67	-5.1	-0.3	6.5e-7	Morning vs. evening chronotype;Chronotype;
CESC	cis	rs7799006	0.606	rs12669625	chr7:2315950	C/T	cg12745145	chr7:2261452	MAD1L1	-0.32	-5.06	-0.3	8.03e-7	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs875971	1.000	rs1968225	chr7:65874773	T/C	cg10691866	chr7:65817282	TPST1	-0.34	-5.47	-0.32	1.06e-7	Aortic root size;
CESC	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg10862848	chr6:42927986	GNMT	-0.26	-6.54	-0.37	3.18e-10	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs7662987	0.517	rs1154410	chr4:100006645	A/G	cg12011299	chr4:100065546	ADH4	0.58	6.6	0.38	2.23e-10	Smoking initiation;
CESC	cis	rs10504229	0.906	rs113745779	chr8:58191301	C/G	cg24829409	chr8:58192753	C8orf71	-0.76	-9.93	-0.52	5.87e-20	Developmental language disorder (linguistic errors);
CESC	trans	rs116095464	0.681	rs9687745	chr5:229309	C/T	cg00938859	chr5:1591904	SDHAP3	0.62	6.79	0.38	7.53e-11	Breast cancer;
CESC	cis	rs11122272	0.668	rs1122131	chr1:231476501	A/G	cg06096015	chr1:231504339	EGLN1	0.44	6.47	0.37	4.74e-10	Hemoglobin concentration;
CESC	cis	rs4974559	0.790	rs6850727	chr4:1323273	G/C	cg02980000	chr4:1222292	CTBP1	0.67	7.63	0.42	4.21e-13	Systolic blood pressure;
CESC	cis	rs2439831	0.681	rs2278859	chr15:43632960	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.9	10.79	0.55	9.67e-23	Lung cancer in ever smokers;
CESC	cis	rs1008375	1.000	rs28545485	chr4:17645376	C/T	cg16339924	chr4:17578868	LAP3	0.56	7.02	0.4	1.9e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	trans	rs931812	1.000	rs4734494	chr8:101917721	T/C	cg20993868	chr7:22813445	NA	0.44	6.31	0.36	1.18e-9	Attention deficit hyperactivity disorder and conduct disorder;
CESC	cis	rs796364	0.806	rs11679658	chr2:200923081	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.86	-7.81	-0.43	1.3e-13	Schizophrenia;
CESC	cis	rs853679	0.517	rs9368553	chr6:28082265	T/C	cg22143856	chr6:28129313	ZNF389	0.52	6.71	0.38	1.21e-10	Depression;
CESC	cis	rs853679	0.517	rs9368554	chr6:28082711	T/C	cg19592336	chr6:28129416	ZNF389	0.6	7.98	0.44	4.4e-14	Depression;
CESC	cis	rs7605827	0.930	rs7602186	chr2:15510003	C/T	cg19274914	chr2:15703543	NA	0.33	5.96	0.34	7.81e-9	Educational attainment (years of education);
CESC	cis	rs10242455	0.702	rs45448997	chr7:99041598	G/C	cg18809830	chr7:99032528	PTCD1	-0.63	-5.13	-0.3	5.68e-7	Blood metabolite levels;
CESC	cis	rs875971	0.502	rs6460311	chr7:66111873	C/T	cg18527119	chr7:66119851	NA	0.52	5.58	0.32	5.98e-8	Aortic root size;
CESC	cis	rs896854	0.654	rs4735339	chr8:95974373	C/T	cg13393036	chr8:95962371	TP53INP1	-0.49	-10.52	-0.54	7.38e-22	Type 2 diabetes;
CESC	cis	rs7107174	0.892	rs2510033	chr11:77941771	T/G	cg02023728	chr11:77925099	USP35	0.48	6.3	0.36	1.24e-9	Testicular germ cell tumor;
CESC	cis	rs67072384	0.818	rs2291290	chr11:72465877	T/C	cg04827223	chr11:72435913	ARAP1	-0.7	-7.1	-0.4	1.16e-11	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
CESC	cis	rs763121	0.853	rs138712	chr22:39141600	C/T	cg21395723	chr22:39101663	GTPBP1	0.46	5.97	0.34	7.43e-9	Menopause (age at onset);
CESC	cis	rs741677	0.586	rs58180134	chr17:499297	C/A	cg15660573	chr17:549704	VPS53	-0.58	-7.27	-0.41	4.13e-12	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
CESC	cis	rs9815354	0.638	rs76276404	chr3:41931770	A/G	cg03022575	chr3:42003672	ULK4	0.71	6.44	0.37	5.46e-10	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs5769765	0.773	rs9616382	chr22:50312979	C/T	cg02269571	chr22:50332266	NA	-0.56	-6.99	-0.39	2.26e-11	Schizophrenia;
CESC	cis	rs4555082	1.000	rs4334224	chr14:105759198	C/T	cg13114125	chr14:105738426	BRF1	-0.74	-9.45	-0.5	1.92e-18	Mean platelet volume;Platelet distribution width;
CESC	cis	rs7914558	1.000	rs7899084	chr10:104872547	A/T	cg04362960	chr10:104952993	NT5C2	0.46	5.92	0.34	9.98e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs6665290	0.901	rs61834005	chr1:227202789	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.16	-25.99	-0.85	7.59e-75	Myeloid white cell count;
CESC	cis	rs78456975	1.000	rs6712176	chr2:1556393	C/T	cg26248373	chr2:1572462	NA	-0.59	-5.69	-0.33	3.31e-8	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs4631830	0.900	rs10763546	chr10:51536399	C/G	cg16070123	chr10:51489643	NA	-0.35	-5.25	-0.31	3.12e-7	Prostate-specific antigen levels;
CESC	cis	rs7590720	0.851	rs13006614	chr2:216876204	C/T	cg12620499	chr2:216877984	MREG	0.84	12.23	0.6	1.46e-27	Alcohol dependence;
CESC	cis	rs4689592	0.513	rs3857178	chr4:7066516	G/A	cg19539972	chr4:7069911	GRPEL1	0.79	9.97	0.52	4.37e-20	Monocyte percentage of white cells;
CESC	cis	rs853679	0.517	rs4713144	chr6:28106790	C/G	cg12963246	chr6:28129442	ZNF389	0.57	7.78	0.43	1.65e-13	Depression;
CESC	cis	rs780096	0.546	rs2293571	chr2:27729480	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.31	-5.76	-0.33	2.33e-8	Total body bone mineral density;
CESC	cis	rs738322	0.935	rs75387	chr22:38572057	C/T	cg25457927	chr22:38595422	NA	-0.3	-5.46	-0.32	1.1e-7	Cutaneous nevi;
CESC	cis	rs6968419	0.788	rs67915501	chr7:115822036	C/T	cg02561103	chr7:115862891	TES	-0.39	-5.24	-0.31	3.34e-7	Intraocular pressure;
CESC	cis	rs11608355	0.521	rs7967632	chr12:109848000	C/G	cg19025524	chr12:109796872	NA	-0.53	-7.24	-0.41	4.76e-12	Neuroticism;
CESC	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg11494091	chr17:61959527	GH2	0.73	12.52	0.61	1.41e-28	Prudent dietary pattern;
CESC	cis	rs9325144	0.534	rs1843866	chr12:38703160	G/T	cg26384229	chr12:38710491	ALG10B	0.59	8.79	0.48	1.96e-16	Morning vs. evening chronotype;
CESC	cis	rs6842047	0.809	rs3087505	chr4:187179486	A/G	cg02012338	chr4:187126139	CYP4V2	0.62	5.06	0.3	8e-7	Blood protein levels;
CESC	cis	rs6540556	0.769	rs17389198	chr1:209922058	G/A	cg05527609	chr1:210001259	C1orf107	-0.66	-7.62	-0.42	4.65e-13	Red blood cell count;
CESC	cis	rs6032067	0.929	rs17424474	chr20:43804797	C/A	cg10761708	chr20:43804764	PI3	0.53	6.33	0.36	1.04e-9	Blood protein levels;
CESC	cis	rs910316	0.967	rs1071989	chr14:75564659	G/T	cg11812906	chr14:75593930	NEK9	0.89	15.08	0.68	1.6e-37	Height;
CESC	cis	rs10861342	1.000	rs10861358	chr12:105559563	G/A	cg23923672	chr12:105501055	KIAA1033	0.68	5.48	0.32	9.87e-8	IgG glycosylation;
CESC	cis	rs10883723	0.669	rs2001595	chr10:104395085	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.58	6.96	0.39	2.65e-11	Allergic disease (asthma, hay fever or eczema);
CESC	trans	rs9467711	0.606	rs34878490	chr6:26370572	C/T	cg06606381	chr12:133084897	FBRSL1	-0.76	-6.86	-0.39	4.71e-11	Autism spectrum disorder or schizophrenia;
CESC	cis	rs6662572	1.000	rs6662999	chr1:46119351	C/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.53	5.57	0.32	6.17e-8	Blood protein levels;
CESC	cis	rs2070433	0.706	rs3788265	chr21:47833789	G/T	cg12379764	chr21:47803548	PCNT	0.62	6.42	0.37	6.28e-10	Lymphocyte counts;
CESC	cis	rs4268898	0.610	rs34216622	chr2:24463445	G/C	cg20701182	chr2:24300061	SF3B14	0.63	6.89	0.39	4.11e-11	Asthma;
CESC	cis	rs6952808	0.823	rs58222895	chr7:1885064	G/A	cg04267008	chr7:1944627	MAD1L1	-0.6	-7.33	-0.41	2.73e-12	Bipolar disorder and schizophrenia;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg13786513	chr19:45648562	NA	0.52	7.14	0.4	8.81e-12	Fibrinogen levels;
CESC	cis	rs9362426	0.708	rs6907825	chr6:88102822	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.52	6.14	0.35	2.93e-9	Depressive episodes in bipolar disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07645393	chr12:112123605	ACAD10;BRAP	0.56	6.02	0.35	5.65e-9	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17397401	chr15:75230745	COX5A	-0.56	-6.61	-0.38	2.13e-10	Gut microbiome composition (summer);
CESC	cis	rs6121246	0.559	rs6060919	chr20:30331922	A/T	cg13852791	chr20:30311386	BCL2L1	0.85	11.17	0.57	5.35e-24	Mean corpuscular hemoglobin;
CESC	cis	rs9815354	0.680	rs73073274	chr3:42022810	T/C	cg03022575	chr3:42003672	ULK4	0.75	6.64	0.38	1.72e-10	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs6598955	0.724	rs4659420	chr1:26614333	G/A	cg04990556	chr1:26633338	UBXN11	-0.8	-11.56	-0.58	2.7e-25	Obesity-related traits;
CESC	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.5	-6.23	-0.36	1.83e-9	Longevity;Endometriosis;
CESC	cis	rs1153858	0.943	rs8038342	chr15:45651537	T/C	cg21132104	chr15:45694354	SPATA5L1	0.85	11.64	0.58	1.47e-25	Homoarginine levels;
CESC	cis	rs4911259	0.552	rs62208880	chr20:31463284	T/C	cg13636640	chr20:31349939	DNMT3B	-0.53	-7.33	-0.41	2.78e-12	Inflammatory bowel disease;
CESC	cis	rs6736093	0.733	rs34974772	chr2:112810011	T/C	cg12686935	chr2:112915763	FBLN7	-0.43	-5.65	-0.33	4.2e-8	Coronary artery disease;
CESC	cis	rs9303401	0.538	rs35454383	chr17:56475599	C/T	cg25039879	chr17:56429692	SUPT4H1	0.61	5.93	0.34	9.22e-9	Cognitive test performance;
CESC	cis	rs5753618	0.583	rs8141150	chr22:31800336	C/T	cg00478049	chr22:31556069	RNF185	-0.42	-5.03	-0.3	8.97e-7	Colorectal cancer;
CESC	cis	rs17826219	0.706	rs61643715	chr17:29057762	A/G	cg14008862	chr17:28927542	LRRC37B2	0.65	5.12	0.3	5.86e-7	Body mass index;
CESC	cis	rs4555082	1.000	rs4555082	chr14:105758964	C/T	cg06808227	chr14:105710500	BRF1	-0.52	-6.31	-0.36	1.16e-9	Mean platelet volume;Platelet distribution width;
CESC	cis	rs2836974	0.932	rs56306759	chr21:40608106	G/A	cg11644478	chr21:40555479	PSMG1	1.01	16.0	0.7	8.5e-41	Cognitive function;
CESC	cis	rs7772486	0.686	rs9390349	chr6:146054430	T/G	cg05347473	chr6:146136440	FBXO30	-0.51	-6.75	-0.38	9.36e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1348850	0.914	rs4893961	chr2:178411075	A/G	cg22681709	chr2:178499509	PDE11A	-0.39	-5.8	-0.34	1.91e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	trans	rs12310956	0.532	rs1352211	chr12:33983132	G/A	cg26384229	chr12:38710491	ALG10B	0.48	6.64	0.38	1.82e-10	Morning vs. evening chronotype;
CESC	cis	rs9611565	0.649	rs5758434	chr22:42116163	G/A	cg06634786	chr22:41940651	POLR3H	0.45	5.07	0.3	7.43e-7	Vitiligo;
CESC	cis	rs13256369	0.802	rs12680019	chr8:8561698	A/G	cg18904891	chr8:8559673	CLDN23	0.72	8.03	0.44	3.21e-14	Obesity-related traits;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg14435640	chr8:41436176	AGPAT6	-0.46	-6.07	-0.35	4.4e-9	Asthma;
CESC	cis	rs7666738	0.546	rs1813970	chr4:98887167	A/G	cg05340658	chr4:99064831	C4orf37	-0.56	-6.92	-0.39	3.48e-11	Colonoscopy-negative controls vs population controls;
CESC	cis	rs5753618	0.561	rs4820963	chr22:31698166	C/T	cg13145458	chr22:31556086	RNF185	0.52	5.81	0.34	1.81e-8	Colorectal cancer;
CESC	cis	rs9649213	0.574	rs34717219	chr7:97962271	A/C	cg00277769	chr7:97922759	BAIAP2L1	-0.34	-5.62	-0.33	4.75e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs9916302	0.904	rs35285898	chr17:37555872	A/C	cg20243544	chr17:37824526	PNMT	-0.51	-6.5	-0.37	4.03e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs9389248	0.500	rs116273677	chr6:135339135	A/C	cg22676075	chr6:135203613	NA	0.52	7.42	0.41	1.64e-12	High light scatter reticulocyte percentage of red cells;
CESC	trans	rs11039798	0.841	rs10839174	chr11:48931185	G/A	cg15704280	chr7:45808275	SEPT13	0.7	6.56	0.37	2.74e-10	Axial length;
CESC	cis	rs13315871	0.722	rs3952239	chr3:58312057	G/T	cg20936604	chr3:58311152	NA	-0.52	-5.31	-0.31	2.3e-7	Cholesterol, total;
CESC	cis	rs34779708	0.966	rs4934732	chr10:35431684	T/C	cg04310649	chr10:35416472	CREM	-0.53	-6.62	-0.38	2.02e-10	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs763014	0.931	rs7192508	chr16:630367	C/T	cg00802000	chr16:706648	WDR90	-0.42	-6.36	-0.36	8.74e-10	Height;
CESC	cis	rs2721195	0.874	rs2721173	chr8:145744429	C/T	cg17328964	chr8:145687451	CYHR1	-0.42	-5.89	-0.34	1.17e-8	Age at first birth;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg17424859	chr6:71319002	NA	0.47	6.14	0.35	3.01e-9	Ulcerative colitis;
CESC	cis	rs2777491	0.957	rs7181911	chr15:41674060	T/C	cg20272979	chr15:41787780	ITPKA	0.36	5.11	0.3	6.11e-7	Ulcerative colitis;
CESC	cis	rs7666738	0.830	rs13121766	chr4:98935766	A/C	cg03467027	chr4:99064603	C4orf37	0.45	5.62	0.33	4.92e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2836974	0.899	rs2836938	chr21:40574191	C/T	cg27266027	chr21:40555129	PSMG1	0.45	5.33	0.31	2.07e-7	Cognitive function;
CESC	cis	rs4699052	0.963	rs6849319	chr4:104192742	G/C	cg16532752	chr4:104119610	CENPE	-0.43	-5.96	-0.34	8.21e-9	Testicular germ cell tumor;
CESC	cis	rs769267	0.792	rs4808961	chr19:19577215	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	7.23	0.41	5.22e-12	Tonsillectomy;
CESC	cis	rs7116495	0.609	rs10898812	chr11:71698801	G/A	cg18441811	chr11:71824068	C11orf51	-0.82	-5.33	-0.31	2.05e-7	Severe influenza A (H1N1) infection;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg23246789	chr2:179316083	PRKRA;DFNB59;MIR548N	-0.52	-6.1	-0.35	3.66e-9	Ulcerative colitis;
CESC	cis	rs1153858	1.000	rs1145091	chr15:45649996	A/G	cg10760299	chr15:45669010	GATM	0.37	5.17	0.3	4.63e-7	Homoarginine levels;
CESC	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg09737314	chr17:6899359	ALOX12	0.46	8.04	0.44	3.09e-14	Tonsillectomy;
CESC	cis	rs2228479	0.557	rs12933317	chr16:89828220	A/G	cg04013166	chr16:89971882	TCF25	0.77	6.55	0.37	3.05e-10	Skin colour saturation;
CESC	cis	rs7044106	0.762	rs12003646	chr9:123470621	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.76	10.99	0.56	2.09e-23	Hip circumference adjusted for BMI;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg00019576	chr8:144337537	ZFP41	-0.46	-6.32	-0.36	1.1e-9	Systemic lupus erythematosus;
CESC	cis	rs9660180	0.620	rs3817856	chr1:1663831	C/T	cg13866156	chr1:1669148	SLC35E2	0.53	7.2	0.4	6.16e-12	Body mass index;
CESC	cis	rs11098499	0.691	rs9996644	chr4:120238877	G/T	cg09307838	chr4:120376055	NA	0.78	10.46	0.54	1.15e-21	Corneal astigmatism;
CESC	cis	rs2573652	0.722	rs12595247	chr15:100541689	C/T	cg00587665	chr15:100533223	ADAMTS17	-0.43	-6.94	-0.39	3.07e-11	Height;
CESC	cis	rs1707322	0.752	rs61784798	chr1:46173481	C/T	cg03146154	chr1:46216737	IPP	0.82	11.53	0.58	3.39e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg27539627	chr3:122513065	DIRC2;HSPBAP1	0.5	6.37	0.36	8.51e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg11494091	chr17:61959527	GH2	0.73	12.66	0.61	4.86e-29	Prudent dietary pattern;
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg07318050	chr1:233086124	C1orf57	-0.42	-6.73	-0.38	1.06e-10	Vertical cup-disc ratio;
CESC	cis	rs9393777	0.582	rs6936561	chr6:26640895	C/T	cg12826209	chr6:26865740	GUSBL1	0.75	8.79	0.48	1.88e-16	Intelligence (multi-trait analysis);
CESC	cis	rs9467711	0.606	rs2073527	chr6:26374978	T/C	cg14345882	chr6:26364793	BTN3A2	0.63	6.39	0.37	7.52e-10	Autism spectrum disorder or schizophrenia;
CESC	cis	rs6484504	0.532	rs2774403	chr11:31320530	A/T	cg14844989	chr11:31128820	NA	0.37	5.34	0.31	2.01e-7	Red blood cell count;
CESC	cis	rs12545109	0.800	rs1553969	chr8:57420187	A/G	cg09654669	chr8:57350985	NA	-0.45	-6.27	-0.36	1.47e-9	Obesity-related traits;
CESC	cis	rs9488822	0.636	rs7745074	chr6:116347432	G/A	cg05304507	chr6:116381966	FRK	0.25	6.58	0.37	2.49e-10	Cholesterol, total;LDL cholesterol;
CESC	cis	rs11785400	0.793	rs4430071	chr8:143737680	T/C	cg10596483	chr8:143751796	JRK	0.43	5.41	0.32	1.37e-7	Schizophrenia;
CESC	cis	rs79387448	1.000	rs79387448	chr2:103215410	C/T	cg09003973	chr2:102972529	NA	0.65	5.14	0.3	5.33e-7	Gut microbiota (bacterial taxa);
CESC	cis	rs2408955	0.504	rs11168441	chr12:48576054	G/A	cg04545296	chr12:48745243	ZNF641	0.35	5.9	0.34	1.09e-8	Glycated hemoglobin levels;
CESC	cis	rs4253772	0.637	rs9627402	chr22:46702586	C/T	cg00784671	chr22:46762841	CELSR1	-0.5	-5.56	-0.32	6.44e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs7508	0.694	rs2073573	chr8:17921673	G/T	cg18067069	chr8:17937731	ASAH1	-0.39	-5.19	-0.3	4.21e-7	Atrial fibrillation;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg19760249	chr17:79254595	SLC38A10	0.46	6.74	0.38	9.63e-11	Fibrinogen levels;
CESC	cis	rs3026101	0.578	rs1806238	chr17:5295502	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.43	5.68	0.33	3.57e-8	Body mass index;
CESC	cis	rs10197940	0.662	rs10175134	chr2:152299355	G/A	cg19508488	chr2:152266495	RIF1	0.51	5.62	0.33	4.95e-8	Lung cancer;
CESC	cis	rs10129255	0.500	rs2105989	chr14:107138216	C/T	cg23076370	chr14:107095027	NA	-0.65	-9.65	-0.51	4.39e-19	Kawasaki disease;
CESC	cis	rs4665809	1.000	rs3910272	chr2:26287842	T/A	cg08470875	chr2:26401718	FAM59B	-0.62	-6.71	-0.38	1.2e-10	Gut microbiome composition (summer);
CESC	cis	rs9287719	0.967	rs2287061	chr2:10743153	C/T	cg00105475	chr2:10696890	NA	0.39	5.64	0.33	4.44e-8	Prostate cancer;
CESC	cis	rs9325144	0.600	rs6582634	chr12:38748041	G/A	cg26384229	chr12:38710491	ALG10B	0.54	7.68	0.43	3.07e-13	Morning vs. evening chronotype;
CESC	cis	rs2797160	1.000	rs1832979	chr6:125997436	A/G	cg05901451	chr6:126070800	HEY2	-0.45	-6.69	-0.38	1.3100000000000001e-10	Endometrial cancer;
CESC	cis	rs7091068	0.518	rs1409337	chr10:95439822	T/C	cg20715218	chr10:95462985	C10orf4	0.53	6.42	0.37	6.42e-10	Urinary tract infection frequency;
CESC	cis	rs2243480	0.803	rs35480979	chr7:65357084	A/G	cg18252515	chr7:66147081	NA	-1.01	-9.73	-0.51	2.51e-19	Diabetic kidney disease;
CESC	cis	rs4076764	0.846	rs4255362	chr1:163424630	G/A	cg24596788	chr1:163392923	NA	-0.41	-5.81	-0.34	1.8e-8	Motion sickness;
CESC	trans	rs629535	0.814	rs62513371	chr8:70077779	T/A	cg21567404	chr3:27674614	NA	-0.89	-10.61	-0.55	3.89e-22	Dupuytren's disease;
CESC	cis	rs2816062	0.813	rs2745321	chr1:18889198	G/C	cg18795169	chr1:18902165	NA	-0.91	-17.87	-0.74	2.1e-47	Urate levels in lean individuals;
CESC	cis	rs12586317	0.511	rs75552348	chr14:35385747	G/A	cg05294307	chr14:35346193	BAZ1A	-0.53	-5.24	-0.31	3.25e-7	Psoriasis;
CESC	cis	rs7202877	0.610	rs4888381	chr16:75356847	C/A	cg04384234	chr16:75411784	CFDP1	-0.48	-5.67	-0.33	3.64e-8	Type 2 diabetes;Type 1 diabetes;
CESC	cis	rs7267979	0.966	rs6050532	chr20:25308793	A/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.89	-18.7	-0.75	2.48e-50	Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22153931	chr7:43917675	URGCP	-0.56	-6.22	-0.36	1.93e-9	Gut microbiome composition (summer);
CESC	cis	rs9388451	0.868	rs1268083	chr6:126049040	T/C	cg05901451	chr6:126070800	HEY2	0.62	9.2	0.49	1.12e-17	Brugada syndrome;
CESC	cis	rs1153858	1.000	rs67744121	chr15:45677237	C/G	cg14582100	chr15:45693742	SPATA5L1	0.42	5.95	0.34	8.38e-9	Homoarginine levels;
CESC	cis	rs11763147	1	rs11763147	chr7:65326821	C/T	cg14393609	chr7:65229607	NA	-0.52	-7.0	-0.4	2.1e-11	Corneal structure;
CESC	cis	rs5769765	1.000	rs34774661	chr22:50267508	C/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.46	5.32	0.31	2.21e-7	Schizophrenia;
CESC	cis	rs826838	1.000	rs10880785	chr12:38655405	T/G	cg13010199	chr12:38710504	ALG10B	0.59	8.31	0.45	4.93e-15	Heart rate;
CESC	cis	rs7385804	0.761	rs568733	chr7:100311662	G/T	cg16850897	chr7:100343110	ZAN	0.46	6.26	0.36	1.56e-9	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
CESC	cis	rs1801251	0.778	rs709933	chr2:233733144	G/A	cg25237894	chr2:233734115	C2orf82	-0.49	-8.48	-0.46	1.55e-15	Coronary artery disease;
CESC	cis	rs10752881	1.000	rs10911191	chr1:182984524	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.82	12.96	0.62	4.48e-30	Colorectal cancer;
CESC	cis	rs7044106	0.791	rs4617229	chr9:123480696	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.69	10.03	0.52	2.72e-20	Hip circumference adjusted for BMI;
CESC	cis	rs2050392	0.517	rs619864	chr10:30750950	A/G	cg18806716	chr10:30721971	MAP3K8	0.48	7.34	0.41	2.68e-12	Inflammatory bowel disease;
CESC	cis	rs72945132	0.825	rs12287883	chr11:70122369	C/T	cg00319359	chr11:70116639	PPFIA1	0.78	7.78	0.43	1.6e-13	Coronary artery disease;
CESC	trans	rs9834373	0.573	rs9874385	chr3:78522298	C/T	cg21593409	chr16:88706389	IL17C	-0.42	-6.04	-0.35	5.2e-9	Protein quantitative trait loci;
CESC	cis	rs736408	0.522	rs11130310	chr3:52674667	C/T	cg17372223	chr3:52568218	NT5DC2	0.42	6.43	0.37	5.79e-10	Bipolar disorder;
CESC	cis	rs3733585	0.673	rs4495037	chr4:9954050	C/G	cg00071950	chr4:10020882	SLC2A9	-0.69	-11.34	-0.57	1.42e-24	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs11098499	0.863	rs3822191	chr4:120428101	A/T	cg09307838	chr4:120376055	NA	0.95	13.17	0.63	8.54e-31	Corneal astigmatism;
CESC	trans	rs10510776	0.875	rs11710973	chr3:55217512	C/T	cg27011042	chr15:89456239	MFGE8	0.6	6.24	0.36	1.77e-9	Cancer;
CESC	cis	rs6060717	0.610	rs2794383	chr20:34615152	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.49	6.23	0.36	1.86e-9	Hip circumference adjusted for BMI;
CESC	cis	rs6582630	0.519	rs7294300	chr12:38277359	C/A	cg13010199	chr12:38710504	ALG10B	0.52	6.38	0.36	8.04e-10	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs13064411	0.627	rs28536176	chr3:113143625	T/C	cg18753928	chr3:113234510	CCDC52	-0.49	-5.5	-0.32	8.88e-8	Response to simvastatin treatment (PCSK9 protein level change);
CESC	cis	rs8072100	0.811	rs1912483	chr17:45443494	A/G	cg08085267	chr17:45401833	C17orf57	-0.56	-7.4	-0.41	1.81e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs1799949	1.000	rs4793229	chr17:41418334	C/T	cg06001716	chr17:41278141	BRCA1;NBR2	-0.38	-5.11	-0.3	6.32e-7	Menopause (age at onset);
CESC	cis	rs12497850	1.000	rs1352420	chr3:48757291	A/G	cg06212747	chr3:49208901	KLHDC8B	0.63	8.36	0.46	3.47e-15	Parkinson's disease;
CESC	cis	rs7829975	0.688	rs7827182	chr8:8380471	C/G	cg15556689	chr8:8085844	FLJ10661	0.54	6.61	0.38	2.1e-10	Mood instability;
CESC	trans	rs9858542	0.953	rs9827708	chr3:49649989	C/G	cg21659725	chr3:3221576	CRBN	-0.52	-6.47	-0.37	4.63e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs6076065	0.963	rs6048777	chr20:23373302	C/T	cg11657817	chr20:23433608	CST11	0.36	5.35	0.31	1.92e-7	Facial morphology (factor 15, philtrum width);
CESC	cis	rs1552244	0.882	rs9757159	chr3:10039166	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.74	-9.37	-0.5	3.42e-18	Alzheimer's disease;
CESC	cis	rs11098499	0.754	rs12513083	chr4:120249612	A/T	cg09307838	chr4:120376055	NA	0.77	10.49	0.54	9.15e-22	Corneal astigmatism;
CESC	cis	rs9311474	0.508	rs17052256	chr3:52593119	A/G	cg18099408	chr3:52552593	STAB1	-0.36	-6.1	-0.35	3.79e-9	Electroencephalogram traits;
CESC	cis	rs3857067	0.680	rs1509946	chr4:95109078	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.58	-8.62	-0.47	6.01e-16	QT interval;
CESC	cis	rs13118159	0.801	rs1128427	chr4:1330759	T/C	cg00684032	chr4:1343700	KIAA1530	0.37	5.57	0.32	6.36e-8	Longevity;
CESC	cis	rs7771547	0.573	rs629297	chr6:36398146	C/T	cg07856975	chr6:36356162	ETV7	0.36	5.42	0.32	1.37e-7	Platelet distribution width;
CESC	cis	rs1799949	1.000	rs11649954	chr17:41420035	A/G	cg25072359	chr17:41440525	NA	0.46	6.21	0.36	2.04e-9	Menopause (age at onset);
CESC	cis	rs2235642	0.893	rs2076445	chr16:1592266	A/T	cg10465839	chr16:1584050	IFT140;TMEM204	-0.32	-5.2	-0.3	3.91e-7	Coronary artery disease;
CESC	cis	rs5769765	0.779	rs12170530	chr22:50318422	T/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.62	-6.38	-0.37	7.75e-10	Schizophrenia;
CESC	cis	rs854765	0.647	rs854767	chr17:18018263	A/C	cg09796270	chr17:17721594	SREBF1	-0.37	-5.03	-0.3	8.99e-7	Total body bone mineral density;
CESC	cis	rs7811142	1.000	rs7811142	chr7:100065443	A/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.99	9.5	0.5	1.31e-18	Platelet count;
CESC	cis	rs10504229	0.683	rs7843919	chr8:58130792	T/C	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs3820928	0.692	rs2396434	chr2:227775223	G/T	cg11843606	chr2:227700838	RHBDD1	-0.54	-7.52	-0.42	8.7e-13	Pulmonary function;
CESC	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg07092213	chr7:1199455	ZFAND2A	-0.42	-5.63	-0.33	4.63e-8	Longevity;Endometriosis;
CESC	cis	rs9649213	0.593	rs6465683	chr7:98026092	C/A	cg00277769	chr7:97922759	BAIAP2L1	-0.31	-5.07	-0.3	7.35e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs8067354	0.645	rs1874548	chr17:57841357	A/G	cg13753209	chr17:57696993	CLTC	0.56	6.1	0.35	3.83e-9	Hemoglobin concentration;
CESC	trans	rs12310956	0.515	rs1405031	chr12:33958931	A/C	cg26384229	chr12:38710491	ALG10B	0.48	6.68	0.38	1.36e-10	Morning vs. evening chronotype;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg16968475	chr7:2027283	MAD1L1	0.47	6.32	0.36	1.12e-9	Fibrinogen levels;
CESC	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.55	7.01	0.4	1.98e-11	Prudent dietary pattern;
CESC	cis	rs11077998	1.000	rs11077998	chr17:80483946	C/G	cg20173014	chr17:80541737	FOXK2	0.32	5.09	0.3	6.92e-7	Reticulocyte fraction of red cells;
CESC	cis	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg18402987	chr7:1209562	NA	0.63	7.41	0.41	1.73e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg20009499	chr17:57232567	SKA2;PRR11	-0.48	-6.23	-0.36	1.8e-9	Height;
CESC	cis	rs2820292	0.670	rs6701026	chr1:201814004	C/T	cg11586189	chr1:201857591	SHISA4	0.33	5.47	0.32	1.02e-7	Waist circumference;Body mass index (joint analysis main effects and smoking interaction);Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);
CESC	cis	rs826838	1.000	rs7953227	chr12:38946193	G/A	cg13010199	chr12:38710504	ALG10B	0.6	8.69	0.47	3.84e-16	Heart rate;
CESC	cis	rs10504229	0.683	rs55637580	chr8:58135419	C/T	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs11997175	0.646	rs4733180	chr8:33700520	C/T	ch.8.33884649F	chr8:33765107	NA	0.56	7.43	0.42	1.52e-12	Body mass index;
CESC	cis	rs2836974	0.899	rs34176878	chr21:40548855	C/A	cg17971929	chr21:40555470	PSMG1	1.05	16.42	0.71	2.82e-42	Cognitive function;
CESC	cis	rs7103648	0.742	rs34937994	chr11:47389638	C/T	cg20307385	chr11:47447363	PSMC3	0.9	13.35	0.63	1.96e-31	Diastolic blood pressure;Systolic blood pressure;
CESC	cis	rs2839186	0.721	rs3788252	chr21:47661235	C/T	cg13126279	chr21:47581558	C21orf56	-0.48	-6.57	-0.37	2.6200000000000003e-10	Testicular germ cell tumor;
CESC	cis	rs3087591	1.000	rs6505234	chr17:29688299	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.45	-5.61	-0.33	5.02e-8	Hip circumference;
CESC	cis	rs7412746	0.658	rs10305714	chr1:150800655	C/T	cg17724175	chr1:150552817	MCL1	-0.39	-6.13	-0.35	3.12e-9	Melanoma;
CESC	cis	rs35955747	0.902	rs7288735	chr22:31679546	G/A	cg25791279	chr22:32026902	PISD	-0.5	-6.01	-0.35	6.19e-9	Neutrophil count;Sum basophil neutrophil counts;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg02205746	chr16:2732724	KCTD5	-0.42	-6.06	-0.35	4.58e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg14159672	chr1:205819179	PM20D1	0.81	12.97	0.62	3.97e-30	Menarche (age at onset);
CESC	cis	rs896854	0.608	rs7004862	chr8:95876963	T/G	cg23172400	chr8:95962367	TP53INP1	-0.41	-8.39	-0.46	3.02e-15	Type 2 diabetes;
CESC	cis	rs11958404	0.932	rs72818127	chr5:157452227	C/T	cg05962755	chr5:157440814	NA	0.63	7.2	0.4	6.33e-12	IgG glycosylation;
CESC	cis	rs7772486	0.846	rs2748496	chr6:146321829	T/A	cg23711669	chr6:146136114	FBXO30	0.79	10.98	0.56	2.31e-23	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6540559	0.673	rs11805830	chr1:209984969	C/T	cg22029157	chr1:209979665	IRF6	0.77	8.9	0.48	9.08e-17	Cleft lip with or without cleft palate;
CESC	cis	rs798554	0.679	rs2533877	chr7:2882421	G/A	cg09658497	chr7:2847517	GNA12	-0.35	-5.09	-0.3	6.89e-7	Height;
CESC	cis	rs9902453	0.933	rs1128156	chr17:28513176	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	7.84	0.43	1.12e-13	Coffee consumption (cups per day);
CESC	cis	rs1552244	0.810	rs6809572	chr3:10100145	G/A	cg16606324	chr3:10149918	C3orf24	0.43	5.11	0.3	6.19e-7	Alzheimer's disease;
CESC	cis	rs909674	0.690	rs1972280	chr22:39831986	T/A	cg24399712	chr22:39784796	NA	-0.8	-11.01	-0.56	1.84e-23	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs13191362	1.000	rs34653853	chr6:163114362	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.66	6.73	0.38	1.07e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs72781680	1.000	rs72781679	chr2:24237712	G/A	cg20701182	chr2:24300061	SF3B14	0.82	6.96	0.39	2.66e-11	Lymphocyte counts;
CESC	cis	rs6752107	0.967	rs10210302	chr2:234158839	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.45	6.46	0.37	5.04e-10	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs4713118	0.662	rs9468274	chr6:28026077	G/T	cg23281280	chr6:28129359	ZNF389	0.5	6.56	0.37	2.75e-10	Parkinson's disease;
CESC	cis	rs1348850	0.632	rs13008857	chr2:178514468	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.6	7.68	0.43	3.1e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs704795	0.836	rs1083865	chr2:27620827	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.28	-5.72	-0.33	2.89e-8	Menopause (age at onset);
CESC	cis	rs3733585	0.673	rs4312757	chr4:9956145	T/A	cg02734326	chr4:10020555	SLC2A9	-0.41	-5.87	-0.34	1.32e-8	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs7666738	0.830	rs35235971	chr4:98999833	G/T	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.62e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs67311347	1.000	rs28871903	chr3:40511094	T/G	cg24209194	chr3:40518798	ZNF619	0.5	6.09	0.35	4.06e-9	Renal cell carcinoma;
CESC	cis	rs4891159	0.790	rs8087557	chr18:74116848	G/C	cg24786174	chr18:74118243	ZNF516	-0.78	-12.64	-0.61	5.42e-29	Longevity;
CESC	cis	rs1559088	1.000	rs1559087	chr19:33551041	A/G	cg27124370	chr19:33622961	WDR88	0.41	5.1	0.3	6.57e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs9318086	0.712	rs1886970	chr13:24440498	T/C	cg25267304	chr13:24462978	PCOTH;MIPEP	0.42	5.71	0.33	3.03e-8	Myopia (pathological);
CESC	cis	rs35306767	0.903	rs11813210	chr10:919796	G/A	cg26597838	chr10:835615	NA	0.87	9.02	0.48	3.81e-17	Eosinophil percentage of granulocytes;
CESC	cis	rs12101261	0.560	rs1035144	chr14:81445121	C/T	cg06600135	chr14:81408086	NA	0.38	5.07	0.3	7.42e-7	Graves' disease;
CESC	cis	rs7188697	0.922	rs28479997	chr16:58614877	G/A	cg02549819	chr16:58548995	SETD6	0.44	5.43	0.32	1.26e-7	QT interval;
CESC	cis	rs1538970	0.781	rs11211139	chr1:46015751	G/T	cg05343316	chr1:45956843	TESK2	0.91	11.61	0.58	1.88e-25	Platelet count;
CESC	cis	rs7809950	1.000	rs2712214	chr7:107188031	G/A	cg23024343	chr7:107201750	COG5	-0.42	-5.87	-0.34	1.33e-8	Coronary artery disease;
CESC	cis	rs9834373	0.853	rs13322524	chr3:78495720	A/G	cg06138941	chr3:78371609	NA	-0.43	-5.48	-0.32	9.88e-8	Protein quantitative trait loci;
CESC	cis	rs9611565	0.512	rs9607841	chr22:42186838	G/A	cg03806693	chr22:41940476	POLR3H	-1.17	-13.7	-0.64	1.12e-32	Vitiligo;
CESC	cis	rs916888	0.610	rs199436	chr17:44789285	C/T	cg15921436	chr17:44337874	NA	-0.43	-5.31	-0.31	2.32e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs9302635	0.550	rs35959677	chr16:72200801	G/T	cg16558253	chr16:72132732	DHX38	-0.41	-5.05	-0.3	8.41e-7	Blood protein levels;
CESC	cis	rs4243830	0.850	rs12046229	chr1:6580397	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	0.69	5.11	0.3	6.23e-7	Body mass index;
CESC	cis	rs12474201	0.588	rs3768719	chr2:46987935	T/G	cg06386533	chr2:46925753	SOCS5	0.55	7.46	0.42	1.21e-12	Height;
CESC	cis	rs10504229	1.000	rs61733801	chr8:58192513	A/G	cg24829409	chr8:58192753	C8orf71	-0.76	-9.93	-0.52	5.87e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs10754283	0.967	rs7552896	chr1:90103194	A/G	cg21401794	chr1:90099060	LRRC8C	0.69	9.31	0.5	4.95e-18	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs72945132	0.882	rs59398290	chr11:70134819	G/A	cg00319359	chr11:70116639	PPFIA1	0.78	7.67	0.43	3.32e-13	Coronary artery disease;
CESC	cis	rs13108904	0.875	rs1732099	chr4:1282696	T/C	cg16405210	chr4:1374714	KIAA1530	0.47	5.97	0.34	7.48e-9	Obesity-related traits;
CESC	cis	rs4665809	0.549	rs62130460	chr2:26472718	T/C	cg08470875	chr2:26401718	FAM59B	0.7	6.92	0.39	3.47e-11	Gut microbiome composition (summer);
CESC	cis	rs2066819	1.000	rs2643626	chr12:56726518	C/T	cg26316697	chr12:56727976	PAN2	-0.7	-6.72	-0.38	1.08e-10	Psoriasis vulgaris;
CESC	cis	rs1843834	0.539	rs1494109	chr2:225441833	G/A	cg12698349	chr2:225449008	CUL3	0.62	8.74	0.47	2.73e-16	IgE levels in asthmatics (D.p. specific);
CESC	cis	rs10504229	0.683	rs11787247	chr8:58131528	G/T	cg21724239	chr8:58056113	NA	0.58	5.95	0.34	8.29e-9	Developmental language disorder (linguistic errors);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25183890	chr8:94929275	PDP1	0.57	6.31	0.36	1.16e-9	Gut microbiome composition (summer);
CESC	cis	rs7044106	0.762	rs1158553	chr9:123400974	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.75	10.86	0.55	5.79e-23	Hip circumference adjusted for BMI;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg09247696	chr2:74756297	HTRA2;AUP1	0.46	6.48	0.37	4.38e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs12597458	0.763	rs3213422	chr16:72042682	A/C	cg01557791	chr16:72042693	DHODH	0.85	12.82	0.62	1.36e-29	Prostate cancer;
CESC	cis	rs9300255	0.602	rs2851450	chr12:123703501	C/T	cg19016782	chr12:123741754	C12orf65	-0.45	-6.55	-0.37	2.97e-10	Neutrophil percentage of white cells;
CESC	cis	rs3740713	1.000	rs76062966	chr11:18462404	C/A	cg23797887	chr11:18477753	LDHAL6A	-0.52	-5.2	-0.3	3.93e-7	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs7520050	0.931	rs11211189	chr1:46261584	A/T	cg03146154	chr1:46216737	IPP	-0.47	-6.09	-0.35	4.04e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs863345	0.967	rs1418845	chr1:158479691	A/C	cg12129480	chr1:158549410	OR10X1	-0.3	-6.0	-0.35	6.55e-9	Pneumococcal bacteremia;
CESC	cis	rs3733585	0.637	rs6850684	chr4:9964380	G/T	cg00071950	chr4:10020882	SLC2A9	-0.73	-11.83	-0.59	3.28e-26	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs1218582	0.741	rs11264281	chr1:154867221	A/G	cg06221963	chr1:154839813	KCNN3	-0.7	-12.09	-0.6	4.16e-27	Prostate cancer;
CESC	cis	rs7149242	0.662	rs4905998	chr14:101181781	A/G	cg18089426	chr14:101175970	NA	-0.4	-6.66	-0.38	1.61e-10	Platelet count;
CESC	cis	rs595982	0.702	rs626974	chr19:49375900	T/C	cg03707168	chr19:49379127	PPP1R15A	0.32	5.14	0.3	5.38e-7	Red cell distribution width;
CESC	cis	rs9309473	0.950	rs6546858	chr2:73838613	G/A	cg20560298	chr2:73613845	ALMS1	-0.43	-5.74	-0.33	2.61e-8	Metabolite levels;
CESC	cis	rs3733585	0.605	rs4697710	chr4:10122649	T/C	cg00071950	chr4:10020882	SLC2A9	-0.65	-9.67	-0.51	3.96e-19	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs7618915	0.501	rs34739010	chr3:52766122	A/G	cg17372223	chr3:52568218	NT5DC2	0.43	6.43	0.37	5.85e-10	Bipolar disorder;
CESC	cis	rs9443645	0.527	rs9361479	chr6:79723755	T/A	cg05283184	chr6:79620031	NA	-0.38	-5.51	-0.32	8.57e-8	Intelligence (multi-trait analysis);
CESC	cis	rs11098499	0.754	rs34425882	chr4:120253177	G/A	cg09307838	chr4:120376055	NA	0.77	10.49	0.54	9.15e-22	Corneal astigmatism;
CESC	cis	rs400736	1.000	rs400736	chr1:8078309	T/C	cg25007680	chr1:8021821	PARK7	0.72	10.41	0.54	1.66e-21	Response to antidepressants and depression;
CESC	cis	rs9486719	1.000	rs34236778	chr6:96884556	C/A	cg18709589	chr6:96969512	KIAA0776	-0.53	-5.81	-0.34	1.75e-8	Migraine;Coronary artery disease;
CESC	cis	rs3749237	0.595	rs3924462	chr3:49524236	T/G	cg02487422	chr3:49467188	NICN1	0.56	8.19	0.45	1.09e-14	Resting heart rate;
CESC	cis	rs12291225	0.679	rs11023178	chr11:14310282	G/A	cg19336497	chr11:14380999	RRAS2	-0.37	-5.29	-0.31	2.58e-7	Sense of smell;
CESC	cis	rs6060717	0.571	rs6060761	chr20:34612487	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-7.98	-0.44	4.46e-14	Hip circumference adjusted for BMI;
CESC	cis	rs7223966	1.000	rs9903897	chr17:61716705	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.46	-5.66	-0.33	3.84e-8	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs35110281	0.748	rs162403	chr21:44963365	C/G	cg21573476	chr21:45109991	RRP1B	-0.44	-6.09	-0.35	4.02e-9	Mean corpuscular volume;
CESC	cis	rs12188164	0.965	rs11743639	chr5:450710	C/T	cg17553881	chr5:443987	EXOC3;C5orf55	-0.38	-6.14	-0.35	2.97e-9	Cystic fibrosis severity;
CESC	cis	rs875971	0.862	rs10950033	chr7:65739673	A/G	cg11764359	chr7:65958608	NA	-0.79	-12.0	-0.59	9.01e-27	Aortic root size;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg21595175	chr5:180670701	SNORD95;GNB2L1	-0.48	-6.56	-0.37	2.83e-10	Fibrinogen levels;
CESC	trans	rs1814175	0.645	rs847630	chr11:49926360	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.43	-6.36	-0.36	8.98e-10	Height;
CESC	cis	rs6963495	0.745	rs73192150	chr7:105211610	A/C	cg02135003	chr7:105160482	PUS7	-0.48	-5.51	-0.32	8.52e-8	Bipolar disorder (body mass index interaction);
CESC	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.52	-5.95	-0.34	8.69e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs763014	0.966	rs35642938	chr16:642249	T/C	cg07256732	chr16:621771	PIGQ	-0.3	-5.21	-0.3	3.88e-7	Height;
CESC	cis	rs5769765	0.862	rs138857	chr22:50199589	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.48	-5.2	-0.3	4.02e-7	Schizophrenia;
CESC	trans	rs2657294	0.620	rs4746261	chr10:76845632	C/T	cg20074007	chr10:99161109	RRP12	0.48	6.13	0.35	3.22e-9	Pneumonia;
CESC	cis	rs9527	0.590	rs2281877	chr10:104866062	C/T	cg04362960	chr10:104952993	NT5C2	0.44	5.54	0.32	7.12e-8	Arsenic metabolism;
CESC	cis	rs9322193	0.566	rs6912330	chr6:150229947	A/C	cg01145232	chr6:150245071	RAET1G	-0.53	-6.78	-0.38	7.71e-11	Lung cancer;
CESC	cis	rs863345	0.504	rs857707	chr1:158564383	A/G	cg12129480	chr1:158549410	OR10X1	-0.3	-5.57	-0.32	6.31e-8	Pneumococcal bacteremia;
CESC	cis	rs8114671	0.562	rs1013677	chr20:33468793	C/T	cg24642439	chr20:33292090	TP53INP2	0.44	5.56	0.32	6.67e-8	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17261830	chr14:75593525	NEK9	0.49	6.01	0.35	6.01e-9	Gut microbiome composition (summer);
CESC	cis	rs3806843	0.778	rs2531346	chr5:140126139	T/G	cg26395211	chr5:140044315	WDR55	0.39	5.13	0.3	5.55e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs9916302	0.768	rs62077464	chr17:37656056	C/G	cg00129232	chr17:37814104	STARD3	-0.56	-7.49	-0.42	1.05e-12	Glomerular filtration rate (creatinine);
CESC	cis	rs10911232	0.507	rs10797829	chr1:183033228	C/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.86	-13.63	-0.64	2.03e-32	Hypertriglyceridemia;
CESC	cis	rs561341	0.941	rs736678	chr17:30347423	G/T	cg23018236	chr17:30244563	NA	-0.55	-5.16	-0.3	4.77e-7	Hip circumference adjusted for BMI;
CESC	cis	rs916888	0.773	rs199451	chr17:44801784	G/A	cg01570182	chr17:44337453	NA	0.93	10.53	0.54	6.68e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs9550616	0.801	rs9579788	chr13:20728013	T/C	cg27436003	chr13:20734544	GJA3	0.36	5.15	0.3	5.04e-7	Facial emotion recognition (happy faces);
CESC	cis	rs1062177	0.756	rs2964588	chr5:151118386	C/T	cg12924095	chr5:151150029	G3BP1	-0.43	-5.29	-0.31	2.55e-7	Preschool internalizing problems;
CESC	cis	rs113835537	0.529	rs11824771	chr11:66262550	T/C	cg24851651	chr11:66362959	CCS	0.41	5.1	0.3	6.55e-7	Airway imaging phenotypes;
CESC	cis	rs79057730	0.599	rs34411410	chr7:811721	G/A	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.87	7.34	0.41	2.59e-12	Initial pursuit acceleration;
CESC	cis	rs7560272	0.669	rs7598660	chr2:73740425	C/T	cg20560298	chr2:73613845	ALMS1	-0.37	-5.13	-0.3	5.74e-7	Schizophrenia;
CESC	cis	rs561341	1.000	rs4795667	chr17:30244443	T/C	cg12193833	chr17:30244370	NA	-0.71	-7.29	-0.41	3.58e-12	Hip circumference adjusted for BMI;
CESC	trans	rs1888221	0.510	rs7027148	chr9:117832663	A/C	cg11017500	chr13:111290755	CARKD	-0.46	-6.01	-0.35	5.99e-9	Glucose homeostasis traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08162257	chr15:90777190	CIB1;C15orf58	0.57	6.31	0.36	1.19e-9	Gut microbiome composition (summer);
CESC	cis	rs7605827	0.893	rs7572131	chr2:15691886	G/A	cg19274914	chr2:15703543	NA	0.36	6.39	0.37	7.29e-10	Educational attainment (years of education);
CESC	cis	rs2204008	0.774	rs8186954	chr12:38318566	C/A	cg26384229	chr12:38710491	ALG10B	0.66	9.82	0.52	1.26e-19	Bladder cancer;
CESC	cis	rs7078219	0.505	rs10883362	chr10:101286984	C/T	cg09788492	chr10:101292477	NKX2-3	0.33	6.31	0.36	1.14e-9	Dental caries;
CESC	cis	rs2832191	0.716	rs7284006	chr21:30475186	T/A	cg24692254	chr21:30365293	RNF160	0.99	17.24	0.73	3.61e-45	Dental caries;
CESC	cis	rs4835473	0.699	rs4835127	chr4:144919125	C/A	cg25736465	chr4:144833511	NA	0.42	6.28	0.36	1.38e-9	Immature fraction of reticulocytes;
CESC	cis	rs1799949	0.896	rs8176098	chr17:41268206	A/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.46	6.39	0.37	7.27e-10	Menopause (age at onset);
CESC	cis	rs2075671	0.855	rs62483567	chr7:100286435	G/A	cg16850897	chr7:100343110	ZAN	-0.7	-8.82	-0.48	1.62e-16	Other erythrocyte phenotypes;
CESC	cis	rs2115630	0.875	rs8039472	chr15:85361644	A/G	cg11189052	chr15:85197271	WDR73	-0.45	-5.86	-0.34	1.34e-8	P wave terminal force;
CESC	cis	rs977987	0.966	rs62060551	chr16:75502312	A/C	cg03315344	chr16:75512273	CHST6	0.53	7.74	0.43	2.16e-13	Dupuytren's disease;
CESC	cis	rs2635047	0.593	rs7239323	chr18:44636506	G/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.42	-5.3	-0.31	2.46e-7	Educational attainment;
CESC	trans	rs1728785	1.000	rs7192341	chr16:68569224	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.63	7.39	0.41	1.91e-12	Ulcerative colitis;
CESC	cis	rs778371	0.723	rs283470	chr2:233656918	G/A	cg08000102	chr2:233561755	GIGYF2	0.79	13.28	0.63	3.33e-31	Schizophrenia;
CESC	trans	rs11764590	0.813	rs11768212	chr7:1992582	A/C	cg11693508	chr17:37793320	STARD3	0.64	6.36	0.36	8.65e-10	Neuroticism;
CESC	cis	rs514406	0.505	rs405208	chr1:53176674	C/T	cg08859206	chr1:53392774	SCP2	-0.59	-7.79	-0.43	1.5e-13	Monocyte count;
CESC	cis	rs7085104	0.632	rs4290163	chr10:104610926	G/T	cg04362960	chr10:104952993	NT5C2	0.45	5.85	0.34	1.48e-8	Immature fraction of reticulocytes;Schizophrenia;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg07617175	chr5:99871683	FAM174A	-0.48	-6.56	-0.37	2.85e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs11690935	0.632	rs34242651	chr2:172553999	G/A	cg13550731	chr2:172543902	DYNC1I2	0.6	8.37	0.46	3.42e-15	Schizophrenia;
CESC	cis	rs7872515	0.838	rs6479403	chr9:94829156	A/G	cg01248375	chr9:94877805	SPTLC1	0.52	5.74	0.33	2.53e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs9926296	0.712	rs258319	chr16:89732024	A/T	cg03605463	chr16:89740564	NA	0.63	7.49	0.42	1.02e-12	Vitiligo;
CESC	cis	rs6748734	0.625	rs7355583	chr2:241821707	T/C	cg04034577	chr2:241836375	C2orf54	-0.29	-5.32	-0.31	2.23e-7	Urinary metabolites;
CESC	cis	rs561341	1.000	rs113115092	chr17:30284164	G/A	cg12193833	chr17:30244370	NA	-0.71	-6.53	-0.37	3.38e-10	Hip circumference adjusted for BMI;
CESC	cis	rs4664293	1.000	rs6432540	chr2:160450703	G/A	cg08347373	chr2:160653686	CD302	-0.32	-5.35	-0.31	1.93e-7	Monocyte percentage of white cells;
CESC	cis	rs6598163	0.517	rs11246827	chr12:132296423	G/A	cg10319629	chr12:132285459	NA	0.41	5.61	0.33	5.04e-8	Migraine;
CESC	cis	rs3785574	0.745	rs2854162	chr17:61975610	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	-0.6	-7.38	-0.41	2.04e-12	Height;
CESC	cis	rs929354	0.713	rs6459733	chr7:156930550	G/C	cg05182265	chr7:156933206	UBE3C	-0.5	-7.27	-0.41	4.15e-12	Body mass index;
CESC	cis	rs597539	0.615	rs629426	chr11:68671104	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.78	10.1	0.53	1.74e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs9649213	0.593	rs3779193	chr7:98028466	T/C	cg21770322	chr7:97807741	LMTK2	0.56	8.63	0.47	5.86e-16	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs684232	0.623	rs391002	chr17:535441	T/G	cg12384639	chr17:618140	VPS53	0.41	5.28	0.31	2.7e-7	Prostate cancer;
CESC	cis	rs2235544	0.565	rs928441	chr1:54473368	C/A	cg25741118	chr1:54482237	LDLRAD1	-0.25	-6.26	-0.36	1.55e-9	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
CESC	cis	rs6502050	0.835	rs34673303	chr17:80085144	G/C	cg23985595	chr17:80112537	CCDC57	0.42	6.55	0.37	2.99e-10	Life satisfaction;
CESC	cis	rs17253792	0.822	rs112374071	chr14:56061919	C/T	cg01858014	chr14:56050164	KTN1	-0.77	-5.28	-0.31	2.7e-7	Putamen volume;
CESC	cis	rs858239	0.601	rs2068459	chr7:23154313	A/C	cg23682824	chr7:23144976	KLHL7	0.49	6.49	0.37	4.19e-10	Cerebrospinal fluid biomarker levels;
CESC	cis	rs561341	1.000	rs527256	chr17:30321293	C/G	cg00745463	chr17:30367425	LRRC37B	-0.82	-7.51	-0.42	9.09e-13	Hip circumference adjusted for BMI;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg27331759	chr16:347891	AXIN1	0.45	6.26	0.36	1.54e-9	Fibrinogen levels;
CESC	cis	rs1801251	1.000	rs67013068	chr2:233608253	G/C	cg25237894	chr2:233734115	C2orf82	0.43	7.49	0.42	1e-12	Coronary artery disease;
CESC	cis	rs637571	0.522	rs679581	chr11:65746653	A/G	cg02202077	chr11:65769826	EIF1AD;BANF1	0.46	6.09	0.35	3.91e-9	Eosinophil percentage of white cells;
CESC	cis	rs6502050	0.805	rs7503095	chr17:80107354	G/A	cg01763666	chr17:80159506	CCDC57	-0.37	-5.14	-0.3	5.28e-7	Life satisfaction;
CESC	cis	rs1461503	0.868	rs10790543	chr11:122838311	A/C	cg27398637	chr11:122830231	C11orf63	-0.56	-8.42	-0.46	2.35e-15	Menarche (age at onset);
CESC	cis	rs2282335	0.507	rs2498421	chr9:71855357	A/G	cg14075627	chr9:71863002	TJP2	0.41	5.36	0.31	1.84e-7	Renal sinus fat;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg03289548	chr10:114580989	NA	0.58	7.94	0.44	5.6e-14	Fibrinogen levels;
CESC	cis	rs9640161	0.711	rs60268791	chr7:150023800	G/T	cg10018233	chr7:150070692	REPIN1	0.45	7.41	0.41	1.72e-12	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	7.72	0.43	2.43e-13	Prudent dietary pattern;
CESC	cis	rs8077889	0.645	rs1230396	chr17:41843029	A/C	cg26893861	chr17:41843967	DUSP3	-1.09	-22.71	-0.81	3.88e-64	Triglycerides;
CESC	cis	rs6558174	0.965	rs4872524	chr8:22489537	A/G	cg03733263	chr8:22462867	KIAA1967	0.44	5.91	0.34	1.06e-8	Breast cancer;
CESC	cis	rs68170813	0.559	rs76933738	chr7:106814574	T/C	cg02696742	chr7:106810147	HBP1	-0.55	-5.3	-0.31	2.44e-7	Coronary artery disease;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg14093526	chr11:134094620	VPS26B;NCAPD3	-0.46	-6.3	-0.36	1.26e-9	Ulcerative colitis;
CESC	cis	rs4713118	0.662	rs9468278	chr6:28028482	C/T	cg12963246	chr6:28129442	ZNF389	0.5	6.4	0.37	6.93e-10	Parkinson's disease;
CESC	cis	rs644799	0.544	rs525087	chr11:95632266	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.44	5.86	0.34	1.37e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04078658	chr7:2054064	MAD1L1	-0.49	-6.04	-0.35	5.14e-9	Gut microbiome composition (summer);
CESC	cis	rs72627123	0.867	rs73303122	chr14:74486797	A/G	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.73	5.65	0.33	4.06e-8	Morning vs. evening chronotype;
CESC	cis	rs7917772	0.502	rs10748827	chr10:104368336	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.55	7.7	0.43	2.66e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs11098499	0.754	rs2036860	chr4:120248934	A/G	cg09307838	chr4:120376055	NA	0.78	10.55	0.54	5.92e-22	Corneal astigmatism;
CESC	cis	rs853679	0.517	rs4713145	chr6:28106827	T/C	cg20151795	chr6:28129481	ZNF389	0.46	5.97	0.34	7.59e-9	Depression;
CESC	cis	rs72781680	1.000	rs72781649	chr2:24210864	A/G	cg08917208	chr2:24149416	ATAD2B	0.92	8.28	0.45	6.31e-15	Lymphocyte counts;
CESC	cis	rs9815354	1.000	rs1716668	chr3:41907850	T/C	cg03022575	chr3:42003672	ULK4	0.44	5.16	0.3	4.85e-7	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs35123781	0.955	rs34530707	chr5:139059016	G/A	cg10513866	chr5:139070639	NA	0.4	5.92	0.34	1.02e-8	Schizophrenia;
CESC	cis	rs4076764	1.000	rs7540279	chr1:163429970	A/T	cg24596788	chr1:163392923	NA	-0.47	-6.88	-0.39	4.37e-11	Motion sickness;
CESC	cis	rs4006360	0.543	rs7502165	chr17:39268037	A/C	cg18442075	chr17:40169520	DNAJC7;NKIRAS2	-0.42	-5.3	-0.31	2.44e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs514406	0.929	rs12354395	chr1:53327663	A/G	cg24675658	chr1:53192096	ZYG11B	-0.6	-7.58	-0.42	5.81e-13	Monocyte count;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg26233408	chr17:78210670	SLC26A11	0.47	6.19	0.36	2.24e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs6964587	1.000	rs2282970	chr7:91584281	A/G	cg17063962	chr7:91808500	NA	0.57	7.72	0.43	2.46e-13	Breast cancer;
CESC	cis	rs9457247	1.000	rs409356	chr6:167405226	T/A	cg07741184	chr6:167504864	NA	0.28	5.1	0.3	6.54e-7	Crohn's disease;
CESC	trans	rs208520	0.690	rs12192851	chr6:66705862	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.95	12.6	0.61	7.7e-29	Exhaled nitric oxide output;
CESC	cis	rs1008375	0.932	rs11935124	chr4:17668200	G/A	cg02297831	chr4:17616191	MED28	-0.47	-5.45	-0.32	1.15e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs1126510	0.752	rs11666367	chr19:47120381	A/G	cg07844738	chr19:47129343	PTGIR	0.32	5.06	0.3	7.99e-7	Ulcerative colitis;
CESC	cis	rs4665809	1.000	rs750451	chr2:26324241	G/A	cg25036284	chr2:26402008	FAM59B	-0.59	-6.79	-0.39	7.13e-11	Gut microbiome composition (summer);
CESC	cis	rs13191362	0.507	rs2849524	chr6:163127070	C/T	cg06582575	chr6:163149167	PACRG;PARK2	-0.51	-5.97	-0.34	7.61e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs7520050	0.902	rs9429088	chr1:46497500	T/A	cg24296786	chr1:45957014	TESK2	0.41	5.21	0.3	3.75e-7	Red blood cell count;Reticulocyte count;
CESC	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.89	13.43	0.64	1e-31	Prudent dietary pattern;
CESC	cis	rs7520050	0.933	rs11211203	chr1:46315592	A/G	cg24296786	chr1:45957014	TESK2	0.43	5.42	0.32	1.32e-7	Red blood cell count;Reticulocyte count;
CESC	cis	rs4253772	0.591	rs6519994	chr22:46656805	A/G	cg18190219	chr22:46762943	CELSR1	0.4	5.13	0.3	5.73e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs7408868	0.706	rs7257550	chr19:15292088	C/G	cg14696996	chr19:15285081	NOTCH3	0.98	10.56	0.54	5.55e-22	Pulse pressure;
CESC	cis	rs12681366	0.734	rs2919672	chr8:95437147	G/A	cg13257157	chr8:95487014	RAD54B	0.38	5.19	0.3	4.26e-7	Nonsyndromic cleft lip with cleft palate;
CESC	cis	rs875971	0.862	rs11769079	chr7:65842128	G/A	cg10691866	chr7:65817282	TPST1	-0.32	-5.27	-0.31	2.89e-7	Aortic root size;
CESC	cis	rs4819052	0.851	rs2838855	chr21:46680566	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.9	-13.65	-0.64	1.75e-32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs28374715	0.528	rs7178360	chr15:41631175	T/A	cg02330683	chr15:41787940	ITPKA	0.48	5.65	0.33	4.05e-8	Ulcerative colitis;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg01307507	chr17:77751480	CBX2	-0.45	-6.01	-0.35	6.01e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs9611519	0.964	rs4820428	chr22:41537589	C/T	cg03806693	chr22:41940476	POLR3H	0.6	6.26	0.36	1.56e-9	Neuroticism;
CESC	cis	rs2425143	0.547	rs6141583	chr20:34572834	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.54	5.03	0.3	8.86e-7	Blood protein levels;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg18909525	chr9:132403873	ASB6	0.49	6.2	0.36	2.11e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs7937682	0.575	rs10789851	chr11:111750955	G/C	cg22437258	chr11:111473054	SIK2	-0.47	-5.24	-0.31	3.21e-7	Primary sclerosing cholangitis;
CESC	cis	rs2404602	0.647	rs7178250	chr15:77099107	T/C	cg23625390	chr15:77176239	SCAPER	-0.47	-6.51	-0.37	3.72e-10	Blood metabolite levels;
CESC	cis	rs1018836	0.884	rs13279263	chr8:91648780	T/C	cg16814680	chr8:91681699	NA	-0.7	-9.86	-0.52	9.97e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs8078723	1.000	rs3213762	chr17:38178627	A/G	cg17467752	chr17:38218738	THRA	0.68	10.32	0.54	3.24e-21	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CESC	cis	rs4803468	1.000	rs284648	chr19:41926790	T/C	cg09537434	chr19:41945824	ATP5SL	-1.1	-20.32	-0.78	5.54e-56	Height;
CESC	cis	rs7927592	0.956	rs11228269	chr11:68289796	A/G	cg16797656	chr11:68205561	LRP5	0.38	5.23	0.31	3.44e-7	Total body bone mineral density;
CESC	trans	rs66573146	0.656	rs111560662	chr4:6952766	C/T	cg07817883	chr1:32538562	TMEM39B	1.29	8.52	0.46	1.25e-15	Granulocyte percentage of myeloid white cells;
CESC	cis	rs7811142	1.000	rs68116612	chr7:100006493	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.79	8.0	0.44	3.92e-14	Platelet count;
CESC	trans	rs2727020	0.553	rs61904166	chr11:49581461	T/C	cg15704280	chr7:45808275	SEPT13	-0.94	-16.11	-0.7	3.47e-41	Coronary artery disease;
CESC	cis	rs4654899	0.758	rs7530739	chr1:21447480	C/A	cg05370193	chr1:21551575	ECE1	0.38	5.86	0.34	1.38e-8	Superior frontal gyrus grey matter volume;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04769705	chr14:69262517	C14orf181	-0.46	-6.1	-0.35	3.78e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs8092503	1.000	rs1819886	chr18:52493622	A/G	cg12377874	chr18:52495404	RAB27B	0.34	5.75	0.33	2.49e-8	Childhood body mass index;
CESC	cis	rs7149337	0.805	rs2999357	chr14:51606001	C/G	cg23942311	chr14:51606299	NA	0.48	8.34	0.46	4.23e-15	Cancer;
CESC	cis	rs757110	0.770	rs11024271	chr11:17395540	T/C	cg15432903	chr11:17409602	KCNJ11	0.6	8.46	0.46	1.82e-15	Type 2 diabetes;
CESC	cis	rs834811	0.797	rs2633365	chr7:135879797	A/G	cg01726295	chr7:135938950	NA	0.37	6.18	0.36	2.36e-9	Post-traumatic stress disorder;
CESC	cis	rs7584330	0.910	rs880930	chr2:238396872	G/C	cg14458575	chr2:238380390	NA	0.69	10.02	0.52	3.03e-20	Prostate cancer;
CESC	trans	rs931812	0.825	rs34235568	chr8:101895761	C/T	cg20993868	chr7:22813445	NA	0.54	7.62	0.42	4.41e-13	Attention deficit hyperactivity disorder and conduct disorder;
CESC	cis	rs9549367	0.789	rs8001506	chr13:113867153	A/C	cg00898013	chr13:113819073	PROZ	-0.51	-7.33	-0.41	2.72e-12	Platelet distribution width;
CESC	cis	rs4481887	0.893	rs10888349	chr1:248448625	T/C	cg00666640	chr1:248458726	OR2T12	0.39	6.69	0.38	1.29e-10	Common traits (Other);
CESC	cis	rs1008375	0.966	rs6449329	chr4:17703677	T/C	cg16339924	chr4:17578868	LAP3	0.62	7.68	0.43	3.01e-13	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs274567	0.501	rs274571	chr5:131712125	A/G	cg24060327	chr5:131705240	SLC22A5	0.76	10.65	0.55	2.72e-22	Blood metabolite levels;
CESC	cis	rs10791323	0.569	rs1119851	chr11:133742842	T/C	cg15485101	chr11:133734466	NA	0.3	5.22	0.31	3.6e-7	Childhood ear infection;
CESC	cis	rs11792861	0.926	rs3750451	chr9:111822866	C/T	cg13535736	chr9:111863775	C9orf5	-0.52	-6.91	-0.39	3.69e-11	Menarche (age at onset);
CESC	cis	rs12617721	0.756	rs3754889	chr2:99088633	T/G	cg10123293	chr2:99228465	UNC50	0.39	5.13	0.3	5.6e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs4853012	0.838	rs4452177	chr2:74345206	A/G	cg01017244	chr2:74357527	NA	0.68	9.93	0.52	5.7e-20	Gestational age at birth (maternal effect);
CESC	cis	rs6963495	0.818	rs55794529	chr7:105165747	T/C	cg13798780	chr7:105162888	PUS7	0.78	8.06	0.44	2.68e-14	Bipolar disorder (body mass index interaction);
CESC	cis	rs12540874	0.759	rs12718572	chr7:50573325	C/T	cg18232548	chr7:50535776	DDC	-0.42	-5.61	-0.33	5.03e-8	Systemic sclerosis;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03533382	chr5:126853128	PRRC1	0.49	6.21	0.36	2.06e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs7811142	1.000	rs68116612	chr7:100006493	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.88	9.47	0.5	1.64e-18	Platelet count;
CESC	cis	rs7666738	0.830	rs10029849	chr4:99059362	T/C	cg05340658	chr4:99064831	C4orf37	0.84	12.83	0.62	1.22e-29	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4819052	0.851	rs4819043	chr21:46660078	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.89	13.04	0.63	2.35e-30	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs1707322	0.721	rs10890346	chr1:46223892	C/T	cg03146154	chr1:46216737	IPP	-0.8	-11.29	-0.57	2.13e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg26338869	chr17:61819248	STRADA	0.69	9.13	0.49	1.8e-17	Prudent dietary pattern;
CESC	cis	rs2455799	0.613	rs2470536	chr3:15715156	G/C	cg16303742	chr3:15540471	COLQ	-0.38	-5.89	-0.34	1.17e-8	Mean platelet volume;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg12360373	chr16:28834065	ATXN2L	-0.42	-6.4	-0.37	7e-10	Gambling;
CESC	cis	rs2836974	0.932	rs2836955	chr21:40619887	G/A	cg11644478	chr21:40555479	PSMG1	0.96	13.84	0.65	3.74e-33	Cognitive function;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18855356	chr1:16957483	CROCCL1	-0.58	-6.56	-0.37	2.8e-10	Gut microbiome composition (summer);
CESC	cis	rs12541635	0.934	rs57715289	chr8:106967124	A/T	cg10147462	chr8:107024639	NA	0.41	5.57	0.32	6.41e-8	Age of smoking initiation;
CESC	cis	rs2625529	0.713	rs12903980	chr15:72165549	C/T	cg16672083	chr15:72433130	SENP8	-0.4	-5.2	-0.3	3.9e-7	Red blood cell count;
CESC	cis	rs2279817	0.691	rs7543007	chr1:17990475	A/G	cg21791023	chr1:18019539	ARHGEF10L	-0.55	-7.23	-0.41	5.02e-12	Neuroticism;
CESC	cis	rs875971	0.545	rs6460281	chr7:65681115	A/C	cg19163074	chr7:65112434	INTS4L2	-0.46	-5.04	-0.3	8.45e-7	Aortic root size;
CESC	cis	rs7917772	0.636	rs7894154	chr10:104524647	G/A	cg04362960	chr10:104952993	NT5C2	0.45	5.11	0.3	6.07e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	trans	rs9929218	0.581	rs4783676	chr16:68801077	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.87	14.08	0.65	5.39e-34	Colorectal cancer;
CESC	cis	rs765787	0.530	rs4544188	chr15:45535393	C/A	cg24006582	chr15:45444508	DUOX1	-0.59	-7.23	-0.41	5.15e-12	Uric acid levels;
CESC	cis	rs4434138	0.683	rs13063160	chr3:52602274	T/C	cg18099408	chr3:52552593	STAB1	-0.32	-5.43	-0.32	1.28e-7	Intelligence (multi-trait analysis);
CESC	cis	rs13242816	0.881	rs56034786	chr7:116106360	T/C	cg04696780	chr7:116139425	CAV2	-0.62	-5.69	-0.33	3.31e-8	P wave duration;
CESC	cis	rs71277158	0.688	rs73879178	chr3:169872834	C/T	cg04067573	chr3:169899625	PHC3	0.71	7.16	0.4	7.88e-12	Prostate cancer;
CESC	cis	rs796364	0.806	rs74938253	chr2:201008386	T/G	cg23649088	chr2:200775458	C2orf69	-0.58	-5.71	-0.33	3.07e-8	Schizophrenia;
CESC	cis	rs3782089	1.000	rs11602375	chr11:65296540	C/T	cg21890820	chr11:65308645	LTBP3	1.14	8.54	0.46	1.05e-15	Height;
CESC	trans	rs2733310	0.744	rs8040866	chr15:57162897	G/C	cg13494055	chr3:59115467	NA	-0.45	-6.17	-0.35	2.58e-9	Mean platelet volume;
CESC	cis	rs9291683	0.546	rs13146686	chr4:10034933	A/G	cg11266682	chr4:10021025	SLC2A9	0.62	11.63	0.58	1.54e-25	Bone mineral density;
CESC	cis	rs11098499	0.909	rs78332141	chr4:120375782	C/T	cg24375607	chr4:120327624	NA	0.46	5.66	0.33	3.94e-8	Corneal astigmatism;
CESC	cis	rs911555	0.723	rs6575986	chr14:103886671	G/A	cg24130564	chr14:104152367	KLC1	-0.52	-7.05	-0.4	1.56e-11	Intelligence (multi-trait analysis);
CESC	cis	rs9811920	0.609	rs9817005	chr3:99682692	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.64	-10.1	-0.53	1.62e-20	Axial length;
CESC	cis	rs6060717	0.536	rs6060676	chr20:34498551	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.63	5.44	0.32	1.22e-7	Hip circumference adjusted for BMI;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg07423198	chr12:123458881	ABCB9;OGFOD2	-0.52	-6.7	-0.38	1.25e-10	Fibrinogen levels;
CESC	cis	rs5763662	1.000	rs5763805	chr22:30538398	T/C	cg21388335	chr22:29999516	NF2	-0.74	-5.03	-0.3	9.22e-7	LDL cholesterol levels;LDL cholesterol;
CESC	trans	rs2670321	0.706	rs2200019	chr3:99095896	C/T	cg03764381	chr16:10275410	GRIN2A	-0.39	-6.05	-0.35	4.91e-9	RR interval (heart rate);
CESC	cis	rs965469	0.846	rs7271575	chr20:3333877	C/T	cg25506879	chr20:3388711	C20orf194	-0.54	-5.81	-0.34	1.82e-8	IFN-related cytopenia;
CESC	cis	rs9649213	0.502	rs6465680	chr7:98005778	A/G	cg21770322	chr7:97807741	LMTK2	0.56	8.56	0.47	9.14e-16	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs35110281	0.591	rs162369	chr21:44931965	G/A	cg21573476	chr21:45109991	RRP1B	-0.39	-5.51	-0.32	8.43e-8	Mean corpuscular volume;
CESC	cis	rs9311474	0.607	rs11711421	chr3:52561779	C/T	cg18099408	chr3:52552593	STAB1	-0.32	-5.51	-0.32	8.6e-8	Electroencephalogram traits;
CESC	cis	rs2404618	0.504	rs2906567	chr8:1494118	C/T	cg02903104	chr8:1507517	DLGAP2	0.36	6.8	0.39	6.72e-11	Lung cancer;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg08395899	chr10:12085052	UPF2	-0.46	-6.09	-0.35	3.91e-9	Asthma;
CESC	cis	rs6964587	0.610	rs6942852	chr7:91437883	A/C	cg17063962	chr7:91808500	NA	0.39	5.43	0.32	1.25e-7	Breast cancer;
CESC	cis	rs9549260	0.564	rs9549270	chr13:41284193	G/T	cg21288729	chr13:41239152	FOXO1	0.6	7.25	0.41	4.55e-12	Red blood cell count;
CESC	cis	rs1008375	0.932	rs4698626	chr4:17605821	G/C	cg16339924	chr4:17578868	LAP3	0.63	8.08	0.44	2.34e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs4595586	0.545	rs11615584	chr12:39409350	C/G	cg13010199	chr12:38710504	ALG10B	0.45	5.67	0.33	3.75e-8	Morning vs. evening chronotype;
CESC	cis	rs4727027	0.933	rs6955564	chr7:148866173	A/G	cg23158103	chr7:148848205	ZNF398	-0.36	-5.99	-0.35	6.97e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs9815354	0.951	rs9831404	chr3:41871825	T/G	cg03022575	chr3:42003672	ULK4	0.49	5.52	0.32	7.99e-8	Pulse pressure;Diastolic blood pressure;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg26767085	chr19:7977494	MAP2K7	0.44	6.1	0.35	3.74e-9	Fibrinogen levels;
CESC	cis	rs3091242	0.933	rs4649084	chr1:25752617	A/G	cg02931644	chr1:25747376	RHCE	0.38	6.25	0.36	1.67e-9	Erythrocyte sedimentation rate;
CESC	cis	rs9649213	0.574	rs13238610	chr7:97909277	T/C	cg24562669	chr7:97807699	LMTK2	0.49	6.98	0.39	2.41e-11	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs17253792	0.915	rs77161327	chr14:56178565	A/G	cg01858014	chr14:56050164	KTN1	-0.94	-7.27	-0.41	4.03e-12	Putamen volume;
CESC	cis	rs35955747	0.934	rs5997981	chr22:31808827	A/G	cg25791279	chr22:32026902	PISD	-0.45	-5.45	-0.32	1.14e-7	Neutrophil count;Sum basophil neutrophil counts;
CESC	cis	rs7937682	0.737	rs679032	chr11:111423286	G/T	cg09085632	chr11:111637200	PPP2R1B	-0.78	-10.25	-0.53	5.65e-21	Primary sclerosing cholangitis;
CESC	cis	rs9733	0.628	rs11807409	chr1:150683423	C/T	cg17724175	chr1:150552817	MCL1	0.45	7.31	0.41	3.23e-12	Tonsillectomy;
CESC	cis	rs8114671	0.562	rs6087649	chr20:33510662	A/G	cg24642439	chr20:33292090	TP53INP2	0.44	5.32	0.31	2.18e-7	Height;
CESC	cis	rs9611565	0.512	rs1534932	chr22:42150146	C/T	cg17376030	chr22:41985996	PMM1	-0.78	-8.17	-0.45	1.24e-14	Vitiligo;
CESC	cis	rs10791097	0.694	rs4436551	chr11:130755739	A/G	cg12179176	chr11:130786555	SNX19	-0.65	-10.45	-0.54	1.3e-21	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs7666738	0.747	rs2865955	chr4:99040518	A/C	cg03467027	chr4:99064603	C4orf37	0.47	5.98	0.34	7.19e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9796	0.689	rs28497404	chr15:41449510	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.48	-7.16	-0.4	8.13e-12	Menopause (age at onset);
CESC	cis	rs7412746	0.621	rs72704656	chr1:150828307	A/G	cg04414720	chr1:150670196	GOLPH3L	0.56	7.4	0.41	1.81e-12	Melanoma;
CESC	cis	rs9287719	0.901	rs55861579	chr2:10763340	T/A	cg02196655	chr2:10830764	NOL10	-0.36	-5.44	-0.32	1.23e-7	Prostate cancer;
CESC	cis	rs6577655	0.561	rs6577654	chr8:135593610	G/A	cg17885191	chr8:135476712	NA	0.48	5.24	0.31	3.23e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CESC	trans	rs7618501	0.966	rs13085679	chr3:49869631	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.59	8.36	0.46	3.66e-15	Intelligence (multi-trait analysis);
CESC	cis	rs1862618	0.511	rs2591952	chr5:56120769	T/A	cg18230493	chr5:56204884	C5orf35	-0.72	-8.76	-0.47	2.37e-16	Initial pursuit acceleration;
CESC	cis	rs67311347	1.000	rs73078162	chr3:40477109	G/A	cg24209194	chr3:40518798	ZNF619	0.51	6.2	0.36	2.18e-9	Renal cell carcinoma;
CESC	cis	rs72634258	1.000	rs72634258	chr1:8150638	T/C	cg00042356	chr1:8021962	PARK7	0.8	7.41	0.41	1.75e-12	Inflammatory bowel disease;
CESC	cis	rs904092	0.720	rs931635	chr4:100210847	A/G	cg12011299	chr4:100065546	ADH4	-0.51	-5.9	-0.34	1.11e-8	Alcohol dependence;
CESC	cis	rs10464366	0.544	rs953874	chr7:39147916	G/A	cg18850127	chr7:39170497	POU6F2	0.36	5.06	0.3	7.92e-7	IgG glycosylation;
CESC	cis	rs1847202	0.859	rs4501056	chr3:72948908	A/T	cg10804678	chr3:72788309	NA	-0.38	-5.21	-0.3	3.81e-7	Motion sickness;
CESC	cis	rs12893668	0.703	rs34186780	chr14:104027595	T/G	cg24130564	chr14:104152367	KLC1	-0.47	-5.77	-0.33	2.21e-8	Reticulocyte count;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg01008941	chr4:39046077	KLHL5	-0.44	-6.29	-0.36	1.3e-9	Gambling;
CESC	cis	rs7666738	0.830	rs35276471	chr4:99068691	A/T	cg17366294	chr4:99064904	C4orf37	0.61	8.5	0.46	1.41e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9486715	0.867	rs6568428	chr6:96903604	A/G	cg18709589	chr6:96969512	KIAA0776	0.46	6.52	0.37	3.61e-10	Headache;
CESC	cis	rs6083	0.536	rs4528512	chr15:58852226	A/T	cg05156742	chr15:59063176	FAM63B	0.56	7.41	0.41	1.73e-12	Schizophrenia;
CESC	cis	rs7662987	0.517	rs2602880	chr4:100040653	C/T	cg12011299	chr4:100065546	ADH4	0.6	6.56	0.37	2.83e-10	Smoking initiation;
CESC	cis	rs9300255	0.663	rs7953929	chr12:123758235	C/G	cg05973401	chr12:123451056	ABCB9	0.52	5.34	0.31	1.95e-7	Neutrophil percentage of white cells;
CESC	trans	rs7944735	0.507	rs7114598	chr11:48101766	C/T	cg15704280	chr7:45808275	SEPT13	0.61	7.51	0.42	9.22e-13	Intraocular pressure;
CESC	cis	rs514406	0.861	rs554760	chr1:53266749	G/A	cg16325326	chr1:53192061	ZYG11B	-0.9	-15.33	-0.69	2.02e-38	Monocyte count;
CESC	cis	rs28489187	0.706	rs2300634	chr1:85791257	T/C	cg16011679	chr1:85725395	C1orf52	0.53	6.22	0.36	1.89e-9	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	cis	rs713587	0.563	rs11686663	chr2:25107759	C/T	cg01884057	chr2:25150051	NA	0.34	6.44	0.37	5.53e-10	Body mass index in non-asthmatics;
CESC	cis	rs11098499	0.954	rs17005535	chr4:120411562	C/T	cg09307838	chr4:120376055	NA	0.94	13.64	0.64	1.94e-32	Corneal astigmatism;
CESC	cis	rs28830936	0.528	rs11630242	chr15:42124643	T/C	cg17847044	chr15:42102381	MAPKBP1	-0.42	-7.02	-0.4	1.81e-11	Diastolic blood pressure;
CESC	cis	rs597539	0.652	rs668576	chr11:68668208	A/G	cg18350739	chr11:68623251	NA	-0.46	-7.1	-0.4	1.15e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg20589815	chr10:47656205	NA	0.44	6.03	0.35	5.56e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	trans	rs1373453	0.808	rs80332434	chr12:70071897	T/C	cg19702771	chr4:82058885	PRKG2	0.74	6.01	0.35	6.27e-9	Orofacial clefts;
CESC	cis	rs6460942	0.915	rs62448596	chr7:12446869	C/T	cg06484146	chr7:12443880	VWDE	-0.73	-8.75	-0.47	2.6e-16	Coronary artery disease;
CESC	cis	rs12477438	0.798	rs9808541	chr2:99642179	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.75	-10.87	-0.56	5.17e-23	Chronic sinus infection;
CESC	cis	rs12449964	0.524	rs7224756	chr17:17572342	G/A	cg04398451	chr17:18023971	MYO15A	0.37	5.05	0.3	8.1e-7	Coronary artery disease or ischemic stroke;
CESC	cis	rs9322193	0.884	rs2342858	chr6:150127103	C/T	cg07701084	chr6:150067640	NUP43	0.43	5.8	0.34	1.88e-8	Lung cancer;
CESC	cis	rs2120019	0.938	rs2304903	chr15:75315778	A/G	cg17294928	chr15:75287854	SCAMP5	-0.79	-9.08	-0.49	2.52e-17	Blood trace element (Zn levels);
CESC	trans	rs6089829	0.962	rs6011548	chr20:61666063	C/T	cg23505145	chr19:12996616	KLF1	0.52	6.8	0.39	6.85e-11	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs2732480	0.500	rs2450989	chr12:48653408	A/G	cg04545296	chr12:48745243	ZNF641	-0.39	-6.58	-0.37	2.45e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs5753618	0.504	rs5753661	chr22:31899797	C/A	cg13145458	chr22:31556086	RNF185	-0.48	-5.69	-0.33	3.28e-8	Colorectal cancer;
CESC	cis	rs1881797	1.000	rs12071797	chr1:247686871	A/G	cg11166453	chr1:247681781	NA	0.44	5.77	0.33	2.24e-8	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs7618915	1.000	rs3852064	chr3:52349412	G/T	cg05564831	chr3:52568323	NT5DC2	0.45	5.67	0.33	3.7e-8	Bipolar disorder;
CESC	cis	rs10463316	1.000	rs10463316	chr5:150746034	A/G	cg03212797	chr5:150827313	SLC36A1	-0.45	-5.38	-0.31	1.61e-7	Metabolite levels (Pyroglutamine);
CESC	cis	rs9815354	0.680	rs57525756	chr3:41843591	A/C	cg03022575	chr3:42003672	ULK4	0.7	6.04	0.35	5.26e-9	Pulse pressure;Diastolic blood pressure;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00016223	chr6:36515007	STK38	0.57	6.47	0.37	4.62e-10	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06676579	chr20:25176178	ENTPD6	0.59	6.55	0.37	2.94e-10	Gut microbiome composition (summer);
CESC	trans	rs10242455	0.571	rs56167514	chr7:99161347	A/G	cg09045935	chr12:6379348	NA	0.82	6.99	0.39	2.2e-11	Blood metabolite levels;
CESC	trans	rs208520	0.690	rs12189780	chr6:66759619	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.95	12.16	0.6	2.56e-27	Exhaled nitric oxide output;
CESC	cis	rs3733585	0.673	rs9994937	chr4:9964799	G/T	cg11266682	chr4:10021025	SLC2A9	-0.6	-10.89	-0.56	4.59e-23	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs7188697	0.922	rs40188	chr16:58567761	T/A	cg02549819	chr16:58548995	SETD6	-0.42	-5.24	-0.31	3.24e-7	QT interval;
CESC	cis	rs853679	0.550	rs6901017	chr6:28152583	T/C	cg19592336	chr6:28129416	ZNF389	0.52	7.11	0.4	1.07e-11	Depression;
CESC	cis	rs7615952	0.800	rs11915699	chr3:125632684	A/G	cg05084668	chr3:125655381	ALG1L	-0.43	-5.11	-0.3	6.31e-7	Blood pressure (smoking interaction);
CESC	cis	rs11958404	0.932	rs11949394	chr5:157425198	A/G	cg05962755	chr5:157440814	NA	0.61	6.6	0.38	2.26e-10	IgG glycosylation;
CESC	cis	rs10504229	0.679	rs2317991	chr8:58035080	C/T	cg24829409	chr8:58192753	C8orf71	0.45	5.9	0.34	1.11e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs4450798	0.793	rs28454765	chr3:13758013	A/G	cg05589046	chr3:13742034	LOC285375	0.39	6.1	0.35	3.76e-9	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs1559088	0.948	rs7259333	chr19:33579128	T/C	cg27124370	chr19:33622961	WDR88	0.47	6.2	0.36	2.2e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs3771570	0.892	rs55751610	chr2:242346057	C/T	cg21155796	chr2:242212141	HDLBP	0.58	5.06	0.3	7.83e-7	Prostate cancer;
CESC	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg07677032	chr17:61819896	STRADA	0.46	6.18	0.35	2.43e-9	Prudent dietary pattern;
CESC	cis	rs10504229	0.906	rs7846666	chr8:58172302	T/C	cg24829409	chr8:58192753	C8orf71	-0.62	-8.69	-0.47	3.85e-16	Developmental language disorder (linguistic errors);
CESC	trans	rs11764590	0.715	rs55810445	chr7:2103739	C/T	cg11693508	chr17:37793320	STARD3	0.68	6.48	0.37	4.5e-10	Neuroticism;
CESC	cis	rs7666738	0.830	rs11944107	chr4:98931638	G/C	cg05340658	chr4:99064831	C4orf37	0.82	12.17	0.6	2.24e-27	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6439153	0.743	rs71331685	chr3:128711425	T/A	cg24203234	chr3:128598194	ACAD9	0.41	5.39	0.31	1.59e-7	Pneumococcal bacteremia;
CESC	cis	rs11583043	0.708	rs11590358	chr1:101560214	C/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.51	5.48	0.32	9.72e-8	Ulcerative colitis;Inflammatory bowel disease;
CESC	cis	rs728616	0.558	rs12767261	chr10:82162323	G/A	cg05935833	chr10:81318306	SFTPA2	-0.46	-5.71	-0.33	3.09e-8	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs3617	0.573	rs2336668	chr3:52919096	G/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	-0.3	-5.19	-0.3	4.15e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
CESC	cis	rs829883	0.966	rs249815	chr12:98893709	A/G	cg25150519	chr12:98850993	NA	0.71	9.74	0.51	2.31e-19	Colorectal adenoma (advanced);
CESC	cis	rs10927875	1.000	rs3979179	chr1:16306846	A/G	cg22431228	chr1:16359049	CLCNKA	-0.35	-5.29	-0.31	2.53e-7	Dilated cardiomyopathy;
CESC	cis	rs911555	0.755	rs4906329	chr14:103942669	A/G	cg12935359	chr14:103987150	CKB	0.66	9.55	0.51	8.86e-19	Intelligence (multi-trait analysis);
CESC	cis	rs6952808	0.792	rs13224989	chr7:1953766	C/G	cg02951883	chr7:2050386	MAD1L1	-0.48	-6.44	-0.37	5.51e-10	Bipolar disorder and schizophrenia;
CESC	cis	rs4964805	0.606	rs7312606	chr12:104188385	C/G	cg02344784	chr12:104178138	NT5DC3	0.46	6.57	0.37	2.73e-10	Attention deficit hyperactivity disorder;
CESC	cis	rs3749237	0.595	rs35701831	chr3:49515000	A/C	cg06212747	chr3:49208901	KLHDC8B	0.47	6.33	0.36	1.04e-9	Resting heart rate;
CESC	cis	rs4919687	0.550	rs10437480	chr10:104453024	C/G	cg04362960	chr10:104952993	NT5C2	0.44	5.18	0.3	4.47e-7	Colorectal cancer;
CESC	cis	rs644799	0.965	rs598876	chr11:95560853	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	9.15	0.49	1.57e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs3096299	0.685	rs12446145	chr16:89542695	C/T	cg08392591	chr16:89556376	ANKRD11	0.59	8.04	0.44	3.06e-14	Multiple myeloma (IgH translocation);
CESC	cis	rs896854	0.654	rs2011566	chr8:95971921	G/A	cg26343298	chr8:95960752	TP53INP1	0.37	6.13	0.35	3.11e-9	Type 2 diabetes;
CESC	cis	rs6598955	0.671	rs41285347	chr1:26644399	C/T	cg19743891	chr1:26644573	UBXN11;CD52	0.35	5.09	0.3	6.68e-7	Obesity-related traits;
CESC	cis	rs1348850	1.000	rs3927978	chr2:178443854	A/G	cg23306229	chr2:178417860	TTC30B	-0.54	-7.09	-0.4	1.2e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs9733	0.744	rs4970976	chr1:150779524	T/A	cg13175981	chr1:150552382	MCL1	0.52	7.14	0.4	8.93e-12	Tonsillectomy;
CESC	cis	rs858239	0.806	rs10268610	chr7:23274764	A/G	cg23682824	chr7:23144976	KLHL7	0.43	5.55	0.32	7.01e-8	Cerebrospinal fluid biomarker levels;
CESC	cis	rs6500395	1.000	rs9933976	chr16:48590145	A/G	cg04672837	chr16:48644449	N4BP1	0.51	6.42	0.37	6.2e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs617791	0.508	rs1047464	chr11:65769456	A/T	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.44	-5.12	-0.3	6.02e-7	Breast cancer;
CESC	cis	rs7843479	0.932	rs68023663	chr8:21794379	T/C	cg17168535	chr8:21777572	XPO7	0.51	7.2	0.4	6.18e-12	Mean corpuscular volume;
CESC	cis	rs769267	0.930	rs4808955	chr19:19552413	T/C	cg03709012	chr19:19516395	GATAD2A	1.0	14.75	0.67	2.39e-36	Tonsillectomy;
CESC	trans	rs12310956	0.515	rs1852221	chr12:33945489	G/T	cg26384229	chr12:38710491	ALG10B	0.47	6.56	0.37	2.74e-10	Morning vs. evening chronotype;
CESC	cis	rs113835537	0.529	rs75003264	chr11:66256099	G/A	cg24851651	chr11:66362959	CCS	0.53	6.26	0.36	1.57e-9	Airway imaging phenotypes;
CESC	cis	rs4555082	0.957	rs2975216	chr14:105713134	T/C	cg13114125	chr14:105738426	BRF1	-0.68	-8.55	-0.47	9.7e-16	Mean platelet volume;Platelet distribution width;
CESC	cis	rs9894429	0.646	rs9905639	chr17:79614154	A/G	cg13777783	chr17:79615861	NA	-0.35	-5.98	-0.34	7.27e-9	Eye color traits;
CESC	cis	rs2408955	0.561	rs9971924	chr12:48479832	C/G	cg04545296	chr12:48745243	ZNF641	-0.35	-6.1	-0.35	3.7e-9	Glycated hemoglobin levels;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg25362248	chr1:31192015	MATN1	0.48	6.35	0.36	9.41e-10	Thyroid stimulating hormone;
CESC	cis	rs113835537	0.529	rs2305532	chr11:66298594	C/T	cg22134325	chr11:66188745	NPAS4	0.39	5.94	0.34	8.94e-9	Airway imaging phenotypes;
CESC	cis	rs921968	0.643	rs3845836	chr2:219504955	C/T	cg02176678	chr2:219576539	TTLL4	0.39	6.7	0.38	1.24e-10	Mean corpuscular hemoglobin concentration;
CESC	cis	rs4835473	0.778	rs6856553	chr4:144747126	C/T	cg25736465	chr4:144833511	NA	-0.35	-5.4	-0.32	1.46e-7	Immature fraction of reticulocytes;
CESC	cis	rs7631605	0.875	rs11714125	chr3:37024256	T/C	cg22985146	chr3:37219077	LRRFIP2	-0.33	-5.09	-0.3	6.91e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs6426558	0.537	rs10495253	chr1:227471820	A/T	cg10327440	chr1:227177885	CDC42BPA	0.48	5.96	0.34	8.16e-9	Neutrophil percentage of white cells;
CESC	cis	rs2404602	0.583	rs2139190	chr15:76555539	G/C	cg26408565	chr15:76604113	ETFA	-0.41	-5.98	-0.34	7.19e-9	Blood metabolite levels;
CESC	cis	rs6963495	0.818	rs9769403	chr7:105163091	G/A	cg13798780	chr7:105162888	PUS7	0.78	8.04	0.44	2.99e-14	Bipolar disorder (body mass index interaction);
CESC	cis	rs2932538	0.883	rs6696991	chr1:113095661	C/T	cg22162597	chr1:113214053	CAPZA1	0.47	6.21	0.36	2.05e-9	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CESC	cis	rs853679	0.517	rs35512245	chr6:28079953	T/C	cg08968635	chr6:28129556	ZNF389	0.4	5.36	0.31	1.84e-7	Depression;
CESC	cis	rs2985684	0.789	rs1957979	chr14:50063332	A/G	cg02151108	chr14:50098012	C14orf104	-0.38	-5.03	-0.3	8.89e-7	Carotid intima media thickness;
CESC	cis	rs7914558	0.933	rs10883814	chr10:104737404	T/C	cg04362960	chr10:104952993	NT5C2	0.44	5.67	0.33	3.68e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg21164723	chr1:214776304	CENPF	0.45	6.19	0.36	2.34e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs853679	0.550	rs1150689	chr6:28165099	T/C	cg17949981	chr6:28129498	ZNF389	0.42	5.48	0.32	9.8e-8	Depression;
CESC	cis	rs9311474	0.508	rs11718420	chr3:52611413	T/C	cg18404041	chr3:52824283	ITIH1	-0.38	-6.5	-0.37	4.06e-10	Electroencephalogram traits;
CESC	cis	rs9513593	1.000	rs12100212	chr13:99966921	C/T	cg21788972	chr13:99853209	UBAC2	0.62	7.01	0.4	1.94e-11	Psoriasis;
CESC	cis	rs1153858	0.621	rs2413769	chr15:45561868	A/C	cg14582100	chr15:45693742	SPATA5L1	0.43	5.77	0.33	2.21e-8	Homoarginine levels;
CESC	cis	rs7208859	0.673	rs73263776	chr17:29211331	G/C	cg13385521	chr17:29058706	SUZ12P	0.66	5.03	0.3	9.15e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs72781680	0.898	rs72796154	chr2:23933839	G/A	cg08917208	chr2:24149416	ATAD2B	1.09	10.05	0.53	2.47e-20	Lymphocyte counts;
CESC	cis	rs7824557	0.547	rs2736287	chr8:11228006	G/A	cg21775007	chr8:11205619	TDH	-0.55	-8.58	-0.47	8.11e-16	Retinal vascular caliber;
CESC	cis	rs7666738	0.830	rs13110410	chr4:98920018	T/C	cg17366294	chr4:99064904	C4orf37	0.57	7.94	0.44	5.78e-14	Colonoscopy-negative controls vs population controls;
CESC	cis	rs854765	0.964	rs854762	chr17:18009102	G/A	cg04398451	chr17:18023971	MYO15A	0.69	9.7	0.51	3.1400000000000002e-19	Total body bone mineral density;
CESC	cis	rs2180341	0.960	rs1543432	chr6:127698018	T/C	cg24812749	chr6:127587940	RNF146	1.04	14.79	0.67	1.71e-36	Breast cancer;
CESC	cis	rs6460942	0.597	rs4721107	chr7:12535105	T/G	cg06484146	chr7:12443880	VWDE	-0.73	-7.77	-0.43	1.68e-13	Coronary artery disease;
CESC	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg24642844	chr7:1081250	C7orf50	-0.75	-8.99	-0.48	4.94e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs6724607	1.000	rs6724607	chr2:191466532	C/T	cg21644426	chr2:191273491	MFSD6	0.48	6.43	0.37	6.04e-10	Pulse pressure;
CESC	cis	rs9640161	0.789	rs34728606	chr7:150054694	G/A	cg27494647	chr7:150038898	RARRES2	0.44	5.36	0.31	1.83e-7	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg11905131	chr22:24372483	LOC391322	0.68	9.8	0.52	1.55e-19	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs10028773	0.600	rs4001390	chr4:120265783	G/C	cg09307838	chr4:120376055	NA	0.76	10.03	0.52	2.87e-20	Educational attainment;
CESC	cis	rs4718428	0.662	rs34577323	chr7:66310041	G/C	cg18252515	chr7:66147081	NA	-0.45	-5.06	-0.3	7.84e-7	Corneal structure;
CESC	cis	rs5167	0.677	rs12709889	chr19:45453239	A/G	cg13119609	chr19:45449297	APOC2	-0.39	-5.47	-0.32	1.06e-7	Blood protein levels;
CESC	cis	rs17818399	0.612	rs4952834	chr2:46777462	C/G	cg02822958	chr2:46747628	ATP6V1E2	0.42	5.45	0.32	1.17e-7	Height;
CESC	cis	rs7872515	0.775	rs1970121	chr9:94870152	A/C	cg01248375	chr9:94877805	SPTLC1	-0.56	-6.1	-0.35	3.81e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs2950393	0.929	rs2290893	chr12:57078620	A/G	cg05584118	chr12:57595605	LRP1	-0.37	-5.23	-0.31	3.42e-7	Platelet distribution width;
CESC	cis	rs7568458	0.709	rs2028898	chr2:85777270	G/A	cg02493740	chr2:85810744	VAMP5	-0.57	-8.33	-0.46	4.41e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CESC	cis	rs1862618	0.853	rs252898	chr5:56188931	T/C	cg22800045	chr5:56110881	MAP3K1	0.8	9.58	0.51	7.41e-19	Initial pursuit acceleration;
CESC	cis	rs116095464	0.558	rs59113266	chr5:279965	T/C	cg22857025	chr5:266934	NA	-1.29	-18.38	-0.75	3.21e-49	Breast cancer;
CESC	cis	rs2836974	0.602	rs2037925	chr21:40699931	C/T	cg11890956	chr21:40555474	PSMG1	-0.94	-15.22	-0.68	5.25e-38	Cognitive function;
CESC	cis	rs10540	0.908	rs1044707	chr11:491334	G/T	cg21784768	chr11:537496	LRRC56	0.56	5.27	0.31	2.84e-7	Body mass index;
CESC	cis	rs10504229	1.000	rs17805602	chr8:58179915	A/G	cg14926445	chr8:58193284	C8orf71	-0.51	-5.47	-0.32	1.03e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs10871290	0.551	rs3863435	chr16:74465396	C/G	cg01733217	chr16:74700730	RFWD3	-0.67	-9.16	-0.49	1.5e-17	Breast cancer;
CESC	cis	rs2304069	1.000	rs216126	chr5:149428424	G/C	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.47	5.26	0.31	2.99e-7	HIV-1 control;
CESC	cis	rs8060686	0.858	rs7199443	chr16:67841129	T/G	cg26727032	chr16:67993705	SLC12A4	-0.66	-9.55	-0.51	8.9e-19	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs13256369	0.708	rs11249886	chr8:8562021	T/A	cg00074818	chr8:8560427	CLDN23	0.35	5.2	0.3	4e-7	Obesity-related traits;
CESC	cis	rs763014	0.898	rs916414	chr16:632073	C/T	cg00908189	chr16:619842	PIGQ	0.67	9.34	0.5	4.24e-18	Height;
CESC	cis	rs2742417	0.603	rs2742374	chr3:45784082	T/C	cg04837898	chr3:45731254	SACM1L	-0.46	-6.0	-0.35	6.47e-9	Response to anti-depressant treatment in major depressive disorder;
CESC	cis	rs853679	0.766	rs9368561	chr6:28168343	C/T	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.78	6.82	0.39	6.25e-11	Depression;
CESC	cis	rs6570726	0.537	rs1280279	chr6:145884048	G/T	cg05347473	chr6:146136440	FBXO30	0.58	6.06	0.35	4.72e-9	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg06873352	chr17:61820015	STRADA	0.72	12.35	0.6	5.73e-28	Prudent dietary pattern;
CESC	cis	rs8062405	0.755	rs62034358	chr16:28587597	G/T	cg01378222	chr16:28622494	SULT1A1	0.3	5.09	0.3	6.77e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg04904834	chr1:179851103	TOR1AIP1	-0.45	-6.45	-0.37	5.13e-10	Gambling;
CESC	cis	rs6088580	0.609	rs945674	chr20:32964247	G/C	cg06115741	chr20:33292138	TP53INP2	-0.46	-5.98	-0.34	7.28e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs1348850	0.914	rs6710575	chr2:178377311	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.84	11.89	0.59	1.99e-26	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs300703	0.542	rs443419	chr2:189800	C/T	cg21211680	chr2:198530	NA	-0.86	-9.39	-0.5	2.94e-18	Blood protein levels;
CESC	cis	rs7666738	0.830	rs13125537	chr4:98978428	A/G	cg17366294	chr4:99064904	C4orf37	0.59	8.43	0.46	2.31e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs919433	0.680	rs67580728	chr2:198431258	C/T	cg03934865	chr2:198174659	NA	0.37	5.06	0.3	7.77e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs8005677	1.000	rs4982710	chr14:23398902	C/T	cg25600027	chr14:23388339	RBM23	-0.42	-5.11	-0.3	6.27e-7	Cognitive ability (multi-trait analysis);
CESC	cis	rs2842992	0.830	rs752779	chr6:160133957	G/A	cg11366901	chr6:160182831	ACAT2	0.84	11.06	0.56	1.28e-23	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs2929278	0.561	rs3099045	chr15:43923955	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.47	7.23	0.41	5.15e-12	Schizophrenia;
CESC	cis	rs561341	1.000	rs55736640	chr17:30333848	G/A	cg19193384	chr17:30244184	NA	-0.69	-6.15	-0.35	2.92e-9	Hip circumference adjusted for BMI;
CESC	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg00080972	chr5:178986291	RUFY1	-0.48	-7.76	-0.43	1.8e-13	Lung cancer;
CESC	cis	rs2996428	0.628	rs6667526	chr1:3774603	G/A	cg23277830	chr1:3704460	LRRC47	0.35	5.22	0.31	3.6e-7	Red cell distribution width;
CESC	cis	rs17401966	1.000	rs1049887	chr1:10460485	T/C	cg15208524	chr1:10270712	KIF1B	0.48	6.04	0.35	5.3e-9	Hepatocellular carcinoma;
CESC	cis	rs9649465	1.000	rs3807635	chr7:123382152	A/C	cg04330084	chr7:123175371	IQUB	-0.38	-5.06	-0.3	8.01e-7	Migraine;
CESC	cis	rs367615	0.552	rs2963010	chr5:108737043	T/C	cg17395555	chr5:108820864	NA	-0.52	-8.5	-0.46	1.36e-15	Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs2011503	1.000	rs7256028	chr19:19628240	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.49	5.09	0.3	6.83e-7	Bipolar disorder;
CESC	cis	rs2276314	1.000	rs1540042	chr18:33555236	C/T	cg19628046	chr18:33552617	C18orf21	0.56	6.32	0.36	1.12e-9	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs9611565	0.802	rs2234058	chr22:41777883	G/A	cg06481639	chr22:41940642	POLR3H	-0.61	-6.49	-0.37	4.09e-10	Vitiligo;
CESC	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.91	13.98	0.65	1.24e-33	Prudent dietary pattern;
CESC	cis	rs514406	0.929	rs557920	chr1:53338757	C/A	cg08736216	chr1:53307985	ZYG11A	-0.45	-7.32	-0.41	2.94e-12	Monocyte count;
CESC	cis	rs12701220	0.522	rs12334290	chr7:1054517	A/G	cg20821713	chr7:1055600	C7orf50	-0.5	-6.5	-0.37	4.04e-10	Bronchopulmonary dysplasia;
CESC	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg26354017	chr1:205819088	PM20D1	0.83	13.36	0.63	1.77e-31	Menarche (age at onset);
CESC	cis	rs5769765	0.908	rs9627800	chr22:50319351	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.62	-6.38	-0.37	7.75e-10	Schizophrenia;
CESC	cis	rs2066819	1.000	rs744051	chr12:56667298	C/T	cg26714650	chr12:56694279	CS	1.35	9.44	0.5	2.01e-18	Psoriasis vulgaris;
CESC	cis	rs7216064	1.000	rs12602655	chr17:65909442	A/G	cg07042672	chr17:66097459	LOC651250	-0.52	-5.35	-0.31	1.9e-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs7786877	0.680	rs28584500	chr7:100216341	G/A	cg16850897	chr7:100343110	ZAN	-0.58	-6.23	-0.36	1.83e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs7659604	0.521	rs4833232	chr4:122684367	C/T	cg19671926	chr4:122722719	EXOSC9	0.6	7.64	0.42	4e-13	Type 2 diabetes;
CESC	cis	rs7618915	0.547	rs62255362	chr3:52699741	C/G	cg18404041	chr3:52824283	ITIH1	-0.39	-6.58	-0.37	2.56e-10	Bipolar disorder;
CESC	trans	rs637571	0.522	rs491973	chr11:65727301	A/G	cg17712092	chr4:129076599	LARP1B	0.7	9.65	0.51	4.53e-19	Eosinophil percentage of white cells;
CESC	trans	rs61931739	0.500	rs11053218	chr12:34474792	A/C	cg26384229	chr12:38710491	ALG10B	-0.66	-9.5	-0.5	1.3e-18	Morning vs. evening chronotype;
CESC	cis	rs67311347	0.866	rs11712426	chr3:40330322	G/A	cg09455208	chr3:40491958	NA	0.43	7.12	0.4	1.02e-11	Renal cell carcinoma;
CESC	cis	rs7582720	1.000	rs72926783	chr2:203815740	T/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.36	0.41	2.34e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs66686620	0.943	rs6546472	chr2:69260300	A/G	cg12800200	chr2:69260302	ANTXR1	-0.44	-6.48	-0.37	4.34e-10	Breast cancer;
CESC	cis	rs2880765	0.835	rs28874135	chr15:86031503	G/A	cg10818794	chr15:86012489	AKAP13	-0.35	-5.42	-0.32	1.32e-7	Coronary artery disease;
CESC	cis	rs4665809	1.000	rs4665308	chr2:26330514	C/A	cg26314531	chr2:26401878	FAM59B	-0.62	-6.99	-0.39	2.29e-11	Gut microbiome composition (summer);
CESC	cis	rs736801	0.808	rs72797306	chr5:131800750	G/C	cg21138405	chr5:131827807	IRF1	-0.4	-5.88	-0.34	1.25e-8	Breast cancer;Mosquito bite size;
CESC	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	13.83	0.65	4.07e-33	Prudent dietary pattern;
CESC	cis	rs3733585	0.673	rs4467563	chr4:9953460	A/T	cg11266682	chr4:10021025	SLC2A9	-0.58	-11.0	-0.56	2.04e-23	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs7772486	0.754	rs4360151	chr6:146255079	A/C	cg05347473	chr6:146136440	FBXO30	-0.52	-6.88	-0.39	4.23e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4853012	0.941	rs4852329	chr2:74354544	A/G	cg20891558	chr2:74357851	NA	0.84	10.44	0.54	1.35e-21	Gestational age at birth (maternal effect);
CESC	cis	rs4819052	1.000	rs9306123	chr21:46709922	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.87	11.27	0.57	2.42e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg24327389	chr8:11882982	NA	-0.47	-6.66	-0.38	1.61e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs2439831	0.850	rs28413881	chr15:44174099	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.64	6.52	0.37	3.62e-10	Lung cancer in ever smokers;
CESC	cis	rs10540	1.000	rs61876340	chr11:495699	A/C	cg03576123	chr11:487126	PTDSS2	-1.12	-11.17	-0.57	5.31e-24	Body mass index;
CESC	cis	rs2243480	0.706	rs34466769	chr7:65453292	A/C	cg13147721	chr7:65941812	NA	-0.6	-6.44	-0.37	5.49e-10	Diabetic kidney disease;
CESC	cis	rs7772486	0.701	rs2244308	chr6:146213706	C/T	cg23711669	chr6:146136114	FBXO30	0.82	11.64	0.58	1.47e-25	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs16910800	0.731	rs16910754	chr11:23192015	A/G	cg20040320	chr11:23191996	NA	0.6	5.98	0.34	7.28e-9	Cancer;
CESC	cis	rs3858526	0.959	rs10838901	chr11:5959128	G/A	cg05234568	chr11:5960015	NA	-0.62	-6.78	-0.38	7.84e-11	DNA methylation (variation);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg18149561	chr19:13905866	ZSWIM4	-0.47	-6.44	-0.37	5.44e-10	Fibrinogen levels;
CESC	cis	rs2249625	0.874	rs2254147	chr6:72920943	C/G	cg18830697	chr6:72922368	RIMS1	-0.4	-5.76	-0.33	2.38e-8	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CESC	cis	rs7917772	0.599	rs2863717	chr10:104519829	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.44	-5.1	-0.3	6.44e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22647065	chr19:19612767	GATAD2A	-0.56	-6.24	-0.36	1.74e-9	Gut microbiome composition (summer);
CESC	cis	rs6089584	1.000	rs6089584	chr20:60564086	G/C	cg06108461	chr20:60628389	TAF4	-0.78	-11.45	-0.58	6.38e-25	Body mass index;
CESC	cis	rs898097	0.578	rs2380173	chr17:80909157	G/T	cg15369054	chr17:80825471	TBCD	0.38	5.52	0.32	8e-8	Breast cancer;
CESC	cis	rs262150	0.672	rs2730230	chr7:158788529	A/G	cg19418458	chr7:158789849	NA	-0.4	-6.3	-0.36	1.26e-9	Facial morphology (factor 20);
CESC	cis	rs35110281	0.627	rs11701746	chr21:44975137	C/T	cg04455712	chr21:45112962	RRP1B	0.36	5.42	0.32	1.37e-7	Mean corpuscular volume;
CESC	cis	rs9311474	1.000	rs2276834	chr3:52325759	A/G	cg07507251	chr3:52567010	NT5DC2	0.32	5.6	0.33	5.34e-8	Electroencephalogram traits;
CESC	cis	rs7847628	0.587	rs10760117	chr9:123586737	T/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.45	7.78	0.43	1.61e-13	Birth weight;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13334819	chr7:99746414	C7orf59	0.6	6.94	0.39	2.97e-11	Gut microbiome composition (summer);
CESC	cis	rs9660992	0.547	rs12143121	chr1:205199142	A/G	cg21643547	chr1:205240462	TMCC2	-0.39	-5.51	-0.32	8.53e-8	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs1862618	0.525	rs2662016	chr5:56269047	A/G	cg18230493	chr5:56204884	C5orf35	0.69	8.07	0.44	2.39e-14	Initial pursuit acceleration;
CESC	trans	rs945270	0.512	rs10148235	chr14:56195565	T/C	cg18102697	chr4:83542773	C4orf11	-0.43	-6.41	-0.37	6.52e-10	Subcortical brain region volumes;
CESC	cis	rs589448	0.967	rs2617835	chr12:69753420	C/A	cg20891283	chr12:69753455	YEATS4	1.0	17.29	0.73	2.3e-45	Cerebrospinal fluid biomarker levels;
CESC	cis	rs6456156	0.565	rs6921588	chr6:167494397	G/T	cg07741184	chr6:167504864	NA	0.41	6.55	0.37	3.06e-10	Primary biliary cholangitis;
CESC	cis	rs6942756	1.000	rs73472312	chr7:128925217	T/C	cg02491457	chr7:128862824	NA	-0.67	-8.86	-0.48	1.2e-16	White matter hyperintensity burden;
CESC	cis	rs9486715	0.867	rs2499774	chr6:97006581	C/G	cg18709589	chr6:96969512	KIAA0776	-0.45	-6.32	-0.36	1.1e-9	Headache;
CESC	cis	rs7904368	0.806	rs7087360	chr10:16872337	C/A	cg14835575	chr10:16859367	RSU1	0.48	5.13	0.3	5.58e-7	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
CESC	cis	rs123509	0.913	rs123506	chr3:42775976	T/C	cg12982090	chr3:42733453	KBTBD5	0.7	8.39	0.46	2.89e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs6582630	0.555	rs10880613	chr12:38509553	C/T	cg13010199	chr12:38710504	ALG10B	0.53	6.69	0.38	1.35e-10	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs1182196	0.533	rs2527521	chr7:2904928	A/G	cg09658497	chr7:2847517	GNA12	0.35	5.33	0.31	2.06e-7	Plateletcrit;
CESC	cis	rs11792861	0.926	rs72607163	chr9:111803128	G/T	cg13535736	chr9:111863775	C9orf5	-0.5	-6.57	-0.37	2.63e-10	Menarche (age at onset);
CESC	cis	rs6088590	0.735	rs6060001	chr20:33294353	C/T	cg24642439	chr20:33292090	TP53INP2	-0.64	-8.35	-0.46	3.79e-15	Coronary artery disease;
CESC	trans	rs72766638	0.895	rs72766630	chr9:136926791	G/T	cg10765909	chr12:53715428	AAAS	-0.73	-6.54	-0.37	3.18e-10	Mosquito bite size;
CESC	cis	rs73206853	0.764	rs60027620	chr12:111103669	T/G	cg12870014	chr12:110450643	ANKRD13A	0.65	5.48	0.32	9.72e-8	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs11252926	0.537	rs6560836	chr10:444997	C/T	cg18196295	chr10:418757	DIP2C	0.52	7.01	0.4	2.01e-11	Psychosis in Alzheimer's disease;
CESC	cis	rs477895	0.653	rs34089806	chr11:63887987	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.92	9.97	0.52	4.46e-20	Mean platelet volume;
CESC	cis	rs6426558	0.502	rs10916080	chr1:227232040	A/G	cg10327440	chr1:227177885	CDC42BPA	0.53	6.51	0.37	3.79e-10	Neutrophil percentage of white cells;
CESC	cis	rs67311347	1.000	rs112619360	chr3:40432645	T/G	cg09455208	chr3:40491958	NA	0.41	6.84	0.39	5.6e-11	Renal cell carcinoma;
CESC	cis	rs4434138	0.568	rs6414569	chr3:52708075	A/T	cg07507251	chr3:52567010	NT5DC2	0.32	5.49	0.32	9.27e-8	Intelligence (multi-trait analysis);
CESC	cis	rs763014	0.931	rs2071981	chr16:630025	C/G	cg07256732	chr16:621771	PIGQ	-0.31	-5.38	-0.31	1.61e-7	Height;
CESC	cis	rs4243830	0.510	rs7518459	chr1:6596678	C/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.98	-9.94	-0.52	5.48e-20	Body mass index;
CESC	cis	rs1577917	0.771	rs9294337	chr6:86248460	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.55	7.67	0.43	3.2e-13	Response to antipsychotic treatment;
CESC	cis	rs6502050	0.761	rs9908277	chr17:80060829	T/C	cg23985595	chr17:80112537	CCDC57	0.41	6.27	0.36	1.49e-9	Life satisfaction;
CESC	trans	rs17685	0.633	rs3801471	chr7:75696188	T/G	cg19862616	chr7:65841803	NCRNA00174	0.86	12.43	0.61	2.86e-28	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs736408	0.609	rs2336545	chr3:52787603	C/T	cg07507251	chr3:52567010	NT5DC2	-0.39	-6.87	-0.39	4.44e-11	Bipolar disorder;
CESC	cis	rs10751667	0.666	rs7934963	chr11:957220	C/T	cg06064525	chr11:970664	AP2A2	-0.49	-9.81	-0.52	1.38e-19	Alzheimer's disease (late onset);
CESC	cis	rs11958404	0.932	rs72816542	chr5:157416402	C/T	cg05962755	chr5:157440814	NA	0.62	6.47	0.37	4.68e-10	IgG glycosylation;
CESC	trans	rs634534	0.622	rs531612	chr11:65705432	C/T	cg17712092	chr4:129076599	LARP1B	-0.65	-8.31	-0.45	4.97e-15	Sum eosinophil basophil counts;Eosinophil counts;
CESC	cis	rs1008375	1.000	rs1006722	chr4:17618713	A/G	cg04450456	chr4:17643702	FAM184B	-0.37	-5.29	-0.31	2.51e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs2439831	0.850	rs56909447	chr15:44137618	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.66	6.03	0.35	5.4e-9	Lung cancer in ever smokers;
CESC	cis	rs10465746	0.935	rs4258241	chr1:84437929	G/A	cg10977910	chr1:84465055	TTLL7	0.47	6.32	0.36	1.13e-9	Obesity-related traits;
CESC	cis	rs1552244	0.572	rs73117481	chr3:10160132	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.79	8.79	0.47	1.98e-16	Alzheimer's disease;
CESC	cis	rs17253792	0.558	rs10083353	chr14:56066370	G/T	cg01858014	chr14:56050164	KTN1	-0.86	-6.7	-0.38	1.21e-10	Putamen volume;
CESC	cis	rs5750830	0.594	rs1010169	chr22:39778167	C/T	cg01416388	chr22:39784598	NA	0.58	7.37	0.41	2.2e-12	Intelligence (multi-trait analysis);
CESC	cis	rs11785400	0.793	rs13248524	chr8:143739343	T/C	cg24634471	chr8:143751801	JRK	0.45	5.75	0.33	2.41e-8	Schizophrenia;
CESC	cis	rs4472734	1.000	rs6540832	chr1:214627139	G/A	cg00063699	chr1:214624242	PTPN14	-0.33	-5.05	-0.3	8.33e-7	Height;
CESC	cis	rs9388451	0.874	rs9398787	chr6:126090608	A/G	cg10911889	chr6:126070802	HEY2	0.39	5.38	0.31	1.62e-7	Brugada syndrome;
CESC	cis	rs7945705	0.818	rs2742537	chr11:8908389	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.45	-7.38	-0.41	2.07e-12	Hemoglobin concentration;
CESC	cis	rs2576037	0.562	rs477826	chr18:44397649	A/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.33	5.29	0.31	2.52e-7	Personality dimensions;
CESC	cis	rs7274811	0.711	rs291689	chr20:32003974	A/G	cg21523528	chr20:32077966	CBFA2T2	-0.53	-6.25	-0.36	1.66e-9	Height;
CESC	cis	rs16854884	0.710	rs1867607	chr3:143809274	T/C	cg01302019	chr3:143689584	C3orf58	-0.33	-5.05	-0.3	8.1e-7	Economic and political preferences (feminism/equality);
CESC	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.48	-5.72	-0.33	2.89e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs79839061	0.636	rs73207778	chr4:836762	C/T	cg07828340	chr4:882639	GAK	0.83	5.73	0.33	2.7e-8	Intelligence (multi-trait analysis);
CESC	cis	rs7772486	0.790	rs9390365	chr6:146235626	A/G	cg05347473	chr6:146136440	FBXO30	-0.57	-7.31	-0.41	3.07e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs959260	1.000	rs2033607	chr17:73367288	A/G	cg12999837	chr17:73267436	MIF4GD	-0.46	-5.63	-0.33	4.55e-8	Systemic lupus erythematosus;
CESC	cis	rs4660306	0.672	rs534534	chr1:46024701	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.61	-7.6	-0.42	5.15e-13	Homocysteine levels;
CESC	cis	rs6952808	0.692	rs59619245	chr7:2068630	C/T	cg21782813	chr7:2030301	MAD1L1	0.53	7.71	0.43	2.54e-13	Bipolar disorder and schizophrenia;
CESC	cis	rs4665809	0.590	rs1469523	chr2:26474631	T/A	cg08470875	chr2:26401718	FAM59B	0.75	7.78	0.43	1.63e-13	Gut microbiome composition (summer);
CESC	cis	rs116979167	0.514	rs1706915	chr7:105196437	A/G	cg13798780	chr7:105162888	PUS7	0.52	6.29	0.36	1.28e-9	Bipolar disorder (body mass index interaction);
CESC	cis	rs6968419	0.755	rs3807983	chr7:115898991	T/C	cg02561103	chr7:115862891	TES	-0.41	-5.42	-0.32	1.37e-7	Intraocular pressure;
CESC	cis	rs7666738	0.791	rs62318641	chr4:98816964	T/C	cg17366294	chr4:99064904	C4orf37	0.52	6.98	0.39	2.3e-11	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10479542	0.683	rs7380706	chr5:178961872	C/T	cg05457628	chr5:178986728	RUFY1	0.37	5.06	0.3	7.91e-7	Lung cancer;
CESC	cis	rs8072100	0.651	rs1912484	chr17:45443664	C/G	cg25173405	chr17:45401733	C17orf57	-0.44	-5.48	-0.32	9.98e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs7208859	0.673	rs73277984	chr17:29196133	T/C	cg19761014	chr17:28927070	LRRC37B2	0.63	5.27	0.31	2.88e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs2549003	1.000	rs2548997	chr5:131835395	C/T	cg00255919	chr5:131827918	IRF1	-0.55	-9.23	-0.49	8.9e-18	Asthma (sex interaction);
CESC	cis	rs1552244	0.816	rs13076197	chr3:10019773	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.87	11.29	0.57	2.21e-24	Alzheimer's disease;
CESC	cis	rs7809950	1.000	rs2107713	chr7:107232369	C/T	cg23024343	chr7:107201750	COG5	-0.4	-5.26	-0.31	3e-7	Coronary artery disease;
CESC	cis	rs4662945	0.603	rs1453147	chr2:130271510	A/C	cg05962382	chr2:130345044	NA	-0.42	-5.94	-0.34	9.16e-9	Response to cytidine analogues (gemcitabine);
CESC	cis	rs514406	0.861	rs503296	chr1:53283088	A/G	cg24675658	chr1:53192096	ZYG11B	0.56	7.0	0.4	2.04e-11	Monocyte count;
CESC	cis	rs921968	0.643	rs532475	chr2:219434208	C/T	cg02176678	chr2:219576539	TTLL4	0.41	7.15	0.4	8.68e-12	Mean corpuscular hemoglobin concentration;
CESC	cis	rs367943	0.799	rs10057321	chr5:112974729	A/G	cg12552261	chr5:112820674	MCC	0.54	6.14	0.35	2.99e-9	Type 2 diabetes;
CESC	cis	rs2439831	0.681	rs7168940	chr15:43633334	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.85	12.61	0.61	7.13e-29	Lung cancer in ever smokers;
CESC	cis	rs910316	1.000	rs12889309	chr14:75593902	C/T	cg08847533	chr14:75593920	NEK9	1.02	20.32	0.78	5.6e-56	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08151832	chr16:66835414	CCDC79	-0.75	-8.9	-0.48	9.32e-17	Gut microbiome composition (summer);
CESC	cis	rs2842992	0.915	rs2842958	chr6:160108425	A/G	cg11366901	chr6:160182831	ACAT2	0.76	9.59	0.51	7.1e-19	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs2731664	0.721	rs2450333	chr5:176899546	G/A	cg23176889	chr5:176863531	GRK6	-0.64	-11.42	-0.57	7.61e-25	Intelligence (multi-trait analysis);
CESC	cis	rs17376456	0.569	rs6556839	chr5:93206292	T/C	cg25358565	chr5:93447407	FAM172A	-0.7	-7.43	-0.42	1.45e-12	Diabetic retinopathy;
CESC	cis	rs17253792	0.822	rs77415412	chr14:56154146	A/G	cg01858014	chr14:56050164	KTN1	-0.97	-7.54	-0.42	7.36e-13	Putamen volume;
CESC	trans	rs561341	1.000	rs2344312	chr17:30243583	G/T	cg20587970	chr11:113659929	NA	-0.83	-10.33	-0.54	3.1e-21	Hip circumference adjusted for BMI;
CESC	trans	rs877282	0.797	rs11253329	chr10:753200	A/T	cg22713356	chr15:30763199	NA	0.93	8.39	0.46	3e-15	Uric acid levels;
CESC	cis	rs2839186	0.721	rs3788252	chr21:47661235	C/T	cg11766577	chr21:47581405	C21orf56	-0.46	-6.23	-0.36	1.84e-9	Testicular germ cell tumor;
CESC	cis	rs7605827	0.930	rs6431709	chr2:15638296	T/C	cg19274914	chr2:15703543	NA	0.34	6.03	0.35	5.48e-9	Educational attainment (years of education);
CESC	cis	rs1348850	0.632	rs11682717	chr2:178499240	C/G	cg23306229	chr2:178417860	TTC30B	0.6	7.47	0.42	1.17e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs7618915	0.501	rs13085775	chr3:52678370	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	7.64	0.42	4.02e-13	Bipolar disorder;
CESC	trans	rs11250098	0.574	rs4554431	chr8:10771638	T/A	cg15556689	chr8:8085844	FLJ10661	-0.55	-6.79	-0.38	7.52e-11	Morning vs. evening chronotype;
CESC	cis	rs7274811	0.681	rs291674	chr20:31954890	C/G	cg21523528	chr20:32077966	CBFA2T2	-0.53	-6.27	-0.36	1.48e-9	Height;
CESC	cis	rs2404602	0.618	rs12442266	chr15:76567142	T/C	cg05617483	chr15:76483344	C15orf27	0.4	5.42	0.32	1.34e-7	Blood metabolite levels;
CESC	cis	rs12900413	0.603	rs12907030	chr15:90301439	C/T	cg24249390	chr15:90295951	MESP1	-0.4	-5.36	-0.31	1.79e-7	Coronary artery aneurysm in Kawasaki disease;
CESC	cis	rs12477438	0.798	rs6740267	chr2:99561867	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.73	-10.77	-0.55	1.13e-22	Chronic sinus infection;
CESC	cis	rs2576037	0.796	rs2571033	chr18:44578552	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.33	-5.13	-0.3	5.49e-7	Personality dimensions;
CESC	cis	rs1595825	0.945	rs59553483	chr2:198855201	T/C	cg00982548	chr2:198649783	BOLL	-0.46	-5.26	-0.31	2.96e-7	Ulcerative colitis;
CESC	cis	rs818427	0.896	rs458451	chr5:112224331	T/C	cg07820702	chr5:112228657	REEP5	-0.43	-5.36	-0.31	1.85e-7	Total body bone mineral density;
CESC	cis	rs2072499	0.838	rs2758619	chr1:156162559	A/G	cg06970220	chr1:156163860	SLC25A44	0.39	5.23	0.31	3.48e-7	Testicular germ cell tumor;
CESC	cis	rs7666738	0.791	rs10856933	chr4:98958542	C/A	cg03676636	chr4:99064102	C4orf37	0.33	5.11	0.3	6.05e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6540559	1.000	rs12070337	chr1:209992127	G/A	cg10074409	chr1:209979377	IRF6	0.4	6.3	0.36	1.2e-9	Cleft lip with or without cleft palate;
CESC	cis	rs875971	0.862	rs1981799	chr7:65955559	T/C	cg12463550	chr7:65579703	CRCP	0.55	6.86	0.39	4.77e-11	Aortic root size;
CESC	cis	rs4595586	0.545	rs7308161	chr12:39363459	A/G	cg26384229	chr12:38710491	ALG10B	0.47	6.59	0.38	2.39e-10	Morning vs. evening chronotype;
CESC	cis	rs793571	0.590	rs347115	chr15:59082959	C/T	cg05156742	chr15:59063176	FAM63B	0.63	8.29	0.45	5.64e-15	Schizophrenia;
CESC	cis	rs10504229	0.593	rs17794451	chr8:58019217	C/T	cg22535103	chr8:58192502	C8orf71	-0.9	-8.95	-0.48	6.29e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs546131	0.928	rs535719	chr11:34853382	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.53	6.88	0.39	4.38e-11	Lung disease severity in cystic fibrosis;
CESC	cis	rs13114435	0.723	rs17331744	chr4:183815561	T/C	cg00486011	chr4:183851557	NA	0.37	5.37	0.31	1.76e-7	Obesity-related traits;
CESC	cis	rs853679	0.607	rs17763089	chr6:27835218	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.75	-5.22	-0.31	3.68e-7	Depression;
CESC	trans	rs6693388	0.647	rs2999508	chr1:151934447	A/C	cg26164907	chr7:155616192	NA	-0.31	-6.12	-0.35	3.43e-9	Blood metabolite ratios;
CESC	cis	rs936229	0.690	rs2445618	chr15:75035256	T/C	cg14664628	chr15:75095509	CSK	-0.8	-10.89	-0.56	4.5e-23	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CESC	cis	rs7618915	0.501	rs3733041	chr3:52731598	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.61	8.78	0.47	2.04e-16	Bipolar disorder;
CESC	cis	rs965469	1.000	rs1040727	chr20:3264292	G/A	cg25506879	chr20:3388711	C20orf194	-0.58	-6.06	-0.35	4.6e-9	IFN-related cytopenia;
CESC	cis	rs2066819	1.000	rs79750959	chr12:56702012	C/A	cg26734620	chr12:56694298	CS	1.03	6.25	0.36	1.65e-9	Psoriasis vulgaris;
CESC	cis	rs1915146	0.967	rs7086481	chr10:126844523	A/T	cg00406319	chr10:126851303	NA	-0.47	-7.55	-0.42	6.88e-13	Menarche (age at onset);
CESC	cis	rs7618915	0.524	rs35249778	chr3:52661640	G/C	cg17372223	chr3:52568218	NT5DC2	0.43	6.43	0.37	5.88e-10	Bipolar disorder;
CESC	cis	rs7520050	0.966	rs6672898	chr1:46290588	G/A	cg03146154	chr1:46216737	IPP	-0.47	-6.15	-0.35	2.87e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs113835537	0.529	rs11227510	chr11:66281220	T/C	cg24851651	chr11:66362959	CCS	0.45	5.55	0.32	6.92e-8	Airway imaging phenotypes;
CESC	cis	rs9926296	0.585	rs4785595	chr16:89835521	C/T	cg07648498	chr16:89883185	FANCA	-0.42	-5.07	-0.3	7.51e-7	Vitiligo;
CESC	cis	rs2011503	1.000	rs34667451	chr19:19617017	C/T	cg11584989	chr19:19387371	SF4	0.62	7.13	0.4	9.66e-12	Bipolar disorder;
CESC	cis	rs735860	0.572	rs186003	chr6:53185124	A/C	cg10236188	chr6:53219634	NA	0.35	5.21	0.3	3.89e-7	Glaucoma;
CESC	cis	rs7107174	0.892	rs10899490	chr11:78105879	C/T	cg02023728	chr11:77925099	USP35	0.39	5.4	0.31	1.49e-7	Testicular germ cell tumor;
CESC	cis	rs9399401	0.710	rs7765770	chr6:142687305	C/T	cg04461802	chr6:142623433	GPR126	0.36	5.31	0.31	2.29e-7	Chronic obstructive pulmonary disease;
CESC	cis	rs2836950	0.565	rs7279497	chr21:40531306	A/G	cg11890956	chr21:40555474	PSMG1	0.61	8.63	0.47	5.77e-16	Menarche (age at onset);
CESC	cis	rs2839186	0.500	rs13052701	chr21:47660045	A/T	cg02776659	chr21:47717406	C21orf57	-0.37	-5.1	-0.3	6.38e-7	Testicular germ cell tumor;
CESC	cis	rs863345	0.584	rs6657638	chr1:158497184	C/G	cg12129480	chr1:158549410	OR10X1	-0.35	-6.86	-0.39	4.78e-11	Pneumococcal bacteremia;
CESC	cis	rs477692	0.673	rs487120	chr10:131367552	C/T	cg05714579	chr10:131428358	MGMT	0.44	5.73	0.33	2.69e-8	Response to temozolomide;
CESC	cis	rs3785574	0.962	rs2665842	chr17:61878535	G/A	cg07677032	chr17:61819896	STRADA	0.41	5.17	0.3	4.59e-7	Height;
CESC	cis	rs2880765	0.835	rs4843062	chr15:86040137	A/G	cg19183879	chr15:85880815	NA	-0.26	-5.38	-0.31	1.6e-7	Coronary artery disease;
CESC	cis	rs6831352	0.918	rs28987088	chr4:100059139	T/C	cg13256891	chr4:100009986	ADH5	-0.77	-8.45	-0.46	1.97e-15	Alcohol dependence;
CESC	cis	rs941873	0.900	rs4979861	chr10:81131595	A/G	cg09469691	chr10:81107165	PPIF	0.54	7.07	0.4	1.36e-11	Height;
CESC	cis	rs7809799	1.000	rs7809799	chr7:98760504	G/A	cg05967295	chr7:98741636	SMURF1	-0.78	-5.45	-0.32	1.17e-7	Ulcerative colitis;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg06376129	chr1:205180539	DSTYK	-0.42	-6.04	-0.35	5.29e-9	Fibrinogen levels;
CESC	cis	rs1256061	0.603	rs1256045	chr14:64729760	A/C	cg23250157	chr14:64679961	SYNE2	0.53	7.64	0.42	4.09e-13	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg11301795	chr4:187892539	NA	-0.75	-12.33	-0.6	6.74e-28	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs8114671	0.562	rs6087642	chr20:33468306	T/C	cg24642439	chr20:33292090	TP53INP2	0.42	5.16	0.3	4.83e-7	Height;
CESC	cis	rs7834588	0.523	rs4512370	chr8:63829835	C/T	cg20602954	chr8:63776762	NKAIN3	0.3	5.04	0.3	8.69e-7	Response to Vitamin E supplementation;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06866400	chr6:143771904	ADAT2;PEX3	0.61	7.16	0.4	8.03e-12	Gut microbiome composition (summer);
CESC	cis	rs6500395	1.000	rs2355297	chr16:48685338	T/C	cg04672837	chr16:48644449	N4BP1	-0.51	-6.36	-0.36	8.64e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs4523957	0.579	rs903161	chr17:2092006	A/T	cg16513277	chr17:2031491	SMG6	-0.62	-8.71	-0.47	3.3e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs2404618	0.624	rs4338133	chr8:1477507	T/C	cg13402656	chr8:1511478	DLGAP2	-0.52	-7.23	-0.41	5.24e-12	Lung cancer;
CESC	cis	rs2658782	0.507	rs4457713	chr11:93037430	C/T	cg15737290	chr11:93063684	CCDC67	0.52	7.21	0.4	5.96e-12	Pulmonary function decline;
CESC	cis	rs875971	0.862	rs2420174	chr7:65645361	C/T	cg18876405	chr7:65276391	NA	-0.53	-7.38	-0.41	2.09e-12	Aortic root size;
CESC	cis	rs3091242	0.933	rs35497030	chr1:25783066	A/G	cg12412775	chr1:25698385	RHCE	0.3	5.31	0.31	2.36e-7	Erythrocyte sedimentation rate;
CESC	cis	rs7772486	0.875	rs9322046	chr6:146393625	A/G	cg05347473	chr6:146136440	FBXO30	0.5	6.92	0.39	3.47e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4906332	1.000	rs17617832	chr14:103943140	T/C	cg09975044	chr14:104007538	NA	0.47	6.39	0.37	7.49e-10	Coronary artery disease;
CESC	cis	rs17376456	0.825	rs10053405	chr5:93275403	A/G	cg25358565	chr5:93447407	FAM172A	-1.08	-9.43	-0.5	2.2e-18	Diabetic retinopathy;
CESC	cis	rs9914988	0.943	rs9907178	chr17:27124307	G/C	cg20469991	chr17:27169893	C17orf63	-0.47	-5.18	-0.3	4.35e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CESC	cis	rs6121246	0.909	rs6089058	chr20:30326338	T/G	cg13852791	chr20:30311386	BCL2L1	0.82	8.74	0.47	2.63e-16	Mean corpuscular hemoglobin;
CESC	cis	rs2933343	0.679	rs789254	chr3:128574593	A/G	cg25356066	chr3:128598488	ACAD9	0.6	8.4	0.46	2.69e-15	IgG glycosylation;
CESC	cis	rs67311347	0.910	rs7651204	chr3:40512835	C/T	cg09455208	chr3:40491958	NA	-0.49	-8.32	-0.46	4.59e-15	Renal cell carcinoma;
CESC	cis	rs7223966	1.000	rs15637	chr17:61772050	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.58	7.44	0.42	1.42e-12	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs362272	0.545	rs2749785	chr4:3325179	G/C	cg14583973	chr4:3374767	RGS12	0.33	5.7	0.33	3.26e-8	Serum sulfate level;
CESC	cis	rs1023500	0.573	rs6002592	chr22:42476754	A/C	cg15557168	chr22:42548783	NA	0.44	6.19	0.36	2.31e-9	Schizophrenia;
CESC	cis	rs3815700	1.000	rs8113165	chr19:33096316	C/T	cg02997394	chr19:33096574	ANKRD27	0.71	7.28	0.41	3.78e-12	Eosinophilic esophagitis;
CESC	cis	rs769267	0.896	rs11882123	chr19:19386339	A/G	cg03709012	chr19:19516395	GATAD2A	0.96	14.18	0.66	2.35e-34	Tonsillectomy;
CESC	cis	rs9611565	0.649	rs202645	chr22:41798520	A/G	cg03806693	chr22:41940476	POLR3H	1.2	14.89	0.68	7.3e-37	Vitiligo;
CESC	cis	rs7666738	0.830	rs7659420	chr4:98878714	G/C	cg17366294	chr4:99064904	C4orf37	0.56	7.84	0.43	1.13e-13	Colonoscopy-negative controls vs population controls;
CESC	trans	rs17181170	0.595	rs6798262	chr3:87208779	A/T	ch.2.199792288R	chr2:200084043	NA	-0.46	-6.02	-0.35	5.93e-9	Prostate cancer;
CESC	cis	rs5753618	0.583	rs5753612	chr22:31821479	T/C	cg13145458	chr22:31556086	RNF185	-0.5	-5.96	-0.34	7.96e-9	Colorectal cancer;
CESC	cis	rs2880765	0.835	rs11633604	chr15:86031579	T/G	cg10818794	chr15:86012489	AKAP13	-0.35	-5.42	-0.32	1.32e-7	Coronary artery disease;
CESC	cis	rs3740713	1.000	rs75740864	chr11:18470689	C/G	cg23797887	chr11:18477753	LDHAL6A	-0.52	-5.1	-0.3	6.32e-7	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs367943	0.603	rs1864066	chr5:112997865	C/T	cg12552261	chr5:112820674	MCC	0.45	5.78	0.33	2.08e-8	Type 2 diabetes;
CESC	cis	rs9911578	0.904	rs7209253	chr17:56908987	C/T	cg05425664	chr17:57184151	TRIM37	-0.5	-6.92	-0.39	3.44e-11	Intelligence (multi-trait analysis);
CESC	cis	rs853679	0.517	rs9368556	chr6:28131153	T/C	cg19592336	chr6:28129416	ZNF389	0.61	8.03	0.44	3.13e-14	Depression;
CESC	cis	rs6502050	0.835	rs67149434	chr17:80128007	G/A	cg23985595	chr17:80112537	CCDC57	-0.41	-6.57	-0.37	2.61e-10	Life satisfaction;
CESC	cis	rs6089829	0.855	rs6090205	chr20:61665269	A/G	cg16240275	chr20:61666158	NCRNA00029	0.5	8.96	0.48	6.1e-17	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs2235642	0.685	rs2667681	chr16:1653206	C/T	cg03771183	chr16:1608904	IFT140	0.38	5.56	0.32	6.72e-8	Coronary artery disease;
CESC	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg12419862	chr22:24373484	LOC391322	-0.72	-9.94	-0.52	5.32e-20	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs7772486	0.875	rs6570738	chr6:146412695	G/A	cg23711669	chr6:146136114	FBXO30	0.77	11.23	0.57	3.4e-24	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg07308232	chr7:1071921	C7orf50	-0.41	-5.46	-0.32	1.12e-7	Longevity;Endometriosis;
CESC	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg24642844	chr7:1081250	C7orf50	-0.76	-9.26	-0.49	7.23e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs250677	0.687	rs384979	chr5:148459267	C/T	cg18129178	chr5:148520854	ABLIM3	0.51	5.99	0.35	6.91e-9	Breast cancer;
CESC	cis	rs5769707	0.681	rs135879	chr22:50018651	C/T	cg20744362	chr22:50050164	C22orf34	0.39	6.07	0.35	4.52e-9	Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs16857609	0.564	rs12232972	chr2:218257272	C/T	cg15335768	chr2:218268053	DIRC3	-0.4	-5.69	-0.33	3.32e-8	Breast cancer;Breast cancer (estrogen-receptor negative);
CESC	cis	rs10089	0.953	rs4836359	chr5:127385518	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.78	10.15	0.53	1.14e-20	Ileal carcinoids;
CESC	cis	rs6032067	0.929	rs34412950	chr20:43805132	C/A	cg11264863	chr20:43835661	SEMG1	0.51	5.56	0.32	6.63e-8	Blood protein levels;
CESC	cis	rs854765	0.583	rs4077198	chr17:17834563	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.57	8.17	0.45	1.29e-14	Total body bone mineral density;
CESC	trans	rs17764205	0.777	rs10424519	chr19:3253532	C/G	cg22364819	chr2:127864926	BIN1	-0.7	-6.01	-0.35	6.17e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs763121	0.853	rs9306329	chr22:39072454	C/T	cg14440974	chr22:39074834	NA	-0.42	-5.89	-0.34	1.14e-8	Menopause (age at onset);
CESC	cis	rs4790333	0.845	rs7210932	chr17:2272024	A/G	cg02569219	chr17:2266849	SGSM2	-0.48	-6.82	-0.39	6.18e-11	Proinsulin levels;
CESC	cis	rs45535039	1.000	rs7946919	chr11:119140832	A/G	cg16724696	chr11:118992527	HINFP	0.44	5.32	0.31	2.2e-7	Plateletcrit;
CESC	cis	rs8062405	1.000	rs55991577	chr16:28843025	C/T	cg08761264	chr16:28874980	SH2B1	-0.45	-5.67	-0.33	3.78e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs2985684	0.901	rs57119148	chr14:50097226	T/C	cg02151108	chr14:50098012	C14orf104	-0.41	-5.48	-0.32	9.72e-8	Carotid intima media thickness;
CESC	cis	rs60871478	0.730	rs62432226	chr7:792973	T/C	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.61	5.89	0.34	1.14e-8	Cerebrospinal P-tau181p levels;
CESC	cis	rs6493487	0.512	rs80355962	chr15:51142997	C/T	cg02338191	chr15:51200825	AP4E1	0.58	5.73	0.33	2.69e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs9325144	0.647	rs11168819	chr12:39011082	C/A	cg26384229	chr12:38710491	ALG10B	-0.54	-7.52	-0.42	8.38e-13	Morning vs. evening chronotype;
CESC	cis	rs3820928	1.000	rs61067328	chr2:227761256	G/A	cg05526886	chr2:227700861	RHBDD1	-0.42	-5.37	-0.31	1.69e-7	Pulmonary function;
CESC	cis	rs6502050	0.835	rs8065565	chr17:80115399	A/G	cg23985595	chr17:80112537	CCDC57	-0.41	-6.52	-0.37	3.5e-10	Life satisfaction;
CESC	cis	rs7208859	0.623	rs60890550	chr17:29030861	A/G	cg19761014	chr17:28927070	LRRC37B2	0.77	6.17	0.35	2.5e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs7116495	0.609	rs1541304	chr11:71714078	T/C	cg26138937	chr11:71823887	C11orf51	-1.31	-8.57	-0.47	8.45e-16	Severe influenza A (H1N1) infection;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg09373211	chr1:154193749	C1orf43;UBAP2L	0.49	6.2	0.36	2.21e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg00862481	chr16:29998852	TAOK2	0.48	6.84	0.39	5.41e-11	Fibrinogen levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18229107	chr14:64854676	MTHFD1	0.58	6.2	0.36	2.17e-9	Gut microbiome composition (summer);
CESC	cis	rs1218582	0.741	rs2335407	chr1:154843347	A/G	cg09359103	chr1:154839909	KCNN3	0.71	13.61	0.64	2.38e-32	Prostate cancer;
CESC	cis	rs34779708	0.931	rs34876468	chr10:35424450	G/A	cg04310649	chr10:35416472	CREM	-0.5	-6.04	-0.35	5.31e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs7631605	0.875	rs56304874	chr3:37245983	G/T	cg22985146	chr3:37219077	LRRFIP2	-0.35	-5.64	-0.33	4.33e-8	Cerebrospinal P-tau181p levels;
CESC	cis	rs751837	0.591	rs10138133	chr14:103424897	A/G	cg10087771	chr14:103399429	CDC42BPB	0.54	5.13	0.3	5.73e-7	Large B-cell lymphoma;
CESC	cis	rs7264396	0.616	rs6142476	chr20:34581216	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-8.75	-0.47	2.58e-16	Total cholesterol levels;
CESC	cis	rs9987353	0.589	rs1053036	chr8:9060077	A/G	cg06636001	chr8:8085503	FLJ10661	-0.55	-6.71	-0.38	1.14e-10	Recombination measurement;
CESC	cis	rs10129255	0.500	rs34326748	chr14:107190760	G/C	cg07958169	chr14:107095056	NA	-0.54	-8.29	-0.45	5.63e-15	Kawasaki disease;
CESC	cis	rs3091242	0.967	rs1053438	chr1:25687901	T/C	cg02931644	chr1:25747376	RHCE	-0.4	-6.53	-0.37	3.35e-10	Erythrocyte sedimentation rate;
CESC	cis	rs17711722	0.653	rs2460421	chr7:65491123	A/T	cg06456125	chr7:65229604	NA	-0.43	-5.77	-0.33	2.18e-8	Calcium levels;
CESC	cis	rs1005277	0.579	rs2474584	chr10:38416389	C/T	cg00409905	chr10:38381863	ZNF37A	-0.48	-6.39	-0.37	7.35e-10	Extrinsic epigenetic age acceleration;
CESC	cis	rs4722166	0.532	rs6963866	chr7:22757341	C/T	cg05472934	chr7:22766657	IL6	0.49	6.38	0.36	7.9e-10	Lung cancer;
CESC	cis	rs9300255	0.722	rs11830103	chr12:123823546	A/G	cg19016782	chr12:123741754	C12orf65	0.44	6.2	0.36	2.22e-9	Neutrophil percentage of white cells;
CESC	cis	rs5750830	0.621	rs743838	chr22:39824707	T/G	cg11247378	chr22:39784982	NA	-0.62	-8.9	-0.48	9.2e-17	Intelligence (multi-trait analysis);
CESC	cis	rs3092073	0.624	rs11696196	chr20:44574533	C/T	cg00981651	chr20:44574847	PCIF1	0.36	5.26	0.31	2.98e-7	Intelligence (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07867023	chr3:51428648	RBM15B	0.58	6.18	0.35	2.41e-9	Gut microbiome composition (summer);
CESC	cis	rs57677839	1	rs57677839	chr11:17028189	G/A	cg15084286	chr11:17036142	PLEKHA7	1.04	17.83	0.74	2.95e-47	Coronary artery disease;
CESC	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg03452623	chr4:187889614	NA	-0.88	-15.91	-0.7	1.82e-40	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1018836	0.608	rs10111060	chr8:91491152	T/C	cg16814680	chr8:91681699	NA	-0.55	-7.66	-0.43	3.56e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs9916302	0.904	rs7223331	chr17:37482930	A/G	cg07936489	chr17:37558343	FBXL20	0.8	11.69	0.58	9.64e-26	Glomerular filtration rate (creatinine);
CESC	cis	rs3540	0.533	rs12708585	chr15:91052285	C/T	cg10434728	chr15:90938212	IQGAP1	-0.41	-7.26	-0.41	4.35e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	trans	rs629535	0.773	rs489206	chr8:70064883	T/C	cg21567404	chr3:27674614	NA	0.89	10.5	0.54	8.86e-22	Dupuytren's disease;
CESC	cis	rs7208859	0.623	rs383436	chr17:28959179	A/G	cg13385521	chr17:29058706	SUZ12P	0.75	5.43	0.32	1.27e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs7598759	0.527	rs12987949	chr2:232367511	A/G	cg19187155	chr2:232395269	NMUR1	0.61	10.12	0.53	1.43e-20	Noise-induced hearing loss;
CESC	cis	rs1707322	1.000	rs4660334	chr1:46462126	A/C	cg06784218	chr1:46089804	CCDC17	0.33	5.74	0.33	2.61e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs12579753	0.719	rs4418884	chr12:82277006	C/T	cg23701643	chr12:82153290	PPFIA2	-0.37	-5.4	-0.31	1.48e-7	Resting heart rate;
CESC	cis	rs910316	1.000	rs11159117	chr14:75584867	C/T	cg16144293	chr14:75469539	EIF2B2	-0.4	-5.15	-0.3	5.11e-7	Height;
CESC	cis	rs769267	0.930	rs1054284	chr19:19616953	T/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.59	7.4	0.41	1.75e-12	Tonsillectomy;
CESC	cis	rs4268898	0.662	rs9784114	chr2:24437517	C/T	cg08917208	chr2:24149416	ATAD2B	0.55	5.27	0.31	2.89e-7	Asthma;
CESC	cis	rs8170	0.603	rs3810204	chr19:17448660	T/C	cg04749549	chr19:17459798	NA	-0.33	-5.23	-0.31	3.52e-7	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
CESC	trans	rs10506458	0.915	rs998506	chr12:63400017	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.34	-18.35	-0.75	4.19e-49	Hemostatic factors and hematological phenotypes;
CESC	cis	rs1862618	0.802	rs194058	chr5:56188977	G/A	cg24531977	chr5:56204891	C5orf35	-0.88	-11.2	-0.57	4.22e-24	Initial pursuit acceleration;
CESC	cis	rs10791323	0.569	rs10750541	chr11:133713189	A/C	cg06766960	chr11:133703094	NA	0.38	5.17	0.3	4.52e-7	Childhood ear infection;
CESC	cis	rs12681366	0.708	rs12680029	chr8:95404646	T/C	cg13257157	chr8:95487014	RAD54B	0.39	5.21	0.3	3.82e-7	Nonsyndromic cleft lip with cleft palate;
CESC	cis	rs965469	1.000	rs6051709	chr20:3263685	T/C	cg25506879	chr20:3388711	C20orf194	-0.55	-5.98	-0.35	7.01e-9	IFN-related cytopenia;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg19630242	chr6:163987817	QKI	0.43	6.87	0.39	4.5e-11	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs938554	0.513	rs4529048	chr4:9997112	G/T	cg11266682	chr4:10021025	SLC2A9	0.46	6.96	0.39	2.6e-11	Blood metabolite levels;
CESC	cis	rs17125944	0.505	rs75838476	chr14:53242362	G/A	cg00686598	chr14:53173677	PSMC6	1.42	11.99	0.59	9.42e-27	Alzheimer's disease (late onset);
CESC	cis	rs13343954	0.518	rs7252086	chr19:33534929	T/C	cg27124370	chr19:33622961	WDR88	0.5	6.65	0.38	1.63e-10	Colorectal cancer;
CESC	cis	rs9322193	0.923	rs9383812	chr6:150033491	C/T	cg09699651	chr6:150184138	LRP11	0.42	5.48	0.32	1.01e-7	Lung cancer;
CESC	cis	rs736408	0.609	rs2336545	chr3:52787603	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	-0.4	-7.16	-0.4	8.12e-12	Bipolar disorder;
CESC	cis	rs6866344	0.570	rs1071881	chr5:178135917	C/T	cg10224037	chr5:178157518	ZNF354A	0.72	8.53	0.46	1.11e-15	Neutrophil percentage of white cells;
CESC	cis	rs3820068	0.532	rs6701009	chr1:15935614	T/C	cg16988262	chr1:15930761	NA	0.32	5.24	0.31	3.34e-7	Systolic blood pressure;
CESC	cis	rs1348850	0.872	rs7559521	chr2:178452328	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.61	-8.16	-0.45	1.36e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09435861	chr6:110968114	CDK19	-0.59	-7.09	-0.4	1.19e-11	Gut microbiome composition (summer);
CESC	cis	rs10256972	0.967	rs4723338	chr7:1036241	A/G	cg04025307	chr7:1156635	C7orf50	0.4	6.31	0.36	1.19e-9	Longevity;Endometriosis;
CESC	cis	rs1003719	0.788	rs2835582	chr21:38458773	C/G	cg10648535	chr21:38446584	PIGP;TTC3	0.63	8.72	0.47	3.19e-16	Eye color traits;
CESC	cis	rs6580649	0.941	rs4589362	chr12:48478664	T/C	cg24011408	chr12:48396354	COL2A1	-0.4	-5.04	-0.3	8.67e-7	Lung cancer;
CESC	cis	rs10911232	0.507	rs12037585	chr1:183000041	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.84	13.19	0.63	6.74e-31	Hypertriglyceridemia;
CESC	cis	rs7666738	0.791	rs6840669	chr4:99016020	G/T	cg05340658	chr4:99064831	C4orf37	0.8	12.51	0.61	1.52e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs523522	0.923	rs3916065	chr12:120934624	A/C	cg12219531	chr12:120966889	COQ5	0.75	9.99	0.52	3.7e-20	High light scatter reticulocyte count;
CESC	trans	rs931812	0.691	rs884488	chr8:101898523	C/G	cg20993868	chr7:22813445	NA	0.4	5.99	0.35	6.7e-9	Attention deficit hyperactivity disorder and conduct disorder;
CESC	cis	rs11122272	0.735	rs2790881	chr1:231534181	A/G	cg06096015	chr1:231504339	EGLN1	0.43	6.15	0.35	2.9e-9	Hemoglobin concentration;
CESC	cis	rs2228479	0.717	rs2074904	chr16:89811546	A/G	cg00800038	chr16:89945340	TCF25	-0.9	-7.51	-0.42	9.11e-13	Skin colour saturation;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04504578	chr17:36831313	C17orf96	-0.53	-6.06	-0.35	4.56e-9	Gut microbiome composition (summer);
CESC	cis	rs9911578	0.967	rs3826353	chr17:57075299	C/T	cg12560992	chr17:57184187	TRIM37	0.98	16.9	0.72	5.45e-44	Intelligence (multi-trait analysis);
CESC	cis	rs7116495	0.529	rs575871	chr11:71778822	A/G	cg10381502	chr11:71823885	C11orf51	-0.81	-6.21	-0.36	2.06e-9	Severe influenza A (H1N1) infection;
CESC	cis	rs12477438	0.735	rs12474477	chr2:99690408	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-10.52	-0.54	7.38e-22	Chronic sinus infection;
CESC	cis	rs1152591	0.562	rs1272715	chr14:64651989	A/T	cg23250157	chr14:64679961	SYNE2	0.39	5.48	0.32	1e-7	Atrial fibrillation;
CESC	cis	rs2370759	1.000	rs2225152	chr10:32574759	T/C	cg01819863	chr10:32635814	EPC1	1.17	13.3	0.63	2.82e-31	Sexual dysfunction (female);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg02294791	chr11:1855606	SYT8	0.34	6.05	0.35	4.96e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs644799	1.000	rs543530	chr11:95545170	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.92	13.87	0.65	2.93e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs10744422	0.858	rs7980541	chr12:123379477	C/T	cg25930673	chr12:123319894	HIP1R	-0.66	-5.16	-0.3	4.93e-7	Schizophrenia;
CESC	cis	rs4601790	0.601	rs66864335	chr11:65390803	G/A	cg24147428	chr11:65409760	SIPA1	-0.42	-5.9	-0.34	1.11e-8	Blood pressure (age interaction);
CESC	cis	rs2625529	0.503	rs7162299	chr15:72414065	A/G	cg16672083	chr15:72433130	SENP8	0.46	7.13	0.4	9.41e-12	Red blood cell count;
CESC	cis	rs1005277	0.579	rs1740745	chr10:38520056	T/C	cg25427524	chr10:38739819	LOC399744	-0.73	-10.95	-0.56	2.97e-23	Extrinsic epigenetic age acceleration;
CESC	cis	rs1862618	0.853	rs252921	chr5:56137787	G/A	cg18230493	chr5:56204884	C5orf35	-0.74	-9.05	-0.49	3.27e-17	Initial pursuit acceleration;
CESC	trans	rs2090104	0.739	rs4834203	chr4:128488553	A/G	cg23537305	chr3:29355071	RBMS3	0.39	6.11	0.35	3.52e-9	IgG glycosylation;
CESC	cis	rs13108904	0.557	rs1680033	chr4:1243404	C/T	cg19318889	chr4:1322082	MAEA	-0.48	-6.18	-0.36	2.38e-9	Obesity-related traits;
CESC	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	22.16	0.81	2.75e-62	Prudent dietary pattern;
CESC	cis	rs6912958	0.712	rs2307379	chr6:88366771	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.51	-6.79	-0.38	7.55e-11	Monocyte percentage of white cells;
CESC	cis	rs3780486	0.757	rs10758189	chr9:33125804	A/G	cg13443165	chr9:33130375	B4GALT1	0.44	6.29	0.36	1.29e-9	IgG glycosylation;
CESC	cis	rs7666738	0.791	rs7377018	chr4:99034962	C/T	cg03467027	chr4:99064603	C4orf37	0.48	6.05	0.35	4.87e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs477692	1.000	rs538969	chr10:131410608	C/T	cg05714579	chr10:131428358	MGMT	0.48	6.48	0.37	4.34e-10	Response to temozolomide;
CESC	cis	rs17345786	0.906	rs56171035	chr3:101111108	G/C	cg11279151	chr3:101281821	RG9MTD1	-0.45	-5.06	-0.3	7.87e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6952808	0.630	rs1860832	chr7:2161849	G/A	cg23048001	chr7:2026167	MAD1L1	0.46	5.93	0.34	9.5e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs1707322	0.716	rs6699444	chr1:46135120	G/C	cg03146154	chr1:46216737	IPP	0.82	11.51	0.58	3.87e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs1008375	0.900	rs6851783	chr4:17578469	A/G	cg02297831	chr4:17616191	MED28	0.52	6.01	0.35	6.19e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs7618915	0.501	rs2336146	chr3:52626646	A/G	cg05564831	chr3:52568323	NT5DC2	0.48	7.64	0.42	4.06e-13	Bipolar disorder;
CESC	cis	rs7894051	1.000	rs11101721	chr10:135190358	C/G	cg12428399	chr10:135191333	PAOX	0.58	5.05	0.3	8.42e-7	Lifespan;
CESC	trans	rs877282	0.898	rs11253340	chr10:764786	G/T	cg22713356	chr15:30763199	NA	1.16	11.35	0.57	1.37e-24	Uric acid levels;
CESC	cis	rs1799949	1.000	rs35330014	chr17:41212547	C/T	cg25072359	chr17:41440525	NA	0.44	5.91	0.34	1.04e-8	Menopause (age at onset);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg01084379	chr5:179160712	MAML1	0.45	6.29	0.36	1.33e-9	Gut microbiota (bacterial taxa);
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg07792822	chr1:157961914	KIRREL	-0.44	-6.9	-0.39	3.71e-11	Vertical cup-disc ratio;
CESC	cis	rs2456568	0.900	rs2456559	chr11:93668858	A/T	cg26875233	chr11:93583750	C11orf90	-0.29	-5.1	-0.3	6.61e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
CESC	trans	rs875971	0.929	rs778712	chr7:65849978	C/T	cg26939375	chr7:64535504	NA	0.47	6.14	0.35	3.02e-9	Aortic root size;
CESC	cis	rs3540	0.576	rs1974519	chr15:91036460	A/G	cg22089800	chr15:90895588	ZNF774	0.61	8.14	0.45	1.57e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs3793683	0.571	rs12781152	chr10:134590257	G/C	cg18305652	chr10:134549665	INPP5A	0.48	6.82	0.39	6.13e-11	Migraine;
CESC	cis	rs11098499	0.909	rs79704848	chr4:120309351	T/A	cg09307838	chr4:120376055	NA	0.92	12.66	0.61	4.96e-29	Corneal astigmatism;
CESC	cis	rs12586317	0.531	rs60049741	chr14:35719842	G/A	cg16230307	chr14:35515116	FAM177A1	0.41	5.13	0.3	5.54e-7	Psoriasis;
CESC	cis	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg21782813	chr7:2030301	MAD1L1	0.44	6.13	0.35	3.23e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs7618915	0.531	rs77146033	chr3:52701501	G/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.71	0.38	1.17e-10	Bipolar disorder;
CESC	cis	rs2963155	0.518	rs1438732	chr5:142756266	G/C	cg17617527	chr5:142782415	NR3C1	0.83	7.39	0.41	1.88e-12	Breast cancer;
CESC	cis	rs12497850	0.931	rs7430501	chr3:48890119	C/T	cg02487422	chr3:49467188	NICN1	0.4	5.11	0.3	6.09e-7	Parkinson's disease;
CESC	cis	rs12121840	0.688	rs285438	chr1:165518186	C/T	cg16553119	chr1:165599451	MGST3	0.44	5.28	0.31	2.73e-7	Interleukin-1-receptor antagonist levels;
CESC	trans	rs561341	1.000	rs560132	chr17:30320019	C/T	cg20587970	chr11:113659929	NA	-1.48	-19.59	-0.77	1.98e-53	Hip circumference adjusted for BMI;
CESC	trans	rs60843830	1.000	rs62114544	chr2:269679	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.69	8.58	0.47	8.3e-16	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs7927592	0.763	rs7119422	chr11:68331154	C/T	cg16797656	chr11:68205561	LRP5	-0.5	-7.81	-0.43	1.31e-13	Total body bone mineral density;
CESC	cis	rs798554	0.679	rs1636249	chr7:2884283	T/G	cg19717773	chr7:2847554	GNA12	-0.45	-6.63	-0.38	1.87e-10	Height;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg06757925	chr1:70671216	LRRC40;SFRS11	0.48	6.64	0.38	1.8e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs6952808	0.601	rs3800882	chr7:2120758	G/A	cg08027265	chr7:2291960	NA	-0.4	-6.2	-0.36	2.19e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs11792861	0.591	rs10979632	chr9:111732140	G/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.63	9.75	0.51	2.16e-19	Menarche (age at onset);
CESC	cis	rs6964587	1.000	rs12333563	chr7:91667326	G/A	cg17063962	chr7:91808500	NA	0.59	8.15	0.45	1.47e-14	Breast cancer;
CESC	cis	rs6952808	0.692	rs60755037	chr7:2030104	G/A	cg22963979	chr7:1858916	MAD1L1	-0.38	-5.14	-0.3	5.29e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs3857067	1.000	rs1588385	chr4:95017161	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.52	-8.04	-0.44	3.04e-14	QT interval;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06051243	chr13:28024682	MTIF3	-0.64	-7.61	-0.42	4.74e-13	Gut microbiome composition (summer);
CESC	cis	rs8018808	0.935	rs963283	chr14:77901456	C/A	cg20045696	chr14:77926864	AHSA1	0.42	5.79	0.33	2.04e-8	Myeloid white cell count;
CESC	cis	rs1008375	0.931	rs6837181	chr4:17701253	A/C	cg02297831	chr4:17616191	MED28	0.49	5.91	0.34	1.03e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs11718455	0.767	rs11130019	chr3:43989348	C/A	cg08738300	chr3:44038990	NA	0.45	5.93	0.34	9.54e-9	Coronary artery disease;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg02399652	chr3:169684620	LOC100128164;SEC62	0.47	6.18	0.35	2.42e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs10479542	0.721	rs6894113	chr5:178974789	G/C	cg26516362	chr5:178986906	RUFY1	0.39	5.82	0.34	1.66e-8	Lung cancer;
CESC	cis	rs35306767	0.903	rs12769873	chr10:936526	G/T	cg10556349	chr10:835070	NA	0.56	5.41	0.32	1.4e-7	Eosinophil percentage of granulocytes;
CESC	cis	rs9929218	0.953	rs3118235	chr16:68732977	A/G	cg02972257	chr16:68554789	NA	-0.46	-5.2	-0.3	4.05e-7	Colorectal cancer;
CESC	cis	rs4906332	1.000	rs12889703	chr14:103872951	T/A	cg09975044	chr14:104007538	NA	0.46	6.24	0.36	1.74e-9	Coronary artery disease;
CESC	cis	rs4237845	0.715	rs4760340	chr12:58275176	A/T	cg02175503	chr12:58329896	NA	0.51	6.59	0.38	2.3e-10	Intelligence (multi-trait analysis);
CESC	cis	rs10129255	0.509	rs756583	chr14:107136019	C/T	cg07958169	chr14:107095056	NA	-0.46	-6.89	-0.39	4.09e-11	Kawasaki disease;
CESC	cis	rs3785574	0.927	rs2008018	chr17:61954471	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.56	7.09	0.4	1.18e-11	Height;
CESC	cis	rs1558375	0.679	rs31674	chr7:87068464	T/C	cg00919237	chr7:87102261	ABCB4	0.39	5.39	0.31	1.53e-7	Gallbladder cancer;
CESC	cis	rs3096299	0.685	rs3803682	chr16:89544636	C/T	cg02187348	chr16:89574699	SPG7	0.61	8.55	0.47	9.9e-16	Multiple myeloma (IgH translocation);
CESC	cis	rs6430585	0.697	rs6724569	chr2:136516970	G/A	cg07169764	chr2:136633963	MCM6	1.26	16.59	0.71	7.22e-43	Corneal structure;
CESC	cis	rs6088580	0.634	rs2225837	chr20:33005634	C/T	cg24642439	chr20:33292090	TP53INP2	-0.53	-6.99	-0.39	2.17e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs9733	0.596	rs6678013	chr1:150623285	T/G	cg09365446	chr1:150670422	GOLPH3L	0.42	5.98	0.34	7.35e-9	Tonsillectomy;
CESC	trans	rs916888	0.738	rs199515	chr17:44856641	C/G	cg27125505	chr17:43679177	LOC644172	-0.5	-7.24	-0.41	4.79e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg21354621	chr12:46384284	SFRS2IP	0.5	6.42	0.37	6.35e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs2228479	0.850	rs62054611	chr16:89817017	T/C	cg00800038	chr16:89945340	TCF25	-0.91	-7.54	-0.42	7.39e-13	Skin colour saturation;
CESC	cis	rs4819052	0.851	rs35560973	chr21:46662573	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.73	9.86	0.52	9.76e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs365060	0.542	rs5021634	chr2:109582357	A/G	cg03398303	chr18:12702742	PSMG2;CEP76	-0.56	-6.1	-0.35	3.74e-9	Beard thickness;
CESC	cis	rs875971	0.658	rs432667	chr7:65514633	A/G	cg10691866	chr7:65817282	TPST1	-0.34	-5.49	-0.32	9.58e-8	Aortic root size;
CESC	cis	rs6459804	0.588	rs78762416	chr7:157511142	G/A	cg05731713	chr7:157510257	PTPRN2	0.38	5.22	0.31	3.67e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs9905704	0.918	rs654743	chr17:56736490	T/C	cg12560992	chr17:57184187	TRIM37	0.59	6.98	0.39	2.34e-11	Testicular germ cell tumor;
CESC	cis	rs4927850	0.918	rs4361313	chr3:195752260	A/G	cg01181863	chr3:195395398	SDHAP2	-0.5	-5.85	-0.34	1.47e-8	Pancreatic cancer;
CESC	cis	rs854765	0.583	rs4414547	chr17:17859052	G/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.54	7.08	0.4	1.28e-11	Total body bone mineral density;
CESC	cis	rs9926296	0.605	rs6500453	chr16:89858657	C/G	cg27121462	chr16:89883253	FANCA	0.73	10.57	0.54	5.03e-22	Vitiligo;
CESC	cis	rs4242434	0.927	rs13264187	chr8:22506098	C/T	cg03733263	chr8:22462867	KIAA1967	0.93	14.29	0.66	9.47e-35	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CESC	cis	rs12579753	0.719	rs11115060	chr12:82269624	C/T	cg23701643	chr12:82153290	PPFIA2	-0.36	-5.29	-0.31	2.57e-7	Resting heart rate;
CESC	cis	rs561341	0.941	rs17780080	chr17:30343146	G/A	cg19193384	chr17:30244184	NA	-0.7	-6.34	-0.36	9.87e-10	Hip circumference adjusted for BMI;
CESC	cis	rs9322193	0.886	rs9767555	chr6:149968158	T/C	cg04369109	chr6:150039330	LATS1	-0.37	-5.12	-0.3	5.82e-7	Lung cancer;
CESC	cis	rs3096299	0.685	rs4785571	chr16:89565169	A/G	cg08392591	chr16:89556376	ANKRD11	0.61	8.38	0.46	3.2e-15	Multiple myeloma (IgH translocation);
CESC	cis	rs1570884	0.516	rs9316463	chr13:50176844	G/A	cg08779649	chr13:50194554	NA	0.39	6.7	0.38	1.25e-10	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
CESC	cis	rs7618915	0.501	rs3755798	chr3:52741160	G/A	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.36	6.57	0.37	2.58e-10	Bipolar disorder;
CESC	cis	rs116979167	0.630	rs56230603	chr7:105165268	A/G	cg19920283	chr7:105172520	RINT1	0.69	6.56	0.37	2.85e-10	Bipolar disorder (body mass index interaction);
CESC	cis	rs4746818	0.793	rs2008553	chr10:70860475	C/G	cg11621586	chr10:70884670	VPS26A	0.77	9.07	0.49	2.66e-17	Left atrial antero-posterior diameter;
CESC	cis	rs28647808	1.000	rs28504382	chr9:136275674	A/G	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.9	5.73	0.33	2.75e-8	Blood protein levels;
CESC	cis	rs17826219	0.568	rs2626985	chr17:29077437	A/G	cg14008862	chr17:28927542	LRRC37B2	0.65	5.14	0.3	5.34e-7	Body mass index;
CESC	cis	rs10504229	0.610	rs6999661	chr8:58127391	C/G	cg02725872	chr8:58115012	NA	-0.45	-6.84	-0.39	5.31e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs10504229	0.638	rs6981055	chr8:58113941	T/C	cg21724239	chr8:58056113	NA	0.58	5.93	0.34	9.45e-9	Developmental language disorder (linguistic errors);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14774511	chr12:3371886	TSPAN9	-0.5	-6.05	-0.35	5.03e-9	Gut microbiome composition (summer);
CESC	cis	rs853679	0.517	rs1947862	chr6:28105196	C/T	cg23281280	chr6:28129359	ZNF389	0.6	8.13	0.45	1.68e-14	Depression;
CESC	cis	rs950776	0.593	rs601079	chr15:78869579	T/A	cg06917634	chr15:78832804	PSMA4	-0.59	-7.85	-0.43	1.01e-13	Sudden cardiac arrest;
CESC	cis	rs597539	0.652	rs604524	chr11:68629929	G/A	cg01988459	chr11:68622903	NA	-0.41	-5.44	-0.32	1.23e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs9614461	0.609	rs9614653	chr22:45767391	A/G	cg15911859	chr22:45810043	RIBC2;SMC1B	-0.66	-7.54	-0.42	7.43e-13	Tonsillectomy;
CESC	cis	rs10751667	0.643	rs10794343	chr11:925493	C/T	cg20946044	chr11:1010712	AP2A2	-0.39	-5.26	-0.31	2.98e-7	Alzheimer's disease (late onset);
CESC	cis	rs2985684	1.000	rs1957977	chr14:50090603	A/G	cg02151108	chr14:50098012	C14orf104	-0.45	-5.79	-0.34	1.98e-8	Carotid intima media thickness;
CESC	cis	rs17253792	0.545	rs12883972	chr14:56018020	A/G	cg01858014	chr14:56050164	KTN1	-0.87	-6.37	-0.36	8.34e-10	Putamen volume;
CESC	cis	rs2576037	0.526	rs538221	chr18:44375111	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.71	11.44	0.57	6.9e-25	Personality dimensions;
CESC	cis	rs4819052	0.819	rs13046807	chr21:46672286	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.47	5.79	0.34	2e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs55794721	0.509	rs6699896	chr1:25762902	A/T	cg02931644	chr1:25747376	RHCE	0.47	8.04	0.44	3.09e-14	Plateletcrit;Mean corpuscular volume;
CESC	cis	rs17376456	0.877	rs2290937	chr5:93356515	A/T	cg25358565	chr5:93447407	FAM172A	1.01	10.46	0.54	1.16e-21	Diabetic retinopathy;
CESC	cis	rs6500602	0.855	rs1139652	chr16:4476089	T/C	cg08645402	chr16:4508243	NA	0.37	5.25	0.31	3.07e-7	Schizophrenia;
CESC	cis	rs17750015	0.733	rs12454365	chr18:54396215	G/A	cg18434998	chr18:54306185	TXNL1	-0.44	-5.65	-0.33	4.12e-8	Depression and alcohol dependence;
CESC	trans	rs1814175	0.630	rs1722019	chr11:49904102	G/A	cg15704280	chr7:45808275	SEPT13	-0.81	-11.22	-0.57	3.66e-24	Height;
CESC	cis	rs769267	0.965	rs13964	chr19:19468710	C/G	cg15052019	chr19:19431593	KIAA0892;SF4	-0.42	-5.31	-0.31	2.38e-7	Tonsillectomy;
CESC	cis	rs739401	0.572	rs7111857	chr11:3068106	A/G	cg05729581	chr11:3078854	CARS	0.4	5.45	0.32	1.14e-7	Longevity;
CESC	cis	rs7605827	0.897	rs2178238	chr2:15533520	C/T	cg19274914	chr2:15703543	NA	0.36	6.59	0.38	2.3e-10	Educational attainment (years of education);
CESC	cis	rs660498	0.507	rs11015783	chr10:27729745	A/G	cg08398567	chr10:27609333	NA	0.38	5.17	0.3	4.72e-7	Asthma (childhood onset);
CESC	cis	rs1348850	0.793	rs12990917	chr2:178487259	T/G	cg23306229	chr2:178417860	TTC30B	0.56	7.25	0.41	4.62e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs7224668	0.647	rs8070549	chr17:79247099	A/G	cg05632623	chr17:78450055	NPTX1	-0.29	-5.11	-0.3	6.07e-7	IgG glycosylation;
CESC	cis	rs1218582	0.510	rs2878411	chr1:154823545	C/T	cg06221963	chr1:154839813	KCNN3	-0.5	-7.45	-0.42	1.34e-12	Prostate cancer;
CESC	cis	rs7666738	0.830	rs13137859	chr4:99050319	A/G	cg03676636	chr4:99064102	C4orf37	0.33	5.12	0.3	5.93e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs854765	0.663	rs1052299	chr17:17750419	A/G	cg04398451	chr17:18023971	MYO15A	0.64	9.33	0.5	4.27e-18	Total body bone mineral density;
CESC	cis	rs2637266	0.935	rs2252652	chr10:78405022	C/T	cg18941641	chr10:78392320	NA	0.43	8.31	0.45	4.93e-15	Pulmonary function;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12368702	chr16:53165711	CHD9	0.55	6.11	0.35	3.62e-9	Gut microbiome composition (summer);
CESC	cis	rs763121	0.853	rs5750630	chr22:38985818	A/C	cg14440974	chr22:39074834	NA	-0.4	-5.23	-0.31	3.43e-7	Menopause (age at onset);
CESC	cis	rs36051895	0.623	rs10118434	chr9:5238460	A/G	cg02405213	chr9:5042618	JAK2	-0.54	-6.57	-0.37	2.6e-10	Pediatric autoimmune diseases;
CESC	cis	rs854765	0.565	rs854768	chr17:18018806	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.6	8.42	0.46	2.45e-15	Total body bone mineral density;
CESC	cis	rs9309473	0.950	rs13408433	chr2:73883072	G/A	cg20560298	chr2:73613845	ALMS1	-0.53	-6.77	-0.38	8.13e-11	Metabolite levels;
CESC	cis	rs7666738	0.791	rs6851549	chr4:99029827	G/A	cg03467027	chr4:99064603	C4orf37	0.49	6.23	0.36	1.82e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4268898	0.610	rs72791170	chr2:24449776	C/T	cg08917208	chr2:24149416	ATAD2B	0.53	5.24	0.31	3.2e-7	Asthma;
CESC	cis	rs7044106	0.791	rs4617229	chr9:123480696	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.82	13.01	0.62	2.85e-30	Hip circumference adjusted for BMI;
CESC	cis	rs11785693	0.909	rs62489557	chr8:4968371	A/G	cg26367366	chr8:4980734	NA	0.86	7.35	0.41	2.48e-12	Neuroticism (multi-trait analysis);Neuroticism;
CESC	cis	rs7116495	0.609	rs7126394	chr11:71685429	A/G	cg07596299	chr11:71824057	C11orf51	-0.83	-5.39	-0.31	1.58e-7	Severe influenza A (H1N1) infection;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05129610	chr7:23053937	FAM126A	-0.58	-7.45	-0.42	1.33e-12	Gut microbiome composition (summer);
CESC	trans	rs7246760	0.867	rs73011937	chr19:9832530	T/C	cg02900749	chr2:68251473	NA	-0.8	-7.31	-0.41	3.22e-12	Pursuit maintenance gain;
CESC	cis	rs7524258	0.868	rs4243824	chr1:7289777	G/A	cg07173049	chr1:7289937	CAMTA1	0.47	6.96	0.39	2.59e-11	Tourette's syndrome or obsessive-compulsive disorder;
CESC	cis	rs950776	0.722	rs471889	chr15:78870235	T/C	cg06917634	chr15:78832804	PSMA4	-0.5	-6.19	-0.36	2.26e-9	Sudden cardiac arrest;
CESC	cis	rs362272	0.524	rs7435601	chr4:3369645	A/G	cg08886695	chr4:3369023	RGS12	-0.39	-5.41	-0.32	1.38e-7	Serum sulfate level;
CESC	cis	rs2735413	0.875	rs12925138	chr16:78083923	C/T	cg04733911	chr16:78082701	NA	-0.53	-8.89	-0.48	9.44e-17	Systolic blood pressure (alcohol consumption interaction);
CESC	cis	rs698833	0.852	rs4953092	chr2:44565293	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.51	6.54	0.37	3.2e-10	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs6942756	0.876	rs1559486	chr7:129015894	C/T	cg02491457	chr7:128862824	NA	-0.58	-8.11	-0.45	1.92e-14	White matter hyperintensity burden;
CESC	cis	rs752010	1.000	rs752010	chr1:42093015	C/T	cg06885757	chr1:42089581	HIVEP3	0.49	8.08	0.44	2.28e-14	Lupus nephritis in systemic lupus erythematosus;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07954941	chr9:132176642	NA	-0.51	-6.0	-0.35	6.4e-9	Gut microbiome composition (summer);
CESC	cis	rs2479724	0.870	rs6902650	chr6:41764080	G/A	cg17623882	chr6:41773611	USP49	0.41	5.74	0.33	2.52e-8	Menarche (age at onset);
CESC	cis	rs9322193	0.923	rs9322200	chr6:149951214	G/A	cg07701084	chr6:150067640	NUP43	0.43	6.0	0.35	6.52e-9	Lung cancer;
CESC	cis	rs7937682	0.632	rs11214015	chr11:111719417	A/T	cg09085632	chr11:111637200	PPP2R1B	-0.85	-10.9	-0.56	4.27e-23	Primary sclerosing cholangitis;
CESC	cis	rs9858542	0.953	rs12330269	chr3:49513910	G/A	cg07274523	chr3:49395745	GPX1	0.66	8.05	0.44	2.78e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	trans	rs2207136	0.835	rs2143881	chr6:50852887	C/A	cg06522515	chr3:184090630	THPO	-0.36	-6.24	-0.36	1.69e-9	Myopia;
CESC	cis	rs6714710	0.603	rs11123974	chr2:98605982	A/G	cg26665480	chr2:98280029	ACTR1B	0.51	7.12	0.4	9.97e-12	Posterior cortical atrophy and Alzheimer's disease;
CESC	trans	rs8073060	0.586	rs7221203	chr17:34015532	T/C	cg19694781	chr19:47549865	TMEM160	-0.71	-6.74	-0.38	9.95e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	cis	rs4689388	0.853	rs11729672	chr4:6293838	A/G	cg00701064	chr4:6280414	WFS1	0.68	11.71	0.58	8.68e-26	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs597539	0.652	rs11603827	chr11:68719221	C/T	cg01988459	chr11:68622903	NA	-0.45	-5.89	-0.34	1.15e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg00436174	chr2:128051630	ERCC3	0.45	6.12	0.35	3.42e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs8111998	0.826	rs10420648	chr19:22767819	G/A	cg19914732	chr19:22715077	NA	-0.37	-5.18	-0.3	4.45e-7	Corneal structure;
CESC	cis	rs7666738	0.830	rs11725095	chr4:99009711	T/A	cg05340658	chr4:99064831	C4orf37	0.8	12.51	0.61	1.52e-28	Colonoscopy-negative controls vs population controls;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg10173240	chr14:90849342	NA	-0.42	-6.05	-0.35	4.87e-9	Gambling;
CESC	trans	rs459571	0.959	rs456205	chr9:136911146	G/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.67	-8.79	-0.48	1.98e-16	Platelet distribution width;
CESC	cis	rs7666738	0.830	rs62318471	chr4:98925848	G/A	cg05340658	chr4:99064831	C4orf37	0.82	12.2	0.6	1.81e-27	Colonoscopy-negative controls vs population controls;
CESC	cis	rs35306767	0.761	rs12770173	chr10:1027108	A/C	cg26597838	chr10:835615	NA	0.76	7.15	0.4	8.67e-12	Eosinophil percentage of granulocytes;
CESC	cis	rs2562152	0.786	rs216594	chr16:103009	A/T	cg02949481	chr16:131562	MPG	0.54	5.8	0.34	1.91e-8	Glioblastoma;
CESC	cis	rs1476670	0.710	rs2485993	chr1:44503040	C/T	cg09470012	chr1:44509516	NA	-0.32	-5.14	-0.3	5.45e-7	Eotaxin levels;
CESC	cis	rs7666738	0.830	rs10010223	chr4:99021758	G/A	cg03676636	chr4:99064102	C4orf37	0.33	5.15	0.3	5.05e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7412746	0.634	rs4451553	chr1:150937329	C/T	cg17724175	chr1:150552817	MCL1	0.39	5.92	0.34	1e-8	Melanoma;
CESC	cis	rs1355223	0.752	rs17293467	chr11:34677360	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.48	-6.11	-0.35	3.49e-9	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs4820539	1.000	rs6003518	chr22:23471533	C/T	cg14186256	chr22:23484241	RTDR1	0.82	14.65	0.67	5.33e-36	Bone mineral density;
CESC	cis	rs7927771	0.524	rs11039402	chr11:47826090	A/C	cg18512352	chr11:47633146	NA	0.35	5.33	0.31	2.05e-7	Subjective well-being;
CESC	cis	rs2075371	1.000	rs378358	chr7:133970628	A/G	cg11752832	chr7:134001865	SLC35B4	0.52	6.77	0.38	8.06e-11	Mean platelet volume;
CESC	cis	rs3747547	0.818	rs7023756	chr9:37946629	A/G	cg13774184	chr9:37916125	SHB	-0.59	-6.06	-0.35	4.57e-9	Metabolite levels (Dihydroxy docosatrienoic acid);
CESC	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg24846343	chr22:24311635	DDTL	0.47	7.71	0.43	2.57e-13	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs9399135	0.967	rs6902954	chr6:135313994	C/A	cg22676075	chr6:135203613	NA	0.51	7.23	0.41	5.22e-12	Red blood cell count;
CESC	cis	rs9291683	0.546	rs13110307	chr4:10044364	T/C	cg11266682	chr4:10021025	SLC2A9	0.65	12.28	0.6	9.55e-28	Bone mineral density;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20919922	chr2:75185588	POLE4	0.55	6.07	0.35	4.44e-9	Gut microbiome composition (summer);
CESC	cis	rs7208859	0.623	rs1061346	chr17:29114229	G/A	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.79e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs3087591	0.960	rs12943508	chr17:29599954	C/G	cg24425628	chr17:29625626	OMG;NF1	0.46	5.73	0.33	2.79e-8	Hip circumference;
CESC	cis	rs35306767	0.903	rs13377166	chr10:886259	G/A	cg25019033	chr10:957182	NA	-0.56	-6.04	-0.35	5.1e-9	Eosinophil percentage of granulocytes;
CESC	cis	rs769267	0.930	rs7254748	chr19:19397479	A/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.42	5.32	0.31	2.18e-7	Tonsillectomy;
CESC	cis	rs6723226	0.598	rs2710629	chr2:32765844	C/T	cg02381751	chr2:32503542	YIPF4	0.49	6.43	0.37	6.07e-10	Intelligence (multi-trait analysis);
CESC	cis	rs11098499	0.775	rs10029303	chr4:120286755	T/A	cg24375607	chr4:120327624	NA	0.42	5.19	0.3	4.19e-7	Corneal astigmatism;
CESC	cis	rs1784581	0.588	rs7765624	chr6:162427462	C/A	cg17173639	chr6:162384350	PARK2	0.57	8.58	0.47	7.87e-16	Itch intensity from mosquito bite;
CESC	cis	rs2404602	0.583	rs11072580	chr15:76540231	G/A	cg22467129	chr15:76604101	ETFA	-0.39	-6.26	-0.36	1.52e-9	Blood metabolite levels;
CESC	cis	rs4604732	0.631	rs12080860	chr1:247623053	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.55	7.01	0.4	1.92e-11	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs963731	0.649	rs297135	chr2:39304793	G/A	cg04010122	chr2:39346883	SOS1	-0.76	-5.74	-0.33	2.65e-8	Corticobasal degeneration;
CESC	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.5	-6.28	-0.36	1.35e-9	Longevity;Endometriosis;
CESC	cis	rs6088590	0.542	rs6059956	chr20:33220070	A/G	cg08999081	chr20:33150536	PIGU	0.68	11.6	0.58	1.92e-25	Coronary artery disease;
CESC	cis	rs1862618	0.671	rs832531	chr5:56228401	A/G	cg18230493	chr5:56204884	C5orf35	-0.61	-8.34	-0.46	4.24e-15	Initial pursuit acceleration;
CESC	cis	rs873946	0.586	rs3793684	chr10:134568645	G/A	cg18305652	chr10:134549665	INPP5A	0.45	6.26	0.36	1.53e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs561341	0.941	rs550213	chr17:30317518	C/G	cg12193833	chr17:30244370	NA	-0.58	-5.96	-0.34	7.88e-9	Hip circumference adjusted for BMI;
CESC	cis	rs12893668	0.703	rs4906338	chr14:104050357	A/G	cg08213375	chr14:104286397	PPP1R13B	0.33	5.12	0.3	5.83e-7	Reticulocyte count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10798048	chr1:16399867	FAM131C	0.52	6.14	0.35	2.95e-9	Gut microbiome composition (summer);
CESC	cis	rs287982	1.000	rs13404815	chr2:9967766	A/G	cg10881225	chr2:9984929	TAF1B	0.4	5.16	0.3	4.94e-7	Nonsyndromic cleft lip with cleft palate;
CESC	cis	rs11734570	0.581	rs75356782	chr4:38600053	T/G	cg18361445	chr4:38666374	KLF3;FLJ13197	0.61	7.42	0.41	1.56e-12	Inflammatory bowel disease;Crohn's disease;
CESC	trans	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg13565492	chr6:43139072	SRF	-0.61	-6.32	-0.36	1.1e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs780096	0.545	rs6716894	chr2:27583273	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.29	-5.22	-0.31	3.58e-7	Total body bone mineral density;
CESC	cis	rs4713118	0.621	rs4713133	chr6:28034041	T/C	cg26335602	chr6:28129616	ZNF389	0.48	6.14	0.35	3.05e-9	Parkinson's disease;
CESC	cis	rs116095464	0.558	rs3213838	chr5:223890	G/C	cg10591111	chr5:226296	SDHA	-0.52	-6.52	-0.37	3.47e-10	Breast cancer;
CESC	cis	rs2072732	0.861	rs72629494	chr1:2951349	T/C	cg15211996	chr1:2936768	ACTRT2	0.34	5.95	0.34	8.31e-9	Plateletcrit;
CESC	cis	rs514406	0.644	rs6661196	chr1:53203664	A/G	cg08736216	chr1:53307985	ZYG11A	0.3	5.07	0.3	7.55e-7	Monocyte count;
CESC	cis	rs290268	0.838	rs1333635	chr9:93566406	A/G	cg02608019	chr9:93564028	SYK	0.68	10.27	0.53	4.93e-21	Platelet count;
CESC	cis	rs76025697	1	rs76025697	chr5:179184488	G/A	cg14593053	chr5:179126677	CANX	0.41	5.39	0.31	1.55e-7	Granulocyte percentage of myeloid white cells;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Granulocyte count;
CESC	cis	rs4891159	0.548	rs690423	chr18:74117984	G/A	cg24786174	chr18:74118243	ZNF516	0.85	15.89	0.7	2.23e-40	Longevity;
CESC	cis	rs12893597	0.715	rs34486942	chr14:76831530	G/A	cg20290672	chr14:76816747	NA	-0.4	-5.64	-0.33	4.31e-8	Maximal oxygen uptake response;
CESC	cis	rs2836950	0.501	rs2836985	chr21:40701169	A/G	cg17971929	chr21:40555470	PSMG1	-0.6	-7.92	-0.44	6.45e-14	Menarche (age at onset);
CESC	cis	rs4629180	0.701	rs10202801	chr2:102106670	T/C	cg04415270	chr2:102091202	RFX8	-0.31	-5.39	-0.31	1.53e-7	Chronic rhinosinusitis with nasal polyps;
CESC	cis	rs72781680	0.581	rs116520786	chr2:24272645	C/T	cg08917208	chr2:24149416	ATAD2B	0.67	6.42	0.37	6.2e-10	Lymphocyte counts;
CESC	cis	rs1055129	0.560	rs2305913	chr17:73922941	T/C	cg08125733	chr17:73851984	WBP2	0.52	7.15	0.4	8.32e-12	White matter hyperintensity burden;
CESC	cis	rs258892	0.895	rs34252662	chr5:72054308	G/C	cg21869765	chr5:72125136	TNPO1	-0.43	-5.36	-0.31	1.8e-7	Small cell lung carcinoma;
CESC	cis	rs3815700	1.000	rs7248273	chr19:33096816	C/T	cg24916020	chr19:33096688	ANKRD27	0.59	5.79	0.33	2.01e-8	Eosinophilic esophagitis;
CESC	cis	rs425277	1.000	rs196128	chr1:2078444	T/G	cg04315214	chr1:2043799	PRKCZ	-0.38	-5.3	-0.31	2.42e-7	Height;
CESC	cis	rs12995491	0.731	rs56188884	chr2:88508657	G/A	cg07952391	chr2:88470173	THNSL2	-0.54	-8.13	-0.45	1.61e-14	Response to metformin (IC50);
CESC	cis	rs7666738	0.680	rs11097613	chr4:99079991	G/T	cg17366294	chr4:99064904	C4orf37	0.55	7.47	0.42	1.15e-12	Colonoscopy-negative controls vs population controls;
CESC	cis	rs870825	0.860	rs72703529	chr4:185607351	T/C	cg04058563	chr4:185651563	MLF1IP	0.54	5.24	0.31	3.27e-7	Blood protein levels;
CESC	cis	rs12497850	0.931	rs7628719	chr3:48995487	C/T	cg02487422	chr3:49467188	NICN1	0.43	5.48	0.32	9.87e-8	Parkinson's disease;
CESC	cis	rs1552244	0.882	rs67631672	chr3:10004768	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.69	-8.57	-0.47	8.51e-16	Alzheimer's disease;
CESC	cis	rs7666738	0.830	rs7696568	chr4:99005333	A/T	cg05340658	chr4:99064831	C4orf37	0.8	12.44	0.61	2.83e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10779751	1.000	rs7549109	chr1:11278813	C/G	cg08854313	chr1:11322531	MTOR	-0.93	-14.42	-0.66	3.33e-35	Body mass index;
CESC	cis	rs801193	1.000	rs2707845	chr7:66198798	C/T	cg18876405	chr7:65276391	NA	0.54	7.28	0.41	3.88e-12	Aortic root size;
CESC	cis	rs7824557	0.603	rs6995404	chr8:11182148	C/G	cg21775007	chr8:11205619	TDH	0.46	7.13	0.4	9.66e-12	Retinal vascular caliber;
CESC	cis	rs2228479	0.850	rs11649162	chr16:89807131	C/A	cg00800038	chr16:89945340	TCF25	-0.89	-7.39	-0.41	1.95e-12	Skin colour saturation;
CESC	cis	rs634534	0.561	rs613924	chr11:65769295	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.45	6.84	0.39	5.62e-11	Sum eosinophil basophil counts;Eosinophil counts;
CESC	cis	rs2559856	1.000	rs2695282	chr12:102089502	A/G	cg15068132	chr12:102092402	CHPT1	0.42	5.52	0.32	7.97e-8	Blood protein levels;
CESC	cis	rs17818399	0.926	rs35682608	chr2:46836542	A/T	cg02822958	chr2:46747628	ATP6V1E2	0.47	5.64	0.33	4.45e-8	Height;
CESC	cis	rs7216064	1.000	rs34872586	chr17:65863466	T/C	cg12091567	chr17:66097778	LOC651250	-0.85	-8.7	-0.47	3.61e-16	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs17209837	1.000	rs2072383	chr7:87081349	A/G	cg00919237	chr7:87102261	ABCB4	-0.53	-6.11	-0.35	3.63e-9	Gallbladder cancer;
CESC	cis	rs4862750	0.872	rs6821507	chr4:187876829	G/T	cg03647317	chr4:187891568	NA	0.39	5.75	0.33	2.5e-8	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2070433	0.539	rs1008548	chr21:47959692	G/A	cg12379764	chr21:47803548	PCNT	0.63	8.17	0.45	1.26e-14	Lymphocyte counts;
CESC	cis	rs6662572	0.901	rs28484896	chr1:46184200	C/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.51	5.49	0.32	9.48e-8	Blood protein levels;
CESC	cis	rs763014	0.932	rs2384972	chr16:674424	G/A	cg00802000	chr16:706648	WDR90	-0.43	-6.57	-0.37	2.64e-10	Height;
CESC	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg07677032	chr17:61819896	STRADA	0.46	6.12	0.35	3.31e-9	Prudent dietary pattern;
CESC	cis	rs672059	1.000	rs480132	chr1:183161779	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.54	7.05	0.4	1.59e-11	Hypertriglyceridemia;
CESC	cis	rs35306767	0.903	rs11253475	chr10:907262	C/A	cg20503657	chr10:835505	NA	0.78	7.74	0.43	2.14e-13	Eosinophil percentage of granulocytes;
CESC	cis	rs9399135	0.967	rs6925424	chr6:135313948	T/A	cg24558204	chr6:135376177	HBS1L	0.53	7.28	0.41	3.85e-12	Red blood cell count;
CESC	cis	rs7310409	0.544	rs1169292	chr12:121426478	C/T	cg25281562	chr12:121454272	C12orf43	0.57	7.06	0.4	1.47e-11	Liver enzyme levels (gamma-glutamyl transferase);C-reactive protein;Pancreatic cancer;
CESC	cis	rs6540556	0.517	rs1474655	chr1:209884730	G/C	cg05527609	chr1:210001259	C1orf107	-0.73	-7.15	-0.4	8.66e-12	Red blood cell count;
CESC	cis	rs4819052	1.000	rs2838830	chr21:46664227	T/G	cg11663144	chr21:46675770	NA	-0.51	-7.07	-0.4	1.4e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs7264396	0.563	rs2425137	chr20:34345396	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.79	-9.16	-0.49	1.5e-17	Total cholesterol levels;
CESC	cis	rs10979	1.000	rs9484769	chr6:143896719	A/G	cg25407410	chr6:143891975	LOC285740	-0.61	-9.2	-0.49	1.13e-17	Hypospadias;
CESC	cis	rs3820068	0.705	rs7533125	chr1:15883744	T/C	cg18192808	chr1:15853278	DNAJC16	0.43	5.17	0.3	4.6e-7	Systolic blood pressure;
CESC	cis	rs4665809	1.000	rs3910272	chr2:26287842	T/A	cg04944784	chr2:26401820	FAM59B	-0.8	-8.93	-0.48	7.17e-17	Gut microbiome composition (summer);
CESC	cis	rs13256369	0.756	rs13280759	chr8:8562995	G/T	cg17143192	chr8:8559678	CLDN23	0.78	8.81	0.48	1.63e-16	Obesity-related traits;
CESC	cis	rs7772486	0.754	rs9373476	chr6:146139741	C/G	cg05347473	chr6:146136440	FBXO30	0.55	7.1	0.4	1.16e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2576037	0.583	rs593340	chr18:44418346	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.33	5.33	0.31	2.11e-7	Personality dimensions;
CESC	cis	rs561341	1.000	rs537166	chr17:30326827	C/T	cg12193833	chr17:30244370	NA	-0.59	-5.92	-0.34	9.93e-9	Hip circumference adjusted for BMI;
CESC	cis	rs116095464	0.558	rs62344300	chr5:246336	A/G	cg22857025	chr5:266934	NA	-1.27	-18.37	-0.75	3.49e-49	Breast cancer;
CESC	trans	rs561341	0.714	rs55925849	chr17:30253085	C/T	cg27661571	chr11:113659931	NA	-0.87	-7.9	-0.44	7.5e-14	Hip circumference adjusted for BMI;
CESC	cis	rs6952808	0.929	rs34145223	chr7:1926237	G/A	cg04267008	chr7:1944627	MAD1L1	-0.71	-9.09	-0.49	2.4e-17	Bipolar disorder and schizophrenia;
CESC	cis	rs9287719	0.901	rs13034017	chr2:10739592	C/T	cg02196655	chr2:10830764	NOL10	-0.37	-5.72	-0.33	2.87e-8	Prostate cancer;
CESC	cis	rs7927771	0.864	rs11600581	chr11:47448497	T/C	cg20307385	chr11:47447363	PSMC3	-0.63	-7.6	-0.42	5.12e-13	Subjective well-being;
CESC	cis	rs2569991	0.636	rs2600222	chr3:12937617	C/G	cg22481960	chr3:13008800	IQSEC1	-0.56	-6.6	-0.38	2.26e-10	Periodontitis (DPAL);
CESC	cis	rs918629	0.761	rs3777165	chr5:95291425	A/G	cg16656078	chr5:95278638	ELL2	0.39	5.13	0.3	5.68e-7	IgG glycosylation;
CESC	cis	rs4332037	0.707	rs56070303	chr7:1891015	C/T	cg13880726	chr7:1868755	MAD1L1	-0.48	-5.08	-0.3	7.23e-7	Bipolar disorder;
CESC	cis	rs829883	0.872	rs1641637	chr12:98890564	G/A	cg25150519	chr12:98850993	NA	0.7	9.64	0.51	4.82e-19	Colorectal adenoma (advanced);
CESC	cis	rs6938	0.618	rs12911254	chr15:75166335	G/A	cg09165964	chr15:75287851	SCAMP5	0.47	6.65	0.38	1.68e-10	Breast cancer;
CESC	cis	rs6696846	0.905	rs11240349	chr1:205041015	G/A	cg00857998	chr1:205179979	DSTYK	0.55	7.13	0.4	9.68e-12	Red blood cell count;
CESC	cis	rs4555082	0.872	rs7153832	chr14:105730563	G/T	cg27165867	chr14:105738592	BRF1	-0.48	-5.42	-0.32	1.32e-7	Mean platelet volume;Platelet distribution width;
CESC	cis	rs3862030	0.500	rs11191327	chr10:104303883	T/C	cg22532475	chr10:104410764	TRIM8	-0.33	-5.69	-0.33	3.3e-8	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
CESC	cis	rs35110281	0.782	rs1454650	chr21:45012353	C/T	cg01579765	chr21:45077557	HSF2BP	-0.56	-9.51	-0.5	1.24e-18	Mean corpuscular volume;
CESC	cis	rs1707322	0.656	rs3014210	chr1:46066608	A/G	cg03146154	chr1:46216737	IPP	-0.73	-9.89	-0.52	7.72e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg23200371	chr12:56367680	RAB5B	-0.47	-6.14	-0.35	3.03e-9	Fibrinogen levels;
CESC	cis	rs4891159	0.790	rs660029	chr18:74149668	A/G	cg24786174	chr18:74118243	ZNF516	0.77	12.55	0.61	1.19e-28	Longevity;
CESC	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.64	7.45	0.42	1.33e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs4604732	0.578	rs79203328	chr1:247626581	C/G	cg12754571	chr1:247694271	LOC148824;OR2C3	0.44	5.44	0.32	1.21e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs9733	0.544	rs2867302	chr1:150653650	T/C	cg04414720	chr1:150670196	GOLPH3L	0.63	9.01	0.48	4.11e-17	Tonsillectomy;
CESC	cis	rs3126085	0.935	rs4845429	chr1:152225376	G/C	cg03465714	chr1:152285911	FLG	-0.42	-5.35	-0.31	1.93e-7	Atopic dermatitis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06913508	chr2:207630136	FASTKD2;MDH1B	0.61	7.1	0.4	1.16e-11	Gut microbiome composition (summer);
CESC	cis	rs7429990	0.932	rs810334	chr3:47935303	G/T	cg11946769	chr3:48343235	NME6	0.42	5.11	0.3	6.05e-7	Educational attainment (years of education);
CESC	cis	rs11098499	0.657	rs7664458	chr4:120371967	A/G	cg24375607	chr4:120327624	NA	0.47	5.89	0.34	1.14e-8	Corneal astigmatism;
CESC	cis	rs8002861	0.967	rs7994883	chr13:44478805	A/G	cg19180546	chr13:44453867	C13orf31;CCDC122	-0.41	-5.34	-0.31	1.99e-7	Leprosy;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg17157516	chr1:35332203	DLGAP3	-0.42	-6.26	-0.36	1.59e-9	Gambling;
CESC	cis	rs7714584	1.000	rs11955172	chr5:150254378	T/C	cg22134413	chr5:150180641	NA	0.51	5.92	0.34	9.88e-9	Crohn's disease;
CESC	cis	rs7618915	0.508	rs13065851	chr3:52644836	T/A	cg18099408	chr3:52552593	STAB1	-0.32	-5.31	-0.31	2.35e-7	Bipolar disorder;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg25940730	chr4:16228647	TAPT1;FLJ39653	0.46	6.08	0.35	4.12e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs2425143	0.908	rs74784474	chr20:34422464	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.79	-7.17	-0.4	7.71e-12	Blood protein levels;
CESC	cis	rs6752107	1.000	rs34123137	chr2:234167881	T/A	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.4	6.04	0.35	5.16e-9	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs832540	0.695	rs702686	chr5:56201350	A/G	cg18230493	chr5:56204884	C5orf35	-0.58	-7.57	-0.42	6.2800000000000005e-13	Coronary artery disease;
CESC	cis	rs6963495	0.818	rs9769403	chr7:105163091	G/A	cg02135003	chr7:105160482	PUS7	-0.46	-5.55	-0.32	6.92e-8	Bipolar disorder (body mass index interaction);
CESC	cis	rs344364	0.511	rs2982453	chr16:1949520	G/A	cg03013636	chr16:1946785	NA	0.48	6.62	0.38	2.02e-10	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs9287719	0.967	rs6733416	chr2:10738684	C/T	cg00105475	chr2:10696890	NA	0.39	5.61	0.33	4.96e-8	Prostate cancer;
CESC	cis	rs2991971	1.000	rs622798	chr1:46015271	T/G	cg05343316	chr1:45956843	TESK2	-0.51	-6.5	-0.37	3.93e-10	High light scatter reticulocyte count;
CESC	cis	rs116095464	0.558	rs9654452	chr5:299561	C/T	cg12570787	chr5:219185	SDHA;CCDC127	0.5	5.17	0.3	4.68e-7	Breast cancer;
CESC	cis	rs1986734	0.576	rs2068062	chr4:77417214	A/C	cg20311846	chr4:77356250	SHROOM3	-0.28	-5.68	-0.33	3.55e-8	Eosinophilic esophagitis (pediatric);Metabolite levels (small molecules and protein measures);
CESC	cis	rs2276314	0.793	rs77590522	chr18:33629410	C/G	cg19628046	chr18:33552617	C18orf21	0.52	5.57	0.32	6.4e-8	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs10465746	0.935	rs1871925	chr1:84464468	C/G	cg10977910	chr1:84465055	TTLL7	0.48	6.4	0.37	6.99e-10	Obesity-related traits;
CESC	cis	rs1790761	0.505	rs4320958	chr11:67310334	G/A	cg00290607	chr11:67383545	NA	-0.37	-5.39	-0.31	1.54e-7	Mean corpuscular volume;
CESC	cis	rs2295499	0.744	rs2282768	chr4:2716147	A/C	cg27239842	chr4:2403781	ZFYVE28	-0.33	-5.57	-0.32	6.26e-8	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
CESC	cis	rs57506017	0.585	rs2302633	chr7:12270815	C/T	cg23422036	chr7:12250390	TMEM106B	0.39	5.17	0.3	4.57e-7	Neuroticism;
CESC	cis	rs1059312	0.932	rs4760589	chr12:129284382	T/C	cg09035930	chr12:129282057	SLC15A4	0.75	10.74	0.55	1.41e-22	Systemic lupus erythematosus;
CESC	cis	rs2070488	0.766	rs4679050	chr3:38482007	G/A	cg24069376	chr3:38537580	EXOG	0.35	5.99	0.35	6.93e-9	Electrocardiographic conduction measures;
CESC	cis	rs9911578	0.692	rs411988	chr17:56709034	G/A	cg12560992	chr17:57184187	TRIM37	0.83	12.95	0.62	4.96e-30	Intelligence (multi-trait analysis);
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg00373665	chr1:234735703	NA	0.47	6.1	0.35	3.66e-9	Systemic lupus erythematosus;
CESC	cis	rs9916302	0.904	rs11869109	chr17:37518205	G/T	cg20243544	chr17:37824526	PNMT	-0.48	-6.07	-0.35	4.42e-9	Glomerular filtration rate (creatinine);
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg16676734	chr14:93582668	ITPK1	-0.46	-6.2	-0.36	2.16e-9	Asthma;
CESC	cis	rs12410462	1.000	rs75637482	chr1:227622944	A/T	cg23173402	chr1:227635558	NA	0.57	5.92	0.34	9.9e-9	Major depressive disorder;
CESC	cis	rs9929218	0.520	rs1078621	chr16:68778996	C/T	cg02972257	chr16:68554789	NA	-0.42	-5.25	-0.31	3.07e-7	Colorectal cancer;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg02984193	chr15:91260561	BLM	-0.38	-6.04	-0.35	5.31e-9	Gambling;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09485063	chr2:75107440	HK2	-0.59	-6.84	-0.39	5.49e-11	Gut microbiome composition (summer);
CESC	cis	rs1023500	0.551	rs2301521	chr22:42423110	G/C	cg04733989	chr22:42467013	NAGA	0.8	11.11	0.56	8.81e-24	Schizophrenia;
CESC	trans	rs7922314	0.571	rs61865718	chr10:64740407	C/A	cg06935979	chr1:232941706	KIAA1383	-0.63	-6.19	-0.36	2.23e-9	Cutaneous psoriasis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10700647	chr1:28832638	SNHG3-RCC1;SNHG3	-0.52	-6.2	-0.36	2.16e-9	Gut microbiome composition (summer);
CESC	cis	rs2050392	1.000	rs2253585	chr10:30696503	C/T	cg18806716	chr10:30721971	MAP3K8	-0.42	-6.16	-0.35	2.62e-9	Inflammatory bowel disease;
CESC	cis	rs9611565	0.659	rs4822037	chr22:41945113	G/T	cg17376030	chr22:41985996	PMM1	0.72	7.8	0.43	1.43e-13	Vitiligo;
CESC	cis	rs3204270	0.639	rs7216239	chr17:79660187	C/T	cg26965718	chr17:79658957	HGS	-0.78	-5.6	-0.33	5.27e-8	Dental caries;
CESC	cis	rs7959452	0.535	rs4761228	chr12:69682327	G/A	cg14784868	chr12:69753453	YEATS4	0.72	10.15	0.53	1.15e-20	Blood protein levels;
CESC	cis	rs9443645	0.869	rs6913028	chr6:79513590	C/T	cg05283184	chr6:79620031	NA	-0.43	-6.71	-0.38	1.19e-10	Intelligence (multi-trait analysis);
CESC	cis	rs28374715	0.578	rs7169543	chr15:41620405	T/C	cg18705301	chr15:41695430	NDUFAF1	-1.05	-15.34	-0.69	1.9e-38	Ulcerative colitis;
CESC	cis	rs1552244	0.882	rs112621205	chr3:10017916	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.75	-9.49	-0.5	1.38e-18	Alzheimer's disease;
CESC	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg10150615	chr22:24372951	LOC391322	-0.55	-7.35	-0.41	2.42e-12	Liver enzyme levels (gamma-glutamyl transferase);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23113715	chr22:25800663	NA	0.55	6.54	0.37	3.17e-10	Gut microbiome composition (summer);
CESC	cis	rs2243480	1.000	rs7794661	chr7:65389730	T/C	cg25894440	chr7:65020034	NA	-0.6	-5.16	-0.3	4.78e-7	Diabetic kidney disease;
CESC	trans	rs561341	0.883	rs7406056	chr17:30220224	C/T	cg20587970	chr11:113659929	NA	-1.03	-12.68	-0.61	4.19e-29	Hip circumference adjusted for BMI;
CESC	cis	rs12887734	0.524	rs722637	chr14:104261723	G/T	cg08213375	chr14:104286397	PPP1R13B	-0.39	-6.78	-0.38	7.94e-11	Schizophrenia;Autism spectrum disorder or schizophrenia;
CESC	trans	rs2154294	0.625	rs10151297	chr14:42649081	C/T	cg07368857	chr3:71276336	FOXP1	-0.33	-6.21	-0.36	1.99e-9	Alcoholism (12-month weekly alcohol consumption);
CESC	cis	rs1983891	0.874	rs2395779	chr6:41511950	C/T	cg20194872	chr6:41519635	FOXP4	0.52	7.45	0.42	1.29e-12	Prostate cancer;
CESC	cis	rs2404602	0.647	rs10851889	chr15:77023336	C/T	cg23625390	chr15:77176239	SCAPER	-0.46	-6.5	-0.37	4.05e-10	Blood metabolite levels;
CESC	cis	rs7216064	1.000	rs4569324	chr17:65872750	C/T	cg07042672	chr17:66097459	LOC651250	-0.53	-5.47	-0.32	1.04e-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs12681366	0.663	rs10216902	chr8:95479978	A/G	cg13257157	chr8:95487014	RAD54B	0.39	5.41	0.32	1.44e-7	Nonsyndromic cleft lip with cleft palate;
CESC	trans	rs7246760	0.867	rs12462694	chr19:9778032	C/T	cg02900749	chr2:68251473	NA	-0.84	-7.5	-0.42	9.88e-13	Pursuit maintenance gain;
CESC	cis	rs7923609	1.000	rs4399232	chr10:64999490	C/T	cg01631684	chr10:65280961	REEP3	-0.45	-5.56	-0.32	6.57e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs2576037	0.542	rs4630643	chr18:44508142	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.49	-6.61	-0.38	2.05e-10	Personality dimensions;
CESC	cis	rs6582630	0.502	rs7311700	chr12:38463232	T/A	cg26384229	chr12:38710491	ALG10B	0.72	10.64	0.55	3.12e-22	Drug-induced liver injury (flucloxacillin);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03442064	chr6:41515050	FOXP4	0.51	6.93	0.39	3.19e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs34638657	0.732	rs12597010	chr16:82199971	G/A	cg09439754	chr16:82129088	HSD17B2	-0.37	-6.42	-0.37	6.31e-10	Lung adenocarcinoma;
CESC	cis	rs3820068	0.705	rs4646083	chr1:15825564	G/A	cg17385448	chr1:15911702	AGMAT	0.4	6.12	0.35	3.37e-9	Systolic blood pressure;
CESC	trans	rs3942852	0.806	rs1875696	chr11:48133526	G/A	cg15704280	chr7:45808275	SEPT13	-0.63	-7.32	-0.41	3.02e-12	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs4642101	0.597	rs9839768	chr3:12821403	C/T	cg24848339	chr3:12840334	CAND2	0.39	6.1	0.35	3.65e-9	QRS complex (12-leadsum);
CESC	cis	rs4073582	0.595	rs801734	chr11:65931216	T/C	cg14036092	chr11:66035641	RAB1B	0.54	7.56	0.42	6.63e-13	Gout;
CESC	cis	rs8103278	1.000	rs9807819	chr19:46239598	C/T	cg12641515	chr19:46296257	DMWD	-0.54	-6.33	-0.36	1.02e-9	Coronary artery disease;
CESC	cis	rs8170	0.603	rs971693	chr19:17422649	G/C	cg04749549	chr19:17459798	NA	-0.33	-5.19	-0.3	4.13e-7	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
CESC	cis	rs8062405	0.755	rs12445823	chr16:28588049	A/C	cg01378222	chr16:28622494	SULT1A1	0.3	5.09	0.3	6.77e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs1008375	1.000	rs1558378	chr4:17650351	T/C	cg02297831	chr4:17616191	MED28	0.61	7.82	0.43	1.23e-13	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs7267979	1.000	rs6050598	chr20:25397257	C/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.86	18.01	0.74	6.69e-48	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	7.61	0.42	4.95e-13	Prudent dietary pattern;
CESC	cis	rs17209837	0.607	rs4148821	chr7:87079602	G/C	cg00919237	chr7:87102261	ABCB4	-0.52	-6.69	-0.38	1.3e-10	Gallbladder cancer;
CESC	cis	rs9733	0.596	rs72702536	chr1:150662574	C/T	cg09365446	chr1:150670422	GOLPH3L	0.42	5.91	0.34	1.03e-8	Tonsillectomy;
CESC	cis	rs8031584	0.697	rs8036176	chr15:31175269	A/G	cg08704250	chr15:31115839	NA	-0.71	-9.06	-0.49	2.94e-17	Huntington's disease progression;
CESC	cis	rs7833790	0.632	rs6473308	chr8:82707708	G/A	cg02079420	chr8:82753780	SNX16	0.54	8.01	0.44	3.69e-14	Diastolic blood pressure;
CESC	cis	rs7927771	0.839	rs11039308	chr11:47622412	G/A	cg20307385	chr11:47447363	PSMC3	-0.42	-5.16	-0.3	4.79e-7	Subjective well-being;
CESC	cis	rs7219021	0.705	rs999475	chr17:46988044	C/T	cg16584676	chr17:46985605	UBE2Z	-0.61	-7.13	-0.4	9.68e-12	Schizophrenia or bipolar disorder;
CESC	cis	rs2932538	0.961	rs6537747	chr1:113179597	C/T	cg22162597	chr1:113214053	CAPZA1	-0.49	-6.49	-0.37	4.14e-10	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CESC	cis	rs875971	0.638	rs6460305	chr7:66060408	G/A	cg14393609	chr7:65229607	NA	-0.45	-5.98	-0.34	7.2e-9	Aortic root size;
CESC	trans	rs208520	0.690	rs12204512	chr6:66710486	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.95	12.41	0.61	3.59e-28	Exhaled nitric oxide output;
CESC	trans	rs7615952	0.599	rs6803160	chr3:125709554	G/T	cg07211511	chr3:129823064	LOC729375	-0.57	-6.53	-0.37	3.29e-10	Blood pressure (smoking interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24816464	chr3:86061715	CADM2	-0.58	-6.89	-0.39	4.17e-11	Gut microbiome composition (summer);
CESC	cis	rs4790333	0.562	rs2447108	chr17:2257993	C/T	cg02569219	chr17:2266849	SGSM2	0.39	5.15	0.3	5e-7	Proinsulin levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22939802	chr11:118024134	SCN4B	0.51	6.74	0.38	9.58e-11	Gut microbiome composition (summer);
CESC	cis	rs55788414	0.932	rs28514797	chr16:81185070	G/A	cg06400318	chr16:81190750	PKD1L2	-0.6	-6.82	-0.39	6.19e-11	Left ventricular obstructive tract defect (maternal effect);
CESC	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg10862848	chr6:42927986	GNMT	-0.31	-7.73	-0.43	2.2e-13	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs4604732	0.603	rs10802512	chr1:247633730	G/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.45	6.62	0.38	2.03e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs2952156	0.959	rs907087	chr17:37828787	G/A	cg20243544	chr17:37824526	PNMT	0.67	8.24	0.45	8.01e-15	Asthma;
CESC	cis	rs7255436	0.965	rs7254882	chr19:8453822	A/G	cg16745616	chr19:8428856	ANGPTL4	-0.39	-5.88	-0.34	1.2e-8	HDL cholesterol;
CESC	cis	rs854765	0.583	rs8070722	chr17:17813562	C/T	cg04398451	chr17:18023971	MYO15A	-0.67	-9.59	-0.51	6.66e-19	Total body bone mineral density;
CESC	cis	rs2425143	1.000	rs1970357	chr20:34339200	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.8	7.3	0.41	3.39e-12	Blood protein levels;
CESC	cis	rs17376456	0.809	rs10476602	chr5:93445255	T/C	cg21475434	chr5:93447410	FAM172A	0.81	7.64	0.42	3.93e-13	Diabetic retinopathy;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg05985164	chr12:57881757	MARS	-0.38	-6.29	-0.36	1.33e-9	Gambling;
CESC	cis	rs9814567	1.000	rs13071551	chr3:134310867	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.45	6.06	0.35	4.58e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs1670533	1.000	rs641987	chr4:1077542	C/T	cg04106633	chr4:1044584	NA	0.4	5.09	0.3	6.88e-7	Recombination rate (females);
CESC	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg22535103	chr8:58192502	C8orf71	-0.95	-9.94	-0.52	5.59e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs12701220	0.803	rs12701432	chr7:1052453	C/T	cg26769984	chr7:1090371	C7orf50	0.52	6.04	0.35	5.25e-9	Bronchopulmonary dysplasia;
CESC	cis	rs6502050	0.805	rs8082653	chr17:80162382	G/A	cg11859384	chr17:80120422	CCDC57	-0.37	-5.15	-0.3	4.98e-7	Life satisfaction;
CESC	cis	rs9318086	0.712	rs12875437	chr13:24453956	A/G	cg25267304	chr13:24462978	PCOTH;MIPEP	0.43	6.17	0.35	2.48e-9	Myopia (pathological);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06296553	chr12:124810874	NCOR2	-0.55	-6.54	-0.37	3.18e-10	Gut microbiome composition (summer);
CESC	cis	rs6762	0.748	rs1130663	chr11:837582	G/A	cg23754390	chr11:835074	CD151	0.33	5.99	0.35	6.98e-9	Mean platelet volume;
CESC	cis	rs3733585	0.699	rs4339211	chr4:9947658	C/T	cg00071950	chr4:10020882	SLC2A9	-0.73	-12.14	-0.6	2.87e-27	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs6448317	0.954	rs13116026	chr4:24922242	T/A	cg21108841	chr4:24914750	CCDC149	-0.56	-6.71	-0.38	1.2e-10	Heschl's gyrus morphology;
CESC	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg15383120	chr6:291909	DUSP22	-0.68	-8.82	-0.48	1.55e-16	Menopause (age at onset);
CESC	cis	rs61931739	0.817	rs1687002	chr12:34170263	T/C	cg19457237	chr12:34500585	NA	-0.37	-5.23	-0.31	3.38e-7	Morning vs. evening chronotype;
CESC	cis	rs2486288	0.656	rs7165039	chr15:45570413	C/G	cg21132104	chr15:45694354	SPATA5L1	-0.57	-6.66	-0.38	1.55e-10	Glomerular filtration rate;
CESC	cis	rs894734	0.535	rs2366144	chr12:54324069	G/T	cg12374095	chr12:54320830	NA	-0.36	-5.22	-0.31	3.67e-7	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
CESC	cis	rs798554	0.757	rs1713919	chr7:2864706	C/A	cg04166393	chr7:2884313	GNA12	0.63	8.13	0.45	1.62e-14	Height;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg05060602	chr4:183838922	DCTD	0.46	6.07	0.35	4.38e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs10504229	0.593	rs76922080	chr8:57985837	C/G	cg22535103	chr8:58192502	C8orf71	-0.9	-8.84	-0.48	1.37e-16	Developmental language disorder (linguistic errors);
CESC	cis	rs3808502	0.525	rs13280813	chr8:11425105	G/T	cg27411982	chr8:10470053	RP1L1	-0.42	-5.08	-0.3	7.13e-7	Neuroticism;
CESC	cis	rs832540	0.656	rs6862118	chr5:56106474	G/A	cg14703610	chr5:56206110	C5orf35	0.42	5.19	0.3	4.13e-7	Coronary artery disease;
CESC	cis	rs10905065	0.965	rs10795541	chr10:5811954	A/G	cg11519256	chr10:5708881	ASB13	-0.45	-6.23	-0.36	1.86e-9	Menopause (age at onset);
CESC	cis	rs7666738	0.830	rs991168	chr4:98928293	T/C	cg03467027	chr4:99064603	C4orf37	0.46	5.59	0.32	5.78e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9894429	0.634	rs11655346	chr17:79572399	A/G	cg13777783	chr17:79615861	NA	0.37	6.32	0.36	1.12e-9	Eye color traits;
CESC	cis	rs3793683	0.520	rs4880426	chr10:134590610	G/A	cg18305652	chr10:134549665	INPP5A	0.5	7.2	0.4	6.35e-12	Migraine;
CESC	trans	rs4904167	0.812	rs1779551	chr14:84641871	C/T	cg11516540	chr7:4743394	FOXK1	-0.47	-6.18	-0.35	2.46e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs15676	0.561	rs10739736	chr9:131577981	A/T	cg00228799	chr9:131580591	ENDOG	0.44	5.45	0.32	1.16e-7	Blood metabolite levels;
CESC	cis	rs7208859	0.673	rs216424	chr17:28943064	T/G	cg19761014	chr17:28927070	LRRC37B2	0.91	8.53	0.46	1.13e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18815539	chr4:25162020	SEPSECS	-0.55	-6.54	-0.37	3.23e-10	Gut microbiome composition (summer);
CESC	cis	rs6674176	0.660	rs6680421	chr1:44408969	A/C	cg15962314	chr1:44399869	ARTN	-0.27	-5.1	-0.3	6.54e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs778371	0.723	rs1973675	chr2:233636450	C/T	cg08000102	chr2:233561755	GIGYF2	-0.82	-14.35	-0.66	6.24e-35	Schizophrenia;
CESC	cis	rs8031584	0.872	rs11634761	chr15:31243173	A/C	cg08704250	chr15:31115839	NA	-0.6	-7.54	-0.42	7.32e-13	Huntington's disease progression;
CESC	cis	rs6998277	0.830	rs965661	chr8:103597586	C/T	cg10187029	chr8:103597600	NA	0.75	9.93	0.52	5.94e-20	Migraine;
CESC	cis	rs12995491	0.698	rs34352413	chr2:88498754	T/G	cg18490616	chr2:88469792	THNSL2	-0.52	-7.69	-0.43	2.81e-13	Response to metformin (IC50);
CESC	cis	rs9322193	0.887	rs3777949	chr6:149917157	G/A	cg07701084	chr6:150067640	NUP43	0.44	6.25	0.36	1.62e-9	Lung cancer;
CESC	cis	rs2594989	1.000	rs2594989	chr3:11316143	C/T	cg00170343	chr3:11313890	ATG7	0.58	5.35	0.31	1.87e-7	Circulating chemerin levels;
CESC	cis	rs2932538	0.922	rs12143068	chr1:113138110	A/G	cg22162597	chr1:113214053	CAPZA1	0.54	7.08	0.4	1.3e-11	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CESC	cis	rs7208859	0.573	rs216442	chr17:28931197	T/G	cg13385521	chr17:29058706	SUZ12P	0.77	5.67	0.33	3.8e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.44	5.23	0.31	3.52e-7	Renal function-related traits (BUN);
CESC	cis	rs875971	0.638	rs35986979	chr7:66088990	G/A	cg11764359	chr7:65958608	NA	-0.72	-9.45	-0.5	1.81e-18	Aortic root size;
CESC	cis	rs9322193	0.962	rs9322220	chr6:150104033	G/C	cg04369109	chr6:150039330	LATS1	-0.4	-5.4	-0.31	1.48e-7	Lung cancer;
CESC	cis	rs801193	1.000	rs3778909	chr7:66255646	G/C	cg25985355	chr7:65971099	NA	-0.31	-5.14	-0.3	5.33e-7	Aortic root size;
CESC	cis	rs10876993	0.890	rs774888	chr12:58036506	A/G	cg18357645	chr12:58087776	OS9	0.59	9.03	0.49	3.56e-17	Celiac disease or Rheumatoid arthritis;
CESC	cis	rs875971	0.522	rs10807697	chr7:65416170	A/G	cg14393609	chr7:65229607	NA	0.52	7.11	0.4	1.1e-11	Aortic root size;
CESC	cis	rs4474465	0.688	rs10751296	chr11:78277277	C/T	cg27205649	chr11:78285834	NARS2	-0.5	-6.69	-0.38	1.33e-10	Alzheimer's disease (survival time);
CESC	cis	rs1008375	0.932	rs7677212	chr4:17675932	A/G	cg02297831	chr4:17616191	MED28	-0.46	-5.49	-0.32	9.64e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs9325144	0.560	rs7304568	chr12:38632408	G/A	cg13010199	chr12:38710504	ALG10B	-0.41	-5.53	-0.32	7.66e-8	Morning vs. evening chronotype;
CESC	cis	rs854765	0.583	rs11078405	chr17:17824978	G/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.53	7.31	0.41	3.19e-12	Total body bone mineral density;
CESC	cis	rs7254114	0.578	rs4804574	chr19:11317482	G/A	cg02815516	chr19:11306319	KANK2	0.41	6.63	0.38	1.92e-10	Immature fraction of reticulocytes;
CESC	cis	rs57506017	0.585	rs10950394	chr7:12263587	C/T	cg23422036	chr7:12250390	TMEM106B	0.39	5.23	0.31	3.51e-7	Neuroticism;
CESC	cis	rs4665809	0.652	rs11685594	chr2:26402846	A/G	cg08470875	chr2:26401718	FAM59B	-0.7	-7.43	-0.41	1.54e-12	Gut microbiome composition (summer);
CESC	cis	rs12530845	0.673	rs73725437	chr7:135327853	G/A	cg23117316	chr7:135346802	PL-5283	-0.55	-6.2	-0.36	2.17e-9	Red blood cell traits;
CESC	cis	rs9457247	0.967	rs2769346	chr6:167370999	A/G	cg23791538	chr6:167370224	RNASET2	0.61	8.65	0.47	5.15e-16	Crohn's disease;
CESC	cis	rs2295499	0.643	rs12509102	chr4:2710962	G/C	cg08330972	chr4:2403930	ZFYVE28	-0.33	-5.41	-0.32	1.41e-7	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
CESC	cis	rs858239	0.633	rs858300	chr7:23244631	A/G	cg23682824	chr7:23144976	KLHL7	0.42	5.62	0.33	4.85e-8	Cerebrospinal fluid biomarker levels;
CESC	cis	rs1215050	0.716	rs11940331	chr4:99054041	G/C	cg05340658	chr4:99064831	C4orf37	0.59	7.92	0.44	6.47e-14	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs9287719	0.967	rs7600820	chr2:10740044	A/G	cg00105475	chr2:10696890	NA	0.39	5.61	0.33	4.96e-8	Prostate cancer;
CESC	cis	rs1862618	0.853	rs6450409	chr5:56101399	A/G	cg18230493	chr5:56204884	C5orf35	-0.66	-8.28	-0.45	6.32e-15	Initial pursuit acceleration;
CESC	cis	rs2576037	0.526	rs2571027	chr18:44561516	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.55	7.6	0.42	5.28e-13	Personality dimensions;
CESC	cis	rs9488822	0.596	rs13192549	chr6:116338352	C/A	cg05304507	chr6:116381966	FRK	0.22	5.44	0.32	1.21e-7	Cholesterol, total;LDL cholesterol;
CESC	trans	rs3741404	0.791	rs7102177	chr11:63909228	T/C	cg15268290	chr11:83690587	DLG2	0.43	6.04	0.35	5.23e-9	Platelet count;
CESC	trans	rs1814175	0.817	rs11040651	chr11:49938395	G/A	cg03929089	chr4:120376271	NA	-0.93	-15.69	-0.69	1.12e-39	Height;
CESC	cis	rs9902453	0.765	rs12601647	chr17:28164953	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.77	10.29	0.53	4.06e-21	Coffee consumption (cups per day);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg27605355	chr17:74472963	RHBDF2	0.45	6.78	0.38	7.79e-11	Fibrinogen levels;
CESC	cis	rs7511006	0.895	rs5771270	chr22:50682865	G/A	cg16473166	chr22:50639996	SELO	0.49	6.16	0.35	2.76e-9	Obesity-related traits;
CESC	cis	rs17376456	0.569	rs10067754	chr5:93093110	T/A	cg25358565	chr5:93447407	FAM172A	0.68	7.24	0.41	5.01e-12	Diabetic retinopathy;
CESC	cis	rs9359856	0.510	rs74437492	chr6:90338728	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.73	-7.79	-0.43	1.55e-13	Bipolar disorder;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg10522326	chr1:16134171	UQCRHL	-0.51	-6.96	-0.39	2.75e-11	Asthma;
CESC	trans	rs1814175	0.712	rs9665784	chr11:50030617	C/T	cg03929089	chr4:120376271	NA	-0.94	-16.17	-0.7	2.25e-41	Height;
CESC	cis	rs10979	1.000	rs9376756	chr6:143886125	C/T	cg25407410	chr6:143891975	LOC285740	-0.53	-7.64	-0.42	4.07e-13	Hypospadias;
CESC	cis	rs5769765	0.505	rs4561759	chr22:50256686	C/T	cg02269571	chr22:50332266	NA	0.46	5.46	0.32	1.08e-7	Schizophrenia;
CESC	cis	rs7945705	0.818	rs2742552	chr11:8876852	C/T	cg09997546	chr11:8931473	C11orf17;ST5	-0.31	-5.14	-0.3	5.27e-7	Hemoglobin concentration;
CESC	cis	rs10504229	1.000	rs67105789	chr8:58192002	G/T	cg22535103	chr8:58192502	C8orf71	-1.05	-13.08	-0.63	1.71e-30	Developmental language disorder (linguistic errors);
CESC	trans	rs7307889	0.793	rs7486988	chr12:6009745	C/A	cg18407955	chr7:158110685	PTPRN2	-0.69	-6.46	-0.37	4.88e-10	Obesity-related traits;
CESC	cis	rs7680126	0.633	rs2868937	chr4:10303081	C/T	cg00071950	chr4:10020882	SLC2A9	-0.55	-6.2	-0.36	2.1e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	cis	rs17376456	0.877	rs10061080	chr5:93420559	A/G	cg21475434	chr5:93447410	FAM172A	0.83	7.47	0.42	1.18e-12	Diabetic retinopathy;
CESC	cis	rs7615952	0.932	rs7630077	chr3:125649676	T/C	cg05084668	chr3:125655381	ALG1L	-0.51	-5.95	-0.34	8.3e-9	Blood pressure (smoking interaction);
CESC	cis	rs11122272	0.735	rs2808585	chr1:231514218	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.57	-7.82	-0.43	1.29e-13	Hemoglobin concentration;
CESC	cis	rs2760061	0.598	rs849904	chr1:228137145	G/C	cg01973587	chr1:228161476	NA	0.38	5.84	0.34	1.54e-8	Diastolic blood pressure;
CESC	cis	rs7255436	0.965	rs4044435	chr19:8448177	T/C	cg10174797	chr19:8464628	RAB11B	0.36	5.09	0.3	6.92e-7	HDL cholesterol;
CESC	cis	rs7618915	1.000	rs3852063	chr3:52349204	A/G	cg14092988	chr3:52407081	DNAH1	0.41	5.4	0.31	1.52e-7	Bipolar disorder;
CESC	cis	rs6933660	0.745	rs9322320	chr6:151751908	C/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.86	14.41	0.66	3.84e-35	Menarche (age at onset);
CESC	cis	rs3106136	0.609	rs12500027	chr4:95107918	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.46	-6.29	-0.36	1.34e-9	Capecitabine sensitivity;
CESC	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg06873352	chr17:61820015	STRADA	0.73	13.09	0.63	1.57e-30	Prudent dietary pattern;
CESC	cis	rs7520050	0.966	rs7524495	chr1:46266932	T/C	cg03146154	chr1:46216737	IPP	-0.47	-6.19	-0.36	2.34e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs7072216	0.763	rs1061437	chr10:100176154	C/T	cg26618903	chr10:100175079	PYROXD2	-0.37	-5.65	-0.33	4.05e-8	Metabolite levels;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04579211	chr15:41221939	DLL4	0.46	6.22	0.36	1.88e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs6967414	0.579	rs11980762	chr7:6756878	G/A	cg09896999	chr7:6746977	ZNF12	-0.52	-6.19	-0.36	2.31e-9	Hematocrit;Hemoglobin concentration;
CESC	cis	rs1808579	0.904	rs1652343	chr18:21131929	T/C	cg14672496	chr18:21087552	C18orf8	0.42	6.09	0.35	3.92e-9	Hip circumference;Body mass index;BMI (adjusted for smoking behaviour);
CESC	cis	rs9788333	0.707	rs12584557	chr13:21886171	C/A	cg21970626	chr13:21893289	NA	-0.41	-6.3	-0.36	1.23e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs2836974	0.899	rs34176878	chr21:40548855	C/A	cg11644478	chr21:40555479	PSMG1	1.01	16.61	0.71	6.05e-43	Cognitive function;
CESC	cis	rs4979906	1.000	rs4979786	chr10:79444965	T/C	cg07817648	chr10:79422355	NA	-0.61	-6.53	-0.37	3.37e-10	Mortality in heart failure;
CESC	cis	rs7119	1.000	rs7119	chr15:77777632	C/T	cg17802220	chr15:77601643	NA	-0.34	-5.31	-0.31	2.34e-7	Type 2 diabetes;
CESC	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg10150615	chr22:24372951	LOC391322	-0.53	-7.12	-0.4	1.01e-11	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs1570884	0.516	rs2094108	chr13:50171550	G/A	cg08779649	chr13:50194554	NA	0.39	6.71	0.38	1.17e-10	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
CESC	cis	rs950776	0.518	rs12915428	chr15:78823368	G/A	cg24631222	chr15:78858424	CHRNA5	-0.42	-5.33	-0.31	2.09e-7	Sudden cardiac arrest;
CESC	cis	rs7072216	0.763	rs3814140	chr10:100170762	C/T	cg26618903	chr10:100175079	PYROXD2	-0.38	-5.79	-0.34	1.99e-8	Metabolite levels;
CESC	cis	rs748404	0.631	rs6493084	chr15:43647627	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.55	8.42	0.46	2.44e-15	Lung cancer;
CESC	cis	rs2228479	0.850	rs11644213	chr16:89837367	C/T	cg14709524	chr16:89940631	TCF25	-0.82	-6.46	-0.37	4.99e-10	Skin colour saturation;
CESC	cis	rs4700695	0.668	rs36837	chr5:65480007	C/A	cg21114390	chr5:65439923	SFRS12	-0.47	-5.71	-0.33	2.96e-8	Facial morphology (factor 19);
CESC	cis	rs7659604	1.000	rs34952897	chr4:122664409	C/T	cg19671926	chr4:122722719	EXOSC9	-0.44	-5.21	-0.3	3.76e-7	Type 2 diabetes;
CESC	cis	rs7777484	0.534	rs2533890	chr7:2828743	C/T	cg09658497	chr7:2847517	GNA12	-0.46	-7.11	-0.4	1.1e-11	Height;
CESC	cis	rs9486715	0.758	rs2971610	chr6:97027380	C/T	cg06623918	chr6:96969491	KIAA0776	-0.95	-15.19	-0.68	6.76e-38	Headache;
CESC	trans	rs650950	0.528	rs646660	chr11:35528452	C/T	cg14871650	chr4:170541668	CLCN3	0.53	6.54	0.37	3.09e-10	Bronchopulmonary dysplasia;
CESC	cis	rs7786877	0.761	rs11772705	chr7:100298904	T/C	cg20848291	chr7:100343083	ZAN	-0.78	-9.93	-0.52	5.71e-20	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs5850	0.602	rs1005786	chr7:23145837	G/C	cg27449745	chr7:23145252	KLHL7	-0.58	-7.72	-0.43	2.32e-13	Blood protein levels;
CESC	cis	rs1707322	1.000	rs9803784	chr1:46401907	T/C	cg06784218	chr1:46089804	CCDC17	0.33	5.63	0.33	4.7e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7666738	0.830	rs28810677	chr4:99043193	C/T	cg24818145	chr4:99064322	C4orf37	0.38	5.04	0.3	8.49e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6502050	0.835	rs3935816	chr17:80137173	C/T	cg11859384	chr17:80120422	CCDC57	-0.36	-5.05	-0.3	8.38e-7	Life satisfaction;
CESC	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.6	0.38	2.17e-10	Prudent dietary pattern;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14290704	chr9:2015039	SMARCA2	-0.57	-6.75	-0.38	9.11e-11	Gut microbiome composition (summer);
CESC	cis	rs9303401	0.614	rs66480139	chr17:57101538	G/A	cg12560992	chr17:57184187	TRIM37	0.5	5.26	0.31	2.91e-7	Cognitive test performance;
CESC	cis	rs12681288	0.862	rs7015529	chr8:1020249	A/G	cg15309053	chr8:964076	NA	0.39	6.44	0.37	5.74e-10	Schizophrenia;
CESC	cis	rs11785400	1.000	rs3735994	chr8:143742683	C/T	cg10596483	chr8:143751796	JRK	0.43	5.65	0.33	4.1e-8	Schizophrenia;
CESC	cis	rs708547	1.000	rs10003229	chr4:57809598	A/C	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.68	-7.05	-0.4	1.54e-11	Response to bleomycin (chromatid breaks);
CESC	cis	rs7680126	0.596	rs917826	chr4:10295595	C/G	cg00071950	chr4:10020882	SLC2A9	-0.53	-5.95	-0.34	8.63e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg15652120	chr12:96588210	ELK3	0.51	6.79	0.38	7.4e-11	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs2295499	0.754	rs12499258	chr4:2715758	G/A	cg08330972	chr4:2403930	ZFYVE28	-0.34	-5.54	-0.32	7.22e-8	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
CESC	cis	rs9457247	0.765	rs4710171	chr6:167430186	A/G	cg23791538	chr6:167370224	RNASET2	-0.54	-7.44	-0.42	1.37e-12	Crohn's disease;
CESC	cis	rs2303745	0.589	rs1864116	chr19:17393015	C/T	cg22549504	chr19:17448937	GTPBP3	0.49	5.52	0.32	8.25e-8	Systemic lupus erythematosus;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg21800906	chr11:32914818	QSER1	0.54	7.15	0.4	8.24e-12	Gut microbiota (bacterial taxa);
CESC	cis	rs17807624	1.000	rs17807624	chr8:11463015	A/G	cg21775007	chr8:11205619	TDH	-0.4	-5.92	-0.34	1.02e-8	Systemic lupus erythematosus;
CESC	cis	rs28386778	0.830	rs7209321	chr17:61855668	A/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	10.51	0.54	8.06e-22	Prudent dietary pattern;
CESC	cis	rs816535	1	rs816535	chr20:26255996	C/T	cg20395967	chr20:26190347	MIR663	0.27	5.05	0.3	8.39e-7	Parkinson disease and lewy body pathology;
CESC	cis	rs270601	0.770	rs932019	chr5:131599370	T/C	cg24060327	chr5:131705240	SLC22A5	-0.48	-6.27	-0.36	1.45e-9	Acylcarnitine levels;
CESC	cis	rs4654899	0.828	rs4654735	chr1:21432001	T/C	cg05370193	chr1:21551575	ECE1	0.4	6.16	0.35	2.68e-9	Superior frontal gyrus grey matter volume;
CESC	cis	rs660498	0.507	rs34354872	chr10:27735673	T/G	cg08398567	chr10:27609333	NA	0.39	5.29	0.31	2.61e-7	Asthma (childhood onset);
CESC	trans	rs11039798	0.764	rs11040030	chr11:48800985	C/T	cg15704280	chr7:45808275	SEPT13	0.71	6.44	0.37	5.59e-10	Axial length;
CESC	trans	rs3780486	0.846	rs10758192	chr9:33131651	G/A	cg20290983	chr6:43655470	MRPS18A	0.99	18.35	0.75	4.06e-49	IgG glycosylation;
CESC	cis	rs3858526	0.523	rs10838749	chr11:5884246	A/G	cg05234568	chr11:5960015	NA	-0.62	-8.76	-0.47	2.37e-16	DNA methylation (variation);
CESC	cis	rs72781680	0.715	rs72796332	chr2:24142060	G/A	cg08917208	chr2:24149416	ATAD2B	0.57	5.62	0.33	4.79e-8	Lymphocyte counts;
CESC	cis	rs644799	0.582	rs473157	chr11:95596874	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.56	7.26	0.41	4.34e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	trans	rs3780486	0.757	rs10758189	chr9:33125804	A/G	cg20290983	chr6:43655470	MRPS18A	0.97	17.6	0.73	1.83e-46	IgG glycosylation;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03449513	chr6:51275386	NA	-0.6	-7.26	-0.41	4.35e-12	Gut microbiome composition (summer);
CESC	cis	rs911555	0.755	rs6575988	chr14:103900827	G/T	cg24130564	chr14:104152367	KLC1	0.52	7.2	0.4	6.15e-12	Intelligence (multi-trait analysis);
CESC	cis	rs2997447	0.655	rs12094933	chr1:26374779	T/C	cg19633962	chr1:26362018	EXTL1	-0.49	-5.3	-0.31	2.39e-7	QRS complex (12-leadsum);
CESC	cis	rs172166	0.694	rs9295760	chr6:28147385	G/A	cg23281280	chr6:28129359	ZNF389	0.42	6.23	0.36	1.84e-9	Cardiac Troponin-T levels;
CESC	cis	rs1023500	0.596	rs133350	chr22:42429049	A/G	cg15557168	chr22:42548783	NA	-0.39	-5.2	-0.3	3.9e-7	Schizophrenia;
CESC	cis	rs11645898	0.935	rs72787078	chr16:72158493	C/T	cg14768367	chr16:72042858	DHODH	-0.71	-6.06	-0.35	4.62e-9	Blood protein levels;
CESC	cis	rs6963495	0.818	rs9769403	chr7:105163091	G/A	cg19920283	chr7:105172520	RINT1	0.69	6.56	0.37	2.85e-10	Bipolar disorder (body mass index interaction);
CESC	cis	rs9322193	0.923	rs2342857	chr6:150130673	G/A	cg07701084	chr6:150067640	NUP43	0.43	5.8	0.34	1.88e-8	Lung cancer;
CESC	cis	rs1790761	0.505	rs7941395	chr11:67347417	A/G	cg14500267	chr11:67383377	NA	-0.31	-5.12	-0.3	5.81e-7	Mean corpuscular volume;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg12598099	chr18:60189407	ZCCHC2	0.46	6.55	0.37	3.01e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs9915657	0.933	rs17246133	chr17:70140485	A/G	cg06234051	chr17:70120541	SOX9	-0.36	-5.43	-0.32	1.26e-7	Thyroid hormone levels;
CESC	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.55	0.37	2.91e-10	Prudent dietary pattern;
CESC	cis	rs9611565	0.559	rs4822048	chr22:41988225	C/T	cg17376030	chr22:41985996	PMM1	0.81	8.45	0.46	1.98e-15	Vitiligo;
CESC	cis	rs28647808	0.748	rs114667516	chr9:136258537	A/G	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.85	5.74	0.33	2.59e-8	Blood protein levels;
CESC	cis	rs8177253	0.530	rs8177177	chr3:133463195	A/G	cg18769074	chr3:133464867	TF	0.3	5.75	0.33	2.44e-8	Iron status biomarkers;
CESC	cis	rs1707322	0.613	rs1473840	chr1:46601197	A/G	cg06784218	chr1:46089804	CCDC17	-0.34	-5.35	-0.31	1.88e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9309473	0.718	rs6546829	chr2:73613789	C/G	cg20560298	chr2:73613845	ALMS1	-0.5	-6.76	-0.38	8.74e-11	Metabolite levels;
CESC	cis	rs72781680	0.706	rs72796108	chr2:23904990	C/A	cg20701182	chr2:24300061	SF3B14	0.79	6.83	0.39	5.68e-11	Lymphocyte counts;
CESC	cis	rs55823223	0.680	rs57287238	chr17:73850940	T/C	cg10935138	chr17:73851978	WBP2	0.84	9.76	0.51	2.08e-19	Psoriasis;
CESC	cis	rs3820068	0.608	rs10927836	chr1:16034368	G/C	cg17385448	chr1:15911702	AGMAT	0.38	6.08	0.35	4.28e-9	Systolic blood pressure;
CESC	cis	rs2243480	0.901	rs778693	chr7:65872345	T/G	cg13147721	chr7:65941812	NA	-0.95	-8.95	-0.48	6.27e-17	Diabetic kidney disease;
CESC	cis	rs10479542	0.929	rs10078796	chr5:178978883	T/A	cg09060608	chr5:178986726	RUFY1	0.51	7.81	0.43	1.38e-13	Lung cancer;
CESC	cis	rs2294693	0.679	rs4317403	chr6:40971173	C/T	cg14418226	chr6:40996092	UNC5CL	0.48	5.26	0.31	2.99e-7	Gastric cancer;Non-cardia gastric cancer;
CESC	cis	rs7666738	0.830	rs6854703	chr4:98977586	A/T	cg03467027	chr4:99064603	C4orf37	0.42	5.29	0.31	2.5e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3733585	0.753	rs1122141	chr4:9947278	T/C	cg02734326	chr4:10020555	SLC2A9	-0.45	-6.7	-0.38	1.25e-10	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs796364	1.000	rs4410273	chr2:200818258	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.86	8.35	0.46	3.88e-15	Schizophrenia;
CESC	cis	rs10200159	1.000	rs6760959	chr2:55821501	T/A	cg13617705	chr2:55845095	SMEK2	0.68	5.13	0.3	5.67e-7	Vitiligo;
CESC	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.4	-5.99	-0.35	6.84e-9	Longevity;Endometriosis;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg27497049	chr8:94712646	FAM92A1	-0.48	-6.7	-0.38	1.23e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs3733585	0.673	rs10018204	chr4:9964570	C/T	cg00071950	chr4:10020882	SLC2A9	-0.73	-11.77	-0.59	5.14e-26	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs7666738	0.791	rs6833691	chr4:98951508	A/G	cg17366294	chr4:99064904	C4orf37	0.59	8.47	0.46	1.75e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs936229	0.871	rs2290574	chr15:75135447	T/C	cg14664628	chr15:75095509	CSK	-0.84	-11.18	-0.57	4.95e-24	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CESC	cis	rs11098499	0.954	rs10031665	chr4:120422852	T/C	cg09307838	chr4:120376055	NA	0.93	13.08	0.63	1.67e-30	Corneal astigmatism;
CESC	trans	rs4424809	1.000	rs76502189	chr13:85278841	A/G	cg22095490	chr18:77560089	NA	-0.87	-6.37	-0.36	8.48e-10	Age-related hearing impairment (SNP x SNP interaction);
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg22929018	chr2:207024348	EEF1B2;NDUFS1	-0.47	-6.31	-0.36	1.14e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs909002	0.800	rs10914459	chr1:32096918	T/C	cg13919466	chr1:32135498	COL16A1	-0.45	-8.04	-0.44	2.96e-14	Intelligence (multi-trait analysis);
CESC	cis	rs10779751	1.000	rs6679878	chr1:11306882	A/G	cg08854313	chr1:11322531	MTOR	0.8	10.84	0.55	6.7e-23	Body mass index;
CESC	cis	rs72781680	0.611	rs7602797	chr2:24318148	C/T	cg06627628	chr2:24431161	ITSN2	-0.68	-6.58	-0.37	2.44e-10	Lymphocyte counts;
CESC	cis	rs875971	0.862	rs880166	chr7:65670762	T/C	cg10691866	chr7:65817282	TPST1	0.31	5.18	0.3	4.45e-7	Aortic root size;
CESC	cis	rs798766	1.000	rs1665364	chr4:1727206	A/G	cg07041428	chr4:1763019	NA	0.39	5.34	0.31	2.03e-7	Bladder cancer;Urinary bladder cancer;
CESC	cis	rs3733585	0.699	rs4515163	chr4:9959603	C/T	cg00071950	chr4:10020882	SLC2A9	-0.73	-11.79	-0.59	4.58e-26	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs2294693	0.945	rs11756893	chr6:41010058	A/C	cg14418226	chr6:40996092	UNC5CL	0.5	5.75	0.33	2.42e-8	Gastric cancer;Non-cardia gastric cancer;
CESC	cis	rs9399135	0.967	rs11755229	chr6:135369913	A/G	cg24558204	chr6:135376177	HBS1L	0.49	6.77	0.38	8.11e-11	Red blood cell count;
CESC	trans	rs11098499	0.530	rs114866537	chr4:120258608	A/T	cg25214090	chr10:38739885	LOC399744	0.61	8.64	0.47	5.37e-16	Corneal astigmatism;
CESC	cis	rs672059	1.000	rs563026	chr1:183161037	A/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.55	-7.11	-0.4	1.06e-11	Hypertriglyceridemia;
CESC	cis	rs7726839	0.540	rs72705097	chr5:655067	G/A	cg16447950	chr5:562315	NA	-0.58	-6.53	-0.37	3.38e-10	Obesity-related traits;
CESC	cis	rs8062405	1.000	rs72793812	chr16:28840381	A/G	cg05966235	chr16:28915196	ATP2A1	0.35	5.12	0.3	5.8e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs7666738	0.830	rs4392515	chr4:98957431	A/G	cg03676636	chr4:99064102	C4orf37	0.33	5.11	0.3	6.05e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9596863	0.821	rs4884722	chr13:54429821	C/A	ch.13.53330881F	chr13:54432880	NA	-0.63	-5.37	-0.31	1.74e-7	Epilepsy and lamotrigine-induced maculopapular eruptions;
CESC	cis	rs10504229	1.000	rs17805326	chr8:58169533	A/C	cg05313129	chr8:58192883	C8orf71	-0.56	-6.49	-0.37	4.31e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs514406	0.668	rs520281	chr1:53365235	G/C	cg24675658	chr1:53192096	ZYG11B	-0.65	-8.83	-0.48	1.43e-16	Monocyte count;
CESC	cis	rs910316	1.000	rs3742773	chr14:75579643	A/G	cg08847533	chr14:75593920	NEK9	1.0	19.49	0.77	4.1e-53	Height;
CESC	cis	rs8070128	0.601	rs8080602	chr17:17954728	G/C	cg04398451	chr17:18023971	MYO15A	0.73	10.55	0.54	5.95e-22	Total body bone mineral density;
CESC	cis	rs6714710	0.603	rs895438	chr2:98382886	G/A	cg26665480	chr2:98280029	ACTR1B	0.68	9.18	0.49	1.31e-17	Posterior cortical atrophy and Alzheimer's disease;
CESC	cis	rs10463316	0.894	rs6579863	chr5:150761946	A/T	cg03212797	chr5:150827313	SLC36A1	-0.46	-6.02	-0.35	5.83e-9	Metabolite levels (Pyroglutamine);
CESC	cis	rs4595586	0.679	rs5017082	chr12:39314564	A/C	cg26384229	chr12:38710491	ALG10B	-0.41	-6.03	-0.35	5.42e-9	Morning vs. evening chronotype;
CESC	cis	rs7520050	0.778	rs3013597	chr1:46128356	C/A	cg24296786	chr1:45957014	TESK2	-0.47	-6.17	-0.35	2.61e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs2243480	1.000	rs958550	chr7:65635679	C/T	cg18252515	chr7:66147081	NA	1.22	11.33	0.57	1.59e-24	Diabetic kidney disease;
CESC	cis	rs9611565	0.512	rs4820446	chr22:42215684	C/T	cg06481639	chr22:41940642	POLR3H	-0.58	-5.71	-0.33	3.03e-8	Vitiligo;
CESC	cis	rs853679	0.517	rs9357065	chr6:28129580	T/C	cg12963246	chr6:28129442	ZNF389	0.56	7.34	0.41	2.67e-12	Depression;
CESC	trans	rs1814175	0.935	rs7479914	chr11:49661351	T/C	cg15704280	chr7:45808275	SEPT13	-1.0	-17.79	-0.74	4.04e-47	Height;
CESC	cis	rs7605378	0.752	rs769960	chr2:200710706	G/T	cg23649088	chr2:200775458	C2orf69	-0.58	-7.37	-0.41	2.12e-12	Osteoporosis;
CESC	cis	rs7000551	0.689	rs2469753	chr8:22383225	T/C	cg12081754	chr8:22256438	SLC39A14	0.39	5.22	0.31	3.56e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CESC	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.64	7.45	0.42	1.33e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs12497850	0.931	rs7616815	chr3:48779715	C/T	cg03060546	chr3:49711283	APEH	0.4	5.03	0.3	9.02e-7	Parkinson's disease;
CESC	cis	rs7044106	0.762	rs10760107	chr9:123383630	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.74	10.8	0.55	8.88e-23	Hip circumference adjusted for BMI;
CESC	cis	rs7249142	0.562	rs10418053	chr19:19287164	A/G	cg27384695	chr19:19271486	LOC729991-MEF2B;MEF2B	0.28	5.06	0.3	7.92e-7	IgG glycosylation;
CESC	cis	rs11098499	0.866	rs6847778	chr4:120293582	A/G	cg09307838	chr4:120376055	NA	0.87	11.85	0.59	2.74e-26	Corneal astigmatism;
CESC	cis	rs13108904	0.557	rs1680033	chr4:1243404	C/T	cg02475777	chr4:1388615	CRIPAK	-0.47	-6.05	-0.35	4.85e-9	Obesity-related traits;
CESC	cis	rs1799949	1.000	rs8176212	chr17:41226601	G/C	cg05368731	chr17:41323189	NBR1	0.8	11.09	0.56	9.98e-24	Menopause (age at onset);
CESC	cis	rs999943	0.846	rs999942	chr6:33624902	G/C	cg14003231	chr6:33640908	ITPR3	0.7	12.36	0.6	4.99e-28	Obesity (extreme);
CESC	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg12419862	chr22:24373484	LOC391322	-0.8	-11.75	-0.59	6.16e-26	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs1797885	0.934	rs2648312	chr3:12547147	C/T	cg26432171	chr3:12704882	RAF1	0.46	5.67	0.33	3.78e-8	Immature fraction of reticulocytes;
CESC	cis	rs3733585	0.631	rs7699671	chr4:10125874	C/T	cg05927159	chr4:10118984	WDR1	0.35	5.11	0.3	6.14e-7	Cleft plate (environmental tobacco smoke interaction);
CESC	trans	rs8073060	0.586	rs2523114	chr17:34023762	G/A	cg19694781	chr19:47549865	TMEM160	-0.74	-6.91	-0.39	3.64e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	cis	rs11785693	0.862	rs11783719	chr8:4991311	G/T	cg26367366	chr8:4980734	NA	0.88	8.07	0.44	2.52e-14	Neuroticism (multi-trait analysis);Neuroticism;
CESC	cis	rs6460942	1.000	rs7791634	chr7:12401482	A/T	cg06484146	chr7:12443880	VWDE	-0.7	-8.06	-0.44	2.57e-14	Coronary artery disease;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg14223017	chr19:2151266	AP3D1	0.49	6.99	0.39	2.29e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs8038465	0.622	rs7182124	chr15:73915254	C/T	cg15420318	chr15:73925796	NPTN	0.49	6.9	0.39	3.75e-11	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs4665809	1.000	rs4233708	chr2:26291345	C/T	cg04944784	chr2:26401820	FAM59B	-0.66	-7.66	-0.43	3.61e-13	Gut microbiome composition (summer);
CESC	cis	rs6714710	0.603	rs6738389	chr2:98386731	A/G	cg26665480	chr2:98280029	ACTR1B	0.6	8.42	0.46	2.46e-15	Posterior cortical atrophy and Alzheimer's disease;
CESC	cis	rs9443645	0.803	rs12195716	chr6:79535412	T/C	cg05283184	chr6:79620031	NA	-0.44	-6.88	-0.39	4.19e-11	Intelligence (multi-trait analysis);
CESC	cis	rs2836974	0.563	rs997147	chr21:40695325	A/G	cg11644478	chr21:40555479	PSMG1	-0.79	-11.6	-0.58	1.99e-25	Cognitive function;
CESC	cis	rs2066819	0.818	rs773652	chr12:56674766	G/A	cg26316697	chr12:56727976	PAN2	-0.69	-6.64	-0.38	1.74e-10	Psoriasis vulgaris;
CESC	cis	rs9457247	0.846	rs2757052	chr6:167380174	T/C	cg23791538	chr6:167370224	RNASET2	0.6	8.57	0.47	8.75e-16	Crohn's disease;
CESC	cis	rs9611565	0.649	rs2064189	chr22:42127999	A/G	cg06481639	chr22:41940642	POLR3H	0.47	5.48	0.32	9.85e-8	Vitiligo;
CESC	cis	rs8114671	0.869	rs1407202	chr20:33651967	C/T	cg07148914	chr20:33460835	GGT7	-0.4	-5.17	-0.3	4.66e-7	Height;
CESC	cis	rs11190604	1.000	rs11190602	chr10:102297256	T/C	cg07080220	chr10:102295463	HIF1AN	0.7	6.5	0.37	3.99e-10	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs4423214	0.840	rs2017686	chr11:71187061	C/G	cg05163923	chr11:71159392	DHCR7	-0.68	-7.76	-0.43	1.82e-13	Vitamin D levels;
CESC	cis	rs2228479	0.850	rs17226512	chr16:89839976	T/C	cg04013166	chr16:89971882	TCF25	0.78	6.69	0.38	1.3e-10	Skin colour saturation;
CESC	cis	rs76878669	0.606	rs2282531	chr11:66099494	C/T	cg18002602	chr11:66138449	SLC29A2	-0.43	-7.1	-0.4	1.13e-11	Educational attainment (years of education);
CESC	cis	rs16867321	0.950	rs12477283	chr2:181501355	G/T	cg23363182	chr2:181467187	NA	-0.43	-5.69	-0.33	3.39e-8	Obesity;
CESC	cis	rs17666538	1.000	rs61064968	chr8:587933	T/C	cg13264159	chr8:625131	ERICH1	0.74	5.14	0.3	5.34e-7	IgG glycosylation;
CESC	cis	rs7618915	0.571	rs34115864	chr3:52612178	A/G	cg05564831	chr3:52568323	NT5DC2	0.46	6.98	0.39	2.33e-11	Bipolar disorder;
CESC	trans	rs2812533	0.689	rs2616070	chr10:71426695	C/G	cg23618638	chr7:22123315	NA	0.47	6.19	0.36	2.28e-9	Type 2 diabetes;
CESC	cis	rs367615	0.660	rs10061221	chr5:108839038	C/T	cg17395555	chr5:108820864	NA	0.63	11.09	0.56	9.78e-24	Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs870825	0.860	rs11132253	chr4:185595472	C/T	cg04058563	chr4:185651563	MLF1IP	0.51	5.23	0.31	3.48e-7	Blood protein levels;
CESC	cis	rs4595586	0.870	rs10444553	chr12:39294076	C/G	cg26384229	chr12:38710491	ALG10B	0.36	5.15	0.3	4.97e-7	Morning vs. evening chronotype;
CESC	cis	rs9399135	0.933	rs28384512	chr6:135376232	C/T	cg24558204	chr6:135376177	HBS1L	0.5	6.85	0.39	5.08e-11	Red blood cell count;
CESC	cis	rs9611565	0.694	rs202664	chr22:41813886	C/T	cg17376030	chr22:41985996	PMM1	-0.62	-6.71	-0.38	1.16e-10	Vitiligo;
CESC	cis	rs2637266	0.703	rs1660907	chr10:78494859	A/C	cg18941641	chr10:78392320	NA	0.38	7.26	0.41	4.32e-12	Pulmonary function;
CESC	cis	rs4722166	0.508	rs1474348	chr7:22767908	C/G	cg05265849	chr7:22767390	IL6	0.51	6.58	0.37	2.56e-10	Lung cancer;
CESC	cis	rs595982	0.559	rs117227130	chr19:49367959	A/G	cg15549821	chr19:49342101	PLEKHA4	-0.71	-7.96	-0.44	5.22e-14	Red cell distribution width;
CESC	cis	rs7635838	0.859	rs7632040	chr3:11427455	A/G	cg00170343	chr3:11313890	ATG7	0.42	5.57	0.32	6.37e-8	HDL cholesterol;
CESC	cis	rs7267979	1.000	rs2027003	chr20:25350498	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.84	-15.92	-0.7	1.72e-40	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs10089	1.000	rs10064357	chr5:127417272	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.78	10.3	0.53	3.74e-21	Ileal carcinoids;
CESC	cis	rs10504229	1.000	rs72652905	chr8:58188355	A/G	cg22535103	chr8:58192502	C8orf71	-1.05	-12.84	-0.62	1.17e-29	Developmental language disorder (linguistic errors);
CESC	cis	rs9660180	0.967	rs12034740	chr1:1728969	C/A	cg03396347	chr1:1875803	NA	-0.42	-6.55	-0.37	3.03e-10	Body mass index;
CESC	cis	rs1395	0.813	rs11685326	chr2:27453679	A/G	cg22903471	chr2:27725779	GCKR	-0.42	-5.13	-0.3	5.64e-7	Blood metabolite levels;
CESC	cis	rs2832191	0.967	rs2251377	chr21:30530599	T/C	cg24692254	chr21:30365293	RNF160	0.73	10.75	0.55	1.34e-22	Dental caries;
CESC	trans	rs5757949	0.530	rs139062	chr22:40881793	T/C	cg04870523	chr3:115231438	NA	-0.36	-6.31	-0.36	1.17e-9	Height;
CESC	cis	rs6964587	0.610	rs7788951	chr7:91468765	A/T	cg17063962	chr7:91808500	NA	0.44	5.92	0.34	9.84e-9	Breast cancer;
CESC	cis	rs68170813	0.559	rs17427123	chr7:106823661	G/A	cg02696742	chr7:106810147	HBP1	-0.55	-5.32	-0.31	2.24e-7	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04515913	chr15:89182103	ISG20	0.54	6.3	0.36	1.24e-9	Gut microbiome composition (summer);
CESC	cis	rs7659604	0.539	rs7686200	chr4:122764553	C/T	cg19748678	chr4:122722346	EXOSC9	0.79	9.89	0.52	7.63e-20	Type 2 diabetes;
CESC	cis	rs6728642	1.000	rs113863815	chr2:97657813	A/G	cg26665480	chr2:98280029	ACTR1B	-0.87	-6.48	-0.37	4.39e-10	Bipolar disorder lithium response (continuous) or schizophrenia;
CESC	cis	rs7116495	1.000	rs482013	chr11:71803962	G/A	cg10381502	chr11:71823885	C11orf51	-0.66	-5.4	-0.31	1.51e-7	Severe influenza A (H1N1) infection;
CESC	trans	rs916888	0.773	rs199443	chr17:44819565	C/T	cg23590916	chr17:43697445	MGC57346	0.65	6.72	0.38	1.14e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs116095464	0.558	rs7356696	chr5:284251	A/G	cg22857025	chr5:266934	NA	-1.29	-18.38	-0.75	3.21e-49	Breast cancer;
CESC	cis	rs854765	0.583	rs28428991	chr17:17827649	C/T	cg04398451	chr17:18023971	MYO15A	-0.67	-9.6	-0.51	6.42e-19	Total body bone mineral density;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg23586121	chr10:134586462	INPP5A	0.5	6.44	0.37	5.47e-10	Fibrinogen levels;
CESC	cis	rs1552244	1.000	rs55822690	chr3:10128003	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.89	12.15	0.6	2.73e-27	Alzheimer's disease;
CESC	cis	rs35110281	0.774	rs1378080	chr21:45011315	T/A	cg21573476	chr21:45109991	RRP1B	-0.42	-5.66	-0.33	3.93e-8	Mean corpuscular volume;
CESC	cis	rs2842992	0.872	rs9456440	chr6:160074463	G/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.63	7.63	0.42	4.36e-13	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs2380220	0.574	rs9374322	chr6:95998994	G/A	cg15832292	chr6:96025679	MANEA	0.63	7.18	0.4	7.12e-12	Behavioural disinhibition (generation interaction);
CESC	cis	rs2836950	0.520	rs8133927	chr21:40689961	G/T	cg11890956	chr21:40555474	PSMG1	-0.66	-9.11	-0.49	2.05e-17	Menarche (age at onset);
CESC	cis	rs250677	0.687	rs42364	chr5:148438858	T/A	cg18129178	chr5:148520854	ABLIM3	-0.51	-5.84	-0.34	1.5e-8	Breast cancer;
CESC	cis	rs6500395	1.000	rs8052640	chr16:48604096	G/T	cg04672837	chr16:48644449	N4BP1	0.5	6.19	0.36	2.23e-9	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg11494091	chr17:61959527	GH2	-0.76	-14.01	-0.65	9.39e-34	Prudent dietary pattern;
CESC	cis	rs875971	1.000	rs709597	chr7:65825983	A/G	cg10691866	chr7:65817282	TPST1	0.32	5.23	0.31	3.41e-7	Aortic root size;
CESC	cis	rs4746818	0.901	rs4746816	chr10:70874866	G/T	cg04149295	chr10:70884716	VPS26A	0.59	5.1	0.3	6.57e-7	Left atrial antero-posterior diameter;
CESC	cis	rs2952156	1.000	rs1565923	chr17:37858678	A/G	cg07936489	chr17:37558343	FBXL20	-0.5	-5.8	-0.34	1.89e-8	Asthma;
CESC	cis	rs950776	0.616	rs56276142	chr15:78889795	T/C	cg06917634	chr15:78832804	PSMA4	0.56	7.31	0.41	3.14e-12	Sudden cardiac arrest;
CESC	trans	rs2727020	0.675	rs1684258	chr11:49340020	G/A	cg03929089	chr4:120376271	NA	0.63	6.83	0.39	5.73e-11	Coronary artery disease;
CESC	cis	rs7084402	0.967	rs12569559	chr10:60312711	T/G	cg07615347	chr10:60278583	BICC1	-0.58	-8.72	-0.47	3.19e-16	Refractive error;
CESC	cis	rs7208859	0.623	rs8067338	chr17:29102345	T/C	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.91e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs9916302	0.904	rs620686	chr17:37453617	A/G	cg15445000	chr17:37608096	MED1	-0.4	-6.54	-0.37	3.14e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs7020830	0.823	rs7019699	chr9:37125081	C/A	cg14294708	chr9:37120828	ZCCHC7	1.27	25.81	0.85	2.72e-74	Schizophrenia;
CESC	cis	rs472402	0.560	rs2288444	chr5:6619923	A/G	cg10789808	chr5:6633262	NSUN2;SRD5A1	-0.48	-6.37	-0.36	8.51e-10	Response to amphetamines;
CESC	trans	rs17211056	0.744	rs2584281	chr18:73347313	C/T	cg07370845	chr6:26108434	HIST1H1T	-0.7	-6.75	-0.38	9.51e-11	Serum uric acid levels in response to allopurinol in gout;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg18394496	chr11:62554881	TMEM179B	-0.47	-6.19	-0.36	2.34e-9	Ulcerative colitis;
CESC	cis	rs654950	0.875	rs55865698	chr1:41986758	C/T	cg06885757	chr1:42089581	HIVEP3	-0.42	-6.54	-0.37	3.09e-10	Airway imaging phenotypes;
CESC	cis	rs2228479	1.000	rs4257207	chr16:89947861	T/A	cg06558623	chr16:89946397	TCF25	1.15	9.14	0.49	1.65e-17	Skin colour saturation;
CESC	trans	rs1945213	0.694	rs34828123	chr11:55837868	T/A	cg03929089	chr4:120376271	NA	0.76	7.26	0.41	4.31e-12	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs951366	0.966	rs11240565	chr1:205722958	C/T	cg07167872	chr1:205819463	PM20D1	-0.39	-5.51	-0.32	8.44e-8	Menarche (age at onset);
CESC	cis	rs4604732	0.642	rs10802514	chr1:247637749	A/C	cg12758973	chr1:247694275	LOC148824;OR2C3	0.34	5.11	0.3	6.28e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs9815354	0.812	rs76966288	chr3:41825055	G/A	cg03022575	chr3:42003672	ULK4	0.72	6.35	0.36	9.22e-10	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs3096299	0.746	rs9931120	chr16:89501357	A/G	cg02187348	chr16:89574699	SPG7	0.53	6.96	0.39	2.74e-11	Multiple myeloma (IgH translocation);
CESC	cis	rs2439831	0.717	rs2447198	chr15:43895118	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.66	8.31	0.45	5.03e-15	Lung cancer in ever smokers;
CESC	cis	rs9916302	0.768	rs62077464	chr17:37656056	C/G	cg15445000	chr17:37608096	MED1	0.4	6.59	0.38	2.41e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs7223966	0.621	rs9906747	chr17:61639694	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.47	-5.36	-0.31	1.8e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs2576037	0.899	rs2576035	chr18:44587654	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.48	6.21	0.36	2.01e-9	Personality dimensions;
CESC	cis	rs763121	0.889	rs9610971	chr22:38910810	C/T	cg14440974	chr22:39074834	NA	-0.38	-5.03	-0.3	9.08e-7	Menopause (age at onset);
CESC	cis	rs1008375	0.966	rs10939735	chr4:17578891	A/G	cg27347728	chr4:17578864	LAP3	0.49	5.58	0.32	5.82e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs4665809	0.590	rs3806514	chr2:26466772	C/T	cg04944784	chr2:26401820	FAM59B	0.96	10.83	0.55	7.34e-23	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14312959	chr17:79008933	FLJ90757;BAIAP2	0.69	8.52	0.46	1.23e-15	Gut microbiome composition (summer);
CESC	cis	rs6087990	0.735	rs2424921	chr20:31385814	C/T	cg13636640	chr20:31349939	DNMT3B	0.8	13.07	0.63	1.79e-30	Ulcerative colitis;
CESC	cis	rs7520050	0.751	rs2991975	chr1:46024526	A/G	cg03146154	chr1:46216737	IPP	-0.51	-6.51	-0.37	3.81e-10	Red blood cell count;Reticulocyte count;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg05590948	chr1:27874430	AHDC1	0.54	7.18	0.4	7e-12	Fibrinogen levels;
CESC	cis	rs11227306	0.934	rs2303384	chr11:65640204	C/T	cg04055107	chr11:65626734	MUS81;CFL1	-0.49	-5.45	-0.32	1.17e-7	DNA methylation (variation);
CESC	cis	rs36051895	0.659	rs11999076	chr9:5037694	C/T	cg02405213	chr9:5042618	JAK2	-0.44	-5.5	-0.32	8.83e-8	Pediatric autoimmune diseases;
CESC	cis	rs1215050	0.791	rs783950	chr4:98878395	C/T	cg05340658	chr4:99064831	C4orf37	-0.5	-6.66	-0.38	1.55e-10	Waist-to-hip ratio adjusted for body mass index;
CESC	trans	rs7656342	0.808	rs10003216	chr4:9766749	A/G	cg07806421	chr2:139259153	SPOPL	-0.52	-6.12	-0.35	3.33e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs9354308	0.868	rs9345695	chr6:66554270	C/T	cg07460842	chr6:66804631	NA	-0.43	-5.09	-0.3	6.95e-7	Metabolite levels;
CESC	cis	rs56235845	0.694	rs4976643	chr5:176760227	A/C	cg17509989	chr5:176798049	RGS14	0.49	6.05	0.35	4.98e-9	Hemoglobin concentration;Hematocrit;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00399115	chr16:20911682	DCUN1D3;LYRM1	0.62	7.02	0.4	1.81e-11	Gut microbiome composition (summer);
CESC	cis	rs8114671	0.562	rs6087642	chr20:33468306	T/C	cg07148914	chr20:33460835	GGT7	0.45	6.09	0.35	3.95e-9	Height;
CESC	cis	rs17293817	0.589	rs17293789	chr10:1426013	C/T	cg04271617	chr10:1416546	ADARB2	0.33	5.27	0.31	2.88e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs10504073	0.584	rs10504070	chr8:49978554	A/G	cg00325661	chr8:49890786	NA	-0.59	-9.02	-0.48	3.93e-17	Blood metabolite ratios;
CESC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg13108601	chr6:41748242	FRS3;PRICKLE4	-0.54	-6.06	-0.35	4.54e-9	Lung cancer in ever smokers;
CESC	cis	rs1008375	1.000	rs11737138	chr4:17657986	G/A	cg02297831	chr4:17616191	MED28	0.53	6.75	0.38	9.49e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs7524258	0.868	rs7544314	chr1:7266744	G/C	cg07173049	chr1:7289937	CAMTA1	0.43	6.36	0.36	8.76e-10	Tourette's syndrome or obsessive-compulsive disorder;
CESC	cis	rs2124969	0.506	rs62175396	chr2:161043603	G/A	cg03641300	chr2:160917029	PLA2R1	-0.58	-5.99	-0.35	6.85e-9	Waist circumference adjusted for body mass index;
CESC	cis	rs7843479	0.601	rs10101881	chr8:21830158	A/G	cg17168535	chr8:21777572	XPO7	0.67	9.95	0.52	5.21e-20	Mean corpuscular volume;
CESC	cis	rs4803455	0.565	rs1800470	chr19:41858921	G/A	cg14132834	chr19:41945861	ATP5SL	-0.43	-5.04	-0.3	8.46e-7	Migraine;Coronary artery disease;
CESC	trans	rs116095464	0.558	rs55664502	chr5:270485	T/C	cg00938859	chr5:1591904	SDHAP3	0.63	6.9	0.39	3.88e-11	Breast cancer;
CESC	cis	rs2440129	0.611	rs11571335	chr17:6904263	C/T	cg03407747	chr17:6899364	ALOX12	0.49	8.48	0.46	1.57e-15	Tonsillectomy;
CESC	cis	rs2274273	0.686	rs66531545	chr14:55587460	T/C	cg04306507	chr14:55594613	LGALS3	0.31	5.45	0.32	1.16e-7	Protein biomarker;
CESC	trans	rs10463316	0.894	rs6864722	chr5:150752942	G/A	cg24389359	chr12:111284228	CCDC63	-0.35	-6.17	-0.35	2.52e-9	Metabolite levels (Pyroglutamine);
CESC	cis	rs12291225	0.585	rs11023194	chr11:14369769	T/C	cg19336497	chr11:14380999	RRAS2	-0.45	-6.83	-0.39	5.91e-11	Sense of smell;
CESC	cis	rs9309473	0.950	rs2947860	chr2:73855386	A/G	cg20560298	chr2:73613845	ALMS1	-0.51	-6.5	-0.37	3.96e-10	Metabolite levels;
CESC	cis	rs962856	1.000	rs1601531	chr2:67598104	T/C	cg09028215	chr2:67624308	ETAA1	-0.42	-5.44	-0.32	1.2e-7	Pancreatic cancer;
CESC	cis	rs7666738	0.830	rs3846443	chr4:99032666	G/A	cg17366294	chr4:99064904	C4orf37	0.62	8.91	0.48	8.69e-17	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2011503	0.825	rs4808932	chr19:19358819	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.53	5.56	0.32	6.43e-8	Bipolar disorder;
CESC	cis	rs4237845	0.773	rs6650218	chr12:58289078	T/A	cg02175503	chr12:58329896	NA	0.63	9.03	0.49	3.6e-17	Intelligence (multi-trait analysis);
CESC	cis	rs28830936	0.966	rs1918310	chr15:42065253	A/C	cg11010575	chr15:42129464	JMJD7-PLA2G4B;JMJD7	-0.43	-5.98	-0.34	7.31e-9	Diastolic blood pressure;
CESC	cis	rs6964587	1.000	rs12530646	chr7:91588036	A/G	cg01689657	chr7:91764605	CYP51A1	-0.29	-5.32	-0.31	2.24e-7	Breast cancer;
CESC	cis	rs7666738	0.716	rs13136721	chr4:99085602	G/A	cg24818145	chr4:99064322	C4orf37	0.4	5.05	0.3	8.16e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11792861	0.926	rs17729523	chr9:111773317	T/C	cg05043794	chr9:111880884	C9orf5	-0.41	-6.73	-0.38	1.02e-10	Menarche (age at onset);
CESC	cis	rs8005677	0.828	rs3794452	chr14:23386682	T/G	cg01529538	chr14:23388837	RBM23	0.42	5.78	0.33	2.13e-8	Cognitive ability (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16882830	chr7:148823965	ZNF398;ZNF425	0.55	6.17	0.35	2.54e-9	Gut microbiome composition (summer);
CESC	cis	rs2708240	0.577	rs10246256	chr7:147554807	C/T	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.39	-5.93	-0.34	9.18e-9	QT interval (drug interaction);
CESC	trans	rs7618501	1.000	rs7431106	chr3:49808374	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.59	8.49	0.46	1.51e-15	Intelligence (multi-trait analysis);
CESC	cis	rs780096	0.546	rs2293572	chr2:27728777	C/G	cg24768116	chr2:27665128	KRTCAP3	0.29	5.21	0.31	3.73e-7	Total body bone mineral density;
CESC	cis	rs7666738	0.716	rs6817529	chr4:99023213	T/C	cg03467027	chr4:99064603	C4orf37	0.46	5.81	0.34	1.8e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9902453	0.967	rs8082175	chr17:28430303	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	7.99	0.44	4.06e-14	Coffee consumption (cups per day);
CESC	cis	rs11711311	1.000	rs3732793	chr3:113442198	C/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.72	10.31	0.54	3.58e-21	IgG glycosylation;
CESC	cis	rs7772486	0.686	rs1045820	chr6:145947080	C/T	cg23711669	chr6:146136114	FBXO30	0.89	13.06	0.63	1.99e-30	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs11122272	0.615	rs1465740	chr1:231495255	T/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.55	-7.47	-0.42	1.15e-12	Hemoglobin concentration;
CESC	cis	rs826838	0.967	rs1684414	chr12:39129553	A/G	cg26384229	chr12:38710491	ALG10B	-0.67	-11.01	-0.56	1.82e-23	Heart rate;
CESC	cis	rs7618915	0.501	rs55678971	chr3:52717229	T/A	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.34	5.97	0.34	7.74e-9	Bipolar disorder;
CESC	trans	rs916888	0.773	rs199534	chr17:44824213	T/G	cg22968622	chr17:43663579	NA	1.31	17.59	0.73	1.99e-46	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs7618915	0.571	rs6762457	chr3:52609157	G/A	cg17372223	chr3:52568218	NT5DC2	0.43	6.39	0.37	7.37e-10	Bipolar disorder;
CESC	cis	rs8141529	0.673	rs132548	chr22:29317559	C/G	cg02153584	chr22:29168773	CCDC117	-0.5	-6.46	-0.37	4.97e-10	Lymphocyte counts;
CESC	cis	rs2204008	0.687	rs1733404	chr12:38123395	G/T	cg26384229	chr12:38710491	ALG10B	-0.68	-9.64	-0.51	4.94e-19	Bladder cancer;
CESC	trans	rs4843747	0.671	rs9921236	chr16:88117015	G/T	cg26811252	chr16:29126840	RRN3P2	0.66	8.88	0.48	1.06e-16	Menopause (age at onset);
CESC	trans	rs35110281	0.805	rs2838330	chr21:45023876	T/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.53	6.95	0.39	2.77e-11	Mean corpuscular volume;
CESC	cis	rs875971	0.964	rs2161065	chr7:65932905	A/G	cg18876405	chr7:65276391	NA	0.52	7.03	0.4	1.8e-11	Aortic root size;
CESC	cis	rs9487051	0.604	rs9320282	chr6:109619377	A/G	cg01475377	chr6:109611718	NA	-0.43	-6.7	-0.38	1.26e-10	Reticulocyte fraction of red cells;
CESC	cis	rs5753618	0.561	rs13054220	chr22:31704492	A/G	cg13145458	chr22:31556086	RNF185	-0.52	-5.87	-0.34	1.3e-8	Colorectal cancer;
CESC	trans	rs116095464	0.558	rs28729548	chr5:229025	C/T	cg00938859	chr5:1591904	SDHAP3	0.61	6.74	0.38	9.82e-11	Breast cancer;
CESC	cis	rs501120	1.000	rs503859	chr10:44753560	G/C	cg09554077	chr10:44749378	NA	0.52	6.89	0.39	3.96e-11	Coronary artery disease;Coronary heart disease;
CESC	cis	rs72945132	0.882	rs6592554	chr11:70226040	G/A	cg00319359	chr11:70116639	PPFIA1	0.73	7.1	0.4	1.11e-11	Coronary artery disease;
CESC	cis	rs7208859	0.623	rs216433	chr17:28921860	T/C	cg04154034	chr17:28927549	LRRC37B2	0.67	6.02	0.35	5.73e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs585510	1	rs585510	chr12:121000133	A/G	cg27279351	chr12:120934652	DYNLL1	0.68	8.85	0.48	1.27e-16	Reticulocyte fraction of red cells;
CESC	cis	rs17376456	0.877	rs55832164	chr5:93436579	C/T	cg21475434	chr5:93447410	FAM172A	0.83	7.47	0.42	1.17e-12	Diabetic retinopathy;
CESC	cis	rs12540874	0.500	rs12719030	chr7:50485073	T/C	cg18232548	chr7:50535776	DDC	-0.4	-5.55	-0.32	6.94e-8	Systemic sclerosis;
CESC	cis	rs9393777	0.588	rs11967935	chr6:26560672	A/C	cg12292205	chr6:26970375	C6orf41	-0.44	-5.06	-0.3	7.92e-7	Intelligence (multi-trait analysis);
CESC	cis	rs2486288	0.656	rs8037583	chr15:45546378	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.58	-7.1	-0.4	1.12e-11	Glomerular filtration rate;
CESC	cis	rs1707322	0.789	rs7540578	chr1:46252144	C/T	cg06784218	chr1:46089804	CCDC17	0.37	6.38	0.37	7.69e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs7615952	0.512	rs2979351	chr3:125363599	C/T	cg07211511	chr3:129823064	LOC729375	-0.59	-7.28	-0.41	3.84e-12	Blood pressure (smoking interaction);
CESC	cis	rs2070488	0.965	rs4679060	chr3:38536261	T/C	cg24069376	chr3:38537580	EXOG	-0.48	-8.93	-0.48	7.12e-17	Electrocardiographic conduction measures;
CESC	cis	rs2522056	1.000	rs2706383	chr5:131792402	G/A	cg24060327	chr5:131705240	SLC22A5	0.62	7.16	0.4	7.72e-12	Lymphocyte counts;Fibrinogen;
CESC	cis	rs7824557	0.767	rs2060463	chr8:11161610	T/G	cg21775007	chr8:11205619	TDH	0.51	7.5	0.42	9.85e-13	Retinal vascular caliber;
CESC	cis	rs9611565	0.659	rs28623192	chr22:41940524	A/G	cg06634786	chr22:41940651	POLR3H	-0.64	-6.62	-0.38	2.02e-10	Vitiligo;
CESC	cis	rs959260	1.000	rs4789189	chr17:73397985	C/G	cg12999837	chr17:73267436	MIF4GD	-0.52	-5.97	-0.34	7.43e-9	Systemic lupus erythematosus;
CESC	cis	rs6988985	0.560	rs2078674	chr8:143928233	G/T	cg10324643	chr8:143916377	GML	0.34	5.08	0.3	7.2e-7	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
CESC	cis	rs796364	0.755	rs6739563	chr2:201134216	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.57	5.27	0.31	2.87e-7	Schizophrenia;
CESC	cis	rs9611565	0.512	rs5751147	chr22:42139054	G/A	cg06481639	chr22:41940642	POLR3H	0.59	5.84	0.34	1.51e-8	Vitiligo;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg09135206	chr1:21503313	EIF4G3	-0.42	-6.08	-0.35	4.27e-9	Gambling;
CESC	cis	rs11098499	0.754	rs10006259	chr4:120242145	C/T	cg09307838	chr4:120376055	NA	0.79	10.62	0.55	3.51e-22	Corneal astigmatism;
CESC	cis	rs9486719	0.947	rs2499801	chr6:96854594	G/A	cg06623918	chr6:96969491	KIAA0776	0.82	7.96	0.44	5.17e-14	Migraine;Coronary artery disease;
CESC	cis	rs4689592	0.513	rs3857177	chr4:7066332	G/A	cg19539972	chr4:7069911	GRPEL1	0.76	9.56	0.51	8.66e-19	Monocyte percentage of white cells;
CESC	cis	rs7552404	1.000	rs11161510	chr1:76210289	A/G	cg03433033	chr1:76189801	ACADM	-0.66	-7.78	-0.43	1.64e-13	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs477895	0.938	rs28395875	chr11:64024048	G/C	cg04317338	chr11:64019027	PLCB3	0.7	5.94	0.34	8.74e-9	Mean platelet volume;
CESC	cis	rs7772486	0.686	rs9497380	chr6:145955305	T/C	cg23711669	chr6:146136114	FBXO30	0.87	12.64	0.61	5.6e-29	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4925386	0.840	rs6143034	chr20:60920545	T/C	cg24112000	chr20:60950667	NA	-0.44	-5.47	-0.32	1.03e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CESC	trans	rs79976124	0.837	rs10944858	chr6:66646039	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.72	8.26	0.45	6.99e-15	Type 2 diabetes;
CESC	cis	rs2439831	0.867	rs2412780	chr15:43655794	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	13.11	0.63	1.34e-30	Lung cancer in ever smokers;
CESC	cis	rs7829975	0.807	rs519019	chr8:8595104	A/T	cg17143192	chr8:8559678	CLDN23	-0.46	-5.73	-0.33	2.69e-8	Mood instability;
CESC	cis	rs826838	1.000	rs11168367	chr12:38913397	T/G	cg26384229	chr12:38710491	ALG10B	0.82	14.44	0.66	2.91e-35	Heart rate;
CESC	cis	rs71403859	0.803	rs10500562	chr16:71627731	A/C	cg08717414	chr16:71523259	ZNF19	-0.8	-7.06	-0.4	1.43e-11	Post bronchodilator FEV1;
CESC	cis	rs1348850	0.874	rs4893822	chr2:178285727	G/T	cg23306229	chr2:178417860	TTC30B	0.57	6.62	0.38	1.96e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs6456156	0.586	rs6456150	chr6:167468922	A/G	cg07741184	chr6:167504864	NA	0.36	6.19	0.36	2.29e-9	Primary biliary cholangitis;
CESC	cis	rs9486719	1.000	rs2499807	chr6:96864053	T/G	cg18709589	chr6:96969512	KIAA0776	0.52	5.67	0.33	3.8e-8	Migraine;Coronary artery disease;
CESC	cis	rs10089	0.953	rs758180	chr5:127354423	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.77	9.94	0.52	5.42e-20	Ileal carcinoids;
CESC	cis	rs2014572	0.875	rs10405008	chr19:57753643	C/G	cg24459738	chr19:57751996	ZNF805	0.49	7.01	0.4	2.03e-11	Hyperactive-impulsive symptoms;
CESC	cis	rs2997447	0.761	rs61776582	chr1:26437262	A/C	cg24596570	chr1:26146463	FAM54B;LOC646471	0.62	5.33	0.31	2.07e-7	QRS complex (12-leadsum);
CESC	cis	rs7618915	0.547	rs2289250	chr3:52682946	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.51	-6.93	-0.39	3.28e-11	Bipolar disorder;
CESC	cis	rs763014	0.966	rs4984675	chr16:670117	T/C	cg00908189	chr16:619842	PIGQ	0.61	8.38	0.46	3.19e-15	Height;
CESC	cis	rs4595586	0.525	rs7972595	chr12:39338000	G/A	cg13010199	chr12:38710504	ALG10B	0.46	5.75	0.33	2.49e-8	Morning vs. evening chronotype;
CESC	trans	rs800888	0.865	rs13266941	chr8:116535753	T/C	cg19047077	chr12:105044897	CHST11	-0.46	-6.01	-0.35	6.09e-9	Monocyte percentage of white cells;
CESC	cis	rs4722166	0.568	rs1880241	chr7:22759469	A/G	cg05472934	chr7:22766657	IL6	0.39	5.39	0.31	1.54e-7	Lung cancer;
CESC	cis	rs1395	0.778	rs4665960	chr2:27467598	C/T	cg22903471	chr2:27725779	GCKR	-0.42	-5.13	-0.3	5.53e-7	Blood metabolite levels;
CESC	cis	rs12824058	0.831	rs12320318	chr12:130812335	T/C	cg26677194	chr12:130822605	PIWIL1	0.52	6.81	0.39	6.58e-11	Menopause (age at onset);
CESC	cis	rs1797081	0.934	rs1797077	chr10:16853252	C/T	cg23933602	chr10:16859644	RSU1	1.11	22.74	0.81	3.16e-64	Platelet distribution width;
CESC	cis	rs8031584	0.958	rs7176569	chr15:31244495	G/T	cg08109568	chr15:31115862	NA	0.7	9.32	0.5	4.58e-18	Huntington's disease progression;
CESC	trans	rs4954683	0.735	rs1568880	chr2:141761303	C/A	cg04488373	chr7:63385990	NA	0.43	6.03	0.35	5.49e-9	IgG glycosylation;
CESC	cis	rs367615	0.501	rs447849	chr5:108951190	A/C	cg17395555	chr5:108820864	NA	-0.34	-5.44	-0.32	1.2e-7	Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs1005277	0.522	rs289649	chr10:37975384	T/C	cg25427524	chr10:38739819	LOC399744	-0.64	-9.46	-0.5	1.72e-18	Extrinsic epigenetic age acceleration;
CESC	trans	rs853679	0.882	rs3757188	chr6:28107357	T/C	cg06606381	chr12:133084897	FBRSL1	-0.67	-6.64	-0.38	1.82e-10	Depression;
CESC	cis	rs2032447	0.839	rs199751	chr6:26015583	T/C	cg12310025	chr6:25882481	NA	-0.5	-7.07	-0.4	1.4e-11	Intelligence (multi-trait analysis);
CESC	cis	rs1538970	0.924	rs7531253	chr1:45890183	T/C	cg06784218	chr1:46089804	CCDC17	0.33	5.46	0.32	1.11e-7	Platelet count;
CESC	cis	rs3749237	0.595	rs4955412	chr3:49418168	A/C	cg02487422	chr3:49467188	NICN1	0.55	7.99	0.44	4.23e-14	Resting heart rate;
CESC	cis	rs523522	0.962	rs4767903	chr12:120930046	G/A	cg12219531	chr12:120966889	COQ5	0.74	9.56	0.51	8.22e-19	High light scatter reticulocyte count;
CESC	cis	rs1552244	1.000	rs17032277	chr3:10077023	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.87	11.84	0.59	2.99e-26	Alzheimer's disease;
CESC	trans	rs656319	0.625	rs4526366	chr8:9890179	C/G	cg15556689	chr8:8085844	FLJ10661	-0.58	-6.78	-0.38	8e-11	Myopia (pathological);
CESC	cis	rs2576037	0.583	rs9304336	chr18:44461687	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.51	-6.86	-0.39	4.94e-11	Personality dimensions;
CESC	cis	rs9915657	0.773	rs9894696	chr17:70099487	C/T	cg09344028	chr17:70110421	NA	0.38	7.4	0.41	1.79e-12	Thyroid hormone levels;
CESC	cis	rs11792861	0.926	rs12683988	chr9:111867290	T/C	cg05043794	chr9:111880884	C9orf5	-0.42	-6.93	-0.39	3.22e-11	Menarche (age at onset);
CESC	cis	rs2836974	0.897	rs4817996	chr21:40525759	G/C	cg27266027	chr21:40555129	PSMG1	0.49	6.01	0.35	6.14e-9	Cognitive function;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg13600755	chr15:59499084	LDHAL6B;MYO1E	0.45	6.08	0.35	4.09e-9	Fibrinogen levels;
CESC	cis	rs875971	0.862	rs949930	chr7:65766822	C/G	cg11764359	chr7:65958608	NA	-0.79	-12.0	-0.59	9.01e-27	Aortic root size;
CESC	cis	rs9287719	0.934	rs6432110	chr2:10738018	T/A	cg00105475	chr2:10696890	NA	0.39	5.61	0.33	4.96e-8	Prostate cancer;
CESC	cis	rs67311347	1.000	rs4974017	chr3:40473519	C/T	cg24209194	chr3:40518798	ZNF619	0.49	6.52	0.37	3.61e-10	Renal cell carcinoma;
CESC	cis	rs7520050	0.898	rs34175029	chr1:46483871	C/T	cg03146154	chr1:46216737	IPP	-0.47	-6.05	-0.35	4.92e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs2404602	0.583	rs4381566	chr15:76589262	A/G	cg22467129	chr15:76604101	ETFA	-0.37	-5.67	-0.33	3.81e-8	Blood metabolite levels;
CESC	cis	rs9322193	0.926	rs9766562	chr6:150109845	C/G	cg13206674	chr6:150067644	NUP43	0.42	5.83	0.34	1.61e-8	Lung cancer;
CESC	cis	rs1144333	0.737	rs1144339	chr1:76280543	A/G	cg22875332	chr1:76189707	ACADM	-0.53	-5.15	-0.3	5.11e-7	Attention function in attention deficit hyperactive disorder;
CESC	cis	rs9649213	0.593	rs6465665	chr7:97934150	T/C	cg21770322	chr7:97807741	LMTK2	0.54	8.08	0.44	2.24e-14	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs116095464	0.681	rs1574220	chr5:314518	T/C	cg22857025	chr5:266934	NA	-1.17	-10.43	-0.54	1.42e-21	Breast cancer;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg21685218	chr6:143771971	PEX3;ADAT2	-0.46	-6.59	-0.38	2.33e-10	Gambling;
CESC	cis	rs7116495	0.609	rs2276384	chr11:71701523	A/G	cg18441811	chr11:71824068	C11orf51	0.79	5.55	0.32	6.77e-8	Severe influenza A (H1N1) infection;
CESC	cis	rs1008375	0.618	rs13129002	chr4:17567513	A/G	cg02297831	chr4:17616191	MED28	0.45	5.31	0.31	2.31e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs7772486	0.790	rs2814880	chr6:146208937	T/G	cg05347473	chr6:146136440	FBXO30	0.55	7.1	0.4	1.15e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs3785574	0.962	rs62077483	chr17:61806380	C/T	cg07677032	chr17:61819896	STRADA	0.42	5.38	0.31	1.61e-7	Height;
CESC	cis	rs698833	0.926	rs1067394	chr2:44638123	A/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.51	6.62	0.38	2.01e-10	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg06877462	chr1:205807181	PM20D1	0.37	5.26	0.31	3.01e-7	Menarche (age at onset);
CESC	cis	rs7618915	0.501	rs767418	chr3:52767427	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.36	6.48	0.37	4.53e-10	Bipolar disorder;
CESC	cis	rs1707322	1.000	rs785507	chr1:46541558	C/T	cg03146154	chr1:46216737	IPP	-0.74	-9.66	-0.51	4.01e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs1953600	0.837	rs2236556	chr10:81932790	T/C	cg00277334	chr10:82204260	NA	0.46	6.48	0.37	4.47e-10	Sarcoidosis;
CESC	cis	rs72781680	0.898	rs12612492	chr2:24093756	C/T	cg08917208	chr2:24149416	ATAD2B	0.98	9.51	0.5	1.25e-18	Lymphocyte counts;
CESC	cis	rs2050392	0.931	rs2265187	chr10:30690844	C/T	cg25182066	chr10:30743637	MAP3K8	-0.38	-5.07	-0.3	7.57e-7	Inflammatory bowel disease;
CESC	cis	rs11252926	0.510	rs4881371	chr10:554514	G/A	cg16386425	chr10:429943	DIP2C	-0.42	-5.34	-0.31	1.97e-7	Psychosis in Alzheimer's disease;
CESC	cis	rs12497850	0.897	rs9884022	chr3:48956862	G/C	cg02487422	chr3:49467188	NICN1	0.4	5.21	0.3	3.77e-7	Parkinson's disease;
CESC	cis	rs3820068	0.603	rs59558854	chr1:15971399	T/G	cg13390004	chr1:15929781	NA	0.36	5.74	0.33	2.61e-8	Systolic blood pressure;
CESC	trans	rs1829883	0.636	rs2968351	chr5:98728753	G/A	cg23861655	chr4:57411219	NA	0.39	6.43	0.37	6e-10	Hemostatic factors and hematological phenotypes;
CESC	cis	rs597539	0.616	rs513476	chr11:68698996	C/T	cg06028808	chr11:68637592	NA	0.41	5.06	0.3	7.97e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs1218582	0.772	rs906593	chr1:154885255	G/A	cg06221963	chr1:154839813	KCNN3	-0.66	-11.27	-0.57	2.55e-24	Prostate cancer;
CESC	cis	rs72627123	0.656	rs765720	chr14:74541326	C/T	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.78	5.36	0.31	1.81e-7	Morning vs. evening chronotype;
CESC	cis	rs2228479	0.681	rs4287569	chr16:89957815	A/G	cg00800038	chr16:89945340	TCF25	-0.61	-6.89	-0.39	4.14e-11	Skin colour saturation;
CESC	cis	rs7818345	0.967	rs12543061	chr8:19286181	G/T	cg11303988	chr8:19266685	CSGALNACT1	-0.35	-6.58	-0.37	2.43e-10	Language performance in older adults (adjusted for episodic memory);
CESC	cis	rs10791097	0.694	rs4370948	chr11:130755700	A/C	cg12179176	chr11:130786555	SNX19	0.65	10.22	0.53	6.85e-21	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs3540	0.576	rs1974519	chr15:91036460	A/G	cg10434728	chr15:90938212	IQGAP1	0.42	7.46	0.42	1.28e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs35306767	0.953	rs34405399	chr10:981015	G/A	cg20503657	chr10:835505	NA	0.65	7.15	0.4	8.29e-12	Eosinophil percentage of granulocytes;
CESC	trans	rs3741489	1.000	rs2306545	chr12:133419296	G/A	cg24132527	chr5:140019269	TMCO6	1.1	7.42	0.41	1.61e-12	Cognitive function;
CESC	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg04234412	chr22:24373322	LOC391322	-0.58	-8.33	-0.46	4.27e-15	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs2576037	0.544	rs629097	chr18:44378097	T/C	cg19077165	chr18:44547161	KATNAL2	-0.62	-9.41	-0.5	2.43e-18	Personality dimensions;
CESC	cis	rs7833790	0.724	rs6473311	chr8:82726682	G/A	cg02079420	chr8:82753780	SNX16	0.55	8.17	0.45	1.24e-14	Diastolic blood pressure;
CESC	cis	rs3092073	0.624	rs11906879	chr20:44591324	C/T	cg17986701	chr20:44574422	PCIF1	-0.35	-5.27	-0.31	2.78e-7	Intelligence (multi-trait analysis);
CESC	cis	rs875971	0.830	rs28714531	chr7:65968237	G/A	cg18252515	chr7:66147081	NA	-0.47	-6.11	-0.35	3.53e-9	Aortic root size;
CESC	cis	rs9902453	0.791	rs2729451	chr17:28131334	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.66	-8.47	-0.46	1.74e-15	Coffee consumption (cups per day);
CESC	cis	rs17125944	1.000	rs17125944	chr14:53400629	C/T	cg00686598	chr14:53173677	PSMC6	-0.9	-7.19	-0.4	6.43e-12	Alzheimer's disease (late onset);
CESC	cis	rs3815700	1.000	rs10404211	chr19:33093565	C/T	cg02997394	chr19:33096574	ANKRD27	0.66	5.52	0.32	8.23e-8	Eosinophilic esophagitis;
CESC	cis	rs12477438	0.765	rs12468807	chr2:99691994	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-10.57	-0.54	5.22e-22	Chronic sinus infection;
CESC	cis	rs7208859	0.623	rs73269923	chr17:29102571	C/T	cg13385521	chr17:29058706	SUZ12P	0.85	6.63	0.38	1.86e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01494614	chr11:10562837	RNF141	0.6	7.32	0.41	2.96e-12	Gut microbiome composition (summer);
CESC	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg03188948	chr7:1209495	NA	0.7	7.05	0.4	1.59e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs896854	0.596	rs7823059	chr8:95974961	T/C	cg16049864	chr8:95962084	TP53INP1	-0.65	-11.4	-0.57	9.17e-25	Type 2 diabetes;
CESC	cis	rs6089829	0.851	rs6122346	chr20:61661822	C/G	cg03213289	chr20:61660250	NA	0.39	6.06	0.35	4.64e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs17001868	0.568	rs6001894	chr22:40779197	T/C	cg07138101	chr22:40742427	ADSL	0.51	5.15	0.3	5.01e-7	Mammographic density (dense area);
CESC	cis	rs7834588	0.543	rs1455572	chr8:63844564	A/T	cg20602954	chr8:63776762	NKAIN3	0.32	5.32	0.31	2.25e-7	Response to Vitamin E supplementation;
CESC	cis	rs769267	0.930	rs2301786	chr19:19413947	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.59	7.6	0.42	5.05e-13	Tonsillectomy;
CESC	cis	rs763121	0.853	rs3747174	chr22:39069181	T/C	cg21395723	chr22:39101663	GTPBP1	0.42	5.32	0.31	2.17e-7	Menopause (age at onset);
CESC	cis	rs1034435	0.755	rs5767172	chr22:48892314	A/C	cg05992904	chr22:48892994	FAM19A5	-0.57	-9.99	-0.52	3.86e-20	Late-onset Alzheimer's disease;
CESC	cis	rs2354432	0.607	rs2297752	chr1:146765454	C/G	cg25205988	chr1:146714368	CHD1L	-0.96	-10.35	-0.54	2.56e-21	Mitochondrial DNA levels;
CESC	cis	rs10504229	0.683	rs7835498	chr8:58129780	A/C	cg24829409	chr8:58192753	C8orf71	-0.58	-7.2	-0.4	6.31e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg18402987	chr7:1209562	NA	0.76	7.56	0.42	6.59e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs1050631	0.536	rs1785928	chr18:33725931	A/G	cg25426722	chr18:33708991	SLC39A6;ELP2	-0.6	-8.01	-0.44	3.64e-14	Esophageal squamous cell cancer (length of survival);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05221349	chr4:100870488	LOC256880;H2AFZ	0.43	6.5	0.37	3.99e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs9911578	1.000	rs4636974	chr17:56965373	C/G	cg05425664	chr17:57184151	TRIM37	-0.51	-7.03	-0.4	1.75e-11	Intelligence (multi-trait analysis);
CESC	cis	rs11630290	0.806	rs11631544	chr15:64098557	A/G	cg12036633	chr15:63758958	NA	-0.54	-5.2	-0.3	4.01e-7	Iris characteristics;
CESC	cis	rs1799949	1.000	rs33920795	chr17:41329010	A/G	cg05368731	chr17:41323189	NBR1	0.79	10.98	0.56	2.21e-23	Menopause (age at onset);
CESC	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg18538332	chr22:24372958	LOC391322	0.64	9.06	0.49	2.9e-17	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs3820068	0.608	rs12734937	chr1:16047726	T/C	cg17385448	chr1:15911702	AGMAT	0.38	5.97	0.34	7.5e-9	Systolic blood pressure;
CESC	cis	rs11677370	0.561	rs12986995	chr2:3826965	G/A	cg17052675	chr2:3827356	NA	-0.46	-6.01	-0.35	5.96e-9	Type 2 diabetes;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg27549887	chr15:48623952	DUT	-0.4	-6.11	-0.35	3.63e-9	Gambling;
CESC	cis	rs60871478	1.000	rs62432253	chr7:802928	A/G	cg27478167	chr7:817139	HEATR2	-0.52	-5.54	-0.32	7.14e-8	Cerebrospinal P-tau181p levels;
CESC	cis	rs6582630	0.502	rs11514371	chr12:38306306	G/C	cg13010199	chr12:38710504	ALG10B	0.45	5.65	0.33	4.06e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs11688816	1.000	rs11688816	chr2:63053048	G/A	cg17519650	chr2:63277830	OTX1	-0.47	-6.53	-0.37	3.26e-10	Body mass index;
CESC	cis	rs2836974	0.932	rs11910151	chr21:40560262	T/C	cg17971929	chr21:40555470	PSMG1	1.07	17.1	0.72	1.07e-44	Cognitive function;
CESC	cis	rs6942407	0.545	rs6465101	chr7:86859065	C/G	cg02420886	chr7:86849541	C7orf23	0.55	5.14	0.3	5.44e-7	Food allergy;
CESC	cis	rs1371867	0.846	rs1660328	chr8:101303450	A/G	cg11906718	chr8:101322791	RNF19A	0.46	5.91	0.34	1.03e-8	Atrioventricular conduction;
CESC	cis	rs6460942	0.597	rs7811374	chr7:12517437	T/C	cg20607287	chr7:12443886	VWDE	-0.7	-7.58	-0.42	5.83e-13	Coronary artery disease;
CESC	cis	rs67311347	1.000	rs13324109	chr3:40460767	T/C	cg24209194	chr3:40518798	ZNF619	0.46	6.03	0.35	5.43e-9	Renal cell carcinoma;
CESC	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	22.27	0.81	1.17e-62	Prudent dietary pattern;
CESC	cis	rs459571	0.959	rs378740	chr9:136890876	C/A	cg13789015	chr9:136890014	NCRNA00094	0.56	7.88	0.44	8.36e-14	Platelet distribution width;
CESC	trans	rs12599106	0.625	rs12923277	chr16:34896261	G/A	cg01171360	chr6:293285	DUSP22	-0.65	-8.49	-0.46	1.46e-15	Menopause (age at onset);
CESC	cis	rs965513	0.932	rs10818050	chr9:100538923	A/G	cg13688889	chr9:100608707	NA	-0.56	-8.1	-0.45	2.01e-14	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
CESC	cis	rs2439831	0.702	rs7175032	chr15:44060236	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.71	8.09	0.45	2.1e-14	Lung cancer in ever smokers;
CESC	cis	rs2991971	0.967	rs6661321	chr1:45954599	C/G	cg15605315	chr1:45957053	TESK2	0.5	6.64	0.38	1.76e-10	High light scatter reticulocyte count;
CESC	cis	rs1218582	0.710	rs9794000	chr1:154878876	T/A	cg03351412	chr1:154909251	PMVK	0.69	9.38	0.5	3.14e-18	Prostate cancer;
CESC	cis	rs1949733	0.675	rs2688235	chr4:8450546	T/C	cg11789530	chr4:8429930	ACOX3	0.76	10.94	0.56	3.06e-23	Response to antineoplastic agents;
CESC	trans	rs7107217	1.000	rs1873872	chr11:129473993	A/T	cg25001845	chr14:75201709	FCF1	-0.46	-6.24	-0.36	1.75e-9	Breast cancer;Type 2 diabetes;
CESC	cis	rs2841277	0.676	rs10438247	chr14:105411781	G/A	cg21017887	chr14:105400489	NA	0.42	6.94	0.39	3e-11	Rheumatoid arthritis;
CESC	cis	rs2898681	0.561	rs6855240	chr4:53740787	G/A	cg00791764	chr4:53727839	RASL11B	0.54	5.37	0.31	1.7e-7	Optic nerve measurement (cup area);
CESC	cis	rs57221529	0.766	rs12521051	chr5:560440	A/G	cg09021430	chr5:549028	NA	0.4	5.19	0.3	4.19e-7	Lung disease severity in cystic fibrosis;
CESC	cis	rs853679	0.517	rs6922063	chr6:28094366	G/A	cg12963246	chr6:28129442	ZNF389	0.6	8.28	0.45	5.95e-15	Depression;
CESC	cis	rs2290720	0.965	rs703713	chr12:101682211	A/G	cg22051763	chr12:101673672	UTP20	0.48	5.66	0.33	3.88e-8	Brain structure (hippocampal volume);
CESC	cis	rs9916302	0.904	rs8081338	chr17:37406139	C/T	cg00129232	chr17:37814104	STARD3	-0.57	-7.33	-0.41	2.77e-12	Glomerular filtration rate (creatinine);
CESC	cis	rs6547741	0.844	rs7586655	chr2:27915659	A/G	cg27432699	chr2:27873401	GPN1	-0.59	-8.72	-0.47	3.22e-16	Oral cavity cancer;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg13633529	chr15:101141955	ASB7;LINS1	0.46	6.6	0.38	2.22e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs2032447	0.670	rs198845	chr6:26107790	A/C	cg18357526	chr6:26021779	HIST1H4A	0.59	7.98	0.44	4.36e-14	Intelligence (multi-trait analysis);
CESC	cis	rs7647973	0.588	rs9883000	chr3:49667691	A/G	cg13072238	chr3:49761600	GMPPB	-0.45	-5.4	-0.31	1.51e-7	Menarche (age at onset);
CESC	cis	rs9486719	1.000	rs12190397	chr6:97036465	G/A	cg06623918	chr6:96969491	KIAA0776	-0.8	-8.21	-0.45	9.56e-15	Migraine;Coronary artery disease;
CESC	cis	rs3858526	0.584	rs10734560	chr11:5864503	G/T	cg05234568	chr11:5960015	NA	-0.65	-8.98	-0.48	5.17e-17	DNA methylation (variation);
CESC	cis	rs4629710	0.545	rs11154621	chr6:131547341	A/G	cg12606694	chr6:131520996	AKAP7	0.42	5.47	0.32	1.05e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs12971120	0.891	rs12605820	chr18:72167802	G/A	cg25817165	chr18:72167213	CNDP2	-0.58	-7.09	-0.4	1.24e-11	Refractive error;
CESC	cis	rs9486719	0.857	rs11751075	chr6:97065751	G/A	cg18709589	chr6:96969512	KIAA0776	-0.49	-5.45	-0.32	1.14e-7	Migraine;Coronary artery disease;
CESC	cis	rs875971	0.862	rs778705	chr7:65861115	G/A	cg19163074	chr7:65112434	INTS4L2	-0.41	-5.11	-0.3	6.29e-7	Aortic root size;
CESC	cis	rs11997175	1.000	rs10453046	chr8:33773179	T/C	ch.8.33884649F	chr8:33765107	NA	0.63	8.08	0.44	2.24e-14	Body mass index;
CESC	cis	rs4689592	0.503	rs2292461	chr4:7058473	C/T	cg06697600	chr4:7070879	GRPEL1	-0.49	-6.97	-0.39	2.45e-11	Monocyte percentage of white cells;
CESC	cis	rs4330281	0.740	rs4643736	chr3:17792256	G/T	cg20981856	chr3:17787350	NA	0.36	5.08	0.3	7.15e-7	Schizophrenia;
CESC	cis	rs9443189	0.570	rs485906	chr6:76300550	A/C	cg01950844	chr6:76311363	SENP6	0.87	9.54	0.51	9.61e-19	Prostate cancer;
CESC	cis	rs875971	0.597	rs11763224	chr7:65983615	G/T	cg11764359	chr7:65958608	NA	0.79	9.05	0.49	3.06e-17	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10787120	chr14:96857745	AK7	0.58	6.32	0.36	1.11e-9	Gut microbiome composition (summer);
CESC	cis	rs597583	0.664	rs10892133	chr11:117383694	C/T	cg27161313	chr11:117392002	DSCAML1	-0.49	-5.99	-0.35	6.96e-9	Putamen volume;
CESC	cis	rs6762	0.748	rs5030780	chr11:838110	C/T	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.78	-11.0	-0.56	1.92e-23	Mean platelet volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03902233	chr6:122792987	PKIB;SERINC1	0.56	6.49	0.37	4.29e-10	Gut microbiome composition (summer);
CESC	cis	rs637571	0.522	rs28578718	chr11:65748400	C/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.44	6.5	0.37	4.05e-10	Eosinophil percentage of white cells;
CESC	cis	rs6087771	0.682	rs2038397	chr20:30217759	A/G	cg13852791	chr20:30311386	BCL2L1	0.67	7.77	0.43	1.7e-13	Subcortical brain region volumes;Putamen volume;
CESC	cis	rs735396	0.595	rs2258287	chr12:121454313	G/T	cg02403541	chr12:121454288	C12orf43	0.8	11.98	0.59	9.82e-27	N-glycan levels;
CESC	cis	rs7945705	0.869	rs11042154	chr11:9029700	A/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.32	-5.18	-0.3	4.35e-7	Hemoglobin concentration;
CESC	cis	rs9916302	0.904	rs3744348	chr17:37417575	C/G	cg20243544	chr17:37824526	PNMT	0.47	5.8	0.34	1.85e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs3733585	0.699	rs12498150	chr4:9950537	C/T	cg11266682	chr4:10021025	SLC2A9	-0.58	-11.18	-0.57	4.91e-24	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg20887711	chr4:1340912	KIAA1530	0.89	11.78	0.59	4.87e-26	Longevity;
CESC	cis	rs929596	0.639	rs7571915	chr2:234586574	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.46	-5.76	-0.33	2.28e-8	Total bilirubin levels in HIV-1 infection;
CESC	cis	rs34172651	0.517	rs11642954	chr16:24824248	G/A	cg06028605	chr16:24865363	SLC5A11	0.51	7.47	0.42	1.14e-12	Intelligence (multi-trait analysis);
CESC	cis	rs708547	0.599	rs1718864	chr4:57887471	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.48	6.68	0.38	1.38e-10	Response to bleomycin (chromatid breaks);
CESC	cis	rs4911259	0.552	rs13042651	chr20:31467423	C/T	cg13636640	chr20:31349939	DNMT3B	-0.54	-7.44	-0.42	1.45e-12	Inflammatory bowel disease;
CESC	cis	rs2635047	0.684	rs7236105	chr18:44757226	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.42	5.51	0.32	8.53e-8	Educational attainment;
CESC	cis	rs965469	0.779	rs2207995	chr20:3294484	T/C	cg25506879	chr20:3388711	C20orf194	-0.48	-5.35	-0.31	1.92e-7	IFN-related cytopenia;
CESC	cis	rs4450131	0.522	rs876352	chr10:126337350	C/T	cg20435097	chr10:126320824	FAM53B	0.29	5.21	0.3	3.84e-7	White blood cell count (basophil);
CESC	cis	rs2836974	0.568	rs377098	chr21:40535216	G/A	cg11644478	chr21:40555479	PSMG1	-0.83	-12.81	-0.62	1.5e-29	Cognitive function;
CESC	cis	rs2075371	0.932	rs1862052	chr7:133981227	G/A	cg11752832	chr7:134001865	SLC35B4	0.52	6.74	0.38	9.65e-11	Mean platelet volume;
CESC	cis	rs7412746	0.611	rs36008098	chr1:150856806	G/A	cg04414720	chr1:150670196	GOLPH3L	0.45	5.9	0.34	1.12e-8	Melanoma;
CESC	cis	rs9814567	1.000	rs17694011	chr3:134213981	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.44	-5.99	-0.35	6.9e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs875971	0.862	rs6955837	chr7:66043142	C/T	cg18876405	chr7:65276391	NA	-0.53	-7.25	-0.41	4.64e-12	Aortic root size;
CESC	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg24503407	chr1:205819492	PM20D1	0.66	10.86	0.56	5.52e-23	Monocyte percentage of white cells;
CESC	cis	rs752010	0.530	rs10789401	chr1:42081111	A/G	cg06885757	chr1:42089581	HIVEP3	0.7	11.21	0.57	3.92e-24	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs7666738	0.830	rs10440379	chr4:98902822	G/T	cg17366294	chr4:99064904	C4orf37	0.56	7.62	0.42	4.5e-13	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3796619	1.000	rs11247973	chr4:1094314	G/A	cg27284194	chr4:1044797	NA	0.37	5.59	0.32	5.6e-8	Recombination rate (males);
CESC	cis	rs9457247	1.000	rs430097	chr6:167405073	A/G	cg23791538	chr6:167370224	RNASET2	-0.59	-8.42	-0.46	2.44e-15	Crohn's disease;
CESC	cis	rs796364	0.664	rs4673660	chr2:200915395	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.7	7.24	0.41	5.01e-12	Schizophrenia;
CESC	cis	rs909674	0.818	rs5757680	chr22:39844793	C/T	cg01416388	chr22:39784598	NA	0.5	6.05	0.35	4.9e-9	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs7095944	0.583	rs12218394	chr10:126480591	G/C	cg08799069	chr10:126477246	METTL10	-0.4	-5.79	-0.34	1.97e-8	Asthma;
CESC	cis	rs875971	0.545	rs316316	chr7:65614257	C/T	cg18876405	chr7:65276391	NA	-0.5	-5.87	-0.34	1.28e-8	Aortic root size;
CESC	cis	rs763014	1.000	rs763014	chr16:675680	T/C	cg07343612	chr16:622815	PIGQ	-0.56	-8.21	-0.45	9.95e-15	Height;
CESC	cis	rs6062788	0.524	rs6122362	chr20:61701245	C/T	cg20652954	chr20:61716293	NA	-0.32	-5.34	-0.31	1.96e-7	Body mass index;
CESC	cis	rs3820068	0.553	rs7545782	chr1:15955227	G/C	cg17385448	chr1:15911702	AGMAT	0.43	6.93	0.39	3.22e-11	Systolic blood pressure;
CESC	cis	rs1499614	0.901	rs3936	chr7:66126489	C/T	cg13147721	chr7:65941812	NA	-0.93	-8.6	-0.47	7.11e-16	Gout;
CESC	cis	rs10504229	1.000	rs75037501	chr8:58170136	T/G	cg24829409	chr8:58192753	C8orf71	-0.76	-9.92	-0.52	6.14e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs523522	0.962	rs12371550	chr12:120987643	C/T	cg27279351	chr12:120934652	DYNLL1	0.68	8.94	0.48	6.97e-17	High light scatter reticulocyte count;
CESC	cis	rs5758659	0.714	rs5758574	chr22:42481400	G/C	cg00645731	chr22:42541494	CYP2D7P1	0.32	5.59	0.32	5.67e-8	Cognitive function;
CESC	cis	rs1799949	1.000	rs2292595	chr17:41290674	G/C	cg05368731	chr17:41323189	NBR1	0.8	11.27	0.57	2.51e-24	Menopause (age at onset);
CESC	cis	rs17401966	1.000	rs12141416	chr1:10327867	A/G	cg15208524	chr1:10270712	KIF1B	0.41	5.29	0.31	2.61e-7	Hepatocellular carcinoma;
CESC	cis	rs7927771	0.832	rs10769262	chr11:47411581	G/A	cg20307385	chr11:47447363	PSMC3	0.62	7.61	0.42	4.7e-13	Subjective well-being;
CESC	cis	rs7834588	0.523	rs1455576	chr8:63822440	C/T	cg20602954	chr8:63776762	NKAIN3	-0.31	-5.3	-0.31	2.45e-7	Response to Vitamin E supplementation;
CESC	cis	rs17431357	1.000	rs117894641	chr12:120939099	T/C	cg25045489	chr12:120971538	RNF10	-0.93	-5.46	-0.32	1.1e-7	Insulin resistance/response;
CESC	cis	rs17376456	1.000	rs59472588	chr5:93511981	A/G	cg25358565	chr5:93447407	FAM172A	1.16	11.62	0.58	1.67e-25	Diabetic retinopathy;
CESC	trans	rs11989744	0.500	rs7826517	chr8:23568841	G/A	cg03492747	chr16:86543808	FOXF1	-0.84	-13.4	-0.64	1.32e-31	Waist-hip ratio;
CESC	cis	rs763014	1.000	rs7205409	chr16:642610	A/G	cg00908189	chr16:619842	PIGQ	0.63	8.84	0.48	1.33e-16	Height;
CESC	cis	rs80282103	0.618	rs12250141	chr10:1160106	A/T	cg08668510	chr10:1095578	IDI1	0.88	5.57	0.32	6.15e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs722599	0.651	rs7159354	chr14:75253847	A/G	cg08847533	chr14:75593920	NEK9	0.45	5.58	0.32	5.85e-8	IgG glycosylation;
CESC	cis	rs9354308	0.677	rs9363462	chr6:66557612	A/T	cg07460842	chr6:66804631	NA	-0.42	-5.07	-0.3	7.32e-7	Metabolite levels;
CESC	cis	rs9987353	0.522	rs2929466	chr8:9063899	G/T	cg06636001	chr8:8085503	FLJ10661	-0.42	-5.12	-0.3	6.02e-7	Recombination measurement;
CESC	cis	rs6456156	0.586	rs13210649	chr6:167473193	T/G	cg23791538	chr6:167370224	RNASET2	-0.52	-6.7	-0.38	1.24e-10	Primary biliary cholangitis;
CESC	cis	rs2760061	0.819	rs1745417	chr1:228204279	C/T	cg02753203	chr1:228287806	NA	0.53	7.87	0.44	9.03e-14	Diastolic blood pressure;
CESC	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg05064044	chr6:292385	DUSP22	0.68	8.74	0.47	2.71e-16	Menopause (age at onset);
CESC	cis	rs9549367	0.713	rs2146750	chr13:113822530	A/G	cg18105134	chr13:113819100	PROZ	0.6	7.07	0.4	1.37e-11	Platelet distribution width;
CESC	cis	rs561341	1.000	rs530715	chr17:30320544	T/G	cg00745463	chr17:30367425	LRRC37B	-0.69	-7.02	-0.4	1.88e-11	Hip circumference adjusted for BMI;
CESC	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg07157834	chr1:205819609	PM20D1	0.73	10.77	0.55	1.16e-22	Menarche (age at onset);
CESC	cis	rs798943	0.806	rs10242653	chr7:120865801	C/A	cg09857513	chr7:120969044	WNT16	0.3	5.04	0.3	8.74e-7	Bone mineral density (paediatric, upper limb);
CESC	cis	rs9916302	0.706	rs9908131	chr17:37520449	T/C	cg07936489	chr17:37558343	FBXL20	0.9	9.75	0.51	2.09e-19	Glomerular filtration rate (creatinine);
CESC	cis	rs34779708	0.931	rs79749947	chr10:35277081	A/T	cg03585969	chr10:35415529	CREM	0.77	10.16	0.53	1.05e-20	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs8077889	0.871	rs17675370	chr17:41900030	T/C	cg26893861	chr17:41843967	DUSP3	0.83	9.86	0.52	9.44e-20	Triglycerides;
CESC	cis	rs1045714	0.895	rs4719594	chr7:2639790	G/A	cg20813462	chr7:2646259	IQCE	0.65	5.61	0.33	5.2e-8	Urate levels in lean individuals;
CESC	cis	rs709400	0.859	rs7693	chr14:104023704	C/T	cg24130564	chr14:104152367	KLC1	-0.43	-5.23	-0.31	3.5e-7	Body mass index;
CESC	cis	rs6461049	0.765	rs1476887	chr7:2151633	T/C	cg05863683	chr7:1912471	MAD1L1	0.38	5.48	0.32	1.01e-7	Schizophrenia;
CESC	cis	rs9311474	0.607	rs13076398	chr3:52573096	G/A	cg17372223	chr3:52568218	NT5DC2	0.48	7.6	0.42	5.21e-13	Electroencephalogram traits;
CESC	trans	rs916888	0.821	rs70602	chr17:44859715	T/C	cg22433210	chr17:43662623	NA	-0.91	-10.51	-0.54	7.86e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs796364	0.806	rs203769	chr2:200900866	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.84	-7.93	-0.44	6.25e-14	Schizophrenia;
CESC	cis	rs6860806	0.507	rs270608	chr5:131648406	C/T	cg24060327	chr5:131705240	SLC22A5	-0.73	-10.01	-0.52	3.26e-20	Breast cancer;
CESC	cis	rs561341	1.000	rs56903735	chr17:30254393	T/A	cg19193384	chr17:30244184	NA	-0.61	-6.35	-0.36	9.48e-10	Hip circumference adjusted for BMI;
CESC	cis	rs853679	0.517	rs9380049	chr6:28048535	A/G	cg20151795	chr6:28129481	ZNF389	0.44	5.59	0.33	5.5e-8	Depression;
CESC	cis	rs116095464	0.614	rs62344292	chr5:244630	G/A	cg10591111	chr5:226296	SDHA	-0.52	-6.38	-0.36	7.94e-10	Breast cancer;
CESC	cis	rs7949030	0.626	rs1061093	chr11:62334908	G/C	cg13298116	chr11:62369859	EML3;MTA2	0.66	9.78	0.51	1.8e-19	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs796364	0.950	rs56155997	chr2:200768491	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.83	-6.37	-0.36	8.12e-10	Schizophrenia;
CESC	cis	rs2303759	0.709	rs10411679	chr19:49826480	A/T	cg22590775	chr19:49891494	CCDC155	0.45	5.04	0.3	8.62e-7	Multiple sclerosis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02896403	chr1:155231989	SCAMP3	0.6	6.69	0.38	1.34e-10	Gut microbiome composition (summer);
CESC	cis	rs11718455	1.000	rs4682928	chr3:44037192	T/C	cg08738300	chr3:44038990	NA	0.48	6.41	0.37	6.74e-10	Coronary artery disease;
CESC	cis	rs524023	0.957	rs538737	chr11:64355772	C/G	cg07220939	chr11:64358617	SLC22A12	0.36	5.6	0.33	5.43e-8	Urate levels in obese individuals;
CESC	cis	rs798554	0.723	rs798518	chr7:2777825	A/G	cg18446336	chr7:2847575	GNA12	-0.36	-5.49	-0.32	9.34e-8	Height;
CESC	cis	rs2637266	0.756	rs2583063	chr10:78558048	T/C	cg18941641	chr10:78392320	NA	0.41	7.83	0.43	1.17e-13	Pulmonary function;
CESC	cis	rs2072732	0.861	rs12041583	chr1:2950886	A/G	cg15211996	chr1:2936768	ACTRT2	0.34	5.95	0.34	8.31e-9	Plateletcrit;
CESC	cis	rs8017423	0.647	rs4900037	chr14:90821478	A/G	cg14092571	chr14:90743983	NA	-0.42	-6.44	-0.37	5.66e-10	Mortality in heart failure;
CESC	cis	rs12681366	0.537	rs2919659	chr8:95471772	T/C	cg13257157	chr8:95487014	RAD54B	0.45	5.44	0.32	1.23e-7	Nonsyndromic cleft lip with cleft palate;
CESC	cis	rs875971	1.000	rs1363055	chr7:65943275	A/G	cg11764359	chr7:65958608	NA	0.97	15.5	0.69	5.25e-39	Aortic root size;
CESC	cis	rs1499972	0.941	rs62264819	chr3:117671941	T/C	cg07612923	chr3:117604196	NA	0.89	7.41	0.41	1.71e-12	Schizophrenia;
CESC	cis	rs9487051	0.676	rs9400268	chr6:109600550	C/T	cg12927641	chr6:109611667	NA	-0.36	-5.49	-0.32	9.3e-8	Reticulocyte fraction of red cells;
CESC	cis	rs17401966	0.931	rs2185252	chr1:10415912	T/C	cg15208524	chr1:10270712	KIF1B	0.41	5.18	0.3	4.35e-7	Hepatocellular carcinoma;
CESC	cis	rs2273669	0.667	rs78714994	chr6:109350351	G/C	cg05315195	chr6:109294784	ARMC2	-0.67	-6.32	-0.36	1.13e-9	Prostate cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07849438	chr12:19593035	AEBP2	0.56	6.45	0.37	5.22e-10	Gut microbiome composition (summer);
CESC	cis	rs3741151	1.000	rs1892856	chr11:73017971	G/C	cg17517138	chr11:73019481	ARHGEF17	1.13	7.47	0.42	1.15e-12	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs4523957	0.583	rs4349181	chr17:2040963	A/G	cg16513277	chr17:2031491	SMG6	-0.76	-11.08	-0.56	1.09e-23	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs561341	1.000	rs8073186	chr17:30244956	T/C	cg19193384	chr17:30244184	NA	-0.56	-5.99	-0.35	6.81e-9	Hip circumference adjusted for BMI;
CESC	cis	rs796364	0.951	rs11675980	chr2:201051150	A/G	cg23649088	chr2:200775458	C2orf69	-0.55	-5.41	-0.32	1.39e-7	Schizophrenia;
CESC	cis	rs9457247	1.000	rs385113	chr6:167403971	A/G	cg23791538	chr6:167370224	RNASET2	-0.59	-8.42	-0.46	2.44e-15	Crohn's disease;
CESC	cis	rs2302190	0.882	rs11656888	chr17:56546725	T/A	cg25885038	chr17:56607967	SEPT4	-0.41	-5.58	-0.32	5.79e-8	Vitamin D levels;
CESC	cis	rs6952808	0.636	rs6964522	chr7:1953523	C/T	cg20295408	chr7:1910781	MAD1L1	-0.44	-5.8	-0.34	1.91e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs6430585	0.583	rs58509842	chr2:136586027	G/A	cg07169764	chr2:136633963	MCM6	1.28	18.2	0.75	1.4e-48	Corneal structure;
CESC	trans	rs3925158	0.510	rs4955394	chr3:38293463	C/G	cg23247845	chr10:3679085	NA	0.66	6.06	0.35	4.74e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs3733585	0.773	rs13107466	chr4:10019390	G/A	cg00071950	chr4:10020882	SLC2A9	0.91	17.5	0.73	4.14e-46	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs5758511	0.680	rs5758684	chr22:42649509	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.58	8.64	0.47	5.58e-16	Birth weight;
CESC	cis	rs2066819	1.000	rs79436528	chr12:56686997	C/T	cg26734620	chr12:56694298	CS	1.07	6.58	0.37	2.56e-10	Psoriasis vulgaris;
CESC	cis	rs7666738	0.830	rs28417577	chr4:99053007	T/C	cg03676636	chr4:99064102	C4orf37	0.33	5.12	0.3	5.93e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1799949	1.000	rs11656097	chr17:41290613	G/T	cg23758822	chr17:41437982	NA	1.02	15.64	0.69	1.65e-39	Menopause (age at onset);
CESC	cis	rs763121	0.853	rs1065201	chr22:39069510	T/C	cg06544989	chr22:39130855	UNC84B	0.5	8.88	0.48	1.05e-16	Menopause (age at onset);
CESC	cis	rs4665809	0.877	rs35224700	chr2:26298037	T/C	cg25036284	chr2:26402008	FAM59B	0.68	7.36	0.41	2.38e-12	Gut microbiome composition (summer);
CESC	cis	rs2075371	1.000	rs2505	chr7:133979552	C/T	cg11752832	chr7:134001865	SLC35B4	0.54	7.02	0.4	1.91e-11	Mean platelet volume;
CESC	cis	rs2425143	1.000	rs113203744	chr20:34253656	C/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.61	5.14	0.3	5.43e-7	Blood protein levels;
CESC	cis	rs4766566	0.501	rs3742004	chr12:111798553	A/G	cg10833066	chr12:111807467	FAM109A	0.34	5.22	0.31	3.69e-7	Atrial fibrillation;Renal underexcretion gout;Gout;Renal overload gout;
CESC	cis	rs5995756	0.736	rs1883123	chr22:39996882	C/T	cg03390717	chr22:39966585	CACNA1I	-0.31	-5.4	-0.31	1.46e-7	Autism spectrum disorder or schizophrenia;
CESC	trans	rs11098499	0.722	rs28713555	chr4:120251995	C/T	cg25214090	chr10:38739885	LOC399744	0.62	8.7	0.47	3.58e-16	Corneal astigmatism;
CESC	cis	rs9660992	0.573	rs1318187	chr1:205206172	T/A	cg00857998	chr1:205179979	DSTYK	0.56	6.88	0.39	4.29e-11	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs7020830	0.858	rs7856690	chr9:37127545	A/T	cg14294708	chr9:37120828	ZCCHC7	1.11	20.06	0.78	4.3e-55	Schizophrenia;
CESC	cis	rs9322193	0.884	rs62439836	chr6:149990309	A/G	cg07701084	chr6:150067640	NUP43	0.45	6.27	0.36	1.45e-9	Lung cancer;
CESC	trans	rs8026198	0.568	rs1678984	chr15:42616332	T/G	cg11538410	chr8:142141455	DENND3	0.61	6.04	0.35	5.32e-9	Fibrinogen levels;
CESC	cis	rs854765	0.583	rs8065970	chr17:17858771	A/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.54	7.08	0.4	1.28e-11	Total body bone mineral density;
CESC	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg06873352	chr17:61820015	STRADA	0.72	12.61	0.61	7.18e-29	Prudent dietary pattern;
CESC	cis	rs12477438	0.520	rs11689265	chr2:99799267	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	15.11	0.68	1.23e-37	Chronic sinus infection;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11658038	chr5:141303204	KIAA0141	0.53	6.03	0.35	5.39e-9	Gut microbiome composition (summer);
CESC	trans	rs7307889	0.793	rs59382088	chr12:5995398	G/A	cg18407955	chr7:158110685	PTPRN2	-0.72	-6.18	-0.35	2.39e-9	Obesity-related traits;
CESC	cis	rs6493487	0.512	rs1438926	chr15:51351145	G/T	cg02338191	chr15:51200825	AP4E1	0.58	5.42	0.32	1.31e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs9649213	0.574	rs7802541	chr7:97933855	C/A	cg00277769	chr7:97922759	BAIAP2L1	-0.32	-5.11	-0.3	6.13e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs55871839	0.708	rs2326213	chr8:59812459	A/G	cg07426533	chr8:59803705	TOX	-0.47	-7.01	-0.4	1.95e-11	Pneumonia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09571097	chr17:899782	TIMM22	-0.61	-7.43	-0.42	1.54e-12	Gut microbiome composition (summer);
CESC	cis	rs61931739	0.500	rs7310576	chr12:34474735	T/C	cg23762105	chr12:34175262	ALG10	-0.39	-5.05	-0.3	8.28e-7	Morning vs. evening chronotype;
CESC	cis	rs1499972	0.938	rs861673	chr3:117733019	A/G	cg07612923	chr3:117604196	NA	-0.78	-6.32	-0.36	1.08e-9	Schizophrenia;
CESC	cis	rs2439831	0.867	rs45585139	chr15:43700427	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.77	8.68	0.47	4.05e-16	Lung cancer in ever smokers;
CESC	cis	rs7937682	0.924	rs12791699	chr11:111505880	T/C	cg09085632	chr11:111637200	PPP2R1B	-0.99	-16.01	-0.7	8.36e-41	Primary sclerosing cholangitis;
CESC	cis	rs7618915	0.508	rs12498066	chr3:52627660	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.48	6.8	0.39	6.78e-11	Bipolar disorder;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg15084499	chr1:227505916	CDC42BPA	0.46	6.67	0.38	1.52e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs10504229	1.000	rs76023408	chr8:58193345	A/G	cg05313129	chr8:58192883	C8orf71	-0.51	-5.98	-0.34	7.31e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs77741769	0.571	rs3883901	chr12:121256520	A/G	cg02419362	chr12:121203948	SPPL3	0.34	5.57	0.32	6.14e-8	Mean corpuscular volume;
CESC	cis	rs12477438	0.520	rs1453563	chr2:99720267	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.78	12.89	0.62	7.58e-30	Chronic sinus infection;
CESC	cis	rs965469	0.779	rs6037516	chr20:3233142	C/G	cg25506879	chr20:3388711	C20orf194	-0.51	-5.57	-0.32	6.1e-8	IFN-related cytopenia;
CESC	cis	rs10178409	1	rs10178409	chr2:73855507	G/T	cg20560298	chr2:73613845	ALMS1	-0.42	-5.08	-0.3	7.04e-7	Urinary metabolites;
CESC	cis	rs3762637	0.943	rs9872708	chr3:122242807	C/G	cg24169773	chr3:122142474	KPNA1	-0.59	-6.94	-0.39	3.01e-11	LDL cholesterol levels;
CESC	cis	rs6460942	0.597	rs6968664	chr7:12515493	T/C	cg20607287	chr7:12443886	VWDE	-0.63	-7.11	-0.4	1.1e-11	Coronary artery disease;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg05062854	chr22:32435553	NA	0.43	6.65	0.38	1.67e-10	Gambling;
CESC	cis	rs1552244	1.000	rs6789156	chr3:10124120	C/T	cg08888203	chr3:10149979	C3orf24	0.5	6.17	0.35	2.58e-9	Alzheimer's disease;
CESC	cis	rs10504229	1.000	rs66870803	chr8:58180022	G/C	cg22535103	chr8:58192502	C8orf71	-1.05	-13.27	-0.63	3.63e-31	Developmental language disorder (linguistic errors);
CESC	cis	rs4243830	0.571	rs60256927	chr1:6614747	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	0.95	9.29	0.5	5.77e-18	Body mass index;
CESC	trans	rs6582630	0.634	rs10748443	chr12:38734062	G/T	cg23762105	chr12:34175262	ALG10	-0.45	-6.01	-0.35	5.97e-9	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs17253792	0.732	rs28380739	chr14:56088402	G/A	cg01858014	chr14:56050164	KTN1	-0.85	-6.99	-0.39	2.22e-11	Putamen volume;
CESC	cis	rs14403	1.000	rs9803713	chr1:243672000	C/G	cg21452805	chr1:244014465	NA	0.49	5.47	0.32	1.04e-7	Schizophrenia;
CESC	cis	rs1707322	0.691	rs11211174	chr1:46220816	C/G	cg03146154	chr1:46216737	IPP	0.82	11.54	0.58	3.18e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs1552244	1.000	rs112847840	chr3:10101652	C/T	cg00166722	chr3:10149974	C3orf24	0.53	6.65	0.38	1.64e-10	Alzheimer's disease;
CESC	cis	rs9309473	1.000	rs1881245	chr2:73649928	G/A	cg20560298	chr2:73613845	ALMS1	-0.5	-6.81	-0.39	6.38e-11	Metabolite levels;
CESC	trans	rs17685	0.672	rs55807301	chr7:75807401	C/A	cg19862616	chr7:65841803	NCRNA00174	0.82	11.72	0.58	7.99e-26	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs10911232	0.507	rs3935384	chr1:183028970	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.86	13.58	0.64	3.12e-32	Hypertriglyceridemia;
CESC	cis	rs6459788	0.502	rs9692347	chr7:157232659	C/T	cg03453431	chr7:157225567	NA	-0.41	-6.99	-0.39	2.19e-11	Epstein-Barr virus copy number in lymphoblastoid cell lines;
CESC	cis	rs362272	0.545	rs2748447	chr4:3337831	G/A	cg08886695	chr4:3369023	RGS12	-0.41	-5.6	-0.33	5.29e-8	Serum sulfate level;
CESC	cis	rs2337406	0.714	rs8022729	chr14:107225161	C/T	cg07958169	chr14:107095056	NA	0.49	5.6	0.33	5.37e-8	Alzheimer's disease (late onset);
CESC	cis	rs2764980	1.000	rs2764979	chr10:3283882	T/C	cg11630169	chr10:3283847	NA	-0.37	-5.13	-0.3	5.54e-7	Attention deficit hyperactivity disorder and conduct disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01034784	chr2:95831832	ZNF2	-0.64	-7.76	-0.43	1.8e-13	Gut microbiome composition (summer);
CESC	cis	rs2806561	0.765	rs2806565	chr1:23507068	A/G	cg12483005	chr1:23474871	LUZP1	0.39	6.15	0.35	2.85e-9	Height;
CESC	cis	rs853679	0.517	rs9393884	chr6:28046789	A/G	cg19592336	chr6:28129416	ZNF389	0.63	8.61	0.47	6.75e-16	Depression;
CESC	cis	rs28374715	0.578	rs8036026	chr15:41630499	C/G	cg20272979	chr15:41787780	ITPKA	0.46	5.41	0.32	1.41e-7	Ulcerative colitis;
CESC	cis	rs7618915	0.570	rs4687633	chr3:52630548	G/A	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.38	6.65	0.38	1.63e-10	Bipolar disorder;
CESC	cis	rs2120019	1.000	rs12901243	chr15:75374233	C/T	cg17294928	chr15:75287854	SCAMP5	-0.59	-6.65	-0.38	1.64e-10	Blood trace element (Zn levels);
CESC	cis	rs6460942	0.778	rs17444259	chr7:12462428	C/T	cg10578991	chr7:12443926	VWDE	-0.43	-5.59	-0.32	5.71e-8	Coronary artery disease;
CESC	cis	rs4665809	1.000	rs12471809	chr2:26307140	A/G	cg08470875	chr2:26401718	FAM59B	-0.47	-5.22	-0.31	3.6e-7	Gut microbiome composition (summer);
CESC	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg03188948	chr7:1209495	NA	0.73	7.02	0.4	1.85e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs8062405	1.000	rs72793812	chr16:28840381	A/G	cg08761264	chr16:28874980	SH2B1	-0.44	-5.36	-0.31	1.85e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs9894429	0.966	rs6565605	chr17:79589359	C/T	cg18240062	chr17:79603768	NPLOC4	0.7	9.81	0.52	1.35e-19	Eye color traits;
CESC	cis	rs11122272	0.670	rs2474632	chr1:231484361	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.53	-7.34	-0.41	2.63e-12	Hemoglobin concentration;
CESC	cis	rs2228479	0.850	rs1800344	chr16:89816367	T/G	cg14709524	chr16:89940631	TCF25	0.93	6.94	0.39	3.03e-11	Skin colour saturation;
CESC	cis	rs2415984	0.622	rs1761026	chr14:46930139	T/C	cg14871534	chr14:47121158	RPL10L	0.36	5.52	0.32	7.98e-8	Number of children ever born;
CESC	cis	rs11098499	0.863	rs2306456	chr4:120472422	C/G	cg24375607	chr4:120327624	NA	0.45	5.54	0.32	7.33e-8	Corneal astigmatism;
CESC	cis	rs1707322	0.721	rs12045096	chr1:46114428	A/G	cg03146154	chr1:46216737	IPP	0.82	11.52	0.58	3.64e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7072216	0.763	rs2274245	chr10:100175082	C/T	cg26618903	chr10:100175079	PYROXD2	-0.38	-5.9	-0.34	1.11e-8	Metabolite levels;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg07264050	chr8:48920858	UBE2V2	-0.39	-6.09	-0.35	3.98e-9	Gambling;
CESC	cis	rs11677370	0.561	rs10084170	chr2:3820204	G/C	cg17052675	chr2:3827356	NA	-0.44	-5.86	-0.34	1.34e-8	Type 2 diabetes;
CESC	cis	rs6460942	0.597	rs17448193	chr7:12525641	G/A	cg10578991	chr7:12443926	VWDE	-0.49	-5.13	-0.3	5.63e-7	Coronary artery disease;
CESC	cis	rs4233366	0.959	rs2070901	chr1:161185058	G/T	cg13853198	chr1:161185092	FCER1G	0.42	6.56	0.37	2.88e-10	Asthma;
CESC	cis	rs12477438	0.520	rs4402818	chr2:99717608	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.93	16.07	0.7	5.04e-41	Chronic sinus infection;
CESC	cis	rs12442242	0.522	rs16966212	chr15:38360289	T/C	cg19084031	chr15:38361362	NA	0.96	6.56	0.37	2.83e-10	Total body bone mineral density;
CESC	cis	rs875971	0.660	rs7807930	chr7:66087165	C/T	cg18876405	chr7:65276391	NA	-0.57	-7.53	-0.42	7.86e-13	Aortic root size;
CESC	cis	rs427394	0.582	rs274661	chr5:6704848	C/T	cg10857441	chr5:6722123	POLS	-0.42	-5.07	-0.3	7.61e-7	Menopause (age at onset);
CESC	trans	rs61931739	0.517	rs1843737	chr12:34015305	A/G	cg26384229	chr12:38710491	ALG10B	0.45	6.33	0.36	1.02e-9	Morning vs. evening chronotype;
CESC	cis	rs863345	0.604	rs10797021	chr1:158490341	T/C	cg12129480	chr1:158549410	OR10X1	-0.34	-6.85	-0.39	5.17e-11	Pneumococcal bacteremia;
CESC	cis	rs9527	0.590	rs7910900	chr10:104829898	C/T	cg04362960	chr10:104952993	NT5C2	0.42	5.26	0.31	2.98e-7	Arsenic metabolism;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03818826	chr16:70323689	AARS	-0.57	-6.74	-0.38	9.83e-11	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22841110	chr11:64053472	BAD;GPR137	0.54	6.17	0.35	2.5e-9	Gut microbiome composition (summer);
CESC	cis	rs10861342	1.000	rs12229846	chr12:105553066	A/C	cg23923672	chr12:105501055	KIAA1033	0.66	5.44	0.32	1.21e-7	IgG glycosylation;
CESC	cis	rs4604732	0.631	rs56704806	chr1:247626148	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.57	7.17	0.4	7.39e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs28602670	1	rs28602670	chr15:78768167	C/G	cg24631222	chr15:78858424	CHRNA5	0.65	7.69	0.43	2.83e-13	Post bronchodilator FEV1;
CESC	trans	rs60380162	0.963	rs11579302	chr1:87730211	T/G	cg20163645	chr8:1900353	ARHGEF10	-0.43	-6.03	-0.35	5.48e-9	Loneliness (linear analysis);
CESC	cis	rs3096299	0.866	rs4238829	chr16:89462262	G/A	cg02187348	chr16:89574699	SPG7	0.51	6.75	0.38	9.37e-11	Multiple myeloma (IgH translocation);
CESC	cis	rs10743315	0.778	rs965861	chr12:19360719	A/G	cg02471346	chr12:19282374	PLEKHA5	-0.48	-5.16	-0.3	4.87e-7	Gut microbiota (bacterial taxa);
CESC	cis	rs4737010	0.530	rs4026	chr8:41645710	C/T	cg08923054	chr8:41654455	ANK1	0.53	6.71	0.38	1.16e-10	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
CESC	cis	rs9322193	0.923	rs9322208	chr6:149979683	A/T	cg04369109	chr6:150039330	LATS1	-0.4	-5.54	-0.32	7.28e-8	Lung cancer;
CESC	trans	rs208520	0.690	rs1100981	chr6:66852052	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.0	-12.93	-0.62	5.39e-30	Exhaled nitric oxide output;
CESC	trans	rs1814175	0.645	rs847635	chr11:49923323	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.43	-6.36	-0.36	8.98e-10	Height;
CESC	cis	rs7649275	0.882	rs2612024	chr3:53779580	G/C	cg21503701	chr3:53781065	CACNA1D	-0.4	-5.28	-0.31	2.66e-7	Trans fatty acid levels;
CESC	cis	rs6445797	0.632	rs2004199	chr3:56645866	A/G	cg13792233	chr3:56591045	CCDC66	-0.4	-5.31	-0.31	2.28e-7	Gastritis;
CESC	cis	rs7845219	0.544	rs7016078	chr8:95922615	G/A	cg13393036	chr8:95962371	TP53INP1	-0.43	-8.22	-0.45	9.43e-15	Type 2 diabetes;
CESC	cis	rs4665809	0.590	rs3792007	chr2:26497541	C/T	cg26314531	chr2:26401878	FAM59B	0.8	8.22	0.45	9.18e-15	Gut microbiome composition (summer);
CESC	cis	rs4561483	0.771	rs7202234	chr16:11942322	A/G	cg08843971	chr16:11963173	GSPT1	0.49	7.15	0.4	8.44e-12	Testicular germ cell tumor;
CESC	cis	rs6087990	0.806	rs2424918	chr20:31382770	C/T	cg13636640	chr20:31349939	DNMT3B	0.82	13.25	0.63	4.5e-31	Ulcerative colitis;
CESC	cis	rs7551222	0.752	rs10900597	chr1:204522489	C/T	cg20240347	chr1:204465584	NA	-0.28	-5.62	-0.33	4.73e-8	Schizophrenia;
CESC	cis	rs172166	0.694	rs9295760	chr6:28147385	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.47	-6.14	-0.35	2.93e-9	Cardiac Troponin-T levels;
CESC	cis	rs9916302	0.904	rs55689507	chr17:37404436	G/C	cg07936489	chr17:37558343	FBXL20	-0.8	-11.2	-0.57	4.38e-24	Glomerular filtration rate (creatinine);
CESC	cis	rs116095464	0.558	rs6882584	chr5:223411	A/C	cg22857025	chr5:266934	NA	-1.27	-18.89	-0.76	5.51e-51	Breast cancer;
CESC	cis	rs7020830	0.898	rs7846747	chr9:37167539	A/C	cg14294708	chr9:37120828	ZCCHC7	1.23	23.92	0.83	3.7e-68	Schizophrenia;
CESC	cis	rs2228479	0.681	rs3212346	chr16:89982358	G/A	cg04287289	chr16:89883240	FANCA	0.55	5.18	0.3	4.49e-7	Skin colour saturation;
CESC	cis	rs2050392	0.517	rs656600	chr10:30765654	G/A	cg25182066	chr10:30743637	MAP3K8	-0.52	-7.65	-0.43	3.64e-13	Inflammatory bowel disease;
CESC	trans	rs7618501	0.699	rs2777888	chr3:49898000	A/G	cg21659725	chr3:3221576	CRBN	0.59	8.31	0.45	5.04e-15	Intelligence (multi-trait analysis);
CESC	cis	rs1707322	1.000	rs6695421	chr1:46380207	T/C	cg05343316	chr1:45956843	TESK2	0.45	5.55	0.32	6.79e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs10751667	0.643	rs6597969	chr11:928843	C/T	cg20946044	chr11:1010712	AP2A2	-0.39	-5.26	-0.31	2.96e-7	Alzheimer's disease (late onset);
CESC	cis	rs10504229	0.596	rs6991216	chr8:58115586	T/C	cg02725872	chr8:58115012	NA	-0.45	-7.05	-0.4	1.52e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs9811920	0.838	rs12488245	chr3:99835254	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.41	5.13	0.3	5.53e-7	Axial length;
CESC	cis	rs4665809	1.000	rs6546744	chr2:26302161	A/G	cg04944784	chr2:26401820	FAM59B	-0.67	-7.66	-0.43	3.48e-13	Gut microbiome composition (summer);
CESC	cis	rs67460515	0.892	rs11929238	chr3:161045937	A/T	cg03342759	chr3:160939853	NMD3	-0.54	-7.73	-0.43	2.27e-13	Parkinson's disease;
CESC	cis	rs9486719	1.000	rs2472882	chr6:96863474	C/T	cg18709589	chr6:96969512	KIAA0776	0.52	5.67	0.33	3.8e-8	Migraine;Coronary artery disease;
CESC	trans	rs208520	0.661	rs207079	chr6:66770462	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.0	-12.55	-0.61	1.11e-28	Exhaled nitric oxide output;
CESC	cis	rs1799949	0.965	rs34633610	chr17:41419385	A/G	cg25072359	chr17:41440525	NA	0.49	6.51	0.37	3.85e-10	Menopause (age at onset);
CESC	cis	rs17431357	1.000	rs73225245	chr12:120970633	C/T	cg25045489	chr12:120971538	RNF10	-0.93	-5.46	-0.32	1.1e-7	Insulin resistance/response;
CESC	trans	rs4942242	0.663	rs7319346	chr13:44218201	T/C	cg19169023	chr15:41853346	TYRO3	-0.61	-7.66	-0.43	3.59e-13	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs3096299	0.967	rs2965932	chr16:89477051	C/T	cg02187348	chr16:89574699	SPG7	-0.51	-6.86	-0.39	4.81e-11	Multiple myeloma (IgH translocation);
CESC	cis	rs9309473	0.950	rs10198549	chr2:73794404	A/G	cg20560298	chr2:73613845	ALMS1	-0.54	-7.08	-0.4	1.31e-11	Metabolite levels;
CESC	cis	rs2980439	0.525	rs2945238	chr8:8170136	A/C	cg15556689	chr8:8085844	FLJ10661	0.46	5.53	0.32	7.68e-8	Neuroticism;
CESC	cis	rs963731	0.649	rs297151	chr2:39326511	A/C	cg04010122	chr2:39346883	SOS1	-0.67	-5.42	-0.32	1.33e-7	Corticobasal degeneration;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg22461615	chr4:83821917	THAP9	-0.4	-6.36	-0.36	8.84e-10	Gambling;
CESC	cis	rs6815814	0.950	rs56289835	chr4:38811845	G/C	cg02016764	chr4:38805732	TLR1	-0.62	-7.43	-0.42	1.5e-12	Breast cancer;
CESC	cis	rs2979489	0.891	rs7822839	chr8:30354453	A/G	cg26383811	chr8:30366931	RBPMS	0.77	9.85	0.52	1.02e-19	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CESC	cis	rs9479482	1.000	rs11155697	chr6:150357423	C/T	cg03788504	chr6:150331562	NA	-0.38	-7.2	-0.4	6.04e-12	Alopecia areata;
CESC	cis	rs79349575	0.783	rs4794003	chr17:47029904	C/T	cg26022315	chr17:47021804	SNF8	0.39	5.16	0.3	4.94e-7	Type 2 diabetes;
CESC	cis	rs2070488	0.804	rs7646429	chr3:38467713	A/G	cg24069376	chr3:38537580	EXOG	0.35	5.92	0.34	9.72e-9	Electrocardiographic conduction measures;
CESC	cis	rs10504229	0.724	rs58715581	chr8:58134568	A/G	cg21724239	chr8:58056113	NA	0.58	5.95	0.34	8.29e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs113835537	0.529	rs75685325	chr11:66235242	A/G	cg24851651	chr11:66362959	CCS	0.54	6.39	0.37	7.56e-10	Airway imaging phenotypes;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg13696300	chr17:18162128	FLII	0.51	6.78	0.38	7.83e-11	Thyroid stimulating hormone;
CESC	cis	rs2290405	0.527	rs4690332	chr4:910520	C/T	cg04824913	chr4:887549	GAK	-0.71	-10.42	-0.54	1.6e-21	Systemic sclerosis;
CESC	cis	rs1003719	0.762	rs1015551	chr21:38449510	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.62	8.64	0.47	5.56e-16	Eye color traits;
CESC	cis	rs7659604	0.521	rs4833773	chr4:122689245	C/T	cg19748678	chr4:122722346	EXOSC9	-0.48	-6.14	-0.35	2.95e-9	Type 2 diabetes;
CESC	cis	rs992157	0.735	rs13393821	chr2:219076742	C/G	cg00012203	chr2:219082015	ARPC2	0.86	12.41	0.61	3.57e-28	Colorectal cancer;
CESC	cis	rs9926296	0.605	rs7205053	chr16:89856763	G/C	cg07648498	chr16:89883185	FANCA	0.45	5.56	0.32	6.55e-8	Vitiligo;
CESC	cis	rs62481355	1.000	rs62481355	chr7:127201664	C/T	cg25922125	chr7:127225783	GCC1	-0.47	-6.14	-0.35	3.03e-9	Type 2 diabetes;
CESC	cis	rs933688	0.509	rs2941895	chr5:90520510	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.41	-5.16	-0.3	4.85e-7	Smoking behavior;
CESC	cis	rs6088590	0.561	rs6059918	chr20:33150503	C/T	cg24642439	chr20:33292090	TP53INP2	0.62	8.24	0.45	8.14e-15	Coronary artery disease;
CESC	cis	rs17023223	0.537	rs55836852	chr1:119725401	G/A	cg05756136	chr1:119680316	WARS2	-0.47	-5.69	-0.33	3.34e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CESC	cis	rs7395581	0.918	rs1055510	chr11:47292237	A/G	cg25783544	chr11:47291846	MADD	0.62	8.26	0.45	6.99e-15	HDL cholesterol;
CESC	cis	rs8018808	0.905	rs4903586	chr14:77938633	C/G	cg20045696	chr14:77926864	AHSA1	-0.47	-6.54	-0.37	3.13e-10	Myeloid white cell count;
CESC	cis	rs7666738	0.830	rs1426662	chr4:98990319	C/T	cg18180107	chr4:99064573	C4orf37	0.4	5.21	0.31	3.72e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs72945132	0.825	rs947811	chr11:70209142	A/T	cg14191688	chr11:70257035	CTTN	0.41	5.12	0.3	6.02e-7	Coronary artery disease;
CESC	cis	rs1355223	0.902	rs7102625	chr11:34739717	A/C	cg11058730	chr11:34937778	PDHX;APIP	0.47	6.32	0.36	1.09e-9	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs910316	0.934	rs7141705	chr14:75655352	G/C	cg08847533	chr14:75593920	NEK9	-0.94	-16.63	-0.71	5.2e-43	Height;
CESC	cis	rs7666738	0.830	rs2019163	chr4:99022747	C/T	cg03467027	chr4:99064603	C4orf37	0.46	5.81	0.34	1.8e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7829975	0.688	rs7827182	chr8:8380471	C/G	cg06636001	chr8:8085503	FLJ10661	0.51	6.4	0.37	7.17e-10	Mood instability;
CESC	cis	rs868036	0.609	rs2127163	chr15:68090842	C/T	cg08079166	chr15:68083412	MAP2K5	0.42	5.77	0.33	2.23e-8	Restless legs syndrome;
CESC	cis	rs9443645	0.901	rs6912683	chr6:79543492	C/A	cg05283184	chr6:79620031	NA	-0.45	-6.98	-0.39	2.36e-11	Intelligence (multi-trait analysis);
CESC	cis	rs11203032	1.000	rs11203033	chr10:90964731	C/G	cg16672925	chr10:90967113	CH25H	-0.57	-5.75	-0.33	2.5e-8	Heart failure;
CESC	trans	rs4929949	0.607	rs10840038	chr11:8440949	T/C	cg10624583	chr12:53440492	TENC1	-0.45	-6.22	-0.36	1.95e-9	Body mass index;
CESC	cis	rs3106136	0.967	rs61004493	chr4:95163317	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.45	-6.8	-0.39	6.92e-11	Capecitabine sensitivity;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg08328324	chr8:33370759	C8orf41	-0.46	-6.17	-0.35	2.57e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs2933343	1.000	rs876756	chr3:128627623	G/A	cg25356066	chr3:128598488	ACAD9	0.61	7.44	0.42	1.42e-12	IgG glycosylation;
CESC	cis	rs965469	0.947	rs56689368	chr20:3332921	G/A	cg25506879	chr20:3388711	C20orf194	-0.54	-5.78	-0.33	2.14e-8	IFN-related cytopenia;
CESC	cis	rs60154123	0.730	rs583148	chr1:210463553	A/C	cg22029157	chr1:209979665	IRF6	0.49	5.99	0.35	6.7e-9	Coronary artery disease;
CESC	cis	rs1395	0.778	rs2078616	chr2:27441904	A/G	cg22903471	chr2:27725779	GCKR	-0.42	-5.17	-0.3	4.56e-7	Blood metabolite levels;
CESC	cis	rs7202877	0.656	rs4887812	chr16:75310052	G/A	cg04384234	chr16:75411784	CFDP1	-0.46	-5.22	-0.31	3.57e-7	Type 2 diabetes;Type 1 diabetes;
CESC	cis	rs6121246	0.559	rs6121038	chr20:30254773	T/G	cg13852791	chr20:30311386	BCL2L1	0.79	10.13	0.53	1.34e-20	Mean corpuscular hemoglobin;
CESC	cis	rs3768617	0.510	rs3768629	chr1:183074582	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.88	14.2	0.66	2.09e-34	Fuchs's corneal dystrophy;
CESC	cis	rs651907	0.557	rs34624546	chr3:101374226	T/G	cg12386194	chr3:101231763	SENP7	0.44	5.38	0.31	1.64e-7	Colorectal cancer;
CESC	cis	rs6546537	0.955	rs2312215	chr2:69839825	T/A	cg10773587	chr2:69614142	GFPT1	-0.53	-6.49	-0.37	4.2e-10	Serum thyroid-stimulating hormone levels;
CESC	cis	rs6754311	0.773	rs309176	chr2:136622216	T/C	cg07169764	chr2:136633963	MCM6	-0.69	-8.56	-0.47	9.42e-16	Mosquito bite size;
CESC	cis	rs2629540	0.855	rs12776722	chr10:126469833	G/A	cg08799069	chr10:126477246	METTL10	0.67	8.46	0.46	1.85e-15	Cocaine dependence;
CESC	cis	rs2760061	0.626	rs2796057	chr1:228124414	G/C	cg02753203	chr1:228287806	NA	-0.5	-7.22	-0.41	5.36e-12	Diastolic blood pressure;
CESC	cis	rs561341	1.000	rs2470243	chr17:30290955	C/T	cg00745463	chr17:30367425	LRRC37B	-0.85	-7.72	-0.43	2.36e-13	Hip circumference adjusted for BMI;
CESC	cis	rs9660992	0.710	rs1180721	chr1:205232696	T/C	cg00857998	chr1:205179979	DSTYK	0.45	5.22	0.31	3.7e-7	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs2180341	0.814	rs6940933	chr6:127732740	C/G	cg24812749	chr6:127587940	RNF146	0.84	11.84	0.59	3.11e-26	Breast cancer;
CESC	cis	rs4319547	0.695	rs11057797	chr12:122860732	G/A	cg05707623	chr12:122985044	ZCCHC8	0.56	6.28	0.36	1.35e-9	Body mass index;
CESC	cis	rs6752107	0.967	rs55835501	chr2:234157733	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.45	6.29	0.36	1.29e-9	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs258892	0.895	rs9293443	chr5:72055622	T/C	cg21869765	chr5:72125136	TNPO1	-0.42	-5.32	-0.31	2.2e-7	Small cell lung carcinoma;
CESC	cis	rs7560272	0.501	rs2421674	chr2:73955432	G/A	cg20560298	chr2:73613845	ALMS1	0.43	5.89	0.34	1.14e-8	Schizophrenia;
CESC	cis	rs7089973	0.604	rs11196942	chr10:116596872	G/A	cg25233709	chr10:116636983	FAM160B1	0.38	6.02	0.35	5.7e-9	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs6665290	0.836	rs12593	chr1:227172290	A/G	cg10327440	chr1:227177885	CDC42BPA	1.18	27.58	0.86	7.27e-80	Myeloid white cell count;
CESC	cis	rs2439831	0.867	rs2264876	chr15:43757419	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.83	12.14	0.6	2.88e-27	Lung cancer in ever smokers;
CESC	cis	rs34779708	0.733	rs59287215	chr10:35543994	C/T	cg04310649	chr10:35416472	CREM	-0.47	-5.38	-0.31	1.67e-7	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs2073300	0.609	rs34648279	chr20:23402935	T/G	cg12062639	chr20:23401060	NAPB	1.06	8.23	0.45	8.54e-15	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs2066819	0.901	rs773665	chr12:56717466	C/T	cg26714650	chr12:56694279	CS	1.28	15.86	0.7	2.7e-40	Psoriasis vulgaris;
CESC	cis	rs72634258	0.572	rs66692705	chr1:7938565	T/C	cg00042356	chr1:8021962	PARK7	0.58	5.63	0.33	4.56e-8	Inflammatory bowel disease;
CESC	cis	rs514406	0.798	rs504816	chr1:53307957	T/G	cg27535305	chr1:53392650	SCP2	-0.31	-5.07	-0.3	7.6e-7	Monocyte count;
CESC	cis	rs12142240	0.698	rs77185326	chr1:46818417	T/C	cg10495392	chr1:46806563	NSUN4	0.57	6.27	0.36	1.47e-9	Menopause (age at onset);
CESC	trans	rs61931739	0.500	rs7306334	chr12:34482900	A/G	cg13010199	chr12:38710504	ALG10B	-0.51	-6.68	-0.38	1.39e-10	Morning vs. evening chronotype;
CESC	cis	rs9916302	0.784	rs4795382	chr17:37700860	A/G	cg00129232	chr17:37814104	STARD3	-0.57	-7.44	-0.42	1.39e-12	Glomerular filtration rate (creatinine);
CESC	cis	rs2243480	1.000	rs186378	chr7:65582058	A/C	cg18252515	chr7:66147081	NA	-1.39	-13.92	-0.65	1.93e-33	Diabetic kidney disease;
CESC	cis	rs12701220	0.817	rs7798459	chr7:1087965	C/T	cg26769984	chr7:1090371	C7orf50	0.55	6.84	0.39	5.59e-11	Bronchopulmonary dysplasia;
CESC	cis	rs7772486	0.720	rs7752286	chr6:146072662	C/T	cg05347473	chr6:146136440	FBXO30	-0.54	-7.0	-0.4	2.06e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7666738	0.830	rs13134216	chr4:98919765	C/T	cg03676636	chr4:99064102	C4orf37	0.34	5.15	0.3	5.17e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs28647808	0.881	rs7040821	chr9:136263584	C/A	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.84	5.73	0.33	2.7e-8	Blood protein levels;
CESC	cis	rs9311474	0.607	rs4687625	chr3:52563718	C/T	cg07507251	chr3:52567010	NT5DC2	0.47	8.71	0.47	3.29e-16	Electroencephalogram traits;
CESC	trans	rs2727020	0.729	rs10839283	chr11:49490943	T/C	cg03929089	chr4:120376271	NA	0.74	9.57	0.51	7.96e-19	Coronary artery disease;
CESC	cis	rs7927592	0.913	rs12294029	chr11:68257059	A/C	cg16797656	chr11:68205561	LRP5	0.41	5.75	0.33	2.51e-8	Total body bone mineral density;
CESC	cis	rs7666738	0.830	rs17027090	chr4:98897923	G/T	cg05340658	chr4:99064831	C4orf37	0.76	11.13	0.56	7.59e-24	Colonoscopy-negative controls vs population controls;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg05964000	chr1:55564130	USP24	0.4	6.36	0.36	8.69e-10	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs9287719	0.967	rs2010080	chr2:10736552	A/T	cg02196655	chr2:10830764	NOL10	-0.37	-5.72	-0.33	2.87e-8	Prostate cancer;
CESC	cis	rs2842992	0.830	rs2758320	chr6:160070676	T/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.64	7.76	0.43	1.91e-13	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs8031584	0.541	rs1983459	chr15:31208749	C/T	cg08704250	chr15:31115839	NA	-0.63	-8.9	-0.48	9.14e-17	Huntington's disease progression;
CESC	cis	rs13191362	1.000	rs1333963	chr6:163192571	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.64	5.98	0.34	7.35e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs2295499	0.700	rs12503424	chr4:2702807	A/G	cg08330972	chr4:2403930	ZFYVE28	-0.33	-5.31	-0.31	2.29e-7	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
CESC	cis	rs476633	0.691	rs28735224	chr15:41537539	C/T	cg20272979	chr15:41787780	ITPKA	0.38	5.69	0.33	3.3e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs10789491	1.000	rs1890473	chr1:47149794	C/T	cg15501359	chr1:47185051	KIAA0494	0.73	8.12	0.45	1.79e-14	Response to hepatitis C treatment;
CESC	trans	rs8073060	0.586	rs2011897	chr17:34054408	A/T	cg19694781	chr19:47549865	TMEM160	0.74	6.8	0.39	6.82e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	cis	rs875971	0.862	rs11765791	chr7:65936574	A/G	cg11764359	chr7:65958608	NA	0.79	11.28	0.57	2.34e-24	Aortic root size;
CESC	cis	rs12464559	0.649	rs6708645	chr2:152620387	A/T	cg01189475	chr2:152685088	ARL5A	0.65	5.72	0.33	2.94e-8	Response to cognitive-behavioural therapy in anxiety disorder;
CESC	cis	rs3126085	0.935	rs1466757	chr1:152212469	G/A	cg03465714	chr1:152285911	FLG	-0.44	-5.37	-0.31	1.73e-7	Atopic dermatitis;
CESC	cis	rs7666738	0.830	rs4699331	chr4:99059816	T/C	cg05340658	chr4:99064831	C4orf37	0.83	12.92	0.62	5.92e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4253772	0.530	rs6008662	chr22:46713917	G/A	cg00784671	chr22:46762841	CELSR1	-0.39	-5.15	-0.3	5.07e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs780096	0.546	rs8179225	chr2:27737181	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.33	-5.84	-0.34	1.54e-8	Total body bone mineral density;
CESC	cis	rs3126085	1.000	rs3126098	chr1:152311923	T/C	cg03465714	chr1:152285911	FLG	0.44	5.29	0.31	2.61e-7	Atopic dermatitis;
CESC	cis	rs9611565	0.592	rs5758406	chr22:42076641	A/G	cg17376030	chr22:41985996	PMM1	-0.67	-7.42	-0.41	1.63e-12	Vitiligo;
CESC	trans	rs1945213	0.694	rs11227113	chr11:55828024	C/T	cg15704280	chr7:45808275	SEPT13	0.76	7.31	0.41	3.2e-12	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs72781680	0.581	rs116520786	chr2:24272645	C/T	cg06627628	chr2:24431161	ITSN2	-0.63	-5.96	-0.34	8.13e-9	Lymphocyte counts;
CESC	cis	rs7246657	0.943	rs13343471	chr19:37932130	A/G	cg23950597	chr19:37808831	NA	-0.6	-5.81	-0.34	1.8e-8	Coronary artery calcification;
CESC	cis	rs9322193	0.962	rs3805749	chr6:150093682	C/T	cg04369109	chr6:150039330	LATS1	-0.46	-6.31	-0.36	1.16e-9	Lung cancer;
CESC	cis	rs6546550	0.935	rs1531025	chr2:70055505	G/T	cg02498382	chr2:70120550	SNRNP27	-0.39	-6.78	-0.38	7.57e-11	Prevalent atrial fibrillation;
CESC	cis	rs11690935	0.632	rs17581284	chr2:172659376	C/T	cg13550731	chr2:172543902	DYNC1I2	0.54	7.63	0.42	4.37e-13	Schizophrenia;
CESC	cis	rs853679	0.546	rs200981	chr6:27833174	A/G	cg17221315	chr6:27791827	HIST1H4J	0.63	5.19	0.3	4.29e-7	Depression;
CESC	cis	rs9649213	0.593	rs62478200	chr7:97980045	A/G	cg24562669	chr7:97807699	LMTK2	0.51	7.63	0.42	4.29e-13	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs763121	1.000	rs138464	chr22:38906432	C/T	cg06022373	chr22:39101656	GTPBP1	-0.71	-11.0	-0.56	1.95e-23	Menopause (age at onset);
CESC	trans	rs10174398	0.668	rs10205578	chr2:51185310	A/C	cg04766043	chr13:114770710	RASA3	0.45	6.01	0.35	6.1e-9	Body mass index;
CESC	cis	rs7607369	0.536	rs6436092	chr2:219669148	T/A	cg02176678	chr2:219576539	TTLL4	-0.36	-6.16	-0.35	2.75e-9	Red blood cell count;Amyotrophic lateral sclerosis;
CESC	cis	rs7223966	1.000	rs78172786	chr17:61847114	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.54	6.24	0.36	1.74e-9	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg23048001	chr7:2026167	MAD1L1	-0.47	-6.25	-0.36	1.59e-9	Bipolar disorder and schizophrenia;
CESC	trans	rs7319075	0.657	rs9533543	chr13:44173400	A/G	cg01999652	chr6:28220110	ZKSCAN4	0.5	6.19	0.36	2.3e-9	Photic sneeze reflex;
CESC	cis	rs896854	0.738	rs1713669	chr8:95958637	C/G	cg13393036	chr8:95962371	TP53INP1	-0.49	-9.7	-0.51	3.16e-19	Type 2 diabetes;
CESC	cis	rs780096	0.546	rs8179225	chr2:27737181	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.3	-5.33	-0.31	2.12e-7	Total body bone mineral density;
CESC	cis	rs2637266	1.000	rs7073355	chr10:78354419	G/A	cg18941641	chr10:78392320	NA	0.42	7.79	0.43	1.49e-13	Pulmonary function;
CESC	cis	rs7680126	0.596	rs917826	chr4:10295595	C/G	cg11266682	chr4:10021025	SLC2A9	-0.43	-5.66	-0.33	4.02e-8	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	cis	rs7647973	0.626	rs9830730	chr3:49675875	G/C	cg03060546	chr3:49711283	APEH	0.69	8.34	0.46	4.18e-15	Menarche (age at onset);
CESC	cis	rs9902453	0.868	rs12944395	chr17:28323499	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.67	-8.49	-0.46	1.52e-15	Coffee consumption (cups per day);
CESC	cis	rs238295	0.766	rs6139762	chr20:5546694	C/T	cg24001556	chr20:5591874	RP5-1022P6.2	0.45	5.04	0.3	8.51e-7	Occipital cortical area (total cortical area interaction);
CESC	cis	rs3824867	0.804	rs12419342	chr11:47468545	C/T	cg20307385	chr11:47447363	PSMC3	0.53	6.42	0.37	6.37e-10	Mean corpuscular hemoglobin;
CESC	trans	rs6089829	0.962	rs6122352	chr20:61668284	T/C	cg23505145	chr19:12996616	KLF1	0.51	6.68	0.38	1.37e-10	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs1552244	1.000	rs17032276	chr3:10076975	A/C	cg00149659	chr3:10157352	C3orf10	0.76	9.51	0.5	1.26e-18	Alzheimer's disease;
CESC	cis	rs7107174	0.786	rs4945269	chr11:78047077	A/G	cg02023728	chr11:77925099	USP35	0.39	5.51	0.32	8.54e-8	Testicular germ cell tumor;
CESC	cis	rs2842992	0.692	rs9347342	chr6:160193129	T/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.83	11.61	0.58	1.77e-25	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs6089829	0.925	rs2277767	chr20:61666937	G/A	cg16240275	chr20:61666158	NCRNA00029	0.5	8.96	0.48	6.1e-17	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs9283706	0.594	rs10515036	chr5:66343787	A/G	cg11590213	chr5:66331682	MAST4	-0.39	-5.4	-0.31	1.5e-7	Coronary artery disease;
CESC	cis	rs7666738	0.791	rs62318907	chr4:99037120	C/T	cg05340658	chr4:99064831	C4orf37	0.82	12.88	0.62	8.31e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6540559	0.808	rs11119358	chr1:210042456	T/C	cg23283495	chr1:209979779	IRF6	0.47	6.26	0.36	1.54e-9	Cleft lip with or without cleft palate;
CESC	cis	rs6540556	0.859	rs1007693	chr1:209931799	C/T	cg23920097	chr1:209922102	NA	-0.36	-5.28	-0.31	2.75e-7	Red blood cell count;
CESC	cis	rs9300255	0.664	rs12316131	chr12:123817796	T/C	cg00376283	chr12:123451042	ABCB9	-0.59	-6.96	-0.39	2.67e-11	Neutrophil percentage of white cells;
CESC	cis	rs1218582	0.710	rs7553195	chr1:154837796	T/C	cg03351412	chr1:154909251	PMVK	0.59	7.6	0.42	5.09e-13	Prostate cancer;
CESC	cis	rs7666738	0.830	rs62321587	chr4:98997958	T/C	cg03467027	chr4:99064603	C4orf37	0.43	5.38	0.31	1.66e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6460942	0.591	rs4721080	chr7:12337785	T/C	cg06484146	chr7:12443880	VWDE	-0.63	-7.02	-0.4	1.91e-11	Coronary artery disease;
CESC	trans	rs2099077	0.737	rs972797	chr5:102813577	C/A	cg07434438	chr16:72961899	ZFHX3	0.47	6.21	0.36	2.03e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs9322193	0.962	rs10872656	chr6:150120580	A/C	cg13206674	chr6:150067644	NUP43	0.43	6.03	0.35	5.54e-9	Lung cancer;
CESC	cis	rs6952808	0.575	rs6950330	chr7:1953606	T/C	cg20295408	chr7:1910781	MAD1L1	-0.4	-5.22	-0.31	3.55e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs9291683	0.566	rs13122689	chr4:10044648	A/G	cg02734326	chr4:10020555	SLC2A9	0.45	6.19	0.36	2.29e-9	Bone mineral density;
CESC	cis	rs4919044	0.545	rs9420603	chr10:94777490	T/C	cg26979504	chr10:94451518	HHEX	-0.47	-5.15	-0.3	5.16e-7	Coronary artery disease;
CESC	cis	rs13256369	0.951	rs10503394	chr8:8565775	A/G	cg18904891	chr8:8559673	CLDN23	0.72	8.32	0.46	4.58e-15	Obesity-related traits;
CESC	trans	rs6572548	0.504	rs1956082	chr14:49665496	A/C	cg22328890	chr16:68298258	SLC7A6	-0.53	-6.13	-0.35	3.23e-9	Subjective well-being;
CESC	cis	rs1348850	0.874	rs6742951	chr2:178340766	G/C	cg23306229	chr2:178417860	TTC30B	0.65	7.93	0.44	6.03e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs11792861	0.816	rs744980	chr9:111690388	C/T	cg05043794	chr9:111880884	C9orf5	-0.37	-6.07	-0.35	4.34e-9	Menarche (age at onset);
CESC	cis	rs9322193	0.887	rs11155662	chr6:149913867	T/G	cg07701084	chr6:150067640	NUP43	0.4	5.38	0.31	1.61e-7	Lung cancer;
CESC	cis	rs11112613	0.713	rs58066965	chr12:105952505	C/G	cg03607813	chr12:105948248	NA	0.59	7.41	0.41	1.75e-12	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CESC	cis	rs10752881	0.839	rs2093983	chr1:183094210	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.89	14.39	0.66	4.39e-35	Colorectal cancer;
CESC	cis	rs2832191	1.000	rs2832189	chr21:30487414	C/T	cg24692254	chr21:30365293	RNF160	-0.73	-10.98	-0.56	2.27e-23	Dental caries;
CESC	cis	rs6076065	1.000	rs2424538	chr20:23382076	A/G	cg12062639	chr20:23401060	NAPB	0.41	5.16	0.3	4.95e-7	Facial morphology (factor 15, philtrum width);
CESC	cis	rs28374715	0.681	rs59000092	chr15:41626148	A/G	cg20272979	chr15:41787780	ITPKA	0.39	5.21	0.3	3.76e-7	Ulcerative colitis;
CESC	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg03404566	chr17:6899310	ALOX12	0.39	6.66	0.38	1.6e-10	Tonsillectomy;
CESC	cis	rs7666738	0.830	rs2903150	chr4:99027184	T/C	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.58e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2439831	0.867	rs2255051	chr15:43846161	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.69	8.9	0.48	8.94e-17	Lung cancer in ever smokers;
CESC	cis	rs34779708	0.931	rs12767414	chr10:35390193	C/T	cg04310649	chr10:35416472	CREM	-0.53	-6.34	-0.36	1.01e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs853679	0.546	rs17695758	chr6:27837183	T/C	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.93	6.78	0.38	7.9e-11	Depression;
CESC	cis	rs854765	0.583	rs2350977	chr17:17802779	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.6	8.44	0.46	2.08e-15	Total body bone mineral density;
CESC	cis	rs12586317	0.547	rs4982236	chr14:35468046	C/G	cg05294307	chr14:35346193	BAZ1A	-0.51	-5.45	-0.32	1.16e-7	Psoriasis;
CESC	cis	rs561341	1.000	rs530715	chr17:30320544	T/G	cg19193384	chr17:30244184	NA	-0.61	-6.51	-0.37	3.85e-10	Hip circumference adjusted for BMI;
CESC	cis	rs798766	1.000	rs798762	chr4:1731150	T/C	cg10756475	chr4:1757242	NA	0.46	6.14	0.35	3.07e-9	Bladder cancer;Urinary bladder cancer;
CESC	cis	rs1008375	1.000	rs2159584	chr4:17620568	G/A	cg02297831	chr4:17616191	MED28	0.55	6.81	0.39	6.7e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs6060717	0.536	rs11697851	chr20:34524494	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.78	-6.98	-0.39	2.32e-11	Hip circumference adjusted for BMI;
CESC	cis	rs561341	0.830	rs2301765	chr17:30202056	T/A	cg19193384	chr17:30244184	NA	0.5	5.15	0.3	5.17e-7	Hip circumference adjusted for BMI;
CESC	cis	rs875971	0.965	rs28682868	chr7:65689809	C/T	cg11764359	chr7:65958608	NA	-0.93	-14.86	-0.67	9.49e-37	Aortic root size;
CESC	cis	rs11864453	0.826	rs2072142	chr16:72132713	C/T	cg16558253	chr16:72132732	DHX38	-0.61	-9.68	-0.51	3.5e-19	Fibrinogen levels;
CESC	cis	rs920590	0.510	rs4922101	chr8:19648895	A/G	cg03894339	chr8:19674705	INTS10	0.74	7.74	0.43	2.11e-13	Acute lymphoblastic leukemia (childhood);
CESC	trans	rs7246657	0.943	rs6508733	chr19:38000548	A/T	cg24637308	chr11:6592297	DNHD1	0.51	6.15	0.35	2.89e-9	Coronary artery calcification;
CESC	cis	rs2120019	1.000	rs8036197	chr15:75370232	T/C	cg09165964	chr15:75287851	SCAMP5	-0.67	-8.12	-0.45	1.76e-14	Blood trace element (Zn levels);
CESC	cis	rs17401966	0.838	rs8019	chr1:10366487	T/G	cg15208524	chr1:10270712	KIF1B	0.42	5.42	0.32	1.32e-7	Hepatocellular carcinoma;
CESC	cis	rs2963155	0.518	rs10515522	chr5:142758394	A/G	cg17617527	chr5:142782415	NR3C1	0.74	6.55	0.37	3e-10	Breast cancer;
CESC	cis	rs3125734	0.633	rs6479792	chr10:63983264	T/G	cg09941381	chr10:64027924	RTKN2	-0.31	-5.13	-0.3	5.5e-7	Rheumatoid arthritis;
CESC	trans	rs11098499	0.754	rs4443261	chr4:120249301	T/C	cg25214090	chr10:38739885	LOC399744	0.62	8.64	0.47	5.24e-16	Corneal astigmatism;
CESC	cis	rs4481887	0.962	rs10788769	chr1:248457426	C/T	cg00666640	chr1:248458726	OR2T12	0.4	6.62	0.38	1.97e-10	Common traits (Other);
CESC	cis	rs7917772	0.503	rs7914389	chr10:104295402	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.54	7.41	0.41	1.67e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs10911232	0.507	rs2151669	chr1:183055398	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.85	13.7	0.64	1.21e-32	Hypertriglyceridemia;
CESC	cis	rs4589502	1.000	rs8023363	chr15:67154654	G/A	cg12317470	chr15:67143691	NA	0.66	6.42	0.37	6.24e-10	Lung cancer (smoking interaction);
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg26080111	chr7:559651	PDGFA	-0.51	-6.44	-0.37	5.55e-10	Asthma;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg07691761	chr5:131892711	RAD50	-0.48	-6.18	-0.35	2.44e-9	Fibrinogen levels;
CESC	cis	rs9486719	1.000	rs9486719	chr6:97060124	G/A	cg06623918	chr6:96969491	KIAA0776	-0.82	-9.89	-0.52	7.87e-20	Migraine;Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06662685	chr11:2907073	CDKN1C	-0.64	-7.55	-0.42	6.98e-13	Gut microbiome composition (summer);
CESC	cis	rs1552244	1.000	rs12152515	chr3:10143976	C/T	cg08888203	chr3:10149979	C3orf24	0.45	5.82	0.34	1.68e-8	Alzheimer's disease;
CESC	cis	rs13082711	0.516	rs1388785	chr3:27371843	T/C	cg02860705	chr3:27208620	NA	-0.55	-6.94	-0.39	2.99e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CESC	cis	rs4853012	0.838	rs72915068	chr2:74356185	G/A	cg01017244	chr2:74357527	NA	0.8	11.7	0.58	8.91e-26	Gestational age at birth (maternal effect);
CESC	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg04155289	chr7:94953770	PON1	-0.45	-6.83	-0.39	5.85e-11	Paraoxonase activity;
CESC	cis	rs7818688	1.000	rs7832570	chr8:96023795	A/T	cg16049864	chr8:95962084	TP53INP1	0.61	5.77	0.33	2.17e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs12900413	0.645	rs28407340	chr15:90311864	C/T	cg24249390	chr15:90295951	MESP1	-0.41	-5.66	-0.33	4.03e-8	Coronary artery aneurysm in Kawasaki disease;
CESC	cis	rs3105593	1.000	rs28718130	chr15:50909489	G/A	cg08437265	chr15:50716283	USP8	0.4	5.13	0.3	5.69e-7	QT interval;
CESC	cis	rs6964587	1.000	rs6952671	chr7:91597934	C/A	cg17063962	chr7:91808500	NA	0.57	7.82	0.43	1.22e-13	Breast cancer;
CESC	cis	rs644799	0.930	rs587123	chr11:95560539	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	9.09	0.49	2.43e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs801193	0.569	rs2659907	chr7:66164032	G/A	cg18252515	chr7:66147081	NA	-0.47	-6.42	-0.37	6.18e-10	Aortic root size;
CESC	cis	rs1008375	0.932	rs4698626	chr4:17605821	G/C	cg27347728	chr4:17578864	LAP3	0.43	5.29	0.31	2.51e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs798766	1.000	rs798755	chr4:1720824	A/G	cg05874882	chr4:1763078	NA	-0.6	-8.64	-0.47	5.49e-16	Bladder cancer;Urinary bladder cancer;
CESC	cis	rs6951245	1.000	rs11764748	chr7:1094508	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.59	6.93	0.39	3.28e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs3213545	0.700	rs2260399	chr12:121469653	C/T	cg02403541	chr12:121454288	C12orf43	0.68	9.72	0.51	2.62e-19	Subjective well-being;Cardiovascular disease risk factors;
CESC	cis	rs67478160	0.584	rs2295148	chr14:104195610	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.59	-8.78	-0.47	2.09e-16	Schizophrenia;
CESC	cis	rs7223966	1.000	rs8067431	chr17:61817048	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.45	-5.09	-0.3	6.84e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs6540559	0.673	rs7525951	chr1:210018306	C/T	cg22029157	chr1:209979665	IRF6	-0.66	-7.44	-0.42	1.42e-12	Cleft lip with or without cleft palate;
CESC	cis	rs3091242	0.933	rs35403885	chr1:25784551	G/A	cg02931644	chr1:25747376	RHCE	-0.39	-6.53	-0.37	3.37e-10	Erythrocyte sedimentation rate;
CESC	cis	rs2836974	0.965	rs2836965	chr21:40633631	C/G	cg11644478	chr21:40555479	PSMG1	-1.01	-15.63	-0.69	1.82e-39	Cognitive function;
CESC	cis	rs7647973	0.580	rs2334958	chr3:49252364	C/T	cg07636037	chr3:49044803	WDR6	0.8	13.31	0.63	2.63e-31	Menarche (age at onset);
CESC	cis	rs9303401	1.000	rs9303401	chr17:56847945	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.74	9.58	0.51	7.58e-19	Cognitive test performance;
CESC	cis	rs7647973	0.593	rs4855885	chr3:49690199	G/A	cg06212747	chr3:49208901	KLHDC8B	0.62	7.06	0.4	1.46e-11	Menarche (age at onset);
CESC	cis	rs13191362	1.000	rs73035025	chr6:163000988	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.5	5.17	0.3	4.64e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs7940866	0.903	rs10791109	chr11:130850377	A/C	cg12179176	chr11:130786555	SNX19	0.55	7.92	0.44	6.66e-14	Schizophrenia;
CESC	cis	rs4665809	0.590	rs13387855	chr2:26420708	T/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.09	-13.46	-0.64	8.09e-32	Gut microbiome composition (summer);
CESC	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	21.97	0.8	1.29e-61	Prudent dietary pattern;
CESC	cis	rs873946	0.590	rs12783478	chr10:134550700	A/G	cg18305652	chr10:134549665	INPP5A	0.51	7.67	0.43	3.3e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs5769765	0.955	rs8139758	chr22:50261123	G/T	cg02269571	chr22:50332266	NA	0.46	6.28	0.36	1.39e-9	Schizophrenia;
CESC	cis	rs12900413	0.687	rs28752094	chr15:90311645	G/A	cg24249390	chr15:90295951	MESP1	-0.41	-5.63	-0.33	4.51e-8	Coronary artery aneurysm in Kawasaki disease;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg17397401	chr15:75230745	COX5A	0.43	6.01	0.35	5.98e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs11650494	0.908	rs11650087	chr17:47362923	T/A	cg08112188	chr17:47440006	ZNF652	1.25	8.25	0.45	7.6e-15	Prostate cancer;
CESC	cis	rs727505	0.866	rs66852389	chr7:124724348	T/A	cg23710748	chr7:124431027	NA	-0.4	-6.52	-0.37	3.56e-10	Lewy body disease;
CESC	cis	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg13880726	chr7:1868755	MAD1L1	0.5	6.65	0.38	1.65e-10	Bipolar disorder and schizophrenia;
CESC	cis	rs9902453	0.817	rs880749	chr17:28059970	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.66	-8.41	-0.46	2.55e-15	Coffee consumption (cups per day);
CESC	cis	rs9399135	0.967	rs9389251	chr6:135325717	A/G	cg22676075	chr6:135203613	NA	0.51	7.23	0.41	5.22e-12	Red blood cell count;
CESC	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg18402987	chr7:1209562	NA	0.57	6.64	0.38	1.72e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg22105103	chr4:187893119	NA	0.51	7.69	0.43	2.88e-13	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7659604	0.539	rs3217773	chr4:122739121	A/G	cg06713675	chr4:122721982	EXOSC9	-0.51	-7.02	-0.4	1.9e-11	Type 2 diabetes;
CESC	cis	rs7666738	0.830	rs34461023	chr4:99023751	C/T	cg17366294	chr4:99064904	C4orf37	0.61	8.77	0.47	2.15e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1950626	0.787	rs34857222	chr14:101391354	G/T	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.8	10.8	0.55	9.22e-23	Pelvic organ prolapse (moderate/severe);
CESC	cis	rs10465746	0.846	rs12146038	chr1:84405065	A/T	cg10977910	chr1:84465055	TTLL7	0.46	6.25	0.36	1.67e-9	Obesity-related traits;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg13353311	chr5:59996240	DEPDC1B	-0.45	-6.32	-0.36	1.09e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs59918340	0.523	rs4961255	chr8:142208248	T/C	cg18755752	chr8:142205143	DENND3	-0.44	-5.6	-0.33	5.28e-8	Immature fraction of reticulocytes;
CESC	cis	rs72945132	0.619	rs61887436	chr11:70243337	C/T	cg00319359	chr11:70116639	PPFIA1	0.65	5.51	0.32	8.7e-8	Coronary artery disease;
CESC	cis	rs12725198	0.507	rs41393951	chr1:16053493	C/T	cg18133145	chr1:16060689	PLEKHM2	-0.53	-6.33	-0.36	1.05e-9	Cardiac Troponin-T levels;
CESC	cis	rs3741404	0.609	rs669913	chr11:63869879	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.72	10.02	0.52	2.95e-20	Platelet count;
CESC	cis	rs568617	0.953	rs658938	chr11:65651830	A/G	cg04055107	chr11:65626734	MUS81;CFL1	-0.69	-7.4	-0.41	1.81e-12	Crohn's disease;
CESC	cis	rs7586673	0.930	rs7591506	chr2:161960925	T/G	cg22496339	chr2:162101262	NA	0.5	6.62	0.38	1.94e-10	Intelligence (multi-trait analysis);
CESC	trans	rs9329221	0.683	rs3105738	chr8:9889914	A/T	cg06636001	chr8:8085503	FLJ10661	-0.55	-7.56	-0.42	6.49e-13	Neuroticism;
CESC	cis	rs9309473	0.950	rs1918863	chr2:73644481	A/G	cg20560298	chr2:73613845	ALMS1	-0.49	-6.75	-0.38	9.2e-11	Metabolite levels;
CESC	cis	rs6500395	1.000	rs1386040	chr16:48631207	A/G	cg04672837	chr16:48644449	N4BP1	0.52	6.65	0.38	1.7e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs826838	1.000	rs11168676	chr12:38977304	A/G	cg13010199	chr12:38710504	ALG10B	0.58	8.14	0.45	1.59e-14	Heart rate;
CESC	cis	rs7666738	0.546	rs2098935	chr4:98914376	A/G	cg17366294	chr4:99064904	C4orf37	0.52	6.57	0.37	2.65e-10	Colonoscopy-negative controls vs population controls;
CESC	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg07167872	chr1:205819463	PM20D1	0.77	12.69	0.61	3.68e-29	Menarche (age at onset);
CESC	cis	rs12188164	0.543	rs2672757	chr5:454732	A/G	cg16584290	chr5:462447	EXOC3	0.48	7.35	0.41	2.48e-12	Cystic fibrosis severity;
CESC	cis	rs2576037	0.583	rs644731	chr18:44426877	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.35	5.69	0.33	3.3e-8	Personality dimensions;
CESC	cis	rs763121	0.853	rs9610986	chr22:39025277	T/C	cg06544989	chr22:39130855	UNC84B	0.5	8.66	0.47	4.77e-16	Menopause (age at onset);
CESC	cis	rs1348850	0.914	rs12612857	chr2:178467144	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.66	8.68	0.47	4.07e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs7267979	1.000	rs761025	chr20:25426968	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.83	16.43	0.71	2.68e-42	Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg07454192	chr8:74888262	TMEM70	0.46	6.44	0.37	5.6e-10	Systemic lupus erythematosus;
CESC	cis	rs910316	1.000	rs2098297	chr14:75619118	G/T	cg08847533	chr14:75593920	NEK9	-1.03	-20.52	-0.78	1.11e-56	Height;
CESC	cis	rs6736093	0.966	rs35189728	chr2:112720228	C/G	cg12686935	chr2:112915763	FBLN7	-0.43	-5.56	-0.32	6.75e-8	Coronary artery disease;
CESC	cis	rs8060686	0.545	rs9922165	chr16:68181177	C/A	cg26727032	chr16:67993705	SLC12A4	-0.5	-6.15	-0.35	2.84e-9	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs875971	0.862	rs6952182	chr7:65683317	T/G	cg10691866	chr7:65817282	TPST1	0.32	5.3	0.31	2.49e-7	Aortic root size;
CESC	cis	rs11997175	0.583	rs34540455	chr8:33799300	C/T	ch.8.33884649F	chr8:33765107	NA	0.47	5.96	0.34	8.11e-9	Body mass index;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17185401	chr1:110052093	AMIGO1	0.59	7.0	0.4	2.05e-11	Gut microbiome composition (summer);
CESC	cis	rs561341	0.941	rs17780086	chr17:30343282	G/A	cg00745463	chr17:30367425	LRRC37B	-0.88	-7.7	-0.43	2.74e-13	Hip circumference adjusted for BMI;
CESC	cis	rs17376456	0.877	rs13185660	chr5:93336500	G/A	cg25358565	chr5:93447407	FAM172A	1.09	10.4	0.54	1.88e-21	Diabetic retinopathy;
CESC	cis	rs9291683	0.566	rs13144709	chr4:10044182	C/T	cg11266682	chr4:10021025	SLC2A9	0.65	12.28	0.6	9.55e-28	Bone mineral density;
CESC	cis	rs2032447	0.839	rs199750	chr6:26016462	A/G	cg12310025	chr6:25882481	NA	0.45	6.51	0.37	3.85e-10	Intelligence (multi-trait analysis);
CESC	cis	rs769267	0.930	rs4808965	chr19:19631655	A/G	cg03709012	chr19:19516395	GATAD2A	1.01	15.11	0.68	1.22e-37	Tonsillectomy;
CESC	cis	rs2637266	1.000	rs1907314	chr10:78337948	G/A	cg18941641	chr10:78392320	NA	0.42	7.59	0.42	5.44e-13	Pulmonary function;
CESC	cis	rs6496667	0.557	rs2526002	chr15:90965655	C/T	cg22089800	chr15:90895588	ZNF774	0.43	5.53	0.32	7.57e-8	Rheumatoid arthritis;
CESC	cis	rs9788682	1.000	rs7164594	chr15:78803057	C/T	cg24631222	chr15:78858424	CHRNA5	0.71	8.67	0.47	4.33e-16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs4853012	0.887	rs6737314	chr2:74339586	A/G	cg05776053	chr2:74358815	NA	0.46	5.72	0.33	2.84e-8	Gestational age at birth (maternal effect);
CESC	cis	rs7605827	0.930	rs11675921	chr2:15569376	C/T	cg19274914	chr2:15703543	NA	-0.32	-5.48	-0.32	9.98e-8	Educational attainment (years of education);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26871885	chr11:207525	RIC8A;BET1L	0.67	7.88	0.44	8.52e-14	Gut microbiome composition (summer);
CESC	cis	rs9611519	0.580	rs7286603	chr22:41440061	T/C	cg03806693	chr22:41940476	POLR3H	-0.51	-6.04	-0.35	5.14e-9	Neuroticism;
CESC	cis	rs6088580	0.634	rs6088502	chr20:33037644	A/T	cg06115741	chr20:33292138	TP53INP2	0.47	6.04	0.35	5.1e-9	Glomerular filtration rate (creatinine);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg18727501	chr4:89513542	HERC3	-0.37	-6.02	-0.35	5.93e-9	Gambling;
CESC	cis	rs9660180	0.620	rs3817856	chr1:1663831	C/T	cg27541892	chr1:1571801	CDK11B	-0.59	-7.94	-0.44	5.84e-14	Body mass index;
CESC	cis	rs2404602	0.684	rs157759	chr15:76846990	T/A	cg23625390	chr15:77176239	SCAPER	0.41	5.69	0.33	3.37e-8	Blood metabolite levels;
CESC	cis	rs4566357	0.615	rs12474622	chr2:227912793	A/G	cg11843606	chr2:227700838	RHBDD1	-0.5	-6.83	-0.39	5.8e-11	Coronary artery disease;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg19606096	chr12:93861141	MRPL42	0.52	7.2	0.4	6.21e-12	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg16739247	chr1:76252438	SNORD45C;SNORD45A;RABGGTB	-0.43	-6.16	-0.35	2.65e-9	Gambling;
CESC	cis	rs4253772	0.591	rs6007795	chr22:46686792	C/G	cg18190219	chr22:46762943	CELSR1	-0.43	-5.4	-0.31	1.46e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs9902453	0.967	rs17825877	chr17:28515188	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	7.84	0.43	1.07e-13	Coffee consumption (cups per day);
CESC	cis	rs3782089	1.000	rs3782089	chr11:65336819	C/T	cg00206168	chr11:65308501	LTBP3	0.91	6.6	0.38	2.2e-10	Height;
CESC	cis	rs35146811	0.807	rs6953441	chr7:99617067	G/A	cg13334819	chr7:99746414	C7orf59	-0.45	-5.24	-0.31	3.34e-7	Coronary artery disease;
CESC	cis	rs6088580	0.608	rs8114616	chr20:32969092	G/T	cg24642439	chr20:33292090	TP53INP2	-0.5	-6.65	-0.38	1.72e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs7618915	0.547	rs11130315	chr3:52697163	A/G	cg17372223	chr3:52568218	NT5DC2	0.44	6.63	0.38	1.86e-10	Bipolar disorder;
CESC	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.54	-6.1	-0.35	3.74e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2228479	0.717	rs11644967	chr16:89806614	T/A	cg00800038	chr16:89945340	TCF25	-0.66	-6.35	-0.36	9.43e-10	Skin colour saturation;
CESC	cis	rs9611565	0.694	rs202617	chr22:41822793	C/T	cg03806693	chr22:41940476	POLR3H	1.18	14.22	0.66	1.73e-34	Vitiligo;
CESC	cis	rs13392177	0.684	rs6720449	chr2:219080978	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.52	-6.43	-0.37	5.97e-10	Pyoderma gangrenosum in inflammatory bowel disease;
CESC	cis	rs7520050	0.931	rs6697557	chr1:46307809	G/A	cg03146154	chr1:46216737	IPP	-0.48	-6.3	-0.36	1.25e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs11155671	0.530	rs9322228	chr6:150209309	C/G	cg09699651	chr6:150184138	LRP11	0.55	7.7	0.43	2.78e-13	Testicular germ cell tumor;
CESC	cis	rs7254114	0.645	rs61045132	chr19:11303068	C/T	cg02815516	chr19:11306319	KANK2	-0.37	-5.73	-0.33	2.74e-8	Immature fraction of reticulocytes;
CESC	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg23978390	chr7:1156363	C7orf50	0.6	8.64	0.47	5.54e-16	Longevity;Endometriosis;
CESC	cis	rs875971	0.522	rs56028712	chr7:65466565	C/T	cg08632164	chr7:65971372	NA	-0.32	-5.17	-0.3	4.72e-7	Aortic root size;
CESC	cis	rs78456975	0.699	rs17091772	chr2:1519679	A/C	cg26248373	chr2:1572462	NA	-0.5	-5.1	-0.3	6.47e-7	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs1799949	0.930	rs1554063	chr17:41287145	T/C	cg25072359	chr17:41440525	NA	0.48	7.1	0.4	1.18e-11	Menopause (age at onset);
CESC	cis	rs7607369	0.580	rs17573731	chr2:219652153	T/C	cg02176678	chr2:219576539	TTLL4	-0.48	-8.58	-0.47	8.14e-16	Red blood cell count;Amyotrophic lateral sclerosis;
CESC	cis	rs3785574	0.638	rs2854182	chr17:61969062	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.75	9.58	0.51	7.43e-19	Height;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg23811096	chr1:33502772	AK2	-0.48	-6.37	-0.36	8.52e-10	Asthma;
CESC	cis	rs6952808	0.609	rs12699453	chr7:1953056	C/T	cg20295408	chr7:1910781	MAD1L1	-0.44	-5.8	-0.34	1.91e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs9733	0.596	rs12085275	chr1:150650265	T/C	cg04414720	chr1:150670196	GOLPH3L	0.63	9.01	0.48	4.11e-17	Tonsillectomy;
CESC	cis	rs7223966	1.000	rs6504171	chr17:61710010	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	7.44	0.42	1.37e-12	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs10504229	0.683	rs7459925	chr8:58111771	G/A	cg22535103	chr8:58192502	C8orf71	-0.8	-8.98	-0.48	5.05e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs6089584	0.924	rs6142906	chr20:60552554	G/C	cg13770153	chr20:60521292	NA	-0.45	-5.8	-0.34	1.89e-8	Body mass index;
CESC	cis	rs6912958	0.935	rs6454629	chr6:88165515	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.58	-7.97	-0.44	4.72e-14	Monocyte percentage of white cells;
CESC	cis	rs9581857	0.556	rs1885991	chr13:28040470	G/A	cg22138327	chr13:27999177	GTF3A	0.64	7.1	0.4	1.16e-11	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
CESC	cis	rs10504229	0.683	rs7463453	chr8:58112053	A/G	cg21724239	chr8:58056113	NA	0.58	5.93	0.34	9.45e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs9311474	0.597	rs6778735	chr3:52565100	T/C	cg15147215	chr3:52552868	STAB1	-0.39	-7.14	-0.4	8.74e-12	Electroencephalogram traits;
CESC	cis	rs7412746	0.611	rs4970985	chr1:150887442	C/T	cg22823121	chr1:150693482	HORMAD1	-0.36	-5.06	-0.3	7.78e-7	Melanoma;
CESC	cis	rs514406	0.825	rs28817407	chr1:53226116	G/A	cg08736216	chr1:53307985	ZYG11A	0.42	7.11	0.4	1.06e-11	Monocyte count;
CESC	cis	rs1729951	0.546	rs835632	chr3:136676525	A/T	cg04103450	chr3:136751342	NA	0.39	5.24	0.31	3.34e-7	Neuroticism;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01170069	chr5:32599084	SUB1	-0.54	-6.71	-0.38	1.18e-10	Gut microbiome composition (summer);
CESC	cis	rs2380220	1.000	rs9400318	chr6:95972381	T/A	cg15832292	chr6:96025679	MANEA	0.68	6.27	0.36	1.49e-9	Behavioural disinhibition (generation interaction);
CESC	cis	rs2625529	0.730	rs1481861	chr15:72240129	A/G	cg16672083	chr15:72433130	SENP8	0.42	6.0	0.35	6.62e-9	Red blood cell count;
CESC	cis	rs4268898	0.608	rs72793980	chr2:24428859	T/C	cg20701182	chr2:24300061	SF3B14	0.54	6.13	0.35	3.17e-9	Asthma;
CESC	cis	rs5750830	0.649	rs5750813	chr22:39795228	G/C	cg05872129	chr22:39784769	NA	-0.82	-11.28	-0.57	2.39e-24	Intelligence (multi-trait analysis);
CESC	cis	rs798554	0.797	rs798491	chr7:2800521	A/G	cg09658497	chr7:2847517	GNA12	-0.43	-6.03	-0.35	5.55e-9	Height;
CESC	cis	rs6570726	0.818	rs437978	chr6:145809134	A/G	cg23711669	chr6:146136114	FBXO30	0.88	13.11	0.63	1.36e-30	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs801193	0.569	rs11772819	chr7:66217970	T/C	cg11764359	chr7:65958608	NA	0.7	10.02	0.52	3.02e-20	Aortic root size;
CESC	cis	rs4665809	0.590	rs4665318	chr2:26424517	C/T	cg26314531	chr2:26401878	FAM59B	0.73	7.72	0.43	2.42e-13	Gut microbiome composition (summer);
CESC	cis	rs12765878	1.000	rs11191849	chr10:105650880	T/A	cg11005552	chr10:105648138	OBFC1	0.36	5.24	0.31	3.32e-7	Coronary artery disease;
CESC	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg24101359	chr6:42928495	GNMT	0.68	10.8	0.55	9.07e-23	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs593982	0.920	rs1108922	chr11:65423930	C/T	cg08755490	chr11:65554678	OVOL1	-1.11	-8.33	-0.46	4.31e-15	Atopic dermatitis;
CESC	cis	rs12497850	0.931	rs12493289	chr3:48905161	G/A	cg06212747	chr3:49208901	KLHDC8B	0.67	8.99	0.48	4.66e-17	Parkinson's disease;
CESC	cis	rs12928939	0.517	rs12934512	chr16:71965230	C/G	cg03805757	chr16:71968109	PKD1L3	-0.59	-6.62	-0.38	2.01e-10	Post bronchodilator FEV1;
CESC	cis	rs2404602	0.598	rs71405204	chr15:76635305	C/G	cg00316803	chr15:76480434	C15orf27	0.46	6.13	0.35	3.21e-9	Blood metabolite levels;
CESC	cis	rs4713118	0.513	rs149955	chr6:28036225	G/C	cg18032046	chr6:28092343	ZSCAN16	-0.47	-5.92	-0.34	9.86e-9	Parkinson's disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg18029778	chr7:104654746	MLL5;LOC100216545	-0.44	-6.05	-0.35	4.84e-9	Fibrinogen levels;
CESC	cis	rs2115630	1.000	rs7183401	chr15:85371944	G/T	cg12501888	chr15:85177176	SCAND2	-0.4	-5.23	-0.31	3.48e-7	P wave terminal force;
CESC	cis	rs7512552	0.839	rs17596326	chr1:150433819	A/G	cg15654264	chr1:150340011	RPRD2	0.39	5.19	0.3	4.1e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs35110281	0.693	rs2838345	chr21:45092715	C/T	cg01579765	chr21:45077557	HSF2BP	-0.52	-9.24	-0.49	8.14e-18	Mean corpuscular volume;
CESC	cis	rs9916302	0.851	rs2338795	chr17:37399364	T/G	cg20243544	chr17:37824526	PNMT	0.48	6.01	0.35	5.96e-9	Glomerular filtration rate (creatinine);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg25867694	chr22:31503597	SELM	-0.5	-6.78	-0.38	7.63e-11	Fibrinogen levels;
CESC	trans	rs7839040	0.698	rs997281	chr8:82923482	A/G	cg14472086	chr9:107730925	NA	-0.47	-6.33	-0.36	1.02e-9	Response to methotrexate in juvenile idiopathic arthritis;
CESC	cis	rs7178572	0.568	rs11632941	chr15:77533888	A/G	cg22256960	chr15:77711686	NA	-0.53	-6.69	-0.38	1.33e-10	Type 2 diabetes;
CESC	cis	rs9916302	0.555	rs12940193	chr17:37652178	T/G	cg20243544	chr17:37824526	PNMT	0.5	6.35	0.36	9.07e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs290268	0.874	rs290988	chr9:93562955	C/G	cg02608019	chr9:93564028	SYK	0.63	9.64	0.51	4.92e-19	Platelet count;
CESC	cis	rs1461503	0.966	rs7110154	chr11:122843300	A/G	cg27398637	chr11:122830231	C11orf63	-0.55	-8.32	-0.45	4.77e-15	Menarche (age at onset);
CESC	cis	rs7772486	0.790	rs6924159	chr6:146267873	A/G	cg05347473	chr6:146136440	FBXO30	-0.57	-7.26	-0.41	4.32e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs10751667	0.714	rs7396700	chr11:963863	A/C	cg06064525	chr11:970664	AP2A2	-0.47	-9.32	-0.5	4.88e-18	Alzheimer's disease (late onset);
CESC	cis	rs6570726	0.791	rs2096201	chr6:145934273	C/T	cg23711669	chr6:146136114	FBXO30	0.99	15.04	0.68	2.25e-37	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7267979	1.000	rs6050542	chr20:25318879	T/C	cg08601574	chr20:25228251	PYGB	-0.39	-5.61	-0.33	5.02e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs858239	0.539	rs4294098	chr7:23185995	G/A	cg23682824	chr7:23144976	KLHL7	0.5	6.56	0.37	2.77e-10	Cerebrospinal fluid biomarker levels;
CESC	cis	rs10979	0.597	rs9496685	chr6:143908690	G/A	cg25407410	chr6:143891975	LOC285740	-0.49	-6.57	-0.37	2.58e-10	Hypospadias;
CESC	cis	rs7666738	0.830	rs35433756	chr4:99070555	C/T	cg18180107	chr4:99064573	C4orf37	0.4	5.03	0.3	9.17e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4665809	0.567	rs6711402	chr2:26430983	A/G	cg08470875	chr2:26401718	FAM59B	-0.69	-7.09	-0.4	1.25e-11	Gut microbiome composition (summer);
CESC	cis	rs4720575	0.839	rs10255464	chr7:47097043	A/G	cg00036614	chr7:47093842	NA	-0.41	-6.46	-0.37	5.1e-10	Angiotensin-converting enzyme inhibitor intolerance;
CESC	cis	rs589448	0.902	rs315138	chr12:69764850	A/T	cg14784868	chr12:69753453	YEATS4	0.89	14.23	0.66	1.66e-34	Cerebrospinal fluid biomarker levels;
CESC	cis	rs75804782	0.641	rs72987321	chr2:239352765	T/G	cg18131467	chr2:239335373	ASB1	-0.67	-5.91	-0.34	1.06e-8	Morning vs. evening chronotype;Chronotype;
CESC	cis	rs365132	0.875	rs4490607	chr5:176349386	T/C	cg16309518	chr5:176445507	NA	-0.37	-5.38	-0.31	1.6e-7	Menarche and menopause (age at onset);Menopause (age at onset);
CESC	cis	rs3749237	0.595	rs4855873	chr3:49459114	A/C	cg06212747	chr3:49208901	KLHDC8B	0.52	7.08	0.4	1.3e-11	Resting heart rate;
CESC	cis	rs847577	0.609	rs17435590	chr7:97784061	T/C	cg21770322	chr7:97807741	LMTK2	0.83	13.85	0.65	3.33e-33	Breast cancer;
CESC	cis	rs875971	1.000	rs6979382	chr7:65886375	C/T	cg11764359	chr7:65958608	NA	0.97	15.73	0.69	7.9e-40	Aortic root size;
CESC	cis	rs2243480	1.000	rs2707831	chr7:66062511	G/A	cg12463550	chr7:65579703	CRCP	0.74	5.83	0.34	1.61e-8	Diabetic kidney disease;
CESC	cis	rs2070677	0.935	rs4351775	chr10:135402200	C/T	cg20169779	chr10:135381914	SYCE1	-0.78	-10.55	-0.54	5.78e-22	Gout;
CESC	trans	rs61931739	0.500	rs7979240	chr12:34509026	C/T	cg26384229	chr12:38710491	ALG10B	0.7	10.53	0.54	6.75e-22	Morning vs. evening chronotype;
CESC	cis	rs2820292	0.595	rs10800793	chr1:201825750	A/G	cg06775570	chr1:201857621	SHISA4	-0.31	-5.06	-0.3	7.68e-7	Waist circumference;Body mass index (joint analysis main effects and smoking interaction);Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);
CESC	cis	rs34526934	0.608	rs34720456	chr2:177027292	G/A	cg14324370	chr2:177042789	NA	-0.5	-6.1	-0.35	3.65e-9	Obstructive sleep apnea trait (apnea hypopnea index);
CESC	cis	rs7772486	0.875	rs10457794	chr6:146415608	A/G	cg05347473	chr6:146136440	FBXO30	0.51	6.68	0.38	1.37e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9611565	0.649	rs202645	chr22:41798520	A/G	cg17376030	chr22:41985996	PMM1	-0.7	-7.47	-0.42	1.14e-12	Vitiligo;
CESC	cis	rs644799	0.648	rs1255181	chr11:95472148	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.51	7.05	0.4	1.58e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs227584	0.663	rs2040810	chr17:42243771	C/T	cg13607699	chr17:42295918	UBTF	-0.42	-5.33	-0.31	2.09e-7	Bone mineral density (hip);Bone mineral density;
CESC	cis	rs6964587	0.904	rs2023785	chr7:91547369	C/A	cg01689657	chr7:91764605	CYP51A1	-0.28	-5.06	-0.3	7.76e-7	Breast cancer;
CESC	cis	rs3096299	0.719	rs2965945	chr16:89514017	T/C	cg02187348	chr16:89574699	SPG7	0.63	8.79	0.48	1.97e-16	Multiple myeloma (IgH translocation);
CESC	cis	rs10256972	0.933	rs35696159	chr7:1047194	A/G	cg02099474	chr7:1027990	CYP2W1	-0.34	-5.12	-0.3	6.01e-7	Longevity;Endometriosis;
CESC	cis	rs17253792	0.822	rs75016910	chr14:56050466	C/G	cg01858014	chr14:56050164	KTN1	-0.97	-7.16	-0.4	8.08e-12	Putamen volume;
CESC	cis	rs9733	0.596	rs7412396	chr1:150666797	C/T	cg17724175	chr1:150552817	MCL1	0.41	6.18	0.35	2.39e-9	Tonsillectomy;
CESC	cis	rs2274273	0.805	rs7159808	chr14:55624327	G/T	cg04306507	chr14:55594613	LGALS3	0.29	5.82	0.34	1.72e-8	Protein biomarker;
CESC	cis	rs8018808	1.000	rs4903580	chr14:77850978	C/T	cg20045696	chr14:77926864	AHSA1	-0.41	-5.68	-0.33	3.54e-8	Myeloid white cell count;
CESC	cis	rs2011503	0.943	rs8102502	chr19:19652746	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.47	5.1	0.3	6.63e-7	Bipolar disorder;
CESC	cis	rs9487051	0.676	rs6933326	chr6:109601333	C/T	cg12927641	chr6:109611667	NA	-0.36	-5.47	-0.32	1.04e-7	Reticulocyte fraction of red cells;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg04338281	chr16:54962385	NA	-0.47	-6.42	-0.37	6.23e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs4665809	0.590	rs5001914	chr2:26415429	A/G	cg26314531	chr2:26401878	FAM59B	-0.83	-9.26	-0.49	7.37e-18	Gut microbiome composition (summer);
CESC	cis	rs61776719	0.500	rs11210866	chr1:38449565	T/C	cg18451016	chr1:38461880	NA	0.42	6.29	0.36	1.33e-9	Coronary artery disease;
CESC	cis	rs6502050	0.529	rs35585236	chr17:80116641	T/C	cg23985595	chr17:80112537	CCDC57	-0.41	-6.46	-0.37	4.88e-10	Life satisfaction;
CESC	cis	rs2072732	0.861	rs72629493	chr1:2951347	G/A	cg15211996	chr1:2936768	ACTRT2	0.34	5.95	0.34	8.31e-9	Plateletcrit;
CESC	cis	rs116095464	0.558	rs7710005	chr5:233572	A/G	cg12570787	chr5:219185	SDHA;CCDC127	0.49	5.1	0.3	6.58e-7	Breast cancer;
CESC	cis	rs10504229	0.683	rs11785260	chr8:58132906	A/G	cg21724239	chr8:58056113	NA	0.58	5.95	0.34	8.29e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs8060686	0.920	rs56845922	chr16:67770828	T/C	cg26727032	chr16:67993705	SLC12A4	-0.57	-5.98	-0.34	7.34e-9	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs7917772	0.539	rs12572775	chr10:104285594	A/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.39	-5.38	-0.31	1.67e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs2204008	0.805	rs2874289	chr12:38258420	G/A	cg26384229	chr12:38710491	ALG10B	0.74	10.62	0.55	3.58e-22	Bladder cancer;
CESC	cis	rs4728302	0.869	rs13228262	chr7:133598288	A/G	cg10665199	chr7:133106180	EXOC4	0.42	5.83	0.34	1.57e-8	Intelligence;Intelligence (multi-trait analysis);
CESC	cis	rs1609391	0.567	rs835633	chr3:136676496	T/C	cg04103450	chr3:136751342	NA	0.4	5.28	0.31	2.7e-7	Neuroticism;
CESC	cis	rs853679	0.517	rs9380047	chr6:28037893	G/T	cg23281280	chr6:28129359	ZNF389	0.57	7.67	0.43	3.3e-13	Depression;
CESC	cis	rs801193	0.844	rs732465	chr7:65998450	T/C	cg11764359	chr7:65958608	NA	0.53	6.98	0.39	2.34e-11	Aortic root size;
CESC	cis	rs9309711	0.643	rs4264589	chr2:3481098	G/T	cg15506890	chr2:3487001	NA	-0.49	-6.23	-0.36	1.83e-9	Neurofibrillary tangles;
CESC	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg02725872	chr8:58115012	NA	-0.42	-5.8	-0.34	1.84e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs798554	0.796	rs2158694	chr7:2863443	T/G	cg13628971	chr7:2884303	GNA12	0.67	8.72	0.47	3.16e-16	Height;
CESC	cis	rs4555082	0.874	rs2816611	chr14:105722976	G/C	cg06808227	chr14:105710500	BRF1	-0.64	-7.65	-0.43	3.72e-13	Mean platelet volume;Platelet distribution width;
CESC	trans	rs1728785	1.000	rs698717	chr16:68560199	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.64	7.42	0.41	1.61e-12	Ulcerative colitis;
CESC	cis	rs3812831	0.662	rs418027	chr13:114929344	A/C	cg08824895	chr13:115047677	UPF3A	0.41	5.34	0.31	1.98e-7	Schizophrenia;
CESC	cis	rs6815814	0.950	rs5743595	chr4:38802644	A/G	cg02016764	chr4:38805732	TLR1	-0.63	-7.49	-0.42	1.05e-12	Breast cancer;
CESC	cis	rs9611565	0.840	rs4822025	chr22:41776646	C/G	cg17376030	chr22:41985996	PMM1	0.65	7.06	0.4	1.45e-11	Vitiligo;
CESC	cis	rs56235845	0.665	rs4976685	chr5:176766177	C/T	cg16006841	chr5:176797999	RGS14	-0.49	-6.44	-0.37	5.56e-10	Hemoglobin concentration;Hematocrit;
CESC	cis	rs875971	0.520	rs160645	chr7:65556307	A/G	cg11764359	chr7:65958608	NA	-0.8	-8.87	-0.48	1.14e-16	Aortic root size;
CESC	cis	rs651907	0.535	rs2290859	chr3:101525625	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.47	6.17	0.35	2.48e-9	Colorectal cancer;
CESC	cis	rs7107174	1.000	rs11237456	chr11:78040780	C/G	cg02023728	chr11:77925099	USP35	0.4	5.73	0.33	2.69e-8	Testicular germ cell tumor;
CESC	cis	rs9660992	0.539	rs113699533	chr1:205122895	G/A	cg00857998	chr1:205179979	DSTYK	0.58	7.45	0.42	1.34e-12	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs116095464	0.558	rs11959126	chr5:283880	T/G	cg22857025	chr5:266934	NA	-1.29	-18.38	-0.75	3.21e-49	Breast cancer;
CESC	cis	rs9479482	0.967	rs11752529	chr6:150347971	C/T	cg03788504	chr6:150331562	NA	-0.37	-7.03	-0.4	1.8e-11	Alopecia areata;
CESC	cis	rs514406	0.929	rs555741	chr1:53318851	T/G	cg16325326	chr1:53192061	ZYG11B	0.81	12.77	0.62	2.07e-29	Monocyte count;
CESC	cis	rs1005277	0.579	rs1740742	chr10:38518860	C/T	cg00409905	chr10:38381863	ZNF37A	-0.52	-7.03	-0.4	1.8e-11	Extrinsic epigenetic age acceleration;
CESC	cis	rs10751667	1.000	rs11246359	chr11:967943	T/C	cg20946044	chr11:1010712	AP2A2	-0.44	-5.91	-0.34	1.06e-8	Alzheimer's disease (late onset);
CESC	cis	rs3733585	0.673	rs4235347	chr4:9951956	C/T	cg02734326	chr4:10020555	SLC2A9	-0.39	-5.64	-0.33	4.45e-8	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs4253772	0.744	rs9627278	chr22:46643432	C/G	cg24881330	chr22:46731750	TRMU	0.64	6.28	0.36	1.41e-9	LDL cholesterol;Cholesterol, total;
CESC	cis	rs6714710	0.603	rs13023980	chr2:98502987	T/C	cg26665480	chr2:98280029	ACTR1B	0.57	7.97	0.44	4.74e-14	Posterior cortical atrophy and Alzheimer's disease;
CESC	cis	rs7119	0.717	rs35268067	chr15:77753688	C/G	cg17802220	chr15:77601643	NA	-0.52	-7.27	-0.41	4.08e-12	Type 2 diabetes;
CESC	cis	rs1862618	0.853	rs832568	chr5:56153776	G/A	cg18230493	chr5:56204884	C5orf35	-0.73	-8.61	-0.47	6.69e-16	Initial pursuit acceleration;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg18732869	chr19:6739680	TRIP10	-0.44	-6.12	-0.35	3.4e-9	Fibrinogen levels;
CESC	trans	rs1814175	0.645	rs1721995	chr11:49915488	A/G	cg15704280	chr7:45808275	SEPT13	-0.98	-18.48	-0.75	1.48e-49	Height;
CESC	cis	rs1552244	0.935	rs2272124	chr3:10138189	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.85	-12.1	-0.6	3.91e-27	Alzheimer's disease;
CESC	trans	rs1945213	0.694	rs12422168	chr11:55866840	A/G	cg15704280	chr7:45808275	SEPT13	0.69	6.65	0.38	1.66e-10	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs67311347	0.956	rs6771527	chr3:40506548	T/C	cg09455208	chr3:40491958	NA	-0.48	-8.14	-0.45	1.52e-14	Renal cell carcinoma;
CESC	cis	rs472402	0.580	rs3736316	chr5:6656210	G/A	cg10789808	chr5:6633262	NSUN2;SRD5A1	-0.55	-7.06	-0.4	1.43e-11	Response to amphetamines;
CESC	cis	rs9581857	0.615	rs79793528	chr13:28007823	G/A	cg01674679	chr13:27998804	GTF3A	-0.71	-5.67	-0.33	3.75e-8	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
CESC	cis	rs9929218	1.000	rs2113199	chr16:68814502	A/G	cg02972257	chr16:68554789	NA	0.48	5.71	0.33	2.96e-8	Colorectal cancer;
CESC	cis	rs12701220	0.689	rs12701824	chr7:1102364	G/A	cg02733842	chr7:1102375	C7orf50	-0.41	-5.07	-0.3	7.39e-7	Bronchopulmonary dysplasia;
CESC	cis	rs2839186	0.609	rs2839189	chr21:47694357	C/T	cg10351095	chr21:47802916	PCNT	0.48	5.89	0.34	1.15e-8	Testicular germ cell tumor;
CESC	cis	rs6499129	0.764	rs16957291	chr16:67326102	T/A	cg26727032	chr16:67993705	SLC12A4	-0.51	-5.59	-0.32	5.61e-8	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs896854	0.684	rs10098778	chr8:95992020	C/T	cg16049864	chr8:95962084	TP53INP1	-0.65	-11.72	-0.58	7.7e-26	Type 2 diabetes;
CESC	cis	rs8058578	0.945	rs34480360	chr16:30798689	G/A	cg02466173	chr16:30829666	NA	-0.5	-7.57	-0.42	6.04e-13	Multiple myeloma;
CESC	cis	rs9611565	0.802	rs9611577	chr22:41793090	T/G	cg06634786	chr22:41940651	POLR3H	-0.7	-7.53	-0.42	8e-13	Vitiligo;
CESC	cis	rs7843479	0.965	rs11775479	chr8:21859991	C/T	cg17168535	chr8:21777572	XPO7	0.48	6.58	0.37	2.51e-10	Mean corpuscular volume;
CESC	cis	rs561341	1.000	rs8073186	chr17:30244956	T/C	cg13647721	chr17:30228624	UTP6	0.7	6.81	0.39	6.38e-11	Hip circumference adjusted for BMI;
CESC	cis	rs873946	0.564	rs12242672	chr10:134555609	A/T	cg27297192	chr10:134578999	INPP5A	0.37	5.07	0.3	7.4e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs8099014	0.731	rs4940391	chr18:56105868	A/G	cg12827950	chr18:55968429	NEDD4L	-0.52	-5.54	-0.32	7.23e-8	Platelet count;
CESC	trans	rs9348721	0.673	rs9358934	chr6:26363755	G/C	cg06606381	chr12:133084897	FBRSL1	-0.76	-7.01	-0.4	1.97e-11	Intelligence (multi-trait analysis);
CESC	cis	rs68170813	0.641	rs6979368	chr7:107089009	C/G	cg02696742	chr7:106810147	HBP1	-0.56	-5.19	-0.3	4.1e-7	Coronary artery disease;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg11074549	chr14:75642944	TMED10	-0.52	-6.48	-0.37	4.46e-10	Ulcerative colitis;
CESC	cis	rs6032067	0.641	rs34313230	chr20:43755858	C/G	cg10761708	chr20:43804764	PI3	0.5	5.25	0.31	3.12e-7	Blood protein levels;
CESC	cis	rs12477438	0.501	rs12613624	chr2:99732741	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.78	-12.89	-0.62	7.58e-30	Chronic sinus infection;
CESC	cis	rs9308433	0.529	rs4655332	chr1:214490756	G/A	cg06198575	chr1:214491504	SMYD2	0.49	5.8	0.34	1.83e-8	IgG glycosylation;
CESC	cis	rs9309711	0.621	rs7586472	chr2:3473670	G/A	cg15506890	chr2:3487001	NA	-0.43	-5.37	-0.31	1.7e-7	Neurofibrillary tangles;
CESC	cis	rs6570726	0.689	rs411785	chr6:145888398	G/A	cg05347473	chr6:146136440	FBXO30	0.58	7.49	0.42	1.03e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7617480	0.648	rs9882443	chr3:48749064	G/A	cg07636037	chr3:49044803	WDR6	0.75	9.52	0.5	1.15e-18	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CESC	cis	rs4474465	1.000	rs12280198	chr11:78161361	C/T	cg27205649	chr11:78285834	NARS2	-0.42	-5.19	-0.3	4.2e-7	Alzheimer's disease (survival time);
CESC	cis	rs854572	0.870	rs757158	chr7:94955528	C/T	cg01874867	chr7:94954059	PON1	-0.43	-6.27	-0.36	1.44e-9	Paraoxonase activity;
CESC	cis	rs11122272	0.733	rs2749700	chr1:231522734	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.59	-8.22	-0.45	9.37e-15	Hemoglobin concentration;
CESC	cis	rs1448094	0.549	rs57614821	chr12:86235361	A/C	cg00310523	chr12:86230176	RASSF9	0.38	5.72	0.33	2.8e-8	Major depressive disorder;
CESC	cis	rs710216	0.917	rs900836	chr1:43412727	T/C	cg22176566	chr1:43424700	SLC2A1	-0.5	-5.54	-0.32	7.23e-8	Red cell distribution width;
CESC	cis	rs921968	0.643	rs522377	chr2:219437476	T/C	cg02176678	chr2:219576539	TTLL4	0.41	7.08	0.4	1.27e-11	Mean corpuscular hemoglobin concentration;
CESC	cis	rs67517081	1	rs67517081	chr16:30987380	GT/G	cg02466173	chr16:30829666	NA	0.52	8.52	0.46	1.21e-15	Mean corpuscular hemoglobin;
CESC	cis	rs7197653	0.748	rs11350	chr16:68335392	A/G	cg26727032	chr16:67993705	SLC12A4	-0.54	-5.18	-0.3	4.42e-7	Magnesium levels;
CESC	trans	rs10789640	1.000	rs1347913	chr11:96577720	A/G	cg26796443	chr12:15844458	EPS8	0.44	6.01	0.35	6.01e-9	Immunoglobulin A vasculitis;
CESC	cis	rs2832077	0.527	rs2250141	chr21:30241984	A/T	cg24692254	chr21:30365293	RNF160	0.53	6.83	0.39	5.96e-11	Cognitive test performance;
CESC	cis	rs3820068	0.608	rs2057304	chr1:16017710	A/G	cg13390004	chr1:15929781	NA	0.33	5.13	0.3	5.64e-7	Systolic blood pressure;
CESC	cis	rs1799949	0.896	rs8176086	chr17:41274778	G/A	cg25072359	chr17:41440525	NA	0.43	5.78	0.33	2.04e-8	Menopause (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15708604	chr19:15490658	AKAP8	0.51	6.12	0.35	3.35e-9	Gut microbiome composition (summer);
CESC	cis	rs8005677	1.000	rs4981449	chr14:23388871	C/G	cg01529538	chr14:23388837	RBM23	0.51	6.87	0.39	4.64e-11	Cognitive ability (multi-trait analysis);
CESC	cis	rs4665809	1.000	rs1550382	chr2:26266877	T/G	cg27170947	chr2:26402098	FAM59B	-0.6	-7.09	-0.4	1.18e-11	Gut microbiome composition (summer);
CESC	cis	rs34526934	0.608	rs7606110	chr2:177028551	T/C	cg14324370	chr2:177042789	NA	-0.5	-6.1	-0.35	3.65e-9	Obstructive sleep apnea trait (apnea hypopnea index);
CESC	cis	rs2249694	0.572	rs9418984	chr10:135322356	C/G	cg20169779	chr10:135381914	SYCE1	-0.42	-5.62	-0.33	4.72e-8	Obesity-related traits;
CESC	cis	rs909674	0.818	rs5757678	chr22:39843409	A/G	cg24399712	chr22:39784796	NA	0.81	10.69	0.55	2.13e-22	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs9487051	0.676	rs9374077	chr6:109600194	C/T	cg12927641	chr6:109611667	NA	-0.36	-5.43	-0.32	1.28e-7	Reticulocyte fraction of red cells;
CESC	cis	rs67311347	1.000	rs9829800	chr3:40443927	T/C	cg24209194	chr3:40518798	ZNF619	0.47	6.08	0.35	4.1e-9	Renal cell carcinoma;
CESC	cis	rs6964587	1.000	rs6979085	chr7:91673623	C/T	cg17063962	chr7:91808500	NA	0.58	7.89	0.44	8.08e-14	Breast cancer;
CESC	trans	rs687914	0.710	rs938662	chr2:45864578	A/G	cg12506373	chr2:27440548	CAD	0.59	6.13	0.35	3.15e-9	Diastolic blood pressure;
CESC	cis	rs36051895	0.632	rs7850425	chr9:5170645	G/T	cg02405213	chr9:5042618	JAK2	-0.51	-5.94	-0.34	8.91e-9	Pediatric autoimmune diseases;
CESC	trans	rs11098499	0.866	rs12499602	chr4:120284387	T/A	cg25214090	chr10:38739885	LOC399744	0.65	9.11	0.49	2.04e-17	Corneal astigmatism;
CESC	cis	rs2688608	0.592	rs7909544	chr10:75484004	G/C	cg23231163	chr10:75533350	FUT11	-0.36	-5.42	-0.32	1.37e-7	Inflammatory bowel disease;
CESC	cis	rs9303401	0.646	rs8067682	chr17:57219391	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.56	7.28	0.41	3.7e-12	Cognitive test performance;
CESC	cis	rs950776	0.518	rs1504545	chr15:78818471	C/G	cg24631222	chr15:78858424	CHRNA5	0.4	5.03	0.3	8.89e-7	Sudden cardiac arrest;
CESC	cis	rs10899021	0.790	rs12280434	chr11:74332827	C/T	cg25880958	chr11:74394337	NA	-0.74	-7.95	-0.44	5.44e-14	Response to metformin (IC50);
CESC	cis	rs9796	0.621	rs9972349	chr15:41491656	A/G	cg20272979	chr15:41787780	ITPKA	0.35	5.25	0.31	3.11e-7	Menopause (age at onset);
CESC	cis	rs7264396	0.790	rs6579255	chr20:34219496	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.88	-11.94	-0.59	1.35e-26	Total cholesterol levels;
CESC	cis	rs9896933	0.832	rs77512810	chr17:80804589	C/T	cg20578329	chr17:80767326	TBCD	-0.77	-8.12	-0.45	1.77e-14	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
CESC	cis	rs9309473	0.950	rs10169213	chr2:73787234	G/C	cg20560298	chr2:73613845	ALMS1	-0.53	-6.93	-0.39	3.19e-11	Metabolite levels;
CESC	cis	rs910316	0.763	rs175016	chr14:75459633	C/T	cg08847533	chr14:75593920	NEK9	-0.9	-15.8	-0.7	4.65e-40	Height;
CESC	cis	rs35110281	0.744	rs162396	chr21:44947807	T/C	cg01579765	chr21:45077557	HSF2BP	-0.56	-9.81	-0.52	1.43e-19	Mean corpuscular volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07086847	chr8:145550618	DGAT1	0.61	7.1	0.4	1.15e-11	Gut microbiome composition (summer);
CESC	cis	rs2204008	0.715	rs12815986	chr12:38343869	G/A	cg26384229	chr12:38710491	ALG10B	0.74	10.74	0.55	1.39e-22	Bladder cancer;
CESC	cis	rs6952808	0.689	rs11771625	chr7:2050401	C/T	cg21782813	chr7:2030301	MAD1L1	0.53	7.58	0.42	5.68e-13	Bipolar disorder and schizophrenia;
CESC	cis	rs3749237	0.595	rs17595772	chr3:49409704	G/A	cg06212747	chr3:49208901	KLHDC8B	0.53	7.2	0.4	6.08e-12	Resting heart rate;
CESC	cis	rs909674	0.541	rs5750812	chr22:39793079	G/A	cg05872129	chr22:39784769	NA	-0.85	-12.1	-0.6	3.94e-27	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg25959527	chr3:195163920	ACAP2	-0.48	-6.26	-0.36	1.55e-9	Fibrinogen levels;
CESC	cis	rs9905704	0.918	rs304282	chr17:56785571	T/C	cg12560992	chr17:57184187	TRIM37	0.59	7.1	0.4	1.16e-11	Testicular germ cell tumor;
CESC	trans	rs7335046	1.000	rs9517667	chr13:99915135	G/A	cg14259717	chr11:18433732	LDHC	0.64	6.31	0.36	1.14e-9	Basal cell carcinoma;
CESC	cis	rs12479064	0.703	rs28382977	chr2:100018304	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.65	-7.82	-0.43	1.29e-13	Chronic sinus infection;
CESC	cis	rs853679	0.517	rs9380059	chr6:28132358	A/C	cg08968635	chr6:28129556	ZNF389	0.4	5.22	0.31	3.69e-7	Depression;
CESC	cis	rs9399135	0.967	rs12661423	chr6:135349570	C/T	cg24558204	chr6:135376177	HBS1L	0.55	7.74	0.43	2.05e-13	Red blood cell count;
CESC	cis	rs11123610	0.520	rs35752035	chr2:3721353	G/C	cg19052272	chr2:3704530	ALLC	-0.48	-5.86	-0.34	1.37e-8	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CESC	cis	rs4555082	0.834	rs11849607	chr14:105745383	G/A	cg13114125	chr14:105738426	BRF1	-0.88	-10.98	-0.56	2.32e-23	Mean platelet volume;Platelet distribution width;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg12035827	chr1:10855226	CASZ1	-0.45	-6.03	-0.35	5.51e-9	Fibrinogen levels;
CESC	cis	rs853679	1.000	rs2799079	chr6:28235176	A/C	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.67	7.09	0.4	1.23e-11	Depression;
CESC	cis	rs3733585	0.673	rs7376948	chr4:9954708	G/A	cg00071950	chr4:10020882	SLC2A9	-0.69	-11.35	-0.57	1.36e-24	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs4132509	1.000	rs2168812	chr1:243777066	G/A	cg21452805	chr1:244014465	NA	0.44	5.22	0.31	3.64e-7	RR interval (heart rate);
CESC	cis	rs7666738	0.830	rs1426667	chr4:98949772	T/C	cg03676636	chr4:99064102	C4orf37	0.33	5.09	0.3	6.71e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg01238044	chr22:24384105	GSTT1	-0.45	-5.56	-0.32	6.55e-8	Liver enzyme levels (gamma-glutamyl transferase);
CESC	trans	rs4716602	0.596	rs12386632	chr7:156158221	G/A	cg07175507	chr18:77160758	NFATC1	-0.45	-6.14	-0.35	3e-9	Anti-saccade response;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09174674	chr1:9884042	CLSTN1	0.62	6.85	0.39	5.06e-11	Gut microbiome composition (summer);
CESC	cis	rs2952156	0.920	rs2934956	chr17:37830447	T/A	cg20243544	chr17:37824526	PNMT	0.63	8.11	0.45	1.92e-14	Asthma;
CESC	cis	rs7666738	0.830	rs6854594	chr4:99065312	A/T	cg03467027	chr4:99064603	C4orf37	0.48	6.01	0.35	6.26e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs568617	0.903	rs601863	chr11:65646557	C/A	cg00576331	chr11:65640516	EFEMP2	0.45	5.3	0.31	2.48e-7	Crohn's disease;
CESC	cis	rs8062405	0.824	rs28698667	chr16:28533071	C/T	cg07382826	chr16:28625726	SULT1A1	0.31	5.05	0.3	8.32e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg26593380	chr7:4749206	FOXK1	0.49	6.8	0.39	6.91e-11	Fibrinogen levels;
CESC	cis	rs7503807	0.688	rs901060	chr17:78594990	G/A	cg09596252	chr17:78655493	RPTOR	0.37	5.21	0.3	3.84e-7	Obesity;
CESC	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg21724239	chr8:58056113	NA	0.59	5.64	0.33	4.27e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs258892	0.895	rs2338792	chr5:72066860	G/C	cg21869765	chr5:72125136	TNPO1	-0.43	-5.35	-0.31	1.93e-7	Small cell lung carcinoma;
CESC	cis	rs1514687	0.534	rs11674407	chr2:1464530	G/C	cg13703866	chr2:1479523	TPO	-0.83	-5.33	-0.31	2.11e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);
CESC	cis	rs10751667	0.961	rs7396670	chr11:929269	A/G	cg06064525	chr11:970664	AP2A2	-0.43	-7.7	-0.43	2.72e-13	Alzheimer's disease (late onset);
CESC	cis	rs6541297	1.000	rs6665260	chr1:230279067	G/T	cg20703242	chr1:230279135	GALNT2	0.68	10.87	0.56	5.47e-23	Coronary artery disease;
CESC	trans	rs629535	0.821	rs660144	chr8:70035629	T/C	cg21567404	chr3:27674614	NA	0.93	11.25	0.57	2.83e-24	Dupuytren's disease;
CESC	cis	rs17655565	1.000	rs73309373	chr12:52701409	C/T	cg08257133	chr12:52711352	KRT83	0.54	6.78	0.38	7.83e-11	Plasma amyloid beta peptide concentrations (ABx-42);
CESC	cis	rs9322193	0.923	rs9322196	chr6:149940781	T/G	cg13206674	chr6:150067644	NUP43	0.41	5.77	0.33	2.21e-8	Lung cancer;
CESC	cis	rs798554	0.759	rs2644309	chr7:2889034	T/C	cg09658497	chr7:2847517	GNA12	-0.37	-5.1	-0.3	6.42e-7	Height;
CESC	cis	rs17401966	0.838	rs12127604	chr1:10352800	T/G	cg15208524	chr1:10270712	KIF1B	0.41	5.32	0.31	2.16e-7	Hepatocellular carcinoma;
CESC	cis	rs2979489	0.838	rs2979513	chr8:30397925	G/C	cg26383811	chr8:30366931	RBPMS	-0.8	-9.99	-0.52	3.88e-20	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CESC	cis	rs7605827	0.576	rs35785577	chr2:15659611	A/G	cg19274914	chr2:15703543	NA	0.36	6.31	0.36	1.18e-9	Educational attainment (years of education);
CESC	cis	rs79057730	0.599	rs6951032	chr7:794092	C/T	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.93	7.84	0.43	1.12e-13	Initial pursuit acceleration;
CESC	cis	rs2742417	0.603	rs1962800	chr3:45779943	C/T	cg04837898	chr3:45731254	SACM1L	-0.54	-6.9	-0.39	3.84e-11	Response to anti-depressant treatment in major depressive disorder;
CESC	cis	rs9467711	0.606	rs9379863	chr6:26372427	A/G	cg12826209	chr6:26865740	GUSBL1	0.62	5.24	0.31	3.25e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs6952808	0.689	rs1107591	chr7:2041638	G/A	cg23048001	chr7:2026167	MAD1L1	0.47	6.17	0.35	2.48e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs7539409	0.604	rs910183	chr1:84297285	A/G	cg10977910	chr1:84465055	TTLL7	0.75	7.16	0.4	7.79e-12	Alzheimer's disease;
CESC	cis	rs17401966	1.000	rs4846210	chr1:10322153	A/G	cg15208524	chr1:10270712	KIF1B	0.5	6.47	0.37	4.65e-10	Hepatocellular carcinoma;
CESC	cis	rs250677	0.652	rs36045	chr5:148441184	A/G	cg18129178	chr5:148520854	ABLIM3	0.58	6.03	0.35	5.58e-9	Breast cancer;
CESC	cis	rs4843747	0.697	rs72818533	chr16:88073841	G/A	cg06915872	chr16:87998081	BANP	0.49	5.83	0.34	1.62e-8	Menopause (age at onset);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg14702927	chr19:46366445	FOXA3;SYMPK	-0.49	-6.15	-0.35	2.79e-9	Ulcerative colitis;
CESC	cis	rs12681288	0.676	rs2701927	chr8:995886	G/A	cg15309053	chr8:964076	NA	0.42	7.18	0.4	6.95e-12	Schizophrenia;
CESC	cis	rs7845219	0.506	rs12548999	chr8:95929843	C/T	cg23172400	chr8:95962367	TP53INP1	-0.36	-6.63	-0.38	1.9e-10	Type 2 diabetes;
CESC	cis	rs2075371	1.000	rs2544211	chr7:133973230	A/G	cg00033643	chr7:134001901	SLC35B4	0.41	5.2	0.3	4e-7	Mean platelet volume;
CESC	cis	rs4819052	0.851	rs2838867	chr21:46713092	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.71	8.95	0.48	6.48e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs7070678	0.870	rs10826651	chr10:29814475	A/T	cg06477056	chr5:175110609	HRH2	0.35	6.59	0.38	2.31e-10	Platelet thrombus formation;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg05102190	chr7:143078242	ZYX	-0.42	-5.99	-0.35	6.66e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs7561273	0.565	rs6545275	chr2:24331860	A/G	cg06627628	chr2:24431161	ITSN2	-0.46	-5.42	-0.32	1.34e-7	Quantitative traits;
CESC	cis	rs950169	0.512	rs4374136	chr15:84645007	C/G	cg17507749	chr15:85114479	UBE2QP1	0.61	5.99	0.35	6.73e-9	Schizophrenia;
CESC	cis	rs1215050	0.791	rs983187	chr4:98816350	A/T	cg05340658	chr4:99064831	C4orf37	0.51	6.57	0.37	2.63e-10	Waist-to-hip ratio adjusted for body mass index;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg08125682	chr16:11038455	CLEC16A	-0.45	-6.35	-0.36	9.34e-10	Fibrinogen levels;
CESC	cis	rs10504229	0.683	rs882429	chr8:58129292	A/G	cg24829409	chr8:58192753	C8orf71	-0.58	-7.2	-0.4	6.31e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs6831352	1.000	rs1126670	chr4:100052733	C/A	cg12011299	chr4:100065546	ADH4	0.69	8.43	0.46	2.17e-15	Alcohol dependence;
CESC	cis	rs9486719	0.857	rs1157316	chr6:96869710	G/A	cg06623918	chr6:96969491	KIAA0776	0.89	10.34	0.54	2.9e-21	Migraine;Coronary artery disease;
CESC	cis	rs5758511	0.773	rs10154700	chr22:42365073	G/T	cg00645731	chr22:42541494	CYP2D7P1	0.36	5.07	0.3	7.65e-7	Birth weight;
CESC	cis	rs977987	0.806	rs4888405	chr16:75428196	A/C	cg03315344	chr16:75512273	CHST6	0.37	5.34	0.31	1.97e-7	Dupuytren's disease;
CESC	cis	rs13720	0.722	rs163795	chr20:57577505	C/G	cg23907860	chr20:57583709	CTSZ	-0.43	-5.31	-0.31	2.33e-7	Platelet distribution width;
CESC	cis	rs904092	0.786	rs62305755	chr4:100150020	G/A	cg12011299	chr4:100065546	ADH4	0.54	6.09	0.35	3.89e-9	Alcohol dependence;
CESC	cis	rs11630290	0.806	rs10519220	chr15:64047120	C/T	cg12036633	chr15:63758958	NA	0.53	5.32	0.31	2.17e-7	Iris characteristics;
CESC	cis	rs3020736	0.500	rs4147641	chr22:42482502	C/G	cg04733989	chr22:42467013	NAGA	-0.79	-12.03	-0.59	6.75e-27	Autism spectrum disorder or schizophrenia;
CESC	cis	rs12325245	0.536	rs8058781	chr16:58653838	G/A	cg01152986	chr16:58549298	SETD6	0.86	5.07	0.3	7.43e-7	Schizophrenia;
CESC	cis	rs920590	0.684	rs59565447	chr8:19668430	A/T	cg17834443	chr8:19674713	INTS10	0.59	6.51	0.37	3.66e-10	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs2380220	0.935	rs7748857	chr6:96001887	A/G	cg04719120	chr6:96025338	MANEA	0.51	5.04	0.3	8.77e-7	Behavioural disinhibition (generation interaction);
CESC	cis	rs7523050	0.730	rs72984628	chr1:109460808	G/A	cg08274380	chr1:109419600	GPSM2	0.79	5.91	0.34	1.04e-8	Fat distribution (HIV);
CESC	cis	rs4819052	1.000	rs2297285	chr21:46705621	A/G	cg11663144	chr21:46675770	NA	0.46	6.01	0.35	6.01e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs6860806	0.507	rs273917	chr5:131659618	A/G	cg18758796	chr5:131593413	PDLIM4	0.41	5.66	0.33	4e-8	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17169043	chr6:170863845	PSMB1;TBP	0.54	5.99	0.35	6.68e-9	Gut microbiome composition (summer);
CESC	cis	rs6500602	0.673	rs4786512	chr16:4573040	A/G	cg08645402	chr16:4508243	NA	0.43	6.47	0.37	4.77e-10	Schizophrenia;
CESC	cis	rs1784581	0.588	rs7453474	chr6:162421736	C/T	cg17173639	chr6:162384350	PARK2	0.57	8.73	0.47	2.94e-16	Itch intensity from mosquito bite;
CESC	cis	rs17539620	0.519	rs4077066	chr6:154838448	C/G	cg20019720	chr6:154832845	CNKSR3	0.43	6.26	0.36	1.52e-9	Lipoprotein (a) levels;
CESC	cis	rs2180341	0.722	rs9388555	chr6:127576363	G/A	cg27446573	chr6:127587934	RNF146	0.87	12.33	0.6	6.52e-28	Breast cancer;
CESC	cis	rs34311866	0.808	rs11248059	chr4:960331	C/G	cg07828340	chr4:882639	GAK	0.89	6.51	0.37	3.69e-10	Parkinson's disease;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg24441975	chr1:39339062	MYCBP	-0.47	-6.23	-0.36	1.78e-9	Ulcerative colitis;
CESC	cis	rs4561483	0.799	rs33635	chr16:11991944	C/T	cg08843971	chr16:11963173	GSPT1	-0.41	-5.74	-0.33	2.62e-8	Testicular germ cell tumor;
CESC	cis	rs9467711	0.606	rs12174602	chr6:26372827	C/T	cg12826209	chr6:26865740	GUSBL1	0.63	5.37	0.31	1.7e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs2302190	0.882	rs9903173	chr17:56607358	C/T	cg25885038	chr17:56607967	SEPT4	-0.41	-5.72	-0.33	2.91e-8	Vitamin D levels;
CESC	cis	rs72634258	0.796	rs6703955	chr1:8165975	C/G	cg00042356	chr1:8021962	PARK7	-0.47	-5.04	-0.3	8.61e-7	Inflammatory bowel disease;
CESC	cis	rs728616	0.867	rs4520539	chr10:81740529	C/G	cg05935833	chr10:81318306	SFTPA2	-0.52	-5.06	-0.3	7.72e-7	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs9911578	0.933	rs11868348	chr17:57179238	C/T	cg05425664	chr17:57184151	TRIM37	-0.53	-7.31	-0.41	3.19e-12	Intelligence (multi-trait analysis);
CESC	cis	rs6963495	0.818	rs73190167	chr7:105160418	A/G	cg13798780	chr7:105162888	PUS7	0.78	8.04	0.44	2.99e-14	Bipolar disorder (body mass index interaction);
CESC	cis	rs7666738	0.925	rs34423396	chr4:99049031	T/A	cg05340658	chr4:99064831	C4orf37	0.69	9.38	0.5	3.07e-18	Colonoscopy-negative controls vs population controls;
CESC	trans	rs2963826	0.589	rs298091	chr5:58996603	A/T	cg04590956	chr2:70057467	GMCL1	0.5	6.36	0.36	8.73e-10	Obesity-related traits;
CESC	cis	rs9894429	0.505	rs35570626	chr17:79611084	A/G	cg18240062	chr17:79603768	NPLOC4	0.54	7.05	0.4	1.56e-11	Eye color traits;
CESC	cis	rs1862618	0.529	rs978406	chr5:56259808	A/T	cg24531977	chr5:56204891	C5orf35	0.91	12.2	0.6	1.8e-27	Initial pursuit acceleration;
CESC	cis	rs7618915	0.501	rs767418	chr3:52767427	C/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.31	5.57	0.32	6.31e-8	Bipolar disorder;
CESC	cis	rs1348850	0.793	rs13000048	chr2:178337089	C/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.74	10.26	0.53	4.96e-21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs1003719	0.788	rs1543748	chr21:38446581	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.62	8.7	0.47	3.48e-16	Eye color traits;
CESC	cis	rs1552244	1.000	rs6772315	chr3:10113644	G/A	cg00166722	chr3:10149974	C3orf24	0.53	6.65	0.38	1.64e-10	Alzheimer's disease;
CESC	cis	rs801193	0.569	rs7800620	chr7:66223688	T/C	cg12463550	chr7:65579703	CRCP	0.49	6.31	0.36	1.17e-9	Aortic root size;
CESC	cis	rs1062746	0.683	rs891094	chr16:87378001	C/G	cg02258303	chr16:87377426	FBXO31	0.5	6.31	0.36	1.2e-9	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
CESC	cis	rs9467773	0.901	rs1407045	chr6:26476155	A/G	cg11502198	chr6:26597334	ABT1	0.4	5.46	0.32	1.12e-7	Intelligence (multi-trait analysis);
CESC	cis	rs11203032	0.831	rs10887925	chr10:90938902	G/T	cg16672925	chr10:90967113	CH25H	0.72	7.17	0.4	7.66e-12	Heart failure;
CESC	cis	rs7945705	0.935	rs2653567	chr11:8889630	T/C	cg12365402	chr11:9010492	NRIP3	-0.32	-5.24	-0.31	3.31e-7	Hemoglobin concentration;
CESC	cis	rs2603127	0.768	rs9864741	chr3:108489823	G/A	cg03329597	chr3:108125523	MYH15	0.6	5.38	0.31	1.63e-7	Hemostatic factors and hematological phenotypes;
CESC	cis	rs7208859	0.623	rs75136574	chr17:28934549	C/A	cg13385521	chr17:29058706	SUZ12P	0.78	5.67	0.33	3.78e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs1062177	1.000	rs62394155	chr5:151248069	G/A	cg00977110	chr5:151150581	G3BP1	0.63	6.59	0.38	2.35e-10	Preschool internalizing problems;
CESC	cis	rs738322	0.775	rs4375	chr22:38539041	T/C	cg25457927	chr22:38595422	NA	-0.28	-5.18	-0.3	4.37e-7	Cutaneous nevi;
CESC	cis	rs9325144	0.624	rs10783333	chr12:39118931	A/T	cg26384229	chr12:38710491	ALG10B	0.53	7.39	0.41	1.94e-12	Morning vs. evening chronotype;
CESC	cis	rs7666738	0.753	rs7698541	chr4:98986351	T/A	cg03467027	chr4:99064603	C4orf37	0.44	5.54	0.32	7.12e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7662987	0.793	rs12697	chr4:99993376	C/T	cg13256891	chr4:100009986	ADH5	0.59	5.18	0.3	4.35e-7	Smoking initiation;
CESC	cis	rs9894429	0.646	rs7210026	chr17:79612382	T/C	cg21984481	chr17:79567631	NPLOC4	-0.35	-5.41	-0.32	1.43e-7	Eye color traits;
CESC	cis	rs7247513	0.639	rs12984441	chr19:12760287	A/C	cg11738485	chr19:12877000	HOOK2	0.48	6.05	0.35	4.86e-9	Bipolar disorder;
CESC	cis	rs17125944	0.615	rs12587286	chr14:53304751	C/T	cg00686598	chr14:53173677	PSMC6	1.09	8.28	0.45	6.22e-15	Alzheimer's disease (late onset);
CESC	cis	rs735860	0.737	rs2397139	chr6:53150804	C/G	cg10236188	chr6:53219634	NA	-0.34	-5.1	-0.3	6.53e-7	Glaucoma;
CESC	cis	rs11122272	0.735	rs2790891	chr1:231513190	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.57	-7.82	-0.43	1.29e-13	Hemoglobin concentration;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg19741408	chr1:90460434	ZNF326;LOC492303	0.46	6.15	0.35	2.91e-9	Systemic lupus erythematosus;
CESC	cis	rs7845219	0.544	rs7016078	chr8:95922615	G/A	cg23172400	chr8:95962367	TP53INP1	-0.38	-7.19	-0.4	6.78e-12	Type 2 diabetes;
CESC	cis	rs7412746	0.658	rs6657388	chr1:150748786	A/G	cg22823121	chr1:150693482	HORMAD1	0.47	6.48	0.37	4.52e-10	Melanoma;
CESC	cis	rs1862618	1.000	rs1862618	chr5:56096315	C/G	cg03609598	chr5:56110824	MAP3K1	-0.5	-5.45	-0.32	1.15e-7	Initial pursuit acceleration;
CESC	cis	rs6688613	0.694	rs12062326	chr1:166820186	G/A	ch.1.3259774R	chr1:166827647	TADA1	0.58	5.86	0.34	1.38e-8	Refractive astigmatism;
CESC	cis	rs4665809	0.652	rs10779956	chr2:26405985	A/G	cg26314531	chr2:26401878	FAM59B	-0.83	-9.14	-0.49	1.64e-17	Gut microbiome composition (summer);
CESC	cis	rs769267	0.965	rs4808200	chr19:19554803	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.46	5.78	0.33	2.12e-8	Tonsillectomy;
CESC	cis	rs7903847	0.642	rs7903562	chr10:99154782	T/C	cg20016023	chr10:99160130	RRP12	-0.29	-5.06	-0.3	7.87e-7	Granulocyte percentage of myeloid white cells;
CESC	cis	rs4604732	0.631	rs10802509	chr1:247627158	C/T	cg12758973	chr1:247694275	LOC148824;OR2C3	0.51	6.36	0.36	8.65e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs9399401	0.626	rs13198644	chr6:142783233	A/G	cg03128060	chr6:142623767	GPR126	0.3	5.03	0.3	8.92e-7	Chronic obstructive pulmonary disease;
CESC	cis	rs12824058	0.831	rs12297939	chr12:130811923	G/C	cg24838063	chr12:130822603	PIWIL1	0.62	8.55	0.47	9.78e-16	Menopause (age at onset);
CESC	cis	rs875971	0.825	rs801202	chr7:66023929	C/T	cg10691866	chr7:65817282	TPST1	0.33	5.51	0.32	8.51e-8	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09360458	chr1:14075560	PRDM2	-0.6	-7.05	-0.4	1.51e-11	Gut microbiome composition (summer);
CESC	cis	rs7903847	0.596	rs9787426	chr10:99155327	A/G	cg20016023	chr10:99160130	RRP12	-0.3	-5.16	-0.3	4.77e-7	Granulocyte percentage of myeloid white cells;
CESC	cis	rs7927592	0.913	rs4084149	chr11:68288567	A/G	cg20283391	chr11:68216788	NA	-0.62	-7.54	-0.42	7.69e-13	Total body bone mineral density;
CESC	cis	rs72781680	0.898	rs2339851	chr2:23938883	G/A	cg20701182	chr2:24300061	SF3B14	0.78	6.91	0.39	3.5e-11	Lymphocyte counts;
CESC	cis	rs8017423	0.967	rs7150093	chr14:90724661	C/T	cg14092571	chr14:90743983	NA	0.54	8.12	0.45	1.74e-14	Mortality in heart failure;
CESC	cis	rs597539	0.652	rs11603827	chr11:68719221	C/T	cg06028808	chr11:68637592	NA	0.47	5.47	0.32	1.03e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs662064	0.544	rs12725704	chr1:10613351	T/C	cg20482658	chr1:10539492	PEX14	0.34	5.55	0.32	7.02e-8	Asthma;
CESC	cis	rs9815354	0.951	rs9864331	chr3:41762217	G/A	cg03022575	chr3:42003672	ULK4	0.51	5.1	0.3	6.62e-7	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs2629540	0.781	rs2293064	chr10:126396511	C/G	cg08799069	chr10:126477246	METTL10	0.47	6.06	0.35	4.75e-9	Cocaine dependence;
CESC	cis	rs853679	0.517	rs6932109	chr6:28078303	A/G	cg18032046	chr6:28092343	ZSCAN16	0.5	5.85	0.34	1.41e-8	Depression;
CESC	cis	rs733592	0.524	rs10875726	chr12:48425992	A/G	cg04545296	chr12:48745243	ZNF641	-0.29	-5.46	-0.32	1.07e-7	Plateletcrit;
CESC	cis	rs6860806	0.507	rs272892	chr5:131664349	C/T	cg24060327	chr5:131705240	SLC22A5	-0.78	-10.93	-0.56	3.25e-23	Breast cancer;
CESC	cis	rs4642101	0.597	rs9865624	chr3:12822786	T/A	cg05775895	chr3:12838266	CAND2	0.39	5.93	0.34	9.32e-9	QRS complex (12-leadsum);
CESC	cis	rs1270639	0.778	rs2707942	chr7:157445750	G/C	cg13357408	chr7:157437802	PTPRN2	0.62	7.26	0.41	4.32e-12	Colorectal cancer;
CESC	cis	rs6502050	0.835	rs62078304	chr17:80085224	G/A	cg11859384	chr17:80120422	CCDC57	0.38	5.13	0.3	5.62e-7	Life satisfaction;
CESC	cis	rs10504229	0.683	rs72650839	chr8:58130029	C/T	cg02725872	chr8:58115012	NA	-0.46	-7.13	-0.4	9.4e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs367615	0.506	rs1428932	chr5:108792479	A/G	cg17395555	chr5:108820864	NA	-0.58	-9.89	-0.52	7.61e-20	Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs12900413	0.603	rs12906832	chr15:90301314	C/G	cg24249390	chr15:90295951	MESP1	-0.4	-5.4	-0.31	1.52e-7	Coronary artery aneurysm in Kawasaki disease;
CESC	cis	rs2836974	0.644	rs11088471	chr21:40699313	A/G	cg22974920	chr21:40686053	BRWD1	-0.45	-5.55	-0.32	6.91e-8	Cognitive function;
CESC	cis	rs10492096	0.947	rs61918022	chr12:6614521	C/T	cg13857086	chr12:6580257	VAMP1	0.61	6.04	0.35	5.24e-9	Hip geometry;
CESC	cis	rs3815700	1.000	rs2287670	chr19:33095057	G/A	cg02997394	chr19:33096574	ANKRD27	0.71	7.07	0.4	1.39e-11	Eosinophilic esophagitis;
CESC	cis	rs3540	0.553	rs2158406	chr15:90994499	T/C	cg22089800	chr15:90895588	ZNF774	0.64	8.76	0.47	2.32e-16	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs798554	0.679	rs7807978	chr7:2814635	C/T	cg09658497	chr7:2847517	GNA12	-0.36	-5.42	-0.32	1.32e-7	Height;
CESC	cis	rs763121	0.853	rs6001188	chr22:39062194	T/C	cg06022373	chr22:39101656	GTPBP1	0.91	14.85	0.67	1.02e-36	Menopause (age at onset);
CESC	cis	rs3820928	0.874	rs3752896	chr2:227886925	C/T	cg05526886	chr2:227700861	RHBDD1	-0.43	-5.49	-0.32	9.36e-8	Pulmonary function;
CESC	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.48	0.37	4.52e-10	Prudent dietary pattern;
CESC	trans	rs7615952	0.688	rs12638224	chr3:125541320	C/T	cg07211511	chr3:129823064	LOC729375	-0.84	-9.55	-0.51	9.43e-19	Blood pressure (smoking interaction);
CESC	cis	rs8070740	0.841	rs4790771	chr17:5324966	G/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.51	6.35	0.36	9.3e-10	Menopause (age at onset);
CESC	cis	rs2243480	1.000	rs781142	chr7:65438778	C/T	cg25894440	chr7:65020034	NA	-0.63	-5.61	-0.33	5.13e-8	Diabetic kidney disease;
CESC	cis	rs4566357	0.615	rs10184991	chr2:227916533	G/A	cg05526886	chr2:227700861	RHBDD1	-0.51	-6.67	-0.38	1.53e-10	Coronary artery disease;
CESC	cis	rs11098499	0.738	rs28687057	chr4:120280812	A/G	cg09307838	chr4:120376055	NA	0.87	12.16	0.6	2.41e-27	Corneal astigmatism;
CESC	cis	rs7618915	0.547	rs62253703	chr3:52632357	T/C	cg18404041	chr3:52824283	ITIH1	-0.39	-6.55	-0.37	2.96e-10	Bipolar disorder;
CESC	cis	rs56775891	1.000	rs34945223	chr18:77575871	A/G	cg13263691	chr18:77568018	NA	0.5	7.31	0.41	3.06e-12	Schizophrenia;
CESC	cis	rs35306767	0.953	rs12259338	chr10:969377	C/T	cg10556349	chr10:835070	NA	0.53	5.71	0.33	2.99e-8	Eosinophil percentage of granulocytes;
CESC	cis	rs35110281	0.744	rs230645	chr21:44918607	A/G	cg21573476	chr21:45109991	RRP1B	0.4	5.7	0.33	3.15e-8	Mean corpuscular volume;
CESC	cis	rs6831352	0.918	rs17817359	chr4:100054197	G/T	cg13256891	chr4:100009986	ADH5	-0.77	-8.45	-0.46	1.97e-15	Alcohol dependence;
CESC	cis	rs748404	0.660	rs690512	chr15:43717678	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.57	7.55	0.42	7.19e-13	Lung cancer;
CESC	trans	rs1814175	0.630	rs1722019	chr11:49904102	G/A	cg03929089	chr4:120376271	NA	-0.71	-9.17	-0.49	1.39e-17	Height;
CESC	cis	rs1878931	0.582	rs27232	chr16:3436782	G/A	cg02880119	chr16:3481970	NA	0.41	5.25	0.31	3.12e-7	Body mass index (adult);
CESC	cis	rs950169	0.840	rs4842853	chr15:84942304	G/T	cg17507749	chr15:85114479	UBE2QP1	0.59	6.52	0.37	3.46e-10	Schizophrenia;
CESC	trans	rs3780486	0.846	rs4584234	chr9:33147479	G/A	cg04842962	chr6:43655489	MRPS18A	0.96	17.4	0.73	9.89e-46	IgG glycosylation;
CESC	cis	rs514406	0.607	rs6696940	chr1:53203427	C/T	cg16325326	chr1:53192061	ZYG11B	-0.98	-17.51	-0.73	3.83e-46	Monocyte count;
CESC	cis	rs853679	0.517	rs9380057	chr6:28104634	G/T	cg12963246	chr6:28129442	ZNF389	0.57	7.78	0.43	1.65e-13	Depression;
CESC	cis	rs9300255	0.596	rs11057202	chr12:123720775	G/T	cg00376283	chr12:123451042	ABCB9	0.67	9.05	0.49	3.14e-17	Neutrophil percentage of white cells;
CESC	cis	rs11122272	0.705	rs2486742	chr1:231507254	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-7.03	-0.4	1.77e-11	Hemoglobin concentration;
CESC	cis	rs34734847	0.703	rs7978125	chr12:121167039	A/G	cg26008908	chr12:120799332	MSI1	0.33	5.23	0.31	3.4e-7	Mean corpuscular volume;
CESC	cis	rs79976124	0.837	rs11751994	chr6:66644028	A/C	cg07460842	chr6:66804631	NA	0.71	8.33	0.46	4.36e-15	Type 2 diabetes;
CESC	trans	rs1814175	0.935	rs11040465	chr11:49689323	C/T	cg03929089	chr4:120376271	NA	-0.85	-12.76	-0.62	2.21e-29	Height;
CESC	trans	rs2235573	0.653	rs3026670	chr22:38426774	T/C	cg19894588	chr14:64061835	NA	0.49	6.37	0.36	8.46e-10	Glioblastoma;Glioma;
CESC	cis	rs17021463	0.676	rs17311887	chr4:95313228	T/C	cg11021082	chr4:95130006	SMARCAD1	0.52	7.09	0.4	1.2e-11	Testicular germ cell tumor;
CESC	cis	rs10540	1.000	rs12418639	chr11:473300	A/C	cg03352830	chr11:487213	PTDSS2	-0.69	-6.76	-0.38	8.81e-11	Body mass index;
CESC	trans	rs561341	1.000	rs546748	chr17:30324293	A/C	cg27661571	chr11:113659931	NA	-0.55	-6.25	-0.36	1.67e-9	Hip circumference adjusted for BMI;
CESC	cis	rs5769707	0.749	rs7286706	chr22:50058346	G/C	cg05373962	chr22:49881684	NA	-0.36	-6.39	-0.37	7.36e-10	Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs1552244	1.000	rs56394721	chr3:10150795	A/G	cg08888203	chr3:10149979	C3orf24	0.5	6.38	0.37	7.71e-10	Alzheimer's disease;
CESC	cis	rs9815354	0.812	rs73071338	chr3:41824328	G/A	cg03022575	chr3:42003672	ULK4	0.7	6.2	0.36	2.11e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs113835537	0.529	rs11227500	chr11:66273233	T/C	cg22134325	chr11:66188745	NPAS4	0.35	5.57	0.32	6.18e-8	Airway imaging phenotypes;
CESC	cis	rs4862750	0.872	rs7664463	chr4:187876686	A/C	cg07414643	chr4:187882934	NA	0.48	6.84	0.39	5.59e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4665809	0.590	rs35656275	chr2:26494695	G/C	cg26314531	chr2:26401878	FAM59B	0.81	8.6	0.47	7.16e-16	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05996236	chr5:178286857	ZNF354B	0.62	6.7	0.38	1.24e-10	Gut microbiome composition (summer);
CESC	cis	rs2635047	0.777	rs9944807	chr18:44788908	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.41	5.34	0.31	2e-7	Educational attainment;
CESC	cis	rs60843830	0.517	rs58416198	chr2:175580	T/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.62	6.91	0.39	3.66e-11	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs6964587	1.000	rs10280927	chr7:91582205	G/A	cg17063962	chr7:91808500	NA	-0.57	-7.68	-0.43	3.06e-13	Breast cancer;
CESC	cis	rs7107174	0.892	rs4945265	chr11:78027458	G/A	cg02023728	chr11:77925099	USP35	0.48	6.41	0.37	6.64e-10	Testicular germ cell tumor;
CESC	cis	rs3857067	0.806	rs17302467	chr4:95112056	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.6	-9.12	-0.49	1.97e-17	QT interval;
CESC	cis	rs258892	0.895	rs155427	chr5:72115763	A/G	cg21869765	chr5:72125136	TNPO1	-0.44	-5.65	-0.33	4.05e-8	Small cell lung carcinoma;
CESC	cis	rs2075371	1.000	rs447266	chr7:133989543	A/G	cg00033643	chr7:134001901	SLC35B4	0.44	5.66	0.33	3.97e-8	Mean platelet volume;
CESC	cis	rs9858542	0.953	rs6446272	chr3:49463287	G/A	cg07274523	chr3:49395745	GPX1	0.67	8.23	0.45	8.41e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs5769765	0.908	rs9616376	chr22:50310829	A/G	cg02269571	chr22:50332266	NA	-0.57	-6.99	-0.39	2.29e-11	Schizophrenia;
CESC	cis	rs703842	0.616	rs1875125	chr12:58227241	T/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.58	6.82	0.39	5.98e-11	Multiple sclerosis;
CESC	cis	rs10242455	0.702	rs115279860	chr7:98994492	C/T	cg18809830	chr7:99032528	PTCD1	-0.83	-5.55	-0.32	6.86e-8	Blood metabolite levels;
CESC	cis	rs8067354	0.872	rs7224006	chr17:57896338	C/T	cg02344993	chr17:57696989	CLTC	-0.48	-6.15	-0.35	2.86e-9	Hemoglobin concentration;
CESC	cis	rs7618915	0.570	rs4687633	chr3:52630548	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.48	6.81	0.39	6.45e-11	Bipolar disorder;
CESC	cis	rs12497850	0.931	rs9835307	chr3:48857805	T/C	cg02487422	chr3:49467188	NICN1	0.4	5.15	0.3	5.11e-7	Parkinson's disease;
CESC	cis	rs9814567	0.752	rs7633868	chr3:134331048	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.4	-5.09	-0.3	6.84e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs4862750	0.872	rs9997374	chr4:187877549	T/A	cg07414643	chr4:187882934	NA	0.54	7.55	0.42	6.98e-13	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg18992706	chr13:44453352	CCDC122;C13orf31	-0.45	-6.04	-0.35	5.15e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs9911578	0.967	rs11079354	chr17:56594460	G/A	cg05425664	chr17:57184151	TRIM37	0.5	7.06	0.4	1.5e-11	Intelligence (multi-trait analysis);
CESC	cis	rs6912958	0.535	rs1753154	chr6:88032843	G/C	cg04972856	chr6:88032051	C6orf162;GJB7	0.32	5.18	0.3	4.43e-7	Monocyte percentage of white cells;
CESC	cis	rs977987	0.741	rs10514393	chr16:75344476	C/T	cg03315344	chr16:75512273	CHST6	0.4	5.73	0.33	2.77e-8	Dupuytren's disease;
CESC	cis	rs9443189	0.526	rs10943250	chr6:76208445	C/G	cg01950844	chr6:76311363	SENP6	0.77	8.12	0.45	1.79e-14	Prostate cancer;
CESC	cis	rs10504229	0.683	rs11785260	chr8:58132906	A/G	cg24829409	chr8:58192753	C8orf71	-0.58	-7.2	-0.4	6.31e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs4253772	0.530	rs715518	chr22:46754177	C/G	cg00784671	chr22:46762841	CELSR1	-0.64	-6.12	-0.35	3.28e-9	LDL cholesterol;Cholesterol, total;
CESC	cis	rs2559856	1.000	rs2695288	chr12:102088112	T/C	cg12213457	chr12:102090980	CHPT1	-0.36	-5.34	-0.31	2.02e-7	Blood protein levels;
CESC	cis	rs2361710	0.611	rs12051781	chr17:78074468	A/G	cg06718696	chr17:78121285	EIF4A3	0.61	7.35	0.41	2.49e-12	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21685663	chr1:154245266	HAX1	0.57	6.05	0.35	4.85e-9	Gut microbiome composition (summer);
CESC	cis	rs9300255	0.537	rs1618679	chr12:123650714	A/G	cg05973401	chr12:123451056	ABCB9	0.5	5.81	0.34	1.79e-8	Neutrophil percentage of white cells;
CESC	cis	rs11203032	0.831	rs7074977	chr10:90948409	C/T	cg16672925	chr10:90967113	CH25H	0.44	5.06	0.3	7.68e-7	Heart failure;
CESC	cis	rs3733585	0.699	rs7683283	chr4:9969974	T/C	cg11266682	chr4:10021025	SLC2A9	-0.58	-11.05	-0.56	1.37e-23	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs2559856	1.000	rs2695285	chr12:102089043	G/A	cg12213457	chr12:102090980	CHPT1	-0.37	-5.56	-0.32	6.46e-8	Blood protein levels;
CESC	cis	rs9815354	0.953	rs1716694	chr3:41986399	G/T	cg03022575	chr3:42003672	ULK4	-0.44	-5.17	-0.3	4.69e-7	Pulse pressure;Diastolic blood pressure;
CESC	trans	rs1908814	0.516	rs7812563	chr8:11794488	T/G	cg15556689	chr8:8085844	FLJ10661	0.5	6.18	0.35	2.46e-9	Neuroticism;
CESC	cis	rs2933343	0.700	rs789240	chr3:128630635	T/C	cg11901034	chr3:128598214	ACAD9	-0.39	-5.71	-0.33	3.1e-8	IgG glycosylation;
CESC	cis	rs17376456	0.741	rs10036829	chr5:93309897	G/C	cg25358565	chr5:93447407	FAM172A	1.07	10.61	0.55	3.7e-22	Diabetic retinopathy;
CESC	cis	rs7666738	0.830	rs4699588	chr4:98973789	A/G	cg17366294	chr4:99064904	C4orf37	0.59	8.43	0.46	2.31e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs13191362	1.000	rs13220048	chr6:163004325	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.83	8.39	0.46	3.02e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs7098414	0.511	rs12262228	chr10:82160425	C/T	cg00277334	chr10:82204260	NA	-0.52	-7.68	-0.43	3.1400000000000003e-13	Post bronchodilator FEV1;
CESC	trans	rs17685	0.753	rs1639617	chr7:75701728	A/G	cg19862616	chr7:65841803	NCRNA00174	0.87	12.7	0.62	3.58e-29	Coffee consumption;Coffee consumption (cups per day);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11296937	chr11:64084966	PRDX5;TRMT112	0.53	6.3	0.36	1.25e-9	Gut microbiome composition (summer);
CESC	cis	rs1552244	1.000	rs61077902	chr3:10126153	T/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.89	12.19	0.6	2.01e-27	Alzheimer's disease;
CESC	cis	rs2576037	0.583	rs646128	chr18:44397691	A/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.34	5.39	0.31	1.59e-7	Personality dimensions;
CESC	cis	rs7666738	0.830	rs13134216	chr4:98919765	C/T	cg03467027	chr4:99064603	C4orf37	0.44	5.44	0.32	1.2e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7618915	0.571	rs67539070	chr3:52711974	T/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.64	0.38	1.82e-10	Bipolar disorder;
CESC	cis	rs761746	0.960	rs3818134	chr22:31926725	C/T	cg25791279	chr22:32026902	PISD	-0.54	-6.28	-0.36	1.41e-9	Intelligence;
CESC	cis	rs798554	0.718	rs1636247	chr7:2881917	A/G	cg13628971	chr7:2884303	GNA12	0.64	8.52	0.46	1.18e-15	Height;
CESC	cis	rs6484504	0.576	rs208093	chr11:31184400	C/T	cg14844989	chr11:31128820	NA	0.4	5.34	0.31	1.96e-7	Red blood cell count;
CESC	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.45	5.98	0.34	7.23e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7605827	0.930	rs12989038	chr2:15549862	A/T	cg19274914	chr2:15703543	NA	0.33	5.94	0.34	8.8e-9	Educational attainment (years of education);
CESC	cis	rs1008375	1.000	rs2159584	chr4:17620568	G/A	cg16339924	chr4:17578868	LAP3	0.61	7.65	0.43	3.64e-13	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	trans	rs2115172	0.836	rs4835799	chr5:122762229	A/G	cg20588892	chr5:87565114	TMEM161B	0.46	6.04	0.35	5.27e-9	Weight;
CESC	cis	rs10751667	0.666	rs7396677	chr11:958878	C/T	cg06064525	chr11:970664	AP2A2	-0.47	-9.35	-0.5	3.78e-18	Alzheimer's disease (late onset);
CESC	cis	rs2984613	1	rs2984613	chr1:156197380	C/T	cg25208724	chr1:156163844	SLC25A44	0.84	13.14	0.63	1.08e-30	Intracerebral hemorrhage;White matter hyperintensity burden;
CESC	cis	rs11190604	1.000	rs2273694	chr10:102256496	G/T	cg07080220	chr10:102295463	HIF1AN	0.66	6.37	0.36	8.35e-10	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs1499614	0.901	rs3936	chr7:66126489	C/T	cg18252515	chr7:66147081	NA	-1.42	-14.43	-0.66	3.04e-35	Gout;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg20284440	chr14:52118688	FRMD6	0.48	6.87	0.39	4.5e-11	Systemic lupus erythematosus;
CESC	cis	rs9811920	0.683	rs1718235	chr3:99583484	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.38	-6.32	-0.36	1.13e-9	Axial length;
CESC	cis	rs2295359	1.000	rs11209006	chr1:67619259	T/G	cg03340356	chr1:67600835	NA	0.3	5.04	0.3	8.52e-7	Psoriasis;
CESC	cis	rs763121	0.853	rs5750659	chr22:39068789	T/C	cg21395723	chr22:39101663	GTPBP1	0.42	5.32	0.31	2.17e-7	Menopause (age at onset);
CESC	cis	rs4595586	0.505	rs11613808	chr12:39390823	T/A	cg26384229	chr12:38710491	ALG10B	0.63	8.92	0.48	7.92e-17	Morning vs. evening chronotype;
CESC	cis	rs6728642	0.908	rs7588921	chr2:98021001	C/T	cg26665480	chr2:98280029	ACTR1B	-0.76	-6.65	-0.38	1.62e-10	Bipolar disorder lithium response (continuous) or schizophrenia;
CESC	cis	rs611744	0.625	rs11991891	chr8:109294858	G/A	cg21045802	chr8:109455806	TTC35	0.56	6.96	0.39	2.67e-11	Dupuytren's disease;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg09730672	chr8:86157838	CA13	-0.44	-6.22	-0.36	1.95e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs11822910	0.724	rs7106223	chr11:57190448	A/G	cg00522883	chr11:57194120	SLC43A3	-0.6	-5.92	-0.34	9.82e-9	Platelet distribution width;
CESC	cis	rs9487051	0.735	rs419106	chr6:109520067	C/G	cg01475377	chr6:109611718	NA	-0.37	-5.55	-0.32	6.76e-8	Reticulocyte fraction of red cells;
CESC	cis	rs2991971	0.933	rs666720	chr1:46020795	T/C	cg03146154	chr1:46216737	IPP	-0.44	-5.49	-0.32	9.48e-8	High light scatter reticulocyte count;
CESC	cis	rs7659604	0.521	rs4833773	chr4:122689245	C/T	cg19671926	chr4:122722719	EXOSC9	0.65	8.55	0.47	9.68e-16	Type 2 diabetes;
CESC	cis	rs10089	1.000	rs1962291	chr5:127445373	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.8	-10.95	-0.56	2.93e-23	Ileal carcinoids;
CESC	cis	rs6736093	0.966	rs11682629	chr2:112744299	G/A	cg12686935	chr2:112915763	FBLN7	-0.42	-5.45	-0.32	1.17e-7	Coronary artery disease;
CESC	cis	rs7666738	0.822	rs11097599	chr4:98959562	T/A	cg05340658	chr4:99064831	C4orf37	0.8	12.36	0.6	5.29e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3015497	0.537	rs3015470	chr14:51155787	A/G	cg26011998	chr14:51135199	SAV1	-0.52	-5.85	-0.34	1.46e-8	Mean platelet volume;
CESC	cis	rs7607369	0.536	rs12623740	chr2:219665715	T/A	cg02176678	chr2:219576539	TTLL4	-0.36	-6.26	-0.36	1.58e-9	Red blood cell count;Amyotrophic lateral sclerosis;
CESC	cis	rs6598955	0.671	rs12090258	chr1:26644698	C/T	cg19743891	chr1:26644573	UBXN11;CD52	0.35	5.09	0.3	6.68e-7	Obesity-related traits;
CESC	cis	rs873946	0.648	rs1548281	chr10:134552982	C/T	cg26818010	chr10:134567672	INPP5A	-0.85	-10.26	-0.53	5.27e-21	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs16867321	0.950	rs12472841	chr2:181491840	C/A	cg23363182	chr2:181467187	NA	-0.42	-5.61	-0.33	5.02e-8	Obesity;
CESC	cis	rs17641971	0.645	rs4873099	chr8:50025683	G/T	cg00325661	chr8:49890786	NA	0.38	5.35	0.31	1.9e-7	Blood metabolite levels;
CESC	cis	rs2115630	0.653	rs61394864	chr15:85170174	T/C	cg12501888	chr15:85177176	SCAND2	-0.5	-6.62	-0.38	1.95e-10	P wave terminal force;
CESC	cis	rs9291683	0.509	rs6849717	chr4:9958719	T/C	cg02734326	chr4:10020555	SLC2A9	-0.48	-7.11	-0.4	1.05e-11	Bone mineral density;
CESC	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.89	13.62	0.64	2.27e-32	Prudent dietary pattern;
CESC	cis	rs4237845	0.551	rs116263297	chr12:58273445	A/C	cg02175503	chr12:58329896	NA	0.51	6.12	0.35	3.33e-9	Intelligence (multi-trait analysis);
CESC	cis	rs6493487	0.512	rs117335843	chr15:51314455	C/G	cg02338191	chr15:51200825	AP4E1	0.59	5.39	0.31	1.56e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs13108904	0.539	rs13145722	chr4:1338422	T/A	cg22903657	chr4:1355424	KIAA1530	-0.4	-5.67	-0.33	3.82e-8	Obesity-related traits;
CESC	cis	rs9611519	0.780	rs3171692	chr22:41642212	C/T	cg03806693	chr22:41940476	POLR3H	-0.72	-7.8	-0.43	1.46e-13	Neuroticism;
CESC	trans	rs2727020	0.688	rs4929894	chr11:49196333	G/C	cg03929089	chr4:120376271	NA	-0.78	-11.59	-0.58	2.11e-25	Coronary artery disease;
CESC	cis	rs6456156	0.586	rs7761977	chr6:167485678	A/G	cg23791538	chr6:167370224	RNASET2	-0.5	-6.37	-0.36	8.51e-10	Primary biliary cholangitis;
CESC	cis	rs2832191	1.000	rs2832185	chr21:30483761	C/G	cg24692254	chr21:30365293	RNF160	-0.7	-10.47	-0.54	1.09e-21	Dental caries;
CESC	cis	rs597539	0.654	rs619727	chr11:68627535	A/G	cg21963583	chr11:68658836	MRPL21	0.41	5.57	0.32	6.29e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs7666738	0.830	rs2903150	chr4:99027184	T/C	cg17366294	chr4:99064904	C4orf37	0.62	8.95	0.48	6.32e-17	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4862750	0.872	rs7672831	chr4:187898882	C/T	cg03647317	chr4:187891568	NA	-0.39	-5.84	-0.34	1.49e-8	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2997447	0.655	rs55820521	chr1:26374286	C/T	cg19633962	chr1:26362018	EXTL1	-0.58	-5.66	-0.33	4.02e-8	QRS complex (12-leadsum);
CESC	cis	rs921968	0.565	rs755112	chr2:219606052	C/T	cg02176678	chr2:219576539	TTLL4	-0.46	-8.21	-0.45	9.84e-15	Mean corpuscular hemoglobin concentration;
CESC	cis	rs9649213	0.593	rs3801255	chr7:98000929	C/T	cg00277769	chr7:97922759	BAIAP2L1	-0.33	-5.41	-0.32	1.41e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs2735413	0.709	rs8051521	chr16:78088156	G/C	cg04733911	chr16:78082701	NA	0.53	8.56	0.47	9.02e-16	Systolic blood pressure (alcohol consumption interaction);
CESC	cis	rs7552167	1.000	rs59960858	chr1:24519437	C/A	cg01960748	chr1:24522592	NA	0.49	6.35	0.36	9.35e-10	Psoriasis vulgaris;
CESC	cis	rs7959452	0.590	rs11177619	chr12:69758871	G/A	cg20891283	chr12:69753455	YEATS4	0.9	14.78	0.67	1.84e-36	Blood protein levels;
CESC	cis	rs454510	0.816	rs347904	chr1:120177620	C/T	cg16322792	chr1:120165303	ZNF697	0.45	7.12	0.4	1.01e-11	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
CESC	cis	rs977987	0.806	rs56343285	chr16:75409797	A/G	cg03315344	chr16:75512273	CHST6	0.4	5.72	0.33	2.88e-8	Dupuytren's disease;
CESC	cis	rs5747327	0.874	rs5747329	chr22:18170207	A/G	cg19898043	chr22:18121309	BCL2L13	-0.42	-5.31	-0.31	2.34e-7	Myeloid white cell count;Granulocyte count;
CESC	cis	rs9611565	0.659	rs169361	chr22:41877989	A/G	cg03806693	chr22:41940476	POLR3H	1.21	14.96	0.68	4.35e-37	Vitiligo;
CESC	cis	rs9910055	0.718	rs7212854	chr17:42254417	A/G	cg19774624	chr17:42201019	HDAC5	-0.68	-9.83	-0.52	1.21e-19	Total body bone mineral density;
CESC	cis	rs9488822	0.676	rs13194714	chr6:116394819	T/A	cg26893134	chr6:116381904	FRK	0.25	6.15	0.35	2.83e-9	Cholesterol, total;LDL cholesterol;
CESC	cis	rs2710642	0.611	rs11125941	chr2:62880818	A/C	cg17519650	chr2:63277830	OTX1	0.49	5.78	0.33	2.11e-8	LDL cholesterol levels;LDL cholesterol;
CESC	cis	rs6088580	0.543	rs4911158	chr20:33239512	T/C	cg08999081	chr20:33150536	PIGU	-0.43	-6.17	-0.35	2.49e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs977987	0.843	rs62062568	chr16:75445324	T/C	cg03315344	chr16:75512273	CHST6	0.4	5.83	0.34	1.57e-8	Dupuytren's disease;
CESC	cis	rs2230307	0.505	rs571579	chr1:100617372	G/A	cg24955406	chr1:100503596	HIAT1	-0.49	-5.18	-0.3	4.35e-7	Carotid intima media thickness;
CESC	cis	rs9322193	0.923	rs12174349	chr6:150039148	G/A	cg04369109	chr6:150039330	LATS1	-0.41	-5.81	-0.34	1.82e-8	Lung cancer;
CESC	cis	rs2404602	0.647	rs11072618	chr15:77019342	A/G	cg23625390	chr15:77176239	SCAPER	-0.4	-5.2	-0.3	4e-7	Blood metabolite levels;
CESC	cis	rs910316	1.000	rs175443	chr14:75601963	C/T	cg08847533	chr14:75593920	NEK9	-0.96	-17.98	-0.74	8.46e-48	Height;
CESC	cis	rs1448094	0.511	rs61930582	chr12:86157387	T/C	cg00310523	chr12:86230176	RASSF9	0.35	5.42	0.32	1.34e-7	Major depressive disorder;
CESC	cis	rs35110281	0.633	rs4819292	chr21:45125223	A/G	cg04455712	chr21:45112962	RRP1B	0.49	7.76	0.43	1.9e-13	Mean corpuscular volume;
CESC	cis	rs4253772	0.550	rs6008615	chr22:46707928	G/A	cg00784671	chr22:46762841	CELSR1	-0.48	-5.52	-0.32	7.99e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs875971	0.638	rs3898855	chr7:66036398	G/C	cg18876405	chr7:65276391	NA	-0.57	-7.75	-0.43	1.97e-13	Aortic root size;
CESC	cis	rs35110281	0.667	rs7282405	chr21:45123611	C/G	cg21573476	chr21:45109991	RRP1B	-0.57	-8.59	-0.47	7.81e-16	Mean corpuscular volume;
CESC	cis	rs3617	0.652	rs60332615	chr3:52867595	C/A	cg11645453	chr3:52864694	ITIH4	-0.26	-5.19	-0.3	4.13e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
CESC	cis	rs10540	1.000	rs61876332	chr11:487101	C/T	cg03352830	chr11:487213	PTDSS2	0.7	6.71	0.38	1.16e-10	Body mass index;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg06408034	chr1:45671987	ZSWIM5	-0.49	-6.4	-0.37	7.19e-10	Height;
CESC	cis	rs10927875	0.632	rs7535248	chr1:16129598	C/T	cg05821634	chr1:16164109	FLJ37453	0.35	5.08	0.3	6.97e-7	Dilated cardiomyopathy;
CESC	cis	rs910316	0.712	rs175037	chr14:75465038	T/C	cg08847533	chr14:75593920	NEK9	-0.9	-15.84	-0.7	3.34e-40	Height;
CESC	cis	rs12142240	0.698	rs72677600	chr1:46834449	G/A	cg00530320	chr1:46809349	NSUN4	0.63	8.16	0.45	1.33e-14	Menopause (age at onset);
CESC	cis	rs7208859	0.623	rs59029591	chr17:29235746	A/C	cg19761014	chr17:28927070	LRRC37B2	0.71	5.63	0.33	4.48e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs2836974	0.545	rs3167757	chr21:40714478	C/T	cg11644478	chr21:40555479	PSMG1	0.61	8.28	0.45	6.17e-15	Cognitive function;
CESC	trans	rs7326068	0.610	rs7990231	chr13:21337838	C/T	cg00192819	chr18:76486611	NA	0.43	6.13	0.35	3.11e-9	Schizophrenia, bipolar disorder and depression (combined);
CESC	cis	rs3106136	0.527	rs2883	chr4:95158610	A/T	cg11021082	chr4:95130006	SMARCAD1	-0.7	-11.57	-0.58	2.49e-25	Capecitabine sensitivity;
CESC	cis	rs11648796	0.765	rs2003832	chr16:769538	G/A	cg27144592	chr16:783916	NARFL	0.5	6.46	0.37	5.09e-10	Height;
CESC	cis	rs9467711	0.606	rs9348712	chr6:26366511	T/A	cg12826209	chr6:26865740	GUSBL1	0.61	5.17	0.3	4.59e-7	Autism spectrum disorder or schizophrenia;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg15057251	chr18:32621312	MAPRE2	0.51	7.13	0.4	9.36e-12	Systemic lupus erythematosus;
CESC	cis	rs4819052	1.000	rs3746980	chr21:46711580	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.63	7.65	0.43	3.8e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs2842992	0.915	rs2758335	chr6:160111011	G/A	cg11366901	chr6:160182831	ACAT2	0.76	9.68	0.51	3.64e-19	Age-related macular degeneration (geographic atrophy);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18145393	chr4:520203	PIGG	-0.64	-6.83	-0.39	5.71e-11	Gut microbiome composition (summer);
CESC	cis	rs2361718	0.527	rs7211994	chr17:78152514	A/G	cg06718696	chr17:78121285	EIF4A3	-0.49	-6.71	-0.38	1.2e-10	Yeast infection;
CESC	cis	rs4664308	1.000	rs17831191	chr2:160911332	T/C	cg03641300	chr2:160917029	PLA2R1	-0.68	-10.17	-0.53	9.82e-21	Idiopathic membranous nephropathy;
CESC	cis	rs939658	0.805	rs6495374	chr15:79434031	C/T	cg17916960	chr15:79447300	NA	-0.36	-6.06	-0.35	4.67e-9	Refractive error;
CESC	cis	rs7666738	0.830	rs10014986	chr4:99000687	A/C	cg18180107	chr4:99064573	C4orf37	0.4	5.23	0.31	3.41e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs67311347	1.000	rs12633431	chr3:40505740	C/T	cg09455208	chr3:40491958	NA	-0.48	-8.14	-0.45	1.52e-14	Renal cell carcinoma;
CESC	cis	rs17253792	0.732	rs75796044	chr14:56034128	C/T	cg01858014	chr14:56050164	KTN1	-0.82	-6.56	-0.37	2.83e-10	Putamen volume;
CESC	cis	rs7666738	0.830	rs1813972	chr4:98886828	C/A	cg17366294	chr4:99064904	C4orf37	0.54	7.41	0.41	1.65e-12	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4434138	0.683	rs13063160	chr3:52602274	T/C	cg18337363	chr3:52569053	NT5DC2	0.3	5.57	0.32	6.38e-8	Intelligence (multi-trait analysis);
CESC	trans	rs561341	1.000	rs508192	chr17:30315147	C/T	cg20587970	chr11:113659929	NA	1.36	16.18	0.7	2.03e-41	Hip circumference adjusted for BMI;
CESC	cis	rs3785574	1.000	rs3785574	chr17:61763185	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.59	6.94	0.39	2.92e-11	Height;
CESC	cis	rs4268898	0.896	rs2702042	chr2:24546542	C/T	cg06627628	chr2:24431161	ITSN2	-0.69	-8.44	-0.46	2.11e-15	Asthma;
CESC	cis	rs9583531	0.527	rs2391866	chr13:111363294	A/T	cg24331049	chr13:111365604	ING1	0.75	10.98	0.56	2.28e-23	Coronary artery disease;
CESC	cis	rs7666738	0.830	rs13139078	chr4:99020774	C/T	cg03467027	chr4:99064603	C4orf37	0.46	5.81	0.34	1.8e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1950626	0.716	rs34572720	chr14:101447150	G/A	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.82	11.17	0.57	5.57e-24	Pelvic organ prolapse (moderate/severe);
CESC	cis	rs344364	0.511	rs12599337	chr16:1946751	A/G	cg03013636	chr16:1946785	NA	-0.41	-5.63	-0.33	4.71e-8	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs6456156	0.716	rs6905876	chr6:167521562	C/T	cg07741184	chr6:167504864	NA	0.36	5.99	0.35	6.67e-9	Primary biliary cholangitis;
CESC	cis	rs4664304	0.754	rs17829052	chr2:160821067	G/A	cg03641300	chr2:160917029	PLA2R1	-0.41	-5.59	-0.33	5.5e-8	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs3126085	0.935	rs4326625	chr1:152223996	C/T	cg09127314	chr1:152161683	NA	0.47	5.09	0.3	6.96e-7	Atopic dermatitis;
CESC	cis	rs2629540	0.924	rs2629541	chr10:126425866	G/A	cg08799069	chr10:126477246	METTL10	0.69	8.41	0.46	2.52e-15	Cocaine dependence;
CESC	cis	rs7809950	1.000	rs4727681	chr7:107096144	T/C	cg23024343	chr7:107201750	COG5	-0.41	-5.78	-0.33	2.12e-8	Coronary artery disease;
CESC	cis	rs12477438	0.501	rs13000731	chr2:99795231	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.78	12.45	0.61	2.6e-28	Chronic sinus infection;
CESC	cis	rs4268898	0.560	rs2384007	chr2:24514841	A/G	cg20701182	chr2:24300061	SF3B14	0.54	5.71	0.33	2.99e-8	Asthma;
CESC	cis	rs916888	0.610	rs199453	chr17:44800946	C/T	cg17911788	chr17:44343683	NA	-0.43	-6.77	-0.38	8.27e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs2354432	0.556	rs57388899	chr1:146773422	T/C	cg25205988	chr1:146714368	CHD1L	-0.96	-10.48	-0.54	1.03e-21	Mitochondrial DNA levels;
CESC	cis	rs9733	0.596	rs12089989	chr1:150715782	G/A	cg04414720	chr1:150670196	GOLPH3L	0.54	7.57	0.42	6.18e-13	Tonsillectomy;
CESC	cis	rs6952808	0.895	rs12669518	chr7:1921429	G/C	cg02951883	chr7:2050386	MAD1L1	-0.49	-6.5	-0.37	3.96e-10	Bipolar disorder and schizophrenia;
CESC	cis	rs7582720	1.000	rs114123510	chr2:203831212	T/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.36	0.41	2.34e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00815117	chr17:27085788	C17orf63	-0.61	-6.72	-0.38	1.1e-10	Gut microbiome composition (summer);
CESC	cis	rs2063714	0.658	rs12196864	chr6:157212862	C/T	cg23222435	chr6:157204239	ARID1B	-0.42	-5.43	-0.32	1.27e-7	Sitting height ratio;
CESC	cis	rs8033133	0.957	rs7162559	chr15:25352341	C/T	cg14481604	chr15:25334117	SNORD116-22	0.36	5.21	0.3	3.76e-7	Blood osmolality (transformed sodium);
CESC	cis	rs3733585	0.624	rs58130873	chr4:9972081	T/C	cg11266682	chr4:10021025	SLC2A9	-0.58	-10.87	-0.56	5.3e-23	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs12477438	0.765	rs4851183	chr2:99629149	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.62	-8.67	-0.47	4.43e-16	Chronic sinus infection;
CESC	cis	rs11792861	0.926	rs75472294	chr9:111804239	G/A	cg05043794	chr9:111880884	C9orf5	-0.4	-6.65	-0.38	1.7e-10	Menarche (age at onset);
CESC	cis	rs10979	1.000	rs9496671	chr6:143884742	G/A	cg25407410	chr6:143891975	LOC285740	-0.63	-9.54	-0.51	9.83e-19	Hypospadias;
CESC	cis	rs701145	0.556	rs355764	chr3:154013480	A/T	cg16511985	chr3:153974050	SGEF	0.42	5.94	0.34	8.7e-9	Coronary artery disease;
CESC	cis	rs910316	1.000	rs4903289	chr14:75623988	C/T	cg08847533	chr14:75593920	NEK9	-1.0	-20.02	-0.78	6.05e-55	Height;
CESC	cis	rs7772486	0.719	rs702307	chr6:145993454	C/G	cg23711669	chr6:146136114	FBXO30	-1.0	-15.53	-0.69	4.13e-39	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6540556	0.608	rs2205985	chr1:209912100	A/G	cg05527609	chr1:210001259	C1orf107	-0.43	-5.07	-0.3	7.55e-7	Red blood cell count;
CESC	cis	rs965469	0.948	rs2236094	chr20:3260368	C/G	cg25506879	chr20:3388711	C20orf194	0.56	6.12	0.35	3.35e-9	IFN-related cytopenia;
CESC	cis	rs4555082	0.957	rs2816608	chr14:105718407	A/G	cg13114125	chr14:105738426	BRF1	0.58	7.46	0.42	1.26e-12	Mean platelet volume;Platelet distribution width;
CESC	cis	rs896854	0.654	rs4735337	chr8:95973465	T/C	cg09323728	chr8:95962352	TP53INP1	-0.4	-8.71	-0.47	3.25e-16	Type 2 diabetes;
CESC	cis	rs116095464	0.558	rs10080225	chr5:232175	A/G	cg22857025	chr5:266934	NA	-1.29	-18.24	-0.75	1.01e-48	Breast cancer;
CESC	cis	rs853679	1.000	rs9986596	chr6:28219661	G/A	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.78	7.97	0.44	4.83e-14	Depression;
CESC	cis	rs7914558	1.000	rs10509757	chr10:104752960	C/T	cg15744005	chr10:104629667	AS3MT	-0.34	-5.59	-0.32	5.64e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	trans	rs1728785	1.000	rs11075680	chr16:68565700	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.61	7.42	0.41	1.57e-12	Ulcerative colitis;
CESC	cis	rs7647973	0.769	rs6446204	chr3:49034879	T/C	cg07636037	chr3:49044803	WDR6	0.87	11.14	0.56	6.91e-24	Menarche (age at onset);
CESC	cis	rs1799949	1.000	rs33926631	chr17:41304463	T/C	cg25072359	chr17:41440525	NA	0.43	5.76	0.33	2.39e-8	Menopause (age at onset);
CESC	cis	rs35306767	0.903	rs10904577	chr10:922077	A/G	cg20503657	chr10:835505	NA	0.76	7.59	0.42	5.51e-13	Eosinophil percentage of granulocytes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08708735	chr7:1609515	KIAA1908;PSMG3	0.65	7.72	0.43	2.33e-13	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.830	rs28852677	chr4:99039509	T/G	cg24818145	chr4:99064322	C4orf37	0.38	5.04	0.3	8.49e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6964587	0.934	rs7798973	chr7:91588360	G/A	cg17063962	chr7:91808500	NA	0.58	7.94	0.44	5.67e-14	Breast cancer;
CESC	cis	rs4665809	0.590	rs7604564	chr2:26501953	C/A	cg26119090	chr2:26468346	HADHA;HADHB	1.05	11.85	0.59	2.86e-26	Gut microbiome composition (summer);
CESC	cis	rs7584330	0.740	rs12471291	chr2:238441751	T/G	cg06639874	chr2:238417703	MLPH	-0.37	-5.23	-0.31	3.41e-7	Prostate cancer;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg13063040	chr8:145669623	NFKBIL2	-0.47	-6.54	-0.37	3.23e-10	Fibrinogen levels;
CESC	cis	rs7940866	0.838	rs10750455	chr11:130800330	C/T	cg12179176	chr11:130786555	SNX19	0.67	10.2	0.53	8.24e-21	Schizophrenia;
CESC	cis	rs11650776	1	rs11650776	chr17:37641402	G/A	cg00129232	chr17:37814104	STARD3	-0.54	-7.14	-0.4	9.08e-12	Lung function (FEV1);
CESC	trans	rs1728785	1.000	rs1728765	chr16:68589433	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.65	7.81	0.43	1.32e-13	Ulcerative colitis;
CESC	cis	rs2180341	0.782	rs6912552	chr6:127722946	C/G	cg24812749	chr6:127587940	RNF146	-0.82	-11.93	-0.59	1.46e-26	Breast cancer;
CESC	cis	rs7618915	0.533	rs35107891	chr3:52613656	G/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.39	6.77	0.38	8.17e-11	Bipolar disorder;
CESC	trans	rs17808461	1.000	rs7214574	chr17:31374848	C/A	cg01914314	chr5:157117640	NA	-0.51	-6.22	-0.36	1.98e-9	Obesity-related traits;
CESC	cis	rs2425143	1.000	rs7267759	chr20:34257284	G/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.61	5.16	0.3	4.75e-7	Blood protein levels;
CESC	cis	rs854765	0.693	rs8079418	chr17:17924060	C/T	cg16928487	chr17:17741425	SREBF1	-0.52	-9.13	-0.49	1.83e-17	Total body bone mineral density;
CESC	cis	rs11148252	0.532	rs9536262	chr13:53303074	A/C	cg00495681	chr13:53174319	NA	-0.62	-8.67	-0.47	4.54e-16	Lewy body disease;
CESC	trans	rs7615952	0.512	rs2979336	chr3:125357470	G/A	cg07211511	chr3:129823064	LOC729375	-0.59	-7.19	-0.4	6.46e-12	Blood pressure (smoking interaction);
CESC	cis	rs4662945	0.525	rs28625431	chr2:130303333	A/G	cg05903289	chr2:130345205	NA	-0.44	-7.02	-0.4	1.91e-11	Response to cytidine analogues (gemcitabine);
CESC	cis	rs2836974	0.644	rs719230	chr21:40676307	C/T	cg11644478	chr21:40555479	PSMG1	-0.81	-12.01	-0.59	8.15e-27	Cognitive function;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg27022615	chr11:70049105	FADD	-0.47	-6.09	-0.35	4.05e-9	Height;
CESC	cis	rs4974559	0.947	rs6847321	chr4:1347374	C/T	cg02475777	chr4:1388615	CRIPAK	0.5	5.09	0.3	6.83e-7	Systolic blood pressure;
CESC	cis	rs6963495	0.818	rs73192126	chr7:105175415	T/C	cg19920283	chr7:105172520	RINT1	0.68	6.44	0.37	5.53e-10	Bipolar disorder (body mass index interaction);
CESC	cis	rs561341	1.000	rs2344312	chr17:30243583	G/T	cg13647721	chr17:30228624	UTP6	0.7	7.41	0.41	1.68e-12	Hip circumference adjusted for BMI;
CESC	cis	rs3820928	0.904	rs10188570	chr2:227792540	G/A	cg05526886	chr2:227700861	RHBDD1	-0.48	-5.83	-0.34	1.62e-8	Pulmonary function;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23348582	chr14:82000250	SEL1L	0.53	6.09	0.35	4.03e-9	Gut microbiome composition (summer);
CESC	cis	rs2645694	0.532	rs2645706	chr4:77829606	A/C	cg18351406	chr4:77819688	ANKRD56	0.49	5.92	0.34	9.69e-9	Emphysema distribution in smoking;
CESC	cis	rs7103648	0.897	rs3758675	chr11:47400602	G/A	cg20307385	chr11:47447363	PSMC3	0.95	14.26	0.66	1.26e-34	Diastolic blood pressure;Systolic blood pressure;
CESC	cis	rs965469	0.779	rs6037544	chr20:3290570	A/G	cg25506879	chr20:3388711	C20orf194	-0.49	-5.4	-0.31	1.48e-7	IFN-related cytopenia;
CESC	trans	rs16893526	0.858	rs1931644	chr6:82579675	T/C	cg07163173	chr2:67624373	ETAA1	0.79	6.0	0.35	6.4e-9	Coronary heart disease;
CESC	cis	rs9486715	0.867	rs9384585	chr6:96875664	C/T	cg18709589	chr6:96969512	KIAA0776	0.45	6.46	0.37	5.05e-10	Headache;
CESC	cis	rs1218582	0.741	rs11264281	chr1:154867221	A/G	cg16680214	chr1:154839983	KCNN3	-0.53	-8.23	-0.45	8.61e-15	Prostate cancer;
CESC	cis	rs6912958	0.559	rs376633	chr6:88042785	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.45	8.01	0.44	3.73e-14	Monocyte percentage of white cells;
CESC	cis	rs875971	0.862	rs3926380	chr7:66080645	G/T	cg12463550	chr7:65579703	CRCP	-0.53	-6.77	-0.38	8.05e-11	Aortic root size;
CESC	trans	rs5756813	0.688	rs8140207	chr22:38130459	G/T	cg19894588	chr14:64061835	NA	-0.65	-7.57	-0.42	6.16e-13	Optic cup area;Vertical cup-disc ratio;
CESC	cis	rs7666738	0.830	rs1426668	chr4:98945585	T/A	cg03676636	chr4:99064102	C4orf37	0.34	5.11	0.3	6.15e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs35306767	0.953	rs12762973	chr10:960761	C/G	cg25019033	chr10:957182	NA	-0.66	-7.71	-0.43	2.59e-13	Eosinophil percentage of granulocytes;
CESC	cis	rs7605827	0.930	rs11691392	chr2:15498781	C/T	cg19274914	chr2:15703543	NA	0.31	5.64	0.33	4.41e-8	Educational attainment (years of education);
CESC	cis	rs12042938	0.507	rs1655299	chr1:231732161	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.58	-8.44	-0.46	2.13e-15	Neuranatomic and neurocognitive phenotypes;
CESC	cis	rs9916302	0.706	rs1874226	chr17:37729031	C/T	cg07936489	chr17:37558343	FBXL20	0.97	11.36	0.57	1.21e-24	Glomerular filtration rate (creatinine);
CESC	cis	rs66573146	0.572	rs66819208	chr4:6946128	A/G	cg26116260	chr4:7069785	GRPEL1	-0.8	-5.23	-0.31	3.39e-7	Granulocyte percentage of myeloid white cells;
CESC	cis	rs7208859	0.673	rs73271887	chr17:29154935	T/C	cg19761014	chr17:28927070	LRRC37B2	0.74	6.03	0.35	5.43e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs853679	0.517	rs9348797	chr6:28137533	G/C	cg19592336	chr6:28129416	ZNF389	0.58	7.71	0.43	2.54e-13	Depression;
CESC	cis	rs546131	0.928	rs550313	chr11:34830919	C/T	cg06937548	chr11:34938143	PDHX;APIP	0.53	6.55	0.37	3.03e-10	Lung disease severity in cystic fibrosis;
CESC	cis	rs7916697	0.947	rs7916410	chr10:69995667	T/C	cg06988349	chr10:69991859	ATOH7	-0.37	-5.96	-0.34	8.14e-9	Optic disc area;
CESC	cis	rs2486288	0.656	rs11854365	chr15:45558083	G/A	cg21132104	chr15:45694354	SPATA5L1	-0.55	-6.71	-0.38	1.16e-10	Glomerular filtration rate;
CESC	cis	rs476633	0.691	rs28409265	chr15:41539404	G/A	cg12386646	chr15:41787261	ITPKA	0.35	5.19	0.3	4.24e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs7618501	0.538	rs9856572	chr3:50109073	A/T	cg24110177	chr3:50126178	RBM5	0.54	7.52	0.42	8.46e-13	Intelligence (multi-trait analysis);
CESC	cis	rs12618769	0.625	rs72819970	chr2:99034554	C/G	cg10123293	chr2:99228465	UNC50	0.38	5.06	0.3	7.83e-7	Bipolar disorder;
CESC	cis	rs1506636	0.962	rs1019220	chr7:123365122	G/A	cg03229431	chr7:123269106	ASB15	-0.52	-6.91	-0.39	3.58e-11	Plateletcrit;Platelet count;
CESC	trans	rs7618501	0.966	rs13063621	chr3:49821625	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.59	8.41	0.46	2.54e-15	Intelligence (multi-trait analysis);
CESC	cis	rs12497850	0.931	rs6446253	chr3:48911443	C/T	cg07636037	chr3:49044803	WDR6	1.02	19.13	0.76	7.5e-52	Parkinson's disease;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg07017209	chr1:220263177	BPNT1	-0.48	-6.3	-0.36	1.2e-9	Ulcerative colitis;
CESC	cis	rs3806843	0.801	rs801170	chr5:140115343	C/T	cg26395211	chr5:140044315	WDR55	0.45	5.99	0.35	6.94e-9	Depressive symptoms (multi-trait analysis);
CESC	cis	rs1035144	0.506	rs7150858	chr14:81280425	T/C	cg06600135	chr14:81408086	NA	-0.47	-6.42	-0.37	6.37e-10	Male sexual orientation;
CESC	cis	rs2033711	0.783	rs8113810	chr19:58932106	A/G	cg26874164	chr19:58962979	ZNF324B	0.54	7.41	0.41	1.7e-12	Uric acid clearance;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg24128593	chr6:151712759	ZBTB2	-0.51	-6.52	-0.37	3.52e-10	Ulcerative colitis;
CESC	cis	rs67311347	0.544	rs9877105	chr3:40333366	T/C	cg09455208	chr3:40491958	NA	0.35	6.27	0.36	1.43e-9	Renal cell carcinoma;
CESC	cis	rs7555523	0.830	rs6426936	chr1:165684707	C/T	cg24409356	chr1:165738333	TMCO1	-0.84	-7.71	-0.43	2.57e-13	Intraocular pressure;Glaucoma (high intraocular pressure);
CESC	cis	rs4665809	1.000	rs6704930	chr2:26325705	G/A	cg04944784	chr2:26401820	FAM59B	-0.66	-7.53	-0.42	8.04e-13	Gut microbiome composition (summer);
CESC	cis	rs2267137	0.835	rs2267133	chr22:29765382	A/T	cg07256473	chr22:29710276	RASL10A	0.41	6.38	0.36	8.08e-10	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	trans	rs8016982	0.520	rs7160599	chr14:81713739	C/T	cg26740341	chr6:22874184	NA	0.44	6.07	0.35	4.53e-9	Schizophrenia;
CESC	cis	rs2243480	1.000	rs160639	chr7:65579987	C/G	cg13147721	chr7:65941812	NA	-0.96	-9.13	-0.49	1.79e-17	Diabetic kidney disease;
CESC	cis	rs2559856	1.000	rs2695288	chr12:102088112	T/C	cg15068132	chr12:102092402	CHPT1	-0.42	-5.59	-0.33	5.5e-8	Blood protein levels;
CESC	cis	rs7727544	0.571	rs12521097	chr5:131575338	G/A	cg04518342	chr5:131593106	PDLIM4	0.38	5.33	0.31	2.1e-7	Blood metabolite levels;
CESC	cis	rs7618915	0.547	rs11130323	chr3:52770277	T/C	cg07507251	chr3:52567010	NT5DC2	0.42	7.2	0.4	6.23e-12	Bipolar disorder;
CESC	cis	rs7186908	0.793	rs7191623	chr16:72212044	G/A	cg01557791	chr16:72042693	DHODH	-0.7	-7.32	-0.41	2.88e-12	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs1044826	0.642	rs2118981	chr3:139178853	A/G	cg00490450	chr3:139108681	COPB2	0.4	5.03	0.3	9.23e-7	Obesity-related traits;
CESC	cis	rs4665809	0.590	rs13016807	chr2:26496186	G/C	cg04944784	chr2:26401820	FAM59B	0.92	9.76	0.51	2.02e-19	Gut microbiome composition (summer);
CESC	cis	rs854765	0.718	rs7224815	chr17:17845800	A/T	cg16928487	chr17:17741425	SREBF1	-0.57	-9.45	-0.5	1.91e-18	Total body bone mineral density;
CESC	cis	rs7917772	0.503	rs11191330	chr10:104306160	G/T	ch.10.2196322F	chr10:104248062	ACTR1A	0.43	5.38	0.31	1.64e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs7264396	0.790	rs761826	chr20:34194243	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-8.45	-0.46	2.02e-15	Total cholesterol levels;
CESC	cis	rs12477438	0.765	rs62154638	chr2:99639584	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.64	-8.73	-0.47	2.94e-16	Chronic sinus infection;
CESC	cis	rs7520050	0.931	rs1707333	chr1:46547035	C/G	cg03146154	chr1:46216737	IPP	-0.44	-5.69	-0.33	3.34e-8	Red blood cell count;Reticulocyte count;
CESC	cis	rs4665809	0.590	rs66477033	chr2:26472497	T/C	cg08470875	chr2:26401718	FAM59B	0.75	7.78	0.43	1.63e-13	Gut microbiome composition (summer);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg26071963	chr14:88945568	PTPN21	0.51	6.93	0.39	3.24e-11	Fibrinogen levels;
CESC	cis	rs6570726	0.764	rs9399553	chr6:145873664	A/T	cg23711669	chr6:146136114	FBXO30	1.03	15.92	0.7	1.7e-40	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9787249	0.957	rs12239844	chr1:40217258	T/C	cg19912559	chr1:40204330	PPIE	0.42	6.48	0.37	4.44e-10	Blood protein levels;
CESC	cis	rs6681460	0.966	rs10889642	chr1:67143334	T/G	cg02459107	chr1:67143332	SGIP1	0.36	5.15	0.3	4.99e-7	Presence of antiphospholipid antibodies;
CESC	cis	rs116095464	0.558	rs62344345	chr5:257420	C/T	cg22496380	chr5:211416	CCDC127	-0.73	-8.39	-0.46	2.99e-15	Breast cancer;
CESC	cis	rs734999	0.505	rs4648659	chr1:2560903	T/G	cg20673091	chr1:2541236	MMEL1	-0.48	-8.01	-0.44	3.71e-14	Ulcerative colitis;
CESC	cis	rs10751667	1.000	rs10751667	chr11:941941	A/T	cg01483505	chr11:975446	AP2A2	0.39	5.24	0.31	3.27e-7	Alzheimer's disease (late onset);
CESC	cis	rs425277	0.628	rs262662	chr1:2085033	A/G	cg24578937	chr1:2090814	PRKCZ	0.38	6.65	0.38	1.71e-10	Height;
CESC	cis	rs61776719	0.520	rs11485595	chr1:38411350	C/T	cg12658694	chr1:38397304	INPP5B	0.64	9.15	0.49	1.53e-17	Coronary artery disease;
CESC	cis	rs13720	0.722	rs191490	chr20:57576180	A/G	cg23907860	chr20:57583709	CTSZ	-0.49	-6.01	-0.35	6.26e-9	Platelet distribution width;
CESC	cis	rs6998277	1.000	rs6998277	chr8:103639941	T/C	cg10187029	chr8:103597600	NA	0.47	5.56	0.32	6.59e-8	Migraine;
CESC	cis	rs7208859	0.673	rs11652370	chr17:29097223	G/A	cg14008862	chr17:28927542	LRRC37B2	0.55	5.21	0.3	3.78e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs7937682	0.883	rs484834	chr11:111465761	G/C	cg22437258	chr11:111473054	SIK2	0.71	9.19	0.49	1.16e-17	Primary sclerosing cholangitis;
CESC	cis	rs870825	0.860	rs72703519	chr4:185602707	G/A	cg04058563	chr4:185651563	MLF1IP	0.54	5.24	0.31	3.27e-7	Blood protein levels;
CESC	cis	rs9916302	0.904	rs2303316	chr17:37704217	A/G	cg20243544	chr17:37824526	PNMT	0.48	6.03	0.35	5.4e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs11098499	0.566	rs7664440	chr4:120578540	A/G	cg24375607	chr4:120327624	NA	0.44	5.31	0.31	2.3e-7	Corneal astigmatism;
CESC	cis	rs11711311	1.000	rs9826808	chr3:113455644	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.72	10.27	0.53	4.81e-21	IgG glycosylation;
CESC	cis	rs11785400	0.731	rs4736363	chr8:143742112	C/A	cg10596483	chr8:143751796	JRK	0.41	5.28	0.31	2.64e-7	Schizophrenia;
CESC	cis	rs875971	0.964	rs55748098	chr7:65763618	T/C	cg11764359	chr7:65958608	NA	-0.94	-15.5	-0.69	5.29e-39	Aortic root size;
CESC	trans	rs116095464	0.558	rs9654453	chr5:299621	T/C	cg00938859	chr5:1591904	SDHAP3	0.71	6.56	0.37	2.86e-10	Breast cancer;
CESC	cis	rs6570726	0.791	rs398408	chr6:145801020	G/A	cg05347473	chr6:146136440	FBXO30	0.57	7.38	0.41	2.04e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs8062405	0.755	rs4788074	chr16:28593597	A/G	cg07382826	chr16:28625726	SULT1A1	-0.4	-6.69	-0.38	1.3e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs780096	0.546	rs35073769	chr2:27731376	C/T	cg12648201	chr2:27665141	KRTCAP3	-0.33	-5.84	-0.34	1.52e-8	Total body bone mineral density;
CESC	cis	rs10504229	0.683	rs2318148	chr8:58114955	G/A	cg24829409	chr8:58192753	C8orf71	-0.58	-7.2	-0.4	6.31e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs780096	0.565	rs813592	chr2:27721971	T/C	cg02592271	chr2:27665507	KRTCAP3	-0.32	-6.54	-0.37	3.19e-10	Total body bone mineral density;
CESC	cis	rs3785574	0.962	rs2584632	chr17:61880641	G/A	cg06420487	chr17:61919686	SMARCD2	0.45	5.36	0.31	1.82e-7	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14001871	chr13:113488290	ATP11A	-0.5	-6.07	-0.35	4.51e-9	Gut microbiome composition (summer);
CESC	cis	rs12497850	1.000	rs4858828	chr3:48724811	C/T	cg07636037	chr3:49044803	WDR6	0.9	15.21	0.68	5.33e-38	Parkinson's disease;
CESC	cis	rs9311474	0.508	rs7625743	chr3:52606366	C/G	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.33	6.0	0.35	6.28e-9	Electroencephalogram traits;
CESC	cis	rs9300255	0.770	rs28683528	chr12:123845351	C/T	cg19016782	chr12:123741754	C12orf65	0.44	6.2	0.36	2.22e-9	Neutrophil percentage of white cells;
CESC	cis	rs7020830	0.898	rs7857936	chr9:37078491	T/C	cg14294708	chr9:37120828	ZCCHC7	1.24	23.78	0.83	1.08e-67	Schizophrenia;
CESC	cis	rs7552404	0.731	rs1689275	chr1:76409655	T/C	cg03433033	chr1:76189801	ACADM	-0.58	-6.33	-0.36	1.04e-9	Blood metabolite levels;Acylcarnitine levels;
CESC	trans	rs9929218	0.817	rs8055912	chr16:68802068	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.63	-8.45	-0.46	1.98e-15	Colorectal cancer;
CESC	cis	rs826838	1.000	rs10880826	chr12:38672787	G/C	cg26384229	chr12:38710491	ALG10B	0.81	14.2	0.66	2.04e-34	Heart rate;
CESC	cis	rs13256369	1.000	rs7004438	chr8:8574379	C/T	cg18904891	chr8:8559673	CLDN23	0.7	8.19	0.45	1.14e-14	Obesity-related traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08222081	chr3:150264537	SERP1;EIF2A	0.55	6.06	0.35	4.78e-9	Gut microbiome composition (summer);
CESC	cis	rs1355223	0.525	rs12280958	chr11:34872799	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.55	-6.64	-0.38	1.81e-10	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs36051895	0.522	rs12341844	chr9:5177872	C/T	cg02405213	chr9:5042618	JAK2	-0.5	-6.5	-0.37	3.92e-10	Pediatric autoimmune diseases;
CESC	cis	rs12586317	0.620	rs79832710	chr14:35547434	G/T	cg16230307	chr14:35515116	FAM177A1	0.96	10.2	0.53	7.97e-21	Psoriasis;
CESC	cis	rs3767633	0.858	rs7532448	chr1:161862745	C/T	cg09175582	chr1:161736000	ATF6	0.85	6.91	0.39	3.53e-11	IgG glycosylation;
CESC	trans	rs9354308	0.903	rs1938064	chr6:66559172	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.54	-6.52	-0.37	3.47e-10	Metabolite levels;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg08052428	chr9:135996421	RALGDS	-0.45	-6.62	-0.38	1.97e-10	Gambling;
CESC	cis	rs780096	0.506	rs2288155	chr2:27714526	T/C	cg24768116	chr2:27665128	KRTCAP3	-0.28	-5.15	-0.3	5.11e-7	Total body bone mineral density;
CESC	cis	rs9815354	1.000	rs6599179	chr3:41855284	C/T	cg03022575	chr3:42003672	ULK4	0.45	5.21	0.31	3.73e-7	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs2354432	0.943	rs6660219	chr1:146691404	A/T	cg25205988	chr1:146714368	CHD1L	1.1	11.55	0.58	3.01e-25	Mitochondrial DNA levels;
CESC	cis	rs10200159	1.000	rs6739788	chr2:55862355	A/T	cg13617705	chr2:55845095	SMEK2	0.68	5.33	0.31	2.07e-7	Vitiligo;
CESC	cis	rs7223966	0.921	rs67018565	chr17:61928055	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.53	6.36	0.36	8.58e-10	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs2243480	0.522	rs12698511	chr7:65474919	G/T	cg18252515	chr7:66147081	NA	-1.21	-9.19	-0.49	1.22e-17	Diabetic kidney disease;
CESC	cis	rs3820928	0.874	rs4675137	chr2:227883910	G/C	cg05526886	chr2:227700861	RHBDD1	-0.43	-5.48	-0.32	9.75e-8	Pulmonary function;
CESC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg10392504	chr7:5464594	TNRC18	0.48	6.0	0.35	6.47e-9	Tetralogy of Fallot;
CESC	cis	rs875971	0.862	rs6952182	chr7:65683317	T/G	cg13147721	chr7:65941812	NA	0.37	5.04	0.3	8.48e-7	Aortic root size;
CESC	cis	rs7927771	1.000	rs7105282	chr11:47805614	C/A	cg05585544	chr11:47624801	NA	-0.5	-7.79	-0.43	1.48e-13	Subjective well-being;
CESC	cis	rs7552167	0.789	rs6424162	chr1:24512576	T/C	cg01960748	chr1:24522592	NA	-0.4	-5.15	-0.3	5.17e-7	Psoriasis vulgaris;
CESC	cis	rs947211	0.948	rs12565968	chr1:205755046	A/G	cg26354017	chr1:205819088	PM20D1	-0.44	-5.74	-0.33	2.56e-8	Parkinson's disease;
CESC	cis	rs6938	0.618	rs1133323	chr15:75212225	C/T	cg09165964	chr15:75287851	SCAMP5	0.45	6.13	0.35	3.2e-9	Breast cancer;
CESC	cis	rs8020095	0.528	rs4636843	chr14:67730600	G/A	cg19548862	chr14:67692701	FAM71D	-0.45	-5.43	-0.32	1.28e-7	Depression (quantitative trait);
CESC	cis	rs7618915	0.547	rs6768697	chr3:52703615	C/T	cg07507251	chr3:52567010	NT5DC2	0.42	7.32	0.41	2.95e-12	Bipolar disorder;
CESC	cis	rs8058578	0.945	rs8058961	chr16:30809063	G/A	cg00531865	chr16:30841666	NA	-0.4	-5.11	-0.3	6.28e-7	Multiple myeloma;
CESC	cis	rs6831352	0.959	rs4699710	chr4:100051819	C/T	cg13256891	chr4:100009986	ADH5	0.72	8.45	0.46	1.94e-15	Alcohol dependence;
CESC	cis	rs10979	0.964	rs9496683	chr6:143898845	G/A	cg25407410	chr6:143891975	LOC285740	-0.6	-9.01	-0.48	4.13e-17	Hypospadias;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg24170415	chr4:185747632	ACSL1	-0.45	-6.39	-0.37	7.34e-10	Gambling;
CESC	cis	rs2115536	0.935	rs11854390	chr15:80224817	C/T	cg00225070	chr15:80189496	MTHFS	0.4	5.35	0.31	1.88e-7	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CESC	cis	rs67366981	0.720	rs4396457	chr14:77685379	G/A	cg22824376	chr14:77648248	TMEM63C	0.78	7.51	0.42	9.21e-13	Obsessive-compulsive symptoms;
CESC	cis	rs11190604	1.000	rs2489048	chr10:102348497	G/T	cg07080220	chr10:102295463	HIF1AN	0.59	5.38	0.31	1.67e-7	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs796364	0.951	rs281776	chr2:200834282	T/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.9	9.11	0.49	2.07e-17	Schizophrenia;
CESC	cis	rs6835098	0.924	rs1991727	chr4:174163169	A/G	cg08422745	chr4:174089978	GALNT7	-0.69	-9.95	-0.52	5.02e-20	Dementia and core Alzheimer's disease neuropathologic changes;
CESC	cis	rs2191566	0.922	rs7245749	chr19:44513932	G/A	cg20607764	chr19:44506953	ZNF230	-0.58	-7.6	-0.42	5.17e-13	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs2011503	1.000	rs6511029	chr19:19471419	G/T	cg17414380	chr19:19431394	KIAA0892;SF4	-0.5	-5.08	-0.3	7.2e-7	Bipolar disorder;
CESC	cis	rs1545257	0.537	rs12988283	chr2:24642086	G/C	cg06627628	chr2:24431161	ITSN2	-0.48	-5.88	-0.34	1.25e-8	Sjögren's syndrome;
CESC	cis	rs12042107	0.967	rs12089815	chr1:91189933	G/A	cg13456504	chr1:91191583	NA	0.36	6.49	0.37	4.31e-10	Educational attainment;
CESC	cis	rs7618915	0.547	rs12496476	chr3:52708737	A/G	cg05564831	chr3:52568323	NT5DC2	0.44	6.68	0.38	1.37e-10	Bipolar disorder;
CESC	cis	rs7188861	0.768	rs1646026	chr16:11382695	C/T	cg01510278	chr16:11456238	NA	0.33	5.1	0.3	6.53e-7	HDL cholesterol;
CESC	cis	rs3858526	0.676	rs10838772	chr11:5895754	T/C	cg13902645	chr11:5959945	NA	-0.56	-6.71	-0.38	1.21e-10	DNA methylation (variation);
CESC	cis	rs1986734	0.560	rs4859683	chr4:77419073	C/T	cg20311846	chr4:77356250	SHROOM3	-0.26	-5.28	-0.31	2.63e-7	Eosinophilic esophagitis (pediatric);Metabolite levels (small molecules and protein measures);
CESC	cis	rs1023500	0.596	rs133352	chr22:42434022	C/A	cg04733989	chr22:42467013	NAGA	0.8	11.87	0.59	2.45e-26	Schizophrenia;
CESC	cis	rs13256369	0.802	rs2280560	chr8:8560602	C/T	cg18904891	chr8:8559673	CLDN23	0.71	7.96	0.44	4.92e-14	Obesity-related traits;
CESC	cis	rs9913156	0.670	rs4470203	chr17:4567798	G/A	cg00122941	chr17:4613640	ARRB2	-0.6	-7.37	-0.41	2.24e-12	Lymphocyte counts;
CESC	cis	rs6460942	0.915	rs7803056	chr7:12306913	A/C	cg06484146	chr7:12443880	VWDE	-0.47	-6.41	-0.37	6.52e-10	Coronary artery disease;
CESC	cis	rs6912958	0.535	rs448580	chr6:88040399	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.52	8.84	0.48	1.35e-16	Monocyte percentage of white cells;
CESC	cis	rs2295499	0.773	rs2298961	chr4:2644961	T/A	cg08330972	chr4:2403930	ZFYVE28	-0.32	-5.23	-0.31	3.4e-7	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
CESC	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg20887711	chr4:1340912	KIAA1530	0.85	11.44	0.58	6.72e-25	Longevity;
CESC	cis	rs763121	0.819	rs138700	chr22:39129999	A/G	cg06022373	chr22:39101656	GTPBP1	0.94	16.52	0.71	1.23e-42	Menopause (age at onset);
CESC	cis	rs6952808	0.792	rs2056478	chr7:1953897	C/T	cg00106254	chr7:1943704	MAD1L1	-0.46	-5.66	-0.33	4.01e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs9926296	0.605	rs6500453	chr16:89858657	C/G	cg01097406	chr16:89675127	NA	-0.33	-5.04	-0.3	8.63e-7	Vitiligo;
CESC	cis	rs959260	0.925	rs9747801	chr17:73396572	C/T	cg20590849	chr17:73267439	MIF4GD	-0.54	-6.24	-0.36	1.75e-9	Systemic lupus erythematosus;
CESC	cis	rs3806843	0.735	rs2563314	chr5:140047289	A/G	cg16179182	chr5:140090404	VTRNA1-1	0.39	5.11	0.3	6.21e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs4566357	0.557	rs6707158	chr2:227911269	A/G	cg05526886	chr2:227700861	RHBDD1	-0.45	-5.99	-0.35	6.98e-9	Coronary artery disease;
CESC	cis	rs12220238	1.000	rs11000936	chr10:75992383	A/T	cg19889307	chr10:75911429	ADK;AP3M1	0.65	6.47	0.37	4.65e-10	Soluble interleukin-2 receptor subunit alpha;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg03798359	chr20:2443604	SNRPB;SNORD119	-0.37	-6.47	-0.37	4.81e-10	Gambling;
CESC	cis	rs7089973	0.604	rs8181444	chr10:116588981	C/T	cg23260525	chr10:116636907	FAM160B1	0.4	7.19	0.4	6.76e-12	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs9926296	0.682	rs258328	chr16:89730314	C/T	cg04287289	chr16:89883240	FANCA	-0.44	-5.61	-0.33	5e-8	Vitiligo;
CESC	cis	rs4665809	0.938	rs35844686	chr2:26304949	A/G	cg22920501	chr2:26401640	FAM59B	0.72	8.12	0.45	1.74e-14	Gut microbiome composition (summer);
CESC	cis	rs9291683	0.588	rs3756237	chr4:10013378	G/A	cg00071950	chr4:10020882	SLC2A9	0.91	17.5	0.73	4.16e-46	Bone mineral density;
CESC	cis	rs798554	0.686	rs2644298	chr7:2858448	G/C	cg13628971	chr7:2884303	GNA12	0.4	5.36	0.31	1.85e-7	Height;
CESC	cis	rs8067354	0.540	rs72840315	chr17:58018142	G/C	cg13753209	chr17:57696993	CLTC	0.51	5.63	0.33	4.57e-8	Hemoglobin concentration;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg11312980	chr14:64931897	AKAP5	-0.43	-6.08	-0.35	4.27e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs9905704	0.918	rs11655808	chr17:56854517	T/C	cg12560992	chr17:57184187	TRIM37	0.6	6.94	0.39	2.93e-11	Testicular germ cell tumor;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg06225581	chr5:140080094	ZMAT2	0.46	6.09	0.35	3.9e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs853679	0.517	rs4713145	chr6:28106827	T/C	cg12963246	chr6:28129442	ZNF389	0.57	7.77	0.43	1.75e-13	Depression;
CESC	cis	rs597539	0.552	rs6591360	chr11:68718669	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.69	8.44	0.46	2.12e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs13253111	0.624	rs1979330	chr8:28096051	T/A	cg26534493	chr8:28060551	NA	0.48	7.41	0.41	1.73e-12	Childhood body mass index;
CESC	cis	rs8072100	0.544	rs7214993	chr17:45386797	C/G	cg08085267	chr17:45401833	C17orf57	-0.42	-5.23	-0.31	3.44e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.58	7.28	0.41	3.71e-12	Prudent dietary pattern;
CESC	cis	rs2576037	0.796	rs2576039	chr18:44582148	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.61	-8.66	-0.47	4.73e-16	Personality dimensions;
CESC	cis	rs870825	0.860	rs28799091	chr4:185598594	G/A	cg04058563	chr4:185651563	MLF1IP	0.6	6.11	0.35	3.53e-9	Blood protein levels;
CESC	cis	rs1799949	0.965	rs8067269	chr17:41235799	C/T	cg25072359	chr17:41440525	NA	0.52	7.92	0.44	6.72e-14	Menopause (age at onset);
CESC	cis	rs113835537	0.529	rs10896125	chr11:66288733	G/C	cg22134325	chr11:66188745	NPAS4	0.35	5.59	0.32	5.52e-8	Airway imaging phenotypes;
CESC	cis	rs9549367	0.789	rs12584981	chr13:113881185	T/C	cg18105134	chr13:113819100	PROZ	-0.65	-8.04	-0.44	2.97e-14	Platelet distribution width;
CESC	cis	rs7267979	1.000	rs2500424	chr20:25391969	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.83	-15.68	-0.69	1.2e-39	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg03188948	chr7:1209495	NA	0.53	7.14	0.4	8.8e-12	Longevity;Endometriosis;
CESC	cis	rs9815354	0.812	rs73073337	chr3:41837497	T/C	cg03022575	chr3:42003672	ULK4	0.7	6.04	0.35	5.26e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs7539624	0.898	rs2896828	chr1:223898685	T/C	cg10100437	chr1:223903862	CAPN2	-0.41	-6.16	-0.35	2.68e-9	Schizophrenia;
CESC	cis	rs4969178	0.832	rs4969185	chr17:76398157	G/C	cg05887092	chr17:76393375	PGS1	0.58	9.21	0.49	1.01e-17	HDL cholesterol levels;
CESC	cis	rs6867032	1.000	rs6867032	chr5:2015103	G/T	cg26168224	chr5:2018326	NA	-0.97	-19.64	-0.77	1.28e-53	Gut microbiome composition (winter);
CESC	cis	rs2836974	0.899	rs34433511	chr21:40618883	A/C	cg17971929	chr21:40555470	PSMG1	1.06	16.39	0.71	3.75e-42	Cognitive function;
CESC	trans	rs7246760	0.867	rs7259075	chr19:9778776	G/A	cg02900749	chr2:68251473	NA	-0.85	-7.53	-0.42	8.04e-13	Pursuit maintenance gain;
CESC	cis	rs61931739	0.500	rs11053271	chr12:34545407	C/A	cg19457237	chr12:34500585	NA	-0.37	-5.08	-0.3	6.97e-7	Morning vs. evening chronotype;
CESC	cis	rs11098499	0.909	rs28581362	chr4:120283548	T/A	cg09307838	chr4:120376055	NA	0.87	12.16	0.6	2.41e-27	Corneal astigmatism;
CESC	trans	rs629535	0.862	rs655028	chr8:70049047	T/C	cg21567404	chr3:27674614	NA	0.93	11.25	0.57	2.83e-24	Dupuytren's disease;
CESC	cis	rs7224314	1.000	rs7219229	chr17:65380171	C/T	cg01507342	chr17:65387096	PITPNC1	-0.48	-5.68	-0.33	3.45e-8	Diisocyanate-induced asthma;
CESC	cis	rs1018836	0.923	rs2023626	chr8:91619264	G/T	cg16814680	chr8:91681699	NA	0.74	10.56	0.54	5.67e-22	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs4919694	0.901	rs12251035	chr10:104671459	A/C	cg04362960	chr10:104952993	NT5C2	0.78	6.58	0.37	2.5e-10	Arsenic metabolism;
CESC	cis	rs9311474	0.629	rs13081028	chr3:52555316	G/A	cg18591801	chr3:52553433	STAB1	-0.3	-5.89	-0.34	1.19e-8	Electroencephalogram traits;
CESC	cis	rs4853012	0.838	rs72911122	chr2:74344119	C/G	cg20891558	chr2:74357851	NA	0.81	11.91	0.59	1.82e-26	Gestational age at birth (maternal effect);
CESC	cis	rs116095464	0.558	rs1812843	chr5:267658	A/G	cg22496380	chr5:211416	CCDC127	-0.74	-8.46	-0.46	1.86e-15	Breast cancer;
CESC	cis	rs1775715	0.737	rs11008695	chr10:32216887	T/G	cg18675610	chr10:32216311	ARHGAP12	0.37	5.63	0.33	4.69e-8	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs12476592	0.571	rs7606045	chr2:63826528	T/G	cg17519650	chr2:63277830	OTX1	-0.44	-5.23	-0.31	3.39e-7	Childhood ear infection;
CESC	cis	rs1799949	0.896	rs35908185	chr17:41255111	A/T	cg23758822	chr17:41437982	NA	1.01	15.72	0.69	8.46e-40	Menopause (age at onset);
CESC	cis	rs875971	0.862	rs801203	chr7:66023012	A/G	cg18252515	chr7:66147081	NA	0.46	5.96	0.34	8.08e-9	Aortic root size;
CESC	cis	rs2737618	0.722	rs1986405	chr1:200095935	C/G	cg21825944	chr1:200113062	NR5A2	-0.41	-6.13	-0.35	3.19e-9	Uric acid levels;
CESC	cis	rs1707322	1.000	rs10890350	chr1:46262378	G/A	cg06784218	chr1:46089804	CCDC17	0.33	5.68	0.33	3.51e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg06958567	chr18:52495541	RAB27B	-0.51	-7.04	-0.4	1.7e-11	Height;
CESC	cis	rs7927771	0.524	rs10838774	chr11:47856114	A/G	cg20307385	chr11:47447363	PSMC3	0.65	9.24	0.49	8.43e-18	Subjective well-being;
CESC	cis	rs7264396	0.733	rs6060515	chr20:34211779	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.64	7.52	0.42	8.28e-13	Total cholesterol levels;
CESC	trans	rs11098499	0.754	rs28652763	chr4:120242312	C/T	cg25214090	chr10:38739885	LOC399744	0.61	8.47	0.46	1.73e-15	Corneal astigmatism;
CESC	trans	rs9929218	0.906	rs10852450	chr16:68749529	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.8	-10.57	-0.54	5.06e-22	Colorectal cancer;
CESC	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg11494091	chr17:61959527	GH2	0.73	12.39	0.61	4.19e-28	Prudent dietary pattern;
CESC	cis	rs6669072	0.590	rs10922922	chr1:91237055	G/A	cg08895590	chr1:91227319	NA	0.34	5.8	0.34	1.85e-8	Cognitive function;
CESC	cis	rs7537660	1.000	rs7522811	chr1:248005213	C/G	cg12080717	chr1:248004886	OR11L1	0.41	5.27	0.31	2.76e-7	Platelet distribution width;
CESC	cis	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg04267008	chr7:1944627	MAD1L1	-0.57	-6.89	-0.39	4.08e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs7683537	0.725	rs28837443	chr4:185641497	G/A	cg04058563	chr4:185651563	MLF1IP	0.64	7.1	0.4	1.15e-11	Systemic lupus erythematosus;
CESC	cis	rs7666738	0.830	rs7679299	chr4:99057620	C/A	cg18180107	chr4:99064573	C4orf37	0.41	5.24	0.31	3.24e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs67366981	0.841	rs55903932	chr14:77706389	T/C	cg22824376	chr14:77648248	TMEM63C	0.72	5.76	0.33	2.35e-8	Obsessive-compulsive symptoms;
CESC	cis	rs8103278	0.507	rs3745802	chr19:46271177	G/T	cg12641515	chr19:46296257	DMWD	0.73	9.86	0.52	9.65e-20	Coronary artery disease;
CESC	cis	rs4423214	1.000	rs3750997	chr11:71158841	A/C	cg24826892	chr11:71159390	DHCR7	0.46	5.48	0.32	9.79e-8	Vitamin D levels;
CESC	cis	rs12912251	1.000	rs2132157	chr15:38992547	A/G	cg01338139	chr15:38987640	C15orf53	-0.49	-5.59	-0.32	5.54e-8	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
CESC	cis	rs10504229	0.953	rs66676208	chr8:58173866	C/T	cg14926445	chr8:58193284	C8orf71	-0.51	-5.47	-0.32	1.03e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs2119480	0.762	rs401084	chr13:111310086	C/G	cg16216153	chr13:111290848	CARKD	-0.35	-5.16	-0.3	4.88e-7	Diastolic blood pressure;
CESC	cis	rs4132509	0.744	rs10927068	chr1:243923452	C/T	cg21452805	chr1:244014465	NA	0.57	6.8	0.39	7.09e-11	RR interval (heart rate);
CESC	cis	rs1904096	0.506	rs7697827	chr4:95184748	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.61	-9.28	-0.5	6.25e-18	Type 2 diabetes;
CESC	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg11494091	chr17:61959527	GH2	0.73	12.55	0.61	1.13e-28	Prudent dietary pattern;
CESC	trans	rs7672847	0.547	rs6818590	chr4:170478577	A/C	cg19308436	chr1:237949471	RYR2	0.65	6.9	0.39	3.89e-11	Subjective well-being;
CESC	cis	rs78456975	1.000	rs13392535	chr2:1542634	G/T	cg01028140	chr2:1542097	TPO	-0.61	-5.79	-0.34	2e-8	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs3820068	0.655	rs72645823	chr1:15887442	C/T	cg18192808	chr1:15853278	DNAJC16	0.43	5.17	0.3	4.6e-7	Systolic blood pressure;
CESC	cis	rs6952808	1.000	rs4449693	chr7:1884630	G/C	cg02951883	chr7:2050386	MAD1L1	-0.42	-5.37	-0.31	1.75e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs5757676	0.858	rs6001585	chr22:39812986	G/T	cg11247378	chr22:39784982	NA	-0.62	-7.76	-0.43	1.85e-13	IgG glycosylation;
CESC	trans	rs629535	0.814	rs654452	chr8:70074344	C/G	cg21567404	chr3:27674614	NA	0.88	10.34	0.54	2.74e-21	Dupuytren's disease;
CESC	cis	rs7659604	0.560	rs769238	chr4:122744942	G/A	cg06713675	chr4:122721982	EXOSC9	-0.5	-6.96	-0.39	2.65e-11	Type 2 diabetes;
CESC	cis	rs6968419	0.714	rs17138472	chr7:115892738	A/G	cg02561103	chr7:115862891	TES	-0.39	-5.05	-0.3	8.05e-7	Intraocular pressure;
CESC	cis	rs4253772	0.614	rs11090859	chr22:46687460	T/G	cg10231785	chr22:46692440	CN5H6.4;GTSE1	0.59	6.21	0.36	2.02e-9	LDL cholesterol;Cholesterol, total;
CESC	cis	rs662064	0.755	rs6667629	chr1:10524467	T/C	cg20482658	chr1:10539492	PEX14	0.29	5.03	0.3	8.89e-7	Asthma;
CESC	cis	rs11190604	1.000	rs2295780	chr10:102305965	A/G	cg07080220	chr10:102295463	HIF1AN	0.62	5.58	0.32	5.83e-8	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs9611565	0.512	rs2899347	chr22:42158204	T/C	cg03806693	chr22:41940476	POLR3H	1.2	13.99	0.65	1.16e-33	Vitiligo;
CESC	trans	rs62103177	0.608	rs4799115	chr18:77736365	A/T	cg05926928	chr17:57297772	GDPD1	-0.68	-6.29	-0.36	1.34e-9	Opioid sensitivity;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg08450091	chr3:82857215	NA	0.5	7.17	0.4	7.33e-12	Fibrinogen levels;
CESC	cis	rs703842	1.000	rs2069502	chr12:58144665	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	-0.69	-8.69	-0.47	3.91e-16	Multiple sclerosis;
CESC	cis	rs56235845	0.796	rs13153019	chr5:176782218	T/C	cg16006841	chr5:176797999	RGS14	0.62	6.35	0.36	9.51e-10	Hemoglobin concentration;Hematocrit;
CESC	cis	rs7586673	0.866	rs747003	chr2:161916409	C/T	cg21518248	chr2:162101506	NA	-0.47	-6.46	-0.37	4.99e-10	Intelligence (multi-trait analysis);
CESC	cis	rs735860	0.737	rs2115564	chr6:53173482	C/A	cg10236188	chr6:53219634	NA	-0.36	-5.26	-0.31	2.98e-7	Glaucoma;
CESC	cis	rs7552404	0.924	rs67757078	chr1:76169456	G/A	cg03433033	chr1:76189801	ACADM	0.7	9.43	0.5	2.18e-18	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs4332037	0.522	rs4721098	chr7:1881527	G/C	cg23422044	chr7:1970798	MAD1L1	0.51	5.35	0.31	1.86e-7	Bipolar disorder;
CESC	cis	rs123509	0.687	rs73075301	chr3:42832650	C/T	cg12982090	chr3:42733453	KBTBD5	-0.66	-7.52	-0.42	8.26e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs116095464	0.558	rs9654452	chr5:299561	C/T	cg22857025	chr5:266934	NA	-1.28	-17.85	-0.74	2.52e-47	Breast cancer;
CESC	cis	rs13191362	1.000	rs13204013	chr6:163002480	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.88	9.16	0.49	1.46e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	trans	rs3808502	0.525	rs9650661	chr8:11427133	G/T	cg15556689	chr8:8085844	FLJ10661	-0.58	-6.84	-0.39	5.45e-11	Neuroticism;
CESC	cis	rs798554	0.757	rs1182188	chr7:2869985	T/C	cg13628971	chr7:2884303	GNA12	0.64	8.55	0.46	1.02e-15	Height;
CESC	cis	rs425277	0.959	rs77665022	chr1:2065958	C/T	cg16545954	chr1:2118288	C1orf86	0.33	5.59	0.32	5.77e-8	Height;
CESC	trans	rs7107217	1.000	rs1873872	chr11:129473993	A/T	cg10434075	chr17:55038112	COIL	0.49	6.29	0.36	1.33e-9	Breast cancer;Type 2 diabetes;
CESC	cis	rs875971	0.798	rs12698522	chr7:65967341	T/C	cg12463550	chr7:65579703	CRCP	0.5	6.3	0.36	1.21e-9	Aortic root size;
CESC	cis	rs782590	0.774	rs782632	chr2:55898290	C/G	cg18811423	chr2:55921094	PNPT1	0.78	12.9	0.62	7e-30	Metabolic syndrome;
CESC	cis	rs9549367	0.713	rs576463	chr13:113846614	C/T	cg18105134	chr13:113819100	PROZ	0.53	6.78	0.38	7.56e-11	Platelet distribution width;
CESC	cis	rs9611565	0.592	rs80477	chr22:42001183	C/T	cg03806693	chr22:41940476	POLR3H	0.84	9.77	0.51	1.84e-19	Vitiligo;
CESC	cis	rs1538970	1.000	rs9326141	chr1:45828943	A/G	cg03146154	chr1:46216737	IPP	-0.44	-5.2	-0.3	4e-7	Platelet count;
CESC	cis	rs9768139	0.733	rs13221388	chr7:158119270	G/A	cg27057461	chr7:158136379	PTPRN2	-0.33	-5.17	-0.3	4.6e-7	Calcium levels;
CESC	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg24642844	chr7:1081250	C7orf50	-0.76	-9.26	-0.49	7.23e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs9487051	0.597	rs351732	chr6:109507691	G/T	cg01475377	chr6:109611718	NA	-0.39	-5.17	-0.3	4.54e-7	Reticulocyte fraction of red cells;
CESC	cis	rs7618501	0.602	rs2245365	chr3:50097319	C/A	cg24308560	chr3:49941425	MST1R	0.62	9.16	0.49	1.45e-17	Intelligence (multi-trait analysis);
CESC	cis	rs7605827	0.866	rs2032692	chr2:15616847	A/G	cg19274914	chr2:15703543	NA	0.33	5.96	0.34	8.22e-9	Educational attainment (years of education);
CESC	cis	rs2481665	0.608	rs2476194	chr1:62594593	C/T	cg18591186	chr1:62594603	INADL	-0.79	-12.14	-0.6	2.94e-27	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs11997175	0.603	rs4739381	chr8:33806892	C/A	ch.8.33884649F	chr8:33765107	NA	0.44	5.25	0.31	3.19e-7	Body mass index;
CESC	cis	rs5753618	0.504	rs7284622	chr22:31907985	G/A	cg13145458	chr22:31556086	RNF185	-0.48	-5.69	-0.33	3.33e-8	Colorectal cancer;
CESC	cis	rs3857067	1.000	rs115969971	chr4:95023550	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.52	-8.04	-0.44	3.04e-14	QT interval;
CESC	cis	rs8180040	0.654	rs6791062	chr3:47174343	T/A	cg27129171	chr3:47204927	SETD2	0.66	9.85	0.52	1.07e-19	Colorectal cancer;
CESC	cis	rs3096299	0.658	rs34590044	chr16:89543157	A/C	cg08392591	chr16:89556376	ANKRD11	0.56	7.65	0.43	3.78e-13	Multiple myeloma (IgH translocation);
CESC	trans	rs3808502	0.585	rs4549730	chr8:11239078	T/G	cg15556689	chr8:8085844	FLJ10661	-0.48	-6.09	-0.35	3.85e-9	Neuroticism;
CESC	cis	rs3820928	0.874	rs2228557	chr2:227872182	G/A	cg05526886	chr2:227700861	RHBDD1	-0.44	-5.49	-0.32	9.38e-8	Pulmonary function;
CESC	cis	rs7072216	0.763	rs6584198	chr10:100169906	G/C	cg26618903	chr10:100175079	PYROXD2	-0.37	-5.76	-0.33	2.33e-8	Metabolite levels;
CESC	cis	rs4835473	0.864	rs17750354	chr4:144658505	T/A	cg25736465	chr4:144833511	NA	-0.33	-5.25	-0.31	3.1e-7	Immature fraction of reticulocytes;
CESC	cis	rs2836974	0.583	rs2410124	chr21:40704760	C/G	cg17971929	chr21:40555470	PSMG1	-0.87	-12.56	-0.61	1.04e-28	Cognitive function;
CESC	cis	rs796364	0.806	rs1605900	chr2:200870197	C/G	cg23649088	chr2:200775458	C2orf69	0.6	5.37	0.31	1.74e-7	Schizophrenia;
CESC	cis	rs7927771	0.524	rs10458915	chr11:47864392	T/A	cg20307385	chr11:47447363	PSMC3	0.63	8.77	0.47	2.17e-16	Subjective well-being;
CESC	cis	rs10504229	0.906	rs112793785	chr8:58190537	T/C	cg24829409	chr8:58192753	C8orf71	-0.75	-10.01	-0.52	3.22e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs2243480	1.000	rs34637256	chr7:65360131	G/A	cg18252515	chr7:66147081	NA	-1.06	-9.89	-0.52	7.86e-20	Diabetic kidney disease;
CESC	cis	rs7267979	0.744	rs6050463	chr20:25208990	G/A	cg08601574	chr20:25228251	PYGB	0.38	5.48	0.32	9.93e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7202877	0.706	rs247423	chr16:75456631	C/A	cg04384234	chr16:75411784	CFDP1	0.48	5.68	0.33	3.58e-8	Type 2 diabetes;Type 1 diabetes;
CESC	cis	rs2637266	0.745	rs2579733	chr10:78441896	C/T	cg18941641	chr10:78392320	NA	-0.39	-7.08	-0.4	1.31e-11	Pulmonary function;
CESC	cis	rs1983170	1.000	rs597288	chr1:91999296	C/T	cg25838465	chr1:92012736	NA	0.45	5.42	0.32	1.35e-7	Eosinophil percentage of white cells;
CESC	cis	rs3105593	0.966	rs2063010	chr15:50941131	A/G	cg08437265	chr15:50716283	USP8	0.41	5.34	0.31	1.96e-7	QT interval;
CESC	cis	rs8036030	0.604	rs11852686	chr15:74715205	A/G	cg14664628	chr15:75095509	CSK	-0.45	-5.47	-0.32	1.04e-7	Airflow obstruction;
CESC	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg04025307	chr7:1156635	C7orf50	0.59	10.37	0.54	2.19e-21	Longevity;Endometriosis;
CESC	cis	rs7296418	0.922	rs1727293	chr12:123648032	C/T	cg05973401	chr12:123451056	ABCB9	0.52	6.71	0.38	1.19e-10	Platelet count;
CESC	cis	rs7666738	0.830	rs35235971	chr4:98999833	G/T	cg05340658	chr4:99064831	C4orf37	0.8	12.44	0.61	2.83e-28	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13570982	chr14:55596240	LGALS3	0.6	6.7	0.38	1.25e-10	Gut microbiome composition (summer);
CESC	cis	rs1862618	0.671	rs2034244	chr5:56242774	T/C	cg22800045	chr5:56110881	MAP3K1	-0.59	-7.59	-0.42	5.38e-13	Initial pursuit acceleration;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26929161	chr20:50701266	ZFP64	-0.5	-6.27	-0.36	1.43e-9	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09274451	chr16:89353600	ANKRD11	-0.57	-6.26	-0.36	1.56e-9	Gut microbiome composition (summer);
CESC	cis	rs1707322	1.000	rs7539800	chr1:46262129	C/G	cg05343316	chr1:45956843	TESK2	-0.49	-5.92	-0.34	9.91e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs11625487	0.957	rs10145540	chr14:77957354	C/T	cg20065768	chr16:29796685	NA	0.48	6.6	0.38	2.24e-10	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
CESC	cis	rs11098499	1.000	rs28374891	chr4:120183550	G/A	cg24375607	chr4:120327624	NA	0.43	5.16	0.3	4.79e-7	Corneal astigmatism;
CESC	cis	rs939574	0.818	rs6744146	chr2:220070597	T/A	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-0.58	-5.55	-0.32	7.07e-8	Platelet distribution width;
CESC	cis	rs2836974	0.549	rs34160989	chr21:40554118	C/G	cg17971929	chr21:40555470	PSMG1	0.78	7.7	0.43	2.8e-13	Cognitive function;
CESC	cis	rs7223966	1.000	rs9901507	chr17:61765524	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.46	-5.58	-0.32	5.85e-8	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs6761276	0.649	rs3811055	chr2:113831182	A/T	cg12858261	chr2:113808755	IL1F8	0.46	5.68	0.33	3.63e-8	Protein quantitative trait loci;
CESC	cis	rs13385	0.769	rs13359060	chr5:139605202	C/T	cg26211634	chr5:139558579	C5orf32	0.47	5.16	0.3	4.78e-7	Atrial fibrillation;
CESC	cis	rs6460942	0.908	rs79175014	chr7:12245378	T/G	cg06484146	chr7:12443880	VWDE	-0.66	-6.67	-0.38	1.44e-10	Coronary artery disease;
CESC	cis	rs1152591	0.792	rs1152595	chr14:64674981	T/C	cg23250157	chr14:64679961	SYNE2	0.5	6.8	0.39	7.12e-11	Atrial fibrillation;
CESC	trans	rs2018683	0.677	rs55718000	chr7:28975625	T/C	cg19402173	chr7:128379420	CALU	-0.48	-6.38	-0.36	7.9e-10	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CESC	cis	rs16989760	0.661	rs67935422	chr22:32020413	G/A	cg01338084	chr22:32026380	PISD	1.19	8.21	0.45	9.91e-15	Age-related hearing impairment;
CESC	cis	rs936229	0.861	rs11634474	chr15:75116184	C/G	cg14664628	chr15:75095509	CSK	-0.98	-16.2	-0.71	1.69e-41	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CESC	cis	rs9815354	0.812	rs73077365	chr3:41851559	T/C	cg03022575	chr3:42003672	ULK4	0.66	6.0	0.35	6.55e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs1799949	1.000	rs8074136	chr17:41342313	A/C	cg05368731	chr17:41323189	NBR1	0.77	10.46	0.54	1.12e-21	Menopause (age at onset);
CESC	cis	rs9322193	0.962	rs4816	chr6:150114745	G/A	cg13206674	chr6:150067644	NUP43	0.41	5.78	0.33	2.05e-8	Lung cancer;
CESC	cis	rs11252926	0.501	rs2050971	chr10:525530	T/G	cg03684893	chr10:554711	DIP2C	0.46	6.99	0.39	2.2e-11	Psychosis in Alzheimer's disease;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg08885106	chr8:144550663	ZC3H3	-0.45	-6.21	-0.36	2.02e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs1448094	0.817	rs73176252	chr12:86347649	T/A	cg02569458	chr12:86230093	RASSF9	0.39	5.68	0.33	3.61e-8	Major depressive disorder;
CESC	cis	rs736408	0.677	rs678	chr3:52820981	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	5.63	0.33	4.47e-8	Bipolar disorder;
CESC	cis	rs7429990	1.000	rs1665982	chr3:47905079	A/G	cg11946769	chr3:48343235	NME6	-0.52	-5.62	-0.33	4.91e-8	Educational attainment (years of education);
CESC	cis	rs9640161	0.789	rs10952250	chr7:150025966	T/C	cg21361702	chr7:150065534	REPIN1	0.46	5.44	0.32	1.18e-7	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs787274	0.718	rs10739379	chr9:115640976	C/G	cg13803584	chr9:115635662	SNX30	-0.7	-5.45	-0.32	1.16e-7	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs7605827	0.930	rs763356	chr2:15518816	G/T	cg19274914	chr2:15703543	NA	0.35	6.27	0.36	1.43e-9	Educational attainment (years of education);
CESC	cis	rs9291683	0.546	rs10939672	chr4:10052136	A/G	cg00071950	chr4:10020882	SLC2A9	0.81	14.25	0.66	1.38e-34	Bone mineral density;
CESC	cis	rs1552244	0.554	rs6768339	chr3:10006079	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	0.58	7.36	0.41	2.35e-12	Alzheimer's disease;
CESC	cis	rs62432291	0.681	rs450538	chr6:159659523	A/G	cg14500486	chr6:159655392	FNDC1	-0.62	-6.34	-0.36	9.83e-10	Joint mobility (Beighton score);
CESC	cis	rs10504229	1.000	rs6989060	chr8:58178989	T/G	cg24829409	chr8:58192753	C8orf71	-0.76	-10.0	-0.52	3.53e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs3008870	0.959	rs2985816	chr1:67387750	G/T	cg08660285	chr1:67390436	MIER1;WDR78	1.06	14.98	0.68	3.54e-37	Lymphocyte percentage of white cells;
CESC	cis	rs4819052	0.808	rs2246697	chr21:46689999	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.92	13.78	0.65	6.16e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs9913156	0.793	rs9916135	chr17:4568115	A/C	cg00122941	chr17:4613640	ARRB2	-0.82	-9.66	-0.51	4.06e-19	Lymphocyte counts;
CESC	cis	rs2249694	0.960	rs4335490	chr10:135402350	T/C	cg20169779	chr10:135381914	SYCE1	-0.4	-5.86	-0.34	1.4e-8	Obesity-related traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08074427	chr7:43798806	BLVRA	0.65	7.33	0.41	2.76e-12	Gut microbiome composition (summer);
CESC	cis	rs2456568	0.867	rs1395384	chr11:93663250	C/T	cg26875233	chr11:93583750	C11orf90	0.3	5.25	0.31	3.2e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
CESC	cis	rs1005277	0.505	rs10827835	chr10:38150709	G/A	cg25427524	chr10:38739819	LOC399744	0.68	9.93	0.52	5.76e-20	Extrinsic epigenetic age acceleration;
CESC	cis	rs1670533	1.000	rs62879260	chr4:1050850	T/C	cg27284194	chr4:1044797	NA	0.44	5.49	0.32	9.49e-8	Recombination rate (females);
CESC	cis	rs8077577	0.747	rs3817992	chr17:18194011	C/A	cg16794390	chr17:18148240	FLII	0.41	6.45	0.37	5.26e-10	Obesity-related traits;
CESC	cis	rs72781680	0.800	rs6718635	chr2:24066183	A/C	cg08917208	chr2:24149416	ATAD2B	1.13	10.31	0.54	3.47e-21	Lymphocyte counts;
CESC	cis	rs60871478	0.545	rs35400476	chr7:795686	A/G	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.49	5.13	0.3	5.66e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs829883	0.724	rs3168521	chr12:98908547	C/T	cg25150519	chr12:98850993	NA	-0.64	-7.9	-0.44	7.53e-14	Colorectal adenoma (advanced);
CESC	cis	rs9616064	0.506	rs2542038	chr22:47059282	C/T	cg25730555	chr22:47059586	GRAMD4	0.47	7.13	0.4	9.5e-12	Urate levels in obese individuals;
CESC	cis	rs7618915	0.547	rs34610878	chr3:52759169	G/C	cg18404041	chr3:52824283	ITIH1	-0.41	-6.75	-0.38	9.55e-11	Bipolar disorder;
CESC	trans	rs875971	0.660	rs1860470	chr7:66103694	G/C	cg26939375	chr7:64535504	NA	-0.59	-7.96	-0.44	5.08e-14	Aortic root size;
CESC	cis	rs28374715	0.578	rs10518717	chr15:41623368	C/G	cg18705301	chr15:41695430	NDUFAF1	-1.06	-15.79	-0.7	4.85e-40	Ulcerative colitis;
CESC	cis	rs9611565	0.512	rs1534932	chr22:42150146	C/T	cg06634786	chr22:41940651	POLR3H	0.71	7.05	0.4	1.59e-11	Vitiligo;
CESC	trans	rs11098499	0.863	rs3775843	chr4:120427844	T/C	cg25214090	chr10:38739885	LOC399744	0.71	9.77	0.51	1.88e-19	Corneal astigmatism;
CESC	cis	rs921968	0.643	rs659185	chr2:219335935	C/T	cg02176678	chr2:219576539	TTLL4	0.38	6.75	0.38	9.19e-11	Mean corpuscular hemoglobin concentration;
CESC	cis	rs2243480	1.000	rs402418	chr7:65509469	G/A	cg18252515	chr7:66147081	NA	-1.28	-12.48	-0.61	2.04e-28	Diabetic kidney disease;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg08810106	chr16:18936940	SMG1	0.5	6.31	0.36	1.16e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs4450798	0.744	rs9653971	chr3:13749727	T/C	cg05589046	chr3:13742034	LOC285375	0.38	5.72	0.33	2.82e-8	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs3785574	0.962	rs2584621	chr17:61912436	G/A	cg07677032	chr17:61819896	STRADA	0.42	5.33	0.31	2.08e-7	Height;
CESC	cis	rs2836974	0.865	rs7282624	chr21:40667040	C/T	cg11644478	chr21:40555479	PSMG1	1.02	16.14	0.7	2.71e-41	Cognitive function;
CESC	cis	rs10870270	0.956	rs4880405	chr10:133787021	G/A	cg26149184	chr10:133730230	NA	0.39	5.32	0.31	2.24e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs10911232	0.507	rs4652767	chr1:183002483	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.85	13.33	0.63	2.22e-31	Hypertriglyceridemia;
CESC	cis	rs79839061	0.656	rs28662837	chr4:879776	G/A	cg07828340	chr4:882639	GAK	1.07	8.55	0.47	9.76e-16	Intelligence (multi-trait analysis);
CESC	cis	rs2288073	0.801	rs2384008	chr2:24373150	A/G	cg06627628	chr2:24431161	ITSN2	-0.74	-9.43	-0.5	2.09e-18	Venous thromboembolism (SNP x SNP interaction);
CESC	cis	rs875971	0.862	rs11769079	chr7:65842128	G/A	cg18252515	chr7:66147081	NA	-0.43	-5.62	-0.33	4.86e-8	Aortic root size;
CESC	cis	rs637571	0.544	rs55704213	chr11:65730002	C/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.73	10.26	0.53	5.13e-21	Eosinophil percentage of white cells;
CESC	cis	rs9649213	0.593	rs6973775	chr7:98004685	G/A	cg00277769	chr7:97922759	BAIAP2L1	-0.33	-5.43	-0.32	1.28e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs4315565	0.764	rs4594480	chr2:69287998	G/A	cg12800200	chr2:69260302	ANTXR1	-0.42	-6.08	-0.35	4.23e-9	Height;
CESC	cis	rs6502050	0.799	rs4789681	chr17:80100546	G/A	cg23985595	chr17:80112537	CCDC57	-0.42	-6.57	-0.37	2.72e-10	Life satisfaction;
CESC	cis	rs7116495	1.000	rs4944232	chr11:71642258	A/G	cg10381502	chr11:71823885	C11orf51	0.67	5.65	0.33	4.19e-8	Severe influenza A (H1N1) infection;
CESC	cis	rs8053891	0.756	rs9928413	chr16:72001110	C/T	cg04254540	chr16:71951199	KIAA0174	-0.42	-5.49	-0.32	9.18e-8	Coronary artery disease;
CESC	cis	rs116095464	0.558	rs13354585	chr5:242263	G/C	cg10591111	chr5:226296	SDHA	-0.52	-6.43	-0.37	6.06e-10	Breast cancer;
CESC	cis	rs2481665	0.817	rs2476198	chr1:62611071	C/A	cg18591186	chr1:62594603	INADL	-0.42	-5.18	-0.3	4.3e-7	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs1552244	1.000	rs17032277	chr3:10077023	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.78	-10.37	-0.54	2.25e-21	Alzheimer's disease;
CESC	cis	rs7666738	0.830	rs957742	chr4:99029409	C/T	cg03467027	chr4:99064603	C4orf37	0.49	6.18	0.35	2.44e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2439831	0.850	rs16950562	chr15:44036364	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.69	6.68	0.38	1.39e-10	Lung cancer in ever smokers;
CESC	cis	rs2742234	0.518	rs2505514	chr10:43633248	A/G	cg15436174	chr10:43711423	RASGEF1A	-0.5	-5.66	-0.33	3.84e-8	Hirschsprung disease;
CESC	cis	rs1008375	0.966	rs6449313	chr4:17588320	A/G	cg02297831	chr4:17616191	MED28	0.5	5.95	0.34	8.67e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs35110281	0.748	rs2838322	chr21:44998615	G/C	cg21573476	chr21:45109991	RRP1B	-0.45	-6.29	-0.36	1.28e-9	Mean corpuscular volume;
CESC	cis	rs921968	0.565	rs12694439	chr2:219590871	A/G	cg02176678	chr2:219576539	TTLL4	-0.43	-7.59	-0.42	5.51e-13	Mean corpuscular hemoglobin concentration;
CESC	cis	rs1950626	0.699	rs12880424	chr14:101459660	C/T	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.83	10.01	0.52	3.28e-20	Pelvic organ prolapse (moderate/severe);
CESC	cis	rs4144743	1.000	rs67615769	chr17:45325478	A/G	cg18085866	chr17:45331354	ITGB3	-0.61	-6.56	-0.37	2.75e-10	Body mass index;
CESC	cis	rs7584330	0.518	rs74003104	chr2:238446823	C/T	cg14458575	chr2:238380390	NA	0.67	6.29	0.36	1.3e-9	Prostate cancer;
CESC	cis	rs2276314	1.000	rs62101367	chr18:33550884	C/T	cg05985134	chr18:33552581	C18orf21	0.67	7.84	0.43	1.07e-13	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs6701037	0.566	rs729675	chr1:175136946	T/C	cg00321850	chr1:175162397	KIAA0040	0.44	6.24	0.36	1.75e-9	Alcohol dependence;
CESC	trans	rs7839040	0.698	rs7841753	chr8:82929864	G/A	cg14472086	chr9:107730925	NA	-0.48	-6.3	-0.36	1.26e-9	Response to methotrexate in juvenile idiopathic arthritis;
CESC	cis	rs4835473	0.897	rs17693780	chr4:144658716	G/T	cg25736465	chr4:144833511	NA	-0.34	-5.3	-0.31	2.46e-7	Immature fraction of reticulocytes;
CESC	cis	rs72781680	0.848	rs56218741	chr2:23977377	A/C	cg08917208	chr2:24149416	ATAD2B	0.96	8.7	0.47	3.55e-16	Lymphocyte counts;
CESC	cis	rs3781663	0.553	rs875108	chr11:70004695	G/A	cg06393558	chr11:69982916	ANO1	-0.34	-5.86	-0.34	1.39e-8	Survival in rectal cancer;
CESC	cis	rs2425143	1.000	rs8116836	chr20:34453362	T/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.61	5.51	0.32	8.37e-8	Blood protein levels;
CESC	cis	rs644799	0.511	rs10831420	chr11:95478209	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.46	5.84	0.34	1.55e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs2032447	0.517	rs7767546	chr6:25904067	T/C	cg12310025	chr6:25882481	NA	-0.6	-9.04	-0.49	3.29e-17	Intelligence (multi-trait analysis);
CESC	cis	rs1348850	0.645	rs11889272	chr2:178432378	C/T	cg22681709	chr2:178499509	PDE11A	-0.55	-6.66	-0.38	1.53e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs75804782	0.641	rs2340870	chr2:239356026	C/T	cg18131467	chr2:239335373	ASB1	-0.68	-5.91	-0.34	1.05e-8	Morning vs. evening chronotype;Chronotype;
CESC	cis	rs2576037	0.583	rs8094654	chr18:44527397	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.78	12.57	0.61	1e-28	Personality dimensions;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02113521	chr15:22892956	CYFIP1	0.54	6.11	0.35	3.5e-9	Gut microbiome composition (summer);
CESC	cis	rs2243480	0.808	rs12698508	chr7:65411958	A/T	cg12463550	chr7:65579703	CRCP	0.7	5.45	0.32	1.16e-7	Diabetic kidney disease;
CESC	trans	rs7615952	0.515	rs4267608	chr3:125680500	C/T	cg07211511	chr3:129823064	LOC729375	-0.64	-6.36	-0.36	8.64e-10	Blood pressure (smoking interaction);
CESC	cis	rs6867032	0.874	rs4975786	chr5:2004724	T/C	cg26168224	chr5:2018326	NA	-0.83	-13.39	-0.64	1.4e-31	Gut microbiome composition (winter);
CESC	trans	rs877282	0.898	rs12356744	chr10:757477	G/C	cg22713356	chr15:30763199	NA	1.05	9.16	0.49	1.45e-17	Uric acid levels;
CESC	cis	rs6570726	0.875	rs1883407	chr6:145823432	T/C	cg23711669	chr6:146136114	FBXO30	0.76	11.32	0.57	1.68e-24	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7044106	0.791	rs10984998	chr9:123481516	G/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.73	10.81	0.55	8.21e-23	Hip circumference adjusted for BMI;
CESC	cis	rs597539	0.616	rs10896386	chr11:68722694	C/T	cg01988459	chr11:68622903	NA	-0.45	-6.02	-0.35	5.69e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs35110281	0.667	rs2838354	chr21:45119857	T/C	cg04455712	chr21:45112962	RRP1B	0.49	7.5	0.42	9.42e-13	Mean corpuscular volume;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg04068686	chr19:5719947	TMEM146;LONP1	-0.42	-6.08	-0.35	4.13e-9	Gambling;
CESC	cis	rs7666738	0.830	rs7673880	chr4:99057262	A/G	cg17366294	chr4:99064904	C4orf37	0.62	8.78	0.47	2.05e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs8067545	0.586	rs2703819	chr17:20121401	A/G	cg13482628	chr17:19912719	NA	-0.41	-5.58	-0.32	5.98e-8	Schizophrenia;
CESC	cis	rs10504229	0.906	rs116341227	chr8:58190532	G/C	cg24829409	chr8:58192753	C8orf71	-0.75	-10.01	-0.52	3.22e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs3733585	0.699	rs6449179	chr4:9969117	G/A	cg02734326	chr4:10020555	SLC2A9	-0.39	-5.57	-0.32	6.13e-8	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs3780486	0.846	rs3780490	chr9:33129839	A/G	cg13443165	chr9:33130375	B4GALT1	0.45	6.46	0.37	5.07e-10	IgG glycosylation;
CESC	trans	rs3942852	0.712	rs10742828	chr11:48104555	A/G	cg03929089	chr4:120376271	NA	-0.6	-6.89	-0.39	4.03e-11	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs9443645	0.901	rs2050659	chr6:79734369	A/C	cg05283184	chr6:79620031	NA	-0.44	-6.74	-0.38	9.96e-11	Intelligence (multi-trait analysis);
CESC	cis	rs10463316	0.817	rs12653378	chr5:150802366	A/G	cg03212797	chr5:150827313	SLC36A1	-0.48	-6.2	-0.36	2.1e-9	Metabolite levels (Pyroglutamine);
CESC	cis	rs258892	0.895	rs6882092	chr5:72086928	G/A	cg21869765	chr5:72125136	TNPO1	-0.42	-5.42	-0.32	1.36e-7	Small cell lung carcinoma;
CESC	cis	rs11997175	0.646	rs61693382	chr8:33697255	A/C	ch.8.33884649F	chr8:33765107	NA	0.56	7.43	0.41	1.54e-12	Body mass index;
CESC	cis	rs854765	0.647	rs2056842	chr17:18009028	C/T	cg16928487	chr17:17741425	SREBF1	-0.54	-8.79	-0.48	1.88e-16	Total body bone mineral density;
CESC	cis	rs1912483	0.545	rs35161461	chr17:45401757	A/G	cg08085267	chr17:45401833	C17orf57	-0.64	-7.73	-0.43	2.18e-13	Coronary artery disease;
CESC	cis	rs4692589	1.000	rs12643956	chr4:170932819	A/C	cg19918862	chr4:170955249	NA	0.36	5.63	0.33	4.66e-8	Anxiety disorder;
CESC	cis	rs7084402	0.967	rs1649046	chr10:60326109	T/C	cg07615347	chr10:60278583	BICC1	0.61	9.55	0.51	8.96e-19	Refractive error;
CESC	cis	rs763121	0.889	rs4820335	chr22:38935927	C/G	cg06544989	chr22:39130855	UNC84B	-0.45	-7.93	-0.44	6.12e-14	Menopause (age at onset);
CESC	cis	rs8020095	0.571	rs7158228	chr14:67562723	T/C	cg19548862	chr14:67692701	FAM71D	-0.47	-5.63	-0.33	4.6e-8	Depression (quantitative trait);
CESC	cis	rs875971	1.000	rs778685	chr7:65836176	G/T	cg12463550	chr7:65579703	CRCP	0.59	7.45	0.42	1.29e-12	Aortic root size;
CESC	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg26354017	chr1:205819088	PM20D1	0.5	7.2	0.4	6.35e-12	Menarche (age at onset);
CESC	cis	rs7640424	0.826	rs7635063	chr3:107818777	C/T	cg09227934	chr3:107805635	CD47	-0.53	-6.97	-0.39	2.48e-11	Body mass index;
CESC	cis	rs6582630	0.519	rs8186881	chr12:38310285	A/G	cg26384229	chr12:38710491	ALG10B	0.71	10.65	0.55	2.8e-22	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs55788414	1.000	rs28395434	chr16:81182222	G/A	cg06400318	chr16:81190750	PKD1L2	-0.6	-7.01	-0.4	1.96e-11	Left ventricular obstructive tract defect (maternal effect);
CESC	cis	rs67311347	0.910	rs7617361	chr3:40373259	G/T	cg24209194	chr3:40518798	ZNF619	0.46	6.06	0.35	4.64e-9	Renal cell carcinoma;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg00735591	chr19:10828665	DNM2;MIR638	-0.47	-6.1	-0.35	3.7e-9	Asthma;
CESC	cis	rs864537	0.646	rs1723018	chr1:167433420	A/G	cg22356347	chr1:167427500	CD247	-0.36	-7.69	-0.43	2.94e-13	Celiac disease or Rheumatoid arthritis;Celiac disease;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg24543097	chr20:388556	RBCK1	0.44	6.29	0.36	1.27e-9	Thyroid stimulating hormone;
CESC	cis	rs736408	0.570	rs11130327	chr3:52793239	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	6.62	0.38	2.02e-10	Bipolar disorder;
CESC	cis	rs4969178	0.965	rs3817295	chr17:76394526	T/A	cg05887092	chr17:76393375	PGS1	0.57	9.02	0.48	3.94e-17	HDL cholesterol levels;
CESC	cis	rs6674176	0.628	rs7556565	chr1:44416090	C/T	cg13606994	chr1:44402422	ARTN	-0.37	-5.53	-0.32	7.66e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs2979489	0.891	rs2915625	chr8:30382651	G/A	cg26383811	chr8:30366931	RBPMS	-0.81	-9.9	-0.52	7.35e-20	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CESC	cis	rs950776	0.518	rs8025429	chr15:78836362	G/A	cg06917634	chr15:78832804	PSMA4	-0.77	-11.76	-0.59	5.63e-26	Sudden cardiac arrest;
CESC	cis	rs208520	0.526	rs9354370	chr6:66808209	C/T	cg07460842	chr6:66804631	NA	1.11	25.48	0.84	3.14e-73	Exhaled nitric oxide output;
CESC	cis	rs7662987	0.517	rs2602882	chr4:100040765	C/T	cg13256891	chr4:100009986	ADH5	0.74	7.89	0.44	7.94e-14	Smoking initiation;
CESC	cis	rs45535039	0.922	rs12287028	chr11:119123949	A/T	cg16724696	chr11:118992527	HINFP	0.42	5.27	0.31	2.84e-7	Plateletcrit;
CESC	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.75	10.61	0.55	3.65e-22	Prudent dietary pattern;
CESC	cis	rs9467711	0.675	rs58825580	chr6:26365679	T/G	cg14345882	chr6:26364793	BTN3A2	0.57	6.08	0.35	4.24e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs2235642	0.928	rs2076435	chr16:1607574	C/T	cg03771183	chr16:1608904	IFT140	0.42	6.16	0.35	2.64e-9	Coronary artery disease;
CESC	cis	rs7296418	0.754	rs1619283	chr12:123717362	A/G	cg05973401	chr12:123451056	ABCB9	0.49	6.24	0.36	1.71e-9	Platelet count;
CESC	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg23708337	chr7:1209742	NA	0.55	5.54	0.32	7.28e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2243480	1.000	rs937108	chr7:65428452	G/A	cg13147721	chr7:65941812	NA	-0.87	-8.59	-0.47	7.56e-16	Diabetic kidney disease;
CESC	trans	rs561341	1.000	rs2470243	chr17:30290955	C/T	cg27661571	chr11:113659931	NA	-0.87	-8.06	-0.44	2.57e-14	Hip circumference adjusted for BMI;
CESC	cis	rs1670533	0.769	rs6814833	chr4:1057679	A/C	cg04106633	chr4:1044584	NA	0.41	5.19	0.3	4.11e-7	Recombination rate (females);
CESC	cis	rs7412746	0.658	rs7526489	chr1:150726238	C/T	cg22823121	chr1:150693482	HORMAD1	0.45	6.25	0.36	1.6e-9	Melanoma;
CESC	cis	rs12950390	0.853	rs11655336	chr17:45858836	A/G	cg00777063	chr17:45855553	NA	0.38	5.77	0.33	2.2e-8	IgG glycosylation;
CESC	trans	rs6921919	0.562	rs13198809	chr6:28323702	G/A	cg01620082	chr3:125678407	NA	-0.82	-6.39	-0.37	7.58e-10	Autism spectrum disorder or schizophrenia;
CESC	cis	rs1395	0.778	rs6749393	chr2:27451000	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.46	6.02	0.35	5.83e-9	Blood metabolite levels;
CESC	trans	rs1814175	0.817	rs7929173	chr11:49944007	T/C	cg03929089	chr4:120376271	NA	-0.93	-16.26	-0.71	1.03e-41	Height;
CESC	cis	rs2637266	1.000	rs12260379	chr10:78365036	C/T	cg18941641	chr10:78392320	NA	0.42	7.87	0.44	8.96e-14	Pulmonary function;
CESC	cis	rs7927771	1.000	rs9909	chr11:47799775	C/G	cg18512352	chr11:47633146	NA	-0.61	-9.6	-0.51	6.38e-19	Subjective well-being;
CESC	cis	rs875971	0.528	rs801213	chr7:66014918	C/T	cg25405998	chr7:65216604	CCT6P1	-0.46	-5.22	-0.31	3.71e-7	Aortic root size;
CESC	cis	rs2976388	0.578	rs13254358	chr8:143823876	G/A	cg24634471	chr8:143751801	JRK	-0.46	-5.04	-0.3	8.7e-7	Urinary tract infection frequency;
CESC	cis	rs4713118	0.513	rs149951	chr6:28033087	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.46	-5.96	-0.34	7.97e-9	Parkinson's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22346429	chr12:132504721	EP400	-0.58	-6.04	-0.35	5.29e-9	Gut microbiome composition (summer);
CESC	trans	rs5769765	0.862	rs9616380	chr22:50312225	T/C	cg09872104	chr7:134855509	C7orf49	-0.55	-6.27	-0.36	1.47e-9	Schizophrenia;
CESC	cis	rs4268898	0.662	rs12052954	chr2:24425620	C/T	cg20701182	chr2:24300061	SF3B14	-0.68	-7.35	-0.41	2.43e-12	Asthma;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg26593722	chr16:87376314	FBXO31	0.47	7.06	0.4	1.46e-11	Fibrinogen levels;
CESC	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg07677032	chr17:61819896	STRADA	0.47	6.28	0.36	1.4e-9	Prudent dietary pattern;
CESC	cis	rs8017423	0.935	rs3742667	chr14:90767856	T/C	cg14092571	chr14:90743983	NA	0.55	8.31	0.45	4.97e-15	Mortality in heart failure;
CESC	cis	rs3780486	0.957	rs10971434	chr9:33168891	C/A	cg13443165	chr9:33130375	B4GALT1	0.41	5.41	0.32	1.43e-7	IgG glycosylation;
CESC	cis	rs6732160	0.588	rs28626211	chr2:73378522	G/A	cg01422370	chr2:73384389	NA	0.57	9.07	0.49	2.73e-17	Intelligence (multi-trait analysis);
CESC	cis	rs10883723	0.962	rs1056739	chr10:104236542	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.54	7.34	0.41	2.67e-12	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	7.63	0.42	4.19e-13	Prudent dietary pattern;
CESC	cis	rs6546550	0.935	rs10202159	chr2:70062454	G/T	cg02498382	chr2:70120550	SNRNP27	-0.39	-6.78	-0.38	7.75e-11	Prevalent atrial fibrillation;
CESC	cis	rs2836974	0.932	rs2234543	chr21:40572072	G/A	cg27266027	chr21:40555129	PSMG1	0.45	5.33	0.31	2.07e-7	Cognitive function;
CESC	cis	rs2295499	0.615	rs57978437	chr4:2711162	C/T	cg27239842	chr4:2403781	ZFYVE28	-0.34	-5.82	-0.34	1.69e-8	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
CESC	cis	rs1707322	0.686	rs2991986	chr1:46081282	A/G	cg06784218	chr1:46089804	CCDC17	-0.42	-7.33	-0.41	2.79e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7772486	0.727	rs4896843	chr6:146063451	T/C	cg23711669	chr6:146136114	FBXO30	-0.96	-14.29	-0.66	9.59e-35	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs854765	0.693	rs9907246	chr17:17770965	T/C	cg04398451	chr17:18023971	MYO15A	0.63	9.0	0.48	4.49e-17	Total body bone mineral density;
CESC	cis	rs2404618	0.506	rs12156177	chr8:1493684	C/T	cg13402656	chr8:1511478	DLGAP2	-0.5	-7.01	-0.4	1.97e-11	Lung cancer;
CESC	cis	rs17376456	0.877	rs10035340	chr5:93490465	C/T	cg21475434	chr5:93447410	FAM172A	0.9	7.77	0.43	1.68e-13	Diabetic retinopathy;
CESC	cis	rs113835537	0.529	rs78999944	chr11:66251228	C/G	cg22134325	chr11:66188745	NPAS4	0.35	5.48	0.32	1.01e-7	Airway imaging phenotypes;
CESC	cis	rs6860806	0.507	rs273917	chr5:131659618	A/G	cg24060327	chr5:131705240	SLC22A5	-0.76	-10.69	-0.55	2.14e-22	Breast cancer;
CESC	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.65	7.48	0.42	1.09e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs709400	0.593	rs12898029	chr14:103877884	T/C	cg12935359	chr14:103987150	CKB	0.49	7.32	0.41	2.96e-12	Body mass index;
CESC	cis	rs1215050	0.744	rs966380	chr4:98435389	C/T	cg05340658	chr4:99064831	C4orf37	0.44	5.44	0.32	1.21e-7	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs3105593	1.000	rs11634746	chr15:50941496	T/A	cg08437265	chr15:50716283	USP8	0.41	5.34	0.31	1.96e-7	QT interval;
CESC	cis	rs6991838	0.584	rs34494846	chr8:66514632	T/C	cg13398993	chr8:66546079	ARMC1	-0.45	-5.37	-0.31	1.75e-7	Intelligence (multi-trait analysis);
CESC	cis	rs514406	0.755	rs10888754	chr1:53228751	C/G	cg25767906	chr1:53392781	SCP2	0.43	6.0	0.35	6.48e-9	Monocyte count;
CESC	cis	rs6973256	0.583	rs2042000	chr7:133322697	T/C	cg10665199	chr7:133106180	EXOC4	0.43	5.65	0.33	4.24e-8	Intelligence (multi-trait analysis);
CESC	cis	rs35110281	0.774	rs2838323	chr21:44999086	G/A	cg21573476	chr21:45109991	RRP1B	-0.41	-5.7	-0.33	3.11e-8	Mean corpuscular volume;
CESC	cis	rs34172651	0.583	rs4787649	chr16:24700215	C/T	cg00339695	chr16:24857497	SLC5A11	-0.44	-5.94	-0.34	9.13e-9	Intelligence (multi-trait analysis);
CESC	cis	rs35110281	0.712	rs1454648	chr21:45053815	C/T	cg21573476	chr21:45109991	RRP1B	-0.5	-6.85	-0.39	5.03e-11	Mean corpuscular volume;
CESC	cis	rs2635047	0.615	rs1512238	chr18:44748467	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.39	5.04	0.3	8.74e-7	Educational attainment;
CESC	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg22105103	chr4:187893119	NA	0.46	6.55	0.37	2.98e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2243480	1.000	rs160639	chr7:65579987	C/G	cg18252515	chr7:66147081	NA	-1.31	-12.88	-0.62	8.56e-30	Diabetic kidney disease;
CESC	cis	rs875971	1.000	rs778696	chr7:65870813	C/G	cg18876405	chr7:65276391	NA	0.52	6.87	0.39	4.49e-11	Aortic root size;
CESC	cis	rs1552244	0.572	rs67227131	chr3:10172744	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.7	7.22	0.41	5.35e-12	Alzheimer's disease;
CESC	cis	rs2439831	0.867	rs3101443	chr15:43912372	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.68	8.42	0.46	2.36e-15	Lung cancer in ever smokers;
CESC	cis	rs2576037	0.901	rs2571021	chr18:44583498	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.63	-9.27	-0.49	6.93e-18	Personality dimensions;
CESC	cis	rs9611565	0.559	rs132768	chr22:42013523	C/A	cg17376030	chr22:41985996	PMM1	-0.8	-8.91	-0.48	8.57e-17	Vitiligo;
CESC	cis	rs6952808	0.500	rs3800902	chr7:2144378	C/T	cg05863683	chr7:1912471	MAD1L1	0.37	5.39	0.31	1.56e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs2882667	0.824	rs1560656	chr5:138470789	A/G	cg04439458	chr5:138467593	SIL1	0.33	5.23	0.31	3.53e-7	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs17711722	0.565	rs4275112	chr7:65198619	T/G	cg11764359	chr7:65958608	NA	-0.48	-5.96	-0.34	8.14e-9	Calcium levels;
CESC	cis	rs7116495	0.609	rs10793014	chr11:71698838	A/G	cg18441811	chr11:71824068	C11orf51	-0.82	-5.33	-0.31	2.05e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs677665	0.537	rs72641831	chr1:9335173	G/T	cg25755851	chr1:9335794	NA	0.96	14.2	0.66	2.07e-34	Eosinophil percentage of white cells;
CESC	cis	rs4862750	0.872	rs1991254	chr4:187875375	T/G	cg03647317	chr4:187891568	NA	-0.38	-5.26	-0.31	3.01e-7	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2777491	0.915	rs28578057	chr15:41621921	G/A	cg02330683	chr15:41787940	ITPKA	0.45	6.56	0.37	2.73e-10	Ulcerative colitis;
CESC	cis	rs9916302	0.768	rs11078900	chr17:37614641	C/T	cg20243544	chr17:37824526	PNMT	0.5	6.37	0.36	8.22e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs4969178	0.930	rs4580257	chr17:76403028	T/G	cg05887092	chr17:76393375	PGS1	0.59	9.14	0.49	1.74e-17	HDL cholesterol levels;
CESC	cis	rs7208859	0.673	rs9899525	chr17:29120296	T/A	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.1e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs7618915	0.547	rs6768697	chr3:52703615	C/T	cg17372223	chr3:52568218	NT5DC2	0.44	6.57	0.37	2.69e-10	Bipolar disorder;
CESC	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg22907277	chr7:1156413	C7orf50	0.46	6.56	0.37	2.81e-10	Longevity;Endometriosis;
CESC	cis	rs8112211	0.911	rs2270095	chr19:38840896	A/G	cg14299480	chr19:38876666	GGN	-0.45	-6.02	-0.35	5.76e-9	Blood protein levels;
CESC	cis	rs4665809	0.590	rs7586047	chr2:26447335	A/G	cg25036284	chr2:26402008	FAM59B	-0.86	-9.4	-0.5	2.73e-18	Gut microbiome composition (summer);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg00746487	chr13:99293520	NA	0.45	6.36	0.36	8.59e-10	Fibrinogen levels;
CESC	cis	rs853679	0.517	rs9380060	chr6:28132603	G/A	cg17949981	chr6:28129498	ZNF389	0.45	5.57	0.32	6.26e-8	Depression;
CESC	cis	rs7072216	0.770	rs1061123	chr10:100176997	A/G	cg26618903	chr10:100175079	PYROXD2	-0.33	-5.06	-0.3	7.69e-7	Metabolite levels;
CESC	cis	rs3126085	0.735	rs4845744	chr1:152185095	T/A	cg26876637	chr1:152193138	HRNR	0.48	5.44	0.32	1.21e-7	Atopic dermatitis;
CESC	cis	rs4835473	0.800	rs1849134	chr4:144879413	A/T	cg25736465	chr4:144833511	NA	0.41	6.17	0.35	2.52e-9	Immature fraction of reticulocytes;
CESC	cis	rs7811142	0.830	rs11771936	chr7:99943283	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.15	12.02	0.59	7.59e-27	Platelet count;
CESC	cis	rs72781680	1.000	rs7588286	chr2:24071427	A/G	cg08917208	chr2:24149416	ATAD2B	0.93	8.48	0.46	1.57e-15	Lymphocyte counts;
CESC	cis	rs13082711	0.522	rs533175	chr3:27361432	A/G	cg02860705	chr3:27208620	NA	-0.38	-5.24	-0.31	3.32e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CESC	cis	rs17253792	0.915	rs79894275	chr14:56180285	C/T	cg01858014	chr14:56050164	KTN1	-0.94	-7.27	-0.41	4.03e-12	Putamen volume;
CESC	cis	rs853679	0.517	rs1904840	chr6:28108232	C/T	cg26335602	chr6:28129616	ZNF389	0.54	7.14	0.4	8.92e-12	Depression;
CESC	cis	rs921968	0.541	rs562510	chr2:219443001	A/C	cg02176678	chr2:219576539	TTLL4	0.5	8.86	0.48	1.18e-16	Mean corpuscular hemoglobin concentration;
CESC	cis	rs9611565	0.659	rs1810460	chr22:41927700	C/T	cg06634786	chr22:41940651	POLR3H	-0.63	-6.64	-0.38	1.8e-10	Vitiligo;
CESC	cis	rs10899021	0.790	rs7932194	chr11:74327378	C/G	cg25880958	chr11:74394337	NA	-0.74	-7.91	-0.44	7.23e-14	Response to metformin (IC50);
CESC	cis	rs2439831	0.850	rs28595038	chr15:44044859	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.7	7.97	0.44	4.82e-14	Lung cancer in ever smokers;
CESC	cis	rs7592578	0.882	rs7569128	chr2:191446691	C/A	cg27211696	chr2:191398769	TMEM194B	0.59	5.3	0.31	2.46e-7	Diastolic blood pressure;
CESC	cis	rs13191362	0.507	rs2849540	chr6:163094522	G/A	cg21926612	chr6:163149169	PACRG;PARK2	-0.64	-7.59	-0.42	5.39e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs1538970	0.851	rs61788285	chr1:45919234	A/C	cg03146154	chr1:46216737	IPP	0.47	5.44	0.32	1.23e-7	Platelet count;
CESC	cis	rs1879734	0.731	rs12044337	chr1:54160558	C/T	cg23596471	chr1:54105337	GLIS1	0.35	5.66	0.33	3.96e-8	Mitral valve prolapse;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17597744	chr8:53627099	RB1CC1	0.6	6.5	0.37	3.92e-10	Gut microbiome composition (summer);
CESC	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg11965913	chr1:205819406	PM20D1	0.47	7.09	0.4	1.2e-11	Menarche (age at onset);
CESC	cis	rs9473147	0.543	rs9369716	chr6:47552180	A/T	cg20196966	chr6:47445060	CD2AP	0.39	5.05	0.3	8.37e-7	Platelet distribution width;Mean platelet volume;
CESC	cis	rs1552244	0.882	rs17050699	chr3:10037167	G/A	cg08888203	chr3:10149979	C3orf24	0.48	6.07	0.35	4.37e-9	Alzheimer's disease;
CESC	cis	rs11190604	1.000	rs1054399	chr10:102312565	C/T	cg07080220	chr10:102295463	HIF1AN	0.6	5.72	0.33	2.85e-8	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs3096299	0.933	rs3096297	chr16:89453155	T/G	cg08822215	chr16:89438651	ANKRD11	-0.41	-6.14	-0.35	3.07e-9	Multiple myeloma (IgH translocation);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg18654971	chr5:54469363	MIR449C;CDC20B	0.52	6.65	0.38	1.71e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs57506017	0.565	rs6460895	chr7:12252540	C/G	cg23422036	chr7:12250390	TMEM106B	-0.39	-5.24	-0.31	3.21e-7	Neuroticism;
CESC	cis	rs1005277	0.505	rs10827835	chr10:38150709	G/A	cg00409905	chr10:38381863	ZNF37A	0.55	7.56	0.42	6.68e-13	Extrinsic epigenetic age acceleration;
CESC	cis	rs12893597	0.715	rs12892786	chr14:76833888	C/T	cg20290672	chr14:76816747	NA	-0.37	-5.24	-0.31	3.36e-7	Maximal oxygen uptake response;
CESC	cis	rs11249608	0.548	rs7732719	chr5:178463054	A/G	cg01312482	chr5:178451176	ZNF879	-0.45	-6.05	-0.35	4.95e-9	Pubertal anthropometrics;
CESC	cis	rs9467711	0.606	rs9393713	chr6:26373678	C/T	cg12826209	chr6:26865740	GUSBL1	0.59	5.19	0.3	4.14e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs7927771	0.524	rs12286721	chr11:47701528	G/T	cg18512352	chr11:47633146	NA	-0.36	-5.57	-0.32	6.2e-8	Subjective well-being;
CESC	trans	rs1814175	0.511	rs61905634	chr11:49819736	G/A	cg15704280	chr7:45808275	SEPT13	-1.02	-20.13	-0.78	2.46e-55	Height;
CESC	cis	rs1005277	0.522	rs9418276	chr10:37940116	G/T	cg25517755	chr10:38738941	LOC399744	-0.42	-5.52	-0.32	8.28e-8	Extrinsic epigenetic age acceleration;
CESC	cis	rs4566357	0.615	rs4675140	chr2:227908665	C/T	cg05526886	chr2:227700861	RHBDD1	-0.47	-6.05	-0.35	5.03e-9	Coronary artery disease;
CESC	trans	rs4332037	0.802	rs73048106	chr7:1929019	G/T	cg11693508	chr17:37793320	STARD3	0.64	6.13	0.35	3.11e-9	Bipolar disorder;
CESC	cis	rs10847980	1.000	rs10847980	chr12:123387922	G/T	cg19120225	chr12:123595024	PITPNM2	-0.67	-5.52	-0.32	8.14e-8	Adiponectin levels;
CESC	cis	rs10876993	0.928	rs1689592	chr12:58057773	C/T	cg18357645	chr12:58087776	OS9	0.64	10.45	0.54	1.28e-21	Celiac disease or Rheumatoid arthritis;
CESC	cis	rs6912958	0.703	rs9359748	chr6:88095500	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.72	10.34	0.54	2.88e-21	Monocyte percentage of white cells;
CESC	cis	rs863345	0.604	rs10908656	chr1:158461016	A/G	cg12129480	chr1:158549410	OR10X1	-0.36	-7.14	-0.4	8.93e-12	Pneumococcal bacteremia;
CESC	cis	rs1005277	0.579	rs1621040	chr10:38497232	T/C	cg25427524	chr10:38739819	LOC399744	-0.73	-11.04	-0.56	1.47e-23	Extrinsic epigenetic age acceleration;
CESC	cis	rs8072100	0.840	rs9895746	chr17:45479099	C/A	cg25173405	chr17:45401733	C17orf57	-0.41	-5.47	-0.32	1.04e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs801193	0.591	rs721717	chr7:66130292	G/T	cg10691866	chr7:65817282	TPST1	0.31	5.34	0.31	2e-7	Aortic root size;
CESC	cis	rs17376456	0.877	rs56373208	chr5:93491276	C/A	cg21475434	chr5:93447410	FAM172A	0.9	7.77	0.43	1.68e-13	Diabetic retinopathy;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg07934232	chr19:36619082	NA	-0.49	-6.15	-0.35	2.81e-9	Ulcerative colitis;
CESC	cis	rs17253792	0.822	rs77197405	chr14:56159662	T/A	cg01858014	chr14:56050164	KTN1	-0.97	-7.59	-0.42	5.34e-13	Putamen volume;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg05224827	chr14:50999389	MAP4K5;ATL1	-0.47	-6.67	-0.38	1.48e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs4654899	0.802	rs12127519	chr1:21247365	C/T	cg05370193	chr1:21551575	ECE1	0.38	5.53	0.32	7.69e-8	Superior frontal gyrus grey matter volume;
CESC	cis	rs17655565	1.000	rs60696802	chr12:52693176	C/T	cg08257133	chr12:52711352	KRT83	0.46	5.1	0.3	6.49e-7	Plasma amyloid beta peptide concentrations (ABx-42);
CESC	cis	rs17401966	0.931	rs11587854	chr1:10447622	G/A	cg15208524	chr1:10270712	KIF1B	0.41	5.23	0.31	3.51e-7	Hepatocellular carcinoma;
CESC	cis	rs2882667	0.931	rs7720150	chr5:138334069	C/A	cg04439458	chr5:138467593	SIL1	-0.31	-5.35	-0.31	1.9e-7	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs9487051	0.872	rs6924776	chr6:109612276	A/G	cg01475377	chr6:109611718	NA	-0.5	-8.41	-0.46	2.52e-15	Reticulocyte fraction of red cells;
CESC	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.57	7.45	0.42	1.32e-12	Prudent dietary pattern;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg08292080	chr16:56398010	AMFR	0.42	6.2	0.36	2.1e-9	Fibrinogen levels;
CESC	cis	rs7618915	0.571	rs1961959	chr3:52585760	G/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.38	6.56	0.37	2.85e-10	Bipolar disorder;
CESC	cis	rs2429369	0.528	rs2526376	chr17:56427142	A/C	cg25039879	chr17:56429692	SUPT4H1	0.43	5.44	0.32	1.18e-7	Cognitive function;
CESC	cis	rs1152591	0.543	rs1152592	chr14:64676098	A/G	cg21174375	chr14:64681225	SYNE2	0.63	9.06	0.49	2.95e-17	Atrial fibrillation;
CESC	cis	rs9815354	0.761	rs73083326	chr3:41927150	G/T	cg03022575	chr3:42003672	ULK4	0.71	6.44	0.37	5.46e-10	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs7589342	0.862	rs6745887	chr2:106468039	G/A	cg16077055	chr2:106428750	NCK2	0.54	7.78	0.43	1.66e-13	Addiction;
CESC	cis	rs7615952	0.736	rs9866347	chr3:125669925	C/T	cg05084668	chr3:125655381	ALG1L	-0.83	-7.89	-0.44	7.91e-14	Blood pressure (smoking interaction);
CESC	trans	rs10489896	0.541	rs12760253	chr1:234577514	G/C	cg10395685	chr11:86085715	CCDC81	-0.43	-6.27	-0.36	1.48e-9	Cognitive test performance;
CESC	cis	rs2439831	0.867	rs8039638	chr15:43634405	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.84	12.56	0.61	1.02e-28	Lung cancer in ever smokers;
CESC	cis	rs992157	0.735	rs10932765	chr2:219099484	T/C	cg00012203	chr2:219082015	ARPC2	0.84	12.22	0.6	1.49e-27	Colorectal cancer;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg22692790	chr10:70748415	KIAA1279	-0.46	-6.15	-0.35	2.9e-9	Asthma;
CESC	cis	rs9443189	0.763	rs2748952	chr6:76444360	G/A	cg01950844	chr6:76311363	SENP6	-0.61	-6.73	-0.38	1.02e-10	Prostate cancer;
CESC	cis	rs7017914	0.967	rs62508819	chr8:71718106	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.42	-5.39	-0.31	1.54e-7	Bone mineral density;
CESC	trans	rs1814175	0.645	rs4411280	chr11:49962750	A/G	cg03929089	chr4:120376271	NA	-0.92	-15.24	-0.68	4.49e-38	Height;
CESC	cis	rs7618915	0.501	rs3755798	chr3:52741160	G/A	cg18404041	chr3:52824283	ITIH1	-0.39	-6.63	-0.38	1.85e-10	Bipolar disorder;
CESC	cis	rs35146811	0.961	rs1880949	chr7:99722266	A/C	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	-0.44	-5.42	-0.32	1.34e-7	Coronary artery disease;
CESC	cis	rs2455799	0.613	rs7614204	chr3:15792748	A/G	cg09340198	chr3:15902540	ANKRD28	-0.33	-5.16	-0.3	4.94e-7	Mean platelet volume;
CESC	cis	rs4834770	1.000	rs878374	chr4:120237564	A/G	cg09307838	chr4:120376055	NA	0.48	5.92	0.34	1e-8	Blood protein levels;
CESC	cis	rs6084875	0.733	rs6052854	chr20:4742399	A/G	cg05143360	chr20:4741328	NA	0.54	7.41	0.41	1.71e-12	Systemic lupus erythematosus;
CESC	cis	rs113835537	0.559	rs74933537	chr11:66274958	A/C	cg22134325	chr11:66188745	NPAS4	0.36	5.62	0.33	4.73e-8	Airway imaging phenotypes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14487595	chr6:43597054	MAD2L1BP;GTPBP2	0.62	7.58	0.42	5.74e-13	Gut microbiome composition (summer);
CESC	cis	rs2439831	0.850	rs28578398	chr15:44075046	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.68	7.97	0.44	4.59e-14	Lung cancer in ever smokers;
CESC	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	10.16	0.53	1.09e-20	Prudent dietary pattern;
CESC	cis	rs6952808	0.500	rs3800902	chr7:2144378	C/T	cg02951883	chr7:2050386	MAD1L1	-0.46	-5.94	-0.34	8.76e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs7267979	1.000	rs6083844	chr20:25386832	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.87	-18.03	-0.74	5.63e-48	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs6502050	0.805	rs6502057	chr17:80082060	A/G	cg23985595	chr17:80112537	CCDC57	0.41	6.4	0.37	7.12e-10	Life satisfaction;
CESC	trans	rs116095464	0.558	rs7356696	chr5:284251	A/G	cg00938859	chr5:1591904	SDHAP3	0.65	7.03	0.4	1.73e-11	Breast cancer;
CESC	cis	rs9611565	0.512	rs4820446	chr22:42215684	C/T	cg03806693	chr22:41940476	POLR3H	-1.17	-13.64	-0.64	1.9e-32	Vitiligo;
CESC	cis	rs7224737	1.000	rs8074708	chr17:40286354	A/G	cg16550651	chr17:40268381	KAT2A	-0.36	-5.08	-0.3	7.28e-7	Fibrinogen levels;
CESC	cis	rs13191362	1.000	rs13215491	chr6:163010325	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.87	8.98	0.48	5.33e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs4919087	0.683	rs1687371	chr10:98978183	T/A	cg25902810	chr10:99078978	FRAT1	-0.5	-5.7	-0.33	3.19e-8	Monocyte count;
CESC	cis	rs4595586	0.655	rs4142847	chr12:39395128	C/T	cg26384229	chr12:38710491	ALG10B	0.43	6.28	0.36	1.35e-9	Morning vs. evening chronotype;
CESC	cis	rs34779708	0.733	rs4444023	chr10:35548354	G/A	cg04310649	chr10:35416472	CREM	-0.45	-5.14	-0.3	5.34e-7	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs9318086	0.904	rs9580769	chr13:24439724	T/C	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.38	-5.27	-0.31	2.88e-7	Myopia (pathological);
CESC	cis	rs13034020	0.522	rs12464096	chr2:61239332	G/C	cg18625361	chr2:61244694	PEX13;PUS10	0.66	5.9	0.34	1.13e-8	Hodgkin's lymphoma;
CESC	cis	rs13108904	0.934	rs4974596	chr4:1301052	A/G	cg00684032	chr4:1343700	KIAA1530	0.41	5.72	0.33	2.93e-8	Obesity-related traits;
CESC	cis	rs2011503	1.000	rs8101219	chr19:19643715	G/A	cg11584989	chr19:19387371	SF4	0.58	6.67	0.38	1.52e-10	Bipolar disorder;
CESC	cis	rs1153858	1.000	rs7167900	chr15:45639471	A/G	cg21132104	chr15:45694354	SPATA5L1	0.82	11.02	0.56	1.72e-23	Homoarginine levels;
CESC	cis	rs6545883	0.929	rs778140	chr2:61682976	C/T	cg15711740	chr2:61764176	XPO1	-0.4	-5.24	-0.31	3.24e-7	Tuberculosis;
CESC	cis	rs15676	0.947	rs2293966	chr9:131591832	G/A	cg00228799	chr9:131580591	ENDOG	0.44	5.53	0.32	7.59e-8	Blood metabolite levels;
CESC	cis	rs617791	0.508	rs10791837	chr11:65774596	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.44	-5.12	-0.3	6.02e-7	Breast cancer;
CESC	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg02071572	chr4:1403502	NA	0.34	5.1	0.3	6.55e-7	Longevity;
CESC	trans	rs1814175	0.791	rs1722011	chr11:49899340	G/C	cg03929089	chr4:120376271	NA	-0.92	-15.84	-0.7	3.16e-40	Height;
CESC	cis	rs9388451	0.874	rs1159974	chr6:126090277	C/T	cg05901451	chr6:126070800	HEY2	0.65	9.21	0.49	1.03e-17	Brugada syndrome;
CESC	cis	rs9512730	0.517	rs1967772	chr13:28036062	G/A	cg08193333	chr13:27998609	GTF3A	0.42	5.23	0.31	3.39e-7	Schizophrenia;
CESC	cis	rs3126085	0.935	rs56013982	chr1:152176503	C/T	cg03465714	chr1:152285911	FLG	0.47	5.25	0.31	3.07e-7	Atopic dermatitis;
CESC	cis	rs2635047	0.542	rs1512235	chr18:44781569	A/G	cg24371990	chr18:44770781	NA	0.34	5.47	0.32	1.06e-7	Educational attainment;
CESC	cis	rs11051970	0.559	rs11051992	chr12:32564667	G/T	cg24626660	chr12:32551988	NA	0.35	5.03	0.3	9.04e-7	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs208520	0.690	rs851464	chr6:66839802	C/T	cg07460842	chr6:66804631	NA	-0.99	-13.42	-0.64	1.15e-31	Exhaled nitric oxide output;
CESC	trans	rs17685	0.753	rs10476	chr7:75696420	C/T	cg19862616	chr7:65841803	NCRNA00174	-0.82	-12.12	-0.6	3.49e-27	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs7666738	0.830	rs34164616	chr4:99015251	G/A	cg03676636	chr4:99064102	C4orf37	0.33	5.16	0.3	4.86e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs1814175	0.817	rs28679516	chr11:50055998	G/A	cg03929089	chr4:120376271	NA	-0.94	-15.72	-0.69	8.37e-40	Height;
CESC	cis	rs10479542	0.766	rs6894980	chr5:178974592	C/T	cg00080972	chr5:178986291	RUFY1	0.36	5.22	0.31	3.64e-7	Lung cancer;
CESC	cis	rs694739	0.734	rs663743	chr11:64107735	G/A	cg23796481	chr11:64053134	BAD;GPR137	0.71	8.52	0.46	1.22e-15	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CESC	cis	rs9948	0.655	rs17119564	chr2:97384728	G/A	cg01990225	chr2:97406019	LMAN2L	-0.97	-7.25	-0.41	4.52e-12	Erectile dysfunction and prostate cancer treatment;
CESC	trans	rs7107217	1.000	rs1873872	chr11:129473993	A/T	cg12997958	chr17:18161617	FLII	-0.48	-6.07	-0.35	4.38e-9	Breast cancer;Type 2 diabetes;
CESC	cis	rs4713118	0.662	rs9393881	chr6:28023751	C/G	cg19592336	chr6:28129416	ZNF389	0.53	6.82	0.39	6.18e-11	Parkinson's disease;
CESC	cis	rs1348850	0.651	rs4893821	chr2:178229352	A/G	cg23306229	chr2:178417860	TTC30B	-0.54	-6.97	-0.39	2.51e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs7508679	1.000	rs7248104	chr19:7224431	A/G	cg00428638	chr19:7224713	INSR	0.55	8.71	0.47	3.34e-16	Hypothyroidism;
CESC	cis	rs826838	0.904	rs10880981	chr12:38763911	G/A	cg13010199	chr12:38710504	ALG10B	0.62	8.74	0.47	2.7e-16	Heart rate;
CESC	cis	rs514406	0.861	rs503015	chr1:53254456	T/C	cg16325326	chr1:53192061	ZYG11B	-0.88	-14.98	-0.68	3.69e-37	Monocyte count;
CESC	cis	rs5758659	0.714	rs133376	chr22:42466905	C/T	cg04733989	chr22:42467013	NAGA	0.41	5.53	0.32	7.61e-8	Cognitive function;
CESC	cis	rs7845219	0.544	rs9643350	chr8:95917276	C/A	cg16049864	chr8:95962084	TP53INP1	-0.47	-6.91	-0.39	3.49e-11	Type 2 diabetes;
CESC	cis	rs9467711	0.606	rs9379854	chr6:26362854	T/C	cg12826209	chr6:26865740	GUSBL1	0.62	5.31	0.31	2.27e-7	Autism spectrum disorder or schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15472170	chr1:12012720	PLOD1	-0.55	-6.43	-0.37	5.93e-10	Gut microbiome composition (summer);
CESC	cis	rs11051970	0.592	rs11052002	chr12:32590854	T/A	cg24626660	chr12:32551988	NA	0.36	5.21	0.3	3.77e-7	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs3857067	0.772	rs10516947	chr4:95110897	A/T	cg11021082	chr4:95130006	SMARCAD1	-0.6	-9.12	-0.49	1.97e-17	QT interval;
CESC	cis	rs7666738	0.791	rs11735105	chr4:98937357	C/T	cg03467027	chr4:99064603	C4orf37	0.48	5.91	0.34	1.03e-8	Colonoscopy-negative controls vs population controls;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg02671019	chr1:24829462	RCAN3	-0.44	-6.01	-0.35	6.21e-9	Fibrinogen levels;
CESC	cis	rs2997447	0.633	rs11247848	chr1:26357667	G/A	cg19633962	chr1:26362018	EXTL1	-0.57	-5.6	-0.33	5.4e-8	QRS complex (12-leadsum);
CESC	cis	rs1552244	0.554	rs2272121	chr3:10047680	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.62	7.99	0.44	4.24e-14	Alzheimer's disease;
CESC	cis	rs10504229	0.679	rs16920056	chr8:58106218	C/A	cg22535103	chr8:58192502	C8orf71	-0.77	-8.76	-0.47	2.37e-16	Developmental language disorder (linguistic errors);
CESC	cis	rs77106637	0.860	rs1552224	chr11:72433098	A/C	cg04827223	chr11:72435913	ARAP1	-0.62	-6.53	-0.37	3.25e-10	Type 2 diabetes;
CESC	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg22764044	chr5:178986830	RUFY1	0.49	7.39	0.41	1.93e-12	Lung cancer;
CESC	cis	rs2576037	0.526	rs4890707	chr18:44497724	C/G	cg19077165	chr18:44547161	KATNAL2	-0.54	-8.01	-0.44	3.56e-14	Personality dimensions;
CESC	cis	rs1506636	1.000	rs635072	chr7:123403255	G/A	cg03229431	chr7:123269106	ASB15	0.51	6.76	0.38	8.9e-11	Plateletcrit;Platelet count;
CESC	cis	rs2243480	1.000	rs1723270	chr7:65469830	T/G	cg13147721	chr7:65941812	NA	-0.9	-8.73	-0.47	2.9e-16	Diabetic kidney disease;
CESC	cis	rs9815354	1.000	rs9865780	chr3:41895802	A/G	cg03022575	chr3:42003672	ULK4	0.45	5.23	0.31	3.48e-7	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs950169	0.922	rs11631096	chr15:85100929	G/C	cg17507749	chr15:85114479	UBE2QP1	0.56	6.24	0.36	1.7e-9	Schizophrenia;
CESC	cis	rs9486719	0.741	rs976356	chr6:96849437	T/A	cg18709589	chr6:96969512	KIAA0776	0.55	5.67	0.33	3.72e-8	Migraine;Coronary artery disease;
CESC	cis	rs2730245	0.636	rs710421	chr7:158668575	T/C	cg24397884	chr7:158709396	WDR60	0.7	10.13	0.53	1.3e-20	Height;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg04665974	chr16:30103391	TBX6	-0.49	-6.29	-0.36	1.27e-9	Fibrinogen levels;
CESC	cis	rs7829975	0.533	rs13274028	chr8:8729193	A/C	cg15556689	chr8:8085844	FLJ10661	0.42	5.18	0.3	4.44e-7	Mood instability;
CESC	trans	rs561341	1.000	rs506766	chr17:30289659	T/C	cg20587970	chr11:113659929	NA	-1.42	-16.62	-0.71	5.47e-43	Hip circumference adjusted for BMI;
CESC	cis	rs34779708	0.931	rs35886556	chr10:35334985	C/T	cg04310649	chr10:35416472	CREM	-0.49	-5.83	-0.34	1.57e-8	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg12419862	chr22:24373484	LOC391322	-0.73	-10.35	-0.54	2.67e-21	Liver enzyme levels (gamma-glutamyl transferase);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18044720	chr4:87857031	AFF1	-0.69	-7.52	-0.42	8.31e-13	Gut microbiome composition (summer);
CESC	cis	rs3733585	0.673	rs6850143	chr4:9958924	T/C	cg11266682	chr4:10021025	SLC2A9	-0.6	-11.2	-0.57	4.42e-24	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs10504229	1.000	rs67236942	chr8:58176525	T/C	cg05313129	chr8:58192883	C8orf71	-0.55	-6.37	-0.36	8.42e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs1801251	0.963	rs283481	chr2:233648091	A/G	cg08000102	chr2:233561755	GIGYF2	0.67	9.28	0.5	6.17e-18	Coronary artery disease;
CESC	cis	rs11785400	0.793	rs1056012	chr8:143740167	A/G	cg24634471	chr8:143751801	JRK	0.45	5.75	0.33	2.41e-8	Schizophrenia;
CESC	cis	rs244293	0.701	rs4793783	chr17:53025480	T/C	cg19360675	chr17:53046073	COX11;STXBP4	-0.44	-5.85	-0.34	1.48e-8	Menarche (age at onset);
CESC	cis	rs2839186	0.771	rs2280957	chr21:47642272	A/G	cg10351095	chr21:47802916	PCNT	0.46	6.26	0.36	1.55e-9	Testicular germ cell tumor;
CESC	cis	rs854765	0.624	rs9899634	chr17:17727943	A/T	cg09796270	chr17:17721594	SREBF1	-0.4	-5.47	-0.32	1.04e-7	Total body bone mineral density;
CESC	cis	rs6062302	0.549	rs4809586	chr20:62249402	C/T	cg06363034	chr20:62225388	GMEB2	-0.5	-6.41	-0.37	6.66e-10	Glioblastoma;
CESC	cis	rs7917772	0.619	rs2801050	chr10:104509393	T/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.51	5.94	0.34	9.14e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs4944092	0.793	rs94111	chr11:75915139	A/G	cg04588336	chr11:75916460	WNT11	-0.52	-8.5	-0.46	1.44e-15	PR interval;
CESC	cis	rs35110281	0.805	rs2838317	chr21:44991791	A/C	cg01579765	chr21:45077557	HSF2BP	-0.58	-10.06	-0.53	2.19e-20	Mean corpuscular volume;
CESC	cis	rs1355223	0.966	rs11602318	chr11:34766983	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.45	5.91	0.34	1.03e-8	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs6088590	0.965	rs6120727	chr20:33374102	T/C	cg24642439	chr20:33292090	TP53INP2	0.84	11.76	0.59	5.5e-26	Coronary artery disease;
CESC	cis	rs9790314	1.000	rs1600209	chr3:161038217	A/T	cg04691961	chr3:161091175	C3orf57	-0.43	-5.56	-0.32	6.47e-8	Morning vs. evening chronotype;
CESC	cis	rs3125734	0.608	rs7094950	chr10:64019744	T/C	cg09941381	chr10:64027924	RTKN2	-0.32	-5.24	-0.31	3.22e-7	Rheumatoid arthritis;
CESC	cis	rs58688157	0.660	rs12797496	chr11:583767	C/T	cg02461776	chr11:598696	PHRF1	0.51	5.55	0.32	6.99e-8	Systemic lupus erythematosus;
CESC	cis	rs344364	0.511	rs2982449	chr16:1947878	C/G	cg26617929	chr16:1858877	NA	-0.49	-5.15	-0.3	5.09e-7	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg23708337	chr7:1209742	NA	0.5	5.63	0.33	4.68e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs478304	0.651	rs11532071	chr11:65500198	C/A	cg10518572	chr11:65560635	OVOL1	-0.32	-6.19	-0.36	2.31e-9	Acne (severe);
CESC	cis	rs2842992	0.830	rs2758352	chr6:160122921	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.71	9.01	0.48	4.16e-17	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs9324022	0.584	rs72698722	chr14:101181881	C/T	cg18089426	chr14:101175970	NA	0.59	8.29	0.45	5.59e-15	Plateletcrit;
CESC	cis	rs2836974	0.897	rs3945	chr21:40566067	A/G	cg27266027	chr21:40555129	PSMG1	0.47	5.41	0.32	1.42e-7	Cognitive function;
CESC	cis	rs9309473	0.500	rs1528169	chr2:73669186	T/C	cg20560298	chr2:73613845	ALMS1	0.48	6.92	0.39	3.47e-11	Metabolite levels;
CESC	cis	rs950027	0.549	rs11070452	chr15:45594836	C/A	cg21132104	chr15:45694354	SPATA5L1	-0.57	-6.84	-0.39	5.62e-11	Response to fenofibrate (adiponectin levels);
CESC	cis	rs10540	1.000	rs10540	chr11:494662	G/A	cg21784768	chr11:537496	LRRC56	-0.54	-5.11	-0.3	6.29e-7	Body mass index;
CESC	cis	rs9815354	0.812	rs17218441	chr3:41987044	A/G	cg03022575	chr3:42003672	ULK4	0.68	6.1	0.35	3.75e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs2645694	0.626	rs2645708	chr4:77822682	G/A	cg10057126	chr4:77819792	ANKRD56	0.58	8.6	0.47	7.31e-16	Emphysema distribution in smoking;
CESC	cis	rs7267979	1.000	rs2257991	chr20:25270339	C/T	cg08601574	chr20:25228251	PYGB	-0.37	-5.36	-0.31	1.83e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs10256972	0.900	rs4388364	chr7:1033045	T/G	cg07930192	chr7:1003750	NA	0.4	5.36	0.31	1.77e-7	Longevity;Endometriosis;
CESC	cis	rs12477438	0.520	rs1044575	chr2:99812070	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.89	15.94	0.7	1.46e-40	Chronic sinus infection;
CESC	cis	rs4665809	0.567	rs6711402	chr2:26430983	A/G	cg27170947	chr2:26402098	FAM59B	-0.83	-9.3	-0.5	5.43e-18	Gut microbiome composition (summer);
CESC	cis	rs10479542	0.784	rs7702303	chr5:178986436	G/A	cg19723775	chr5:179050963	HNRNPH1	0.43	5.76	0.33	2.31e-8	Lung cancer;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg04389328	chr22:20104991	RANBP1;TRMT2A	-0.45	-6.27	-0.36	1.43e-9	Ulcerative colitis;
CESC	trans	rs7866350	0.604	rs1935389	chr9:100994470	A/G	cg12639324	chr10:92617735	HTR7	0.44	6.79	0.38	7.38e-11	Post-traumatic stress disorder;
CESC	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg24503407	chr1:205819492	PM20D1	0.82	13.93	0.65	1.88e-33	Menarche (age at onset);
CESC	cis	rs7617480	0.610	rs4955420	chr3:49208865	A/G	cg06212747	chr3:49208901	KLHDC8B	0.78	12.53	0.61	1.3e-28	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CESC	cis	rs9584850	0.794	rs17470961	chr13:99135314	A/G	cg20750642	chr13:99100586	FARP1	-0.36	-5.59	-0.32	5.6e-8	Neuroticism;
CESC	cis	rs2635047	0.713	rs9952628	chr18:44754651	G/A	cg24371990	chr18:44770781	NA	0.41	6.53	0.37	3.3e-10	Educational attainment;
CESC	cis	rs10788264	0.504	rs7898942	chr10:124024608	G/T	cg09507567	chr10:124027408	NA	-0.39	-5.39	-0.31	1.57e-7	Total body bone mineral density;
CESC	trans	rs9987353	0.840	rs329994	chr8:9123233	A/G	cg03981592	chr3:86061698	CADM2	0.45	6.05	0.35	4.98e-9	Recombination measurement;
CESC	trans	rs1557351	0.723	rs1942348	chr18:54724697	A/G	cg11433624	chr6:7146702	RREB1	0.4	6.48	0.37	4.37e-10	Multiple sclerosis (age of onset);
CESC	cis	rs7772486	0.790	rs2265917	chr6:146212285	A/G	cg05347473	chr6:146136440	FBXO30	0.55	7.05	0.4	1.57e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7122539	0.768	rs7931485	chr11:66578635	G/A	cg24851651	chr11:66362959	CCS	0.39	5.27	0.31	2.84e-7	HIV-1 susceptibility;
CESC	cis	rs4901869	0.897	rs12878587	chr14:59339378	C/G	cg02291164	chr14:59296302	NA	0.45	7.81	0.43	1.3e-13	Panic disorder;
CESC	cis	rs1843834	0.539	rs6713629	chr2:225410973	A/T	cg22455342	chr2:225449267	CUL3	0.71	9.84	0.52	1.1e-19	IgE levels in asthmatics (D.p. specific);
CESC	cis	rs3126085	0.778	rs9887901	chr1:152248552	A/C	cg03465714	chr1:152285911	FLG	-0.45	-5.56	-0.32	6.52e-8	Atopic dermatitis;
CESC	cis	rs116095464	0.614	rs62344292	chr5:244630	G/A	cg22857025	chr5:266934	NA	-1.27	-18.37	-0.75	3.49e-49	Breast cancer;
CESC	trans	rs9329221	0.513	rs4841296	chr8:10105447	C/G	cg15556689	chr8:8085844	FLJ10661	-0.53	-6.35	-0.36	9.15e-10	Neuroticism;
CESC	cis	rs7577696	0.554	rs3769605	chr2:32322456	A/G	cg02381751	chr2:32503542	YIPF4	-0.45	-5.48	-0.32	9.83e-8	Inflammatory biomarkers;
CESC	cis	rs4718428	0.705	rs11028	chr7:66276217	T/C	cg12165864	chr7:66369176	NA	-0.57	-6.4	-0.37	7.18e-10	Corneal structure;
CESC	trans	rs208520	0.690	rs6932475	chr6:66863155	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.99	-12.92	-0.62	6e-30	Exhaled nitric oxide output;
CESC	cis	rs7178572	0.568	rs7176302	chr15:77671216	C/G	cg22256960	chr15:77711686	NA	-0.53	-6.79	-0.38	7.5e-11	Type 2 diabetes;
CESC	cis	rs4132509	1.000	rs9782883	chr1:243892532	A/G	cg21452805	chr1:244014465	NA	0.47	5.86	0.34	1.39e-8	RR interval (heart rate);
CESC	cis	rs2985684	0.841	rs7158577	chr14:50058633	C/T	cg04989706	chr14:50066350	PPIL5	-0.45	-5.05	-0.3	8.23e-7	Carotid intima media thickness;
CESC	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg24739457	chr1:205821442	NA	0.47	6.16	0.35	2.69e-9	Menarche (age at onset);
CESC	cis	rs17253792	0.822	rs75555677	chr14:56096429	G/A	cg01858014	chr14:56050164	KTN1	-0.85	-6.99	-0.39	2.22e-11	Putamen volume;
CESC	cis	rs7811142	1.000	rs11761784	chr7:100039970	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.85	8.83	0.48	1.5e-16	Platelet count;
CESC	cis	rs9457247	1.000	rs422694	chr6:167406074	G/T	cg07741184	chr6:167504864	NA	0.29	5.31	0.31	2.32e-7	Crohn's disease;
CESC	cis	rs977987	0.836	rs7198873	chr16:75474754	G/A	cg03315344	chr16:75512273	CHST6	0.42	6.0	0.35	6.52e-9	Dupuytren's disease;
CESC	cis	rs2880765	0.743	rs11630410	chr15:86004741	T/A	cg10818794	chr15:86012489	AKAP13	-0.33	-5.06	-0.3	7.66e-7	Coronary artery disease;
CESC	cis	rs477692	0.935	rs554458	chr10:131427372	A/G	cg26102564	chr10:131424627	MGMT	0.38	5.64	0.33	4.41e-8	Response to temozolomide;
CESC	cis	rs425277	0.606	rs3128295	chr1:2068480	C/T	cg04315214	chr1:2043799	PRKCZ	0.5	8.03	0.44	3.26e-14	Height;
CESC	cis	rs2735413	0.918	rs4888731	chr16:78080418	A/G	cg04733911	chr16:78082701	NA	-0.53	-9.11	-0.49	2.11e-17	Systolic blood pressure (alcohol consumption interaction);
CESC	cis	rs1348850	0.874	rs2166558	chr2:178373652	G/T	cg23306229	chr2:178417860	TTC30B	0.65	8.02	0.44	3.42e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs9303280	0.806	rs10852936	chr17:38031714	C/T	cg19468946	chr17:37922297	IKZF3	-0.41	-5.4	-0.31	1.49e-7	Self-reported allergy;
CESC	cis	rs780094	0.544	rs780108	chr2:27684957	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.26	-5.28	-0.31	2.7e-7	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
CESC	cis	rs909674	0.818	rs8137426	chr22:39844350	T/G	cg11247378	chr22:39784982	NA	-0.63	-8.49	-0.46	1.52e-15	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01755728	chr3:49449714	TCTA;RHOA	0.61	7.22	0.41	5.6e-12	Gut microbiome composition (summer);
CESC	cis	rs1059312	0.808	rs4760537	chr12:129301299	C/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.83	-12.2	-0.6	1.77e-27	Systemic lupus erythematosus;
CESC	cis	rs1008375	0.863	rs7680984	chr4:17600884	A/G	cg02297831	chr4:17616191	MED28	0.55	6.96	0.39	2.69e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs9611565	0.694	rs202656	chr22:41842203	T/A	cg17376030	chr22:41985996	PMM1	-0.75	-7.99	-0.44	4.24e-14	Vitiligo;
CESC	cis	rs34172651	0.583	rs200541	chr16:24733141	A/G	cg06505273	chr16:24850292	NA	-0.52	-5.93	-0.34	9.48e-9	Intelligence (multi-trait analysis);
CESC	cis	rs10242455	0.702	rs59240302	chr7:99072991	C/G	cg25640893	chr7:99214727	ZNF498	0.69	5.12	0.3	5.75e-7	Blood metabolite levels;
CESC	cis	rs7107174	0.892	rs10899482	chr11:78060081	A/C	cg02023728	chr11:77925099	USP35	0.38	5.3	0.31	2.47e-7	Testicular germ cell tumor;
CESC	cis	rs514406	0.825	rs487453	chr1:53271225	T/C	cg24675658	chr1:53192096	ZYG11B	0.56	7.62	0.42	4.5e-13	Monocyte count;
CESC	cis	rs63406760	1	rs63406760	chr12:123742692	TG/T	cg00376283	chr12:123451042	ABCB9	0.7	8.63	0.47	5.59e-16	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs6088580	0.608	rs1205342	chr20:32921842	C/T	cg08999081	chr20:33150536	PIGU	-0.64	-11.02	-0.56	1.75e-23	Glomerular filtration rate (creatinine);
CESC	cis	rs7818345	0.967	rs11204040	chr8:19288525	T/A	cg11303988	chr8:19266685	CSGALNACT1	0.36	6.63	0.38	1.9e-10	Language performance in older adults (adjusted for episodic memory);
CESC	cis	rs7618501	0.633	rs4688690	chr3:50022292	G/A	cg24308560	chr3:49941425	MST1R	-0.63	-9.02	-0.48	3.95e-17	Intelligence (multi-trait analysis);
CESC	cis	rs897080	0.552	rs1067384	chr2:44644554	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	5.89	0.34	1.14e-8	Height;
CESC	cis	rs6466055	0.720	rs12668097	chr7:104996472	A/G	cg04380332	chr7:105027541	SRPK2	0.41	5.54	0.32	7.35e-8	Schizophrenia;
CESC	cis	rs5750830	0.594	rs1010169	chr22:39778167	C/T	cg02038168	chr22:39784481	NA	0.62	7.91	0.44	6.96e-14	Intelligence (multi-trait analysis);
CESC	cis	rs2708240	0.967	rs2080156	chr7:147571384	G/C	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.34	-5.53	-0.32	7.72e-8	QT interval (drug interaction);
CESC	cis	rs8031584	0.723	rs11632229	chr15:31179534	A/G	cg08704250	chr15:31115839	NA	0.64	8.72	0.47	3.03e-16	Huntington's disease progression;
CESC	cis	rs72781680	0.716	rs2712086	chr2:24004739	G/C	cg08917208	chr2:24149416	ATAD2B	0.61	5.99	0.35	6.76e-9	Lymphocyte counts;
CESC	cis	rs4460629	0.804	rs56112907	chr1:155070862	C/A	cg01019262	chr1:155095195	NA	-0.3	-5.05	-0.3	8.13e-7	Serum magnesium levels;
CESC	cis	rs2235642	0.691	rs2281235	chr16:1603535	T/C	cg03715980	chr16:1756201	MAPK8IP3	0.38	5.04	0.3	8.44e-7	Coronary artery disease;
CESC	cis	rs1609391	0.561	rs6439675	chr3:136625436	G/A	cg15507776	chr3:136538369	TMEM22	0.81	12.07	0.6	5.03e-27	Neuroticism;
CESC	cis	rs57221529	0.766	rs17563576	chr5:560476	A/G	cg16447950	chr5:562315	NA	-0.7	-7.68	-0.43	3.1e-13	Lung disease severity in cystic fibrosis;
CESC	cis	rs7618915	0.547	rs2878726	chr3:52748271	C/G	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.54	0.37	3.13e-10	Bipolar disorder;
CESC	cis	rs7666738	0.791	rs11730069	chr4:98945772	A/G	cg03676636	chr4:99064102	C4orf37	0.34	5.11	0.3	6.15e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9487051	0.872	rs9386791	chr6:109608497	C/T	cg12927641	chr6:109611667	NA	-0.43	-6.7	-0.38	1.22e-10	Reticulocyte fraction of red cells;
CESC	cis	rs2658782	1.000	rs2658781	chr11:93166368	C/T	cg15737290	chr11:93063684	CCDC67	-0.52	-6.65	-0.38	1.66e-10	Pulmonary function decline;
CESC	cis	rs6831352	0.703	rs4235435	chr4:100039578	C/T	cg13256891	chr4:100009986	ADH5	0.69	8.13	0.45	1.61e-14	Alcohol dependence;
CESC	cis	rs7618915	0.621	rs6788993	chr3:52605136	T/C	cg18337363	chr3:52569053	NT5DC2	0.29	5.3	0.31	2.49e-7	Bipolar disorder;
CESC	cis	rs798554	0.797	rs798486	chr7:2803037	A/G	cg19717773	chr7:2847554	GNA12	-0.57	-8.09	-0.44	2.2e-14	Height;
CESC	cis	rs2463822	1.000	rs2513747	chr11:62098735	T/C	cg06239285	chr11:62104954	ASRGL1	0.89	8.97	0.48	5.69e-17	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs6987853	0.814	rs2923447	chr8:42439848	G/T	cg09913449	chr8:42400586	C8orf40	0.45	7.62	0.42	4.56e-13	Mean corpuscular hemoglobin concentration;
CESC	cis	rs701145	0.556	rs355763	chr3:154012881	C/T	cg16511985	chr3:153974050	SGEF	0.43	6.08	0.35	4.21e-9	Coronary artery disease;
CESC	cis	rs250677	0.522	rs17109208	chr5:148378475	G/A	cg18129178	chr5:148520854	ABLIM3	-0.46	-5.15	-0.3	5.01e-7	Breast cancer;
CESC	cis	rs7223966	1.000	rs2874121	chr17:61731024	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.56	6.72	0.38	1.12e-10	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs780096	0.526	rs72819536	chr2:27682850	G/T	cg21248554	chr2:27665150	KRTCAP3	-0.33	-6.7	-0.38	1.27e-10	Total body bone mineral density;
CESC	cis	rs3793683	0.545	rs12784446	chr10:134589094	T/G	cg26818010	chr10:134567672	INPP5A	-0.9	-11.16	-0.57	6e-24	Migraine;
CESC	cis	rs13118159	0.550	rs10016557	chr4:1363628	C/T	cg05025164	chr4:1340916	KIAA1530	-0.68	-8.85	-0.48	1.26e-16	Longevity;
CESC	cis	rs7586879	0.681	rs6545790	chr2:25109302	A/G	cg01884057	chr2:25150051	NA	0.37	7.1	0.4	1.18e-11	Body mass index;
CESC	cis	rs1552244	1.000	rs55822690	chr3:10128003	A/G	cg08888203	chr3:10149979	C3orf24	0.48	6.18	0.36	2.36e-9	Alzheimer's disease;
CESC	cis	rs6754311	0.773	rs4988226	chr2:136610598	A/G	cg07169764	chr2:136633963	MCM6	-0.69	-8.56	-0.47	9.42e-16	Mosquito bite size;
CESC	cis	rs67311347	1.000	rs11720360	chr3:40448397	G/A	cg24209194	chr3:40518798	ZNF619	0.51	6.29	0.36	1.29e-9	Renal cell carcinoma;
CESC	cis	rs4481887	0.893	rs7538645	chr1:248478137	C/T	cg00666640	chr1:248458726	OR2T12	0.36	5.98	0.34	7.16e-9	Common traits (Other);
CESC	cis	rs938554	0.612	rs9991278	chr4:10002665	A/G	cg00071950	chr4:10020882	SLC2A9	0.5	5.9	0.34	1.12e-8	Blood metabolite levels;
CESC	cis	rs5769765	0.955	rs5769761	chr22:50263641	G/T	cg22709217	chr22:50311962	ALG12;CRELD2	0.46	5.32	0.31	2.21e-7	Schizophrenia;
CESC	cis	rs8141529	0.509	rs12628211	chr22:29239250	T/C	cg02153584	chr22:29168773	CCDC117	0.58	7.61	0.42	4.73e-13	Lymphocyte counts;
CESC	cis	rs1552244	1.000	rs7610821	chr3:10136150	C/T	cg00149659	chr3:10157352	C3orf10	0.72	9.05	0.49	3.14e-17	Alzheimer's disease;
CESC	cis	rs2836974	0.829	rs34227163	chr21:40551943	A/G	cg11890956	chr21:40555474	PSMG1	1.15	22.21	0.81	1.91e-62	Cognitive function;
CESC	cis	rs2637266	0.626	rs1660914	chr10:78525319	T/A	cg18941641	chr10:78392320	NA	0.41	7.54	0.42	7.33e-13	Pulmonary function;
CESC	cis	rs2072499	0.966	rs11587860	chr1:156156951	G/C	cg25208724	chr1:156163844	SLC25A44	0.97	17.41	0.73	9.07e-46	Testicular germ cell tumor;
CESC	cis	rs4555082	0.830	rs2816614	chr14:105727359	C/T	cg27165867	chr14:105738592	BRF1	-0.52	-5.66	-0.33	3.92e-8	Mean platelet volume;Platelet distribution width;
CESC	cis	rs2455799	0.634	rs1345160	chr3:15862026	C/T	cg16303742	chr3:15540471	COLQ	-0.36	-5.6	-0.33	5.46e-8	Mean platelet volume;
CESC	trans	rs7980799	0.649	rs11052732	chr12:33657801	A/G	cg26384229	chr12:38710491	ALG10B	-0.58	-8.17	-0.45	1.26e-14	Heart rate;Heart rate variability traits (RMSSD);
CESC	cis	rs7666738	0.830	rs921522	chr4:98841608	C/T	cg03676636	chr4:99064102	C4orf37	0.36	5.62	0.33	4.8e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs8180040	0.932	rs12489046	chr3:47527683	T/G	cg27129171	chr3:47204927	SETD2	0.62	9.22	0.49	9.43e-18	Colorectal cancer;
CESC	cis	rs524281	0.861	rs918299	chr11:65927607	C/T	cg14036092	chr11:66035641	RAB1B	-0.56	-5.81	-0.34	1.78e-8	Electroencephalogram traits;
CESC	cis	rs2841277	0.708	rs9671643	chr14:105408030	A/G	cg19901468	chr14:105411992	AHNAK2	-0.6	-8.79	-0.48	1.91e-16	Rheumatoid arthritis;
CESC	cis	rs7923609	1.000	rs10822149	chr10:64987412	G/A	cg01631684	chr10:65280961	REEP3	-0.45	-5.56	-0.32	6.57e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg00120358	chr1:100615552	LRRC39;CCDC76	0.38	6.2	0.36	2.12e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs13256369	0.851	rs11786125	chr8:8564570	T/G	cg00074818	chr8:8560427	CLDN23	0.37	5.45	0.32	1.16e-7	Obesity-related traits;
CESC	cis	rs9611565	0.765	rs132915	chr22:41805782	T/C	cg06481639	chr22:41940642	POLR3H	0.62	6.52	0.37	3.49e-10	Vitiligo;
CESC	cis	rs9902453	0.967	rs61240589	chr17:28449035	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	8.01	0.44	3.58e-14	Coffee consumption (cups per day);
CESC	cis	rs7512552	0.839	rs6703652	chr1:150465953	T/G	cg15654264	chr1:150340011	RPRD2	0.39	5.13	0.3	5.66e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs7666738	0.753	rs10029372	chr4:98859002	T/C	cg05340658	chr4:99064831	C4orf37	0.74	10.7	0.55	1.97e-22	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3785574	0.962	rs62077483	chr17:61806380	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.1	19.45	0.77	5.95e-53	Height;
CESC	cis	rs11122449	1	rs11122449	chr1:230300481	C/T	cg20703242	chr1:230279135	GALNT2	0.35	5.54	0.32	7.21e-8	Red cell distribution width;
CESC	cis	rs6754311	0.731	rs892715	chr2:136576577	T/C	cg15123519	chr2:136567270	LCT	0.33	5.62	0.33	4.81e-8	Mosquito bite size;
CESC	cis	rs13385	0.769	rs17118781	chr5:139642929	C/T	cg26211634	chr5:139558579	C5orf32	0.47	5.07	0.3	7.63e-7	Atrial fibrillation;
CESC	cis	rs9430161	0.579	rs11121669	chr1:11039567	T/C	cg02454025	chr1:11042201	C1orf127	0.86	13.22	0.63	5.34e-31	Ewing sarcoma;
CESC	cis	rs12824058	0.767	rs4759654	chr12:130815559	A/G	cg26677194	chr12:130822605	PIWIL1	0.52	6.81	0.39	6.58e-11	Menopause (age at onset);
CESC	cis	rs734999	0.588	rs2843401	chr1:2528133	T/C	cg20673091	chr1:2541236	MMEL1	-0.44	-7.23	-0.41	5.08e-12	Ulcerative colitis;
CESC	cis	rs1799949	0.536	rs4793227	chr17:41412250	A/C	cg25072359	chr17:41440525	NA	0.53	7.84	0.43	1.11e-13	Menopause (age at onset);
CESC	cis	rs899997	0.814	rs28661610	chr15:78985317	G/A	cg04896959	chr15:78267971	NA	-0.47	-6.46	-0.37	5.02e-10	Coronary artery disease or large artery stroke;
CESC	trans	rs11098499	0.863	rs10019674	chr4:120443489	C/T	cg25214090	chr10:38739885	LOC399744	-0.66	-9.07	-0.49	2.81e-17	Corneal astigmatism;
CESC	cis	rs7223966	1.000	rs8075061	chr17:61804723	A/G	cg11494091	chr17:61959527	GH2	0.38	5.19	0.3	4.28e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs1707322	0.752	rs12062535	chr1:46222880	G/A	cg05343316	chr1:45956843	TESK2	0.51	6.32	0.36	1.09e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9399137	0.507	rs7754722	chr6:135260303	T/C	cg22676075	chr6:135203613	NA	-0.58	-7.73	-0.43	2.21e-13	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	cis	rs7508	1.000	rs7508	chr8:17913970	G/A	cg18067069	chr8:17937731	ASAH1	-0.43	-5.13	-0.3	5.74e-7	Atrial fibrillation;
CESC	cis	rs3026101	0.723	rs1806248	chr17:5310411	T/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.42	5.61	0.33	4.97e-8	Body mass index;
CESC	cis	rs8027181	1.000	rs8030477	chr15:73085815	C/T	cg25632853	chr15:73088954	NA	0.37	6.62	0.38	1.97e-10	Triglyceride levels;
CESC	trans	rs7618501	0.633	rs9866695	chr3:50069452	G/T	cg21659725	chr3:3221576	CRBN	-0.49	-6.67	-0.38	1.52e-10	Intelligence (multi-trait analysis);
CESC	trans	rs57221529	0.766	rs58015612	chr5:580665	A/T	cg25482853	chr8:67687455	SGK3	1.0	10.02	0.52	2.96e-20	Lung disease severity in cystic fibrosis;
CESC	cis	rs9311474	0.507	rs6787154	chr3:52784416	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.62	8.78	0.47	2.09e-16	Electroencephalogram traits;
CESC	cis	rs12142240	0.698	rs10158236	chr1:46820896	G/T	cg00530320	chr1:46809349	NSUN4	0.6	8.04	0.44	2.96e-14	Menopause (age at onset);
CESC	cis	rs2243480	1.000	rs6970243	chr7:65388490	C/A	cg18252515	chr7:66147081	NA	-1.06	-9.79	-0.52	1.67e-19	Diabetic kidney disease;
CESC	cis	rs12048904	0.647	rs7528268	chr1:101329295	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.89	12.15	0.6	2.69e-27	Multiple sclerosis;
CESC	cis	rs7582720	1.000	rs72926769	chr2:203798318	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.38	0.41	1.99e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs12142240	0.698	rs72677587	chr1:46813982	G/A	cg10495392	chr1:46806563	NSUN4	0.57	6.28	0.36	1.39e-9	Menopause (age at onset);
CESC	cis	rs875971	0.638	rs6460305	chr7:66060408	G/A	cg25985355	chr7:65971099	NA	0.33	5.41	0.32	1.39e-7	Aortic root size;
CESC	cis	rs2304069	0.659	rs216141	chr5:149443994	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.48	-6.57	-0.37	2.64e-10	HIV-1 control;
CESC	cis	rs71277158	0.688	rs56316750	chr3:169782754	G/A	cg04067573	chr3:169899625	PHC3	0.73	7.26	0.41	4.37e-12	Prostate cancer;
CESC	cis	rs7772486	0.817	rs9322047	chr6:146400394	G/A	cg05347473	chr6:146136440	FBXO30	0.49	6.59	0.38	2.32e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7116495	0.609	rs7111379	chr11:71826319	C/T	cg26138937	chr11:71823887	C11orf51	1.22	7.75	0.43	2.02e-13	Severe influenza A (H1N1) infection;
CESC	cis	rs6740322	0.895	rs6710656	chr2:43566941	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.67	-7.38	-0.41	2.08e-12	Coronary artery disease;
CESC	cis	rs2463822	1.000	rs118049526	chr11:62107508	C/T	cg06239285	chr11:62104954	ASRGL1	-1.03	-8.95	-0.48	6.23e-17	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs73206853	0.764	rs16940881	chr12:110937818	G/C	cg12870014	chr12:110450643	ANKRD13A	0.65	5.59	0.32	5.78e-8	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg25204440	chr1:209979598	IRF6	0.75	12.39	0.61	4.04e-28	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
CESC	cis	rs17711722	0.522	rs6957759	chr7:65271785	A/G	cg06456125	chr7:65229604	NA	0.4	5.38	0.31	1.64e-7	Calcium levels;
CESC	cis	rs4660306	1.000	rs1044717	chr1:45976587	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.61	-7.65	-0.43	3.77e-13	Homocysteine levels;
CESC	cis	rs710216	0.917	rs900834	chr1:43412343	A/G	cg03128534	chr1:43423976	SLC2A1	-0.56	-6.53	-0.37	3.37e-10	Red cell distribution width;
CESC	cis	rs6089584	0.888	rs6061979	chr20:60617141	C/G	cg06108461	chr20:60628389	TAF4	-0.92	-14.55	-0.67	1.22e-35	Body mass index;
CESC	cis	rs6951245	0.507	rs11976805	chr7:1138716	C/T	cg04025307	chr7:1156635	C7orf50	0.42	5.99	0.35	6.98e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7666738	0.830	rs6853266	chr4:99047528	G/T	cg05340658	chr4:99064831	C4orf37	0.81	12.16	0.6	2.51e-27	Colonoscopy-negative controls vs population controls;
CESC	cis	rs910316	1.000	rs4899546	chr14:75594946	G/C	cg16144293	chr14:75469539	EIF2B2	-0.39	-5.04	-0.3	8.76e-7	Height;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg23697400	chr5:64064613	SDCCAG10;SFRS12IP1	-0.45	-6.1	-0.35	3.77e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs7989336	0.612	rs8001097	chr13:96945882	C/A	cg02571835	chr13:96230311	CLDN10	-0.37	-5.33	-0.31	2.09e-7	Obesity;
CESC	cis	rs9911578	0.935	rs2302189	chr17:56584205	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	-0.42	-5.5	-0.32	8.99e-8	Intelligence (multi-trait analysis);
CESC	trans	rs7615952	0.932	rs13065725	chr3:125632289	C/A	cg07211511	chr3:129823064	LOC729375	-1.08	-13.68	-0.64	1.38e-32	Blood pressure (smoking interaction);
CESC	cis	rs12497850	0.805	rs11130176	chr3:48844077	A/G	cg03060546	chr3:49711283	APEH	0.43	5.34	0.31	2.05e-7	Parkinson's disease;
CESC	trans	rs7937682	0.855	rs571462	chr11:111487106	C/G	cg18187862	chr3:45730750	SACM1L	0.48	6.01	0.35	6.26e-9	Primary sclerosing cholangitis;
CESC	cis	rs801193	0.569	rs2659892	chr7:66200305	A/G	cg11764359	chr7:65958608	NA	0.73	10.55	0.54	5.73e-22	Aortic root size;
CESC	cis	rs8031584	0.678	rs36047941	chr15:31159235	A/G	cg14829155	chr15:31115871	NA	-0.76	-10.54	-0.54	6.55e-22	Huntington's disease progression;
CESC	cis	rs2730245	1.000	rs2730245	chr7:158724789	G/C	cg15303052	chr7:158526867	ESYT2	0.43	5.16	0.3	4.88e-7	Height;
CESC	cis	rs10479542	0.784	rs7703730	chr5:178986632	C/A	cg19723775	chr5:179050963	HNRNPH1	-0.42	-5.53	-0.32	7.86e-8	Lung cancer;
CESC	cis	rs9287719	1.000	rs9679122	chr2:10751710	T/C	cg02196655	chr2:10830764	NOL10	-0.38	-5.79	-0.34	1.96e-8	Prostate cancer;
CESC	cis	rs854765	0.618	rs8066982	chr17:17851377	T/C	cg04398451	chr17:18023971	MYO15A	-0.69	-9.72	-0.51	2.77e-19	Total body bone mineral density;
CESC	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.89	13.57	0.64	3.26e-32	Prudent dietary pattern;
CESC	cis	rs9916302	0.904	rs7210488	chr17:37539819	T/G	cg15445000	chr17:37608096	MED1	-0.41	-6.64	-0.38	1.74e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs7580658	0.857	rs2896980	chr2:128139959	T/C	cg10021288	chr2:128175891	PROC	-0.4	-6.38	-0.36	8.05e-10	Protein C levels;
CESC	cis	rs2836950	0.545	rs8132424	chr21:40584412	A/T	cg17971929	chr21:40555470	PSMG1	0.59	7.8	0.43	1.45e-13	Menarche (age at onset);
CESC	cis	rs4979906	1.000	rs11002244	chr10:79446207	T/C	cg07817648	chr10:79422355	NA	-0.6	-6.36	-0.36	8.96e-10	Mortality in heart failure;
CESC	cis	rs6752107	1.000	rs13009506	chr2:234175706	A/C	cg23050873	chr2:234184376	ATG16L1;SCARNA5	-0.4	-6.1	-0.35	3.77e-9	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs514406	0.929	rs554301	chr1:53321948	A/T	cg25767906	chr1:53392781	SCP2	0.46	5.94	0.34	8.83e-9	Monocyte count;
CESC	cis	rs4332037	0.851	rs28728306	chr7:1961814	C/A	cg23422044	chr7:1970798	MAD1L1	-0.57	-5.99	-0.35	6.71e-9	Bipolar disorder;
CESC	cis	rs9309473	1.000	rs10186501	chr2:73697844	C/T	cg20560298	chr2:73613845	ALMS1	-0.46	-6.24	-0.36	1.7e-9	Metabolite levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01804278	chr11:63894802	MACROD1	-0.53	-6.24	-0.36	1.69e-9	Gut microbiome composition (summer);
CESC	cis	rs4253772	0.591	rs8143066	chr22:46656607	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.68	8.01	0.44	3.75e-14	LDL cholesterol;Cholesterol, total;
CESC	cis	rs863345	0.967	rs11265001	chr1:158488902	A/G	cg12129480	chr1:158549410	OR10X1	-0.3	-5.7	-0.33	3.24e-8	Pneumococcal bacteremia;
CESC	cis	rs9324022	0.929	rs9635184	chr14:101173056	C/T	cg18089426	chr14:101175970	NA	0.63	7.15	0.4	8.28e-12	Plateletcrit;
CESC	cis	rs8177253	1.000	rs6439439	chr3:133481498	G/T	cg12373951	chr3:133503437	NA	0.42	6.19	0.36	2.33e-9	Iron status biomarkers;
CESC	cis	rs2440129	0.611	rs1042356	chr17:6902743	G/A	cg22741997	chr17:6900356	ALOX12	0.41	6.47	0.37	4.68e-10	Tonsillectomy;
CESC	cis	rs17253792	0.598	rs12880362	chr14:56017929	G/C	cg01858014	chr14:56050164	KTN1	-0.87	-6.37	-0.36	8.34e-10	Putamen volume;
CESC	cis	rs2273669	0.667	rs76249006	chr6:109366740	G/A	cg05315195	chr6:109294784	ARMC2	-0.67	-6.33	-0.36	1.02e-9	Prostate cancer;
CESC	cis	rs7084402	0.565	rs6481407	chr10:60335090	C/T	cg07615347	chr10:60278583	BICC1	-0.36	-5.15	-0.3	5.05e-7	Refractive error;
CESC	cis	rs7945705	0.902	rs10769980	chr11:9014180	G/A	cg09997546	chr11:8931473	C11orf17;ST5	0.35	5.91	0.34	1.03e-8	Hemoglobin concentration;
CESC	cis	rs644799	0.672	rs11021307	chr11:95501407	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.78	11.71	0.58	8.64e-26	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs9926296	0.585	rs8058009	chr16:89856439	G/C	cg08547343	chr16:90038815	CENPBD1;AFG3L1	-0.61	-5.84	-0.34	1.52e-8	Vitiligo;
CESC	cis	rs8092503	0.953	rs2052326	chr18:52489444	G/C	cg12377874	chr18:52495404	RAB27B	-0.35	-6.04	-0.35	5.21e-9	Childhood body mass index;
CESC	cis	rs1799949	1.000	rs11657835	chr17:41291953	C/G	cg25072359	chr17:41440525	NA	0.46	6.1	0.35	3.77e-9	Menopause (age at onset);
CESC	cis	rs9291683	0.935	rs1860911	chr4:10275057	C/T	cg11266682	chr4:10021025	SLC2A9	0.48	8.64	0.47	5.26e-16	Bone mineral density;
CESC	cis	rs853679	0.550	rs6901017	chr6:28152583	T/C	cg23161317	chr6:28129485	ZNF389	0.42	5.45	0.32	1.17e-7	Depression;
CESC	cis	rs34779708	0.966	rs17499811	chr10:35456215	G/A	cg04310649	chr10:35416472	CREM	-0.51	-6.27	-0.36	1.43e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs9834373	0.887	rs71324630	chr3:78486657	G/A	cg06138941	chr3:78371609	NA	-0.42	-5.14	-0.3	5.43e-7	Protein quantitative trait loci;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg20725256	chr12:133294261	PGAM5	0.48	6.54	0.37	3.18e-10	Fibrinogen levels;
CESC	cis	rs7542091	0.704	rs1108628	chr1:210041150	A/G	cg09509183	chr1:209979624	IRF6	0.39	5.52	0.32	8.24e-8	Monobrow;
CESC	cis	rs1371867	0.846	rs1788180	chr8:101333368	A/G	cg11906718	chr8:101322791	RNF19A	0.46	5.91	0.34	1.03e-8	Atrioventricular conduction;
CESC	cis	rs637571	0.522	rs12797319	chr11:65735672	G/A	cg02202077	chr11:65769826	EIF1AD;BANF1	0.45	5.85	0.34	1.46e-8	Eosinophil percentage of white cells;
CESC	cis	rs35306767	0.855	rs11253468	chr10:903261	G/A	cg25019033	chr10:957182	NA	-0.57	-6.07	-0.35	4.38e-9	Eosinophil percentage of granulocytes;
CESC	cis	rs4304924	0.500	rs7339081	chr13:79235501	A/G	cg07926092	chr13:79233506	RNF219	0.62	7.29	0.41	3.66e-12	Large artery stroke;
CESC	cis	rs147858478	1	rs147858478	chr5:131682785	CCTGAGTT/C	cg07395648	chr5:131743802	NA	-0.44	-5.83	-0.34	1.61e-8	High light scatter reticulocyte percentage of red cells;
CESC	cis	rs3820068	0.581	rs34453754	chr1:15993208	G/C	cg13390004	chr1:15929781	NA	0.33	5.17	0.3	4.59e-7	Systolic blood pressure;
CESC	cis	rs2652822	0.507	rs7176597	chr15:63494482	G/A	cg02713581	chr15:63449717	RPS27L	0.47	5.58	0.32	6.07e-8	Metabolic traits;
CESC	cis	rs10089	0.953	rs3805615	chr5:127519049	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.75	10.07	0.53	2.04e-20	Ileal carcinoids;
CESC	cis	rs35306767	0.714	rs12762955	chr10:1078782	A/C	cg26597838	chr10:835615	NA	0.5	5.35	0.31	1.86e-7	Eosinophil percentage of granulocytes;
CESC	cis	rs6540559	0.673	rs17015330	chr1:210012795	T/G	cg22029157	chr1:209979665	IRF6	0.65	7.26	0.41	4.19e-12	Cleft lip with or without cleft palate;
CESC	cis	rs2046867	0.818	rs1502754	chr3:72895345	G/T	cg25664220	chr3:72788482	NA	-0.44	-6.42	-0.37	6.31e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CESC	cis	rs1218582	0.741	rs10908446	chr1:154869559	G/A	cg24250549	chr1:154909240	PMVK	0.74	11.19	0.57	4.71e-24	Prostate cancer;
CESC	cis	rs1451375	0.794	rs11238134	chr7:50542927	A/C	cg14593290	chr7:50529359	DDC	-0.51	-5.81	-0.34	1.82e-8	Malaria;
CESC	cis	rs425277	0.583	rs3128334	chr1:2038662	G/A	cg23803603	chr1:2058230	PRKCZ	-0.35	-6.19	-0.36	2.22e-9	Height;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg25180585	chr17:49230756	NME1;NME1-NME2	0.46	6.15	0.35	2.82e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs8111998	0.826	rs4932775	chr19:22766651	A/G	cg19914732	chr19:22715077	NA	-0.37	-5.18	-0.3	4.45e-7	Corneal structure;
CESC	cis	rs2273669	0.667	rs12208578	chr6:109369745	T/C	cg05315195	chr6:109294784	ARMC2	-0.67	-6.06	-0.35	4.74e-9	Prostate cancer;
CESC	cis	rs3733585	0.588	rs6449154	chr4:9956404	C/T	cg02734326	chr4:10020555	SLC2A9	-0.41	-5.87	-0.34	1.32e-8	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs2070488	0.745	rs9838792	chr3:38546726	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.78	-12.49	-0.61	1.89e-28	Electrocardiographic conduction measures;
CESC	cis	rs801193	1.000	rs10274773	chr7:66133578	G/A	cg25985355	chr7:65971099	NA	0.32	5.23	0.31	3.53e-7	Aortic root size;
CESC	cis	rs7246657	0.943	rs1015848	chr19:37945274	A/C	cg23950597	chr19:37808831	NA	-0.62	-6.3	-0.36	1.26e-9	Coronary artery calcification;
CESC	cis	rs1862618	0.713	rs832549	chr5:56183542	C/T	cg22800045	chr5:56110881	MAP3K1	0.81	9.72	0.51	2.76e-19	Initial pursuit acceleration;
CESC	cis	rs7598759	0.548	rs11693738	chr2:232360484	C/T	cg19187155	chr2:232395269	NMUR1	0.61	10.26	0.53	5.03e-21	Noise-induced hearing loss;
CESC	cis	rs6500395	0.926	rs2883643	chr16:48693018	C/G	cg04672837	chr16:48644449	N4BP1	0.47	5.52	0.32	8.02e-8	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs28386778	0.965	rs2854154	chr17:61981696	C/A	cg22520471	chr17:61851767	DDX42;CCDC47	-0.88	-13.1	-0.63	1.46e-30	Prudent dietary pattern;
CESC	cis	rs9837602	1.000	rs6790535	chr3:99807735	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.46	6.48	0.37	4.54e-10	Breast cancer;
CESC	cis	rs4237845	0.636	rs11172371	chr12:58286188	C/T	cg02175503	chr12:58329896	NA	0.6	7.13	0.4	9.58e-12	Intelligence (multi-trait analysis);
CESC	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg01238044	chr22:24384105	GSTT1	-0.7	-9.26	-0.49	7.25e-18	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs2073300	0.609	rs6137941	chr20:23400848	G/A	cg16736954	chr20:23401023	NAPB	0.77	5.65	0.33	4.24e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs847577	0.587	rs34307903	chr7:97728449	C/A	cg24562669	chr7:97807699	LMTK2	0.81	13.36	0.63	1.77e-31	Breast cancer;
CESC	cis	rs9291683	0.620	rs7699512	chr4:10125808	C/T	cg00071950	chr4:10020882	SLC2A9	-0.56	-8.54	-0.46	1.07e-15	Bone mineral density;
CESC	trans	rs28549925	0.590	rs17136923	chr7:16991838	G/A	cg12639933	chr12:57626296	SHMT2	0.95	6.1	0.35	3.74e-9	Congenital heart disease (maternal effect);Conotruncal heart defects (maternal effects);
CESC	cis	rs7635838	0.718	rs2248971	chr3:11403441	T/C	cg00170343	chr3:11313890	ATG7	0.5	7.05	0.4	1.57e-11	HDL cholesterol;
CESC	cis	rs10504229	0.683	rs6998040	chr8:58110155	G/T	cg24829409	chr8:58192753	C8orf71	0.59	7.14	0.4	9.02e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs769267	0.965	rs2916068	chr19:19516433	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.56	7.28	0.41	3.9e-12	Tonsillectomy;
CESC	cis	rs769267	0.930	rs2301784	chr19:19390749	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	7.34	0.41	2.56e-12	Tonsillectomy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25179358	chr12:49741623	DNAJC22	0.56	6.51	0.37	3.73e-10	Gut microbiome composition (summer);
CESC	cis	rs13040088	1.000	rs2273412	chr20:61553802	G/A	cg23096297	chr20:61557774	DIDO1	0.99	10.8	0.55	9.12e-23	Menopause (age at onset);
CESC	cis	rs2286503	0.966	rs6949233	chr7:22858191	T/G	cg13679077	chr7:22862647	TOMM7	0.4	5.19	0.3	4.26e-7	Fibrinogen;
CESC	cis	rs5769765	0.908	rs9616388	chr22:50313438	T/C	cg26441486	chr22:50317300	CRELD2	0.42	5.34	0.31	2.02e-7	Schizophrenia;
CESC	cis	rs780094	0.564	rs4665978	chr2:27648726	T/C	cg12648201	chr2:27665141	KRTCAP3	-0.28	-5.5	-0.32	8.99e-8	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
CESC	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg10150615	chr22:24372951	LOC391322	-0.58	-7.92	-0.44	6.72e-14	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs2075371	1.000	rs8134	chr7:133974519	A/G	cg20476274	chr7:133979776	SLC35B4	0.68	10.07	0.53	2.09e-20	Mean platelet volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26290973	chr17:78897137	RPTOR	-0.52	-6.01	-0.35	6.03e-9	Gut microbiome composition (summer);
CESC	cis	rs1799949	1.000	rs2037075	chr17:41305826	G/T	cg23758822	chr17:41437982	NA	1.03	15.41	0.69	1.08e-38	Menopause (age at onset);
CESC	cis	rs1218582	0.772	rs4240874	chr1:154885779	C/T	cg09359103	chr1:154839909	KCNN3	-0.66	-12.18	-0.6	2.2e-27	Prostate cancer;
CESC	cis	rs9300255	0.568	rs1727300	chr12:123664205	C/T	cg00376283	chr12:123451042	ABCB9	0.71	8.92	0.48	7.69e-17	Neutrophil percentage of white cells;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg18866267	chr4:3310044	NA	0.43	6.26	0.36	1.52e-9	Fibrinogen levels;
CESC	trans	rs208520	0.690	rs207114	chr6:66791703	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.01	-12.67	-0.61	4.51e-29	Exhaled nitric oxide output;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21415969	chr3:123304010	PTPLB	0.58	6.49	0.37	4.24e-10	Gut microbiome composition (summer);
CESC	cis	rs1538970	0.924	rs3790582	chr1:45887288	T/C	cg05343316	chr1:45956843	TESK2	0.87	12.0	0.59	9.05e-27	Platelet count;
CESC	cis	rs17253792	0.822	rs10135426	chr14:56054644	A/G	cg01858014	chr14:56050164	KTN1	-0.82	-6.43	-0.37	5.88e-10	Putamen volume;
CESC	cis	rs9399135	0.967	rs9376085	chr6:135371224	T/C	cg22676075	chr6:135203613	NA	0.5	7.06	0.4	1.43e-11	Red blood cell count;
CESC	cis	rs7945705	0.837	rs10769981	chr11:9024460	T/C	cg09997546	chr11:8931473	C11orf17;ST5	0.34	5.69	0.33	3.31e-8	Hemoglobin concentration;
CESC	cis	rs1008375	1.000	rs1558377	chr4:17650758	A/G	cg16339924	chr4:17578868	LAP3	0.65	8.27	0.45	6.38e-15	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs2011503	0.941	rs17751061	chr19:19413092	C/T	cg11584989	chr19:19387371	SF4	0.61	7.28	0.41	3.73e-12	Bipolar disorder;
CESC	cis	rs1797081	0.967	rs780633	chr10:16863161	C/T	cg23933602	chr10:16859644	RSU1	1.11	25.59	0.84	1.41e-73	Platelet distribution width;
CESC	cis	rs4819052	0.851	rs34101026	chr21:46662200	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.46	5.81	0.34	1.81e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs11098499	0.691	rs10028773	chr4:120265259	C/G	cg09307838	chr4:120376055	NA	-0.76	-9.9	-0.52	7.03e-20	Corneal astigmatism;
CESC	cis	rs1691799	0.867	rs1168309	chr12:66726439	A/G	cg16791601	chr12:66731901	HELB	0.77	13.71	0.64	1.04e-32	White blood cell count (basophil);
CESC	cis	rs79349575	0.783	rs12453374	chr17:46994846	G/C	cg16584676	chr17:46985605	UBE2Z	0.53	6.59	0.38	2.42e-10	Type 2 diabetes;
CESC	cis	rs7660520	0.524	rs6839881	chr4:183729137	A/T	cg12483801	chr4:183727862	NA	0.69	6.76	0.38	8.68e-11	Pediatric autoimmune diseases;
CESC	cis	rs12368653	0.557	rs903067	chr12:58011857	G/A	cg18357645	chr12:58087776	OS9	-0.36	-5.05	-0.3	8.41e-7	Multiple sclerosis;
CESC	cis	rs9303401	0.614	rs34058624	chr17:57118121	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.89	11.06	0.56	1.21e-23	Cognitive test performance;
CESC	cis	rs6502050	0.865	rs8079388	chr17:80162798	C/A	cg23985595	chr17:80112537	CCDC57	-0.4	-6.48	-0.37	4.35e-10	Life satisfaction;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09312767	chr1:29063505	YTHDF2	0.66	7.37	0.41	2.12e-12	Gut microbiome composition (summer);
CESC	cis	rs6460942	0.732	rs73677575	chr7:12286532	A/G	cg06484146	chr7:12443880	VWDE	-0.59	-6.3	-0.36	1.25e-9	Coronary artery disease;
CESC	trans	rs6700559	0.810	rs2808248	chr1:200592275	T/C	cg05185519	chr16:2972941	FLYWCH1	0.5	6.51	0.37	3.76e-10	Coronary artery disease;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg18565702	chr13:113241891	TUBGCP3	-0.52	-6.43	-0.37	6.07e-10	Ulcerative colitis;
CESC	trans	rs6011002	0.816	rs6010991	chr20:62281580	C/T	cg17720233	chr1:151128310	TNFAIP8L2	0.83	6.05	0.35	4.81e-9	Dental caries;
CESC	trans	rs12599106	0.625	rs12923277	chr16:34896261	G/A	cg26668828	chr6:292823	DUSP22	-0.71	-9.32	-0.5	4.65e-18	Menopause (age at onset);
CESC	cis	rs9324022	0.722	rs72698709	chr14:101165747	C/T	cg18089426	chr14:101175970	NA	0.55	5.64	0.33	4.41e-8	Plateletcrit;
CESC	cis	rs2842992	0.789	rs2277072	chr6:160182845	A/G	cg11366901	chr6:160182831	ACAT2	0.83	10.52	0.54	7.54e-22	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs1799949	1.000	rs36036395	chr17:41181297	T/C	cg05368731	chr17:41323189	NBR1	0.8	10.68	0.55	2.21e-22	Menopause (age at onset);
CESC	cis	rs853679	0.517	rs9393886	chr6:28050039	T/G	cg20151795	chr6:28129481	ZNF389	0.44	5.59	0.33	5.5e-8	Depression;
CESC	cis	rs9818758	0.607	rs11552724	chr3:49156473	C/G	cg00383909	chr3:49044727	WDR6	0.89	6.56	0.37	2.82e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CESC	cis	rs68170813	0.559	rs6949961	chr7:106850755	G/T	cg02696742	chr7:106810147	HBP1	0.53	5.06	0.3	7.88e-7	Coronary artery disease;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg23654174	chr1:47779667	STIL	0.45	6.14	0.35	2.93e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg27127099	chr5:150158597	C5orf62	-0.44	-6.21	-0.36	2.06e-9	Fibrinogen levels;
CESC	cis	rs6456156	0.565	rs12525345	chr6:167478875	T/C	cg07741184	chr6:167504864	NA	0.36	6.21	0.36	2.01e-9	Primary biliary cholangitis;
CESC	cis	rs1008375	0.966	rs12503540	chr4:17698781	C/G	cg16339924	chr4:17578868	LAP3	-0.52	-6.08	-0.35	4.15e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs7618915	0.501	rs11714030	chr3:52765882	C/T	cg05564831	chr3:52568323	NT5DC2	0.46	7.01	0.4	2.03e-11	Bipolar disorder;
CESC	cis	rs7937682	0.889	rs11213969	chr11:111528441	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.0	-16.54	-0.71	1.09e-42	Primary sclerosing cholangitis;
CESC	cis	rs6541297	1.000	rs6674744	chr1:230279011	C/T	cg20703242	chr1:230279135	GALNT2	0.71	11.01	0.56	1.89e-23	Coronary artery disease;
CESC	cis	rs7818345	0.967	rs11787230	chr8:19280982	C/G	cg11303988	chr8:19266685	CSGALNACT1	0.36	6.67	0.38	1.53e-10	Language performance in older adults (adjusted for episodic memory);
CESC	cis	rs10479542	0.583	rs4131080	chr5:179044292	G/A	cg22764044	chr5:178986830	RUFY1	0.43	6.05	0.35	4.98e-9	Lung cancer;
CESC	cis	rs1364705	1.000	rs12676931	chr8:120279927	A/C	cg09273054	chr8:120220131	MAL2	-0.61	-7.15	-0.4	8.64e-12	Hippocampal atrophy;
CESC	cis	rs2235642	0.750	rs1894649	chr16:1657284	C/G	cg03771183	chr16:1608904	IFT140	0.39	5.8	0.34	1.9e-8	Coronary artery disease;
CESC	cis	rs12541335	0.639	rs35068739	chr8:22201719	T/C	cg02463440	chr8:22132932	PIWIL2	0.39	6.0	0.35	6.34e-9	Hypertriglyceridemia;
CESC	cis	rs7772486	0.782	rs7747576	chr6:146277827	C/T	cg05347473	chr6:146136440	FBXO30	-0.56	-7.11	-0.4	1.09e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9611565	0.512	rs5758465	chr22:42175314	T/C	cg06481639	chr22:41940642	POLR3H	0.59	5.76	0.33	2.35e-8	Vitiligo;
CESC	cis	rs9815354	0.812	rs73081392	chr3:41923009	G/A	cg03022575	chr3:42003672	ULK4	0.68	5.92	0.34	9.93e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs801193	0.548	rs2659904	chr7:66178602	C/A	cg10691866	chr7:65817282	TPST1	-0.34	-5.65	-0.33	4.11e-8	Aortic root size;
CESC	cis	rs4604732	0.631	rs35046441	chr1:247626812	G/A	cg12758973	chr1:247694275	LOC148824;OR2C3	0.51	6.36	0.36	8.65e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs7246657	0.941	rs12982333	chr19:37794724	A/G	cg23950597	chr19:37808831	NA	-0.58	-6.21	-0.36	2.08e-9	Coronary artery calcification;
CESC	cis	rs2522056	0.932	rs1012793	chr5:131781345	G/C	cg24060327	chr5:131705240	SLC22A5	0.64	7.56	0.42	6.71e-13	Lymphocyte counts;Fibrinogen;
CESC	cis	rs6087771	0.926	rs6058431	chr20:30297133	C/T	cg13852791	chr20:30311386	BCL2L1	0.82	10.41	0.54	1.7e-21	Subcortical brain region volumes;Putamen volume;
CESC	cis	rs4443100	0.535	rs13055979	chr22:23474085	C/T	cg14186256	chr22:23484241	RTDR1	0.55	6.29	0.36	1.33e-9	Serum parathyroid hormone levels;
CESC	cis	rs7666738	0.753	rs6826709	chr4:98714553	C/G	cg17366294	chr4:99064904	C4orf37	0.55	7.56	0.42	6.57e-13	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3096299	0.802	rs3102336	chr16:89442006	C/T	cg02187348	chr16:89574699	SPG7	0.49	6.38	0.36	7.93e-10	Multiple myeloma (IgH translocation);
CESC	cis	rs2576037	0.542	rs4630643	chr18:44508142	G/A	cg19077165	chr18:44547161	KATNAL2	-0.61	-9.05	-0.49	3.22e-17	Personality dimensions;
CESC	cis	rs66573146	0.656	rs66905212	chr4:6949508	G/C	cg26116260	chr4:7069785	GRPEL1	-0.83	-5.11	-0.3	6.23e-7	Granulocyte percentage of myeloid white cells;
CESC	cis	rs2204008	0.745	rs12146863	chr12:38502346	G/A	cg13010199	chr12:38710504	ALG10B	0.46	5.97	0.34	7.59e-9	Bladder cancer;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg14685339	chr14:77787351	POMT2;GSTZ1	0.59	7.7	0.43	2.72e-13	Gut microbiota (bacterial taxa);
CESC	cis	rs1552244	0.626	rs2886396	chr3:10037670	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.73	-9.22	-0.49	9.33e-18	Alzheimer's disease;
CESC	cis	rs9858542	0.953	rs7623659	chr3:49414791	C/T	cg07274523	chr3:49395745	GPX1	0.68	8.44	0.46	2.17e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs9308731	0.548	rs7581735	chr2:111937714	T/G	cg04202892	chr2:111875749	ACOXL	0.37	5.17	0.3	4.65e-7	Chronic lymphocytic leukemia;
CESC	cis	rs5750830	0.621	rs5757665	chr22:39821641	A/G	cg05872129	chr22:39784769	NA	-0.81	-10.75	-0.55	1.29e-22	Intelligence (multi-trait analysis);
CESC	cis	rs6582630	0.537	rs12823925	chr12:38409323	C/T	cg13010199	chr12:38710504	ALG10B	0.46	5.98	0.35	7.04e-9	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs3806843	0.966	rs2563261	chr5:140137713	G/T	cg16179182	chr5:140090404	VTRNA1-1	0.43	5.62	0.33	4.82e-8	Depressive symptoms (multi-trait analysis);
CESC	cis	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04577441	chr4:100870687	LOC256880;H2AFZ	-0.48	-5.8	-0.34	1.86e-8	Gut microbiome composition (summer);
CESC	cis	rs8060686	0.641	rs1125332	chr16:68227780	A/G	cg26727032	chr16:67993705	SLC12A4	-0.54	-5.87	-0.34	1.27e-8	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs4523957	0.855	rs12602764	chr17:2123200	A/T	cg16513277	chr17:2031491	SMG6	-0.63	-8.77	-0.47	2.19e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs7520050	0.807	rs6656279	chr1:46124088	C/G	cg03146154	chr1:46216737	IPP	0.52	6.88	0.39	4.27e-11	Red blood cell count;Reticulocyte count;
CESC	trans	rs17764205	0.777	rs28729385	chr19:3258882	T/C	cg03776506	chr16:30581384	ZNF688	-0.72	-6.01	-0.35	6.18e-9	Bipolar disorder and schizophrenia;
CESC	trans	rs877282	0.898	rs36064821	chr10:760952	C/T	cg22713356	chr15:30763199	NA	1.13	11.2	0.57	4.33e-24	Uric acid levels;
CESC	cis	rs950776	0.518	rs12910978	chr15:78810017	A/G	cg06917634	chr15:78832804	PSMA4	0.78	11.39	0.57	9.64e-25	Sudden cardiac arrest;
CESC	cis	rs11098499	0.954	rs11098524	chr4:120390032	A/G	cg09160332	chr4:120329925	NA	-0.4	-5.09	-0.3	6.87e-7	Corneal astigmatism;
CESC	cis	rs2243480	0.522	rs1638736	chr7:66092308	A/T	cg18252515	chr7:66147081	NA	-1.12	-9.13	-0.49	1.86e-17	Diabetic kidney disease;
CESC	cis	rs7208859	0.623	rs11650982	chr17:29129955	A/G	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.1e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs2742234	0.541	rs10899779	chr10:43723976	C/T	cg07801480	chr10:43725741	RASGEF1A	-0.42	-5.32	-0.31	2.19e-7	Hirschsprung disease;
CESC	trans	rs6091540	0.597	rs35601305	chr20:51077427	A/T	cg04610675	chr1:3713158	LRRC47	-0.63	-6.03	-0.35	5.61e-9	Body mass index (joint analysis main effects and smoking interaction);BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;
CESC	cis	rs11792861	0.926	rs2271878	chr9:111868885	G/A	cg05043794	chr9:111880884	C9orf5	-0.42	-6.93	-0.39	3.22e-11	Menarche (age at onset);
CESC	cis	rs7680126	0.596	rs11731652	chr4:10292984	T/C	cg00071950	chr4:10020882	SLC2A9	-0.53	-5.99	-0.35	6.88e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	cis	rs10504229	1.000	rs73607863	chr8:58170178	A/G	cg14926445	chr8:58193284	C8orf71	-0.51	-5.49	-0.32	9.29e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs6952808	0.531	rs3779002	chr7:2183219	C/T	cg21782813	chr7:2030301	MAD1L1	0.49	6.89	0.39	4.07e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs2952156	0.920	rs2934951	chr17:37833328	A/G	cg00129232	chr17:37814104	STARD3	-0.74	-10.18	-0.53	9.06e-21	Asthma;
CESC	cis	rs950027	0.787	rs2433616	chr15:45728599	A/G	cg21132104	chr15:45694354	SPATA5L1	0.5	5.81	0.34	1.8e-8	Response to fenofibrate (adiponectin levels);
CESC	cis	rs68170813	0.559	rs12537730	chr7:106844281	T/C	cg02696742	chr7:106810147	HBP1	-0.53	-5.14	-0.3	5.31e-7	Coronary artery disease;
CESC	cis	rs400736	0.930	rs2745722	chr1:8056669	G/A	cg25007680	chr1:8021821	PARK7	0.71	10.24	0.53	5.99e-21	Response to antidepressants and depression;
CESC	trans	rs2727020	0.658	rs7111215	chr11:49430552	T/C	cg15704280	chr7:45808275	SEPT13	-0.9	-15.45	-0.69	7.77e-39	Coronary artery disease;
CESC	cis	rs2228479	0.850	rs1800339	chr16:89839637	C/A	cg14709524	chr16:89940631	TCF25	0.91	6.74	0.38	1e-10	Skin colour saturation;
CESC	cis	rs896854	0.654	rs13278601	chr8:95972974	G/C	cg23172400	chr8:95962367	TP53INP1	-0.44	-9.15	-0.49	1.63e-17	Type 2 diabetes;
CESC	cis	rs9399135	0.869	rs9402675	chr6:135325794	C/G	cg22676075	chr6:135203613	NA	0.51	7.23	0.41	5.22e-12	Red blood cell count;
CESC	cis	rs8031584	0.678	rs4779790	chr15:31164595	T/C	cg14829155	chr15:31115871	NA	-0.76	-10.54	-0.54	6.55e-22	Huntington's disease progression;
CESC	cis	rs7552404	0.883	rs2185436	chr1:76203783	A/G	cg22875332	chr1:76189707	ACADM	0.72	10.03	0.52	2.87e-20	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs4132509	1.000	rs10927040	chr1:243731693	T/C	cg21452805	chr1:244014465	NA	0.45	5.5	0.32	8.93e-8	RR interval (heart rate);
CESC	cis	rs722599	0.562	rs2193597	chr14:75234329	G/A	cg11812906	chr14:75593930	NEK9	0.47	5.73	0.33	2.76e-8	IgG glycosylation;
CESC	cis	rs1552244	0.752	rs9867091	chr3:10043429	T/C	cg00166722	chr3:10149974	C3orf24	0.49	6.13	0.35	3.24e-9	Alzheimer's disease;
CESC	cis	rs72945132	0.882	rs12295111	chr11:70131882	C/A	cg00319359	chr11:70116639	PPFIA1	0.78	7.78	0.43	1.6e-13	Coronary artery disease;
CESC	cis	rs6772849	0.805	rs13325747	chr3:128336023	G/A	cg16766828	chr3:128327626	NA	-0.31	-5.19	-0.3	4.14e-7	Monocyte percentage of white cells;Monocyte count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08930741	chr1:59369549	NA	0.58	6.27	0.36	1.44e-9	Gut microbiome composition (summer);
CESC	cis	rs7647973	0.626	rs9830730	chr3:49675875	G/C	cg06212747	chr3:49208901	KLHDC8B	0.64	7.75	0.43	1.94e-13	Menarche (age at onset);
CESC	cis	rs55871839	0.559	rs4737527	chr8:59823491	A/G	cg07426533	chr8:59803705	TOX	0.45	6.03	0.35	5.45e-9	Pneumonia;
CESC	cis	rs9403521	1.000	rs116980222	chr6:143998987	C/T	cg21026257	chr6:143998961	PHACTR2	0.46	5.03	0.3	8.98e-7	Obesity-related traits;
CESC	cis	rs7918232	0.627	rs10829165	chr10:27319465	A/G	cg14240646	chr10:27532245	ACBD5	-0.5	-5.72	-0.33	2.84e-8	Breast cancer;
CESC	cis	rs7843479	0.601	rs11785043	chr8:21810377	C/T	cg17168535	chr8:21777572	XPO7	0.74	11.73	0.58	7.12e-26	Mean corpuscular volume;
CESC	cis	rs875971	0.862	rs7796162	chr7:65745758	T/C	cg11764359	chr7:65958608	NA	-0.79	-11.67	-0.58	1.16e-25	Aortic root size;
CESC	cis	rs6598955	0.671	rs55791848	chr1:26582711	G/A	cg19743891	chr1:26644573	UBXN11;CD52	0.37	5.19	0.3	4.16e-7	Obesity-related traits;
CESC	cis	rs6967414	0.681	rs11979878	chr7:6753803	A/G	cg00387323	chr7:6746715	ZNF12	0.59	5.78	0.33	2.14e-8	Hematocrit;Hemoglobin concentration;
CESC	cis	rs4253772	0.591	rs11703435	chr22:46685563	C/T	cg00784671	chr22:46762841	CELSR1	-0.57	-5.5	-0.32	8.75e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs113835537	0.597	rs3737525	chr11:66306355	A/G	cg22134325	chr11:66188745	NPAS4	0.45	6.69	0.38	1.29e-10	Airway imaging phenotypes;
CESC	cis	rs7605827	0.930	rs2241237	chr2:15656157	A/T	cg19274914	chr2:15703543	NA	0.37	6.68	0.38	1.43e-10	Educational attainment (years of education);
CESC	cis	rs9916302	0.904	rs801426	chr17:37441109	C/T	cg19468946	chr17:37922297	IKZF3	0.41	5.42	0.32	1.37e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs1559088	0.847	rs7254758	chr19:33608047	T/A	cg17764715	chr19:33622953	WDR88	0.46	6.02	0.35	5.63e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs2649044	1	rs2649044	chr11:9763969	C/T	cg03108697	chr11:9732066	SWAP70	-0.36	-5.46	-0.32	1.12e-7	Diastolic blood pressure;
CESC	cis	rs2370759	1.000	rs76467481	chr10:32610740	T/G	cg01819863	chr10:32635814	EPC1	1.1	11.55	0.58	2.99e-25	Sexual dysfunction (female);
CESC	cis	rs10206020	0.842	rs7609325	chr2:1574718	G/A	cg12573674	chr2:1569213	NA	-0.46	-5.2	-0.3	3.96e-7	IgG glycosylation;
CESC	cis	rs9733	0.596	rs72702557	chr1:150680130	A/G	cg17724175	chr1:150552817	MCL1	0.45	7.31	0.41	3.23e-12	Tonsillectomy;
CESC	cis	rs6754311	0.551	rs6739713	chr2:136488978	A/G	cg07169764	chr2:136633963	MCM6	0.6	6.42	0.37	6.25e-10	Mosquito bite size;
CESC	cis	rs12325245	0.536	rs12931051	chr16:58626534	C/T	cg05725404	chr16:58534157	NDRG4	-0.63	-5.34	-0.31	2.01e-7	Schizophrenia;
CESC	cis	rs1670533	0.932	rs4690214	chr4:1054636	T/C	cg04106633	chr4:1044584	NA	0.41	5.2	0.3	4.01e-7	Recombination rate (females);
CESC	cis	rs10751667	0.666	rs7396677	chr11:958878	C/T	cg20946044	chr11:1010712	AP2A2	-0.38	-5.26	-0.31	2.95e-7	Alzheimer's disease (late onset);
CESC	cis	rs2273669	0.667	rs117412830	chr6:109336617	A/G	cg05315195	chr6:109294784	ARMC2	-0.67	-6.06	-0.35	4.74e-9	Prostate cancer;
CESC	cis	rs10504229	0.871	rs56372514	chr8:58157166	A/G	cg02725872	chr8:58115012	NA	-0.37	-5.8	-0.34	1.9e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs5769765	0.542	rs5770725	chr22:50256309	C/T	cg02269571	chr22:50332266	NA	0.46	5.43	0.32	1.29e-7	Schizophrenia;
CESC	trans	rs208520	0.874	rs208469	chr6:66915891	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.84	-9.91	-0.52	6.69e-20	Exhaled nitric oxide output;
CESC	cis	rs637571	0.726	rs689274	chr11:65665988	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.51	-6.5	-0.37	3.91e-10	Eosinophil percentage of white cells;
CESC	trans	rs877282	0.898	rs11253348	chr10:765852	C/T	cg22713356	chr15:30763199	NA	1.15	11.2	0.57	4.37e-24	Uric acid levels;
CESC	trans	rs637571	0.522	rs503524	chr11:65751764	C/T	cg17712092	chr4:129076599	LARP1B	0.76	10.71	0.55	1.8e-22	Eosinophil percentage of white cells;
CESC	cis	rs9486719	0.857	rs9285393	chr6:97020917	C/A	cg18709589	chr6:96969512	KIAA0776	-0.45	-5.22	-0.31	3.57e-7	Migraine;Coronary artery disease;
CESC	cis	rs9311474	0.581	rs13621	chr3:52558133	T/C	cg18404041	chr3:52824283	ITIH1	-0.37	-6.38	-0.36	7.8e-10	Electroencephalogram traits;
CESC	cis	rs1048238	0.525	rs848214	chr1:16265422	A/G	cg22431228	chr1:16359049	CLCNKA	0.37	6.57	0.37	2.6e-10	Systolic blood pressure;
CESC	cis	rs7666738	0.830	rs1534319	chr4:98964804	T/C	cg18180107	chr4:99064573	C4orf37	0.4	5.14	0.3	5.26e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg18088712	chr1:16810147	CROCCL2	0.53	7.08	0.4	1.27e-11	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs7312933	0.703	rs10880264	chr12:42586535	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.48	6.33	0.36	1.04e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg21156815	chr8:22526736	BIN3	-0.45	-6.24	-0.36	1.73e-9	Fibrinogen levels;
CESC	cis	rs11997175	0.624	rs12677772	chr8:33772521	T/C	ch.8.33884649F	chr8:33765107	NA	0.54	6.71	0.38	1.2e-10	Body mass index;
CESC	cis	rs4764124	0.646	rs2075268	chr12:14956476	A/G	cg19759883	chr12:14956454	WBP11;C12orf60	0.58	8.58	0.47	8.3e-16	Pubertal anthropometrics;
CESC	cis	rs11792861	0.855	rs72607165	chr9:111814498	C/T	cg13535736	chr9:111863775	C9orf5	-0.52	-6.91	-0.39	3.63e-11	Menarche (age at onset);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg02809263	chr1:70671218	LRRC40;SFRS11	0.49	6.37	0.36	8.38e-10	Gut microbiota (bacterial taxa);
CESC	trans	rs11098499	0.863	rs3775849	chr4:120450908	G/C	cg25214090	chr10:38739885	LOC399744	0.7	9.62	0.51	5.47e-19	Corneal astigmatism;
CESC	cis	rs6815814	0.950	rs11722813	chr4:38810769	C/T	cg02016764	chr4:38805732	TLR1	-0.6	-7.3	-0.41	3.31e-12	Breast cancer;
CESC	cis	rs7772486	0.686	rs9399565	chr6:146081906	G/T	cg05347473	chr6:146136440	FBXO30	-0.51	-6.65	-0.38	1.63e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6951245	0.572	rs73264010	chr7:1040477	T/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.61	-5.43	-0.32	1.24e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7666738	0.753	rs13111199	chr4:98953705	A/G	cg03676636	chr4:99064102	C4orf37	0.33	5.11	0.3	6.05e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs853679	0.517	rs9380052	chr6:28064623	A/G	cg23161317	chr6:28129485	ZNF389	0.48	5.98	0.34	7.37e-9	Depression;
CESC	cis	rs873946	0.586	rs36084869	chr10:134566069	G/A	cg18305652	chr10:134549665	INPP5A	0.45	6.26	0.36	1.53e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs7552404	1.000	rs11161511	chr1:76210477	A/G	cg22875332	chr1:76189707	ACADM	-0.6	-7.14	-0.4	8.84e-12	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs4604732	0.527	rs60444724	chr1:247623164	T/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.58	7.31	0.41	3.2e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs703842	1.000	rs11172335	chr12:58175201	C/T	cg18357645	chr12:58087776	OS9	-0.43	-5.99	-0.35	6.98e-9	Multiple sclerosis;
CESC	cis	rs2408955	0.522	rs7139330	chr12:48483484	A/C	cg24011408	chr12:48396354	COL2A1	-0.48	-7.3	-0.41	3.37e-12	Glycated hemoglobin levels;
CESC	cis	rs10851478	0.529	rs12901929	chr15:49675308	T/C	cg08060515	chr15:49448048	GALK2;COPS2	0.54	6.82	0.39	6.08e-11	Oral cavity cancer;
CESC	cis	rs10461617	0.512	rs7715746	chr5:56048837	C/T	cg12311346	chr5:56204834	C5orf35	-0.5	-6.19	-0.36	2.31e-9	Type 2 diabetes;
CESC	cis	rs3540	0.618	rs2301832	chr15:91040725	A/T	cg10434728	chr15:90938212	IQGAP1	-0.41	-7.27	-0.41	4.01e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs2996428	0.667	rs111640545	chr1:3752792	G/A	cg13057898	chr1:3703894	LRRC47	0.45	6.15	0.35	2.86e-9	Red cell distribution width;
CESC	cis	rs6570726	0.557	rs403956	chr6:145829956	T/C	cg05347473	chr6:146136440	FBXO30	0.72	9.12	0.49	2e-17	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6460942	0.597	rs13227809	chr7:12525557	G/A	cg10578991	chr7:12443926	VWDE	-0.49	-5.13	-0.3	5.63e-7	Coronary artery disease;
CESC	cis	rs17253792	0.822	rs58589065	chr14:56152478	T/C	cg01858014	chr14:56050164	KTN1	-0.82	-6.87	-0.39	4.53e-11	Putamen volume;
CESC	cis	rs9916302	0.784	rs34473775	chr17:37396201	G/T	cg07936489	chr17:37558343	FBXL20	-0.78	-11.15	-0.57	6.4e-24	Glomerular filtration rate (creatinine);
CESC	cis	rs9362426	0.887	rs1209113	chr6:88079456	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.48	6.04	0.35	5.08e-9	Depressive episodes in bipolar disorder;
CESC	cis	rs10208940	0.841	rs7581931	chr2:68791641	A/G	cg12452813	chr2:68675892	NA	0.52	5.25	0.31	3.12e-7	Urate levels in lean individuals;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11852674	chr15:91478847	UNC45A	0.62	7.17	0.4	7.57e-12	Gut microbiome composition (summer);
CESC	cis	rs7615952	0.866	rs13063119	chr3:125643847	G/A	cg05084668	chr3:125655381	ALG1L	-0.48	-5.69	-0.33	3.34e-8	Blood pressure (smoking interaction);
CESC	cis	rs9527	0.590	rs10883836	chr10:104891198	T/C	cg04362960	chr10:104952993	NT5C2	0.44	5.54	0.32	7.12e-8	Arsenic metabolism;
CESC	cis	rs2228479	0.850	rs11647174	chr16:89958538	G/A	cg04013166	chr16:89971882	TCF25	0.76	6.53	0.37	3.28e-10	Skin colour saturation;
CESC	cis	rs3091242	0.728	rs706845	chr1:25730713	G/A	cg12412775	chr1:25698385	RHCE	-0.31	-5.47	-0.32	1.05e-7	Erythrocyte sedimentation rate;
CESC	cis	rs2278034	0.578	rs881753	chr3:195606770	C/T	cg00031303	chr3:195681400	NA	-0.4	-5.56	-0.32	6.62e-8	Bronchopulmonary dysplasia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21117678	chr7:101459024	CUX1	0.59	6.61	0.38	2.09e-10	Gut microbiome composition (summer);
CESC	cis	rs9303401	0.538	rs10515155	chr17:56481944	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.94	11.36	0.57	1.25e-24	Cognitive test performance;
CESC	cis	rs12618769	0.597	rs17502889	chr2:99031745	A/G	cg10123293	chr2:99228465	UNC50	0.38	5.04	0.3	8.58e-7	Bipolar disorder;
CESC	cis	rs2228479	0.850	rs1800331	chr16:89858417	C/A	cg00800038	chr16:89945340	TCF25	-0.9	-7.49	-0.42	1.01e-12	Skin colour saturation;
CESC	cis	rs4665809	0.556	rs10221814	chr2:26442759	C/T	cg27170947	chr2:26402098	FAM59B	-0.87	-10.18	-0.53	9.01e-21	Gut microbiome composition (summer);
CESC	cis	rs6460942	0.659	rs13247370	chr7:12514632	T/C	cg20607287	chr7:12443886	VWDE	-0.64	-7.14	-0.4	9.12e-12	Coronary artery disease;
CESC	cis	rs644799	1.000	rs12786522	chr11:95522858	G/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.71	9.55	0.51	8.96e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs10751667	0.643	rs7396767	chr11:938808	G/A	cg20946044	chr11:1010712	AP2A2	-0.41	-5.64	-0.33	4.31e-8	Alzheimer's disease (late onset);
CESC	cis	rs9811920	0.529	rs793442	chr3:99581062	A/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.6	-9.78	-0.51	1.78e-19	Axial length;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg23152667	chr5:77072348	TBCA	-0.49	-6.39	-0.37	7.45e-10	Ulcerative colitis;
CESC	cis	rs2708240	0.577	rs10233374	chr7:147566772	C/T	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	0.4	6.68	0.38	1.37e-10	QT interval (drug interaction);
CESC	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.48	-5.2	-0.3	4.05e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2243480	0.908	rs4718273	chr7:65216099	G/A	cg13147721	chr7:65941812	NA	0.88	8.15	0.45	1.43e-14	Diabetic kidney disease;
CESC	cis	rs820218	0.798	rs2305529	chr17:73702253	G/A	cg01592526	chr17:73663357	RECQL5;SAP30BP	-0.4	-5.57	-0.32	6.34e-8	Rotator cuff tears;
CESC	cis	rs1707322	0.717	rs28752166	chr1:46213309	G/A	cg05343316	chr1:45956843	TESK2	0.51	6.32	0.36	1.09e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.89	13.67	0.64	1.49e-32	Prudent dietary pattern;
CESC	cis	rs10982213	0.830	rs10739412	chr9:117183166	A/G	cg00969271	chr9:117093052	ORM2	0.42	5.83	0.34	1.63e-8	Interleukin-6 levels;
CESC	cis	rs17666538	0.585	rs4735812	chr8:607766	C/G	cg13264159	chr8:625131	ERICH1	-0.69	-5.18	-0.3	4.44e-7	IgG glycosylation;
CESC	cis	rs2404602	0.735	rs12906143	chr15:76709523	T/A	cg00316803	chr15:76480434	C15orf27	0.37	5.07	0.3	7.52e-7	Blood metabolite levels;
CESC	cis	rs992157	1.000	rs992157	chr2:219154781	A/G	cg00012203	chr2:219082015	ARPC2	-0.79	-10.7	-0.55	1.9e-22	Colorectal cancer;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg08703324	chr15:43785408	TP53BP1	-0.45	-6.71	-0.38	1.18e-10	Gambling;
CESC	cis	rs597583	0.715	rs1940040	chr11:117393294	G/C	cg27161313	chr11:117392002	DSCAML1	-0.52	-6.44	-0.37	5.55e-10	Putamen volume;
CESC	cis	rs7408868	0.908	rs2074619	chr19:15276919	G/A	cg14696996	chr19:15285081	NOTCH3	1.11	11.51	0.58	3.92e-25	Pulse pressure;
CESC	cis	rs9487051	0.676	rs9400267	chr6:109600164	T/C	cg01475377	chr6:109611718	NA	-0.44	-6.85	-0.39	5.1e-11	Reticulocyte fraction of red cells;
CESC	cis	rs6952808	0.543	rs4719436	chr7:2141239	G/A	cg05863683	chr7:1912471	MAD1L1	0.37	5.39	0.31	1.53e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs7811142	0.830	rs7341507	chr7:99951315	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.15	12.25	0.6	1.24e-27	Platelet count;
CESC	cis	rs425277	0.539	rs3128337	chr1:2045882	A/G	cg19257562	chr1:2043853	PRKCZ	0.41	6.65	0.38	1.67e-10	Height;
CESC	cis	rs8064299	0.967	rs880827	chr17:72767435	C/T	cg25054828	chr17:72772726	NAT9;TMEM104	-0.64	-9.16	-0.49	1.44e-17	Monocyte count;
CESC	trans	rs11039798	0.588	rs7946443	chr11:48545504	G/A	cg03929089	chr4:120376271	NA	0.62	6.07	0.35	4.44e-9	Axial length;
CESC	cis	rs9916302	0.904	rs8066704	chr17:37477218	C/T	cg15445000	chr17:37608096	MED1	-0.43	-7.01	-0.4	1.94e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs2979489	0.945	rs17627903	chr8:30351812	T/C	cg26383811	chr8:30366931	RBPMS	-0.79	-9.72	-0.51	2.78e-19	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CESC	cis	rs875971	0.540	rs781152	chr7:65479572	T/A	cg11764359	chr7:65958608	NA	0.6	7.4	0.41	1.85e-12	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06191203	chr2:152266755	RIF1	0.59	6.75	0.38	9.52e-11	Gut microbiome composition (summer);
CESC	cis	rs780096	0.526	rs1406295	chr2:27689700	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.36	-7.38	-0.41	2.02e-12	Total body bone mineral density;
CESC	cis	rs9325144	0.560	rs1601745	chr12:38647828	G/A	cg26384229	chr12:38710491	ALG10B	-0.62	-9.63	-0.51	4.99e-19	Morning vs. evening chronotype;
CESC	cis	rs2247341	0.893	rs743569	chr4:1719620	T/G	cg07465881	chr4:1713556	SLBP	-0.53	-6.58	-0.37	2.43e-10	Hip circumference adjusted for BMI;Height;
CESC	cis	rs1395	0.571	rs114507490	chr2:27527246	T/A	cg22903471	chr2:27725779	GCKR	-0.49	-5.98	-0.34	7.31e-9	Blood metabolite levels;
CESC	cis	rs4595586	0.545	rs12833238	chr12:39373898	T/C	cg26384229	chr12:38710491	ALG10B	0.54	7.53	0.42	7.85e-13	Morning vs. evening chronotype;
CESC	cis	rs870825	0.698	rs66462315	chr4:185623917	C/T	cg04058563	chr4:185651563	MLF1IP	0.64	7.05	0.4	1.59e-11	Blood protein levels;
CESC	cis	rs1775715	0.870	rs11008696	chr10:32218614	G/A	cg18675610	chr10:32216311	ARHGAP12	0.37	5.63	0.33	4.55e-8	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs12136530	0.593	rs12404362	chr1:19739958	A/G	cg01832549	chr1:19774989	CAPZB	-0.45	-6.22	-0.36	1.97e-9	Lead levels in blood;
CESC	cis	rs2274273	0.662	rs4525413	chr14:55661138	A/T	cg04306507	chr14:55594613	LGALS3	0.29	5.05	0.3	8.35e-7	Protein biomarker;
CESC	cis	rs7872515	0.536	rs10992201	chr9:94780754	C/A	cg01248375	chr9:94877805	SPTLC1	0.6	5.37	0.31	1.75e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs9486715	0.867	rs4839834	chr6:96882109	C/A	cg06623918	chr6:96969491	KIAA0776	0.93	14.47	0.66	2.36e-35	Headache;
CESC	cis	rs734999	0.588	rs2764841	chr1:2529360	G/A	cg18854424	chr1:2615690	NA	-0.27	-5.45	-0.32	1.14e-7	Ulcerative colitis;
CESC	cis	rs2731664	0.792	rs2731662	chr5:176872494	C/T	cg23176889	chr5:176863531	GRK6	0.65	11.47	0.58	5.47e-25	Intelligence (multi-trait analysis);
CESC	cis	rs6460942	0.749	rs62448592	chr7:12435985	A/T	cg06484146	chr7:12443880	VWDE	-0.78	-9.1	-0.49	2.28e-17	Coronary artery disease;
CESC	cis	rs7945705	0.875	rs2653616	chr11:8885892	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.47	-7.86	-0.43	9.42e-14	Hemoglobin concentration;
CESC	cis	rs2836974	0.831	rs2836964	chr21:40631006	T/C	cg27266027	chr21:40555129	PSMG1	0.46	5.36	0.31	1.84e-7	Cognitive function;
CESC	cis	rs7618915	0.547	rs11709448	chr3:52647449	T/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.36	6.3	0.36	1.23e-9	Bipolar disorder;
CESC	cis	rs3858526	0.883	rs4758183	chr11:5925178	C/G	cg05234568	chr11:5960015	NA	-0.56	-6.53	-0.37	3.41e-10	DNA methylation (variation);
CESC	cis	rs2286503	0.780	rs12113458	chr7:22855628	G/T	cg13679077	chr7:22862647	TOMM7	0.52	6.65	0.38	1.7e-10	Fibrinogen;
CESC	cis	rs1003719	0.582	rs2835634	chr21:38528270	T/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.59	-8.03	-0.44	3.23e-14	Eye color traits;
CESC	cis	rs3806843	1.000	rs4151680	chr5:140186657	A/G	cg26395211	chr5:140044315	WDR55	-0.42	-5.33	-0.31	2.07e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs4803468	1.000	rs2241709	chr19:41912250	C/T	cg14132834	chr19:41945861	ATP5SL	-0.58	-7.23	-0.41	5.16e-12	Height;
CESC	cis	rs3096299	0.719	rs12934708	chr16:89523790	C/T	cg16743903	chr16:89593216	SPG7	-0.43	-5.48	-0.32	1.01e-7	Multiple myeloma (IgH translocation);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg14415759	chr7:44887690	H2AFV	-0.5	-6.16	-0.35	2.65e-9	Ulcerative colitis;
CESC	cis	rs2860975	0.620	rs7898759	chr10:96800354	T/C	cg09036531	chr10:96991505	NA	-0.37	-5.25	-0.31	3.05e-7	Immune response to smallpox vaccine (IL-6);
CESC	cis	rs798554	0.660	rs2644275	chr7:2854010	G/A	cg19717773	chr7:2847554	GNA12	-0.54	-8.49	-0.46	1.47e-15	Height;
CESC	cis	rs684232	0.644	rs1227030	chr17:619882	C/T	cg15660573	chr17:549704	VPS53	-0.65	-8.94	-0.48	6.89e-17	Prostate cancer;
CESC	cis	rs30380	0.506	rs469735	chr5:96130014	T/C	cg16492584	chr5:96139282	ERAP1	-0.49	-6.54	-0.37	3.1e-10	Cerebrospinal fluid biomarker levels;
CESC	cis	rs11711311	0.955	rs10934247	chr3:113534941	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.6	8.0	0.44	3.82e-14	IgG glycosylation;
CESC	cis	rs367943	0.712	rs26966	chr5:112740434	T/C	cg12552261	chr5:112820674	MCC	0.4	5.31	0.31	2.28e-7	Type 2 diabetes;
CESC	cis	rs950776	0.518	rs62008194	chr15:78813805	G/T	cg06917634	chr15:78832804	PSMA4	0.79	11.86	0.59	2.51e-26	Sudden cardiac arrest;
CESC	cis	rs9611565	0.879	rs5758311	chr22:41759375	G/T	cg03806693	chr22:41940476	POLR3H	-0.73	-8.86	-0.48	1.2e-16	Vitiligo;
CESC	cis	rs9300255	0.602	rs2695478	chr12:123689521	C/T	cg00376283	chr12:123451042	ABCB9	0.61	6.48	0.37	4.39e-10	Neutrophil percentage of white cells;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09639837	chr10:30722502	MAP3K8	0.55	6.15	0.35	2.79e-9	Gut microbiome composition (summer);
CESC	cis	rs8177253	0.665	rs7646118	chr3:133450039	C/T	cg24879335	chr3:133465180	TF	0.37	6.45	0.37	5.33e-10	Iron status biomarkers;
CESC	cis	rs28374715	0.635	rs28557159	chr15:41657353	T/C	cg02330683	chr15:41787940	ITPKA	0.43	5.76	0.33	2.29e-8	Ulcerative colitis;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg17508018	chr19:40854374	C19orf47;PLD3	-0.46	-6.27	-0.36	1.42e-9	Asthma;
CESC	cis	rs644799	0.965	rs10831430	chr11:95509638	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.94	14.63	0.67	6.13e-36	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs17376456	0.825	rs28412976	chr5:93248377	T/C	cg21475434	chr5:93447410	FAM172A	0.8	6.35	0.36	9.43e-10	Diabetic retinopathy;
CESC	cis	rs6976053	0.518	rs314353	chr7:100406144	A/G	cg03098644	chr7:100410630	EPHB4	-0.45	-5.87	-0.34	1.31e-8	Plasminogen activator inhibitor type 1 levels (PAI-1);
CESC	cis	rs2921073	0.605	rs2976933	chr8:8254875	A/G	cg18904891	chr8:8559673	CLDN23	0.44	5.26	0.31	2.98e-7	Parkinson's disease;
CESC	cis	rs1577917	0.958	rs13207354	chr6:86700263	A/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.45	-5.82	-0.34	1.67e-8	Response to antipsychotic treatment;
CESC	cis	rs7605827	0.930	rs4668918	chr2:15661992	A/T	cg19274914	chr2:15703543	NA	0.38	6.74	0.38	9.73e-11	Educational attainment (years of education);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09145019	chr1:17972199	ARHGEF10L	-0.57	-6.19	-0.36	2.25e-9	Gut microbiome composition (summer);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg07015081	chr10:22048367	DNAJC1	0.49	6.49	0.37	4.25e-10	Fibrinogen levels;
CESC	cis	rs3105593	1.000	rs56118429	chr15:50923849	T/A	cg08437265	chr15:50716283	USP8	0.41	5.32	0.31	2.2e-7	QT interval;
CESC	cis	rs2635047	0.811	rs12958943	chr18:44786818	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.43	5.58	0.32	6.01e-8	Educational attainment;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10705951	chr16:29985294	TAOK2	-0.65	-6.75	-0.38	9.56e-11	Gut microbiome composition (summer);
CESC	cis	rs2839186	0.814	rs2839167	chr21:47661587	A/G	cg13012494	chr21:47604986	C21orf56	0.48	6.47	0.37	4.75e-10	Testicular germ cell tumor;
CESC	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg03188948	chr7:1209495	NA	0.41	5.21	0.31	3.72e-7	Longevity;Endometriosis;
CESC	trans	rs5756813	0.635	rs4820301	chr22:38126364	G/A	cg19894588	chr14:64061835	NA	-0.65	-7.41	-0.41	1.7e-12	Optic cup area;Vertical cup-disc ratio;
CESC	trans	rs3780486	0.846	rs7864705	chr9:33140352	A/C	cg20290983	chr6:43655470	MRPS18A	0.98	18.78	0.76	1.33e-50	IgG glycosylation;
CESC	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.64	7.25	0.41	4.65e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs12615721	0.534	rs72928187	chr2:81735213	G/A	cg06867613	chr15:35838691	ATPBD4	0.75	6.02	0.35	5.66e-9	Pulmonary function decline;
CESC	cis	rs2644899	0.715	rs2607415	chr19:41262687	C/G	cg24958765	chr19:41283667	RAB4B	-0.59	-6.75	-0.38	9.12e-11	Post bronchodilator FEV1/FVC ratio;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg15959319	chr5:32174494	GOLPH3	-0.5	-6.33	-0.36	1.03e-9	Ulcerative colitis;
CESC	cis	rs6461049	0.765	rs1476887	chr7:2151633	T/C	cg21782813	chr7:2030301	MAD1L1	0.42	5.86	0.34	1.38e-8	Schizophrenia;
CESC	cis	rs17376456	0.877	rs13185660	chr5:93336500	G/A	cg21475434	chr5:93447410	FAM172A	0.77	6.74	0.38	9.6e-11	Diabetic retinopathy;
CESC	cis	rs9908102	0.740	rs55776918	chr17:12907892	A/G	cg26162695	chr17:12921313	ELAC2	0.49	5.34	0.31	1.96e-7	Schizophrenia;
CESC	cis	rs4595586	0.545	rs58154430	chr12:39386649	C/T	cg13010199	chr12:38710504	ALG10B	0.44	5.51	0.32	8.37e-8	Morning vs. evening chronotype;
CESC	cis	rs11229555	0.874	rs12800710	chr11:58314540	C/T	cg15696309	chr11:58395628	NA	-0.4	-5.14	-0.3	5.44e-7	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs9388451	0.874	rs13209968	chr6:126089285	G/C	cg05901451	chr6:126070800	HEY2	-0.65	-9.25	-0.49	7.92e-18	Brugada syndrome;
CESC	cis	rs920590	0.758	rs7012358	chr8:19662498	C/T	cg17834443	chr8:19674713	INTS10	0.58	6.59	0.38	2.3e-10	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs10876993	0.680	rs2277322	chr12:58009202	T/C	cg18357645	chr12:58087776	OS9	-0.54	-8.16	-0.45	1.38e-14	Celiac disease or Rheumatoid arthritis;
CESC	cis	rs12142240	0.698	rs72886907	chr1:46814265	C/T	cg00530320	chr1:46809349	NSUN4	0.59	7.85	0.43	1.01e-13	Menopause (age at onset);
CESC	cis	rs425277	1.000	rs262657	chr1:2088577	G/A	cg16545954	chr1:2118288	C1orf86	0.33	5.47	0.32	1.02e-7	Height;
CESC	cis	rs7819412	0.715	rs35223712	chr8:11043926	C/T	cg21775007	chr8:11205619	TDH	-0.37	-5.15	-0.3	5.01e-7	Triglycerides;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05985164	chr12:57881757	MARS	0.52	6.46	0.37	5.02e-10	Gut microbiome composition (summer);
CESC	cis	rs6594499	0.872	rs10038058	chr5:110443281	A/G	cg04022379	chr5:110408740	TSLP	0.34	5.8	0.34	1.86e-8	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs4665809	0.590	rs17528653	chr2:26507724	T/C	cg04944784	chr2:26401820	FAM59B	0.91	9.37	0.5	3.37e-18	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.791	rs7657399	chr4:98851861	T/C	cg05340658	chr4:99064831	C4orf37	0.74	10.7	0.55	1.97e-22	Colonoscopy-negative controls vs population controls;
CESC	cis	rs875971	0.862	rs1167408	chr7:65556108	G/A	cg18876405	chr7:65276391	NA	-0.57	-7.55	-0.42	6.85e-13	Aortic root size;
CESC	cis	rs11098499	0.754	rs1980025	chr4:120252806	A/G	cg09307838	chr4:120376055	NA	-0.78	-10.65	-0.55	2.84e-22	Corneal astigmatism;
CESC	cis	rs6460942	0.915	rs79232243	chr7:12459494	G/A	cg06484146	chr7:12443880	VWDE	-0.79	-9.25	-0.49	7.67e-18	Coronary artery disease;
CESC	cis	rs9831754	0.654	rs9837024	chr3:78451637	C/T	cg06138941	chr3:78371609	NA	0.5	6.24	0.36	1.76e-9	Calcium levels;
CESC	cis	rs10771431	0.597	rs3759274	chr12:9353875	T/C	cg08997352	chr12:9597637	DDX12	-0.7	-8.86	-0.48	1.17e-16	Breast size;
CESC	cis	rs208520	0.633	rs7738469	chr6:66807446	T/C	cg07460842	chr6:66804631	NA	-1.0	-13.38	-0.63	1.55e-31	Exhaled nitric oxide output;
CESC	cis	rs6500395	1.000	rs3848319	chr16:48610933	T/C	cg04672837	chr16:48644449	N4BP1	0.51	6.47	0.37	4.73e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs12477438	0.539	rs720228	chr2:99704547	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.87	15.97	0.7	1.12e-40	Chronic sinus infection;
CESC	cis	rs1152591	0.524	rs1255990	chr14:64661523	A/G	cg23250157	chr14:64679961	SYNE2	-0.41	-5.73	-0.33	2.79e-8	Atrial fibrillation;
CESC	cis	rs2303745	0.589	rs10401700	chr19:17397700	A/C	cg04248312	chr19:17393744	ANKLE1	-0.92	-15.23	-0.68	4.55e-38	Systemic lupus erythematosus;
CESC	cis	rs2486288	0.656	rs62026703	chr15:45569929	G/T	cg21132104	chr15:45694354	SPATA5L1	-0.57	-6.66	-0.38	1.55e-10	Glomerular filtration rate;
CESC	cis	rs6933660	0.745	rs3778608	chr6:151738131	A/G	cg02564969	chr6:151773285	C6orf211;RMND1	0.63	8.67	0.47	4.41e-16	Menarche (age at onset);
CESC	cis	rs514406	0.861	rs554760	chr1:53266749	G/A	cg08859206	chr1:53392774	SCP2	0.56	7.29	0.41	3.54e-12	Monocyte count;
CESC	cis	rs8112211	1.000	rs8112211	chr19:38824581	C/T	cg14299480	chr19:38876666	GGN	-0.44	-6.06	-0.35	4.58e-9	Blood protein levels;
CESC	cis	rs1953600	0.645	rs2819950	chr10:81935279	G/A	cg00277334	chr10:82204260	NA	0.56	8.25	0.45	7.41e-15	Sarcoidosis;
CESC	cis	rs2576037	0.501	rs557661	chr18:44365657	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.52	-7.08	-0.4	1.26e-11	Personality dimensions;
CESC	cis	rs1256061	0.654	rs1256040	chr14:64738394	G/A	cg23250157	chr14:64679961	SYNE2	0.46	6.46	0.37	5e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs9916302	0.904	rs8079303	chr17:37530755	G/C	cg15445000	chr17:37608096	MED1	-0.41	-6.76	-0.38	8.97e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs2878628	0.650	rs56098033	chr3:52758571	T/A	cg18404041	chr3:52824283	ITIH1	-0.4	-6.81	-0.39	6.39e-11	Intelligence (multi-trait analysis);
CESC	cis	rs34779708	0.966	rs1478463	chr10:35473035	G/A	cg03585969	chr10:35415529	CREM	0.77	10.56	0.54	5.56e-22	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs12079745	0.793	rs12092506	chr1:169405517	A/G	cg09363564	chr1:169337483	NME7;BLZF1	-1.26	-7.33	-0.41	2.72e-12	QT interval;
CESC	cis	rs9896052	0.559	rs7220850	chr17:73436994	T/C	cg25649188	chr17:73499917	CASKIN2	0.48	5.51	0.32	8.56e-8	Sight-threatening diabetic retinopathy in type 2 diabetes;
CESC	cis	rs651907	0.535	rs13094911	chr3:101519021	T/C	cg12386194	chr3:101231763	SENP7	0.41	5.11	0.3	6.03e-7	Colorectal cancer;
CESC	cis	rs10416265	0.502	rs7245411	chr19:33543029	A/T	cg27124370	chr19:33622961	WDR88	0.52	6.96	0.39	2.62e-11	Bone properties (heel);
CESC	cis	rs10504229	0.906	rs111838497	chr8:58185620	A/C	cg14926445	chr8:58193284	C8orf71	-0.51	-5.52	-0.32	8.28e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs514406	0.679	rs12563825	chr1:53238324	G/T	cg16325326	chr1:53192061	ZYG11B	-0.57	-8.76	-0.47	2.34e-16	Monocyte count;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg01755728	chr3:49449714	TCTA;RHOA	-0.5	-7.06	-0.4	1.48e-11	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs1385374	0.502	rs923077	chr12:129276708	C/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.6	-5.41	-0.32	1.39e-7	Systemic lupus erythematosus;
CESC	cis	rs9910055	0.529	rs228749	chr17:42174570	A/G	cg08499158	chr17:42289980	UBTF	0.43	5.15	0.3	5.12e-7	Total body bone mineral density;
CESC	cis	rs4654899	0.785	rs9426736	chr1:21505931	T/G	cg05370193	chr1:21551575	ECE1	0.39	6.04	0.35	5.15e-9	Superior frontal gyrus grey matter volume;
CESC	cis	rs7666738	0.830	rs62321598	chr4:99014237	C/T	cg05340658	chr4:99064831	C4orf37	0.8	12.51	0.61	1.52e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4819052	0.851	rs7275468	chr21:46656499	C/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.71	9.36	0.5	3.47e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs3820928	0.874	rs6707265	chr2:227849255	T/A	cg11843606	chr2:227700838	RHBDD1	-0.49	-6.3	-0.36	1.22e-9	Pulmonary function;
CESC	cis	rs7666738	0.716	rs2865982	chr4:99031661	T/G	cg03467027	chr4:99064603	C4orf37	0.49	6.18	0.35	2.44e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6546550	0.901	rs6546553	chr2:70111711	C/A	cg02498382	chr2:70120550	SNRNP27	-0.37	-6.33	-0.36	1.06e-9	Prevalent atrial fibrillation;
CESC	cis	rs897984	0.645	rs9938550	chr16:30999142	A/G	cg00531865	chr16:30841666	NA	0.5	6.84	0.39	5.57e-11	Dementia with Lewy bodies;
CESC	cis	rs11031096	0.727	rs7932702	chr11:4124372	C/T	cg18678763	chr11:4115507	RRM1	-0.46	-6.26	-0.36	1.58e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	cis	rs1059312	0.500	rs12303338	chr12:129276641	C/T	cg09035930	chr12:129282057	SLC15A4	-0.49	-6.3	-0.36	1.2e-9	Systemic lupus erythematosus;
CESC	trans	rs340849	0.503	rs12733434	chr1:214135997	G/T	cg00358451	chr1:249141919	ZNF672	0.44	6.0	0.35	6.54e-9	Alzheimer's disease;
CESC	cis	rs875971	0.545	rs73148639	chr7:65855329	A/T	cg25405998	chr7:65216604	CCT6P1	0.45	5.15	0.3	4.97e-7	Aortic root size;
CESC	trans	rs459571	1.000	rs459571	chr9:136912626	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.65	-8.37	-0.46	3.35e-15	Platelet distribution width;
CESC	cis	rs2014572	0.510	rs8111661	chr19:57752326	C/G	cg12963866	chr19:57752005	ZNF805	0.52	7.21	0.41	5.78e-12	Hyperactive-impulsive symptoms;
CESC	cis	rs3820068	0.581	rs16851876	chr1:15950628	A/T	cg13390004	chr1:15929781	NA	-0.35	-5.67	-0.33	3.79e-8	Systolic blood pressure;
CESC	cis	rs74181299	0.684	rs11126028	chr2:65338150	C/G	cg05010058	chr2:65284262	CEP68	-0.33	-5.21	-0.3	3.75e-7	Pulse pressure;
CESC	cis	rs941873	0.805	rs10762860	chr10:81117794	C/G	cg09469691	chr10:81107165	PPIF	0.54	7.25	0.41	4.69e-12	Height;
CESC	cis	rs1799949	0.965	rs9646418	chr17:41425901	A/G	cg25072359	chr17:41440525	NA	0.49	7.46	0.42	1.23e-12	Menopause (age at onset);
CESC	cis	rs9581857	0.725	rs117947621	chr13:28022267	T/C	cg22138327	chr13:27999177	GTF3A	0.65	5.16	0.3	4.75e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
CESC	cis	rs7666738	0.830	rs880472	chr4:98922595	C/A	cg05340658	chr4:99064831	C4orf37	0.82	12.2	0.6	1.81e-27	Colonoscopy-negative controls vs population controls;
CESC	trans	rs10242455	0.557	rs73401516	chr7:99068351	C/A	cg09045935	chr12:6379348	NA	0.9	7.62	0.42	4.55e-13	Blood metabolite levels;
CESC	cis	rs962856	0.575	rs4671801	chr2:67622438	A/G	cg09028215	chr2:67624308	ETAA1	-0.44	-5.23	-0.31	3.44e-7	Pancreatic cancer;
CESC	trans	rs677673	1.000	rs669016	chr20:10467427	A/G	cg16021678	chr13:55475951	NA	0.52	6.68	0.38	1.4e-10	Body mass index (change over time) in chronic obstructive pulmonary disease;
CESC	cis	rs3916	0.955	rs35599677	chr12:121141458	G/A	cg21892295	chr12:121157589	UNC119B	-0.36	-5.1	-0.3	6.41e-7	Urinary metabolites (H-NMR features);
CESC	cis	rs9649465	0.967	rs13225110	chr7:123340849	C/T	cg04330084	chr7:123175371	IQUB	-0.39	-5.26	-0.31	2.95e-7	Migraine;
CESC	cis	rs3820928	0.874	rs7594505	chr2:227878562	C/G	cg11843606	chr2:227700838	RHBDD1	-0.48	-6.14	-0.35	2.99e-9	Pulmonary function;
CESC	cis	rs400736	0.729	rs2493215	chr1:8007716	C/T	cg25007680	chr1:8021821	PARK7	0.58	7.96	0.44	4.95e-14	Response to antidepressants and depression;
CESC	cis	rs6952808	0.564	rs55865401	chr7:2145720	G/C	cg02951883	chr7:2050386	MAD1L1	-0.49	-6.41	-0.37	6.57e-10	Bipolar disorder and schizophrenia;
CESC	cis	rs72901758	0.768	rs55834800	chr17:76252261	G/T	cg26068271	chr17:76253126	NA	0.46	6.47	0.37	4.69e-10	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
CESC	cis	rs72901758	0.768	rs11659046	chr17:76245718	G/A	cg26068271	chr17:76253126	NA	0.51	7.68	0.43	3.15e-13	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
CESC	cis	rs425277	0.565	rs2480711	chr1:2111376	A/G	cg16545954	chr1:2118288	C1orf86	0.36	7.13	0.4	9.74e-12	Height;
CESC	cis	rs561341	0.831	rs11658469	chr17:30206426	T/C	cg19193384	chr17:30244184	NA	0.49	5.1	0.3	6.47e-7	Hip circumference adjusted for BMI;
CESC	cis	rs4654899	0.929	rs7515845	chr1:21314455	G/A	cg05370193	chr1:21551575	ECE1	0.39	5.85	0.34	1.45e-8	Superior frontal gyrus grey matter volume;
CESC	cis	rs854765	0.647	rs741782	chr17:18019712	T/C	cg16928487	chr17:17741425	SREBF1	-0.45	-7.13	-0.4	9.28e-12	Total body bone mineral density;
CESC	cis	rs35110281	0.591	rs230642	chr21:44915533	A/C	cg01579765	chr21:45077557	HSF2BP	0.45	7.64	0.42	4.02e-13	Mean corpuscular volume;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg17630641	chr17:39804879	NA	-0.42	-6.22	-0.36	1.92e-9	Gambling;
CESC	cis	rs1218582	0.804	rs4845678	chr1:154853295	A/G	cg09359103	chr1:154839909	KCNN3	-0.62	-11.84	-0.59	3.02e-26	Prostate cancer;
CESC	cis	rs858239	0.600	rs2003555	chr7:23122915	C/T	cg23682824	chr7:23144976	KLHL7	0.54	7.58	0.42	5.85e-13	Cerebrospinal fluid biomarker levels;
CESC	cis	rs7662987	1.000	rs6852848	chr4:100001932	A/T	cg13256891	chr4:100009986	ADH5	0.75	5.69	0.33	3.41e-8	Smoking initiation;
CESC	cis	rs3015497	0.561	rs4578563	chr14:51159585	G/A	cg26011998	chr14:51135199	SAV1	-0.54	-5.82	-0.34	1.71e-8	Mean platelet volume;
CESC	cis	rs4148883	0.504	rs4585310	chr4:100120233	T/C	cg13256891	chr4:100009986	ADH5	-0.51	-6.73	-0.38	1.04e-10	Alcohol dependence;
CESC	cis	rs6543140	0.890	rs61122764	chr2:102999520	A/G	cg04239558	chr2:103089729	SLC9A4	0.48	6.04	0.35	5.08e-9	Blood protein levels;
CESC	cis	rs4665809	0.590	rs35532350	chr2:26441605	T/C	cg25036284	chr2:26402008	FAM59B	-0.86	-9.4	-0.5	2.74e-18	Gut microbiome composition (summer);
CESC	cis	rs7618915	0.547	rs12496634	chr3:52709259	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	7.03	0.4	1.78e-11	Bipolar disorder;
CESC	cis	rs524023	0.874	rs475642	chr11:64424691	C/A	cg07220939	chr11:64358617	SLC22A12	-0.35	-5.42	-0.32	1.32e-7	Urate levels in obese individuals;
CESC	cis	rs6951245	0.810	rs117800627	chr7:1081075	G/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-6.15	-0.35	2.88e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs10504229	0.575	rs4590436	chr8:57996539	A/C	cg22535103	chr8:58192502	C8orf71	-0.56	-6.58	-0.37	2.48e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs1008375	1.000	rs10939742	chr4:17659936	G/T	cg16339924	chr4:17578868	LAP3	0.55	6.83	0.39	5.81e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24058025	chr1:44412156	IPO13	0.56	6.07	0.35	4.43e-9	Gut microbiome composition (summer);
CESC	cis	rs10197940	0.624	rs10497081	chr2:152353395	T/G	cg19508488	chr2:152266495	RIF1	0.51	5.45	0.32	1.17e-7	Lung cancer;
CESC	cis	rs7539624	0.947	rs7524132	chr1:223903500	C/T	cg10100437	chr1:223903862	CAPN2	-0.39	-5.73	-0.33	2.71e-8	Schizophrenia;
CESC	cis	rs4835473	0.800	rs4835330	chr4:144767456	T/C	cg25736465	chr4:144833511	NA	0.45	6.65	0.38	1.67e-10	Immature fraction of reticulocytes;
CESC	cis	rs2354432	0.556	rs11239965	chr1:146753907	C/A	cg25205988	chr1:146714368	CHD1L	-0.92	-7.89	-0.44	7.91e-14	Mitochondrial DNA levels;
CESC	cis	rs7762018	0.514	rs60671539	chr6:170165981	A/G	cg08044140	chr6:170176415	C6orf70	-0.4	-5.46	-0.32	1.09e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs9560113	0.550	rs1163633	chr13:112231561	G/T	cg10483660	chr13:112241077	NA	-0.44	-7.48	-0.42	1.07e-12	Menarche (age at onset);
CESC	cis	rs66887589	0.934	rs2715016	chr4:120452356	T/C	cg09307838	chr4:120376055	NA	-0.52	-6.93	-0.39	3.16e-11	Diastolic blood pressure;
CESC	cis	rs3857536	0.813	rs9354405	chr6:66948575	G/T	cg07460842	chr6:66804631	NA	-0.42	-5.32	-0.31	2.2e-7	Blood trace element (Cu levels);
CESC	cis	rs9916302	0.706	rs9909304	chr17:37500508	G/T	cg07936489	chr17:37558343	FBXL20	0.88	9.63	0.51	5.22e-19	Glomerular filtration rate (creatinine);
CESC	cis	rs10504229	1.000	rs73609760	chr8:58192170	A/G	cg14926445	chr8:58193284	C8orf71	-0.51	-5.39	-0.31	1.58e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs4803468	1.000	rs284648	chr19:41926790	T/C	cg14132834	chr19:41945861	ATP5SL	-0.67	-8.35	-0.46	3.74e-15	Height;
CESC	cis	rs72945132	0.825	rs7941965	chr11:70213182	T/C	cg00319359	chr11:70116639	PPFIA1	0.72	6.9	0.39	3.72e-11	Coronary artery disease;
CESC	cis	rs754466	0.510	rs10824579	chr10:79590685	C/T	cg17075019	chr10:79541650	NA	-0.74	-11.98	-0.59	1.04e-26	Liver enzyme levels (gamma-glutamyl transferase);
CESC	trans	rs4771450	0.925	rs7333033	chr13:103978262	G/T	cg17025674	chr5:127537216	NA	-0.5	-6.38	-0.36	7.73e-10	Uric acid levels;
CESC	cis	rs36051895	0.593	rs62541903	chr9:5146952	G/C	cg02405213	chr9:5042618	JAK2	-0.5	-6.07	-0.35	4.52e-9	Pediatric autoimmune diseases;
CESC	cis	rs13108904	0.967	rs1316419	chr4:1293997	C/T	cg00684032	chr4:1343700	KIAA1530	0.39	5.46	0.32	1.11e-7	Obesity-related traits;
CESC	cis	rs1707322	1.000	rs4660328	chr1:46444831	G/T	cg06784218	chr1:46089804	CCDC17	0.33	5.63	0.33	4.7e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg13771624	chr9:140409915	PNPLA7	0.45	6.45	0.37	5.38e-10	Fibrinogen levels;
CESC	cis	rs12701220	0.894	rs12701406	chr7:1050283	G/A	cg26769984	chr7:1090371	C7orf50	0.65	7.42	0.41	1.64e-12	Bronchopulmonary dysplasia;
CESC	cis	rs7072216	0.763	rs3814142	chr10:100171104	C/G	cg26618903	chr10:100175079	PYROXD2	-0.38	-5.79	-0.34	1.99e-8	Metabolite levels;
CESC	cis	rs8067354	0.540	rs7221472	chr17:58036737	C/T	cg13753209	chr17:57696993	CLTC	0.54	5.68	0.33	3.57e-8	Hemoglobin concentration;
CESC	cis	rs62408225	1.000	rs2325291	chr6:90986686	G/A	cg06866423	chr6:90926672	BACH2	0.43	5.11	0.3	6.3e-7	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs8014204	0.736	rs2111705	chr14:75261641	G/A	cg08847533	chr14:75593920	NEK9	0.42	5.32	0.31	2.22e-7	Caffeine consumption;
CESC	cis	rs7129220	0.512	rs1867138	chr11:10228728	A/G	cg01453529	chr11:10209919	SBF2	-0.44	-5.16	-0.3	4.8e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CESC	cis	rs6062302	0.522	rs914558	chr20:62216976	A/G	cg06363034	chr20:62225388	GMEB2	-0.52	-6.57	-0.37	2.61e-10	Glioblastoma;
CESC	cis	rs477895	0.838	rs11607007	chr11:64007976	C/T	cg04317338	chr11:64019027	PLCB3	0.91	10.17	0.53	1.01e-20	Mean platelet volume;
CESC	cis	rs514406	0.861	rs35517489	chr1:53304062	G/C	cg16325326	chr1:53192061	ZYG11B	0.85	14.02	0.65	8.69e-34	Monocyte count;
CESC	cis	rs1348850	0.632	rs13008857	chr2:178514468	G/A	cg23306229	chr2:178417860	TTC30B	0.6	7.53	0.42	7.75e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	trans	rs9987353	0.840	rs329994	chr8:9123233	A/G	cg20257372	chr17:1945152	OVCA2;DPH1	-0.47	-6.31	-0.36	1.2e-9	Recombination measurement;
CESC	cis	rs2404602	0.608	rs17361504	chr15:76601871	A/G	cg05617483	chr15:76483344	C15orf27	0.4	5.39	0.31	1.55e-7	Blood metabolite levels;
CESC	trans	rs747782	0.639	rs17198985	chr11:48183565	T/C	cg15704280	chr7:45808275	SEPT13	0.7	6.47	0.37	4.83e-10	Intraocular pressure;
CESC	cis	rs35110281	0.712	rs167930	chr21:44946625	G/A	cg04455712	chr21:45112962	RRP1B	0.33	5.05	0.3	8.3e-7	Mean corpuscular volume;
CESC	cis	rs4835473	0.897	rs2590034	chr4:144847931	A/G	cg25736465	chr4:144833511	NA	0.39	6.0	0.35	6.44e-9	Immature fraction of reticulocytes;
CESC	cis	rs4689592	0.554	rs66925245	chr4:7071999	C/T	cg26116260	chr4:7069785	GRPEL1	-0.86	-9.54	-0.51	9.81e-19	Monocyte percentage of white cells;
CESC	cis	rs11098499	1.000	rs7659194	chr4:120207147	T/G	cg09307838	chr4:120376055	NA	0.88	11.93	0.59	1.55e-26	Corneal astigmatism;
CESC	cis	rs6540556	0.723	rs11119331	chr1:209889712	G/A	cg05527609	chr1:210001259	C1orf107	-0.67	-7.36	-0.41	2.32e-12	Red blood cell count;
CESC	cis	rs8072100	0.688	rs8079142	chr17:45442049	G/A	cg25173405	chr17:45401733	C17orf57	-0.44	-5.48	-0.32	9.98e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs11785693	0.862	rs62491171	chr8:4987177	G/A	cg26367366	chr8:4980734	NA	0.73	7.3	0.41	3.26e-12	Neuroticism (multi-trait analysis);Neuroticism;
CESC	cis	rs7949030	0.626	rs11231141	chr11:62326265	T/C	cg11742103	chr11:62369870	EML3;MTA2	0.66	10.04	0.52	2.66e-20	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	trans	rs35146811	0.735	rs858506	chr7:99820050	T/C	cg13215871	chr17:75784724	NA	-0.34	-6.39	-0.37	7.46e-10	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26796815	chr5:134094372	DDX46	0.6	7.13	0.4	9.72e-12	Gut microbiome composition (summer);
CESC	cis	rs17095355	1.000	rs12254785	chr10:111699607	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.43	-5.23	-0.31	3.37e-7	Biliary atresia;
CESC	trans	rs561341	0.830	rs2301765	chr17:30202056	T/A	cg27661571	chr11:113659931	NA	0.6	6.09	0.35	3.88e-9	Hip circumference adjusted for BMI;
CESC	cis	rs3015469	0.626	rs10133759	chr14:51151693	A/C	cg26011998	chr14:51135199	SAV1	-0.46	-5.29	-0.31	2.61e-7	Plasma amyloid beta peptide concentrations (ABx-40);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg03768513	chr22:24552594	CABIN1	-0.43	-6.48	-0.37	4.55e-10	Gambling;
CESC	cis	rs651907	0.514	rs11706494	chr3:101509475	A/T	cg12386194	chr3:101231763	SENP7	0.41	5.11	0.3	6.03e-7	Colorectal cancer;
CESC	cis	rs4665809	1.000	rs6739061	chr2:26256147	C/T	cg27170947	chr2:26402098	FAM59B	-0.59	-6.98	-0.39	2.31e-11	Gut microbiome composition (summer);
CESC	cis	rs270601	0.770	rs61352298	chr5:131600589	G/C	cg18758796	chr5:131593413	PDLIM4	0.48	6.97	0.39	2.55e-11	Acylcarnitine levels;
CESC	cis	rs9796	0.558	rs4445868	chr15:41531991	C/T	cg20272979	chr15:41787780	ITPKA	0.38	5.56	0.32	6.59e-8	Menopause (age at onset);
CESC	cis	rs7659604	1.000	rs35224452	chr4:122664677	C/T	cg19671926	chr4:122722719	EXOSC9	-0.44	-5.19	-0.3	4.27e-7	Type 2 diabetes;
CESC	cis	rs9733	0.596	rs72702585	chr1:150696427	G/A	cg18016565	chr1:150552671	MCL1	0.34	5.28	0.31	2.67e-7	Tonsillectomy;
CESC	cis	rs3785574	0.962	rs2584628	chr17:61894578	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.59	7.17	0.4	7.34e-12	Height;
CESC	cis	rs9322193	0.884	rs7450246	chr6:150023653	C/T	cg04369109	chr6:150039330	LATS1	-0.41	-5.86	-0.34	1.37e-8	Lung cancer;
CESC	cis	rs798554	1.000	rs798560	chr7:2758309	A/G	cg18446336	chr7:2847575	GNA12	-0.36	-5.4	-0.31	1.5e-7	Height;
CESC	cis	rs854765	0.505	rs4506969	chr17:17899839	A/G	cg04398451	chr17:18023971	MYO15A	-0.71	-10.35	-0.54	2.56e-21	Total body bone mineral density;
CESC	cis	rs7613875	0.663	rs6762477	chr3:50093209	G/A	cg24110177	chr3:50126178	RBM5	0.54	7.47	0.42	1.2e-12	Body mass index;
CESC	cis	rs853679	0.517	rs56364346	chr6:28050762	T/G	cg23161317	chr6:28129485	ZNF389	0.5	6.31	0.36	1.19e-9	Depression;
CESC	cis	rs9796	0.621	rs690733	chr15:41476465	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.43	-6.41	-0.37	6.77e-10	Menopause (age at onset);
CESC	cis	rs2439831	0.850	rs7183809	chr15:44120868	T/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.67	7.46	0.42	1.21e-12	Lung cancer in ever smokers;
CESC	cis	rs10504229	0.593	rs17192845	chr8:58053339	C/T	cg24829409	chr8:58192753	C8orf71	-0.7	-7.71	-0.43	2.5e-13	Developmental language disorder (linguistic errors);
CESC	cis	rs10504229	1.000	rs58382845	chr8:58169851	A/C	cg24829409	chr8:58192753	C8orf71	-0.75	-9.71	-0.51	2.88e-19	Developmental language disorder (linguistic errors);
CESC	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg04025307	chr7:1156635	C7orf50	0.55	9.79	0.52	1.5700000000000001e-19	Longevity;Endometriosis;
CESC	cis	rs137699	1.000	rs5757632	chr22:39756097	A/C	cg05872129	chr22:39784769	NA	-0.41	-5.34	-0.31	1.99e-7	IgG glycosylation;
CESC	cis	rs6693567	0.586	rs4970979	chr1:150483840	C/T	cg09579323	chr1:150459698	TARS2	0.42	5.3	0.31	2.46e-7	Migraine;
CESC	cis	rs66887589	0.627	rs3872807	chr4:120360251	T/A	cg09307838	chr4:120376055	NA	0.53	7.15	0.4	8.37e-12	Diastolic blood pressure;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25808892	chr17:6459352	PITPNM3	0.54	6.35	0.36	9.53e-10	Gut microbiome composition (summer);
CESC	cis	rs853679	0.517	rs4713141	chr6:28101678	G/C	cg23161317	chr6:28129485	ZNF389	0.52	6.66	0.38	1.53e-10	Depression;
CESC	cis	rs7264396	0.635	rs6060709	chr20:34536022	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.81	-11.25	-0.57	2.92e-24	Total cholesterol levels;
CESC	cis	rs2228479	0.850	rs17226980	chr16:89825065	G/A	cg00800038	chr16:89945340	TCF25	-0.92	-7.67	-0.43	3.37e-13	Skin colour saturation;
CESC	cis	rs854765	0.583	rs11078406	chr17:17840823	G/T	cg04398451	chr17:18023971	MYO15A	-0.7	-10.37	-0.54	2.22e-21	Total body bone mineral density;
CESC	cis	rs4819052	1.000	rs2297284	chr21:46705345	G/A	cg11663144	chr21:46675770	NA	-0.48	-6.53	-0.37	3.28e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs9811920	0.638	rs793471	chr3:99546335	A/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.61	-9.64	-0.51	4.8e-19	Axial length;
CESC	cis	rs6546550	0.935	rs11673826	chr2:70041033	G/A	cg02498382	chr2:70120550	SNRNP27	-0.37	-6.38	-0.36	8.01e-10	Prevalent atrial fibrillation;
CESC	cis	rs7927592	0.913	rs10047412	chr11:68232912	T/C	cg20283391	chr11:68216788	NA	-0.61	-7.28	-0.41	3.81e-12	Total body bone mineral density;
CESC	cis	rs77956314	0.515	rs7302025	chr12:117442902	C/T	cg02017074	chr12:117425053	FBXW8	0.77	8.36	0.46	3.66e-15	Subcortical brain region volumes;Hippocampal volume;
CESC	cis	rs9311474	0.508	rs6786043	chr3:52604861	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.6	8.66	0.47	4.81e-16	Electroencephalogram traits;
CESC	cis	rs57221529	0.654	rs12515813	chr5:671826	A/T	cg16447950	chr5:562315	NA	-0.66	-6.92	-0.39	3.34e-11	Lung disease severity in cystic fibrosis;
CESC	cis	rs4975709	0.589	rs4975745	chr5:1861058	G/C	cg17650747	chr5:1873721	NA	0.41	5.66	0.33	3.83e-8	Cardiovascular disease risk factors;
CESC	cis	rs10504229	0.906	rs56138544	chr8:58184558	A/C	cg24829409	chr8:58192753	C8orf71	-0.76	-9.93	-0.52	5.87e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs2354432	0.505	rs4424556	chr1:146863973	G/C	cg25205988	chr1:146714368	CHD1L	1.01	8.93	0.48	7.3e-17	Mitochondrial DNA levels;
CESC	cis	rs9649213	0.593	rs55825602	chr7:98013039	T/C	cg00277769	chr7:97922759	BAIAP2L1	-0.32	-5.32	-0.31	2.25e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs1552244	1.000	rs67569278	chr3:10149893	T/C	cg00166722	chr3:10149974	C3orf24	0.43	5.08	0.3	7.1e-7	Alzheimer's disease;
CESC	cis	rs7312774	1.000	rs7312774	chr12:107305728	G/A	cg16260113	chr12:107380972	MTERFD3	0.64	6.07	0.35	4.3e-9	Severe influenza A (H1N1) infection;
CESC	cis	rs7666738	0.830	rs13148363	chr4:98847498	T/C	cg05340658	chr4:99064831	C4orf37	0.69	9.73	0.51	2.51e-19	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9467711	0.606	rs9348726	chr6:26605206	G/A	cg21479132	chr6:26055353	NA	0.63	5.57	0.32	6.12e-8	Autism spectrum disorder or schizophrenia;
CESC	trans	rs9858542	0.953	rs71324979	chr3:49619651	T/C	cg21659725	chr3:3221576	CRBN	-0.53	-6.48	-0.37	4.5e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs10751667	1.000	rs12798036	chr11:947585	T/C	cg06064525	chr11:970664	AP2A2	-0.39	-7.03	-0.4	1.72e-11	Alzheimer's disease (late onset);
CESC	cis	rs9287719	0.967	rs7587114	chr2:10739963	C/T	cg02196655	chr2:10830764	NOL10	-0.37	-5.72	-0.33	2.87e-8	Prostate cancer;
CESC	cis	rs992157	0.796	rs55680399	chr2:219160621	T/C	cg00012203	chr2:219082015	ARPC2	0.75	9.97	0.52	4.31e-20	Colorectal cancer;
CESC	trans	rs1998359	0.520	rs177878	chr14:38127890	A/G	cg06045799	chr4:47465578	COMMD8	0.52	6.04	0.35	5.23e-9	Self-reported allergy;
CESC	cis	rs262150	0.788	rs2657408	chr7:158782275	A/G	cg09640425	chr7:158790006	NA	-0.36	-5.17	-0.3	4.7e-7	Facial morphology (factor 20);
CESC	cis	rs17253792	0.822	rs74824071	chr14:56095142	T/G	cg01858014	chr14:56050164	KTN1	-0.85	-6.99	-0.39	2.22e-11	Putamen volume;
CESC	cis	rs10504229	1.000	rs66495524	chr8:58187365	C/T	cg24829409	chr8:58192753	C8orf71	-0.76	-9.93	-0.52	5.87e-20	Developmental language disorder (linguistic errors);
CESC	trans	rs2727020	0.521	rs7131163	chr11:49574774	C/T	cg15704280	chr7:45808275	SEPT13	-0.84	-10.3	-0.53	3.95e-21	Coronary artery disease;
CESC	cis	rs6912958	0.559	rs107689	chr6:88069333	G/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.35	5.87	0.34	1.3e-8	Monocyte percentage of white cells;
CESC	cis	rs9910055	0.659	rs6503488	chr17:42246158	T/G	cg13607699	chr17:42295918	UBTF	0.58	7.54	0.42	7.45e-13	Total body bone mineral density;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10156544	chr12:104324016	LOC253724;HSP90B1	0.63	7.23	0.41	5.17e-12	Gut microbiome composition (summer);
CESC	cis	rs12893668	0.663	rs12889731	chr14:104087482	C/T	cg24130564	chr14:104152367	KLC1	-0.48	-6.02	-0.35	5.86e-9	Reticulocyte count;
CESC	cis	rs7116495	0.737	rs661290	chr11:71766014	A/G	cg10381502	chr11:71823885	C11orf51	-1.15	-7.18	-0.4	7e-12	Severe influenza A (H1N1) infection;
CESC	cis	rs7666738	0.830	rs880472	chr4:98922595	C/A	cg03467027	chr4:99064603	C4orf37	0.46	5.59	0.32	5.78e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs778371	0.697	rs6717048	chr2:233586427	T/C	cg08000102	chr2:233561755	GIGYF2	0.84	14.62	0.67	6.79e-36	Schizophrenia;
CESC	cis	rs2576037	0.796	rs2576039	chr18:44582148	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.45	5.71	0.33	3.02e-8	Personality dimensions;
CESC	cis	rs3733585	0.725	rs6449201	chr4:9973894	C/T	cg00071950	chr4:10020882	SLC2A9	-0.69	-11.21	-0.57	3.85e-24	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs11785400	0.793	rs10956992	chr8:143736235	A/C	cg24634471	chr8:143751801	JRK	0.45	5.86	0.34	1.34e-8	Schizophrenia;
CESC	cis	rs12956009	0.583	rs9653016	chr18:44894189	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.51	6.59	0.38	2.42e-10	Educational attainment (years of education);
CESC	cis	rs875971	0.660	rs7807930	chr7:66087165	C/T	cg14393609	chr7:65229607	NA	-0.46	-6.13	-0.35	3.21e-9	Aortic root size;
CESC	cis	rs2070488	1.000	rs1841777	chr3:38484819	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.93	16.68	0.72	3.43e-43	Electrocardiographic conduction measures;
CESC	trans	rs9467711	0.606	rs13203358	chr6:26590578	A/T	cg06606381	chr12:133084897	FBRSL1	-0.78	-7.16	-0.4	7.76e-12	Autism spectrum disorder or schizophrenia;
CESC	cis	rs7666738	0.830	rs28485415	chr4:99060340	G/A	cg03676636	chr4:99064102	C4orf37	0.34	5.07	0.3	7.32e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11763147	1	rs11763147	chr7:65326821	C/T	cg05332525	chr7:65337924	VKORC1L1	-0.52	-6.44	-0.37	5.63e-10	Corneal structure;
CESC	cis	rs6976053	0.518	rs314358	chr7:100410657	A/G	cg20848291	chr7:100343083	ZAN	0.4	5.5	0.32	9.14e-8	Plasminogen activator inhibitor type 1 levels (PAI-1);
CESC	cis	rs919433	0.783	rs787980	chr2:198239225	C/T	cg20885578	chr2:198174922	NA	0.4	5.36	0.31	1.8e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	trans	rs4349753	0.617	rs10061660	chr5:144090021	A/G	cg25299750	chr6:35109124	TCP11	0.49	6.04	0.35	5.13e-9	Photic sneeze reflex;
CESC	cis	rs9399135	0.773	rs949895	chr6:135405359	C/T	cg22676075	chr6:135203613	NA	0.38	5.06	0.3	8.02e-7	Red blood cell count;
CESC	cis	rs16854884	0.741	rs55909524	chr3:143794734	T/C	cg06585982	chr3:143692056	C3orf58	0.44	5.44	0.32	1.24e-7	Economic and political preferences (feminism/equality);
CESC	cis	rs7100689	0.555	rs1934146	chr10:82062121	C/A	cg00277334	chr10:82204260	NA	-0.61	-8.08	-0.44	2.35e-14	Post bronchodilator FEV1;
CESC	cis	rs4604732	0.631	rs56704806	chr1:247626148	T/C	cg12754571	chr1:247694271	LOC148824;OR2C3	0.44	5.44	0.32	1.21e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs60871478	0.636	rs73045423	chr7:893952	G/A	cg15782153	chr7:917662	C7orf20	0.52	5.72	0.33	2.91e-8	Cerebrospinal P-tau181p levels;
CESC	cis	rs17376456	0.825	rs72786702	chr5:93254656	A/C	cg25358565	chr5:93447407	FAM172A	1.13	10.44	0.54	1.31e-21	Diabetic retinopathy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16773294	chr8:55048378	MRPL15	-0.64	-7.75	-0.43	2.02e-13	Gut microbiome composition (summer);
CESC	cis	rs1552244	0.882	rs13063929	chr3:10010308	T/C	cg08888203	chr3:10149979	C3orf24	0.47	5.89	0.34	1.14e-8	Alzheimer's disease;
CESC	cis	rs10887741	0.646	rs11202502	chr10:89437933	C/T	cg13926569	chr10:89418898	PAPSS2	0.41	6.04	0.35	5.06e-9	Exercise (leisure time);
CESC	cis	rs2408955	0.542	rs7975632	chr12:48443048	C/T	cg24011408	chr12:48396354	COL2A1	0.48	7.22	0.41	5.44e-12	Glycated hemoglobin levels;
CESC	cis	rs2235642	0.928	rs9932984	chr16:1605051	A/G	cg08296037	chr16:1584118	IFT140;TMEM204	-0.31	-5.17	-0.3	4.64e-7	Coronary artery disease;
CESC	cis	rs7551222	0.752	rs4252725	chr1:204513256	A/G	cg20240347	chr1:204465584	NA	-0.26	-5.18	-0.3	4.43e-7	Schizophrenia;
CESC	cis	rs698813	0.674	rs6544751	chr2:44495845	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.49	5.54	0.32	7.16e-8	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
CESC	cis	rs2204008	0.683	rs11519834	chr12:38053575	T/A	cg13010199	chr12:38710504	ALG10B	0.54	6.69	0.38	1.28e-10	Bladder cancer;
CESC	cis	rs3806843	0.801	rs801171	chr5:140115303	G/A	cg26395211	chr5:140044315	WDR55	0.45	6.02	0.35	5.83e-9	Depressive symptoms (multi-trait analysis);
CESC	cis	rs597539	0.616	rs513476	chr11:68698996	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.81	10.5	0.54	8.5e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs6570726	0.935	rs365658	chr6:145844588	C/T	cg05347473	chr6:146136440	FBXO30	0.48	6.54	0.37	3.18e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9611565	0.918	rs9611561	chr22:41757234	C/G	cg17376030	chr22:41985996	PMM1	0.65	6.95	0.39	2.9100000000000002e-11	Vitiligo;
CESC	cis	rs4665809	0.590	rs7582341	chr2:26416301	A/G	cg25036284	chr2:26402008	FAM59B	-0.84	-9.59	-0.51	7.03e-19	Gut microbiome composition (summer);
CESC	cis	rs9733	0.818	rs10888388	chr1:150687296	C/T	cg13175981	chr1:150552382	MCL1	0.62	9.15	0.49	1.59e-17	Tonsillectomy;
CESC	cis	rs12701220	0.655	rs7799656	chr7:1140515	C/T	cg04025307	chr7:1156635	C7orf50	0.46	5.28	0.31	2.69e-7	Bronchopulmonary dysplasia;
CESC	cis	rs889312	0.500	rs3099460	chr5:56133748	G/C	cg14703610	chr5:56206110	C5orf35	0.5	6.63	0.38	1.84e-10	Breast cancer;Breast cancer (early onset);
CESC	cis	rs4665809	0.838	rs2243834	chr2:26357748	A/C	cg08470875	chr2:26401718	FAM59B	0.45	5.19	0.3	4.19e-7	Gut microbiome composition (summer);
CESC	cis	rs10905065	0.898	rs4748916	chr10:5820394	A/G	cg11519256	chr10:5708881	ASB13	-0.39	-5.12	-0.3	5.82e-7	Menopause (age at onset);
CESC	cis	rs6964587	0.692	rs2374550	chr7:91820987	A/G	cg17063962	chr7:91808500	NA	0.46	6.5	0.37	4.05e-10	Breast cancer;
CESC	cis	rs6831352	0.918	rs13133633	chr4:100058697	C/G	cg12011299	chr4:100065546	ADH4	-0.6	-6.62	-0.38	2.04e-10	Alcohol dependence;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg05321307	chr8:1798729	ARHGEF10	0.46	6.15	0.35	2.9e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg20064231	chr18:74608296	ZNF236	0.48	6.4	0.37	6.93e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs2832077	0.943	rs2832094	chr21:30165910	G/A	cg03476357	chr21:30257390	N6AMT1	-0.49	-5.11	-0.3	6.07e-7	Cognitive test performance;
CESC	cis	rs12144309	0.554	rs1970559	chr1:114377148	T/C	cg13572289	chr1:114447746	DCLRE1B;AP4B1	0.44	5.2	0.3	3.99e-7	Coronary artery disease;
CESC	cis	rs875971	0.862	rs10263690	chr7:65766453	G/C	cg19163074	chr7:65112434	INTS4L2	0.4	5.16	0.3	4.86e-7	Aortic root size;
CESC	cis	rs2979489	0.891	rs17626867	chr8:30311177	G/T	cg26383811	chr8:30366931	RBPMS	-0.83	-9.83	-0.52	1.25e-19	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CESC	cis	rs4604732	0.588	rs7552461	chr1:247628644	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.53	6.57	0.37	2.7e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs11608355	0.545	rs11613023	chr12:109898047	T/C	cg05360138	chr12:110035743	NA	0.82	8.92	0.48	7.93e-17	Neuroticism;
CESC	cis	rs258892	0.947	rs266436	chr5:72174553	G/A	cg21869765	chr5:72125136	TNPO1	0.45	5.6	0.33	5.35e-8	Small cell lung carcinoma;
CESC	cis	rs1008375	0.966	rs6832962	chr4:17652133	T/C	cg16339924	chr4:17578868	LAP3	0.75	9.36	0.5	3.65e-18	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs1448094	0.556	rs61930626	chr12:86167445	A/G	cg00310523	chr12:86230176	RASSF9	0.41	6.23	0.36	1.85e-9	Major depressive disorder;
CESC	cis	rs853679	0.550	rs1225598	chr6:28160799	T/G	cg23281280	chr6:28129359	ZNF389	0.49	6.77	0.38	8.23e-11	Depression;
CESC	cis	rs113835537	0.529	rs2279864	chr11:66247844	G/A	cg24851651	chr11:66362959	CCS	0.46	5.78	0.33	2.12e-8	Airway imaging phenotypes;
CESC	cis	rs8060686	0.920	rs112894876	chr16:67812039	G/C	cg26727032	chr16:67993705	SLC12A4	-0.59	-6.16	-0.35	2.69e-9	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs3105593	1.000	rs3131584	chr15:50847401	G/A	cg08437265	chr15:50716283	USP8	0.41	5.35	0.31	1.89e-7	QT interval;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg02738677	chr3:133265129	NA	0.48	6.53	0.37	3.43e-10	Fibrinogen levels;
CESC	cis	rs801193	0.660	rs2659914	chr7:66156914	C/T	cg11764359	chr7:65958608	NA	0.89	13.97	0.65	1.29e-33	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23539498	chr22:35654203	HMGXB4	-0.6	-7.47	-0.42	1.14e-12	Gut microbiome composition (summer);
CESC	cis	rs9910055	0.659	rs6503488	chr17:42246158	T/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.5	7.52	0.42	8.32e-13	Total body bone mineral density;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg21934588	chr1:10532847	DFFA	-0.46	-6.18	-0.35	2.41e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs2637266	0.626	rs2588329	chr10:78552782	C/T	cg18941641	chr10:78392320	NA	0.42	7.93	0.44	6.02e-14	Pulmonary function;
CESC	cis	rs709400	0.894	rs56017123	chr14:104075277	G/A	cg24130564	chr14:104152367	KLC1	-0.44	-5.25	-0.31	3.06e-7	Body mass index;
CESC	cis	rs798554	0.757	rs960273	chr7:2857876	T/C	cg19717773	chr7:2847554	GNA12	-0.57	-7.91	-0.44	7.21e-14	Height;
CESC	trans	rs35110281	0.776	rs9306159	chr21:45061839	G/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.54	7.11	0.4	1.1e-11	Mean corpuscular volume;
CESC	cis	rs4561483	0.767	rs33633	chr16:11994857	A/C	cg08843971	chr16:11963173	GSPT1	-0.53	-7.9	-0.44	7.4e-14	Testicular germ cell tumor;
CESC	cis	rs6912958	0.559	rs6921504	chr6:88058972	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.47	8.18	0.45	1.18e-14	Monocyte percentage of white cells;
CESC	cis	rs7666738	0.830	rs13106434	chr4:98991651	T/A	cg03467027	chr4:99064603	C4orf37	0.44	5.51	0.32	8.65e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10078	0.571	rs2241597	chr5:480509	A/G	cg08916839	chr5:415575	AHRR	0.59	7.02	0.4	1.92e-11	Fat distribution (HIV);
CESC	cis	rs68170813	0.559	rs1018947	chr7:106851939	A/T	cg02696742	chr7:106810147	HBP1	-0.54	-5.33	-0.31	2.14e-7	Coronary artery disease;
CESC	cis	rs3091242	0.933	rs3093584	chr1:25668714	T/C	cg02931644	chr1:25747376	RHCE	-0.4	-6.55	-0.37	2.93e-10	Erythrocyte sedimentation rate;
CESC	cis	rs7542091	0.704	rs9429825	chr1:210052133	C/G	cg09509183	chr1:209979624	IRF6	0.38	5.52	0.32	8.15e-8	Monobrow;
CESC	cis	rs1018836	0.786	rs10086401	chr8:91572818	C/T	cg16814680	chr8:91681699	NA	-0.63	-9.25	-0.49	7.74e-18	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs7301826	0.651	rs4759794	chr12:131297348	T/G	cg11011512	chr12:131303247	STX2	0.46	5.57	0.32	6.37e-8	Plasma plasminogen activator levels;
CESC	cis	rs6575793	0.904	rs7493050	chr14:101037599	A/G	cg18516195	chr14:101012996	BEGAIN	0.46	6.33	0.36	1.02e-9	Menarche (age at onset);
CESC	cis	rs1847202	1.000	rs7634188	chr3:72941289	A/G	cg25664220	chr3:72788482	NA	0.38	5.69	0.33	3.35e-8	Motion sickness;
CESC	cis	rs796364	0.806	rs115717210	chr2:201006247	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.75	-6.83	-0.39	5.71e-11	Schizophrenia;
CESC	cis	rs597539	0.652	rs622082	chr11:68703959	A/G	cg04772025	chr11:68637568	NA	0.51	6.21	0.36	2.09e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg19764399	chr13:48669116	MED4	-0.48	-6.39	-0.37	7.45e-10	Asthma;
CESC	cis	rs7107174	1.000	rs11602622	chr11:78010830	A/G	cg02023728	chr11:77925099	USP35	0.42	6.02	0.35	5.91e-9	Testicular germ cell tumor;
CESC	cis	rs780096	0.526	rs780102	chr2:27659491	T/C	cg24768116	chr2:27665128	KRTCAP3	-0.3	-5.57	-0.32	6.2e-8	Total body bone mineral density;
CESC	cis	rs9527	0.637	rs7096169	chr10:104618695	A/G	cg15744005	chr10:104629667	AS3MT	-0.38	-5.79	-0.34	1.95e-8	Arsenic metabolism;
CESC	cis	rs1799949	1.000	rs8176103	chr17:41267050	G/A	cg06001716	chr17:41278141	BRCA1;NBR2	0.4	5.47	0.32	1.04e-7	Menopause (age at onset);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg07744562	chr6:90539506	CASP8AP2	-0.4	-6.05	-0.35	4.88e-9	Gambling;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg05299703	chr18:43678513	ATP5A1	-0.47	-6.19	-0.36	2.31e-9	Height;
CESC	cis	rs870825	0.616	rs57086463	chr4:185639525	G/A	cg04058563	chr4:185651563	MLF1IP	0.64	7.09	0.4	1.21e-11	Blood protein levels;
CESC	cis	rs425277	0.958	rs626479	chr1:2110260	A/G	cg16545954	chr1:2118288	C1orf86	-0.34	-5.66	-0.33	3.94e-8	Height;
CESC	cis	rs11997175	0.545	rs5005657	chr8:33668913	C/G	ch.8.33884649F	chr8:33765107	NA	0.52	6.44	0.37	5.64e-10	Body mass index;
CESC	cis	rs79839061	0.562	rs10516158	chr4:942439	A/G	cg07828340	chr4:882639	GAK	-1.04	-7.71	-0.43	2.5e-13	Intelligence (multi-trait analysis);
CESC	trans	rs2727020	0.656	rs7925524	chr11:49437542	G/A	cg03929089	chr4:120376271	NA	-0.68	-8.24	-0.45	7.75e-15	Coronary artery disease;
CESC	cis	rs3749237	0.615	rs55957735	chr3:49438158	G/A	cg06212747	chr3:49208901	KLHDC8B	0.53	7.2	0.4	6.14e-12	Resting heart rate;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19682514	chr1:61549327	NFIA	0.55	6.58	0.37	2.48e-10	Gut microbiome composition (summer);
CESC	cis	rs2952156	0.883	rs12150603	chr17:37834715	G/A	cg07936489	chr17:37558343	FBXL20	-0.62	-8.29	-0.45	5.6e-15	Asthma;
CESC	cis	rs6121246	0.559	rs6060915	chr20:30330306	A/G	cg13852791	chr20:30311386	BCL2L1	0.84	10.76	0.55	1.19e-22	Mean corpuscular hemoglobin;
CESC	cis	rs597539	0.652	rs646586	chr11:68681653	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	-0.72	-9.4	-0.5	2.65e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs9325144	0.624	rs10783329	chr12:39113951	C/T	cg26384229	chr12:38710491	ALG10B	-0.54	-7.5	-0.42	9.82e-13	Morning vs. evening chronotype;
CESC	cis	rs7208859	0.623	rs9896603	chr17:29078512	C/G	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.17e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs77956314	0.515	rs12299065	chr12:117442304	A/G	cg02017074	chr12:117425053	FBXW8	0.78	8.3	0.45	5.2e-15	Subcortical brain region volumes;Hippocampal volume;
CESC	cis	rs2415984	0.622	rs12435397	chr14:46940867	G/A	cg14871534	chr14:47121158	RPL10L	-0.37	-5.63	-0.33	4.64e-8	Number of children ever born;
CESC	cis	rs35110281	0.693	rs2838344	chr21:45089877	C/T	cg04455712	chr21:45112962	RRP1B	0.45	7.3	0.41	3.34e-12	Mean corpuscular volume;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg09351035	chr11:748060	TALDO1	-0.46	-6.5	-0.37	3.89e-10	Gambling;
CESC	cis	rs11958404	0.932	rs72816583	chr5:157432647	T/C	cg05962755	chr5:157440814	NA	0.62	6.56	0.37	2.74e-10	IgG glycosylation;
CESC	cis	rs1775715	0.835	rs12266771	chr10:32231380	G/A	cg04359828	chr10:32216031	ARHGAP12	0.36	5.1	0.3	6.56e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs11098499	0.909	rs10020034	chr4:120294331	A/G	cg24375607	chr4:120327624	NA	0.47	5.62	0.33	4.89e-8	Corneal astigmatism;
CESC	cis	rs10752881	1.000	rs10752883	chr1:182980963	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.83	13.29	0.63	3.24e-31	Colorectal cancer;
CESC	cis	rs172166	0.694	rs1150666	chr6:28123928	T/C	cg20151795	chr6:28129481	ZNF389	0.36	5.07	0.3	7.41e-7	Cardiac Troponin-T levels;
CESC	trans	rs7615952	0.866	rs1976459	chr3:125647486	A/T	cg07211511	chr3:129823064	LOC729375	-1.14	-15.22	-0.68	5.24e-38	Blood pressure (smoking interaction);
CESC	cis	rs728616	0.614	rs61859189	chr10:82089250	T/C	cg05935833	chr10:81318306	SFTPA2	-0.37	-5.32	-0.31	2.16e-7	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs3791556	0.898	rs3828222	chr2:240109568	A/G	cg03281426	chr2:240109471	HDAC4	-0.56	-7.38	-0.41	2.02e-12	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs3806843	0.741	rs4912597	chr5:140106857	C/G	cg16179182	chr5:140090404	VTRNA1-1	0.44	5.74	0.33	2.54e-8	Depressive symptoms (multi-trait analysis);
CESC	cis	rs3733585	0.673	rs6814664	chr4:9956228	C/T	cg00071950	chr4:10020882	SLC2A9	-0.7	-11.52	-0.58	3.7e-25	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs9640161	0.750	rs11765644	chr7:150026339	C/G	cg27494647	chr7:150038898	RARRES2	0.4	5.03	0.3	9.11e-7	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs1707322	0.691	rs11211175	chr1:46220884	C/G	cg03146154	chr1:46216737	IPP	0.76	10.91	0.56	4.01e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7264396	0.676	rs6060730	chr20:34558503	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.77	-10.29	-0.53	4.22e-21	Total cholesterol levels;
CESC	cis	rs10256972	0.967	rs1881122	chr7:1040946	A/T	cg09177884	chr7:1199841	ZFAND2A	-0.41	-5.13	-0.3	5.59e-7	Longevity;Endometriosis;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg14584159	chr10:134351371	INPP5A	-0.39	-6.06	-0.35	4.56e-9	Gambling;
CESC	cis	rs1707322	0.655	rs3014240	chr1:46089225	C/G	cg03146154	chr1:46216737	IPP	-0.79	-11.05	-0.56	1.36e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg01022859	chr17:60767314	MRC2	0.42	6.35	0.36	9.16e-10	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs1707322	0.691	rs61784799	chr1:46177748	A/G	cg03146154	chr1:46216737	IPP	-0.82	-11.53	-0.58	3.39e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7809950	0.953	rs2520263	chr7:107179119	T/C	cg23024343	chr7:107201750	COG5	-0.43	-6.01	-0.35	6.18e-9	Coronary artery disease;
CESC	cis	rs651907	0.514	rs12636046	chr3:101434448	T/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.43	5.52	0.32	8.14e-8	Colorectal cancer;
CESC	cis	rs36051895	0.589	rs7874785	chr9:5196695	C/T	cg02405213	chr9:5042618	JAK2	0.51	5.94	0.34	8.88e-9	Pediatric autoimmune diseases;
CESC	cis	rs9311474	0.502	rs4687624	chr3:52563572	C/T	cg18337363	chr3:52569053	NT5DC2	0.28	5.08	0.3	7.06e-7	Electroencephalogram traits;
CESC	cis	rs798554	0.797	rs798488	chr7:2802522	T/C	cg18446336	chr7:2847575	GNA12	-0.39	-5.9	-0.34	1.1e-8	Height;
CESC	trans	rs3780486	1.000	rs10813957	chr9:33153527	G/T	cg20290983	chr6:43655470	MRPS18A	0.88	11.8	0.59	4.13e-26	IgG glycosylation;
CESC	cis	rs875971	0.522	rs6960048	chr7:65408039	A/G	cg06456125	chr7:65229604	NA	0.46	5.99	0.35	6.93e-9	Aortic root size;
CESC	cis	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg05863683	chr7:1912471	MAD1L1	0.42	6.21	0.36	2.09e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs7666738	0.830	rs6829567	chr4:99047340	T/C	cg05340658	chr4:99064831	C4orf37	0.82	12.88	0.62	8.44e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs34779708	0.931	rs34375045	chr10:35362356	A/C	cg04310649	chr10:35416472	CREM	-0.51	-6.02	-0.35	5.75e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs9790314	1.000	rs459697	chr3:161093420	G/A	cg04691961	chr3:161091175	C3orf57	-0.42	-5.17	-0.3	4.57e-7	Morning vs. evening chronotype;
CESC	cis	rs9584850	0.834	rs3783005	chr13:99111337	A/T	cg20750642	chr13:99100586	FARP1	0.36	5.38	0.31	1.61e-7	Neuroticism;
CESC	cis	rs1322639	0.614	rs6937001	chr6:169565086	C/T	cg04662567	chr6:169592167	NA	0.46	5.14	0.3	5.32e-7	Pulse pressure;
CESC	cis	rs3747547	0.818	rs11794350	chr9:37947420	C/G	cg13774184	chr9:37916125	SHB	-0.57	-5.96	-0.34	8.04e-9	Metabolite levels (Dihydroxy docosatrienoic acid);
CESC	cis	rs9549367	0.789	rs9549715	chr13:113908240	G/C	cg18105134	chr13:113819100	PROZ	-0.72	-8.87	-0.48	1.09e-16	Platelet distribution width;
CESC	cis	rs17376456	0.877	rs13173952	chr5:93307557	A/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.64	5.65	0.33	4.1e-8	Diabetic retinopathy;
CESC	cis	rs977987	0.806	rs8050769	chr16:75388434	C/T	cg03315344	chr16:75512273	CHST6	0.4	5.83	0.34	1.61e-8	Dupuytren's disease;
CESC	cis	rs10979	0.964	rs12526234	chr6:143898680	A/T	cg25407410	chr6:143891975	LOC285740	-0.61	-9.12	-0.49	1.91e-17	Hypospadias;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14056620	chr7:44836144	PPIA	0.6	6.89	0.39	3.98e-11	Gut microbiome composition (summer);
CESC	cis	rs6912958	0.712	rs6454641	chr6:88371060	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.54	-7.17	-0.4	7.28e-12	Monocyte percentage of white cells;
CESC	cis	rs9549260	0.785	rs10507484	chr13:41218134	T/C	cg21288729	chr13:41239152	FOXO1	0.67	8.73	0.47	2.88e-16	Red blood cell count;
CESC	cis	rs1941023	0.503	rs894591	chr11:60132647	T/C	cg08716584	chr11:60157161	MS4A7	-0.55	-8.95	-0.48	6.42e-17	Congenital heart disease (maternal effect);
CESC	cis	rs6120849	0.754	rs13433216	chr20:33616301	T/C	cg06115741	chr20:33292138	TP53INP2	0.53	5.05	0.3	8.15e-7	Protein C levels;
CESC	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.75	6.54	0.37	3.16e-10	Platelet count;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg19863752	chr5:175970067	NA	-0.45	-6.17	-0.35	2.49e-9	Fibrinogen levels;
CESC	cis	rs898097	0.841	rs4986136	chr17:80865119	A/G	cg10494973	chr17:80897199	TBCD	-0.43	-5.05	-0.3	8.33e-7	Breast cancer;
CESC	cis	rs1862618	0.671	rs2591955	chr5:56244948	C/T	cg22800045	chr5:56110881	MAP3K1	-0.61	-7.83	-0.43	1.21e-13	Initial pursuit acceleration;
CESC	cis	rs514406	0.644	rs928451	chr1:53195800	A/G	cg16325326	chr1:53192061	ZYG11B	-1.0	-17.81	-0.74	3.35e-47	Monocyte count;
CESC	trans	rs1116547	0.602	rs3846722	chr5:112825424	G/A	cg10115368	chr14:100435663	NA	0.5	6.0	0.35	6.41e-9	Cerebral amyloid angiopathy;
CESC	cis	rs6952808	0.689	rs12668156	chr7:2019875	G/A	cg04267008	chr7:1944627	MAD1L1	-0.65	-7.73	-0.43	2.18e-13	Bipolar disorder and schizophrenia;
CESC	cis	rs820218	0.743	rs2053508	chr17:73685659	A/G	cg01592526	chr17:73663357	RECQL5;SAP30BP	-0.45	-6.13	-0.35	3.18e-9	Rotator cuff tears;
CESC	cis	rs1707322	1.000	rs12124291	chr1:46432132	G/A	cg03146154	chr1:46216737	IPP	0.72	9.82	0.52	1.31e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16791218	chr16:88105809	BANP	-0.6	-6.71	-0.38	1.17e-10	Gut microbiome composition (summer);
CESC	cis	rs4665809	1.000	rs10202478	chr2:26276049	T/C	cg26314531	chr2:26401878	FAM59B	-0.7	-7.87	-0.44	9.29e-14	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20250570	chr10:1034318	GTPBP4	0.6	6.99	0.39	2.28e-11	Gut microbiome composition (summer);
CESC	cis	rs72945132	0.882	rs7942613	chr11:70210675	C/T	cg14191688	chr11:70257035	CTTN	0.43	5.42	0.32	1.34e-7	Coronary artery disease;
CESC	cis	rs12893668	0.572	rs2273175	chr14:104160141	T/C	cg08213375	chr14:104286397	PPP1R13B	0.32	5.38	0.31	1.64e-7	Reticulocyte count;
CESC	cis	rs7903847	0.619	rs9888116	chr10:99159482	G/A	cg20016023	chr10:99160130	RRP12	-0.3	-5.22	-0.31	3.54e-7	Granulocyte percentage of myeloid white cells;
CESC	trans	rs11098499	0.657	rs7664458	chr4:120371967	A/G	cg25214090	chr10:38739885	LOC399744	0.7	9.92	0.52	6.5e-20	Corneal astigmatism;
CESC	cis	rs30380	1.000	rs469758	chr5:96121715	C/T	cg16492584	chr5:96139282	ERAP1	-0.35	-5.35	-0.31	1.89e-7	Cerebrospinal fluid biomarker levels;
CESC	cis	rs847577	0.677	rs4729403	chr7:97707841	G/C	cg21770322	chr7:97807741	LMTK2	-0.48	-7.17	-0.4	7.61e-12	Breast cancer;
CESC	cis	rs2635047	0.811	rs12962421	chr18:44787498	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.42	5.51	0.32	8.36e-8	Educational attainment;
CESC	cis	rs9658691	0.607	rs9658788	chr10:90776486	T/C	cg03111039	chr10:90751583	FAS;ACTA2	-0.61	-5.33	-0.31	2.13e-7	Mosquito bite size;
CESC	cis	rs6752107	1.000	rs6431654	chr2:234161769	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.48	6.81	0.39	6.56e-11	Crohn's disease;Inflammatory bowel disease;
CESC	trans	rs637571	0.584	rs659824	chr11:65636509	A/G	cg17712092	chr4:129076599	LARP1B	-0.73	-9.51	-0.5	1.24e-18	Eosinophil percentage of white cells;
CESC	cis	rs2075371	1.000	rs432487	chr7:133990114	T/G	cg00033643	chr7:134001901	SLC35B4	0.44	5.6	0.33	5.4e-8	Mean platelet volume;
CESC	cis	rs2404602	0.536	rs12915248	chr15:76765615	A/T	cg22467129	chr15:76604101	ETFA	-0.38	-5.95	-0.34	8.31e-9	Blood metabolite levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16354201	chr1:33938307	ZSCAN20	-0.59	-7.12	-0.4	9.92e-12	Gut microbiome composition (summer);
CESC	cis	rs916888	0.821	rs70600	chr17:44860021	C/T	cg17911788	chr17:44343683	NA	-0.55	-6.95	-0.39	2.86e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs4665809	0.590	rs2289019	chr2:26420809	G/C	cg22920501	chr2:26401640	FAM59B	-0.86	-10.17	-0.53	1.03e-20	Gut microbiome composition (summer);
CESC	cis	rs2832191	1.000	rs2832183	chr21:30482150	G/A	cg08807101	chr21:30365312	RNF160	-0.67	-9.18	-0.49	1.29e-17	Dental caries;
CESC	cis	rs13191362	0.507	rs2023015	chr6:163060528	A/T	cg06582575	chr6:163149167	PACRG;PARK2	-0.5	-5.97	-0.34	7.63e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs7091068	0.518	rs726817	chr10:95459817	C/T	cg20715218	chr10:95462985	C10orf4	0.54	6.65	0.38	1.62e-10	Urinary tract infection frequency;
CESC	cis	rs6580649	0.941	rs11609399	chr12:48501161	A/T	cg05342945	chr12:48394962	COL2A1	0.55	6.35	0.36	9.14e-10	Lung cancer;
CESC	cis	rs4720575	1.000	rs4724535	chr7:47100396	G/A	cg00036614	chr7:47093842	NA	-0.42	-6.48	-0.37	4.39e-10	Angiotensin-converting enzyme inhibitor intolerance;
CESC	cis	rs7937682	1.000	rs4936661	chr11:111587495	G/A	cg22437258	chr11:111473054	SIK2	-0.67	-7.62	-0.42	4.63e-13	Primary sclerosing cholangitis;
CESC	cis	rs965469	1.000	rs2236087	chr20:3255905	C/T	cg25506879	chr20:3388711	C20orf194	-0.57	-5.93	-0.34	9.53e-9	IFN-related cytopenia;
CESC	cis	rs9486719	1.000	rs12207570	chr6:96987884	A/C	cg06623918	chr6:96969491	KIAA0776	-0.8	-8.32	-0.46	4.68e-15	Migraine;Coronary artery disease;
CESC	cis	rs9447004	0.583	rs28360541	chr6:74432427	T/G	cg23004174	chr6:74404879	CD109	0.36	5.13	0.3	5.67e-7	Blood protein levels;Calcium levels;
CESC	cis	rs8017423	0.967	rs7154683	chr14:90700692	A/G	cg14092571	chr14:90743983	NA	-0.58	-8.43	-0.46	2.31e-15	Mortality in heart failure;
CESC	cis	rs2625529	0.652	rs8036307	chr15:72175120	A/G	cg16672083	chr15:72433130	SENP8	0.47	6.88	0.39	4.35e-11	Red blood cell count;
CESC	cis	rs1670533	0.932	rs2248083	chr4:1052166	A/C	cg27284194	chr4:1044797	NA	0.43	5.25	0.31	3.05e-7	Recombination rate (females);
CESC	cis	rs6087771	0.651	rs6060775	chr20:30286191	A/G	cg13852791	chr20:30311386	BCL2L1	0.56	6.47	0.37	4.76e-10	Subcortical brain region volumes;Putamen volume;
CESC	cis	rs11249608	0.548	rs11960161	chr5:178453837	A/G	cg01312482	chr5:178451176	ZNF879	-0.46	-6.48	-0.37	4.52e-10	Pubertal anthropometrics;
CESC	cis	rs2070488	0.965	rs7640050	chr3:38525864	A/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.96	17.83	0.74	2.96e-47	Electrocardiographic conduction measures;
CESC	cis	rs60154123	0.730	rs583148	chr1:210463553	A/C	cg25204440	chr1:209979598	IRF6	0.45	5.04	0.3	8.61e-7	Coronary artery disease;
CESC	cis	rs1448094	0.872	rs7300073	chr12:86393513	A/C	cg02569458	chr12:86230093	RASSF9	0.34	5.16	0.3	4.86e-7	Major depressive disorder;
CESC	cis	rs4481887	1.000	rs4430369	chr1:248464330	A/G	cg00666640	chr1:248458726	OR2T12	0.41	6.59	0.38	2.41e-10	Common traits (Other);
CESC	cis	rs9611565	0.512	rs4822052	chr22:42193741	G/A	cg03806693	chr22:41940476	POLR3H	-1.06	-12.08	-0.6	4.51e-27	Vitiligo;
CESC	cis	rs7937682	0.632	rs2070894	chr11:111780837	G/A	cg22437258	chr11:111473054	SIK2	-0.5	-5.6	-0.33	5.39e-8	Primary sclerosing cholangitis;
CESC	cis	rs3733585	0.699	rs6449159	chr4:9960498	G/A	cg02734326	chr4:10020555	SLC2A9	-0.43	-6.01	-0.35	6.1e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg27086024	chr14:67982146	TMEM229B	-0.47	-6.34	-0.36	1.01e-9	Asthma;
CESC	cis	rs6089584	1.000	rs6089581	chr20:60562394	G/A	cg06108461	chr20:60628389	TAF4	-0.78	-11.36	-0.57	1.25e-24	Body mass index;
CESC	cis	rs1499972	0.618	rs62264768	chr3:117642924	T/C	cg07612923	chr3:117604196	NA	0.69	6.32	0.36	1.12e-9	Schizophrenia;
CESC	cis	rs1707322	1.000	rs12124291	chr1:46432132	G/A	cg06784218	chr1:46089804	CCDC17	0.33	5.63	0.33	4.7e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs1552244	0.882	rs68080705	chr3:10025743	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.76	-9.55	-0.51	9.12e-19	Alzheimer's disease;
CESC	cis	rs1865721	0.761	rs11660256	chr18:73219532	C/T	cg26385618	chr18:73139727	C18orf62	-0.53	-7.75	-0.43	2.02e-13	Intelligence;
CESC	trans	rs997295	0.529	rs12592315	chr15:68040266	A/G	cg18012350	chr15:74753669	UBL7	0.52	6.89	0.39	4.05e-11	Motion sickness;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg14105000	chr17:55193516	AKAP1	0.41	5.99	0.35	6.69e-9	Fibrinogen levels;
CESC	cis	rs9527	0.590	rs7074395	chr10:104844928	A/C	cg04362960	chr10:104952993	NT5C2	-0.44	-5.41	-0.32	1.39e-7	Arsenic metabolism;
CESC	cis	rs9399135	0.967	rs6569990	chr6:135365818	C/T	cg24558204	chr6:135376177	HBS1L	0.5	6.85	0.39	5.16e-11	Red blood cell count;
CESC	trans	rs72766638	0.895	rs55924785	chr9:136929586	C/T	cg10765909	chr12:53715428	AAAS	-0.74	-6.66	-0.38	1.53e-10	Mosquito bite size;
CESC	cis	rs9910055	0.550	rs113844752	chr17:42297631	C/A	cg08499158	chr17:42289980	UBTF	-0.49	-6.04	-0.35	5.06e-9	Total body bone mineral density;
CESC	cis	rs9926296	0.529	rs7195906	chr16:89806347	A/T	cg03388025	chr16:89894329	SPIRE2	0.39	7.45	0.42	1.29e-12	Vitiligo;
CESC	cis	rs6499255	0.951	rs11642030	chr16:69605211	A/C	cg15192750	chr16:69999425	NA	0.53	6.13	0.35	3.22e-9	IgE levels;
CESC	cis	rs10504229	0.683	rs7816733	chr8:58129855	G/A	cg24829409	chr8:58192753	C8orf71	-0.58	-7.2	-0.4	6.31e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs4819052	0.788	rs4819051	chr21:46693128	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.75	10.02	0.52	2.97e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs2303759	0.918	rs8107548	chr19:49870643	T/C	cg24324837	chr19:49891574	CCDC155	0.48	5.59	0.32	5.74e-8	Multiple sclerosis;
CESC	cis	rs6942756	0.806	rs10248810	chr7:128993806	G/A	cg02491457	chr7:128862824	NA	-0.6	-8.49	-0.46	1.45e-15	White matter hyperintensity burden;
CESC	cis	rs6089829	1.000	rs6089828	chr20:61668998	C/T	cg03213289	chr20:61660250	NA	0.39	5.96	0.34	7.99e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs1799949	0.965	rs11650132	chr17:41326087	T/G	cg05368731	chr17:41323189	NBR1	0.78	10.62	0.55	3.44e-22	Menopause (age at onset);
CESC	cis	rs11252926	0.966	rs61831030	chr10:578869	C/T	cg18196295	chr10:418757	DIP2C	-0.5	-5.67	-0.33	3.69e-8	Psychosis in Alzheimer's disease;
CESC	cis	rs2996428	0.667	rs11578581	chr1:3770642	G/A	cg23277830	chr1:3704460	LRRC47	0.34	5.05	0.3	8.41e-7	Red cell distribution width;
CESC	cis	rs1729951	0.575	rs12494558	chr3:136678781	C/G	cg04103450	chr3:136751342	NA	0.4	5.39	0.31	1.55e-7	Neuroticism;
CESC	cis	rs1707322	1.000	rs785517	chr1:46567535	A/T	cg06784218	chr1:46089804	CCDC17	-0.36	-5.93	-0.34	9.35e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs561341	1.000	rs72821952	chr17:30248133	T/A	cg19193384	chr17:30244184	NA	-0.64	-5.9	-0.34	1.12e-8	Hip circumference adjusted for BMI;
CESC	cis	rs6866344	0.661	rs72812606	chr5:178129094	A/T	cg10224037	chr5:178157518	ZNF354A	0.68	7.49	0.42	1.02e-12	Neutrophil percentage of white cells;
CESC	cis	rs10504229	0.683	rs58438731	chr8:58134790	C/T	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs6088590	1.000	rs6120708	chr20:33335526	G/A	cg24642439	chr20:33292090	TP53INP2	0.83	11.6	0.58	2.04e-25	Coronary artery disease;
CESC	cis	rs7223966	1.000	rs7220892	chr17:61908316	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.71	0.38	1.15e-10	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs13191362	1.000	rs67840803	chr6:163049048	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.83	9.06	0.49	3.05e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs2859741	0.546	rs2134846	chr1:37500723	G/A	cg09363841	chr1:37513479	NA	-0.52	-7.69	-0.43	2.85e-13	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
CESC	trans	rs9951602	0.512	rs4799247	chr18:76653449	G/A	cg02800362	chr5:177631904	HNRNPAB	0.66	8.63	0.47	5.9e-16	Obesity-related traits;
CESC	cis	rs2599510	0.744	rs2254106	chr2:32768797	G/A	cg02381751	chr2:32503542	YIPF4	0.53	6.84	0.39	5.46e-11	Interleukin-18 levels;
CESC	cis	rs35110281	0.714	rs7277539	chr21:45053011	A/G	cg04455712	chr21:45112962	RRP1B	0.4	5.9	0.34	1.08e-8	Mean corpuscular volume;
CESC	cis	rs933688	1.000	rs1895448	chr5:90743854	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.08	14.36	0.66	5.48e-35	Smoking behavior;
CESC	cis	rs67311347	1.000	rs12630072	chr3:40517190	T/G	cg09455208	chr3:40491958	NA	0.51	8.34	0.46	4.1e-15	Renal cell carcinoma;
CESC	cis	rs10751667	0.643	rs7395592	chr11:934094	C/G	cg06064525	chr11:970664	AP2A2	-0.54	-10.85	-0.55	5.96e-23	Alzheimer's disease (late onset);
CESC	cis	rs947211	0.898	rs1772156	chr1:205752894	T/C	cg26354017	chr1:205819088	PM20D1	0.43	5.42	0.32	1.31e-7	Parkinson's disease;
CESC	trans	rs57221529	0.766	rs4957053	chr5:575927	T/C	cg25482853	chr8:67687455	SGK3	1.01	10.17	0.53	9.74e-21	Lung disease severity in cystic fibrosis;
CESC	cis	rs10504229	1.000	rs67546820	chr8:58168567	G/A	cg22535103	chr8:58192502	C8orf71	-1.05	-13.24	-0.63	4.54e-31	Developmental language disorder (linguistic errors);
CESC	cis	rs11792861	0.926	rs7855282	chr9:111802614	T/A	cg05043794	chr9:111880884	C9orf5	-0.4	-6.64	-0.38	1.8e-10	Menarche (age at onset);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg17952549	chr19:58983050	ZNF324	0.51	6.68	0.38	1.42e-10	Fibrinogen levels;
CESC	cis	rs7264396	0.690	rs2425180	chr20:34447160	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.62	7.36	0.41	2.25e-12	Total cholesterol levels;
CESC	cis	rs9649213	0.593	rs6465682	chr7:98016417	C/A	cg21770322	chr7:97807741	LMTK2	0.55	8.31	0.45	5.11e-15	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs3096299	0.658	rs12443705	chr16:89547054	C/G	cg00750074	chr16:89608354	SPG7	-0.43	-6.27	-0.36	1.42e-9	Multiple myeloma (IgH translocation);
CESC	cis	rs12477438	0.765	rs7605218	chr2:99593080	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.64	-8.71	-0.47	3.43e-16	Chronic sinus infection;
CESC	cis	rs6540559	1.000	rs7522250	chr1:209962539	T/C	cg22029157	chr1:209979665	IRF6	0.69	9.9	0.52	7.09e-20	Cleft lip with or without cleft palate;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11808854	chr20:60697627	LSM14B	0.55	6.23	0.36	1.79e-9	Gut microbiome composition (summer);
CESC	trans	rs11250098	0.503	rs7821826	chr8:10769439	C/T	cg06636001	chr8:8085503	FLJ10661	-0.49	-6.07	-0.35	4.38e-9	Morning vs. evening chronotype;
CESC	cis	rs2439831	0.867	rs2447208	chr15:43933895	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.78	8.32	0.46	4.72e-15	Lung cancer in ever smokers;
CESC	cis	rs8072100	0.875	rs12451409	chr17:45544856	A/G	cg25173405	chr17:45401733	C17orf57	-0.46	-6.03	-0.35	5.59e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs12048904	0.964	rs17123467	chr1:101331760	G/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.52	6.63	0.38	1.93e-10	Multiple sclerosis;
CESC	cis	rs875971	0.522	rs781144	chr7:65440344	C/G	cg05332525	chr7:65337924	VKORC1L1	0.47	5.55	0.32	6.82e-8	Aortic root size;
CESC	cis	rs7618915	0.571	rs7623199	chr3:52605974	C/T	cg07507251	chr3:52567010	NT5DC2	0.42	7.37	0.41	2.11e-12	Bipolar disorder;
CESC	cis	rs2108622	0.785	rs3093199	chr19:15989871	T/A	cg13772218	chr19:15982569	NA	0.31	6.07	0.35	4.34e-9	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CESC	cis	rs5758659	0.714	rs2284087	chr22:42485671	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.32	5.51	0.32	8.37e-8	Cognitive function;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg27315239	chr1:53593711	SLC1A7	-0.47	-7.85	-0.43	1.01e-13	Gambling;
CESC	cis	rs6502050	0.835	rs7212441	chr17:80080047	T/G	cg23985595	chr17:80112537	CCDC57	0.42	6.56	0.37	2.87e-10	Life satisfaction;
CESC	cis	rs13256369	0.851	rs13267036	chr8:8566685	G/A	cg00074818	chr8:8560427	CLDN23	0.36	5.09	0.3	6.79e-7	Obesity-related traits;
CESC	cis	rs1609391	0.543	rs9828009	chr3:136631275	C/T	cg15507776	chr3:136538369	TMEM22	0.81	11.89	0.59	2.08e-26	Neuroticism;
CESC	cis	rs9611565	0.802	rs9611571	chr22:41784867	G/A	cg06481639	chr22:41940642	POLR3H	-0.63	-6.84	-0.39	5.31e-11	Vitiligo;
CESC	cis	rs597539	0.652	rs514296	chr11:68654182	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.77	10.3	0.53	3.96e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.76	10.79	0.55	9.97e-23	Prudent dietary pattern;
CESC	cis	rs7000551	0.751	rs2461482	chr8:22382898	C/T	cg12081754	chr8:22256438	SLC39A14	0.46	6.21	0.36	2.06e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CESC	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg07677032	chr17:61819896	STRADA	0.45	5.92	0.34	1.01e-8	Prudent dietary pattern;
CESC	cis	rs11676348	0.818	rs7423433	chr2:218985084	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.46	-6.03	-0.35	5.51e-9	Ulcerative colitis;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg17524854	chr12:67663046	CAND1	-0.46	-6.12	-0.35	3.34e-9	Height;
CESC	cis	rs4072980	0.524	rs16824514	chr1:38395947	A/T	cg18451016	chr1:38461880	NA	0.42	5.93	0.34	9.41e-9	Coronary artery disease;
CESC	cis	rs898097	0.578	rs6502021	chr17:80907728	T/C	cg15664640	chr17:80829946	TBCD	0.41	5.98	0.34	7.36e-9	Breast cancer;
CESC	cis	rs910316	1.000	rs12588240	chr14:75612083	C/A	cg08847533	chr14:75593920	NEK9	1.02	19.83	0.77	2.88e-54	Height;
CESC	cis	rs17764205	0.929	rs10420960	chr19:3256721	G/A	cg04171554	chr19:2761892	SGTA	-0.55	-5.15	-0.3	4.97e-7	Bipolar disorder and schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02780181	chr11:6704622	MRPL17	0.77	8.8	0.48	1.79e-16	Gut microbiome composition (summer);
CESC	cis	rs7267979	0.816	rs422148	chr20:25512604	G/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.78	14.49	0.66	1.95e-35	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs367615	0.660	rs4632850	chr5:108832883	C/G	cg17395555	chr5:108820864	NA	0.64	11.03	0.56	1.56e-23	Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs6499129	1.000	rs7195790	chr16:67522289	A/G	cg26727032	chr16:67993705	SLC12A4	-0.57	-5.78	-0.33	2.08e-8	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs7089973	0.872	rs35010779	chr10:116631816	A/C	cg25233709	chr10:116636983	FAM160B1	0.34	5.03	0.3	9.07e-7	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs4780401	0.693	rs8191277	chr16:11764082	A/G	cg01061890	chr16:11836724	TXNDC11	-0.39	-5.03	-0.3	9.21e-7	Rheumatoid arthritis;
CESC	cis	rs7402982	0.625	rs4966009	chr15:99203496	C/T	cg03437748	chr15:99193247	IGF1R	0.62	8.27	0.45	6.53e-15	Birth weight;
CESC	cis	rs10838687	0.673	rs2290148	chr11:47346145	G/A	cg25783544	chr11:47291846	MADD	0.57	6.53	0.37	3.43e-10	Proinsulin levels;
CESC	cis	rs4523957	0.553	rs2641440	chr17:2027182	G/C	cg16513277	chr17:2031491	SMG6	-0.76	-11.17	-0.57	5.37e-24	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs1808579	0.904	rs891387	chr18:21103909	A/G	cg14672496	chr18:21087552	C18orf8	0.37	5.27	0.31	2.88e-7	Hip circumference;Body mass index;BMI (adjusted for smoking behaviour);
CESC	cis	rs9322193	0.887	rs9505824	chr6:149954799	A/G	cg13206674	chr6:150067644	NUP43	0.43	6.18	0.35	2.39e-9	Lung cancer;
CESC	cis	rs10504229	0.520	rs55967509	chr8:57992448	A/G	cg22535103	chr8:58192502	C8orf71	-0.66	-7.06	-0.4	1.45e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs853679	0.517	rs17774663	chr6:28120898	G/A	cg22143856	chr6:28129313	ZNF389	0.53	6.73	0.38	1.06e-10	Depression;
CESC	cis	rs832540	0.931	rs2662040	chr5:56246610	A/G	cg24531977	chr5:56204891	C5orf35	0.41	5.12	0.3	5.87e-7	Coronary artery disease;
CESC	cis	rs617791	0.508	rs747526	chr11:65776071	C/A	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.38	-5.03	-0.3	8.96e-7	Breast cancer;
CESC	trans	rs10463316	0.894	rs3846712	chr5:150759813	C/A	cg24389359	chr12:111284228	CCDC63	-0.33	-6.02	-0.35	5.66e-9	Metabolite levels (Pyroglutamine);
CESC	cis	rs910316	1.000	rs175442	chr14:75603564	T/C	cg16144293	chr14:75469539	EIF2B2	0.4	5.26	0.31	3e-7	Height;
CESC	cis	rs5498	0.809	rs1056538	chr19:10402938	G/A	cg22910295	chr19:10403862	ICAM5	0.43	6.06	0.35	4.55e-9	Lymphocyte counts;Soluble ICAM-1;Blood protein levels;
CESC	cis	rs2370759	1.000	rs2370759	chr10:32634972	G/A	cg05361325	chr10:32636312	EPC1	-0.56	-5.21	-0.3	3.82e-7	Sexual dysfunction (female);
CESC	cis	rs597539	0.652	rs11603827	chr11:68719221	C/T	cg21963583	chr11:68658836	MRPL21	0.4	5.32	0.31	2.26e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs3812565	0.506	rs4259518	chr9:139322503	T/C	cg14019695	chr9:139328340	INPP5E	0.37	5.42	0.32	1.31e-7	Granulocyte percentage of myeloid white cells;
CESC	cis	rs7666738	0.830	rs7674095	chr4:99048158	T/A	cg03467027	chr4:99064603	C4orf37	0.47	5.98	0.34	7.19e-9	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20018561	chr13:52586135	ALG11;ATP7B	0.55	6.43	0.37	6e-10	Gut microbiome composition (summer);
CESC	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	22.27	0.81	1.17e-62	Prudent dietary pattern;
CESC	trans	rs2932538	0.744	rs6537742	chr1:113085197	G/T	cg17706972	chr6:152126337	ESR1	0.39	6.04	0.35	5.08e-9	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CESC	cis	rs7605827	0.930	rs6431696	chr2:15540009	C/A	cg19274914	chr2:15703543	NA	0.38	6.87	0.39	4.61e-11	Educational attainment (years of education);
CESC	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg05025164	chr4:1340916	KIAA1530	0.8	10.93	0.56	3.33e-23	Longevity;
CESC	cis	rs4805272	0.539	rs17591634	chr19:29331628	A/C	cg12756686	chr19:29218302	NA	-0.49	-5.97	-0.34	7.41e-9	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
CESC	cis	rs1801251	1.000	rs13004406	chr2:233584557	A/T	cg25237894	chr2:233734115	C2orf82	-0.49	-8.38	-0.46	3.1e-15	Coronary artery disease;
CESC	cis	rs2933343	0.700	rs789238	chr3:128636715	A/G	cg24203234	chr3:128598194	ACAD9	0.39	5.27	0.31	2.86e-7	IgG glycosylation;
CESC	cis	rs5760092	0.755	rs915589	chr22:24261004	C/T	cg18538332	chr22:24372958	LOC391322	0.76	9.27	0.49	6.62e-18	Urinary 1,3-butadiene metabolite levels in smokers;
CESC	cis	rs9443645	0.901	rs3805747	chr6:79672522	A/G	cg05283184	chr6:79620031	NA	-0.41	-6.41	-0.37	6.48e-10	Intelligence (multi-trait analysis);
CESC	cis	rs1707322	0.721	rs6699418	chr1:46100181	G/A	cg06784218	chr1:46089804	CCDC17	0.41	7.31	0.41	3.1e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs10089	1.000	rs883074	chr5:127445823	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.68	-9.16	-0.49	1.43e-17	Ileal carcinoids;
CESC	cis	rs1062177	1.000	rs41494545	chr5:151235094	A/G	cg00977110	chr5:151150581	G3BP1	-0.63	-7.01	-0.4	1.97e-11	Preschool internalizing problems;
CESC	cis	rs8067354	0.645	rs9910518	chr17:57812067	T/C	cg02344993	chr17:57696989	CLTC	0.68	8.07	0.44	2.5e-14	Hemoglobin concentration;
CESC	cis	rs10883723	0.810	rs2296589	chr10:104248106	T/A	cg22532475	chr10:104410764	TRIM8	-0.34	-5.72	-0.33	2.86e-8	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs7296418	0.699	rs1109559	chr12:123757861	C/T	cg05973401	chr12:123451056	ABCB9	0.47	6.2	0.36	2.13e-9	Platelet count;
CESC	cis	rs801193	1.000	rs2659915	chr7:66153101	A/G	cg14393609	chr7:65229607	NA	0.48	6.56	0.37	2.75e-10	Aortic root size;
CESC	cis	rs12893668	0.572	rs35011804	chr14:104151400	C/T	cg24130564	chr14:104152367	KLC1	-0.48	-6.36	-0.36	8.88e-10	Reticulocyte count;
CESC	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg07092213	chr7:1199455	ZFAND2A	-0.5	-5.93	-0.34	9.31e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs35110281	0.807	rs2838328	chr21:45023234	G/C	cg01579765	chr21:45077557	HSF2BP	-0.58	-10.11	-0.53	1.53e-20	Mean corpuscular volume;
CESC	cis	rs6089584	0.888	rs6061966	chr20:60607936	C/G	cg13770153	chr20:60521292	NA	-0.45	-5.79	-0.33	2.03e-8	Body mass index;
CESC	cis	rs2836974	0.863	rs8128026	chr21:40533702	T/C	cg27266027	chr21:40555129	PSMG1	0.46	5.57	0.32	6.36e-8	Cognitive function;
CESC	cis	rs62103177	0.810	rs62103189	chr18:77627815	G/A	cg12964065	chr18:77638022	KCNG2	0.58	5.46	0.32	1.07e-7	Opioid sensitivity;
CESC	cis	rs10540	0.915	rs12419209	chr11:494510	T/C	cg03934478	chr11:495069	RNH1	0.53	5.13	0.3	5.68e-7	Body mass index;
CESC	trans	rs2963826	0.589	rs298091	chr5:58996603	A/T	cg01510332	chr19:59087201	MGC2752	0.48	6.14	0.35	3.05e-9	Obesity-related traits;
CESC	cis	rs3749237	0.595	rs4855859	chr3:49526300	C/T	cg03060546	chr3:49711283	APEH	0.77	11.82	0.59	3.5e-26	Resting heart rate;
CESC	cis	rs8031584	1.000	rs1474380	chr15:31269235	T/C	cg14298792	chr15:30685198	CHRFAM7A	-0.45	-5.32	-0.31	2.24e-7	Huntington's disease progression;
CESC	cis	rs4555082	0.874	rs28625632	chr14:105748849	G/T	cg27165867	chr14:105738592	BRF1	-0.48	-5.1	-0.3	6.44e-7	Mean platelet volume;Platelet distribution width;
CESC	cis	rs1413885	0.516	rs7537733	chr1:65838229	G/A	cg14976592	chr1:65886160	LEPROT;LEPR	0.46	6.08	0.35	4.16e-9	Anticoagulant levels;
CESC	trans	rs2749592	0.550	rs10764135	chr10:37866845	C/T	cg12057190	chr19:54976211	LENG9;CDC42EP5	-0.42	-6.0	-0.35	6.45e-9	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs7809950	1.000	rs2712201	chr7:107145564	T/C	cg23024343	chr7:107201750	COG5	-0.43	-6.04	-0.35	5.25e-9	Coronary artery disease;
CESC	cis	rs8013055	0.846	rs12893999	chr14:105970842	C/G	cg23356831	chr14:105996513	TMEM121	0.37	5.11	0.3	6.19e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
CESC	cis	rs172166	0.694	rs9295760	chr6:28147385	G/A	cg26335602	chr6:28129616	ZNF389	0.37	5.41	0.32	1.38e-7	Cardiac Troponin-T levels;
CESC	cis	rs1953600	1.000	rs1953600	chr10:81911725	A/G	cg04850286	chr10:81895943	PLAC9	0.29	5.04	0.3	8.56e-7	Sarcoidosis;
CESC	cis	rs898097	0.841	rs2271918	chr17:80861206	A/G	cg15369054	chr17:80825471	TBCD	0.55	7.29	0.41	3.61e-12	Breast cancer;
CESC	cis	rs9649213	0.574	rs7790229	chr7:97919338	G/A	cg21770322	chr7:97807741	LMTK2	0.54	7.92	0.44	6.73e-14	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs12347191	0.500	rs925486	chr9:100619733	C/T	cg13688889	chr9:100608707	NA	-0.91	-13.42	-0.64	1.07e-31	Orofacial clefts;
CESC	cis	rs798554	0.836	rs798490	chr7:2801542	C/T	cg04166393	chr7:2884313	GNA12	0.62	8.04	0.44	2.97e-14	Height;
CESC	cis	rs9467711	0.606	rs9366655	chr6:26377385	C/G	cg12826209	chr6:26865740	GUSBL1	0.63	5.62	0.33	4.82e-8	Autism spectrum disorder or schizophrenia;
CESC	cis	rs853679	0.882	rs9380069	chr6:28203300	A/G	cg26335602	chr6:28129616	ZNF389	0.56	5.8	0.34	1.86e-8	Depression;
CESC	cis	rs11696501	0.694	rs2171371	chr20:44273482	T/C	cg11783356	chr20:44313418	WFDC10B	-0.33	-5.22	-0.31	3.57e-7	Brain structure;
CESC	cis	rs12477438	0.520	rs4850897	chr2:99768419	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.77	12.85	0.62	1.02e-29	Chronic sinus infection;
CESC	cis	rs947211	0.950	rs1775145	chr1:205756143	C/A	cg14893161	chr1:205819251	PM20D1	0.39	5.19	0.3	4.12e-7	Parkinson's disease;
CESC	cis	rs1799949	1.000	rs33994002	chr17:41328818	T/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	8.55	0.46	1.01e-15	Menopause (age at onset);
CESC	cis	rs6952808	0.595	rs3778982	chr7:2166233	T/C	cg21782813	chr7:2030301	MAD1L1	0.51	7.25	0.41	4.52e-12	Bipolar disorder and schizophrenia;
CESC	cis	rs2228479	0.764	rs35518096	chr16:89961140	C/A	cg04013166	chr16:89971882	TCF25	0.7	7.2	0.4	6.05e-12	Skin colour saturation;
CESC	cis	rs13191362	1.000	rs67094146	chr6:163145412	G/C	cg14584255	chr6:163149320	PACRG;PARK2	0.5	5.46	0.32	1.12e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs7124681	0.584	rs12226590	chr11:47571808	T/C	cg20307385	chr11:47447363	PSMC3	0.62	8.47	0.46	1.68e-15	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22997124	chr22:24200000	SLC2A11	0.6	6.66	0.38	1.55e-10	Gut microbiome composition (summer);
CESC	cis	rs9948	0.655	rs56913233	chr2:97405896	A/G	cg01990225	chr2:97406019	LMAN2L	-1.02	-7.77	-0.43	1.76e-13	Erectile dysfunction and prostate cancer treatment;
CESC	cis	rs6701037	0.625	rs34270511	chr1:175128543	C/T	cg00321850	chr1:175162397	KIAA0040	-0.43	-6.2	-0.36	2.1e-9	Alcohol dependence;
CESC	cis	rs1267303	1.000	rs1267303	chr1:46990457	A/G	cg25110126	chr1:46999211	NA	0.63	8.22	0.45	9.17e-15	Monobrow;
CESC	cis	rs652260	0.967	rs667295	chr19:7901634	G/A	cg26014689	chr19:7917955	EVI5L	-0.44	-5.95	-0.34	8.63e-9	Menarche (age at onset);
CESC	cis	rs7927771	0.524	rs10838782	chr11:47877800	A/G	cg20307385	chr11:47447363	PSMC3	0.63	8.69	0.47	3.88e-16	Subjective well-being;
CESC	cis	rs6502050	0.835	rs7209474	chr17:80136418	C/T	cg23985595	chr17:80112537	CCDC57	-0.4	-6.33	-0.36	1.02e-9	Life satisfaction;
CESC	cis	rs9916302	0.904	rs11867312	chr17:37597748	C/T	cg00129232	chr17:37814104	STARD3	-0.56	-7.35	-0.41	2.4e-12	Glomerular filtration rate (creatinine);
CESC	cis	rs875971	0.862	rs6960446	chr7:65733259	A/G	cg18876405	chr7:65276391	NA	-0.51	-7.01	-0.4	1.94e-11	Aortic root size;
CESC	cis	rs10744422	0.925	rs2880678	chr12:123317099	C/T	cg25930673	chr12:123319894	HIP1R	-0.65	-5.28	-0.31	2.72e-7	Schizophrenia;
CESC	cis	rs826838	0.967	rs1684413	chr12:39128704	G/A	cg26384229	chr12:38710491	ALG10B	-0.67	-11.01	-0.56	1.82e-23	Heart rate;
CESC	cis	rs9457247	0.765	rs12212247	chr6:167413539	T/C	cg23791538	chr6:167370224	RNASET2	-0.55	-7.59	-0.42	5.41e-13	Crohn's disease;
CESC	cis	rs2635047	0.811	rs10502880	chr18:44770746	T/C	cg19077165	chr18:44547161	KATNAL2	-0.39	-5.19	-0.3	4.25e-7	Educational attainment;
CESC	cis	rs2408955	0.522	rs11168408	chr12:48498327	G/A	cg24011408	chr12:48396354	COL2A1	-0.52	-7.73	-0.43	2.24e-13	Glycated hemoglobin levels;
CESC	cis	rs1878931	0.580	rs7204571	chr16:3402444	T/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.93	13.47	0.64	7.47e-32	Body mass index (adult);
CESC	cis	rs6701037	1.000	rs6425323	chr1:175125036	C/T	cg00321850	chr1:175162397	KIAA0040	-0.42	-5.88	-0.34	1.22e-8	Alcohol dependence;
CESC	trans	rs6990917	0.590	rs6999075	chr8:68792070	A/G	cg23652123	chr19:49303202	BCAT2	0.89	6.1	0.35	3.83e-9	Adverse response to lamotrigine and phenytoin;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12498916	chr11:65265145	MALAT1	0.67	7.31	0.41	3.11e-12	Gut microbiome composition (summer);
CESC	cis	rs2836974	0.627	rs7278985	chr21:40653767	C/T	cg11644478	chr21:40555479	PSMG1	-0.84	-12.62	-0.61	6.4e-29	Cognitive function;
CESC	cis	rs6541297	1.000	rs2352723	chr1:230291868	C/T	cg05784532	chr1:230284198	GALNT2	-0.48	-5.69	-0.33	3.38e-8	Coronary artery disease;
CESC	cis	rs4689388	0.853	rs1079214	chr4:6282157	T/C	cg00701064	chr4:6280414	WFS1	0.72	12.0	0.59	8.66e-27	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs10392	0.543	rs4812336	chr20:37547374	G/A	cg27552599	chr20:37590471	DHX35	0.39	5.56	0.32	6.57e-8	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
CESC	cis	rs9311474	0.581	rs13621	chr3:52558133	T/C	cg17372223	chr3:52568218	NT5DC2	0.53	8.47	0.46	1.77e-15	Electroencephalogram traits;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg07077115	chr13:28024429	MTIF3	-0.48	-6.39	-0.37	7.37e-10	Height;
CESC	trans	rs1814175	0.817	rs7483795	chr11:49704930	G/A	cg03929089	chr4:120376271	NA	-0.92	-14.97	-0.68	4.04e-37	Height;
CESC	cis	rs7546094	1.000	rs7546094	chr1:113154400	C/T	cg22162597	chr1:113214053	CAPZA1	0.4	6.13	0.35	3.09e-9	Platelet distribution width;
CESC	cis	rs6952808	0.501	rs4721429	chr7:2171704	T/C	cg04267008	chr7:1944627	MAD1L1	-0.53	-6.32	-0.36	1.08e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs950027	0.620	rs1145093	chr15:45649813	C/A	cg21132104	chr15:45694354	SPATA5L1	0.66	8.52	0.46	1.22e-15	Response to fenofibrate (adiponectin levels);
CESC	cis	rs3008870	1.000	rs2815370	chr1:67503727	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-1.0	-13.54	-0.64	4.16e-32	Lymphocyte percentage of white cells;
CESC	cis	rs17376456	0.569	rs2045021	chr5:93224222	G/A	cg25358565	chr5:93447407	FAM172A	-0.7	-7.53	-0.42	8.2e-13	Diabetic retinopathy;
CESC	cis	rs875971	0.540	rs1723268	chr7:65473080	A/C	cg11987759	chr7:65425863	GUSB	-0.48	-6.58	-0.37	2.54e-10	Aortic root size;
CESC	cis	rs7089973	0.966	rs749649	chr10:116641999	G/A	cg23260525	chr10:116636907	FAM160B1	0.34	5.32	0.31	2.2e-7	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs1620921	0.505	rs4708892	chr6:161209101	T/C	cg01280913	chr6:161186852	NA	-0.38	-5.66	-0.33	3.96e-8	Lipoprotein (a) - cholesterol levels;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg03484612	chr15:75095495	CSK	0.45	6.44	0.37	5.7e-10	Fibrinogen levels;
CESC	cis	rs9611565	0.559	rs9611619	chr22:41986714	C/T	cg06481639	chr22:41940642	POLR3H	-0.65	-6.38	-0.37	7.65e-10	Vitiligo;
CESC	trans	rs61931739	0.500	rs7312938	chr12:34378708	C/T	cg26384229	chr12:38710491	ALG10B	0.69	10.35	0.54	2.55e-21	Morning vs. evening chronotype;
CESC	cis	rs2652834	0.808	rs28583444	chr15:63357852	T/G	cg05507819	chr15:63340323	TPM1	0.62	6.13	0.35	3.16e-9	HDL cholesterol;
CESC	cis	rs8077577	0.945	rs11653988	chr17:18088833	C/T	cg16794390	chr17:18148240	FLII	0.41	5.71	0.33	3.05e-8	Obesity-related traits;
CESC	cis	rs1964356	0.967	rs2953802	chr8:8851881	G/A	cg15556689	chr8:8085844	FLJ10661	0.41	5.4	0.31	1.5e-7	Mean corpuscular volume;
CESC	cis	rs13108904	0.870	rs4493483	chr4:1279916	G/A	cg00684032	chr4:1343700	KIAA1530	0.39	5.43	0.32	1.27e-7	Obesity-related traits;
CESC	cis	rs9420	0.961	rs11604325	chr11:57497011	C/A	cg19752551	chr11:57585705	CTNND1	-0.36	-5.07	-0.3	7.55e-7	Schizophrenia;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg16216227	chr4:174293382	SAP30	-0.44	-6.33	-0.36	1.07e-9	Thyroid stimulating hormone;
CESC	cis	rs854765	0.616	rs8076747	chr17:17853595	C/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.47	6.06	0.35	4.67e-9	Total body bone mineral density;
CESC	cis	rs728616	0.614	rs61859198	chr10:82114628	C/A	cg05935833	chr10:81318306	SFTPA2	-0.46	-5.8	-0.34	1.84e-8	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs9549367	0.789	rs7999579	chr13:113879357	T/C	cg18105134	chr13:113819100	PROZ	-0.66	-8.24	-0.45	8.04e-15	Platelet distribution width;
CESC	cis	rs17253792	0.822	rs17253723	chr14:56154015	A/G	cg01858014	chr14:56050164	KTN1	-0.97	-7.54	-0.42	7.36e-13	Putamen volume;
CESC	cis	rs7666738	0.830	rs10005173	chr4:98816062	T/C	cg17366294	chr4:99064904	C4orf37	0.54	7.47	0.42	1.14e-12	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2354432	0.556	rs1932979	chr1:146708912	A/G	cg25205988	chr1:146714368	CHD1L	-1.04	-8.53	-0.46	1.14e-15	Mitochondrial DNA levels;
CESC	cis	rs1550582	0.548	rs7828645	chr8:135497385	A/G	cg17885191	chr8:135476712	NA	-0.88	-11.63	-0.58	1.52e-25	Educational attainment;
CESC	cis	rs875971	0.825	rs7384021	chr7:66077904	A/G	cg10691866	chr7:65817282	TPST1	0.33	5.53	0.32	7.81e-8	Aortic root size;
CESC	cis	rs79057730	0.527	rs34519158	chr7:811114	G/A	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.87	7.34	0.41	2.59e-12	Initial pursuit acceleration;
CESC	trans	rs12681287	0.547	rs7465511	chr8:87521481	C/T	cg27317242	chr8:23145699	R3HCC1	-0.51	-6.08	-0.35	4.09e-9	Caudate activity during reward;
CESC	cis	rs5771069	0.897	rs137858	chr22:50445601	T/C	cg03721641	chr22:50451245	IL17REL	0.34	5.77	0.33	2.17e-8	Ulcerative colitis;
CESC	cis	rs9326248	0.530	rs7114963	chr11:116875983	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.59	5.44	0.32	1.2e-7	Blood protein levels;
CESC	trans	rs9325144	0.647	rs11168104	chr12:38857616	G/T	cg10679878	chr6:156759499	NA	-0.33	-6.0	-0.35	6.61e-9	Morning vs. evening chronotype;
CESC	cis	rs9486719	1.000	rs2064947	chr6:97052754	C/T	cg18709589	chr6:96969512	KIAA0776	-0.49	-5.49	-0.32	9.47e-8	Migraine;Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21789229	chr4:54232186	SCFD2	0.61	7.35	0.41	2.44e-12	Gut microbiome composition (summer);
CESC	cis	rs453301	0.658	rs3855900	chr8:8901921	A/G	cg15556689	chr8:8085844	FLJ10661	-0.51	-6.24	-0.36	1.77e-9	Joint mobility (Beighton score);
CESC	trans	rs1814175	0.586	rs2866862	chr11:49954588	T/C	cg03929089	chr4:120376271	NA	-0.89	-14.87	-0.67	8.52e-37	Height;
CESC	cis	rs1538970	0.847	rs781230	chr1:45880751	C/T	cg24296786	chr1:45957014	TESK2	0.45	5.44	0.32	1.23e-7	Platelet count;
CESC	cis	rs853679	0.574	rs1233705	chr6:28166447	C/G	cg12963246	chr6:28129442	ZNF389	0.5	6.95	0.39	2.85e-11	Depression;
CESC	cis	rs9560113	0.573	rs9560132	chr13:112237456	C/T	cg10483660	chr13:112241077	NA	0.4	6.81	0.39	6.61e-11	Menarche (age at onset);
CESC	cis	rs8072100	0.666	rs9913503	chr17:45776330	T/G	cg08085267	chr17:45401833	C17orf57	-0.42	-5.31	-0.31	2.37e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	trans	rs12713956	0.748	rs570877	chr2:21251040	A/C	cg13097573	chr17:47957986	NA	-0.82	-6.45	-0.37	5.32e-10	LDL cholesterol;
CESC	cis	rs6546550	0.835	rs13002091	chr2:70118388	C/T	cg02498382	chr2:70120550	SNRNP27	-0.42	-7.58	-0.42	6e-13	Prevalent atrial fibrillation;
CESC	cis	rs4713118	0.824	rs742046	chr6:27739254	A/G	cg17221315	chr6:27791827	HIST1H4J	0.47	5.83	0.34	1.6e-8	Parkinson's disease;
CESC	cis	rs853679	0.824	rs34712084	chr6:28043828	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.75	-6.28	-0.36	1.36e-9	Depression;
CESC	cis	rs4455778	0.536	rs38769	chr7:48940934	C/T	cg26309511	chr7:48887640	NA	0.35	5.06	0.3	7.72e-7	Lung cancer in never smokers;
CESC	cis	rs477692	0.692	rs7905095	chr10:131448143	C/T	cg24747557	chr10:131355152	MGMT	0.38	5.25	0.31	3.06e-7	Response to temozolomide;
CESC	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg11494091	chr17:61959527	GH2	0.72	12.38	0.61	4.46e-28	Prudent dietary pattern;
CESC	cis	rs12410462	1.000	rs12407171	chr1:227642282	G/A	cg04117972	chr1:227635322	NA	0.62	6.11	0.35	3.55e-9	Major depressive disorder;
CESC	cis	rs9322193	0.923	rs7740278	chr6:149961252	C/T	cg13206674	chr6:150067644	NUP43	0.44	6.4	0.37	7e-10	Lung cancer;
CESC	cis	rs7618915	0.547	rs12496476	chr3:52708737	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.49	7.14	0.4	9.06e-12	Bipolar disorder;
CESC	cis	rs763121	0.853	rs5750633	chr22:38993467	A/G	cg06022373	chr22:39101656	GTPBP1	0.94	17.17	0.73	5.98e-45	Menopause (age at onset);
CESC	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg02475777	chr4:1388615	CRIPAK	0.73	9.3	0.5	5.53e-18	Longevity;
CESC	cis	rs1059312	1.000	rs12814773	chr12:129280786	C/T	cg09035930	chr12:129282057	SLC15A4	0.79	11.27	0.57	2.42e-24	Systemic lupus erythematosus;
CESC	cis	rs6952808	0.792	rs12536261	chr7:1953571	G/A	cg02951883	chr7:2050386	MAD1L1	-0.5	-6.84	-0.39	5.53e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs6815814	0.851	rs11736207	chr4:38766285	G/A	cg02016764	chr4:38805732	TLR1	-0.68	-7.31	-0.41	3.06e-12	Breast cancer;
CESC	cis	rs13256369	1.000	rs13267501	chr8:8574058	G/A	cg17143192	chr8:8559678	CLDN23	0.74	8.73	0.47	2.86e-16	Obesity-related traits;
CESC	cis	rs11785400	0.793	rs4430070	chr8:143729184	G/C	cg24634471	chr8:143751801	JRK	0.45	5.68	0.33	3.46e-8	Schizophrenia;
CESC	cis	rs896854	0.625	rs4735336	chr8:95973410	A/C	cg23172400	chr8:95962367	TP53INP1	0.39	7.9	0.44	7.65e-14	Type 2 diabetes;
CESC	cis	rs8051149	0.688	rs12444533	chr16:87869711	C/T	cg03408354	chr16:87871219	SLC7A5	-0.47	-5.77	-0.33	2.23e-8	Blood metabolite levels;
CESC	cis	rs1355223	0.902	rs1258470	chr11:34729265	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.47	6.27	0.36	1.48e-9	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs7582720	1.000	rs72926786	chr2:203816494	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.36	0.41	2.34e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13323047	chr6:7261517	NA	-0.61	-6.87	-0.39	4.63e-11	Gut microbiome composition (summer);
CESC	cis	rs6963495	0.818	rs73190202	chr7:105166510	A/G	cg13798780	chr7:105162888	PUS7	0.78	8.02	0.44	3.36e-14	Bipolar disorder (body mass index interaction);
CESC	cis	rs3888647	0.622	rs4758618	chr11:2995186	A/T	cg25174290	chr11:3078921	CARS	0.52	7.06	0.4	1.48e-11	Type 2 diabetes;
CESC	cis	rs9911578	1.000	rs6503887	chr17:56993320	T/C	cg12560992	chr17:57184187	TRIM37	0.93	15.26	0.68	3.55e-38	Intelligence (multi-trait analysis);
CESC	cis	rs614226	1.000	rs7174	chr12:121017171	A/G	cg01236616	chr12:121019343	POP5	1.49	18.26	0.75	8.44e-49	Type 1 diabetes nephropathy;
CESC	cis	rs778371	0.915	rs748002	chr2:233757679	G/A	cg08000102	chr2:233561755	GIGYF2	-0.81	-13.04	-0.63	2.34e-30	Schizophrenia;
CESC	cis	rs818427	0.555	rs410701	chr5:112206416	G/A	cg07820702	chr5:112228657	REEP5	0.41	5.51	0.32	8.44e-8	Total body bone mineral density;
CESC	cis	rs2836974	0.644	rs4818017	chr21:40690561	G/T	cg11644478	chr21:40555479	PSMG1	-0.78	-11.54	-0.58	3.25e-25	Cognitive function;
CESC	cis	rs1005277	0.579	rs2504148	chr10:38400788	A/G	cg25427524	chr10:38739819	LOC399744	-0.65	-9.43	-0.5	2.21e-18	Extrinsic epigenetic age acceleration;
CESC	cis	rs7811142	0.830	rs6979910	chr7:99940630	A/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.95	10.96	0.56	2.58e-23	Platelet count;
CESC	cis	rs11249608	0.548	rs6867208	chr5:178455575	G/A	cg01312482	chr5:178451176	ZNF879	-0.46	-6.42	-0.37	6.42e-10	Pubertal anthropometrics;
CESC	cis	rs2731664	0.792	rs1130857	chr5:176863519	G/C	cg23176889	chr5:176863531	GRK6	-0.63	-10.64	-0.55	2.94e-22	Intelligence (multi-trait analysis);
CESC	cis	rs34172651	0.606	rs7194189	chr16:24703484	G/T	cg06028605	chr16:24865363	SLC5A11	-0.45	-6.71	-0.38	1.16e-10	Intelligence (multi-trait analysis);
CESC	cis	rs78456975	1.000	rs11883965	chr2:1560062	T/C	cg26248373	chr2:1572462	NA	-0.59	-5.7	-0.33	3.11e-8	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.57	-6.92	-0.39	3.45e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs897080	0.552	rs1067369	chr2:44652654	A/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	5.87	0.34	1.28e-8	Height;
CESC	cis	rs709400	0.663	rs8015918	chr14:103942991	A/G	cg12935359	chr14:103987150	CKB	-0.51	-7.44	-0.42	1.39e-12	Body mass index;
CESC	trans	rs13035304	0.543	rs13017715	chr2:130500081	A/G	cg18827756	chr15:42130735	JMJD7-PLA2G4B;PLA2G4B	0.37	6.1	0.35	3.71e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
CESC	cis	rs3820068	0.705	rs16851731	chr1:15860240	A/G	cg18192808	chr1:15853278	DNAJC16	0.49	6.0	0.35	6.43e-9	Systolic blood pressure;
CESC	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg03188948	chr7:1209495	NA	0.73	7.02	0.4	1.85e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs1882538	0.538	rs7803848	chr7:133108547	C/T	cg10665199	chr7:133106180	EXOC4	0.61	8.37	0.46	3.26e-15	Intelligence (multi-trait analysis);
CESC	cis	rs7666738	0.830	rs3846443	chr4:99032666	G/A	cg18180107	chr4:99064573	C4orf37	0.41	5.27	0.31	2.78e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs13223928	0.666	rs9986825	chr7:3151177	C/T	cg19214707	chr7:3157722	NA	0.4	5.69	0.33	3.43e-8	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
CESC	cis	rs2228479	0.702	rs12600151	chr16:89831558	C/T	cg04013166	chr16:89971882	TCF25	0.78	6.69	0.38	1.3e-10	Skin colour saturation;
CESC	cis	rs2073300	0.609	rs6137941	chr20:23400848	G/A	cg12062639	chr20:23401060	NAPB	1.07	8.23	0.45	8.58e-15	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs2549003	0.933	rs3846731	chr5:131814264	T/C	cg21138405	chr5:131827807	IRF1	0.54	9.38	0.5	3.2e-18	Asthma (sex interaction);
CESC	cis	rs4713118	0.516	rs7739216	chr6:28079946	G/T	cg18032046	chr6:28092343	ZSCAN16	-0.58	-6.75	-0.38	9.45e-11	Parkinson's disease;
CESC	cis	rs7542091	0.704	rs4133950	chr1:210044393	C/G	cg09509183	chr1:209979624	IRF6	0.39	5.58	0.32	6.08e-8	Monobrow;
CESC	cis	rs763121	0.853	rs2072794	chr22:39150543	G/T	cg21395723	chr22:39101663	GTPBP1	0.45	5.65	0.33	4.18e-8	Menopause (age at onset);
CESC	cis	rs8070128	0.637	rs4925133	chr17:17884801	A/G	cg16928487	chr17:17741425	SREBF1	-0.46	-7.51	-0.42	8.88e-13	Total body bone mineral density;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13613210	chr9:99181598	ZNF367	0.53	6.37	0.36	8.42e-10	Gut microbiome composition (summer);
CESC	cis	rs919433	0.929	rs7592511	chr2:198177974	A/G	cg10820045	chr2:198174542	NA	-0.44	-6.85	-0.39	5.28e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs9837602	1.000	rs28714363	chr3:99752068	G/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.53	7.45	0.42	1.36e-12	Breast cancer;
CESC	cis	rs11583043	1.000	rs17100939	chr1:101443701	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.5	5.51	0.32	8.64e-8	Ulcerative colitis;Inflammatory bowel disease;
CESC	cis	rs3738443	0.672	rs6691539	chr1:247372672	C/T	cg07706540	chr1:247373924	NA	-0.43	-5.21	-0.3	3.8e-7	Alcohol dependence;
CESC	cis	rs6426558	0.559	rs485234	chr1:227317747	A/G	cg10327440	chr1:227177885	CDC42BPA	0.47	5.9	0.34	1.13e-8	Neutrophil percentage of white cells;
CESC	cis	rs7589342	0.929	rs13024715	chr2:106433950	A/G	cg16077055	chr2:106428750	NCK2	0.53	7.56	0.42	6.6e-13	Addiction;
CESC	cis	rs2033711	0.870	rs7409473	chr19:58939165	A/G	cg11952622	chr19:58962976	ZNF324B	0.46	6.14	0.35	3.08e-9	Uric acid clearance;
CESC	cis	rs5769765	0.624	rs2285187	chr22:50185432	A/G	cg02269571	chr22:50332266	NA	-0.48	-6.12	-0.35	3.38e-9	Schizophrenia;
CESC	cis	rs12142240	0.698	rs56063031	chr1:46825433	C/T	cg00530320	chr1:46809349	NSUN4	0.6	8.04	0.44	2.96e-14	Menopause (age at onset);
CESC	cis	rs4713118	0.586	rs6905522	chr6:28086479	A/C	cg17949981	chr6:28129498	ZNF389	0.45	5.63	0.33	4.71e-8	Parkinson's disease;
CESC	cis	rs1568889	0.838	rs6484359	chr11:28262328	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.8	13.6	0.64	2.62e-32	Bipolar disorder;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	ch.1.448124R	chr1:12054885	MFN2	-0.46	-6.12	-0.35	3.39e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs2573652	0.723	rs2727201	chr15:100515311	A/G	cg09918751	chr15:100517450	ADAMTS17	-0.45	-8.84	-0.48	1.38e-16	Height;
CESC	cis	rs5758659	0.714	rs2413668	chr22:42505841	G/A	cg04733989	chr22:42467013	NAGA	-0.43	-6.05	-0.35	4.98e-9	Cognitive function;
CESC	cis	rs12477438	0.520	rs8179690	chr2:99795300	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.82	-14.98	-0.68	3.63e-37	Chronic sinus infection;
CESC	cis	rs919433	0.929	rs4850788	chr2:198182940	G/A	cg03934865	chr2:198174659	NA	-0.49	-7.67	-0.43	3.2e-13	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg12012699	chr18:46986876	DYM	0.45	6.23	0.36	1.82e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs7246657	0.943	rs10415937	chr19:37830064	T/G	cg24637308	chr11:6592297	DNHD1	0.53	6.17	0.35	2.55e-9	Coronary artery calcification;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg07649988	chr10:102106576	SCD	-0.46	-6.17	-0.35	2.48e-9	Fibrinogen levels;
CESC	cis	rs12995491	0.731	rs55705009	chr2:88500718	T/G	cg04169830	chr2:88471460	THNSL2	0.33	5.13	0.3	5.63e-7	Response to metformin (IC50);
CESC	cis	rs916888	0.610	rs199436	chr17:44789285	C/T	cg17911788	chr17:44343683	NA	0.43	6.62	0.38	1.97e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg11494091	chr17:61959527	GH2	0.76	13.39	0.64	1.42e-31	Prudent dietary pattern;
CESC	cis	rs593982	0.920	rs10896044	chr11:65554680	C/G	cg08755490	chr11:65554678	OVOL1	1.36	19.23	0.76	3.57e-52	Atopic dermatitis;
CESC	cis	rs7219021	1.000	rs57185954	chr17:46844961	T/C	cg16584676	chr17:46985605	UBE2Z	-0.69	-7.64	-0.42	3.92e-13	Schizophrenia or bipolar disorder;
CESC	cis	rs2130392	0.926	rs7677893	chr4:185625523	T/C	cg21366198	chr4:185655624	MLF1IP	-0.5	-6.95	-0.39	2.76e-11	Kawasaki disease;
CESC	cis	rs4642101	0.765	rs3901665	chr3:12824610	C/A	cg24848339	chr3:12840334	CAND2	0.38	5.89	0.34	1.18e-8	QRS complex (12-leadsum);
CESC	cis	rs7618915	0.571	rs1961959	chr3:52585760	G/C	cg17372223	chr3:52568218	NT5DC2	0.44	6.36	0.36	8.64e-10	Bipolar disorder;
CESC	cis	rs1448094	0.511	rs10746353	chr12:86150146	A/T	cg02569458	chr12:86230093	RASSF9	-0.42	-6.44	-0.37	5.67e-10	Major depressive disorder;
CESC	cis	rs7927771	0.832	rs10838698	chr11:47385923	G/A	cg20307385	chr11:47447363	PSMC3	0.57	6.65	0.38	1.71e-10	Subjective well-being;
CESC	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	22.35	0.81	6.51e-63	Prudent dietary pattern;
CESC	cis	rs9303401	0.659	rs11079357	chr17:56902778	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	1.01	12.69	0.61	3.78e-29	Cognitive test performance;
CESC	cis	rs34976449	1	rs34976449	chr1:8498326	T/TG	cg00120948	chr1:8484417	RERE	-0.4	-6.27	-0.36	1.48e-9	Lymphocyte counts;
CESC	cis	rs3925075	1.000	rs55742763	chr16:31340368	G/A	cg02846316	chr16:31340340	ITGAM	0.4	6.38	0.36	8.06e-10	IgA nephropathy;
CESC	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg03188948	chr7:1209495	NA	0.7	6.94	0.39	3.06e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs1552244	0.882	rs6443276	chr3:10008905	C/A	cg00166722	chr3:10149974	C3orf24	0.46	5.72	0.33	2.8e-8	Alzheimer's disease;
CESC	cis	rs9322193	0.923	rs10782315	chr6:150064229	T/C	cg09699651	chr6:150184138	LRP11	0.4	5.2	0.3	4.03e-7	Lung cancer;
CESC	cis	rs73019876	0.869	rs2522093	chr19:22125596	A/G	cg11619707	chr19:22235551	ZNF257	-0.29	-5.22	-0.31	3.65e-7	Testicular germ cell tumor;
CESC	cis	rs9858542	0.953	rs6766581	chr3:49539401	T/C	cg03060546	chr3:49711283	APEH	-0.54	-6.12	-0.35	3.44e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs4819052	1.000	rs2297284	chr21:46705345	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.64	7.85	0.43	1.05e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs7267979	0.966	rs6037083	chr20:25290543	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.88	-18.23	-0.75	1.11e-48	Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs4942242	0.640	rs17538959	chr13:44229911	T/G	cg19169023	chr15:41853346	TYRO3	-0.65	-8.31	-0.45	5.16e-15	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs1577917	0.652	rs75593931	chr6:86719539	A/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.49	-6.37	-0.36	8.3e-10	Response to antipsychotic treatment;
CESC	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg02475777	chr4:1388615	CRIPAK	0.75	9.66	0.51	4.22e-19	Longevity;
CESC	cis	rs2637266	0.783	rs4980006	chr10:78477993	G/C	cg18941641	chr10:78392320	NA	0.44	8.37	0.46	3.26e-15	Pulmonary function;
CESC	cis	rs9649213	0.593	rs10953257	chr7:97960664	A/G	cg00277769	chr7:97922759	BAIAP2L1	0.34	5.73	0.33	2.79e-8	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg22968622	chr17:43663579	NA	1.36	18.55	0.75	8.09e-50	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs2228479	0.850	rs11640336	chr16:89941153	T/C	cg00800038	chr16:89945340	TCF25	-0.82	-7.14	-0.4	9e-12	Skin colour saturation;
CESC	cis	rs2033711	0.783	rs11671113	chr19:58958087	C/T	cg00825309	chr19:58991885	ZNF446	-0.57	-8.37	-0.46	3.38e-15	Uric acid clearance;
CESC	trans	rs877282	0.853	rs12777155	chr10:754731	G/C	cg22713356	chr15:30763199	NA	0.93	8.39	0.46	3e-15	Uric acid levels;
CESC	cis	rs2014572	0.967	rs4801452	chr19:57768066	A/G	cg24459738	chr19:57751996	ZNF805	-0.53	-7.55	-0.42	6.91e-13	Hyperactive-impulsive symptoms;
CESC	cis	rs9287719	0.967	rs6759714	chr2:10747207	A/G	cg02196655	chr2:10830764	NOL10	-0.38	-5.79	-0.34	1.96e-8	Prostate cancer;
CESC	trans	rs7656342	0.808	rs10003216	chr4:9766749	A/G	cg05263743	chr2:161263709	RBMS1	-0.54	-6.26	-0.36	1.51e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs1862618	0.853	rs252904	chr5:56118733	A/T	cg18230493	chr5:56204884	C5orf35	-0.7	-8.29	-0.45	5.67e-15	Initial pursuit acceleration;
CESC	cis	rs13118159	0.641	rs4974598	chr4:1313220	C/T	cg02018176	chr4:1364513	KIAA1530	0.43	5.99	0.35	6.99e-9	Longevity;
CESC	cis	rs4665809	0.878	rs6720312	chr2:26364934	A/G	cg26119090	chr2:26468346	HADHA;HADHB	0.76	9.03	0.49	3.54e-17	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22607980	chr1:89357197	GTF2B	-0.6	-6.74	-0.38	9.88e-11	Gut microbiome composition (summer);
CESC	cis	rs117623576	0.941	rs7070675	chr10:32407269	G/T	cg03047570	chr10:32398778	NA	-0.79	-6.88	-0.39	4.27e-11	Anti-saccade response;
CESC	cis	rs7618915	0.533	rs35107891	chr3:52613656	G/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	5.71	0.33	2.98e-8	Bipolar disorder;
CESC	cis	rs2228479	0.850	rs17226973	chr16:89825248	T/C	cg00800038	chr16:89945340	TCF25	-0.92	-7.67	-0.43	3.37e-13	Skin colour saturation;
CESC	cis	rs9322193	0.923	rs9800580	chr6:149953981	C/T	cg07701084	chr6:150067640	NUP43	0.46	6.45	0.37	5.26e-10	Lung cancer;
CESC	cis	rs10504229	0.906	rs111838497	chr8:58185620	A/C	cg05313129	chr8:58192883	C8orf71	-0.55	-6.29	-0.36	1.34e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs2235642	0.928	rs56289115	chr16:1608934	A/G	cg03771183	chr16:1608904	IFT140	0.42	6.17	0.35	2.54e-9	Coronary artery disease;
CESC	cis	rs7927592	0.956	rs7944870	chr11:68309108	C/G	cg16797656	chr11:68205561	LRP5	0.38	5.33	0.31	2.06e-7	Total body bone mineral density;
CESC	cis	rs7666738	0.830	rs62321597	chr4:99014221	C/A	cg17366294	chr4:99064904	C4orf37	0.6	8.62	0.47	6.37e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1670533	0.615	rs59985183	chr4:1087171	G/T	cg27284194	chr4:1044797	NA	0.47	6.2	0.36	2.1e-9	Recombination rate (females);
CESC	cis	rs9311474	0.607	rs11711421	chr3:52561779	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.37	5.27	0.31	2.89e-7	Electroencephalogram traits;
CESC	cis	rs7605827	0.930	rs879972	chr2:15703031	G/C	cg19274914	chr2:15703543	NA	0.3	5.34	0.31	2.03e-7	Educational attainment (years of education);
CESC	cis	rs4925386	1.000	rs1889201	chr20:60923075	C/T	cg24112000	chr20:60950667	NA	0.5	7.21	0.4	5.92e-12	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19143282	chr18:77507733	CTDP1	-0.66	-7.91	-0.44	7.09e-14	Gut microbiome composition (summer);
CESC	cis	rs11250464	0.833	rs11250467	chr10:1409662	A/G	cg26394196	chr10:1453818	ADARB2	-0.42	-5.66	-0.33	3.91e-8	Radiation response;
CESC	cis	rs597539	0.518	rs35093305	chr11:68730729	A/G	cg01988459	chr11:68622903	NA	-0.43	-5.78	-0.33	2.13e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs2439831	0.850	rs2228368	chr15:44102010	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.64	5.89	0.34	1.15e-8	Lung cancer in ever smokers;
CESC	trans	rs208520	0.690	rs1738970	chr6:66809491	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.97	-12.82	-0.62	1.31e-29	Exhaled nitric oxide output;
CESC	cis	rs11864453	0.793	rs7197453	chr16:72079127	G/C	cg16558253	chr16:72132732	DHX38	-0.56	-8.26	-0.45	7.22e-15	Fibrinogen levels;
CESC	cis	rs250677	0.652	rs250670	chr5:148446646	G/T	cg18129178	chr5:148520854	ABLIM3	-0.51	-5.83	-0.34	1.58e-8	Breast cancer;
CESC	cis	rs6964587	0.692	rs4729025	chr7:91847504	C/T	cg17063962	chr7:91808500	NA	0.46	6.56	0.37	2.8e-10	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11884792	chr2:192542902	OBFC2A	-0.6	-6.73	-0.38	1.06e-10	Gut microbiome composition (summer);
CESC	cis	rs2576037	0.796	rs2247221	chr18:44580082	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.44	5.72	0.33	2.8e-8	Personality dimensions;
CESC	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg14893161	chr1:205819251	PM20D1	0.84	13.8	0.65	5.19e-33	Menarche (age at onset);
CESC	cis	rs1008375	0.900	rs3822235	chr4:17694916	C/T	cg16339924	chr4:17578868	LAP3	-0.54	-6.7	-0.38	1.21e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg22850304	chr1:39325639	RRAGC	-0.48	-6.38	-0.36	8.04e-10	Fibrinogen levels;
CESC	trans	rs7615952	0.512	rs4234285	chr3:125404477	G/A	cg07211511	chr3:129823064	LOC729375	-0.6	-7.32	-0.41	3e-12	Blood pressure (smoking interaction);
CESC	cis	rs6456156	0.711	rs1855025	chr6:167537594	A/G	cg07741184	chr6:167504864	NA	-0.31	-5.27	-0.31	2.87e-7	Primary biliary cholangitis;
CESC	cis	rs6460942	0.591	rs62448727	chr7:12332362	G/C	cg06484146	chr7:12443880	VWDE	-0.66	-7.27	-0.41	4.01e-12	Coronary artery disease;
CESC	cis	rs1577917	1.000	rs12216328	chr6:86703418	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.47	-5.97	-0.34	7.47e-9	Response to antipsychotic treatment;
CESC	trans	rs8017423	1.000	rs8011810	chr14:90685669	A/G	cg01911440	chr17:78818045	RPTOR	-0.4	-6.05	-0.35	4.95e-9	Mortality in heart failure;
CESC	cis	rs7927771	0.965	rs11039416	chr11:47846711	G/A	cg20307385	chr11:47447363	PSMC3	-0.49	-6.04	-0.35	5.24e-9	Subjective well-being;
CESC	cis	rs3126085	0.877	rs4845742	chr1:152183949	G/A	cg26876637	chr1:152193138	HRNR	0.48	5.44	0.32	1.21e-7	Atopic dermatitis;
CESC	cis	rs4713118	0.586	rs6905516	chr6:28086478	A/G	cg17949981	chr6:28129498	ZNF389	0.45	5.63	0.33	4.71e-8	Parkinson's disease;
CESC	cis	rs1707322	1.000	rs6671754	chr1:46433990	A/G	cg06784218	chr1:46089804	CCDC17	0.33	5.63	0.33	4.7e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9858542	0.543	rs2230929	chr3:49343175	G/A	cg00383909	chr3:49044727	WDR6	0.57	5.28	0.31	2.75e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs6772849	0.896	rs61112519	chr3:128338176	T/A	cg16766828	chr3:128327626	NA	-0.31	-5.13	-0.3	5.67e-7	Monocyte percentage of white cells;Monocyte count;
CESC	cis	rs863345	0.967	rs10489835	chr1:158521392	G/A	cg12129480	chr1:158549410	OR10X1	-0.32	-6.39	-0.37	7.54e-10	Pneumococcal bacteremia;
CESC	cis	rs6502050	0.777	rs4625783	chr17:80086395	T/C	cg23985595	chr17:80112537	CCDC57	0.42	6.55	0.37	2.99e-10	Life satisfaction;
CESC	trans	rs12356475	0.710	rs10822686	chr10:67733250	C/T	cg06876107	chr14:102771053	RAGE	0.51	6.0	0.35	6.35e-9	Psoriatic arthritis;
CESC	trans	rs7824557	0.507	rs7010590	chr8:11062882	C/T	cg15556689	chr8:8085844	FLJ10661	0.59	7.64	0.42	3.94e-13	Retinal vascular caliber;
CESC	cis	rs4589502	1.000	rs4589502	chr15:67155069	C/T	cg09911534	chr15:67153556	NA	-0.46	-5.16	-0.3	4.95e-7	Lung cancer (smoking interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07395075	chr16:56642428	MT2A	-0.56	-6.53	-0.37	3.35e-10	Gut microbiome composition (summer);
CESC	cis	rs7044106	0.762	rs10739570	chr9:123381222	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.8	12.37	0.6	4.9e-28	Hip circumference adjusted for BMI;
CESC	cis	rs7666738	0.830	rs113999196	chr4:99041961	C/T	cg24818145	chr4:99064322	C4orf37	0.38	5.04	0.3	8.49e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs60154123	0.764	rs1418257	chr1:210452846	G/A	cg21951975	chr1:209979733	IRF6	0.46	5.81	0.34	1.83e-8	Coronary artery disease;
CESC	cis	rs1018836	0.663	rs2205152	chr8:91483618	C/T	cg16814680	chr8:91681699	NA	0.55	7.37	0.41	2.16e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs875971	0.545	rs1796219	chr7:66110964	A/G	cg18527119	chr7:66119851	NA	0.55	5.92	0.34	9.78e-9	Aortic root size;
CESC	cis	rs10088262	0.629	rs6990565	chr8:124785645	C/A	cg02993010	chr8:124780839	FAM91A1	-0.67	-8.34	-0.46	4.24e-15	Pancreatic cancer;
CESC	cis	rs12042052	1.000	rs6669303	chr1:232912728	G/A	cg06935979	chr1:232941706	KIAA1383	0.64	6.16	0.35	2.69e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CESC	cis	rs1729951	0.575	rs1682357	chr3:136692009	G/A	cg04103450	chr3:136751342	NA	0.41	5.37	0.31	1.72e-7	Neuroticism;
CESC	cis	rs1775715	0.737	rs55859032	chr10:32213239	C/T	cg18675610	chr10:32216311	ARHGAP12	0.36	5.54	0.32	7.38e-8	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs793571	0.502	rs421829	chr15:59079902	G/C	cg05156742	chr15:59063176	FAM63B	0.78	11.21	0.57	3.83e-24	Schizophrenia;
CESC	cis	rs427394	0.582	rs4701751	chr5:6704137	C/T	cg10857441	chr5:6722123	POLS	-0.43	-5.13	-0.3	5.64e-7	Menopause (age at onset);
CESC	cis	rs10089	0.904	rs2195921	chr5:127489754	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.76	9.88	0.52	8.3e-20	Ileal carcinoids;
CESC	cis	rs7078219	0.714	rs11190136	chr10:101287681	A/G	cg09788492	chr10:101292477	NKX2-3	0.31	5.03	0.3	8.88e-7	Dental caries;
CESC	cis	rs10744422	1.000	rs7959441	chr12:123363825	C/T	cg22842854	chr12:123319900	HIP1R	-0.61	-5.05	-0.3	8.19e-7	Schizophrenia;
CESC	cis	rs4718428	0.576	rs12698546	chr7:66266906	G/T	cg12165864	chr7:66369176	NA	-0.58	-6.35	-0.36	9.1e-10	Corneal structure;
CESC	cis	rs1580019	0.568	rs2122633	chr7:32523870	G/T	cg06627557	chr7:32535165	LSM5;AVL9	1.02	16.56	0.71	9.36e-43	Cognitive ability;
CESC	trans	rs208520	0.690	rs1580430	chr6:66715162	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.94	12.31	0.6	7.54e-28	Exhaled nitric oxide output;
CESC	cis	rs1800795	0.901	rs2069833	chr7:22767664	C/T	cg13104385	chr7:22767384	IL6	0.42	5.83	0.34	1.59e-8	Cerebrospinal fluid clusterin levels in APOEe4- carriers;
CESC	trans	rs9467711	0.745	rs9467714	chr6:26340785	C/T	cg06606381	chr12:133084897	FBRSL1	-0.58	-6.28	-0.36	1.38e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs72781680	0.799	rs2551332	chr2:23988950	T/C	cg08917208	chr2:24149416	ATAD2B	0.61	5.95	0.34	8.65e-9	Lymphocyte counts;
CESC	cis	rs7666738	0.830	rs28728124	chr4:99001116	G/T	cg18180107	chr4:99064573	C4orf37	0.4	5.23	0.31	3.41e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs12682352	0.602	rs635594	chr8:8613387	C/T	cg15556689	chr8:8085844	FLJ10661	-0.49	-6.05	-0.35	4.92e-9	Neuroticism;
CESC	cis	rs1801251	0.964	rs13007783	chr2:233566679	G/A	cg08000102	chr2:233561755	GIGYF2	0.66	9.02	0.48	3.78e-17	Coronary artery disease;
CESC	cis	rs7666738	0.822	rs13110418	chr4:99046963	G/A	cg18180107	chr4:99064573	C4orf37	0.41	5.29	0.31	2.51e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1218582	0.772	rs2174507	chr1:154887949	C/T	cg03351412	chr1:154909251	PMVK	0.7	9.52	0.5	1.11e-18	Prostate cancer;
CESC	cis	rs6121246	0.609	rs2377317	chr20:30402502	A/G	cg13852791	chr20:30311386	BCL2L1	-0.82	-10.54	-0.54	6.41e-22	Mean corpuscular hemoglobin;
CESC	cis	rs116095464	0.558	rs7731089	chr5:290422	A/C	cg12570787	chr5:219185	SDHA;CCDC127	0.52	5.41	0.32	1.38e-7	Breast cancer;
CESC	cis	rs4595586	0.505	rs11613808	chr12:39390823	T/A	cg13010199	chr12:38710504	ALG10B	0.45	5.67	0.33	3.75e-8	Morning vs. evening chronotype;
CESC	cis	rs6546550	0.935	rs1056482	chr2:70108256	A/T	cg02498382	chr2:70120550	SNRNP27	-0.35	-6.06	-0.35	4.62e-9	Prevalent atrial fibrillation;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg19823710	chr17:29233276	C17orf42	0.49	6.23	0.36	1.83e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs7937682	0.883	rs2212520	chr11:111462096	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.9	-12.87	-0.62	9.33e-30	Primary sclerosing cholangitis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15813951	chr18:268135	THOC1	0.58	6.46	0.37	5.07e-10	Gut microbiome composition (summer);
CESC	trans	rs2727020	0.729	rs4315497	chr11:49214499	G/A	cg03929089	chr4:120376271	NA	0.78	11.95	0.59	1.29e-26	Coronary artery disease;
CESC	cis	rs2882667	0.822	rs13187096	chr5:138404088	C/A	cg04439458	chr5:138467593	SIL1	-0.37	-5.89	-0.34	1.15e-8	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs6543140	0.964	rs4851578	chr2:103028951	T/G	cg04239558	chr2:103089729	SLC9A4	0.45	5.76	0.33	2.28e-8	Blood protein levels;
CESC	cis	rs67311347	1.000	rs897117	chr3:40437294	C/T	cg09455208	chr3:40491958	NA	-0.44	-7.62	-0.42	4.63e-13	Renal cell carcinoma;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg19711839	chr3:127842684	RUVBL1	-0.48	-6.19	-0.36	2.29e-9	Ulcerative colitis;
CESC	cis	rs4764124	0.652	rs6488712	chr12:14939332	G/A	cg19759883	chr12:14956454	WBP11;C12orf60	0.54	7.85	0.43	1e-13	Pubertal anthropometrics;
CESC	cis	rs854765	0.547	rs7209003	chr17:17907393	T/A	cg04398451	chr17:18023971	MYO15A	-0.69	-10.33	-0.54	3.02e-21	Total body bone mineral density;
CESC	cis	rs1670533	1.000	rs6858612	chr4:1053353	C/T	cg04106633	chr4:1044584	NA	0.39	5.1	0.3	6.39e-7	Recombination rate (females);
CESC	cis	rs1448094	0.802	rs11117146	chr12:86382870	C/T	cg02569458	chr12:86230093	RASSF9	-0.37	-5.45	-0.32	1.14e-7	Major depressive disorder;
CESC	cis	rs6828523	0.698	rs56004315	chr4:175859382	C/T	cg14561282	chr4:175839468	ADAM29	0.44	5.11	0.3	6.21e-7	Breast cancer;
CESC	cis	rs3925075	0.833	rs11641202	chr16:31330161	A/G	cg02846316	chr16:31340340	ITGAM	0.38	6.07	0.35	4.41e-9	IgA nephropathy;
CESC	cis	rs559928	0.606	rs11605856	chr11:63925528	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.66	5.92	0.34	9.68e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CESC	cis	rs6580649	0.941	rs1018973	chr12:48441692	C/G	cg05342945	chr12:48394962	COL2A1	-0.51	-5.9	-0.34	1.09e-8	Lung cancer;
CESC	cis	rs4803468	0.935	rs12602	chr19:41889748	T/C	cg14132834	chr19:41945861	ATP5SL	-0.67	-8.2	-0.45	1.02e-14	Height;
CESC	cis	rs11690935	0.959	rs10803863	chr2:172535337	T/C	cg13550731	chr2:172543902	DYNC1I2	0.94	14.64	0.67	5.97e-36	Schizophrenia;
CESC	cis	rs55788414	0.932	rs9940186	chr16:81182199	A/T	cg06400318	chr16:81190750	PKD1L2	-0.6	-7.01	-0.4	1.96e-11	Left ventricular obstructive tract defect (maternal effect);
CESC	cis	rs6120849	0.754	rs3818253	chr20:33596876	C/T	cg06115741	chr20:33292138	TP53INP2	0.53	5.11	0.3	6.15e-7	Protein C levels;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg25377475	chr1:236030556	LYST	-0.4	-6.43	-0.37	5.95e-10	Gambling;
CESC	cis	rs8114671	0.562	rs3746450	chr20:33508588	G/T	cg06115741	chr20:33292138	TP53INP2	0.46	5.58	0.32	6.06e-8	Height;
CESC	cis	rs7927771	0.524	rs1563820	chr11:47833398	A/T	cg20307385	chr11:47447363	PSMC3	-0.58	-8.03	-0.44	3.12e-14	Subjective well-being;
CESC	cis	rs7918232	0.891	rs10443987	chr10:27375377	A/T	cg14240646	chr10:27532245	ACBD5	-0.67	-6.24	-0.36	1.75e-9	Breast cancer;
CESC	cis	rs7246657	0.943	rs3803895	chr19:37898669	A/G	cg23950597	chr19:37808831	NA	-0.55	-5.99	-0.35	6.88e-9	Coronary artery calcification;
CESC	cis	rs6800768	0.633	rs60706278	chr3:24101424	T/A	cg10674438	chr3:24145617	LOC152024	-0.41	-5.55	-0.32	6.85e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.52	0.37	3.63e-10	Prudent dietary pattern;
CESC	cis	rs2302729	0.545	rs10161275	chr12:2771018	A/G	cg19945202	chr12:2788847	CACNA1C	-0.46	-6.84	-0.39	5.6e-11	Sleep quality;
CESC	cis	rs926938	0.527	rs360584	chr1:115463181	G/A	cg12756093	chr1:115239321	AMPD1	0.45	6.28	0.36	1.41e-9	Autism;
CESC	cis	rs10979	0.965	rs9390111	chr6:143894272	T/C	cg25407410	chr6:143891975	LOC285740	-0.61	-9.2	-0.49	1.13e-17	Hypospadias;
CESC	cis	rs7520050	0.933	rs6656022	chr1:46394315	A/G	cg24296786	chr1:45957014	TESK2	0.44	5.49	0.32	9.64e-8	Red blood cell count;Reticulocyte count;
CESC	cis	rs9303401	0.659	rs62083436	chr17:57031742	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.99	12.6	0.61	7.67e-29	Cognitive test performance;
CESC	cis	rs2235544	0.565	rs637590	chr1:54461703	A/G	cg25741118	chr1:54482237	LDLRAD1	0.22	5.49	0.32	9.64e-8	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
CESC	cis	rs597539	0.652	rs553875	chr11:68695144	T/G	cg01988459	chr11:68622903	NA	-0.45	-5.92	-0.34	9.72e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs9733	0.519	rs7529194	chr1:150622620	A/T	cg09365446	chr1:150670422	GOLPH3L	0.42	6.02	0.35	5.67e-9	Tonsillectomy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12833168	chr14:39856160	NA	-0.64	-7.74	-0.43	2.08e-13	Gut microbiome composition (summer);
CESC	cis	rs3785574	0.962	rs2584633	chr17:61879501	T/C	cg06420487	chr17:61919686	SMARCD2	0.45	5.36	0.31	1.82e-7	Height;
CESC	cis	rs6089584	0.927	rs2296081	chr20:60572663	G/T	cg24733560	chr20:60626293	TAF4	0.37	5.37	0.31	1.69e-7	Body mass index;
CESC	cis	rs796364	0.951	rs72932280	chr2:200996851	G/C	cg23649088	chr2:200775458	C2orf69	-0.53	-5.18	-0.3	4.34e-7	Schizophrenia;
CESC	cis	rs1413885	0.516	rs11208637	chr1:65836553	C/T	cg14976592	chr1:65886160	LEPROT;LEPR	0.46	5.91	0.34	1.03e-8	Anticoagulant levels;
CESC	cis	rs2070997	0.591	rs4065994	chr9:133666116	G/C	cg11464064	chr9:133710261	ABL1	0.49	5.59	0.32	5.67e-8	Response to amphetamines;
CESC	cis	rs2180341	0.960	rs7766802	chr6:127709871	T/G	cg27446573	chr6:127587934	RNF146	1.04	14.59	0.67	8.45e-36	Breast cancer;
CESC	cis	rs769267	0.895	rs2965182	chr19:19548246	A/G	cg03709012	chr19:19516395	GATAD2A	1.01	16.06	0.7	5.36e-41	Tonsillectomy;
CESC	cis	rs611744	0.647	rs689275	chr8:109241822	T/C	cg21045802	chr8:109455806	TTC35	0.46	5.7	0.33	3.25e-8	Dupuytren's disease;
CESC	cis	rs10504229	1.000	rs72650899	chr8:58180525	G/T	cg05313129	chr8:58192883	C8orf71	-0.55	-6.37	-0.36	8.42e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs6732160	0.588	rs13407363	chr2:73372558	T/C	cg01422370	chr2:73384389	NA	0.53	8.49	0.46	1.51e-15	Intelligence (multi-trait analysis);
CESC	cis	rs514406	0.929	rs1672908	chr1:53340885	A/G	cg24675658	chr1:53192096	ZYG11B	-0.62	-7.79	-0.43	1.5e-13	Monocyte count;
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg06814102	chr11:64880135	TM7SF2	-0.44	-7.02	-0.4	1.88e-11	Vertical cup-disc ratio;
CESC	cis	rs9790314	0.936	rs466399	chr3:161091194	G/T	cg04691961	chr3:161091175	C3orf57	-0.39	-5.09	-0.3	6.91e-7	Morning vs. evening chronotype;
CESC	cis	rs7916697	0.947	rs4745950	chr10:69996455	A/G	cg06988349	chr10:69991859	ATOH7	-0.38	-6.28	-0.36	1.34e-9	Optic disc area;
CESC	cis	rs12134245	0.747	rs11164929	chr1:92012836	G/C	cg02896835	chr1:92012615	NA	-0.57	-7.87	-0.44	9.32e-14	Breast cancer;
CESC	cis	rs2235642	0.928	rs2076435	chr16:1607574	C/T	cg09080909	chr16:1797204	MAPK8IP3	-0.37	-5.2	-0.3	4.07e-7	Coronary artery disease;
CESC	cis	rs1355223	0.902	rs7121272	chr11:34752562	T/G	cg11058730	chr11:34937778	PDHX;APIP	-0.47	-6.24	-0.36	1.75e-9	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs782590	0.729	rs706548	chr2:55850106	C/G	cg18811423	chr2:55921094	PNPT1	0.63	8.79	0.48	1.88e-16	Metabolic syndrome;
CESC	cis	rs6519955	0.765	rs7292527	chr22:46423125	G/T	cg05468064	chr22:46423449	NA	-0.46	-7.89	-0.44	7.89e-14	Dupuytren's disease;
CESC	cis	rs875971	0.862	rs2024192	chr7:66041447	G/T	cg10691866	chr7:65817282	TPST1	0.33	5.47	0.32	1.02e-7	Aortic root size;
CESC	cis	rs7617480	0.648	rs10865953	chr3:48759562	C/T	cg06212747	chr3:49208901	KLHDC8B	0.45	5.08	0.3	7.18e-7	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CESC	cis	rs11792861	0.926	rs58795279	chr9:111851902	A/T	cg13535736	chr9:111863775	C9orf5	-0.51	-6.74	-0.38	9.82e-11	Menarche (age at onset);
CESC	cis	rs7917772	0.503	rs1536308	chr10:104288777	T/G	cg22532475	chr10:104410764	TRIM8	-0.35	-5.97	-0.34	7.47e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs9640161	0.789	rs36035506	chr7:150057843	C/T	cg17279839	chr7:150038598	RARRES2	0.46	5.51	0.32	8.38e-8	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg21782813	chr7:2030301	MAD1L1	0.37	5.06	0.3	7.96e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs854765	0.547	rs8069811	chr17:17922280	G/A	cg16928487	chr17:17741425	SREBF1	-0.57	-10.14	-0.53	1.24e-20	Total body bone mineral density;
CESC	cis	rs3617	0.573	rs56383738	chr3:52908398	T/C	cg07507251	chr3:52567010	NT5DC2	-0.32	-5.24	-0.31	3.21e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
CESC	cis	rs2075371	1.000	rs2244700	chr7:133987374	A/G	cg11752832	chr7:134001865	SLC35B4	0.57	7.47	0.42	1.2e-12	Mean platelet volume;
CESC	cis	rs17376456	0.542	rs10070350	chr5:93103753	C/G	cg21475434	chr5:93447410	FAM172A	0.49	5.04	0.3	8.6e-7	Diabetic retinopathy;
CESC	cis	rs1729951	0.546	rs361246	chr3:136695667	G/A	cg15507776	chr3:136538369	TMEM22	0.41	5.16	0.3	4.86e-7	Neuroticism;
CESC	cis	rs9905704	0.846	rs304298	chr17:56839689	G/A	cg12560992	chr17:57184187	TRIM37	0.62	7.8	0.43	1.45e-13	Testicular germ cell tumor;
CESC	trans	rs3942852	0.774	rs11039519	chr11:48130094	G/C	cg03929089	chr4:120376271	NA	-0.56	-6.34	-0.36	1.01e-9	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs929354	0.707	rs1182445	chr7:157024428	C/G	cg05182265	chr7:156933206	UBE3C	0.51	7.52	0.42	8.71e-13	Body mass index;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg14528254	chr7:5862839	ZNF815	-0.43	-6.01	-0.35	6e-9	Fibrinogen levels;
CESC	cis	rs9733	0.596	rs6661872	chr1:150628357	C/G	cg09365446	chr1:150670422	GOLPH3L	0.42	5.98	0.34	7.35e-9	Tonsillectomy;
CESC	cis	rs6448317	0.954	rs11946846	chr4:24922703	G/A	cg21108841	chr4:24914750	CCDC149	-0.56	-6.71	-0.38	1.2e-10	Heschl's gyrus morphology;
CESC	cis	rs11792861	0.855	rs116127510	chr9:111868344	G/A	cg13535736	chr9:111863775	C9orf5	-0.5	-6.66	-0.38	1.6e-10	Menarche (age at onset);
CESC	cis	rs34779708	0.931	rs13376871	chr10:35369056	A/G	cg04310649	chr10:35416472	CREM	-0.52	-6.39	-0.37	7.31e-10	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs17253792	0.822	rs75995456	chr14:56073194	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.76	5.39	0.31	1.56e-7	Putamen volume;
CESC	cis	rs4888262	0.526	rs8062959	chr16:74627628	T/C	cg01733217	chr16:74700730	RFWD3	0.86	11.88	0.59	2.16e-26	Testicular germ cell tumor;
CESC	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.99	-17.24	-0.73	3.53e-45	Prudent dietary pattern;
CESC	cis	rs1008375	1.000	rs56308330	chr4:17643050	G/A	cg02297831	chr4:17616191	MED28	0.53	6.64	0.38	1.76e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs763121	0.853	rs2281019	chr22:39064378	T/A	cg06544989	chr22:39130855	UNC84B	0.48	8.4	0.46	2.69e-15	Menopause (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18124955	chr2:173292329	ITGA6	0.56	6.04	0.35	5.1e-9	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21869951	chr1:43824422	CDC20	0.59	6.78	0.38	7.81e-11	Gut microbiome composition (summer);
CESC	cis	rs2228479	0.850	rs17233448	chr16:89816424	G/T	cg06558623	chr16:89946397	TCF25	1.16	9.28	0.5	6.08e-18	Skin colour saturation;
CESC	cis	rs9911578	1.000	rs4372750	chr17:57013803	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	-0.39	-5.17	-0.3	4.61e-7	Intelligence (multi-trait analysis);
CESC	cis	rs9311474	0.569	rs7614981	chr3:52566914	G/T	cg05564831	chr3:52568323	NT5DC2	0.52	8.82	0.48	1.62e-16	Electroencephalogram traits;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg04904834	chr1:179851103	TOR1AIP1	-0.52	-6.85	-0.39	5.27e-11	Height;
CESC	cis	rs9329289	0.510	rs1155447	chr10:2553240	C/T	cg15501526	chr10:2543763	NA	0.47	7.57	0.42	6.16e-13	Age-related hearing impairment;
CESC	cis	rs60843830	1.000	rs60484953	chr2:221560	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.88	11.52	0.58	3.63e-25	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs12586317	0.547	rs77780729	chr14:35496176	C/A	cg16230307	chr14:35515116	FAM177A1	1.11	11.71	0.58	8.54e-26	Psoriasis;
CESC	trans	rs61931739	1.000	rs12311881	chr12:34036100	A/G	cg26384229	chr12:38710491	ALG10B	-0.46	-6.19	-0.36	2.28e-9	Morning vs. evening chronotype;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg25371538	chr10:6186663	PFKFB3	-0.45	-6.08	-0.35	4.06e-9	Fibrinogen levels;
CESC	cis	rs2760061	0.583	rs1745413	chr1:228212456	A/G	cg02753203	chr1:228287806	NA	0.8	11.37	0.57	1.2e-24	Diastolic blood pressure;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg07664667	chr16:778351	HAGHL	-0.52	-6.7	-0.38	1.25e-10	Ulcerative colitis;
CESC	cis	rs12602172	1	rs12602172	chr17:38163567	G/A	cg17467752	chr17:38218738	THRA	0.69	10.55	0.54	5.78e-22	Neutrophil percentage of white cells;Granulocyte percentage of myeloid white cells;
CESC	cis	rs2130392	0.926	rs10428357	chr4:185636217	T/A	cg21366198	chr4:185655624	MLF1IP	-0.5	-7.02	-0.4	1.81e-11	Kawasaki disease;
CESC	cis	rs4665809	1.000	rs4665817	chr2:26305167	G/A	cg25036284	chr2:26402008	FAM59B	-0.74	-8.4	-0.46	2.72e-15	Gut microbiome composition (summer);
CESC	cis	rs858239	0.509	rs57611130	chr7:23184552	C/A	cg23682824	chr7:23144976	KLHL7	0.49	6.33	0.36	1.04e-9	Cerebrospinal fluid biomarker levels;
CESC	cis	rs7937682	0.632	rs10789850	chr11:111750829	C/T	cg09085632	chr11:111637200	PPP2R1B	0.86	10.98	0.56	2.39e-23	Primary sclerosing cholangitis;
CESC	cis	rs9486719	1.000	rs12208011	chr6:96991105	G/A	cg06623918	chr6:96969491	KIAA0776	-0.79	-8.2	-0.45	1.07e-14	Migraine;Coronary artery disease;
CESC	cis	rs9858542	0.953	rs9818590	chr3:49525096	A/G	cg03060546	chr3:49711283	APEH	-0.55	-6.28	-0.36	1.34e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs17401966	0.931	rs34225619	chr1:10371987	C/T	cg15208524	chr1:10270712	KIF1B	0.45	5.54	0.32	7.26e-8	Hepatocellular carcinoma;
CESC	cis	rs2882667	1.000	rs10064201	chr5:138309405	C/T	cg04439458	chr5:138467593	SIL1	-0.35	-5.59	-0.32	5.75e-8	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs4927850	0.957	rs4927851	chr3:195751853	A/G	cg00031303	chr3:195681400	NA	0.46	5.81	0.34	1.74e-8	Pancreatic cancer;
CESC	cis	rs1008375	0.932	rs964012	chr4:17619184	A/G	cg15017067	chr4:17643749	FAM184B	0.39	5.46	0.32	1.09e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs7937682	0.575	rs34695265	chr11:111719128	T/C	cg22437258	chr11:111473054	SIK2	-0.48	-5.38	-0.31	1.66e-7	Primary sclerosing cholangitis;
CESC	cis	rs3617	0.573	rs9880978	chr3:52923251	C/G	cg07507251	chr3:52567010	NT5DC2	0.35	5.89	0.34	1.18e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
CESC	cis	rs6460942	0.597	rs4719315	chr7:12528634	A/G	cg20607287	chr7:12443886	VWDE	-0.71	-7.7	-0.43	2.69e-13	Coronary artery disease;
CESC	cis	rs9649465	0.967	rs12531955	chr7:123377066	G/A	cg04330084	chr7:123175371	IQUB	-0.38	-5.18	-0.3	4.46e-7	Migraine;
CESC	cis	rs875971	0.862	rs13232191	chr7:65986648	A/G	cg11764359	chr7:65958608	NA	0.79	11.32	0.57	1.67e-24	Aortic root size;
CESC	cis	rs2075371	0.501	rs1643051	chr7:134025372	A/G	cg20476274	chr7:133979776	SLC35B4	-0.44	-5.58	-0.32	6.07e-8	Mean platelet volume;
CESC	cis	rs7772486	0.875	rs9322046	chr6:146393625	A/G	cg23711669	chr6:146136114	FBXO30	0.79	11.78	0.59	4.98e-26	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs17253792	0.822	rs28392709	chr14:56093685	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.79	5.91	0.34	1.06e-8	Putamen volume;
CESC	cis	rs801193	0.660	rs2659897	chr7:66187715	A/G	cg11764359	chr7:65958608	NA	-0.89	-13.96	-0.65	1.37e-33	Aortic root size;
CESC	cis	rs9649465	1.000	rs10215473	chr7:123380681	C/G	cg04330084	chr7:123175371	IQUB	-0.38	-5.12	-0.3	5.79e-7	Migraine;
CESC	cis	rs12971120	1.000	rs12971120	chr18:72174023	A/G	cg26446133	chr18:72167187	CNDP2	-0.75	-9.76	-0.51	2.08e-19	Refractive error;
CESC	cis	rs34779708	0.931	rs12248333	chr10:35362977	A/G	cg03585969	chr10:35415529	CREM	0.75	9.56	0.51	8.47e-19	Inflammatory bowel disease;Crohn's disease;
CESC	trans	rs1814175	0.645	rs847639	chr11:49919603	C/T	cg03929089	chr4:120376271	NA	-0.92	-15.2	-0.68	6e-38	Height;
CESC	cis	rs7224737	1.000	rs9889640	chr17:40293497	C/T	cg20291162	chr17:40259547	DHX58	-0.4	-5.48	-0.32	9.96e-8	Fibrinogen levels;
CESC	cis	rs801193	0.839	rs12534943	chr7:66070520	A/G	cg11764359	chr7:65958608	NA	-0.54	-7.05	-0.4	1.59e-11	Aortic root size;
CESC	cis	rs2415984	0.622	rs8022305	chr14:46946545	C/T	cg14871534	chr14:47121158	RPL10L	-0.36	-5.37	-0.31	1.69e-7	Number of children ever born;
CESC	cis	rs477692	1.000	rs503660	chr10:131418999	A/G	cg05714579	chr10:131428358	MGMT	0.47	6.31	0.36	1.18e-9	Response to temozolomide;
CESC	cis	rs7605827	0.930	rs2049719	chr2:15515058	A/G	cg19274914	chr2:15703543	NA	0.32	5.55	0.32	6.84e-8	Educational attainment (years of education);
CESC	cis	rs9303401	0.659	rs3809724	chr17:57061238	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.0	11.29	0.57	2.2e-24	Cognitive test performance;
CESC	cis	rs10504229	0.593	rs16921589	chr8:58024387	C/A	cg22535103	chr8:58192502	C8orf71	-0.67	-7.19	-0.4	6.53e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs2380220	0.576	rs4498363	chr6:96042338	A/C	cg15832292	chr6:96025679	MANEA	0.74	7.8	0.43	1.41e-13	Behavioural disinhibition (generation interaction);
CESC	cis	rs2732480	0.538	rs1387260	chr12:48703091	A/C	cg24011408	chr12:48396354	COL2A1	0.43	5.91	0.34	1.07e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs875971	1.000	rs10244498	chr7:66116056	A/G	cg10691866	chr7:65817282	TPST1	-0.36	-6.03	-0.35	5.48e-9	Aortic root size;
CESC	cis	rs4481887	0.927	rs4427440	chr1:248480337	T/A	cg00666640	chr1:248458726	OR2T12	0.36	5.98	0.34	7.16e-9	Common traits (Other);
CESC	cis	rs7107174	1.000	rs1385601	chr11:77936064	A/C	cg02023728	chr11:77925099	USP35	0.41	5.89	0.34	1.17e-8	Testicular germ cell tumor;
CESC	cis	rs1707322	1.000	rs1707322	chr1:46505147	C/T	cg05343316	chr1:45956843	TESK2	0.43	5.32	0.31	2.23e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs1691799	0.863	rs1168291	chr12:66732488	T/C	cg16791601	chr12:66731901	HELB	-0.75	-12.95	-0.62	4.83e-30	White blood cell count (basophil);
CESC	cis	rs6439153	0.933	rs34193129	chr3:128691407	G/A	cg25356066	chr3:128598488	ACAD9	0.53	6.9	0.39	3.76e-11	Pneumococcal bacteremia;
CESC	cis	rs796364	0.901	rs13030683	chr2:201061535	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.56	5.51	0.32	8.54e-8	Schizophrenia;
CESC	cis	rs12912251	0.948	rs34141940	chr15:38989657	G/A	cg01338139	chr15:38987640	C15orf53	-0.46	-5.27	-0.31	2.89e-7	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
CESC	cis	rs597539	0.617	rs598353	chr11:68635770	C/A	cg18350739	chr11:68623251	NA	-0.46	-7.02	-0.4	1.88e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs12540874	0.670	rs3887826	chr7:50544961	G/A	cg18232548	chr7:50535776	DDC	-0.44	-6.13	-0.35	3.24e-9	Systemic sclerosis;
CESC	cis	rs2635047	0.615	rs2576052	chr18:44690107	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.33	-5.07	-0.3	7.57e-7	Educational attainment;
CESC	cis	rs13006833	0.668	rs2582736	chr2:191144892	A/T	cg25963032	chr2:191064776	C2orf88	0.37	5.05	0.3	8.21e-7	Urinary metabolites;
CESC	cis	rs34779708	0.966	rs7077242	chr10:35481965	A/C	cg04310649	chr10:35416472	CREM	0.54	6.55	0.37	3.05e-10	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs240764	0.736	rs9968897	chr6:100945858	G/A	cg21058520	chr6:100914733	NA	0.36	5.68	0.33	3.48e-8	Neuroticism;
CESC	cis	rs4665809	1.000	rs2289022	chr2:26350136	G/T	cg27170947	chr2:26402098	FAM59B	-0.59	-7.07	-0.4	1.36e-11	Gut microbiome composition (summer);
CESC	cis	rs4148883	0.504	rs9307238	chr4:100136182	A/G	cg12011299	chr4:100065546	ADH4	-0.5	-7.07	-0.4	1.36e-11	Alcohol dependence;
CESC	cis	rs9818758	0.607	rs9862483	chr3:49195441	G/A	cg00383909	chr3:49044727	WDR6	0.85	6.44	0.37	5.54e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CESC	cis	rs1670533	0.872	rs10017931	chr4:1060747	G/A	cg27284194	chr4:1044797	NA	0.49	6.28	0.36	1.37e-9	Recombination rate (females);
CESC	cis	rs2274273	0.837	rs6573017	chr14:55802243	G/A	cg04306507	chr14:55594613	LGALS3	0.32	6.38	0.36	7.9e-10	Protein biomarker;
CESC	cis	rs1348850	0.645	rs13431091	chr2:178434615	A/G	cg23306229	chr2:178417860	TTC30B	0.85	9.38	0.5	3.05e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs7044106	0.708	rs10984992	chr9:123473416	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.82	13.0	0.62	3.26e-30	Hip circumference adjusted for BMI;
CESC	cis	rs72945132	0.823	rs12292240	chr11:70152612	T/C	cg14191688	chr11:70257035	CTTN	0.42	5.34	0.31	1.95e-7	Coronary artery disease;
CESC	cis	rs2777491	0.574	rs11858812	chr15:41731550	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.06	-16.94	-0.72	3.99e-44	Ulcerative colitis;
CESC	cis	rs472402	0.580	rs11738248	chr5:6657494	C/T	cg10789808	chr5:6633262	NSUN2;SRD5A1	-0.55	-7.07	-0.4	1.41e-11	Response to amphetamines;
CESC	cis	rs6570726	0.935	rs419854	chr6:145844085	A/C	cg05347473	chr6:146136440	FBXO30	0.48	6.54	0.37	3.18e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs10411936	0.626	rs8109817	chr19:16587889	T/C	cg10248733	chr19:16607483	C19orf44;CALR3	0.55	6.62	0.38	2.03e-10	White blood cell count;Multiple sclerosis;
CESC	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.61	0.38	2.15e-10	Prudent dietary pattern;
CESC	trans	rs637571	0.524	rs674363	chr11:65699134	G/A	cg17712092	chr4:129076599	LARP1B	-0.64	-8.24	-0.45	7.94e-15	Eosinophil percentage of white cells;
CESC	cis	rs4253772	0.550	rs9615913	chr22:46668515	A/T	cg09491104	chr22:46646882	C22orf40	0.54	8.1	0.45	2.06e-14	LDL cholesterol;Cholesterol, total;
CESC	cis	rs6088590	1.000	rs6120705	chr20:33313740	T/C	cg08999081	chr20:33150536	PIGU	0.58	8.95	0.48	6.2e-17	Coronary artery disease;
CESC	cis	rs10256972	0.721	rs6975972	chr7:1070468	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.51	-6.37	-0.36	8.23e-10	Longevity;Endometriosis;
CESC	cis	rs5750830	0.594	rs1010170	chr22:39778327	C/T	cg11247378	chr22:39784982	NA	0.57	8.18	0.45	1.22e-14	Intelligence (multi-trait analysis);
CESC	cis	rs2549003	1.000	rs2070724	chr5:131822072	A/G	cg02551604	chr5:131831745	NA	-0.37	-5.27	-0.31	2.81e-7	Asthma (sex interaction);
CESC	cis	rs75804782	0.521	rs56387296	chr2:239426298	A/G	cg18131467	chr2:239335373	ASB1	-0.71	-5.45	-0.32	1.16e-7	Morning vs. evening chronotype;Chronotype;
CESC	cis	rs9443645	0.869	rs7762022	chr6:79502859	C/A	cg05283184	chr6:79620031	NA	-0.43	-6.75	-0.38	9.12e-11	Intelligence (multi-trait analysis);
CESC	cis	rs4819052	0.851	rs2838865	chr21:46712299	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.48	6.01	0.35	6.21e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs67478160	0.643	rs2223937	chr14:104286380	A/G	cg08213375	chr14:104286397	PPP1R13B	0.54	10.66	0.55	2.59e-22	Schizophrenia;
CESC	cis	rs35955747	0.870	rs5997986	chr22:31834939	C/T	cg25791279	chr22:32026902	PISD	-0.44	-5.3	-0.31	2.44e-7	Neutrophil count;Sum basophil neutrophil counts;
CESC	cis	rs12995491	0.731	rs12992162	chr2:88508773	G/C	cg07952391	chr2:88470173	THNSL2	-0.48	-6.94	-0.39	2.99e-11	Response to metformin (IC50);
CESC	cis	rs12497850	0.931	rs7626445	chr3:49114544	C/T	cg07636037	chr3:49044803	WDR6	1.05	19.43	0.77	6.66e-53	Parkinson's disease;
CESC	cis	rs7618915	0.501	rs62253740	chr3:52684128	A/T	cg17372223	chr3:52568218	NT5DC2	0.42	6.47	0.37	4.6e-10	Bipolar disorder;
CESC	cis	rs1799949	1.000	rs4793191	chr17:41204377	A/G	cg25072359	chr17:41440525	NA	0.45	5.96	0.34	7.83e-9	Menopause (age at onset);
CESC	cis	rs7666738	0.830	rs4441757	chr4:98927059	T/C	cg17366294	chr4:99064904	C4orf37	0.6	8.23	0.45	8.65e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4889855	0.530	rs4890048	chr17:78549602	G/A	cg16591659	chr17:78472290	NA	0.31	5.22	0.31	3.6e-7	Fractional excretion of uric acid;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg02370978	chr2:86333167	PTCD3;POLR1A	-0.41	-6.22	-0.36	1.89e-9	Gambling;
CESC	cis	rs9324022	0.929	rs72698721	chr14:101181189	G/A	cg18089426	chr14:101175970	NA	0.57	7.01	0.4	1.92e-11	Plateletcrit;
CESC	cis	rs2404602	0.669	rs17367297	chr15:77158026	A/C	cg26408565	chr15:76604113	ETFA	-0.39	-5.68	-0.33	3.6e-8	Blood metabolite levels;
CESC	trans	rs7615952	0.599	rs67575510	chr3:125742355	C/G	cg07211511	chr3:129823064	LOC729375	-0.59	-6.62	-0.38	2e-10	Blood pressure (smoking interaction);
CESC	cis	rs208520	0.507	rs3903670	chr6:66812183	T/C	cg07460842	chr6:66804631	NA	-1.11	-27.23	-0.86	9.42e-79	Exhaled nitric oxide output;
CESC	cis	rs7100689	0.577	rs7901663	chr10:82153488	C/G	cg00277334	chr10:82204260	NA	-0.46	-6.3	-0.36	1.24e-9	Post bronchodilator FEV1;
CESC	cis	rs6502050	0.835	rs34960918	chr17:80113925	A/G	cg11859384	chr17:80120422	CCDC57	-0.39	-5.37	-0.31	1.76e-7	Life satisfaction;
CESC	trans	rs17808461	1.000	rs16592	chr17:31373094	C/T	cg01914314	chr5:157117640	NA	-0.51	-6.22	-0.36	1.98e-9	Obesity-related traits;
CESC	cis	rs2733201	1.000	rs2412849	chr15:44276555	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.63	-5.57	-0.32	6.31e-8	Lipoprotein phospholipase A2 activity in cardiovascular disease;
CESC	cis	rs7940866	0.838	rs10736592	chr11:130800572	C/T	cg14779329	chr11:130786720	SNX19	0.33	5.08	0.3	6.99e-7	Schizophrenia;
CESC	cis	rs9486719	1.000	rs12190508	chr6:96898269	T/C	cg06623918	chr6:96969491	KIAA0776	-0.81	-8.3	-0.45	5.21e-15	Migraine;Coronary artery disease;
CESC	cis	rs13118159	0.934	rs4974608	chr4:1356780	C/T	cg13395646	chr4:1353034	KIAA1530	-0.42	-5.76	-0.33	2.38e-8	Longevity;
CESC	cis	rs2242073	0.660	rs6710715	chr2:209002681	A/G	cg10392614	chr2:208977121	NA	-0.37	-5.04	-0.3	8.79e-7	Attention deficit hyperactivity disorder;
CESC	cis	rs9929218	1.000	rs13330350	chr16:68800849	C/T	cg02972257	chr16:68554789	NA	0.43	5.22	0.31	3.65e-7	Colorectal cancer;
CESC	cis	rs7412746	0.524	rs58304714	chr1:150831561	T/A	cg17724175	chr1:150552817	MCL1	0.4	5.99	0.35	6.69e-9	Melanoma;
CESC	cis	rs12618769	0.625	rs3769733	chr2:99100716	A/G	cg10123293	chr2:99228465	UNC50	0.39	5.13	0.3	5.6e-7	Bipolar disorder;
CESC	cis	rs904092	0.720	rs1229976	chr4:100202078	C/T	cg12011299	chr4:100065546	ADH4	-0.56	-6.34	-0.36	9.78e-10	Alcohol dependence;
CESC	cis	rs2549003	0.966	rs10065633	chr5:131816716	T/C	cg02551604	chr5:131831745	NA	-0.37	-5.22	-0.31	3.53e-7	Asthma (sex interaction);
CESC	cis	rs8177253	0.606	rs6787177	chr3:133450720	C/T	cg18769074	chr3:133464867	TF	0.33	6.02	0.35	5.71e-9	Iron status biomarkers;
CESC	cis	rs2836974	0.897	rs7280375	chr21:40552408	C/T	cg11890956	chr21:40555474	PSMG1	-1.11	-21.17	-0.79	6.49e-59	Cognitive function;
CESC	cis	rs11055008	0.620	rs12816452	chr12:12833006	A/T	cg04607235	chr12:12878440	APOLD1	-0.49	-6.53	-0.37	3.41e-10	Pulse pressure;
CESC	cis	rs2204008	0.729	rs114133083	chr12:38182923	G/C	cg26384229	chr12:38710491	ALG10B	-0.43	-5.88	-0.34	1.22e-8	Bladder cancer;
CESC	cis	rs701145	0.556	rs355762	chr3:154012614	G/A	cg16511985	chr3:153974050	SGEF	0.43	5.89	0.34	1.14e-8	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03556369	chr5:172721020	NA	-0.57	-6.52	-0.37	3.52e-10	Gut microbiome composition (summer);
CESC	cis	rs7772486	0.625	rs2050027	chr6:146116113	C/G	cg23711669	chr6:146136114	FBXO30	-0.91	-13.64	-0.64	1.86e-32	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs3749237	0.595	rs4855861	chr3:49525962	G/T	cg06212747	chr3:49208901	KLHDC8B	0.49	6.55	0.37	3.02e-10	Resting heart rate;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg09863028	chr2:242076577	PASK	-0.48	-6.31	-0.36	1.17e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs77741769	0.571	rs4766979	chr12:121281748	G/A	cg02419362	chr12:121203948	SPPL3	0.34	5.59	0.32	5.6e-8	Mean corpuscular volume;
CESC	cis	rs673253	0.638	rs552638	chr1:44043392	G/A	cg19743044	chr1:44115203	KDM4A	0.41	5.13	0.3	5.74e-7	Intelligence (multi-trait analysis);
CESC	cis	rs7666738	0.830	rs36028444	chr4:98968635	G/T	cg17366294	chr4:99064904	C4orf37	0.59	8.43	0.46	2.22e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11785400	0.793	rs9297972	chr8:143723660	C/T	cg24634471	chr8:143751801	JRK	0.45	5.8	0.34	1.84e-8	Schizophrenia;
CESC	cis	rs9916302	0.660	rs665413	chr17:37455678	T/A	cg07936489	chr17:37558343	FBXL20	0.89	9.69	0.51	3.32e-19	Glomerular filtration rate (creatinine);
CESC	cis	rs763014	0.932	rs34498660	chr16:666149	A/G	cg09263875	chr16:632152	PIGQ	0.69	11.78	0.59	4.76e-26	Height;
CESC	cis	rs9291683	0.525	rs12506455	chr4:10031569	T/A	cg02734326	chr4:10020555	SLC2A9	0.49	6.88	0.39	4.19e-11	Bone mineral density;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg11608447	chr9:38620746	ANKRD18A;C9orf122	-0.41	-6.36	-0.36	9.05e-10	Fibrinogen levels;
CESC	trans	rs687914	0.710	rs938662	chr2:45864578	A/G	cg06110578	chr6:43597079	MAD2L1BP;GTPBP2	0.69	7.04	0.4	1.62e-11	Diastolic blood pressure;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg11050527	chr8:54755511	ATP6V1H	0.5	6.6	0.38	2.17e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs35160687	0.545	rs1863050	chr2:86558376	G/A	cg01119172	chr2:86362222	SNORD94;PTCD3	-0.43	-5.73	-0.33	2.77e-8	Night sleep phenotypes;
CESC	cis	rs1355223	0.902	rs11607035	chr11:34718911	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.47	-6.07	-0.35	4.41e-9	Systemic lupus erythematosus and Systemic sclerosis;
CESC	trans	rs13095912	1.000	rs2034344	chr3:185337788	T/C	cg04313601	chr11:10315759	SBF2	0.47	6.0	0.35	6.5e-9	Systolic blood pressure;
CESC	cis	rs2797160	0.967	rs1777182	chr6:126013614	T/A	cg05901451	chr6:126070800	HEY2	0.46	6.48	0.37	4.42e-10	Endometrial cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22520562	chr4:82392859	RASGEF1B	0.55	6.13	0.35	3.22e-9	Gut microbiome composition (summer);
CESC	cis	rs1018836	0.773	rs7837109	chr8:91639178	C/T	cg16814680	chr8:91681699	NA	-0.77	-11.86	-0.59	2.53e-26	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs2425143	0.818	rs2378414	chr20:34534374	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.77	-6.96	-0.39	2.72e-11	Blood protein levels;
CESC	cis	rs2635047	0.601	rs2576058	chr18:44641397	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.41	5.56	0.32	6.58e-8	Educational attainment;
CESC	cis	rs9362426	0.708	rs4707367	chr6:88101188	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.47	-5.61	-0.33	4.99e-8	Depressive episodes in bipolar disorder;
CESC	cis	rs2243480	1.000	rs7456042	chr7:65299778	T/C	cg12463550	chr7:65579703	CRCP	0.68	5.62	0.33	4.83e-8	Diabetic kidney disease;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg15851312	chr15:73076263	ADPGK	0.43	6.09	0.35	3.9e-9	Systemic lupus erythematosus;
CESC	cis	rs3747547	1.000	rs17418324	chr9:37921712	G/A	cg13774184	chr9:37916125	SHB	-0.72	-6.06	-0.35	4.75e-9	Metabolite levels (Dihydroxy docosatrienoic acid);
CESC	cis	rs1957429	0.614	rs380741	chr14:65322027	C/T	cg23373153	chr14:65346875	NA	-0.75	-5.88	-0.34	1.26e-8	Pediatric areal bone mineral density (radius);
CESC	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	6.01	0.35	5.97e-9	Electroencephalogram traits;
CESC	cis	rs897984	0.684	rs6950	chr16:30995669	T/C	cg00531865	chr16:30841666	NA	0.51	7.02	0.4	1.84e-11	Dementia with Lewy bodies;
CESC	cis	rs736408	0.509	rs3774349	chr3:52722335	A/C	cg15147215	chr3:52552868	STAB1	-0.31	-5.54	-0.32	7.15e-8	Bipolar disorder;
CESC	cis	rs3749237	0.557	rs7631908	chr3:49425707	T/G	cg07636037	chr3:49044803	WDR6	0.62	8.97	0.48	5.41e-17	Resting heart rate;
CESC	cis	rs9911578	1.000	rs9904879	chr17:56864422	G/A	cg12560992	chr17:57184187	TRIM37	0.92	15.58	0.69	2.71e-39	Intelligence (multi-trait analysis);
CESC	cis	rs7833986	0.501	rs2976044	chr8:56986737	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.53	6.91	0.39	3.64e-11	Height;
CESC	cis	rs8070128	0.637	rs4925133	chr17:17884801	A/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.53	6.98	0.39	2.4e-11	Total body bone mineral density;
CESC	cis	rs9543976	0.800	rs4885318	chr13:76151537	G/A	cg01531495	chr13:76123901	UCHL3	0.55	5.48	0.32	9.76e-8	Diabetic retinopathy;
CESC	cis	rs35520189	0.591	rs34027384	chr2:113698094	G/A	cg06156847	chr2:113672199	IL1F7	0.38	5.38	0.31	1.6e-7	Obstructive sleep apnea trait (apnea hypopnea index);
CESC	cis	rs1018836	0.545	rs4236827	chr8:91688943	A/T	cg16814680	chr8:91681699	NA	-0.99	-17.68	-0.74	9.37e-47	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs709400	0.520	rs28583452	chr14:103938664	C/A	cg12935359	chr14:103987150	CKB	-0.51	-7.44	-0.42	1.39e-12	Body mass index;
CESC	cis	rs921968	0.541	rs647990	chr2:219441428	T/C	cg02176678	chr2:219576539	TTLL4	0.5	8.86	0.48	1.18e-16	Mean corpuscular hemoglobin concentration;
CESC	cis	rs11583043	0.874	rs11578366	chr1:101396852	T/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.46	5.17	0.3	4.71e-7	Ulcerative colitis;Inflammatory bowel disease;
CESC	trans	rs1223629	1.000	rs1223630	chr10:95906215	T/C	cg21019522	chr11:2920789	SLC22A18;SLC22A18AS	-0.72	-6.02	-0.35	5.71e-9	Glucose homeostasis traits;
CESC	cis	rs7772486	0.875	rs13198450	chr6:146370524	C/A	cg23711669	chr6:146136114	FBXO30	0.85	12.56	0.61	1.02e-28	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7927771	0.524	rs7107922	chr11:47669289	C/A	cg20307385	chr11:47447363	PSMC3	0.62	8.74	0.47	2.81e-16	Subjective well-being;
CESC	cis	rs1878931	0.535	rs7188903	chr16:3412861	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.73	9.09	0.49	2.36e-17	Body mass index (adult);
CESC	cis	rs514406	0.861	rs503015	chr1:53254456	T/C	cg24675658	chr1:53192096	ZYG11B	0.53	6.69	0.38	1.29e-10	Monocyte count;
CESC	cis	rs7923609	1.000	rs7073746	chr10:64904071	A/G	cg01631684	chr10:65280961	REEP3	-0.45	-5.48	-0.32	9.94e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7809950	0.678	rs2395869	chr7:106940098	C/A	cg23024343	chr7:107201750	COG5	-0.49	-6.26	-0.36	1.56e-9	Coronary artery disease;
CESC	cis	rs4970988	0.640	rs7524734	chr1:150655686	C/T	cg04414720	chr1:150670196	GOLPH3L	0.63	9.01	0.48	4.11e-17	Urate levels;
CESC	cis	rs7432375	0.610	rs7621932	chr3:136517016	C/T	cg15507776	chr3:136538369	TMEM22	0.6	8.0	0.44	3.8e-14	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
CESC	cis	rs2637266	0.935	rs1866890	chr10:78397073	C/T	cg18941641	chr10:78392320	NA	0.45	8.6	0.47	7.12e-16	Pulmonary function;
CESC	cis	rs16966142	1.000	rs3890534	chr16:89835289	A/G	cg27121462	chr16:89883253	FANCA	-0.62	-5.28	-0.31	2.65e-7	Caffeine consumption;
CESC	cis	rs820218	0.962	rs707707	chr17:73669521	C/T	cg01592526	chr17:73663357	RECQL5;SAP30BP	0.43	5.55	0.32	7.06e-8	Rotator cuff tears;
CESC	cis	rs6502050	0.871	rs8066137	chr17:80074316	T/C	cg11859384	chr17:80120422	CCDC57	0.4	5.5	0.32	8.88e-8	Life satisfaction;
CESC	cis	rs7692995	1.000	rs6449353	chr4:18033488	T/C	cg08925142	chr4:18023851	LCORL	-0.44	-5.08	-0.3	7.08e-7	Height;
CESC	cis	rs9581857	0.725	rs117947621	chr13:28022267	T/C	cg01674679	chr13:27998804	GTF3A	-0.68	-5.35	-0.31	1.87e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
CESC	cis	rs4481887	0.861	rs10788776	chr1:248479177	T/C	cg00666640	chr1:248458726	OR2T12	0.34	5.76	0.33	2.35e-8	Common traits (Other);
CESC	cis	rs8005677	0.962	rs34917191	chr14:23387628	T/C	cg25600027	chr14:23388339	RBM23	-0.43	-5.33	-0.31	2.08e-7	Cognitive ability (multi-trait analysis);
CESC	cis	rs225245	0.610	rs321608	chr17:33880636	A/G	cg05299278	chr17:33885742	SLFN14	0.38	5.2	0.3	3.9e-7	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
CESC	cis	rs2204008	0.522	rs12370263	chr12:38113311	A/G	cg13010199	chr12:38710504	ALG10B	0.47	5.65	0.33	4.15e-8	Bladder cancer;
CESC	cis	rs3796619	0.924	rs4690209	chr4:1077575	G/A	cg27284194	chr4:1044797	NA	0.36	5.5	0.32	9.08e-8	Recombination rate (males);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26421181	chr17:73937284	FBF1	0.56	6.11	0.35	3.6e-9	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22340067	chr1:11967826	NA	-0.53	-6.05	-0.35	4.92e-9	Gut microbiome composition (summer);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg16285215	chr12:31477228	FAM60A;FLJ13224	0.51	6.55	0.37	2.91e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs55823223	0.680	rs57287238	chr17:73850940	T/C	cg06969265	chr17:73775802	H3F3B	0.63	6.83	0.39	5.7e-11	Psoriasis;
CESC	cis	rs9926296	0.581	rs6500457	chr16:89898764	C/G	cg04287289	chr16:89883240	FANCA	-0.59	-7.86	-0.43	9.69e-14	Vitiligo;
CESC	trans	rs17780086	0.529	rs7406406	chr17:30220153	T/G	cg20587970	chr11:113659929	NA	-0.61	-8.13	-0.45	1.7e-14	Height;
CESC	cis	rs2806561	0.929	rs6669568	chr1:23540469	G/A	cg12483005	chr1:23474871	LUZP1	-0.33	-5.33	-0.31	2.07e-7	Height;
CESC	cis	rs12541335	0.639	rs35068739	chr8:22201719	T/C	cg27266060	chr8:22091797	NA	0.38	7.85	0.43	1.04e-13	Hypertriglyceridemia;
CESC	cis	rs1153858	1.000	rs67831559	chr15:45649307	G/T	cg14582100	chr15:45693742	SPATA5L1	0.43	6.13	0.35	3.12e-9	Homoarginine levels;
CESC	cis	rs3091242	0.809	rs660129	chr1:25727438	C/T	cg27572855	chr1:25598939	RHD	0.43	7.08	0.4	1.32e-11	Erythrocyte sedimentation rate;
CESC	cis	rs4481887	0.893	rs10158180	chr1:248481423	C/T	cg00666640	chr1:248458726	OR2T12	0.36	5.98	0.34	7.16e-9	Common traits (Other);
CESC	cis	rs1023500	0.505	rs134891	chr22:42675882	T/C	cg05082376	chr22:42548792	NA	-0.36	-5.4	-0.32	1.46e-7	Schizophrenia;
CESC	trans	rs8073060	0.586	rs7213804	chr17:34010931	T/G	cg19694781	chr19:47549865	TMEM160	-0.74	-6.91	-0.39	3.64e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	cis	rs7615952	0.932	rs9841157	chr3:125635655	C/A	cg05084668	chr3:125655381	ALG1L	-0.49	-5.52	-0.32	8e-8	Blood pressure (smoking interaction);
CESC	cis	rs941408	0.515	rs1640262	chr19:2779134	C/T	cg06609049	chr19:2785107	THOP1	-0.85	-13.19	-0.63	6.79e-31	Total cholesterol levels;
CESC	cis	rs921968	0.643	rs535830	chr2:219372233	C/G	cg02176678	chr2:219576539	TTLL4	0.39	6.75	0.38	9.18e-11	Mean corpuscular hemoglobin concentration;
CESC	cis	rs644799	0.540	rs10831419	chr11:95478037	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.41	5.16	0.3	4.78e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs684232	0.623	rs365118	chr17:580543	G/A	cg15660573	chr17:549704	VPS53	-0.84	-12.4	-0.61	3.84e-28	Prostate cancer;
CESC	cis	rs870825	0.860	rs10015194	chr4:185598925	C/T	cg04058563	chr4:185651563	MLF1IP	0.6	6.11	0.35	3.53e-9	Blood protein levels;
CESC	cis	rs1355223	0.902	rs1258464	chr11:34731496	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.5	-6.84	-0.39	5.55e-11	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs425277	1.000	rs12401379	chr1:2058580	G/C	cg04315214	chr1:2043799	PRKCZ	-0.43	-6.01	-0.35	6.02e-9	Height;
CESC	cis	rs9649213	0.533	rs62478235	chr7:98030349	G/C	cg09267113	chr7:98030324	BAIAP2L1	-0.45	-5.92	-0.34	9.68e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs780096	0.546	rs7563162	chr2:27631191	C/T	cg22903471	chr2:27725779	GCKR	-0.51	-7.18	-0.4	7.11e-12	Total body bone mineral density;
CESC	cis	rs6963495	0.818	rs73192125	chr7:105175068	A/C	cg19920283	chr7:105172520	RINT1	0.76	7.82	0.43	1.25e-13	Bipolar disorder (body mass index interaction);
CESC	cis	rs3204270	0.639	rs6565620	chr17:79658100	C/T	cg26965718	chr17:79658957	HGS	-0.73	-5.52	-0.32	8.05e-8	Dental caries;
CESC	cis	rs2440129	0.611	rs434473	chr17:6904934	A/G	cg03762994	chr17:6899332	ALOX12	-0.33	-5.45	-0.32	1.17e-7	Tonsillectomy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21629349	chr11:60691880	TMEM132A	0.61	7.43	0.42	1.53e-12	Gut microbiome composition (summer);
CESC	cis	rs3733585	0.638	rs6414766	chr4:9956474	G/A	cg11266682	chr4:10021025	SLC2A9	-0.59	-11.13	-0.56	7.46e-24	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs6952808	0.723	rs11766575	chr7:2005747	T/C	cg23048001	chr7:2026167	MAD1L1	0.48	6.07	0.35	4.45e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs11098499	0.569	rs55845118	chr4:120290913	T/C	cg24375607	chr4:120327624	NA	0.42	5.19	0.3	4.19e-7	Corneal astigmatism;
CESC	cis	rs72781680	0.898	rs72780121	chr2:23995918	T/C	cg20701182	chr2:24300061	SF3B14	0.63	5.65	0.33	4.21e-8	Lymphocyte counts;
CESC	cis	rs12926788	0.546	rs200531	chr16:24756172	G/A	cg00339695	chr16:24857497	SLC5A11	-0.5	-6.57	-0.37	2.58e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs748404	0.723	rs560134	chr15:43555699	A/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.51	7.98	0.44	4.38e-14	Lung cancer;
CESC	cis	rs6499255	0.951	rs7198242	chr16:69648495	C/T	cg15192750	chr16:69999425	NA	-0.49	-5.75	-0.33	2.45e-8	IgE levels;
CESC	cis	rs2075371	0.933	rs2544182	chr7:133949793	C/T	cg11752832	chr7:134001865	SLC35B4	0.53	6.82	0.39	6.3e-11	Mean platelet volume;
CESC	cis	rs12477438	0.520	rs11695751	chr2:99708247	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.87	16.09	0.7	4.08e-41	Chronic sinus infection;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02466711	chr8:102218365	ZNF706	0.63	7.2	0.4	6.33e-12	Gut microbiome composition (summer);
CESC	cis	rs9868809	0.881	rs34368826	chr3:48670827	G/T	cg07636037	chr3:49044803	WDR6	-0.63	-5.15	-0.3	5.14e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs4835473	0.722	rs7662277	chr4:144920638	A/T	cg25736465	chr4:144833511	NA	-0.46	-6.94	-0.39	2.96e-11	Immature fraction of reticulocytes;
CESC	cis	rs9858542	0.953	rs6766581	chr3:49539401	T/C	cg07274523	chr3:49395745	GPX1	0.66	8.05	0.44	2.78e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs4689388	0.926	rs6446480	chr4:6295565	C/T	cg14416269	chr4:6271139	WFS1	0.44	7.35	0.41	2.47e-12	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs3785574	0.745	rs2854162	chr17:61975610	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	-1.05	-17.17	-0.73	6.45e-45	Height;
CESC	cis	rs4665809	0.941	rs11126336	chr2:26245931	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.69	-7.57	-0.42	6.33e-13	Gut microbiome composition (summer);
CESC	cis	rs7089973	0.872	rs11818115	chr10:116634891	G/A	cg25233709	chr10:116636983	FAM160B1	0.34	5.03	0.3	9.07e-7	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg06873352	chr17:61820015	STRADA	0.72	12.8	0.62	1.61e-29	Prudent dietary pattern;
CESC	cis	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg18402987	chr7:1209562	NA	0.64	6.63	0.38	1.93e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs9926296	0.618	rs8058179	chr16:89846987	C/T	cg04287289	chr16:89883240	FANCA	-0.56	-7.6	-0.42	4.97e-13	Vitiligo;
CESC	cis	rs8067354	0.645	rs2173119	chr17:57859705	C/T	cg02344993	chr17:57696989	CLTC	0.57	6.21	0.36	2.03e-9	Hemoglobin concentration;
CESC	cis	rs941873	0.869	rs7917610	chr10:81117237	T/C	cg09469691	chr10:81107165	PPIF	0.56	7.56	0.42	6.79e-13	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19701658	chr3:160286309	NA	-0.45	-6.25	-0.36	1.6e-9	Gut microbiome composition (summer);
CESC	cis	rs11190604	1.000	rs7084810	chr10:102297546	A/G	cg07080220	chr10:102295463	HIF1AN	0.7	6.5	0.37	3.99e-10	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs514406	0.767	rs551591	chr1:53301876	A/G	cg27535305	chr1:53392650	SCP2	-0.31	-5.07	-0.3	7.62e-7	Monocyte count;
CESC	cis	rs2191566	1.000	rs384544	chr19:44505255	A/T	cg20607764	chr19:44506953	ZNF230	0.6	7.73	0.43	2.19e-13	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs4642101	0.662	rs1969154	chr3:12829156	A/G	cg05775895	chr3:12838266	CAND2	0.35	5.3	0.31	2.46e-7	QRS complex (12-leadsum);
CESC	trans	rs11971186	0.793	rs412791	chr7:126494124	C/T	cg10894441	chr11:111169905	C11orf92;C11orf93	-0.47	-6.07	-0.35	4.43e-9	Chemerin levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20770540	chr3:123304003	PTPLB	0.56	6.1	0.35	3.78e-9	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14024780	chr1:179262948	SOAT1	0.59	6.3	0.36	1.23e-9	Gut microbiome composition (summer);
CESC	cis	rs2204008	0.775	rs12099736	chr12:38344111	C/G	cg13010199	chr12:38710504	ALG10B	0.48	6.05	0.35	4.92e-9	Bladder cancer;
CESC	trans	rs9650657	0.589	rs6985109	chr8:10761585	A/G	cg15556689	chr8:8085844	FLJ10661	0.54	6.57	0.37	2.63e-10	Neuroticism;
CESC	cis	rs921968	0.565	rs2037622	chr2:219609440	T/C	cg02176678	chr2:219576539	TTLL4	-0.47	-8.3	-0.45	5.29e-15	Mean corpuscular hemoglobin concentration;
CESC	cis	rs7937682	0.883	rs517982	chr11:111462687	T/C	cg22437258	chr11:111473054	SIK2	0.71	9.19	0.49	1.16e-17	Primary sclerosing cholangitis;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg13932339	chr15:25684205	UBE3A	-0.39	-6.25	-0.36	1.6e-9	Gambling;
CESC	cis	rs73206853	0.764	rs56838584	chr12:110666136	A/G	cg12870014	chr12:110450643	ANKRD13A	0.69	5.93	0.34	9.34e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs367615	0.680	rs77013	chr5:108963086	T/A	cg17395555	chr5:108820864	NA	0.44	6.06	0.35	4.65e-9	Colorectal cancer (SNP x SNP interaction);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg06510563	chr19:11308259	KANK2	-0.41	-6.31	-0.36	1.16e-9	Gambling;
CESC	cis	rs10504229	1.000	rs61998258	chr8:58192284	T/C	cg24829409	chr8:58192753	C8orf71	-0.76	-9.93	-0.52	5.87e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs425277	0.606	rs2503705	chr1:2076741	A/G	cg23803603	chr1:2058230	PRKCZ	0.33	5.76	0.33	2.38e-8	Height;
CESC	cis	rs9303401	0.659	rs62083410	chr17:56964386	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.01	12.45	0.61	2.57e-28	Cognitive test performance;
CESC	trans	rs1814175	0.645	rs11040703	chr11:50024961	C/T	cg15704280	chr7:45808275	SEPT13	-1.0	-18.54	-0.75	9.01e-50	Height;
CESC	cis	rs8017423	0.967	rs7158180	chr14:90729117	C/T	cg14092571	chr14:90743983	NA	-0.56	-8.38	-0.46	3.07e-15	Mortality in heart failure;
CESC	cis	rs1799949	1.000	rs34534709	chr17:41302940	C/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.64	8.64	0.47	5.23e-16	Menopause (age at onset);
CESC	cis	rs9929218	0.551	rs8051095	chr16:68722049	G/A	cg02972257	chr16:68554789	NA	-0.42	-5.17	-0.3	4.63e-7	Colorectal cancer;
CESC	cis	rs12477438	0.798	rs2123686	chr2:99690135	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.62	-8.67	-0.47	4.43e-16	Chronic sinus infection;
CESC	cis	rs17666538	0.585	rs336444	chr8:633123	C/G	cg02524346	chr8:600233	NA	-0.74	-6.46	-0.37	5.11e-10	IgG glycosylation;
CESC	cis	rs7665939	1.000	rs11942826	chr4:190109362	C/T	cg14840187	chr4:190284988	NA	-0.69	-6.9	-0.39	3.74e-11	Amyotrophic lateral sclerosis;
CESC	cis	rs7772486	0.713	rs79248977	chr6:146319388	C/A	cg05347473	chr6:146136440	FBXO30	0.5	6.47	0.37	4.8e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs13242816	0.881	rs35210394	chr7:116104911	C/G	cg04696780	chr7:116139425	CAV2	-0.62	-5.69	-0.33	3.31e-8	P wave duration;
CESC	cis	rs74181299	0.819	rs2252867	chr2:65296280	T/C	cg05010058	chr2:65284262	CEP68	0.35	6.1	0.35	3.66e-9	Pulse pressure;
CESC	cis	rs733592	0.507	rs3825403	chr12:48457159	G/A	cg24011408	chr12:48396354	COL2A1	-0.5	-8.34	-0.46	4.03e-15	Plateletcrit;
CESC	cis	rs7267979	0.789	rs9927	chr20:25277244	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.85	16.51	0.71	1.4e-42	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs2439831	0.681	rs1549525	chr15:43627855	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.91	10.99	0.56	2.1e-23	Lung cancer in ever smokers;
CESC	cis	rs10189230	0.868	rs1367242	chr2:222353441	A/G	cg14652038	chr2:222343519	EPHA4	0.35	7.22	0.41	5.49e-12	Urate levels in lean individuals;
CESC	cis	rs1552244	0.572	rs3894323	chr3:10168967	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.78	8.84	0.48	1.4e-16	Alzheimer's disease;
CESC	cis	rs763121	0.819	rs5750658	chr22:39060917	C/T	cg06544989	chr22:39130855	UNC84B	0.49	8.49	0.46	1.53e-15	Menopause (age at onset);
CESC	cis	rs6502050	0.835	rs8065556	chr17:80091176	G/C	cg23985595	chr17:80112537	CCDC57	-0.42	-6.6	-0.38	2.18e-10	Life satisfaction;
CESC	cis	rs2243480	0.803	rs55700941	chr7:65389800	T/A	cg12463550	chr7:65579703	CRCP	0.73	5.61	0.33	5.07e-8	Diabetic kidney disease;
CESC	cis	rs3780486	1.000	rs3780486	chr9:33139453	C/T	cg13443165	chr9:33130375	B4GALT1	0.4	5.33	0.31	2.1e-7	IgG glycosylation;
CESC	cis	rs9303401	1.000	rs6503882	chr17:56915761	T/C	cg12560992	chr17:57184187	TRIM37	0.49	5.6	0.33	5.26e-8	Cognitive test performance;
CESC	cis	rs7772486	0.875	rs13204280	chr6:146415368	T/C	cg23711669	chr6:146136114	FBXO30	0.81	11.91	0.59	1.71e-26	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs36051895	0.623	rs10283473	chr9:5244708	C/A	cg02405213	chr9:5042618	JAK2	-0.56	-6.78	-0.38	7.92e-11	Pediatric autoimmune diseases;
CESC	cis	rs4702	0.611	rs1894401	chr15:91429042	C/T	cg05469396	chr15:91419421	FURIN	0.4	5.54	0.32	7.14e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs6701037	0.566	rs13373754	chr1:175139275	C/A	cg00321850	chr1:175162397	KIAA0040	0.46	6.45	0.37	5.37e-10	Alcohol dependence;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09129563	chr1:179198950	ABL2	0.56	6.17	0.35	2.49e-9	Gut microbiome composition (summer);
CESC	cis	rs2637266	1.000	rs2637268	chr10:78332213	G/T	cg18941641	chr10:78392320	NA	0.41	7.47	0.42	1.14e-12	Pulmonary function;
CESC	cis	rs7927771	0.832	rs896816	chr11:47394338	T/C	cg05585544	chr11:47624801	NA	0.48	7.12	0.4	1.01e-11	Subjective well-being;
CESC	cis	rs684232	0.602	rs331014	chr17:532103	C/T	cg15660573	chr17:549704	VPS53	-0.81	-11.96	-0.59	1.19e-26	Prostate cancer;
CESC	cis	rs875971	0.540	rs781152	chr7:65479572	T/A	cg18876405	chr7:65276391	NA	0.73	10.35	0.54	2.61e-21	Aortic root size;
CESC	cis	rs853679	0.517	rs9380058	chr6:28127444	T/C	cg19592336	chr6:28129416	ZNF389	0.63	8.37	0.46	3.45e-15	Depression;
CESC	cis	rs763014	0.932	rs2384972	chr16:674424	G/A	cg09263875	chr16:632152	PIGQ	0.68	11.67	0.58	1.11e-25	Height;
CESC	cis	rs9815354	0.812	rs17218103	chr3:41943724	A/G	cg03022575	chr3:42003672	ULK4	0.71	6.45	0.37	5.42e-10	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs7618915	0.501	rs34754793	chr3:52629177	A/T	cg18337363	chr3:52569053	NT5DC2	0.29	5.27	0.31	2.85e-7	Bipolar disorder;
CESC	cis	rs9322193	0.683	rs113281309	chr6:150108425	T/G	cg04369109	chr6:150039330	LATS1	-0.4	-5.44	-0.32	1.21e-7	Lung cancer;
CESC	cis	rs12681366	0.663	rs2919662	chr8:95470272	C/A	cg13257157	chr8:95487014	RAD54B	0.39	5.34	0.31	2.04e-7	Nonsyndromic cleft lip with cleft palate;
CESC	cis	rs13118159	0.801	rs1128427	chr4:1330759	T/C	cg16405210	chr4:1374714	KIAA1530	-0.58	-7.82	-0.43	1.29e-13	Longevity;
CESC	cis	rs4523957	0.928	rs216201	chr17:2198800	C/T	cg16513277	chr17:2031491	SMG6	0.62	8.52	0.46	1.23e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs4523957	0.928	rs216204	chr17:2196659	G/A	cg16513277	chr17:2031491	SMG6	0.59	8.08	0.44	2.29e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs4704187	0.687	rs922390	chr5:74401269	A/G	cg03227963	chr5:74354835	NA	0.32	5.94	0.34	8.7e-9	Response to amphetamines;
CESC	cis	rs752010	0.905	rs2038977	chr1:42094659	A/G	cg06885757	chr1:42089581	HIVEP3	0.54	9.01	0.48	4.17e-17	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg13880726	chr7:1868755	MAD1L1	0.51	6.78	0.38	8e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs853679	0.517	rs4711165	chr6:28115184	T/G	cg23281280	chr6:28129359	ZNF389	0.6	8.0	0.44	3.86e-14	Depression;
CESC	cis	rs11168351	0.517	rs10875754	chr12:48557922	G/C	cg24011408	chr12:48396354	COL2A1	0.49	8.02	0.44	3.33e-14	Bipolar disorder and schizophrenia;
CESC	cis	rs12477438	0.520	rs11883676	chr2:99800814	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.86	15.21	0.68	5.36e-38	Chronic sinus infection;
CESC	cis	rs67311347	1.000	rs7628796	chr3:40507332	G/A	cg01475735	chr3:40494733	NA	0.43	5.4	0.31	1.47e-7	Renal cell carcinoma;
CESC	cis	rs12188164	0.931	rs115554641	chr5:443236	C/G	cg17553881	chr5:443987	EXOC3;C5orf55	-0.39	-6.19	-0.36	2.26e-9	Cystic fibrosis severity;
CESC	cis	rs7811142	0.943	rs28660238	chr7:100023308	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.79	8.12	0.45	1.81e-14	Platelet count;
CESC	cis	rs4665809	0.525	rs4665324	chr2:26447147	A/C	cg27170947	chr2:26402098	FAM59B	-0.87	-9.85	-0.52	1.01e-19	Gut microbiome composition (summer);
CESC	cis	rs1801251	1.000	rs3816334	chr2:233708806	A/G	cg25237894	chr2:233734115	C2orf82	-0.46	-8.06	-0.44	2.65e-14	Coronary artery disease;
CESC	cis	rs2070488	1.000	rs2268758	chr3:38514049	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.94	17.13	0.72	8.71e-45	Electrocardiographic conduction measures;
CESC	cis	rs1559088	0.803	rs10405770	chr19:33616549	C/T	cg27124370	chr19:33622961	WDR88	0.43	5.59	0.32	5.74e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	trans	rs2727020	0.521	rs7930855	chr11:49521660	C/T	cg03929089	chr4:120376271	NA	0.69	7.89	0.44	8.11e-14	Coronary artery disease;
CESC	cis	rs9768139	0.733	rs12698209	chr7:158117595	A/G	cg06219351	chr7:158114137	PTPRN2	0.46	7.33	0.41	2.74e-12	Calcium levels;
CESC	cis	rs2549003	1.000	rs2070722	chr5:131824486	A/C	cg00255919	chr5:131827918	IRF1	0.51	8.84	0.48	1.4e-16	Asthma (sex interaction);
CESC	cis	rs6788895	1.000	rs76801042	chr3:150482720	A/C	cg09723797	chr3:150481914	SIAH2	0.73	5.55	0.32	6.95e-8	Breast cancer;
CESC	cis	rs752010	0.645	rs1109254	chr1:42091770	T/C	cg06885757	chr1:42089581	HIVEP3	0.72	11.4	0.57	9.16e-25	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs965469	1.000	rs6037553	chr20:3313884	A/G	cg25506879	chr20:3388711	C20orf194	-0.59	-6.26	-0.36	1.53e-9	IFN-related cytopenia;
CESC	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg07677032	chr17:61819896	STRADA	0.46	6.0	0.35	6.43e-9	Prudent dietary pattern;
CESC	cis	rs8141529	0.719	rs2097461	chr22:29191879	T/C	cg02153584	chr22:29168773	CCDC117	0.7	10.01	0.52	3.2e-20	Lymphocyte counts;
CESC	cis	rs9790314	1.000	rs9846756	chr3:160983809	A/C	cg03342759	chr3:160939853	NMD3	-0.49	-6.41	-0.37	6.64e-10	Morning vs. evening chronotype;
CESC	cis	rs861020	0.771	rs654470	chr1:210014093	A/T	cg05527609	chr1:210001259	C1orf107	1.06	15.26	0.68	3.65e-38	Orofacial clefts;
CESC	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	13.67	0.64	1.47e-32	Prudent dietary pattern;
CESC	cis	rs7834588	0.523	rs1455578	chr8:63818756	G/T	cg20602954	chr8:63776762	NKAIN3	0.31	5.22	0.31	3.58e-7	Response to Vitamin E supplementation;
CESC	cis	rs1003719	0.591	rs2018521	chr21:38517264	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.49	-6.43	-0.37	6.06e-10	Eye color traits;
CESC	cis	rs7580658	0.963	rs4233584	chr2:128060163	C/T	cg10021288	chr2:128175891	PROC	-0.41	-6.54	-0.37	3.2e-10	Protein C levels;
CESC	cis	rs116095464	0.558	rs113796397	chr5:246503	A/G	cg22857025	chr5:266934	NA	-1.28	-16.82	-0.72	1.05e-43	Breast cancer;
CESC	cis	rs3126085	0.935	rs11204967	chr1:152249720	A/G	cg03465714	chr1:152285911	FLG	0.42	5.51	0.32	8.52e-8	Atopic dermatitis;
CESC	cis	rs8017423	0.967	rs11623275	chr14:90721335	C/T	cg14092571	chr14:90743983	NA	-0.55	-8.26	-0.45	6.87e-15	Mortality in heart failure;
CESC	cis	rs1003719	0.751	rs55740803	chr21:38542761	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.57	-7.66	-0.43	3.53e-13	Eye color traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16556111	chr5:92918829	NR2F1	-0.66	-7.6	-0.42	5.2e-13	Gut microbiome composition (summer);
CESC	cis	rs9300255	0.770	rs12299125	chr12:123862447	C/T	cg00376283	chr12:123451042	ABCB9	-0.58	-6.67	-0.38	1.45e-10	Neutrophil percentage of white cells;
CESC	cis	rs3733585	0.699	rs6449159	chr4:9960498	G/A	cg00071950	chr4:10020882	SLC2A9	-0.73	-11.79	-0.59	4.58e-26	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs7666738	0.830	rs34244876	chr4:99031336	G/A	cg17366294	chr4:99064904	C4orf37	0.62	8.95	0.48	6.32e-17	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7100689	0.646	rs1538815	chr10:82137670	A/G	cg00277334	chr10:82204260	NA	-0.57	-7.59	-0.42	5.36e-13	Post bronchodilator FEV1;
CESC	cis	rs6460942	1.000	rs79659770	chr7:12326371	T/C	cg06484146	chr7:12443880	VWDE	-0.82	-8.77	-0.47	2.16e-16	Coronary artery disease;
CESC	cis	rs5769765	1.000	rs5770741	chr22:50270215	A/G	cg26441486	chr22:50317300	CRELD2	-0.39	-5.5	-0.32	8.72e-8	Schizophrenia;
CESC	cis	rs1448094	0.511	rs10506918	chr12:86227913	A/G	cg19622623	chr12:86230825	RASSF9	0.45	5.78	0.33	2.13e-8	Major depressive disorder;
CESC	cis	rs8114671	0.562	rs2378294	chr20:33500378	G/A	cg06115741	chr20:33292138	TP53INP2	0.47	5.73	0.33	2.73e-8	Height;
CESC	cis	rs17711722	0.727	rs1880555	chr7:65432567	T/C	cg05332525	chr7:65337924	VKORC1L1	0.5	6.17	0.35	2.53e-9	Calcium levels;
CESC	cis	rs3011225	0.691	rs3791102	chr1:44366617	C/T	cg15962314	chr1:44399869	ARTN	0.27	5.04	0.3	8.61e-7	Amyotrophic lateral sclerosis (age of onset);
CESC	cis	rs1552244	0.882	rs13063929	chr3:10010308	T/C	cg00166722	chr3:10149974	C3orf24	0.46	5.7	0.33	3.23e-8	Alzheimer's disease;
CESC	cis	rs6460942	1.000	rs112996286	chr7:12315741	G/C	cg10578991	chr7:12443926	VWDE	-0.61	-6.41	-0.37	6.66e-10	Coronary artery disease;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg16902244	chr1:24117464	LYPLA2	-0.45	-6.43	-0.37	6.05e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs10504229	0.683	rs77548248	chr8:58117542	G/A	cg21724239	chr8:58056113	NA	0.58	5.97	0.34	7.54e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs875971	1.000	rs1540651	chr7:65650121	C/T	cg11764359	chr7:65958608	NA	-0.92	-14.66	-0.67	5e-36	Aortic root size;
CESC	cis	rs2758596	0.850	rs2495270	chr1:156181530	A/G	cg24450063	chr1:156163899	SLC25A44	0.81	7.6	0.42	5.01e-13	Paclitaxel disposition in epithelial ovarian cancer;
CESC	cis	rs959260	0.920	rs4789187	chr17:73394784	A/G	cg20590849	chr17:73267439	MIF4GD	-0.57	-6.29	-0.36	1.31e-9	Systemic lupus erythematosus;
CESC	cis	rs4906332	0.966	rs12588705	chr14:103865477	T/A	cg09975044	chr14:104007538	NA	0.46	6.34	0.36	9.93e-10	Coronary artery disease;
CESC	cis	rs6541297	0.703	rs618520	chr1:230309771	T/C	cg20703242	chr1:230279135	GALNT2	-0.43	-5.59	-0.33	5.51e-8	Coronary artery disease;
CESC	cis	rs7680126	0.633	rs887732	chr4:10183117	G/C	cg11266682	chr4:10021025	SLC2A9	-0.41	-5.28	-0.31	2.75e-7	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	cis	rs5750830	0.649	rs5750820	chr22:39825322	T/G	cg11247378	chr22:39784982	NA	-0.65	-9.51	-0.5	1.18e-18	Intelligence (multi-trait analysis);
CESC	cis	rs36051895	0.586	rs12342421	chr9:5065750	G/C	cg02405213	chr9:5042618	JAK2	-0.49	-5.85	-0.34	1.45e-8	Pediatric autoimmune diseases;
CESC	trans	rs1728785	1.000	rs6499181	chr16:68593002	A/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.65	7.84	0.43	1.09e-13	Ulcerative colitis;
CESC	cis	rs7267979	1.000	rs1888999	chr20:25291848	C/T	cg08601574	chr20:25228251	PYGB	0.35	5.09	0.3	6.78e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs10208940	0.920	rs11893513	chr2:68760647	C/T	cg12452813	chr2:68675892	NA	0.51	5.12	0.3	5.77e-7	Urate levels in lean individuals;
CESC	cis	rs2066819	1.000	rs17118409	chr12:56630764	G/A	cg26734620	chr12:56694298	CS	1.05	6.75	0.38	9.35e-11	Psoriasis vulgaris;
CESC	cis	rs3096299	0.702	rs2086824	chr16:89471246	G/T	cg02187348	chr16:89574699	SPG7	-0.47	-5.9	-0.34	1.08e-8	Multiple myeloma (IgH translocation);
CESC	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg07167872	chr1:205819463	PM20D1	0.87	15.56	0.69	3.22e-39	Menarche (age at onset);
CESC	trans	rs7980799	0.935	rs7312012	chr12:33517984	A/G	cg26384229	chr12:38710491	ALG10B	-0.47	-6.44	-0.37	5.7e-10	Heart rate;Heart rate variability traits (RMSSD);
CESC	cis	rs7212590	0.655	rs16943969	chr17:58031153	A/G	cg20303301	chr17:57937339	TUBD1	-0.55	-5.57	-0.32	6.25e-8	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs72781680	1.000	rs72781675	chr2:24232092	G/A	cg20701182	chr2:24300061	SF3B14	0.79	6.92	0.39	3.37e-11	Lymphocyte counts;
CESC	cis	rs9399135	0.967	rs9389254	chr6:135330709	C/T	cg22676075	chr6:135203613	NA	0.51	7.23	0.41	5.22e-12	Red blood cell count;
CESC	cis	rs9733	0.596	rs72702552	chr1:150677462	G/A	cg18016565	chr1:150552671	MCL1	0.33	5.14	0.3	5.43e-7	Tonsillectomy;
CESC	cis	rs3806843	0.648	rs702399	chr5:140024432	C/T	cg26395211	chr5:140044315	WDR55	0.45	5.69	0.33	3.36e-8	Depressive symptoms (multi-trait analysis);
CESC	cis	rs7959452	1.000	rs7959452	chr12:69735492	A/G	cg20891283	chr12:69753455	YEATS4	0.57	7.72	0.43	2.38e-13	Blood protein levels;
CESC	cis	rs6460942	1.000	rs6970095	chr7:12403840	G/A	cg17427002	chr7:12443146	VWDE	-0.52	-5.27	-0.31	2.82e-7	Coronary artery disease;
CESC	cis	rs116095464	0.558	rs7713524	chr5:276200	C/T	cg22857025	chr5:266934	NA	1.28	18.9	0.76	5.1e-51	Breast cancer;
CESC	cis	rs7527798	0.592	rs12144801	chr1:207857773	A/G	cg21110645	chr1:207815933	NA	-0.33	-5.86	-0.34	1.33e-8	Erythrocyte sedimentation rate;
CESC	cis	rs4819052	0.807	rs4819047	chr21:46665139	C/T	cg11663144	chr21:46675770	NA	-0.62	-9.77	-0.51	1.85e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs116095464	0.558	rs2288458	chr5:231260	C/T	cg12570787	chr5:219185	SDHA;CCDC127	0.5	5.22	0.31	3.68e-7	Breast cancer;
CESC	cis	rs10751667	0.666	rs6597960	chr11:977036	C/T	cg06064525	chr11:970664	AP2A2	-0.47	-9.12	-0.49	1.9e-17	Alzheimer's disease (late onset);
CESC	cis	rs7665939	1.000	rs72727639	chr4:190107992	G/C	cg09826759	chr4:190284978	NA	-0.87	-7.17	-0.4	7.56e-12	Amyotrophic lateral sclerosis;
CESC	cis	rs9325144	0.560	rs11183090	chr12:38662293	G/C	cg26384229	chr12:38710491	ALG10B	-0.62	-9.6	-0.51	6.43e-19	Morning vs. evening chronotype;
CESC	cis	rs72945132	0.882	rs56176527	chr11:70162513	A/G	cg00319359	chr11:70116639	PPFIA1	0.78	7.71	0.43	2.52e-13	Coronary artery disease;
CESC	cis	rs67311347	0.544	rs2887965	chr3:40334154	A/G	cg09455208	chr3:40491958	NA	-0.37	-6.65	-0.38	1.71e-10	Renal cell carcinoma;
CESC	cis	rs763014	0.931	rs59476302	chr16:629006	C/T	cg07343612	chr16:622815	PIGQ	-0.57	-8.42	-0.46	2.43e-15	Height;
CESC	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg18538332	chr22:24372958	LOC391322	0.66	9.36	0.5	3.68e-18	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs6690583	0.623	rs898036	chr1:85521904	A/T	cg22153463	chr1:85462885	MCOLN2	0.77	7.48	0.42	1.11e-12	Serum sulfate level;
CESC	cis	rs8038465	0.874	rs2291011	chr15:74000839	G/A	cg15420318	chr15:73925796	NPTN	0.4	5.64	0.33	4.32e-8	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs8014204	0.836	rs12588415	chr14:75278211	G/A	cg08847533	chr14:75593920	NEK9	0.46	5.82	0.34	1.69e-8	Caffeine consumption;
CESC	cis	rs7666738	0.791	rs2903151	chr4:99027218	T/C	cg05340658	chr4:99064831	C4orf37	0.83	13.1	0.63	1.43e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1008375	0.932	rs6449317	chr4:17631253	T/C	cg02297831	chr4:17616191	MED28	0.66	8.2	0.45	1.06e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	trans	rs7726839	0.540	rs72703092	chr5:599269	G/A	cg25482853	chr8:67687455	SGK3	1.04	10.14	0.53	1.27e-20	Obesity-related traits;
CESC	cis	rs12681288	0.782	rs12549337	chr8:1030187	A/G	cg15309053	chr8:964076	NA	0.39	6.08	0.35	4.06e-9	Schizophrenia;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg14908186	chr13:113863106	CUL4A;PCID2	-0.46	-6.18	-0.35	2.36e-9	Ulcerative colitis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10182541	chr17:7145706	GABARAP	0.59	6.48	0.37	4.38e-10	Gut microbiome composition (summer);
CESC	cis	rs73206853	0.698	rs56327628	chr12:111117931	A/C	cg12870014	chr12:110450643	ANKRD13A	0.64	5.25	0.31	3.11e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs6665290	0.904	rs1045252	chr1:227181555	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.22	-34.49	-0.9	5.68e-100	Myeloid white cell count;
CESC	cis	rs9902453	0.791	rs7219163	chr17:28210703	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.68	8.82	0.48	1.58e-16	Coffee consumption (cups per day);
CESC	cis	rs941873	0.900	rs4979862	chr10:81131599	G/A	cg11057378	chr10:81107060	PPIF	0.35	5.6	0.33	5.37e-8	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16376036	chr11:117015095	PAFAH1B2	0.5	6.33	0.36	1.01e-9	Gut microbiome composition (summer);
CESC	cis	rs7914558	1.000	rs2275271	chr10:104814162	T/C	cg15744005	chr10:104629667	AS3MT	-0.34	-5.49	-0.32	9.49e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs7904368	0.568	rs7075036	chr10:16864810	C/T	cg23933602	chr10:16859644	RSU1	0.9	13.78	0.65	6.23e-33	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
CESC	cis	rs936229	1.000	rs936228	chr15:75132164	T/C	cg14664628	chr15:75095509	CSK	-0.84	-11.32	-0.57	1.77e-24	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CESC	cis	rs2243480	0.711	rs1626926	chr7:65435792	C/T	cg12463550	chr7:65579703	CRCP	0.67	5.54	0.32	7.11e-8	Diabetic kidney disease;
CESC	cis	rs1564271	0.506	rs1148163	chr10:26929671	G/C	cg13837822	chr10:26931731	LOC731789	0.47	7.04	0.4	1.61e-11	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;
CESC	cis	rs832540	0.556	rs4146565	chr5:56093825	T/C	cg24531977	chr5:56204891	C5orf35	-0.49	-5.87	-0.34	1.3e-8	Coronary artery disease;
CESC	cis	rs10504229	0.639	rs72650811	chr8:58115661	G/A	cg21724239	chr8:58056113	NA	0.58	5.95	0.34	8.29e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs854765	0.618	rs8066982	chr17:17851377	T/C	cg09796270	chr17:17721594	SREBF1	0.45	6.15	0.35	2.87e-9	Total body bone mineral density;
CESC	cis	rs1267303	0.642	rs3737740	chr1:47000596	G/A	cg25110126	chr1:46999211	NA	1.06	11.91	0.59	1.8e-26	Monobrow;
CESC	trans	rs11039798	1.000	rs115429994	chr11:48761183	C/G	cg15704280	chr7:45808275	SEPT13	0.7	6.42	0.37	6.38e-10	Axial length;
CESC	cis	rs709400	0.628	rs6575983	chr14:103869849	C/G	cg12935359	chr14:103987150	CKB	-0.45	-6.87	-0.39	4.66e-11	Body mass index;
CESC	cis	rs2479724	0.901	rs33954419	chr6:41786136	A/G	cg17623882	chr6:41773611	USP49	-0.39	-5.48	-0.32	9.83e-8	Menarche (age at onset);
CESC	cis	rs3617	0.573	rs9850563	chr3:52912214	G/A	cg07507251	chr3:52567010	NT5DC2	-0.33	-5.51	-0.32	8.65e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
CESC	cis	rs4332037	0.950	rs62442895	chr7:1936938	G/A	cg23422044	chr7:1970798	MAD1L1	-0.53	-5.39	-0.31	1.58e-7	Bipolar disorder;
CESC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg16080015	chr7:5085479	RBAK	0.46	6.35	0.36	9.21e-10	Intelligence (multi-trait analysis);
CESC	cis	rs10857712	0.754	rs2297031	chr10:135232654	C/T	cg01444801	chr10:135216882	MTG1	-0.47	-5.41	-0.32	1.44e-7	Systemic lupus erythematosus;
CESC	cis	rs1976403	0.510	rs1697421	chr1:21823292	C/T	cg04349561	chr1:21808255	NBPF3	-0.37	-5.3	-0.31	2.43e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs763014	0.931	rs11648728	chr16:635525	C/T	cg09781414	chr16:715207	WDR90	-0.33	-5.04	-0.3	8.57e-7	Height;
CESC	cis	rs9300255	0.568	rs1790102	chr12:123704890	G/A	cg00376283	chr12:123451042	ABCB9	0.7	8.89	0.48	9.66e-17	Neutrophil percentage of white cells;
CESC	cis	rs7107174	1.000	rs10899479	chr11:78052539	A/G	cg02023728	chr11:77925099	USP35	0.47	6.25	0.36	1.63e-9	Testicular germ cell tumor;
CESC	cis	rs3733585	0.673	rs10018204	chr4:9964570	C/T	cg02734326	chr4:10020555	SLC2A9	-0.44	-6.1	-0.35	3.77e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs7647973	1.000	rs11710434	chr3:49346130	T/C	cg06212747	chr3:49208901	KLHDC8B	0.59	7.8	0.43	1.42e-13	Menarche (age at onset);
CESC	cis	rs728616	0.867	rs723191	chr10:81707920	A/G	cg05935833	chr10:81318306	SFTPA2	-0.51	-5.04	-0.3	8.51e-7	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs6575793	1.000	rs8006543	chr14:101033420	C/T	cg18516195	chr14:101012996	BEGAIN	0.47	6.41	0.37	6.55e-10	Menarche (age at onset);
CESC	cis	rs7945705	0.692	rs2742470	chr11:9004002	C/T	cg09997546	chr11:8931473	C11orf17;ST5	-0.3	-5.11	-0.3	6.27e-7	Hemoglobin concentration;
CESC	cis	rs9894429	0.869	rs9748184	chr17:79596280	A/G	cg13777783	chr17:79615861	NA	-0.34	-5.65	-0.33	4.22e-8	Eye color traits;
CESC	cis	rs6662572	0.737	rs4474301	chr1:46255272	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.45	-5.08	-0.3	7.27e-7	Blood protein levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07473634	chr13:113647389	MCF2L	-0.47	-6.29	-0.36	1.33e-9	Gut microbiome composition (summer);
CESC	cis	rs875971	0.522	rs2949690	chr7:65483242	C/T	cg11764359	chr7:65958608	NA	-0.67	-8.72	-0.47	3.06e-16	Aortic root size;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg13116478	chr1:9217203	NA	0.46	6.36	0.36	8.66e-10	Fibrinogen levels;
CESC	cis	rs4555082	0.834	rs28846738	chr14:105745781	A/G	cg10792982	chr14:105748885	BRF1	0.42	5.53	0.32	7.54e-8	Mean platelet volume;Platelet distribution width;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11087911	chr8:64081408	YTHDF3	0.57	6.41	0.37	6.45e-10	Gut microbiome composition (summer);
CESC	cis	rs12618769	0.652	rs17034171	chr2:99221095	A/G	cg10123293	chr2:99228465	UNC50	0.4	5.32	0.31	2.2e-7	Bipolar disorder;
CESC	cis	rs12477438	0.765	rs10193039	chr2:99692373	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.61	-8.65	-0.47	5.2e-16	Chronic sinus infection;
CESC	cis	rs4722166	0.695	rs4722177	chr7:22798531	T/C	cg05472934	chr7:22766657	IL6	0.63	8.31	0.45	4.87e-15	Lung cancer;
CESC	trans	rs3741404	0.825	rs60452247	chr11:63981507	G/A	cg15268290	chr11:83690587	DLG2	0.43	6.03	0.35	5.48e-9	Platelet count;
CESC	cis	rs6831352	0.918	rs13110764	chr4:100062466	C/T	cg12011299	chr4:100065546	ADH4	-0.57	-6.5	-0.37	3.86e-10	Alcohol dependence;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19863752	chr5:175970067	NA	0.53	6.0	0.35	6.36e-9	Gut microbiome composition (summer);
CESC	cis	rs12893668	0.572	rs34000399	chr14:104101417	T/C	cg24130564	chr14:104152367	KLC1	-0.51	-6.72	-0.38	1.08e-10	Reticulocyte count;
CESC	cis	rs17376456	0.877	rs12716460	chr5:93416733	A/G	cg21475434	chr5:93447410	FAM172A	0.82	7.36	0.41	2.32e-12	Diabetic retinopathy;
CESC	cis	rs78707713	0.535	rs3812705	chr10:71211146	A/G	cg12610070	chr10:71211762	TSPAN15	-0.32	-6.87	-0.39	4.44e-11	Venous thromboembolism;
CESC	cis	rs7666738	0.830	rs13138438	chr4:99050545	C/A	cg24818145	chr4:99064322	C4orf37	0.38	5.04	0.3	8.49e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs757110	0.770	rs4439492	chr11:17386733	C/T	cg15432903	chr11:17409602	KCNJ11	0.58	8.14	0.45	1.5e-14	Type 2 diabetes;
CESC	cis	rs9488822	0.676	rs4354188	chr6:116327936	T/C	cg26893134	chr6:116381904	FRK	0.25	6.02	0.35	5.89e-9	Cholesterol, total;LDL cholesterol;
CESC	trans	rs61931739	0.500	rs11615231	chr12:34413330	T/C	cg13010199	chr12:38710504	ALG10B	0.49	6.34	0.36	9.81e-10	Morning vs. evening chronotype;
CESC	trans	rs7824557	0.527	rs4634600	chr8:11239017	T/A	cg06636001	chr8:8085503	FLJ10661	-0.48	-6.23	-0.36	1.83e-9	Retinal vascular caliber;
CESC	cis	rs9929218	0.817	rs3118228	chr16:68710737	T/G	cg02972257	chr16:68554789	NA	0.55	6.06	0.35	4.57e-9	Colorectal cancer;
CESC	cis	rs4713118	0.527	rs9461433	chr6:28095172	C/T	cg23161317	chr6:28129485	ZNF389	0.51	6.5	0.37	3.98e-10	Parkinson's disease;
CESC	cis	rs5757676	0.858	rs6001585	chr22:39812986	G/T	cg01416388	chr22:39784598	NA	-0.64	-7.0	-0.4	2.09e-11	IgG glycosylation;
CESC	cis	rs9325144	0.505	rs6582691	chr12:38806894	T/C	cg13010199	chr12:38710504	ALG10B	-0.48	-6.82	-0.39	6.08e-11	Morning vs. evening chronotype;
CESC	cis	rs9549367	0.713	rs4907598	chr13:113861385	C/T	cg00898013	chr13:113819073	PROZ	0.45	6.92	0.39	3.35e-11	Platelet distribution width;
CESC	cis	rs4664293	0.967	rs35975814	chr2:160547791	G/A	cg08347373	chr2:160653686	CD302	-0.33	-5.38	-0.31	1.66e-7	Monocyte percentage of white cells;
CESC	cis	rs9814567	1.000	rs6802654	chr3:134217072	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.44	-5.99	-0.35	6.9e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs6088590	1.000	rs2236270	chr20:33523155	G/T	cg06115741	chr20:33292138	TP53INP2	0.64	7.76	0.43	1.85e-13	Coronary artery disease;
CESC	cis	rs9311474	0.713	rs352166	chr3:52238677	C/T	cg05564831	chr3:52568323	NT5DC2	0.34	5.06	0.3	8.01e-7	Electroencephalogram traits;
CESC	cis	rs2228479	0.850	rs3785281	chr16:89824263	G/C	cg06558623	chr16:89946397	TCF25	1.17	9.38	0.5	3.19e-18	Skin colour saturation;
CESC	cis	rs7412746	0.621	rs7518156	chr1:150945794	A/C	cg22823121	chr1:150693482	HORMAD1	0.37	5.22	0.31	3.62e-7	Melanoma;
CESC	cis	rs10242455	0.702	rs73403286	chr7:99154865	A/C	cg25640893	chr7:99214727	ZNF498	0.78	5.5	0.32	8.75e-8	Blood metabolite levels;
CESC	cis	rs847577	0.609	rs17435847	chr7:97792820	G/A	cg21770322	chr7:97807741	LMTK2	0.86	14.88	0.67	8e-37	Breast cancer;
CESC	cis	rs909674	0.731	rs4821897	chr22:39835587	A/G	cg11247378	chr22:39784982	NA	-0.69	-9.46	-0.5	1.79e-18	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs5758511	0.508	rs28715885	chr22:42441091	T/G	cg00645731	chr22:42541494	CYP2D7P1	0.55	7.51	0.42	8.91e-13	Birth weight;
CESC	cis	rs3733585	0.781	rs4292328	chr4:9970962	C/T	cg00071950	chr4:10020882	SLC2A9	-0.79	-14.74	-0.67	2.47e-36	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs9393777	0.513	rs6936555	chr6:26640886	C/T	cg12292205	chr6:26970375	C6orf41	-0.5	-5.72	-0.33	2.9e-8	Intelligence (multi-trait analysis);
CESC	cis	rs10504229	0.724	rs72649117	chr8:58037639	A/G	cg22535103	chr8:58192502	C8orf71	-0.6	-6.76	-0.38	8.68e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs9916302	0.851	rs11657899	chr17:37626963	G/A	cg20243544	chr17:37824526	PNMT	0.51	6.5	0.37	3.97e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs16867321	0.590	rs2194688	chr2:181577733	C/G	cg23363182	chr2:181467187	NA	0.45	6.63	0.38	1.87e-10	Obesity;
CESC	cis	rs6598955	1.000	rs10902728	chr1:26598281	T/C	cg04990556	chr1:26633338	UBXN11	0.84	10.87	0.56	5.24e-23	Obesity-related traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00911289	chr3:128840257	RAB43	-0.63	-6.94	-0.39	2.98e-11	Gut microbiome composition (summer);
CESC	cis	rs6893300	0.961	rs11744616	chr5:179209113	G/T	cg14593053	chr5:179126677	CANX	-0.51	-5.69	-0.33	3.44e-8	Resting heart rate;
CESC	cis	rs9457247	0.967	rs2149084	chr6:167370988	G/C	cg07741184	chr6:167504864	NA	-0.3	-5.25	-0.31	3.1e-7	Crohn's disease;
CESC	cis	rs360798	0.532	rs2421816	chr2:63075033	C/A	cg17519650	chr2:63277830	OTX1	0.48	5.76	0.33	2.32e-8	Coronary artery disease;
CESC	cis	rs9911578	0.803	rs8069033	chr17:57131581	T/A	cg12560992	chr17:57184187	TRIM37	-1.02	-17.96	-0.74	9.86e-48	Intelligence (multi-trait analysis);
CESC	cis	rs258892	0.841	rs266427	chr5:72130751	A/G	cg21869765	chr5:72125136	TNPO1	0.44	5.62	0.33	4.78e-8	Small cell lung carcinoma;
CESC	cis	rs2635047	0.967	rs2668786	chr18:44708472	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.52	7.13	0.4	9.45e-12	Educational attainment;
CESC	cis	rs7914558	0.966	rs1971589	chr10:104744406	A/G	cg08650961	chr10:104748594	CNNM2	0.32	5.18	0.3	4.39e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs7243790	0.805	rs12458588	chr18:51903693	G/T	cg04730925	chr18:51795821	POLI	-0.42	-5.58	-0.32	5.95e-8	Diastolic blood pressure;
CESC	cis	rs1045714	0.895	rs4721860	chr7:2639994	C/T	cg20813462	chr7:2646259	IQCE	0.65	5.65	0.33	4.16e-8	Urate levels in lean individuals;
CESC	cis	rs7103648	0.669	rs7114011	chr11:47811309	A/C	cg10504702	chr11:47789108	FNBP4	0.41	5.17	0.3	4.63e-7	Diastolic blood pressure;Systolic blood pressure;
CESC	cis	rs62229266	0.693	rs2835264	chr21:37435965	C/T	cg08632701	chr21:37451849	NA	-0.4	-5.58	-0.32	6.01e-8	Mitral valve prolapse;
CESC	cis	rs4664293	0.967	rs9646765	chr2:160565648	T/C	cg08347373	chr2:160653686	CD302	-0.33	-5.35	-0.31	1.95e-7	Monocyte percentage of white cells;
CESC	cis	rs10979	1.000	rs35354710	chr6:143886454	A/G	cg25407410	chr6:143891975	LOC285740	-0.62	-9.52	-0.51	1.1e-18	Hypospadias;
CESC	cis	rs7084402	0.935	rs4948524	chr10:60351224	C/A	cg07615347	chr10:60278583	BICC1	0.54	8.28	0.45	6.13e-15	Refractive error;
CESC	cis	rs11112613	0.762	rs17037308	chr12:105949847	T/G	cg03607813	chr12:105948248	NA	0.67	8.31	0.45	5.16e-15	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CESC	cis	rs13108904	0.557	rs1250097	chr4:1238338	C/T	cg02018176	chr4:1364513	KIAA1530	-0.38	-5.07	-0.3	7.43e-7	Obesity-related traits;
CESC	cis	rs5769765	0.837	rs8142737	chr22:50291889	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.44	-5.09	-0.3	6.87e-7	Schizophrenia;
CESC	cis	rs4268898	0.662	rs12052954	chr2:24425620	C/T	cg08917208	chr2:24149416	ATAD2B	-0.54	-5.42	-0.32	1.31e-7	Asthma;
CESC	cis	rs10927875	0.632	rs2862162	chr1:16142960	A/C	cg19025461	chr1:16163610	FLJ37453	-0.35	-5.12	-0.3	5.82e-7	Dilated cardiomyopathy;
CESC	trans	rs8026198	0.568	rs1659221	chr15:42615411	A/C	cg11538410	chr8:142141455	DENND3	0.61	6.04	0.35	5.11e-9	Fibrinogen levels;
CESC	cis	rs11625487	0.609	rs78677337	chr14:77966223	G/A	cg20045696	chr14:77926864	AHSA1	-0.71	-5.27	-0.31	2.88e-7	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
CESC	cis	rs1008375	0.931	rs2109519	chr4:17695453	A/G	cg02297831	chr4:17616191	MED28	0.45	5.47	0.32	1.04e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs4819052	0.851	rs2838864	chr21:46711474	A/T	cg11663144	chr21:46675770	NA	0.56	8.73	0.47	2.9e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs853679	0.607	rs17763089	chr6:27835218	G/A	cg01620082	chr3:125678407	NA	-0.76	-6.48	-0.37	4.51e-10	Depression;
CESC	cis	rs4332037	0.707	rs73046323	chr7:1882795	G/A	cg23422044	chr7:1970798	MAD1L1	-0.54	-5.78	-0.33	2.12e-8	Bipolar disorder;
CESC	cis	rs9911578	1.000	rs2079703	chr17:56603978	G/A	cg12560992	chr17:57184187	TRIM37	-0.93	-15.59	-0.69	2.43e-39	Intelligence (multi-trait analysis);
CESC	trans	rs637571	0.780	rs677029	chr11:65683531	A/G	cg17712092	chr4:129076599	LARP1B	0.94	13.86	0.65	3.29e-33	Eosinophil percentage of white cells;
CESC	cis	rs11864453	0.713	rs3764312	chr16:72125733	A/C	cg01557791	chr16:72042693	DHODH	-0.46	-5.92	-0.34	9.98e-9	Fibrinogen levels;
CESC	trans	rs9650657	0.538	rs6984496	chr8:10796093	G/T	cg15556689	chr8:8085844	FLJ10661	-0.58	-7.4	-0.41	1.75e-12	Neuroticism;
CESC	cis	rs9311474	0.607	rs28661185	chr3:52567188	G/T	cg18099408	chr3:52552593	STAB1	-0.38	-6.6	-0.38	2.24e-10	Electroencephalogram traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09690373	chr8:29120781	KIF13B	-0.71	-8.96	-0.48	6.12e-17	Gut microbiome composition (summer);
CESC	cis	rs6430585	0.583	rs2839740	chr2:136648883	G/T	cg07169764	chr2:136633963	MCM6	1.27	17.79	0.74	4.01e-47	Corneal structure;
CESC	cis	rs62283056	0.636	rs17718958	chr4:6275735	G/A	cg00701064	chr4:6280414	WFS1	-0.57	-5.26	-0.31	2.92e-7	Cisplatin-induced ototoxicity;
CESC	cis	rs9309473	1.000	rs10187416	chr2:73713741	T/G	cg20560298	chr2:73613845	ALMS1	-0.49	-6.69	-0.38	1.3e-10	Metabolite levels;
CESC	trans	rs561341	1.000	rs501312	chr17:30329066	A/G	cg20587970	chr11:113659929	NA	-1.43	-18.64	-0.75	3.98e-50	Hip circumference adjusted for BMI;
CESC	cis	rs9403521	1.000	rs12528456	chr6:144003706	A/G	cg18240653	chr6:144019428	PHACTR2	-0.46	-5.24	-0.31	3.35e-7	Obesity-related traits;
CESC	cis	rs10461617	0.592	rs6450403	chr5:56062737	A/C	cg12311346	chr5:56204834	C5orf35	-0.56	-7.1	-0.4	1.17e-11	Type 2 diabetes;
CESC	cis	rs6089829	0.926	rs1060489	chr20:61665921	C/T	cg08564027	chr20:61660810	NA	0.91	15.61	0.69	2.1e-39	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs656900	0.715	rs673079	chr15:80115406	G/A	cg02196730	chr15:80188777	MTHFS	-0.39	-5.03	-0.3	9.2e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs7937682	0.737	rs663763	chr11:111422217	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.76	-10.13	-0.53	1.34e-20	Primary sclerosing cholangitis;
CESC	cis	rs3820068	0.581	rs16851848	chr1:15927698	G/A	cg16988262	chr1:15930761	NA	0.35	5.65	0.33	4.18e-8	Systolic blood pressure;
CESC	cis	rs780096	0.546	rs12473776	chr2:27636474	A/G	cg22903471	chr2:27725779	GCKR	-0.5	-7.16	-0.4	7.71e-12	Total body bone mineral density;
CESC	cis	rs2730245	0.505	rs1188956	chr7:158690576	G/A	cg14689365	chr7:158441557	NCAPG2	0.42	5.25	0.31	3.18e-7	Height;
CESC	cis	rs926938	0.618	rs360617	chr1:115404099	G/A	cg12756093	chr1:115239321	AMPD1	0.48	6.79	0.38	7.45e-11	Autism;
CESC	cis	rs8114671	0.562	rs1060615	chr20:33478381	C/T	cg07148914	chr20:33460835	GGT7	-0.43	-5.7	-0.33	3.12e-8	Height;
CESC	cis	rs7223966	1.000	rs2665826	chr17:61944924	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.53	6.32	0.36	1.1e-9	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs4595586	0.545	rs12820138	chr12:39357049	A/G	cg26384229	chr12:38710491	ALG10B	0.54	7.54	0.42	7.28e-13	Morning vs. evening chronotype;
CESC	cis	rs3733585	0.699	rs6449159	chr4:9960498	G/A	cg11266682	chr4:10021025	SLC2A9	-0.6	-11.2	-0.57	4.42e-24	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs853679	0.517	rs9368556	chr6:28131153	T/C	cg23161317	chr6:28129485	ZNF389	0.52	6.48	0.37	4.37e-10	Depression;
CESC	cis	rs344364	0.511	rs12596510	chr16:1949480	G/A	cg03013636	chr16:1946785	NA	0.48	6.62	0.38	2.02e-10	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs1218582	0.710	rs7553195	chr1:154837796	T/C	cg16680214	chr1:154839983	KCNN3	-0.52	-8.24	-0.45	7.81e-15	Prostate cancer;
CESC	cis	rs56046484	0.956	rs34054841	chr15:85601346	C/G	cg08123816	chr15:85640762	PDE8A	-0.48	-6.03	-0.35	5.39e-9	Testicular germ cell tumor;
CESC	cis	rs4253772	0.591	rs6008361	chr22:46652372	A/G	cg24881330	chr22:46731750	TRMU	-0.85	-9.56	-0.51	8.81e-19	LDL cholesterol;Cholesterol, total;
CESC	cis	rs10504229	0.724	rs73603871	chr8:58107612	A/G	cg02725872	chr8:58115012	NA	-0.43	-6.81	-0.39	6.53e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs539096	0.540	rs37452	chr1:44297573	A/C	cg12908607	chr1:44402522	ARTN	-0.46	-6.77	-0.38	8.18e-11	Intelligence (multi-trait analysis);
CESC	cis	rs902774	0.554	rs4919749	chr12:53358034	C/T	cg05393297	chr12:53359155	NA	-0.64	-9.09	-0.49	2.45e-17	Prostate cancer;
CESC	cis	rs854765	0.724	rs62072049	chr17:17906520	T/C	cg09796270	chr17:17721594	SREBF1	0.45	6.43	0.37	5.78e-10	Total body bone mineral density;
CESC	cis	rs561341	0.941	rs8066558	chr17:30272879	G/T	cg00745463	chr17:30367425	LRRC37B	-0.68	-6.78	-0.38	7.66e-11	Hip circumference adjusted for BMI;
CESC	cis	rs78456975	0.943	rs7602369	chr2:1574754	T/C	cg26248373	chr2:1572462	NA	-0.54	-5.25	-0.31	3.14e-7	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs8060686	0.641	rs79375669	chr16:68099262	A/T	cg26727032	chr16:67993705	SLC12A4	-0.55	-6.15	-0.35	2.9e-9	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs11123610	0.520	rs59726279	chr2:3718655	A/G	cg19052272	chr2:3704530	ALLC	-0.48	-5.85	-0.34	1.41e-8	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CESC	trans	rs6570726	0.764	rs9403726	chr6:145901686	G/T	cg03826317	chr10:25465503	LOC100128811;GPR158	0.31	6.11	0.35	3.47e-9	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs9858542	0.953	rs9858280	chr3:49597737	T/C	cg21659725	chr3:3221576	CRBN	-0.52	-6.36	-0.36	8.69e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs3824867	0.879	rs4752837	chr11:47465955	G/A	cg20307385	chr11:47447363	PSMC3	0.51	6.09	0.35	3.96e-9	Mean corpuscular hemoglobin;
CESC	cis	rs4730250	0.707	rs3729876	chr7:106786952	T/C	cg02696742	chr7:106810147	HBP1	0.56	5.3	0.31	2.45e-7	Osteoarthritis;
CESC	cis	rs11098499	0.779	rs10857066	chr4:120286596	C/T	cg24375607	chr4:120327624	NA	0.42	5.18	0.3	4.34e-7	Corneal astigmatism;
CESC	cis	rs896543	0.657	rs10179774	chr2:237487588	C/T	cg25295825	chr2:237489920	CXCR7	0.55	6.22	0.36	1.89e-9	Alcohol dependence (age at onset);
CESC	cis	rs1505368	0.567	rs972491	chr2:213316573	A/G	cg20637307	chr2:213403960	ERBB4	-0.45	-7.04	-0.4	1.64e-11	Symmetrical dimethylarginine levels;
CESC	cis	rs16867321	0.639	rs13028421	chr2:181444035	G/T	cg23363182	chr2:181467187	NA	0.5	7.37	0.41	2.12e-12	Obesity;
CESC	cis	rs3858526	0.920	rs11039548	chr11:5930283	G/A	cg13902645	chr11:5959945	NA	-0.62	-7.29	-0.41	3.54e-12	DNA methylation (variation);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg04730839	chr6:42985884	KLHDC3	-0.37	-6.09	-0.35	3.98e-9	Gambling;
CESC	cis	rs17376456	0.877	rs10044139	chr5:93407803	T/C	cg25358565	chr5:93447407	FAM172A	1.13	10.9	0.56	4.19e-23	Diabetic retinopathy;
CESC	cis	rs1218582	0.772	rs2335408	chr1:154915977	G/A	cg03351412	chr1:154909251	PMVK	0.68	8.94	0.48	6.9e-17	Prostate cancer;
CESC	cis	rs28374715	0.681	rs59000092	chr15:41626148	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.78	-11.24	-0.57	3.19e-24	Ulcerative colitis;
CESC	cis	rs801193	0.636	rs2659895	chr7:66196471	C/A	cg11764359	chr7:65958608	NA	0.89	13.96	0.65	1.41e-33	Aortic root size;
CESC	cis	rs962856	0.619	rs6546300	chr2:67595196	T/G	cg09028215	chr2:67624308	ETAA1	-0.44	-5.29	-0.31	2.54e-7	Pancreatic cancer;
CESC	cis	rs11122272	0.735	rs2790885	chr1:231529925	C/T	cg06096015	chr1:231504339	EGLN1	0.43	6.15	0.35	2.9e-9	Hemoglobin concentration;
CESC	cis	rs7666738	0.830	rs13133619	chr4:99067312	C/G	cg03467027	chr4:99064603	C4orf37	-0.49	-6.15	-0.35	2.89e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7605827	0.893	rs7575722	chr2:15597551	G/A	cg19274914	chr2:15703543	NA	0.32	5.61	0.33	5.05e-8	Educational attainment (years of education);
CESC	trans	rs6572548	0.504	rs1956082	chr14:49665496	A/C	cg06611277	chr10:26987120	PDSS1	-0.54	-6.12	-0.35	3.43e-9	Subjective well-being;
CESC	cis	rs3733585	0.699	rs6449174	chr4:9966422	C/T	cg00071950	chr4:10020882	SLC2A9	-0.66	-10.67	-0.55	2.49e-22	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs116095464	0.558	rs28418643	chr5:240859	A/G	cg22857025	chr5:266934	NA	-1.29	-18.85	-0.76	7.29e-51	Breast cancer;
CESC	cis	rs73019876	0.869	rs7253518	chr19:22145667	C/T	cg11619707	chr19:22235551	ZNF257	-0.28	-5.19	-0.3	4.11e-7	Testicular germ cell tumor;
CESC	cis	rs9733	0.818	rs12130363	chr1:150688596	T/C	cg13175981	chr1:150552382	MCL1	0.62	9.15	0.49	1.59e-17	Tonsillectomy;
CESC	cis	rs425277	0.585	rs3107157	chr1:2061969	A/G	cg24578937	chr1:2090814	PRKCZ	-0.32	-5.51	-0.32	8.62e-8	Height;
CESC	trans	rs10242455	0.571	rs55830753	chr7:99292222	A/G	cg09045935	chr12:6379348	NA	0.76	6.07	0.35	4.42e-9	Blood metabolite levels;
CESC	cis	rs959260	0.688	rs1435093	chr17:73357586	G/A	cg20590849	chr17:73267439	MIF4GD	-0.56	-6.11	-0.35	3.55e-9	Systemic lupus erythematosus;
CESC	cis	rs9457247	0.534	rs4710149	chr6:167386346	T/C	cg23791538	chr6:167370224	RNASET2	0.7	10.12	0.53	1.44e-20	Crohn's disease;
CESC	cis	rs920590	0.758	rs1817836	chr8:19664852	T/C	cg03894339	chr8:19674705	INTS10	0.62	7.36	0.41	2.35e-12	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs34779708	0.658	rs4934715	chr10:35364992	G/T	cg03585969	chr10:35415529	CREM	0.76	9.79	0.52	1.5700000000000001e-19	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs7811142	0.887	rs4074838	chr7:100032665	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.11	10.96	0.56	2.75e-23	Platelet count;
CESC	cis	rs875971	0.825	rs1000464	chr7:65777909	G/C	cg18876405	chr7:65276391	NA	-0.5	-6.92	-0.39	3.39e-11	Aortic root size;
CESC	cis	rs6570726	0.967	rs6903252	chr6:145922777	A/G	cg23711669	chr6:146136114	FBXO30	0.79	11.69	0.58	9.6e-26	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9309473	1.000	rs7580825	chr2:73635148	G/A	cg20560298	chr2:73613845	ALMS1	-0.55	-7.19	-0.4	6.6e-12	Metabolite levels;
CESC	cis	rs11252926	0.624	rs7085214	chr10:468133	A/G	cg03684893	chr10:554711	DIP2C	-0.39	-5.83	-0.34	1.59e-8	Psychosis in Alzheimer's disease;
CESC	cis	rs35110281	0.563	rs162371	chr21:44931489	G/T	cg01579765	chr21:45077557	HSF2BP	-0.51	-8.73	-0.47	2.83e-16	Mean corpuscular volume;
CESC	cis	rs72781680	0.898	rs12623333	chr2:24111823	T/G	cg08917208	chr2:24149416	ATAD2B	0.93	8.61	0.47	6.66e-16	Lymphocyte counts;
CESC	cis	rs2832191	0.720	rs7277028	chr21:30494604	T/C	cg24692254	chr21:30365293	RNF160	-0.79	-12.11	-0.6	3.54e-27	Dental caries;
CESC	cis	rs72781680	0.821	rs72790329	chr2:24129277	A/G	cg08917208	chr2:24149416	ATAD2B	0.57	5.62	0.33	4.79e-8	Lymphocyte counts;
CESC	cis	rs763121	0.853	rs2281019	chr22:39064378	T/A	cg06022373	chr22:39101656	GTPBP1	0.88	13.95	0.65	1.51e-33	Menopause (age at onset);
CESC	cis	rs6121246	0.559	rs10439607	chr20:30258541	G/A	cg13852791	chr20:30311386	BCL2L1	0.76	9.73	0.51	2.51e-19	Mean corpuscular hemoglobin;
CESC	cis	rs10751667	0.600	rs10751665	chr11:941300	G/A	cg20946044	chr11:1010712	AP2A2	-0.41	-5.64	-0.33	4.31e-8	Alzheimer's disease (late onset);
CESC	cis	rs2415984	0.622	rs10131871	chr14:46931700	A/G	cg14871534	chr14:47121158	RPL10L	0.35	5.42	0.32	1.36e-7	Number of children ever born;
CESC	cis	rs5758659	0.682	rs133306	chr22:42396150	G/A	cg15557168	chr22:42548783	NA	-0.43	-6.34	-0.36	9.99e-10	Cognitive function;
CESC	cis	rs2282526	0.587	rs91424	chr21:44921161	A/G	cg01579765	chr21:45077557	HSF2BP	0.4	6.35	0.36	9.35e-10	Mean corpuscular hemoglobin;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08979686	chr20:44600644	ZNF335	0.5	6.15	0.35	2.88e-9	Gut microbiome composition (summer);
CESC	cis	rs2404602	0.672	rs35374222	chr15:77071394	G/T	cg23625390	chr15:77176239	SCAPER	-0.4	-5.23	-0.31	3.44e-7	Blood metabolite levels;
CESC	cis	rs6570726	0.846	rs1935616	chr6:145943512	C/T	cg05347473	chr6:146136440	FBXO30	0.53	6.89	0.39	4.01e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1008375	1.000	rs10939748	chr4:17691230	T/C	cg16339924	chr4:17578868	LAP3	0.64	7.7	0.43	2.69e-13	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs2594989	0.895	rs2606741	chr3:11392426	G/A	cg00170343	chr3:11313890	ATG7	0.48	5.15	0.3	4.97e-7	Circulating chemerin levels;
CESC	cis	rs870825	0.616	rs6814278	chr4:185644417	G/C	cg04058563	chr4:185651563	MLF1IP	0.63	6.96	0.39	2.59e-11	Blood protein levels;
CESC	cis	rs12824058	0.831	rs12310049	chr12:130811260	C/G	cg26677194	chr12:130822605	PIWIL1	0.52	6.81	0.39	6.58e-11	Menopause (age at onset);
CESC	cis	rs718433	0.616	rs2222916	chr14:22212602	C/T	cg02257791	chr14:22217085	NA	-0.32	-5.09	-0.3	6.83e-7	Intraocular pressure;
CESC	cis	rs7714584	1.000	rs75071288	chr5:150224379	C/T	cg22134413	chr5:150180641	NA	0.52	5.64	0.33	4.31e-8	Crohn's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10168434	chr2:71295172	NAGK	0.58	6.34	0.36	9.76e-10	Gut microbiome composition (summer);
CESC	cis	rs11871801	1.000	rs12938856	chr17:40570649	T/C	cg21433558	chr17:40837037	CNTNAP1	0.46	5.03	0.3	8.91e-7	Crohn's disease;
CESC	cis	rs7918232	0.830	rs7915902	chr10:27410734	T/C	cg14442939	chr10:27389572	ANKRD26	0.68	6.73	0.38	1.04e-10	Breast cancer;
CESC	cis	rs3820928	1.000	rs4675116	chr2:227769607	A/C	cg05526886	chr2:227700861	RHBDD1	-0.44	-5.76	-0.33	2.36e-8	Pulmonary function;
CESC	cis	rs1552244	1.000	rs67569278	chr3:10149893	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.89	11.36	0.57	1.23e-24	Alzheimer's disease;
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg01034784	chr2:95831832	ZNF2	-0.4	-6.2	-0.36	2.21e-9	Vertical cup-disc ratio;
CESC	cis	rs6952808	0.609	rs4721190	chr7:1954732	A/G	cg20295408	chr7:1910781	MAD1L1	0.43	5.55	0.32	6.95e-8	Bipolar disorder and schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12629250	chr15:20149347	NA	-0.59	-6.74	-0.38	9.94e-11	Gut microbiome composition (summer);
CESC	trans	rs2235573	0.551	rs84770	chr22:38390128	T/G	cg19894588	chr14:64061835	NA	0.6	7.74	0.43	2.14e-13	Glioblastoma;Glioma;
CESC	cis	rs67478160	0.583	rs12879612	chr14:104233618	T/A	cg08213375	chr14:104286397	PPP1R13B	0.55	11.06	0.56	1.25e-23	Schizophrenia;
CESC	cis	rs9911578	0.935	rs420878	chr17:56709077	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.39	5.17	0.3	4.54e-7	Intelligence (multi-trait analysis);
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg09783738	chr11:109964017	ZC3H12C	0.44	6.05	0.35	5.01e-9	Thyroid stimulating hormone;
CESC	cis	rs514406	0.722	rs7552139	chr1:53387379	G/C	cg16325326	chr1:53192061	ZYG11B	0.82	13.0	0.62	3.08e-30	Monocyte count;
CESC	cis	rs7618915	0.501	rs2289247	chr3:52727257	C/T	cg17372223	chr3:52568218	NT5DC2	0.38	5.68	0.33	3.48e-8	Bipolar disorder;
CESC	cis	rs11608355	0.672	rs9943689	chr12:109890339	G/A	cg05360138	chr12:110035743	NA	0.54	6.03	0.35	5.44e-9	Neuroticism;
CESC	cis	rs533581	0.866	rs562812	chr16:88970944	G/A	cg16701003	chr16:89028210	CBFA2T3	0.48	6.61	0.38	2.1e-10	Social autistic-like traits;
CESC	cis	rs712039	0.652	rs829161	chr17:35763863	C/T	cg16670864	chr17:35848621	DUSP14	-0.44	-5.73	-0.33	2.7e-8	Tuberculosis;
CESC	cis	rs597539	0.615	rs629426	chr11:68671104	A/G	cg01988459	chr11:68622903	NA	-0.41	-5.65	-0.33	4.1e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs9303401	0.703	rs9911583	chr17:57210721	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	-0.54	-7.03	-0.4	1.79e-11	Cognitive test performance;
CESC	cis	rs7552404	0.960	rs12085123	chr1:76149749	G/A	cg22875332	chr1:76189707	ACADM	0.66	7.79	0.43	1.53e-13	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs9487051	0.676	rs9398196	chr6:109601554	A/G	cg01475377	chr6:109611718	NA	-0.45	-7.1	-0.4	1.13e-11	Reticulocyte fraction of red cells;
CESC	cis	rs9322193	0.607	rs12210822	chr6:150226492	C/T	cg01145232	chr6:150245071	RAET1G	0.52	6.64	0.38	1.79e-10	Lung cancer;
CESC	cis	rs4713118	0.662	rs9468275	chr6:28026136	G/T	cg12963246	chr6:28129442	ZNF389	0.5	6.4	0.37	6.93e-10	Parkinson's disease;
CESC	cis	rs6460942	1.000	rs73053531	chr7:12317474	T/C	cg10578991	chr7:12443926	VWDE	-0.61	-6.41	-0.37	6.66e-10	Coronary artery disease;
CESC	cis	rs10751667	0.621	rs4075990	chr11:976614	T/C	cg20946044	chr11:1010712	AP2A2	-0.39	-5.4	-0.31	1.48e-7	Alzheimer's disease (late onset);
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg01398415	chr1:226309536	NA	0.46	6.12	0.35	3.36e-9	Systemic lupus erythematosus;
CESC	trans	rs11098499	0.698	rs4422403	chr4:120258194	C/T	cg25214090	chr10:38739885	LOC399744	0.61	8.64	0.47	5.37e-16	Corneal astigmatism;
CESC	cis	rs2235544	0.664	rs12036530	chr1:54476323	T/C	cg09175620	chr1:54484536	LDLRAD1	-0.29	-5.09	-0.3	6.88e-7	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
CESC	cis	rs11030122	0.702	rs4910866	chr11:3950554	A/T	cg18678763	chr11:4115507	RRM1	-0.45	-6.05	-0.35	4.94e-9	Mean platelet volume;Platelet distribution width;
CESC	cis	rs7412746	0.552	rs4970980	chr1:150864992	A/C	cg22823121	chr1:150693482	HORMAD1	0.36	5.07	0.3	7.36e-7	Melanoma;
CESC	cis	rs7474896	0.515	rs2505233	chr10:38340265	C/T	cg25427524	chr10:38739819	LOC399744	-0.44	-5.09	-0.3	6.89e-7	Obesity (extreme);
CESC	cis	rs28680850	0.541	rs28501642	chr8:1379528	G/A	cg06035437	chr8:1398411	NA	-0.49	-5.12	-0.3	5.95e-7	Triglycerides;
CESC	trans	rs1941687	0.527	rs1493914	chr18:31362327	C/T	cg27147174	chr7:100797783	AP1S1	-0.5	-6.71	-0.38	1.16e-10	Subjective well-being (multi-trait analysis);Subjective well-being;
CESC	cis	rs2857078	0.772	rs4793086	chr17:42320751	C/T	cg19774624	chr17:42201019	HDAC5	0.54	7.16	0.4	7.85e-12	Red cell distribution width;Reticulocyte count;
CESC	cis	rs2228479	0.850	rs1800355	chr16:89813194	C/T	cg06558623	chr16:89946397	TCF25	1.15	9.14	0.49	1.65e-17	Skin colour saturation;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14799209	chr7:106809543	HBP1	0.45	6.12	0.35	3.35e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs1862618	1.000	rs1862618	chr5:56096315	C/G	cg12311346	chr5:56204834	C5orf35	-0.71	-8.71	-0.47	3.27e-16	Initial pursuit acceleration;
CESC	cis	rs3008870	0.755	rs1121824	chr1:67475616	C/A	cg02640540	chr1:67518911	SLC35D1	0.45	5.43	0.32	1.25e-7	Lymphocyte percentage of white cells;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg22599477	chr4:25507245	NA	0.47	6.03	0.35	5.51e-9	Fibrinogen levels;
CESC	cis	rs6460942	0.597	rs13221702	chr7:12519076	A/G	cg20607287	chr7:12443886	VWDE	0.68	7.42	0.41	1.58e-12	Coronary artery disease;
CESC	cis	rs514406	0.505	rs440871	chr1:53173052	C/T	cg16325326	chr1:53192061	ZYG11B	0.89	15.2	0.68	5.86e-38	Monocyte count;
CESC	trans	rs17508449	0.819	rs75290614	chr1:114242872	C/T	cg23028848	chr11:57092561	TNKS1BP1	-0.81	-6.39	-0.37	7.62e-10	Leprosy;
CESC	cis	rs7017914	0.967	rs6472538	chr8:71586971	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.09	-0.3	6.93e-7	Bone mineral density;
CESC	cis	rs12497850	0.864	rs4955410	chr3:49181218	A/G	cg02487422	chr3:49467188	NICN1	0.43	5.48	0.32	9.68e-8	Parkinson's disease;
CESC	cis	rs7917772	0.636	rs2249850	chr10:104512006	A/G	cg04362960	chr10:104952993	NT5C2	-0.49	-5.57	-0.32	6.4e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs11112613	0.762	rs17037312	chr12:105950085	C/T	cg03607813	chr12:105948248	NA	0.68	8.4	0.46	2.82e-15	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CESC	cis	rs7584330	0.518	rs74003105	chr2:238446851	T/C	cg14458575	chr2:238380390	NA	0.67	6.29	0.36	1.3e-9	Prostate cancer;
CESC	cis	rs4561483	0.832	rs171656	chr16:11953167	C/T	cg08843971	chr16:11963173	GSPT1	-0.56	-8.06	-0.44	2.56e-14	Testicular germ cell tumor;
CESC	cis	rs873946	0.564	rs2803992	chr10:134550882	T/C	cg26818010	chr10:134567672	INPP5A	-0.76	-9.44	-0.5	2.02e-18	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs12155623	0.619	rs870397	chr8:49861225	C/T	cg22283653	chr8:49824208	NA	0.35	5.11	0.3	6.31e-7	Sudden cardiac arrest;
CESC	cis	rs6480314	0.764	rs2394462	chr10:69981743	A/G	cg06988349	chr10:69991859	ATOH7	-0.33	-5.21	-0.3	3.8e-7	Optic nerve measurement (disc area);
CESC	cis	rs11718455	0.960	rs35869565	chr3:44002394	G/C	cg08738300	chr3:44038990	NA	0.46	6.15	0.35	2.8e-9	Coronary artery disease;
CESC	cis	rs56235845	0.694	rs11949401	chr5:176765989	A/G	cg06060754	chr5:176797920	RGS14	0.42	5.26	0.31	2.91e-7	Hemoglobin concentration;Hematocrit;
CESC	cis	rs12220238	1.000	rs10824102	chr10:75948915	C/A	cg19889307	chr10:75911429	ADK;AP3M1	0.6	5.09	0.3	6.71e-7	Soluble interleukin-2 receptor subunit alpha;
CESC	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.47	-6.85	-0.39	5.15e-11	Longevity;Endometriosis;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg13884470	chr9:86595151	HNRNPK;RMI1	-0.47	-6.57	-0.37	2.69e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs11676348	0.818	rs6436033	chr2:218983763	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.46	-5.98	-0.34	7.31e-9	Ulcerative colitis;
CESC	cis	rs9916302	0.904	rs7210488	chr17:37539819	T/G	cg00129232	chr17:37814104	STARD3	0.57	7.41	0.41	1.71e-12	Glomerular filtration rate (creatinine);
CESC	cis	rs6597981	0.592	rs10902218	chr11:743813	C/T	cg17628894	chr11:804452	LRDD	0.3	6.03	0.35	5.62e-9	Breast cancer;
CESC	cis	rs807669	0.903	rs807666	chr22:19160549	C/T	cg02655711	chr22:19163373	SLC25A1	0.98	14.85	0.67	1e-36	Metabolite levels;
CESC	cis	rs40363	0.723	rs757269	chr16:3538003	A/G	cg22508957	chr16:3507546	NAT15	-0.67	-7.27	-0.41	3.98e-12	Tuberculosis;
CESC	cis	rs9815354	1.000	rs1607908	chr3:41905196	T/G	cg03022575	chr3:42003672	ULK4	0.44	5.16	0.3	4.85e-7	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs1707322	0.650	rs4660879	chr1:46105401	C/A	cg03146154	chr1:46216737	IPP	0.76	10.71	0.55	1.75e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg01961018	chr14:67999752	PLEKHH1	-0.42	-6.3	-0.36	1.26e-9	Gambling;
CESC	cis	rs6460942	0.659	rs13247187	chr7:12551851	T/C	cg20607287	chr7:12443886	VWDE	-0.7	-7.64	-0.42	3.99e-13	Coronary artery disease;
CESC	cis	rs1707322	0.752	rs28719889	chr1:46202283	C/T	cg06784218	chr1:46089804	CCDC17	0.41	7.2	0.4	6.2e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs367615	0.680	rs2256556	chr5:108964907	C/T	cg17395555	chr5:108820864	NA	-0.43	-6.17	-0.35	2.61e-9	Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs10754283	0.756	rs17441836	chr1:90135433	C/T	cg21401794	chr1:90099060	LRRC8C	0.64	8.16	0.45	1.36e-14	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs593982	0.843	rs552312	chr11:65477349	C/T	cg08755490	chr11:65554678	OVOL1	1.17	10.74	0.55	1.45e-22	Atopic dermatitis;
CESC	trans	rs60843830	1.000	rs3828165	chr2:220889	G/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.66	8.02	0.44	3.32e-14	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs1801251	0.963	rs6739638	chr2:233576015	G/A	cg25237894	chr2:233734115	C2orf82	0.5	8.5	0.46	1.39e-15	Coronary artery disease;
CESC	cis	rs6500602	0.627	rs9934267	chr16:4534366	G/C	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.36	5.17	0.3	4.59e-7	Schizophrenia;
CESC	cis	rs636291	0.510	rs1307487	chr1:10506667	G/A	cg07384165	chr1:10488281	NA	-0.58	-8.62	-0.47	6.39e-16	Prostate cancer;
CESC	cis	rs875971	0.862	rs801195	chr7:66026115	A/G	cg18876405	chr7:65276391	NA	-0.53	-7.25	-0.41	4.64e-12	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17267720	chr15:34396248	PGBD4	-0.62	-7.98	-0.44	4.4e-14	Gut microbiome composition (summer);
CESC	cis	rs9911578	1.000	rs12936058	chr17:57017420	T/C	cg12560992	chr17:57184187	TRIM37	0.93	15.33	0.69	2.06e-38	Intelligence (multi-trait analysis);
CESC	trans	rs1994135	0.630	rs11052760	chr12:33724949	A/T	cg26384229	chr12:38710491	ALG10B	0.58	7.82	0.43	1.26e-13	Resting heart rate;
CESC	cis	rs56775891	0.959	rs11663602	chr18:77578191	G/T	cg13263691	chr18:77568018	NA	0.45	6.82	0.39	6.14e-11	Schizophrenia;
CESC	cis	rs155076	1.000	rs261427	chr13:21860998	G/A	cg11317459	chr13:21872234	NA	-1.08	-12.18	-0.6	2.06e-27	White matter hyperintensity burden;
CESC	cis	rs6499255	0.951	rs78772829	chr16:69607098	G/A	cg15192750	chr16:69999425	NA	0.49	5.72	0.33	2.8e-8	IgE levels;
CESC	cis	rs412050	0.501	rs78329092	chr22:22126203	C/T	cg17089214	chr22:22089827	YPEL1	0.65	5.29	0.31	2.53e-7	Attention deficit hyperactivity disorder;
CESC	cis	rs6952808	0.595	rs3778984	chr7:2166514	T/C	cg23048001	chr7:2026167	MAD1L1	0.45	5.88	0.34	1.22e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs8005677	0.926	rs34344888	chr14:23387585	A/G	cg01529538	chr14:23388837	RBM23	0.51	6.87	0.39	4.64e-11	Cognitive ability (multi-trait analysis);
CESC	cis	rs2425143	0.643	rs6058324	chr20:34388789	G/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.68	5.93	0.34	9.19e-9	Blood protein levels;
CESC	cis	rs7193541	0.684	rs4888264	chr16:74681632	T/G	cg01733217	chr16:74700730	RFWD3	1.05	20.24	0.78	1.09e-55	Multiple myeloma;
CESC	cis	rs2841277	0.708	rs28600075	chr14:105408315	T/C	cg15352829	chr14:105391018	PLD4	-0.59	-10.35	-0.54	2.66e-21	Rheumatoid arthritis;
CESC	cis	rs7786877	0.500	rs2272572	chr7:100285888	C/T	cg16850897	chr7:100343110	ZAN	-0.71	-8.68	-0.47	4.13e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs16866061	1.000	rs12470077	chr2:225334971	T/C	cg12698349	chr2:225449008	CUL3	0.71	10.61	0.55	3.75e-22	Acute graft versus host disease in bone marrow transplantation (recipient effect);
CESC	cis	rs2288073	0.965	rs13387930	chr2:24414400	A/G	cg06627628	chr2:24431161	ITSN2	-0.8	-9.85	-0.52	1.03e-19	Venous thromboembolism (SNP x SNP interaction);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg02457282	chr5:121297575	SRFBP1	-0.53	-6.8	-0.39	6.74e-11	Fibrinogen levels;
CESC	trans	rs17211056	0.744	rs2584281	chr18:73347313	C/T	cg05934483	chr2:156763934	NA	-0.65	-6.23	-0.36	1.78e-9	Serum uric acid levels in response to allopurinol in gout;
CESC	cis	rs6502050	0.805	rs4356529	chr17:80157797	A/G	cg23985595	chr17:80112537	CCDC57	0.39	6.24	0.36	1.72e-9	Life satisfaction;
CESC	cis	rs2011503	1.000	rs2965184	chr19:19545428	C/T	cg11584989	chr19:19387371	SF4	-0.61	-7.28	-0.41	3.87e-12	Bipolar disorder;
CESC	cis	rs4718428	0.672	rs36038499	chr7:66289615	A/G	cg12165864	chr7:66369176	NA	-0.64	-7.19	-0.4	6.43e-12	Corneal structure;
CESC	cis	rs896854	0.738	rs481887	chr8:95967838	A/G	cg16049864	chr8:95962084	TP53INP1	0.63	9.79	0.52	1.67e-19	Type 2 diabetes;
CESC	cis	rs7772486	0.754	rs4360151	chr6:146255079	A/C	cg23711669	chr6:146136114	FBXO30	-0.81	-11.61	-0.58	1.87e-25	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4253772	0.513	rs6008612	chr22:46707907	G/A	cg09491104	chr22:46646882	C22orf40	-0.62	-9.1	-0.49	2.17e-17	LDL cholesterol;Cholesterol, total;
CESC	cis	rs9796	0.689	rs692153	chr15:41452681	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.48	-7.13	-0.4	9.77e-12	Menopause (age at onset);
CESC	cis	rs2295359	1.000	rs10889661	chr1:67625309	T/A	cg17031739	chr1:67600172	NA	0.4	5.23	0.31	3.44e-7	Psoriasis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21153026	chr5:130599493	CDC42SE2	0.57	6.3	0.36	1.24e-9	Gut microbiome composition (summer);
CESC	cis	rs60871478	0.679	rs6962050	chr7:817201	A/G	cg00934597	chr7:893267	UNC84A	0.53	5.34	0.31	2.03e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs2688608	0.592	rs10762559	chr10:75486453	G/C	cg23231163	chr10:75533350	FUT11	-0.36	-5.42	-0.32	1.33e-7	Inflammatory bowel disease;
CESC	cis	rs4689592	0.513	rs2358718	chr4:7068743	A/C	cg06697600	chr4:7070879	GRPEL1	0.48	7.4	0.41	1.84e-12	Monocyte percentage of white cells;
CESC	trans	rs3942852	0.955	rs1910364	chr11:48113232	A/G	cg03929089	chr4:120376271	NA	-0.56	-6.02	-0.35	5.85e-9	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs1218582	0.710	rs4845687	chr1:154878911	A/G	cg16680214	chr1:154839983	KCNN3	-0.44	-6.69	-0.38	1.28e-10	Prostate cancer;
CESC	trans	rs2963826	0.589	rs298091	chr5:58996603	A/T	cg18827097	chr2:3522506	ADI1	0.49	6.45	0.37	5.42e-10	Obesity-related traits;
CESC	cis	rs9611565	0.592	rs1811113	chr22:42073134	C/T	cg03806693	chr22:41940476	POLR3H	1.09	12.68	0.61	4.09e-29	Vitiligo;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17548431	chr4:160024475	NA	0.65	7.74	0.43	2.1e-13	Gut microbiome composition (summer);
CESC	cis	rs4654899	0.965	rs17418249	chr1:21390582	C/T	cg05370193	chr1:21551575	ECE1	0.39	5.85	0.34	1.45e-8	Superior frontal gyrus grey matter volume;
CESC	cis	rs28595532	0.702	rs56217716	chr4:119338490	T/G	cg21605333	chr4:119757512	SEC24D	1.01	5.58	0.32	5.98e-8	Cannabis dependence symptom count;
CESC	cis	rs7772486	0.875	rs9376975	chr6:146355581	T/G	cg23711669	chr6:146136114	FBXO30	0.85	12.46	0.61	2.27e-28	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs589448	0.934	rs554591	chr12:69753847	T/C	cg20891283	chr12:69753455	YEATS4	1.0	17.27	0.73	2.72e-45	Cerebrospinal fluid biomarker levels;
CESC	trans	rs687914	0.710	rs938662	chr2:45864578	A/G	cg08286599	chr2:191208694	INPP1	0.6	6.04	0.35	5.31e-9	Diastolic blood pressure;
CESC	cis	rs780096	0.506	rs2950834	chr2:27627366	G/A	cg12648201	chr2:27665141	KRTCAP3	-0.33	-6.22	-0.36	1.93e-9	Total body bone mineral density;
CESC	cis	rs10927875	0.800	rs1627145	chr1:16328116	C/T	cg22431228	chr1:16359049	CLCNKA	-0.49	-8.15	-0.45	1.45e-14	Dilated cardiomyopathy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21451265	chr1:97187319	PTBP2	0.54	6.49	0.37	4.26e-10	Gut microbiome composition (summer);
CESC	cis	rs1348850	0.914	rs7591807	chr2:178252986	A/G	cg23306229	chr2:178417860	TTC30B	0.64	8.07	0.44	2.52e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs718433	0.584	rs7160973	chr14:22216675	C/A	cg02257791	chr14:22217085	NA	-0.32	-5.08	-0.3	7.19e-7	Intraocular pressure;
CESC	cis	rs1451375	0.583	rs3807555	chr7:50610569	A/G	cg14593290	chr7:50529359	DDC	0.49	5.95	0.34	8.34e-9	Malaria;
CESC	cis	rs1879734	0.731	rs72660654	chr1:54157287	C/T	cg23596471	chr1:54105337	GLIS1	0.34	5.6	0.33	5.27e-8	Mitral valve prolapse;
CESC	cis	rs7587476	0.682	rs13009646	chr2:215691259	T/A	cg04004882	chr2:215674386	BARD1	0.53	5.91	0.34	1.05e-8	Neuroblastoma;
CESC	cis	rs7937682	0.924	rs6589244	chr11:111534333	T/C	cg09085632	chr11:111637200	PPP2R1B	-1.01	-16.19	-0.71	1.91e-41	Primary sclerosing cholangitis;
CESC	cis	rs950169	0.922	rs4338765	chr15:84916836	G/T	cg17507749	chr15:85114479	UBE2QP1	0.57	6.29	0.36	1.28e-9	Schizophrenia;
CESC	cis	rs801193	0.569	rs3846973	chr7:66120035	T/C	cg18876405	chr7:65276391	NA	-0.45	-6.21	-0.36	2e-9	Aortic root size;
CESC	cis	rs11098499	0.954	rs9998585	chr4:120396802	T/A	cg24375607	chr4:120327624	NA	0.45	5.67	0.33	3.64e-8	Corneal astigmatism;
CESC	cis	rs6460942	1.000	rs6460942	chr7:12420989	T/C	cg20607287	chr7:12443886	VWDE	-0.74	-8.74	-0.47	2.77e-16	Coronary artery disease;
CESC	cis	rs2243480	1.000	rs316304	chr7:65616894	T/C	cg12463550	chr7:65579703	CRCP	0.74	5.76	0.33	2.34e-8	Diabetic kidney disease;
CESC	trans	rs1814175	0.645	rs28441045	chr11:50048971	C/T	cg03929089	chr4:120376271	NA	-0.91	-14.82	-0.67	1.29e-36	Height;
CESC	cis	rs4975709	0.589	rs4975707	chr5:1864028	C/T	cg12288994	chr5:1860383	NA	0.39	6.63	0.38	1.84e-10	Cardiovascular disease risk factors;
CESC	trans	rs9937837	1.000	rs9937837	chr16:31298939	A/C	cg04903759	chr3:167238645	WDR49	0.49	6.07	0.35	4.3e-9	Systemic lupus erythematosus;
CESC	cis	rs3741151	0.773	rs73544710	chr11:73162273	A/G	cg17517138	chr11:73019481	ARHGEF17	1.0	7.41	0.41	1.74e-12	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs10911251	0.546	rs3768625	chr1:183078712	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.86	13.75	0.65	7.63e-33	Colorectal cancer;
CESC	cis	rs9300255	0.602	rs1402274	chr12:123686224	T/C	cg19016782	chr12:123741754	C12orf65	-0.45	-6.4	-0.37	6.92e-10	Neutrophil percentage of white cells;
CESC	cis	rs3780486	0.846	rs6476399	chr9:33123013	A/G	cg13443165	chr9:33130375	B4GALT1	0.45	6.46	0.37	4.92e-10	IgG glycosylation;
CESC	cis	rs7666738	0.962	rs4699605	chr4:99064379	A/G	cg17366294	chr4:99064904	C4orf37	0.54	7.18	0.4	7.09e-12	Colonoscopy-negative controls vs population controls;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg01509141	chr13:44453359	CCDC122;C13orf31	-0.44	-6.31	-0.36	1.16e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs7666738	0.546	rs1456207	chr4:98676911	G/A	cg17366294	chr4:99064904	C4orf37	0.48	5.84	0.34	1.52e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1218582	0.772	rs10908445	chr1:154849590	A/G	cg03351412	chr1:154909251	PMVK	-0.54	-7.11	-0.4	1.07e-11	Prostate cancer;
CESC	cis	rs2289328	1.000	rs2289328	chr15:40705417	G/A	cg13931752	chr15:40660718	DISP2	0.45	5.22	0.31	3.68e-7	Intelligence (multi-trait analysis);Cognitive ability;Cognitive ability (multi-trait analysis);
CESC	cis	rs2075371	0.897	rs1646733	chr7:134002228	C/A	cg20476274	chr7:133979776	SLC35B4	0.63	8.77	0.47	2.15e-16	Mean platelet volume;
CESC	cis	rs2731664	0.792	rs335432	chr5:176866258	G/A	cg23176889	chr5:176863531	GRK6	-0.64	-10.93	-0.56	3.27e-23	Intelligence (multi-trait analysis);
CESC	trans	rs16949788	1.000	rs75532475	chr15:66832466	A/G	cg08302325	chr6:106551827	PRDM1	0.68	6.09	0.35	3.95e-9	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs4665809	1.000	rs1371553	chr2:26262948	G/A	cg25036284	chr2:26402008	FAM59B	-0.61	-6.94	-0.39	3.06e-11	Gut microbiome composition (summer);
CESC	cis	rs4819052	0.851	rs2838865	chr21:46712299	C/T	cg11663144	chr21:46675770	NA	-0.61	-9.57	-0.51	8e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs1799949	0.773	rs2137990	chr17:41317896	T/A	cg05368731	chr17:41323189	NBR1	-0.59	-8.23	-0.45	8.35e-15	Menopause (age at onset);
CESC	cis	rs7412746	0.658	rs7526489	chr1:150726238	C/T	cg17724175	chr1:150552817	MCL1	0.42	6.48	0.37	4.47e-10	Melanoma;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg04321497	chr2:179391695	TTN;MIR548N	0.41	6.15	0.35	2.86e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs7656342	0.686	rs6822889	chr4:9826757	C/T	cg00071950	chr4:10020882	SLC2A9	0.36	5.05	0.3	8.21e-7	Gut microbiota (bacterial taxa);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03130149	chr11:3819041	PGAP2;NUP98	0.48	6.35	0.36	9.37e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs853679	0.517	rs9393895	chr6:28127621	T/C	cg26335602	chr6:28129616	ZNF389	0.52	6.81	0.39	6.59e-11	Depression;
CESC	cis	rs1801251	0.778	rs778338	chr2:233740227	A/G	cg08000102	chr2:233561755	GIGYF2	-0.6	-8.07	-0.44	2.43e-14	Coronary artery disease;
CESC	cis	rs2637266	0.653	rs846614	chr10:78549265	A/C	cg18941641	chr10:78392320	NA	0.39	7.43	0.41	1.54e-12	Pulmonary function;
CESC	cis	rs12477438	0.798	rs4850891	chr2:99574642	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-10.51	-0.54	7.92e-22	Chronic sinus infection;
CESC	cis	rs1348850	0.872	rs13004955	chr2:178398923	A/T	cg23306229	chr2:178417860	TTC30B	-0.61	-7.34	-0.41	2.62e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs10489525	0.583	rs6691374	chr1:115642818	T/C	cg01522456	chr1:115632236	TSPAN2	0.64	7.44	0.42	1.4e-12	Autism;
CESC	cis	rs2075371	1.000	rs432487	chr7:133990114	T/G	cg11752832	chr7:134001865	SLC35B4	0.54	7.02	0.4	1.88e-11	Mean platelet volume;
CESC	cis	rs7914558	0.966	rs7908280	chr10:104816947	C/G	cg04362960	chr10:104952993	NT5C2	0.47	6.3	0.36	1.23e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs524281	0.861	rs10896091	chr11:65950825	T/C	cg14036092	chr11:66035641	RAB1B	-0.56	-5.57	-0.32	6.24e-8	Electroencephalogram traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24002010	chr19:55741862	TMEM86B;SAPS1	-0.54	-6.13	-0.35	3.16e-9	Gut microbiome composition (summer);
CESC	cis	rs1256061	0.646	rs1256059	chr14:64710417	A/G	cg23250157	chr14:64679961	SYNE2	0.5	7.32	0.41	2.92e-12	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15702823	chr6:10838819	NA	0.58	6.31	0.36	1.19e-9	Gut microbiome composition (summer);
CESC	cis	rs6502050	0.835	rs8067138	chr17:80111026	T/C	cg11859384	chr17:80120422	CCDC57	-0.39	-5.37	-0.31	1.76e-7	Life satisfaction;
CESC	cis	rs9443645	0.527	rs9359362	chr6:79723756	T/C	cg05283184	chr6:79620031	NA	-0.38	-5.51	-0.32	8.57e-8	Intelligence (multi-trait analysis);
CESC	cis	rs2236918	1.000	rs1627006	chr1:242038004	C/T	cg17736920	chr1:242011382	EXO1	0.68	9.02	0.48	3.89e-17	Menopause (age at onset);
CESC	cis	rs123509	0.913	rs121993	chr3:42776601	T/C	cg12982090	chr3:42733453	KBTBD5	0.7	8.44	0.46	2.1e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs1552244	0.882	rs13084194	chr3:10031492	T/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.83	10.05	0.53	2.43e-20	Alzheimer's disease;
CESC	cis	rs875971	1.000	rs6963646	chr7:65685767	T/C	cg11764359	chr7:65958608	NA	-0.92	-14.69	-0.67	3.83e-36	Aortic root size;
CESC	cis	rs425277	0.583	rs4648807	chr1:2040898	A/G	cg23803603	chr1:2058230	PRKCZ	-0.36	-6.58	-0.37	2.55e-10	Height;
CESC	cis	rs3857067	0.934	rs2865336	chr4:95029357	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.5	-7.61	-0.42	4.77e-13	QT interval;
CESC	cis	rs7666738	0.830	rs6811940	chr4:98777898	G/A	cg17366294	chr4:99064904	C4orf37	0.58	8.3	0.45	5.45e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10876993	0.821	rs1629032	chr12:58038686	C/T	cg18357645	chr12:58087776	OS9	0.59	9.08	0.49	2.55e-17	Celiac disease or Rheumatoid arthritis;
CESC	cis	rs13191362	1.000	rs55822577	chr6:163069710	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.88	8.18	0.45	1.18e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs2249625	0.844	rs2496515	chr6:72905741	C/T	cg18830697	chr6:72922368	RIMS1	0.37	5.3	0.31	2.4e-7	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CESC	cis	rs4819052	0.851	rs2236446	chr21:46678985	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.88	12.92	0.62	6.11e-30	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs9486719	1.000	rs11153058	chr6:97012746	C/T	cg06623918	chr6:96969491	KIAA0776	-0.8	-8.3	-0.45	5.39e-15	Migraine;Coronary artery disease;
CESC	cis	rs514406	0.708	rs546334	chr1:53326210	T/C	cg25767906	chr1:53392781	SCP2	-0.52	-7.38	-0.41	2.05e-12	Monocyte count;
CESC	cis	rs959260	1.000	rs4789180	chr17:73374396	G/T	cg20590849	chr17:73267439	MIF4GD	-0.58	-6.61	-0.38	2.14e-10	Systemic lupus erythematosus;
CESC	cis	rs9611565	0.512	rs2050031	chr22:42152266	A/G	cg03806693	chr22:41940476	POLR3H	1.19	14.1	0.65	4.45e-34	Vitiligo;
CESC	cis	rs2033711	0.870	rs6510152	chr19:58953319	C/T	cg00825309	chr19:58991885	ZNF446	-0.58	-8.51	-0.46	1.34e-15	Uric acid clearance;
CESC	cis	rs72781680	1.000	rs12616985	chr2:24165511	A/C	cg20701182	chr2:24300061	SF3B14	0.64	5.74	0.33	2.63e-8	Lymphocyte counts;
CESC	cis	rs6952808	0.636	rs6964522	chr7:1953523	C/T	cg02951883	chr7:2050386	MAD1L1	-0.4	-5.31	-0.31	2.32e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs2404602	0.716	rs12438077	chr15:76863601	T/C	cg22467129	chr15:76604101	ETFA	-0.35	-5.24	-0.31	3.24e-7	Blood metabolite levels;
CESC	cis	rs6009527	1.000	rs737834	chr22:49573190	C/T	cg12746016	chr22:49560550	NA	0.34	5.2	0.3	4.03e-7	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);
CESC	trans	rs3942852	0.568	rs1039484	chr11:48097948	A/G	cg03929089	chr4:120376271	NA	-0.63	-7.77	-0.43	1.71e-13	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs9926296	0.533	rs10852623	chr16:89865242	T/C	cg21285383	chr16:89894308	SPIRE2	0.3	5.49	0.32	9.52e-8	Vitiligo;
CESC	cis	rs9611565	0.659	rs1569516	chr22:41910244	C/T	cg03806693	chr22:41940476	POLR3H	-1.2	-14.96	-0.68	4.1e-37	Vitiligo;
CESC	cis	rs1371867	0.846	rs1788197	chr8:101290928	T/C	cg11906718	chr8:101322791	RNF19A	0.43	5.45	0.32	1.17e-7	Atrioventricular conduction;
CESC	trans	rs629535	0.773	rs655299	chr8:70074534	C/T	cg21567404	chr3:27674614	NA	0.88	10.34	0.54	2.74e-21	Dupuytren's disease;
CESC	cis	rs11792861	0.781	rs17729408	chr9:111740860	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	-0.53	-6.76	-0.38	8.89e-11	Menarche (age at onset);
CESC	trans	rs7726839	0.540	rs72707016	chr5:665148	A/G	cg25482853	chr8:67687455	SGK3	0.97	9.73	0.51	2.43e-19	Obesity-related traits;
CESC	cis	rs9527	0.641	rs34130454	chr10:104903638	A/G	cg04362960	chr10:104952993	NT5C2	0.44	5.54	0.32	7.12e-8	Arsenic metabolism;
CESC	trans	rs2823962	0.759	rs2823930	chr21:18014269	G/A	cg06419850	chr17:4688683	VMO1	-0.42	-6.08	-0.35	4.12e-9	Amyotrophic lateral sclerosis;
CESC	cis	rs5758659	0.652	rs129857	chr22:42399686	C/T	cg15557168	chr22:42548783	NA	0.44	6.54	0.37	3.24e-10	Cognitive function;
CESC	cis	rs1005277	0.579	rs1780115	chr10:38524773	C/T	cg25427524	chr10:38739819	LOC399744	-0.73	-10.95	-0.56	2.97e-23	Extrinsic epigenetic age acceleration;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17757281	chr20:44604666	NA	-0.54	-6.88	-0.39	4.41e-11	Gut microbiome composition (summer);
CESC	cis	rs9291683	0.609	rs55959894	chr4:10026580	G/A	cg11266682	chr4:10021025	SLC2A9	0.7	14.15	0.66	3.01e-34	Bone mineral density;
CESC	trans	rs6828577	0.819	rs298975	chr4:119636395	G/T	cg05098011	chr1:151736092	OAZ3;MRPL9	0.48	6.03	0.35	5.43e-9	Perioperative myocardial infarction in coronary artery bypass surgery;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg07016325	chr14:96968745	PAPOLA	-0.48	-6.28	-0.36	1.4e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.87	13.73	0.64	9.48e-33	Prudent dietary pattern;
CESC	cis	rs3858526	0.883	rs1453429	chr11:5933478	C/T	cg05234568	chr11:5960015	NA	-0.57	-6.76	-0.38	9e-11	DNA methylation (variation);
CESC	trans	rs66573146	0.572	rs67750430	chr4:6957266	T/G	cg07817883	chr1:32538562	TMEM39B	1.25	8.75	0.47	2.56e-16	Granulocyte percentage of myeloid white cells;
CESC	cis	rs10504229	0.728	rs56180705	chr8:58149734	T/C	cg24829409	chr8:58192753	C8orf71	-0.68	-8.19	-0.45	1.09e-14	Developmental language disorder (linguistic errors);
CESC	cis	rs5758659	1.000	rs5751255	chr22:42648408	C/T	cg15557168	chr22:42548783	NA	-0.51	-8.05	-0.44	2.87e-14	Cognitive function;
CESC	cis	rs11098499	0.615	rs59867181	chr4:120556467	C/T	cg09307838	chr4:120376055	NA	-0.63	-8.23	-0.45	8.44e-15	Corneal astigmatism;
CESC	cis	rs244293	0.673	rs12944690	chr17:53029614	A/G	cg19360675	chr17:53046073	COX11;STXBP4	-0.42	-5.6	-0.33	5.26e-8	Menarche (age at onset);
CESC	cis	rs2777491	0.957	rs2015781	chr15:41648967	C/G	cg20272979	chr15:41787780	ITPKA	0.35	5.16	0.3	4.94e-7	Ulcerative colitis;
CESC	cis	rs17253792	0.908	rs74354306	chr14:56065778	T/G	cg01858014	chr14:56050164	KTN1	-0.87	-6.75	-0.38	9.11e-11	Putamen volume;
CESC	cis	rs2228479	0.850	rs12598316	chr16:89916600	C/A	cg06558623	chr16:89946397	TCF25	1.15	8.27	0.45	6.45e-15	Skin colour saturation;
CESC	cis	rs7520050	0.966	rs4660319	chr1:46341623	C/T	cg03146154	chr1:46216737	IPP	-0.49	-6.37	-0.36	8.44e-10	Red blood cell count;Reticulocyte count;
CESC	cis	rs1595825	0.838	rs80172713	chr2:198508044	T/C	cg00982548	chr2:198649783	BOLL	-0.48	-5.12	-0.3	5.91e-7	Ulcerative colitis;
CESC	cis	rs8014204	0.816	rs10144023	chr14:75291531	T/C	cg08847533	chr14:75593920	NEK9	0.41	5.32	0.31	2.19e-7	Caffeine consumption;
CESC	cis	rs477692	0.563	rs12266634	chr10:131412659	G/C	cg05714579	chr10:131428358	MGMT	-0.73	-10.79	-0.55	9.88e-23	Response to temozolomide;
CESC	cis	rs6598955	0.670	rs6663950	chr1:26560131	T/C	cg04990556	chr1:26633338	UBXN11	-0.79	-11.53	-0.58	3.46e-25	Obesity-related traits;
CESC	cis	rs1364705	1.000	rs1364705	chr8:120224806	C/T	cg09273054	chr8:120220131	MAL2	-0.62	-7.31	-0.41	3.25e-12	Hippocampal atrophy;
CESC	cis	rs2282802	0.685	rs4913079	chr5:139683029	A/G	cg26211634	chr5:139558579	C5orf32	0.48	6.99	0.39	2.2e-11	Intelligence (multi-trait analysis);
CESC	cis	rs1348850	0.632	rs10167783	chr2:178519041	G/A	cg22681709	chr2:178499509	PDE11A	-0.59	-8.97	-0.48	5.51e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	trans	rs208520	1.000	rs12209225	chr6:66996443	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.83	9.05	0.49	3.13e-17	Exhaled nitric oxide output;
CESC	cis	rs6460942	0.841	rs62448597	chr7:12449110	G/C	cg19099843	chr7:12443191	VWDE	-0.5	-5.26	-0.31	2.97e-7	Coronary artery disease;
CESC	cis	rs854765	0.547	rs4925135	chr17:17952868	T/C	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.5	-6.33	-0.36	1.03e-9	Total body bone mineral density;
CESC	cis	rs7666738	0.830	rs2098934	chr4:98992403	A/G	cg18180107	chr4:99064573	C4orf37	0.4	5.23	0.31	3.41e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6087990	0.863	rs1569686	chr20:31367079	G/T	cg13636640	chr20:31349939	DNMT3B	0.89	15.66	0.69	1.46e-39	Ulcerative colitis;
CESC	cis	rs72627123	0.867	rs75754154	chr14:74473578	C/A	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.82	5.9	0.34	1.11e-8	Morning vs. evening chronotype;
CESC	cis	rs3741404	0.825	rs11604782	chr11:63946650	G/A	cg04317338	chr11:64019027	PLCB3	0.54	6.4	0.37	7.17e-10	Platelet count;
CESC	cis	rs6076065	0.707	rs2424555	chr20:23417705	A/G	cg11657817	chr20:23433608	CST11	0.39	5.68	0.33	3.62e-8	Facial morphology (factor 15, philtrum width);
CESC	cis	rs7618915	0.508	rs7628578	chr3:52628321	A/T	cg05564831	chr3:52568323	NT5DC2	0.48	7.67	0.43	3.21e-13	Bipolar disorder;
CESC	cis	rs6679073	1.000	rs6679073	chr1:205756484	A/C	cg23034840	chr1:205782522	SLC41A1	0.73	9.57	0.51	7.98e-19	Prostate-specific antigen levels;
CESC	cis	rs7726839	0.540	rs3762951	chr5:662613	C/G	cg16447950	chr5:562315	NA	-0.61	-6.66	-0.38	1.57e-10	Obesity-related traits;
CESC	cis	rs796364	1.000	rs281774	chr2:200814572	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.9	8.98	0.48	5.3e-17	Schizophrenia;
CESC	cis	rs6964587	1.000	rs12666179	chr7:91574110	T/C	cg17063962	chr7:91808500	NA	-0.57	-7.69	-0.43	2.84e-13	Breast cancer;
CESC	cis	rs2249694	0.959	rs4129223	chr10:135403948	A/G	cg19469447	chr10:135341870	CYP2E1	0.36	5.11	0.3	6.24e-7	Obesity-related traits;
CESC	cis	rs4654899	0.680	rs4233274	chr1:21121678	C/T	cg05370193	chr1:21551575	ECE1	0.35	5.25	0.31	3.15e-7	Superior frontal gyrus grey matter volume;
CESC	cis	rs113835537	0.529	rs75003264	chr11:66256099	G/A	cg22134325	chr11:66188745	NPAS4	0.46	7.03	0.4	1.78e-11	Airway imaging phenotypes;
CESC	cis	rs8170	0.603	rs4808621	chr19:17414267	C/T	cg04749549	chr19:17459798	NA	-0.33	-5.33	-0.31	2.15e-7	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
CESC	cis	rs76878669	0.538	rs1785633	chr11:66107527	C/A	cg18002602	chr11:66138449	SLC29A2	0.41	6.75	0.38	9.45e-11	Educational attainment (years of education);
CESC	cis	rs965469	0.947	rs965468	chr20:3381443	C/T	cg25506879	chr20:3388711	C20orf194	-0.58	-6.09	-0.35	3.93e-9	IFN-related cytopenia;
CESC	cis	rs7618915	0.547	rs8906	chr3:52739520	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.49	6.99	0.39	2.23e-11	Bipolar disorder;
CESC	cis	rs13253111	0.624	rs28372101	chr8:28099384	G/T	cg26534493	chr8:28060551	NA	0.46	7.29	0.41	3.66e-12	Childhood body mass index;
CESC	cis	rs7219021	0.770	rs7217007	chr17:46844697	C/T	cg16584676	chr17:46985605	UBE2Z	0.45	5.47	0.32	1.06e-7	Schizophrenia or bipolar disorder;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg19460713	chr2:201170819	SPATS2L	-0.43	-6.06	-0.35	4.65e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs7726839	0.718	rs6887972	chr5:597274	C/G	cg09021430	chr5:549028	NA	-0.44	-6.14	-0.35	3.06e-9	Obesity-related traits;
CESC	trans	rs853679	0.556	rs34588114	chr6:28080628	C/A	cg01620082	chr3:125678407	NA	-0.81	-6.34	-0.36	1.01e-9	Depression;
CESC	cis	rs7605827	0.930	rs3755129	chr2:15523549	T/C	cg19274914	chr2:15703543	NA	0.35	6.27	0.36	1.43e-9	Educational attainment (years of education);
CESC	cis	rs6977660	0.507	rs4721822	chr7:19771693	T/C	cg05791153	chr7:19748676	TWISTNB	0.76	6.91	0.39	3.51e-11	Thyroid stimulating hormone;
CESC	cis	rs2239547	0.522	rs9311485	chr3:52987645	T/G	cg11645453	chr3:52864694	ITIH4	-0.32	-5.37	-0.31	1.69e-7	Schizophrenia;
CESC	cis	rs1552244	1.000	rs9827740	chr3:10120531	T/C	cg00149659	chr3:10157352	C3orf10	0.73	8.89	0.48	9.97e-17	Alzheimer's disease;
CESC	cis	rs4319547	1.000	rs9705654	chr12:123083508	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.55	-6.53	-0.37	3.33e-10	Body mass index;
CESC	cis	rs5753618	0.504	rs9609329	chr22:31966313	A/C	cg02404636	chr22:31891804	SFI1	0.45	6.09	0.35	3.97e-9	Colorectal cancer;
CESC	cis	rs3126085	0.935	rs10888466	chr1:152166223	A/C	cg03465714	chr1:152285911	FLG	0.44	5.42	0.32	1.35e-7	Atopic dermatitis;
CESC	trans	rs11039798	0.588	rs6485857	chr11:48556511	C/A	cg03929089	chr4:120376271	NA	0.62	6.07	0.35	4.44e-9	Axial length;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg26879696	chr10:114206778	VTI1A;ZDHHC6	0.53	7.01	0.4	1.95e-11	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7618915	0.501	rs34739010	chr3:52766122	A/G	cg05564831	chr3:52568323	NT5DC2	0.44	6.83	0.39	5.67e-11	Bipolar disorder;
CESC	cis	rs6942756	0.806	rs6967464	chr7:128909727	T/C	cg02491457	chr7:128862824	NA	0.64	9.27	0.49	6.86e-18	White matter hyperintensity burden;
CESC	cis	rs10751667	0.643	rs10902234	chr11:935578	A/G	cg06064525	chr11:970664	AP2A2	-0.5	-9.97	-0.52	4.29e-20	Alzheimer's disease (late onset);
CESC	cis	rs2742234	0.915	rs2742233	chr10:43610558	C/T	cg15436174	chr10:43711423	RASGEF1A	-0.41	-5.07	-0.3	7.38e-7	Hirschsprung disease;
CESC	cis	rs708547	0.874	rs1713978	chr4:57875879	G/A	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.52	-5.54	-0.32	7.27e-8	Response to bleomycin (chromatid breaks);
CESC	cis	rs4253772	0.638	rs6007845	chr22:46718417	A/T	cg09491104	chr22:46646882	C22orf40	0.54	8.27	0.45	6.76e-15	LDL cholesterol;Cholesterol, total;
CESC	cis	rs698833	1.000	rs698833	chr2:44735438	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.44	5.09	0.3	6.87e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23695184	chr11:1316916	TOLLIP	-0.55	-6.13	-0.35	3.16e-9	Gut microbiome composition (summer);
CESC	cis	rs853679	0.550	rs1225599	chr6:28165190	C/T	cg19592336	chr6:28129416	ZNF389	0.51	7.03	0.4	1.73e-11	Depression;
CESC	cis	rs6860806	0.507	rs200837	chr5:131699958	G/A	cg07395648	chr5:131743802	NA	-0.41	-5.19	-0.3	4.24e-7	Breast cancer;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg03817476	chr2:201727403	CLK1	-0.43	-6.13	-0.35	3.11e-9	Gambling;
CESC	cis	rs57506017	0.585	rs1060700	chr7:12275818	A/G	cg23422036	chr7:12250390	TMEM106B	0.39	5.24	0.31	3.35e-7	Neuroticism;
CESC	cis	rs11792861	0.555	rs4978767	chr9:111762925	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.64	9.74	0.51	2.26e-19	Menarche (age at onset);
CESC	cis	rs13256369	1.000	rs1109619	chr8:8571616	G/T	cg18904891	chr8:8559673	CLDN23	0.69	8.05	0.44	2.89e-14	Obesity-related traits;
CESC	cis	rs3733585	0.699	rs7658170	chr4:9966593	C/T	cg00071950	chr4:10020882	SLC2A9	0.67	10.86	0.56	5.61e-23	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs909002	0.886	rs11807225	chr1:32083193	G/C	cg13919466	chr1:32135498	COL16A1	-0.47	-8.28	-0.45	6.11e-15	Intelligence (multi-trait analysis);
CESC	trans	rs7615952	0.599	rs6766327	chr3:125723677	C/G	cg07211511	chr3:129823064	LOC729375	-0.54	-6.22	-0.36	1.97e-9	Blood pressure (smoking interaction);
CESC	cis	rs10489525	0.583	rs12034918	chr1:115626285	C/T	cg01522456	chr1:115632236	TSPAN2	0.6	6.95	0.39	2.82e-11	Autism;
CESC	cis	rs10791097	0.739	rs12279359	chr11:130730544	G/A	cg09137382	chr11:130731461	NA	0.39	5.86	0.34	1.36e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs8177253	0.829	rs9813689	chr3:133514822	C/T	cg11941060	chr3:133502564	NA	-0.53	-7.01	-0.4	1.95e-11	Iron status biomarkers;
CESC	cis	rs12738007	0.544	rs12408688	chr1:29431072	C/T	cg01925633	chr1:29338769	EPB41	0.35	5.03	0.3	9.04e-7	Schizophrenia;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg01161919	chr16:30750542	SRCAP	0.44	6.18	0.35	2.45e-9	Fibrinogen levels;
CESC	cis	rs9300255	0.537	rs1716182	chr12:123686127	A/C	cg05973401	chr12:123451056	ABCB9	0.5	5.74	0.33	2.53e-8	Neutrophil percentage of white cells;
CESC	cis	rs9768139	0.708	rs11771764	chr7:158119871	A/G	cg25566285	chr7:158114605	PTPRN2	0.48	7.73	0.43	2.31e-13	Calcium levels;
CESC	cis	rs2380220	0.576	rs4498363	chr6:96042338	A/C	cg23517279	chr6:96025343	MANEA	0.54	5.28	0.31	2.74e-7	Behavioural disinhibition (generation interaction);
CESC	cis	rs1499614	1.000	rs60326618	chr7:66166358	G/A	cg13147721	chr7:65941812	NA	-0.94	-8.9	-0.48	9.08e-17	Gout;
CESC	cis	rs10791323	0.628	rs1893850	chr11:133705356	T/C	cg06766960	chr11:133703094	NA	-0.39	-5.6	-0.33	5.25e-8	Childhood ear infection;
CESC	cis	rs6662572	0.737	rs11211206	chr1:46323192	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.44	-5.04	-0.3	8.65e-7	Blood protein levels;
CESC	cis	rs6690583	0.623	rs12030730	chr1:85454109	C/G	cg22153463	chr1:85462885	MCOLN2	0.7	7.02	0.4	1.87e-11	Serum sulfate level;
CESC	trans	rs12229918	0.540	rs10784460	chr12:65863584	C/T	ch.2.195648145F	chr2:195939902	NA	0.49	6.1	0.35	3.81e-9	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
CESC	cis	rs6860806	0.661	rs4705927	chr5:131578608	C/G	cg11843238	chr5:131593191	PDLIM4	0.36	5.24	0.31	3.32e-7	Breast cancer;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg11412766	chr2:55276306	RTN4	-0.4	-6.35	-0.36	9.23e-10	Gambling;
CESC	cis	rs9487051	0.807	rs1915835	chr6:109597483	C/T	cg01475377	chr6:109611718	NA	-0.51	-8.56	-0.47	9.09e-16	Reticulocyte fraction of red cells;
CESC	cis	rs2576037	0.526	rs2510444	chr18:44376849	G/T	cg19077165	chr18:44547161	KATNAL2	-0.52	-7.65	-0.43	3.72e-13	Personality dimensions;
CESC	cis	rs4253772	0.591	rs10854854	chr22:46684706	C/G	cg10541313	chr22:46663664	TTC38	0.61	5.07	0.3	7.65e-7	LDL cholesterol;Cholesterol, total;
CESC	trans	rs116095464	0.558	rs10060089	chr5:205565	G/A	cg00938859	chr5:1591904	SDHAP3	0.66	6.26	0.36	1.55e-9	Breast cancer;
CESC	cis	rs514406	0.698	rs511599	chr1:53362818	T/C	cg08736216	chr1:53307985	ZYG11A	-0.38	-6.48	-0.37	4.45e-10	Monocyte count;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg05927802	chr8:110346885	ENY2;NUDCD1	-0.38	-6.0	-0.35	6.6e-9	Gambling;
CESC	cis	rs9457247	0.935	rs9348211	chr6:167375173	G/C	cg25258033	chr6:167368657	RNASET2	-0.4	-6.11	-0.35	3.49e-9	Crohn's disease;
CESC	cis	rs6570726	0.818	rs399516	chr6:145810849	C/A	cg23711669	chr6:146136114	FBXO30	0.88	13.31	0.63	2.77e-31	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6785206	0.667	rs2253125	chr3:128329793	T/C	cg16766828	chr3:128327626	NA	-0.44	-5.13	-0.3	5.56e-7	Lymphocyte percentage of white cells;
CESC	cis	rs5753618	0.561	rs1858821	chr22:31676454	T/C	cg00478049	chr22:31556069	RNF185	0.46	5.21	0.3	3.75e-7	Colorectal cancer;
CESC	cis	rs1348850	0.651	rs4893935	chr2:178240601	C/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.61	8.32	0.45	4.84e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03870845	chr17:52978014	TOM1L1	0.57	6.93	0.39	3.2e-11	Gut microbiome composition (summer);
CESC	cis	rs6952808	0.689	rs4719391	chr7:2048136	T/C	cg05863683	chr7:1912471	MAD1L1	0.47	7.07	0.4	1.37e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs2836633	0.965	rs2836621	chr21:40054149	C/T	cg12884169	chr21:40033163	ERG	0.36	5.79	0.34	1.95e-8	Coronary artery disease;
CESC	cis	rs78456975	0.941	rs13423300	chr2:1553809	C/A	cg01028140	chr2:1542097	TPO	-0.5	-5.26	-0.31	3.03e-7	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs863345	0.504	rs857698	chr1:158561166	A/T	cg12129480	chr1:158549410	OR10X1	-0.3	-5.58	-0.32	6.04e-8	Pneumococcal bacteremia;
CESC	cis	rs7605827	0.930	rs1990753	chr2:15612403	G/C	cg19274914	chr2:15703543	NA	0.35	6.13	0.35	3.19e-9	Educational attainment (years of education);
CESC	cis	rs9611519	0.589	rs8138917	chr22:41412425	T/C	cg03806693	chr22:41940476	POLR3H	-0.51	-6.04	-0.35	5.11e-9	Neuroticism;
CESC	cis	rs3096299	0.746	rs9931120	chr16:89501357	A/G	cg08822215	chr16:89438651	ANKRD11	-0.36	-5.31	-0.31	2.34e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs1957429	0.614	rs73279833	chr14:65352523	A/G	cg23373153	chr14:65346875	NA	-0.92	-6.68	-0.38	1.43e-10	Pediatric areal bone mineral density (radius);
CESC	cis	rs17253792	0.822	rs74653073	chr14:56079528	T/C	cg01858014	chr14:56050164	KTN1	-0.93	-7.29	-0.41	3.53e-12	Putamen volume;
CESC	cis	rs7336332	0.662	rs9581862	chr13:28039993	T/G	cg22138327	chr13:27999177	GTF3A	0.64	7.1	0.4	1.16e-11	Weight;
CESC	cis	rs9487051	0.768	rs2483913	chr6:109521042	G/A	cg01475377	chr6:109611718	NA	-0.46	-6.93	-0.39	3.18e-11	Reticulocyte fraction of red cells;
CESC	cis	rs7666738	0.800	rs28427190	chr4:98989106	A/G	cg03467027	chr4:99064603	C4orf37	0.44	5.56	0.32	6.57e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11190604	1.000	rs10883499	chr10:102232188	T/A	cg07080220	chr10:102295463	HIF1AN	0.55	5.56	0.32	6.43e-8	Palmitoleic acid (16:1n-7) levels;
CESC	trans	rs10242455	0.702	rs73403247	chr7:99088730	G/A	cg09045935	chr12:6379348	NA	0.89	7.38	0.41	2.01e-12	Blood metabolite levels;
CESC	cis	rs597539	0.652	rs488363	chr11:68658298	C/G	cg21963583	chr11:68658836	MRPL21	0.38	5.47	0.32	1.03e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs769267	0.930	rs751856	chr19:19602945	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.46	5.96	0.34	8.05e-9	Tonsillectomy;
CESC	cis	rs3733585	0.673	rs4519796	chr4:9955936	A/G	cg02734326	chr4:10020555	SLC2A9	-0.4	-5.77	-0.33	2.19e-8	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs796364	0.906	rs1658810	chr2:200816382	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.91	9.08	0.49	2.59e-17	Schizophrenia;
CESC	cis	rs13082711	0.911	rs17019721	chr3:27424799	A/G	cg02860705	chr3:27208620	NA	0.52	6.53	0.37	3.36e-10	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CESC	cis	rs9467711	0.606	rs12174602	chr6:26372827	C/T	cg14345882	chr6:26364793	BTN3A2	0.59	6.07	0.35	4.33e-9	Autism spectrum disorder or schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03069383	chr2:18741691	RDH14	0.57	6.61	0.38	2.16e-10	Gut microbiome composition (summer);
CESC	cis	rs4481887	0.927	rs4537599	chr1:248508741	G/A	cg00666640	chr1:248458726	OR2T12	0.41	6.62	0.38	1.97e-10	Common traits (Other);
CESC	cis	rs769267	0.895	rs2965183	chr19:19545696	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.47	5.94	0.34	8.83e-9	Tonsillectomy;
CESC	cis	rs3785574	0.962	rs2727329	chr17:61924566	C/T	cg06873352	chr17:61820015	STRADA	0.47	6.77	0.38	8.31e-11	Height;
CESC	trans	rs11098499	0.954	rs28429722	chr4:120300093	G/A	cg25214090	chr10:38739885	LOC399744	0.68	9.2	0.49	1.14e-17	Corneal astigmatism;
CESC	cis	rs7202877	0.610	rs3844219	chr16:75370230	G/T	cg04384234	chr16:75411784	CFDP1	-0.47	-5.57	-0.32	6.39e-8	Type 2 diabetes;Type 1 diabetes;
CESC	cis	rs4704187	0.687	rs9918293	chr5:74514828	T/C	cg03227963	chr5:74354835	NA	0.28	5.13	0.3	5.48e-7	Response to amphetamines;
CESC	cis	rs6714710	0.603	rs12988571	chr2:98405695	C/T	cg26665480	chr2:98280029	ACTR1B	0.59	8.24	0.45	7.8e-15	Posterior cortical atrophy and Alzheimer's disease;
CESC	cis	rs4955124	0.558	rs4502621	chr3:32019900	C/G	cg05935571	chr3:32023257	ZNF860;OSBPL10	0.94	8.49	0.46	1.54e-15	Schizophrenia;
CESC	cis	rs137603	0.502	rs137627	chr22:39716341	G/A	cg01093212	chr22:39715156	SNORD43;RPL3	-0.42	-5.45	-0.32	1.15e-7	Primary biliary cholangitis;
CESC	trans	rs11039798	0.920	rs116109043	chr11:48976940	C/T	cg15704280	chr7:45808275	SEPT13	0.7	6.56	0.37	2.74e-10	Axial length;
CESC	cis	rs3780486	0.813	rs3780488	chr9:33133812	T/C	cg13443165	chr9:33130375	B4GALT1	0.46	6.59	0.38	2.3e-10	IgG glycosylation;
CESC	cis	rs763014	0.931	rs7199839	chr16:636126	T/C	cg00908189	chr16:619842	PIGQ	0.65	9.02	0.48	4.04e-17	Height;
CESC	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.87	12.78	0.62	1.9e-29	Prudent dietary pattern;
CESC	cis	rs5750830	0.621	rs5750810	chr22:39792943	A/G	cg01416388	chr22:39784598	NA	-0.57	-7.42	-0.41	1.62e-12	Intelligence (multi-trait analysis);
CESC	cis	rs8133932	0.576	rs2839039	chr21:47321499	T/G	cg14185626	chr21:47401492	COL6A1	0.46	5.11	0.3	6.08e-7	Schizophrenia;
CESC	cis	rs7089973	0.604	rs11196952	chr10:116607592	G/A	cg03647239	chr10:116582469	FAM160B1	0.43	5.35	0.31	1.94e-7	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs597539	0.690	rs7129960	chr11:68622456	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.79	9.39	0.5	2.91e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs2228479	0.850	rs2239358	chr16:89827330	C/G	cg06558623	chr16:89946397	TCF25	1.17	9.29	0.5	5.76e-18	Skin colour saturation;
CESC	cis	rs7937682	0.889	rs521155	chr11:111492563	G/A	cg22437258	chr11:111473054	SIK2	0.72	9.66	0.51	4.24e-19	Primary sclerosing cholangitis;
CESC	cis	rs7666738	0.830	rs7687958	chr4:99014495	T/C	cg03676636	chr4:99064102	C4orf37	0.33	5.16	0.3	4.86e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs28830936	0.510	rs12440605	chr15:42102285	A/G	cg11010575	chr15:42129464	JMJD7-PLA2G4B;JMJD7	0.32	5.06	0.3	7.67e-7	Diastolic blood pressure;
CESC	cis	rs6061231	1.000	rs67941642	chr20:60958108	C/T	cg24112000	chr20:60950667	NA	-0.56	-7.79	-0.43	1.52e-13	Colorectal cancer;
CESC	cis	rs9581857	0.725	rs9319366	chr13:28017722	C/T	cg22138327	chr13:27999177	GTF3A	0.65	5.22	0.31	3.6e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11588710	chr3:191670637	NA	-0.56	-6.45	-0.37	5.32e-10	Gut microbiome composition (summer);
CESC	cis	rs1862618	0.853	rs43184	chr5:56141777	G/C	cg24549020	chr5:56110836	MAP3K1	0.68	7.72	0.43	2.37e-13	Initial pursuit acceleration;
CESC	cis	rs6598955	0.515	rs61776655	chr1:26541430	T/C	cg19743891	chr1:26644573	UBXN11;CD52	-0.27	-5.21	-0.31	3.73e-7	Obesity-related traits;
CESC	cis	rs1018836	0.923	rs2213886	chr8:91554163	G/C	cg16814680	chr8:91681699	NA	-0.72	-10.63	-0.55	3.14e-22	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	trans	rs11098499	0.779	rs10011097	chr4:120310359	T/G	cg25214090	chr10:38739885	LOC399744	0.68	9.2	0.49	1.14e-17	Corneal astigmatism;
CESC	cis	rs7586879	0.616	rs6545814	chr2:25131316	A/G	cg01884057	chr2:25150051	NA	0.36	6.97	0.39	2.55e-11	Body mass index;
CESC	cis	rs7945705	0.935	rs2568061	chr11:8886260	A/G	cg12365402	chr11:9010492	NRIP3	-0.32	-5.07	-0.3	7.37e-7	Hemoglobin concentration;
CESC	cis	rs5771225	0.505	rs2341111	chr22:50690322	G/C	cg16473166	chr22:50639996	SELO	0.47	5.22	0.31	3.56e-7	Late-onset Alzheimer's disease;
CESC	cis	rs17433780	0.897	rs12142922	chr1:89489915	A/G	cg09516651	chr1:89888402	LOC400759	0.68	9.49	0.5	1.43e-18	Carotid intima media thickness;
CESC	cis	rs7666738	0.687	rs6839454	chr4:99073914	T/C	cg17366294	chr4:99064904	C4orf37	0.59	8.08	0.44	2.29e-14	Colonoscopy-negative controls vs population controls;
CESC	cis	rs597539	0.652	rs579136	chr11:68637476	C/G	cg21963583	chr11:68658836	MRPL21	0.4	5.52	0.32	8.06e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs10489525	0.583	rs6660550	chr1:115650850	C/G	cg01522456	chr1:115632236	TSPAN2	0.6	6.87	0.39	4.5e-11	Autism;
CESC	cis	rs875971	0.522	rs4718285	chr7:65292005	A/G	cg06456125	chr7:65229604	NA	0.44	5.75	0.33	2.47e-8	Aortic root size;
CESC	cis	rs7666738	0.830	rs11097605	chr4:98985167	T/C	cg18180107	chr4:99064573	C4orf37	0.39	5.13	0.3	5.6e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg07677032	chr17:61819896	STRADA	0.45	5.97	0.34	7.74e-9	Prudent dietary pattern;
CESC	cis	rs938554	0.784	rs11726102	chr4:9951664	T/C	cg00071950	chr4:10020882	SLC2A9	-0.5	-5.82	-0.34	1.7e-8	Blood metabolite levels;
CESC	cis	rs1538970	1.000	rs9326141	chr1:45828943	A/G	cg05343316	chr1:45956843	TESK2	-0.83	-11.33	-0.57	1.53e-24	Platelet count;
CESC	trans	rs208515	0.518	rs12209790	chr6:66662965	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.87	10.74	0.55	1.42e-22	Exhaled nitric oxide levels;
CESC	cis	rs6460942	1.000	rs7792759	chr7:12311715	A/G	cg10578991	chr7:12443926	VWDE	0.51	5.51	0.32	8.58e-8	Coronary artery disease;
CESC	cis	rs208520	0.802	rs4710314	chr6:66883656	G/A	cg07460842	chr6:66804631	NA	-0.94	-12.15	-0.6	2.75e-27	Exhaled nitric oxide output;
CESC	cis	rs3105593	1.000	rs3105593	chr15:50845018	C/T	cg08437265	chr15:50716283	USP8	0.45	5.74	0.33	2.63e-8	QT interval;
CESC	cis	rs514406	0.621	rs2003250	chr1:53196666	T/C	cg08859206	chr1:53392774	SCP2	0.56	7.11	0.4	1.1e-11	Monocyte count;
CESC	cis	rs2404602	0.692	rs60658665	chr15:77042508	T/C	cg22467129	chr15:76604101	ETFA	-0.34	-5.16	-0.3	4.84e-7	Blood metabolite levels;
CESC	cis	rs2836950	0.762	rs8134638	chr21:40644170	T/C	cg11644478	chr21:40555479	PSMG1	-0.58	-7.17	-0.4	7.64e-12	Menarche (age at onset);
CESC	cis	rs8031584	0.736	rs11635775	chr15:31160640	A/G	cg08109568	chr15:31115862	NA	-0.68	-9.08	-0.49	2.54e-17	Huntington's disease progression;
CESC	cis	rs9905704	0.718	rs1271647	chr17:56655872	G/C	cg12560992	chr17:57184187	TRIM37	-0.64	-5.98	-0.34	7.36e-9	Testicular germ cell tumor;
CESC	cis	rs7772486	0.686	rs857879	chr6:145974043	C/A	cg23711669	chr6:146136114	FBXO30	-0.88	-13.04	-0.63	2.31e-30	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs8017423	0.605	rs4904676	chr14:90819220	G/A	cg14092571	chr14:90743983	NA	0.44	6.62	0.38	1.93e-10	Mortality in heart failure;
CESC	cis	rs7605827	0.930	rs6759785	chr2:15529269	A/C	cg19274914	chr2:15703543	NA	0.36	6.59	0.38	2.3e-10	Educational attainment (years of education);
CESC	cis	rs2073300	1.000	rs6137957	chr20:23437384	G/A	cg12062639	chr20:23401060	NAPB	0.87	5.85	0.34	1.43e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs9457247	0.967	rs2149092	chr6:167372978	C/T	cg23791538	chr6:167370224	RNASET2	0.6	8.49	0.46	1.53e-15	Crohn's disease;
CESC	cis	rs7605827	0.836	rs4396685	chr2:15634407	C/T	cg19274914	chr2:15703543	NA	0.35	6.23	0.36	1.83e-9	Educational attainment (years of education);
CESC	trans	rs877282	0.583	rs10904562	chr10:819058	T/C	cg22713356	chr15:30763199	NA	1.06	9.67	0.51	3.87e-19	Uric acid levels;
CESC	cis	rs897984	0.806	rs4889571	chr16:30949047	A/G	cg02466173	chr16:30829666	NA	0.48	8.01	0.44	3.58e-14	Dementia with Lewy bodies;
CESC	cis	rs10504073	0.584	rs55908480	chr8:49923431	G/A	cg00325661	chr8:49890786	NA	0.53	7.95	0.44	5.42e-14	Blood metabolite ratios;
CESC	cis	rs7937682	0.883	rs1789351	chr11:111456436	T/A	cg09085632	chr11:111637200	PPP2R1B	-0.93	-13.43	-0.64	1.06e-31	Primary sclerosing cholangitis;
CESC	cis	rs2130392	1.000	rs4862406	chr4:185629339	G/A	cg21366198	chr4:185655624	MLF1IP	0.43	6.06	0.35	4.64e-9	Kawasaki disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08352268	chr17:6947337	SLC16A11	-0.51	-6.18	-0.35	2.46e-9	Gut microbiome composition (summer);
CESC	cis	rs17376456	0.825	rs17372615	chr5:93124768	C/T	cg25358565	chr5:93447407	FAM172A	1.1	10.84	0.55	6.88e-23	Diabetic retinopathy;
CESC	cis	rs7927771	0.524	rs11039345	chr11:47720228	A/G	cg20307385	chr11:47447363	PSMC3	0.61	8.61	0.47	6.76e-16	Subjective well-being;
CESC	cis	rs13385	0.769	rs10477333	chr5:139617885	T/C	cg26211634	chr5:139558579	C5orf32	0.48	5.29	0.31	2.54e-7	Atrial fibrillation;
CESC	cis	rs9467711	0.659	rs13220261	chr6:26499185	C/T	cg14345882	chr6:26364793	BTN3A2	0.62	5.11	0.3	6.12e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs6142102	0.517	rs8119076	chr20:32525715	A/G	cg08999081	chr20:33150536	PIGU	0.35	5.26	0.31	3.03e-7	Skin pigmentation;
CESC	cis	rs2274273	0.773	rs8006525	chr14:55813394	T/G	cg04306507	chr14:55594613	LGALS3	0.32	6.31	0.36	1.19e-9	Protein biomarker;
CESC	cis	rs4906332	1.000	rs35366629	chr14:103903054	A/G	cg09975044	chr14:104007538	NA	0.47	6.56	0.37	2.79e-10	Coronary artery disease;
CESC	cis	rs35110281	0.806	rs1454649	chr21:45032982	C/T	cg21573476	chr21:45109991	RRP1B	-0.49	-6.79	-0.38	7.52e-11	Mean corpuscular volume;
CESC	cis	rs6688613	0.765	rs56229522	chr1:166816108	T/A	ch.1.3259774R	chr1:166827647	TADA1	0.6	6.27	0.36	1.5e-9	Refractive astigmatism;
CESC	cis	rs7937682	0.883	rs1789351	chr11:111456436	T/A	cg22437258	chr11:111473054	SIK2	0.71	9.07	0.49	2.69e-17	Primary sclerosing cholangitis;
CESC	cis	rs1799949	1.000	rs12944458	chr17:41180772	C/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.39	5.13	0.3	5.51e-7	Menopause (age at onset);
CESC	cis	rs875971	0.895	rs6460300	chr7:65952924	A/G	cg11764359	chr7:65958608	NA	0.96	15.03	0.68	2.41e-37	Aortic root size;
CESC	cis	rs17253792	0.732	rs8017891	chr14:56172967	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	-0.69	-5.95	-0.34	8.65e-9	Putamen volume;
CESC	cis	rs2576037	0.583	rs501062	chr18:44411135	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.77	12.78	0.62	1.89e-29	Personality dimensions;
CESC	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.41	-5.26	-0.31	2.98e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs4474465	0.562	rs10793318	chr11:78215898	A/C	cg27205649	chr11:78285834	NARS2	0.44	5.27	0.31	2.84e-7	Alzheimer's disease (survival time);
CESC	cis	rs826838	1.000	rs11169031	chr12:39056738	T/C	cg26384229	chr12:38710491	ALG10B	0.81	13.7	0.64	1.14e-32	Heart rate;
CESC	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.55	-6.16	-0.35	2.62e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs8016947	0.506	rs7157054	chr14:35785129	G/A	cg16230307	chr14:35515116	FAM177A1	-0.42	-5.27	-0.31	2.77e-7	Psoriasis;
CESC	cis	rs3820068	0.581	rs72645881	chr1:15928203	C/T	cg16988262	chr1:15930761	NA	0.35	5.65	0.33	4.18e-8	Systolic blood pressure;
CESC	cis	rs9322193	0.884	rs933055	chr6:150130837	A/G	cg05861140	chr6:150128134	PCMT1	-0.37	-5.33	-0.31	2.07e-7	Lung cancer;
CESC	cis	rs7824557	1.000	rs2736371	chr8:11105529	A/G	cg21775007	chr8:11205619	TDH	-0.38	-5.34	-0.31	1.96e-7	Retinal vascular caliber;
CESC	cis	rs8077577	0.747	rs12449313	chr17:18221010	A/G	cg16794390	chr17:18148240	FLII	0.4	6.34	0.36	9.98e-10	Obesity-related traits;
CESC	cis	rs2033711	0.870	rs11084545	chr19:58951693	G/C	cg11952622	chr19:58962976	ZNF324B	0.5	6.85	0.39	5.17e-11	Uric acid clearance;
CESC	cis	rs7666738	0.830	rs1426666	chr4:99030887	A/G	cg18180107	chr4:99064573	C4orf37	0.42	5.43	0.32	1.29e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2637266	0.703	rs846579	chr10:78498535	G/C	cg18941641	chr10:78392320	NA	0.39	7.5	0.42	9.94e-13	Pulmonary function;
CESC	cis	rs6541297	0.941	rs6690424	chr1:230278892	C/T	cg20703242	chr1:230279135	GALNT2	0.68	10.87	0.56	5.47e-23	Coronary artery disease;
CESC	cis	rs9486719	0.947	rs12194971	chr6:96911073	T/C	cg18709589	chr6:96969512	KIAA0776	-0.54	-5.97	-0.34	7.42e-9	Migraine;Coronary artery disease;
CESC	cis	rs9649465	1.000	rs2109724	chr7:123325391	C/T	cg04330084	chr7:123175371	IQUB	-0.38	-5.22	-0.31	3.69e-7	Migraine;
CESC	cis	rs9790314	0.905	rs7633186	chr3:161003124	A/G	cg03342759	chr3:160939853	NMD3	-0.46	-6.12	-0.35	3.33e-9	Morning vs. evening chronotype;
CESC	cis	rs7408868	0.908	rs1044006	chr19:15285052	T/C	cg14696996	chr19:15285081	NOTCH3	1.09	11.5	0.58	4.26e-25	Pulse pressure;
CESC	cis	rs875971	0.545	rs1638735	chr7:66095738	C/T	cg11764359	chr7:65958608	NA	0.72	8.59	0.47	7.82e-16	Aortic root size;
CESC	cis	rs10504229	1.000	rs3814486	chr8:58191226	A/T	cg24829409	chr8:58192753	C8orf71	-0.76	-9.93	-0.52	5.87e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs10479542	0.784	rs7703730	chr5:178986632	C/A	cg22764044	chr5:178986830	RUFY1	-0.43	-6.2	-0.36	2.14e-9	Lung cancer;
CESC	cis	rs35110281	0.837	rs7279958	chr21:45016016	C/A	cg21573476	chr21:45109991	RRP1B	-0.45	-6.37	-0.36	8.28e-10	Mean corpuscular volume;
CESC	cis	rs7605827	0.930	rs6705287	chr2:15529368	A/C	cg19274914	chr2:15703543	NA	0.37	6.74	0.38	9.98e-11	Educational attainment (years of education);
CESC	cis	rs898097	0.841	rs11656358	chr17:80853956	G/A	cg10494973	chr17:80897199	TBCD	0.5	5.73	0.33	2.65e-8	Breast cancer;
CESC	cis	rs367615	0.959	rs4957830	chr5:108911758	G/T	cg17395555	chr5:108820864	NA	0.51	7.48	0.42	1.11e-12	Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs35110281	0.633	rs4819289	chr21:45120237	A/G	cg04455712	chr21:45112962	RRP1B	0.49	7.59	0.42	5.47e-13	Mean corpuscular volume;
CESC	cis	rs10911363	0.592	rs10797886	chr1:183479090	T/C	cg09173681	chr1:183549694	NCF2	0.52	7.84	0.43	1.12e-13	Systemic lupus erythematosus;
CESC	cis	rs7927592	0.913	rs6591340	chr11:68297636	A/G	cg20283391	chr11:68216788	NA	-0.63	-7.58	-0.42	5.67e-13	Total body bone mineral density;
CESC	cis	rs10779751	0.770	rs12075896	chr1:11200350	C/A	cg08854313	chr1:11322531	MTOR	-0.74	-8.99	-0.48	4.74e-17	Body mass index;
CESC	cis	rs7107174	1.000	rs55761949	chr11:77993860	A/G	cg02023728	chr11:77925099	USP35	0.48	6.64	0.38	1.74e-10	Testicular germ cell tumor;
CESC	cis	rs7098414	0.511	rs7899513	chr10:82150559	G/A	cg00277334	chr10:82204260	NA	-0.5	-7.5	-0.42	9.84e-13	Post bronchodilator FEV1;
CESC	cis	rs7659604	1.000	rs10016433	chr4:122664771	A/G	cg19671926	chr4:122722719	EXOSC9	-0.44	-5.3	-0.31	2.49e-7	Type 2 diabetes;
CESC	cis	rs2549003	1.000	rs2070727	chr5:131820275	C/A	cg21138405	chr5:131827807	IRF1	0.54	9.24	0.49	8.12e-18	Asthma (sex interaction);
CESC	cis	rs7772486	0.790	rs7753092	chr6:146248863	C/T	cg23711669	chr6:146136114	FBXO30	-0.93	-13.61	-0.64	2.34e-32	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9916302	0.706	rs439537	chr17:37734482	T/C	cg00129232	chr17:37814104	STARD3	-0.6	-6.11	-0.35	3.53e-9	Glomerular filtration rate (creatinine);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12799349	chr18:9475500	RALBP1	0.5	6.3	0.36	1.21e-9	Gut microbiome composition (summer);
CESC	cis	rs2635047	1.000	rs2684841	chr18:44724262	C/T	cg24371990	chr18:44770781	NA	0.34	5.46	0.32	1.07e-7	Educational attainment;
CESC	cis	rs11997175	0.520	rs6994803	chr8:33817796	A/G	ch.8.33884649F	chr8:33765107	NA	0.59	7.38	0.41	2.05e-12	Body mass index;
CESC	cis	rs6489785	0.509	rs3213570	chr12:121222411	C/G	cg02419362	chr12:121203948	SPPL3	0.35	5.72	0.33	2.88e-8	Longevity;Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs7089973	0.604	rs7919649	chr10:116609576	T/C	cg03647239	chr10:116582469	FAM160B1	0.45	5.62	0.33	4.93e-8	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs3820928	0.845	rs2177596	chr2:227890283	A/T	cg05526886	chr2:227700861	RHBDD1	-0.43	-5.47	-0.32	1.04e-7	Pulmonary function;
CESC	cis	rs7089973	0.872	rs7072356	chr10:116634651	T/C	cg23260525	chr10:116636907	FAM160B1	0.37	6.25	0.36	1.67e-9	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs225245	0.782	rs321601	chr17:33892087	A/C	cg05299278	chr17:33885742	SLFN14	-0.38	-5.53	-0.32	7.64e-8	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
CESC	cis	rs1152591	0.562	rs872227	chr14:64656165	T/C	cg21174375	chr14:64681225	SYNE2	0.56	8.15	0.45	1.49e-14	Atrial fibrillation;
CESC	cis	rs921968	0.565	rs6733892	chr2:219616002	C/A	cg02176678	chr2:219576539	TTLL4	-0.47	-8.63	-0.47	5.97e-16	Mean corpuscular hemoglobin concentration;
CESC	cis	rs9649213	0.613	rs6961129	chr7:97975542	T/G	cg24562669	chr7:97807699	LMTK2	0.51	7.63	0.42	4.29e-13	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg02951883	chr7:2050386	MAD1L1	-0.45	-5.87	-0.34	1.31e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs7429990	0.965	rs4296617	chr3:48068308	T/C	cg11946769	chr3:48343235	NME6	-0.5	-6.09	-0.35	4.02e-9	Educational attainment (years of education);
CESC	cis	rs4625783	0.583	rs11077974	chr17:80095193	A/G	cg11859384	chr17:80120422	CCDC57	-0.38	-5.14	-0.3	5.29e-7	Blood metabolite levels;
CESC	cis	rs62229266	0.618	rs11088334	chr21:37466829	A/T	cg08632701	chr21:37451849	NA	-0.46	-6.26	-0.36	1.57e-9	Mitral valve prolapse;
CESC	cis	rs8067545	0.750	rs7223305	chr17:19990986	A/G	cg13482628	chr17:19912719	NA	0.37	5.09	0.3	6.81e-7	Schizophrenia;
CESC	cis	rs7918232	0.941	rs4749230	chr10:27441218	C/T	cg14240646	chr10:27532245	ACBD5	-0.65	-6.43	-0.37	5.89e-10	Breast cancer;
CESC	cis	rs6687430	0.512	rs11121587	chr1:10618109	A/G	cg20482658	chr1:10539492	PEX14	0.4	8.15	0.45	1.46e-14	Hand grip strength;
CESC	cis	rs9486715	1.000	rs6899647	chr6:97065661	A/G	cg18709589	chr6:96969512	KIAA0776	-0.46	-6.48	-0.37	4.56e-10	Headache;
CESC	cis	rs425277	0.606	rs451061	chr1:2075068	C/G	cg19257562	chr1:2043853	PRKCZ	-0.32	-5.23	-0.31	3.46e-7	Height;
CESC	cis	rs7296418	0.961	rs4148863	chr12:123569375	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.33	-5.32	-0.31	2.23e-7	Platelet count;
CESC	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg03188948	chr7:1209495	NA	0.69	6.69	0.38	1.33e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs6032067	0.852	rs17424613	chr20:43806441	C/T	cg10761708	chr20:43804764	PI3	0.53	6.33	0.36	1.04e-9	Blood protein levels;
CESC	cis	rs2985684	0.625	rs4900931	chr14:50022793	A/T	cg04989706	chr14:50066350	PPIL5	-0.45	-5.18	-0.3	4.43e-7	Carotid intima media thickness;
CESC	cis	rs6912958	0.525	rs59322	chr6:88020521	C/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.5	8.34	0.46	4.21e-15	Monocyte percentage of white cells;
CESC	cis	rs1799949	0.860	rs8176279	chr17:41210396	A/C	cg25072359	chr17:41440525	NA	0.47	6.91	0.39	3.6e-11	Menopause (age at onset);
CESC	cis	rs916888	0.738	rs199515	chr17:44856641	C/G	cg14517863	chr17:44321492	NA	-0.41	-5.42	-0.32	1.33e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs7666738	0.830	rs1111541	chr4:99033860	A/G	cg05340658	chr4:99064831	C4orf37	-0.83	-12.78	-0.62	1.81e-29	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1348850	0.651	rs4893935	chr2:178240601	C/G	cg22681709	chr2:178499509	PDE11A	-0.35	-5.35	-0.31	1.92e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	trans	rs1814175	0.645	rs1851853	chr11:49953434	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.43	-6.26	-0.36	1.53e-9	Height;
CESC	cis	rs3785574	0.962	rs35448669	chr17:61938923	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.08	19.85	0.77	2.44e-54	Height;
CESC	cis	rs4455778	0.600	rs4244233	chr7:49130572	T/A	cg26309511	chr7:48887640	NA	0.34	5.12	0.3	5.92e-7	Lung cancer in never smokers;
CESC	cis	rs9457247	0.765	rs9457251	chr6:167426707	T/C	cg07741184	chr6:167504864	NA	0.35	6.34	0.36	9.89e-10	Crohn's disease;
CESC	cis	rs1153858	1.000	rs10519021	chr15:45631795	G/A	cg14582100	chr15:45693742	SPATA5L1	0.41	5.89	0.34	1.18e-8	Homoarginine levels;
CESC	cis	rs7707921	0.752	rs2897554	chr5:81276241	C/T	cg15871215	chr5:81402204	ATG10	0.5	7.28	0.41	3.82e-12	Breast cancer;
CESC	cis	rs1577917	1.000	rs12201735	chr6:86656939	C/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.45	-5.86	-0.34	1.4e-8	Response to antipsychotic treatment;
CESC	cis	rs208520	0.565	rs1385222	chr6:66753013	C/T	cg07460842	chr6:66804631	NA	1.0	20.54	0.78	9.87e-57	Exhaled nitric oxide output;
CESC	cis	rs2073300	1.000	rs115730610	chr20:23442621	G/A	cg12062639	chr20:23401060	NAPB	0.9	6.28	0.36	1.4e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs926938	0.606	rs6537844	chr1:115289295	G/A	cg12756093	chr1:115239321	AMPD1	-0.42	-5.23	-0.31	3.46e-7	Autism;
CESC	cis	rs4979906	1.000	rs11002241	chr10:79445327	C/T	cg00983440	chr10:79422392	NA	-0.49	-5.15	-0.3	4.97e-7	Mortality in heart failure;
CESC	cis	rs4689388	0.581	rs4476672	chr4:6281496	A/G	cg14416269	chr4:6271139	WFS1	0.41	5.23	0.31	3.47e-7	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs2109514	1.000	rs2270189	chr7:116140616	A/G	cg12739419	chr7:116140593	CAV2	-0.37	-6.71	-0.38	1.17e-10	Prevalent atrial fibrillation;
CESC	cis	rs9303401	0.659	rs17741087	chr17:56550300	C/T	cg25039879	chr17:56429692	SUPT4H1	0.53	5.39	0.31	1.55e-7	Cognitive test performance;
CESC	cis	rs9926296	0.656	rs2376883	chr16:89826926	A/G	cg04287289	chr16:89883240	FANCA	0.57	7.62	0.42	4.55e-13	Vitiligo;
CESC	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.48	-5.11	-0.3	6.3e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7809950	0.678	rs2237660	chr7:106862963	T/A	cg23024343	chr7:107201750	COG5	-0.59	-7.11	-0.4	1.07e-11	Coronary artery disease;
CESC	cis	rs1670533	1.000	rs62294756	chr4:1097676	G/A	cg04106633	chr4:1044584	NA	-0.4	-5.18	-0.3	4.5e-7	Recombination rate (females);
CESC	cis	rs8180040	0.654	rs6766230	chr3:47196209	C/A	cg27129171	chr3:47204927	SETD2	0.67	9.81	0.52	1.36e-19	Colorectal cancer;
CESC	cis	rs4282054	0.631	rs13081155	chr3:52732429	A/G	cg18404041	chr3:52824283	ITIH1	-0.36	-6.45	-0.37	5.17e-10	Cognitive function;
CESC	cis	rs4665809	0.759	rs62128394	chr2:26364026	T/G	cg26119090	chr2:26468346	HADHA;HADHB	0.84	9.21	0.49	1.06e-17	Gut microbiome composition (summer);
CESC	cis	rs13191362	1.000	rs67046187	chr6:163068532	C/A	cg14584255	chr6:163149320	PACRG;PARK2	0.54	5.6	0.33	5.3e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21243608	chr8:74205946	RDH10;RPL7	0.55	6.61	0.38	2.1e-10	Gut microbiome composition (summer);
CESC	cis	rs13191362	1.000	rs35593345	chr6:163174981	G/C	cg21926612	chr6:163149169	PACRG;PARK2	1.06	9.79	0.52	1.61e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs9875589	0.957	rs1108341	chr3:13937328	T/A	cg19554555	chr3:13937349	NA	0.52	6.57	0.37	2.63e-10	Ovarian reserve;
CESC	cis	rs4253772	0.550	rs6008598	chr22:46704243	C/T	cg10541313	chr22:46663664	TTC38	0.65	5.67	0.33	3.8e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs4808199	1.000	rs4808199	chr19:19545099	C/T	cg03709012	chr19:19516395	GATAD2A	1.11	12.74	0.62	2.57e-29	Nonalcoholic fatty liver disease;
CESC	cis	rs11792861	0.591	rs4978763	chr9:111728067	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.59	8.87	0.48	1.07e-16	Menarche (age at onset);
CESC	cis	rs1008375	0.966	rs7666888	chr4:17695722	C/T	cg02297831	chr4:17616191	MED28	0.42	5.13	0.3	5.72e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs9872999	1	rs9872999	chr3:133457514	C/T	cg16262614	chr3:133464971	TF	0.41	8.07	0.44	2.47e-14	Iron status biomarkers;
CESC	cis	rs72634258	0.945	rs12736494	chr1:8136016	G/A	cg00042356	chr1:8021962	PARK7	0.82	7.73	0.43	2.19e-13	Inflammatory bowel disease;
CESC	cis	rs9611565	0.512	rs132784	chr22:42052363	G/A	cg06481639	chr22:41940642	POLR3H	0.6	6.16	0.35	2.74e-9	Vitiligo;
CESC	cis	rs2072732	0.861	rs10909865	chr1:2956163	A/G	cg15211996	chr1:2936768	ACTRT2	0.34	6.04	0.35	5.27e-9	Plateletcrit;
CESC	cis	rs892961	0.932	rs2170863	chr17:75415037	C/T	cg05865280	chr17:75406074	SEPT9	0.63	12.78	0.62	1.79e-29	Airflow obstruction;
CESC	cis	rs7927771	0.864	rs755554	chr11:47432034	G/C	cg20307385	chr11:47447363	PSMC3	0.69	8.95	0.48	6.16e-17	Subjective well-being;
CESC	cis	rs4268898	0.662	rs9917315	chr2:24431501	C/A	cg20701182	chr2:24300061	SF3B14	0.68	7.16	0.4	7.75e-12	Asthma;
CESC	cis	rs10186029	0.657	rs11689895	chr2:213938553	G/T	cg08319019	chr2:214017104	IKZF2	0.4	5.07	0.3	7.39e-7	Systemic sclerosis;
CESC	cis	rs4862750	0.758	rs2375915	chr4:187896255	A/C	cg10295955	chr4:187884368	NA	-1.07	-19.89	-0.77	1.66e-54	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	7.7	0.43	2.77e-13	Prudent dietary pattern;
CESC	cis	rs7618915	0.532	rs13060675	chr3:52674300	T/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.48	6.96	0.39	2.64e-11	Bipolar disorder;
CESC	cis	rs13191362	1.000	rs34697913	chr6:163000187	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.83	8.39	0.46	3.02e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs16854884	0.586	rs7650172	chr3:143729408	G/C	cg06585982	chr3:143692056	C3orf58	0.52	6.99	0.39	2.18e-11	Economic and political preferences (feminism/equality);
CESC	cis	rs11098499	0.954	rs3733523	chr4:120423719	C/T	cg24375607	chr4:120327624	NA	0.46	5.66	0.33	3.87e-8	Corneal astigmatism;
CESC	cis	rs9660180	0.934	rs12729990	chr1:1812035	T/A	cg17747265	chr1:1875780	NA	-0.6	-9.77	-0.51	1.87e-19	Body mass index;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg09799633	chr5:172199460	DUSP1	-0.5	-6.66	-0.38	1.53e-10	Asthma;
CESC	cis	rs2576037	0.562	rs612519	chr18:44379490	G/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.34	5.5	0.32	8.89e-8	Personality dimensions;
CESC	trans	rs7824557	0.527	rs2736305	chr8:11237773	T/C	cg06636001	chr8:8085503	FLJ10661	-0.48	-6.13	-0.35	3.25e-9	Retinal vascular caliber;
CESC	cis	rs13102973	0.965	rs4280794	chr4:135857174	T/C	cg14419869	chr4:135874104	NA	0.33	5.13	0.3	5.73e-7	Subjective well-being;
CESC	cis	rs7000551	0.725	rs4871998	chr8:22308150	A/T	cg12081754	chr8:22256438	SLC39A14	0.44	6.01	0.35	6.21e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CESC	cis	rs4319547	0.695	rs10773167	chr12:122934001	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.55	-6.27	-0.36	1.5e-9	Body mass index;
CESC	cis	rs55883249	0.957	rs62119393	chr2:9718247	C/T	cg23886495	chr2:9695866	ADAM17	0.57	5.37	0.31	1.74e-7	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
CESC	cis	rs2294693	0.786	rs12055704	chr6:40988504	C/T	cg14769373	chr6:40998127	UNC5CL	-0.46	-5.7	-0.33	3.24e-8	Gastric cancer;Non-cardia gastric cancer;
CESC	cis	rs514406	0.683	rs10157120	chr1:53210888	A/G	cg08736216	chr1:53307985	ZYG11A	-0.4	-6.38	-0.36	8e-10	Monocyte count;
CESC	cis	rs3091242	0.900	rs1883427	chr1:25744468	C/T	cg27572855	chr1:25598939	RHD	0.46	7.61	0.42	4.81e-13	Erythrocyte sedimentation rate;
CESC	cis	rs9611565	0.659	rs11090049	chr22:41915329	C/T	cg03806693	chr22:41940476	POLR3H	-1.21	-15.26	-0.68	3.73e-38	Vitiligo;
CESC	cis	rs1387259	0.899	rs7307566	chr12:48604682	A/G	cg04545296	chr12:48745243	ZNF641	0.4	6.74	0.38	9.66e-11	Obstructive sleep apnea trait (apnea hypopnea index);
CESC	cis	rs7917772	0.636	rs2863718	chr10:104519631	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.44	-5.12	-0.3	5.79e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs8028182	0.636	rs8034317	chr15:75764343	G/A	cg20655648	chr15:75932815	IMP3	0.48	6.02	0.35	5.83e-9	Sudden cardiac arrest;
CESC	cis	rs1775715	0.737	rs2808028	chr10:32101189	G/A	cg18675610	chr10:32216311	ARHGAP12	0.34	5.27	0.31	2.85e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs8070128	0.568	rs3935505	chr17:17882020	T/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.52	6.77	0.38	8.32e-11	Total body bone mineral density;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg07776409	chr17:27182127	ERAL1	-0.47	-6.07	-0.35	4.37e-9	Height;
CESC	trans	rs61148964	0.826	rs11913459	chr22:37228603	G/A	cg14267671	chr19:45572412	SFRS16	0.77	7.11	0.4	1.11e-11	Scarlet fever;
CESC	cis	rs2249694	0.919	rs10857768	chr10:135402703	A/G	cg20169779	chr10:135381914	SYCE1	-0.41	-5.79	-0.34	1.94e-8	Obesity-related traits;
CESC	cis	rs1707322	1.000	rs785465	chr1:46522577	G/T	cg03146154	chr1:46216737	IPP	0.7	9.41	0.5	2.42e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs6831352	0.918	rs2851251	chr4:100044111	A/G	cg12011299	chr4:100065546	ADH4	0.59	6.66	0.38	1.56e-10	Alcohol dependence;
CESC	cis	rs9858542	0.953	rs9859556	chr3:49455986	G/T	cg07274523	chr3:49395745	GPX1	0.65	7.92	0.44	6.53e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs854765	0.583	rs8065416	chr17:17851162	C/T	cg16928487	chr17:17741425	SREBF1	-0.57	-9.57	-0.51	7.66e-19	Total body bone mineral density;
CESC	cis	rs1799949	1.000	rs1960605	chr17:41305397	C/T	cg23758822	chr17:41437982	NA	1.03	15.83	0.7	3.63e-40	Menopause (age at onset);
CESC	cis	rs7811142	0.830	rs7792525	chr7:99972122	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.1	11.05	0.56	1.37e-23	Platelet count;
CESC	cis	rs1475911	1.000	rs12482477	chr21:43517233	T/A	cg19766460	chr21:43528205	UMODL1;C21orf128	0.59	6.65	0.38	1.64e-10	IgG glycosylation;
CESC	cis	rs9309473	1.000	rs6546837	chr2:73677898	G/C	cg20560298	chr2:73613845	ALMS1	-0.46	-6.17	-0.35	2.53e-9	Metabolite levels;
CESC	cis	rs7845219	0.544	rs7017487	chr8:95922752	A/G	cg13393036	chr8:95962371	TP53INP1	0.43	8.37	0.46	3.4e-15	Type 2 diabetes;
CESC	cis	rs7666738	0.830	rs1559859	chr4:99024325	C/T	cg03676636	chr4:99064102	C4orf37	0.34	5.1	0.3	6.59e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7727544	0.709	rs441969	chr5:131702120	G/A	cg24060327	chr5:131705240	SLC22A5	-0.63	-7.98	-0.44	4.32e-14	Blood metabolite levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25388971	chr5:1085895	SLC12A7	-0.51	-6.11	-0.35	3.55e-9	Gut microbiome composition (summer);
CESC	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.45	5.36	0.31	1.79e-7	Renal function-related traits (BUN);
CESC	cis	rs10751667	0.857	rs6597961	chr11:976677	T/C	cg06064525	chr11:970664	AP2A2	-0.37	-6.51	-0.37	3.85e-10	Alzheimer's disease (late onset);
CESC	cis	rs694739	0.726	rs516124	chr11:64128423	G/T	cg02228329	chr11:64053129	BAD;GPR137	0.62	7.81	0.43	1.3e-13	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CESC	cis	rs1008375	0.898	rs2079892	chr4:17577163	G/A	cg02297831	chr4:17616191	MED28	0.5	6.07	0.35	4.52e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs2842992	0.789	rs3818300	chr6:160201677	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.78	9.62	0.51	5.44e-19	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs11190604	1.000	rs11190613	chr10:102313997	C/T	cg07080220	chr10:102295463	HIF1AN	-0.62	-5.92	-0.34	9.93e-9	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs9908102	0.740	rs73981609	chr17:12903938	T/C	cg26162695	chr17:12921313	ELAC2	0.5	5.49	0.32	9.61e-8	Schizophrenia;
CESC	cis	rs10540	1.000	rs61876335	chr11:488878	T/C	cg03576123	chr11:487126	PTDSS2	-1.04	-10.29	-0.53	4.01e-21	Body mass index;
CESC	cis	rs938554	0.513	rs3775948	chr4:9995182	G/C	cg11266682	chr4:10021025	SLC2A9	0.5	7.24	0.41	4.79e-12	Blood metabolite levels;
CESC	cis	rs9486719	0.741	rs2499799	chr6:96851676	T/C	cg06623918	chr6:96969491	KIAA0776	0.74	7.03	0.4	1.77e-11	Migraine;Coronary artery disease;
CESC	trans	rs2965280	0.793	rs8101748	chr19:34822331	C/G	cg05799317	chr6:165723796	C6orf118	0.81	6.0	0.35	6.45e-9	Colorectal cancer;
CESC	cis	rs2635047	0.901	rs2684837	chr18:44749884	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.42	5.58	0.32	6.06e-8	Educational attainment;
CESC	trans	rs801193	1.000	rs2707854	chr7:66212597	G/A	cg26939375	chr7:64535504	NA	0.64	8.77	0.47	2.19e-16	Aortic root size;
CESC	cis	rs8060686	0.858	rs7198357	chr16:67884619	A/G	cg26727032	chr16:67993705	SLC12A4	0.64	9.34	0.5	4.23e-18	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs7605378	0.528	rs281787	chr2:200784238	C/T	cg23649088	chr2:200775458	C2orf69	-0.73	-9.47	-0.5	1.61e-18	Osteoporosis;
CESC	cis	rs5753037	0.653	rs131286	chr22:30158351	C/T	cg01021169	chr22:30184971	ASCC2	-0.45	-6.27	-0.36	1.48e-9	Type 1 diabetes;
CESC	cis	rs853679	0.517	rs4713135	chr6:28039586	G/A	cg23161317	chr6:28129485	ZNF389	0.5	6.19	0.36	2.3e-9	Depression;
CESC	cis	rs9394159	0.583	rs4713650	chr6:33616828	C/T	cg14003231	chr6:33640908	ITPR3	-0.44	-8.02	-0.44	3.37e-14	Graves' disease;
CESC	cis	rs61332075	0.501	rs55706928	chr2:239445806	T/C	cg18131467	chr2:239335373	ASB1	-0.7	-5.59	-0.32	5.74e-8	Lung function (FEV1/FVC);
CESC	cis	rs853679	0.517	rs9468286	chr6:28079428	C/T	cg17949981	chr6:28129498	ZNF389	0.45	5.63	0.33	4.71e-8	Depression;
CESC	trans	rs9325144	0.723	rs11169519	chr12:39177441	G/A	cg23762105	chr12:34175262	ALG10	0.45	6.06	0.35	4.7e-9	Morning vs. evening chronotype;
CESC	cis	rs3857067	1.000	rs28876091	chr4:95000394	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.52	-8.0	-0.44	3.93e-14	QT interval;
CESC	cis	rs10911232	0.507	rs3934578	chr1:183027216	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.87	13.49	0.64	6.27e-32	Hypertriglyceridemia;
CESC	cis	rs7412746	0.611	rs1889740	chr1:150799755	C/T	cg04414720	chr1:150670196	GOLPH3L	0.47	6.42	0.37	6.09e-10	Melanoma;
CESC	cis	rs9457247	1.000	rs415842	chr6:167406681	G/A	cg23791538	chr6:167370224	RNASET2	-0.59	-8.54	-0.46	1.09e-15	Crohn's disease;
CESC	cis	rs7927592	0.763	rs596494	chr11:68251054	T/G	cg16797656	chr11:68205561	LRP5	0.5	7.71	0.43	2.59e-13	Total body bone mineral density;
CESC	cis	rs9733	0.596	rs72702523	chr1:150650425	G/T	cg18016565	chr1:150552671	MCL1	0.33	5.14	0.3	5.34e-7	Tonsillectomy;
CESC	cis	rs1348850	0.874	rs6742951	chr2:178340766	G/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.89	12.4	0.61	3.73e-28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs6963495	0.818	rs73192145	chr7:105203628	A/C	cg19920283	chr7:105172520	RINT1	0.68	6.26	0.36	1.56e-9	Bipolar disorder (body mass index interaction);
CESC	cis	rs12477438	0.798	rs6542848	chr2:99573732	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.73	-10.49	-0.54	9.44e-22	Chronic sinus infection;
CESC	cis	rs7590720	1.000	rs4674058	chr2:216909368	A/G	cg12620499	chr2:216877984	MREG	0.91	12.11	0.6	3.59e-27	Alcohol dependence;
CESC	cis	rs2832191	0.765	rs2832162	chr21:30461808	G/A	cg08807101	chr21:30365312	RNF160	0.79	11.13	0.56	7.53e-24	Dental caries;
CESC	cis	rs12142240	0.698	rs17361763	chr1:46810670	T/C	cg10495392	chr1:46806563	NSUN4	0.59	6.35	0.36	9.17e-10	Menopause (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21902160	chr7:29689075	LOC646762	-0.48	-6.08	-0.35	4.15e-9	Gut microbiome composition (summer);
CESC	cis	rs8062405	1.000	rs62037365	chr16:28868962	C/G	cg08761264	chr16:28874980	SH2B1	-0.47	-5.84	-0.34	1.49e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs6835098	0.962	rs3733477	chr4:174090004	G/A	cg08422745	chr4:174089978	GALNT7	-0.81	-11.84	-0.59	3.03e-26	Dementia and core Alzheimer's disease neuropathologic changes;
CESC	cis	rs6912958	0.559	rs173333	chr6:88047754	T/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.72	10.99	0.56	2.06e-23	Monocyte percentage of white cells;
CESC	cis	rs4819052	0.788	rs35323494	chr21:46703739	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.9	12.44	0.61	2.65e-28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs1814175	0.817	rs11493756	chr11:50017885	T/C	cg15704280	chr7:45808275	SEPT13	-1.05	-20.74	-0.79	2.04e-57	Height;
CESC	cis	rs1799949	0.501	rs9675035	chr17:41415016	A/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.41	5.64	0.33	4.45e-8	Menopause (age at onset);
CESC	cis	rs1552244	0.938	rs9873794	chr3:10074153	T/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.8	-10.76	-0.55	1.2e-22	Alzheimer's disease;
CESC	cis	rs10504229	0.773	rs1874373	chr8:58194423	T/C	cg02725872	chr8:58115012	NA	-0.34	-5.09	-0.3	6.69e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs7618915	0.547	rs13064064	chr3:52657002	T/C	cg07507251	chr3:52567010	NT5DC2	0.4	6.98	0.39	2.43e-11	Bipolar disorder;
CESC	cis	rs3820068	0.577	rs9728986	chr1:16040603	G/A	cg17385448	chr1:15911702	AGMAT	0.38	6.08	0.35	4.28e-9	Systolic blood pressure;
CESC	cis	rs9649213	0.593	rs6465672	chr7:97963717	C/T	cg08684580	chr7:98029266	BAIAP2L1	0.34	5.49	0.32	9.58e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs853679	0.517	rs34716816	chr6:28046169	C/A	cg12963246	chr6:28129442	ZNF389	0.55	7.35	0.41	2.46e-12	Depression;
CESC	cis	rs2742234	0.955	rs1800861	chr10:43613843	G/T	cg07801480	chr10:43725741	RASGEF1A	0.38	5.27	0.31	2.82e-7	Hirschsprung disease;
CESC	cis	rs1707322	0.827	rs12125508	chr1:46246010	A/G	cg05343316	chr1:45956843	TESK2	0.47	5.73	0.33	2.75e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs4853012	0.775	rs12465641	chr2:74337715	A/G	cg20891558	chr2:74357851	NA	-0.66	-9.0	-0.48	4.51e-17	Gestational age at birth (maternal effect);
CESC	cis	rs6502050	0.835	rs7219180	chr17:80079968	C/G	cg11859384	chr17:80120422	CCDC57	0.38	5.15	0.3	5.1e-7	Life satisfaction;
CESC	cis	rs12586317	0.514	rs74590021	chr14:35490113	T/G	cg16230307	chr14:35515116	FAM177A1	0.99	10.62	0.55	3.59e-22	Psoriasis;
CESC	cis	rs9303401	0.659	rs34878689	chr17:56694330	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.02	11.73	0.58	7.25e-26	Cognitive test performance;
CESC	cis	rs8077577	0.747	rs16961153	chr17:18227101	A/G	cg16794390	chr17:18148240	FLII	-0.4	-6.2	-0.36	2.1e-9	Obesity-related traits;
CESC	cis	rs12682352	0.602	rs6993494	chr8:8667444	C/T	cg17143192	chr8:8559678	CLDN23	0.45	5.31	0.31	2.34e-7	Neuroticism;
CESC	cis	rs1775715	0.870	rs1755084	chr10:32253709	C/T	cg18675610	chr10:32216311	ARHGAP12	0.35	5.38	0.31	1.64e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs2033711	0.870	rs7259841	chr19:58951123	T/C	cg13877915	chr19:58951672	ZNF132	0.42	6.23	0.36	1.84e-9	Uric acid clearance;
CESC	cis	rs1843834	0.539	rs6749402	chr2:225443901	T/G	cg22455342	chr2:225449267	CUL3	0.7	9.61	0.51	6.05e-19	IgE levels in asthmatics (D.p. specific);
CESC	cis	rs10392	0.543	rs6015981	chr20:37533958	A/G	cg27552599	chr20:37590471	DHX35	0.39	5.64	0.33	4.42e-8	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
CESC	cis	rs3126085	1.000	rs72696989	chr1:152248674	A/C	cg03465714	chr1:152285911	FLG	0.49	5.43	0.32	1.24e-7	Atopic dermatitis;
CESC	cis	rs16858210	0.837	rs11716104	chr3:183581999	G/C	cg25686905	chr3:183603175	PARL	-0.33	-6.08	-0.35	4.24e-9	Menopause (age at onset);
CESC	cis	rs656900	0.669	rs665629	chr15:80119231	C/A	cg02196730	chr15:80188777	MTHFS	-0.4	-5.29	-0.31	2.52e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs2549003	0.870	rs10053046	chr5:131821558	A/G	cg00255919	chr5:131827918	IRF1	0.51	8.68	0.47	4.19e-16	Asthma (sex interaction);
CESC	cis	rs1862618	0.853	rs2113078	chr5:56087190	C/T	cg03609598	chr5:56110824	MAP3K1	-0.49	-5.08	-0.3	7.22e-7	Initial pursuit acceleration;
CESC	cis	rs12765878	1.000	rs11191847	chr10:105650626	G/C	cg24587175	chr10:105670608	OBFC1	0.33	5.43	0.32	1.28e-7	Coronary artery disease;
CESC	cis	rs1559088	0.803	rs10411529	chr19:33616256	A/C	cg17764715	chr19:33622953	WDR88	0.44	5.59	0.33	5.51e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs5758659	0.652	rs5758553	chr22:42431429	G/A	cg04733989	chr22:42467013	NAGA	0.47	6.62	0.38	2.04e-10	Cognitive function;
CESC	cis	rs7481584	0.624	rs80871	chr11:3049843	A/C	cg25174290	chr11:3078921	CARS	-0.45	-6.27	-0.36	1.48e-9	Calcium levels;
CESC	cis	rs473651	0.935	rs540636	chr2:239358341	T/C	cg21699342	chr2:239360505	ASB1	0.58	10.26	0.53	5.15e-21	Multiple system atrophy;
CESC	cis	rs992157	0.700	rs10165153	chr2:219159629	T/C	cg00012203	chr2:219082015	ARPC2	0.75	9.7	0.51	3.1e-19	Colorectal cancer;
CESC	cis	rs7662987	0.818	rs4699701	chr4:99998447	G/A	cg13256891	chr4:100009986	ADH5	-0.82	-6.07	-0.35	4.52e-9	Smoking initiation;
CESC	cis	rs2718058	0.519	rs2598047	chr7:37888488	G/T	cg24998770	chr7:37888106	TXNDC3	0.34	5.17	0.3	4.53e-7	Alzheimer's disease (late onset);
CESC	cis	rs1552244	0.816	rs56271597	chr3:10042790	C/T	cg08888203	chr3:10149979	C3orf24	0.48	6.09	0.35	3.99e-9	Alzheimer's disease;
CESC	cis	rs801193	1.000	rs10274773	chr7:66133578	G/A	cg06456125	chr7:65229604	NA	-0.39	-5.09	-0.3	6.82e-7	Aortic root size;
CESC	cis	rs11098499	0.909	rs28632018	chr4:120386730	T/C	cg24375607	chr4:120327624	NA	0.44	5.48	0.32	9.91e-8	Corneal astigmatism;
CESC	cis	rs6121246	0.609	rs4453755	chr20:30331047	G/A	cg13852791	chr20:30311386	BCL2L1	0.81	10.36	0.54	2.4e-21	Mean corpuscular hemoglobin;
CESC	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg11235426	chr6:292522	DUSP22	-0.72	-9.67	-0.51	3.98e-19	Menopause (age at onset);
CESC	cis	rs35110281	0.687	rs4819284	chr21:45084548	C/T	cg21573476	chr21:45109991	RRP1B	-0.43	-6.14	-0.35	3.04e-9	Mean corpuscular volume;
CESC	cis	rs7666738	0.830	rs62318906	chr4:99037110	C/T	cg17366294	chr4:99064904	C4orf37	0.61	8.77	0.47	2.27e-16	Colonoscopy-negative controls vs population controls;
CESC	trans	rs7944735	0.567	rs7111404	chr11:48011283	C/G	cg15704280	chr7:45808275	SEPT13	0.68	6.1	0.35	3.77e-9	Intraocular pressure;
CESC	cis	rs1577917	0.771	rs9450290	chr6:86233397	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.57	7.9	0.44	7.24e-14	Response to antipsychotic treatment;
CESC	cis	rs853679	0.517	rs1947862	chr6:28105196	C/T	cg26335602	chr6:28129616	ZNF389	0.53	6.86	0.39	4.81e-11	Depression;
CESC	cis	rs2243480	1.000	rs73142122	chr7:65311298	C/A	cg12463550	chr7:65579703	CRCP	0.69	5.53	0.32	7.85e-8	Diabetic kidney disease;
CESC	cis	rs801193	1.000	rs7785213	chr7:66138978	A/C	cg11764359	chr7:65958608	NA	-0.69	-8.94	-0.48	6.63e-17	Aortic root size;
CESC	cis	rs4727027	0.901	rs4727018	chr7:148822247	G/C	cg23158103	chr7:148848205	ZNF398	-0.41	-6.47	-0.37	4.71e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs8141529	0.871	rs5762877	chr22:29277555	G/A	cg02153584	chr22:29168773	CCDC117	0.55	7.25	0.41	4.5e-12	Lymphocyte counts;
CESC	cis	rs7605827	0.930	rs2049718	chr2:15518589	A/G	cg19274914	chr2:15703543	NA	-0.34	-6.09	-0.35	4.04e-9	Educational attainment (years of education);
CESC	cis	rs875971	0.862	rs2088655	chr7:65795711	T/C	cg19163074	chr7:65112434	INTS4L2	0.41	5.18	0.3	4.32e-7	Aortic root size;
CESC	cis	rs875971	0.964	rs12668936	chr7:65914404	C/T	cg12463550	chr7:65579703	CRCP	0.56	7.09	0.4	1.2e-11	Aortic root size;
CESC	cis	rs17711722	0.727	rs781151	chr7:65479878	T/C	cg06456125	chr7:65229604	NA	0.43	5.49	0.32	9.18e-8	Calcium levels;
CESC	cis	rs873946	0.504	rs4880275	chr10:134576552	C/T	cg26818010	chr10:134567672	INPP5A	-0.83	-10.11	-0.53	1.59e-20	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs13256369	0.901	rs4841015	chr8:8567140	C/G	cg18904891	chr8:8559673	CLDN23	0.67	7.69	0.43	2.98e-13	Obesity-related traits;
CESC	cis	rs12893668	0.628	rs57072546	chr14:104063723	T/C	cg24130564	chr14:104152367	KLC1	-0.49	-6.16	-0.35	2.64e-9	Reticulocyte count;
CESC	cis	rs826838	0.616	rs10880751	chr12:38627485	C/T	cg26384229	chr12:38710491	ALG10B	0.47	6.36	0.36	8.58e-10	Heart rate;
CESC	cis	rs2777491	0.789	rs316617	chr15:41795900	C/T	cg18705301	chr15:41695430	NDUFAF1	0.58	8.2	0.45	1.03e-14	Ulcerative colitis;
CESC	cis	rs780096	0.526	rs1260342	chr2:27663416	G/T	cg21248554	chr2:27665150	KRTCAP3	-0.36	-7.38	-0.41	2.02e-12	Total body bone mineral density;
CESC	cis	rs1862618	0.713	rs832550	chr5:56182589	C/T	cg22800045	chr5:56110881	MAP3K1	0.81	9.66	0.51	4.1e-19	Initial pursuit acceleration;
CESC	cis	rs9858542	1.000	rs13316695	chr3:49684917	C/G	cg07274523	chr3:49395745	GPX1	0.67	8.54	0.46	1.03e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs1707322	0.691	rs12031182	chr1:46220999	C/T	cg06784218	chr1:46089804	CCDC17	0.43	7.58	0.42	5.65e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9611565	0.525	rs9611548	chr22:41704143	G/T	cg06481639	chr22:41940642	POLR3H	-0.53	-5.64	-0.33	4.31e-8	Vitiligo;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg21871735	chr16:2015157	SNHG9;RPS2;SNORA78	0.52	6.76	0.38	8.9e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs9322193	0.923	rs2297928	chr6:150039720	G/C	cg07701084	chr6:150067640	NUP43	0.48	6.85	0.39	5.03e-11	Lung cancer;
CESC	cis	rs3785574	0.621	rs1051684	chr17:62006497	A/G	cg11494091	chr17:61959527	GH2	-0.39	-5.62	-0.33	4.94e-8	Height;
CESC	cis	rs2952156	1.000	rs2643195	chr17:37853118	A/G	cg00129232	chr17:37814104	STARD3	-0.71	-9.57	-0.51	7.77e-19	Asthma;
CESC	cis	rs1348850	0.914	rs1348849	chr2:178358072	C/T	cg23306229	chr2:178417860	TTC30B	0.66	8.32	0.46	4.61e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs17376456	0.877	rs10065056	chr5:93380123	G/T	cg21475434	chr5:93447410	FAM172A	0.77	6.95	0.39	2.86e-11	Diabetic retinopathy;
CESC	cis	rs3749237	0.595	rs3870338	chr3:49557051	A/G	cg07636037	chr3:49044803	WDR6	0.61	9.06	0.49	2.96e-17	Resting heart rate;
CESC	cis	rs1218582	0.741	rs11264281	chr1:154867221	A/G	cg24250549	chr1:154909240	PMVK	0.62	8.49	0.46	1.46e-15	Prostate cancer;
CESC	cis	rs854572	0.870	rs757158	chr7:94955528	C/T	cg21856205	chr7:94953877	PON1	-0.48	-7.06	-0.4	1.5e-11	Paraoxonase activity;
CESC	cis	rs2635047	0.967	rs7242978	chr18:44633424	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.56	-7.81	-0.43	1.3e-13	Educational attainment;
CESC	cis	rs9649213	0.593	rs6944262	chr7:97985415	T/G	cg08684580	chr7:98029266	BAIAP2L1	-0.36	-5.86	-0.34	1.38e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7089973	0.604	rs7920216	chr10:116611794	G/A	cg23260525	chr10:116636907	FAM160B1	0.38	6.84	0.39	5.48e-11	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs9522267	0.535	rs11069900	chr13:112233285	G/A	cg10483660	chr13:112241077	NA	-0.33	-5.79	-0.33	2.04e-8	Hepatitis;
CESC	cis	rs9916302	0.861	rs11078912	chr17:37671490	A/G	cg00129232	chr17:37814104	STARD3	-0.58	-8.15	-0.45	1.43e-14	Glomerular filtration rate (creatinine);
CESC	cis	rs11785400	0.793	rs4457308	chr8:143733922	G/A	cg10596483	chr8:143751796	JRK	0.43	5.53	0.32	7.5e-8	Schizophrenia;
CESC	cis	rs34779708	0.966	rs17591163	chr10:35465279	G/C	cg04310649	chr10:35416472	CREM	-0.52	-6.33	-0.36	1.06e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs5769765	0.954	rs1569954	chr22:50244071	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	0.47	5.47	0.32	1.07e-7	Schizophrenia;
CESC	cis	rs1461503	0.932	rs10790544	chr11:122838330	T/C	cg27398637	chr11:122830231	C11orf63	-0.57	-8.68	-0.47	4.17e-16	Menarche (age at onset);
CESC	cis	rs12617721	0.645	rs114544871	chr2:99045485	T/G	cg10123293	chr2:99228465	UNC50	0.39	5.1	0.3	6.52e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs7267979	0.899	rs2104734	chr20:25526668	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.76	13.66	0.64	1.58e-32	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs9381040	1.000	rs2093396	chr6:41155000	G/A	cg03526776	chr6:41159608	TREML2	0.39	6.54	0.37	3.21e-10	Alzheimer's disease (late onset);
CESC	cis	rs3026101	0.624	rs12601818	chr17:5320438	A/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.42	5.49	0.32	9.32e-8	Body mass index;
CESC	trans	rs9467711	0.606	rs9393715	chr6:26375645	G/A	cg06606381	chr12:133084897	FBRSL1	-0.76	-6.67	-0.38	1.48e-10	Autism spectrum disorder or schizophrenia;
CESC	cis	rs9311474	1.000	rs7629072	chr3:52305633	C/T	cg17372223	chr3:52568218	NT5DC2	0.39	5.92	0.34	9.69e-9	Electroencephalogram traits;
CESC	cis	rs514406	0.548	rs6670871	chr1:53212082	A/C	cg08736216	chr1:53307985	ZYG11A	0.4	6.55	0.37	3.06e-10	Monocyte count;
CESC	cis	rs1215050	0.791	rs1669745	chr4:98842047	G/A	cg05340658	chr4:99064831	C4orf37	-0.5	-6.49	-0.37	4.24e-10	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs9486715	0.867	rs4240553	chr6:96965324	T/C	cg18709589	chr6:96969512	KIAA0776	0.47	6.57	0.37	2.6200000000000003e-10	Headache;
CESC	cis	rs684232	0.602	rs394747	chr17:562495	C/G	cg15660573	chr17:549704	VPS53	0.81	11.99	0.59	9.32e-27	Prostate cancer;
CESC	cis	rs6754311	0.731	rs745500	chr2:136583192	G/A	cg15123519	chr2:136567270	LCT	0.33	5.59	0.33	5.51e-8	Mosquito bite size;
CESC	cis	rs3820928	0.874	rs10189579	chr2:227864876	A/G	cg11843606	chr2:227700838	RHBDD1	-0.42	-5.45	-0.32	1.12e-7	Pulmonary function;
CESC	trans	rs55704346	0.534	rs2292406	chr4:25393475	T/A	cg01822600	chr1:245751692	KIF26B	0.42	6.17	0.35	2.58e-9	Tonsillectomy;
CESC	cis	rs3820928	0.874	rs1917123	chr2:227889783	T/G	cg11843606	chr2:227700838	RHBDD1	-0.44	-5.72	-0.33	2.88e-8	Pulmonary function;
CESC	cis	rs9815354	0.723	rs79741604	chr3:41947321	C/T	cg03022575	chr3:42003672	ULK4	0.71	6.45	0.37	5.42e-10	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs7959452	0.535	rs7308481	chr12:69659299	A/G	cg14784868	chr12:69753453	YEATS4	0.74	10.82	0.55	7.97e-23	Blood protein levels;
CESC	cis	rs896854	0.654	rs4735337	chr8:95973465	T/C	cg23172400	chr8:95962367	TP53INP1	-0.45	-9.24	-0.49	8.35e-18	Type 2 diabetes;
CESC	cis	rs6963495	0.818	rs73190161	chr7:105156871	C/T	cg02135003	chr7:105160482	PUS7	-0.46	-5.55	-0.32	6.92e-8	Bipolar disorder (body mass index interaction);
CESC	cis	rs9925964	0.967	rs1549293	chr16:31141993	C/T	cg02466173	chr16:30829666	NA	0.34	5.08	0.3	6.96e-7	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs3008870	1.000	rs2009319	chr1:67481070	G/T	cg02640540	chr1:67518911	SLC35D1	0.51	5.43	0.32	1.25e-7	Lymphocyte percentage of white cells;
CESC	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg04025307	chr7:1156635	C7orf50	0.5	8.19	0.45	1.09e-14	Longevity;Endometriosis;
CESC	cis	rs3857536	0.813	rs7768944	chr6:66951088	C/T	cg07460842	chr6:66804631	NA	-0.42	-5.29	-0.31	2.55e-7	Blood trace element (Cu levels);
CESC	cis	rs703842	0.616	rs10783851	chr12:58231155	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	-0.56	-6.46	-0.37	5e-10	Multiple sclerosis;
CESC	cis	rs936229	0.749	rs6495127	chr15:75194490	C/T	cg14664628	chr15:75095509	CSK	-0.69	-8.38	-0.46	3.12e-15	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CESC	cis	rs4253772	0.550	rs12165597	chr22:46705584	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.67	6.46	0.37	5.02e-10	LDL cholesterol;Cholesterol, total;
CESC	cis	rs6502050	0.805	rs6502061	chr17:80086158	C/T	cg11859384	chr17:80120422	CCDC57	0.38	5.13	0.3	5.62e-7	Life satisfaction;
CESC	cis	rs6032067	0.929	rs2267864	chr20:43805279	C/G	cg10761708	chr20:43804764	PI3	0.41	5.06	0.3	7.86e-7	Blood protein levels;
CESC	cis	rs1799949	1.000	rs36036395	chr17:41181297	T/C	cg23758822	chr17:41437982	NA	1.03	14.68	0.67	3.99e-36	Menopause (age at onset);
CESC	cis	rs8031584	0.958	rs11637469	chr15:31238783	T/C	cg08704250	chr15:31115839	NA	-0.63	-8.12	-0.45	1.8e-14	Huntington's disease progression;
CESC	cis	rs875971	0.660	rs7807930	chr7:66087165	C/T	cg11764359	chr7:65958608	NA	-0.73	-9.65	-0.51	4.47e-19	Aortic root size;
CESC	cis	rs12200782	0.505	rs7765920	chr6:26514771	C/T	cg11502198	chr6:26597334	ABT1	0.6	6.88	0.39	4.26e-11	Small cell lung carcinoma;
CESC	cis	rs589448	0.902	rs315131	chr12:69761839	T/G	cg22834771	chr12:69754056	YEATS4	-0.57	-7.68	-0.43	3.15e-13	Cerebrospinal fluid biomarker levels;
CESC	cis	rs6032067	0.777	rs34233258	chr20:43788265	G/A	cg10761708	chr20:43804764	PI3	0.56	6.55	0.37	3.01e-10	Blood protein levels;
CESC	cis	rs7666738	0.822	rs979946	chr4:98921235	C/A	cg03676636	chr4:99064102	C4orf37	0.34	5.14	0.3	5.32e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs738322	0.967	rs133018	chr22:38572761	G/A	cg17652424	chr22:38574118	PLA2G6	-0.34	-6.04	-0.35	5.08e-9	Cutaneous nevi;
CESC	cis	rs3087591	0.960	rs2071009	chr17:29558082	T/C	cg24425628	chr17:29625626	OMG;NF1	-0.45	-5.59	-0.32	5.73e-8	Hip circumference;
CESC	cis	rs9926296	0.605	rs12709094	chr16:89853017	A/G	cg03388025	chr16:89894329	SPIRE2	0.41	7.89	0.44	7.86e-14	Vitiligo;
CESC	cis	rs4819052	0.851	rs13052312	chr21:46662359	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.75	9.94	0.52	5.31e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs6089584	0.586	rs1079755	chr20:60615262	G/A	cg06108461	chr20:60628389	TAF4	-0.59	-7.89	-0.44	7.98e-14	Body mass index;
CESC	cis	rs9457247	0.602	rs9457262	chr6:167473685	A/G	cg07741184	chr6:167504864	NA	0.38	6.7	0.38	1.22e-10	Crohn's disease;
CESC	cis	rs72781680	0.848	rs72780199	chr2:24016269	A/C	cg20701182	chr2:24300061	SF3B14	0.63	5.65	0.33	4.21e-8	Lymphocyte counts;
CESC	cis	rs2303759	0.830	rs7257053	chr19:49894456	C/G	cg22307029	chr19:49891270	CCDC155	0.74	8.79	0.48	1.95e-16	Multiple sclerosis;
CESC	cis	rs853679	0.517	rs11552219	chr6:28126834	C/T	cg08968635	chr6:28129556	ZNF389	0.4	5.22	0.31	3.69e-7	Depression;
CESC	trans	rs765547	0.956	rs2410618	chr8:19853500	G/A	cg12649343	chr22:47023005	GRAMD4	-0.3	-6.12	-0.35	3.27e-9	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
CESC	cis	rs7586879	0.681	rs28836469	chr2:25117215	A/G	cg01884057	chr2:25150051	NA	0.37	7.12	0.4	1.03e-11	Body mass index;
CESC	cis	rs6866344	0.570	rs4266420	chr5:178137161	C/G	cg10224037	chr5:178157518	ZNF354A	0.71	8.44	0.46	2.11e-15	Neutrophil percentage of white cells;
CESC	cis	rs7617773	0.780	rs11706277	chr3:48360433	A/G	cg11946769	chr3:48343235	NME6	0.91	11.67	0.58	1.12e-25	Coronary artery disease;
CESC	cis	rs3771570	1.000	rs73020143	chr2:242261240	T/A	cg21155796	chr2:242212141	HDLBP	0.59	5.03	0.3	9.15e-7	Prostate cancer;
CESC	trans	rs7615952	0.512	rs4234285	chr3:125404477	G/A	cg21747405	chr11:67723411	NA	-0.45	-6.91	-0.39	3.66e-11	Blood pressure (smoking interaction);
CESC	cis	rs9611565	0.681	rs132918	chr22:41808350	C/T	cg06481639	chr22:41940642	POLR3H	0.58	6.34	0.36	9.76e-10	Vitiligo;
CESC	cis	rs2486288	0.656	rs1719236	chr15:45577783	G/T	cg21132104	chr15:45694354	SPATA5L1	-0.53	-6.16	-0.35	2.67e-9	Glomerular filtration rate;
CESC	cis	rs9467711	0.790	rs13195402	chr6:26463575	G/T	cg21479132	chr6:26055353	NA	0.82	5.71	0.33	3.05e-8	Autism spectrum disorder or schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02709840	chr16:67062875	CBFB	0.61	6.68	0.38	1.37e-10	Gut microbiome composition (summer);
CESC	cis	rs477895	0.653	rs11602181	chr11:63896591	C/G	cg04317338	chr11:64019027	PLCB3	0.79	8.11	0.45	1.95e-14	Mean platelet volume;
CESC	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.38	-5.64	-0.33	4.42e-8	Electroencephalogram traits;
CESC	cis	rs854765	0.583	rs9890341	chr17:17823175	G/C	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.55	7.28	0.41	3.9e-12	Total body bone mineral density;
CESC	cis	rs1050631	0.527	rs592261	chr18:33752244	G/A	cg25426722	chr18:33708991	SLC39A6;ELP2	0.58	7.8	0.43	1.41e-13	Esophageal squamous cell cancer (length of survival);
CESC	cis	rs72781680	1.000	rs72781665	chr2:24223086	G/A	cg20701182	chr2:24300061	SF3B14	0.66	5.79	0.34	1.95e-8	Lymphocyte counts;
CESC	cis	rs763014	0.966	rs15564	chr16:677854	G/T	cg07256732	chr16:621771	PIGQ	-0.3	-5.32	-0.31	2.26e-7	Height;
CESC	cis	rs4566357	1.000	rs10933167	chr2:227925969	T/C	cg11843606	chr2:227700838	RHBDD1	-0.43	-5.45	-0.32	1.16e-7	Coronary artery disease;
CESC	cis	rs2228479	0.867	rs62052168	chr16:89947203	G/A	cg00800038	chr16:89945340	TCF25	-0.95	-8.0	-0.44	3.92e-14	Skin colour saturation;
CESC	cis	rs7258465	1.000	rs4808801	chr19:18571141	A/G	cg15073853	chr19:18549131	ISYNA1	-0.36	-5.06	-0.3	7.9e-7	Breast cancer;
CESC	cis	rs6088580	0.634	rs6058041	chr20:33018008	A/G	cg24642439	chr20:33292090	TP53INP2	0.51	6.76	0.38	8.73e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs3026101	0.671	rs12603639	chr17:5320808	G/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.43	5.59	0.32	5.61e-8	Body mass index;
CESC	cis	rs10504229	0.683	rs61364624	chr8:58134339	T/A	cg21724239	chr8:58056113	NA	0.58	5.95	0.34	8.29e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs3793683	0.597	rs2182620	chr10:134590715	C/T	cg27286337	chr10:134555280	INPP5A	0.7	8.14	0.45	1.6e-14	Migraine;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg11190155	chr3:9975447	CRELD1	-0.49	-6.38	-0.36	7.97e-10	Height;
CESC	cis	rs736408	0.546	rs3733046	chr3:52621627	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	7.55	0.42	7.03e-13	Bipolar disorder;
CESC	cis	rs830124	0.602	rs1678952	chr12:122385151	C/A	cg22168489	chr12:122356033	WDR66	-0.37	-5.03	-0.3	9.21e-7	Urinary metabolites;
CESC	cis	rs3936840	0.647	rs942024	chr14:102979463	C/T	cg18135206	chr14:102964638	TECPR2	0.43	5.66	0.33	3.93e-8	Plateletcrit;
CESC	cis	rs4253772	0.550	rs6007830	chr22:46711323	C/T	cg00784671	chr22:46762841	CELSR1	-0.48	-5.58	-0.32	5.83e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs12477438	0.520	rs11123763	chr2:99750673	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.85	15.81	0.7	4.17e-40	Chronic sinus infection;
CESC	cis	rs8141529	0.778	rs763073	chr22:29215542	G/A	cg02153584	chr22:29168773	CCDC117	0.63	9.03	0.49	3.69e-17	Lymphocyte counts;
CESC	cis	rs7666738	0.830	rs59751489	chr4:98933802	A/G	cg05340658	chr4:99064831	C4orf37	0.82	12.54	0.61	1.29e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs798766	1.000	rs1665364	chr4:1727206	A/G	cg05874882	chr4:1763078	NA	0.6	8.08	0.44	2.24e-14	Bladder cancer;Urinary bladder cancer;
CESC	cis	rs6952808	0.692	rs12666575	chr7:2004421	C/T	cg21782813	chr7:2030301	MAD1L1	0.5	7.01	0.4	2.01e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs919433	0.963	rs4850786	chr2:198178608	A/G	cg10820045	chr2:198174542	NA	0.37	5.04	0.3	8.74e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs9291683	0.530	rs11723591	chr4:9985398	T/A	cg11266682	chr4:10021025	SLC2A9	0.58	11.31	0.57	1.86e-24	Bone mineral density;
CESC	trans	rs2727020	0.894	rs10839265	chr11:49369733	C/T	cg03929089	chr4:120376271	NA	-0.65	-7.61	-0.42	4.95e-13	Coronary artery disease;
CESC	trans	rs948562	0.744	rs113707421	chr11:58217142	T/A	cg24637035	chr12:120445227	CCDC64	-0.5	-6.06	-0.35	4.67e-9	Lymphoma;
CESC	trans	rs7672847	0.546	rs10461329	chr4:170518527	G/C	cg19308436	chr1:237949471	RYR2	0.57	6.33	0.36	1.04e-9	Subjective well-being;
CESC	cis	rs1707322	1.000	rs1707317	chr1:46510642	C/T	cg05343316	chr1:45956843	TESK2	-0.49	-5.89	-0.34	1.19e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7772486	0.875	rs7739418	chr6:146359188	G/A	cg23711669	chr6:146136114	FBXO30	0.76	11.02	0.56	1.67e-23	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs3820928	0.874	rs4234066	chr2:227882180	G/A	cg11843606	chr2:227700838	RHBDD1	-0.46	-6.09	-0.35	3.87e-9	Pulmonary function;
CESC	cis	rs977987	0.736	rs11865296	chr16:75473693	C/T	cg03315344	chr16:75512273	CHST6	0.43	6.11	0.35	3.48e-9	Dupuytren's disease;
CESC	cis	rs514406	0.861	rs4926932	chr1:53247495	C/T	cg08859206	chr1:53392774	SCP2	0.54	7.15	0.4	8.22e-12	Monocyte count;
CESC	cis	rs34172651	0.517	rs11639856	chr16:24788645	A/T	cg06505273	chr16:24850292	NA	-0.46	-5.68	-0.33	3.53e-8	Intelligence (multi-trait analysis);
CESC	cis	rs7666738	0.830	rs10440379	chr4:98902822	G/T	cg05340658	chr4:99064831	C4orf37	0.74	10.67	0.55	2.43e-22	Colonoscopy-negative controls vs population controls;
CESC	cis	rs116095464	0.558	rs10079760	chr5:230778	A/G	cg22496380	chr5:211416	CCDC127	-0.71	-8.24	-0.45	7.97e-15	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05643703	chr1:17332012	ATP13A2	-0.59	-6.58	-0.37	2.47e-10	Gut microbiome composition (summer);
CESC	cis	rs7811142	0.830	rs11761253	chr7:99939321	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.09	11.28	0.57	2.4e-24	Platelet count;
CESC	cis	rs736408	0.774	rs4687551	chr3:52823448	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	-0.36	-6.18	-0.35	2.41e-9	Bipolar disorder;
CESC	cis	rs7552404	0.731	rs5745458	chr1:76345429	G/A	cg22875332	chr1:76189707	ACADM	-0.58	-6.06	-0.35	4.53e-9	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs3820928	0.967	rs4675113	chr2:227766339	G/A	cg11843606	chr2:227700838	RHBDD1	-0.43	-5.71	-0.33	3.04e-8	Pulmonary function;
CESC	cis	rs1538970	0.884	rs781232	chr1:45890399	C/T	cg24296786	chr1:45957014	TESK2	0.44	5.35	0.31	1.87e-7	Platelet count;
CESC	trans	rs13360092	0.764	rs77197369	chr5:50541122	G/A	cg03200537	chr16:87022121	NA	0.69	6.01	0.35	6.12e-9	Verbal declarative memory;
CESC	cis	rs7945705	0.902	rs7930026	chr11:9013639	T/C	cg09997546	chr11:8931473	C11orf17;ST5	0.35	5.83	0.34	1.61e-8	Hemoglobin concentration;
CESC	trans	rs6759922	1.000	rs4557006	chr2:22443840	C/T	cg21162304	chr4:80247171	NAA11	0.39	6.23	0.36	1.83e-9	Subjective well-being (multi-trait analysis);
CESC	cis	rs2075371	0.501	rs1646654	chr7:134027547	G/C	cg20476274	chr7:133979776	SLC35B4	0.42	5.25	0.31	3.11e-7	Mean platelet volume;
CESC	cis	rs372883	0.648	rs1003772	chr21:30736145	A/T	cg24692254	chr21:30365293	RNF160	0.53	6.56	0.37	2.86e-10	Pancreatic cancer;
CESC	trans	rs561341	0.700	rs8079471	chr17:30218317	A/G	cg20587970	chr11:113659929	NA	-0.63	-8.24	-0.45	8.02e-15	Hip circumference adjusted for BMI;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg03255221	chr20:57617810	SLMO2	-0.48	-6.25	-0.36	1.62e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs1003719	0.743	rs2835615	chr21:38497303	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.64	-8.74	-0.47	2.66e-16	Eye color traits;
CESC	cis	rs4253772	0.513	rs6008597	chr22:46703904	A/C	cg18190219	chr22:46762943	CELSR1	-0.56	-6.44	-0.37	5.69e-10	LDL cholesterol;Cholesterol, total;
CESC	cis	rs477895	0.629	rs7130030	chr11:63933733	T/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.93	10.25	0.53	5.38e-21	Mean platelet volume;
CESC	cis	rs55728055	0.661	rs7286496	chr22:31983760	G/A	cg01338084	chr22:32026380	PISD	1.26	8.55	0.47	9.7e-16	Age-related hearing impairment;
CESC	cis	rs6547741	1.000	rs10165098	chr2:27796526	C/T	cg27432699	chr2:27873401	GPN1	0.49	6.92	0.39	3.35e-11	Oral cavity cancer;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03425468	chr1:155164676	MIR92B	0.43	6.05	0.35	4.98e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs10751667	0.580	rs10751664	chr11:927077	T/G	cg20946044	chr11:1010712	AP2A2	-0.39	-5.26	-0.31	2.96e-7	Alzheimer's disease (late onset);
CESC	cis	rs2235544	0.664	rs41366847	chr1:54476967	C/G	cg25741118	chr1:54482237	LDLRAD1	-0.24	-6.21	-0.36	2.01e-9	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
CESC	cis	rs3733585	0.699	rs4621431	chr4:9947590	C/T	cg00071950	chr4:10020882	SLC2A9	-0.72	-10.91	-0.56	3.85e-23	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs1218582	0.772	rs4240874	chr1:154885779	C/T	cg16680214	chr1:154839983	KCNN3	-0.45	-6.79	-0.39	7.19e-11	Prostate cancer;
CESC	cis	rs3820068	0.705	rs4646022	chr1:15839112	G/A	cg17385448	chr1:15911702	AGMAT	0.37	5.87	0.34	1.27e-8	Systolic blood pressure;
CESC	cis	rs875971	1.000	rs4718343	chr7:65874288	T/G	cg10691866	chr7:65817282	TPST1	-0.34	-5.47	-0.32	1.06e-7	Aortic root size;
CESC	cis	rs17826219	0.706	rs57698184	chr17:29064918	T/C	cg14008862	chr17:28927542	LRRC37B2	0.64	5.11	0.3	6.29e-7	Body mass index;
CESC	cis	rs875971	0.830	rs809025	chr7:65849819	C/G	cg11764359	chr7:65958608	NA	0.81	11.89	0.59	2.11e-26	Aortic root size;
CESC	cis	rs7666738	0.830	rs11097606	chr4:99011486	C/T	cg17366294	chr4:99064904	C4orf37	0.6	8.71	0.47	3.23e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	7.7	0.43	2.77e-13	Prudent dietary pattern;
CESC	cis	rs17209837	0.607	rs11561963	chr7:87116550	T/A	cg00919237	chr7:87102261	ABCB4	-0.46	-5.72	-0.33	2.88e-8	Gallbladder cancer;
CESC	cis	rs875971	0.964	rs6978429	chr7:65959876	T/G	cg18876405	chr7:65276391	NA	0.48	6.31	0.36	1.16e-9	Aortic root size;
CESC	cis	rs4722166	0.573	rs35436671	chr7:22775508	G/A	cg13104385	chr7:22767384	IL6	0.48	6.34	0.36	9.73e-10	Lung cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17365369	chr19:52773256	ZNF766	0.52	6.3	0.36	1.25e-9	Gut microbiome composition (summer);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg00587834	chr3:51749959	GRM2	0.43	6.44	0.37	5.68e-10	Fibrinogen levels;
CESC	cis	rs35110281	0.774	rs9978811	chr21:44998683	C/T	cg04455712	chr21:45112962	RRP1B	0.38	5.83	0.34	1.57e-8	Mean corpuscular volume;
CESC	cis	rs7666738	0.546	rs6827131	chr4:98744810	C/G	cg05340658	chr4:99064831	C4orf37	0.54	6.63	0.38	1.89e-10	Colonoscopy-negative controls vs population controls;
CESC	cis	rs36051895	0.632	rs10115962	chr9:5140841	T/C	cg02405213	chr9:5042618	JAK2	-0.49	-6.21	-0.36	2.09e-9	Pediatric autoimmune diseases;
CESC	cis	rs72945132	0.638	rs627079	chr11:70165505	G/T	cg00319359	chr11:70116639	PPFIA1	0.64	6.7	0.38	1.22e-10	Coronary artery disease;
CESC	trans	rs7937682	0.889	rs578022	chr11:111490552	G/T	cg18187862	chr3:45730750	SACM1L	0.48	6.01	0.35	6.26e-9	Primary sclerosing cholangitis;
CESC	cis	rs7666738	0.830	rs1967980	chr4:98966426	C/G	cg03676636	chr4:99064102	C4orf37	0.33	5.08	0.3	7.24e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4253772	0.637	rs11703173	chr22:46660367	G/A	cg10541313	chr22:46663664	TTC38	0.67	5.69	0.33	3.43e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs739401	0.611	rs417957	chr11:3046231	A/G	cg25174290	chr11:3078921	CARS	0.57	8.19	0.45	1.14e-14	Longevity;
CESC	cis	rs662064	0.963	rs10864460	chr1:10563671	C/G	cg20482658	chr1:10539492	PEX14	-0.32	-6.31	-0.36	1.18e-9	Asthma;
CESC	cis	rs1642645	0.831	rs7529102	chr1:42493322	T/C	cg16685388	chr1:42384056	HIVEP3	0.37	5.61	0.33	5.2e-8	Left ventricular obstructive tract defect (maternal effect);
CESC	cis	rs4665809	0.590	rs7579504	chr2:26439995	T/C	cg27170947	chr2:26402098	FAM59B	-0.87	-9.89	-0.52	7.6e-20	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00902691	chr17:75191018	SEC14L1	-0.62	-7.06	-0.4	1.49e-11	Gut microbiome composition (summer);
CESC	cis	rs4423214	0.921	rs12807827	chr11:71203790	A/C	cg05163923	chr11:71159392	DHCR7	0.8	10.79	0.55	9.45e-23	Vitamin D levels;
CESC	cis	rs7809950	1.000	rs986994	chr7:107104115	G/T	cg23024343	chr7:107201750	COG5	-0.42	-5.88	-0.34	1.22e-8	Coronary artery disease;
CESC	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.45	5.85	0.34	1.45e-8	Lymphocyte counts;
CESC	cis	rs1055129	0.537	rs10852766	chr17:73951864	T/C	cg08125733	chr17:73851984	WBP2	-0.48	-6.26	-0.36	1.58e-9	White matter hyperintensity burden;
CESC	cis	rs7618915	0.508	rs7628578	chr3:52628321	A/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	5.79	0.34	1.96e-8	Bipolar disorder;
CESC	cis	rs2228479	0.718	rs62054253	chr16:89896932	T/C	cg00800038	chr16:89945340	TCF25	-0.85	-6.5	-0.37	3.94e-10	Skin colour saturation;
CESC	cis	rs2075371	0.796	rs7780583	chr7:133960716	C/G	cg11752832	chr7:134001865	SLC35B4	0.53	6.88	0.39	4.35e-11	Mean platelet volume;
CESC	cis	rs9611565	0.918	rs9538	chr22:41755857	G/T	cg06634786	chr22:41940651	POLR3H	-0.68	-7.03	-0.4	1.78e-11	Vitiligo;
CESC	cis	rs2404602	0.692	rs12913810	chr15:77166675	T/C	cg22467129	chr15:76604101	ETFA	-0.35	-5.27	-0.31	2.8e-7	Blood metabolite levels;
CESC	cis	rs4665809	1.000	rs3910272	chr2:26287842	T/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.83	-9.25	-0.49	7.55e-18	Gut microbiome composition (summer);
CESC	cis	rs7615952	0.641	rs7618515	chr3:125790578	C/T	cg02807482	chr3:125708958	NA	-0.4	-5.24	-0.31	3.28e-7	Blood pressure (smoking interaction);
CESC	cis	rs9309473	1.000	rs6710438	chr2:73820108	C/G	cg20560298	chr2:73613845	ALMS1	0.53	6.78	0.38	7.95e-11	Metabolite levels;
CESC	cis	rs6570726	0.791	rs11155432	chr6:145898761	T/C	cg23711669	chr6:146136114	FBXO30	0.97	14.97	0.68	4.06e-37	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7103648	1.000	rs2293579	chr11:47440758	G/A	cg20307385	chr11:47447363	PSMC3	0.98	16.54	0.71	1.05e-42	Diastolic blood pressure;Systolic blood pressure;
CESC	cis	rs561341	0.825	rs2008368	chr17:30347397	T/C	cg00745463	chr17:30367425	LRRC37B	-0.88	-7.75	-0.43	2.01e-13	Hip circumference adjusted for BMI;
CESC	trans	rs10500991	0.587	rs11606732	chr11:24888760	A/T	cg07129253	chr8:30890560	PURG;WRN	-0.5	-6.6	-0.38	2.23e-10	Iron status biomarkers;
CESC	cis	rs2742234	1.000	rs1864399	chr10:43610455	T/C	cg07801480	chr10:43725741	RASGEF1A	0.39	5.39	0.31	1.59e-7	Hirschsprung disease;
CESC	cis	rs847577	0.609	rs705308	chr7:97695363	C/A	cg21770322	chr7:97807741	LMTK2	-0.84	-15.24	-0.68	4.17e-38	Breast cancer;
CESC	cis	rs1799949	0.931	rs34410138	chr17:41279770	A/G	cg23758822	chr17:41437982	NA	1.01	15.45	0.69	8.04e-39	Menopause (age at onset);
CESC	cis	rs875971	0.964	rs778735	chr7:65814809	C/A	cg10691866	chr7:65817282	TPST1	-0.35	-5.76	-0.33	2.29e-8	Aortic root size;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg25433267	chr10:77161647	C10orf41;ZNF503	-0.51	-6.8	-0.39	6.82e-11	Fibrinogen levels;
CESC	cis	rs10735851	1	rs10735851	chr12:53743064	G/A	cg26875137	chr12:53738046	NA	0.37	5.42	0.32	1.37e-7	Total body bone mineral density;
CESC	cis	rs4948523	0.530	rs67362351	chr10:60306548	C/A	cg07615347	chr10:60278583	BICC1	-0.57	-8.14	-0.45	1.58e-14	Myopia;
CESC	cis	rs6076065	1.000	rs2424533	chr20:23375907	C/T	cg12062639	chr20:23401060	NAPB	0.41	5.16	0.3	4.95e-7	Facial morphology (factor 15, philtrum width);
CESC	cis	rs9311474	0.713	rs352168	chr3:52237970	C/T	cg05564831	chr3:52568323	NT5DC2	0.41	6.29	0.36	1.3e-9	Electroencephalogram traits;
CESC	cis	rs4974559	0.739	rs10012819	chr4:1324758	G/C	cg02980000	chr4:1222292	CTBP1	0.82	7.38	0.41	2.1e-12	Systolic blood pressure;
CESC	trans	rs7944735	0.607	rs34895872	chr11:48021778	A/G	cg03929089	chr4:120376271	NA	0.57	6.47	0.37	4.84e-10	Intraocular pressure;
CESC	cis	rs2404602	0.692	rs35498563	chr15:76958868	C/T	cg26408565	chr15:76604113	ETFA	-0.4	-5.71	-0.33	3.06e-8	Blood metabolite levels;
CESC	cis	rs2839186	0.732	rs55904887	chr21:47707811	A/G	cg10351095	chr21:47802916	PCNT	-0.5	-6.8	-0.39	7.02e-11	Testicular germ cell tumor;
CESC	cis	rs1045902	0.967	rs1469530	chr2:73464948	C/T	cg01422370	chr2:73384389	NA	0.43	7.29	0.41	3.57e-12	Intelligence (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23485473	chr3:52874468	TMEM110	-0.55	-6.91	-0.39	3.68e-11	Gut microbiome composition (summer);
CESC	cis	rs9916302	0.808	rs6503515	chr17:37606433	G/T	cg15445000	chr17:37608096	MED1	0.41	6.76	0.38	8.83e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs5760092	0.755	rs915589	chr22:24261004	C/T	cg01238044	chr22:24384105	GSTT1	0.73	8.27	0.45	6.35e-15	Urinary 1,3-butadiene metabolite levels in smokers;
CESC	cis	rs2243480	1.000	rs1715235	chr7:65488394	T/C	cg13147721	chr7:65941812	NA	-0.89	-8.55	-0.47	9.65e-16	Diabetic kidney disease;
CESC	cis	rs9322193	0.884	rs9688794	chr6:149953257	C/T	cg13206674	chr6:150067644	NUP43	0.41	5.77	0.33	2.21e-8	Lung cancer;
CESC	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg21280719	chr6:42927975	GNMT	-0.27	-6.51	-0.37	3.67e-10	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs4319547	0.915	rs7314638	chr12:122983460	A/G	cg23029597	chr12:123009494	RSRC2	-0.5	-5.52	-0.32	7.88e-8	Body mass index;
CESC	cis	rs7937682	0.924	rs495460	chr11:111504777	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.99	-16.01	-0.7	8.36e-41	Primary sclerosing cholangitis;
CESC	cis	rs7216064	1.000	rs35243555	chr17:65876477	G/C	cg12091567	chr17:66097778	LOC651250	-0.86	-8.82	-0.48	1.55e-16	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs561341	1.000	rs72823789	chr17:30284084	G/A	cg00745463	chr17:30367425	LRRC37B	-0.85	-7.72	-0.43	2.36e-13	Hip circumference adjusted for BMI;
CESC	cis	rs7089973	0.604	rs17663387	chr10:116588060	C/G	cg03647239	chr10:116582469	FAM160B1	0.43	5.54	0.32	7.25e-8	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs7776786	0.934	rs13243526	chr7:18812917	C/T	cg13420273	chr7:18810212	HDAC9	-0.34	-5.07	-0.3	7.44e-7	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs10979	0.562	rs9399446	chr6:143874639	G/C	cg25407410	chr6:143891975	LOC285740	-0.41	-5.68	-0.33	3.61e-8	Hypospadias;
CESC	cis	rs875971	0.545	rs67397473	chr7:65633305	A/G	cg19163074	chr7:65112434	INTS4L2	-0.46	-5.05	-0.3	8.07e-7	Aortic root size;
CESC	cis	rs854765	0.583	rs8070128	chr17:17804725	C/T	cg04398451	chr17:18023971	MYO15A	0.64	8.92	0.48	7.89e-17	Total body bone mineral density;
CESC	cis	rs870825	0.616	rs7692104	chr4:185650895	T/G	cg04058563	chr4:185651563	MLF1IP	0.63	6.96	0.39	2.74e-11	Blood protein levels;
CESC	cis	rs875971	0.545	rs67688847	chr7:65626051	G/A	cg11764359	chr7:65958608	NA	0.79	9.51	0.5	1.18e-18	Aortic root size;
CESC	cis	rs7552404	1.000	rs12091720	chr1:76186949	G/A	cg22875332	chr1:76189707	ACADM	0.65	7.61	0.42	4.8e-13	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs7072216	0.652	rs11189600	chr10:100179274	A/G	cg26618903	chr10:100175079	PYROXD2	0.32	5.04	0.3	8.63e-7	Metabolite levels;
CESC	cis	rs12410462	0.681	rs4131980	chr1:227572123	A/G	cg04117972	chr1:227635322	NA	0.75	6.21	0.36	2e-9	Major depressive disorder;
CESC	cis	rs9611565	0.659	rs73178626	chr22:41928371	T/G	cg17376030	chr22:41985996	PMM1	0.72	7.9	0.44	7.33e-14	Vitiligo;
CESC	cis	rs11250464	0.755	rs11250468	chr10:1410060	A/G	cg08668359	chr10:1443807	ADARB2	0.59	7.3	0.41	3.35e-12	Radiation response;
CESC	cis	rs79387448	0.701	rs11465596	chr2:102987093	C/A	cg09003973	chr2:102972529	NA	1.15	8.92	0.48	8.09e-17	Gut microbiota (bacterial taxa);
CESC	cis	rs2299587	0.642	rs2073570	chr8:17782627	C/G	cg08627089	chr8:17753878	FGL1	-0.4	-5.35	-0.31	1.94e-7	Economic and political preferences;
CESC	cis	rs4141404	0.706	rs5753698	chr22:31970054	A/C	cg13145458	chr22:31556086	RNF185	-0.5	-5.88	-0.34	1.26e-8	Paclitaxel-induced neuropathy;
CESC	cis	rs12545109	0.837	rs6474063	chr8:57355545	C/T	cg09654669	chr8:57350985	NA	-0.59	-7.28	-0.41	3.76e-12	Obesity-related traits;
CESC	cis	rs854765	0.547	rs4459604	chr17:17888549	A/G	cg04398451	chr17:18023971	MYO15A	-0.74	-10.53	-0.54	6.78e-22	Total body bone mineral density;
CESC	cis	rs7160336	0.641	rs4899503	chr14:74683937	C/T	cg08255017	chr14:74727001	VSX2	0.39	5.78	0.33	2.06e-8	Blood protein levels;
CESC	cis	rs6831352	0.918	rs2602893	chr4:100044095	G/T	cg12011299	chr4:100065546	ADH4	0.59	6.66	0.38	1.56e-10	Alcohol dependence;
CESC	cis	rs7666738	0.791	rs12233867	chr4:98950233	A/G	cg05340658	chr4:99064831	C4orf37	0.8	12.48	0.61	2e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10129255	0.500	rs6576232	chr14:107195328	A/G	cg07958169	chr14:107095056	NA	-0.53	-8.18	-0.45	1.23e-14	Kawasaki disease;
CESC	cis	rs9815354	1.000	rs9840532	chr3:41885697	A/G	cg03022575	chr3:42003672	ULK4	0.45	5.29	0.31	2.59e-7	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs28386778	0.734	rs12946669	chr17:62006007	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.54	6.7	0.38	1.26e-10	Prudent dietary pattern;
CESC	cis	rs367615	0.552	rs10042721	chr5:108713970	C/T	cg17395555	chr5:108820864	NA	-0.44	-7.39	-0.41	1.95e-12	Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs7666738	0.830	rs10050008	chr4:99025313	T/G	cg17366294	chr4:99064904	C4orf37	0.62	8.95	0.48	6.32e-17	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2777491	1.000	rs1757455	chr15:41761332	G/T	cg02330683	chr15:41787940	ITPKA	0.47	7.04	0.4	1.64e-11	Ulcerative colitis;
CESC	cis	rs2645694	0.533	rs2645680	chr4:77820956	T/C	cg18351406	chr4:77819688	ANKRD56	0.53	6.59	0.38	2.39e-10	Emphysema distribution in smoking;
CESC	cis	rs7618915	0.547	rs2878726	chr3:52748271	C/G	cg18099408	chr3:52552593	STAB1	-0.31	-5.13	-0.3	5.6e-7	Bipolar disorder;
CESC	cis	rs2832191	0.716	rs2692625	chr21:30446360	C/G	cg08807101	chr21:30365312	RNF160	0.93	14.2	0.66	2.05e-34	Dental caries;
CESC	cis	rs2652822	0.550	rs12593078	chr15:63517347	A/G	cg02713581	chr15:63449717	RPS27L	0.49	6.06	0.35	4.59e-9	Metabolic traits;
CESC	cis	rs1862618	0.853	rs832554	chr5:56115036	A/G	cg03609598	chr5:56110824	MAP3K1	-0.49	-5.25	-0.31	3.17e-7	Initial pursuit acceleration;
CESC	cis	rs4665809	1.000	rs6546736	chr2:26293878	C/T	cg26314531	chr2:26401878	FAM59B	0.57	6.55	0.37	2.94e-10	Gut microbiome composition (summer);
CESC	cis	rs3858526	0.514	rs4595572	chr11:5864045	T/G	cg13902645	chr11:5959945	NA	-0.68	-10.17	-0.53	9.73e-21	DNA methylation (variation);
CESC	cis	rs9814567	1.000	rs6790466	chr3:134197740	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.45	-6.11	-0.35	3.53e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs798554	0.642	rs2533871	chr7:2883006	C/G	cg18446336	chr7:2847575	GNA12	-0.36	-5.64	-0.33	4.32e-8	Height;
CESC	cis	rs1538970	0.774	rs67683090	chr1:45977803	T/G	cg03146154	chr1:46216737	IPP	0.49	5.57	0.32	6.31e-8	Platelet count;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg06646493	chr1:116519019	SLC22A15	0.47	6.31	0.36	1.18e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs117623576	0.680	rs211415	chr10:32397358	C/T	cg03047570	chr10:32398778	NA	0.68	7.25	0.41	4.54e-12	Anti-saccade response;
CESC	cis	rs10463316	0.894	rs10476769	chr5:150763970	A/G	cg03212797	chr5:150827313	SLC36A1	-0.46	-6.02	-0.35	5.83e-9	Metabolite levels (Pyroglutamine);
CESC	cis	rs854765	0.547	rs4925135	chr17:17952868	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.62	-8.81	-0.48	1.7e-16	Total body bone mineral density;
CESC	cis	rs4906332	0.966	rs12894275	chr14:103901424	A/G	cg09975044	chr14:104007538	NA	-0.45	-6.29	-0.36	1.31e-9	Coronary artery disease;
CESC	cis	rs2040771	0.774	rs9604935	chr22:19211665	C/T	cg02655711	chr22:19163373	SLC25A1	0.41	5.98	0.34	7.37e-9	Metabolite levels (small molecules and protein measures);
CESC	cis	rs2281845	1.000	rs2281845	chr1:201081943	C/T	cg17810781	chr1:201082982	CACNA1S	0.39	5.38	0.31	1.62e-7	Permanent tooth development;
CESC	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	22.29	0.81	1.02e-62	Prudent dietary pattern;
CESC	cis	rs12545109	0.879	rs1513317	chr8:57372966	C/G	cg09654669	chr8:57350985	NA	-0.57	-6.67	-0.38	1.46e-10	Obesity-related traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12955121	chr20:33680750	TRPC4AP	-0.63	-7.27	-0.41	3.93e-12	Gut microbiome composition (summer);
CESC	cis	rs9443645	0.507	rs1475046	chr6:79461801	G/A	cg05283184	chr6:79620031	NA	-0.39	-6.1	-0.35	3.68e-9	Intelligence (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08732623	chr10:127408269	C10orf137	0.55	6.29	0.36	1.27e-9	Gut microbiome composition (summer);
CESC	cis	rs2304069	0.545	rs7728248	chr5:149394965	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.47	6.36	0.36	8.69e-10	HIV-1 control;
CESC	cis	rs6426558	0.537	rs4500279	chr1:227484482	G/A	cg10327440	chr1:227177885	CDC42BPA	0.48	6.06	0.35	4.74e-9	Neutrophil percentage of white cells;
CESC	cis	rs4665809	0.759	rs62128394	chr2:26364026	T/G	cg08470875	chr2:26401718	FAM59B	0.65	6.89	0.39	3.98e-11	Gut microbiome composition (summer);
CESC	cis	rs2070997	0.816	rs9695008	chr9:133720877	C/T	cg11464064	chr9:133710261	ABL1	0.56	5.54	0.32	7.2e-8	Response to amphetamines;
CESC	cis	rs2180341	0.781	rs877102	chr6:127587086	T/C	cg24812749	chr6:127587940	RNF146	0.85	12.06	0.6	5.6e-27	Breast cancer;
CESC	cis	rs2635047	0.638	rs2684840	chr18:44737230	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.41	5.45	0.32	1.18e-7	Educational attainment;
CESC	cis	rs616402	0.527	rs11121581	chr1:10577740	A/G	cg17425144	chr1:10567563	PEX14	0.39	6.28	0.36	1.34e-9	Breast size;
CESC	cis	rs7301826	0.627	rs61937256	chr12:131302645	G/A	cg11011512	chr12:131303247	STX2	-0.45	-5.49	-0.32	9.37e-8	Plasma plasminogen activator levels;
CESC	cis	rs8072100	0.840	rs2136751	chr17:45456093	A/G	cg25173405	chr17:45401733	C17orf57	-0.43	-5.64	-0.33	4.34e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs769267	0.965	rs1010207	chr19:19416045	T/C	cg03709012	chr19:19516395	GATAD2A	0.96	14.17	0.66	2.58e-34	Tonsillectomy;
CESC	cis	rs4689592	0.554	rs3822270	chr4:7069804	C/A	cg26116260	chr4:7069785	GRPEL1	0.99	14.45	0.66	2.63e-35	Monocyte percentage of white cells;
CESC	cis	rs425277	0.958	rs262660	chr1:2086757	A/G	cg24578937	chr1:2090814	PRKCZ	0.55	9.48	0.5	1.47e-18	Height;
CESC	cis	rs1707322	0.752	rs28545085	chr1:46201950	G/A	cg05343316	chr1:45956843	TESK2	0.51	6.32	0.36	1.09e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs1218582	0.803	rs7531728	chr1:154840516	C/A	cg09359103	chr1:154839909	KCNN3	-0.68	-12.36	-0.6	5.1e-28	Prostate cancer;
CESC	cis	rs1034435	0.505	rs5768690	chr22:48902117	G/A	cg05992904	chr22:48892994	FAM19A5	-0.46	-6.57	-0.37	2.64e-10	Late-onset Alzheimer's disease;
CESC	cis	rs13256369	1.000	rs9329165	chr8:8576642	C/T	cg17143192	chr8:8559678	CLDN23	-0.73	-8.93	-0.48	7.46e-17	Obesity-related traits;
CESC	cis	rs7666738	0.791	rs62318907	chr4:99037120	C/T	cg17366294	chr4:99064904	C4orf37	0.61	8.73	0.47	2.88e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs780096	0.526	rs3845686	chr2:27655447	T/G	cg21248554	chr2:27665150	KRTCAP3	-0.33	-6.68	-0.38	1.4e-10	Total body bone mineral density;
CESC	cis	rs2797685	0.945	rs1773138	chr1:7891797	C/T	cg04725166	chr1:7887271	PER3	-0.47	-6.42	-0.37	6.44e-10	Crohn's disease;
CESC	cis	rs6500602	0.701	rs6500614	chr16:4573938	A/G	cg08645402	chr16:4508243	NA	0.42	6.06	0.35	4.64e-9	Schizophrenia;
CESC	cis	rs6121246	0.559	rs6060922	chr20:30333909	C/T	cg13852791	chr20:30311386	BCL2L1	0.85	11.17	0.57	5.35e-24	Mean corpuscular hemoglobin;
CESC	cis	rs4665809	1.000	rs2891490	chr2:26325927	T/C	cg25036284	chr2:26402008	FAM59B	-0.57	-6.53	-0.37	3.25e-10	Gut microbiome composition (summer);
CESC	cis	rs734999	0.505	rs4445406	chr1:2539400	T/C	cg20673091	chr1:2541236	MMEL1	0.45	7.76	0.43	1.9e-13	Ulcerative colitis;
CESC	cis	rs4971059	0.654	rs4276913	chr1:155131673	A/G	cg22049894	chr1:155113146	DPM3	0.45	5.73	0.33	2.76e-8	Breast cancer;
CESC	cis	rs17401966	1.000	rs11121532	chr1:10277898	G/T	cg15208524	chr1:10270712	KIF1B	0.51	6.64	0.38	1.78e-10	Hepatocellular carcinoma;
CESC	cis	rs897984	0.721	rs28360557	chr16:30983260	A/C	cg02466173	chr16:30829666	NA	0.47	7.96	0.44	4.96e-14	Dementia with Lewy bodies;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg27305525	chr1:154955752	FLAD1	0.46	6.01	0.35	6.07e-9	Systemic lupus erythematosus;
CESC	cis	rs1005277	0.579	rs2474571	chr10:38384639	T/G	cg25517755	chr10:38738941	LOC399744	-0.47	-6.08	-0.35	4.08e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs711830	1.000	rs2113559	chr2:177031099	A/G	cg13092806	chr2:177043255	NA	0.85	11.04	0.56	1.49e-23	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
CESC	cis	rs4665809	0.590	rs962217	chr2:26438276	T/C	cg26314531	chr2:26401878	FAM59B	-0.85	-8.89	-0.48	9.94e-17	Gut microbiome composition (summer);
CESC	cis	rs2576037	0.526	rs2156050	chr18:44455873	A/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.32	5.08	0.3	7.02e-7	Personality dimensions;
CESC	cis	rs11122272	0.675	rs1416913	chr1:231533206	A/C	cg06096015	chr1:231504339	EGLN1	0.43	6.15	0.35	2.9e-9	Hemoglobin concentration;
CESC	cis	rs66573146	1.000	rs6812391	chr4:6963893	G/A	cg00086871	chr4:6988644	TBC1D14	1.16	6.56	0.37	2.82e-10	Granulocyte percentage of myeloid white cells;
CESC	cis	rs8005677	0.611	rs11624528	chr14:23459156	A/G	cg23176270	chr14:23476067	C14orf93	0.45	5.45	0.32	1.13e-7	Cognitive ability (multi-trait analysis);
CESC	trans	rs2727020	0.734	rs1164664	chr11:49295542	T/G	cg03929089	chr4:120376271	NA	0.68	8.49	0.46	1.48e-15	Coronary artery disease;
CESC	cis	rs16858210	0.837	rs11716104	chr3:183581999	G/C	cg03417191	chr3:183542750	MAP6D1	-0.45	-5.72	-0.33	2.92e-8	Menopause (age at onset);
CESC	cis	rs1003719	0.788	rs4572679	chr21:38453227	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.62	8.67	0.47	4.41e-16	Eye color traits;
CESC	cis	rs7640424	0.649	rs17233248	chr3:107899513	T/C	cg09227934	chr3:107805635	CD47	-0.45	-5.82	-0.34	1.66e-8	Body mass index;
CESC	cis	rs5769765	0.955	rs8139758	chr22:50261123	G/T	cg22709217	chr22:50311962	ALG12;CRELD2	0.46	5.32	0.31	2.21e-7	Schizophrenia;
CESC	cis	rs1355223	0.583	rs2941058	chr11:34880245	C/G	cg11058730	chr11:34937778	PDHX;APIP	0.84	13.21	0.63	5.91e-31	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs11577318	0.853	rs7537477	chr1:26618829	C/T	cg18121669	chr1:26560928	CCDC21	0.43	5.12	0.3	5.78e-7	Granulocyte percentage of myeloid white cells;
CESC	cis	rs6938	0.534	rs11854704	chr15:75221015	C/T	cg14664628	chr15:75095509	CSK	-0.57	-7.48	-0.42	1.11e-12	Breast cancer;
CESC	cis	rs921968	0.541	rs10205073	chr2:219412784	C/A	cg02176678	chr2:219576539	TTLL4	-0.55	-9.98	-0.52	4.06e-20	Mean corpuscular hemoglobin concentration;
CESC	cis	rs6502050	0.871	rs8082577	chr17:80070581	T/C	cg11859384	chr17:80120422	CCDC57	0.42	5.7	0.33	3.17e-8	Life satisfaction;
CESC	cis	rs7084402	0.967	rs1427223	chr10:60290966	T/C	cg07615347	chr10:60278583	BICC1	0.6	9.42	0.5	2.31e-18	Refractive error;
CESC	cis	rs9788682	0.633	rs2656070	chr15:78730252	A/G	cg24631222	chr15:78858424	CHRNA5	-0.63	-7.56	-0.42	6.53e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs10754283	0.871	rs72712569	chr1:90125657	G/C	cg21401794	chr1:90099060	LRRC8C	-0.64	-8.24	-0.45	8.17e-15	Amyotrophic lateral sclerosis (sporadic);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03016991	chr12:109124380	CORO1C	-0.57	-6.62	-0.38	1.94e-10	Gut microbiome composition (summer);
CESC	cis	rs28655083	0.956	rs8060627	chr16:77077065	A/G	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.4	-5.25	-0.31	3.17e-7	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7312933	0.510	rs1907705	chr12:42451122	T/A	cg01256987	chr12:42539512	GXYLT1	-0.44	-6.68	-0.38	1.42e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs728616	0.614	rs61859199	chr10:82118613	G/T	cg05935833	chr10:81318306	SFTPA2	-0.46	-5.84	-0.34	1.53e-8	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs6693567	0.565	rs6685252	chr1:150259945	T/A	cg09579323	chr1:150459698	TARS2	-0.45	-5.84	-0.34	1.52e-8	Migraine;
CESC	cis	rs66530629	0.917	rs9259	chr1:25168124	C/G	cg22509179	chr1:25234806	RUNX3	-0.38	-5.14	-0.3	5.43e-7	Plateletcrit;
CESC	cis	rs7089973	0.604	rs7095816	chr10:116585109	T/C	cg25233709	chr10:116636983	FAM160B1	0.35	5.74	0.33	2.59e-8	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs11871801	0.918	rs34527783	chr17:40568094	A/G	cg21433558	chr17:40837037	CNTNAP1	0.46	5.03	0.3	9.08e-7	Crohn's disease;
CESC	cis	rs7267979	0.739	rs6138555	chr20:25242910	G/A	cg08601574	chr20:25228251	PYGB	0.4	5.58	0.32	5.86e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs1552244	1.000	rs17032277	chr3:10077023	T/C	cg00149659	chr3:10157352	C3orf10	0.77	9.66	0.51	4.22e-19	Alzheimer's disease;
CESC	cis	rs863345	0.604	rs12078065	chr1:158465063	T/C	cg12129480	chr1:158549410	OR10X1	-0.35	-6.97	-0.39	2.46e-11	Pneumococcal bacteremia;
CESC	cis	rs11098499	0.697	rs28655325	chr4:120372999	A/G	cg24375607	chr4:120327624	NA	0.46	5.77	0.33	2.17e-8	Corneal astigmatism;
CESC	cis	rs7618915	0.508	rs13065851	chr3:52644836	T/A	cg07507251	chr3:52567010	NT5DC2	0.42	7.29	0.41	3.61e-12	Bipolar disorder;
CESC	cis	rs3796352	1.000	rs35576914	chr3:53092270	G/A	cg12962167	chr3:53033115	SFMBT1	0.7	6.13	0.35	3.23e-9	Immune reponse to smallpox (secreted IL-2);
CESC	cis	rs887829	0.569	rs3755319	chr2:234667582	A/C	cg02227331	chr2:234663937	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.35	5.17	0.3	4.55e-7	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CESC	trans	rs208520	0.874	rs208515	chr6:66945749	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.86	-9.92	-0.52	6.4e-20	Exhaled nitric oxide output;
CESC	cis	rs11229030	0.893	rs2264054	chr11:57209488	G/A	cg00522883	chr11:57194120	SLC43A3	-0.48	-6.38	-0.36	8.04e-10	Crohn's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11430096	chr6:110968061	CDK19	-0.56	-6.45	-0.37	5.36e-10	Gut microbiome composition (summer);
CESC	cis	rs73110464	0.609	rs727266	chr12:53356411	C/T	cg05393297	chr12:53359155	NA	-0.71	-10.27	-0.53	4.78e-21	Cancer (pleiotropy);
CESC	cis	rs782590	0.837	rs782584	chr2:55921116	C/G	cg18811423	chr2:55921094	PNPT1	-0.82	-14.1	-0.65	4.63e-34	Metabolic syndrome;
CESC	trans	rs1814175	0.817	rs7946556	chr11:49944874	G/A	cg15704280	chr7:45808275	SEPT13	-1.03	-20.29	-0.78	7.13e-56	Height;
CESC	cis	rs7208859	0.623	rs12006	chr17:29110652	G/A	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.91e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs2404602	0.692	rs58973160	chr15:77000342	T/C	cg26408565	chr15:76604113	ETFA	-0.39	-5.54	-0.32	7.14e-8	Blood metabolite levels;
CESC	cis	rs10504229	0.953	rs17805380	chr8:58171128	C/A	cg22535103	chr8:58192502	C8orf71	-1.05	-13.27	-0.63	3.63e-31	Developmental language disorder (linguistic errors);
CESC	cis	rs853679	0.517	rs9393893	chr6:28109262	T/C	cg17949981	chr6:28129498	ZNF389	0.44	5.53	0.32	7.84e-8	Depression;
CESC	cis	rs72829446	0.530	rs8071847	chr17:7407327	A/G	cg02795151	chr17:7402630	POLR2A	0.6	6.56	0.37	2.83e-10	Androgen levels;
CESC	cis	rs769267	1.000	rs7247309	chr19:19439631	A/T	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.42	-5.4	-0.31	1.51e-7	Tonsillectomy;
CESC	cis	rs10791097	0.739	rs11222358	chr11:130730497	G/A	cg12179176	chr11:130786555	SNX19	0.55	8.05	0.44	2.81e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs6952808	1.000	rs4449693	chr7:1884630	G/C	cg22963979	chr7:1858916	MAD1L1	-0.43	-5.85	-0.34	1.43e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs6967414	0.786	rs7804259	chr7:6755448	C/G	cg00387323	chr7:6746715	ZNF12	0.62	5.69	0.33	3.43e-8	Hematocrit;Hemoglobin concentration;
CESC	trans	rs2115172	0.836	rs4835799	chr5:122762229	A/G	cg03533382	chr5:126853128	PRRC1	0.49	6.45	0.37	5.27e-10	Weight;
CESC	cis	rs11098499	0.863	rs3775849	chr4:120450908	G/C	cg24375607	chr4:120327624	NA	0.43	5.21	0.3	3.82e-7	Corneal astigmatism;
CESC	cis	rs9470366	0.509	rs4713996	chr6:36629714	C/T	cg08179530	chr6:36648295	CDKN1A	-0.62	-9.36	-0.5	3.66e-18	QRS duration;
CESC	cis	rs3008870	0.536	rs2208576	chr1:67513401	C/G	cg08660285	chr1:67390436	MIER1;WDR78	-0.41	-5.28	-0.31	2.71e-7	Lymphocyte percentage of white cells;
CESC	cis	rs477692	0.905	rs4751106	chr10:131424653	G/T	cg05714579	chr10:131428358	MGMT	-0.58	-8.26	-0.45	6.85e-15	Response to temozolomide;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg25141720	chr9:89561826	GAS1	0.5	6.28	0.36	1.37e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs9359856	0.564	rs76069351	chr6:90425043	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.62	-5.86	-0.34	1.38e-8	Bipolar disorder;
CESC	cis	rs4974559	0.739	rs1250121	chr4:1263521	A/G	cg02980000	chr4:1222292	CTBP1	-0.74	-7.78	-0.43	1.59e-13	Systolic blood pressure;
CESC	cis	rs9287719	0.746	rs6742448	chr2:10759126	G/A	cg00105475	chr2:10696890	NA	0.35	5.07	0.3	7.65e-7	Prostate cancer;
CESC	cis	rs35306767	0.903	rs12244355	chr10:944465	T/C	cg20503657	chr10:835505	NA	0.83	8.51	0.46	1.3e-15	Eosinophil percentage of granulocytes;
CESC	cis	rs4523957	0.928	rs10852932	chr17:2143460	G/T	cg16513277	chr17:2031491	SMG6	-0.6	-8.15	-0.45	1.48e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs875971	0.862	rs11763189	chr7:65983529	G/A	cg12463550	chr7:65579703	CRCP	0.49	6.18	0.35	2.46e-9	Aortic root size;
CESC	cis	rs2880765	0.805	rs34598679	chr15:86042205	G/A	cg10818794	chr15:86012489	AKAP13	-0.34	-5.26	-0.31	3.02e-7	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01565083	chr17:80042523	FASN	-0.63	-7.29	-0.41	3.53e-12	Gut microbiome composition (summer);
CESC	cis	rs6674176	0.597	rs3762422	chr1:44400532	T/A	cg23954153	chr1:44402353	ARTN	-0.37	-5.94	-0.34	8.94e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs9790314	0.586	rs11713185	chr3:161111357	C/G	cg03342759	chr3:160939853	NMD3	-0.43	-5.6	-0.33	5.46e-8	Morning vs. evening chronotype;
CESC	cis	rs4654899	0.785	rs12070677	chr1:21337322	A/G	cg05370193	chr1:21551575	ECE1	0.38	5.84	0.34	1.55e-8	Superior frontal gyrus grey matter volume;
CESC	trans	rs11039798	1.000	rs12280020	chr11:48618844	G/C	cg15704280	chr7:45808275	SEPT13	0.65	6.28	0.36	1.39e-9	Axial length;
CESC	cis	rs769267	1.000	rs7246748	chr19:19433105	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.42	-5.4	-0.31	1.51e-7	Tonsillectomy;
CESC	cis	rs12136530	0.577	rs12066114	chr1:19792527	A/G	cg01832549	chr1:19774989	CAPZB	-0.39	-5.54	-0.32	7.36e-8	Lead levels in blood;
CESC	cis	rs8141529	0.764	rs5762824	chr22:29222930	C/T	cg15103426	chr22:29168792	CCDC117	0.68	9.65	0.51	4.52e-19	Lymphocyte counts;
CESC	cis	rs9309473	0.500	rs13022837	chr2:73912567	T/A	cg20560298	chr2:73613845	ALMS1	0.52	7.24	0.41	4.84e-12	Metabolite levels;
CESC	trans	rs12229918	0.540	rs10784460	chr12:65863584	C/T	cg16723182	chr1:148753544	NBPF16	0.48	6.1	0.35	3.83e-9	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10538494	chr14:97263716	VRK1	0.6	7.08	0.4	1.26e-11	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06996663	chr8:54756036	ATP6V1H	0.51	6.03	0.35	5.52e-9	Gut microbiome composition (summer);
CESC	cis	rs9291683	0.632	rs13101785	chr4:10042915	T/A	cg02734326	chr4:10020555	SLC2A9	0.47	6.53	0.37	3.29e-10	Bone mineral density;
CESC	cis	rs12134245	0.747	rs11164912	chr1:92005191	A/T	cg02896835	chr1:92012615	NA	-0.53	-6.82	-0.39	6.09e-11	Breast cancer;
CESC	cis	rs1862618	0.853	rs2548664	chr5:56133555	G/A	cg12311346	chr5:56204834	C5orf35	-0.74	-8.81	-0.48	1.63e-16	Initial pursuit acceleration;
CESC	cis	rs6032067	0.641	rs17423416	chr20:43758144	G/T	cg10761708	chr20:43804764	PI3	0.5	5.25	0.31	3.12e-7	Blood protein levels;
CESC	cis	rs77861329	1.000	rs9847073	chr3:52144947	C/T	cg08692210	chr3:52188851	WDR51A	-0.82	-7.21	-0.4	6.02e-12	Macrophage inflammatory protein 1b levels;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg18502522	chr15:75165624	SCAMP2	-0.41	-6.24	-0.36	1.74e-9	Gambling;
CESC	cis	rs9302635	0.626	rs34508528	chr16:72215115	C/T	cg01557791	chr16:72042693	DHODH	-0.74	-7.69	-0.43	2.89e-13	Blood protein levels;
CESC	cis	rs637571	0.584	rs659824	chr11:65636509	A/G	cg26695010	chr11:65641043	EFEMP2	0.51	6.35	0.36	9.23e-10	Eosinophil percentage of white cells;
CESC	cis	rs9611565	0.512	rs5758450	chr22:42141640	G/A	cg06481639	chr22:41940642	POLR3H	0.59	5.85	0.34	1.45e-8	Vitiligo;
CESC	cis	rs11030122	0.632	rs4910596	chr11:4084604	A/G	cg18678763	chr11:4115507	RRM1	-0.51	-6.87	-0.39	4.56e-11	Mean platelet volume;Platelet distribution width;
CESC	cis	rs1218582	0.741	rs10908447	chr1:154869742	C/T	cg03351412	chr1:154909251	PMVK	0.55	6.82	0.39	5.99e-11	Prostate cancer;
CESC	cis	rs4072980	0.524	rs28477803	chr1:38398694	C/T	cg18451016	chr1:38461880	NA	0.42	6.06	0.35	4.65e-9	Coronary artery disease;
CESC	cis	rs2836974	0.555	rs35909862	chr21:40621158	G/A	cg17971929	chr21:40555470	PSMG1	-0.88	-12.71	-0.62	3.15e-29	Cognitive function;
CESC	cis	rs46522	0.585	rs79049364	chr17:47014991	T/A	cg16584676	chr17:46985605	UBE2Z	0.49	5.87	0.34	1.31e-8	Coronary heart disease;
CESC	cis	rs9487051	0.646	rs9487049	chr6:109615905	A/T	cg01475377	chr6:109611718	NA	-0.39	-5.39	-0.31	1.55e-7	Reticulocyte fraction of red cells;
CESC	cis	rs344364	0.511	rs56077812	chr16:1948870	T/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.55	-6.2	-0.36	2.15e-9	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs4975709	0.589	rs931508	chr5:1861224	C/G	cg11168104	chr5:1857477	NA	-0.41	-6.12	-0.35	3.34e-9	Cardiovascular disease risk factors;
CESC	cis	rs9911578	1.000	rs8079774	chr17:56908188	A/G	cg05425664	chr17:57184151	TRIM37	-0.5	-6.92	-0.39	3.44e-11	Intelligence (multi-trait analysis);
CESC	cis	rs7089973	0.604	rs11196939	chr10:116593175	A/G	cg23260525	chr10:116636907	FAM160B1	-0.37	-6.45	-0.37	5.25e-10	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs559928	0.606	rs11231726	chr11:63987339	C/T	cg18225595	chr11:63971243	STIP1	0.67	6.02	0.35	5.73e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CESC	cis	rs896854	0.902	rs726816	chr8:95968413	T/G	cg26343298	chr8:95960752	TP53INP1	0.34	5.33	0.31	2.15e-7	Type 2 diabetes;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg16444294	chr16:28925790	RABEP2	0.44	6.26	0.36	1.56e-9	Fibrinogen levels;
CESC	cis	rs9303401	0.659	rs17741087	chr17:56550300	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.98	11.87	0.59	2.46e-26	Cognitive test performance;
CESC	cis	rs10832963	0.961	rs10832954	chr11:18643559	G/A	cg09201001	chr11:18656081	SPTY2D1	0.82	12.36	0.6	5.21e-28	Breast cancer;
CESC	cis	rs8177253	0.965	rs1525889	chr3:133490033	A/C	cg11941060	chr3:133502564	NA	-0.46	-6.11	-0.35	3.45e-9	Iron status biomarkers;
CESC	cis	rs72792276	1.000	rs72794370	chr5:127444907	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.65	5.18	0.3	4.47e-7	Red cell distribution width;
CESC	trans	rs1945213	0.694	rs34537090	chr11:55843285	G/C	cg03929089	chr4:120376271	NA	0.7	6.69	0.38	1.35e-10	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs26868	0.742	rs26848	chr16:2263516	A/G	cg02248941	chr16:2239361	CASKIN1	0.42	7.07	0.4	1.37e-11	Height;
CESC	cis	rs73001065	0.792	rs17216588	chr19:19664077	C/T	cg03709012	chr19:19516395	GATAD2A	0.97	5.89	0.34	1.18e-8	LDL cholesterol;
CESC	cis	rs6502050	0.835	rs7502078	chr17:80131879	C/A	cg23985595	chr17:80112537	CCDC57	-0.41	-6.47	-0.37	4.67e-10	Life satisfaction;
CESC	cis	rs7811142	0.830	rs73401450	chr7:99981859	G/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.1	11.2	0.57	4.36e-24	Platelet count;
CESC	cis	rs9814567	0.806	rs6806810	chr3:134323522	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.38	-5.06	-0.3	7.86e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg04347867	chr16:56965804	HERPUD1	-0.41	-6.27	-0.36	1.47e-9	Gambling;
CESC	cis	rs7208859	0.573	rs11654035	chr17:29136426	T/C	cg13385521	chr17:29058706	SUZ12P	0.84	6.62	0.38	1.98e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs1950626	0.833	rs12891189	chr14:101415523	C/T	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.79	10.67	0.55	2.42e-22	Pelvic organ prolapse (moderate/severe);
CESC	cis	rs6580649	0.941	rs72644843	chr12:48465061	A/G	cg24011408	chr12:48396354	COL2A1	-0.41	-5.27	-0.31	2.86e-7	Lung cancer;
CESC	cis	rs7546094	1.000	rs10857963	chr1:113091487	C/T	cg22162597	chr1:113214053	CAPZA1	0.38	5.77	0.33	2.22e-8	Platelet distribution width;
CESC	cis	rs2230307	0.536	rs6577152	chr1:100434610	A/G	cg24955406	chr1:100503596	HIAT1	0.56	5.61	0.33	5.15e-8	Carotid intima media thickness;
CESC	cis	rs4665809	1.000	rs10048648	chr2:26320315	T/C	cg26314531	chr2:26401878	FAM59B	-0.59	-6.74	-0.38	9.88e-11	Gut microbiome composition (summer);
CESC	cis	rs853679	0.517	rs17711344	chr6:28077602	A/G	cg12963246	chr6:28129442	ZNF389	-0.51	-6.8	-0.39	6.82e-11	Depression;
CESC	cis	rs9790314	1.000	rs3849524	chr3:161015589	C/T	cg04691961	chr3:161091175	C3orf57	-0.47	-6.17	-0.35	2.58e-9	Morning vs. evening chronotype;
CESC	cis	rs6938	0.534	rs12907898	chr15:75207872	C/T	cg13906792	chr15:75199810	C15orf17	-0.34	-5.18	-0.3	4.47e-7	Breast cancer;
CESC	cis	rs11997175	0.646	rs6984073	chr8:33700070	G/A	ch.8.33884649F	chr8:33765107	NA	0.56	7.34	0.41	2.56e-12	Body mass index;
CESC	cis	rs7666738	0.791	rs4440223	chr4:99044796	G/A	cg18180107	chr4:99064573	C4orf37	0.41	5.29	0.31	2.51e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs889398	0.771	rs8048550	chr16:69891759	T/G	cg09409435	chr16:70099608	PDXDC2	0.42	5.27	0.31	2.9e-7	Body mass index;
CESC	cis	rs8031584	0.723	rs711224	chr15:31127921	G/C	cg14829155	chr15:31115871	NA	0.78	10.92	0.56	3.52e-23	Huntington's disease progression;
CESC	trans	rs11722228	0.522	rs1109472	chr4:10134448	C/G	cg26043149	chr18:55253948	FECH	0.96	12.78	0.62	1.91e-29	Gout;Urate levels;Serum uric acid levels;
CESC	cis	rs9309473	1.000	rs7594511	chr2:73681639	A/G	cg20560298	chr2:73613845	ALMS1	-0.54	-7.1	-0.4	1.14e-11	Metabolite levels;
CESC	cis	rs5758511	0.508	rs2854827	chr22:42461918	G/A	cg00645731	chr22:42541494	CYP2D7P1	0.49	7.12	0.4	1.01e-11	Birth weight;
CESC	cis	rs796364	1.000	rs11694369	chr2:200741720	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.82	-6.31	-0.36	1.14e-9	Schizophrenia;
CESC	cis	rs1707322	0.721	rs11211165	chr1:46157906	C/T	cg06784218	chr1:46089804	CCDC17	0.43	7.63	0.42	4.11e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs4853012	0.887	rs6737314	chr2:74339586	A/G	cg19729930	chr2:74357872	NA	0.77	10.52	0.54	7.52e-22	Gestational age at birth (maternal effect);
CESC	cis	rs7666738	0.830	rs11723283	chr4:99001617	C/T	cg18180107	chr4:99064573	C4orf37	0.4	5.23	0.31	3.41e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs12497850	0.931	rs9840050	chr3:49133310	A/G	cg03060546	chr3:49711283	APEH	0.52	6.31	0.36	1.17e-9	Parkinson's disease;
CESC	cis	rs11587400	0.593	rs2336365	chr1:115175415	G/T	cg12756093	chr1:115239321	AMPD1	-0.42	-5.69	-0.33	3.28e-8	Autism;
CESC	cis	rs6502050	0.835	rs4789668	chr17:80161990	C/T	cg23985595	chr17:80112537	CCDC57	-0.4	-6.48	-0.37	4.35e-10	Life satisfaction;
CESC	cis	rs12545109	0.842	rs2582379	chr8:57395243	C/T	cg09654669	chr8:57350985	NA	0.61	6.93	0.39	3.18e-11	Obesity-related traits;
CESC	cis	rs4665809	1.000	rs4665821	chr2:26309949	A/C	cg26314531	chr2:26401878	FAM59B	-0.61	-6.94	-0.39	2.97e-11	Gut microbiome composition (summer);
CESC	cis	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25073725	chr4:100010060	ADH5	0.49	5.06	0.3	7.85e-7	Gut microbiome composition (summer);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg21005948	chr18:46065258	KIAA0427	-0.44	-6.36	-0.36	8.94e-10	Fibrinogen levels;
CESC	cis	rs2832191	0.716	rs1888439	chr21:30454457	A/G	cg08807101	chr21:30365312	RNF160	0.91	13.95	0.65	1.49e-33	Dental caries;
CESC	cis	rs477692	0.935	rs568918	chr10:131414455	A/G	cg05714579	chr10:131428358	MGMT	0.5	7.01	0.4	2.02e-11	Response to temozolomide;
CESC	cis	rs941408	1.000	rs1736176	chr19:2790394	G/A	cg00079169	chr19:2811669	THOP1	0.45	6.36	0.36	8.56e-10	Total cholesterol levels;
CESC	cis	rs898097	1.000	rs898097	chr17:80904310	C/T	cg10494973	chr17:80897199	TBCD	-0.49	-5.75	-0.33	2.42e-8	Breast cancer;
CESC	trans	rs12356475	0.710	rs10822686	chr10:67733250	C/T	cg16754766	chr12:42877927	PRICKLE1	0.59	6.63	0.38	1.89e-10	Psoriatic arthritis;
CESC	cis	rs13108904	0.901	rs7673398	chr4:1300077	G/A	cg16405210	chr4:1374714	KIAA1530	-0.48	-6.09	-0.35	3.96e-9	Obesity-related traits;
CESC	cis	rs2519796	0.531	rs2519104	chr9:136805973	G/A	cg13751417	chr9:136814406	VAV2	-0.43	-5.67	-0.33	3.79e-8	Hematocrit;Hemoglobin concentration;
CESC	cis	rs2836974	0.897	rs2836933	chr21:40564202	C/G	cg27266027	chr21:40555129	PSMG1	0.46	5.49	0.32	9.23e-8	Cognitive function;
CESC	cis	rs7223966	0.921	rs11655493	chr17:61733052	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.62	0.38	2.03e-10	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs514406	0.792	rs1242201	chr1:53344748	G/A	cg25767906	chr1:53392781	SCP2	-0.56	-7.4	-0.41	1.8e-12	Monocyte count;
CESC	cis	rs1152591	0.643	rs3020449	chr14:64773392	C/T	cg23250157	chr14:64679961	SYNE2	-0.42	-5.56	-0.32	6.47e-8	Atrial fibrillation;
CESC	cis	rs35306767	0.715	rs1250891	chr10:1040159	G/C	cg25019033	chr10:957182	NA	-0.59	-5.94	-0.34	9.09e-9	Eosinophil percentage of granulocytes;
CESC	cis	rs66887589	0.837	rs6534135	chr4:120406302	A/G	cg09307838	chr4:120376055	NA	0.53	7.12	0.4	1.04e-11	Diastolic blood pressure;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00301775	chr5:40798454	PRKAA1	-0.54	-6.4	-0.37	7.2e-10	Gut microbiome composition (summer);
CESC	cis	rs13256369	0.951	rs13260947	chr8:8565883	A/G	cg17143192	chr8:8559678	CLDN23	0.76	8.9	0.48	9.21e-17	Obesity-related traits;
CESC	cis	rs2370759	1.000	rs11594963	chr10:32625736	G/A	cg05361325	chr10:32636312	EPC1	-0.55	-5.04	-0.3	8.59e-7	Sexual dysfunction (female);
CESC	cis	rs425277	0.585	rs3107157	chr1:2061969	A/G	cg16545954	chr1:2118288	C1orf86	-0.34	-6.35	-0.36	9.49e-10	Height;
CESC	cis	rs7727544	0.735	rs272894	chr5:131662460	C/T	cg24060327	chr5:131705240	SLC22A5	-0.68	-9.01	-0.48	4.2e-17	Blood metabolite levels;
CESC	cis	rs17384381	0.953	rs12138621	chr1:85783970	T/C	cg16011679	chr1:85725395	C1orf52	0.78	7.92	0.44	6.43e-14	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs763121	0.889	rs6001209	chr22:39121252	C/T	cg14440974	chr22:39074834	NA	0.4	5.43	0.32	1.25e-7	Menopause (age at onset);
CESC	cis	rs7666738	0.830	rs7691864	chr4:98971376	G/C	cg05340658	chr4:99064831	C4orf37	0.77	11.73	0.58	7.21e-26	Colonoscopy-negative controls vs population controls;
CESC	cis	rs40363	0.645	rs250631	chr16:3523215	G/C	cg05754148	chr16:3507555	NAT15	0.57	8.16	0.45	1.33e-14	Tuberculosis;
CESC	cis	rs77741769	0.571	rs11065292	chr12:121289155	T/C	cg02419362	chr12:121203948	SPPL3	0.34	5.55	0.32	7.07e-8	Mean corpuscular volume;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg03346442	chr12:117316882	HRK	-0.53	-6.41	-0.37	6.56e-10	Ulcerative colitis;
CESC	cis	rs2243480	1.000	rs35058610	chr7:65390925	G/A	cg13147721	chr7:65941812	NA	-0.85	-8.1	-0.45	2e-14	Diabetic kidney disease;
CESC	cis	rs9787249	0.957	rs6670841	chr1:40220284	C/G	cg24920358	chr1:40204285	PPIE	0.41	6.1	0.35	3.84e-9	Blood protein levels;
CESC	cis	rs9858542	0.953	rs6446264	chr3:49417243	C/A	cg07274523	chr3:49395745	GPX1	0.67	8.37	0.46	3.46e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs727505	0.607	rs67673811	chr7:124802694	C/G	cg23710748	chr7:124431027	NA	-0.4	-6.21	-0.36	2.04e-9	Lewy body disease;
CESC	cis	rs473651	0.935	rs1103770	chr2:239339281	G/C	cg18131467	chr2:239335373	ASB1	0.94	14.13	0.66	3.57e-34	Multiple system atrophy;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04550740	chr15:52821405	MYO5A	-0.47	-6.42	-0.37	6.17e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs8017423	0.935	rs2236403	chr14:90736325	C/T	cg14092571	chr14:90743983	NA	0.54	8.26	0.45	7.21e-15	Mortality in heart failure;
CESC	cis	rs1008375	0.966	rs4698619	chr4:17580955	G/A	cg16339924	chr4:17578868	LAP3	0.74	9.68	0.51	3.59e-19	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs514406	0.505	rs395169	chr1:53174071	G/A	cg16325326	chr1:53192061	ZYG11B	0.94	16.51	0.71	1.35e-42	Monocyte count;
CESC	cis	rs7520050	1.000	rs12410070	chr1:46358882	T/C	cg03146154	chr1:46216737	IPP	-0.46	-5.86	-0.34	1.36e-8	Red blood cell count;Reticulocyte count;
CESC	cis	rs8114671	0.562	rs6087644	chr20:33480917	G/C	cg07148914	chr20:33460835	GGT7	0.51	6.56	0.37	2.85e-10	Height;
CESC	cis	rs12410462	1.000	rs6672162	chr1:227632335	G/A	cg04117972	chr1:227635322	NA	0.64	6.48	0.37	4.36e-10	Major depressive disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23019286	chr1:227728774	NA	-0.61	-7.82	-0.43	1.27e-13	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.830	rs28867087	chr4:98880349	T/A	cg05340658	chr4:99064831	C4orf37	0.78	11.7	0.58	9.27e-26	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04879577	chr6:90121826	RRAGD	0.57	6.2	0.36	2.15e-9	Gut microbiome composition (summer);
CESC	cis	rs4665809	0.590	rs4665321	chr2:26433801	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.09	-12.46	-0.61	2.41e-28	Gut microbiome composition (summer);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg10294252	chr15:74912474	CLK3	0.42	6.03	0.35	5.59e-9	Fibrinogen levels;
CESC	cis	rs11098499	0.865	rs1112817	chr4:120297800	T/C	cg09307838	chr4:120376055	NA	0.92	12.66	0.61	4.96e-29	Corneal astigmatism;
CESC	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg21280719	chr6:42927975	GNMT	0.3	6.81	0.39	6.56e-11	Alzheimer's disease in APOE e4+ carriers;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg13325346	chr17:37353483	CACNB1	-0.43	-6.04	-0.35	5.26e-9	Asthma;
CESC	cis	rs1218582	0.772	rs4240874	chr1:154885779	C/T	cg03351412	chr1:154909251	PMVK	0.69	9.25	0.49	7.88e-18	Prostate cancer;
CESC	cis	rs9303401	0.614	rs35308719	chr17:57163501	C/T	cg12560992	chr17:57184187	TRIM37	0.51	5.25	0.31	3.19e-7	Cognitive test performance;
CESC	cis	rs67311347	0.866	rs2371183	chr3:40334247	C/T	cg01475735	chr3:40494733	NA	0.39	5.03	0.3	9e-7	Renal cell carcinoma;
CESC	cis	rs6445797	0.632	rs2054987	chr3:56593105	G/C	cg13792233	chr3:56591045	CCDC66	0.39	5.07	0.3	7.5e-7	Gastritis;
CESC	cis	rs7020830	0.867	rs13301916	chr9:37361455	A/C	cg14294708	chr9:37120828	ZCCHC7	1.14	20.49	0.78	1.39e-56	Schizophrenia;
CESC	cis	rs35740288	0.721	rs4843093	chr15:86237433	G/A	cg20737812	chr15:86336631	KLHL25	-0.37	-5.03	-0.3	8.94e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
CESC	trans	rs4862750	0.914	rs11943333	chr4:187872455	A/G	cg19305040	chr4:184580401	C4orf41;RWDD4A	-0.48	-6.37	-0.36	8.39e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs400736	0.930	rs226249	chr1:8021778	A/G	cg25007680	chr1:8021821	PARK7	0.7	10.13	0.53	1.36e-20	Response to antidepressants and depression;
CESC	cis	rs7927771	1.000	rs4752857	chr11:47655752	C/T	cg05585544	chr11:47624801	NA	-0.53	-8.41	-0.46	2.57e-15	Subjective well-being;
CESC	cis	rs4665809	1.000	rs4665309	chr2:26335502	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.67	-7.53	-0.42	7.92e-13	Gut microbiome composition (summer);
CESC	cis	rs858239	0.509	rs6962213	chr7:23188109	G/A	cg23682824	chr7:23144976	KLHL7	0.49	6.51	0.37	3.84e-10	Cerebrospinal fluid biomarker levels;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg12843872	chr7:90894352	FZD1	0.5	6.79	0.38	7.23e-11	Systemic lupus erythematosus;
CESC	cis	rs864643	0.773	rs11129837	chr3:39589963	A/G	cg13882414	chr3:39194867	CSRNP1	0.44	5.55	0.32	6.82e-8	Attention deficit hyperactivity disorder;
CESC	cis	rs7523050	0.730	rs35100394	chr1:109433989	C/G	cg08274380	chr1:109419600	GPSM2	0.91	6.41	0.37	6.51e-10	Fat distribution (HIV);
CESC	cis	rs727505	0.721	rs67277928	chr7:124776704	G/T	cg23710748	chr7:124431027	NA	-0.34	-5.67	-0.33	3.72e-8	Lewy body disease;
CESC	cis	rs8017423	0.935	rs11621820	chr14:90727154	C/T	cg14092571	chr14:90743983	NA	-0.55	-8.33	-0.46	4.46e-15	Mortality in heart failure;
CESC	cis	rs6714710	0.603	rs34503448	chr2:98587288	A/G	cg26665480	chr2:98280029	ACTR1B	0.66	8.95	0.48	6.21e-17	Posterior cortical atrophy and Alzheimer's disease;
CESC	cis	rs6964587	0.967	rs7781221	chr7:91664645	A/G	cg17063962	chr7:91808500	NA	0.6	8.31	0.45	4.96e-15	Breast cancer;
CESC	cis	rs2249694	0.960	rs9630033	chr10:135418505	G/T	cg19469447	chr10:135341870	CYP2E1	0.37	5.21	0.3	3.76e-7	Obesity-related traits;
CESC	cis	rs7615952	0.641	rs61048217	chr3:125807905	G/T	cg04553112	chr3:125709451	NA	-0.55	-5.82	-0.34	1.71e-8	Blood pressure (smoking interaction);
CESC	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	22.27	0.81	1.17e-62	Prudent dietary pattern;
CESC	cis	rs9868809	0.764	rs2633958	chr3:48635432	A/G	cg00383909	chr3:49044727	WDR6	-0.73	-5.52	-0.32	8.05e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs2243480	1.000	rs1638734	chr7:66097539	A/C	cg12463550	chr7:65579703	CRCP	0.75	5.85	0.34	1.42e-8	Diabetic kidney disease;
CESC	cis	rs9916302	0.706	rs4794808	chr17:37531916	C/T	cg07936489	chr17:37558343	FBXL20	0.9	9.82	0.52	1.27e-19	Glomerular filtration rate (creatinine);
CESC	cis	rs7666738	0.830	rs6852015	chr4:99054373	C/A	cg03467027	chr4:99064603	C4orf37	0.47	5.98	0.34	7.19e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4523957	0.583	rs2760743	chr17:2017079	A/C	cg16513277	chr17:2031491	SMG6	0.72	10.18	0.53	9.13e-21	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs4803468	1.000	rs3213861	chr19:41919944	A/C	cg14132834	chr19:41945861	ATP5SL	-0.67	-8.23	-0.45	8.57e-15	Height;
CESC	cis	rs7223966	1.000	rs11542436	chr17:61778689	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.56	6.68	0.38	1.44e-10	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs2688608	0.620	rs7098444	chr10:75580042	C/T	cg23231163	chr10:75533350	FUT11	-0.33	-5.03	-0.3	8.86e-7	Inflammatory bowel disease;
CESC	cis	rs35306767	0.807	rs72778228	chr10:938435	A/G	cg20503657	chr10:835505	NA	1.08	10.04	0.53	2.52e-20	Eosinophil percentage of granulocytes;
CESC	cis	rs17376456	1.000	rs58734583	chr5:93532155	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.63	5.33	0.31	2.14e-7	Diabetic retinopathy;
CESC	cis	rs7666738	0.791	rs60028147	chr4:99046618	G/A	cg03676636	chr4:99064102	C4orf37	0.33	5.08	0.3	7.13e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6088590	0.561	rs11167239	chr20:33140472	G/A	cg06115741	chr20:33292138	TP53INP2	0.51	6.54	0.37	3.21e-10	Coronary artery disease;
CESC	cis	rs6449957	0.639	rs251398	chr5:67509801	C/T	cg23036683	chr5:67512108	NA	-0.44	-6.08	-0.35	4.19e-9	Cleft lip with or without cleft palate;
CESC	cis	rs10779751	0.734	rs2259886	chr1:11137778	C/T	cg08854313	chr1:11322531	MTOR	0.79	11.01	0.56	1.87e-23	Body mass index;
CESC	cis	rs9916302	0.904	rs8076494	chr17:37516722	A/G	cg07936489	chr17:37558343	FBXL20	0.77	10.42	0.54	1.51e-21	Glomerular filtration rate (creatinine);
CESC	cis	rs798766	0.953	rs798751	chr4:1719572	A/G	cg05874882	chr4:1763078	NA	-0.61	-8.52	-0.46	1.19e-15	Bladder cancer;Urinary bladder cancer;
CESC	cis	rs6665290	0.904	rs6690803	chr1:227189106	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.15	-29.58	-0.88	6e-86	Myeloid white cell count;
CESC	cis	rs9457247	0.602	rs12208359	chr6:167458455	G/A	cg07741184	chr6:167504864	NA	0.37	6.45	0.37	5.33e-10	Crohn's disease;
CESC	cis	rs72781680	0.716	rs2712065	chr2:23973603	C/T	cg08917208	chr2:24149416	ATAD2B	-0.57	-5.74	-0.33	2.62e-8	Lymphocyte counts;
CESC	cis	rs644799	0.511	rs1016030	chr11:95472693	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.66	9.23	0.49	8.69e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs11758351	0.660	rs55848726	chr6:26224434	T/C	cg23601095	chr6:26197514	HIST1H3D	0.91	9.96	0.52	4.64e-20	Gout;Renal underexcretion gout;
CESC	cis	rs7219021	0.886	rs3887854	chr17:46868710	A/G	cg16584676	chr17:46985605	UBE2Z	0.57	6.46	0.37	5.01e-10	Schizophrenia or bipolar disorder;
CESC	cis	rs10504229	0.953	rs59265461	chr8:58189701	A/T	cg14926445	chr8:58193284	C8orf71	-0.51	-5.52	-0.32	8.28e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg02161503	chr7:157955692	PTPRN2	0.43	7.72	0.43	2.42e-13	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CESC	cis	rs17095355	1.000	rs1376111	chr10:111707255	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.45	-5.4	-0.31	1.51e-7	Biliary atresia;
CESC	cis	rs7635838	0.826	rs9867963	chr3:11469126	C/T	cg00170343	chr3:11313890	ATG7	0.45	5.95	0.34	8.26e-9	HDL cholesterol;
CESC	cis	rs7680126	0.500	rs11735668	chr4:10148655	C/G	cg11266682	chr4:10021025	SLC2A9	-0.5	-6.48	-0.37	4.42e-10	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	cis	rs1862618	0.671	rs2591955	chr5:56244948	C/T	cg18230493	chr5:56204884	C5orf35	0.61	7.97	0.44	4.79e-14	Initial pursuit acceleration;
CESC	cis	rs4727963	0.846	rs1554700	chr7:122739121	T/C	cg03640110	chr7:122635026	TAS2R16	-0.36	-5.61	-0.33	5.12e-8	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
CESC	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg17330251	chr7:94953956	PON1	-0.56	-9.23	-0.49	9.23e-18	Paraoxonase activity;
CESC	cis	rs6952808	0.893	rs35487994	chr7:1920171	G/A	cg13880726	chr7:1868755	MAD1L1	0.41	5.39	0.31	1.54e-7	Bipolar disorder and schizophrenia;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg19465159	chr13:112631672	NA	-0.46	-6.45	-0.37	5.42e-10	Systemic lupus erythematosus;
CESC	cis	rs3820068	0.603	rs72645887	chr1:15929905	G/C	cg16988262	chr1:15930761	NA	0.35	5.65	0.33	4.18e-8	Systolic blood pressure;
CESC	cis	rs3733585	0.699	rs6844316	chr4:9958977	A/G	cg02734326	chr4:10020555	SLC2A9	-0.43	-6.01	-0.35	6.1e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs1448094	0.511	rs56291271	chr12:86162287	G/A	cg00310523	chr12:86230176	RASSF9	0.35	5.59	0.32	5.75e-8	Major depressive disorder;
CESC	cis	rs116095464	0.558	rs55776650	chr5:273826	G/A	cg12570787	chr5:219185	SDHA;CCDC127	0.52	5.42	0.32	1.31e-7	Breast cancer;
CESC	cis	rs79976124	0.879	rs17432710	chr6:66621744	T/C	cg07460842	chr6:66804631	NA	0.75	8.72	0.47	3.21e-16	Type 2 diabetes;
CESC	cis	rs2617583	0.935	rs1354139	chr5:1451782	T/C	cg07151155	chr5:1473589	LPCAT1	-0.33	-5.06	-0.3	7.93e-7	Breast cancer;
CESC	cis	rs2735413	0.670	rs4522431	chr16:78111152	C/T	cg04733911	chr16:78082701	NA	0.4	5.69	0.33	3.4e-8	Systolic blood pressure (alcohol consumption interaction);
CESC	cis	rs61931739	0.500	rs11053290	chr12:34582392	C/T	cg23762105	chr12:34175262	ALG10	0.4	5.17	0.3	4.62e-7	Morning vs. evening chronotype;
CESC	cis	rs2235544	0.579	rs11804837	chr1:54482915	G/A	cg09175620	chr1:54484536	LDLRAD1	-0.28	-5.12	-0.3	5.76e-7	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
CESC	trans	rs2391518	0.639	rs2968999	chr4:130784545	G/A	cg24601559	chr2:43328536	NA	0.35	6.02	0.35	5.87e-9	Body mass index;
CESC	cis	rs7552404	0.960	rs12085123	chr1:76149749	G/A	cg03433033	chr1:76189801	ACADM	0.68	8.1	0.45	1.98e-14	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs7829975	0.782	rs6990746	chr8:8547811	A/G	cg06636001	chr8:8085503	FLJ10661	-0.46	-6.0	-0.35	6.38e-9	Mood instability;
CESC	cis	rs9398803	0.897	rs9398804	chr6:126703390	T/A	cg19875578	chr6:126661172	C6orf173	0.46	6.34	0.36	1e-9	Male-pattern baldness;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09596239	chr2:130940036	SMPD4;FAM128B	-0.61	-6.9	-0.39	3.89e-11	Gut microbiome composition (summer);
CESC	cis	rs7714584	1.000	rs7716903	chr5:150258574	C/A	cg22134413	chr5:150180641	NA	0.48	5.35	0.31	1.86e-7	Crohn's disease;
CESC	cis	rs1451375	0.652	rs7803903	chr7:50625945	C/T	cg14593290	chr7:50529359	DDC	0.45	5.45	0.32	1.15e-7	Malaria;
CESC	cis	rs801193	0.935	rs2659899	chr7:66186721	A/G	cg06456125	chr7:65229604	NA	0.39	5.05	0.3	8.06e-7	Aortic root size;
CESC	cis	rs4713118	0.629	rs149899	chr6:28019979	C/T	cg23161317	chr6:28129485	ZNF389	0.49	6.17	0.35	2.49e-9	Parkinson's disease;
CESC	cis	rs10242455	0.702	rs6956305	chr7:99241310	A/G	cg25640893	chr7:99214727	ZNF498	0.78	5.24	0.31	3.31e-7	Blood metabolite levels;
CESC	cis	rs8177253	0.898	rs8177258	chr3:133480387	C/A	cg11941060	chr3:133502564	NA	-0.47	-6.27	-0.36	1.48e-9	Iron status biomarkers;
CESC	cis	rs35306767	0.951	rs61833265	chr10:990143	C/T	cg20503657	chr10:835505	NA	0.75	7.64	0.42	4.08e-13	Eosinophil percentage of granulocytes;
CESC	cis	rs7927771	0.894	rs12798346	chr11:47583121	C/T	cg18512352	chr11:47633146	NA	-0.6	-9.28	-0.5	6.06e-18	Subjective well-being;
CESC	cis	rs7666738	0.830	rs10031292	chr4:99056877	A/G	cg03676636	chr4:99064102	C4orf37	0.33	5.08	0.3	7.18e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs34779708	0.733	rs60616028	chr10:35543802	G/A	cg03585969	chr10:35415529	CREM	0.52	5.66	0.33	3.89e-8	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs4835473	0.932	rs7664248	chr4:144653707	C/T	cg25736465	chr4:144833511	NA	0.38	5.75	0.33	2.41e-8	Immature fraction of reticulocytes;
CESC	cis	rs9560113	0.580	rs9560115	chr13:112193619	G/A	cg10483660	chr13:112241077	NA	0.4	6.57	0.37	2.59e-10	Menarche (age at onset);
CESC	cis	rs7666738	0.830	rs1593572	chr4:98979322	A/G	cg05340658	chr4:99064831	C4orf37	-0.77	-11.6	-0.58	1.98e-25	Colonoscopy-negative controls vs population controls;
CESC	cis	rs896854	0.548	rs574183	chr8:95973816	A/G	cg13393036	chr8:95962371	TP53INP1	0.45	8.19	0.45	1.1e-14	Type 2 diabetes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18758298	chr6:167040735	RPS6KA2	-0.52	-6.05	-0.35	4.92e-9	Gut microbiome composition (summer);
CESC	cis	rs1152591	0.543	rs1152590	chr14:64681193	C/T	cg23250157	chr14:64679961	SYNE2	0.4	5.78	0.33	2.06e-8	Atrial fibrillation;
CESC	cis	rs710865	0.519	rs3748759	chr1:19487656	C/T	cg13387374	chr1:19411106	UBR4	-0.51	-6.87	-0.39	4.68e-11	Brain structure;
CESC	cis	rs6938	0.534	rs59945415	chr15:75228427	C/A	cg09165964	chr15:75287851	SCAMP5	0.47	6.32	0.36	1.12e-9	Breast cancer;
CESC	cis	rs72781680	1.000	rs74704838	chr2:24158270	C/A	cg08917208	chr2:24149416	ATAD2B	0.94	8.66	0.47	4.66e-16	Lymphocyte counts;
CESC	cis	rs853679	0.517	rs17774663	chr6:28120898	G/A	cg08968635	chr6:28129556	ZNF389	0.41	5.28	0.31	2.7e-7	Depression;
CESC	cis	rs2576037	0.796	rs2571031	chr18:44577063	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.43	5.66	0.33	3.98e-8	Personality dimensions;
CESC	cis	rs11229555	1.000	rs12799215	chr11:58405674	C/T	cg15696309	chr11:58395628	NA	-0.44	-5.69	-0.33	3.36e-8	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs6546550	0.713	rs6718517	chr2:70018462	T/C	cg02498382	chr2:70120550	SNRNP27	-0.34	-5.75	-0.33	2.43e-8	Prevalent atrial fibrillation;
CESC	cis	rs644799	1.000	rs525404	chr11:95566520	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	13.66	0.64	1.57e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs2952156	0.684	rs931992	chr17:37821435	G/T	cg20243544	chr17:37824526	PNMT	0.67	9.11	0.49	2.03e-17	Asthma;
CESC	cis	rs870825	0.616	rs7683615	chr4:185618373	C/T	cg04058563	chr4:185651563	MLF1IP	0.64	7.05	0.4	1.59e-11	Blood protein levels;
CESC	trans	rs4689592	0.503	rs4689064	chr4:7055603	A/G	cg07817883	chr1:32538562	TMEM39B	0.6	6.16	0.35	2.63e-9	Monocyte percentage of white cells;
CESC	cis	rs7267979	0.844	rs6107027	chr20:25288632	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.79	14.66	0.67	4.74e-36	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs2228479	0.702	rs17233176	chr16:89832751	G/C	cg04013166	chr16:89971882	TCF25	0.78	6.69	0.38	1.3e-10	Skin colour saturation;
CESC	cis	rs2455799	0.634	rs1584326	chr3:15903951	G/A	cg16303742	chr3:15540471	COLQ	-0.38	-5.93	-0.34	9.55e-9	Mean platelet volume;
CESC	cis	rs2836974	0.526	rs418359	chr21:40536734	T/C	cg17971929	chr21:40555470	PSMG1	-0.87	-12.83	-0.62	1.2e-29	Cognitive function;
CESC	cis	rs798554	0.723	rs798518	chr7:2777825	A/G	cg19717773	chr7:2847554	GNA12	-0.56	-8.04	-0.44	2.94e-14	Height;
CESC	cis	rs6938	0.534	rs12913293	chr15:75184458	G/C	cg14664628	chr15:75095509	CSK	-0.58	-8.0	-0.44	3.88e-14	Breast cancer;
CESC	cis	rs60154123	0.772	rs701942	chr1:210429392	C/G	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.5	5.32	0.31	2.26e-7	Coronary artery disease;
CESC	cis	rs9287719	0.901	rs6432109	chr2:10736821	A/G	cg00105475	chr2:10696890	NA	0.39	5.61	0.33	4.96e-8	Prostate cancer;
CESC	cis	rs72772090	0.539	rs11741100	chr5:96113245	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.58	-5.04	-0.3	8.6e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs7618501	0.521	rs952594	chr3:49908023	G/A	cg24110177	chr3:50126178	RBM5	-0.54	-7.2	-0.4	6.37e-12	Intelligence (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07155158	chr17:79164542	AZI1	-0.54	-6.61	-0.38	2.08e-10	Gut microbiome composition (summer);
CESC	cis	rs7662987	1.000	rs4699699	chr4:99997179	C/G	cg13256891	chr4:100009986	ADH5	-0.83	-6.1	-0.35	3.82e-9	Smoking initiation;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg09616526	chr16:21415657	NPIPL3	0.41	6.04	0.35	5.07e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs208520	0.690	rs207081	chr6:66773742	A/G	cg07460842	chr6:66804631	NA	-0.99	-13.2	-0.63	6.27e-31	Exhaled nitric oxide output;
CESC	cis	rs2439831	0.850	rs7169322	chr15:44131014	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.68	7.43	0.42	1.45e-12	Lung cancer in ever smokers;
CESC	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.43	-5.72	-0.33	2.9e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs9486715	0.929	rs2025044	chr6:97067028	A/G	cg18709589	chr6:96969512	KIAA0776	-0.46	-6.31	-0.36	1.19e-9	Headache;
CESC	cis	rs7772486	0.719	rs702317	chr6:146005010	C/T	cg05347473	chr6:146136440	FBXO30	-0.52	-6.32	-0.36	1.1e-9	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7666738	0.791	rs2865953	chr4:99040319	C/T	cg03467027	chr4:99064603	C4orf37	0.47	6.0	0.35	6.55e-9	Colonoscopy-negative controls vs population controls;
CESC	trans	rs7107217	1.000	rs1873872	chr11:129473993	A/T	cg21156815	chr8:22526736	BIN3	0.45	6.11	0.35	3.55e-9	Breast cancer;Type 2 diabetes;
CESC	cis	rs1707322	1.000	rs785506	chr1:46540652	C/T	cg05343316	chr1:45956843	TESK2	-0.44	-5.26	-0.31	2.94e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs6540559	0.673	rs17015218	chr1:209967915	A/G	cg21951975	chr1:209979733	IRF6	0.61	7.76	0.43	1.91e-13	Cleft lip with or without cleft palate;
CESC	cis	rs9486719	0.552	rs9399923	chr6:96850379	G/A	cg06623918	chr6:96969491	KIAA0776	0.74	8.38	0.46	3.17e-15	Migraine;Coronary artery disease;
CESC	cis	rs1451375	0.572	rs11575463	chr7:50547173	A/G	cg14593290	chr7:50529359	DDC	-0.56	-6.93	-0.39	3.18e-11	Malaria;
CESC	cis	rs6500395	1.000	rs2080508	chr16:48690665	G/C	cg04672837	chr16:48644449	N4BP1	-0.51	-6.36	-0.36	8.64e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs116095464	0.558	rs62344345	chr5:257420	C/T	cg22857025	chr5:266934	NA	-1.29	-18.21	-0.75	1.29e-48	Breast cancer;
CESC	cis	rs7959452	0.590	rs6581889	chr12:69757429	T/C	cg22834771	chr12:69754056	YEATS4	-0.48	-6.38	-0.37	7.7e-10	Blood protein levels;
CESC	cis	rs832540	0.931	rs702679	chr5:56221328	A/G	cg14703610	chr5:56206110	C5orf35	0.52	6.88	0.39	4.3e-11	Coronary artery disease;
CESC	cis	rs7818688	0.697	rs76631135	chr8:95980988	G/T	cg16049864	chr8:95962084	TP53INP1	0.55	5.55	0.32	6.92e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs34286592	1.000	rs34286592	chr16:29820480	C/T	cg27338089	chr16:29820515	MAZ	0.56	5.56	0.32	6.51e-8	Multiple sclerosis;
CESC	cis	rs1707322	1.000	rs11211222	chr1:46367757	T/C	cg06784218	chr1:46089804	CCDC17	0.32	5.57	0.32	6.35e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs1994135	0.630	rs11052757	chr12:33719879	A/G	cg26384229	chr12:38710491	ALG10B	0.58	7.82	0.43	1.26e-13	Resting heart rate;
CESC	cis	rs7826238	0.564	rs2921053	chr8:8319963	G/C	cg06636001	chr8:8085503	FLJ10661	0.56	7.19	0.4	6.56e-12	Systolic blood pressure;
CESC	cis	rs7674212	0.537	rs2623060	chr4:104047504	G/A	cg16532752	chr4:104119610	CENPE	-0.44	-6.02	-0.35	5.8e-9	Type 2 diabetes;
CESC	cis	rs17376456	0.825	rs66564678	chr5:93165894	C/T	cg21475434	chr5:93447410	FAM172A	0.82	7.34	0.41	2.67e-12	Diabetic retinopathy;
CESC	cis	rs4665809	0.556	rs4665314	chr2:26415912	T/C	cg25036284	chr2:26402008	FAM59B	-0.83	-9.55	-0.51	8.86e-19	Gut microbiome composition (summer);
CESC	cis	rs1055129	0.681	rs7221792	chr17:73834690	T/G	cg08125733	chr17:73851984	WBP2	0.55	7.57	0.42	6.36e-13	White matter hyperintensity burden;
CESC	cis	rs78889164	0.956	rs6510375	chr19:33850871	A/G	cg02272751	chr19:33882848	PEPD	-0.5	-6.44	-0.37	5.56e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7666738	0.791	rs10856934	chr4:99010844	A/G	cg17366294	chr4:99064904	C4orf37	-0.61	-8.85	-0.48	1.23e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9894429	0.966	rs7405901	chr17:79587813	T/C	cg18240062	chr17:79603768	NPLOC4	0.72	10.27	0.53	4.71e-21	Eye color traits;
CESC	cis	rs7666738	0.830	rs114722517	chr4:99042061	G/A	cg05340658	chr4:99064831	C4orf37	0.82	12.88	0.62	8.44e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7508	0.694	rs12541181	chr8:17923499	C/G	cg18067069	chr8:17937731	ASAH1	-0.4	-5.42	-0.32	1.36e-7	Atrial fibrillation;
CESC	cis	rs9926296	0.609	rs4785709	chr16:89796665	G/A	cg04287289	chr16:89883240	FANCA	-0.62	-8.06	-0.44	2.59e-14	Vitiligo;
CESC	cis	rs9902453	0.904	rs9897794	chr17:28296327	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.65	8.59	0.47	7.72e-16	Coffee consumption (cups per day);
CESC	cis	rs4727963	0.792	rs11769400	chr7:122727366	A/G	cg03640110	chr7:122635026	TAS2R16	-0.41	-6.31	-0.36	1.2e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
CESC	cis	rs2455799	0.613	rs4685258	chr3:15792315	G/A	cg09340198	chr3:15902540	ANKRD28	-0.33	-5.16	-0.3	4.94e-7	Mean platelet volume;
CESC	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg22907277	chr7:1156413	C7orf50	0.4	5.97	0.34	7.42e-9	Longevity;Endometriosis;
CESC	cis	rs34375054	0.624	rs12832525	chr12:125680366	T/C	cg25124228	chr12:125621409	AACS	-0.47	-5.32	-0.31	2.19e-7	Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs7674212	0.570	rs6813563	chr4:104099110	G/A	cg16532752	chr4:104119610	CENPE	-0.44	-6.01	-0.35	6.03e-9	Type 2 diabetes;
CESC	cis	rs962856	0.575	rs673005	chr2:67654381	C/G	cg09028215	chr2:67624308	ETAA1	-0.43	-5.3	-0.31	2.49e-7	Pancreatic cancer;
CESC	cis	rs10242455	0.867	rs2687087	chr7:99294472	G/A	cg07715041	chr7:99302981	CYP3A7	-0.44	-5.48	-0.32	9.68e-8	Blood metabolite levels;
CESC	cis	rs453301	0.682	rs2929308	chr8:9084121	T/A	cg15556689	chr8:8085844	FLJ10661	-0.52	-6.76	-0.38	8.51e-11	Joint mobility (Beighton score);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01524091	chr6:44281032	AARS2	0.59	7.21	0.4	6e-12	Gut microbiome composition (summer);
CESC	cis	rs7259376	0.936	rs4932760	chr19:22540455	T/G	cg02657401	chr19:22469223	NA	-0.25	-5.09	-0.3	6.84e-7	Menopause (age at onset);
CESC	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.64	-8.92	-0.48	7.89e-17	Prudent dietary pattern;
CESC	cis	rs10088262	0.540	rs6988602	chr8:124788502	C/T	cg02993010	chr8:124780839	FAM91A1	0.57	6.68	0.38	1.38e-10	Pancreatic cancer;
CESC	cis	rs1008375	0.966	rs7658240	chr4:17588950	A/G	cg27347728	chr4:17578864	LAP3	-0.5	-5.88	-0.34	1.26e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	trans	rs61931739	1.000	rs11502817	chr12:34010676	T/C	cg26384229	chr12:38710491	ALG10B	-0.45	-6.19	-0.36	2.24e-9	Morning vs. evening chronotype;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg25974586	chr20:32031867	SNTA1	0.55	7.41	0.41	1.72e-12	Gut microbiota (bacterial taxa);
CESC	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg11494091	chr17:61959527	GH2	0.73	12.52	0.61	1.41e-28	Prudent dietary pattern;
CESC	cis	rs6496667	0.779	rs7175476	chr15:91027184	G/C	cg13834112	chr15:90361639	NA	0.39	5.05	0.3	8.11e-7	Rheumatoid arthritis;
CESC	cis	rs1976403	0.659	rs10799700	chr1:21820968	G/C	cg04349561	chr1:21808255	NBPF3	-0.4	-5.84	-0.34	1.49e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs1008375	0.932	rs9884565	chr4:17655096	A/G	cg02297831	chr4:17616191	MED28	0.61	7.82	0.43	1.26e-13	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs1153858	1.000	rs4395020	chr15:45652889	A/C	cg14582100	chr15:45693742	SPATA5L1	0.43	6.07	0.35	4.35e-9	Homoarginine levels;
CESC	cis	rs60515486	0.702	rs11039194	chr11:47374928	C/G	cg25783544	chr11:47291846	MADD	0.55	5.1	0.3	6.34e-7	Lymphocyte counts;
CESC	cis	rs7618915	0.547	rs62255362	chr3:52699741	C/G	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	5.7	0.33	3.27e-8	Bipolar disorder;
CESC	cis	rs67460515	0.563	rs4521287	chr3:160812752	C/T	cg03342759	chr3:160939853	NMD3	-0.5	-6.2	-0.36	2.15e-9	Parkinson's disease;
CESC	cis	rs6540556	0.954	rs10489342	chr1:209935778	A/G	cg23920097	chr1:209922102	NA	-0.37	-5.59	-0.32	5.64e-8	Red blood cell count;
CESC	cis	rs514406	0.679	rs499239	chr1:53310594	A/G	cg08736216	chr1:53307985	ZYG11A	-0.4	-7.29	-0.41	3.55e-12	Monocyte count;
CESC	cis	rs9672608	1.000	rs9672608	chr15:78797463	T/A	cg24631222	chr15:78858424	CHRNA5	0.63	7.13	0.4	9.76e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs6964587	0.967	rs12538325	chr7:91757479	A/G	cg17063962	chr7:91808500	NA	0.54	7.23	0.41	5.27e-12	Breast cancer;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg15421363	chr5:131826865	IRF1	-0.45	-6.48	-0.37	4.48e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs6540559	0.673	rs17015224	chr1:209968918	G/A	cg09509183	chr1:209979624	IRF6	0.56	5.86	0.34	1.4e-8	Cleft lip with or without cleft palate;
CESC	cis	rs7084402	0.967	rs1649063	chr10:60309215	G/A	cg07615347	chr10:60278583	BICC1	0.59	9.34	0.5	4.21e-18	Refractive error;
CESC	cis	rs7923609	0.905	rs10740129	chr10:65250808	G/A	cg01631684	chr10:65280961	REEP3	-0.43	-5.4	-0.31	1.49e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs798766	1.000	rs798724	chr4:1704643	C/T	cg05874882	chr4:1763078	NA	-0.58	-8.13	-0.45	1.7e-14	Bladder cancer;Urinary bladder cancer;
CESC	cis	rs7772486	0.869	rs2777473	chr6:146301494	G/A	cg05347473	chr6:146136440	FBXO30	0.5	6.72	0.38	1.08e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1799949	1.000	rs8176273	chr17:41211653	A/G	cg23758822	chr17:41437982	NA	1.03	15.1	0.68	1.35e-37	Menopause (age at onset);
CESC	cis	rs2439831	0.867	rs2470134	chr15:43849886	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.83	-8.53	-0.46	1.12e-15	Lung cancer in ever smokers;
CESC	cis	rs7520050	0.966	rs34102169	chr1:46424864	G/T	cg24296786	chr1:45957014	TESK2	0.44	5.49	0.32	9.54e-8	Red blood cell count;Reticulocyte count;
CESC	trans	rs79976124	0.837	rs10455591	chr6:66650584	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.76	8.79	0.48	1.94e-16	Type 2 diabetes;
CESC	cis	rs854765	0.547	rs9896837	chr17:17924868	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.64	9.36	0.5	3.63e-18	Total body bone mineral density;
CESC	cis	rs6831352	0.918	rs28987088	chr4:100059139	T/C	cg12011299	chr4:100065546	ADH4	-0.6	-6.62	-0.38	2.04e-10	Alcohol dependence;
CESC	cis	rs72829446	0.530	rs8075009	chr17:7374508	A/T	cg02795151	chr17:7402630	POLR2A	0.58	5.99	0.35	6.89e-9	Androgen levels;
CESC	cis	rs2279817	0.863	rs2354291	chr1:18027554	G/T	cg21791023	chr1:18019539	ARHGEF10L	-0.56	-8.38	-0.46	3.16e-15	Neuroticism;
CESC	cis	rs3820928	0.874	rs4675134	chr2:227843489	C/T	cg05526886	chr2:227700861	RHBDD1	-0.42	-5.26	-0.31	3.05e-7	Pulmonary function;
CESC	cis	rs4899260	0.826	rs1274955	chr14:69289312	A/C	cg03189333	chr14:69283534	NA	0.45	5.05	0.3	8.35e-7	Celiac disease;
CESC	cis	rs9303401	0.659	rs62083368	chr17:56878062	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.01	12.68	0.61	4.11e-29	Cognitive test performance;
CESC	cis	rs2050392	0.590	rs694346	chr10:30711929	C/T	cg18806716	chr10:30721971	MAP3K8	-0.63	-9.24	-0.49	8.53e-18	Inflammatory bowel disease;
CESC	cis	rs754466	0.580	rs1866437	chr10:79526766	A/G	cg17075019	chr10:79541650	NA	-0.83	-12.94	-0.62	5.15e-30	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs1799949	1.000	rs11649954	chr17:41420035	A/G	cg23758822	chr17:41437982	NA	1.05	16.17	0.7	2.15e-41	Menopause (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05707704	chr2:73144283	EMX1	0.54	6.08	0.35	4.15e-9	Gut microbiome composition (summer);
CESC	cis	rs4713118	0.540	rs469227	chr6:27970705	A/C	cg12963246	chr6:28129442	ZNF389	0.41	5.56	0.32	6.7e-8	Parkinson's disease;
CESC	cis	rs4253772	0.530	rs9615990	chr22:46804154	G/A	cg09491104	chr22:46646882	C22orf40	-0.5	-5.55	-0.32	7.09e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs6912958	0.935	rs2179844	chr6:88165773	C/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.58	-8.0	-0.44	3.87e-14	Monocyte percentage of white cells;
CESC	cis	rs9747201	0.963	rs11077982	chr17:80147377	G/C	cg09264619	chr17:80180166	NA	-0.42	-5.05	-0.3	8.04e-7	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs2979489	0.786	rs62508366	chr8:30369499	G/A	cg26383811	chr8:30366931	RBPMS	-0.81	-9.99	-0.52	3.71e-20	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CESC	cis	rs8014204	1.000	rs4553560	chr14:75334199	T/C	cg11812906	chr14:75593930	NEK9	-0.41	-5.1	-0.3	6.63e-7	Caffeine consumption;
CESC	cis	rs7412746	0.658	rs1546376	chr1:150937661	A/G	cg22823121	chr1:150693482	HORMAD1	0.4	5.59	0.32	5.53e-8	Melanoma;
CESC	cis	rs3820068	0.581	rs3940061	chr1:15941276	C/T	cg16988262	chr1:15930761	NA	0.34	5.52	0.32	7.98e-8	Systolic blood pressure;
CESC	cis	rs7264396	0.561	rs6060750	chr20:34596371	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.71	-8.78	-0.47	2.12e-16	Total cholesterol levels;
CESC	cis	rs13191362	1.000	rs66789102	chr6:163104432	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.05	10.88	0.56	4.76e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	trans	rs11098499	0.863	rs2170276	chr4:120485824	A/C	cg25214090	chr10:38739885	LOC399744	0.66	9.03	0.49	3.57e-17	Corneal astigmatism;
CESC	cis	rs2880765	0.835	rs1872074	chr15:86033184	T/G	cg10818794	chr15:86012489	AKAP13	-0.35	-5.39	-0.31	1.6e-7	Coronary artery disease;
CESC	cis	rs611744	0.870	rs613261	chr8:109165949	A/G	cg21045802	chr8:109455806	TTC35	0.45	5.49	0.32	9.39e-8	Dupuytren's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24641125	chr21:40721130	HMGN1	-0.63	-7.12	-0.4	1.04e-11	Gut microbiome composition (summer);
CESC	cis	rs1707322	1.000	rs4660332	chr1:46461418	T/A	cg06784218	chr1:46089804	CCDC17	0.36	6.01	0.35	5.95e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9733	0.544	rs72700902	chr1:150633347	C/T	cg17724175	chr1:150552817	MCL1	0.45	7.31	0.41	3.14e-12	Tonsillectomy;
CESC	cis	rs9611565	0.659	rs4822035	chr22:41935912	A/G	cg17376030	chr22:41985996	PMM1	-0.74	-8.27	-0.45	6.75e-15	Vitiligo;
CESC	cis	rs6582630	0.555	rs10880624	chr12:38526316	C/T	cg13010199	chr12:38710504	ALG10B	0.49	6.43	0.37	6.06e-10	Drug-induced liver injury (flucloxacillin);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg05522046	chr3:52931664	TMEM110	-0.47	-6.85	-0.39	5.26e-11	Gambling;
CESC	cis	rs1005277	0.541	rs2505193	chr10:38394638	G/C	cg25427524	chr10:38739819	LOC399744	-0.66	-9.5	-0.5	1.29e-18	Extrinsic epigenetic age acceleration;
CESC	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg06873352	chr17:61820015	STRADA	0.73	12.96	0.62	4.39e-30	Prudent dietary pattern;
CESC	cis	rs5753618	0.583	rs9606839	chr22:31802710	A/C	cg02404636	chr22:31891804	SFI1	0.41	5.6	0.33	5.36e-8	Colorectal cancer;
CESC	cis	rs7412746	0.611	rs2228099	chr1:150808889	C/G	cg22823121	chr1:150693482	HORMAD1	0.41	6.08	0.35	4.28e-9	Melanoma;
CESC	cis	rs6424115	0.733	rs2502996	chr1:24199041	T/C	cg10978503	chr1:24200527	CNR2	0.33	6.63	0.38	1.85e-10	Immature fraction of reticulocytes;
CESC	cis	rs11638352	0.661	rs2706491	chr15:44423829	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	-0.56	-5.29	-0.31	2.53e-7	Lipoprotein phospholipase A2 activity in cardiovascular disease;
CESC	cis	rs757110	0.866	rs5215	chr11:17408630	C/T	cg15432903	chr11:17409602	KCNJ11	0.7	9.78	0.52	1.68e-19	Type 2 diabetes;
CESC	trans	rs7666738	0.830	rs4292341	chr4:98959724	C/T	cg24789503	chr3:195384528	SDHAP2	0.42	6.04	0.35	5.05e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2832191	0.791	rs4817270	chr21:30480368	G/A	cg08807101	chr21:30365312	RNF160	-0.76	-10.82	-0.55	7.78e-23	Dental caries;
CESC	cis	rs7246657	0.882	rs6508716	chr19:37819010	T/C	cg23950597	chr19:37808831	NA	-0.55	-6.04	-0.35	5.24e-9	Coronary artery calcification;
CESC	cis	rs1707322	0.721	rs7520123	chr1:46235219	C/G	cg06784218	chr1:46089804	CCDC17	0.4	7.28	0.41	3.81e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2108622	0.727	rs12610967	chr19:15977929	C/A	cg13772218	chr19:15982569	NA	0.29	5.69	0.33	3.28e-8	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CESC	cis	rs12579753	0.917	rs10778833	chr12:82197983	G/T	cg24719984	chr12:82153464	PPFIA2	-0.33	-5.04	-0.3	8.55e-7	Resting heart rate;
CESC	cis	rs9911578	1.000	rs12952832	chr17:56906254	T/C	cg12560992	chr17:57184187	TRIM37	0.94	15.75	0.7	6.57e-40	Intelligence (multi-trait analysis);
CESC	cis	rs752010	0.714	rs2182606	chr1:42082375	T/C	cg06885757	chr1:42089581	HIVEP3	0.51	8.96	0.48	5.79e-17	Lupus nephritis in systemic lupus erythematosus;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04194001	chr2:43823104	THADA	0.59	7.0	0.4	2.14e-11	Gut microbiome composition (summer);
CESC	cis	rs8017423	0.605	rs2149652	chr14:90813429	T/C	cg14092571	chr14:90743983	NA	0.52	8.04	0.44	2.92e-14	Mortality in heart failure;
CESC	cis	rs2481665	0.904	rs2481677	chr1:62632571	G/A	cg18591186	chr1:62594603	INADL	-0.47	-5.55	-0.32	7.09e-8	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs1401999	0.966	rs4148585	chr3:183670642	A/G	cg01324343	chr3:183735012	ABCC5	0.64	13.59	0.64	2.93e-32	Anterior chamber depth;
CESC	cis	rs4973397	0.686	rs10933370	chr2:232289960	C/A	cg09339159	chr2:232260559	B3GNT7	0.5	5.41	0.32	1.38e-7	Anti-saccade response;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg14971544	chr1:54955149	NA	-0.51	-6.31	-0.36	1.17e-9	Asthma;
CESC	cis	rs1210638	0.575	rs11703200	chr22:18959169	G/A	cg23029801	chr22:18958135	DGCR5	0.47	5.12	0.3	5.79e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
CESC	cis	rs57709857	0.957	rs1488936	chr8:38213739	A/T	cg01506891	chr8:38243824	LETM2	0.48	5.07	0.3	7.53e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs17253792	0.822	rs77599953	chr14:56058905	C/T	cg01858014	chr14:56050164	KTN1	-0.87	-6.75	-0.38	9.11e-11	Putamen volume;
CESC	cis	rs7618501	0.633	rs55751738	chr3:49972101	A/G	cg24110177	chr3:50126178	RBM5	-0.54	-7.55	-0.42	7.06e-13	Intelligence (multi-trait analysis);
CESC	cis	rs13256369	0.708	rs11249886	chr8:8562021	T/A	cg17143192	chr8:8559678	CLDN23	0.78	9.13	0.49	1.82e-17	Obesity-related traits;
CESC	cis	rs3767633	0.528	rs6671373	chr1:161890796	C/G	cg27519958	chr1:161735129	ATF6	-0.48	-6.02	-0.35	5.83e-9	IgG glycosylation;
CESC	cis	rs7943191	0.805	rs12226821	chr11:62369018	C/G	cg22862634	chr11:62369728	EML3;MTA2	0.48	6.39	0.37	7.6e-10	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
CESC	cis	rs2370759	1.000	rs76467481	chr10:32610740	T/G	cg18270830	chr10:32634957	EPC1	0.67	6.41	0.37	6.52e-10	Sexual dysfunction (female);
CESC	cis	rs4713118	0.587	rs9393899	chr6:28133528	G/C	cg19592336	chr6:28129416	ZNF389	0.61	8.03	0.44	3.13e-14	Parkinson's disease;
CESC	cis	rs3815700	1.000	rs8109885	chr19:33095557	A/G	cg24916020	chr19:33096688	ANKRD27	0.59	5.72	0.33	2.85e-8	Eosinophilic esophagitis;
CESC	cis	rs3747547	0.892	rs56408868	chr9:38003124	G/T	cg13774184	chr9:37916125	SHB	-0.73	-6.23	-0.36	1.82e-9	Metabolite levels (Dihydroxy docosatrienoic acid);
CESC	cis	rs709400	0.859	rs7154948	chr14:104022944	C/T	cg12935359	chr14:103987150	CKB	-0.48	-6.37	-0.36	8.14e-10	Body mass index;
CESC	cis	rs2836974	0.931	rs12151994	chr21:40690397	A/C	cg27266027	chr21:40555129	PSMG1	0.44	5.24	0.31	3.26e-7	Cognitive function;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg23610820	chr19:43774921	PSG9	-0.43	-6.35	-0.36	9.06e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs9311474	0.569	rs7614981	chr3:52566914	G/T	cg25934064	chr3:52569026	NT5DC2	0.25	5.19	0.3	4.14e-7	Electroencephalogram traits;
CESC	cis	rs7635838	0.617	rs346075	chr3:11294027	T/G	cg00170343	chr3:11313890	ATG7	0.58	8.54	0.46	1.1e-15	HDL cholesterol;
CESC	cis	rs7129220	0.528	rs11042633	chr11:10141558	G/A	cg01453529	chr11:10209919	SBF2	-0.4	-5.07	-0.3	7.4e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CESC	cis	rs10979	0.931	rs9484771	chr6:143896897	T/A	cg25407410	chr6:143891975	LOC285740	-0.61	-9.2	-0.49	1.07e-17	Hypospadias;
CESC	cis	rs3087591	0.960	rs12942397	chr17:29462498	C/A	cg24425628	chr17:29625626	OMG;NF1	0.42	5.17	0.3	4.57e-7	Hip circumference;
CESC	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg23131131	chr22:24373011	LOC391322	-0.71	-10.07	-0.53	2.01e-20	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs1499972	0.680	rs62264772	chr3:117647281	G/A	cg07612923	chr3:117604196	NA	0.69	6.15	0.35	2.83e-9	Schizophrenia;
CESC	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg23131131	chr22:24373011	LOC391322	0.63	8.65	0.47	5.05e-16	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs875971	0.862	rs12537823	chr7:65720884	C/T	cg12463550	chr7:65579703	CRCP	0.46	5.84	0.34	1.51e-8	Aortic root size;
CESC	cis	rs13108904	0.539	rs13135102	chr4:1330983	A/C	cg00684032	chr4:1343700	KIAA1530	0.54	8.25	0.45	7.48e-15	Obesity-related traits;
CESC	cis	rs9894429	0.816	rs7406040	chr17:79597583	A/C	cg21984481	chr17:79567631	NPLOC4	-0.56	-8.99	-0.48	4.98e-17	Eye color traits;
CESC	cis	rs951366	0.966	rs11240565	chr1:205722958	C/T	cg14893161	chr1:205819251	PM20D1	-0.5	-6.99	-0.39	2.22e-11	Menarche (age at onset);
CESC	cis	rs7605827	1.000	rs7605827	chr2:15598740	A/T	cg19274914	chr2:15703543	NA	0.32	5.67	0.33	3.71e-8	Educational attainment (years of education);
CESC	cis	rs77741769	0.534	rs58918988	chr12:121332953	G/A	cg02419362	chr12:121203948	SPPL3	0.35	5.6	0.33	5.33e-8	Mean corpuscular volume;
CESC	cis	rs1538970	0.962	rs3219463	chr1:45806432	C/T	cg05343316	chr1:45956843	TESK2	0.84	10.56	0.54	5.37e-22	Platelet count;
CESC	cis	rs875971	0.545	rs11767262	chr7:65767224	T/A	cg11764359	chr7:65958608	NA	0.79	10.15	0.53	1.14e-20	Aortic root size;
CESC	cis	rs7577696	0.606	rs212747	chr2:32414704	A/G	cg02381751	chr2:32503542	YIPF4	0.45	5.33	0.31	2.12e-7	Inflammatory biomarkers;
CESC	trans	rs853679	0.546	rs13214023	chr6:28332141	A/G	cg06606381	chr12:133084897	FBRSL1	0.89	8.23	0.45	8.28e-15	Depression;
CESC	cis	rs10883723	0.810	rs6584507	chr10:104254623	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.54	7.43	0.42	1.49e-12	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs1400745	0.729	rs1741196	chr14:35347020	G/A	cg16230307	chr14:35515116	FAM177A1	0.44	5.25	0.31	3.18e-7	Monocyte count;
CESC	trans	rs3816587	0.839	rs6840622	chr4:25423123	C/T	cg01822600	chr1:245751692	KIF26B	0.41	6.04	0.35	5.19e-9	Rheumatoid arthritis;
CESC	cis	rs1256061	0.603	rs1256036	chr14:64743332	C/T	cg23250157	chr14:64679961	SYNE2	0.53	7.63	0.42	4.14e-13	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs2404602	0.647	rs11852395	chr15:77087785	T/C	cg23625390	chr15:77176239	SCAPER	-0.4	-5.24	-0.31	3.32e-7	Blood metabolite levels;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg15133824	chr2:97523823	ANKRD39	-0.42	-6.32	-0.36	1.09e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs11828289	0.660	rs79067807	chr11:23228262	T/C	cg20040320	chr11:23191996	NA	-0.7	-6.07	-0.35	4.45e-9	Cancer;
CESC	trans	rs61931739	0.500	rs6488222	chr12:34526289	G/A	cg13010199	chr12:38710504	ALG10B	0.5	6.42	0.37	6.3e-10	Morning vs. evening chronotype;
CESC	cis	rs875971	0.862	rs10950043	chr7:65988610	T/C	cg18876405	chr7:65276391	NA	0.53	7.28	0.41	3.9e-12	Aortic root size;
CESC	cis	rs6461049	0.765	rs4719431	chr7:2140312	T/C	cg08027265	chr7:2291960	NA	-0.38	-5.86	-0.34	1.39e-8	Schizophrenia;
CESC	cis	rs7267979	1.000	rs910997	chr20:25267301	G/A	cg08601574	chr20:25228251	PYGB	0.39	5.65	0.33	4.08e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7814319	1.000	rs2643338	chr8:97247469	A/G	cg20787634	chr8:97240163	UQCRB	-0.52	-6.66	-0.38	1.61e-10	Lung function (FVC);
CESC	cis	rs2721195	0.719	rs4925812	chr8:145808035	C/T	cg11211951	chr8:145729740	GPT	0.42	7.02	0.4	1.91e-11	Age at first birth;
CESC	cis	rs2576037	0.526	rs10853547	chr18:44530548	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.68	10.91	0.56	3.89e-23	Personality dimensions;
CESC	cis	rs7647973	0.580	rs4955432	chr3:49266772	C/T	cg07636037	chr3:49044803	WDR6	0.81	13.43	0.64	1.05e-31	Menarche (age at onset);
CESC	cis	rs9790314	0.846	rs12495310	chr3:160970956	T/A	cg03342759	chr3:160939853	NMD3	-0.51	-7.39	-0.41	1.96e-12	Morning vs. evening chronotype;
CESC	cis	rs6499255	0.951	rs9788837	chr16:69688413	A/G	cg15192750	chr16:69999425	NA	0.5	5.77	0.33	2.19e-8	IgE levels;
CESC	cis	rs2985684	1.000	rs2985696	chr14:50094913	C/A	cg02151108	chr14:50098012	C14orf104	-0.44	-5.59	-0.32	5.6e-8	Carotid intima media thickness;
CESC	cis	rs2486288	0.656	rs8040185	chr15:45552081	G/A	cg21132104	chr15:45694354	SPATA5L1	-0.54	-6.55	-0.37	3.03e-10	Glomerular filtration rate;
CESC	cis	rs1862618	0.802	rs2591949	chr5:56132627	T/C	cg24531977	chr5:56204891	C5orf35	-0.89	-11.26	-0.57	2.62e-24	Initial pursuit acceleration;
CESC	cis	rs2519796	0.531	rs2810534	chr9:136806225	A/G	cg13751417	chr9:136814406	VAV2	-0.43	-5.74	-0.33	2.59e-8	Hematocrit;Hemoglobin concentration;
CESC	cis	rs3096299	0.933	rs2965938	chr16:89491336	C/T	cg08822215	chr16:89438651	ANKRD11	-0.36	-5.48	-0.32	1.01e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs12142240	0.698	rs67941619	chr1:46838219	A/G	cg10495392	chr1:46806563	NSUN4	0.58	6.26	0.36	1.54e-9	Menopause (age at onset);
CESC	cis	rs4253772	0.637	rs36125344	chr22:46655779	G/C	cg24881330	chr22:46731750	TRMU	0.79	6.34	0.36	1.01e-9	LDL cholesterol;Cholesterol, total;
CESC	cis	rs6951245	0.744	rs10275401	chr7:1213943	A/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.45	5.26	0.31	2.94e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs1799949	0.965	rs8176322	chr17:41195773	A/G	cg05368731	chr17:41323189	NBR1	0.75	10.32	0.54	3.35e-21	Menopause (age at onset);
CESC	cis	rs7666738	0.830	rs11729753	chr4:98803267	T/A	cg05340658	chr4:99064831	C4orf37	0.75	11.11	0.56	8.68e-24	Colonoscopy-negative controls vs population controls;
CESC	cis	rs68170813	0.523	rs7781947	chr7:106902219	A/G	cg02696742	chr7:106810147	HBP1	-0.52	-5.09	-0.3	6.84e-7	Coronary artery disease;
CESC	cis	rs7264396	1.000	rs224440	chr20:34159447	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.56	-7.32	-0.41	2.92e-12	Total cholesterol levels;
CESC	cis	rs1707322	0.752	rs61784793	chr1:46149285	G/A	cg03146154	chr1:46216737	IPP	0.82	11.53	0.58	3.39e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20307448	chr11:134132814	ACAD8	-0.6	-6.93	-0.39	3.14e-11	Gut microbiome composition (summer);
CESC	cis	rs2952156	0.684	rs931992	chr17:37821435	G/T	cg07936489	chr17:37558343	FBXL20	-0.64	-8.56	-0.47	9.02e-16	Asthma;
CESC	cis	rs4906332	1.000	rs34479426	chr14:103881823	G/C	cg09975044	chr14:104007538	NA	0.45	6.26	0.36	1.58e-9	Coronary artery disease;
CESC	cis	rs1546924	0.570	rs197413	chr1:112308972	G/A	cg23955903	chr1:112298873	DDX20;C1orf183	0.43	5.55	0.32	6.88e-8	Body mass index;
CESC	cis	rs7071206	0.947	rs10824560	chr10:79416901	C/T	cg07817648	chr10:79422355	NA	-0.87	-11.2	-0.57	4.32e-24	Bone mineral density;
CESC	cis	rs9916302	0.851	rs6503502	chr17:37501855	A/G	cg19468946	chr17:37922297	IKZF3	0.4	5.22	0.31	3.56e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs28386778	0.769	rs6504179	chr17:61812995	T/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.68	9.28	0.5	6.06e-18	Prudent dietary pattern;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13668930	chr13:21563168	LATS2	-0.59	-6.73	-0.38	1.03e-10	Gut microbiome composition (summer);
CESC	cis	rs9733	0.566	rs72702554	chr1:150678234	A/G	cg04414720	chr1:150670196	GOLPH3L	0.62	8.93	0.48	7.24e-17	Tonsillectomy;
CESC	cis	rs12410462	0.681	rs76705164	chr1:227615570	G/A	cg04117972	chr1:227635322	NA	0.78	7.15	0.4	8.36e-12	Major depressive disorder;
CESC	cis	rs1008375	0.966	rs6833808	chr4:17652526	T/A	cg02297831	chr4:17616191	MED28	0.62	7.86	0.43	9.58e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs7923609	1.000	rs7070296	chr10:65070438	T/A	cg01631684	chr10:65280961	REEP3	-0.43	-5.42	-0.32	1.33e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs9916302	0.706	rs439537	chr17:37734482	T/C	cg07936489	chr17:37558343	FBXL20	-0.97	-10.88	-0.56	4.83e-23	Glomerular filtration rate (creatinine);
CESC	cis	rs1552244	0.816	rs56387520	chr3:10042782	C/T	cg08888203	chr3:10149979	C3orf24	0.48	6.0	0.35	6.52e-9	Alzheimer's disease;
CESC	cis	rs4835473	0.897	rs7695328	chr4:144624921	A/G	cg25736465	chr4:144833511	NA	0.37	5.56	0.32	6.67e-8	Immature fraction of reticulocytes;
CESC	cis	rs514406	0.505	rs12726160	chr1:53175099	A/G	cg16325326	chr1:53192061	ZYG11B	0.82	13.68	0.64	1.33e-32	Monocyte count;
CESC	trans	rs1908814	0.516	rs11996277	chr8:11800031	G/A	cg15556689	chr8:8085844	FLJ10661	0.53	6.67	0.38	1.51e-10	Neuroticism;
CESC	cis	rs11581903	0.568	rs34087138	chr1:53083567	G/A	cg19751897	chr1:52520827	TXNDC12;BTF3L4	0.71	5.21	0.31	3.72e-7	Joint mobility (Beighton score);
CESC	cis	rs1215050	0.755	rs6851840	chr4:98776366	A/G	cg05340658	chr4:99064831	C4orf37	0.53	6.89	0.39	4.01e-11	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs9733	0.687	rs12410050	chr1:150857141	A/G	cg13175981	chr1:150552382	MCL1	0.55	7.44	0.42	1.39e-12	Tonsillectomy;
CESC	cis	rs4713118	0.629	rs203887	chr6:28021269	C/T	cg19592336	chr6:28129416	ZNF389	0.53	6.46	0.37	5.06e-10	Parkinson's disease;
CESC	cis	rs8062405	0.755	rs4788078	chr16:28559981	G/A	cg07382826	chr16:28625726	SULT1A1	0.4	6.69	0.38	1.3e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs6424115	0.965	rs2502986	chr1:24135292	G/T	cg10978503	chr1:24200527	CNR2	0.28	5.66	0.33	3.88e-8	Immature fraction of reticulocytes;
CESC	cis	rs7937682	0.889	rs559482	chr11:111497902	G/A	cg22437258	chr11:111473054	SIK2	0.71	9.22	0.49	9.53e-18	Primary sclerosing cholangitis;
CESC	cis	rs10504229	0.635	rs72649130	chr8:58053810	G/T	cg02725872	chr8:58115012	NA	-0.42	-5.64	-0.33	4.38e-8	Developmental language disorder (linguistic errors);
CESC	trans	rs11039798	1.000	rs7104642	chr11:48588534	C/T	cg15704280	chr7:45808275	SEPT13	0.7	6.57	0.37	2.68e-10	Axial length;
CESC	cis	rs524023	0.957	rs893006	chr11:64365796	C/A	cg07220939	chr11:64358617	SLC22A12	-0.34	-5.12	-0.3	5.79e-7	Urate levels in obese individuals;
CESC	cis	rs14403	1.000	rs74777638	chr1:243661742	T/C	cg21452805	chr1:244014465	NA	0.49	5.62	0.33	4.93e-8	Schizophrenia;
CESC	cis	rs2933343	0.672	rs1872545	chr3:128645039	G/C	cg24203234	chr3:128598194	ACAD9	0.44	5.94	0.34	9.15e-9	IgG glycosylation;
CESC	cis	rs5769765	1.000	rs5769765	chr22:50271176	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	0.46	5.32	0.31	2.21e-7	Schizophrenia;
CESC	trans	rs11098499	0.754	rs878372	chr4:120238780	A/C	cg25214090	chr10:38739885	LOC399744	0.61	8.51	0.46	1.33e-15	Corneal astigmatism;
CESC	cis	rs2635047	0.638	rs2668762	chr18:44667871	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.44	-5.51	-0.32	8.49e-8	Educational attainment;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10949413	chr6:26158832	HIST1H2BD	0.51	6.06	0.35	4.68e-9	Gut microbiome composition (summer);
CESC	cis	rs3749237	0.595	rs11130196	chr3:49490149	A/C	cg02487422	chr3:49467188	NICN1	0.58	8.47	0.46	1.72e-15	Resting heart rate;
CESC	cis	rs7408868	1.000	rs10407320	chr19:15275716	G/C	cg14696996	chr19:15285081	NOTCH3	1.11	11.47	0.58	5.57e-25	Pulse pressure;
CESC	cis	rs780096	0.526	rs13472	chr2:27600239	G/A	cg22903471	chr2:27725779	GCKR	-0.55	-7.87	-0.44	9.28e-14	Total body bone mineral density;
CESC	cis	rs8177179	1.000	rs8177179	chr3:133463457	G/A	cg24879335	chr3:133465180	TF	0.44	8.37	0.46	3.38e-15	Iron status biomarkers (transferrin levels);
CESC	cis	rs9611565	0.592	rs5996039	chr22:41981957	A/G	cg03806693	chr22:41940476	POLR3H	-0.87	-10.5	-0.54	8.63e-22	Vitiligo;
CESC	cis	rs644799	0.932	rs480079	chr11:95643777	A/T	cg03916912	chr11:95522834	CEP57;FAM76B	-0.81	-12.52	-0.61	1.46e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs9549260	0.564	rs9549279	chr13:41315582	C/G	cg21288729	chr13:41239152	FOXO1	-0.6	-8.0	-0.44	3.93e-14	Red blood cell count;
CESC	cis	rs28489187	0.706	rs233059	chr1:85798936	G/A	cg16011679	chr1:85725395	C1orf52	0.48	5.68	0.33	3.58e-8	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	cis	rs4819052	0.679	rs4819053	chr21:46711357	C/T	cg11663144	chr21:46675770	NA	0.41	6.01	0.35	6.06e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs4689388	0.791	rs1046317	chr4:6304242	T/C	cg25554036	chr4:6271136	WFS1	0.52	7.79	0.43	1.47e-13	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs12618769	0.625	rs4850880	chr2:99212417	C/T	cg10123293	chr2:99228465	UNC50	0.4	5.19	0.3	4.2e-7	Bipolar disorder;
CESC	cis	rs71403859	0.730	rs17356316	chr16:71746921	C/T	cg08717414	chr16:71523259	ZNF19	-0.7	-5.57	-0.32	6.22e-8	Post bronchodilator FEV1;
CESC	cis	rs1801251	1.000	rs13003675	chr2:233584109	C/T	cg08000102	chr2:233561755	GIGYF2	0.7	9.66	0.51	4.15e-19	Coronary artery disease;
CESC	cis	rs10979	0.597	rs9496691	chr6:143910970	T/C	cg25407410	chr6:143891975	LOC285740	-0.48	-6.41	-0.37	6.52e-10	Hypospadias;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08527179	chr2:85132050	TMSB10	-0.62	-7.66	-0.43	3.55e-13	Gut microbiome composition (summer);
CESC	cis	rs10504229	0.683	rs67035623	chr8:58139963	G/T	cg02725872	chr8:58115012	NA	-0.45	-7.12	-0.4	1.02e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs12042052	0.793	rs7534632	chr1:232910796	G/A	cg06935979	chr1:232941706	KIAA1383	0.6	5.2	0.3	3.92e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CESC	cis	rs2204008	0.683	rs11522927	chr12:38137537	C/T	cg13010199	chr12:38710504	ALG10B	0.55	6.73	0.38	1.07e-10	Bladder cancer;
CESC	cis	rs7618501	0.633	rs4688755	chr3:50064424	G/A	cg24110177	chr3:50126178	RBM5	0.52	7.15	0.4	8.33e-12	Intelligence (multi-trait analysis);
CESC	cis	rs4746818	0.793	rs2805914	chr10:70859291	A/G	cg11621586	chr10:70884670	VPS26A	0.81	7.86	0.43	9.48e-14	Left atrial antero-posterior diameter;
CESC	cis	rs77861329	1.000	rs72964044	chr3:52092670	G/C	cg08692210	chr3:52188851	WDR51A	0.8	7.04	0.4	1.61e-11	Macrophage inflammatory protein 1b levels;
CESC	cis	rs9847710	0.733	rs2581790	chr3:53101780	A/G	cg18337363	chr3:52569053	NT5DC2	-0.31	-5.18	-0.3	4.32e-7	Ulcerative colitis;
CESC	trans	rs61931739	0.534	rs1912773	chr12:34097401	T/C	cg26384229	chr12:38710491	ALG10B	0.59	8.25	0.45	7.65e-15	Morning vs. evening chronotype;
CESC	cis	rs12995491	0.698	rs34352413	chr2:88498754	T/G	cg14558114	chr2:88469736	THNSL2	-0.49	-7.16	-0.4	7.82e-12	Response to metformin (IC50);
CESC	cis	rs947211	0.898	rs1775146	chr1:205756168	A/G	cg17178900	chr1:205818956	PM20D1	0.39	5.23	0.31	3.42e-7	Parkinson's disease;
CESC	cis	rs722599	0.683	rs2302834	chr14:75279395	T/A	cg11812906	chr14:75593930	NEK9	0.45	5.47	0.32	1.02e-7	IgG glycosylation;
CESC	trans	rs1557351	0.569	rs8093490	chr18:54719691	A/G	cg11433624	chr6:7146702	RREB1	0.37	6.14	0.35	3.05e-9	Multiple sclerosis (age of onset);
CESC	cis	rs6952808	0.929	rs11768206	chr7:1932151	T/G	cg08061076	chr7:1943177	MAD1L1	-0.38	-5.05	-0.3	8.05e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs897080	0.515	rs1145519	chr2:44708709	C/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	5.57	0.32	6.38e-8	Height;
CESC	cis	rs2836950	0.762	rs8134638	chr21:40644170	T/C	cg11890956	chr21:40555474	PSMG1	-0.64	-8.05	-0.44	2.88e-14	Menarche (age at onset);
CESC	cis	rs9649213	0.593	rs6465675	chr7:97982103	C/T	cg00277769	chr7:97922759	BAIAP2L1	0.33	5.5	0.32	8.83e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs1008375	1.000	rs10027755	chr4:17615954	G/C	cg04450456	chr4:17643702	FAM184B	0.38	5.42	0.32	1.34e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs2404602	0.552	rs11634428	chr15:77084582	T/C	cg06336613	chr15:77223807	RCN2	0.42	5.13	0.3	5.69e-7	Blood metabolite levels;
CESC	cis	rs7666738	0.830	rs28465658	chr4:99035866	T/C	cg03467027	chr4:99064603	C4orf37	0.47	5.97	0.34	7.51e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4555082	0.834	rs2735825	chr14:105710900	G/A	cg27165867	chr14:105738592	BRF1	-0.52	-5.47	-0.32	1.06e-7	Mean platelet volume;Platelet distribution width;
CESC	cis	rs4665809	1.000	rs2384323	chr2:26306473	C/T	cg08470875	chr2:26401718	FAM59B	-0.48	-5.27	-0.31	2.89e-7	Gut microbiome composition (summer);
CESC	cis	rs3818285	0.515	rs4918471	chr10:111660500	C/A	cg00817464	chr10:111662876	XPNPEP1	-0.55	-7.59	-0.42	5.37e-13	Superior crus of antihelix expression;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26943399	chr4:76649977	USO1	0.57	7.1	0.4	1.12e-11	Gut microbiome composition (summer);
CESC	cis	rs7071206	1.000	rs7071206	chr10:79401316	C/T	cg00983440	chr10:79422392	NA	0.61	7.71	0.43	2.6e-13	Bone mineral density;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06772644	chr1:40997203	ZNF684	0.6	6.52	0.37	3.54e-10	Gut microbiome composition (summer);
CESC	cis	rs1552244	0.572	rs2054478	chr3:10172211	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.66	-7.32	-0.41	2.98e-12	Alzheimer's disease;
CESC	cis	rs7937682	0.889	rs558736	chr11:111500760	C/G	cg22437258	chr11:111473054	SIK2	0.69	9.08	0.49	2.56e-17	Primary sclerosing cholangitis;
CESC	cis	rs5769765	1.000	rs5770728	chr22:50259984	G/A	cg26441486	chr22:50317300	CRELD2	-0.4	-5.59	-0.32	5.61e-8	Schizophrenia;
CESC	cis	rs1008375	1.000	rs7697889	chr4:17617961	G/T	cg16339924	chr4:17578868	LAP3	0.61	7.62	0.42	4.4e-13	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs2034088	0.833	rs11247554	chr17:407465	C/A	cg06217071	chr17:408420	NA	0.5	9.66	0.51	4.2e-19	Hip circumference adjusted for BMI;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg08799632	chr2:129026331	HS6ST1	0.49	6.91	0.39	3.61e-11	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs6061231	0.724	rs1570027	chr20:60968596	A/G	cg24112000	chr20:60950667	NA	-0.6	-7.28	-0.41	3.89e-12	Colorectal cancer;
CESC	cis	rs7084402	0.934	rs1593673	chr10:60294170	C/T	cg07615347	chr10:60278583	BICC1	0.6	9.42	0.5	2.35e-18	Refractive error;
CESC	cis	rs9911578	1.000	rs368186	chr17:56736659	A/G	cg12560992	chr17:57184187	TRIM37	0.93	15.58	0.69	2.6e-39	Intelligence (multi-trait analysis);
CESC	trans	rs17514846	0.565	rs2521498	chr15:91442152	A/T	cg02854288	chr3:61236911	FHIT	0.42	6.0	0.35	6.43e-9	Coronary artery disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg05792856	chr11:34379731	ABTB2	-0.47	-6.46	-0.37	4.94e-10	Fibrinogen levels;
CESC	cis	rs2576037	0.583	rs8086286	chr18:44467515	A/G	cg19077165	chr18:44547161	KATNAL2	0.61	9.25	0.49	7.89e-18	Personality dimensions;
CESC	trans	rs7672847	0.547	rs76005534	chr4:170490455	T/A	cg19308436	chr1:237949471	RYR2	0.61	6.42	0.37	6.22e-10	Subjective well-being;
CESC	cis	rs10911232	0.507	rs3934579	chr1:183027432	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.87	13.49	0.64	6.27e-32	Hypertriglyceridemia;
CESC	cis	rs763014	0.865	rs8675	chr16:633843	A/G	cg09263875	chr16:632152	PIGQ	0.66	11.04	0.56	1.45e-23	Height;
CESC	cis	rs9649213	0.593	rs7776638	chr7:97993506	C/T	cg08684580	chr7:98029266	BAIAP2L1	-0.35	-5.8	-0.34	1.85e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs11252926	0.550	rs10795122	chr10:466830	C/T	cg03684893	chr10:554711	DIP2C	-0.41	-6.08	-0.35	4.16e-9	Psychosis in Alzheimer's disease;
CESC	cis	rs4144743	0.877	rs7218773	chr17:45324211	C/T	cg18085866	chr17:45331354	ITGB3	-0.66	-7.64	-0.43	3.87e-13	Body mass index;
CESC	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg21782813	chr7:2030301	MAD1L1	0.44	6.15	0.35	2.79e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs9660180	0.967	rs11260623	chr1:1781456	G/T	cg05132306	chr1:1846340	CALML6	-0.3	-6.3	-0.36	1.24e-9	Body mass index;
CESC	cis	rs34172651	0.517	rs11647120	chr16:24819806	A/G	cg00339695	chr16:24857497	SLC5A11	0.5	6.54	0.37	3.11e-10	Intelligence (multi-trait analysis);
CESC	cis	rs9911578	1.000	rs4636974	chr17:56965373	C/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.4	5.28	0.31	2.71e-7	Intelligence (multi-trait analysis);
CESC	cis	rs2901656	0.583	rs6702667	chr1:172400484	A/C	cg03748243	chr1:172413542	C1orf105;PIGC	0.47	6.68	0.38	1.42e-10	Red cell distribution width;Platelet distribution width;
CESC	cis	rs7178572	1.000	rs7178572	chr15:77747190	A/G	cg22256960	chr15:77711686	NA	-0.58	-7.96	-0.44	4.91e-14	Type 2 diabetes;
CESC	cis	rs6430585	0.528	rs309167	chr2:136669264	C/T	cg07169764	chr2:136633963	MCM6	1.1	14.81	0.67	1.43e-36	Corneal structure;
CESC	cis	rs7412746	0.611	rs72704679	chr1:150897477	C/T	cg04414720	chr1:150670196	GOLPH3L	0.44	5.86	0.34	1.37e-8	Melanoma;
CESC	cis	rs4665809	0.627	rs35461456	chr2:26482361	C/G	cg22920501	chr2:26401640	FAM59B	0.91	10.38	0.54	2.08e-21	Gut microbiome composition (summer);
CESC	cis	rs9611565	0.659	rs56319767	chr22:41933837	G/A	cg17376030	chr22:41985996	PMM1	0.72	7.81	0.43	1.35e-13	Vitiligo;
CESC	cis	rs4481887	1.000	rs10888351	chr1:248451608	G/A	cg00666640	chr1:248458726	OR2T12	0.39	6.44	0.37	5.74e-10	Common traits (Other);
CESC	cis	rs3820928	0.874	rs10439363	chr2:227815065	C/T	cg05526886	chr2:227700861	RHBDD1	-0.46	-5.88	-0.34	1.25e-8	Pulmonary function;
CESC	cis	rs10461617	0.535	rs7709874	chr5:56047451	C/T	cg12311346	chr5:56204834	C5orf35	-0.5	-6.2	-0.36	2.21e-9	Type 2 diabetes;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg26270411	chr20:43514327	YWHAB	0.44	6.18	0.35	2.41e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs9300255	0.537	rs10772993	chr12:123644714	A/G	cg00376283	chr12:123451042	ABCB9	0.57	6.44	0.37	5.55e-10	Neutrophil percentage of white cells;
CESC	cis	rs17376456	0.877	rs12716457	chr5:93397627	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.6	5.03	0.3	9.15e-7	Diabetic retinopathy;
CESC	cis	rs736408	0.522	rs11716747	chr3:52748857	C/T	cg17372223	chr3:52568218	NT5DC2	0.43	6.55	0.37	2.92e-10	Bipolar disorder;
CESC	trans	rs10776614	0.799	rs1345109	chr10:49765211	A/C	cg19218067	chr2:181235115	NA	-0.49	-6.14	-0.35	2.98e-9	Self-employment;
CESC	trans	rs7246760	0.867	rs34648216	chr19:9850690	T/A	cg02900749	chr2:68251473	NA	-0.84	-7.32	-0.41	2.99e-12	Pursuit maintenance gain;
CESC	trans	rs561341	0.830	rs7218801	chr17:30217778	A/G	cg20587970	chr11:113659929	NA	0.97	11.45	0.58	6.48e-25	Hip circumference adjusted for BMI;
CESC	cis	rs514406	0.621	rs928452	chr1:53195926	G/C	cg08736216	chr1:53307985	ZYG11A	0.4	6.33	0.36	1.04e-9	Monocyte count;
CESC	cis	rs9649213	0.593	rs6465665	chr7:97934150	T/C	cg00277769	chr7:97922759	BAIAP2L1	-0.35	-5.69	-0.33	3.35e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs3096299	0.781	rs2170839	chr16:89409452	C/G	cg00750074	chr16:89608354	SPG7	-0.42	-5.72	-0.33	2.8e-8	Multiple myeloma (IgH translocation);
CESC	cis	rs6540559	1.000	rs17015259	chr1:209982923	G/A	cg22442454	chr1:209979470	IRF6	0.5	6.22	0.36	1.98e-9	Cleft lip with or without cleft palate;
CESC	cis	rs17407555	0.738	rs73212870	chr4:10111798	C/G	cg00071950	chr4:10020882	SLC2A9	-0.53	-5.41	-0.32	1.44e-7	Schizophrenia (age at onset);
CESC	cis	rs853679	0.713	rs200991	chr6:27815494	A/C	cg17221315	chr6:27791827	HIST1H4J	-0.57	-5.85	-0.34	1.41e-8	Depression;
CESC	cis	rs896854	0.517	rs1011795	chr8:95951073	G/A	cg23172400	chr8:95962367	TP53INP1	-0.41	-7.23	-0.41	5.14e-12	Type 2 diabetes;
CESC	cis	rs896854	0.875	rs4735333	chr8:95955074	G/A	cg23172400	chr8:95962367	TP53INP1	-0.46	-9.8	-0.52	1.51e-19	Type 2 diabetes;
CESC	cis	rs1348850	0.918	rs4893966	chr2:178470138	A/G	cg23306229	chr2:178417860	TTC30B	0.6	7.59	0.42	5.59e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs9467711	0.606	rs13203358	chr6:26590578	A/T	cg14345882	chr6:26364793	BTN3A2	0.55	5.71	0.33	3.02e-8	Autism spectrum disorder or schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08037327	chr7:150211061	GIMAP7	-0.54	-6.44	-0.37	5.53e-10	Gut microbiome composition (summer);
CESC	cis	rs9733	0.596	rs72702504	chr1:150635374	G/C	cg17724175	chr1:150552817	MCL1	0.44	7.24	0.41	4.8e-12	Tonsillectomy;
CESC	cis	rs9291683	0.588	rs35099040	chr4:10018839	T/C	cg02734326	chr4:10020555	SLC2A9	0.52	7.42	0.41	1.61e-12	Bone mineral density;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg21790971	chr4:54244117	FIP1L1	-0.46	-6.13	-0.35	3.25e-9	Height;
CESC	cis	rs9291683	0.588	rs13113730	chr4:10017628	C/T	cg11266682	chr4:10021025	SLC2A9	0.72	14.87	0.67	8.73e-37	Bone mineral density;
CESC	cis	rs367943	0.712	rs9326886	chr5:112728458	A/C	cg12552261	chr5:112820674	MCC	0.38	5.08	0.3	7.02e-7	Type 2 diabetes;
CESC	cis	rs13118159	0.801	rs1128427	chr4:1330759	T/C	cg02018176	chr4:1364513	KIAA1530	0.4	5.71	0.33	3.05e-8	Longevity;
CESC	cis	rs7666738	0.791	rs1967978	chr4:98966152	T/C	cg03467027	chr4:99064603	C4orf37	0.44	5.57	0.32	6.41e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs769267	0.895	rs1858999	chr19:19497669	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.6	-7.71	-0.43	2.58e-13	Tonsillectomy;
CESC	cis	rs9733	0.596	rs12086472	chr1:150697710	G/A	cg09365446	chr1:150670422	GOLPH3L	0.42	5.84	0.34	1.55e-8	Tonsillectomy;
CESC	cis	rs754466	0.580	rs12356063	chr10:79558131	G/C	cg17075019	chr10:79541650	NA	-0.87	-13.75	-0.65	7.54e-33	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs2243480	1.000	rs313803	chr7:65514731	G/A	cg12463550	chr7:65579703	CRCP	0.67	5.38	0.31	1.67e-7	Diabetic kidney disease;
CESC	cis	rs4268898	0.722	rs7563958	chr2:24422381	C/A	cg06627628	chr2:24431161	ITSN2	0.58	7.6	0.42	5.29e-13	Asthma;
CESC	cis	rs2933343	0.700	rs6787833	chr3:128656184	A/G	cg11901034	chr3:128598214	ACAD9	-0.36	-5.27	-0.31	2.84e-7	IgG glycosylation;
CESC	cis	rs3806843	0.932	rs2563269	chr5:140136468	G/T	cg26395211	chr5:140044315	WDR55	0.44	5.53	0.32	7.53e-8	Depressive symptoms (multi-trait analysis);
CESC	cis	rs3820068	0.532	rs78917815	chr1:15920821	A/G	cg16988262	chr1:15930761	NA	0.35	5.63	0.33	4.6e-8	Systolic blood pressure;
CESC	cis	rs10504229	0.953	rs75585481	chr8:58192202	T/C	cg05313129	chr8:58192883	C8orf71	-0.55	-6.29	-0.36	1.34e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs172166	0.694	rs203876	chr6:28046673	T/C	cg23161317	chr6:28129485	ZNF389	0.39	5.48	0.32	1.01e-7	Cardiac Troponin-T levels;
CESC	cis	rs6061231	0.624	rs8668	chr20:60964064	C/T	cg23531748	chr20:60969906	CABLES2	-0.42	-5.62	-0.33	4.9e-8	Colorectal cancer;
CESC	cis	rs317689	0.788	rs317679	chr12:69693172	A/C	cg14784868	chr12:69753453	YEATS4	0.49	5.18	0.3	4.3e-7	Response to diuretic therapy;
CESC	cis	rs9649213	0.593	rs2394854	chr7:98027306	A/G	cg08684580	chr7:98029266	BAIAP2L1	-0.35	-5.73	-0.33	2.66e-8	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg23830810	chr12:120967582	COQ5	0.4	6.16	0.35	2.64e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs6460942	0.511	rs13245890	chr7:12543134	A/C	cg06484146	chr7:12443880	VWDE	-0.71	-7.37	-0.41	2.24e-12	Coronary artery disease;
CESC	cis	rs4713118	0.621	rs4713133	chr6:28034041	T/C	cg20151795	chr6:28129481	ZNF389	0.4	5.09	0.3	6.94e-7	Parkinson's disease;
CESC	cis	rs4835473	0.932	rs35655934	chr4:144655850	T/C	cg25736465	chr4:144833511	NA	-0.33	-5.22	-0.31	3.68e-7	Immature fraction of reticulocytes;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg15097968	chr15:63449935	RPS27L	0.47	6.21	0.36	1.98e-9	Systemic lupus erythematosus;
CESC	cis	rs10479542	0.642	rs6879665	chr5:178974581	T/A	cg09060608	chr5:178986726	RUFY1	0.46	6.44	0.37	5.53e-10	Lung cancer;
CESC	cis	rs597539	0.652	rs602364	chr11:68662167	C/T	cg04772025	chr11:68637568	NA	0.5	6.07	0.35	4.44e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs8060686	0.623	rs74024145	chr16:68153382	G/C	cg26727032	chr16:67993705	SLC12A4	-0.59	-8.09	-0.44	2.19e-14	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs67311347	0.911	rs9849224	chr3:40392562	T/C	cg01475735	chr3:40494733	NA	-0.41	-5.33	-0.31	2.06e-7	Renal cell carcinoma;
CESC	cis	rs709400	0.658	rs72708874	chr14:103899251	T/G	cg12935359	chr14:103987150	CKB	-0.55	-7.97	-0.44	4.6e-14	Body mass index;
CESC	trans	rs2085496	0.764	rs1596751	chr2:193807860	A/G	ch.20.38346083F	chr20:38912669	NA	0.48	6.35	0.36	9.56e-10	Neuroticism;
CESC	cis	rs4665809	0.652	rs7585891	chr2:26403766	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-1.06	-12.59	-0.61	8.63e-29	Gut microbiome composition (summer);
CESC	cis	rs2295359	0.892	rs4655686	chr1:67638004	T/A	cg17031739	chr1:67600172	NA	0.4	5.2	0.3	4.05e-7	Psoriasis;
CESC	cis	rs950776	0.593	rs588765	chr15:78865425	T/C	cg06917634	chr15:78832804	PSMA4	-0.61	-8.21	-0.45	1.01e-14	Sudden cardiac arrest;
CESC	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg01238044	chr22:24384105	GSTT1	-0.45	-5.73	-0.33	2.72e-8	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs763014	0.898	rs62030902	chr16:638264	C/G	cg09263875	chr16:632152	PIGQ	0.69	11.43	0.57	7.14e-25	Height;
CESC	cis	rs2576037	1.000	rs2576037	chr18:44585420	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.34	-5.14	-0.3	5.33e-7	Personality dimensions;
CESC	cis	rs4819052	0.851	rs9979545	chr21:46679805	G/A	cg11663144	chr21:46675770	NA	-0.61	-9.69	-0.51	3.44e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25043602	chr13:113489734	ATP11A	-0.57	-6.08	-0.35	4.29e-9	Gut microbiome composition (summer);
CESC	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg23708337	chr7:1209742	NA	0.55	5.41	0.32	1.41e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs5753618	0.555	rs9609302	chr22:31895987	A/C	cg00478049	chr22:31556069	RNF185	-0.44	-5.12	-0.3	5.86e-7	Colorectal cancer;
CESC	cis	rs7208859	0.623	rs78071511	chr17:29128154	C/T	cg14008862	chr17:28927542	LRRC37B2	0.65	5.14	0.3	5.34e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs3749237	0.595	rs1464568	chr3:49458266	G/A	cg06212747	chr3:49208901	KLHDC8B	0.48	6.58	0.37	2.44e-10	Resting heart rate;
CESC	cis	rs896854	1.000	rs896854	chr8:95960511	T/C	cg26343298	chr8:95960752	TP53INP1	0.37	5.94	0.34	8.73e-9	Type 2 diabetes;
CESC	cis	rs8077889	0.871	rs8065043	chr17:41900984	G/A	cg26893861	chr17:41843967	DUSP3	0.77	10.14	0.53	1.23e-20	Triglycerides;
CESC	cis	rs1799949	1.000	rs2271574	chr17:41327648	T/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.42	5.73	0.33	2.75e-8	Menopause (age at onset);
CESC	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg10819733	chr22:24237672	NA	-0.4	-5.61	-0.33	5e-8	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs3733585	0.699	rs6834893	chr4:9959123	C/T	cg11266682	chr4:10021025	SLC2A9	-0.6	-11.2	-0.57	4.42e-24	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs9908102	0.740	rs7216413	chr17:12900471	T/G	cg26162695	chr17:12921313	ELAC2	0.52	5.72	0.33	2.91e-8	Schizophrenia;
CESC	cis	rs2072499	0.966	rs2842864	chr1:156159217	G/A	cg25208724	chr1:156163844	SLC25A44	1.01	18.98	0.76	2.67e-51	Testicular germ cell tumor;
CESC	cis	rs3858526	0.628	rs1840177	chr11:5944627	T/G	cg13902645	chr11:5959945	NA	0.69	9.37	0.5	3.3e-18	DNA methylation (variation);
CESC	cis	rs2243480	1.000	rs1499614	chr7:65730798	A/T	cg12463550	chr7:65579703	CRCP	0.75	5.94	0.34	8.79e-9	Diabetic kidney disease;
CESC	cis	rs55883249	1.000	rs62119392	chr2:9714033	G/C	cg23886495	chr2:9695866	ADAM17	0.58	5.48	0.32	1e-7	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
CESC	trans	rs7618501	1.000	rs3749240	chr3:49750188	T/A	cg21582582	chr3:182698605	DCUN1D1	-0.44	-6.0	-0.35	6.29e-9	Intelligence (multi-trait analysis);
CESC	cis	rs3096299	0.702	rs2086825	chr16:89471542	C/T	cg02187348	chr16:89574699	SPG7	0.47	5.88	0.34	1.21e-8	Multiple myeloma (IgH translocation);
CESC	cis	rs9325144	0.560	rs7314632	chr12:38636979	C/T	cg13010199	chr12:38710504	ALG10B	-0.43	-5.88	-0.34	1.2e-8	Morning vs. evening chronotype;
CESC	cis	rs763121	0.853	rs2205802	chr22:39046327	T/C	cg21395723	chr22:39101663	GTPBP1	0.43	5.33	0.31	2.09e-7	Menopause (age at onset);
CESC	cis	rs1799949	1.000	rs12950607	chr17:41299928	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.67	9.36	0.5	3.44e-18	Menopause (age at onset);
CESC	cis	rs11209002	0.614	rs7552205	chr1:67551741	C/A	cg02640540	chr1:67518911	SLC35D1	0.45	5.24	0.31	3.29e-7	Crohn's disease;
CESC	cis	rs546131	0.963	rs539044	chr11:34841542	G/T	cg06937548	chr11:34938143	PDHX;APIP	0.53	6.78	0.38	7.84e-11	Lung disease severity in cystic fibrosis;
CESC	cis	rs5769707	0.967	rs763127	chr22:50006078	C/T	cg05373962	chr22:49881684	NA	-0.38	-6.82	-0.39	6.24e-11	Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs4268898	0.760	rs4665675	chr2:24468132	C/T	cg06627628	chr2:24431161	ITSN2	-0.52	-6.46	-0.37	5.01e-10	Asthma;
CESC	cis	rs11252926	0.574	rs4881254	chr10:453567	C/T	cg16386425	chr10:429943	DIP2C	-0.57	-7.38	-0.41	2.09e-12	Psychosis in Alzheimer's disease;
CESC	cis	rs731174	0.921	rs6686264	chr1:38192337	A/T	cg12339802	chr1:38156545	C1orf109	-0.46	-5.69	-0.33	3.29e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs2549003	1.000	rs9282763	chr5:131822133	T/C	cg21138405	chr5:131827807	IRF1	0.54	9.32	0.5	4.74e-18	Asthma (sex interaction);
CESC	cis	rs919433	0.963	rs10199410	chr2:198155776	A/T	cg10820045	chr2:198174542	NA	-0.41	-6.31	-0.36	1.14e-9	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs9457247	0.515	rs1951459	chr6:167402536	G/A	cg23791538	chr6:167370224	RNASET2	0.65	9.13	0.49	1.77e-17	Crohn's disease;
CESC	cis	rs4862750	0.872	rs13143414	chr4:187878213	G/A	cg10295955	chr4:187884368	NA	-1.03	-20.7	-0.79	2.66e-57	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1322639	0.806	rs1322640	chr6:169586887	T/C	cg04662567	chr6:169592167	NA	0.52	6.83	0.39	5.66e-11	Pulse pressure;
CESC	cis	rs11758351	0.518	rs79922979	chr6:26224975	A/G	cg23601095	chr6:26197514	HIST1H3D	0.91	9.96	0.52	4.64e-20	Gout;Renal underexcretion gout;
CESC	cis	rs3892630	0.878	rs1061686	chr19:33204544	C/T	cg22980127	chr19:33182716	NUDT19	-0.95	-9.53	-0.51	1.07e-18	Red blood cell traits;
CESC	cis	rs2486288	0.656	rs1706770	chr15:45575062	T/C	cg09092052	chr15:45571596	NA	0.49	5.92	0.34	9.97e-9	Glomerular filtration rate;
CESC	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg06877462	chr1:205807181	PM20D1	0.4	5.65	0.33	4.22e-8	Menarche (age at onset);
CESC	cis	rs793571	0.688	rs7179399	chr15:59165527	T/C	cg05156742	chr15:59063176	FAM63B	-0.5	-6.7	-0.38	1.26e-10	Schizophrenia;
CESC	cis	rs35123781	1.000	rs9687282	chr5:139065988	T/G	cg10513866	chr5:139070639	NA	0.38	5.68	0.33	3.45e-8	Schizophrenia;
CESC	cis	rs1580019	0.523	rs13236410	chr7:32690663	G/A	cg07520158	chr7:32535189	LSM5;AVL9	0.49	6.21	0.36	2.07e-9	Cognitive ability;
CESC	cis	rs9457247	0.765	rs10455982	chr6:167448728	C/T	cg23791538	chr6:167370224	RNASET2	-0.55	-7.66	-0.43	3.42e-13	Crohn's disease;
CESC	cis	rs11792861	0.926	rs7870597	chr9:111871864	T/C	cg05043794	chr9:111880884	C9orf5	-0.42	-6.93	-0.39	3.22e-11	Menarche (age at onset);
CESC	cis	rs9611565	0.592	rs9611612	chr22:41961189	T/C	cg06481639	chr22:41940642	POLR3H	-0.57	-6.29	-0.36	1.28e-9	Vitiligo;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19756253	chr3:128118221	EEFSEC	-0.61	-6.7	-0.38	1.26e-10	Gut microbiome composition (summer);
CESC	cis	rs17711722	0.565	rs4275112	chr7:65198619	T/G	cg05332525	chr7:65337924	VKORC1L1	-0.47	-6.01	-0.35	6.07e-9	Calcium levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17001531	chr1:16825540	NA	0.51	6.28	0.36	1.39e-9	Gut microbiome composition (summer);
CESC	cis	rs10504229	1.000	rs113379801	chr8:58173686	C/G	cg05313129	chr8:58192883	C8orf71	-0.54	-6.22	-0.36	1.96e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs7811142	0.830	rs61735533	chr7:99955866	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.87	8.33	0.46	4.25e-15	Platelet count;
CESC	cis	rs17376456	0.825	rs10052662	chr5:93271385	A/G	cg25358565	chr5:93447407	FAM172A	1.13	10.22	0.53	6.99e-21	Diabetic retinopathy;
CESC	cis	rs853679	0.517	rs6932109	chr6:28078303	A/G	cg17949981	chr6:28129498	ZNF389	-0.49	-6.34	-0.36	9.94e-10	Depression;
CESC	cis	rs11608355	0.618	rs7958220	chr12:109830980	T/C	cg19025524	chr12:109796872	NA	-0.55	-7.83	-0.43	1.17e-13	Neuroticism;
CESC	cis	rs4665809	0.627	rs13032756	chr2:26489730	A/T	cg08470875	chr2:26401718	FAM59B	0.76	8.07	0.44	2.41e-14	Gut microbiome composition (summer);
CESC	cis	rs4704187	0.663	rs28448485	chr5:74425775	G/A	cg03227963	chr5:74354835	NA	0.31	5.77	0.33	2.21e-8	Response to amphetamines;
CESC	cis	rs9393692	0.620	rs9379842	chr6:26289310	C/T	cg00631329	chr6:26305371	NA	0.34	5.66	0.33	3.99e-8	Educational attainment;
CESC	cis	rs9894429	0.634	rs9709130	chr17:79583948	C/T	cg18240062	chr17:79603768	NPLOC4	0.54	7.13	0.4	9.28e-12	Eye color traits;
CESC	cis	rs7772486	0.625	rs2050027	chr6:146116113	C/G	cg05347473	chr6:146136440	FBXO30	-0.53	-7.0	-0.39	2.13e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs8028182	0.636	rs4564532	chr15:75706296	C/G	cg20655648	chr15:75932815	IMP3	0.49	6.39	0.37	7.49e-10	Sudden cardiac arrest;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg09326324	chr1:161123937	UFC1	-0.49	-6.58	-0.37	2.56e-10	Height;
CESC	cis	rs6594499	0.872	rs10055177	chr5:110450584	T/G	cg04022379	chr5:110408740	TSLP	0.32	5.67	0.33	3.82e-8	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs589448	0.902	rs315131	chr12:69761839	T/G	cg14784868	chr12:69753453	YEATS4	0.89	14.23	0.66	1.66e-34	Cerebrospinal fluid biomarker levels;
CESC	trans	rs7944735	0.507	rs7396592	chr11:48100837	T/C	cg15704280	chr7:45808275	SEPT13	-0.63	-7.63	-0.42	4.32e-13	Intraocular pressure;
CESC	cis	rs892961	0.932	rs7224442	chr17:75413439	A/G	cg05865280	chr17:75406074	SEPT9	0.62	12.67	0.61	4.57e-29	Airflow obstruction;
CESC	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.56	-7.28	-0.41	3.86e-12	Longevity;Endometriosis;
CESC	cis	rs1005277	0.579	rs1780116	chr10:38526621	C/T	cg25517755	chr10:38738941	LOC399744	-0.49	-6.39	-0.37	7.49e-10	Extrinsic epigenetic age acceleration;
CESC	trans	rs1728785	1.000	rs1728764	chr16:68572292	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.61	7.44	0.42	1.41e-12	Ulcerative colitis;
CESC	cis	rs9467711	0.606	rs9393711	chr6:26370659	C/T	cg12826209	chr6:26865740	GUSBL1	0.62	5.22	0.31	3.66e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs951366	0.966	rs11240565	chr1:205722958	C/T	cg07157834	chr1:205819609	PM20D1	-0.45	-6.06	-0.35	4.73e-9	Menarche (age at onset);
CESC	cis	rs4727027	0.704	rs12535115	chr7:148895087	C/T	cg23583168	chr7:148888333	NA	-0.94	-16.97	-0.72	3.29e-44	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs854765	0.547	rs2955353	chr17:17948979	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.62	-8.81	-0.48	1.7e-16	Total body bone mineral density;
CESC	cis	rs7223966	1.000	rs113134232	chr17:61715461	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.49	5.15	0.3	5.09e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18222961	chr2:48009935	MSH6	0.57	6.11	0.35	3.46e-9	Gut microbiome composition (summer);
CESC	cis	rs6547741	0.935	rs12714204	chr2:27787540	T/C	cg21248554	chr2:27665150	KRTCAP3	0.25	5.26	0.31	3.04e-7	Oral cavity cancer;
CESC	cis	rs2075371	0.933	rs2544181	chr7:133944934	C/T	cg20476274	chr7:133979776	SLC35B4	0.64	9.32	0.5	4.89e-18	Mean platelet volume;
CESC	cis	rs6912958	0.703	rs9362427	chr6:88097634	G/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.46	7.65	0.43	3.71e-13	Monocyte percentage of white cells;
CESC	cis	rs798554	0.644	rs1639040	chr7:2884116	G/T	cg09658497	chr7:2847517	GNA12	-0.35	-5.09	-0.3	6.67e-7	Height;
CESC	cis	rs4969178	0.896	rs12602206	chr17:76397133	A/G	cg20026190	chr17:76395443	PGS1	0.49	7.78	0.43	1.67e-13	HDL cholesterol levels;
CESC	cis	rs6545883	0.929	rs2593635	chr2:61634706	A/C	cg15711740	chr2:61764176	XPO1	0.4	5.19	0.3	4.19e-7	Tuberculosis;
CESC	cis	rs514406	0.644	rs6662414	chr1:53198893	A/G	cg27535305	chr1:53392650	SCP2	0.36	6.31	0.36	1.14e-9	Monocyte count;
CESC	cis	rs2549003	1.000	rs2549002	chr5:131829578	C/A	cg21138405	chr5:131827807	IRF1	-0.63	-11.43	-0.57	7.32e-25	Asthma (sex interaction);
CESC	cis	rs2204008	0.782	rs11514339	chr12:38236670	G/A	cg26384229	chr12:38710491	ALG10B	0.73	10.35	0.54	2.55e-21	Bladder cancer;
CESC	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg07677032	chr17:61819896	STRADA	0.45	5.9	0.34	1.1e-8	Prudent dietary pattern;
CESC	cis	rs1881797	0.932	rs10925071	chr1:247686521	C/T	cg18198730	chr1:247681584	NA	-0.6	-8.55	-0.46	9.99e-16	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs6088580	0.634	rs6059851	chr20:33047945	G/A	cg08999081	chr20:33150536	PIGU	0.66	11.8	0.59	4.25e-26	Glomerular filtration rate (creatinine);
CESC	cis	rs597539	0.652	rs569777	chr11:68706848	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.79	10.38	0.54	2.13e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs950027	0.620	rs35861938	chr15:45637343	T/C	cg21132104	chr15:45694354	SPATA5L1	0.67	8.55	0.46	1.01e-15	Response to fenofibrate (adiponectin levels);
CESC	cis	rs9811920	0.569	rs793445	chr3:99576644	T/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.52	-6.38	-0.36	8e-10	Axial length;
CESC	trans	rs208515	0.525	rs12193034	chr6:66677866	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.89	11.12	0.56	7.77e-24	Exhaled nitric oxide levels;
CESC	cis	rs11190604	1.000	rs11190595	chr10:102291761	T/C	cg07080220	chr10:102295463	HIF1AN	0.7	6.48	0.37	4.34e-10	Palmitoleic acid (16:1n-7) levels;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg09784724	chr6:90038647	UBE2J1	0.44	6.66	0.38	1.59e-10	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs2839186	0.900	rs2839196	chr21:47708037	G/A	cg10351095	chr21:47802916	PCNT	-0.48	-6.63	-0.38	1.83e-10	Testicular germ cell tumor;
CESC	cis	rs17384381	1.000	rs12118950	chr1:85864519	T/C	cg16011679	chr1:85725395	C1orf52	0.8	8.08	0.44	2.26e-14	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs854765	0.583	rs7503334	chr17:17779458	C/T	cg04398451	chr17:18023971	MYO15A	0.64	8.99	0.48	4.72e-17	Total body bone mineral density;
CESC	cis	rs1670533	1.000	rs2100411	chr4:1074412	T/C	cg04106633	chr4:1044584	NA	0.4	5.09	0.3	6.88e-7	Recombination rate (females);
CESC	cis	rs1059312	0.932	rs4760589	chr12:129284382	T/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.71	-10.09	-0.53	1.81e-20	Systemic lupus erythematosus;
CESC	cis	rs4665809	1.000	rs10170359	chr2:26272219	G/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.77	-8.65	-0.47	5e-16	Gut microbiome composition (summer);
CESC	cis	rs67311347	1.000	rs7642552	chr3:40424816	T/C	cg09455208	chr3:40491958	NA	0.42	6.94	0.39	3.09e-11	Renal cell carcinoma;
CESC	cis	rs9549367	0.826	rs2302755	chr13:113898418	C/T	cg18105134	chr13:113819100	PROZ	-0.69	-8.63	-0.47	5.68e-16	Platelet distribution width;
CESC	cis	rs734999	0.505	rs10797439	chr1:2540364	G/A	cg18854424	chr1:2615690	NA	0.3	5.99	0.35	6.97e-9	Ulcerative colitis;
CESC	cis	rs4862750	0.914	rs9998558	chr4:187874691	A/G	cg11301795	chr4:187892539	NA	-0.71	-11.21	-0.57	3.97e-24	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7647973	0.769	rs7434187	chr3:49032967	C/T	cg07636037	chr3:49044803	WDR6	0.87	11.22	0.57	3.57e-24	Menarche (age at onset);
CESC	cis	rs709400	0.930	rs2274268	chr14:104029378	C/G	cg12935359	chr14:103987150	CKB	-0.49	-6.35	-0.36	9.57e-10	Body mass index;
CESC	cis	rs9837602	0.529	rs793495	chr3:99507934	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.59	9.77	0.51	1.87e-19	Breast cancer;
CESC	cis	rs428668	0.523	rs6898671	chr5:150677643	A/T	cg11125805	chr5:150678162	SLC36A3	0.7	11.11	0.56	8.41e-24	Skin aging (microtopography measurement);
CESC	cis	rs6964587	1.000	rs7811564	chr7:91663364	A/G	cg17063962	chr7:91808500	NA	0.6	8.31	0.45	4.96e-15	Breast cancer;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg13576045	chr11:9635311	NA	-0.47	-6.92	-0.39	3.46e-11	Gambling;
CESC	cis	rs9443189	0.723	rs2748947	chr6:76437921	C/T	cg01950844	chr6:76311363	SENP6	-0.64	-7.04	-0.4	1.69e-11	Prostate cancer;
CESC	cis	rs7191439	0.657	rs3826076	chr16:88780518	C/T	cg02389323	chr16:88786976	FAM38A	-0.72	-6.39	-0.37	7.56e-10	Plateletcrit;
CESC	cis	rs9868809	0.881	rs57334642	chr3:48666795	C/T	cg07636037	chr3:49044803	WDR6	-0.63	-5.15	-0.3	5.14e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs17253792	0.822	rs28549152	chr14:56091239	A/G	cg01858014	chr14:56050164	KTN1	-0.85	-6.99	-0.39	2.22e-11	Putamen volume;
CESC	cis	rs2072732	0.861	rs12034794	chr1:2937551	T/G	cg03976712	chr1:2946727	NA	0.34	5.38	0.31	1.61e-7	Plateletcrit;
CESC	trans	rs11098499	0.691	rs12510133	chr4:120271344	A/C	cg25214090	chr10:38739885	LOC399744	0.6	8.3	0.45	5.33e-15	Corneal astigmatism;
CESC	cis	rs763014	0.898	rs8060921	chr16:635988	C/A	cg00908189	chr16:619842	PIGQ	0.65	9.02	0.48	4.04e-17	Height;
CESC	cis	rs2625529	0.590	rs3803471	chr15:72500786	A/G	cg16672083	chr15:72433130	SENP8	-0.4	-5.25	-0.31	3.08e-7	Red blood cell count;
CESC	cis	rs9614461	0.826	rs9614649	chr22:45746097	C/A	cg23503501	chr22:45809793	SMC1B;RIBC2	0.66	6.6	0.38	2.17e-10	Tonsillectomy;
CESC	cis	rs2742234	0.868	rs2505512	chr10:43633596	G/A	cg07801480	chr10:43725741	RASGEF1A	0.37	5.26	0.31	2.98e-7	Hirschsprung disease;
CESC	cis	rs6121246	0.583	rs28815498	chr20:30351560	T/C	cg13852791	chr20:30311386	BCL2L1	0.85	11.17	0.57	5.24e-24	Mean corpuscular hemoglobin;
CESC	cis	rs4604732	0.631	rs74154672	chr1:247625625	C/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.57	7.17	0.4	7.39e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs7843479	1.000	rs17615788	chr8:21814739	C/T	cg17168535	chr8:21777572	XPO7	0.49	6.73	0.38	1.02e-10	Mean corpuscular volume;
CESC	cis	rs2415984	0.622	rs1955262	chr14:46940639	A/G	cg14871534	chr14:47121158	RPL10L	-0.36	-5.42	-0.32	1.37e-7	Number of children ever born;
CESC	cis	rs7336332	0.598	rs74183666	chr13:28007765	A/T	cg01674679	chr13:27998804	GTF3A	-0.59	-5.34	-0.31	1.99e-7	Weight;
CESC	cis	rs12368653	0.525	rs1564374	chr12:58010163	C/T	cg18357645	chr12:58087776	OS9	0.37	5.24	0.31	3.36e-7	Multiple sclerosis;
CESC	cis	rs7666738	0.830	rs6846229	chr4:99016546	C/T	cg05340658	chr4:99064831	C4orf37	0.82	13.05	0.63	2.08e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6674176	0.932	rs12410334	chr1:44442521	A/C	cg13606994	chr1:44402422	ARTN	-0.37	-5.45	-0.32	1.16e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs9467711	0.606	rs9393712	chr6:26371000	G/C	cg12826209	chr6:26865740	GUSBL1	0.62	5.22	0.31	3.66e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs9487051	0.676	rs1521905	chr6:109594515	T/C	cg01475377	chr6:109611718	NA	-0.44	-6.99	-0.39	2.19e-11	Reticulocyte fraction of red cells;
CESC	cis	rs2354432	0.660	rs10751415	chr1:146830785	T/A	cg25205988	chr1:146714368	CHD1L	0.99	9.12	0.49	1.88e-17	Mitochondrial DNA levels;
CESC	cis	rs2540647	0.561	rs2518802	chr22:18975345	A/C	cg12798833	chr22:18958832	DGCR5	0.5	5.46	0.32	1.1e-7	Blood metabolite ratios;
CESC	cis	rs2108622	0.727	rs62106157	chr19:15980448	G/A	cg13772218	chr19:15982569	NA	0.3	5.87	0.34	1.27e-8	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CESC	cis	rs897984	0.644	rs73524556	chr16:30823162	G/A	cg00531865	chr16:30841666	NA	-0.55	-8.33	-0.46	4.28e-15	Dementia with Lewy bodies;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24294819	chr8:117887282	RAD21	0.63	7.17	0.4	7.66e-12	Gut microbiome composition (summer);
CESC	cis	rs17253792	0.822	rs78820104	chr14:56068854	C/T	cg01858014	chr14:56050164	KTN1	-0.85	-6.99	-0.39	2.22e-11	Putamen volume;
CESC	cis	rs1059312	1.000	rs7136092	chr12:129280164	G/C	cg09035930	chr12:129282057	SLC15A4	0.76	10.73	0.55	1.59e-22	Systemic lupus erythematosus;
CESC	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	7.65	0.43	3.69e-13	Prudent dietary pattern;
CESC	cis	rs7666738	0.830	rs1534318	chr4:98965058	C/T	cg17366294	chr4:99064904	C4orf37	0.59	8.35	0.46	3.96e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7833790	0.963	rs72686466	chr8:82758928	G/T	cg07697082	chr8:82753677	SNX16	-0.39	-5.32	-0.31	2.19e-7	Diastolic blood pressure;
CESC	cis	rs2933343	0.700	rs876754	chr3:128627753	T/C	cg25356066	chr3:128598488	ACAD9	0.6	8.46	0.46	1.79e-15	IgG glycosylation;
CESC	cis	rs614226	1.000	rs591992	chr12:121019323	T/C	cg01236616	chr12:121019343	POP5	1.49	18.26	0.75	8.44e-49	Type 1 diabetes nephropathy;
CESC	cis	rs17253792	0.822	rs8009608	chr14:56062590	C/T	cg01858014	chr14:56050164	KTN1	-0.87	-6.75	-0.38	9.11e-11	Putamen volume;
CESC	cis	rs2354432	0.607	rs66486822	chr1:146802653	T/A	cg25205988	chr1:146714368	CHD1L	-1.03	-9.0	-0.48	4.56e-17	Mitochondrial DNA levels;
CESC	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg09177884	chr7:1199841	ZFAND2A	-0.7	-9.95	-0.52	4.89e-20	Longevity;Endometriosis;
CESC	cis	rs62005083	1.000	rs62006762	chr14:74617438	A/T	cg05179529	chr14:74551516	LIN52;ALDH6A1	0.66	5.24	0.31	3.3e-7	Mean corpuscular volume;
CESC	cis	rs910316	0.763	rs4556	chr14:75476071	G/C	cg16144293	chr14:75469539	EIF2B2	-0.39	-5.2	-0.3	3.96e-7	Height;
CESC	cis	rs9311474	0.652	rs411457	chr3:52228150	A/T	cg18099408	chr3:52552593	STAB1	0.34	5.74	0.33	2.54e-8	Electroencephalogram traits;
CESC	cis	rs4665809	0.589	rs4665842	chr2:26448954	A/G	cg04944784	chr2:26401820	FAM59B	-0.96	-10.46	-0.54	1.19e-21	Gut microbiome composition (summer);
CESC	cis	rs17854409	1.000	rs6010770	chr20:61494225	G/T	cg05147244	chr20:61493195	TCFL5	0.9	6.48	0.37	4.57e-10	Obesity-related traits;
CESC	cis	rs3096299	0.658	rs34590044	chr16:89543157	A/C	cg02187348	chr16:89574699	SPG7	0.62	8.67	0.47	4.33e-16	Multiple myeloma (IgH translocation);
CESC	cis	rs11608355	0.515	rs11610558	chr12:109925865	C/T	cg05360138	chr12:110035743	NA	0.81	8.75	0.47	2.52e-16	Neuroticism;
CESC	cis	rs6991838	0.584	rs35941313	chr8:66499733	G/T	cg13398993	chr8:66546079	ARMC1	-0.48	-5.77	-0.33	2.22e-8	Intelligence (multi-trait analysis);
CESC	cis	rs11252926	0.604	rs2050970	chr10:515870	C/T	cg16386425	chr10:429943	DIP2C	-0.45	-5.75	-0.33	2.46e-8	Psychosis in Alzheimer's disease;
CESC	cis	rs3785574	0.962	rs2727324	chr17:61922102	G/C	cg11494091	chr17:61959527	GH2	0.39	5.61	0.33	5.06e-8	Height;
CESC	cis	rs2380220	0.872	rs7750757	chr6:95997118	A/G	cg15832292	chr6:96025679	MANEA	0.7	6.74	0.38	9.88e-11	Behavioural disinhibition (generation interaction);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg21939482	chr7:6388130	C7orf70	-0.52	-7.7	-0.43	2.73e-13	Gambling;
CESC	cis	rs7605827	0.930	rs10208972	chr2:15676686	G/A	cg19274914	chr2:15703543	NA	0.38	6.72	0.38	1.08e-10	Educational attainment (years of education);
CESC	cis	rs2124969	0.548	rs983916	chr2:161015066	T/G	cg03641300	chr2:160917029	PLA2R1	-0.58	-6.01	-0.35	6.14e-9	Waist circumference adjusted for body mass index;
CESC	cis	rs7640424	0.649	rs62262420	chr3:107909940	C/T	cg09227934	chr3:107805635	CD47	-0.45	-5.67	-0.33	3.73e-8	Body mass index;
CESC	cis	rs8180040	1.000	rs2302278	chr3:47361082	G/T	cg27129171	chr3:47204927	SETD2	-0.64	-9.73	-0.51	2.57e-19	Colorectal cancer;
CESC	cis	rs7937682	0.632	rs10891297	chr11:111770150	C/T	cg22437258	chr11:111473054	SIK2	-0.5	-5.52	-0.32	8.11e-8	Primary sclerosing cholangitis;
CESC	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg16145915	chr7:1198662	ZFAND2A	-0.61	-9.36	-0.5	3.46e-18	Longevity;Endometriosis;
CESC	cis	rs9322193	0.923	rs9480031	chr6:150080011	A/C	cg04369109	chr6:150039330	LATS1	-0.43	-5.99	-0.35	6.69e-9	Lung cancer;
CESC	cis	rs2288912	0.838	rs2239375	chr19:45459851	T/C	cg13119609	chr19:45449297	APOC2	0.47	7.7	0.43	2.64e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs9303401	0.538	rs10515155	chr17:56481944	A/G	cg25039879	chr17:56429692	SUPT4H1	0.63	6.49	0.37	4.2e-10	Cognitive test performance;
CESC	cis	rs11696845	0.626	rs6073537	chr20:43378270	A/G	cg25301532	chr20:43378953	KCNK15	-0.36	-5.86	-0.34	1.36e-8	Obesity-related traits;
CESC	cis	rs2625529	0.590	rs2856929	chr15:72496762	T/C	cg16672083	chr15:72433130	SENP8	-0.42	-5.53	-0.32	7.78e-8	Red blood cell count;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg04104609	chr2:219523980	ZNF142;BCS1L	-0.45	-6.45	-0.37	5.19e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs2880765	0.566	rs12911430	chr15:86011264	A/T	cg19183879	chr15:85880815	NA	-0.31	-5.9	-0.34	1.12e-8	Coronary artery disease;
CESC	cis	rs7116495	0.609	rs628025	chr11:71802351	A/C	cg10381502	chr11:71823885	C11orf51	-1.08	-6.75	-0.38	9.47e-11	Severe influenza A (H1N1) infection;
CESC	cis	rs10504229	0.683	rs72649187	chr8:58108320	A/G	cg02725872	chr8:58115012	NA	-0.43	-6.81	-0.39	6.53e-11	Developmental language disorder (linguistic errors);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13319197	chr11:46142000	PHF21A	0.63	7.35	0.41	2.42e-12	Gut microbiome composition (summer);
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg10668512	chr15:42565522	GANC;TMEM87A	0.47	6.22	0.36	1.9e-9	Systemic lupus erythematosus;
CESC	cis	rs5758659	0.714	rs5758578	chr22:42490292	A/C	cg04733989	chr22:42467013	NAGA	-0.44	-6.16	-0.35	2.63e-9	Cognitive function;
CESC	cis	rs61931739	0.817	rs11833948	chr12:34276942	G/T	cg19457237	chr12:34500585	NA	-0.39	-5.38	-0.31	1.65e-7	Morning vs. evening chronotype;
CESC	cis	rs7833986	0.501	rs2976018	chr8:57014752	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.62	7.54	0.42	7.58e-13	Height;
CESC	cis	rs7829975	0.777	rs486781	chr8:8639740	A/G	cg06636001	chr8:8085503	FLJ10661	-0.43	-5.55	-0.32	6.79e-8	Mood instability;
CESC	trans	rs681383	1.000	rs58102861	chr18:8331365	C/T	cg27042584	chr16:51168485	NA	0.49	5.99	0.35	6.68e-9	Sitting height ratio;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05049160	chr22:36693009	MYH9	-0.48	-6.35	-0.36	9.44e-10	Gut microbiome composition (summer);
CESC	trans	rs11098499	0.863	rs6853998	chr4:120475860	C/A	cg25214090	chr10:38739885	LOC399744	0.66	9.03	0.49	3.57e-17	Corneal astigmatism;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18887680	chr5:78907942	PAPD4	-0.57	-6.7	-0.38	1.24e-10	Gut microbiome composition (summer);
CESC	trans	rs6572548	0.504	rs1956082	chr14:49665496	A/C	cg25485084	chr12:118809325	TAOK3	-0.47	-6.2	-0.36	2.1e-9	Subjective well-being;
CESC	cis	rs853679	0.505	rs200992	chr6:27814677	A/G	cg26587870	chr6:27730563	NA	-0.62	-5.31	-0.31	2.33e-7	Depression;
CESC	cis	rs9611565	0.694	rs202637	chr22:41853928	A/G	cg03806693	chr22:41940476	POLR3H	1.2	14.33	0.66	7.01e-35	Vitiligo;
CESC	cis	rs853679	0.517	rs3757185	chr6:28107776	T/A	cg26335602	chr6:28129616	ZNF389	0.54	7.25	0.41	4.45e-12	Depression;
CESC	cis	rs7044106	0.648	rs2031369	chr9:123360294	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.66	9.35	0.5	3.69e-18	Hip circumference adjusted for BMI;
CESC	cis	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.54	-6.6	-0.38	2.26e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs514406	0.861	rs11206026	chr1:53281708	G/A	cg08859206	chr1:53392774	SCP2	-0.56	-7.33	-0.41	2.8e-12	Monocyte count;
CESC	cis	rs9733	0.596	rs12086630	chr1:150650955	T/C	cg18016565	chr1:150552671	MCL1	0.33	5.14	0.3	5.34e-7	Tonsillectomy;
CESC	cis	rs7809950	0.906	rs2253269	chr7:107201114	C/T	cg23024343	chr7:107201750	COG5	-0.41	-5.72	-0.33	2.85e-8	Coronary artery disease;
CESC	cis	rs11583043	0.575	rs12727971	chr1:101589175	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.48	5.32	0.31	2.25e-7	Ulcerative colitis;Inflammatory bowel disease;
CESC	cis	rs9733	0.744	rs11204737	chr1:150847647	C/T	cg22823121	chr1:150693482	HORMAD1	-0.37	-5.45	-0.32	1.15e-7	Tonsillectomy;
CESC	cis	rs7904368	0.806	rs45495501	chr10:16861476	G/A	cg23933602	chr10:16859644	RSU1	0.66	5.76	0.33	2.3e-8	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
CESC	trans	rs8014252	0.667	rs2877657	chr14:70823932	A/G	cg03123320	chr1:229394665	NA	-0.46	-6.04	-0.35	5.13e-9	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
CESC	cis	rs910316	1.000	rs7145159	chr14:75583268	A/G	cg11812906	chr14:75593930	NEK9	0.9	15.69	0.69	1.08e-39	Height;
CESC	cis	rs3768617	0.510	rs10911249	chr1:183080690	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.87	13.96	0.65	1.41e-33	Fuchs's corneal dystrophy;
CESC	cis	rs9926296	0.715	rs2115401	chr16:89740609	A/G	cg03605463	chr16:89740564	NA	-0.57	-7.15	-0.4	8.48e-12	Vitiligo;
CESC	cis	rs2479106	0.791	rs56944968	chr9:126712126	G/A	cg16191174	chr9:126692580	DENND1A	0.42	5.64	0.33	4.33e-8	Polycystic ovary syndrome;
CESC	cis	rs6120849	0.754	rs1885116	chr20:33600560	A/G	cg24642439	chr20:33292090	TP53INP2	0.67	6.69	0.38	1.3e-10	Protein C levels;
CESC	cis	rs870825	0.616	rs7681824	chr4:185617525	A/G	cg04058563	chr4:185651563	MLF1IP	0.64	7.05	0.4	1.59e-11	Blood protein levels;
CESC	cis	rs4970988	0.556	rs6695123	chr1:150563483	T/C	cg13175981	chr1:150552382	MCL1	0.44	5.28	0.31	2.76e-7	Urate levels;
CESC	cis	rs72781680	0.898	rs12619592	chr2:23971415	C/A	cg20701182	chr2:24300061	SF3B14	0.62	5.49	0.32	9.46e-8	Lymphocyte counts;
CESC	cis	rs7769051	1.000	rs7769051	chr6:133146796	G/T	cg07930552	chr6:133119739	C6orf192	0.72	7.2	0.4	6.09e-12	Type 2 diabetes nephropathy;
CESC	cis	rs9287719	0.967	rs7605461	chr2:10738134	G/A	cg02196655	chr2:10830764	NOL10	-0.37	-5.72	-0.33	2.87e-8	Prostate cancer;
CESC	cis	rs7772486	0.790	rs2485632	chr6:146193228	A/G	cg23711669	chr6:146136114	FBXO30	1.01	15.47	0.69	6.84e-39	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs637571	0.522	rs1151512	chr11:65757533	G/A	cg02202077	chr11:65769826	EIF1AD;BANF1	0.46	6.13	0.35	3.1e-9	Eosinophil percentage of white cells;
CESC	cis	rs10242455	0.850	rs57367781	chr7:99116819	G/A	cg25640893	chr7:99214727	ZNF498	0.71	5.19	0.3	4.21e-7	Blood metabolite levels;
CESC	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.54	6.63	0.38	1.87e-10	Prudent dietary pattern;
CESC	cis	rs400736	0.576	rs10864328	chr1:8164456	G/C	cg25007680	chr1:8021821	PARK7	-0.45	-5.89	-0.34	1.15e-8	Response to antidepressants and depression;
CESC	cis	rs12347191	0.500	rs907582	chr9:100621926	T/C	cg13688889	chr9:100608707	NA	-0.91	-13.28	-0.63	3.27e-31	Orofacial clefts;
CESC	cis	rs55665837	0.583	rs78843135	chr11:14411254	T/G	cg19336497	chr11:14380999	RRAS2	-0.36	-5.28	-0.31	2.64e-7	Vitamin D levels;
CESC	cis	rs12995491	0.731	rs56188884	chr2:88508657	G/A	cg04511125	chr2:88470314	THNSL2	-0.52	-7.7	-0.43	2.77e-13	Response to metformin (IC50);
CESC	cis	rs644799	0.525	rs3016206	chr11:95536724	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.74	10.63	0.55	3.24e-22	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs9486719	0.947	rs2472908	chr6:96875998	A/T	cg18709589	chr6:96969512	KIAA0776	0.53	5.81	0.34	1.75e-8	Migraine;Coronary artery disease;
CESC	cis	rs7666738	0.830	rs6840766	chr4:99016260	C/G	cg03676636	chr4:99064102	C4orf37	0.33	5.16	0.3	4.86e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9911578	1.000	rs6503887	chr17:56993320	T/C	cg05425664	chr17:57184151	TRIM37	-0.5	-6.81	-0.39	6.5500000000000006e-11	Intelligence (multi-trait analysis);
CESC	cis	rs736801	0.740	rs17622378	chr5:131778452	A/G	cg07395648	chr5:131743802	NA	-0.43	-5.41	-0.32	1.38e-7	Breast cancer;Mosquito bite size;
CESC	cis	rs9457247	1.000	rs407515	chr6:167407544	G/C	cg23791538	chr6:167370224	RNASET2	-0.61	-8.81	-0.48	1.71e-16	Crohn's disease;
CESC	cis	rs78456975	0.739	rs13405352	chr2:1518726	C/T	cg01028140	chr2:1542097	TPO	-0.52	-5.71	-0.33	3.04e-8	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs9318086	0.776	rs1326130	chr13:24447664	A/C	cg25267304	chr13:24462978	PCOTH;MIPEP	0.39	5.66	0.33	3.95e-8	Myopia (pathological);
CESC	trans	rs12356475	0.710	rs10822686	chr10:67733250	C/T	cg16116244	chr1:16939841	NBPF1	0.52	6.05	0.35	4.84e-9	Psoriatic arthritis;
CESC	cis	rs6987853	0.933	rs2923430	chr8:42391195	T/C	cg09913449	chr8:42400586	C8orf40	0.4	6.34	0.36	9.76e-10	Mean corpuscular hemoglobin concentration;
CESC	cis	rs1348850	0.914	rs10194648	chr2:178337031	G/A	cg23306229	chr2:178417860	TTC30B	0.66	8.36	0.46	3.59e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs10504229	0.516	rs4361758	chr8:57990401	C/T	cg24829409	chr8:58192753	C8orf71	-0.36	-5.11	-0.3	6.21e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs929354	1.000	rs1182381	chr7:157043473	G/A	cg05182265	chr7:156933206	UBE3C	0.43	5.84	0.34	1.49e-8	Body mass index;
CESC	cis	rs113835537	0.529	rs2277302	chr11:66240882	T/C	cg24851651	chr11:66362959	CCS	0.46	5.98	0.35	7.05e-9	Airway imaging phenotypes;
CESC	cis	rs853679	0.517	rs9393894	chr6:28112562	A/G	cg20151795	chr6:28129481	ZNF389	0.45	5.7	0.33	3.12e-8	Depression;
CESC	cis	rs7949030	0.626	rs72927213	chr11:62351198	G/C	cg11742103	chr11:62369870	EML3;MTA2	0.65	9.67	0.51	3.75e-19	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs7666738	0.830	rs13328005	chr4:99055480	T/C	cg03467027	chr4:99064603	C4orf37	0.47	5.85	0.34	1.47e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9486719	1.000	rs2499816	chr6:96878206	C/T	cg06623918	chr6:96969491	KIAA0776	0.81	8.29	0.45	5.61e-15	Migraine;Coronary artery disease;
CESC	cis	rs7923609	0.846	rs7090111	chr10:65077994	C/G	cg01631684	chr10:65280961	REEP3	-0.43	-5.38	-0.31	1.6e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs2463822	0.513	rs72919445	chr11:62029078	A/C	cg06239285	chr11:62104954	ASRGL1	-0.96	-7.69	-0.43	2.93e-13	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs11191270	0.554	rs11191274	chr10:104140350	G/A	cg15320455	chr10:103880129	LDB1	0.7	5.69	0.33	3.32e-8	Intelligence (multi-trait analysis);
CESC	cis	rs7829975	0.623	rs10087493	chr8:8373557	A/G	cg15556689	chr8:8085844	FLJ10661	-0.49	-6.13	-0.35	3.2e-9	Mood instability;
CESC	cis	rs6879260	1.000	rs7706951	chr5:179733407	C/T	cg23248424	chr5:179741104	GFPT2	-0.57	-7.86	-0.43	9.98e-14	Height;
CESC	cis	rs10504229	0.679	rs75402323	chr8:58136227	A/G	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs4665809	0.590	rs2891496	chr2:26452605	G/A	cg27170947	chr2:26402098	FAM59B	0.87	9.93	0.52	5.78e-20	Gut microbiome composition (summer);
CESC	cis	rs4975709	0.589	rs4975747	chr5:1862836	G/A	cg11168104	chr5:1857477	NA	-0.38	-5.65	-0.33	4.15e-8	Cardiovascular disease risk factors;
CESC	cis	rs4699052	0.625	rs28397882	chr4:104282836	G/A	cg16532752	chr4:104119610	CENPE	-0.37	-5.3	-0.31	2.46e-7	Testicular germ cell tumor;
CESC	cis	rs4654899	0.802	rs2167811	chr1:21194510	A/G	cg05370193	chr1:21551575	ECE1	-0.37	-5.41	-0.32	1.43e-7	Superior frontal gyrus grey matter volume;
CESC	cis	rs4727963	0.792	rs12667916	chr7:122740976	A/G	cg03640110	chr7:122635026	TAS2R16	0.4	6.2	0.36	2.14e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
CESC	cis	rs853679	0.517	rs9393891	chr6:28079160	C/T	cg19592336	chr6:28129416	ZNF389	0.6	7.98	0.44	4.4e-14	Depression;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg26203883	chr20:36156320	BLCAP	-0.48	-6.11	-0.35	3.61e-9	Fibrinogen levels;
CESC	cis	rs9611565	0.729	rs9611570	chr22:41782721	G/T	cg06481639	chr22:41940642	POLR3H	-0.62	-6.8	-0.39	6.94e-11	Vitiligo;
CESC	cis	rs2797160	0.967	rs6910786	chr6:126017141	A/T	cg05901451	chr6:126070800	HEY2	0.46	6.58	0.37	2.44e-10	Endometrial cancer;
CESC	cis	rs854765	0.583	rs2350977	chr17:17802779	A/G	cg04398451	chr17:18023971	MYO15A	-0.61	-8.31	-0.45	5.04e-15	Total body bone mineral density;
CESC	cis	rs1008375	1.000	rs6818639	chr4:17633049	A/G	cg15017067	chr4:17643749	FAM184B	0.36	5.19	0.3	4.25e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs7044106	0.708	rs920745	chr9:123429943	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.81	12.82	0.62	1.3e-29	Hip circumference adjusted for BMI;
CESC	cis	rs11719291	0.833	rs73080361	chr3:48832146	G/A	cg00383909	chr3:49044727	WDR6	0.89	5.53	0.32	7.75e-8	Cognitive function;
CESC	cis	rs4808199	0.948	rs2301668	chr19:19452249	G/A	cg03709012	chr19:19516395	GATAD2A	1.13	12.03	0.59	6.84e-27	Nonalcoholic fatty liver disease;
CESC	trans	rs1945213	0.694	rs17149976	chr11:55839746	T/C	cg15704280	chr7:45808275	SEPT13	0.76	7.31	0.41	3.15e-12	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs6736093	0.966	rs11686647	chr2:112684397	T/A	cg12686935	chr2:112915763	FBLN7	-0.43	-5.56	-0.32	6.75e-8	Coronary artery disease;
CESC	cis	rs7267979	1.000	rs6076339	chr20:25348712	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.85	-17.1	-0.72	1.14e-44	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs72781680	0.898	rs12619525	chr2:23999565	G/C	cg20701182	chr2:24300061	SF3B14	0.63	5.65	0.33	4.21e-8	Lymphocyte counts;
CESC	cis	rs4253772	0.591	rs8143066	chr22:46656607	C/T	cg24881330	chr22:46731750	TRMU	0.88	10.03	0.52	2.79e-20	LDL cholesterol;Cholesterol, total;
CESC	cis	rs3733585	0.699	rs4473653	chr4:9971058	A/G	cg11266682	chr4:10021025	SLC2A9	-0.57	-10.58	-0.54	4.9e-22	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs10883723	0.810	rs2296590	chr10:104262628	G/A	cg22532475	chr10:104410764	TRIM8	-0.34	-5.73	-0.33	2.77e-8	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs919433	0.783	rs787980	chr2:198239225	C/T	cg10820045	chr2:198174542	NA	0.41	5.98	0.34	7.35e-9	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs4927850	1.000	rs7627868	chr3:195753473	A/T	cg12923728	chr3:195709715	SDHAP1	-0.67	-8.99	-0.48	4.91e-17	Pancreatic cancer;
CESC	cis	rs2294693	0.945	rs10947944	chr6:41004657	T/C	cg14769373	chr6:40998127	UNC5CL	-0.47	-6.17	-0.35	2.5e-9	Gastric cancer;Non-cardia gastric cancer;
CESC	cis	rs801193	0.967	rs34356500	chr7:66236607	G/T	cg18876405	chr7:65276391	NA	0.56	7.27	0.41	3.94e-12	Aortic root size;
CESC	trans	rs116095464	0.614	rs10067482	chr5:219328	T/G	cg00938859	chr5:1591904	SDHAP3	0.6	6.66	0.38	1.55e-10	Breast cancer;
CESC	trans	rs13398848	1.000	rs76942868	chr2:84201661	G/A	cg23262351	chr6:79576851	IRAK1BP1	-0.69	-6.08	-0.35	4.1e-9	Conduct disorder (symptom count);Conduct disorder;
CESC	cis	rs2836974	0.627	rs9981301	chr21:40686078	G/C	cg17971929	chr21:40555470	PSMG1	-0.85	-12.27	-0.6	1.01e-27	Cognitive function;
CESC	cis	rs3741404	0.594	rs11231704	chr11:63898182	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.52	-6.67	-0.38	1.46e-10	Platelet count;
CESC	cis	rs12711979	0.509	rs13000873	chr2:3823705	T/C	cg17052675	chr2:3827356	NA	-0.66	-11.01	-0.56	1.79e-23	Itch intensity from mosquito bite adjusted by bite size;
CESC	cis	rs902774	0.554	rs4503623	chr12:53353759	T/C	cg25025879	chr12:53359317	NA	-0.49	-6.45	-0.37	5.28e-10	Prostate cancer;
CESC	cis	rs9733	0.519	rs7529194	chr1:150622620	A/T	cg17724175	chr1:150552817	MCL1	0.41	6.7	0.38	1.28e-10	Tonsillectomy;
CESC	cis	rs6952808	0.691	rs2398709	chr7:2112548	C/T	cg21782813	chr7:2030301	MAD1L1	0.5	7.23	0.41	5.12e-12	Bipolar disorder and schizophrenia;
CESC	cis	rs11098499	0.580	rs12509234	chr4:120319434	T/C	cg09307838	chr4:120376055	NA	0.91	12.36	0.6	5.06e-28	Corneal astigmatism;
CESC	cis	rs6728642	1.000	rs11900461	chr2:97615993	C/T	cg26665480	chr2:98280029	ACTR1B	-0.73	-6.14	-0.35	2.94e-9	Bipolar disorder lithium response (continuous) or schizophrenia;
CESC	cis	rs12216125	0.554	rs6942196	chr6:26072804	A/G	cg16482183	chr6:26056742	HIST1H1C	0.39	5.31	0.31	2.35e-7	Iron status biomarkers;
CESC	cis	rs1862618	0.853	rs252910	chr5:56192983	G/A	cg03609598	chr5:56110824	MAP3K1	-0.52	-5.22	-0.31	3.71e-7	Initial pursuit acceleration;
CESC	cis	rs17125944	0.505	rs74620173	chr14:53194068	G/T	cg00686598	chr14:53173677	PSMC6	1.36	11.76	0.59	5.6e-26	Alzheimer's disease (late onset);
CESC	cis	rs514406	0.929	rs1672909	chr1:53340824	A/G	cg08859206	chr1:53392774	SCP2	-0.63	-8.36	-0.46	3.53e-15	Monocyte count;
CESC	cis	rs9914988	0.943	rs7217547	chr17:27106872	C/G	cg20469991	chr17:27169893	C17orf63	-0.43	-5.24	-0.31	3.27e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CESC	cis	rs6750047	0.546	rs1367696	chr2:38286914	C/T	cg07380506	chr2:38303506	CYP1B1	0.46	5.9	0.34	1.12e-8	Cutaneous malignant melanoma;Melanoma;
CESC	cis	rs7520050	0.897	rs4440807	chr1:46470878	T/C	cg03146154	chr1:46216737	IPP	-0.46	-5.87	-0.34	1.31e-8	Red blood cell count;Reticulocyte count;
CESC	cis	rs72781680	0.611	rs72781696	chr2:24267014	C/T	cg06627628	chr2:24431161	ITSN2	-0.65	-6.21	-0.36	2.08e-9	Lymphocyte counts;
CESC	cis	rs9814567	0.964	rs6776203	chr3:134234345	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.45	-6.15	-0.35	2.79e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs10927875	0.632	rs4661667	chr1:16162731	C/T	cg18973939	chr1:16164122	FLJ37453	0.36	5.5	0.32	8.96e-8	Dilated cardiomyopathy;
CESC	cis	rs4665809	0.556	rs1560869	chr2:26417095	T/C	cg25036284	chr2:26402008	FAM59B	-0.84	-9.59	-0.51	7.03e-19	Gut microbiome composition (summer);
CESC	cis	rs7309	0.622	rs4664396	chr2:161901650	C/T	cg22496339	chr2:162101262	NA	-0.4	-5.06	-0.3	7.81e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
CESC	cis	rs2070997	0.607	rs72765060	chr9:133712404	T/C	cg11464064	chr9:133710261	ABL1	0.71	7.92	0.44	6.42e-14	Response to amphetamines;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03855276	chr3:51705097	TEX264	0.62	6.7	0.38	1.23e-10	Gut microbiome composition (summer);
CESC	cis	rs9733	0.544	rs2867302	chr1:150653650	T/C	cg17724175	chr1:150552817	MCL1	0.44	7.21	0.41	5.8e-12	Tonsillectomy;
CESC	cis	rs3806843	0.735	rs801167	chr5:140081423	A/G	cg16179182	chr5:140090404	VTRNA1-1	-0.4	-5.06	-0.3	7.79e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs523522	0.962	rs11065154	chr12:120971417	T/C	cg12219531	chr12:120966889	COQ5	0.75	9.99	0.52	3.7e-20	High light scatter reticulocyte count;
CESC	cis	rs6952808	0.862	rs4721135	chr7:1912222	A/G	cg02951883	chr7:2050386	MAD1L1	-0.39	-5.2	-0.3	4.04e-7	Bipolar disorder and schizophrenia;
CESC	trans	rs61931739	0.500	rs11053217	chr12:34470036	A/C	cg26384229	chr12:38710491	ALG10B	0.55	7.57	0.42	6.05e-13	Morning vs. evening chronotype;
CESC	cis	rs826838	0.935	rs1843639	chr12:39178919	C/A	cg26384229	chr12:38710491	ALG10B	0.78	13.22	0.63	5.37e-31	Heart rate;
CESC	cis	rs2243480	1.000	rs778679	chr7:65840911	A/G	cg13147721	chr7:65941812	NA	-0.95	-8.95	-0.48	6.27e-17	Diabetic kidney disease;
CESC	cis	rs2522056	1.000	rs886286	chr5:131795597	A/G	cg24060327	chr5:131705240	SLC22A5	0.59	6.63	0.38	1.85e-10	Lymphocyte counts;Fibrinogen;
CESC	cis	rs208520	0.837	rs208509	chr6:66941706	A/G	cg07460842	chr6:66804631	NA	-0.82	-9.92	-0.52	6.45e-20	Exhaled nitric oxide output;
CESC	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg23978390	chr7:1156363	C7orf50	0.51	6.84	0.39	5.58e-11	Longevity;Endometriosis;
CESC	cis	rs9322193	0.607	rs4870078	chr6:150201812	A/G	cg01145232	chr6:150245071	RAET1G	-0.45	-5.42	-0.32	1.35e-7	Lung cancer;
CESC	cis	rs2839186	0.934	rs17176520	chr21:47682081	T/C	cg00815214	chr21:47717953	NA	-0.35	-5.19	-0.3	4.17e-7	Testicular germ cell tumor;
CESC	cis	rs10540	1.000	rs12794284	chr11:477623	C/T	cg03934478	chr11:495069	RNH1	0.52	5.19	0.3	4.26e-7	Body mass index;
CESC	cis	rs897080	0.515	rs1067345	chr2:44618897	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.51	5.94	0.34	8.71e-9	Height;
CESC	cis	rs7953249	0.656	rs2243616	chr12:121406370	G/T	cg25281562	chr12:121454272	C12orf43	-0.46	-5.73	-0.33	2.78e-8	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
CESC	cis	rs2439831	0.867	rs2243434	chr15:43689867	A/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.91	11.14	0.56	6.61e-24	Lung cancer in ever smokers;
CESC	cis	rs763121	0.853	rs6001204	chr22:39100239	T/C	cg06022373	chr22:39101656	GTPBP1	0.95	17.82	0.74	3.23e-47	Menopause (age at onset);
CESC	cis	rs2635047	0.811	rs28471970	chr18:44788439	G/C	cg24371990	chr18:44770781	NA	0.41	6.53	0.37	3.34e-10	Educational attainment;
CESC	cis	rs801193	0.569	rs11761542	chr7:66218196	G/A	cg18252515	chr7:66147081	NA	-0.46	-6.2	-0.36	2.15e-9	Aortic root size;
CESC	cis	rs61931739	0.534	rs4001713	chr12:34154195	A/C	cg19457237	chr12:34500585	NA	0.4	5.53	0.32	7.53e-8	Morning vs. evening chronotype;
CESC	cis	rs17407555	0.606	rs3775945	chr4:10011996	A/T	cg11266682	chr4:10021025	SLC2A9	-0.47	-5.69	-0.33	3.28e-8	Schizophrenia (age at onset);
CESC	cis	rs2294693	0.853	rs9296350	chr6:40977623	G/A	cg14769373	chr6:40998127	UNC5CL	-0.43	-5.87	-0.34	1.27e-8	Gastric cancer;Non-cardia gastric cancer;
CESC	cis	rs9611565	0.559	rs132768	chr22:42013523	C/A	cg03806693	chr22:41940476	POLR3H	1.08	12.76	0.62	2.14e-29	Vitiligo;
CESC	cis	rs4523957	0.583	rs2760740	chr17:2020989	A/G	cg16513277	chr17:2031491	SMG6	-0.7	-9.8	-0.52	1.47e-19	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs35110281	0.782	rs6518302	chr21:45018478	A/G	cg04455712	chr21:45112962	RRP1B	0.4	5.87	0.34	1.28e-8	Mean corpuscular volume;
CESC	trans	rs61931739	0.500	rs11053177	chr12:34412829	G/A	cg26384229	chr12:38710491	ALG10B	0.53	7.41	0.41	1.75e-12	Morning vs. evening chronotype;
CESC	cis	rs36051895	0.632	rs10115335	chr9:5140963	A/T	cg02405213	chr9:5042618	JAK2	-0.48	-6.12	-0.35	3.39e-9	Pediatric autoimmune diseases;
CESC	cis	rs3785574	0.927	rs2008018	chr17:61954471	C/T	cg11494091	chr17:61959527	GH2	0.44	6.35	0.36	9.23e-10	Height;
CESC	cis	rs977987	0.778	rs8057849	chr16:75443816	T/C	cg03315344	chr16:75512273	CHST6	0.41	5.86	0.34	1.35e-8	Dupuytren's disease;
CESC	cis	rs637571	0.522	rs566590	chr11:65754062	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.44	6.53	0.37	3.42e-10	Eosinophil percentage of white cells;
CESC	cis	rs7949030	0.596	rs11231137	chr11:62315699	G/A	cg22862634	chr11:62369728	EML3;MTA2	0.47	6.21	0.36	2.02e-9	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs2425143	0.908	rs6060605	chr20:34378132	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.83	-7.4	-0.41	1.77e-12	Blood protein levels;
CESC	cis	rs17376456	0.877	rs17374627	chr5:93296306	C/T	cg25358565	chr5:93447407	FAM172A	1.09	10.18	0.53	9.53e-21	Diabetic retinopathy;
CESC	cis	rs13102973	0.965	rs6853276	chr4:135881445	A/T	cg14419869	chr4:135874104	NA	0.35	5.57	0.32	6.18e-8	Subjective well-being;
CESC	cis	rs9682041	0.696	rs6774380	chr3:170091644	T/A	cg11886554	chr3:170076028	SKIL	0.7	6.49	0.37	4.1e-10	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CESC	cis	rs2070488	1.000	rs6772046	chr3:38479660	C/T	cg24069376	chr3:38537580	EXOG	0.46	8.26	0.45	7.14e-15	Electrocardiographic conduction measures;
CESC	cis	rs6540559	0.673	rs17015309	chr1:210007218	C/T	cg22029157	chr1:209979665	IRF6	0.71	7.61	0.42	4.72e-13	Cleft lip with or without cleft palate;
CESC	cis	rs7772486	0.719	rs7753770	chr6:146066161	G/A	cg23711669	chr6:146136114	FBXO30	-1.01	-15.7	-0.69	1.03e-39	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1003719	0.762	rs6517402	chr21:38447423	A/C	cg10648535	chr21:38446584	PIGP;TTC3	0.62	8.71	0.47	3.4e-16	Eye color traits;
CESC	cis	rs4919694	0.572	rs12262258	chr10:104900272	G/A	cg04362960	chr10:104952993	NT5C2	0.63	6.25	0.36	1.66e-9	Arsenic metabolism;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08885106	chr8:144550663	ZC3H3	-0.56	-6.59	-0.38	2.31e-10	Gut microbiome composition (summer);
CESC	cis	rs9916302	0.706	rs6503500	chr17:37485925	C/T	cg07936489	chr17:37558343	FBXL20	-0.91	-10.22	-0.53	7.02e-21	Glomerular filtration rate (creatinine);
CESC	cis	rs12474201	0.832	rs4952843	chr2:46957845	A/G	cg06386533	chr2:46925753	SOCS5	0.84	11.6	0.58	1.9e-25	Height;
CESC	cis	rs2439831	0.681	rs484029	chr15:43619560	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	13.07	0.63	1.81e-30	Lung cancer in ever smokers;
CESC	cis	rs6461049	0.765	rs4719431	chr7:2140312	T/C	cg23048001	chr7:2026167	MAD1L1	0.45	5.89	0.34	1.16e-8	Schizophrenia;
CESC	cis	rs1799949	1.000	rs35668327	chr17:41273095	G/A	cg06001716	chr17:41278141	BRCA1;NBR2	0.38	5.23	0.31	3.41e-7	Menopause (age at onset);
CESC	cis	rs425277	0.917	rs12410859	chr1:2038732	C/T	cg16545954	chr1:2118288	C1orf86	0.33	5.39	0.31	1.56e-7	Height;
CESC	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	10.23	0.53	6.6e-21	Prudent dietary pattern;
CESC	cis	rs977987	0.872	rs7206665	chr16:75475287	A/C	cg03315344	chr16:75512273	CHST6	0.42	6.02	0.35	5.67e-9	Dupuytren's disease;
CESC	cis	rs703842	0.892	rs1021469	chr12:58208164	C/T	cg00677455	chr12:58241039	CTDSP2	0.53	6.77	0.38	8.13e-11	Multiple sclerosis;
CESC	cis	rs17376456	0.825	rs10054790	chr5:93272520	A/G	cg25358565	chr5:93447407	FAM172A	1.16	10.12	0.53	1.48e-20	Diabetic retinopathy;
CESC	cis	rs7829975	0.582	rs11783950	chr8:8597831	A/C	cg15556689	chr8:8085844	FLJ10661	-0.43	-5.25	-0.31	3.18e-7	Mood instability;
CESC	trans	rs853679	0.546	rs34371502	chr6:28081758	T/C	cg01620082	chr3:125678407	NA	-0.81	-6.34	-0.36	1.01e-9	Depression;
CESC	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.52	0.37	3.61e-10	Prudent dietary pattern;
CESC	cis	rs9611565	0.546	rs739132	chr22:42123099	A/T	cg03806693	chr22:41940476	POLR3H	1.14	13.61	0.64	2.45e-32	Vitiligo;
CESC	cis	rs7552404	0.727	rs7547056	chr1:76279267	C/T	cg10523679	chr1:76189770	ACADM	0.7	6.97	0.39	2.5e-11	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs1348850	0.651	rs1901824	chr2:178225466	T/C	cg22681709	chr2:178499509	PDE11A	-0.39	-5.89	-0.34	1.15e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	trans	rs7980799	0.935	rs2892701	chr12:33547395	C/T	cg26384229	chr12:38710491	ALG10B	0.44	6.25	0.36	1.66e-9	Heart rate;Heart rate variability traits (RMSSD);
CESC	cis	rs4692589	1.000	rs4692589	chr4:170935245	C/T	cg19918862	chr4:170955249	NA	-0.36	-5.71	-0.33	2.97e-8	Anxiety disorder;
CESC	cis	rs1401999	0.510	rs2293001	chr3:183700211	C/T	cg01324343	chr3:183735012	ABCC5	0.39	6.72	0.38	1.11e-10	Anterior chamber depth;
CESC	trans	rs4904167	0.812	rs12881717	chr14:84668514	G/A	cg19167227	chr15:84044884	NA	-0.43	-6.19	-0.36	2.27e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs7949030	0.504	rs2516633	chr11:62371773	A/C	cg02375832	chr11:62437615	C11orf48	0.38	5.48	0.32	1.01e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.46	-6.04	-0.35	5.26e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs514406	0.861	rs7526275	chr1:53245849	C/T	cg08736216	chr1:53307985	ZYG11A	0.43	7.25	0.41	4.64e-12	Monocyte count;
CESC	cis	rs3747547	0.786	rs72726024	chr9:38020824	G/T	cg13774184	chr9:37916125	SHB	-0.73	-6.25	-0.36	1.61e-9	Metabolite levels (Dihydroxy docosatrienoic acid);
CESC	cis	rs1153858	1.000	rs12437840	chr15:45669055	C/A	cg14582100	chr15:45693742	SPATA5L1	0.42	5.95	0.34	8.38e-9	Homoarginine levels;
CESC	cis	rs7605378	0.528	rs281791	chr2:200850402	A/G	cg17644776	chr2:200775616	C2orf69	-0.54	-6.63	-0.38	1.84e-10	Osteoporosis;
CESC	trans	rs8073060	0.545	rs3859282	chr17:34006111	T/C	cg19694781	chr19:47549865	TMEM160	-0.71	-6.74	-0.38	9.95e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	cis	rs36051895	0.659	rs12343065	chr9:5083533	C/T	cg02405213	chr9:5042618	JAK2	-0.55	-6.66	-0.38	1.58e-10	Pediatric autoimmune diseases;
CESC	cis	rs75804782	0.572	rs72982580	chr2:239447783	A/G	cg18131467	chr2:239335373	ASB1	-0.69	-5.55	-0.32	6.89e-8	Morning vs. evening chronotype;Chronotype;
CESC	cis	rs736408	0.774	rs4687551	chr3:52823448	C/T	cg07507251	chr3:52567010	NT5DC2	-0.33	-5.41	-0.32	1.42e-7	Bipolar disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13173722	chr20:60553138	TAF4	-0.62	-6.84	-0.39	5.38e-11	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00745463	chr17:30367425	LRRC37B	-0.57	-6.39	-0.37	7.48e-10	Gut microbiome composition (summer);
CESC	cis	rs2576037	0.526	rs11082562	chr18:44522671	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.43	7.19	0.4	6.49e-12	Personality dimensions;
CESC	cis	rs10097731	0.808	rs80141261	chr8:82034453	T/C	cg25230327	chr8:82042993	NA	-0.6	-7.01	-0.4	1.98e-11	Serum total protein level;
CESC	cis	rs4665809	0.590	rs9309474	chr2:26448830	T/A	cg26314531	chr2:26401878	FAM59B	-0.85	-9.04	-0.49	3.44e-17	Gut microbiome composition (summer);
CESC	cis	rs55871839	0.533	rs7813733	chr8:59852429	C/T	cg07426533	chr8:59803705	TOX	0.41	5.33	0.31	2.12e-7	Pneumonia;
CESC	cis	rs4481887	1.000	rs4474293	chr1:248470438	T/C	cg00666640	chr1:248458726	OR2T12	0.39	6.36	0.36	8.71e-10	Common traits (Other);
CESC	cis	rs4835473	0.868	rs1822841	chr4:144842638	G/T	cg25736465	chr4:144833511	NA	0.46	7.16	0.4	7.86e-12	Immature fraction of reticulocytes;
CESC	cis	rs910316	1.000	rs7147118	chr14:75610170	G/C	cg11812906	chr14:75593930	NEK9	0.92	16.16	0.7	2.31e-41	Height;
CESC	cis	rs9611565	0.921	rs5751077	chr22:41720728	G/C	cg03806693	chr22:41940476	POLR3H	-0.67	-8.06	-0.44	2.57e-14	Vitiligo;
CESC	cis	rs2732480	0.557	rs2634682	chr12:48732943	T/C	cg04545296	chr12:48745243	ZNF641	0.44	7.22	0.41	5.36e-12	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs2835872	0.758	rs8134288	chr21:39036989	T/C	cg06728970	chr21:39037746	KCNJ6	0.3	5.53	0.32	7.57e-8	Electroencephalographic traits in alcoholism;
CESC	cis	rs5769765	1.000	rs761879	chr22:50241210	G/A	cg02269571	chr22:50332266	NA	0.47	6.19	0.36	2.34e-9	Schizophrenia;
CESC	trans	rs10841784	0.917	rs7962919	chr12:21466507	G/A	cg00566759	chr18:28682345	DSC2	0.48	6.61	0.38	2.13e-10	Childhood ear infection;
CESC	cis	rs870825	0.616	rs2310108	chr4:185639475	C/T	cg04058563	chr4:185651563	MLF1IP	0.64	7.09	0.4	1.21e-11	Blood protein levels;
CESC	cis	rs6460942	0.687	rs74753576	chr7:12463926	G/A	cg10578991	chr7:12443926	VWDE	-0.49	-6.22	-0.36	1.91e-9	Coronary artery disease;
CESC	trans	rs9858542	0.953	rs9837341	chr3:49664767	A/G	cg21659725	chr3:3221576	CRBN	-0.52	-6.3	-0.36	1.21e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs1552244	0.882	rs13089863	chr3:10032259	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	0.69	7.77	0.43	1.78e-13	Alzheimer's disease;
CESC	cis	rs6088580	0.634	rs6087577	chr20:32955423	C/T	cg06115741	chr20:33292138	TP53INP2	0.45	5.71	0.33	3e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs7546094	1.000	rs6537743	chr1:113092527	A/G	cg22162597	chr1:113214053	CAPZA1	0.37	5.67	0.33	3.73e-8	Platelet distribution width;
CESC	trans	rs7618501	0.538	rs9856572	chr3:50109073	A/T	cg21659725	chr3:3221576	CRBN	-0.5	-7.03	-0.4	1.75e-11	Intelligence (multi-trait analysis);
CESC	cis	rs77106637	0.860	rs75896506	chr11:72429579	G/A	cg03713592	chr11:72463424	ARAP1	1.21	10.49	0.54	9.08e-22	Type 2 diabetes;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg18675616	chr4:1962842	WHSC1	-0.4	-6.05	-0.35	4.94e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs4555082	0.718	rs75139030	chr14:105710853	A/AG	cg27165867	chr14:105738592	BRF1	-0.51	-5.42	-0.32	1.31e-7	Mean platelet volume;Platelet distribution width;
CESC	cis	rs250677	0.522	rs10477400	chr5:148359598	T/C	cg18129178	chr5:148520854	ABLIM3	0.47	5.16	0.3	4.85e-7	Breast cancer;
CESC	cis	rs6500602	0.701	rs4785969	chr16:4536934	A/T	cg08645402	chr16:4508243	NA	0.42	6.08	0.35	4.2e-9	Schizophrenia;
CESC	trans	rs17307778	0.908	rs2404053	chr11:25357432	A/C	cg22888484	chr20:37075185	SNHG11	-0.63	-6.17	-0.35	2.61e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs34638657	0.732	rs7206093	chr16:82201884	G/A	cg09439754	chr16:82129088	HSD17B2	-0.35	-6.12	-0.35	3.29e-9	Lung adenocarcinoma;
CESC	cis	rs561341	0.882	rs2428337	chr17:30299467	C/T	cg19193384	chr17:30244184	NA	-0.68	-6.43	-0.37	5.9e-10	Hip circumference adjusted for BMI;
CESC	cis	rs1046896	0.552	rs12602280	chr17:80805421	G/C	cg02398342	chr17:80708632	TBCD;FN3K	0.44	5.22	0.31	3.7e-7	Glycated hemoglobin levels;
CESC	cis	rs10540	1.000	rs12419716	chr11:503385	C/G	cg03576123	chr11:487126	PTDSS2	-1.12	-11.21	-0.57	3.93e-24	Body mass index;
CESC	cis	rs1215050	0.791	rs1215049	chr4:98848280	C/T	cg05340658	chr4:99064831	C4orf37	0.52	6.87	0.39	4.52e-11	Waist-to-hip ratio adjusted for body mass index;
CESC	trans	rs11098499	0.570	rs6832740	chr4:120546136	T/C	cg25214090	chr10:38739885	LOC399744	0.63	8.89	0.48	9.62e-17	Corneal astigmatism;
CESC	cis	rs1062177	1.000	rs17741826	chr5:151149262	C/T	cg00977110	chr5:151150581	G3BP1	-0.64	-7.04	-0.4	1.6e-11	Preschool internalizing problems;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16835415	chr5:154136941	LARP1	-0.6	-6.47	-0.37	4.82e-10	Gut microbiome composition (summer);
CESC	cis	rs875971	0.838	rs2173570	chr7:65762963	T/A	cg11764359	chr7:65958608	NA	-0.94	-15.58	-0.69	2.66e-39	Aortic root size;
CESC	cis	rs7666738	0.830	rs13119995	chr4:99026790	T/C	cg05340658	chr4:99064831	C4orf37	0.83	13.1	0.63	1.43e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2011503	1.000	rs2916075	chr19:19530590	G/C	cg11584989	chr19:19387371	SF4	0.63	7.29	0.41	3.54e-12	Bipolar disorder;
CESC	cis	rs734999	0.588	rs3748818	chr1:2525660	G/A	cg20673091	chr1:2541236	MMEL1	0.44	7.27	0.41	4.13e-12	Ulcerative colitis;
CESC	cis	rs3785574	0.927	rs2008018	chr17:61954471	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	7.72	0.43	2.35e-13	Height;
CESC	cis	rs736408	0.648	rs3774355	chr3:52817778	G/A	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.35	5.86	0.34	1.39e-8	Bipolar disorder;
CESC	cis	rs8020095	0.571	rs6573726	chr14:67324528	A/G	cg19548862	chr14:67692701	FAM71D	-0.49	-6.09	-0.35	3.85e-9	Depression (quantitative trait);
CESC	cis	rs3740713	1.000	rs73438697	chr11:18462377	G/A	cg23797887	chr11:18477753	LDHAL6A	-0.52	-5.05	-0.3	8.21e-7	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs7772486	0.790	rs2254283	chr6:146204289	T/C	cg05347473	chr6:146136440	FBXO30	0.56	7.25	0.41	4.46e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs314370	0.818	rs13245899	chr7:100497131	A/G	cg10426581	chr7:100472382	SRRT	0.75	8.08	0.44	2.26e-14	Resting heart rate;
CESC	cis	rs1185460	0.967	rs1786685	chr11:118938957	G/A	cg23280166	chr11:118938394	VPS11	0.57	7.86	0.43	9.66e-14	Coronary artery disease;
CESC	cis	rs4253772	0.591	rs73886791	chr22:46687212	A/G	cg24881330	chr22:46731750	TRMU	0.94	10.35	0.54	2.62e-21	LDL cholesterol;Cholesterol, total;
CESC	cis	rs637571	0.726	rs669371	chr11:65674153	G/T	cg26695010	chr11:65641043	EFEMP2	0.51	6.27	0.36	1.46e-9	Eosinophil percentage of white cells;
CESC	cis	rs2204008	0.837	rs11168334	chr12:37961768	A/G	cg26384229	chr12:38710491	ALG10B	0.72	10.57	0.54	5.09e-22	Bladder cancer;
CESC	cis	rs12048904	1.000	rs12048904	chr1:101331536	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.51	-6.61	-0.38	2.14e-10	Multiple sclerosis;
CESC	cis	rs10504229	1.000	rs17217047	chr8:58180296	G/A	cg05313129	chr8:58192883	C8orf71	-0.55	-6.37	-0.36	8.42e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs7726839	0.540	rs74553517	chr5:665671	C/T	cg09021430	chr5:549028	NA	-0.42	-5.16	-0.3	4.75e-7	Obesity-related traits;
CESC	cis	rs9640161	0.789	rs3735174	chr7:150020489	T/C	cg21361702	chr7:150065534	REPIN1	0.5	5.79	0.34	2e-8	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs75477785	0.590	rs1040426	chr1:210134631	T/C	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.91	6.32	0.36	1.09e-9	Cleft lip with or without cleft palate;
CESC	cis	rs11626933	1.000	rs61989986	chr14:90739180	G/A	cg14092571	chr14:90743983	NA	-0.97	-15.2	-0.68	5.94e-38	Gut microbiota (bacterial taxa);
CESC	cis	rs17854409	0.803	rs1048109	chr20:61472120	G/A	cg07645718	chr20:61493192	TCFL5	0.79	5.2	0.3	3.98e-7	Obesity-related traits;
CESC	cis	rs10276381	0.685	rs56398224	chr7:28205748	A/AT	cg23620719	chr7:28220237	JAZF1	0.71	5.84	0.34	1.55e-8	Crohn's disease;
CESC	cis	rs6089829	0.855	rs4809459	chr20:61661345	C/T	cg16240275	chr20:61666158	NCRNA00029	0.5	8.95	0.48	6.42e-17	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18487508	chr19:39926862	RPS16	0.56	6.55	0.37	2.98e-10	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10717766	chr19:5134118	KDM4B	-0.58	-6.71	-0.38	1.19e-10	Gut microbiome composition (summer);
CESC	cis	rs992157	0.710	rs12694432	chr2:219082330	A/G	cg00012203	chr2:219082015	ARPC2	0.85	12.32	0.6	7.16e-28	Colorectal cancer;
CESC	cis	rs250677	0.687	rs171636	chr5:148434545	G/A	cg18129178	chr5:148520854	ABLIM3	-0.54	-5.36	-0.31	1.78e-7	Breast cancer;
CESC	cis	rs2228479	0.850	rs11646766	chr16:89838578	A/T	cg14709524	chr16:89940631	TCF25	0.91	6.74	0.38	1e-10	Skin colour saturation;
CESC	cis	rs4319547	0.695	rs12314643	chr12:122917423	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.49	-6.09	-0.35	3.91e-9	Body mass index;
CESC	trans	rs9693444	0.898	rs4732697	chr8:29519861	A/G	cg06795559	chr20:5931181	MCM8;TRMT6	-0.44	-6.47	-0.37	4.7e-10	Breast cancer;
CESC	cis	rs7020830	0.898	rs308492	chr9:37298020	C/T	cg14294708	chr9:37120828	ZCCHC7	1.22	23.27	0.82	5.31e-66	Schizophrenia;
CESC	cis	rs7412746	0.658	rs17660092	chr1:150797748	T/C	cg09365446	chr1:150670422	GOLPH3L	0.38	5.14	0.3	5.31e-7	Melanoma;
CESC	cis	rs7017914	0.967	rs56112621	chr8:71588394	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.09	-0.3	6.93e-7	Bone mineral density;
CESC	cis	rs2251381	0.778	rs2471947	chr21:30534219	G/T	cg08807101	chr21:30365312	RNF160	0.66	7.96	0.44	5.02e-14	Selective IgA deficiency;
CESC	cis	rs4665809	1.000	rs6704930	chr2:26325705	G/A	cg22920501	chr2:26401640	FAM59B	-0.67	-8.05	-0.44	2.86e-14	Gut microbiome composition (summer);
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg16806347	chr16:70488291	FUK	-0.5	-6.39	-0.37	7.3e-10	Asthma;
CESC	cis	rs7666738	0.830	rs34628820	chr4:99004764	C/T	cg05340658	chr4:99064831	C4orf37	0.8	12.44	0.61	2.83e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4665809	0.652	rs7585891	chr2:26403766	G/A	cg04944784	chr2:26401820	FAM59B	-0.91	-10.4	-0.54	1.82e-21	Gut microbiome composition (summer);
CESC	cis	rs7539409	0.651	rs979757	chr1:84296605	T/C	cg10977910	chr1:84465055	TTLL7	0.77	7.37	0.41	2.12e-12	Alzheimer's disease;
CESC	cis	rs6912958	0.559	rs369674	chr6:88043402	C/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.43	-7.64	-0.42	4.03e-13	Monocyte percentage of white cells;
CESC	cis	rs7264396	0.635	rs7263302	chr20:34545858	T/C	cg17201900	chr20:34330562	RBM39	0.5	5.21	0.3	3.88e-7	Total cholesterol levels;
CESC	cis	rs12142240	0.731	rs12385693	chr1:46818921	A/C	cg00530320	chr1:46809349	NSUN4	0.53	6.76	0.38	8.67e-11	Menopause (age at onset);
CESC	cis	rs13191362	1.000	rs4489133	chr6:163137793	C/T	cg06582575	chr6:163149167	PACRG;PARK2	1.05	10.33	0.54	2.97e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs6963495	0.818	rs56055535	chr7:105163574	C/A	cg02135003	chr7:105160482	PUS7	-0.47	-5.59	-0.33	5.51e-8	Bipolar disorder (body mass index interaction);
CESC	cis	rs1348850	0.789	rs2197611	chr2:178369036	G/C	cg22681709	chr2:178499509	PDE11A	-0.41	-5.89	-0.34	1.15e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs2795502	0.873	rs2795527	chr10:43270240	T/C	cg20628663	chr10:43360327	NA	-0.7	-7.56	-0.42	6.52e-13	Blood protein levels;
CESC	cis	rs853679	0.517	rs9468286	chr6:28079428	C/T	cg08968635	chr6:28129556	ZNF389	0.4	5.36	0.31	1.84e-7	Depression;
CESC	trans	rs8073060	0.614	rs225275	chr17:33972567	G/C	cg19694781	chr19:47549865	TMEM160	-0.73	-7.32	-0.41	3.05e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	cis	rs9303029	1.000	rs9898723	chr17:80439907	A/G	cg04942655	chr17:80303572	NA	-0.5	-5.24	-0.31	3.3e-7	Protein quantitative trait loci;
CESC	cis	rs6998277	1.000	rs34217554	chr8:103646352	T/C	cg10187029	chr8:103597600	NA	0.57	6.44	0.37	5.46e-10	Migraine;
CESC	cis	rs4253772	0.513	rs6008700	chr22:46722560	C/T	cg18190219	chr22:46762943	CELSR1	-0.44	-5.69	-0.33	3.37e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs634534	0.622	rs552130	chr11:65732800	T/C	cg17985854	chr11:65770987	BANF1;EIF1AD	0.45	6.81	0.39	6.63e-11	Sum eosinophil basophil counts;Eosinophil counts;
CESC	cis	rs8070740	0.617	rs1058119	chr17:5323125	C/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.54	7.29	0.41	3.59e-12	Menopause (age at onset);
CESC	cis	rs13191362	0.935	rs116735807	chr6:163010615	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.5	5.17	0.3	4.63e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs6430585	0.528	rs6743537	chr2:136702601	C/T	cg07169764	chr2:136633963	MCM6	1.12	15.25	0.68	3.87e-38	Corneal structure;
CESC	trans	rs9987128	0.649	rs7838112	chr8:2975517	A/G	cg13438961	chr1:41250071	KCNQ4	-0.63	-6.71	-0.38	1.18e-10	Inflammatory skin disease;
CESC	cis	rs9611565	0.921	rs5751080	chr22:41736267	A/G	cg03806693	chr22:41940476	POLR3H	-0.71	-8.53	-0.46	1.12e-15	Vitiligo;
CESC	cis	rs11676348	0.712	rs11687434	chr2:218945143	A/G	cg00012203	chr2:219082015	ARPC2	-0.43	-5.36	-0.31	1.77e-7	Ulcerative colitis;
CESC	cis	rs1018836	0.545	rs7840203	chr8:91701223	A/G	cg16814680	chr8:91681699	NA	-0.96	-16.7	-0.72	2.78e-43	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs56235845	0.694	rs9313758	chr5:176773091	T/G	cg16006841	chr5:176797999	RGS14	0.45	5.63	0.33	4.51e-8	Hemoglobin concentration;Hematocrit;
CESC	cis	rs1552244	1.000	rs17032283	chr3:10081545	C/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.8	-11.3	-0.57	1.93e-24	Alzheimer's disease;
CESC	cis	rs13130787	0.802	rs280097	chr4:94937860	T/C	cg11021082	chr4:95130006	SMARCAD1	0.4	5.52	0.32	8e-8	Colorectal cancer;
CESC	cis	rs11203032	1.000	rs17117088	chr10:90961799	G/A	cg16672925	chr10:90967113	CH25H	0.75	7.18	0.4	6.97e-12	Heart failure;
CESC	cis	rs7508679	1.000	rs4804411	chr19:7222377	G/C	cg09779027	chr19:7224513	INSR	0.53	8.56	0.47	9.04e-16	Hypothyroidism;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19856334	chr2:172290437	DCAF17;METTL8	0.57	6.01	0.35	6.1e-9	Gut microbiome composition (summer);
CESC	trans	rs11989744	0.500	rs7826966	chr8:23569106	G/T	cg03492747	chr16:86543808	FOXF1	-0.84	-13.39	-0.64	1.42e-31	Waist-hip ratio;
CESC	cis	rs57506017	0.540	rs7804736	chr7:12266867	G/T	cg23422036	chr7:12250390	TMEM106B	0.38	5.14	0.3	5.24e-7	Neuroticism;
CESC	cis	rs875971	0.545	rs73142233	chr7:65686280	T/A	cg25405998	chr7:65216604	CCT6P1	0.51	5.54	0.32	7.29e-8	Aortic root size;
CESC	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg07332563	chr6:291687	DUSP22	-0.69	-9.03	-0.49	3.7e-17	Menopause (age at onset);
CESC	cis	rs4665809	0.838	rs7565843	chr2:26292912	G/C	cg08470875	chr2:26401718	FAM59B	-0.46	-5.14	-0.3	5.45e-7	Gut microbiome composition (summer);
CESC	cis	rs7618915	0.571	rs12487445	chr3:52618319	A/C	cg17372223	chr3:52568218	NT5DC2	0.44	6.41	0.37	6.63e-10	Bipolar disorder;
CESC	cis	rs6089584	0.816	rs6061411	chr20:60634716	C/A	cg24733560	chr20:60626293	TAF4	0.49	7.08	0.4	1.3e-11	Body mass index;
CESC	cis	rs17021463	0.673	rs4699459	chr4:95292702	G/A	cg11021082	chr4:95130006	SMARCAD1	0.5	6.74	0.38	9.77e-11	Testicular germ cell tumor;
CESC	cis	rs853679	0.517	rs6932109	chr6:28078303	A/G	cg23161317	chr6:28129485	ZNF389	-0.54	-7.17	-0.4	7.39e-12	Depression;
CESC	cis	rs2361718	0.967	rs12942941	chr17:78103013	C/T	cg06718696	chr17:78121285	EIF4A3	0.46	6.17	0.35	2.54e-9	Yeast infection;
CESC	cis	rs16973500	0.808	rs72801797	chr16:71975300	A/G	cg00732059	chr16:71740210	PHLPP2	-0.49	-5.26	-0.31	2.96e-7	Response to anti-TNF therapy in rheumatoid arthritis;Attention deficit hyperactivity disorder and conduct disorder;
CESC	cis	rs829661	0.532	rs11127276	chr2:30794215	C/T	cg12454169	chr2:30669597	LCLAT1	-0.43	-5.3	-0.31	2.44e-7	Midgestational circulating levels of PBDEs (fetal genetic effect);
CESC	cis	rs9394438	0.628	rs804843	chr6:37545923	A/G	cg00985040	chr6:37553208	NA	-0.35	-5.84	-0.34	1.55e-8	IgG glycosylation;
CESC	cis	rs367615	0.552	rs2963022	chr5:108727185	A/G	cg17395555	chr5:108820864	NA	-0.46	-7.56	-0.42	6.45e-13	Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs12325245	0.536	rs34129245	chr16:58588191	A/G	cg01152986	chr16:58549298	SETD6	0.89	5.4	0.32	1.45e-7	Schizophrenia;
CESC	cis	rs7903847	0.596	rs7922512	chr10:99155685	C/A	cg20016023	chr10:99160130	RRP12	-0.3	-5.16	-0.3	4.77e-7	Granulocyte percentage of myeloid white cells;
CESC	cis	rs919433	0.783	rs787979	chr2:198242868	A/T	cg10820045	chr2:198174542	NA	0.4	5.79	0.34	1.96e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	trans	rs10411161	0.702	rs10402630	chr19:52384570	G/A	cg22319618	chr22:45562946	NUP50	-0.71	-7.04	-0.4	1.66e-11	Breast cancer;
CESC	cis	rs4148883	0.689	rs1311621	chr4:100014018	T/C	cg12011299	chr4:100065546	ADH4	0.67	10.12	0.53	1.43e-20	Alcohol dependence;
CESC	cis	rs9733	0.569	rs11588404	chr1:150688529	C/A	cg04414720	chr1:150670196	GOLPH3L	0.62	8.86	0.48	1.21e-16	Tonsillectomy;
CESC	cis	rs11785400	0.762	rs2280880	chr8:143721929	C/A	cg24634471	chr8:143751801	JRK	0.43	5.38	0.31	1.64e-7	Schizophrenia;
CESC	cis	rs1215050	0.765	rs783925	chr4:98969881	T/C	cg05340658	chr4:99064831	C4orf37	-0.54	-7.32	-0.41	2.98e-12	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs9584850	0.507	rs59704350	chr13:99160430	T/A	cg20750642	chr13:99100586	FARP1	-0.41	-5.71	-0.33	3e-8	Neuroticism;
CESC	cis	rs35306767	0.953	rs35693858	chr10:979813	C/T	cg20503657	chr10:835505	NA	0.65	6.93	0.39	3.13e-11	Eosinophil percentage of granulocytes;
CESC	cis	rs2235544	0.565	rs928443	chr1:54473516	C/T	cg25741118	chr1:54482237	LDLRAD1	0.24	5.81	0.34	1.74e-8	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
CESC	cis	rs2046867	0.862	rs62252360	chr3:72838551	C/T	cg25664220	chr3:72788482	NA	-0.4	-5.92	-0.34	9.97e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05463257	chr3:182782445	MCCC1	-0.69	-8.36	-0.46	3.48e-15	Gut microbiome composition (summer);
CESC	cis	rs425277	0.628	rs10797427	chr1:2060732	C/T	cg13918804	chr1:2043761	PRKCZ	0.28	5.42	0.32	1.36e-7	Height;
CESC	cis	rs7208859	0.623	rs11652533	chr17:29060601	A/C	cg14008862	chr17:28927542	LRRC37B2	0.65	5.12	0.3	5.86e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs853679	0.517	rs9295761	chr6:28147987	A/G	cg20151795	chr6:28129481	ZNF389	0.41	5.25	0.31	3.07e-7	Depression;
CESC	cis	rs34779708	0.966	rs12761675	chr10:35438337	C/T	cg04310649	chr10:35416472	CREM	0.52	6.31	0.36	1.14e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs6860806	0.631	rs6863548	chr5:131575920	G/A	cg18758796	chr5:131593413	PDLIM4	0.45	6.62	0.38	1.99e-10	Breast cancer;
CESC	cis	rs9547996	0.959	rs9548003	chr13:38233206	A/G	cg17979426	chr13:38220150	TRPC4	-0.39	-5.4	-0.31	1.51e-7	Diastolic blood pressure;
CESC	cis	rs11098499	0.754	rs12507565	chr4:120251121	G/A	cg09307838	chr4:120376055	NA	0.77	10.49	0.54	9.15e-22	Corneal astigmatism;
CESC	cis	rs10504229	0.683	rs16921819	chr8:58107936	G/T	cg22535103	chr8:58192502	C8orf71	-0.77	-8.76	-0.47	2.37e-16	Developmental language disorder (linguistic errors);
CESC	cis	rs10927875	1.000	rs12138117	chr1:16305279	T/C	cg21385522	chr1:16154831	NA	-0.77	-9.72	-0.51	2.64e-19	Dilated cardiomyopathy;
CESC	cis	rs9733	0.715	rs12402006	chr1:150869829	G/A	cg13175981	chr1:150552382	MCL1	0.47	6.14	0.35	3.05e-9	Tonsillectomy;
CESC	cis	rs4665809	0.590	rs1056389	chr2:26502875	T/C	cg27170947	chr2:26402098	FAM59B	0.84	9.12	0.49	1.92e-17	Gut microbiome composition (summer);
CESC	cis	rs7312774	0.748	rs12320535	chr12:107295813	T/C	cg16260113	chr12:107380972	MTERFD3	0.61	5.7	0.33	3.21e-8	Severe influenza A (H1N1) infection;
CESC	cis	rs7089973	0.604	rs7897937	chr10:116591318	A/G	cg25233709	chr10:116636983	FAM160B1	0.38	5.9	0.34	1.12e-8	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs9549260	0.755	rs7328677	chr13:41229905	A/G	cg21288729	chr13:41239152	FOXO1	0.65	8.51	0.46	1.27e-15	Red blood cell count;
CESC	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg02018176	chr4:1364513	KIAA1530	-0.56	-7.24	-0.41	4.85e-12	Longevity;
CESC	cis	rs1552244	0.748	rs113890152	chr3:10085986	A/G	cg08888203	chr3:10149979	C3orf24	0.46	5.92	0.34	9.91e-9	Alzheimer's disease;
CESC	cis	rs6496667	0.738	rs58438191	chr15:91045751	G/A	cg13834112	chr15:90361639	NA	0.41	5.56	0.32	6.61e-8	Rheumatoid arthritis;
CESC	cis	rs4975709	0.686	rs2307118	chr5:1881916	A/C	cg15595755	chr5:1867978	NA	0.49	7.59	0.42	5.59e-13	Cardiovascular disease risk factors;
CESC	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg24503407	chr1:205819492	PM20D1	0.86	15.17	0.68	7.42e-38	Menarche (age at onset);
CESC	cis	rs4237845	0.773	rs6650217	chr12:58289072	T/G	cg02175503	chr12:58329896	NA	0.63	9.03	0.49	3.6e-17	Intelligence (multi-trait analysis);
CESC	cis	rs6952808	0.723	rs4721295	chr7:2036669	G/T	cg23048001	chr7:2026167	MAD1L1	-0.46	-6.06	-0.35	4.76e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs965469	1.000	rs6051722	chr20:3274435	A/G	cg25506879	chr20:3388711	C20orf194	-0.55	-5.96	-0.34	7.97e-9	IFN-related cytopenia;
CESC	cis	rs11122272	0.735	rs11122281	chr1:231519842	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.57	-7.75	-0.43	2.03e-13	Hemoglobin concentration;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03686870	chr4:103682143	MANBA	0.66	7.49	0.42	9.97e-13	Gut microbiome composition (summer);
CESC	cis	rs270601	0.770	rs932019	chr5:131599370	T/C	cg09877947	chr5:131593287	PDLIM4	0.51	6.8	0.39	6.73e-11	Acylcarnitine levels;
CESC	cis	rs67311347	1.000	rs28434528	chr3:40484893	A/G	cg09455208	chr3:40491958	NA	0.44	7.54	0.42	7.53e-13	Renal cell carcinoma;
CESC	cis	rs6967414	0.786	rs7782227	chr7:6748594	T/C	cg00387323	chr7:6746715	ZNF12	0.66	6.25	0.36	1.65e-9	Hematocrit;Hemoglobin concentration;
CESC	cis	rs780094	0.544	rs2303370	chr2:27651375	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.27	-5.38	-0.31	1.67e-7	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
CESC	cis	rs7605827	0.930	rs4668451	chr2:15675285	C/T	cg19274914	chr2:15703543	NA	0.38	6.8	0.39	7.12e-11	Educational attainment (years of education);
CESC	cis	rs763121	0.853	rs1569716	chr22:38998519	C/A	cg06022373	chr22:39101656	GTPBP1	0.91	16.13	0.7	3.08e-41	Menopause (age at onset);
CESC	cis	rs2859741	0.608	rs534853	chr1:37474726	T/C	cg09363841	chr1:37513479	NA	-0.52	-7.16	-0.4	7.76e-12	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
CESC	trans	rs11264799	0.765	rs2152710	chr1:157626964	A/G	cg22691776	chr3:15032403	NR2C2	0.34	6.22	0.36	1.93e-9	IgA nephropathy;
CESC	cis	rs208515	0.556	rs1872309	chr6:66660432	A/C	cg07460842	chr6:66804631	NA	0.73	8.52	0.46	1.25e-15	Exhaled nitric oxide levels;
CESC	cis	rs9322193	0.772	rs7738696	chr6:150170121	A/G	cg09699651	chr6:150184138	LRP11	0.48	5.97	0.34	7.51e-9	Lung cancer;
CESC	trans	rs208520	0.690	rs12201219	chr6:66748862	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.95	12.04	0.59	6.44e-27	Exhaled nitric oxide output;
CESC	cis	rs79349575	0.783	rs318095	chr17:46974734	T/C	cg16584676	chr17:46985605	UBE2Z	0.53	6.58	0.37	2.57e-10	Type 2 diabetes;
CESC	cis	rs12824058	0.831	rs4759451	chr12:130812739	G/A	cg24838063	chr12:130822603	PIWIL1	0.61	8.41	0.46	2.59e-15	Menopause (age at onset);
CESC	cis	rs7762018	0.769	rs4716385	chr6:170127608	G/T	cg05834625	chr6:170176447	C6orf70	0.56	6.06	0.35	4.76e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs4766566	0.694	rs3847952	chr12:111746678	T/G	cg10833066	chr12:111807467	FAM109A	0.32	5.13	0.3	5.64e-7	Atrial fibrillation;Renal underexcretion gout;Gout;Renal overload gout;
CESC	cis	rs9733	0.536	rs10888385	chr1:150574302	T/C	cg13175981	chr1:150552382	MCL1	0.71	10.58	0.55	4.63e-22	Tonsillectomy;
CESC	cis	rs9815354	1.000	rs6789260	chr3:41776350	G/C	cg03022575	chr3:42003672	ULK4	0.56	5.56	0.32	6.59e-8	Pulse pressure;Diastolic blood pressure;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg03535255	chr16:87492531	ZCCHC14	-0.35	-6.25	-0.36	1.64e-9	Gambling;
CESC	cis	rs7666738	0.830	rs4345191	chr4:98945408	A/G	cg03467027	chr4:99064603	C4orf37	0.46	5.82	0.34	1.74e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg02353165	chr6:42928485	GNMT	0.95	18.3	0.75	6.48e-49	Alzheimer's disease in APOE e4+ carriers;
CESC	trans	rs6089829	0.889	rs6090206	chr20:61668363	G/A	cg23505145	chr19:12996616	KLF1	0.52	6.74	0.38	1.01e-10	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs10129255	0.530	rs11624912	chr14:107129907	A/G	cg07958169	chr14:107095056	NA	-0.52	-8.31	-0.45	5.03e-15	Kawasaki disease;
CESC	cis	rs6812193	0.518	rs7664593	chr4:77187916	C/T	cg20311846	chr4:77356250	SHROOM3	0.27	5.14	0.3	5.43e-7	Parkinson's disease;
CESC	cis	rs72781680	0.898	rs56216411	chr2:23934533	G/A	cg20701182	chr2:24300061	SF3B14	0.78	6.91	0.39	3.5e-11	Lymphocyte counts;
CESC	cis	rs35110281	0.626	rs162367	chr21:44934857	A/G	cg01579765	chr21:45077557	HSF2BP	-0.48	-8.57	-0.47	8.58e-16	Mean corpuscular volume;
CESC	cis	rs1008375	0.966	rs2286773	chr4:17616214	C/A	cg02297831	chr4:17616191	MED28	0.6	7.69	0.43	2.89e-13	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs1371867	0.846	rs1788181	chr8:101334068	C/T	cg11906718	chr8:101322791	RNF19A	0.46	5.91	0.34	1.03e-8	Atrioventricular conduction;
CESC	cis	rs202629	1	rs202629	chr22:41849975	C/T	cg17376030	chr22:41985996	PMM1	-0.56	-6.22	-0.36	1.92e-9	Cannabis dependence symptom count;
CESC	cis	rs72781680	1.000	rs72796389	chr2:24171761	A/G	cg20701182	chr2:24300061	SF3B14	0.64	5.74	0.33	2.63e-8	Lymphocyte counts;
CESC	cis	rs9311474	0.967	rs11717383	chr3:52287468	G/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.95	0.39	2.9100000000000002e-11	Electroencephalogram traits;
CESC	cis	rs4460629	0.901	rs4745	chr1:155106227	A/T	cg02153340	chr1:155202674	NA	0.35	5.08	0.3	7.12e-7	Serum magnesium levels;
CESC	cis	rs1348850	0.750	rs12997716	chr2:178494629	G/A	cg23306229	chr2:178417860	TTC30B	0.55	7.02	0.4	1.91e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs7618915	0.547	rs6768697	chr3:52703615	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.49	7.14	0.4	9.06e-12	Bipolar disorder;
CESC	cis	rs12681366	0.734	rs10112606	chr8:95396066	T/C	cg13257157	chr8:95487014	RAD54B	0.38	5.11	0.3	6.3e-7	Nonsyndromic cleft lip with cleft palate;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg18885107	chr1:46664327	POMGNT1	-0.4	-6.03	-0.35	5.6e-9	Gambling;
CESC	cis	rs875971	0.862	rs709596	chr7:65825913	A/G	cg18876405	chr7:65276391	NA	0.53	7.39	0.41	1.87e-12	Aortic root size;
CESC	cis	rs4689388	0.610	rs4328980	chr4:6281756	A/G	cg00701064	chr4:6280414	WFS1	0.65	9.23	0.49	8.68e-18	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs7927771	1.000	rs34910028	chr11:47758449	T/C	cg18512352	chr11:47633146	NA	-0.6	-9.5	-0.5	1.32e-18	Subjective well-being;
CESC	cis	rs5758343	1	rs5758343	chr22:41816652	A/T	cg06634786	chr22:41940651	POLR3H	0.73	7.3	0.41	3.43e-12	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs6933660	0.745	rs6557138	chr6:151732017	C/T	cg02564969	chr6:151773285	C6orf211;RMND1	0.64	8.72	0.47	3.02e-16	Menarche (age at onset);
CESC	cis	rs1707322	0.963	rs11211229	chr1:46400517	A/C	cg05343316	chr1:45956843	TESK2	0.44	5.42	0.32	1.36e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs1577917	0.917	rs35738006	chr6:86646309	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.47	-6.02	-0.35	5.83e-9	Response to antipsychotic treatment;
CESC	cis	rs722599	0.639	rs2193596	chr14:75234101	A/C	cg08847533	chr14:75593920	NEK9	0.5	5.84	0.34	1.55e-8	IgG glycosylation;
CESC	cis	rs8040855	0.627	rs12905036	chr15:85637788	C/T	cg08123816	chr15:85640762	PDE8A	-0.41	-6.02	-0.35	5.7e-9	Bulimia nervosa;
CESC	cis	rs6460942	0.908	rs112897715	chr7:12241541	T/C	cg06484146	chr7:12443880	VWDE	-0.46	-5.04	-0.3	8.63e-7	Coronary artery disease;
CESC	cis	rs7264396	0.676	rs6058380	chr20:34552900	T/G	cg17201900	chr20:34330562	RBM39	0.49	5.11	0.3	6.08e-7	Total cholesterol levels;
CESC	cis	rs2839186	1.000	rs2839181	chr21:47685939	A/G	cg10351095	chr21:47802916	PCNT	-0.56	-7.82	-0.43	1.26e-13	Testicular germ cell tumor;
CESC	cis	rs4909189	1.000	rs4909189	chr7:158136986	A/T	cg06219351	chr7:158114137	PTPRN2	0.61	8.54	0.46	1.06e-15	Response to amphetamines;
CESC	cis	rs2857078	0.732	rs9893756	chr17:42321109	T/C	cg08499158	chr17:42289980	UBTF	0.48	5.88	0.34	1.23e-8	Red cell distribution width;Reticulocyte count;
CESC	cis	rs80130819	0.688	rs4760692	chr12:48587549	T/C	cg05342945	chr12:48394962	COL2A1	-0.52	-6.07	-0.35	4.5e-9	Prostate cancer;
CESC	cis	rs6089584	0.566	rs6061401	chr20:60607482	G/A	cg06108461	chr20:60628389	TAF4	-0.62	-8.19	-0.45	1.14e-14	Body mass index;
CESC	cis	rs7917772	0.636	rs2486757	chr10:104535145	C/T	cg04362960	chr10:104952993	NT5C2	-0.48	-5.38	-0.31	1.65e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs6540559	0.673	rs11805830	chr1:209984969	C/T	cg10074409	chr1:209979377	IRF6	0.4	5.29	0.31	2.52e-7	Cleft lip with or without cleft palate;
CESC	cis	rs4803468	1.000	rs11883104	chr19:41923799	T/C	cg09537434	chr19:41945824	ATP5SL	-1.1	-20.39	-0.78	3.13e-56	Height;
CESC	cis	rs875971	0.862	rs3893216	chr7:65790707	G/C	cg18876405	chr7:65276391	NA	-0.54	-7.4	-0.41	1.81e-12	Aortic root size;
CESC	cis	rs1808579	0.935	rs12964689	chr18:21116998	A/G	cg14672496	chr18:21087552	C18orf8	0.42	6.48	0.37	4.52e-10	Hip circumference;Body mass index;BMI (adjusted for smoking behaviour);
CESC	cis	rs801193	0.569	rs13242290	chr7:66121885	G/A	cg10691866	chr7:65817282	TPST1	0.31	5.34	0.31	1.95e-7	Aortic root size;
CESC	cis	rs863345	0.604	rs12075228	chr1:158502256	C/T	cg12129480	chr1:158549410	OR10X1	-0.34	-6.84	-0.39	5.41e-11	Pneumococcal bacteremia;
CESC	cis	rs763014	0.966	rs4984677	chr16:671682	A/G	cg07256732	chr16:621771	PIGQ	-0.32	-5.62	-0.33	4.76e-8	Height;
CESC	cis	rs7513165	0.935	rs12097666	chr1:204162212	A/G	cg23788856	chr1:204159729	KISS1	-0.37	-5.08	-0.3	7.27e-7	Psychosis proneness (hypomanic personality scale);Psychosis proneness (hypomanic personality scale and perceptual aberration scale);Psychosis proneness (hypomanic personality scale and revised social anhedonia scale);Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale);
CESC	cis	rs889312	0.500	rs11960484	chr5:56109154	C/T	cg14703610	chr5:56206110	C5orf35	-0.48	-6.32	-0.36	1.09e-9	Breast cancer;Breast cancer (early onset);
CESC	cis	rs6545883	0.801	rs778142	chr2:61681428	G/T	cg15711740	chr2:61764176	XPO1	-0.41	-5.34	-0.31	2.04e-7	Tuberculosis;
CESC	cis	rs11718455	0.883	rs6795366	chr3:44005735	C/T	cg08738300	chr3:44038990	NA	0.44	5.86	0.34	1.35e-8	Coronary artery disease;
CESC	cis	rs62432291	0.681	rs378547	chr6:159662525	A/G	cg14500486	chr6:159655392	FNDC1	0.55	5.38	0.31	1.68e-7	Joint mobility (Beighton score);
CESC	cis	rs9894429	0.809	rs9889642	chr17:79591762	T/C	cg21984481	chr17:79567631	NPLOC4	-0.47	-7.63	-0.42	4.29e-13	Eye color traits;
CESC	trans	rs79243044	0.786	rs16932549	chr11:5560909	C/T	cg13404532	chr3:128483276	RAB7A	-0.48	-6.01	-0.35	6.09e-9	QRS duration in Tripanosoma cruzi seropositivity;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg25932386	chr2:37459326	CEBPZ;C2orf56	-0.46	-6.02	-0.35	5.78e-9	Asthma;
CESC	cis	rs7085104	0.660	rs3781286	chr10:104595719	C/T	cg15744005	chr10:104629667	AS3MT	-0.34	-5.32	-0.31	2.26e-7	Immature fraction of reticulocytes;Schizophrenia;
CESC	cis	rs875971	0.830	rs1167406	chr7:65556936	G/C	cg12463550	chr7:65579703	CRCP	-0.54	-6.65	-0.38	1.65e-10	Aortic root size;
CESC	cis	rs7726839	0.794	rs10474792	chr5:600058	G/A	cg09021430	chr5:549028	NA	-0.44	-6.23	-0.36	1.84e-9	Obesity-related traits;
CESC	cis	rs12497850	0.931	rs9682444	chr3:48852639	A/G	cg07636037	chr3:49044803	WDR6	1.03	18.76	0.76	1.49e-50	Parkinson's disease;
CESC	cis	rs8072100	0.713	rs4968318	chr17:45451894	G/A	cg08085267	chr17:45401833	C17orf57	-0.51	-6.35	-0.36	9.29e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs6987853	0.563	rs2974312	chr8:42455846	C/T	cg09913449	chr8:42400586	C8orf40	0.33	5.17	0.3	4.66e-7	Mean corpuscular hemoglobin concentration;
CESC	cis	rs1552244	1.000	rs2160869	chr3:10079255	G/A	cg08888203	chr3:10149979	C3orf24	0.47	6.03	0.35	5.45e-9	Alzheimer's disease;
CESC	cis	rs11792861	0.816	rs11790105	chr9:111731785	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.51	6.5	0.37	3.86e-10	Menarche (age at onset);
CESC	cis	rs56104184	0.775	rs73061699	chr19:49400511	T/C	cg21252483	chr19:49399788	TULP2	-0.52	-5.69	-0.33	3.36e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	trans	rs9329221	0.683	rs814359	chr8:9883132	T/G	cg06636001	chr8:8085503	FLJ10661	-0.53	-7.0	-0.4	2.05e-11	Neuroticism;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg17883223	chr7:56854974	NA	-0.38	-6.17	-0.35	2.51e-9	Thyroid stimulating hormone;
CESC	cis	rs2832191	0.692	rs8134627	chr21:30349069	C/T	cg24692254	chr21:30365293	RNF160	-0.97	-17.29	-0.73	2.35e-45	Dental caries;
CESC	cis	rs736408	0.677	rs2286798	chr3:52821177	G/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	-0.34	-5.78	-0.33	2.11e-8	Bipolar disorder;
CESC	cis	rs7618501	0.633	rs12496973	chr3:50002245	T/C	cg24110177	chr3:50126178	RBM5	-0.53	-7.35	-0.41	2.48e-12	Intelligence (multi-trait analysis);
CESC	cis	rs12681366	0.663	rs6980687	chr8:95481913	A/G	cg13257157	chr8:95487014	RAD54B	0.37	5.03	0.3	8.9e-7	Nonsyndromic cleft lip with cleft palate;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14770633	chr2:27851514	GPN1;CCDC121	0.59	7.23	0.41	5.12e-12	Gut microbiome composition (summer);
CESC	cis	rs9905704	0.647	rs10221208	chr17:57047885	T/C	cg12560992	chr17:57184187	TRIM37	0.62	7.89	0.44	7.8e-14	Testicular germ cell tumor;
CESC	cis	rs35306767	0.903	rs7077278	chr10:911291	A/G	cg10556349	chr10:835070	NA	-0.59	-5.7	-0.33	3.11e-8	Eosinophil percentage of granulocytes;
CESC	trans	rs1814175	0.817	rs7950856	chr11:49976394	C/T	cg15704280	chr7:45808275	SEPT13	-1.03	-21.34	-0.8	1.71e-59	Height;
CESC	cis	rs208515	0.525	rs10498841	chr6:66663706	C/T	cg07460842	chr6:66804631	NA	0.83	10.33	0.54	3.09e-21	Exhaled nitric oxide levels;
CESC	cis	rs2795502	0.872	rs2744062	chr10:43254789	T/A	cg20628663	chr10:43360327	NA	-0.7	-7.32	-0.41	2.96e-12	Blood protein levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11543725	chr11:10329292	NA	0.53	6.41	0.37	6.45e-10	Gut microbiome composition (summer);
CESC	cis	rs7107174	0.901	rs2912	chr11:77926292	G/A	cg02023728	chr11:77925099	USP35	0.47	5.97	0.34	7.71e-9	Testicular germ cell tumor;
CESC	trans	rs4689592	0.503	rs10516184	chr4:7060959	C/T	cg07817883	chr1:32538562	TMEM39B	-0.64	-6.42	-0.37	6.17e-10	Monocyte percentage of white cells;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12538369	chr19:40932019	SERTAD1	-0.63	-7.57	-0.42	6.39e-13	Gut microbiome composition (summer);
CESC	cis	rs3857536	0.740	rs6455080	chr6:66887413	T/A	cg07460842	chr6:66804631	NA	-0.42	-5.39	-0.31	1.53e-7	Blood trace element (Cu levels);
CESC	cis	rs7429990	0.932	rs7620736	chr3:48109969	C/T	cg11946769	chr3:48343235	NME6	-0.45	-5.53	-0.32	7.61e-8	Educational attainment (years of education);
CESC	cis	rs4595586	0.525	rs7136425	chr12:39376005	C/A	cg26384229	chr12:38710491	ALG10B	0.54	7.53	0.42	7.85e-13	Morning vs. evening chronotype;
CESC	cis	rs6088590	1.000	rs10048849	chr20:33419680	C/T	cg24642439	chr20:33292090	TP53INP2	0.84	11.75	0.59	6.21e-26	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22529720	chr7:139044624	LUC7L2	0.57	6.38	0.36	7.84e-10	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08262876	chr10:102757026	LZTS2	-0.7	-8.3	-0.45	5.22e-15	Gut microbiome composition (summer);
CESC	trans	rs10241579	0.803	rs10254706	chr7:52769619	A/C	cg18715243	chr8:37658755	GPR124	-0.48	-6.12	-0.35	3.35e-9	Inhibitory control;
CESC	cis	rs10788264	0.504	rs10749451	chr10:124028040	C/T	cg09507567	chr10:124027408	NA	0.39	5.41	0.32	1.42e-7	Total body bone mineral density;
CESC	cis	rs875971	0.789	rs10260426	chr7:65736042	G/T	cg18876405	chr7:65276391	NA	-0.5	-6.92	-0.39	3.36e-11	Aortic root size;
CESC	trans	rs11722228	0.508	rs73212864	chr4:10104191	G/A	cg26043149	chr18:55253948	FECH	0.92	10.72	0.55	1.62e-22	Gout;Urate levels;Serum uric acid levels;
CESC	cis	rs6484504	0.576	rs158144	chr11:31211795	A/C	cg14844989	chr11:31128820	NA	-0.41	-5.88	-0.34	1.22e-8	Red blood cell count;
CESC	cis	rs1048238	0.525	rs848214	chr1:16265422	A/G	cg21385522	chr1:16154831	NA	-0.43	-5.48	-0.32	9.88e-8	Systolic blood pressure;
CESC	cis	rs7084402	0.967	rs1658457	chr10:60302716	T/C	cg07615347	chr10:60278583	BICC1	0.6	9.43	0.5	2.17e-18	Refractive error;
CESC	cis	rs6570726	0.875	rs12524077	chr6:145866333	G/C	cg05347473	chr6:146136440	FBXO30	0.48	6.45	0.37	5.27e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs870825	0.616	rs28660669	chr4:185623312	C/T	cg04058563	chr4:185651563	MLF1IP	0.64	7.05	0.4	1.59e-11	Blood protein levels;
CESC	cis	rs72777070	0.895	rs12615784	chr2:9789403	A/G	cg14973360	chr2:9800511	NA	-0.49	-5.15	-0.3	5.19e-7	Platelet-derived growth factor BB levels;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg00526316	chr1:151043472	GABPB2	-0.42	-6.32	-0.36	1.12e-9	Gambling;
CESC	cis	rs7511006	1.000	rs7364173	chr22:50681029	C/T	cg16473166	chr22:50639996	SELO	-0.5	-6.27	-0.36	1.43e-9	Obesity-related traits;
CESC	cis	rs9611565	0.729	rs73176689	chr22:41782633	T/C	cg17376030	chr22:41985996	PMM1	0.68	7.25	0.41	4.6e-12	Vitiligo;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20856064	chr3:49027210	P4HTM	0.62	6.72	0.38	1.09e-10	Gut microbiome composition (summer);
CESC	cis	rs684232	0.666	rs1227028	chr17:573298	G/A	cg15660573	chr17:549704	VPS53	-0.64	-8.78	-0.47	2.09e-16	Prostate cancer;
CESC	cis	rs9811920	0.809	rs793443	chr3:99573547	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.44	-7.39	-0.41	1.95e-12	Axial length;
CESC	cis	rs1348850	0.526	rs6723014	chr2:178410586	G/A	cg23306229	chr2:178417860	TTC30B	0.85	7.9	0.44	7.47e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs9660992	0.649	rs72745216	chr1:205261016	G/A	cg00857998	chr1:205179979	DSTYK	0.49	5.51	0.32	8.52e-8	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg09742643	chr7:157958748	PTPRN2	0.38	6.56	0.37	2.79e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CESC	cis	rs854765	0.583	rs4413022	chr17:17858280	G/C	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.55	7.14	0.4	8.73e-12	Total body bone mineral density;
CESC	cis	rs9457247	1.000	rs932644	chr6:167404187	A/C	cg25258033	chr6:167368657	RNASET2	0.39	5.88	0.34	1.26e-8	Crohn's disease;
CESC	cis	rs763121	0.853	rs138704	chr22:39133410	A/G	cg06022373	chr22:39101656	GTPBP1	0.93	17.3	0.73	2.21e-45	Menopause (age at onset);
CESC	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg05552183	chr6:42928497	GNMT	0.85	14.72	0.67	3.1e-36	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg02951883	chr7:2050386	MAD1L1	-0.44	-5.62	-0.33	4.93e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs57221529	0.709	rs72706612	chr5:561198	C/T	cg16447950	chr5:562315	NA	-0.71	-7.83	-0.43	1.2e-13	Lung disease severity in cystic fibrosis;
CESC	cis	rs6088580	0.634	rs4911421	chr20:32998948	T/C	cg24642439	chr20:33292090	TP53INP2	-0.53	-6.99	-0.39	2.17e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs2635047	0.967	rs2684820	chr18:44664304	G/A	cg19077165	chr18:44547161	KATNAL2	-0.43	-5.85	-0.34	1.47e-8	Educational attainment;
CESC	cis	rs12200560	0.505	rs4839848	chr6:97076577	G/A	cg06623918	chr6:96969491	KIAA0776	0.51	6.46	0.37	5.04e-10	Coronary heart disease;
CESC	cis	rs832540	0.556	rs4146565	chr5:56093825	T/C	cg22800045	chr5:56110881	MAP3K1	0.5	5.99	0.35	6.89e-9	Coronary artery disease;
CESC	cis	rs11122272	0.735	rs2790877	chr1:231535427	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.57	-7.7	-0.43	2.8e-13	Hemoglobin concentration;
CESC	trans	rs637571	0.522	rs12792888	chr11:65761446	C/T	cg17712092	chr4:129076599	LARP1B	0.74	10.21	0.53	7.53e-21	Eosinophil percentage of white cells;
CESC	cis	rs1878931	0.501	rs9302871	chr16:3415512	T/C	cg05754148	chr16:3507555	NAT15	-0.39	-5.24	-0.31	3.25e-7	Body mass index (adult);
CESC	cis	rs9768139	0.733	rs34173461	chr7:158122175	C/G	cg24154853	chr7:158122151	PTPRN2	0.4	6.24	0.36	1.72e-9	Calcium levels;
CESC	cis	rs873946	0.590	rs12783478	chr10:134550700	A/G	cg27286337	chr10:134555280	INPP5A	0.64	7.64	0.42	4.1e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs10870270	0.956	rs7915388	chr10:133734972	G/A	cg26149184	chr10:133730230	NA	0.38	5.15	0.3	5.07e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs10504229	0.679	rs111843870	chr8:58126798	A/G	cg02725872	chr8:58115012	NA	-0.45	-6.84	-0.39	5.31e-11	Developmental language disorder (linguistic errors);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02458088	chr16:77228411	MON1B	-0.61	-6.87	-0.39	4.5e-11	Gut microbiome composition (summer);
CESC	cis	rs8077889	0.917	rs4793038	chr17:41916761	A/T	cg26893861	chr17:41843967	DUSP3	0.72	9.71	0.51	2.94e-19	Triglycerides;
CESC	cis	rs10492096	0.783	rs11064220	chr12:6592574	C/T	cg13857086	chr12:6580257	VAMP1	0.52	5.2	0.3	4.07e-7	Hip geometry;
CESC	cis	rs73206853	0.698	rs73191806	chr12:110899913	A/G	cg12870014	chr12:110450643	ANKRD13A	0.63	5.18	0.3	4.34e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs7264396	1.000	rs224437	chr20:34154371	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.52	-6.44	-0.37	5.45e-10	Total cholesterol levels;
CESC	cis	rs6088590	0.542	rs6059956	chr20:33220070	A/G	cg06115741	chr20:33292138	TP53INP2	0.53	6.71	0.38	1.17e-10	Coronary artery disease;
CESC	cis	rs1862618	0.573	rs832532	chr5:56221938	T/C	cg12311346	chr5:56204834	C5orf35	-0.86	-10.64	-0.55	2.93e-22	Initial pursuit acceleration;
CESC	trans	rs6715284	0.892	rs72937112	chr2:202228108	T/C	cg00425217	chr19:13205470	NFIX	-0.61	-6.07	-0.35	4.33e-9	Rheumatoid arthritis;
CESC	cis	rs7100689	0.725	rs10736340	chr10:82061071	C/T	cg09936400	chr10:82049201	MAT1A	0.37	5.3	0.31	2.41e-7	Post bronchodilator FEV1;
CESC	cis	rs875971	0.895	rs10447522	chr7:65796074	A/G	cg19163074	chr7:65112434	INTS4L2	0.41	5.18	0.3	4.32e-7	Aortic root size;
CESC	cis	rs7772486	0.840	rs2777478	chr6:146309117	T/C	cg05347473	chr6:146136440	FBXO30	0.56	7.37	0.41	2.14e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2832191	0.791	rs28633762	chr21:30500070	C/T	cg08807101	chr21:30365312	RNF160	-0.72	-9.88	-0.52	8.5e-20	Dental caries;
CESC	cis	rs5750830	0.594	rs6001568	chr22:39775786	G/A	cg11247378	chr22:39784982	NA	-0.6	-8.83	-0.48	1.42e-16	Intelligence (multi-trait analysis);
CESC	cis	rs2777491	0.915	rs28583065	chr15:41608470	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.6	-8.98	-0.48	5.23e-17	Ulcerative colitis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04015759	chr2:27718181	FNDC4	0.52	6.78	0.38	7.8e-11	Gut microbiome composition (summer);
CESC	cis	rs8014204	0.762	rs10148293	chr14:75296831	C/T	cg08847533	chr14:75593920	NEK9	-0.43	-5.66	-0.33	3.84e-8	Caffeine consumption;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14965979	chr2:44588995	PREPL;C2orf34	0.61	6.69	0.38	1.36e-10	Gut microbiome composition (summer);
CESC	cis	rs796364	0.951	rs12620298	chr2:201047184	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.66	-6.35	-0.36	9.11e-10	Schizophrenia;
CESC	cis	rs9487051	0.676	rs6903107	chr6:109597711	A/G	cg12927641	chr6:109611667	NA	-0.37	-5.5	-0.32	8.91e-8	Reticulocyte fraction of red cells;
CESC	cis	rs2236918	0.901	rs1776132	chr1:242024473	C/G	cg17736920	chr1:242011382	EXO1	0.68	8.76	0.47	2.39e-16	Menopause (age at onset);
CESC	cis	rs4654899	0.758	rs17453044	chr1:21517361	A/G	cg05370193	chr1:21551575	ECE1	0.4	6.12	0.35	3.27e-9	Superior frontal gyrus grey matter volume;
CESC	trans	rs1814175	0.645	rs10128731	chr11:50023554	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.41	-6.01	-0.35	6.08e-9	Height;
CESC	cis	rs8133932	0.654	rs420386	chr21:47364816	G/A	cg14185626	chr21:47401492	COL6A1	-0.48	-5.34	-0.31	1.98e-7	Schizophrenia;
CESC	trans	rs877282	1.000	rs12779159	chr10:772143	T/C	cg22713356	chr15:30763199	NA	1.25	12.53	0.61	1.33e-28	Uric acid levels;
CESC	cis	rs644799	1.000	rs632388	chr11:95563775	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	9.15	0.49	1.57e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	trans	rs3780486	0.846	rs6476399	chr9:33123013	A/G	cg04842962	chr6:43655489	MRPS18A	1.0	19.44	0.77	6.43e-53	IgG glycosylation;
CESC	cis	rs72627123	0.656	rs17096949	chr14:74602360	A/T	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.73	5.03	0.3	8.99e-7	Morning vs. evening chronotype;
CESC	cis	rs4919087	0.962	rs10748691	chr10:98983955	C/T	cg25902810	chr10:99078978	FRAT1	0.71	10.14	0.53	1.27e-20	Monocyte count;
CESC	cis	rs3733585	0.673	rs4697914	chr4:9952266	G/A	cg02734326	chr4:10020555	SLC2A9	-0.39	-5.64	-0.33	4.45e-8	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs965469	0.779	rs2236088	chr20:3256342	T/C	cg25506879	chr20:3388711	C20orf194	-0.49	-5.36	-0.31	1.8e-7	IFN-related cytopenia;
CESC	cis	rs10504229	1.000	rs72650900	chr8:58185675	T/A	cg14926445	chr8:58193284	C8orf71	-0.51	-5.52	-0.32	8.28e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs208520	1.000	rs208529	chr6:66957549	T/C	cg07460842	chr6:66804631	NA	-0.8	-9.14	-0.49	1.64e-17	Exhaled nitric oxide output;
CESC	cis	rs1799949	1.000	rs12936831	chr17:41331816	C/T	cg05368731	chr17:41323189	NBR1	0.76	10.35	0.54	2.73e-21	Menopause (age at onset);
CESC	cis	rs116095464	0.614	rs10061564	chr5:271329	T/C	cg20965017	chr5:231967	SDHA	-0.47	-5.3	-0.31	2.46e-7	Breast cancer;
CESC	cis	rs5769765	0.671	rs138844	chr22:50184484	T/G	cg02269571	chr22:50332266	NA	-0.49	-6.24	-0.36	1.68e-9	Schizophrenia;
CESC	cis	rs17711722	0.528	rs73138179	chr7:65294482	G/T	cg25405998	chr7:65216604	CCT6P1	0.53	6.68	0.38	1.37e-10	Calcium levels;
CESC	cis	rs6541297	0.941	rs6693579	chr1:230282707	T/C	cg20703242	chr1:230279135	GALNT2	0.75	8.14	0.45	1.57e-14	Coronary artery disease;
CESC	cis	rs9926296	0.585	rs8058009	chr16:89856439	G/A	cg03388025	chr16:89894329	SPIRE2	0.35	6.19	0.36	2.29e-9	Vitiligo;
CESC	cis	rs6754311	0.731	rs4954490	chr2:136608231	G/A	cg07169764	chr2:136633963	MCM6	-0.69	-8.48	-0.46	1.59e-15	Mosquito bite size;
CESC	cis	rs769267	0.930	rs4808959	chr19:19572108	T/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.47	5.93	0.34	9.53e-9	Tonsillectomy;
CESC	cis	rs10504229	0.683	rs10504224	chr8:58143735	A/G	cg22535103	chr8:58192502	C8orf71	-0.89	-9.47	-0.5	1.64e-18	Developmental language disorder (linguistic errors);
CESC	cis	rs9549367	0.789	rs9549698	chr13:113877701	A/G	cg00898013	chr13:113819073	PROZ	-0.48	-7.12	-0.4	1.04e-11	Platelet distribution width;
CESC	cis	rs7523050	0.643	rs34572569	chr1:109401856	A/T	cg08274380	chr1:109419600	GPSM2	0.86	5.69	0.33	3.36e-8	Fat distribution (HIV);
CESC	cis	rs1218582	0.772	rs10796934	chr1:154849479	C/G	cg16680214	chr1:154839983	KCNN3	-0.44	-6.81	-0.39	6.66e-11	Prostate cancer;
CESC	cis	rs5167	0.677	rs2238682	chr19:45458593	C/T	cg13119609	chr19:45449297	APOC2	0.38	5.35	0.31	1.89e-7	Blood protein levels;
CESC	cis	rs208520	0.661	rs7747492	chr6:66857788	A/T	cg07460842	chr6:66804631	NA	-1.01	-13.48	-0.64	6.84e-32	Exhaled nitric oxide output;
CESC	cis	rs910316	0.737	rs175071	chr14:75498177	A/G	cg16144293	chr14:75469539	EIF2B2	0.39	5.27	0.31	2.78e-7	Height;
CESC	cis	rs9309473	0.748	rs2421552	chr2:73758803	C/T	cg20560298	chr2:73613845	ALMS1	-0.51	-6.53	-0.37	3.43e-10	Metabolite levels;
CESC	cis	rs7527798	0.592	rs11118278	chr1:207831357	C/G	cg21110645	chr1:207815933	NA	-0.32	-5.41	-0.32	1.38e-7	Erythrocyte sedimentation rate;
CESC	cis	rs11122272	0.668	rs2790874	chr1:231537988	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.55	-7.47	-0.42	1.14e-12	Hemoglobin concentration;
CESC	cis	rs7949030	0.688	rs11231155	chr11:62365619	A/G	cg23462726	chr11:62437636	C11orf83;C11orf48	-0.4	-5.25	-0.31	3.13e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs798554	0.757	rs1182176	chr7:2874601	A/G	cg19717773	chr7:2847554	GNA12	-0.52	-7.61	-0.42	4.94e-13	Height;
CESC	cis	rs6933660	0.646	rs6915598	chr6:151778664	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.68	7.25	0.41	4.66e-12	Menarche (age at onset);
CESC	cis	rs7208859	0.623	rs34756112	chr17:29113016	A/G	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.79e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs7618915	0.547	rs4687638	chr3:52651966	A/C	cg05564831	chr3:52568323	NT5DC2	0.45	6.8	0.39	6.82e-11	Bipolar disorder;
CESC	trans	rs208520	0.690	rs207108	chr6:66794096	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.0	-12.83	-0.62	1.2e-29	Exhaled nitric oxide output;
CESC	cis	rs4474465	0.920	rs7947852	chr11:78198030	T/C	cg27205649	chr11:78285834	NARS2	-0.43	-5.54	-0.32	7.3900000000000007e-08	Alzheimer's disease (survival time);
CESC	trans	rs78049276	0.736	rs72957606	chr4:148400011	A/G	cg13149281	chr14:23389818	RBM23;PRMT5	-0.69	-7.51	-0.42	8.92e-13	Pulse pressure;
CESC	cis	rs10791097	0.694	rs3190331	chr11:130748131	C/T	cg09137382	chr11:130731461	NA	-0.37	-5.56	-0.32	6.53e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs1953600	0.668	rs3122586	chr10:81950326	C/T	cg00277334	chr10:82204260	NA	0.54	7.95	0.44	5.46e-14	Sarcoidosis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10777407	chr15:23311741	HERC2P2	-0.5	-6.46	-0.37	4.92e-10	Gut microbiome composition (summer);
CESC	cis	rs7772486	0.686	rs7744014	chr6:146123818	G/A	cg23711669	chr6:146136114	FBXO30	0.87	13.02	0.62	2.64e-30	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7647973	0.506	rs11920251	chr3:49356671	C/T	cg06212747	chr3:49208901	KLHDC8B	0.65	9.43	0.5	2.14e-18	Menarche (age at onset);
CESC	cis	rs6121246	0.529	rs750144	chr20:30179027	C/T	cg13852791	chr20:30311386	BCL2L1	-0.58	-5.66	-0.33	3.9e-8	Mean corpuscular hemoglobin;
CESC	cis	rs875971	0.862	rs10274883	chr7:66116091	C/T	cg18876405	chr7:65276391	NA	-0.45	-6.18	-0.35	2.43e-9	Aortic root size;
CESC	cis	rs6674970	0.627	rs2864700	chr1:151028929	C/T	cg04469105	chr1:151031679	CDC42SE1;MLLT11	-0.41	-5.39	-0.31	1.59e-7	Childhood ear infection;
CESC	cis	rs55894132	1	rs55894132	chr14:23408837	C/G	cg01529538	chr14:23388837	RBM23	0.46	6.04	0.35	5.2e-9	Intelligence (multi-trait analysis);
CESC	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg04025307	chr7:1156635	C7orf50	0.5	8.5	0.46	1.36e-15	Longevity;Endometriosis;
CESC	cis	rs7223966	1.000	rs11658329	chr17:61763031	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.56	-7.22	-0.41	5.34e-12	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs911555	0.511	rs8007489	chr14:104054572	A/G	cg24130564	chr14:104152367	KLC1	0.69	11.13	0.56	7.58e-24	Intelligence (multi-trait analysis);
CESC	trans	rs6600671	1.000	rs11249351	chr1:121171942	G/A	cg17023122	chr1:144479586	NA	0.44	6.17	0.35	2.6e-9	Hip geometry;
CESC	cis	rs12682352	0.652	rs1567398	chr8:8726804	A/C	cg06636001	chr8:8085503	FLJ10661	-0.39	-5.04	-0.3	8.72e-7	Neuroticism;
CESC	cis	rs11871801	0.517	rs35635959	chr17:40772288	T/C	cg16308533	chr17:40838983	CNTNAP1	0.39	5.12	0.3	5.95e-7	Crohn's disease;
CESC	cis	rs155076	1.000	rs598754	chr13:21845010	C/A	cg11317459	chr13:21872234	NA	-1.01	-11.12	-0.56	7.88e-24	White matter hyperintensity burden;
CESC	cis	rs765787	0.530	rs2899379	chr15:45534799	C/T	cg24006582	chr15:45444508	DUOX1	0.58	6.97	0.39	2.5e-11	Uric acid levels;
CESC	cis	rs11690935	0.959	rs6745143	chr2:172650382	G/A	cg13550731	chr2:172543902	DYNC1I2	-0.96	-14.76	-0.67	2.21e-36	Schizophrenia;
CESC	cis	rs6061231	0.631	rs2427318	chr20:60975727	G/T	cg22633769	chr20:60982531	CABLES2	0.56	7.21	0.4	5.96e-12	Colorectal cancer;
CESC	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg18765753	chr7:1198926	ZFAND2A	-0.4	-5.04	-0.3	8.66e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs9399401	0.667	rs1329707	chr6:142724439	T/C	cg03128060	chr6:142623767	GPR126	0.39	6.58	0.37	2.57e-10	Chronic obstructive pulmonary disease;
CESC	cis	rs3782774	0.564	rs12580347	chr12:3388932	T/C	cg17043230	chr12:3427729	NA	-0.29	-5.07	-0.3	7.47e-7	Coronary artery disease;
CESC	cis	rs3796352	1.000	rs71301808	chr3:53085577	C/G	cg07884673	chr3:53033167	SFMBT1	0.65	5.63	0.33	4.49e-8	Immune reponse to smallpox (secreted IL-2);
CESC	cis	rs4953318	0.577	rs67087783	chr2:46363544	C/T	cg12428440	chr2:46370979	PRKCE	0.48	6.02	0.35	5.94e-9	Red blood cell count;Hematocrit;Red blood cell traits;
CESC	cis	rs10504229	0.683	rs55714371	chr8:58131846	T/G	cg24829409	chr8:58192753	C8orf71	-0.58	-7.2	-0.4	6.31e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs9894429	0.608	rs8477	chr17:79618059	C/T	cg13777783	chr17:79615861	NA	-0.33	-5.48	-0.32	9.69e-8	Eye color traits;
CESC	cis	rs1552244	0.626	rs2886396	chr3:10037670	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	10.84	0.55	6.79e-23	Alzheimer's disease;
CESC	cis	rs763121	0.853	rs6001184	chr22:39052116	C/T	cg06022373	chr22:39101656	GTPBP1	0.88	13.91	0.65	2.06e-33	Menopause (age at onset);
CESC	cis	rs4566357	0.615	rs2272202	chr2:227914625	C/T	cg11843606	chr2:227700838	RHBDD1	0.43	5.81	0.34	1.82e-8	Coronary artery disease;
CESC	cis	rs10887741	0.546	rs7903516	chr10:89441102	T/C	cg13926569	chr10:89418898	PAPSS2	0.5	8.01	0.44	3.6e-14	Exercise (leisure time);
CESC	cis	rs7086627	0.515	rs10887896	chr10:82210144	A/C	cg00277334	chr10:82204260	NA	-0.9	-15.67	-0.69	1.3e-39	Post bronchodilator FEV1;
CESC	cis	rs6570726	0.689	rs411785	chr6:145888398	G/A	cg23711669	chr6:146136114	FBXO30	1.01	15.56	0.69	3.07e-39	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg02018176	chr4:1364513	KIAA1530	0.6	7.43	0.42	1.47e-12	Longevity;
CESC	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	22.34	0.81	6.93e-63	Prudent dietary pattern;
CESC	cis	rs9611565	0.512	rs5751148	chr22:42139078	A/G	cg03806693	chr22:41940476	POLR3H	1.16	13.59	0.64	2.85e-32	Vitiligo;
CESC	cis	rs7084402	0.967	rs1649022	chr10:60285867	A/G	cg07615347	chr10:60278583	BICC1	0.59	9.44	0.5	2.04e-18	Refractive error;
CESC	cis	rs1046896	0.562	rs9912684	chr17:80873067	C/T	cg19046167	chr17:80928561	B3GNTL1	0.49	6.1	0.35	3.66e-9	Glycated hemoglobin levels;
CESC	cis	rs9402673	0.517	rs978036	chr6:135342903	C/T	cg22676075	chr6:135203613	NA	0.51	7.36	0.41	2.34e-12	Reticulocyte count;High light scatter reticulocyte count;
CESC	cis	rs7772486	0.875	rs1331640	chr6:146427250	G/A	cg23711669	chr6:146136114	FBXO30	0.86	12.46	0.61	2.39e-28	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1059312	0.771	rs7974764	chr12:129296588	G/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.82	-12.1	-0.6	3.83e-27	Systemic lupus erythematosus;
CESC	cis	rs4665809	0.556	rs6730311	chr2:26419474	C/T	cg08470875	chr2:26401718	FAM59B	-0.76	-8.63	-0.47	5.63e-16	Gut microbiome composition (summer);
CESC	cis	rs7587476	0.784	rs13008641	chr2:215698033	T/C	cg04004882	chr2:215674386	BARD1	0.5	5.42	0.32	1.36e-7	Neuroblastoma;
CESC	cis	rs10504229	0.683	rs6980540	chr8:58127022	A/G	cg22535103	chr8:58192502	C8orf71	-0.84	-9.44	-0.5	2.04e-18	Developmental language disorder (linguistic errors);
CESC	cis	rs597539	0.652	rs507520	chr11:68666054	C/T	cg18350739	chr11:68623251	NA	-0.48	-7.33	-0.41	2.84e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg11301795	chr4:187892539	NA	-0.81	-14.18	-0.66	2.37e-34	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7296418	0.961	rs4275659	chr12:123447928	C/T	cg00376283	chr12:123451042	ABCB9	-0.72	-10.34	-0.54	2.83e-21	Platelet count;
CESC	cis	rs4555082	0.834	rs11622165	chr14:105759761	C/A	cg13114125	chr14:105738426	BRF1	-0.88	-10.43	-0.54	1.41e-21	Mean platelet volume;Platelet distribution width;
CESC	cis	rs7666738	0.927	rs6832373	chr4:99051967	A/G	cg17366294	chr4:99064904	C4orf37	0.62	8.84	0.48	1.41e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7666738	0.515	rs13434650	chr4:98889886	A/G	cg17366294	chr4:99064904	C4orf37	0.51	6.37	0.36	8.15e-10	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9814567	1.000	rs7648990	chr3:134244390	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.45	-6.15	-0.35	2.87e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs360798	0.512	rs4671050	chr2:62988169	G/T	cg17519650	chr2:63277830	OTX1	-0.59	-7.62	-0.42	4.57e-13	Coronary artery disease;
CESC	cis	rs11190604	1.000	rs7905961	chr10:102297391	G/C	cg07080220	chr10:102295463	HIF1AN	0.6	5.82	0.34	1.72e-8	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs12220238	1.000	rs12252705	chr10:75984863	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.62	6.0	0.35	6.42e-9	Soluble interleukin-2 receptor subunit alpha;
CESC	cis	rs727505	1.000	rs720613	chr7:124452670	C/T	cg23710748	chr7:124431027	NA	-0.4	-6.42	-0.37	6.38e-10	Lewy body disease;
CESC	cis	rs7208859	0.673	rs1347359	chr17:28914529	T/C	cg04154034	chr17:28927549	LRRC37B2	0.66	5.83	0.34	1.63e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs7178572	0.568	rs11853460	chr15:77515319	C/T	cg22256960	chr15:77711686	NA	-0.53	-6.69	-0.38	1.33e-10	Type 2 diabetes;
CESC	cis	rs1801251	1.000	rs3816334	chr2:233708806	A/G	cg08000102	chr2:233561755	GIGYF2	-0.7	-10.07	-0.53	2.08e-20	Coronary artery disease;
CESC	cis	rs6088580	0.542	rs6059882	chr20:33090167	T/C	cg24642439	chr20:33292090	TP53INP2	0.5	6.55	0.37	2.92e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs11098499	0.604	rs2389886	chr4:120570422	C/T	cg09307838	chr4:120376055	NA	0.75	9.44	0.5	1.97e-18	Corneal astigmatism;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg09391093	chr10:38265555	ZNF25	0.51	6.86	0.39	4.97e-11	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs736408	0.562	rs12497998	chr3:52793602	C/T	cg05564831	chr3:52568323	NT5DC2	0.45	6.88	0.39	4.28e-11	Bipolar disorder;
CESC	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg24101359	chr6:42928495	GNMT	-0.6	-9.12	-0.49	1.92e-17	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs854765	0.547	rs2955384	chr17:17939573	C/T	cg26588076	chr17:17741631	SREBF1	-0.32	-5.09	-0.3	6.95e-7	Total body bone mineral density;
CESC	cis	rs6460942	0.915	rs62448602	chr7:12457145	T/G	cg20607287	chr7:12443886	VWDE	-0.78	-9.15	-0.49	1.61e-17	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18598152	chr14:24020957	NA	-0.57	-6.64	-0.38	1.81e-10	Gut microbiome composition (summer);
CESC	cis	rs4253772	0.591	rs6519993	chr22:46656479	A/G	cg24881330	chr22:46731750	TRMU	0.89	9.99	0.52	3.68e-20	LDL cholesterol;Cholesterol, total;
CESC	cis	rs1862618	0.853	rs252904	chr5:56118733	A/T	cg12311346	chr5:56204834	C5orf35	-0.73	-8.74	-0.47	2.69e-16	Initial pursuit acceleration;
CESC	cis	rs2932538	0.922	rs12138335	chr1:113122760	T/C	cg22162597	chr1:113214053	CAPZA1	0.6	7.33	0.41	2.75e-12	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CESC	cis	rs9303280	0.806	rs36038753	chr17:38035370	G/T	cg20243544	chr17:37824526	PNMT	0.5	6.54	0.37	3.21e-10	Self-reported allergy;
CESC	cis	rs4727027	0.899	rs7791496	chr7:148863674	C/G	cg23158103	chr7:148848205	ZNF398	-0.42	-6.88	-0.39	4.26e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs7084402	0.967	rs1649085	chr10:60292042	T/C	cg07615347	chr10:60278583	BICC1	0.6	9.41	0.5	2.54e-18	Refractive error;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg27514509	chr10:100167426	PYROXD2	0.44	6.27	0.36	1.43e-9	Fibrinogen levels;
CESC	cis	rs6460942	1.000	rs111761262	chr7:12415916	T/C	cg20607287	chr7:12443886	VWDE	-0.81	-9.28	-0.5	6.09e-18	Coronary artery disease;
CESC	cis	rs3096299	0.503	rs4785677	chr16:89555101	A/G	cg00750074	chr16:89608354	SPG7	-0.39	-5.49	-0.32	9.54e-8	Multiple myeloma (IgH translocation);
CESC	cis	rs7122539	0.839	rs6591223	chr11:66609289	C/T	cg24851651	chr11:66362959	CCS	0.38	5.24	0.31	3.36e-7	HIV-1 susceptibility;
CESC	cis	rs270601	0.739	rs1979981	chr5:131601720	G/A	cg18301423	chr5:131593218	PDLIM4	0.38	5.5	0.32	8.83e-8	Acylcarnitine levels;
CESC	trans	rs13098911	0.540	rs34442130	chr3:46024529	T/A	cg10236987	chr1:228114221	WNT9A	0.6	6.17	0.35	2.61e-9	Celiac disease;
CESC	cis	rs769267	0.929	rs34538000	chr19:19481379	G/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.59	-7.76	-0.43	1.81e-13	Tonsillectomy;
CESC	cis	rs4925386	0.921	rs11204472	chr20:60920887	G/A	cg15193198	chr20:60906057	LAMA5	0.28	5.1	0.3	6.37e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs9457247	1.000	rs239935	chr6:167411788	G/A	cg07741184	chr6:167504864	NA	0.3	5.46	0.32	1.11e-7	Crohn's disease;
CESC	cis	rs875971	0.545	rs75840613	chr7:65841386	G/A	cg25405998	chr7:65216604	CCT6P1	0.45	5.08	0.3	7.23e-7	Aortic root size;
CESC	cis	rs10504229	1.000	rs17216648	chr8:58169429	C/T	cg05313129	chr8:58192883	C8orf71	-0.56	-6.45	-0.37	5.22e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs9837602	0.507	rs793453	chr3:99529095	A/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.4	5.39	0.31	1.52e-7	Breast cancer;
CESC	cis	rs712039	0.617	rs60118041	chr17:35803252	G/A	cg16670864	chr17:35848621	DUSP14	0.41	5.13	0.3	5.52e-7	Tuberculosis;
CESC	cis	rs4665809	0.590	rs34728554	chr2:26481959	C/G	cg04944784	chr2:26401820	FAM59B	0.96	10.5	0.54	8.76e-22	Gut microbiome composition (summer);
CESC	cis	rs9399137	0.507	rs4896129	chr6:135349845	C/T	cg22676075	chr6:135203613	NA	0.53	7.15	0.4	8.67e-12	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	cis	rs2204008	0.715	rs11514282	chr12:38169056	G/T	cg13010199	chr12:38710504	ALG10B	0.55	6.84	0.39	5.39e-11	Bladder cancer;
CESC	cis	rs7772486	0.875	rs9403768	chr6:146406458	A/C	cg05347473	chr6:146136440	FBXO30	0.5	6.55	0.37	2.93e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9303401	1.000	rs1390006	chr17:56890663	C/T	cg12560992	chr17:57184187	TRIM37	-0.49	-5.53	-0.32	7.66e-8	Cognitive test performance;
CESC	cis	rs7666738	0.753	rs17483788	chr4:98985623	G/A	cg18180107	chr4:99064573	C4orf37	0.4	5.19	0.3	4.29e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs806215	1.000	rs806214	chr7:127237003	C/T	cg25922125	chr7:127225783	GCC1	-0.44	-5.22	-0.31	3.67e-7	Type 2 diabetes;
CESC	cis	rs7666738	0.830	rs10005120	chr4:99038200	A/G	cg18180107	chr4:99064573	C4orf37	0.41	5.29	0.31	2.55e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs798554	0.655	rs798492	chr7:2799184	C/T	cg13628971	chr7:2884303	GNA12	-0.39	-5.23	-0.31	3.43e-7	Height;
CESC	cis	rs9640161	0.830	rs7800196	chr7:150061534	C/G	cg17279839	chr7:150038598	RARRES2	0.4	5.46	0.32	1.11e-7	Blood protein levels;Circulating chemerin levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08450501	chr3:136580965	NCK1	0.6	6.3	0.36	1.22e-9	Gut microbiome composition (summer);
CESC	cis	rs801193	0.569	rs2659893	chr7:66199993	G/A	cg10691866	chr7:65817282	TPST1	-0.32	-5.44	-0.32	1.19e-7	Aortic root size;
CESC	cis	rs7917772	0.503	rs10748825	chr10:104293609	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.54	7.41	0.41	1.67e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs11718455	0.767	rs9861276	chr3:43989595	C/T	cg08738300	chr3:44038990	NA	0.43	5.66	0.33	3.93e-8	Coronary artery disease;
CESC	cis	rs10883723	0.810	rs7090276	chr10:104281239	G/T	ch.10.2196322F	chr10:104248062	ACTR1A	0.42	5.18	0.3	4.34e-7	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs1109430	0.661	rs4844509	chr1:210338874	G/T	cg02304930	chr1:210405566	SERTAD4;C1orf133	-0.87	-7.22	-0.41	5.57e-12	Orofacial clefts;
CESC	cis	rs68170813	0.559	rs12540475	chr7:106886295	C/T	cg02696742	chr7:106810147	HBP1	-0.52	-5.08	-0.3	7.2e-7	Coronary artery disease;
CESC	cis	rs7811142	1.000	rs7783159	chr7:100017454	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.73	6.82	0.39	6.2e-11	Platelet count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18108695	chr21:46962546	SLC19A1	0.54	6.16	0.35	2.75e-9	Gut microbiome composition (summer);
CESC	cis	rs9611565	0.921	rs6002333	chr22:41719469	C/T	cg06481639	chr22:41940642	POLR3H	-0.65	-6.95	-0.39	2.87e-11	Vitiligo;
CESC	cis	rs992157	0.764	rs10932774	chr2:219191569	A/G	cg20019365	chr2:219134978	PNKD;AAMP	0.58	7.59	0.42	5.57e-13	Colorectal cancer;
CESC	cis	rs11997175	0.595	rs6468204	chr8:33774748	T/C	ch.8.33884649F	chr8:33765107	NA	0.51	5.75	0.33	2.5e-8	Body mass index;
CESC	cis	rs6461049	0.765	rs1476887	chr7:2151633	T/C	cg08027265	chr7:2291960	NA	-0.43	-6.45	-0.37	5.18e-10	Schizophrenia;
CESC	cis	rs72781680	0.950	rs72798404	chr2:24180125	C/T	cg20701182	chr2:24300061	SF3B14	0.78	6.82	0.39	5.98e-11	Lymphocyte counts;
CESC	cis	rs1008375	0.966	rs3796813	chr4:17591648	A/G	cg27347728	chr4:17578864	LAP3	0.42	5.11	0.3	6.07e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs1153858	1.000	rs16942568	chr15:45677390	T/C	cg21132104	chr15:45694354	SPATA5L1	0.86	11.62	0.58	1.67e-25	Homoarginine levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10822008	chr15:90437384	AP3S2	0.53	6.37	0.36	8.2e-10	Gut microbiome composition (summer);
CESC	cis	rs7552404	0.731	rs11161845	chr1:76367559	T/C	cg10523679	chr1:76189770	ACADM	0.63	6.08	0.35	4.14e-9	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs9435341	0.965	rs1762485	chr1:107625056	C/T	cg02990361	chr1:107599529	PRMT6	-0.45	-5.15	-0.3	5.08e-7	Facial morphology (factor 21, depth of nasal alae);
CESC	cis	rs17376456	0.877	rs10059230	chr5:93450347	A/G	cg25358565	chr5:93447407	FAM172A	1.15	11.8	0.59	4.11e-26	Diabetic retinopathy;
CESC	cis	rs896854	0.608	rs7004862	chr8:95876963	T/G	cg13393036	chr8:95962371	TP53INP1	-0.44	-9.23	-0.49	8.8e-18	Type 2 diabetes;
CESC	cis	rs2070488	0.965	rs7640050	chr3:38525864	A/C	cg24069376	chr3:38537580	EXOG	0.5	9.07	0.49	2.76e-17	Electrocardiographic conduction measures;
CESC	cis	rs6502050	0.871	rs6502055	chr17:80070868	G/T	cg23985595	chr17:80112537	CCDC57	0.43	6.68	0.38	1.44e-10	Life satisfaction;
CESC	cis	rs12541635	0.932	rs1835267	chr8:107044435	C/T	cg10147462	chr8:107024639	NA	0.42	5.97	0.34	7.44e-9	Age of smoking initiation;
CESC	cis	rs11792861	0.890	rs3750465	chr9:111900677	T/C	cg05043794	chr9:111880884	C9orf5	-0.42	-6.94	-0.39	3.04e-11	Menarche (age at onset);
CESC	cis	rs7605827	0.893	rs6733695	chr2:15525714	T/C	cg19274914	chr2:15703543	NA	0.35	6.27	0.36	1.43e-9	Educational attainment (years of education);
CESC	cis	rs4727027	0.866	rs2373438	chr7:148780287	C/A	cg23158103	chr7:148848205	ZNF398	-0.4	-6.49	-0.37	4.19e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs11696501	0.739	rs4812938	chr20:44249919	T/A	cg11783356	chr20:44313418	WFDC10B	-0.35	-5.46	-0.32	1.1e-7	Brain structure;
CESC	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg07677032	chr17:61819896	STRADA	-0.44	-5.62	-0.33	4.91e-8	Prudent dietary pattern;
CESC	cis	rs2243480	1.000	rs1723267	chr7:65473314	G/A	cg18252515	chr7:66147081	NA	-1.19	-11.57	-0.58	2.56e-25	Diabetic kidney disease;
CESC	cis	rs2652834	0.851	rs4238372	chr15:63351488	G/A	cg05507819	chr15:63340323	TPM1	0.62	6.08	0.35	4.22e-9	HDL cholesterol;
CESC	cis	rs7927592	0.956	rs10896348	chr11:68357368	T/C	cg20283391	chr11:68216788	NA	-0.48	-6.08	-0.35	4.28e-9	Total body bone mineral density;
CESC	cis	rs1552244	1.000	rs6414438	chr3:10073824	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.86	11.65	0.58	1.32e-25	Alzheimer's disease;
CESC	cis	rs2274273	0.588	rs7154831	chr14:55823965	A/C	cg04306507	chr14:55594613	LGALS3	0.3	5.26	0.31	2.92e-7	Protein biomarker;
CESC	cis	rs10504229	0.906	rs113857287	chr8:58191683	T/C	cg05313129	chr8:58192883	C8orf71	-0.56	-6.38	-0.37	7.65e-10	Developmental language disorder (linguistic errors);
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg26216002	chr1:10093067	UBE4B	-0.44	-6.0	-0.35	6.54e-9	Asthma;
CESC	trans	rs9467711	0.606	rs9366656	chr6:26434630	T/C	cg06606381	chr12:133084897	FBRSL1	-0.82	-6.98	-0.39	2.4e-11	Autism spectrum disorder or schizophrenia;
CESC	cis	rs2243480	1.000	rs10247526	chr7:65780696	T/G	cg12463550	chr7:65579703	CRCP	-0.74	-5.73	-0.33	2.74e-8	Diabetic kidney disease;
CESC	cis	rs1461503	0.966	rs10790545	chr11:122838350	G/C	cg27398637	chr11:122830231	C11orf63	-0.56	-8.42	-0.46	2.35e-15	Menarche (age at onset);
CESC	cis	rs9399135	0.967	rs9389256	chr6:135331254	A/C	cg24558204	chr6:135376177	HBS1L	0.52	7.18	0.4	7.04e-12	Red blood cell count;
CESC	trans	rs78049276	0.562	rs55965782	chr4:148378442	T/C	cg13149281	chr14:23389818	RBM23;PRMT5	-0.7	-8.43	-0.46	2.19e-15	Pulse pressure;
CESC	cis	rs9560113	0.573	rs9560133	chr13:112240013	C/A	cg10483660	chr13:112241077	NA	0.41	7.02	0.4	1.86e-11	Menarche (age at onset);
CESC	cis	rs7666738	0.830	rs921522	chr4:98841608	C/T	cg17366294	chr4:99064904	C4orf37	0.54	7.53	0.42	8.11e-13	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4704187	0.663	rs9654428	chr5:74466884	A/C	cg03227963	chr5:74354835	NA	0.28	5.21	0.3	3.77e-7	Response to amphetamines;
CESC	cis	rs1670533	1.000	rs6857085	chr4:1095920	C/A	cg27284194	chr4:1044797	NA	-0.47	-5.98	-0.34	7.28e-9	Recombination rate (females);
CESC	cis	rs2898681	0.521	rs6833350	chr4:53740868	A/G	cg00791764	chr4:53727839	RASL11B	0.54	5.37	0.31	1.7e-7	Optic nerve measurement (cup area);
CESC	cis	rs698833	0.892	rs698797	chr2:44689905	G/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.48	6.12	0.35	3.42e-9	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs1448094	0.511	rs7968059	chr12:86163606	A/G	cg02569458	chr12:86230093	RASSF9	0.49	7.62	0.42	4.61e-13	Major depressive disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07845895	chr21:34776100	IFNGR2	-0.62	-6.93	-0.39	3.22e-11	Gut microbiome composition (summer);
CESC	cis	rs459571	0.959	rs460888	chr9:136913123	C/G	cg13789015	chr9:136890014	NCRNA00094	0.57	8.16	0.45	1.4e-14	Platelet distribution width;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02148352	chr8:30209571	NA	-0.57	-6.55	-0.37	2.91e-10	Gut microbiome composition (summer);
CESC	cis	rs892961	0.932	rs9916143	chr17:75409282	C/G	cg05865280	chr17:75406074	SEPT9	-0.67	-14.22	-0.66	1.75e-34	Airflow obstruction;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg02386725	chr1:162467755	UHMK1	-0.45	-6.09	-0.35	3.92e-9	Ulcerative colitis;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg10690677	chr1:87019175	CLCA4	0.5	6.78	0.38	7.62e-11	Fibrinogen levels;
CESC	cis	rs7618915	0.547	rs11130314	chr3:52697082	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	7.04	0.4	1.62e-11	Bipolar disorder;
CESC	cis	rs977987	0.778	rs7206541	chr16:75436713	A/T	cg03315344	chr16:75512273	CHST6	0.41	5.85	0.34	1.43e-8	Dupuytren's disease;
CESC	cis	rs9682041	0.800	rs7643085	chr3:170070371	A/G	cg11886554	chr3:170076028	SKIL	0.82	6.83	0.39	5.75e-11	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CESC	cis	rs947211	0.948	rs1775143	chr1:205755550	C/T	cg14159672	chr1:205819179	PM20D1	0.41	5.3	0.31	2.45e-7	Parkinson's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27326226	chr13:20767778	GJB2	-0.54	-6.29	-0.36	1.29e-9	Gut microbiome composition (summer);
CESC	cis	rs4555082	0.874	rs2816613	chr14:105726367	C/T	cg13114125	chr14:105738426	BRF1	-0.85	-10.46	-0.54	1.18e-21	Mean platelet volume;Platelet distribution width;
CESC	cis	rs1465370	0.682	rs62471720	chr7:130016359	C/G	cg04743876	chr7:130013617	NA	0.31	5.84	0.34	1.5e-8	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
CESC	cis	rs4595586	0.545	rs7307303	chr12:39368976	A/G	cg26384229	chr12:38710491	ALG10B	0.54	7.53	0.42	7.85e-13	Morning vs. evening chronotype;
CESC	cis	rs12893668	0.703	rs55751606	chr14:104028806	G/A	cg24130564	chr14:104152367	KLC1	-0.47	-5.8	-0.34	1.87e-8	Reticulocyte count;
CESC	cis	rs6893300	0.785	rs6895902	chr5:179201847	C/T	cg14593053	chr5:179126677	CANX	-0.46	-5.26	-0.31	3.02e-7	Resting heart rate;
CESC	cis	rs10479542	0.583	rs4131080	chr5:179044292	G/A	cg09060608	chr5:178986726	RUFY1	0.49	7.0	0.39	2.12e-11	Lung cancer;
CESC	cis	rs6088580	0.634	rs6120644	chr20:33023810	G/A	cg06115741	chr20:33292138	TP53INP2	0.48	6.14	0.35	3e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs7608623	0.679	rs7561273	chr2:24247514	C/T	cg20701182	chr2:24300061	SF3B14	0.38	5.22	0.31	3.55e-7	Obesity-related traits;
CESC	cis	rs7937682	0.824	rs539524	chr11:111477325	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.95	-14.88	-0.67	8.31e-37	Primary sclerosing cholangitis;
CESC	cis	rs290268	0.838	rs290987	chr9:93563267	T/A	cg02608019	chr9:93564028	SYK	0.63	9.64	0.51	4.92e-19	Platelet count;
CESC	cis	rs6430585	1.000	rs6430585	chr2:136506927	A/C	cg07169764	chr2:136633963	MCM6	-0.96	-13.1	-0.63	1.42e-30	Corneal structure;
CESC	cis	rs1568889	0.877	rs57202579	chr11:28221677	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.77	10.37	0.54	2.26e-21	Bipolar disorder;
CESC	cis	rs2243480	0.615	rs34363376	chr7:65939536	T/C	cg12463550	chr7:65579703	CRCP	0.68	5.2	0.3	3.9e-7	Diabetic kidney disease;
CESC	cis	rs258892	0.895	rs11960081	chr5:72064490	C/G	cg21869765	chr5:72125136	TNPO1	-0.43	-5.35	-0.31	1.93e-7	Small cell lung carcinoma;
CESC	cis	rs3820928	0.874	rs1949807	chr2:227891861	A/G	cg05526886	chr2:227700861	RHBDD1	-0.45	-5.79	-0.34	1.96e-8	Pulmonary function;
CESC	trans	rs61931739	0.500	rs11519123	chr12:34436478	A/G	cg26384229	chr12:38710491	ALG10B	0.54	7.46	0.42	1.25e-12	Morning vs. evening chronotype;
CESC	cis	rs34172651	0.517	rs189919	chr16:24737741	G/A	cg02428538	chr16:24856791	SLC5A11	0.6	6.1	0.35	3.72e-9	Intelligence (multi-trait analysis);
CESC	trans	rs61931739	0.500	rs11615231	chr12:34413330	T/C	cg26384229	chr12:38710491	ALG10B	0.69	10.44	0.54	1.39e-21	Morning vs. evening chronotype;
CESC	trans	rs79976124	0.879	rs12214948	chr6:66633603	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.73	8.2	0.45	1.02e-14	Type 2 diabetes;
CESC	cis	rs11249608	0.590	rs36051170	chr5:178447971	T/C	cg21905437	chr5:178450457	ZNF879	0.6	8.59	0.47	7.5e-16	Pubertal anthropometrics;
CESC	cis	rs801193	0.569	rs2659908	chr7:66160822	G/A	cg10691866	chr7:65817282	TPST1	-0.32	-5.44	-0.32	1.19e-7	Aortic root size;
CESC	cis	rs6942756	0.806	rs9641846	chr7:128873679	G/A	cg02491457	chr7:128862824	NA	0.64	9.54	0.51	1.02e-18	White matter hyperintensity burden;
CESC	cis	rs9911578	0.967	rs6503893	chr17:57149695	G/A	cg05425664	chr17:57184151	TRIM37	-0.54	-7.38	-0.41	2.07e-12	Intelligence (multi-trait analysis);
CESC	cis	rs7267979	1.000	rs2424710	chr20:25283886	C/G	cg08601574	chr20:25228251	PYGB	0.37	5.2	0.3	3.93e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs2710642	0.821	rs56373728	chr2:63095792	G/A	cg17519650	chr2:63277830	OTX1	0.57	7.26	0.41	4.23e-12	LDL cholesterol levels;LDL cholesterol;
CESC	cis	rs11190604	1.000	rs3750630	chr10:102275780	A/G	cg07080220	chr10:102295463	HIF1AN	0.63	6.11	0.35	3.57e-9	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs1008375	0.966	rs6832414	chr4:17696866	C/G	cg04450456	chr4:17643702	FAM184B	0.36	5.15	0.3	5.16e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs2228479	0.850	rs62054609	chr16:89816569	C/A	cg04013166	chr16:89971882	TCF25	0.77	6.66	0.38	1.58e-10	Skin colour saturation;
CESC	cis	rs7666738	0.830	rs4619898	chr4:98959646	G/A	cg18180107	chr4:99064573	C4orf37	0.4	5.14	0.3	5.33e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs72848980	0.706	rs11191732	chr10:105331761	G/A	cg00126946	chr10:105363258	SH3PXD2A	0.5	6.69	0.38	1.3100000000000001e-10	White matter hyperintensity burden;
CESC	cis	rs9649213	0.593	rs7807455	chr7:97957622	C/A	cg21770322	chr7:97807741	LMTK2	0.56	8.61	0.47	6.55e-16	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs73206853	0.563	rs7960761	chr12:111164415	T/C	cg04375036	chr12:111181819	PPP1CC	-0.64	-5.09	-0.3	6.87e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs7618915	0.501	rs3755798	chr3:52741160	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.61	8.72	0.47	3.13e-16	Bipolar disorder;
CESC	cis	rs1003719	0.680	rs2257091	chr21:38522618	G/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.59	-8.0	-0.44	4.01e-14	Eye color traits;
CESC	cis	rs6812193	0.518	rs6822055	chr4:77196188	C/T	cg20311846	chr4:77356250	SHROOM3	-0.28	-5.23	-0.31	3.53e-7	Parkinson's disease;
CESC	cis	rs9399135	0.636	rs7749106	chr6:135268142	G/A	cg12549451	chr6:135224345	NA	0.37	5.5	0.32	8.9e-8	Red blood cell count;
CESC	cis	rs1728785	1.000	rs6499181	chr16:68593002	A/T	cg02972257	chr16:68554789	NA	-0.59	-6.7	-0.38	1.23e-10	Ulcerative colitis;
CESC	cis	rs1707322	0.685	rs28617418	chr1:46189526	T/A	cg05343316	chr1:45956843	TESK2	0.51	6.2	0.36	2.19e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2075371	1.000	rs2505	chr7:133979552	C/T	cg00033643	chr7:134001901	SLC35B4	0.42	5.38	0.31	1.61e-7	Mean platelet volume;
CESC	cis	rs11190604	1.000	rs10883513	chr10:102316964	A/G	cg07080220	chr10:102295463	HIF1AN	0.66	6.07	0.35	4.51e-9	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs559928	0.692	rs12146487	chr11:64026639	G/A	cg18225595	chr11:63971243	STIP1	0.61	5.2	0.3	4.04e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CESC	trans	rs629535	0.547	rs72654095	chr8:70120770	A/G	cg21567404	chr3:27674614	NA	-0.84	-9.29	-0.5	5.78e-18	Dupuytren's disease;
CESC	cis	rs875971	1.000	rs7789768	chr7:65938980	A/C	cg12463550	chr7:65579703	CRCP	0.56	7.09	0.4	1.2e-11	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16586002	chr3:196594898	SENP5	0.53	6.01	0.35	6.03e-9	Gut microbiome composition (summer);
CESC	cis	rs919433	0.889	rs6711624	chr2:198207607	C/G	cg10820045	chr2:198174542	NA	-0.4	-5.8	-0.34	1.84e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs72781680	0.898	rs56179550	chr2:23934867	C/T	cg08917208	chr2:24149416	ATAD2B	1.1	10.15	0.53	1.18e-20	Lymphocyte counts;
CESC	cis	rs4862750	0.914	rs9998558	chr4:187874691	A/G	cg10295955	chr4:187884368	NA	-0.98	-17.53	-0.73	3.27e-46	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs113835537	0.529	rs17065	chr11:66277035	G/A	cg22134325	chr11:66188745	NPAS4	0.45	7.09	0.4	1.2e-11	Airway imaging phenotypes;
CESC	cis	rs6502050	0.835	rs7502548	chr17:80087569	T/C	cg23985595	chr17:80112537	CCDC57	0.42	6.55	0.37	2.99e-10	Life satisfaction;
CESC	cis	rs60871478	1.000	rs62432860	chr7:807522	G/C	cg27478167	chr7:817139	HEATR2	-0.47	-5.61	-0.33	5.18e-8	Cerebrospinal P-tau181p levels;
CESC	cis	rs2929278	0.617	rs575082	chr15:44110142	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.52	-6.84	-0.39	5.34e-11	Schizophrenia;
CESC	cis	rs1830074	1	rs1830074	chr7:6718674	T/C	cg09896999	chr7:6746977	ZNF12	-0.31	-5.04	-0.3	8.69e-7	Body mass index;
CESC	cis	rs10242455	0.702	rs78640327	chr7:99167139	G/C	cg18809830	chr7:99032528	PTCD1	-0.88	-5.81	-0.34	1.79e-8	Blood metabolite levels;
CESC	cis	rs10504229	0.906	rs7003285	chr8:58173108	A/G	cg05313129	chr8:58192883	C8orf71	-0.55	-6.37	-0.36	8.42e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs2235642	0.701	rs2281230	chr16:1601767	T/C	cg03771183	chr16:1608904	IFT140	0.38	5.39	0.31	1.53e-7	Coronary artery disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg00907473	chr1:90459283	ZNF326;LOC492303	0.51	6.56	0.37	2.76e-10	Fibrinogen levels;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg14862950	chr11:66112661	BRMS1	-0.44	-6.41	-0.37	6.58e-10	Gambling;
CESC	cis	rs4819052	0.851	rs9754134	chr21:46661751	T/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.46	5.79	0.34	2e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs138880	0.542	rs9616371	chr22:50306338	G/A	cg02269571	chr22:50332266	NA	-0.67	-6.59	-0.38	2.36e-10	Schizophrenia;
CESC	cis	rs425277	0.500	rs908744	chr1:2038893	G/A	cg04315214	chr1:2043799	PRKCZ	0.53	9.3	0.5	5.59e-18	Height;
CESC	cis	rs9926296	0.585	rs8058009	chr16:89856439	G/A	cg27121462	chr16:89883253	FANCA	0.53	6.51	0.37	3.79e-10	Vitiligo;
CESC	cis	rs780096	0.506	rs1647285	chr2:27714511	A/C	cg12648201	chr2:27665141	KRTCAP3	-0.35	-6.56	-0.37	2.85e-10	Total body bone mineral density;
CESC	cis	rs35306767	0.953	rs34405399	chr10:981015	G/A	cg26597838	chr10:835615	NA	0.71	8.13	0.45	1.61e-14	Eosinophil percentage of granulocytes;
CESC	cis	rs6540559	0.543	rs650728	chr1:210433351	C/T	cg23283495	chr1:209979779	IRF6	0.44	5.41	0.32	1.43e-7	Cleft lip with or without cleft palate;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg15005908	chr6:114292723	HDAC2	-0.45	-6.15	-0.35	2.78e-9	Fibrinogen levels;
CESC	cis	rs875971	0.862	rs10276077	chr7:65728411	A/G	cg12463550	chr7:65579703	CRCP	-0.46	-5.9	-0.34	1.11e-8	Aortic root size;
CESC	cis	rs9916302	0.851	rs677888	chr17:37461018	T/G	cg15445000	chr17:37608096	MED1	-0.39	-5.94	-0.34	9.14e-9	Glomerular filtration rate (creatinine);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24339935	chr9:100174143	TDRD7	0.61	7.44	0.42	1.44e-12	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02724903	chr13:114260339	TFDP1	-0.59	-6.81	-0.39	6.68e-11	Gut microbiome composition (summer);
CESC	cis	rs8020095	0.571	rs8010261	chr14:67608117	C/T	cg19548862	chr14:67692701	FAM71D	-0.47	-5.74	-0.33	2.53e-8	Depression (quantitative trait);
CESC	cis	rs62408225	1.000	rs1847472	chr6:90973159	A/C	cg06866423	chr6:90926672	BACH2	-0.46	-5.38	-0.31	1.61e-7	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs965469	0.779	rs2236121	chr20:3304320	A/G	cg17110299	chr20:3385021	C20orf194	0.39	5.12	0.3	5.91e-7	IFN-related cytopenia;
CESC	cis	rs858239	0.539	rs2178139	chr7:23191636	A/G	cg23682824	chr7:23144976	KLHL7	0.51	6.77	0.38	8.05e-11	Cerebrospinal fluid biomarker levels;
CESC	cis	rs12477438	0.765	rs12612688	chr2:99613091	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.61	-8.52	-0.46	1.23e-15	Chronic sinus infection;
CESC	cis	rs7819412	0.775	rs4545055	chr8:10935366	T/C	cg21775007	chr8:11205619	TDH	-0.37	-5.06	-0.3	7.87e-7	Triglycerides;
CESC	cis	rs2645694	0.626	rs2703124	chr4:77820626	G/T	cg18351406	chr4:77819688	ANKRD56	0.55	6.88	0.39	4.42e-11	Emphysema distribution in smoking;
CESC	cis	rs2108622	0.727	rs9305069	chr19:15983386	A/G	cg13772218	chr19:15982569	NA	0.31	6.04	0.35	5.12e-9	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CESC	cis	rs4665809	0.567	rs6711402	chr2:26430983	A/G	cg22920501	chr2:26401640	FAM59B	-0.84	-9.34	-0.5	4.02e-18	Gut microbiome composition (summer);
CESC	cis	rs763121	0.853	rs5757203	chr22:39044152	G/C	cg14440974	chr22:39074834	NA	-0.4	-5.48	-0.32	9.77e-8	Menopause (age at onset);
CESC	cis	rs2046867	0.862	rs11922180	chr3:72836119	A/G	cg25664220	chr3:72788482	NA	0.45	6.53	0.37	3.36e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CESC	cis	rs12497850	1.000	rs10865952	chr3:48744484	A/G	cg02487422	chr3:49467188	NICN1	0.4	5.13	0.3	5.69e-7	Parkinson's disease;
CESC	cis	rs1729951	0.575	rs1654923	chr3:136692620	A/T	cg25687071	chr3:136751404	NA	0.39	5.19	0.3	4.27e-7	Neuroticism;
CESC	cis	rs11098499	0.697	rs28458294	chr4:120238924	T/C	cg09307838	chr4:120376055	NA	0.78	10.39	0.54	1.94e-21	Corneal astigmatism;
CESC	cis	rs7618915	0.501	rs3733041	chr3:52731598	T/C	cg17372223	chr3:52568218	NT5DC2	0.43	6.58	0.37	2.51e-10	Bipolar disorder;
CESC	cis	rs826838	1.000	rs826838	chr12:39106731	C/T	cg26384229	chr12:38710491	ALG10B	-0.62	-9.94	-0.52	5.55e-20	Heart rate;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg20697630	chr1:20960374	PINK1	-0.45	-6.13	-0.35	3.26e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs1003719	0.646	rs2835671	chr21:38581125	T/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.6	-8.07	-0.44	2.45e-14	Eye color traits;
CESC	cis	rs950169	0.845	rs4502182	chr15:84923520	A/G	cg17507749	chr15:85114479	UBE2QP1	0.57	6.33	0.36	1.04e-9	Schizophrenia;
CESC	cis	rs10129255	0.556	rs8010005	chr14:107186226	A/G	cg07958169	chr14:107095056	NA	-0.54	-8.51	-0.46	1.3e-15	Kawasaki disease;
CESC	cis	rs7267979	1.000	rs2257432	chr20:25271086	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	18.62	0.75	4.72e-50	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs9790314	1.000	rs4597724	chr3:160963110	A/G	cg04691961	chr3:161091175	C3orf57	-0.42	-5.44	-0.32	1.2e-7	Morning vs. evening chronotype;
CESC	cis	rs7659604	1.000	rs6814995	chr4:122664963	A/T	cg19748678	chr4:122722346	EXOSC9	-0.45	-5.38	-0.31	1.65e-7	Type 2 diabetes;
CESC	cis	rs9658691	0.607	rs34891735	chr10:90779212	A/T	cg03111039	chr10:90751583	FAS;ACTA2	-0.61	-5.33	-0.31	2.13e-7	Mosquito bite size;
CESC	cis	rs1552244	1.000	rs6442146	chr3:10073544	C/T	cg08888203	chr3:10149979	C3orf24	0.46	5.99	0.35	6.66e-9	Alzheimer's disease;
CESC	cis	rs10504229	1.000	rs60231757	chr8:58169937	T/C	cg24829409	chr8:58192753	C8orf71	-0.76	-10.0	-0.52	3.53e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs8114671	0.562	rs6120758	chr20:33492523	C/T	cg07148914	chr20:33460835	GGT7	0.46	6.13	0.35	3.19e-9	Height;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg15598609	chr8:102239510	NA	0.42	6.05	0.35	5.01e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs13108904	0.967	rs13109112	chr4:1290481	C/A	cg00684032	chr4:1343700	KIAA1530	0.4	5.51	0.32	8.35e-8	Obesity-related traits;
CESC	cis	rs3741151	0.656	rs12290785	chr11:73259012	G/T	cg17517138	chr11:73019481	ARHGEF17	0.86	6.82	0.39	6.26e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs10276381	1.000	rs7796417	chr7:28186119	G/C	cg23620719	chr7:28220237	JAZF1	0.74	7.96	0.44	5.1e-14	Crohn's disease;
CESC	cis	rs637571	0.522	rs1786175	chr11:65754808	G/A	cg02202077	chr11:65769826	EIF1AD;BANF1	0.45	5.99	0.35	6.68e-9	Eosinophil percentage of white cells;
CESC	trans	rs2963826	0.589	rs298091	chr5:58996603	A/T	cg01078248	chr7:123197661	NDUFA5	0.49	6.4	0.37	6.89e-10	Obesity-related traits;
CESC	cis	rs10461617	0.512	rs7715746	chr5:56048837	C/T	cg22800045	chr5:56110881	MAP3K1	0.6	7.55	0.42	6.87e-13	Type 2 diabetes;
CESC	cis	rs734999	0.566	rs10797435	chr1:2534801	G/C	cg18854424	chr1:2615690	NA	0.27	5.24	0.31	3.32e-7	Ulcerative colitis;
CESC	cis	rs9911578	0.967	rs686425	chr17:56776730	A/G	cg05425664	chr17:57184151	TRIM37	-0.5	-6.97	-0.39	2.5e-11	Intelligence (multi-trait analysis);
CESC	cis	rs7949030	0.653	rs2516634	chr11:62367186	G/A	cg22862634	chr11:62369728	EML3;MTA2	-0.53	-7.37	-0.41	2.15e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs4964805	0.657	rs11111781	chr12:104187440	C/T	cg02344784	chr12:104178138	NT5DC3	0.47	6.73	0.38	1.04e-10	Attention deficit hyperactivity disorder;
CESC	cis	rs35110281	0.667	rs4819287	chr21:45120147	A/G	cg01579765	chr21:45077557	HSF2BP	-0.52	-8.54	-0.46	1.05e-15	Mean corpuscular volume;
CESC	cis	rs736408	0.509	rs1108842	chr3:52720080	A/C	cg25934064	chr3:52569026	NT5DC2	0.26	5.53	0.32	7.53e-8	Bipolar disorder;
CESC	cis	rs17826219	0.706	rs28469200	chr17:29133572	T/A	cg13385521	chr17:29058706	SUZ12P	0.77	6.37	0.36	8.45e-10	Body mass index;
CESC	cis	rs262147	0.610	rs2657363	chr7:158684273	C/T	cg02254261	chr7:158964346	NA	-0.69	-5.62	-0.33	4.82e-8	Hippocampal volume;
CESC	trans	rs9467711	0.659	rs3734542	chr6:26468326	G/A	cg01620082	chr3:125678407	NA	-0.76	-6.33	-0.36	1.05e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs17253792	0.822	rs13379353	chr14:56050478	G/C	cg01858014	chr14:56050164	KTN1	-0.92	-7.38	-0.41	2.06e-12	Putamen volume;
CESC	cis	rs4819052	1.000	rs13047688	chr21:46669290	G/A	cg11663144	chr21:46675770	NA	-0.51	-7.1	-0.4	1.15e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs2576037	0.523	rs590923	chr18:44404259	G/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.51	-6.96	-0.39	2.67e-11	Personality dimensions;
CESC	cis	rs2235642	0.787	rs2235646	chr16:1601287	A/G	cg07639376	chr16:1584516	IFT140;TMEM204	-0.32	-5.11	-0.3	6.21e-7	Coronary artery disease;
CESC	trans	rs10435719	0.867	rs6999030	chr8:11795308	G/A	cg15556689	chr8:8085844	FLJ10661	0.49	6.09	0.35	3.95e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
CESC	trans	rs916888	0.779	rs430685	chr17:44859148	T/C	cg27125505	chr17:43679177	LOC644172	-0.48	-6.69	-0.38	1.34e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs909674	0.865	rs5757683	chr22:39850174	G/A	cg01416388	chr22:39784598	NA	-0.58	-6.97	-0.39	2.56e-11	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs2760061	0.598	rs590657	chr1:228117581	A/C	cg01973587	chr1:228161476	NA	0.35	5.31	0.31	2.32e-7	Diastolic blood pressure;
CESC	trans	rs13160161	0.507	rs13182733	chr5:39049988	C/G	cg09550024	chr10:96698366	CYP2C9	-0.47	-6.15	-0.35	2.89e-9	Obesity-related traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15722731	chr6:122720674	HSF2	0.66	8.46	0.46	1.83e-15	Gut microbiome composition (summer);
CESC	cis	rs8031584	0.678	rs798127	chr15:31117403	T/C	cg08109568	chr15:31115862	NA	0.73	10.06	0.53	2.26e-20	Huntington's disease progression;
CESC	cis	rs2243480	1.000	rs313802	chr7:65516373	A/G	cg12463550	chr7:65579703	CRCP	0.67	5.38	0.31	1.67e-7	Diabetic kidney disease;
CESC	cis	rs10911232	0.524	rs10911209	chr1:183013988	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.87	13.67	0.64	1.52e-32	Hypertriglyceridemia;
CESC	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.63	7.27	0.41	4.09e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs875971	0.862	rs778736	chr7:65813848	C/T	cg19163074	chr7:65112434	INTS4L2	-0.41	-5.18	-0.3	4.32e-7	Aortic root size;
CESC	cis	rs6831352	0.838	rs2851250	chr4:100044113	G/C	cg13256891	chr4:100009986	ADH5	0.74	8.21	0.45	9.57e-15	Alcohol dependence;
CESC	cis	rs7267979	1.000	rs2482928	chr20:25331530	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.85	-16.43	-0.71	2.69e-42	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs4835473	0.864	rs57137521	chr4:144625198	T/A	cg25736465	chr4:144833511	NA	-0.37	-5.54	-0.32	7.12e-8	Immature fraction of reticulocytes;
CESC	trans	rs1814175	0.817	rs7929173	chr11:49944007	T/C	cg15704280	chr7:45808275	SEPT13	-1.03	-21.21	-0.79	4.77e-59	Height;
CESC	cis	rs2303745	0.589	rs11882562	chr19:17395055	C/G	cg04248312	chr19:17393744	ANKLE1	0.93	14.99	0.68	3.44e-37	Systemic lupus erythematosus;
CESC	trans	rs57221529	0.766	rs72703064	chr5:587825	T/C	cg25482853	chr8:67687455	SGK3	1.01	9.99	0.52	3.67e-20	Lung disease severity in cystic fibrosis;
CESC	cis	rs1050631	1.000	rs1107840	chr18:33707164	A/C	cg25426722	chr18:33708991	SLC39A6;ELP2	0.45	5.83	0.34	1.6e-8	Esophageal squamous cell cancer (length of survival);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23895234	chr1:26561325	CCDC21	0.58	6.34	0.36	9.86e-10	Gut microbiome composition (summer);
CESC	cis	rs644799	0.509	rs561635	chr11:95634232	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	-0.46	-6.04	-0.35	5.32e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs897984	0.542	rs11865038	chr16:31095171	C/T	cg00531865	chr16:30841666	NA	-0.39	-5.42	-0.32	1.33e-7	Dementia with Lewy bodies;
CESC	cis	rs6598955	0.670	rs11247892	chr1:26592727	A/G	cg04990556	chr1:26633338	UBXN11	-0.73	-10.29	-0.53	4.21e-21	Obesity-related traits;
CESC	cis	rs9910055	0.571	rs28897216	chr17:42240824	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.67	8.91	0.48	8.58e-17	Total body bone mineral density;
CESC	cis	rs1552244	0.751	rs12715665	chr3:10021601	C/T	cg00166722	chr3:10149974	C3orf24	0.51	6.26	0.36	1.58e-9	Alzheimer's disease;
CESC	cis	rs6582630	0.576	rs4882375	chr12:38371939	G/T	cg26384229	chr12:38710491	ALG10B	-0.43	-5.59	-0.32	5.6e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs654950	0.841	rs2759247	chr1:41991756	G/C	cg06885757	chr1:42089581	HIVEP3	-0.44	-6.75	-0.38	9.38e-11	Airway imaging phenotypes;
CESC	cis	rs2070433	0.851	rs8129793	chr21:47925719	T/C	cg12379764	chr21:47803548	PCNT	0.49	5.97	0.34	7.67e-9	Lymphocyte counts;
CESC	cis	rs17345786	0.906	rs12638137	chr3:101150964	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.5	-5.55	-0.32	7.07e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9311474	0.597	rs6778735	chr3:52565100	T/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.39	7.43	0.42	1.45e-12	Electroencephalogram traits;
CESC	cis	rs2637266	0.739	rs2579768	chr10:78415481	A/G	cg18941641	chr10:78392320	NA	0.4	7.34	0.41	2.6e-12	Pulmonary function;
CESC	cis	rs1552244	0.882	rs13084194	chr3:10031492	T/A	cg00166722	chr3:10149974	C3orf24	0.51	6.06	0.35	4.6e-9	Alzheimer's disease;
CESC	cis	rs7666738	0.830	rs11932887	chr4:99072965	C/G	cg18180107	chr4:99064573	C4orf37	0.42	5.23	0.31	3.45e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7618501	0.633	rs9853222	chr3:50022926	T/C	cg24110177	chr3:50126178	RBM5	-0.52	-7.06	-0.4	1.42e-11	Intelligence (multi-trait analysis);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg07483432	chr12:72079704	TMEM19	0.47	6.75	0.38	9.32e-11	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg04139749	chr14:77786727	GSTZ1;POMT2	0.48	6.2	0.36	2.21e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs4563143	0.675	rs112383987	chr19:29261081	C/T	cg14983838	chr19:29218262	NA	0.5	6.16	0.35	2.67e-9	Methadone dose in opioid dependence;
CESC	cis	rs6752107	1.000	rs13391356	chr2:234170369	T/C	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.38	5.83	0.34	1.61e-8	Crohn's disease;Inflammatory bowel disease;
CESC	trans	rs1945213	0.694	rs11227181	chr11:55856053	C/T	cg03929089	chr4:120376271	NA	0.77	7.35	0.41	2.48e-12	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs57244997	0.872	rs11759694	chr6:162405705	C/G	cg17173639	chr6:162384350	PARK2	0.69	7.17	0.4	7.53e-12	Mosquito bite size;
CESC	cis	rs4975709	0.589	rs931508	chr5:1861224	C/G	cg17650747	chr5:1873721	NA	0.4	5.58	0.32	5.96e-8	Cardiovascular disease risk factors;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg11201273	chr8:38088865	DDHD2	-0.52	-6.36	-0.36	8.91e-10	Ulcerative colitis;
CESC	cis	rs17666538	0.535	rs4338080	chr8:615598	A/G	cg02524346	chr8:600233	NA	0.83	6.05	0.35	4.92e-9	IgG glycosylation;
CESC	cis	rs11711311	1.000	rs62268169	chr3:113493860	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.71	9.99	0.52	3.72e-20	IgG glycosylation;
CESC	cis	rs5753037	0.809	rs140150	chr22:30185719	C/G	cg01021169	chr22:30184971	ASCC2	-0.38	-5.03	-0.3	9.16e-7	Type 1 diabetes;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg03900353	chr1:212732456	NA	0.46	6.1	0.35	3.78e-9	Systemic lupus erythematosus;
CESC	cis	rs7605827	0.930	rs11692646	chr2:15559198	C/G	cg19274914	chr2:15703543	NA	-0.38	-6.93	-0.39	3.19e-11	Educational attainment (years of education);
CESC	cis	rs6502050	0.835	rs8078087	chr17:80113322	T/G	cg23985595	chr17:80112537	CCDC57	-0.42	-6.65	-0.38	1.69e-10	Life satisfaction;
CESC	cis	rs1008375	0.897	rs1006723	chr4:17618524	G/A	cg15017067	chr4:17643749	FAM184B	0.38	5.39	0.31	1.54e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg04925196	chr12:51592141	POU6F1	0.52	6.83	0.39	5.95e-11	Fibrinogen levels;
CESC	cis	rs13191362	1.000	rs34591938	chr6:163087003	C/G	cg21926612	chr6:163149169	PACRG;PARK2	1.03	10.8	0.55	8.68e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs7945705	0.747	rs2653605	chr11:8993309	C/G	cg14711859	chr11:8959438	ASCL3	0.34	5.48	0.32	9.95e-8	Hemoglobin concentration;
CESC	cis	rs1545257	0.505	rs894466	chr2:24633771	T/C	cg06627628	chr2:24431161	ITSN2	-0.47	-5.62	-0.33	4.94e-8	Sjögren's syndrome;
CESC	cis	rs11264213	0.901	rs55762724	chr1:36382702	C/T	cg27506609	chr1:36549197	TEKT2	0.66	5.55	0.32	6.79e-8	Schizophrenia;
CESC	cis	rs9831754	0.704	rs6774325	chr3:78458727	G/A	cg06138941	chr3:78371609	NA	-0.49	-6.11	-0.35	3.54e-9	Calcium levels;
CESC	cis	rs7552404	0.924	rs2153126	chr1:76199345	C/G	cg22875332	chr1:76189707	ACADM	0.73	10.04	0.53	2.51e-20	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs2576037	0.796	rs2571033	chr18:44578552	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.6	-8.71	-0.47	3.35e-16	Personality dimensions;
CESC	cis	rs2072732	0.861	rs12034794	chr1:2937551	T/G	cg15211996	chr1:2936768	ACTRT2	0.35	5.74	0.33	2.63e-8	Plateletcrit;
CESC	cis	rs10754283	0.967	rs10737706	chr1:90112579	G/T	cg21401794	chr1:90099060	LRRC8C	0.7	9.44	0.5	1.97e-18	Amyotrophic lateral sclerosis (sporadic);
CESC	trans	rs208520	0.690	rs74707865	chr6:66717352	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.95	12.24	0.6	1.32e-27	Exhaled nitric oxide output;
CESC	cis	rs9660180	0.967	rs6603802	chr1:1812521	C/T	cg17747265	chr1:1875780	NA	-0.56	-9.11	-0.49	2.1e-17	Body mass index;
CESC	cis	rs875971	0.862	rs10278014	chr7:66051264	C/T	cg18876405	chr7:65276391	NA	-0.53	-7.25	-0.41	4.64e-12	Aortic root size;
CESC	cis	rs1003719	0.788	rs4817845	chr21:38447132	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.62	8.7	0.47	3.48e-16	Eye color traits;
CESC	cis	rs7927592	0.513	rs7950129	chr11:68202903	A/G	cg01657329	chr11:68192670	LRP5	-0.55	-7.22	-0.41	5.47e-12	Total body bone mineral density;
CESC	cis	rs1862618	0.671	rs2591956	chr5:56244604	G/A	cg18230493	chr5:56204884	C5orf35	0.6	7.88	0.44	8.63e-14	Initial pursuit acceleration;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg10446143	chr21:44394730	PKNOX1	0.53	7.09	0.4	1.22e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs67311347	1.000	rs7612015	chr3:40399974	A/C	cg09455208	chr3:40491958	NA	0.45	7.85	0.43	1.06e-13	Renal cell carcinoma;
CESC	cis	rs9457247	0.756	rs2345572	chr6:167403441	A/T	cg25258033	chr6:167368657	RNASET2	0.39	5.83	0.34	1.64e-8	Crohn's disease;
CESC	cis	rs9399137	0.507	rs6940878	chr6:135366309	G/A	cg22676075	chr6:135203613	NA	0.55	7.36	0.41	2.37e-12	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	cis	rs1005277	0.540	rs2145487	chr10:38010077	A/G	cg00409905	chr10:38381863	ZNF37A	-0.5	-6.82	-0.39	6.06e-11	Extrinsic epigenetic age acceleration;
CESC	cis	rs2440129	0.611	rs1042356	chr17:6902743	G/A	cg03760483	chr17:6899297	ALOX12	0.42	7.47	0.42	1.13e-12	Tonsillectomy;
CESC	cis	rs6952808	0.689	rs4719391	chr7:2048136	T/C	cg08027265	chr7:2291960	NA	-0.34	-5.08	-0.3	7.23e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs17401966	1.000	rs11121552	chr1:10435324	C/A	cg15208524	chr1:10270712	KIF1B	0.49	6.21	0.36	2.04e-9	Hepatocellular carcinoma;
CESC	cis	rs950169	0.526	rs698620	chr15:85177208	G/A	cg12501888	chr15:85177176	SCAND2	-0.51	-6.84	-0.39	5.41e-11	Schizophrenia;
CESC	cis	rs6565180	0.962	rs6565182	chr16:30374381	C/T	cg17640201	chr16:30407289	ZNF48	-0.92	-13.42	-0.64	1.15e-31	Tonsillectomy;
CESC	cis	rs8038465	0.592	rs58443257	chr15:73930707	A/T	cg15420318	chr15:73925796	NPTN	0.47	6.68	0.38	1.41e-10	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs8028182	0.549	rs10775209	chr15:75634759	G/A	cg20655648	chr15:75932815	IMP3	-0.43	-5.34	-0.31	2.03e-7	Sudden cardiac arrest;
CESC	cis	rs6460942	0.841	rs17444203	chr7:12461864	C/G	cg06484146	chr7:12443880	VWDE	0.75	10.63	0.55	3.35e-22	Coronary artery disease;
CESC	trans	rs35110281	0.837	rs2838341	chr21:45076443	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.5	6.69	0.38	1.33e-10	Mean corpuscular volume;
CESC	cis	rs2281558	0.583	rs7260957	chr20:25722462	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.5	5.63	0.33	4.51e-8	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;
CESC	trans	rs916888	0.773	rs199535	chr17:44822662	A/G	cg22968622	chr17:43663579	NA	1.27	17.97	0.74	9.18e-48	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs9875589	0.509	rs1601870	chr3:14024162	T/C	cg19554555	chr3:13937349	NA	-0.43	-5.66	-0.33	4.01e-8	Ovarian reserve;
CESC	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	7.64	0.43	3.85e-13	Prudent dietary pattern;
CESC	cis	rs2522056	0.932	rs2522064	chr5:131806488	G/A	cg24060327	chr5:131705240	SLC22A5	0.61	6.89	0.39	4.11e-11	Lymphocyte counts;Fibrinogen;
CESC	trans	rs116095464	0.558	rs112343653	chr5:257174	G/A	cg00938859	chr5:1591904	SDHAP3	0.63	6.77	0.38	8.35e-11	Breast cancer;
CESC	cis	rs10883723	0.810	rs2296588	chr10:104248087	T/C	cg22532475	chr10:104410764	TRIM8	-0.34	-5.72	-0.33	2.86e-8	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs6429082	0.818	rs291340	chr1:235674379	C/T	cg26050004	chr1:235667680	B3GALNT2	0.66	8.03	0.44	3.27e-14	Adiposity;
CESC	cis	rs5753618	0.504	rs8142121	chr22:31882785	G/A	cg13145458	chr22:31556086	RNF185	-0.51	-5.89	-0.34	1.19e-8	Colorectal cancer;
CESC	cis	rs10129255	0.500	rs8014529	chr14:107192302	G/A	cg23076370	chr14:107095027	NA	-0.65	-9.53	-0.51	1.09e-18	Kawasaki disease;
CESC	cis	rs3091242	0.935	rs4233043	chr1:25765483	A/G	cg03538708	chr1:25844672	NA	-0.39	-5.87	-0.34	1.31e-8	Erythrocyte sedimentation rate;
CESC	cis	rs2370759	1.000	rs79806114	chr10:32618022	T/C	cg18270830	chr10:32634957	EPC1	0.71	6.75	0.38	9.25e-11	Sexual dysfunction (female);
CESC	cis	rs11648796	0.765	rs2003832	chr16:769538	G/A	cg09781414	chr16:715207	WDR90	-0.42	-5.16	-0.3	4.87e-7	Height;
CESC	cis	rs9811920	0.965	rs9289981	chr3:99868104	A/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.41	5.48	0.32	1.01e-7	Axial length;
CESC	cis	rs7819412	0.807	rs4840542	chr8:10944809	G/T	cg21775007	chr8:11205619	TDH	-0.42	-5.66	-0.33	3.99e-8	Triglycerides;
CESC	cis	rs2486288	0.656	rs8041702	chr15:45547093	C/T	cg09092052	chr15:45571596	NA	0.48	5.63	0.33	4.53e-8	Glomerular filtration rate;
CESC	cis	rs17253792	0.822	rs10151664	chr14:56029533	A/G	cg01858014	chr14:56050164	KTN1	-0.84	-7.0	-0.4	2.1e-11	Putamen volume;
CESC	cis	rs9322193	0.923	rs35961297	chr6:149989065	T/C	cg07701084	chr6:150067640	NUP43	0.45	6.27	0.36	1.42e-9	Lung cancer;
CESC	cis	rs1862618	0.525	rs2662016	chr5:56269047	A/G	cg12311346	chr5:56204834	C5orf35	0.78	9.45	0.5	1.93e-18	Initial pursuit acceleration;
CESC	cis	rs56104184	0.775	rs56149557	chr19:49401384	C/A	cg21252483	chr19:49399788	TULP2	-0.52	-5.69	-0.33	3.36e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	trans	rs9388451	0.537	rs1739383	chr6:126098915	G/T	cg05039488	chr6:79577232	IRAK1BP1	-0.56	-7.42	-0.41	1.59e-12	Brugada syndrome;
CESC	cis	rs40363	0.680	rs72778116	chr16:3530752	A/G	cg05754148	chr16:3507555	NAT15	0.67	6.43	0.37	5.88e-10	Tuberculosis;
CESC	cis	rs9916302	0.706	rs8075737	chr17:37727316	C/T	cg20243544	chr17:37824526	PNMT	-0.53	-5.57	-0.32	6.26e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs61931739	0.500	rs11053243	chr12:34514155	T/C	cg06521331	chr12:34319734	NA	-0.37	-5.09	-0.3	6.85e-7	Morning vs. evening chronotype;
CESC	cis	rs2072732	0.861	rs6679678	chr1:2950594	T/C	cg15211996	chr1:2936768	ACTRT2	0.34	5.95	0.34	8.31e-9	Plateletcrit;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg00692549	chr1:11072455	TARDBP	0.46	6.31	0.36	1.18e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs2191566	0.576	rs393195	chr19:44493142	T/G	cg20607764	chr19:44506953	ZNF230	0.41	5.17	0.3	4.57e-7	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs56046484	0.956	rs17541572	chr15:85665247	C/T	cg08123816	chr15:85640762	PDE8A	0.5	6.0	0.35	6.52e-9	Testicular germ cell tumor;
CESC	cis	rs12477438	1.000	rs11897712	chr2:99735697	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.66	-7.79	-0.43	1.54e-13	Chronic sinus infection;
CESC	cis	rs11638352	1.000	rs2412852	chr15:44303086	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	-0.49	-5.16	-0.3	4.75e-7	Lipoprotein phospholipase A2 activity in cardiovascular disease;
CESC	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.43	-5.85	-0.34	1.46e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg23182539	chr10:121355708	TIAL1	-0.45	-6.03	-0.35	5.41e-9	Height;
CESC	cis	rs703842	1.000	rs10877019	chr12:58172929	A/G	cg18357645	chr12:58087776	OS9	0.42	5.8	0.34	1.88e-8	Multiple sclerosis;
CESC	cis	rs1707322	1.000	rs9429186	chr1:46539687	C/T	cg06784218	chr1:46089804	CCDC17	-0.33	-5.55	-0.32	7e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg15112475	chr7:1198522	ZFAND2A	-0.44	-7.12	-0.4	1.04e-11	Longevity;Endometriosis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26357606	chr6:43230825	TTBK1	-0.52	-6.07	-0.35	4.39e-9	Gut microbiome composition (summer);
CESC	cis	rs117623576	0.941	rs72778716	chr10:32370541	G/A	cg03047570	chr10:32398778	NA	-0.79	-7.14	-0.4	8.95e-12	Anti-saccade response;
CESC	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.78	7.08	0.4	1.3e-11	Platelet count;
CESC	cis	rs752010	0.967	rs752011	chr1:42092929	C/T	cg06885757	chr1:42089581	HIVEP3	0.49	7.94	0.44	5.62e-14	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs7666738	0.830	rs4699593	chr4:98980628	A/G	cg03467027	chr4:99064603	C4orf37	0.43	5.44	0.32	1.18e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10479542	0.583	rs4131080	chr5:179044292	G/A	cg00080972	chr5:178986291	RUFY1	0.44	6.81	0.39	6.34e-11	Lung cancer;
CESC	cis	rs78889164	0.956	rs79661676	chr19:33863054	C/T	cg02272751	chr19:33882848	PEPD	-0.5	-6.67	-0.38	1.5e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs561341	0.882	rs16967101	chr17:30377162	A/G	cg00745463	chr17:30367425	LRRC37B	-0.62	-6.07	-0.35	4.46e-9	Hip circumference adjusted for BMI;
CESC	cis	rs2857078	0.720	rs9906669	chr17:42305706	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.41	5.1	0.3	6.35e-7	Red cell distribution width;Reticulocyte count;
CESC	cis	rs875971	0.660	rs7807944	chr7:66087195	C/G	cg06456125	chr7:65229604	NA	-0.4	-5.13	-0.3	5.51e-7	Aortic root size;
CESC	cis	rs853679	0.517	rs9380065	chr6:28144751	A/G	cg26335602	chr6:28129616	ZNF389	0.52	6.85	0.39	5.22e-11	Depression;
CESC	cis	rs7216064	1.000	rs4791212	chr17:65975385	C/T	cg07042672	chr17:66097459	LOC651250	-0.54	-5.84	-0.34	1.55e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	trans	rs4950322	0.518	rs4950304	chr1:146588267	C/T	cg04954894	chr8:38089920	DDHD2	-0.58	-6.2	-0.36	2.14e-9	Protein quantitative trait loci;
CESC	cis	rs769267	0.929	rs34538000	chr19:19481379	G/T	cg03709012	chr19:19516395	GATAD2A	-0.99	-15.52	-0.69	4.48e-39	Tonsillectomy;
CESC	cis	rs11098499	0.863	rs11731756	chr4:120478696	T/G	cg24375607	chr4:120327624	NA	0.45	5.51	0.32	8.55e-8	Corneal astigmatism;
CESC	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg21724239	chr8:58056113	NA	0.56	5.25	0.31	3.19e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs12900413	0.603	rs2351494	chr15:90299541	C/T	cg24249390	chr15:90295951	MESP1	-0.4	-5.42	-0.32	1.33e-7	Coronary artery aneurysm in Kawasaki disease;
CESC	trans	rs7819412	0.668	rs2409721	chr8:11038244	A/T	cg06636001	chr8:8085503	FLJ10661	-0.62	-7.98	-0.44	4.38e-14	Triglycerides;
CESC	cis	rs7618501	0.633	rs4688757	chr3:50035323	T/C	cg24308560	chr3:49941425	MST1R	-0.64	-9.3	-0.5	5.56e-18	Intelligence (multi-trait analysis);
CESC	cis	rs13108904	0.967	rs900029	chr4:1279145	C/T	cg00684032	chr4:1343700	KIAA1530	0.4	5.58	0.32	6e-8	Obesity-related traits;
CESC	cis	rs4722166	0.630	rs12537614	chr7:22789551	C/G	cg05265849	chr7:22767390	IL6	0.54	6.81	0.39	6.34e-11	Lung cancer;
CESC	cis	rs7808935	0.789	rs2040668	chr7:27958773	G/T	cg05786569	chr7:27702416	HIBADH	-0.49	-5.49	-0.32	9.4e-8	Prostate cancer;
CESC	cis	rs2573652	0.722	rs11636084	chr15:100543394	A/G	cg09918751	chr15:100517450	ADAMTS17	-0.29	-5.48	-0.32	9.68e-8	Height;
CESC	cis	rs2576037	0.796	rs6507718	chr18:44581284	G/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.33	-5.15	-0.3	4.98e-7	Personality dimensions;
CESC	cis	rs597539	0.652	rs673821	chr11:68678718	G/T	cg01988459	chr11:68622903	NA	-0.49	-6.94	-0.39	2.98e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs8067354	0.830	rs2453913	chr17:57860150	G/T	cg13753209	chr17:57696993	CLTC	0.49	6.69	0.38	1.29e-10	Hemoglobin concentration;
CESC	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg06873352	chr17:61820015	STRADA	0.72	12.78	0.62	1.79e-29	Prudent dietary pattern;
CESC	cis	rs9325144	0.534	rs6582538	chr12:38629997	A/C	cg26384229	chr12:38710491	ALG10B	-0.59	-9.01	-0.48	4.09e-17	Morning vs. evening chronotype;
CESC	cis	rs2273669	0.667	rs116189763	chr6:109302894	T/C	cg05315195	chr6:109294784	ARMC2	-0.65	-6.08	-0.35	4.15e-9	Prostate cancer;
CESC	cis	rs17401966	0.858	rs61778404	chr1:10432879	A/G	cg15208524	chr1:10270712	KIF1B	0.4	5.15	0.3	5.09e-7	Hepatocellular carcinoma;
CESC	cis	rs6963495	0.556	rs818481	chr7:105158467	G/C	cg13798780	chr7:105162888	PUS7	0.51	6.3	0.36	1.26e-9	Bipolar disorder (body mass index interaction);
CESC	cis	rs1799949	0.930	rs4584865	chr17:41424919	C/G	cg25072359	chr17:41440525	NA	0.46	6.06	0.35	4.72e-9	Menopause (age at onset);
CESC	cis	rs2273669	0.667	rs11153156	chr6:109365911	C/T	cg05315195	chr6:109294784	ARMC2	-0.67	-6.32	-0.36	1.13e-9	Prostate cancer;
CESC	trans	rs3794271	0.706	rs9971816	chr12:20826911	C/T	cg09704049	chr3:38348016	SLC22A14	0.45	6.29	0.36	1.31e-9	Response to TNF-alpha inhibitors in rheumatoid arthritis;
CESC	cis	rs9916302	0.904	rs612194	chr17:37442707	T/A	cg20243544	chr17:37824526	PNMT	-0.44	-5.45	-0.32	1.13e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs4434138	0.594	rs7653028	chr3:52763000	A/T	cg18404041	chr3:52824283	ITIH1	-0.38	-6.35	-0.36	9.29e-10	Intelligence (multi-trait analysis);
CESC	cis	rs727563	0.569	rs73178647	chr22:41964168	G/A	cg06634786	chr22:41940651	POLR3H	-0.68	-6.73	-0.38	1.03e-10	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs10788264	0.544	rs9630110	chr10:124017308	C/T	cg09507567	chr10:124027408	NA	-0.42	-5.86	-0.34	1.36e-8	Total body bone mineral density;
CESC	cis	rs8103278	0.507	rs2041975	chr19:46238555	T/C	cg12641515	chr19:46296257	DMWD	0.73	9.82	0.52	1.34e-19	Coronary artery disease;
CESC	cis	rs2842992	0.724	rs2273827	chr6:160211339	C/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.85	12.01	0.59	8.38e-27	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs27434	0.583	rs34759	chr5:96153133	T/C	cg16492584	chr5:96139282	ERAP1	-0.38	-5.54	-0.32	7.47e-8	Ankylosing spondylitis;
CESC	cis	rs6570726	0.905	rs421032	chr6:145827771	A/G	cg05347473	chr6:146136440	FBXO30	0.44	5.99	0.35	6.71e-9	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs11039798	0.777	rs2202454	chr11:49011009	T/C	cg15704280	chr7:45808275	SEPT13	0.69	6.46	0.37	4.91e-10	Axial length;
CESC	cis	rs4689388	0.926	rs5018647	chr4:6292799	A/C	cg00701064	chr4:6280414	WFS1	0.7	12.37	0.61	4.71e-28	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs1018836	0.923	rs10956748	chr8:91621537	T/A	cg16814680	chr8:91681699	NA	-0.71	-9.99	-0.52	3.79e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs909674	0.541	rs5750816	chr22:39810379	A/G	cg01416388	chr22:39784598	NA	0.55	6.97	0.39	2.47e-11	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27184249	chr1:38010230	SNIP1	-0.6	-6.76	-0.38	8.63e-11	Gut microbiome composition (summer);
CESC	cis	rs10191773	0.535	rs11685514	chr2:113100014	C/T	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.71	-7.55	-0.42	6.9e-13	Yeast infection;
CESC	cis	rs3750965	1.000	rs3750965	chr11:68840160	A/G	cg01403660	chr11:68851641	TPCN2	0.43	5.6	0.33	5.29e-8	Hair color;
CESC	cis	rs4727027	0.704	rs2269972	chr7:148914047	C/T	cg23583168	chr7:148888333	NA	0.93	16.39	0.71	3.53e-42	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs10540	0.908	rs1044707	chr11:491334	G/T	cg03352830	chr11:487213	PTDSS2	-0.74	-7.21	-0.4	5.98e-12	Body mass index;
CESC	cis	rs7192750	0.583	rs8046916	chr16:72047751	C/G	cg14768367	chr16:72042858	DHODH	-0.72	-5.69	-0.33	3.32e-8	LDL cholesterol levels;Total cholesterol levels;
CESC	cis	rs7829975	0.714	rs7823757	chr8:8670177	T/A	cg15556689	chr8:8085844	FLJ10661	0.43	5.44	0.32	1.2e-7	Mood instability;
CESC	cis	rs13191362	0.935	rs35942036	chr6:163163297	C/T	cg06582575	chr6:163149167	PACRG;PARK2	1.01	10.08	0.53	1.98e-20	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs6912958	0.559	rs6921504	chr6:88058972	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	0.33	5.56	0.32	6.64e-8	Monocyte percentage of white cells;
CESC	cis	rs228437	1.000	rs1474828	chr6:134926962	A/C	cg24504307	chr6:134963096	NA	0.58	6.2	0.36	2.2e-9	Melanoma;
CESC	cis	rs7666738	0.716	rs1426660	chr4:98876792	T/A	cg05340658	chr4:99064831	C4orf37	0.75	11.16	0.57	5.89e-24	Colonoscopy-negative controls vs population controls;
CESC	cis	rs801193	0.844	rs7779971	chr7:66161790	T/C	cg06456125	chr7:65229604	NA	0.4	5.23	0.31	3.51e-7	Aortic root size;
CESC	cis	rs1008375	0.932	rs13127157	chr4:17618049	A/G	cg16339924	chr4:17578868	LAP3	-0.76	-9.51	-0.5	1.22e-18	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs8031584	0.678	rs4779497	chr15:31151365	T/A	cg08109568	chr15:31115862	NA	-0.72	-9.73	-0.51	2.44e-19	Huntington's disease progression;
CESC	cis	rs6952808	1.000	rs12540579	chr7:1882227	C/A	cg13880726	chr7:1868755	MAD1L1	0.52	7.14	0.4	8.73e-12	Bipolar disorder and schizophrenia;
CESC	cis	rs2952156	0.920	rs9303274	chr17:37836353	T/C	cg07936489	chr17:37558343	FBXL20	-0.6	-7.98	-0.44	4.39e-14	Asthma;
CESC	cis	rs736408	0.562	rs2072390	chr3:52780509	A/T	cg18099408	chr3:52552593	STAB1	-0.34	-5.7	-0.33	3.12e-8	Bipolar disorder;
CESC	trans	rs10411161	0.702	rs11879436	chr19:52397815	T/A	cg22319618	chr22:45562946	NUP50	-0.74	-7.44	-0.42	1.37e-12	Breast cancer;
CESC	cis	rs2857078	0.720	rs9901595	chr17:42305699	G/A	cg13607699	chr17:42295918	UBTF	0.78	11.36	0.57	1.25e-24	Red cell distribution width;Reticulocyte count;
CESC	cis	rs853679	0.517	rs2275508	chr6:28094731	T/C	cg26335602	chr6:28129616	ZNF389	0.54	7.25	0.41	4.48e-12	Depression;
CESC	cis	rs9640161	0.789	rs3735172	chr7:150028958	C/T	cg21361702	chr7:150065534	REPIN1	-0.53	-6.25	-0.36	1.62e-9	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs4237845	0.773	rs6650218	chr12:58289078	T/A	cg00677455	chr12:58241039	CTDSP2	0.44	5.78	0.33	2.09e-8	Intelligence (multi-trait analysis);
CESC	cis	rs9914544	0.564	rs1859083	chr17:18843306	C/T	cg26306683	chr17:18585705	ZNF286B	-0.38	-5.54	-0.32	7.34e-8	Educational attainment (years of education);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18452880	chr6:170151829	C6orf70;TCTE3	0.58	6.86	0.39	4.75e-11	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02262025	chr16:75657287	ADAT1	0.53	6.11	0.35	3.59e-9	Gut microbiome composition (summer);
CESC	cis	rs9325144	0.647	rs12231313	chr12:39101929	C/T	cg26384229	chr12:38710491	ALG10B	-0.5	-7.06	-0.4	1.47e-11	Morning vs. evening chronotype;
CESC	cis	rs1800795	0.652	rs7802307	chr7:22766433	T/A	cg13104385	chr7:22767384	IL6	0.38	5.23	0.31	3.48e-7	Cerebrospinal fluid clusterin levels in APOEe4- carriers;
CESC	cis	rs7107174	1.000	rs2510043	chr11:77977481	C/G	cg02023728	chr11:77925099	USP35	0.39	5.79	0.34	1.99e-8	Testicular germ cell tumor;
CESC	cis	rs919433	0.929	rs1366836	chr2:198172148	T/G	cg10820045	chr2:198174542	NA	-0.44	-6.93	-0.39	3.21e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs7511006	1.000	rs17836662	chr22:50672154	A/G	cg16473166	chr22:50639996	SELO	-0.49	-6.13	-0.35	3.17e-9	Obesity-related traits;
CESC	cis	rs1799949	1.000	rs12936816	chr17:41301709	C/T	cg06001716	chr17:41278141	BRCA1;NBR2	0.39	5.26	0.31	3e-7	Menopause (age at onset);
CESC	cis	rs2243480	1.000	rs36068983	chr7:65408991	C/T	cg12463550	chr7:65579703	CRCP	0.7	5.58	0.32	5.87e-8	Diabetic kidney disease;
CESC	cis	rs7666738	0.830	rs35213297	chr4:98984049	T/C	cg17366294	chr4:99064904	C4orf37	0.57	8.16	0.45	1.4e-14	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3806843	1.000	rs1548701	chr5:140164557	T/C	cg26395211	chr5:140044315	WDR55	-0.42	-5.43	-0.32	1.26e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs11030122	0.702	rs10835399	chr11:3989182	G/A	cg18678763	chr11:4115507	RRM1	-0.47	-6.22	-0.36	1.92e-9	Mean platelet volume;Platelet distribution width;
CESC	cis	rs12765878	1.000	rs11191847	chr10:105650626	G/C	cg11005552	chr10:105648138	OBFC1	0.36	5.24	0.31	3.32e-7	Coronary artery disease;
CESC	cis	rs7811142	1.000	rs4989959	chr7:100032288	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.11	10.96	0.56	2.75e-23	Platelet count;
CESC	cis	rs965469	1.000	rs6051751	chr20:3310049	G/C	cg25506879	chr20:3388711	C20orf194	-0.57	-6.15	-0.35	2.79e-9	IFN-related cytopenia;
CESC	cis	rs3785574	0.962	rs8079161	chr17:61808561	C/G	cg06420487	chr17:61919686	SMARCD2	0.46	5.56	0.32	6.51e-8	Height;
CESC	cis	rs9916302	0.904	rs9904334	chr17:37468336	G/A	cg07936489	chr17:37558343	FBXL20	0.78	11.03	0.56	1.58e-23	Glomerular filtration rate (creatinine);
CESC	cis	rs911555	0.755	rs4143998	chr14:103955247	T/C	cg24130564	chr14:104152367	KLC1	-0.5	-6.58	-0.37	2.56e-10	Intelligence (multi-trait analysis);
CESC	cis	rs6968419	0.788	rs6946058	chr7:115839253	A/C	cg02561103	chr7:115862891	TES	-0.39	-5.26	-0.31	2.93e-7	Intraocular pressure;
CESC	cis	rs5753618	0.504	rs9606847	chr22:31901789	G/C	cg02404636	chr22:31891804	SFI1	0.42	5.85	0.34	1.47e-8	Colorectal cancer;
CESC	cis	rs2228479	0.850	rs1800331	chr16:89858417	C/A	cg19635926	chr16:89946313	TCF25	0.68	5.17	0.3	4.65e-7	Skin colour saturation;
CESC	cis	rs13242816	1.000	rs67982517	chr7:116075363	A/G	cg04696780	chr7:116139425	CAV2	-0.64	-5.73	-0.33	2.71e-8	P wave duration;
CESC	cis	rs2243480	0.901	rs778730	chr7:65823325	T/A	cg18252515	chr7:66147081	NA	-1.4	-14.22	-0.66	1.75e-34	Diabetic kidney disease;
CESC	cis	rs703842	0.963	rs923829	chr12:58174306	T/C	cg18357645	chr12:58087776	OS9	-0.39	-5.55	-0.32	6.84e-8	Multiple sclerosis;
CESC	cis	rs7402982	0.625	rs7179841	chr15:99204652	C/T	cg03437748	chr15:99193247	IGF1R	0.61	7.81	0.43	1.3e-13	Birth weight;
CESC	cis	rs12477438	0.520	rs4851187	chr2:99745860	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.83	-14.22	-0.66	1.71e-34	Chronic sinus infection;
CESC	cis	rs6120849	0.754	rs1885117	chr20:33600740	C/T	cg24642439	chr20:33292090	TP53INP2	0.67	6.69	0.38	1.3e-10	Protein C levels;
CESC	cis	rs3845702	1.000	rs262279	chr2:180869145	G/A	cg01881094	chr2:180872142	CWC22	0.65	6.99	0.39	2.21e-11	Schizophrenia;
CESC	cis	rs9393777	0.623	rs9348719	chr6:26470032	T/C	cg14345882	chr6:26364793	BTN3A2	0.43	5.4	0.31	1.5e-7	Intelligence (multi-trait analysis);
CESC	cis	rs9457247	1.000	rs406095	chr6:167409087	C/T	cg07741184	chr6:167504864	NA	0.3	5.52	0.32	8.06e-8	Crohn's disease;
CESC	cis	rs2404618	0.506	rs12156177	chr8:1493684	C/T	cg02903104	chr8:1507517	DLGAP2	0.29	5.56	0.32	6.42e-8	Lung cancer;
CESC	cis	rs2072438	0.505	rs7034074	chr9:123923029	A/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.37	5.29	0.31	2.57e-7	Rheumatoid arthritis;
CESC	trans	rs801193	1.000	rs4717319	chr7:66242593	A/G	cg26939375	chr7:64535504	NA	0.66	9.1	0.49	2.19e-17	Aortic root size;
CESC	cis	rs7927592	0.763	rs4340059	chr11:68362433	A/G	cg16797656	chr11:68205561	LRP5	0.47	7.07	0.4	1.35e-11	Total body bone mineral density;
CESC	cis	rs763014	0.931	rs62030903	chr16:638323	T/A	cg00908189	chr16:619842	PIGQ	0.63	8.33	0.46	4.24e-15	Height;
CESC	cis	rs2777491	0.915	rs28583065	chr15:41608470	T/C	cg02330683	chr15:41787940	ITPKA	0.46	6.69	0.38	1.35e-10	Ulcerative colitis;
CESC	cis	rs3785574	0.962	rs2584632	chr17:61880641	G/A	cg07677032	chr17:61819896	STRADA	0.41	5.17	0.3	4.59e-7	Height;
CESC	cis	rs4481887	0.676	rs28684663	chr1:248548325	T/C	cg26353448	chr1:248524236	OR2T4	-0.38	-5.61	-0.33	5.16e-8	Common traits (Other);
CESC	cis	rs8017423	0.967	rs11159957	chr14:90715972	A/G	cg14092571	chr14:90743983	NA	0.58	8.84	0.48	1.32e-16	Mortality in heart failure;
CESC	cis	rs4665809	0.878	rs6748745	chr2:26364190	C/T	cg25036284	chr2:26402008	FAM59B	-0.65	-7.73	-0.43	2.18e-13	Gut microbiome composition (summer);
CESC	cis	rs2576037	0.526	rs1893427	chr18:44434987	C/T	cg19077165	chr18:44547161	KATNAL2	-0.53	-7.83	-0.43	1.17e-13	Personality dimensions;
CESC	cis	rs11098499	0.863	rs34868248	chr4:120442430	A/G	cg24375607	chr4:120327624	NA	0.43	5.24	0.31	3.36e-7	Corneal astigmatism;
CESC	cis	rs3008870	0.959	rs2985810	chr1:67376162	T/C	cg02640540	chr1:67518911	SLC35D1	0.49	5.21	0.3	3.81e-7	Lymphocyte percentage of white cells;
CESC	cis	rs7512552	0.780	rs1260411	chr1:150382088	G/A	cg15654264	chr1:150340011	RPRD2	0.4	5.3	0.31	2.45e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs6426558	0.537	rs498020	chr1:227304180	G/A	cg10327440	chr1:227177885	CDC42BPA	0.47	5.84	0.34	1.48e-8	Neutrophil percentage of white cells;
CESC	cis	rs7481584	0.624	rs413368	chr11:3047646	C/G	cg08508325	chr11:3079039	CARS	0.29	5.08	0.3	7.06e-7	Calcium levels;
CESC	cis	rs9322193	0.923	rs9371207	chr6:150179223	A/G	cg13206674	chr6:150067644	NUP43	0.4	5.39	0.31	1.57e-7	Lung cancer;
CESC	cis	rs67311347	1.000	rs1466237	chr3:40462026	C/G	cg09455208	chr3:40491958	NA	0.44	7.58	0.42	5.75e-13	Renal cell carcinoma;
CESC	cis	rs17209837	0.607	rs45560338	chr7:87111106	T/C	cg00919237	chr7:87102261	ABCB4	-0.49	-6.5	-0.37	4.02e-10	Gallbladder cancer;
CESC	cis	rs7666738	0.830	rs6839203	chr4:98839814	C/G	cg17366294	chr4:99064904	C4orf37	0.53	7.17	0.4	7.39e-12	Colonoscopy-negative controls vs population controls;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg20845262	chr7:62514736	NA	0.38	6.26	0.36	1.57e-9	Fibrinogen levels;
CESC	cis	rs736408	0.688	rs2239551	chr3:52818579	A/G	cg18404041	chr3:52824283	ITIH1	0.47	7.99	0.44	4.19e-14	Bipolar disorder;
CESC	cis	rs896854	0.654	rs10429443	chr8:95971164	A/G	cg16049864	chr8:95962084	TP53INP1	-0.64	-11.08	-0.56	1.07e-23	Type 2 diabetes;
CESC	cis	rs35306767	0.859	rs11817793	chr10:878895	C/T	cg26597838	chr10:835615	NA	0.86	9.15	0.49	1.61e-17	Eosinophil percentage of granulocytes;
CESC	cis	rs116095464	0.558	rs10462755	chr5:246748	T/C	cg20965017	chr5:231967	SDHA	-0.48	-5.4	-0.31	1.47e-7	Breast cancer;
CESC	cis	rs2012796	1.000	rs10450894	chr14:81825172	T/A	cg02996355	chr14:81879375	NA	0.5	5.86	0.34	1.34e-8	Night sleep phenotypes;
CESC	cis	rs6430585	0.759	rs12467770	chr2:136536095	G/A	cg07169764	chr2:136633963	MCM6	1.28	16.93	0.72	4.28e-44	Corneal structure;
CESC	cis	rs7100689	0.646	rs7077712	chr10:82134894	A/G	cg00277334	chr10:82204260	NA	-0.57	-7.51	-0.42	9.08e-13	Post bronchodilator FEV1;
CESC	cis	rs4819052	0.851	rs8133045	chr21:46658137	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.9	13.17	0.63	8.39e-31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs6502050	0.865	rs56193110	chr17:80151501	A/G	cg11859384	chr17:80120422	CCDC57	-0.38	-5.18	-0.3	4.43e-7	Life satisfaction;
CESC	cis	rs1448094	0.511	rs2405616	chr12:86148042	A/G	cg02569458	chr12:86230093	RASSF9	-0.42	-6.44	-0.37	5.67e-10	Major depressive disorder;
CESC	cis	rs7177699	0.557	rs55870734	chr15:79117917	A/T	cg04896959	chr15:78267971	NA	0.32	5.04	0.3	8.54e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
CESC	cis	rs7103648	0.669	rs7927445	chr11:47780754	G/T	cg20307385	chr11:47447363	PSMC3	0.8	12.17	0.6	2.22e-27	Diastolic blood pressure;Systolic blood pressure;
CESC	cis	rs116095464	0.558	rs10057674	chr5:266813	C/T	cg22857025	chr5:266934	NA	-1.3	-18.55	-0.75	8.05e-50	Breast cancer;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg16636271	chr6:139694487	CITED2	-0.46	-6.16	-0.35	2.65e-9	Ulcerative colitis;
CESC	cis	rs7605827	0.866	rs7598936	chr2:15597289	A/G	cg19274914	chr2:15703543	NA	0.33	5.91	0.34	1.04e-8	Educational attainment (years of education);
CESC	cis	rs10256972	0.616	rs6463001	chr7:1108272	A/C	cg07308232	chr7:1071921	C7orf50	-0.54	-7.55	-0.42	7.14e-13	Longevity;Endometriosis;
CESC	cis	rs262150	0.659	rs2730275	chr7:158793397	A/G	cg19418458	chr7:158789849	NA	-0.5	-8.0	-0.44	3.77e-14	Facial morphology (factor 20);
CESC	cis	rs17345786	0.511	rs13061565	chr3:101392270	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.47	6.08	0.35	4.17e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9443189	0.570	rs7755068	chr6:76405700	A/G	cg01950844	chr6:76311363	SENP6	0.88	9.29	0.5	6.05e-18	Prostate cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10078639	chr10:116286586	ABLIM1	0.55	6.51	0.37	3.8e-10	Gut microbiome composition (summer);
CESC	cis	rs986417	0.901	rs10134736	chr14:60998540	A/T	cg00859478	chr14:60978094	SIX6	0.47	5.06	0.3	7.87e-7	Gut microbiota (bacterial taxa);
CESC	cis	rs9911578	1.000	rs8067571	chr17:56868856	C/T	cg05425664	chr17:57184151	TRIM37	-0.49	-6.87	-0.39	4.62e-11	Intelligence (multi-trait analysis);
CESC	cis	rs12579753	0.917	rs12316644	chr12:82205497	C/T	cg21193143	chr12:82153300	PPFIA2	0.33	5.1	0.3	6.43e-7	Resting heart rate;
CESC	cis	rs8133932	0.654	rs2839050	chr21:47326666	G/A	cg14185626	chr21:47401492	COL6A1	0.47	5.1	0.3	6.46e-7	Schizophrenia;
CESC	cis	rs697003	0.966	rs701929	chr1:211846876	C/T	cg26036067	chr1:211849175	NEK2	0.39	5.08	0.3	7.27e-7	Red cell distribution width;
CESC	cis	rs654950	0.934	rs638859	chr1:42001444	A/G	cg06885757	chr1:42089581	HIVEP3	0.63	10.13	0.53	1.33e-20	Airway imaging phenotypes;
CESC	cis	rs4423214	0.879	rs12803256	chr11:71132868	A/G	cg05163923	chr11:71159392	DHCR7	0.77	10.29	0.53	4.06e-21	Vitamin D levels;
CESC	cis	rs853679	0.517	rs34716816	chr6:28046169	C/A	cg19592336	chr6:28129416	ZNF389	0.6	7.97	0.44	4.69e-14	Depression;
CESC	cis	rs9399135	0.967	rs4451151	chr6:135310546	C/T	cg22676075	chr6:135203613	NA	0.52	7.27	0.41	3.94e-12	Red blood cell count;
CESC	cis	rs34779708	0.733	rs7086715	chr10:35541840	A/G	cg04310649	chr10:35416472	CREM	-0.47	-5.39	-0.31	1.59e-7	Inflammatory bowel disease;Crohn's disease;
CESC	trans	rs1814175	0.645	rs11040535	chr11:49808669	C/T	cg03929089	chr4:120376271	NA	-0.86	-13.34	-0.63	2.07e-31	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12049088	chr22:36784491	MYH9	-0.6	-7.25	-0.41	4.58e-12	Gut microbiome composition (summer);
CESC	cis	rs6933660	0.745	rs3778608	chr6:151738131	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.87	14.33	0.66	7.18e-35	Menarche (age at onset);
CESC	cis	rs6460942	0.915	rs1595802	chr7:12439672	C/T	cg06484146	chr7:12443880	VWDE	-0.74	-8.94	-0.48	6.6e-17	Coronary artery disease;
CESC	trans	rs1953600	0.715	rs1079242	chr10:81917708	C/T	cg02976843	chr17:2843257	RAP1GAP2	-0.41	-6.64	-0.38	1.81e-10	Sarcoidosis;
CESC	trans	rs12541635	0.833	rs4099936	chr8:107099297	G/A	cg19509715	chr3:44037128	NA	-0.37	-6.02	-0.35	5.82e-9	Age of smoking initiation;
CESC	trans	rs2727020	0.615	rs10128582	chr11:49447424	C/T	cg15704280	chr7:45808275	SEPT13	-0.9	-15.46	-0.69	7.41e-39	Coronary artery disease;
CESC	cis	rs9457247	1.000	rs430293	chr6:167404958	A/G	cg07741184	chr6:167504864	NA	0.28	5.1	0.3	6.54e-7	Crohn's disease;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg00521551	chr11:64646313	EHD1	0.56	7.26	0.41	4.2e-12	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	trans	rs66573146	0.572	rs68169399	chr4:6952491	T/A	cg07817883	chr1:32538562	TMEM39B	1.19	8.25	0.45	7.66e-15	Granulocyte percentage of myeloid white cells;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg15806109	chr3:125802485	SLC41A3	-0.46	-6.08	-0.35	4.24e-9	Height;
CESC	cis	rs11252926	0.574	rs7068976	chr10:453112	A/G	cg18196295	chr10:418757	DIP2C	0.54	7.3	0.41	3.33e-12	Psychosis in Alzheimer's disease;
CESC	cis	rs4689388	0.890	rs4342257	chr4:6290037	G/C	cg14416269	chr4:6271139	WFS1	0.46	7.84	0.43	1.13e-13	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg10314295	chr10:75936245	ADK	0.51	6.71	0.38	1.16e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg03452623	chr4:187889614	NA	-0.94	-19.16	-0.76	6.22e-52	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs763121	0.853	rs3747174	chr22:39069181	T/C	cg06544989	chr22:39130855	UNC84B	0.5	8.88	0.48	1.05e-16	Menopause (age at onset);
CESC	trans	rs10500991	0.737	rs59125323	chr11:24882489	T/C	cg07129253	chr8:30890560	PURG;WRN	-0.54	-6.73	-0.38	1.05e-10	Iron status biomarkers;
CESC	cis	rs7937682	0.889	rs1940529	chr11:111498523	G/C	cg09085632	chr11:111637200	PPP2R1B	-1.01	-15.97	-0.7	1.14e-40	Primary sclerosing cholangitis;
CESC	cis	rs2637266	0.703	rs846578	chr10:78499508	T/G	cg18941641	chr10:78392320	NA	0.4	7.58	0.42	5.69e-13	Pulmonary function;
CESC	cis	rs11098499	0.863	rs13149407	chr4:120437825	A/G	cg09307838	chr4:120376055	NA	0.93	12.69	0.61	3.78e-29	Corneal astigmatism;
CESC	cis	rs1215050	0.704	rs783915	chr4:99023151	C/G	cg05340658	chr4:99064831	C4orf37	0.58	7.82	0.43	1.27e-13	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs73019876	0.869	rs2522094	chr19:22125569	A/G	cg11619707	chr19:22235551	ZNF257	-0.29	-5.46	-0.32	1.07e-7	Testicular germ cell tumor;
CESC	cis	rs7666738	0.830	rs2015828	chr4:98984594	A/G	cg18180107	chr4:99064573	C4orf37	0.4	5.19	0.3	4.24e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7086627	0.515	rs10887895	chr10:82210011	A/G	cg03267442	chr10:82210566	NA	-0.34	-5.6	-0.33	5.45e-8	Post bronchodilator FEV1;
CESC	cis	rs12478296	0.892	rs11893879	chr2:243010411	G/A	cg06360820	chr2:242988706	NA	-0.72	-9.14	-0.49	1.74e-17	Obesity-related traits;
CESC	cis	rs832540	0.931	rs331499	chr5:56210923	C/T	cg12311346	chr5:56204834	C5orf35	-0.42	-5.26	-0.31	2.99e-7	Coronary artery disease;
CESC	cis	rs17023223	0.537	rs12064033	chr1:119709558	G/A	cg05756136	chr1:119680316	WARS2	-0.47	-5.69	-0.33	3.34e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CESC	cis	rs11648796	0.765	rs2003832	chr16:769538	G/A	cg00802000	chr16:706648	WDR90	-0.47	-5.75	-0.33	2.48e-8	Height;
CESC	cis	rs3020736	0.500	rs6519306	chr22:42501217	T/C	cg15557168	chr22:42548783	NA	0.45	6.57	0.37	2.72e-10	Autism spectrum disorder or schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07667977	chr2:32236247	MEMO1	-0.65	-7.75	-0.43	1.97e-13	Gut microbiome composition (summer);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg06659889	chr3:12599050	MKRN2	0.53	6.87	0.39	4.46e-11	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs2732480	0.557	rs2732441	chr12:48723324	C/G	cg04545296	chr12:48745243	ZNF641	0.43	7.3	0.41	3.34e-12	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs7119	0.717	rs11629652	chr15:77779951	C/A	cg17802220	chr15:77601643	NA	-0.51	-7.18	-0.4	7.24e-12	Type 2 diabetes;
CESC	trans	rs7937682	0.889	rs7948236	chr11:111499933	C/A	cg18187862	chr3:45730750	SACM1L	0.51	6.48	0.37	4.4e-10	Primary sclerosing cholangitis;
CESC	cis	rs853679	0.517	rs12174753	chr6:28042465	C/G	cg26335602	chr6:28129616	ZNF389	0.53	7.05	0.4	1.55e-11	Depression;
CESC	cis	rs10504229	1.000	rs76944716	chr8:58191643	T/C	cg14926445	chr8:58193284	C8orf71	-0.53	-5.61	-0.33	5.1e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs7605827	0.930	rs2380649	chr2:15532612	A/C	cg19274914	chr2:15703543	NA	0.35	6.39	0.37	7.22e-10	Educational attainment (years of education);
CESC	trans	rs6828577	0.862	rs298974	chr4:119636034	A/G	cg05098011	chr1:151736092	OAZ3;MRPL9	0.48	6.02	0.35	5.93e-9	Perioperative myocardial infarction in coronary artery bypass surgery;
CESC	cis	rs2204008	0.754	rs11514074	chr12:38401128	C/T	cg26384229	chr12:38710491	ALG10B	0.74	10.72	0.55	1.66e-22	Bladder cancer;
CESC	cis	rs1797081	0.840	rs10904820	chr10:16848473	A/G	cg23933602	chr10:16859644	RSU1	1.07	20.8	0.79	1.24e-57	Platelet distribution width;
CESC	cis	rs7666738	0.830	rs6829567	chr4:99047340	T/C	cg18180107	chr4:99064573	C4orf37	0.41	5.29	0.31	2.51e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7044106	0.762	rs13291660	chr9:123392748	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.78	11.76	0.59	5.52e-26	Hip circumference adjusted for BMI;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06363516	chr2:241530274	CAPN10	-0.62	-7.72	-0.43	2.36e-13	Gut microbiome composition (summer);
CESC	cis	rs6963495	0.818	rs118134111	chr7:105161229	A/C	cg19920283	chr7:105172520	RINT1	0.69	6.56	0.37	2.85e-10	Bipolar disorder (body mass index interaction);
CESC	cis	rs9309473	1.000	rs6707722	chr2:73654363	G/A	cg20560298	chr2:73613845	ALMS1	-0.46	-6.2	-0.36	2.19e-9	Metabolite levels;
CESC	cis	rs7107174	1.000	rs2510037	chr11:77966099	A/G	cg02023728	chr11:77925099	USP35	0.41	6.0	0.35	6.28e-9	Testicular germ cell tumor;
CESC	cis	rs3858526	0.959	rs11039540	chr11:5928334	C/T	cg05234568	chr11:5960015	NA	-0.55	-6.36	-0.36	8.79e-10	DNA methylation (variation);
CESC	cis	rs1707322	0.752	rs6678444	chr1:46229847	A/G	cg06784218	chr1:46089804	CCDC17	0.39	6.87	0.39	4.55e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.54	6.73	0.38	1.02e-10	Prudent dietary pattern;
CESC	cis	rs1707322	1.000	rs785497	chr1:46591903	G/C	cg06784218	chr1:46089804	CCDC17	-0.36	-5.93	-0.34	9.35e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs742614	0.576	rs2747537	chr20:32405217	A/G	cg06304546	chr20:32448765	NA	-0.4	-5.09	-0.3	6.9e-7	Stearic acid (18:0) levels;
CESC	trans	rs6445797	0.589	rs11715395	chr3:56681949	G/A	cg15444621	chr13:113611794	NA	0.34	6.07	0.35	4.3e-9	Gastritis;
CESC	cis	rs1005277	0.579	rs2505198	chr10:38393183	A/C	cg25427524	chr10:38739819	LOC399744	-0.69	-10.25	-0.53	5.52e-21	Extrinsic epigenetic age acceleration;
CESC	cis	rs597539	0.652	rs668576	chr11:68668208	A/G	cg01988459	chr11:68622903	NA	-0.42	-5.79	-0.34	1.99e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs643506	0.874	rs4936786	chr11:111727227	C/T	cg09085632	chr11:111637200	PPP2R1B	0.4	5.21	0.31	3.71e-7	Breast cancer;
CESC	cis	rs5769765	0.773	rs6520065	chr22:50294470	A/T	cg26441486	chr22:50317300	CRELD2	0.39	5.41	0.32	1.4e-7	Schizophrenia;
CESC	cis	rs6772849	1.000	rs6772849	chr3:128306418	T/C	cg16766828	chr3:128327626	NA	-0.31	-5.06	-0.3	7.77e-7	Monocyte percentage of white cells;Monocyte count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20455436	chr19:55994860	ZNF628	-0.54	-6.05	-0.35	4.85e-9	Gut microbiome composition (summer);
CESC	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg14893161	chr1:205819251	PM20D1	0.87	15.37	0.69	1.47e-38	Menarche (age at onset);
CESC	cis	rs796364	0.806	rs112486506	chr2:201073947	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.71	-5.95	-0.34	8.33e-9	Schizophrenia;
CESC	cis	rs1499972	0.648	rs57945129	chr3:117641724	C/T	cg07612923	chr3:117604196	NA	0.66	5.98	0.34	7.1e-9	Schizophrenia;
CESC	cis	rs2243480	0.803	rs36127118	chr7:65565505	A/G	cg13147721	chr7:65941812	NA	-0.94	-8.87	-0.48	1.1e-16	Diabetic kidney disease;
CESC	cis	rs7103648	0.669	rs11039332	chr11:47695840	G/A	cg20307385	chr11:47447363	PSMC3	0.82	12.4	0.61	3.87e-28	Diastolic blood pressure;Systolic blood pressure;
CESC	cis	rs1799949	1.000	rs4793192	chr17:41204390	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.64	8.65	0.47	4.88e-16	Menopause (age at onset);
CESC	cis	rs6460942	0.597	rs10273045	chr7:12519371	T/C	cg02935154	chr7:12443704	VWDE	-0.48	-5.09	-0.3	6.85e-7	Coronary artery disease;
CESC	cis	rs898097	0.625	rs2125479	chr17:80890262	A/G	cg15664640	chr17:80829946	TBCD	-0.45	-6.14	-0.35	2.96e-9	Breast cancer;
CESC	cis	rs172166	0.694	rs1150666	chr6:28123928	T/C	cg22143856	chr6:28129313	ZNF389	0.38	5.26	0.31	3.01e-7	Cardiac Troponin-T levels;
CESC	cis	rs6061231	0.740	rs11698650	chr20:60958374	A/T	cg22541963	chr20:60982533	CABLES2	0.42	5.33	0.31	2.12e-7	Colorectal cancer;
CESC	cis	rs5769765	1.000	rs8138941	chr22:50290678	G/A	cg02269571	chr22:50332266	NA	-0.45	-6.07	-0.35	4.4e-9	Schizophrenia;
CESC	cis	rs10887741	0.624	rs7088341	chr10:89427820	C/T	cg13926569	chr10:89418898	PAPSS2	0.42	6.63	0.38	1.91e-10	Exercise (leisure time);
CESC	trans	rs561341	0.739	rs7213369	chr17:30211878	G/A	cg20587970	chr11:113659929	NA	0.59	7.5	0.42	9.74e-13	Hip circumference adjusted for BMI;
CESC	cis	rs9926296	0.548	rs12447465	chr16:89829895	C/T	cg07648498	chr16:89883185	FANCA	0.43	5.46	0.32	1.1e-7	Vitiligo;
CESC	cis	rs9457247	0.565	rs12193698	chr6:167512073	C/A	cg07741184	chr6:167504864	NA	0.43	7.65	0.43	3.84e-13	Crohn's disease;
CESC	cis	rs17376456	0.569	rs7702348	chr5:93065683	A/G	cg25358565	chr5:93447407	FAM172A	-0.5	-5.79	-0.34	1.94e-8	Diabetic retinopathy;
CESC	cis	rs9611565	0.512	rs768414	chr22:42135751	T/C	cg06634786	chr22:41940651	POLR3H	0.68	6.72	0.38	1.13e-10	Vitiligo;
CESC	cis	rs2479106	0.963	rs1627536	chr9:126542704	A/T	cg16191174	chr9:126692580	DENND1A	-0.5	-6.87	-0.39	4.56e-11	Polycystic ovary syndrome;
CESC	cis	rs2204008	0.837	rs11495548	chr12:38076756	C/T	cg26384229	chr12:38710491	ALG10B	0.74	10.7	0.55	1.96e-22	Bladder cancer;
CESC	cis	rs7191700	0.583	rs243314	chr16:11385104	G/C	cg00044050	chr16:11439710	C16orf75	0.44	5.23	0.31	3.46e-7	Multiple sclerosis;
CESC	cis	rs13108904	0.967	rs11247986	chr4:1294347	G/A	cg22903657	chr4:1355424	KIAA1530	-0.38	-5.19	-0.3	4.23e-7	Obesity-related traits;
CESC	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg07157834	chr1:205819609	PM20D1	0.81	13.02	0.62	2.83e-30	Menarche (age at onset);
CESC	cis	rs2303759	0.543	rs7255778	chr19:49906608	G/A	cg22590775	chr19:49891494	CCDC155	0.52	6.13	0.35	3.15e-9	Multiple sclerosis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26422674	chr12:10766150	MAGOHB	0.59	7.18	0.4	6.84e-12	Gut microbiome composition (summer);
CESC	cis	rs2120019	0.938	rs2304903	chr15:75315778	A/G	cg09165964	chr15:75287851	SCAMP5	-0.81	-9.93	-0.52	5.63e-20	Blood trace element (Zn levels);
CESC	cis	rs6570726	0.791	rs7765675	chr6:145915077	A/C	cg23711669	chr6:146136114	FBXO30	0.97	14.47	0.66	2.25e-35	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs747782	0.582	rs7949865	chr11:48346202	A/C	cg15704280	chr7:45808275	SEPT13	-0.66	-6.17	-0.35	2.52e-9	Intraocular pressure;
CESC	cis	rs9908102	0.740	rs2286336	chr17:12915941	C/T	cg26162695	chr17:12921313	ELAC2	-0.55	-6.03	-0.35	5.49e-9	Schizophrenia;
CESC	cis	rs60871478	0.787	rs4720928	chr7:808002	T/C	cg05535760	chr7:792225	HEATR2	0.87	10.78	0.55	1.07e-22	Cerebrospinal P-tau181p levels;
CESC	cis	rs7666738	0.830	rs11097600	chr4:98959564	T/G	cg17366294	chr4:99064904	C4orf37	0.58	8.28	0.45	6.25e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs736408	0.609	rs13087772	chr3:52782274	T/G	cg17372223	chr3:52568218	NT5DC2	0.44	6.55	0.37	3e-10	Bipolar disorder;
CESC	cis	rs524023	0.914	rs2277311	chr11:64387932	G/A	cg07220939	chr11:64358617	SLC22A12	-0.36	-5.45	-0.32	1.17e-7	Urate levels in obese individuals;
CESC	cis	rs7084402	0.967	rs7087998	chr10:60271531	A/G	cg07615347	chr10:60278583	BICC1	-0.57	-8.63	-0.47	5.58e-16	Refractive error;
CESC	cis	rs2249625	0.874	rs2496509	chr6:72893667	C/A	cg18830697	chr6:72922368	RIMS1	-0.37	-5.31	-0.31	2.35e-7	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CESC	cis	rs6964587	1.000	rs7802788	chr7:91736874	A/G	cg17063962	chr7:91808500	NA	0.54	7.46	0.42	1.24e-12	Breast cancer;
CESC	cis	rs6912958	0.559	rs183599	chr6:88061024	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.72	10.92	0.56	3.53e-23	Monocyte percentage of white cells;
CESC	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg24642844	chr7:1081250	C7orf50	-0.75	-9.03	-0.49	3.61e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs425277	0.500	rs908744	chr1:2038893	G/A	cg23803603	chr1:2058230	PRKCZ	-0.37	-6.78	-0.38	8.01e-11	Height;
CESC	cis	rs30380	0.587	rs30185	chr5:96125465	G/A	cg16492584	chr5:96139282	ERAP1	-0.47	-6.63	-0.38	1.89e-10	Cerebrospinal fluid biomarker levels;
CESC	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.78	10.75	0.55	1.31e-22	Prudent dietary pattern;
CESC	cis	rs11264213	0.901	rs74879824	chr1:36413117	T/A	cg27506609	chr1:36549197	TEKT2	0.67	5.54	0.32	7.16e-8	Schizophrenia;
CESC	cis	rs7568458	0.684	rs67988001	chr2:85787123	C/T	cg02493740	chr2:85810744	VAMP5	-0.57	-8.37	-0.46	3.29e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CESC	cis	rs9311474	0.508	rs2878628	chr3:52584715	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.51	-7.53	-0.42	8.18e-13	Electroencephalogram traits;
CESC	trans	rs916888	0.821	rs199525	chr17:44847834	T/G	cg27125505	chr17:43679177	LOC644172	0.51	6.75	0.38	9.27e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs7044106	0.708	rs2416760	chr9:123374639	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.72	10.65	0.55	2.8e-22	Hip circumference adjusted for BMI;
CESC	cis	rs8017423	0.647	rs12590712	chr14:90822481	T/C	cg14092571	chr14:90743983	NA	0.44	6.77	0.38	8.12e-11	Mortality in heart failure;
CESC	cis	rs9837602	0.745	rs792834	chr3:99476121	C/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.44	-5.65	-0.33	4.12e-8	Breast cancer;
CESC	cis	rs2276314	1.000	rs2298716	chr18:33552598	C/T	cg19628046	chr18:33552617	C18orf21	0.6	6.79	0.38	7.47e-11	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs713587	0.713	rs11682135	chr2:25205377	G/A	cg01884057	chr2:25150051	NA	-0.37	-6.94	-0.39	2.96e-11	Body mass index in non-asthmatics;
CESC	cis	rs12586317	0.547	rs2273154	chr14:35433187	C/T	cg16230307	chr14:35515116	FAM177A1	0.97	10.42	0.54	1.61e-21	Psoriasis;
CESC	cis	rs9902453	1.000	rs4575590	chr17:28361969	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.62	-7.84	-0.43	1.11e-13	Coffee consumption (cups per day);
CESC	cis	rs7084402	1.000	rs1427202	chr10:60267917	A/T	cg07615347	chr10:60278583	BICC1	-0.6	-9.2	-0.49	1.08e-17	Refractive error;
CESC	cis	rs2479106	0.963	rs7850870	chr9:126509996	C/T	cg16191174	chr9:126692580	DENND1A	0.47	6.44	0.37	5.5e-10	Polycystic ovary syndrome;
CESC	cis	rs11763147	1	rs11763147	chr7:65326821	C/T	cg11987759	chr7:65425863	GUSB	0.48	6.62	0.38	1.97e-10	Corneal structure;
CESC	cis	rs4594175	0.962	rs8008182	chr14:51608357	C/T	cg23942311	chr14:51606299	NA	0.39	5.96	0.34	8.22e-9	Cancer;
CESC	cis	rs2455799	0.573	rs2255248	chr3:15754849	A/G	cg16303742	chr3:15540471	COLQ	0.37	5.8	0.34	1.9e-8	Mean platelet volume;
CESC	cis	rs1799949	1.000	rs34572725	chr17:41428666	G/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.42	5.79	0.33	2.03e-8	Menopause (age at onset);
CESC	trans	rs3087243	0.755	rs231733	chr2:204694465	A/G	cg01841312	chr10:38069945	NA	0.39	6.44	0.37	5.64e-10	Rheumatoid arthritis;Hypothyroidism;Type 1 diabetes;
CESC	cis	rs9611565	0.546	rs34077262	chr22:42061639	A/G	cg06634786	chr22:41940651	POLR3H	0.54	5.67	0.33	3.81e-8	Vitiligo;
CESC	cis	rs10189230	0.967	rs13026659	chr2:222353014	C/T	cg14652038	chr2:222343519	EPHA4	0.36	7.67	0.43	3.21e-13	Urate levels in lean individuals;
CESC	cis	rs9911578	0.935	rs7216698	chr17:57007495	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.38	5.04	0.3	8.69e-7	Intelligence (multi-trait analysis);
CESC	cis	rs7618915	0.547	rs4687636	chr3:52633929	G/A	cg18404041	chr3:52824283	ITIH1	-0.4	-6.71	-0.38	1.19e-10	Bipolar disorder;
CESC	cis	rs116095464	0.510	rs73016876	chr5:244475	T/C	cg10591111	chr5:226296	SDHA	-0.52	-6.31	-0.36	1.17e-9	Breast cancer;
CESC	cis	rs12042107	0.740	rs7548936	chr1:91207757	C/G	cg13456504	chr1:91191583	NA	-0.3	-5.16	-0.3	4.8e-7	Educational attainment;
CESC	cis	rs13191362	1.000	rs34192365	chr6:163012382	T/G	cg06582575	chr6:163149167	PACRG;PARK2	0.82	8.22	0.45	9.12e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs9811920	0.809	rs35422475	chr3:99711545	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.43	-5.67	-0.33	3.72e-8	Axial length;
CESC	cis	rs8177253	0.763	rs8177224	chr3:133474003	C/G	cg12373951	chr3:133503437	NA	-0.36	-5.04	-0.3	8.45e-7	Iron status biomarkers;
CESC	cis	rs561341	0.941	rs7215147	chr17:30266711	G/A	cg23018236	chr17:30244563	NA	-0.41	-5.08	-0.3	7.12e-7	Hip circumference adjusted for BMI;
CESC	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.54	0.37	3.16e-10	Prudent dietary pattern;
CESC	cis	rs2963155	0.518	rs72801090	chr5:142774692	C/T	cg17617527	chr5:142782415	NR3C1	0.84	7.59	0.42	5.45e-13	Breast cancer;
CESC	cis	rs17818399	0.712	rs13008088	chr2:46781580	C/G	cg02822958	chr2:46747628	ATP6V1E2	0.42	5.34	0.31	1.99e-7	Height;
CESC	cis	rs9457247	1.000	rs400176	chr6:167406238	T/C	cg23791538	chr6:167370224	RNASET2	-0.59	-8.54	-0.46	1.09e-15	Crohn's disease;
CESC	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg04234412	chr22:24373322	LOC391322	-0.64	-9.39	-0.5	2.83e-18	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs34779708	0.897	rs9787566	chr10:35279455	T/A	cg04310649	chr10:35416472	CREM	-0.5	-5.97	-0.34	7.61e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs10791323	0.627	rs2723614	chr11:133705871	T/G	cg15485101	chr11:133734466	NA	0.41	6.54	0.37	3.11e-10	Childhood ear infection;
CESC	cis	rs9399135	0.684	rs1135205	chr6:135281795	C/T	cg22676075	chr6:135203613	NA	0.48	6.59	0.38	2.37e-10	Red blood cell count;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	ch.12.2922115F	chr12:133248407	POLE	-0.56	-7.42	-0.41	1.62e-12	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs8031584	0.678	rs8028173	chr15:31155749	A/G	cg14829155	chr15:31115871	NA	-0.76	-10.62	-0.55	3.5e-22	Huntington's disease progression;
CESC	cis	rs6754311	0.773	rs188680	chr2:136630989	A/G	cg07169764	chr2:136633963	MCM6	-0.7	-8.51	-0.46	1.28e-15	Mosquito bite size;
CESC	cis	rs6460942	1.000	rs7796485	chr7:12405676	G/A	cg20607287	chr7:12443886	VWDE	-0.79	-8.72	-0.47	3.1e-16	Coronary artery disease;
CESC	cis	rs270601	0.710	rs4705852	chr5:131602807	A/G	cg18301423	chr5:131593218	PDLIM4	0.38	5.49	0.32	9.57e-8	Acylcarnitine levels;
CESC	cis	rs12142240	0.698	rs72677596	chr1:46833930	C/T	cg00530320	chr1:46809349	NSUN4	0.63	8.16	0.45	1.33e-14	Menopause (age at onset);
CESC	cis	rs7678296	1.000	rs59175692	chr4:37195539	C/T	cg06805348	chr4:37245195	KIAA1239	0.45	5.12	0.3	5.74e-7	3-hydroxypropylmercapturic acid levels in smokers;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14420186	chr9:91926487	CKS2	0.62	7.11	0.4	1.1e-11	Gut microbiome composition (summer);
CESC	cis	rs4713118	0.621	rs9295755	chr6:28033174	C/T	cg08968635	chr6:28129556	ZNF389	-0.39	-5.22	-0.31	3.69e-7	Parkinson's disease;
CESC	cis	rs151234	0.676	rs231970	chr16:28567004	A/G	cg01378222	chr16:28622494	SULT1A1	-0.56	-7.05	-0.4	1.57e-11	Platelet distribution width;
CESC	cis	rs9443645	0.901	rs10943605	chr6:79655477	G/A	cg05283184	chr6:79620031	NA	-0.42	-6.46	-0.37	5.06e-10	Intelligence (multi-trait analysis);
CESC	cis	rs9309473	0.632	rs6706179	chr2:73578577	C/T	cg20560298	chr2:73613845	ALMS1	-0.45	-6.09	-0.35	3.94e-9	Metabolite levels;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg21155778	chr12:95611301	FGD6;VEZT	-0.45	-6.11	-0.35	3.53e-9	Fibrinogen levels;
CESC	cis	rs1941023	0.606	rs7926219	chr11:60180335	C/T	cg08716584	chr11:60157161	MS4A7	-0.43	-6.34	-0.36	1.01e-9	Congenital heart disease (maternal effect);
CESC	cis	rs2710642	0.611	rs6706506	chr2:62861824	T/C	cg17519650	chr2:63277830	OTX1	0.47	5.54	0.32	7.36e-8	LDL cholesterol levels;LDL cholesterol;
CESC	cis	rs6964587	1.000	rs12539231	chr7:91634963	G/A	cg17063962	chr7:91808500	NA	0.58	8.01	0.44	3.65e-14	Breast cancer;
CESC	cis	rs11792861	0.816	rs72607157	chr9:111748001	T/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.52	6.67	0.38	1.46e-10	Menarche (age at onset);
CESC	cis	rs7666738	0.861	rs28829607	chr4:98964325	G/C	cg05340658	chr4:99064831	C4orf37	0.8	12.39	0.61	3.96e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7412746	0.611	rs16827671	chr1:150738759	T/C	cg09365446	chr1:150670422	GOLPH3L	0.41	5.38	0.31	1.67e-7	Melanoma;
CESC	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg05313129	chr8:58192883	C8orf71	-0.48	-5.27	-0.31	2.89e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs9815354	0.638	rs113712591	chr3:42050624	C/T	cg03022575	chr3:42003672	ULK4	0.76	6.71	0.38	1.21e-10	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs17376456	0.877	rs10059630	chr5:93459807	C/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.62	5.44	0.32	1.23e-7	Diabetic retinopathy;
CESC	cis	rs9346455	0.614	rs9294899	chr6:72016302	G/T	cg27238071	chr6:71998145	OGFRL1	0.64	6.17	0.35	2.52e-9	Antipsychotic drug-induced weight gain (time interaction);Antipsychotic drug-induced weight gain;
CESC	cis	rs7666738	0.791	rs1426674	chr4:98924247	C/A	cg03467027	chr4:99064603	C4orf37	0.46	5.59	0.32	5.78e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1005277	0.579	rs2505194	chr10:38393881	C/T	cg25517755	chr10:38738941	LOC399744	-0.47	-6.01	-0.35	6.02e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs660899	0.588	rs37470	chr1:44277948	G/C	cg11704212	chr1:44303111	ST3GAL3	-0.38	-5.07	-0.3	7.46e-7	Hypertension risk in short sleep duration;
CESC	cis	rs9611565	0.512	rs132784	chr22:42052363	G/A	cg17376030	chr22:41985996	PMM1	-0.79	-8.79	-0.48	1.94e-16	Vitiligo;
CESC	cis	rs4481887	1.000	rs10888352	chr1:248451965	G/A	cg00666640	chr1:248458726	OR2T12	0.41	6.72	0.38	1.09e-10	Common traits (Other);
CESC	cis	rs801193	0.591	rs4506088	chr7:66135457	G/A	cg10691866	chr7:65817282	TPST1	0.31	5.32	0.31	2.24e-7	Aortic root size;
CESC	cis	rs1042058	0.565	rs650110	chr10:30753132	A/G	cg25182066	chr10:30743637	MAP3K8	-0.52	-7.26	-0.41	4.3e-12	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CESC	cis	rs4563143	0.675	rs73029049	chr19:29275534	C/A	cg12756686	chr19:29218302	NA	0.58	7.52	0.42	8.38e-13	Methadone dose in opioid dependence;
CESC	cis	rs9902453	1.000	rs62070312	chr17:28438877	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.64	8.09	0.45	2.1e-14	Coffee consumption (cups per day);
CESC	cis	rs2991971	0.967	rs644915	chr1:46007002	T/C	cg05343316	chr1:45956843	TESK2	-0.51	-6.57	-0.37	2.7e-10	High light scatter reticulocyte count;
CESC	cis	rs801193	0.636	rs10233806	chr7:66118248	G/C	cg18876405	chr7:65276391	NA	-0.46	-6.2	-0.36	2.13e-9	Aortic root size;
CESC	cis	rs3741404	0.825	rs60452247	chr11:63981507	G/A	cg18225595	chr11:63971243	STIP1	0.72	9.78	0.52	1.71e-19	Platelet count;
CESC	cis	rs3820068	0.603	rs6668726	chr1:15962614	G/A	cg13390004	chr1:15929781	NA	0.37	5.89	0.34	1.18e-8	Systolic blood pressure;
CESC	cis	rs826838	0.874	rs11183816	chr12:38834656	T/G	cg26384229	chr12:38710491	ALG10B	0.83	14.57	0.67	1.05e-35	Heart rate;
CESC	cis	rs9911578	0.874	rs302865	chr17:56756977	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.16	0.3	4.9e-7	Intelligence (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01057248	chr19:2887520	NA	-0.51	-6.09	-0.35	3.86e-9	Gut microbiome composition (summer);
CESC	cis	rs7044106	0.762	rs1886337	chr9:123443776	G/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.36	5.83	0.34	1.58e-8	Hip circumference adjusted for BMI;
CESC	cis	rs854765	0.964	rs854762	chr17:18009102	G/A	cg09796270	chr17:17721594	SREBF1	-0.4	-5.35	-0.31	1.94e-7	Total body bone mineral density;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg14474966	chr17:77808999	CBX4	0.45	6.51	0.37	3.68e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs2228479	0.850	rs62052212	chr16:89981960	G/A	cg04013166	chr16:89971882	TCF25	0.77	6.5	0.37	4.07e-10	Skin colour saturation;
CESC	cis	rs9457247	0.765	rs9457259	chr6:167444281	C/T	cg07741184	chr6:167504864	NA	0.35	6.32	0.36	1.11e-9	Crohn's disease;
CESC	cis	rs920590	0.758	rs1826420	chr8:19664878	G/T	cg17834443	chr8:19674713	INTS10	0.58	6.73	0.38	1.07e-10	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs6540556	0.723	rs12059226	chr1:209906675	A/G	cg05527609	chr1:210001259	C1orf107	-0.65	-7.38	-0.41	2.1e-12	Red blood cell count;
CESC	cis	rs9311474	0.508	rs6788887	chr3:52605005	T/C	cg17372223	chr3:52568218	NT5DC2	0.4	5.93	0.34	9.47e-9	Electroencephalogram traits;
CESC	cis	rs939574	0.790	rs72955447	chr2:220098287	G/A	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.88	7.4	0.41	1.81e-12	Platelet distribution width;
CESC	cis	rs1448094	0.512	rs7960130	chr12:86243191	T/C	cg02569458	chr12:86230093	RASSF9	0.49	7.22	0.41	5.67e-12	Major depressive disorder;
CESC	cis	rs3749237	0.595	rs3870337	chr3:49557095	G/T	cg02487422	chr3:49467188	NICN1	0.56	8.28	0.45	6.25e-15	Resting heart rate;
CESC	cis	rs3733585	0.699	rs13328050	chr4:9951120	G/T	cg00071950	chr4:10020882	SLC2A9	-0.68	-10.81	-0.55	8.56e-23	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs8072100	0.817	rs12449647	chr17:45548958	C/A	cg25173405	chr17:45401733	C17orf57	-0.47	-6.16	-0.35	2.71e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs7937682	0.889	rs1789359	chr11:111475995	T/A	cg09085632	chr11:111637200	PPP2R1B	-0.95	-14.72	-0.67	3.09e-36	Primary sclerosing cholangitis;
CESC	cis	rs2836974	0.897	rs35386515	chr21:40532047	C/T	cg11644478	chr21:40555479	PSMG1	1.02	16.67	0.72	3.53e-43	Cognitive function;
CESC	cis	rs262150	0.837	rs2657404	chr7:158783155	C/T	cg19418458	chr7:158789849	NA	-0.48	-8.08	-0.44	2.31e-14	Facial morphology (factor 20);
CESC	cis	rs3750965	0.920	rs10896420	chr11:68863047	G/A	cg01403660	chr11:68851641	TPCN2	0.4	5.48	0.32	9.89e-8	Hair color;
CESC	cis	rs72945132	0.882	rs55915603	chr11:70210067	G/T	cg00319359	chr11:70116639	PPFIA1	0.78	7.27	0.41	3.99e-12	Coronary artery disease;
CESC	cis	rs7666738	0.791	rs13127542	chr4:98949159	C/T	cg17366294	chr4:99064904	C4orf37	0.6	8.53	0.46	1.1e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1799949	0.929	rs799906	chr17:41278116	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	7.87	0.44	8.99e-14	Menopause (age at onset);
CESC	cis	rs736408	0.812	rs6778329	chr3:52824610	G/A	cg17372223	chr3:52568218	NT5DC2	0.36	5.11	0.3	6.16e-7	Bipolar disorder;
CESC	cis	rs17253792	0.822	rs17253730	chr14:56157911	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.82	5.73	0.33	2.74e-8	Putamen volume;
CESC	cis	rs796364	0.806	rs1605900	chr2:200870197	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.85	7.68	0.43	3.06e-13	Schizophrenia;
CESC	cis	rs1707322	0.650	rs4660879	chr1:46105401	C/A	cg06784218	chr1:46089804	CCDC17	0.41	7.31	0.41	3.1e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14094460	chr4:43900946	NA	-0.54	-7.39	-0.41	1.92e-12	Gut microbiome composition (summer);
CESC	cis	rs11864453	0.578	rs2072141	chr16:72133211	G/A	cg01557791	chr16:72042693	DHODH	-0.43	-5.66	-0.33	3.85e-8	Fibrinogen levels;
CESC	cis	rs4555082	0.874	rs3000075	chr14:105713219	C/T	cg13114125	chr14:105738426	BRF1	0.76	9.66	0.51	4.03e-19	Mean platelet volume;Platelet distribution width;
CESC	cis	rs4665809	1.000	rs4665299	chr2:26256840	A/C	cg25036284	chr2:26402008	FAM59B	-0.71	-7.95	-0.44	5.27e-14	Gut microbiome composition (summer);
CESC	cis	rs736408	0.546	rs3733046	chr3:52621627	C/T	cg18404041	chr3:52824283	ITIH1	-0.38	-6.52	-0.37	3.62e-10	Bipolar disorder;
CESC	cis	rs9611565	0.694	rs202613	chr22:41821993	C/A	cg03806693	chr22:41940476	POLR3H	1.2	14.5	0.67	1.86e-35	Vitiligo;
CESC	cis	rs1443512	0.812	rs1975472	chr12:54337083	A/G	cg12374095	chr12:54320830	NA	-0.45	-6.24	-0.36	1.69e-9	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
CESC	cis	rs1153858	1.000	rs7402650	chr15:45701895	C/T	cg21132104	chr15:45694354	SPATA5L1	0.86	11.69	0.58	9.6e-26	Homoarginine levels;
CESC	cis	rs1005277	0.529	rs1780125	chr10:38531376	A/G	cg00409905	chr10:38381863	ZNF37A	-0.51	-6.84	-0.39	5.62e-11	Extrinsic epigenetic age acceleration;
CESC	cis	rs12497850	0.931	rs9867373	chr3:48960938	A/T	cg07636037	chr3:49044803	WDR6	1.03	19.55	0.77	2.54e-53	Parkinson's disease;
CESC	cis	rs796364	0.813	rs7565417	chr2:201057491	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.6	6.11	0.35	3.55e-9	Schizophrenia;
CESC	cis	rs4566357	0.930	rs12621916	chr2:227923564	T/C	cg11843606	chr2:227700838	RHBDD1	-0.42	-5.28	-0.31	2.76e-7	Coronary artery disease;
CESC	cis	rs875971	0.862	rs6460302	chr7:65960257	C/G	cg18252515	chr7:66147081	NA	-0.42	-5.42	-0.32	1.35e-7	Aortic root size;
CESC	cis	rs722599	0.599	rs3825708	chr14:75200697	C/T	cg11812906	chr14:75593930	NEK9	0.43	5.19	0.3	4.19e-7	IgG glycosylation;
CESC	cis	rs3813567	0.702	rs7164665	chr15:78953919	T/C	cg24631222	chr15:78858424	CHRNA5	0.48	5.19	0.3	4.27e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
CESC	cis	rs362272	0.524	rs13150241	chr4:3367281	A/G	cg14583973	chr4:3374767	RGS12	0.31	5.49	0.32	9.61e-8	Serum sulfate level;
CESC	cis	rs9303401	0.614	rs68100606	chr17:56500898	G/A	cg25039879	chr17:56429692	SUPT4H1	0.53	5.47	0.32	1.05e-7	Cognitive test performance;
CESC	cis	rs9916302	0.800	rs11869259	chr17:37518141	C/A	cg07936489	chr17:37558343	FBXL20	0.81	11.81	0.59	3.83e-26	Glomerular filtration rate (creatinine);
CESC	cis	rs9926296	0.565	rs8055825	chr16:89832848	C/T	cg03388025	chr16:89894329	SPIRE2	0.43	8.17	0.45	1.27e-14	Vitiligo;
CESC	cis	rs2243480	1.000	rs35432774	chr7:65393019	G/C	cg13147721	chr7:65941812	NA	-0.83	-7.92	-0.44	6.77e-14	Diabetic kidney disease;
CESC	cis	rs1006703	0.544	rs8082265	chr17:3838761	C/T	cg06463185	chr17:3833770	ATP2A3	-0.64	-6.26	-0.36	1.58e-9	Glucose homeostasis traits;
CESC	cis	rs4722166	0.695	rs4722177	chr7:22798531	T/C	cg13104385	chr7:22767384	IL6	0.39	5.69	0.33	3.41e-8	Lung cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09299076	chr16:89795781	ZNF276	-0.52	-6.04	-0.35	5.3300000000000004e-09	Gut microbiome composition (summer);
CESC	cis	rs40363	0.951	rs250632	chr16:3523047	C/T	cg21433313	chr16:3507492	NAT15	0.66	8.34	0.46	4.08e-15	Tuberculosis;
CESC	cis	rs7546094	0.967	rs910697	chr1:113063125	A/G	cg22162597	chr1:113214053	CAPZA1	0.39	6.15	0.35	2.82e-9	Platelet distribution width;
CESC	cis	rs113835537	0.529	rs4930379	chr11:66255674	G/A	cg22134325	chr11:66188745	NPAS4	0.35	5.48	0.32	1.01e-7	Airway imaging phenotypes;
CESC	cis	rs1215050	0.791	rs2123099	chr4:98803456	A/G	cg05340658	chr4:99064831	C4orf37	0.52	6.88	0.39	4.36e-11	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs1707322	0.963	rs11211238	chr1:46449415	G/A	cg05343316	chr1:45956843	TESK2	0.44	5.42	0.32	1.36e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2243480	0.901	rs35823062	chr7:65965821	A/G	cg13147721	chr7:65941812	NA	-0.94	-8.87	-0.48	1.09e-16	Diabetic kidney disease;
CESC	cis	rs7666738	0.830	rs4323111	chr4:98952276	A/G	cg05340658	chr4:99064831	C4orf37	0.78	11.82	0.59	3.43e-26	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02464656	chr6:44214659	HSP90AB1	-0.63	-7.57	-0.42	6.36e-13	Gut microbiome composition (summer);
CESC	trans	rs637571	0.522	rs528736	chr11:65705108	A/G	cg17712092	chr4:129076599	LARP1B	0.75	10.26	0.53	5.18e-21	Eosinophil percentage of white cells;
CESC	trans	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg27125505	chr17:43679177	LOC644172	0.51	6.58	0.37	2.46e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs780096	0.565	rs11681351	chr2:27743423	G/A	cg17158414	chr2:27665306	KRTCAP3	-0.28	-5.11	-0.3	6.26e-7	Total body bone mineral density;
CESC	cis	rs9311474	0.508	rs2878628	chr3:52584715	C/T	cg05564831	chr3:52568323	NT5DC2	-0.47	-7.29	-0.41	3.47e-12	Electroencephalogram traits;
CESC	cis	rs7552404	0.924	rs1251075	chr1:76190569	C/G	cg22875332	chr1:76189707	ACADM	0.71	9.71	0.51	2.96e-19	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs2836974	0.526	rs418359	chr21:40536734	T/C	cg11644478	chr21:40555479	PSMG1	-0.83	-12.81	-0.62	1.5e-29	Cognitive function;
CESC	cis	rs1348850	0.632	rs12616288	chr2:178503813	G/T	cg23306229	chr2:178417860	TTC30B	0.59	7.3	0.41	3.35e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs11785400	0.793	rs10956992	chr8:143736235	A/C	cg10596483	chr8:143751796	JRK	0.42	5.37	0.31	1.69e-7	Schizophrenia;
CESC	cis	rs10479542	0.503	rs12719865	chr5:178993566	C/T	cg14820908	chr5:178986412	RUFY1	0.51	7.76	0.43	1.85e-13	Lung cancer;
CESC	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg05313129	chr8:58192883	C8orf71	-0.48	-5.27	-0.31	2.89e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs9818758	0.556	rs11716614	chr3:49017208	C/G	cg00383909	chr3:49044727	WDR6	0.98	5.88	0.34	1.21e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CESC	cis	rs11098499	0.909	rs6842762	chr4:120398236	A/T	cg09307838	chr4:120376055	NA	0.92	13.12	0.63	1.21e-30	Corneal astigmatism;
CESC	cis	rs7666738	0.830	rs10034330	chr4:99064849	G/A	cg17366294	chr4:99064904	C4orf37	0.62	8.8	0.48	1.82e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs12208915	0.559	rs4706738	chr6:79514153	A/G	cg05283184	chr6:79620031	NA	0.37	5.16	0.3	4.95e-7	Left atrial antero-posterior diameter;
CESC	cis	rs35110281	0.659	rs11702544	chr21:45091861	C/T	cg01579765	chr21:45077557	HSF2BP	-0.54	-9.39	-0.5	2.98e-18	Mean corpuscular volume;
CESC	cis	rs11638352	1.000	rs2412850	chr15:44278161	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.63	-5.6	-0.33	5.48e-8	Lipoprotein phospholipase A2 activity in cardiovascular disease;
CESC	cis	rs9457247	0.602	rs4710175	chr6:167467800	A/G	cg23791538	chr6:167370224	RNASET2	-0.55	-7.27	-0.41	3.96e-12	Crohn's disease;
CESC	cis	rs2836974	0.829	rs8128191	chr21:40527311	A/G	cg17971929	chr21:40555470	PSMG1	1.05	16.66	0.72	4.09e-43	Cognitive function;
CESC	cis	rs9300255	0.739	rs2337934	chr12:123745359	A/G	cg19016782	chr12:123741754	C12orf65	-0.5	-7.24	-0.41	4.92e-12	Neutrophil percentage of white cells;
CESC	cis	rs3820068	0.705	rs72643701	chr1:15866219	G/A	cg17385448	chr1:15911702	AGMAT	0.37	5.91	0.34	1.03e-8	Systolic blood pressure;
CESC	cis	rs514406	0.758	rs532242	chr1:53308665	C/G	cg08859206	chr1:53392774	SCP2	-0.56	-7.34	-0.41	2.69e-12	Monocyte count;
CESC	cis	rs4665809	0.590	rs2303892	chr2:26461733	C/G	cg27170947	chr2:26402098	FAM59B	0.87	9.85	0.52	1.01e-19	Gut microbiome composition (summer);
CESC	cis	rs2046867	0.661	rs7637050	chr3:72910790	A/C	cg25664220	chr3:72788482	NA	-0.35	-5.23	-0.31	3.37e-7	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CESC	cis	rs17431357	1.000	rs73225238	chr12:120967488	G/A	cg25045489	chr12:120971538	RNF10	-0.93	-5.46	-0.32	1.1e-7	Insulin resistance/response;
CESC	cis	rs881375	0.967	rs7034653	chr9:123687372	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.39	5.24	0.31	3.22e-7	Rheumatoid arthritis;
CESC	cis	rs6088590	1.000	rs6119524	chr20:33373813	C/T	cg06115741	chr20:33292138	TP53INP2	0.59	7.31	0.41	3.17e-12	Coronary artery disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg14223017	chr19:2151266	AP3D1	-0.48	-6.83	-0.39	5.68e-11	Fibrinogen levels;
CESC	cis	rs10504229	0.683	rs1495865	chr8:58141160	T/G	cg21724239	chr8:58056113	NA	0.58	5.95	0.34	8.37e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs2243480	1.000	rs1701750	chr7:65467145	T/C	cg18252515	chr7:66147081	NA	-1.13	-10.9	-0.56	4.18e-23	Diabetic kidney disease;
CESC	cis	rs9300255	0.596	rs10734900	chr12:123743445	G/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.32	-5.03	-0.3	9.21e-7	Neutrophil percentage of white cells;
CESC	cis	rs9303401	1.000	rs7218362	chr17:56888299	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.72	9.43	0.5	2.21e-18	Cognitive test performance;
CESC	cis	rs3026101	0.671	rs56113612	chr17:5297761	A/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.43	5.68	0.33	3.57e-8	Body mass index;
CESC	cis	rs7267979	1.000	rs2259928	chr20:25281834	G/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	18.72	0.75	2.09e-50	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs40363	0.680	rs72778116	chr16:3530752	A/G	cg21433313	chr16:3507492	NAT15	0.66	7.1	0.4	1.16e-11	Tuberculosis;
CESC	cis	rs17854409	0.881	rs6011430	chr20:61497014	C/T	cg07645718	chr20:61493192	TCFL5	-0.7	-5.55	-0.32	6.85e-8	Obesity-related traits;
CESC	cis	rs10256972	0.616	rs6463001	chr7:1108272	A/C	cg04025307	chr7:1156635	C7orf50	0.41	6.62	0.38	2.03e-10	Longevity;Endometriosis;
CESC	cis	rs3087591	0.919	rs2018624	chr17:29560777	T/G	cg24425628	chr17:29625626	OMG;NF1	-0.43	-5.39	-0.31	1.56e-7	Hip circumference;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08729914	chr12:64845936	TBK1	0.59	7.08	0.4	1.26e-11	Gut microbiome composition (summer);
CESC	cis	rs709400	1.000	rs57218990	chr14:104128007	T/A	cg12935359	chr14:103987150	CKB	-0.45	-6.09	-0.35	3.94e-9	Body mass index;
CESC	cis	rs7618915	1.000	rs34569561	chr3:52287293	T/C	cg18404041	chr3:52824283	ITIH1	-0.36	-5.68	-0.33	3.45e-8	Bipolar disorder;
CESC	cis	rs17376456	0.877	rs28418572	chr5:93144161	A/C	cg21475434	chr5:93447410	FAM172A	0.8	7.24	0.41	4.96e-12	Diabetic retinopathy;
CESC	cis	rs6866344	0.601	rs4419608	chr5:178097049	C/T	cg03877680	chr5:178157825	ZNF354A	0.56	5.98	0.34	7.36e-9	Neutrophil percentage of white cells;
CESC	cis	rs2708240	1.000	rs2708238	chr7:147575818	G/A	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.35	-5.77	-0.33	2.23e-8	QT interval (drug interaction);
CESC	cis	rs2050392	0.789	rs303438	chr10:30733493	C/T	cg18806716	chr10:30721971	MAP3K8	0.46	6.82	0.39	6.1e-11	Inflammatory bowel disease;
CESC	cis	rs41308713	0.606	rs77984335	chr20:37073286	G/A	cg09132763	chr20:37064059	LOC388796;SNORA71D	0.79	5.15	0.3	5.07e-7	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
CESC	cis	rs6840258	1.000	rs72667750	chr4:87930425	C/T	cg08197287	chr4:87952173	AFF1	-0.41	-5.24	-0.31	3.23e-7	Mean corpuscular volume;Basophil percentage of granulocytes;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg00306426	chr1:70687415	SFRS11	-0.49	-6.05	-0.35	4.9e-9	Ulcerative colitis;
CESC	cis	rs1862618	0.671	rs2591961	chr5:56238597	A/G	cg14703610	chr5:56206110	C5orf35	-0.41	-5.11	-0.3	6.05e-7	Initial pursuit acceleration;
CESC	cis	rs2996428	0.561	rs12134919	chr1:3744641	G/A	cg10555106	chr1:3691387	LOC388588	0.36	5.15	0.3	5.05e-7	Red cell distribution width;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg14851770	chr14:50065970	PPIL5	-0.45	-6.08	-0.35	4.15e-9	Fibrinogen levels;
CESC	cis	rs561341	1.000	rs555629	chr17:30294136	T/C	cg19193384	chr17:30244184	NA	-0.68	-6.43	-0.37	5.9e-10	Hip circumference adjusted for BMI;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24103018	chr19:17420930	DDA1	0.68	8.37	0.46	3.37e-15	Gut microbiome composition (summer);
CESC	cis	rs3008870	1.000	rs2815348	chr1:67472165	G/C	cg02640540	chr1:67518911	SLC35D1	0.51	5.43	0.32	1.25e-7	Lymphocyte percentage of white cells;
CESC	cis	rs2742234	0.541	rs4648313	chr10:43716739	G/A	cg07801480	chr10:43725741	RASGEF1A	-0.4	-5.24	-0.31	3.22e-7	Hirschsprung disease;
CESC	cis	rs6831352	0.879	rs34360292	chr4:100051303	T/C	cg12011299	chr4:100065546	ADH4	-0.59	-6.52	-0.37	3.62e-10	Alcohol dependence;
CESC	cis	rs7953249	0.656	rs2251468	chr12:121405126	A/C	cg02403541	chr12:121454288	C12orf43	0.53	6.93	0.39	3.21e-11	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
CESC	cis	rs7552404	0.656	rs11161792	chr1:76336746	C/T	cg03433033	chr1:76189801	ACADM	0.63	6.2	0.36	2.2e-9	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs4237845	0.837	rs7971877	chr12:58287630	T/G	cg02175503	chr12:58329896	NA	0.56	7.37	0.41	2.17e-12	Intelligence (multi-trait analysis);
CESC	cis	rs9457247	1.000	rs439237	chr6:167391392	A/G	cg07741184	chr6:167504864	NA	0.31	5.53	0.32	7.87e-8	Crohn's disease;
CESC	cis	rs3741151	1.000	rs111882289	chr11:73053714	T/C	cg17517138	chr11:73019481	ARHGEF17	1.03	7.15	0.4	8.41e-12	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs763014	0.898	rs8060921	chr16:635988	C/A	cg09781414	chr16:715207	WDR90	-0.33	-5.04	-0.3	8.57e-7	Height;
CESC	cis	rs7923609	0.846	rs7075901	chr10:65280994	C/A	cg01631684	chr10:65280961	REEP3	-0.44	-5.47	-0.32	1.05e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs10791323	0.572	rs1114367	chr11:133737304	G/T	cg15485101	chr11:133734466	NA	0.36	6.08	0.35	4.13e-9	Childhood ear infection;
CESC	cis	rs12586317	0.553	rs3809448	chr14:35515096	C/T	cg16230307	chr14:35515116	FAM177A1	1.13	11.81	0.59	3.79e-26	Psoriasis;
CESC	cis	rs2367563	0.964	rs7980442	chr12:96056774	T/C	cg19013339	chr12:96052514	NTN4	0.37	5.35	0.31	1.92e-7	Allergic dermatitis (nickel);
CESC	cis	rs9910055	0.659	rs7214540	chr17:42256604	A/G	cg13607699	chr17:42295918	UBTF	0.56	7.08	0.4	1.31e-11	Total body bone mineral density;
CESC	cis	rs6942756	0.774	rs6946288	chr7:129004277	A/G	cg02491457	chr7:128862824	NA	-0.54	-7.47	-0.42	1.15e-12	White matter hyperintensity burden;
CESC	cis	rs3820928	0.874	rs4675132	chr2:227841792	A/C	cg11843606	chr2:227700838	RHBDD1	-0.5	-6.48	-0.37	4.5e-10	Pulmonary function;
CESC	trans	rs9322193	0.962	rs2342764	chr6:150156204	G/A	cg26879899	chr11:78413596	ODZ4	-0.43	-6.05	-0.35	4.79e-9	Lung cancer;
CESC	cis	rs6484504	0.576	rs208066	chr11:31156206	C/G	cg14844989	chr11:31128820	NA	-0.42	-5.49	-0.32	9.55e-8	Red blood cell count;
CESC	cis	rs9788333	0.762	rs4441120	chr13:21886863	T/A	cg25811766	chr13:21894605	NA	0.78	11.17	0.57	5.26e-24	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs76878669	0.561	rs1784029	chr11:66099987	C/T	cg18002602	chr11:66138449	SLC29A2	0.4	6.69	0.38	1.35e-10	Educational attainment (years of education);
CESC	cis	rs951366	0.903	rs708723	chr1:205739266	C/T	cg17178900	chr1:205818956	PM20D1	0.54	8.02	0.44	3.47e-14	Menarche (age at onset);
CESC	cis	rs6088590	0.931	rs12625149	chr20:33425812	A/C	cg08999081	chr20:33150536	PIGU	-0.55	-8.29	-0.45	5.91e-15	Coronary artery disease;
CESC	cis	rs6942756	1.000	rs2141075	chr7:128877305	C/T	cg02491457	chr7:128862824	NA	0.7	10.1	0.53	1.63e-20	White matter hyperintensity burden;
CESC	cis	rs7772486	0.875	rs6913797	chr6:146413758	A/G	cg23711669	chr6:146136114	FBXO30	0.78	11.68	0.58	1.09e-25	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs11088226	0.692	rs2833863	chr21:33886986	A/G	cg09050820	chr6:167586206	TCP10L2	0.52	6.51	0.37	3.78e-10	Gastritis;
CESC	cis	rs10504229	0.679	rs11783965	chr8:58130510	T/G	cg02725872	chr8:58115012	NA	-0.45	-7.05	-0.4	1.52e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs1552244	1.000	rs13319597	chr3:10126312	A/C	cg00149659	chr3:10157352	C3orf10	-0.68	-8.53	-0.46	1.15e-15	Alzheimer's disease;
CESC	cis	rs1395	0.710	rs1992291	chr2:27504312	A/G	cg22903471	chr2:27725779	GCKR	-0.44	-5.51	-0.32	8.64e-8	Blood metabolite levels;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg24158916	chr21:33662961	MRAP	0.41	6.07	0.35	4.49e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs10089	0.904	rs3087889	chr5:127524944	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.72	9.47	0.5	1.63e-18	Ileal carcinoids;
CESC	cis	rs7584330	0.628	rs73098849	chr2:238389739	G/A	cg14458575	chr2:238380390	NA	0.62	5.56	0.32	6.65e-8	Prostate cancer;
CESC	cis	rs977987	0.788	rs7184525	chr16:75437186	A/G	cg03315344	chr16:75512273	CHST6	0.41	5.86	0.34	1.35e-8	Dupuytren's disease;
CESC	cis	rs7927771	1.000	rs12421210	chr11:47779586	C/T	cg20307385	chr11:47447363	PSMC3	-0.51	-6.24	-0.36	1.74e-9	Subjective well-being;
CESC	cis	rs3741151	0.773	rs17310374	chr11:73274874	T/C	cg17517138	chr11:73019481	ARHGEF17	1.03	7.57	0.42	6.07e-13	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs7412746	0.503	rs72704639	chr1:150798335	A/C	cg04414720	chr1:150670196	GOLPH3L	0.48	6.55	0.37	2.97e-10	Melanoma;
CESC	cis	rs10791097	0.694	rs2236711	chr11:130739284	G/A	cg12179176	chr11:130786555	SNX19	0.65	10.06	0.53	2.26e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs7945705	0.747	rs2568045	chr11:9004060	T/C	cg12365402	chr11:9010492	NRIP3	-0.39	-6.55	-0.37	2.93e-10	Hemoglobin concentration;
CESC	cis	rs6912958	0.559	rs369674	chr6:88043402	C/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.74	-11.62	-0.58	1.69e-25	Monocyte percentage of white cells;
CESC	cis	rs17376456	0.877	rs10059630	chr5:93459807	C/A	cg25358565	chr5:93447407	FAM172A	1.15	11.8	0.59	4.11e-26	Diabetic retinopathy;
CESC	cis	rs727505	1.000	rs10228201	chr7:124449895	A/G	cg23710748	chr7:124431027	NA	-0.44	-6.83	-0.39	5.96e-11	Lewy body disease;
CESC	cis	rs6570726	0.791	rs9399558	chr6:145911730	T/C	cg23711669	chr6:146136114	FBXO30	0.97	14.47	0.66	2.25e-35	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs11690935	0.549	rs62183819	chr2:172904520	G/T	cg13550731	chr2:172543902	DYNC1I2	0.47	6.11	0.35	3.64e-9	Schizophrenia;
CESC	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg22105103	chr4:187893119	NA	0.5	7.43	0.42	1.48e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs896854	0.653	rs13266313	chr8:95975302	C/T	cg23172400	chr8:95962367	TP53INP1	-0.45	-9.25	-0.49	8.02e-18	Type 2 diabetes;
CESC	cis	rs2180341	1.000	rs6569477	chr6:127589302	T/A	cg27446573	chr6:127587934	RNF146	1.07	15.89	0.7	2.11e-40	Breast cancer;
CESC	cis	rs10504229	0.953	rs114806125	chr8:58182416	C/T	cg05313129	chr8:58192883	C8orf71	-0.46	-5.71	-0.33	3.1e-8	Developmental language disorder (linguistic errors);
CESC	trans	rs9307551	0.779	rs13124357	chr4:80512302	G/A	cg02747103	chr19:603718	HCN2	-0.41	-6.15	-0.35	2.79e-9	Refractive error;
CESC	cis	rs514406	0.679	rs541852	chr1:53256834	A/G	cg08859206	chr1:53392774	SCP2	0.71	11.12	0.56	7.71e-24	Monocyte count;
CESC	cis	rs3768617	0.811	rs12144261	chr1:183014148	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.65	8.79	0.48	1.91e-16	Fuchs's corneal dystrophy;
CESC	cis	rs698833	0.819	rs698772	chr2:44580634	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.47	5.87	0.34	1.3e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs9457247	0.967	rs2149083	chr6:167370971	G/C	cg25258033	chr6:167368657	RNASET2	-0.41	-6.12	-0.35	3.35e-9	Crohn's disease;
CESC	trans	rs864643	0.773	rs11129837	chr3:39589963	A/G	cg15637191	chr17:38020667	IKZF3	0.46	6.41	0.37	6.61e-10	Attention deficit hyperactivity disorder;
CESC	trans	rs9951602	0.512	rs4799249	chr18:76654370	A/G	cg02800362	chr5:177631904	HNRNPAB	0.66	8.63	0.47	5.9e-16	Obesity-related traits;
CESC	cis	rs13191362	0.938	rs13213746	chr6:163167777	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.68	7.21	0.4	5.89e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs875971	0.508	rs6947808	chr7:66045082	A/G	cg06456125	chr7:65229604	NA	-0.39	-5.37	-0.31	1.75e-7	Aortic root size;
CESC	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.51	-7.02	-0.4	1.83e-11	Lymphocyte counts;
CESC	cis	rs12971120	1.000	rs734559	chr18:72179579	G/A	cg25817165	chr18:72167213	CNDP2	-0.63	-7.96	-0.44	4.95e-14	Refractive error;
CESC	cis	rs9300255	0.602	rs1790116	chr12:123618544	G/T	cg05973401	chr12:123451056	ABCB9	0.51	5.89	0.34	1.15e-8	Neutrophil percentage of white cells;
CESC	cis	rs9399135	0.967	rs13218642	chr6:135309940	A/G	cg22676075	chr6:135203613	NA	0.52	7.22	0.41	5.65e-12	Red blood cell count;
CESC	cis	rs1395	0.778	rs6709602	chr2:27405497	C/T	cg22903471	chr2:27725779	GCKR	-0.42	-5.21	-0.3	3.77e-7	Blood metabolite levels;
CESC	cis	rs798554	0.757	rs1182177	chr7:2874540	C/T	cg04166393	chr7:2884313	GNA12	0.58	7.31	0.41	3.2e-12	Height;
CESC	cis	rs761746	0.739	rs5753690	chr22:31950005	C/T	cg25791279	chr22:32026902	PISD	0.64	7.11	0.4	1.1e-11	Intelligence;
CESC	cis	rs4727963	0.846	rs4316096	chr7:122712475	C/A	cg03640110	chr7:122635026	TAS2R16	-0.37	-5.79	-0.34	1.96e-8	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
CESC	cis	rs2836974	0.932	rs35571600	chr21:40590624	A/C	cg11644478	chr21:40555479	PSMG1	1.03	16.42	0.71	2.79e-42	Cognitive function;
CESC	cis	rs2262909	0.962	rs390730	chr19:22233509	C/A	cg11619707	chr19:22235551	ZNF257	-0.32	-5.13	-0.3	5.65e-7	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
CESC	cis	rs2996428	0.667	rs11578581	chr1:3770642	G/A	cg13057898	chr1:3703894	LRRC47	0.44	6.05	0.35	4.92e-9	Red cell distribution width;
CESC	cis	rs4253772	0.550	rs6007819	chr22:46704916	C/G	cg24881330	chr22:46731750	TRMU	0.84	7.55	0.42	7.21e-13	LDL cholesterol;Cholesterol, total;
CESC	cis	rs2243480	0.803	rs35268390	chr7:65416536	C/G	cg12463550	chr7:65579703	CRCP	0.69	5.72	0.33	2.85e-8	Diabetic kidney disease;
CESC	cis	rs1595825	0.891	rs7583917	chr2:198576950	A/G	cg00982548	chr2:198649783	BOLL	-0.48	-5.14	-0.3	5.46e-7	Ulcerative colitis;
CESC	trans	rs4716602	0.596	rs12386682	chr7:156158265	C/T	cg07175507	chr18:77160758	NFATC1	-0.45	-6.14	-0.35	3e-9	Anti-saccade response;
CESC	cis	rs2732480	0.577	rs2634684	chr12:48730875	C/T	cg24011408	chr12:48396354	COL2A1	-0.39	-5.21	-0.3	3.83e-7	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg19752117	chr17:4850710	PFN1	-0.41	-6.07	-0.35	4.31e-9	Gambling;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16249355	chr17:76310516	NA	0.58	6.93	0.39	3.29e-11	Gut microbiome composition (summer);
CESC	cis	rs11155671	0.530	rs3823021	chr6:150210999	G/C	cg09699651	chr6:150184138	LRP11	0.55	7.7	0.43	2.78e-13	Testicular germ cell tumor;
CESC	cis	rs76878669	0.561	rs2236679	chr11:66108894	G/C	cg18002602	chr11:66138449	SLC29A2	-0.41	-6.86	-0.39	4.86e-11	Educational attainment (years of education);
CESC	cis	rs7659604	0.605	rs67772833	chr4:122723106	G/A	cg06713675	chr4:122721982	EXOSC9	-0.42	-6.08	-0.35	4.24e-9	Type 2 diabetes;
CESC	cis	rs1799949	1.000	rs4534897	chr17:41431808	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.42	5.79	0.33	2.03e-8	Menopause (age at onset);
CESC	trans	rs9388451	0.587	rs1739385	chr6:126099939	G/A	cg05039488	chr6:79577232	IRAK1BP1	-0.6	-8.11	-0.45	1.85e-14	Brugada syndrome;
CESC	cis	rs2230307	0.536	rs473759	chr1:100557282	C/G	cg24955406	chr1:100503596	HIAT1	0.53	5.41	0.32	1.38e-7	Carotid intima media thickness;
CESC	cis	rs9303280	0.806	rs12709365	chr17:38027400	A/G	cg19468946	chr17:37922297	IKZF3	-0.41	-5.45	-0.32	1.16e-7	Self-reported allergy;
CESC	cis	rs12701220	0.553	rs9639882	chr7:1133731	G/A	cg26769984	chr7:1090371	C7orf50	0.62	6.91	0.39	3.64e-11	Bronchopulmonary dysplasia;
CESC	cis	rs5750830	0.649	rs4821894	chr22:39809820	G/C	cg01416388	chr22:39784598	NA	-0.58	-7.12	-0.4	9.99e-12	Intelligence (multi-trait analysis);
CESC	cis	rs2832191	0.765	rs2832162	chr21:30461808	G/A	cg24692254	chr21:30365293	RNF160	0.83	13.0	0.62	3.29e-30	Dental caries;
CESC	cis	rs2294693	0.947	rs9369254	chr6:40989408	T/C	cg14769373	chr6:40998127	UNC5CL	-0.48	-6.67	-0.38	1.52e-10	Gastric cancer;Non-cardia gastric cancer;
CESC	cis	rs11750568	1.000	rs6601013	chr5:178507927	G/A	cg10208897	chr5:178548229	ADAMTS2	0.38	5.07	0.3	7.58e-7	Height;
CESC	cis	rs9399401	0.667	rs11155242	chr6:142691549	A/C	cg03128060	chr6:142623767	GPR126	0.37	6.51	0.37	3.66e-10	Chronic obstructive pulmonary disease;
CESC	cis	rs13118159	0.550	rs4974614	chr4:1373489	A/G	cg02018176	chr4:1364513	KIAA1530	0.61	7.81	0.43	1.35e-13	Longevity;
CESC	cis	rs853679	0.517	rs1340004	chr6:28103691	C/T	cg23281280	chr6:28129359	ZNF389	0.48	5.91	0.34	1.02e-8	Depression;
CESC	cis	rs4253772	0.530	rs9615955	chr22:46743931	A/G	cg10541313	chr22:46663664	TTC38	0.73	5.12	0.3	6.01e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs4665809	0.590	rs35656275	chr2:26494695	G/C	cg27170947	chr2:26402098	FAM59B	0.83	9.39	0.5	2.98e-18	Gut microbiome composition (summer);
CESC	cis	rs6582630	0.519	rs4294627	chr12:38293982	C/T	cg13010199	chr12:38710504	ALG10B	0.45	5.65	0.33	4.06e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs3820928	0.874	rs2229813	chr2:227892720	C/T	cg11843606	chr2:227700838	RHBDD1	-0.48	-6.46	-0.37	5.02e-10	Pulmonary function;
CESC	cis	rs13102973	1.000	rs11722746	chr4:135850567	A/T	cg14419869	chr4:135874104	NA	0.33	5.15	0.3	5.11e-7	Subjective well-being;
CESC	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg22520471	chr17:61851767	DDX42;CCDC47	-0.89	-13.83	-0.65	4.21e-33	Prudent dietary pattern;
CESC	cis	rs950776	0.518	rs2292117	chr15:78834689	C/T	cg06917634	chr15:78832804	PSMA4	0.77	11.63	0.58	1.53e-25	Sudden cardiac arrest;
CESC	cis	rs4642101	0.597	rs9839769	chr3:12821405	C/T	cg05775895	chr3:12838266	CAND2	0.41	6.3	0.36	1.2e-9	QRS complex (12-leadsum);
CESC	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg26516362	chr5:178986906	RUFY1	-0.47	-7.52	-0.42	8.25e-13	Lung cancer;
CESC	trans	rs11039798	0.764	rs7294013	chr11:48762416	G/A	cg15704280	chr7:45808275	SEPT13	0.7	6.42	0.37	6.38e-10	Axial length;
CESC	cis	rs4892230	1	rs4892230	chr18:72155572	G/A	cg26446133	chr18:72167187	CNDP2	-0.57	-7.77	-0.43	1.77e-13	Mononucleosis;
CESC	cis	rs4975709	0.610	rs1531994	chr5:1859297	T/C	cg11168104	chr5:1857477	NA	-0.35	-5.1	-0.3	6.37e-7	Cardiovascular disease risk factors;
CESC	cis	rs17376456	0.825	rs13156202	chr5:93157721	C/T	cg25358565	chr5:93447407	FAM172A	-1.09	-10.74	-0.55	1.38e-22	Diabetic retinopathy;
CESC	trans	rs3008706	0.920	rs2987043	chr9:16002831	G/T	cg09705784	chr17:76565232	DNAH17	0.56	6.01	0.35	6.16e-9	Bilirubin levels;
CESC	cis	rs17253792	0.822	rs8013714	chr14:56172286	T/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.69	5.94	0.34	8.99e-9	Putamen volume;
CESC	cis	rs4595586	0.811	rs6580849	chr12:39303639	C/A	cg26384229	chr12:38710491	ALG10B	-0.4	-5.72	-0.33	2.94e-8	Morning vs. evening chronotype;
CESC	cis	rs2204008	0.837	rs11612125	chr12:38213212	C/T	cg13010199	chr12:38710504	ALG10B	0.54	6.69	0.38	1.28e-10	Bladder cancer;
CESC	cis	rs10911232	0.507	rs11582514	chr1:182992161	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.84	13.23	0.63	5.2e-31	Hypertriglyceridemia;
CESC	cis	rs4819052	0.851	rs8131143	chr21:46671646	C/G	cg11663144	chr21:46675770	NA	0.62	9.8	0.52	1.48e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs6089829	0.962	rs6122350	chr20:61664617	A/G	cg23505145	chr19:12996616	KLF1	0.52	6.74	0.38	1e-10	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs1256061	0.603	rs928554	chr14:64694195	C/T	cg21174375	chr14:64681225	SYNE2	0.49	6.51	0.37	3.74e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs713587	0.719	rs58048722	chr2:25187825	C/T	cg01884057	chr2:25150051	NA	-0.39	-7.31	-0.41	3.2e-12	Body mass index in non-asthmatics;
CESC	cis	rs400736	0.671	rs863171	chr1:7992615	A/G	cg25007680	chr1:8021821	PARK7	0.56	8.09	0.44	2.22e-14	Response to antidepressants and depression;
CESC	cis	rs9322193	0.923	rs62441279	chr6:150042330	G/A	cg07701084	chr6:150067640	NUP43	0.48	6.69	0.38	1.35e-10	Lung cancer;
CESC	cis	rs9611565	0.649	rs139553	chr22:42187199	A/G	cg06481639	chr22:41940642	POLR3H	0.48	5.56	0.32	6.43e-8	Vitiligo;
CESC	cis	rs7617480	0.648	rs6801211	chr3:48774420	C/G	cg06212747	chr3:49208901	KLHDC8B	0.48	5.91	0.34	1.05e-8	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CESC	cis	rs6582630	0.502	rs11504451	chr12:38425294	G/A	cg13010199	chr12:38710504	ALG10B	0.45	5.76	0.33	2.38e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs2242073	0.660	rs11679743	chr2:209004632	C/T	cg10392614	chr2:208977121	NA	-0.37	-5.04	-0.3	8.76e-7	Attention deficit hyperactivity disorder;
CESC	cis	rs10771431	0.597	rs10843142	chr12:9357502	A/G	cg08997352	chr12:9597637	DDX12	-0.73	-9.2	-0.49	1.08e-17	Breast size;
CESC	cis	rs863345	0.604	rs1342950	chr1:158463723	G/A	cg12129480	chr1:158549410	OR10X1	-0.35	-6.97	-0.39	2.46e-11	Pneumococcal bacteremia;
CESC	cis	rs8062405	0.755	rs4787455	chr16:28589455	G/A	cg07382826	chr16:28625726	SULT1A1	0.4	6.58	0.37	2.54e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg22967283	chr7:4815538	KIAA0415	-0.48	-6.5	-0.37	4.01e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs3741404	0.609	rs641430	chr11:63869531	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.71	-9.96	-0.52	4.58e-20	Platelet count;
CESC	cis	rs7666738	0.830	rs13138063	chr4:99050438	A/C	cg03467027	chr4:99064603	C4orf37	0.47	5.89	0.34	1.2e-8	Colonoscopy-negative controls vs population controls;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg21058987	chr14:50778937	L2HGDH;ATP5S	-0.39	-6.04	-0.35	5.12e-9	Gambling;
CESC	cis	rs875971	0.862	rs6955837	chr7:66043142	C/T	cg19163074	chr7:65112434	INTS4L2	0.42	5.25	0.31	3.16e-7	Aortic root size;
CESC	cis	rs72781680	0.800	rs72780112	chr2:23991182	C/T	cg08917208	chr2:24149416	ATAD2B	0.95	8.71	0.47	3.45e-16	Lymphocyte counts;
CESC	cis	rs763014	0.898	rs1045277	chr16:633125	T/C	cg00908189	chr16:619842	PIGQ	0.67	9.34	0.5	4.24e-18	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02263426	chr18:14378524	NA	-0.57	-6.58	-0.37	2.46e-10	Gut microbiome composition (summer);
CESC	cis	rs7772486	0.686	rs4895684	chr6:146114023	A/C	cg23711669	chr6:146136114	FBXO30	-0.87	-12.9	-0.62	7.1e-30	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4665809	0.531	rs3892649	chr2:26457267	T/G	cg26119090	chr2:26468346	HADHA;HADHB	1.1	12.71	0.62	3.31e-29	Gut microbiome composition (summer);
CESC	cis	rs12142240	0.698	rs67276232	chr1:46825484	T/G	cg10495392	chr1:46806563	NSUN4	0.59	6.38	0.36	7.87e-10	Menopause (age at onset);
CESC	cis	rs72781680	0.660	rs72780104	chr2:23983715	A/G	cg20701182	chr2:24300061	SF3B14	0.63	5.54	0.32	7.13e-8	Lymphocyte counts;
CESC	cis	rs2295499	0.674	rs34626871	chr4:2637560	C/T	cg27239842	chr4:2403781	ZFYVE28	-0.33	-5.39	-0.31	1.56e-7	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg07314337	chr2:153574424	ARL6IP6;PRPF40A	-0.47	-6.29	-0.36	1.28e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs7116495	0.609	rs12275171	chr11:71835373	C/T	cg10381502	chr11:71823885	C11orf51	1.06	6.77	0.38	8.27e-11	Severe influenza A (H1N1) infection;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg04921776	chr17:59564657	NA	0.48	6.76	0.38	8.69e-11	Thyroid stimulating hormone;
CESC	cis	rs881375	0.678	rs10818488	chr9:123705087	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.41	5.9	0.34	1.11e-8	Rheumatoid arthritis;
CESC	cis	rs6912958	0.712	rs6930600	chr6:88349787	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.32	-5.24	-0.31	3.32e-7	Monocyte percentage of white cells;
CESC	cis	rs782590	0.902	rs3762513	chr2:55762957	C/T	cg18811423	chr2:55921094	PNPT1	0.79	12.54	0.61	1.21e-28	Metabolic syndrome;
CESC	cis	rs35110281	0.837	rs2838336	chr21:45071741	A/G	cg01579765	chr21:45077557	HSF2BP	0.57	9.79	0.52	1.58e-19	Mean corpuscular volume;
CESC	cis	rs7618915	0.501	rs11130308	chr3:52639257	G/C	cg17372223	chr3:52568218	NT5DC2	0.42	6.42	0.37	6.33e-10	Bipolar disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12720424	chr1:94713229	NA	-0.64	-7.73	-0.43	2.24e-13	Gut microbiome composition (summer);
CESC	trans	rs629535	0.590	rs62513427	chr8:70138891	A/T	cg21567404	chr3:27674614	NA	-0.83	-9.14	-0.49	1.69e-17	Dupuytren's disease;
CESC	cis	rs3015497	0.653	rs2356455	chr14:51093142	G/A	cg09863266	chr14:51125203	SAV1	-0.33	-5.14	-0.3	5.35e-7	Mean platelet volume;
CESC	cis	rs36051895	0.659	rs62543863	chr9:5085417	C/T	cg02405213	chr9:5042618	JAK2	-0.53	-6.43	-0.37	6.08e-10	Pediatric autoimmune diseases;
CESC	cis	rs8072100	0.738	rs9915222	chr17:45448615	G/T	cg25173405	chr17:45401733	C17orf57	-0.42	-5.27	-0.31	2.8e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs3106136	0.967	rs3106135	chr4:95138308	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.46	-7.01	-0.4	1.94e-11	Capecitabine sensitivity;
CESC	trans	rs1814175	0.817	rs12287396	chr11:49819798	G/C	cg15704280	chr7:45808275	SEPT13	-1.02	-20.13	-0.78	2.46e-55	Height;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg18153499	chr19:47142459	NA	-0.45	-6.39	-0.37	7.43e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs875971	0.825	rs4587224	chr7:65736182	G/A	cg10691866	chr7:65817282	TPST1	0.31	5.37	0.31	1.75e-7	Aortic root size;
CESC	cis	rs514406	0.929	rs485631	chr1:53330245	A/G	cg08859206	chr1:53392774	SCP2	-0.57	-7.34	-0.41	2.62e-12	Monocyte count;
CESC	cis	rs672059	1.000	rs652753	chr1:183156569	A/T	ch.1.3577855R	chr1:183094577	LAMC1	0.54	6.99	0.39	2.28e-11	Hypertriglyceridemia;
CESC	cis	rs3768617	0.510	rs2027078	chr1:183073478	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.83	13.29	0.63	3.25e-31	Fuchs's corneal dystrophy;
CESC	cis	rs875971	0.545	rs17138149	chr7:65693180	A/G	cg18876405	chr7:65276391	NA	0.44	5.28	0.31	2.72e-7	Aortic root size;
CESC	cis	rs875971	1.000	rs4718307	chr7:65610988	A/G	cg10691866	chr7:65817282	TPST1	0.33	5.52	0.32	8.27e-8	Aortic root size;
CESC	trans	rs853679	0.607	rs13197574	chr6:28060239	T/C	cg06606381	chr12:133084897	FBRSL1	-1.08	-7.66	-0.43	3.42e-13	Depression;
CESC	cis	rs2075371	1.000	rs2544221	chr7:133993014	G/C	cg20476274	chr7:133979776	SLC35B4	0.64	9.16	0.49	1.44e-17	Mean platelet volume;
CESC	cis	rs56399783	0.901	rs17300022	chr7:2808517	C/T	cg19731401	chr7:2775893	GNA12	-0.64	-5.63	-0.33	4.61e-8	Childhood ear infection;
CESC	cis	rs7542091	0.813	rs2049999	chr1:210031331	A/G	cg21951975	chr1:209979733	IRF6	0.45	7.63	0.42	4.36e-13	Monobrow;
CESC	cis	rs4523957	0.928	rs216209	chr17:2195130	A/G	cg16513277	chr17:2031491	SMG6	0.56	7.52	0.42	8.5e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21919602	chr1:242011447	EXO1	0.61	7.15	0.4	8.45e-12	Gut microbiome composition (summer);
CESC	cis	rs1775715	0.737	rs2799018	chr10:32202069	C/T	cg18675610	chr10:32216311	ARHGAP12	0.35	5.46	0.32	1.08e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs11792861	0.816	rs11788336	chr9:111688387	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.51	6.66	0.38	1.56e-10	Menarche (age at onset);
CESC	cis	rs6061231	0.583	rs2427313	chr20:60970675	G/A	cg22633769	chr20:60982531	CABLES2	0.65	8.0	0.44	3.78e-14	Colorectal cancer;
CESC	cis	rs314370	1.000	rs314370	chr7:100453208	T/C	cg10426581	chr7:100472382	SRRT	0.82	7.99	0.44	4.27e-14	Resting heart rate;
CESC	cis	rs7666738	0.606	rs6852813	chr4:99084671	G/A	cg24818145	chr4:99064322	C4orf37	0.39	5.13	0.3	5.73e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1799949	1.000	rs11659028	chr17:41195025	T/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.39	5.05	0.3	8.17e-7	Menopause (age at onset);
CESC	cis	rs67478160	0.619	rs11628481	chr14:104241499	C/T	cg08213375	chr14:104286397	PPP1R13B	0.55	11.02	0.56	1.72e-23	Schizophrenia;
CESC	cis	rs514406	0.792	rs481440	chr1:53344976	C/T	cg08736216	chr1:53307985	ZYG11A	-0.36	-6.33	-0.36	1.02e-9	Monocyte count;
CESC	trans	rs2018683	0.803	rs12700920	chr7:28984924	A/G	cg19402173	chr7:128379420	CALU	-0.59	-7.71	-0.43	2.54e-13	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CESC	cis	rs611744	0.625	rs11779824	chr8:109278689	G/A	cg21045802	chr8:109455806	TTC35	0.49	6.17	0.35	2.48e-9	Dupuytren's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02430562	chr19:4831721	TICAM1	0.56	6.27	0.36	1.46e-9	Gut microbiome composition (summer);
CESC	cis	rs9486719	1.000	rs6923212	chr6:97061940	A/G	cg06623918	chr6:96969491	KIAA0776	-0.8	-8.3	-0.45	5.48e-15	Migraine;Coronary artery disease;
CESC	cis	rs17818399	0.547	rs62134736	chr2:46766446	G/A	cg06386533	chr2:46925753	SOCS5	0.49	5.13	0.3	5.63e-7	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01772563	chr7:95064399	PON2	0.67	8.14	0.45	1.57e-14	Gut microbiome composition (summer);
CESC	cis	rs6547741	0.844	rs55826602	chr2:27863452	A/G	cg27432699	chr2:27873401	GPN1	-0.59	-8.65	-0.47	4.89e-16	Oral cavity cancer;
CESC	cis	rs10504073	0.647	rs4873312	chr8:49991145	A/G	cg00325661	chr8:49890786	NA	0.55	8.05	0.44	2.78e-14	Blood metabolite ratios;
CESC	trans	rs1814175	0.615	rs11040654	chr11:49939485	T/G	cg11707556	chr5:10655725	ANKRD33B	-0.43	-6.36	-0.36	8.98e-10	Height;
CESC	cis	rs1799949	1.000	rs8176296	chr17:41203591	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.64	8.65	0.47	4.88e-16	Menopause (age at onset);
CESC	cis	rs77697190	1.000	rs78284524	chr14:103844854	G/A	cg09975044	chr14:104007538	NA	-0.86	-5.42	-0.32	1.32e-7	Mean corpuscular hemoglobin;
CESC	cis	rs1552244	0.935	rs35586456	chr3:10116938	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	11.8	0.59	4.3e-26	Alzheimer's disease;
CESC	cis	rs11122272	0.735	rs2808602	chr1:231537303	A/G	cg06096015	chr1:231504339	EGLN1	0.42	6.07	0.35	4.33e-9	Hemoglobin concentration;
CESC	cis	rs8016982	0.651	rs1885601	chr14:81641210	C/T	cg01989461	chr14:81687754	GTF2A1	0.74	11.25	0.57	3e-24	Schizophrenia;
CESC	cis	rs7809799	1.000	rs117557270	chr7:98780753	C/T	cg05967295	chr7:98741636	SMURF1	0.89	5.57	0.32	6.3e-8	Ulcerative colitis;
CESC	cis	rs6598163	0.517	rs11246827	chr12:132296423	G/A	cg07389463	chr12:132296394	NA	0.43	6.18	0.35	2.46e-9	Migraine;
CESC	cis	rs78648104	0.541	rs56987137	chr6:50879555	C/T	cg11790335	chr6:50679857	TFAP2D	0.55	5.37	0.31	1.72e-7	Systolic blood pressure;
CESC	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg06873352	chr17:61820015	STRADA	0.73	12.96	0.62	4.39e-30	Prudent dietary pattern;
CESC	trans	rs877282	1.000	rs10904552	chr10:774326	A/G	cg22713356	chr15:30763199	NA	1.13	11.36	0.57	1.23e-24	Uric acid levels;
CESC	cis	rs1551570	0.755	rs2290687	chr19:10229521	C/T	cg00593900	chr19:10206746	ANGPTL6	0.37	6.1	0.35	3.68e-9	Narcolepsy;
CESC	cis	rs4862750	0.837	rs1863404	chr4:187874654	T/C	cg11301795	chr4:187892539	NA	-0.71	-11.21	-0.57	3.97e-24	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1499614	1.000	rs2707828	chr7:66171377	G/A	cg12463550	chr7:65579703	CRCP	0.73	5.73	0.33	2.78e-8	Gout;
CESC	cis	rs9611565	0.525	rs9611548	chr22:41704143	G/T	cg17376030	chr22:41985996	PMM1	0.54	5.84	0.34	1.53e-8	Vitiligo;
CESC	cis	rs2735413	0.881	rs4888732	chr16:78080505	A/G	cg04733911	chr16:78082701	NA	-0.51	-8.38	-0.46	3.17e-15	Systolic blood pressure (alcohol consumption interaction);
CESC	cis	rs60154123	0.554	rs1338290	chr1:210465467	G/A	cg25204440	chr1:209979598	IRF6	0.48	5.21	0.3	3.75e-7	Coronary artery disease;
CESC	cis	rs853679	0.517	rs34716816	chr6:28046169	C/A	cg23161317	chr6:28129485	ZNF389	0.5	6.31	0.36	1.19e-9	Depression;
CESC	cis	rs12313068	0.709	rs10849698	chr12:110504798	C/G	cg12870014	chr12:110450643	ANKRD13A	0.83	9.51	0.5	1.22e-18	Intelligence (multi-trait analysis);
CESC	cis	rs728616	0.614	rs17678737	chr10:82133985	A/G	cg05935833	chr10:81318306	SFTPA2	-0.46	-5.7	-0.33	3.26e-8	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs425277	0.628	rs3107145	chr1:2047547	G/A	cg04315214	chr1:2043799	PRKCZ	0.64	11.01	0.56	1.81e-23	Height;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg02213487	chr11:118928076	HYOU1	-0.51	-6.32	-0.36	1.11e-9	Ulcerative colitis;
CESC	cis	rs9733	0.596	rs7538493	chr1:150655421	T/C	cg18016565	chr1:150552671	MCL1	0.33	5.14	0.3	5.34e-7	Tonsillectomy;
CESC	cis	rs10870270	1.000	rs3935905	chr10:133758262	A/C	cg17892150	chr10:133769511	PPP2R2D	-0.85	-12.56	-0.61	1.02e-28	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs911555	0.755	rs12432803	chr14:103930032	C/T	cg24130564	chr14:104152367	KLC1	0.49	6.32	0.36	1.11e-9	Intelligence (multi-trait analysis);
CESC	cis	rs651907	0.535	rs35799195	chr3:101521927	A/G	cg12386194	chr3:101231763	SENP7	0.41	5.11	0.3	6.03e-7	Colorectal cancer;
CESC	cis	rs1395	0.778	rs12465084	chr2:27414203	G/C	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.44	5.85	0.34	1.44e-8	Blood metabolite levels;
CESC	cis	rs11098499	0.818	rs10008791	chr4:120431469	A/C	cg09307838	chr4:120376055	NA	0.93	12.81	0.62	1.5e-29	Corneal astigmatism;
CESC	cis	rs8005677	1.000	rs4982706	chr14:23381697	C/T	cg01529538	chr14:23388837	RBM23	0.51	6.87	0.39	4.64e-11	Cognitive ability (multi-trait analysis);
CESC	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.88	9.46	0.5	1.8e-18	Platelet count;
CESC	cis	rs212524	0.544	rs7551107	chr1:21559702	C/A	cg05370193	chr1:21551575	ECE1	0.4	6.34	0.36	9.62e-10	Height;
CESC	cis	rs60154123	0.772	rs664072	chr1:210422160	G/A	cg22029157	chr1:209979665	IRF6	0.49	5.59	0.32	5.6e-8	Coronary artery disease;
CESC	cis	rs763014	0.966	rs15564	chr16:677854	G/T	cg09263875	chr16:632152	PIGQ	0.66	11.46	0.58	5.98e-25	Height;
CESC	cis	rs8017423	0.967	rs55962513	chr14:90729460	C/G	cg14092571	chr14:90743983	NA	-0.56	-8.38	-0.46	3.07e-15	Mortality in heart failure;
CESC	cis	rs4919044	0.756	rs2486686	chr10:94778511	G/T	cg26979504	chr10:94451518	HHEX	-0.47	-5.15	-0.3	5.16e-7	Coronary artery disease;
CESC	cis	rs9287719	0.934	rs10201077	chr2:10752426	A/C	cg00105475	chr2:10696890	NA	0.38	5.41	0.32	1.43e-7	Prostate cancer;
CESC	cis	rs36051895	0.659	rs59225790	chr9:5042757	G/A	cg02405213	chr9:5042618	JAK2	-0.49	-5.86	-0.34	1.38e-8	Pediatric autoimmune diseases;
CESC	cis	rs853679	0.517	rs9393891	chr6:28079160	C/T	cg23281280	chr6:28129359	ZNF389	0.58	7.93	0.44	6.31e-14	Depression;
CESC	cis	rs501120	1.000	rs620828	chr10:44760958	A/G	cg09554077	chr10:44749378	NA	0.52	6.89	0.39	4.1e-11	Coronary artery disease;Coronary heart disease;
CESC	cis	rs875971	0.895	rs7788984	chr7:65915616	A/G	cg10691866	chr7:65817282	TPST1	-0.35	-5.76	-0.33	2.36e-8	Aortic root size;
CESC	cis	rs965469	0.779	rs2236119	chr20:3303576	G/T	cg25506879	chr20:3388711	C20orf194	-0.49	-5.36	-0.31	1.79e-7	IFN-related cytopenia;
CESC	cis	rs7914558	1.000	rs7094843	chr10:104806654	A/C	cg15744005	chr10:104629667	AS3MT	-0.34	-5.49	-0.32	9.49e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs1514687	0.534	rs60151917	chr2:1473286	A/T	cg13703866	chr2:1479523	TPO	-0.77	-5.24	-0.31	3.35e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);
CESC	cis	rs684232	0.688	rs2657633	chr17:600502	C/T	cg15660573	chr17:549704	VPS53	-0.67	-9.4	-0.5	2.73e-18	Prostate cancer;
CESC	cis	rs1448094	0.512	rs6539926	chr12:86244460	G/A	cg00310523	chr12:86230176	RASSF9	0.35	5.46	0.32	1.1e-7	Major depressive disorder;
CESC	cis	rs875971	0.660	rs801211	chr7:66015689	T/G	cg06456125	chr7:65229604	NA	-0.39	-5.1	-0.3	6.54e-7	Aortic root size;
CESC	cis	rs2832191	0.791	rs2832181	chr21:30481371	G/T	cg08807101	chr21:30365312	RNF160	-0.77	-11.04	-0.56	1.46e-23	Dental caries;
CESC	cis	rs6540556	0.723	rs12034758	chr1:209920545	G/A	cg05527609	chr1:210001259	C1orf107	-0.65	-7.5	-0.42	9.5e-13	Red blood cell count;
CESC	cis	rs3741151	0.773	rs6592526	chr11:73208911	C/T	cg17517138	chr11:73019481	ARHGEF17	0.98	7.17	0.4	7.42e-12	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs4665809	0.590	rs34728554	chr2:26481959	C/G	cg27170947	chr2:26402098	FAM59B	0.87	9.85	0.52	1.01e-19	Gut microbiome composition (summer);
CESC	cis	rs7829975	0.714	rs11777085	chr8:8672429	G/C	cg06636001	chr8:8085503	FLJ10661	0.43	5.53	0.32	7.54e-8	Mood instability;
CESC	trans	rs561341	0.882	rs16967101	chr17:30377162	A/G	cg20587970	chr11:113659929	NA	-1.06	-12.78	-0.62	1.88e-29	Hip circumference adjusted for BMI;
CESC	cis	rs3845702	0.736	rs72960701	chr2:180851202	A/T	cg01881094	chr2:180872142	CWC22	1.03	8.81	0.48	1.65e-16	Schizophrenia;
CESC	cis	rs7592578	0.766	rs62182885	chr2:191437024	A/G	cg10560079	chr2:191398806	TMEM194B	-0.61	-5.19	-0.3	4.22e-7	Diastolic blood pressure;
CESC	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg24642844	chr7:1081250	C7orf50	-0.77	-9.3	-0.5	5.54e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2777491	1.000	rs11631770	chr15:41737059	T/C	cg02330683	chr15:41787940	ITPKA	0.45	6.56	0.37	2.89e-10	Ulcerative colitis;
CESC	cis	rs7772486	0.641	rs2253757	chr6:146199686	C/T	cg13319975	chr6:146136371	FBXO30	-0.42	-5.04	-0.3	8.68e-7	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7264396	0.563	rs2425117	chr20:34323776	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.87	-10.47	-0.54	1.06e-21	Total cholesterol levels;
CESC	cis	rs2455799	0.502	rs2470532	chr3:15696909	A/C	cg16303742	chr3:15540471	COLQ	0.4	6.32	0.36	1.11e-9	Mean platelet volume;
CESC	cis	rs4664308	0.935	rs17216980	chr2:160960932	G/A	cg03641300	chr2:160917029	PLA2R1	-0.62	-8.98	-0.48	5.24e-17	Idiopathic membranous nephropathy;
CESC	cis	rs4566357	1.000	rs7567789	chr2:227922104	T/C	cg11843606	chr2:227700838	RHBDD1	-0.41	-5.27	-0.31	2.78e-7	Coronary artery disease;
CESC	cis	rs7412746	0.611	rs4970985	chr1:150887442	C/T	cg04414720	chr1:150670196	GOLPH3L	-0.45	-5.99	-0.35	6.85e-9	Melanoma;
CESC	cis	rs853679	0.517	rs3173443	chr6:28137027	T/G	cg18032046	chr6:28092343	ZSCAN16	-0.57	-6.59	-0.38	2.36e-10	Depression;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg03531512	chr22:26908677	TFIP11	0.41	6.01	0.35	6.26e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs12497850	1.000	rs6788650	chr3:48749543	T/C	cg06212747	chr3:49208901	KLHDC8B	0.61	8.15	0.45	1.46e-14	Parkinson's disease;
CESC	cis	rs7255374	0.566	rs7255904	chr19:41529020	C/T	cg27089200	chr19:41531976	NA	0.44	7.3	0.41	3.27e-12	DDT metabolite (p,p'-DDE levels);
CESC	cis	rs8114671	0.869	rs66535333	chr20:33656666	G/A	cg06115741	chr20:33292138	TP53INP2	-0.44	-5.31	-0.31	2.27e-7	Height;
CESC	cis	rs10256972	0.967	rs7799110	chr7:1039065	A/G	cg23978390	chr7:1156363	C7orf50	0.43	5.71	0.33	3.06e-8	Longevity;Endometriosis;
CESC	cis	rs7560272	0.501	rs2421676	chr2:73966087	G/A	cg20560298	chr2:73613845	ALMS1	0.4	5.5	0.32	8.75e-8	Schizophrenia;
CESC	cis	rs72829446	0.530	rs2228132	chr17:7411770	C/T	cg02795151	chr17:7402630	POLR2A	0.62	6.48	0.37	4.49e-10	Androgen levels;
CESC	cis	rs4906332	1.000	rs3783397	chr14:103947289	A/G	cg09975044	chr14:104007538	NA	0.44	6.19	0.36	2.31e-9	Coronary artery disease;
CESC	cis	rs6502050	0.835	rs3935816	chr17:80137173	C/T	cg23985595	chr17:80112537	CCDC57	-0.39	-6.27	-0.36	1.44e-9	Life satisfaction;
CESC	cis	rs2842992	0.915	rs2758321	chr6:160071611	C/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.62	7.29	0.41	3.65e-12	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs7123876	0.587	rs11602616	chr11:72364077	T/C	cg03713592	chr11:72463424	ARAP1	0.62	5.08	0.3	7.13e-7	Body mass index;
CESC	cis	rs7188697	0.922	rs1549607	chr16:58583975	A/G	cg21335942	chr16:58549945	SETD6	-0.46	-5.35	-0.31	1.9e-7	QT interval;
CESC	cis	rs651907	0.535	rs12631513	chr3:101517476	A/C	cg12386194	chr3:101231763	SENP7	0.41	5.11	0.3	6.03e-7	Colorectal cancer;
CESC	cis	rs1003719	0.788	rs61701101	chr21:38450317	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.62	8.64	0.47	5.56e-16	Eye color traits;
CESC	cis	rs7481584	0.624	rs516443	chr11:3047294	A/G	cg25174290	chr11:3078921	CARS	-0.45	-6.3	-0.36	1.21e-9	Calcium levels;
CESC	cis	rs7917772	0.503	rs11191326	chr10:104302959	C/T	cg22532475	chr10:104410764	TRIM8	-0.34	-5.76	-0.33	2.3e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg24869748	chr6:86303744	SNX14	-0.47	-6.47	-0.37	4.72e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs4595586	0.545	rs7486598	chr12:39371159	C/T	cg26384229	chr12:38710491	ALG10B	0.53	7.51	0.42	8.86e-13	Morning vs. evening chronotype;
CESC	cis	rs9640161	0.830	rs7800196	chr7:150061534	C/G	cg10018233	chr7:150070692	REPIN1	0.39	6.47	0.37	4.6e-10	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs7301826	0.651	rs2037789	chr12:131288292	C/T	cg11011512	chr12:131303247	STX2	-0.47	-5.79	-0.34	2e-8	Plasma plasminogen activator levels;
CESC	cis	rs2235642	0.787	rs2235646	chr16:1601287	A/G	cg09080909	chr16:1797204	MAPK8IP3	-0.37	-5.06	-0.3	7.96e-7	Coronary artery disease;
CESC	cis	rs10088262	0.629	rs12549683	chr8:124798276	G/C	cg15047889	chr8:124780837	FAM91A1	-0.52	-6.58	-0.37	2.57e-10	Pancreatic cancer;
CESC	cis	rs636291	0.517	rs12565133	chr1:10544988	A/C	cg20482658	chr1:10539492	PEX14	0.26	5.36	0.31	1.84e-7	Prostate cancer;
CESC	cis	rs9911578	0.933	rs2632508	chr17:56533235	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.4	5.3	0.31	2.49e-7	Intelligence (multi-trait analysis);
CESC	cis	rs10754283	0.967	rs7528433	chr1:90114071	T/C	cg21401794	chr1:90099060	LRRC8C	0.68	9.03	0.49	3.6e-17	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs561341	1.000	rs2470243	chr17:30290955	C/T	cg19193384	chr17:30244184	NA	-0.71	-6.6	-0.38	2.17e-10	Hip circumference adjusted for BMI;
CESC	cis	rs796364	0.616	rs6718118	chr2:200691852	G/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.56	-5.4	-0.31	1.46e-7	Schizophrenia;
CESC	cis	rs2836974	0.644	rs7281853	chr21:40693490	A/G	cg17971929	chr21:40555470	PSMG1	-0.8	-11.0	-0.56	2.03e-23	Cognitive function;
CESC	cis	rs1348850	0.793	rs13027299	chr2:178455501	T/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.6	7.9	0.44	7.42e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs7542091	0.637	rs9429826	chr1:210052146	G/A	cg21951975	chr1:209979733	IRF6	0.46	7.95	0.44	5.33e-14	Monobrow;
CESC	cis	rs17401966	0.838	rs4846207	chr1:10313811	T/C	cg15208524	chr1:10270712	KIF1B	0.39	5.13	0.3	5.5e-7	Hepatocellular carcinoma;
CESC	cis	rs4819052	0.851	rs13052312	chr21:46662359	T/C	cg11663144	chr21:46675770	NA	-0.63	-10.04	-0.53	2.57e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs7397814	0.558	rs4764447	chr12:9579109	C/T	cg27502298	chr12:9555721	NA	0.79	10.72	0.55	1.65e-22	IgG glycosylation;
CESC	cis	rs514406	0.607	rs11206000	chr1:53205923	A/C	cg24675658	chr1:53192096	ZYG11B	0.63	8.83	0.48	1.44e-16	Monocyte count;
CESC	cis	rs9733	0.596	rs12085275	chr1:150650265	T/C	cg17724175	chr1:150552817	MCL1	0.44	7.21	0.41	5.8e-12	Tonsillectomy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09829838	chr6:42952307	PPP2R5D	0.52	6.04	0.35	5.32e-9	Gut microbiome composition (summer);
CESC	cis	rs453301	0.653	rs11784393	chr8:8903134	C/T	cg15556689	chr8:8085844	FLJ10661	0.51	6.5	0.37	3.86e-10	Joint mobility (Beighton score);
CESC	cis	rs10504229	0.683	rs16921810	chr8:58106067	A/G	cg24829409	chr8:58192753	C8orf71	-0.56	-7.01	-0.4	1.97e-11	Developmental language disorder (linguistic errors);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg18320648	chr2:152266336	RIF1	-0.5	-6.83	-0.39	5.94e-11	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs7589728	0.563	rs2292868	chr2:88475047	A/G	cg04511125	chr2:88470314	THNSL2	-0.67	-6.37	-0.36	8.22e-10	Plasma clusterin levels;
CESC	cis	rs1499972	0.618	rs62264778	chr3:117653627	G/T	cg07612923	chr3:117604196	NA	0.68	6.16	0.35	2.74e-9	Schizophrenia;
CESC	cis	rs796364	0.901	rs4673762	chr2:201065171	C/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.62	5.79	0.33	2.03e-8	Schizophrenia;
CESC	cis	rs617791	0.530	rs10896073	chr11:65762814	T/C	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.38	-5.11	-0.3	6.15e-7	Breast cancer;
CESC	cis	rs12042107	0.740	rs10801826	chr1:91206578	C/T	cg13456504	chr1:91191583	NA	-0.34	-5.79	-0.34	1.99e-8	Educational attainment;
CESC	cis	rs12701220	0.655	rs6463317	chr7:1159243	G/A	cg01324507	chr7:1177794	C7orf50	0.54	5.35	0.31	1.88e-7	Bronchopulmonary dysplasia;
CESC	cis	rs10504229	0.500	rs9772760	chr8:57986999	G/C	cg22535103	chr8:58192502	C8orf71	-0.47	-5.88	-0.34	1.24e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs7811142	0.830	rs6955367	chr7:99961194	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.95	11.67	0.58	1.1e-25	Platelet count;
CESC	cis	rs1448094	0.512	rs7137596	chr12:86239884	C/G	cg02569458	chr12:86230093	RASSF9	0.48	7.32	0.41	2.89e-12	Major depressive disorder;
CESC	cis	rs6952808	0.692	rs56727870	chr7:2029940	T/C	cg08027265	chr7:2291960	NA	-0.37	-5.53	-0.32	7.61e-8	Bipolar disorder and schizophrenia;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg06160880	chr1:235324713	RBM34	-0.52	-6.05	-0.35	4.93e-9	Ulcerative colitis;
CESC	cis	rs4629710	0.592	rs10484763	chr6:131549060	T/C	cg12606694	chr6:131520996	AKAP7	0.43	5.43	0.32	1.26e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs7666738	0.830	rs58696666	chr4:99006913	C/T	cg03467027	chr4:99064603	C4orf37	0.44	5.51	0.32	8.65e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6500602	0.647	rs4786519	chr16:4584406	C/T	cg08645402	chr16:4508243	NA	0.5	8.21	0.45	9.85e-15	Schizophrenia;
CESC	cis	rs6724607	1.000	rs13410230	chr2:191446252	A/G	cg27211696	chr2:191398769	TMEM194B	0.49	7.29	0.41	3.51e-12	Pulse pressure;
CESC	cis	rs3809863	0.602	rs7225700	chr17:45391804	T/C	cg08085267	chr17:45401833	C17orf57	-0.68	-9.09	-0.49	2.38e-17	Glaucoma (primary open-angle);
CESC	cis	rs4665809	0.556	rs10221814	chr2:26442759	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-1.06	-12.27	-0.6	1.02e-27	Gut microbiome composition (summer);
CESC	cis	rs8031584	1.000	rs35811129	chr15:31241346	G/A	cg14298792	chr15:30685198	CHRFAM7A	-0.48	-5.41	-0.32	1.39e-7	Huntington's disease progression;
CESC	cis	rs17601876	0.843	rs28490942	chr15:51559845	G/C	cg19946085	chr15:51559439	CYP19A1	-0.32	-5.15	-0.3	5.01e-7	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
CESC	cis	rs8114671	0.836	rs6060165	chr20:33619480	A/C	cg24642439	chr20:33292090	TP53INP2	-0.44	-5.29	-0.31	2.57e-7	Height;
CESC	cis	rs6963495	0.606	rs6969426	chr7:105147150	G/A	cg13798780	chr7:105162888	PUS7	0.75	7.64	0.43	3.87e-13	Bipolar disorder (body mass index interaction);
CESC	cis	rs875971	0.898	rs6977501	chr7:65693342	T/C	cg11764359	chr7:65958608	NA	-0.92	-14.87	-0.67	9.11e-37	Aortic root size;
CESC	cis	rs8070624	0.543	rs4299203	chr17:17878159	T/G	cg16928487	chr17:17741425	SREBF1	-0.62	-10.37	-0.54	2.2e-21	Total body bone mineral density;
CESC	trans	rs7937682	0.883	rs631490	chr11:111452040	G/C	cg18187862	chr3:45730750	SACM1L	0.48	6.13	0.35	3.15e-9	Primary sclerosing cholangitis;
CESC	cis	rs6831352	0.819	rs896992	chr4:100002372	C/T	cg21548116	chr4:100009993	ADH5	0.46	5.12	0.3	5.86e-7	Alcohol dependence;
CESC	cis	rs3820928	0.874	rs116652884	chr2:227902285	C/T	cg11843606	chr2:227700838	RHBDD1	-0.5	-6.54	-0.37	3.22e-10	Pulmonary function;
CESC	cis	rs7937682	0.889	rs564086	chr11:111501079	C/G	cg22437258	chr11:111473054	SIK2	0.68	9.04	0.49	3.37e-17	Primary sclerosing cholangitis;
CESC	trans	rs17685	0.753	rs2108274	chr7:75781636	C/A	cg19862616	chr7:65841803	NCRNA00174	0.87	12.64	0.61	5.4e-29	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs7100689	0.577	rs1417219	chr10:82041409	C/T	cg09936400	chr10:82049201	MAT1A	0.41	6.24	0.36	1.7e-9	Post bronchodilator FEV1;
CESC	cis	rs17039065	0.920	rs12507588	chr4:109448257	G/A	cg16022748	chr4:109541635	LOC285456;RPL34	0.63	5.67	0.33	3.65e-8	Gut microbiome composition (summer);
CESC	cis	rs12325245	0.536	rs17821549	chr16:58554780	C/T	cg02549819	chr16:58548995	SETD6	0.93	6.23	0.36	1.85e-9	Schizophrenia;
CESC	cis	rs10463316	0.894	rs869198	chr5:150745893	G/T	cg03212797	chr5:150827313	SLC36A1	0.55	7.31	0.41	3.13e-12	Metabolite levels (Pyroglutamine);
CESC	cis	rs2836950	0.545	rs8132143	chr21:40584258	A/T	cg17971929	chr21:40555470	PSMG1	-0.6	-7.94	-0.44	5.64e-14	Menarche (age at onset);
CESC	cis	rs3796352	1.000	rs71301814	chr3:53117663	G/A	cg15956490	chr3:53032818	SFMBT1	0.63	5.22	0.31	3.63e-7	Immune reponse to smallpox (secreted IL-2);
CESC	cis	rs863345	0.604	rs11264976	chr1:158446927	G/A	cg12129480	chr1:158549410	OR10X1	-0.36	-7.18	-0.4	7.1e-12	Pneumococcal bacteremia;
CESC	cis	rs2836974	0.666	rs2836975	chr21:40663620	A/G	cg11890956	chr21:40555474	PSMG1	-0.96	-15.83	-0.7	3.49e-40	Cognitive function;
CESC	cis	rs12142240	0.698	rs45449893	chr1:46859024	A/G	cg10495392	chr1:46806563	NSUN4	0.56	6.17	0.35	2.61e-9	Menopause (age at onset);
CESC	cis	rs1348850	0.914	rs12104588	chr2:178253675	G/A	cg23306229	chr2:178417860	TTC30B	0.64	8.07	0.44	2.52e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs10504229	0.679	rs72649120	chr8:58040308	C/T	cg24829409	chr8:58192753	C8orf71	-0.5	-6.25	-0.36	1.61e-9	Developmental language disorder (linguistic errors);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10205151	chr7:931109	C7orf20	-0.65	-7.31	-0.41	3.18e-12	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25989624	chr9:132199563	NA	-0.62	-6.57	-0.37	2.63e-10	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12058646	chr3:45017840	ZDHHC3;EXOSC7	-0.61	-7.13	-0.4	9.32e-12	Gut microbiome composition (summer);
CESC	cis	rs9902453	0.817	rs62068620	chr17:28167674	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	8.38	0.46	3.08e-15	Coffee consumption (cups per day);
CESC	cis	rs1552244	0.554	rs34883592	chr3:10046165	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.56	-7.26	-0.41	4.31e-12	Alzheimer's disease;
CESC	cis	rs854765	0.583	rs11656840	chr17:17837354	C/T	cg16928487	chr17:17741425	SREBF1	-0.56	-9.73	-0.51	2.53e-19	Total body bone mineral density;
CESC	cis	rs826838	0.933	rs1906263	chr12:38653362	T/C	cg26384229	chr12:38710491	ALG10B	0.82	14.26	0.66	1.22e-34	Heart rate;
CESC	cis	rs7615952	0.673	rs115942855	chr3:125601960	G/A	cg05084668	chr3:125655381	ALG1L	-0.82	-7.68	-0.43	3.04e-13	Blood pressure (smoking interaction);
CESC	cis	rs8133932	0.608	rs403192	chr21:47360641	C/T	cg14185626	chr21:47401492	COL6A1	-0.46	-5.14	-0.3	5.24e-7	Schizophrenia;
CESC	cis	rs1218582	0.772	rs4845682	chr1:154877105	T/C	cg03351412	chr1:154909251	PMVK	0.69	9.39	0.5	2.91e-18	Prostate cancer;
CESC	cis	rs7818345	0.967	rs10107416	chr8:19286253	A/G	cg11303988	chr8:19266685	CSGALNACT1	-0.3	-5.52	-0.32	8.16e-8	Language performance in older adults (adjusted for episodic memory);
CESC	cis	rs12545109	0.842	rs10958482	chr8:57389331	G/T	cg09654669	chr8:57350985	NA	-0.57	-7.13	-0.4	9.65e-12	Obesity-related traits;
CESC	cis	rs34779708	0.931	rs34304999	chr10:35365705	C/T	cg04310649	chr10:35416472	CREM	-0.49	-5.92	-0.34	9.74e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs4595586	0.545	rs1607041	chr12:39368206	C/T	cg13010199	chr12:38710504	ALG10B	0.44	5.51	0.32	8.37e-8	Morning vs. evening chronotype;
CESC	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg26338869	chr17:61819248	STRADA	0.67	8.9	0.48	9.05e-17	Prudent dietary pattern;
CESC	cis	rs1018836	0.818	rs2285232	chr8:91546162	C/G	cg16814680	chr8:91681699	NA	-0.63	-9.06	-0.49	2.89e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs7605827	0.930	rs4668910	chr2:15608013	C/A	cg19274914	chr2:15703543	NA	0.38	6.75	0.38	9.33e-11	Educational attainment (years of education);
CESC	cis	rs3087591	1.000	rs9902893	chr17:29625638	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.41	-5.04	-0.3	8.71e-7	Hip circumference;
CESC	cis	rs9926296	0.712	rs2434872	chr16:89716915	C/G	cg03605463	chr16:89740564	NA	0.66	7.83	0.43	1.14e-13	Vitiligo;
CESC	cis	rs4566357	0.539	rs10933164	chr2:227860671	A/G	cg05526886	chr2:227700861	RHBDD1	-0.62	-7.23	-0.41	5.21e-12	Coronary artery disease;
CESC	cis	rs1862618	0.853	rs860580	chr5:56149429	G/T	cg24549020	chr5:56110836	MAP3K1	-0.6	-7.14	-0.4	8.97e-12	Initial pursuit acceleration;
CESC	cis	rs9649213	0.593	rs7778015	chr7:97920270	T/C	cg21770322	chr7:97807741	LMTK2	0.55	8.18	0.45	1.17e-14	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7927771	1.000	rs10838757	chr11:47763016	T/C	cg18512352	chr11:47633146	NA	-0.61	-9.62	-0.51	5.51e-19	Subjective well-being;
CESC	cis	rs2797160	1.000	rs1739378	chr6:126012262	C/A	cg05901451	chr6:126070800	HEY2	0.46	6.68	0.38	1.4e-10	Endometrial cancer;
CESC	cis	rs7659604	0.540	rs11734075	chr4:122695685	C/T	cg19748678	chr4:122722346	EXOSC9	-0.45	-5.73	-0.33	2.73e-8	Type 2 diabetes;
CESC	cis	rs3087591	1.000	rs2051507	chr17:29700101	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.46	-5.84	-0.34	1.51e-8	Hip circumference;
CESC	cis	rs12541635	0.677	rs6469032	chr8:107057509	A/T	cg10147462	chr8:107024639	NA	0.47	6.96	0.39	2.64e-11	Age of smoking initiation;
CESC	cis	rs7258465	1.000	rs34746918	chr19:18539744	C/T	cg25828334	chr19:18545568	ISYNA1	-0.32	-5.15	-0.3	5e-7	Breast cancer;
CESC	cis	rs172166	0.637	rs1233691	chr6:28153897	T/G	cg23281280	chr6:28129359	ZNF389	0.39	5.92	0.34	9.72e-9	Cardiac Troponin-T levels;
CESC	cis	rs4253772	0.938	rs9626814	chr22:46637254	C/T	cg24881330	chr22:46731750	TRMU	0.53	5.3	0.31	2.41e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs6952808	1.000	rs6957894	chr7:1887362	G/A	cg13880726	chr7:1868755	MAD1L1	0.51	6.98	0.39	2.4e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs13102973	0.965	rs55967588	chr4:135860189	G/A	cg14419869	chr4:135874104	NA	0.34	5.24	0.31	3.3e-7	Subjective well-being;
CESC	cis	rs3733585	0.605	rs4697926	chr4:10124567	G/T	cg11266682	chr4:10021025	SLC2A9	0.56	10.27	0.53	4.87e-21	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs2576037	0.526	rs2156050	chr18:44455873	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.42	6.86	0.39	4.72e-11	Personality dimensions;
CESC	cis	rs1799949	0.965	rs11650132	chr17:41326087	T/G	cg23758822	chr17:41437982	NA	1.04	15.67	0.69	1.25e-39	Menopause (age at onset);
CESC	cis	rs941873	0.868	rs10740497	chr10:81126380	T/C	cg11057378	chr10:81107060	PPIF	0.36	5.84	0.34	1.55e-8	Height;
CESC	cis	rs7927592	0.956	rs60212556	chr11:68305494	C/T	cg20283391	chr11:68216788	NA	-0.5	-5.91	-0.34	1.02e-8	Total body bone mineral density;
CESC	trans	rs861318	0.838	rs855866	chr1:159052720	A/G	cg08477332	chr1:153590243	S100A14	0.64	6.03	0.35	5.59e-9	Obesity-related traits;
CESC	cis	rs1562975	0.609	rs12505944	chr4:109411822	G/A	cg16022748	chr4:109541635	LOC285456;RPL34	0.42	5.4	0.31	1.48e-7	Height;
CESC	cis	rs4689388	0.824	rs4467645	chr4:6294305	C/T	cg00701064	chr4:6280414	WFS1	0.68	11.71	0.58	8.68e-26	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs13382862	0.895	rs2289082	chr2:20881958	A/T	cg14780466	chr2:20870812	GDF7	0.41	7.25	0.41	4.48e-12	Abdominal aortic aneurysm;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09410845	chr2:203241870	BMPR2	-0.61	-6.57	-0.37	2.66e-10	Gut microbiome composition (summer);
CESC	trans	rs17508449	0.819	rs2146018	chr1:114195330	C/A	cg23028848	chr11:57092561	TNKS1BP1	-0.75	-6.05	-0.35	4.88e-9	Leprosy;
CESC	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.52	6.35	0.36	9.24e-10	Prudent dietary pattern;
CESC	cis	rs11690935	0.843	rs9784070	chr2:172785007	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.84	-12.21	-0.6	1.67e-27	Schizophrenia;
CESC	cis	rs250677	0.687	rs36048	chr5:148441713	G/C	cg18129178	chr5:148520854	ABLIM3	-0.52	-5.94	-0.34	8.86e-9	Breast cancer;
CESC	cis	rs34375054	0.526	rs883315	chr12:125676889	T/C	cg05341575	chr12:125625032	AACS	-0.36	-5.23	-0.31	3.51e-7	Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs2108622	0.727	rs12611308	chr19:15978586	C/T	cg13772218	chr19:15982569	NA	0.29	5.69	0.33	3.28e-8	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CESC	cis	rs7818688	1.000	rs73276437	chr8:96035511	A/G	cg16049864	chr8:95962084	TP53INP1	0.6	5.79	0.34	2e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs7829975	0.688	rs7817376	chr8:8380530	C/T	cg06636001	chr8:8085503	FLJ10661	-0.49	-6.17	-0.35	2.56e-9	Mood instability;
CESC	cis	rs2380220	0.872	rs4546494	chr6:95990626	A/C	cg15832292	chr6:96025679	MANEA	0.64	6.19	0.36	2.22e-9	Behavioural disinhibition (generation interaction);
CESC	cis	rs875971	1.000	rs7789554	chr7:65946038	A/G	cg11764359	chr7:65958608	NA	0.97	15.5	0.69	5.25e-39	Aortic root size;
CESC	cis	rs55871839	0.708	rs13268621	chr8:59811724	T/G	cg07426533	chr8:59803705	TOX	-0.47	-7.01	-0.4	1.95e-11	Pneumonia;
CESC	cis	rs4975709	0.610	rs1531994	chr5:1859297	T/C	cg12288994	chr5:1860383	NA	0.4	6.66	0.38	1.53e-10	Cardiovascular disease risk factors;
CESC	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg24829409	chr8:58192753	C8orf71	-0.69	-7.74	-0.43	2.07e-13	Developmental language disorder (linguistic errors);
CESC	cis	rs367943	0.712	rs6896650	chr5:112681048	T/C	cg12552261	chr5:112820674	MCC	0.4	5.25	0.31	3.09e-7	Type 2 diabetes;
CESC	cis	rs6831352	1.000	rs1126673	chr4:100045616	C/T	cg13256891	chr4:100009986	ADH5	0.72	8.31	0.45	5.11e-15	Alcohol dependence;
CESC	cis	rs6570726	0.935	rs453609	chr6:145812332	T/C	cg05347473	chr6:146136440	FBXO30	0.48	6.36	0.36	8.67e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4835473	0.897	rs6831477	chr4:144630640	G/A	cg25736465	chr4:144833511	NA	0.4	6.09	0.35	3.86e-9	Immature fraction of reticulocytes;
CESC	cis	rs4689388	0.926	rs10937717	chr4:6295087	T/A	cg14416269	chr4:6271139	WFS1	0.44	7.22	0.41	5.49e-12	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs9435341	1.000	rs1762484	chr1:107613923	A/C	cg09367891	chr1:107599246	PRMT6	-0.69	-8.25	-0.45	7.61e-15	Facial morphology (factor 21, depth of nasal alae);
CESC	cis	rs4819052	0.851	rs9974628	chr21:46672647	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.46	5.75	0.33	2.4e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs2191566	1.000	rs367499	chr19:44504981	G/A	cg20607764	chr19:44506953	ZNF230	0.6	7.68	0.43	2.99e-13	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs7044106	0.791	rs735110	chr9:123488940	T/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.87	13.69	0.64	1.22e-32	Hip circumference adjusted for BMI;
CESC	cis	rs67311347	1.000	rs4973993	chr3:40452960	T/C	cg09455208	chr3:40491958	NA	0.51	8.55	0.47	9.79e-16	Renal cell carcinoma;
CESC	cis	rs9868809	0.772	rs9811318	chr3:48702606	A/G	cg07636037	chr3:49044803	WDR6	-0.69	-6.17	-0.35	2.56e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs9393777	0.513	rs7759969	chr6:26663096	T/A	cg12826209	chr6:26865740	GUSBL1	0.76	8.46	0.46	1.79e-15	Intelligence (multi-trait analysis);
CESC	cis	rs736408	0.648	rs3774355	chr3:52817778	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.45	5.67	0.33	3.7e-8	Bipolar disorder;
CESC	cis	rs72781680	0.706	rs72794290	chr2:23896106	A/T	cg08917208	chr2:24149416	ATAD2B	1.17	10.84	0.55	6.84e-23	Lymphocyte counts;
CESC	cis	rs1552244	1.000	rs6442150	chr3:10122575	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	11.97	0.59	1.11e-26	Alzheimer's disease;
CESC	cis	rs7089973	0.604	rs8181444	chr10:116588981	C/T	cg03647239	chr10:116582469	FAM160B1	0.43	5.29	0.31	2.6e-7	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs62432291	0.764	rs433256	chr6:159660105	C/T	cg14500486	chr6:159655392	FNDC1	-0.62	-6.34	-0.36	9.83e-10	Joint mobility (Beighton score);
CESC	cis	rs7223966	1.000	rs9903903	chr17:61762044	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.58	7.42	0.41	1.55e-12	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs2797160	0.904	rs1739370	chr6:126011231	C/T	cg05901451	chr6:126070800	HEY2	0.48	7.04	0.4	1.63e-11	Endometrial cancer;
CESC	cis	rs12497850	0.931	rs7430501	chr3:48890119	C/T	cg07636037	chr3:49044803	WDR6	1.02	18.99	0.76	2.3e-51	Parkinson's disease;
CESC	cis	rs10461617	0.617	rs6874733	chr5:56069600	A/G	cg12311346	chr5:56204834	C5orf35	-0.55	-6.81	-0.39	6.5e-11	Type 2 diabetes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21767207	chr19:36236454	PSENEN;U2AF1L4	0.67	8.03	0.44	3.11e-14	Gut microbiome composition (summer);
CESC	cis	rs1729951	0.575	rs2163896	chr3:136691177	G/A	cg03617693	chr3:136751559	NA	0.39	5.38	0.31	1.68e-7	Neuroticism;
CESC	cis	rs1451375	0.617	rs10276473	chr7:50612997	A/C	cg14593290	chr7:50529359	DDC	-0.49	-6.05	-0.35	4.91e-9	Malaria;
CESC	cis	rs4889855	0.516	rs4890041	chr17:78521114	A/T	cg16591659	chr17:78472290	NA	0.35	5.81	0.34	1.81e-8	Fractional excretion of uric acid;
CESC	cis	rs2836974	0.965	rs2836965	chr21:40633631	C/G	cg17971929	chr21:40555470	PSMG1	-1.06	-15.79	-0.7	4.77e-40	Cognitive function;
CESC	cis	rs4460629	0.742	rs7548955	chr1:155082298	T/C	cg01019262	chr1:155095195	NA	-0.3	-5.09	-0.3	6.75e-7	Serum magnesium levels;
CESC	cis	rs2404602	0.608	rs12439484	chr15:76602937	A/C	cg22467129	chr15:76604101	ETFA	-0.41	-6.23	-0.36	1.83e-9	Blood metabolite levels;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg23325985	chr12:49350513	ARF3	0.44	6.23	0.36	1.86e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs2573652	0.755	rs1469830	chr15:100517403	G/T	cg09918751	chr15:100517450	ADAMTS17	0.45	8.82	0.48	1.56e-16	Height;
CESC	cis	rs9291683	0.618	rs13137343	chr4:10043028	C/A	cg02734326	chr4:10020555	SLC2A9	0.47	6.53	0.37	3.29e-10	Bone mineral density;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18220030	chr1:110090737	GNAI3	-0.54	-6.45	-0.37	5.34e-10	Gut microbiome composition (summer);
CESC	cis	rs875971	0.545	rs73142245	chr7:65691649	A/G	cg18876405	chr7:65276391	NA	0.5	5.5	0.32	8.91e-8	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12333112	chr17:38278849	MSL1	0.55	6.02	0.35	5.8e-9	Gut microbiome composition (summer);
CESC	cis	rs9611565	0.625	rs9607819	chr22:41958862	C/G	cg06634786	chr22:41940651	POLR3H	-0.6	-6.45	-0.37	5.32e-10	Vitiligo;
CESC	cis	rs2120019	0.638	rs12050628	chr15:75333494	G/A	cg09165964	chr15:75287851	SCAMP5	0.94	15.9	0.7	1.93e-40	Blood trace element (Zn levels);
CESC	cis	rs7412746	0.611	rs1889741	chr1:150869045	T/C	cg17724175	chr1:150552817	MCL1	0.33	5.15	0.3	5.17e-7	Melanoma;
CESC	cis	rs8177253	0.666	rs8177197	chr3:133469530	G/A	cg24879335	chr3:133465180	TF	0.32	5.06	0.3	7.71e-7	Iron status biomarkers;
CESC	cis	rs7772486	0.743	rs9390344	chr6:146012755	C/G	cg23711669	chr6:146136114	FBXO30	-0.83	-11.77	-0.59	5.44e-26	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs3008870	0.755	rs2755251	chr1:67496425	G/T	cg02640540	chr1:67518911	SLC35D1	0.44	5.4	0.31	1.48e-7	Lymphocyte percentage of white cells;
CESC	cis	rs4699052	0.626	rs10017383	chr4:104249957	G/A	cg16532752	chr4:104119610	CENPE	-0.41	-5.85	-0.34	1.44e-8	Testicular germ cell tumor;
CESC	cis	rs6893300	0.961	rs62406223	chr5:179218361	C/T	cg14593053	chr5:179126677	CANX	-0.51	-5.62	-0.33	4.9e-8	Resting heart rate;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg02853107	chr4:41984968	DCAF4L1	0.43	6.22	0.36	1.93e-9	Fibrinogen levels;
CESC	cis	rs12534701	1.000	rs13232266	chr7:154681363	A/T	cg24255201	chr7:154684926	DPP6	0.5	6.91	0.39	3.61e-11	Colorectal cancer (diet interaction);
CESC	cis	rs454510	0.816	rs347904	chr1:120177620	C/T	cg11530693	chr1:120165357	ZNF697	0.45	5.73	0.33	2.66e-8	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06438337	chr1:202858236	RABIF	0.55	6.1	0.35	3.78e-9	Gut microbiome composition (summer);
CESC	cis	rs7618915	0.547	rs11130311	chr3:52675005	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	7.01	0.4	2e-11	Bipolar disorder;
CESC	cis	rs909002	0.772	rs10914452	chr1:32074575	G/A	cg13919466	chr1:32135498	COL16A1	-0.47	-8.52	-0.46	1.24e-15	Intelligence (multi-trait analysis);
CESC	cis	rs992157	0.585	rs62182795	chr2:219100202	C/T	cg00012203	chr2:219082015	ARPC2	-0.74	-9.9	-0.52	7.06e-20	Colorectal cancer;
CESC	cis	rs3924048	0.559	rs6541038	chr1:12626210	G/T	cg00291366	chr1:12616550	NA	0.37	6.5	0.37	3.87e-10	Optic cup area;
CESC	cis	rs1691799	0.777	rs11176145	chr12:66719795	A/G	cg16791601	chr12:66731901	HELB	0.59	8.69	0.47	3.93e-16	White blood cell count (basophil);
CESC	cis	rs7124681	0.585	rs10838773	chr11:47834346	G/A	cg20307385	chr11:47447363	PSMC3	0.6	8.27	0.45	6.34e-15	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
CESC	cis	rs919433	0.963	rs10199410	chr2:198155776	A/T	cg03934865	chr2:198174659	NA	-0.46	-6.97	-0.39	2.51e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	trans	rs9467711	0.606	rs12174623	chr6:26373086	C/T	cg06606381	chr12:133084897	FBRSL1	-0.76	-7.04	-0.4	1.64e-11	Autism spectrum disorder or schizophrenia;
CESC	cis	rs1559088	0.948	rs7257858	chr19:33591231	T/C	cg27124370	chr19:33622961	WDR88	0.45	6.0	0.35	6.49e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs34779708	0.733	rs4007271	chr10:35546611	C/T	cg03585969	chr10:35415529	CREM	0.55	6.37	0.36	8.28e-10	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs796364	0.951	rs11675980	chr2:201051150	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.66	-6.35	-0.36	9.11e-10	Schizophrenia;
CESC	cis	rs9303280	0.806	rs12941333	chr17:38040534	C/T	cg19468946	chr17:37922297	IKZF3	-0.41	-5.42	-0.32	1.31e-7	Self-reported allergy;
CESC	cis	rs7666738	0.830	rs28729647	chr4:99059552	T/C	cg18180107	chr4:99064573	C4orf37	0.41	5.2	0.3	3.91e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4862307	0.688	rs6552741	chr4:184990335	A/G	cg06737308	chr4:185021514	ENPP6	-0.46	-6.34	-0.36	9.93e-10	Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	cis	rs1348850	0.958	rs1405713	chr2:178461560	G/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.62	8.62	0.47	6.11e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs10089	1.000	rs10478798	chr5:127442394	C/T	cg19767477	chr5:127420684	SLC12A2	-0.42	-5.66	-0.33	3.84e-8	Ileal carcinoids;
CESC	cis	rs652260	0.819	rs55656533	chr19:7902976	G/C	cg26014689	chr19:7917955	EVI5L	-0.44	-5.92	-0.34	9.75e-9	Menarche (age at onset);
CESC	cis	rs854765	0.583	rs8073001	chr17:17831716	A/C	cg09796270	chr17:17721594	SREBF1	-0.45	-6.44	-0.37	5.45e-10	Total body bone mineral density;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12149777	chr4:139937459	CCRN4L	0.66	7.91	0.44	6.78e-14	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13786666	chr9:86536028	KIF27	0.54	6.53	0.37	3.34e-10	Gut microbiome composition (summer);
CESC	cis	rs11190604	1.000	rs10883497	chr10:102228519	A/G	cg07080220	chr10:102295463	HIF1AN	0.57	5.82	0.34	1.7e-8	Palmitoleic acid (16:1n-7) levels;
CESC	trans	rs11039798	0.610	rs11530356	chr11:48836290	C/A	cg15704280	chr7:45808275	SEPT13	0.71	6.44	0.37	5.59e-10	Axial length;
CESC	cis	rs1707322	1.000	rs7526369	chr1:46390560	G/C	cg05343316	chr1:45956843	TESK2	0.44	5.42	0.32	1.36e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs12200560	0.505	rs211163	chr6:97067654	A/G	cg06623918	chr6:96969491	KIAA0776	0.46	5.8	0.34	1.92e-8	Coronary heart disease;
CESC	cis	rs10504229	0.683	rs16921843	chr8:58113338	T/C	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs875971	0.522	rs1917563	chr7:65415647	C/T	cg11987759	chr7:65425863	GUSB	0.47	6.37	0.36	8.53e-10	Aortic root size;
CESC	cis	rs7703051	0.901	rs6896136	chr5:74787310	T/C	cg03227963	chr5:74354835	NA	0.3	5.38	0.31	1.67e-7	LDL cholesterol;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
CESC	cis	rs6860806	0.661	rs6871350	chr5:131580220	A/G	cg22638593	chr5:131593259	PDLIM4	0.43	5.67	0.33	3.68e-8	Breast cancer;
CESC	cis	rs4434138	0.568	rs6414569	chr3:52708075	A/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.36	6.45	0.37	5.14e-10	Intelligence (multi-trait analysis);
CESC	cis	rs2304069	0.545	rs7445660	chr5:149413610	A/C	cg12661370	chr5:149340060	SLC26A2	0.48	6.49	0.37	4.12e-10	HIV-1 control;
CESC	cis	rs10510653	0.522	rs58075697	chr3:32023275	G/C	cg05935571	chr3:32023257	ZNF860;OSBPL10	0.96	8.71	0.47	3.43e-16	Schizophrenia;
CESC	cis	rs3820068	0.705	rs4646110	chr1:15817318	A/T	cg17385448	chr1:15911702	AGMAT	0.39	6.13	0.35	3.14e-9	Systolic blood pressure;
CESC	cis	rs7267979	0.873	rs6083853	chr20:25404541	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.82	-15.69	-0.69	1.07e-39	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs752010	0.756	rs943374	chr1:42056194	A/G	cg06885757	chr1:42089581	HIVEP3	0.48	7.8	0.43	1.47e-13	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.64	0.38	1.75e-10	Prudent dietary pattern;
CESC	cis	rs9916302	0.752	rs9901219	chr17:37558369	T/G	cg07936489	chr17:37558343	FBXL20	0.98	13.6	0.64	2.6e-32	Glomerular filtration rate (creatinine);
CESC	cis	rs2836974	0.966	rs7283516	chr21:40690537	A/G	cg11890956	chr21:40555474	PSMG1	1.13	19.25	0.76	2.85e-52	Cognitive function;
CESC	cis	rs2425143	1.000	rs6058311	chr20:34321895	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.6	5.3	0.31	2.46e-7	Blood protein levels;
CESC	trans	rs1003719	0.715	rs762139	chr21:38568475	A/T	cg12989020	chr6:157098657	ARID1B	-0.43	-6.06	-0.35	4.69e-9	Eye color traits;
CESC	cis	rs1707322	0.963	rs10789484	chr1:46406978	G/C	cg06784218	chr1:46089804	CCDC17	0.33	5.63	0.33	4.7e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs8114671	0.967	rs1415774	chr20:33765616	C/T	cg24642439	chr20:33292090	TP53INP2	-0.43	-5.23	-0.31	3.49e-7	Height;
CESC	trans	rs561341	1.000	rs757009	chr17:30243937	A/G	cg20587970	chr11:113659929	NA	-0.83	-10.48	-0.54	9.94e-22	Hip circumference adjusted for BMI;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01627046	chr12:125473657	DHX37	0.7	7.65	0.43	3.84e-13	Gut microbiome composition (summer);
CESC	cis	rs911555	0.755	rs975892	chr14:103883349	A/T	cg24130564	chr14:104152367	KLC1	-0.5	-6.75	-0.38	9.28e-11	Intelligence (multi-trait analysis);
CESC	cis	rs67311347	0.549	rs60249586	chr3:40246659	G/A	cg09455208	chr3:40491958	NA	0.33	5.24	0.31	3.34e-7	Renal cell carcinoma;
CESC	trans	rs9951602	0.512	rs73494176	chr18:76644895	T/C	cg02800362	chr5:177631904	HNRNPAB	0.62	8.16	0.45	1.36e-14	Obesity-related traits;
CESC	cis	rs6831352	0.918	rs17218239	chr4:100057020	G/A	cg13256891	chr4:100009986	ADH5	-0.77	-8.45	-0.46	1.97e-15	Alcohol dependence;
CESC	cis	rs718433	0.584	rs7158042	chr14:22221077	A/G	cg02257791	chr14:22217085	NA	0.33	5.24	0.31	3.32e-7	Intraocular pressure;
CESC	cis	rs1190552	0.846	rs11623570	chr14:102959277	G/T	cg18135206	chr14:102964638	TECPR2	0.41	5.13	0.3	5.7e-7	Blood protein levels;
CESC	cis	rs763121	0.853	rs138706	chr22:39137834	C/G	cg06022373	chr22:39101656	GTPBP1	0.92	17.08	0.72	1.33e-44	Menopause (age at onset);
CESC	trans	rs61931739	0.500	rs28692887	chr12:34457075	G/A	cg26384229	chr12:38710491	ALG10B	0.69	10.44	0.54	1.34e-21	Morning vs. evening chronotype;
CESC	cis	rs2712184	1.000	rs2712184	chr2:217682779	G/T	cg05032264	chr2:217675019	NA	-0.37	-5.6	-0.33	5.43e-8	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
CESC	trans	rs10435719	0.867	rs34583868	chr8:11791383	G/T	cg15556689	chr8:8085844	FLJ10661	0.52	6.35	0.36	9.52e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
CESC	cis	rs7312933	1.000	rs12372623	chr12:42531666	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.44	5.86	0.34	1.38e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs7927592	0.956	rs12365160	chr11:68250419	A/G	cg20283391	chr11:68216788	NA	-0.51	-6.17	-0.35	2.55e-9	Total body bone mineral density;
CESC	cis	rs1790761	0.587	rs7934075	chr11:67295949	T/C	cg08355456	chr11:67383691	NA	-0.32	-5.15	-0.3	5.13e-7	Mean corpuscular volume;
CESC	cis	rs13118159	0.725	rs71614967	chr4:1341291	A/G	cg00684032	chr4:1343700	KIAA1530	0.44	6.79	0.38	7.31e-11	Longevity;
CESC	cis	rs4073405	0.584	rs2902433	chr11:45301131	G/C	cg27235148	chr11:45376932	NA	-0.29	-5.11	-0.3	6.11e-7	Schizophrenia;
CESC	trans	rs13179617	0.928	rs11952146	chr5:60818863	A/G	cg05478497	chr12:4274287	NA	-0.35	-6.02	-0.35	5.91e-9	Intelligence (multi-trait analysis);
CESC	cis	rs208520	0.690	rs2797693	chr6:66868985	T/C	cg07460842	chr6:66804631	NA	-0.99	-13.52	-0.64	4.76e-32	Exhaled nitric oxide output;
CESC	trans	rs9325144	0.647	rs11168104	chr12:38857616	G/T	cg23762105	chr12:34175262	ALG10	0.46	6.04	0.35	5.3e-9	Morning vs. evening chronotype;
CESC	cis	rs12618769	0.597	rs17031146	chr2:99036683	A/G	cg10123293	chr2:99228465	UNC50	0.4	5.48	0.32	9.88e-8	Bipolar disorder;
CESC	cis	rs3781913	1.000	rs3781913	chr11:72373496	A/C	cg04827223	chr11:72435913	ARAP1	0.33	5.1	0.3	6.56e-7	Rheumatoid arthritis;
CESC	cis	rs7927771	0.524	rs12785949	chr11:47729770	C/T	cg18512352	chr11:47633146	NA	0.34	5.26	0.31	3e-7	Subjective well-being;
CESC	cis	rs10504229	0.953	rs6991035	chr8:58183374	C/T	cg05313129	chr8:58192883	C8orf71	-0.55	-6.29	-0.36	1.34e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs798766	1.000	rs798762	chr4:1731150	T/C	cg07041428	chr4:1763019	NA	-0.41	-5.78	-0.33	2.1e-8	Bladder cancer;Urinary bladder cancer;
CESC	cis	rs6800768	0.633	rs62255803	chr3:24149030	T/C	cg10674438	chr3:24145617	LOC152024	-0.47	-6.46	-0.37	5.08e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs4268898	0.552	rs4665663	chr2:24372139	G/C	cg06627628	chr2:24431161	ITSN2	0.6	8.31	0.45	5.17e-15	Asthma;
CESC	cis	rs9660992	0.548	rs1172152	chr1:205220718	T/A	cg00857998	chr1:205179979	DSTYK	0.56	6.84	0.39	5.58e-11	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs6460942	0.915	rs62447639	chr7:12486803	T/C	cg06484146	chr7:12443880	VWDE	-0.77	-8.63	-0.47	5.59e-16	Coronary artery disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg13453304	chr18:77493499	CTDP1	0.51	6.54	0.37	3.15e-10	Fibrinogen levels;
CESC	cis	rs56046484	0.871	rs35000527	chr15:85553781	A/G	cg08123816	chr15:85640762	PDE8A	-0.5	-5.94	-0.34	9.11e-9	Testicular germ cell tumor;
CESC	cis	rs344364	0.511	rs1742463	chr16:1946110	A/G	cg03013636	chr16:1946785	NA	0.48	6.62	0.38	2.02e-10	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs9872999	1	rs9872999	chr3:133457514	C/T	cg18769074	chr3:133464867	TF	0.3	5.87	0.34	1.33e-8	Iron status biomarkers;
CESC	cis	rs8027181	1.000	rs4776613	chr15:73080731	C/T	cg25632853	chr15:73088954	NA	0.37	6.38	0.37	7.72e-10	Triglyceride levels;
CESC	cis	rs7772486	0.817	rs2748491	chr6:146327759	T/C	cg23711669	chr6:146136114	FBXO30	0.82	11.62	0.58	1.68e-25	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs11577318	0.812	rs3795683	chr1:26632831	C/A	cg00813993	chr1:26644493	UBXN11;CD52	-0.4	-6.52	-0.37	3.53e-10	Granulocyte percentage of myeloid white cells;
CESC	cis	rs6088580	0.634	rs9789792	chr20:32957709	G/A	cg06115741	chr20:33292138	TP53INP2	-0.46	-5.89	-0.34	1.14e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs7666738	0.830	rs17558193	chr4:99049593	A/G	cg18180107	chr4:99064573	C4orf37	0.41	5.29	0.31	2.51e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg10137979	chr8:110346498	ENY2;NUDCD1	-0.42	-6.01	-0.35	5.95e-9	Fibrinogen levels;
CESC	cis	rs460214	0.528	rs6517474	chr21:40023133	G/A	cg05519781	chr21:40033154	ERG	-0.46	-5.5	-0.32	8.79e-8	Response to cognitive-behavioural therapy in anxiety disorder;
CESC	cis	rs6089829	0.889	rs6062773	chr20:61663262	G/C	cg16240275	chr20:61666158	NCRNA00029	0.5	8.97	0.48	5.67e-17	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs992157	0.560	rs12992937	chr2:219087072	A/T	cg00012203	chr2:219082015	ARPC2	-0.74	-9.9	-0.52	7.06e-20	Colorectal cancer;
CESC	cis	rs4635969	0.718	rs27071	chr5:1346081	T/C	cg06550200	chr5:1325588	CLPTM1L	-0.69	-7.86	-0.43	9.7e-14	Testicular germ cell tumor;Testicular germ cell cancer;
CESC	cis	rs9311474	0.502	rs4687624	chr3:52563572	C/T	cg17372223	chr3:52568218	NT5DC2	0.51	7.91	0.44	6.97e-14	Electroencephalogram traits;
CESC	trans	rs10506458	0.688	rs60936040	chr12:63416461	G/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.05	-13.59	-0.64	2.8099999999999997e-32	Hemostatic factors and hematological phenotypes;
CESC	cis	rs651907	0.557	rs12629658	chr3:101356535	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.46	5.86	0.34	1.35e-8	Colorectal cancer;
CESC	cis	rs7666738	0.830	rs10049985	chr4:99023517	C/T	cg17366294	chr4:99064904	C4orf37	0.61	8.76	0.47	2.35e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7833986	0.501	rs72653986	chr8:57035048	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.57	7.28	0.41	3.83e-12	Height;
CESC	cis	rs3820068	0.603	rs35509554	chr1:15993514	C/T	cg18133145	chr1:16060689	PLEKHM2	-0.42	-5.37	-0.31	1.76e-7	Systolic blood pressure;
CESC	cis	rs13253111	0.646	rs36046709	chr8:28078214	A/T	cg26534493	chr8:28060551	NA	0.53	8.16	0.45	1.37e-14	Childhood body mass index;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10481400	chr16:67596437	CTCF	0.56	6.16	0.35	2.63e-9	Gut microbiome composition (summer);
CESC	cis	rs854765	0.547	rs7224047	chr17:17932931	G/A	cg04398451	chr17:18023971	MYO15A	-0.71	-10.37	-0.54	2.34e-21	Total body bone mineral density;
CESC	trans	rs9987353	0.840	rs329994	chr8:9123233	A/G	cg11654179	chr12:57998762	DTX3	-0.46	-6.02	-0.35	5.64e-9	Recombination measurement;
CESC	cis	rs72781680	1.000	rs72796351	chr2:24158425	T/C	cg08917208	chr2:24149416	ATAD2B	0.94	8.66	0.47	4.66e-16	Lymphocyte counts;
CESC	cis	rs34734847	1.000	rs34734847	chr12:121154221	T/C	cg21892295	chr12:121157589	UNC119B	-0.42	-6.65	-0.38	1.66e-10	Mean corpuscular volume;
CESC	cis	rs875971	0.767	rs1695815	chr7:65831344	A/G	cg10691866	chr7:65817282	TPST1	-0.34	-5.46	-0.32	1.08e-7	Aortic root size;
CESC	cis	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg13880726	chr7:1868755	MAD1L1	0.51	6.78	0.38	8e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs13191362	1.000	rs35017019	chr6:162982581	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.82	8.45	0.46	2e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs3820928	0.967	rs4675114	chr2:227768362	C/T	cg05526886	chr2:227700861	RHBDD1	-0.43	-5.54	-0.32	7.16e-8	Pulmonary function;
CESC	cis	rs2228479	0.557	rs34420680	chr16:89809171	C/T	cg06558623	chr16:89946397	TCF25	1.16	9.1	0.49	2.17e-17	Skin colour saturation;
CESC	cis	rs7818345	0.845	rs4256608	chr8:19267560	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.35	6.13	0.35	3.21e-9	Language performance in older adults (adjusted for episodic memory);
CESC	cis	rs10927875	0.596	rs1806990	chr1:16129377	G/A	cg05821634	chr1:16164109	FLJ37453	0.35	5.08	0.3	6.97e-7	Dilated cardiomyopathy;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg04787407	chr4:99916511	METAP1	-0.46	-6.5	-0.37	3.9e-10	Height;
CESC	cis	rs1008375	1.000	rs28501187	chr4:17643620	G/A	cg16339924	chr4:17578868	LAP3	0.58	7.25	0.41	4.56e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg22907277	chr7:1156413	C7orf50	0.42	5.07	0.3	7.35e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs11864453	1.000	rs7201491	chr16:72034312	G/A	cg16558253	chr16:72132732	DHX38	-0.46	-6.77	-0.38	8.41e-11	Fibrinogen levels;
CESC	cis	rs933688	1.000	rs10073657	chr5:90689749	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.97	12.98	0.62	3.7e-30	Smoking behavior;
CESC	cis	rs7617480	0.648	rs6801211	chr3:48774420	C/G	cg07636037	chr3:49044803	WDR6	0.82	12.17	0.6	2.33e-27	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CESC	cis	rs3733585	0.699	rs6449157	chr4:9960442	G/A	cg11266682	chr4:10021025	SLC2A9	-0.6	-11.22	-0.57	3.77e-24	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs116095464	0.558	rs7708515	chr5:234989	C/G	cg12570787	chr5:219185	SDHA;CCDC127	0.5	5.3	0.31	2.49e-7	Breast cancer;
CESC	cis	rs77861329	1.000	rs352148	chr3:52208898	A/G	cg08692210	chr3:52188851	WDR51A	0.77	6.3	0.36	1.21e-9	Macrophage inflammatory protein 1b levels;
CESC	cis	rs611744	0.870	rs596703	chr8:109160146	A/G	cg21045802	chr8:109455806	TTC35	-0.44	-5.45	-0.32	1.13e-7	Dupuytren's disease;
CESC	cis	rs138171347	1	rs138171347	chr17:5183203	AAAAT/A	cg24500398	chr17:5266808	RABEP1	-0.47	-6.74	-0.38	9.85e-11	White blood cell count;
CESC	cis	rs28374715	0.635	rs8023530	chr15:41647775	T/C	cg20272979	chr15:41787780	ITPKA	0.38	5.17	0.3	4.7e-7	Ulcerative colitis;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg15437133	chr10:77160907	ZNF503;C10orf41	-0.48	-6.75	-0.38	9.49e-11	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs17376456	1.000	rs59472588	chr5:93511981	A/G	cg21475434	chr5:93447410	FAM172A	0.85	7.73	0.43	2.19e-13	Diabetic retinopathy;
CESC	cis	rs2228479	0.850	rs62056091	chr16:89930414	G/A	cg00800038	chr16:89945340	TCF25	-0.93	-7.46	-0.42	1.28e-12	Skin colour saturation;
CESC	cis	rs910316	0.789	rs12894419	chr14:75471802	C/T	cg16144293	chr14:75469539	EIF2B2	-0.4	-5.27	-0.31	2.82e-7	Height;
CESC	cis	rs1801251	1.000	rs2675974	chr2:233727071	A/G	cg25237894	chr2:233734115	C2orf82	0.47	8.51	0.46	1.31e-15	Coronary artery disease;
CESC	cis	rs739401	0.967	rs451041	chr11:3060725	C/T	cg08508325	chr11:3079039	CARS	-0.4	-7.47	-0.42	1.14e-12	Longevity;
CESC	cis	rs6461049	0.765	rs10224497	chr7:2149967	A/G	cg08027265	chr7:2291960	NA	-0.37	-5.63	-0.33	4.58e-8	Schizophrenia;
CESC	cis	rs6460942	0.915	rs6945067	chr7:12444731	A/C	cg06484146	chr7:12443880	VWDE	-0.73	-8.75	-0.47	2.6e-16	Coronary artery disease;
CESC	cis	rs1005277	0.579	rs116912400	chr10:38479207	G/T	cg25427524	chr10:38739819	LOC399744	-0.7	-10.24	-0.53	6.01e-21	Extrinsic epigenetic age acceleration;
CESC	cis	rs13256369	0.851	rs11786125	chr8:8564570	T/G	cg18904891	chr8:8559673	CLDN23	0.71	8.07	0.44	2.44e-14	Obesity-related traits;
CESC	cis	rs8017423	0.845	rs8005870	chr14:90723172	A/C	cg14092571	chr14:90743983	NA	-0.56	-8.36	-0.46	3.6e-15	Mortality in heart failure;
CESC	cis	rs27434	0.660	rs26493	chr5:96155318	C/T	cg16492584	chr5:96139282	ERAP1	-0.46	-5.52	-0.32	7.92e-8	Ankylosing spondylitis;
CESC	cis	rs3105593	1.000	rs3131573	chr15:50869601	G/A	cg08437265	chr15:50716283	USP8	0.41	5.29	0.31	2.62e-7	QT interval;
CESC	cis	rs72781680	0.821	rs11894756	chr2:24170214	A/G	cg08917208	chr2:24149416	ATAD2B	-0.6	-5.96	-0.34	8.12e-9	Lymphocyte counts;
CESC	cis	rs9399135	0.967	rs9376082	chr6:135346389	T/A	cg24558204	chr6:135376177	HBS1L	0.51	7.19	0.4	6.72e-12	Red blood cell count;
CESC	cis	rs1799949	0.965	rs4793230	chr17:41427403	A/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.51	7.22	0.41	5.61e-12	Menopause (age at onset);
CESC	cis	rs9486719	1.000	rs12207570	chr6:96987884	A/C	cg18709589	chr6:96969512	KIAA0776	-0.5	-5.5	-0.32	9.03e-8	Migraine;Coronary artery disease;
CESC	cis	rs3820928	0.904	rs1835159	chr2:227764057	A/G	cg05526886	chr2:227700861	RHBDD1	-0.42	-5.45	-0.32	1.15e-7	Pulmonary function;
CESC	cis	rs6570726	0.791	rs9403734	chr6:145931459	C/G	cg23711669	chr6:146136114	FBXO30	0.99	15.04	0.68	2.25e-37	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs9785234	0.540	rs10819950	chr9:98935333	C/T	cg09119967	chr20:9494838	C20orf103	-0.38	-6.07	-0.35	4.37e-9	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs13191362	0.935	rs7763118	chr6:162954720	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.71	7.16	0.4	8.16e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs892961	1.000	rs892961	chr17:75400100	A/T	cg05865280	chr17:75406074	SEPT9	0.59	6.11	0.35	3.49e-9	Airflow obstruction;
CESC	cis	rs875971	0.660	rs801190	chr7:66033033	C/T	cg11764359	chr7:65958608	NA	-0.71	-9.5	-0.5	1.32e-18	Aortic root size;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg05688084	chr1:19578805	MRTO4;KIAA0090	0.42	6.41	0.37	6.8e-10	Gambling;
CESC	cis	rs7107174	0.892	rs10793310	chr11:78099014	T/G	cg02023728	chr11:77925099	USP35	0.47	6.17	0.35	2.54e-9	Testicular germ cell tumor;
CESC	cis	rs11958404	0.615	rs7703242	chr5:157447920	T/C	cg05962755	chr5:157440814	NA	0.38	5.65	0.33	4.21e-8	IgG glycosylation;
CESC	trans	rs1814175	0.645	rs847632	chr11:49926097	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.42	-6.25	-0.36	1.68e-9	Height;
CESC	cis	rs1707322	0.752	rs11488313	chr1:46224780	G/C	cg05343316	chr1:45956843	TESK2	0.5	6.29	0.36	1.32e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs73058052	1.000	rs3760707	chr19:50084454	T/C	cg09250473	chr19:50168907	IRF3;BCL2L12	0.56	5.26	0.31	2.94e-7	Fibrinogen levels;
CESC	cis	rs1552244	1.000	rs55882090	chr3:10139082	C/T	cg00166722	chr3:10149974	C3orf24	0.46	5.89	0.34	1.18e-8	Alzheimer's disease;
CESC	cis	rs7264396	0.563	rs6060569	chr20:34290731	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.89	-10.78	-0.55	1.03e-22	Total cholesterol levels;
CESC	cis	rs4253772	0.744	rs1134224	chr22:46633371	A/T	cg09491104	chr22:46646882	C22orf40	-0.57	-8.87	-0.48	1.14e-16	LDL cholesterol;Cholesterol, total;
CESC	cis	rs2230307	0.536	rs57637634	chr1:100447467	G/A	cg24955406	chr1:100503596	HIAT1	0.51	5.16	0.3	4.74e-7	Carotid intima media thickness;
CESC	trans	rs74054849	0.850	rs6692555	chr1:16012657	C/T	cg06826283	chr7:600452	PRKAR1B	-0.7	-6.22	-0.36	1.96e-9	Alcoholic chronic pancreatitis;
CESC	cis	rs7666738	0.830	rs10028692	chr4:98962585	C/T	cg05340658	chr4:99064831	C4orf37	0.8	12.39	0.61	3.96e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3780486	0.713	rs3780489	chr9:33129844	G/T	cg13443165	chr9:33130375	B4GALT1	0.45	6.46	0.37	5.07e-10	IgG glycosylation;
CESC	cis	rs10751667	1.000	rs10794349	chr11:945678	T/C	cg01483505	chr11:975446	AP2A2	0.4	5.27	0.31	2.9e-7	Alzheimer's disease (late onset);
CESC	cis	rs11098499	0.820	rs6829903	chr4:120506884	C/T	cg09307838	chr4:120376055	NA	0.93	12.6	0.61	7.82e-29	Corneal astigmatism;
CESC	cis	rs2191566	0.506	rs396116	chr19:44494583	A/G	cg20607764	chr19:44506953	ZNF230	0.45	5.69	0.33	3.34e-8	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs854765	0.547	rs7223696	chr17:17915791	G/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.54	7.38	0.41	2.08e-12	Total body bone mineral density;
CESC	cis	rs12995491	0.731	rs17435433	chr2:88509616	A/G	cg14558114	chr2:88469736	THNSL2	-0.49	-6.96	-0.39	2.6e-11	Response to metformin (IC50);
CESC	cis	rs34779708	0.966	rs6481941	chr10:35440141	G/A	cg03585969	chr10:35415529	CREM	0.76	9.96	0.52	4.69e-20	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs12497850	0.864	rs4955410	chr3:49181218	A/G	cg03060546	chr3:49711283	APEH	0.51	6.31	0.36	1.14e-9	Parkinson's disease;
CESC	cis	rs798554	0.679	rs2533877	chr7:2882421	G/A	cg18446336	chr7:2847575	GNA12	-0.36	-5.64	-0.33	4.32e-8	Height;
CESC	cis	rs72781680	0.898	rs17462670	chr2:24026579	T/C	cg20701182	chr2:24300061	SF3B14	0.63	5.65	0.33	4.21e-8	Lymphocyte counts;
CESC	trans	rs9650657	0.537	rs7016385	chr8:10779472	A/G	cg15556689	chr8:8085844	FLJ10661	0.5	6.11	0.35	3.6e-9	Neuroticism;
CESC	cis	rs7692995	1.000	rs7696532	chr4:18029299	C/T	cg08925142	chr4:18023851	LCORL	-0.44	-5.08	-0.3	7.07e-7	Height;
CESC	cis	rs921968	0.643	rs832801	chr2:219488698	G/A	cg02176678	chr2:219576539	TTLL4	0.37	6.33	0.36	1.07e-9	Mean corpuscular hemoglobin concentration;
CESC	cis	rs7618915	0.571	rs11130307	chr3:52607682	G/A	cg17372223	chr3:52568218	NT5DC2	0.43	6.36	0.36	9.03e-10	Bipolar disorder;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg07552157	chr3:142720316	SR140	-0.46	-6.1	-0.35	3.65e-9	Ulcerative colitis;
CESC	cis	rs7829975	0.774	rs11775523	chr8:8679176	A/G	cg06636001	chr8:8085503	FLJ10661	0.45	5.82	0.34	1.69e-8	Mood instability;
CESC	cis	rs4906332	1.000	rs12896612	chr14:103877868	A/G	cg09975044	chr14:104007538	NA	0.45	6.17	0.35	2.56e-9	Coronary artery disease;
CESC	cis	rs412000	0.554	rs2680700	chr17:56440542	G/T	cg12560992	chr17:57184187	TRIM37	0.63	7.72	0.43	2.38e-13	Primary tooth development (time to first tooth eruption);
CESC	cis	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg04267008	chr7:1944627	MAD1L1	-0.57	-6.89	-0.39	4.08e-11	Bipolar disorder and schizophrenia;
CESC	trans	rs4596713	0.538	rs7030146	chr9:71756390	T/G	cg16512924	chr15:28394682	HERC2	0.51	6.62	0.38	1.93e-10	Headache;
CESC	cis	rs4654899	0.802	rs76122612	chr1:21243059	C/T	cg05370193	chr1:21551575	ECE1	0.38	5.51	0.32	8.66e-8	Superior frontal gyrus grey matter volume;
CESC	cis	rs12477438	0.520	rs11123761	chr2:99705903	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.92	15.78	0.7	5.4e-40	Chronic sinus infection;
CESC	cis	rs736408	0.609	rs62255396	chr3:52782839	C/T	cg18404041	chr3:52824283	ITIH1	-0.41	-6.79	-0.38	7.35e-11	Bipolar disorder;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg01431559	chr13:73305955	C13orf34	0.38	6.03	0.35	5.38e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs3820068	0.603	rs72645900	chr1:15931980	A/T	cg16988262	chr1:15930761	NA	0.33	5.35	0.31	1.89e-7	Systolic blood pressure;
CESC	cis	rs5758659	0.652	rs133340	chr22:42417687	A/T	cg15557168	chr22:42548783	NA	0.44	6.6	0.38	2.28e-10	Cognitive function;
CESC	cis	rs34779708	0.966	rs12784482	chr10:35446865	A/G	cg03585969	chr10:35415529	CREM	0.77	10.24	0.53	6.08e-21	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs11722228	1.000	rs11722228	chr4:9915741	C/T	cg00071950	chr4:10020882	SLC2A9	0.57	8.47	0.46	1.73e-15	Gout;Urate levels;Serum uric acid levels;
CESC	cis	rs1152591	0.562	rs1272715	chr14:64651989	A/T	cg21174375	chr14:64681225	SYNE2	0.55	7.73	0.43	2.17e-13	Atrial fibrillation;
CESC	cis	rs28830936	1.000	rs4924575	chr15:42096926	C/T	cg11010575	chr15:42129464	JMJD7-PLA2G4B;JMJD7	-0.41	-5.59	-0.32	5.56e-8	Diastolic blood pressure;
CESC	cis	rs4689388	0.890	rs6446481	chr4:6295583	C/A	cg00701064	chr4:6280414	WFS1	0.66	11.15	0.57	6.2e-24	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs3020736	0.500	rs8138678	chr22:42516229	A/G	cg04733989	chr22:42467013	NAGA	-0.78	-11.72	-0.58	7.82e-26	Autism spectrum disorder or schizophrenia;
CESC	cis	rs8028182	0.549	rs11072542	chr15:75634599	G/A	cg20655648	chr15:75932815	IMP3	-0.43	-5.36	-0.31	1.78e-7	Sudden cardiac arrest;
CESC	cis	rs9948	1.000	rs62152793	chr2:97484948	C/T	cg01990225	chr2:97406019	LMAN2L	-0.78	-5.5	-0.32	9.06e-8	Erectile dysfunction and prostate cancer treatment;
CESC	cis	rs10504229	0.516	rs58244172	chr8:57987805	G/A	cg24829409	chr8:58192753	C8orf71	-0.36	-5.08	-0.3	7.21e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs4665809	1.000	rs11678157	chr2:26321526	T/C	cg26314531	chr2:26401878	FAM59B	-0.59	-6.74	-0.38	9.88e-11	Gut microbiome composition (summer);
CESC	cis	rs8070624	0.574	rs11078408	chr17:17876011	A/G	cg04398451	chr17:18023971	MYO15A	-0.75	-10.67	-0.55	2.48e-22	Total body bone mineral density;
CESC	cis	rs875971	0.964	rs9691480	chr7:65944306	A/C	cg11764359	chr7:65958608	NA	0.97	15.5	0.69	5.25e-39	Aortic root size;
CESC	cis	rs7532866	0.885	rs7552065	chr1:26731951	G/T	cg17456097	chr1:26900765	RPS6KA1	-0.47	-6.04	-0.35	5.31e-9	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01222216	chr16:2648276	PDPK1	-0.57	-6.63	-0.38	1.89e-10	Gut microbiome composition (summer);
CESC	cis	rs60871478	0.588	rs6952577	chr7:872100	C/T	cg15782153	chr7:917662	C7orf20	-0.47	-5.12	-0.3	5.77e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs6089829	0.962	rs6122352	chr20:61668284	T/C	cg08564027	chr20:61660810	NA	0.9	15.44	0.69	8.75e-39	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs7618501	1.000	rs4855867	chr3:49745822	C/T	cg21659725	chr3:3221576	CRBN	-0.82	-13.57	-0.64	3.35e-32	Intelligence (multi-trait analysis);
CESC	cis	rs11048434	0.736	rs12821842	chr12:9108984	G/A	cg23795048	chr12:9217529	LOC144571	0.35	5.4	0.31	1.52e-7	Sjögren's syndrome;
CESC	cis	rs28830936	0.932	rs1105881	chr15:42072530	C/G	cg11010575	chr15:42129464	JMJD7-PLA2G4B;JMJD7	-0.46	-6.35	-0.36	9.24e-10	Diastolic blood pressure;
CESC	cis	rs798554	0.797	rs798497	chr7:2795957	A/G	cg19717773	chr7:2847554	GNA12	-0.57	-8.18	-0.45	1.18e-14	Height;
CESC	cis	rs1008375	0.966	rs4698621	chr4:17587565	C/T	cg16339924	chr4:17578868	LAP3	0.74	9.65	0.51	4.51e-19	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs4727027	0.901	rs6944781	chr7:148829566	A/G	cg23583168	chr7:148888333	NA	-0.74	-10.89	-0.56	4.6e-23	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs7923609	1.000	rs4595427	chr10:65012944	A/C	cg01631684	chr10:65280961	REEP3	-0.44	-5.48	-0.32	9.99e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs9914578	1.000	rs9914578	chr17:2005136	C/G	cg16513277	chr17:2031491	SMG6	-0.58	-6.67	-0.38	1.51e-10	Body mass index;
CESC	cis	rs10479542	0.766	rs6894980	chr5:178974592	C/T	cg09060608	chr5:178986726	RUFY1	0.42	5.76	0.33	2.31e-8	Lung cancer;
CESC	cis	rs4665809	1.000	rs1371553	chr2:26262948	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.7	-7.87	-0.44	8.94e-14	Gut microbiome composition (summer);
CESC	trans	rs3794271	0.706	rs9971816	chr12:20826911	C/T	cg04108127	chr1:222885781	AIDA;C1orf58	-0.4	-6.08	-0.35	4.13e-9	Response to TNF-alpha inhibitors in rheumatoid arthritis;
CESC	cis	rs6568686	0.627	rs174377	chr6:111908646	C/A	cg22127309	chr6:111907043	TRAF3IP2	0.53	5.2	0.3	3.91e-7	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
CESC	cis	rs10504229	1.000	rs77823122	chr8:58170161	A/G	cg22535103	chr8:58192502	C8orf71	-1.05	-12.98	-0.62	3.88e-30	Developmental language disorder (linguistic errors);
CESC	cis	rs35306767	0.903	rs61830933	chr10:934195	G/A	cg20503657	chr10:835505	NA	1.07	9.91	0.52	6.79e-20	Eosinophil percentage of granulocytes;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg18126572	chr7:43909213	MRPS24	-0.5	-6.35	-0.36	9.05e-10	Ulcerative colitis;
CESC	trans	rs208520	0.690	rs10455595	chr6:66738034	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.95	12.26	0.6	1.09e-27	Exhaled nitric oxide output;
CESC	cis	rs863345	0.604	rs10908658	chr1:158465256	A/G	cg12129480	chr1:158549410	OR10X1	-0.35	-6.97	-0.39	2.46e-11	Pneumococcal bacteremia;
CESC	cis	rs9916302	0.851	rs11868029	chr17:37650304	A/G	cg20243544	chr17:37824526	PNMT	0.48	5.93	0.34	9.26e-9	Glomerular filtration rate (creatinine);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg14014699	chr9:139685500	TMEM141	-0.42	-6.35	-0.36	9.45e-10	Gambling;
CESC	cis	rs8072100	0.782	rs62074054	chr17:45771816	T/C	cg08085267	chr17:45401833	C17orf57	-0.43	-5.43	-0.32	1.27e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs2404602	0.692	rs34272342	chr15:77012276	A/C	cg22467129	chr15:76604101	ETFA	-0.34	-5.16	-0.3	4.84e-7	Blood metabolite levels;
CESC	cis	rs4642101	0.737	rs4447735	chr3:12825513	C/T	cg05775895	chr3:12838266	CAND2	0.39	5.99	0.35	6.8e-9	QRS complex (12-leadsum);
CESC	cis	rs2280018	0.526	rs2966128	chr16:15153389	G/T	cg07549590	chr16:15018862	NA	-0.6	-9.63	-0.51	5.22e-19	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04228274	chr13:21751145	MRP63;SKA3	0.53	6.06	0.35	4.54e-9	Gut microbiome composition (summer);
CESC	cis	rs3126085	0.877	rs4457589	chr1:152247860	T/C	cg03465714	chr1:152285911	FLG	-0.45	-5.56	-0.32	6.52e-8	Atopic dermatitis;
CESC	cis	rs12701220	0.689	rs12701824	chr7:1102364	G/A	cg26769984	chr7:1090371	C7orf50	0.59	5.84	0.34	1.5e-8	Bronchopulmonary dysplasia;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg06852250	chr1:171750693	METTL13	0.44	6.06	0.35	4.74e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs6121246	0.559	rs1062794	chr20:30381758	G/C	cg13852791	chr20:30311386	BCL2L1	0.85	11.17	0.57	5.35e-24	Mean corpuscular hemoglobin;
CESC	cis	rs7224314	1.000	rs62084078	chr17:65386886	T/C	cg01507342	chr17:65387096	PITPNC1	-0.47	-5.66	-0.33	3.86e-8	Diisocyanate-induced asthma;
CESC	cis	rs992157	0.735	rs13388024	chr2:219097773	A/G	cg20019365	chr2:219134978	PNKD;AAMP	0.67	9.4	0.5	2.62e-18	Colorectal cancer;
CESC	cis	rs4803468	0.904	rs60781668	chr19:41944842	A/T	cg09537434	chr19:41945824	ATP5SL	1.06	19.74	0.77	5.61e-54	Height;
CESC	cis	rs4713118	0.515	rs9368549	chr6:28050047	T/A	cg19592336	chr6:28129416	ZNF389	0.6	7.97	0.44	4.69e-14	Parkinson's disease;
CESC	cis	rs72627123	0.656	rs75646425	chr14:74529433	A/G	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.78	5.36	0.31	1.81e-7	Morning vs. evening chronotype;
CESC	cis	rs3806843	0.657	rs2563283	chr5:140105978	C/A	cg16179182	chr5:140090404	VTRNA1-1	0.42	5.51	0.32	8.6e-8	Depressive symptoms (multi-trait analysis);
CESC	cis	rs11098499	0.954	rs2306455	chr4:120421969	G/A	cg24375607	chr4:120327624	NA	0.46	5.66	0.33	3.87e-8	Corneal astigmatism;
CESC	cis	rs765787	0.530	rs2554456	chr15:45521138	A/C	cg24006582	chr15:45444508	DUOX1	-0.57	-6.9	-0.39	3.81e-11	Uric acid levels;
CESC	cis	rs4664308	0.935	rs877200	chr2:160903723	G/C	cg03641300	chr2:160917029	PLA2R1	-0.65	-9.79	-0.52	1.63e-19	Idiopathic membranous nephropathy;
CESC	cis	rs2016266	0.784	rs12424778	chr12:53737840	A/T	cg26875137	chr12:53738046	NA	0.36	5.24	0.31	3.23e-7	Bone mineral density (spine);Bone mineral density;
CESC	trans	rs7656342	0.808	rs10003216	chr4:9766749	A/G	cg09061317	chr1:28995172	GMEB1	-0.54	-6.25	-0.36	1.64e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs2455799	0.613	rs6772879	chr3:15741793	G/A	cg16303742	chr3:15540471	COLQ	-0.34	-5.33	-0.31	2.12e-7	Mean platelet volume;
CESC	cis	rs7584330	0.666	rs72620817	chr2:238353661	C/T	cg14458575	chr2:238380390	NA	0.84	10.63	0.55	3.16e-22	Prostate cancer;
CESC	cis	rs34779708	0.931	rs4934711	chr10:35360310	G/A	cg03585969	chr10:35415529	CREM	0.76	9.9	0.52	7.07e-20	Inflammatory bowel disease;Crohn's disease;
CESC	trans	rs3942852	0.568	rs1039484	chr11:48097948	A/G	cg15704280	chr7:45808275	SEPT13	-0.72	-9.38	-0.5	3.02e-18	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs1256061	0.624	rs1152578	chr14:64697037	T/C	cg21174375	chr14:64681225	SYNE2	0.48	6.36	0.36	8.86e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs798766	0.779	rs55895920	chr4:1735930	C/T	cg05874882	chr4:1763078	NA	-0.56	-7.3	-0.41	3.31e-12	Bladder cancer;Urinary bladder cancer;
CESC	cis	rs1413885	0.525	rs1334878	chr1:65846124	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.47	6.19	0.36	2.29e-9	Anticoagulant levels;
CESC	cis	rs4629180	0.540	rs6747670	chr2:102130368	T/C	cg04415270	chr2:102091202	RFX8	-0.31	-5.27	-0.31	2.85e-7	Chronic rhinosinusitis with nasal polyps;
CESC	cis	rs13118159	0.778	rs12640984	chr4:1338834	G/A	cg20887711	chr4:1340912	KIAA1530	0.44	5.95	0.34	8.58e-9	Longevity;
CESC	trans	rs1908814	0.516	rs10113062	chr8:11793249	A/G	cg15556689	chr8:8085844	FLJ10661	0.5	6.13	0.35	3.13e-9	Neuroticism;
CESC	cis	rs7208859	0.623	rs55724095	chr17:29153058	A/G	cg19761014	chr17:28927070	LRRC37B2	0.72	5.91	0.34	1.03e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs9303401	0.614	rs8081058	chr17:57160513	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.88	11.1	0.56	8.94e-24	Cognitive test performance;
CESC	cis	rs977987	0.750	rs4888406	chr16:75432334	G/T	cg03315344	chr16:75512273	CHST6	0.39	5.71	0.33	2.98e-8	Dupuytren's disease;
CESC	cis	rs9486715	0.867	rs4131519	chr6:96964939	G/A	cg18709589	chr6:96969512	KIAA0776	0.47	6.59	0.38	2.32e-10	Headache;
CESC	cis	rs7918232	0.941	rs788220	chr10:27447205	T/C	cg14240646	chr10:27532245	ACBD5	0.68	6.45	0.37	5.14e-10	Breast cancer;
CESC	cis	rs10489202	1.000	rs4656564	chr1:167928992	T/C	cg24449463	chr1:168025552	DCAF6	-0.45	-5.26	-0.31	3.02e-7	Schizophrenia;
CESC	cis	rs896854	0.902	rs896852	chr8:95960886	G/T	cg13393036	chr8:95962371	TP53INP1	-0.55	-12.25	-0.6	1.25e-27	Type 2 diabetes;
CESC	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg09177884	chr7:1199841	ZFAND2A	-0.54	-7.08	-0.4	1.29e-11	Longevity;Endometriosis;
CESC	cis	rs4148883	0.675	rs10000357	chr4:100099942	G/C	cg13256891	chr4:100009986	ADH5	0.53	6.93	0.39	3.23e-11	Alcohol dependence;
CESC	cis	rs1506636	1.000	rs1911145	chr7:123363658	A/G	cg03229431	chr7:123269106	ASB15	-0.52	-6.91	-0.39	3.58e-11	Plateletcrit;Platelet count;
CESC	cis	rs10484885	0.775	rs55926724	chr6:90417450	A/C	cg13799429	chr6:90582589	CASP8AP2	-0.72	-8.14	-0.45	1.6e-14	QRS interval (sulfonylurea treatment interaction);
CESC	cis	rs9393777	0.513	rs13190754	chr6:26587406	G/A	cg11502198	chr6:26597334	ABT1	0.49	5.14	0.3	5.26e-7	Intelligence (multi-trait analysis);
CESC	cis	rs4481887	0.893	rs6681339	chr1:248482761	C/G	cg00666640	chr1:248458726	OR2T12	0.34	5.64	0.33	4.3e-8	Common traits (Other);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg05491930	chr6:99872786	SFRS18	-0.45	-7.27	-0.41	3.99e-12	Gambling;
CESC	cis	rs7917772	0.536	rs3961456	chr10:104425304	A/T	cg22532475	chr10:104410764	TRIM8	0.41	6.63	0.38	1.84e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs17854409	1.000	rs66634465	chr20:61482306	C/T	cg05147244	chr20:61493195	TCFL5	0.94	6.28	0.36	1.34e-9	Obesity-related traits;
CESC	cis	rs7772486	0.790	rs2814880	chr6:146208937	T/G	cg23711669	chr6:146136114	FBXO30	0.92	13.39	0.64	1.41e-31	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs911555	0.723	rs6575982	chr14:103862681	G/A	cg12935359	chr14:103987150	CKB	0.62	8.89	0.48	9.4e-17	Intelligence (multi-trait analysis);
CESC	cis	rs3892630	1.000	rs3892630	chr19:33181484	A/G	cg22980127	chr19:33182716	NUDT19	-1.04	-12.0	-0.59	8.48e-27	Red blood cell traits;
CESC	cis	rs858239	0.669	rs1618339	chr7:23229774	T/C	cg23682824	chr7:23144976	KLHL7	0.46	6.37	0.36	8.19e-10	Cerebrospinal fluid biomarker levels;
CESC	cis	rs9303401	0.592	rs12936771	chr17:56725052	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.03	13.13	0.63	1.12e-30	Cognitive test performance;
CESC	cis	rs7259376	0.782	rs113181884	chr19:22586084	A/C	cg02657401	chr19:22469223	NA	0.27	5.33	0.31	2.13e-7	Menopause (age at onset);
CESC	cis	rs1801251	0.574	rs2250660	chr2:233752551	G/C	cg08000102	chr2:233561755	GIGYF2	-0.49	-6.46	-0.37	4.92e-10	Coronary artery disease;
CESC	cis	rs1371867	0.810	rs2860518	chr8:101238120	G/T	cg11906718	chr8:101322791	RNF19A	-0.42	-5.41	-0.32	1.44e-7	Atrioventricular conduction;
CESC	cis	rs7647973	0.626	rs1996663	chr3:49878264	C/G	cg07636037	chr3:49044803	WDR6	-0.5	-6.07	-0.35	4.44e-9	Menarche (age at onset);
CESC	cis	rs962856	0.619	rs6731934	chr2:67559553	A/G	cg09028215	chr2:67624308	ETAA1	-0.46	-5.56	-0.32	6.51e-8	Pancreatic cancer;
CESC	cis	rs2262909	0.925	rs56073035	chr19:22276298	C/G	cg11619707	chr19:22235551	ZNF257	0.35	5.76	0.33	2.38e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
CESC	cis	rs2733201	1.000	rs2114421	chr15:44313055	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	-0.49	-5.16	-0.3	4.75e-7	Lipoprotein phospholipase A2 activity in cardiovascular disease;
CESC	cis	rs6433857	0.594	rs10202422	chr2:181524944	C/T	cg23363182	chr2:181467187	NA	-0.46	-6.23	-0.36	1.85e-9	Body mass index;
CESC	cis	rs727505	1.000	rs28622327	chr7:124526213	C/T	cg23710748	chr7:124431027	NA	-0.48	-7.52	-0.42	8.73e-13	Lewy body disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15653194	chr7:2559473	LFNG	0.53	6.0	0.35	6.56e-9	Gut microbiome composition (summer);
CESC	cis	rs11608355	0.508	rs11066411	chr12:109804194	A/G	cg19025524	chr12:109796872	NA	-0.5	-6.3	-0.36	1.25e-9	Neuroticism;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg19455953	chr2:207630073	FASTKD2;MDH1B	-0.42	-6.18	-0.35	2.35e-9	Gambling;
CESC	cis	rs7520050	0.778	rs3014238	chr1:46090214	A/G	cg24296786	chr1:45957014	TESK2	0.47	6.03	0.35	5.36e-9	Red blood cell count;Reticulocyte count;
CESC	trans	rs17536732	0.685	rs77388367	chr4:162856790	G/A	cg12177677	chr2:158300475	CYTIP	-0.63	-6.2	-0.36	2.17e-9	Risky sexual behaviors (alcohol dependence interaction);
CESC	cis	rs12200560	0.505	rs2387378	chr6:97077504	C/A	cg06623918	chr6:96969491	KIAA0776	0.5	6.42	0.37	6.42e-10	Coronary heart disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25730717	chr7:148726076	PDIA4	0.66	7.81	0.43	1.35e-13	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.830	rs2865978	chr4:99017946	G/T	cg17366294	chr4:99064904	C4orf37	0.61	8.76	0.47	2.35e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4561483	0.619	rs12597429	chr16:12062396	A/G	cg08843971	chr16:11963173	GSPT1	-0.39	-5.35	-0.31	1.88e-7	Testicular germ cell tumor;
CESC	cis	rs12325245	0.536	rs71389028	chr16:58663260	G/A	cg01152986	chr16:58549298	SETD6	0.86	5.07	0.3	7.43e-7	Schizophrenia;
CESC	trans	rs7618501	0.722	rs9853458	chr3:49783211	A/C	cg21659725	chr3:3221576	CRBN	-0.83	-13.55	-0.64	3.87e-32	Intelligence (multi-trait analysis);
CESC	cis	rs2486288	0.656	rs12915314	chr15:45551491	C/G	cg21132104	chr15:45694354	SPATA5L1	-0.54	-6.55	-0.37	3.03e-10	Glomerular filtration rate;
CESC	cis	rs9649213	0.593	rs1132971	chr7:97921533	A/G	cg21770322	chr7:97807741	LMTK2	0.55	8.18	0.45	1.17e-14	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs28829049	0.535	rs12565185	chr1:19498309	G/A	cg13387374	chr1:19411106	UBR4	0.43	5.44	0.32	1.2e-7	QRS duration in Tripanosoma cruzi seropositivity;
CESC	cis	rs116095464	0.558	rs7715108	chr5:264661	A/G	cg22857025	chr5:266934	NA	-1.3	-18.55	-0.75	8.05e-50	Breast cancer;
CESC	cis	rs1707322	0.650	rs4553239	chr1:46150486	C/A	cg03146154	chr1:46216737	IPP	0.82	11.61	0.58	1.79e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2243480	1.000	rs781149	chr7:65481284	C/T	cg12463550	chr7:65579703	CRCP	0.72	5.92	0.34	9.68e-9	Diabetic kidney disease;
CESC	cis	rs4474465	0.850	rs7936232	chr11:78266602	A/G	cg27205649	chr11:78285834	NARS2	0.45	5.57	0.32	6.11e-8	Alzheimer's disease (survival time);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg08874067	chr13:19449177	NA	-0.48	-6.65	-0.38	1.7e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs7605827	0.930	rs4668903	chr2:15530051	C/G	cg19274914	chr2:15703543	NA	0.36	6.59	0.38	2.3e-10	Educational attainment (years of education);
CESC	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.65	-8.72	-0.47	3.21e-16	Longevity;Endometriosis;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg20713439	chr5:140027088	NDUFA2;IK	-0.44	-6.35	-0.36	9.51e-10	Gambling;
CESC	cis	rs11690935	0.632	rs6433323	chr2:172873060	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.48	-6.81	-0.39	6.61e-11	Schizophrenia;
CESC	cis	rs1862618	0.671	rs252897	chr5:56223000	G/A	cg22800045	chr5:56110881	MAP3K1	0.62	7.98	0.44	4.48e-14	Initial pursuit acceleration;
CESC	cis	rs2011503	0.941	rs10403273	chr19:19372968	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.53	5.51	0.32	8.53e-8	Bipolar disorder;
CESC	trans	rs877282	1.000	rs12219807	chr10:772870	A/C	cg22713356	chr15:30763199	NA	1.12	11.31	0.57	1.87e-24	Uric acid levels;
CESC	cis	rs6987853	0.787	rs1343874	chr8:42424746	C/T	cg09913449	chr8:42400586	C8orf40	0.46	7.77	0.43	1.72e-13	Mean corpuscular hemoglobin concentration;
CESC	cis	rs2282802	0.685	rs6867870	chr5:139641896	C/A	cg26211634	chr5:139558579	C5orf32	0.53	7.66	0.43	3.55e-13	Intelligence (multi-trait analysis);
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg05879720	chr5:154135170	LARP1	-0.48	-6.14	-0.35	3.07e-9	Asthma;
CESC	cis	rs3733585	0.673	rs7434391	chr4:9967682	C/G	cg00071950	chr4:10020882	SLC2A9	-0.7	-11.44	-0.58	6.69e-25	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs8017423	0.967	rs11628881	chr14:90713833	C/T	cg14092571	chr14:90743983	NA	-0.58	-8.72	-0.47	3.01e-16	Mortality in heart failure;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09902448	chr6:158454220	SYNJ2	-0.59	-6.54	-0.37	3.22e-10	Gut microbiome composition (summer);
CESC	cis	rs7772486	0.875	rs2224120	chr6:146343280	A/C	cg23711669	chr6:146136114	FBXO30	0.86	12.49	0.61	1.81e-28	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs425277	0.606	rs2459984	chr1:2086312	A/G	cg24578937	chr1:2090814	PRKCZ	0.34	6.06	0.35	4.68e-9	Height;
CESC	cis	rs1976403	0.633	rs1780324	chr1:21821757	A/G	cg04349561	chr1:21808255	NBPF3	-0.38	-5.44	-0.32	1.22e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7605827	0.897	rs12692271	chr2:15640317	T/C	cg19274914	chr2:15703543	NA	0.36	6.32	0.36	1.13e-9	Educational attainment (years of education);
CESC	cis	rs9815354	0.812	rs73069208	chr3:41939198	C/T	cg03022575	chr3:42003672	ULK4	0.71	6.44	0.37	5.46e-10	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs28830936	0.966	rs2303518	chr15:42109975	T/G	cg11010575	chr15:42129464	JMJD7-PLA2G4B;JMJD7	-0.41	-5.9	-0.34	1.13e-8	Diastolic blood pressure;
CESC	cis	rs6831352	0.819	rs1230155	chr4:99989259	C/T	cg13256891	chr4:100009986	ADH5	0.67	8.0	0.44	3.87e-14	Alcohol dependence;
CESC	cis	rs1552244	1.000	rs6442148	chr3:10078289	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-10.99	-0.56	2.21e-23	Alzheimer's disease;
CESC	cis	rs2072732	0.768	rs12045368	chr1:2960192	A/G	cg15211996	chr1:2936768	ACTRT2	0.34	5.45	0.32	1.18e-7	Plateletcrit;
CESC	cis	rs12142240	0.659	rs1984491	chr1:46858607	T/G	cg10495392	chr1:46806563	NSUN4	0.56	6.17	0.35	2.61e-9	Menopause (age at onset);
CESC	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg22105103	chr4:187893119	NA	0.51	7.69	0.43	2.88e-13	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg27037969	chr12:125549952	AACS	-0.43	-6.12	-0.35	3.39e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs1847202	0.859	rs6771288	chr3:72939471	A/G	cg25664220	chr3:72788482	NA	-0.4	-6.04	-0.35	5.12e-9	Motion sickness;
CESC	cis	rs35306767	0.903	rs12244253	chr10:889320	G/T	cg26597838	chr10:835615	NA	0.87	9.13	0.49	1.86e-17	Eosinophil percentage of granulocytes;
CESC	cis	rs6502050	0.842	rs8080305	chr17:80074516	A/C	cg23985595	chr17:80112537	CCDC57	0.41	6.42	0.37	6.41e-10	Life satisfaction;
CESC	cis	rs2880765	0.545	rs11631739	chr15:86012578	T/C	cg19183879	chr15:85880815	NA	-0.31	-5.77	-0.33	2.24e-8	Coronary artery disease;
CESC	cis	rs6714710	0.535	rs13006932	chr2:98370698	T/A	cg26665480	chr2:98280029	ACTR1B	0.62	8.32	0.45	4.84e-15	Posterior cortical atrophy and Alzheimer's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11553177	chr17:26988816	SUPT6H;SDF2	0.65	7.68	0.43	3.16e-13	Gut microbiome composition (summer);
CESC	cis	rs9926296	0.546	rs7187436	chr16:89845110	A/T	cg27121462	chr16:89883253	FANCA	0.77	11.14	0.56	6.73e-24	Vitiligo;
CESC	cis	rs3096299	0.967	rs28689480	chr16:89460093	T/C	cg00750074	chr16:89608354	SPG7	-0.39	-5.41	-0.32	1.41e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs1799949	1.000	rs4793194	chr17:41218333	G/A	cg05368731	chr17:41323189	NBR1	0.79	11.1	0.56	8.99e-24	Menopause (age at onset);
CESC	cis	rs875971	0.522	rs1617484	chr7:65463095	G/A	cg05332525	chr7:65337924	VKORC1L1	0.45	5.32	0.31	2.19e-7	Aortic root size;
CESC	cis	rs7191439	0.728	rs4238687	chr16:88788903	T/G	cg02389323	chr16:88786976	FAM38A	1.02	8.35	0.46	3.8e-15	Plateletcrit;
CESC	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg07167872	chr1:205819463	PM20D1	0.76	12.94	0.62	5.37e-30	Menarche (age at onset);
CESC	cis	rs453301	0.658	rs9329175	chr8:8866661	C/T	cg15556689	chr8:8085844	FLJ10661	-0.46	-5.41	-0.32	1.38e-7	Joint mobility (Beighton score);
CESC	cis	rs5769765	0.908	rs9616370	chr22:50306316	A/G	cg02269571	chr22:50332266	NA	0.49	5.91	0.34	1.07e-8	Schizophrenia;
CESC	cis	rs17431357	0.609	rs73230305	chr12:120984775	C/T	cg25045489	chr12:120971538	RNF10	-0.93	-5.46	-0.32	1.1e-7	Insulin resistance/response;
CESC	cis	rs1568889	1.000	rs12794100	chr11:28332785	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.77	9.78	0.51	1.76e-19	Bipolar disorder;
CESC	cis	rs9649213	0.593	rs35941058	chr7:97918159	T/C	cg24562669	chr7:97807699	LMTK2	0.47	6.73	0.38	1.07e-10	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs13256369	0.708	rs11783670	chr8:8559394	G/A	cg18904891	chr8:8559673	CLDN23	0.72	8.02	0.44	3.5e-14	Obesity-related traits;
CESC	cis	rs66573146	0.572	rs67750430	chr4:6957266	T/G	cg00086871	chr4:6988644	TBC1D14	1.03	6.77	0.38	8.47e-11	Granulocyte percentage of myeloid white cells;
CESC	cis	rs941873	0.772	rs7920127	chr10:81122914	T/C	cg11057378	chr10:81107060	PPIF	0.35	5.67	0.33	3.7e-8	Height;
CESC	cis	rs4843747	0.671	rs9921236	chr16:88117015	G/T	cg03395651	chr16:88107091	BANP	0.49	5.59	0.32	5.52e-8	Menopause (age at onset);
CESC	cis	rs2832077	0.505	rs9305386	chr21:30386751	A/G	cg03476357	chr21:30257390	N6AMT1	0.56	5.32	0.31	2.21e-7	Cognitive test performance;
CESC	cis	rs6952808	0.756	rs12537348	chr7:1948172	C/G	cg02951883	chr7:2050386	MAD1L1	-0.49	-6.55	-0.37	3.01e-10	Bipolar disorder and schizophrenia;
CESC	cis	rs9300255	0.596	rs10734901	chr12:123743447	G/A	cg19016782	chr12:123741754	C12orf65	-0.38	-5.73	-0.33	2.74e-8	Neutrophil percentage of white cells;
CESC	cis	rs6952808	0.531	rs1107351	chr7:2177093	G/A	cg02951883	chr7:2050386	MAD1L1	-0.48	-6.24	-0.36	1.71e-9	Bipolar disorder and schizophrenia;
CESC	trans	rs208520	0.690	rs7739253	chr6:66861052	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.99	-12.92	-0.62	6e-30	Exhaled nitric oxide output;
CESC	cis	rs12791968	0.527	rs4755924	chr11:45013328	A/G	cg11846598	chr11:44996168	LOC221122	-0.53	-6.1	-0.35	3.84e-9	Inhibitory control;
CESC	cis	rs10779751	0.922	rs2295079	chr1:11322565	C/G	cg08854313	chr1:11322531	MTOR	0.92	14.5	0.67	1.74e-35	Body mass index;
CESC	cis	rs9916302	0.706	rs9944459	chr17:37484185	T/C	cg07936489	chr17:37558343	FBXL20	0.94	10.63	0.55	3.23e-22	Glomerular filtration rate (creatinine);
CESC	cis	rs3008870	0.959	rs56707923	chr1:67388016	T/C	cg02640540	chr1:67518911	SLC35D1	0.48	5.19	0.3	4.09e-7	Lymphocyte percentage of white cells;
CESC	cis	rs67311347	1.000	rs9865348	chr3:40397658	A/C	cg24209194	chr3:40518798	ZNF619	0.42	5.26	0.31	3.05e-7	Renal cell carcinoma;
CESC	trans	rs61931739	0.500	rs34061369	chr12:34519283	C/T	cg26384229	chr12:38710491	ALG10B	0.71	10.63	0.55	3.31e-22	Morning vs. evening chronotype;
CESC	cis	rs933688	1.000	rs10073657	chr5:90689749	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.16	15.41	0.69	1.04e-38	Smoking behavior;
CESC	cis	rs2573652	1.000	rs2727199	chr15:100514417	C/T	cg00587665	chr15:100533223	ADAMTS17	-0.41	-6.46	-0.37	4.99e-10	Height;
CESC	cis	rs7267979	0.816	rs1044573	chr20:25206654	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.68	11.27	0.57	2.52e-24	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs3784262	0.934	rs4646611	chr15:58265083	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.32	-5.27	-0.31	2.83e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
CESC	cis	rs8053891	0.756	rs35259348	chr16:72003952	G/C	cg04254540	chr16:71951199	KIAA0174	-0.43	-5.17	-0.3	4.7e-7	Coronary artery disease;
CESC	cis	rs938554	0.578	rs7663032	chr4:9993838	C/T	cg11266682	chr4:10021025	SLC2A9	0.51	7.58	0.42	5.78e-13	Blood metabolite levels;
CESC	cis	rs5769765	1.000	rs5770741	chr22:50270215	A/G	cg02269571	chr22:50332266	NA	0.46	6.28	0.36	1.39e-9	Schizophrenia;
CESC	cis	rs909674	0.515	rs9611170	chr22:39784845	G/C	cg05872129	chr22:39784769	NA	-0.88	-12.46	-0.61	2.31e-28	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07183060	chr2:32288561	SPAST	0.64	8.0	0.44	3.94e-14	Gut microbiome composition (summer);
CESC	cis	rs7208859	0.623	rs7503542	chr17:29073830	A/C	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.1e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs4722166	0.695	rs56061963	chr7:22800397	T/C	cg13104385	chr7:22767384	IL6	0.38	5.59	0.32	5.64e-8	Lung cancer;
CESC	cis	rs568617	0.626	rs78028320	chr11:65582015	G/A	cg04055107	chr11:65626734	MUS81;CFL1	0.72	6.11	0.35	3.48e-9	Crohn's disease;
CESC	cis	rs1950626	0.833	rs35436326	chr14:101396148	G/A	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.78	10.03	0.52	2.73e-20	Pelvic organ prolapse (moderate/severe);
CESC	cis	rs12291225	0.637	rs8570	chr11:14300759	C/G	cg19336497	chr11:14380999	RRAS2	-0.37	-5.31	-0.31	2.32e-7	Sense of smell;
CESC	trans	rs11088226	0.681	rs2833899	chr21:33933263	T/C	cg09050820	chr6:167586206	TCP10L2	0.84	7.8	0.43	1.41e-13	Gastritis;
CESC	cis	rs72781680	1.000	rs72798418	chr2:24188922	A/G	cg08917208	chr2:24149416	ATAD2B	0.94	8.54	0.46	1.09e-15	Lymphocyte counts;
CESC	cis	rs1832871	0.616	rs55675950	chr6:158773994	T/A	cg07165851	chr6:158734300	TULP4	0.59	6.34	0.36	1.01e-9	Height;
CESC	cis	rs6460942	0.908	rs75704904	chr7:12233583	G/A	cg06484146	chr7:12443880	VWDE	-0.47	-5.22	-0.31	3.54e-7	Coronary artery disease;
CESC	cis	rs11252926	0.673	rs816620	chr10:645916	A/G	cg08603382	chr10:743973	NA	-0.39	-5.4	-0.32	1.45e-7	Psychosis in Alzheimer's disease;
CESC	cis	rs11123610	0.520	rs35482526	chr2:3720707	C/G	cg10645314	chr2:3704589	ALLC	-0.5	-5.24	-0.31	3.22e-7	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CESC	cis	rs9863	0.862	rs6488912	chr12:124442752	T/C	cg00084347	chr12:124393913	DNAH10	0.27	5.32	0.31	2.17e-7	White blood cell count;
CESC	cis	rs2842992	0.872	rs2758315	chr6:160158640	T/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.71	9.33	0.5	4.3e-18	Age-related macular degeneration (geographic atrophy);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg15450734	chr14:103541957	NA	0.59	7.87	0.44	8.79e-14	Gut microbiota (bacterial taxa);
CESC	cis	rs11785400	1.000	rs11776301	chr8:143737142	A/G	cg10596483	chr8:143751796	JRK	0.43	5.66	0.33	4.01e-8	Schizophrenia;
CESC	cis	rs514406	0.798	rs576650	chr1:53327207	C/T	cg08736216	chr1:53307985	ZYG11A	-0.44	-7.39	-0.41	1.95e-12	Monocyte count;
CESC	cis	rs2304069	0.954	rs2340463	chr5:149409294	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.9	11.22	0.57	3.6e-24	HIV-1 control;
CESC	cis	rs6938	0.534	rs1133322	chr15:75212357	A/G	cg17294928	chr15:75287854	SCAMP5	0.49	6.42	0.37	6.42e-10	Breast cancer;
CESC	cis	rs9913156	0.589	rs7213481	chr17:4547906	C/T	cg00122941	chr17:4613640	ARRB2	0.86	9.95	0.52	5.12e-20	Lymphocyte counts;
CESC	cis	rs7666738	0.830	rs17558151	chr4:99048699	T/C	cg05340658	chr4:99064831	C4orf37	0.8	12.39	0.61	3.91e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs35110281	0.807	rs2838328	chr21:45023234	G/C	cg21573476	chr21:45109991	RRP1B	-0.44	-6.18	-0.35	2.47e-9	Mean corpuscular volume;
CESC	cis	rs7542091	0.506	rs992976	chr1:210066658	A/T	cg22029157	chr1:209979665	IRF6	-0.42	-6.34	-0.36	9.83e-10	Monobrow;
CESC	cis	rs829883	1.000	rs1347956	chr12:98889564	A/G	cg25150519	chr12:98850993	NA	0.7	9.62	0.51	5.65e-19	Colorectal adenoma (advanced);
CESC	cis	rs7202877	0.656	rs8048677	chr16:75392028	C/G	cg04384234	chr16:75411784	CFDP1	-0.47	-5.73	-0.33	2.72e-8	Type 2 diabetes;Type 1 diabetes;
CESC	cis	rs2651899	0.867	rs2742675	chr1:3079905	A/G	cg07622451	chr1:3079886	PRDM16	0.31	5.64	0.33	4.34e-8	Migraine;
CESC	cis	rs4253772	0.530	rs6008623	chr22:46710024	G/A	cg00784671	chr22:46762841	CELSR1	-0.48	-5.51	-0.32	8.51e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs10504229	0.871	rs16921952	chr8:58163317	A/T	cg22535103	chr8:58192502	C8orf71	-0.87	-11.25	-0.57	3e-24	Developmental language disorder (linguistic errors);
CESC	cis	rs9815354	1.000	rs9824731	chr3:41889698	G/T	cg03022575	chr3:42003672	ULK4	0.58	5.94	0.34	9.04e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs7615952	0.641	rs12487875	chr3:125787224	C/A	cg02807482	chr3:125708958	NA	-0.4	-5.24	-0.31	3.28e-7	Blood pressure (smoking interaction);
CESC	cis	rs10089	0.953	rs1036171	chr5:127402798	C/T	cg19767477	chr5:127420684	SLC12A2	-0.4	-5.28	-0.31	2.63e-7	Ileal carcinoids;
CESC	cis	rs2455799	0.593	rs13085352	chr3:15914845	T/C	cg09340198	chr3:15902540	ANKRD28	-0.32	-5.1	-0.3	6.52e-7	Mean platelet volume;
CESC	cis	rs274567	0.501	rs274571	chr5:131712125	A/G	cg18758796	chr5:131593413	PDLIM4	-0.43	-5.96	-0.34	8.15e-9	Blood metabolite levels;
CESC	cis	rs7107174	0.892	rs1017907	chr11:77959124	A/T	cg02023728	chr11:77925099	USP35	0.43	6.07	0.35	4.5e-9	Testicular germ cell tumor;
CESC	cis	rs7727544	0.735	rs273914	chr5:131660431	A/T	cg24060327	chr5:131705240	SLC22A5	-0.68	-9.14	-0.49	1.69e-17	Blood metabolite levels;
CESC	cis	rs3793683	0.545	rs12784407	chr10:134589631	A/G	cg27297192	chr10:134578999	INPP5A	0.39	5.14	0.3	5.28e-7	Migraine;
CESC	cis	rs2274273	0.662	rs67588230	chr14:55667030	C/T	cg04306507	chr14:55594613	LGALS3	0.31	5.33	0.31	2.11e-7	Protein biomarker;
CESC	cis	rs7772486	0.790	rs9497435	chr6:146265340	C/A	cg05347473	chr6:146136440	FBXO30	-0.52	-6.88	-0.39	4.23e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs826838	0.935	rs1160162	chr12:38959795	G/A	cg26384229	chr12:38710491	ALG10B	0.82	14.16	0.66	2.77e-34	Heart rate;
CESC	cis	rs11098499	0.863	rs7699064	chr4:120428309	A/G	cg09307838	chr4:120376055	NA	-0.95	-13.35	-0.63	1.95e-31	Corneal astigmatism;
CESC	cis	rs7914558	1.000	rs4917994	chr10:104811699	C/T	cg08650961	chr10:104748594	CNNM2	0.31	5.19	0.3	4.18e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg27507545	chr10:103880405	LDB1	0.49	6.31	0.36	1.18e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg25934064	chr3:52569026	NT5DC2	0.28	5.78	0.33	2.05e-8	Electroencephalogram traits;
CESC	cis	rs138880	0.542	rs9616210	chr22:50317346	C/T	cg02269571	chr22:50332266	NA	-0.65	-6.12	-0.35	3.3e-9	Schizophrenia;
CESC	cis	rs17407555	0.821	rs4292329	chr4:10144459	C/G	cg00071950	chr4:10020882	SLC2A9	-0.57	-5.63	-0.33	4.7e-8	Schizophrenia (age at onset);
CESC	cis	rs11122272	0.735	rs2486740	chr1:231517552	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.57	-7.82	-0.43	1.29e-13	Hemoglobin concentration;
CESC	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg07092213	chr7:1199455	ZFAND2A	-0.45	-6.24	-0.36	1.71e-9	Longevity;Endometriosis;
CESC	cis	rs9916302	0.904	rs8077104	chr17:37530510	A/G	cg07936489	chr17:37558343	FBXL20	0.82	11.97	0.59	1.11e-26	Glomerular filtration rate (creatinine);
CESC	cis	rs4835473	0.689	rs1849123	chr4:144899648	T/G	cg25736465	chr4:144833511	NA	0.4	6.13	0.35	3.19e-9	Immature fraction of reticulocytes;
CESC	cis	rs1620921	0.505	rs2115869	chr6:161207892	C/T	cg01280913	chr6:161186852	NA	-0.36	-5.29	-0.31	2.53e-7	Lipoprotein (a) - cholesterol levels;
CESC	cis	rs10088262	0.629	rs6990565	chr8:124785645	C/A	cg20713898	chr8:124780851	FAM91A1	-0.65	-8.55	-0.47	9.93e-16	Pancreatic cancer;
CESC	cis	rs7618915	0.501	rs11714030	chr3:52765882	C/T	cg18404041	chr3:52824283	ITIH1	-0.38	-6.35	-0.36	9.12e-10	Bipolar disorder;
CESC	cis	rs4665809	0.590	rs5001914	chr2:26415429	A/G	cg22920501	chr2:26401640	FAM59B	-0.86	-10.09	-0.53	1.75e-20	Gut microbiome composition (summer);
CESC	cis	rs761746	0.739	rs5998054	chr22:31994406	C/A	cg25791279	chr22:32026902	PISD	0.62	7.14	0.4	9.13e-12	Intelligence;
CESC	cis	rs400736	0.602	rs10864330	chr1:8168564	C/T	cg25007680	chr1:8021821	PARK7	-0.57	-7.67	-0.43	3.36e-13	Response to antidepressants and depression;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26595336	chr15:82338380	MEX3B	0.6	6.71	0.38	1.19e-10	Gut microbiome composition (summer);
CESC	cis	rs3820068	0.581	rs58567918	chr1:15925823	A/G	cg17385448	chr1:15911702	AGMAT	0.41	6.69	0.38	1.33e-10	Systolic blood pressure;
CESC	trans	rs11098499	0.865	rs10213221	chr4:120255926	G/A	cg25214090	chr10:38739885	LOC399744	0.64	8.96	0.48	5.79e-17	Corneal astigmatism;
CESC	cis	rs1256061	0.669	rs1256065	chr14:64698932	G/T	cg23250157	chr14:64679961	SYNE2	0.52	7.36	0.41	2.37e-12	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs6963495	0.769	rs11556986	chr7:105177041	A/T	cg02135003	chr7:105160482	PUS7	-0.43	-5.46	-0.32	1.12e-7	Bipolar disorder (body mass index interaction);
CESC	cis	rs1707322	0.721	rs11211151	chr1:46112752	T/C	cg06784218	chr1:46089804	CCDC17	0.43	7.4	0.41	1.77e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs11785400	0.793	rs750530	chr8:143744931	G/A	cg10596483	chr8:143751796	JRK	0.42	5.34	0.31	1.97e-7	Schizophrenia;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg15044954	chr7:89874365	C7orf63	0.48	6.02	0.35	5.76e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs2354432	0.607	rs57078845	chr1:146722222	G/A	cg25205988	chr1:146714368	CHD1L	-0.97	-7.86	-0.43	9.67e-14	Mitochondrial DNA levels;
CESC	cis	rs7084402	0.967	rs1658491	chr10:60281354	C/T	cg07615347	chr10:60278583	BICC1	-0.59	-9.48	-0.5	1.48e-18	Refractive error;
CESC	cis	rs2274273	0.686	rs2296489	chr14:55624977	T/C	cg04306507	chr14:55594613	LGALS3	0.31	5.26	0.31	2.99e-7	Protein biomarker;
CESC	cis	rs1707322	0.964	rs12067716	chr1:46434428	T/A	cg06784218	chr1:46089804	CCDC17	0.36	6.06	0.35	4.65e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25291941	chr8:99129319	POP1;HRSP12	0.66	7.55	0.42	6.97e-13	Gut microbiome composition (summer);
CESC	cis	rs10789491	0.953	rs11211337	chr1:47133811	T/C	cg15501359	chr1:47185051	KIAA0494	0.8	8.59	0.47	7.41e-16	Response to hepatitis C treatment;
CESC	cis	rs9341808	0.667	rs2322632	chr6:80845608	G/A	cg08355045	chr6:80787529	NA	0.32	5.1	0.3	6.44e-7	Sitting height ratio;
CESC	cis	rs611744	0.647	rs702808	chr8:109252554	T/C	cg21045802	chr8:109455806	TTC35	0.46	5.67	0.33	3.65e-8	Dupuytren's disease;
CESC	cis	rs3820068	0.581	rs72645893	chr1:15930943	C/G	cg17385448	chr1:15911702	AGMAT	0.41	6.69	0.38	1.33e-10	Systolic blood pressure;
CESC	cis	rs4953318	0.619	rs10198247	chr2:46362677	C/T	cg12428440	chr2:46370979	PRKCE	-0.48	-6.54	-0.37	3.08e-10	Red blood cell count;Hematocrit;Red blood cell traits;
CESC	cis	rs62408225	1.000	rs969577	chr6:90982387	T/C	cg06866423	chr6:90926672	BACH2	0.43	5.25	0.31	3.17e-7	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs1348850	0.914	rs12616443	chr2:178315751	A/G	cg22681709	chr2:178499509	PDE11A	-0.39	-5.78	-0.33	2.1e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs7618915	0.501	rs34157897	chr3:52716937	T/C	cg18337363	chr3:52569053	NT5DC2	0.29	5.36	0.31	1.85e-7	Bipolar disorder;
CESC	cis	rs7618501	1.000	rs7634902	chr3:49762662	G/T	cg24308560	chr3:49941425	MST1R	0.5	6.81	0.39	6.39e-11	Intelligence (multi-trait analysis);
CESC	cis	rs4268898	0.516	rs7597149	chr2:24371962	C/T	cg06627628	chr2:24431161	ITSN2	0.6	8.31	0.45	5.17e-15	Asthma;
CESC	cis	rs7246865	0.510	rs7253742	chr19:17171689	C/T	cg16202187	chr19:17186497	HAUS8;MYO9B	-0.49	-6.45	-0.37	5.16e-10	Reticulocyte fraction of red cells;
CESC	cis	rs4969178	0.931	rs3826323	chr17:76400268	C/G	cg20026190	chr17:76395443	PGS1	0.46	7.35	0.41	2.41e-12	HDL cholesterol levels;
CESC	cis	rs9948	0.786	rs62152775	chr2:97448474	G/T	cg01990225	chr2:97406019	LMAN2L	-0.92	-7.51	-0.42	9.04e-13	Erectile dysfunction and prostate cancer treatment;
CESC	cis	rs3741151	0.773	rs74881062	chr11:73245769	G/A	cg17517138	chr11:73019481	ARHGEF17	1.05	7.72	0.43	2.46e-13	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg26668828	chr6:292823	DUSP22	-0.72	-9.53	-0.51	1.03e-18	Menopause (age at onset);
CESC	cis	rs3820068	0.705	rs4646077	chr1:15827136	C/T	cg18192808	chr1:15853278	DNAJC16	0.47	5.78	0.33	2.05e-8	Systolic blood pressure;
CESC	cis	rs72781680	0.652	rs72794281	chr2:23893265	G/A	cg08917208	chr2:24149416	ATAD2B	1.19	11.0	0.56	1.91e-23	Lymphocyte counts;
CESC	cis	rs5769765	0.862	rs9616386	chr22:50313179	G/A	cg02269571	chr22:50332266	NA	-0.56	-6.99	-0.39	2.26e-11	Schizophrenia;
CESC	cis	rs854765	0.724	rs62072049	chr17:17906520	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.49	6.79	0.38	7.39e-11	Total body bone mineral density;
CESC	cis	rs870825	0.860	rs61165411	chr4:185604461	G/A	cg04058563	chr4:185651563	MLF1IP	0.6	5.43	0.32	1.28e-7	Blood protein levels;
CESC	cis	rs703842	0.616	rs10783850	chr12:58229377	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.58	6.84	0.39	5.5e-11	Multiple sclerosis;
CESC	cis	rs7666738	0.830	rs13108871	chr4:98803872	T/C	cg03467027	chr4:99064603	C4orf37	0.44	5.57	0.32	6.4e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2836974	0.897	rs34394827	chr21:40528087	T/C	cg27266027	chr21:40555129	PSMG1	0.46	5.59	0.32	5.74e-8	Cognitive function;
CESC	cis	rs4423214	0.559	rs11234042	chr11:71239086	C/A	cg05163923	chr11:71159392	DHCR7	-0.57	-6.18	-0.36	2.35e-9	Vitamin D levels;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg04180460	chr3:41240962	CTNNB1	-0.41	-6.1	-0.35	3.66e-9	Gambling;
CESC	cis	rs67478160	0.529	rs12880413	chr14:104267407	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.51	-7.09	-0.4	1.2e-11	Schizophrenia;
CESC	cis	rs12900413	0.603	rs2118848	chr15:90302503	T/C	cg24249390	chr15:90295951	MESP1	-0.38	-5.03	-0.3	9.13e-7	Coronary artery aneurysm in Kawasaki disease;
CESC	cis	rs9875589	0.509	rs7614591	chr3:14061118	A/T	cg19554555	chr3:13937349	NA	-0.44	-5.6	-0.33	5.43e-8	Ovarian reserve;
CESC	cis	rs2576037	0.901	rs2576036	chr18:44587102	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.65	9.4	0.5	2.65e-18	Personality dimensions;
CESC	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.56	0.37	2.75e-10	Prudent dietary pattern;
CESC	cis	rs1862618	1.000	rs1862618	chr5:56096315	C/G	cg24549020	chr5:56110836	MAP3K1	0.57	6.52	0.37	3.46e-10	Initial pursuit acceleration;
CESC	cis	rs1552244	0.688	rs7645137	chr3:10020549	A/AT	cg00166722	chr3:10149974	C3orf24	0.49	6.04	0.35	5.24e-9	Alzheimer's disease;
CESC	cis	rs35110281	0.667	rs2155722	chr21:45096206	A/G	cg21573476	chr21:45109991	RRP1B	0.52	7.89	0.44	8.04e-14	Mean corpuscular volume;
CESC	trans	rs2115172	0.836	rs4835799	chr5:122762229	A/G	cg03670158	chr17:41323431	NBR1	0.47	6.25	0.36	1.63e-9	Weight;
CESC	cis	rs9916302	0.904	rs7210488	chr17:37539819	T/G	cg07936489	chr17:37558343	FBXL20	0.82	11.85	0.59	2.73e-26	Glomerular filtration rate (creatinine);
CESC	cis	rs7808935	0.591	rs62451117	chr7:27942357	T/C	cg05786569	chr7:27702416	HIBADH	0.49	5.46	0.32	1.09e-7	Prostate cancer;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg15855450	chr6:26103952	HIST1H4C	0.46	6.01	0.35	6.19e-9	Ulcerative colitis;
CESC	cis	rs11723261	0.621	rs3829	chr4:134851	T/C	cg12746427	chr4:53362	ZNF718;ZNF595	0.43	5.08	0.3	7.2e-7	Immune response to smallpox vaccine (IL-6);
CESC	cis	rs10838687	0.736	rs2279238	chr11:47282024	C/T	cg25783544	chr11:47291846	MADD	0.56	6.37	0.36	8.42e-10	Proinsulin levels;
CESC	cis	rs4927850	1.000	rs7614767	chr3:195753451	C/T	cg01181863	chr3:195395398	SDHAP2	-0.49	-6.01	-0.35	5.97e-9	Pancreatic cancer;
CESC	cis	rs736408	0.509	rs1108842	chr3:52720080	A/C	cg05564831	chr3:52568323	NT5DC2	0.48	8.16	0.45	1.34e-14	Bipolar disorder;
CESC	cis	rs67478160	0.619	rs12885018	chr14:104273812	A/G	cg08213375	chr14:104286397	PPP1R13B	0.54	10.76	0.55	1.22e-22	Schizophrenia;
CESC	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg06873352	chr17:61820015	STRADA	0.72	12.67	0.61	4.43e-29	Prudent dietary pattern;
CESC	cis	rs67460515	0.563	rs1599388	chr3:160846866	A/G	cg03342759	chr3:160939853	NMD3	-0.53	-6.82	-0.39	6.24e-11	Parkinson's disease;
CESC	cis	rs875971	0.505	rs1723275	chr7:65504633	G/C	cg14393609	chr7:65229607	NA	-0.54	-7.31	-0.41	3.09e-12	Aortic root size;
CESC	cis	rs769267	0.896	rs10405625	chr19:19579046	T/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.46	5.94	0.34	8.86e-9	Tonsillectomy;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg22834172	chr17:37774349	NA	-0.49	-6.4	-0.37	6.99e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs7666738	0.830	rs10050008	chr4:99025313	T/G	cg24818145	chr4:99064322	C4orf37	0.39	5.09	0.3	6.95e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4819052	0.851	rs4819049	chr21:46673086	C/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.47	5.79	0.34	1.94e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs10504229	0.953	rs67886764	chr8:58187117	T/C	cg24829409	chr8:58192753	C8orf71	-0.76	-9.93	-0.52	5.87e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs4595586	0.545	rs1375796	chr12:39410592	G/T	cg26384229	chr12:38710491	ALG10B	0.61	8.54	0.46	1.07e-15	Morning vs. evening chronotype;
CESC	cis	rs3818285	0.515	rs12258440	chr10:111676799	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.51	-7.11	-0.4	1.11e-11	Superior crus of antihelix expression;
CESC	cis	rs7772486	0.686	rs9376956	chr6:145949844	T/C	cg23711669	chr6:146136114	FBXO30	0.87	12.67	0.61	4.52e-29	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs12136530	0.774	rs4912097	chr1:19784410	C/G	cg01832549	chr1:19774989	CAPZB	-0.42	-5.99	-0.35	6.9e-9	Lead levels in blood;
CESC	cis	rs6690583	0.623	rs12041012	chr1:85515644	G/A	cg22153463	chr1:85462885	MCOLN2	0.76	7.37	0.41	2.23e-12	Serum sulfate level;
CESC	cis	rs459571	0.959	rs416390	chr9:136908549	C/G	cg13789015	chr9:136890014	NCRNA00094	-0.58	-8.34	-0.46	4e-15	Platelet distribution width;
CESC	cis	rs7267979	1.000	rs6115153	chr20:25325567	T/C	cg08601574	chr20:25228251	PYGB	-0.38	-5.51	-0.32	8.54e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs3008870	1.000	rs2755250	chr1:67495283	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.98	13.07	0.63	1.83e-30	Lymphocyte percentage of white cells;
CESC	cis	rs9611565	0.512	rs8141103	chr22:42136930	T/C	cg17376030	chr22:41985996	PMM1	-0.78	-8.33	-0.46	4.43e-15	Vitiligo;
CESC	cis	rs8060686	0.641	rs12446007	chr16:68189054	C/T	cg26727032	chr16:67993705	SLC12A4	-0.53	-6.02	-0.35	5.67e-9	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs9303401	0.538	rs10515155	chr17:56481944	A/G	cg12560992	chr17:57184187	TRIM37	0.52	5.18	0.3	4.38e-7	Cognitive test performance;
CESC	cis	rs977987	0.815	rs11861810	chr16:75461829	A/G	cg03315344	chr16:75512273	CHST6	0.41	5.91	0.34	1.07e-8	Dupuytren's disease;
CESC	cis	rs7666738	0.830	rs2865951	chr4:99040191	C/T	cg03676636	chr4:99064102	C4orf37	0.33	5.1	0.3	6.46e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9916302	0.561	rs12453198	chr17:37741879	T/C	cg07936489	chr17:37558343	FBXL20	-0.87	-8.8	-0.48	1.82e-16	Glomerular filtration rate (creatinine);
CESC	cis	rs2599510	0.811	rs2710625	chr2:32822957	G/A	cg02381751	chr2:32503542	YIPF4	0.48	5.87	0.34	1.3e-8	Interleukin-18 levels;
CESC	cis	rs6087990	0.735	rs6058883	chr20:31365719	C/T	cg13636640	chr20:31349939	DNMT3B	-0.78	-12.89	-0.62	7.56e-30	Ulcerative colitis;
CESC	cis	rs2836950	0.545	rs2836959	chr21:40623668	T/G	cg11890956	chr21:40555474	PSMG1	-0.66	-9.46	-0.5	1.72e-18	Menarche (age at onset);
CESC	cis	rs6539267	0.885	rs34762209	chr12:106722466	T/C	cg00173435	chr12:106696525	TCP11L2	0.51	5.47	0.32	1.05e-7	Tourette syndrome;
CESC	cis	rs494003	1.000	rs72922733	chr11:65520746	A/G	cg04055107	chr11:65626734	MUS81;CFL1	0.65	5.08	0.3	7.06e-7	Systemic lupus erythematosus;
CESC	cis	rs7551222	0.752	rs2290854	chr1:204516025	A/G	cg20240347	chr1:204465584	NA	-0.28	-5.75	-0.33	2.49e-8	Schizophrenia;
CESC	cis	rs9467711	0.606	rs9393713	chr6:26373678	C/T	cg14345882	chr6:26364793	BTN3A2	0.57	6.22	0.36	1.92e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs1348850	0.914	rs4893961	chr2:178411075	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.72	9.98	0.52	4.07e-20	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs2865126	0.743	rs8084621	chr18:10749429	T/C	cg21165219	chr18:10698044	FAM38B	-0.51	-5.16	-0.3	4.83e-7	Metabolite levels (5-HIAA/ MHPG Ratio);
CESC	cis	rs2295499	0.660	rs11490068	chr4:2639106	A/C	cg27239842	chr4:2403781	ZFYVE28	-0.31	-5.19	-0.3	4.18e-7	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
CESC	cis	rs7077164	0.960	rs1227777	chr10:71581131	A/G	cg20696214	chr10:71583771	COL13A1	0.47	6.74	0.38	9.88e-11	Non-alcoholic fatty liver disease histology (lobular);
CESC	cis	rs796364	0.760	rs2202922	chr2:200882610	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.84	7.71	0.43	2.62e-13	Schizophrenia;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg18560442	chr1:39174410	NA	0.5	7.0	0.4	2.13e-11	Fibrinogen levels;
CESC	cis	rs4474465	0.688	rs4367973	chr11:78284545	C/A	cg27205649	chr11:78285834	NARS2	0.49	6.39	0.37	7.22e-10	Alzheimer's disease (survival time);
CESC	trans	rs10489896	0.541	rs6682410	chr1:234570685	G/A	cg23817893	chr11:86085932	CCDC81	-0.45	-6.21	-0.36	2.04e-9	Cognitive test performance;
CESC	cis	rs7561273	0.609	rs2080727	chr2:24350907	A/G	cg20701182	chr2:24300061	SF3B14	0.46	5.96	0.34	7.86e-9	Quantitative traits;
CESC	cis	rs2120019	0.935	rs12591119	chr15:75355944	A/G	cg09165964	chr15:75287851	SCAMP5	-0.73	-8.47	-0.46	1.7e-15	Blood trace element (Zn levels);
CESC	cis	rs9611565	0.506	rs4822020	chr22:41700203	C/T	cg17376030	chr22:41985996	PMM1	0.49	5.43	0.32	1.26e-7	Vitiligo;
CESC	cis	rs2486288	0.656	rs1706770	chr15:45575062	T/C	cg21132104	chr15:45694354	SPATA5L1	-0.63	-7.55	-0.42	7.11e-13	Glomerular filtration rate;
CESC	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg07677032	chr17:61819896	STRADA	0.45	5.92	0.34	1.01e-8	Prudent dietary pattern;
CESC	cis	rs835154	0.845	rs835155	chr5:14875868	A/G	cg18064842	chr5:14874549	NA	0.43	6.97	0.39	2.57e-11	Blood metabolite levels;
CESC	cis	rs7811142	0.830	rs11761253	chr7:99939321	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.15	12.01	0.59	7.93e-27	Platelet count;
CESC	cis	rs2050392	0.624	rs2489842	chr10:30721991	T/C	cg25182066	chr10:30743637	MAP3K8	-0.45	-5.81	-0.34	1.76e-8	Inflammatory bowel disease;
CESC	cis	rs4727027	0.933	rs12532104	chr7:148864233	A/C	cg23583168	chr7:148888333	NA	-0.81	-12.7	-0.62	3.49e-29	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs875971	0.545	rs10950029	chr7:65634321	A/C	cg19163074	chr7:65112434	INTS4L2	-0.46	-5.1	-0.3	6.4e-7	Aortic root size;
CESC	cis	rs2477686	0.526	rs1998759	chr1:2397174	C/T	cg11214544	chr1:2391121	NA	-0.41	-6.31	-0.36	1.16e-9	Non-obstructive azoospermia;
CESC	cis	rs754466	0.580	rs2579178	chr10:79529215	A/G	cg17075019	chr10:79541650	NA	0.83	12.22	0.6	1.52e-27	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs651907	0.557	rs3806654	chr3:101396529	G/C	cg12386194	chr3:101231763	SENP7	0.45	5.71	0.33	3.05e-8	Colorectal cancer;
CESC	cis	rs123509	0.913	rs339685	chr3:42782952	C/G	cg12982090	chr3:42733453	KBTBD5	0.72	8.68	0.47	4.15e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs12477438	0.520	rs13035311	chr2:99717322	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.92	15.86	0.7	2.85e-40	Chronic sinus infection;
CESC	cis	rs2839186	0.596	rs4819217	chr21:47644092	G/T	cg12516959	chr21:47718080	NA	-0.35	-5.2	-0.3	4.04e-7	Testicular germ cell tumor;
CESC	cis	rs514406	0.929	rs11206035	chr1:53323571	T/C	cg24675658	chr1:53192096	ZYG11B	-0.6	-7.61	-0.42	4.78e-13	Monocyte count;
CESC	trans	rs11674184	0.714	rs16857668	chr2:11723110	G/A	cg14768519	chr17:79870056	SIRT7;PCYT2	-0.41	-6.11	-0.35	3.55e-9	Endometriosis;
CESC	trans	rs7618501	0.633	rs2353579	chr3:50027774	C/T	cg21659725	chr3:3221576	CRBN	0.5	6.87	0.39	4.44e-11	Intelligence (multi-trait analysis);
CESC	cis	rs1448094	0.549	rs57614821	chr12:86235361	A/C	cg02569458	chr12:86230093	RASSF9	0.54	7.75	0.43	2.02e-13	Major depressive disorder;
CESC	cis	rs6952808	0.630	rs10239050	chr7:2158390	A/G	cg08027265	chr7:2291960	NA	-0.42	-6.34	-0.36	9.87e-10	Bipolar disorder and schizophrenia;
CESC	cis	rs9908102	0.746	rs2286340	chr17:12898787	C/G	cg26162695	chr17:12921313	ELAC2	0.54	5.73	0.33	2.69e-8	Schizophrenia;
CESC	trans	rs1814175	0.645	rs847635	chr11:49923323	G/A	cg03929089	chr4:120376271	NA	-0.92	-15.2	-0.68	6e-38	Height;
CESC	cis	rs832540	0.931	rs2591960	chr5:56238811	A/T	cg12311346	chr5:56204834	C5orf35	0.54	6.6	0.38	2.25e-10	Coronary artery disease;
CESC	cis	rs863345	0.604	rs10797022	chr1:158494193	T/C	cg12129480	chr1:158549410	OR10X1	-0.35	-6.86	-0.39	4.75e-11	Pneumococcal bacteremia;
CESC	cis	rs7945705	0.935	rs1883098	chr11:8890594	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.49	-8.54	-0.46	1.09e-15	Hemoglobin concentration;
CESC	cis	rs875971	0.862	rs17747530	chr7:65994729	G/C	cg12463550	chr7:65579703	CRCP	0.51	6.36	0.36	8.66e-10	Aortic root size;
CESC	cis	rs7666738	0.830	rs1426667	chr4:98949772	T/C	cg17366294	chr4:99064904	C4orf37	0.59	8.52	0.46	1.24e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2658782	0.547	rs3020052	chr11:93055184	C/G	cg15737290	chr11:93063684	CCDC67	0.54	7.41	0.41	1.68e-12	Pulmonary function decline;
CESC	cis	rs7945705	0.869	rs7925728	chr11:9013002	A/G	cg12365402	chr11:9010492	NRIP3	-0.45	-7.88	-0.44	8.45e-14	Hemoglobin concentration;
CESC	cis	rs4323050	0.510	rs4273414	chr4:144914295	G/C	cg25736465	chr4:144833511	NA	0.43	6.44	0.37	5.61e-10	High light scatter reticulocyte percentage of red cells;
CESC	cis	rs9910055	0.531	rs6503490	chr17:42246656	A/G	cg19774624	chr17:42201019	HDAC5	-0.81	-12.5	-0.61	1.77e-28	Total body bone mineral density;
CESC	cis	rs3858526	0.959	rs1840179	chr11:5949148	A/G	cg02574844	chr11:5959923	NA	-0.44	-5.44	-0.32	1.21e-7	DNA methylation (variation);
CESC	cis	rs9479482	1.000	rs11155696	chr6:150357283	G/A	cg03788504	chr6:150331562	NA	-0.38	-7.3	-0.41	3.26e-12	Alopecia areata;
CESC	cis	rs1801251	0.963	rs283481	chr2:233648091	A/G	cg25237894	chr2:233734115	C2orf82	0.46	7.81	0.43	1.33e-13	Coronary artery disease;
CESC	cis	rs35849525	0.814	rs35491931	chr3:49993462	T/A	cg24308560	chr3:49941425	MST1R	-0.53	-6.43	-0.37	6.09e-10	Intelligence (multi-trait analysis);
CESC	cis	rs736408	0.716	rs2300149	chr3:52822921	C/T	cg05564831	chr3:52568323	NT5DC2	0.44	6.46	0.37	4.92e-10	Bipolar disorder;
CESC	cis	rs9611565	0.765	rs132921	chr22:41812044	G/A	cg03806693	chr22:41940476	POLR3H	1.04	12.98	0.62	3.76e-30	Vitiligo;
CESC	cis	rs2456568	0.803	rs10831141	chr11:93640728	C/T	cg26875233	chr11:93583750	C11orf90	-0.3	-5.19	-0.3	4.16e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
CESC	cis	rs514406	0.929	rs1672909	chr1:53340824	A/G	cg08736216	chr1:53307985	ZYG11A	-0.4	-6.5	-0.37	3.9e-10	Monocyte count;
CESC	cis	rs5750830	0.649	rs4821893	chr22:39797779	G/A	cg01416388	chr22:39784598	NA	-0.59	-7.37	-0.41	2.23e-12	Intelligence (multi-trait analysis);
CESC	cis	rs8002861	0.846	rs12869521	chr13:44478346	A/G	cg14210620	chr13:44453864	C13orf31;CCDC122	-0.43	-5.57	-0.32	6.35e-8	Leprosy;
CESC	cis	rs3026101	0.671	rs3026136	chr17:5310308	G/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.42	5.6	0.33	5.31e-8	Body mass index;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg01596986	chr13:48611463	NUDT15	0.47	6.63	0.38	1.86e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs6963495	0.818	rs73190149	chr7:105152793	C/T	cg19920283	chr7:105172520	RINT1	0.69	6.54	0.37	3.09e-10	Bipolar disorder (body mass index interaction);
CESC	cis	rs7267979	0.933	rs2258728	chr20:25276343	G/A	cg08601574	chr20:25228251	PYGB	0.38	5.48	0.32	9.97e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs17253792	0.822	rs77315200	chr14:56072643	C/A	cg01858014	chr14:56050164	KTN1	-0.85	-6.99	-0.39	2.22e-11	Putamen volume;
CESC	cis	rs8141529	0.764	rs5752807	chr22:29223169	A/G	cg02153584	chr22:29168773	CCDC117	0.65	9.21	0.49	1.03e-17	Lymphocyte counts;
CESC	cis	rs35849525	0.776	rs7615318	chr3:49987475	C/T	cg03060546	chr3:49711283	APEH	-0.47	-5.43	-0.32	1.3e-7	Intelligence (multi-trait analysis);
CESC	cis	rs11785400	0.762	rs4401833	chr8:143739731	A/T	cg24634471	chr8:143751801	JRK	0.45	5.75	0.33	2.41e-8	Schizophrenia;
CESC	cis	rs7605827	0.930	rs13026732	chr2:15695429	G/A	cg19274914	chr2:15703543	NA	0.3	5.34	0.31	2.03e-7	Educational attainment (years of education);
CESC	cis	rs6860806	0.507	rs273912	chr5:131661349	A/C	cg18758796	chr5:131593413	PDLIM4	-0.4	-5.53	-0.32	7.69e-8	Breast cancer;
CESC	trans	rs9858542	0.953	rs9837027	chr3:49597013	C/T	cg21659725	chr3:3221576	CRBN	-0.52	-6.35	-0.36	9.31e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs2742234	0.955	rs2435385	chr10:43665750	A/G	cg07801480	chr10:43725741	RASGEF1A	0.4	5.59	0.32	5.67e-8	Hirschsprung disease;
CESC	cis	rs7474896	0.559	rs1735641	chr10:38184852	C/A	cg25427524	chr10:38739819	LOC399744	0.48	5.27	0.31	2.88e-7	Obesity (extreme);
CESC	cis	rs875971	0.545	rs73142233	chr7:65686280	T/A	cg18876405	chr7:65276391	NA	0.49	5.39	0.31	1.58e-7	Aortic root size;
CESC	cis	rs7208859	0.623	rs9912283	chr17:29110373	A/G	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.91e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs4253772	0.513	rs6008597	chr22:46703904	A/C	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.66	6.5	0.37	4.07e-10	LDL cholesterol;Cholesterol, total;
CESC	cis	rs858239	0.730	rs10255155	chr7:23402147	A/T	cg23682824	chr7:23144976	KLHL7	-0.39	-5.03	-0.3	9.15e-7	Cerebrospinal fluid biomarker levels;
CESC	trans	rs9951602	0.512	rs1599636	chr18:76643916	G/A	cg02800362	chr5:177631904	HNRNPAB	0.62	8.1	0.45	1.96e-14	Obesity-related traits;
CESC	cis	rs1552244	0.882	rs6443279	chr3:10053599	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.76	-9.76	-0.51	2.03e-19	Alzheimer's disease;
CESC	cis	rs7943191	0.768	rs34065644	chr11:62371938	C/T	cg11742103	chr11:62369870	EML3;MTA2	0.57	8.06	0.44	2.69e-14	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
CESC	cis	rs10206020	0.885	rs6746052	chr2:1576811	T/C	cg26248373	chr2:1572462	NA	-0.59	-6.93	-0.39	3.22e-11	IgG glycosylation;
CESC	cis	rs9908102	0.740	rs56131975	chr17:12912870	T/C	cg26162695	chr17:12921313	ELAC2	0.52	5.71	0.33	3.04e-8	Schizophrenia;
CESC	cis	rs1003719	0.628	rs2252402	chr21:38520720	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.44	5.65	0.33	4.14e-8	Eye color traits;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg06866400	chr6:143771904	ADAT2;PEX3	-0.48	-6.84	-0.39	5.57e-11	Fibrinogen levels;
CESC	cis	rs736408	0.545	rs6445529	chr3:52662722	T/A	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.36	6.54	0.37	3.24e-10	Bipolar disorder;
CESC	cis	rs9815354	0.812	rs57809229	chr3:41840162	G/A	cg03022575	chr3:42003672	ULK4	0.7	6.04	0.35	5.26e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs7223966	1.000	rs752621	chr17:61901880	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.53	6.18	0.35	2.43e-9	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs875971	0.825	rs66981195	chr7:66079035	C/A	cg11764359	chr7:65958608	NA	-0.78	-11.32	-0.57	1.76e-24	Aortic root size;
CESC	cis	rs17376456	0.877	rs13156865	chr5:93390908	C/A	cg25358565	chr5:93447407	FAM172A	1.11	11.19	0.57	4.5e-24	Diabetic retinopathy;
CESC	cis	rs1008375	0.898	rs4698623	chr4:17594702	T/C	cg02297831	chr4:17616191	MED28	0.46	5.68	0.33	3.58e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs561341	1.000	rs576985	chr17:30323323	C/T	cg00745463	chr17:30367425	LRRC37B	-0.82	-7.51	-0.42	9.09e-13	Hip circumference adjusted for BMI;
CESC	cis	rs11214589	0.774	rs10891544	chr11:113256152	A/C	cg14159747	chr11:113255604	NA	-0.37	-6.68	-0.38	1.36e-10	Neuroticism;
CESC	cis	rs1799949	1.000	rs4793229	chr17:41418334	C/T	cg05368731	chr17:41323189	NBR1	-0.79	-10.92	-0.56	3.62e-23	Menopause (age at onset);
CESC	cis	rs11030122	0.702	rs10835312	chr11:3950253	G/A	cg18678763	chr11:4115507	RRM1	-0.45	-6.05	-0.35	4.94e-9	Mean platelet volume;Platelet distribution width;
CESC	cis	rs73001065	0.901	rs73002956	chr19:19578743	A/G	cg03709012	chr19:19516395	GATAD2A	0.98	5.63	0.33	4.53e-8	LDL cholesterol;
CESC	trans	rs801193	1.000	rs3778909	chr7:66255646	G/C	cg14393609	chr7:65229607	NA	0.47	6.33	0.36	1.04e-9	Aortic root size;
CESC	cis	rs1552244	0.744	rs6763366	chr3:10033544	T/C	cg00166722	chr3:10149974	C3orf24	0.48	5.92	0.34	9.76e-9	Alzheimer's disease;
CESC	cis	rs9393777	0.513	rs9393741	chr6:26654189	A/G	cg14345882	chr6:26364793	BTN3A2	0.41	5.12	0.3	5.79e-7	Intelligence (multi-trait analysis);
CESC	cis	rs10504229	0.817	rs55949560	chr8:58167603	T/C	cg05313129	chr8:58192883	C8orf71	-0.46	-5.85	-0.34	1.46e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs477895	0.838	rs72922039	chr11:64013116	A/C	cg18225595	chr11:63971243	STIP1	0.52	5.29	0.31	2.54e-7	Mean platelet volume;
CESC	cis	rs11252926	0.562	rs11252792	chr10:544369	G/A	cg18196295	chr10:418757	DIP2C	-0.45	-6.06	-0.35	4.78e-9	Psychosis in Alzheimer's disease;
CESC	cis	rs7223966	1.000	rs7209435	chr17:61712964	T/C	cg11494091	chr17:61959527	GH2	0.38	5.44	0.32	1.24e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs1862618	0.671	rs832531	chr5:56228401	A/G	cg20203395	chr5:56204925	C5orf35	-0.39	-5.3	-0.31	2.39e-7	Initial pursuit acceleration;
CESC	cis	rs61776719	0.747	rs28428561	chr1:38434306	G/A	cg04673462	chr1:38461896	NA	-0.43	-6.48	-0.37	4.47e-10	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25096566	chr6:136871941	MAP7	0.52	6.21	0.36	2.08e-9	Gut microbiome composition (summer);
CESC	cis	rs1862618	0.613	rs252889	chr5:56227069	C/A	cg22800045	chr5:56110881	MAP3K1	0.59	7.75	0.43	2.03e-13	Initial pursuit acceleration;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05843430	chr2:198299934	SF3B1	0.55	6.06	0.35	4.71e-9	Gut microbiome composition (summer);
CESC	cis	rs208520	0.690	rs207740	chr6:66764132	T/G	cg07460842	chr6:66804631	NA	0.96	13.07	0.63	1.89e-30	Exhaled nitric oxide output;
CESC	cis	rs7927771	0.864	rs112060627	chr11:47426956	G/A	cg05585544	chr11:47624801	NA	-0.47	-6.87	-0.39	4.49e-11	Subjective well-being;
CESC	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.44	-5.47	-0.32	1.03e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs10504229	0.683	rs73603877	chr8:58108428	C/T	cg02725872	chr8:58115012	NA	-0.43	-6.81	-0.39	6.53e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs1152591	0.524	rs1255990	chr14:64661523	A/G	cg21174375	chr14:64681225	SYNE2	-0.56	-7.78	-0.43	1.58e-13	Atrial fibrillation;
CESC	cis	rs11122272	0.735	rs2247132	chr1:231493359	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.55	-7.59	-0.42	5.45e-13	Hemoglobin concentration;
CESC	cis	rs7605378	0.528	rs281767	chr2:200823281	C/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.46	5.16	0.3	4.93e-7	Osteoporosis;
CESC	cis	rs9640161	0.789	rs1464752	chr7:150021284	C/T	cg10018233	chr7:150070692	REPIN1	0.43	6.83	0.39	5.68e-11	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg13880726	chr7:1868755	MAD1L1	0.51	6.78	0.38	8e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs4253772	0.530	rs715518	chr22:46754177	C/G	cg18190219	chr22:46762943	CELSR1	-0.67	-6.16	-0.35	2.72e-9	LDL cholesterol;Cholesterol, total;
CESC	cis	rs748404	0.578	rs573615	chr15:43614281	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.55	8.75	0.47	2.5e-16	Lung cancer;
CESC	cis	rs9486719	1.000	rs12193732	chr6:96942609	G/A	cg06623918	chr6:96969491	KIAA0776	-0.83	-8.64	-0.47	5.35e-16	Migraine;Coronary artery disease;
CESC	cis	rs11792861	0.589	rs2176692	chr9:111927723	G/A	cg13535736	chr9:111863775	C9orf5	-0.51	-6.52	-0.37	3.44e-10	Menarche (age at onset);
CESC	cis	rs3540	0.597	rs1978149	chr15:91036976	A/G	cg22089800	chr15:90895588	ZNF774	0.64	8.75	0.47	2.5e-16	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs11122272	0.735	rs2474634	chr1:231487017	T/C	cg06096015	chr1:231504339	EGLN1	0.43	6.29	0.36	1.33e-9	Hemoglobin concentration;
CESC	cis	rs4642101	0.597	rs12638595	chr3:12819281	T/C	cg24848339	chr3:12840334	CAND2	0.4	6.14	0.35	2.96e-9	QRS complex (12-leadsum);
CESC	cis	rs875971	0.545	rs4718348	chr7:65906576	A/G	cg11764359	chr7:65958608	NA	0.8	9.69	0.51	3.4e-19	Aortic root size;
CESC	cis	rs9611565	0.802	rs132916	chr22:41806768	C/G	cg06634786	chr22:41940651	POLR3H	0.53	6.1	0.35	3.7e-9	Vitiligo;
CESC	cis	rs2880765	0.835	rs4360875	chr15:86040394	A/G	cg10818794	chr15:86012489	AKAP13	-0.34	-5.25	-0.31	3.11e-7	Coronary artery disease;
CESC	cis	rs2880765	0.835	rs11638498	chr15:86023018	T/C	cg10818794	chr15:86012489	AKAP13	-0.33	-5.2	-0.3	4.08e-7	Coronary artery disease;
CESC	trans	rs9936075	0.519	rs74010668	chr16:7416136	A/T	cg24715815	chr2:183642235	DNAJC10	0.53	6.15	0.35	2.8e-9	Platelet-derived growth factor BB levels;
CESC	cis	rs17376456	0.877	rs10476599	chr5:93383423	A/G	cg21475434	chr5:93447410	FAM172A	0.79	6.94	0.39	2.95e-11	Diabetic retinopathy;
CESC	cis	rs473651	0.904	rs10929275	chr2:239323169	A/G	cg21699342	chr2:239360505	ASB1	0.51	8.55	0.46	1.03e-15	Multiple system atrophy;
CESC	cis	rs13108904	0.557	rs1250086	chr4:1248051	G/A	cg19318889	chr4:1322082	MAEA	-0.49	-6.36	-0.36	8.91e-10	Obesity-related traits;
CESC	cis	rs9640161	0.789	rs28432021	chr7:150046235	G/C	cg17279839	chr7:150038598	RARRES2	0.48	5.83	0.34	1.61e-8	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs1059312	1.000	rs9738216	chr12:129281788	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.71	-10.02	-0.52	3.07e-20	Systemic lupus erythematosus;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg02471486	chr8:71016278	NA	0.43	6.03	0.35	5.34e-9	Fibrinogen levels;
CESC	cis	rs9322193	0.962	rs10214845	chr6:150104260	A/G	cg04369109	chr6:150039330	LATS1	-0.4	-5.4	-0.31	1.48e-7	Lung cancer;
CESC	cis	rs7618501	0.633	rs9814664	chr3:50078541	C/T	cg24110177	chr3:50126178	RBM5	0.52	7.28	0.41	3.76e-12	Intelligence (multi-trait analysis);
CESC	cis	rs875971	0.964	rs160635	chr7:65528918	T/C	cg10691866	chr7:65817282	TPST1	-0.34	-5.46	-0.32	1.09e-7	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01125366	chr10:72218306	NA	0.51	6.12	0.35	3.34e-9	Gut microbiome composition (summer);
CESC	cis	rs3784262	1.000	rs7165247	chr15:58251786	C/T	cg12031962	chr15:58353849	ALDH1A2	0.3	5.04	0.3	8.73e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
CESC	cis	rs7666738	0.830	rs10014986	chr4:99000687	A/C	cg17366294	chr4:99064904	C4orf37	0.6	8.61	0.47	6.47e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2249625	1.000	rs1819065	chr6:72907749	G/T	cg18830697	chr6:72922368	RIMS1	-0.44	-6.25	-0.36	1.61e-9	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CESC	cis	rs3008870	0.958	rs12131222	chr1:67438535	A/T	cg08660285	chr1:67390436	MIER1;WDR78	-1.06	-15.19	-0.68	6.65e-38	Lymphocyte percentage of white cells;
CESC	cis	rs8180040	0.764	rs4682852	chr3:47177772	C/T	cg27129171	chr3:47204927	SETD2	0.73	11.42	0.57	7.7e-25	Colorectal cancer;
CESC	cis	rs9611565	0.512	rs2899349	chr22:42164660	T/C	cg06481639	chr22:41940642	POLR3H	0.6	5.92	0.34	9.88e-9	Vitiligo;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg09060316	chr2:26467451	HADHB;HADHA	0.48	6.16	0.35	2.75e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs9583531	0.550	rs7985098	chr13:111386416	G/A	cg24331049	chr13:111365604	ING1	0.73	11.02	0.56	1.66e-23	Coronary artery disease;
CESC	cis	rs7666738	0.830	rs62318470	chr4:98925846	A/C	cg17366294	chr4:99064904	C4orf37	0.6	8.23	0.45	8.65e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs12912251	0.591	rs3104150	chr15:39003585	T/C	cg10631289	chr15:39006617	NA	-0.48	-5.28	-0.31	2.66e-7	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
CESC	trans	rs2963826	0.589	rs298091	chr5:58996603	A/T	cg04309212	chr2:223183932	NA	0.5	6.66	0.38	1.58e-10	Obesity-related traits;
CESC	cis	rs2404602	0.716	rs8030411	chr15:76699855	A/G	cg26408565	chr15:76604113	ETFA	-0.41	-5.97	-0.34	7.59e-9	Blood metabolite levels;
CESC	cis	rs2832077	0.506	rs2832088	chr21:30158620	G/A	cg24692254	chr21:30365293	RNF160	-0.5	-6.04	-0.35	5.21e-9	Cognitive test performance;
CESC	cis	rs9308731	0.644	rs10189015	chr2:111918472	G/A	cg04202892	chr2:111875749	ACOXL	0.44	6.33	0.36	1.04e-9	Chronic lymphocytic leukemia;
CESC	cis	rs9910055	1.000	rs2071167	chr17:42287519	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.55	-6.58	-0.37	2.52e-10	Total body bone mineral density;
CESC	cis	rs9322193	0.962	rs4869966	chr6:150084850	A/G	cg07701084	chr6:150067640	NUP43	0.44	5.95	0.34	8.59e-9	Lung cancer;
CESC	cis	rs684232	0.602	rs34167561	chr17:509268	G/A	cg15660573	chr17:549704	VPS53	-0.82	-12.01	-0.59	8.07e-27	Prostate cancer;
CESC	cis	rs11229555	0.645	rs1986404	chr11:58194614	T/C	cg15696309	chr11:58395628	NA	-0.42	-5.05	-0.3	8.13e-7	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CESC	trans	rs561341	1.000	rs8077092	chr17:30281992	T/C	cg20587970	chr11:113659929	NA	-1.12	-14.05	-0.65	6.66e-34	Hip circumference adjusted for BMI;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13898051	chr5:916145	TRIP13	-0.64	-7.37	-0.41	2.21e-12	Gut microbiome composition (summer);
CESC	cis	rs12477438	0.520	rs2632283	chr2:99776000	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.79	12.62	0.61	6.6e-29	Chronic sinus infection;
CESC	cis	rs6546537	1.000	rs6712370	chr2:69855094	C/G	cg10773587	chr2:69614142	GFPT1	0.5	6.22	0.36	1.89e-9	Serum thyroid-stimulating hormone levels;
CESC	cis	rs56104184	0.723	rs73063522	chr19:49408358	C/G	cg21252483	chr19:49399788	TULP2	-0.49	-5.56	-0.32	6.67e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	cis	rs9325144	0.647	rs10875953	chr12:39050536	G/C	cg26384229	chr12:38710491	ALG10B	-0.52	-7.29	-0.41	3.56e-12	Morning vs. evening chronotype;
CESC	cis	rs6964587	0.692	rs12536220	chr7:91805595	T/G	cg17063962	chr7:91808500	NA	0.44	6.38	0.36	7.97e-10	Breast cancer;
CESC	cis	rs2455799	0.613	rs4684259	chr3:15791279	G/A	cg16303742	chr3:15540471	COLQ	-0.39	-6.14	-0.35	3.01e-9	Mean platelet volume;
CESC	cis	rs11031096	0.782	rs2284450	chr11:4149214	A/T	cg18678763	chr11:4115507	RRM1	-0.45	-6.24	-0.36	1.69e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	cis	rs12142240	0.659	rs1984491	chr1:46858607	T/G	cg00530320	chr1:46809349	NSUN4	0.6	8.27	0.45	6.54e-15	Menopause (age at onset);
CESC	cis	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg17911788	chr17:44343683	NA	-0.63	-8.1	-0.45	2.09e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs9318086	0.935	rs2025701	chr13:24440581	A/G	cg25267304	chr13:24462978	PCOTH;MIPEP	0.4	5.57	0.32	6.39e-8	Myopia (pathological);
CESC	cis	rs116095464	0.619	rs2303741	chr5:218356	T/C	cg22857025	chr5:266934	NA	-1.27	-18.89	-0.76	5.51e-51	Breast cancer;
CESC	cis	rs6933660	0.800	rs3800273	chr6:151759035	G/C	cg02564969	chr6:151773285	C6orf211;RMND1	0.62	8.57	0.47	8.91e-16	Menarche (age at onset);
CESC	cis	rs1008375	0.931	rs6449328	chr4:17700474	C/T	cg02297831	chr4:17616191	MED28	0.48	5.76	0.33	2.36e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs1862618	0.853	rs10051747	chr5:56083289	C/A	cg22800045	chr5:56110881	MAP3K1	0.85	10.2	0.53	7.88e-21	Initial pursuit acceleration;
CESC	cis	rs1799949	1.000	rs12944430	chr17:41330820	C/G	cg23758822	chr17:41437982	NA	1.03	15.5	0.69	5.3e-39	Menopause (age at onset);
CESC	cis	rs7917772	0.503	rs11191347	chr10:104351617	C/T	ch.10.2196322F	chr10:104248062	ACTR1A	0.42	5.19	0.3	4.14e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs1059312	1.000	rs2291350	chr12:129283711	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.73	-10.41	-0.54	1.69e-21	Systemic lupus erythematosus;
CESC	cis	rs72802342	0.510	rs12932952	chr16:75365486	C/T	cg04384234	chr16:75411784	CFDP1	-0.46	-5.48	-0.32	1.01e-7	Advanced age-related macular degeneration;
CESC	cis	rs9640161	0.711	rs3735170	chr7:150034184	T/C	cg21361702	chr7:150065534	REPIN1	0.53	5.74	0.33	2.53e-8	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs75804782	0.521	rs72993073	chr2:239412925	G/A	cg18131467	chr2:239335373	ASB1	-0.73	-5.36	-0.31	1.81e-7	Morning vs. evening chronotype;Chronotype;
CESC	cis	rs10754283	0.967	rs1320563	chr1:90121032	G/A	cg21401794	chr1:90099060	LRRC8C	0.67	8.84	0.48	1.36e-16	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs1790761	0.505	rs7941648	chr11:67347595	C/T	cg00290607	chr11:67383545	NA	-0.36	-5.33	-0.31	2.14e-7	Mean corpuscular volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14546712	chr8:41478669	AGPAT6	-0.63	-6.87	-0.39	4.66e-11	Gut microbiome composition (summer);
CESC	cis	rs10845606	1.000	rs10845607	chr12:12835228	C/T	cg04607235	chr12:12878440	APOLD1	-0.73	-8.21	-0.45	9.75e-15	Systemic lupus erythematosus;
CESC	cis	rs9309473	0.528	rs10191517	chr2:73558403	G/A	cg20560298	chr2:73613845	ALMS1	-0.49	-6.66	-0.38	1.55e-10	Metabolite levels;
CESC	cis	rs7772486	0.840	rs2474355	chr6:146312540	C/G	cg05347473	chr6:146136440	FBXO30	0.56	7.25	0.41	4.63e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6952808	0.691	rs2398709	chr7:2112548	C/T	cg08027265	chr7:2291960	NA	-0.41	-6.23	-0.36	1.78e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs7666738	0.791	rs28579101	chr4:98843203	T/C	cg17366294	chr4:99064904	C4orf37	0.52	7.13	0.4	9.5e-12	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9733	0.519	rs1336899	chr1:150678910	T/C	cg04414720	chr1:150670196	GOLPH3L	0.62	8.92	0.48	8.04e-17	Tonsillectomy;
CESC	cis	rs6088580	0.634	rs6059860	chr20:33063830	A/C	cg08999081	chr20:33150536	PIGU	0.66	11.55	0.58	2.83e-25	Glomerular filtration rate (creatinine);
CESC	cis	rs910316	0.726	rs12882664	chr14:75446778	C/T	cg16144293	chr14:75469539	EIF2B2	-0.41	-5.25	-0.31	3.05e-7	Height;
CESC	cis	rs76419734	0.558	rs7696836	chr4:106583826	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	0.73	9.65	0.51	4.57e-19	Post bronchodilator FEV1;
CESC	cis	rs6541297	0.699	rs4846915	chr1:230296470	C/A	cg20703242	chr1:230279135	GALNT2	0.61	6.92	0.39	3.31e-11	Coronary artery disease;
CESC	trans	rs7089973	0.523	rs7093330	chr10:116744574	T/A	cg17463145	chr7:79084011	MAGI2	0.32	6.36	0.36	8.92e-10	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg06059318	chr7:72936700	BAZ1B	-0.46	-6.61	-0.38	2.14e-10	Gambling;
CESC	cis	rs7577696	0.597	rs212751	chr2:32418808	T/A	cg02381751	chr2:32503542	YIPF4	0.45	5.41	0.32	1.4e-7	Inflammatory biomarkers;
CESC	cis	rs61935443	0.778	rs78522691	chr12:95267340	G/T	cg21533806	chr12:95267307	NA	0.56	6.87	0.39	4.56e-11	Schizophrenia;
CESC	cis	rs9649213	0.593	rs6975156	chr7:97925534	T/C	cg00277769	chr7:97922759	BAIAP2L1	-0.34	-5.62	-0.33	4.89e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs4563143	0.675	rs56293553	chr19:29270455	A/G	cg12756686	chr19:29218302	NA	0.58	7.52	0.42	8.38e-13	Methadone dose in opioid dependence;
CESC	cis	rs12220238	0.908	rs10824086	chr10:75912668	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.65	6.18	0.36	2.35e-9	Soluble interleukin-2 receptor subunit alpha;
CESC	cis	rs2777491	0.874	rs1655556	chr15:41777935	A/C	cg20272979	chr15:41787780	ITPKA	0.42	6.19	0.36	2.29e-9	Ulcerative colitis;
CESC	cis	rs6570726	0.764	rs376257	chr6:145862949	G/A	cg05347473	chr6:146136440	FBXO30	0.58	7.33	0.41	2.84e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs5758659	0.652	rs133305	chr22:42395960	C/T	cg15557168	chr22:42548783	NA	-0.43	-6.34	-0.36	9.99e-10	Cognitive function;
CESC	cis	rs8077577	0.731	rs11869952	chr17:18221713	T/C	cg16794390	chr17:18148240	FLII	0.4	6.34	0.36	9.98e-10	Obesity-related traits;
CESC	cis	rs6570726	0.791	rs10457788	chr6:145921136	T/A	cg05347473	chr6:146136440	FBXO30	0.57	7.24	0.41	4.72e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1552244	1.000	rs13319597	chr3:10126312	A/C	cg00166722	chr3:10149974	C3orf24	-0.51	-6.7	-0.38	1.26e-10	Alzheimer's disease;
CESC	cis	rs7772486	0.720	rs702320	chr6:146006654	G/A	cg23711669	chr6:146136114	FBXO30	-0.99	-14.35	-0.66	5.95e-35	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs72781680	0.950	rs72798404	chr2:24180125	C/T	cg08917208	chr2:24149416	ATAD2B	1.12	10.07	0.53	2.16e-20	Lymphocyte counts;
CESC	cis	rs13385	0.769	rs67836595	chr5:139603615	G/A	cg26211634	chr5:139558579	C5orf32	0.49	5.39	0.31	1.58e-7	Atrial fibrillation;
CESC	cis	rs6540559	0.673	rs17317411	chr1:209961314	C/T	cg25204440	chr1:209979598	IRF6	-0.61	-5.84	-0.34	1.53e-8	Cleft lip with or without cleft palate;
CESC	cis	rs2294693	0.730	rs9369248	chr6:40959664	G/T	cg14769373	chr6:40998127	UNC5CL	0.41	5.16	0.3	4.87e-7	Gastric cancer;Non-cardia gastric cancer;
CESC	cis	rs7107174	1.000	rs2511156	chr11:77971167	G/C	cg02023728	chr11:77925099	USP35	0.48	6.34	0.36	9.87e-10	Testicular germ cell tumor;
CESC	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg22907277	chr7:1156413	C7orf50	0.45	6.55	0.37	2.97e-10	Longevity;Endometriosis;
CESC	cis	rs9467711	0.659	rs13216828	chr6:26373507	G/A	cg12826209	chr6:26865740	GUSBL1	0.62	5.34	0.31	1.96e-7	Autism spectrum disorder or schizophrenia;
CESC	trans	rs709082	0.742	rs709098	chr3:191469920	A/C	cg25305879	chr2:106814630	NA	0.4	6.63	0.38	1.89e-10	Colonoscopy-negative controls vs population controls;
CESC	cis	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg01035013	chr16:56458628	AMFR	-0.41	-5.72	-0.33	2.89e-8	Gambling;
CESC	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg01238044	chr22:24384105	GSTT1	-0.52	-6.6	-0.38	2.26e-10	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs798554	0.836	rs798526	chr7:2775542	G/C	cg09658497	chr7:2847517	GNA12	-0.43	-6.09	-0.35	4.01e-9	Height;
CESC	trans	rs6572548	0.504	rs1956082	chr14:49665496	A/C	cg26084319	chr14:21905280	CHD8	-0.55	-6.14	-0.35	2.94e-9	Subjective well-being;
CESC	cis	rs6460942	0.778	rs74993124	chr7:12462917	A/G	cg06484146	chr7:12443880	VWDE	-0.75	-10.31	-0.54	3.55e-21	Coronary artery disease;
CESC	cis	rs17095355	1.000	rs734164	chr10:111698160	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.43	-5.2	-0.3	4.01e-7	Biliary atresia;
CESC	cis	rs1881797	0.932	rs4551631	chr1:247667663	C/T	cg21399703	chr1:247681439	NA	-0.65	-8.75	-0.47	2.54e-16	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs2842992	0.830	rs2758352	chr6:160122921	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.73	8.83	0.48	1.43e-16	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs6748734	0.843	rs6749674	chr2:241834501	G/C	cg04034577	chr2:241836375	C2orf54	-0.49	-8.75	-0.47	2.51e-16	Urinary metabolites;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07007882	chr1:2517512	C1orf93	-0.52	-6.03	-0.35	5.56e-9	Gut microbiome composition (summer);
CESC	cis	rs3026101	0.671	rs12602061	chr17:5302645	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.42	5.6	0.33	5.31e-8	Body mass index;
CESC	cis	rs3126085	0.935	rs1390487	chr1:152194601	G/A	cg03465714	chr1:152285911	FLG	-0.43	-5.19	-0.3	4.12e-7	Atopic dermatitis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17917959	chr17:79197229	AZI1	0.56	6.19	0.36	2.33e-9	Gut microbiome composition (summer);
CESC	trans	rs2115172	0.836	rs4835799	chr5:122762229	A/G	cg16265552	chr3:113667068	ZDHHC23	0.47	6.31	0.36	1.19e-9	Weight;
CESC	cis	rs67460515	0.892	rs4856703	chr3:161047720	G/T	cg03342759	chr3:160939853	NMD3	-0.54	-7.73	-0.43	2.27e-13	Parkinson's disease;
CESC	cis	rs11191419	1	rs11191419	chr10:104612335	T/A	cg15744005	chr10:104629667	AS3MT	-0.37	-5.49	-0.32	9.33e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs4819052	0.851	rs12626188	chr21:46669258	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.9	12.86	0.62	9.59e-30	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs7618915	0.533	rs35107891	chr3:52613656	G/C	cg07507251	chr3:52567010	NT5DC2	0.43	7.43	0.41	1.54e-12	Bipolar disorder;
CESC	cis	rs7666738	0.830	rs1025203	chr4:99023073	G/A	cg18180107	chr4:99064573	C4orf37	0.41	5.18	0.3	4.37e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11871801	0.915	rs647397	chr17:40679398	G/A	cg14558262	chr17:40713999	COASY	0.47	5.15	0.3	5.2e-7	Crohn's disease;
CESC	cis	rs72627123	0.867	rs73301479	chr14:74467757	G/A	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.79	5.74	0.33	2.6e-8	Morning vs. evening chronotype;
CESC	cis	rs35306767	0.953	rs12259338	chr10:969377	C/T	cg26597838	chr10:835615	NA	0.79	9.46	0.5	1.69e-18	Eosinophil percentage of granulocytes;
CESC	cis	rs10504229	0.683	rs55868006	chr8:58135703	C/T	cg24829409	chr8:58192753	C8orf71	-0.58	-7.2	-0.4	6.31e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs6089829	0.926	rs7273917	chr20:61665975	G/A	cg08564027	chr20:61660810	NA	0.9	15.31	0.69	2.47e-38	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs798554	0.757	rs1183085	chr7:2875570	G/A	cg19717773	chr7:2847554	GNA12	-0.56	-8.02	-0.44	3.48e-14	Height;
CESC	cis	rs3733585	0.699	rs4515163	chr4:9959603	C/T	cg11266682	chr4:10021025	SLC2A9	-0.6	-11.2	-0.57	4.42e-24	Cleft plate (environmental tobacco smoke interaction);
CESC	trans	rs61931739	0.500	rs10772154	chr12:34373271	A/C	cg26384229	chr12:38710491	ALG10B	0.54	7.46	0.42	1.25e-12	Morning vs. evening chronotype;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg03016991	chr12:109124380	CORO1C	-0.44	-6.08	-0.35	4.1e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs4253772	0.637	rs9627402	chr22:46702586	C/T	cg09491104	chr22:46646882	C22orf40	-0.54	-6.29	-0.36	1.28e-9	LDL cholesterol;Cholesterol, total;
CESC	cis	rs2732480	0.500	rs1387257	chr12:48636666	C/A	cg04545296	chr12:48745243	ZNF641	0.39	6.47	0.37	4.62e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs2243480	1.000	rs6460260	chr7:65215455	T/C	cg25894440	chr7:65020034	NA	0.65	5.42	0.32	1.36e-7	Diabetic kidney disease;
CESC	cis	rs9322193	0.923	rs9766037	chr6:149938057	A/C	cg13206674	chr6:150067644	NUP43	0.43	6.13	0.35	3.26e-9	Lung cancer;
CESC	cis	rs1552244	1.000	rs1552244	chr3:10135577	A/G	cg08888203	chr3:10149979	C3orf24	0.46	6.03	0.35	5.45e-9	Alzheimer's disease;
CESC	cis	rs7772486	0.846	rs2492856	chr6:146323928	A/G	cg23711669	chr6:146136114	FBXO30	0.76	10.57	0.54	5.07e-22	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs853679	0.517	rs9368558	chr6:28133306	A/G	cg20151795	chr6:28129481	ZNF389	0.44	5.55	0.32	6.85e-8	Depression;
CESC	cis	rs7412746	0.658	rs2089082	chr1:150800090	T/G	cg17724175	chr1:150552817	MCL1	0.41	6.29	0.36	1.27e-9	Melanoma;
CESC	cis	rs9649213	0.593	rs3801264	chr7:97950620	A/G	cg08684580	chr7:98029266	BAIAP2L1	-0.35	-5.69	-0.33	3.38e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs977987	0.671	rs9922008	chr16:75335406	T/C	cg03315344	chr16:75512273	CHST6	0.41	5.36	0.31	1.78e-7	Dupuytren's disease;
CESC	cis	rs1185460	0.967	rs4454730	chr11:118937444	G/A	cg23280166	chr11:118938394	VPS11	0.57	8.01	0.44	3.63e-14	Coronary artery disease;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg13625205	chr1:151584902	SNX27	-0.47	-6.39	-0.37	7.59e-10	Ulcerative colitis;
CESC	cis	rs7949030	0.653	rs2849030	chr11:62366986	G/A	cg02375832	chr11:62437615	C11orf48	0.36	5.16	0.3	4.92e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs12701220	0.655	rs12702117	chr7:1148702	T/C	cg26769984	chr7:1090371	C7orf50	0.54	6.34	0.36	9.95e-10	Bronchopulmonary dysplasia;
CESC	cis	rs2625529	0.730	rs12912771	chr15:72162928	A/T	cg16672083	chr15:72433130	SENP8	-0.39	-5.99	-0.35	6.93e-9	Red blood cell count;
CESC	cis	rs7267979	0.903	rs6115118	chr20:25246734	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.82	15.08	0.68	1.65e-37	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7666738	0.830	rs62321569	chr4:98984250	T/A	cg03467027	chr4:99064603	C4orf37	0.44	5.54	0.32	7.12e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs35306767	0.807	rs12768348	chr10:899224	T/G	cg20503657	chr10:835505	NA	1.09	9.8	0.52	1.52e-19	Eosinophil percentage of granulocytes;
CESC	cis	rs7786808	0.712	rs12671981	chr7:158202971	G/A	cg09998033	chr7:158218633	PTPRN2	-0.4	-5.72	-0.33	2.82e-8	Obesity-related traits;
CESC	cis	rs12249377	0.519	rs4520504	chr10:92602373	T/C	cg14313238	chr10:92632228	RPP30	0.44	5.51	0.32	8.63e-8	White matter microstructure (global fractional anisotropy);
CESC	cis	rs9435341	0.965	rs6669831	chr1:107608607	G/A	cg09367891	chr1:107599246	PRMT6	-0.56	-7.07	-0.4	1.38e-11	Facial morphology (factor 21, depth of nasal alae);
CESC	cis	rs6952808	0.595	rs3800916	chr7:2166072	C/T	cg04267008	chr7:1944627	MAD1L1	-0.59	-7.03	-0.4	1.77e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs15676	0.783	rs10988119	chr9:131564585	T/C	cg00228799	chr9:131580591	ENDOG	-0.49	-6.09	-0.35	3.93e-9	Blood metabolite levels;
CESC	cis	rs2742417	1.000	rs2742423	chr3:45733430	A/G	cg10512202	chr3:45649293	LIMD1	0.36	5.16	0.3	4.87e-7	Response to anti-depressant treatment in major depressive disorder;
CESC	cis	rs7259376	0.936	rs2195965	chr19:22538111	C/T	cg02657401	chr19:22469223	NA	-0.25	-5.07	-0.3	7.33e-7	Menopause (age at onset);
CESC	cis	rs11190604	1.000	rs11190551	chr10:102204734	A/G	cg07080220	chr10:102295463	HIF1AN	0.55	5.51	0.32	8.5e-8	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs1545257	0.537	rs11125583	chr2:24646278	C/A	cg06627628	chr2:24431161	ITSN2	-0.49	-5.87	-0.34	1.3e-8	Sjögren's syndrome;
CESC	cis	rs5769765	0.955	rs7511159	chr22:50307896	A/G	cg26441486	chr22:50317300	CRELD2	0.39	5.19	0.3	4.11e-7	Schizophrenia;
CESC	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg26354017	chr1:205819088	PM20D1	-0.82	-13.11	-0.63	1.33e-30	Menarche (age at onset);
CESC	cis	rs116095464	0.558	rs3213838	chr5:223890	G/C	cg12570787	chr5:219185	SDHA;CCDC127	0.52	5.65	0.33	4.24e-8	Breast cancer;
CESC	cis	rs7615952	0.641	rs7640158	chr3:125808011	G/A	cg18479299	chr3:125709523	NA	-0.48	-5.06	-0.3	7.98e-7	Blood pressure (smoking interaction);
CESC	trans	rs875971	1.000	rs4718343	chr7:65874288	T/G	cg26939375	chr7:64535504	NA	0.47	6.06	0.35	4.77e-9	Aortic root size;
CESC	cis	rs854765	0.547	rs9897761	chr17:17912011	A/T	cg04398451	chr17:18023971	MYO15A	-0.69	-10.33	-0.54	3.02e-21	Total body bone mineral density;
CESC	cis	rs7666738	0.791	rs62318907	chr4:99037120	C/T	cg24818145	chr4:99064322	C4orf37	0.39	5.06	0.3	7.72e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6694270	0.529	rs35941610	chr1:19104930	C/T	cg19637330	chr1:19110922	NA	-0.49	-6.04	-0.35	5.13e-9	Drug-induced liver injury (nitrofurantoin);
CESC	cis	rs2228479	0.850	rs2238525	chr16:89809902	T/C	cg27121462	chr16:89883253	FANCA	0.65	5.31	0.31	2.35e-7	Skin colour saturation;
CESC	cis	rs8062405	0.755	rs2077031	chr16:28603168	T/A	cg01378222	chr16:28622494	SULT1A1	0.31	5.16	0.3	4.92e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs4803468	1.000	rs11880539	chr19:41918949	A/C	cg14132834	chr19:41945861	ATP5SL	0.59	7.37	0.41	2.2e-12	Height;
CESC	cis	rs1143633	0.566	rs12987491	chr2:113691499	G/A	cg12858261	chr2:113808755	IL1F8	-0.44	-5.38	-0.31	1.63e-7	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs11166629	1.000	rs2873014	chr8:135645860	C/T	cg27224718	chr8:135614730	ZFAT	-0.49	-6.17	-0.35	2.58e-9	Smoking quantity;
CESC	cis	rs642858	0.543	rs1933743	chr6:140291158	T/C	cg27524944	chr6:140295369	NA	-0.32	-5.59	-0.32	5.74e-8	Type 2 diabetes;
CESC	cis	rs6460942	0.597	rs17277369	chr7:12536192	A/G	cg20607287	chr7:12443886	VWDE	-0.72	-7.71	-0.43	2.51e-13	Coronary artery disease;
CESC	cis	rs1707322	0.721	rs9793568	chr1:46130373	G/A	cg06784218	chr1:46089804	CCDC17	0.43	7.48	0.42	1.07e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs13191362	0.507	rs1954810	chr6:163061749	C/T	cg06582575	chr6:163149167	PACRG;PARK2	-0.51	-6.06	-0.35	4.65e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs4253772	0.591	rs6007727	chr22:46650959	G/A	cg24881330	chr22:46731750	TRMU	0.89	10.09	0.53	1.86e-20	LDL cholesterol;Cholesterol, total;
CESC	cis	rs4635554	0.640	rs12997242	chr2:21381177	G/A	cg00673290	chr2:21266727	APOB	0.32	5.07	0.3	7.3e-7	Hypertriglyceridemia;
CESC	cis	rs17384381	1.000	rs17388521	chr1:85897904	A/G	cg16011679	chr1:85725395	C1orf52	-0.75	-7.68	-0.43	3.17e-13	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg26338869	chr17:61819248	STRADA	0.69	9.02	0.48	3.77e-17	Prudent dietary pattern;
CESC	cis	rs9467711	0.606	rs9393705	chr6:26361011	G/A	cg12826209	chr6:26865740	GUSBL1	0.61	5.17	0.3	4.52e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs35955747	0.934	rs131200	chr22:31703272	T/C	cg25791279	chr22:32026902	PISD	0.49	5.88	0.34	1.25e-8	Neutrophil count;Sum basophil neutrophil counts;
CESC	cis	rs875971	0.540	rs4717275	chr7:65265180	C/T	cg06456125	chr7:65229604	NA	-0.44	-5.65	-0.33	4.22e-8	Aortic root size;
CESC	cis	rs3008870	1.000	rs2755256	chr1:67471692	A/T	cg02640540	chr1:67518911	SLC35D1	0.51	5.43	0.32	1.25e-7	Lymphocyte percentage of white cells;
CESC	cis	rs6032067	0.929	rs6017512	chr20:43835038	G/A	cg10761708	chr20:43804764	PI3	0.5	5.91	0.34	1.02e-8	Blood protein levels;
CESC	cis	rs1832871	0.630	rs11754501	chr6:158710451	A/G	cg07165851	chr6:158734300	TULP4	0.56	6.34	0.36	9.74e-10	Height;
CESC	cis	rs4595586	0.545	rs12831116	chr12:39401456	C/T	cg13010199	chr12:38710504	ALG10B	0.45	5.67	0.33	3.75e-8	Morning vs. evening chronotype;
CESC	cis	rs1801251	0.929	rs12694917	chr2:233707611	C/T	cg25237894	chr2:233734115	C2orf82	-0.46	-8.11	-0.45	1.84e-14	Coronary artery disease;
CESC	cis	rs7904368	0.754	rs7076779	chr10:16852667	C/T	cg23933602	chr10:16859644	RSU1	0.65	6.33	0.36	1.02e-9	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
CESC	cis	rs9287719	0.810	rs7601748	chr2:10785446	A/G	cg02196655	chr2:10830764	NOL10	-0.37	-5.64	-0.33	4.27e-8	Prostate cancer;
CESC	cis	rs8014204	0.839	rs6574197	chr14:75331487	A/G	cg11812906	chr14:75593930	NEK9	-0.41	-5.06	-0.3	7.77e-7	Caffeine consumption;
CESC	trans	rs931812	0.964	rs2102290	chr8:101919844	G/C	cg20993868	chr7:22813445	NA	0.46	6.55	0.37	3.03e-10	Attention deficit hyperactivity disorder and conduct disorder;
CESC	cis	rs6665290	0.582	rs72764213	chr1:227207391	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.16	-25.65	-0.84	9.23e-74	Myeloid white cell count;
CESC	cis	rs9911578	1.000	rs12938772	chr17:56776320	T/C	cg05425664	chr17:57184151	TRIM37	-0.5	-7.01	-0.4	1.97e-11	Intelligence (multi-trait analysis);
CESC	cis	rs8067545	0.559	rs3874846	chr17:20297545	T/G	cg13482628	chr17:19912719	NA	0.39	5.1	0.3	6.6e-7	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26593380	chr7:4749206	FOXK1	-0.69	-8.02	-0.44	3.39e-14	Gut microbiome composition (summer);
CESC	cis	rs2354432	1.000	rs11239944	chr1:146691015	C/T	cg25205988	chr1:146714368	CHD1L	0.84	10.61	0.55	3.88e-22	Mitochondrial DNA levels;
CESC	cis	rs3785574	0.962	rs2665840	chr17:61873307	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	-0.79	-10.52	-0.54	7.28e-22	Height;
CESC	cis	rs6142102	0.625	rs4911381	chr20:32550345	C/G	cg08999081	chr20:33150536	PIGU	-0.33	-5.09	-0.3	6.91e-7	Skin pigmentation;
CESC	cis	rs6964587	0.839	rs13246743	chr7:91453945	G/T	cg17063962	chr7:91808500	NA	0.5	6.39	0.37	7.42e-10	Breast cancer;
CESC	cis	rs4955124	0.558	rs62244393	chr3:32020533	T/G	cg05935571	chr3:32023257	ZNF860;OSBPL10	0.96	8.7	0.47	3.56e-16	Schizophrenia;
CESC	cis	rs477895	1.000	rs7938380	chr11:64034866	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.73	6.44	0.37	5.47e-10	Mean platelet volume;
CESC	cis	rs933688	1.000	rs12654787	chr5:90713259	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.18	14.23	0.66	1.63e-34	Smoking behavior;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18050295	chr3:12949921	IQSEC1	-0.61	-6.6	-0.38	2.19e-10	Gut microbiome composition (summer);
CESC	cis	rs16854884	0.837	rs6767236	chr3:143758399	A/C	cg06585982	chr3:143692056	C3orf58	0.48	5.74	0.33	2.57e-8	Economic and political preferences (feminism/equality);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg05075692	chr10:11321989	CUGBP2	0.43	6.17	0.35	2.58e-9	Fibrinogen levels;
CESC	trans	rs7656342	0.808	rs10003216	chr4:9766749	A/G	cg19603075	chr15:89010536	MRPS11;MRPL46	-0.54	-6.37	-0.36	8.23e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs2985684	0.894	rs2281837	chr14:50065359	C/G	cg10008539	chr14:50087325	RPL36AL;MGAT2	-0.44	-5.36	-0.31	1.84e-7	Carotid intima media thickness;
CESC	trans	rs2727020	0.796	rs7131672	chr11:49274421	A/C	cg03929089	chr4:120376271	NA	0.7	8.57	0.47	8.49e-16	Coronary artery disease;
CESC	trans	rs9929218	0.508	rs1559366	chr16:68799611	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.87	14.08	0.65	5.39e-34	Colorectal cancer;
CESC	cis	rs703842	0.585	rs10877022	chr12:58223937	A/G	cg00677455	chr12:58241039	CTDSP2	0.78	10.61	0.55	3.74e-22	Multiple sclerosis;
CESC	cis	rs9487051	0.872	rs9386793	chr6:109610002	C/A	cg21918786	chr6:109611834	NA	-0.4	-6.01	-0.35	6.17e-9	Reticulocyte fraction of red cells;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24544309	chr1:27096392	ARID1A	-0.49	-6.01	-0.35	6.25e-9	Gut microbiome composition (summer);
CESC	trans	rs7246760	0.881	rs68018725	chr19:9855919	C/T	cg02900749	chr2:68251473	NA	-0.77	-7.15	-0.4	8.22e-12	Pursuit maintenance gain;
CESC	cis	rs10832963	1.000	rs10832956	chr11:18645668	A/G	cg20219074	chr11:18656078	SPTY2D1	0.81	12.1	0.6	3.92e-27	Breast cancer;
CESC	cis	rs7666738	0.753	rs11097607	chr4:99011640	C/T	cg18180107	chr4:99064573	C4orf37	0.4	5.26	0.31	3.03e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs801193	0.904	rs4718403	chr7:66242729	C/G	cg26939375	chr7:64535504	NA	0.66	9.12	0.49	1.89e-17	Aortic root size;
CESC	cis	rs2425143	1.000	rs4602287	chr20:34368028	C/G	cg23207816	chr20:34252616	CPNE1;RBM12	-0.72	-6.67	-0.38	1.52e-10	Blood protein levels;
CESC	cis	rs9640161	0.742	rs11983355	chr7:150016697	A/C	cg10018233	chr7:150070692	REPIN1	0.47	7.29	0.41	3.54e-12	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs3096299	0.900	rs2911258	chr16:89480760	A/G	cg02034447	chr16:89574710	SPG7	0.42	5.29	0.31	2.54e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs7811142	0.830	rs6965458	chr7:99973402	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.71	6.1	0.35	3.74e-9	Platelet count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14591195	chr17:7382608	ZBTB4	-0.59	-6.3	-0.36	1.27e-9	Gut microbiome composition (summer);
CESC	cis	rs2013441	0.670	rs12937327	chr17:19978984	C/T	cg12073167	chr17:19770448	ULK2	-0.43	-5.21	-0.3	3.88e-7	Obesity-related traits;
CESC	cis	rs853679	0.517	rs9368550	chr6:28051803	T/A	cg18032046	chr6:28092343	ZSCAN16	-0.53	-6.09	-0.35	3.91e-9	Depression;
CESC	cis	rs7618915	0.501	rs34754793	chr3:52629177	A/T	cg18404041	chr3:52824283	ITIH1	-0.38	-6.52	-0.37	3.57e-10	Bipolar disorder;
CESC	cis	rs992157	0.698	rs6746089	chr2:219170377	A/G	cg20019365	chr2:219134978	PNKD;AAMP	0.64	8.53	0.46	1.17e-15	Colorectal cancer;
CESC	cis	rs6912958	0.559	rs242287	chr6:88071825	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.47	7.94	0.44	5.76e-14	Monocyte percentage of white cells;
CESC	trans	rs2213920	0.573	rs10982772	chr9:118277948	T/G	cg19746719	chr20:55904677	SPO11	0.47	6.14	0.35	3.01e-9	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
CESC	cis	rs10463316	0.894	rs7708499	chr5:150765906	A/C	cg03212797	chr5:150827313	SLC36A1	-0.46	-6.04	-0.35	5.23e-9	Metabolite levels (Pyroglutamine);
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg03550773	chr14:35163458	NA	-0.46	-6.28	-0.36	1.39e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs9487051	0.872	rs9400269	chr6:109606065	C/G	cg01475377	chr6:109611718	NA	-0.51	-8.27	-0.45	6.49e-15	Reticulocyte fraction of red cells;
CESC	cis	rs9916302	0.904	rs7223331	chr17:37482930	A/G	cg20243544	chr17:37824526	PNMT	-0.47	-5.94	-0.34	9.04e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs7631605	0.819	rs4678922	chr3:37022864	A/T	cg22985146	chr3:37219077	LRRFIP2	-0.33	-5.08	-0.3	7.06e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.73	-10.27	-0.53	4.75e-21	Prudent dietary pattern;
CESC	cis	rs11642862	0.710	rs17849880	chr16:30999198	C/T	cg02466173	chr16:30829666	NA	-0.57	-5.21	-0.3	3.81e-7	Tonsillectomy;
CESC	cis	rs3820928	0.874	rs1917127	chr2:227895125	A/G	cg11843606	chr2:227700838	RHBDD1	-0.48	-6.38	-0.36	8.04e-10	Pulmonary function;
CESC	cis	rs7923609	0.967	rs10761751	chr10:65154885	A/G	cg01631684	chr10:65280961	REEP3	-0.42	-5.32	-0.31	2.21e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs9894429	1.000	rs9747349	chr17:79584297	C/T	cg13777783	chr17:79615861	NA	-0.35	-5.79	-0.34	1.99e-8	Eye color traits;
CESC	cis	rs7044106	0.791	rs10739572	chr9:123489815	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.35	5.61	0.33	4.98e-8	Hip circumference adjusted for BMI;
CESC	cis	rs3760982	0.585	rs67704568	chr19:44294019	T/C	cg11993925	chr19:44307056	LYPD5	0.34	5.73	0.33	2.66e-8	Breast cancer (estrogen-receptor negative);Breast cancer;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg10667709	chr2:218712772	TNS1	-0.46	-6.35	-0.36	9.22e-10	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs1062177	0.855	rs62395861	chr5:151269270	A/G	cg12924095	chr5:151150029	G3BP1	0.43	5.35	0.31	1.93e-7	Preschool internalizing problems;
CESC	cis	rs4713118	0.662	rs149969	chr6:27977737	A/G	cg08968635	chr6:28129556	ZNF389	0.36	5.09	0.3	6.94e-7	Parkinson's disease;
CESC	cis	rs7666738	0.830	rs7657490	chr4:99043973	C/T	cg18180107	chr4:99064573	C4orf37	0.41	5.29	0.31	2.51e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs57221529	0.766	rs12521988	chr5:556421	C/T	cg25482853	chr8:67687455	SGK3	1.11	11.94	0.59	1.39e-26	Lung disease severity in cystic fibrosis;
CESC	cis	rs597539	0.617	rs598353	chr11:68635770	C/A	cg06028808	chr11:68637592	NA	0.43	5.12	0.3	5.87e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs2288073	0.965	rs10185445	chr2:24410976	A/C	cg06627628	chr2:24431161	ITSN2	0.71	8.38	0.46	3.04e-15	Venous thromboembolism (SNP x SNP interaction);
CESC	cis	rs9322193	0.962	rs4816	chr6:150114745	G/A	cg07701084	chr6:150067640	NUP43	0.42	5.78	0.33	2.07e-8	Lung cancer;
CESC	cis	rs1707322	1.000	rs12060274	chr1:46291062	G/T	cg05343316	chr1:45956843	TESK2	0.41	5.05	0.3	8.05e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs6088580	0.524	rs6088564	chr20:33249444	A/G	cg24642439	chr20:33292090	TP53INP2	-0.47	-5.53	-0.32	7.81e-8	Glomerular filtration rate (creatinine);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg12168153	chr19:55770892	SAPS1	0.44	6.04	0.35	5.1e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs7659604	0.540	rs13140070	chr4:122713899	C/T	cg19671926	chr4:122722719	EXOSC9	0.67	8.87	0.48	1.12e-16	Type 2 diabetes;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg12251659	chr12:122018385	KDM2B	-0.46	-6.13	-0.35	3.21e-9	Fibrinogen levels;
CESC	cis	rs3740713	1.000	rs61081934	chr11:18454317	G/A	cg23797887	chr11:18477753	LDHAL6A	-0.53	-5.11	-0.3	6.1e-7	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs4535700	0.501	rs60517461	chr7:56017645	G/T	cg09872392	chr7:56161020	PHKG1	0.41	5.85	0.34	1.43e-8	Macular telangiectasia type 2;
CESC	cis	rs4665809	0.590	rs35746418	chr2:26455002	C/G	cg25036284	chr2:26402008	FAM59B	0.86	9.4	0.5	2.74e-18	Gut microbiome composition (summer);
CESC	cis	rs4665809	0.590	rs7579504	chr2:26439995	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.1	-12.68	-0.61	4e-29	Gut microbiome composition (summer);
CESC	trans	rs61931739	0.534	rs12372557	chr12:34363843	C/T	cg26384229	chr12:38710491	ALG10B	0.68	10.06	0.53	2.22e-20	Morning vs. evening chronotype;
CESC	cis	rs854765	0.616	rs8070624	chr17:17843396	G/A	cg16928487	chr17:17741425	SREBF1	-0.56	-9.22	-0.49	9.83e-18	Total body bone mineral density;
CESC	trans	rs1285495	0.627	rs10912059	chr1:187354887	C/T	cg08679808	chr17:79886116	LOC92659;MAFG	-0.49	-6.23	-0.36	1.85e-9	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
CESC	cis	rs9929218	0.953	rs28608872	chr16:68802038	A/G	cg02972257	chr16:68554789	NA	0.43	5.22	0.31	3.65e-7	Colorectal cancer;
CESC	cis	rs11585357	0.895	rs877552	chr1:17631236	C/T	cg08277548	chr1:17600880	PADI3	-0.55	-5.34	-0.31	2.02e-7	Hair shape;
CESC	cis	rs2839186	0.814	rs2839167	chr21:47661587	A/G	cg05896524	chr21:47604654	C21orf56	0.4	5.26	0.31	2.95e-7	Testicular germ cell tumor;
CESC	trans	rs634534	0.591	rs688862	chr11:65733393	A/G	cg17712092	chr4:129076599	LARP1B	0.59	7.59	0.42	5.38e-13	Sum eosinophil basophil counts;Eosinophil counts;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05899727	chr19:17970713	RPL18AP3;RPL18A	-0.63	-7.14	-0.4	9.2e-12	Gut microbiome composition (summer);
CESC	cis	rs11587400	0.572	rs2268697	chr1:115227493	A/G	cg12756093	chr1:115239321	AMPD1	0.51	7.18	0.4	7.15e-12	Autism;
CESC	cis	rs2777491	1.000	rs1757455	chr15:41761332	G/T	cg20272979	chr15:41787780	ITPKA	0.44	6.5	0.37	4.02e-10	Ulcerative colitis;
CESC	cis	rs1707322	1.000	rs6682683	chr1:46342337	A/G	cg05343316	chr1:45956843	TESK2	0.44	5.55	0.32	7.05e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs863345	0.604	rs2054991	chr1:158506083	A/G	cg12129480	chr1:158549410	OR10X1	0.33	6.82	0.39	6.24e-11	Pneumococcal bacteremia;
CESC	cis	rs2295499	0.643	rs3733215	chr4:2698364	C/T	cg27239842	chr4:2403781	ZFYVE28	-0.33	-5.58	-0.32	5.88e-8	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
CESC	cis	rs36051895	0.632	rs12352022	chr9:5161836	T/G	cg02405213	chr9:5042618	JAK2	-0.54	-6.46	-0.37	4.86e-10	Pediatric autoimmune diseases;
CESC	cis	rs7527798	0.592	rs12411037	chr1:207857158	T/C	cg21110645	chr1:207815933	NA	-0.3	-5.16	-0.3	4.79e-7	Erythrocyte sedimentation rate;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg12909921	chr17:37558512	FBXL20	0.5	6.49	0.37	4.12e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs78707713	0.841	rs76628955	chr10:71208625	C/T	cg12610070	chr10:71211762	TSPAN15	-0.36	-6.48	-0.37	4.36e-10	Venous thromboembolism;
CESC	trans	rs11098499	0.542	rs10440343	chr4:120309787	G/C	cg25214090	chr10:38739885	LOC399744	0.68	9.2	0.49	1.14e-17	Corneal astigmatism;
CESC	cis	rs11098499	0.954	rs9993199	chr4:120392873	A/G	cg24375607	chr4:120327624	NA	-0.43	-5.4	-0.31	1.49e-7	Corneal astigmatism;
CESC	cis	rs6502050	0.761	rs12150321	chr17:80061558	T/C	cg23985595	chr17:80112537	CCDC57	0.41	6.28	0.36	1.38e-9	Life satisfaction;
CESC	cis	rs13095912	1.000	rs36066570	chr3:185314454	C/A	cg11274856	chr3:185301563	NA	0.37	6.08	0.35	4.07e-9	Systolic blood pressure;
CESC	trans	rs4906172	0.773	rs941793	chr14:102507461	A/G	cg17920195	chr4:129149383	NA	0.32	6.28	0.36	1.37e-9	Menopause (age at onset);
CESC	cis	rs1062177	0.901	rs1549622	chr5:151266049	A/G	cg00977110	chr5:151150581	G3BP1	0.67	7.43	0.42	1.46e-12	Preschool internalizing problems;
CESC	cis	rs2522056	1.000	rs2522063	chr5:131805591	G/T	cg24060327	chr5:131705240	SLC22A5	0.61	6.93	0.39	3.22e-11	Lymphocyte counts;Fibrinogen;
CESC	cis	rs2109514	0.902	rs717957	chr7:116113107	G/C	cg12739419	chr7:116140593	CAV2	-0.38	-6.85	-0.39	5.19e-11	Prevalent atrial fibrillation;
CESC	trans	rs35110281	0.693	rs11089093	chr21:45121161	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.48	6.2	0.36	2.13e-9	Mean corpuscular volume;
CESC	cis	rs1790761	0.520	rs12805884	chr11:67387977	G/A	cg14500267	chr11:67383377	NA	-0.36	-5.67	-0.33	3.77e-8	Mean corpuscular volume;
CESC	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg07677032	chr17:61819896	STRADA	0.48	6.53	0.37	3.3e-10	Prudent dietary pattern;
CESC	trans	rs4843747	0.605	rs4072779	chr16:88107290	C/T	cg26811252	chr16:29126840	RRN3P2	0.67	9.46	0.5	1.77e-18	Menopause (age at onset);
CESC	cis	rs12681366	0.734	rs13281619	chr8:95396886	A/G	cg13257157	chr8:95487014	RAD54B	0.38	5.14	0.3	5.22e-7	Nonsyndromic cleft lip with cleft palate;
CESC	cis	rs9916302	0.821	rs12938268	chr17:37572139	G/A	cg07936489	chr17:37558343	FBXL20	-0.78	-10.65	-0.55	2.75e-22	Glomerular filtration rate (creatinine);
CESC	cis	rs6089829	0.962	rs6062778	chr20:61663959	A/G	cg03213289	chr20:61660250	NA	0.39	6.07	0.35	4.42e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs6740322	0.895	rs6738717	chr2:43573670	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.66	-7.33	-0.41	2.79e-12	Coronary artery disease;
CESC	cis	rs3925075	0.966	rs11645917	chr16:31359826	C/T	cg02846316	chr16:31340340	ITGAM	0.42	6.6	0.38	2.24e-10	IgA nephropathy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13531596	chr19:39894559	NA	0.52	6.0	0.35	6.45e-9	Gut microbiome composition (summer);
CESC	cis	rs56104184	0.723	rs73063524	chr19:49409004	T/C	cg21252483	chr19:49399788	TULP2	-0.49	-5.56	-0.32	6.67e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg03591709	chr4:110481296	CCDC109B	-0.55	-7.4	-0.41	1.82e-12	Fibrinogen levels;
CESC	cis	rs8005677	1.000	rs8006409	chr14:23396511	A/G	cg25600027	chr14:23388339	RBM23	-0.43	-5.27	-0.31	2.85e-7	Cognitive ability (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21047938	chr2:10192422	KLF11	-0.55	-6.04	-0.35	5.07e-9	Gut microbiome composition (summer);
CESC	cis	rs7937682	0.889	rs1784786	chr11:111486043	A/G	cg09085632	chr11:111637200	PPP2R1B	0.93	13.96	0.65	1.41e-33	Primary sclerosing cholangitis;
CESC	cis	rs17376456	0.877	rs34184666	chr5:93444584	T/C	cg25358565	chr5:93447407	FAM172A	1.15	11.35	0.57	1.34e-24	Diabetic retinopathy;
CESC	cis	rs6662572	1.000	rs72688460	chr1:46111094	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.52	5.65	0.33	4.09e-8	Blood protein levels;
CESC	cis	rs782590	0.607	rs2061032	chr2:55679490	T/C	cg18811423	chr2:55921094	PNPT1	0.46	6.35	0.36	9.5e-10	Metabolic syndrome;
CESC	cis	rs10489525	0.599	rs34710929	chr1:115606608	G/A	cg12756093	chr1:115239321	AMPD1	-0.45	-5.54	-0.32	7.32e-8	Autism;
CESC	cis	rs6582630	0.519	rs11181526	chr12:38360230	A/G	cg13010199	chr12:38710504	ALG10B	0.45	5.77	0.33	2.24e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs9287719	0.837	rs4233882	chr2:10755564	A/G	cg02196655	chr2:10830764	NOL10	-0.37	-5.51	-0.32	8.5e-8	Prostate cancer;
CESC	cis	rs3785574	0.962	rs114027117	chr17:61939935	T/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.78	10.57	0.54	5.09e-22	Height;
CESC	cis	rs4974559	0.790	rs11933855	chr4:1315183	C/T	cg02980000	chr4:1222292	CTBP1	0.61	7.14	0.4	8.92e-12	Systolic blood pressure;
CESC	cis	rs4746818	1.000	rs7916991	chr10:70895373	C/A	cg11621586	chr10:70884670	VPS26A	0.83	8.36	0.46	3.65e-15	Left atrial antero-posterior diameter;
CESC	cis	rs6831352	0.918	rs2213035	chr4:100064233	G/A	cg12011299	chr4:100065546	ADH4	-0.58	-6.31	-0.36	1.14e-9	Alcohol dependence;
CESC	cis	rs12618769	0.597	rs72819965	chr2:99023719	G/C	cg10123293	chr2:99228465	UNC50	0.4	5.23	0.31	3.48e-7	Bipolar disorder;
CESC	cis	rs7208859	0.623	rs12103508	chr17:29086781	T/G	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.17e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs10788972	0.787	rs6674720	chr1:54539339	C/G	cg25741118	chr1:54482237	LDLRAD1	-0.22	-5.25	-0.31	3.19e-7	Parkinson disease and lewy body pathology;
CESC	cis	rs875971	0.508	rs10258739	chr7:66062935	A/T	cg14393609	chr7:65229607	NA	-0.4	-5.7	-0.33	3.2e-8	Aortic root size;
CESC	cis	rs2749592	0.550	rs12255038	chr10:37869332	T/C	cg00409905	chr10:38381863	ZNF37A	0.43	5.63	0.33	4.61e-8	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs16973500	0.732	rs1549292	chr16:71983664	A/C	cg09427745	chr16:71932006	KIAA0174	-0.49	-5.19	-0.3	4.28e-7	Response to anti-TNF therapy in rheumatoid arthritis;Attention deficit hyperactivity disorder and conduct disorder;
CESC	cis	rs12188164	1.000	rs34847072	chr5:437862	G/C	cg17553881	chr5:443987	EXOC3;C5orf55	-0.34	-5.45	-0.32	1.17e-7	Cystic fibrosis severity;
CESC	cis	rs7666738	0.830	rs7694889	chr4:98855596	T/C	cg17366294	chr4:99064904	C4orf37	0.54	7.48	0.42	1.1e-12	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7267979	0.966	rs2227890	chr20:25260931	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	18.61	0.75	5.21e-50	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs9467773	0.620	rs3800303	chr6:26598188	A/G	cg11502198	chr6:26597334	ABT1	0.49	7.04	0.4	1.64e-11	Intelligence (multi-trait analysis);
CESC	cis	rs60154123	0.772	rs614167	chr1:210425895	T/C	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.5	5.23	0.31	3.37e-7	Coronary artery disease;
CESC	cis	rs561341	0.824	rs1978115	chr17:30220776	A/C	cg13647721	chr17:30228624	UTP6	0.59	5.59	0.32	5.55e-8	Hip circumference adjusted for BMI;
CESC	cis	rs2072732	0.861	rs55863899	chr1:2955245	C/G	cg15211996	chr1:2936768	ACTRT2	0.36	5.08	0.3	7.07e-7	Plateletcrit;
CESC	cis	rs6540556	0.723	rs12120361	chr1:209913473	A/C	cg23920097	chr1:209922102	NA	-0.39	-5.22	-0.31	3.7e-7	Red blood cell count;
CESC	cis	rs72781680	0.848	rs715646	chr2:24010566	G/A	cg20701182	chr2:24300061	SF3B14	0.63	5.65	0.33	4.21e-8	Lymphocyte counts;
CESC	cis	rs3741151	0.687	rs7933355	chr11:73236817	G/C	cg17517138	chr11:73019481	ARHGEF17	0.78	6.37	0.36	8.35e-10	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs6987853	0.966	rs2974338	chr8:42391945	A/G	cg09913449	chr8:42400586	C8orf40	0.39	6.13	0.35	3.15e-9	Mean corpuscular hemoglobin concentration;
CESC	cis	rs6982240	0.514	rs7002268	chr8:142277340	A/G	cg00131261	chr8:142287264	NA	-0.54	-7.39	-0.41	1.93e-12	Tonsillectomy;
CESC	cis	rs7188697	0.743	rs11859781	chr16:58602589	T/A	cg02549819	chr16:58548995	SETD6	0.43	5.4	0.31	1.51e-7	QT interval;
CESC	cis	rs11098499	0.909	rs11098530	chr4:120413154	C/T	cg24375607	chr4:120327624	NA	0.46	5.63	0.33	4.52e-8	Corneal astigmatism;
CESC	cis	rs7818688	0.697	rs35032356	chr8:95977484	G/T	cg16049864	chr8:95962084	TP53INP1	0.57	5.73	0.33	2.79e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs4253772	0.872	rs78864133	chr22:46638486	C/T	cg00784671	chr22:46762841	CELSR1	-0.5	-5.25	-0.31	3.2e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs7412746	0.611	rs752376	chr1:150941381	C/T	cg22823121	chr1:150693482	HORMAD1	0.36	5.09	0.3	6.86e-7	Melanoma;
CESC	cis	rs1218582	0.772	rs4845400	chr1:154872523	C/T	cg09359103	chr1:154839909	KCNN3	-0.65	-12.33	-0.6	6.58e-28	Prostate cancer;
CESC	cis	rs734999	0.549	rs60733400	chr1:2516781	G/A	cg20673091	chr1:2541236	MMEL1	0.42	6.69	0.38	1.36e-10	Ulcerative colitis;
CESC	cis	rs7927771	0.725	rs11039265	chr11:47523214	C/A	cg05585544	chr11:47624801	NA	-0.52	-7.88	-0.44	8.44e-14	Subjective well-being;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg12508534	chr6:34855789	TAF11;ANKS1A	-0.44	-6.15	-0.35	2.89e-9	Fibrinogen levels;
CESC	cis	rs524023	0.874	rs506338	chr11:64440920	T/C	cg07220939	chr11:64358617	SLC22A12	-0.35	-5.41	-0.32	1.41e-7	Urate levels in obese individuals;
CESC	cis	rs6547741	1.000	rs6737921	chr2:27839107	T/C	cg21248554	chr2:27665150	KRTCAP3	0.24	5.08	0.3	7.28e-7	Oral cavity cancer;
CESC	cis	rs6964587	0.610	rs6950682	chr7:91464218	G/T	cg17063962	chr7:91808500	NA	0.43	5.85	0.34	1.48e-8	Breast cancer;
CESC	cis	rs2249625	0.526	rs17725666	chr6:72889711	G/A	cg18830697	chr6:72922368	RIMS1	0.4	5.75	0.33	2.45e-8	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CESC	cis	rs4834770	1.000	rs10034579	chr4:120244029	A/C	cg09307838	chr4:120376055	NA	0.44	5.24	0.31	3.25e-7	Blood protein levels;
CESC	cis	rs909002	0.849	rs10914458	chr1:32096746	T/C	cg13919466	chr1:32135498	COL16A1	-0.47	-8.19	-0.45	1.15e-14	Intelligence (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06633814	chr18:77155955	NFATC1	0.56	6.05	0.35	4.87e-9	Gut microbiome composition (summer);
CESC	cis	rs116095464	0.558	rs61492827	chr5:225774	A/G	cg12570787	chr5:219185	SDHA;CCDC127	0.52	5.65	0.33	4.24e-8	Breast cancer;
CESC	cis	rs6460942	0.908	rs77034890	chr7:12244506	A/T	cg06484146	chr7:12443880	VWDE	-0.67	-6.56	-0.37	2.76e-10	Coronary artery disease;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg09071838	chr13:25497213	CENPJ	-0.49	-7.03	-0.4	1.8e-11	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs7772486	0.902	rs2748500	chr6:146314852	C/A	cg23711669	chr6:146136114	FBXO30	0.73	10.44	0.54	1.35e-21	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	-0.52	-6.45	-0.37	5.35e-10	Prudent dietary pattern;
CESC	cis	rs1707322	1.000	rs785506	chr1:46540652	C/T	cg03146154	chr1:46216737	IPP	-0.7	-9.2	-0.49	1.08e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7193541	0.684	rs7191665	chr16:74688948	T/G	cg01733217	chr16:74700730	RFWD3	1.05	20.16	0.78	2e-55	Multiple myeloma;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02872018	chr2:192746213	NA	-0.52	-6.47	-0.37	4.67e-10	Gut microbiome composition (summer);
CESC	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg07308232	chr7:1071921	C7orf50	-0.5	-6.98	-0.39	2.43e-11	Longevity;Endometriosis;
CESC	cis	rs3749237	0.595	rs4955412	chr3:49418168	A/C	cg07636037	chr3:49044803	WDR6	0.62	8.97	0.48	5.41e-17	Resting heart rate;
CESC	cis	rs7592578	0.766	rs35818159	chr2:191409616	C/G	cg10560079	chr2:191398806	TMEM194B	-0.64	-5.35	-0.31	1.91e-7	Diastolic blood pressure;
CESC	cis	rs7116495	0.609	rs2845860	chr11:71716661	C/T	cg18441811	chr11:71824068	C11orf51	-0.83	-5.61	-0.33	4.97e-8	Severe influenza A (H1N1) infection;
CESC	cis	rs9733	0.744	rs11204737	chr1:150847647	C/T	cg18016565	chr1:150552671	MCL1	-0.35	-5.74	-0.33	2.55e-8	Tonsillectomy;
CESC	cis	rs7208859	0.673	rs216420	chr17:28938508	C/T	cg14008862	chr17:28927542	LRRC37B2	0.69	6.05	0.35	5.04e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs9649213	0.593	rs7797943	chr7:97946902	T/C	cg00277769	chr7:97922759	BAIAP2L1	-0.35	-5.73	-0.33	2.75e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs933688	0.759	rs1423593	chr5:90752351	T/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.05	10.98	0.56	2.38e-23	Smoking behavior;
CESC	cis	rs11958404	0.932	rs72816549	chr5:157417957	G/A	cg05962755	chr5:157440814	NA	0.62	6.72	0.38	1.08e-10	IgG glycosylation;
CESC	cis	rs1808579	0.935	rs4800488	chr18:21117571	C/A	cg14672496	chr18:21087552	C18orf8	0.4	6.11	0.35	3.52e-9	Hip circumference;Body mass index;BMI (adjusted for smoking behaviour);
CESC	trans	rs561341	1.000	rs8070262	chr17:30262467	A/G	cg20587970	chr11:113659929	NA	-0.8	-9.97	-0.52	4.47e-20	Hip circumference adjusted for BMI;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg23539780	chr8:10696689	PINX1	-0.51	-6.97	-0.39	2.48e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs8068544	0.606	rs77681389	chr17:40154419	T/C	cg26502583	chr17:39992600	KLHL10;NT5C3L	-0.76	-6.07	-0.35	4.34e-9	Reticulocyte fraction of red cells;Reticulocyte count;
CESC	cis	rs35306767	0.855	rs11253499	chr10:944090	A/C	cg20503657	chr10:835505	NA	0.85	8.61	0.47	6.57e-16	Eosinophil percentage of granulocytes;
CESC	cis	rs761746	0.960	rs9956	chr22:32015450	T/G	cg25791279	chr22:32026902	PISD	0.57	6.69	0.38	1.32e-10	Intelligence;
CESC	cis	rs1862618	0.853	rs190414	chr5:56116772	C/A	cg18230493	chr5:56204884	C5orf35	-0.7	-8.4	-0.46	2.71e-15	Initial pursuit acceleration;
CESC	cis	rs5750830	0.649	rs7949	chr22:39827553	G/A	cg02038168	chr22:39784481	NA	-0.6	-7.6	-0.42	5.15e-13	Intelligence (multi-trait analysis);
CESC	cis	rs6580649	0.941	rs10492080	chr12:48501411	A/G	cg05342945	chr12:48394962	COL2A1	0.55	6.35	0.36	9.14e-10	Lung cancer;
CESC	cis	rs6121246	0.697	rs6087716	chr20:30229040	C/T	cg13852791	chr20:30311386	BCL2L1	0.77	7.87	0.44	9.26e-14	Mean corpuscular hemoglobin;
CESC	cis	rs2262909	0.925	rs73019838	chr19:22247732	T/A	cg11619707	chr19:22235551	ZNF257	0.32	5.12	0.3	5.9e-7	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
CESC	cis	rs6695640	0.820	rs6586539	chr1:17743669	C/T	cg01904812	chr1:17746340	RCC2	0.35	5.07	0.3	7.53e-7	Mean platelet volume;
CESC	cis	rs10129255	0.833	rs7156689	chr14:107224272	T/C	cg23076370	chr14:107095027	NA	-0.44	-5.25	-0.31	3.12e-7	Kawasaki disease;
CESC	cis	rs763121	0.888	rs2235229	chr22:39124912	A/G	cg06022373	chr22:39101656	GTPBP1	0.71	11.41	0.57	8.78e-25	Menopause (age at onset);
CESC	cis	rs4268898	0.931	rs2111882	chr2:24434424	A/G	cg20701182	chr2:24300061	SF3B14	-0.47	-5.51	-0.32	8.54e-8	Asthma;
CESC	cis	rs11048434	0.736	rs1476911	chr12:9090859	C/T	cg04155231	chr12:9217510	LOC144571	0.32	5.15	0.3	5.17e-7	Sjögren's syndrome;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18086592	chr12:13153464	HTR7P;HEBP1	0.57	6.07	0.35	4.53e-9	Gut microbiome composition (summer);
CESC	cis	rs9467711	0.606	rs9379856	chr6:26366836	A/C	cg12826209	chr6:26865740	GUSBL1	0.61	5.17	0.3	4.59e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs4555082	0.874	rs2245329	chr14:105719181	T/C	cg13114125	chr14:105738426	BRF1	-0.81	-10.13	-0.53	1.37e-20	Mean platelet volume;Platelet distribution width;
CESC	cis	rs2014572	0.967	rs10413037	chr19:57771883	A/G	cg24459738	chr19:57751996	ZNF805	-0.49	-6.85	-0.39	5.05e-11	Hyperactive-impulsive symptoms;
CESC	cis	rs9790314	0.871	rs466626	chr3:161103629	A/C	cg03342759	chr3:160939853	NMD3	-0.45	-6.04	-0.35	5.09e-9	Morning vs. evening chronotype;
CESC	cis	rs7267979	1.000	rs453329	chr20:25440593	G/A	cg08601574	chr20:25228251	PYGB	0.37	5.3	0.31	2.47e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs250677	0.687	rs250673	chr5:148445798	C/T	cg18129178	chr5:148520854	ABLIM3	-0.51	-5.83	-0.34	1.58e-8	Breast cancer;
CESC	cis	rs6120849	0.754	rs6120797	chr20:33606002	G/A	cg06115741	chr20:33292138	TP53INP2	0.53	5.05	0.3	8.15e-7	Protein C levels;
CESC	cis	rs1707322	1.000	rs785470	chr1:46519622	C/A	cg05343316	chr1:45956843	TESK2	-0.44	-5.44	-0.32	1.2e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs4713118	0.629	rs203888	chr6:28021589	C/T	cg22143856	chr6:28129313	ZNF389	0.41	5.32	0.31	2.25e-7	Parkinson's disease;
CESC	cis	rs769267	0.965	rs12977937	chr19:19429975	C/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.45	5.43	0.32	1.28e-7	Tonsillectomy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18272703	chr1:1069929	NA	-0.52	-6.36	-0.36	9.02e-10	Gut microbiome composition (summer);
CESC	trans	rs11779988	0.543	rs379066	chr8:17881835	T/C	cg02574033	chr7:141398961	KIAA1147	-0.42	-6.14	-0.35	2.97e-9	Breast cancer;
CESC	cis	rs7208859	0.623	rs11656844	chr17:29060597	G/T	cg14008862	chr17:28927542	LRRC37B2	0.65	5.12	0.3	5.86e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs2835872	0.758	rs1709832	chr21:39038167	A/C	cg06728970	chr21:39037746	KCNJ6	0.29	5.43	0.32	1.29e-7	Electroencephalographic traits in alcoholism;
CESC	cis	rs9649213	0.537	rs35997266	chr7:97965566	T/C	cg00277769	chr7:97922759	BAIAP2L1	-0.33	-5.41	-0.32	1.39e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7552404	0.727	rs1159214	chr1:76317910	G/T	cg10523679	chr1:76189770	ACADM	-0.65	-6.63	-0.38	1.85e-10	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs116095464	0.614	rs62344292	chr5:244630	G/A	cg12570787	chr5:219185	SDHA;CCDC127	0.5	5.27	0.31	2.9e-7	Breast cancer;
CESC	cis	rs67478160	0.583	rs12879612	chr14:104233618	T/A	cg01849466	chr14:104193079	ZFYVE21	-0.48	-6.64	-0.38	1.75e-10	Schizophrenia;
CESC	cis	rs12477438	0.501	rs9941561	chr2:99753829	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.87	15.48	0.69	6.26e-39	Chronic sinus infection;
CESC	cis	rs7772486	0.713	rs2328704	chr6:146020494	T/C	cg23711669	chr6:146136114	FBXO30	-0.82	-11.85	-0.59	2.76e-26	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs4791774	0.540	rs7218002	chr17:8923718	A/T	cg02337062	chr3:49203509	CCDC71	0.47	6.17	0.35	2.51e-9	Nonsyndromic cleft lip with or without cleft palate;
CESC	cis	rs9287719	0.967	rs3814388	chr2:10702099	A/T	cg02196655	chr2:10830764	NOL10	-0.36	-5.42	-0.32	1.31e-7	Prostate cancer;
CESC	cis	rs2303759	0.918	rs10405465	chr19:49869298	C/T	cg22307029	chr19:49891270	CCDC155	0.55	6.66	0.38	1.59e-10	Multiple sclerosis;
CESC	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg07677032	chr17:61819896	STRADA	0.5	6.78	0.38	7.61e-11	Prudent dietary pattern;
CESC	cis	rs6933660	0.646	rs3816778	chr6:151773353	G/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.67	9.92	0.52	6.22e-20	Menarche (age at onset);
CESC	cis	rs9611565	0.532	rs202627	chr22:41847367	A/T	cg17376030	chr22:41985996	PMM1	-0.56	-6.2	-0.36	2.14e-9	Vitiligo;
CESC	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	10.16	0.53	1.09e-20	Prudent dietary pattern;
CESC	cis	rs12586317	0.513	rs74564132	chr14:35472882	C/T	cg16230307	chr14:35515116	FAM177A1	0.98	10.57	0.54	5.04e-22	Psoriasis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14128173	chr9:131115745	SLC27A4	-0.54	-6.54	-0.37	3.12e-10	Gut microbiome composition (summer);
CESC	cis	rs477895	0.653	rs11602181	chr11:63896591	C/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.87	9.52	0.5	1.16e-18	Mean platelet volume;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg04232466	chr8:21988724	HR	0.47	6.52	0.37	3.52e-10	Systemic lupus erythematosus;
CESC	cis	rs947211	0.948	rs1775143	chr1:205755550	C/T	cg24503407	chr1:205819492	PM20D1	0.39	5.21	0.3	3.74e-7	Parkinson's disease;
CESC	trans	rs2282526	0.615	rs162377	chr21:44926001	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.49	6.11	0.35	3.53e-9	Mean corpuscular hemoglobin;
CESC	trans	rs2115172	0.836	rs4835799	chr5:122762229	A/G	cg08052428	chr9:135996421	RALGDS	0.46	6.26	0.36	1.57e-9	Weight;
CESC	cis	rs6466055	0.720	rs1204077	chr7:104984019	T/C	cg04380332	chr7:105027541	SRPK2	0.43	5.6	0.33	5.33e-8	Schizophrenia;
CESC	cis	rs3785574	0.962	rs2597632	chr17:61894739	A/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.1	19.27	0.76	2.4e-52	Height;
CESC	cis	rs34779708	0.966	rs1213392	chr10:35430285	C/T	cg04310649	chr10:35416472	CREM	-0.5	-6.22	-0.36	1.93e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs780096	0.526	rs704795	chr2:27716494	G/A	cg17158414	chr2:27665306	KRTCAP3	-0.33	-6.23	-0.36	1.81e-9	Total body bone mineral density;
CESC	cis	rs79839061	0.610	rs2279182	chr4:882625	T/G	cg07828340	chr4:882639	GAK	1.07	8.55	0.47	9.76e-16	Intelligence (multi-trait analysis);
CESC	cis	rs6752107	0.967	rs11680130	chr2:234157258	G/A	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.34	5.24	0.31	3.22e-7	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs6060717	0.536	rs11167279	chr20:34509107	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.77	-6.96	-0.39	2.63e-11	Hip circumference adjusted for BMI;
CESC	cis	rs55788414	0.932	rs34110030	chr16:81185211	G/A	cg06400318	chr16:81190750	PKD1L2	-0.61	-6.81	-0.39	6.38e-11	Left ventricular obstructive tract defect (maternal effect);
CESC	cis	rs6732160	0.588	rs13390460	chr2:73371476	G/A	cg01422370	chr2:73384389	NA	0.56	8.81	0.48	1.72e-16	Intelligence (multi-trait analysis);
CESC	cis	rs8017423	0.967	rs11621364	chr14:90709115	A/G	cg14092571	chr14:90743983	NA	-0.57	-8.44	-0.46	2.09e-15	Mortality in heart failure;
CESC	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg01171360	chr6:293285	DUSP22	-0.67	-8.82	-0.48	1.61e-16	Menopause (age at onset);
CESC	cis	rs9457247	0.765	rs1322077	chr6:167424293	T/C	cg07741184	chr6:167504864	NA	0.35	6.33	0.36	1.04e-9	Crohn's disease;
CESC	cis	rs12477438	0.765	rs7571390	chr2:99626593	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.64	-8.96	-0.48	5.91e-17	Chronic sinus infection;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg08413366	chr10:75255930	PPP3CB	0.53	6.95	0.39	2.85e-11	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs1862618	0.802	rs986049	chr5:56110233	G/A	cg18230493	chr5:56204884	C5orf35	-0.7	-8.55	-0.47	9.85e-16	Initial pursuit acceleration;
CESC	cis	rs7208859	0.623	rs34756112	chr17:29113016	A/G	cg14008862	chr17:28927542	LRRC37B2	0.65	5.14	0.3	5.34e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs644799	1.000	rs3748256	chr11:95521953	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.55	6.93	0.39	3.22e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs9388451	0.839	rs4897157	chr6:126102981	A/T	cg05901451	chr6:126070800	HEY2	-0.63	-9.05	-0.49	3.22e-17	Brugada syndrome;
CESC	cis	rs8141529	0.732	rs2269577	chr22:29196757	G/C	cg02153584	chr22:29168773	CCDC117	0.7	10.05	0.53	2.35e-20	Lymphocyte counts;
CESC	cis	rs116979167	0.545	rs1706914	chr7:105196445	A/T	cg13798780	chr7:105162888	PUS7	0.52	6.29	0.36	1.28e-9	Bipolar disorder (body mass index interaction);
CESC	cis	rs7772486	0.875	rs10457792	chr6:146412415	T/C	cg23711669	chr6:146136114	FBXO30	0.81	12.17	0.6	2.27e-27	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9322193	0.962	rs7740784	chr6:150154500	C/T	cg13206674	chr6:150067644	NUP43	0.4	5.47	0.32	1.02e-7	Lung cancer;
CESC	trans	rs7656342	0.808	rs10003216	chr4:9766749	A/G	cg08635242	chr17:28706081	CPD	-0.53	-6.11	-0.35	3.49e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs6942756	1.000	rs6949950	chr7:128914818	G/A	cg02491457	chr7:128862824	NA	-0.7	-9.86	-0.52	9.97e-20	White matter hyperintensity burden;
CESC	cis	rs9467711	0.606	rs34622023	chr6:26362119	A/T	cg12826209	chr6:26865740	GUSBL1	0.62	5.4	0.32	1.45e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs6679073	1.000	rs10494874	chr1:205754688	C/G	cg14893161	chr1:205819251	PM20D1	0.44	6.12	0.35	3.29e-9	Prostate-specific antigen levels;
CESC	cis	rs5769765	1.000	rs4824106	chr22:50267822	T/C	cg02269571	chr22:50332266	NA	0.46	6.28	0.36	1.39e-9	Schizophrenia;
CESC	cis	rs733592	0.507	rs56129148	chr12:48485530	T/C	cg04545296	chr12:48745243	ZNF641	-0.29	-5.44	-0.32	1.19e-7	Plateletcrit;
CESC	cis	rs5758659	0.652	rs133323	chr22:42405922	T/C	cg04733989	chr22:42467013	NAGA	0.44	5.85	0.34	1.41e-8	Cognitive function;
CESC	cis	rs7617773	0.539	rs2017858	chr3:48382282	G/T	cg11946769	chr3:48343235	NME6	0.66	8.34	0.46	4.12e-15	Coronary artery disease;
CESC	cis	rs7927771	0.524	rs10742820	chr11:47781057	C/T	cg18512352	chr11:47633146	NA	-0.35	-5.47	-0.32	1.03e-7	Subjective well-being;
CESC	trans	rs9951602	0.512	rs12607561	chr18:76644284	G/A	cg02800362	chr5:177631904	HNRNPAB	0.62	8.1	0.45	1.96e-14	Obesity-related traits;
CESC	cis	rs6952808	0.692	rs6950627	chr7:2086672	C/T	cg23048001	chr7:2026167	MAD1L1	0.47	6.1	0.35	3.7e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs909674	0.818	rs8136980	chr22:39844574	G/A	cg24399712	chr22:39784796	NA	-0.82	-10.79	-0.55	9.65e-23	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs9399135	0.935	rs2150680	chr6:135347131	G/C	cg24558204	chr6:135376177	HBS1L	0.52	7.29	0.41	3.48e-12	Red blood cell count;
CESC	cis	rs2832191	0.967	rs2898160	chr21:30487496	A/G	cg24692254	chr21:30365293	RNF160	-0.73	-10.87	-0.56	5.11e-23	Dental caries;
CESC	cis	rs941873	0.805	rs10824747	chr10:81118464	T/C	cg09469691	chr10:81107165	PPIF	0.55	7.3	0.41	3.43e-12	Height;
CESC	cis	rs4666360	1.000	rs6725416	chr2:20336773	C/T	cg23291376	chr2:20336282	NA	-0.36	-6.06	-0.35	4.55e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel);
CESC	trans	rs561341	1.000	rs8073186	chr17:30244956	T/C	cg27661571	chr11:113659931	NA	-0.65	-6.77	-0.38	8.15e-11	Hip circumference adjusted for BMI;
CESC	cis	rs9788682	0.748	rs637137	chr15:78873976	T/A	cg24631222	chr15:78858424	CHRNA5	0.81	10.17	0.53	9.9e-21	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs7267979	0.903	rs2474769	chr20:25248725	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.82	15.62	0.69	2.01e-39	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs10779751	0.734	rs2791658	chr1:11127871	A/G	cg08854313	chr1:11322531	MTOR	0.77	10.41	0.54	1.73e-21	Body mass index;
CESC	cis	rs4595586	0.545	rs12828866	chr12:39391925	C/A	cg26384229	chr12:38710491	ALG10B	0.54	7.64	0.42	3.96e-13	Morning vs. evening chronotype;
CESC	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg05552183	chr6:42928497	GNMT	-0.76	-11.68	-0.58	1.03e-25	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs7085104	0.632	rs3781287	chr10:104595420	A/C	cg04362960	chr10:104952993	NT5C2	0.52	6.9	0.39	3.87e-11	Immature fraction of reticulocytes;Schizophrenia;
CESC	cis	rs896854	0.714	rs6471503	chr8:95990283	G/A	cg26343298	chr8:95960752	TP53INP1	0.36	6.05	0.35	4.98e-9	Type 2 diabetes;
CESC	cis	rs875971	0.540	rs1723268	chr7:65473080	A/C	cg18876405	chr7:65276391	NA	0.69	9.68	0.51	3.58e-19	Aortic root size;
CESC	cis	rs763121	0.853	rs1013338	chr22:38974154	C/A	cg06544989	chr22:39130855	UNC84B	0.49	8.99	0.48	4.98e-17	Menopause (age at onset);
CESC	cis	rs7666738	0.830	rs1593572	chr4:98979322	A/G	cg17366294	chr4:99064904	C4orf37	-0.57	-8.06	-0.44	2.56e-14	Colonoscopy-negative controls vs population controls;
CESC	cis	rs727505	1.000	rs34986416	chr7:124441017	A/G	cg23710748	chr7:124431027	NA	-0.49	-7.66	-0.43	3.43e-13	Lewy body disease;
CESC	cis	rs2361718	0.500	rs8068856	chr17:78100731	A/G	cg20811857	chr17:78079795	GAA	-0.42	-6.09	-0.35	4.03e-9	Yeast infection;
CESC	cis	rs9790314	0.846	rs4856714	chr3:160961824	T/C	cg03342759	chr3:160939853	NMD3	-0.51	-7.37	-0.41	2.12e-12	Morning vs. evening chronotype;
CESC	cis	rs7811142	1.000	rs11559117	chr7:100076614	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.13	13.06	0.63	1.98e-30	Platelet count;
CESC	cis	rs7927771	0.542	rs6485775	chr11:47773518	A/G	cg20307385	chr11:47447363	PSMC3	-0.56	-7.74	-0.43	2.15e-13	Subjective well-being;
CESC	cis	rs796364	0.951	rs10931888	chr2:201022952	T/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.7	-6.78	-0.38	7.69e-11	Schizophrenia;
CESC	cis	rs4474465	0.646	rs7937417	chr11:78284470	A/G	cg27205649	chr11:78285834	NARS2	0.51	6.9	0.39	3.78e-11	Alzheimer's disease (survival time);
CESC	cis	rs2742417	0.603	rs2253979	chr3:45773320	A/G	cg04837898	chr3:45731254	SACM1L	-0.46	-6.11	-0.35	3.5e-9	Response to anti-depressant treatment in major depressive disorder;
CESC	cis	rs2404602	0.740	rs34924128	chr15:76965169	T/G	cg26408565	chr15:76604113	ETFA	-0.39	-5.64	-0.33	4.39e-8	Blood metabolite levels;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg01669482	chr16:25043131	NA	-0.46	-6.64	-0.38	1.79e-10	Gambling;
CESC	cis	rs875971	0.522	rs1617484	chr7:65463095	G/A	cg06456125	chr7:65229604	NA	0.41	5.22	0.31	3.61e-7	Aortic root size;
CESC	cis	rs7084402	0.565	rs4948522	chr10:60334575	T/C	cg07615347	chr10:60278583	BICC1	0.42	6.09	0.35	3.97e-9	Refractive error;
CESC	trans	rs7937682	0.889	rs7926485	chr11:111536670	G/A	cg18187862	chr3:45730750	SACM1L	0.47	6.04	0.35	5.2e-9	Primary sclerosing cholangitis;
CESC	cis	rs1832871	0.643	rs9456282	chr6:158724743	A/G	cg07165851	chr6:158734300	TULP4	0.62	6.41	0.37	6.77e-10	Height;
CESC	cis	rs4901869	0.966	rs12893803	chr14:59329655	T/C	cg02291164	chr14:59296302	NA	0.44	7.45	0.42	1.36e-12	Panic disorder;
CESC	trans	rs1814175	0.817	rs12277258	chr11:49940216	T/C	cg03929089	chr4:120376271	NA	-0.93	-16.26	-0.71	1.03e-41	Height;
CESC	cis	rs7666738	0.830	rs1967977	chr4:98966141	A/G	cg17366294	chr4:99064904	C4orf37	0.6	8.52	0.46	1.2e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9487051	0.676	rs13195816	chr6:109598624	T/C	cg01475377	chr6:109611718	NA	-0.43	-6.66	-0.38	1.61e-10	Reticulocyte fraction of red cells;
CESC	cis	rs977987	0.843	rs10459859	chr16:75381950	T/C	cg03315344	chr16:75512273	CHST6	0.39	5.62	0.33	4.88e-8	Dupuytren's disease;
CESC	cis	rs3806843	0.706	rs1089305	chr5:140066306	T/C	cg26395211	chr5:140044315	WDR55	0.47	6.03	0.35	5.51e-9	Depressive symptoms (multi-trait analysis);
CESC	cis	rs9549260	0.651	rs9549251	chr13:41228650	A/G	cg21288729	chr13:41239152	FOXO1	0.65	8.51	0.46	1.32e-15	Red blood cell count;
CESC	cis	rs10504229	1.000	rs67039591	chr8:58174553	T/A	cg05313129	chr8:58192883	C8orf71	-0.55	-6.37	-0.36	8.42e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs6963495	0.745	rs75805443	chr7:105162828	A/G	cg19920283	chr7:105172520	RINT1	0.69	6.56	0.37	2.85e-10	Bipolar disorder (body mass index interaction);
CESC	cis	rs7589728	0.514	rs74426843	chr2:88459388	C/T	cg14558114	chr2:88469736	THNSL2	0.57	5.4	0.31	1.5e-7	Plasma clusterin levels;
CESC	cis	rs1862618	0.853	rs832554	chr5:56115036	A/G	cg22800045	chr5:56110881	MAP3K1	0.81	9.91	0.52	6.85e-20	Initial pursuit acceleration;
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg15919258	chr14:90849921	NA	-0.4	-6.15	-0.35	2.78e-9	Vertical cup-disc ratio;
CESC	cis	rs4808199	1.000	rs12977524	chr19:19568244	A/G	cg03709012	chr19:19516395	GATAD2A	1.16	13.34	0.63	2.07e-31	Nonalcoholic fatty liver disease;
CESC	cis	rs1669338	0.588	rs3804783	chr3:3184442	C/T	cg16797762	chr3:3221439	CRBN	-0.59	-6.2	-0.36	2.14e-9	White matter integrity;
CESC	cis	rs10540	1.000	rs61876332	chr11:487101	C/T	cg03934478	chr11:495069	RNH1	0.55	5.31	0.31	2.37e-7	Body mass index;
CESC	cis	rs830124	0.602	rs1375654	chr12:122385711	C/T	cg22168489	chr12:122356033	WDR66	-0.38	-5.05	-0.3	8.27e-7	Urinary metabolites;
CESC	cis	rs9303280	0.806	rs2872507	chr17:38040763	C/T	cg19468946	chr17:37922297	IKZF3	-0.41	-5.45	-0.32	1.13e-7	Self-reported allergy;
CESC	cis	rs10504229	1.000	rs17805549	chr8:58179653	T/C	cg14926445	chr8:58193284	C8orf71	-0.51	-5.47	-0.32	1.03e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs4713118	0.513	rs149954	chr6:28035246	G/A	cg19592336	chr6:28129416	ZNF389	0.45	6.44	0.37	5.6e-10	Parkinson's disease;
CESC	cis	rs847577	0.569	rs7804318	chr7:97796635	A/G	cg24562669	chr7:97807699	LMTK2	-0.8	-13.09	-0.63	1.57e-30	Breast cancer;
CESC	cis	rs4713118	0.662	rs13218430	chr6:28029837	T/C	cg12963246	chr6:28129442	ZNF389	0.5	6.4	0.37	6.93e-10	Parkinson's disease;
CESC	cis	rs9814567	1.000	rs7426847	chr3:134267519	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.45	6.08	0.35	4.21e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs9768139	0.935	rs10155946	chr7:158122116	C/T	cg24154853	chr7:158122151	PTPRN2	-0.4	-6.41	-0.37	6.55e-10	Calcium levels;
CESC	cis	rs6502050	0.835	rs4789751	chr17:80092373	G/T	cg01763666	chr17:80159506	CCDC57	-0.37	-5.1	-0.3	6.55e-7	Life satisfaction;
CESC	cis	rs7312933	0.510	rs61942483	chr12:42499538	T/A	cg01256987	chr12:42539512	GXYLT1	-0.47	-7.29	-0.41	3.49e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs6502050	0.835	rs7502548	chr17:80087569	T/C	cg11859384	chr17:80120422	CCDC57	0.38	5.11	0.3	6.03e-7	Life satisfaction;
CESC	trans	rs6445797	0.632	rs11130538	chr3:56700769	A/G	cg15444621	chr13:113611794	NA	0.34	6.03	0.35	5.54e-9	Gastritis;
CESC	cis	rs9914988	0.943	rs2046759	chr17:27138817	T/C	cg20469991	chr17:27169893	C17orf63	-0.48	-5.25	-0.31	3.18e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CESC	cis	rs11083475	0.714	rs1471432	chr19:39260282	G/A	cg07905965	chr19:39260460	NA	0.36	5.39	0.31	1.54e-7	Heart rate;
CESC	cis	rs2014572	1.000	rs2014572	chr19:57760018	G/A	cg24459738	chr19:57751996	ZNF805	-0.53	-7.48	-0.42	1.08e-12	Hyperactive-impulsive symptoms;
CESC	cis	rs829883	0.966	rs249818	chr12:98896994	A/C	cg25150519	chr12:98850993	NA	0.71	9.74	0.51	2.31e-19	Colorectal adenoma (advanced);
CESC	trans	rs1829883	0.600	rs2948748	chr5:98742134	A/G	cg23861655	chr4:57411219	NA	0.39	6.38	0.36	7.86e-10	Hemostatic factors and hematological phenotypes;
CESC	cis	rs1050631	0.564	rs1785925	chr18:33727186	C/A	cg25426722	chr18:33708991	SLC39A6;ELP2	0.59	8.21	0.45	9.72e-15	Esophageal squamous cell cancer (length of survival);
CESC	cis	rs6724607	1.000	rs13410230	chr2:191446252	A/G	cg21644426	chr2:191273491	MFSD6	0.47	6.48	0.37	4.45e-10	Pulse pressure;
CESC	cis	rs7772486	0.790	rs6917482	chr6:146243581	C/T	cg05347473	chr6:146136440	FBXO30	-0.55	-7.05	-0.4	1.57e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs262150	0.659	rs2527236	chr7:158796644	C/T	cg04111992	chr7:158790115	NA	-0.33	-5.14	-0.3	5.26e-7	Facial morphology (factor 20);
CESC	cis	rs55794721	0.509	rs4649085	chr1:25778832	G/A	cg02931644	chr1:25747376	RHCE	0.46	7.97	0.44	4.84e-14	Plateletcrit;Mean corpuscular volume;
CESC	cis	rs7208859	0.623	rs9911784	chr17:29124580	A/C	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.1e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs6963495	0.818	rs73190183	chr7:105163022	G/A	cg19920283	chr7:105172520	RINT1	0.69	6.56	0.37	2.85e-10	Bipolar disorder (body mass index interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07822143	chr4:146019674	ABCE1;ANAPC10	-0.72	-8.83	-0.48	1.42e-16	Gut microbiome composition (summer);
CESC	cis	rs897984	0.542	rs59061704	chr16:31062704	G/C	cg02466173	chr16:30829666	NA	-0.43	-7.37	-0.41	2.18e-12	Dementia with Lewy bodies;
CESC	cis	rs9611565	0.879	rs4820437	chr22:41761290	T/C	cg06481639	chr22:41940642	POLR3H	-0.44	-5.15	-0.3	5.2e-7	Vitiligo;
CESC	cis	rs7267979	1.000	rs7019	chr20:25278278	C/T	cg08601574	chr20:25228251	PYGB	0.37	5.2	0.3	3.93e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs12476592	0.602	rs11125977	chr2:63809549	C/T	cg17519650	chr2:63277830	OTX1	0.48	5.48	0.32	9.68e-8	Childhood ear infection;
CESC	cis	rs1153858	1.000	rs12595087	chr15:45655232	A/G	cg21132104	chr15:45694354	SPATA5L1	0.86	11.64	0.58	1.46e-25	Homoarginine levels;
CESC	cis	rs10242455	0.702	rs73397447	chr7:99010949	G/T	cg25640893	chr7:99214727	ZNF498	1.05	6.32	0.36	1.09e-9	Blood metabolite levels;
CESC	cis	rs6502050	0.835	rs7406529	chr17:80080877	C/T	cg11859384	chr17:80120422	CCDC57	0.38	5.13	0.3	5.62e-7	Life satisfaction;
CESC	cis	rs6834538	0.597	rs4834291	chr4:113482718	C/T	cg05166686	chr4:113558556	LARP7;C4orf21	0.43	5.32	0.31	2.17e-7	Free thyroxine concentration;
CESC	cis	rs4835473	0.832	rs55935372	chr4:144621779	A/G	cg25736465	chr4:144833511	NA	-0.41	-5.97	-0.34	7.55e-9	Immature fraction of reticulocytes;
CESC	cis	rs10256972	0.684	rs2363279	chr7:1096143	A/G	cg04025307	chr7:1156635	C7orf50	0.49	7.92	0.44	6.39e-14	Longevity;Endometriosis;
CESC	cis	rs9796	0.689	rs28409432	chr15:41447454	G/A	cg20272979	chr15:41787780	ITPKA	0.34	5.12	0.3	6.01e-7	Menopause (age at onset);
CESC	cis	rs9660180	0.967	rs12044597	chr1:1708801	A/G	cg05132306	chr1:1846340	CALML6	-0.32	-6.83	-0.39	5.89e-11	Body mass index;
CESC	cis	rs3768617	0.510	rs2093984	chr1:183094314	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.87	13.4	0.64	1.29e-31	Fuchs's corneal dystrophy;
CESC	cis	rs9929218	0.954	rs60302411	chr16:68824220	A/C	cg02972257	chr16:68554789	NA	0.45	5.38	0.31	1.66e-7	Colorectal cancer;
CESC	trans	rs61931739	0.534	rs6488189	chr12:33995865	C/T	cg26384229	chr12:38710491	ALG10B	0.59	8.17	0.45	1.3e-14	Morning vs. evening chronotype;
CESC	cis	rs12541335	0.590	rs11136002	chr8:22217082	C/T	cg02788857	chr8:22132959	PIWIL2	0.32	5.65	0.33	4.12e-8	Hypertriglyceridemia;
CESC	cis	rs11792861	0.816	rs7027263	chr9:111699569	G/A	cg13535736	chr9:111863775	C9orf5	-0.47	-6.26	-0.36	1.55e-9	Menarche (age at onset);
CESC	cis	rs4728302	0.869	rs7792546	chr7:133595502	G/T	cg10665199	chr7:133106180	EXOC4	0.4	5.55	0.32	7.05e-8	Intelligence;Intelligence (multi-trait analysis);
CESC	cis	rs7973683	0.513	rs57316347	chr12:124389053	A/G	cg00084347	chr12:124393913	DNAH10	0.27	5.21	0.3	3.81e-7	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
CESC	cis	rs748404	0.578	rs478028	chr15:43610772	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.55	8.75	0.47	2.5e-16	Lung cancer;
CESC	cis	rs3784262	1.000	rs12903551	chr15:58268372	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.31	-5.07	-0.3	7.49e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
CESC	cis	rs67311347	1.000	rs11539046	chr3:40503809	G/A	cg01475735	chr3:40494733	NA	0.44	5.47	0.32	1.05e-7	Renal cell carcinoma;
CESC	cis	rs2795502	1.000	rs3121279	chr10:43378449	T/A	cg20628663	chr10:43360327	NA	0.52	6.14	0.35	3e-9	Blood protein levels;
CESC	cis	rs7264396	0.563	rs2425086	chr20:34302873	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.63	6.7	0.38	1.23e-10	Total cholesterol levels;
CESC	cis	rs977987	0.742	rs12928898	chr16:75462081	G/A	cg03315344	chr16:75512273	CHST6	0.41	5.91	0.34	1.07e-8	Dupuytren's disease;
CESC	cis	rs35306767	0.903	rs11253467	chr10:901244	A/G	cg25019033	chr10:957182	NA	-0.59	-6.44	-0.37	5.47e-10	Eosinophil percentage of granulocytes;
CESC	trans	rs17685	0.664	rs9801113	chr7:75792031	C/T	cg19862616	chr7:65841803	NCRNA00174	0.84	12.03	0.59	6.77e-27	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs8017423	0.935	rs7160304	chr14:90752908	G/T	cg14092571	chr14:90743983	NA	-0.6	-9.06	-0.49	2.86e-17	Mortality in heart failure;
CESC	cis	rs6460942	0.915	rs62447640	chr7:12488282	A/T	cg02935154	chr7:12443704	VWDE	-0.57	-5.94	-0.34	9.02e-9	Coronary artery disease;
CESC	cis	rs6121246	0.909	rs6088962	chr20:30268184	C/T	cg13852791	chr20:30311386	BCL2L1	0.8	7.34	0.41	2.62e-12	Mean corpuscular hemoglobin;
CESC	trans	rs879500	0.653	rs4131805	chr18:26059112	T/C	cg18984002	chr17:36876514	MLLT6	0.44	6.21	0.36	2.08e-9	Lung function (FVC);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13100218	chr1:117487539	PTGFRN	-0.54	-6.05	-0.35	4.82e-9	Gut microbiome composition (summer);
CESC	cis	rs6570726	0.935	rs366621	chr6:145861275	A/G	cg05347473	chr6:146136440	FBXO30	0.47	6.19	0.36	2.29e-9	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6963495	0.818	rs73190183	chr7:105163022	G/A	cg13798780	chr7:105162888	PUS7	0.78	8.04	0.44	2.99e-14	Bipolar disorder (body mass index interaction);
CESC	cis	rs727505	0.954	rs1525613	chr7:124658636	A/G	cg23710748	chr7:124431027	NA	-0.45	-6.98	-0.39	2.31e-11	Lewy body disease;
CESC	cis	rs568617	0.716	rs111953392	chr11:65595697	G/A	cg04055107	chr11:65626734	MUS81;CFL1	1.01	8.46	0.46	1.84e-15	Crohn's disease;
CESC	cis	rs8062405	1.000	rs72793811	chr16:28839392	G/A	cg08761264	chr16:28874980	SH2B1	-0.44	-5.36	-0.31	1.85e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs9911578	0.935	rs420878	chr17:56709077	A/G	cg05425664	chr17:57184151	TRIM37	-0.51	-7.15	-0.4	8.32e-12	Intelligence (multi-trait analysis);
CESC	cis	rs8060686	0.623	rs7201591	chr16:68086105	A/G	cg26727032	chr16:67993705	SLC12A4	-0.59	-8.18	-0.45	1.22e-14	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs863345	0.512	rs2852636	chr1:158586352	T/C	cg12129480	chr1:158549410	OR10X1	-0.29	-5.44	-0.32	1.24e-7	Pneumococcal bacteremia;
CESC	cis	rs7542091	0.704	rs1883331	chr1:210043483	A/G	cg22029157	chr1:209979665	IRF6	0.5	7.98	0.44	4.32e-14	Monobrow;
CESC	cis	rs3096299	0.754	rs2965816	chr16:89514183	G/T	cg08392591	chr16:89556376	ANKRD11	-0.56	-7.56	-0.42	6.6e-13	Multiple myeloma (IgH translocation);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg07590406	chr3:58292066	RPP14	-0.42	-6.12	-0.35	3.39e-9	Gambling;
CESC	cis	rs7949030	0.688	rs11231155	chr11:62365619	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.62	9.27	0.49	6.6e-18	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs992157	0.767	rs2382822	chr2:219173327	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.62	-8.23	-0.45	8.74e-15	Colorectal cancer;
CESC	cis	rs2797160	0.684	rs1832937	chr6:125985934	A/G	cg05901451	chr6:126070800	HEY2	0.45	6.69	0.38	1.35e-10	Endometrial cancer;
CESC	cis	rs1018836	0.884	rs7008765	chr8:91632589	C/T	cg16814680	chr8:91681699	NA	-0.72	-9.98	-0.52	3.92e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs854765	0.718	rs12943500	chr17:17790588	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.46	-6.06	-0.35	4.57e-9	Total body bone mineral density;
CESC	cis	rs35306767	0.903	rs11253492	chr10:936873	T/C	cg25019033	chr10:957182	NA	-0.56	-6.07	-0.35	4.4e-9	Eosinophil percentage of granulocytes;
CESC	cis	rs2302190	0.769	rs7211294	chr17:56462783	G/A	cg25885038	chr17:56607967	SEPT4	-0.41	-5.49	-0.32	9.52e-8	Vitamin D levels;
CESC	cis	rs9790314	0.875	rs7615592	chr3:160981548	A/C	cg03342759	chr3:160939853	NMD3	-0.43	-5.54	-0.32	7.15e-8	Morning vs. evening chronotype;
CESC	cis	rs7617480	0.648	rs6796790	chr3:48780317	G/A	cg07636037	chr3:49044803	WDR6	0.82	12.17	0.6	2.33e-27	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CESC	cis	rs1969363	0.531	rs11495331	chr12:38110702	A/G	cg26384229	chr12:38710491	ALG10B	0.39	5.29	0.31	2.61e-7	Morning vs. evening chronotype;
CESC	cis	rs56104184	0.578	rs7254608	chr19:49395774	G/T	cg21252483	chr19:49399788	TULP2	-0.39	-5.5	-0.32	9.11e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	cis	rs2777491	1.000	rs316609	chr15:41743828	T/A	cg02330683	chr15:41787940	ITPKA	0.47	7.08	0.4	1.26e-11	Ulcerative colitis;
CESC	cis	rs13064411	0.696	rs6766615	chr3:113219342	T/C	cg18753928	chr3:113234510	CCDC52	-0.5	-6.04	-0.35	5.2e-9	Response to simvastatin treatment (PCSK9 protein level change);
CESC	cis	rs1401999	0.674	rs562	chr3:183637845	T/C	cg01324343	chr3:183735012	ABCC5	0.47	9.3	0.5	5.34e-18	Anterior chamber depth;
CESC	cis	rs4819052	0.765	rs2838852	chr21:46677037	C/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.77	10.14	0.53	1.26e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs35306767	0.903	rs11253495	chr10:937064	C/T	cg20503657	chr10:835505	NA	0.81	8.26	0.45	6.95e-15	Eosinophil percentage of granulocytes;
CESC	cis	rs2576037	0.526	rs9962523	chr18:44486414	A/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.58	-7.94	-0.44	5.65e-14	Personality dimensions;
CESC	cis	rs9905704	0.836	rs302875	chr17:56767874	A/G	cg12560992	chr17:57184187	TRIM37	-0.61	-7.14	-0.4	8.77e-12	Testicular germ cell tumor;
CESC	cis	rs2228479	0.702	rs17226841	chr16:89828484	C/T	cg04013166	chr16:89971882	TCF25	0.78	6.69	0.38	1.33e-10	Skin colour saturation;
CESC	cis	rs926392	0.589	rs2019032	chr20:37680326	C/A	cg16355469	chr20:37678765	NA	0.61	7.37	0.41	2.17e-12	Dialysis-related mortality;
CESC	cis	rs7208859	0.623	rs79607958	chr17:28934548	T/G	cg19761014	chr17:28927070	LRRC37B2	0.82	6.21	0.36	2.01e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs9359856	0.564	rs17584290	chr6:90467114	T/G	cg13799429	chr6:90582589	CASP8AP2	-0.61	-5.64	-0.33	4.36e-8	Bipolar disorder;
CESC	cis	rs10242455	0.764	rs2740564	chr7:99295693	T/C	cg07715041	chr7:99302981	CYP3A7	-0.44	-5.56	-0.32	6.73e-8	Blood metabolite levels;
CESC	cis	rs2637266	0.562	rs35305451	chr10:78408479	A/G	cg18941641	chr10:78392320	NA	-0.32	-5.11	-0.3	6.16e-7	Pulmonary function;
CESC	cis	rs9910055	0.659	rs7207464	chr17:42245033	C/T	cg08499158	chr17:42289980	UBTF	-0.5	-6.39	-0.37	7.31e-10	Total body bone mineral density;
CESC	cis	rs17001868	0.568	rs3788579	chr22:40742989	T/C	cg07138101	chr22:40742427	ADSL	0.57	5.42	0.32	1.37e-7	Mammographic density (dense area);
CESC	cis	rs7219021	0.926	rs11657940	chr17:46852616	G/A	cg16584676	chr17:46985605	UBE2Z	-0.56	-6.27	-0.36	1.48e-9	Schizophrenia or bipolar disorder;
CESC	cis	rs477692	0.699	rs557311	chr10:131389484	A/G	cg05714579	chr10:131428358	MGMT	0.45	5.88	0.34	1.21e-8	Response to temozolomide;
CESC	trans	rs7618501	0.815	rs3819325	chr3:49843723	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.58	8.12	0.45	1.72e-14	Intelligence (multi-trait analysis);
CESC	cis	rs3824867	0.920	rs3740685	chr11:47468791	C/T	cg20307385	chr11:47447363	PSMC3	0.51	6.27	0.36	1.43e-9	Mean corpuscular hemoglobin;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg19826439	chr1:226297528	NA	-0.47	-6.7	-0.38	1.23e-10	Fibrinogen levels;
CESC	cis	rs9457247	0.967	rs2015864	chr6:167381476	T/C	cg07741184	chr6:167504864	NA	-0.32	-5.89	-0.34	1.15e-8	Crohn's disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg11636714	chr8:42128950	IKBKB	-0.43	-6.2	-0.36	2.13e-9	Fibrinogen levels;
CESC	cis	rs4662945	0.603	rs1453147	chr2:130271510	A/C	cg05903289	chr2:130345205	NA	-0.36	-5.3	-0.31	2.45e-7	Response to cytidine analogues (gemcitabine);
CESC	cis	rs1799949	1.000	rs12942277	chr17:41187974	G/C	cg23758822	chr17:41437982	NA	1.03	14.48	0.66	2.1e-35	Menopause (age at onset);
CESC	cis	rs2637266	0.703	rs728435	chr10:78527897	T/A	cg18941641	chr10:78392320	NA	0.39	7.55	0.42	6.84e-13	Pulmonary function;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg15980914	chr19:28297092	NA	0.5	6.63	0.38	1.89e-10	Fibrinogen levels;
CESC	cis	rs17818399	0.749	rs13000560	chr2:46790997	G/T	cg02822958	chr2:46747628	ATP6V1E2	0.45	5.24	0.31	3.31e-7	Height;
CESC	cis	rs72634258	0.945	rs2294889	chr1:8075934	A/G	cg00042356	chr1:8021962	PARK7	0.78	7.13	0.4	9.61e-12	Inflammatory bowel disease;
CESC	cis	rs9818758	0.607	rs13077498	chr3:49313978	C/T	cg00383909	chr3:49044727	WDR6	0.8	6.08	0.35	4.24e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CESC	cis	rs875971	0.545	rs6460276	chr7:65647277	G/A	cg19163074	chr7:65112434	INTS4L2	-0.46	-5.05	-0.3	8.07e-7	Aortic root size;
CESC	trans	rs11098499	0.580	rs12509234	chr4:120319434	T/C	cg25214090	chr10:38739885	LOC399744	0.71	9.79	0.52	1.6e-19	Corneal astigmatism;
CESC	cis	rs3096299	0.933	rs2965934	chr16:89481229	C/G	cg08822215	chr16:89438651	ANKRD11	-0.37	-5.73	-0.33	2.75e-8	Multiple myeloma (IgH translocation);
CESC	cis	rs7246657	0.891	rs7253114	chr19:37988725	G/A	cg23950597	chr19:37808831	NA	-0.56	-6.26	-0.36	1.51e-9	Coronary artery calcification;
CESC	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg05195085	chr7:157951403	PTPRN2	0.41	7.77	0.43	1.73e-13	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CESC	cis	rs875971	0.862	rs801203	chr7:66023012	A/G	cg11764359	chr7:65958608	NA	-0.78	-11.22	-0.57	3.73e-24	Aortic root size;
CESC	cis	rs10851478	0.872	rs7172906	chr15:49922775	C/G	cg08060515	chr15:49448048	GALK2;COPS2	0.42	5.2	0.3	3.95e-7	Oral cavity cancer;
CESC	cis	rs9457247	0.534	rs9356551	chr6:167400345	T/C	cg23791538	chr6:167370224	RNASET2	0.67	9.65	0.51	4.6e-19	Crohn's disease;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg09755102	chr1:33283495	S100PBP;YARS	0.52	7.15	0.4	8.58e-12	Systemic lupus erythematosus;
CESC	cis	rs1799949	0.930	rs4584865	chr17:41424919	C/G	cg05368731	chr17:41323189	NBR1	0.79	10.8	0.55	9.2e-23	Menopause (age at onset);
CESC	cis	rs4237845	0.788	rs1962047	chr12:58292707	G/A	cg00677455	chr12:58241039	CTDSP2	0.6	7.5	0.42	9.64e-13	Intelligence (multi-trait analysis);
CESC	cis	rs4595586	0.545	rs6580894	chr12:39371951	A/G	cg26384229	chr12:38710491	ALG10B	0.51	7.07	0.4	1.38e-11	Morning vs. evening chronotype;
CESC	cis	rs763121	0.962	rs5757135	chr22:38952573	C/T	cg06022373	chr22:39101656	GTPBP1	0.74	11.52	0.58	3.59e-25	Menopause (age at onset);
CESC	cis	rs7560272	0.564	rs10496190	chr2:73638823	C/G	cg20560298	chr2:73613845	ALMS1	0.39	5.63	0.33	4.61e-8	Schizophrenia;
CESC	cis	rs9611565	0.694	rs202622	chr22:41825342	T/G	cg06634786	chr22:41940651	POLR3H	0.71	7.08	0.4	1.28e-11	Vitiligo;
CESC	cis	rs875971	0.755	rs76288834	chr7:66069802	G/A	cg18252515	chr7:66147081	NA	0.45	5.88	0.34	1.23e-8	Aortic root size;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg15340270	chr11:62420901	INTS5	-0.47	-6.47	-0.37	4.79e-10	Asthma;
CESC	cis	rs12477438	0.501	rs6751927	chr2:99740175	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.87	16.09	0.7	4.08e-41	Chronic sinus infection;
CESC	cis	rs7618915	0.570	rs11130312	chr3:52675055	A/C	cg05564831	chr3:52568323	NT5DC2	0.45	6.84	0.39	5.32e-11	Bipolar disorder;
CESC	cis	rs9814567	0.928	rs6768323	chr3:134268737	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.45	6.08	0.35	4.21e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs75804782	0.521	rs72982598	chr2:239455052	G/A	cg18131467	chr2:239335373	ASB1	-0.67	-5.69	-0.33	3.4e-8	Morning vs. evening chronotype;Chronotype;
CESC	trans	rs9467711	0.659	rs35555795	chr6:26509382	C/T	cg06606381	chr12:133084897	FBRSL1	-0.96	-7.07	-0.4	1.39e-11	Autism spectrum disorder or schizophrenia;
CESC	cis	rs9888739	1.000	rs9938063	chr16:31302938	C/T	cg15817542	chr16:31343056	ITGAM	0.42	5.24	0.31	3.27e-7	Systemic lupus erythematosus;
CESC	cis	rs3213545	0.700	rs10849829	chr12:121470256	A/G	cg02403541	chr12:121454288	C12orf43	-0.65	-9.35	-0.5	3.9e-18	Subjective well-being;Cardiovascular disease risk factors;
CESC	cis	rs7582720	1.000	rs72932561	chr2:203848402	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.36	0.41	2.34e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs1167827	0.680	rs1167796	chr7:75173180	C/T	cg09988129	chr7:74988866	PMS2L2;STAG3L1	-0.47	-5.94	-0.34	9.11e-9	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs7666738	0.791	rs12233867	chr4:98950233	A/G	cg03467027	chr4:99064603	C4orf37	0.45	5.67	0.33	3.69e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4862750	0.794	rs7672272	chr4:187896774	T/G	cg03647317	chr4:187891568	NA	-0.39	-5.79	-0.34	1.98e-8	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7072216	0.763	rs7091709	chr10:100167605	G/A	cg26618903	chr10:100175079	PYROXD2	-0.35	-5.34	-0.31	1.95e-7	Metabolite levels;
CESC	cis	rs6570726	0.791	rs401331	chr6:145831408	A/G	cg05347473	chr6:146136440	FBXO30	0.59	7.61	0.42	4.79e-13	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6963495	0.615	rs2697021	chr7:105151029	A/C	cg19920283	chr7:105172520	RINT1	0.53	6.19	0.36	2.3e-9	Bipolar disorder (body mass index interaction);
CESC	cis	rs17039065	1.000	rs75264077	chr4:109393185	T/G	cg16022748	chr4:109541635	LOC285456;RPL34	0.64	5.41	0.32	1.44e-7	Gut microbiome composition (summer);
CESC	cis	rs863345	0.647	rs923663	chr1:158507732	A/T	cg12129480	chr1:158549410	OR10X1	0.36	7.25	0.41	4.44e-12	Pneumococcal bacteremia;
CESC	cis	rs798554	0.679	rs2533877	chr7:2882421	G/A	cg13628971	chr7:2884303	GNA12	0.64	8.77	0.47	2.21e-16	Height;
CESC	cis	rs4409675	0.576	rs6598912	chr1:28233289	C/T	cg23691781	chr1:28212827	C1orf38	0.27	5.51	0.32	8.54e-8	Corneal astigmatism;
CESC	cis	rs2180341	0.960	rs7756884	chr6:127684018	A/G	cg24812749	chr6:127587940	RNF146	1.05	15.07	0.68	1.77e-37	Breast cancer;
CESC	cis	rs60843830	1.000	rs11553746	chr2:272203	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.79	10.16	0.53	1.04e-20	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs9611565	0.765	rs132907	chr22:41801268	A/C	cg17376030	chr22:41985996	PMM1	-0.68	-7.12	-0.4	1.02e-11	Vitiligo;
CESC	cis	rs5750830	0.594	rs1010170	chr22:39778327	C/T	cg02038168	chr22:39784481	NA	0.54	6.59	0.38	2.32e-10	Intelligence (multi-trait analysis);
CESC	cis	rs1879734	0.731	rs72660653	chr1:54157283	G/C	cg23596471	chr1:54105337	GLIS1	0.33	5.51	0.32	8.53e-8	Mitral valve prolapse;
CESC	cis	rs7584330	0.910	rs880932	chr2:238396963	A/G	cg14458575	chr2:238380390	NA	0.7	10.44	0.54	1.34e-21	Prostate cancer;
CESC	cis	rs2011503	0.843	rs2860494	chr19:19470426	T/C	cg11584989	chr19:19387371	SF4	-0.64	-7.52	-0.42	8.54e-13	Bipolar disorder;
CESC	cis	rs1707322	1.000	rs1612419	chr1:46546945	T/C	cg03146154	chr1:46216737	IPP	-0.73	-9.53	-0.51	1.06e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs672059	1.000	rs546183	chr1:183157753	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.54	6.97	0.39	2.51e-11	Hypertriglyceridemia;
CESC	cis	rs6460942	0.597	rs6961238	chr7:12535428	C/T	cg20607287	chr7:12443886	VWDE	-0.72	-7.71	-0.43	2.51e-13	Coronary artery disease;
CESC	cis	rs9790314	0.540	rs9844862	chr3:161076188	G/A	cg03342759	chr3:160939853	NMD3	-0.41	-5.95	-0.34	8.38e-9	Morning vs. evening chronotype;
CESC	cis	rs7666738	0.830	rs10021709	chr4:99030587	G/A	cg17366294	chr4:99064904	C4orf37	0.62	8.95	0.48	6.32e-17	Colonoscopy-negative controls vs population controls;
CESC	cis	rs12973672	0.812	rs10421096	chr19:35764559	C/T	cg12095397	chr19:35769544	USF2	0.49	5.81	0.34	1.77e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs9325144	0.505	rs10785560	chr12:38636622	C/T	cg26384229	chr12:38710491	ALG10B	0.68	10.93	0.56	3.49e-23	Morning vs. evening chronotype;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04150382	chr12:121533801	NA	-0.51	-6.22	-0.36	1.89e-9	Gut microbiome composition (summer);
CESC	cis	rs6502050	0.777	rs7406162	chr17:80086386	C/T	cg11859384	chr17:80120422	CCDC57	0.38	5.12	0.3	6.01e-7	Life satisfaction;
CESC	cis	rs752010	0.644	rs6700390	chr1:42112554	A/G	cg06885757	chr1:42089581	HIVEP3	0.49	7.8	0.43	1.42e-13	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs875971	0.862	rs1643375	chr7:65872677	T/C	cg12463550	chr7:65579703	CRCP	0.49	6.21	0.36	2.07e-9	Aortic root size;
CESC	cis	rs4629180	0.586	rs1995826	chr2:102129420	A/G	cg04415270	chr2:102091202	RFX8	0.34	5.71	0.33	3.02e-8	Chronic rhinosinusitis with nasal polyps;
CESC	cis	rs950776	0.518	rs12914694	chr15:78814444	G/A	cg24631222	chr15:78858424	CHRNA5	-0.43	-5.51	-0.32	8.36e-8	Sudden cardiac arrest;
CESC	cis	rs3540	0.554	rs12443252	chr15:91064690	C/T	cg22089800	chr15:90895588	ZNF774	-0.63	-8.22	-0.45	8.89e-15	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs67311347	1.000	rs73076046	chr3:40447724	C/T	cg09455208	chr3:40491958	NA	0.52	8.6	0.47	7.23e-16	Renal cell carcinoma;
CESC	cis	rs6502050	0.835	rs4789666	chr17:80162276	C/T	cg23985595	chr17:80112537	CCDC57	-0.4	-6.48	-0.37	4.35e-10	Life satisfaction;
CESC	cis	rs875971	0.638	rs35986979	chr7:66088990	G/A	cg14393609	chr7:65229607	NA	-0.46	-6.14	-0.35	2.97e-9	Aortic root size;
CESC	cis	rs11098499	0.863	rs3733525	chr4:120447048	A/G	cg24375607	chr4:120327624	NA	0.43	5.22	0.31	3.68e-7	Corneal astigmatism;
CESC	cis	rs1862618	0.853	rs190414	chr5:56116772	C/A	cg24549020	chr5:56110836	MAP3K1	0.67	7.71	0.43	2.56e-13	Initial pursuit acceleration;
CESC	trans	rs948562	0.690	rs75365860	chr11:58169496	C/G	cg24637035	chr12:120445227	CCDC64	-0.49	-6.13	-0.35	3.26e-9	Lymphoma;
CESC	cis	rs3858526	0.727	rs10769353	chr11:5954809	C/T	cg02574844	chr11:5959923	NA	0.51	8.06	0.44	2.7e-14	DNA methylation (variation);
CESC	cis	rs11098499	0.687	rs71610270	chr4:120287436	A/G	cg09307838	chr4:120376055	NA	0.87	12.16	0.6	2.41e-27	Corneal astigmatism;
CESC	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg16405210	chr4:1374714	KIAA1530	-0.94	-13.46	-0.64	8.05e-32	Longevity;
CESC	cis	rs7666738	0.791	rs7684521	chr4:99071219	A/G	cg03467027	chr4:99064603	C4orf37	0.48	5.91	0.34	1.03e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9831754	0.704	rs9823412	chr3:78457646	T/C	cg06138941	chr3:78371609	NA	-0.49	-6.11	-0.35	3.54e-9	Calcium levels;
CESC	cis	rs6991838	0.584	rs3765205	chr8:66517486	C/T	cg13398993	chr8:66546079	ARMC1	-0.46	-5.65	-0.33	4.19e-8	Intelligence (multi-trait analysis);
CESC	cis	rs7191439	0.858	rs4238685	chr16:88775220	T/C	cg27087555	chr16:88793112	FAM38A	-1.32	-10.7	-0.55	1.9e-22	Plateletcrit;
CESC	cis	rs2637266	0.599	rs2395425	chr10:78461920	C/T	cg18941641	chr10:78392320	NA	0.4	7.1	0.4	1.13e-11	Pulmonary function;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg01911186	chr12:12765398	CREBL2	0.54	7.27	0.41	3.94e-12	Gut microbiota (bacterial taxa);
CESC	cis	rs1153858	1.000	rs4625670	chr15:45652926	C/T	cg21132104	chr15:45694354	SPATA5L1	0.85	11.64	0.58	1.47e-25	Homoarginine levels;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg01987347	chr13:111567478	ANKRD10	-0.44	-6.09	-0.35	3.94e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs763014	0.931	rs7192508	chr16:630367	C/T	cg09263875	chr16:632152	PIGQ	0.67	11.07	0.56	1.14e-23	Height;
CESC	cis	rs17021463	0.617	rs34872198	chr4:95326957	T/C	cg11021082	chr4:95130006	SMARCAD1	0.49	6.63	0.38	1.92e-10	Testicular germ cell tumor;
CESC	trans	rs11148252	0.574	rs2038826	chr13:53280013	G/A	cg18335740	chr13:41363409	SLC25A15	0.52	7.11	0.4	1.1e-11	Lewy body disease;
CESC	cis	rs1915146	0.546	rs2681919	chr10:126859029	A/G	cg23000734	chr10:126850823	CTBP2	0.53	8.02	0.44	3.36e-14	Menarche (age at onset);
CESC	cis	rs9910055	0.708	rs2631298	chr17:42219832	T/C	cg08499158	chr17:42289980	UBTF	-0.52	-6.47	-0.37	4.74e-10	Total body bone mineral density;
CESC	cis	rs4835473	0.831	rs1912743	chr4:144914858	C/G	cg25736465	chr4:144833511	NA	0.43	6.38	0.36	8.02e-10	Immature fraction of reticulocytes;
CESC	cis	rs10927875	0.631	rs28579893	chr1:16347534	A/G	cg21385522	chr1:16154831	NA	0.59	6.95	0.39	2.82e-11	Dilated cardiomyopathy;
CESC	cis	rs4253772	0.530	rs9615961	chr22:46754993	T/C	cg24881330	chr22:46731750	TRMU	0.8	5.72	0.33	2.91e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs6088590	0.561	rs6087605	chr20:33180624	G/T	cg24642439	chr20:33292090	TP53INP2	0.63	8.39	0.46	3.03e-15	Coronary artery disease;
CESC	cis	rs1552244	0.572	rs67227131	chr3:10172744	G/A	cg00149659	chr3:10157352	C3orf10	0.89	9.53	0.51	1.08e-18	Alzheimer's disease;
CESC	cis	rs2011503	1.000	rs111406321	chr19:19637437	G/A	cg11584989	chr19:19387371	SF4	0.61	7.03	0.4	1.79e-11	Bipolar disorder;
CESC	cis	rs6584283	0.875	rs10748783	chr10:101285872	C/A	cg09788492	chr10:101292477	NKX2-3	0.34	6.34	0.36	9.91e-10	Ulcerative colitis;
CESC	cis	rs7809950	0.817	rs2712195	chr7:107127496	C/T	cg23024343	chr7:107201750	COG5	-0.57	-7.42	-0.41	1.55e-12	Coronary artery disease;
CESC	cis	rs2243480	1.000	rs316329	chr7:65608416	A/C	cg18252515	chr7:66147081	NA	-1.44	-14.38	-0.66	4.77e-35	Diabetic kidney disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08692210	chr3:52188851	WDR51A	0.6	6.79	0.38	7.29e-11	Gut microbiome composition (summer);
CESC	cis	rs1707322	0.717	rs1135812	chr1:46095272	T/C	cg03146154	chr1:46216737	IPP	0.81	11.43	0.57	7.16e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs6502050	0.769	rs11658272	chr17:80084596	C/T	cg23985595	chr17:80112537	CCDC57	0.42	6.55	0.37	2.99e-10	Life satisfaction;
CESC	cis	rs3741151	0.773	rs73544783	chr11:73221256	C/G	cg17517138	chr11:73019481	ARHGEF17	0.98	7.25	0.41	4.61e-12	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs6424115	0.760	rs2999566	chr1:24051124	A/G	cg15997130	chr1:24165203	NA	0.42	5.65	0.33	4.11e-8	Immature fraction of reticulocytes;
CESC	cis	rs17376456	0.825	rs28645862	chr5:93233128	G/C	cg21475434	chr5:93447410	FAM172A	0.77	6.77	0.38	8.36e-11	Diabetic retinopathy;
CESC	cis	rs2367563	1.000	rs7315571	chr12:96058277	A/G	cg19013339	chr12:96052514	NTN4	0.35	5.15	0.3	4.97e-7	Allergic dermatitis (nickel);
CESC	cis	rs7811142	1.000	rs7809801	chr7:100072031	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.87	9.14	0.49	1.7e-17	Platelet count;
CESC	cis	rs739401	0.572	rs739399	chr11:3016452	A/G	cg25174290	chr11:3078921	CARS	0.51	7.05	0.4	1.52e-11	Longevity;
CESC	cis	rs7666738	0.830	rs62318906	chr4:99037110	C/T	cg18180107	chr4:99064573	C4orf37	0.41	5.29	0.31	2.52e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4604732	0.631	rs34924545	chr1:247626892	G/T	cg12758973	chr1:247694275	LOC148824;OR2C3	0.51	6.36	0.36	8.65e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs7666738	0.830	rs1426662	chr4:98990319	C/T	cg03467027	chr4:99064603	C4orf37	0.44	5.51	0.32	8.53e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs17376456	0.825	rs13171131	chr5:93223028	C/T	cg25358565	chr5:93447407	FAM172A	1.11	10.53	0.54	6.8e-22	Diabetic retinopathy;
CESC	cis	rs9910055	0.529	rs575798	chr17:42181796	A/C	cg13607699	chr17:42295918	UBTF	-0.49	-6.0	-0.35	6.38e-9	Total body bone mineral density;
CESC	cis	rs898097	0.801	rs68141193	chr17:80878816	C/T	cg05255149	chr17:80675120	FN3KRP	-0.44	-5.16	-0.3	4.82e-7	Breast cancer;
CESC	cis	rs9926296	0.542	rs12599531	chr16:89909401	C/T	cg04287289	chr16:89883240	FANCA	-0.56	-7.25	-0.41	4.5e-12	Vitiligo;
CESC	cis	rs9322193	0.962	rs3805749	chr6:150093682	C/T	cg09699651	chr6:150184138	LRP11	0.4	5.04	0.3	8.58e-7	Lung cancer;
CESC	cis	rs7208859	0.573	rs7214313	chr17:29138596	T/C	cg13385521	chr17:29058706	SUZ12P	0.78	6.41	0.37	6.5e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	trans	rs60843830	1.000	rs3791221	chr2:226933	A/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.64	8.04	0.44	2.92e-14	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs7520050	0.743	rs61789988	chr1:46085242	G/C	cg03146154	chr1:46216737	IPP	-0.47	-6.14	-0.35	2.94e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs8064299	0.597	rs2053748	chr17:72775911	A/G	cg25054828	chr17:72772726	NAT9;TMEM104	-0.85	-14.15	-0.66	2.98e-34	Monocyte count;
CESC	cis	rs3126085	0.935	rs3126094	chr1:152308243	T/C	cg03465714	chr1:152285911	FLG	0.43	5.26	0.31	2.94e-7	Atopic dermatitis;
CESC	cis	rs7312933	0.558	rs11181467	chr12:42765250	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.5	6.34	0.36	9.95e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs80130819	0.748	rs1387255	chr12:48648943	C/T	cg05342945	chr12:48394962	COL2A1	-0.51	-5.37	-0.31	1.71e-7	Prostate cancer;
CESC	cis	rs7208859	0.673	rs73263981	chr17:28920502	A/G	cg17105886	chr17:28927953	LRRC37B2	0.6	5.17	0.3	4.56e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs7071206	0.740	rs2048781	chr10:79422975	T/C	cg07817648	chr10:79422355	NA	-0.82	-10.39	-0.54	2.02e-21	Bone mineral density;
CESC	cis	rs10751667	1.000	rs6597965	chr11:964476	A/G	cg06064525	chr11:970664	AP2A2	-0.38	-6.73	-0.38	1.06e-10	Alzheimer's disease (late onset);
CESC	cis	rs208520	0.874	rs208517	chr6:66947040	G/T	cg07460842	chr6:66804631	NA	-0.9	-10.89	-0.56	4.59e-23	Exhaled nitric oxide output;
CESC	cis	rs9916302	0.706	rs28482878	chr17:37497100	A/G	cg07936489	chr17:37558343	FBXL20	0.88	9.63	0.51	5.22e-19	Glomerular filtration rate (creatinine);
CESC	cis	rs6570726	0.791	rs378937	chr6:145834745	C/T	cg23711669	chr6:146136114	FBXO30	0.96	14.91	0.68	6.19e-37	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs727563	0.552	rs4822045	chr22:41985958	C/A	cg17376030	chr22:41985996	PMM1	0.81	8.45	0.46	1.98e-15	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs4561483	0.583	rs11647580	chr16:11957609	G/C	cg08843971	chr16:11963173	GSPT1	0.46	6.34	0.36	1.01e-9	Testicular germ cell tumor;
CESC	cis	rs875971	1.000	rs6970030	chr7:65968679	T/C	cg18876405	chr7:65276391	NA	0.48	6.31	0.36	1.16e-9	Aortic root size;
CESC	cis	rs2439831	0.702	rs3784275	chr15:44091386	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.63	5.15	0.3	5.02e-7	Lung cancer in ever smokers;
CESC	cis	rs9611565	0.921	rs761366	chr22:41744022	C/G	cg06481639	chr22:41940642	POLR3H	-0.64	-6.77	-0.38	8.31e-11	Vitiligo;
CESC	cis	rs730566	0.640	rs6442112	chr3:48316034	A/G	cg07636037	chr3:49044803	WDR6	0.41	5.35	0.31	1.92e-7	Prion diseases;
CESC	cis	rs6963495	0.818	rs6957192	chr7:105150255	A/C	cg13798780	chr7:105162888	PUS7	-0.76	-8.02	-0.44	3.38e-14	Bipolar disorder (body mass index interaction);
CESC	cis	rs9811920	0.638	rs704581	chr3:99556160	A/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.62	-10.12	-0.53	1.44e-20	Axial length;
CESC	cis	rs2250402	0.510	rs2291619	chr15:40329033	C/T	cg01081584	chr15:40268610	EIF2AK4	0.62	6.08	0.35	4.11e-9	Corneal curvature;
CESC	cis	rs7246657	1.000	rs7247672	chr19:37743928	A/G	cg23950597	chr19:37808831	NA	-0.61	-6.37	-0.36	8.38e-10	Coronary artery calcification;
CESC	cis	rs9649213	0.593	rs6970801	chr7:97925240	T/C	cg24562669	chr7:97807699	LMTK2	0.48	6.92	0.39	3.3e-11	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs4481887	0.927	rs4405158	chr1:248490647	A/C	cg00666640	chr1:248458726	OR2T12	0.36	6.17	0.35	2.56e-9	Common traits (Other);
CESC	cis	rs479844	1.000	rs479844	chr11:65551957	A/G	cg08755490	chr11:65554678	OVOL1	0.51	6.68	0.38	1.41e-10	Allergic disease (asthma, hay fever or eczema);Atopic march;Atopic dermatitis;
CESC	cis	rs4689388	0.926	rs4343789	chr4:6285228	C/G	cg14416269	chr4:6271139	WFS1	0.49	8.41	0.46	2.63e-15	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs2836974	0.932	rs11910151	chr21:40560262	T/C	cg11644478	chr21:40555479	PSMG1	1.04	17.32	0.73	1.85e-45	Cognitive function;
CESC	cis	rs2832191	0.671	rs2409332	chr21:30512779	G/A	cg08807101	chr21:30365312	RNF160	-0.53	-6.24	-0.36	1.76e-9	Dental caries;
CESC	cis	rs1691799	0.899	rs1168299	chr12:66736074	C/G	cg16791601	chr12:66731901	HELB	-0.78	-14.03	-0.65	8.41e-34	White blood cell count (basophil);
CESC	cis	rs10924309	0.889	rs10924308	chr1:245858131	C/T	cg00036263	chr1:245852353	KIF26B	-0.44	-5.36	-0.31	1.83e-7	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
CESC	cis	rs1801251	1.000	rs56777991	chr2:233635388	A/C	cg08000102	chr2:233561755	GIGYF2	0.65	9.23	0.49	9.15e-18	Coronary artery disease;
CESC	cis	rs5750830	0.649	rs4821894	chr22:39809820	G/C	cg11247378	chr22:39784982	NA	-0.62	-9.11	-0.49	2.11e-17	Intelligence (multi-trait analysis);
CESC	cis	rs77741769	0.571	rs3897746	chr12:121324727	A/G	cg02419362	chr12:121203948	SPPL3	0.34	5.58	0.32	5.97e-8	Mean corpuscular volume;
CESC	cis	rs2635047	1.000	rs2684825	chr18:44666415	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.45	5.98	0.34	7.34e-9	Educational attainment;
CESC	cis	rs769267	0.930	rs7254927	chr19:19404786	C/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.42	5.33	0.31	2.07e-7	Tonsillectomy;
CESC	cis	rs9303401	0.659	rs714959	chr17:56628601	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	1.0	12.44	0.61	2.75e-28	Cognitive test performance;
CESC	cis	rs12497850	0.765	rs12487580	chr3:49182932	G/A	cg03060546	chr3:49711283	APEH	0.55	6.8	0.39	7.11e-11	Parkinson's disease;
CESC	cis	rs116095464	0.510	rs10057501	chr5:239545	T/C	cg22857025	chr5:266934	NA	-1.29	-18.69	-0.75	2.75e-50	Breast cancer;
CESC	cis	rs4330281	0.715	rs7609916	chr3:17804464	A/G	cg20981856	chr3:17787350	NA	0.36	5.1	0.3	6.56e-7	Schizophrenia;
CESC	cis	rs6754311	0.551	rs9287442	chr2:136522710	A/G	cg07169764	chr2:136633963	MCM6	-0.73	-9.28	-0.5	6.09e-18	Mosquito bite size;
CESC	cis	rs796364	0.616	rs6710393	chr2:200697246	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.59	5.67	0.33	3.73e-8	Schizophrenia;
CESC	cis	rs7811142	1.000	rs4472444	chr7:100070758	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.83	8.4	0.46	2.81e-15	Platelet count;
CESC	cis	rs3096299	0.719	rs2353581	chr16:89518908	T/C	cg16743903	chr16:89593216	SPG7	-0.43	-5.53	-0.32	7.85e-8	Multiple myeloma (IgH translocation);
CESC	trans	rs916888	0.773	rs199534	chr17:44824213	T/G	cg04282206	chr17:62833786	PLEKHM1P	0.55	6.41	0.37	6.72e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs2070677	0.542	rs7086127	chr10:135393731	T/C	cg20169779	chr10:135381914	SYCE1	-0.76	-10.07	-0.53	2.11e-20	Gout;
CESC	cis	rs9649213	0.593	rs12704983	chr7:97927045	G/A	cg21770322	chr7:97807741	LMTK2	0.54	8.13	0.45	1.67e-14	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs2777491	0.874	rs1655556	chr15:41777935	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.69	-10.64	-0.55	2.98e-22	Ulcerative colitis;
CESC	cis	rs763014	0.932	rs34498660	chr16:666149	A/G	cg07343612	chr16:622815	PIGQ	-0.57	-8.32	-0.46	4.64e-15	Height;
CESC	cis	rs4975616	0.869	rs370348	chr5:1331219	A/G	cg06550200	chr5:1325588	CLPTM1L	-0.7	-11.17	-0.57	5.42e-24	Lung cancer;
CESC	cis	rs644799	0.965	rs565771	chr11:95644179	T/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	12.77	0.62	1.95e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs9303280	0.806	rs11078927	chr17:38064405	C/T	cg19468946	chr17:37922297	IKZF3	-0.39	-5.11	-0.3	6.07e-7	Self-reported allergy;
CESC	cis	rs9549367	0.789	rs3850451	chr13:113905812	C/G	cg00898013	chr13:113819073	PROZ	-0.56	-7.64	-0.42	4.01e-13	Platelet distribution width;
CESC	cis	rs7618501	1.000	rs695238	chr3:49869158	A/C	cg24308560	chr3:49941425	MST1R	-0.52	-6.97	-0.39	2.55e-11	Intelligence (multi-trait analysis);
CESC	cis	rs2247341	0.965	rs2854921	chr4:1715250	C/T	cg07465881	chr4:1713556	SLBP	-0.54	-6.75	-0.38	9.2e-11	Hip circumference adjusted for BMI;Height;
CESC	cis	rs909002	0.800	rs3134718	chr1:32089839	C/T	cg13919466	chr1:32135498	COL16A1	-0.46	-8.29	-0.45	5.77e-15	Intelligence (multi-trait analysis);
CESC	cis	rs3820068	0.581	rs6666373	chr1:15939884	A/T	cg13390004	chr1:15929781	NA	0.37	5.96	0.34	8.08e-9	Systolic blood pressure;
CESC	cis	rs4862750	0.872	rs9998172	chr4:187898773	T/C	cg10295955	chr4:187884368	NA	-1.08	-23.24	-0.82	6.56e-66	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15304928	chr1:201123562	TMEM9	-0.58	-6.52	-0.37	3.61e-10	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02453779	chr11:105948520	AASDHPPT;KBTBD3	0.54	6.48	0.37	4.54e-10	Gut microbiome composition (summer);
CESC	cis	rs372883	0.600	rs2832295	chr21:30739843	C/T	cg08807101	chr21:30365312	RNF160	0.46	5.31	0.31	2.28e-7	Pancreatic cancer;
CESC	cis	rs6860806	0.507	rs2631369	chr5:131705266	G/C	cg24060327	chr5:131705240	SLC22A5	0.8	11.21	0.57	3.88e-24	Breast cancer;
CESC	cis	rs28647808	0.881	rs28622217	chr9:136267323	A/G	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.84	5.73	0.33	2.7e-8	Blood protein levels;
CESC	cis	rs1163251	0.837	rs592762	chr1:120247355	A/G	cg19096424	chr1:120255104	PHGDH	0.52	6.67	0.38	1.52e-10	Blood metabolite levels;
CESC	cis	rs2273669	0.588	rs79465564	chr6:109350290	C/T	cg05315195	chr6:109294784	ARMC2	-0.67	-6.06	-0.35	4.74e-9	Prostate cancer;
CESC	cis	rs9733	0.519	rs1134067	chr1:150721175	G/T	cg04414720	chr1:150670196	GOLPH3L	0.59	7.82	0.43	1.29e-13	Tonsillectomy;
CESC	cis	rs34779708	0.931	rs17582416	chr10:35287650	A/C	cg03585969	chr10:35415529	CREM	0.6	7.43	0.42	1.54e-12	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs72772090	0.634	rs17402639	chr5:96107005	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.64	-5.7	-0.33	3.24e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs4713118	0.621	rs4713133	chr6:28034041	T/C	cg12963246	chr6:28129442	ZNF389	0.53	6.91	0.39	3.61e-11	Parkinson's disease;
CESC	trans	rs848353	0.901	rs73424667	chr7:108596103	T/C	cg03555276	chr13:113260139	NA	0.56	6.03	0.35	5.42e-9	Smoking behavior;
CESC	cis	rs4664308	0.935	rs6744567	chr2:160933781	C/G	cg03641300	chr2:160917029	PLA2R1	-0.67	-9.84	-0.52	1.11e-19	Idiopathic membranous nephropathy;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg05051117	chr1:205719564	NUCKS1	-0.5	-6.41	-0.37	6.79e-10	Ulcerative colitis;
CESC	cis	rs7402982	0.934	rs8027457	chr15:99204101	A/G	cg03437748	chr15:99193247	IGF1R	0.73	11.64	0.58	1.45e-25	Birth weight;
CESC	cis	rs10504229	1.000	rs60651159	chr8:58174074	T/C	cg22535103	chr8:58192502	C8orf71	-1.05	-13.27	-0.63	3.63e-31	Developmental language disorder (linguistic errors);
CESC	cis	rs1322639	0.614	rs6908401	chr6:169564716	A/C	cg04662567	chr6:169592167	NA	0.47	5.09	0.3	6.8e-7	Pulse pressure;
CESC	cis	rs1801251	0.896	rs6719061	chr2:233695885	C/T	cg25237894	chr2:233734115	C2orf82	-0.37	-6.57	-0.37	2.58e-10	Coronary artery disease;
CESC	cis	rs6089584	0.606	rs2273989	chr20:60579138	G/A	cg24733560	chr20:60626293	TAF4	0.44	6.56	0.37	2.88e-10	Body mass index;
CESC	cis	rs12618769	0.597	rs3754885	chr2:99121708	G/T	cg10123293	chr2:99228465	UNC50	0.39	5.13	0.3	5.6e-7	Bipolar disorder;
CESC	cis	rs9311474	0.508	rs11714565	chr3:52606292	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.67	0.38	1.47e-10	Electroencephalogram traits;
CESC	cis	rs10779751	0.770	rs1417131	chr1:11191922	T/C	cg08854313	chr1:11322531	MTOR	-0.72	-8.53	-0.46	1.1e-15	Body mass index;
CESC	cis	rs10504073	0.669	rs11779189	chr8:50030592	C/G	cg00325661	chr8:49890786	NA	-0.5	-7.48	-0.42	1.06e-12	Blood metabolite ratios;
CESC	cis	rs861020	0.771	rs661849	chr1:210001233	C/T	cg05527609	chr1:210001259	C1orf107	1.1	15.21	0.68	5.39e-38	Orofacial clefts;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg01708236	chr6:44233446	NFKBIE	0.51	6.65	0.38	1.69e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs2625529	0.652	rs2929525	chr15:72287856	G/A	cg16672083	chr15:72433130	SENP8	0.42	6.3	0.36	1.27e-9	Red blood cell count;
CESC	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.62	7.84	0.43	1.09e-13	Prudent dietary pattern;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02079951	chr2:54013962	LOC100302652;ASB3;ERLEC1	0.64	6.93	0.39	3.15e-11	Gut microbiome composition (summer);
CESC	cis	rs35306767	0.903	rs17159970	chr10:935601	T/C	cg20503657	chr10:835505	NA	0.84	8.51	0.46	1.32e-15	Eosinophil percentage of granulocytes;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg13930080	chr1:23494472	LUZP1	-0.48	-6.05	-0.35	4.86e-9	Asthma;
CESC	trans	rs6414928	0.516	rs10155587	chr5:25941938	A/T	cg17053223	chr7:94535617	PPP1R9A	-0.55	-6.02	-0.35	5.92e-9	Facial morphology (factor 5, width of mouth relative to central midface);
CESC	cis	rs425277	0.585	rs3107143	chr1:2045372	G/C	cg24578937	chr1:2090814	PRKCZ	-0.34	-6.01	-0.35	5.99e-9	Height;
CESC	cis	rs7914558	1.000	rs943036	chr10:104836047	T/C	cg15744005	chr10:104629667	AS3MT	-0.34	-5.49	-0.32	9.51e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs644799	0.562	rs1254989	chr11:95508121	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.64	9.07	0.49	2.67e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs5758659	0.652	rs133324	chr22:42406371	C/A	cg15557168	chr22:42548783	NA	-0.42	-6.25	-0.36	1.59e-9	Cognitive function;
CESC	cis	rs7091068	0.671	rs620890	chr10:95405424	G/A	cg20715218	chr10:95462985	C10orf4	-0.51	-5.37	-0.31	1.76e-7	Urinary tract infection frequency;
CESC	cis	rs3862260	0.509	rs7552885	chr1:120164966	C/T	cg11530693	chr1:120165357	ZNF697	0.69	10.58	0.55	4.58e-22	Systemic lupus erythematosus;
CESC	cis	rs6540559	1.000	rs6659367	chr1:209982408	G/T	cg12034118	chr1:209979487	IRF6	0.42	5.31	0.31	2.37e-7	Cleft lip with or without cleft palate;
CESC	cis	rs7914558	0.966	rs7908280	chr10:104816947	C/G	cg08650961	chr10:104748594	CNNM2	0.31	5.18	0.3	4.44e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs748404	0.660	rs690367	chr15:43748304	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.51	-7.88	-0.44	8.28e-14	Lung cancer;
CESC	cis	rs8103278	0.864	rs2070737	chr19:46282890	A/T	cg11657440	chr19:46296263	DMWD	-0.62	-7.75	-0.43	1.96e-13	Coronary artery disease;
CESC	cis	rs644148	0.867	rs2571060	chr19:44971647	C/G	cg15540054	chr19:45004280	ZNF180	-0.72	-8.77	-0.47	2.23e-16	Personality dimensions;
CESC	trans	rs12599106	0.629	rs1391904	chr16:34548934	C/T	cg21548813	chr6:291882	DUSP22	-0.46	-6.05	-0.35	4.84e-9	Menopause (age at onset);
CESC	cis	rs6088580	0.634	rs2378133	chr20:32919505	C/G	cg06115741	chr20:33292138	TP53INP2	-0.43	-5.5	-0.32	8.96e-8	Glomerular filtration rate (creatinine);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18003189	chr10:30723096	MAP3K8	0.58	6.83	0.39	5.92e-11	Gut microbiome composition (summer);
CESC	cis	rs875971	1.000	rs7792762	chr7:66004138	T/C	cg12463550	chr7:65579703	CRCP	0.57	7.19	0.4	6.64e-12	Aortic root size;
CESC	cis	rs7618915	0.501	rs2079929	chr3:52765646	C/T	cg07507251	chr3:52567010	NT5DC2	0.33	5.64	0.33	4.28e-8	Bipolar disorder;
CESC	cis	rs10089	1.000	rs3792866	chr5:127479900	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.77	10.14	0.53	1.26e-20	Ileal carcinoids;
CESC	cis	rs1707322	1.000	rs7553924	chr1:46352624	T/C	cg03146154	chr1:46216737	IPP	0.71	9.86	0.52	9.69e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs11227306	0.934	rs7940691	chr11:65640906	C/T	cg04055107	chr11:65626734	MUS81;CFL1	-0.46	-5.18	-0.3	4.36e-7	DNA methylation (variation);
CESC	cis	rs3617	0.539	rs4687687	chr3:52948332	A/G	cg07507251	chr3:52567010	NT5DC2	-0.31	-5.09	-0.3	6.93e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
CESC	cis	rs748404	0.631	rs6493083	chr15:43637985	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.6	7.62	0.42	4.6e-13	Lung cancer;
CESC	cis	rs7520050	0.966	rs7550746	chr1:46351719	T/A	cg24296786	chr1:45957014	TESK2	0.43	5.45	0.32	1.15e-7	Red blood cell count;Reticulocyte count;
CESC	cis	rs9287719	0.967	rs4555318	chr2:10744295	C/G	cg00105475	chr2:10696890	NA	0.39	5.64	0.33	4.44e-8	Prostate cancer;
CESC	cis	rs8070740	0.836	rs4444392	chr17:5324588	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.52	6.4	0.37	6.85e-10	Menopause (age at onset);
CESC	trans	rs10776614	0.799	rs10857596	chr10:49764674	G/A	cg19218067	chr2:181235115	NA	0.49	6.0	0.35	6.35e-9	Self-employment;
CESC	cis	rs9916302	0.904	rs7223438	chr17:37521355	T/C	cg07936489	chr17:37558343	FBXL20	0.78	10.74	0.55	1.4e-22	Glomerular filtration rate (creatinine);
CESC	cis	rs4253772	0.591	rs9615343	chr22:46690824	C/G	cg00784671	chr22:46762841	CELSR1	-0.58	-5.61	-0.33	4.99e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs4955124	0.643	rs12629399	chr3:32039864	T/C	cg05935571	chr3:32023257	ZNF860;OSBPL10	0.89	6.63	0.38	1.88e-10	Schizophrenia;
CESC	cis	rs13108904	0.557	rs1680030	chr4:1245500	A/T	cg02475777	chr4:1388615	CRIPAK	-0.47	-6.03	-0.35	5.48e-9	Obesity-related traits;
CESC	cis	rs2486288	0.656	rs11637838	chr15:45550657	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.54	-6.42	-0.37	6.18e-10	Glomerular filtration rate;
CESC	cis	rs4665809	1.000	rs12475854	chr2:26267375	G/A	cg26314531	chr2:26401878	FAM59B	-0.6	-6.82	-0.39	6.33e-11	Gut microbiome composition (summer);
CESC	cis	rs1790761	0.505	rs2370141	chr11:67348529	A/G	cg00290607	chr11:67383545	NA	-0.36	-5.33	-0.31	2.14e-7	Mean corpuscular volume;
CESC	cis	rs8072100	0.676	rs9905308	chr17:45409386	T/A	cg25173405	chr17:45401733	C17orf57	-0.48	-6.27	-0.36	1.47e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg25635913	chr19:4497977	HDGF2	0.45	6.03	0.35	5.48e-9	Fibrinogen levels;
CESC	cis	rs10927875	0.632	rs6677321	chr1:16149301	A/C	cg18973939	chr1:16164122	FLJ37453	0.38	5.66	0.33	3.9e-8	Dilated cardiomyopathy;
CESC	cis	rs1005277	0.579	rs2472178	chr10:38384750	T/C	cg25517755	chr10:38738941	LOC399744	-0.44	-5.75	-0.33	2.43e-8	Extrinsic epigenetic age acceleration;
CESC	cis	rs4423214	1.000	rs4944955	chr11:71167677	C/T	cg24826892	chr11:71159390	DHCR7	0.44	5.08	0.3	7.05e-7	Vitamin D levels;
CESC	cis	rs60843830	1.000	rs62114544	chr2:269679	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.78	10.02	0.52	2.91e-20	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs3818285	0.556	rs944966	chr10:111658334	C/G	cg00817464	chr10:111662876	XPNPEP1	-0.54	-7.32	-0.41	2.98e-12	Superior crus of antihelix expression;
CESC	cis	rs1348850	0.632	rs1405718	chr2:178499809	C/T	cg23306229	chr2:178417860	TTC30B	0.57	7.18	0.4	7.14e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs4927850	0.752	rs7618864	chr3:195749561	G/A	cg12923728	chr3:195709715	SDHAP1	-0.68	-9.17	-0.49	1.32e-17	Pancreatic cancer;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg20881074	chr2:45236659	SIX2	-0.47	-6.45	-0.37	5.18e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs17253792	0.731	rs74829671	chr14:56112759	G/C	cg01858014	chr14:56050164	KTN1	-0.87	-7.0	-0.39	2.15e-11	Putamen volume;
CESC	cis	rs1670533	1.000	rs7679432	chr4:1050521	G/A	cg27284194	chr4:1044797	NA	0.45	5.54	0.32	7.32e-8	Recombination rate (females);
CESC	cis	rs2839186	0.903	rs61182475	chr21:47707050	T/A	cg10351095	chr21:47802916	PCNT	-0.5	-6.78	-0.38	7.81e-11	Testicular germ cell tumor;
CESC	cis	rs11098499	0.909	rs71614422	chr4:120359340	G/A	cg24375607	chr4:120327624	NA	0.46	5.78	0.33	2.1e-8	Corneal astigmatism;
CESC	cis	rs9925964	0.748	rs11640961	chr16:30979818	C/T	cg02466173	chr16:30829666	NA	0.35	5.37	0.31	1.69e-7	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs9640161	0.673	rs34489187	chr7:150044379	G/A	cg13722127	chr7:150037890	RARRES2	0.38	5.08	0.3	7.09e-7	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs9640161	0.663	rs1916932	chr7:150021644	T/C	cg13722127	chr7:150037890	RARRES2	0.34	5.18	0.3	4.29e-7	Blood protein levels;Circulating chemerin levels;
CESC	trans	rs17764205	0.568	rs72987040	chr19:3251116	C/A	cg12868887	chr11:70244470	CTTN	0.78	6.05	0.35	4.84e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs3858526	0.635	rs2045046	chr11:5875867	A/C	cg05234568	chr11:5960015	NA	-0.49	-5.28	-0.31	2.67e-7	DNA methylation (variation);
CESC	cis	rs854765	0.547	rs9894138	chr17:17964345	G/A	cg04398451	chr17:18023971	MYO15A	0.73	10.38	0.54	2.08e-21	Total body bone mineral density;
CESC	cis	rs2455799	0.613	rs4467435	chr3:15791671	A/G	cg16303742	chr3:15540471	COLQ	-0.39	-6.14	-0.35	3.01e-9	Mean platelet volume;
CESC	cis	rs9815354	0.716	rs73828280	chr3:41833907	A/T	cg03022575	chr3:42003672	ULK4	0.54	5.32	0.31	2.26e-7	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs11711311	1.000	rs9828099	chr3:113518402	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.74	10.44	0.54	1.33e-21	IgG glycosylation;
CESC	cis	rs1799949	0.965	rs9911630	chr17:41188342	A/G	cg07153921	chr17:41440717	NA	-0.4	-5.23	-0.31	3.49e-7	Menopause (age at onset);
CESC	trans	rs7726839	0.540	rs3749618	chr5:602650	A/G	cg25482853	chr8:67687455	SGK3	0.98	9.72	0.51	2.69e-19	Obesity-related traits;
CESC	cis	rs1008375	0.966	rs6832387	chr4:17697546	G/T	cg02297831	chr4:17616191	MED28	0.44	5.4	0.32	1.45e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs8060686	0.641	rs73612690	chr16:68153200	G/A	cg26727032	chr16:67993705	SLC12A4	-0.52	-6.29	-0.36	1.28e-9	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg26338869	chr17:61819248	STRADA	0.7	9.28	0.5	6.22e-18	Prudent dietary pattern;
CESC	cis	rs2228479	0.850	rs11644213	chr16:89837367	C/T	cg00800038	chr16:89945340	TCF25	0.83	7.26	0.41	4.35e-12	Skin colour saturation;
CESC	cis	rs4713118	0.662	rs9468275	chr6:28026136	G/T	cg19592336	chr6:28129416	ZNF389	0.54	6.94	0.39	3e-11	Parkinson's disease;
CESC	cis	rs938554	0.779	rs13106991	chr4:9959011	G/A	cg00071950	chr4:10020882	SLC2A9	-0.5	-5.59	-0.33	5.5e-8	Blood metabolite levels;
CESC	cis	rs3892630	0.588	rs2287881	chr19:33333155	A/G	cg13157960	chr19:33183277	NUDT19	-0.54	-5.66	-0.33	3.91e-8	Red blood cell traits;
CESC	cis	rs72781680	0.898	rs72796396	chr2:24178154	G/A	cg08917208	chr2:24149416	ATAD2B	0.94	8.58	0.47	7.87e-16	Lymphocyte counts;
CESC	cis	rs9486719	1.000	rs12205728	chr6:96891838	T/C	cg18709589	chr6:96969512	KIAA0776	-0.53	-5.81	-0.34	1.75e-8	Migraine;Coronary artery disease;
CESC	cis	rs11945232	1.000	rs28406846	chr4:88343468	C/G	cg23841344	chr4:88312519	HSD17B11	-0.65	-8.19	-0.45	1.13e-14	Intelligence (multi-trait analysis);
CESC	trans	rs7618501	0.669	rs7634084	chr3:49949834	A/T	cg21659725	chr3:3221576	CRBN	0.52	7.49	0.42	1.03e-12	Intelligence (multi-trait analysis);
CESC	cis	rs72949976	1.000	rs72949976	chr2:214034104	C/T	cg08319019	chr2:214017104	IKZF2	-0.44	-5.49	-0.32	9.55e-8	Lung cancer;Squamous cell lung carcinoma;
CESC	cis	rs1046896	0.586	rs9897951	chr17:80810662	T/C	cg05255149	chr17:80675120	FN3KRP	0.47	5.17	0.3	4.56e-7	Glycated hemoglobin levels;
CESC	cis	rs3026101	0.671	rs2301740	chr17:5319620	C/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.4	5.22	0.31	3.64e-7	Body mass index;
CESC	cis	rs7084402	0.905	rs1896244	chr10:60276182	A/G	cg07615347	chr10:60278583	BICC1	-0.6	-9.67	-0.51	3.99e-19	Refractive error;
CESC	cis	rs8031584	0.918	rs1425292	chr15:31285422	G/A	cg08109568	chr15:31115862	NA	-0.72	-9.55	-0.51	9.12e-19	Huntington's disease progression;
CESC	cis	rs9039	0.959	rs12148920	chr16:9183900	C/G	cg08831531	chr16:9218945	NA	0.4	5.96	0.34	8.09e-9	Menopause (age at onset);
CESC	trans	rs11976180	0.569	rs12703565	chr7:143754401	C/T	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.67	-6.84	-0.39	5.52e-11	Obesity-related traits;
CESC	cis	rs2841277	0.708	rs10083496	chr14:105402786	G/A	cg14403583	chr14:105418241	AHNAK2	-0.56	-7.82	-0.43	1.22e-13	Rheumatoid arthritis;
CESC	cis	rs9815354	0.812	rs73071236	chr3:41992042	A/G	cg03022575	chr3:42003672	ULK4	0.65	5.79	0.34	1.94e-8	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs6867032	0.527	rs4975777	chr5:1973324	G/T	cg26168224	chr5:2018326	NA	-0.76	-11.03	-0.56	1.63e-23	Gut microbiome composition (winter);
CESC	cis	rs7927592	0.913	rs67605986	chr11:68300955	C/T	cg20283391	chr11:68216788	NA	-0.62	-7.44	-0.42	1.42e-12	Total body bone mineral density;
CESC	trans	rs4927850	1.000	rs7627868	chr3:195753473	A/T	cg16724585	chr3:197361211	NA	-0.56	-7.2	-0.4	6.32e-12	Pancreatic cancer;
CESC	cis	rs796364	0.760	rs2202922	chr2:200882610	C/T	cg23649088	chr2:200775458	C2orf69	0.6	5.44	0.32	1.23e-7	Schizophrenia;
CESC	cis	rs7618915	0.571	rs1961959	chr3:52585760	G/C	cg05564831	chr3:52568323	NT5DC2	0.46	6.84	0.39	5.57e-11	Bipolar disorder;
CESC	cis	rs1843834	0.505	rs940317	chr2:225358118	C/T	cg12698349	chr2:225449008	CUL3	0.62	8.83	0.48	1.45e-16	IgE levels in asthmatics (D.p. specific);
CESC	cis	rs10751667	0.666	rs7395823	chr11:942701	T/C	cg01483505	chr11:975446	AP2A2	0.38	5.18	0.3	4.33e-7	Alzheimer's disease (late onset);
CESC	cis	rs853679	0.550	rs1233701	chr6:28168726	C/G	cg26335602	chr6:28129616	ZNF389	-0.49	-6.7	-0.38	1.21e-10	Depression;
CESC	cis	rs1018836	0.818	rs715057	chr8:91624340	T/C	cg16814680	chr8:91681699	NA	-0.71	-10.75	-0.55	1.3e-22	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	trans	rs12356475	0.710	rs10822686	chr10:67733250	C/T	cg16807097	chr12:56660896	COQ10A	0.49	6.0	0.35	6.34e-9	Psoriatic arthritis;
CESC	cis	rs921968	0.541	rs3755041	chr2:219442499	A/T	cg02176678	chr2:219576539	TTLL4	-0.54	-9.75	-0.51	2.1e-19	Mean corpuscular hemoglobin concentration;
CESC	cis	rs116095464	0.558	rs34629844	chr5:200829	A/G	cg22857025	chr5:266934	NA	-1.26	-14.5	-0.67	1.85e-35	Breast cancer;
CESC	trans	rs6572548	0.504	rs1956082	chr14:49665496	A/C	cg22515636	chr2:109150313	NA	-0.55	-6.14	-0.35	2.93e-9	Subjective well-being;
CESC	cis	rs76878669	0.516	rs7104570	chr11:66159098	A/G	cg18002602	chr11:66138449	SLC29A2	0.44	7.33	0.41	2.73e-12	Educational attainment (years of education);
CESC	cis	rs6032067	0.929	rs11699850	chr20:43809049	T/C	cg10761708	chr20:43804764	PI3	0.52	6.27	0.36	1.45e-9	Blood protein levels;
CESC	cis	rs4699052	0.507	rs10005997	chr4:104301711	C/G	cg16532752	chr4:104119610	CENPE	-0.51	-6.59	-0.38	2.33e-10	Testicular germ cell tumor;
CESC	cis	rs7618501	0.602	rs2526743	chr3:50115245	G/A	cg24110177	chr3:50126178	RBM5	0.52	7.23	0.41	5.03e-12	Intelligence (multi-trait analysis);
CESC	cis	rs763121	1.000	rs763121	chr22:38879940	C/T	cg14440974	chr22:39074834	NA	0.39	5.41	0.32	1.42e-7	Menopause (age at onset);
CESC	cis	rs2929278	0.617	rs2955969	chr15:44114527	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	-0.52	-6.84	-0.39	5.34e-11	Schizophrenia;
CESC	cis	rs8177253	0.828	rs8177259	chr3:133480388	T/C	cg11941060	chr3:133502564	NA	-0.48	-6.65	-0.38	1.67e-10	Iron status biomarkers;
CESC	cis	rs8077889	0.703	rs231534	chr17:41945564	C/T	cg26893861	chr17:41843967	DUSP3	-0.66	-6.85	-0.39	5.17e-11	Triglycerides;
CESC	cis	rs2276314	0.857	rs3737474	chr18:33613595	T/C	cg05985134	chr18:33552581	C18orf21	0.62	7.16	0.4	8.04e-12	Endometriosis;Drug-induced torsades de pointes;
CESC	trans	rs801193	0.935	rs2659916	chr7:66151352	C/G	cg26939375	chr7:64535504	NA	0.64	8.81	0.48	1.69e-16	Aortic root size;
CESC	cis	rs9916302	0.904	rs8079560	chr17:37497661	C/T	cg00129232	chr17:37814104	STARD3	0.55	7.29	0.41	3.49e-12	Glomerular filtration rate (creatinine);
CESC	cis	rs3733585	0.673	rs4580649	chr4:9948461	G/A	cg02734326	chr4:10020555	SLC2A9	-0.39	-5.51	-0.32	8.39e-8	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs2455799	0.634	rs4685266	chr3:15908766	A/G	cg16303742	chr3:15540471	COLQ	-0.35	-5.28	-0.31	2.74e-7	Mean platelet volume;
CESC	cis	rs7833790	0.654	rs7835342	chr8:82698092	A/G	cg27398817	chr8:82754497	SNX16	-0.42	-5.32	-0.31	2.24e-7	Diastolic blood pressure;
CESC	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg07507251	chr3:52567010	NT5DC2	0.46	8.95	0.48	6.17e-17	Electroencephalogram traits;
CESC	cis	rs7020830	0.505	rs12553878	chr9:37095705	C/T	cg14294708	chr9:37120828	ZCCHC7	0.82	11.64	0.58	1.4e-25	Schizophrenia;
CESC	cis	rs7666738	0.753	rs10004827	chr4:99037953	A/C	cg18180107	chr4:99064573	C4orf37	0.41	5.29	0.31	2.52e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg23228694	chr20:35089521	DLGAP4	0.45	6.17	0.35	2.55e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs12048904	0.619	rs10783153	chr1:101328230	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.84	11.38	0.57	1.04e-24	Multiple sclerosis;
CESC	cis	rs7811142	0.943	rs11769886	chr7:99998607	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.05	10.05	0.53	2.46e-20	Platelet count;
CESC	cis	rs9914988	0.943	rs9902953	chr17:27139834	C/A	cg20469991	chr17:27169893	C17orf63	-0.48	-5.25	-0.31	3.18e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CESC	cis	rs10504229	0.871	rs7002070	chr8:58153817	A/G	cg02725872	chr8:58115012	NA	-0.37	-5.8	-0.34	1.92e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs709400	0.663	rs11623869	chr14:103883633	G/T	cg12935359	chr14:103987150	CKB	-0.53	-7.87	-0.44	9e-14	Body mass index;
CESC	cis	rs1775715	0.870	rs1755080	chr10:32255195	G/A	cg04359828	chr10:32216031	ARHGAP12	0.35	5.17	0.3	4.72e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs9910055	0.659	rs2246287	chr17:42232442	C/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.5	7.52	0.42	8.32e-13	Total body bone mineral density;
CESC	cis	rs11190604	1.000	rs10883496	chr10:102221931	T/C	cg07080220	chr10:102295463	HIF1AN	0.55	5.56	0.32	6.43e-8	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs7927771	0.524	rs10838758	chr11:47771476	T/C	cg18512352	chr11:47633146	NA	0.34	5.24	0.31	3.22e-7	Subjective well-being;
CESC	cis	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg08027265	chr7:2291960	NA	-0.34	-5.07	-0.3	7.4e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs9287719	0.967	rs13034061	chr2:10739651	C/T	cg00105475	chr2:10696890	NA	0.39	5.61	0.33	4.96e-8	Prostate cancer;
CESC	cis	rs7772486	0.686	rs4896833	chr6:145965673	T/G	cg23711669	chr6:146136114	FBXO30	0.87	12.7	0.62	3.51e-29	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7412746	0.622	rs11552229	chr1:150783985	T/C	cg04414720	chr1:150670196	GOLPH3L	0.57	7.56	0.42	6.79e-13	Melanoma;
CESC	cis	rs933688	1.000	rs6867219	chr5:90718008	T/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.16	14.28	0.66	1.09e-34	Smoking behavior;
CESC	cis	rs3780486	0.846	rs7850878	chr9:33126570	A/G	cg13443165	chr9:33130375	B4GALT1	0.46	6.61	0.38	2.05e-10	IgG glycosylation;
CESC	cis	rs2115536	1.000	rs7163338	chr15:80198408	C/G	cg11839771	chr15:80205821	ST20	-0.41	-5.79	-0.34	1.98e-8	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CESC	cis	rs4555082	0.957	rs3825762	chr14:105752404	T/C	cg27165867	chr14:105738592	BRF1	-0.47	-5.44	-0.32	1.23e-7	Mean platelet volume;Platelet distribution width;
CESC	cis	rs11577318	0.853	rs4450008	chr1:26643860	C/A	cg00813993	chr1:26644493	UBXN11;CD52	-0.39	-6.32	-0.36	1.1e-9	Granulocyte percentage of myeloid white cells;
CESC	cis	rs6540556	0.954	rs7536882	chr1:209936673	C/G	cg23920097	chr1:209922102	NA	-0.36	-5.35	-0.31	1.93e-7	Red blood cell count;
CESC	cis	rs13130787	0.638	rs1595511	chr4:94938945	A/G	cg11021082	chr4:95130006	SMARCAD1	0.42	6.05	0.35	5.05e-9	Colorectal cancer;
CESC	cis	rs911555	0.755	rs1138400	chr14:103956833	A/G	cg12935359	chr14:103987150	CKB	-0.57	-8.24	-0.45	7.75e-15	Intelligence (multi-trait analysis);
CESC	cis	rs10979	1.000	rs9390110	chr6:143893413	A/G	cg25407410	chr6:143891975	LOC285740	-0.6	-9.02	-0.48	3.8e-17	Hypospadias;
CESC	cis	rs6088580	0.634	rs6058073	chr20:33116483	T/C	cg06115741	chr20:33292138	TP53INP2	0.45	5.75	0.33	2.48e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs1109430	0.661	rs12059828	chr1:210247222	T/C	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.92	6.23	0.36	1.82e-9	Orofacial clefts;
CESC	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg11905131	chr22:24372483	LOC391322	-0.73	-10.65	-0.55	2.71e-22	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs2742417	0.603	rs2742398	chr3:45759036	A/G	cg04837898	chr3:45731254	SACM1L	-0.5	-6.58	-0.37	2.44e-10	Response to anti-depressant treatment in major depressive disorder;
CESC	cis	rs7829975	0.777	rs486781	chr8:8639740	A/G	cg17143192	chr8:8559678	CLDN23	-0.47	-5.79	-0.33	2.03e-8	Mood instability;
CESC	cis	rs5753618	0.509	rs5997913	chr22:31593959	C/A	cg13145458	chr22:31556086	RNF185	0.48	5.45	0.32	1.15e-7	Colorectal cancer;
CESC	cis	rs6502050	0.842	rs8080305	chr17:80074516	A/C	cg11859384	chr17:80120422	CCDC57	0.4	5.5	0.32	8.88e-8	Life satisfaction;
CESC	cis	rs5750830	0.649	rs2413590	chr22:39790191	G/C	cg11247378	chr22:39784982	NA	-0.64	-9.61	-0.51	5.94e-19	Intelligence (multi-trait analysis);
CESC	cis	rs116095464	0.558	rs10462755	chr5:246748	T/C	cg12570787	chr5:219185	SDHA;CCDC127	0.51	5.37	0.31	1.73e-7	Breast cancer;
CESC	trans	rs2488856	0.601	rs2455962	chr14:43555789	A/C	cg14326805	chr9:71737756	TJP2	0.38	6.24	0.36	1.76e-9	Osteoprotegerin levels;
CESC	cis	rs2742234	0.590	rs2505557	chr10:43666016	C/T	cg07801480	chr10:43725741	RASGEF1A	0.46	5.76	0.33	2.3e-8	Hirschsprung disease;
CESC	cis	rs78707713	0.841	rs13377102	chr10:71213386	T/A	cg12610070	chr10:71211762	TSPAN15	-0.34	-5.91	-0.34	1.06e-8	Venous thromboembolism;
CESC	cis	rs6964587	0.869	rs11769294	chr7:91549937	C/T	cg17063962	chr7:91808500	NA	0.54	7.43	0.42	1.46e-12	Breast cancer;
CESC	cis	rs728616	0.558	rs17616964	chr10:82137541	A/G	cg05935833	chr10:81318306	SFTPA2	-0.46	-5.66	-0.33	3.97e-8	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs9916302	0.904	rs57399933	chr17:37551189	A/G	cg00129232	chr17:37814104	STARD3	0.56	7.35	0.41	2.4e-12	Glomerular filtration rate (creatinine);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15717853	chr1:182573596	RGS16	0.57	6.71	0.38	1.15e-10	Gut microbiome composition (summer);
CESC	cis	rs3105593	1.000	rs56080544	chr15:50950970	T/C	cg08437265	chr15:50716283	USP8	0.43	5.5	0.32	8.84e-8	QT interval;
CESC	cis	rs9905704	0.918	rs302867	chr17:56752819	C/T	cg12560992	chr17:57184187	TRIM37	-0.59	-7.0	-0.39	2.11e-11	Testicular germ cell tumor;
CESC	cis	rs6032067	0.777	rs34085254	chr20:43786170	T/G	cg11264863	chr20:43835661	SEMG1	0.49	5.1	0.3	6.53e-7	Blood protein levels;
CESC	cis	rs2832191	0.716	rs8132085	chr21:30501389	G/T	cg24692254	chr21:30365293	RNF160	-0.95	-15.43	-0.69	9.31e-39	Dental caries;
CESC	cis	rs34779708	0.931	rs11010101	chr10:35411045	T/A	cg03585969	chr10:35415529	CREM	0.77	10.38	0.54	2.06e-21	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs1568889	1.000	rs35697240	chr11:28287342	G/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.76	9.77	0.51	1.92e-19	Bipolar disorder;
CESC	cis	rs9834373	0.811	rs9822678	chr3:78496448	C/T	cg06138941	chr3:78371609	NA	-0.41	-5.1	-0.3	6.42e-7	Protein quantitative trait loci;
CESC	cis	rs4835473	0.900	rs34614750	chr4:144693522	G/T	cg25736465	chr4:144833511	NA	-0.33	-5.15	-0.3	5e-7	Immature fraction of reticulocytes;
CESC	cis	rs34779708	0.931	rs4934720	chr10:35376800	T/C	cg04310649	chr10:35416472	CREM	-0.51	-6.06	-0.35	4.62e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs3540	0.597	rs1978149	chr15:91036976	A/G	cg10434728	chr15:90938212	IQGAP1	0.43	7.8	0.43	1.43e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs2243480	0.901	rs2900904	chr7:65204264	C/G	cg12463550	chr7:65579703	CRCP	0.69	5.33	0.31	2.15e-7	Diabetic kidney disease;
CESC	cis	rs1144333	1.000	rs76192904	chr1:76359995	C/T	cg03433033	chr1:76189801	ACADM	0.55	5.46	0.32	1.08e-7	Attention function in attention deficit hyperactive disorder;
CESC	trans	rs62103177	0.810	rs62103187	chr18:77627633	G/C	cg05926928	chr17:57297772	GDPD1	1.18	10.14	0.53	1.27e-20	Opioid sensitivity;
CESC	cis	rs9488822	0.636	rs12524932	chr6:116330266	G/A	cg15226275	chr6:116381976	FRK	0.24	6.15	0.35	2.9e-9	Cholesterol, total;LDL cholesterol;
CESC	cis	rs2072732	0.768	rs57893585	chr1:2944671	T/A	cg15211996	chr1:2936768	ACTRT2	0.35	5.74	0.33	2.65e-8	Plateletcrit;
CESC	cis	rs9303401	0.614	rs2007993	chr17:56590643	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.0	12.26	0.6	1.16e-27	Cognitive test performance;
CESC	cis	rs9902453	1.000	rs9912741	chr17:28359511	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.62	-7.84	-0.43	1.11e-13	Coffee consumption (cups per day);
CESC	cis	rs854765	0.583	rs8073001	chr17:17831716	A/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.57	-8.16	-0.45	1.37e-14	Total body bone mineral density;
CESC	cis	rs9322193	0.962	rs2275046	chr6:150157001	A/G	cg07701084	chr6:150067640	NUP43	0.44	5.89	0.34	1.14e-8	Lung cancer;
CESC	cis	rs6693567	0.545	rs1932934	chr1:150449195	G/A	cg09579323	chr1:150459698	TARS2	0.44	5.81	0.34	1.83e-8	Migraine;
CESC	cis	rs6570726	0.846	rs411468	chr6:145832792	A/G	cg05347473	chr6:146136440	FBXO30	0.49	6.69	0.38	1.3100000000000001e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs734999	0.505	rs4073285	chr1:2539796	C/T	cg20673091	chr1:2541236	MMEL1	0.46	7.58	0.42	5.79e-13	Ulcerative colitis;
CESC	cis	rs4654899	1.000	rs10916937	chr1:21439785	A/G	cg05370193	chr1:21551575	ECE1	0.4	6.05	0.35	5.01e-9	Superior frontal gyrus grey matter volume;
CESC	cis	rs1538970	0.961	rs7553318	chr1:45843086	A/G	cg03146154	chr1:46216737	IPP	0.46	5.5	0.32	8.84e-8	Platelet count;
CESC	cis	rs2576037	0.558	rs7244778	chr18:44541915	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.43	7.08	0.4	1.26e-11	Personality dimensions;
CESC	cis	rs875971	0.660	rs10272357	chr7:66063074	G/A	cg14393609	chr7:65229607	NA	-0.45	-5.98	-0.34	7.2e-9	Aortic root size;
CESC	cis	rs1799949	1.000	rs16941	chr17:41244435	T/C	cg05368731	chr17:41323189	NBR1	0.77	10.72	0.55	1.6e-22	Menopause (age at onset);
CESC	cis	rs11190604	1.000	rs2495760	chr10:102318771	T/C	cg07080220	chr10:102295463	HIF1AN	0.63	5.62	0.33	4.8e-8	Palmitoleic acid (16:1n-7) levels;
CESC	trans	rs2983496	0.901	rs79571844	chr6:166036238	T/C	cg09657256	chr17:42153683	G6PC3	0.6	6.07	0.35	4.45e-9	Cortisol levels (saliva);
CESC	cis	rs6860806	0.507	rs272872	chr5:131675864	C/T	cg24060327	chr5:131705240	SLC22A5	0.74	10.31	0.53	3.65e-21	Breast cancer;
CESC	cis	rs2836974	0.590	rs11911822	chr21:40607843	C/T	cg11890956	chr21:40555474	PSMG1	-0.96	-15.89	-0.7	2.07e-40	Cognitive function;
CESC	cis	rs11190604	1.000	rs11190599	chr10:102295420	C/T	cg07080220	chr10:102295463	HIF1AN	0.7	6.5	0.37	3.99e-10	Palmitoleic acid (16:1n-7) levels;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg17079530	chr11:117014700	PAFAH1B2	-0.48	-6.5	-0.37	3.94e-10	Asthma;
CESC	cis	rs736408	0.511	rs12637632	chr3:52708073	A/T	cg07507251	chr3:52567010	NT5DC2	0.4	6.93	0.39	3.18e-11	Bipolar disorder;
CESC	cis	rs9309473	0.528	rs11126396	chr2:73565143	C/T	cg20560298	chr2:73613845	ALMS1	-0.46	-6.33	-0.36	1.06e-9	Metabolite levels;
CESC	cis	rs9733	0.596	rs56058687	chr1:150635066	C/T	cg09365446	chr1:150670422	GOLPH3L	0.42	5.92	0.34	9.7e-9	Tonsillectomy;
CESC	cis	rs992157	1.000	rs13429408	chr2:219142860	C/A	cg00012203	chr2:219082015	ARPC2	0.81	10.87	0.56	5.2e-23	Colorectal cancer;
CESC	cis	rs9549260	0.755	rs9549244	chr13:41218685	C/T	cg21288729	chr13:41239152	FOXO1	0.7	9.16	0.49	1.5e-17	Red blood cell count;
CESC	cis	rs782590	0.935	rs782652	chr2:55862775	C/A	cg18811423	chr2:55921094	PNPT1	0.78	12.31	0.6	7.6e-28	Metabolic syndrome;
CESC	cis	rs6665290	0.904	rs2297415	chr1:227172903	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.2	-28.86	-0.87	9.05e-84	Myeloid white cell count;
CESC	trans	rs591166	0.967	rs521663	chr18:57822240	A/G	cg05268347	chr19:41218064	ADCK4	-0.39	-6.2	-0.36	2.1e-9	Body mass index;
CESC	cis	rs909674	0.775	rs8138462	chr22:39839670	G/C	cg01416388	chr22:39784598	NA	-0.59	-7.5	-0.42	9.7e-13	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs9329289	0.590	rs11251295	chr10:2563183	C/T	cg05625103	chr10:2543513	NA	0.44	6.2	0.36	2.11e-9	Age-related hearing impairment;
CESC	cis	rs4665809	0.590	rs3806514	chr2:26466772	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.06	12.34	0.6	5.85e-28	Gut microbiome composition (summer);
CESC	cis	rs897984	0.537	rs8045637	chr16:30818662	C/T	cg00531865	chr16:30841666	NA	-0.58	-8.72	-0.47	3.09e-16	Dementia with Lewy bodies;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg27383975	chr19:17356182	NR2F6	-0.42	-6.08	-0.35	4.11e-9	Gambling;
CESC	cis	rs7666738	0.830	rs10470893	chr4:99038756	C/T	cg03467027	chr4:99064603	C4orf37	0.47	5.98	0.34	7.19e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs208520	0.874	rs208515	chr6:66945749	A/G	cg07460842	chr6:66804631	NA	-0.9	-10.84	-0.55	6.76e-23	Exhaled nitric oxide output;
CESC	cis	rs853679	0.517	rs9368557	chr6:28131537	T/C	cg12963246	chr6:28129442	ZNF389	0.56	7.38	0.41	1.99e-12	Depression;
CESC	cis	rs2522056	1.000	rs2522056	chr5:131801726	C/T	cg24060327	chr5:131705240	SLC22A5	0.57	6.65	0.38	1.68e-10	Lymphocyte counts;Fibrinogen;
CESC	cis	rs643506	0.845	rs7114594	chr11:111768113	A/G	cg17089665	chr11:111648010	NA	-0.38	-5.51	-0.32	8.36e-8	Breast cancer;
CESC	cis	rs926938	0.527	rs11084	chr1:115537933	A/G	cg12756093	chr1:115239321	AMPD1	0.46	6.32	0.36	1.1e-9	Autism;
CESC	cis	rs3126085	0.735	rs4845752	chr1:152226576	C/A	cg03465714	chr1:152285911	FLG	-0.45	-5.49	-0.32	9.55e-8	Atopic dermatitis;
CESC	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg21724239	chr8:58056113	NA	0.59	5.45	0.32	1.18e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs10911232	0.542	rs12128323	chr1:183050087	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.86	13.61	0.64	2.34e-32	Hypertriglyceridemia;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg25837350	chr11:61584442	FADS1	-0.46	-6.28	-0.36	1.36e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs9462846	0.919	rs9471966	chr6:42891022	G/A	cg05552183	chr6:42928497	GNMT	0.42	5.06	0.3	7.7e-7	Blood protein levels;
CESC	cis	rs6439153	0.967	rs12695513	chr3:128722312	T/C	cg25356066	chr3:128598488	ACAD9	0.53	6.92	0.39	3.33e-11	Pneumococcal bacteremia;
CESC	cis	rs7824557	0.564	rs2736293	chr8:11234613	T/A	cg21775007	chr8:11205619	TDH	-0.54	-8.08	-0.44	2.28e-14	Retinal vascular caliber;
CESC	cis	rs12477438	0.798	rs7570657	chr2:99654281	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.63	-8.56	-0.47	9.04e-16	Chronic sinus infection;
CESC	cis	rs2243480	0.706	rs34466769	chr7:65453292	A/C	cg18252515	chr7:66147081	NA	-0.66	-6.58	-0.37	2.44e-10	Diabetic kidney disease;
CESC	cis	rs2637266	0.600	rs11001822	chr10:78325833	T/C	cg18941641	chr10:78392320	NA	-0.34	-5.29	-0.31	2.53e-7	Pulmonary function;
CESC	cis	rs684232	0.583	rs2657626	chr17:603052	A/G	cg15660573	chr17:549704	VPS53	-0.66	-9.29	-0.5	6.03e-18	Prostate cancer;
CESC	trans	rs61931739	0.500	rs7310576	chr12:34474735	T/C	cg26384229	chr12:38710491	ALG10B	0.53	7.41	0.41	1.67e-12	Morning vs. evening chronotype;
CESC	cis	rs1862618	0.802	rs194058	chr5:56188977	G/A	cg03609598	chr5:56110824	MAP3K1	-0.51	-5.42	-0.32	1.36e-7	Initial pursuit acceleration;
CESC	trans	rs3102460	0.618	rs3123697	chr1:244580348	C/T	cg01977209	chr2:236293433	NA	0.48	6.15	0.35	2.8e-9	Obesity-related traits;
CESC	cis	rs514406	0.571	rs11206004	chr1:53210958	G/A	cg08859206	chr1:53392774	SCP2	0.63	9.28	0.5	6.3e-18	Monocyte count;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05744073	chr17:1953268	MIR132	0.49	6.4	0.37	6.91e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs2073300	0.609	rs6137917	chr20:23360369	G/A	cg12062639	chr20:23401060	NAPB	1.08	8.67	0.47	4.32e-16	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs11992186	0.505	rs7845203	chr8:8145440	A/G	cg15556689	chr8:8085844	FLJ10661	0.51	6.27	0.36	1.45e-9	Neuroticism;
CESC	cis	rs734999	0.505	rs10797438	chr1:2540262	C/T	cg18854424	chr1:2615690	NA	0.31	6.24	0.36	1.72e-9	Ulcerative colitis;
CESC	trans	rs9467711	0.606	rs9358936	chr6:26370657	A/G	cg06606381	chr12:133084897	FBRSL1	-0.76	-6.86	-0.39	4.71e-11	Autism spectrum disorder or schizophrenia;
CESC	cis	rs2250402	0.510	rs8031319	chr15:40323692	A/G	cg20255370	chr15:40268687	EIF2AK4	-0.6	-5.16	-0.3	4.91e-7	Corneal curvature;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg10415122	chr15:75981489	CSPG4	-0.42	-6.12	-0.35	3.38e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs514406	0.929	rs1672909	chr1:53340824	A/G	cg16325326	chr1:53192061	ZYG11B	0.83	12.86	0.62	9.57e-30	Monocyte count;
CESC	cis	rs4665809	0.589	rs4665841	chr2:26448950	G/A	cg08470875	chr2:26401718	FAM59B	-0.77	-8.44	-0.46	2.16e-15	Gut microbiome composition (summer);
CESC	cis	rs11828289	0.660	rs75816907	chr11:23175126	G/A	cg20040320	chr11:23191996	NA	-0.68	-5.88	-0.34	1.25e-8	Cancer;
CESC	cis	rs7666738	0.830	rs1869082	chr4:98841254	T/A	cg05340658	chr4:99064831	C4orf37	0.71	10.18	0.53	9.12e-21	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1209950	0.512	rs374575	chr21:40193914	C/T	cg02119577	chr21:40195074	ETS2	-0.43	-5.21	-0.3	3.8e-7	Non-small cell lung cancer (survival);
CESC	cis	rs77216612	0.877	rs66561220	chr12:12878765	T/C	cg04607235	chr12:12878440	APOLD1	-1.05	-16.39	-0.71	3.48e-42	Lymphocyte counts;
CESC	cis	rs6461049	0.800	rs3800909	chr7:2159594	C/G	cg23048001	chr7:2026167	MAD1L1	0.45	5.94	0.34	8.72e-9	Schizophrenia;
CESC	cis	rs4665809	0.652	rs10779956	chr2:26405985	A/G	cg04944784	chr2:26401820	FAM59B	-0.94	-10.74	-0.55	1.46e-22	Gut microbiome composition (summer);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04238871	chr10:126431886	FAM53B	0.49	6.79	0.38	7.54e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs6460942	1.000	rs112996286	chr7:12315741	G/C	cg06484146	chr7:12443880	VWDE	-0.81	-8.78	-0.47	2.13e-16	Coronary artery disease;
CESC	cis	rs2637266	0.703	rs846624	chr10:78541381	G/A	cg18941641	chr10:78392320	NA	0.4	7.55	0.42	6.94e-13	Pulmonary function;
CESC	cis	rs17826219	0.568	rs9898097	chr17:29072672	T/G	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.79e-10	Body mass index;
CESC	cis	rs55788414	0.932	rs35326835	chr16:81190413	T/C	cg06400318	chr16:81190750	PKD1L2	-0.65	-6.98	-0.39	2.39e-11	Left ventricular obstructive tract defect (maternal effect);
CESC	cis	rs2997447	0.669	rs61776624	chr1:26474580	A/C	cg24596570	chr1:26146463	FAM54B;LOC646471	0.63	5.44	0.32	1.2e-7	QRS complex (12-leadsum);
CESC	cis	rs7726839	0.507	rs111707179	chr5:593308	T/A	cg16447950	chr5:562315	NA	-0.6	-6.04	-0.35	5.18e-9	Obesity-related traits;
CESC	cis	rs7811142	0.779	rs28680963	chr7:99905475	C/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.69	5.7	0.33	3.17e-8	Platelet count;
CESC	cis	rs17711722	0.523	rs365896	chr7:65510697	A/G	cg07424592	chr7:64974309	NA	0.35	5.15	0.3	5.03e-7	Calcium levels;
CESC	cis	rs7432375	0.610	rs28458819	chr3:136522314	A/G	cg15507776	chr3:136538369	TMEM22	0.61	7.9	0.44	7.59e-14	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
CESC	cis	rs11690935	0.921	rs908670	chr2:172690180	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.95	-14.38	-0.66	4.76e-35	Schizophrenia;
CESC	cis	rs9462846	0.725	rs6927188	chr6:42912589	C/T	cg05552183	chr6:42928497	GNMT	-0.55	-6.23	-0.36	1.78e-9	Blood protein levels;
CESC	cis	rs4654899	1.000	rs6697555	chr1:21287938	C/T	cg05370193	chr1:21551575	ECE1	0.36	5.35	0.31	1.89e-7	Superior frontal gyrus grey matter volume;
CESC	cis	rs6121246	0.567	rs6060261	chr20:30192948	C/G	cg13852791	chr20:30311386	BCL2L1	0.58	5.56	0.32	6.65e-8	Mean corpuscular hemoglobin;
CESC	cis	rs7659604	1.000	rs28532673	chr4:122664323	A/G	cg19748678	chr4:122722346	EXOSC9	-0.43	-5.2	-0.3	4.07e-7	Type 2 diabetes;
CESC	cis	rs997295	0.554	rs7180312	chr15:68105256	G/A	cg08079166	chr15:68083412	MAP2K5	0.4	6.38	0.37	7.7e-10	Motion sickness;
CESC	cis	rs1707322	1.000	rs4660335	chr1:46474718	C/T	cg06784218	chr1:46089804	CCDC17	0.36	6.13	0.35	3.11e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs4660261	0.526	rs2485996	chr1:44354661	C/T	cg12908607	chr1:44402522	ARTN	-0.48	-6.97	-0.39	2.54e-11	Intelligence (multi-trait analysis);
CESC	cis	rs12541335	0.639	rs7834182	chr8:22163112	G/A	cg26039829	chr8:22132926	PIWIL2	0.36	5.49	0.32	9.37e-8	Hypertriglyceridemia;
CESC	cis	rs2576037	0.501	rs557661	chr18:44365657	A/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.34	5.39	0.31	1.54e-7	Personality dimensions;
CESC	cis	rs10089	0.953	rs4835940	chr5:127406596	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.77	10.17	0.53	9.95e-21	Ileal carcinoids;
CESC	cis	rs1348850	0.561	rs1838890	chr2:178410938	C/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.67	6.09	0.35	3.87e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs12476592	0.602	rs7563623	chr2:63720210	A/G	cg17519650	chr2:63277830	OTX1	-0.47	-5.4	-0.31	1.46e-7	Childhood ear infection;
CESC	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.64	7.2	0.4	6.15e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs6754311	0.731	rs309168	chr2:136670298	C/T	cg07169764	chr2:136633963	MCM6	0.68	8.49	0.46	1.51e-15	Mosquito bite size;
CESC	cis	rs6456156	0.586	rs12529876	chr6:167461501	G/A	cg07741184	chr6:167504864	NA	0.35	6.08	0.35	4.1e-9	Primary biliary cholangitis;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg24249734	chr3:127872125	EEFSEC	-0.46	-6.46	-0.37	4.91e-10	Gambling;
CESC	cis	rs1784581	0.532	rs7767219	chr6:162423088	T/C	cg17173639	chr6:162384350	PARK2	0.56	8.63	0.47	5.61e-16	Itch intensity from mosquito bite;
CESC	cis	rs75477785	1.000	rs3753517	chr1:209978098	C/T	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.88	5.74	0.33	2.62e-8	Cleft lip with or without cleft palate;
CESC	cis	rs9581857	0.685	rs9319367	chr13:28042197	T/C	cg01674679	chr13:27998804	GTF3A	-0.69	-5.52	-0.32	8.1e-8	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
CESC	cis	rs514406	0.793	rs4500255	chr1:53213279	A/G	cg27535305	chr1:53392650	SCP2	0.32	5.65	0.33	4.2e-8	Monocyte count;
CESC	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.89	13.34	0.63	2.04e-31	Prudent dietary pattern;
CESC	cis	rs4665809	0.531	rs3892649	chr2:26457267	T/G	cg22920501	chr2:26401640	FAM59B	0.91	10.38	0.54	2.08e-21	Gut microbiome composition (summer);
CESC	cis	rs3820928	0.839	rs4673174	chr2:227801316	A/T	cg11843606	chr2:227700838	RHBDD1	-0.43	-5.79	-0.33	2.02e-8	Pulmonary function;
CESC	cis	rs7615952	0.576	rs6804482	chr3:125815762	C/T	cg15145296	chr3:125709740	NA	-0.56	-5.97	-0.34	7.52e-9	Blood pressure (smoking interaction);
CESC	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	13.6	0.64	2.58e-32	Prudent dietary pattern;
CESC	cis	rs300703	0.810	rs72772835	chr2:134554	C/T	cg21211680	chr2:198530	NA	-0.86	-6.1	-0.35	3.76e-9	Blood protein levels;
CESC	cis	rs258892	0.895	rs155426	chr5:72117128	G/T	cg21869765	chr5:72125136	TNPO1	-0.44	-5.45	-0.32	1.16e-7	Small cell lung carcinoma;
CESC	cis	rs524023	0.874	rs495130	chr11:64449307	C/T	cg19131476	chr11:64387923	NRXN2	-0.33	-5.05	-0.3	8.04e-7	Urate levels in obese individuals;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19892525	chr11:108157498	ATM	-0.67	-7.38	-0.41	2.1e-12	Gut microbiome composition (summer);
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg13981034	chr14:21860709	SNORD9;CHD8	-0.46	-6.22	-0.36	1.9e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7267979	1.000	rs6132835	chr20:25434667	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.87	17.99	0.74	7.78e-48	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs9322193	0.923	rs11155674	chr6:150032247	T/C	cg04369109	chr6:150039330	LATS1	-0.41	-5.81	-0.34	1.82e-8	Lung cancer;
CESC	cis	rs6582630	0.539	rs4882324	chr12:38499180	T/C	cg26384229	chr12:38710491	ALG10B	-0.42	-5.57	-0.32	6.38e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg15147215	chr3:52552868	STAB1	-0.37	-6.79	-0.39	7.28e-11	Electroencephalogram traits;
CESC	cis	rs25645	0.792	rs8077456	chr17:38128765	C/G	cg17467752	chr17:38218738	THRA	-0.4	-5.26	-0.31	3.01e-7	Myeloid white cell count;
CESC	cis	rs66530629	0.917	rs6665083	chr1:25148291	G/T	cg22509179	chr1:25234806	RUNX3	-0.42	-5.38	-0.31	1.63e-7	Plateletcrit;
CESC	cis	rs1559088	0.948	rs6510346	chr19:33598526	T/A	cg17764715	chr19:33622953	WDR88	0.49	6.5	0.37	4.04e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs7666738	0.830	rs13118945	chr4:98968586	T/G	cg17366294	chr4:99064904	C4orf37	0.59	8.43	0.46	2.22e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7267979	1.000	rs2482941	chr20:25361216	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.84	-15.92	-0.7	1.72e-40	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs28830936	0.510	rs11858843	chr15:42092915	C/A	cg11010575	chr15:42129464	JMJD7-PLA2G4B;JMJD7	-0.33	-5.21	-0.3	3.77e-7	Diastolic blood pressure;
CESC	cis	rs7927592	0.956	rs7106259	chr11:68298512	T/G	cg20283391	chr11:68216788	NA	-0.49	-5.88	-0.34	1.22e-8	Total body bone mineral density;
CESC	cis	rs738322	1.000	rs4381	chr22:38570791	T/C	cg25457927	chr22:38595422	NA	-0.3	-5.46	-0.32	1.1e-7	Cutaneous nevi;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10522587	chr1:120166026	ZNF697	-0.58	-6.39	-0.37	7.49e-10	Gut microbiome composition (summer);
CESC	cis	rs938554	0.513	rs1014290	chr4:10001861	G/A	cg11266682	chr4:10021025	SLC2A9	0.44	6.59	0.38	2.4e-10	Blood metabolite levels;
CESC	cis	rs2832191	0.692	rs2254872	chr21:30414724	C/T	cg08807101	chr21:30365312	RNF160	0.96	14.99	0.68	3.24e-37	Dental caries;
CESC	cis	rs1218582	0.772	rs2335408	chr1:154915977	G/A	cg06221963	chr1:154839813	KCNN3	-0.67	-11.27	-0.57	2.54e-24	Prostate cancer;
CESC	cis	rs796364	0.806	rs203767	chr2:200902411	G/A	cg23649088	chr2:200775458	C2orf69	-0.56	-5.08	-0.3	7.29e-7	Schizophrenia;
CESC	cis	rs7811142	1.000	rs7794485	chr7:100068936	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.1	10.34	0.54	2.75e-21	Platelet count;
CESC	cis	rs10465746	0.725	rs4907188	chr1:84361608	C/T	cg10977910	chr1:84465055	TTLL7	0.56	7.78	0.43	1.63e-13	Obesity-related traits;
CESC	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	10.23	0.53	6.6e-21	Prudent dietary pattern;
CESC	cis	rs7084402	0.967	rs1614258	chr10:60308407	C/T	cg07615347	chr10:60278583	BICC1	0.59	9.34	0.5	4.23e-18	Refractive error;
CESC	cis	rs12497850	0.931	rs4974085	chr3:48924900	C/T	cg06641503	chr3:48959341	ARIH2	-0.33	-5.2	-0.3	3.97e-7	Parkinson's disease;
CESC	cis	rs8114671	0.562	rs6088636	chr20:33469746	C/T	cg06115741	chr20:33292138	TP53INP2	0.45	5.48	0.32	9.68e-8	Height;
CESC	cis	rs9359856	0.564	rs3818133	chr6:90374456	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.62	-5.7	-0.33	3.12e-8	Bipolar disorder;
CESC	cis	rs7727544	0.548	rs4705938	chr5:131694077	A/G	cg16647868	chr5:131706066	SLC22A5	0.4	5.3	0.31	2.44e-7	Blood metabolite levels;
CESC	cis	rs12142240	0.667	rs45524035	chr1:46862780	C/T	cg00530320	chr1:46809349	NSUN4	0.6	8.27	0.45	6.54e-15	Menopause (age at onset);
CESC	cis	rs780094	0.606	rs6729709	chr2:27583156	G/A	cg21248554	chr2:27665150	KRTCAP3	-0.26	-5.34	-0.31	1.97e-7	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
CESC	cis	rs2637266	0.745	rs2579732	chr10:78442778	T/C	cg18941641	chr10:78392320	NA	0.43	7.9	0.44	7.62e-14	Pulmonary function;
CESC	cis	rs9915657	0.870	rs4140902	chr17:70133750	A/G	cg06234051	chr17:70120541	SOX9	-0.44	-6.49	-0.37	4.2e-10	Thyroid hormone levels;
CESC	cis	rs7833790	0.660	rs67666182	chr8:82772037	A/G	cg07697082	chr8:82753677	SNX16	-0.37	-5.84	-0.34	1.48e-8	Diastolic blood pressure;
CESC	cis	rs4665809	0.793	rs6546715	chr2:26261520	G/A	cg27170947	chr2:26402098	FAM59B	-0.57	-6.75	-0.38	9.46e-11	Gut microbiome composition (summer);
CESC	cis	rs2439831	0.681	rs2444036	chr15:43694108	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.8	11.56	0.58	2.63e-25	Lung cancer in ever smokers;
CESC	cis	rs7631605	0.905	rs58129217	chr3:37011624	G/A	cg22985146	chr3:37219077	LRRFIP2	-0.33	-5.22	-0.31	3.63e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs765787	0.530	rs28396110	chr15:45536909	A/G	cg24006582	chr15:45444508	DUOX1	-0.59	-7.32	-0.41	3.04e-12	Uric acid levels;
CESC	cis	rs6736093	1.000	rs11673729	chr2:112665961	T/A	cg12686935	chr2:112915763	FBLN7	-0.42	-5.35	-0.31	1.91e-7	Coronary artery disease;
CESC	cis	rs9309711	0.544	rs9309712	chr2:3491327	G/T	cg10845886	chr2:3471009	TTC15	-0.58	-8.01	-0.44	3.57e-14	Neurofibrillary tangles;
CESC	cis	rs3820068	0.581	rs67806552	chr1:15927138	T/C	cg17385448	chr1:15911702	AGMAT	0.44	7.16	0.4	7.97e-12	Systolic blood pressure;
CESC	cis	rs7605827	0.897	rs13022830	chr2:15696542	T/C	cg19274914	chr2:15703543	NA	0.3	5.34	0.31	2.03e-7	Educational attainment (years of education);
CESC	cis	rs34779708	0.897	rs9665538	chr10:35461038	T/C	cg03585969	chr10:35415529	CREM	0.75	10.2	0.53	8e-21	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs7116495	0.609	rs10736783	chr11:71654143	G/A	cg26138937	chr11:71823887	C11orf51	-1.23	-8.41	-0.46	2.56e-15	Severe influenza A (H1N1) infection;
CESC	cis	rs6088580	0.668	rs1205337	chr20:32926041	T/A	cg24642439	chr20:33292090	TP53INP2	-0.52	-6.74	-0.38	9.67e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs763121	0.853	rs3788544	chr22:39064966	C/T	cg14440974	chr22:39074834	NA	-0.42	-5.7	-0.33	3.21e-8	Menopause (age at onset);
CESC	cis	rs2243480	1.000	rs60683927	chr7:65394768	T/C	cg12463550	chr7:65579703	CRCP	0.7	5.7	0.33	3.21e-8	Diabetic kidney disease;
CESC	cis	rs76878669	0.561	rs905770	chr11:66156765	A/G	cg18002602	chr11:66138449	SLC29A2	0.42	7.05	0.4	1.51e-11	Educational attainment (years of education);
CESC	cis	rs6088590	0.648	rs6058105	chr20:33271719	C/T	cg08999081	chr20:33150536	PIGU	0.66	10.77	0.55	1.17e-22	Coronary artery disease;
CESC	cis	rs801193	1.000	rs2659906	chr7:66165310	T/C	cg18876405	chr7:65276391	NA	0.54	7.28	0.41	3.88e-12	Aortic root size;
CESC	cis	rs5167	0.586	rs4803774	chr19:45450872	A/G	cg13119609	chr19:45449297	APOC2	0.51	8.12	0.45	1.76e-14	Blood protein levels;
CESC	cis	rs9733	0.596	rs7549795	chr1:150656873	G/A	cg18016565	chr1:150552671	MCL1	0.33	5.14	0.3	5.34e-7	Tonsillectomy;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg15727783	chr10:105727545	SLK	-0.39	-6.11	-0.35	3.61e-9	Gambling;
CESC	cis	rs875971	0.651	rs313829	chr7:65552497	A/G	cg11764359	chr7:65958608	NA	-0.88	-11.65	-0.58	1.33e-25	Aortic root size;
CESC	cis	rs826838	0.967	rs10875979	chr12:39095149	G/A	cg26384229	chr12:38710491	ALG10B	0.67	11.07	0.56	1.19e-23	Heart rate;
CESC	cis	rs2832191	0.740	rs2832175	chr21:30475606	A/G	cg24692254	chr21:30365293	RNF160	-0.98	-17.11	-0.72	9.72e-45	Dental caries;
CESC	cis	rs73206853	0.563	rs80044246	chr12:111133535	C/A	cg12870014	chr12:110450643	ANKRD13A	0.72	6.19	0.36	2.27e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs10751667	0.643	rs7396046	chr11:937176	T/C	cg20946044	chr11:1010712	AP2A2	-0.39	-5.44	-0.32	1.23e-7	Alzheimer's disease (late onset);
CESC	cis	rs4563143	0.704	rs16961809	chr19:29226299	C/T	cg12667521	chr19:29218732	NA	0.4	5.65	0.33	4.03e-8	Methadone dose in opioid dependence;
CESC	cis	rs9488822	0.676	rs13194714	chr6:116394819	T/A	cg05304507	chr6:116381966	FRK	0.26	6.72	0.38	1.13e-10	Cholesterol, total;LDL cholesterol;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg22768615	chr10:131567747	NA	-0.48	-6.28	-0.36	1.39e-9	Systemic lupus erythematosus;
CESC	trans	rs6073597	1.000	rs6031980	chr20:43714384	C/T	cg00549575	chr11:8008752	EIF3F	0.45	6.16	0.35	2.75e-9	Positive affect;
CESC	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg02071572	chr4:1403502	NA	0.38	5.53	0.32	7.8e-8	Longevity;
CESC	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.56	-6.37	-0.36	8.15e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs9435341	0.965	rs55909997	chr1:107581039	G/A	cg09367891	chr1:107599246	PRMT6	0.7	8.3	0.45	5.32e-15	Facial morphology (factor 21, depth of nasal alae);
CESC	cis	rs9611565	0.659	rs9611609	chr22:41945357	C/A	cg17376030	chr22:41985996	PMM1	0.67	7.28	0.41	3.74e-12	Vitiligo;
CESC	cis	rs854765	0.693	rs11657074	chr17:17770355	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.49	-6.88	-0.39	4.22e-11	Total body bone mineral density;
CESC	trans	rs916888	0.821	rs199525	chr17:44847834	T/G	cg04282206	chr17:62833786	PLEKHM1P	0.54	6.22	0.36	1.95e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs11677416	1.000	rs11677416	chr2:113529240	A/G	cg27083787	chr2:113543245	IL1A	0.54	6.88	0.39	4.33e-11	Response to antipsychotic treatment in schizophrenia (working memory);
CESC	cis	rs12291225	0.679	rs11238	chr11:14288128	A/C	cg19336497	chr11:14380999	RRAS2	0.38	5.54	0.32	7.2e-8	Sense of smell;
CESC	trans	rs61931739	0.534	rs2220547	chr12:34106255	G/A	cg26384229	chr12:38710491	ALG10B	0.59	8.21	0.45	9.8e-15	Morning vs. evening chronotype;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27514703	chr19:50380514	AKT1S1;TBC1D17	0.62	6.75	0.38	9.36e-11	Gut microbiome composition (summer);
CESC	cis	rs4665809	0.590	rs11552518	chr2:26455127	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.1	12.71	0.62	3.31e-29	Gut microbiome composition (summer);
CESC	cis	rs11077998	0.967	rs4789786	chr17:80504352	A/G	cg10255544	chr17:80519551	FOXK2	-0.51	-8.21	-0.45	9.89e-15	Reticulocyte fraction of red cells;
CESC	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg03188948	chr7:1209495	NA	0.53	6.2	0.36	2.19e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs4835473	0.831	rs1579816	chr4:144787925	C/T	cg25736465	chr4:144833511	NA	0.44	6.58	0.37	2.48e-10	Immature fraction of reticulocytes;
CESC	cis	rs28489187	0.683	rs11161611	chr1:85868679	C/A	cg16011679	chr1:85725395	C1orf52	-0.48	-5.7	-0.33	3.19e-8	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12205742	chr18:68097929	NA	-0.56	-6.45	-0.37	5.17e-10	Gut microbiome composition (summer);
CESC	cis	rs1950626	0.623	rs34603287	chr14:101433831	G/A	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.69	9.23	0.49	8.76e-18	Pelvic organ prolapse (moderate/severe);
CESC	cis	rs4253772	0.530	rs11090865	chr22:46731689	G/T	cg09491104	chr22:46646882	C22orf40	-0.53	-5.89	-0.34	1.18e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs9640161	0.742	rs2108854	chr7:150017408	C/T	cg21361702	chr7:150065534	REPIN1	-0.55	-6.51	-0.37	3.69e-10	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs7267979	0.932	rs6138588	chr20:25487523	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.76	13.57	0.64	3.43e-32	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs10504229	0.512	rs117968470	chr8:58014651	C/G	cg24829409	chr8:58192753	C8orf71	-0.67	-7.32	-0.41	3e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs7811142	0.779	rs111312383	chr7:99905325	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.03	9.59	0.51	6.65e-19	Platelet count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14385985	chr10:70587144	STOX1	0.59	6.77	0.38	8.03e-11	Gut microbiome composition (summer);
CESC	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg04234412	chr22:24373322	LOC391322	-0.52	-7.31	-0.41	3.09e-12	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs6460942	0.597	rs7811374	chr7:12517437	T/C	cg10578991	chr7:12443926	VWDE	-0.48	-5.06	-0.3	7.85e-7	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01496715	chr11:252450	PSMD13	-0.59	-6.65	-0.38	1.69e-10	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00402069	chr5:89770788	POLR3G;MBLAC2	0.52	6.23	0.36	1.8e-9	Gut microbiome composition (summer);
CESC	cis	rs6831352	0.840	rs29001223	chr4:100047433	C/T	cg12011299	chr4:100065546	ADH4	-0.59	-6.52	-0.37	3.62e-10	Alcohol dependence;
CESC	cis	rs733592	0.723	rs10875766	chr12:48593580	G/C	cg04545296	chr12:48745243	ZNF641	0.29	5.05	0.3	8.3e-7	Plateletcrit;
CESC	cis	rs12586317	0.547	rs28395170	chr14:35506988	C/T	cg16230307	chr14:35515116	FAM177A1	1.08	11.39	0.57	9.94e-25	Psoriasis;
CESC	cis	rs34172651	0.917	rs2059134	chr16:24816492	C/T	cg00152838	chr16:24741724	TNRC6A	0.47	5.05	0.3	8.12e-7	Intelligence (multi-trait analysis);
CESC	cis	rs919433	1.000	rs1560277	chr2:198187903	C/T	cg03934865	chr2:198174659	NA	0.41	5.94	0.34	8.76e-9	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09809474	chr1:1840100	NA	0.51	6.08	0.35	4.1e-9	Gut microbiome composition (summer);
CESC	cis	rs6439153	0.933	rs810952	chr3:128685905	A/G	cg25356066	chr3:128598488	ACAD9	0.52	6.7	0.38	1.25e-10	Pneumococcal bacteremia;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg13857382	chr1:175162153	KIAA0040	-0.42	-6.06	-0.35	4.62e-9	Gambling;
CESC	cis	rs62005083	1.000	rs62005158	chr14:74613284	A/G	cg05179529	chr14:74551516	LIN52;ALDH6A1	0.74	5.42	0.32	1.34e-7	Mean corpuscular volume;
CESC	cis	rs4862750	0.914	rs11943333	chr4:187872455	A/G	cg27532560	chr4:187881888	NA	-0.32	-5.03	-0.3	9.08e-7	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9457247	1.000	rs389946	chr6:167407268	T/C	cg23791538	chr6:167370224	RNASET2	-0.59	-8.54	-0.46	1.09e-15	Crohn's disease;
CESC	cis	rs2540647	0.614	rs34595355	chr22:18952113	G/A	cg12798833	chr22:18958832	DGCR5	0.82	7.43	0.42	1.47e-12	Blood metabolite ratios;
CESC	cis	rs7224737	0.957	rs6503687	chr17:40295397	G/A	cg20291162	chr17:40259547	DHX58	-0.4	-5.48	-0.32	9.96e-8	Fibrinogen levels;
CESC	cis	rs524023	0.957	rs893006	chr11:64365796	C/A	cg19131476	chr11:64387923	NRXN2	-0.34	-5.18	-0.3	4.38e-7	Urate levels in obese individuals;
CESC	cis	rs4819052	0.851	rs2838831	chr21:46664775	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.9	13.19	0.63	7.09e-31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs7666738	0.830	rs11097598	chr4:98946057	T/C	cg03467027	chr4:99064603	C4orf37	0.47	5.87	0.34	1.28e-8	Colonoscopy-negative controls vs population controls;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg23429981	chr6:97345948	NDUFAF4	-0.46	-6.45	-0.37	5.28e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs1862618	0.853	rs6450408	chr5:56098146	T/C	cg24549020	chr5:56110836	MAP3K1	0.65	7.36	0.41	2.38e-12	Initial pursuit acceleration;
CESC	trans	rs966321	0.773	rs4654426	chr1:4331783	C/T	cg01726854	chr17:56429881	SUPT4H1	-0.45	-6.18	-0.35	2.39e-9	Factor VII;
CESC	cis	rs2033711	0.902	rs4801589	chr19:58953398	C/G	cg11952622	chr19:58962976	ZNF324B	0.47	6.47	0.37	4.74e-10	Uric acid clearance;
CESC	cis	rs2014572	0.967	rs10413671	chr19:57763489	G/A	cg12963866	chr19:57752005	ZNF805	-0.48	-6.47	-0.37	4.61e-10	Hyperactive-impulsive symptoms;
CESC	cis	rs2404602	0.716	rs17363713	chr15:76746128	G/C	cg22467129	chr15:76604101	ETFA	-0.38	-5.73	-0.33	2.75e-8	Blood metabolite levels;
CESC	cis	rs736408	0.609	rs13095332	chr3:52787242	C/T	cg07507251	chr3:52567010	NT5DC2	0.43	7.45	0.42	1.34e-12	Bipolar disorder;
CESC	cis	rs7412746	0.611	rs7532045	chr1:150821847	G/A	cg04414720	chr1:150670196	GOLPH3L	0.49	6.6	0.38	2.27e-10	Melanoma;
CESC	cis	rs11098499	0.780	rs7680914	chr4:120563053	A/G	cg09307838	chr4:120376055	NA	0.86	11.62	0.58	1.75e-25	Corneal astigmatism;
CESC	cis	rs36051895	0.659	rs61284219	chr9:5062816	C/A	cg02405213	chr9:5042618	JAK2	-0.48	-5.99	-0.35	6.93e-9	Pediatric autoimmune diseases;
CESC	cis	rs1448094	0.512	rs6539932	chr12:86247497	T/C	cg19622623	chr12:86230825	RASSF9	-0.47	-5.94	-0.34	8.76e-9	Major depressive disorder;
CESC	cis	rs6921919	0.583	rs9468355	chr6:28341877	A/G	cg02339392	chr6:28234615	ZNF187	-0.36	-5.26	-0.31	3.02e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs9322193	0.923	rs9322204	chr6:149957183	A/C	cg13206674	chr6:150067644	NUP43	0.41	5.77	0.33	2.2e-8	Lung cancer;
CESC	cis	rs1559088	0.847	rs10416218	chr19:33599127	T/C	cg27124370	chr19:33622961	WDR88	0.45	6.0	0.35	6.63e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs72945132	0.882	rs7941933	chr11:70123351	G/A	cg00319359	chr11:70116639	PPFIA1	0.81	7.73	0.43	2.24e-13	Coronary artery disease;
CESC	cis	rs9311474	0.629	rs13081028	chr3:52555316	G/A	cg18099408	chr3:52552593	STAB1	-0.45	-8.34	-0.46	4.12e-15	Electroencephalogram traits;
CESC	cis	rs425277	0.583	rs10910046	chr1:2041155	C/T	cg16545954	chr1:2118288	C1orf86	-0.32	-6.06	-0.35	4.57e-9	Height;
CESC	cis	rs7267979	0.966	rs6050611	chr20:25414419	A/G	cg08601574	chr20:25228251	PYGB	0.36	5.38	0.31	1.64e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7085104	0.700	rs7096183	chr10:104609466	T/C	cg15744005	chr10:104629667	AS3MT	-0.37	-5.8	-0.34	1.84e-8	Immature fraction of reticulocytes;Schizophrenia;
CESC	cis	rs79349575	0.783	rs1994970	chr17:47014127	C/T	cg16584676	chr17:46985605	UBE2Z	-0.55	-6.96	-0.39	2.63e-11	Type 2 diabetes;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg26695780	chr7:66021476	LOC493754	0.51	6.75	0.38	9.06e-11	Fibrinogen levels;
CESC	cis	rs1580019	0.563	rs34319173	chr7:32585904	G/A	cg07520158	chr7:32535189	LSM5;AVL9	0.52	6.42	0.37	6.41e-10	Cognitive ability;
CESC	cis	rs5753037	0.615	rs131279	chr22:30155251	G/C	cg01021169	chr22:30184971	ASCC2	-0.44	-6.23	-0.36	1.83e-9	Type 1 diabetes;
CESC	cis	rs28386778	0.704	rs1051688	chr17:62006433	G/C	cg26338869	chr17:61819248	STRADA	-0.62	-7.85	-0.43	1.04e-13	Prudent dietary pattern;
CESC	cis	rs12497850	0.864	rs4521268	chr3:49137904	G/T	cg06212747	chr3:49208901	KLHDC8B	0.73	9.64	0.51	4.67e-19	Parkinson's disease;
CESC	cis	rs818427	0.964	rs459102	chr5:112228765	C/A	cg07820702	chr5:112228657	REEP5	-0.47	-6.13	-0.35	3.17e-9	Total body bone mineral density;
CESC	cis	rs7582720	1.000	rs72926771	chr2:203801226	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.38	0.41	1.99e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs514406	0.893	rs1242315	chr1:53417181	A/G	cg06600287	chr1:53387719	ECHDC2	-0.29	-5.03	-0.3	8.93e-7	Monocyte count;
CESC	cis	rs11098499	1.000	rs11098500	chr4:120219239	T/A	cg09307838	chr4:120376055	NA	0.88	11.84	0.59	2.97e-26	Corneal astigmatism;
CESC	cis	rs4819052	0.851	rs28622522	chr21:46676599	G/T	cg11663144	chr21:46675770	NA	-0.63	-9.84	-0.52	1.12e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg17372223	chr3:52568218	NT5DC2	0.54	8.99	0.48	4.87e-17	Electroencephalogram traits;
CESC	cis	rs11673344	0.528	rs476194	chr19:37410733	T/C	cg27390819	chr19:37464633	NA	-0.34	-5.12	-0.3	5.88e-7	Obesity-related traits;
CESC	cis	rs11252926	0.550	rs10795122	chr10:466830	C/T	cg16386425	chr10:429943	DIP2C	-0.5	-6.28	-0.36	1.41e-9	Psychosis in Alzheimer's disease;
CESC	cis	rs1355223	0.902	rs12800220	chr11:34701617	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.48	-6.45	-0.37	5.28e-10	Systemic lupus erythematosus and Systemic sclerosis;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg25067120	chr7:126893287	GRM8	0.39	6.0	0.35	6.58e-9	Gambling;
CESC	cis	rs2439831	0.850	rs11856795	chr15:44160582	G/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.63	5.6	0.33	5.26e-8	Lung cancer in ever smokers;
CESC	cis	rs7824557	0.628	rs7820301	chr8:11228672	G/A	cg21775007	chr8:11205619	TDH	0.55	8.48	0.46	1.57e-15	Retinal vascular caliber;
CESC	cis	rs7481584	1.000	rs2239898	chr11:3024462	G/A	cg25174290	chr11:3078921	CARS	-0.43	-5.43	-0.32	1.27e-7	Calcium levels;
CESC	cis	rs6866344	0.570	rs1132336	chr5:178140090	C/T	cg10224037	chr5:178157518	ZNF354A	0.74	8.75	0.47	2.53e-16	Neutrophil percentage of white cells;
CESC	cis	rs9905704	0.918	rs385793	chr17:56730593	G/A	cg12560992	chr17:57184187	TRIM37	0.59	7.02	0.4	1.86e-11	Testicular germ cell tumor;
CESC	cis	rs1552244	0.938	rs7652951	chr3:10063763	A/C	cg08888203	chr3:10149979	C3orf24	0.5	6.33	0.36	1.05e-9	Alzheimer's disease;
CESC	cis	rs832540	0.519	rs6450411	chr5:56265771	A/G	cg14703610	chr5:56206110	C5orf35	0.5	6.57	0.37	2.71e-10	Coronary artery disease;
CESC	cis	rs6540559	0.673	rs1073150	chr1:210017083	G/A	cg25204440	chr1:209979598	IRF6	0.53	5.27	0.31	2.8e-7	Cleft lip with or without cleft palate;
CESC	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.51	-5.7	-0.33	3.21e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19304507	chr22:30278992	MTMR3	0.53	6.29	0.36	1.33e-9	Gut microbiome composition (summer);
CESC	cis	rs12995491	1.000	rs12995491	chr2:88527414	C/T	cg07952391	chr2:88470173	THNSL2	0.53	8.03	0.44	3.22e-14	Response to metformin (IC50);
CESC	cis	rs9796	0.689	rs6492983	chr15:41436049	T/G	cg12426344	chr15:41135900	SPINT1	-0.24	-5.19	-0.3	4.12e-7	Menopause (age at onset);
CESC	cis	rs12681288	0.523	rs6983944	chr8:955147	A/G	cg04851639	chr8:1020857	NA	-0.31	-6.26	-0.36	1.55e-9	Schizophrenia;
CESC	cis	rs4466137	0.645	rs6894022	chr5:82982945	T/C	cg16102102	chr5:83017553	HAPLN1	-0.39	-6.01	-0.35	6.1e-9	Prostate cancer;
CESC	cis	rs728616	0.681	rs56184245	chr10:82018556	C/T	cg05935833	chr10:81318306	SFTPA2	-0.44	-5.74	-0.33	2.55e-8	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs2456568	0.803	rs10831140	chr11:93640689	G/A	cg26875233	chr11:93583750	C11orf90	-0.3	-5.19	-0.3	4.16e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
CESC	cis	rs8141529	0.871	rs5762877	chr22:29277555	G/A	cg15103426	chr22:29168792	CCDC117	0.61	8.02	0.44	3.45e-14	Lymphocyte counts;
CESC	cis	rs9828933	0.808	rs3733125	chr3:63981635	C/T	cg16258503	chr3:63850278	ATXN7;THOC7	-0.89	-6.07	-0.35	4.49e-9	Type 2 diabetes;
CESC	cis	rs9649213	0.537	rs35997266	chr7:97965566	T/C	cg08684580	chr7:98029266	BAIAP2L1	-0.35	-5.7	-0.33	3.24e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7618915	0.501	rs3774366	chr3:52641255	T/C	cg18404041	chr3:52824283	ITIH1	-0.38	-6.48	-0.37	4.35e-10	Bipolar disorder;
CESC	cis	rs76917914	0.820	rs7846880	chr9:100822940	G/A	cg03040243	chr9:100819229	NANS	0.51	5.84	0.34	1.5e-8	Immature fraction of reticulocytes;
CESC	cis	rs798554	0.757	rs1182198	chr7:2862906	C/T	cg04166393	chr7:2884313	GNA12	0.66	8.32	0.46	4.71e-15	Height;
CESC	cis	rs6582630	0.519	rs11182457	chr12:38538331	G/A	cg13010199	chr12:38710504	ALG10B	0.53	6.86	0.39	4.74e-11	Drug-induced liver injury (flucloxacillin);
CESC	trans	rs4843747	0.519	rs12599755	chr16:88107006	A/G	cg26811252	chr16:29126840	RRN3P2	0.7	9.83	0.52	1.19e-19	Menopause (age at onset);
CESC	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg07308232	chr7:1071921	C7orf50	-0.42	-5.96	-0.34	8.05e-9	Longevity;Endometriosis;
CESC	cis	rs832540	0.669	rs173764	chr5:56198920	C/T	cg22800045	chr5:56110881	MAP3K1	0.53	6.88	0.39	4.39e-11	Coronary artery disease;
CESC	cis	rs62244186	0.520	rs9311361	chr3:44796132	T/G	cg15225532	chr3:44803084	KIF15;KIAA1143	0.48	6.21	0.36	2e-9	Depressive symptoms;
CESC	trans	rs17764205	0.929	rs8101042	chr19:3254124	C/G	cg19548313	chr19:1065712	HMHA1	-0.5	-6.15	-0.35	2.82e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs11997175	0.609	rs4733459	chr8:33663793	T/C	ch.8.33884649F	chr8:33765107	NA	0.46	5.9	0.34	1.12e-8	Body mass index;
CESC	cis	rs2832191	0.967	rs1999321	chr21:30530233	A/C	cg08807101	chr21:30365312	RNF160	0.65	8.66	0.47	4.64e-16	Dental caries;
CESC	cis	rs9527	0.590	rs3781281	chr10:104852648	A/G	cg04362960	chr10:104952993	NT5C2	-0.48	-6.07	-0.35	4.42e-9	Arsenic metabolism;
CESC	cis	rs1355223	0.525	rs10836316	chr11:34874295	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.55	-6.59	-0.38	2.37e-10	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs367943	0.666	rs7703503	chr5:112962334	A/C	cg12552261	chr5:112820674	MCC	0.44	5.66	0.33	3.85e-8	Type 2 diabetes;
CESC	cis	rs7618915	0.547	rs7642198	chr3:52677960	T/C	cg18099408	chr3:52552593	STAB1	-0.3	-5.04	-0.3	8.71e-7	Bipolar disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03641858	chr19:12777774	MORG1;MAN2B1	0.58	6.68	0.38	1.44e-10	Gut microbiome composition (summer);
CESC	cis	rs9815354	1.000	rs6791806	chr3:41889995	C/T	cg03022575	chr3:42003672	ULK4	0.45	5.23	0.31	3.48e-7	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs6088590	1.000	rs6119512	chr20:33306904	T/C	cg06115741	chr20:33292138	TP53INP2	0.6	7.34	0.41	2.7e-12	Coronary artery disease;
CESC	cis	rs9811920	0.715	rs6810262	chr3:99906342	C/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.37	5.68	0.33	3.47e-8	Axial length;
CESC	cis	rs7520050	0.966	rs11589562	chr1:46466721	C/T	cg24296786	chr1:45957014	TESK2	-0.46	-5.96	-0.34	7.89e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs17711722	1.000	rs17711722	chr7:65271197	C/T	cg26939375	chr7:64535504	NA	-0.76	-10.82	-0.55	7.64e-23	Calcium levels;
CESC	cis	rs11112613	0.713	rs11112589	chr12:105951226	C/G	cg03607813	chr12:105948248	NA	-0.6	-7.49	-0.42	1.02e-12	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CESC	cis	rs5769765	0.908	rs9627788	chr22:50300438	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.46	-5.33	-0.31	2.15e-7	Schizophrenia;
CESC	cis	rs6987853	0.749	rs2974367	chr8:42431194	G/C	cg09913449	chr8:42400586	C8orf40	0.44	7.44	0.42	1.43e-12	Mean corpuscular hemoglobin concentration;
CESC	cis	rs8062405	0.895	rs56186137	chr16:28825953	A/G	cg08761264	chr16:28874980	SH2B1	-0.45	-5.7	-0.33	3.19e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs875971	0.862	rs7786892	chr7:65628876	G/A	cg10691866	chr7:65817282	TPST1	0.31	5.24	0.31	3.28e-7	Aortic root size;
CESC	cis	rs950169	1.000	rs79318564	chr15:84786150	G/A	cg17507749	chr15:85114479	UBE2QP1	0.61	6.66	0.38	1.56e-10	Schizophrenia;
CESC	cis	rs4604732	0.536	rs4433437	chr1:247636580	A/T	cg12754571	chr1:247694271	LOC148824;OR2C3	0.42	5.38	0.31	1.64e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs11696501	0.688	rs6130894	chr20:44322673	G/A	cg11783356	chr20:44313418	WFDC10B	-0.31	-5.08	-0.3	7.02e-7	Brain structure;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg12996903	chr3:50275575	GNAI2	-0.47	-6.0	-0.35	6.62e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs4523957	0.890	rs216217	chr17:2145090	G/A	cg16513277	chr17:2031491	SMG6	0.6	8.16	0.45	1.34e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs9300255	0.602	rs1626899	chr12:123708063	A/G	cg00376283	chr12:123451042	ABCB9	0.7	8.89	0.48	9.66e-17	Neutrophil percentage of white cells;
CESC	cis	rs7084402	0.967	rs1658486	chr10:60288081	A/T	cg07615347	chr10:60278583	BICC1	0.6	9.41	0.5	2.54e-18	Refractive error;
CESC	cis	rs7618915	0.547	rs10865973	chr3:52718154	A/T	cg17372223	chr3:52568218	NT5DC2	0.44	6.62	0.38	2.04e-10	Bipolar disorder;
CESC	cis	rs727505	1.000	rs988699	chr7:124409814	C/T	cg23710748	chr7:124431027	NA	-0.47	-7.44	-0.42	1.43e-12	Lewy body disease;
CESC	cis	rs9611565	0.649	rs139559	chr22:42191636	A/G	cg06481639	chr22:41940642	POLR3H	-0.48	-5.49	-0.32	9.59e-8	Vitiligo;
CESC	cis	rs7208859	0.623	rs9906957	chr17:29157755	C/T	cg19761014	chr17:28927070	LRRC37B2	0.74	6.11	0.35	3.61e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg24829409	chr8:58192753	C8orf71	-0.66	-7.93	-0.44	6.14e-14	Developmental language disorder (linguistic errors);
CESC	cis	rs12142240	0.698	rs6703669	chr1:46862555	C/T	cg00530320	chr1:46809349	NSUN4	0.6	8.27	0.45	6.54e-15	Menopause (age at onset);
CESC	cis	rs9911578	0.967	rs8072712	chr17:57162464	A/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.09	0.3	6.85e-7	Intelligence (multi-trait analysis);
CESC	cis	rs3126085	0.734	rs3120653	chr1:152284854	A/G	cg03465714	chr1:152285911	FLG	0.42	5.21	0.3	3.83e-7	Atopic dermatitis;
CESC	cis	rs6982240	0.569	rs6992278	chr8:142279383	C/G	cg27411547	chr8:142287226	NA	-0.53	-7.82	-0.43	1.26e-13	Tonsillectomy;
CESC	cis	rs8077889	0.956	rs116979403	chr17:41849105	G/A	cg26893861	chr17:41843967	DUSP3	0.85	9.78	0.51	1.75e-19	Triglycerides;
CESC	cis	rs9287719	0.935	rs7600495	chr2:10739800	A/G	cg00105475	chr2:10696890	NA	0.39	5.61	0.33	4.96e-8	Prostate cancer;
CESC	cis	rs34891900	0.507	rs5992088	chr22:18135912	C/T	cg19898043	chr22:18121309	BCL2L13	-0.53	-6.32	-0.36	1.13e-9	Sum neutrophil eosinophil counts;
CESC	cis	rs8028182	0.636	rs4886699	chr15:75692303	A/C	cg20655648	chr15:75932815	IMP3	0.47	6.01	0.35	5.98e-9	Sudden cardiac arrest;
CESC	cis	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg23048001	chr7:2026167	MAD1L1	-0.4	-5.44	-0.32	1.21e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg23708337	chr7:1209742	NA	0.56	5.79	0.34	1.95e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7481584	0.624	rs421196	chr11:3048582	T/G	cg08508325	chr11:3079039	CARS	0.29	5.08	0.3	7.06e-7	Calcium levels;
CESC	cis	rs2742234	0.541	rs10793424	chr10:43717116	G/T	cg15436174	chr10:43711423	RASGEF1A	0.47	5.58	0.32	5.81e-8	Hirschsprung disease;
CESC	cis	rs7312774	0.618	rs7953088	chr12:107334539	G/C	cg16260113	chr12:107380972	MTERFD3	0.79	7.12	0.4	9.88e-12	Severe influenza A (H1N1) infection;
CESC	cis	rs959260	1.000	rs2891713	chr17:73386622	G/C	cg12999837	chr17:73267436	MIF4GD	-0.47	-5.48	-0.32	9.82e-8	Systemic lupus erythematosus;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25161114	chr18:61089948	VPS4B	0.58	6.37	0.36	8.32e-10	Gut microbiome composition (summer);
CESC	cis	rs10465746	0.780	rs2389649	chr1:84379449	C/T	cg10977910	chr1:84465055	TTLL7	0.51	6.95	0.39	2.82e-11	Obesity-related traits;
CESC	cis	rs897984	0.542	rs8061047	chr16:31068960	T/C	cg02466173	chr16:30829666	NA	-0.42	-7.33	-0.41	2.8e-12	Dementia with Lewy bodies;
CESC	cis	rs10504073	0.584	rs56134839	chr8:49918899	C/T	cg00325661	chr8:49890786	NA	0.55	8.31	0.45	5.1e-15	Blood metabolite ratios;
CESC	cis	rs4665809	1.000	rs750450	chr2:26324631	A/G	cg25036284	chr2:26402008	FAM59B	-0.6	-6.98	-0.39	2.36e-11	Gut microbiome composition (summer);
CESC	cis	rs6430585	0.528	rs75753154	chr2:136665711	T/C	cg07169764	chr2:136633963	MCM6	1.28	19.05	0.76	1.45e-51	Corneal structure;
CESC	cis	rs17376456	0.825	rs13155452	chr5:93164449	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.59	-5.2	-0.3	3.95e-7	Diabetic retinopathy;
CESC	cis	rs2663905	0.611	rs2663924	chr15:81392903	T/G	cg07050504	chr15:81391682	NA	-0.4	-5.32	-0.31	2.16e-7	QT interval (drug interaction);
CESC	cis	rs9858542	0.953	rs1987628	chr3:49399259	G/A	cg07274523	chr3:49395745	GPX1	0.66	8.22	0.45	8.84e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs72627123	0.737	rs61475846	chr14:74485781	T/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.73	5.65	0.33	4.06e-8	Morning vs. evening chronotype;
CESC	cis	rs780096	0.506	rs2303369	chr2:27715416	C/T	cg02592271	chr2:27665507	KRTCAP3	-0.27	-5.32	-0.31	2.21e-7	Total body bone mineral density;
CESC	cis	rs3741404	0.574	rs638227	chr11:63871549	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.71	9.9	0.52	7.1e-20	Platelet count;
CESC	cis	rs7662987	0.517	rs1154406	chr4:100008494	T/C	cg12011299	chr4:100065546	ADH4	0.59	6.45	0.37	5.25e-10	Smoking initiation;
CESC	cis	rs10766533	1.000	rs10766533	chr11:19224677	A/T	cg14704941	chr11:19224659	CSRP3	0.34	5.84	0.34	1.5e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;Red blood cell count;
CESC	cis	rs804280	0.662	rs11250164	chr8:11610686	C/T	cg26752888	chr8:11627280	NEIL2	0.58	5.7	0.33	3.12e-8	Myopia (pathological);
CESC	cis	rs2625529	0.617	rs62023343	chr15:72174963	C/A	cg16672083	chr15:72433130	SENP8	0.42	6.4	0.37	7.07e-10	Red blood cell count;
CESC	cis	rs36051895	0.589	rs6476950	chr9:5218416	A/T	cg02405213	chr9:5042618	JAK2	-0.57	-6.78	-0.38	8e-11	Pediatric autoimmune diseases;
CESC	cis	rs34638657	0.872	rs2967349	chr16:82194405	G/C	cg09439754	chr16:82129088	HSD17B2	-0.36	-5.25	-0.31	3.08e-7	Lung adenocarcinoma;
CESC	cis	rs9910055	0.659	rs112114764	chr17:42201041	G/T	cg13607699	chr17:42295918	UBTF	-0.59	-7.74	-0.43	2.11e-13	Total body bone mineral density;
CESC	cis	rs6860806	0.661	rs3763112	chr5:131586480	A/G	cg11843238	chr5:131593191	PDLIM4	0.37	5.37	0.31	1.73e-7	Breast cancer;
CESC	cis	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg14930269	chr3:49142045	QARS	0.36	5.1	0.3	6.61e-7	Intelligence (multi-trait analysis);
CESC	cis	rs4820539	1.000	rs756631	chr22:23463183	A/G	cg14186256	chr22:23484241	RTDR1	0.82	14.91	0.68	6.48e-37	Bone mineral density;
CESC	cis	rs10504229	1.000	rs17216620	chr8:58169412	A/G	cg24829409	chr8:58192753	C8orf71	-0.76	-10.0	-0.52	3.53e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs7851660	0.967	rs7847126	chr9:100600635	A/C	cg13688889	chr9:100608707	NA	-0.68	-10.61	-0.55	3.8e-22	Strep throat;
CESC	trans	rs1814175	0.817	rs28502006	chr11:50049930	T/C	cg03929089	chr4:120376271	NA	-0.94	-15.72	-0.69	8.37e-40	Height;
CESC	cis	rs9611565	0.729	rs203320	chr22:41913477	T/C	cg03806693	chr22:41940476	POLR3H	-0.8	-10.19	-0.53	8.67e-21	Vitiligo;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg25098497	chr12:13254403	GSG1	-0.5	-6.62	-0.38	2.04e-10	Fibrinogen levels;
CESC	cis	rs2637266	0.514	rs11516642	chr10:78473522	G/T	cg18941641	chr10:78392320	NA	-0.31	-5.03	-0.3	9.14e-7	Pulmonary function;
CESC	cis	rs7647973	0.506	rs11920251	chr3:49356671	C/T	cg07636037	chr3:49044803	WDR6	0.72	11.29	0.57	2.1e-24	Menarche (age at onset);
CESC	cis	rs3858526	1.000	rs10838909	chr11:5960490	G/A	cg02574844	chr11:5959923	NA	-0.43	-5.12	-0.3	5.86e-7	DNA methylation (variation);
CESC	cis	rs57221529	0.766	rs72703064	chr5:587825	T/C	cg16447950	chr5:562315	NA	-0.62	-6.52	-0.37	3.51e-10	Lung disease severity in cystic fibrosis;
CESC	cis	rs2576037	0.583	rs12386118	chr18:44540376	C/G	cg19077165	chr18:44547161	KATNAL2	-0.65	-9.92	-0.52	6.22e-20	Personality dimensions;
CESC	cis	rs6500602	0.627	rs934929	chr16:4587789	A/G	cg08645402	chr16:4508243	NA	-0.41	-6.23	-0.36	1.79e-9	Schizophrenia;
CESC	cis	rs3845702	0.736	rs259810	chr2:180787821	T/C	cg01881094	chr2:180872142	CWC22	-1.06	-8.92	-0.48	7.99e-17	Schizophrenia;
CESC	cis	rs4523957	0.614	rs2760736	chr17:2036653	A/G	cg16513277	chr17:2031491	SMG6	-0.78	-11.57	-0.58	2.42e-25	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs763014	0.865	rs8675	chr16:633843	A/G	cg00802000	chr16:706648	WDR90	-0.39	-5.84	-0.34	1.53e-8	Height;
CESC	cis	rs1950626	0.569	rs4143956	chr14:101434356	A/T	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.69	9.23	0.49	8.76e-18	Pelvic organ prolapse (moderate/severe);
CESC	cis	rs9300255	0.602	rs1727316	chr12:123618603	C/T	cg19016782	chr12:123741754	C12orf65	-0.42	-5.9	-0.34	1.08e-8	Neutrophil percentage of white cells;
CESC	cis	rs875971	0.964	rs55748098	chr7:65763618	T/C	cg18876405	chr7:65276391	NA	-0.51	-7.01	-0.4	1.98e-11	Aortic root size;
CESC	cis	rs7552404	0.924	rs1313071	chr1:76195542	C/G	cg03433033	chr1:76189801	ACADM	0.71	9.8	0.52	1.5e-19	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs853679	0.542	rs2295594	chr6:28053097	G/A	cg23161317	chr6:28129485	ZNF389	0.5	6.31	0.36	1.19e-9	Depression;
CESC	cis	rs12291225	0.679	rs4756786	chr11:14285900	C/A	cg19336497	chr11:14380999	RRAS2	-0.39	-5.63	-0.33	4.63e-8	Sense of smell;
CESC	cis	rs2730245	0.510	rs2788471	chr7:158649786	G/T	cg01943577	chr7:158741284	NA	-0.44	-5.81	-0.34	1.82e-8	Height;
CESC	cis	rs854765	0.583	rs12603148	chr17:17865257	C/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.47	6.08	0.35	4.28e-9	Total body bone mineral density;
CESC	cis	rs801193	0.967	rs2707841	chr7:66157020	A/G	cg11764359	chr7:65958608	NA	0.71	9.39	0.5	2.85e-18	Aortic root size;
CESC	cis	rs703842	0.616	rs10783850	chr12:58229377	T/C	cg02175503	chr12:58329896	NA	0.48	5.92	0.34	9.68e-9	Multiple sclerosis;
CESC	cis	rs3096299	0.933	rs2965934	chr16:89481229	C/G	cg16743903	chr16:89593216	SPG7	-0.41	-5.26	-0.31	2.98e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs4665809	1.000	rs4665308	chr2:26330514	C/A	cg08470875	chr2:26401718	FAM59B	-0.47	-5.24	-0.31	3.31e-7	Gut microbiome composition (summer);
CESC	cis	rs7077164	1.000	rs1227769	chr10:71586296	C/T	cg20696214	chr10:71583771	COL13A1	-0.45	-6.12	-0.35	3.28e-9	Non-alcoholic fatty liver disease histology (lobular);
CESC	cis	rs9300255	0.722	rs67624109	chr12:123824635	C/T	cg00376283	chr12:123451042	ABCB9	-0.59	-6.25	-0.36	1.6e-9	Neutrophil percentage of white cells;
CESC	cis	rs9611565	0.659	rs202653	chr22:41840158	C/T	cg06481639	chr22:41940642	POLR3H	0.52	5.68	0.33	3.48e-8	Vitiligo;
CESC	cis	rs5769765	0.908	rs9616211	chr22:50317676	G/A	cg02269571	chr22:50332266	NA	-0.57	-6.6	-0.38	2.28e-10	Schizophrenia;
CESC	trans	rs2099077	0.867	rs1014772	chr5:102788681	C/T	cg07434438	chr16:72961899	ZFHX3	-0.49	-6.68	-0.38	1.4e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs1005277	0.579	rs1780145	chr10:38537070	A/G	cg25427524	chr10:38739819	LOC399744	-0.7	-10.26	-0.53	5.29e-21	Extrinsic epigenetic age acceleration;
CESC	cis	rs4919044	0.866	rs1475366	chr10:94781857	T/C	cg16508068	chr10:94451736	HHEX	-0.5	-5.07	-0.3	7.38e-7	Coronary artery disease;
CESC	cis	rs763121	0.819	rs6001205	chr22:39100264	T/A	cg14440974	chr22:39074834	NA	-0.42	-5.68	-0.33	3.48e-8	Menopause (age at onset);
CESC	cis	rs6952808	0.595	rs3800916	chr7:2166072	C/T	cg08027265	chr7:2291960	NA	-0.45	-6.96	-0.39	2.71e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs3087591	0.801	rs2012535	chr17:29561391	A/T	cg24425628	chr17:29625626	OMG;NF1	-0.42	-5.14	-0.3	5.39e-7	Hip circumference;
CESC	cis	rs3092073	0.603	rs4810477	chr20:44544654	C/T	cg00981651	chr20:44574847	PCIF1	0.36	5.17	0.3	4.56e-7	Intelligence (multi-trait analysis);
CESC	cis	rs7666738	0.830	rs11942114	chr4:99066261	C/G	cg03467027	chr4:99064603	C4orf37	0.47	5.92	0.34	9.84e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3785574	0.962	rs2665842	chr17:61878535	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.8	10.57	0.54	4.93e-22	Height;
CESC	cis	rs9287719	0.967	rs715246	chr2:10736355	G/A	cg02196655	chr2:10830764	NOL10	-0.37	-5.72	-0.33	2.87e-8	Prostate cancer;
CESC	cis	rs9549367	0.756	rs2316463	chr13:113901406	C/T	cg18105134	chr13:113819100	PROZ	-0.68	-8.09	-0.44	2.23e-14	Platelet distribution width;
CESC	cis	rs660899	0.595	rs37471	chr1:44277548	A/G	cg11704212	chr1:44303111	ST3GAL3	0.39	5.17	0.3	4.6e-7	Hypertension risk in short sleep duration;
CESC	cis	rs2758596	0.850	rs2842879	chr1:156163695	G/T	cg24450063	chr1:156163899	SLC25A44	0.84	8.45	0.46	1.99e-15	Paclitaxel disposition in epithelial ovarian cancer;
CESC	cis	rs8062405	0.964	rs78613234	chr16:28839425	T/C	cg08761264	chr16:28874980	SH2B1	-0.47	-5.83	-0.34	1.64e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12126786	chr5:77656518	SCAMP1	0.55	6.47	0.37	4.81e-10	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22795212	chr1:33938026	ZSCAN20	-0.53	-6.14	-0.35	3.08e-9	Gut microbiome composition (summer);
CESC	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	13.55	0.64	3.96e-32	Prudent dietary pattern;
CESC	cis	rs7552404	0.924	rs3818855	chr1:76198785	C/T	cg22875332	chr1:76189707	ACADM	0.73	10.17	0.53	1.02e-20	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs8038465	0.622	rs17185525	chr15:73885539	T/C	cg15420318	chr15:73925796	NPTN	0.48	6.76	0.38	8.67e-11	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs367943	1.000	rs348928	chr5:112815295	C/T	cg12552261	chr5:112820674	MCC	-0.62	-7.78	-0.43	1.58e-13	Type 2 diabetes;
CESC	cis	rs57221529	0.766	rs4527146	chr5:555236	A/G	cg16447950	chr5:562315	NA	-0.68	-7.54	-0.42	7.63e-13	Lung disease severity in cystic fibrosis;
CESC	cis	rs9715521	0.867	rs6840137	chr4:59830872	A/G	cg11281224	chr4:60001000	NA	-0.51	-6.68	-0.38	1.43e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	trans	rs79976124	0.800	rs6918860	chr6:66637741	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.69	7.91	0.44	6.93e-14	Type 2 diabetes;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg18439323	chr14:23755769	HOMEZ	0.42	6.09	0.35	3.85e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs11657217	1.000	rs11657217	chr17:77709339	C/G	cg06901238	chr17:77706717	ENPP7	0.45	5.85	0.34	1.47e-8	Diastolic blood pressure response to hydrochlorothiazide in hypertension;
CESC	cis	rs11608355	0.515	rs11614551	chr12:109931630	G/A	cg05360138	chr12:110035743	NA	0.82	8.85	0.48	1.27e-16	Neuroticism;
CESC	cis	rs6831352	0.918	rs29001211	chr4:100051941	C/T	cg13256891	chr4:100009986	ADH5	-0.77	-8.43	-0.46	2.27e-15	Alcohol dependence;
CESC	cis	rs2200578	1.000	rs60025964	chr2:99880577	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.48	5.11	0.3	6.16e-7	IgG glycosylation;
CESC	cis	rs8114671	0.562	rs959829	chr20:33346047	T/C	cg07148914	chr20:33460835	GGT7	-0.49	-6.25	-0.36	1.62e-9	Height;
CESC	trans	rs61931739	0.500	rs34080094	chr12:34547952	G/A	cg26384229	chr12:38710491	ALG10B	0.71	10.74	0.55	1.43e-22	Morning vs. evening chronotype;
CESC	cis	rs9430161	0.611	rs35033941	chr1:11034382	C/T	cg27631724	chr1:11040367	C1orf127	0.38	6.21	0.36	2.02e-9	Ewing sarcoma;
CESC	cis	rs4237845	1.000	rs4237845	chr12:58302436	A/G	cg00677455	chr12:58241039	CTDSP2	-0.5	-6.27	-0.36	1.44e-9	Intelligence (multi-trait analysis);
CESC	cis	rs1797885	0.524	rs2255648	chr3:12598963	A/G	cg26432171	chr3:12704882	RAF1	-0.53	-7.11	-0.4	1.09e-11	Immature fraction of reticulocytes;
CESC	cis	rs7666738	0.830	rs17550735	chr4:99014076	T/G	cg03467027	chr4:99064603	C4orf37	0.44	5.63	0.33	4.57e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6968419	0.755	rs3807982	chr7:115898885	T/C	cg02561103	chr7:115862891	TES	-0.41	-5.42	-0.32	1.37e-7	Intraocular pressure;
CESC	cis	rs9649213	0.593	rs6944262	chr7:97985415	T/G	cg21770322	chr7:97807741	LMTK2	0.58	9.02	0.48	4.04e-17	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs4665809	0.556	rs10221814	chr2:26442759	C/T	cg04944784	chr2:26401820	FAM59B	-0.96	-10.87	-0.56	5.25e-23	Gut microbiome composition (summer);
CESC	cis	rs2842992	0.915	rs2758321	chr6:160071611	C/G	cg11366901	chr6:160182831	ACAT2	0.75	9.24	0.49	8.53e-18	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs9914544	1.000	rs9916245	chr17:18766825	C/G	cg26378065	chr17:18585709	ZNF286B	0.45	5.46	0.32	1.1e-7	Educational attainment (years of education);
CESC	cis	rs9902453	0.904	rs7208579	chr17:28263067	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	9.16	0.49	1.49e-17	Coffee consumption (cups per day);
CESC	trans	rs875971	0.660	rs7807944	chr7:66087195	C/G	cg26939375	chr7:64535504	NA	-0.64	-8.59	-0.47	7.53e-16	Aortic root size;
CESC	cis	rs1799949	0.965	rs35521261	chr17:41313612	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.43	5.84	0.34	1.49e-8	Menopause (age at onset);
CESC	cis	rs1355223	0.525	rs55796371	chr11:34872769	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.55	-6.64	-0.38	1.81e-10	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs896854	0.517	rs1011795	chr8:95951073	G/A	cg09323728	chr8:95962352	TP53INP1	-0.35	-6.51	-0.37	3.77e-10	Type 2 diabetes;
CESC	cis	rs11190604	1.000	rs2489039	chr10:102328036	T/A	cg07080220	chr10:102295463	HIF1AN	0.57	5.46	0.32	1.1e-7	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs10504229	0.954	rs903717	chr8:58167856	A/G	cg02725872	chr8:58115012	NA	-0.31	-5.24	-0.31	3.24e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs5498	0.809	rs2075742	chr19:10401607	G/C	cg10604476	chr19:10403908	ICAM5	0.44	6.21	0.36	1.99e-9	Lymphocyte counts;Soluble ICAM-1;Blood protein levels;
CESC	cis	rs6952808	0.792	rs2056478	chr7:1953897	C/T	cg04267008	chr7:1944627	MAD1L1	-0.72	-9.35	-0.5	3.92e-18	Bipolar disorder and schizophrenia;
CESC	cis	rs9611565	0.546	rs2092274	chr22:42123737	A/G	cg03806693	chr22:41940476	POLR3H	1.04	11.92	0.59	1.69e-26	Vitiligo;
CESC	trans	rs1945213	0.659	rs17149979	chr11:55840862	A/G	cg15704280	chr7:45808275	SEPT13	0.76	7.31	0.41	3.15e-12	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs4805272	0.512	rs66830923	chr19:29321277	C/T	cg12756686	chr19:29218302	NA	0.5	6.32	0.36	1.12e-9	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
CESC	cis	rs2842992	0.692	rs9347342	chr6:160193129	T/C	cg11366901	chr6:160182831	ACAT2	0.65	8.38	0.46	3.24e-15	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs7267979	0.565	rs3752273	chr20:25594783	A/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.71	-11.82	-0.59	3.68e-26	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs4722166	0.645	rs1404006	chr7:22795077	T/C	cg05265849	chr7:22767390	IL6	0.45	6.17	0.35	2.57e-9	Lung cancer;
CESC	cis	rs3008870	0.755	rs2815365	chr1:67499628	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.6	7.97	0.44	4.75e-14	Lymphocyte percentage of white cells;
CESC	cis	rs66573146	0.572	rs67252699	chr4:6946411	A/G	cg00086871	chr4:6988644	TBC1D14	1.05	6.92	0.39	3.44e-11	Granulocyte percentage of myeloid white cells;
CESC	cis	rs798766	1.000	rs798756	chr4:1707447	T/C	cg10756475	chr4:1757242	NA	0.4	5.24	0.31	3.25e-7	Bladder cancer;Urinary bladder cancer;
CESC	cis	rs1707322	0.656	rs2991981	chr1:46057144	A/G	cg06784218	chr1:46089804	CCDC17	-0.43	-7.47	-0.42	1.19e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs113835537	0.529	rs11550299	chr11:66254085	G/T	cg22134325	chr11:66188745	NPAS4	0.35	5.48	0.32	1.01e-7	Airway imaging phenotypes;
CESC	cis	rs561341	0.941	rs8081016	chr17:30331751	A/G	cg12193833	chr17:30244370	NA	-0.73	-6.71	-0.38	1.14e-10	Hip circumference adjusted for BMI;
CESC	cis	rs7666738	0.830	rs2019163	chr4:99022747	C/T	cg05340658	chr4:99064831	C4orf37	0.82	12.99	0.62	3.34e-30	Colonoscopy-negative controls vs population controls;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg07874155	chr5:138089656	CTNNA1	0.46	6.33	0.36	1.05e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs501120	0.525	rs1704229	chr10:44689529	G/A	cg09554077	chr10:44749378	NA	0.4	5.22	0.31	3.64e-7	Coronary artery disease;Coronary heart disease;
CESC	cis	rs7666738	0.830	rs13110498	chr4:98959150	G/A	cg18180107	chr4:99064573	C4orf37	0.4	5.12	0.3	5.85e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4665809	0.531	rs12990692	chr2:26464939	C/T	cg25036284	chr2:26402008	FAM59B	0.88	9.99	0.52	3.79e-20	Gut microbiome composition (summer);
CESC	cis	rs1707322	0.963	rs6429581	chr1:46319096	G/A	cg03146154	chr1:46216737	IPP	0.78	10.75	0.55	1.29e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs1797081	1.000	rs2603807	chr10:16872797	A/G	cg23933602	chr10:16859644	RSU1	1.1	23.18	0.82	1.1000000000000001e-65	Platelet distribution width;
CESC	cis	rs7726839	0.561	rs72703050	chr5:582917	A/C	cg09021430	chr5:549028	NA	-0.43	-5.74	-0.33	2.6e-8	Obesity-related traits;
CESC	cis	rs854765	0.575	rs2955357	chr17:17946401	T/C	cg09796270	chr17:17721594	SREBF1	-0.38	-5.12	-0.3	5.97e-7	Total body bone mineral density;
CESC	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	7.9	0.44	7.68e-14	Prudent dietary pattern;
CESC	cis	rs514406	0.584	rs7548832	chr1:53193576	A/T	cg16325326	chr1:53192061	ZYG11B	0.93	15.59	0.69	2.59e-39	Monocyte count;
CESC	cis	rs72781680	0.699	rs72796125	chr2:23919169	C/T	cg08917208	chr2:24149416	ATAD2B	1.13	10.24	0.53	5.87e-21	Lymphocyte counts;
CESC	cis	rs12541635	0.677	rs6999580	chr8:107018254	C/T	cg10147462	chr8:107024639	NA	0.46	6.95	0.39	2.77e-11	Age of smoking initiation;
CESC	cis	rs11958404	0.932	rs76228149	chr5:157434486	G/A	cg05962755	chr5:157440814	NA	0.62	6.56	0.37	2.74e-10	IgG glycosylation;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg22481606	chr17:56429567	SUPT4H1	-0.42	-6.24	-0.36	1.7e-9	Gambling;
CESC	cis	rs7618915	0.547	rs7642198	chr3:52677960	T/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.5	0.37	3.92e-10	Bipolar disorder;
CESC	cis	rs62283056	0.512	rs4568307	chr4:6284965	A/G	cg14416269	chr4:6271139	WFS1	0.44	6.32	0.36	1.09e-9	Cisplatin-induced ototoxicity;
CESC	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg06873352	chr17:61820015	STRADA	0.73	12.26	0.6	1.15e-27	Prudent dietary pattern;
CESC	cis	rs4588572	0.643	rs10063319	chr5:77758425	T/C	cg11547950	chr5:77652471	NA	-0.44	-5.48	-0.32	9.67e-8	Triglycerides;
CESC	cis	rs17293817	0.958	rs12779875	chr10:1438597	A/C	cg08482957	chr10:1437944	ADARB2	0.37	5.3	0.31	2.48e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.43	8.38	0.46	3.04e-15	Electroencephalogram traits;
CESC	cis	rs6088580	0.634	rs6142153	chr20:32968747	C/G	cg08999081	chr20:33150536	PIGU	-0.64	-11.19	-0.57	4.76e-24	Glomerular filtration rate (creatinine);
CESC	cis	rs62064224	0.593	rs916663	chr17:30835833	A/C	cg09324608	chr17:30823087	MYO1D	-0.43	-6.39	-0.37	7.46e-10	Schizophrenia;
CESC	cis	rs71403859	0.730	rs12927768	chr16:71645263	G/A	cg08717414	chr16:71523259	ZNF19	-0.76	-6.58	-0.37	2.55e-10	Post bronchodilator FEV1;
CESC	cis	rs9908102	0.740	rs8078394	chr17:12910602	C/T	cg26162695	chr17:12921313	ELAC2	0.52	5.71	0.33	3.04e-8	Schizophrenia;
CESC	cis	rs11255291	0.668	rs719748	chr10:7731885	A/G	cg26051552	chr10:7670683	ITIH5	0.4	5.71	0.33	3.05e-8	Ovarian reserve;
CESC	cis	rs9487051	0.872	rs9487043	chr6:109610474	C/T	cg21918786	chr6:109611834	NA	-0.41	-6.12	-0.35	3.29e-9	Reticulocyte fraction of red cells;
CESC	cis	rs1862618	0.853	rs832582	chr5:56177743	G/A	cg24549020	chr5:56110836	MAP3K1	0.67	7.49	0.42	1.02e-12	Initial pursuit acceleration;
CESC	cis	rs6489785	0.710	rs2393717	chr12:121220375	G/C	cg02419362	chr12:121203948	SPPL3	0.36	5.75	0.33	2.46e-8	Longevity;Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs6484504	0.516	rs1999250	chr11:31287455	C/T	cg14844989	chr11:31128820	NA	-0.39	-5.45	-0.32	1.13e-7	Red blood cell count;
CESC	cis	rs477692	0.870	rs512655	chr10:131424547	T/A	cg05714579	chr10:131428358	MGMT	0.57	8.16	0.45	1.36e-14	Response to temozolomide;
CESC	cis	rs6570726	0.791	rs11155433	chr6:145907831	A/G	cg23711669	chr6:146136114	FBXO30	-0.95	-14.35	-0.66	5.85e-35	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6942756	0.876	rs2303303	chr7:129019736	G/A	cg02491457	chr7:128862824	NA	-0.58	-8.08	-0.44	2.33e-14	White matter hyperintensity burden;
CESC	cis	rs9486719	1.000	rs34209750	chr6:96882215	G/T	cg06623918	chr6:96969491	KIAA0776	-0.81	-8.29	-0.45	5.61e-15	Migraine;Coronary artery disease;
CESC	cis	rs7818688	1.000	rs10100842	chr8:96025903	A/G	cg16049864	chr8:95962084	TP53INP1	0.6	5.77	0.33	2.25e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17282769	chr12:11802362	ETV6	0.6	6.87	0.39	4.54e-11	Gut microbiome composition (summer);
CESC	cis	rs919433	0.963	rs10153881	chr2:198171098	T/C	cg03934865	chr2:198174659	NA	-0.41	-5.69	-0.33	3.37e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs854765	1.000	rs854765	chr17:18012730	T/C	cg04398451	chr17:18023971	MYO15A	0.71	9.84	0.52	1.16e-19	Total body bone mineral density;
CESC	cis	rs1642645	0.831	rs12042133	chr1:42499365	A/C	cg16685388	chr1:42384056	HIVEP3	-0.38	-5.68	-0.33	3.55e-8	Left ventricular obstructive tract defect (maternal effect);
CESC	cis	rs9311474	0.508	rs1570	chr3:52586682	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.49	7.17	0.4	7.6e-12	Electroencephalogram traits;
CESC	cis	rs780096	0.526	rs780112	chr2:27665361	C/G	cg24768116	chr2:27665128	KRTCAP3	-0.3	-5.57	-0.32	6.2e-8	Total body bone mineral density;
CESC	cis	rs514406	0.505	rs269290	chr1:53167027	A/T	cg16325326	chr1:53192061	ZYG11B	0.9	15.66	0.69	1.42e-39	Monocyte count;
CESC	cis	rs9443189	0.762	rs2748943	chr6:76435543	C/T	cg01950844	chr6:76311363	SENP6	-0.68	-7.22	-0.41	5.51e-12	Prostate cancer;
CESC	cis	rs9303401	0.614	rs3087762	chr17:56568680	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.99	12.2	0.6	1.8e-27	Cognitive test performance;
CESC	cis	rs35110281	0.659	rs11909064	chr21:45092095	G/C	cg21573476	chr21:45109991	RRP1B	-0.58	-8.36	-0.46	3.59e-15	Mean corpuscular volume;
CESC	cis	rs9910055	0.762	rs184478	chr17:42209751	C/G	cg08499158	chr17:42289980	UBTF	0.54	6.89	0.39	4.06e-11	Total body bone mineral density;
CESC	cis	rs7927592	0.956	rs55816191	chr11:68262979	G/T	cg16797656	chr11:68205561	LRP5	0.41	6.17	0.35	2.54e-9	Total body bone mineral density;
CESC	cis	rs9611565	0.592	rs5996038	chr22:41965300	T/C	cg06481639	chr22:41940642	POLR3H	-0.59	-6.48	-0.37	4.52e-10	Vitiligo;
CESC	cis	rs7429990	0.965	rs319685	chr3:47931984	C/A	cg11946769	chr3:48343235	NME6	0.42	5.13	0.3	5.71e-7	Educational attainment (years of education);
CESC	cis	rs13191362	1.000	rs4260737	chr6:163137746	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.66	6.56	0.37	2.8e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg06459454	chr8:146033798	ZNF517	0.46	6.05	0.35	4.82e-9	Fibrinogen levels;
CESC	cis	rs2645694	0.626	rs2703151	chr4:77834095	A/G	cg18351406	chr4:77819688	ANKRD56	0.43	5.31	0.31	2.33e-7	Emphysema distribution in smoking;
CESC	trans	rs9325144	0.647	rs12831609	chr12:39051576	C/A	cg23762105	chr12:34175262	ALG10	0.46	6.01	0.35	6.13e-9	Morning vs. evening chronotype;
CESC	cis	rs826838	0.900	rs11169301	chr12:39128497	C/A	cg13010199	chr12:38710504	ALG10B	0.59	7.86	0.43	9.9e-14	Heart rate;
CESC	cis	rs1552244	1.000	rs7648104	chr3:10073311	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.78	-10.37	-0.54	2.25e-21	Alzheimer's disease;
CESC	cis	rs6701037	0.566	rs1014555	chr1:175134249	C/T	cg00321850	chr1:175162397	KIAA0040	0.44	6.32	0.36	1.11e-9	Alcohol dependence;
CESC	cis	rs1552244	0.882	rs13099507	chr3:10031603	G/A	cg00166722	chr3:10149974	C3orf24	0.51	6.06	0.35	4.6e-9	Alzheimer's disease;
CESC	cis	rs11822910	0.724	rs60961847	chr11:57184224	G/A	cg00522883	chr11:57194120	SLC43A3	0.61	6.1	0.35	3.7e-9	Platelet distribution width;
CESC	cis	rs921968	0.565	rs13408427	chr2:219628389	C/T	cg02176678	chr2:219576539	TTLL4	-0.44	-7.59	-0.42	5.38e-13	Mean corpuscular hemoglobin concentration;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17036024	chr1:161359810	NA	0.67	7.32	0.41	2.9e-12	Gut microbiome composition (summer);
CESC	cis	rs6987853	0.830	rs9643888	chr8:42352007	T/C	cg09913449	chr8:42400586	C8orf40	-0.34	-5.3	-0.31	2.38e-7	Mean corpuscular hemoglobin concentration;
CESC	cis	rs13108904	0.967	rs12502916	chr4:1276349	G/A	cg00684032	chr4:1343700	KIAA1530	-0.37	-5.1	-0.3	6.61e-7	Obesity-related traits;
CESC	cis	rs2243480	1.000	rs316313	chr7:65593548	G/A	cg12463550	chr7:65579703	CRCP	0.73	5.68	0.33	3.5e-8	Diabetic kidney disease;
CESC	cis	rs2404602	0.692	rs12911174	chr15:77149943	G/A	cg26408565	chr15:76604113	ETFA	-0.39	-5.63	-0.33	4.54e-8	Blood metabolite levels;
CESC	trans	rs360798	0.532	rs1906202	chr2:62806359	A/G	cg07814414	chr15:31774773	NA	-0.43	-6.26	-0.36	1.55e-9	Coronary artery disease;
CESC	cis	rs9611565	0.512	rs139560	chr22:42194962	A/G	cg17376030	chr22:41985996	PMM1	0.78	8.47	0.46	1.69e-15	Vitiligo;
CESC	cis	rs3126085	0.935	rs4845741	chr1:152183474	A/G	cg26876637	chr1:152193138	HRNR	0.47	5.43	0.32	1.28e-7	Atopic dermatitis;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg22033559	chr17:7143253	PHF23	-0.48	-6.51	-0.37	3.7e-10	Asthma;
CESC	cis	rs2380220	0.606	rs7754906	chr6:95992429	C/T	cg15832292	chr6:96025679	MANEA	0.58	6.58	0.37	2.52e-10	Behavioural disinhibition (generation interaction);
CESC	cis	rs6089829	1.000	rs6089829	chr20:61669036	C/T	cg03213289	chr20:61660250	NA	-0.35	-5.31	-0.31	2.29e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs72829446	0.530	rs111259369	chr17:7383082	C/T	cg02795151	chr17:7402630	POLR2A	0.55	5.86	0.34	1.41e-8	Androgen levels;
CESC	cis	rs9640161	0.789	rs2159234	chr7:150020422	A/T	cg10018233	chr7:150070692	REPIN1	0.45	7.08	0.4	1.3e-11	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs7618915	0.501	rs6617	chr3:52740182	C/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.53	8.0	0.44	3.89e-14	Bipolar disorder;
CESC	cis	rs5758659	0.652	rs133358	chr22:42442539	A/T	cg19513890	chr22:42538836	CYP2D7P1	-0.38	-5.65	-0.33	4.12e-8	Cognitive function;
CESC	cis	rs4555082	0.957	rs2975216	chr14:105713134	T/C	cg06808227	chr14:105710500	BRF1	-0.58	-7.35	-0.41	2.43e-12	Mean platelet volume;Platelet distribution width;
CESC	cis	rs34172651	0.517	rs12920774	chr16:24830750	T/C	cg00339695	chr16:24857497	SLC5A11	0.53	6.43	0.37	5.81e-10	Intelligence (multi-trait analysis);
CESC	cis	rs6951245	0.706	rs1133116	chr7:1195215	A/C	cg18402987	chr7:1209562	NA	0.76	8.49	0.46	1.46e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs6693567	0.565	rs7513182	chr1:150442612	A/G	cg09579323	chr1:150459698	TARS2	-0.47	-5.95	-0.34	8.27e-9	Migraine;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08601628	chr8:10555466	C8orf74	-0.59	-6.56	-0.37	2.8e-10	Gut microbiome composition (summer);
CESC	cis	rs3858526	0.917	rs10769386	chr11:5973420	C/T	cg13902645	chr11:5959945	NA	0.57	6.57	0.37	2.64e-10	DNA methylation (variation);
CESC	cis	rs67460515	0.630	rs7638370	chr3:160921793	G/T	cg03342759	chr3:160939853	NMD3	-0.55	-7.46	-0.42	1.22e-12	Parkinson's disease;
CESC	cis	rs12579753	0.879	rs11115009	chr12:82165409	G/T	cg24719984	chr12:82153464	PPFIA2	0.36	5.26	0.31	2.93e-7	Resting heart rate;
CESC	trans	rs386965	0.524	rs7196953	chr16:79649394	C/T	cg27092986	chr12:7858592	NA	0.41	6.08	0.35	4.07e-9	Multiple sclerosis;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg04791456	chr3:57505743	DNAH12	0.52	6.97	0.39	2.54e-11	Fibrinogen levels;
CESC	cis	rs3806843	0.735	rs778596	chr5:140037272	G/A	cg26395211	chr5:140044315	WDR55	0.48	6.24	0.36	1.71e-9	Depressive symptoms (multi-trait analysis);
CESC	cis	rs1005277	0.579	rs2504148	chr10:38400788	A/G	cg25517755	chr10:38738941	LOC399744	-0.46	-5.91	-0.34	1.05e-8	Extrinsic epigenetic age acceleration;
CESC	cis	rs7940866	0.874	rs7111478	chr11:130819628	A/G	cg12179176	chr11:130786555	SNX19	0.63	8.57	0.47	8.74e-16	Schizophrenia;
CESC	cis	rs1707322	1.000	rs7527079	chr1:46413450	C/G	cg06784218	chr1:46089804	CCDC17	0.33	5.63	0.33	4.7e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs889398	0.769	rs12927052	chr16:69857043	A/G	cg09409435	chr16:70099608	PDXDC2	-0.43	-5.36	-0.31	1.81e-7	Body mass index;
CESC	cis	rs868036	1.000	rs1871307	chr15:68100623	C/T	cg08079166	chr15:68083412	MAP2K5	0.43	6.75	0.38	9.54e-11	Restless legs syndrome;
CESC	cis	rs9790314	0.905	rs7613358	chr3:160949296	T/C	cg03342759	chr3:160939853	NMD3	-0.47	-6.45	-0.37	5.26e-10	Morning vs. evening chronotype;
CESC	cis	rs6963495	0.606	rs6969426	chr7:105147150	G/A	cg19920283	chr7:105172520	RINT1	0.66	6.19	0.36	2.33e-9	Bipolar disorder (body mass index interaction);
CESC	cis	rs9611565	0.694	rs79011	chr22:41866938	A/G	cg06634786	chr22:41940651	POLR3H	0.62	6.8	0.39	6.99e-11	Vitiligo;
CESC	cis	rs3747547	0.710	rs11789061	chr9:37950230	A/G	cg13774184	chr9:37916125	SHB	-0.56	-5.93	-0.34	9.34e-9	Metabolite levels (Dihydroxy docosatrienoic acid);
CESC	cis	rs12497850	0.931	rs12493289	chr3:48905161	G/A	cg03060546	chr3:49711283	APEH	0.44	5.38	0.31	1.61e-7	Parkinson's disease;
CESC	cis	rs12586317	0.547	rs10134907	chr14:35499211	A/C	cg16230307	chr14:35515116	FAM177A1	0.99	10.61	0.55	3.72e-22	Psoriasis;
CESC	trans	rs60843830	1.000	rs3791224	chr2:221981	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.66	7.92	0.44	6.77e-14	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs7714584	1.000	rs11748151	chr5:150226292	C/T	cg22134413	chr5:150180641	NA	0.52	5.64	0.33	4.31e-8	Crohn's disease;
CESC	cis	rs7539624	0.588	rs1892077	chr1:223895116	A/G	cg10100437	chr1:223903862	CAPN2	0.41	5.1	0.3	6.45e-7	Schizophrenia;
CESC	cis	rs6504663	1.000	rs6504661	chr17:48580126	A/T	cg03168497	chr17:48586147	MYCBPAP	-0.45	-5.89	-0.34	1.19e-8	Visceral fat;
CESC	cis	rs2404602	0.735	rs2454450	chr15:76831236	G/A	cg23625390	chr15:77176239	SCAPER	-0.43	-5.83	-0.34	1.57e-8	Blood metabolite levels;
CESC	trans	rs304172	0.793	rs188585	chr3:62779444	G/T	cg14089474	chr19:45280184	CBLC	0.55	6.21	0.36	2.06e-9	IgG glycosylation;
CESC	cis	rs9911578	0.967	rs9894274	chr17:56977919	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.39	5.05	0.3	8.26e-7	Intelligence (multi-trait analysis);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg13689028	chr9:135230112	SETX	-0.44	-6.08	-0.35	4.27e-9	Fibrinogen levels;
CESC	cis	rs4901869	0.966	rs9972206	chr14:59336095	A/G	cg02291164	chr14:59296302	NA	0.45	7.73	0.43	2.21e-13	Panic disorder;
CESC	cis	rs2066819	1.000	rs75265219	chr12:56640341	G/A	cg26714650	chr12:56694279	CS	-1.42	-10.05	-0.53	2.39e-20	Psoriasis vulgaris;
CESC	cis	rs17209837	1.000	rs17149647	chr7:87086931	T/C	cg00919237	chr7:87102261	ABCB4	-0.54	-6.2	-0.36	2.14e-9	Gallbladder cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27512018	chr19:11039304	YIPF2;C19orf52	0.67	8.13	0.45	1.65e-14	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.830	rs13122054	chr4:98972974	G/A	cg17366294	chr4:99064904	C4orf37	0.59	8.46	0.46	1.87e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9611565	0.527	rs73178638	chr22:41942904	T/C	cg17376030	chr22:41985996	PMM1	0.76	7.95	0.44	5.38e-14	Vitiligo;
CESC	cis	rs1499972	0.938	rs1499971	chr3:117719537	A/C	cg07612923	chr3:117604196	NA	-0.77	-5.71	-0.33	3.06e-8	Schizophrenia;
CESC	cis	rs6088590	0.502	rs6059861	chr20:33068563	A/T	cg06115741	chr20:33292138	TP53INP2	0.46	5.98	0.34	7.34e-9	Coronary artery disease;
CESC	cis	rs919433	0.889	rs788001	chr2:198213720	C/T	cg03934865	chr2:198174659	NA	0.44	6.47	0.37	4.71e-10	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs3092073	0.624	rs3848714	chr20:44547176	T/C	cg00981651	chr20:44574847	PCIF1	0.39	5.76	0.33	2.35e-8	Intelligence (multi-trait analysis);
CESC	cis	rs7555523	0.887	rs10800155	chr1:165723770	A/G	cg24409356	chr1:165738333	TMCO1	0.82	7.36	0.41	2.38e-12	Intraocular pressure;Glaucoma (high intraocular pressure);
CESC	cis	rs1143633	0.509	rs2068777	chr2:113696126	A/G	cg12858261	chr2:113808755	IL1F8	0.52	6.15	0.35	2.88e-9	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs709400	0.832	rs10145755	chr14:104121984	C/T	cg24130564	chr14:104152367	KLC1	-0.42	-5.41	-0.32	1.44e-7	Body mass index;
CESC	cis	rs7089973	0.624	rs10885613	chr10:116589400	G/A	cg03647239	chr10:116582469	FAM160B1	0.43	5.29	0.31	2.6e-7	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs7772486	0.875	rs2073287	chr6:146350264	T/C	cg23711669	chr6:146136114	FBXO30	0.79	11.25	0.57	2.93e-24	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs9951602	0.573	rs78623099	chr18:76646228	G/T	cg02800362	chr5:177631904	HNRNPAB	0.61	7.97	0.44	4.84e-14	Obesity-related traits;
CESC	cis	rs1879734	0.731	rs6588486	chr1:54166777	G/A	cg23596471	chr1:54105337	GLIS1	0.35	5.58	0.32	5.97e-8	Mitral valve prolapse;
CESC	cis	rs12410462	0.681	rs6682883	chr1:227635598	G/A	cg23173402	chr1:227635558	NA	0.7	6.32	0.36	1.12e-9	Major depressive disorder;
CESC	cis	rs7666738	0.716	rs2865982	chr4:99031661	T/G	cg05340658	chr4:99064831	C4orf37	0.83	13.1	0.63	1.43e-30	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11098499	0.954	rs17009122	chr4:120362403	G/A	cg25214090	chr10:38739885	LOC399744	0.7	9.9	0.52	7.24e-20	Corneal astigmatism;
CESC	cis	rs6922893	1.000	rs4707871	chr6:71662709	G/C	cg10766373	chr6:71666121	B3GAT2	-0.34	-5.37	-0.31	1.69e-7	Obesity-related traits;
CESC	trans	rs7246760	0.867	rs3859512	chr19:9932831	C/T	cg02900749	chr2:68251473	NA	-0.8	-6.75	-0.38	9.06e-11	Pursuit maintenance gain;
CESC	cis	rs7829975	0.658	rs907181	chr8:8702875	T/C	cg15556689	chr8:8085844	FLJ10661	0.44	5.63	0.33	4.53e-8	Mood instability;
CESC	cis	rs950027	0.572	rs12910764	chr15:45609360	T/C	cg21132104	chr15:45694354	SPATA5L1	-0.59	-7.19	-0.4	6.67e-12	Response to fenofibrate (adiponectin levels);
CESC	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.04	10.66	0.55	2.5e-22	Platelet count;
CESC	trans	rs7937682	1.000	rs4936661	chr11:111587495	G/A	cg18187862	chr3:45730750	SACM1L	-0.56	-6.37	-0.36	8.31e-10	Primary sclerosing cholangitis;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg17859048	chr1:151170906	PIP5K1A	-0.41	-6.12	-0.35	3.35e-9	Gambling;
CESC	cis	rs4665809	0.652	rs6728090	chr2:26524726	C/T	cg27170947	chr2:26402098	FAM59B	-0.63	-6.91	-0.39	3.7e-11	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.830	rs1365458	chr4:98950961	C/T	cg03676636	chr4:99064102	C4orf37	0.32	5.03	0.3	9.16e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01517940	chr14:69865233	SLC39A9;ERH	-0.59	-7.12	-0.4	1.02e-11	Gut microbiome composition (summer);
CESC	cis	rs2996428	0.561	rs2275827	chr1:3746585	T/G	cg13057898	chr1:3703894	LRRC47	0.35	5.21	0.3	3.84e-7	Red cell distribution width;
CESC	cis	rs12136530	0.774	rs9651024	chr1:19768954	T/C	cg01832549	chr1:19774989	CAPZB	-0.46	-6.41	-0.37	6.76e-10	Lead levels in blood;
CESC	cis	rs1862618	0.853	rs832582	chr5:56177743	G/A	cg03609598	chr5:56110824	MAP3K1	-0.51	-5.41	-0.32	1.4e-7	Initial pursuit acceleration;
CESC	cis	rs4964805	0.657	rs1866293	chr12:104186655	C/T	cg02344784	chr12:104178138	NT5DC3	0.46	6.57	0.37	2.73e-10	Attention deficit hyperactivity disorder;
CESC	cis	rs7291412	0.540	rs9627391	chr22:46447097	C/T	cg05468064	chr22:46423449	NA	0.33	5.21	0.3	3.86e-7	Dupuytren's disease;Subjective well-being;
CESC	cis	rs9311474	0.607	rs11711421	chr3:52561779	C/T	cg18404041	chr3:52824283	ITIH1	-0.37	-6.4	-0.37	7.08e-10	Electroencephalogram traits;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg08083689	chr4:8442326	ACOX3	0.49	6.06	0.35	4.67e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs7259376	0.869	rs4932984	chr19:22533255	T/C	cg02657401	chr19:22469223	NA	-0.27	-5.33	-0.31	2.08e-7	Menopause (age at onset);
CESC	cis	rs3015497	0.789	rs923908	chr14:51123595	C/T	cg09863266	chr14:51125203	SAV1	-0.35	-5.4	-0.31	1.51e-7	Mean platelet volume;
CESC	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	10.26	0.53	5.01e-21	Prudent dietary pattern;
CESC	cis	rs709400	0.628	rs12879085	chr14:103874420	G/A	cg12935359	chr14:103987150	CKB	0.48	7.19	0.4	6.57e-12	Body mass index;
CESC	cis	rs2440129	0.611	rs434473	chr17:6904934	A/G	cg05657792	chr17:6899758	ALOX12	-0.38	-6.3	-0.36	1.26e-9	Tonsillectomy;
CESC	cis	rs6952808	0.760	rs11764960	chr7:1950532	G/A	cg02951883	chr7:2050386	MAD1L1	-0.5	-6.64	-0.38	1.73e-10	Bipolar disorder and schizophrenia;
CESC	cis	rs6500395	1.000	rs12597569	chr16:48693342	C/T	cg04672837	chr16:48644449	N4BP1	-0.51	-6.36	-0.36	8.64e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs60154123	0.730	rs608791	chr1:210464638	C/T	cg23283495	chr1:209979779	IRF6	0.4	5.28	0.31	2.7e-7	Coronary artery disease;
CESC	cis	rs7481584	0.646	rs434114	chr11:3050210	A/G	cg08508325	chr11:3079039	CARS	0.29	5.16	0.3	4.96e-7	Calcium levels;
CESC	cis	rs3020736	0.500	rs4147638	chr22:42487900	G/A	cg12850546	chr22:42539477	CYP2D7P1	0.43	5.13	0.3	5.47e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs9640161	0.702	rs11765692	chr7:150026567	C/T	cg10018233	chr7:150070692	REPIN1	0.46	7.34	0.41	2.59e-12	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs2933343	0.621	rs728838	chr3:128589013	A/G	cg25356066	chr3:128598488	ACAD9	0.57	8.23	0.45	8.66e-15	IgG glycosylation;
CESC	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg07332563	chr6:291687	DUSP22	-0.68	-8.9	-0.48	9.08e-17	Menopause (age at onset);
CESC	cis	rs10242455	0.867	rs2687078	chr7:99304712	C/T	cg07715041	chr7:99302981	CYP3A7	-0.42	-5.37	-0.31	1.71e-7	Blood metabolite levels;
CESC	cis	rs4819052	0.851	rs2838844	chr21:46670733	A/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.45	5.6	0.33	5.33e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs1218582	0.774	rs4845680	chr1:154863195	A/G	cg06221963	chr1:154839813	KCNN3	-0.66	-11.44	-0.58	6.67e-25	Prostate cancer;
CESC	cis	rs7666738	0.753	rs35194639	chr4:99053819	G/C	cg17366294	chr4:99064904	C4orf37	0.61	8.78	0.47	2.13e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs597539	0.617	rs686348	chr11:68636996	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.77	9.59	0.51	6.99e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs12134245	0.755	rs11164928	chr1:92012678	G/A	cg21854759	chr1:92012499	NA	-0.45	-5.71	-0.33	3.04e-8	Breast cancer;
CESC	cis	rs66573146	0.831	rs56320732	chr4:6974319	G/A	cg00086871	chr4:6988644	TBC1D14	1.15	7.48	0.42	1.08e-12	Granulocyte percentage of myeloid white cells;
CESC	cis	rs4665809	0.590	rs35656275	chr2:26494695	G/C	cg22920501	chr2:26401640	FAM59B	0.89	10.2	0.53	7.89e-21	Gut microbiome composition (summer);
CESC	cis	rs4423214	1.000	rs2040323	chr11:71172783	A/C	cg24826892	chr11:71159390	DHCR7	0.46	5.11	0.3	6.18e-7	Vitamin D levels;
CESC	cis	rs116095464	0.558	rs6878061	chr5:223072	A/G	cg12570787	chr5:219185	SDHA;CCDC127	0.53	5.74	0.33	2.63e-8	Breast cancer;
CESC	cis	rs853679	0.546	rs175597	chr6:27810626	T/C	cg26587870	chr6:27730563	NA	-0.59	-5.19	-0.3	4.16e-7	Depression;
CESC	cis	rs1799949	1.000	rs12951869	chr17:41187567	T/G	cg23758822	chr17:41437982	NA	1.03	14.75	0.67	2.37e-36	Menopause (age at onset);
CESC	cis	rs2294693	0.945	rs9369260	chr6:41010368	C/G	cg14418226	chr6:40996092	UNC5CL	-0.58	-6.39	-0.37	7.4e-10	Gastric cancer;Non-cardia gastric cancer;
CESC	cis	rs2280018	0.526	rs1510148	chr16:15167379	T/A	cg27102117	chr16:15229624	NA	0.54	8.13	0.45	1.7e-14	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg16145071	chr2:101727897	TBC1D8	0.47	6.77	0.38	8.16e-11	Fibrinogen levels;
CESC	cis	rs8099014	0.731	rs4261624	chr18:56101290	T/A	cg12827950	chr18:55968429	NEDD4L	-0.53	-5.78	-0.33	2.09e-8	Platelet count;
CESC	cis	rs7618915	0.547	rs2590846	chr3:52692359	C/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	7.13	0.4	9.62e-12	Bipolar disorder;
CESC	cis	rs1348850	0.837	rs4243388	chr2:178284604	T/G	cg23306229	chr2:178417860	TTC30B	0.65	8.41	0.46	2.59e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs4563143	0.675	rs73025085	chr19:29247018	C/A	cg12756686	chr19:29218302	NA	0.58	7.52	0.42	8.38e-13	Methadone dose in opioid dependence;
CESC	cis	rs9814567	1.000	rs13096604	chr3:134250099	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.45	6.08	0.35	4.21e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs62344088	0.744	rs76038312	chr5:229005	A/G	cg22496380	chr5:211416	CCDC127	-0.9	-5.46	-0.32	1.12e-7	Asthma (childhood onset);
CESC	cis	rs7909074	0.898	rs10793565	chr10:45388231	G/C	cg04218760	chr10:45406644	TMEM72	-0.3	-5.05	-0.3	8.19e-7	Mean corpuscular volume;
CESC	cis	rs892961	0.932	rs7208671	chr17:75413129	T/C	cg05865280	chr17:75406074	SEPT9	0.62	12.67	0.61	4.57e-29	Airflow obstruction;
CESC	cis	rs208520	0.526	rs9363522	chr6:66816642	C/T	cg07460842	chr6:66804631	NA	-1.09	-26.19	-0.85	1.77e-75	Exhaled nitric oxide output;
CESC	trans	rs60843830	0.964	rs17713568	chr2:242132	G/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.67	8.4	0.46	2.72e-15	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs8062405	0.679	rs72793818	chr16:28893137	G/A	cg08761264	chr16:28874980	SH2B1	-0.46	-5.79	-0.34	1.98e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs897984	0.762	rs12930545	chr16:30938811	A/G	cg00531865	chr16:30841666	NA	0.51	7.12	0.4	1.01e-11	Dementia with Lewy bodies;
CESC	cis	rs2439831	0.681	rs825740	chr15:43592408	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.91	10.62	0.55	3.44e-22	Lung cancer in ever smokers;
CESC	cis	rs2839186	0.739	rs2280958	chr21:47642016	C/T	cg13012494	chr21:47604986	C21orf56	0.44	5.86	0.34	1.38e-8	Testicular germ cell tumor;
CESC	cis	rs763121	0.853	rs35522482	chr22:39063015	C/A	cg06544989	chr22:39130855	UNC84B	0.48	8.4	0.46	2.69e-15	Menopause (age at onset);
CESC	cis	rs2204008	0.837	rs73112346	chr12:38357606	C/T	cg13010199	chr12:38710504	ALG10B	0.53	6.62	0.38	2.03e-10	Bladder cancer;
CESC	cis	rs2236918	0.622	rs1776177	chr1:242012149	C/T	cg17736920	chr1:242011382	EXO1	0.52	6.67	0.38	1.49e-10	Menopause (age at onset);
CESC	cis	rs2735413	0.711	rs12921476	chr16:78079846	G/C	cg04733911	chr16:78082701	NA	-0.52	-8.51	-0.46	1.27e-15	Systolic blood pressure (alcohol consumption interaction);
CESC	cis	rs7412746	0.658	rs11581757	chr1:150892244	A/G	cg22823121	chr1:150693482	HORMAD1	0.39	5.46	0.32	1.11e-7	Melanoma;
CESC	cis	rs853679	0.517	rs9380059	chr6:28132358	A/C	cg23161317	chr6:28129485	ZNF389	0.52	6.48	0.37	4.37e-10	Depression;
CESC	cis	rs5753618	0.504	rs9609329	chr22:31966313	A/C	cg00478049	chr22:31556069	RNF185	-0.48	-5.72	-0.33	2.91e-8	Colorectal cancer;
CESC	cis	rs1545257	0.537	rs2339948	chr2:24641012	A/T	cg06627628	chr2:24431161	ITSN2	-0.48	-5.82	-0.34	1.67e-8	Sjögren's syndrome;
CESC	cis	rs2486288	0.656	rs8039540	chr15:45551842	C/G	cg21132104	chr15:45694354	SPATA5L1	-0.54	-6.55	-0.37	3.03e-10	Glomerular filtration rate;
CESC	cis	rs10089	1.000	rs1559263	chr5:127512873	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.72	9.43	0.5	2.16e-18	Ileal carcinoids;
CESC	trans	rs9329221	0.683	rs658385	chr8:9892177	C/T	cg15556689	chr8:8085844	FLJ10661	-0.58	-7.59	-0.42	5.61e-13	Neuroticism;
CESC	cis	rs9322193	0.926	rs2342860	chr6:150098777	T/C	cg05861140	chr6:150128134	PCMT1	-0.36	-5.16	-0.3	4.89e-7	Lung cancer;
CESC	cis	rs76419734	0.510	rs17036102	chr4:106603098	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	-0.71	-9.14	-0.49	1.71e-17	Post bronchodilator FEV1;
CESC	cis	rs72772090	0.539	rs11739020	chr5:96113838	C/T	cg17330273	chr5:96107758	CAST;ERAP1	0.62	5.54	0.32	7.4e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs9611565	0.568	rs2413656	chr22:42129357	G/T	cg06481639	chr22:41940642	POLR3H	0.48	5.62	0.33	4.86e-8	Vitiligo;
CESC	trans	rs16850073	0.689	rs9998340	chr4:74657255	A/G	cg13990905	chr1:179846837	TOR1AIP2	0.44	6.19	0.36	2.28e-9	Granulocyte percentage of myeloid white cells;Blood protein levels;Monocyte percentage of white cells;Sum neutrophil eosinophil counts;White blood cell count;
CESC	cis	rs7671266	0.628	rs11734783	chr4:10240663	C/T	cg00071950	chr4:10020882	SLC2A9	0.47	5.17	0.3	4.66e-7	Cardiovascular disease risk factors;
CESC	cis	rs4604732	0.631	rs74154676	chr1:247625894	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.57	7.17	0.4	7.39e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs2276314	0.857	rs72883058	chr18:33612917	G/A	cg19628046	chr18:33552617	C18orf21	0.51	5.79	0.33	2.04e-8	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs7772486	0.790	rs7753092	chr6:146248863	C/T	cg05347473	chr6:146136440	FBXO30	-0.55	-7.03	-0.4	1.78e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs12579753	0.917	rs7138651	chr12:82253615	A/G	cg23701643	chr12:82153290	PPFIA2	0.35	5.19	0.3	4.15e-7	Resting heart rate;
CESC	cis	rs11723261	0.564	rs61792258	chr4:137264	G/A	cg12746427	chr4:53362	ZNF718;ZNF595	0.43	5.1	0.3	6.37e-7	Immune response to smallpox vaccine (IL-6);
CESC	cis	rs9640161	0.789	rs34311995	chr7:150059255	T/C	cg10018233	chr7:150070692	REPIN1	0.38	5.88	0.34	1.25e-8	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs1008375	0.966	rs4698636	chr4:17632834	T/C	cg16339924	chr4:17578868	LAP3	0.57	7.1	0.4	1.17e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs34172651	0.517	rs11639856	chr16:24788645	A/T	cg00339695	chr16:24857497	SLC5A11	-0.45	-5.97	-0.34	7.41e-9	Intelligence (multi-trait analysis);
CESC	cis	rs7998202	0.667	rs282586	chr13:113351474	T/C	cg02820901	chr13:113351484	ATP11A	0.67	5.77	0.33	2.17e-8	Glycated hemoglobin levels;
CESC	cis	rs9788682	1.000	rs7164594	chr15:78803057	C/T	cg06917634	chr15:78832804	PSMA4	-0.55	-6.27	-0.36	1.47e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs67311347	1.000	rs7612015	chr3:40399974	A/C	cg01475735	chr3:40494733	NA	-0.41	-5.27	-0.31	2.87e-7	Renal cell carcinoma;
CESC	cis	rs7618915	0.571	rs6798246	chr3:52599922	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	6.78	0.38	7.94e-11	Bipolar disorder;
CESC	cis	rs4919087	0.892	rs10882881	chr10:99010067	T/A	cg25902810	chr10:99078978	FRAT1	0.66	9.39	0.5	2.88e-18	Monocyte count;
CESC	cis	rs4835473	0.900	rs35906127	chr4:144655553	G/C	cg25736465	chr4:144833511	NA	-0.33	-5.15	-0.3	5.14e-7	Immature fraction of reticulocytes;
CESC	cis	rs7635838	0.927	rs13082150	chr3:11437813	T/C	cg00170343	chr3:11313890	ATG7	0.41	5.39	0.31	1.52e-7	HDL cholesterol;
CESC	cis	rs12586317	0.620	rs12588810	chr14:35554484	C/T	cg16230307	chr14:35515116	FAM177A1	0.94	9.93	0.52	5.75e-20	Psoriasis;
CESC	cis	rs977987	0.843	rs10431974	chr16:75435461	A/G	cg03315344	chr16:75512273	CHST6	0.4	5.67	0.33	3.74e-8	Dupuytren's disease;
CESC	cis	rs11587400	0.614	rs2878745	chr1:115078547	T/C	cg12756093	chr1:115239321	AMPD1	0.37	5.08	0.3	7.3e-7	Autism;
CESC	cis	rs9834373	0.769	rs9856198	chr3:78496305	A/G	cg06138941	chr3:78371609	NA	-0.41	-5.12	-0.3	5.98e-7	Protein quantitative trait loci;
CESC	cis	rs6752107	0.967	rs56049444	chr2:234157688	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.43	5.92	0.34	1.02e-8	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs4835473	0.932	rs10033382	chr4:144888256	A/G	cg25736465	chr4:144833511	NA	0.41	6.27	0.36	1.43e-9	Immature fraction of reticulocytes;
CESC	trans	rs1973993	0.967	rs1555543	chr1:96944797	A/C	cg10631902	chr5:14652156	NA	0.53	7.39	0.41	1.89e-12	Weight;
CESC	cis	rs853679	0.517	rs4713144	chr6:28106790	C/G	cg22143856	chr6:28129313	ZNF389	0.52	6.77	0.38	8.31e-11	Depression;
CESC	cis	rs7827545	1.000	rs6578237	chr8:135569358	C/G	cg17885191	chr8:135476712	NA	-0.41	-5.76	-0.33	2.34e-8	Hypertension (SNP x SNP interaction);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg14597223	chr7:56119231	PSPH;CCT6A	-0.52	-7.19	-0.4	6.62e-12	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs3760982	0.585	rs11673490	chr19:44298885	C/A	cg11993925	chr19:44307056	LYPD5	0.34	5.85	0.34	1.45e-8	Breast cancer (estrogen-receptor negative);Breast cancer;
CESC	cis	rs3820068	0.608	rs11544523	chr1:15904318	C/T	cg18192808	chr1:15853278	DNAJC16	0.44	5.21	0.3	3.82e-7	Systolic blood pressure;
CESC	cis	rs6088580	0.634	rs6058051	chr20:33044862	G/A	cg06115741	chr20:33292138	TP53INP2	0.47	6.08	0.35	4.22e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs2180341	1.000	rs6569479	chr6:127606588	A/G	cg24812749	chr6:127587940	RNF146	1.06	15.34	0.69	1.95e-38	Breast cancer;
CESC	cis	rs6032067	0.777	rs2868234	chr20:43794026	C/T	cg10761708	chr20:43804764	PI3	0.56	6.55	0.37	3.01e-10	Blood protein levels;
CESC	cis	rs4970988	0.556	rs6695123	chr1:150563483	T/C	cg18016565	chr1:150552671	MCL1	-0.35	-5.15	-0.3	5.01e-7	Urate levels;
CESC	trans	rs11098499	0.909	rs35165976	chr4:120325630	G/A	cg25214090	chr10:38739885	LOC399744	0.7	9.92	0.52	6.5e-20	Corneal astigmatism;
CESC	cis	rs2276314	0.947	rs3898595	chr18:33565885	T/A	cg05985134	chr18:33552581	C18orf21	0.64	7.43	0.42	1.5e-12	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs9815354	0.951	rs1617271	chr3:41914000	G/T	cg03022575	chr3:42003672	ULK4	0.44	5.16	0.3	4.85e-7	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs8141529	0.509	rs5762863	chr22:29253335	A/C	cg02153584	chr22:29168773	CCDC117	0.6	8.06	0.44	2.66e-14	Lymphocyte counts;
CESC	cis	rs9790314	1.000	rs336543	chr3:161061080	C/T	cg03342759	chr3:160939853	NMD3	0.46	6.0	0.35	6.31e-9	Morning vs. evening chronotype;
CESC	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.44	-5.84	-0.34	1.5e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs11696845	0.626	rs4810439	chr20:43377870	C/G	cg25301532	chr20:43378953	KCNK15	-0.35	-5.67	-0.33	3.82e-8	Obesity-related traits;
CESC	cis	rs2303745	0.589	rs6512182	chr19:17399476	G/T	cg04248312	chr19:17393744	ANKLE1	-0.92	-14.85	-0.67	1.01e-36	Systemic lupus erythematosus;
CESC	cis	rs709400	0.894	rs61996721	chr14:104061352	G/A	cg12935359	chr14:103987150	CKB	-0.49	-6.42	-0.37	6.23e-10	Body mass index;
CESC	cis	rs7552404	0.924	rs7546641	chr1:76158035	T/C	cg10523679	chr1:76189770	ACADM	0.76	9.99	0.52	3.63e-20	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs7660520	0.557	rs76004373	chr4:183731011	C/G	cg03209412	chr4:183728196	NA	0.59	5.26	0.31	3.05e-7	Pediatric autoimmune diseases;
CESC	cis	rs727563	0.552	rs4822045	chr22:41985958	C/A	cg06634786	chr22:41940651	POLR3H	-0.67	-6.46	-0.37	4.85e-10	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs909674	0.734	rs5757675	chr22:39838892	G/T	cg01416388	chr22:39784598	NA	-0.59	-7.53	-0.42	8.07e-13	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs875971	0.862	rs7783779	chr7:65796626	A/G	cg19163074	chr7:65112434	INTS4L2	0.42	5.3	0.31	2.46e-7	Aortic root size;
CESC	cis	rs72781680	1.000	rs12620594	chr2:24194490	G/A	cg20701182	chr2:24300061	SF3B14	0.64	5.74	0.33	2.56e-8	Lymphocyte counts;
CESC	cis	rs478304	0.651	rs11532071	chr11:65500198	C/A	cg27068330	chr11:65405492	SIPA1	-0.45	-5.46	-0.32	1.08e-7	Acne (severe);
CESC	trans	rs2727020	0.521	rs7101761	chr11:49598178	G/A	cg15704280	chr7:45808275	SEPT13	-0.86	-9.72	-0.51	2.72e-19	Coronary artery disease;
CESC	cis	rs7116495	1.000	rs73543633	chr11:71828844	T/C	cg26138937	chr11:71823887	C11orf51	0.8	6.42	0.37	6.17e-10	Severe influenza A (H1N1) infection;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14491479	chr8:144623711	ZC3H3	0.58	7.1	0.4	1.17e-11	Gut microbiome composition (summer);
CESC	cis	rs10504073	0.584	rs7823690	chr8:49943831	G/A	cg00325661	chr8:49890786	NA	0.56	8.53	0.46	1.16e-15	Blood metabolite ratios;
CESC	cis	rs7914558	0.901	rs35525740	chr10:104941112	A/T	cg15744005	chr10:104629667	AS3MT	-0.31	-5.04	-0.3	8.72e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs12900413	0.959	rs12908026	chr15:90318884	C/T	cg24249390	chr15:90295951	MESP1	-0.41	-5.3	-0.31	2.39e-7	Coronary artery aneurysm in Kawasaki disease;
CESC	cis	rs763121	0.853	rs3761454	chr22:39066820	C/T	cg06544989	chr22:39130855	UNC84B	0.49	8.54	0.46	1.06e-15	Menopause (age at onset);
CESC	cis	rs56346965	0.506	rs2159818	chr2:191532789	A/G	cg27211696	chr2:191398769	TMEM194B	-0.43	-5.49	-0.32	9.55e-8	Bone mineral density (Ward's triangle area);
CESC	cis	rs514406	0.929	rs12354395	chr1:53327663	A/G	cg08859206	chr1:53392774	SCP2	-0.64	-8.54	-0.46	1.04e-15	Monocyte count;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg12066592	chr14:34931026	C14orf147	-0.41	-6.1	-0.35	3.82e-9	Gambling;
CESC	cis	rs4919087	0.810	rs1572437	chr10:99029278	A/G	cg25902810	chr10:99078978	FRAT1	0.66	9.22	0.49	9.48e-18	Monocyte count;
CESC	cis	rs9911578	1.000	rs2079703	chr17:56603978	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	-0.39	-5.16	-0.3	4.83e-7	Intelligence (multi-trait analysis);
CESC	cis	rs6430585	0.646	rs12476116	chr2:136497199	A/G	cg07169764	chr2:136633963	MCM6	1.37	16.25	0.71	1.09e-41	Corneal structure;
CESC	cis	rs3760982	0.546	rs73048681	chr19:44289945	T/C	cg11993925	chr19:44307056	LYPD5	0.47	8.09	0.44	2.19e-14	Breast cancer (estrogen-receptor negative);Breast cancer;
CESC	cis	rs2243480	1.000	rs4718270	chr7:65202407	A/G	cg13147721	chr7:65941812	NA	-0.88	-8.11	-0.45	1.87e-14	Diabetic kidney disease;
CESC	cis	rs875971	1.000	rs1182882	chr7:65562063	C/T	cg10691866	chr7:65817282	TPST1	0.33	5.23	0.31	3.45e-7	Aortic root size;
CESC	cis	rs7894051	1.000	rs7894051	chr10:135184421	C/G	cg24905316	chr10:135186343	ECHS1	-0.68	-6.89	-0.39	4.11e-11	Lifespan;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg21364231	chr7:152161058	LOC100128822	-0.47	-6.13	-0.35	3.23e-9	Fibrinogen levels;
CESC	cis	rs12824058	0.831	rs12297939	chr12:130811923	G/C	cg26677194	chr12:130822605	PIWIL1	0.52	6.81	0.39	6.58e-11	Menopause (age at onset);
CESC	cis	rs67311347	1.000	rs6762997	chr3:40478151	C/T	cg01475735	chr3:40494733	NA	-0.41	-5.33	-0.31	2.08e-7	Renal cell carcinoma;
CESC	cis	rs4474465	0.850	rs4945289	chr11:78245334	G/T	cg27205649	chr11:78285834	NARS2	0.43	5.41	0.32	1.41e-7	Alzheimer's disease (survival time);
CESC	cis	rs4891159	0.548	rs609487	chr18:74134382	C/G	cg24786174	chr18:74118243	ZNF516	-0.82	-15.51	-0.69	4.65e-39	Longevity;
CESC	cis	rs4665809	1.000	rs6750681	chr2:26329677	C/T	cg27170947	chr2:26402098	FAM59B	-0.58	-6.85	-0.39	5.18e-11	Gut microbiome composition (summer);
CESC	cis	rs4642101	0.618	rs7612317	chr3:12820558	C/T	cg05775895	chr3:12838266	CAND2	0.41	6.36	0.36	8.94e-10	QRS complex (12-leadsum);
CESC	cis	rs782590	0.557	rs7592219	chr2:55887176	T/C	cg18811423	chr2:55921094	PNPT1	-0.6	-8.04	-0.44	3.03e-14	Metabolic syndrome;
CESC	cis	rs9649213	0.593	rs2240349	chr7:97984663	C/T	cg24562669	chr7:97807699	LMTK2	0.51	7.63	0.42	4.29e-13	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs11583043	0.957	rs6577223	chr1:101499750	G/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.52	5.57	0.32	6.2e-8	Ulcerative colitis;Inflammatory bowel disease;
CESC	cis	rs12497850	0.864	rs4513485	chr3:49139966	G/A	cg02487422	chr3:49467188	NICN1	0.45	5.68	0.33	3.57e-8	Parkinson's disease;
CESC	cis	rs10504229	1.000	rs73609747	chr8:58189104	G/C	cg14926445	chr8:58193284	C8orf71	-0.51	-5.52	-0.32	8.28e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs875971	0.862	rs801194	chr7:66028495	T/C	cg12463550	chr7:65579703	CRCP	-0.5	-6.34	-0.36	9.71e-10	Aortic root size;
CESC	trans	rs853679	0.546	rs200948	chr6:27835272	T/C	cg06606381	chr12:133084897	FBRSL1	-0.83	-7.8	-0.43	1.44e-13	Depression;
CESC	cis	rs61008539	0.815	rs6960062	chr7:884665	A/G	cg00475322	chr7:917719	C7orf20	0.59	9.15	0.49	1.52e-17	Perceived unattractiveness to mosquitoes;
CESC	cis	rs34421088	0.564	rs6983129	chr8:11591136	A/C	cg12395012	chr8:11607386	GATA4	-0.4	-6.12	-0.35	3.29e-9	Neuroticism;
CESC	cis	rs56804039	1.000	rs6986470	chr8:8381430	A/G	cg15556689	chr8:8085844	FLJ10661	-0.49	-5.28	-0.31	2.66e-7	Cervical cancer;
CESC	cis	rs853679	0.517	rs9468298	chr6:28122345	A/G	cg08968635	chr6:28129556	ZNF389	0.4	5.22	0.31	3.57e-7	Depression;
CESC	trans	rs11039798	0.528	rs10769559	chr11:49032446	T/C	cg03929089	chr4:120376271	NA	0.61	6.36	0.36	9.02e-10	Axial length;
CESC	cis	rs9486715	0.867	rs7451950	chr6:96879974	T/C	cg06623918	chr6:96969491	KIAA0776	0.91	14.05	0.65	6.83e-34	Headache;
CESC	cis	rs6951245	0.608	rs10252234	chr7:1114381	C/T	cg24642844	chr7:1081250	C7orf50	-0.44	-5.88	-0.34	1.22e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs4713118	0.621	rs9295756	chr6:28033396	G/T	cg23281280	chr6:28129359	ZNF389	0.52	6.86	0.39	4.93e-11	Parkinson's disease;
CESC	cis	rs6912958	0.559	rs451465	chr6:88043372	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.45	-7.86	-0.43	9.48e-14	Monocyte percentage of white cells;
CESC	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg24846343	chr22:24311635	DDTL	0.62	10.38	0.54	2.11e-21	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs2070488	0.896	rs11914389	chr3:38527215	T/C	cg24069376	chr3:38537580	EXOG	0.48	8.61	0.47	6.72e-16	Electrocardiographic conduction measures;
CESC	cis	rs3096299	0.874	rs3102342	chr16:89451575	T/C	cg08392591	chr16:89556376	ANKRD11	0.4	5.09	0.3	6.77e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs662064	0.963	rs636291	chr1:10556097	G/A	cg07384165	chr1:10488281	NA	-0.42	-5.48	-0.32	9.81e-8	Asthma;
CESC	cis	rs6831352	0.918	rs34071486	chr4:100051087	A/G	cg13256891	chr4:100009986	ADH5	-0.77	-8.43	-0.46	2.27e-15	Alcohol dependence;
CESC	cis	rs919433	0.963	rs12618612	chr2:198171058	G/T	cg03934865	chr2:198174659	NA	-0.41	-5.46	-0.32	1.11e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs9733	0.596	rs6678013	chr1:150623285	T/G	cg17724175	chr1:150552817	MCL1	0.44	7.21	0.41	5.75e-12	Tonsillectomy;
CESC	cis	rs9611565	0.512	rs6002474	chr22:42168181	A/G	cg03806693	chr22:41940476	POLR3H	1.18	13.88	0.65	2.76e-33	Vitiligo;
CESC	cis	rs208520	0.674	rs207103	chr6:66795568	G/T	cg07460842	chr6:66804631	NA	-1.0	-13.33	-0.63	2.21e-31	Exhaled nitric oxide output;
CESC	cis	rs1448094	0.512	rs10779216	chr12:86240315	A/G	cg02569458	chr12:86230093	RASSF9	-0.49	-7.4	-0.41	1.79e-12	Major depressive disorder;
CESC	cis	rs3096299	0.967	rs11648663	chr16:89466307	C/T	cg16743903	chr16:89593216	SPG7	-0.4	-5.11	-0.3	6.25e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs9322193	0.886	rs9485408	chr6:149940024	T/C	cg13206674	chr6:150067644	NUP43	0.43	6.27	0.36	1.44e-9	Lung cancer;
CESC	cis	rs4727027	0.933	rs10238826	chr7:148830888	A/G	cg23583168	chr7:148888333	NA	-0.73	-10.82	-0.55	7.76e-23	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs9894429	0.646	rs9904137	chr17:79613925	C/T	cg13777783	chr17:79615861	NA	-0.36	-6.04	-0.35	5.09e-9	Eye color traits;
CESC	cis	rs7666738	0.830	rs34135615	chr4:99001325	C/T	cg03467027	chr4:99064603	C4orf37	0.44	5.51	0.32	8.65e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs66573146	0.808	rs73202120	chr4:7005588	A/G	cg00086871	chr4:6988644	TBC1D14	0.98	7.65	0.43	3.79e-13	Granulocyte percentage of myeloid white cells;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01413268	chr19:51602462	CTU1	-0.49	-6.6	-0.38	2.28e-10	Gut microbiome composition (summer);
CESC	cis	rs17401966	0.838	rs2105212	chr1:10281012	T/C	cg15208524	chr1:10270712	KIF1B	0.39	5.14	0.3	5.23e-7	Hepatocellular carcinoma;
CESC	cis	rs7666738	0.830	rs7664051	chr4:98766970	C/G	cg17366294	chr4:99064904	C4orf37	0.57	7.91	0.44	6.78e-14	Colonoscopy-negative controls vs population controls;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg00776160	chr1:149815087	HIST2H2AA3;HIST2H2AA4	-0.44	-6.34	-0.36	9.62e-10	Gambling;
CESC	cis	rs1218582	0.774	rs4845680	chr1:154863195	A/G	cg09359103	chr1:154839909	KCNN3	-0.65	-12.4	-0.61	3.83e-28	Prostate cancer;
CESC	cis	rs9611565	0.500	rs2011053	chr22:42121278	G/A	cg06634786	chr22:41940651	POLR3H	0.45	5.04	0.3	8.76e-7	Vitiligo;
CESC	cis	rs7188697	0.922	rs2090727	chr16:58604161	A/G	cg21335942	chr16:58549945	SETD6	-0.45	-5.2	-0.3	4.06e-7	QT interval;
CESC	cis	rs3741151	0.686	rs2298469	chr11:73133030	T/C	cg17517138	chr11:73019481	ARHGEF17	0.65	5.56	0.32	6.5e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs7618915	0.547	rs11720432	chr3:52672742	T/C	cg17372223	chr3:52568218	NT5DC2	0.43	6.45	0.37	5.37e-10	Bipolar disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18151858	chr13:21635991	LATS2	-0.53	-6.32	-0.36	1.1e-9	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.576	rs7660951	chr4:98651581	T/A	cg17366294	chr4:99064904	C4orf37	0.52	6.43	0.37	6.02e-10	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10504229	1.000	rs116995796	chr8:58181960	G/A	cg24829409	chr8:58192753	C8orf71	-0.76	-9.93	-0.52	5.87e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs735396	1.000	rs2464195	chr12:121435475	G/A	cg02403541	chr12:121454288	C12orf43	0.63	9.13	0.49	1.82e-17	N-glycan levels;
CESC	cis	rs25645	0.744	rs66826786	chr17:38206092	T/C	cg17467752	chr17:38218738	THRA	-0.53	-6.73	-0.38	1.06e-10	Myeloid white cell count;
CESC	cis	rs798554	0.836	rs2260230	chr7:2822986	T/A	cg04166393	chr7:2884313	GNA12	0.57	7.16	0.4	7.92e-12	Height;
CESC	cis	rs3785574	0.962	rs2584614	chr17:61929445	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.58	7.25	0.41	4.5e-12	Height;
CESC	cis	rs8103278	1.000	rs35302007	chr19:46219145	G/C	cg12641515	chr19:46296257	DMWD	-0.49	-5.63	-0.33	4.69e-8	Coronary artery disease;
CESC	cis	rs1005277	0.579	rs1740735	chr10:38497777	A/C	cg00409905	chr10:38381863	ZNF37A	-0.5	-6.75	-0.38	9.28e-11	Extrinsic epigenetic age acceleration;
CESC	cis	rs13191362	1.000	rs66529337	chr6:163005662	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.49	5.36	0.31	1.82e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg23131131	chr22:24373011	LOC391322	-0.66	-8.91	-0.48	8.58e-17	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs7945705	0.846	rs2742540	chr11:8899528	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.42	6.8	0.39	7.05e-11	Hemoglobin concentration;
CESC	cis	rs1552244	0.752	rs9867091	chr3:10043429	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.76	-9.69	-0.51	3.35e-19	Alzheimer's disease;
CESC	trans	rs1814175	0.587	rs7937757	chr11:49978342	G/A	cg15704280	chr7:45808275	SEPT13	-1.01	-19.02	-0.76	1.83e-51	Height;
CESC	cis	rs12497850	0.931	rs3774628	chr3:48801840	C/T	cg06212747	chr3:49208901	KLHDC8B	0.65	8.94	0.48	6.96e-17	Parkinson's disease;
CESC	cis	rs8062405	0.755	rs111693583	chr16:28583610	C/T	cg01378222	chr16:28622494	SULT1A1	0.32	5.34	0.31	1.98e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs6963495	0.769	rs73192134	chr7:105189338	T/C	cg13798780	chr7:105162888	PUS7	0.77	7.85	0.43	1.02e-13	Bipolar disorder (body mass index interaction);
CESC	cis	rs7666738	0.723	rs35327100	chr4:98977788	C/A	cg05340658	chr4:99064831	C4orf37	0.79	12.26	0.6	1.12e-27	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4919087	0.962	rs10786324	chr10:99054387	A/G	cg25902810	chr10:99078978	FRAT1	0.71	10.4	0.54	1.79e-21	Monocyte count;
CESC	cis	rs35306767	0.855	rs11253465	chr10:897208	A/C	cg26597838	chr10:835615	NA	0.83	8.8	0.48	1.8e-16	Eosinophil percentage of granulocytes;
CESC	cis	rs796364	0.806	rs77853713	chr2:201006880	A/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.75	-6.83	-0.39	5.71e-11	Schizophrenia;
CESC	cis	rs4704187	0.687	rs1422696	chr5:74464415	T/C	cg03227963	chr5:74354835	NA	0.29	5.2	0.3	3.9e-7	Response to amphetamines;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08021833	chr19:5785663	PRR22;DUS3L	-0.59	-6.54	-0.37	3.19e-10	Gut microbiome composition (summer);
CESC	trans	rs2018683	0.707	rs917216	chr7:28971472	A/G	cg19402173	chr7:128379420	CALU	-0.53	-7.04	-0.4	1.63e-11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CESC	cis	rs7512552	0.839	rs1627235	chr1:150358858	C/T	cg15654264	chr1:150340011	RPRD2	0.39	5.17	0.3	4.68e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs3785574	0.925	rs2727340	chr17:61970224	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.58	7.15	0.4	8.66e-12	Height;
CESC	cis	rs7246657	0.943	rs7252325	chr19:37930645	A/G	cg23950597	chr19:37808831	NA	-0.55	-6.12	-0.35	3.28e-9	Coronary artery calcification;
CESC	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	21.96	0.8	1.36e-61	Prudent dietary pattern;
CESC	cis	rs17711722	0.701	rs4467826	chr7:65368708	A/G	cg05332525	chr7:65337924	VKORC1L1	0.51	6.32	0.36	1.09e-9	Calcium levels;
CESC	cis	rs597539	0.652	rs559032	chr11:68710847	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.78	10.36	0.54	2.36e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs3749237	0.595	rs12489092	chr3:49550914	G/C	cg06212747	chr3:49208901	KLHDC8B	0.49	6.61	0.38	2.15e-10	Resting heart rate;
CESC	cis	rs4925325	0.876	rs6089560	chr20:60517325	T/G	cg06108461	chr20:60628389	TAF4	-0.5	-5.96	-0.34	7.84e-9	Obesity-related traits;
CESC	cis	rs7666738	0.830	rs4443295	chr4:99044935	G/A	cg05340658	chr4:99064831	C4orf37	0.8	12.39	0.61	3.91e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11203032	1.000	rs17117126	chr10:90964026	A/G	cg16672925	chr10:90967113	CH25H	0.74	7.14	0.4	8.86e-12	Heart failure;
CESC	cis	rs9457247	0.935	rs2149093	chr6:167373045	T/C	cg23791538	chr6:167370224	RNASET2	0.57	8.19	0.45	1.13e-14	Crohn's disease;
CESC	cis	rs4713118	0.662	rs149946	chr6:27970031	A/C	cg17949981	chr6:28129498	ZNF389	-0.42	-5.16	-0.3	4.85e-7	Parkinson's disease;
CESC	cis	rs2370759	1.000	rs11599044	chr10:32615445	A/G	cg18270830	chr10:32634957	EPC1	0.7	6.77	0.38	8.3e-11	Sexual dysfunction (female);
CESC	cis	rs9443645	0.901	rs4565265	chr6:79741958	A/G	cg05283184	chr6:79620031	NA	-0.43	-6.62	-0.38	1.97e-10	Intelligence (multi-trait analysis);
CESC	cis	rs17023223	0.509	rs56195272	chr1:119713997	A/T	cg05756136	chr1:119680316	WARS2	-0.47	-5.69	-0.33	3.34e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CESC	cis	rs9929218	0.608	rs35158985	chr16:68796746	A/G	cg02972257	chr16:68554789	NA	0.46	5.79	0.34	1.98e-8	Colorectal cancer;
CESC	cis	rs873946	0.648	rs3793673	chr10:134547732	A/C	cg06453172	chr10:134556979	INPP5A	-0.43	-5.68	-0.33	3.47e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs7264396	0.563	rs6060560	chr20:34278890	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.6	5.87	0.34	1.33e-8	Total cholesterol levels;
CESC	cis	rs67311347	1.000	rs9834052	chr3:40399060	G/A	cg01475735	chr3:40494733	NA	-0.41	-5.27	-0.31	2.87e-7	Renal cell carcinoma;
CESC	cis	rs12541335	0.639	rs7834182	chr8:22163112	G/A	cg27266060	chr8:22091797	NA	0.37	7.21	0.4	6.01e-12	Hypertriglyceridemia;
CESC	cis	rs3008870	0.792	rs72673729	chr1:67441673	T/TG	cg08660285	chr1:67390436	MIER1;WDR78	-1.02	-14.1	-0.65	4.75e-34	Lymphocyte percentage of white cells;
CESC	cis	rs2228479	0.867	rs76885005	chr16:89966668	A/G	cg04013166	chr16:89971882	TCF25	0.76	7.2	0.4	6.4e-12	Skin colour saturation;
CESC	cis	rs1538970	0.781	rs11211139	chr1:46015751	G/T	cg03146154	chr1:46216737	IPP	0.52	5.81	0.34	1.78e-8	Platelet count;
CESC	cis	rs7524258	0.868	rs7538921	chr1:7267007	T/C	cg07173049	chr1:7289937	CAMTA1	0.46	6.75	0.38	9.34e-11	Tourette's syndrome or obsessive-compulsive disorder;
CESC	cis	rs12541635	0.677	rs1006480	chr8:106975524	T/C	cg10147462	chr8:107024639	NA	0.43	6.28	0.36	1.42e-9	Age of smoking initiation;
CESC	cis	rs2180341	0.961	rs7774468	chr6:127592501	G/C	cg24812749	chr6:127587940	RNF146	1.06	15.28	0.68	3.03e-38	Breast cancer;
CESC	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg26338869	chr17:61819248	STRADA	0.69	9.11	0.49	2.04e-17	Prudent dietary pattern;
CESC	cis	rs7100689	0.646	rs1934693	chr10:82125650	T/C	cg00277334	chr10:82204260	NA	-0.58	-7.76	-0.43	1.84e-13	Post bronchodilator FEV1;
CESC	cis	rs2032447	0.869	rs2230655	chr6:26033506	A/G	cg02841227	chr6:26021843	HIST1H4A	-0.41	-5.15	-0.3	5.2e-7	Intelligence (multi-trait analysis);
CESC	cis	rs2302190	0.882	rs9903050	chr17:56636908	T/C	cg25885038	chr17:56607967	SEPT4	-0.4	-5.43	-0.32	1.27e-7	Vitamin D levels;
CESC	cis	rs7662987	1.000	rs7662987	chr4:99991642	T/C	cg13256891	chr4:100009986	ADH5	-0.83	-6.09	-0.35	3.92e-9	Smoking initiation;
CESC	cis	rs8180040	0.691	rs12489211	chr3:47221451	T/A	cg27129171	chr3:47204927	SETD2	0.69	10.44	0.54	1.33e-21	Colorectal cancer;
CESC	cis	rs2880765	0.714	rs6497187	chr15:86011350	A/G	cg10818794	chr15:86012489	AKAP13	-0.35	-5.41	-0.32	1.42e-7	Coronary artery disease;
CESC	cis	rs12478296	1.000	rs57603292	chr2:243028537	G/A	cg06360820	chr2:242988706	NA	-0.88	-8.78	-0.47	2.01e-16	Obesity-related traits;
CESC	cis	rs10504229	1.000	rs7007805	chr8:58179327	G/A	cg05313129	chr8:58192883	C8orf71	-0.55	-6.37	-0.36	8.42e-10	Developmental language disorder (linguistic errors);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10009930	chr1:9599403	SLC25A33	0.59	7.08	0.4	1.27e-11	Gut microbiome composition (summer);
CESC	cis	rs1552244	1.000	rs113522867	chr3:10154503	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.86	-11.97	-0.59	1.09e-26	Alzheimer's disease;
CESC	cis	rs10465746	0.967	rs4907191	chr1:84444165	A/G	cg10977910	chr1:84465055	TTLL7	-0.48	-6.61	-0.38	2.05e-10	Obesity-related traits;
CESC	cis	rs6121246	0.567	rs6120890	chr20:30207659	T/G	cg13852791	chr20:30311386	BCL2L1	0.66	6.6	0.38	2.23e-10	Mean corpuscular hemoglobin;
CESC	cis	rs10883723	0.738	rs3781290	chr10:104244948	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.53	7.44	0.42	1.39e-12	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs13102973	0.965	rs4629509	chr4:135872410	C/T	cg14419869	chr4:135874104	NA	-0.4	-6.29	-0.36	1.32e-9	Subjective well-being;
CESC	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	22.12	0.81	3.97e-62	Prudent dietary pattern;
CESC	cis	rs6121246	0.909	rs6087778	chr20:30354142	G/A	cg13852791	chr20:30311386	BCL2L1	0.81	8.61	0.47	6.48e-16	Mean corpuscular hemoglobin;
CESC	cis	rs568617	1.000	rs568617	chr11:65653242	C/T	cg04055107	chr11:65626734	MUS81;CFL1	0.69	7.43	0.42	1.47e-12	Crohn's disease;
CESC	cis	rs10751667	0.600	rs10751672	chr11:948712	T/C	cg20946044	chr11:1010712	AP2A2	-0.4	-5.52	-0.32	8.07e-8	Alzheimer's disease (late onset);
CESC	cis	rs6762	0.748	rs1130663	chr11:837582	G/A	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.68	-8.68	-0.47	3.97e-16	Mean platelet volume;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg21034903	chr2:172544336	DYNC1I2	0.41	6.49	0.37	4.18e-10	Gambling;
CESC	cis	rs2985684	0.846	rs11157693	chr14:50048426	T/C	cg10008539	chr14:50087325	RPL36AL;MGAT2	-0.43	-5.25	-0.31	3.09e-7	Carotid intima media thickness;
CESC	cis	rs10911251	0.546	rs2027084	chr1:183110801	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.84	13.1	0.63	1.49e-30	Colorectal cancer;
CESC	cis	rs7666738	0.830	rs17483521	chr4:98974058	A/T	cg17366294	chr4:99064904	C4orf37	0.58	8.34	0.46	4.23e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7833986	0.501	rs2668007	chr8:56944111	C/T	cg26371346	chr8:56986568	SNORD54;RPS20	0.63	5.54	0.32	7.33e-8	Height;
CESC	trans	rs634534	0.622	rs593525	chr11:65727799	T/C	cg17712092	chr4:129076599	LARP1B	0.62	8.36	0.46	3.66e-15	Sum eosinophil basophil counts;Eosinophil counts;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg17176517	chr3:125239027	SNX4	-0.48	-6.35	-0.36	9.14e-10	Ulcerative colitis;
CESC	cis	rs644799	0.622	rs1255167	chr11:95500213	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.59	7.99	0.44	4.21e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs4563143	0.675	rs56407818	chr19:29279379	G/A	cg14983838	chr19:29218262	NA	0.49	5.71	0.33	3e-8	Methadone dose in opioid dependence;
CESC	cis	rs11792861	0.816	rs7021366	chr9:111727670	C/G	cg13535736	chr9:111863775	C9orf5	-0.48	-6.31	-0.36	1.16e-9	Menarche (age at onset);
CESC	cis	rs7208859	0.623	rs216433	chr17:28921860	T/C	cg17105886	chr17:28927953	LRRC37B2	0.61	5.4	0.31	1.47e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs9300255	0.602	rs2510885	chr12:123614813	G/C	cg00376283	chr12:123451042	ABCB9	0.68	8.55	0.47	9.82e-16	Neutrophil percentage of white cells;
CESC	cis	rs853679	0.517	rs9368554	chr6:28082711	T/C	cg23161317	chr6:28129485	ZNF389	0.51	6.53	0.37	3.44e-10	Depression;
CESC	cis	rs3806843	0.868	rs2262574	chr5:140123635	G/T	cg26395211	chr5:140044315	WDR55	0.4	5.13	0.3	5.51e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs7659604	0.521	rs4240263	chr4:122683623	C/T	cg19671926	chr4:122722719	EXOSC9	0.62	7.93	0.44	6.28e-14	Type 2 diabetes;
CESC	cis	rs875971	0.825	rs59466412	chr7:65565358	A/G	cg19163074	chr7:65112434	INTS4L2	0.46	5.57	0.32	6.37e-8	Aortic root size;
CESC	cis	rs7116495	0.609	rs577435	chr11:71794681	C/T	cg26138937	chr11:71823887	C11orf51	-1.26	-7.96	-0.44	5.12e-14	Severe influenza A (H1N1) infection;
CESC	cis	rs4722585	0.533	rs6964215	chr7:26196819	G/A	cg07876897	chr7:26191696	NFE2L3	0.41	5.17	0.3	4.66e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
CESC	cis	rs7098414	0.511	rs4934126	chr10:82151598	A/G	cg00277334	chr10:82204260	NA	-0.5	-7.37	-0.41	2.23e-12	Post bronchodilator FEV1;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07343429	chr11:1785120	HCCA2;CTSD	0.56	6.32	0.36	1.08e-9	Gut microbiome composition (summer);
CESC	cis	rs3812762	0.917	rs905289	chr11:8753552	A/G	cg03980550	chr11:8754370	ST5	0.35	5.07	0.3	7.53e-7	Hypospadias;
CESC	cis	rs6502050	0.835	rs8073645	chr17:80110957	C/T	cg23985595	chr17:80112537	CCDC57	-0.42	-6.58	-0.37	2.43e-10	Life satisfaction;
CESC	cis	rs6580649	0.941	rs17122613	chr12:48460016	T/C	cg24011408	chr12:48396354	COL2A1	-0.41	-5.27	-0.31	2.86e-7	Lung cancer;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg08115172	chr1:1990868	PRKCZ	0.44	6.08	0.35	4.21e-9	Fibrinogen levels;
CESC	cis	rs3020736	0.500	rs6002605	chr22:42494335	A/G	cg04733989	chr22:42467013	NAGA	-0.83	-12.62	-0.61	6.45e-29	Autism spectrum disorder or schizophrenia;
CESC	cis	rs926392	0.572	rs6129159	chr20:37675011	A/T	cg16355469	chr20:37678765	NA	0.58	6.98	0.39	2.33e-11	Dialysis-related mortality;
CESC	cis	rs9611519	0.542	rs8139770	chr22:41416181	C/T	cg03806693	chr22:41940476	POLR3H	-0.5	-5.82	-0.34	1.69e-8	Neuroticism;
CESC	cis	rs1372520	0.684	rs2619347	chr4:90745770	G/A	cg15133208	chr4:90757351	SNCA	-0.4	-5.35	-0.31	1.87e-7	Neuroticism;
CESC	cis	rs4665809	0.590	rs3792007	chr2:26497541	C/T	cg08470875	chr2:26401718	FAM59B	0.7	7.01	0.4	2.02e-11	Gut microbiome composition (summer);
CESC	cis	rs6429082	0.608	rs4659836	chr1:235564412	G/A	cg26050004	chr1:235667680	B3GALNT2	-0.55	-6.94	-0.39	3e-11	Adiposity;
CESC	cis	rs736408	0.521	rs13074853	chr3:52779801	T/C	cg07507251	chr3:52567010	NT5DC2	0.33	5.62	0.33	4.71e-8	Bipolar disorder;
CESC	cis	rs10256972	0.685	rs10263665	chr7:1110628	A/G	cg07308232	chr7:1071921	C7orf50	-0.55	-7.65	-0.43	3.77e-13	Longevity;Endometriosis;
CESC	cis	rs10540	1.000	rs79440439	chr11:478147	A/C	cg03352830	chr11:487213	PTDSS2	0.77	7.6	0.42	5.08e-13	Body mass index;
CESC	cis	rs6500395	0.926	rs7192297	chr16:48670421	G/A	cg04672837	chr16:48644449	N4BP1	0.51	6.43	0.37	6.06e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs77106637	0.858	rs7109575	chr11:72463435	G/A	cg04827223	chr11:72435913	ARAP1	-0.57	-5.44	-0.32	1.19e-7	Type 2 diabetes;
CESC	cis	rs7216064	1.000	rs8079754	chr17:65887896	A/G	cg07042672	chr17:66097459	LOC651250	-0.5	-5.28	-0.31	2.68e-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs5763662	1.000	rs5753029	chr22:30557939	G/T	cg21388335	chr22:29999516	NF2	-0.74	-5.04	-0.3	8.8e-7	LDL cholesterol levels;LDL cholesterol;
CESC	cis	rs2243480	1.000	rs34560516	chr7:65404092	A/T	cg13147721	chr7:65941812	NA	-0.88	-8.15	-0.45	1.47e-14	Diabetic kidney disease;
CESC	cis	rs9303280	0.901	rs2305479	chr17:38062217	C/T	cg20243544	chr17:37824526	PNMT	0.54	7.29	0.41	3.53e-12	Self-reported allergy;
CESC	cis	rs9300255	0.602	rs1790116	chr12:123618544	G/T	cg19016782	chr12:123741754	C12orf65	-0.42	-5.93	-0.34	9.43e-9	Neutrophil percentage of white cells;
CESC	cis	rs7078219	0.543	rs4919342	chr10:101282553	G/C	cg09788492	chr10:101292477	NKX2-3	0.33	6.12	0.35	3.3e-9	Dental caries;
CESC	cis	rs4319547	0.695	rs6488958	chr12:122880704	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.55	-6.3	-0.36	1.22e-9	Body mass index;
CESC	cis	rs7116495	0.609	rs10793014	chr11:71698838	A/G	cg26138937	chr11:71823887	C11orf51	-1.26	-8.07	-0.44	2.43e-14	Severe influenza A (H1N1) infection;
CESC	cis	rs10899021	0.920	rs61901541	chr11:74317985	T/C	cg25880958	chr11:74394337	NA	-0.76	-7.95	-0.44	5.53e-14	Response to metformin (IC50);
CESC	cis	rs9916302	0.706	rs903507	chr17:37726423	A/G	cg20243544	chr17:37824526	PNMT	0.52	5.16	0.3	4.91e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs3105593	1.000	rs2899462	chr15:50939254	C/A	cg08437265	chr15:50716283	USP8	0.41	5.26	0.31	2.94e-7	QT interval;
CESC	trans	rs11039798	0.541	rs12283728	chr11:48796407	G/A	cg15704280	chr7:45808275	SEPT13	0.7	6.31	0.36	1.18e-9	Axial length;
CESC	cis	rs911555	0.723	rs6575991	chr14:103908433	C/T	cg12935359	chr14:103987150	CKB	0.65	9.56	0.51	8.31e-19	Intelligence (multi-trait analysis);
CESC	cis	rs875971	0.516	rs6945322	chr7:65336056	T/C	cg26939375	chr7:64535504	NA	0.76	10.86	0.55	5.77e-23	Aortic root size;
CESC	cis	rs892961	0.932	rs7207891	chr17:75413922	G/C	cg05865280	chr17:75406074	SEPT9	0.62	12.5	0.61	1.65e-28	Airflow obstruction;
CESC	cis	rs3096299	0.967	rs28575874	chr16:89469890	C/T	cg08392591	chr16:89556376	ANKRD11	0.41	5.32	0.31	2.2e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs1185460	0.967	rs1786685	chr11:118938957	G/A	cg01677386	chr11:118938358	VPS11	-0.43	-5.45	-0.32	1.14e-7	Coronary artery disease;
CESC	cis	rs3859192	0.599	rs2227319	chr17:38170845	G/A	cg17344932	chr17:38183730	MED24;SNORD124	0.63	9.36	0.5	3.67e-18	White blood cell count;
CESC	cis	rs9287719	0.967	rs10167129	chr2:10758575	G/A	cg00105475	chr2:10696890	NA	0.37	5.4	0.31	1.52e-7	Prostate cancer;
CESC	cis	rs7937682	0.632	rs12785809	chr11:111776055	T/A	cg22437258	chr11:111473054	SIK2	-0.5	-5.5	-0.32	8.78e-8	Primary sclerosing cholangitis;
CESC	cis	rs477692	0.647	rs11016853	chr10:131443990	A/G	cg05714579	chr10:131428358	MGMT	-0.6	-8.63	-0.47	5.73e-16	Response to temozolomide;
CESC	cis	rs4563143	0.663	rs2218396	chr19:29236392	C/T	cg12756686	chr19:29218302	NA	0.44	6.27	0.36	1.48e-9	Methadone dose in opioid dependence;
CESC	cis	rs11112613	0.775	rs12305225	chr12:105963266	G/C	cg03607813	chr12:105948248	NA	0.48	5.62	0.33	4.79e-8	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CESC	cis	rs7666738	0.861	rs5014702	chr4:99052102	C/A	cg18180107	chr4:99064573	C4orf37	0.41	5.23	0.31	3.5e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1448094	0.512	rs61930862	chr12:86246567	A/G	cg02569458	chr12:86230093	RASSF9	0.49	7.27	0.41	3.98e-12	Major depressive disorder;
CESC	cis	rs3858526	0.642	rs55732658	chr11:5894602	A/C	cg13902645	chr11:5959945	NA	-0.56	-6.72	-0.38	1.12e-10	DNA methylation (variation);
CESC	cis	rs6083	0.571	rs56010348	chr15:58848120	T/G	cg05156742	chr15:59063176	FAM63B	-0.71	-9.99	-0.52	3.75e-20	Schizophrenia;
CESC	trans	rs66573146	0.831	rs56320732	chr4:6974319	G/A	cg07817883	chr1:32538562	TMEM39B	1.25	8.46	0.46	1.88e-15	Granulocyte percentage of myeloid white cells;
CESC	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.74	6.69	0.38	1.36e-10	Platelet count;
CESC	cis	rs4604732	0.631	rs35046441	chr1:247626812	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.57	7.17	0.4	7.39e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs477692	1.000	rs485576	chr10:131425496	G/C	cg05714579	chr10:131428358	MGMT	0.53	7.22	0.41	5.66e-12	Response to temozolomide;
CESC	cis	rs7618915	0.501	rs62253740	chr3:52684128	A/T	cg18404041	chr3:52824283	ITIH1	-0.38	-6.51	-0.37	3.7e-10	Bipolar disorder;
CESC	cis	rs1413885	0.549	rs1334877	chr1:65846406	C/T	cg14976592	chr1:65886160	LEPROT;LEPR	0.46	6.14	0.35	3.05e-9	Anticoagulant levels;
CESC	cis	rs6088590	0.502	rs6059861	chr20:33068563	A/T	cg08999081	chr20:33150536	PIGU	0.66	11.81	0.59	3.83e-26	Coronary artery disease;
CESC	cis	rs6570726	0.935	rs421268	chr6:145845558	A/T	cg05347473	chr6:146136440	FBXO30	0.49	6.62	0.38	1.96e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9814567	1.000	rs3846055	chr3:134203973	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.46	-6.26	-0.36	1.54e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs34779708	0.966	rs12784482	chr10:35446865	A/G	cg04310649	chr10:35416472	CREM	-0.51	-6.18	-0.35	2.39e-9	Inflammatory bowel disease;Crohn's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23549086	chr19:8008681	TIMM44	0.57	6.52	0.37	3.47e-10	Gut microbiome composition (summer);
CESC	cis	rs9858542	0.953	rs9818590	chr3:49525096	A/G	cg07274523	chr3:49395745	GPX1	0.66	8.05	0.44	2.82e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs11785400	0.793	rs11785376	chr8:143730412	C/T	cg24634471	chr8:143751801	JRK	0.45	5.78	0.33	2.12e-8	Schizophrenia;
CESC	cis	rs7429990	0.813	rs7637622	chr3:48093051	G/A	cg11946769	chr3:48343235	NME6	-0.44	-5.37	-0.31	1.69e-7	Educational attainment (years of education);
CESC	cis	rs6762	0.692	rs7928925	chr11:839155	G/A	cg23754390	chr11:835074	CD151	0.31	5.34	0.31	2e-7	Mean platelet volume;
CESC	cis	rs4819052	0.851	rs58644915	chr21:46669912	T/C	cg11663144	chr21:46675770	NA	-0.63	-9.92	-0.52	6.25e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs2072732	0.821	rs12033401	chr1:2944086	C/T	cg15211996	chr1:2936768	ACTRT2	0.36	5.59	0.32	5.62e-8	Plateletcrit;
CESC	cis	rs2594989	1.000	rs2594967	chr3:11349748	T/G	cg00170343	chr3:11313890	ATG7	0.56	5.14	0.3	5.26e-7	Circulating chemerin levels;
CESC	cis	rs8141529	0.504	rs6005915	chr22:29233262	A/G	cg02153584	chr22:29168773	CCDC117	0.54	6.48	0.37	4.35e-10	Lymphocyte counts;
CESC	cis	rs59918340	0.764	rs10101692	chr8:142230823	C/T	cg23750338	chr8:142222470	SLC45A4	0.63	9.67	0.51	3.91e-19	Immature fraction of reticulocytes;
CESC	trans	rs7246657	0.943	rs4803460	chr19:37885228	T/C	cg24637308	chr11:6592297	DNHD1	0.53	6.08	0.35	4.15e-9	Coronary artery calcification;
CESC	cis	rs2878628	0.596	rs57039206	chr3:52758570	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	7.95	0.44	5.39e-14	Intelligence (multi-trait analysis);
CESC	cis	rs8078723	0.738	rs4065321	chr17:38143548	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.35	5.05	0.3	8.08e-7	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CESC	cis	rs997295	0.554	rs4261477	chr15:68073968	G/T	cg08079166	chr15:68083412	MAP2K5	0.39	6.23	0.36	1.84e-9	Motion sickness;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg07263984	chr5:115177777	ATG12;AP3S1	-0.52	-6.46	-0.37	4.91e-10	Asthma;
CESC	cis	rs2120019	0.935	rs8043181	chr15:75380424	T/C	cg09165964	chr15:75287851	SCAMP5	-0.68	-8.14	-0.45	1.5e-14	Blood trace element (Zn levels);
CESC	cis	rs875971	0.642	rs35526611	chr7:66094008	C/T	cg14393609	chr7:65229607	NA	-0.45	-5.95	-0.34	8.52e-9	Aortic root size;
CESC	cis	rs2439831	0.850	rs3742982	chr15:44176681	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.68	7.63	0.42	4.31e-13	Lung cancer in ever smokers;
CESC	cis	rs10504229	0.683	rs11784908	chr8:58131472	T/C	cg24829409	chr8:58192753	C8orf71	-0.58	-7.2	-0.4	6.31e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs4862750	0.872	rs4862747	chr4:187877236	A/T	cg06074448	chr4:187884817	NA	0.38	5.55	0.32	6.81e-8	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9322193	0.962	rs4869730	chr6:150129323	A/G	cg05861140	chr6:150128134	PCMT1	-0.37	-5.34	-0.31	2.02e-7	Lung cancer;
CESC	cis	rs6430585	0.583	rs9636213	chr2:136589278	G/A	cg07169764	chr2:136633963	MCM6	-1.15	-17.68	-0.74	9.35e-47	Corneal structure;
CESC	cis	rs35306767	0.903	rs11253462	chr10:889323	T/G	cg10556349	chr10:835070	NA	0.53	5.09	0.3	6.75e-7	Eosinophil percentage of granulocytes;
CESC	cis	rs7814319	0.870	rs2292836	chr8:97239613	A/C	cg20787634	chr8:97240163	UQCRB	-0.63	-8.18	-0.45	1.19e-14	Lung function (FVC);
CESC	cis	rs9910055	0.762	rs1135215	chr17:42253519	T/C	cg10896456	chr17:42255109	ASB16;C17orf65	0.41	5.99	0.35	6.89e-9	Total body bone mineral density;
CESC	cis	rs2764980	1.000	rs2764978	chr10:3283385	C/G	cg11630169	chr10:3283847	NA	-0.37	-5.36	-0.31	1.84e-7	Attention deficit hyperactivity disorder and conduct disorder;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg19839691	chr15:64673790	KIAA0101	0.46	6.13	0.35	3.12e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs4819052	0.851	rs1999334	chr21:46670457	A/G	cg11663144	chr21:46675770	NA	-0.56	-8.72	-0.47	3.04e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs4523957	0.893	rs9909895	chr17:2161633	G/A	cg16513277	chr17:2031491	SMG6	-0.6	-8.18	-0.45	1.22e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs4713118	0.527	rs35949862	chr6:28115367	A/G	cg08968635	chr6:28129556	ZNF389	0.41	5.28	0.31	2.68e-7	Parkinson's disease;
CESC	cis	rs1003719	0.788	rs4817849	chr21:38469796	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.63	8.77	0.47	2.14e-16	Eye color traits;
CESC	cis	rs17401966	1.000	rs12132635	chr1:10430479	G/A	cg15208524	chr1:10270712	KIF1B	0.49	6.21	0.36	2.06e-9	Hepatocellular carcinoma;
CESC	cis	rs3026445	0.761	rs67917264	chr12:110554818	A/G	cg12870014	chr12:110450643	ANKRD13A	0.46	5.9	0.34	1.13e-8	QT interval;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg24696268	chr4:49526636	NA	0.44	6.13	0.35	3.17e-9	Ulcerative colitis;
CESC	cis	rs96067	0.805	rs6425966	chr1:36611287	C/T	cg24686825	chr1:36642396	MAP7D1	0.5	5.48	0.32	9.68e-8	Corneal structure;
CESC	cis	rs5758511	0.508	rs2413667	chr22:42472237	A/C	cg00645731	chr22:42541494	CYP2D7P1	0.56	7.6	0.42	5.14e-13	Birth weight;
CESC	cis	rs13256369	1.000	rs4840352	chr8:8573508	A/G	cg17143192	chr8:8559678	CLDN23	0.75	8.87	0.48	1.11e-16	Obesity-related traits;
CESC	cis	rs11190604	1.000	rs9420782	chr10:102235015	G/A	cg07080220	chr10:102295463	HIF1AN	0.55	5.52	0.32	8.2e-8	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs2952156	0.920	rs2247862	chr17:37829129	A/G	cg00129232	chr17:37814104	STARD3	-0.72	-9.63	-0.51	5.06e-19	Asthma;
CESC	cis	rs11650494	0.908	rs57390430	chr17:47374886	G/A	cg08112188	chr17:47440006	ZNF652	1.11	7.71	0.43	2.48e-13	Prostate cancer;
CESC	cis	rs3771570	1.000	rs62193221	chr2:242354632	T/C	cg21155796	chr2:242212141	HDLBP	0.58	5.06	0.3	7.83e-7	Prostate cancer;
CESC	trans	rs17508449	0.819	rs3761934	chr1:114189067	G/T	cg23028848	chr11:57092561	TNKS1BP1	-0.75	-6.05	-0.35	4.88e-9	Leprosy;
CESC	cis	rs61931739	0.500	rs7311302	chr12:34557211	T/C	cg06521331	chr12:34319734	NA	-0.36	-5.03	-0.3	9.01e-7	Morning vs. evening chronotype;
CESC	cis	rs1008375	1.000	rs4698635	chr4:17630242	C/A	cg16339924	chr4:17578868	LAP3	0.64	8.12	0.45	1.79e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	trans	rs116095464	0.558	rs10462754	chr5:246669	T/C	cg00938859	chr5:1591904	SDHAP3	0.63	6.92	0.39	3.29e-11	Breast cancer;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg14159818	chr20:3749519	C20orf27	0.48	6.55	0.37	3.01e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs7666738	0.830	rs1834647	chr4:98882915	G/A	cg03676636	chr4:99064102	C4orf37	0.34	5.08	0.3	7.07e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs7937682	0.889	rs1940529	chr11:111498523	G/C	cg18187862	chr3:45730750	SACM1L	0.51	6.4	0.37	7.15e-10	Primary sclerosing cholangitis;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg08882882	chr6:84937375	KIAA1009	-0.46	-6.21	-0.36	2.06e-9	Height;
CESC	cis	rs4653767	0.573	rs708770	chr1:226912135	C/T	cg10327440	chr1:227177885	CDC42BPA	-0.42	-5.58	-0.32	5.99e-8	Parkinson's disease;
CESC	cis	rs9457247	1.000	rs385863	chr6:167386615	C/G	cg23791538	chr6:167370224	RNASET2	-0.6	-8.65	-0.47	4.96e-16	Crohn's disease;
CESC	trans	rs561341	0.941	rs736678	chr17:30347423	G/T	cg27661571	chr11:113659931	NA	-0.83	-7.34	-0.41	2.56e-12	Hip circumference adjusted for BMI;
CESC	cis	rs4665809	0.652	rs7585891	chr2:26403766	G/A	cg26314531	chr2:26401878	FAM59B	-0.82	-9.04	-0.49	3.33e-17	Gut microbiome composition (summer);
CESC	cis	rs9549367	0.756	rs9603814	chr13:113900782	C/T	cg00898013	chr13:113819073	PROZ	0.5	7.38	0.41	2.06e-12	Platelet distribution width;
CESC	cis	rs7811142	0.830	rs78256546	chr7:99952970	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.13	11.76	0.59	5.69e-26	Platelet count;
CESC	cis	rs2836633	0.929	rs2836610	chr21:40044502	C/T	cg12884169	chr21:40033163	ERG	0.39	6.09	0.35	3.99e-9	Coronary artery disease;
CESC	cis	rs8005677	1.000	rs4982712	chr14:23403728	A/G	cg01529538	chr14:23388837	RBM23	0.5	6.56	0.37	2.83e-10	Cognitive ability (multi-trait analysis);
CESC	cis	rs9611565	0.694	rs7285041	chr22:41829149	G/T	cg17376030	chr22:41985996	PMM1	-0.76	-8.1	-0.45	2.03e-14	Vitiligo;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19857114	chr3:176741225	TBL1XR1	-0.59	-6.55	-0.37	2.99e-10	Gut microbiome composition (summer);
CESC	cis	rs8067354	0.872	rs2645488	chr17:57889405	T/G	cg02344993	chr17:57696989	CLTC	0.48	6.3	0.36	1.2e-9	Hemoglobin concentration;
CESC	cis	rs11098499	0.954	rs66506550	chr4:120371445	T/A	cg24375607	chr4:120327624	NA	0.47	5.89	0.34	1.14e-8	Corneal astigmatism;
CESC	cis	rs875971	0.862	rs6460279	chr7:65662761	T/C	cg12463550	chr7:65579703	CRCP	-0.51	-6.5	-0.37	3.9e-10	Aortic root size;
CESC	cis	rs7173419	0.716	rs7162812	chr15:28233734	G/A	cg20906524	chr15:28200668	OCA2	-0.42	-5.86	-0.34	1.39e-8	Eye color;
CESC	cis	rs4629180	0.675	rs6742474	chr2:102091075	G/A	cg21388029	chr2:102003306	CREG2	0.34	5.36	0.31	1.82e-7	Chronic rhinosinusitis with nasal polyps;
CESC	trans	rs9987353	0.840	rs329994	chr8:9123233	A/G	cg04078585	chr17:71165907	SSTR2	0.45	6.29	0.36	1.31e-9	Recombination measurement;
CESC	cis	rs11252926	0.537	rs6560836	chr10:444997	C/T	cg03684893	chr10:554711	DIP2C	-0.35	-5.1	-0.3	6.52e-7	Psychosis in Alzheimer's disease;
CESC	cis	rs2282802	0.685	rs35214989	chr5:139636127	T/C	cg26211634	chr5:139558579	C5orf32	0.49	7.1	0.4	1.13e-11	Intelligence (multi-trait analysis);
CESC	cis	rs8038465	0.904	rs11852484	chr15:73988652	G/A	cg15420318	chr15:73925796	NPTN	0.41	5.67	0.33	3.71e-8	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs71277158	0.688	rs16854836	chr3:169804730	T/C	cg04067573	chr3:169899625	PHC3	0.67	6.83	0.39	5.86e-11	Prostate cancer;
CESC	cis	rs875971	1.000	rs778696	chr7:65870813	C/G	cg11764359	chr7:65958608	NA	0.96	15.23	0.68	4.78e-38	Aortic root size;
CESC	cis	rs1707322	0.896	rs809774	chr1:46560244	T/A	cg03146154	chr1:46216737	IPP	-0.69	-9.1	-0.49	2.16e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs5769765	1.000	rs738711	chr22:50282603	A/G	cg26441486	chr22:50317300	CRELD2	-0.39	-5.5	-0.32	8.72e-8	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09965679	chr14:75179859	FCF1;KIAA0317	-0.53	-6.23	-0.36	1.87e-9	Gut microbiome composition (summer);
CESC	cis	rs3785574	0.927	rs2008018	chr17:61954471	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.74	9.73	0.51	2.47e-19	Height;
CESC	cis	rs7072216	0.763	rs9787550	chr10:100169051	C/T	cg26618903	chr10:100175079	PYROXD2	-0.36	-5.53	-0.32	7.84e-8	Metabolite levels;
CESC	cis	rs12134245	0.719	rs61798831	chr1:91996588	C/T	cg02896835	chr1:92012615	NA	-0.53	-6.87	-0.39	4.57e-11	Breast cancer;
CESC	cis	rs2573652	1.000	rs2727199	chr15:100514417	C/T	cg09918751	chr15:100517450	ADAMTS17	-0.39	-7.21	-0.4	5.96e-12	Height;
CESC	cis	rs4253772	0.550	rs6007823	chr22:46706249	C/T	cg00784671	chr22:46762841	CELSR1	-0.49	-5.59	-0.32	5.56e-8	LDL cholesterol;Cholesterol, total;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg08695707	chr1:197871847	C1orf53	0.46	6.11	0.35	3.62e-9	Systemic lupus erythematosus;
CESC	cis	rs1538970	0.816	rs9727262	chr1:45998579	T/G	cg06784218	chr1:46089804	CCDC17	0.35	5.63	0.33	4.57e-8	Platelet count;
CESC	cis	rs7621025	0.505	rs61789642	chr3:136109696	C/T	cg15507776	chr3:136538369	TMEM22	-0.73	-5.84	-0.34	1.56e-8	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
CESC	cis	rs873946	0.564	rs12242672	chr10:134555609	A/T	cg06453172	chr10:134556979	INPP5A	-0.4	-5.32	-0.31	2.19e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs1506636	1.000	rs10225428	chr7:123357646	A/G	cg03229431	chr7:123269106	ASB15	-0.49	-6.57	-0.37	2.58e-10	Plateletcrit;Platelet count;
CESC	cis	rs10791097	0.694	rs1893017	chr11:130756253	C/T	cg09137382	chr11:130731461	NA	0.34	5.1	0.3	6.52e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs9649465	1.000	rs12537287	chr7:123364747	G/A	cg04330084	chr7:123175371	IQUB	-0.39	-5.23	-0.31	3.47e-7	Migraine;
CESC	cis	rs3741404	0.791	rs7102177	chr11:63909228	T/C	cg04317338	chr11:64019027	PLCB3	0.47	5.62	0.33	4.95e-8	Platelet count;
CESC	cis	rs1046896	0.538	rs3803771	chr17:80687758	G/A	cg02398342	chr17:80708632	TBCD;FN3K	-0.5	-6.76	-0.38	8.98e-11	Glycated hemoglobin levels;
CESC	cis	rs6541297	0.878	rs4846905	chr1:230279582	C/T	cg05784532	chr1:230284198	GALNT2	-0.43	-5.45	-0.32	1.13e-7	Coronary artery disease;
CESC	cis	rs763121	0.849	rs12004	chr22:38877461	T/G	cg06022373	chr22:39101656	GTPBP1	0.81	11.63	0.58	1.51e-25	Menopause (age at onset);
CESC	trans	rs1814175	0.791	rs10769593	chr11:49616217	T/C	cg15704280	chr7:45808275	SEPT13	-0.98	-18.02	-0.74	6.21e-48	Height;
CESC	cis	rs1559088	0.948	rs12460195	chr19:33584479	G/A	cg17764715	chr19:33622953	WDR88	0.49	6.32	0.36	1.11e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs501120	0.925	rs684521	chr10:44752523	G/A	cg09554077	chr10:44749378	NA	0.55	7.18	0.4	6.98e-12	Coronary artery disease;Coronary heart disease;
CESC	cis	rs11098499	0.865	rs10213221	chr4:120255926	G/A	cg09307838	chr4:120376055	NA	0.81	10.99	0.56	2.15e-23	Corneal astigmatism;
CESC	cis	rs7552404	1.000	rs4949872	chr1:76131392	C/G	cg22875332	chr1:76189707	ACADM	0.62	7.17	0.4	7.45e-12	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs7615952	0.641	rs7618515	chr3:125790578	C/T	cg15145296	chr3:125709740	NA	-0.54	-5.73	-0.33	2.67e-8	Blood pressure (smoking interaction);
CESC	cis	rs3820068	0.705	rs2145397	chr1:15896199	G/A	cg17385448	chr1:15911702	AGMAT	0.36	5.52	0.32	8.12e-8	Systolic blood pressure;
CESC	cis	rs1580019	0.961	rs3801328	chr7:32496930	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.73	10.15	0.53	1.14e-20	Cognitive ability;
CESC	cis	rs854765	0.583	rs8080823	chr17:17864048	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.55	7.47	0.42	1.16e-12	Total body bone mineral density;
CESC	cis	rs3806843	0.771	rs2563334	chr5:140107065	C/G	cg16179182	chr5:140090404	VTRNA1-1	0.44	5.74	0.33	2.54e-8	Depressive symptoms (multi-trait analysis);
CESC	cis	rs709400	1.000	rs7150141	chr14:104129352	G/A	cg12935359	chr14:103987150	CKB	-0.43	-5.84	-0.34	1.54e-8	Body mass index;
CESC	cis	rs6460942	0.915	rs6968695	chr7:12443878	G/C	cg19099843	chr7:12443191	VWDE	-0.5	-5.26	-0.31	2.97e-7	Coronary artery disease;
CESC	cis	rs6665290	0.935	rs17600627	chr1:227201449	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.19	-30.52	-0.88	1.02e-88	Myeloid white cell count;
CESC	cis	rs6089584	0.850	rs6142939	chr20:60627729	A/G	cg24733560	chr20:60626293	TAF4	0.47	6.72	0.38	1.09e-10	Body mass index;
CESC	cis	rs3733585	0.638	rs17185835	chr4:9958180	T/G	cg00071950	chr4:10020882	SLC2A9	-0.72	-11.7	-0.58	8.89e-26	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs7949030	0.653	rs17773169	chr11:62318530	G/T	cg13298116	chr11:62369859	EML3;MTA2	0.61	9.27	0.49	6.61e-18	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs1448094	0.512	rs6539929	chr12:86244932	T/C	cg00310523	chr12:86230176	RASSF9	0.35	5.46	0.32	1.1e-7	Major depressive disorder;
CESC	cis	rs6502050	0.835	rs4789738	chr17:80123053	G/A	cg23985595	chr17:80112537	CCDC57	-0.41	-6.57	-0.37	2.6200000000000003e-10	Life satisfaction;
CESC	cis	rs9309473	0.847	rs4547554	chr2:73867862	G/C	cg20560298	chr2:73613845	ALMS1	-0.53	-6.79	-0.39	7.23e-11	Metabolite levels;
CESC	cis	rs10504229	1.000	rs72650887	chr8:58177343	G/A	cg14926445	chr8:58193284	C8orf71	-0.51	-5.47	-0.32	1.03e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs9611519	0.964	rs20551	chr22:41548008	A/G	cg03806693	chr22:41940476	POLR3H	-0.63	-6.34	-0.36	9.61e-10	Neuroticism;
CESC	cis	rs7537052	0.669	rs475591	chr1:36642420	T/C	cg24686825	chr1:36642396	MAP7D1	-0.72	-10.23	-0.53	6.26e-21	Schizophrenia;
CESC	cis	rs763121	0.853	rs5750659	chr22:39068789	T/C	cg14440974	chr22:39074834	NA	-0.42	-5.89	-0.34	1.14e-8	Menopause (age at onset);
CESC	cis	rs7647973	1.000	rs13322887	chr3:49555583	G/A	cg02487422	chr3:49467188	NICN1	-0.41	-5.35	-0.31	1.86e-7	Menarche (age at onset);
CESC	cis	rs4253772	0.513	rs9306512	chr22:46716603	T/C	cg10231785	chr22:46692440	CN5H6.4;GTSE1	0.56	6.03	0.35	5.48e-9	LDL cholesterol;Cholesterol, total;
CESC	cis	rs1348850	0.632	rs12471621	chr2:178502353	T/C	cg23306229	chr2:178417860	TTC30B	0.6	7.57	0.42	6.27e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs1218582	0.741	rs4339857	chr1:154888962	A/G	cg06221963	chr1:154839813	KCNN3	-0.66	-11.21	-0.57	4.07e-24	Prostate cancer;
CESC	cis	rs28386778	0.863	rs3760252	chr17:61852186	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.63	8.19	0.45	1.1e-14	Prudent dietary pattern;
CESC	cis	rs6728642	0.708	rs56807297	chr2:97861340	A/C	cg26665480	chr2:98280029	ACTR1B	-0.8	-7.2	-0.4	6.39e-12	Bipolar disorder lithium response (continuous) or schizophrenia;
CESC	cis	rs2742234	0.579	rs2503881	chr10:43686026	T/C	cg07801480	chr10:43725741	RASGEF1A	0.41	5.29	0.31	2.56e-7	Hirschsprung disease;
CESC	cis	rs2295359	0.892	rs12401432	chr1:67656931	C/G	cg03340356	chr1:67600835	NA	0.32	5.27	0.31	2.81e-7	Psoriasis;
CESC	trans	rs2415984	0.846	rs8022067	chr14:46851304	C/A	cg14945696	chr3:52713679	PBRM1	-0.39	-6.04	-0.35	5.21e-9	Number of children ever born;
CESC	cis	rs7107174	1.000	rs10899460	chr11:78010080	A/G	cg02023728	chr11:77925099	USP35	0.5	6.66	0.38	1.62e-10	Testicular germ cell tumor;
CESC	cis	rs910316	0.737	rs108621	chr14:75480637	T/C	cg08847533	chr14:75593920	NEK9	-0.88	-15.06	-0.68	1.95e-37	Height;
CESC	cis	rs2346177	0.519	rs35509718	chr2:46696793	T/C	cg02822958	chr2:46747628	ATP6V1E2	0.45	5.59	0.32	5.67e-8	HDL cholesterol;
CESC	cis	rs634534	0.561	rs14157	chr11:65769780	T/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.45	6.84	0.39	5.62e-11	Sum eosinophil basophil counts;Eosinophil counts;
CESC	cis	rs10883723	0.773	rs2296587	chr10:104245588	G/A	cg22532475	chr10:104410764	TRIM8	-0.43	-6.72	-0.38	1.14e-10	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs7666738	0.830	rs17550610	chr4:99008273	T/C	cg03467027	chr4:99064603	C4orf37	0.44	5.51	0.32	8.65e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7726839	0.540	rs3749615	chr5:601485	C/T	cg16447950	chr5:562315	NA	-0.61	-6.31	-0.36	1.19e-9	Obesity-related traits;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg07797907	chr16:2389905	ABCA17P;ABCA3	-0.48	-6.64	-0.38	1.73e-10	Fibrinogen levels;
CESC	cis	rs9796	0.870	rs8030306	chr15:41261821	T/A	cg18705301	chr15:41695430	NDUFAF1	-0.47	-6.97	-0.39	2.55e-11	Menopause (age at onset);
CESC	cis	rs35955747	0.714	rs5997989	chr22:31839950	T/C	cg25791279	chr22:32026902	PISD	-0.41	-5.03	-0.3	9.17e-7	Neutrophil count;Sum basophil neutrophil counts;
CESC	trans	rs17716202	0.702	rs16885789	chr5:55897825	A/G	cg14306956	chr9:37027384	PAX5	-0.59	-6.28	-0.36	1.37e-9	Psychosis in Alzheimer's disease;
CESC	cis	rs6686643	1.000	rs959617	chr1:165616881	C/G	cg19407955	chr1:165599744	MGST3	-0.48	-5.2	-0.3	3.93e-7	Total ventricular volume;
CESC	cis	rs4665809	1.000	rs6546728	chr2:26276531	G/C	cg08470875	chr2:26401718	FAM59B	-0.62	-6.71	-0.38	1.2e-10	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25180585	chr17:49230756	NME1;NME1-NME2	0.66	7.72	0.43	2.42e-13	Gut microbiome composition (summer);
CESC	cis	rs7584330	0.554	rs2325838	chr2:238386515	C/A	cg14458575	chr2:238380390	NA	0.67	5.72	0.33	2.87e-8	Prostate cancer;
CESC	cis	rs10129255	0.500	rs1974468	chr14:107142166	A/G	cg07958169	chr14:107095056	NA	-0.56	-9.0	-0.48	4.47e-17	Kawasaki disease;
CESC	cis	rs9796	0.689	rs11855797	chr15:41434679	C/T	cg12426344	chr15:41135900	SPINT1	-0.24	-5.31	-0.31	2.37e-7	Menopause (age at onset);
CESC	cis	rs9905704	0.681	rs7211133	chr17:56558918	G/A	cg12560992	chr17:57184187	TRIM37	-0.59	-5.55	-0.32	6.76e-8	Testicular germ cell tumor;
CESC	cis	rs7100689	0.646	rs1340375	chr10:82129039	C/T	cg00277334	chr10:82204260	NA	-0.58	-7.76	-0.43	1.84e-13	Post bronchodilator FEV1;
CESC	cis	rs7937682	0.883	rs484834	chr11:111465761	G/C	cg09085632	chr11:111637200	PPP2R1B	-0.9	-12.87	-0.62	9.33e-30	Primary sclerosing cholangitis;
CESC	trans	rs57221529	0.766	rs72706608	chr5:559203	C/T	cg25482853	chr8:67687455	SGK3	1.11	11.94	0.59	1.39e-26	Lung disease severity in cystic fibrosis;
CESC	cis	rs6502050	0.777	rs11077969	chr17:80085633	A/G	cg23985595	chr17:80112537	CCDC57	0.42	6.55	0.37	2.99e-10	Life satisfaction;
CESC	cis	rs722599	0.748	rs59112602	chr14:75358817	C/G	cg11812906	chr14:75593930	NEK9	-0.46	-5.51	-0.32	8.57e-8	IgG glycosylation;
CESC	cis	rs7336332	0.600	rs9579083	chr13:28017270	G/C	cg22138327	chr13:27999177	GTF3A	0.63	5.74	0.33	2.57e-8	Weight;
CESC	cis	rs1707322	1.000	rs11211228	chr1:46399840	G/A	cg06784218	chr1:46089804	CCDC17	0.33	5.63	0.33	4.7e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2777491	1.000	rs2777491	chr15:41735710	T/G	cg02330683	chr15:41787940	ITPKA	0.47	7.03	0.4	1.76e-11	Ulcerative colitis;
CESC	cis	rs4727027	0.866	rs10435245	chr7:148816081	C/G	cg23583168	chr7:148888333	NA	-0.78	-12.19	-0.6	1.97e-27	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	trans	rs11098499	0.648	rs2002047	chr4:120257228	A/G	cg25214090	chr10:38739885	LOC399744	0.64	9.08	0.49	2.59e-17	Corneal astigmatism;
CESC	cis	rs4474465	0.790	rs6592784	chr11:78234790	C/T	cg02023728	chr11:77925099	USP35	-0.41	-5.09	-0.3	6.75e-7	Alzheimer's disease (survival time);
CESC	cis	rs7618915	0.570	rs11714088	chr3:52758942	A/C	cg05564831	chr3:52568323	NT5DC2	0.44	6.58	0.37	2.57e-10	Bipolar disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10081115	chr2:190686883	PMS1	-0.62	-6.51	-0.37	3.8e-10	Gut microbiome composition (summer);
CESC	cis	rs1552244	1.000	rs68045038	chr3:10151828	A/G	cg00149659	chr3:10157352	C3orf10	0.74	9.04	0.49	3.31e-17	Alzheimer's disease;
CESC	cis	rs67478160	0.608	rs34066659	chr14:104263427	A/C	cg08213375	chr14:104286397	PPP1R13B	0.54	10.8	0.55	8.68e-23	Schizophrenia;
CESC	cis	rs344364	0.511	rs2982453	chr16:1949520	G/A	cg26617929	chr16:1858877	NA	-0.49	-5.15	-0.3	5.09e-7	Glomerular filtration rate in chronic kidney disease;
CESC	trans	rs55704346	0.534	rs6448354	chr4:25389584	A/C	cg01822600	chr1:245751692	KIF26B	0.42	6.17	0.35	2.58e-9	Tonsillectomy;
CESC	cis	rs1707322	0.686	rs1084086	chr1:46041100	A/C	cg05343316	chr1:45956843	TESK2	-0.53	-6.53	-0.37	3.33e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs10924309	0.924	rs10802245	chr1:245858321	G/A	cg00036263	chr1:245852353	KIF26B	-0.42	-5.22	-0.31	3.69e-7	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
CESC	cis	rs3793683	0.556	rs2803989	chr10:134560596	C/T	cg27286337	chr10:134555280	INPP5A	0.65	8.4	0.46	2.71e-15	Migraine;
CESC	cis	rs4948102	0.642	rs766333	chr7:56126704	T/A	cg09872392	chr7:56161020	PHKG1	-0.46	-7.55	-0.42	7.19e-13	Plasma homocysteine levels (post-methionine load test);
CESC	cis	rs4665809	0.941	rs2289021	chr2:26362515	A/C	cg25036284	chr2:26402008	FAM59B	0.52	6.4	0.37	7.18e-10	Gut microbiome composition (summer);
CESC	cis	rs8180040	0.966	rs11130128	chr3:47486632	T/C	cg27129171	chr3:47204927	SETD2	-0.63	-9.47	-0.5	1.6e-18	Colorectal cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15144236	chr6:144385792	PLAGL1	0.58	6.76	0.38	8.55e-11	Gut microbiome composition (summer);
CESC	cis	rs11785400	1.000	rs754957	chr8:143746416	A/G	cg10596483	chr8:143751796	JRK	0.43	5.67	0.33	3.79e-8	Schizophrenia;
CESC	cis	rs6952808	0.595	rs2398705	chr7:2164995	G/A	cg08027265	chr7:2291960	NA	-0.46	-7.08	-0.4	1.27e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs1256061	0.603	rs1256039	chr14:64738979	G/C	cg23250157	chr14:64679961	SYNE2	0.53	7.64	0.42	4.09e-13	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs514406	0.825	rs487453	chr1:53271225	T/C	cg08736216	chr1:53307985	ZYG11A	0.32	5.66	0.33	3.97e-8	Monocyte count;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg02602601	chr12:56618057	OBFC2B	-0.49	-6.43	-0.37	5.9e-10	Ulcerative colitis;
CESC	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg22535103	chr8:58192502	C8orf71	-0.96	-9.81	-0.52	1.45e-19	Developmental language disorder (linguistic errors);
CESC	cis	rs9325144	0.560	rs10876005	chr12:39126149	C/G	cg26384229	chr12:38710491	ALG10B	-0.51	-7.46	-0.42	1.23e-12	Morning vs. evening chronotype;
CESC	cis	rs36051895	0.589	rs6476948	chr9:5204404	C/T	cg02405213	chr9:5042618	JAK2	-0.49	-5.69	-0.33	3.41e-8	Pediatric autoimmune diseases;
CESC	cis	rs2066819	1.000	rs77447765	chr12:56690662	G/A	cg26714650	chr12:56694279	CS	-1.52	-10.39	-0.54	1.95e-21	Psoriasis vulgaris;
CESC	cis	rs12824058	0.831	rs4759653	chr12:130812604	T/C	cg23887609	chr12:130822674	PIWIL1	0.45	5.82	0.34	1.69e-8	Menopause (age at onset);
CESC	cis	rs5753618	0.561	rs9609264	chr22:31746719	C/G	cg13145458	chr22:31556086	RNF185	-0.49	-5.57	-0.32	6.31e-8	Colorectal cancer;
CESC	cis	rs896543	0.515	rs62189825	chr2:237494954	C/T	cg25295825	chr2:237489920	CXCR7	0.66	5.85	0.34	1.47e-8	Alcohol dependence (age at onset);
CESC	cis	rs9457247	0.515	rs2757039	chr6:167370353	G/T	cg23791538	chr6:167370224	RNASET2	0.69	9.94	0.52	5.51e-20	Crohn's disease;
CESC	cis	rs113835537	0.808	rs10896128	chr11:66324529	G/A	cg24851651	chr11:66362959	CCS	0.55	5.29	0.31	2.6e-7	Airway imaging phenotypes;
CESC	cis	rs7811142	1.000	rs1073	chr7:100031612	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.11	10.96	0.56	2.75e-23	Platelet count;
CESC	cis	rs1552244	0.935	rs2272124	chr3:10138189	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	12.7	0.62	3.48e-29	Alzheimer's disease;
CESC	cis	rs2439831	0.717	rs2447198	chr15:43895118	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.81	8.75	0.47	2.56e-16	Lung cancer in ever smokers;
CESC	cis	rs9311474	0.508	rs4687629	chr3:52615227	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.5	7.37	0.41	2.21e-12	Electroencephalogram traits;
CESC	cis	rs17253792	0.822	rs10083303	chr14:56068521	T/C	cg01858014	chr14:56050164	KTN1	-0.85	-6.99	-0.39	2.22e-11	Putamen volume;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg15249164	chr21:35288186	ATP5O	-0.37	-6.09	-0.35	4.03e-9	Gambling;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03438090	chr2:239143093	NA	0.57	6.27	0.36	1.49e-9	Gut microbiome composition (summer);
CESC	cis	rs4595586	0.545	rs11615634	chr12:39364704	A/C	cg26384229	chr12:38710491	ALG10B	0.54	7.7	0.43	2.7e-13	Morning vs. evening chronotype;
CESC	cis	rs7914558	1.000	rs67908413	chr10:104764989	T/C	cg04362960	chr10:104952993	NT5C2	0.46	6.13	0.35	3.2e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs9611565	0.918	rs4822024	chr22:41757647	G/A	cg17376030	chr22:41985996	PMM1	0.6	6.42	0.37	6.13e-10	Vitiligo;
CESC	cis	rs780096	0.526	rs704795	chr2:27716494	G/A	cg12648201	chr2:27665141	KRTCAP3	-0.37	-6.94	-0.39	2.95e-11	Total body bone mineral density;
CESC	cis	rs4268898	0.662	rs2303291	chr2:24431184	C/T	cg20701182	chr2:24300061	SF3B14	0.69	7.17	0.4	7.69e-12	Asthma;
CESC	cis	rs9814567	1.000	rs6765505	chr3:134208132	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.43	-5.98	-0.34	7.11e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs801193	0.935	rs2659899	chr7:66186721	A/G	cg11764359	chr7:65958608	NA	0.71	9.39	0.5	2.85e-18	Aortic root size;
CESC	cis	rs7267979	0.932	rs928121	chr20:25534818	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.75	13.63	0.64	2.09e-32	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs8064299	0.597	rs2016126	chr17:72784932	G/A	cg25054828	chr17:72772726	NAT9;TMEM104	0.83	13.98	0.65	1.23e-33	Monocyte count;
CESC	cis	rs6088590	0.735	rs6060001	chr20:33294353	C/T	cg06115741	chr20:33292138	TP53INP2	-0.48	-5.82	-0.34	1.66e-8	Coronary artery disease;
CESC	cis	rs9300255	0.544	rs1790100	chr12:123656725	G/T	cg00376283	chr12:123451042	ABCB9	0.7	8.86	0.48	1.19e-16	Neutrophil percentage of white cells;
CESC	cis	rs1862618	0.671	rs2591965	chr5:56236176	T/C	cg14703610	chr5:56206110	C5orf35	-0.41	-5.19	-0.3	4.15e-7	Initial pursuit acceleration;
CESC	cis	rs1552244	0.882	rs56224841	chr3:10044014	A/C	cg00149659	chr3:10157352	C3orf10	0.7	8.26	0.45	6.82e-15	Alzheimer's disease;
CESC	cis	rs7903847	0.619	rs76094900	chr10:99158164	G/A	cg20016023	chr10:99160130	RRP12	-0.3	-5.14	-0.3	5.4e-7	Granulocyte percentage of myeloid white cells;
CESC	cis	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg13880726	chr7:1868755	MAD1L1	0.5	6.63	0.38	1.86e-10	Bipolar disorder and schizophrenia;
CESC	trans	rs10411161	0.702	rs8110073	chr19:52383123	C/A	cg22319618	chr22:45562946	NUP50	-0.69	-6.55	-0.37	2.98e-10	Breast cancer;
CESC	cis	rs3749237	0.576	rs3877784	chr3:49539417	C/T	cg06212747	chr3:49208901	KLHDC8B	0.49	6.55	0.37	3.02e-10	Resting heart rate;
CESC	cis	rs7789940	0.809	rs12533836	chr7:75935622	G/T	cg10167463	chr7:75959203	YWHAG	-0.44	-5.2	-0.3	3.99e-7	Multiple sclerosis;
CESC	cis	rs9916302	0.904	rs2061338	chr17:37421767	T/C	cg20243544	chr17:37824526	PNMT	0.46	5.76	0.33	2.31e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs1728785	0.892	rs1170427	chr16:68603852	G/T	cg02972257	chr16:68554789	NA	-0.59	-6.71	-0.38	1.2e-10	Ulcerative colitis;
CESC	cis	rs763121	0.853	rs6001175	chr22:39018334	T/C	cg06022373	chr22:39101656	GTPBP1	0.95	17.19	0.73	5.31e-45	Menopause (age at onset);
CESC	cis	rs7267979	0.773	rs6132821	chr20:25226192	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.72	11.88	0.59	2.28e-26	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs36051895	0.632	rs12337904	chr9:5144606	C/G	cg02405213	chr9:5042618	JAK2	-0.51	-6.4	-0.37	7.16e-10	Pediatric autoimmune diseases;
CESC	cis	rs1006703	0.544	rs8068346	chr17:3838717	T/C	cg06463185	chr17:3833770	ATP2A3	-0.63	-6.05	-0.35	5.04e-9	Glucose homeostasis traits;
CESC	cis	rs9916302	0.904	rs602688	chr17:37439496	C/T	cg20243544	chr17:37824526	PNMT	0.46	5.92	0.34	9.84e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs4282054	0.631	rs13081155	chr3:52732429	A/G	cg25934064	chr3:52569026	NT5DC2	0.26	5.5	0.32	9.11e-8	Cognitive function;
CESC	cis	rs1799949	0.965	rs8070179	chr17:41202688	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.44	6.23	0.36	1.86e-9	Menopause (age at onset);
CESC	cis	rs4474465	0.646	rs10793337	chr11:78285875	A/T	cg01578073	chr11:78285783	NARS2	-0.45	-5.11	-0.3	6.27e-7	Alzheimer's disease (survival time);
CESC	cis	rs8071789	1.000	rs8071789	chr17:38006333	C/T	cg19468946	chr17:37922297	IKZF3	-0.37	-5.07	-0.3	7.42e-7	Selective IgA deficiency;
CESC	cis	rs796364	0.951	rs12996313	chr2:200997916	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.7	-6.73	-0.38	1.06e-10	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03410407	chr10:39023676	NA	-0.58	-6.24	-0.36	1.73e-9	Gut microbiome composition (summer);
CESC	cis	rs11240074	0.516	rs55679008	chr1:146919919	A/G	cg25205988	chr1:146714368	CHD1L	-0.64	-5.26	-0.31	2.92e-7	Type 2 diabetes;
CESC	cis	rs2463822	0.583	rs72917377	chr11:62025930	A/G	cg06239285	chr11:62104954	ASRGL1	-1.05	-7.91	-0.44	7.04e-14	Chronic obstructive pulmonary disease-related biomarkers;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13597198	chr19:3208049	NCLN	-0.57	-6.37	-0.36	8.24e-10	Gut microbiome composition (summer);
CESC	cis	rs6963495	0.719	rs73190172	chr7:105161210	T/C	cg02135003	chr7:105160482	PUS7	-0.46	-5.55	-0.32	6.92e-8	Bipolar disorder (body mass index interaction);
CESC	cis	rs9527	0.590	rs11191578	chr10:104902337	A/T	cg04362960	chr10:104952993	NT5C2	0.44	5.54	0.32	7.12e-8	Arsenic metabolism;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16138787	chr5:107929274	NA	-0.59	-7.12	-0.4	1.03e-11	Gut microbiome composition (summer);
CESC	cis	rs7084402	1.000	rs6481401	chr10:60268880	A/C	cg07615347	chr10:60278583	BICC1	-0.57	-8.72	-0.47	3.03e-16	Refractive error;
CESC	cis	rs12898370	0.641	rs11632999	chr15:77436995	T/G	cg17802220	chr15:77601643	NA	-0.52	-5.61	-0.33	4.96e-8	Risky sexual behaviors (alcohol dependence interaction);
CESC	cis	rs5758659	0.652	rs133313	chr22:42401749	G/T	cg15557168	chr22:42548783	NA	-0.42	-6.17	-0.35	2.52e-9	Cognitive function;
CESC	cis	rs561341	1.000	rs55643307	chr17:30263074	T/C	cg19193384	chr17:30244184	NA	-0.65	-5.94	-0.34	8.95e-9	Hip circumference adjusted for BMI;
CESC	trans	rs9850225	0.719	rs4856616	chr3:80466481	A/C	cg22465281	chr5:65017296	NLN;SGTB	-0.38	-6.03	-0.35	5.61e-9	Erectile dysfunction in type 1 diabetes;
CESC	cis	rs7208859	0.623	rs55638872	chr17:29149552	G/C	cg13385521	chr17:29058706	SUZ12P	0.8	6.38	0.37	7.71e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs4474465	0.688	rs7942527	chr11:78280322	A/G	cg01578073	chr11:78285783	NARS2	-0.44	-5.1	-0.3	6.33e-7	Alzheimer's disease (survival time);
CESC	cis	rs6938	0.618	rs12911254	chr15:75166335	G/A	cg17294928	chr15:75287854	SCAMP5	0.51	6.95	0.39	2.85e-11	Breast cancer;
CESC	trans	rs11098499	0.863	rs11098532	chr4:120490726	C/A	cg25214090	chr10:38739885	LOC399744	0.64	8.66	0.47	4.67e-16	Corneal astigmatism;
CESC	cis	rs3749237	0.595	rs6784820	chr3:49450864	C/T	cg03060546	chr3:49711283	APEH	-0.74	-11.37	-0.57	1.15e-24	Resting heart rate;
CESC	cis	rs4253772	0.872	rs4253776	chr22:46629479	C/T	cg00784671	chr22:46762841	CELSR1	0.43	5.41	0.32	1.41e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs7523050	0.643	rs35924015	chr1:109404626	T/C	cg08274380	chr1:109419600	GPSM2	0.82	5.78	0.33	2.08e-8	Fat distribution (HIV);
CESC	cis	rs6032067	0.777	rs34855539	chr20:43799036	T/G	cg10761708	chr20:43804764	PI3	0.55	6.57	0.37	2.7e-10	Blood protein levels;
CESC	cis	rs1799949	1.000	rs4793231	chr17:41427469	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.62	8.41	0.46	2.62e-15	Menopause (age at onset);
CESC	cis	rs523522	0.962	rs9788155	chr12:120938408	G/A	cg12219531	chr12:120966889	COQ5	0.75	9.99	0.52	3.7e-20	High light scatter reticulocyte count;
CESC	cis	rs1949733	1.000	rs1949733	chr4:8503359	C/T	cg11789530	chr4:8429930	ACOX3	-0.74	-10.53	-0.54	7.09e-22	Response to antineoplastic agents;
CESC	cis	rs7703051	0.864	rs6873472	chr5:74768347	C/A	cg03227963	chr5:74354835	NA	0.29	5.35	0.31	1.93e-7	LDL cholesterol;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
CESC	cis	rs8017423	0.615	rs12586761	chr14:90820897	A/G	cg14092571	chr14:90743983	NA	0.43	6.55	0.37	2.93e-10	Mortality in heart failure;
CESC	cis	rs4665809	1.000	rs6546766	chr2:26328680	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.67	-7.55	-0.42	7.15e-13	Gut microbiome composition (summer);
CESC	cis	rs6460942	0.597	rs17448913	chr7:12533984	T/C	cg06484146	chr7:12443880	VWDE	-0.73	-7.77	-0.43	1.68e-13	Coronary artery disease;
CESC	cis	rs4835473	0.771	rs4443231	chr4:144900654	A/G	cg25736465	chr4:144833511	NA	0.4	6.03	0.35	5.56e-9	Immature fraction of reticulocytes;
CESC	cis	rs9611565	0.592	rs5758427	chr22:42099688	A/G	cg03806693	chr22:41940476	POLR3H	1.05	11.94	0.59	1.39e-26	Vitiligo;
CESC	cis	rs9916302	0.904	rs4795357	chr17:37569551	T/C	cg15445000	chr17:37608096	MED1	0.4	6.35	0.36	9.2e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs4474465	0.688	rs4945302	chr11:78283454	T/C	cg27205649	chr11:78285834	NARS2	0.48	6.31	0.36	1.14e-9	Alzheimer's disease (survival time);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05414835	chr15:59225898	SLTM	-0.57	-6.57	-0.37	2.7e-10	Gut microbiome composition (summer);
CESC	cis	rs12950390	0.853	rs28589850	chr17:45855713	A/G	cg00777063	chr17:45855553	NA	-0.39	-5.83	-0.34	1.6e-8	IgG glycosylation;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg10352719	chr14:24769404	DHRS1;C14orf21	-0.47	-6.37	-0.36	8.24e-10	Height;
CESC	cis	rs7666738	0.800	rs13106995	chr4:99028790	A/T	cg24818145	chr4:99064322	C4orf37	0.39	5.09	0.3	6.95e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3008870	1.000	rs12039172	chr1:67447450	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-1.04	-14.57	-0.67	9.76e-36	Lymphocyte percentage of white cells;
CESC	cis	rs67478160	0.643	rs876002	chr14:104239697	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.5	-6.89	-0.39	4.13e-11	Schizophrenia;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg00419759	chr1:114301964	PHTF1	0.58	7.48	0.42	1.11e-12	Gut microbiota (bacterial taxa);
CESC	cis	rs561341	1.000	rs4795669	chr17:30244701	C/T	cg12193833	chr17:30244370	NA	-0.72	-7.38	-0.41	2.07e-12	Hip circumference adjusted for BMI;
CESC	cis	rs2576037	0.501	rs8089938	chr18:44459497	C/T	cg19077165	chr18:44547161	KATNAL2	-0.53	-7.64	-0.42	3.99e-13	Personality dimensions;
CESC	cis	rs896854	0.738	rs2515226	chr8:95965743	G/A	cg09323728	chr8:95962352	TP53INP1	0.36	6.98	0.39	2.32e-11	Type 2 diabetes;
CESC	cis	rs1799949	0.965	rs8070179	chr17:41202688	G/A	cg25072359	chr17:41440525	NA	0.48	7.22	0.41	5.65e-12	Menopause (age at onset);
CESC	cis	rs2235544	0.565	rs605182	chr1:54466956	A/G	cg25741118	chr1:54482237	LDLRAD1	0.24	5.8	0.34	1.91e-8	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
CESC	cis	rs4268898	0.662	rs2303296	chr2:24432839	A/G	cg08917208	chr2:24149416	ATAD2B	0.55	5.27	0.31	2.89e-7	Asthma;
CESC	cis	rs11098499	0.657	rs9996569	chr4:120299004	G/C	cg09307838	chr4:120376055	NA	0.92	12.66	0.61	4.96e-29	Corneal astigmatism;
CESC	cis	rs7582720	0.943	rs72934762	chr2:203756677	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.39	0.41	1.96e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs796364	0.806	rs76568708	chr2:200929531	C/T	cg23649088	chr2:200775458	C2orf69	-0.59	-5.36	-0.31	1.78e-7	Schizophrenia;
CESC	cis	rs34638657	0.646	rs72628279	chr16:82199664	A/C	cg09439754	chr16:82129088	HSD17B2	-0.37	-6.4	-0.37	6.93e-10	Lung adenocarcinoma;
CESC	cis	rs2243480	1.000	rs160648	chr7:65543384	C/A	cg12463550	chr7:65579703	CRCP	0.65	5.11	0.3	6.05e-7	Diabetic kidney disease;
CESC	cis	rs9910055	0.530	rs11652651	chr17:42302907	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	-0.34	-5.07	-0.3	7.49e-7	Total body bone mineral density;
CESC	cis	rs2762353	0.595	rs10498728	chr6:25751320	A/T	cg03264133	chr6:25882463	NA	-0.62	-9.3	-0.5	5.29e-18	Blood metabolite levels;
CESC	trans	rs11722228	0.522	rs77691548	chr4:10136115	T/G	cg26043149	chr18:55253948	FECH	1.01	13.16	0.63	8.63e-31	Gout;Urate levels;Serum uric acid levels;
CESC	cis	rs4819052	1.000	rs4818769	chr21:46667451	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.58	6.95	0.39	2.84e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs1316952	0.831	rs74624536	chr12:124393076	T/G	cg12597309	chr12:124393772	DNAH10	0.34	5.16	0.3	4.8e-7	Visceral adipose tissue adjusted for BMI;Visceral adipose tissue/subcutaneous adipose tissue ratio;
CESC	cis	rs6502050	0.835	rs9902485	chr17:80093701	C/T	cg01763666	chr17:80159506	CCDC57	-0.37	-5.1	-0.3	6.61e-7	Life satisfaction;
CESC	cis	rs6546550	0.901	rs6546559	chr2:70145833	G/A	cg02498382	chr2:70120550	SNRNP27	-0.39	-6.82	-0.39	5.98e-11	Prevalent atrial fibrillation;
CESC	cis	rs853679	0.517	rs9357066	chr6:28129831	T/C	cg19592336	chr6:28129416	ZNF389	0.61	8.03	0.44	3.13e-14	Depression;
CESC	cis	rs5750830	0.594	rs1010169	chr22:39778167	C/T	cg24399712	chr22:39784796	NA	0.83	11.48	0.58	5.08e-25	Intelligence (multi-trait analysis);
CESC	cis	rs4803468	1.000	rs878083	chr19:41897688	G/A	cg14132834	chr19:41945861	ATP5SL	-0.6	-7.48	-0.42	1.07e-12	Height;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg17274400	chr12:8234945	NECAP1	-0.52	-6.71	-0.38	1.19e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs4481887	0.962	rs4244177	chr1:248468279	C/T	cg00666640	chr1:248458726	OR2T12	0.39	6.36	0.36	8.71e-10	Common traits (Other);
CESC	cis	rs9325144	1.000	rs10506124	chr12:39019236	C/A	cg26384229	chr12:38710491	ALG10B	-0.47	-5.8	-0.34	1.87e-8	Morning vs. evening chronotype;
CESC	cis	rs4808199	0.842	rs11085259	chr19:19445856	C/T	cg03709012	chr19:19516395	GATAD2A	1.1	12.41	0.61	3.6e-28	Nonalcoholic fatty liver disease;
CESC	cis	rs116095464	0.558	rs56342538	chr5:225796	T/C	cg22496380	chr5:211416	CCDC127	-0.74	-8.72	-0.47	3.15e-16	Breast cancer;
CESC	cis	rs524281	0.861	rs10896087	chr11:65924549	A/G	cg14036092	chr11:66035641	RAB1B	-0.56	-5.57	-0.32	6.24e-8	Electroencephalogram traits;
CESC	cis	rs62229266	0.804	rs62230822	chr21:37429945	T/C	cg12218747	chr21:37451666	NA	-0.43	-6.01	-0.35	6.17e-9	Mitral valve prolapse;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg03388569	chr15:40426063	NA	-0.37	-6.09	-0.35	3.89e-9	Thyroid stimulating hormone;
CESC	cis	rs4665809	0.549	rs72809635	chr2:26411674	G/A	cg25036284	chr2:26402008	FAM59B	0.73	7.84	0.43	1.13e-13	Gut microbiome composition (summer);
CESC	cis	rs709400	0.628	rs7155014	chr14:103863970	C/G	cg12935359	chr14:103987150	CKB	-0.52	-7.92	-0.44	6.43e-14	Body mass index;
CESC	cis	rs60843830	0.623	rs55932737	chr2:107543	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.51	6.08	0.35	4.21e-9	Spherical equivalent (joint analysis main effects and education interaction);
CESC	trans	rs941207	0.542	rs11171979	chr12:57195983	C/G	cg26462586	chr2:11164677	NA	0.4	6.6	0.38	2.25e-10	Platelet count;
CESC	cis	rs765787	0.530	rs11636367	chr15:45535862	A/G	cg24006582	chr15:45444508	DUOX1	-0.59	-7.2	-0.4	6.34e-12	Uric acid levels;
CESC	cis	rs703842	1.000	rs10747783	chr12:58176614	T/C	cg18357645	chr12:58087776	OS9	-0.4	-5.62	-0.33	4.76e-8	Multiple sclerosis;
CESC	cis	rs9910055	0.571	rs28897216	chr17:42240824	A/G	cg13607699	chr17:42295918	UBTF	0.56	7.21	0.41	5.79e-12	Total body bone mineral density;
CESC	cis	rs950169	0.840	rs72748702	chr15:84915246	A/G	cg17507749	chr15:85114479	UBE2QP1	0.56	6.28	0.36	1.4e-9	Schizophrenia;
CESC	cis	rs3733585	0.598	rs28677023	chr4:9958326	C/A	cg00071950	chr4:10020882	SLC2A9	-0.73	-11.79	-0.59	4.58e-26	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs4862750	0.837	rs1863404	chr4:187874654	T/C	cg07414643	chr4:187882934	NA	0.54	7.78	0.43	1.65e-13	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9894429	1.000	rs4074916	chr17:79579248	G/A	cg21984481	chr17:79567631	NPLOC4	0.49	7.98	0.44	4.42e-14	Eye color traits;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg18492115	chr19:7528785	ARHGEF18	0.48	6.46	0.37	4.85e-10	Fibrinogen levels;
CESC	cis	rs7267979	1.000	rs1077889	chr20:25267893	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	18.46	0.75	1.72e-49	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs4819052	0.851	rs1056101	chr21:46678702	C/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.49	6.13	0.35	3.26e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg06891006	chr4:10084680	WDR1	0.42	5.55	0.32	6.92e-8	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs2204008	0.744	rs1115514	chr12:38280140	C/T	cg26384229	chr12:38710491	ALG10B	0.65	9.03	0.49	3.55e-17	Bladder cancer;
CESC	cis	rs936229	0.813	rs1350193	chr15:75084281	G/C	cg14664628	chr15:75095509	CSK	-0.91	-13.32	-0.63	2.5e-31	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CESC	cis	rs898097	0.756	rs11655103	chr17:80813467	T/C	cg05255149	chr17:80675120	FN3KRP	-0.45	-5.26	-0.31	2.99e-7	Breast cancer;
CESC	cis	rs7965445	1.000	rs12423722	chr12:131866652	G/T	cg06712767	chr12:131118561	NA	0.54	5.07	0.3	7.33e-7	Mortality in heart failure;
CESC	cis	rs72945132	1.000	rs72945132	chr11:70113901	G/C	cg00319359	chr11:70116639	PPFIA1	0.84	7.86	0.43	9.71e-14	Coronary artery disease;
CESC	cis	rs888194	0.934	rs12314392	chr12:110010866	A/G	cg19025524	chr12:109796872	NA	-0.35	-5.13	-0.3	5.48e-7	Neuroticism;
CESC	cis	rs6546550	0.901	rs4852375	chr2:70125988	C/G	cg02498382	chr2:70120550	SNRNP27	-0.43	-7.41	-0.41	1.65e-12	Prevalent atrial fibrillation;
CESC	trans	rs853679	0.546	rs71537572	chr6:27970715	T/C	cg06606381	chr12:133084897	FBRSL1	-1.1	-8.82	-0.48	1.61e-16	Depression;
CESC	cis	rs798554	0.757	rs1182179	chr7:2873648	A/G	cg13628971	chr7:2884303	GNA12	0.61	7.92	0.44	6.39e-14	Height;
CESC	cis	rs6568686	0.627	rs174387	chr6:111915023	C/T	cg22127309	chr6:111907043	TRAF3IP2	0.53	5.36	0.31	1.82e-7	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
CESC	cis	rs5769765	0.862	rs138856	chr22:50199378	G/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.48	-5.2	-0.3	4.02e-7	Schizophrenia;
CESC	cis	rs597539	0.652	rs544370	chr11:68653232	C/T	cg06028808	chr11:68637592	NA	0.41	5.2	0.3	4.05e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs8092503	1.000	rs12959833	chr18:52492579	A/G	cg12377874	chr18:52495404	RAB27B	-0.37	-5.96	-0.34	8.15e-9	Childhood body mass index;
CESC	cis	rs6912958	0.781	rs3757368	chr6:88224495	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-5.11	-0.3	6.11e-7	Monocyte percentage of white cells;
CESC	cis	rs17253792	0.915	rs76957332	chr14:56195370	G/A	cg01858014	chr14:56050164	KTN1	-0.97	-7.52	-0.42	8.7e-13	Putamen volume;
CESC	cis	rs8077577	0.747	rs11872031	chr17:18150814	G/A	cg16794390	chr17:18148240	FLII	0.42	6.35	0.36	9.46e-10	Obesity-related traits;
CESC	cis	rs992157	0.835	rs4674282	chr2:219144230	A/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.68	-8.89	-0.48	9.33e-17	Colorectal cancer;
CESC	cis	rs2901656	0.640	rs9425316	chr1:172400860	C/T	cg03748243	chr1:172413542	C1orf105;PIGC	0.56	8.63	0.47	5.87e-16	Red cell distribution width;Platelet distribution width;
CESC	cis	rs875971	0.862	rs6962717	chr7:65883735	G/A	cg11764359	chr7:65958608	NA	0.81	11.89	0.59	2.11e-26	Aortic root size;
CESC	cis	rs950169	0.922	rs62029585	chr15:84951874	C/G	cg17507749	chr15:85114479	UBE2QP1	0.58	6.2	0.36	2.15e-9	Schizophrenia;
CESC	cis	rs3820068	0.603	rs72647128	chr1:15963908	T/C	cg17385448	chr1:15911702	AGMAT	0.42	6.89	0.39	4.06e-11	Systolic blood pressure;
CESC	cis	rs472402	0.560	rs2303705	chr5:6622017	A/C	cg10789808	chr5:6633262	NSUN2;SRD5A1	-0.48	-6.56	-0.37	2.77e-10	Response to amphetamines;
CESC	cis	rs722599	0.748	rs11623342	chr14:75347937	A/C	cg08847533	chr14:75593920	NEK9	-0.45	-5.36	-0.31	1.81e-7	IgG glycosylation;
CESC	cis	rs4819052	0.851	rs2838833	chr21:46665160	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.73	9.65	0.51	4.32e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs3741151	0.892	rs2027760	chr11:73036481	G/A	cg17517138	chr11:73019481	ARHGEF17	0.61	5.21	0.3	3.89e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23635580	chr17:41476114	ARL4D	-0.58	-7.09	-0.4	1.25e-11	Gut microbiome composition (summer);
CESC	cis	rs10242455	0.867	rs2687142	chr7:99320570	A/G	cg07715041	chr7:99302981	CYP3A7	-0.43	-5.42	-0.32	1.36e-7	Blood metabolite levels;
CESC	cis	rs208520	0.955	rs9345808	chr6:67008262	C/T	cg07460842	chr6:66804631	NA	0.64	7.48	0.42	1.12e-12	Exhaled nitric oxide output;
CESC	cis	rs13108904	0.650	rs3796618	chr4:1349602	T/A	cg16405210	chr4:1374714	KIAA1530	-0.54	-6.68	-0.38	1.42e-10	Obesity-related traits;
CESC	cis	rs1670533	1.000	rs7669622	chr4:1058659	A/G	cg27284194	chr4:1044797	NA	0.49	6.18	0.35	2.44e-9	Recombination rate (females);
CESC	cis	rs8049040	0.547	rs891131	chr16:71432417	G/A	cg08717414	chr16:71523259	ZNF19	-0.61	-6.71	-0.38	1.19e-10	Blood protein levels;
CESC	cis	rs4654899	1.000	rs6682368	chr1:21506914	G/A	cg05370193	chr1:21551575	ECE1	0.41	6.22	0.36	1.96e-9	Superior frontal gyrus grey matter volume;
CESC	cis	rs11235843	0.602	rs1830069	chr11:73433229	C/G	cg18195628	chr11:73498948	MRPL48	-0.47	-5.15	-0.3	5.14e-7	Hand grip strength;
CESC	cis	rs9811920	0.690	rs7623587	chr3:99906751	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.36	5.74	0.33	2.56e-8	Axial length;
CESC	cis	rs4555082	0.681	rs28588570	chr14:105709606	A/T	cg13114125	chr14:105738426	BRF1	-0.75	-9.35	-0.5	3.93e-18	Mean platelet volume;Platelet distribution width;
CESC	cis	rs35110281	0.806	rs1454649	chr21:45032982	C/T	cg04455712	chr21:45112962	RRP1B	0.38	5.49	0.32	9.39e-8	Mean corpuscular volume;
CESC	cis	rs10242455	0.702	rs79285548	chr7:99058396	T/C	cg18809830	chr7:99032528	PTCD1	-0.85	-5.63	-0.33	4.58e-8	Blood metabolite levels;
CESC	cis	rs853679	0.517	rs9368554	chr6:28082711	T/C	cg12963246	chr6:28129442	ZNF389	0.56	7.63	0.42	4.26e-13	Depression;
CESC	cis	rs2777491	0.957	rs7163788	chr15:41704789	A/G	cg12386646	chr15:41787261	ITPKA	0.35	5.16	0.3	4.92e-7	Ulcerative colitis;
CESC	cis	rs72781680	0.898	rs72798041	chr2:23953076	T/C	cg08917208	chr2:24149416	ATAD2B	1.13	10.25	0.53	5.6e-21	Lymphocyte counts;
CESC	cis	rs4664304	0.781	rs3828323	chr2:160808075	C/T	cg03641300	chr2:160917029	PLA2R1	-0.41	-5.42	-0.32	1.35e-7	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs453301	0.686	rs6987107	chr8:8893581	A/G	cg15556689	chr8:8085844	FLJ10661	-0.5	-6.09	-0.35	3.89e-9	Joint mobility (Beighton score);
CESC	cis	rs7552404	1.000	rs11161510	chr1:76210289	A/G	cg10523679	chr1:76189770	ACADM	-0.69	-7.9	-0.44	7.72e-14	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs72627123	0.867	rs74635757	chr14:74489225	C/T	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.73	5.65	0.33	4.06e-8	Morning vs. evening chronotype;
CESC	cis	rs193541	0.632	rs4835896	chr5:122121240	C/T	cg19412675	chr5:122181750	SNX24	-0.43	-5.12	-0.3	5.97e-7	Glucose homeostasis traits;
CESC	cis	rs6088580	0.634	rs1205336	chr20:32926336	G/A	cg06115741	chr20:33292138	TP53INP2	-0.45	-5.69	-0.33	3.36e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs7618915	0.501	rs34739010	chr3:52766122	A/G	cg18337363	chr3:52569053	NT5DC2	0.28	5.03	0.3	9.16e-7	Bipolar disorder;
CESC	cis	rs1707322	0.752	rs12047629	chr1:46162802	G/A	cg06784218	chr1:46089804	CCDC17	0.41	7.21	0.41	5.75e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs4713118	0.621	rs4713134	chr6:28034121	T/C	cg23281280	chr6:28129359	ZNF389	0.53	7.06	0.4	1.5e-11	Parkinson's disease;
CESC	cis	rs1577917	1.000	rs1857964	chr6:86635994	A/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-5.94	-0.34	8.86e-9	Response to antipsychotic treatment;
CESC	cis	rs12545109	0.800	rs1371936	chr8:57422715	A/G	cg09654669	chr8:57350985	NA	-0.55	-6.58	-0.37	2.56e-10	Obesity-related traits;
CESC	cis	rs35306767	0.671	rs11253473	chr10:906826	A/G	cg25019033	chr10:957182	NA	-0.57	-6.07	-0.35	4.31e-9	Eosinophil percentage of granulocytes;
CESC	cis	rs40363	0.645	rs1690447	chr16:3519211	T/C	cg05754148	chr16:3507555	NAT15	0.57	8.2	0.45	1.02e-14	Tuberculosis;
CESC	cis	rs9527	0.544	rs3781280	chr10:104863843	T/G	cg04362960	chr10:104952993	NT5C2	0.43	5.42	0.32	1.37e-7	Arsenic metabolism;
CESC	cis	rs9814567	0.964	rs9820425	chr3:134223018	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.44	-5.98	-0.35	7.05e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09806633	chr1:36689896	THRAP3	0.66	7.35	0.41	2.49e-12	Gut microbiome composition (summer);
CESC	cis	rs11112613	0.595	rs871219	chr12:105938519	C/A	cg03607813	chr12:105948248	NA	0.61	6.84	0.39	5.62e-11	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CESC	cis	rs9443645	0.670	rs79209669	chr6:79719623	C/G	cg05283184	chr6:79620031	NA	-0.43	-6.61	-0.38	2.06e-10	Intelligence (multi-trait analysis);
CESC	cis	rs9300255	0.639	rs1716171	chr12:123716376	C/T	cg05973401	chr12:123451056	ABCB9	0.51	5.66	0.33	3.91e-8	Neutrophil percentage of white cells;
CESC	cis	rs1691799	0.867	rs1168339	chr12:66759236	T/G	cg16791601	chr12:66731901	HELB	-0.79	-14.11	-0.65	4.25e-34	White blood cell count (basophil);
CESC	cis	rs8040855	0.690	rs8041189	chr15:85686327	A/G	cg08123816	chr15:85640762	PDE8A	0.41	5.76	0.33	2.38e-8	Bulimia nervosa;
CESC	cis	rs11122272	0.701	rs2749702	chr1:231523808	A/G	cg06096015	chr1:231504339	EGLN1	0.43	6.18	0.35	2.46e-9	Hemoglobin concentration;
CESC	cis	rs870825	0.860	rs34985821	chr4:185599489	G/A	cg04058563	chr4:185651563	MLF1IP	0.56	5.25	0.31	3.12e-7	Blood protein levels;
CESC	cis	rs17433780	0.666	rs2624	chr1:89518623	C/T	cg09516651	chr1:89888402	LOC400759	-0.66	-10.09	-0.53	1.81e-20	Carotid intima media thickness;
CESC	cis	rs7662987	0.793	rs4699700	chr4:99998335	A/G	cg13256891	chr4:100009986	ADH5	-0.59	-5.13	-0.3	5.71e-7	Smoking initiation;
CESC	cis	rs7927771	0.864	rs7937331	chr11:47430458	T/C	cg05585544	chr11:47624801	NA	0.42	6.19	0.36	2.3e-9	Subjective well-being;
CESC	trans	rs12356475	0.710	rs10822686	chr10:67733250	C/T	cg13596910	chr17:42254336	C17orf65;ASB16	-0.54	-6.38	-0.36	7.84e-10	Psoriatic arthritis;
CESC	cis	rs921968	0.584	rs2305833	chr2:219305404	G/C	cg02176678	chr2:219576539	TTLL4	0.38	6.44	0.37	5.62e-10	Mean corpuscular hemoglobin concentration;
CESC	cis	rs6540556	0.834	rs6700223	chr1:209935031	G/A	cg05527609	chr1:210001259	C1orf107	-0.4	-5.11	-0.3	6.08e-7	Red blood cell count;
CESC	cis	rs2204008	0.712	rs12371182	chr12:38321143	A/C	cg26384229	chr12:38710491	ALG10B	0.73	10.34	0.54	2.85e-21	Bladder cancer;
CESC	cis	rs2033711	0.870	rs7259841	chr19:58951123	T/C	cg11952622	chr19:58962976	ZNF324B	0.49	6.7	0.38	1.22e-10	Uric acid clearance;
CESC	cis	rs56399783	0.901	rs55767077	chr7:2774608	C/T	cg19731401	chr7:2775893	GNA12	0.69	6.13	0.35	3.19e-9	Childhood ear infection;
CESC	cis	rs6089829	0.925	rs11086152	chr20:61664656	T/C	cg08564027	chr20:61660810	NA	0.9	15.42	0.69	9.97e-39	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs367943	0.666	rs10074214	chr5:112702214	A/G	cg12552261	chr5:112820674	MCC	0.39	5.08	0.3	7.03e-7	Type 2 diabetes;
CESC	cis	rs367943	0.698	rs7718310	chr5:112970628	A/G	cg12552261	chr5:112820674	MCC	0.44	5.63	0.33	4.63e-8	Type 2 diabetes;
CESC	cis	rs9916302	0.706	rs7503377	chr17:37708841	A/G	cg00129232	chr17:37814104	STARD3	-0.56	-5.56	-0.32	6.57e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs3106136	0.546	rs2632417	chr4:95137542	G/C	cg11021082	chr4:95130006	SMARCAD1	-0.7	-11.56	-0.58	2.74e-25	Capecitabine sensitivity;
CESC	cis	rs4242434	0.927	rs746011	chr8:22457804	C/T	cg03733263	chr8:22462867	KIAA1967	0.97	14.07	0.65	5.82e-34	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CESC	cis	rs829880	0.558	rs249820	chr12:98897473	A/G	cg25150519	chr12:98850993	NA	0.51	5.97	0.34	7.65e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6089584	0.507	rs6061989	chr20:60627893	C/T	cg06108461	chr20:60628389	TAF4	-0.61	-8.18	-0.45	1.16e-14	Body mass index;
CESC	cis	rs9660180	0.967	rs2272908	chr1:1721479	A/G	cg23982607	chr1:1823379	GNB1	0.75	12.17	0.6	2.38e-27	Body mass index;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04902364	chr7:128696229	LOC286016;TNPO3	-0.64	-7.43	-0.42	1.5e-12	Gut microbiome composition (summer);
CESC	cis	rs6580649	0.941	rs7957764	chr12:48429701	C/T	cg24011408	chr12:48396354	COL2A1	-0.43	-5.35	-0.31	1.95e-7	Lung cancer;
CESC	cis	rs459571	0.839	rs10993895	chr9:136887726	C/T	cg13789015	chr9:136890014	NCRNA00094	-0.56	-8.08	-0.44	2.35e-14	Platelet distribution width;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg02034563	chr2:179060011	OSBPL6	0.45	6.2	0.36	2.15e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs7584330	0.638	rs13429533	chr2:238448712	A/G	cg14458575	chr2:238380390	NA	0.41	6.2	0.36	2.15e-9	Prostate cancer;
CESC	cis	rs12477438	0.520	rs13030961	chr2:99799520	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.85	14.88	0.67	7.98e-37	Chronic sinus infection;
CESC	cis	rs514406	0.929	rs557715	chr1:53321593	C/G	cg25767906	chr1:53392781	SCP2	-0.45	-5.76	-0.33	2.27e-8	Monocyte count;
CESC	trans	rs7943203	1.000	rs1960006	chr11:108294107	A/G	cg01416241	chr5:148737479	PCYOX1L	-0.48	-6.24	-0.36	1.74e-9	Red blood cell count;Mean corpuscular volume;
CESC	cis	rs7267979	0.934	rs6037085	chr20:25305202	C/T	cg08601574	chr20:25228251	PYGB	-0.39	-5.7	-0.33	3.23e-8	Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs916888	0.773	rs538628	chr17:44787313	G/C	cg10053473	chr17:62856997	LRRC37A3	-0.7	-7.51	-0.42	9.29e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg09033563	chr22:24373618	LOC391322	-0.43	-5.67	-0.33	3.73e-8	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs10927875	0.631	rs945418	chr1:16344730	T/C	cg22431228	chr1:16359049	CLCNKA	-0.5	-8.35	-0.46	3.76e-15	Dilated cardiomyopathy;
CESC	cis	rs2011503	0.882	rs10407933	chr19:19364319	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.54	5.73	0.33	2.76e-8	Bipolar disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21582780	chr11:59327931	NA	-0.64	-7.9	-0.44	7.63e-14	Gut microbiome composition (summer);
CESC	cis	rs6430585	0.528	rs309152	chr2:136657252	C/T	cg07169764	chr2:136633963	MCM6	-0.96	-13.31	-0.63	2.63e-31	Corneal structure;
CESC	trans	rs7937682	0.710	rs674230	chr11:111437887	A/G	cg18187862	chr3:45730750	SACM1L	0.57	7.18	0.4	7.14e-12	Primary sclerosing cholangitis;
CESC	trans	rs916888	0.821	rs199514	chr17:44856881	G/A	cg07870213	chr5:140052090	DND1	-0.62	-6.81	-0.39	6.5e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs28386778	0.965	rs2854154	chr17:61981696	C/A	cg11494091	chr17:61959527	GH2	-0.79	-14.06	-0.65	6.61e-34	Prudent dietary pattern;
CESC	cis	rs11997175	0.546	rs1561913	chr8:33587002	A/T	ch.8.33884649F	chr8:33765107	NA	0.56	7.31	0.41	3.18e-12	Body mass index;
CESC	cis	rs5760092	0.572	rs738806	chr22:24234172	A/G	cg11905131	chr22:24372483	LOC391322	-0.59	-6.94	-0.39	3.06e-11	Urinary 1,3-butadiene metabolite levels in smokers;
CESC	cis	rs3768617	0.510	rs1886501	chr1:183095234	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.89	14.39	0.66	4.39e-35	Fuchs's corneal dystrophy;
CESC	cis	rs1707322	0.890	rs2297883	chr1:46511487	G/C	cg06784218	chr1:46089804	CCDC17	-0.33	-5.65	-0.33	4.08e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs644799	0.932	rs523934	chr11:95641775	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.65	8.52	0.46	1.24e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs477692	0.549	rs7079744	chr10:131454790	G/A	cg05714579	chr10:131428358	MGMT	-0.42	-5.63	-0.33	4.47e-8	Response to temozolomide;
CESC	cis	rs4888262	0.545	rs8052923	chr16:74680105	C/T	cg01733217	chr16:74700730	RFWD3	0.9	12.18	0.6	2.13e-27	Testicular germ cell tumor;
CESC	cis	rs17376456	0.569	rs6881815	chr5:93105666	A/G	cg25358565	chr5:93447407	FAM172A	0.68	7.25	0.41	4.53e-12	Diabetic retinopathy;
CESC	cis	rs8114671	0.562	rs8116657	chr20:33476474	C/G	cg07148914	chr20:33460835	GGT7	0.52	6.78	0.38	7.94e-11	Height;
CESC	cis	rs3008870	0.958	rs34367328	chr1:67445321	T/C	cg08660285	chr1:67390436	MIER1;WDR78	-1.06	-15.19	-0.68	6.65e-38	Lymphocyte percentage of white cells;
CESC	cis	rs2294693	0.945	rs9369255	chr6:40989503	T/C	cg14769373	chr6:40998127	UNC5CL	-0.48	-6.38	-0.36	7.9e-10	Gastric cancer;Non-cardia gastric cancer;
CESC	cis	rs7267979	0.816	rs6138593	chr20:25504492	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.79	14.8	0.67	1.56e-36	Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs9646096	0.558	rs1830656	chr13:38004096	C/G	cg01311313	chr8:35252359	UNC5D	-0.5	-6.32	-0.36	1.1e-9	Age-related macular degeneration;
CESC	cis	rs939658	0.805	rs8036435	chr15:79420031	T/C	cg17916960	chr15:79447300	NA	-0.37	-6.1	-0.35	3.72e-9	Refractive error;
CESC	cis	rs4604732	0.631	rs11490199	chr1:247625737	A/G	cg12758973	chr1:247694275	LOC148824;OR2C3	0.51	6.36	0.36	8.65e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs8028182	0.609	rs10220738	chr15:75666546	A/T	cg20655648	chr15:75932815	IMP3	-0.45	-5.72	-0.33	2.86e-8	Sudden cardiac arrest;
CESC	cis	rs9314323	0.862	rs7813520	chr8:26263260	C/T	cg11498726	chr8:26250323	BNIP3L	-0.44	-6.46	-0.37	4.91e-10	Red cell distribution width;
CESC	cis	rs7107174	1.000	rs1006441	chr11:77932126	G/C	cg02023728	chr11:77925099	USP35	0.49	6.28	0.36	1.41e-9	Testicular germ cell tumor;
CESC	cis	rs12497850	0.931	rs7623023	chr3:48914238	G/A	cg06212747	chr3:49208901	KLHDC8B	0.67	9.3	0.5	5.49e-18	Parkinson's disease;
CESC	cis	rs1552244	0.572	rs17032426	chr3:10167112	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.68	-7.7	-0.43	2.64e-13	Alzheimer's disease;
CESC	cis	rs7714584	1.000	rs10078968	chr5:150244273	C/A	cg22134413	chr5:150180641	NA	0.49	5.7	0.33	3.1e-8	Crohn's disease;
CESC	cis	rs798766	0.953	rs13123646	chr4:1740539	T/C	cg10756475	chr4:1757242	NA	0.48	6.56	0.37	2.85e-10	Bladder cancer;Urinary bladder cancer;
CESC	cis	rs5758659	0.729	rs134866	chr22:42650663	C/T	cg00645731	chr22:42541494	CYP2D7P1	-0.3	-5.25	-0.31	3.1e-7	Cognitive function;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg06985640	chr6:89790434	PNRC1	-0.51	-6.5	-0.37	3.88e-10	Ulcerative colitis;
CESC	cis	rs425277	1.000	rs385039	chr1:2077409	C/T	cg04315214	chr1:2043799	PRKCZ	0.37	5.26	0.31	2.99e-7	Height;
CESC	cis	rs7818382	1.000	rs7818382	chr8:96054000	C/T	cg16049864	chr8:95962084	TP53INP1	-0.52	-8.53	-0.46	1.13e-15	Alzheimer's disease (late onset);
CESC	cis	rs6570726	0.935	rs395948	chr6:145820185	G/A	cg05347473	chr6:146136440	FBXO30	0.49	6.71	0.38	1.2e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs734999	0.549	rs3828154	chr1:2524943	G/A	cg20673091	chr1:2541236	MMEL1	0.43	7.25	0.41	4.49e-12	Ulcerative colitis;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg02290708	chr21:35747831	FAM165B	-0.44	-6.14	-0.35	2.99e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs9303542	0.559	rs56038617	chr17:46612578	C/T	cg04904318	chr17:46607828	HOXB1	-0.6	-5.74	-0.33	2.54e-8	Ovarian cancer;Epithelial ovarian cancer;
CESC	cis	rs798554	0.686	rs2527690	chr7:2854250	C/T	cg09658497	chr7:2847517	GNA12	-0.34	-5.09	-0.3	6.95e-7	Height;
CESC	cis	rs62408225	1.000	rs905670	chr6:90958502	G/A	cg06866423	chr6:90926672	BACH2	0.44	5.34	0.31	2.01e-7	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs7520050	0.933	rs4504835	chr1:46455571	G/A	cg03146154	chr1:46216737	IPP	-0.47	-6.06	-0.35	4.57e-9	Red blood cell count;Reticulocyte count;
CESC	trans	rs1814175	0.765	rs1721990	chr11:49912154	G/C	cg03929089	chr4:120376271	NA	-0.93	-16.26	-0.71	1.03e-41	Height;
CESC	cis	rs470119	0.966	rs140523	chr22:50962782	C/G	cg12969734	chr22:50962224	SCO2	0.4	6.13	0.35	3.24e-9	Mean corpuscular hemoglobin;
CESC	cis	rs71636778	0.543	rs34409791	chr1:27245363	A/G	cg12203394	chr1:27248618	NUDC	0.66	5.55	0.32	6.85e-8	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
CESC	cis	rs3741151	1.000	rs75114310	chr11:73042047	C/T	cg17517138	chr11:73019481	ARHGEF17	1.09	7.65	0.43	3.64e-13	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs2342371	0.756	rs3973	chr3:196124278	A/G	cg15048948	chr3:196158458	UBXN7	-0.53	-7.02	-0.4	1.85e-11	Fat distribution (HIV);
CESC	cis	rs34779708	0.931	rs68039650	chr10:35385499	C/A	cg04310649	chr10:35416472	CREM	-0.51	-6.06	-0.35	4.62e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs4665809	0.618	rs7579199	chr2:26266496	G/A	cg27170947	chr2:26402098	FAM59B	-0.58	-6.85	-0.39	5.29e-11	Gut microbiome composition (summer);
CESC	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.64	7.45	0.42	1.33e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs11122272	0.735	rs2491403	chr1:231511185	C/T	cg06096015	chr1:231504339	EGLN1	0.43	6.18	0.35	2.46e-9	Hemoglobin concentration;
CESC	cis	rs9837602	1.000	rs34626154	chr3:99756312	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.52	7.03	0.4	1.75e-11	Breast cancer;
CESC	cis	rs7772486	0.806	rs2265477	chr6:146212338	T/C	cg05347473	chr6:146136440	FBXO30	0.49	6.45	0.37	5.3e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7618915	0.547	rs62255371	chr3:52747321	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.5	7.14	0.4	9.2e-12	Bipolar disorder;
CESC	cis	rs10504073	0.584	rs7820270	chr8:49971395	G/T	cg00325661	chr8:49890786	NA	0.57	8.65	0.47	5.15e-16	Blood metabolite ratios;
CESC	cis	rs9291683	0.609	rs55959894	chr4:10026580	G/A	cg00071950	chr4:10020882	SLC2A9	0.89	16.34	0.71	5.44e-42	Bone mineral density;
CESC	cis	rs853679	0.517	rs17711344	chr6:28077602	A/G	cg18032046	chr6:28092343	ZSCAN16	0.56	6.45	0.37	5.16e-10	Depression;
CESC	cis	rs10504229	1.000	rs59383954	chr8:58189689	G/A	cg05313129	chr8:58192883	C8orf71	-0.55	-6.29	-0.36	1.34e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs10979	0.965	rs9376759	chr6:143886959	G/A	cg25407410	chr6:143891975	LOC285740	-0.59	-8.84	-0.48	1.32e-16	Hypospadias;
CESC	cis	rs2204008	0.744	rs11514358	chr12:38255526	G/A	cg26384229	chr12:38710491	ALG10B	0.72	10.26	0.53	5.3e-21	Bladder cancer;
CESC	cis	rs873946	0.648	rs12767126	chr10:134556992	C/T	cg26818010	chr10:134567672	INPP5A	-0.9	-10.88	-0.56	4.78e-23	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs1707322	1.000	rs6675222	chr1:46326576	G/T	cg05343316	chr1:45956843	TESK2	0.44	5.51	0.32	8.33e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7666738	0.830	rs4345191	chr4:98945408	A/G	cg05340658	chr4:99064831	C4orf37	0.82	12.66	0.61	4.8e-29	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9911578	1.000	rs2531729	chr17:56539890	C/T	cg05425664	chr17:57184151	TRIM37	-0.5	-6.94	-0.39	2.97e-11	Intelligence (multi-trait analysis);
CESC	cis	rs2576037	0.526	rs7234570	chr18:44459656	A/G	cg19077165	chr18:44547161	KATNAL2	-0.54	-7.94	-0.44	5.81e-14	Personality dimensions;
CESC	cis	rs736408	0.562	rs2072390	chr3:52780509	A/T	cg17372223	chr3:52568218	NT5DC2	0.42	6.33	0.36	1.04e-9	Bipolar disorder;
CESC	cis	rs3008870	1.000	rs912797	chr1:67413478	A/G	cg02640540	chr1:67518911	SLC35D1	0.51	5.58	0.32	5.89e-8	Lymphocyte percentage of white cells;
CESC	trans	rs3780486	0.846	rs10813960	chr9:33180362	C/T	cg20290983	chr6:43655470	MRPS18A	0.85	12.26	0.6	1.09e-27	IgG glycosylation;
CESC	cis	rs113835537	0.529	rs80100524	chr11:66245936	C/T	cg24851651	chr11:66362959	CCS	0.46	5.78	0.33	2.12e-8	Airway imaging phenotypes;
CESC	cis	rs2836974	0.627	rs8127986	chr21:40687211	A/T	cg22974920	chr21:40686053	BRWD1	-0.42	-5.14	-0.3	5.31e-7	Cognitive function;
CESC	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.82	8.33	0.46	4.25e-15	Platelet count;
CESC	cis	rs7949030	0.596	rs11231138	chr11:62316195	C/G	cg22862634	chr11:62369728	EML3;MTA2	0.59	8.11	0.45	1.89e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs7613875	0.620	rs34312088	chr3:50032133	C/T	cg24110177	chr3:50126178	RBM5	-0.56	-7.77	-0.43	1.72e-13	Body mass index;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg23837253	chr19:47759802	CCDC9	-0.45	-6.46	-0.37	5.11e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs4523957	0.583	rs2984942	chr17:2030155	A/G	cg16513277	chr17:2031491	SMG6	-0.77	-11.25	-0.57	2.98e-24	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs11997175	0.756	rs4739435	chr8:33818818	A/G	ch.8.33884649F	chr8:33765107	NA	0.66	9.06	0.49	3.03e-17	Body mass index;
CESC	cis	rs17376456	0.690	rs6892055	chr5:93113023	A/T	cg21475434	chr5:93447410	FAM172A	0.8	7.15	0.4	8.45e-12	Diabetic retinopathy;
CESC	cis	rs589448	0.967	rs634512	chr12:69754012	C/T	cg22834771	chr12:69754056	YEATS4	-0.55	-7.29	-0.41	3.67e-12	Cerebrospinal fluid biomarker levels;
CESC	cis	rs2243480	1.000	rs160655	chr7:65533214	T/C	cg12463550	chr7:65579703	CRCP	0.65	5.08	0.3	7.08e-7	Diabetic kidney disease;
CESC	cis	rs10504229	1.000	rs9650139	chr8:58190508	G/T	cg22535103	chr8:58192502	C8orf71	-1.04	-13.21	-0.63	5.76e-31	Developmental language disorder (linguistic errors);
CESC	cis	rs16854884	0.657	rs16854819	chr3:143736126	C/T	cg06585982	chr3:143692056	C3orf58	-0.51	-6.76	-0.38	8.98e-11	Economic and political preferences (feminism/equality);
CESC	trans	rs9325144	0.600	rs12227663	chr12:38734922	C/T	cg23762105	chr12:34175262	ALG10	0.48	6.23	0.36	1.81e-9	Morning vs. evening chronotype;
CESC	cis	rs4891159	0.548	rs12454625	chr18:74128751	A/G	cg24786174	chr18:74118243	ZNF516	0.84	15.96	0.7	1.24e-40	Longevity;
CESC	cis	rs8050907	0.590	rs10500325	chr16:4553192	A/G	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.81	5.25	0.31	3.13e-7	Obesity-related traits;
CESC	cis	rs501120	1.000	rs504799	chr10:44753456	C/T	cg09554077	chr10:44749378	NA	0.52	6.89	0.39	3.96e-11	Coronary artery disease;Coronary heart disease;
CESC	cis	rs7772486	0.846	rs7755440	chr6:146375906	T/C	cg05347473	chr6:146136440	FBXO30	0.5	6.41	0.37	6.45e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7618915	0.571	rs2289249	chr3:52597664	G/A	cg17372223	chr3:52568218	NT5DC2	0.43	6.31	0.36	1.19e-9	Bipolar disorder;
CESC	cis	rs9649213	0.613	rs2286074	chr7:97952011	G/A	cg00277769	chr7:97922759	BAIAP2L1	-0.34	-5.61	-0.33	4.97e-8	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09676606	chr12:102132872	SYCP3	-0.63	-6.85	-0.39	5.27e-11	Gut microbiome composition (summer);
CESC	cis	rs7829975	0.840	rs555617	chr8:8592845	C/G	cg18904891	chr8:8559673	CLDN23	-0.42	-5.12	-0.3	5.84e-7	Mood instability;
CESC	cis	rs2019216	0.542	rs8073228	chr17:21909838	C/G	cg22648282	chr17:21454238	C17orf51	-0.46	-6.12	-0.35	3.38e-9	Pelvic organ prolapse;
CESC	cis	rs6973256	0.605	rs7794168	chr7:133357606	T/C	cg10665199	chr7:133106180	EXOC4	0.46	6.29	0.36	1.28e-9	Intelligence (multi-trait analysis);
CESC	cis	rs10504229	0.906	rs67389108	chr8:58193718	G/A	cg05313129	chr8:58192883	C8orf71	-0.52	-6.03	-0.35	5.41e-9	Developmental language disorder (linguistic errors);
CESC	trans	rs11098499	0.909	rs28714195	chr4:120316950	A/T	cg25214090	chr10:38739885	LOC399744	0.69	9.38	0.5	3.13e-18	Corneal astigmatism;
CESC	cis	rs2637266	0.783	rs2395436	chr10:78488513	G/T	cg18941641	chr10:78392320	NA	0.45	8.7	0.47	3.5e-16	Pulmonary function;
CESC	cis	rs9915657	0.870	rs35271702	chr17:70140516	G/A	cg06234051	chr17:70120541	SOX9	-0.45	-6.56	-0.37	2.8e-10	Thyroid hormone levels;
CESC	cis	rs4523957	0.583	rs9889861	chr17:2041369	A/G	cg16513277	chr17:2031491	SMG6	-0.79	-11.73	-0.58	6.95e-26	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	trans	rs948562	0.744	rs74406537	chr11:58220360	G/A	cg24637035	chr12:120445227	CCDC64	-0.5	-6.06	-0.35	4.67e-9	Lymphoma;
CESC	cis	rs7927771	0.832	rs4752994	chr11:47411065	A/T	cg18512352	chr11:47633146	NA	0.54	8.0	0.44	3.78e-14	Subjective well-being;
CESC	cis	rs7586879	0.616	rs10206196	chr2:25137323	T/C	cg01884057	chr2:25150051	NA	0.4	7.71	0.43	2.62e-13	Body mass index;
CESC	cis	rs2836974	0.897	rs12481860	chr21:40537836	T/A	cg17971929	chr21:40555470	PSMG1	1.06	16.27	0.71	9.28e-42	Cognitive function;
CESC	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg03188948	chr7:1209495	NA	0.53	5.98	0.35	7.04e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs6502050	0.799	rs7212023	chr17:80170354	G/A	cg11859384	chr17:80120422	CCDC57	-0.38	-5.25	-0.31	3.06e-7	Life satisfaction;
CESC	cis	rs644799	0.544	rs1622515	chr11:95523433	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.59	7.98	0.44	4.44e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs722599	0.748	rs20578	chr14:75367807	C/T	cg11812906	chr14:75593930	NEK9	-0.47	-5.69	-0.33	3.32e-8	IgG glycosylation;
CESC	cis	rs1144333	0.850	rs1251273	chr1:76288617	A/G	cg10523679	chr1:76189770	ACADM	-0.56	-5.28	-0.31	2.65e-7	Attention function in attention deficit hyperactive disorder;
CESC	cis	rs8114671	0.562	rs1060615	chr20:33478381	C/T	cg24642439	chr20:33292090	TP53INP2	-0.44	-5.41	-0.32	1.44e-7	Height;
CESC	cis	rs4665809	0.590	rs13387855	chr2:26420708	T/G	cg26314531	chr2:26401878	FAM59B	-0.83	-9.29	-0.5	5.94e-18	Gut microbiome composition (summer);
CESC	cis	rs2228479	0.681	rs11642428	chr16:89971909	A/T	cg04013166	chr16:89971882	TCF25	0.71	8.49	0.46	1.48e-15	Skin colour saturation;
CESC	cis	rs763014	0.898	rs1045277	chr16:633125	T/C	cg00802000	chr16:706648	WDR90	-0.41	-6.12	-0.35	3.33e-9	Height;
CESC	cis	rs2066819	1.000	rs871130	chr12:56648777	A/G	cg26734620	chr12:56694298	CS	-1.04	-6.73	-0.38	1.06e-10	Psoriasis vulgaris;
CESC	cis	rs17431357	0.881	rs73230303	chr12:120980289	T/C	cg25045489	chr12:120971538	RNF10	-0.93	-5.46	-0.32	1.1e-7	Insulin resistance/response;
CESC	cis	rs9311474	0.539	rs12489828	chr3:52567014	G/T	cg18337363	chr3:52569053	NT5DC2	0.34	6.6	0.38	2.29e-10	Electroencephalogram traits;
CESC	cis	rs936229	0.784	rs12906946	chr15:75153140	A/G	cg14664628	chr15:75095509	CSK	-0.75	-9.19	-0.49	1.21e-17	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CESC	cis	rs12701220	0.901	rs12701710	chr7:1090396	A/G	cg26769984	chr7:1090371	C7orf50	-0.65	-7.66	-0.43	3.44e-13	Bronchopulmonary dysplasia;
CESC	cis	rs67478160	0.643	rs6575997	chr14:104228546	C/T	cg08213375	chr14:104286397	PPP1R13B	-0.51	-10.29	-0.53	3.98e-21	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02758053	chr19:56165495	U2AF2	0.6	6.63	0.38	1.92e-10	Gut microbiome composition (summer);
CESC	cis	rs1144713	0.531	rs2683491	chr12:32250865	A/T	cg01321189	chr12:32259338	BICD1	0.45	5.8	0.34	1.84e-8	Obesity-related traits;
CESC	cis	rs62229266	0.804	rs11088331	chr21:37421872	T/C	cg08632701	chr21:37451849	NA	-0.37	-5.2	-0.3	3.98e-7	Mitral valve prolapse;
CESC	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg24642844	chr7:1081250	C7orf50	-0.82	-9.97	-0.52	4.47e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs1348850	0.567	rs1405714	chr2:178538584	A/G	cg22681709	chr2:178499509	PDE11A	0.55	8.72	0.47	3.16e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs7666738	0.830	rs10031292	chr4:99056877	A/G	cg17366294	chr4:99064904	C4orf37	0.6	8.74	0.47	2.74e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.35	-5.13	-0.3	5.55e-7	Longevity;Endometriosis;
CESC	cis	rs4737010	0.536	rs6474365	chr8:41662940	G/T	cg08923054	chr8:41654455	ANK1	0.61	7.59	0.42	5.37e-13	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
CESC	cis	rs9322193	0.923	rs9322209	chr6:150012362	A/G	cg13206674	chr6:150067644	NUP43	0.45	6.49	0.37	4.24e-10	Lung cancer;
CESC	cis	rs2303759	0.830	rs7257053	chr19:49894456	C/G	cg24324837	chr19:49891574	CCDC155	0.54	6.33	0.36	1.02e-9	Multiple sclerosis;
CESC	cis	rs7618501	0.633	rs4688690	chr3:50022292	G/A	cg24110177	chr3:50126178	RBM5	-0.53	-7.23	-0.41	5.13e-12	Intelligence (multi-trait analysis);
CESC	cis	rs9796	0.689	rs9888710	chr15:41446153	G/C	cg18705301	chr15:41695430	NDUFAF1	-0.46	-6.85	-0.39	5.07e-11	Menopause (age at onset);
CESC	cis	rs34779708	0.931	rs1926554	chr10:35344969	C/T	cg04310649	chr10:35416472	CREM	-0.49	-5.87	-0.34	1.31e-8	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs2430307	0.556	rs3930019	chr7:76541610	C/T	cg15770687	chr7:76625569	PMS2L11	0.6	5.9	0.34	1.13e-8	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
CESC	trans	rs3741489	1.000	rs4758889	chr12:133475533	C/T	cg24132527	chr5:140019269	TMCO6	1.1	7.39	0.41	1.91e-12	Cognitive function;
CESC	cis	rs9814567	0.964	rs4539979	chr3:134287597	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.42	-5.74	-0.33	2.62e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs2075371	0.965	rs1862049	chr7:133978344	A/T	cg00033643	chr7:134001901	SLC35B4	0.41	5.32	0.31	2.2e-7	Mean platelet volume;
CESC	trans	rs12429889	0.831	rs6562808	chr13:74745973	T/C	cg03455107	chr17:54509207	ANKFN1	0.36	6.23	0.36	1.87e-9	Sudden cardiac arrest;
CESC	cis	rs9322193	0.923	rs4354168	chr6:150017778	C/T	cg04369109	chr6:150039330	LATS1	-0.38	-5.31	-0.31	2.29e-7	Lung cancer;
CESC	cis	rs4979906	1.000	rs12264636	chr10:79448539	C/G	cg07817648	chr10:79422355	NA	0.6	6.34	0.36	1.01e-9	Mortality in heart failure;
CESC	cis	rs2645694	0.626	rs2703140	chr4:77830057	C/G	cg18351406	chr4:77819688	ANKRD56	0.53	6.34	0.36	9.71e-10	Emphysema distribution in smoking;
CESC	cis	rs2235544	0.565	rs665421	chr1:54469883	T/C	cg25741118	chr1:54482237	LDLRAD1	0.24	5.76	0.33	2.29e-8	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
CESC	cis	rs2733201	1.000	rs2615285	chr15:44417376	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	-0.61	-5.62	-0.33	4.75e-8	Lipoprotein phospholipase A2 activity in cardiovascular disease;
CESC	cis	rs523522	0.923	rs2235217	chr12:120884328	C/T	cg12219531	chr12:120966889	COQ5	0.71	8.97	0.48	5.62e-17	High light scatter reticulocyte count;
CESC	cis	rs11690935	0.655	rs17614941	chr2:172541378	A/G	cg13550731	chr2:172543902	DYNC1I2	0.56	8.36	0.46	3.61e-15	Schizophrenia;
CESC	cis	rs9300255	0.739	rs2337934	chr12:123745359	A/G	cg05973401	chr12:123451056	ABCB9	0.5	5.68	0.33	3.53e-8	Neutrophil percentage of white cells;
CESC	cis	rs1044826	0.619	rs6439856	chr3:139134868	A/T	cg00490450	chr3:139108681	COPB2	-0.41	-5.04	-0.3	8.46e-7	Obesity-related traits;
CESC	cis	rs9905704	0.918	rs12952362	chr17:56900870	A/G	cg12560992	chr17:57184187	TRIM37	0.61	7.05	0.4	1.54e-11	Testicular germ cell tumor;
CESC	cis	rs4851870	1.000	rs13025634	chr2:106440678	C/T	cg16077055	chr2:106428750	NCK2	-0.39	-5.12	-0.3	5.84e-7	Addiction;
CESC	cis	rs6502050	0.835	rs34867501	chr17:80121358	T/C	cg23985595	chr17:80112537	CCDC57	-0.41	-6.57	-0.37	2.6200000000000003e-10	Life satisfaction;
CESC	cis	rs7647973	1.000	rs1982861	chr3:49577665	A/G	cg02487422	chr3:49467188	NICN1	0.41	5.33	0.31	2.06e-7	Menarche (age at onset);
CESC	cis	rs67311347	0.866	rs2371183	chr3:40334247	C/T	cg24209194	chr3:40518798	ZNF619	-0.42	-5.46	-0.32	1.12e-7	Renal cell carcinoma;
CESC	cis	rs6701037	1.000	rs6701037	chr1:175120079	G/T	cg00321850	chr1:175162397	KIAA0040	0.4	5.51	0.32	8.33e-8	Alcohol dependence;
CESC	cis	rs11690935	0.959	rs6709156	chr2:172591944	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.97	-14.93	-0.68	5.55e-37	Schizophrenia;
CESC	cis	rs6061231	0.505	rs13037253	chr20:60928724	G/A	cg22633769	chr20:60982531	CABLES2	0.6	6.28	0.36	1.39e-9	Colorectal cancer;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg09854775	chr9:137029881	RNU6ATAC	0.48	6.1	0.35	3.82e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs1707322	0.752	rs11211147	chr1:46110094	A/G	cg06784218	chr1:46089804	CCDC17	0.4	7.04	0.4	1.69e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2980436	1	rs2980436	chr8:8092025	A/G	cg06636001	chr8:8085503	FLJ10661	-0.6	-7.28	-0.41	3.85e-12	Schizophrenia;
CESC	cis	rs2073300	1.000	rs6137976	chr20:23463241	C/T	cg12062639	chr20:23401060	NAPB	0.92	6.06	0.35	4.62e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs2251381	0.750	rs8129616	chr21:30520085	C/T	cg24692254	chr21:30365293	RNF160	-0.79	-10.84	-0.55	6.83e-23	Selective IgA deficiency;
CESC	cis	rs617791	0.530	rs55947178	chr11:65754230	G/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.44	-5.04	-0.3	8.66e-7	Breast cancer;
CESC	cis	rs7772486	0.686	rs7744014	chr6:146123818	G/A	cg05347473	chr6:146136440	FBXO30	0.52	6.84	0.39	5.37e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2929278	0.617	rs11070410	chr15:44057045	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.49	-7.71	-0.43	2.5e-13	Schizophrenia;
CESC	cis	rs9291683	0.588	rs3756236	chr4:10013463	T/A	cg02734326	chr4:10020555	SLC2A9	0.52	7.43	0.42	1.5e-12	Bone mineral density;
CESC	cis	rs732765	0.648	rs8019391	chr14:75409682	T/C	cg21190982	chr14:75180524	FCF1;KIAA0317	-0.38	-5.28	-0.31	2.64e-7	Non-small cell lung cancer;
CESC	cis	rs4805272	0.626	rs6509072	chr19:29331703	C/G	cg12756686	chr19:29218302	NA	0.42	5.84	0.34	1.56e-8	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
CESC	cis	rs61008539	0.893	rs4719460	chr7:859610	C/T	cg00934597	chr7:893267	UNC84A	0.48	6.55	0.37	3.04e-10	Perceived unattractiveness to mosquitoes;
CESC	cis	rs1003719	0.614	rs1053808	chr21:38525356	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.56	-7.4	-0.41	1.78e-12	Eye color traits;
CESC	cis	rs9649213	0.574	rs62479853	chr7:97917158	G/T	cg08684580	chr7:98029266	BAIAP2L1	-0.33	-5.13	-0.3	5.56e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs3540	0.533	rs2256097	chr15:90971331	A/T	cg22089800	chr15:90895588	ZNF774	0.63	8.39	0.46	2.99e-15	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs801193	1.000	rs10234018	chr7:66146284	A/T	cg14393609	chr7:65229607	NA	-0.51	-6.93	-0.39	3.27e-11	Aortic root size;
CESC	cis	rs7412746	0.611	rs9661876	chr1:150910911	C/T	cg04414720	chr1:150670196	GOLPH3L	0.45	5.96	0.34	8.13e-9	Melanoma;
CESC	cis	rs7647973	0.667	rs11721148	chr3:49646669	G/A	cg07636037	chr3:49044803	WDR6	0.6	7.17	0.4	7.33e-12	Menarche (age at onset);
CESC	cis	rs10504229	0.683	rs67048677	chr8:58140023	C/G	cg24829409	chr8:58192753	C8orf71	-0.59	-7.31	-0.41	3.16e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs9611565	0.512	rs6519289	chr22:42170432	A/C	cg03806693	chr22:41940476	POLR3H	1.19	14.03	0.65	7.9e-34	Vitiligo;
CESC	cis	rs12497850	0.931	rs4974082	chr3:48999323	G/A	cg03060546	chr3:49711283	APEH	0.52	6.49	0.37	4.27e-10	Parkinson's disease;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg27172057	chr12:64616385	C12orf66	-0.5	-6.41	-0.37	6.48e-10	Height;
CESC	cis	rs12477438	0.798	rs1349778	chr2:99645011	G/C	cg08885076	chr2:99613938	TSGA10	-0.38	-5.06	-0.3	7.82e-7	Chronic sinus infection;
CESC	cis	rs763121	0.853	rs8138996	chr22:39047435	G/T	cg14440974	chr22:39074834	NA	-0.4	-5.48	-0.32	9.77e-8	Menopause (age at onset);
CESC	trans	rs11098499	0.569	rs10023641	chr4:120258410	C/G	cg25214090	chr10:38739885	LOC399744	0.61	8.64	0.47	5.37e-16	Corneal astigmatism;
CESC	cis	rs9916302	0.731	rs11868030	chr17:37650332	A/G	cg07936489	chr17:37558343	FBXL20	-0.81	-11.96	-0.59	1.17e-26	Glomerular filtration rate (creatinine);
CESC	trans	rs1557351	0.723	rs1893445	chr18:54722694	G/A	cg11433624	chr6:7146702	RREB1	0.38	6.14	0.35	2.94e-9	Multiple sclerosis (age of onset);
CESC	cis	rs9611565	0.659	rs12483998	chr22:41935362	A/G	cg03806693	chr22:41940476	POLR3H	-1.19	-14.84	-0.67	1.11e-36	Vitiligo;
CESC	cis	rs7772486	0.754	rs4896832	chr6:145964151	G/A	cg23711669	chr6:146136114	FBXO30	0.98	14.9	0.68	6.68e-37	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs561341	0.830	rs2301765	chr17:30202056	T/A	cg12193833	chr17:30244370	NA	0.54	5.5	0.32	9.16e-8	Hip circumference adjusted for BMI;
CESC	cis	rs17539620	0.624	rs62432737	chr6:154834772	G/A	cg17771515	chr6:154831774	CNKSR3	0.58	5.79	0.34	1.98e-8	Lipoprotein (a) levels;
CESC	cis	rs10751667	0.666	rs7944815	chr11:959776	C/T	cg20946044	chr11:1010712	AP2A2	-0.38	-5.28	-0.31	2.65e-7	Alzheimer's disease (late onset);
CESC	cis	rs4665809	1.000	rs6704930	chr2:26325705	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.66	-7.36	-0.41	2.36e-12	Gut microbiome composition (summer);
CESC	cis	rs708547	0.874	rs73242624	chr4:57847420	C/G	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.59	-6.0	-0.35	6.48e-9	Response to bleomycin (chromatid breaks);
CESC	cis	rs9611565	0.729	rs73176689	chr22:41782633	T/C	cg03806693	chr22:41940476	POLR3H	-1.18	-14.86	-0.67	9.94e-37	Vitiligo;
CESC	cis	rs7216064	0.532	rs8065296	chr17:66018562	T/A	cg07042672	chr17:66097459	LOC651250	0.61	7.95	0.44	5.31e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs3733585	0.631	rs7699671	chr4:10125874	C/T	cg00071950	chr4:10020882	SLC2A9	-0.67	-10.43	-0.54	1.42e-21	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs10504229	1.000	rs67237174	chr8:58175776	T/C	cg22535103	chr8:58192502	C8orf71	-1.06	-13.35	-0.63	2.01e-31	Developmental language disorder (linguistic errors);
CESC	trans	rs9329221	0.572	rs4841295	chr8:10105115	C/T	cg15556689	chr8:8085844	FLJ10661	0.56	6.82	0.39	6e-11	Neuroticism;
CESC	cis	rs875971	0.545	rs316323	chr7:65610989	C/T	cg18876405	chr7:65276391	NA	-0.51	-5.96	-0.34	8.21e-9	Aortic root size;
CESC	cis	rs4721295	0.573	rs3779000	chr7:2181628	G/A	cg04267008	chr7:1944627	MAD1L1	-0.58	-6.84	-0.39	5.46e-11	Schizophrenia, schizoaffective disorder or bipolar disorder;
CESC	cis	rs4665809	0.531	rs12990692	chr2:26464939	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.06	12.34	0.6	5.85e-28	Gut microbiome composition (summer);
CESC	cis	rs8103278	0.507	rs62111759	chr19:46296230	A/T	cg11657440	chr19:46296263	DMWD	0.85	13.25	0.63	4.38e-31	Coronary artery disease;
CESC	cis	rs9287719	0.967	rs10167129	chr2:10758575	G/A	cg02196655	chr2:10830764	NOL10	-0.37	-5.67	-0.33	3.73e-8	Prostate cancer;
CESC	trans	rs10203140	0.893	rs2355192	chr2:52261494	A/G	ch.9.14534598R	chr9:14544598	NA	0.58	6.03	0.35	5.35e-9	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg01811378	chr1:120611586	NOTCH2	-0.43	-6.02	-0.35	5.72e-9	Fibrinogen levels;
CESC	cis	rs9894429	1.000	rs4074915	chr17:79579230	G/A	cg18240062	chr17:79603768	NPLOC4	-0.72	-10.27	-0.53	4.82e-21	Eye color traits;
CESC	cis	rs634534	0.562	rs642293	chr11:65730217	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.74	10.78	0.55	1.02e-22	Sum eosinophil basophil counts;Eosinophil counts;
CESC	cis	rs7666738	0.830	rs35938349	chr4:98974998	T/C	cg03467027	chr4:99064603	C4orf37	0.43	5.4	0.31	1.49e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs910316	0.967	rs8013444	chr14:75661981	A/G	cg16144293	chr14:75469539	EIF2B2	0.41	5.31	0.31	2.3e-7	Height;
CESC	cis	rs250677	0.522	rs7702695	chr5:148402550	T/A	cg18129178	chr5:148520854	ABLIM3	-0.48	-5.35	-0.31	1.89e-7	Breast cancer;
CESC	cis	rs2130392	0.702	rs12108497	chr4:185571557	C/T	cg21366198	chr4:185655624	MLF1IP	-0.51	-6.76	-0.38	8.81e-11	Kawasaki disease;
CESC	cis	rs873946	0.504	rs12254034	chr10:134571007	T/C	cg26818010	chr10:134567672	INPP5A	-0.85	-10.62	-0.55	3.48e-22	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs10504229	0.593	rs12155520	chr8:58014318	C/T	cg02725872	chr8:58115012	NA	-0.38	-5.1	-0.3	6.54e-7	Developmental language disorder (linguistic errors);
CESC	trans	rs3118233	1	rs3118233	chr16:68733646	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.71	-9.39	-0.5	2.78e-18	Red cell distribution width;
CESC	cis	rs7843479	0.601	rs7220	chr8:21863290	G/A	cg17168535	chr8:21777572	XPO7	0.72	11.14	0.56	6.59e-24	Mean corpuscular volume;
CESC	cis	rs3096299	0.658	rs12443705	chr16:89547054	C/G	cg16743903	chr16:89593216	SPG7	-0.44	-5.63	-0.33	4.7e-8	Multiple myeloma (IgH translocation);
CESC	cis	rs4234798	0.500	rs34694340	chr4:7221424	A/C	cg18431297	chr4:7219810	SORCS2	0.6	10.15	0.53	1.15e-20	Insulin-like growth factors;
CESC	cis	rs72781680	0.898	rs17462433	chr2:24012758	T/C	cg20701182	chr2:24300061	SF3B14	0.63	5.65	0.33	4.21e-8	Lymphocyte counts;
CESC	cis	rs6860806	0.507	rs2631362	chr5:131707293	A/G	cg18758796	chr5:131593413	PDLIM4	-0.46	-6.43	-0.37	5.87e-10	Breast cancer;
CESC	trans	rs7335046	1.000	rs7322759	chr13:99909678	C/G	cg14259717	chr11:18433732	LDHC	0.6	6.06	0.35	4.74e-9	Basal cell carcinoma;
CESC	cis	rs713587	0.571	rs2438679	chr2:25317653	C/T	cg01884057	chr2:25150051	NA	-0.3	-5.2	-0.3	3.95e-7	Body mass index in non-asthmatics;
CESC	cis	rs62344088	0.590	rs58563514	chr5:177837	C/T	cg22857025	chr5:266934	NA	-1.1	-8.56	-0.47	9.31e-16	Asthma (childhood onset);
CESC	cis	rs524023	0.957	rs528211	chr11:64351721	C/T	cg07220939	chr11:64358617	SLC22A12	0.34	5.24	0.31	3.3e-7	Urate levels in obese individuals;
CESC	cis	rs7264396	0.733	rs6058305	chr20:34310757	C/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.63	7.58	0.42	5.71e-13	Total cholesterol levels;
CESC	cis	rs3858526	0.523	rs10838750	chr11:5886246	C/T	cg13902645	chr11:5959945	NA	0.68	10.41	0.54	1.68e-21	DNA methylation (variation);
CESC	cis	rs11031096	0.711	rs4910891	chr11:4153408	A/G	cg18678763	chr11:4115507	RRM1	-0.46	-6.31	-0.36	1.19e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	cis	rs290268	0.838	rs290993	chr9:93559572	G/A	cg02608019	chr9:93564028	SYK	0.67	10.21	0.53	7.53e-21	Platelet count;
CESC	cis	rs72945132	0.882	rs56770826	chr11:70128874	A/G	cg00319359	chr11:70116639	PPFIA1	0.78	7.78	0.43	1.6e-13	Coronary artery disease;
CESC	cis	rs780096	0.546	rs4665976	chr2:27640325	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.32	-5.99	-0.35	6.73e-9	Total body bone mineral density;
CESC	cis	rs9640161	0.636	rs3735171	chr7:150033882	A/G	cg21361702	chr7:150065534	REPIN1	0.51	5.53	0.32	7.51e-8	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs2549003	0.870	rs61175929	chr5:131821548	C/G	cg21138405	chr5:131827807	IRF1	0.54	9.32	0.5	4.74e-18	Asthma (sex interaction);
CESC	cis	rs6696846	0.749	rs61822566	chr1:205078660	T/C	cg00857998	chr1:205179979	DSTYK	0.51	6.96	0.39	2.6e-11	Red blood cell count;
CESC	trans	rs6991952	0.845	rs7822766	chr8:25742279	A/T	cg04738309	chr5:111093624	C5orf13	-0.49	-6.02	-0.35	5.8e-9	Inguinal hernia;
CESC	cis	rs832540	0.629	rs10461616	chr5:56080347	T/C	cg24531977	chr5:56204891	C5orf35	-0.48	-6.0	-0.35	6.53e-9	Coronary artery disease;
CESC	cis	rs7772486	0.743	rs9403742	chr6:146060193	A/C	cg23711669	chr6:146136114	FBXO30	0.84	12.33	0.6	6.55e-28	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7940866	0.740	rs7131121	chr11:130806424	A/G	cg12179176	chr11:130786555	SNX19	0.66	10.11	0.53	1.6e-20	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00945735	chr7:41982767	NA	0.58	6.62	0.38	2.03e-10	Gut microbiome composition (summer);
CESC	cis	rs8077577	0.671	rs9909104	chr17:18248021	T/C	cg16794390	chr17:18148240	FLII	0.38	6.2	0.36	2.19e-9	Obesity-related traits;
CESC	cis	rs6963495	0.818	rs73192126	chr7:105175415	T/C	cg02135003	chr7:105160482	PUS7	-0.46	-5.45	-0.32	1.13e-7	Bipolar disorder (body mass index interaction);
CESC	cis	rs7561273	0.586	rs11896092	chr2:24317827	G/A	cg20701182	chr2:24300061	SF3B14	0.52	6.63	0.38	1.89e-10	Quantitative traits;
CESC	cis	rs10504229	0.683	rs72650839	chr8:58130029	C/T	cg24829409	chr8:58192753	C8orf71	-0.57	-7.07	-0.4	1.33e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs3858526	0.959	rs61876223	chr11:5943393	G/A	cg13902645	chr11:5959945	NA	-0.65	-7.8	-0.43	1.39e-13	DNA methylation (variation);
CESC	cis	rs10791097	0.720	rs6590518	chr11:130733530	C/T	cg12179176	chr11:130786555	SNX19	0.65	9.77	0.51	1.9e-19	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs861020	0.630	rs628445	chr1:210004953	C/T	cg05527609	chr1:210001259	C1orf107	0.74	9.67	0.51	3.97e-19	Orofacial clefts;
CESC	trans	rs6089829	0.925	rs2277767	chr20:61666937	G/A	cg23505145	chr19:12996616	KLF1	0.52	6.8	0.39	6.85e-11	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7618915	0.547	rs11130317	chr3:52731483	C/T	cg18404041	chr3:52824283	ITIH1	-0.4	-6.78	-0.38	7.81e-11	Bipolar disorder;
CESC	cis	rs6121246	0.559	rs1484994	chr20:30305975	A/G	cg13852791	chr20:30311386	BCL2L1	0.86	11.09	0.56	9.96e-24	Mean corpuscular hemoglobin;
CESC	trans	rs877282	0.945	rs11253398	chr10:790012	T/C	cg22713356	chr15:30763199	NA	1.32	13.44	0.64	9.25e-32	Uric acid levels;
CESC	cis	rs7927771	0.524	rs7123952	chr11:47852057	T/C	cg20307385	chr11:47447363	PSMC3	0.62	8.66	0.47	4.58e-16	Subjective well-being;
CESC	cis	rs12497850	1.000	rs1352420	chr3:48757291	A/G	cg03060546	chr3:49711283	APEH	0.46	5.73	0.33	2.76e-8	Parkinson's disease;
CESC	trans	rs4716602	0.596	rs12386634	chr7:156158373	G/A	cg07175507	chr18:77160758	NFATC1	-0.44	-6.01	-0.35	6.12e-9	Anti-saccade response;
CESC	trans	rs916888	0.773	rs199447	chr17:44812188	C/T	cg22968622	chr17:43663579	NA	1.31	17.87	0.74	2.04e-47	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs7116495	1.000	rs7127865	chr11:71747781	G/C	cg10381502	chr11:71823885	C11orf51	-0.68	-5.65	-0.33	4.05e-8	Severe influenza A (H1N1) infection;
CESC	cis	rs10206020	0.885	rs11899557	chr2:1576123	G/T	cg26248373	chr2:1572462	NA	-0.59	-6.93	-0.39	3.22e-11	IgG glycosylation;
CESC	cis	rs10979	0.965	rs34373782	chr6:143888258	A/G	cg25407410	chr6:143891975	LOC285740	-0.61	-9.14	-0.49	1.72e-17	Hypospadias;
CESC	cis	rs2016266	0.859	rs7953656	chr12:53738433	G/T	cg26875137	chr12:53738046	NA	0.36	5.24	0.31	3.23e-7	Bone mineral density (spine);Bone mineral density;
CESC	cis	rs35306767	0.903	rs17159970	chr10:935601	T/C	cg10556349	chr10:835070	NA	0.62	5.91	0.34	1.04e-8	Eosinophil percentage of granulocytes;
CESC	cis	rs2933343	0.700	rs1683777	chr3:128624880	T/G	cg25356066	chr3:128598488	ACAD9	0.58	7.92	0.44	6.51e-14	IgG glycosylation;
CESC	cis	rs6439153	0.933	rs6799008	chr3:128717387	G/T	cg24203234	chr3:128598194	ACAD9	0.42	5.48	0.32	9.9e-8	Pneumococcal bacteremia;
CESC	cis	rs8002861	0.846	rs12428112	chr13:44475821	C/A	cg14210620	chr13:44453864	C13orf31;CCDC122	-0.42	-5.39	-0.31	1.58e-7	Leprosy;
CESC	trans	rs1545843	0.564	rs2255396	chr12:84890315	G/T	cg03015433	chr16:56623111	MT3	0.33	6.01	0.35	6.09e-9	Major depressive disorder;
CESC	cis	rs9300255	0.602	rs1727314	chr12:123640664	C/A	cg00376283	chr12:123451042	ABCB9	0.7	8.86	0.48	1.16e-16	Neutrophil percentage of white cells;
CESC	cis	rs7666738	0.546	rs34621463	chr4:98793357	G/C	cg17366294	chr4:99064904	C4orf37	0.52	6.61	0.38	2.09e-10	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6710529	1	rs6710529	chr2:219645553	G/A	cg02176678	chr2:219576539	TTLL4	-0.43	-7.5	-0.42	9.95e-13	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7107174	1.000	rs7101429	chr11:77992967	A/G	cg02023728	chr11:77925099	USP35	0.46	6.05	0.35	4.83e-9	Testicular germ cell tumor;
CESC	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	ch.3.1021608R	chr3:48511432	SHISA5	0.45	6.18	0.35	2.47e-9	Metabolic traits;
CESC	cis	rs4253772	0.938	rs9626814	chr22:46637254	C/T	cg00784671	chr22:46762841	CELSR1	-0.41	-5.6	-0.33	5.35e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs1552244	1.000	rs9849434	chr3:10133710	A/G	cg16606324	chr3:10149918	C3orf24	-0.42	-5.25	-0.31	3.14e-7	Alzheimer's disease;
CESC	cis	rs151234	0.565	rs11401	chr16:28602991	A/G	cg01378222	chr16:28622494	SULT1A1	-0.5	-7.64	-0.42	4e-13	Platelet distribution width;
CESC	cis	rs9457247	1.000	rs1794693	chr6:167405670	T/C	cg23791538	chr6:167370224	RNASET2	-0.59	-8.54	-0.46	1.09e-15	Crohn's disease;
CESC	cis	rs1552244	0.572	rs12107622	chr3:10171898	T/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.66	-7.32	-0.41	2.98e-12	Alzheimer's disease;
CESC	cis	rs73206853	0.764	rs67715513	chr12:110562910	G/A	cg12870014	chr12:110450643	ANKRD13A	0.65	5.62	0.33	4.77e-8	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs9911578	0.967	rs302842	chr17:56728102	C/G	cg05425664	chr17:57184151	TRIM37	-0.51	-7.21	-0.4	6.03e-12	Intelligence (multi-trait analysis);
CESC	cis	rs10191773	0.589	rs72831641	chr2:112955815	A/G	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.67	-6.61	-0.38	2.05e-10	Yeast infection;
CESC	cis	rs9486719	0.948	rs11152952	chr6:96894303	A/G	cg06623918	chr6:96969491	KIAA0776	-0.81	-8.29	-0.45	5.61e-15	Migraine;Coronary artery disease;
CESC	cis	rs3733585	0.673	rs7672947	chr4:9961368	G/C	cg02734326	chr4:10020555	SLC2A9	-0.43	-6.01	-0.35	6.1e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	trans	rs7615952	0.512	rs34651730	chr3:125358640	T/C	cg07211511	chr3:129823064	LOC729375	-0.59	-7.28	-0.41	3.84e-12	Blood pressure (smoking interaction);
CESC	cis	rs9457247	1.000	rs407515	chr6:167407544	G/C	cg25258033	chr6:167368657	RNASET2	0.4	6.14	0.35	2.93e-9	Crohn's disease;
CESC	cis	rs2880765	0.835	rs12910373	chr15:86046802	G/C	cg10818794	chr15:86012489	AKAP13	-0.34	-5.22	-0.31	3.68e-7	Coronary artery disease;
CESC	cis	rs67072384	0.818	rs2291293	chr11:72470653	C/T	cg04827223	chr11:72435913	ARAP1	-0.65	-5.64	-0.33	4.42e-8	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
CESC	cis	rs6964587	1.000	rs2075881	chr7:91734552	T/C	cg17063962	chr7:91808500	NA	0.54	7.37	0.41	2.16e-12	Breast cancer;
CESC	cis	rs524281	0.773	rs10791861	chr11:66008470	G/A	cg14036092	chr11:66035641	RAB1B	-0.53	-5.31	-0.31	2.38e-7	Electroencephalogram traits;
CESC	cis	rs2836974	0.836	rs1041440	chr21:40627325	C/T	cg11644478	chr21:40555479	PSMG1	1.01	16.02	0.7	7.49e-41	Cognitive function;
CESC	cis	rs6831352	0.918	rs13110764	chr4:100062466	C/T	cg13256891	chr4:100009986	ADH5	-0.65	-7.06	-0.4	1.48e-11	Alcohol dependence;
CESC	cis	rs6598955	0.724	rs12132137	chr1:26631243	C/T	cg00852783	chr1:26633632	UBXN11	0.43	6.26	0.36	1.55e-9	Obesity-related traits;
CESC	cis	rs7474896	0.559	rs10740949	chr10:37978435	A/G	cg00409905	chr10:38381863	ZNF37A	-0.46	-5.39	-0.31	1.59e-7	Obesity (extreme);
CESC	cis	rs7909074	0.966	rs4948645	chr10:45391481	A/G	cg05187965	chr10:45406764	TMEM72	-0.33	-5.31	-0.31	2.32e-7	Mean corpuscular volume;
CESC	cis	rs9911578	0.967	rs72628392	chr17:56506160	A/G	cg12560992	chr17:57184187	TRIM37	-0.9	-15.09	-0.68	1.52e-37	Intelligence (multi-trait analysis);
CESC	cis	rs2204008	0.687	rs11181339	chr12:38322271	G/T	cg26384229	chr12:38710491	ALG10B	0.57	8.17	0.45	1.26e-14	Bladder cancer;
CESC	cis	rs738322	0.718	rs3761445	chr22:38595411	G/A	cg17652424	chr22:38574118	PLA2G6	0.31	5.39	0.31	1.53e-7	Cutaneous nevi;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26439759	chr12:102514173	C12orf48	-0.55	-6.27	-0.36	1.42e-9	Gut microbiome composition (summer);
CESC	cis	rs4790333	0.529	rs3101409	chr17:2258147	C/T	cg02569219	chr17:2266849	SGSM2	0.39	5.15	0.3	5.02e-7	Proinsulin levels;
CESC	trans	rs1908814	0.516	rs7825529	chr8:11794444	C/T	cg15556689	chr8:8085844	FLJ10661	0.51	6.32	0.36	1.1e-9	Neuroticism;
CESC	cis	rs4986172	0.700	rs71373536	chr17:43221808	G/A	cg10701640	chr17:43249399	NA	0.42	6.33	0.36	1.06e-9	Height;
CESC	cis	rs2549003	1.000	rs2549003	chr5:131829297	A/G	cg21138405	chr5:131827807	IRF1	0.64	11.77	0.59	5.28e-26	Asthma (sex interaction);
CESC	cis	rs9768139	0.566	rs729099	chr7:158114152	C/T	cg24154853	chr7:158122151	PTPRN2	0.38	5.65	0.33	4.21e-8	Calcium levels;
CESC	cis	rs10464366	0.544	rs34866559	chr7:39166071	G/A	cg18850127	chr7:39170497	POU6F2	0.39	5.51	0.32	8.38e-8	IgG glycosylation;
CESC	cis	rs35110281	0.720	rs162376	chr21:44926759	G/T	cg01579765	chr21:45077557	HSF2BP	0.54	9.04	0.49	3.44e-17	Mean corpuscular volume;
CESC	cis	rs644799	1.000	rs473148	chr11:95628606	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.59	7.42	0.41	1.61e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs9649213	0.593	rs3779193	chr7:98028466	T/C	cg00277769	chr7:97922759	BAIAP2L1	-0.31	-5.14	-0.3	5.46e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs4563143	0.675	rs56407818	chr19:29279379	G/A	cg12756686	chr19:29218302	NA	0.59	7.5	0.42	9.53e-13	Methadone dose in opioid dependence;
CESC	cis	rs2243480	1.000	rs316307	chr7:65570171	C/T	cg25894440	chr7:65020034	NA	-0.61	-5.04	-0.3	8.69e-7	Diabetic kidney disease;
CESC	cis	rs9649213	0.593	rs13246725	chr7:97914898	C/G	cg08684580	chr7:98029266	BAIAP2L1	-0.33	-5.26	-0.31	2.92e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs5769765	0.908	rs9616217	chr22:50318946	C/T	cg26441486	chr22:50317300	CRELD2	0.48	5.97	0.34	7.77e-9	Schizophrenia;
CESC	cis	rs73019876	0.836	rs2666438	chr19:22144259	A/G	cg11619707	chr19:22235551	ZNF257	-0.28	-5.21	-0.3	3.89e-7	Testicular germ cell tumor;
CESC	cis	rs1670533	1.000	rs1670534	chr4:1087265	T/C	cg27284194	chr4:1044797	NA	0.48	6.17	0.35	2.6e-9	Recombination rate (females);
CESC	cis	rs8005677	1.000	rs1956881	chr14:23394069	A/C	cg25600027	chr14:23388339	RBM23	-0.43	-5.31	-0.31	2.36e-7	Cognitive ability (multi-trait analysis);
CESC	cis	rs875971	0.798	rs7789615	chr7:65878661	A/G	cg18876405	chr7:65276391	NA	0.53	7.32	0.41	3.01e-12	Aortic root size;
CESC	cis	rs896854	0.653	rs13266313	chr8:95975302	C/T	cg16049864	chr8:95962084	TP53INP1	-0.65	-11.4	-0.57	9.17e-25	Type 2 diabetes;
CESC	cis	rs832540	0.552	rs252924	chr5:56205643	A/G	cg24531977	chr5:56204891	C5orf35	-0.56	-7.03	-0.4	1.71e-11	Coronary artery disease;
CESC	cis	rs9291683	0.620	rs11722946	chr4:10125990	A/G	cg11266682	chr4:10021025	SLC2A9	-0.48	-8.53	-0.46	1.18e-15	Bone mineral density;
CESC	cis	rs9486715	1.000	rs7752277	chr6:97065131	C/T	cg18709589	chr6:96969512	KIAA0776	-0.46	-6.58	-0.37	2.44e-10	Headache;
CESC	cis	rs12973672	1.000	rs1052033	chr19:35770471	C/T	cg12095397	chr19:35769544	USF2	0.54	7.35	0.41	2.49e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs6691722	0.503	rs4140519	chr1:24708304	C/T	cg18323236	chr1:24743029	NIPAL3	0.38	5.58	0.32	5.82e-8	Response to interferon beta in multiple sclerosis;
CESC	cis	rs10743315	0.778	rs7399032	chr12:19371546	T/C	cg02471346	chr12:19282374	PLEKHA5	-0.5	-5.31	-0.31	2.35e-7	Gut microbiota (bacterial taxa);
CESC	cis	rs2243480	0.803	rs13224048	chr7:65993766	G/A	cg12463550	chr7:65579703	CRCP	0.72	5.55	0.32	6.96e-8	Diabetic kidney disease;
CESC	cis	rs7666738	0.830	rs28802909	chr4:99039410	G/A	cg03467027	chr4:99064603	C4orf37	0.47	5.98	0.34	7.19e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4790333	1.000	rs4790332	chr17:2262611	G/A	cg02569219	chr17:2266849	SGSM2	0.47	6.24	0.36	1.71e-9	Proinsulin levels;
CESC	cis	rs769267	0.895	rs2905435	chr19:19495954	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	-0.49	-6.26	-0.36	1.5e-9	Tonsillectomy;
CESC	cis	rs79387448	0.655	rs79091585	chr2:102917243	C/T	cg09003973	chr2:102972529	NA	1.11	8.63	0.47	5.6e-16	Gut microbiota (bacterial taxa);
CESC	cis	rs28489187	0.683	rs2892888	chr1:85866147	A/G	cg16011679	chr1:85725395	C1orf52	-0.46	-5.5	-0.32	9.09e-8	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	cis	rs4803455	0.565	rs1025497	chr19:41871254	A/G	cg08477640	chr19:41863820	B9D2	0.5	7.3	0.41	3.44e-12	Migraine;Coronary artery disease;
CESC	cis	rs7613875	0.580	rs11709503	chr3:49991167	G/T	cg24308560	chr3:49941425	MST1R	-0.55	-7.67	-0.43	3.37e-13	Body mass index;
CESC	cis	rs3806843	0.735	rs2563306	chr5:140070017	C/T	cg26395211	chr5:140044315	WDR55	0.47	5.94	0.34	9.08e-9	Depressive symptoms (multi-trait analysis);
CESC	cis	rs694739	1.000	rs1783521	chr11:64106291	T/C	cg02228329	chr11:64053129	BAD;GPR137	0.66	8.61	0.47	6.83e-16	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CESC	cis	rs425277	0.606	rs2460001	chr1:2111030	T/C	cg12718519	chr1:2058417	PRKCZ	0.26	5.62	0.33	4.81e-8	Height;
CESC	cis	rs738322	0.967	rs133024	chr22:38574066	C/T	cg25457927	chr22:38595422	NA	0.29	5.45	0.32	1.15e-7	Cutaneous nevi;
CESC	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg09033563	chr22:24373618	LOC391322	-0.52	-7.05	-0.4	1.6e-11	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs9902453	0.765	rs2264302	chr17:28057095	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.76	-10.3	-0.53	3.95e-21	Coffee consumption (cups per day);
CESC	trans	rs78579285	0.510	rs78759106	chr16:88788535	T/C	cg15076811	chr1:11001038	NA	0.7	6.01	0.35	6.01e-9	Joint mobility (Beighton score);
CESC	cis	rs4713118	0.662	rs149901	chr6:27965503	C/T	cg26335602	chr6:28129616	ZNF389	0.41	5.57	0.32	6.18e-8	Parkinson's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01233736	chr2:223725624	ACSL3	0.69	8.2	0.45	1.03e-14	Gut microbiome composition (summer);
CESC	cis	rs1799949	0.965	rs9897425	chr17:41430179	C/G	cg07153921	chr17:41440717	NA	-0.42	-5.61	-0.33	4.96e-8	Menopause (age at onset);
CESC	trans	rs8026198	0.568	rs2918460	chr15:42617644	A/G	cg19625216	chr1:249132108	ZNF672	-0.72	-6.04	-0.35	5.32e-9	Fibrinogen levels;
CESC	cis	rs4919694	0.572	rs12255989	chr10:104867206	C/T	cg04362960	chr10:104952993	NT5C2	0.63	6.25	0.36	1.66e-9	Arsenic metabolism;
CESC	cis	rs9910055	0.659	rs2251165	chr17:42234748	T/C	cg10896456	chr17:42255109	ASB16;C17orf65	0.53	8.09	0.44	2.18e-14	Total body bone mineral density;
CESC	cis	rs7178572	0.568	rs11854193	chr15:77458136	C/A	cg22256960	chr15:77711686	NA	-0.54	-6.83	-0.39	5.7e-11	Type 2 diabetes;
CESC	cis	rs7249921	0.833	rs7255878	chr19:35667192	C/T	cg15419183	chr19:35660584	FXYD5	0.53	8.27	0.45	6.42e-15	Platelet count;
CESC	cis	rs9814567	0.702	rs9871226	chr3:134331466	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.4	-5.1	-0.3	6.38e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs9987353	0.544	rs2929470	chr8:9062490	A/G	cg06636001	chr8:8085503	FLJ10661	-0.51	-6.14	-0.35	2.95e-9	Recombination measurement;
CESC	cis	rs12586317	0.586	rs2295103	chr14:35515920	C/G	cg16230307	chr14:35515116	FAM177A1	1.08	11.39	0.57	9.7e-25	Psoriasis;
CESC	cis	rs10791323	0.572	rs4353292	chr11:133742656	A/G	cg03690763	chr11:133734501	NA	-0.32	-5.41	-0.32	1.41e-7	Childhood ear infection;
CESC	cis	rs2274273	0.934	rs8021940	chr14:55719715	G/A	cg04306507	chr14:55594613	LGALS3	0.29	5.83	0.34	1.65e-8	Protein biomarker;
CESC	cis	rs116095464	0.867	rs10074958	chr5:230828	C/T	cg10591111	chr5:226296	SDHA	-0.51	-6.19	-0.36	2.28e-9	Breast cancer;
CESC	cis	rs3096299	0.719	rs2353581	chr16:89518908	T/C	cg02034447	chr16:89574710	SPG7	0.51	6.43	0.37	5.91e-10	Multiple myeloma (IgH translocation);
CESC	cis	rs644799	1.000	rs12291986	chr11:95523030	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.92	14.1	0.65	4.64e-34	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs1005277	0.579	rs176880	chr10:38401417	C/G	cg25427524	chr10:38739819	LOC399744	0.64	9.23	0.49	8.8e-18	Extrinsic epigenetic age acceleration;
CESC	cis	rs9303401	0.659	rs62083436	chr17:57031742	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.99	12.38	0.61	4.28e-28	Cognitive test performance;
CESC	cis	rs3892630	0.817	rs35408716	chr19:33187961	A/C	cg22980127	chr19:33182716	NUDT19	1.02	11.58	0.58	2.23e-25	Red blood cell traits;
CESC	cis	rs2836950	0.501	rs2836985	chr21:40701169	A/G	cg11644478	chr21:40555479	PSMG1	-0.56	-7.65	-0.43	3.72e-13	Menarche (age at onset);
CESC	cis	rs919433	0.963	rs1366837	chr2:198160501	T/C	cg03934865	chr2:198174659	NA	-0.47	-7.07	-0.4	1.38e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs61931739	0.500	rs11053282	chr12:34561151	T/C	cg19457237	chr12:34500585	NA	-0.37	-5.08	-0.3	6.97e-7	Morning vs. evening chronotype;
CESC	cis	rs4803468	1.000	rs1473248	chr19:41923314	C/T	cg14132834	chr19:41945861	ATP5SL	0.68	8.39	0.46	2.9e-15	Height;
CESC	cis	rs9457247	0.663	rs2301436	chr6:167437988	C/T	cg25258033	chr6:167368657	RNASET2	0.35	5.03	0.3	8.85e-7	Crohn's disease;
CESC	cis	rs548181	0.611	rs1293672	chr11:125461034	A/G	cg03464685	chr11:125439445	EI24	1.24	9.78	0.51	1.74e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	trans	rs6964833	0.872	rs4717903	chr7:74068167	T/C	cg07504079	chr7:72649617	NCF1B	-0.55	-6.23	-0.36	1.79e-9	Menarche (age at onset);
CESC	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.47	0.37	4.83e-10	Prudent dietary pattern;
CESC	cis	rs3796352	1.000	rs11707780	chr3:53084326	A/G	cg15956490	chr3:53032818	SFMBT1	-0.54	-5.38	-0.31	1.61e-7	Immune reponse to smallpox (secreted IL-2);
CESC	cis	rs35110281	0.807	rs6518301	chr21:45016818	T/C	cg04455712	chr21:45112962	RRP1B	0.4	6.21	0.36	2.07e-9	Mean corpuscular volume;
CESC	cis	rs16858210	0.607	rs953419	chr3:183585883	C/T	cg25686905	chr3:183603175	PARL	0.33	5.84	0.34	1.49e-8	Menopause (age at onset);
CESC	cis	rs9948	1.000	rs2276654	chr2:97492479	G/A	cg01990225	chr2:97406019	LMAN2L	-0.75	-5.44	-0.32	1.24e-7	Erectile dysfunction and prostate cancer treatment;
CESC	cis	rs7539542	0.556	rs10753928	chr1:202891045	A/C	cg19681188	chr1:202830198	LOC148709	-0.41	-5.19	-0.3	4.09e-7	Mean platelet volume;
CESC	cis	rs7551222	0.752	rs4951389	chr1:204475834	G/T	cg20240347	chr1:204465584	NA	-0.27	-5.43	-0.32	1.26e-7	Schizophrenia;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg06911843	chr21:38639729	DSCR3	-0.5	-6.72	-0.38	1.11e-10	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs1707322	1.000	rs11211204	chr1:46317864	A/G	cg05343316	chr1:45956843	TESK2	0.44	5.55	0.32	7.05e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs6952808	0.636	rs6964522	chr7:1953523	C/T	cg05863683	chr7:1912471	MAD1L1	0.38	5.89	0.34	1.19e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs6502050	0.604	rs9897355	chr17:80078095	G/A	cg11859384	chr17:80120422	CCDC57	0.38	5.16	0.3	4.82e-7	Life satisfaction;
CESC	cis	rs561341	1.000	rs561341	chr17:30316385	T/G	cg12193833	chr17:30244370	NA	-0.7	-6.49	-0.37	4.19e-10	Hip circumference adjusted for BMI;
CESC	cis	rs7772486	0.713	rs1986729	chr6:146194831	G/A	cg05347473	chr6:146136440	FBXO30	0.6	7.63	0.42	4.27e-13	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs17431357	1.000	rs117094839	chr12:120922159	G/T	cg25045489	chr12:120971538	RNF10	-0.93	-5.46	-0.32	1.1e-7	Insulin resistance/response;
CESC	cis	rs9649213	0.593	rs7797943	chr7:97946902	T/C	cg24562669	chr7:97807699	LMTK2	0.49	7.19	0.4	6.8e-12	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7949030	0.523	rs12223627	chr11:62368557	G/C	cg13298116	chr11:62369859	EML3;MTA2	0.53	7.46	0.42	1.26e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs6502050	0.731	rs11867299	chr17:80088675	C/A	cg01763666	chr17:80159506	CCDC57	-0.37	-5.1	-0.3	6.55e-7	Life satisfaction;
CESC	cis	rs6076065	0.630	rs2424559	chr20:23430519	A/G	cg11657817	chr20:23433608	CST11	0.48	7.81	0.43	1.32e-13	Facial morphology (factor 15, philtrum width);
CESC	cis	rs10479542	0.892	rs7723230	chr5:178980474	T/C	cg21226059	chr5:178986404	RUFY1	0.49	7.57	0.42	6.27e-13	Lung cancer;
CESC	cis	rs7666738	0.830	rs28497822	chr4:98906873	C/T	cg05340658	chr4:99064831	C4orf37	0.74	10.68	0.55	2.18e-22	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10276381	1.000	rs10281214	chr7:28185544	G/C	cg23620719	chr7:28220237	JAZF1	0.74	7.95	0.44	5.56e-14	Crohn's disease;
CESC	cis	rs801193	0.569	rs2659908	chr7:66160822	G/A	cg18876405	chr7:65276391	NA	0.45	6.09	0.35	3.92e-9	Aortic root size;
CESC	cis	rs5750830	0.594	rs5757648	chr22:39775156	G/A	cg11247378	chr22:39784982	NA	-0.51	-7.72	-0.43	2.36e-13	Intelligence (multi-trait analysis);
CESC	cis	rs9487051	0.872	rs6924815	chr6:109612344	A/G	cg21918786	chr6:109611834	NA	-0.4	-6.1	-0.35	3.81e-9	Reticulocyte fraction of red cells;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg20706768	chr7:55225183	EGFR	0.45	6.24	0.36	1.77e-9	Fibrinogen levels;
CESC	cis	rs9300255	0.569	rs1790115	chr12:123620270	C/G	cg00376283	chr12:123451042	ABCB9	0.71	8.69	0.47	3.84e-16	Neutrophil percentage of white cells;
CESC	cis	rs9649213	0.574	rs36099592	chr7:98002331	T/C	cg00277769	chr7:97922759	BAIAP2L1	-0.33	-5.41	-0.32	1.41e-7	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs4471313	1.000	rs1095095	chr1:170354049	T/C	cg14876685	chr7:99177937	NA	-0.41	-6.21	-0.36	2.03e-9	Waist-hip ratio;
CESC	cis	rs9916302	0.800	rs11869259	chr17:37518141	C/A	cg20243544	chr17:37824526	PNMT	-0.48	-6.07	-0.35	4.42e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs1862618	0.853	rs832554	chr5:56115036	A/G	cg18230493	chr5:56204884	C5orf35	-0.73	-8.91	-0.48	8.16e-17	Initial pursuit acceleration;
CESC	cis	rs1256061	0.603	rs1256038	chr14:64740739	T/C	cg21174375	chr14:64681225	SYNE2	0.51	6.82	0.39	6.15e-11	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg18173830	chr6:4776623	CDYL	0.5	6.29	0.36	1.3e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs2576037	0.583	rs9954336	chr18:44465945	A/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.33	5.26	0.31	3e-7	Personality dimensions;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21883765	chr7:127032075	ZNF800	-0.53	-6.07	-0.35	4.44e-9	Gut microbiome composition (summer);
CESC	cis	rs9291683	0.588	rs13113730	chr4:10017628	C/T	cg02734326	chr4:10020555	SLC2A9	0.52	7.43	0.42	1.51e-12	Bone mineral density;
CESC	cis	rs6499129	0.702	rs8044843	chr16:67318242	A/G	cg26727032	chr16:67993705	SLC12A4	-0.52	-5.77	-0.33	2.19e-8	Waist-to-hip ratio adjusted for body mass index;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05909891	chr12:19565983	NA	-0.66	-7.86	-0.43	9.7e-14	Gut microbiome composition (summer);
CESC	cis	rs6952808	0.595	rs3778983	chr7:2166319	T/G	cg05863683	chr7:1912471	MAD1L1	0.36	5.34	0.31	1.99e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs698813	0.637	rs4952706	chr2:44500536	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.47	5.17	0.3	4.69e-7	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
CESC	cis	rs10504073	0.584	rs11776843	chr8:49928449	C/T	cg00325661	chr8:49890786	NA	0.54	8.2	0.45	1.02e-14	Blood metabolite ratios;
CESC	cis	rs12701220	0.655	rs7778968	chr7:1144622	C/G	cg04025307	chr7:1156635	C7orf50	0.41	5.09	0.3	6.95e-7	Bronchopulmonary dysplasia;
CESC	cis	rs2404602	0.669	rs12441484	chr15:77109875	G/A	cg26408565	chr15:76604113	ETFA	-0.38	-5.52	-0.32	8.03e-8	Blood metabolite levels;
CESC	trans	rs61931739	0.963	rs12298565	chr12:34036188	C/T	cg26384229	chr12:38710491	ALG10B	-0.46	-6.16	-0.35	2.75e-9	Morning vs. evening chronotype;
CESC	cis	rs10504229	1.000	rs57941207	chr8:58169821	A/G	cg05313129	chr8:58192883	C8orf71	-0.53	-6.09	-0.35	3.95e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs12824058	0.831	rs4759452	chr12:130812799	G/A	cg24838063	chr12:130822603	PIWIL1	0.62	8.55	0.47	9.78e-16	Menopause (age at onset);
CESC	cis	rs6580649	0.941	rs17122613	chr12:48460016	T/C	cg05342945	chr12:48394962	COL2A1	0.51	5.91	0.34	1.07e-8	Lung cancer;
CESC	cis	rs9840812	0.623	rs1394092	chr3:136196071	C/T	cg15507776	chr3:136538369	TMEM22	0.42	5.1	0.3	6.63e-7	Fibrinogen levels;
CESC	cis	rs6977955	1.000	rs740122	chr7:28166442	G/A	cg23620719	chr7:28220237	JAZF1	0.44	5.11	0.3	6.3e-7	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs6502050	0.835	rs8078795	chr17:80126320	C/T	cg11859384	chr17:80120422	CCDC57	-0.39	-5.34	-0.31	1.97e-7	Life satisfaction;
CESC	cis	rs7188697	0.885	rs1646010	chr16:58549204	G/C	cg02549819	chr16:58548995	SETD6	-0.41	-5.09	-0.3	6.9e-7	QT interval;
CESC	cis	rs477895	0.713	rs11601024	chr11:63943074	A/G	cg04317338	chr11:64019027	PLCB3	0.88	9.06	0.49	2.95e-17	Mean platelet volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21490846	chr12:1905324	CACNA2D4	0.54	6.07	0.35	4.42e-9	Gut microbiome composition (summer);
CESC	cis	rs7618915	0.547	rs2590846	chr3:52692359	C/G	cg07507251	chr3:52567010	NT5DC2	0.4	7.06	0.4	1.5e-11	Bipolar disorder;
CESC	cis	rs2109514	0.765	rs9649392	chr7:116107386	G/A	cg12739419	chr7:116140593	CAV2	-0.34	-6.04	-0.35	5.09e-9	Prevalent atrial fibrillation;
CESC	cis	rs708547	0.647	rs1277308	chr4:57897864	C/T	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.45	-5.89	-0.34	1.19e-8	Response to bleomycin (chromatid breaks);
CESC	cis	rs4713118	0.597	rs172166	chr6:28020820	C/G	cg18032046	chr6:28092343	ZSCAN16	-0.51	-5.78	-0.33	2.12e-8	Parkinson's disease;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg09133422	chr1:155292660	RUSC1;C1orf104	-0.47	-6.52	-0.37	3.47e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs2832191	1.000	rs2832191	chr21:30489300	A/C	cg08807101	chr21:30365312	RNF160	-0.66	-9.18	-0.49	1.29e-17	Dental caries;
CESC	trans	rs1814175	0.817	rs7927373	chr11:49957640	A/C	cg15704280	chr7:45808275	SEPT13	-1.03	-20.41	-0.78	2.75e-56	Height;
CESC	cis	rs7618915	0.501	rs35526119	chr3:52749334	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.38	6.76	0.38	8.76e-11	Bipolar disorder;
CESC	cis	rs17253792	0.915	rs79100824	chr14:56179606	C/T	cg01858014	chr14:56050164	KTN1	-0.94	-7.27	-0.41	4.03e-12	Putamen volume;
CESC	cis	rs875971	0.862	rs4718377	chr7:66049678	C/T	cg10691866	chr7:65817282	TPST1	0.33	5.47	0.32	1.02e-7	Aortic root size;
CESC	cis	rs7507204	0.906	rs11671513	chr19:3429937	C/T	cg08380311	chr19:3435252	NFIC	0.57	6.94	0.39	2.94e-11	Height;
CESC	cis	rs780096	0.526	rs704795	chr2:27716494	G/A	cg21248554	chr2:27665150	KRTCAP3	-0.37	-7.61	-0.42	4.7e-13	Total body bone mineral density;
CESC	cis	rs853679	0.550	rs6901017	chr6:28152583	T/C	cg23281280	chr6:28129359	ZNF389	0.5	7.01	0.4	2e-11	Depression;
CESC	cis	rs4925386	0.959	rs4925385	chr20:60920624	A/G	cg15193198	chr20:60906057	LAMA5	0.28	5.15	0.3	4.99e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs637571	0.544	rs617791	chr11:65702523	C/G	cg26695010	chr11:65641043	EFEMP2	-0.46	-5.76	-0.33	2.29e-8	Eosinophil percentage of white cells;
CESC	cis	rs875971	0.520	rs2420597	chr7:65915986	A/G	cg11764359	chr7:65958608	NA	0.81	11.81	0.59	3.86e-26	Aortic root size;
CESC	cis	rs9303401	1.000	rs6503877	chr17:56841948	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.74	9.58	0.51	7.58e-19	Cognitive test performance;
CESC	cis	rs4474465	0.679	rs4945288	chr11:78244823	C/A	cg27205649	chr11:78285834	NARS2	0.43	5.28	0.31	2.69e-7	Alzheimer's disease (survival time);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15998195	chr3:196439051	PIGX;C3orf34	0.54	6.04	0.35	5.07e-9	Gut microbiome composition (summer);
CESC	cis	rs7264396	0.563	rs6058322	chr20:34367277	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	0.86	10.2	0.53	7.89e-21	Total cholesterol levels;
CESC	cis	rs6860806	0.507	rs272892	chr5:131664349	C/T	cg07395648	chr5:131743802	NA	-0.43	-5.7	-0.33	3.25e-8	Breast cancer;
CESC	cis	rs7084402	0.967	rs1649028	chr10:60280428	A/G	cg07615347	chr10:60278583	BICC1	-0.59	-9.45	-0.5	1.94e-18	Refractive error;
CESC	cis	rs9359856	0.510	rs17293240	chr6:90396370	C/T	cg13799429	chr6:90582589	CASP8AP2	0.74	8.6	0.47	6.93e-16	Bipolar disorder;
CESC	cis	rs6570726	0.526	rs72994723	chr6:145722948	G/A	cg23711669	chr6:146136114	FBXO30	-0.53	-7.12	-0.4	1.01e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1862618	0.671	rs28397234	chr5:56248428	T/G	cg18230493	chr5:56204884	C5orf35	0.62	8.1	0.45	1.99e-14	Initial pursuit acceleration;
CESC	trans	rs561341	0.660	rs7406043	chr17:30220152	C/G	cg20587970	chr11:113659929	NA	-1.03	-12.68	-0.61	4.19e-29	Hip circumference adjusted for BMI;
CESC	cis	rs67311347	1.000	rs9848083	chr3:40466979	A/G	cg01475735	chr3:40494733	NA	0.38	5.03	0.3	9.02e-7	Renal cell carcinoma;
CESC	cis	rs5753618	0.561	rs5749265	chr22:31796897	A/C	cg00478049	chr22:31556069	RNF185	-0.43	-5.11	-0.3	6.22e-7	Colorectal cancer;
CESC	cis	rs9322193	0.884	rs10872646	chr6:150067675	A/G	cg07701084	chr6:150067640	NUP43	0.47	6.58	0.37	2.47e-10	Lung cancer;
CESC	cis	rs10504229	1.000	rs61733801	chr8:58192513	A/G	cg14926445	chr8:58193284	C8orf71	-0.51	-5.52	-0.32	8.28e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs55986470	0.646	rs79795396	chr2:239419181	T/C	cg18131467	chr2:239335373	ASB1	-0.77	-5.49	-0.32	9.37e-8	Chronotype;
CESC	cis	rs11792861	0.591	rs10979632	chr9:111732140	G/C	cg05043794	chr9:111880884	C9orf5	-0.31	-5.65	-0.33	4.04e-8	Menarche (age at onset);
CESC	cis	rs3126085	0.935	rs6675889	chr1:152213066	G/A	cg03465714	chr1:152285911	FLG	-0.43	-5.17	-0.3	4.53e-7	Atopic dermatitis;
CESC	cis	rs875971	0.862	rs1875057	chr7:65731855	A/G	cg18876405	chr7:65276391	NA	-0.52	-7.1	-0.4	1.16e-11	Aortic root size;
CESC	cis	rs11190604	1.000	rs7071271	chr10:102264824	G/A	cg07080220	chr10:102295463	HIF1AN	0.64	5.88	0.34	1.23e-8	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs4713118	0.621	rs4713134	chr6:28034121	T/C	cg17949981	chr6:28129498	ZNF389	0.42	5.2	0.3	3.96e-7	Parkinson's disease;
CESC	cis	rs1008375	0.932	rs6844593	chr4:17659039	T/C	cg16339924	chr4:17578868	LAP3	0.68	8.66	0.47	4.83e-16	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs644799	0.710	rs10765771	chr11:95521044	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.75	11.15	0.57	6.1e-24	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs8067545	0.611	rs2526486	chr17:20101626	T/G	cg13482628	chr17:19912719	NA	-0.42	-5.68	-0.33	3.6e-8	Schizophrenia;
CESC	cis	rs17376456	0.877	rs10055741	chr5:93297187	C/T	cg25358565	chr5:93447407	FAM172A	1.07	10.61	0.55	3.92e-22	Diabetic retinopathy;
CESC	cis	rs2191566	0.576	rs405763	chr19:44493547	A/G	cg20607764	chr19:44506953	ZNF230	0.44	5.58	0.32	5.9e-8	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs6570726	0.935	rs391524	chr6:145823844	A/G	cg23711669	chr6:146136114	FBXO30	0.81	12.04	0.59	6.44e-27	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1062177	1.000	rs12653926	chr5:151250248	C/A	cg00977110	chr5:151150581	G3BP1	0.63	6.6	0.38	2.26e-10	Preschool internalizing problems;
CESC	cis	rs875971	0.545	rs67775320	chr7:65658779	T/C	cg19163074	chr7:65112434	INTS4L2	-0.46	-5.05	-0.3	8.07e-7	Aortic root size;
CESC	cis	rs12497850	0.931	rs6442130	chr3:48778027	A/G	cg07636037	chr3:49044803	WDR6	0.88	13.3	0.63	2.85e-31	Parkinson's disease;
CESC	cis	rs72781680	0.611	rs2303289	chr2:24342242	C/G	cg08917208	chr2:24149416	ATAD2B	-0.58	-5.5	-0.32	8.73e-8	Lymphocyte counts;
CESC	cis	rs10504229	1.000	rs56168206	chr8:58184485	G/A	cg05313129	chr8:58192883	C8orf71	-0.55	-6.29	-0.36	1.34e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs7618915	0.501	rs11130308	chr3:52639257	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	7.55	0.42	7.15e-13	Bipolar disorder;
CESC	cis	rs7618915	1.000	rs59565798	chr3:52307169	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.41	5.23	0.31	3.47e-7	Bipolar disorder;
CESC	cis	rs2011503	1.000	rs16996127	chr19:19627310	T/G	cg11584989	chr19:19387371	SF4	0.55	6.57	0.37	2.7e-10	Bipolar disorder;
CESC	cis	rs2777491	0.957	rs7181911	chr15:41674060	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.66	-9.88	-0.52	8.63e-20	Ulcerative colitis;
CESC	trans	rs1814175	0.616	rs1722020	chr11:49904189	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.43	-6.36	-0.36	8.98e-10	Height;
CESC	cis	rs73019876	0.772	rs2359814	chr19:22171947	A/G	cg11619707	chr19:22235551	ZNF257	-0.28	-5.13	-0.3	5.6e-7	Testicular germ cell tumor;
CESC	cis	rs7937682	0.556	rs7108048	chr11:111352299	T/C	cg09085632	chr11:111637200	PPP2R1B	0.47	5.32	0.31	2.24e-7	Primary sclerosing cholangitis;
CESC	cis	rs780096	0.527	rs59644396	chr2:27646083	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.32	-5.96	-0.34	8.03e-9	Total body bone mineral density;
CESC	cis	rs7192750	0.527	rs30433	chr16:72145404	T/C	cg14768367	chr16:72042858	DHODH	0.73	5.69	0.33	3.35e-8	LDL cholesterol levels;Total cholesterol levels;
CESC	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg18337363	chr3:52569053	NT5DC2	0.3	5.85	0.34	1.45e-8	Bipolar disorder;
CESC	cis	rs854765	0.583	rs4534911	chr17:17852330	A/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.51	6.37	0.36	8.55e-10	Total body bone mineral density;
CESC	cis	rs10089	1.000	rs3805607	chr5:127477418	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.76	10.3	0.53	3.71e-21	Ileal carcinoids;
CESC	cis	rs9818941	0.824	rs7628186	chr3:157800499	T/C	cg08654915	chr3:157813417	NA	0.44	7.37	0.41	2.18e-12	Height;
CESC	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg26338869	chr17:61819248	STRADA	0.67	8.82	0.48	1.57e-16	Prudent dietary pattern;
CESC	cis	rs858239	0.539	rs28716381	chr7:23189015	G/A	cg23682824	chr7:23144976	KLHL7	0.51	6.83	0.39	5.81e-11	Cerebrospinal fluid biomarker levels;
CESC	cis	rs10979	1.000	rs9386033	chr6:143888520	T/C	cg25407410	chr6:143891975	LOC285740	-0.61	-9.14	-0.49	1.72e-17	Hypospadias;
CESC	cis	rs1552244	0.816	rs17050701	chr3:10041554	A/G	cg00149659	chr3:10157352	C3orf10	0.7	8.31	0.45	5.08e-15	Alzheimer's disease;
CESC	cis	rs9487051	0.676	rs6568560	chr6:109592851	G/A	cg12927641	chr6:109611667	NA	-0.37	-5.56	-0.32	6.55e-8	Reticulocyte fraction of red cells;
CESC	cis	rs7666738	0.830	rs3911282	chr4:99037602	T/A	cg03676636	chr4:99064102	C4orf37	0.33	5.12	0.3	6.01e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs787274	0.543	rs4978509	chr9:115635641	C/G	cg13803584	chr9:115635662	SNX30	-0.69	-6.74	-0.38	1.01e-10	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs1153858	1.000	rs61365925	chr15:45650311	T/C	cg14582100	chr15:45693742	SPATA5L1	0.43	6.15	0.35	2.82e-9	Homoarginine levels;
CESC	cis	rs9419702	0.568	rs7075233	chr10:133545170	A/G	cg04492858	chr10:133558786	NA	-0.45	-6.51	-0.37	3.77e-10	Survival in rectal cancer;
CESC	cis	rs2842992	0.830	rs1998365	chr6:160179535	A/T	cg26839252	chr6:160211577	TCP1;MRPL18	0.45	5.15	0.3	5.03e-7	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs1552244	0.810	rs35711405	chr3:10116939	C/T	cg08888203	chr3:10149979	C3orf24	0.54	6.69	0.38	1.3e-10	Alzheimer's disease;
CESC	cis	rs6686643	0.762	rs6672982	chr1:165612815	T/A	cg19407955	chr1:165599744	MGST3	-0.54	-5.68	-0.33	3.55e-8	Total ventricular volume;
CESC	cis	rs4566357	1.000	rs3820926	chr2:227926621	G/T	cg11843606	chr2:227700838	RHBDD1	-0.43	-5.45	-0.32	1.16e-7	Coronary artery disease;
CESC	cis	rs801193	1.000	rs7783924	chr7:66209057	A/C	cg18876405	chr7:65276391	NA	0.54	7.28	0.41	3.88e-12	Aortic root size;
CESC	cis	rs1348850	0.526	rs10803912	chr2:178407176	A/C	cg22681709	chr2:178499509	PDE11A	0.49	5.29	0.31	2.53e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs1552244	0.872	rs6792951	chr3:10119603	C/A	cg16606324	chr3:10149918	C3orf24	0.43	5.36	0.31	1.81e-7	Alzheimer's disease;
CESC	cis	rs72781680	1.000	rs72781634	chr2:24199102	C/T	cg20701182	chr2:24300061	SF3B14	0.63	5.64	0.33	4.45e-8	Lymphocyte counts;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16144348	chr4:83812518	SEC31A	0.62	7.32	0.41	2.89e-12	Gut microbiome composition (summer);
CESC	cis	rs7607369	0.782	rs514799	chr2:219411203	A/G	cg02176678	chr2:219576539	TTLL4	0.5	9.0	0.48	4.36e-17	Red blood cell count;Amyotrophic lateral sclerosis;
CESC	cis	rs11785400	1.000	rs3735999	chr8:143746069	T/C	cg10596483	chr8:143751796	JRK	0.43	5.67	0.33	3.79e-8	Schizophrenia;
CESC	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg11494091	chr17:61959527	GH2	-0.72	-12.28	-0.6	9.61e-28	Prudent dietary pattern;
CESC	cis	rs11997175	0.624	rs7465686	chr8:33718321	G/A	ch.8.33884649F	chr8:33765107	NA	0.5	6.27	0.36	1.46e-9	Body mass index;
CESC	cis	rs763121	0.819	rs8137829	chr22:39061030	G/A	cg06022373	chr22:39101656	GTPBP1	0.88	13.88	0.65	2.66e-33	Menopause (age at onset);
CESC	cis	rs7618915	0.547	rs34017441	chr3:52742413	T/C	cg18099408	chr3:52552593	STAB1	-0.32	-5.3	-0.31	2.45e-7	Bipolar disorder;
CESC	cis	rs3806843	0.838	rs2337514	chr5:140132732	T/C	cg26395211	chr5:140044315	WDR55	0.39	5.15	0.3	5.18e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs78456975	1.000	rs6712176	chr2:1556393	C/T	cg01028140	chr2:1542097	TPO	-0.51	-5.44	-0.32	1.24e-7	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs4974559	0.895	rs57037487	chr4:1386652	A/G	cg02980000	chr4:1222292	CTBP1	0.74	8.88	0.48	1.07e-16	Systolic blood pressure;
CESC	trans	rs875971	0.767	rs1695815	chr7:65831344	A/G	cg26939375	chr7:64535504	NA	0.47	6.06	0.35	4.66e-9	Aortic root size;
CESC	cis	rs6860806	0.661	rs28472559	chr5:131581611	G/A	cg04518342	chr5:131593106	PDLIM4	0.41	6.08	0.35	4.16e-9	Breast cancer;
CESC	cis	rs6120849	0.754	rs6088691	chr20:33633758	C/T	cg06115741	chr20:33292138	TP53INP2	0.53	5.05	0.3	8.15e-7	Protein C levels;
CESC	cis	rs924607	1.000	rs1697978	chr5:642829	A/G	cg09021430	chr5:549028	NA	-0.38	-6.85	-0.39	5.11e-11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs919433	0.889	rs788001	chr2:198213720	C/T	cg10820045	chr2:198174542	NA	0.39	5.78	0.33	2.05e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs9300255	0.602	rs1716168	chr12:123651966	C/G	cg00376283	chr12:123451042	ABCB9	-0.69	-8.65	-0.47	4.95e-16	Neutrophil percentage of white cells;
CESC	cis	rs11122272	0.677	rs2808615	chr1:231550171	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.58	7.93	0.44	5.95e-14	Hemoglobin concentration;
CESC	cis	rs965513	0.530	rs1912995	chr9:100530899	A/G	cg13688889	chr9:100608707	NA	-0.42	-5.56	-0.32	6.74e-8	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
CESC	cis	rs35955747	0.677	rs4820974	chr22:31869467	A/C	cg25791279	chr22:32026902	PISD	-0.44	-5.27	-0.31	2.81e-7	Neutrophil count;Sum basophil neutrophil counts;
CESC	cis	rs735539	1.000	rs9579929	chr13:21282724	C/T	cg04906043	chr13:21280425	IL17D	0.39	6.03	0.35	5.58e-9	Dental caries;
CESC	cis	rs1008375	0.932	rs13109475	chr4:17677565	C/G	cg02297831	chr4:17616191	MED28	-0.46	-5.49	-0.32	9.2e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs853679	0.517	rs7755442	chr6:28039015	T/C	cg23281280	chr6:28129359	ZNF389	0.57	7.78	0.43	1.61e-13	Depression;
CESC	cis	rs6963495	0.546	rs2697020	chr7:105150046	C/T	cg13798780	chr7:105162888	PUS7	0.5	6.09	0.35	4.04e-9	Bipolar disorder (body mass index interaction);
CESC	cis	rs2836974	0.931	rs2989330	chr21:40716209	A/G	cg17971929	chr21:40555470	PSMG1	0.88	10.63	0.55	3.21e-22	Cognitive function;
CESC	cis	rs1799949	0.965	rs4793237	chr17:41436595	A/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.52	7.37	0.41	2.17e-12	Menopause (age at onset);
CESC	cis	rs9487051	0.807	rs7748641	chr6:109592381	C/T	cg21918786	chr6:109611834	NA	-0.39	-6.04	-0.35	5.09e-9	Reticulocyte fraction of red cells;
CESC	cis	rs6032067	0.777	rs13042694	chr20:43799368	G/A	cg10761708	chr20:43804764	PI3	0.56	6.66	0.38	1.58e-10	Blood protein levels;
CESC	cis	rs16866061	1.000	rs72974269	chr2:225454907	C/T	cg12698349	chr2:225449008	CUL3	0.74	10.43	0.54	1.41e-21	Acute graft versus host disease in bone marrow transplantation (recipient effect);
CESC	cis	rs1862618	0.853	rs2113079	chr5:56157951	A/G	cg24549020	chr5:56110836	MAP3K1	0.66	7.53	0.42	7.74e-13	Initial pursuit acceleration;
CESC	cis	rs9814567	0.806	rs9839705	chr3:134323819	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.38	-5.06	-0.3	7.86e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs5167	0.504	rs4803781	chr19:45459671	C/T	cg20090143	chr19:45452003	APOC2	0.36	6.35	0.36	9.53e-10	Blood protein levels;
CESC	cis	rs10463316	0.894	rs7729216	chr5:150762277	A/G	cg03212797	chr5:150827313	SLC36A1	-0.46	-6.02	-0.35	5.83e-9	Metabolite levels (Pyroglutamine);
CESC	cis	rs7264396	1.000	rs224424	chr20:34147998	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.55	-7.09	-0.4	1.25e-11	Total cholesterol levels;
CESC	cis	rs55871839	0.708	rs10093993	chr8:59811454	T/C	cg07426533	chr8:59803705	TOX	-0.47	-7.01	-0.4	1.95e-11	Pneumonia;
CESC	cis	rs7666738	0.830	rs10010698	chr4:98981594	C/T	cg03676636	chr4:99064102	C4orf37	0.33	5.13	0.3	5.6e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs17253792	0.822	rs77676035	chr14:56096229	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.79	5.91	0.34	1.06e-8	Putamen volume;
CESC	cis	rs644799	0.932	rs10831447	chr11:95663017	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	-0.63	-7.09	-0.4	1.22e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs60843830	1.000	rs36216559	chr2:262335	A/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.8	10.47	0.54	1.11e-21	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs4889855	0.530	rs12451459	chr17:78589668	G/A	cg16591659	chr17:78472290	NA	0.34	5.48	0.32	9.83e-8	Fractional excretion of uric acid;
CESC	cis	rs9322193	0.923	rs2184369	chr6:150097817	G/A	cg05861140	chr6:150128134	PCMT1	-0.37	-5.24	-0.31	3.23e-7	Lung cancer;
CESC	cis	rs1152591	0.524	rs1255992	chr14:64662895	A/G	cg23250157	chr14:64679961	SYNE2	0.41	5.87	0.34	1.31e-8	Atrial fibrillation;
CESC	cis	rs7833790	0.724	rs10958045	chr8:82722994	T/C	cg17211192	chr8:82754475	SNX16	-0.58	-7.39	-0.41	1.95e-12	Diastolic blood pressure;
CESC	cis	rs11581903	0.568	rs6686035	chr1:53080008	A/C	cg19751897	chr1:52520827	TXNDC12;BTF3L4	0.64	5.09	0.3	6.92e-7	Joint mobility (Beighton score);
CESC	cis	rs7824557	0.628	rs58283816	chr8:11192551	G/C	cg21775007	chr8:11205619	TDH	0.55	8.74	0.47	2.75e-16	Retinal vascular caliber;
CESC	cis	rs9911578	0.967	rs7502208	chr17:57165097	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.17	0.3	4.51e-7	Intelligence (multi-trait analysis);
CESC	trans	rs9693444	0.898	rs4732697	chr8:29519861	A/G	cg03350042	chr15:40733177	BAHD1	-0.43	-6.47	-0.37	4.82e-10	Breast cancer;
CESC	cis	rs798554	0.797	rs1182184	chr7:2872446	G/A	cg09658497	chr7:2847517	GNA12	-0.45	-6.53	-0.37	3.25e-10	Height;
CESC	cis	rs2011503	0.782	rs8113006	chr19:19669441	C/G	cg11584989	chr19:19387371	SF4	-0.46	-5.21	-0.3	3.87e-7	Bipolar disorder;
CESC	cis	rs11711311	0.910	rs62265549	chr3:113396234	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.67	8.6	0.47	7.08e-16	IgG glycosylation;
CESC	cis	rs6141600	0.760	rs2746103	chr20:34703934	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.4	-5.37	-0.31	1.72e-7	Height;Hip circumference;
CESC	cis	rs617219	0.550	rs115009495	chr5:78433831	C/T	cg22188827	chr5:78429774	NA	-0.43	-5.09	-0.3	6.87e-7	Betaine levels in individuals undergoing cardiac evaluation;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02544571	chr7:139187165	NA	-0.59	-6.43	-0.37	5.78e-10	Gut microbiome composition (summer);
CESC	cis	rs796364	0.760	rs74993507	chr2:201068684	C/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.75	-5.97	-0.34	7.5e-9	Schizophrenia;
CESC	cis	rs2997447	0.655	rs2275950	chr1:26385003	T/C	cg19633962	chr1:26362018	EXTL1	-0.56	-5.72	-0.33	2.87e-8	QRS complex (12-leadsum);
CESC	cis	rs2228479	0.850	rs76075456	chr16:89834270	T/C	cg04013166	chr16:89971882	TCF25	0.78	6.69	0.38	1.3e-10	Skin colour saturation;
CESC	cis	rs3820068	0.581	rs72645890	chr1:15930602	A/G	cg13390004	chr1:15929781	NA	0.35	5.58	0.32	5.83e-8	Systolic blood pressure;
CESC	cis	rs1124376	1.000	rs61138004	chr3:20145855	C/G	cg05072819	chr3:20081367	KAT2B	0.51	5.51	0.32	8.5e-8	Bipolar disorder and schizophrenia;
CESC	trans	rs853679	0.599	rs13193295	chr6:28003228	C/G	cg01620082	chr3:125678407	NA	-0.81	-6.37	-0.36	8.23e-10	Depression;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg21947590	chr19:620162	POLRMT	0.45	6.25	0.36	1.67e-9	Fibrinogen levels;
CESC	cis	rs5758511	0.689	rs17478227	chr22:42654327	C/G	cg00645731	chr22:42541494	CYP2D7P1	-0.54	-7.04	-0.4	1.64e-11	Birth weight;
CESC	cis	rs7829975	0.623	rs10087493	chr8:8373557	A/G	cg06636001	chr8:8085503	FLJ10661	-0.49	-6.27	-0.36	1.45e-9	Mood instability;
CESC	trans	rs1814175	0.585	rs4881661	chr11:50000117	A/G	cg15704280	chr7:45808275	SEPT13	-1.0	-18.49	-0.75	1.41e-49	Height;
CESC	cis	rs7786877	0.583	rs41303510	chr7:100226129	C/T	cg20848291	chr7:100343083	ZAN	-0.67	-7.01	-0.4	1.96e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs131777	0.526	rs86337	chr22:51020668	C/A	cg00083937	chr22:51039805	MAPK8IP2	0.36	5.18	0.3	4.48e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	cis	rs4660261	0.526	rs810680	chr1:44347856	C/T	cg12908607	chr1:44402522	ARTN	-0.48	-6.94	-0.39	3.05e-11	Intelligence (multi-trait analysis);
CESC	trans	rs2727020	0.702	rs609054	chr11:49219725	C/G	cg03929089	chr4:120376271	NA	0.78	11.83	0.59	3.28e-26	Coronary artery disease;
CESC	cis	rs9788333	0.695	rs12871086	chr13:21890224	A/T	cg21970626	chr13:21893289	NA	-0.42	-6.31	-0.36	1.14e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs12410462	0.579	rs116423559	chr1:227575014	A/G	cg23173402	chr1:227635558	NA	0.68	5.62	0.33	4.88e-8	Major depressive disorder;
CESC	cis	rs7772486	0.686	rs2328708	chr6:146095739	G/A	cg23711669	chr6:146136114	FBXO30	-0.86	-12.57	-0.61	1.01e-28	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs17253792	0.822	rs17253723	chr14:56154015	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.81	5.68	0.33	3.46e-8	Putamen volume;
CESC	cis	rs7312774	0.618	rs12316286	chr12:107343020	C/A	cg16260113	chr12:107380972	MTERFD3	0.81	7.42	0.41	1.55e-12	Severe influenza A (H1N1) infection;
CESC	cis	rs6598955	0.670	rs3795685	chr1:26601385	A/G	cg00852783	chr1:26633632	UBXN11	-0.4	-5.86	-0.34	1.37e-8	Obesity-related traits;
CESC	cis	rs2880765	0.743	rs6497191	chr15:86011501	T/C	cg10818794	chr15:86012489	AKAP13	-0.35	-5.4	-0.31	1.49e-7	Coronary artery disease;
CESC	trans	rs61931739	0.500	rs7484658	chr12:34515879	A/G	cg26384229	chr12:38710491	ALG10B	0.54	7.55	0.42	7.05e-13	Morning vs. evening chronotype;
CESC	cis	rs2073300	0.609	rs6132606	chr20:23367453	G/A	cg12062639	chr20:23401060	NAPB	1.07	8.85	0.48	1.29e-16	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs7264396	0.790	rs3787166	chr20:34229072	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.8	-9.09	-0.49	2.4e-17	Total cholesterol levels;
CESC	cis	rs7666738	0.927	rs4699328	chr4:99055890	C/T	cg03467027	chr4:99064603	C4orf37	0.48	6.0	0.35	6.63e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs66782572	1	rs66782572	chr3:52567617	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.35	5.17	0.3	4.67e-7	Hemoglobin concentration;
CESC	trans	rs1545843	0.564	rs2061477	chr12:84909015	G/A	cg03015433	chr16:56623111	MT3	0.34	6.14	0.35	3.07e-9	Major depressive disorder;
CESC	cis	rs8180040	0.966	rs13072802	chr3:47346415	G/C	cg27129171	chr3:47204927	SETD2	0.66	10.03	0.52	2.81e-20	Colorectal cancer;
CESC	cis	rs4665809	0.652	rs7585891	chr2:26403766	G/A	cg25036284	chr2:26402008	FAM59B	-0.82	-9.33	-0.5	4.47e-18	Gut microbiome composition (summer);
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg19701416	chr10:28592092	NA	0.45	6.04	0.35	5.14e-9	Systemic lupus erythematosus;
CESC	cis	rs4819052	0.851	rs1056101	chr21:46678702	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.96	14.51	0.67	1.65e-35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs1799949	1.000	rs4793192	chr17:41204390	T/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.41	5.6	0.33	5.36e-8	Menopause (age at onset);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg02916964	chr12:56326165	DGKA	-0.47	-6.09	-0.35	3.96e-9	Fibrinogen levels;
CESC	cis	rs599083	0.530	rs546803	chr11:68186392	C/T	cg16797656	chr11:68205561	LRP5	-0.41	-5.33	-0.31	2.11e-7	Bone mineral density (spine);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05966498	chr5:10761293	DAP	0.58	6.36	0.36	8.77e-10	Gut microbiome composition (summer);
CESC	cis	rs2425143	1.000	rs74785978	chr20:34373234	G/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.7	6.06	0.35	4.71e-9	Blood protein levels;
CESC	cis	rs2836974	0.644	rs11088472	chr21:40699376	A/C	cg17971929	chr21:40555470	PSMG1	-0.85	-12.3	-0.6	8.25e-28	Cognitive function;
CESC	cis	rs9790314	0.521	rs2122527	chr3:161091636	G/A	cg04691961	chr3:161091175	C3orf57	-0.37	-5.11	-0.3	6.1e-7	Morning vs. evening chronotype;
CESC	cis	rs7666738	0.830	rs113999196	chr4:99041961	C/T	cg05340658	chr4:99064831	C4orf37	0.82	12.88	0.62	8.44e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7666738	0.544	rs35160902	chr4:98974690	A/T	cg05340658	chr4:99064831	C4orf37	0.78	11.86	0.59	2.6e-26	Colonoscopy-negative controls vs population controls;
CESC	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg11494091	chr17:61959527	GH2	0.73	12.66	0.61	4.86e-29	Prudent dietary pattern;
CESC	cis	rs2742234	0.590	rs1254962	chr10:43696992	G/A	cg15436174	chr10:43711423	RASGEF1A	0.5	5.85	0.34	1.45e-8	Hirschsprung disease;
CESC	cis	rs2836974	0.897	rs8128102	chr21:40606414	G/A	cg17971929	chr21:40555470	PSMG1	1.04	15.63	0.69	1.86e-39	Cognitive function;
CESC	cis	rs597539	0.690	rs11228383	chr11:68623228	T/G	cg01988459	chr11:68622903	NA	-0.41	-5.3	-0.31	2.4e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs792448	0.743	rs7519959	chr1:212498652	T/C	cg01059126	chr1:212459029	PPP2R5A	-0.43	-5.31	-0.31	2.29e-7	White blood cell count (basophil);
CESC	cis	rs473651	0.935	rs474478	chr2:239335473	C/T	cg18131467	chr2:239335373	ASB1	1.04	20.94	0.79	4e-58	Multiple system atrophy;
CESC	cis	rs6502050	0.731	rs4789730	chr17:80145983	T/A	cg23985595	chr17:80112537	CCDC57	-0.4	-6.33	-0.36	1.06e-9	Life satisfaction;
CESC	cis	rs1003719	0.788	rs2835586	chr21:38461326	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.63	8.77	0.47	2.21e-16	Eye color traits;
CESC	cis	rs11958404	1.000	rs72816528	chr5:157410949	G/A	cg05962755	chr5:157440814	NA	0.53	6.02	0.35	5.72e-9	IgG glycosylation;
CESC	cis	rs2295359	1.000	rs963427	chr1:67609347	A/G	cg03340356	chr1:67600835	NA	0.36	5.83	0.34	1.62e-8	Psoriasis;
CESC	cis	rs1707322	1.000	rs12124291	chr1:46432132	G/A	cg05343316	chr1:45956843	TESK2	0.44	5.42	0.32	1.36e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs13191362	0.935	rs35049401	chr6:162968464	T/G	cg21926612	chr6:163149169	PACRG;PARK2	0.83	7.54	0.42	7.47e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	trans	rs9929218	1.000	rs2113199	chr16:68814502	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.64	-8.36	-0.46	3.57e-15	Colorectal cancer;
CESC	cis	rs763121	0.853	rs5757187	chr22:39021522	A/G	cg06544989	chr22:39130855	UNC84B	-0.51	-8.83	-0.48	1.41e-16	Menopause (age at onset);
CESC	cis	rs9640161	0.702	rs1962004	chr7:150020381	G/A	cg17279839	chr7:150038598	RARRES2	0.47	5.43	0.32	1.25e-7	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs2737618	0.651	rs2249156	chr1:200083541	A/G	cg21825944	chr1:200113062	NR5A2	0.47	7.17	0.4	7.36e-12	Uric acid levels;
CESC	trans	rs1814175	0.676	rs1851859	chr11:49860405	A/T	cg11707556	chr5:10655725	ANKRD33B	-0.42	-6.12	-0.35	3.39e-9	Height;
CESC	cis	rs734999	0.505	rs4445406	chr1:2539400	T/C	cg18854424	chr1:2615690	NA	0.29	5.71	0.33	2.95e-8	Ulcerative colitis;
CESC	trans	rs35110281	0.805	rs3788062	chr21:44991159	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.51	6.89	0.39	4.12e-11	Mean corpuscular volume;
CESC	cis	rs344364	0.511	rs2917519	chr16:1950479	C/A	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.55	-6.2	-0.36	2.15e-9	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs12497850	0.864	rs3212	chr3:49145741	T/C	cg03060546	chr3:49711283	APEH	0.52	6.32	0.36	1.07e-9	Parkinson's disease;
CESC	cis	rs2242194	0.816	rs11264296	chr1:154994750	T/C	cg24250549	chr1:154909240	PMVK	0.39	5.1	0.3	6.46e-7	Schizophrenia;
CESC	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg23708337	chr7:1209742	NA	0.52	5.16	0.3	4.88e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2273669	0.667	rs12215736	chr6:109330367	A/G	cg05315195	chr6:109294784	ARMC2	-0.67	-6.32	-0.36	1.13e-9	Prostate cancer;
CESC	cis	rs896854	0.846	rs2340584	chr8:95916811	A/G	cg26343298	chr8:95960752	TP53INP1	0.32	5.25	0.31	3.1e-7	Type 2 diabetes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09657265	chr6:123110763	SMPDL3A	0.54	6.06	0.35	4.54e-9	Gut microbiome composition (summer);
CESC	cis	rs1499972	0.938	rs861001	chr3:117720355	C/T	cg07612923	chr3:117604196	NA	0.75	5.5	0.32	8.82e-8	Schizophrenia;
CESC	trans	rs6073597	1.000	rs6031980	chr20:43714384	C/T	cg04761648	chr13:26829199	CDK8	0.46	6.3	0.36	1.26e-9	Positive affect;
CESC	cis	rs1538970	0.924	rs4660855	chr1:45899795	A/G	cg03146154	chr1:46216737	IPP	0.44	5.09	0.3	6.74e-7	Platelet count;
CESC	cis	rs10504229	0.683	rs903706	chr8:58128134	T/G	cg21724239	chr8:58056113	NA	0.58	5.95	0.34	8.29e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs2228479	0.850	rs17227263	chr16:89810598	G/A	cg06558623	chr16:89946397	TCF25	1.17	9.44	0.5	1.96e-18	Skin colour saturation;
CESC	cis	rs2180341	1.000	rs4895822	chr6:127642703	T/C	cg27446573	chr6:127587934	RNF146	1.09	16.35	0.71	5.12e-42	Breast cancer;
CESC	cis	rs7429990	0.965	rs4392441	chr3:48077701	C/T	cg11946769	chr3:48343235	NME6	-0.43	-5.22	-0.31	3.62e-7	Educational attainment (years of education);
CESC	cis	rs2072732	0.821	rs7412983	chr1:2943183	A/C	cg15211996	chr1:2936768	ACTRT2	0.35	5.74	0.33	2.65e-8	Plateletcrit;
CESC	cis	rs6460942	0.915	rs17444141	chr7:12460971	T/G	cg02935154	chr7:12443704	VWDE	-0.58	-6.16	-0.35	2.73e-9	Coronary artery disease;
CESC	cis	rs7264396	0.635	rs6058344	chr20:34475038	A/G	cg17201900	chr20:34330562	RBM39	0.5	5.07	0.3	7.37e-7	Total cholesterol levels;
CESC	cis	rs2072499	0.898	rs2758609	chr1:156202868	G/A	cg24450063	chr1:156163899	SLC25A44	0.8	11.95	0.59	1.24e-26	Testicular germ cell tumor;
CESC	cis	rs2404602	0.735	rs11629888	chr15:76719880	A/T	cg23625390	chr15:77176239	SCAPER	-0.41	-5.32	-0.31	2.23e-7	Blood metabolite levels;
CESC	cis	rs910316	0.967	rs10246	chr14:75544470	T/A	cg11812906	chr14:75593930	NEK9	0.9	15.29	0.68	2.79e-38	Height;
CESC	cis	rs7811142	0.830	rs1063945	chr7:99930447	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.15	12.01	0.59	7.93e-27	Platelet count;
CESC	cis	rs875971	0.660	rs801211	chr7:66015689	T/G	cg25985355	chr7:65971099	NA	0.32	5.34	0.31	2e-7	Aortic root size;
CESC	cis	rs9640161	0.673	rs34489187	chr7:150044379	G/A	cg21361702	chr7:150065534	REPIN1	0.57	6.01	0.35	6.25e-9	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs477692	0.967	rs488143	chr10:131407369	A/C	cg05714579	chr10:131428358	MGMT	0.54	7.59	0.42	5.45e-13	Response to temozolomide;
CESC	cis	rs9911578	1.000	rs9901114	chr17:56575208	G/A	cg12560992	chr17:57184187	TRIM37	-0.91	-15.23	-0.68	4.63e-38	Intelligence (multi-trait analysis);
CESC	cis	rs12048904	0.619	rs10875346	chr1:101328083	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.89	12.15	0.6	2.69e-27	Multiple sclerosis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01198208	chr4:87893007	AFF1	-0.55	-6.19	-0.36	2.24e-9	Gut microbiome composition (summer);
CESC	cis	rs13256369	1.000	rs7843488	chr8:8576217	C/T	cg18904891	chr8:8559673	CLDN23	0.69	7.99	0.44	4.17e-14	Obesity-related traits;
CESC	cis	rs738322	1.000	rs738320	chr22:38568715	G/T	cg17652424	chr22:38574118	PLA2G6	-0.34	-6.03	-0.35	5.39e-9	Cutaneous nevi;
CESC	cis	rs34172651	0.517	rs8059004	chr16:24837905	G/A	cg06505273	chr16:24850292	NA	0.51	6.29	0.36	1.32e-9	Intelligence (multi-trait analysis);
CESC	cis	rs35110281	0.682	rs162379	chr21:44925334	A/G	cg01579765	chr21:45077557	HSF2BP	0.44	7.75	0.43	2.03e-13	Mean corpuscular volume;
CESC	cis	rs2191566	0.555	rs397964	chr19:44493969	A/T	cg20607764	chr19:44506953	ZNF230	0.47	5.95	0.34	8.31e-9	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs11966931	0.711	rs11964340	chr6:108111651	G/T	cg10566610	chr6:108093680	SCML4	0.28	5.06	0.3	7.83e-7	Neutrophil percentage of white cells;
CESC	cis	rs9486719	0.522	rs4839683	chr6:96851933	A/G	cg06623918	chr6:96969491	KIAA0776	0.75	8.48	0.46	1.63e-15	Migraine;Coronary artery disease;
CESC	cis	rs2842992	0.915	rs2842980	chr6:160100116	A/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.67	8.1	0.45	2.05e-14	Age-related macular degeneration (geographic atrophy);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg17351116	chr20:25371719	ABHD12	0.48	6.04	0.35	5.22e-9	Gut microbiota (bacterial taxa);
CESC	trans	rs11098499	0.954	rs10005644	chr4:120298477	T/C	cg25214090	chr10:38739885	LOC399744	0.68	9.2	0.49	1.14e-17	Corneal astigmatism;
CESC	cis	rs910316	1.000	rs2268617	chr14:75608728	G/A	cg11812906	chr14:75593930	NEK9	0.9	15.64	0.69	1.67e-39	Height;
CESC	cis	rs9311474	0.652	rs614288	chr3:52220203	T/C	cg15147215	chr3:52552868	STAB1	-0.34	-5.69	-0.33	3.29e-8	Electroencephalogram traits;
CESC	cis	rs28595532	0.748	rs72670248	chr4:119335536	A/C	cg21605333	chr4:119757512	SEC24D	1.01	5.58	0.32	5.98e-8	Cannabis dependence symptom count;
CESC	cis	rs1799949	1.000	rs11654731	chr17:41326940	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.6	7.84	0.43	1.07e-13	Menopause (age at onset);
CESC	cis	rs7811142	0.775	rs1059129	chr7:99926522	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.84	9.03	0.49	3.56e-17	Platelet count;
CESC	cis	rs6594713	0.717	rs13436825	chr5:112817687	T/A	cg12552261	chr5:112820674	MCC	0.56	5.5	0.32	8.78e-8	Brain cytoarchitecture;
CESC	cis	rs698833	0.548	rs6544760	chr2:44553014	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.55	5.84	0.34	1.52e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs7589728	0.563	rs78168096	chr2:88473575	G/A	cg14558114	chr2:88469736	THNSL2	0.59	5.43	0.32	1.25e-7	Plasma clusterin levels;
CESC	cis	rs10979	0.557	rs9390117	chr6:143907590	C/T	cg25407410	chr6:143891975	LOC285740	-0.49	-6.31	-0.36	1.16e-9	Hypospadias;
CESC	cis	rs1707322	1.000	rs6671754	chr1:46433990	A/G	cg05343316	chr1:45956843	TESK2	0.44	5.42	0.32	1.36e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs2270927	1.000	rs2270927	chr5:75591710	C/G	cg13563193	chr19:33072644	PDCD5	0.73	6.43	0.37	6.06e-10	Mean corpuscular volume;
CESC	cis	rs896543	0.702	rs6715324	chr2:237495510	C/T	cg25295825	chr2:237489920	CXCR7	0.73	9.34	0.5	4.06e-18	Alcohol dependence (age at onset);
CESC	cis	rs1552244	0.882	rs13062917	chr3:10017032	T/A	cg08888203	chr3:10149979	C3orf24	0.49	6.17	0.35	2.49e-9	Alzheimer's disease;
CESC	cis	rs9457247	1.000	rs389946	chr6:167407268	T/C	cg07741184	chr6:167504864	NA	0.29	5.31	0.31	2.32e-7	Crohn's disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg27067419	chr5:54830434	PPAP2A;RNF138P1	-0.45	-6.68	-0.38	1.43e-10	Fibrinogen levels;
CESC	cis	rs9322193	0.926	rs9285525	chr6:150122389	C/G	cg04369109	chr6:150039330	LATS1	-0.39	-5.35	-0.31	1.93e-7	Lung cancer;
CESC	cis	rs9311474	0.508	rs11714565	chr3:52606292	C/T	cg18404041	chr3:52824283	ITIH1	-0.38	-6.5	-0.37	4e-10	Electroencephalogram traits;
CESC	cis	rs15676	0.947	rs6478854	chr9:131588888	G/C	cg00228799	chr9:131580591	ENDOG	-0.44	-5.5	-0.32	9.01e-8	Blood metabolite levels;
CESC	cis	rs4481887	0.741	rs1361413	chr1:248529521	C/G	cg26353448	chr1:248524236	OR2T4	0.35	5.03	0.3	9.14e-7	Common traits (Other);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02013961	chr6:142468197	VTA1	0.57	6.26	0.36	1.56e-9	Gut microbiome composition (summer);
CESC	cis	rs910316	1.000	rs7147118	chr14:75610170	G/C	cg08847533	chr14:75593920	NEK9	1.03	20.54	0.78	9.98e-57	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16929187	chr11:71791555	LRTOMT;NUMA1	0.57	6.1	0.35	3.73e-9	Gut microbiome composition (summer);
CESC	cis	rs875971	0.505	rs1167385	chr7:65513308	G/A	cg14393609	chr7:65229607	NA	-0.52	-7.15	-0.4	8.31e-12	Aortic root size;
CESC	cis	rs769267	0.896	rs10405625	chr19:19579046	T/G	cg03709012	chr19:19516395	GATAD2A	1.01	15.7	0.69	1.01e-39	Tonsillectomy;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg07136949	chr6:7986672	MGC26597	0.47	6.33	0.36	1.04e-9	Ulcerative colitis;
CESC	cis	rs6062302	0.522	rs6090476	chr20:62248001	G/A	cg06363034	chr20:62225388	GMEB2	-0.5	-6.41	-0.37	6.66e-10	Glioblastoma;
CESC	cis	rs854765	0.551	rs12600546	chr17:17867614	A/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.55	7.06	0.4	1.45e-11	Total body bone mineral density;
CESC	cis	rs9329289	0.888	rs11251273	chr10:2540300	G/C	cg18171855	chr10:2543474	NA	0.39	6.02	0.35	5.73e-9	Age-related hearing impairment;
CESC	cis	rs4243830	0.850	rs908273	chr1:6588604	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.81	-8.53	-0.46	1.1e-15	Body mass index;
CESC	cis	rs6076065	0.748	rs2281431	chr20:23399304	C/G	cg11657817	chr20:23433608	CST11	0.41	6.17	0.35	2.49e-9	Facial morphology (factor 15, philtrum width);
CESC	cis	rs2841277	0.676	rs10438246	chr14:105410183	T/C	cg17340268	chr14:105411764	AHNAK2	-0.51	-6.88	-0.39	4.35e-11	Rheumatoid arthritis;
CESC	cis	rs2842992	0.724	rs4709368	chr6:160204127	C/T	cg11366901	chr6:160182831	ACAT2	-0.62	-7.88	-0.44	8.54e-14	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs769267	0.899	rs67720221	chr19:19440864	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	-0.44	-5.46	-0.32	1.1e-7	Tonsillectomy;
CESC	cis	rs6860806	0.661	rs6871350	chr5:131580220	A/G	cg18301423	chr5:131593218	PDLIM4	0.38	5.37	0.31	1.73e-7	Breast cancer;
CESC	cis	rs7000551	0.751	rs2469770	chr8:22379856	G/A	cg12081754	chr8:22256438	SLC39A14	0.46	6.08	0.35	4.16e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CESC	cis	rs3820928	0.874	rs1054413	chr2:227867719	A/G	cg05526886	chr2:227700861	RHBDD1	0.42	5.22	0.31	3.66e-7	Pulmonary function;
CESC	cis	rs28374715	0.532	rs28535540	chr15:41659277	G/A	cg20272979	chr15:41787780	ITPKA	0.41	5.1	0.3	6.62e-7	Ulcerative colitis;
CESC	cis	rs9916302	0.904	rs602282	chr17:37433021	C/T	cg07936489	chr17:37558343	FBXL20	-0.79	-11.24	-0.57	3.08e-24	Glomerular filtration rate (creatinine);
CESC	cis	rs6066835	0.572	rs4616535	chr20:47248808	C/T	cg18078177	chr20:47281410	PREX1	0.66	5.11	0.3	6.29e-7	Multiple myeloma;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04165840	chr10:105156204	USMG5;PDCD11	0.56	6.57	0.37	2.63e-10	Gut microbiome composition (summer);
CESC	cis	rs9649213	0.593	rs12672092	chr7:97986557	C/A	cg24562669	chr7:97807699	LMTK2	0.51	7.63	0.42	4.29e-13	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs1862618	0.756	rs13356762	chr5:56110992	G/T	cg24531977	chr5:56204891	C5orf35	-0.87	-11.43	-0.57	7.27e-25	Initial pursuit acceleration;
CESC	trans	rs17307778	1.000	rs1477571	chr11:25358529	C/T	cg22888484	chr20:37075185	SNHG11	-0.63	-6.17	-0.35	2.61e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs6860806	0.507	rs272891	chr5:131664394	G/T	cg07395648	chr5:131743802	NA	-0.43	-5.68	-0.33	3.62e-8	Breast cancer;
CESC	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg22907277	chr7:1156413	C7orf50	0.44	6.41	0.37	6.75e-10	Longevity;Endometriosis;
CESC	cis	rs1707322	1.000	rs10890370	chr1:46389217	C/T	cg06784218	chr1:46089804	CCDC17	0.33	5.69	0.33	3.41e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9297145	0.958	rs11975761	chr7:98766688	G/A	cg05967295	chr7:98741636	SMURF1	-0.98	-12.85	-0.62	1.04e-29	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
CESC	cis	rs9443645	0.901	rs4706079	chr6:79615208	G/A	cg05283184	chr6:79620031	NA	-0.44	-6.64	-0.38	1.79e-10	Intelligence (multi-trait analysis);
CESC	trans	rs116095464	0.867	rs10074958	chr5:230828	C/T	cg00938859	chr5:1591904	SDHAP3	0.62	6.74	0.38	9.96e-11	Breast cancer;
CESC	cis	rs2732480	0.577	rs1489109	chr12:48738780	C/A	cg04545296	chr12:48745243	ZNF641	0.44	7.29	0.41	3.69e-12	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs9916302	0.629	rs9972882	chr17:37807698	A/C	cg00129232	chr17:37814104	STARD3	-0.69	-8.91	-0.48	8.28e-17	Glomerular filtration rate (creatinine);
CESC	cis	rs62229266	0.804	rs56279140	chr21:37424361	C/T	cg12218747	chr21:37451666	NA	-0.43	-6.09	-0.35	3.99e-9	Mitral valve prolapse;
CESC	cis	rs9430161	0.579	rs6694011	chr1:11036935	G/A	cg27631724	chr1:11040367	C1orf127	0.46	7.81	0.43	1.36e-13	Ewing sarcoma;
CESC	cis	rs35160687	0.623	rs11689971	chr2:86474471	A/G	cg01119172	chr2:86362222	SNORD94;PTCD3	-0.39	-5.18	-0.3	4.5e-7	Night sleep phenotypes;
CESC	cis	rs17764205	0.777	rs17696630	chr19:3261995	A/G	cg02612712	chr19:3985498	EEF2	-0.71	-5.74	-0.33	2.6e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs67460515	0.892	rs7610985	chr3:161062848	G/A	cg03342759	chr3:160939853	NMD3	-0.54	-7.84	-0.43	1.13e-13	Parkinson's disease;
CESC	cis	rs9486719	0.656	rs6924957	chr6:96853579	G/T	cg18709589	chr6:96969512	KIAA0776	0.44	5.46	0.32	1.11e-7	Migraine;Coronary artery disease;
CESC	cis	rs1799949	1.000	rs2175957	chr17:41286822	T/G	cg06001716	chr17:41278141	BRCA1;NBR2	0.38	5.17	0.3	4.51e-7	Menopause (age at onset);
CESC	cis	rs1552244	0.882	rs3755783	chr3:10029289	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.82	9.57	0.51	8.02e-19	Alzheimer's disease;
CESC	cis	rs4891159	0.756	rs3892540	chr18:74118058	C/T	cg24786174	chr18:74118243	ZNF516	-0.73	-11.26	-0.57	2.72e-24	Longevity;
CESC	cis	rs17253792	0.822	rs77676035	chr14:56096229	G/A	cg01858014	chr14:56050164	KTN1	-0.85	-6.99	-0.39	2.22e-11	Putamen volume;
CESC	cis	rs9325144	0.624	rs12231544	chr12:38901956	C/T	cg26384229	chr12:38710491	ALG10B	-0.56	-7.86	-0.43	9.61e-14	Morning vs. evening chronotype;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14049615	chr4:87928107	AFF1	0.58	6.85	0.39	5.27e-11	Gut microbiome composition (summer);
CESC	cis	rs1728785	1.000	rs1728801	chr16:68571457	A/C	cg02972257	chr16:68554789	NA	-0.55	-6.34	-0.36	9.7e-10	Ulcerative colitis;
CESC	cis	rs1267303	0.642	rs6696219	chr1:47000408	T/C	cg25110126	chr1:46999211	NA	0.84	10.81	0.55	8.26e-23	Monobrow;
CESC	cis	rs939574	0.722	rs55951006	chr2:220132151	C/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.89	6.96	0.39	2.6e-11	Platelet distribution width;
CESC	cis	rs9814567	1.000	rs2370641	chr3:134222161	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.43	-5.98	-0.34	7.14e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs597539	0.652	rs667989	chr11:68685776	T/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.81	10.36	0.54	2.49e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs4601790	0.601	rs66864335	chr11:65390803	G/A	cg26668713	chr11:65405903	SIPA1	0.69	7.63	0.42	4.32e-13	Blood pressure (age interaction);
CESC	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg03452623	chr4:187889614	NA	-0.87	-14.81	-0.67	1.44e-36	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs858239	0.508	rs7805071	chr7:23190212	C/T	cg23682824	chr7:23144976	KLHL7	0.46	5.85	0.34	1.45e-8	Cerebrospinal fluid biomarker levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14426517	chr6:153323975	MTRF1L	0.56	6.46	0.37	5.11e-10	Gut microbiome composition (summer);
CESC	trans	rs7980799	0.653	rs1384598	chr12:33622899	T/A	cg26384229	chr12:38710491	ALG10B	-0.55	-7.81	-0.43	1.32e-13	Heart rate;Heart rate variability traits (RMSSD);
CESC	cis	rs3796352	1.000	rs3097417	chr3:53088601	C/G	cg12962167	chr3:53033115	SFMBT1	-0.63	-5.95	-0.34	8.59e-9	Immune reponse to smallpox (secreted IL-2);
CESC	cis	rs6665290	0.904	rs1045287	chr1:227178962	C/T	cg10327440	chr1:227177885	CDC42BPA	1.2	30.4	0.88	2.27e-88	Myeloid white cell count;
CESC	cis	rs1799949	1.000	rs1135214	chr17:41292323	T/C	cg05368731	chr17:41323189	NBR1	0.78	10.79	0.55	9.37e-23	Menopause (age at onset);
CESC	cis	rs7666738	0.830	rs4699591	chr4:98974171	A/G	cg03676636	chr4:99064102	C4orf37	0.34	5.2	0.3	3.93e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27050990	chr7:2629313	IQCE	-0.51	-6.05	-0.35	5e-9	Gut microbiome composition (summer);
CESC	cis	rs853679	0.517	rs9295759	chr6:28124469	C/T	cg22143856	chr6:28129313	ZNF389	0.52	6.6	0.38	2.24e-10	Depression;
CESC	cis	rs6963495	0.818	rs73192141	chr7:105201129	T/G	cg13798780	chr7:105162888	PUS7	0.77	7.57	0.42	6.35e-13	Bipolar disorder (body mass index interaction);
CESC	cis	rs9513593	1.000	rs12861519	chr13:100029555	A/C	cg21788972	chr13:99853209	UBAC2	0.6	6.98	0.39	2.4e-11	Psoriasis;
CESC	cis	rs853679	0.517	rs1947863	chr6:28099344	G/A	cg26335602	chr6:28129616	ZNF389	0.54	7.3	0.41	3.37e-12	Depression;
CESC	cis	rs563538	1	rs563538	chr13:37433721	A/G	cg00891593	chr13:37393154	RFXAP	-0.68	-5.12	-0.3	5.95e-7	Spontaneous preterm birth (preterm birth);
CESC	trans	rs66887589	0.616	rs11732621	chr4:120212883	A/C	cg25214090	chr10:38739885	LOC399744	0.43	6.11	0.35	3.56e-9	Diastolic blood pressure;
CESC	cis	rs9467711	0.606	rs2393667	chr6:26421345	T/C	cg14345882	chr6:26364793	BTN3A2	0.61	5.84	0.34	1.56e-8	Autism spectrum disorder or schizophrenia;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg22053042	chr19:50119262	PRR12	0.48	6.28	0.36	1.38e-9	Fibrinogen levels;
CESC	cis	rs11098499	1.000	rs13435802	chr4:120177960	A/T	cg24375607	chr4:120327624	NA	-0.42	-5.07	-0.3	7.43e-7	Corneal astigmatism;
CESC	cis	rs4604732	0.631	rs12039596	chr1:247624766	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.57	7.17	0.4	7.39e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs736408	0.609	rs13061423	chr3:52790213	T/C	cg18404041	chr3:52824283	ITIH1	-0.43	-7.12	-0.4	9.93e-12	Bipolar disorder;
CESC	cis	rs1005277	0.579	rs1780122	chr10:38529509	C/A	cg00409905	chr10:38381863	ZNF37A	-0.51	-6.77	-0.38	8.46e-11	Extrinsic epigenetic age acceleration;
CESC	cis	rs9487051	0.676	rs7773775	chr6:109600339	T/C	cg12927641	chr6:109611667	NA	-0.36	-5.43	-0.32	1.28e-7	Reticulocyte fraction of red cells;
CESC	cis	rs28647808	0.881	rs7029386	chr9:136263736	T/C	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.84	5.73	0.33	2.7e-8	Blood protein levels;
CESC	cis	rs477692	0.544	rs7923750	chr10:131446895	G/C	cg24747557	chr10:131355152	MGMT	0.46	6.19	0.36	2.33e-9	Response to temozolomide;
CESC	cis	rs9814567	1.000	rs2056603	chr3:134312749	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.42	-5.71	-0.33	2.97e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs1707322	0.752	rs8179296	chr1:46143791	G/A	cg05343316	chr1:45956843	TESK2	0.51	6.2	0.36	2.19e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs74181299	0.819	rs2723086	chr2:65297686	C/T	cg05010058	chr2:65284262	CEP68	0.34	5.7	0.33	3.14e-8	Pulse pressure;
CESC	cis	rs7202877	0.706	rs8055609	chr16:75402088	C/T	cg04384234	chr16:75411784	CFDP1	-0.47	-5.79	-0.33	2.02e-8	Type 2 diabetes;Type 1 diabetes;
CESC	cis	rs2228479	0.867	rs35542367	chr16:89965825	G/C	cg04013166	chr16:89971882	TCF25	0.76	7.2	0.4	6.4e-12	Skin colour saturation;
CESC	cis	rs2797160	0.651	rs6939969	chr6:126034563	C/T	cg05901451	chr6:126070800	HEY2	0.5	7.45	0.42	1.3e-12	Endometrial cancer;
CESC	cis	rs60871478	0.636	rs10245785	chr7:894422	T/C	cg15782153	chr7:917662	C7orf20	0.52	5.69	0.33	3.4e-8	Cerebrospinal P-tau181p levels;
CESC	cis	rs6952808	0.798	rs28970524	chr7:1927484	C/T	cg04267008	chr7:1944627	MAD1L1	-0.72	-9.22	-0.49	9.39e-18	Bipolar disorder and schizophrenia;
CESC	cis	rs7216064	1.000	rs60432293	chr17:65860407	T/C	cg12091567	chr17:66097778	LOC651250	-0.81	-9.17	-0.49	1.36e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs454510	0.857	rs838990	chr1:120193252	A/G	cg16322792	chr1:120165303	ZNF697	0.39	6.16	0.35	2.64e-9	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
CESC	cis	rs2075371	0.501	rs1613152	chr7:134019837	A/G	cg20476274	chr7:133979776	SLC35B4	0.41	5.32	0.31	2.16e-7	Mean platelet volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10705503	chr12:102513685	C12orf48;NUP37	0.53	6.15	0.35	2.88e-9	Gut microbiome composition (summer);
CESC	cis	rs896854	0.715	rs12548874	chr8:95935164	A/C	cg16049864	chr8:95962084	TP53INP1	0.59	9.79	0.52	1.58e-19	Type 2 diabetes;
CESC	cis	rs9291683	0.620	rs7699512	chr4:10125808	C/T	cg11266682	chr4:10021025	SLC2A9	-0.48	-8.58	-0.47	8.08e-16	Bone mineral density;
CESC	cis	rs9815354	0.812	rs56332587	chr3:42012714	T/C	cg03022575	chr3:42003672	ULK4	0.68	6.13	0.35	3.21e-9	Pulse pressure;Diastolic blood pressure;
CESC	trans	rs12599106	0.707	rs2163977	chr16:34916134	A/G	cg15383120	chr6:291909	DUSP22	-0.61	-7.62	-0.42	4.6e-13	Menopause (age at onset);
CESC	cis	rs9549367	0.756	rs2302756	chr13:113900197	G/A	cg18105134	chr13:113819100	PROZ	0.66	8.0	0.44	3.96e-14	Platelet distribution width;
CESC	cis	rs72945132	0.678	rs12786421	chr11:70235314	G/C	cg14191688	chr11:70257035	CTTN	0.41	5.12	0.3	5.9e-7	Coronary artery disease;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg07589813	chr16:14726517	BFAR	0.45	6.56	0.37	2.87e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs11165623	0.792	rs12132069	chr1:96918809	A/C	cg10631902	chr5:14652156	NA	-0.57	-8.53	-0.46	1.11e-15	Hip circumference;Waist circumference;
CESC	cis	rs36051895	0.659	rs12349508	chr9:5184222	T/G	cg02405213	chr9:5042618	JAK2	-0.6	-7.02	-0.4	1.92e-11	Pediatric autoimmune diseases;
CESC	cis	rs1881797	0.932	rs41305741	chr1:247689543	A/G	cg05639522	chr1:247681581	NA	0.45	5.99	0.35	6.71e-9	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs9322193	0.923	rs12175504	chr6:149985215	T/G	cg07701084	chr6:150067640	NUP43	0.41	5.56	0.32	6.68e-8	Lung cancer;
CESC	cis	rs9611565	0.694	rs5758389	chr22:41941749	T/C	cg06481639	chr22:41940642	POLR3H	-0.47	-5.45	-0.32	1.14e-7	Vitiligo;
CESC	cis	rs7412746	0.634	rs2124952	chr1:150923774	T/A	cg22823121	chr1:150693482	HORMAD1	0.4	5.7	0.33	3.2e-8	Melanoma;
CESC	cis	rs561341	1.000	rs473356	chr17:30321762	G/C	cg19193384	chr17:30244184	NA	-0.7	-6.58	-0.37	2.49e-10	Hip circumference adjusted for BMI;
CESC	trans	rs2472476	0.900	rs2274870	chr9:107515214	G/A	cg14553338	chr2:66689807	MEIS1	0.41	6.16	0.35	2.76e-9	Obesity-related traits;
CESC	cis	rs13191362	0.935	rs66507030	chr6:162953825	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.77	7.22	0.41	5.52e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs4722166	0.598	rs4722171	chr7:22785717	A/G	cg13104385	chr7:22767384	IL6	0.48	6.36	0.36	8.7e-10	Lung cancer;
CESC	cis	rs7615952	0.576	rs66671308	chr3:125793526	T/G	cg04553112	chr3:125709451	NA	-0.54	-5.75	-0.33	2.4e-8	Blood pressure (smoking interaction);
CESC	cis	rs6879260	1.000	rs6874653	chr5:179730843	A/G	cg13944838	chr5:179740914	GFPT2	-0.7	-9.03	-0.49	3.57e-17	Height;
CESC	cis	rs2236918	0.710	rs1635510	chr1:242027500	G/T	cg17736920	chr1:242011382	EXO1	0.55	6.97	0.39	2.52e-11	Menopause (age at onset);
CESC	cis	rs4665809	0.590	rs35532350	chr2:26441605	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.1	-12.68	-0.61	4e-29	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04841405	chr16:1501118	CLCN7	-0.57	-6.5	-0.37	3.9e-10	Gut microbiome composition (summer);
CESC	cis	rs12142240	0.692	rs7529674	chr1:46818508	T/C	cg10495392	chr1:46806563	NSUN4	0.57	6.27	0.36	1.47e-9	Menopause (age at onset);
CESC	cis	rs4555082	0.915	rs28594491	chr14:105758018	G/A	cg13114125	chr14:105738426	BRF1	-0.88	-10.96	-0.56	2.66e-23	Mean platelet volume;Platelet distribution width;
CESC	cis	rs7811142	1.000	rs11761725	chr7:100039815	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.01	9.29	0.5	5.83e-18	Platelet count;
CESC	cis	rs9815354	0.812	rs17215589	chr3:41831203	C/T	cg03022575	chr3:42003672	ULK4	0.7	6.04	0.35	5.26e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs9467773	0.523	rs2498399	chr6:26706544	T/C	cg26531700	chr6:26746687	NA	-0.4	-5.87	-0.34	1.31e-8	Intelligence (multi-trait analysis);
CESC	cis	rs4665809	1.000	rs10048683	chr2:26320519	C/T	cg25036284	chr2:26402008	FAM59B	-0.59	-6.94	-0.39	3e-11	Gut microbiome composition (summer);
CESC	cis	rs8114671	0.935	rs6142313	chr20:33780427	A/G	cg06115741	chr20:33292138	TP53INP2	-0.42	-5.12	-0.3	6.02e-7	Height;
CESC	cis	rs1178968	1.000	rs4717085	chr7:72764807	C/T	cg25889504	chr7:72793014	NA	0.48	5.06	0.3	7.68e-7	Triglyceride levels;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg16632891	chr1:54872978	SSBP3	-0.48	-7.04	-0.4	1.68e-11	Gambling;
CESC	cis	rs10504229	0.639	rs16921812	chr8:58106737	C/T	cg21724239	chr8:58056113	NA	0.57	5.9	0.34	1.08e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs2797160	0.905	rs1418640	chr6:125999866	G/A	cg05901451	chr6:126070800	HEY2	-0.45	-6.67	-0.38	1.44e-10	Endometrial cancer;
CESC	cis	rs7618915	0.501	rs13060048	chr3:52598608	G/A	cg18337363	chr3:52569053	NT5DC2	0.29	5.26	0.31	3.02e-7	Bipolar disorder;
CESC	cis	rs7552404	1.000	rs4949872	chr1:76131392	C/G	cg03433033	chr1:76189801	ACADM	0.64	7.52	0.42	8.38e-13	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs9640161	0.789	rs1464753	chr7:150021350	G/C	cg10018233	chr7:150070692	REPIN1	0.43	6.83	0.39	5.68e-11	Blood protein levels;Circulating chemerin levels;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg13950250	chr8:104430401	DCAF13	0.47	6.58	0.37	2.56e-10	Thyroid stimulating hormone;
CESC	trans	rs2727020	0.724	rs4109837	chr11:49372051	A/T	cg03929089	chr4:120376271	NA	-0.67	-7.86	-0.43	9.42e-14	Coronary artery disease;
CESC	cis	rs12995491	0.902	rs6737641	chr2:88529471	A/T	cg14558114	chr2:88469736	THNSL2	-0.49	-7.1	-0.4	1.13e-11	Response to metformin (IC50);
CESC	cis	rs1878931	0.555	rs27228	chr16:3431933	C/T	cg02880119	chr16:3481970	NA	0.45	5.35	0.31	1.92e-7	Body mass index (adult);
CESC	cis	rs7959452	0.536	rs4761237	chr12:69776461	C/G	cg20891283	chr12:69753455	YEATS4	0.9	14.98	0.68	3.6e-37	Blood protein levels;
CESC	cis	rs7116495	0.588	rs547208	chr11:71779668	A/G	cg10381502	chr11:71823885	C11orf51	-0.68	-5.44	-0.32	1.2e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs5995756	0.736	rs5995755	chr22:39999013	A/G	cg03390717	chr22:39966585	CACNA1I	-0.33	-5.81	-0.34	1.8e-8	Autism spectrum disorder or schizophrenia;
CESC	cis	rs875971	0.862	rs1981799	chr7:65955559	T/C	cg18876405	chr7:65276391	NA	0.5	6.48	0.37	4.33e-10	Aortic root size;
CESC	cis	rs7666738	0.515	rs13131874	chr4:98779183	A/G	cg05340658	chr4:99064831	C4orf37	0.54	6.59	0.38	2.39e-10	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4689388	0.782	rs4262051	chr4:6281775	G/A	cg25554036	chr4:6271136	WFS1	0.56	8.86	0.48	1.18e-16	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs67311347	0.544	rs2278927	chr3:40350447	G/A	cg09455208	chr3:40491958	NA	0.35	6.3	0.36	1.24e-9	Renal cell carcinoma;
CESC	cis	rs4713675	0.565	rs4713670	chr6:33699882	C/T	cg15676125	chr6:33679581	C6orf125	-0.33	-5.03	-0.3	9.07e-7	Plateletcrit;
CESC	cis	rs863345	0.565	rs10908668	chr1:158501933	C/T	cg12129480	chr1:158549410	OR10X1	-0.34	-6.76	-0.38	8.6e-11	Pneumococcal bacteremia;
CESC	cis	rs763014	0.932	rs2269560	chr16:682442	A/C	cg07343612	chr16:622815	PIGQ	-0.54	-7.79	-0.43	1.54e-13	Height;
CESC	cis	rs11997175	0.574	rs872489	chr8:33646401	T/C	ch.8.33884649F	chr8:33765107	NA	0.65	8.33	0.46	4.44e-15	Body mass index;
CESC	cis	rs595982	0.527	rs17206707	chr19:49361441	A/C	cg15549821	chr19:49342101	PLEKHA4	-0.71	-7.95	-0.44	5.23e-14	Red cell distribution width;
CESC	cis	rs35306767	0.761	rs11253560	chr10:1047226	T/G	cg25019033	chr10:957182	NA	-0.56	-5.57	-0.32	6.34e-8	Eosinophil percentage of granulocytes;
CESC	cis	rs2204008	0.837	rs11168341	chr12:37961951	C/T	cg26384229	chr12:38710491	ALG10B	0.75	11.23	0.57	3.47e-24	Bladder cancer;
CESC	cis	rs270601	0.721	rs270621	chr5:131605821	C/A	cg04518342	chr5:131593106	PDLIM4	0.36	5.07	0.3	7.43e-7	Acylcarnitine levels;
CESC	cis	rs7666738	0.830	rs17027058	chr4:98864671	G/A	cg05340658	chr4:99064831	C4orf37	0.76	11.29	0.57	2.18e-24	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1878931	0.597	rs2680221	chr16:3462595	A/G	cg22508957	chr16:3507546	NAT15	0.4	5.2	0.3	4e-7	Body mass index (adult);
CESC	cis	rs4253772	0.530	rs6008616	chr22:46707954	A/G	cg00784671	chr22:46762841	CELSR1	-0.48	-5.59	-0.32	5.77e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs35306767	0.855	rs55697724	chr10:885622	T/C	cg20503657	chr10:835505	NA	1.09	9.95	0.52	4.95e-20	Eosinophil percentage of granulocytes;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg18585107	chr11:64138839	RPS6KA4	0.49	6.37	0.36	8.12e-10	Fibrinogen levels;
CESC	trans	rs208520	0.739	rs1935894	chr6:66891434	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.91	-11.15	-0.57	6.51e-24	Exhaled nitric oxide output;
CESC	cis	rs7523050	0.730	rs67312582	chr1:109423976	A/G	cg08274380	chr1:109419600	GPSM2	0.91	6.41	0.37	6.51e-10	Fat distribution (HIV);
CESC	cis	rs1670533	1.000	rs6852850	chr4:1052857	C/G	cg27284194	chr4:1044797	NA	0.46	5.83	0.34	1.6e-8	Recombination rate (females);
CESC	cis	rs9325144	0.555	rs1825806	chr12:38692547	G/A	cg26384229	chr12:38710491	ALG10B	0.58	8.47	0.46	1.67e-15	Morning vs. evening chronotype;
CESC	cis	rs4588572	0.537	rs7705718	chr5:77730349	T/C	cg11547950	chr5:77652471	NA	-0.39	-5.31	-0.31	2.36e-7	Triglycerides;
CESC	cis	rs9948	1.000	rs72811627	chr2:97517749	C/A	cg01990225	chr2:97406019	LMAN2L	-0.76	-5.41	-0.32	1.43e-7	Erectile dysfunction and prostate cancer treatment;
CESC	cis	rs2795502	0.938	rs3121281	chr10:43400753	A/G	cg27426351	chr10:43362370	NA	0.49	5.97	0.34	7.63e-9	Blood protein levels;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg16221875	chr6:21588597	NA	-0.45	-6.24	-0.36	1.76e-9	Gambling;
CESC	cis	rs1953600	0.645	rs2573351	chr10:81931441	A/G	cg00277334	chr10:82204260	NA	-0.57	-8.34	-0.46	4.09e-15	Sarcoidosis;
CESC	cis	rs2760061	0.819	rs1745416	chr1:228204497	G/A	cg02753203	chr1:228287806	NA	0.53	7.86	0.43	9.88e-14	Diastolic blood pressure;
CESC	cis	rs2481665	0.904	rs2457817	chr1:62604570	T/C	cg18591186	chr1:62594603	INADL	-0.52	-6.21	-0.36	2.07e-9	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs10771431	0.713	rs17794353	chr12:9361783	C/T	cg08997352	chr12:9597637	DDX12	0.72	10.21	0.53	7.38e-21	Breast size;
CESC	cis	rs10908458	0.584	rs10908455	chr1:155067283	C/T	cg27045062	chr1:155054711	EFNA3	-0.37	-5.04	-0.3	8.49e-7	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs10791323	0.569	rs2156680	chr11:133742292	T/G	cg15485101	chr11:133734466	NA	0.3	5.22	0.31	3.56e-7	Childhood ear infection;
CESC	cis	rs4819052	0.851	rs2236444	chr21:46678226	T/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.48	5.91	0.34	1.06e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs6089829	0.855	rs6062781	chr20:61667128	G/A	cg23505145	chr19:12996616	KLF1	0.52	6.8	0.39	6.85e-11	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	ch.7.1578169F	chr7:72409005	POM121	-0.58	-7.09	-0.4	1.25e-11	Gut microbiome composition (summer);
CESC	cis	rs9457247	0.967	rs86755	chr6:167403108	T/C	cg23791538	chr6:167370224	RNASET2	-0.59	-8.32	-0.46	4.54e-15	Crohn's disease;
CESC	cis	rs60843830	0.662	rs6721594	chr2:305203	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	-0.69	-9.09	-0.49	2.36e-17	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs1005277	0.579	rs2474563	chr10:38375938	T/C	cg00409905	chr10:38381863	ZNF37A	-0.45	-6.04	-0.35	5.25e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs936229	0.749	rs6495126	chr15:75175026	C/T	cg14664628	chr15:75095509	CSK	0.73	9.39	0.5	2.94e-18	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CESC	cis	rs60871478	0.786	rs55899111	chr7:827843	C/G	cg05729249	chr7:766119	PRKAR1B;HEATR2	-0.56	-5.54	-0.32	7.21e-8	Cerebrospinal P-tau181p levels;
CESC	trans	rs9467711	0.659	rs35304979	chr6:26356347	C/A	cg06606381	chr12:133084897	FBRSL1	-0.76	-6.87	-0.39	4.66e-11	Autism spectrum disorder or schizophrenia;
CESC	cis	rs11792861	0.855	rs116127510	chr9:111868344	G/A	cg05043794	chr9:111880884	C9orf5	-0.42	-6.93	-0.39	3.22e-11	Menarche (age at onset);
CESC	cis	rs35740288	0.721	rs11636347	chr15:86241233	A/G	cg20737812	chr15:86336631	KLHL25	-0.38	-5.1	-0.3	6.57e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
CESC	cis	rs7177699	0.534	rs4387568	chr15:79109514	C/G	cg04896959	chr15:78267971	NA	0.33	5.27	0.31	2.83e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
CESC	cis	rs8031584	0.781	rs4779498	chr15:31177476	C/T	cg14829155	chr15:31115871	NA	-0.65	-8.92	-0.48	7.84e-17	Huntington's disease progression;
CESC	cis	rs8014204	0.935	rs10141438	chr14:75354600	A/G	cg08847533	chr14:75593920	NEK9	-0.44	-5.4	-0.32	1.45e-7	Caffeine consumption;
CESC	cis	rs8180040	0.620	rs9875235	chr3:47083621	G/A	cg27129171	chr3:47204927	SETD2	0.66	9.82	0.52	1.32e-19	Colorectal cancer;
CESC	cis	rs9649213	0.574	rs6979373	chr7:97961844	T/C	cg00277769	chr7:97922759	BAIAP2L1	-0.34	-5.62	-0.33	4.75e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs763121	0.853	rs3788544	chr22:39064966	C/T	cg06022373	chr22:39101656	GTPBP1	0.85	12.82	0.62	1.3e-29	Menopause (age at onset);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg14240963	chr22:36925312	EIF3D	-0.5	-6.49	-0.37	4.23e-10	Fibrinogen levels;
CESC	cis	rs12618769	0.597	rs4851140	chr2:99079339	T/C	cg10123293	chr2:99228465	UNC50	0.39	5.17	0.3	4.69e-7	Bipolar disorder;
CESC	cis	rs920590	0.758	rs2898491	chr8:19661883	C/T	cg01411142	chr8:19674711	INTS10	0.52	5.86	0.34	1.39e-8	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs453301	0.686	rs13252797	chr8:8861430	A/G	cg15556689	chr8:8085844	FLJ10661	0.46	5.5	0.32	9e-8	Joint mobility (Beighton score);
CESC	cis	rs6456156	0.586	rs2001114	chr6:167486578	A/G	cg23791538	chr6:167370224	RNASET2	-0.54	-6.93	-0.39	3.1e-11	Primary biliary cholangitis;
CESC	cis	rs9911578	0.935	rs2567912	chr17:56731270	T/C	cg12560992	chr17:57184187	TRIM37	0.93	15.47	0.69	6.63e-39	Intelligence (multi-trait analysis);
CESC	cis	rs853679	0.517	rs9393891	chr6:28079160	C/T	cg20151795	chr6:28129481	ZNF389	0.45	5.87	0.34	1.29e-8	Depression;
CESC	cis	rs728616	0.614	rs61859209	chr10:82128309	G/A	cg05935833	chr10:81318306	SFTPA2	-0.45	-5.74	-0.33	2.59e-8	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs801193	1.000	rs11773829	chr7:66141074	G/A	cg11764359	chr7:65958608	NA	-0.67	-8.67	-0.47	4.51e-16	Aortic root size;
CESC	cis	rs9796	0.553	rs7171437	chr15:41315168	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.57	-7.96	-0.44	5.05e-14	Menopause (age at onset);
CESC	cis	rs28647808	1.000	rs7031883	chr9:136276519	T/C	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.9	5.73	0.33	2.75e-8	Blood protein levels;
CESC	cis	rs875971	0.825	rs7384021	chr7:66077904	A/G	cg18876405	chr7:65276391	NA	-0.53	-7.2	-0.4	6.41e-12	Aortic root size;
CESC	trans	rs5756813	0.661	rs2246503	chr22:38204540	C/A	cg19894588	chr14:64061835	NA	-0.68	-8.45	-0.46	1.98e-15	Optic cup area;Vertical cup-disc ratio;
CESC	cis	rs7666738	0.753	rs4699604	chr4:99056353	T/C	cg18180107	chr4:99064573	C4orf37	0.41	5.26	0.31	2.94e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3820068	0.603	rs72647120	chr1:15956769	G/T	cg16988262	chr1:15930761	NA	0.34	5.49	0.32	9.2e-8	Systolic blood pressure;
CESC	cis	rs875971	0.545	rs12673308	chr7:65631361	C/A	cg11764359	chr7:65958608	NA	0.79	9.51	0.5	1.18e-18	Aortic root size;
CESC	cis	rs8180040	0.620	rs6442055	chr3:47110722	A/G	cg27129171	chr3:47204927	SETD2	0.69	10.02	0.52	3.07e-20	Colorectal cancer;
CESC	trans	rs9397240	1.000	rs9397240	chr6:155648579	C/G	cg05807698	chr11:118193562	NA	-0.42	-6.17	-0.35	2.48e-9	Life satisfaction;
CESC	cis	rs12477438	0.765	rs7605218	chr2:99593080	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.62	-8.7	-0.47	3.67e-16	Chronic sinus infection;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22858966	chr12:89919202	WDR51B;GALNT4	0.67	7.98	0.44	4.53e-14	Gut microbiome composition (summer);
CESC	cis	rs9399401	0.626	rs12664563	chr6:142785201	A/G	cg03128060	chr6:142623767	GPR126	0.31	5.13	0.3	5.54e-7	Chronic obstructive pulmonary disease;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg18136715	chr10:79551995	DLG5	0.41	6.27	0.36	1.48e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs1552244	1.000	rs34179822	chr3:10140017	A/G	cg00149659	chr3:10157352	C3orf10	0.72	9.04	0.49	3.45e-17	Alzheimer's disease;
CESC	cis	rs7605827	0.866	rs9710889	chr2:15533779	G/A	cg19274914	chr2:15703543	NA	0.36	6.59	0.38	2.3e-10	Educational attainment (years of education);
CESC	cis	rs7208859	0.623	rs8081299	chr17:29104296	G/A	cg13385521	chr17:29058706	SUZ12P	0.79	6.24	0.36	1.68e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs7412746	0.611	rs4509581	chr1:150774465	A/G	cg22823121	chr1:150693482	HORMAD1	0.46	6.33	0.36	1.02e-9	Melanoma;
CESC	cis	rs9733	0.650	rs2048558	chr1:150571730	A/G	cg13175981	chr1:150552382	MCL1	0.72	10.77	0.55	1.17e-22	Tonsillectomy;
CESC	cis	rs7429990	0.965	rs2053767	chr3:47999674	A/G	cg11946769	chr3:48343235	NME6	0.44	5.37	0.31	1.76e-7	Educational attainment (years of education);
CESC	cis	rs7615952	0.932	rs6438948	chr3:125650045	A/T	cg05084668	chr3:125655381	ALG1L	0.5	5.97	0.34	7.43e-9	Blood pressure (smoking interaction);
CESC	cis	rs4713118	0.662	rs149969	chr6:27977737	A/G	cg23161317	chr6:28129485	ZNF389	0.49	6.63	0.38	1.85e-10	Parkinson's disease;
CESC	cis	rs523522	0.962	rs10849757	chr12:120964014	G/A	cg12219531	chr12:120966889	COQ5	0.75	9.99	0.52	3.7e-20	High light scatter reticulocyte count;
CESC	cis	rs11098499	0.954	rs10006525	chr4:120408931	T/G	cg09307838	chr4:120376055	NA	0.95	13.85	0.65	3.54e-33	Corneal astigmatism;
CESC	trans	rs875971	1.000	rs778696	chr7:65870813	C/G	cg26939375	chr7:64535504	NA	0.47	6.14	0.35	3.07e-9	Aortic root size;
CESC	cis	rs4237845	0.844	rs4628718	chr12:58301600	A/C	cg00677455	chr12:58241039	CTDSP2	0.62	7.69	0.43	2.86e-13	Intelligence (multi-trait analysis);
CESC	cis	rs4780401	0.609	rs4780399	chr16:11828701	A/T	cg01061890	chr16:11836724	TXNDC11	-0.56	-7.71	-0.43	2.58e-13	Rheumatoid arthritis;
CESC	cis	rs4704187	0.687	rs57646262	chr5:74527472	C/T	cg03227963	chr5:74354835	NA	0.28	5.17	0.3	4.61e-7	Response to amphetamines;
CESC	cis	rs1448094	0.533	rs2169572	chr12:86170370	G/T	cg00310523	chr12:86230176	RASSF9	-0.38	-5.81	-0.34	1.83e-8	Major depressive disorder;
CESC	cis	rs644799	0.623	rs17207890	chr11:95490754	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.8	11.01	0.56	1.82e-23	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs7666738	0.791	rs1896156	chr4:99020882	C/G	cg17366294	chr4:99064904	C4orf37	0.61	8.76	0.47	2.35e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4665809	0.652	rs7585891	chr2:26403766	G/A	cg27170947	chr2:26402098	FAM59B	-0.82	-9.61	-0.51	6.07e-19	Gut microbiome composition (summer);
CESC	cis	rs7474896	0.515	rs688608	chr10:38331624	G/A	cg25427524	chr10:38739819	LOC399744	0.52	5.4	0.31	1.49e-7	Obesity (extreme);
CESC	cis	rs12422267	0.536	rs58521339	chr12:132609486	T/C	cg09764611	chr12:132620959	NA	-0.58	-6.91	-0.39	3.7e-11	Plasma amyloid beta peptide concentrations (ABx-40);
CESC	cis	rs72781680	0.898	rs55761273	chr2:23957849	A/G	cg08917208	chr2:24149416	ATAD2B	0.96	8.67	0.47	4.28e-16	Lymphocyte counts;
CESC	cis	rs7246657	0.550	rs10411176	chr19:37686953	G/T	cg23950597	chr19:37808831	NA	-0.61	-5.07	-0.3	7.36e-7	Coronary artery calcification;
CESC	cis	rs9910055	0.530	rs11652651	chr17:42302907	A/G	cg08499158	chr17:42289980	UBTF	0.41	5.27	0.31	2.83e-7	Total body bone mineral density;
CESC	cis	rs12971120	0.783	rs7229256	chr18:72169129	T/A	cg26446133	chr18:72167187	CNDP2	-0.74	-11.03	-0.56	1.57e-23	Refractive error;
CESC	cis	rs8180040	0.966	rs11719877	chr3:47425473	C/T	cg27129171	chr3:47204927	SETD2	0.63	9.65	0.51	4.34e-19	Colorectal cancer;
CESC	cis	rs6460942	0.908	rs3887296	chr7:12257966	A/G	cg06484146	chr7:12443880	VWDE	-0.55	-5.68	-0.33	3.58e-8	Coronary artery disease;
CESC	cis	rs10504229	1.000	rs67105789	chr8:58192002	G/T	cg24829409	chr8:58192753	C8orf71	-0.76	-9.93	-0.52	5.87e-20	Developmental language disorder (linguistic errors);
CESC	trans	rs10411161	0.702	rs16983196	chr19:52384779	C/A	cg22319618	chr22:45562946	NUP50	-0.71	-7.04	-0.4	1.66e-11	Breast cancer;
CESC	cis	rs12220238	0.915	rs12217890	chr10:76024496	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.56	5.23	0.31	3.48e-7	Soluble interleukin-2 receptor subunit alpha;
CESC	cis	rs561341	1.000	rs506766	chr17:30289659	T/C	cg12193833	chr17:30244370	NA	-0.73	-6.39	-0.37	7.3e-10	Hip circumference adjusted for BMI;
CESC	cis	rs929354	0.742	rs7785227	chr7:156999297	C/T	cg05182265	chr7:156933206	UBE3C	-0.51	-7.47	-0.42	1.2e-12	Body mass index;
CESC	cis	rs9611565	0.512	rs139560	chr22:42194962	A/G	cg06481639	chr22:41940642	POLR3H	-0.58	-5.89	-0.34	1.16e-8	Vitiligo;
CESC	trans	rs648516	0.765	rs9315568	chr13:38835360	C/T	cg14728235	chr20:57415177	GNASAS;GNAS	-0.33	-6.01	-0.35	6.14e-9	Schizophrenia;
CESC	cis	rs6987853	0.787	rs2923405	chr8:42448126	T/G	cg09913449	chr8:42400586	C8orf40	0.46	7.88	0.44	8.72e-14	Mean corpuscular hemoglobin concentration;
CESC	cis	rs4253772	0.575	rs9615983	chr22:46793314	G/A	cg24881330	chr22:46731750	TRMU	0.75	5.74	0.33	2.56e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs7264396	0.563	rs2425138	chr20:34345710	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.9	-10.79	-0.55	9.97e-23	Total cholesterol levels;
CESC	cis	rs4975709	0.589	rs1684967	chr5:1863055	G/C	cg15595755	chr5:1867978	NA	0.53	8.79	0.48	1.94e-16	Cardiovascular disease risk factors;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg07332178	chr7:43798019	BLVRA	-0.42	-6.01	-0.35	6.06e-9	Gambling;
CESC	cis	rs9303401	0.659	rs34913878	chr17:56897094	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	1.01	12.68	0.61	4.11e-29	Cognitive test performance;
CESC	cis	rs1218582	0.772	rs6656435	chr1:154876869	G/A	cg03351412	chr1:154909251	PMVK	0.69	9.39	0.5	2.91e-18	Prostate cancer;
CESC	cis	rs909674	0.731	rs4821897	chr22:39835587	A/G	cg05872129	chr22:39784769	NA	-0.88	-10.85	-0.55	6.08e-23	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg13309018	chr9:130965761	CIZ1;DNM1	-0.45	-6.43	-0.37	6.05e-10	Gambling;
CESC	cis	rs910316	1.000	rs9805979	chr14:75566209	G/A	cg11812906	chr14:75593930	NEK9	0.89	15.08	0.68	1.6e-37	Height;
CESC	cis	rs2066819	1.000	rs2306693	chr12:56680531	T/C	cg26804944	chr12:56660921	COQ10A	-0.85	-5.19	-0.3	4.22e-7	Psoriasis vulgaris;
CESC	cis	rs9926296	0.607	rs2079672	chr16:89884917	A/G	cg27121462	chr16:89883253	FANCA	-0.6	-7.97	-0.44	4.76e-14	Vitiligo;
CESC	cis	rs1348850	0.632	rs13008833	chr2:178514439	G/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.6	7.68	0.43	3.1e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs6088590	1.000	rs11698977	chr20:33449691	C/T	cg06115741	chr20:33292138	TP53INP2	0.62	7.76	0.43	1.81e-13	Coronary artery disease;
CESC	cis	rs561341	0.714	rs55925849	chr17:30253085	C/T	cg12193833	chr17:30244370	NA	-0.76	-6.85	-0.39	5.14e-11	Hip circumference adjusted for BMI;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19133618	chr9:22008970	CDKN2B;CDKN2BAS	0.52	6.08	0.35	4.15e-9	Gut microbiome composition (summer);
CESC	cis	rs2404602	0.647	rs12905181	chr15:77098431	A/G	cg23625390	chr15:77176239	SCAPER	-0.47	-6.51	-0.37	3.72e-10	Blood metabolite levels;
CESC	cis	rs11098499	0.562	rs58583086	chr4:120556362	A/G	cg09307838	chr4:120376055	NA	-0.64	-8.6	-0.47	6.94e-16	Corneal astigmatism;
CESC	cis	rs7953249	0.656	rs2178463	chr12:121389721	A/G	cg02403541	chr12:121454288	C12orf43	-0.52	-6.82	-0.39	6.14e-11	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
CESC	cis	rs9325144	0.505	rs7955162	chr12:38711658	G/A	cg13010199	chr12:38710504	ALG10B	0.46	6.63	0.38	1.91e-10	Morning vs. evening chronotype;
CESC	cis	rs9926296	0.682	rs258328	chr16:89730314	C/T	cg27121462	chr16:89883253	FANCA	-0.48	-5.78	-0.33	2.13e-8	Vitiligo;
CESC	cis	rs2991971	0.967	rs10789465	chr1:45971759	T/C	cg05343316	chr1:45956843	TESK2	-0.51	-6.75	-0.38	9.56e-11	High light scatter reticulocyte count;
CESC	cis	rs1799949	1.000	rs8176220	chr17:41222462	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.67	9.17	0.49	1.32e-17	Menopause (age at onset);
CESC	cis	rs2742234	0.541	rs1254958	chr10:43702143	C/T	cg07801480	chr10:43725741	RASGEF1A	-0.41	-5.33	-0.31	2.14e-7	Hirschsprung disease;
CESC	trans	rs347313	1.000	rs347281	chr1:162313037	C/A	cg16315582	chr11:104839349	CASP4	-0.43	-6.09	-0.35	3.85e-9	Body mass index (change over time);
CESC	cis	rs1862618	0.853	rs252921	chr5:56137787	G/A	cg22800045	chr5:56110881	MAP3K1	0.81	9.96	0.52	4.58e-20	Initial pursuit acceleration;
CESC	cis	rs4665809	0.590	rs10197494	chr2:26445550	A/G	cg25036284	chr2:26402008	FAM59B	-0.86	-9.4	-0.5	2.74e-18	Gut microbiome composition (summer);
CESC	cis	rs4727027	0.933	rs10277119	chr7:148849942	T/C	cg23158103	chr7:148848205	ZNF398	-0.41	-6.56	-0.37	2.83e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs6088580	0.524	rs6088560	chr20:33228549	T/C	cg24642439	chr20:33292090	TP53INP2	-0.45	-5.26	-0.31	2.96e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs9486719	0.895	rs12190520	chr6:96928620	A/C	cg06623918	chr6:96969491	KIAA0776	-0.81	-8.3	-0.45	5.45e-15	Migraine;Coronary artery disease;
CESC	cis	rs9611565	0.592	rs1811113	chr22:42073134	C/T	cg17376030	chr22:41985996	PMM1	-0.79	-8.55	-0.47	9.65e-16	Vitiligo;
CESC	cis	rs34779708	0.966	rs12257770	chr10:35517234	A/G	cg03585969	chr10:35415529	CREM	0.67	8.37	0.46	3.26e-15	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs2839186	0.770	rs2330353	chr21:47669648	T/A	cg13126279	chr21:47581558	C21orf56	-0.49	-6.64	-0.38	1.77e-10	Testicular germ cell tumor;
CESC	cis	rs4727963	0.755	rs6943941	chr7:122705651	G/A	cg03640110	chr7:122635026	TAS2R16	-0.4	-6.26	-0.36	1.58e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
CESC	cis	rs3785574	0.962	rs4968660	chr17:61792221	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.1	19.64	0.77	1.26e-53	Height;
CESC	cis	rs1707322	0.896	rs785512	chr1:46534543	A/G	cg05343316	chr1:45956843	TESK2	-0.44	-5.26	-0.31	2.94e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs11098499	0.863	rs11098531	chr4:120465001	G/A	cg09307838	chr4:120376055	NA	0.91	12.73	0.62	2.82e-29	Corneal astigmatism;
CESC	cis	rs7474896	0.583	rs4934898	chr10:37990395	G/C	cg00409905	chr10:38381863	ZNF37A	-0.48	-5.53	-0.32	7.85e-8	Obesity (extreme);
CESC	cis	rs9325144	0.647	rs11168741	chr12:38989120	C/T	cg26384229	chr12:38710491	ALG10B	-0.52	-7.33	-0.41	2.83e-12	Morning vs. evening chronotype;
CESC	cis	rs1904096	0.506	rs13434570	chr4:95168019	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.68	-11.1	-0.56	9.37e-24	Type 2 diabetes;
CESC	cis	rs36051895	0.623	rs6476952	chr9:5236924	T/C	cg02405213	chr9:5042618	JAK2	-0.57	-7.07	-0.4	1.35e-11	Pediatric autoimmune diseases;
CESC	cis	rs938554	0.692	rs13111638	chr4:9996890	A/G	cg11266682	chr4:10021025	SLC2A9	0.47	5.81	0.34	1.76e-8	Blood metabolite levels;
CESC	cis	rs116095464	0.614	rs28736753	chr5:274081	G/A	cg10591111	chr5:226296	SDHA	-0.56	-6.71	-0.38	1.18e-10	Breast cancer;
CESC	cis	rs6088590	0.930	rs6120723	chr20:33364655	C/T	cg06115741	chr20:33292138	TP53INP2	0.59	7.27	0.41	4.05e-12	Coronary artery disease;
CESC	cis	rs9611565	0.649	rs202645	chr22:41798520	A/G	cg06634786	chr22:41940651	POLR3H	0.74	7.68	0.43	3.08e-13	Vitiligo;
CESC	cis	rs4713118	0.616	rs9348789	chr6:28025486	C/T	cg22143856	chr6:28129313	ZNF389	0.42	5.26	0.31	2.91e-7	Parkinson's disease;
CESC	cis	rs7044106	0.791	rs10985008	chr9:123492960	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.37	5.89	0.34	1.15e-8	Hip circumference adjusted for BMI;
CESC	cis	rs875971	0.964	rs6978429	chr7:65959876	T/G	cg10691866	chr7:65817282	TPST1	-0.34	-5.59	-0.32	5.57e-8	Aortic root size;
CESC	cis	rs6460942	1.000	rs6460935	chr7:12401317	A/T	cg13733410	chr7:12443478	VWDE	-0.54	-5.35	-0.31	1.9e-7	Coronary artery disease;
CESC	cis	rs6831352	0.918	rs2602893	chr4:100044095	G/T	cg13256891	chr4:100009986	ADH5	0.74	8.21	0.45	9.57e-15	Alcohol dependence;
CESC	cis	rs910316	1.000	rs12589876	chr14:75544189	G/A	cg08847533	chr14:75593920	NEK9	1.0	19.05	0.76	1.49e-51	Height;
CESC	cis	rs17039065	0.920	rs7674961	chr4:109440528	G/A	cg16022748	chr4:109541635	LOC285456;RPL34	0.67	6.4	0.37	7.14e-10	Gut microbiome composition (summer);
CESC	trans	rs208520	0.690	rs12208977	chr6:66725257	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.95	12.24	0.6	1.32e-27	Exhaled nitric oxide output;
CESC	cis	rs9309473	0.607	rs10198301	chr2:73581600	T/A	cg20560298	chr2:73613845	ALMS1	-0.46	-6.22	-0.36	1.92e-9	Metabolite levels;
CESC	cis	rs870825	0.587	rs35845099	chr4:185639762	A/G	cg04058563	chr4:185651563	MLF1IP	0.64	7.09	0.4	1.21e-11	Blood protein levels;
CESC	cis	rs7412746	0.611	rs2864873	chr1:150814174	A/G	cg17724175	chr1:150552817	MCL1	0.4	6.13	0.35	3.2e-9	Melanoma;
CESC	cis	rs875971	0.862	rs13226170	chr7:65999298	G/A	cg19163074	chr7:65112434	INTS4L2	-0.43	-5.34	-0.31	2e-7	Aortic root size;
CESC	cis	rs6915183	1.000	rs6919988	chr6:166706319	T/A	cg14022523	chr6:166756177	SFT2D1	0.57	7.5	0.42	9.76e-13	Longevity;
CESC	cis	rs7635838	0.819	rs4684781	chr3:11516299	G/A	cg00170343	chr3:11313890	ATG7	0.42	5.65	0.33	4.07e-8	HDL cholesterol;
CESC	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg27094323	chr7:1216898	NA	-0.4	-5.49	-0.32	9.19e-8	Longevity;Endometriosis;
CESC	cis	rs763014	0.865	rs4006748	chr16:632225	T/C	cg00908189	chr16:619842	PIGQ	0.67	9.34	0.5	4.24e-18	Height;
CESC	cis	rs7666738	0.830	rs3852123	chr4:98697586	A/G	cg05340658	chr4:99064831	C4orf37	0.77	11.22	0.57	3.61e-24	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7116495	1.000	rs11235440	chr11:71826644	A/G	cg10381502	chr11:71823885	C11orf51	0.66	5.6	0.33	5.26e-8	Severe influenza A (H1N1) infection;
CESC	cis	rs4822044	0.560	rs7284839	chr22:42010902	C/T	cg03806693	chr22:41940476	POLR3H	1.08	12.76	0.62	2.14e-29	Cannabis dependence symptom count;
CESC	cis	rs2985684	0.789	rs1957979	chr14:50063332	A/G	cg04989706	chr14:50066350	PPIL5	-0.46	-5.15	-0.3	5.08e-7	Carotid intima media thickness;
CESC	cis	rs9611565	0.512	rs768414	chr22:42135751	T/C	cg06481639	chr22:41940642	POLR3H	0.59	5.84	0.34	1.51e-8	Vitiligo;
CESC	cis	rs367943	0.966	rs348945	chr5:112822889	C/T	cg12552261	chr5:112820674	MCC	-0.63	-7.96	-0.44	4.96e-14	Type 2 diabetes;
CESC	cis	rs780096	0.526	rs1647276	chr2:27688601	C/T	cg22903471	chr2:27725779	GCKR	-0.52	-7.39	-0.41	1.88e-12	Total body bone mineral density;
CESC	cis	rs6964587	0.626	rs10280301	chr7:91524258	A/T	cg17063962	chr7:91808500	NA	-0.46	-6.48	-0.37	4.55e-10	Breast cancer;
CESC	cis	rs1448094	0.556	rs17279916	chr12:86170647	G/A	cg02569458	chr12:86230093	RASSF9	0.57	8.39	0.46	3e-15	Major depressive disorder;
CESC	trans	rs7246657	0.882	rs59224125	chr19:37963205	T/C	cg01833234	chr11:6592585	DNHD1	0.52	6.0	0.35	6.5e-9	Coronary artery calcification;
CESC	cis	rs6540559	0.546	rs75308488	chr1:210030639	T/C	cg25204440	chr1:209979598	IRF6	0.66	5.89	0.34	1.19e-8	Cleft lip with or without cleft palate;
CESC	cis	rs2645694	0.626	rs2645705	chr4:77830434	G/A	cg10057126	chr4:77819792	ANKRD56	0.6	8.45	0.46	1.91e-15	Emphysema distribution in smoking;
CESC	cis	rs2439831	1.000	rs2264239	chr15:43765533	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.9	10.56	0.54	5.46e-22	Lung cancer in ever smokers;
CESC	cis	rs7618915	0.524	rs10433615	chr3:52638482	C/T	cg17372223	chr3:52568218	NT5DC2	0.43	6.43	0.37	5.84e-10	Bipolar disorder;
CESC	cis	rs7923452	1.000	rs7923452	chr10:30751171	T/C	cg18806716	chr10:30721971	MAP3K8	0.51	6.08	0.35	4.28e-9	Itch intensity from mosquito bite;
CESC	cis	rs72901758	0.768	rs11650317	chr17:76251306	A/T	cg26068271	chr17:76253126	NA	0.47	6.64	0.38	1.76e-10	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
CESC	cis	rs6466055	0.720	rs1121194	chr7:104981133	T/C	cg04380332	chr7:105027541	SRPK2	0.4	5.43	0.32	1.29e-7	Schizophrenia;
CESC	cis	rs847577	0.722	rs1013886	chr7:97709861	A/G	cg24562669	chr7:97807699	LMTK2	-0.64	-10.42	-0.54	1.58e-21	Breast cancer;
CESC	cis	rs6460942	0.908	rs117451929	chr7:12265149	A/T	cg20607287	chr7:12443886	VWDE	-0.6	-6.3	-0.36	1.21e-9	Coronary artery disease;
CESC	trans	rs74054849	0.850	rs72878901	chr1:16023530	G/A	cg06826283	chr7:600452	PRKAR1B	0.69	6.14	0.35	3e-9	Alcoholic chronic pancreatitis;
CESC	cis	rs6496667	1.000	rs6496667	chr15:90893668	C/A	cg22089800	chr15:90895588	ZNF774	0.56	5.62	0.33	4.73e-8	Rheumatoid arthritis;
CESC	cis	rs703842	1.000	rs10431505	chr12:58178589	A/G	cg00599273	chr12:58146742	CDK4	0.34	5.11	0.3	6.1e-7	Multiple sclerosis;
CESC	cis	rs4629180	0.675	rs4851459	chr2:102109006	T/A	cg04415270	chr2:102091202	RFX8	-0.3	-5.28	-0.31	2.66e-7	Chronic rhinosinusitis with nasal polyps;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg23497857	chr14:24685372	MDP1	-0.43	-6.12	-0.35	3.29e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs10504229	0.679	rs72649132	chr8:58054615	G/A	cg21724239	chr8:58056113	NA	0.52	5.05	0.3	8.08e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs4713118	0.662	rs9468276	chr6:28027688	A/C	cg23281280	chr6:28129359	ZNF389	0.5	6.56	0.37	2.75e-10	Parkinson's disease;
CESC	cis	rs7193541	0.585	rs3851729	chr16:74485529	A/G	cg01733217	chr16:74700730	RFWD3	-0.84	-13.27	-0.63	3.78e-31	Multiple myeloma;
CESC	cis	rs1124376	0.935	rs12490215	chr3:20156185	A/G	cg05072819	chr3:20081367	KAT2B	0.47	5.52	0.32	7.96e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs2832191	0.647	rs11170	chr21:30378090	C/T	cg24692254	chr21:30365293	RNF160	0.97	16.48	0.71	1.71e-42	Dental caries;
CESC	cis	rs9911578	0.765	rs66954617	chr17:56999427	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.4	5.31	0.31	2.27e-7	Intelligence (multi-trait analysis);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg15216636	chr19:6739886	TRIP10	-0.51	-6.96	-0.39	2.74e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs10911251	0.528	rs10911264	chr1:183115040	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.87	13.8	0.65	5.11e-33	Colorectal cancer;
CESC	cis	rs977987	0.705	rs4888377	chr16:75325686	C/G	cg03315344	chr16:75512273	CHST6	0.39	5.26	0.31	3.01e-7	Dupuytren's disease;
CESC	cis	rs7429990	0.965	rs7430879	chr3:48038714	C/T	cg11946769	chr3:48343235	NME6	-0.44	-5.38	-0.31	1.63e-7	Educational attainment (years of education);
CESC	cis	rs2014572	0.967	rs8106734	chr19:57763546	C/T	cg24459738	chr19:57751996	ZNF805	-0.52	-7.47	-0.42	1.17e-12	Hyperactive-impulsive symptoms;
CESC	trans	rs1285495	0.627	rs10912059	chr1:187354887	C/T	cg08198330	chr19:15483731	AKAP8	0.49	6.06	0.35	4.68e-9	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
CESC	cis	rs4803468	1.000	rs6508977	chr19:41909346	A/G	cg09537434	chr19:41945824	ATP5SL	-1.04	-18.7	-0.75	2.39e-50	Height;
CESC	cis	rs4803468	1.000	rs878082	chr19:41897674	G/A	cg14132834	chr19:41945861	ATP5SL	-0.56	-6.89	-0.39	4.02e-11	Height;
CESC	cis	rs2832077	0.527	rs2250141	chr21:30241984	A/T	cg08807101	chr21:30365312	RNF160	0.52	6.32	0.36	1.08e-9	Cognitive test performance;
CESC	cis	rs875971	0.660	rs3764903	chr7:66098482	G/A	cg14393609	chr7:65229607	NA	-0.44	-5.89	-0.34	1.14e-8	Aortic root size;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg16907669	chr6:3064109	NA	-0.43	-6.11	-0.35	3.48e-9	Gambling;
CESC	cis	rs35520189	0.556	rs13026837	chr2:113705673	G/A	cg06156847	chr2:113672199	IL1F7	0.37	5.31	0.31	2.3e-7	Obstructive sleep apnea trait (apnea hypopnea index);
CESC	cis	rs3106136	0.934	rs34396188	chr4:95191292	A/C	cg11021082	chr4:95130006	SMARCAD1	-0.37	-5.28	-0.31	2.71e-7	Capecitabine sensitivity;
CESC	cis	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg11890956	chr21:40555474	PSMG1	-0.52	-6.78	-0.38	7.82e-11	Cognitive function;
CESC	cis	rs4727027	0.704	rs2269972	chr7:148914047	C/T	cg23158103	chr7:148848205	ZNF398	0.33	5.21	0.3	3.82e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs2933343	0.621	rs4927921	chr3:128568868	A/G	cg25356066	chr3:128598488	ACAD9	-0.61	-8.54	-0.46	1.06e-15	IgG glycosylation;
CESC	cis	rs478304	0.654	rs7934036	chr11:65451020	G/T	cg27068330	chr11:65405492	SIPA1	-0.4	-5.06	-0.3	7.68e-7	Acne (severe);
CESC	cis	rs2072732	0.904	rs9661525	chr1:2952840	A/C	cg03976712	chr1:2946727	NA	0.35	5.74	0.33	2.56e-8	Plateletcrit;
CESC	cis	rs4835473	0.900	rs35395070	chr4:144693436	T/C	cg25736465	chr4:144833511	NA	-0.33	-5.15	-0.3	5e-7	Immature fraction of reticulocytes;
CESC	cis	rs8072100	0.777	rs9914653	chr17:45537395	T/C	cg25173405	chr17:45401733	C17orf57	-0.43	-5.76	-0.33	2.39e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs7829975	0.840	rs555617	chr8:8592845	C/G	cg15556689	chr8:8085844	FLJ10661	-0.44	-5.49	-0.32	9.49e-8	Mood instability;
CESC	cis	rs9399137	0.507	rs11758774	chr6:135383789	T/G	cg22676075	chr6:135203613	NA	0.53	6.88	0.39	4.41e-11	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	cis	rs2108622	0.727	rs7254940	chr19:15984508	C/T	cg13772218	chr19:15982569	NA	0.3	5.96	0.34	7.91e-9	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CESC	cis	rs3126085	0.935	rs10888471	chr1:152200849	G/T	cg03465714	chr1:152285911	FLG	0.41	5.19	0.3	4.26e-7	Atopic dermatitis;
CESC	cis	rs79349575	0.783	rs62075818	chr17:46982327	T/A	cg16584676	chr17:46985605	UBE2Z	0.53	6.6	0.38	2.25e-10	Type 2 diabetes;
CESC	cis	rs2014572	0.967	rs10412975	chr19:57770554	C/A	cg12963866	chr19:57752005	ZNF805	-0.49	-6.54	-0.37	3.17e-10	Hyperactive-impulsive symptoms;
CESC	cis	rs2070488	0.965	rs9877282	chr3:38541452	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.94	-17.61	-0.73	1.79e-46	Electrocardiographic conduction measures;
CESC	cis	rs13082711	0.554	rs6804440	chr3:27398150	C/T	cg02860705	chr3:27208620	NA	0.76	8.61	0.47	6.59e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15238519	chr22:50683529	TUBGCP6	0.6	7.21	0.4	5.82e-12	Gut microbiome composition (summer);
CESC	cis	rs1799949	1.000	rs33945274	chr17:41280073	G/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.45	6.3	0.36	1.21e-9	Menopause (age at onset);
CESC	cis	rs7618501	0.540	rs11130241	chr3:50131459	A/T	cg24110177	chr3:50126178	RBM5	0.51	6.95	0.39	2.75e-11	Intelligence (multi-trait analysis);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg24368588	chr20:61903974	ARFGAP1	-0.46	-6.18	-0.35	2.42e-9	Ulcerative colitis;
CESC	cis	rs7927771	1.000	rs12421210	chr11:47779586	C/T	cg18512352	chr11:47633146	NA	-0.61	-9.63	-0.51	5.17e-19	Subjective well-being;
CESC	cis	rs1023500	0.505	rs134874	chr22:42661144	A/G	cg04733989	chr22:42467013	NAGA	0.64	9.52	0.5	1.13e-18	Schizophrenia;
CESC	cis	rs601339	1.000	rs525215	chr12:123179771	G/A	cg11919336	chr12:123188078	GPR109A	0.48	6.44	0.37	5.44e-10	Adiponectin levels;
CESC	trans	rs73568641	0.583	rs73570675	chr6:154077590	T/A	cg08374472	chr16:87445639	ZCCHC14	-0.46	-6.12	-0.35	3.26e-9	Methadone dose in opioid dependence;
CESC	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg07092213	chr7:1199455	ZFAND2A	-0.52	-6.12	-0.35	3.44e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs11039798	0.507	rs56994343	chr11:48896970	G/A	cg15704280	chr7:45808275	SEPT13	0.64	6.59	0.38	2.31e-10	Axial length;
CESC	cis	rs2073300	0.609	rs1076776	chr20:23427399	C/T	cg12062639	chr20:23401060	NAPB	-0.96	-7.71	-0.43	2.5e-13	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs10504229	0.679	rs4737454	chr8:58033965	A/T	cg22535103	chr8:58192502	C8orf71	-0.57	-6.56	-0.37	2.78e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs7598759	0.712	rs6727510	chr2:232332016	T/C	cg19187155	chr2:232395269	NMUR1	0.39	6.12	0.35	3.36e-9	Noise-induced hearing loss;
CESC	cis	rs9916302	0.851	rs12936996	chr17:37665554	A/G	cg15445000	chr17:37608096	MED1	-0.4	-6.72	-0.38	1.1e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs9487051	0.872	rs9487032	chr6:109605323	G/T	cg01475377	chr6:109611718	NA	-0.5	-8.14	-0.45	1.55e-14	Reticulocyte fraction of red cells;
CESC	cis	rs11098499	0.863	rs6853998	chr4:120475860	C/A	cg09307838	chr4:120376055	NA	0.9	12.45	0.61	2.6e-28	Corneal astigmatism;
CESC	cis	rs7772486	0.686	rs9390347	chr6:146044747	G/T	cg23711669	chr6:146136114	FBXO30	-0.87	-12.9	-0.62	7e-30	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4563143	0.663	rs5025682	chr19:29238670	A/C	cg14983838	chr19:29218262	NA	0.47	5.9	0.34	1.09e-8	Methadone dose in opioid dependence;
CESC	cis	rs7546094	1.000	rs902289	chr1:113236087	C/T	cg22162597	chr1:113214053	CAPZA1	-0.38	-5.88	-0.34	1.22e-8	Platelet distribution width;
CESC	cis	rs3126085	0.935	rs4845423	chr1:152184950	T/G	cg03465714	chr1:152285911	FLG	-0.42	-5.14	-0.3	5.24e-7	Atopic dermatitis;
CESC	cis	rs67311347	1.000	rs12108041	chr3:40487535	C/T	cg24209194	chr3:40518798	ZNF619	0.5	6.16	0.35	2.72e-9	Renal cell carcinoma;
CESC	trans	rs66573146	0.572	rs73199995	chr4:6955801	G/C	cg07817883	chr1:32538562	TMEM39B	1.25	8.67	0.47	4.31e-16	Granulocyte percentage of myeloid white cells;
CESC	cis	rs3736485	0.966	rs10220909	chr15:51762412	C/A	cg08986416	chr15:51914746	DMXL2	-0.41	-5.28	-0.31	2.69e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs9486719	1.000	rs2142653	chr6:96871520	C/A	cg06623918	chr6:96969491	KIAA0776	0.81	8.29	0.45	5.61e-15	Migraine;Coronary artery disease;
CESC	cis	rs10411936	0.682	rs8103805	chr19:16598433	T/G	cg10248733	chr19:16607483	C19orf44;CALR3	0.58	6.85	0.39	5.22e-11	White blood cell count;Multiple sclerosis;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg09717923	chr16:1440498	NA	0.43	6.29	0.36	1.29e-9	Fibrinogen levels;
CESC	cis	rs4819052	0.565	rs35776291	chr21:46706142	T/C	cg11663144	chr21:46675770	NA	-0.43	-6.43	-0.37	5.97e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs1814175	0.645	rs10742953	chr11:49807491	C/G	cg03929089	chr4:120376271	NA	0.84	12.34	0.6	5.97e-28	Height;
CESC	cis	rs35110281	0.681	rs162343	chr21:44957072	A/G	cg21573476	chr21:45109991	RRP1B	-0.42	-6.01	-0.35	6.09e-9	Mean corpuscular volume;
CESC	cis	rs10504229	0.683	rs6980540	chr8:58127022	A/G	cg21724239	chr8:58056113	NA	0.57	5.76	0.33	2.29e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs875971	0.638	rs6960778	chr7:66071597	C/T	cg14393609	chr7:65229607	NA	-0.45	-5.97	-0.34	7.78e-9	Aortic root size;
CESC	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg07677032	chr17:61819896	STRADA	0.46	6.1	0.35	3.83e-9	Prudent dietary pattern;
CESC	cis	rs2836950	0.565	rs2836930	chr21:40545656	A/G	cg11644478	chr21:40555479	PSMG1	-0.57	-7.9	-0.44	7.71e-14	Menarche (age at onset);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg13169780	chr17:7591570	TP53;WRAP53	0.44	6.28	0.36	1.42e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs13118159	0.801	rs13147602	chr4:1332175	A/G	cg05025164	chr4:1340916	KIAA1530	0.65	8.87	0.48	1.09e-16	Longevity;
CESC	cis	rs769267	0.930	rs10282	chr19:19619317	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	7.46	0.42	1.23e-12	Tonsillectomy;
CESC	cis	rs2075371	0.501	rs1646653	chr7:134024686	A/G	cg20476274	chr7:133979776	SLC35B4	0.41	5.11	0.3	6.13e-7	Mean platelet volume;
CESC	cis	rs62064224	0.702	rs2302277	chr17:30791509	C/G	cg12855166	chr17:30846586	MYO1D	0.4	5.11	0.3	6.32e-7	Schizophrenia;
CESC	cis	rs2836974	0.965	rs7354783	chr21:40652992	G/A	cg17971929	chr21:40555470	PSMG1	1.08	16.28	0.71	9.03e-42	Cognitive function;
CESC	cis	rs7772486	0.875	rs7766595	chr6:146364507	A/T	cg23711669	chr6:146136114	FBXO30	0.83	12.12	0.6	3.46e-27	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7914558	0.869	rs10883842	chr10:104941589	C/T	cg04362960	chr10:104952993	NT5C2	0.47	6.21	0.36	2.01e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs2115536	0.967	rs934137	chr15:80211768	T/C	cg00225070	chr15:80189496	MTHFS	0.54	7.36	0.41	2.36e-12	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CESC	cis	rs10911232	0.507	rs10911199	chr1:182998036	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.84	13.19	0.63	6.74e-31	Hypertriglyceridemia;
CESC	cis	rs9926296	0.605	rs12599180	chr16:89839306	C/T	cg07648498	chr16:89883185	FANCA	-0.46	-6.0	-0.35	6.29e-9	Vitiligo;
CESC	cis	rs6547741	1.000	rs2384654	chr2:27847364	C/T	cg27432699	chr2:27873401	GPN1	0.49	6.95	0.39	2.84e-11	Oral cavity cancer;
CESC	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg11494091	chr17:61959527	GH2	0.75	13.31	0.63	2.77e-31	Prudent dietary pattern;
CESC	cis	rs116095464	0.619	rs2303741	chr5:218356	T/C	cg10591111	chr5:226296	SDHA	-0.51	-6.35	-0.36	9.22e-10	Breast cancer;
CESC	cis	rs10465746	0.746	rs6699501	chr1:84389993	A/G	cg10977910	chr1:84465055	TTLL7	0.5	6.8	0.39	6.77e-11	Obesity-related traits;
CESC	cis	rs867529	0.600	rs335120	chr2:89072731	A/G	cg26627705	chr2:89060884	NA	0.36	5.12	0.3	5.76e-7	Height;
CESC	cis	rs2929278	0.617	rs694461	chr15:44096063	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.55	-7.31	-0.41	3.12e-12	Schizophrenia;
CESC	cis	rs6121246	0.559	rs6087779	chr20:30370566	T/C	cg13852791	chr20:30311386	BCL2L1	0.85	11.17	0.57	5.35e-24	Mean corpuscular hemoglobin;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00265317	chr16:70472993	ST3GAL2	0.61	7.17	0.4	7.29e-12	Gut microbiome composition (summer);
CESC	cis	rs919433	0.783	rs787979	chr2:198242868	A/T	cg20885578	chr2:198174922	NA	0.4	5.3	0.31	2.5e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs7267979	1.000	rs2482911	chr20:25395528	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.85	-16.45	-0.71	2.19e-42	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs9902453	0.935	rs9898424	chr17:28392946	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.62	-7.84	-0.43	1.11e-13	Coffee consumption (cups per day);
CESC	cis	rs12545109	0.765	rs1960727	chr8:57411368	G/A	cg09654669	chr8:57350985	NA	-0.54	-6.35	-0.36	9.45e-10	Obesity-related traits;
CESC	cis	rs1008375	0.898	rs10008445	chr4:17593978	G/T	cg02297831	chr4:17616191	MED28	0.51	6.27	0.36	1.43e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs2072732	0.861	rs2993479	chr1:2967039	A/T	cg15211996	chr1:2936768	ACTRT2	0.31	5.65	0.33	4.22e-8	Plateletcrit;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24367984	chr17:1945160	OVCA2;DPH1	0.58	6.88	0.39	4.37e-11	Gut microbiome composition (summer);
CESC	trans	rs17685	0.753	rs4732542	chr7:75663203	A/G	cg19862616	chr7:65841803	NCRNA00174	0.79	11.49	0.58	4.78e-25	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs3806843	0.735	rs702394	chr5:140086786	A/G	cg26395211	chr5:140044315	WDR55	0.48	6.2	0.36	2.2e-9	Depressive symptoms (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09089653	chr5:134734307	H2AFY	-0.57	-6.36	-0.36	8.61e-10	Gut microbiome composition (summer);
CESC	cis	rs6430585	0.528	rs6750549	chr2:136707480	A/G	cg07169764	chr2:136633963	MCM6	1.29	20.09	0.78	3.63e-55	Corneal structure;
CESC	cis	rs5743618	0.537	rs6832466	chr4:38770543	A/G	cg02016764	chr4:38805732	TLR1	-0.33	-5.16	-0.3	4.84e-7	Asthma;Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs7772486	0.875	rs2207785	chr6:146332784	T/G	cg05347473	chr6:146136440	FBXO30	0.51	6.72	0.38	1.12e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs12791968	0.659	rs12808379	chr11:45009273	C/G	cg11846598	chr11:44996168	LOC221122	-0.49	-6.04	-0.35	5.16e-9	Inhibitory control;
CESC	cis	rs873946	0.586	rs12259688	chr10:134549628	A/G	cg27286337	chr10:134555280	INPP5A	0.63	7.32	0.41	3.03e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs5167	0.504	rs3760625	chr19:45456941	G/A	cg13119609	chr19:45449297	APOC2	0.49	8.03	0.44	3.23e-14	Blood protein levels;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg14094063	chr7:140624470	BRAF	-0.45	-6.07	-0.35	4.46e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs524023	0.914	rs80841	chr11:64437490	T/C	cg19131476	chr11:64387923	NRXN2	-0.33	-5.03	-0.3	9e-7	Urate levels in obese individuals;
CESC	trans	rs208520	0.690	rs866452	chr6:66849936	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.95	-12.79	-0.62	1.72e-29	Exhaled nitric oxide output;
CESC	trans	rs6570726	0.791	rs6914203	chr6:145899975	C/A	cg03826317	chr10:25465503	LOC100128811;GPR158	0.31	6.15	0.35	2.91e-9	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg09312254	chr12:112450979	ERP29;TMEM116	-0.47	-6.49	-0.37	4.28e-10	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs11098499	0.863	rs7669520	chr4:120515278	T/C	cg24375607	chr4:120327624	NA	0.45	5.53	0.32	7.69e-8	Corneal astigmatism;
CESC	cis	rs75804782	0.557	rs10178728	chr2:239360121	T/A	cg18131467	chr2:239335373	ASB1	-0.62	-6.91	-0.39	3.61e-11	Morning vs. evening chronotype;Chronotype;
CESC	cis	rs826838	1.000	rs11183469	chr12:38752311	G/A	cg26384229	chr12:38710491	ALG10B	0.84	14.74	0.67	2.59e-36	Heart rate;
CESC	cis	rs9308433	0.529	rs1391553	chr1:214474119	T/C	cg06198575	chr1:214491504	SMYD2	0.49	5.84	0.34	1.54e-8	IgG glycosylation;
CESC	cis	rs2204008	0.555	rs7310307	chr12:38107497	G/T	cg26384229	chr12:38710491	ALG10B	0.72	10.07	0.53	2.16e-20	Bladder cancer;
CESC	cis	rs4689388	0.926	rs6446480	chr4:6295565	C/T	cg00701064	chr4:6280414	WFS1	0.66	11.07	0.56	1.2e-23	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	trans	rs4129059	0.834	rs72759620	chr1:214684150	G/A	cg08158662	chr12:34489995	NA	0.55	6.21	0.36	2e-9	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs704	0.585	rs1007398	chr17:26665648	A/G	cg10494684	chr17:26645200	TMEM97	-0.4	-5.52	-0.32	7.96e-8	Osteoprotegerin levels;
CESC	cis	rs9303401	0.659	rs7225896	chr17:56637337	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.99	11.38	0.57	1.06e-24	Cognitive test performance;
CESC	cis	rs11148252	0.532	rs9536185	chr13:53179801	G/A	cg00495681	chr13:53174319	NA	0.67	9.0	0.48	4.57e-17	Lewy body disease;
CESC	cis	rs10411936	0.692	rs10413787	chr19:16594967	A/G	cg10248733	chr19:16607483	C19orf44;CALR3	0.58	6.9	0.39	3.75e-11	White blood cell count;Multiple sclerosis;
CESC	cis	rs863345	0.604	rs60104403	chr1:158500847	G/A	cg12129480	chr1:158549410	OR10X1	-0.35	-7.0	-0.4	2.09e-11	Pneumococcal bacteremia;
CESC	trans	rs4716602	0.633	rs10249382	chr7:156159349	G/T	cg07175507	chr18:77160758	NFATC1	-0.44	-6.05	-0.35	4.95e-9	Anti-saccade response;
CESC	cis	rs801193	0.569	rs7782587	chr7:66166472	C/T	cg18876405	chr7:65276391	NA	0.45	6.15	0.35	2.78e-9	Aortic root size;
CESC	cis	rs10504229	1.000	rs59275611	chr8:58195191	G/A	cg22535103	chr8:58192502	C8orf71	-1.08	-13.04	-0.63	2.24e-30	Developmental language disorder (linguistic errors);
CESC	cis	rs2708240	0.875	rs759177	chr7:147575230	T/C	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.35	-5.77	-0.33	2.23e-8	QT interval (drug interaction);
CESC	cis	rs10794720	0.529	rs11250278	chr10:1173765	G/A	cg08668510	chr10:1095578	IDI1	0.84	5.22	0.31	3.6e-7	Glomerular filtration rate in non diabetics (creatinine);Chronic kidney disease;
CESC	cis	rs7178909	0.902	rs3784386	chr15:90437426	A/G	cg19708238	chr15:90437601	AP3S2	0.43	6.1	0.35	3.77e-9	Common traits (Other);
CESC	cis	rs2486288	0.586	rs12909883	chr15:45572054	G/C	cg21132104	chr15:45694354	SPATA5L1	-0.56	-6.7	-0.38	1.22e-10	Glomerular filtration rate;
CESC	cis	rs3768617	0.510	rs3768621	chr1:183090057	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.89	14.36	0.66	5.44e-35	Fuchs's corneal dystrophy;
CESC	cis	rs7089973	0.966	rs61867966	chr10:116584362	T/C	cg23260525	chr10:116636907	FAM160B1	0.36	5.85	0.34	1.46e-8	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs35110281	0.713	rs6518310	chr21:45098670	T/A	cg01579765	chr21:45077557	HSF2BP	-0.54	-9.37	-0.5	3.36e-18	Mean corpuscular volume;
CESC	cis	rs4665809	1.000	rs750451	chr2:26324241	G/A	cg26314531	chr2:26401878	FAM59B	-0.6	-6.8	-0.39	7.03e-11	Gut microbiome composition (summer);
CESC	cis	rs3809566	1.000	rs4774471	chr15:63332645	A/T	cg05507819	chr15:63340323	TPM1	-0.51	-6.31	-0.36	1.16e-9	Platelet count;
CESC	cis	rs12477438	0.520	rs6542869	chr2:99783403	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.87	15.4	0.69	1.21e-38	Chronic sinus infection;
CESC	cis	rs6938	0.618	rs1133323	chr15:75212225	C/T	cg17294928	chr15:75287854	SCAMP5	0.49	6.48	0.37	4.34e-10	Breast cancer;
CESC	cis	rs6987853	0.931	rs3099936	chr8:42384331	C/T	cg09913449	chr8:42400586	C8orf40	-0.39	-6.01	-0.35	6.12e-9	Mean corpuscular hemoglobin concentration;
CESC	cis	rs8180040	0.967	rs4858890	chr3:47405456	A/G	cg27129171	chr3:47204927	SETD2	-0.65	-9.83	-0.52	1.18e-19	Colorectal cancer;
CESC	cis	rs7662987	1.000	rs28730595	chr4:100003333	A/G	cg13256891	chr4:100009986	ADH5	-0.72	-5.38	-0.31	1.62e-7	Smoking initiation;
CESC	cis	rs7020830	0.830	rs308499	chr9:37348059	C/G	cg14294708	chr9:37120828	ZCCHC7	1.1	18.82	0.76	9.37e-51	Schizophrenia;
CESC	cis	rs10851478	0.872	rs12906134	chr15:49969620	G/T	cg08060515	chr15:49448048	GALK2;COPS2	0.43	5.2	0.3	3.97e-7	Oral cavity cancer;
CESC	cis	rs17001868	0.568	rs17001846	chr22:40744053	A/G	cg07138101	chr22:40742427	ADSL	0.58	5.73	0.33	2.75e-8	Mammographic density (dense area);
CESC	cis	rs6964587	0.773	rs62467797	chr7:91889722	G/A	cg17063962	chr7:91808500	NA	0.56	7.01	0.4	1.97e-11	Breast cancer;
CESC	cis	rs1395	0.778	rs62128747	chr2:27412605	T/C	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.44	5.85	0.34	1.44e-8	Blood metabolite levels;
CESC	cis	rs6938	0.514	rs56338926	chr15:75259335	C/A	cg09165964	chr15:75287851	SCAMP5	0.5	6.49	0.37	4.19e-10	Breast cancer;
CESC	cis	rs7552404	0.731	rs5745445	chr1:76344332	G/A	cg03433033	chr1:76189801	ACADM	0.6	5.87	0.34	1.27e-8	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs10097731	0.901	rs10464890	chr8:82042727	A/G	cg25230327	chr8:82042993	NA	-0.57	-6.37	-0.36	8.36e-10	Serum total protein level;
CESC	cis	rs11676348	1.000	rs11676348	chr2:219010146	C/T	cg00012203	chr2:219082015	ARPC2	-0.53	-6.86	-0.39	4.98e-11	Ulcerative colitis;
CESC	cis	rs4689388	0.926	rs4688986	chr4:6285797	C/A	cg25554036	chr4:6271136	WFS1	0.56	9.28	0.5	6.31e-18	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs13108904	0.967	rs1732107	chr4:1276758	G/A	cg00684032	chr4:1343700	KIAA1530	-0.37	-5.04	-0.3	8.62e-7	Obesity-related traits;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg06506598	chr5:79783889	FAM151B	-0.4	-6.03	-0.35	5.42e-9	Gambling;
CESC	cis	rs9457247	1.000	rs239935	chr6:167411788	G/A	cg23791538	chr6:167370224	RNASET2	-0.59	-8.47	-0.46	1.7e-15	Crohn's disease;
CESC	cis	rs12079745	0.590	rs80215043	chr1:169193763	T/C	cg09363564	chr1:169337483	NME7;BLZF1	-1.1	-6.51	-0.37	3.77e-10	QT interval;
CESC	cis	rs3096299	0.933	rs747485	chr16:89474094	T/C	cg02187348	chr16:89574699	SPG7	0.53	7.11	0.4	1.06e-11	Multiple myeloma (IgH translocation);
CESC	cis	rs12541635	0.902	rs59123253	chr8:107006365	C/T	cg10147462	chr8:107024639	NA	0.41	5.72	0.33	2.89e-8	Age of smoking initiation;
CESC	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.65	7.41	0.41	1.72e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs1976403	0.510	rs1697421	chr1:21823292	C/T	cg02390115	chr1:21767211	NBPF3	0.4	5.88	0.34	1.22e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs3733585	0.605	rs4697708	chr4:10121189	A/G	cg11266682	chr4:10021025	SLC2A9	-0.56	-10.47	-0.54	1.08e-21	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs7618915	0.524	rs35249778	chr3:52661640	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.48	7.0	0.4	2.04e-11	Bipolar disorder;
CESC	cis	rs17092148	0.636	rs66535774	chr20:33448560	T/C	cg24642439	chr20:33292090	TP53INP2	-0.51	-5.45	-0.32	1.16e-7	Neuroticism;
CESC	cis	rs1152591	0.624	rs1266927	chr14:64651663	C/A	cg23250157	chr14:64679961	SYNE2	0.44	6.54	0.37	3.15e-10	Atrial fibrillation;
CESC	cis	rs9911578	0.839	rs1871751	chr17:57190368	A/G	cg12560992	chr17:57184187	TRIM37	1.0	17.18	0.73	5.77e-45	Intelligence (multi-trait analysis);
CESC	cis	rs1878931	0.582	rs40633	chr16:3425325	A/G	cg02880119	chr16:3481970	NA	0.41	5.25	0.31	3.2e-7	Body mass index (adult);
CESC	cis	rs6456156	0.692	rs9457270	chr6:167512928	A/G	cg23791538	chr6:167370224	RNASET2	-0.52	-6.72	-0.38	1.09e-10	Primary biliary cholangitis;
CESC	cis	rs769267	0.930	rs892021	chr19:19613480	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.47	6.05	0.35	4.83e-9	Tonsillectomy;
CESC	cis	rs4665809	0.627	rs13032756	chr2:26489730	A/T	cg27170947	chr2:26402098	FAM59B	0.87	10.08	0.53	1.88e-20	Gut microbiome composition (summer);
CESC	cis	rs858239	0.509	rs6975524	chr7:23186452	T/C	cg23682824	chr7:23144976	KLHL7	0.5	6.56	0.37	2.77e-10	Cerebrospinal fluid biomarker levels;
CESC	cis	rs8067545	0.611	rs7216599	chr17:20015600	G/C	cg13482628	chr17:19912719	NA	0.4	5.31	0.31	2.28e-7	Schizophrenia;
CESC	cis	rs4835473	0.932	rs4835305	chr4:144744799	G/A	cg25736465	chr4:144833511	NA	-0.35	-5.43	-0.32	1.28e-7	Immature fraction of reticulocytes;
CESC	cis	rs6676180	0.555	rs871665	chr1:119772663	C/T	cg05756136	chr1:119680316	WARS2	-0.39	-5.16	-0.3	4.82e-7	Monobrow;
CESC	cis	rs5763662	1.000	rs5763681	chr22:30389846	A/G	cg21388335	chr22:29999516	NF2	0.86	5.11	0.3	6.18e-7	LDL cholesterol levels;LDL cholesterol;
CESC	cis	rs1816752	1.000	rs7326932	chr13:25004493	A/T	cg02811702	chr13:24901961	NA	0.37	5.37	0.31	1.73e-7	Obesity-related traits;
CESC	cis	rs7555523	0.887	rs4269750	chr1:165711510	C/T	cg24409356	chr1:165738333	TMCO1	0.97	8.67	0.47	4.48e-16	Intraocular pressure;Glaucoma (high intraocular pressure);
CESC	cis	rs2730245	1.000	rs2730241	chr7:158723014	T/C	cg24397884	chr7:158709396	WDR60	-0.85	-12.59	-0.61	8.25e-29	Height;
CESC	cis	rs11997175	0.546	rs10808337	chr8:33583850	T/C	ch.8.33884649F	chr8:33765107	NA	0.54	6.94	0.39	2.96e-11	Body mass index;
CESC	cis	rs4819052	0.851	rs875621	chr21:46682295	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.45	5.6	0.33	5.3e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg04234412	chr22:24373322	LOC391322	-0.5	-6.94	-0.39	2.98e-11	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs7923452	0.938	rs753173	chr10:30778738	T/C	cg25182066	chr10:30743637	MAP3K8	0.47	5.26	0.31	2.93e-7	Itch intensity from mosquito bite;
CESC	cis	rs941873	0.772	rs1316312	chr10:81110417	G/C	cg08514558	chr10:81106712	PPIF	0.34	5.78	0.33	2.06e-8	Height;
CESC	trans	rs634534	0.622	rs552130	chr11:65732800	T/C	cg17712092	chr4:129076599	LARP1B	0.63	8.48	0.46	1.6e-15	Sum eosinophil basophil counts;Eosinophil counts;
CESC	cis	rs1878931	0.501	rs9635563	chr16:3416940	A/G	cg22508957	chr16:3507546	NAT15	-0.38	-5.54	-0.32	7.15e-8	Body mass index (adult);
CESC	cis	rs6831352	1.000	rs1126671	chr4:100048414	T/C	cg21548116	chr4:100009993	ADH5	0.48	5.15	0.3	4.98e-7	Alcohol dependence;
CESC	trans	rs7726839	0.561	rs72703058	chr5:584519	G/A	cg25482853	chr8:67687455	SGK3	0.88	9.24	0.49	8.24e-18	Obesity-related traits;
CESC	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	13.6	0.64	2.58e-32	Prudent dietary pattern;
CESC	cis	rs644799	0.965	rs11021317	chr11:95517576	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.56	7.02	0.4	1.9e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs9937943	0.512	rs13335886	chr16:74577161	C/G	cg01733217	chr16:74700730	RFWD3	-0.63	-6.72	-0.38	1.09e-10	Neutrophil percentage of white cells;
CESC	cis	rs3125734	0.633	rs1368157	chr10:64001114	T/C	cg09941381	chr10:64027924	RTKN2	-0.32	-5.27	-0.31	2.89e-7	Rheumatoid arthritis;
CESC	cis	rs68170813	0.521	rs75035695	chr7:106818731	T/C	cg02696742	chr7:106810147	HBP1	-0.53	-5.07	-0.3	7.37e-7	Coronary artery disease;
CESC	cis	rs826838	0.559	rs4882276	chr12:38611994	T/C	cg26384229	chr12:38710491	ALG10B	0.46	6.56	0.37	2.76e-10	Heart rate;
CESC	cis	rs910316	0.967	rs12147532	chr14:75651858	T/G	cg16144293	chr14:75469539	EIF2B2	0.4	5.12	0.3	5.93e-7	Height;
CESC	cis	rs7617480	0.617	rs7610519	chr3:48746427	C/G	cg07636037	chr3:49044803	WDR6	0.78	9.79	0.52	1.5700000000000001e-19	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CESC	cis	rs6424115	0.729	rs1737362	chr1:24054800	T/C	cg10978503	chr1:24200527	CNR2	0.27	5.35	0.31	1.88e-7	Immature fraction of reticulocytes;
CESC	cis	rs72945132	0.882	rs12099016	chr11:70195161	C/G	cg00319359	chr11:70116639	PPFIA1	0.72	6.84	0.39	5.42e-11	Coronary artery disease;
CESC	cis	rs7666738	0.830	rs2865981	chr4:99031493	G/A	cg24818145	chr4:99064322	C4orf37	0.39	5.06	0.3	7.81e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs12477438	0.501	rs12995473	chr2:99764884	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.87	15.48	0.69	6.26e-39	Chronic sinus infection;
CESC	cis	rs651907	0.557	rs2303474	chr3:101371899	G/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.47	5.98	0.34	7.09e-9	Colorectal cancer;
CESC	cis	rs79057730	0.599	rs35928068	chr7:805363	G/C	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.91	7.9	0.44	7.25e-14	Initial pursuit acceleration;
CESC	cis	rs3008870	0.755	rs2065002	chr1:67487119	A/C	cg08660285	chr1:67390436	MIER1;WDR78	-0.62	-8.07	-0.44	2.42e-14	Lymphocyte percentage of white cells;
CESC	cis	rs4972806	0.849	rs2071581	chr2:177026148	G/T	cg14324370	chr2:177042789	NA	0.42	5.93	0.34	9.51e-9	IgG glycosylation;
CESC	cis	rs7666738	0.962	rs2865950	chr4:99040061	T/C	cg17366294	chr4:99064904	C4orf37	0.54	7.14	0.4	8.72e-12	Colonoscopy-negative controls vs population controls;
CESC	cis	rs13191362	1.000	rs34655790	chr6:163202739	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.97	9.71	0.51	2.96e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs7714584	1.000	rs80075680	chr5:150223737	C/T	cg22134413	chr5:150180641	NA	0.52	5.64	0.33	4.31e-8	Crohn's disease;
CESC	cis	rs10883723	0.737	rs7074444	chr10:104249922	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.54	7.44	0.42	1.43e-12	Allergic disease (asthma, hay fever or eczema);
CESC	trans	rs4843747	0.671	rs4075599	chr16:88107423	C/G	cg26811252	chr16:29126840	RRN3P2	0.58	7.89	0.44	7.74e-14	Menopause (age at onset);
CESC	cis	rs926938	0.560	rs360610	chr1:115393915	T/C	cg12756093	chr1:115239321	AMPD1	0.46	6.21	0.36	2.03e-9	Autism;
CESC	cis	rs6570726	0.791	rs418701	chr6:145889992	C/T	cg23711669	chr6:146136114	FBXO30	0.97	14.77	0.67	2.05e-36	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs12497850	0.931	rs6446196	chr3:49004723	A/G	cg03060546	chr3:49711283	APEH	0.5	6.05	0.35	4.94e-9	Parkinson's disease;
CESC	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.51	-5.84	-0.34	1.48e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7131987	0.903	rs6487796	chr12:29422764	A/G	cg09582351	chr12:29534625	ERGIC2	-0.36	-5.67	-0.33	3.8e-8	QT interval;
CESC	trans	rs1728785	0.901	rs2862781	chr16:68639234	A/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	7.69	0.43	2.91e-13	Ulcerative colitis;
CESC	cis	rs7191439	0.626	rs8059794	chr16:88787388	C/T	cg27087555	chr16:88793112	FAM38A	-1.28	-11.66	-0.58	1.26e-25	Plateletcrit;
CESC	cis	rs3862030	0.500	rs11191327	chr10:104303883	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.54	7.49	0.42	1e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
CESC	cis	rs155076	1.000	rs567166	chr13:21837519	T/C	cg11317459	chr13:21872234	NA	-1.01	-10.78	-0.55	1.07e-22	White matter hyperintensity burden;
CESC	cis	rs2637266	0.630	rs2588330	chr10:78555185	A/C	cg18941641	chr10:78392320	NA	0.4	7.57	0.42	6.04e-13	Pulmonary function;
CESC	cis	rs9322193	0.923	rs9800686	chr6:149955600	A/C	cg07701084	chr6:150067640	NUP43	0.41	5.57	0.32	6.38e-8	Lung cancer;
CESC	cis	rs12541635	0.677	rs7819501	chr8:107006962	C/T	cg10147462	chr8:107024639	NA	-0.42	-6.25	-0.36	1.61e-9	Age of smoking initiation;
CESC	trans	rs9951602	0.512	rs12458828	chr18:76648522	C/T	cg02800362	chr5:177631904	HNRNPAB	-0.65	-8.44	-0.46	2.15e-15	Obesity-related traits;
CESC	cis	rs6597981	0.675	rs4963120	chr11:825777	A/G	cg01741372	chr11:783889	NA	-0.46	-6.58	-0.37	2.44e-10	Breast cancer;
CESC	trans	rs941207	0.542	rs4277148	chr12:57180855	C/T	cg26462586	chr2:11164677	NA	0.38	6.02	0.35	5.82e-9	Platelet count;
CESC	trans	rs7615952	0.611	rs9681518	chr3:125615130	A/G	cg07211511	chr3:129823064	LOC729375	-0.89	-8.26	-0.45	7.12e-15	Blood pressure (smoking interaction);
CESC	cis	rs7811142	0.830	rs118119933	chr7:99939050	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.01	9.27	0.49	6.73e-18	Platelet count;
CESC	cis	rs9300255	0.620	rs1716173	chr12:123660721	A/T	cg00376283	chr12:123451042	ABCB9	0.71	8.71	0.47	3.27e-16	Neutrophil percentage of white cells;
CESC	trans	rs5756813	0.833	rs5756819	chr22:38188195	A/C	cg19894588	chr14:64061835	NA	0.66	8.84	0.48	1.34e-16	Optic cup area;Vertical cup-disc ratio;
CESC	cis	rs10484885	0.824	rs72919954	chr6:90515665	T/A	cg13799429	chr6:90582589	CASP8AP2	-0.76	-7.13	-0.4	9.38e-12	QRS interval (sulfonylurea treatment interaction);
CESC	cis	rs4253772	0.575	rs74879643	chr22:46660014	T/C	cg00784671	chr22:46762841	CELSR1	-0.54	-5.43	-0.32	1.29e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs11122272	0.735	rs2486727	chr1:231539245	A/G	cg06096015	chr1:231504339	EGLN1	0.41	5.89	0.34	1.15e-8	Hemoglobin concentration;
CESC	cis	rs7267979	0.966	rs2482923	chr20:25308981	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.85	-16.02	-0.7	7.43e-41	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs6502050	0.835	rs62078305	chr17:80085326	G/A	cg23985595	chr17:80112537	CCDC57	0.42	6.63	0.38	1.9e-10	Life satisfaction;
CESC	cis	rs734999	0.588	rs4648653	chr1:2535895	C/T	cg20673091	chr1:2541236	MMEL1	0.42	6.92	0.39	3.35e-11	Ulcerative colitis;
CESC	cis	rs2742417	0.603	rs2064064	chr3:45759995	C/T	cg04837898	chr3:45731254	SACM1L	-0.47	-6.21	-0.36	2.08e-9	Response to anti-depressant treatment in major depressive disorder;
CESC	cis	rs977987	0.898	rs12918797	chr16:75493810	T/C	cg03315344	chr16:75512273	CHST6	0.54	7.9	0.44	7.62e-14	Dupuytren's disease;
CESC	cis	rs6500395	1.000	rs9924078	chr16:48557918	A/C	cg04672837	chr16:48644449	N4BP1	-0.45	-5.14	-0.3	5.39e-7	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs360071	0.528	rs360094	chr1:226064846	C/T	cg17950169	chr1:226067900	TMEM63A	-0.4	-6.17	-0.35	2.6e-9	Response to radiotherapy in prostate cancer (toxicity, rectal bleeding);
CESC	cis	rs7044106	0.500	rs56725168	chr9:123492576	T/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.87	14.04	0.65	7.75e-34	Hip circumference adjusted for BMI;
CESC	cis	rs769267	0.930	rs2301786	chr19:19413947	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.42	5.4	0.31	1.49e-7	Tonsillectomy;
CESC	cis	rs7149337	0.752	rs8021773	chr14:51691528	C/T	cg23942311	chr14:51606299	NA	0.52	8.97	0.48	5.58e-17	Cancer;
CESC	cis	rs977987	0.527	rs62059844	chr16:75429737	T/C	cg03315344	chr16:75512273	CHST6	0.4	5.71	0.33	3e-8	Dupuytren's disease;
CESC	cis	rs72945132	0.882	rs2276001	chr11:70181560	T/C	cg00319359	chr11:70116639	PPFIA1	0.74	7.15	0.4	8.42e-12	Coronary artery disease;
CESC	cis	rs9910055	0.636	rs7089	chr17:42269017	T/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.64	8.4	0.46	2.68e-15	Total body bone mineral density;
CESC	cis	rs1008375	0.931	rs6449309	chr4:17573208	C/T	cg16339924	chr4:17578868	LAP3	0.83	10.42	0.54	1.55e-21	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs9322193	0.923	rs4455682	chr6:150021297	C/T	cg04369109	chr6:150039330	LATS1	-0.38	-5.31	-0.31	2.28e-7	Lung cancer;
CESC	cis	rs10788264	0.518	rs1028632	chr10:124044657	C/G	cg09507567	chr10:124027408	NA	0.44	6.36	0.36	8.56e-10	Total body bone mineral density;
CESC	cis	rs9815354	1.000	rs9864217	chr3:41762206	G/A	cg03022575	chr3:42003672	ULK4	0.51	5.1	0.3	6.62e-7	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs561341	0.660	rs7406043	chr17:30220152	C/G	cg00745463	chr17:30367425	LRRC37B	-0.62	-6.24	-0.36	1.68e-9	Hip circumference adjusted for BMI;
CESC	cis	rs12893668	0.572	rs4900590	chr14:104146421	C/T	cg08213375	chr14:104286397	PPP1R13B	0.33	5.48	0.32	9.74e-8	Reticulocyte count;
CESC	cis	rs4409675	0.576	rs12070659	chr1:28227175	G/A	cg23691781	chr1:28212827	C1orf38	0.28	5.62	0.33	4.73e-8	Corneal astigmatism;
CESC	cis	rs1152591	0.729	rs1255988	chr14:64657684	C/A	cg23250157	chr14:64679961	SYNE2	0.53	7.64	0.43	3.86e-13	Atrial fibrillation;
CESC	cis	rs6502050	0.835	rs28481866	chr17:80105160	G/A	cg23985595	chr17:80112537	CCDC57	-0.42	-6.57	-0.37	2.72e-10	Life satisfaction;
CESC	cis	rs7917772	0.503	rs7068535	chr10:104349127	C/T	ch.10.2196322F	chr10:104248062	ACTR1A	0.42	5.16	0.3	4.94e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs123509	0.874	rs339683	chr3:42788511	G/T	cg12982090	chr3:42733453	KBTBD5	0.72	8.68	0.47	4.13e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs7412746	0.646	rs1972060	chr1:150937594	T/C	cg04414720	chr1:150670196	GOLPH3L	0.44	5.82	0.34	1.72e-8	Melanoma;
CESC	trans	rs2693676	0.504	rs944120	chr14:99603389	A/T	cg17465227	chr4:47427752	GABRB1	0.61	6.49	0.37	4.17e-10	Corneal curvature;
CESC	cis	rs2204008	0.748	rs8186658	chr12:38301461	A/C	cg13010199	chr12:38710504	ALG10B	0.4	5.14	0.3	5.25e-7	Bladder cancer;
CESC	cis	rs778371	1.000	rs778370	chr2:233743363	C/T	cg08000102	chr2:233561755	GIGYF2	-0.82	-13.18	-0.63	7.3e-31	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03899909	chr5:179159660	MAML1	0.58	6.66	0.38	1.54e-10	Gut microbiome composition (summer);
CESC	cis	rs7089973	0.932	rs17794346	chr10:116643095	C/T	cg23260525	chr10:116636907	FAM160B1	-0.34	-5.41	-0.32	1.42e-7	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs597539	0.652	rs557625	chr11:68634722	G/A	cg01988459	chr11:68622903	NA	-0.39	-5.21	-0.3	3.76e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs7666738	0.830	rs2167892	chr4:99048503	G/C	cg03467027	chr4:99064603	C4orf37	0.47	5.98	0.34	7.19e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4332037	0.539	rs4719416	chr7:2106608	G/A	cg23422044	chr7:1970798	MAD1L1	-0.45	-5.35	-0.31	1.89e-7	Bipolar disorder;
CESC	cis	rs853679	0.517	rs868987	chr6:28110148	A/G	cg19592336	chr6:28129416	ZNF389	-0.62	-8.32	-0.46	4.66e-15	Depression;
CESC	cis	rs9902453	0.845	rs3102556	chr17:28042542	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	8.53	0.46	1.15e-15	Coffee consumption (cups per day);
CESC	cis	rs1865721	0.771	rs7231277	chr18:73136724	A/G	cg26385618	chr18:73139727	C18orf62	-0.51	-8.36	-0.46	3.47e-15	Intelligence;
CESC	cis	rs796364	0.813	rs4672686	chr2:201065044	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.58	5.59	0.32	5.73e-8	Schizophrenia;
CESC	trans	rs1116547	0.602	rs6896501	chr5:112906601	C/T	cg10115368	chr14:100435663	NA	0.51	6.04	0.35	5.06e-9	Cerebral amyloid angiopathy;
CESC	cis	rs9811920	0.609	rs4244711	chr3:99657205	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.64	-10.16	-0.53	1.09e-20	Axial length;
CESC	cis	rs6951245	0.507	rs11976805	chr7:1138716	C/T	cg23978390	chr7:1156363	C7orf50	0.48	5.73	0.33	2.66e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs798554	0.757	rs1182181	chr7:2873247	C/G	cg04166393	chr7:2884313	GNA12	0.59	7.77	0.43	1.79e-13	Height;
CESC	cis	rs2012796	1.000	rs7153469	chr14:81820979	T/G	cg02996355	chr14:81879375	NA	0.57	6.82	0.39	6.15e-11	Night sleep phenotypes;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg12767885	chr10:134350658	INPP5A	-0.45	-6.06	-0.35	4.75e-9	Fibrinogen levels;
CESC	cis	rs6088590	1.000	rs6120705	chr20:33313740	T/C	cg24642439	chr20:33292090	TP53INP2	0.84	11.78	0.59	4.81e-26	Coronary artery disease;
CESC	cis	rs4253772	0.591	rs6519994	chr22:46656805	A/G	cg00784671	chr22:46762841	CELSR1	0.39	5.24	0.31	3.33e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs6088580	0.634	rs6059878	chr20:33087166	A/T	cg06115741	chr20:33292138	TP53INP2	0.45	5.8	0.34	1.88e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs1552244	0.816	rs13059144	chr3:10010197	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.86	11.17	0.57	5.32e-24	Alzheimer's disease;
CESC	cis	rs10751667	1.000	rs10902246	chr11:953674	T/C	cg06064525	chr11:970664	AP2A2	-0.39	-7.01	-0.4	1.96e-11	Alzheimer's disease (late onset);
CESC	cis	rs6540559	0.546	rs75308488	chr1:210030639	T/C	cg23283495	chr1:209979779	IRF6	0.49	5.07	0.3	7.43e-7	Cleft lip with or without cleft palate;
CESC	cis	rs17826219	0.706	rs55764512	chr17:29085758	G/A	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.91e-10	Body mass index;
CESC	cis	rs1371867	0.846	rs2047249	chr8:101234126	A/G	cg11906718	chr8:101322791	RNF19A	-0.56	-6.8	-0.39	7.02e-11	Atrioventricular conduction;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg13984512	chr1:145438431	TXNIP	-0.4	-6.38	-0.36	8.03e-10	Gambling;
CESC	cis	rs2637266	0.729	rs846618	chr10:78545455	G/A	cg18941641	chr10:78392320	NA	0.41	7.6	0.42	5.05e-13	Pulmonary function;
CESC	cis	rs2531992	1.000	rs710893	chr16:4014964	A/G	cg05927578	chr16:4029543	ADCY9	0.44	5.55	0.32	6.83e-8	Waist circumference;
CESC	cis	rs11864453	0.679	rs2303285	chr16:72124495	A/C	cg16558253	chr16:72132732	DHX38	-0.55	-8.54	-0.46	1.08e-15	Fibrinogen levels;
CESC	cis	rs9911578	0.967	rs11656413	chr17:57082013	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	-0.39	-5.24	-0.31	3.21e-7	Intelligence (multi-trait analysis);
CESC	cis	rs826838	0.967	rs2069211	chr12:39128892	C/T	cg26384229	chr12:38710491	ALG10B	-0.67	-11.01	-0.56	1.82e-23	Heart rate;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg17224732	chr1:78148372	ZZZ3	-0.41	-6.14	-0.35	3.02e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	trans	rs61931739	0.534	rs10844801	chr12:34230940	A/T	cg26384229	chr12:38710491	ALG10B	0.64	9.4	0.5	2.7e-18	Morning vs. evening chronotype;
CESC	cis	rs12497850	0.931	rs9840684	chr3:48893780	T/C	cg07636037	chr3:49044803	WDR6	1.03	18.76	0.76	1.49e-50	Parkinson's disease;
CESC	cis	rs2274273	1.000	rs7160110	chr14:55594635	A/G	cg04306507	chr14:55594613	LGALS3	0.3	5.87	0.34	1.29e-8	Protein biomarker;
CESC	trans	rs3780486	0.846	rs7873903	chr9:33142728	G/A	cg20290983	chr6:43655470	MRPS18A	0.97	17.15	0.73	7.49e-45	IgG glycosylation;
CESC	cis	rs6685188	0.920	rs10751444	chr1:205662144	A/G	cg14159672	chr1:205819179	PM20D1	-0.41	-5.52	-0.32	7.93e-8	White blood cell count (basophil);Basophil percentage of white cells;
CESC	cis	rs13382862	0.862	rs340595	chr2:20889714	A/G	cg10553204	chr2:20871195	GDF7	-0.37	-5.18	-0.3	4.4e-7	Abdominal aortic aneurysm;
CESC	cis	rs2108622	0.711	rs113343664	chr19:15978993	G/C	cg13772218	chr19:15982569	NA	0.29	5.69	0.33	3.28e-8	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CESC	cis	rs1483890	0.723	rs12629224	chr3:69411188	T/C	cg22125112	chr3:69402811	FRMD4B	0.39	5.17	0.3	4.67e-7	Resting heart rate;
CESC	cis	rs763121	0.853	rs1065201	chr22:39069510	T/C	cg06022373	chr22:39101656	GTPBP1	0.89	14.42	0.66	3.47e-35	Menopause (age at onset);
CESC	cis	rs208520	0.874	rs208481	chr6:66922636	A/G	cg07460842	chr6:66804631	NA	-0.86	-10.49	-0.54	9.23e-22	Exhaled nitric oxide output;
CESC	cis	rs11711311	1.000	rs2242108	chr3:113433903	T/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.71	10.31	0.54	3.46e-21	IgG glycosylation;
CESC	cis	rs17376456	0.569	rs7713956	chr5:93133185	T/C	cg21475434	chr5:93447410	FAM172A	-0.5	-5.11	-0.3	6.26e-7	Diabetic retinopathy;
CESC	cis	rs7666738	0.830	rs1534318	chr4:98965058	C/T	cg03467027	chr4:99064603	C4orf37	0.44	5.46	0.32	1.1e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4665809	1.000	rs6546728	chr2:26276531	G/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.83	-9.25	-0.49	7.55e-18	Gut microbiome composition (summer);
CESC	cis	rs875971	1.000	rs937495	chr7:65779798	A/G	cg12463550	chr7:65579703	CRCP	-0.53	-6.84	-0.39	5.56e-11	Aortic root size;
CESC	cis	rs2797160	1.000	rs6933471	chr6:126017029	T/G	cg05901451	chr6:126070800	HEY2	0.46	6.63	0.38	1.86e-10	Endometrial cancer;
CESC	cis	rs4834770	1.000	rs4336213	chr4:120236469	G/T	cg09307838	chr4:120376055	NA	0.46	5.81	0.34	1.76e-8	Blood protein levels;
CESC	cis	rs4253772	0.745	rs9626823	chr22:46645148	G/A	cg00784671	chr22:46762841	CELSR1	-0.52	-5.42	-0.32	1.35e-7	LDL cholesterol;Cholesterol, total;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07499546	chr1:40839445	SMAP2	0.58	6.49	0.37	4.19e-10	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09326880	chr3:43147587	C3orf39	0.55	6.78	0.38	7.9e-11	Gut microbiome composition (summer);
CESC	cis	rs832540	0.656	rs6893754	chr5:56100006	G/A	cg24531977	chr5:56204891	C5orf35	-0.48	-6.01	-0.35	6.1e-9	Coronary artery disease;
CESC	cis	rs6714710	0.603	rs34502870	chr2:98405929	A/G	cg26665480	chr2:98280029	ACTR1B	0.57	8.03	0.44	3.3e-14	Posterior cortical atrophy and Alzheimer's disease;
CESC	cis	rs9297145	1.000	rs10953280	chr7:98763405	A/G	cg05967295	chr7:98741636	SMURF1	-0.99	-13.09	-0.63	1.6e-30	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
CESC	cis	rs7605827	0.930	rs1997304	chr2:15512073	G/T	cg19274914	chr2:15703543	NA	0.32	5.58	0.32	5.95e-8	Educational attainment (years of education);
CESC	cis	rs5769765	0.954	rs6009900	chr22:50236610	T/C	cg26441486	chr22:50317300	CRELD2	0.4	5.41	0.32	1.43e-7	Schizophrenia;
CESC	cis	rs7605827	0.930	rs1986279	chr2:15617390	G/A	cg19274914	chr2:15703543	NA	0.35	6.13	0.35	3.19e-9	Educational attainment (years of education);
CESC	cis	rs2066819	1.000	rs116535779	chr12:56739261	A/G	cg26316697	chr12:56727976	PAN2	0.72	6.9	0.39	3.81e-11	Psoriasis vulgaris;
CESC	cis	rs6964587	0.626	rs4729014	chr7:91550707	A/G	cg17063962	chr7:91808500	NA	-0.45	-6.29	-0.36	1.29e-9	Breast cancer;
CESC	cis	rs60154123	0.772	rs628908	chr1:210428002	C/T	cg21951975	chr1:209979733	IRF6	0.44	5.69	0.33	3.3e-8	Coronary artery disease;
CESC	cis	rs7666738	0.830	rs62321597	chr4:99014221	C/A	cg03676636	chr4:99064102	C4orf37	0.33	5.16	0.3	4.86e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11264213	0.901	rs72661631	chr1:36417453	A/G	cg27506609	chr1:36549197	TEKT2	0.67	5.54	0.32	7.16e-8	Schizophrenia;
CESC	cis	rs34375054	0.525	rs7133006	chr12:125606123	G/A	cg25124228	chr12:125621409	AACS	-0.54	-6.78	-0.38	7.85e-11	Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs6032067	0.777	rs34855539	chr20:43799036	T/G	cg11264863	chr20:43835661	SEMG1	0.5	5.39	0.31	1.55e-7	Blood protein levels;
CESC	cis	rs763121	0.776	rs4820346	chr22:39125074	C/G	cg06544989	chr22:39130855	UNC84B	-0.46	-7.76	-0.43	1.88e-13	Menopause (age at onset);
CESC	cis	rs8050907	0.590	rs2270364	chr16:4526750	G/A	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.9	5.72	0.33	2.93e-8	Obesity-related traits;
CESC	cis	rs7618915	0.547	rs4687636	chr3:52633929	G/A	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.56	0.37	2.79e-10	Bipolar disorder;
CESC	cis	rs2836950	0.501	rs2056844	chr21:40670460	G/C	cg11644478	chr21:40555479	PSMG1	-0.52	-6.92	-0.39	3.34e-11	Menarche (age at onset);
CESC	trans	rs916888	0.821	rs199525	chr17:44847834	T/G	cg10053473	chr17:62856997	LRRC37A3	-0.7	-7.4	-0.41	1.78e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs2625529	0.652	rs2957736	chr15:72265344	A/G	cg16672083	chr15:72433130	SENP8	0.46	6.78	0.38	7.68e-11	Red blood cell count;
CESC	cis	rs826838	0.967	rs7963716	chr12:38876090	C/T	cg26384229	chr12:38710491	ALG10B	0.82	13.81	0.65	4.71e-33	Heart rate;
CESC	cis	rs1008375	0.898	rs2079892	chr4:17577163	G/A	cg16339924	chr4:17578868	LAP3	0.74	9.68	0.51	3.59e-19	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs1790761	0.520	rs4930461	chr11:67394895	A/G	cg00290607	chr11:67383545	NA	0.39	5.56	0.32	6.72e-8	Mean corpuscular volume;
CESC	cis	rs4555082	0.874	rs2816606	chr14:105716034	C/T	cg27165867	chr14:105738592	BRF1	-0.48	-5.23	-0.31	3.48e-7	Mean platelet volume;Platelet distribution width;
CESC	cis	rs34779708	0.931	rs9663401	chr10:35278849	G/T	cg03585969	chr10:35415529	CREM	0.77	10.16	0.53	1.05e-20	Inflammatory bowel disease;Crohn's disease;
CESC	trans	rs6828577	0.862	rs298994	chr4:119627253	A/G	cg05098011	chr1:151736092	OAZ3;MRPL9	0.48	6.13	0.35	3.21e-9	Perioperative myocardial infarction in coronary artery bypass surgery;
CESC	cis	rs193541	0.564	rs407230	chr5:122345727	G/A	cg19412675	chr5:122181750	SNX24	-0.45	-5.29	-0.31	2.57e-7	Glucose homeostasis traits;
CESC	cis	rs7680126	0.596	rs35782983	chr4:10117728	G/A	cg11266682	chr4:10021025	SLC2A9	-0.48	-6.34	-0.36	9.71e-10	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	cis	rs911555	0.723	rs6575986	chr14:103886671	G/A	cg09975044	chr14:104007538	NA	0.45	5.62	0.33	4.78e-8	Intelligence (multi-trait analysis);
CESC	cis	rs533581	0.866	rs502258	chr16:88968547	G/A	cg16701003	chr16:89028210	CBFA2T3	0.47	6.43	0.37	5.96e-10	Social autistic-like traits;
CESC	cis	rs6032067	0.641	rs74174934	chr20:43761331	T/G	cg10761708	chr20:43804764	PI3	0.47	5.08	0.3	7.16e-7	Blood protein levels;
CESC	trans	rs11098499	1.000	rs1011054	chr4:120202387	A/G	cg25214090	chr10:38739885	LOC399744	-0.63	-8.4	-0.46	2.66e-15	Corneal astigmatism;
CESC	cis	rs12477438	0.798	rs6732579	chr2:99560239	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.73	-10.16	-0.53	1.04e-20	Chronic sinus infection;
CESC	cis	rs7618915	0.547	rs6976	chr3:52728804	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.48	6.88	0.39	4.22e-11	Bipolar disorder;
CESC	cis	rs4819052	0.851	rs28616694	chr21:46674786	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.95	14.0	0.65	1.01e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs35110281	0.714	rs7277539	chr21:45053011	A/G	cg21573476	chr21:45109991	RRP1B	-0.49	-6.87	-0.39	4.55e-11	Mean corpuscular volume;
CESC	cis	rs7267979	0.714	rs6132825	chr20:25238309	A/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.69	10.58	0.54	4.75e-22	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs9309473	0.500	rs11688718	chr2:73760939	C/T	cg20560298	chr2:73613845	ALMS1	-0.51	-7.31	-0.41	3.07e-12	Metabolite levels;
CESC	cis	rs2120019	1.000	rs7173833	chr15:75369618	C/T	cg17294928	chr15:75287854	SCAMP5	-0.51	-5.69	-0.33	3.43e-8	Blood trace element (Zn levels);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg03965764	chr11:45248109	NA	0.46	6.46	0.37	4.86e-10	Fibrinogen levels;
CESC	cis	rs10504229	0.683	rs16921829	chr8:58110950	A/G	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs6540559	0.673	rs7550857	chr1:209956542	C/A	cg10074409	chr1:209979377	IRF6	0.39	5.19	0.3	4.24e-7	Cleft lip with or without cleft palate;
CESC	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg18402987	chr7:1209562	NA	0.76	7.61	0.42	4.74e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs9595066	0.627	rs4941486	chr13:44749157	G/A	cg04068111	chr13:44716778	NA	-0.47	-6.25	-0.36	1.63e-9	Schizophrenia;
CESC	cis	rs7312933	0.558	rs4768411	chr12:42855390	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.47	-6.27	-0.36	1.42e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs7927771	0.832	rs935914	chr11:47387599	C/T	cg18512352	chr11:47633146	NA	0.49	7.0	0.4	2.05e-11	Subjective well-being;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg02404575	chr19:53237871	ZNF611	0.47	6.51	0.37	3.7e-10	Asthma;
CESC	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg02980000	chr4:1222292	CTBP1	0.42	5.15	0.3	5.06e-7	Longevity;
CESC	cis	rs6456156	0.792	rs4710178	chr6:167513532	G/A	cg23791538	chr6:167370224	RNASET2	-0.4	-5.21	-0.3	3.88e-7	Primary biliary cholangitis;
CESC	cis	rs7666738	0.791	rs13125277	chr4:99009922	T/G	cg03676636	chr4:99064102	C4orf37	0.33	5.16	0.3	4.86e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs72781680	0.716	rs2712071	chr2:23990419	A/G	cg08917208	chr2:24149416	ATAD2B	0.59	5.76	0.33	2.3e-8	Lymphocyte counts;
CESC	cis	rs9660180	0.839	rs12040826	chr1:1705287	A/C	cg17747265	chr1:1875780	NA	-0.56	-8.86	-0.48	1.23e-16	Body mass index;
CESC	cis	rs7666738	0.791	rs34088022	chr4:99001508	G/T	cg17366294	chr4:99064904	C4orf37	0.6	8.61	0.47	6.47e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6831352	0.801	rs2602897	chr4:100046293	A/T	cg13256891	chr4:100009986	ADH5	0.77	8.43	0.46	2.27e-15	Alcohol dependence;
CESC	cis	rs1878931	0.531	rs9635548	chr16:3417156	G/A	cg22508957	chr16:3507546	NAT15	-0.38	-5.54	-0.32	7.15e-8	Body mass index (adult);
CESC	cis	rs60871478	0.636	rs56393680	chr7:885696	A/G	cg05535760	chr7:792225	HEATR2	-0.82	-8.48	-0.46	1.62e-15	Cerebrospinal P-tau181p levels;
CESC	trans	rs6073597	1.000	rs6031980	chr20:43714384	C/T	cg14313238	chr10:92632228	RPP30	0.44	6.25	0.36	1.61e-9	Positive affect;
CESC	cis	rs7772486	0.566	rs735536	chr6:146036832	A/C	cg23711669	chr6:146136114	FBXO30	-0.89	-13.19	-0.63	6.74e-31	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21185233	chr4:147442789	SLC10A7	-0.57	-6.96	-0.39	2.63e-11	Gut microbiome composition (summer);
CESC	cis	rs10208940	0.764	rs7583649	chr2:68830939	T/C	cg12452813	chr2:68675892	NA	0.52	5.18	0.3	4.47e-7	Urate levels in lean individuals;
CESC	cis	rs2742234	0.541	rs1254958	chr10:43702143	C/T	cg15436174	chr10:43711423	RASGEF1A	0.5	5.85	0.34	1.45e-8	Hirschsprung disease;
CESC	cis	rs71277158	0.688	rs12488988	chr3:169879860	T/C	cg04067573	chr3:169899625	PHC3	0.71	7.04	0.4	1.62e-11	Prostate cancer;
CESC	cis	rs4862750	0.832	rs6836076	chr4:187899660	A/C	cg10295955	chr4:187884368	NA	-1.08	-23.01	-0.82	4.07e-65	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg00609645	chr6:26205074	HIST1H4E	-0.53	-6.28	-0.36	1.36e-9	Ulcerative colitis;
CESC	cis	rs6582630	0.519	rs7305570	chr12:38349285	G/A	cg26384229	chr12:38710491	ALG10B	0.73	10.95	0.56	2.81e-23	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs9300255	0.569	rs1716170	chr12:123716513	C/T	cg05973401	chr12:123451056	ABCB9	0.51	5.66	0.33	3.91e-8	Neutrophil percentage of white cells;
CESC	cis	rs9926296	0.712	rs2434872	chr16:89716915	C/G	cg27121462	chr16:89883253	FANCA	-0.49	-5.74	-0.33	2.61e-8	Vitiligo;
CESC	cis	rs10504229	0.679	rs16921688	chr8:58054659	T/C	cg22535103	chr8:58192502	C8orf71	-0.77	-8.08	-0.44	2.33e-14	Developmental language disorder (linguistic errors);
CESC	cis	rs1862618	0.613	rs252889	chr5:56227069	C/A	cg24549020	chr5:56110836	MAP3K1	0.47	5.81	0.34	1.78e-8	Initial pursuit acceleration;
CESC	cis	rs2204008	0.837	rs4312131	chr12:38181087	G/T	cg26384229	chr12:38710491	ALG10B	0.74	10.7	0.55	1.96e-22	Bladder cancer;
CESC	cis	rs7772486	0.790	rs9386141	chr6:146268623	T/A	cg05347473	chr6:146136440	FBXO30	-0.52	-6.88	-0.39	4.23e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2952156	0.959	rs1565922	chr17:37831035	A/G	cg20243544	chr17:37824526	PNMT	0.6	7.57	0.42	6.06e-13	Asthma;
CESC	cis	rs793571	0.650	rs12899638	chr15:58920275	G/A	cg05156742	chr15:59063176	FAM63B	0.76	10.71	0.55	1.8e-22	Schizophrenia;
CESC	cis	rs782590	0.837	rs782585	chr2:55922930	C/T	cg18811423	chr2:55921094	PNPT1	0.82	13.59	0.64	2.72e-32	Metabolic syndrome;
CESC	cis	rs9486715	1.000	rs6902835	chr6:97063005	C/G	cg18709589	chr6:96969512	KIAA0776	-0.42	-5.88	-0.34	1.23e-8	Headache;
CESC	cis	rs7726839	1.000	rs7726839	chr5:618586	A/G	cg09021430	chr5:549028	NA	-0.44	-7.13	-0.4	9.83e-12	Obesity-related traits;
CESC	cis	rs8114671	0.805	rs6060168	chr20:33621017	C/T	cg06115741	chr20:33292138	TP53INP2	0.43	5.31	0.31	2.37e-7	Height;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg10893370	chr17:30228961	UTP6	-0.46	-6.14	-0.35	3.01e-9	Height;
CESC	cis	rs55794721	0.509	rs12027135	chr1:25775733	A/T	cg27572855	chr1:25598939	RHD	0.46	7.69	0.43	2.87e-13	Plateletcrit;Mean corpuscular volume;
CESC	cis	rs9811920	0.928	rs2130369	chr3:99873317	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.4	6.5	0.37	3.89e-10	Axial length;
CESC	cis	rs798554	0.757	rs1182181	chr7:2873247	C/G	cg09658497	chr7:2847517	GNA12	-0.45	-6.53	-0.37	3.42e-10	Height;
CESC	cis	rs8020095	0.571	rs7156655	chr14:67356061	T/C	cg19548862	chr14:67692701	FAM71D	-0.48	-5.82	-0.34	1.73e-8	Depression (quantitative trait);
CESC	cis	rs8028182	0.636	rs4243034	chr15:75750969	G/A	cg20655648	chr15:75932815	IMP3	0.51	6.5	0.37	4.07e-10	Sudden cardiac arrest;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00286214	chr16:2771425	PRSS27	0.52	6.31	0.36	1.17e-9	Gut microbiome composition (summer);
CESC	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg10295955	chr4:187884368	NA	-1.08	-23.01	-0.82	4.07e-65	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9303401	0.659	rs7210432	chr17:56668170	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.02	12.93	0.62	5.59e-30	Cognitive test performance;
CESC	cis	rs61931739	0.500	rs11053277	chr12:34553835	T/A	cg06521331	chr12:34319734	NA	-0.36	-5.03	-0.3	9.01e-7	Morning vs. evening chronotype;
CESC	cis	rs1729951	0.546	rs361246	chr3:136695667	G/A	cg25687071	chr3:136751404	NA	0.4	5.35	0.31	1.86e-7	Neuroticism;
CESC	cis	rs4563143	0.704	rs16961809	chr19:29226299	C/T	cg12756686	chr19:29218302	NA	0.49	6.8	0.39	6.72e-11	Methadone dose in opioid dependence;
CESC	cis	rs863345	0.604	rs12123305	chr1:158498955	G/A	cg12129480	chr1:158549410	OR10X1	-0.34	-6.84	-0.39	5.41e-11	Pneumococcal bacteremia;
CESC	cis	rs910316	0.967	rs7146523	chr14:75659880	T/C	cg08847533	chr14:75593920	NEK9	-0.92	-16.11	-0.7	3.53e-41	Height;
CESC	trans	rs2832077	0.527	rs1048546	chr21:30244877	G/T	cg14791747	chr16:20752902	THUMPD1	0.47	6.38	0.36	7.72e-10	Cognitive test performance;
CESC	cis	rs651907	0.557	rs11711079	chr3:101386918	G/A	cg12386194	chr3:101231763	SENP7	0.44	5.48	0.32	9.88e-8	Colorectal cancer;
CESC	cis	rs7811142	0.943	rs11769886	chr7:99998607	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.11	10.85	0.55	6.37e-23	Platelet count;
CESC	cis	rs3892630	0.878	rs1559177	chr19:33210646	A/G	cg22980127	chr19:33182716	NUDT19	1.06	11.38	0.57	1.04e-24	Red blood cell traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14853922	chr1:179051253	TOR3A	0.6	6.99	0.39	2.24e-11	Gut microbiome composition (summer);
CESC	cis	rs6430585	0.640	rs58301703	chr2:136532225	G/A	cg07169764	chr2:136633963	MCM6	1.26	16.81	0.72	1.21e-43	Corneal structure;
CESC	cis	rs9311474	0.508	rs3796353	chr3:52593230	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.36	6.4	0.37	7.06e-10	Electroencephalogram traits;
CESC	cis	rs12368653	0.591	rs1552842	chr12:58012163	A/G	cg00700412	chr12:58011837	NA	-0.47	-7.34	-0.41	2.55e-12	Multiple sclerosis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09148494	chr19:55866345	COX6B2;FAM71E2	-0.63	-7.74	-0.43	2.06e-13	Gut microbiome composition (summer);
CESC	cis	rs7872515	0.887	rs10992234	chr9:94877836	A/G	cg01248375	chr9:94877805	SPTLC1	0.56	6.11	0.35	3.63e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs3126085	0.935	rs4421596	chr1:152181673	G/A	cg03465714	chr1:152285911	FLG	-0.43	-5.16	-0.3	4.81e-7	Atopic dermatitis;
CESC	cis	rs10924309	0.640	rs6700599	chr1:245854047	G/T	cg00036263	chr1:245852353	KIF26B	-0.53	-6.9	-0.39	3.82e-11	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
CESC	cis	rs9584850	0.874	rs4584	chr13:99101869	G/C	cg20750642	chr13:99100586	FARP1	-0.37	-5.55	-0.32	6.95e-8	Neuroticism;
CESC	cis	rs7666738	0.830	rs13137859	chr4:99050319	A/G	cg24818145	chr4:99064322	C4orf37	0.38	5.04	0.3	8.49e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14996805	chr17:56430170	SUPT4H1	-0.51	-6.08	-0.35	4.28e-9	Gut microbiome composition (summer);
CESC	cis	rs40363	0.680	rs4010628	chr16:3529779	G/A	cg05754148	chr16:3507555	NAT15	0.67	6.51	0.37	3.68e-10	Tuberculosis;
CESC	trans	rs1814175	0.527	rs7110797	chr11:49644096	T/C	cg03929089	chr4:120376271	NA	-0.75	-8.45	-0.46	1.96e-15	Height;
CESC	cis	rs7618501	0.633	rs2856234	chr3:50139142	A/G	cg24308560	chr3:49941425	MST1R	0.64	9.54	0.51	9.91e-19	Intelligence (multi-trait analysis);
CESC	cis	rs1878931	0.615	rs4786412	chr16:3440390	C/T	cg21433313	chr16:3507492	NAT15	-0.36	-5.31	-0.31	2.29e-7	Body mass index (adult);
CESC	cis	rs959260	1.000	rs8081927	chr17:73379085	C/T	cg12999837	chr17:73267436	MIF4GD	-0.51	-5.85	-0.34	1.48e-8	Systemic lupus erythematosus;
CESC	trans	rs1908814	0.516	rs13281077	chr8:11794814	C/T	cg15556689	chr8:8085844	FLJ10661	0.53	6.56	0.37	2.75e-10	Neuroticism;
CESC	cis	rs7923452	0.938	rs67812762	chr10:30759479	G/T	cg18806716	chr10:30721971	MAP3K8	0.51	6.11	0.35	3.49e-9	Itch intensity from mosquito bite;
CESC	cis	rs10465746	0.935	rs12758441	chr1:84352034	A/G	cg10977910	chr1:84465055	TTLL7	0.48	6.52	0.37	3.63e-10	Obesity-related traits;
CESC	cis	rs644799	1.000	rs500054	chr11:95593806	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.67	8.17	0.45	1.31e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs7772486	0.597	rs9285508	chr6:146262697	G/T	cg05347473	chr6:146136440	FBXO30	-0.64	-6.93	-0.39	3.24e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	10.13	0.53	1.35e-20	Prudent dietary pattern;
CESC	cis	rs12474201	0.963	rs11676737	chr2:46929873	T/C	cg06386533	chr2:46925753	SOCS5	0.91	12.61	0.61	7.02e-29	Height;
CESC	cis	rs3741798	1.000	rs2160588	chr12:12487447	C/T	cg08615371	chr12:12503544	MANSC1	0.79	6.1	0.35	3.64e-9	Cerebrospinal fluid biomarker levels;
CESC	cis	rs7503807	0.967	rs12940622	chr17:78615571	G/A	cg09596252	chr17:78655493	RPTOR	0.51	7.5	0.42	9.7e-13	Obesity;
CESC	cis	rs4803468	0.967	rs3745290	chr19:41890003	C/T	cg09537434	chr19:41945824	ATP5SL	-1.01	-17.8	-0.74	3.63e-47	Height;
CESC	cis	rs2921073	0.605	rs2976933	chr8:8254875	A/G	cg15556689	chr8:8085844	FLJ10661	0.54	6.79	0.38	7.54e-11	Parkinson's disease;
CESC	cis	rs826838	0.904	rs7973992	chr12:39168233	T/C	cg26384229	chr12:38710491	ALG10B	0.78	13.28	0.63	3.36e-31	Heart rate;
CESC	cis	rs6460942	0.841	rs17444203	chr7:12461864	C/G	cg02935154	chr7:12443704	VWDE	0.56	7.14	0.4	8.79e-12	Coronary artery disease;
CESC	cis	rs9314323	0.693	rs13264882	chr8:26224240	G/T	cg11498726	chr8:26250323	BNIP3L	-0.45	-6.48	-0.37	4.37e-10	Red cell distribution width;
CESC	cis	rs9911578	0.692	rs412000	chr17:56709058	G/C	cg12560992	chr17:57184187	TRIM37	0.83	12.95	0.62	4.96e-30	Intelligence (multi-trait analysis);
CESC	cis	rs10754283	0.967	rs1317864	chr1:90105448	A/G	cg21401794	chr1:90099060	LRRC8C	0.69	9.34	0.5	4.06e-18	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs2576037	0.623	rs2576040	chr18:44582027	A/G	cg19077165	chr18:44547161	KATNAL2	0.57	8.4	0.46	2.66e-15	Personality dimensions;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19182353	chr11:118479428	PHLDB1	-0.52	-6.16	-0.35	2.72e-9	Gut microbiome composition (summer);
CESC	cis	rs2996428	0.601	rs10909804	chr1:3770929	A/G	cg13057898	chr1:3703894	LRRC47	-0.46	-6.32	-0.36	1.09e-9	Red cell distribution width;
CESC	cis	rs17253792	0.822	rs77990307	chr14:56070049	T/C	cg01858014	chr14:56050164	KTN1	-0.85	-6.99	-0.39	2.22e-11	Putamen volume;
CESC	cis	rs2228479	0.850	rs79244293	chr16:89896220	T/C	cg06558623	chr16:89946397	TCF25	1.06	7.64	0.42	4.04e-13	Skin colour saturation;
CESC	cis	rs807669	0.742	rs1206544	chr22:19215039	C/T	cg02655711	chr22:19163373	SLC25A1	0.54	7.95	0.44	5.46e-14	Metabolite levels;
CESC	cis	rs854765	0.583	rs12452254	chr17:17829434	G/A	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.48	6.23	0.36	1.86e-9	Total body bone mineral density;
CESC	cis	rs1008375	1.000	rs10027755	chr4:17615954	G/C	cg16339924	chr4:17578868	LAP3	0.57	7.1	0.4	1.15e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs875971	0.862	rs801194	chr7:66028495	T/C	cg10691866	chr7:65817282	TPST1	0.33	5.47	0.32	1.02e-7	Aortic root size;
CESC	cis	rs644799	1.000	rs544119	chr11:95538624	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.53	6.41	0.37	6.77e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg12661088	chr5:43120934	ZNF131	-0.42	-6.01	-0.35	6.07e-9	Gambling;
CESC	cis	rs6951245	0.706	rs1133116	chr7:1195215	A/C	cg22907277	chr7:1156413	C7orf50	0.47	5.3	0.31	2.48e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs875971	1.000	rs7801282	chr7:65613687	C/T	cg11764359	chr7:65958608	NA	-0.92	-14.57	-0.67	9.81e-36	Aortic root size;
CESC	cis	rs8114671	0.562	rs7266550	chr20:33495510	C/T	cg06115741	chr20:33292138	TP53INP2	0.48	5.79	0.34	1.97e-8	Height;
CESC	trans	rs10506458	1.000	rs17763435	chr12:63416511	A/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	1.27	17.05	0.72	1.67e-44	Hemostatic factors and hematological phenotypes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02176961	chr10:15130767	ACBD7	0.69	7.62	0.42	4.38e-13	Gut microbiome composition (summer);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg26824326	chr1:9664366	TMEM201	0.51	6.65	0.38	1.64e-10	Fibrinogen levels;
CESC	cis	rs6499255	0.857	rs16959035	chr16:69707645	C/A	cg15192750	chr16:69999425	NA	0.46	5.34	0.31	2.04e-7	IgE levels;
CESC	cis	rs4803468	0.967	rs67047091	chr19:41938684	C/T	cg09537434	chr19:41945824	ATP5SL	1.13	21.6	0.8	2.18e-60	Height;
CESC	cis	rs6963495	0.818	rs73190133	chr7:105147821	G/C	cg13798780	chr7:105162888	PUS7	0.76	7.8	0.43	1.47e-13	Bipolar disorder (body mass index interaction);
CESC	cis	rs601339	0.938	rs1696344	chr12:123183059	C/T	cg11919336	chr12:123188078	GPR109A	0.47	6.29	0.36	1.28e-9	Adiponectin levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17199681	chr17:3540328	CTNS;SHPK	0.54	6.25	0.36	1.65e-9	Gut microbiome composition (summer);
CESC	cis	rs9291683	0.588	rs17247314	chr4:10004743	C/G	cg00071950	chr4:10020882	SLC2A9	0.84	15.4	0.69	1.2e-38	Bone mineral density;
CESC	cis	rs1862618	0.853	rs252887	chr5:56166188	A/G	cg12311346	chr5:56204834	C5orf35	-0.74	-8.72	-0.47	3.21e-16	Initial pursuit acceleration;
CESC	cis	rs7827545	1.000	rs7463007	chr8:135567143	C/T	cg17885191	chr8:135476712	NA	0.48	6.36	0.36	8.74e-10	Hypertension (SNP x SNP interaction);
CESC	cis	rs7223966	1.000	rs6504173	chr17:61735056	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	7.55	0.42	7e-13	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg23048001	chr7:2026167	MAD1L1	0.48	6.2	0.36	2.12e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs35110281	0.600	rs914198	chr21:45117456	A/C	cg21573476	chr21:45109991	RRP1B	-0.55	-7.91	-0.44	6.87e-14	Mean corpuscular volume;
CESC	cis	rs7116495	0.609	rs4387373	chr11:71774908	A/G	cg18441811	chr11:71824068	C11orf51	-0.82	-5.14	-0.3	5.31e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs2274273	0.837	rs10141483	chr14:55786871	T/C	cg04306507	chr14:55594613	LGALS3	0.31	6.07	0.35	4.34e-9	Protein biomarker;
CESC	trans	rs11098499	0.954	rs10017543	chr4:120321420	G/A	cg25214090	chr10:38739885	LOC399744	0.72	10.03	0.52	2.88e-20	Corneal astigmatism;
CESC	cis	rs3780486	0.505	rs10758194	chr9:33157419	G/T	cg13443165	chr9:33130375	B4GALT1	0.47	7.23	0.41	5.15e-12	IgG glycosylation;
CESC	cis	rs763121	0.853	rs138713	chr22:39142615	T/C	cg06544989	chr22:39130855	UNC84B	0.48	8.9	0.48	8.98e-17	Menopause (age at onset);
CESC	cis	rs3820068	0.581	rs72645888	chr1:15929922	C/A	cg17385448	chr1:15911702	AGMAT	0.41	6.69	0.38	1.33e-10	Systolic blood pressure;
CESC	cis	rs2952156	0.959	rs1495101	chr17:37832103	C/A	cg07936489	chr17:37558343	FBXL20	-0.55	-6.65	-0.38	1.68e-10	Asthma;
CESC	cis	rs258892	0.895	rs35317818	chr5:72073502	G/C	cg21869765	chr5:72125136	TNPO1	-0.44	-5.52	-0.32	8.21e-8	Small cell lung carcinoma;
CESC	trans	rs6084875	0.641	rs4815733	chr20:4722400	A/T	cg10192164	chr16:30419175	ZNF771	-0.51	-6.15	-0.35	2.79e-9	Systemic lupus erythematosus;
CESC	cis	rs35955747	0.840	rs9621221	chr22:31616169	G/A	cg25791279	chr22:32026902	PISD	-0.48	-5.77	-0.33	2.2e-8	Neutrophil count;Sum basophil neutrophil counts;
CESC	cis	rs748404	0.631	rs6493084	chr15:43647627	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.6	7.64	0.43	3.88e-13	Lung cancer;
CESC	cis	rs10504229	1.000	rs58382845	chr8:58169851	A/C	cg14926445	chr8:58193284	C8orf71	-0.51	-5.48	-0.32	1.01e-7	Developmental language disorder (linguistic errors);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23956071	chr17:4710044	PLD2	0.62	7.43	0.42	1.54e-12	Gut microbiome composition (summer);
CESC	cis	rs3820068	0.656	rs72645829	chr1:15889748	A/G	cg18192808	chr1:15853278	DNAJC16	0.43	5.17	0.3	4.6e-7	Systolic blood pressure;
CESC	cis	rs7590720	0.840	rs705648	chr2:216933792	C/T	cg12620499	chr2:216877984	MREG	0.8	10.1	0.53	1.7e-20	Alcohol dependence;
CESC	cis	rs6484504	0.600	rs366758	chr11:31222499	A/C	cg14844989	chr11:31128820	NA	-0.42	-5.96	-0.34	7.83e-9	Red blood cell count;
CESC	cis	rs7267979	0.714	rs6115107	chr20:25237390	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.71	11.37	0.57	1.18e-24	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs1348850	0.526	rs1345138	chr2:178387100	A/T	cg22681709	chr2:178499509	PDE11A	-0.5	-5.16	-0.3	4.97e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs4665809	1.000	rs6546727	chr2:26275282	C/T	cg04944784	chr2:26401820	FAM59B	-0.66	-7.4	-0.41	1.82e-12	Gut microbiome composition (summer);
CESC	cis	rs709400	0.894	rs10143293	chr14:104063014	G/A	cg12935359	chr14:103987150	CKB	-0.47	-6.18	-0.35	2.46e-9	Body mass index;
CESC	trans	rs6700559	0.810	rs2808250	chr1:200592547	A/T	cg05185519	chr16:2972941	FLYWCH1	-0.48	-6.28	-0.36	1.4e-9	Coronary artery disease;
CESC	cis	rs2933343	0.649	rs789216	chr3:128594503	A/C	cg11901034	chr3:128598214	ACAD9	-0.37	-5.43	-0.32	1.31e-7	IgG glycosylation;
CESC	cis	rs6502050	0.740	rs4789748	chr17:80093061	A/C	cg23985595	chr17:80112537	CCDC57	-0.42	-6.59	-0.38	2.37e-10	Life satisfaction;
CESC	cis	rs7412746	0.634	rs72704658	chr1:150833010	T/C	cg04414720	chr1:150670196	GOLPH3L	0.54	7.03	0.4	1.7e-11	Melanoma;
CESC	cis	rs1395	0.744	rs3739092	chr2:27462076	C/T	cg22903471	chr2:27725779	GCKR	-0.42	-5.14	-0.3	5.24e-7	Blood metabolite levels;
CESC	cis	rs7537660	1.000	rs6667389	chr1:248004614	C/T	cg12080717	chr1:248004886	OR11L1	-0.41	-5.59	-0.32	5.52e-8	Platelet distribution width;
CESC	trans	rs561341	0.714	rs547473	chr17:30297560	T/G	cg20587970	chr11:113659929	NA	-1.12	-14.24	-0.66	1.49e-34	Hip circumference adjusted for BMI;
CESC	trans	rs10743315	0.643	rs17505214	chr12:19307139	A/G	cg09562322	chr12:119419143	SRRM4	-0.5	-6.51	-0.37	3.67e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs8114671	0.562	rs6120757	chr20:33488771	C/T	cg06115741	chr20:33292138	TP53INP2	0.45	5.37	0.31	1.71e-7	Height;
CESC	cis	rs6089584	0.816	rs6061411	chr20:60634716	C/A	cg06108461	chr20:60628389	TAF4	-0.91	-14.02	-0.65	8.74e-34	Body mass index;
CESC	cis	rs10752881	0.809	rs3768613	chr1:183106296	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.84	13.3	0.63	2.85e-31	Colorectal cancer;
CESC	cis	rs116095464	0.558	rs28558836	chr5:285748	C/G	cg22857025	chr5:266934	NA	-1.27	-18.14	-0.74	2.35e-48	Breast cancer;
CESC	cis	rs7772486	0.774	rs2247571	chr6:146219533	T/A	cg23711669	chr6:146136114	FBXO30	0.65	9.31	0.5	4.9e-18	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9311474	0.713	rs352169	chr3:52236762	C/T	cg18099408	chr3:52552593	STAB1	-0.34	-5.88	-0.34	1.24e-8	Electroencephalogram traits;
CESC	cis	rs13108904	0.935	rs13148614	chr4:1248357	G/C	cg00684032	chr4:1343700	KIAA1530	0.35	5.45	0.32	1.16e-7	Obesity-related traits;
CESC	cis	rs9487051	0.872	rs9487034	chr6:109605899	A/G	cg01475377	chr6:109611718	NA	-0.52	-8.44	-0.46	2.16e-15	Reticulocyte fraction of red cells;
CESC	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.64	7.2	0.4	6.35e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs804280	1.000	rs804280	chr8:11612698	G/T	cg12395012	chr8:11607386	GATA4	-0.53	-6.86	-0.39	4.82e-11	Myopia (pathological);
CESC	cis	rs7264396	0.635	rs6058344	chr20:34475038	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.84	-11.47	-0.58	5.38e-25	Total cholesterol levels;
CESC	cis	rs4144743	1.000	rs34182248	chr17:45321359	T/C	cg18085866	chr17:45331354	ITGB3	-0.65	-7.07	-0.4	1.39e-11	Body mass index;
CESC	cis	rs9910055	0.664	rs433610	chr17:42197281	A/G	cg19774624	chr17:42201019	HDAC5	0.75	11.24	0.57	3.24e-24	Total body bone mineral density;
CESC	cis	rs11577318	0.853	rs7537477	chr1:26618829	C/T	cg00852783	chr1:26633632	UBXN11	0.51	7.05	0.4	1.57e-11	Granulocyte percentage of myeloid white cells;
CESC	cis	rs4319547	0.626	rs11057882	chr12:122875046	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.54	-6.14	-0.35	3.08e-9	Body mass index;
CESC	cis	rs1595825	0.891	rs78198610	chr2:198522769	T/C	cg10820045	chr2:198174542	NA	0.41	5.21	0.3	3.79e-7	Ulcerative colitis;
CESC	cis	rs3733585	0.648	rs28513781	chr4:9959334	G/C	cg11266682	chr4:10021025	SLC2A9	-0.6	-11.2	-0.57	4.42e-24	Cleft plate (environmental tobacco smoke interaction);
CESC	trans	rs1421898	0.649	rs6556364	chr5:158157645	C/T	cg19069039	chr12:52238665	NA	-0.51	-6.14	-0.35	3.04e-9	Inflammatory skin disease;
CESC	cis	rs6502050	0.723	rs4789698	chr17:80179786	C/T	cg23985595	chr17:80112537	CCDC57	-0.37	-5.2	-0.3	4.04e-7	Life satisfaction;
CESC	cis	rs61931739	0.782	rs7969373	chr12:34249655	T/G	cg19457237	chr12:34500585	NA	-0.42	-5.72	-0.33	2.86e-8	Morning vs. evening chronotype;
CESC	cis	rs9916302	0.904	rs602282	chr17:37433021	C/T	cg00129232	chr17:37814104	STARD3	-0.55	-7.23	-0.41	5.28e-12	Glomerular filtration rate (creatinine);
CESC	cis	rs7666738	0.570	rs1869351	chr4:99077286	T/C	cg07917127	chr4:99064746	C4orf37	0.4	5.05	0.3	8.3e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs13191362	1.000	rs34228197	chr6:163008232	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.82	8.75	0.47	2.56e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs2797160	0.967	rs4897151	chr6:125993202	T/G	cg05901451	chr6:126070800	HEY2	-0.45	-6.62	-0.38	1.93e-10	Endometrial cancer;
CESC	cis	rs7647973	0.566	rs57630346	chr3:49086215	T/C	cg07636037	chr3:49044803	WDR6	0.85	11.23	0.57	3.3e-24	Menarche (age at onset);
CESC	cis	rs10504229	0.636	rs10958525	chr8:58051528	C/A	cg24829409	chr8:58192753	C8orf71	-0.49	-6.07	-0.35	4.47e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs4665809	0.590	rs13016807	chr2:26496186	G/C	cg26314531	chr2:26401878	FAM59B	0.8	8.22	0.45	9.18e-15	Gut microbiome composition (summer);
CESC	cis	rs7923609	0.875	rs10761741	chr10:65066186	G/T	cg01631684	chr10:65280961	REEP3	-0.42	-5.3	-0.31	2.44e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs6570726	0.818	rs9390338	chr6:145908265	A/G	cg05347473	chr6:146136440	FBXO30	0.57	7.44	0.42	1.37e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6546550	0.867	rs1048266	chr2:70132676	A/G	cg02498382	chr2:70120550	SNRNP27	-0.41	-7.26	-0.41	4.34e-12	Prevalent atrial fibrillation;
CESC	cis	rs1153858	1.000	rs2467858	chr15:45711492	A/G	cg21132104	chr15:45694354	SPATA5L1	0.76	10.15	0.53	1.12e-20	Homoarginine levels;
CESC	cis	rs4481887	0.893	rs28787378	chr1:248504447	C/T	cg00666640	chr1:248458726	OR2T12	0.35	6.01	0.35	6.07e-9	Common traits (Other);
CESC	cis	rs6860806	0.661	rs334902	chr5:131586559	C/G	cg22638593	chr5:131593259	PDLIM4	0.39	5.12	0.3	5.97e-7	Breast cancer;
CESC	cis	rs4665809	1.000	rs4665823	chr2:26312723	A/G	cg04944784	chr2:26401820	FAM59B	-0.66	-7.62	-0.42	4.5e-13	Gut microbiome composition (summer);
CESC	cis	rs1550582	1.000	rs7822348	chr8:135542483	C/G	cg17885191	chr8:135476712	NA	0.58	6.8	0.39	6.89e-11	Educational attainment;
CESC	cis	rs4253772	0.513	rs11090863	chr22:46705407	C/T	cg18190219	chr22:46762943	CELSR1	-0.56	-5.46	-0.32	1.12e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs75477785	1.000	rs1856161	chr1:209959168	C/T	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.81	5.47	0.32	1.04e-7	Cleft lip with or without cleft palate;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg00432497	chr16:89438714	ANKRD11	0.42	6.2	0.36	2.16e-9	Gambling;
CESC	cis	rs826838	0.806	rs826873	chr12:39121305	G/A	cg26384229	chr12:38710491	ALG10B	-0.67	-11.02	-0.56	1.72e-23	Heart rate;
CESC	cis	rs7552404	0.883	rs77773255	chr1:76217193	G/A	cg10523679	chr1:76189770	ACADM	0.73	8.63	0.47	5.66e-16	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs9611565	0.512	rs139560	chr22:42194962	A/G	cg06634786	chr22:41940651	POLR3H	-0.67	-6.8	-0.39	6.74e-11	Vitiligo;
CESC	cis	rs8060686	0.565	rs11555011	chr16:68088485	A/G	cg26727032	chr16:67993705	SLC12A4	-0.55	-6.15	-0.35	2.9e-9	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs736801	0.740	rs12515180	chr5:131785684	C/T	cg21138405	chr5:131827807	IRF1	-0.39	-5.75	-0.33	2.48e-8	Breast cancer;Mosquito bite size;
CESC	cis	rs6754311	0.550	rs10173394	chr2:136522675	C/T	cg15123519	chr2:136567270	LCT	0.33	5.54	0.32	7.14e-8	Mosquito bite size;
CESC	cis	rs9322193	0.926	rs952166	chr6:150119910	A/T	cg05861140	chr6:150128134	PCMT1	-0.37	-5.3	-0.31	2.42e-7	Lung cancer;
CESC	cis	rs7923609	0.934	rs10822153	chr10:65056813	C/A	cg01631684	chr10:65280961	REEP3	-0.43	-5.41	-0.32	1.4e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs11864453	1.000	rs11864453	chr16:72050480	C/T	cg16558253	chr16:72132732	DHX38	-0.5	-7.28	-0.41	3.73e-12	Fibrinogen levels;
CESC	cis	rs597539	0.615	rs629426	chr11:68671104	A/G	cg04772025	chr11:68637568	NA	0.49	5.92	0.34	9.91e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs13064411	0.597	rs2291905	chr3:113010466	C/T	cg18753928	chr3:113234510	CCDC52	-0.39	-5.08	-0.3	7.21e-7	Response to simvastatin treatment (PCSK9 protein level change);
CESC	cis	rs4319547	0.760	rs61954973	chr12:123074168	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.58	-6.75	-0.38	9.5e-11	Body mass index;
CESC	cis	rs7818345	0.935	rs6990217	chr8:19276661	G/C	cg11303988	chr8:19266685	CSGALNACT1	0.32	5.85	0.34	1.45e-8	Language performance in older adults (adjusted for episodic memory);
CESC	cis	rs10465746	0.780	rs11163862	chr1:84355418	A/T	cg10977910	chr1:84465055	TTLL7	-0.51	-7.17	-0.4	7.25e-12	Obesity-related traits;
CESC	cis	rs3820928	0.874	rs7582251	chr2:227791703	G/T	cg05526886	chr2:227700861	RHBDD1	-0.4	-5.2	-0.3	3.93e-7	Pulmonary function;
CESC	cis	rs2120019	0.938	rs59094290	chr15:75308561	G/T	cg09165964	chr15:75287851	SCAMP5	-0.76	-9.14	-0.49	1.69e-17	Blood trace element (Zn levels);
CESC	trans	rs2727020	0.664	rs4929893	chr11:49196332	C/T	cg15704280	chr7:45808275	SEPT13	-0.83	-13.12	-0.63	1.27e-30	Coronary artery disease;
CESC	trans	rs1223629	1.000	rs12244826	chr10:95945985	G/T	cg16346422	chr11:2920819	SLC22A18;SLC22A18AS	-0.65	-6.0	-0.35	6.41e-9	Glucose homeostasis traits;
CESC	cis	rs6831352	0.918	rs29001195	chr4:100054244	G/T	cg12011299	chr4:100065546	ADH4	-0.6	-6.62	-0.38	2.04e-10	Alcohol dependence;
CESC	cis	rs736408	0.507	rs6445531	chr3:52717282	T/C	cg18337363	chr3:52569053	NT5DC2	0.29	5.36	0.31	1.85e-7	Bipolar disorder;
CESC	cis	rs5753037	0.653	rs131270	chr22:30149896	C/T	cg01021169	chr22:30184971	ASCC2	-0.46	-6.36	-0.36	8.57e-10	Type 1 diabetes;
CESC	cis	rs6460942	1.000	rs62448566	chr7:12403662	G/A	cg06484146	chr7:12443880	VWDE	-0.7	-8.15	-0.45	1.5e-14	Coronary artery disease;
CESC	cis	rs7618915	0.501	rs3733045	chr3:52643307	A/G	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.71	0.38	1.17e-10	Bipolar disorder;
CESC	cis	rs1552244	0.554	rs6443275	chr3:10008819	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.62	8.08	0.44	2.38e-14	Alzheimer's disease;
CESC	cis	rs765787	0.530	rs11070444	chr15:45513121	T/C	cg24006582	chr15:45444508	DUOX1	0.54	6.54	0.37	3.12e-10	Uric acid levels;
CESC	cis	rs3806843	0.676	rs1583005	chr5:140031537	G/A	cg26395211	chr5:140044315	WDR55	0.53	6.78	0.38	7.57e-11	Depressive symptoms (multi-trait analysis);
CESC	cis	rs3105593	1.000	rs3101853	chr15:50848382	A/T	cg08437265	chr15:50716283	USP8	-0.42	-5.5	-0.32	9.08e-8	QT interval;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg19905802	chr11:62554200	TMEM179B;TAF6L	-0.48	-6.62	-0.38	2.01e-10	Fibrinogen levels;
CESC	cis	rs763121	0.962	rs138711	chr22:39139913	C/T	cg06022373	chr22:39101656	GTPBP1	0.73	10.52	0.54	7.38e-22	Menopause (age at onset);
CESC	cis	rs9325144	0.647	rs12229104	chr12:39110811	T/A	cg26384229	chr12:38710491	ALG10B	-0.51	-7.11	-0.4	1.06e-11	Morning vs. evening chronotype;
CESC	cis	rs1707322	0.752	rs3811436	chr1:46125880	T/C	cg06784218	chr1:46089804	CCDC17	0.41	7.12	0.4	1.04e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs11098499	0.644	rs10012252	chr4:120559139	T/C	cg25214090	chr10:38739885	LOC399744	0.63	8.89	0.48	9.66e-17	Corneal astigmatism;
CESC	cis	rs8067545	1.000	rs3909258	chr17:19945819	C/G	cg13482628	chr17:19912719	NA	0.44	5.85	0.34	1.42e-8	Schizophrenia;
CESC	cis	rs7666738	0.791	rs10017624	chr4:98984009	G/T	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.67e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6429082	0.608	rs4469707	chr1:235570634	T/C	cg26050004	chr1:235667680	B3GALNT2	-0.54	-6.79	-0.38	7.46e-11	Adiposity;
CESC	cis	rs2072732	0.861	rs67872056	chr1:2954165	C/T	cg15211996	chr1:2936768	ACTRT2	0.34	6.04	0.35	5.27e-9	Plateletcrit;
CESC	cis	rs4909189	1.000	rs62493649	chr7:158135556	C/G	cg25566285	chr7:158114605	PTPRN2	0.44	5.97	0.34	7.51e-9	Response to amphetamines;
CESC	trans	rs10776614	0.799	rs7350439	chr10:49765574	A/G	cg19218067	chr2:181235115	NA	0.49	6.0	0.35	6.35e-9	Self-employment;
CESC	cis	rs17209837	1.000	rs4148814	chr7:87091543	T/C	cg00919237	chr7:87102261	ABCB4	-0.51	-5.85	-0.34	1.46e-8	Gallbladder cancer;
CESC	cis	rs17376456	0.542	rs10061069	chr5:93071630	G/C	cg25358565	chr5:93447407	FAM172A	0.47	5.16	0.3	4.73e-7	Diabetic retinopathy;
CESC	cis	rs4555082	0.874	rs2816621	chr14:105732762	A/T	cg06808227	chr14:105710500	BRF1	-0.6	-6.83	-0.39	5.75e-11	Mean platelet volume;Platelet distribution width;
CESC	cis	rs9399135	0.684	rs1135205	chr6:135281795	C/T	cg24558204	chr6:135376177	HBS1L	0.54	7.39	0.41	1.98e-12	Red blood cell count;
CESC	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg02071572	chr4:1403502	NA	0.34	5.05	0.3	8.37e-7	Longevity;
CESC	cis	rs3126085	0.935	rs11204939	chr1:152200942	G/C	cg03465714	chr1:152285911	FLG	-0.43	-5.4	-0.31	1.48e-7	Atopic dermatitis;
CESC	cis	rs7811142	0.830	rs6979910	chr7:99940630	A/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.75	7.68	0.43	3.04e-13	Platelet count;
CESC	cis	rs72781680	0.821	rs72796361	chr2:24160689	A/T	cg08917208	chr2:24149416	ATAD2B	0.63	6.24	0.36	1.73e-9	Lymphocyte counts;
CESC	cis	rs3091242	0.933	rs1534954	chr1:25761924	A/T	cg02931644	chr1:25747376	RHCE	0.43	7.21	0.41	5.74e-12	Erythrocyte sedimentation rate;
CESC	cis	rs875971	0.895	rs7788984	chr7:65915616	A/G	cg12463550	chr7:65579703	CRCP	0.56	7.02	0.4	1.9e-11	Aortic root size;
CESC	cis	rs2652822	0.935	rs12148069	chr15:63443792	A/T	cg02713581	chr15:63449717	RPS27L	0.58	7.51	0.42	8.81e-13	Metabolic traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26155979	chr10:105110866	PCGF6	0.62	6.86	0.39	4.72e-11	Gut microbiome composition (summer);
CESC	cis	rs10504229	1.000	rs72652906	chr8:58188360	C/A	cg22535103	chr8:58192502	C8orf71	-1.05	-12.84	-0.62	1.17e-29	Developmental language disorder (linguistic errors);
CESC	cis	rs977987	0.806	rs11862684	chr16:75461746	T/G	cg03315344	chr16:75512273	CHST6	0.41	5.93	0.34	9.41e-9	Dupuytren's disease;
CESC	cis	rs853679	0.517	rs9368555	chr6:28108967	T/C	cg19592336	chr6:28129416	ZNF389	0.61	8.17	0.45	1.28e-14	Depression;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02933375	chr17:78858828	RPTOR	-0.66	-7.25	-0.41	4.53e-12	Gut microbiome composition (summer);
CESC	cis	rs4076764	0.914	rs6689760	chr1:163358704	A/G	cg24596788	chr1:163392923	NA	0.49	7.32	0.41	3.06e-12	Motion sickness;
CESC	cis	rs714031	0.934	rs4820386	chr22:40068051	C/T	cg21377881	chr22:40064566	CACNA1I	-0.32	-5.09	-0.3	6.65e-7	Schizophrenia;
CESC	cis	rs7829975	0.688	rs7826660	chr8:8379107	C/A	cg15556689	chr8:8085844	FLJ10661	0.53	6.45	0.37	5.3e-10	Mood instability;
CESC	cis	rs17376456	0.877	rs10064520	chr5:93427358	T/C	cg25358565	chr5:93447407	FAM172A	1.18	11.22	0.57	3.75e-24	Diabetic retinopathy;
CESC	cis	rs4660261	0.562	rs3011223	chr1:44318286	T/C	cg13606994	chr1:44402422	ARTN	-0.35	-5.16	-0.3	4.91e-7	Intelligence (multi-trait analysis);
CESC	cis	rs10504229	0.683	rs7459925	chr8:58111771	G/A	cg24829409	chr8:58192753	C8orf71	-0.59	-7.26	-0.41	4.34e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs4665809	1.000	rs6546744	chr2:26302161	A/G	cg08470875	chr2:26401718	FAM59B	-0.48	-5.26	-0.31	3.03e-7	Gut microbiome composition (summer);
CESC	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg22535103	chr8:58192502	C8orf71	-0.93	-10.31	-0.53	3.63e-21	Developmental language disorder (linguistic errors);
CESC	cis	rs863345	0.604	rs975118	chr1:158511445	G/A	cg12129480	chr1:158549410	OR10X1	-0.35	-7.02	-0.4	1.89e-11	Pneumococcal bacteremia;
CESC	cis	rs36051895	0.632	rs10815165	chr9:5149138	T/C	cg02405213	chr9:5042618	JAK2	-0.54	-6.92	-0.39	3.39e-11	Pediatric autoimmune diseases;
CESC	cis	rs11958404	0.615	rs7704746	chr5:157450601	C/G	cg05962755	chr5:157440814	NA	0.38	5.65	0.33	4.06e-8	IgG glycosylation;
CESC	cis	rs3096299	1.000	rs3096299	chr16:89448663	G/A	cg08822215	chr16:89438651	ANKRD11	-0.43	-6.58	-0.37	2.46e-10	Multiple myeloma (IgH translocation);
CESC	cis	rs1008375	0.932	rs4698627	chr4:17605959	T/C	cg27347728	chr4:17578864	LAP3	0.43	5.29	0.31	2.51e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	trans	rs17685	0.712	rs7778735	chr7:75770237	T/C	cg19862616	chr7:65841803	NCRNA00174	0.85	12.41	0.61	3.51e-28	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs11098499	0.954	rs10017543	chr4:120321420	G/A	cg09307838	chr4:120376055	NA	0.91	12.34	0.6	5.98e-28	Corneal astigmatism;
CESC	cis	rs9640161	0.742	rs2159236	chr7:150017214	A/G	cg21361702	chr7:150065534	REPIN1	0.57	6.72	0.38	1.1e-10	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs155076	1.000	rs261431	chr13:21865738	A/G	cg11317459	chr13:21872234	NA	1.05	12.46	0.61	2.33e-28	White matter hyperintensity burden;
CESC	cis	rs11583043	1.000	rs6682873	chr1:101470906	C/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.53	5.78	0.33	2.1e-8	Ulcerative colitis;Inflammatory bowel disease;
CESC	cis	rs1784581	0.802	rs2156747	chr6:162430000	C/G	cg17173639	chr6:162384350	PARK2	-0.63	-10.06	-0.53	2.2e-20	Itch intensity from mosquito bite;
CESC	cis	rs9457247	0.967	rs430145	chr6:167410369	C/T	cg25258033	chr6:167368657	RNASET2	0.4	6.14	0.35	2.93e-9	Crohn's disease;
CESC	cis	rs11098499	0.874	rs7661020	chr4:120106982	T/C	cg09307838	chr4:120376055	NA	0.67	8.17	0.45	1.26e-14	Corneal astigmatism;
CESC	cis	rs3820928	0.874	rs7605032	chr2:227847630	T/G	cg11843606	chr2:227700838	RHBDD1	-0.45	-5.83	-0.34	1.63e-8	Pulmonary function;
CESC	cis	rs367615	0.506	rs2963021	chr5:108800365	C/T	cg17395555	chr5:108820864	NA	0.56	9.53	0.51	1.04e-18	Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs1881797	0.932	rs2387038	chr1:247674919	G/A	cg18198730	chr1:247681584	NA	0.62	7.72	0.43	2.39e-13	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs17376456	0.690	rs6892055	chr5:93113023	A/T	cg25358565	chr5:93447407	FAM172A	1.07	10.4	0.54	1.79e-21	Diabetic retinopathy;
CESC	cis	rs8005677	0.828	rs57822749	chr14:23409967	G/A	cg01529538	chr14:23388837	RBM23	0.44	5.83	0.34	1.63e-8	Cognitive ability (multi-trait analysis);
CESC	cis	rs12893668	0.703	rs35026580	chr14:104042753	A/G	cg24130564	chr14:104152367	KLC1	-0.46	-5.62	-0.33	4.76e-8	Reticulocyte count;
CESC	cis	rs722599	0.683	rs8008475	chr14:75291900	C/T	cg08847533	chr14:75593920	NEK9	0.49	6.07	0.35	4.49e-9	IgG glycosylation;
CESC	cis	rs7818688	0.745	rs11779282	chr8:95945487	A/G	cg16049864	chr8:95962084	TP53INP1	0.54	5.33	0.31	2.14e-7	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs933688	1.000	rs2059208	chr5:90732065	A/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.92	12.4	0.61	3.9e-28	Smoking behavior;
CESC	cis	rs7772486	0.846	rs1854901	chr6:146325685	T/C	cg05347473	chr6:146136440	FBXO30	0.51	6.68	0.38	1.4e-10	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg18462168	chr15:22892545	CYFIP1	-0.43	-6.57	-0.37	2.58e-10	Gambling;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg18585642	chr15:75494022	C15orf39	-0.48	-6.02	-0.35	5.76e-9	Ulcerative colitis;
CESC	cis	rs9302635	0.513	rs8050238	chr16:72154187	C/T	cg01557791	chr16:72042693	DHODH	-0.56	-6.48	-0.37	4.4e-10	Blood protein levels;
CESC	cis	rs8031584	0.505	rs2959036	chr15:31219742	T/G	cg08109568	chr15:31115862	NA	0.68	9.49	0.5	1.38e-18	Huntington's disease progression;
CESC	cis	rs1953600	0.870	rs2245168	chr10:81921918	T/C	cg00277334	chr10:82204260	NA	-0.43	-5.99	-0.35	6.85e-9	Sarcoidosis;
CESC	trans	rs9467711	0.606	rs9379856	chr6:26366836	A/C	cg06606381	chr12:133084897	FBRSL1	-0.76	-6.82	-0.39	6.01e-11	Autism spectrum disorder or schizophrenia;
CESC	cis	rs2243480	1.000	rs56985706	chr7:65394562	C/T	cg13147721	chr7:65941812	NA	-0.83	-7.92	-0.44	6.77e-14	Diabetic kidney disease;
CESC	cis	rs172166	0.694	rs1770131	chr6:28086413	C/T	cg22143856	chr6:28129313	ZNF389	0.38	5.38	0.31	1.6e-7	Cardiac Troponin-T levels;
CESC	trans	rs1667255	0.830	rs2034404	chr18:29156302	A/G	cg11000221	chr17:57643293	DHX40	0.49	6.26	0.36	1.55e-9	Retinol levels;
CESC	cis	rs12586317	0.576	rs12586302	chr14:35691074	G/C	cg16230307	chr14:35515116	FAM177A1	0.42	5.22	0.31	3.57e-7	Psoriasis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14094333	chr4:38666051	KLF3;FLJ13197	0.64	8.1	0.45	1.97e-14	Gut microbiome composition (summer);
CESC	cis	rs2836633	0.929	rs8130434	chr21:40036243	C/T	cg12884169	chr21:40033163	ERG	-0.4	-6.41	-0.37	6.51e-10	Coronary artery disease;
CESC	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg26354017	chr1:205819088	PM20D1	0.76	11.09	0.56	1.03e-23	Menarche (age at onset);
CESC	cis	rs12618769	0.597	rs3769729	chr2:99102810	T/C	cg10123293	chr2:99228465	UNC50	0.41	5.44	0.32	1.24e-7	Bipolar disorder;
CESC	cis	rs11785400	1.000	rs4484678	chr8:143730796	A/G	cg24634471	chr8:143751801	JRK	0.45	5.89	0.34	1.15e-8	Schizophrenia;
CESC	cis	rs6942407	0.546	rs7780698	chr7:86835731	T/G	cg02420886	chr7:86849541	C7orf23	0.57	5.11	0.3	6.32e-7	Food allergy;
CESC	cis	rs6736093	1.000	rs1967530	chr2:112659512	A/T	cg12686935	chr2:112915763	FBLN7	-0.42	-5.17	-0.3	4.56e-7	Coronary artery disease;
CESC	cis	rs9611565	0.921	rs5751080	chr22:41736267	A/G	cg06481639	chr22:41940642	POLR3H	-0.45	-5.21	-0.3	3.78e-7	Vitiligo;
CESC	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg10150615	chr22:24372951	LOC391322	-0.58	-8.04	-0.44	2.95e-14	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs7618501	0.521	rs868891	chr3:49949071	A/G	cg24110177	chr3:50126178	RBM5	-0.52	-7.12	-0.4	1.04e-11	Intelligence (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19349143	chr22:47189686	TBC1D22A	-0.55	-6.39	-0.37	7.28e-10	Gut microbiome composition (summer);
CESC	cis	rs801193	1.000	rs2659909	chr7:66160279	G/A	cg14393609	chr7:65229607	NA	0.46	6.06	0.35	4.71e-9	Aortic root size;
CESC	cis	rs28647808	1.000	rs4962141	chr9:136274478	T/C	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.9	5.73	0.33	2.75e-8	Blood protein levels;
CESC	cis	rs2000999	0.514	rs17604662	chr16:72221464	A/G	cg04254540	chr16:71951199	KIAA0174	-0.67	-5.83	-0.34	1.58e-8	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
CESC	cis	rs72901758	0.768	rs11655421	chr17:76251518	T/A	cg23302638	chr17:76210176	BIRC5	0.47	5.06	0.3	7.71e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
CESC	cis	rs599083	0.530	rs576118	chr11:68177708	C/T	cg01657329	chr11:68192670	LRP5	0.44	5.29	0.31	2.57e-7	Bone mineral density (spine);
CESC	cis	rs151234	0.565	rs9924471	chr16:28591530	G/A	cg01378222	chr16:28622494	SULT1A1	-0.49	-7.59	-0.42	5.35e-13	Platelet distribution width;
CESC	cis	rs4563143	0.675	rs56322221	chr19:29270349	A/T	cg12756686	chr19:29218302	NA	0.58	7.52	0.42	8.38e-13	Methadone dose in opioid dependence;
CESC	cis	rs8072100	0.875	rs9635762	chr17:45648446	A/C	cg08085267	chr17:45401833	C17orf57	0.4	5.16	0.3	4.87e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	trans	rs7107217	1.000	rs1873872	chr11:129473993	A/T	cg19947233	chr4:90032727	TIGD2	0.54	6.91	0.39	3.51e-11	Breast cancer;Type 2 diabetes;
CESC	cis	rs6782228	1.000	rs6782407	chr3:128338748	T/C	cg15607142	chr3:128420513	NA	-0.38	-5.09	-0.3	6.84e-7	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
CESC	cis	rs67311347	1.000	rs4246666	chr3:40407670	C/T	cg24209194	chr3:40518798	ZNF619	0.46	6.03	0.35	5.43e-9	Renal cell carcinoma;
CESC	cis	rs68170813	0.521	rs61673847	chr7:106892431	A/G	cg02696742	chr7:106810147	HBP1	-0.52	-5.08	-0.3	7.2e-7	Coronary artery disease;
CESC	cis	rs6089829	0.962	rs6062780	chr20:61666648	T/C	cg08564027	chr20:61660810	NA	0.9	15.37	0.69	1.54e-38	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs9479482	0.967	rs13209192	chr6:150350099	A/G	cg03788504	chr6:150331562	NA	-0.3	-5.79	-0.33	2.01e-8	Alopecia areata;
CESC	cis	rs9457247	0.967	rs430145	chr6:167410369	C/T	cg07741184	chr6:167504864	NA	0.3	5.52	0.32	8.06e-8	Crohn's disease;
CESC	cis	rs11098499	0.779	rs7356491	chr4:120381974	C/T	cg09307838	chr4:120376055	NA	0.96	13.95	0.65	1.6e-33	Corneal astigmatism;
CESC	cis	rs854765	0.583	rs4413022	chr17:17858280	G/C	cg04398451	chr17:18023971	MYO15A	-0.69	-9.86	-0.52	9.76e-20	Total body bone mineral density;
CESC	cis	rs2732480	0.577	rs2450994	chr12:48721832	G/A	cg04545296	chr12:48745243	ZNF641	0.36	6.27	0.36	1.49e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs9916302	0.800	rs11869259	chr17:37518141	C/A	cg19468946	chr17:37922297	IKZF3	0.4	5.17	0.3	4.69e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs7605827	0.897	rs6729018	chr2:15540676	A/G	cg19274914	chr2:15703543	NA	0.36	6.4	0.37	7.05e-10	Educational attainment (years of education);
CESC	cis	rs853679	0.517	rs2275508	chr6:28094731	T/C	cg20151795	chr6:28129481	ZNF389	0.48	6.41	0.37	6.55e-10	Depression;
CESC	trans	rs877282	0.853	rs4579862	chr10:753298	A/C	cg22713356	chr15:30763199	NA	0.92	8.28	0.45	5.95e-15	Uric acid levels;
CESC	trans	rs722599	0.748	rs2537824	chr14:75367349	T/C	cg00095594	chr1:236228625	NID1	-0.4	-6.17	-0.35	2.6e-9	IgG glycosylation;
CESC	cis	rs9733	0.621	rs12746899	chr1:150579678	A/T	cg18016565	chr1:150552671	MCL1	-0.42	-6.84	-0.39	5.45e-11	Tonsillectomy;
CESC	cis	rs7666738	1.000	rs13124102	chr4:98990696	G/A	cg05340658	chr4:99064831	C4orf37	0.66	9.01	0.48	4.1e-17	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4974559	0.947	rs6847321	chr4:1347374	C/T	cg02980000	chr4:1222292	CTBP1	0.66	6.63	0.38	1.88e-10	Systolic blood pressure;
CESC	cis	rs7216064	1.000	rs6504549	chr17:65888784	A/G	cg12091567	chr17:66097778	LOC651250	-0.83	-9.57	-0.51	8.04e-19	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs7552404	0.883	rs11161493	chr1:76206254	T/A	cg10523679	chr1:76189770	ACADM	0.8	11.03	0.56	1.58e-23	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs7811142	0.943	rs28660238	chr7:100023308	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.84	8.94	0.48	6.94e-17	Platelet count;
CESC	cis	rs7116495	0.609	rs2155145	chr11:71719619	G/T	cg18441811	chr11:71824068	C11orf51	-0.81	-5.37	-0.31	1.74e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs1707322	0.721	rs9793568	chr1:46130373	G/A	cg05343316	chr1:45956843	TESK2	0.5	6.12	0.35	3.43e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs10845606	1.000	rs10845605	chr12:12833468	T/C	cg09462578	chr12:12878428	APOLD1	-0.64	-7.0	-0.39	2.15e-11	Systemic lupus erythematosus;
CESC	cis	rs12477438	0.822	rs6727170	chr2:99588042	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.6	-7.4	-0.41	1.81e-12	Chronic sinus infection;
CESC	trans	rs2898290	0.500	rs11998678	chr8:11830150	A/G	cg06636001	chr8:8085503	FLJ10661	-0.55	-6.58	-0.37	2.44e-10	Systolic blood pressure;
CESC	cis	rs782590	0.620	rs7596377	chr2:55888612	T/A	cg18811423	chr2:55921094	PNPT1	-0.68	-10.2	-0.53	8.21e-21	Metabolic syndrome;
CESC	cis	rs477895	0.713	rs882146	chr11:63976699	G/A	cg18225595	chr11:63971243	STIP1	0.51	5.06	0.3	7.82e-7	Mean platelet volume;
CESC	cis	rs1211375	0.607	rs1203978	chr16:257211	A/C	cg00126636	chr16:237282	NA	0.44	6.65	0.38	1.63e-10	Hematology traits;Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	cis	rs1961456	0.542	rs75501607	chr8:18244753	C/T	cg18736775	chr8:18248649	NAT2	-0.47	-5.35	-0.31	1.89e-7	Total cholesterol levels;
CESC	cis	rs780096	0.526	rs11127013	chr2:27692973	A/G	cg22903471	chr2:27725779	GCKR	-0.55	-7.77	-0.43	1.69e-13	Total body bone mineral density;
CESC	cis	rs7267979	1.000	rs6083825	chr20:25366424	T/C	cg08601574	chr20:25228251	PYGB	-0.38	-5.55	-0.32	6.88e-8	Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs1728785	0.688	rs698718	chr16:68560185	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.61	7.45	0.42	1.32e-12	Ulcerative colitis;
CESC	cis	rs6484504	0.532	rs7116443	chr11:31283170	T/C	cg14844989	chr11:31128820	NA	-0.4	-5.54	-0.32	7.13e-8	Red blood cell count;
CESC	cis	rs9916302	0.851	rs12936996	chr17:37665554	A/G	cg00129232	chr17:37814104	STARD3	0.5	6.59	0.38	2.42e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs9311474	0.507	rs6787154	chr3:52784416	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.59	0.38	2.4e-10	Electroencephalogram traits;
CESC	cis	rs172166	0.637	rs1233691	chr6:28153897	T/G	cg26335602	chr6:28129616	ZNF389	0.37	5.46	0.32	1.09e-7	Cardiac Troponin-T levels;
CESC	cis	rs769267	1.000	rs8103197	chr19:19443466	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.64	-8.44	-0.46	2.15e-15	Tonsillectomy;
CESC	cis	rs514406	0.683	rs10157120	chr1:53210888	A/G	cg08859206	chr1:53392774	SCP2	-0.55	-6.95	-0.39	2.88e-11	Monocyte count;
CESC	cis	rs11098499	0.863	rs7695620	chr4:120452776	G/A	cg24375607	chr4:120327624	NA	0.43	5.21	0.3	3.82e-7	Corneal astigmatism;
CESC	cis	rs7587476	0.784	rs17424051	chr2:215688992	G/C	cg04004882	chr2:215674386	BARD1	0.53	5.83	0.34	1.61e-8	Neuroblastoma;
CESC	cis	rs4253772	0.938	rs11704979	chr22:46632994	G/A	cg18190219	chr22:46762943	CELSR1	-0.61	-5.84	-0.34	1.52e-8	LDL cholesterol;Cholesterol, total;
CESC	trans	rs11098499	0.863	rs6833334	chr4:120504227	C/T	cg25214090	chr10:38739885	LOC399744	0.66	8.85	0.48	1.28e-16	Corneal astigmatism;
CESC	cis	rs898097	0.783	rs11650335	chr17:80835111	A/G	cg05255149	chr17:80675120	FN3KRP	-0.47	-5.42	-0.32	1.37e-7	Breast cancer;
CESC	cis	rs10492096	0.947	rs11064231	chr12:6604415	T/G	cg13857086	chr12:6580257	VAMP1	0.61	6.14	0.35	3.03e-9	Hip geometry;
CESC	cis	rs798554	0.836	rs798500	chr7:2790685	C/T	cg18446336	chr7:2847575	GNA12	0.38	5.86	0.34	1.4e-8	Height;
CESC	cis	rs6495122	0.644	rs62029217	chr15:75261899	C/T	cg17294928	chr15:75287854	SCAMP5	0.49	6.17	0.35	2.54e-9	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
CESC	cis	rs7903847	0.602	rs7916665	chr10:99157573	T/G	cg20016023	chr10:99160130	RRP12	-0.3	-5.14	-0.3	5.27e-7	Granulocyte percentage of myeloid white cells;
CESC	cis	rs2282802	0.711	rs3777095	chr5:139660916	G/A	cg26211634	chr5:139558579	C5orf32	0.51	7.42	0.41	1.55e-12	Intelligence (multi-trait analysis);
CESC	cis	rs11867934	0.532	rs7218795	chr17:17115566	A/G	cg20098446	chr17:17120238	FLCN	0.39	6.03	0.35	5.37e-9	Diabetic retinopathy;
CESC	cis	rs1552244	1.000	rs6791810	chr3:10124444	A/G	cg08888203	chr3:10149979	C3orf24	-0.46	-6.18	-0.35	2.41e-9	Alzheimer's disease;
CESC	cis	rs1568889	0.641	rs34857148	chr11:28481976	T/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.53	5.27	0.31	2.82e-7	Bipolar disorder;
CESC	cis	rs13108904	0.901	rs1316393	chr4:1315619	A/G	cg00684032	chr4:1343700	KIAA1530	-0.47	-6.8	-0.39	6.74e-11	Obesity-related traits;
CESC	cis	rs801193	1.000	rs1553609	chr7:66197139	T/C	cg18876405	chr7:65276391	NA	0.53	7.06	0.4	1.42e-11	Aortic root size;
CESC	cis	rs6459788	0.585	rs6950818	chr7:157235364	C/G	cg06271696	chr7:157225062	NA	-0.44	-7.46	-0.42	1.23e-12	Epstein-Barr virus copy number in lymphoblastoid cell lines;
CESC	trans	rs7618501	1.000	rs9855505	chr3:49792158	T/G	cg21659725	chr3:3221576	CRBN	-0.83	-13.35	-0.63	1.98e-31	Intelligence (multi-trait analysis);
CESC	cis	rs2066819	1.000	rs2371454	chr12:56647243	A/G	cg26714650	chr12:56694279	CS	1.52	10.39	0.54	1.95e-21	Psoriasis vulgaris;
CESC	cis	rs1665050	0.534	rs11858479	chr15:59242706	G/A	cg05156742	chr15:59063176	FAM63B	0.49	6.19	0.36	2.33e-9	Atopic dermatitis;
CESC	cis	rs7301826	0.610	rs4759789	chr12:131296380	A/C	cg11011512	chr12:131303247	STX2	0.47	5.84	0.34	1.49e-8	Plasma plasminogen activator levels;
CESC	cis	rs10208940	0.920	rs34366735	chr2:68771995	A/G	cg12452813	chr2:68675892	NA	0.51	5.11	0.3	6.17e-7	Urate levels in lean individuals;
CESC	cis	rs1670533	0.932	rs6599276	chr4:1056827	T/C	cg27284194	chr4:1044797	NA	0.48	6.0	0.35	6.44e-9	Recombination rate (females);
CESC	trans	rs561341	1.000	rs542132	chr17:30307193	A/T	cg20587970	chr11:113659929	NA	-1.41	-18.23	-0.75	1.08e-48	Hip circumference adjusted for BMI;
CESC	cis	rs2836974	0.965	rs34578707	chr21:40675167	G/A	cg11890956	chr21:40555474	PSMG1	1.11	17.58	0.73	2.21e-46	Cognitive function;
CESC	cis	rs17433780	0.964	rs12121223	chr1:89481583	C/T	cg09516651	chr1:89888402	LOC400759	0.67	9.07	0.49	2.69e-17	Carotid intima media thickness;
CESC	cis	rs977987	0.835	rs7200616	chr16:75366089	G/A	cg03315344	chr16:75512273	CHST6	0.39	5.52	0.32	7.99e-8	Dupuytren's disease;
CESC	cis	rs7223966	1.000	rs112143304	chr17:61822401	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.5	5.17	0.3	4.67e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs10129255	0.957	rs12589190	chr14:107191316	C/T	cg07958169	chr14:107095056	NA	-0.4	-5.51	-0.32	8.54e-8	Kawasaki disease;
CESC	cis	rs60871478	0.838	rs7789321	chr7:800977	A/G	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.63	6.1	0.35	3.75e-9	Cerebrospinal P-tau181p levels;
CESC	cis	rs7811142	0.945	rs6955362	chr7:100056166	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.0	9.6	0.51	6.43e-19	Platelet count;
CESC	cis	rs9796	0.558	rs8043253	chr15:41503730	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.47	-6.94	-0.39	2.93e-11	Menopause (age at onset);
CESC	cis	rs7412746	0.611	rs10888391	chr1:150729983	G/A	cg17724175	chr1:150552817	MCL1	0.42	6.42	0.37	6.31e-10	Melanoma;
CESC	cis	rs13191362	1.000	rs34594856	chr6:163051845	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.84	9.0	0.48	4.4e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg09060823	chr12:56862504	SPRYD4	-0.45	-6.4	-0.37	7.2e-10	Gambling;
CESC	cis	rs6120849	0.951	rs6120848	chr20:33728678	T/C	cg24642439	chr20:33292090	TP53INP2	0.65	6.77	0.38	8.37e-11	Protein C levels;
CESC	cis	rs3862260	0.509	rs7552885	chr1:120164966	C/T	cg16322792	chr1:120165303	ZNF697	0.58	10.95	0.56	2.82e-23	Systemic lupus erythematosus;
CESC	cis	rs72945132	0.825	rs72947052	chr11:70188575	A/G	cg14191688	chr11:70257035	CTTN	0.57	6.33	0.36	1.02e-9	Coronary artery disease;
CESC	cis	rs2635047	0.777	rs9944807	chr18:44788908	A/G	cg24371990	chr18:44770781	NA	0.42	6.57	0.37	2.61e-10	Educational attainment;
CESC	cis	rs5758659	0.652	rs1063392	chr22:42454950	C/T	cg15557168	chr22:42548783	NA	0.47	7.51	0.42	9.02e-13	Cognitive function;
CESC	cis	rs2011503	0.941	rs72999063	chr19:19380596	G/T	cg11584989	chr19:19387371	SF4	0.6	7.21	0.4	5.96e-12	Bipolar disorder;
CESC	cis	rs546131	0.820	rs744841	chr11:34857667	G/A	cg22717608	chr11:34937665	PDHX;APIP	-0.42	-5.31	-0.31	2.35e-7	Lung disease severity in cystic fibrosis;
CESC	cis	rs4789693	1.000	rs4789693	chr17:80421870	A/C	cg04308225	chr17:80449738	NA	0.43	5.12	0.3	5.88e-7	Glucocorticoid-induced osteonecrosis;
CESC	cis	rs10751667	0.600	rs14346	chr11:1011829	T/C	cg01483505	chr11:975446	AP2A2	0.42	5.4	0.31	1.51e-7	Alzheimer's disease (late onset);
CESC	cis	rs9287719	0.967	rs6748036	chr2:10717489	C/T	cg02196655	chr2:10830764	NOL10	-0.36	-5.63	-0.33	4.61e-8	Prostate cancer;
CESC	cis	rs13223928	0.605	rs10951052	chr7:3155301	A/G	cg19214707	chr7:3157722	NA	-0.38	-5.17	-0.3	4.69e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
CESC	cis	rs853679	0.550	rs1225598	chr6:28160799	T/G	cg19592336	chr6:28129416	ZNF389	0.51	6.86	0.39	4.96e-11	Depression;
CESC	cis	rs72781680	1.000	rs72781631	chr2:24195064	G/A	cg08917208	chr2:24149416	ATAD2B	0.94	8.73	0.47	2.91e-16	Lymphocyte counts;
CESC	cis	rs8103278	0.507	rs10401971	chr19:46261982	C/T	cg12641515	chr19:46296257	DMWD	0.74	9.95	0.52	4.96e-20	Coronary artery disease;
CESC	cis	rs1552244	1.000	rs55882090	chr3:10139082	C/T	cg00149659	chr3:10157352	C3orf10	0.72	9.04	0.49	3.45e-17	Alzheimer's disease;
CESC	cis	rs4423214	1.000	rs12278461	chr11:71182185	C/T	cg24826892	chr11:71159390	DHCR7	0.46	5.24	0.31	3.33e-7	Vitamin D levels;
CESC	trans	rs12356475	0.710	rs10822686	chr10:67733250	C/T	cg13683516	chr12:56618066	OBFC2B	0.53	6.18	0.35	2.41e-9	Psoriatic arthritis;
CESC	cis	rs769267	0.896	rs11882123	chr19:19386339	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.43	5.33	0.31	2.11e-7	Tonsillectomy;
CESC	cis	rs9910055	0.639	rs11656871	chr17:42269141	G/C	cg13607699	chr17:42295918	UBTF	0.58	7.4	0.41	1.76e-12	Total body bone mineral density;
CESC	cis	rs9811920	0.809	rs793464	chr3:99626028	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.43	5.64	0.33	4.43e-8	Axial length;
CESC	cis	rs9926296	0.542	rs12599531	chr16:89909401	C/T	cg03605463	chr16:89740564	NA	0.46	5.24	0.31	3.35e-7	Vitiligo;
CESC	cis	rs2180341	1.000	rs2038378	chr6:127590400	C/T	cg27446573	chr6:127587934	RNF146	1.07	15.89	0.7	2.11e-40	Breast cancer;
CESC	cis	rs3820068	0.581	rs61056912	chr1:15926296	A/G	cg13390004	chr1:15929781	NA	0.34	5.45	0.32	1.13e-7	Systolic blood pressure;
CESC	cis	rs5750830	0.594	rs9611169	chr22:39783027	C/T	cg01416388	chr22:39784598	NA	-0.55	-7.1	-0.4	1.17e-11	Intelligence (multi-trait analysis);
CESC	cis	rs11792861	0.926	rs72607172	chr9:111876523	A/G	cg13535736	chr9:111863775	C9orf5	-0.5	-6.65	-0.38	1.64e-10	Menarche (age at onset);
CESC	cis	rs10256972	0.621	rs2280725	chr7:1087426	G/T	cg04025307	chr7:1156635	C7orf50	0.45	7.44	0.42	1.41e-12	Longevity;Endometriosis;
CESC	cis	rs4474465	0.688	rs7124803	chr11:78280822	T/G	cg27205649	chr11:78285834	NARS2	0.53	7.17	0.4	7.43e-12	Alzheimer's disease (survival time);
CESC	cis	rs10752881	0.935	rs4652771	chr1:183023503	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.87	13.5	0.64	6.03e-32	Colorectal cancer;
CESC	cis	rs3771570	1.000	rs62186422	chr2:242249499	A/G	cg21155796	chr2:242212141	HDLBP	0.61	5.29	0.31	2.55e-7	Prostate cancer;
CESC	cis	rs56399783	0.901	rs73049327	chr7:2795544	T/G	cg19731401	chr7:2775893	GNA12	0.63	5.82	0.34	1.69e-8	Childhood ear infection;
CESC	cis	rs4722585	0.605	rs3753098	chr7:26198040	C/T	cg07876897	chr7:26191696	NFE2L3	-0.48	-6.01	-0.35	6.19e-9	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
CESC	cis	rs7100689	0.784	rs7081903	chr10:82162509	T/C	cg00277334	chr10:82204260	NA	-0.59	-7.32	-0.41	3.05e-12	Post bronchodilator FEV1;
CESC	cis	rs6860806	0.661	rs4705927	chr5:131578608	C/G	cg18301423	chr5:131593218	PDLIM4	0.38	5.41	0.32	1.4e-7	Breast cancer;
CESC	cis	rs2576037	0.523	rs1539881	chr18:44477897	C/T	cg19077165	chr18:44547161	KATNAL2	-0.62	-9.56	-0.51	8.74e-19	Personality dimensions;
CESC	cis	rs13118159	0.550	rs4974617	chr4:1373658	T/C	cg01939980	chr4:1354348	KIAA1530	0.44	5.26	0.31	2.9e-7	Longevity;
CESC	cis	rs2228479	0.850	rs17233664	chr16:89810628	C/T	cg04013166	chr16:89971882	TCF25	0.77	6.69	0.38	1.32e-10	Skin colour saturation;
CESC	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg05552183	chr6:42928497	GNMT	0.75	11.48	0.58	4.79e-25	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs7551222	0.752	rs12138846	chr1:204556478	T/A	cg20240347	chr1:204465584	NA	-0.29	-5.97	-0.34	7.54e-9	Schizophrenia;
CESC	cis	rs4523957	0.928	rs441750	chr17:2190767	T/C	cg16513277	chr17:2031491	SMG6	0.59	8.07	0.44	2.51e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs7568498	0.517	rs197261	chr2:161904823	A/G	cg21518248	chr2:162101506	NA	-0.49	-5.14	-0.3	5.45e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);
CESC	cis	rs4481887	0.861	rs4575112	chr1:248473534	A/G	cg00666640	chr1:248458726	OR2T12	0.35	5.93	0.34	9.43e-9	Common traits (Other);
CESC	cis	rs10751667	0.621	rs10794351	chr11:946228	C/T	cg06064525	chr11:970664	AP2A2	-0.49	-9.76	-0.51	2.01e-19	Alzheimer's disease (late onset);
CESC	cis	rs514406	0.505	rs6688064	chr1:53165609	C/T	cg08736216	chr1:53307985	ZYG11A	-0.39	-6.36	-0.36	8.73e-10	Monocyte count;
CESC	cis	rs61931739	0.534	rs28548399	chr12:34188151	G/A	cg19457237	chr12:34500585	NA	-0.39	-5.39	-0.31	1.53e-7	Morning vs. evening chronotype;
CESC	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg12419862	chr22:24373484	LOC391322	-0.87	-13.03	-0.62	2.47e-30	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs1729951	0.575	rs361242	chr3:136698330	C/G	cg25687071	chr3:136751404	NA	0.41	5.37	0.31	1.68e-7	Neuroticism;
CESC	cis	rs4665809	0.877	rs34536218	chr2:26287376	T/A	cg25036284	chr2:26402008	FAM59B	0.67	7.28	0.41	3.75e-12	Gut microbiome composition (summer);
CESC	cis	rs11190604	1.000	rs11190587	chr10:102266638	C/T	cg07080220	chr10:102295463	HIF1AN	0.62	5.63	0.33	4.62e-8	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs1018836	0.923	rs7007102	chr8:91629730	T/A	cg16814680	chr8:91681699	NA	-0.72	-9.95	-0.52	4.95e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs853679	0.599	rs202906	chr6:28011652	C/T	cg23372001	chr6:27791640	HIST1H4J	-0.62	-5.1	-0.3	6.6e-7	Depression;
CESC	cis	rs9435341	0.929	rs1730865	chr1:107605611	A/C	cg09367891	chr1:107599246	PRMT6	0.67	8.13	0.45	1.64e-14	Facial morphology (factor 21, depth of nasal alae);
CESC	cis	rs2440129	0.611	rs11571335	chr17:6904263	C/T	cg03404566	chr17:6899310	ALOX12	0.38	6.41	0.37	6.71e-10	Tonsillectomy;
CESC	cis	rs7605827	0.930	rs2058866	chr2:15519992	G/T	cg19274914	chr2:15703543	NA	0.35	6.27	0.36	1.43e-9	Educational attainment (years of education);
CESC	cis	rs1005277	0.589	rs2749624	chr10:38529865	A/G	cg00409905	chr10:38381863	ZNF37A	-0.51	-6.84	-0.39	5.62e-11	Extrinsic epigenetic age acceleration;
CESC	cis	rs9916302	0.861	rs11078913	chr17:37671714	G/T	cg20243544	chr17:37824526	PNMT	0.45	5.68	0.33	3.61e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs8141529	0.732	rs2347447	chr22:29179739	C/A	cg02153584	chr22:29168773	CCDC117	0.69	9.89	0.52	7.6e-20	Lymphocyte counts;
CESC	cis	rs9399137	0.507	rs6940258	chr6:135366132	C/T	cg22676075	chr6:135203613	NA	0.53	7.14	0.4	9.06e-12	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	cis	rs7100689	0.646	rs10736347	chr10:82134465	G/A	cg00277334	chr10:82204260	NA	-0.57	-7.51	-0.42	9.08e-13	Post bronchodilator FEV1;
CESC	cis	rs10504229	0.511	rs16921553	chr8:57979314	T/C	cg24829409	chr8:58192753	C8orf71	-0.55	-6.24	-0.36	1.74e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs7818688	0.697	rs112076731	chr8:95978121	C/G	cg16049864	chr8:95962084	TP53INP1	0.57	5.73	0.33	2.79e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs367943	1.000	rs168366	chr5:112818587	C/T	cg12552261	chr5:112820674	MCC	0.64	8.14	0.45	1.55e-14	Type 2 diabetes;
CESC	cis	rs2832191	0.655	rs2247110	chr21:30323888	G/A	cg24692254	chr21:30365293	RNF160	-0.99	-17.3	-0.73	2.13e-45	Dental caries;
CESC	cis	rs798554	0.759	rs2644309	chr7:2889034	T/C	cg04166393	chr7:2884313	GNA12	0.6	7.7	0.43	2.75e-13	Height;
CESC	cis	rs9486715	0.867	rs2223238	chr6:96871855	G/A	cg18709589	chr6:96969512	KIAA0776	0.45	6.42	0.37	6.42e-10	Headache;
CESC	cis	rs1448094	0.533	rs2169572	chr12:86170370	G/T	cg02569458	chr12:86230093	RASSF9	-0.5	-7.23	-0.41	5.12e-12	Major depressive disorder;
CESC	cis	rs644799	0.544	rs498553	chr11:95534441	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.57	7.57	0.42	6.3e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs3126085	0.877	rs3126055	chr1:152266364	G/A	cg03465714	chr1:152285911	FLG	0.48	5.94	0.34	9.06e-9	Atopic dermatitis;
CESC	cis	rs57506017	0.585	rs11509153	chr7:12263800	G/A	cg23422036	chr7:12250390	TMEM106B	0.39	5.23	0.31	3.47e-7	Neuroticism;
CESC	cis	rs801193	1.000	rs3778909	chr7:66255646	G/C	cg18876405	chr7:65276391	NA	0.56	7.48	0.42	1.06e-12	Aortic root size;
CESC	trans	rs561341	0.883	rs7219239	chr17:30212016	A/G	cg20587970	chr11:113659929	NA	0.99	11.71	0.58	8.33e-26	Hip circumference adjusted for BMI;
CESC	cis	rs1448094	0.817	rs12370270	chr12:86343303	T/G	cg02569458	chr12:86230093	RASSF9	0.41	5.9	0.34	1.12e-8	Major depressive disorder;
CESC	cis	rs9943753	0.508	rs2075433	chr12:109833920	A/G	cg19025524	chr12:109796872	NA	-0.47	-6.66	-0.38	1.61e-10	HDL cholesterol;
CESC	cis	rs559928	0.606	rs61083753	chr11:63892665	C/T	cg18225595	chr11:63971243	STIP1	0.66	6.6	0.38	2.24e-10	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CESC	cis	rs4555082	0.834	rs4412909	chr14:105759226	T/C	cg06808227	chr14:105710500	BRF1	-0.56	-6.42	-0.37	6.43e-10	Mean platelet volume;Platelet distribution width;
CESC	cis	rs459571	0.920	rs2520094	chr9:136919985	A/T	cg13789015	chr9:136890014	NCRNA00094	0.53	7.43	0.42	1.52e-12	Platelet distribution width;
CESC	cis	rs2404602	0.716	rs12594577	chr15:76828793	A/C	cg22467129	chr15:76604101	ETFA	-0.38	-5.7	-0.33	3.15e-8	Blood metabolite levels;
CESC	cis	rs6815814	0.950	rs114719937	chr4:38808585	G/C	cg02016764	chr4:38805732	TLR1	-0.63	-7.26	-0.41	4.22e-12	Breast cancer;
CESC	cis	rs9611519	1.000	rs6002271	chr22:41566595	C/T	cg03806693	chr22:41940476	POLR3H	-0.57	-5.84	-0.34	1.56e-8	Neuroticism;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23063716	chr15:75743999	SIN3A	0.52	6.23	0.36	1.78e-9	Gut microbiome composition (summer);
CESC	cis	rs9467711	0.606	rs9357006	chr6:26364628	A/C	cg14345882	chr6:26364793	BTN3A2	0.62	6.53	0.37	3.29e-10	Autism spectrum disorder or schizophrenia;
CESC	cis	rs1707322	0.721	rs10890336	chr1:46111056	C/T	cg03146154	chr1:46216737	IPP	0.82	11.49	0.58	4.71e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs7615952	0.673	rs9821905	chr3:125620850	A/G	cg07211511	chr3:129823064	LOC729375	0.8	7.96	0.44	4.92e-14	Blood pressure (smoking interaction);
CESC	cis	rs4076764	0.914	rs6689760	chr1:163358704	A/G	cg06092702	chr1:163392909	NA	0.4	5.94	0.34	9.03e-9	Motion sickness;
CESC	cis	rs1003719	0.762	rs4399800	chr21:38489478	G/T	cg10648535	chr21:38446584	PIGP;TTC3	0.63	8.77	0.47	2.14e-16	Eye color traits;
CESC	cis	rs55692411	0.537	rs35375092	chr3:50065274	G/A	cg24308560	chr3:49941425	MST1R	-0.54	-6.64	-0.38	1.79e-10	Intelligence (multi-trait analysis);
CESC	cis	rs6060960	0.502	rs15817	chr20:30193538	A/G	cg13852791	chr20:30311386	BCL2L1	0.67	6.71	0.38	1.2e-10	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00789004	chr19:44143830	CADM4	0.64	7.03	0.4	1.8e-11	Gut microbiome composition (summer);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg08165151	chr6:88411075	NCRNA00120;AKIRIN2	-0.43	-6.08	-0.35	4.1e-9	Gambling;
CESC	cis	rs8177253	0.761	rs13079426	chr3:133522334	A/G	cg11941060	chr3:133502564	NA	-0.53	-7.18	-0.4	6.91e-12	Iron status biomarkers;
CESC	trans	rs17039065	0.920	rs7695026	chr4:109436476	G/A	cg27151770	chr16:49620536	ZNF423	-0.51	-6.21	-0.36	2.09e-9	Gut microbiome composition (summer);
CESC	cis	rs1030268	0.505	rs77112963	chr7:133259399	G/A	cg10665199	chr7:133106180	EXOC4	0.52	5.45	0.32	1.14e-7	Intelligence (multi-trait analysis);
CESC	cis	rs7666738	0.830	rs60994860	chr4:99046753	G/A	cg17366294	chr4:99064904	C4orf37	0.61	8.78	0.47	2.13e-16	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10777881	chr1:144044138	NA	-0.6	-6.33	-0.36	1.03e-9	Gut microbiome composition (summer);
CESC	cis	rs6938	0.563	rs12917376	chr15:75116167	C/T	cg17294928	chr15:75287854	SCAMP5	0.51	6.56	0.37	2.8e-10	Breast cancer;
CESC	cis	rs873946	0.586	rs3793685	chr10:134569316	G/A	cg27297192	chr10:134578999	INPP5A	0.4	5.13	0.3	5.72e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs4423214	0.819	rs7938885	chr11:71170043	T/C	cg05163923	chr11:71159392	DHCR7	0.83	11.29	0.57	2.17e-24	Vitamin D levels;
CESC	cis	rs6089829	1.000	rs6089828	chr20:61668998	C/T	cg16240275	chr20:61666158	NCRNA00029	0.47	8.2	0.45	1.06e-14	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs1055129	0.537	rs2467100	chr17:73949038	C/G	cg02678768	chr17:74002944	EVPL	0.4	5.56	0.32	6.56e-8	White matter hyperintensity burden;
CESC	cis	rs2404602	0.716	rs17362383	chr15:76650702	A/G	cg26408565	chr15:76604113	ETFA	-0.42	-6.19	-0.36	2.27e-9	Blood metabolite levels;
CESC	cis	rs9308433	0.569	rs1353718	chr1:214459652	A/T	cg06198575	chr1:214491504	SMYD2	0.44	5.17	0.3	4.56e-7	IgG glycosylation;
CESC	cis	rs10791323	0.604	rs2853115	chr11:133707908	C/T	cg15485101	chr11:133734466	NA	-0.39	-6.52	-0.37	3.63e-10	Childhood ear infection;
CESC	cis	rs1976403	0.633	rs1780324	chr1:21821757	A/G	cg21906605	chr1:21766650	NBPF3	0.39	5.08	0.3	7.07e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7605378	0.658	rs4673507	chr2:200710167	G/C	cg23649088	chr2:200775458	C2orf69	0.64	8.68	0.47	3.97e-16	Osteoporosis;
CESC	cis	rs672059	0.812	rs61418038	chr1:183155717	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.54	6.94	0.39	2.98e-11	Hypertriglyceridemia;
CESC	cis	rs4704187	0.687	rs6869345	chr5:74378742	C/T	cg03227963	chr5:74354835	NA	0.32	5.95	0.34	8.68e-9	Response to amphetamines;
CESC	cis	rs853679	0.546	rs200995	chr6:27813694	C/T	cg02228804	chr6:27775720	HIST1H2AI;HIST1H2BL	-0.66	-6.06	-0.35	4.53e-9	Depression;
CESC	cis	rs854765	0.583	rs4413022	chr17:17858280	G/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.57	8.07	0.44	2.47e-14	Total body bone mineral density;
CESC	trans	rs6460942	0.524	rs6948366	chr7:12369905	A/G	cg16269144	chr1:2003326	PRKCZ	0.54	6.53	0.37	3.39e-10	Coronary artery disease;
CESC	cis	rs10489525	0.599	rs7516121	chr1:115604317	A/G	cg12756093	chr1:115239321	AMPD1	-0.44	-5.29	-0.31	2.55e-7	Autism;
CESC	cis	rs6496667	0.509	rs57962570	chr15:90985596	C/G	cg10434728	chr15:90938212	IQGAP1	0.29	5.14	0.3	5.27e-7	Rheumatoid arthritis;
CESC	cis	rs28386778	0.700	rs11079515	chr17:62005645	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	-0.81	-11.44	-0.57	7.04e-25	Prudent dietary pattern;
CESC	cis	rs7264396	0.563	rs2425114	chr20:34322346	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.63	6.86	0.39	4.77e-11	Total cholesterol levels;
CESC	cis	rs863345	0.967	rs7550787	chr1:158469908	C/T	cg12129480	chr1:158549410	OR10X1	-0.31	-6.13	-0.35	3.19e-9	Pneumococcal bacteremia;
CESC	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg17330251	chr7:94953956	PON1	-0.66	-10.45	-0.54	1.26e-21	Paraoxonase activity;
CESC	cis	rs1400745	0.756	rs799682	chr14:35349984	G/C	cg16230307	chr14:35515116	FAM177A1	0.44	5.24	0.31	3.23e-7	Monocyte count;
CESC	trans	rs1814175	0.676	rs11040647	chr11:49935947	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.43	-6.36	-0.36	8.98e-10	Height;
CESC	cis	rs12971120	1.000	rs12971120	chr18:72174023	A/G	cg25817165	chr18:72167213	CNDP2	-0.63	-8.05	-0.44	2.8e-14	Refractive error;
CESC	cis	rs8060686	0.841	rs73594554	chr16:67920049	G/A	cg26727032	chr16:67993705	SLC12A4	-0.57	-6.49	-0.37	4.28e-10	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs4975616	0.869	rs467095	chr5:1336221	T/C	cg26373071	chr5:1325741	CLPTM1L	0.41	6.43	0.37	5.91e-10	Lung cancer;
CESC	cis	rs7618915	0.501	rs7611731	chr3:52692721	T/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	5.85	0.34	1.46e-8	Bipolar disorder;
CESC	cis	rs9362426	0.672	rs12663865	chr6:88103149	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.48	5.62	0.33	4.82e-8	Depressive episodes in bipolar disorder;
CESC	cis	rs4660306	1.000	rs2077808	chr1:45988115	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.61	-7.72	-0.43	2.33e-13	Homocysteine levels;
CESC	cis	rs1862618	0.641	rs252893	chr5:56224714	T/C	cg24531977	chr5:56204891	C5orf35	-0.68	-9.3	-0.5	5.4e-18	Initial pursuit acceleration;
CESC	cis	rs3096299	0.658	rs4291902	chr16:89560315	G/C	cg08392591	chr16:89556376	ANKRD11	0.59	8.03	0.44	3.27e-14	Multiple myeloma (IgH translocation);
CESC	cis	rs9815354	0.767	rs73087378	chr3:41936827	G/A	cg03022575	chr3:42003672	ULK4	0.71	6.44	0.37	5.46e-10	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs35849525	0.814	rs7635601	chr3:50044006	A/T	cg24308560	chr3:49941425	MST1R	-0.52	-6.59	-0.38	2.32e-10	Intelligence (multi-trait analysis);
CESC	cis	rs2592394	0.675	rs711819	chr2:176985696	C/T	cg13092806	chr2:177043255	NA	-0.48	-5.45	-0.32	1.15e-7	Magnesium levels;Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs12136530	0.550	rs3790768	chr1:19698501	G/T	cg01832549	chr1:19774989	CAPZB	-0.42	-5.41	-0.32	1.44e-7	Lead levels in blood;
CESC	cis	rs2952156	0.920	rs2517951	chr17:37853097	C/T	cg00129232	chr17:37814104	STARD3	-0.78	-11.12	-0.56	8.06e-24	Asthma;
CESC	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	22.04	0.8	7.1e-62	Prudent dietary pattern;
CESC	cis	rs3741404	0.583	rs640999	chr11:63869425	C/A	cg18225595	chr11:63971243	STIP1	0.51	6.7	0.38	1.24e-10	Platelet count;
CESC	cis	rs2228479	0.850	rs11642010	chr16:89845111	T/C	cg00800038	chr16:89945340	TCF25	-0.96	-7.49	-0.42	9.97e-13	Skin colour saturation;
CESC	cis	rs796364	0.951	rs12463436	chr2:201061962	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.57	5.85	0.34	1.45e-8	Schizophrenia;
CESC	cis	rs7589728	0.620	rs76687350	chr2:88473832	G/A	cg14558114	chr2:88469736	THNSL2	0.57	5.3	0.31	2.42e-7	Plasma clusterin levels;
CESC	cis	rs858239	0.601	rs11982002	chr7:23163270	C/T	cg23682824	chr7:23144976	KLHL7	0.54	7.39	0.41	1.91e-12	Cerebrospinal fluid biomarker levels;
CESC	cis	rs12477438	0.834	rs11903311	chr2:99701807	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.72	-9.91	-0.52	6.61e-20	Chronic sinus infection;
CESC	cis	rs9393777	0.513	rs9368448	chr6:26649355	T/C	cg12826209	chr6:26865740	GUSBL1	0.73	8.13	0.45	1.7e-14	Intelligence (multi-trait analysis);
CESC	cis	rs5769707	0.839	rs73176988	chr22:49989649	G/T	cg05373962	chr22:49881684	NA	-0.36	-6.13	-0.35	3.16e-9	Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs10504229	0.834	rs7015674	chr8:58153166	C/T	cg22535103	chr8:58192502	C8orf71	-0.9	-11.01	-0.56	1.78e-23	Developmental language disorder (linguistic errors);
CESC	cis	rs6570726	0.791	rs13202312	chr6:145913093	T/G	cg23711669	chr6:146136114	FBXO30	0.97	14.47	0.66	2.25e-35	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9840812	0.577	rs503973	chr3:136059537	C/G	cg15507776	chr3:136538369	TMEM22	-0.54	-6.16	-0.35	2.67e-9	Fibrinogen levels;
CESC	cis	rs7546094	1.000	rs2999154	chr1:113222456	G/T	cg22162597	chr1:113214053	CAPZA1	-0.39	-6.0	-0.35	6.36e-9	Platelet distribution width;
CESC	trans	rs1814175	0.645	rs12364337	chr11:49942580	A/T	cg11707556	chr5:10655725	ANKRD33B	-0.43	-6.36	-0.36	8.98e-10	Height;
CESC	cis	rs2290159	0.948	rs5746255	chr3:12624321	A/G	cg23032965	chr3:12705835	RAF1	0.53	6.05	0.35	4.85e-9	Cholesterol, total;
CESC	cis	rs2832191	0.632	rs2246777	chr21:30309586	T/C	cg08807101	chr21:30365312	RNF160	-0.9	-13.41	-0.64	1.22e-31	Dental caries;
CESC	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	22.02	0.8	8.62e-62	Prudent dietary pattern;
CESC	cis	rs7219021	0.892	rs9913867	chr17:46849602	G/T	cg16584676	chr17:46985605	UBE2Z	-0.52	-5.91	-0.34	1.04e-8	Schizophrenia or bipolar disorder;
CESC	cis	rs951366	0.966	rs11240565	chr1:205722958	C/T	cg24503407	chr1:205819492	PM20D1	-0.46	-6.41	-0.37	6.51e-10	Menarche (age at onset);
CESC	cis	rs7666738	0.830	rs957742	chr4:99029409	C/T	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.58e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7662987	1.000	rs13145727	chr4:99998866	T/A	cg13256891	chr4:100009986	ADH5	-0.83	-5.86	-0.34	1.38e-8	Smoking initiation;
CESC	cis	rs3741404	0.791	rs2282491	chr11:63918373	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.83	12.25	0.6	1.25e-27	Platelet count;
CESC	cis	rs3213545	0.700	rs10849829	chr12:121470256	A/G	cg25281562	chr12:121454272	C12orf43	-0.39	-5.1	-0.3	6.45e-7	Subjective well-being;Cardiovascular disease risk factors;
CESC	cis	rs12476592	0.602	rs2604613	chr2:63832776	G/A	cg17519650	chr2:63277830	OTX1	-0.45	-5.12	-0.3	5.75e-7	Childhood ear infection;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg27365115	chr2:103353231	MFSD9	-0.49	-6.39	-0.37	7.5e-10	Fibrinogen levels;
CESC	cis	rs60154123	0.730	rs583148	chr1:210463553	A/C	cg23283495	chr1:209979779	IRF6	0.4	5.18	0.3	4.42e-7	Coronary artery disease;
CESC	cis	rs6570726	0.577	rs406868	chr6:145809983	C/T	cg23711669	chr6:146136114	FBXO30	0.94	12.6	0.61	7.64e-29	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2075671	0.903	rs11979818	chr7:100293639	A/G	cg16850897	chr7:100343110	ZAN	0.68	8.69	0.47	3.9e-16	Other erythrocyte phenotypes;
CESC	cis	rs11690935	0.798	rs13018768	chr2:172598592	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.97	-14.92	-0.68	6.05e-37	Schizophrenia;
CESC	cis	rs9457247	0.565	rs2239824	chr6:167511799	T/A	cg07741184	chr6:167504864	NA	0.43	7.69	0.43	2.96e-13	Crohn's disease;
CESC	cis	rs9902453	0.845	rs2321331	chr17:28025528	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	8.53	0.46	1.15e-15	Coffee consumption (cups per day);
CESC	cis	rs2625529	0.730	rs7177242	chr15:72184114	A/G	cg16672083	chr15:72433130	SENP8	0.43	6.2	0.36	2.1e-9	Red blood cell count;
CESC	cis	rs1008375	0.932	rs13134570	chr4:17692863	C/T	cg16339924	chr4:17578868	LAP3	-0.69	-8.2	-0.45	1.05e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs4141404	0.851	rs5749248	chr22:31683711	C/A	cg13145458	chr22:31556086	RNF185	0.58	6.05	0.35	5.04e-9	Paclitaxel-induced neuropathy;
CESC	cis	rs9913156	0.793	rs55682338	chr17:4582183	G/A	cg00122941	chr17:4613640	ARRB2	0.84	9.76	0.51	2.01e-19	Lymphocyte counts;
CESC	cis	rs3806933	0.522	rs11241100	chr5:110460958	C/T	cg04022379	chr5:110408740	TSLP	0.45	7.36	0.41	2.27e-12	Eosinophilic esophagitis;
CESC	cis	rs2228479	0.850	rs62056063	chr16:89903680	C/T	cg00800038	chr16:89945340	TCF25	-0.89	-6.89	-0.39	4.13e-11	Skin colour saturation;
CESC	cis	rs965469	1.000	rs6051838	chr20:3389012	A/C	cg25506879	chr20:3388711	C20orf194	-0.57	-6.08	-0.35	4.29e-9	IFN-related cytopenia;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg22734315	chr16:81069742	ATMIN	-0.37	-6.23	-0.36	1.8e-9	Gambling;
CESC	cis	rs727505	0.954	rs66526112	chr7:124504074	C/A	cg23710748	chr7:124431027	NA	-0.48	-7.52	-0.42	8.73e-13	Lewy body disease;
CESC	cis	rs1005277	0.579	rs2474569	chr10:38383491	C/G	cg25427524	chr10:38739819	LOC399744	-0.65	-9.48	-0.5	1.51e-18	Extrinsic epigenetic age acceleration;
CESC	cis	rs412050	0.696	rs56226933	chr22:22339901	C/T	cg17089214	chr22:22089827	YPEL1	0.62	5.14	0.3	5.34e-7	Attention deficit hyperactivity disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00437134	chr2:198364743	HSPE1;HSPD1	0.56	6.65	0.38	1.68e-10	Gut microbiome composition (summer);
CESC	cis	rs35306767	0.807	rs11253513	chr10:968450	C/T	cg10556349	chr10:835070	NA	0.53	5.71	0.33	2.99e-8	Eosinophil percentage of granulocytes;
CESC	cis	rs911555	0.546	rs28798508	chr14:104068970	T/C	cg24130564	chr14:104152367	KLC1	-0.79	-12.75	-0.62	2.33e-29	Intelligence (multi-trait analysis);
CESC	cis	rs9948	0.655	rs17119591	chr2:97435557	G/A	cg01990225	chr2:97406019	LMAN2L	-0.98	-7.37	-0.41	2.17e-12	Erectile dysfunction and prostate cancer treatment;
CESC	cis	rs7762018	0.943	rs7772889	chr6:170142458	T/C	cg05834625	chr6:170176447	C6orf70	0.65	7.37	0.41	2.19e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs372883	0.613	rs1153274	chr21:30660026	T/C	cg24692254	chr21:30365293	RNF160	-0.54	-6.95	-0.39	2.89e-11	Pancreatic cancer;
CESC	cis	rs7089973	0.604	rs8181444	chr10:116588981	C/T	cg25233709	chr10:116636983	FAM160B1	0.38	5.9	0.34	1.12e-8	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs524281	0.773	rs10896105	chr11:66002260	A/G	cg14036092	chr11:66035641	RAB1B	-0.53	-5.31	-0.31	2.38e-7	Electroencephalogram traits;
CESC	cis	rs7666738	0.791	rs2903151	chr4:99027218	T/C	cg17366294	chr4:99064904	C4orf37	0.62	8.95	0.48	6.32e-17	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2635047	0.542	rs2668772	chr18:44770621	T/G	cg24371990	chr18:44770781	NA	0.35	5.75	0.33	2.5e-8	Educational attainment;
CESC	cis	rs7123876	0.830	rs57614870	chr11:72435983	A/G	cg03713592	chr11:72463424	ARAP1	0.6	6.77	0.38	8.21e-11	Body mass index;
CESC	cis	rs9300255	0.679	rs10772998	chr12:123721177	T/G	cg00376283	chr12:123451042	ABCB9	0.72	8.81	0.48	1.66e-16	Neutrophil percentage of white cells;
CESC	cis	rs7116495	0.786	rs1894003	chr11:71750276	A/G	cg10381502	chr11:71823885	C11orf51	-0.66	-5.46	-0.32	1.08e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs9910055	0.529	rs170637	chr17:42186868	C/T	cg19774624	chr17:42201019	HDAC5	0.63	8.89	0.48	9.54e-17	Total body bone mineral density;
CESC	cis	rs3892630	0.824	rs12327732	chr19:33221767	C/T	cg13157960	chr19:33183277	NUDT19	0.54	5.09	0.3	6.83e-7	Red blood cell traits;
CESC	cis	rs7412746	0.658	rs2230061	chr1:150727539	G/A	cg17724175	chr1:150552817	MCL1	0.43	6.53	0.37	3.35e-10	Melanoma;
CESC	cis	rs7795096	0.743	rs9648726	chr7:151537433	C/T	cg17008978	chr7:151542804	PRKAG2	0.39	7.37	0.41	2.2e-12	Bipolar disorder (age of onset and psychotic symptoms);
CESC	cis	rs8070624	0.574	rs11078408	chr17:17876011	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.68	9.67	0.51	3.79e-19	Total body bone mineral density;
CESC	cis	rs10865397	0.506	rs13414160	chr2:73383261	C/A	cg01422370	chr2:73384389	NA	0.46	7.27	0.41	4.11e-12	Intelligence (multi-trait analysis);
CESC	cis	rs7829975	0.522	rs6601689	chr8:8172283	C/T	cg15556689	chr8:8085844	FLJ10661	0.58	6.95	0.39	2.88e-11	Mood instability;
CESC	cis	rs7264396	1.000	rs6088881	chr20:34165609	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.57	7.05	0.4	1.52e-11	Total cholesterol levels;
CESC	cis	rs1559088	1.000	rs7245404	chr19:33550589	C/T	cg17764715	chr19:33622953	WDR88	0.45	5.67	0.33	3.76e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs4925325	0.876	rs6089560	chr20:60517325	T/G	cg23262073	chr20:60523788	NA	-0.57	-7.92	-0.44	6.63e-14	Obesity-related traits;
CESC	cis	rs16917546	1.000	rs10995255	chr10:64402433	G/A	cg03961010	chr10:64397487	ZNF365	-0.37	-6.11	-0.35	3.47e-9	Basal cell carcinoma;
CESC	cis	rs1799949	1.000	rs4793212	chr17:41302750	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.64	8.64	0.47	5.23e-16	Menopause (age at onset);
CESC	cis	rs8072100	0.713	rs11651643	chr17:45483229	A/G	cg08085267	chr17:45401833	C17orf57	-0.52	-6.64	-0.38	1.81e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs977987	0.624	rs59867374	chr16:75432682	G/A	cg03315344	chr16:75512273	CHST6	0.4	5.74	0.33	2.61e-8	Dupuytren's disease;
CESC	cis	rs2842992	0.747	rs9365095	chr6:160192928	T/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.79	9.65	0.51	4.49e-19	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs2832191	0.703	rs2853827	chr21:30443596	T/C	cg08807101	chr21:30365312	RNF160	0.95	14.3	0.66	8.82e-35	Dental caries;
CESC	cis	rs6570726	0.791	rs365747	chr6:145866784	C/T	cg05347473	chr6:146136440	FBXO30	0.58	7.33	0.41	2.84e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs16867321	0.950	rs1919152	chr2:181507765	C/T	cg23363182	chr2:181467187	NA	-0.44	-5.7	-0.33	3.17e-8	Obesity;
CESC	cis	rs6912958	0.781	rs7757636	chr6:88256092	T/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.36	-5.93	-0.34	9.52e-9	Monocyte percentage of white cells;
CESC	cis	rs6430585	0.583	rs4988163	chr2:136628121	G/T	cg07169764	chr2:136633963	MCM6	1.17	17.57	0.73	2.34e-46	Corneal structure;
CESC	cis	rs35110281	0.744	rs230645	chr21:44918607	A/G	cg01579765	chr21:45077557	HSF2BP	0.51	8.74	0.47	2.77e-16	Mean corpuscular volume;
CESC	cis	rs365132	0.875	rs2456178	chr5:176413570	C/G	cg16309518	chr5:176445507	NA	-0.37	-5.35	-0.31	1.9e-7	Menarche and menopause (age at onset);Menopause (age at onset);
CESC	cis	rs8177253	1.000	rs8177252	chr3:133480174	C/A	cg01448562	chr3:133502909	NA	-0.43	-6.11	-0.35	3.59e-9	Iron status biomarkers;
CESC	cis	rs6912958	1.000	rs6912958	chr6:88133315	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.66	-9.08	-0.49	2.62e-17	Monocyte percentage of white cells;
CESC	cis	rs1707322	1.000	rs7553924	chr1:46352624	T/C	cg06784218	chr1:46089804	CCDC17	0.32	5.57	0.32	6.35e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2573652	0.722	rs12903458	chr15:100542673	T/G	cg00587665	chr15:100533223	ADAMTS17	-0.42	-6.74	-0.38	9.83e-11	Height;
CESC	cis	rs1976403	0.633	rs1697422	chr1:21821897	T/C	cg02390115	chr1:21767211	NBPF3	0.36	5.2	0.3	4.08e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs763014	0.593	rs28455838	chr16:681966	T/C	cg09263875	chr16:632152	PIGQ	0.66	11.22	0.57	3.6e-24	Height;
CESC	cis	rs6502050	0.835	rs7213172	chr17:80085703	G/T	cg23985595	chr17:80112537	CCDC57	0.42	6.55	0.37	2.99e-10	Life satisfaction;
CESC	cis	rs4975709	0.589	rs1466607	chr5:1864856	A/G	cg07747251	chr5:1868357	NA	0.33	5.38	0.31	1.6e-7	Cardiovascular disease risk factors;
CESC	cis	rs6912958	0.631	rs9450704	chr6:88182704	G/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.45	-6.01	-0.35	6.24e-9	Monocyte percentage of white cells;
CESC	cis	rs4665809	0.590	rs13016807	chr2:26496186	G/C	cg08470875	chr2:26401718	FAM59B	0.7	7.01	0.4	2.02e-11	Gut microbiome composition (summer);
CESC	cis	rs4925386	0.759	rs2427293	chr20:60925859	A/G	cg24112000	chr20:60950667	NA	0.44	5.34	0.31	2.03e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs801193	0.935	rs11772264	chr7:66176387	T/C	cg25985355	chr7:65971099	NA	-0.31	-5.09	-0.3	6.79e-7	Aortic root size;
CESC	cis	rs7949030	0.626	rs11231144	chr11:62328038	A/G	cg23462726	chr11:62437636	C11orf83;C11orf48	-0.4	-5.29	-0.31	2.51e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	trans	rs9929218	0.954	rs1981871	chr16:68819007	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.65	-8.5	-0.46	1.44e-15	Colorectal cancer;
CESC	cis	rs514406	0.929	rs12145105	chr1:53340564	T/C	cg08859206	chr1:53392774	SCP2	-0.59	-7.59	-0.42	5.48e-13	Monocyte count;
CESC	cis	rs10256972	0.869	rs13236369	chr7:1033799	G/T	cg07308232	chr7:1071921	C7orf50	-0.42	-5.67	-0.33	3.76e-8	Longevity;Endometriosis;
CESC	cis	rs9303401	0.614	rs8081058	chr17:57160513	G/C	cg12560992	chr17:57184187	TRIM37	0.5	5.21	0.3	3.78e-7	Cognitive test performance;
CESC	cis	rs2243480	1.000	rs34529418	chr7:65403209	A/G	cg13147721	chr7:65941812	NA	-0.83	-7.92	-0.44	6.77e-14	Diabetic kidney disease;
CESC	cis	rs2836974	0.897	rs8128102	chr21:40606414	G/A	cg11644478	chr21:40555479	PSMG1	1.04	16.79	0.72	1.35e-43	Cognitive function;
CESC	cis	rs896854	0.846	rs7845219	chr8:95937502	T/C	cg09323728	chr8:95962352	TP53INP1	-0.4	-8.76	-0.47	2.34e-16	Type 2 diabetes;
CESC	cis	rs17711722	0.522	rs4642526	chr7:65216742	G/T	cg14393609	chr7:65229607	NA	0.45	6.3	0.36	1.23e-9	Calcium levels;
CESC	cis	rs826838	0.935	rs1486357	chr12:39073675	A/G	cg13010199	chr12:38710504	ALG10B	0.57	7.91	0.44	7.22e-14	Heart rate;
CESC	cis	rs7296418	0.961	rs1790094	chr12:123586688	T/C	cg05973401	chr12:123451056	ABCB9	0.57	7.44	0.42	1.43e-12	Platelet count;
CESC	cis	rs4253311	0.520	rs10000459	chr4:187124459	A/C	cg24794857	chr4:187113578	CYP4V2	0.49	6.65	0.38	1.62e-10	Plasma renin activity levels;Circulating chromogranin peptide levels;Blood metabolite levels;
CESC	cis	rs4689592	0.503	rs56099074	chr4:7071259	A/G	cg26116260	chr4:7069785	GRPEL1	-0.87	-9.58	-0.51	7.17e-19	Monocyte percentage of white cells;
CESC	cis	rs7666738	0.546	rs17546687	chr4:98769266	T/A	cg05340658	chr4:99064831	C4orf37	0.53	6.42	0.37	6.12e-10	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4665809	0.549	rs17527979	chr2:26428132	A/G	cg27170947	chr2:26402098	FAM59B	-0.77	-8.46	-0.46	1.78e-15	Gut microbiome composition (summer);
CESC	cis	rs9611565	0.765	rs132907	chr22:41801268	A/C	cg06481639	chr22:41940642	POLR3H	0.64	6.56	0.37	2.82e-10	Vitiligo;
CESC	cis	rs76419734	0.558	rs4235415	chr4:106593850	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.77	10.0	0.52	3.46e-20	Post bronchodilator FEV1;
CESC	cis	rs9393777	0.920	rs13191227	chr6:27390115	G/C	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.85	5.45	0.32	1.15e-7	Intelligence (multi-trait analysis);
CESC	cis	rs7631605	0.870	rs11129746	chr3:37001972	C/G	cg22985146	chr3:37219077	LRRFIP2	-0.33	-5.31	-0.31	2.32e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs7811142	1.000	rs11761725	chr7:100039815	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.1	10.35	0.54	2.55e-21	Platelet count;
CESC	cis	rs8092503	1.000	rs3764516	chr18:52494374	A/C	cg12377874	chr18:52495404	RAB27B	-0.33	-5.75	-0.33	2.4e-8	Childhood body mass index;
CESC	trans	rs7577696	0.962	rs13022197	chr2:32343167	A/T	cg12174077	chr18:77897878	ADNP2	0.37	6.17	0.35	2.48e-9	Inflammatory biomarkers;
CESC	cis	rs7949030	0.626	rs35587183	chr11:62318656	C/T	cg22862634	chr11:62369728	EML3;MTA2	0.48	6.44	0.37	5.69e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs854765	0.686	rs8065497	chr17:17782649	A/G	cg16928487	chr17:17741425	SREBF1	0.57	9.44	0.5	2.01e-18	Total body bone mineral density;
CESC	cis	rs1729951	0.575	rs1682357	chr3:136692009	G/A	cg25687071	chr3:136751404	NA	0.4	5.21	0.3	3.75e-7	Neuroticism;
CESC	trans	rs11039798	0.512	rs11040205	chr11:49007360	G/C	cg15704280	chr7:45808275	SEPT13	0.65	6.62	0.38	1.93e-10	Axial length;
CESC	cis	rs832540	0.931	rs702679	chr5:56221328	A/G	cg24531977	chr5:56204891	C5orf35	-0.44	-5.57	-0.32	6.3e-8	Coronary artery disease;
CESC	cis	rs2204008	0.811	rs4882300	chr12:38415224	A/T	cg13010199	chr12:38710504	ALG10B	-0.42	-5.47	-0.32	1.03e-7	Bladder cancer;
CESC	cis	rs897080	0.553	rs1067338	chr2:44624708	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	5.8	0.34	1.88e-8	Height;
CESC	cis	rs17608059	0.545	rs9915045	chr17:13902636	G/T	cg11395062	chr17:14139857	CDRT15	0.46	5.69	0.33	3.3e-8	Temperament;
CESC	cis	rs875971	1.000	rs11974219	chr7:65647410	C/T	cg11764359	chr7:65958608	NA	-0.92	-14.53	-0.67	1.44e-35	Aortic root size;
CESC	cis	rs6582630	0.503	rs4882293	chr12:38388200	G/C	cg26384229	chr12:38710491	ALG10B	-0.47	-6.27	-0.36	1.45e-9	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs3858526	0.628	rs1840177	chr11:5944627	T/G	cg02574844	chr11:5959923	NA	0.48	6.8	0.39	6.81e-11	DNA methylation (variation);
CESC	cis	rs736408	0.527	rs2577831	chr3:52628056	C/A	cg05564831	chr3:52568323	NT5DC2	0.47	8.04	0.44	2.96e-14	Bipolar disorder;
CESC	cis	rs9916302	0.904	rs6503503	chr17:37514373	G/A	cg00129232	chr17:37814104	STARD3	0.52	6.49	0.37	4.13e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs1707322	0.963	rs9787412	chr1:46371596	C/T	cg05343316	chr1:45956843	TESK2	0.44	5.55	0.32	7.05e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs208520	1.000	rs12193077	chr6:66989548	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.85	9.4	0.5	2.73e-18	Exhaled nitric oxide output;
CESC	cis	rs4141404	0.561	rs5994376	chr22:31563555	A/C	cg02404636	chr22:31891804	SFI1	-0.37	-5.17	-0.3	4.66e-7	Paclitaxel-induced neuropathy;
CESC	cis	rs7123876	0.830	rs57614870	chr11:72435983	A/G	cg04827223	chr11:72435913	ARAP1	-0.84	-15.39	-0.69	1.27e-38	Body mass index;
CESC	cis	rs12048904	0.964	rs8888	chr1:101338324	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.57	7.51	0.42	8.93e-13	Multiple sclerosis;
CESC	cis	rs4253772	0.550	rs6008762	chr22:46736228	T/C	cg00784671	chr22:46762841	CELSR1	-0.48	-5.36	-0.31	1.85e-7	LDL cholesterol;Cholesterol, total;
CESC	trans	rs9388451	0.807	rs1269175	chr6:126040435	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.52	6.79	0.38	7.55e-11	Brugada syndrome;
CESC	cis	rs9457247	0.967	rs428805	chr6:167403132	C/A	cg23791538	chr6:167370224	RNASET2	-0.59	-8.32	-0.46	4.54e-15	Crohn's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18902057	chr16:88636444	ZC3H18	-0.59	-6.81	-0.39	6.63e-11	Gut microbiome composition (summer);
CESC	cis	rs6460942	0.915	rs17541242	chr7:12459068	A/G	cg06484146	chr7:12443880	VWDE	-0.79	-9.25	-0.49	7.67e-18	Coronary artery disease;
CESC	cis	rs1670533	1.000	rs10026482	chr4:1051128	C/G	cg27284194	chr4:1044797	NA	0.45	5.54	0.32	7.32e-8	Recombination rate (females);
CESC	cis	rs73001065	0.551	rs10424702	chr19:19508013	A/G	cg03709012	chr19:19516395	GATAD2A	0.9	7.63	0.42	4.28e-13	LDL cholesterol;
CESC	cis	rs9399135	0.935	rs987690	chr6:135350379	A/G	cg22676075	chr6:135203613	NA	0.51	7.36	0.41	2.34e-12	Red blood cell count;
CESC	cis	rs7520050	0.831	rs61783170	chr1:46256329	T/C	cg24296786	chr1:45957014	TESK2	0.41	5.08	0.3	7.28e-7	Red blood cell count;Reticulocyte count;
CESC	cis	rs9549260	0.564	rs9549271	chr13:41295477	T/C	cg21288729	chr13:41239152	FOXO1	0.57	7.17	0.4	7.44e-12	Red blood cell count;
CESC	cis	rs9322193	0.923	rs17745062	chr6:150042215	T/A	cg13206674	chr6:150067644	NUP43	0.45	6.53	0.37	3.38e-10	Lung cancer;
CESC	cis	rs7599312	1.000	rs7599312	chr2:213413231	C/T	cg16329650	chr2:213403929	ERBB4	0.42	5.06	0.3	7.88e-7	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs2479106	0.591	rs7855329	chr9:126352551	A/G	cg16191174	chr9:126692580	DENND1A	0.38	5.19	0.3	4.25e-7	Polycystic ovary syndrome;
CESC	cis	rs7089973	0.604	rs17095662	chr10:116596071	A/C	cg25233709	chr10:116636983	FAM160B1	0.38	6.02	0.35	5.79e-9	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs7188697	0.775	rs8056620	chr16:58604387	T/A	cg02549819	chr16:58548995	SETD6	0.43	5.4	0.31	1.51e-7	QT interval;
CESC	cis	rs9399135	0.967	rs4895439	chr6:135318854	A/T	cg24558204	chr6:135376177	HBS1L	0.53	7.28	0.41	3.85e-12	Red blood cell count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14308291	chr1:36396265	EIF2C3	-0.64	-7.42	-0.41	1.59e-12	Gut microbiome composition (summer);
CESC	cis	rs7829975	0.511	rs2921028	chr8:8340477	T/C	cg15556689	chr8:8085844	FLJ10661	0.53	6.58	0.37	2.58e-10	Mood instability;
CESC	cis	rs763014	0.898	rs2017567	chr16:637212	T/C	cg07256732	chr16:621771	PIGQ	-0.3	-5.15	-0.3	5.13e-7	Height;
CESC	cis	rs9649213	0.593	rs36017146	chr7:97974617	C/T	cg08684580	chr7:98029266	BAIAP2L1	-0.37	-6.03	-0.35	5.46e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs3087591	0.960	rs9807077	chr17:29634457	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.41	-5.05	-0.3	8.18e-7	Hip circumference;
CESC	cis	rs9467711	0.659	rs35680819	chr6:26455814	T/C	cg14345882	chr6:26364793	BTN3A2	0.64	5.28	0.31	2.67e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs3806843	0.966	rs7737424	chr5:140146345	C/T	cg26395211	chr5:140044315	WDR55	-0.39	-5.12	-0.3	5.97e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs7267979	0.866	rs6138609	chr20:25570985	T/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.73	12.77	0.62	1.93e-29	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs10781543	0.810	rs11145756	chr9:139364585	A/G	cg14169450	chr9:139327907	INPP5E	0.5	7.88	0.44	8.58e-14	Monocyte percentage of white cells;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24514954	chr1:24104624	C1orf128	0.61	6.38	0.36	7.91e-10	Gut microbiome composition (summer);
CESC	cis	rs1707322	0.721	rs4609469	chr1:46117185	C/T	cg05343316	chr1:45956843	TESK2	0.5	6.12	0.35	3.43e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2836974	0.897	rs1571709	chr21:40553980	T/C	cg17971929	chr21:40555470	PSMG1	1.07	16.65	0.72	4.28e-43	Cognitive function;
CESC	cis	rs9911578	0.741	rs2611776	chr17:56819636	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.21	0.3	3.88e-7	Intelligence (multi-trait analysis);
CESC	cis	rs853679	0.550	rs1150692	chr6:28173957	A/G	cg23161317	chr6:28129485	ZNF389	0.46	6.0	0.35	6.62e-9	Depression;
CESC	cis	rs3806843	0.966	rs2337516	chr5:140140853	A/G	cg26395211	chr5:140044315	WDR55	0.4	5.08	0.3	7.22e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs2576037	0.901	rs6507719	chr18:44581310	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.62	-9.15	-0.49	1.55e-17	Personality dimensions;
CESC	cis	rs61612642	0.523	rs59004693	chr6:42157392	G/A	cg01092361	chr6:42185687	MRPS10	0.82	7.95	0.44	5.41e-14	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Eosinophil counts;
CESC	cis	rs10733682	1.000	rs10733682	chr9:129460914	C/T	cg00232160	chr9:129468157	NA	0.33	5.2	0.3	3.97e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs35110281	0.548	rs2838350	chr21:45109972	T/C	cg21573476	chr21:45109991	RRP1B	-0.61	-8.84	-0.48	1.4e-16	Mean corpuscular volume;
CESC	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg21724239	chr8:58056113	NA	0.6	5.46	0.32	1.1e-7	Developmental language disorder (linguistic errors);
CESC	trans	rs10832139	0.553	rs1395847	chr11:13931722	T/C	cg11511669	chr12:131556214	GPR133	-0.48	-6.06	-0.35	4.76e-9	P wave terminal force;
CESC	cis	rs36051895	0.623	rs6476957	chr9:5261324	A/G	cg02405213	chr9:5042618	JAK2	-0.52	-6.43	-0.37	5.85e-10	Pediatric autoimmune diseases;
CESC	cis	rs3741404	0.583	rs640999	chr11:63869425	C/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.72	10.02	0.52	2.95e-20	Platelet count;
CESC	cis	rs9916302	0.851	rs11078906	chr17:37662767	C/T	cg15445000	chr17:37608096	MED1	0.41	6.83	0.39	5.8200000000000003e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs1577917	1.000	rs12213149	chr6:86668644	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.47	-6.08	-0.35	4.29e-9	Response to antipsychotic treatment;
CESC	cis	rs79349575	0.749	rs12601672	chr17:47006493	T/C	cg16584676	chr17:46985605	UBE2Z	0.53	6.54	0.37	3.16e-10	Type 2 diabetes;
CESC	cis	rs10463316	0.832	rs246483	chr5:150731062	C/G	cg03212797	chr5:150827313	SLC36A1	-0.52	-6.73	-0.38	1.06e-10	Metabolite levels (Pyroglutamine);
CESC	cis	rs684232	0.644	rs2543781	chr17:602469	C/G	cg15660573	chr17:549704	VPS53	-0.64	-8.93	-0.48	7.06e-17	Prostate cancer;
CESC	trans	rs11039798	0.565	rs7118675	chr11:48532063	C/A	cg15704280	chr7:45808275	SEPT13	0.66	6.68	0.38	1.4e-10	Axial length;
CESC	cis	rs7560272	0.538	rs13000788	chr2:73918312	C/T	cg20560298	chr2:73613845	ALMS1	0.45	6.29	0.36	1.31e-9	Schizophrenia;
CESC	cis	rs514406	0.505	rs269293	chr1:53187767	A/C	cg08859206	chr1:53392774	SCP2	-0.58	-7.73	-0.43	2.26e-13	Monocyte count;
CESC	trans	rs9325144	0.647	rs7980932	chr12:38921583	G/T	cg23762105	chr12:34175262	ALG10	0.46	6.08	0.35	4.08e-9	Morning vs. evening chronotype;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10359931	chr4:3519599	LRPAP1	-0.59	-6.25	-0.36	1.6e-9	Gut microbiome composition (summer);
CESC	cis	rs116095464	0.558	rs28418643	chr5:240859	A/G	cg10591111	chr5:226296	SDHA	-0.52	-6.32	-0.36	1.1e-9	Breast cancer;
CESC	cis	rs5750830	0.649	rs5750820	chr22:39825322	T/G	cg01416388	chr22:39784598	NA	-0.57	-6.95	-0.39	2.87e-11	Intelligence (multi-trait analysis);
CESC	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg11494091	chr17:61959527	GH2	0.72	12.48	0.61	1.93e-28	Prudent dietary pattern;
CESC	cis	rs1048238	0.506	rs7547314	chr1:16186722	G/A	cg22431228	chr1:16359049	CLCNKA	-0.36	-6.44	-0.37	5.62e-10	Systolic blood pressure;
CESC	cis	rs7845219	0.544	rs9643352	chr8:95918288	C/T	cg23172400	chr8:95962367	TP53INP1	-0.37	-6.78	-0.38	7.89e-11	Type 2 diabetes;
CESC	cis	rs9894429	0.789	rs7213849	chr17:79567610	C/T	cg21984481	chr17:79567631	NPLOC4	0.57	9.27	0.49	6.66e-18	Eye color traits;
CESC	cis	rs7980687	0.574	rs10744149	chr12:123708490	T/A	cg19016782	chr12:123741754	C12orf65	-0.42	-6.03	-0.35	5.35e-9	Height;Educational attainment;Head circumference (infant);
CESC	cis	rs1371867	0.846	rs924057	chr8:101266157	A/G	cg11906718	chr8:101322791	RNF19A	-0.42	-5.45	-0.32	1.17e-7	Atrioventricular conduction;
CESC	trans	rs8073060	0.586	rs7208672	chr17:33989759	G/A	cg19694781	chr19:47549865	TMEM160	-0.75	-7.05	-0.4	1.53e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	cis	rs1865760	0.566	rs1539183	chr6:26075051	G/C	cg17691542	chr6:26056736	HIST1H1C	0.42	5.66	0.33	3.97e-8	Height;
CESC	cis	rs10992471	0.756	rs10123342	chr9:95087824	T/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.45	-5.63	-0.33	4.56e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CESC	trans	rs9325144	0.600	rs6582634	chr12:38748041	G/A	cg23762105	chr12:34175262	ALG10	-0.47	-6.33	-0.36	1.05e-9	Morning vs. evening chronotype;
CESC	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.68	-9.34	-0.5	4.24e-18	Longevity;Endometriosis;
CESC	cis	rs12586317	0.547	rs78609489	chr14:35497285	T/C	cg05294307	chr14:35346193	BAZ1A	-0.55	-5.61	-0.33	4.97e-8	Psoriasis;
CESC	cis	rs3820068	0.532	rs72647105	chr1:15935238	C/G	cg13390004	chr1:15929781	NA	0.37	5.96	0.34	8.08e-9	Systolic blood pressure;
CESC	cis	rs9322193	0.923	rs9688350	chr6:150052113	A/T	cg09699651	chr6:150184138	LRP11	0.44	5.63	0.33	4.66e-8	Lung cancer;
CESC	cis	rs7666738	0.830	rs10009943	chr4:99021475	G/A	cg03676636	chr4:99064102	C4orf37	0.33	5.15	0.3	5.05e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4862750	0.874	rs6822062	chr4:187895553	T/C	cg10295955	chr4:187884368	NA	-1.09	-22.92	-0.82	7.71e-65	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7551222	0.752	rs10900596	chr1:204522457	T/C	cg20240347	chr1:204465584	NA	-0.28	-5.6	-0.33	5.23e-8	Schizophrenia;
CESC	trans	rs17514846	0.565	rs2521498	chr15:91442152	A/T	cg10493739	chr9:108456981	TMEM38B	0.44	6.27	0.36	1.49e-9	Coronary artery disease;
CESC	cis	rs9487051	0.597	rs59673	chr6:109548713	C/T	cg01475377	chr6:109611718	NA	-0.4	-5.33	-0.31	2.12e-7	Reticulocyte fraction of red cells;
CESC	cis	rs8177179	0.967	rs9820225	chr3:133449189	A/G	cg17775713	chr3:133465469	TF	0.35	6.26	0.36	1.52e-9	Iron status biomarkers (transferrin levels);
CESC	cis	rs9303401	0.659	rs12602808	chr17:56698420	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	1.04	13.0	0.62	3.27e-30	Cognitive test performance;
CESC	cis	rs2576037	0.526	rs2032215	chr18:44439011	A/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.42	6.74	0.38	1.01e-10	Personality dimensions;
CESC	cis	rs780096	0.526	rs7594812	chr2:27611469	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.34	-6.26	-0.36	1.54e-9	Total body bone mineral density;
CESC	cis	rs6543140	0.964	rs13393175	chr2:103078849	T/G	cg04239558	chr2:103089729	SLC9A4	0.47	6.16	0.35	2.64e-9	Blood protein levels;
CESC	cis	rs367943	0.698	rs2115208	chr5:112973994	A/G	cg12552261	chr5:112820674	MCC	0.43	5.48	0.32	9.97e-8	Type 2 diabetes;
CESC	trans	rs11098499	0.821	rs3775852	chr4:120454556	A/G	cg25214090	chr10:38739885	LOC399744	0.7	9.62	0.51	5.47e-19	Corneal astigmatism;
CESC	cis	rs1218582	0.628	rs12130132	chr1:154880386	C/T	cg06221963	chr1:154839813	KCNN3	-0.56	-8.87	-0.48	1.13e-16	Prostate cancer;
CESC	cis	rs796364	1.000	rs4410273	chr2:200818258	T/C	cg23649088	chr2:200775458	C2orf69	0.56	5.29	0.31	2.59e-7	Schizophrenia;
CESC	cis	rs709400	0.663	rs62007687	chr14:103903763	G/T	cg12935359	chr14:103987150	CKB	-0.56	-8.16	-0.45	1.36e-14	Body mass index;
CESC	cis	rs7937682	1.000	rs11213980	chr11:111562692	A/T	cg09085632	chr11:111637200	PPP2R1B	0.92	12.55	0.61	1.17e-28	Primary sclerosing cholangitis;
CESC	cis	rs9287719	0.967	rs6744854	chr2:10747246	C/G	cg02196655	chr2:10830764	NOL10	-0.38	-5.79	-0.34	1.96e-8	Prostate cancer;
CESC	cis	rs4595586	0.545	rs12815047	chr12:39380901	A/G	cg26384229	chr12:38710491	ALG10B	0.54	7.53	0.42	7.85e-13	Morning vs. evening chronotype;
CESC	cis	rs12618769	0.597	rs4850875	chr2:99069815	A/G	cg10123293	chr2:99228465	UNC50	0.39	5.22	0.31	3.7e-7	Bipolar disorder;
CESC	cis	rs7662987	0.517	rs3018048	chr4:100005538	C/T	cg13256891	chr4:100009986	ADH5	0.75	8.32	0.46	4.75e-15	Smoking initiation;
CESC	cis	rs7481584	0.624	rs511990	chr11:3052936	A/G	cg25174290	chr11:3078921	CARS	-0.45	-6.34	-0.36	9.61e-10	Calcium levels;
CESC	cis	rs4523957	0.533	rs170043	chr17:2200434	G/T	cg16513277	chr17:2031491	SMG6	-0.52	-5.36	-0.31	1.78e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs72615157	0.561	rs113401658	chr7:99858505	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.58	5.38	0.31	1.63e-7	Lung function (FEV1/FVC);
CESC	cis	rs1878931	0.501	rs9635563	chr16:3416940	A/G	cg05754148	chr16:3507555	NAT15	-0.39	-5.19	-0.3	4.24e-7	Body mass index (adult);
CESC	cis	rs6690583	0.623	rs61770879	chr1:85504938	A/C	cg22153463	chr1:85462885	MCOLN2	0.78	7.43	0.42	1.49e-12	Serum sulfate level;
CESC	cis	rs4589502	0.841	rs56401320	chr15:67140517	C/G	cg12317470	chr15:67143691	NA	0.75	6.84	0.39	5.53e-11	Lung cancer (smoking interaction);
CESC	cis	rs597539	0.652	rs636049	chr11:68667198	A/C	cg18350739	chr11:68623251	NA	-0.46	-7.19	-0.4	6.69e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs13031619	0.517	rs10183413	chr2:3684342	T/C	cg19052272	chr2:3704530	ALLC	0.44	5.12	0.3	5.89e-7	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CESC	cis	rs9948	1.000	rs72811623	chr2:97496473	C/T	cg01990225	chr2:97406019	LMAN2L	-0.75	-5.42	-0.32	1.35e-7	Erectile dysfunction and prostate cancer treatment;
CESC	cis	rs6582630	0.555	rs35284307	chr12:38509999	T/G	cg13010199	chr12:38710504	ALG10B	0.46	5.91	0.34	1.03e-8	Drug-induced liver injury (flucloxacillin);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01136232	chr1:25756842	TMEM57	-0.55	-6.13	-0.35	3.12e-9	Gut microbiome composition (summer);
CESC	cis	rs11168351	0.926	rs10875719	chr12:48411158	T/C	cg04545296	chr12:48745243	ZNF641	0.34	5.89	0.34	1.17e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs9796	0.621	rs7170049	chr15:41484287	C/A	cg18705301	chr15:41695430	NDUFAF1	-0.44	-6.47	-0.37	4.69e-10	Menopause (age at onset);
CESC	cis	rs698833	0.926	rs1067406	chr2:44674450	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.46	5.8	0.34	1.9e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg23181591	chr8:123793873	ZHX2	0.52	6.78	0.38	7.62e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs11098499	0.865	rs28753180	chr4:120405367	A/T	cg24375607	chr4:120327624	NA	0.45	5.52	0.32	8.1e-8	Corneal astigmatism;
CESC	cis	rs6121246	0.559	rs6060962	chr20:30397847	A/G	cg13852791	chr20:30311386	BCL2L1	0.85	11.17	0.57	5.35e-24	Mean corpuscular hemoglobin;
CESC	cis	rs9399135	0.967	rs9376085	chr6:135371224	T/C	cg24558204	chr6:135376177	HBS1L	0.49	6.77	0.38	8.11e-11	Red blood cell count;
CESC	cis	rs9595066	1.000	rs7981575	chr13:44710947	C/T	cg04068111	chr13:44716778	NA	-0.52	-6.73	-0.38	1.02e-10	Schizophrenia;
CESC	cis	rs826838	0.802	rs10785619	chr12:38742897	T/A	cg13010199	chr12:38710504	ALG10B	0.43	6.21	0.36	2.06e-9	Heart rate;
CESC	cis	rs6733011	0.502	rs6542847	chr2:99573471	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.4	-5.18	-0.3	4.48e-7	Bipolar disorder;
CESC	cis	rs7312933	0.566	rs11181454	chr12:42746486	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.5	-6.62	-0.38	2e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs8005677	0.962	rs8003934	chr14:23401142	A/G	cg01529538	chr14:23388837	RBM23	0.5	6.72	0.38	1.14e-10	Cognitive ability (multi-trait analysis);
CESC	cis	rs2569991	0.636	rs9211	chr3:12939546	A/G	cg22481960	chr3:13008800	IQSEC1	0.5	6.09	0.35	3.88e-9	Periodontitis (DPAL);
CESC	cis	rs9796	0.717	rs476633	chr15:41392134	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.43	-6.28	-0.36	1.4e-9	Menopause (age at onset);
CESC	cis	rs172166	0.694	rs203877	chr6:28048624	T/C	cg26335602	chr6:28129616	ZNF389	0.38	5.52	0.32	7.89e-8	Cardiac Troponin-T levels;
CESC	cis	rs1153858	1.000	rs7163720	chr15:45639374	G/A	cg14582100	chr15:45693742	SPATA5L1	0.42	6.08	0.35	4.2e-9	Homoarginine levels;
CESC	trans	rs3896439	1.000	rs12141994	chr1:4667996	C/G	cg11038280	chr7:92466132	CDK6	-0.71	-6.11	-0.35	3.61e-9	Dental caries;
CESC	cis	rs6867032	0.687	rs4998338	chr5:2015910	A/G	cg26168224	chr5:2018326	NA	0.96	19.64	0.77	1.3e-53	Gut microbiome composition (winter);
CESC	cis	rs9916302	0.851	rs11078907	chr17:37662954	C/T	cg00129232	chr17:37814104	STARD3	-0.54	-7.14	-0.4	9.08e-12	Glomerular filtration rate (creatinine);
CESC	cis	rs3740540	0.507	rs897293	chr10:126290050	T/G	cg04949429	chr10:126290192	LHPP	0.38	5.36	0.31	1.77e-7	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
CESC	cis	rs7666738	0.830	rs13138059	chr4:99050430	A/G	cg18180107	chr4:99064573	C4orf37	0.4	5.15	0.3	5.15e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7267979	1.000	rs4815407	chr20:25341478	G/C	cg08601574	chr20:25228251	PYGB	-0.38	-5.41	-0.32	1.44e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs56873913	0.904	rs3760708	chr19:50084596	G/C	cg09250473	chr19:50168907	IRF3;BCL2L12	0.45	5.18	0.3	4.38e-7	Schizophrenia;
CESC	cis	rs8062405	0.755	rs4787455	chr16:28589455	G/A	cg01378222	chr16:28622494	SULT1A1	0.3	5.06	0.3	7.89e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs10463316	0.928	rs4958451	chr5:150740007	T/C	cg03212797	chr5:150827313	SLC36A1	-0.53	-6.75	-0.38	9.04e-11	Metabolite levels (Pyroglutamine);
CESC	cis	rs477895	0.713	rs67546972	chr11:63962162	G/A	cg04317338	chr11:64019027	PLCB3	0.9	9.39	0.5	2.86e-18	Mean platelet volume;
CESC	cis	rs13108904	0.518	rs4974602	chr4:1342391	C/T	cg13395646	chr4:1353034	KIAA1530	-0.53	-6.58	-0.37	2.48e-10	Obesity-related traits;
CESC	cis	rs16866061	1.000	rs72974238	chr2:225432470	C/A	cg12698349	chr2:225449008	CUL3	0.76	11.32	0.57	1.67e-24	Acute graft versus host disease in bone marrow transplantation (recipient effect);
CESC	cis	rs3733585	0.673	rs4235348	chr4:9951968	T/C	cg02734326	chr4:10020555	SLC2A9	-0.39	-5.64	-0.33	4.45e-8	Cleft plate (environmental tobacco smoke interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20544562	chr6:12012554	HIVEP1	-0.58	-6.57	-0.37	2.63e-10	Gut microbiome composition (summer);
CESC	cis	rs2295499	0.649	rs55679022	chr4:2707325	T/G	cg27239842	chr4:2403781	ZFYVE28	-0.34	-5.82	-0.34	1.69e-8	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
CESC	cis	rs4713118	0.662	rs149947	chr6:27972433	A/T	cg18032046	chr6:28092343	ZSCAN16	-0.59	-7.05	-0.4	1.58e-11	Parkinson's disease;
CESC	cis	rs12142240	0.659	rs111723629	chr1:46853361	G/T	cg10495392	chr1:46806563	NSUN4	0.56	6.15	0.35	2.86e-9	Menopause (age at onset);
CESC	cis	rs13191362	1.000	rs13209728	chr6:162997533	A/C	cg21926612	chr6:163149169	PACRG;PARK2	0.83	8.86	0.48	1.15e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	trans	rs7922314	0.571	rs16917991	chr10:64737762	A/C	cg06935979	chr1:232941706	KIAA1383	-0.63	-6.09	-0.35	3.89e-9	Cutaneous psoriasis;
CESC	cis	rs3540	0.618	rs11636089	chr15:91039527	C/T	cg10434728	chr15:90938212	IQGAP1	0.43	7.76	0.43	1.89e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs514406	0.861	rs505444	chr1:53251860	C/T	cg08736216	chr1:53307985	ZYG11A	-0.41	-7.04	-0.4	1.66e-11	Monocyte count;
CESC	cis	rs3768617	0.510	rs10797843	chr1:183081995	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.87	14.13	0.66	3.47e-34	Fuchs's corneal dystrophy;
CESC	cis	rs2120019	0.935	rs8043181	chr15:75380424	T/C	cg17294928	chr15:75287854	SCAMP5	-0.61	-6.84	-0.39	5.52e-11	Blood trace element (Zn levels);
CESC	cis	rs11723261	0.564	rs60994255	chr4:77446	G/A	cg12746427	chr4:53362	ZNF718;ZNF595	0.51	6.04	0.35	5.32e-9	Immune response to smallpox vaccine (IL-6);
CESC	cis	rs4253772	0.530	rs11704350	chr22:46671507	C/T	cg00784671	chr22:46762841	CELSR1	-0.57	-5.81	-0.34	1.75e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs780096	0.526	rs13472	chr2:27600239	G/A	cg12648201	chr2:27665141	KRTCAP3	-0.3	-5.4	-0.31	1.48e-7	Total body bone mineral density;
CESC	cis	rs7980687	0.550	rs1727324	chr12:123698603	A/T	cg00376283	chr12:123451042	ABCB9	0.61	6.34	0.36	9.86e-10	Height;Educational attainment;Head circumference (infant);
CESC	cis	rs9926296	0.712	rs258319	chr16:89732024	A/T	cg01097406	chr16:89675127	NA	0.38	5.33	0.31	2.09e-7	Vitiligo;
CESC	cis	rs763121	0.853	rs2284073	chr22:39105948	T/C	cg21395723	chr22:39101663	GTPBP1	0.5	6.84	0.39	5.32e-11	Menopause (age at onset);
CESC	cis	rs4865169	0.967	rs10023088	chr4:57884435	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.36	5.05	0.3	8.34e-7	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26085966	chr14:64319812	SYNE2	0.58	6.12	0.35	3.36e-9	Gut microbiome composition (summer);
CESC	cis	rs35079168	0.923	rs10858277	chr9:137287959	G/A	cg00753924	chr9:137298813	RXRA	-0.36	-5.56	-0.32	6.58e-8	Intelligence;
CESC	cis	rs11252926	0.583	rs4881333	chr10:519164	G/C	cg18196295	chr10:418757	DIP2C	0.4	5.4	0.32	1.46e-7	Psychosis in Alzheimer's disease;
CESC	trans	rs1493916	0.967	rs34341086	chr18:31400141	C/T	cg27147174	chr7:100797783	AP1S1	-0.54	-7.29	-0.41	3.53e-12	Life satisfaction;
CESC	cis	rs9916302	0.653	rs11654954	chr17:37745979	C/T	cg07936489	chr17:37558343	FBXL20	0.9	9.11	0.49	2.13e-17	Glomerular filtration rate (creatinine);
CESC	cis	rs1799949	0.965	rs4793233	chr17:41435437	G/C	cg05368731	chr17:41323189	NBR1	0.77	10.58	0.54	4.75e-22	Menopause (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19318450	chr21:34852305	TMEM50B	0.57	6.35	0.36	9.52e-10	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08754618	chr20:24973613	C20orf3	0.57	6.33	0.36	1.01e-9	Gut microbiome composition (summer);
CESC	cis	rs2836974	0.897	rs2836925	chr21:40532353	T/C	cg27266027	chr21:40555129	PSMG1	0.45	5.46	0.32	1.11e-7	Cognitive function;
CESC	cis	rs769267	0.965	rs1010207	chr19:19416045	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.62	7.88	0.44	8.25e-14	Tonsillectomy;
CESC	cis	rs6088580	0.524	rs6088567	chr20:33263872	A/T	cg08999081	chr20:33150536	PIGU	-0.45	-6.29	-0.36	1.33e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs477692	1.000	rs522891	chr10:131430916	T/C	cg05714579	chr10:131428358	MGMT	-0.51	-6.94	-0.39	2.93e-11	Response to temozolomide;
CESC	cis	rs5758511	0.514	rs3985938	chr22:42511727	G/T	cg00645731	chr22:42541494	CYP2D7P1	0.63	9.78	0.52	1.69e-19	Birth weight;
CESC	cis	rs459482	0.534	rs458255	chr21:42801128	G/A	cg14166395	chr21:42792516	MX1	0.45	5.27	0.31	2.84e-7	IgG glycosylation;
CESC	cis	rs6963495	0.538	rs55967123	chr7:105163678	C/A	cg02135003	chr7:105160482	PUS7	-0.47	-5.59	-0.33	5.51e-8	Bipolar disorder (body mass index interaction);
CESC	cis	rs6594499	0.872	rs6865932	chr5:110436852	G/C	cg04022379	chr5:110408740	TSLP	0.34	6.22	0.36	1.9e-9	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs67311347	1.000	rs9854493	chr3:40423622	T/C	cg09455208	chr3:40491958	NA	0.49	8.0	0.44	3.97e-14	Renal cell carcinoma;
CESC	cis	rs1799949	0.965	rs8176323	chr17:41195711	G/C	cg25072359	chr17:41440525	NA	0.44	5.89	0.34	1.16e-8	Menopause (age at onset);
CESC	cis	rs7772486	0.754	rs6937661	chr6:146113299	T/C	cg23711669	chr6:146136114	FBXO30	-0.97	-14.91	-0.68	6.51e-37	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs36051895	0.659	rs2149555	chr9:5053743	C/T	cg02405213	chr9:5042618	JAK2	-0.49	-5.87	-0.34	1.28e-8	Pediatric autoimmune diseases;
CESC	cis	rs6693567	0.565	rs3125808	chr1:150314272	T/C	cg09579323	chr1:150459698	TARS2	0.49	6.28	0.36	1.35e-9	Migraine;
CESC	cis	rs9457247	1.000	rs408087	chr6:167398952	C/T	cg25258033	chr6:167368657	RNASET2	0.41	6.27	0.36	1.44e-9	Crohn's disease;
CESC	cis	rs7666738	0.606	rs13108868	chr4:99083753	C/T	cg17366294	chr4:99064904	C4orf37	0.43	5.77	0.33	2.15e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs35110281	0.627	rs56369437	chr21:44970275	A/G	cg21573476	chr21:45109991	RRP1B	-0.4	-5.58	-0.32	6.02e-8	Mean corpuscular volume;
CESC	cis	rs7662987	0.517	rs2851268	chr4:100027878	A/G	cg13256891	chr4:100009986	ADH5	0.75	8.03	0.44	3.21e-14	Smoking initiation;
CESC	cis	rs858239	0.601	rs929507	chr7:23166664	G/C	cg23682824	chr7:23144976	KLHL7	0.54	7.61	0.42	4.95e-13	Cerebrospinal fluid biomarker levels;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg27238079	chr10:33247273	ITGB1	-0.46	-6.46	-0.37	5.12e-10	Fibrinogen levels;
CESC	cis	rs9486719	1.000	rs2472889	chr6:96866803	T/G	cg06623918	chr6:96969491	KIAA0776	0.81	8.29	0.45	5.61e-15	Migraine;Coronary artery disease;
CESC	cis	rs7937682	0.632	rs11603779	chr11:111781047	A/C	cg22437258	chr11:111473054	SIK2	-0.5	-5.6	-0.33	5.39e-8	Primary sclerosing cholangitis;
CESC	cis	rs4665809	0.525	rs4665324	chr2:26447147	A/C	cg08470875	chr2:26401718	FAM59B	-0.75	-7.78	-0.43	1.63e-13	Gut microbiome composition (summer);
CESC	cis	rs10871290	0.881	rs3863436	chr16:74468038	T/C	cg01733217	chr16:74700730	RFWD3	-0.7	-9.29	-0.5	6.06e-18	Breast cancer;
CESC	cis	rs643506	1.000	rs612345	chr11:111639122	G/A	cg09085632	chr11:111637200	PPP2R1B	0.53	6.74	0.38	9.89e-11	Breast cancer;
CESC	cis	rs72945132	0.882	rs947781	chr11:70212755	G/A	cg14191688	chr11:70257035	CTTN	0.43	5.37	0.31	1.72e-7	Coronary artery disease;
CESC	cis	rs2576037	0.542	rs4630643	chr18:44508142	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.78	12.9	0.62	7.04e-30	Personality dimensions;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20861091	chr8:144881744	SCRIB	-0.56	-6.87	-0.39	4.59e-11	Gut microbiome composition (summer);
CESC	cis	rs763121	0.853	rs5750662	chr22:39072472	G/A	cg06022373	chr22:39101656	GTPBP1	0.89	14.42	0.66	3.47e-35	Menopause (age at onset);
CESC	cis	rs734999	0.545	rs4648565	chr1:2570023	A/G	cg20673091	chr1:2541236	MMEL1	-0.48	-7.94	-0.44	5.65e-14	Ulcerative colitis;
CESC	cis	rs6968419	0.755	rs4730720	chr7:115895235	C/T	cg02561103	chr7:115862891	TES	0.42	5.48	0.32	1e-7	Intraocular pressure;
CESC	cis	rs3793683	0.597	rs12767469	chr10:134587261	C/G	cg26818010	chr10:134567672	INPP5A	-0.9	-11.01	-0.56	1.89e-23	Migraine;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03823108	chr20:1099106	PSMF1	0.61	6.94	0.39	2.94e-11	Gut microbiome composition (summer);
CESC	cis	rs2290159	0.800	rs11711419	chr3:12667784	A/T	cg23032965	chr3:12705835	RAF1	0.54	5.7	0.33	3.12e-8	Cholesterol, total;
CESC	cis	rs9527	0.545	rs12784384	chr10:104957594	G/C	cg04362960	chr10:104952993	NT5C2	0.44	5.56	0.32	6.74e-8	Arsenic metabolism;
CESC	cis	rs798554	0.959	rs798528	chr7:2772431	A/C	cg19717773	chr7:2847554	GNA12	-0.58	-8.39	-0.46	2.84e-15	Height;
CESC	cis	rs9910055	0.509	rs9916444	chr17:42313512	C/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.41	5.12	0.3	5.78e-7	Total body bone mineral density;
CESC	trans	rs11722228	0.521	rs12501336	chr4:10137351	G/A	cg26043149	chr18:55253948	FECH	1.01	13.15	0.63	9.28e-31	Gout;Urate levels;Serum uric acid levels;
CESC	cis	rs13253111	0.603	rs28605937	chr8:28099179	A/G	cg26534493	chr8:28060551	NA	0.46	7.29	0.41	3.66e-12	Childhood body mass index;
CESC	cis	rs12142240	0.621	rs66828173	chr1:46818166	G/A	cg10495392	chr1:46806563	NSUN4	0.57	6.27	0.36	1.47e-9	Menopause (age at onset);
CESC	cis	rs10504229	0.683	rs56741275	chr8:58136108	C/G	cg02725872	chr8:58115012	NA	-0.45	-7.05	-0.4	1.52e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg12262378	chr17:6899522	ALOX12	0.39	6.78	0.38	7.76e-11	Tonsillectomy;
CESC	trans	rs2207136	0.835	rs61687409	chr6:50857520	A/T	cg06522515	chr3:184090630	THPO	-0.36	-6.24	-0.36	1.69e-9	Myopia;
CESC	cis	rs10823500	0.545	rs7082562	chr10:71945684	A/G	cg04118878	chr10:71993077	PPA1	0.45	5.42	0.32	1.35e-7	Blood protein levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19046697	chr5:92915581	FLJ42709	-0.64	-8.02	-0.44	3.32e-14	Gut microbiome composition (summer);
CESC	cis	rs1178968	0.591	rs10440929	chr7:72786770	A/C	cg25889504	chr7:72793014	NA	0.49	5.18	0.3	4.46e-7	Triglyceride levels;
CESC	cis	rs2440129	0.611	rs1126667	chr17:6902760	C/T	cg03762994	chr17:6899332	ALOX12	-0.42	-7.45	-0.42	1.31e-12	Tonsillectomy;
CESC	cis	rs7267979	1.000	rs4815409	chr20:25346697	C/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.88	-18.07	-0.74	3.95e-48	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs10214930	0.697	rs757396	chr7:27908326	T/C	cg05786569	chr7:27702416	HIBADH	0.44	5.23	0.31	3.39e-7	Hypospadias;
CESC	cis	rs798554	0.796	rs2533884	chr7:2836848	T/G	cg13628971	chr7:2884303	GNA12	0.63	7.93	0.44	6e-14	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14451979	chr2:748557	NA	-0.49	-6.39	-0.37	7.28e-10	Gut microbiome composition (summer);
CESC	cis	rs9322193	0.736	rs10457851	chr6:150096352	T/A	cg04369109	chr6:150039330	LATS1	-0.39	-5.34	-0.31	2.01e-7	Lung cancer;
CESC	cis	rs7264396	0.635	rs6058344	chr20:34475038	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.62	7.47	0.42	1.16e-12	Total cholesterol levels;
CESC	cis	rs4332037	1.000	rs62442899	chr7:1948454	C/T	cg23422044	chr7:1970798	MAD1L1	-0.49	-5.03	-0.3	9.2e-7	Bipolar disorder;
CESC	cis	rs7917772	0.503	rs6584510	chr10:104299868	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.53	7.33	0.41	2.81e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs1801251	0.896	rs7573208	chr2:233696701	C/A	cg25237894	chr2:233734115	C2orf82	-0.37	-6.67	-0.38	1.51e-10	Coronary artery disease;
CESC	cis	rs1707322	0.721	rs6699418	chr1:46100181	G/A	cg03146154	chr1:46216737	IPP	0.76	10.71	0.55	1.75e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9837602	0.507	rs793455	chr3:99526135	C/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.5	-6.04	-0.35	5.21e-9	Breast cancer;
CESC	cis	rs4689388	0.853	rs13114527	chr4:6294655	T/G	cg14416269	chr4:6271139	WFS1	0.46	7.76	0.43	1.79e-13	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs13108904	0.901	rs1316393	chr4:1315619	A/G	cg22903657	chr4:1355424	KIAA1530	0.37	5.1	0.3	6.59e-7	Obesity-related traits;
CESC	cis	rs4803468	1.000	rs2304242	chr19:41944616	G/T	cg08639244	chr19:41945921	ATP5SL	0.43	5.33	0.31	2.07e-7	Height;
CESC	cis	rs60871478	1.000	rs62432861	chr7:807649	G/A	cg27478167	chr7:817139	HEATR2	-0.47	-5.53	-0.32	7.51e-8	Cerebrospinal P-tau181p levels;
CESC	cis	rs951366	0.903	rs708723	chr1:205739266	C/T	cg14893161	chr1:205819251	PM20D1	0.54	8.08	0.44	2.31e-14	Menarche (age at onset);
CESC	cis	rs10242455	0.557	rs77997620	chr7:99070415	G/T	cg25640893	chr7:99214727	ZNF498	0.7	5.17	0.3	4.58e-7	Blood metabolite levels;
CESC	cis	rs9457247	0.602	rs9459854	chr6:167465882	C/T	cg23791538	chr6:167370224	RNASET2	-0.52	-6.87	-0.39	4.45e-11	Crohn's disease;
CESC	trans	rs8014252	0.667	rs57535767	chr14:70791349	A/G	cg03123320	chr1:229394665	NA	-0.49	-6.27	-0.36	1.45e-9	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
CESC	cis	rs6500395	1.000	rs1477134	chr16:48706973	G/A	cg04672837	chr16:48644449	N4BP1	-0.51	-6.53	-0.37	3.33e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs950776	0.752	rs7182583	chr15:78899210	G/C	cg06917634	chr15:78832804	PSMA4	0.53	6.37	0.36	8.42e-10	Sudden cardiac arrest;
CESC	cis	rs10751667	0.666	rs7950967	chr11:955638	G/A	cg06064525	chr11:970664	AP2A2	-0.48	-9.52	-0.5	1.15e-18	Alzheimer's disease (late onset);
CESC	cis	rs611744	0.608	rs1448152	chr8:109278249	C/T	cg21045802	chr8:109455806	TTC35	0.5	6.23	0.36	1.82e-9	Dupuytren's disease;
CESC	cis	rs2816062	0.735	rs2816045	chr1:18892999	A/G	cg18795169	chr1:18902165	NA	-0.92	-18.09	-0.74	3.38e-48	Urate levels in lean individuals;
CESC	cis	rs2762353	0.779	rs1408273	chr6:25840946	C/T	cg03517284	chr6:25882590	NA	0.33	5.23	0.31	3.41e-7	Blood metabolite levels;
CESC	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg24829409	chr8:58192753	C8orf71	-0.67	-7.47	-0.42	1.15e-12	Developmental language disorder (linguistic errors);
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg00353844	chr1:3275283	PRDM16	0.36	6.08	0.35	4.12e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs736408	0.648	rs3774354	chr3:52817675	G/A	cg05564831	chr3:52568323	NT5DC2	0.42	6.09	0.35	3.9e-9	Bipolar disorder;
CESC	cis	rs4699052	0.928	rs2169511	chr4:104192580	G/A	cg16532752	chr4:104119610	CENPE	-0.43	-5.96	-0.34	8.21e-9	Testicular germ cell tumor;
CESC	cis	rs6582630	0.555	rs7978749	chr12:38527141	G/T	cg26384229	chr12:38710491	ALG10B	0.71	10.81	0.55	8.51e-23	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs7833986	0.501	rs72653953	chr8:56970795	C/T	cg26371346	chr8:56986568	SNORD54;RPS20	0.57	5.18	0.3	4.34e-7	Height;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg09964670	chr19:5720572	TMEM146;LONP1	-0.49	-6.37	-0.36	8.33e-10	Ulcerative colitis;
CESC	cis	rs6028335	0.674	rs59096774	chr20:37603529	A/G	cg16355469	chr20:37678765	NA	0.52	5.13	0.3	5.5e-7	Alcohol and nicotine co-dependence;
CESC	cis	rs780096	0.506	rs1647286	chr2:27714517	A/T	cg17158414	chr2:27665306	KRTCAP3	-0.32	-5.98	-0.34	7.07e-9	Total body bone mineral density;
CESC	cis	rs2404602	0.710	rs2469541	chr15:76562118	C/T	cg22467129	chr15:76604101	ETFA	0.39	5.85	0.34	1.47e-8	Blood metabolite levels;
CESC	cis	rs41271951	0.512	rs12058128	chr1:151106113	C/T	cg11822372	chr1:151115635	SEMA6C	-0.63	-5.06	-0.3	7.96e-7	Blood protein levels;
CESC	cis	rs12602901	0.519	rs238238	chr17:4856376	A/G	cg19427746	chr17:4889932	CAMTA2	-0.35	-5.51	-0.32	8.29e-8	Blood metabolite levels;
CESC	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg26338869	chr17:61819248	STRADA	0.68	8.87	0.48	1.08e-16	Prudent dietary pattern;
CESC	cis	rs7811142	1.000	rs67471932	chr7:100009985	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.1	10.82	0.55	7.72e-23	Platelet count;
CESC	cis	rs7937682	0.924	rs489783	chr11:111520522	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.99	-16.01	-0.7	8.36e-41	Primary sclerosing cholangitis;
CESC	cis	rs6964587	0.773	rs17757926	chr7:91987702	T/C	cg17063962	chr7:91808500	NA	0.54	6.79	0.38	7.4e-11	Breast cancer;
CESC	cis	rs1005277	0.505	rs7099777	chr10:38183569	A/C	cg25427524	chr10:38739819	LOC399744	0.69	10.35	0.54	2.68e-21	Extrinsic epigenetic age acceleration;
CESC	cis	rs2760061	0.655	rs686533	chr1:228119604	A/G	cg02753203	chr1:228287806	NA	-0.5	-7.36	-0.41	2.27e-12	Diastolic blood pressure;
CESC	cis	rs9911578	0.874	rs302874	chr17:56767996	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.4	5.15	0.3	4.99e-7	Intelligence (multi-trait analysis);
CESC	cis	rs1862618	0.613	rs252889	chr5:56227069	C/A	cg24531977	chr5:56204891	C5orf35	-0.67	-9.26	-0.49	7.22e-18	Initial pursuit acceleration;
CESC	cis	rs6499755	0.712	rs31090	chr16:55363628	A/G	cg02859129	chr16:55357253	IRX6	0.32	5.05	0.3	8.04e-7	Hypospadias;
CESC	cis	rs12541635	0.677	rs10808408	chr8:107005034	C/T	cg10147462	chr8:107024639	NA	0.42	6.23	0.36	1.83e-9	Age of smoking initiation;
CESC	cis	rs2303745	0.589	rs1465576	chr19:17398487	G/A	cg04248312	chr19:17393744	ANKLE1	-0.93	-15.09	-0.68	1.45e-37	Systemic lupus erythematosus;
CESC	cis	rs514406	0.929	rs2607095	chr1:53325639	T/C	cg25767906	chr1:53392781	SCP2	-0.44	-5.61	-0.33	4.98e-8	Monocyte count;
CESC	cis	rs17641971	0.684	rs4873094	chr8:49989578	G/T	cg00325661	chr8:49890786	NA	0.39	5.5	0.32	8.94e-8	Blood metabolite levels;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg08209184	chr20:35444560	C20orf117	0.45	6.42	0.37	6.31e-10	Fibrinogen levels;
CESC	cis	rs3733585	0.699	rs60045583	chr4:9971950	G/A	cg11266682	chr4:10021025	SLC2A9	-0.58	-10.83	-0.55	7.08e-23	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs67311347	1.000	rs9332450	chr3:40458041	C/T	cg24209194	chr3:40518798	ZNF619	-0.45	-5.86	-0.34	1.39e-8	Renal cell carcinoma;
CESC	trans	rs11191205	0.644	rs12354716	chr10:103386775	C/A	cg12418535	chr2:119607192	EN1	-0.4	-6.0	-0.35	6.56e-9	Intelligence (multi-trait analysis);
CESC	cis	rs642803	0.591	rs620088	chr11:65508986	G/A	cg08755490	chr11:65554678	OVOL1	0.43	5.57	0.32	6.1e-8	Urate levels;
CESC	cis	rs4819052	0.851	rs1999335	chr21:46670613	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.93	13.67	0.64	1.54e-32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs11098499	0.909	rs7681978	chr4:120383775	T/C	cg09307838	chr4:120376055	NA	0.95	13.79	0.65	5.71e-33	Corneal astigmatism;
CESC	cis	rs751728	1.000	rs755496	chr6:33734376	C/G	cg15252951	chr6:33757062	LEMD2	0.46	5.85	0.34	1.41e-8	Crohn's disease;
CESC	cis	rs1552244	1.000	rs4260416	chr3:10125283	C/T	cg16606324	chr3:10149918	C3orf24	0.44	5.49	0.32	9.21e-8	Alzheimer's disease;
CESC	cis	rs896854	0.654	rs1453377	chr8:95969947	C/T	cg13393036	chr8:95962371	TP53INP1	-0.48	-10.15	-0.53	1.13e-20	Type 2 diabetes;
CESC	cis	rs2108622	0.727	rs62107770	chr19:15985425	A/G	cg13772218	chr19:15982569	NA	0.3	5.91	0.34	1.07e-8	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CESC	cis	rs4969178	0.930	rs2292644	chr17:76394449	C/T	cg20026190	chr17:76395443	PGS1	0.49	7.91	0.44	6.98e-14	HDL cholesterol levels;
CESC	cis	rs28386778	0.863	rs3760252	chr17:61852186	G/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	13.51	0.64	5.51e-32	Prudent dietary pattern;
CESC	cis	rs763121	0.853	rs5750649	chr22:39036769	T/C	cg21395723	chr22:39101663	GTPBP1	0.5	6.66	0.38	1.6e-10	Menopause (age at onset);
CESC	cis	rs2228479	0.867	rs62052168	chr16:89947203	G/A	cg14709524	chr16:89940631	TCF25	0.89	6.56	0.37	2.74e-10	Skin colour saturation;
CESC	cis	rs6952808	0.608	rs6461049	chr7:2017445	C/T	cg02951883	chr7:2050386	MAD1L1	0.42	5.41	0.32	1.4e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs2625529	0.557	rs1000281	chr15:72553422	A/G	cg16672083	chr15:72433130	SENP8	0.41	6.17	0.35	2.51e-9	Red blood cell count;
CESC	cis	rs11792861	0.781	rs2151426	chr9:111743797	A/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.52	6.64	0.38	1.77e-10	Menarche (age at onset);
CESC	cis	rs2710642	0.576	rs974344	chr2:62883176	C/G	cg17519650	chr2:63277830	OTX1	0.46	5.55	0.32	6.82e-8	LDL cholesterol levels;LDL cholesterol;
CESC	trans	rs1814175	0.669	rs12416837	chr11:49669761	G/T	cg15704280	chr7:45808275	SEPT13	-0.82	-11.5	-0.58	4.36e-25	Height;
CESC	cis	rs11642862	1.000	rs11642862	chr16:30785824	A/G	cg02466173	chr16:30829666	NA	0.53	5.56	0.32	6.73e-8	Tonsillectomy;
CESC	cis	rs1881797	1.000	rs1881797	chr1:247689532	A/G	cg21399703	chr1:247681439	NA	0.47	6.98	0.39	2.43e-11	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs2439831	0.867	rs6493082	chr15:43634808	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.88	10.46	0.54	1.19e-21	Lung cancer in ever smokers;
CESC	cis	rs7927771	1.000	rs1317149	chr11:47486885	C/T	cg18512352	chr11:47633146	NA	-0.6	-9.02	-0.48	3.9e-17	Subjective well-being;
CESC	cis	rs9905704	0.633	rs2632523	chr17:56506634	G/A	cg12560992	chr17:57184187	TRIM37	0.58	5.6	0.33	5.39e-8	Testicular germ cell tumor;
CESC	cis	rs4253772	0.626	rs9615960	chr22:46752307	G/A	cg00784671	chr22:46762841	CELSR1	-0.68	-6.08	-0.35	4.2e-9	LDL cholesterol;Cholesterol, total;
CESC	cis	rs11677416	1.000	rs7570215	chr2:113527660	G/T	cg27083787	chr2:113543245	IL1A	0.41	5.16	0.3	4.75e-7	Response to antipsychotic treatment in schizophrenia (working memory);
CESC	trans	rs8099014	1.000	rs9319929	chr18:56115825	A/C	cg06677321	chr17:67603831	NA	0.43	6.01	0.35	6.19e-9	Platelet count;
CESC	cis	rs4604732	0.642	rs4400652	chr1:247636479	A/G	cg12758973	chr1:247694275	LOC148824;OR2C3	0.39	5.5	0.32	9.09e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs11122272	0.638	rs2739514	chr1:231514806	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.48	-6.24	-0.36	1.7e-9	Hemoglobin concentration;
CESC	cis	rs10504229	1.000	rs67105789	chr8:58192002	G/T	cg05313129	chr8:58192883	C8orf71	-0.55	-6.29	-0.36	1.34e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs2243480	0.901	rs1701759	chr7:65470932	G/T	cg13147721	chr7:65941812	NA	-0.86	-8.36	-0.46	3.7e-15	Diabetic kidney disease;
CESC	cis	rs7945705	0.818	rs2653613	chr11:8879105	C/T	cg12365402	chr11:9010492	NRIP3	-0.33	-5.25	-0.31	3.05e-7	Hemoglobin concentration;
CESC	cis	rs2832077	0.527	rs59730679	chr21:30226244	T/C	cg08807101	chr21:30365312	RNF160	-0.66	-8.57	-0.47	8.73e-16	Cognitive test performance;
CESC	cis	rs7666738	0.830	rs7697315	chr4:98938764	T/C	cg05340658	chr4:99064831	C4orf37	0.79	11.74	0.58	6.86e-26	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4665809	0.941	rs1470096	chr2:26311482	T/C	cg25036284	chr2:26402008	FAM59B	-0.73	-8.35	-0.46	3.78e-15	Gut microbiome composition (summer);
CESC	cis	rs116095464	0.867	rs7726582	chr5:215349	C/G	cg12570787	chr5:219185	SDHA;CCDC127	0.52	5.5	0.32	8.91e-8	Breast cancer;
CESC	cis	rs9649213	0.593	rs2240349	chr7:97984663	C/T	cg21770322	chr7:97807741	LMTK2	0.57	8.84	0.48	1.39e-16	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs926938	0.520	rs969273	chr1:115256669	G/A	cg12756093	chr1:115239321	AMPD1	-0.52	-6.34	-0.36	9.75e-10	Autism;
CESC	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	7.64	0.43	3.85e-13	Prudent dietary pattern;
CESC	cis	rs4975616	0.869	rs452932	chr5:1330253	T/C	cg26373071	chr5:1325741	CLPTM1L	0.43	6.91	0.39	3.59e-11	Lung cancer;
CESC	cis	rs1401999	0.714	rs13066518	chr3:183635498	T/A	cg01324343	chr3:183735012	ABCC5	0.5	9.97	0.52	4.5e-20	Anterior chamber depth;
CESC	cis	rs2274273	0.905	rs2147961	chr14:55585381	T/C	cg04306507	chr14:55594613	LGALS3	0.31	6.18	0.36	2.38e-9	Protein biomarker;
CESC	cis	rs763121	0.853	rs6519119	chr22:38989007	C/G	cg06544989	chr22:39130855	UNC84B	0.5	8.31	0.45	4.85e-15	Menopause (age at onset);
CESC	trans	rs921968	0.541	rs496674	chr2:219432569	G/A	cg15547669	chr20:2781122	CPXM1	0.36	6.01	0.35	5.97e-9	Mean corpuscular hemoglobin concentration;
CESC	cis	rs10504229	0.683	rs67035623	chr8:58139963	G/T	cg24829409	chr8:58192753	C8orf71	-0.59	-7.31	-0.41	3.16e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs881375	0.967	rs10739580	chr9:123695282	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.38	5.2	0.3	4.07e-7	Rheumatoid arthritis;
CESC	cis	rs787274	1.000	rs1418410	chr9:115465282	A/G	cg13803584	chr9:115635662	SNX30	0.53	5.07	0.3	7.4e-7	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs7584330	0.737	rs1497129	chr2:238369184	C/T	cg14458575	chr2:238380390	NA	0.61	8.58	0.47	7.98e-16	Prostate cancer;
CESC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg13445258	chr3:128369860	RPN1	0.54	7.0	0.4	2.07e-11	Tetralogy of Fallot;
CESC	cis	rs875971	0.789	rs10260426	chr7:65736042	G/T	cg19163074	chr7:65112434	INTS4L2	0.4	5.16	0.3	4.86e-7	Aortic root size;
CESC	cis	rs7727544	0.571	rs12521097	chr5:131575338	G/A	cg14196790	chr5:131705035	SLC22A5	0.34	5.15	0.3	5.02e-7	Blood metabolite levels;
CESC	cis	rs3741151	0.764	rs79892955	chr11:73096280	G/T	cg17517138	chr11:73019481	ARHGEF17	0.84	6.34	0.36	9.67e-10	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs3857067	0.806	rs6825522	chr4:95108140	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.6	-9.05	-0.49	3.25e-17	QT interval;
CESC	cis	rs2019216	0.542	rs3829569	chr17:21909222	T/C	cg22648282	chr17:21454238	C17orf51	-0.44	-5.96	-0.34	7.89e-9	Pelvic organ prolapse;
CESC	cis	rs4665809	0.549	rs34075014	chr2:26520842	T/C	cg26314531	chr2:26401878	FAM59B	0.67	6.4	0.37	6.88e-10	Gut microbiome composition (summer);
CESC	cis	rs514406	0.825	rs7523761	chr1:53250915	T/C	cg27535305	chr1:53392650	SCP2	0.3	5.37	0.31	1.75e-7	Monocyte count;
CESC	cis	rs9488822	0.676	rs3798227	chr6:116324898	A/G	cg05304507	chr6:116381966	FRK	0.26	6.56	0.37	2.82e-10	Cholesterol, total;LDL cholesterol;
CESC	cis	rs523516	0.645	rs657723	chr17:37319103	T/C	cg20555674	chr17:37321631	ARL5C	0.39	6.5	0.37	3.86e-10	IgG glycosylation;
CESC	cis	rs10751667	0.714	rs7395879	chr11:963855	G/C	cg06064525	chr11:970664	AP2A2	-0.47	-9.32	-0.5	4.88e-18	Alzheimer's disease (late onset);
CESC	cis	rs7129220	0.660	rs61878632	chr11:10136032	A/C	cg01453529	chr11:10209919	SBF2	-0.48	-5.62	-0.33	4.73e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CESC	cis	rs6964587	0.692	rs7807490	chr7:91773359	A/G	cg17063962	chr7:91808500	NA	0.44	6.41	0.37	6.51e-10	Breast cancer;
CESC	cis	rs10504229	1.000	rs61998259	chr8:58192290	T/C	cg22535103	chr8:58192502	C8orf71	-1.05	-13.08	-0.63	1.71e-30	Developmental language disorder (linguistic errors);
CESC	cis	rs9300255	0.602	rs949142	chr12:123634043	T/C	cg19016782	chr12:123741754	C12orf65	-0.37	-5.04	-0.3	8.55e-7	Neutrophil percentage of white cells;
CESC	cis	rs7107174	0.892	rs2512534	chr11:77970039	T/A	cg02023728	chr11:77925099	USP35	0.48	6.34	0.36	9.87e-10	Testicular germ cell tumor;
CESC	cis	rs875971	0.862	rs9791713	chr7:66105198	C/A	cg18876405	chr7:65276391	NA	-0.5	-6.67	-0.38	1.46e-10	Aortic root size;
CESC	cis	rs4664308	1.000	rs17341301	chr2:160902420	G/A	cg03641300	chr2:160917029	PLA2R1	-0.65	-9.55	-0.51	9.19e-19	Idiopathic membranous nephropathy;
CESC	cis	rs896854	0.654	rs896846	chr8:95972453	G/A	cg26343298	chr8:95960752	TP53INP1	0.36	5.96	0.34	7.8e-9	Type 2 diabetes;
CESC	cis	rs6456156	0.586	rs1358883	chr6:167467433	C/G	cg07741184	chr6:167504864	NA	-0.34	-5.85	-0.34	1.47e-8	Primary biliary cholangitis;
CESC	cis	rs9488822	0.676	rs12202181	chr6:116327102	A/G	cg26893134	chr6:116381904	FRK	0.25	6.02	0.35	5.89e-9	Cholesterol, total;LDL cholesterol;
CESC	cis	rs2380220	0.541	rs72928283	chr6:96082490	A/C	cg15832292	chr6:96025679	MANEA	-0.78	-8.11	-0.45	1.94e-14	Behavioural disinhibition (generation interaction);
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg07541786	chr7:12610355	SCIN	-0.44	-6.07	-0.35	4.5e-9	Height;
CESC	cis	rs2996428	0.667	rs11578070	chr1:3769871	G/C	cg13057898	chr1:3703894	LRRC47	0.45	6.09	0.35	3.87e-9	Red cell distribution width;
CESC	cis	rs4664308	1.000	rs56297666	chr2:160902023	G/C	cg03641300	chr2:160917029	PLA2R1	-0.66	-9.75	-0.51	2.16e-19	Idiopathic membranous nephropathy;
CESC	cis	rs3733585	0.753	rs1122141	chr4:9947278	T/C	cg00071950	chr4:10020882	SLC2A9	-0.78	-14.02	-0.65	8.94e-34	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs3126085	0.877	rs1552996	chr1:152171104	C/A	cg26876637	chr1:152193138	HRNR	0.44	5.09	0.3	6.66e-7	Atopic dermatitis;
CESC	cis	rs2075371	0.933	rs1868784	chr7:133945932	A/G	cg11752832	chr7:134001865	SLC35B4	0.52	6.71	0.38	1.2e-10	Mean platelet volume;
CESC	cis	rs6540556	0.682	rs932335	chr1:209905734	G/C	cg05527609	chr1:210001259	C1orf107	-0.61	-6.69	-0.38	1.34e-10	Red blood cell count;
CESC	cis	rs12410462	0.581	rs12402691	chr1:227543693	G/A	cg04117972	chr1:227635322	NA	0.6	5.08	0.3	7.29e-7	Major depressive disorder;
CESC	cis	rs8114671	0.804	rs3803936	chr20:33632775	T/C	cg07148914	chr20:33460835	GGT7	-0.41	-5.31	-0.31	2.28e-7	Height;
CESC	cis	rs11997175	0.545	rs66584807	chr8:33667609	A/G	ch.8.33884649F	chr8:33765107	NA	0.55	6.81	0.39	6.5e-11	Body mass index;
CESC	cis	rs875971	0.505	rs2462573	chr7:65507392	C/T	cg18876405	chr7:65276391	NA	-0.68	-9.52	-0.5	1.1e-18	Aortic root size;
CESC	cis	rs3818285	0.655	rs588160	chr10:111641538	C/T	cg00817464	chr10:111662876	XPNPEP1	0.48	7.46	0.42	1.23e-12	Superior crus of antihelix expression;
CESC	cis	rs7134594	0.677	rs9668180	chr12:109860597	T/G	cg19025524	chr12:109796872	NA	-0.41	-5.93	-0.34	9.34e-9	HDL cholesterol;
CESC	cis	rs7248779	0.512	rs12610522	chr19:2413228	C/T	cg22729335	chr19:2427816	TIMM13	1.11	20.27	0.78	8.38e-56	Cortisol levels (saliva);
CESC	cis	rs9911578	1.000	rs1631237	chr17:56734695	A/G	cg12560992	chr17:57184187	TRIM37	0.93	15.58	0.69	2.6e-39	Intelligence (multi-trait analysis);
CESC	cis	rs2243480	1.000	rs160634	chr7:65528664	C/T	cg18252515	chr7:66147081	NA	1.01	10.44	0.54	1.3e-21	Diabetic kidney disease;
CESC	cis	rs9733	0.818	rs11204702	chr1:150663507	C/A	cg13175981	chr1:150552382	MCL1	0.63	9.33	0.5	4.42e-18	Tonsillectomy;
CESC	cis	rs6032067	0.929	rs35475980	chr20:43821080	A/T	cg11264863	chr20:43835661	SEMG1	0.48	5.29	0.31	2.53e-7	Blood protein levels;
CESC	cis	rs1799949	1.000	rs8176126	chr17:41259049	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	-0.45	-6.33	-0.36	1.07e-9	Menopause (age at onset);
CESC	cis	rs7618915	0.501	rs13085775	chr3:52678370	C/T	cg18404041	chr3:52824283	ITIH1	-0.38	-6.5	-0.37	4.04e-10	Bipolar disorder;
CESC	cis	rs10504229	0.906	rs2270608	chr8:58194688	T/C	cg22535103	chr8:58192502	C8orf71	-1.07	-13.39	-0.64	1.44e-31	Developmental language disorder (linguistic errors);
CESC	cis	rs8177253	0.761	rs35332919	chr3:133519002	T/A	cg18769074	chr3:133464867	TF	0.3	5.34	0.31	1.98e-7	Iron status biomarkers;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg20165655	chr11:65339703	FAM89B	0.47	6.41	0.37	6.67e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs7618915	0.524	rs10433615	chr3:52638482	C/T	cg18099408	chr3:52552593	STAB1	-0.31	-5.09	-0.3	6.68e-7	Bipolar disorder;
CESC	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg18402987	chr7:1209562	NA	0.74	7.26	0.41	4.18e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7084402	1.000	rs7074778	chr10:60272248	C/T	cg07615347	chr10:60278583	BICC1	-0.58	-9.2	-0.49	1.1e-17	Refractive error;
CESC	cis	rs6584283	1.000	rs6584283	chr10:101290301	A/G	cg09788492	chr10:101292477	NKX2-3	0.32	5.84	0.34	1.55e-8	Ulcerative colitis;
CESC	cis	rs832540	0.519	rs6895442	chr5:56260998	T/C	cg12311346	chr5:56204834	C5orf35	-0.44	-5.52	-0.32	8.09e-8	Coronary artery disease;
CESC	cis	rs1712517	0.873	rs7913461	chr10:105001325	A/G	cg05636881	chr10:105038444	INA	0.29	5.09	0.3	6.86e-7	Migraine;
CESC	cis	rs13118159	0.836	rs2276903	chr4:1343405	A/G	cg16405210	chr4:1374714	KIAA1530	-0.6	-8.01	-0.44	3.6e-14	Longevity;
CESC	cis	rs4853012	0.887	rs2280642	chr2:74358252	T/A	cg01017244	chr2:74357527	NA	0.73	10.07	0.53	2.09e-20	Gestational age at birth (maternal effect);
CESC	cis	rs769267	0.965	rs4808200	chr19:19554803	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.57	6.99	0.39	2.29e-11	Tonsillectomy;
CESC	cis	rs4955124	0.730	rs59870036	chr3:32044252	G/A	cg05935571	chr3:32023257	ZNF860;OSBPL10	0.8	5.93	0.34	9.37e-9	Schizophrenia;
CESC	cis	rs10504229	1.000	rs73609764	chr8:58192971	G/A	cg05313129	chr8:58192883	C8orf71	-0.55	-6.29	-0.36	1.34e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs10754283	0.967	rs1934045	chr1:90107799	A/C	cg21401794	chr1:90099060	LRRC8C	-0.69	-9.25	-0.49	7.8e-18	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs7771547	0.573	rs629721	chr6:36398229	T/C	cg07856975	chr6:36356162	ETV7	0.36	5.38	0.31	1.67e-7	Platelet distribution width;
CESC	cis	rs3015497	0.626	rs7150204	chr14:51137355	T/C	cg09863266	chr14:51125203	SAV1	-0.35	-5.39	-0.31	1.59e-7	Mean platelet volume;
CESC	cis	rs9649213	0.502	rs6465680	chr7:98005778	A/G	cg08684580	chr7:98029266	BAIAP2L1	-0.35	-5.66	-0.33	4.01e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs6964587	0.869	rs6946764	chr7:91539003	A/G	cg17063962	chr7:91808500	NA	-0.53	-7.0	-0.4	2.06e-11	Breast cancer;
CESC	cis	rs1595825	0.891	rs16867018	chr2:198521490	C/T	cg10820045	chr2:198174542	NA	0.41	5.21	0.3	3.79e-7	Ulcerative colitis;
CESC	cis	rs6696846	0.515	rs12136320	chr1:205110946	T/C	cg00857998	chr1:205179979	DSTYK	0.42	5.53	0.32	7.52e-8	Red blood cell count;
CESC	cis	rs6598955	0.671	rs17163866	chr1:26648088	A/G	cg19743891	chr1:26644573	UBXN11;CD52	0.38	5.44	0.32	1.24e-7	Obesity-related traits;
CESC	cis	rs34330	0.562	rs11055025	chr12:12866619	A/T	cg09462578	chr12:12878428	APOLD1	-0.7	-7.6	-0.42	5.26e-13	Systemic lupus erythematosus;
CESC	cis	rs950776	0.593	rs6495306	chr15:78865893	C/T	cg06917634	chr15:78832804	PSMA4	-0.61	-8.18	-0.45	1.19e-14	Sudden cardiac arrest;
CESC	cis	rs79976124	0.760	rs74295030	chr6:66654441	T/C	cg07460842	chr6:66804631	NA	0.74	8.77	0.47	2.22e-16	Type 2 diabetes;
CESC	cis	rs10739663	0.520	rs1566362	chr9:128163132	C/T	cg14078157	chr9:128172775	NA	0.33	5.16	0.3	4.77e-7	Resting heart rate;
CESC	cis	rs4665809	0.549	rs17527979	chr2:26428132	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.06	-11.84	-0.59	2.96e-26	Gut microbiome composition (summer);
CESC	cis	rs2842992	0.747	rs1547093	chr6:160205991	C/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.78	9.62	0.51	5.44e-19	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs7666738	0.822	rs6815312	chr4:99058220	T/C	cg03676636	chr4:99064102	C4orf37	0.34	5.1	0.3	6.47e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1448094	0.512	rs12314318	chr12:86249238	T/C	cg02569458	chr12:86230093	RASSF9	0.49	7.27	0.41	3.98e-12	Major depressive disorder;
CESC	cis	rs7107174	0.892	rs12284390	chr11:78103902	C/A	cg02023728	chr11:77925099	USP35	0.47	6.17	0.35	2.54e-9	Testicular germ cell tumor;
CESC	cis	rs514406	0.644	rs6661196	chr1:53203664	A/G	cg27535305	chr1:53392650	SCP2	0.35	6.13	0.35	3.1e-9	Monocyte count;
CESC	cis	rs1336900	0.641	rs6587756	chr1:150546865	A/T	cg17724175	chr1:150552817	MCL1	-0.5	-7.92	-0.44	6.38e-14	Blood protein levels;
CESC	cis	rs7666738	0.648	rs33988750	chr4:98985386	T/C	cg17366294	chr4:99064904	C4orf37	0.55	5.99	0.35	6.79e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs12765878	1.000	rs11191843	chr10:105648651	G/C	cg11005552	chr10:105648138	OBFC1	0.35	5.06	0.3	7.92e-7	Coronary artery disease;
CESC	trans	rs10435719	0.834	rs11250176	chr8:11792816	A/G	cg15556689	chr8:8085844	FLJ10661	0.51	6.3	0.36	1.22e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
CESC	trans	rs561341	0.830	rs2301765	chr17:30202056	T/A	cg20587970	chr11:113659929	NA	0.99	11.71	0.58	8.33e-26	Hip circumference adjusted for BMI;
CESC	cis	rs9611565	0.659	rs12483786	chr22:41938536	A/G	cg17376030	chr22:41985996	PMM1	0.73	7.98	0.44	4.57e-14	Vitiligo;
CESC	cis	rs7647973	1.000	rs9860055	chr3:49506900	C/T	cg07636037	chr3:49044803	WDR6	-0.72	-10.25	-0.53	5.58e-21	Menarche (age at onset);
CESC	cis	rs3020736	0.500	rs5996109	chr22:42493098	A/G	cg04733989	chr22:42467013	NAGA	-0.79	-12.03	-0.59	6.75e-27	Autism spectrum disorder or schizophrenia;
CESC	cis	rs1862618	0.853	rs2548664	chr5:56133555	G/A	cg22800045	chr5:56110881	MAP3K1	0.83	9.98	0.52	3.92e-20	Initial pursuit acceleration;
CESC	cis	rs6952808	0.723	rs60995052	chr7:2030007	G/C	cg08027265	chr7:2291960	NA	-0.37	-5.53	-0.32	7.61e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs769267	0.965	rs4808937	chr19:19398005	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.42	5.33	0.31	2.07e-7	Tonsillectomy;
CESC	cis	rs10504229	0.861	rs67966192	chr8:58188172	A/C	cg22535103	chr8:58192502	C8orf71	-0.87	-11.24	-0.57	3.19e-24	Developmental language disorder (linguistic errors);
CESC	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg27194152	chr7:157982427	PTPRN2	0.34	5.42	0.32	1.35e-7	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CESC	cis	rs7666738	0.791	rs2081622	chr4:98927369	T/C	cg05340658	chr4:99064831	C4orf37	0.82	12.2	0.6	1.81e-27	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10504229	1.000	rs67546820	chr8:58168567	G/A	cg24829409	chr8:58192753	C8orf71	-0.75	-9.86	-0.52	9.69e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs1023500	0.551	rs2859438	chr22:42466980	A/T	cg12850546	chr22:42539477	CYP2D7P1	-0.43	-5.15	-0.3	5.05e-7	Schizophrenia;
CESC	cis	rs56309584	0.673	rs12451139	chr17:8119626	G/T	cg06726167	chr17:8076949	TMEM107	-0.5	-5.1	-0.3	6.44e-7	Initial pursuit acceleration;
CESC	cis	rs28374715	0.681	rs11629979	chr15:41626579	A/G	cg20272979	chr15:41787780	ITPKA	0.39	5.21	0.3	3.76e-7	Ulcerative colitis;
CESC	cis	rs13191362	0.938	rs35211042	chr6:162998703	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.83	8.86	0.48	1.15e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs40363	0.645	rs250630	chr16:3524242	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.54	-6.9	-0.39	3.91e-11	Tuberculosis;
CESC	cis	rs9611565	0.512	rs4512	chr22:42206084	G/C	cg06481639	chr22:41940642	POLR3H	-0.61	-5.9	-0.34	1.09e-8	Vitiligo;
CESC	cis	rs2304069	0.507	rs13167061	chr5:149388624	T/G	cg12661370	chr5:149340060	SLC26A2	0.47	6.27	0.36	1.49e-9	HIV-1 control;
CESC	cis	rs561341	0.660	rs7406043	chr17:30220152	C/G	cg12193833	chr17:30244370	NA	-0.58	-6.06	-0.35	4.77e-9	Hip circumference adjusted for BMI;
CESC	trans	rs9467711	0.606	rs72836482	chr6:26359241	A/T	cg06606381	chr12:133084897	FBRSL1	-0.76	-6.87	-0.39	4.66e-11	Autism spectrum disorder or schizophrenia;
CESC	cis	rs4604732	0.631	rs4411161	chr1:247632374	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.49	6.11	0.35	3.52e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs10911232	0.524	rs10737238	chr1:183025303	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.87	13.5	0.64	5.97e-32	Hypertriglyceridemia;
CESC	cis	rs853679	0.517	rs9348796	chr6:28126202	A/G	cg08968635	chr6:28129556	ZNF389	0.4	5.22	0.31	3.69e-7	Depression;
CESC	cis	rs853679	0.517	rs9393893	chr6:28109262	T/C	cg08968635	chr6:28129556	ZNF389	0.41	5.53	0.32	7.61e-8	Depression;
CESC	trans	rs208520	0.661	rs1776361	chr6:66822270	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.0	-13.01	-0.62	3.05e-30	Exhaled nitric oxide output;
CESC	cis	rs1387259	0.839	rs7487682	chr12:48579665	A/C	cg24011408	chr12:48396354	COL2A1	-0.47	-7.02	-0.4	1.82e-11	Obstructive sleep apnea trait (apnea hypopnea index);
CESC	cis	rs6748734	1.000	rs4675863	chr2:241830763	A/T	cg07537917	chr2:241836409	C2orf54	-0.25	-5.17	-0.3	4.61e-7	Urinary metabolites;
CESC	cis	rs2204008	0.627	rs11176531	chr12:38152166	T/G	cg13010199	chr12:38710504	ALG10B	0.52	6.26	0.36	1.52e-9	Bladder cancer;
CESC	cis	rs4642101	0.824	rs9820977	chr3:12842932	G/A	cg05775895	chr3:12838266	CAND2	0.39	5.78	0.33	2.1e-8	QRS complex (12-leadsum);
CESC	cis	rs12956009	0.583	rs1821446	chr18:44894422	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.51	6.78	0.38	8e-11	Educational attainment (years of education);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16321474	chr12:48299386	VDR	0.49	6.05	0.35	5.04e-9	Gut microbiome composition (summer);
CESC	cis	rs425277	0.539	rs3107142	chr1:2044542	T/C	cg04315214	chr1:2043799	PRKCZ	0.64	11.39	0.57	9.95e-25	Height;
CESC	cis	rs11969893	0.850	rs9485417	chr6:101300038	C/T	cg12253828	chr6:101329408	ASCC3	-1.14	-10.08	-0.53	1.91e-20	Economic and political preferences (immigration/crime);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17249942	chr21:45660288	ICOSLG	0.61	6.59	0.38	2.35e-10	Gut microbiome composition (summer);
CESC	cis	rs11958404	0.789	rs72818145	chr5:157476552	G/C	cg05962755	chr5:157440814	NA	0.62	7.23	0.41	5.17e-12	IgG glycosylation;
CESC	cis	rs11711311	1.000	rs7645473	chr3:113516187	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.59	7.86	0.43	9.7e-14	IgG glycosylation;
CESC	cis	rs4604732	0.631	rs12039596	chr1:247624766	A/G	cg12754571	chr1:247694271	LOC148824;OR2C3	0.44	5.44	0.32	1.21e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs1401999	0.966	rs1533682	chr3:183634879	A/G	cg01324343	chr3:183735012	ABCC5	0.64	13.43	0.64	9.95e-32	Anterior chamber depth;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21721210	chr19:39574878	PAPL	0.59	7.51	0.42	8.82e-13	Gut microbiome composition (summer);
CESC	cis	rs4727027	0.680	rs6464941	chr7:148826352	A/G	cg23158103	chr7:148848205	ZNF398	-0.34	-5.17	-0.3	4.72e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs8103278	1.000	rs8108864	chr19:46301671	G/A	cg11657440	chr19:46296263	DMWD	-0.58	-7.23	-0.41	5.09e-12	Coronary artery disease;
CESC	cis	rs9303401	0.659	rs34556735	chr17:56694447	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.03	11.8	0.59	4.12e-26	Cognitive test performance;
CESC	cis	rs853679	0.542	rs6934769	chr6:28090931	A/G	cg22143856	chr6:28129313	ZNF389	0.51	6.62	0.38	2e-10	Depression;
CESC	cis	rs1707322	0.686	rs2230658	chr1:46078854	A/G	cg03146154	chr1:46216737	IPP	-0.79	-10.71	-0.55	1.73e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs1046896	0.594	rs4075209	chr17:80800027	G/T	cg02398342	chr17:80708632	TBCD;FN3K	0.46	5.47	0.32	1.03e-7	Glycated hemoglobin levels;
CESC	cis	rs10504229	0.683	rs2318148	chr8:58114955	G/A	cg02725872	chr8:58115012	NA	-0.45	-7.05	-0.4	1.52e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs7618501	0.602	rs2013208	chr3:50129399	C/T	cg24110177	chr3:50126178	RBM5	0.52	7.2	0.4	6.12e-12	Intelligence (multi-trait analysis);
CESC	cis	rs853679	0.517	rs9368550	chr6:28051803	T/A	cg23281280	chr6:28129359	ZNF389	0.57	7.78	0.43	1.61e-13	Depression;
CESC	cis	rs3105593	1.000	rs3848129	chr15:50892064	C/T	cg08437265	chr15:50716283	USP8	0.42	5.4	0.31	1.5e-7	QT interval;
CESC	cis	rs2276314	1.000	rs8086395	chr18:33564592	C/G	cg05985134	chr18:33552581	C18orf21	0.64	7.43	0.42	1.5e-12	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs13064411	0.696	rs1486897	chr3:113215818	G/A	cg18753928	chr3:113234510	CCDC52	-0.48	-5.62	-0.33	4.91e-8	Response to simvastatin treatment (PCSK9 protein level change);
CESC	cis	rs7267979	0.966	rs2500433	chr20:25296335	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.84	-16.08	-0.7	4.65e-41	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs8060686	0.920	rs73591968	chr16:67803063	G/A	cg26727032	chr16:67993705	SLC12A4	-0.58	-6.02	-0.35	5.68e-9	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs898097	0.841	rs2271918	chr17:80861206	A/G	cg10494973	chr17:80897199	TBCD	0.5	5.52	0.32	7.95e-8	Breast cancer;
CESC	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.63	7.16	0.4	7.99e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs8177253	0.965	rs8177260	chr3:133480458	T/A	cg12373951	chr3:133503437	NA	0.42	6.19	0.36	2.31e-9	Iron status biomarkers;
CESC	cis	rs7523050	0.730	rs41279678	chr1:109440215	G/A	cg08274380	chr1:109419600	GPSM2	0.91	6.37	0.36	8.46e-10	Fat distribution (HIV);
CESC	cis	rs3540	0.618	rs11636089	chr15:91039527	C/T	cg22089800	chr15:90895588	ZNF774	0.64	8.73	0.47	2.93e-16	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs6952808	0.792	rs12531315	chr7:1953650	C/G	cg00106254	chr7:1943704	MAD1L1	-0.47	-5.93	-0.34	9.22e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs4665809	1.000	rs2053367	chr2:26293413	T/C	cg08470875	chr2:26401718	FAM59B	-0.46	-5.12	-0.3	5.98e-7	Gut microbiome composition (summer);
CESC	cis	rs40363	0.723	rs4785936	chr16:3535116	A/G	cg21433313	chr16:3507492	NAT15	-0.62	-6.71	-0.38	1.15e-10	Tuberculosis;
CESC	cis	rs6460942	0.841	rs6968277	chr7:12443795	C/A	cg16278512	chr7:12443529	VWDE	-0.53	-6.67	-0.38	1.47e-10	Coronary artery disease;
CESC	trans	rs4906172	0.773	rs34509705	chr14:102513044	C/G	cg17920195	chr4:129149383	NA	0.32	6.07	0.35	4.43e-9	Menopause (age at onset);
CESC	trans	rs11165623	0.792	rs2104236	chr1:96908690	C/T	cg10631902	chr5:14652156	NA	-0.55	-8.26	-0.45	7.06e-15	Hip circumference;Waist circumference;
CESC	cis	rs9905704	0.918	rs11657676	chr17:56842043	A/G	cg12560992	chr17:57184187	TRIM37	0.61	7.12	0.4	9.95e-12	Testicular germ cell tumor;
CESC	cis	rs853679	0.517	rs4713145	chr6:28106827	T/C	cg17949981	chr6:28129498	ZNF389	0.45	5.72	0.33	2.85e-8	Depression;
CESC	cis	rs4728302	0.934	rs2971963	chr7:133641505	A/G	cg10665199	chr7:133106180	EXOC4	-0.37	-5.04	-0.3	8.73e-7	Intelligence;Intelligence (multi-trait analysis);
CESC	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.38	7.42	0.41	1.55e-12	Bipolar disorder;
CESC	cis	rs7666738	0.830	rs4699593	chr4:98980628	A/G	cg05340658	chr4:99064831	C4orf37	0.79	12.32	0.6	7.31e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9322193	0.884	rs9480009	chr6:150079638	A/G	cg07701084	chr6:150067640	NUP43	0.49	6.81	0.39	6.47e-11	Lung cancer;
CESC	cis	rs9309711	0.737	rs9284795	chr2:3492065	G/A	cg10845886	chr2:3471009	TTC15	-0.79	-10.76	-0.55	1.19e-22	Neurofibrillary tangles;
CESC	cis	rs17826219	0.500	rs2874724	chr17:29072433	T/C	cg14008862	chr17:28927542	LRRC37B2	0.65	5.14	0.3	5.34e-7	Body mass index;
CESC	cis	rs3733585	0.577	rs28558552	chr4:9964913	G/A	cg00071950	chr4:10020882	SLC2A9	-0.69	-10.57	-0.54	5.1e-22	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs2404602	0.684	rs4886819	chr15:76901698	C/T	cg23625390	chr15:77176239	SCAPER	-0.45	-6.16	-0.35	2.64e-9	Blood metabolite levels;
CESC	cis	rs1475911	1.000	rs34421316	chr21:43513989	C/T	cg03240473	chr21:43526662	UMODL1;C21orf128	-0.42	-5.25	-0.31	3.17e-7	IgG glycosylation;
CESC	trans	rs629535	0.773	rs569064	chr8:70065967	A/G	cg21567404	chr3:27674614	NA	0.88	10.34	0.54	2.74e-21	Dupuytren's disease;
CESC	cis	rs7618915	0.501	rs2159644	chr3:52774530	C/T	cg18337363	chr3:52569053	NT5DC2	0.29	5.16	0.3	4.73e-7	Bipolar disorder;
CESC	cis	rs28829049	0.861	rs67113006	chr1:19376566	A/G	cg13387374	chr1:19411106	UBR4	0.47	5.82	0.34	1.67e-8	QRS duration in Tripanosoma cruzi seropositivity;
CESC	cis	rs34779708	0.733	rs11010146	chr10:35541561	T/A	cg04310649	chr10:35416472	CREM	-0.47	-5.39	-0.31	1.59e-7	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs9309711	0.736	rs13409102	chr2:3496321	G/A	cg10845886	chr2:3471009	TTC15	-0.8	-9.61	-0.51	6.12e-19	Neurofibrillary tangles;
CESC	cis	rs727563	0.555	rs5751136	chr22:42075581	T/A	cg17376030	chr22:41985996	PMM1	-0.62	-6.96	-0.39	2.66e-11	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs910316	0.763	rs12588981	chr14:75460561	A/G	cg08847533	chr14:75593920	NEK9	0.89	15.3	0.68	2.72e-38	Height;
CESC	cis	rs910316	1.000	rs10136948	chr14:75511075	C/T	cg11812906	chr14:75593930	NEK9	0.91	15.39	0.69	1.24e-38	Height;
CESC	cis	rs1008375	0.966	rs12503517	chr4:17698725	G/A	cg16339924	chr4:17578868	LAP3	0.58	7.19	0.4	6.76e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs5167	0.566	rs204905	chr19:45460764	G/A	cg13119609	chr19:45449297	APOC2	0.54	8.36	0.46	3.48e-15	Blood protein levels;
CESC	cis	rs2736345	0.516	rs7844858	chr8:11392659	T/A	cg09528494	chr8:11338675	NA	0.32	5.93	0.34	9.53e-9	Sjögren's syndrome;Systemic lupus erythematosus;
CESC	cis	rs1048238	0.506	rs848209	chr1:16256007	T/C	cg22431228	chr1:16359049	CLCNKA	0.36	6.14	0.35	2.93e-9	Systolic blood pressure;
CESC	cis	rs7772486	0.754	rs2064185	chr6:146066814	G/A	cg05347473	chr6:146136440	FBXO30	-0.57	-7.36	-0.41	2.27e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs697003	0.705	rs701926	chr1:211851619	G/T	cg26036067	chr1:211849175	NEK2	-0.48	-5.76	-0.33	2.31e-8	Red cell distribution width;
CESC	cis	rs4141404	0.828	rs2413043	chr22:31648576	G/T	cg02404636	chr22:31891804	SFI1	-0.39	-5.08	-0.3	7.3e-7	Paclitaxel-induced neuropathy;
CESC	cis	rs10751667	0.621	rs10794348	chr11:939941	G/A	cg20946044	chr11:1010712	AP2A2	-0.41	-5.64	-0.33	4.31e-8	Alzheimer's disease (late onset);
CESC	cis	rs9309473	1.000	rs1534471	chr2:73647508	G/A	cg20560298	chr2:73613845	ALMS1	-0.47	-6.41	-0.37	6.68e-10	Metabolite levels;
CESC	cis	rs208520	0.802	rs4710315	chr6:66887594	A/G	cg07460842	chr6:66804631	NA	-0.94	-12.15	-0.6	2.75e-27	Exhaled nitric oxide output;
CESC	cis	rs798554	0.959	rs798528	chr7:2772431	A/C	cg13628971	chr7:2884303	GNA12	0.58	7.41	0.41	1.73e-12	Height;
CESC	trans	rs916888	0.779	rs199528	chr17:44843136	C/T	cg04282206	chr17:62833786	PLEKHM1P	0.54	6.22	0.36	1.95e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs7949030	0.626	rs11231141	chr11:62326265	T/C	cg23462726	chr11:62437636	C11orf83;C11orf48	-0.39	-5.13	-0.3	5.69e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	trans	rs3780486	0.957	rs10971434	chr9:33168891	C/A	cg20290983	chr6:43655470	MRPS18A	0.82	11.55	0.58	2.82e-25	IgG glycosylation;
CESC	cis	rs9814567	0.964	rs12492930	chr3:134222722	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.43	-5.98	-0.34	7.14e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg03383472	chr7:2314947	SNX8	0.48	6.57	0.37	2.66e-10	Fibrinogen levels;
CESC	cis	rs2243480	1.000	rs68189316	chr7:65409169	C/G	cg13147721	chr7:65941812	NA	-0.85	-8.1	-0.45	2e-14	Diabetic kidney disease;
CESC	cis	rs514406	0.798	rs576650	chr1:53327207	C/T	cg24675658	chr1:53192096	ZYG11B	-0.66	-8.7	-0.47	3.67e-16	Monocyte count;
CESC	cis	rs4746818	0.711	rs4745976	chr10:70845181	A/G	cg11621586	chr10:70884670	VPS26A	0.57	6.11	0.35	3.5e-9	Left atrial antero-posterior diameter;
CESC	cis	rs1008375	0.686	rs34338142	chr4:17626174	T/A	cg02297831	chr4:17616191	MED28	0.6	7.7	0.43	2.76e-13	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs4665809	1.000	rs1550381	chr2:26266946	A/G	cg27170947	chr2:26402098	FAM59B	-0.6	-7.08	-0.4	1.26e-11	Gut microbiome composition (summer);
CESC	cis	rs950776	0.684	rs11637635	chr15:78877150	A/G	cg06917634	chr15:78832804	PSMA4	-0.53	-6.54	-0.37	3.19e-10	Sudden cardiac arrest;
CESC	cis	rs2108622	0.683	rs56228205	chr19:15981973	A/C	cg13772218	chr19:15982569	NA	0.29	5.76	0.33	2.32e-8	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CESC	cis	rs12971120	0.891	rs12968731	chr18:72169708	G/T	cg26446133	chr18:72167187	CNDP2	-0.77	-9.8	-0.52	1.46e-19	Refractive error;
CESC	cis	rs11750568	0.967	rs6864287	chr5:178515091	T/C	cg10208897	chr5:178548229	ADAMTS2	0.37	5.26	0.31	3.04e-7	Height;
CESC	cis	rs265548	0.646	rs36689	chr19:17910639	A/G	cg04517722	chr19:17905589	B3GNT3	0.42	5.5	0.32	9.07e-8	Tumor biomarkers;
CESC	cis	rs9457247	0.902	rs366938	chr6:167403538	T/C	cg23791538	chr6:167370224	RNASET2	-0.58	-8.28	-0.45	6.16e-15	Crohn's disease;
CESC	cis	rs9303401	0.614	rs2333409	chr17:57139134	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.88	11.13	0.56	7.31e-24	Cognitive test performance;
CESC	cis	rs909674	0.515	rs9611170	chr22:39784845	G/C	cg01416388	chr22:39784598	NA	-0.64	-8.17	-0.45	1.25e-14	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs826838	0.838	rs11183646	chr12:38799846	A/T	cg26384229	chr12:38710491	ALG10B	0.83	14.61	0.67	7.23e-36	Heart rate;
CESC	cis	rs1008375	0.966	rs6813375	chr4:17649499	T/G	cg04450456	chr4:17643702	FAM184B	0.36	5.06	0.3	7.87e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg16280946	chr22:20716554	NA	0.45	6.24	0.36	1.71e-9	Fibrinogen levels;
CESC	cis	rs7845219	0.544	rs7017487	chr8:95922752	A/G	cg16049864	chr8:95962084	TP53INP1	0.48	7.23	0.41	5.16e-12	Type 2 diabetes;
CESC	cis	rs6952808	0.656	rs73048919	chr7:2103637	C/A	cg02951883	chr7:2050386	MAD1L1	-0.52	-6.72	-0.38	1.14e-10	Bipolar disorder and schizophrenia;
CESC	cis	rs3785574	0.925	rs2727340	chr17:61970224	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.04	16.58	0.71	7.85e-43	Height;
CESC	cis	rs6942756	1.000	rs2402945	chr7:128956256	C/A	cg02491457	chr7:128862824	NA	-0.69	-9.36	-0.5	3.61e-18	White matter hyperintensity burden;
CESC	cis	rs1185460	0.904	rs1003081	chr11:118913993	A/G	cg23280166	chr11:118938394	VPS11	-0.42	-5.89	-0.34	1.16e-8	Coronary artery disease;
CESC	cis	rs7937682	0.601	rs2187388	chr11:111387116	C/T	cg09085632	chr11:111637200	PPP2R1B	0.47	5.56	0.32	6.6e-8	Primary sclerosing cholangitis;
CESC	cis	rs11723261	0.621	rs6599306	chr4:143439	C/G	cg12746427	chr4:53362	ZNF718;ZNF595	-0.42	-5.07	-0.3	7.47e-7	Immune response to smallpox vaccine (IL-6);
CESC	cis	rs2479724	0.776	rs2250428	chr6:41832772	T/A	cg17623882	chr6:41773611	USP49	-0.41	-5.83	-0.34	1.58e-8	Menarche (age at onset);
CESC	cis	rs9814567	1.000	rs3932818	chr3:134206069	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.42	-5.76	-0.33	2.32e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs875971	0.928	rs2036263	chr7:65800197	C/T	cg11764359	chr7:65958608	NA	-0.8	-11.89	-0.59	2.01e-26	Aortic root size;
CESC	trans	rs208520	0.690	rs3899423	chr6:66835285	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.94	-12.87	-0.62	8.91e-30	Exhaled nitric oxide output;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02375201	chr1:27114675	PIGV	0.6	6.36	0.36	8.72e-10	Gut microbiome composition (summer);
CESC	cis	rs8114671	0.836	rs2104083	chr20:33649133	G/A	cg07148914	chr20:33460835	GGT7	-0.4	-5.11	-0.3	6.21e-7	Height;
CESC	cis	rs965513	1.000	rs7032019	chr9:100548144	G/A	cg13688889	chr9:100608707	NA	-0.6	-8.62	-0.47	6.27e-16	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
CESC	cis	rs13118159	0.771	rs13117476	chr4:1334721	A/G	cg02018176	chr4:1364513	KIAA1530	0.41	5.88	0.34	1.26e-8	Longevity;
CESC	cis	rs9549367	0.713	rs3024744	chr13:113821477	A/C	cg18105134	chr13:113819100	PROZ	-0.66	-8.18	-0.45	1.23e-14	Platelet distribution width;
CESC	cis	rs977987	0.751	rs56004344	chr16:75474189	T/C	cg03315344	chr16:75512273	CHST6	0.43	6.12	0.35	3.35e-9	Dupuytren's disease;
CESC	cis	rs2276314	1.000	rs4799832	chr18:33559646	T/C	cg19628046	chr18:33552617	C18orf21	0.55	6.14	0.35	2.99e-9	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs7216064	1.000	rs8079754	chr17:65887896	A/G	cg12091567	chr17:66097778	LOC651250	-0.74	-7.57	-0.42	6.29e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs477895	0.713	rs1059440	chr11:63991801	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.91	-10.18	-0.53	9.02e-21	Mean platelet volume;
CESC	cis	rs2985684	0.846	rs10150624	chr14:50051565	A/G	cg10008539	chr14:50087325	RPL36AL;MGAT2	-0.43	-5.25	-0.31	3.09e-7	Carotid intima media thickness;
CESC	cis	rs7811142	0.720	rs112622797	chr7:99917416	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.06	8.93	0.48	7.46e-17	Platelet count;
CESC	cis	rs796364	0.760	rs1569178	chr2:201024512	T/C	cg23649088	chr2:200775458	C2orf69	-0.6	-5.16	-0.3	4.78e-7	Schizophrenia;
CESC	cis	rs4268898	0.931	rs55642516	chr2:24502305	A/G	cg20701182	chr2:24300061	SF3B14	0.46	5.64	0.33	4.27e-8	Asthma;
CESC	cis	rs6674176	0.660	rs2108202	chr1:44395786	A/G	cg23954153	chr1:44402353	ARTN	0.33	5.18	0.3	4.36e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs61869271	0.799	rs35501899	chr10:116739109	T/G	cg23260525	chr10:116636907	FAM160B1	0.3	5.24	0.31	3.21e-7	Tonsillectomy;
CESC	cis	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg18402987	chr7:1209562	NA	0.72	7.2	0.4	6.12e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs3768617	0.510	rs7518957	chr1:183093028	A/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.86	-14.2	-0.66	2.07e-34	Fuchs's corneal dystrophy;
CESC	cis	rs6502050	0.835	rs7503111	chr17:80101587	A/T	cg11859384	chr17:80120422	CCDC57	-0.39	-5.23	-0.31	3.53e-7	Life satisfaction;
CESC	cis	rs3796619	1.000	rs3796619	chr4:1095281	A/G	cg27284194	chr4:1044797	NA	0.38	5.74	0.33	2.58e-8	Recombination rate (males);
CESC	cis	rs13191362	0.872	rs13215538	chr6:163037975	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.9	10.21	0.53	7.26e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs2354432	0.556	rs59180647	chr1:146772062	C/T	cg25205988	chr1:146714368	CHD1L	-1.0	-8.9	-0.48	9.01e-17	Mitochondrial DNA levels;
CESC	cis	rs1018836	0.570	rs6471084	chr8:91463666	T/C	cg16814680	chr8:91681699	NA	-0.51	-6.88	-0.39	4.41e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs2236918	1.000	rs1629051	chr1:242026344	A/G	cg17736920	chr1:242011382	EXO1	-0.66	-8.71	-0.47	3.31e-16	Menopause (age at onset);
CESC	cis	rs36051895	0.659	rs7859390	chr9:5062473	A/T	cg02405213	chr9:5042618	JAK2	-0.47	-5.65	-0.33	4.1e-8	Pediatric autoimmune diseases;
CESC	cis	rs72781680	0.898	rs72798049	chr2:23958002	C/G	cg08917208	chr2:24149416	ATAD2B	0.96	8.67	0.47	4.28e-16	Lymphocyte counts;
CESC	trans	rs7618501	0.633	rs2008877	chr3:50162291	T/G	cg21659725	chr3:3221576	CRBN	-0.49	-6.69	-0.38	1.3100000000000001e-10	Intelligence (multi-trait analysis);
CESC	cis	rs6089584	1.000	rs3787425	chr20:60559256	C/T	cg06108461	chr20:60628389	TAF4	-0.78	-11.36	-0.57	1.25e-24	Body mass index;
CESC	cis	rs3015497	0.646	rs3015494	chr14:51115157	C/T	cg26011998	chr14:51135199	SAV1	-0.56	-6.27	-0.36	1.45e-9	Mean platelet volume;
CESC	cis	rs6783573	0.965	rs3806703	chr3:46618501	T/C	cg21489266	chr3:46619131	LRRC2;TDGF1	-0.45	-6.47	-0.37	4.7e-10	Cerebrospinal fluid biomarker levels;
CESC	cis	rs5769707	0.967	rs763126	chr22:49988574	G/T	cg05373962	chr22:49881684	NA	0.36	6.15	0.35	2.88e-9	Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs9400271	0.632	rs34981677	chr6:109590920	T/C	cg01475377	chr6:109611718	NA	-0.46	-7.13	-0.4	9.29e-12	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
CESC	cis	rs4925386	0.840	rs6143035	chr20:60920700	C/T	cg24112000	chr20:60950667	NA	0.45	5.55	0.32	6.91e-8	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs6952808	0.564	rs55865401	chr7:2145720	G/C	cg08027265	chr7:2291960	NA	-0.41	-6.28	-0.36	1.35e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs853679	0.517	rs9380065	chr6:28144751	A/G	cg23161317	chr6:28129485	ZNF389	0.47	5.88	0.34	1.21e-8	Depression;
CESC	cis	rs12142240	0.667	rs66990604	chr1:46822073	G/A	cg10495392	chr1:46806563	NSUN4	0.58	6.32	0.36	1.09e-9	Menopause (age at onset);
CESC	cis	rs963731	0.649	rs2373495	chr2:39254627	C/G	cg04010122	chr2:39346883	SOS1	-0.73	-5.35	-0.31	1.87e-7	Corticobasal degeneration;
CESC	cis	rs7264396	0.563	rs6060566	chr20:34288226	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.9	-10.87	-0.56	5.11e-23	Total cholesterol levels;
CESC	cis	rs4563143	0.675	rs56293553	chr19:29270455	A/G	cg14983838	chr19:29218262	NA	0.5	6.16	0.35	2.67e-9	Methadone dose in opioid dependence;
CESC	cis	rs4665809	0.531	rs12987980	chr2:26462093	A/T	cg04944784	chr2:26401820	FAM59B	0.96	10.5	0.54	8.76e-22	Gut microbiome composition (summer);
CESC	cis	rs7264396	0.690	rs2425170	chr20:34442672	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.63	7.24	0.41	4.85e-12	Total cholesterol levels;
CESC	cis	rs1256061	0.603	rs1256038	chr14:64740739	T/C	cg23250157	chr14:64679961	SYNE2	0.53	7.64	0.42	4.09e-13	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs6912958	1.000	rs9294380	chr6:88152667	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.55	-7.48	-0.42	1.08e-12	Monocyte percentage of white cells;
CESC	cis	rs7465272	0.530	rs10103161	chr8:143738571	A/G	cg10596483	chr8:143751796	JRK	0.42	5.46	0.32	1.11e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs7267979	1.000	rs2257991	chr20:25270339	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.9	-18.95	-0.76	3.38e-51	Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19078903	chr1:21112721	HP1BP3	-0.58	-6.4	-0.37	7.03e-10	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01720705	chr1:231175557	FAM89A	0.52	6.11	0.35	3.52e-9	Gut microbiome composition (summer);
CESC	cis	rs875971	0.577	rs34888281	chr7:65585771	C/T	cg14393609	chr7:65229607	NA	-0.41	-5.3	-0.31	2.45e-7	Aortic root size;
CESC	cis	rs59698941	0.943	rs55767930	chr5:132203952	G/A	cg02081065	chr5:132209139	LEAP2	-0.52	-5.12	-0.3	5.8e-7	Apolipoprotein A-IV levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02551604	chr5:131831745	NA	0.55	6.68	0.38	1.4e-10	Gut microbiome composition (summer);
CESC	cis	rs4835473	0.932	rs1877234	chr4:144907927	A/T	cg25736465	chr4:144833511	NA	0.41	6.29	0.36	1.28e-9	Immature fraction of reticulocytes;
CESC	cis	rs738322	0.967	rs133013	chr22:38570912	C/T	cg25457927	chr22:38595422	NA	-0.3	-5.46	-0.32	1.1e-7	Cutaneous nevi;
CESC	cis	rs6580649	1.000	rs3825404	chr12:48399931	A/G	cg24011408	chr12:48396354	COL2A1	0.41	5.3	0.31	2.48e-7	Lung cancer;
CESC	cis	rs9649213	0.593	rs3801254	chr7:98010811	G/A	cg24562669	chr7:97807699	LMTK2	0.51	7.53	0.42	7.86e-13	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs9818758	0.505	rs67286839	chr3:49265744	C/T	cg00383909	chr3:49044727	WDR6	0.82	6.25	0.36	1.63e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CESC	cis	rs4862750	0.872	rs6553029	chr4:187876470	G/T	cg10295955	chr4:187884368	NA	1.03	17.37	0.73	1.17e-45	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4900538	0.927	rs1190544	chr14:102903398	G/A	cg18135206	chr14:102964638	TECPR2	-0.8	-10.72	-0.55	1.65e-22	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	cis	rs11718455	0.921	rs1404482	chr3:43997282	A/G	cg08738300	chr3:44038990	NA	0.44	5.73	0.33	2.75e-8	Coronary artery disease;
CESC	trans	rs10435719	0.867	rs35778860	chr8:11791338	C/T	cg15556689	chr8:8085844	FLJ10661	0.52	6.38	0.36	7.99e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
CESC	cis	rs1144333	0.737	rs1144331	chr1:76272357	G/A	cg10523679	chr1:76189770	ACADM	-0.57	-5.44	-0.32	1.22e-7	Attention function in attention deficit hyperactive disorder;
CESC	cis	rs7665939	1.000	rs72709206	chr4:190109171	T/C	cg09826759	chr4:190284978	NA	-0.87	-7.17	-0.4	7.56e-12	Amyotrophic lateral sclerosis;
CESC	trans	rs7107217	1.000	rs1873872	chr11:129473993	A/T	cg27138088	chr11:842605	TSPAN4;POLR2L	0.52	6.78	0.38	7.84e-11	Breast cancer;Type 2 diabetes;
CESC	cis	rs9322193	0.962	rs9688412	chr6:150124283	A/G	cg04369109	chr6:150039330	LATS1	0.38	5.18	0.3	4.46e-7	Lung cancer;
CESC	cis	rs1552244	1.000	rs7628448	chr3:10146828	G/A	cg00149659	chr3:10157352	C3orf10	0.69	7.88	0.44	8.76e-14	Alzheimer's disease;
CESC	cis	rs10752881	1.000	rs6673559	chr1:182983197	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.83	13.25	0.63	4.18e-31	Colorectal cancer;
CESC	cis	rs7474896	0.515	rs624359	chr10:38299132	T/C	cg25427524	chr10:38739819	LOC399744	0.48	5.48	0.32	9.76e-8	Obesity (extreme);
CESC	cis	rs4722166	0.630	rs13311155	chr7:22789789	A/C	cg05265849	chr7:22767390	IL6	0.58	7.39	0.41	1.9e-12	Lung cancer;
CESC	cis	rs1448094	0.511	rs7967183	chr12:86216845	T/G	cg19622623	chr12:86230825	RASSF9	-0.46	-5.89	-0.34	1.2e-8	Major depressive disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09247696	chr2:74756297	HTRA2;AUP1	-0.56	-6.55	-0.37	2.92e-10	Gut microbiome composition (summer);
CESC	cis	rs1707322	1.000	rs6657720	chr1:46386269	G/A	cg03146154	chr1:46216737	IPP	0.72	9.82	0.52	1.31e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs10504229	1.000	rs73609760	chr8:58192170	A/G	cg22535103	chr8:58192502	C8orf71	-1.04	-12.69	-0.61	3.88e-29	Developmental language disorder (linguistic errors);
CESC	cis	rs1215050	0.740	rs6854802	chr4:99065480	A/C	cg17366294	chr4:99064904	C4orf37	0.4	5.16	0.3	4.9e-7	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs3733585	0.673	rs7434391	chr4:9967682	C/G	cg11266682	chr4:10021025	SLC2A9	-0.58	-10.94	-0.56	3.03e-23	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs853679	0.824	rs1321505	chr6:28052823	A/C	cg18032046	chr6:28092343	ZSCAN16	-0.75	-6.28	-0.36	1.36e-9	Depression;
CESC	cis	rs11630290	1.000	rs72750987	chr15:63999112	G/C	cg12036633	chr15:63758958	NA	-0.56	-5.29	-0.31	2.55e-7	Iris characteristics;
CESC	cis	rs10504073	0.669	rs55948643	chr8:50026403	C/G	cg00325661	chr8:49890786	NA	0.52	7.77	0.43	1.7e-13	Blood metabolite ratios;
CESC	cis	rs2235544	0.565	rs635059	chr1:54469120	G/C	cg25741118	chr1:54482237	LDLRAD1	0.24	5.76	0.33	2.29e-8	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
CESC	cis	rs7216064	0.589	rs7213585	chr17:66062316	A/T	cg07042672	chr17:66097459	LOC651250	-0.66	-8.73	-0.47	2.89e-16	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs12497850	0.863	rs4858799	chr3:48728204	G/C	cg06212747	chr3:49208901	KLHDC8B	0.61	8.1	0.45	1.99e-14	Parkinson's disease;
CESC	cis	rs78456975	1.000	rs13397299	chr2:1564222	A/C	cg26248373	chr2:1572462	NA	-0.53	-5.23	-0.31	3.41e-7	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs4862750	0.872	rs6821507	chr4:187876829	G/T	cg03452623	chr4:187889614	NA	0.87	15.47	0.69	6.4e-39	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg15697793	chr8:1797445	ARHGEF10	0.45	6.3	0.36	1.2e-9	Fibrinogen levels;
CESC	cis	rs727505	0.607	rs10464674	chr7:124791551	A/G	cg23710748	chr7:124431027	NA	-0.4	-6.27	-0.36	1.44e-9	Lewy body disease;
CESC	cis	rs9322193	0.962	rs4869730	chr6:150129323	A/G	cg07701084	chr6:150067640	NUP43	0.43	5.8	0.34	1.86e-8	Lung cancer;
CESC	cis	rs761746	0.705	rs5994415	chr22:32004588	G/A	cg25791279	chr22:32026902	PISD	0.62	7.35	0.41	2.46e-12	Intelligence;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg19014323	chr10:43902618	HNRNPF	0.48	6.31	0.36	1.14e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs898097	0.578	rs8069697	chr17:80908110	T/C	cg10494973	chr17:80897199	TBCD	-0.48	-6.09	-0.35	3.92e-9	Breast cancer;
CESC	cis	rs11583043	0.575	rs12759611	chr1:101587145	T/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.48	5.33	0.31	2.11e-7	Ulcerative colitis;Inflammatory bowel disease;
CESC	cis	rs801193	1.000	rs7789184	chr7:66210195	A/T	cg11764359	chr7:65958608	NA	0.69	9.1	0.49	2.27e-17	Aortic root size;
CESC	cis	rs13256369	0.802	rs35382339	chr8:8559255	G/A	cg17143192	chr8:8559678	CLDN23	0.78	8.72	0.47	3.13e-16	Obesity-related traits;
CESC	cis	rs5753618	0.583	rs34545960	chr22:31812462	G/A	cg00478049	chr22:31556069	RNF185	-0.43	-5.11	-0.3	6.22e-7	Colorectal cancer;
CESC	cis	rs8067545	0.611	rs2703800	chr17:20086562	C/T	cg13482628	chr17:19912719	NA	0.42	5.45	0.32	1.13e-7	Schizophrenia;
CESC	cis	rs875971	0.545	rs10950025	chr7:65623933	G/A	cg25405998	chr7:65216604	CCT6P1	0.45	5.06	0.3	7.71e-7	Aortic root size;
CESC	cis	rs589448	0.902	rs315138	chr12:69764850	A/T	cg20891283	chr12:69753455	YEATS4	0.98	16.88	0.72	6.73e-44	Cerebrospinal fluid biomarker levels;
CESC	cis	rs7223966	1.000	rs11079511	chr17:61858537	C/G	cg11494091	chr17:61959527	GH2	0.38	5.09	0.3	6.85e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs2012796	0.956	rs7147254	chr14:81820503	G/A	cg02996355	chr14:81879375	NA	0.57	6.82	0.39	6.15e-11	Night sleep phenotypes;
CESC	cis	rs698833	0.886	rs698766	chr2:44574277	C/G	cg04920474	chr2:44395004	PPM1B	0.37	5.11	0.3	6.29e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20916237	chr14:105487215	CDCA4	0.56	6.76	0.38	8.8e-11	Gut microbiome composition (summer);
CESC	cis	rs7772486	0.686	rs9376961	chr6:146048737	C/T	cg05347473	chr6:146136440	FBXO30	0.52	6.84	0.39	5.42e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7937682	0.575	rs10789851	chr11:111750955	G/C	cg09085632	chr11:111637200	PPP2R1B	0.91	12.08	0.6	4.6e-27	Primary sclerosing cholangitis;
CESC	cis	rs9611565	0.694	rs5758368	chr22:41862288	C/T	cg17376030	chr22:41985996	PMM1	0.56	6.22	0.36	1.89e-9	Vitiligo;
CESC	cis	rs7312933	0.737	rs10880261	chr12:42573822	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.48	6.22	0.36	1.97e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	trans	rs561341	0.883	rs886224	chr17:30229902	T/C	cg27661571	chr11:113659931	NA	-0.67	-6.69	-0.38	1.33e-10	Hip circumference adjusted for BMI;
CESC	cis	rs6732160	0.845	rs6718690	chr2:73387162	C/T	cg01422370	chr2:73384389	NA	-0.44	-7.64	-0.42	4.02e-13	Intelligence (multi-trait analysis);
CESC	cis	rs12220238	1.000	rs10824096	chr10:75937554	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.58	5.19	0.3	4.22e-7	Soluble interleukin-2 receptor subunit alpha;
CESC	cis	rs11785400	1.000	rs6997771	chr8:143747752	T/G	cg24634471	chr8:143751801	JRK	0.47	6.13	0.35	3.09e-9	Schizophrenia;
CESC	cis	rs7149337	1.000	rs4261445	chr14:51723540	G/A	cg23942311	chr14:51606299	NA	0.45	7.55	0.42	6.92e-13	Cancer;
CESC	cis	rs2932538	0.961	rs4839257	chr1:113219388	A/T	cg22162597	chr1:113214053	CAPZA1	-0.49	-6.58	-0.37	2.48e-10	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CESC	cis	rs7100689	0.646	rs1934694	chr10:82125325	G/A	cg00277334	chr10:82204260	NA	-0.58	-7.76	-0.43	1.84e-13	Post bronchodilator FEV1;
CESC	cis	rs2637266	0.539	rs17231884	chr10:78536425	C/T	cg06894710	chr10:78142662	C10orf11	-0.38	-5.18	-0.3	4.3e-7	Pulmonary function;
CESC	cis	rs34779708	0.931	rs35848945	chr10:35287561	G/T	cg03585969	chr10:35415529	CREM	0.75	9.88	0.52	8.43e-20	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs950776	0.518	rs8053	chr15:78841220	T/C	cg06917634	chr15:78832804	PSMA4	-0.75	-11.27	-0.57	2.48e-24	Sudden cardiac arrest;
CESC	cis	rs7617480	0.648	rs7653408	chr3:48972351	A/C	cg06212747	chr3:49208901	KLHDC8B	0.48	5.69	0.33	3.29e-8	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CESC	cis	rs4819052	0.851	rs4819043	chr21:46660078	G/A	cg11663144	chr21:46675770	NA	-0.62	-9.74	-0.51	2.36e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs2262909	0.849	rs10420483	chr19:22190378	A/G	cg11619707	chr19:22235551	ZNF257	-0.35	-5.78	-0.33	2.04e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
CESC	cis	rs2070433	0.904	rs8130209	chr21:47925984	T/C	cg12379764	chr21:47803548	PCNT	0.5	6.08	0.35	4.26e-9	Lymphocyte counts;
CESC	cis	rs9614461	0.702	rs3788648	chr22:45727180	G/A	cg23503501	chr22:45809793	SMC1B;RIBC2	0.69	6.79	0.38	7.5e-11	Tonsillectomy;
CESC	cis	rs6460942	0.915	rs6965564	chr7:12306013	C/T	cg02935154	chr7:12443704	VWDE	-0.41	-5.61	-0.33	5.05e-8	Coronary artery disease;
CESC	cis	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg07092213	chr7:1199455	ZFAND2A	-0.49	-5.67	-0.33	3.8e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7666738	0.830	rs11722272	chr4:99000839	C/T	cg17366294	chr4:99064904	C4orf37	0.55	7.43	0.41	1.54e-12	Colonoscopy-negative controls vs population controls;
CESC	cis	rs35306767	0.953	rs1106064	chr10:957211	G/A	cg25019033	chr10:957182	NA	-0.67	-8.16	-0.45	1.4e-14	Eosinophil percentage of granulocytes;
CESC	cis	rs61542988	0.535	rs10807813	chr7:22829961	C/T	cg13679077	chr7:22862647	TOMM7	0.64	7.29	0.41	3.52e-12	Fibrinogen levels;
CESC	cis	rs4835473	0.897	rs36083752	chr4:144614530	T/A	cg25736465	chr4:144833511	NA	-0.36	-5.45	-0.32	1.17e-7	Immature fraction of reticulocytes;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg07520141	chr5:10564205	ANKRD33B	0.47	6.09	0.35	3.94e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs2404602	0.669	rs12438540	chr15:76943213	C/G	cg26408565	chr15:76604113	ETFA	-0.4	-5.68	-0.33	3.45e-8	Blood metabolite levels;
CESC	cis	rs763121	0.853	rs5757204	chr22:39046700	A/C	cg21395723	chr22:39101663	GTPBP1	0.43	5.33	0.31	2.09e-7	Menopause (age at onset);
CESC	cis	rs12973672	1.000	rs10421599	chr19:35767933	G/A	cg12095397	chr19:35769544	USF2	0.54	7.33	0.41	2.81e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00602891	chr17:80408864	C17orf62	-0.58	-6.42	-0.37	6.09e-10	Gut microbiome composition (summer);
CESC	cis	rs10751667	0.666	rs12295141	chr11:947065	G/A	cg20946044	chr11:1010712	AP2A2	-0.38	-5.23	-0.31	3.44e-7	Alzheimer's disease (late onset);
CESC	cis	rs73206853	0.563	rs1107652	chr12:111176213	A/G	cg04375036	chr12:111181819	PPP1CC	-0.54	-5.21	-0.31	3.71e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs2842992	0.789	rs9365093	chr6:160175819	C/G	cg26839252	chr6:160211577	TCP1;MRPL18	0.45	5.29	0.31	2.52e-7	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs6032067	0.929	rs17424868	chr20:43818519	T/G	cg10761708	chr20:43804764	PI3	0.53	6.36	0.36	8.83e-10	Blood protein levels;
CESC	cis	rs1775715	0.737	rs1419171	chr10:32214831	C/A	cg26784012	chr10:32216390	ARHGAP12	0.39	5.22	0.31	3.7e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs9611565	0.559	rs7290991	chr22:41964361	C/G	cg06481639	chr22:41940642	POLR3H	-0.57	-6.38	-0.36	7.88e-10	Vitiligo;
CESC	cis	rs9487051	0.676	rs13210693	chr6:109598964	A/G	cg01475377	chr6:109611718	NA	0.43	6.67	0.38	1.53e-10	Reticulocyte fraction of red cells;
CESC	cis	rs711245	0.670	rs7560321	chr2:36822318	C/G	cg15105969	chr2:36825350	FEZ2	-0.47	-5.72	-0.33	2.83e-8	Height;
CESC	cis	rs4665809	0.590	rs10197494	chr2:26445550	A/G	cg04944784	chr2:26401820	FAM59B	-0.96	-10.55	-0.54	5.79e-22	Gut microbiome composition (summer);
CESC	cis	rs9487051	0.872	rs1111863	chr6:109611206	C/T	cg21918786	chr6:109611834	NA	0.38	5.47	0.32	1.05e-7	Reticulocyte fraction of red cells;
CESC	cis	rs17818399	0.926	rs13033177	chr2:46831062	C/A	cg06386533	chr2:46925753	SOCS5	0.46	5.15	0.3	5e-7	Height;
CESC	cis	rs1577917	0.958	rs10944137	chr6:86454314	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.53	-6.91	-0.39	3.68e-11	Response to antipsychotic treatment;
CESC	cis	rs258892	0.895	rs10052974	chr5:72067869	A/G	cg21869765	chr5:72125136	TNPO1	-0.43	-5.35	-0.31	1.93e-7	Small cell lung carcinoma;
CESC	cis	rs3126085	0.935	rs10749669	chr1:152177289	A/C	cg03465714	chr1:152285911	FLG	0.46	5.66	0.33	3.95e-8	Atopic dermatitis;
CESC	cis	rs7824557	0.836	rs2736378	chr8:11119760	G/A	cg21775007	chr8:11205619	TDH	-0.38	-5.68	-0.33	3.46e-8	Retinal vascular caliber;
CESC	cis	rs11853189	0.938	rs75369292	chr15:78555357	T/C	cg22935921	chr15:78556834	DNAJA4	0.61	5.18	0.3	4.45e-7	Red cell distribution width;
CESC	cis	rs7833790	1.000	rs7833384	chr8:82730915	T/C	cg07697082	chr8:82753677	SNX16	0.4	5.62	0.33	4.79e-8	Diastolic blood pressure;
CESC	cis	rs1707322	0.963	rs11211202	chr1:46292382	C/T	cg05343316	chr1:45956843	TESK2	0.43	5.35	0.31	1.92e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs10883723	0.810	rs2296582	chr10:104244139	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.55	7.73	0.43	2.17e-13	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs6728642	0.519	rs72811651	chr2:97572229	G/C	cg26665480	chr2:98280029	ACTR1B	-0.58	-5.28	-0.31	2.75e-7	Bipolar disorder lithium response (continuous) or schizophrenia;
CESC	cis	rs10479542	0.892	rs7723230	chr5:178980474	T/C	cg26516362	chr5:178986906	RUFY1	0.44	7.03	0.4	1.7e-11	Lung cancer;
CESC	cis	rs3796619	1.000	rs1466214	chr4:1073760	C/T	cg27284194	chr4:1044797	NA	0.36	5.47	0.32	1.07e-7	Recombination rate (males);
CESC	cis	rs9513627	0.573	rs12431100	chr13:100184918	C/G	cg25919922	chr13:100150906	NA	-0.76	-8.87	-0.48	1.07e-16	Obesity-related traits;
CESC	cis	rs9322193	0.923	rs10872650	chr6:150082095	A/G	cg04369109	chr6:150039330	LATS1	-0.43	-5.98	-0.35	7.01e-9	Lung cancer;
CESC	cis	rs854765	0.583	rs6502627	chr17:17849671	C/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.54	7.08	0.4	1.28e-11	Total body bone mineral density;
CESC	cis	rs8070128	0.688	rs59304093	chr17:17875407	A/G	cg16928487	chr17:17741425	SREBF1	-0.62	-10.37	-0.54	2.2e-21	Total body bone mineral density;
CESC	cis	rs738322	1.000	rs738320	chr22:38568715	G/T	cg25457927	chr22:38595422	NA	-0.29	-5.52	-0.32	8.04e-8	Cutaneous nevi;
CESC	cis	rs4819052	0.851	rs9974891	chr21:46680767	T/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.74	10.21	0.53	7.28e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs3806933	0.522	rs12522383	chr5:110455266	C/T	cg04022379	chr5:110408740	TSLP	0.42	7.06	0.4	1.44e-11	Eosinophilic esophagitis;
CESC	cis	rs10504229	0.639	rs66667899	chr8:58117065	C/T	cg02725872	chr8:58115012	NA	-0.45	-7.05	-0.4	1.52e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs2637266	0.756	rs2583064	chr10:78557708	A/G	cg18941641	chr10:78392320	NA	0.41	7.83	0.43	1.17e-13	Pulmonary function;
CESC	cis	rs7089973	0.872	rs3180654	chr10:116615045	T/C	cg25233709	chr10:116636983	FAM160B1	0.35	5.08	0.3	7.02e-7	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.4	0.37	7.04e-10	Prudent dietary pattern;
CESC	cis	rs763121	0.853	rs5750668	chr22:39079964	T/C	cg14440974	chr22:39074834	NA	-0.42	-5.66	-0.33	3.87e-8	Menopause (age at onset);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg01446372	chr21:30365398	RNF160	-0.43	-6.04	-0.35	5.25e-9	Gambling;
CESC	trans	rs12599106	0.715	rs34006830	chr16:34878550	C/A	cg05064044	chr6:292385	DUSP22	-0.66	-8.09	-0.45	2.11e-14	Menopause (age at onset);
CESC	cis	rs4919087	1.000	rs4919090	chr10:99088419	C/G	cg25902810	chr10:99078978	FRAT1	-0.66	-8.57	-0.47	8.6e-16	Monocyte count;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg10490227	chr1:40348903	TRIT1	-0.44	-6.34	-0.36	9.93e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19070139	chr6:42928517	GNMT	0.53	6.25	0.36	1.59e-9	Gut microbiome composition (summer);
CESC	cis	rs938554	0.744	rs6449137	chr4:9932479	A/T	cg00071950	chr4:10020882	SLC2A9	-0.44	-5.96	-0.34	8.01e-9	Blood metabolite levels;
CESC	cis	rs4665809	0.938	rs4665822	chr2:26312555	C/G	cg04944784	chr2:26401820	FAM59B	-0.66	-7.53	-0.42	7.95e-13	Gut microbiome composition (summer);
CESC	cis	rs28830936	1.000	rs11637341	chr15:41955825	G/T	cg11010575	chr15:42129464	JMJD7-PLA2G4B;JMJD7	-0.37	-5.32	-0.31	2.16e-7	Diastolic blood pressure;
CESC	cis	rs10504229	0.906	rs17805439	chr8:58172400	T/C	cg05313129	chr8:58192883	C8orf71	-0.55	-6.37	-0.36	8.42e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs7666738	0.830	rs6854994	chr4:98977624	C/G	cg17366294	chr4:99064904	C4orf37	0.59	8.43	0.46	2.31e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg02951883	chr7:2050386	MAD1L1	0.43	5.6	0.33	5.33e-8	Bipolar disorder and schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02120071	chr2:114737129	NA	-0.57	-6.17	-0.35	2.52e-9	Gut microbiome composition (summer);
CESC	cis	rs6860806	0.531	rs2631359	chr5:131707892	C/T	cg07395648	chr5:131743802	NA	0.4	5.19	0.3	4.19e-7	Breast cancer;
CESC	cis	rs8067354	0.574	rs2531899	chr17:58007193	A/G	cg13753209	chr17:57696993	CLTC	-0.55	-5.92	-0.34	1.01e-8	Hemoglobin concentration;
CESC	cis	rs5769765	0.632	rs13056783	chr22:50259152	A/T	cg02269571	chr22:50332266	NA	0.49	6.57	0.37	2.65e-10	Schizophrenia;
CESC	cis	rs2842992	0.789	rs9355748	chr6:160194882	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.79	9.65	0.51	4.49e-19	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs11252926	0.604	rs12359454	chr10:568081	T/C	cg08603382	chr10:743973	NA	-0.47	-6.37	-0.36	8.16e-10	Psychosis in Alzheimer's disease;
CESC	cis	rs7811142	1.000	rs7783550	chr7:99987805	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	-1.03	-11.14	-0.56	6.96e-24	Platelet count;
CESC	cis	rs7666738	0.716	rs13108535	chr4:99046324	A/G	cg05340658	chr4:99064831	C4orf37	0.82	12.88	0.62	8.44e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6963495	0.818	rs73192120	chr7:105171156	C/T	cg13798780	chr7:105162888	PUS7	0.77	7.88	0.44	8.3e-14	Bipolar disorder (body mass index interaction);
CESC	cis	rs2274273	1.000	rs2075603	chr14:55609955	C/A	cg04306507	chr14:55594613	LGALS3	0.28	5.19	0.3	4.11e-7	Protein biomarker;
CESC	cis	rs7666738	0.830	rs17026973	chr4:98680041	T/A	cg17366294	chr4:99064904	C4orf37	0.56	7.61	0.42	4.87e-13	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10129255	0.500	rs12101190	chr14:107192386	C/T	cg07958169	chr14:107095056	NA	-0.54	-8.32	-0.45	4.77e-15	Kawasaki disease;
CESC	cis	rs4604732	0.631	rs35046441	chr1:247626812	G/A	cg12754571	chr1:247694271	LOC148824;OR2C3	0.44	5.44	0.32	1.21e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs11785400	0.642	rs4256574	chr8:143725705	C/T	cg10596483	chr8:143751796	JRK	0.42	5.36	0.31	1.77e-7	Schizophrenia;
CESC	cis	rs6570726	0.967	rs403584	chr6:145807010	G/A	cg23711669	chr6:146136114	FBXO30	0.74	10.9	0.56	4.34e-23	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6912958	0.781	rs9444519	chr6:88290398	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-6.58	-0.37	2.55e-10	Monocyte percentage of white cells;
CESC	cis	rs4727027	0.899	rs11771339	chr7:148854132	A/T	cg23158103	chr7:148848205	ZNF398	-0.42	-6.92	-0.39	3.45e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs2070488	0.804	rs2276541	chr3:38512779	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.82	13.24	0.63	4.69e-31	Electrocardiographic conduction measures;
CESC	cis	rs7264396	0.563	rs78084033	chr20:34219990	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.92	-10.16	-0.53	1.07e-20	Total cholesterol levels;
CESC	cis	rs13385	0.769	rs10045510	chr5:139613188	T/C	cg26211634	chr5:139558579	C5orf32	0.48	5.29	0.31	2.59e-7	Atrial fibrillation;
CESC	cis	rs6952808	1.000	rs4449693	chr7:1884630	G/C	cg04267008	chr7:1944627	MAD1L1	-0.57	-6.78	-0.38	7.96e-11	Bipolar disorder and schizophrenia;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg21939482	chr7:6388130	C7orf70	0.49	6.05	0.35	4.88e-9	Thyroid stimulating hormone;
CESC	cis	rs3091242	0.933	rs35148262	chr1:25766623	A/G	cg27572855	chr1:25598939	RHD	0.5	8.53	0.46	1.12e-15	Erythrocyte sedimentation rate;
CESC	cis	rs2708240	1.000	rs759179	chr7:147574914	A/G	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.35	-5.77	-0.33	2.23e-8	QT interval (drug interaction);
CESC	cis	rs7223966	0.960	rs11659013	chr17:61869559	C/G	cg11494091	chr17:61959527	GH2	0.38	5.17	0.3	4.56e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs8031584	0.958	rs34909055	chr15:31284170	C/T	cg14829155	chr15:31115871	NA	-0.64	-8.34	-0.46	3.98e-15	Huntington's disease progression;
CESC	cis	rs10504229	0.516	rs1866994	chr8:57990092	A/C	cg22535103	chr8:58192502	C8orf71	-0.48	-5.89	-0.34	1.16e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs225245	0.782	rs225293	chr17:33925906	A/G	cg05299278	chr17:33885742	SLFN14	0.37	5.39	0.31	1.6e-7	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
CESC	cis	rs12136530	0.774	rs2088828	chr1:19757646	C/A	cg01832549	chr1:19774989	CAPZB	-0.48	-6.74	-0.38	1.01e-10	Lead levels in blood;
CESC	cis	rs7617773	0.780	rs13090538	chr3:48370769	A/C	cg11946769	chr3:48343235	NME6	0.85	11.68	0.58	1.06e-25	Coronary artery disease;
CESC	cis	rs1448094	0.645	rs8181635	chr12:86465136	C/T	cg02569458	chr12:86230093	RASSF9	-0.38	-5.49	-0.32	9.47e-8	Major depressive disorder;
CESC	cis	rs2281558	0.837	rs56238023	chr20:25516947	C/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.55	7.62	0.42	4.5e-13	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;
CESC	cis	rs8050907	0.744	rs9938647	chr16:4572151	A/G	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.72	5.17	0.3	4.53e-7	Obesity-related traits;
CESC	cis	rs523522	0.962	rs7136951	chr12:120941927	C/T	cg12219531	chr12:120966889	COQ5	0.75	9.95	0.52	5.02e-20	High light scatter reticulocyte count;
CESC	cis	rs7412746	0.611	rs4970931	chr1:150910727	G/A	cg17724175	chr1:150552817	MCL1	0.33	5.08	0.3	7.16e-7	Melanoma;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24043861	chr14:73396628	DCAF4	-0.61	-7.09	-0.4	1.19e-11	Gut microbiome composition (summer);
CESC	cis	rs12586317	0.547	rs60152856	chr14:35421373	G/A	cg05294307	chr14:35346193	BAZ1A	-0.5	-5.36	-0.31	1.77e-7	Psoriasis;
CESC	cis	rs7762018	1.000	rs6923339	chr6:170128033	T/A	cg05834625	chr6:170176447	C6orf70	0.66	7.76	0.43	1.9e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg11494091	chr17:61959527	GH2	0.73	12.52	0.61	1.41e-28	Prudent dietary pattern;
CESC	cis	rs9649213	0.555	rs12667634	chr7:97965442	A/G	cg21770322	chr7:97807741	LMTK2	0.55	8.27	0.45	6.54e-15	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs910316	1.000	rs1043674	chr14:75549370	T/C	cg11812906	chr14:75593930	NEK9	0.91	15.48	0.69	6.13e-39	Height;
CESC	cis	rs2997447	0.706	rs61776622	chr1:26469035	A/G	cg24596570	chr1:26146463	FAM54B;LOC646471	0.62	5.41	0.32	1.44e-7	QRS complex (12-leadsum);
CESC	cis	rs7246657	0.943	rs7255972	chr19:37933841	T/C	cg23950597	chr19:37808831	NA	-0.61	-6.23	-0.36	1.85e-9	Coronary artery calcification;
CESC	cis	rs853679	0.517	rs9393885	chr6:28050009	A/T	cg20151795	chr6:28129481	ZNF389	0.44	5.59	0.33	5.5e-8	Depression;
CESC	cis	rs1801251	1.000	rs35212961	chr2:233582762	C/T	cg08000102	chr2:233561755	GIGYF2	0.69	9.14	0.49	1.67e-17	Coronary artery disease;
CESC	cis	rs2439831	0.850	rs28858500	chr15:44156942	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.63	5.69	0.33	3.28e-8	Lung cancer in ever smokers;
CESC	trans	rs2109514	0.505	rs1633714	chr7:116022538	C/T	cg04319097	chr18:5293279	ZFP161	0.42	6.2	0.36	2.15e-9	Prevalent atrial fibrillation;
CESC	cis	rs9309473	0.519	rs2421670	chr2:73886661	T/G	cg20560298	chr2:73613845	ALMS1	0.51	7.16	0.4	8.01e-12	Metabolite levels;
CESC	cis	rs9303280	0.742	rs11557466	chr17:38024626	C/T	cg19468946	chr17:37922297	IKZF3	-0.41	-5.41	-0.32	1.42e-7	Self-reported allergy;
CESC	cis	rs4819052	0.851	rs4819039	chr21:46659458	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.46	5.79	0.34	2e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs10504229	0.683	rs6999351	chr8:58127227	C/T	cg22535103	chr8:58192502	C8orf71	-0.84	-9.44	-0.5	2.04e-18	Developmental language disorder (linguistic errors);
CESC	cis	rs3858526	0.665	rs10839170	chr11:6003512	C/T	cg05234568	chr11:5960015	NA	-0.41	-5.18	-0.3	4.5e-7	DNA methylation (variation);
CESC	cis	rs6088590	1.000	rs6087632	chr20:33407704	A/C	cg24642439	chr20:33292090	TP53INP2	0.84	11.62	0.58	1.67e-25	Coronary artery disease;
CESC	cis	rs7923609	0.936	rs10822160	chr10:65112796	T/G	cg01631684	chr10:65280961	REEP3	-0.42	-5.15	-0.3	5.01e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs12912251	1.000	rs34356257	chr15:38989605	T/C	cg01338139	chr15:38987640	C15orf53	-0.46	-5.27	-0.31	2.89e-7	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
CESC	cis	rs1620921	0.505	rs11758404	chr6:161210455	A/G	cg01280913	chr6:161186852	NA	-0.38	-5.43	-0.32	1.28e-7	Lipoprotein (a) - cholesterol levels;
CESC	cis	rs2929278	0.561	rs2927071	chr15:43919081	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.52	6.67	0.38	1.51e-10	Schizophrenia;
CESC	cis	rs9911578	1.000	rs4482353	chr17:56896834	A/G	cg12560992	chr17:57184187	TRIM37	0.92	15.58	0.69	2.71e-39	Intelligence (multi-trait analysis);
CESC	cis	rs6540556	0.723	rs12086634	chr1:209880259	T/G	cg05527609	chr1:210001259	C1orf107	-0.75	-7.97	-0.44	4.84e-14	Red blood cell count;
CESC	cis	rs6087990	0.966	rs1883730	chr20:31337487	T/A	cg13636640	chr20:31349939	DNMT3B	0.92	16.62	0.71	5.42e-43	Ulcerative colitis;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg19575883	chr2:172231724	METTL8	-0.45	-6.03	-0.35	5.49e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs1023500	0.551	rs2301521	chr22:42423110	G/C	cg15557168	chr22:42548783	NA	-0.39	-5.16	-0.3	4.79e-7	Schizophrenia;
CESC	cis	rs9902453	0.765	rs3102562	chr17:28040403	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.76	10.16	0.53	1.05e-20	Coffee consumption (cups per day);
CESC	cis	rs7666738	0.712	rs34043080	chr4:99008748	G/C	cg03676636	chr4:99064102	C4orf37	0.33	5.13	0.3	5.51e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3820928	0.839	rs58580037	chr2:227876274	G/T	cg05526886	chr2:227700861	RHBDD1	-0.46	-5.68	-0.33	3.52e-8	Pulmonary function;
CESC	cis	rs12995491	0.843	rs1878809	chr2:88518315	C/T	cg04511125	chr2:88470314	THNSL2	-0.53	-7.46	-0.42	1.26e-12	Response to metformin (IC50);
CESC	cis	rs35955747	0.902	rs2413048	chr22:31686102	G/A	cg25791279	chr22:32026902	PISD	-0.5	-5.99	-0.35	6.9e-9	Neutrophil count;Sum basophil neutrophil counts;
CESC	cis	rs10504229	0.953	rs59265461	chr8:58189701	A/T	cg05313129	chr8:58192883	C8orf71	-0.55	-6.29	-0.36	1.34e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs9322193	0.923	rs10782310	chr6:149943594	A/G	cg07701084	chr6:150067640	NUP43	0.43	6.0	0.35	6.52e-9	Lung cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23660064	chr1:223395288	SUSD4	-0.61	-6.81	-0.39	6.6e-11	Gut microbiome composition (summer);
CESC	cis	rs9911578	0.757	rs4793954	chr17:56629527	G/T	cg05425664	chr17:57184151	TRIM37	0.47	5.54	0.32	7.12e-8	Intelligence (multi-trait analysis);
CESC	cis	rs4665809	0.877	rs35224700	chr2:26298037	T/C	cg26119090	chr2:26468346	HADHA;HADHB	0.81	8.77	0.47	2.26e-16	Gut microbiome composition (summer);
CESC	cis	rs7116495	0.786	rs678193	chr11:71770273	A/C	cg26138937	chr11:71823887	C11orf51	-0.83	-6.95	-0.39	2.81e-11	Severe influenza A (H1N1) infection;
CESC	cis	rs7618915	0.508	rs12498066	chr3:52627660	G/A	cg05564831	chr3:52568323	NT5DC2	0.45	6.97	0.39	2.55e-11	Bipolar disorder;
CESC	cis	rs2637266	0.935	rs6480822	chr10:78354092	A/C	cg18941641	chr10:78392320	NA	0.44	8.21	0.45	9.93e-15	Pulmonary function;
CESC	trans	rs4756846	1.000	rs56030154	chr11:16400608	C/T	cg05579622	chr5:10618622	ANKRD33B	0.76	6.93	0.39	3.14e-11	Obesity and osteoporosis;
CESC	cis	rs10242455	0.702	rs3528	chr7:99055940	T/C	cg18809830	chr7:99032528	PTCD1	-0.61	-5.24	-0.31	3.28e-7	Blood metabolite levels;
CESC	cis	rs6570726	0.764	rs9403726	chr6:145901686	G/T	cg05347473	chr6:146136440	FBXO30	0.53	6.98	0.39	2.33e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs873946	0.529	rs12258248	chr10:134573767	A/G	cg27297192	chr10:134578999	INPP5A	0.38	5.16	0.3	4.81e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs5769765	0.954	rs6009900	chr22:50236610	T/C	cg02269571	chr22:50332266	NA	-0.46	-5.94	-0.34	8.76e-9	Schizophrenia;
CESC	cis	rs40363	0.645	rs6501177	chr16:3523681	C/T	cg21433313	chr16:3507492	NAT15	0.51	8.54	0.46	1.1e-15	Tuberculosis;
CESC	cis	rs7666738	0.830	rs7678567	chr4:99057346	A/G	cg24818145	chr4:99064322	C4orf37	0.39	5.1	0.3	6.52e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27468401	chr16:70285408	EXOSC6	0.56	6.3	0.36	1.23e-9	Gut microbiome composition (summer);
CESC	cis	rs4689388	0.824	rs114669221	chr4:6301459	G/A	cg14416269	chr4:6271139	WFS1	0.47	8.02	0.44	3.4e-14	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs4844614	0.951	rs17049197	chr1:207874704	G/A	cg21110645	chr1:207815933	NA	0.35	5.21	0.3	3.75e-7	LDL cholesterol;
CESC	cis	rs56104184	0.723	rs73063524	chr19:49409004	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.53	-5.47	-0.32	1.06e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	cis	rs9527	0.637	rs7096169	chr10:104618695	A/G	cg04362960	chr10:104952993	NT5C2	0.5	6.12	0.35	3.44e-9	Arsenic metabolism;
CESC	cis	rs7336332	0.511	rs7998978	chr13:27999457	T/C	cg22138327	chr13:27999177	GTF3A	0.86	9.68	0.51	3.52e-19	Weight;
CESC	cis	rs4561483	0.583	rs1019813	chr16:11940829	C/T	cg08843971	chr16:11963173	GSPT1	0.45	6.22	0.36	1.93e-9	Testicular germ cell tumor;
CESC	cis	rs1545257	0.505	rs67786999	chr2:24637160	T/G	cg06627628	chr2:24431161	ITSN2	-0.5	-6.02	-0.35	5.7e-9	Sjögren's syndrome;
CESC	cis	rs4819052	0.851	rs28442024	chr21:46674475	C/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.91	13.59	0.64	2.86e-32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs1707322	1.000	rs6672115	chr1:46272879	T/C	cg05343316	chr1:45956843	TESK2	0.49	5.92	0.34	9.91e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs4665809	1.000	rs12469163	chr2:26283587	T/C	cg08470875	chr2:26401718	FAM59B	-0.46	-5.11	-0.3	6.17e-7	Gut microbiome composition (summer);
CESC	cis	rs1008375	1.000	rs10939746	chr4:17684951	A/G	cg16339924	chr4:17578868	LAP3	-0.49	-6.23	-0.36	1.8e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	trans	rs6084875	0.641	rs6052807	chr20:4721910	G/A	cg10192164	chr16:30419175	ZNF771	-0.51	-6.15	-0.35	2.78e-9	Systemic lupus erythematosus;
CESC	cis	rs9291683	0.526	rs12506122	chr4:10033538	C/A	cg02734326	chr4:10020555	SLC2A9	0.45	6.14	0.35	3.04e-9	Bone mineral density;
CESC	cis	rs28489187	0.706	rs233120	chr1:85788490	A/C	cg16011679	chr1:85725395	C1orf52	0.48	5.65	0.33	4.16e-8	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	cis	rs7680126	0.500	rs4697935	chr4:10149593	C/T	cg11266682	chr4:10021025	SLC2A9	-0.5	-6.48	-0.37	4.35e-10	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	cis	rs17039065	0.920	rs9790677	chr4:109443588	G/T	cg16022748	chr4:109541635	LOC285456;RPL34	0.64	5.8	0.34	1.93e-8	Gut microbiome composition (summer);
CESC	cis	rs13253111	0.624	rs1979329	chr8:28096772	C/G	cg26534493	chr8:28060551	NA	0.48	7.52	0.42	8.73e-13	Childhood body mass index;
CESC	cis	rs7617773	0.780	rs2541	chr3:48339618	A/G	cg11946769	chr3:48343235	NME6	0.89	12.11	0.6	3.63e-27	Coronary artery disease;
CESC	cis	rs12121840	0.607	rs285435	chr1:165518480	G/A	cg16553119	chr1:165599451	MGST3	0.48	5.9	0.34	1.12e-8	Interleukin-1-receptor antagonist levels;
CESC	cis	rs4728302	0.869	rs11770927	chr7:133593126	G/A	cg10665199	chr7:133106180	EXOC4	0.38	5.33	0.31	2.05e-7	Intelligence;Intelligence (multi-trait analysis);
CESC	cis	rs523522	0.847	rs11065132	chr12:120908459	C/T	cg27279351	chr12:120934652	DYNLL1	0.68	8.74	0.47	2.65e-16	High light scatter reticulocyte count;
CESC	cis	rs1008375	0.966	rs758483	chr4:17703614	G/T	cg02297831	chr4:17616191	MED28	-0.55	-6.57	-0.37	2.63e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg02018176	chr4:1364513	KIAA1530	0.47	6.23	0.36	1.85e-9	Longevity;
CESC	trans	rs1814175	0.645	rs28454367	chr11:50045708	G/A	cg15704280	chr7:45808275	SEPT13	-1.01	-18.71	-0.75	2.23e-50	Height;
CESC	cis	rs2228479	0.850	rs11649162	chr16:89807131	C/A	cg06558623	chr16:89946397	TCF25	1.15	9.26	0.49	7.46e-18	Skin colour saturation;
CESC	cis	rs7216064	0.906	rs7223643	chr17:65830282	A/G	cg12091567	chr17:66097778	LOC651250	-0.8	-8.82	-0.48	1.62e-16	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs7223966	1.000	rs9908044	chr17:61747032	A/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.46	-5.6	-0.33	5.23e-8	Hip circumference adjusted for BMI;Body mass index;
CESC	trans	rs10448044	0.750	rs10448045	chr8:80103537	G/C	cg08211306	chr6:46097784	ENPP4	0.45	6.32	0.36	1.08e-9	Suicide in bipolar disorder;
CESC	cis	rs4595586	0.545	rs1839402	chr12:39371615	C/T	cg26384229	chr12:38710491	ALG10B	0.54	7.6	0.42	5e-13	Morning vs. evening chronotype;
CESC	cis	rs453301	0.658	rs12114954	chr8:8904862	T/G	cg06636001	chr8:8085503	FLJ10661	-0.43	-5.3	-0.31	2.42e-7	Joint mobility (Beighton score);
CESC	cis	rs9322193	0.923	rs9372044	chr6:150102003	G/A	cg07701084	chr6:150067640	NUP43	0.42	5.78	0.33	2.07e-8	Lung cancer;
CESC	cis	rs2050392	0.517	rs687036	chr10:30761249	G/A	cg18806716	chr10:30721971	MAP3K8	-0.54	-8.38	-0.46	3.19e-15	Inflammatory bowel disease;
CESC	cis	rs1023500	0.596	rs133350	chr22:42429049	A/G	cg04733989	chr22:42467013	NAGA	0.79	11.0	0.56	1.9e-23	Schizophrenia;
CESC	cis	rs3820068	0.705	rs72645804	chr1:15868387	A/C	cg18192808	chr1:15853278	DNAJC16	0.46	5.44	0.32	1.2e-7	Systolic blood pressure;
CESC	cis	rs6933660	0.800	rs6930557	chr6:151755806	G/A	cg10883421	chr6:151773342	RMND1;C6orf211	0.86	14.38	0.66	4.63e-35	Menarche (age at onset);
CESC	cis	rs12887734	0.524	rs722637	chr14:104261723	G/T	cg01849466	chr14:104193079	ZFYVE21	0.43	5.65	0.33	4.16e-8	Schizophrenia;Autism spectrum disorder or schizophrenia;
CESC	cis	rs6460942	0.915	rs62448621	chr7:12459941	G/A	cg02935154	chr7:12443704	VWDE	-0.58	-6.25	-0.36	1.67e-9	Coronary artery disease;
CESC	trans	rs208520	0.526	rs7771233	chr6:66819784	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.05	-22.37	-0.81	5.49e-63	Exhaled nitric oxide output;
CESC	cis	rs8141529	0.748	rs5762881	chr22:29289346	C/A	cg02153584	chr22:29168773	CCDC117	0.59	7.84	0.43	1.09e-13	Lymphocyte counts;
CESC	trans	rs916888	0.647	rs199524	chr17:44848438	G/T	cg22968622	chr17:43663579	NA	-0.76	-9.96	-0.52	4.68e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs1448094	0.802	rs11513957	chr12:86435551	C/T	cg02569458	chr12:86230093	RASSF9	0.4	5.82	0.34	1.69e-8	Major depressive disorder;
CESC	cis	rs3105593	1.000	rs3109894	chr15:50878574	C/T	cg08437265	chr15:50716283	USP8	0.45	5.89	0.34	1.19e-8	QT interval;
CESC	trans	rs2115172	0.836	rs4835799	chr5:122762229	A/G	cg22515636	chr2:109150313	NA	0.51	6.73	0.38	1.05e-10	Weight;
CESC	cis	rs9318086	0.648	rs35449605	chr13:24472582	G/A	cg25267304	chr13:24462978	PCOTH;MIPEP	0.44	6.27	0.36	1.46e-9	Myopia (pathological);
CESC	cis	rs9649213	0.593	rs3801263	chr7:97965016	A/G	cg24562669	chr7:97807699	LMTK2	0.49	7.17	0.4	7.48e-12	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs4950322	0.515	rs76327075	chr1:146717973	C/T	cg16700924	chr1:146552102	NA	-0.39	-5.1	-0.3	6.63e-7	Protein quantitative trait loci;
CESC	trans	rs17685	0.725	rs7795291	chr7:75725206	C/A	cg19862616	chr7:65841803	NCRNA00174	0.83	11.96	0.59	1.23e-26	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs875971	0.505	rs1167386	chr7:65513096	G/A	cg05332525	chr7:65337924	VKORC1L1	-0.49	-6.03	-0.35	5.48e-9	Aortic root size;
CESC	cis	rs1218582	0.804	rs4845398	chr1:154859038	G/C	cg16680214	chr1:154839983	KCNN3	-0.45	-6.94	-0.39	2.95e-11	Prostate cancer;
CESC	cis	rs12325245	0.536	rs12924708	chr16:58567643	G/A	cg01152986	chr16:58549298	SETD6	0.89	5.4	0.32	1.45e-7	Schizophrenia;
CESC	cis	rs8060686	0.516	rs8059575	chr16:68272635	C/G	cg26727032	chr16:67993705	SLC12A4	-0.56	-7.54	-0.42	7.64e-13	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs2777491	1.000	rs2730055	chr15:41735708	C/A	cg20272979	chr15:41787780	ITPKA	0.45	6.71	0.38	1.15e-10	Ulcerative colitis;
CESC	cis	rs10463316	0.855	rs352701	chr5:150736474	A/G	cg03212797	chr5:150827313	SLC36A1	-0.53	-6.78	-0.38	7.74e-11	Metabolite levels (Pyroglutamine);
CESC	cis	rs727505	0.954	rs1014163	chr7:124443604	G/A	cg23710748	chr7:124431027	NA	-0.45	-7.05	-0.4	1.55e-11	Lewy body disease;
CESC	cis	rs1008375	1.000	rs62295634	chr4:17685346	C/A	cg02297831	chr4:17616191	MED28	0.42	5.29	0.31	2.52e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg17226575	chr8:90914282	OSGIN2	0.48	6.12	0.35	3.43e-9	Tetralogy of Fallot;
CESC	cis	rs9875589	0.915	rs13097822	chr3:13969396	T/A	cg19554555	chr3:13937349	NA	0.53	6.68	0.38	1.36e-10	Ovarian reserve;
CESC	cis	rs2279817	0.743	rs12023874	chr1:18025612	A/G	cg21791023	chr1:18019539	ARHGEF10L	0.54	7.88	0.44	8.25e-14	Neuroticism;
CESC	cis	rs6461049	0.734	rs1558465	chr7:2151398	G/C	cg23048001	chr7:2026167	MAD1L1	0.45	5.77	0.33	2.17e-8	Schizophrenia;
CESC	cis	rs11190604	1.000	rs7078799	chr10:102301447	G/A	cg07080220	chr10:102295463	HIF1AN	0.66	6.04	0.35	5.08e-9	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.47	-5.92	-0.34	9.69e-9	Longevity;Endometriosis;
CESC	cis	rs6461049	0.800	rs2398706	chr7:2156338	A/T	cg05863683	chr7:1912471	MAD1L1	0.38	5.54	0.32	7.16e-8	Schizophrenia;
CESC	cis	rs7927771	0.832	rs10769262	chr11:47411581	G/A	cg05585544	chr11:47624801	NA	0.47	6.95	0.39	2.88e-11	Subjective well-being;
CESC	trans	rs1814175	0.558	rs5025146	chr11:49795724	C/G	cg11707556	chr5:10655725	ANKRD33B	-0.43	-6.19	-0.36	2.29e-9	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21871583	chr3:15374148	SH3BP5	0.59	7.23	0.41	5.04e-12	Gut microbiome composition (summer);
CESC	cis	rs2274273	1.000	rs66871576	chr14:55629050	C/T	cg04306507	chr14:55594613	LGALS3	0.29	5.33	0.31	2.13e-7	Protein biomarker;
CESC	cis	rs4665809	1.000	rs4665305	chr2:26313524	C/T	cg08470875	chr2:26401718	FAM59B	-0.49	-5.29	-0.31	2.54e-7	Gut microbiome composition (summer);
CESC	cis	rs10464366	0.544	rs12668821	chr7:39167846	T/A	cg18850127	chr7:39170497	POU6F2	0.39	5.51	0.32	8.38e-8	IgG glycosylation;
CESC	cis	rs9287719	0.967	rs7592691	chr2:10737426	A/G	cg00105475	chr2:10696890	NA	0.39	5.61	0.33	4.96e-8	Prostate cancer;
CESC	cis	rs3008870	0.959	rs2985808	chr1:67367741	T/C	cg08660285	chr1:67390436	MIER1;WDR78	1.01	13.55	0.64	3.74e-32	Lymphocyte percentage of white cells;
CESC	cis	rs4253772	0.591	rs6007747	chr22:46657261	A/G	cg09491104	chr22:46646882	C22orf40	-0.63	-9.79	-0.52	1.56e-19	LDL cholesterol;Cholesterol, total;
CESC	cis	rs7615952	0.576	rs4646759	chr3:125822946	G/C	cg02807482	chr3:125708958	NA	-0.39	-5.11	-0.3	6.29e-7	Blood pressure (smoking interaction);
CESC	cis	rs35110281	0.837	rs2838340	chr21:45076373	A/G	cg01579765	chr21:45077557	HSF2BP	-0.5	-8.53	-0.46	1.12e-15	Mean corpuscular volume;
CESC	cis	rs7617480	0.648	rs6806356	chr3:48727636	G/A	cg07636037	chr3:49044803	WDR6	0.76	9.49	0.5	1.37e-18	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CESC	cis	rs1355223	0.506	rs1509660	chr11:34865017	A/G	cg11622362	chr11:34938112	PDHX;APIP	0.44	5.29	0.31	2.52e-7	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs7560272	0.723	rs2421548	chr2:73641240	A/G	cg20560298	chr2:73613845	ALMS1	0.5	7.17	0.4	7.57e-12	Schizophrenia;
CESC	cis	rs10838687	0.736	rs11039148	chr11:47274126	T/A	cg25783544	chr11:47291846	MADD	0.54	6.13	0.35	3.09e-9	Proinsulin levels;
CESC	trans	rs931555	0.750	rs11567705	chr5:35861152	C/G	cg11740570	chr11:1032135	MUC6	-0.42	-6.02	-0.35	5.84e-9	Multiple sclerosis;
CESC	cis	rs1799949	0.965	rs11654051	chr17:41419656	C/T	cg05368731	chr17:41323189	NBR1	0.79	10.65	0.55	2.72e-22	Menopause (age at onset);
CESC	trans	rs5756813	0.727	rs13055462	chr22:38184685	A/G	cg19894588	chr14:64061835	NA	-0.64	-8.24	-0.45	7.83e-15	Optic cup area;Vertical cup-disc ratio;
CESC	cis	rs1552244	0.706	rs279545	chr3:9972493	A/G	cg00149659	chr3:10157352	C3orf10	0.53	6.77	0.38	8.43e-11	Alzheimer's disease;
CESC	cis	rs4253772	0.550	rs9615953	chr22:46731024	C/G	cg18190219	chr22:46762943	CELSR1	-0.64	-5.89	-0.34	1.18e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs9443645	0.901	rs9343856	chr6:79678211	G/A	cg05283184	chr6:79620031	NA	-0.42	-6.49	-0.37	4.09e-10	Intelligence (multi-trait analysis);
CESC	cis	rs4481887	0.893	rs4529743	chr1:248473683	G/C	cg00666640	chr1:248458726	OR2T12	0.35	5.93	0.34	9.43e-9	Common traits (Other);
CESC	cis	rs6901004	0.685	rs354550	chr6:111546484	G/A	cg15721981	chr6:111408429	SLC16A10	-0.35	-5.19	-0.3	4.13e-7	Blood metabolite levels;
CESC	cis	rs1348850	0.567	rs4144276	chr2:178523420	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.55	6.81	0.39	6.35e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs60871478	0.838	rs7789321	chr7:800977	A/G	cg13798912	chr7:905769	UNC84A	0.6	5.92	0.34	9.72e-9	Cerebrospinal P-tau181p levels;
CESC	cis	rs9402673	0.558	rs9688342	chr6:135323026	A/T	cg22676075	chr6:135203613	NA	0.51	7.23	0.41	5.22e-12	Reticulocyte count;High light scatter reticulocyte count;
CESC	cis	rs3820068	0.705	rs11587541	chr1:15899478	T/C	cg17385448	chr1:15911702	AGMAT	0.37	5.78	0.33	2.12e-8	Systolic blood pressure;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18354742	chr19:38755139	SPINT2	0.53	6.13	0.35	3.14e-9	Gut microbiome composition (summer);
CESC	cis	rs1784581	0.802	rs9458430	chr6:162426517	G/T	cg17173639	chr6:162384350	PARK2	-0.59	-9.0	-0.48	4.42e-17	Itch intensity from mosquito bite;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg00482248	chr7:73589137	EIF4H	-0.47	-6.29	-0.36	1.33e-9	Asthma;
CESC	cis	rs3858526	0.755	rs10769368	chr11:5962084	C/T	cg05234568	chr11:5960015	NA	0.42	5.23	0.31	3.39e-7	DNA methylation (variation);
CESC	cis	rs2637266	0.783	rs846645	chr10:78516000	A/G	cg18941641	chr10:78392320	NA	0.43	8.42	0.46	2.39e-15	Pulmonary function;
CESC	cis	rs7927771	0.524	rs7933896	chr11:47882782	C/T	cg18512352	chr11:47633146	NA	0.35	5.43	0.32	1.29e-7	Subjective well-being;
CESC	cis	rs12282928	0.743	rs1109906	chr11:48284033	C/T	cg26585981	chr11:48327164	OR4S1	-0.36	-5.05	-0.3	8.36e-7	Migraine - clinic-based;
CESC	cis	rs58688157	0.705	rs12421646	chr11:578844	C/G	cg02461776	chr11:598696	PHRF1	0.51	5.6	0.33	5.41e-8	Systemic lupus erythematosus;
CESC	cis	rs7666738	0.830	rs7663661	chr4:99014761	A/G	cg17366294	chr4:99064904	C4orf37	0.6	8.62	0.47	6.37e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs820218	0.717	rs729778	chr17:73642281	C/T	cg01592526	chr17:73663357	RECQL5;SAP30BP	-0.38	-5.1	-0.3	6.49e-7	Rotator cuff tears;
CESC	cis	rs9916302	0.904	rs1619021	chr17:37739274	G/A	cg00129232	chr17:37814104	STARD3	-0.64	-8.27	-0.45	6.73e-15	Glomerular filtration rate (creatinine);
CESC	cis	rs7107174	1.000	rs7112234	chr11:78102470	G/A	cg02023728	chr11:77925099	USP35	0.4	5.56	0.32	6.61e-8	Testicular germ cell tumor;
CESC	cis	rs7666738	0.791	rs10033211	chr4:98995624	T/A	cg03467027	chr4:99064603	C4orf37	0.44	5.51	0.32	8.65e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs8031584	0.958	rs1043742	chr15:31232581	A/C	cg08109568	chr15:31115862	NA	-0.69	-9.13	-0.49	1.79e-17	Huntington's disease progression;
CESC	cis	rs7551222	0.752	rs10793766	chr1:204549496	C/T	cg20240347	chr1:204465584	NA	-0.29	-5.85	-0.34	1.47e-8	Schizophrenia;
CESC	cis	rs4665809	0.590	rs13016300	chr2:26468365	G/C	cg27170947	chr2:26402098	FAM59B	0.87	9.89	0.52	7.6e-20	Gut microbiome composition (summer);
CESC	cis	rs5167	0.583	rs7252480	chr19:45458925	C/T	cg13119609	chr19:45449297	APOC2	0.38	5.35	0.31	1.89e-7	Blood protein levels;
CESC	cis	rs2288912	0.807	rs3760626	chr19:45457105	A/G	cg20090143	chr19:45452003	APOC2	0.37	6.39	0.37	7.51e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs16867321	0.580	rs2049710	chr2:181587276	G/A	cg23363182	chr2:181467187	NA	0.44	6.59	0.38	2.32e-10	Obesity;
CESC	cis	rs1538970	0.816	rs11211124	chr1:45962409	T/C	cg05343316	chr1:45956843	TESK2	0.93	12.78	0.62	1.91e-29	Platelet count;
CESC	cis	rs9300255	0.596	rs10773002	chr12:123746961	A/T	cg05973401	chr12:123451056	ABCB9	-0.46	-5.59	-0.32	5.52e-8	Neutrophil percentage of white cells;
CESC	cis	rs911555	0.755	rs8010247	chr14:103933556	A/G	cg24130564	chr14:104152367	KLC1	0.48	6.26	0.36	1.53e-9	Intelligence (multi-trait analysis);
CESC	cis	rs116988415	0.584	rs747858	chr14:65239772	G/A	cg25083366	chr14:65239357	SPTB	0.73	5.47	0.32	1.04e-7	Daytime sleep phenotypes;
CESC	cis	rs854765	0.647	rs62073573	chr17:17976354	G/A	cg04398451	chr17:18023971	MYO15A	-0.78	-11.44	-0.58	6.57e-25	Total body bone mineral density;
CESC	cis	rs7940866	0.801	rs2113928	chr11:130835975	A/G	cg12179176	chr11:130786555	SNX19	0.67	10.08	0.53	1.91e-20	Schizophrenia;
CESC	cis	rs875971	0.545	rs6460298	chr7:65907770	T/C	cg11764359	chr7:65958608	NA	0.82	9.91	0.52	6.84e-20	Aortic root size;
CESC	cis	rs11098499	0.780	rs7680914	chr4:120563053	A/G	cg24375607	chr4:120327624	NA	0.44	5.38	0.31	1.65e-7	Corneal astigmatism;
CESC	cis	rs12586317	0.547	rs114371385	chr14:35503724	G/A	cg16230307	chr14:35515116	FAM177A1	0.99	10.61	0.55	3.72e-22	Psoriasis;
CESC	cis	rs11718455	0.960	rs13082990	chr3:44005172	T/C	cg08738300	chr3:44038990	NA	0.46	6.12	0.35	3.34e-9	Coronary artery disease;
CESC	cis	rs6460942	0.597	rs4719315	chr7:12528634	A/G	cg02935154	chr7:12443704	VWDE	-0.55	-5.58	-0.32	6.01e-8	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16562251	chr1:166845621	TADA1	0.69	7.6	0.42	5.2e-13	Gut microbiome composition (summer);
CESC	cis	rs13242816	0.892	rs34205980	chr7:116078406	T/A	cg04696780	chr7:116139425	CAV2	-0.65	-5.7	-0.33	3.2e-8	P wave duration;
CESC	cis	rs6089584	1.000	rs6089583	chr20:60563624	G/A	cg24733560	chr20:60626293	TAF4	0.4	5.77	0.33	2.23e-8	Body mass index;
CESC	cis	rs17818399	0.547	rs35178974	chr2:46763898	T/C	cg02822958	chr2:46747628	ATP6V1E2	0.44	5.16	0.3	4.93e-7	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02847760	chr15:40453199	BUB1B	0.57	6.48	0.37	4.55e-10	Gut microbiome composition (summer);
CESC	cis	rs919433	0.662	rs2043018	chr2:198236958	G/A	cg03934865	chr2:198174659	NA	0.44	6.27	0.36	1.49e-9	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs12586317	0.531	rs57856432	chr14:35719708	G/T	cg16230307	chr14:35515116	FAM177A1	0.41	5.13	0.3	5.54e-7	Psoriasis;
CESC	cis	rs10479542	0.503	rs12719865	chr5:178993566	C/T	cg00080972	chr5:178986291	RUFY1	0.47	7.44	0.42	1.41e-12	Lung cancer;
CESC	cis	rs7666738	0.830	rs1534318	chr4:98965058	C/T	cg18180107	chr4:99064573	C4orf37	0.39	5.09	0.3	6.72e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2832191	0.720	rs7277028	chr21:30494604	T/C	cg08807101	chr21:30365312	RNF160	-0.72	-9.88	-0.52	8.63e-20	Dental caries;
CESC	cis	rs10208940	0.920	rs6742045	chr2:68811850	G/A	cg12452813	chr2:68675892	NA	0.53	5.29	0.31	2.54e-7	Urate levels in lean individuals;
CESC	cis	rs858239	1.000	rs156425	chr7:23309119	C/T	cg23682824	chr7:23144976	KLHL7	-0.42	-5.61	-0.33	4.98e-8	Cerebrospinal fluid biomarker levels;
CESC	cis	rs3733585	0.699	rs6449172	chr4:9966036	A/T	cg00071950	chr4:10020882	SLC2A9	-0.73	-11.82	-0.59	3.44e-26	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs2243480	1.000	rs58062456	chr7:65394852	G/T	cg13147721	chr7:65941812	NA	-0.83	-7.92	-0.44	6.77e-14	Diabetic kidney disease;
CESC	cis	rs72781680	0.898	rs72780118	chr2:23994431	G/A	cg08917208	chr2:24149416	ATAD2B	0.95	8.71	0.47	3.45e-16	Lymphocyte counts;
CESC	cis	rs12971120	0.891	rs2278159	chr18:72178161	T/C	cg25817165	chr18:72167213	CNDP2	-0.61	-7.36	-0.41	2.37e-12	Refractive error;
CESC	cis	rs9457247	0.740	rs13195812	chr6:167443902	C/T	cg23791538	chr6:167370224	RNASET2	-0.54	-7.26	-0.41	4.19e-12	Crohn's disease;
CESC	cis	rs1568889	1.000	rs7945367	chr11:28166272	G/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.79	10.98	0.56	2.37e-23	Bipolar disorder;
CESC	cis	rs72615157	0.561	rs113401658	chr7:99858505	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.7	6.6	0.38	2.24e-10	Lung function (FEV1/FVC);
CESC	cis	rs2066819	0.892	rs2066807	chr12:56740682	C/G	cg26714650	chr12:56694279	CS	-1.39	-9.17	-0.49	1.33e-17	Psoriasis vulgaris;
CESC	cis	rs2066819	1.000	rs78149779	chr12:56694817	A/G	cg26734620	chr12:56694298	CS	1.07	6.58	0.37	2.56e-10	Psoriasis vulgaris;
CESC	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg09177884	chr7:1199841	ZFAND2A	-0.55	-6.22	-0.36	1.92e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2637266	0.935	rs2579751	chr10:78339890	G/A	cg18941641	chr10:78392320	NA	0.41	7.64	0.42	4.06e-13	Pulmonary function;
CESC	trans	rs7672847	0.547	rs58180406	chr4:170413285	G/A	cg19308436	chr1:237949471	RYR2	0.63	6.83	0.39	5.75e-11	Subjective well-being;
CESC	cis	rs6087990	0.735	rs6057647	chr20:31381690	A/T	cg13636640	chr20:31349939	DNMT3B	0.81	12.91	0.62	6.32e-30	Ulcerative colitis;
CESC	cis	rs1862618	0.853	rs252919	chr5:56124111	T/C	cg12311346	chr5:56204834	C5orf35	-0.74	-8.87	-0.48	1.09e-16	Initial pursuit acceleration;
CESC	cis	rs9611519	1.000	rs9611505	chr22:41540279	T/C	cg03806693	chr22:41940476	POLR3H	-0.58	-5.98	-0.34	7.18e-9	Neuroticism;
CESC	cis	rs7582720	1.000	rs72936870	chr2:203789679	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.38	0.41	1.99e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs9400271	0.632	rs949881	chr6:109586240	A/G	cg01475377	chr6:109611718	NA	-0.47	-7.37	-0.41	2.22e-12	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
CESC	cis	rs11203032	0.831	rs11203014	chr10:90940333	C/G	cg16672925	chr10:90967113	CH25H	0.75	7.5	0.42	9.62e-13	Heart failure;
CESC	cis	rs151349	0.555	rs151343	chr20:57583298	C/G	cg23907860	chr20:57583709	CTSZ	0.53	8.61	0.47	6.51e-16	Platelet distribution width;
CESC	cis	rs7408868	1.000	rs4809030	chr19:15273381	A/G	cg14696996	chr19:15285081	NOTCH3	1.11	11.47	0.58	5.57e-25	Pulse pressure;
CESC	cis	rs9487051	0.676	rs2884013	chr6:109599952	C/T	cg12927641	chr6:109611667	NA	-0.36	-5.43	-0.32	1.28e-7	Reticulocyte fraction of red cells;
CESC	cis	rs34779708	0.931	rs2384275	chr10:35297142	A/G	cg03585969	chr10:35415529	CREM	0.75	10.04	0.53	2.57e-20	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs10788264	0.504	rs4751887	chr10:124029758	G/A	cg09507567	chr10:124027408	NA	0.4	5.53	0.32	7.61e-8	Total body bone mineral density;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16987101	chr1:226297828	NA	0.54	6.29	0.36	1.33e-9	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11618788	chr7:65939595	NA	-0.66	-7.76	-0.43	1.89e-13	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27470303	chr10:21823447	MLLT10	0.58	6.06	0.35	4.54e-9	Gut microbiome composition (summer);
CESC	cis	rs3747547	0.642	rs72726054	chr9:38072104	C/G	cg13774184	chr9:37916125	SHB	-0.68	-5.75	-0.33	2.43e-8	Metabolite levels (Dihydroxy docosatrienoic acid);
CESC	cis	rs9309711	0.736	rs13412581	chr2:3497187	G/A	cg10845886	chr2:3471009	TTC15	-0.8	-9.72	-0.51	2.61e-19	Neurofibrillary tangles;
CESC	cis	rs7086627	0.515	rs10887896	chr10:82210144	A/C	cg03267442	chr10:82210566	NA	-0.33	-5.38	-0.31	1.67e-7	Post bronchodilator FEV1;
CESC	cis	rs875971	0.638	rs801205	chr7:66022144	C/A	cg25985355	chr7:65971099	NA	0.32	5.34	0.31	2e-7	Aortic root size;
CESC	cis	rs34779708	0.733	rs7914560	chr10:35548099	G/A	cg04310649	chr10:35416472	CREM	-0.45	-5.14	-0.3	5.34e-7	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs7264396	0.635	rs6060656	chr20:34466382	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.62	7.47	0.42	1.16e-12	Total cholesterol levels;
CESC	cis	rs9660180	0.967	rs12034740	chr1:1728969	C/A	cg13866156	chr1:1669148	SLC35E2	-0.49	-6.44	-0.37	5.52e-10	Body mass index;
CESC	cis	rs6933660	0.676	rs3757316	chr6:151774339	A/G	cg14262678	chr6:151773367	RMND1;C6orf211	-0.68	-9.42	-0.5	2.35e-18	Menarche (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14642636	chr9:71395486	PIP5K1B;FAM122A	-0.52	-6.16	-0.35	2.66e-9	Gut microbiome composition (summer);
CESC	cis	rs3096299	0.967	rs7205785	chr16:89458984	A/G	cg02187348	chr16:89574699	SPG7	0.56	7.39	0.41	1.96e-12	Multiple myeloma (IgH translocation);
CESC	cis	rs7607369	0.679	rs6751527	chr2:219630965	C/G	cg02176678	chr2:219576539	TTLL4	0.47	8.05	0.44	2.74e-14	Red blood cell count;Amyotrophic lateral sclerosis;
CESC	cis	rs8062405	0.723	rs113208333	chr16:28606160	G/T	cg01378222	chr16:28622494	SULT1A1	0.31	5.26	0.31	3.04e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	trans	rs61931739	0.500	rs34287388	chr12:34444626	C/A	cg26384229	chr12:38710491	ALG10B	0.69	10.44	0.54	1.34e-21	Morning vs. evening chronotype;
CESC	cis	rs4713118	0.662	rs9468274	chr6:28026077	G/T	cg26335602	chr6:28129616	ZNF389	0.44	5.61	0.33	5.19e-8	Parkinson's disease;
CESC	cis	rs7618915	0.501	rs3733041	chr3:52731598	T/C	cg18337363	chr3:52569053	NT5DC2	0.29	5.31	0.31	2.32e-7	Bipolar disorder;
CESC	cis	rs11785400	1.000	rs4266629	chr8:143736635	A/G	cg24634471	chr8:143751801	JRK	0.47	6.25	0.36	1.61e-9	Schizophrenia;
CESC	cis	rs7223966	1.000	rs2013288	chr17:61785904	C/T	cg11494091	chr17:61959527	GH2	0.4	5.44	0.32	1.19e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs10740039	0.583	rs1904404	chr10:62502186	A/G	cg02922035	chr10:62493342	NA	-0.44	-5.15	-0.3	4.98e-7	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CESC	cis	rs3925075	1.000	rs4411512	chr16:31347445	C/T	cg02846316	chr16:31340340	ITGAM	0.41	6.52	0.37	3.54e-10	IgA nephropathy;
CESC	cis	rs2243480	1.000	rs2465120	chr7:65620974	C/G	cg18252515	chr7:66147081	NA	-1.36	-13.62	-0.64	2.25e-32	Diabetic kidney disease;
CESC	cis	rs10751667	0.621	rs10794348	chr11:939941	G/A	cg06064525	chr11:970664	AP2A2	-0.52	-10.43	-0.54	1.43e-21	Alzheimer's disease (late onset);
CESC	cis	rs7666738	0.962	rs2865986	chr4:99067907	A/G	cg05340658	chr4:99064831	C4orf37	0.69	9.2	0.49	1.08e-17	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4664304	0.742	rs67017730	chr2:160732793	T/G	cg03641300	chr2:160917029	PLA2R1	-0.41	-5.46	-0.32	1.07e-7	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs807669	0.903	rs807667	chr22:19161327	A/G	cg02655711	chr22:19163373	SLC25A1	-0.94	-14.47	-0.66	2.28e-35	Metabolite levels;
CESC	cis	rs2075371	0.933	rs432336	chr7:133949064	A/G	cg11752832	chr7:134001865	SLC35B4	0.51	6.52	0.37	3.61e-10	Mean platelet volume;
CESC	cis	rs9660992	0.710	rs1151787	chr1:205254238	G/A	cg21643547	chr1:205240462	TMCC2	-0.45	-6.05	-0.35	4.87e-9	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs892961	0.932	rs8066646	chr17:75414192	C/T	cg05865280	chr17:75406074	SEPT9	0.63	12.77	0.62	1.93e-29	Airflow obstruction;
CESC	trans	rs526821	0.595	rs2926309	chr11:55314219	G/A	cg15704280	chr7:45808275	SEPT13	-0.52	-6.37	-0.36	8.32e-10	Pediatric bone mineral density (spine);
CESC	cis	rs6430585	0.583	rs7561565	chr2:136640787	A/C	cg07169764	chr2:136633963	MCM6	1.24	20.1	0.78	3.22e-55	Corneal structure;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg09930017	chr12:125399097	UBC	0.44	6.19	0.36	2.31e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs6088590	1.000	rs910870	chr20:33292893	T/C	cg08999081	chr20:33150536	PIGU	0.47	6.88	0.39	4.36e-11	Coronary artery disease;
CESC	cis	rs9611565	0.659	rs73178641	chr22:41952075	A/T	cg17376030	chr22:41985996	PMM1	0.71	7.61	0.42	4.72e-13	Vitiligo;
CESC	cis	rs9581857	0.547	rs9319374	chr13:28047587	A/C	cg01674679	chr13:27998804	GTF3A	-0.63	-5.18	-0.3	4.47e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
CESC	cis	rs6460942	0.597	rs4721106	chr7:12535053	T/C	cg20607287	chr7:12443886	VWDE	-0.72	-7.71	-0.43	2.51e-13	Coronary artery disease;
CESC	cis	rs7794273	0.851	rs10251998	chr7:18849259	G/A	cg13420273	chr7:18810212	HDAC9	0.35	5.03	0.3	9e-7	Night sleep phenotypes;
CESC	cis	rs9549367	0.789	rs7994324	chr13:113906497	T/C	cg18105134	chr13:113819100	PROZ	-0.69	-8.35	-0.46	3.87e-15	Platelet distribution width;
CESC	trans	rs7246657	0.943	rs28373708	chr19:37976659	C/T	cg24637308	chr11:6592297	DNHD1	0.53	6.13	0.35	3.16e-9	Coronary artery calcification;
CESC	cis	rs1580019	0.921	rs1580023	chr7:32497881	G/A	cg06627557	chr7:32535165	LSM5;AVL9	0.73	10.13	0.53	1.34e-20	Cognitive ability;
CESC	cis	rs11792861	0.890	rs2900481	chr9:111831825	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.42	5.26	0.31	3.04e-7	Menarche (age at onset);
CESC	cis	rs546131	0.928	rs552627	chr11:34826680	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.5	6.28	0.36	1.39e-9	Lung disease severity in cystic fibrosis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16629158	chr2:122042988	TFCP2L1	0.56	6.64	0.38	1.75e-10	Gut microbiome composition (summer);
CESC	cis	rs16917546	0.967	rs10995246	chr10:64391846	C/A	cg03961010	chr10:64397487	ZNF365	-0.38	-6.15	-0.35	2.85e-9	Basal cell carcinoma;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06713521	chr6:7313605	SSR1	0.62	7.45	0.42	1.31e-12	Gut microbiome composition (summer);
CESC	cis	rs8014204	0.762	rs12891131	chr14:75240090	A/G	cg08847533	chr14:75593920	NEK9	0.4	5.26	0.31	2.98e-7	Caffeine consumption;
CESC	cis	rs6088580	0.634	rs6058052	chr20:33047084	A/G	cg08999081	chr20:33150536	PIGU	0.66	11.67	0.58	1.16e-25	Glomerular filtration rate (creatinine);
CESC	cis	rs10504229	0.953	rs67886764	chr8:58187117	T/C	cg22535103	chr8:58192502	C8orf71	-1.05	-13.08	-0.63	1.71e-30	Developmental language disorder (linguistic errors);
CESC	cis	rs2777491	0.574	rs316616	chr15:41746276	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.06	-16.89	-0.72	5.96e-44	Ulcerative colitis;
CESC	cis	rs1215050	0.791	rs260890	chr4:98741698	A/G	cg05340658	chr4:99064831	C4orf37	0.49	6.46	0.37	4.89e-10	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs9837602	0.529	rs1087198	chr3:99524381	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.62	-9.72	-0.51	2.66e-19	Breast cancer;
CESC	trans	rs2417940	0.799	rs2196028	chr12:21020906	C/T	cg19502417	chr1:21930336	RAP1GAP	-0.46	-6.03	-0.35	5.49e-9	Bilirubin levels;
CESC	cis	rs820218	0.798	rs9909259	chr17:73648366	G/A	cg01592526	chr17:73663357	RECQL5;SAP30BP	-0.39	-5.25	-0.31	3.07e-7	Rotator cuff tears;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg07762761	chr8:104033118	ATP6V1C1	-0.52	-7.04	-0.4	1.6e-11	Thyroid stimulating hormone;
CESC	cis	rs853679	0.517	rs3757187	chr6:28107654	T/C	cg20151795	chr6:28129481	ZNF389	0.46	6.0	0.35	6.52e-9	Depression;
CESC	cis	rs10791097	0.694	rs2155750	chr11:130751261	A/C	cg12179176	chr11:130786555	SNX19	0.66	10.37	0.54	2.2e-21	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs12188164	0.582	rs80273890	chr5:483057	C/T	cg15813090	chr5:442598	EXOC3;C5orf55	0.44	6.18	0.36	2.35e-9	Cystic fibrosis severity;
CESC	cis	rs3749237	0.595	rs11130192	chr3:49467206	C/G	cg03060546	chr3:49711283	APEH	0.77	11.69	0.58	9.54e-26	Resting heart rate;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12876261	chr7:56119223	PSPH;CCT6A	0.61	7.26	0.41	4.39e-12	Gut microbiome composition (summer);
CESC	cis	rs10876993	0.928	rs2640629	chr12:58065448	C/T	cg18357645	chr12:58087776	OS9	0.58	9.72	0.51	2.64e-19	Celiac disease or Rheumatoid arthritis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02711724	chr8:130877076	FAM49B	-0.7	-7.77	-0.43	1.74e-13	Gut microbiome composition (summer);
CESC	cis	rs35110281	0.744	rs230645	chr21:44918607	A/G	cg04455712	chr21:45112962	RRP1B	-0.37	-5.65	-0.33	4.03e-8	Mean corpuscular volume;
CESC	cis	rs10504229	0.817	rs114173899	chr8:58170640	G/T	cg05313129	chr8:58192883	C8orf71	-0.56	-6.45	-0.37	5.31e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs10751667	1.000	rs7394449	chr11:962190	T/C	cg20946044	chr11:1010712	AP2A2	-0.43	-5.78	-0.33	2.15e-8	Alzheimer's disease (late onset);
CESC	cis	rs17711722	0.522	rs62469933	chr7:65265639	G/A	cg07424592	chr7:64974309	NA	-0.36	-5.26	-0.31	3e-7	Calcium levels;
CESC	cis	rs9467773	1.000	rs9467779	chr6:26536687	A/T	cg11502198	chr6:26597334	ABT1	-0.4	-5.67	-0.33	3.71e-8	Intelligence (multi-trait analysis);
CESC	cis	rs10791323	0.519	rs329663	chr11:133754543	A/G	cg15485101	chr11:133734466	NA	0.3	5.16	0.3	4.84e-7	Childhood ear infection;
CESC	cis	rs10887741	0.546	rs7078618	chr10:89440911	A/G	cg13926569	chr10:89418898	PAPSS2	0.45	7.13	0.4	9.81e-12	Exercise (leisure time);
CESC	trans	rs4756846	1.000	rs17470624	chr11:16445649	C/T	cg05579622	chr5:10618622	ANKRD33B	0.76	6.9	0.39	3.87e-11	Obesity and osteoporosis;
CESC	cis	rs11078917	1	rs11078917	chr17:37746359	A/C	cg07936489	chr17:37558343	FBXL20	-0.76	-10.13	-0.53	1.39e-20	Mean corpuscular volume;
CESC	cis	rs4819052	1.000	rs4819052	chr21:46699777	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.91	11.99	0.59	9.53e-27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs11122272	0.668	rs1122131	chr1:231476501	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.46	-6.29	-0.36	1.33e-9	Hemoglobin concentration;
CESC	cis	rs2204008	0.837	rs11514225	chr12:38076270	G/A	cg13010199	chr12:38710504	ALG10B	0.54	6.76	0.38	8.83e-11	Bladder cancer;
CESC	cis	rs4665809	1.000	rs4665819	chr2:26309073	A/G	cg04944784	chr2:26401820	FAM59B	-0.67	-7.75	-0.43	2e-13	Gut microbiome composition (summer);
CESC	cis	rs12134245	0.776	rs13447526	chr1:91983174	A/G	cg25838465	chr1:92012736	NA	0.53	7.21	0.4	5.96e-12	Breast cancer;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg02102644	chr17:35969361	SYNRG	-0.47	-6.12	-0.35	3.27e-9	Ulcerative colitis;
CESC	cis	rs6120849	0.754	rs6120812	chr20:33629427	T/C	cg24642439	chr20:33292090	TP53INP2	0.68	6.77	0.38	8.46e-11	Protein C levels;
CESC	cis	rs9457247	0.663	rs2301436	chr6:167437988	C/T	cg07741184	chr6:167504864	NA	0.34	5.97	0.34	7.46e-9	Crohn's disease;
CESC	cis	rs73206853	0.563	rs1050587	chr12:111158161	T/C	cg12870014	chr12:110450643	ANKRD13A	0.64	5.57	0.32	6.19e-8	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	trans	rs459571	0.959	rs2520099	chr9:136918139	T/C	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.57	-7.56	-0.42	6.72e-13	Platelet distribution width;
CESC	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.93	14.18	0.66	2.45e-34	Prudent dietary pattern;
CESC	cis	rs854765	0.724	rs62072049	chr17:17906520	T/C	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.48	6.29	0.36	1.27e-9	Total body bone mineral density;
CESC	cis	rs1008375	1.000	rs2159584	chr4:17620568	G/A	cg04450456	chr4:17643702	FAM184B	0.42	5.98	0.34	7.07e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs6060717	0.610	rs2590965	chr20:34613120	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.59	7.88	0.44	8.32e-14	Hip circumference adjusted for BMI;
CESC	cis	rs9611565	0.503	rs5996062	chr22:42167464	C/G	cg03806693	chr22:41940476	POLR3H	1.18	13.88	0.65	2.76e-33	Vitiligo;
CESC	trans	rs801193	1.000	rs2659915	chr7:66153101	A/G	cg26939375	chr7:64535504	NA	0.62	8.39	0.46	3e-15	Aortic root size;
CESC	cis	rs9611565	0.512	rs4820444	chr22:42202606	A/G	cg17376030	chr22:41985996	PMM1	-0.76	-8.28	-0.45	6.12e-15	Vitiligo;
CESC	cis	rs7666738	0.830	rs62321598	chr4:99014237	C/T	cg03467027	chr4:99064603	C4orf37	0.44	5.63	0.33	4.57e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9733	0.650	rs11204680	chr1:150587140	T/G	cg22823121	chr1:150693482	HORMAD1	-0.36	-5.39	-0.31	1.54e-7	Tonsillectomy;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg20554397	chr5:303564	PDCD6;AHRR	0.45	6.17	0.35	2.55e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs4665809	0.525	rs4665324	chr2:26447147	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.1	-12.71	-0.62	3.31e-29	Gut microbiome composition (summer);
CESC	cis	rs1568889	1.000	rs12803716	chr11:28055111	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.77	10.85	0.55	6.02e-23	Bipolar disorder;
CESC	cis	rs4566357	0.615	rs4350744	chr2:227918146	A/T	cg05526886	chr2:227700861	RHBDD1	-0.52	-6.84	-0.39	5.61e-11	Coronary artery disease;
CESC	cis	rs4481887	0.927	rs10127803	chr1:248476196	A/T	cg00666640	chr1:248458726	OR2T12	0.35	5.93	0.34	9.43e-9	Common traits (Other);
CESC	cis	rs938554	0.612	rs28592748	chr4:9998605	T/C	cg00071950	chr4:10020882	SLC2A9	0.62	7.37	0.41	2.23e-12	Blood metabolite levels;
CESC	cis	rs708547	0.647	rs1718878	chr4:57876955	G/A	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.42	-5.58	-0.32	6.06e-8	Response to bleomycin (chromatid breaks);
CESC	cis	rs6842047	1.000	rs10471184	chr4:187122904	C/T	cg09526685	chr4:187126073	CYP4V2	-0.7	-5.67	-0.33	3.66e-8	Blood protein levels;
CESC	cis	rs730775	0.505	rs325004	chr6:44270365	C/G	cg21130236	chr6:44246755	TMEM151B	-0.27	-5.29	-0.31	2.58e-7	Monocyte percentage of white cells;Monocyte count;
CESC	cis	rs853679	0.517	rs6932109	chr6:28078303	A/G	cg26335602	chr6:28129616	ZNF389	-0.56	-7.66	-0.43	3.42e-13	Depression;
CESC	cis	rs1218582	0.688	rs2135219	chr1:154857217	G/A	cg06221963	chr1:154839813	KCNN3	-0.59	-9.36	-0.5	3.66e-18	Prostate cancer;
CESC	cis	rs17376456	0.877	rs12374463	chr5:93483569	C/G	cg25358565	chr5:93447407	FAM172A	1.15	10.91	0.56	3.79e-23	Diabetic retinopathy;
CESC	cis	rs7208859	0.623	rs11657662	chr17:29076347	A/G	cg14008862	chr17:28927542	LRRC37B2	-0.72	-5.48	-0.32	9.7e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs1799949	0.930	rs8176194	chr17:41231221	A/C	cg25072359	chr17:41440525	NA	0.47	6.45	0.37	5.36e-10	Menopause (age at onset);
CESC	trans	rs57221529	0.709	rs111352378	chr5:577079	G/A	cg25482853	chr8:67687455	SGK3	1.01	10.17	0.53	9.74e-21	Lung disease severity in cystic fibrosis;
CESC	cis	rs17253792	0.822	rs75399477	chr14:56174413	T/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.78	5.35	0.31	1.87e-7	Putamen volume;
CESC	cis	rs736408	0.608	rs6445534	chr3:52743384	G/A	cg07507251	chr3:52567010	NT5DC2	0.32	5.58	0.32	5.82e-8	Bipolar disorder;
CESC	cis	rs3096299	0.658	rs3934737	chr16:89560209	G/A	cg16743903	chr16:89593216	SPG7	-0.49	-6.4	-0.37	7e-10	Multiple myeloma (IgH translocation);
CESC	cis	rs858239	0.614	rs10229956	chr7:23402936	C/G	cg23682824	chr7:23144976	KLHL7	-0.42	-5.26	-0.31	2.93e-7	Cerebrospinal fluid biomarker levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25680105	chr8:82434497	NA	-0.57	-6.05	-0.35	4.93e-9	Gut microbiome composition (summer);
CESC	cis	rs7659604	0.676	rs4516739	chr4:122699741	G/T	cg19748678	chr4:122722346	EXOSC9	0.72	9.38	0.5	3.07e-18	Type 2 diabetes;
CESC	cis	rs9443645	0.527	rs10943596	chr6:79575292	C/T	cg05283184	chr6:79620031	NA	-0.36	-5.1	-0.3	6.62e-7	Intelligence (multi-trait analysis);
CESC	cis	rs7666738	0.830	rs6834014	chr4:98951431	G/A	cg03467027	chr4:99064603	C4orf37	0.45	5.67	0.33	3.69e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6964587	0.934	rs35968894	chr7:91762145	A/G	cg17063962	chr7:91808500	NA	0.52	6.2	0.36	2.15e-9	Breast cancer;
CESC	cis	rs11098499	0.569	rs10023641	chr4:120258410	C/G	cg09307838	chr4:120376055	NA	0.76	10.33	0.54	3.02e-21	Corneal astigmatism;
CESC	cis	rs2075371	0.863	rs9641966	chr7:133961205	G/A	cg00033643	chr7:134001901	SLC35B4	0.4	5.19	0.3	4.14e-7	Mean platelet volume;
CESC	trans	rs61931739	0.500	rs11053208	chr12:34460029	A/G	cg26384229	chr12:38710491	ALG10B	0.56	7.72	0.43	2.42e-13	Morning vs. evening chronotype;
CESC	cis	rs875971	0.964	rs6945032	chr7:65922486	C/T	cg11764359	chr7:65958608	NA	0.97	15.5	0.69	5.25e-39	Aortic root size;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg09333889	chr11:18211133	NA	-0.43	-6.21	-0.36	2.09e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs7551222	0.749	rs6594019	chr1:204568610	T/C	cg20240347	chr1:204465584	NA	-0.26	-5.26	-0.31	2.99e-7	Schizophrenia;
CESC	cis	rs80282103	0.618	rs11250252	chr10:1124939	G/C	cg08668510	chr10:1095578	IDI1	0.72	5.7	0.33	3.12e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs7651736	1.000	rs7651736	chr3:136760598	A/G	cg25687071	chr3:136751404	NA	0.34	5.07	0.3	7.4e-7	Neuroticism;
CESC	cis	rs34638657	0.732	rs2967359	chr16:82202968	G/C	cg09439754	chr16:82129088	HSD17B2	-0.37	-6.4	-0.37	7.17e-10	Lung adenocarcinoma;
CESC	cis	rs6688613	0.579	rs4657609	chr1:166839174	G/A	cg07049167	chr1:166818506	POGK	0.44	5.07	0.3	7.39e-7	Refractive astigmatism;
CESC	trans	rs6693417	0.965	rs6700655	chr1:15759547	A/T	cg23732560	chr3:45267976	TMEM158	-0.54	-6.14	-0.35	3.03e-9	Alcoholic chronic pancreatitis;
CESC	cis	rs3008870	0.727	rs11208971	chr1:67383901	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.64	8.41	0.46	2.52e-15	Lymphocyte percentage of white cells;
CESC	trans	rs9693444	0.898	rs4732697	chr8:29519861	A/G	cg04355093	chr4:85887382	WDFY3;C4orf12	-0.43	-6.15	-0.35	2.78e-9	Breast cancer;
CESC	cis	rs870825	0.616	rs4519838	chr4:185628457	A/G	cg04058563	chr4:185651563	MLF1IP	0.64	7.03	0.4	1.8e-11	Blood protein levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08642743	chr17:74099944	EXOC7	0.58	6.6	0.38	2.29e-10	Gut microbiome composition (summer);
CESC	cis	rs2066819	1.000	rs2643626	chr12:56726518	C/T	cg26734620	chr12:56694298	CS	-0.91	-9.19	-0.49	1.22e-17	Psoriasis vulgaris;
CESC	cis	rs8016982	0.593	rs7160569	chr14:81713686	C/T	cg01989461	chr14:81687754	GTF2A1	0.72	11.27	0.57	2.52e-24	Schizophrenia;
CESC	cis	rs4803468	1.000	rs284663	chr19:41932612	C/T	cg09537434	chr19:41945824	ATP5SL	-1.13	-21.55	-0.8	3.26e-60	Height;
CESC	cis	rs6570726	0.791	rs6900040	chr6:145893134	C/T	cg05347473	chr6:146136440	FBXO30	0.59	7.63	0.42	4.24e-13	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7647973	0.710	rs2029591	chr3:49646981	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.66	-7.54	-0.42	7.41e-13	Menarche (age at onset);
CESC	cis	rs10791097	0.547	rs11222371	chr11:130745719	C/T	cg12179176	chr11:130786555	SNX19	0.68	10.02	0.52	3.03e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs7843479	1.000	rs11775444	chr8:21813018	A/G	cg17168535	chr8:21777572	XPO7	0.5	6.79	0.39	7.23e-11	Mean corpuscular volume;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg18315708	chr14:21673796	NA	0.39	6.05	0.35	4.92e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs1163251	0.902	rs639216	chr1:120217414	C/T	cg19096424	chr1:120255104	PHGDH	0.43	5.22	0.31	3.62e-7	Blood metabolite levels;
CESC	cis	rs870825	0.549	rs28542773	chr4:185617935	A/G	cg04058563	chr4:185651563	MLF1IP	0.64	7.05	0.4	1.59e-11	Blood protein levels;
CESC	cis	rs854765	0.616	rs8070624	chr17:17843396	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.46	6.02	0.35	5.77e-9	Total body bone mineral density;
CESC	cis	rs7258465	0.965	rs10408290	chr19:18542701	C/T	cg25828334	chr19:18545568	ISYNA1	-0.32	-5.21	-0.3	3.84e-7	Breast cancer;
CESC	trans	rs6780666	0.509	rs1461513	chr3:136947731	G/A	cg16900796	chr19:10755136	SLC44A2	-0.42	-6.4	-0.37	6.83e-10	Intelligence (multi-trait analysis);
CESC	cis	rs7301826	0.967	rs4759792	chr12:131296631	G/A	cg11011512	chr12:131303247	STX2	0.4	5.09	0.3	6.83e-7	Plasma plasminogen activator levels;
CESC	cis	rs7210086	0.730	rs76126194	chr17:70638724	G/A	cg04206342	chr17:70636940	NA	-0.31	-6.08	-0.35	4.29e-9	Ulcerative colitis;
CESC	cis	rs873946	0.504	rs3793681	chr10:134564451	T/C	cg27286337	chr10:134555280	INPP5A	0.63	7.33	0.41	2.71e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs6575793	0.532	rs11849489	chr14:101037762	C/G	cg18516195	chr14:101012996	BEGAIN	0.46	5.57	0.32	6.26e-8	Menarche (age at onset);
CESC	cis	rs9287719	0.967	rs12464908	chr2:10761496	T/G	cg02196655	chr2:10830764	NOL10	-0.37	-5.56	-0.32	6.58e-8	Prostate cancer;
CESC	cis	rs2576037	0.583	rs11659693	chr18:44458733	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.35	5.69	0.33	3.42e-8	Personality dimensions;
CESC	cis	rs2836974	0.932	rs13048178	chr21:40561012	G/T	cg11644478	chr21:40555479	PSMG1	1.01	16.06	0.7	5.44e-41	Cognitive function;
CESC	cis	rs11718455	0.920	rs34909426	chr3:44000472	G/A	cg08738300	chr3:44038990	NA	0.46	6.22	0.36	1.96e-9	Coronary artery disease;
CESC	cis	rs4808199	0.947	rs751858	chr19:19602821	G/C	cg03709012	chr19:19516395	GATAD2A	1.11	13.29	0.63	3.07e-31	Nonalcoholic fatty liver disease;
CESC	trans	rs35110281	0.622	rs9977258	chr21:44976485	G/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.61	8.31	0.45	4.9e-15	Mean corpuscular volume;
CESC	cis	rs2066819	1.000	rs2066819	chr12:56750204	C/T	cg26734620	chr12:56694298	CS	0.97	5.81	0.34	1.76e-8	Psoriasis vulgaris;
CESC	cis	rs898097	0.812	rs56274787	chr17:80862682	C/T	cg15664640	chr17:80829946	TBCD	-0.68	-10.03	-0.52	2.82e-20	Breast cancer;
CESC	cis	rs7312933	0.703	rs11181380	chr12:42616040	A/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.49	6.34	0.36	9.66e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs6952808	0.529	rs73038442	chr7:2139457	C/T	cg02951883	chr7:2050386	MAD1L1	-0.46	-5.99	-0.35	6.84e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs34779708	0.966	rs2126984	chr10:35410291	A/G	cg03585969	chr10:35415529	CREM	0.77	9.86	0.52	9.37e-20	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs1862618	0.641	rs170733	chr5:56249251	A/G	cg18230493	chr5:56204884	C5orf35	0.61	7.82	0.43	1.27e-13	Initial pursuit acceleration;
CESC	cis	rs763121	0.925	rs5750654	chr22:39051428	T/C	cg21395723	chr22:39101663	GTPBP1	0.46	5.98	0.34	7.22e-9	Menopause (age at onset);
CESC	cis	rs13385	0.769	rs13163983	chr5:139622572	A/C	cg26211634	chr5:139558579	C5orf32	0.48	5.23	0.31	3.5e-7	Atrial fibrillation;
CESC	cis	rs7267979	0.873	rs6037062	chr20:25202892	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.79	14.91	0.68	6.38e-37	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs965469	1.000	rs6037551	chr20:3306690	T/C	cg25506879	chr20:3388711	C20orf194	-0.58	-6.16	-0.35	2.76e-9	IFN-related cytopenia;
CESC	cis	rs1005277	0.579	rs2474586	chr10:38418882	T/C	cg25427524	chr10:38739819	LOC399744	-0.67	-9.72	-0.51	2.65e-19	Extrinsic epigenetic age acceleration;
CESC	cis	rs7552404	0.731	rs12078299	chr1:76365764	T/A	cg03433033	chr1:76189801	ACADM	0.58	5.68	0.33	3.6e-8	Blood metabolite levels;Acylcarnitine levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24689585	chr15:22957012	CYFIP1	-0.55	-6.53	-0.37	3.42e-10	Gut microbiome composition (summer);
CESC	cis	rs2742234	0.541	rs1254959	chr10:43700979	C/G	cg15436174	chr10:43711423	RASGEF1A	0.5	5.85	0.34	1.45e-8	Hirschsprung disease;
CESC	cis	rs2415984	0.579	rs2255935	chr14:46964271	A/G	cg14871534	chr14:47121158	RPL10L	0.35	5.32	0.31	2.24e-7	Number of children ever born;
CESC	cis	rs736408	0.609	rs13095332	chr3:52787242	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.38	6.63	0.38	1.84e-10	Bipolar disorder;
CESC	cis	rs2075371	0.966	rs1646646	chr7:133996905	G/T	cg20476274	chr7:133979776	SLC35B4	0.67	9.78	0.52	1.72e-19	Mean platelet volume;
CESC	cis	rs17711722	0.565	rs4717276	chr7:65294741	G/T	cg05332525	chr7:65337924	VKORC1L1	0.47	5.88	0.34	1.2e-8	Calcium levels;
CESC	cis	rs916888	0.773	rs199534	chr17:44824213	T/G	cg27589368	chr17:43923255	LOC100128977;IMP5	-0.39	-5.38	-0.31	1.65e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-6.07	-0.35	4.4e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2235544	0.565	rs677481	chr1:54468837	A/C	cg25741118	chr1:54482237	LDLRAD1	0.24	5.77	0.33	2.2e-8	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
CESC	cis	rs10461617	0.531	rs2662033	chr5:56213410	T/G	cg24549020	chr5:56110836	MAP3K1	0.52	5.94	0.34	9.14e-9	Type 2 diabetes;
CESC	cis	rs10504229	0.639	rs112926738	chr8:58054939	A/G	cg22535103	chr8:58192502	C8orf71	-0.77	-8.08	-0.44	2.33e-14	Developmental language disorder (linguistic errors);
CESC	cis	rs62344088	0.590	rs61710713	chr5:181499	G/A	cg22857025	chr5:266934	NA	-1.24	-7.19	-0.4	6.42e-12	Asthma (childhood onset);
CESC	cis	rs769267	0.965	rs12977937	chr19:19429975	C/G	cg15052019	chr19:19431593	KIAA0892;SF4	0.41	5.1	0.3	6.45e-7	Tonsillectomy;
CESC	cis	rs12325245	0.536	rs34161389	chr16:58622604	G/A	cg02549819	chr16:58548995	SETD6	0.95	6.11	0.35	3.54e-9	Schizophrenia;
CESC	cis	rs172166	0.611	rs203882	chr6:28078502	G/A	cg17221315	chr6:27791827	HIST1H4J	0.45	5.81	0.34	1.75e-8	Cardiac Troponin-T levels;
CESC	cis	rs9640161	0.750	rs11765644	chr7:150026339	C/G	cg10018233	chr7:150070692	REPIN1	0.42	6.31	0.36	1.19e-9	Blood protein levels;Circulating chemerin levels;
CESC	trans	rs877282	0.898	rs11253353	chr10:766862	C/A	cg22713356	chr15:30763199	NA	1.18	11.28	0.57	2.33e-24	Uric acid levels;
CESC	cis	rs11792861	0.926	rs7470160	chr9:111844246	C/A	cg13535736	chr9:111863775	C9orf5	-0.51	-6.76	-0.38	8.77e-11	Menarche (age at onset);
CESC	cis	rs12477438	0.798	rs6761570	chr2:99577276	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.7	-10.22	-0.53	6.79e-21	Chronic sinus infection;
CESC	cis	rs116095464	0.558	rs112343653	chr5:257174	G/A	cg22496380	chr5:211416	CCDC127	-0.73	-8.39	-0.46	2.99e-15	Breast cancer;
CESC	cis	rs798554	0.759	rs2644309	chr7:2889034	T/C	cg13628971	chr7:2884303	GNA12	0.63	8.23	0.45	8.48e-15	Height;
CESC	cis	rs4900538	0.855	rs72698597	chr14:102868633	C/T	cg18135206	chr14:102964638	TECPR2	-0.73	-9.33	-0.5	4.35e-18	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	trans	rs10751667	0.961	rs7482484	chr11:927020	C/T	cg00159523	chr10:114713187	TCF7L2	-0.41	-6.13	-0.35	3.1e-9	Alzheimer's disease (late onset);
CESC	cis	rs6088580	0.524	rs6142210	chr20:33223012	C/T	cg08999081	chr20:33150536	PIGU	-0.47	-6.78	-0.38	7.73e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs2290720	0.896	rs1350351	chr12:101713590	G/A	cg22051763	chr12:101673672	UTP20	-0.49	-6.02	-0.35	5.86e-9	Brain structure (hippocampal volume);
CESC	cis	rs1048238	0.506	rs7552077	chr1:16196759	A/G	cg21385522	chr1:16154831	NA	0.45	5.85	0.34	1.45e-8	Systolic blood pressure;
CESC	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg02951883	chr7:2050386	MAD1L1	-0.44	-5.72	-0.33	2.93e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs7520050	0.966	rs785464	chr1:46523089	T/C	cg03146154	chr1:46216737	IPP	-0.44	-5.73	-0.33	2.68e-8	Red blood cell count;Reticulocyte count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23366119	chr18:72162949	CNDP2	-0.55	-6.24	-0.36	1.72e-9	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09720205	chr16:57508738	DOK4	-0.57	-6.34	-0.36	9.79e-10	Gut microbiome composition (summer);
CESC	cis	rs9649213	0.593	rs12728	chr7:97922851	C/T	cg08684580	chr7:98029266	BAIAP2L1	-0.33	-5.21	-0.3	3.8e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7296418	0.699	rs1109559	chr12:123757861	C/T	cg00376283	chr12:123451042	ABCB9	0.61	8.6	0.47	6.93e-16	Platelet count;
CESC	cis	rs911555	0.546	rs28798508	chr14:104068970	T/C	cg12935359	chr14:103987150	CKB	-0.52	-7.65	-0.43	3.64e-13	Intelligence (multi-trait analysis);
CESC	cis	rs7143963	0.636	rs11160706	chr14:103361736	A/G	cg24154132	chr14:103367632	TRAF3	-0.35	-6.57	-0.37	2.6200000000000003e-10	Body mass index;
CESC	cis	rs1448094	0.511	rs61930037	chr12:86154503	G/A	cg00310523	chr12:86230176	RASSF9	0.35	5.49	0.32	9.42e-8	Major depressive disorder;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg01062786	chr14:20929651	TMEM55B	-0.4	-6.32	-0.36	1.09e-9	Gambling;
CESC	cis	rs67311347	1.000	rs1454497	chr3:40496326	C/T	cg09455208	chr3:40491958	NA	-0.48	-8.25	-0.45	7.35e-15	Renal cell carcinoma;
CESC	cis	rs113835537	0.529	rs11227510	chr11:66281220	T/C	cg22134325	chr11:66188745	NPAS4	0.37	5.81	0.34	1.77e-8	Airway imaging phenotypes;
CESC	cis	rs9649213	0.593	rs6465678	chr7:98004057	T/C	cg21770322	chr7:97807741	LMTK2	0.54	8.12	0.45	1.83e-14	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.52	6.46	0.37	4.96e-10	Prudent dietary pattern;
CESC	cis	rs55788414	0.860	rs9929059	chr16:81182117	G/C	cg06400318	chr16:81190750	PKD1L2	-0.6	-7.09	-0.4	1.24e-11	Left ventricular obstructive tract defect (maternal effect);
CESC	cis	rs9443189	0.526	rs9359132	chr6:76289553	G/A	cg01950844	chr6:76311363	SENP6	0.87	9.54	0.51	9.61e-19	Prostate cancer;
CESC	cis	rs853679	0.517	rs9393884	chr6:28046789	A/G	cg08968635	chr6:28129556	ZNF389	0.4	5.44	0.32	1.21e-7	Depression;
CESC	cis	rs9788682	0.947	rs12439240	chr15:78829091	T/C	cg24631222	chr15:78858424	CHRNA5	0.76	9.79	0.52	1.67e-19	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs12142240	0.698	rs7548675	chr1:46809321	C/G	cg00530320	chr1:46809349	NSUN4	0.6	7.98	0.44	4.48e-14	Menopause (age at onset);
CESC	cis	rs16854884	0.545	rs7650459	chr3:143658934	C/G	cg06585982	chr3:143692056	C3orf58	0.56	7.62	0.42	4.47e-13	Economic and political preferences (feminism/equality);
CESC	cis	rs4906332	0.811	rs2756138	chr14:103996733	C/G	cg04998671	chr14:104000505	TRMT61A	0.42	5.17	0.3	4.71e-7	Coronary artery disease;
CESC	cis	rs4654899	0.931	rs7520481	chr1:21140385	T/G	cg05370193	chr1:21551575	ECE1	-0.37	-5.38	-0.31	1.66e-7	Superior frontal gyrus grey matter volume;
CESC	cis	rs27434	0.583	rs468130	chr5:96156029	A/G	cg16492584	chr5:96139282	ERAP1	-0.36	-5.09	-0.3	6.81e-7	Ankylosing spondylitis;
CESC	cis	rs875971	0.660	rs10281080	chr7:66042441	T/C	cg14393609	chr7:65229607	NA	-0.47	-6.31	-0.36	1.16e-9	Aortic root size;
CESC	cis	rs7520050	0.966	rs1768803	chr1:46546208	T/C	cg03146154	chr1:46216737	IPP	-0.44	-5.69	-0.33	3.34e-8	Red blood cell count;Reticulocyte count;
CESC	cis	rs672059	0.513	rs627064	chr1:183165716	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.51	6.42	0.37	6.1e-10	Hypertriglyceridemia;
CESC	cis	rs2806561	0.765	rs9426692	chr1:23508426	C/T	cg12483005	chr1:23474871	LUZP1	0.39	6.06	0.35	4.58e-9	Height;
CESC	cis	rs959260	1.000	rs4788891	chr17:73391145	A/G	cg20590849	chr17:73267439	MIF4GD	-0.55	-6.35	-0.36	9.37e-10	Systemic lupus erythematosus;
CESC	trans	rs1973993	0.691	rs2985636	chr1:96889884	T/A	cg10631902	chr5:14652156	NA	0.61	9.46	0.5	1.8e-18	Weight;
CESC	cis	rs4253772	0.513	rs6008597	chr22:46703904	A/C	cg09491104	chr22:46646882	C22orf40	-0.52	-6.43	-0.37	5.82e-10	LDL cholesterol;Cholesterol, total;
CESC	cis	rs6032067	1.000	rs6032060	chr20:43852454	A/T	cg10761708	chr20:43804764	PI3	0.52	6.26	0.36	1.57e-9	Blood protein levels;
CESC	cis	rs1865721	0.761	rs36002108	chr18:73220472	C/T	cg26385618	chr18:73139727	C18orf62	-0.53	-7.75	-0.43	2.02e-13	Intelligence;
CESC	cis	rs8051149	0.688	rs55776570	chr16:87869516	C/G	cg03408354	chr16:87871219	SLC7A5	-0.46	-5.7	-0.33	3.27e-8	Blood metabolite levels;
CESC	cis	rs35110281	0.837	rs7279968	chr21:45077398	C/G	cg21573476	chr21:45109991	RRP1B	-0.48	-6.85	-0.39	5.03e-11	Mean corpuscular volume;
CESC	cis	rs9311474	0.508	rs12637627	chr3:52619962	G/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.6	8.55	0.46	1.01e-15	Electroencephalogram traits;
CESC	cis	rs12477438	0.520	rs11692699	chr2:99730657	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.86	15.87	0.7	2.48e-40	Chronic sinus infection;
CESC	cis	rs10129255	0.556	rs6576222	chr14:107184681	G/A	cg07958169	chr14:107095056	NA	-0.54	-8.61	-0.47	6.64e-16	Kawasaki disease;
CESC	cis	rs1062177	1.000	rs2915880	chr5:151147334	G/A	cg00977110	chr5:151150581	G3BP1	0.67	7.27	0.41	3.98e-12	Preschool internalizing problems;
CESC	cis	rs11155671	0.530	rs9968871	chr6:150209196	G/A	cg09699651	chr6:150184138	LRP11	0.55	7.44	0.42	1.41e-12	Testicular germ cell tumor;
CESC	cis	rs11997175	0.583	rs7829680	chr8:33794207	C/T	ch.8.33884649F	chr8:33765107	NA	-0.5	-6.42	-0.37	6.32e-10	Body mass index;
CESC	cis	rs6963495	0.818	rs73190200	chr7:105165856	T/C	cg19920283	chr7:105172520	RINT1	0.7	6.66	0.38	1.58e-10	Bipolar disorder (body mass index interaction);
CESC	cis	rs6952808	0.624	rs60137119	chr7:2083664	A/G	cg05863683	chr7:1912471	MAD1L1	0.44	6.45	0.37	5.32e-10	Bipolar disorder and schizophrenia;
CESC	cis	rs4450798	0.649	rs9861903	chr3:13786821	G/T	cg05589046	chr3:13742034	LOC285375	0.34	5.21	0.3	3.86e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs4148883	0.545	rs17595102	chr4:99986316	C/G	cg13256891	chr4:100009986	ADH5	0.52	6.35	0.36	9.15e-10	Alcohol dependence;
CESC	cis	rs6570726	0.875	rs373313	chr6:145857791	T/C	cg05347473	chr6:146136440	FBXO30	0.48	6.44	0.37	5.7e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs3768617	0.528	rs10737241	chr1:183098208	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.87	14.0	0.65	1.04e-33	Fuchs's corneal dystrophy;
CESC	trans	rs12599106	0.625	rs12923277	chr16:34896261	G/A	cg18110333	chr6:292329	DUSP22	-0.73	-9.53	-0.51	1.06e-18	Menopause (age at onset);
CESC	cis	rs780096	0.587	rs6743819	chr2:27567407	G/T	cg24768116	chr2:27665128	KRTCAP3	-0.3	-5.61	-0.33	5.09e-8	Total body bone mineral density;
CESC	cis	rs3741151	0.773	rs73548693	chr11:73286637	G/A	cg17517138	chr11:73019481	ARHGEF17	1.02	7.43	0.42	1.51e-12	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs9733	0.650	rs11204680	chr1:150587140	T/G	cg17724175	chr1:150552817	MCL1	-0.33	-5.36	-0.31	1.83e-7	Tonsillectomy;
CESC	cis	rs7267979	1.000	rs2258201	chr20:25272490	G/C	cg08601574	chr20:25228251	PYGB	0.39	5.57	0.32	6.14e-8	Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs7246760	1.000	rs67509260	chr19:9864321	C/T	cg02900749	chr2:68251473	NA	-0.79	-6.66	-0.38	1.57e-10	Pursuit maintenance gain;
CESC	cis	rs10838687	0.736	rs7118396	chr11:47269936	C/T	cg25783544	chr11:47291846	MADD	0.58	6.61	0.38	2.06e-10	Proinsulin levels;
CESC	cis	rs4332037	0.901	rs7791299	chr7:1935598	T/C	cg23422044	chr7:1970798	MAD1L1	-0.58	-7.08	-0.4	1.33e-11	Bipolar disorder;
CESC	cis	rs2115630	0.691	rs8040066	chr15:85176465	G/C	cg11189052	chr15:85197271	WDR73	-0.47	-6.39	-0.37	7.23e-10	P wave terminal force;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg19635158	chr1:27561056	WDTC1	-0.51	-6.22	-0.36	1.9e-9	Ulcerative colitis;
CESC	cis	rs17666538	0.585	rs1037393	chr8:622634	G/C	cg07234876	chr8:600039	NA	0.85	6.02	0.35	5.83e-9	IgG glycosylation;
CESC	trans	rs61931739	0.500	rs9705909	chr12:34576419	G/C	cg13010199	chr12:38710504	ALG10B	0.52	6.63	0.38	1.86e-10	Morning vs. evening chronotype;
CESC	cis	rs2710642	0.927	rs2539980	chr2:63208460	T/C	cg17519650	chr2:63277830	OTX1	0.62	8.31	0.45	4.87e-15	LDL cholesterol levels;LDL cholesterol;
CESC	cis	rs8099014	0.725	rs4245267	chr18:56096214	C/A	cg12827950	chr18:55968429	NEDD4L	-0.48	-5.34	-0.31	1.96e-7	Platelet count;
CESC	cis	rs7264396	0.563	rs6058312	chr20:34324484	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.88	-10.7	-0.55	1.88e-22	Total cholesterol levels;
CESC	cis	rs826838	0.935	rs980571	chr12:39127532	C/G	cg26384229	chr12:38710491	ALG10B	-0.66	-10.65	-0.55	2.77e-22	Heart rate;
CESC	cis	rs1059312	1.000	rs12814773	chr12:129280786	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.73	-10.15	-0.53	1.14e-20	Systemic lupus erythematosus;
CESC	cis	rs8112211	0.681	rs59898212	chr19:38826656	G/C	cg14299480	chr19:38876666	GGN	-0.44	-6.0	-0.35	6.45e-9	Blood protein levels;
CESC	cis	rs916888	0.773	rs199457	chr17:44795469	C/T	cg01570182	chr17:44337453	NA	0.94	10.66	0.55	2.65e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs12497850	0.931	rs13315711	chr3:48986399	A/T	cg03060546	chr3:49711283	APEH	0.51	6.18	0.35	2.43e-9	Parkinson's disease;
CESC	cis	rs763121	0.813	rs2179143	chr22:39037984	A/G	cg14440974	chr22:39074834	NA	-0.36	-5.18	-0.3	4.33e-7	Menopause (age at onset);
CESC	cis	rs6445797	0.632	rs13097030	chr3:56603675	G/A	cg13792233	chr3:56591045	CCDC66	0.39	5.08	0.3	7.25e-7	Gastritis;
CESC	cis	rs2880765	0.835	rs4842886	chr15:86035773	G/A	cg10818794	chr15:86012489	AKAP13	-0.34	-5.28	-0.31	2.64e-7	Coronary artery disease;
CESC	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.64	7.2	0.4	6.15e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs6570726	0.875	rs416243	chr6:145868081	A/T	cg05347473	chr6:146136440	FBXO30	0.48	6.45	0.37	5.27e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2273669	0.667	rs4509156	chr6:109308952	A/C	cg05315195	chr6:109294784	ARMC2	0.64	6.36	0.36	8.8e-10	Prostate cancer;
CESC	cis	rs9486715	0.838	rs4839840	chr6:96941149	T/C	cg06623918	chr6:96969491	KIAA0776	0.92	14.25	0.66	1.37e-34	Headache;
CESC	cis	rs763121	0.853	rs6001188	chr22:39062194	T/C	cg14440974	chr22:39074834	NA	-0.4	-5.43	-0.32	1.3e-7	Menopause (age at onset);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg10251368	chr16:30662726	PRR14	-0.54	-6.75	-0.38	9.28e-11	Ulcerative colitis;
CESC	cis	rs4148883	0.545	rs17595102	chr4:99986316	C/G	cg12011299	chr4:100065546	ADH4	0.67	9.19	0.49	1.16e-17	Alcohol dependence;
CESC	cis	rs9487051	0.676	rs4406271	chr6:109598213	G/A	cg12927641	chr6:109611667	NA	-0.37	-5.5	-0.32	8.91e-8	Reticulocyte fraction of red cells;
CESC	cis	rs7772486	0.686	rs1292336	chr6:145967818	T/C	cg05347473	chr6:146136440	FBXO30	-0.52	-6.89	-0.39	4.01e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9527	0.590	rs7087459	chr10:104790999	T/C	cg04362960	chr10:104952993	NT5C2	0.42	5.42	0.32	1.33e-7	Arsenic metabolism;
CESC	cis	rs11229555	0.645	rs61905183	chr11:58228463	T/A	cg15696309	chr11:58395628	NA	-0.45	-5.22	-0.31	3.63e-7	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CESC	trans	rs650950	0.528	rs646660	chr11:35528452	C/T	cg26069066	chr20:44044698	PIGT	0.46	6.29	0.36	1.29e-9	Bronchopulmonary dysplasia;
CESC	cis	rs826838	0.935	rs10875816	chr12:38955014	C/A	cg13010199	chr12:38710504	ALG10B	0.59	8.35	0.46	3.8e-15	Heart rate;
CESC	cis	rs12822507	0.684	rs6488533	chr12:12752586	A/G	cg11838227	chr12:12764436	CREBL2	0.42	5.58	0.32	5.87e-8	Systemic lupus erythematosus;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg15941057	chr17:27169869	C17orf63	-0.48	-6.36	-0.36	8.93e-10	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs8103278	0.507	rs10401971	chr19:46261982	C/T	cg06577658	chr19:46296270	DMWD	0.43	5.27	0.31	2.76e-7	Coronary artery disease;
CESC	cis	rs1401999	1.000	rs6443924	chr3:183679532	A/G	cg01324343	chr3:183735012	ABCC5	0.63	13.41	0.64	1.17e-31	Anterior chamber depth;
CESC	cis	rs7809950	0.906	rs62483723	chr7:107186358	A/C	cg23024343	chr7:107201750	COG5	-0.41	-5.65	-0.33	4.03e-8	Coronary artery disease;
CESC	cis	rs7552404	1.000	rs12126607	chr1:76217097	G/A	cg10523679	chr1:76189770	ACADM	0.71	8.42	0.46	2.39e-15	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs6912958	0.703	rs12207825	chr6:88098292	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.46	7.65	0.43	3.71e-13	Monocyte percentage of white cells;
CESC	cis	rs17376456	0.825	rs13182631	chr5:93115701	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.61	5.26	0.31	3.01e-7	Diabetic retinopathy;
CESC	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.49	-5.2	-0.3	4.06e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs2018683	0.600	rs6948880	chr7:29003478	C/T	cg19402173	chr7:128379420	CALU	-0.54	-6.71	-0.38	1.15e-10	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CESC	cis	rs8141529	0.702	rs8137262	chr22:29292135	C/T	cg15103426	chr22:29168792	CCDC117	0.6	7.75	0.43	1.97e-13	Lymphocyte counts;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg14513222	chr9:140079404	ANAPC2	0.5	6.37	0.36	8.23e-10	Ulcerative colitis;
CESC	cis	rs4604732	0.578	rs12036417	chr1:247624805	T/C	cg12758973	chr1:247694275	LOC148824;OR2C3	0.51	6.36	0.36	8.65e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs4654899	0.931	rs2275468	chr1:21220375	T/G	cg05370193	chr1:21551575	ECE1	-0.35	-5.11	-0.3	6.09e-7	Superior frontal gyrus grey matter volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16457027	chr3:9834426	ARPC4;TADA3	0.63	6.74	0.38	9.85e-11	Gut microbiome composition (summer);
CESC	cis	rs9359856	0.564	rs17584108	chr6:90458209	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.6	-5.62	-0.33	4.75e-8	Bipolar disorder;
CESC	cis	rs7474896	0.583	rs11011341	chr10:37998500	G/A	cg25427524	chr10:38739819	LOC399744	-0.44	-5.15	-0.3	5.03e-7	Obesity (extreme);
CESC	cis	rs10504229	0.815	rs72650879	chr8:58164648	A/G	cg24829409	chr8:58192753	C8orf71	-0.67	-7.97	-0.44	4.6e-14	Developmental language disorder (linguistic errors);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg04579211	chr15:41221939	DLL4	-0.43	-6.46	-0.37	5e-10	Gambling;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg09246754	chr10:74855561	P4HA1	0.48	6.55	0.37	2.95e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs12356475	0.710	rs10822686	chr10:67733250	C/T	cg08289140	chr1:1535155	NA	0.51	6.0	0.35	6.36e-9	Psoriatic arthritis;
CESC	cis	rs6728642	0.519	rs62152906	chr2:97572270	T/C	cg26665480	chr2:98280029	ACTR1B	-0.58	-5.28	-0.31	2.75e-7	Bipolar disorder lithium response (continuous) or schizophrenia;
CESC	cis	rs7552404	0.924	rs67757078	chr1:76169456	G/A	cg22875332	chr1:76189707	ACADM	0.69	9.3	0.5	5.49e-18	Blood metabolite levels;Acylcarnitine levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00974835	chr14:74960278	NPC2;ISCA2	0.68	7.7	0.43	2.67e-13	Gut microbiome composition (summer);
CESC	cis	rs2404602	0.692	rs8043474	chr15:76974723	T/C	cg22467129	chr15:76604101	ETFA	-0.34	-5.15	-0.3	5.13e-7	Blood metabolite levels;
CESC	cis	rs7772486	0.727	rs10223508	chr6:146285205	C/T	cg05347473	chr6:146136440	FBXO30	-0.51	-6.52	-0.37	3.48e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs17209837	1.000	rs45502492	chr7:87089898	C/T	cg00919237	chr7:87102261	ABCB4	-0.53	-6.03	-0.35	5.36e-9	Gallbladder cancer;
CESC	cis	rs589448	0.967	rs2617834	chr12:69753365	T/C	cg22834771	chr12:69754056	YEATS4	-0.55	-7.29	-0.41	3.61e-12	Cerebrospinal fluid biomarker levels;
CESC	cis	rs9457247	0.967	rs1590257	chr6:167377782	G/T	cg23791538	chr6:167370224	RNASET2	0.6	8.57	0.47	8.75e-16	Crohn's disease;
CESC	trans	rs3087243	0.755	rs231789	chr2:204699952	C/T	cg01841312	chr10:38069945	NA	0.38	6.43	0.37	5.77e-10	Rheumatoid arthritis;Hypothyroidism;Type 1 diabetes;
CESC	cis	rs672059	1.000	rs659307	chr1:183163078	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.56	7.19	0.4	6.53e-12	Hypertriglyceridemia;
CESC	cis	rs7552404	0.690	rs12723575	chr1:76335203	T/C	cg22875332	chr1:76189707	ACADM	-0.64	-6.77	-0.38	8.23e-11	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs9291683	0.526	rs12506122	chr4:10033538	C/A	cg00071950	chr4:10020882	SLC2A9	0.82	13.85	0.65	3.37e-33	Bone mineral density;
CESC	cis	rs7264396	0.676	rs6060730	chr20:34558503	G/A	cg17201900	chr20:34330562	RBM39	0.51	5.31	0.31	2.37e-7	Total cholesterol levels;
CESC	cis	rs4764487	0.735	rs3181291	chr12:6341499	C/T	cg08284733	chr12:6341482	CD9	0.36	5.39	0.31	1.56e-7	Mean platelet volume;
CESC	cis	rs6088590	1.000	rs28542147	chr20:33376323	G/A	cg24642439	chr20:33292090	TP53INP2	0.84	11.76	0.59	5.5e-26	Coronary artery disease;
CESC	cis	rs7833986	0.501	rs17812659	chr8:56889862	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.57	6.86	0.39	4.81e-11	Height;
CESC	cis	rs634534	0.622	rs624273	chr11:65712413	A/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.46	6.66	0.38	1.62e-10	Sum eosinophil basophil counts;Eosinophil counts;
CESC	cis	rs4974559	0.594	rs59544360	chr4:1313575	G/T	cg02980000	chr4:1222292	CTBP1	0.66	7.16	0.4	7.91e-12	Systolic blood pressure;
CESC	cis	rs7560272	0.538	rs13014700	chr2:73920121	C/G	cg20560298	chr2:73613845	ALMS1	0.45	6.16	0.35	2.73e-9	Schizophrenia;
CESC	cis	rs1005277	0.579	rs2474588	chr10:38420870	A/G	cg00409905	chr10:38381863	ZNF37A	-0.46	-6.18	-0.35	2.39e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs1355223	0.902	rs10501134	chr11:34749137	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.47	-6.13	-0.35	3.23e-9	Systemic lupus erythematosus and Systemic sclerosis;
CESC	trans	rs9486715	0.830	rs2255552	chr6:96999643	A/G	cg16678718	chr17:76497959	DNAH17	-0.44	-6.03	-0.35	5.47e-9	Headache;
CESC	trans	rs3808502	0.516	rs6983727	chr8:11415812	A/G	cg15556689	chr8:8085844	FLJ10661	0.6	7.08	0.4	1.27e-11	Neuroticism;
CESC	cis	rs62408225	0.888	rs58453446	chr6:90948093	G/C	cg06866423	chr6:90926672	BACH2	0.49	5.93	0.34	9.32e-9	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs425277	0.628	rs3107147	chr1:2048729	G/A	cg04315214	chr1:2043799	PRKCZ	0.61	10.75	0.55	1.34e-22	Height;
CESC	cis	rs78456975	1.000	rs10177095	chr2:1570976	C/A	cg26248373	chr2:1572462	NA	-0.56	-5.28	-0.31	2.66e-7	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs1568889	1.000	rs7102106	chr11:28343953	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.76	9.64	0.51	4.7e-19	Bipolar disorder;
CESC	cis	rs11931598	0.702	rs10937780	chr4:7048842	A/G	cg26116260	chr4:7069785	GRPEL1	-0.39	-5.29	-0.31	2.6e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
CESC	cis	rs875971	0.505	rs1167385	chr7:65513308	G/A	cg18876405	chr7:65276391	NA	-0.68	-9.52	-0.5	1.1e-18	Aortic root size;
CESC	cis	rs7762018	0.769	rs74838157	chr6:170077323	G/A	cg05834625	chr6:170176447	C6orf70	0.7	6.82	0.39	6.26e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs2652834	1.000	rs2652832	chr15:63396928	T/C	cg05507819	chr15:63340323	TPM1	0.55	5.13	0.3	5.53e-7	HDL cholesterol;
CESC	cis	rs7945705	0.818	rs1988708	chr11:8882893	C/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.46	-7.75	-0.43	1.95e-13	Hemoglobin concentration;
CESC	cis	rs875971	0.862	rs801194	chr7:66028495	T/C	cg18876405	chr7:65276391	NA	-0.53	-7.25	-0.41	4.64e-12	Aortic root size;
CESC	cis	rs7666738	0.830	rs7662218	chr4:98983126	T/G	cg18180107	chr4:99064573	C4orf37	0.4	5.14	0.3	5.22e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3733585	0.673	rs4467564	chr4:9953472	G/T	cg11266682	chr4:10021025	SLC2A9	-0.58	-11.0	-0.56	2.04e-23	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs7116495	0.609	rs2276384	chr11:71701523	A/G	cg26138937	chr11:71823887	C11orf51	1.14	7.69	0.43	2.82e-13	Severe influenza A (H1N1) infection;
CESC	cis	rs13191362	0.872	rs35443919	chr6:163055804	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.93	9.65	0.51	4.31e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	trans	rs12229918	0.540	rs10784460	chr12:65863584	C/T	cg09253914	chr2:37311580	HEATR5B;CCDC75	-0.5	-6.13	-0.35	3.23e-9	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
CESC	cis	rs875971	0.862	rs3926380	chr7:66080645	G/T	cg11764359	chr7:65958608	NA	-0.78	-11.32	-0.57	1.76e-24	Aortic root size;
CESC	cis	rs9926296	0.568	rs4420527	chr16:89814188	C/T	cg03388025	chr16:89894329	SPIRE2	-0.39	-7.48	-0.42	1.1e-12	Vitiligo;
CESC	cis	rs6952808	0.689	rs2008263	chr7:2048335	A/G	cg05863683	chr7:1912471	MAD1L1	0.47	7.07	0.4	1.37e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs5750830	0.569	rs5750809	chr22:39791491	T/G	cg01416388	chr22:39784598	NA	-0.63	-7.93	-0.44	6.22e-14	Intelligence (multi-trait analysis);
CESC	cis	rs9649213	0.593	rs62478200	chr7:97980045	A/G	cg21770322	chr7:97807741	LMTK2	0.57	8.84	0.48	1.39e-16	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs6860806	0.507	rs273912	chr5:131661349	A/C	cg07395648	chr5:131743802	NA	0.41	5.33	0.31	2.09e-7	Breast cancer;
CESC	cis	rs7914558	0.933	rs12763665	chr10:104653717	G/A	cg15744005	chr10:104629667	AS3MT	-0.34	-5.49	-0.32	9.45e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	trans	rs9586179	1.000	rs10220061	chr13:104047061	A/G	cg13539803	chr13:110424782	IRS2	0.88	6.18	0.35	2.41e-9	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);
CESC	cis	rs524023	0.957	rs12365089	chr11:64364735	A/T	cg07220939	chr11:64358617	SLC22A12	-0.36	-5.55	-0.32	6.77e-8	Urate levels in obese individuals;
CESC	cis	rs6942756	1.000	rs2718084	chr7:128897342	T/C	cg02491457	chr7:128862824	NA	0.69	10.33	0.54	3.15e-21	White matter hyperintensity burden;
CESC	cis	rs61008539	0.893	rs7783487	chr7:860160	A/C	cg00475322	chr7:917719	C7orf20	0.47	6.97	0.39	2.5e-11	Perceived unattractiveness to mosquitoes;
CESC	cis	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg22212156	chr20:32031449	SNTA1	-0.48	-5.94	-0.34	8.98e-9	Ulcerative colitis;
CESC	cis	rs2120019	0.938	rs8028632	chr15:75321262	T/C	cg17294928	chr15:75287854	SCAMP5	-0.76	-8.79	-0.48	1.96e-16	Blood trace element (Zn levels);
CESC	cis	rs7772486	0.692	rs1577916	chr6:146069789	G/A	cg23711669	chr6:146136114	FBXO30	-0.96	-14.87	-0.67	8.61e-37	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs1814175	0.645	rs4625470	chr11:49983769	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.43	-6.26	-0.36	1.53e-9	Height;
CESC	cis	rs7647973	1.000	rs9860055	chr3:49506900	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.59	-7.8	-0.43	1.43e-13	Menarche (age at onset);
CESC	cis	rs7659604	0.539	rs7686084	chr4:122764725	A/C	cg19748678	chr4:122722346	EXOSC9	0.79	10.06	0.53	2.23e-20	Type 2 diabetes;
CESC	cis	rs7412746	0.658	rs2864869	chr1:150734655	G/A	cg09365446	chr1:150670422	GOLPH3L	0.39	5.11	0.3	6.21e-7	Melanoma;
CESC	cis	rs10883723	0.738	rs715438	chr10:104258303	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.53	7.25	0.41	4.46e-12	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs7520050	0.778	rs12404197	chr1:46232420	G/A	cg24296786	chr1:45957014	TESK2	0.46	5.99	0.35	6.97e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs617219	0.889	rs4466139	chr5:78430058	T/C	cg22188827	chr5:78429774	NA	-0.41	-5.03	-0.3	9.19e-7	Betaine levels in individuals undergoing cardiac evaluation;
CESC	cis	rs832540	0.656	rs2408597	chr5:56098632	G/A	cg22800045	chr5:56110881	MAP3K1	0.44	5.36	0.31	1.8e-7	Coronary artery disease;
CESC	cis	rs9341835	0.518	rs2758237	chr6:64218297	G/A	cg03326410	chr6:64151739	NA	0.32	5.15	0.3	5.1e-7	Schizophrenia;
CESC	trans	rs10791097	0.694	rs3190331	chr11:130748131	C/T	cg10101470	chr1:90286633	LRRC8D	-0.44	-6.02	-0.35	5.75e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	trans	rs875971	0.619	rs2302918	chr7:66000932	A/G	cg26939375	chr7:64535504	NA	0.64	8.52	0.46	1.2e-15	Aortic root size;
CESC	cis	rs9611565	0.546	rs5758431	chr22:42109917	A/G	cg03806693	chr22:41940476	POLR3H	1.05	11.94	0.59	1.39e-26	Vitiligo;
CESC	cis	rs7264396	0.561	rs66483315	chr20:34573575	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.52	5.93	0.34	9.55e-9	Total cholesterol levels;
CESC	cis	rs7945705	0.747	rs1980429	chr11:9010474	C/A	cg12365402	chr11:9010492	NRIP3	-0.49	-8.39	-0.46	2.89e-15	Hemoglobin concentration;
CESC	cis	rs12541335	0.639	rs11779277	chr8:22200683	C/T	cg02463440	chr8:22132932	PIWIL2	0.38	5.83	0.34	1.64e-8	Hypertriglyceridemia;
CESC	cis	rs73411413	0.661	rs11599981	chr11:1520063	C/T	cg20027784	chr11:1520631	HCCA2	-0.44	-5.18	-0.3	4.3e-7	Myringotomy;
CESC	cis	rs4665809	0.590	rs6716858	chr2:26423414	G/A	cg08470875	chr2:26401718	FAM59B	-0.63	-7.29	-0.41	3.6e-12	Gut microbiome composition (summer);
CESC	cis	rs2439831	0.850	rs28513374	chr15:44125495	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.63	5.6	0.33	5.26e-8	Lung cancer in ever smokers;
CESC	cis	rs11098499	0.954	rs17046116	chr4:120387259	G/A	cg24375607	chr4:120327624	NA	0.44	5.48	0.32	9.91e-8	Corneal astigmatism;
CESC	cis	rs56235845	0.694	rs12055081	chr5:176757191	C/T	cg16006841	chr5:176797999	RGS14	0.47	5.86	0.34	1.4e-8	Hemoglobin concentration;Hematocrit;
CESC	cis	rs7520050	0.933	rs11211203	chr1:46315592	A/G	cg03146154	chr1:46216737	IPP	-0.47	-6.15	-0.35	2.87e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs116095464	0.850	rs10055295	chr5:243749	G/A	cg20965017	chr5:231967	SDHA	-0.47	-5.38	-0.31	1.65e-7	Breast cancer;
CESC	cis	rs10089	1.000	rs7703634	chr5:127509223	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.71	9.32	0.5	4.86e-18	Ileal carcinoids;
CESC	cis	rs67460515	0.563	rs9876142	chr3:160780968	A/G	cg03342759	chr3:160939853	NMD3	0.49	6.0	0.35	6.59e-9	Parkinson's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03940137	chr1:200708937	CAMSAP1L1	0.67	7.45	0.42	1.36e-12	Gut microbiome composition (summer);
CESC	cis	rs6977955	1.000	rs4722760	chr7:28172183	C/T	cg23620719	chr7:28220237	JAZF1	-0.58	-6.56	-0.37	2.77e-10	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs8092503	1.000	rs12456067	chr18:52499448	C/T	cg12377874	chr18:52495404	RAB27B	0.37	6.11	0.35	3.62e-9	Childhood body mass index;
CESC	cis	rs35146811	0.807	rs6465761	chr7:99620277	G/C	cg22906224	chr7:99728672	NA	0.48	5.73	0.33	2.73e-8	Coronary artery disease;
CESC	trans	rs61931739	0.500	rs34997501	chr12:34549828	C/G	cg13010199	chr12:38710504	ALG10B	0.51	6.58	0.37	2.47e-10	Morning vs. evening chronotype;
CESC	cis	rs897984	0.511	rs7196726	chr16:31092075	G/A	cg02466173	chr16:30829666	NA	-0.4	-6.89	-0.39	3.99e-11	Dementia with Lewy bodies;
CESC	trans	rs3741489	1.000	rs10781661	chr12:133431979	G/A	cg24132527	chr5:140019269	TMCO6	1.17	8.58	0.47	8.06e-16	Cognitive function;
CESC	cis	rs3768617	0.706	rs9943067	chr1:182975102	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.7	10.06	0.53	2.21e-20	Fuchs's corneal dystrophy;
CESC	cis	rs4910157	1	rs4910157	chr11:8941215	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.46	7.29	0.41	3.49e-12	Tonsillectomy;
CESC	cis	rs62229266	0.804	rs880221	chr21:37420785	C/T	cg08632701	chr21:37451849	NA	-0.37	-5.2	-0.3	3.98e-7	Mitral valve prolapse;
CESC	cis	rs7208859	0.573	rs73267829	chr17:29003939	G/A	cg14008862	chr17:28927542	LRRC37B2	0.73	5.8	0.34	1.85e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs1799949	0.965	rs9911630	chr17:41188342	A/G	cg05368731	chr17:41323189	NBR1	0.56	7.56	0.42	6.43e-13	Menopause (age at onset);
CESC	cis	rs2710642	0.962	rs6545972	chr2:63084682	G/A	cg17519650	chr2:63277830	OTX1	0.53	6.77	0.38	8.11e-11	LDL cholesterol levels;LDL cholesterol;
CESC	cis	rs8023845	1.000	rs3759843	chr15:40453075	A/G	cg20259534	chr15:40453036	BUB1B	-0.69	-7.02	-0.4	1.87e-11	Chronic lymphocytic leukemia;
CESC	cis	rs3820068	0.603	rs1122387	chr1:15947282	T/C	cg13390004	chr1:15929781	NA	0.37	5.95	0.34	8.6e-9	Systolic blood pressure;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02040921	chr17:61554411	ACE	0.55	6.25	0.36	1.62e-9	Gut microbiome composition (summer);
CESC	cis	rs7116495	0.609	rs7126394	chr11:71685429	A/G	cg26138937	chr11:71823887	C11orf51	-1.26	-8.05	-0.44	2.83e-14	Severe influenza A (H1N1) infection;
CESC	cis	rs2991971	0.967	rs11211130	chr1:45986852	G/C	cg24296786	chr1:45957014	TESK2	0.66	8.96	0.48	6.06e-17	High light scatter reticulocyte count;
CESC	cis	rs9359856	0.510	rs2768940	chr6:90436319	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.73	-8.34	-0.46	4.01e-15	Bipolar disorder;
CESC	cis	rs4561483	0.603	rs62038777	chr16:11934176	A/C	cg08843971	chr16:11963173	GSPT1	0.5	6.86	0.39	4.99e-11	Testicular germ cell tumor;
CESC	cis	rs9583531	0.600	rs754599	chr13:111354788	C/A	cg15841412	chr13:111365552	ING1	0.49	6.31	0.36	1.19e-9	Coronary artery disease;
CESC	cis	rs2290159	0.800	rs5746193	chr3:12658601	C/T	cg23032965	chr3:12705835	RAF1	0.53	5.68	0.33	3.58e-8	Cholesterol, total;
CESC	cis	rs1018836	0.786	rs7016220	chr8:91606848	A/G	cg16814680	chr8:91681699	NA	-0.71	-10.58	-0.54	4.89e-22	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs897984	0.762	rs2054213	chr16:30971810	A/G	cg02466173	chr16:30829666	NA	0.49	8.16	0.45	1.35e-14	Dementia with Lewy bodies;
CESC	cis	rs11247915	0.561	rs11583258	chr1:26624270	C/T	cg00852783	chr1:26633632	UBXN11	0.42	5.16	0.3	4.82e-7	Obesity-related traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21000493	chr7:39772967	LOC349114	0.58	6.48	0.37	4.45e-10	Gut microbiome composition (summer);
CESC	cis	rs3015497	0.603	rs3015462	chr14:51034617	C/A	cg26011998	chr14:51135199	SAV1	0.49	5.45	0.32	1.16e-7	Mean platelet volume;
CESC	cis	rs5769765	0.862	rs9616385	chr22:50313124	C/T	cg26441486	chr22:50317300	CRELD2	0.41	5.22	0.31	3.7e-7	Schizophrenia;
CESC	cis	rs875971	0.660	rs10281080	chr7:66042441	T/C	cg25985355	chr7:65971099	NA	0.33	5.39	0.31	1.53e-7	Aortic root size;
CESC	cis	rs2075371	0.579	rs11766422	chr7:134018160	T/C	cg11752832	chr7:134001865	SLC35B4	0.43	5.11	0.3	6.32e-7	Mean platelet volume;
CESC	cis	rs4242434	0.927	rs11136093	chr8:22479988	C/G	cg03733263	chr8:22462867	KIAA1967	0.94	12.76	0.62	2.16e-29	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CESC	cis	rs1499614	1.000	rs1267817	chr7:66110040	G/T	cg18252515	chr7:66147081	NA	-1.4	-14.2	-0.66	2.03e-34	Gout;
CESC	cis	rs2204008	0.837	rs7308714	chr12:38274307	T/C	cg26384229	chr12:38710491	ALG10B	0.68	9.7	0.51	3.2e-19	Bladder cancer;
CESC	cis	rs854765	0.647	rs4365346	chr17:17989373	G/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.6	8.56	0.47	9.59e-16	Total body bone mineral density;
CESC	cis	rs2797160	0.935	rs1739372	chr6:126011325	G/A	cg05901451	chr6:126070800	HEY2	0.46	6.67	0.38	1.45e-10	Endometrial cancer;
CESC	cis	rs597539	0.652	rs544370	chr11:68653232	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.79	10.66	0.55	2.67e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs2033711	0.870	rs4801270	chr19:58932762	C/A	cg11952622	chr19:58962976	ZNF324B	0.46	6.13	0.35	3.11e-9	Uric acid clearance;
CESC	cis	rs11792861	0.926	rs56899598	chr9:111867271	A/G	cg05043794	chr9:111880884	C9orf5	-0.41	-6.88	-0.39	4.29e-11	Menarche (age at onset);
CESC	cis	rs2836974	0.533	rs418298	chr21:40536654	A/T	cg27266027	chr21:40555129	PSMG1	0.41	5.22	0.31	3.62e-7	Cognitive function;
CESC	cis	rs765787	0.530	rs12440321	chr15:45529385	G/A	cg24006582	chr15:45444508	DUOX1	0.57	6.94	0.39	3.04e-11	Uric acid levels;
CESC	cis	rs34779708	0.931	rs4934720	chr10:35376800	T/C	cg03585969	chr10:35415529	CREM	0.77	10.07	0.53	2.06e-20	Inflammatory bowel disease;Crohn's disease;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg24809958	chr1:6662478	KLHL21	-0.43	-6.2	-0.36	2.12e-9	Gambling;
CESC	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.43	-5.81	-0.34	1.8e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7020830	0.858	rs1492714	chr9:37141259	T/C	cg14294708	chr9:37120828	ZCCHC7	1.25	25.19	0.84	2.66e-72	Schizophrenia;
CESC	cis	rs854765	0.693	rs11657074	chr17:17770355	G/A	cg04398451	chr17:18023971	MYO15A	0.63	9.0	0.48	4.49e-17	Total body bone mineral density;
CESC	cis	rs362272	0.524	rs6819202	chr4:3368264	G/A	cg14583973	chr4:3374767	RGS12	0.31	5.43	0.32	1.29e-7	Serum sulfate level;
CESC	cis	rs597539	0.652	rs496616	chr11:68672800	G/C	cg01988459	chr11:68622903	NA	-0.42	-5.74	-0.33	2.58e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	trans	rs561341	1.000	rs564714	chr17:30318404	C/T	cg20587970	chr11:113659929	NA	-1.48	-19.58	-0.77	2.15e-53	Hip circumference adjusted for BMI;
CESC	trans	rs3794271	0.706	rs9971816	chr12:20826911	C/T	cg17746819	chr1:100715586	DBT	0.49	6.96	0.39	2.65e-11	Response to TNF-alpha inhibitors in rheumatoid arthritis;
CESC	cis	rs17253792	0.822	rs10147688	chr14:56054642	T/C	cg01858014	chr14:56050164	KTN1	-0.82	-6.43	-0.37	5.88e-10	Putamen volume;
CESC	cis	rs3820928	1.000	rs10167422	chr2:227777554	G/A	cg11843606	chr2:227700838	RHBDD1	-0.43	-5.81	-0.34	1.74e-8	Pulmonary function;
CESC	cis	rs763014	0.931	rs11648728	chr16:635525	C/T	cg09263875	chr16:632152	PIGQ	0.68	11.61	0.58	1.81e-25	Height;
CESC	cis	rs11098499	0.863	rs34868248	chr4:120442430	A/G	cg09307838	chr4:120376055	NA	0.92	12.64	0.61	5.65e-29	Corneal astigmatism;
CESC	cis	rs1048238	0.846	rs945417	chr1:16344625	C/G	cg22431228	chr1:16359049	CLCNKA	-0.55	-11.0	-0.56	2.02e-23	Systolic blood pressure;
CESC	cis	rs13095912	1.000	rs13095912	chr3:185302098	G/A	cg11274856	chr3:185301563	NA	0.37	5.88	0.34	1.22e-8	Systolic blood pressure;
CESC	cis	rs7149242	0.696	rs7141210	chr14:101182470	T/C	cg18089426	chr14:101175970	NA	-0.4	-6.65	-0.38	1.65e-10	Platelet count;
CESC	cis	rs6963495	0.556	rs711433	chr7:105153191	A/G	cg19920283	chr7:105172520	RINT1	-0.52	-6.05	-0.35	4.89e-9	Bipolar disorder (body mass index interaction);
CESC	cis	rs7762018	0.770	rs3823466	chr6:170189926	C/T	cg05834625	chr6:170176447	C6orf70	0.59	6.71	0.38	1.17e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs10880689	1	rs10880689	chr12:37930102	A/G	cg13010199	chr12:38710504	ALG10B	0.46	5.78	0.33	2.05e-8	Resting heart rate;
CESC	trans	rs9325144	0.723	rs11169482	chr12:39164327	A/T	cg23762105	chr12:34175262	ALG10	-0.46	-6.02	-0.35	5.8e-9	Morning vs. evening chronotype;
CESC	cis	rs7618915	0.501	rs55678971	chr3:52717229	T/A	cg18404041	chr3:52824283	ITIH1	-0.41	-6.88	-0.39	4.35e-11	Bipolar disorder;
CESC	cis	rs2235642	0.893	rs2076442	chr16:1591112	G/T	cg08296037	chr16:1584118	IFT140;TMEM204	-0.36	-5.88	-0.34	1.25e-8	Coronary artery disease;
CESC	cis	rs780096	0.546	rs1647284	chr2:27608115	C/T	cg24768116	chr2:27665128	KRTCAP3	-0.29	-5.38	-0.31	1.61e-7	Total body bone mineral density;
CESC	cis	rs3768617	0.528	rs3736888	chr1:183084607	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.89	14.36	0.66	5.49e-35	Fuchs's corneal dystrophy;
CESC	cis	rs798554	0.679	rs1636254	chr7:2885724	T/C	cg13628971	chr7:2884303	GNA12	0.64	8.78	0.47	2.11e-16	Height;
CESC	cis	rs7666738	0.791	rs11097601	chr4:98960103	C/T	cg03676636	chr4:99064102	C4orf37	0.33	5.14	0.3	5.39e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4689388	0.890	rs13130845	chr4:6297646	A/C	cg25554036	chr4:6271136	WFS1	0.52	8.38	0.46	3.1e-15	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs3008870	1.000	rs2065001	chr1:67486509	C/G	cg11518657	chr1:67396239	MIER1	0.48	5.07	0.3	7.66e-7	Lymphocyte percentage of white cells;
CESC	cis	rs9291683	0.554	rs7668175	chr4:10125782	T/C	cg00071950	chr4:10020882	SLC2A9	-0.56	-8.54	-0.46	1.07e-15	Bone mineral density;
CESC	cis	rs34638657	0.753	rs2967375	chr16:82211418	A/G	cg09439754	chr16:82129088	HSD17B2	-0.34	-5.68	-0.33	3.61e-8	Lung adenocarcinoma;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg20505218	chr17:80009845	GPS1;RFNG	-0.51	-6.88	-0.39	4.32e-11	Height;
CESC	cis	rs6570726	0.791	rs12208812	chr6:145900924	T/G	cg23711669	chr6:146136114	FBXO30	1.0	15.5	0.69	5.39e-39	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7605827	0.897	rs6745917	chr2:15537924	G/C	cg19274914	chr2:15703543	NA	0.35	6.16	0.35	2.66e-9	Educational attainment (years of education);
CESC	cis	rs4727027	0.899	rs6944096	chr7:148870026	A/G	cg23583168	chr7:148888333	NA	-0.87	-14.12	-0.66	3.93e-34	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs12477438	0.520	rs6712704	chr2:99719687	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.86	15.87	0.7	2.48e-40	Chronic sinus infection;
CESC	cis	rs921968	0.565	rs6436086	chr2:219640125	T/C	cg02176678	chr2:219576539	TTLL4	-0.43	-7.66	-0.43	3.42e-13	Mean corpuscular hemoglobin concentration;
CESC	cis	rs3857536	0.813	rs6903678	chr6:66931208	C/T	cg07460842	chr6:66804631	NA	0.38	5.06	0.3	7.87e-7	Blood trace element (Cu levels);
CESC	cis	rs9388451	0.839	rs1811852	chr6:126071575	G/C	cg05901451	chr6:126070800	HEY2	-0.64	-9.11	-0.49	2.09e-17	Brugada syndrome;
CESC	cis	rs4727027	0.933	rs7788925	chr7:148831621	A/G	cg23158103	chr7:148848205	ZNF398	-0.4	-6.51	-0.37	3.67e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs9611565	0.659	rs73178632	chr22:41934573	C/T	cg03806693	chr22:41940476	POLR3H	-1.21	-15.42	-0.69	9.91e-39	Vitiligo;
CESC	cis	rs1348850	0.526	rs59972556	chr2:178399561	A/G	cg23306229	chr2:178417860	TTC30B	0.81	7.47	0.42	1.14e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs56399783	0.901	rs11761804	chr7:2792524	C/T	cg19731401	chr7:2775893	GNA12	0.64	5.73	0.33	2.76e-8	Childhood ear infection;
CESC	cis	rs9916302	0.904	rs3744348	chr17:37417575	C/G	cg07936489	chr17:37558343	FBXL20	-0.77	-10.97	-0.56	2.56e-23	Glomerular filtration rate (creatinine);
CESC	cis	rs3617	0.573	rs9880978	chr3:52923251	C/G	cg17372223	chr3:52568218	NT5DC2	0.35	5.17	0.3	4.62e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
CESC	cis	rs514406	0.825	rs7523761	chr1:53250915	T/C	cg08859206	chr1:53392774	SCP2	0.6	8.93	0.48	7.22e-17	Monocyte count;
CESC	cis	rs7412746	0.611	rs7556661	chr1:150892009	C/T	cg04414720	chr1:150670196	GOLPH3L	0.51	6.76	0.38	8.61e-11	Melanoma;
CESC	cis	rs514406	0.798	rs576650	chr1:53327207	C/T	cg06600287	chr1:53387719	ECHDC2	-0.29	-5.06	-0.3	7.92e-7	Monocyte count;
CESC	cis	rs9287719	0.967	rs7563894	chr2:10754649	A/G	cg02196655	chr2:10830764	NOL10	-0.37	-5.69	-0.33	3.39e-8	Prostate cancer;
CESC	cis	rs28374715	0.580	rs8030228	chr15:41636867	A/G	cg02330683	chr15:41787940	ITPKA	0.46	5.83	0.34	1.6e-8	Ulcerative colitis;
CESC	cis	rs35110281	0.744	rs230646	chr21:44918788	A/G	cg04455712	chr21:45112962	RRP1B	0.35	5.21	0.3	3.76e-7	Mean corpuscular volume;
CESC	cis	rs853679	0.517	rs11552219	chr6:28126834	C/T	cg26335602	chr6:28129616	ZNF389	0.52	6.81	0.39	6.59e-11	Depression;
CESC	cis	rs7666738	0.830	rs3907020	chr4:99038583	T/C	cg03467027	chr4:99064603	C4orf37	0.47	5.96	0.34	8.08e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9457247	1.000	rs2769347	chr6:167371737	T/A	cg07741184	chr6:167504864	NA	-0.3	-5.42	-0.32	1.34e-7	Crohn's disease;
CESC	cis	rs17376456	0.825	rs35496867	chr5:93220400	T/C	cg25358565	chr5:93447407	FAM172A	1.09	10.27	0.53	4.95e-21	Diabetic retinopathy;
CESC	cis	rs7412746	0.658	rs4970982	chr1:150865084	G/C	cg17724175	chr1:150552817	MCL1	0.38	5.96	0.34	8.07e-9	Melanoma;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg09270951	chr12:4647414	C12orf4;RAD51AP1	0.44	6.25	0.36	1.65e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs7666738	0.927	rs4699328	chr4:99055890	C/T	cg17366294	chr4:99064904	C4orf37	0.62	8.73	0.47	2.94e-16	Colonoscopy-negative controls vs population controls;
CESC	trans	rs724568	0.642	rs7593116	chr2:67927023	G/A	cg19718508	chr5:176831858	F12	-0.45	-6.33	-0.36	1.06e-9	Major depressive disorder (broad);
CESC	cis	rs2408955	0.541	rs11168428	chr12:48547128	A/G	cg04545296	chr12:48745243	ZNF641	-0.35	-5.97	-0.34	7.77e-9	Glycated hemoglobin levels;
CESC	cis	rs12681366	0.734	rs6991077	chr8:95387805	C/T	cg13257157	chr8:95487014	RAD54B	0.39	5.26	0.31	3.04e-7	Nonsyndromic cleft lip with cleft palate;
CESC	cis	rs7949030	0.588	rs2512562	chr11:62312156	A/G	cg23462726	chr11:62437636	C11orf83;C11orf48	-0.4	-5.42	-0.32	1.37e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs1008375	0.966	rs11733730	chr4:17625209	G/C	cg15017067	chr4:17643749	FAM184B	0.39	5.67	0.33	3.76e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11330941	chr2:17934879	GEN1;SMC6	-0.58	-6.57	-0.37	2.64e-10	Gut microbiome composition (summer);
CESC	cis	rs6032067	0.632	rs35361894	chr20:43794403	G/A	cg10761708	chr20:43804764	PI3	0.56	6.55	0.37	3.01e-10	Blood protein levels;
CESC	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg05025164	chr4:1340916	KIAA1530	0.87	11.81	0.59	3.81e-26	Longevity;
CESC	cis	rs763121	0.853	rs2413547	chr22:39107338	A/G	cg06022373	chr22:39101656	GTPBP1	0.91	14.57	0.67	9.91e-36	Menopause (age at onset);
CESC	cis	rs7605827	0.930	rs7598068	chr2:15596535	A/T	cg19274914	chr2:15703543	NA	0.32	5.69	0.33	3.38e-8	Educational attainment (years of education);
CESC	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg11965913	chr1:205819406	PM20D1	0.83	13.51	0.64	5.44e-32	Menarche (age at onset);
CESC	cis	rs9910055	0.573	rs113184718	chr17:42206543	A/T	cg19774624	chr17:42201019	HDAC5	0.83	13.02	0.62	2.7e-30	Total body bone mineral density;
CESC	cis	rs6089584	0.888	rs2181590	chr20:60622843	T/C	cg13770153	chr20:60521292	NA	-0.44	-5.7	-0.33	3.2e-8	Body mass index;
CESC	cis	rs2836974	0.932	rs8129416	chr21:40617145	C/T	cg11890956	chr21:40555474	PSMG1	1.15	21.07	0.79	1.46e-58	Cognitive function;
CESC	cis	rs3091242	0.933	rs28530483	chr1:25740847	A/C	cg03538708	chr1:25844672	NA	-0.4	-5.86	-0.34	1.41e-8	Erythrocyte sedimentation rate;
CESC	cis	rs897984	0.568	rs8050107	chr16:30893451	C/T	cg02466173	chr16:30829666	NA	0.44	6.27	0.36	1.44e-9	Dementia with Lewy bodies;
CESC	cis	rs9916302	0.851	rs9904919	chr17:37556431	G/C	cg20243544	chr17:37824526	PNMT	-0.49	-6.22	-0.36	1.94e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs12477438	0.798	rs12473029	chr2:99637961	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-10.6	-0.55	4.17e-22	Chronic sinus infection;
CESC	trans	rs208515	0.525	rs10755508	chr6:66675790	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.88	10.9	0.56	4.24e-23	Exhaled nitric oxide levels;
CESC	cis	rs1577917	0.785	rs1885607	chr6:86394905	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.56	7.78	0.43	1.59e-13	Response to antipsychotic treatment;
CESC	cis	rs3733585	0.673	rs7375587	chr4:9954758	A/T	cg11266682	chr4:10021025	SLC2A9	0.58	10.96	0.56	2.77e-23	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs1799949	1.000	rs1545764	chr17:41424565	G/A	cg25072359	chr17:41440525	NA	0.48	6.35	0.36	9.3e-10	Menopause (age at onset);
CESC	trans	rs66573146	0.634	rs56097119	chr4:7018692	C/G	cg07817883	chr1:32538562	TMEM39B	0.94	6.16	0.35	2.69e-9	Granulocyte percentage of myeloid white cells;
CESC	trans	rs6934970	0.932	rs12201407	chr6:113144268	G/T	cg13507084	chr9:34555042	CNTFR	-0.48	-6.18	-0.35	2.45e-9	Bipolar disorder (body mass index interaction);
CESC	cis	rs8114671	0.562	rs2889861	chr20:33405664	C/T	cg24642439	chr20:33292090	TP53INP2	0.44	5.34	0.31	2.02e-7	Height;
CESC	cis	rs919433	0.929	rs10931779	chr2:198166825	A/G	cg03934865	chr2:198174659	NA	-0.48	-7.66	-0.43	3.54e-13	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	trans	rs9975691	1	rs9975691	chr21:14928355	G/T	cg03180457	chr10:43133994	ZNF33B	0.47	6.04	0.35	5.16e-9	Neurofibrillary tangles;
CESC	cis	rs12425451	0.544	rs3741951	chr12:3147080	A/G	cg05389053	chr12:3131226	TEAD4	0.52	5.71	0.33	3.01e-8	Narcolepsy with cataplexy;
CESC	cis	rs7945705	0.747	rs1980428	chr11:9010497	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.4	6.7	0.38	1.28e-10	Hemoglobin concentration;
CESC	cis	rs7666738	0.830	rs10034330	chr4:99064849	G/A	cg18180107	chr4:99064573	C4orf37	0.4	5.14	0.3	5.21e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs73568641	0.583	rs4870224	chr6:154104380	A/G	cg08374472	chr16:87445639	ZCCHC14	0.44	6.01	0.35	6.19e-9	Methadone dose in opioid dependence;
CESC	cis	rs7692995	1.000	rs12511600	chr4:17939921	C/T	cg08925142	chr4:18023851	LCORL	-0.45	-5.3	-0.31	2.5e-7	Height;
CESC	cis	rs16867321	0.627	rs13400001	chr2:181589205	T/C	cg23363182	chr2:181467187	NA	-0.44	-5.74	-0.33	2.59e-8	Obesity;
CESC	cis	rs4665809	0.941	rs41285975	chr2:26351144	T/C	cg25036284	chr2:26402008	FAM59B	-0.59	-6.88	-0.39	4.37e-11	Gut microbiome composition (summer);
CESC	cis	rs6952808	1.000	rs12540579	chr7:1882227	C/A	cg22963979	chr7:1858916	MAD1L1	-0.39	-5.42	-0.32	1.36e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs9733	0.596	rs1415148	chr1:150705755	G/A	cg18016565	chr1:150552671	MCL1	0.34	5.28	0.31	2.67e-7	Tonsillectomy;
CESC	trans	rs916888	0.821	rs199507	chr17:44858855	A/G	cg22968622	chr17:43663579	NA	-1.19	-16.28	-0.71	8.87e-42	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs735396	0.694	rs2264750	chr12:121450165	C/T	cg02403541	chr12:121454288	C12orf43	0.73	10.08	0.53	1.87e-20	N-glycan levels;
CESC	cis	rs6987853	0.830	rs4737048	chr8:42359035	G/T	cg09913449	chr8:42400586	C8orf40	-0.34	-5.3	-0.31	2.41e-7	Mean corpuscular hemoglobin concentration;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18295152	chr5:157170440	LSM11	-0.57	-6.14	-0.35	3.06e-9	Gut microbiome composition (summer);
CESC	cis	rs4862750	0.914	rs11945845	chr4:187874136	T/C	cg03452623	chr4:187889614	NA	-0.84	-13.73	-0.64	9.22e-33	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9921222	0.500	rs11645742	chr16:367516	C/T	cg08923669	chr16:420230	MRPL28	-0.43	-5.04	-0.3	8.76e-7	Bone mineral density (spine);Bone mineral density;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25228510	chr10:62538235	CDK1;CDC2	0.53	6.22	0.36	1.97e-9	Gut microbiome composition (summer);
CESC	cis	rs947211	0.950	rs1775145	chr1:205756143	C/A	cg14159672	chr1:205819179	PM20D1	0.4	5.21	0.3	3.81e-7	Parkinson's disease;
CESC	cis	rs7107174	0.892	rs2510038	chr11:77966034	C/T	cg02023728	chr11:77925099	USP35	0.42	5.53	0.32	7.84e-8	Testicular germ cell tumor;
CESC	cis	rs2290720	0.965	rs7313828	chr12:101722005	A/C	cg22051763	chr12:101673672	UTP20	-0.46	-5.47	-0.32	1.05e-7	Brain structure (hippocampal volume);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02292671	chr10:6244643	PFKFB3	0.61	6.84	0.39	5.55e-11	Gut microbiome composition (summer);
CESC	cis	rs7617480	0.648	rs10865953	chr3:48759562	C/T	cg07636037	chr3:49044803	WDR6	0.79	10.38	0.54	2.06e-21	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CESC	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg07167872	chr1:205819463	PM20D1	0.42	6.42	0.37	6.43e-10	Menarche (age at onset);
CESC	cis	rs875971	0.862	rs6460282	chr7:65691246	T/C	cg18876405	chr7:65276391	NA	-0.56	-7.69	-0.43	2.94e-13	Aortic root size;
CESC	cis	rs2777491	1.000	rs316605	chr15:41771591	G/A	cg02330683	chr15:41787940	ITPKA	0.48	7.14	0.4	9.19e-12	Ulcerative colitis;
CESC	cis	rs6495122	0.618	rs4886413	chr15:75262310	G/C	cg17294928	chr15:75287854	SCAMP5	0.49	6.17	0.35	2.54e-9	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
CESC	cis	rs4423214	0.592	rs7130829	chr11:71237702	A/T	cg05163923	chr11:71159392	DHCR7	-0.54	-5.84	-0.34	1.55e-8	Vitamin D levels;
CESC	cis	rs7474896	0.583	rs4934898	chr10:37990395	G/C	cg25427524	chr10:38739819	LOC399744	-0.47	-5.44	-0.32	1.24e-7	Obesity (extreme);
CESC	cis	rs1018836	0.608	rs6998106	chr8:91479755	G/T	cg16814680	chr8:91681699	NA	-0.56	-7.74	-0.43	2.08e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs853679	0.517	rs9368557	chr6:28131537	T/C	cg19592336	chr6:28129416	ZNF389	0.61	8.03	0.44	3.13e-14	Depression;
CESC	cis	rs2576037	0.526	rs564113	chr18:44364389	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.7	10.89	0.56	4.41e-23	Personality dimensions;
CESC	cis	rs6502050	0.835	rs4789738	chr17:80123053	G/A	cg11859384	chr17:80120422	CCDC57	-0.39	-5.34	-0.31	1.98e-7	Life satisfaction;
CESC	cis	rs2000999	0.524	rs12933482	chr16:72189604	A/G	cg04254540	chr16:71951199	KIAA0174	-0.74	-6.04	-0.35	5.25e-9	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
CESC	cis	rs3820068	0.705	rs57971278	chr1:15838604	G/A	cg18192808	chr1:15853278	DNAJC16	0.47	5.63	0.33	4.47e-8	Systolic blood pressure;
CESC	cis	rs561341	1.000	rs4795668	chr17:30244554	G/A	cg13647721	chr17:30228624	UTP6	0.59	5.28	0.31	2.69e-7	Hip circumference adjusted for BMI;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg16638425	chr16:2946805	FLYWCH2	0.46	6.65	0.38	1.7e-10	Fibrinogen levels;
CESC	cis	rs4423214	1.000	rs2282620	chr11:71183477	C/T	cg05163923	chr11:71159392	DHCR7	0.82	10.82	0.55	7.47e-23	Vitamin D levels;
CESC	cis	rs911555	0.692	rs60235428	chr14:103904350	T/C	cg24130564	chr14:104152367	KLC1	0.5	6.5	0.37	3.98e-10	Intelligence (multi-trait analysis);
CESC	cis	rs13191362	0.507	rs2846536	chr6:163033492	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.47	5.84	0.34	1.56e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs10504229	0.953	rs6990806	chr8:58183113	G/A	cg22535103	chr8:58192502	C8orf71	-1.05	-13.08	-0.63	1.71e-30	Developmental language disorder (linguistic errors);
CESC	cis	rs9768139	0.708	rs896780	chr7:158113972	C/T	cg24154853	chr7:158122151	PTPRN2	0.42	6.48	0.37	4.38e-10	Calcium levels;
CESC	cis	rs1881797	1.000	rs68059491	chr1:247683070	C/T	cg21399703	chr1:247681439	NA	0.61	7.8	0.43	1.41e-13	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs4865169	0.934	rs12650737	chr4:57892475	G/T	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.37	-5.07	-0.3	7.58e-7	Breast cancer;
CESC	cis	rs10752881	0.967	rs8179284	chr1:182974707	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.83	13.29	0.63	3.24e-31	Colorectal cancer;
CESC	cis	rs9457247	1.000	rs422094	chr6:167397033	C/G	cg25258033	chr6:167368657	RNASET2	0.4	5.95	0.34	8.36e-9	Crohn's disease;
CESC	cis	rs11098499	0.863	rs3775845	chr4:120432447	T/C	cg24375607	chr4:120327624	NA	0.44	5.25	0.31	3.06e-7	Corneal astigmatism;
CESC	cis	rs1348850	0.958	rs10497501	chr2:178462299	C/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.62	8.62	0.47	6.11e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs644799	0.862	rs1150361	chr11:95633805	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	12.44	0.61	2.7e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs2573652	1.000	rs12440866	chr15:100517010	G/A	cg09918751	chr15:100517450	ADAMTS17	-0.4	-7.66	-0.43	3.52e-13	Height;
CESC	cis	rs28489187	0.706	rs233066	chr1:85804930	T/C	cg16011679	chr1:85725395	C1orf52	0.54	6.24	0.36	1.7e-9	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26156301	chr20:30193024	ID1	0.6	6.47	0.37	4.8e-10	Gut microbiome composition (summer);
CESC	cis	rs9487051	1.000	rs6568569	chr6:109613196	C/A	cg01475377	chr6:109611718	NA	-0.42	-6.43	-0.37	6.01e-10	Reticulocyte fraction of red cells;
CESC	cis	rs7811142	1.000	rs73161762	chr7:100014846	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.79	6.4	0.37	7.1e-10	Platelet count;
CESC	cis	rs7917772	0.582	rs4919661	chr10:104358403	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.41	5.63	0.33	4.48e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs7296418	0.630	rs11608305	chr12:123791165	C/G	cg05973401	chr12:123451056	ABCB9	0.44	5.57	0.32	6.33e-8	Platelet count;
CESC	cis	rs2842992	0.789	rs9364536	chr6:160225559	G/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.75	9.5	0.5	1.27e-18	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs589448	0.933	rs2249093	chr12:69753512	G/C	cg20891283	chr12:69753455	YEATS4	1.0	17.3	0.73	2.24e-45	Cerebrospinal fluid biomarker levels;
CESC	cis	rs1448094	0.511	rs61930587	chr12:86158793	T/C	cg02569458	chr12:86230093	RASSF9	0.51	7.8	0.43	1.4e-13	Major depressive disorder;
CESC	cis	rs7208859	0.623	rs56812022	chr17:29068733	A/G	cg14008862	chr17:28927542	LRRC37B2	0.65	5.15	0.3	5.11e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs2797160	0.905	rs1418641	chr6:125999854	C/T	cg05901451	chr6:126070800	HEY2	-0.45	-6.67	-0.38	1.44e-10	Endometrial cancer;
CESC	cis	rs9486719	1.000	rs10872018	chr6:97026429	G/A	cg18709589	chr6:96969512	KIAA0776	-0.5	-5.43	-0.32	1.28e-7	Migraine;Coronary artery disease;
CESC	cis	rs3540	0.597	rs11639150	chr15:91042071	C/G	cg22089800	chr15:90895588	ZNF774	-0.64	-8.78	-0.47	2.11e-16	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs9487051	1.000	rs9487051	chr6:109617079	A/G	cg01475377	chr6:109611718	NA	-0.42	-6.4	-0.37	6.83e-10	Reticulocyte fraction of red cells;
CESC	cis	rs4132509	0.625	rs1058304	chr1:243664857	C/T	cg21452805	chr1:244014465	NA	0.4	5.19	0.3	4.23e-7	RR interval (heart rate);
CESC	cis	rs2247341	0.965	rs2854920	chr4:1715349	C/T	cg07465881	chr4:1713556	SLBP	-0.52	-6.42	-0.37	6.44e-10	Hip circumference adjusted for BMI;Height;
CESC	cis	rs5758659	0.652	rs133358	chr22:42442539	A/T	cg04733989	chr22:42467013	NAGA	0.46	6.44	0.37	5.61e-10	Cognitive function;
CESC	cis	rs1034435	0.692	rs6008739	chr22:48892542	T/C	cg05992904	chr22:48892994	FAM19A5	-0.56	-9.87	-0.52	8.9e-20	Late-onset Alzheimer's disease;
CESC	cis	rs5769765	0.773	rs9616383	chr22:50313014	T/C	cg26441486	chr22:50317300	CRELD2	0.41	5.22	0.31	3.7e-7	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25151688	chr15:66585534	DIS3L	-0.54	-6.45	-0.37	5.17e-10	Gut microbiome composition (summer);
CESC	cis	rs6987853	0.583	rs2974311	chr8:42455166	G/A	cg09913449	chr8:42400586	C8orf40	0.34	5.22	0.31	3.58e-7	Mean corpuscular hemoglobin concentration;
CESC	cis	rs4664304	0.629	rs57751799	chr2:160854180	A/T	cg03641300	chr2:160917029	PLA2R1	-0.43	-5.81	-0.34	1.78e-8	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs35955747	0.902	rs713947	chr22:31639509	G/T	cg25791279	chr22:32026902	PISD	-0.49	-5.87	-0.34	1.28e-8	Neutrophil count;Sum basophil neutrophil counts;
CESC	cis	rs12701220	0.817	rs59471534	chr7:1085224	G/A	cg26769984	chr7:1090371	C7orf50	0.56	6.87	0.39	4.63e-11	Bronchopulmonary dysplasia;
CESC	cis	rs12701220	0.696	rs12112029	chr7:1137889	G/A	cg04025307	chr7:1156635	C7orf50	0.46	5.18	0.3	4.46e-7	Bronchopulmonary dysplasia;
CESC	cis	rs763014	0.931	rs1981483	chr16:630665	G/A	cg07256732	chr16:621771	PIGQ	-0.31	-5.38	-0.31	1.61e-7	Height;
CESC	cis	rs2075371	0.611	rs34573600	chr7:134018937	C/T	cg11752832	chr7:134001865	SLC35B4	0.42	5.08	0.3	7.08e-7	Mean platelet volume;
CESC	cis	rs780096	0.526	rs11682621	chr2:27749669	G/A	cg22903471	chr2:27725779	GCKR	-0.52	-7.22	-0.41	5.45e-12	Total body bone mineral density;
CESC	cis	rs11637445	0.627	rs72751453	chr15:68124665	C/A	cg08079166	chr15:68083412	MAP2K5	-0.35	-5.05	-0.3	8.18e-7	Posterior cortical atrophy and Alzheimer's disease;
CESC	cis	rs4803468	1.000	rs10417311	chr19:41902038	G/A	cg08477640	chr19:41863820	B9D2	0.38	5.07	0.3	7.53e-7	Height;
CESC	trans	rs208520	0.954	rs1468153	chr6:67009054	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.73	7.46	0.42	1.25e-12	Exhaled nitric oxide output;
CESC	trans	rs11989868	1.000	rs920614	chr8:14543523	C/T	cg22006392	chr17:927457	ABR	-0.43	-6.0	-0.35	6.42e-9	Obesity-related traits;
CESC	cis	rs2559856	1.000	rs2559857	chr12:102089399	A/C	cg15068132	chr12:102092402	CHPT1	-0.43	-5.64	-0.33	4.26e-8	Blood protein levels;
CESC	cis	rs7552404	0.765	rs1251078	chr1:76189488	C/G	cg10523679	chr1:76189770	ACADM	-0.87	-13.69	-0.64	1.22e-32	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs7312774	0.748	rs1861745	chr12:107301642	C/T	cg16260113	chr12:107380972	MTERFD3	0.71	6.39	0.37	7.64e-10	Severe influenza A (H1N1) infection;
CESC	cis	rs2857078	0.745	rs4793085	chr17:42320732	A/C	cg19774624	chr17:42201019	HDAC5	0.54	7.32	0.41	2.91e-12	Red cell distribution width;Reticulocyte count;
CESC	cis	rs6433857	0.536	rs1901750	chr2:181350739	C/T	cg23363182	chr2:181467187	NA	-0.41	-5.91	-0.34	1.05e-8	Body mass index;
CESC	cis	rs1348850	0.632	rs1358328	chr2:178517532	G/A	cg23306229	chr2:178417860	TTC30B	0.57	6.96	0.39	2.61e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs11098499	0.908	rs12504149	chr4:120318577	G/A	cg24375607	chr4:120327624	NA	0.47	5.73	0.33	2.74e-8	Corneal astigmatism;
CESC	cis	rs7818382	0.967	rs7812465	chr8:96050557	C/T	cg09323728	chr8:95962352	TP53INP1	0.34	7.44	0.42	1.44e-12	Alzheimer's disease (late onset);
CESC	trans	rs116095464	0.558	rs59284383	chr5:284525	C/G	cg00938859	chr5:1591904	SDHAP3	0.65	7.03	0.4	1.73e-11	Breast cancer;
CESC	cis	rs7666738	0.830	rs28878289	chr4:98855181	C/T	cg03467027	chr4:99064603	C4orf37	0.42	5.16	0.3	4.73e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1707322	0.691	rs11211174	chr1:46220816	C/G	cg05343316	chr1:45956843	TESK2	0.51	6.2	0.36	2.19e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg14634842	chr2:232574012	PTMA	-0.49	-6.55	-0.37	3.03e-10	Asthma;
CESC	cis	rs6087990	1.000	rs2424900	chr20:31344342	G/C	cg13636640	chr20:31349939	DNMT3B	0.91	16.04	0.7	6.22e-41	Ulcerative colitis;
CESC	cis	rs9858542	0.953	rs9814873	chr3:49454112	A/G	cg03060546	chr3:49711283	APEH	-0.5	-5.99	-0.35	6.65e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs10463316	0.894	rs7707745	chr5:150765198	G/T	cg03212797	chr5:150827313	SLC36A1	-0.44	-5.7	-0.33	3.24e-8	Metabolite levels (Pyroglutamine);
CESC	cis	rs7089973	0.604	rs61596353	chr10:116597763	T/C	cg25233709	chr10:116636983	FAM160B1	0.38	5.97	0.34	7.44e-9	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs4073582	0.595	rs801736	chr11:65928430	A/T	cg14036092	chr11:66035641	RAB1B	0.54	7.56	0.42	6.63e-13	Gout;
CESC	trans	rs1373453	0.808	rs78879958	chr12:70071943	A/C	cg19702771	chr4:82058885	PRKG2	0.74	6.01	0.35	6.27e-9	Orofacial clefts;
CESC	trans	rs3942852	0.774	rs924715	chr11:48181060	G/A	cg15704280	chr7:45808275	SEPT13	-0.73	-8.22	-0.45	9.33e-15	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs8068544	0.748	rs75881902	chr17:40156612	C/A	cg26502583	chr17:39992600	KLHL10;NT5C3L	-0.76	-6.07	-0.35	4.34e-9	Reticulocyte fraction of red cells;Reticulocyte count;
CESC	cis	rs113835537	0.597	rs3737525	chr11:66306355	A/G	cg24851651	chr11:66362959	CCS	0.55	6.38	0.36	7.96e-10	Airway imaging phenotypes;
CESC	cis	rs6964587	1.000	rs11971885	chr7:91674807	T/C	cg17063962	chr7:91808500	NA	0.59	7.96	0.44	5.09e-14	Breast cancer;
CESC	cis	rs10823500	0.748	rs12355080	chr10:71963608	G/A	cg02100629	chr10:71892760	AIFM2	-0.32	-5.09	-0.3	6.83e-7	Blood protein levels;
CESC	cis	rs2243480	1.000	rs4718334	chr7:65789454	G/A	cg13147721	chr7:65941812	NA	0.92	9.04	0.49	3.39e-17	Diabetic kidney disease;
CESC	cis	rs13191362	0.507	rs13197051	chr6:163201728	A/T	cg06582575	chr6:163149167	PACRG;PARK2	0.47	5.53	0.32	7.67e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs2836974	0.568	rs2183573	chr21:40574305	A/G	cg11890956	chr21:40555474	PSMG1	-0.96	-15.96	-0.7	1.18e-40	Cognitive function;
CESC	cis	rs1670533	0.697	rs658846	chr4:1084723	G/C	cg27284194	chr4:1044797	NA	0.52	5.79	0.34	1.99e-8	Recombination rate (females);
CESC	cis	rs2295499	0.553	rs10937922	chr4:2682663	C/T	cg27239842	chr4:2403781	ZFYVE28	-0.31	-5.24	-0.31	3.26e-7	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
CESC	cis	rs1799949	0.930	rs2298861	chr17:41176831	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	8.16	0.45	1.32e-14	Menopause (age at onset);
CESC	cis	rs12410462	0.892	rs75757169	chr1:227629855	A/G	cg04117972	chr1:227635322	NA	0.64	6.48	0.37	4.36e-10	Major depressive disorder;
CESC	cis	rs11958404	1.000	rs72816529	chr5:157411454	G/C	cg05962755	chr5:157440814	NA	0.62	6.42	0.37	6.09e-10	IgG glycosylation;
CESC	cis	rs9796	0.689	rs8032195	chr15:41448790	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.46	-6.88	-0.39	4.31e-11	Menopause (age at onset);
CESC	cis	rs911555	0.755	rs8014013	chr14:103937372	A/G	cg12935359	chr14:103987150	CKB	0.64	9.14	0.49	1.67e-17	Intelligence (multi-trait analysis);
CESC	cis	rs3806843	0.735	rs2530241	chr5:140054485	C/T	cg26395211	chr5:140044315	WDR55	0.47	5.99	0.35	6.69e-9	Depressive symptoms (multi-trait analysis);
CESC	cis	rs6582630	0.519	rs80226845	chr12:38528231	C/A	cg26384229	chr12:38710491	ALG10B	0.71	10.89	0.56	4.51e-23	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs12479064	0.724	rs3792143	chr2:100057020	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.65	-7.44	-0.42	1.4e-12	Chronic sinus infection;
CESC	cis	rs1552244	0.882	rs9312044	chr3:10037481	T/C	cg00166722	chr3:10149974	C3orf24	0.5	6.2	0.36	2.2e-9	Alzheimer's disease;
CESC	cis	rs782590	0.967	rs17798852	chr2:55805172	A/C	cg18811423	chr2:55921094	PNPT1	0.78	12.57	0.61	1e-28	Metabolic syndrome;
CESC	cis	rs3820068	0.705	rs6656907	chr1:15896984	A/G	cg17385448	chr1:15911702	AGMAT	0.37	5.78	0.33	2.12e-8	Systolic blood pressure;
CESC	cis	rs12900413	0.687	rs12911196	chr15:90310734	G/C	cg24249390	chr15:90295951	MESP1	-0.4	-5.55	-0.32	6.91e-8	Coronary artery aneurysm in Kawasaki disease;
CESC	cis	rs4819052	0.851	rs7276103	chr21:46666078	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.45	5.83	0.34	1.6e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs4927850	0.709	rs6765762	chr3:195652851	G/A	cg12923728	chr3:195709715	SDHAP1	-0.66	-7.81	-0.43	1.33e-13	Pancreatic cancer;
CESC	cis	rs453301	0.682	rs2929451	chr8:9085295	A/T	cg15556689	chr8:8085844	FLJ10661	0.52	6.92	0.39	3.43e-11	Joint mobility (Beighton score);
CESC	trans	rs61931739	0.500	rs12371415	chr12:34521362	C/T	cg26384229	chr12:38710491	ALG10B	0.71	10.63	0.55	3.17e-22	Morning vs. evening chronotype;
CESC	cis	rs4803468	1.000	rs6508977	chr19:41909346	A/G	cg14132834	chr19:41945861	ATP5SL	-0.63	-7.89	-0.44	8.04e-14	Height;
CESC	cis	rs4835473	0.932	rs1988206	chr4:144912497	A/C	cg25736465	chr4:144833511	NA	0.43	6.5	0.37	3.87e-10	Immature fraction of reticulocytes;
CESC	cis	rs2204008	0.806	rs3922574	chr12:38329069	C/T	cg13010199	chr12:38710504	ALG10B	0.47	6.0	0.35	6.62e-9	Bladder cancer;
CESC	trans	rs8073060	0.544	rs225244	chr17:33946581	A/G	cg19694781	chr19:47549865	TMEM160	0.72	6.87	0.39	4.63e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	cis	rs6662572	0.853	rs2065708	chr1:45977685	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.53	5.74	0.33	2.56e-8	Blood protein levels;
CESC	cis	rs12497850	1.000	rs4858828	chr3:48724811	C/T	cg03060546	chr3:49711283	APEH	0.43	5.44	0.32	1.21e-7	Parkinson's disease;
CESC	cis	rs9322193	0.962	rs10452626	chr6:150088617	T/C	cg07701084	chr6:150067640	NUP43	0.44	5.95	0.34	8.59e-9	Lung cancer;
CESC	trans	rs2975734	0.674	rs6983870	chr8:10111294	G/A	cg15556689	chr8:8085844	FLJ10661	-0.58	-6.79	-0.38	7.54e-11	Morning vs. evening chronotype;Chronotype;
CESC	cis	rs1355223	0.506	rs7131229	chr11:34869328	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.53	6.51	0.37	3.71e-10	Systemic lupus erythematosus and Systemic sclerosis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15304497	chr14:75230530	YLPM1	-0.6	-7.22	-0.41	5.64e-12	Gut microbiome composition (summer);
CESC	trans	rs3780486	1.000	rs3780480	chr9:33163486	G/T	cg04842962	chr6:43655489	MRPS18A	0.89	13.16	0.63	8.73e-31	IgG glycosylation;
CESC	cis	rs4975709	0.569	rs1684965	chr5:1865248	A/G	cg11168104	chr5:1857477	NA	-0.35	-5.1	-0.3	6.38e-7	Cardiovascular disease risk factors;
CESC	cis	rs7605827	0.930	rs3805104	chr2:15535147	C/T	cg19274914	chr2:15703543	NA	0.33	5.89	0.34	1.2e-8	Educational attainment (years of education);
CESC	cis	rs2235642	0.505	rs56359342	chr16:1654948	G/A	cg03650551	chr16:1797383	MAPK8IP3	-0.39	-5.29	-0.31	2.53e-7	Coronary artery disease;
CESC	cis	rs875971	0.825	rs801202	chr7:66023929	C/T	cg19163074	chr7:65112434	INTS4L2	0.42	5.25	0.31	3.18e-7	Aortic root size;
CESC	cis	rs477692	0.563	rs7079165	chr10:131430240	G/A	cg05714579	chr10:131428358	MGMT	-0.71	-11.32	-0.57	1.73e-24	Response to temozolomide;
CESC	cis	rs9399135	1.000	rs35123050	chr6:135302740	G/A	cg24558204	chr6:135376177	HBS1L	0.5	6.68	0.38	1.37e-10	Red blood cell count;
CESC	cis	rs4835473	0.897	rs6832749	chr4:144630626	C/T	cg25736465	chr4:144833511	NA	0.4	6.09	0.35	3.86e-9	Immature fraction of reticulocytes;
CESC	cis	rs10504229	0.683	rs2291765	chr8:58142874	C/T	cg22535103	chr8:58192502	C8orf71	-0.69	-8.5	-0.46	1.35e-15	Developmental language disorder (linguistic errors);
CESC	trans	rs9858542	0.953	rs3811697	chr3:49590770	C/T	cg21659725	chr3:3221576	CRBN	-0.52	-6.43	-0.37	5.93e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.5	-5.96	-0.34	8.2e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs6540559	0.673	rs58637469	chr1:209971480	T/A	cg09509183	chr1:209979624	IRF6	0.56	5.86	0.34	1.4e-8	Cleft lip with or without cleft palate;
CESC	cis	rs6580649	0.941	rs72644845	chr12:48503881	G/A	cg05342945	chr12:48394962	COL2A1	0.55	6.32	0.36	1.13e-9	Lung cancer;
CESC	cis	rs34779708	0.966	rs34296409	chr10:35404613	C/G	cg03585969	chr10:35415529	CREM	0.77	10.1	0.53	1.71e-20	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs61931739	0.817	rs10743841	chr12:34252870	T/C	cg19457237	chr12:34500585	NA	-0.39	-5.54	-0.32	7.24e-8	Morning vs. evening chronotype;
CESC	cis	rs7666738	0.830	rs2865990	chr4:99067399	C/A	cg03676636	chr4:99064102	C4orf37	0.33	5.03	0.3	8.89e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9457247	0.602	rs12209395	chr6:167463914	C/T	cg07741184	chr6:167504864	NA	0.36	6.46	0.37	4.92e-10	Crohn's disease;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg14610884	chr6:116575311	TSPYL4	-0.44	-6.02	-0.35	5.78e-9	Asthma;
CESC	cis	rs1558375	0.679	rs31671	chr7:87059403	C/G	cg00919237	chr7:87102261	ABCB4	-0.4	-5.6	-0.33	5.39e-8	Gallbladder cancer;
CESC	cis	rs801193	0.967	rs2707841	chr7:66157020	A/G	cg14393609	chr7:65229607	NA	0.48	6.5	0.37	4e-10	Aortic root size;
CESC	cis	rs3733585	0.673	rs7376505	chr4:9952744	C/A	cg02734326	chr4:10020555	SLC2A9	-0.39	-5.64	-0.33	4.43e-8	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs9322193	0.923	rs10782315	chr6:150064229	T/C	cg07701084	chr6:150067640	NUP43	0.46	6.49	0.37	4.23e-10	Lung cancer;
CESC	cis	rs9399135	0.935	rs11759999	chr6:135370495	G/T	cg24558204	chr6:135376177	HBS1L	0.51	6.94	0.39	3.01e-11	Red blood cell count;
CESC	trans	rs1908814	0.516	rs56102998	chr8:11796675	G/A	cg15556689	chr8:8085844	FLJ10661	0.52	6.37	0.36	8.4e-10	Neuroticism;
CESC	cis	rs778371	0.874	rs938575	chr2:233768788	G/A	cg08000102	chr2:233561755	GIGYF2	-0.82	-10.68	-0.55	2.16e-22	Schizophrenia;
CESC	trans	rs11098499	0.566	rs7664440	chr4:120578540	A/G	cg25214090	chr10:38739885	LOC399744	0.61	8.05	0.44	2.83e-14	Corneal astigmatism;
CESC	cis	rs7923609	0.967	rs10509186	chr10:65207018	C/T	cg01631684	chr10:65280961	REEP3	-0.43	-5.39	-0.31	1.55e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs763014	1.000	rs2269558	chr16:682250	C/T	cg07256732	chr16:621771	PIGQ	-0.31	-5.4	-0.31	1.48e-7	Height;
CESC	cis	rs11098499	0.863	rs28718422	chr4:120466304	C/A	cg24375607	chr4:120327624	NA	0.44	5.36	0.31	1.84e-7	Corneal astigmatism;
CESC	trans	rs875971	0.660	rs801211	chr7:66015689	T/G	cg26939375	chr7:64535504	NA	-0.64	-8.7	-0.47	3.62e-16	Aortic root size;
CESC	cis	rs35110281	0.774	rs162344	chr21:44954522	G/A	cg01579765	chr21:45077557	HSF2BP	-0.55	-9.46	-0.5	1.75e-18	Mean corpuscular volume;
CESC	cis	rs17376456	0.825	rs17372725	chr5:93135588	C/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.61	5.26	0.31	3.01e-7	Diabetic retinopathy;
CESC	cis	rs7666738	0.887	rs34509663	chr4:98982531	C/T	cg05340658	chr4:99064831	C4orf37	0.59	7.9	0.44	7.64e-14	Colonoscopy-negative controls vs population controls;
CESC	cis	rs8017423	0.967	rs12896540	chr14:90729392	T/C	cg14092571	chr14:90743983	NA	0.55	8.12	0.45	1.74e-14	Mortality in heart failure;
CESC	cis	rs72945132	0.882	rs7114200	chr11:70186099	C/A	cg14191688	chr11:70257035	CTTN	0.44	5.34	0.31	2.01e-7	Coronary artery disease;
CESC	cis	rs561341	1.000	rs501312	chr17:30329066	A/G	cg12193833	chr17:30244370	NA	-0.73	-6.71	-0.38	1.14e-10	Hip circumference adjusted for BMI;
CESC	cis	rs34734847	0.703	rs3794215	chr12:121168083	T/C	cg21892295	chr12:121157589	UNC119B	-0.36	-5.86	-0.34	1.34e-8	Mean corpuscular volume;
CESC	cis	rs6570726	0.875	rs1883407	chr6:145823432	T/C	cg05347473	chr6:146136440	FBXO30	0.42	5.72	0.33	2.93e-8	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs79976124	0.879	rs12214239	chr6:66636059	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.73	8.2	0.45	1.02e-14	Type 2 diabetes;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg15991546	chr1:98386723	DPYD	-0.48	-6.37	-0.36	8.48e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs7772486	0.790	rs9376971	chr6:146259505	C/T	cg05347473	chr6:146136440	FBXO30	-0.55	-7.0	-0.39	2.12e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs8017423	0.935	rs8012303	chr14:90715829	G/A	cg14092571	chr14:90743983	NA	-0.58	-8.8	-0.48	1.84e-16	Mortality in heart failure;
CESC	cis	rs2836974	0.623	rs34240248	chr21:40685239	A/G	cg11644478	chr21:40555479	PSMG1	-0.8	-11.52	-0.58	3.61e-25	Cognitive function;
CESC	cis	rs6089584	0.888	rs6061405	chr20:60617033	A/G	cg24733560	chr20:60626293	TAF4	0.42	5.94	0.34	9.14e-9	Body mass index;
CESC	trans	rs1728785	1.000	rs1170434	chr16:68606590	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.71	8.42	0.46	2.43e-15	Ulcerative colitis;
CESC	cis	rs9311474	0.508	rs6786919	chr3:52599789	A/G	cg07507251	chr3:52567010	NT5DC2	0.33	5.7	0.33	3.2e-8	Electroencephalogram traits;
CESC	cis	rs9902453	0.934	rs12453172	chr17:28441590	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	7.73	0.43	2.21e-13	Coffee consumption (cups per day);
CESC	cis	rs4819052	0.851	rs4819042	chr21:46660072	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.91	13.24	0.63	4.51e-31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs3785574	0.962	rs114027117	chr17:61939935	T/A	cg06420487	chr17:61919686	SMARCD2	0.41	5.04	0.3	8.43e-7	Height;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg07546770	chr5:68665590	RAD17;TAF9	0.48	6.05	0.35	4.9e-9	Gut microbiota (bacterial taxa);
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg11289251	chr16:68056774	DDX28;DUS2L	-0.46	-6.08	-0.35	4.09e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg07308232	chr7:1071921	C7orf50	-0.39	-5.26	-0.31	2.92e-7	Longevity;Endometriosis;
CESC	cis	rs6762	0.748	rs7928935	chr11:839127	G/A	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.68	-8.52	-0.46	1.24e-15	Mean platelet volume;
CESC	cis	rs4568518	0.616	rs17661083	chr7:18004853	C/T	cg03009463	chr7:17980271	SNX13	0.4	5.31	0.31	2.35e-7	Measles;
CESC	cis	rs3105593	0.555	rs3098169	chr15:50754339	G/A	cg08437265	chr15:50716283	USP8	0.48	6.43	0.37	5.79e-10	QT interval;
CESC	cis	rs1620921	0.505	rs66496533	chr6:161210741	T/C	cg01280913	chr6:161186852	NA	-0.38	-5.43	-0.32	1.28e-7	Lipoprotein (a) - cholesterol levels;
CESC	trans	rs2085496	0.764	rs1596751	chr2:193807860	A/G	cg13976366	chr11:4414916	TRIM21	0.45	6.17	0.35	2.54e-9	Neuroticism;
CESC	cis	rs3857536	0.813	rs6455091	chr6:66949127	C/G	cg07460842	chr6:66804631	NA	-0.42	-5.29	-0.31	2.55e-7	Blood trace element (Cu levels);
CESC	cis	rs9291683	0.935	rs1860910	chr4:10275470	T/G	cg00071950	chr4:10020882	SLC2A9	0.54	8.24	0.45	7.86e-15	Bone mineral density;
CESC	trans	rs11039798	0.588	rs1814768	chr11:48987455	T/C	cg15704280	chr7:45808275	SEPT13	0.63	6.7	0.38	1.26e-10	Axial length;
CESC	cis	rs4969178	0.930	rs12601079	chr17:76400329	G/A	cg20026190	chr17:76395443	PGS1	0.46	7.35	0.41	2.41e-12	HDL cholesterol levels;
CESC	cis	rs516243	0.871	rs3748687	chr1:10736216	G/A	cg02903756	chr1:10750680	CASZ1	-0.41	-5.72	-0.33	2.88e-8	Migraine - clinic-based;
CESC	cis	rs533581	0.866	rs561795	chr16:88970818	A/G	cg16701003	chr16:89028210	CBFA2T3	0.5	7.29	0.41	3.54e-12	Social autistic-like traits;
CESC	cis	rs12477438	0.501	rs7608938	chr2:99782226	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.77	12.84	0.62	1.16e-29	Chronic sinus infection;
CESC	trans	rs2998286	1.000	rs2998286	chr10:28780373	T/C	cg06484274	chr3:142164840	XRN1	0.46	5.99	0.35	6.71e-9	Sum eosinophil basophil counts;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Eosinophil counts;
CESC	cis	rs72945132	0.882	rs12282678	chr11:70152457	G/A	cg14191688	chr11:70257035	CTTN	0.42	5.34	0.31	1.95e-7	Coronary artery disease;
CESC	cis	rs1707322	1.000	rs6675222	chr1:46326576	G/T	cg06784218	chr1:46089804	CCDC17	0.32	5.57	0.32	6.35e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9902453	0.791	rs3115100	chr17:28045744	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.76	10.15	0.53	1.14e-20	Coffee consumption (cups per day);
CESC	cis	rs7666738	0.791	rs2081621	chr4:98926753	C/A	cg17366294	chr4:99064904	C4orf37	0.6	8.22	0.45	8.9e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs8017423	0.626	rs8003363	chr14:90826840	T/C	cg14092571	chr14:90743983	NA	0.42	6.23	0.36	1.87e-9	Mortality in heart failure;
CESC	cis	rs56046484	0.871	rs34493704	chr15:85558770	A/G	cg08123816	chr15:85640762	PDE8A	-0.49	-5.77	-0.33	2.16e-8	Testicular germ cell tumor;
CESC	cis	rs6459804	1.000	rs6459805	chr7:157510294	T/C	cg05731713	chr7:157510257	PTPRN2	0.41	6.85	0.39	5.2e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs7618915	0.547	rs34610878	chr3:52759169	G/C	cg07507251	chr3:52567010	NT5DC2	0.42	7.2	0.4	6.23e-12	Bipolar disorder;
CESC	cis	rs2249625	0.844	rs2496502	chr6:72885412	G/A	cg18830697	chr6:72922368	RIMS1	-0.39	-5.5	-0.32	8.88e-8	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CESC	cis	rs12824058	0.831	rs7485200	chr12:130811641	C/T	cg24838063	chr12:130822603	PIWIL1	0.64	8.69	0.47	3.72e-16	Menopause (age at onset);
CESC	cis	rs4692589	1.000	rs11727880	chr4:170937467	C/T	cg19918862	chr4:170955249	NA	0.36	5.65	0.33	4.07e-8	Anxiety disorder;
CESC	cis	rs1670533	0.818	rs6835141	chr4:1070140	G/T	cg27284194	chr4:1044797	NA	0.46	5.99	0.35	6.7e-9	Recombination rate (females);
CESC	cis	rs1775148	1	rs1775148	chr1:205757824	C/T	cg17178900	chr1:205818956	PM20D1	0.52	7.72	0.43	2.34e-13	Prostate cancer;
CESC	cis	rs2012796	0.872	rs59397507	chr14:81821334	A/G	cg02996355	chr14:81879375	NA	0.59	6.97	0.39	2.52e-11	Night sleep phenotypes;
CESC	cis	rs1799949	1.000	rs915945	chr17:41179864	C/T	cg25072359	chr17:41440525	NA	0.51	6.61	0.38	2.11e-10	Menopause (age at onset);
CESC	cis	rs17818399	0.653	rs34050156	chr2:46777646	A/G	cg06386533	chr2:46925753	SOCS5	0.53	5.94	0.34	9.12e-9	Height;
CESC	cis	rs9611565	0.512	rs5758450	chr22:42141640	G/A	cg17376030	chr22:41985996	PMM1	-0.79	-8.34	-0.46	4.18e-15	Vitiligo;
CESC	trans	rs7824557	0.527	rs2572376	chr8:11237756	C/A	cg15556689	chr8:8085844	FLJ10661	-0.48	-6.0	-0.35	6.55e-9	Retinal vascular caliber;
CESC	cis	rs782590	0.807	rs782642	chr2:55928444	G/T	cg18811423	chr2:55921094	PNPT1	0.82	13.45	0.64	9e-32	Metabolic syndrome;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg00098451	chr1:16370634	CLCNKB	0.41	6.38	0.36	7.94e-10	Fibrinogen levels;
CESC	cis	rs1008375	1.000	rs6846238	chr4:17629939	A/G	cg02297831	chr4:17616191	MED28	0.55	6.92	0.39	3.33e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs7552404	1.000	rs12127402	chr1:76205643	C/A	cg22875332	chr1:76189707	ACADM	0.66	7.95	0.44	5.33e-14	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs9393777	0.513	rs9393737	chr6:26617306	A/G	cg12292205	chr6:26970375	C6orf41	0.46	5.38	0.31	1.61e-7	Intelligence (multi-trait analysis);
CESC	cis	rs8060686	0.516	rs10852439	chr16:68288331	T/C	cg26727032	chr16:67993705	SLC12A4	-0.61	-8.42	-0.46	2.36e-15	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs1552244	0.882	rs13075842	chr3:10055813	A/C	cg00149659	chr3:10157352	C3orf10	0.69	8.09	0.45	2.13e-14	Alzheimer's disease;
CESC	cis	rs7072216	0.727	rs942808	chr10:100168102	C/A	cg26618903	chr10:100175079	PYROXD2	-0.36	-5.49	-0.32	9.42e-8	Metabolite levels;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg14549262	chr9:131965232	NA	0.49	6.1	0.35	3.69e-9	Thyroid stimulating hormone;
CESC	cis	rs901683	1.000	rs35131026	chr10:46014759	G/A	cg16031567	chr10:46195673	NA	-0.77	-5.04	-0.3	8.57e-7	Red blood cell traits;Mean corpuscular volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08395899	chr10:12085052	UPF2	-0.72	-8.45	-0.46	1.92e-15	Gut microbiome composition (summer);
CESC	cis	rs7520050	0.966	rs2486447	chr1:46545724	G/A	cg03146154	chr1:46216737	IPP	-0.43	-5.53	-0.32	7.77e-8	Red blood cell count;Reticulocyte count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01026192	chr7:2763915	NA	-0.62	-7.03	-0.4	1.77e-11	Gut microbiome composition (summer);
CESC	cis	rs7772486	0.875	rs7767660	chr6:146436550	T/C	cg05347473	chr6:146136440	FBXO30	0.49	6.59	0.38	2.33e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1003719	0.725	rs2187101	chr21:38452379	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.62	8.64	0.47	5.58e-16	Eye color traits;
CESC	cis	rs12145833	0.748	rs11807162	chr1:243454680	C/T	cg02356786	chr1:243265016	LOC731275	0.59	5.48	0.32	9.79e-8	Obesity (early onset extreme);
CESC	cis	rs2304069	0.954	rs1433010	chr5:149383954	C/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.89	-11.55	-0.58	2.96e-25	HIV-1 control;
CESC	cis	rs5769765	0.908	rs9616217	chr22:50318946	C/T	cg02269571	chr22:50332266	NA	-0.55	-6.51	-0.37	3.85e-10	Schizophrenia;
CESC	cis	rs760805	1.000	rs11249204	chr1:25261740	C/T	cg22509179	chr1:25234806	RUNX3	0.61	8.72	0.47	3.08e-16	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs62064224	0.748	rs72813015	chr17:30693331	T/C	cg09324608	chr17:30823087	MYO1D	0.51	7.71	0.43	2.61e-13	Schizophrenia;
CESC	cis	rs55692411	0.537	rs35375092	chr3:50065274	G/A	cg24110177	chr3:50126178	RBM5	-0.44	-5.18	-0.3	4.37e-7	Intelligence (multi-trait analysis);
CESC	cis	rs9291683	0.517	rs11736479	chr4:10017387	G/C	cg00071950	chr4:10020882	SLC2A9	0.91	17.5	0.73	4.14e-46	Bone mineral density;
CESC	cis	rs2204008	0.542	rs34770471	chr12:38009613	C/T	cg26384229	chr12:38710491	ALG10B	0.74	10.71	0.55	1.77e-22	Bladder cancer;
CESC	cis	rs9815354	0.767	rs111708447	chr3:41809583	G/A	cg03022575	chr3:42003672	ULK4	0.68	6.06	0.35	4.7e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs2280018	0.963	rs11075255	chr16:15166232	A/G	cg07549590	chr16:15018862	NA	-0.48	-7.73	-0.43	2.19e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24342864	chr17:17184608	COPS3	-0.63	-8.1	-0.45	2.01e-14	Gut microbiome composition (summer);
CESC	cis	rs116095464	1.000	rs6555160	chr5:311669	A/G	cg22857025	chr5:266934	NA	1.14	10.04	0.53	2.53e-20	Breast cancer;
CESC	trans	rs864643	0.773	rs11129837	chr3:39589963	A/G	cg09491787	chr5:139781927	ANKHD1;ANKHD1-EIF4EBP3	0.47	6.05	0.35	4.89e-9	Attention deficit hyperactivity disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13787782	chr2:239161568	PER2	-0.58	-6.49	-0.37	4.31e-10	Gut microbiome composition (summer);
CESC	cis	rs2204008	0.645	rs9989043	chr12:38238505	G/A	cg26384229	chr12:38710491	ALG10B	-0.47	-6.14	-0.35	2.95e-9	Bladder cancer;
CESC	cis	rs9611565	0.659	rs9611609	chr22:41945357	C/A	cg03806693	chr22:41940476	POLR3H	-1.24	-16.82	-0.72	1.04e-43	Vitiligo;
CESC	trans	rs61931739	0.500	rs35391785	chr12:34444478	C/T	cg26384229	chr12:38710491	ALG10B	0.71	10.54	0.54	6.31e-22	Morning vs. evening chronotype;
CESC	cis	rs7917772	0.503	rs7078435	chr10:104304766	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.53	7.33	0.41	2.72e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs2637266	0.703	rs4437973	chr10:78484971	G/A	cg18941641	chr10:78392320	NA	0.4	7.54	0.42	7.54e-13	Pulmonary function;
CESC	cis	rs2228479	0.850	rs62056061	chr16:89901767	G/A	cg00800038	chr16:89945340	TCF25	-0.89	-6.89	-0.39	4.13e-11	Skin colour saturation;
CESC	cis	rs853679	1.000	rs853679	chr6:28296863	C/A	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.68	7.15	0.4	8.65e-12	Depression;
CESC	trans	rs7944735	0.545	rs4752805	chr11:48018355	A/G	cg15704280	chr7:45808275	SEPT13	0.68	8.16	0.45	1.33e-14	Intraocular pressure;
CESC	cis	rs2635047	0.600	rs2635056	chr18:44710568	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.41	5.59	0.32	5.7e-8	Educational attainment;
CESC	cis	rs3096299	0.934	rs9927904	chr16:89462847	G/A	cg16743903	chr16:89593216	SPG7	-0.42	-5.38	-0.31	1.65e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs736408	0.609	rs2230535	chr3:52800284	T/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.3	5.21	0.3	3.8e-7	Bipolar disorder;
CESC	cis	rs2033711	0.870	rs1465789	chr19:58946056	C/T	cg11952622	chr19:58962976	ZNF324B	0.45	5.93	0.34	9.38e-9	Uric acid clearance;
CESC	cis	rs7819412	0.527	rs7821914	chr8:10805015	A/G	cg21775007	chr8:11205619	TDH	-0.35	-5.13	-0.3	5.68e-7	Triglycerides;
CESC	cis	rs6582618	1	rs6582618	chr12:38726137	A/G	cg26384229	chr12:38710491	ALG10B	0.57	8.32	0.46	4.71e-15	Morning vs. evening chronotype;
CESC	cis	rs4969178	0.600	rs4969183	chr17:76393372	A/G	cg05887092	chr17:76393375	PGS1	0.68	11.47	0.58	5.58e-25	HDL cholesterol levels;
CESC	cis	rs7267979	1.000	rs6050562	chr20:25336186	C/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.84	-16.48	-0.71	1.75e-42	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs1552244	1.000	rs2272125	chr3:10138069	A/C	cg00149659	chr3:10157352	C3orf10	0.71	8.62	0.47	6.15e-16	Alzheimer's disease;
CESC	cis	rs7666738	0.830	rs28594127	chr4:99001121	T/G	cg18180107	chr4:99064573	C4orf37	0.4	5.23	0.31	3.41e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4654899	1.000	rs6663452	chr1:21423154	T/C	cg05370193	chr1:21551575	ECE1	0.39	5.95	0.34	8.65e-9	Superior frontal gyrus grey matter volume;
CESC	trans	rs1814175	0.645	rs7119101	chr11:49955665	G/A	cg15704280	chr7:45808275	SEPT13	-1.01	-19.02	-0.76	1.83e-51	Height;
CESC	cis	rs736408	0.677	rs1042779	chr3:52821011	A/G	cg18404041	chr3:52824283	ITIH1	-0.44	-7.31	-0.41	3.24e-12	Bipolar disorder;
CESC	cis	rs796364	0.806	rs188102	chr2:200903189	T/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.87	-8.14	-0.45	1.58e-14	Schizophrenia;
CESC	cis	rs1882538	0.551	rs6974618	chr7:133084031	C/A	cg10665199	chr7:133106180	EXOC4	0.61	8.41	0.46	2.55e-15	Intelligence (multi-trait analysis);
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg11698762	chr2:74648964	WDR54	0.5	6.75	0.38	9.2e-11	Systemic lupus erythematosus;
CESC	trans	rs79976124	0.837	rs10498840	chr6:66658513	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.81	9.24	0.49	8.29e-18	Type 2 diabetes;
CESC	cis	rs7223966	0.960	rs2319990	chr17:61705397	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	7.3	0.41	3.26e-12	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs7130144	0.541	rs1921572	chr11:130461520	A/G	cg26307797	chr11:130446613	NA	-0.74	-6.41	-0.37	6.65e-10	Urate levels in lean individuals;
CESC	cis	rs7818345	0.967	rs13255677	chr8:19288985	C/T	cg11303988	chr8:19266685	CSGALNACT1	0.33	5.94	0.34	9.12e-9	Language performance in older adults (adjusted for episodic memory);
CESC	cis	rs875971	0.522	rs781144	chr7:65440344	C/G	cg18876405	chr7:65276391	NA	0.73	9.96	0.52	4.56e-20	Aortic root size;
CESC	trans	rs17685	0.671	rs10274404	chr7:75706634	G/A	cg19862616	chr7:65841803	NCRNA00174	0.85	12.47	0.61	2.13e-28	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs853679	0.550	rs9295762	chr6:28155418	C/T	cg20151795	chr6:28129481	ZNF389	-0.38	-5.09	-0.3	6.78e-7	Depression;
CESC	cis	rs7552404	0.961	rs1767458	chr1:76219155	A/G	cg03433033	chr1:76189801	ACADM	0.71	9.78	0.52	1.68e-19	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs9916302	0.861	rs12150493	chr17:37586154	T/C	cg15445000	chr17:37608096	MED1	0.41	6.74	0.38	9.67e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs7184046	0.797	rs13737	chr15:75932129	G/T	cg20655648	chr15:75932815	IMP3	0.53	6.55	0.37	3.06e-10	Height;
CESC	cis	rs901683	1.000	rs17157880	chr10:46014488	A/G	cg16031567	chr10:46195673	NA	-0.77	-5.04	-0.3	8.57e-7	Red blood cell traits;Mean corpuscular volume;
CESC	cis	rs7264396	0.790	rs6060519	chr20:34217383	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.87	-11.93	-0.59	1.51e-26	Total cholesterol levels;
CESC	cis	rs11719291	0.833	rs11709246	chr3:48859498	G/A	cg00383909	chr3:49044727	WDR6	0.92	6.66	0.38	1.62e-10	Cognitive function;
CESC	cis	rs801193	1.000	rs2707845	chr7:66198798	C/T	cg14393609	chr7:65229607	NA	0.47	6.31	0.36	1.17e-9	Aortic root size;
CESC	trans	rs1814175	0.669	rs10839315	chr11:49654406	G/A	cg03929089	chr4:120376271	NA	-0.74	-9.52	-0.5	1.12e-18	Height;
CESC	cis	rs10504229	0.724	rs16922734	chr8:58111192	C/T	cg02725872	chr8:58115012	NA	-0.45	-7.04	-0.4	1.66e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs698833	0.886	rs4953087	chr2:44561627	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.57	7.14	0.4	8.89e-12	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs597539	0.617	rs598353	chr11:68635770	C/A	cg04772025	chr11:68637568	NA	0.55	6.49	0.37	4.17e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs2836974	0.897	rs8132295	chr21:40527774	A/G	cg11644478	chr21:40555479	PSMG1	-1.03	-17.64	-0.73	1.33e-46	Cognitive function;
CESC	cis	rs736408	0.812	rs6778329	chr3:52824610	G/A	cg18337363	chr3:52569053	NT5DC2	0.3	5.09	0.3	6.83e-7	Bipolar disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27488751	chr21:43916608	RSPH1	0.56	6.02	0.35	5.75e-9	Gut microbiome composition (summer);
CESC	trans	rs3780486	0.846	rs10971420	chr9:33125000	T/C	cg04842962	chr6:43655489	MRPS18A	1.01	19.48	0.77	4.55e-53	IgG glycosylation;
CESC	cis	rs8062405	0.690	rs762634	chr16:28603335	T/C	cg07382826	chr16:28625726	SULT1A1	0.4	6.48	0.37	4.38e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs2629540	0.847	rs34032724	chr10:126408869	T/G	cg08799069	chr10:126477246	METTL10	0.59	7.49	0.42	1.02e-12	Cocaine dependence;
CESC	cis	rs7044106	0.500	rs56725168	chr9:123492576	T/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.37	5.89	0.34	1.15e-8	Hip circumference adjusted for BMI;
CESC	cis	rs798554	0.959	rs798558	chr7:2758935	T/G	cg13628971	chr7:2884303	GNA12	0.58	7.46	0.42	1.26e-12	Height;
CESC	cis	rs7520050	0.933	rs6680211	chr1:46315007	C/G	cg24296786	chr1:45957014	TESK2	0.42	5.42	0.32	1.33e-7	Red blood cell count;Reticulocyte count;
CESC	cis	rs7216064	0.906	rs7223643	chr17:65830282	A/G	cg07042672	chr17:66097459	LOC651250	-0.53	-5.91	-0.34	1.04e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25320668	chr1:205196970	TMCC2	0.59	6.92	0.39	3.38e-11	Gut microbiome composition (summer);
CESC	cis	rs796364	0.806	rs12616905	chr2:201007764	C/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.72	-6.48	-0.37	4.47e-10	Schizophrenia;
CESC	cis	rs72829446	0.530	rs4796421	chr17:7379650	C/T	cg02795151	chr17:7402630	POLR2A	0.62	6.47	0.37	4.72e-10	Androgen levels;
CESC	cis	rs9660992	0.736	rs72745207	chr1:205251991	C/G	cg00857998	chr1:205179979	DSTYK	0.47	5.36	0.31	1.83e-7	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs4144027	0.904	rs10438242	chr14:104345075	C/T	cg08213375	chr14:104286397	PPP1R13B	-0.29	-5.07	-0.3	7.56e-7	Blood metabolite levels;
CESC	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg07092213	chr7:1199455	ZFAND2A	-0.43	-5.06	-0.3	7.75e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs10751667	0.621	rs7394681	chr11:952111	C/T	cg06064525	chr11:970664	AP2A2	-0.48	-9.51	-0.5	1.2e-18	Alzheimer's disease (late onset);
CESC	cis	rs7786808	0.712	rs2335167	chr7:158213948	A/C	cg09998033	chr7:158218633	PTPRN2	-0.42	-6.12	-0.35	3.31e-9	Obesity-related traits;
CESC	cis	rs2243480	0.803	rs403089	chr7:65517723	T/C	cg12463550	chr7:65579703	CRCP	0.67	5.38	0.31	1.67e-7	Diabetic kidney disease;
CESC	cis	rs2243480	1.000	rs4718334	chr7:65789454	G/A	cg12463550	chr7:65579703	CRCP	-0.66	-5.3	-0.31	2.46e-7	Diabetic kidney disease;
CESC	cis	rs2576037	0.545	rs9948405	chr18:44494527	C/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.36	5.83	0.34	1.6e-8	Personality dimensions;
CESC	cis	rs1372520	0.684	rs2737030	chr4:90710099	C/T	cg15133208	chr4:90757351	SNCA	-0.4	-5.3	-0.31	2.43e-7	Neuroticism;
CESC	cis	rs7824557	0.767	rs11775635	chr8:11164865	G/A	cg21775007	chr8:11205619	TDH	0.5	7.27	0.41	4e-12	Retinal vascular caliber;
CESC	cis	rs9929218	0.817	rs3114405	chr16:68722377	G/A	cg02972257	chr16:68554789	NA	0.6	6.53	0.37	3.42e-10	Colorectal cancer;
CESC	cis	rs113835537	0.529	rs11227502	chr11:66274148	T/G	cg24851651	chr11:66362959	CCS	0.43	5.41	0.32	1.4e-7	Airway imaging phenotypes;
CESC	cis	rs11711311	0.955	rs34458493	chr3:113396473	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.53	6.58	0.37	2.54e-10	IgG glycosylation;
CESC	cis	rs2072732	0.861	rs6679678	chr1:2950594	T/C	cg03976712	chr1:2946727	NA	0.33	5.45	0.32	1.17e-7	Plateletcrit;
CESC	cis	rs1915146	0.967	rs7086481	chr10:126844523	A/T	cg17191109	chr10:126851326	NA	-0.54	-9.16	-0.49	1.43e-17	Menarche (age at onset);
CESC	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg06873352	chr17:61820015	STRADA	0.72	12.3	0.6	8.09e-28	Prudent dietary pattern;
CESC	trans	rs629535	0.814	rs604254	chr8:70059164	A/G	cg21567404	chr3:27674614	NA	0.89	10.42	0.54	1.56e-21	Dupuytren's disease;
CESC	cis	rs78456975	1.000	rs10205916	chr2:1558451	A/T	cg26248373	chr2:1572462	NA	0.59	5.57	0.32	6.27e-8	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs16917546	0.967	rs10995239	chr10:64388365	A/G	cg03961010	chr10:64397487	ZNF365	-0.39	-6.22	-0.36	1.92e-9	Basal cell carcinoma;
CESC	cis	rs1707322	0.752	rs12062535	chr1:46222880	G/A	cg06784218	chr1:46089804	CCDC17	0.41	7.21	0.41	5.75e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7923609	0.869	rs10733792	chr10:65232539	A/G	cg01631684	chr10:65280961	REEP3	-0.44	-5.44	-0.32	1.2e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs10032549	0.535	rs1511817	chr4:77386678	A/G	cg20311846	chr4:77356250	SHROOM3	0.29	5.48	0.32	1e-7	Glomerular filtration rate;
CESC	cis	rs7301826	0.932	rs1007246	chr12:131280130	T/A	cg11011512	chr12:131303247	STX2	0.41	5.25	0.31	3.1e-7	Plasma plasminogen activator levels;
CESC	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg00852768	chr6:163834924	QKI	-0.4	-6.07	-0.35	4.35e-9	Metabolic traits;
CESC	cis	rs2576037	0.526	rs7240239	chr18:44460037	T/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.32	5.04	0.3	8.76e-7	Personality dimensions;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06130371	chr15:65578830	PARP16	0.55	6.08	0.35	4.22e-9	Gut microbiome composition (summer);
CESC	cis	rs9303280	0.806	rs9907088	chr17:38035116	G/A	cg19468946	chr17:37922297	IKZF3	-0.41	-5.42	-0.32	1.31e-7	Self-reported allergy;
CESC	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg03647317	chr4:187891568	NA	-0.38	-5.7	-0.33	3.21e-8	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs13118159	0.801	rs13147602	chr4:1332175	A/G	cg02018176	chr4:1364513	KIAA1530	0.42	5.61	0.33	5.08e-8	Longevity;
CESC	cis	rs7772486	0.846	rs1474871	chr6:146406294	G/A	cg05347473	chr6:146136440	FBXO30	0.5	6.76	0.38	8.77e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs8067354	0.574	rs2526358	chr17:57942585	A/G	cg02344993	chr17:57696989	CLTC	0.53	5.45	0.32	1.14e-7	Hemoglobin concentration;
CESC	cis	rs9660180	0.967	rs6603803	chr1:1812688	A/G	cg23982607	chr1:1823379	GNB1	-0.8	-13.13	-0.63	1.14e-30	Body mass index;
CESC	cis	rs8038465	0.662	rs7497012	chr15:73968719	G/A	cg15420318	chr15:73925796	NPTN	0.53	7.85	0.43	1.05e-13	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs2516839	0.652	rs2516841	chr1:161010774	A/G	cg11161846	chr1:160990452	F11R	-0.44	-6.06	-0.35	4.53e-9	Granulocyte percentage of myeloid white cells;
CESC	cis	rs2242116	0.734	rs4683294	chr3:46979013	C/G	cg02527881	chr3:46936655	PTH1R	0.4	5.82	0.34	1.69e-8	Birth weight;
CESC	cis	rs13256369	1.000	rs10088439	chr8:8576699	T/G	cg17143192	chr8:8559678	CLDN23	0.71	8.34	0.46	4.02e-15	Obesity-related traits;
CESC	cis	rs116095464	0.558	rs12173244	chr5:269524	G/A	cg20965017	chr5:231967	SDHA	-0.48	-5.44	-0.32	1.22e-7	Breast cancer;
CESC	cis	rs10504229	1.000	rs66936919	chr8:58172868	C/G	cg24829409	chr8:58192753	C8orf71	-0.75	-9.9	-0.52	7.27e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs4665809	0.590	rs7588328	chr2:26469788	G/A	cg27170947	chr2:26402098	FAM59B	0.87	9.85	0.52	1.01e-19	Gut microbiome composition (summer);
CESC	cis	rs72781680	0.752	rs72796130	chr2:23919740	T/C	cg20701182	chr2:24300061	SF3B14	0.79	6.88	0.39	4.25e-11	Lymphocyte counts;
CESC	cis	rs56104184	0.723	rs1058483	chr19:49407660	G/A	cg15549821	chr19:49342101	PLEKHA4	-0.57	-5.73	-0.33	2.67e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	cis	rs7666738	0.830	rs13133619	chr4:99067312	C/G	cg17366294	chr4:99064904	C4orf37	-0.61	-8.72	-0.47	3.14e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1552244	0.935	rs4441636	chr3:10083876	G/A	cg08888203	chr3:10149979	C3orf24	0.46	5.9	0.34	1.11e-8	Alzheimer's disease;
CESC	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg26338869	chr17:61819248	STRADA	0.67	8.79	0.48	1.9e-16	Prudent dietary pattern;
CESC	cis	rs4665809	0.590	rs7604564	chr2:26501953	C/A	cg22920501	chr2:26401640	FAM59B	0.92	10.56	0.54	5.52e-22	Gut microbiome composition (summer);
CESC	cis	rs708547	0.647	rs1718878	chr4:57876955	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.47	6.61	0.38	2.11e-10	Response to bleomycin (chromatid breaks);
CESC	trans	rs61931739	0.500	rs7296061	chr12:34435009	A/G	cg26384229	chr12:38710491	ALG10B	-0.67	-9.97	-0.52	4.27e-20	Morning vs. evening chronotype;
CESC	cis	rs514406	0.621	rs1930306	chr1:53195686	C/G	cg27535305	chr1:53392650	SCP2	0.32	5.13	0.3	5.71e-7	Monocyte count;
CESC	cis	rs477692	0.673	rs579952	chr10:131356084	A/T	cg24747557	chr10:131355152	MGMT	0.39	5.37	0.31	1.72e-7	Response to temozolomide;
CESC	cis	rs6582630	0.502	rs11504451	chr12:38425294	G/A	cg26384229	chr12:38710491	ALG10B	0.68	10.04	0.52	2.6e-20	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs2806561	0.808	rs2294518	chr1:23372771	T/C	cg12483005	chr1:23474871	LUZP1	-0.34	-5.3	-0.31	2.42e-7	Height;
CESC	cis	rs13064447	0.753	rs9811396	chr3:12747915	A/G	cg23032965	chr3:12705835	RAF1	0.41	5.15	0.3	5.14e-7	Major depression and alcohol dependence;
CESC	trans	rs66573146	0.831	rs73088564	chr4:6984553	G/C	cg07817883	chr1:32538562	TMEM39B	1.21	7.99	0.44	4.16e-14	Granulocyte percentage of myeloid white cells;
CESC	cis	rs2425143	1.000	rs74785978	chr20:34373234	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.79	-7.12	-0.4	1.01e-11	Blood protein levels;
CESC	cis	rs4523957	0.651	rs9906705	chr17:2063714	T/G	cg16513277	chr17:2031491	SMG6	-0.72	-10.2	-0.53	8.12e-21	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs1775715	0.737	rs2778650	chr10:32106851	A/G	cg18675610	chr10:32216311	ARHGAP12	0.34	5.27	0.31	2.85e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg18402987	chr7:1209562	NA	0.73	7.36	0.41	2.28e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs13191362	1.000	rs13192894	chr6:163052444	T/A	cg14584255	chr6:163149320	PACRG;PARK2	0.52	5.7	0.33	3.12e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs1552244	1.000	rs67134728	chr3:10151431	G/C	cg08888203	chr3:10149979	C3orf24	0.45	5.71	0.33	3.04e-8	Alzheimer's disease;
CESC	cis	rs921968	0.541	rs593888	chr2:219427597	A/G	cg02176678	chr2:219576539	TTLL4	0.49	8.92	0.48	7.68e-17	Mean corpuscular hemoglobin concentration;
CESC	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.54	6.58	0.37	2.56e-10	Prudent dietary pattern;
CESC	cis	rs684232	0.583	rs10521106	chr17:510707	C/T	cg12384639	chr17:618140	VPS53	0.4	5.1	0.3	6.44e-7	Prostate cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00985205	chr4:71570491	RUFY3	0.55	6.43	0.37	5.96e-10	Gut microbiome composition (summer);
CESC	cis	rs2708240	0.666	rs2538962	chr7:147600604	C/A	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.35	-5.77	-0.33	2.18e-8	QT interval (drug interaction);
CESC	cis	rs2191566	0.691	rs59086054	chr19:44549096	C/A	cg20607764	chr19:44506953	ZNF230	-0.43	-5.52	-0.32	8.25e-8	Acute lymphoblastic leukemia (childhood);
CESC	trans	rs12505749	1.000	rs17756240	chr4:57355192	G/C	cg09583921	chr3:87101925	NA	0.97	6.07	0.35	4.48e-9	Airflow obstruction;
CESC	cis	rs4253772	0.530	rs11090865	chr22:46731689	G/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.65	5.71	0.33	3.07e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs6963495	0.818	rs73190202	chr7:105166510	A/G	cg19920283	chr7:105172520	RINT1	0.7	6.68	0.38	1.39e-10	Bipolar disorder (body mass index interaction);
CESC	cis	rs2439831	0.850	rs12441127	chr15:44021175	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.71	6.76	0.38	8.96e-11	Lung cancer in ever smokers;
CESC	cis	rs1153858	1.000	rs9788780	chr15:45685487	T/A	cg14582100	chr15:45693742	SPATA5L1	0.41	5.77	0.33	2.17e-8	Homoarginine levels;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg02772733	chr9:139703466	C9orf86;LOC100131193	-0.47	-6.68	-0.38	1.36e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs7267979	1.000	rs2258879	chr20:25279213	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	18.72	0.75	2.09e-50	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs763014	1.000	rs2269558	chr16:682250	C/T	cg09263875	chr16:632152	PIGQ	0.68	11.77	0.59	5.12e-26	Height;
CESC	cis	rs412050	1.000	rs239916	chr22:22316272	G/A	cg17089214	chr22:22089827	YPEL1	0.65	6.03	0.35	5.37e-9	Attention deficit hyperactivity disorder;
CESC	cis	rs2235642	0.928	rs56289115	chr16:1608934	A/G	cg09080909	chr16:1797204	MAPK8IP3	-0.37	-5.21	-0.3	3.79e-7	Coronary artery disease;
CESC	cis	rs6500602	0.893	rs4786490	chr16:4491190	C/T	cg08645402	chr16:4508243	NA	-0.44	-6.63	-0.38	1.86e-10	Schizophrenia;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg08318582	chr11:109920663	NA	-0.44	-6.09	-0.35	3.89e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg00761755	chr17:1531579	SLC43A2	0.46	6.13	0.35	3.2e-9	Systemic lupus erythematosus;
CESC	trans	rs1941023	0.672	rs2155710	chr11:60269240	C/T	cg05115468	chr11:62623202	SNORD27;SLC3A2;SNORD26;SNORD28;SNORD25;SNHG1	0.55	6.6	0.38	2.29e-10	Congenital heart disease (maternal effect);
CESC	cis	rs1107366	0.750	rs9825571	chr3:125900161	A/G	cg20988073	chr3:125900093	ALDH1L1	-0.36	-5.12	-0.3	5.96e-7	Metabolite levels;
CESC	cis	rs7833790	0.724	rs4739627	chr8:82734657	A/G	cg07697082	chr8:82753677	SNX16	0.39	6.08	0.35	4.26e-9	Diastolic blood pressure;
CESC	cis	rs2836950	0.501	rs2836983	chr21:40689336	G/A	cg11890956	chr21:40555474	PSMG1	-0.65	-9.1	-0.49	2.28e-17	Menarche (age at onset);
CESC	cis	rs9291683	0.530	rs17246501	chr4:9985710	A/C	cg00071950	chr4:10020882	SLC2A9	0.77	13.84	0.65	3.79e-33	Bone mineral density;
CESC	cis	rs7589728	0.563	rs75606549	chr2:88466069	T/C	cg04511125	chr2:88470314	THNSL2	0.7	6.79	0.38	7.52e-11	Plasma clusterin levels;
CESC	cis	rs287982	0.932	rs11887231	chr2:9967116	C/A	cg10881225	chr2:9984929	TAF1B	0.4	5.16	0.3	4.94e-7	Nonsyndromic cleft lip with cleft palate;
CESC	cis	rs116095464	0.510	rs10057501	chr5:239545	T/C	cg10591111	chr5:226296	SDHA	-0.5	-6.13	-0.35	3.17e-9	Breast cancer;
CESC	cis	rs13095912	0.785	rs6791954	chr3:185335709	C/T	cg11274856	chr3:185301563	NA	-0.37	-5.65	-0.33	4.05e-8	Systolic blood pressure;
CESC	cis	rs5167	0.504	rs7258345	chr19:45453151	T/G	cg13119609	chr19:45449297	APOC2	0.49	8.03	0.44	3.21e-14	Blood protein levels;
CESC	cis	rs7834588	0.523	rs4623409	chr8:63829131	A/G	cg20602954	chr8:63776762	NKAIN3	0.3	5.04	0.3	8.69e-7	Response to Vitamin E supplementation;
CESC	cis	rs8062405	0.964	rs7187333	chr16:28865916	G/A	cg05966235	chr16:28915196	ATP2A1	0.34	5.03	0.3	9.05e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg26354017	chr1:205819088	PM20D1	0.8	11.85	0.59	2.77e-26	Menarche (age at onset);
CESC	cis	rs761746	0.804	rs5749304	chr22:31967775	A/G	cg25791279	chr22:32026902	PISD	-0.55	-6.29	-0.36	1.33e-9	Intelligence;
CESC	cis	rs2721195	0.967	rs1480000	chr8:145702007	C/T	cg15320075	chr8:145703422	NA	-0.71	-10.2	-0.53	7.78e-21	Age at first birth;
CESC	cis	rs10242455	0.702	rs76840929	chr7:98945858	T/C	cg25640893	chr7:99214727	ZNF498	0.85	5.71	0.33	3.01e-8	Blood metabolite levels;
CESC	cis	rs6991838	0.584	rs4737748	chr8:66525865	C/T	cg13398993	chr8:66546079	ARMC1	0.46	5.65	0.33	4.19e-8	Intelligence (multi-trait analysis);
CESC	cis	rs4665809	0.941	rs41285975	chr2:26351144	T/C	cg27170947	chr2:26402098	FAM59B	-0.59	-7.07	-0.4	1.36e-11	Gut microbiome composition (summer);
CESC	cis	rs10504229	0.906	rs73607868	chr8:58172482	T/C	cg05313129	chr8:58192883	C8orf71	-0.55	-6.37	-0.36	8.42e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs7949030	0.591	rs35156678	chr11:62369881	G/A	cg13298116	chr11:62369859	EML3;MTA2	0.65	9.39	0.5	2.97e-18	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg25367318	chr6:138725211	HEBP2	0.48	6.32	0.36	1.1e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs7666738	0.791	rs34790496	chr4:98930516	C/T	cg17366294	chr4:99064904	C4orf37	0.58	8.02	0.44	3.43e-14	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11252926	0.574	rs7068976	chr10:453112	A/G	cg16386425	chr10:429943	DIP2C	-0.55	-7.02	-0.4	1.89e-11	Psychosis in Alzheimer's disease;
CESC	cis	rs116095464	0.558	rs34629844	chr5:200829	A/G	cg22496380	chr5:211416	CCDC127	-0.95	-10.43	-0.54	1.43e-21	Breast cancer;
CESC	cis	rs7737355	0.812	rs7729787	chr5:131066577	A/C	cg06307176	chr5:131281290	NA	0.38	5.15	0.3	5.19e-7	Life satisfaction;
CESC	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.54	0.37	3.16e-10	Prudent dietary pattern;
CESC	cis	rs6460942	0.915	rs7809263	chr7:12450589	C/G	cg16278512	chr7:12443529	VWDE	-0.52	-5.71	-0.33	3.08e-8	Coronary artery disease;
CESC	cis	rs2235642	0.928	rs1057610	chr16:1605537	T/C	cg08296037	chr16:1584118	IFT140;TMEM204	-0.31	-5.19	-0.3	4.13e-7	Coronary artery disease;
CESC	cis	rs9487051	0.837	rs932223	chr6:109586656	A/G	cg01475377	chr6:109611718	NA	-0.48	-7.91	-0.44	7.09e-14	Reticulocyte fraction of red cells;
CESC	cis	rs6860806	0.507	rs274572	chr5:131710917	T/G	cg24060327	chr5:131705240	SLC22A5	0.76	10.65	0.55	2.72e-22	Breast cancer;
CESC	cis	rs1395	0.744	rs4665962	chr2:27515105	A/G	cg22903471	chr2:27725779	GCKR	-0.5	-6.08	-0.35	4.12e-9	Blood metabolite levels;
CESC	cis	rs72781680	0.611	rs36052574	chr2:24306587	A/C	cg08917208	chr2:24149416	ATAD2B	0.6	5.66	0.33	3.99e-8	Lymphocyte counts;
CESC	cis	rs524023	0.914	rs11607663	chr11:64368670	G/C	cg07220939	chr11:64358617	SLC22A12	-0.36	-5.36	-0.31	1.82e-7	Urate levels in obese individuals;
CESC	cis	rs13102973	0.965	rs13108037	chr4:135885643	A/G	cg14419869	chr4:135874104	NA	-0.33	-5.17	-0.3	4.66e-7	Subjective well-being;
CESC	cis	rs1552244	1.000	rs12152512	chr3:10143770	C/T	cg08888203	chr3:10149979	C3orf24	0.45	5.79	0.34	1.94e-8	Alzheimer's disease;
CESC	cis	rs896854	0.654	rs28591375	chr8:95973637	C/G	cg23172400	chr8:95962367	TP53INP1	-0.45	-9.25	-0.49	8.02e-18	Type 2 diabetes;
CESC	cis	rs17666538	0.710	rs12716640	chr8:645376	A/C	cg23958373	chr8:599963	NA	0.8	6.97	0.39	2.54e-11	IgG glycosylation;
CESC	cis	rs4072980	0.545	rs16824518	chr1:38415315	A/C	cg12658694	chr1:38397304	INPP5B	-0.67	-8.89	-0.48	9.96e-17	Coronary artery disease;
CESC	cis	rs8067545	0.611	rs2013443	chr17:20023109	G/C	cg13482628	chr17:19912719	NA	0.43	5.72	0.33	2.88e-8	Schizophrenia;
CESC	cis	rs9311474	1.000	rs7629072	chr3:52305633	C/T	cg25934064	chr3:52569026	NT5DC2	0.27	5.38	0.31	1.61e-7	Electroencephalogram traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	ch.15.1525362R	chr15:89706202	ABHD2	-0.58	-6.64	-0.38	1.74e-10	Gut microbiome composition (summer);
CESC	cis	rs919433	0.783	rs788014	chr2:198228997	G/A	cg03934865	chr2:198174659	NA	0.43	6.18	0.35	2.41e-9	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs7772486	0.686	rs857875	chr6:145980033	T/G	cg23711669	chr6:146136114	FBXO30	-0.91	-13.7	-0.64	1.16e-32	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6693567	0.565	rs834225	chr1:150300727	T/C	cg09579323	chr1:150459698	TARS2	0.48	6.11	0.35	3.63e-9	Migraine;
CESC	cis	rs4819052	0.788	rs4819051	chr21:46693128	C/T	cg11663144	chr21:46675770	NA	-0.62	-9.82	-0.52	1.27e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08524698	chr22:21213167	SNAP29;PI4KA	0.52	6.3	0.36	1.22e-9	Gut microbiome composition (summer);
CESC	cis	rs2832191	0.791	rs2251517	chr21:30531951	T/G	cg08807101	chr21:30365312	RNF160	0.76	10.63	0.55	3.33e-22	Dental caries;
CESC	cis	rs6812193	0.518	rs28864163	chr4:77195106	G/C	cg20311846	chr4:77356250	SHROOM3	0.3	5.2	0.3	4.06e-7	Parkinson's disease;
CESC	cis	rs8005677	0.962	rs10130756	chr14:23396600	C/G	cg01529538	chr14:23388837	RBM23	0.51	6.84	0.39	5.51e-11	Cognitive ability (multi-trait analysis);
CESC	cis	rs7917772	0.636	rs1475644	chr10:104491164	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.46	5.4	0.32	1.45e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs4975709	0.801	rs3797063	chr5:1881549	A/T	cg15595755	chr5:1867978	NA	0.44	6.77	0.38	8.35e-11	Cardiovascular disease risk factors;
CESC	cis	rs117623576	1.000	rs117623576	chr10:32387808	C/T	cg03047570	chr10:32398778	NA	-0.8	-7.21	-0.4	5.83e-12	Anti-saccade response;
CESC	cis	rs2832191	1.000	rs2832190	chr21:30488226	G/A	cg08807101	chr21:30365312	RNF160	-0.67	-9.05	-0.49	3.2e-17	Dental caries;
CESC	cis	rs60311166	1.000	rs7643568	chr3:52578474	A/G	cg13174197	chr3:52720522	GNL3;PBRM1	0.7	5.13	0.3	5.71e-7	CTACK levels;
CESC	trans	rs11039798	1.000	rs7942042	chr11:48520270	A/G	cg15704280	chr7:45808275	SEPT13	0.69	6.39	0.37	7.41e-10	Axial length;
CESC	cis	rs853679	0.517	rs9295759	chr6:28124469	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.61	-6.96	-0.39	2.6e-11	Depression;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26313349	chr1:145589328	NUDT17	0.64	7.67	0.43	3.33e-13	Gut microbiome composition (summer);
CESC	cis	rs733175	0.904	rs3775944	chr4:10019974	G/T	cg00071950	chr4:10020882	SLC2A9	0.56	6.2	0.36	2.16e-9	Psychosis and Alzheimer's disease;
CESC	cis	rs143699489	1	rs143699489	chr3:140927121	A/G	cg16418163	chr3:140950828	ACPL2	0.65	6.52	0.37	3.5e-10	White blood cell count;Granulocyte count;Sum neutrophil eosinophil counts;
CESC	cis	rs4819052	0.851	rs2838858	chr21:46681093	T/A	cg11663144	chr21:46675770	NA	-0.56	-8.66	-0.47	4.69e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs4851551	1.000	rs4851552	chr2:102802333	G/A	cg09363443	chr2:102758946	NA	0.61	5.11	0.3	6.23e-7	Blood protein levels;
CESC	cis	rs2839186	0.770	rs2839171	chr21:47673247	C/T	cg11766577	chr21:47581405	C21orf56	0.49	6.83	0.39	5.68e-11	Testicular germ cell tumor;
CESC	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg17178900	chr1:205818956	PM20D1	0.81	12.96	0.62	4.5e-30	Menarche (age at onset);
CESC	cis	rs250677	0.687	rs250666	chr5:148454622	A/G	cg18129178	chr5:148520854	ABLIM3	-0.51	-5.91	-0.34	1.05e-8	Breast cancer;
CESC	cis	rs858239	0.601	rs1034963	chr7:23148473	T/C	cg23682824	chr7:23144976	KLHL7	0.55	7.81	0.43	1.35e-13	Cerebrospinal fluid biomarker levels;
CESC	cis	rs7666738	0.830	rs7672127	chr4:98938477	A/G	cg17366294	chr4:99064904	C4orf37	0.6	8.29	0.45	5.6e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2991971	0.782	rs10789463	chr1:45927848	C/A	cg24296786	chr1:45957014	TESK2	-0.61	-8.88	-0.48	1.06e-16	High light scatter reticulocyte count;
CESC	cis	rs3767633	0.800	rs6685369	chr1:161754834	T/C	cg09175582	chr1:161736000	ATF6	0.8	6.57	0.37	2.59e-10	IgG glycosylation;
CESC	cis	rs12476592	0.602	rs262488	chr2:63882179	C/T	cg17519650	chr2:63277830	OTX1	-0.45	-5.06	-0.3	8.03e-7	Childhood ear infection;
CESC	cis	rs8062405	1.000	rs80275162	chr16:28863517	T/A	cg08761264	chr16:28874980	SH2B1	-0.45	-5.66	-0.33	3.9e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs9287719	0.901	rs10210859	chr2:10733929	C/T	cg00105475	chr2:10696890	NA	0.39	5.69	0.33	3.35e-8	Prostate cancer;
CESC	cis	rs7618915	0.547	rs12486847	chr3:52691112	T/C	cg18099408	chr3:52552593	STAB1	-0.31	-5.16	-0.3	4.9e-7	Bipolar disorder;
CESC	cis	rs9649213	0.614	rs2240348	chr7:97984077	C/T	cg09267113	chr7:98030324	BAIAP2L1	-0.45	-6.17	-0.35	2.58e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs561341	1.000	rs1557731	chr17:30321567	T/G	cg12193833	chr17:30244370	NA	-0.59	-5.92	-0.34	9.93e-9	Hip circumference adjusted for BMI;
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg19279529	chr19:35760554	USF2	-0.46	-6.21	-0.36	2.03e-9	Vertical cup-disc ratio;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21542780	chr2:234763377	HJURP	0.55	6.07	0.35	4.51e-9	Gut microbiome composition (summer);
CESC	cis	rs2932538	0.922	rs7527076	chr1:113150481	G/A	cg22162597	chr1:113214053	CAPZA1	0.59	7.46	0.42	1.28e-12	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CESC	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.07	20.05	0.78	4.94e-55	Prudent dietary pattern;
CESC	cis	rs1008375	0.932	rs10009933	chr4:17670107	A/C	cg02297831	chr4:17616191	MED28	0.5	5.94	0.34	8.77e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs9300255	0.602	rs11057192	chr12:123693420	T/C	cg00376283	chr12:123451042	ABCB9	0.7	8.83	0.48	1.41e-16	Neutrophil percentage of white cells;
CESC	cis	rs10504229	0.639	rs67002486	chr8:58117218	A/G	cg02725872	chr8:58115012	NA	-0.45	-7.05	-0.4	1.52e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs7772486	0.875	rs1330939	chr6:146308518	T/A	cg05347473	chr6:146136440	FBXO30	0.53	7.12	0.4	1.02e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6500602	0.679	rs736685	chr16:4508606	T/C	cg08645402	chr16:4508243	NA	0.56	8.82	0.48	1.53e-16	Schizophrenia;
CESC	trans	rs17764205	0.777	rs112570652	chr19:3255789	G/A	cg12868887	chr11:70244470	CTTN	0.78	6.08	0.35	4.14e-9	Bipolar disorder and schizophrenia;
CESC	trans	rs7009110	0.527	rs7822342	chr8:81246699	C/T	cg21552319	chr6:24356996	DCDC2;KAAG1	-0.36	-6.09	-0.35	4e-9	Asthma and hay fever;
CESC	cis	rs8028313	0.504	rs2899730	chr15:68172520	G/T	cg26545918	chr15:68124484	LBXCOR1	-0.31	-5.21	-0.3	3.77e-7	Obesity;
CESC	cis	rs62344088	0.590	rs62346174	chr5:296308	C/A	cg22857025	chr5:266934	NA	-1.25	-7.24	-0.41	4.88e-12	Asthma (childhood onset);
CESC	cis	rs11718455	0.960	rs4682713	chr3:44013191	G/C	cg08738300	chr3:44038990	NA	0.47	6.0	0.35	6.51e-9	Coronary artery disease;
CESC	trans	rs7246657	0.943	rs12709813	chr19:37844983	G/A	cg24637308	chr11:6592297	DNHD1	0.53	6.17	0.35	2.55e-9	Coronary artery calcification;
CESC	cis	rs7336332	0.598	rs1885989	chr13:28010117	G/A	cg22138327	chr13:27999177	GTF3A	0.63	5.88	0.34	1.21e-8	Weight;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03321319	chr22:22222323	MAPK1	0.57	6.6	0.38	2.21e-10	Gut microbiome composition (summer);
CESC	cis	rs12926788	0.689	rs34365165	chr16:24856208	G/A	cg04756594	chr16:24857601	SLC5A11	0.45	5.21	0.3	3.83e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs959260	1.000	rs7226070	chr17:73372811	T/C	cg20590849	chr17:73267439	MIF4GD	-0.55	-6.44	-0.37	5.48e-10	Systemic lupus erythematosus;
CESC	cis	rs3020736	0.500	rs5996111	chr22:42493902	C/T	cg04733989	chr22:42467013	NAGA	-0.82	-12.04	-0.59	6.5e-27	Autism spectrum disorder or schizophrenia;
CESC	cis	rs7666738	0.830	rs6831588	chr4:98977356	T/G	cg17366294	chr4:99064904	C4orf37	0.59	8.43	0.46	2.31e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs769267	1.000	rs12985655	chr19:19442434	G/A	cg15052019	chr19:19431593	KIAA0892;SF4	-0.43	-5.46	-0.32	1.11e-7	Tonsillectomy;
CESC	cis	rs2481665	0.680	rs2481671	chr1:62611666	A/C	cg18591186	chr1:62594603	INADL	-0.42	-5.18	-0.3	4.3e-7	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs7264396	0.635	rs2064724	chr20:34522520	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.58	6.99	0.39	2.22e-11	Total cholesterol levels;
CESC	cis	rs3859192	0.599	rs2227319	chr17:38170845	G/A	cg17467752	chr17:38218738	THRA	-0.45	-5.96	-0.34	7.93e-9	White blood cell count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	ch.7.1264585R	chr7:55212640	EGFR	-0.63	-7.27	-0.41	4.16e-12	Gut microbiome composition (summer);
CESC	cis	rs6141600	0.760	rs2746103	chr20:34703934	T/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.4	5.36	0.31	1.81e-7	Height;Hip circumference;
CESC	cis	rs2243480	1.000	rs2961102	chr7:65424658	A/G	cg12463550	chr7:65579703	CRCP	0.69	5.49	0.32	9.63e-8	Diabetic kidney disease;
CESC	cis	rs829883	0.738	rs249846	chr12:98868739	T/C	cg25150519	chr12:98850993	NA	0.85	14.58	0.67	9.66e-36	Colorectal adenoma (advanced);
CESC	cis	rs9911578	0.967	rs6503883	chr17:56917543	C/T	cg05425664	chr17:57184151	TRIM37	-0.5	-6.92	-0.39	3.44e-11	Intelligence (multi-trait analysis);
CESC	cis	rs10883723	0.810	rs10748824	chr10:104274466	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.55	7.58	0.42	5.73e-13	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs10870270	0.956	rs7894	chr10:133769482	G/C	cg08754478	chr10:133766260	PPP2R2D	-0.59	-7.52	-0.42	8.44e-13	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg11387077	chr7:30544503	GGCT	-0.46	-5.99	-0.35	6.71e-9	Ulcerative colitis;
CESC	cis	rs7827545	0.620	rs6578009	chr8:135522989	T/C	cg17885191	chr8:135476712	NA	-0.56	-7.53	-0.42	7.97e-13	Hypertension (SNP x SNP interaction);
CESC	cis	rs7193541	0.640	rs4072222	chr16:74706736	A/C	cg05580060	chr16:74700937	RFWD3	-0.44	-5.73	-0.33	2.67e-8	Multiple myeloma;
CESC	cis	rs736408	0.509	rs13083798	chr3:52649748	A/G	cg18404041	chr3:52824283	ITIH1	-0.32	-5.8	-0.34	1.84e-8	Bipolar disorder;
CESC	cis	rs193541	0.632	rs1363200	chr5:122163802	G/T	cg19412675	chr5:122181750	SNX24	0.45	5.15	0.3	4.98e-7	Glucose homeostasis traits;
CESC	cis	rs858239	0.601	rs6948469	chr7:23174766	G/T	cg23682824	chr7:23144976	KLHL7	0.53	7.35	0.41	2.41e-12	Cerebrospinal fluid biomarker levels;
CESC	cis	rs2997447	0.653	rs56134135	chr1:26440718	A/T	cg24596570	chr1:26146463	FAM54B;LOC646471	0.62	5.33	0.31	2.07e-7	QRS complex (12-leadsum);
CESC	cis	rs7208859	0.673	rs3764421	chr17:29167653	A/C	cg19761014	chr17:28927070	LRRC37B2	0.72	5.68	0.33	3.48e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs7605827	0.866	rs2160696	chr2:15518983	A/T	cg19274914	chr2:15703543	NA	0.36	6.45	0.37	5.37e-10	Educational attainment (years of education);
CESC	cis	rs6952808	0.931	rs12537430	chr7:1868761	A/G	cg04267008	chr7:1944627	MAD1L1	0.55	6.72	0.38	1.11e-10	Bipolar disorder and schizophrenia;
CESC	cis	rs5753618	0.529	rs5749298	chr22:31941032	C/T	cg00478049	chr22:31556069	RNF185	-0.48	-5.81	-0.34	1.79e-8	Colorectal cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02908720	chr7:127292155	SND1	0.59	6.8	0.39	7.02e-11	Gut microbiome composition (summer);
CESC	cis	rs2011503	1.000	rs77427798	chr19:19652982	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.52	5.12	0.3	5.87e-7	Bipolar disorder;
CESC	cis	rs854765	0.647	rs854790	chr17:18028318	C/G	cg04398451	chr17:18023971	MYO15A	-0.78	-10.97	-0.56	2.39e-23	Total body bone mineral density;
CESC	cis	rs7267979	0.932	rs1985737	chr20:25591468	T/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.73	12.75	0.62	2.34e-29	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs10479542	1.000	rs10479542	chr5:178981241	T/A	cg19626725	chr5:178986131	RUFY1	0.39	6.37	0.36	8.51e-10	Lung cancer;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg24043307	chr12:51157954	ATF1	0.47	6.34	0.36	1e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs5758343	1	rs5758343	chr22:41816652	A/T	cg06481639	chr22:41940642	POLR3H	0.64	6.41	0.37	6.77e-10	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs10883723	0.669	rs2001595	chr10:104395085	C/T	cg22532475	chr10:104410764	TRIM8	-0.45	-6.89	-0.39	4.1e-11	Allergic disease (asthma, hay fever or eczema);
CESC	trans	rs60380162	0.963	rs4259617	chr1:87725048	G/A	cg20163645	chr8:1900353	ARHGEF10	-0.43	-6.03	-0.35	5.48e-9	Loneliness (linear analysis);
CESC	cis	rs939658	0.805	rs34222382	chr15:79440748	C/T	cg17916960	chr15:79447300	NA	-0.37	-6.12	-0.35	3.31e-9	Refractive error;
CESC	cis	rs6540559	0.546	rs634601	chr1:210421594	C/T	cg22029157	chr1:209979665	IRF6	0.48	5.89	0.34	1.2e-8	Cleft lip with or without cleft palate;
CESC	cis	rs34779708	0.897	rs11010131	chr10:35513316	A/C	cg03585969	chr10:35415529	CREM	0.75	9.3	0.5	5.36e-18	Inflammatory bowel disease;Crohn's disease;
CESC	trans	rs66573146	0.572	rs66611116	chr4:6953270	A/G	cg07817883	chr1:32538562	TMEM39B	1.14	7.95	0.44	5.27e-14	Granulocyte percentage of myeloid white cells;
CESC	cis	rs2353275	0.655	rs2140669	chr10:88278368	A/G	cg07322936	chr10:88137208	NA	0.95	5.86	0.34	1.4e-8	Asthma (childhood onset);Asthma;
CESC	cis	rs10463316	0.823	rs7700340	chr5:150776320	C/T	cg03212797	chr5:150827313	SLC36A1	-0.45	-5.9	-0.34	1.12e-8	Metabolite levels (Pyroglutamine);
CESC	cis	rs4835473	0.932	rs13147386	chr4:144657739	C/T	cg25736465	chr4:144833511	NA	0.33	5.16	0.3	4.91e-7	Immature fraction of reticulocytes;
CESC	cis	rs80282103	0.618	rs2279256	chr10:1132852	G/A	cg08668510	chr10:1095578	IDI1	0.71	5.54	0.32	7.34e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs853679	0.517	rs9468286	chr6:28079428	C/T	cg22143856	chr6:28129313	ZNF389	0.52	6.71	0.38	1.21e-10	Depression;
CESC	cis	rs2072732	0.861	rs72629497	chr1:2954123	T/C	cg03976712	chr1:2946727	NA	0.33	5.53	0.32	7.83e-8	Plateletcrit;
CESC	cis	rs9303401	1.000	rs1390006	chr17:56890663	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.72	-9.36	-0.5	3.51e-18	Cognitive test performance;
CESC	cis	rs2204008	0.729	rs2892365	chr12:38446760	G/C	cg13010199	chr12:38710504	ALG10B	-0.42	-5.52	-0.32	8.07e-8	Bladder cancer;
CESC	cis	rs67072384	1.000	rs7124056	chr11:72444747	C/T	cg04827223	chr11:72435913	ARAP1	0.66	7.59	0.42	5.37e-13	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
CESC	cis	rs6137287	0.722	rs1007226	chr20:21103987	A/G	cg13880779	chr20:21376337	NKX2-4	0.33	5.14	0.3	5.26e-7	Height;
CESC	cis	rs9916302	0.904	rs6503507	chr17:37525274	C/T	cg00129232	chr17:37814104	STARD3	0.59	7.82	0.43	1.22e-13	Glomerular filtration rate (creatinine);
CESC	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.48	-5.04	-0.3	8.58e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs1008375	1.000	rs28552744	chr4:17620165	A/G	cg02297831	chr4:17616191	MED28	0.53	6.73	0.38	1.04e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs1552244	1.000	rs76041173	chr3:10078695	G/T	cg00166722	chr3:10149974	C3orf24	0.48	6.15	0.35	2.89e-9	Alzheimer's disease;
CESC	cis	rs9837602	1.000	rs6802422	chr3:99778655	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.47	-6.58	-0.37	2.47e-10	Breast cancer;
CESC	cis	rs35110281	0.666	rs9977076	chr21:45085829	G/A	cg21573476	chr21:45109991	RRP1B	-0.59	-8.63	-0.47	5.87e-16	Mean corpuscular volume;
CESC	cis	rs780096	0.526	rs75855890	chr2:27625005	G/T	cg12648201	chr2:27665141	KRTCAP3	-0.29	-5.31	-0.31	2.36e-7	Total body bone mineral density;
CESC	cis	rs1270639	0.778	rs1796272	chr7:157437832	C/T	cg13357408	chr7:157437802	PTPRN2	-0.58	-6.88	-0.39	4.27e-11	Colorectal cancer;
CESC	cis	rs2425143	0.547	rs6141583	chr20:34572834	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-5.8	-0.34	1.88e-8	Blood protein levels;
CESC	cis	rs113835537	0.529	rs7950790	chr11:66258053	G/A	cg22134325	chr11:66188745	NPAS4	0.34	5.27	0.31	2.82e-7	Airway imaging phenotypes;
CESC	cis	rs616402	0.527	rs11584327	chr1:10578791	T/C	cg17425144	chr1:10567563	PEX14	0.38	6.03	0.35	5.6e-9	Breast size;
CESC	cis	rs898097	0.841	rs4986122	chr17:80825500	C/T	cg10494973	chr17:80897199	TBCD	0.51	5.89	0.34	1.14e-8	Breast cancer;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg27376817	chr7:75931888	HSPB1	0.45	6.16	0.35	2.62e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs2439831	0.867	rs16957632	chr15:43642897	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.85	12.05	0.59	6.08e-27	Lung cancer in ever smokers;
CESC	cis	rs4835473	0.897	rs7662736	chr4:144879189	C/T	cg25736465	chr4:144833511	NA	0.39	5.89	0.34	1.16e-8	Immature fraction of reticulocytes;
CESC	cis	rs1552244	0.688	rs7645137	chr3:10020549	A/AT	cg08888203	chr3:10149979	C3orf24	0.49	6.12	0.35	3.29e-9	Alzheimer's disease;
CESC	cis	rs731174	1.000	rs731174	chr1:38196841	C/T	cg12339802	chr1:38156545	C1orf109	0.48	5.6	0.33	5.37e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7412746	0.611	rs111905669	chr1:150777565	T/C	cg09365446	chr1:150670422	GOLPH3L	0.4	5.24	0.31	3.36e-7	Melanoma;
CESC	cis	rs6690583	1.000	rs10443172	chr1:85485768	T/C	cg11262906	chr1:85462892	MCOLN2	-0.52	-5.85	-0.34	1.46e-8	Serum sulfate level;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg22516162	chr12:133363304	GOLGA3	0.46	6.0	0.35	6.52e-9	Fibrinogen levels;
CESC	cis	rs875971	1.000	rs1565531	chr7:65663113	T/A	cg18876405	chr7:65276391	NA	-0.53	-7.16	-0.4	7.93e-12	Aortic root size;
CESC	cis	rs4699052	0.927	rs1870888	chr4:104169326	G/C	cg16532752	chr4:104119610	CENPE	-0.39	-5.31	-0.31	2.27e-7	Testicular germ cell tumor;
CESC	cis	rs1692580	0.870	rs262680	chr1:2167149	C/T	cg21194808	chr1:2205498	SKI	0.39	5.76	0.33	2.38e-8	Coronary artery disease;
CESC	cis	rs6736093	0.931	rs34974369	chr2:112683390	G/A	cg12686935	chr2:112915763	FBLN7	-0.43	-5.56	-0.32	6.75e-8	Coronary artery disease;
CESC	cis	rs6951245	0.572	rs73264010	chr7:1040477	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.56	5.1	0.3	6.34e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs4319547	0.585	rs10846792	chr12:122882374	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.52	-5.99	-0.35	6.78e-9	Body mass index;
CESC	cis	rs3806843	0.932	rs2563256	chr5:140141779	G/T	cg26395211	chr5:140044315	WDR55	0.39	5.17	0.3	4.51e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs7666738	0.830	rs13124127	chr4:98990729	G/A	cg17366294	chr4:99064904	C4orf37	0.59	8.43	0.46	2.2e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6736093	0.763	rs11690440	chr2:112820109	G/A	cg12686935	chr2:112915763	FBLN7	-0.42	-5.5	-0.32	9.14e-8	Coronary artery disease;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg19110795	chr3:196159589	UBXN7	-0.41	-6.14	-0.35	3.03e-9	Gambling;
CESC	trans	rs11098499	0.866	rs11098506	chr4:120284971	A/G	cg25214090	chr10:38739885	LOC399744	0.66	8.99	0.48	4.91e-17	Corneal astigmatism;
CESC	cis	rs4423214	1.000	rs12785878	chr11:71167449	G/T	cg05163923	chr11:71159392	DHCR7	0.76	10.52	0.54	7.37e-22	Vitamin D levels;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg07496882	chr10:112631570	LOC282997;PDCD4	-0.46	-6.08	-0.35	4.12e-9	Ulcerative colitis;
CESC	cis	rs514406	0.893	rs2897561	chr1:53388747	C/A	cg24675658	chr1:53192096	ZYG11B	-0.52	-6.38	-0.36	8.06e-10	Monocyte count;
CESC	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg14893161	chr1:205819251	PM20D1	0.99	19.25	0.76	2.91e-52	Menarche (age at onset);
CESC	cis	rs4268898	0.662	rs17789375	chr2:24502554	G/T	cg06627628	chr2:24431161	ITSN2	-0.97	-11.69	-0.58	1.01e-25	Asthma;
CESC	cis	rs2289583	0.544	rs12050759	chr15:75265191	G/A	cg14664628	chr15:75095509	CSK	0.52	6.07	0.35	4.51e-9	Systemic lupus erythematosus;
CESC	cis	rs155076	0.711	rs4769158	chr13:21881975	T/C	cg25811766	chr13:21894605	NA	0.56	5.64	0.33	4.32e-8	White matter hyperintensity burden;
CESC	trans	rs7922314	0.571	rs61865710	chr10:64735714	T/C	cg06935979	chr1:232941706	KIAA1383	-0.69	-6.41	-0.37	6.71e-10	Cutaneous psoriasis;
CESC	cis	rs9788682	0.747	rs8042059	chr15:78907859	A/C	cg24631222	chr15:78858424	CHRNA5	0.77	9.28	0.5	6.25e-18	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs9902453	0.845	rs7218113	chr17:28372130	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.67	-8.69	-0.47	3.79e-16	Coffee consumption (cups per day);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg02685945	chr6:22570146	HDGFL1	0.57	7.5	0.42	9.38e-13	Fibrinogen levels;
CESC	cis	rs7520050	0.807	rs72688483	chr1:46149209	A/G	cg24296786	chr1:45957014	TESK2	-0.48	-6.14	-0.35	2.96e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs317689	0.918	rs581911	chr12:69738293	C/T	cg14784868	chr12:69753453	YEATS4	0.59	6.63	0.38	1.84e-10	Response to diuretic therapy;
CESC	cis	rs2228479	0.867	rs12919804	chr16:89945369	G/A	cg06558623	chr16:89946397	TCF25	1.06	8.98	0.48	5.17e-17	Skin colour saturation;
CESC	cis	rs9916302	0.706	rs4795385	chr17:37733148	A/G	cg07936489	chr17:37558343	FBXL20	0.97	10.88	0.56	4.83e-23	Glomerular filtration rate (creatinine);
CESC	cis	rs2932538	0.922	rs7551933	chr1:113086706	C/T	cg22162597	chr1:113214053	CAPZA1	-0.58	-7.23	-0.41	5.13e-12	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CESC	cis	rs116095464	0.558	rs2162870	chr5:228129	G/A	cg22857025	chr5:266934	NA	-1.28	-18.8	-0.76	1.06e-50	Breast cancer;
CESC	cis	rs7631605	0.875	rs56198917	chr3:37017798	C/G	cg22985146	chr3:37219077	LRRFIP2	-0.33	-5.05	-0.3	8.06e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs561341	1.000	rs7210970	chr17:30262169	G/A	cg12193833	chr17:30244370	NA	-0.49	-5.49	-0.32	9.5e-8	Hip circumference adjusted for BMI;
CESC	cis	rs2040771	0.740	rs9617783	chr22:19260575	C/A	cg02655711	chr22:19163373	SLC25A1	0.41	5.88	0.34	1.23e-8	Metabolite levels (small molecules and protein measures);
CESC	trans	rs61931739	0.534	rs11053020	chr12:34111092	C/G	cg26384229	chr12:38710491	ALG10B	0.6	8.45	0.46	1.98e-15	Morning vs. evening chronotype;
CESC	cis	rs637571	0.522	rs649000	chr11:65742933	T/C	cg17985854	chr11:65770987	BANF1;EIF1AD	0.45	6.64	0.38	1.82e-10	Eosinophil percentage of white cells;
CESC	cis	rs6500602	0.701	rs6500614	chr16:4573938	A/G	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.35	5.04	0.3	8.82e-7	Schizophrenia;
CESC	cis	rs56235845	0.694	rs4976643	chr5:176760227	A/C	cg06060754	chr5:176797920	RGS14	0.41	5.13	0.3	5.5e-7	Hemoglobin concentration;Hematocrit;
CESC	cis	rs9300255	0.566	rs10744150	chr12:123721614	A/C	cg19016782	chr12:123741754	C12orf65	-0.36	-5.3	-0.31	2.43e-7	Neutrophil percentage of white cells;
CESC	cis	rs10743315	0.557	rs74974316	chr12:19344688	A/G	cg02471346	chr12:19282374	PLEKHA5	0.68	5.06	0.3	7.71e-7	Gut microbiota (bacterial taxa);
CESC	cis	rs600231	0.706	rs10896016	chr11:65335705	C/T	cg17120908	chr11:65337727	SSSCA1	0.52	5.79	0.33	2.02e-8	Bone mineral density;
CESC	cis	rs9913156	0.707	rs72835625	chr17:4560274	G/A	cg19197139	chr17:4613644	ARRB2	0.92	10.46	0.54	1.18e-21	Lymphocyte counts;
CESC	cis	rs35110281	0.811	rs2838339	chr21:45075750	A/G	cg21573476	chr21:45109991	RRP1B	0.5	6.91	0.39	3.52e-11	Mean corpuscular volume;
CESC	cis	rs7084402	0.967	rs1593677	chr10:60291642	A/T	cg07615347	chr10:60278583	BICC1	0.6	9.41	0.5	2.54e-18	Refractive error;
CESC	cis	rs9311474	0.597	rs13303	chr3:52558008	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.38	-5.57	-0.32	6.2e-8	Electroencephalogram traits;
CESC	cis	rs950776	0.518	rs12906284	chr15:78825105	C/T	cg24631222	chr15:78858424	CHRNA5	-0.42	-5.33	-0.31	2.09e-7	Sudden cardiac arrest;
CESC	cis	rs801193	1.000	rs10274773	chr7:66133578	G/A	cg18876405	chr7:65276391	NA	-0.54	-7.06	-0.4	1.46e-11	Aortic root size;
CESC	cis	rs2180341	0.960	rs9375503	chr6:127677071	T/C	cg24812749	chr6:127587940	RNF146	1.05	15.07	0.68	1.77e-37	Breast cancer;
CESC	cis	rs11690935	0.959	rs75922913	chr2:172620152	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.97	-14.87	-0.67	9.1e-37	Schizophrenia;
CESC	cis	rs12042052	0.793	rs12036759	chr1:232925441	A/G	cg06935979	chr1:232941706	KIAA1383	0.75	6.05	0.35	4.96e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CESC	cis	rs9640161	0.663	rs1916932	chr7:150021644	T/C	cg10018233	chr7:150070692	REPIN1	0.45	7.27	0.41	4.12e-12	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs6502050	0.835	rs35857672	chr17:80078303	G/A	cg23985595	chr17:80112537	CCDC57	0.41	6.54	0.37	3.19e-10	Life satisfaction;
CESC	cis	rs6424115	0.729	rs586173	chr1:24055718	A/G	cg10978503	chr1:24200527	CNR2	-0.26	-5.14	-0.3	5.3e-7	Immature fraction of reticulocytes;
CESC	cis	rs9393777	0.513	rs9348728	chr6:26634436	G/A	cg11502198	chr6:26597334	ABT1	0.52	5.34	0.31	1.99e-7	Intelligence (multi-trait analysis);
CESC	cis	rs1448094	0.511	rs10506923	chr12:86152595	C/T	cg00310523	chr12:86230176	RASSF9	-0.31	-5.04	-0.3	8.55e-7	Major depressive disorder;
CESC	cis	rs4819052	0.851	rs2838849	chr21:46671027	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.45	5.6	0.33	5.33e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs11711311	0.955	rs9866806	chr3:113379865	C/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	-0.6	-7.66	-0.43	3.42e-13	IgG glycosylation;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg09559324	chr16:31475905	ARMC5	0.48	6.23	0.36	1.79e-9	Fibrinogen levels;
CESC	trans	rs12310956	0.532	rs10844720	chr12:33987859	G/T	cg26384229	chr12:38710491	ALG10B	0.48	6.64	0.38	1.82e-10	Morning vs. evening chronotype;
CESC	trans	rs1814175	0.615	rs4545557	chr11:50027329	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.42	-6.13	-0.35	3.1e-9	Height;
CESC	cis	rs10504229	0.593	rs78459635	chr8:58004995	G/T	cg02725872	chr8:58115012	NA	-0.38	-5.1	-0.3	6.54e-7	Developmental language disorder (linguistic errors);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17801256	chr1:35734334	ZMYM4	0.58	6.71	0.38	1.19e-10	Gut microbiome composition (summer);
CESC	cis	rs796364	0.806	rs11694236	chr2:200916230	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.84	-7.75	-0.43	1.94e-13	Schizophrenia;
CESC	cis	rs763121	0.819	rs5757133	chr22:38947835	A/G	cg14440974	chr22:39074834	NA	0.38	5.18	0.3	4.38e-7	Menopause (age at onset);
CESC	trans	rs656319	0.647	rs13264668	chr8:9884877	C/T	cg06636001	chr8:8085503	FLJ10661	-0.51	-6.17	-0.35	2.51e-9	Myopia (pathological);
CESC	cis	rs8114671	0.836	rs745849	chr20:33572178	G/A	cg24642439	chr20:33292090	TP53INP2	-0.45	-5.35	-0.31	1.91e-7	Height;
CESC	cis	rs10089	1.000	rs10478796	chr5:127436187	A/G	cg19767477	chr5:127420684	SLC12A2	-0.42	-5.8	-0.34	1.85e-8	Ileal carcinoids;
CESC	cis	rs7618501	0.602	rs2301166	chr3:50148305	C/G	cg24308560	chr3:49941425	MST1R	0.61	8.81	0.48	1.71e-16	Intelligence (multi-trait analysis);
CESC	cis	rs35306767	0.903	rs12260800	chr10:927933	T/C	cg26597838	chr10:835615	NA	0.83	8.95	0.48	6.34e-17	Eosinophil percentage of granulocytes;
CESC	cis	rs10911251	0.527	rs1537520	chr1:183084229	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.89	14.02	0.65	8.78e-34	Colorectal cancer;
CESC	cis	rs611744	0.647	rs6981420	chr8:109266694	T/G	cg21045802	chr8:109455806	TTC35	0.48	5.99	0.35	6.89e-9	Dupuytren's disease;
CESC	cis	rs7618915	0.501	rs34739010	chr3:52766122	A/G	cg18404041	chr3:52824283	ITIH1	-0.39	-6.65	-0.38	1.72e-10	Bipolar disorder;
CESC	cis	rs752010	0.714	rs10890144	chr1:42085397	G/T	cg06885757	chr1:42089581	HIVEP3	0.51	8.81	0.48	1.66e-16	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs769267	0.895	rs2905435	chr19:19495954	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.57	-7.48	-0.42	1.09e-12	Tonsillectomy;
CESC	cis	rs7959452	0.532	rs2291005	chr12:69764388	A/G	cg14784868	chr12:69753453	YEATS4	0.83	12.94	0.62	5.03e-30	Blood protein levels;
CESC	cis	rs6912958	0.525	rs586771	chr6:88064971	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.34	5.75	0.33	2.48e-8	Monocyte percentage of white cells;
CESC	cis	rs847577	0.677	rs10242903	chr7:97741795	C/T	cg24562669	chr7:97807699	LMTK2	-0.57	-8.36	-0.46	3.53e-15	Breast cancer;
CESC	cis	rs8133932	0.654	rs410902	chr21:47341794	G/A	cg14185626	chr21:47401492	COL6A1	-0.45	-5.09	-0.3	6.84e-7	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13076329	chr4:114682704	CAMK2D	0.62	6.82	0.39	6.15e-11	Gut microbiome composition (summer);
CESC	cis	rs7647973	1.000	rs3866330	chr3:49582994	T/C	cg07636037	chr3:49044803	WDR6	0.7	10.34	0.54	2.84e-21	Menarche (age at onset);
CESC	cis	rs13242816	1.000	rs35505552	chr7:116104867	T/A	cg04696780	chr7:116139425	CAV2	-0.62	-5.69	-0.33	3.31e-8	P wave duration;
CESC	cis	rs7647973	1.000	rs6805609	chr3:49471522	C/G	cg07636037	chr3:49044803	WDR6	-0.65	-8.06	-0.44	2.68e-14	Menarche (age at onset);
CESC	cis	rs7429990	0.813	rs7627568	chr3:48093052	A/T	cg11946769	chr3:48343235	NME6	-0.45	-5.4	-0.31	1.51e-7	Educational attainment (years of education);
CESC	cis	rs4253772	0.550	rs6007830	chr22:46711323	C/T	cg18190219	chr22:46762943	CELSR1	-0.58	-6.63	-0.38	1.91e-10	LDL cholesterol;Cholesterol, total;
CESC	cis	rs7635838	0.684	rs2606762	chr3:11343889	G/C	cg00170343	chr3:11313890	ATG7	0.54	7.65	0.43	3.71e-13	HDL cholesterol;
CESC	cis	rs6679073	1.000	rs10494874	chr1:205754688	C/G	cg17178900	chr1:205818956	PM20D1	0.39	5.28	0.31	2.65e-7	Prostate-specific antigen levels;
CESC	cis	rs644799	1.000	rs568668	chr11:95528209	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.52	6.29	0.36	1.32e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs4979906	1.000	rs1609790	chr10:79464078	C/T	cg07817648	chr10:79422355	NA	-0.55	-5.88	-0.34	1.21e-8	Mortality in heart failure;
CESC	cis	rs7584330	0.657	rs10202599	chr2:238352465	A/C	cg14458575	chr2:238380390	NA	0.64	8.81	0.48	1.7e-16	Prostate cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03532930	chr1:2246464	NA	0.54	6.18	0.35	2.39e-9	Gut microbiome composition (summer);
CESC	cis	rs1008375	0.932	rs6449317	chr4:17631253	T/C	cg15017067	chr4:17643749	FAM184B	0.38	5.06	0.3	7.86e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs7267979	0.933	rs2258728	chr20:25276343	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	18.69	0.75	2.61e-50	Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06310022	chr3:114095810	ZBTB20	-0.59	-7.15	-0.4	8.26e-12	Gut microbiome composition (summer);
CESC	cis	rs2303759	0.918	rs2288480	chr19:49867016	C/G	cg22307029	chr19:49891270	CCDC155	0.7	8.38	0.46	3.2e-15	Multiple sclerosis;
CESC	cis	rs12824058	0.831	rs7979497	chr12:130804706	C/T	cg26677194	chr12:130822605	PIWIL1	0.49	6.24	0.36	1.74e-9	Menopause (age at onset);
CESC	cis	rs2479724	0.811	rs6905726	chr6:41750812	T/C	cg17623882	chr6:41773611	USP49	0.41	5.57	0.32	6.22e-8	Menarche (age at onset);
CESC	cis	rs873946	0.648	rs12771651	chr10:134554482	C/A	cg06453172	chr10:134556979	INPP5A	-0.41	-5.35	-0.31	1.91e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs875971	0.522	rs1701760	chr7:65473688	A/G	cg25985355	chr7:65971099	NA	-0.32	-5.32	-0.31	2.16e-7	Aortic root size;
CESC	cis	rs4665809	0.590	rs34728554	chr2:26481959	C/G	cg25036284	chr2:26402008	FAM59B	0.86	9.36	0.5	3.44e-18	Gut microbiome composition (summer);
CESC	cis	rs6570726	0.846	rs426874	chr6:145880630	A/C	cg05347473	chr6:146136440	FBXO30	0.49	6.46	0.37	4.91e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs959260	0.688	rs4789173	chr17:73349497	T/C	cg20590849	chr17:73267439	MIF4GD	-0.56	-6.11	-0.35	3.55e-9	Systemic lupus erythematosus;
CESC	cis	rs10465746	0.725	rs12070578	chr1:84349607	A/G	cg10977910	chr1:84465055	TTLL7	0.56	7.74	0.43	2.09e-13	Obesity-related traits;
CESC	cis	rs951366	0.649	rs7522056	chr1:205735891	A/G	cg07167872	chr1:205819463	PM20D1	0.4	5.5	0.32	8.95e-8	Menarche (age at onset);
CESC	cis	rs4253772	0.701	rs9627280	chr22:46643964	T/C	cg24881330	chr22:46731750	TRMU	0.73	8.07	0.44	2.51e-14	LDL cholesterol;Cholesterol, total;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg13474011	chr10:49515374	NA	0.5	6.54	0.37	3.11e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs2439831	0.681	rs825740	chr15:43592408	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.89	13.12	0.63	1.22e-30	Lung cancer in ever smokers;
CESC	cis	rs12497850	0.931	rs6446253	chr3:48911443	C/T	cg06212747	chr3:49208901	KLHDC8B	0.67	9.12	0.49	1.91e-17	Parkinson's disease;
CESC	cis	rs950776	0.518	rs12902493	chr15:78819275	C/G	cg24631222	chr15:78858424	CHRNA5	-0.41	-5.23	-0.31	3.48e-7	Sudden cardiac arrest;
CESC	cis	rs4819052	0.851	rs2255774	chr21:46683851	A/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.68	9.68	0.51	3.61e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs9346455	1.000	rs9354986	chr6:71996205	G/C	cg27238071	chr6:71998145	OGFRL1	0.56	5.08	0.3	7e-7	Antipsychotic drug-induced weight gain (time interaction);Antipsychotic drug-induced weight gain;
CESC	cis	rs6028335	0.610	rs6729	chr20:37668272	A/G	cg16355469	chr20:37678765	NA	0.52	5.13	0.3	5.47e-7	Alcohol and nicotine co-dependence;
CESC	cis	rs853679	0.517	rs9380052	chr6:28064623	A/G	cg12963246	chr6:28129442	ZNF389	0.51	6.66	0.38	1.59e-10	Depression;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg25215298	chr1:860022	SAMD11	-0.47	-6.49	-0.37	4.18e-10	Ulcerative colitis;
CESC	cis	rs79349575	0.715	rs4793997	chr17:47019672	C/A	cg16584676	chr17:46985605	UBE2Z	0.54	6.67	0.38	1.46e-10	Type 2 diabetes;
CESC	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg26338869	chr17:61819248	STRADA	0.67	8.78	0.47	2.04e-16	Prudent dietary pattern;
CESC	cis	rs4523957	0.547	rs11078856	chr17:2092064	G/A	cg16513277	chr17:2031491	SMG6	-0.64	-8.96	-0.48	6.1e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20723414	chr7:157207071	DNAJB6	-0.56	-6.01	-0.35	5.96e-9	Gut microbiome composition (summer);
CESC	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg26338869	chr17:61819248	STRADA	0.7	9.3	0.5	5.3e-18	Prudent dietary pattern;
CESC	cis	rs7296418	0.619	rs7139321	chr12:123719528	T/G	cg05973401	chr12:123451056	ABCB9	0.49	6.34	0.36	9.63e-10	Platelet count;
CESC	cis	rs853679	0.517	rs4713141	chr6:28101678	G/C	cg26335602	chr6:28129616	ZNF389	0.55	7.34	0.41	2.57e-12	Depression;
CESC	cis	rs2841277	0.708	rs11851053	chr14:105407208	T/C	cg17340268	chr14:105411764	AHNAK2	-0.52	-6.91	-0.39	3.56e-11	Rheumatoid arthritis;
CESC	cis	rs1144713	0.686	rs1144714	chr12:32261252	A/C	cg01321189	chr12:32259338	BICD1	0.34	5.17	0.3	4.67e-7	Obesity-related traits;
CESC	cis	rs853679	0.517	rs4713152	chr6:28137454	G/A	cg19592336	chr6:28129416	ZNF389	0.58	7.71	0.43	2.54e-13	Depression;
CESC	cis	rs9837602	0.529	rs793458	chr3:99520169	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.52	-6.21	-0.36	2.05e-9	Breast cancer;
CESC	cis	rs4853012	0.838	rs58759652	chr2:74344902	A/T	cg20891558	chr2:74357851	NA	0.8	11.63	0.58	1.59e-25	Gestational age at birth (maternal effect);
CESC	cis	rs4654899	1.000	rs6684976	chr1:21367501	G/A	cg05370193	chr1:21551575	ECE1	0.39	5.85	0.34	1.47e-8	Superior frontal gyrus grey matter volume;
CESC	cis	rs2439831	1.000	rs561863	chr15:43761352	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.89	10.58	0.54	4.72e-22	Lung cancer in ever smokers;
CESC	cis	rs477895	0.713	rs12575642	chr11:63979643	G/T	cg18225595	chr11:63971243	STIP1	0.57	5.8	0.34	1.88e-8	Mean platelet volume;
CESC	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg07308232	chr7:1071921	C7orf50	-0.43	-6.06	-0.35	4.66e-9	Longevity;Endometriosis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16600432	chr14:64970085	ZBTB1;ZBTB25	0.54	6.66	0.38	1.53e-10	Gut microbiome composition (summer);
CESC	cis	rs7402982	0.647	rs34038360	chr15:99201573	A/C	cg03437748	chr15:99193247	IGF1R	0.6	8.01	0.44	3.6e-14	Birth weight;
CESC	cis	rs6952808	0.965	rs4719318	chr7:1887930	G/A	cg05863683	chr7:1912471	MAD1L1	0.37	5.49	0.32	9.51e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs11122272	0.735	rs2739510	chr1:231526718	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.56	-7.73	-0.43	2.3e-13	Hemoglobin concentration;
CESC	cis	rs796364	0.865	rs769948	chr2:200728475	C/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.85	8.19	0.45	1.12e-14	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24078387	chr1:53704033	MAGOH	0.65	7.15	0.4	8.47e-12	Gut microbiome composition (summer);
CESC	cis	rs6087990	0.806	rs6141814	chr20:31368960	C/A	cg13636640	chr20:31349939	DNMT3B	0.81	12.5	0.61	1.67e-28	Ulcerative colitis;
CESC	cis	rs77106637	0.929	rs1059000	chr11:72504972	G/C	cg04827223	chr11:72435913	ARAP1	-0.56	-5.77	-0.33	2.16e-8	Type 2 diabetes;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg00670465	chr12:511362	CCDC77	0.5	7.04	0.4	1.66e-11	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs453301	0.653	rs1045529	chr8:8890098	A/G	cg06636001	chr8:8085503	FLJ10661	-0.46	-5.93	-0.34	9.43e-9	Joint mobility (Beighton score);
CESC	cis	rs6912958	0.559	rs242287	chr6:88071825	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.73	10.43	0.54	1.49e-21	Monocyte percentage of white cells;
CESC	cis	rs12142240	0.698	rs68112720	chr1:46813888	T/C	cg00530320	chr1:46809349	NSUN4	0.58	7.89	0.44	8.17e-14	Menopause (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11166252	chr7:17338258	AHR	0.63	7.69	0.43	2.81e-13	Gut microbiome composition (summer);
CESC	cis	rs6500395	1.000	rs28577888	chr16:48673281	T/G	cg04672837	chr16:48644449	N4BP1	0.5	6.19	0.36	2.32e-9	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs62103177	0.733	rs62103193	chr18:77629217	C/T	cg12964065	chr18:77638022	KCNG2	0.58	5.46	0.32	1.07e-7	Opioid sensitivity;
CESC	cis	rs9549260	0.755	rs4943798	chr13:41202948	T/C	cg21288729	chr13:41239152	FOXO1	0.64	8.24	0.45	8.16e-15	Red blood cell count;
CESC	cis	rs9976767	0.637	rs9325635	chr21:43823289	G/A	cg23042151	chr21:43824109	UBASH3A	-0.32	-6.01	-0.35	6.25e-9	Type 1 diabetes;
CESC	cis	rs4819052	0.851	rs2838826	chr21:46655785	A/G	cg11663144	chr21:46675770	NA	-0.58	-8.57	-0.47	8.75e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs12142240	0.738	rs67545510	chr1:46806242	G/T	cg10495392	chr1:46806563	NSUN4	0.59	6.36	0.36	8.9e-10	Menopause (age at onset);
CESC	cis	rs6496667	0.954	rs7162211	chr15:90892585	G/C	cg22089800	chr15:90895588	ZNF774	0.5	5.03	0.3	9.07e-7	Rheumatoid arthritis;
CESC	cis	rs801193	0.773	rs801207	chr7:66020590	T/C	cg14393609	chr7:65229607	NA	-0.41	-5.77	-0.33	2.21e-8	Aortic root size;
CESC	cis	rs6460942	0.597	rs17545416	chr7:12525944	A/T	cg02935154	chr7:12443704	VWDE	-0.55	-5.53	-0.32	7.71e-8	Coronary artery disease;
CESC	cis	rs13392177	0.684	rs11682371	chr2:219079513	G/A	cg00012203	chr2:219082015	ARPC2	-0.66	-8.16	-0.45	1.32e-14	Pyoderma gangrenosum in inflammatory bowel disease;
CESC	cis	rs208520	0.802	rs208499	chr6:66932146	C/T	cg07460842	chr6:66804631	NA	-0.82	-10.01	-0.52	3.23e-20	Exhaled nitric oxide output;
CESC	cis	rs7927592	0.731	rs11228288	chr11:68353550	A/G	cg01657329	chr11:68192670	LRP5	-0.47	-6.12	-0.35	3.37e-9	Total body bone mineral density;
CESC	cis	rs2760061	0.626	rs635563	chr1:228136834	C/T	cg02753203	chr1:228287806	NA	-0.5	-7.36	-0.41	2.27e-12	Diastolic blood pressure;
CESC	cis	rs6701037	0.714	rs2285219	chr1:175130983	A/T	cg00321850	chr1:175162397	KIAA0040	-0.42	-6.14	-0.35	3.03e-9	Alcohol dependence;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg23104823	chr14:45553408	PRPF39	0.49	6.76	0.38	8.87e-11	Systemic lupus erythematosus;
CESC	cis	rs7208859	0.573	rs79505916	chr17:29062326	C/T	cg19761014	chr17:28927070	LRRC37B2	0.77	6.33	0.36	1.06e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	trans	rs7618501	1.000	rs7431106	chr3:49808374	G/A	cg21659725	chr3:3221576	CRBN	0.83	13.63	0.64	2.04e-32	Intelligence (multi-trait analysis);
CESC	cis	rs4555082	0.834	rs2735825	chr14:105710900	G/A	cg13114125	chr14:105738426	BRF1	-0.87	-10.38	-0.54	2.08e-21	Mean platelet volume;Platelet distribution width;
CESC	cis	rs7662987	1.000	rs7684986	chr4:99991676	C/T	cg13256891	chr4:100009986	ADH5	-0.83	-5.86	-0.34	1.38e-8	Smoking initiation;
CESC	cis	rs10504229	1.000	rs59549824	chr8:58186205	A/C	cg14926445	chr8:58193284	C8orf71	-0.51	-5.5	-0.32	9.08e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs853679	0.517	rs4713148	chr6:28115921	G/A	cg19592336	chr6:28129416	ZNF389	0.62	8.12	0.45	1.77e-14	Depression;
CESC	cis	rs7552404	0.920	rs1612097	chr1:76218875	C/T	cg22875332	chr1:76189707	ACADM	0.7	9.65	0.51	4.56e-19	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs875971	0.545	rs73378304	chr7:65640747	G/A	cg18876405	chr7:65276391	NA	0.47	5.73	0.33	2.76e-8	Aortic root size;
CESC	cis	rs12497850	0.931	rs4974079	chr3:48906469	T/G	cg02487422	chr3:49467188	NICN1	0.4	5.15	0.3	5.11e-7	Parkinson's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09324016	chr16:31085582	ZNF668;ZNF646	-0.65	-8.12	-0.45	1.79e-14	Gut microbiome composition (summer);
CESC	cis	rs2304069	0.779	rs245081	chr5:149356075	G/T	cg12661370	chr5:149340060	SLC26A2	0.46	5.49	0.32	9.33e-8	HIV-1 control;
CESC	cis	rs6087990	0.735	rs910083	chr20:31378690	A/C	cg13636640	chr20:31349939	DNMT3B	0.8	13.22	0.63	5.39e-31	Ulcerative colitis;
CESC	cis	rs1030268	0.667	rs12707111	chr7:133330144	C/T	cg10665199	chr7:133106180	EXOC4	0.51	5.42	0.32	1.37e-7	Intelligence (multi-trait analysis);
CESC	cis	rs9549367	0.789	rs2302754	chr13:113898385	C/T	cg18105134	chr13:113819100	PROZ	0.67	8.3	0.45	5.25e-15	Platelet distribution width;
CESC	trans	rs1994135	0.647	rs66542958	chr12:33695385	T/G	cg26384229	chr12:38710491	ALG10B	0.46	6.37	0.36	8.12e-10	Resting heart rate;
CESC	cis	rs7259376	0.875	rs1975175	chr19:22515239	G/C	cg02657401	chr19:22469223	NA	-0.26	-5.26	-0.31	3.01e-7	Menopause (age at onset);
CESC	cis	rs8016982	0.963	rs2099108	chr14:81675420	C/G	cg01989461	chr14:81687754	GTF2A1	0.56	7.3	0.41	3.46e-12	Schizophrenia;
CESC	cis	rs116095464	0.558	rs6555052	chr5:224268	G/A	cg12570787	chr5:219185	SDHA;CCDC127	0.52	5.65	0.33	4.24e-8	Breast cancer;
CESC	cis	rs6460942	0.778	rs76030612	chr7:12462937	C/A	cg06484146	chr7:12443880	VWDE	-0.68	-9.39	-0.5	2.86e-18	Coronary artery disease;
CESC	trans	rs113577745	0.725	rs16867277	chr2:10136592	T/C	cg12379383	chr15:96896940	NA	-0.57	-6.17	-0.35	2.56e-9	Breast cancer;
CESC	cis	rs2404602	0.647	rs1443115	chr15:77041829	T/C	cg23625390	chr15:77176239	SCAPER	-0.4	-5.2	-0.3	4e-7	Blood metabolite levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01293050	chr14:20937714	PNP	0.53	6.12	0.35	3.38e-9	Gut microbiome composition (summer);
CESC	cis	rs10992471	0.756	rs10992303	chr9:95082804	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.44	-5.57	-0.32	6.3e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CESC	cis	rs7666738	0.791	rs7377018	chr4:99034962	C/T	cg05340658	chr4:99064831	C4orf37	0.83	12.92	0.62	5.86e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs763121	0.819	rs5757169	chr22:39003495	G/A	cg06022373	chr22:39101656	GTPBP1	0.95	17.17	0.73	6.29e-45	Menopause (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22046830	chr8:145133508	EXOSC4	0.54	6.37	0.36	8.49e-10	Gut microbiome composition (summer);
CESC	cis	rs329122	0.528	rs329113	chr5:133856408	A/G	cg26284174	chr5:133860141	NA	0.45	5.24	0.31	3.34e-7	Body mass index;Type 2 diabetes;
CESC	cis	rs60154123	0.730	rs608791	chr1:210464638	C/T	cg21951975	chr1:209979733	IRF6	0.45	6.03	0.35	5.39e-9	Coronary artery disease;
CESC	cis	rs1005277	0.579	rs2472178	chr10:38384750	T/C	cg00409905	chr10:38381863	ZNF37A	-0.52	-7.13	-0.4	9.34e-12	Extrinsic epigenetic age acceleration;
CESC	cis	rs1799949	1.000	rs16940	chr17:41245237	A/G	cg05368731	chr17:41323189	NBR1	0.76	10.45	0.54	1.21e-21	Menopause (age at onset);
CESC	cis	rs734999	0.545	rs12752515	chr1:2564465	T/C	cg18854424	chr1:2615690	NA	-0.31	-5.91	-0.34	1.08e-8	Ulcerative colitis;
CESC	cis	rs3747547	0.892	rs11789186	chr9:37975114	A/C	cg13774184	chr9:37916125	SHB	-0.68	-5.85	-0.34	1.47e-8	Metabolite levels (Dihydroxy docosatrienoic acid);
CESC	cis	rs7296418	0.961	rs12425850	chr12:123501972	T/C	cg05973401	chr12:123451056	ABCB9	0.58	7.62	0.42	4.54e-13	Platelet count;
CESC	cis	rs7618915	0.570	rs2336145	chr3:52629750	A/C	cg17372223	chr3:52568218	NT5DC2	0.44	6.46	0.37	4.87e-10	Bipolar disorder;
CESC	cis	rs9733	0.744	rs12126004	chr1:150889877	T/C	cg13175981	chr1:150552382	MCL1	0.53	7.11	0.4	1.09e-11	Tonsillectomy;
CESC	trans	rs57221529	0.766	rs4081846	chr5:574019	G/A	cg25482853	chr8:67687455	SGK3	1.01	10.13	0.53	1.39e-20	Lung disease severity in cystic fibrosis;
CESC	cis	rs13108904	0.557	rs1250097	chr4:1238338	C/T	cg16405210	chr4:1374714	KIAA1530	0.75	10.47	0.54	1.09e-21	Obesity-related traits;
CESC	cis	rs6987853	0.602	rs2974337	chr8:42390873	C/T	cg09913449	chr8:42400586	C8orf40	0.33	5.08	0.3	7.06e-7	Mean corpuscular hemoglobin concentration;
CESC	cis	rs12950390	0.853	rs11655112	chr17:45856563	T/C	cg00777063	chr17:45855553	NA	-0.39	-5.77	-0.33	2.26e-8	IgG glycosylation;
CESC	cis	rs4237845	0.837	rs7954591	chr12:58299037	A/G	cg02175503	chr12:58329896	NA	0.65	9.29	0.5	5.97e-18	Intelligence (multi-trait analysis);
CESC	cis	rs2836974	0.897	rs2026267	chr21:40711477	C/A	cg27266027	chr21:40555129	PSMG1	0.44	5.25	0.31	3.16e-7	Cognitive function;
CESC	cis	rs4604732	0.631	rs74154673	chr1:247625629	G/A	cg12754571	chr1:247694271	LOC148824;OR2C3	0.44	5.44	0.32	1.21e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15985400	chr11:76091674	PRKRIR	0.67	7.48	0.42	1.13e-12	Gut microbiome composition (summer);
CESC	cis	rs11792861	0.589	rs75742991	chr9:111929624	C/G	cg05043794	chr9:111880884	C9orf5	-0.41	-6.25	-0.36	1.67e-9	Menarche (age at onset);
CESC	cis	rs734999	0.566	rs4648658	chr1:2560882	G/A	cg18854424	chr1:2615690	NA	-0.29	-5.92	-0.34	1e-8	Ulcerative colitis;
CESC	trans	rs4932480	0.522	rs4932215	chr15:89746132	C/G	cg24069674	chr6:27230661	NA	-0.42	-6.58	-0.37	2.56e-10	Advanced age-related macular degeneration;Age-related macular degeneration (SNP x mitochondrial G12771A interaction);
CESC	cis	rs9902453	0.791	rs62068629	chr17:28187596	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.65	8.21	0.45	9.9e-15	Coffee consumption (cups per day);
CESC	cis	rs4835473	0.838	rs10024263	chr4:144959327	A/G	cg25736465	chr4:144833511	NA	0.44	6.74	0.38	9.91e-11	Immature fraction of reticulocytes;
CESC	cis	rs736408	0.509	rs1108842	chr3:52720080	A/C	cg18337363	chr3:52569053	NT5DC2	0.31	6.07	0.35	4.5e-9	Bipolar disorder;
CESC	cis	rs140364877	1	rs140364877	chr7:1885178	C/T	cg21782813	chr7:2030301	MAD1L1	0.36	5.05	0.3	8.41e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs7772486	0.805	rs4896831	chr6:145959481	T/C	cg23711669	chr6:146136114	FBXO30	0.82	11.91	0.59	1.77e-26	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9549367	0.789	rs6577035	chr13:113879997	G/A	cg18105134	chr13:113819100	PROZ	-0.66	-8.24	-0.45	8.04e-15	Platelet distribution width;
CESC	cis	rs10479542	0.892	rs7736163	chr5:178980316	G/C	cg21226059	chr5:178986404	RUFY1	0.49	7.57	0.42	6.27e-13	Lung cancer;
CESC	cis	rs3780486	0.801	rs56687083	chr9:33132134	A/G	cg13443165	chr9:33130375	B4GALT1	0.45	6.46	0.37	5e-10	IgG glycosylation;
CESC	cis	rs977987	0.806	rs6564258	chr16:75447363	G/A	cg03315344	chr16:75512273	CHST6	0.41	5.83	0.34	1.59e-8	Dupuytren's disease;
CESC	cis	rs796364	0.806	rs11674293	chr2:201026743	G/A	cg23649088	chr2:200775458	C2orf69	-0.6	-5.16	-0.3	4.78e-7	Schizophrenia;
CESC	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg24829409	chr8:58192753	C8orf71	-0.67	-8.18	-0.45	1.19e-14	Developmental language disorder (linguistic errors);
CESC	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg23978390	chr7:1156363	C7orf50	0.5	6.79	0.38	7.43e-11	Longevity;Endometriosis;
CESC	cis	rs6835098	1.000	rs6826412	chr4:174109622	C/T	cg08422745	chr4:174089978	GALNT7	-0.72	-9.42	-0.5	2.4e-18	Dementia and core Alzheimer's disease neuropathologic changes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00878827	chr14:75229987	YLPM1	0.58	7.2	0.4	6.39e-12	Gut microbiome composition (summer);
CESC	cis	rs3767633	0.858	rs2341468	chr1:161862312	G/A	cg09175582	chr1:161736000	ATF6	0.85	6.91	0.39	3.53e-11	IgG glycosylation;
CESC	cis	rs736408	0.527	rs2577831	chr3:52628056	C/A	cg18099408	chr3:52552593	STAB1	-0.36	-6.59	-0.38	2.39e-10	Bipolar disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17104843	chr1:213032108	FLVCR1;LQK1	0.56	6.39	0.37	7.63e-10	Gut microbiome composition (summer);
CESC	cis	rs6500395	1.000	rs9936004	chr16:48566088	A/G	cg04672837	chr16:48644449	N4BP1	0.49	6.16	0.35	2.68e-9	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs7903847	0.642	rs10882923	chr10:99159018	G/A	cg20016023	chr10:99160130	RRP12	-0.3	-5.22	-0.31	3.54e-7	Granulocyte percentage of myeloid white cells;
CESC	cis	rs6732160	0.510	rs57825971	chr2:73384796	C/G	cg01422370	chr2:73384389	NA	0.46	7.27	0.41	4.11e-12	Intelligence (multi-trait analysis);
CESC	trans	rs4950322	0.518	rs4950305	chr1:146589293	C/A	cg04954894	chr8:38089920	DDHD2	-0.59	-6.42	-0.37	6.13e-10	Protein quantitative trait loci;
CESC	cis	rs7833986	0.501	rs2719233	chr8:56886156	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.57	6.94	0.39	3.07e-11	Height;
CESC	cis	rs3862435	0.572	rs2589967	chr15:90907876	T/C	cg22089800	chr15:90895588	ZNF774	0.5	5.5	0.32	8.81e-8	Response to exercise (triglyceride level interaction);
CESC	cis	rs832540	0.931	rs832535	chr5:56213334	C/T	cg14703610	chr5:56206110	C5orf35	0.53	7.03	0.4	1.78e-11	Coronary artery disease;
CESC	trans	rs8073060	0.586	rs7217533	chr17:34015876	A/G	cg19694781	chr19:47549865	TMEM160	-0.74	-6.91	-0.39	3.64e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	cis	rs9329289	0.926	rs9329290	chr10:2542751	G/T	cg05625103	chr10:2543513	NA	0.37	5.17	0.3	4.52e-7	Age-related hearing impairment;
CESC	cis	rs2361718	0.603	rs12951255	chr17:78085597	A/G	cg06718696	chr17:78121285	EIF4A3	0.42	5.32	0.31	2.19e-7	Yeast infection;
CESC	cis	rs8067354	0.872	rs1292060	chr17:57913849	A/G	cg02344993	chr17:57696989	CLTC	0.47	6.13	0.35	3.16e-9	Hemoglobin concentration;
CESC	cis	rs875971	0.862	rs778720	chr7:65846275	A/C	cg18252515	chr7:66147081	NA	0.43	5.74	0.33	2.57e-8	Aortic root size;
CESC	cis	rs11711311	0.869	rs1026364	chr3:113370010	G/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.49	6.24	0.36	1.74e-9	IgG glycosylation;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05865860	chr7:158649142	WDR60	0.58	6.61	0.38	2.1e-10	Gut microbiome composition (summer);
CESC	cis	rs929354	0.742	rs2107863	chr7:156963731	T/C	cg05182265	chr7:156933206	UBE3C	-0.5	-7.3	-0.41	3.28e-12	Body mass index;
CESC	cis	rs2204008	0.627	rs1851117	chr12:38398987	G/T	cg13010199	chr12:38710504	ALG10B	0.48	6.05	0.35	4.85e-9	Bladder cancer;
CESC	cis	rs2073300	0.609	rs6137920	chr20:23363436	C/T	cg12062639	chr20:23401060	NAPB	1.08	8.67	0.47	4.32e-16	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs2839186	0.585	rs2839154	chr21:47637760	C/T	cg11766577	chr21:47581405	C21orf56	0.4	5.19	0.3	4.22e-7	Testicular germ cell tumor;
CESC	trans	rs61931739	0.534	rs28548399	chr12:34188151	G/A	cg26384229	chr12:38710491	ALG10B	0.65	9.11	0.49	2.1e-17	Morning vs. evening chronotype;
CESC	cis	rs5769765	0.954	rs910799	chr22:50278568	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.48	5.62	0.33	4.93e-8	Schizophrenia;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg07667813	chr19:7985168	SNAPC2	0.47	6.34	0.36	1.01e-9	Height;
CESC	trans	rs324780	0.544	rs3103509	chr12:83889162	C/T	cg22140261	chr22:42466895	NAGA	0.47	6.03	0.35	5.38e-9	Vertical cup-disc ratio;
CESC	cis	rs9443645	0.869	rs2095724	chr6:79742101	C/T	cg05283184	chr6:79620031	NA	-0.43	-6.62	-0.38	1.97e-10	Intelligence (multi-trait analysis);
CESC	cis	rs79057730	0.528	rs4719313	chr7:822501	C/T	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.86	7.4	0.41	1.79e-12	Initial pursuit acceleration;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14012564	chr10:47133876	LOC728643	-0.5	-6.29	-0.36	1.32e-9	Gut microbiome composition (summer);
CESC	cis	rs6570726	0.791	rs401561	chr6:145835917	G/T	cg05347473	chr6:146136440	FBXO30	0.59	7.56	0.42	6.43e-13	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs858239	0.600	rs6461692	chr7:23139695	G/C	cg23682824	chr7:23144976	KLHL7	0.53	7.3	0.41	3.46e-12	Cerebrospinal fluid biomarker levels;
CESC	cis	rs736408	0.812	rs2270197	chr3:52824095	T/G	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.38	6.31	0.36	1.14e-9	Bipolar disorder;
CESC	cis	rs2742234	0.666	rs715106	chr10:43616751	C/A	cg15436174	chr10:43711423	RASGEF1A	-0.47	-5.48	-0.32	1.01e-7	Hirschsprung disease;
CESC	cis	rs3008870	0.755	rs1024230	chr1:67512920	A/C	cg02640540	chr1:67518911	SLC35D1	0.71	9.16	0.49	1.46e-17	Lymphocyte percentage of white cells;
CESC	cis	rs7520050	0.966	rs785479	chr1:46492144	C/T	cg24296786	chr1:45957014	TESK2	0.43	5.44	0.32	1.2e-7	Red blood cell count;Reticulocyte count;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg19071989	chr7:2566113	LFNG	-0.4	-6.68	-0.38	1.42e-10	Gambling;
CESC	trans	rs9467711	0.606	rs9358932	chr6:26362705	A/G	cg06606381	chr12:133084897	FBRSL1	0.75	7.0	0.4	2.08e-11	Autism spectrum disorder or schizophrenia;
CESC	cis	rs911555	0.673	rs7144271	chr14:103890674	A/G	cg09975044	chr14:104007538	NA	0.44	5.6	0.33	5.39e-8	Intelligence (multi-trait analysis);
CESC	trans	rs9886428	0.531	rs34803352	chr8:14042304	T/C	cg20900203	chr3:65748129	MAGI1	0.47	6.01	0.35	5.96e-9	IgG glycosylation;
CESC	cis	rs9325144	0.560	rs12424821	chr12:38649951	C/T	cg26384229	chr12:38710491	ALG10B	-0.6	-8.54	-0.46	1.05e-15	Morning vs. evening chronotype;
CESC	cis	rs9322193	0.923	rs9285524	chr6:150015258	G/A	cg07701084	chr6:150067640	NUP43	0.43	5.83	0.34	1.62e-8	Lung cancer;
CESC	cis	rs4481887	0.962	rs10788770	chr1:248457474	T/G	cg00666640	chr1:248458726	OR2T12	0.42	7.01	0.4	1.98e-11	Common traits (Other);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg08042487	chr21:45739921	PFKL	0.51	6.86	0.39	4.74e-11	Fibrinogen levels;
CESC	cis	rs9309473	0.898	rs28879089	chr2:73812886	G/A	cg20560298	chr2:73613845	ALMS1	-0.54	-7.1	-0.4	1.13e-11	Metabolite levels;
CESC	cis	rs7937682	0.564	rs11600652	chr11:111754368	A/T	cg22437258	chr11:111473054	SIK2	-0.48	-5.31	-0.31	2.31e-7	Primary sclerosing cholangitis;
CESC	cis	rs1799949	0.930	rs2298861	chr17:41176831	G/A	cg05368731	chr17:41323189	NBR1	0.8	10.68	0.55	2.21e-22	Menopause (age at onset);
CESC	cis	rs939658	0.805	rs59104559	chr15:79438784	A/G	cg17916960	chr15:79447300	NA	-0.35	-5.96	-0.34	8.11e-9	Refractive error;
CESC	cis	rs367943	0.698	rs2217296	chr5:112973829	A/T	cg12552261	chr5:112820674	MCC	0.43	5.49	0.32	9.31e-8	Type 2 diabetes;
CESC	cis	rs7927771	0.725	rs11039265	chr11:47523214	C/A	cg20307385	chr11:47447363	PSMC3	-0.53	-6.43	-0.37	6.04e-10	Subjective well-being;
CESC	cis	rs7618915	0.501	rs34754793	chr3:52629177	A/T	cg07507251	chr3:52567010	NT5DC2	0.32	5.5	0.32	8.74e-8	Bipolar disorder;
CESC	cis	rs11039131	0.629	rs67871383	chr11:47335838	T/C	cg05585544	chr11:47624801	NA	-0.36	-5.08	-0.3	7.13e-7	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19412675	chr5:122181750	SNX24	-0.53	-6.13	-0.35	3.11e-9	Gut microbiome composition (summer);
CESC	cis	rs13191362	0.935	rs35378894	chr6:163123933	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.66	6.56	0.37	2.8e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs60871478	0.635	rs4311567	chr7:792295	T/C	cg13798912	chr7:905769	UNC84A	0.6	5.98	0.34	7.1e-9	Cerebrospinal P-tau181p levels;
CESC	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg07677032	chr17:61819896	STRADA	0.41	5.3	0.31	2.41e-7	Prudent dietary pattern;
CESC	cis	rs1692580	0.840	rs262679	chr1:2169792	C/T	cg21194808	chr1:2205498	SKI	0.39	5.43	0.32	1.27e-7	Coronary artery disease;
CESC	cis	rs40363	0.645	rs4786421	chr16:3522303	A/G	cg21433313	chr16:3507492	NAT15	-0.55	-9.5	-0.5	1.3e-18	Tuberculosis;
CESC	cis	rs12079745	0.793	rs10919110	chr1:169214293	G/C	cg09363564	chr1:169337483	NME7;BLZF1	-1.01	-6.29	-0.36	1.31e-9	QT interval;
CESC	cis	rs12586317	0.620	rs8020370	chr14:35581432	G/A	cg16230307	chr14:35515116	FAM177A1	0.92	10.08	0.53	1.98e-20	Psoriasis;
CESC	cis	rs1218582	0.744	rs6674853	chr1:154892753	G/C	cg16680214	chr1:154839983	KCNN3	-0.49	-7.54	-0.42	7.48e-13	Prostate cancer;
CESC	cis	rs7772486	0.720	rs6931553	chr6:146112348	T/C	cg23711669	chr6:146136114	FBXO30	-1.01	-15.52	-0.69	4.34e-39	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7666738	0.830	rs6532715	chr4:99016792	G/A	cg17366294	chr4:99064904	C4orf37	0.61	8.77	0.47	2.15e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7795096	1.000	rs7795096	chr7:151546589	A/G	cg17008978	chr7:151542804	PRKAG2	0.3	5.55	0.32	7.05e-8	Bipolar disorder (age of onset and psychotic symptoms);
CESC	cis	rs9831754	1.000	rs9831754	chr3:78353591	A/C	cg06138941	chr3:78371609	NA	-0.75	-8.85	-0.48	1.3e-16	Calcium levels;
CESC	cis	rs2404602	0.710	rs2469541	chr15:76562118	C/T	cg26408565	chr15:76604113	ETFA	0.37	5.35	0.31	1.88e-7	Blood metabolite levels;
CESC	cis	rs7618915	0.571	rs12487445	chr3:52618319	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.46	6.49	0.37	4.3e-10	Bipolar disorder;
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg16177875	chr15:49102732	CEP152	-0.4	-6.15	-0.35	2.82e-9	Vertical cup-disc ratio;
CESC	cis	rs1005277	0.602	rs1831315	chr10:38473353	T/C	cg25517755	chr10:38738941	LOC399744	-0.49	-6.43	-0.37	6.04e-10	Extrinsic epigenetic age acceleration;
CESC	cis	rs9916302	0.904	rs9898773	chr17:37532507	C/G	cg15445000	chr17:37608096	MED1	-0.4	-6.5	-0.37	3.9e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs9322193	0.566	rs9397070	chr6:150243209	T/C	cg01145232	chr6:150245071	RAET1G	-0.54	-7.09	-0.4	1.24e-11	Lung cancer;
CESC	cis	rs17881320	0.510	rs7221385	chr17:40562081	C/T	cg05878104	chr17:40932452	WNK4	-0.53	-5.49	-0.32	9.56e-8	Atopic dermatitis;
CESC	cis	rs7927771	1.000	rs10838738	chr11:47663049	A/G	cg18512352	chr11:47633146	NA	-0.62	-9.81	-0.52	1.35e-19	Subjective well-being;
CESC	cis	rs798554	0.679	rs798499	chr7:2792013	G/A	cg19717773	chr7:2847554	GNA12	-0.55	-8.76	-0.47	2.37e-16	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25023241	chr1:26560532	CCDC21	0.6	6.55	0.37	3.01e-10	Gut microbiome composition (summer);
CESC	cis	rs6842047	1.000	rs6842047	chr4:187133576	A/C	cg23442198	chr4:187126114	CYP4V2	0.6	5.26	0.31	2.91e-7	Blood protein levels;
CESC	cis	rs4237845	0.742	rs3751330	chr12:58290226	T/C	cg00677455	chr12:58241039	CTDSP2	0.43	5.7	0.33	3.26e-8	Intelligence (multi-trait analysis);
CESC	cis	rs10870270	0.830	rs10781571	chr10:133774316	G/C	cg26149184	chr10:133730230	NA	0.38	5.1	0.3	6.63e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs2228479	0.850	rs62052660	chr16:89847420	T/A	cg00800038	chr16:89945340	TCF25	-0.9	-7.51	-0.42	9.11e-13	Skin colour saturation;
CESC	cis	rs561341	0.883	rs4450460	chr17:30201309	C/T	cg12193833	chr17:30244370	NA	0.54	5.46	0.32	1.09e-7	Hip circumference adjusted for BMI;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13169780	chr17:7591570	TP53;WRAP53	-0.65	-7.98	-0.44	4.31e-14	Gut microbiome composition (summer);
CESC	cis	rs748404	0.631	rs7163288	chr15:43671355	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.61	9.6	0.51	6.29e-19	Lung cancer;
CESC	cis	rs7617773	0.817	rs3937	chr3:48312402	T/C	cg11946769	chr3:48343235	NME6	0.8	10.58	0.54	4.71e-22	Coronary artery disease;
CESC	trans	rs605920	0.561	rs661913	chr18:62751108	A/G	cg26619099	chr11:68973615	NA	-0.42	-6.08	-0.35	4.08e-9	Cardiac Troponin-T levels;
CESC	cis	rs6750795	0.870	rs6754952	chr2:232381245	G/T	cg19187155	chr2:232395269	NMUR1	-0.65	-11.64	-0.58	1.48e-25	Height;
CESC	cis	rs4919087	0.748	rs701819	chr10:98986316	C/A	cg25902810	chr10:99078978	FRAT1	-0.5	-5.59	-0.32	5.53e-8	Monocyte count;
CESC	cis	rs7927771	0.965	rs12364432	chr11:47902883	G/A	cg18512352	chr11:47633146	NA	-0.63	-9.89	-0.52	8.02e-20	Subjective well-being;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg05780616	chr12:96252764	SNRPF	0.45	6.15	0.35	2.84e-9	Systemic lupus erythematosus;
CESC	cis	rs1218582	0.600	rs72702224	chr1:154911689	G/A	cg09359103	chr1:154839909	KCNN3	-0.6	-10.37	-0.54	2.32e-21	Prostate cancer;
CESC	cis	rs7520050	0.807	rs12025621	chr1:46228391	G/A	cg24296786	chr1:45957014	TESK2	0.46	5.99	0.35	6.97e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs329122	0.528	rs11242218	chr5:133848688	G/T	cg26284174	chr5:133860141	NA	0.45	5.13	0.3	5.62e-7	Body mass index;Type 2 diabetes;
CESC	cis	rs9815354	0.812	rs11129935	chr3:41985203	A/C	cg03022575	chr3:42003672	ULK4	0.68	6.1	0.35	3.75e-9	Pulse pressure;Diastolic blood pressure;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27527783	chr7:55540112	VOPP1	-0.52	-6.15	-0.35	2.9e-9	Gut microbiome composition (summer);
CESC	cis	rs9309473	0.950	rs6756885	chr2:73805172	A/G	cg20560298	chr2:73613845	ALMS1	-0.54	-7.03	-0.4	1.76e-11	Metabolite levels;
CESC	cis	rs7259376	0.729	rs3867187	chr19:22570220	C/G	cg02657401	chr19:22469223	NA	-0.27	-5.31	-0.31	2.31e-7	Menopause (age at onset);
CESC	cis	rs9715521	0.900	rs62299249	chr4:59824174	G/A	cg11281224	chr4:60001000	NA	-0.51	-6.67	-0.38	1.45e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs72781680	0.699	rs72794291	chr2:23897935	C/T	cg08917208	chr2:24149416	ATAD2B	1.17	10.79	0.55	9.42e-23	Lymphocyte counts;
CESC	cis	rs4665809	1.000	rs10202478	chr2:26276049	T/C	cg22920501	chr2:26401640	FAM59B	-0.79	-9.59	-0.51	6.87e-19	Gut microbiome composition (summer);
CESC	cis	rs7560272	0.723	rs7585119	chr2:73724679	A/T	cg20560298	chr2:73613845	ALMS1	-0.48	-6.83	-0.39	5.8e-11	Schizophrenia;
CESC	cis	rs72634258	0.503	rs707457	chr1:7831064	C/A	cg26816564	chr1:7831052	VAMP3	0.74	6.94	0.39	3.09e-11	Inflammatory bowel disease;
CESC	cis	rs6952808	0.723	rs4721295	chr7:2036669	G/T	cg21782813	chr7:2030301	MAD1L1	-0.5	-7.37	-0.41	2.22e-12	Bipolar disorder and schizophrenia;
CESC	cis	rs34779708	0.931	rs72789687	chr10:35372489	G/A	cg04310649	chr10:35416472	CREM	-0.51	-6.06	-0.35	4.62e-9	Inflammatory bowel disease;Crohn's disease;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg26420824	chr1:28562883	ATPIF1	0.47	6.11	0.35	3.63e-9	Thyroid stimulating hormone;
CESC	cis	rs1483890	0.723	rs13077078	chr3:69411402	C/A	cg22125112	chr3:69402811	FRMD4B	0.39	5.24	0.31	3.3e-7	Resting heart rate;
CESC	cis	rs858239	0.899	rs2268745	chr7:23317600	G/A	cg23682824	chr7:23144976	KLHL7	0.43	5.54	0.32	7.21e-8	Cerebrospinal fluid biomarker levels;
CESC	cis	rs7551222	0.749	rs11240764	chr1:204569376	A/G	cg20240347	chr1:204465584	NA	-0.27	-5.52	-0.32	7.95e-8	Schizophrenia;
CESC	cis	rs858239	0.600	rs9691762	chr7:23125922	G/C	cg23682824	chr7:23144976	KLHL7	0.55	7.64	0.43	3.9e-13	Cerebrospinal fluid biomarker levels;
CESC	cis	rs909002	0.925	rs10798882	chr1:32108547	C/G	cg13919466	chr1:32135498	COL16A1	0.49	8.77	0.47	2.18e-16	Intelligence (multi-trait analysis);
CESC	cis	rs3540	0.920	rs7182658	chr15:91019248	A/T	cg10434728	chr15:90938212	IQGAP1	0.32	5.49	0.32	9.21e-8	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs1552244	1.000	rs56270432	chr3:10087517	G/C	cg00166722	chr3:10149974	C3orf24	0.52	6.48	0.37	4.4e-10	Alzheimer's disease;
CESC	cis	rs2617583	0.967	rs2617595	chr5:1448246	C/T	cg07151155	chr5:1473589	LPCAT1	-0.37	-5.66	-0.33	3.94e-8	Breast cancer;
CESC	cis	rs7208859	0.623	rs11657369	chr17:29136468	G/A	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.79e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs1729951	0.545	rs1097288	chr3:136693721	C/T	cg03617693	chr3:136751559	NA	0.39	5.38	0.31	1.68e-7	Neuroticism;
CESC	cis	rs11583043	0.958	rs11583674	chr1:101396560	C/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.46	5.17	0.3	4.71e-7	Ulcerative colitis;Inflammatory bowel disease;
CESC	cis	rs7208859	0.615	rs216462	chr17:28895897	T/C	cg19761014	chr17:28927070	LRRC37B2	-0.77	-5.76	-0.33	2.32e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs6991838	0.584	rs4637885	chr8:66497084	T/C	cg13398993	chr8:66546079	ARMC1	-0.48	-5.74	-0.33	2.62e-8	Intelligence (multi-trait analysis);
CESC	cis	rs1950626	0.750	rs34144313	chr14:101431216	C/G	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.83	11.29	0.57	2.14e-24	Pelvic organ prolapse (moderate/severe);
CESC	cis	rs875971	0.862	rs4718319	chr7:65652784	C/A	cg12463550	chr7:65579703	CRCP	-0.49	-6.21	-0.36	2.06e-9	Aortic root size;
CESC	cis	rs35306767	0.903	rs7914758	chr10:891702	T/C	cg20503657	chr10:835505	NA	1.09	9.95	0.52	4.95e-20	Eosinophil percentage of granulocytes;
CESC	cis	rs9457247	0.515	rs2757039	chr6:167370353	G/T	cg25258033	chr6:167368657	RNASET2	-0.38	-5.55	-0.32	7.08e-8	Crohn's disease;
CESC	cis	rs10089	1.000	rs4835941	chr5:127430905	C/T	cg19767477	chr5:127420684	SLC12A2	-0.43	-5.88	-0.34	1.23e-8	Ileal carcinoids;
CESC	cis	rs5769765	1.000	rs2295409	chr22:50261060	G/C	cg26441486	chr22:50317300	CRELD2	-0.39	-5.4	-0.32	1.45e-7	Schizophrenia;
CESC	cis	rs7613875	0.543	rs34034116	chr3:49959156	C/A	cg24308560	chr3:49941425	MST1R	-0.58	-8.38	-0.46	3.04e-15	Body mass index;
CESC	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg07677032	chr17:61819896	STRADA	0.46	6.21	0.36	2.06e-9	Prudent dietary pattern;
CESC	cis	rs67311347	0.866	rs2371183	chr3:40334247	C/T	cg09455208	chr3:40491958	NA	-0.39	-6.55	-0.37	2.9e-10	Renal cell carcinoma;
CESC	cis	rs7666738	0.544	rs35160902	chr4:98974690	A/T	cg17366294	chr4:99064904	C4orf37	0.58	8.21	0.45	9.69e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6912958	1.000	rs2207144	chr6:88150816	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.33	-5.32	-0.31	2.19e-7	Monocyte percentage of white cells;
CESC	cis	rs738322	0.805	rs2016755	chr22:38539604	A/G	cg17652424	chr22:38574118	PLA2G6	-0.29	-5.19	-0.3	4.14e-7	Cutaneous nevi;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04464357	chr3:52931527	TMEM110	0.52	6.09	0.35	3.96e-9	Gut microbiome composition (summer);
CESC	cis	rs11098499	0.789	rs10212719	chr4:120254437	T/C	cg09307838	chr4:120376055	NA	0.8	10.84	0.55	6.73e-23	Corneal astigmatism;
CESC	cis	rs35306767	0.903	rs12761424	chr10:967295	C/T	cg25019033	chr10:957182	NA	-0.66	-8.28	-0.45	6.05e-15	Eosinophil percentage of granulocytes;
CESC	cis	rs3858526	0.606	rs10838883	chr11:5952147	G/A	cg02574844	chr11:5959923	NA	0.53	7.77	0.43	1.78e-13	DNA methylation (variation);
CESC	cis	rs6930083	0.605	rs3829964	chr6:36644498	T/C	cg08179530	chr6:36648295	CDKN1A	0.79	12.27	0.6	1.05e-27	Coronary artery disease;
CESC	cis	rs4253772	0.591	rs6008545	chr22:46686375	C/T	cg24881330	chr22:46731750	TRMU	0.83	8.38	0.46	3.1e-15	LDL cholesterol;Cholesterol, total;
CESC	trans	rs8180040	0.966	rs34634681	chr3:47579102	G/A	cg09317728	chr14:101699148	NA	0.36	6.02	0.35	5.66e-9	Colorectal cancer;
CESC	cis	rs2576037	0.796	rs2571031	chr18:44577063	T/C	cg19077165	chr18:44547161	KATNAL2	0.52	7.41	0.41	1.74e-12	Personality dimensions;
CESC	cis	rs7949030	0.626	rs35587183	chr11:62318656	C/T	cg02375832	chr11:62437615	C11orf48	-0.37	-5.38	-0.31	1.66e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs12541335	0.590	rs11136002	chr8:22217082	C/T	cg02463440	chr8:22132932	PIWIL2	0.38	5.76	0.33	2.38e-8	Hypertriglyceridemia;
CESC	cis	rs7107174	1.000	rs4945274	chr11:78109260	G/A	cg02023728	chr11:77925099	USP35	0.37	5.33	0.31	2.12e-7	Testicular germ cell tumor;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg02667081	chr16:71880439	ATXN1L	-0.46	-6.06	-0.35	4.78e-9	Height;
CESC	cis	rs7100689	0.577	rs10788545	chr10:82034675	A/G	cg00277334	chr10:82204260	NA	-0.53	-6.64	-0.38	1.82e-10	Post bronchodilator FEV1;
CESC	cis	rs875971	1.000	rs6460295	chr7:65882728	T/C	cg18876405	chr7:65276391	NA	0.5	6.68	0.38	1.43e-10	Aortic root size;
CESC	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg06601766	chr17:61851465	DDX42;CCDC47	-0.53	-6.58	-0.37	2.55e-10	Prudent dietary pattern;
CESC	cis	rs1577917	1.000	rs35419329	chr6:86702291	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.47	-5.97	-0.34	7.47e-9	Response to antipsychotic treatment;
CESC	cis	rs818427	0.826	rs439456	chr5:112205207	G/C	cg07820702	chr5:112228657	REEP5	0.43	5.36	0.31	1.85e-7	Total body bone mineral density;
CESC	cis	rs7618915	0.547	rs11130317	chr3:52731483	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.38	6.71	0.38	1.15e-10	Bipolar disorder;
CESC	cis	rs8060686	0.641	rs76053508	chr16:68243054	A/T	cg26727032	chr16:67993705	SLC12A4	-0.53	-5.95	-0.34	8.65e-9	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs727563	0.608	rs2076200	chr22:41985956	G/T	cg06634786	chr22:41940651	POLR3H	-0.67	-6.46	-0.37	4.85e-10	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs34375054	0.624	rs12826658	chr12:125680237	A/G	cg25124228	chr12:125621409	AACS	-0.48	-5.48	-0.32	9.88e-8	Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs3733585	0.699	rs1122142	chr4:9947548	G/C	cg00071950	chr4:10020882	SLC2A9	-0.74	-12.17	-0.6	2.36e-27	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs13040088	1.000	rs910831	chr20:61558775	T/C	cg23096297	chr20:61557774	DIDO1	0.97	10.48	0.54	9.68e-22	Menopause (age at onset);
CESC	cis	rs870825	0.616	rs6552801	chr4:185620623	G/A	cg04058563	chr4:185651563	MLF1IP	0.64	7.05	0.4	1.59e-11	Blood protein levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12168153	chr19:55770892	SAPS1	-0.64	-7.54	-0.42	7.44e-13	Gut microbiome composition (summer);
CESC	trans	rs10411161	0.702	rs8113685	chr19:52383890	C/T	cg22319618	chr22:45562946	NUP50	-0.7	-6.78	-0.38	7.84e-11	Breast cancer;
CESC	cis	rs425277	1.000	rs262672	chr1:2080813	G/T	cg16545954	chr1:2118288	C1orf86	0.33	5.6	0.33	5.35e-8	Height;
CESC	cis	rs7188697	0.922	rs2243463	chr16:58571189	T/C	cg02549819	chr16:58548995	SETD6	-0.42	-5.3	-0.31	2.46e-7	QT interval;
CESC	cis	rs58804349	0.685	rs11239855	chr10:43483879	A/G	cg08461752	chr10:43522343	NA	0.58	5.2	0.3	3.96e-7	Pediatric bone mineral content (radius);
CESC	cis	rs514406	0.792	rs1242201	chr1:53344748	G/A	cg08859206	chr1:53392774	SCP2	-0.71	-9.87	-0.52	8.91e-20	Monocyte count;
CESC	cis	rs10504229	0.724	rs72650827	chr8:58126884	A/T	cg22535103	chr8:58192502	C8orf71	-0.84	-9.44	-0.5	2.04e-18	Developmental language disorder (linguistic errors);
CESC	cis	rs9291683	0.595	rs13150928	chr4:10052961	G/T	cg00071950	chr4:10020882	SLC2A9	0.83	14.82	0.67	1.32e-36	Bone mineral density;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg18409845	chr10:94050143	CPEB3;MARCH5	0.42	6.02	0.35	5.77e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs1552244	1.000	rs13319597	chr3:10126312	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	0.83	11.75	0.59	6.1e-26	Alzheimer's disease;
CESC	cis	rs1348850	0.872	rs10165785	chr2:178293295	C/T	cg22681709	chr2:178499509	PDE11A	-0.44	-6.53	-0.37	3.34e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs1799949	1.000	rs16940	chr17:41245237	A/G	cg25072359	chr17:41440525	NA	0.46	6.2	0.36	2.18e-9	Menopause (age at onset);
CESC	cis	rs832540	0.966	rs252925	chr5:56203773	G/A	cg14703610	chr5:56206110	C5orf35	0.54	7.11	0.4	1.1e-11	Coronary artery disease;
CESC	cis	rs3733585	0.578	rs6837224	chr4:9955255	G/T	cg11266682	chr4:10021025	SLC2A9	-0.57	-10.92	-0.56	3.75e-23	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs1322639	0.574	rs9364360	chr6:169580174	G/A	cg04662567	chr6:169592167	NA	-0.49	-5.11	-0.3	6.06e-7	Pulse pressure;
CESC	trans	rs11098499	0.779	rs7699346	chr4:120310542	C/T	cg25214090	chr10:38739885	LOC399744	0.67	9.03	0.49	3.54e-17	Corneal astigmatism;
CESC	cis	rs9311474	0.508	rs11714565	chr3:52606292	C/T	cg17372223	chr3:52568218	NT5DC2	0.4	5.93	0.34	9.47e-9	Electroencephalogram traits;
CESC	cis	rs74181299	0.964	rs2540948	chr2:65284623	T/C	cg05010058	chr2:65284262	CEP68	0.34	5.85	0.34	1.45e-8	Pulse pressure;
CESC	cis	rs6952808	0.691	rs2398709	chr7:2112548	C/T	cg04267008	chr7:1944627	MAD1L1	-0.62	-7.68	-0.43	3.12e-13	Bipolar disorder and schizophrenia;
CESC	cis	rs2276314	1.000	rs4799835	chr18:33571268	G/A	cg19628046	chr18:33552617	C18orf21	0.57	6.02	0.35	5.73e-9	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs6921919	0.583	rs2041230	chr6:28365515	A/G	cg00651523	chr6:28411279	ZSCAN23	-0.32	-5.08	-0.3	7.26e-7	Autism spectrum disorder or schizophrenia;
CESC	trans	rs12599106	0.625	rs12923277	chr16:34896261	G/A	cg16103275	chr6:290800	DUSP22	0.44	6.06	0.35	4.67e-9	Menopause (age at onset);
CESC	trans	rs11098499	0.954	rs2892848	chr4:120381341	C/T	cg25214090	chr10:38739885	LOC399744	0.7	9.86	0.52	9.48e-20	Corneal astigmatism;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg08898192	chr17:8042067	NA	0.47	6.31	0.36	1.16e-9	Gut microbiota (bacterial taxa);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00352560	chr1:45106266	RNF220	-0.54	-6.09	-0.35	3.99e-9	Gut microbiome composition (summer);
CESC	cis	rs3126085	0.935	rs2184950	chr1:152272776	T/C	cg03465714	chr1:152285911	FLG	0.47	5.59	0.32	5.67e-8	Atopic dermatitis;
CESC	cis	rs684232	0.602	rs34167561	chr17:509268	G/A	cg12384639	chr17:618140	VPS53	0.43	5.52	0.32	8.04e-8	Prostate cancer;
CESC	trans	rs6934970	0.860	rs1455910	chr6:112995882	G/T	cg05146922	chr2:10634174	NA	-0.38	-6.04	-0.35	5.19e-9	Bipolar disorder (body mass index interaction);
CESC	cis	rs10504229	0.863	rs75954631	chr8:58166194	C/A	cg05313129	chr8:58192883	C8orf71	-0.48	-5.18	-0.3	4.41e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs11958404	0.789	rs72818150	chr5:157484121	A/G	cg05962755	chr5:157440814	NA	0.62	7.24	0.41	4.78e-12	IgG glycosylation;
CESC	cis	rs8031584	1.000	rs35811129	chr15:31241346	G/A	cg14829155	chr15:31115871	NA	-0.77	-9.84	-0.52	1.13e-19	Huntington's disease progression;
CESC	cis	rs3091242	0.933	rs35497030	chr1:25783066	A/G	cg27572855	chr1:25598939	RHD	-0.43	-7.03	-0.4	1.72e-11	Erythrocyte sedimentation rate;
CESC	cis	rs7618915	0.501	rs10865974	chr3:52718280	A/C	cg18099408	chr3:52552593	STAB1	0.3	5.15	0.3	5.02e-7	Bipolar disorder;
CESC	cis	rs7647973	1.000	rs4241407	chr3:49600319	C/T	cg07636037	chr3:49044803	WDR6	0.71	10.36	0.54	2.45e-21	Menarche (age at onset);
CESC	cis	rs754466	0.606	rs11002310	chr10:79596030	A/C	cg17075019	chr10:79541650	NA	-0.88	-14.1	-0.65	4.71e-34	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs2797160	0.651	rs1268067	chr6:126036621	T/C	cg05901451	chr6:126070800	HEY2	0.5	7.3	0.41	3.35e-12	Endometrial cancer;
CESC	trans	rs57221529	0.766	rs72706606	chr5:558609	T/C	cg25482853	chr8:67687455	SGK3	1.11	11.94	0.59	1.39e-26	Lung disease severity in cystic fibrosis;
CESC	cis	rs875971	0.825	rs7384021	chr7:66077904	A/G	cg18252515	chr7:66147081	NA	0.47	6.17	0.35	2.57e-9	Aortic root size;
CESC	cis	rs7089973	0.604	rs11196947	chr10:116601372	G/A	cg23260525	chr10:116636907	FAM160B1	0.4	7.2	0.4	6.31e-12	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs2066819	1.000	rs871130	chr12:56648777	A/G	cg26714650	chr12:56694279	CS	1.42	10.05	0.53	2.39e-20	Psoriasis vulgaris;
CESC	cis	rs4919687	0.550	rs11191371	chr10:104459897	G/C	cg04362960	chr10:104952993	NT5C2	0.44	5.16	0.3	4.76e-7	Colorectal cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20390741	chr1:87597574	LOC339524	0.62	7.45	0.42	1.29e-12	Gut microbiome composition (summer);
CESC	cis	rs4665809	0.556	rs6730311	chr2:26419474	C/T	cg26314531	chr2:26401878	FAM59B	-0.84	-9.75	-0.51	2.13e-19	Gut microbiome composition (summer);
CESC	cis	rs7589728	0.563	rs12479338	chr2:88444513	C/T	cg07952391	chr2:88470173	THNSL2	0.62	6.05	0.35	4.86e-9	Plasma clusterin levels;
CESC	cis	rs7412746	0.588	rs10305664	chr1:150839686	A/C	cg22823121	chr1:150693482	HORMAD1	0.45	6.26	0.36	1.57e-9	Melanoma;
CESC	cis	rs2832191	0.692	rs2776240	chr21:30310639	C/T	cg08807101	chr21:30365312	RNF160	0.88	13.66	0.64	1.55e-32	Dental caries;
CESC	cis	rs4604732	0.588	rs7549495	chr1:247627806	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.53	6.57	0.37	2.7e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs35306767	0.903	rs11253458	chr10:882843	T/C	cg26597838	chr10:835615	NA	0.87	9.15	0.49	1.58e-17	Eosinophil percentage of granulocytes;
CESC	cis	rs7193541	0.684	rs8062783	chr16:74691264	C/T	cg01733217	chr16:74700730	RFWD3	-1.05	-20.08	-0.78	3.85e-55	Multiple myeloma;
CESC	cis	rs9859260	0.744	rs406271	chr3:195776976	T/C	cg12923728	chr3:195709715	SDHAP1	0.54	6.98	0.39	2.38e-11	Mean corpuscular volume;
CESC	cis	rs2011503	0.882	rs4808958	chr19:19571752	G/A	cg11584989	chr19:19387371	SF4	0.67	7.61	0.42	4.87e-13	Bipolar disorder;
CESC	cis	rs66573146	0.831	rs11546450	chr4:7032180	G/A	cg00086871	chr4:6988644	TBC1D14	0.97	5.96	0.34	7.99e-9	Granulocyte percentage of myeloid white cells;
CESC	cis	rs6460942	0.591	rs62448727	chr7:12332362	G/C	cg20607287	chr7:12443886	VWDE	-0.63	-6.83	-0.39	5.83e-11	Coronary artery disease;
CESC	cis	rs7772486	0.846	rs9376976	chr6:146355605	T/C	cg23711669	chr6:146136114	FBXO30	0.85	12.46	0.61	2.27e-28	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs193541	0.632	rs2407402	chr5:122107105	G/C	cg19412675	chr5:122181750	SNX24	0.45	5.27	0.31	2.81e-7	Glucose homeostasis traits;
CESC	cis	rs9635726	0.638	rs2952155	chr17:37861718	T/C	cg07936489	chr17:37558343	FBXL20	-0.66	-7.08	-0.4	1.3e-11	Primary biliary cholangitis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15232214	chr8:123964031	ZHX2	-0.55	-6.5	-0.37	3.91e-10	Gut microbiome composition (summer);
CESC	cis	rs56036086	1.000	rs73187250	chr22:50634552	G/A	cg16473166	chr22:50639996	SELO	0.65	5.11	0.3	6.25e-7	Platelet count;Plateletcrit;
CESC	cis	rs2404602	0.692	rs58361452	chr15:76973372	T/C	cg26408565	chr15:76604113	ETFA	-0.39	-5.72	-0.33	2.94e-8	Blood metabolite levels;
CESC	cis	rs56399783	0.901	rs6967664	chr7:2816384	A/G	cg19731401	chr7:2775893	GNA12	0.64	5.75	0.33	2.49e-8	Childhood ear infection;
CESC	cis	rs6782228	1.000	rs35604103	chr3:128334852	C/T	cg15607142	chr3:128420513	NA	-0.37	-5.15	-0.3	5.19e-7	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
CESC	cis	rs782590	0.582	rs2627767	chr2:55926815	A/T	cg18811423	chr2:55921094	PNPT1	0.76	12.23	0.6	1.44e-27	Metabolic syndrome;
CESC	cis	rs769267	0.965	rs12460764	chr19:19431963	G/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.62	-8.04	-0.44	2.94e-14	Tonsillectomy;
CESC	cis	rs3096299	0.658	rs3934737	chr16:89560209	G/A	cg08392591	chr16:89556376	ANKRD11	0.62	8.43	0.46	2.25e-15	Multiple myeloma (IgH translocation);
CESC	cis	rs1448094	0.512	rs11117057	chr12:86248546	C/T	cg19622623	chr12:86230825	RASSF9	-0.46	-5.89	-0.34	1.14e-8	Major depressive disorder;
CESC	cis	rs853679	0.542	rs9393892	chr6:28081394	A/G	cg26335602	chr6:28129616	ZNF389	0.54	7.18	0.4	6.95e-12	Depression;
CESC	cis	rs9916302	0.904	rs11078898	chr17:37536480	A/G	cg00129232	chr17:37814104	STARD3	0.57	7.41	0.41	1.7e-12	Glomerular filtration rate (creatinine);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14311538	chr9:139348775	SEC16A	-0.56	-6.09	-0.35	3.93e-9	Gut microbiome composition (summer);
CESC	trans	rs11264799	0.765	rs12144103	chr1:157620499	A/G	cg22691776	chr3:15032403	NR2C2	0.34	6.29	0.36	1.29e-9	IgA nephropathy;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg04841405	chr16:1501118	CLCN7	0.45	6.21	0.36	2.07e-9	Fibrinogen levels;
CESC	cis	rs4604732	0.631	rs56704806	chr1:247626148	T/C	cg12758973	chr1:247694275	LOC148824;OR2C3	0.51	6.36	0.36	8.65e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs2839186	0.900	rs2839200	chr21:47709095	C/T	cg10351095	chr21:47802916	PCNT	-0.51	-6.89	-0.39	4.11e-11	Testicular germ cell tumor;
CESC	cis	rs9913156	0.696	rs72835620	chr17:4558128	G/A	cg19197139	chr17:4613644	ARRB2	0.91	10.33	0.54	3.1e-21	Lymphocyte counts;
CESC	cis	rs9322193	0.923	rs1934534	chr6:150033032	A/G	cg04369109	chr6:150039330	LATS1	-0.41	-5.71	-0.33	3.04e-8	Lung cancer;
CESC	cis	rs1465370	0.682	rs2239604	chr7:130021331	C/T	cg04743876	chr7:130013617	NA	0.3	5.59	0.32	5.57e-8	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
CESC	cis	rs11711311	0.955	rs9813630	chr3:113377361	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.51	6.45	0.37	5.36e-10	IgG glycosylation;
CESC	cis	rs9322193	0.923	rs12195866	chr6:150014470	A/G	cg05861140	chr6:150128134	PCMT1	-0.36	-5.25	-0.31	3.16e-7	Lung cancer;
CESC	cis	rs425277	0.628	rs3107147	chr1:2048729	G/A	cg24578937	chr1:2090814	PRKCZ	-0.33	-5.77	-0.33	2.21e-8	Height;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg14490552	chr8:101965602	YWHAZ	-0.5	-6.38	-0.36	8.03e-10	Fibrinogen levels;
CESC	trans	rs61931739	0.500	rs7977186	chr12:34431486	C/G	cg13010199	chr12:38710504	ALG10B	0.49	6.3	0.36	1.24e-9	Morning vs. evening chronotype;
CESC	cis	rs7542091	0.704	rs7537294	chr1:210043777	A/G	cg09509183	chr1:209979624	IRF6	0.4	5.78	0.33	2.12e-8	Monobrow;
CESC	cis	rs425277	0.500	rs908744	chr1:2038893	G/A	cg16545954	chr1:2118288	C1orf86	-0.31	-5.97	-0.34	7.74e-9	Height;
CESC	cis	rs854765	0.647	rs6502637	chr17:17986098	A/G	cg04398451	chr17:18023971	MYO15A	-0.76	-11.23	-0.57	3.42e-24	Total body bone mineral density;
CESC	cis	rs6952808	0.656	rs73048919	chr7:2103637	C/A	cg05863683	chr7:1912471	MAD1L1	0.42	6.09	0.35	4.06e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs28829049	0.597	rs12740975	chr1:19437923	G/A	cg13387374	chr1:19411106	UBR4	0.41	5.09	0.3	6.7e-7	QRS duration in Tripanosoma cruzi seropositivity;
CESC	cis	rs5758659	0.935	rs134879	chr22:42664201	A/C	cg05082376	chr22:42548792	NA	-0.38	-5.74	-0.33	2.54e-8	Cognitive function;
CESC	cis	rs11792861	0.926	rs11788904	chr9:111865052	T/C	cg05043794	chr9:111880884	C9orf5	-0.42	-6.93	-0.39	3.22e-11	Menarche (age at onset);
CESC	cis	rs703842	1.000	rs10877015	chr12:58167788	A/G	cg00677455	chr12:58241039	CTDSP2	0.51	6.61	0.38	2.15e-10	Multiple sclerosis;
CESC	cis	rs2742234	0.541	rs7073849	chr10:43740474	G/C	cg15436174	chr10:43711423	RASGEF1A	0.46	5.3	0.31	2.44e-7	Hirschsprung disease;
CESC	cis	rs8002861	0.846	rs12428314	chr13:44476011	C/T	cg19180546	chr13:44453867	C13orf31;CCDC122	-0.45	-5.79	-0.34	1.94e-8	Leprosy;
CESC	cis	rs7772486	0.774	rs2247571	chr6:146219533	T/A	cg05347473	chr6:146136440	FBXO30	0.42	5.85	0.34	1.45e-8	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs1728785	1.000	rs1170445	chr16:68573064	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.61	7.44	0.42	1.41e-12	Ulcerative colitis;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg06725705	chr16:9058264	USP7	-0.48	-6.21	-0.36	1.99e-9	Ulcerative colitis;
CESC	cis	rs10504229	1.000	rs67236942	chr8:58176525	T/C	cg14926445	chr8:58193284	C8orf71	-0.51	-5.47	-0.32	1.03e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs11190604	1.000	rs2495752	chr10:102326115	T/C	cg07080220	chr10:102295463	HIF1AN	0.63	5.98	0.34	7.11e-9	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs853679	0.517	rs9368555	chr6:28108967	T/C	cg08968635	chr6:28129556	ZNF389	0.41	5.53	0.32	7.61e-8	Depression;
CESC	cis	rs2880765	0.835	rs7162502	chr15:86044473	G/T	cg19183879	chr15:85880815	NA	-0.26	-5.29	-0.31	2.52e-7	Coronary artery disease;
CESC	cis	rs6460942	0.915	rs62448598	chr7:12453762	T/C	cg10578991	chr7:12443926	VWDE	-0.5	-5.52	-0.32	7.93e-8	Coronary artery disease;
CESC	cis	rs8072100	0.807	rs2175290	chr17:45479917	C/A	cg25173405	chr17:45401733	C17orf57	-0.42	-5.54	-0.32	7.43e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs514406	0.505	rs374662	chr1:53164549	C/A	cg08859206	chr1:53392774	SCP2	-0.6	-8.05	-0.44	2.89e-14	Monocyte count;
CESC	cis	rs2299587	0.560	rs391299	chr8:17778922	T/C	cg08627089	chr8:17753878	FGL1	-0.41	-5.37	-0.31	1.76e-7	Economic and political preferences;
CESC	cis	rs10129255	0.500	rs4774008	chr14:107137290	A/T	cg07958169	chr14:107095056	NA	-0.57	-9.05	-0.49	3.15e-17	Kawasaki disease;
CESC	cis	rs412050	0.547	rs61763401	chr22:22139847	C/T	cg17089214	chr22:22089827	YPEL1	0.68	5.54	0.32	7.29e-8	Attention deficit hyperactivity disorder;
CESC	trans	rs1814175	0.645	rs11040671	chr11:49958776	G/A	cg15704280	chr7:45808275	SEPT13	-1.01	-19.02	-0.76	1.83e-51	Height;
CESC	cis	rs6502050	0.835	rs6502070	chr17:80112634	G/A	cg23985595	chr17:80112537	CCDC57	-0.41	-6.31	-0.36	1.18e-9	Life satisfaction;
CESC	cis	rs4722166	0.604	rs2390715	chr7:22783878	A/C	cg26061582	chr7:22766209	IL6	0.51	5.5	0.32	9.05e-8	Lung cancer;
CESC	cis	rs9487051	0.676	rs6903107	chr6:109597711	A/G	cg21918786	chr6:109611834	NA	-0.38	-5.52	-0.32	8.19e-8	Reticulocyte fraction of red cells;
CESC	cis	rs57506017	0.585	rs13237715	chr7:12269575	G/C	cg23422036	chr7:12250390	TMEM106B	0.38	5.15	0.3	5.16e-7	Neuroticism;
CESC	cis	rs11711311	0.747	rs2895415	chr3:113345565	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.56	7.44	0.42	1.37e-12	IgG glycosylation;
CESC	cis	rs12142240	0.698	rs41294458	chr1:46810304	T/C	cg10495392	chr1:46806563	NSUN4	0.59	6.34	0.36	9.65e-10	Menopause (age at onset);
CESC	cis	rs9583531	0.629	rs7991766	chr13:111380684	A/G	cg15841412	chr13:111365552	ING1	0.44	5.52	0.32	8.18e-8	Coronary artery disease;
CESC	cis	rs6088590	1.000	rs6119535	chr20:33442138	A/C	cg08999081	chr20:33150536	PIGU	0.48	7.12	0.4	9.85e-12	Coronary artery disease;
CESC	cis	rs7408868	1.000	rs757475	chr19:15273749	C/T	cg14696996	chr19:15285081	NOTCH3	1.11	11.47	0.58	5.57e-25	Pulse pressure;
CESC	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg01171360	chr6:293285	DUSP22	-0.68	-9.07	-0.49	2.81e-17	Menopause (age at onset);
CESC	cis	rs703842	1.000	rs1599932	chr12:58177943	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.71	9.04	0.49	3.3e-17	Multiple sclerosis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14435640	chr8:41436176	AGPAT6	-0.55	-6.11	-0.35	3.59e-9	Gut microbiome composition (summer);
CESC	cis	rs17345786	1.000	rs997739	chr3:101313940	A/G	cg12386194	chr3:101231763	SENP7	0.57	6.55	0.37	3e-10	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2249694	0.960	rs4556495	chr10:135422209	C/T	cg20169779	chr10:135381914	SYCE1	-0.39	-5.64	-0.33	4.39e-8	Obesity-related traits;
CESC	cis	rs963731	0.649	rs297125	chr2:39314969	G/A	cg04010122	chr2:39346883	SOS1	-0.74	-5.39	-0.31	1.54e-7	Corticobasal degeneration;
CESC	cis	rs7000551	0.642	rs2122880	chr8:22375042	C/A	cg12081754	chr8:22256438	SLC39A14	0.38	5.08	0.3	7.12e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CESC	cis	rs7945705	0.869	rs4909952	chr11:8963946	A/G	cg09997546	chr11:8931473	C11orf17;ST5	0.36	5.93	0.34	9.43e-9	Hemoglobin concentration;
CESC	cis	rs4727027	0.868	rs10952799	chr7:148840772	C/T	cg23158103	chr7:148848205	ZNF398	-0.42	-6.97	-0.39	2.57e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs4566357	0.615	rs10198214	chr2:227913314	A/C	cg05526886	chr2:227700861	RHBDD1	-0.46	-6.15	-0.35	2.88e-9	Coronary artery disease;
CESC	cis	rs4819052	0.851	rs9753963	chr21:46661437	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.91	13.24	0.63	4.51e-31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs780096	0.506	rs8395	chr2:27715207	T/A	cg22903471	chr2:27725779	GCKR	-0.59	-8.52	-0.46	1.23e-15	Total body bone mineral density;
CESC	cis	rs950169	0.840	rs4842854	chr15:84942339	T/G	cg17507749	chr15:85114479	UBE2QP1	0.59	6.52	0.37	3.46e-10	Schizophrenia;
CESC	cis	rs631288	0.793	rs10900331	chr1:146733128	C/G	cg25205988	chr1:146714368	CHD1L	1.04	8.67	0.47	4.54e-16	PR interval in Tripanosoma cruzi seropositivity;
CESC	cis	rs4665809	0.549	rs34075014	chr2:26520842	T/C	cg04944784	chr2:26401820	FAM59B	0.81	7.96	0.44	5.13e-14	Gut microbiome composition (summer);
CESC	cis	rs7301826	0.651	rs4759517	chr12:131283698	G/A	cg11011512	chr12:131303247	STX2	0.47	5.77	0.33	2.26e-8	Plasma plasminogen activator levels;
CESC	trans	rs1814175	0.645	rs1608632	chr11:49967148	C/T	cg15704280	chr7:45808275	SEPT13	-1.01	-19.02	-0.76	1.83e-51	Height;
CESC	cis	rs7666738	0.830	rs10010223	chr4:99021758	G/A	cg17366294	chr4:99064904	C4orf37	0.61	8.76	0.47	2.35e-16	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11072298	chr12:113772666	SLC24A6	0.58	6.54	0.37	3.16e-10	Gut microbiome composition (summer);
CESC	cis	rs4689388	0.926	rs10937718	chr4:6295217	T/C	cg14416269	chr4:6271139	WFS1	0.46	7.76	0.43	1.79e-13	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	trans	rs17685	0.784	rs1637043	chr7:75699099	G/A	cg19862616	chr7:65841803	NCRNA00174	0.87	12.71	0.62	3.24e-29	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs17376456	0.825	rs10038831	chr5:93124115	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.61	5.26	0.31	3.01e-7	Diabetic retinopathy;
CESC	cis	rs6691722	0.503	rs1142057	chr1:24706292	C/T	cg18323236	chr1:24743029	NIPAL3	-0.38	-5.77	-0.33	2.25e-8	Response to interferon beta in multiple sclerosis;
CESC	cis	rs780096	1.000	rs780096	chr2:27741072	C/G	cg22903471	chr2:27725779	GCKR	-0.38	-5.2	-0.3	3.98e-7	Total body bone mineral density;
CESC	cis	rs3820068	0.581	rs12385690	chr1:15932932	A/T	cg17385448	chr1:15911702	AGMAT	0.44	7.46	0.42	1.27e-12	Systolic blood pressure;
CESC	cis	rs28489187	0.683	rs12047422	chr1:85848830	T/G	cg16011679	chr1:85725395	C1orf52	0.53	6.17	0.35	2.49e-9	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	cis	rs6866344	0.570	rs1071882	chr5:178136040	C/T	cg10224037	chr5:178157518	ZNF354A	0.7	8.48	0.46	1.65e-15	Neutrophil percentage of white cells;
CESC	cis	rs6669072	0.739	rs3843305	chr1:91243376	G/A	cg08895590	chr1:91227319	NA	-0.36	-6.15	-0.35	2.8e-9	Cognitive function;
CESC	cis	rs875971	0.545	rs67397473	chr7:65633305	A/G	cg25405998	chr7:65216604	CCT6P1	0.45	5.06	0.3	7.71e-7	Aortic root size;
CESC	cis	rs7044106	0.762	rs1411158	chr9:123464804	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.37	5.98	0.34	7.3e-9	Hip circumference adjusted for BMI;
CESC	cis	rs13082711	0.595	rs13075389	chr3:27339586	C/T	cg02860705	chr3:27208620	NA	0.76	9.16	0.49	1.46e-17	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CESC	trans	rs916888	0.610	rs199444	chr17:44818276	T/C	cg22968622	chr17:43663579	NA	0.79	10.74	0.55	1.39e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs6540559	1.000	rs2073485	chr1:209962794	G/A	cg09509183	chr1:209979624	IRF6	0.51	6.27	0.36	1.44e-9	Cleft lip with or without cleft palate;
CESC	cis	rs10779751	0.770	rs11585553	chr1:11233814	G/A	cg08854313	chr1:11322531	MTOR	-0.74	-8.37	-0.46	3.36e-15	Body mass index;
CESC	trans	rs3808502	0.525	rs13280813	chr8:11425105	G/T	cg15556689	chr8:8085844	FLJ10661	-0.55	-6.44	-0.37	5.68e-10	Neuroticism;
CESC	cis	rs716804	0.592	rs10770106	chr11:10312077	A/C	cg01453529	chr11:10209919	SBF2	-0.69	-6.1	-0.35	3.68e-9	Neuroticism;
CESC	cis	rs40363	0.645	rs250630	chr16:3524242	C/T	cg00484396	chr16:3507460	NAT15	0.44	7.27	0.41	4.08e-12	Tuberculosis;
CESC	cis	rs1008375	0.966	rs7675735	chr4:17587137	T/A	cg16339924	chr4:17578868	LAP3	0.73	9.53	0.51	1.03e-18	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg07080049	chr9:96214194	FAM120A;FAM120AOS	0.51	6.46	0.37	5.13e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs3820068	0.581	rs67806552	chr1:15927138	T/C	cg13390004	chr1:15929781	NA	0.34	5.45	0.32	1.13e-7	Systolic blood pressure;
CESC	cis	rs2953174	0.786	rs2953177	chr2:241516616	A/G	cg07929629	chr2:241523174	NA	0.54	5.91	0.34	1.03e-8	Bipolar disorder;
CESC	cis	rs5760092	0.572	rs738806	chr22:24234172	A/G	cg18538332	chr22:24372958	LOC391322	-0.61	-7.38	-0.41	2.02e-12	Urinary 1,3-butadiene metabolite levels in smokers;
CESC	cis	rs79349575	0.811	rs12601072	chr17:46997998	T/C	cg16584676	chr17:46985605	UBE2Z	0.54	6.7	0.38	1.24e-10	Type 2 diabetes;
CESC	cis	rs875971	0.571	rs78668714	chr7:65939451	G/A	cg18527119	chr7:66119851	NA	-0.47	-5.07	-0.3	7.42e-7	Aortic root size;
CESC	cis	rs35306767	0.953	rs12762973	chr10:960761	C/G	cg10556349	chr10:835070	NA	0.59	5.95	0.34	8.58e-9	Eosinophil percentage of granulocytes;
CESC	cis	rs2050392	0.630	rs303426	chr10:30740379	A/G	cg25182066	chr10:30743637	MAP3K8	0.48	6.88	0.39	4.34e-11	Inflammatory bowel disease;
CESC	cis	rs9649213	0.593	rs1468341	chr7:97987696	G/A	cg00277769	chr7:97922759	BAIAP2L1	-0.33	-5.5	-0.32	9.09e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs1065656	0.571	rs12149777	chr16:1834724	A/G	cg08610935	chr16:1836813	NUBP2	-0.47	-6.58	-0.37	2.47e-10	Insulin-like growth factors;
CESC	cis	rs3785574	0.962	rs2727324	chr17:61922102	G/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.71	9.31	0.5	5.06e-18	Height;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg01820765	chr16:85241897	NA	0.43	6.02	0.35	5.82e-9	Fibrinogen levels;
CESC	cis	rs10465746	0.725	rs2024591	chr1:84329235	C/T	cg10977910	chr1:84465055	TTLL7	0.54	7.39	0.41	1.96e-12	Obesity-related traits;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg04574282	chr14:89315467	TTC8	0.37	6.01	0.35	5.98e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs870825	0.616	rs2130393	chr4:185642335	T/C	cg04058563	chr4:185651563	MLF1IP	0.65	7.16	0.4	8e-12	Blood protein levels;
CESC	cis	rs9640161	0.750	rs73170185	chr7:150030191	C/A	cg10018233	chr7:150070692	REPIN1	0.44	6.42	0.37	6.3e-10	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs6582630	0.519	rs8189618	chr12:38276281	A/C	cg13010199	chr12:38710504	ALG10B	0.48	6.04	0.35	5.23e-9	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs4566357	0.615	rs4350744	chr2:227918146	A/T	cg11843606	chr2:227700838	RHBDD1	-0.53	-7.15	-0.4	8.26e-12	Coronary artery disease;
CESC	cis	rs9921222	0.500	rs11645742	chr16:367516	C/T	cg00101154	chr16:420108	MRPL28	-0.45	-5.18	-0.3	4.46e-7	Bone mineral density (spine);Bone mineral density;
CESC	cis	rs4481887	0.861	rs4486480	chr1:248449714	C/T	cg00666640	chr1:248458726	OR2T12	0.41	6.68	0.38	1.37e-10	Common traits (Other);
CESC	cis	rs7659604	0.539	rs1507995	chr4:122748308	G/A	cg20573242	chr4:122745356	CCNA2	0.66	8.14	0.45	1.6e-14	Type 2 diabetes;
CESC	cis	rs3857067	0.772	rs4438731	chr4:95091384	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.61	-9.1	-0.49	2.18e-17	QT interval;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12738349	chr22:24236284	MIF	0.58	7.09	0.4	1.19e-11	Gut microbiome composition (summer);
CESC	cis	rs875971	1.000	rs6946143	chr7:65579722	A/C	cg12463550	chr7:65579703	CRCP	0.56	6.76	0.38	8.75e-11	Aortic root size;
CESC	cis	rs9325144	0.555	rs10748433	chr12:38696352	C/G	cg26384229	chr12:38710491	ALG10B	0.58	8.47	0.46	1.67e-15	Morning vs. evening chronotype;
CESC	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.54	6.7	0.38	1.25e-10	Prudent dietary pattern;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg26450010	chr19:17412054	ABHD8	0.48	6.8	0.39	6.8e-11	Fibrinogen levels;
CESC	cis	rs8044868	0.530	rs9928157	chr16:72117073	T/C	cg16558253	chr16:72132732	DHX38	-0.39	-6.08	-0.35	4.27e-9	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CESC	cis	rs1552244	1.000	rs113771705	chr3:10075983	T/C	cg00166722	chr3:10149974	C3orf24	0.46	5.88	0.34	1.21e-8	Alzheimer's disease;
CESC	cis	rs4588572	0.642	rs7722126	chr5:77645784	T/C	cg11547950	chr5:77652471	NA	-0.43	-6.23	-0.36	1.85e-9	Triglycerides;
CESC	cis	rs568617	0.953	rs658524	chr11:65647260	A/G	cg19792802	chr11:65647270	CTSW	-0.35	-5.31	-0.31	2.33e-7	Crohn's disease;
CESC	trans	rs6089829	0.962	rs7273930	chr20:61666017	G/A	cg23505145	chr19:12996616	KLF1	0.53	6.86	0.39	4.74e-11	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs3942852	0.622	rs6485806	chr11:48102806	A/G	cg03929089	chr4:120376271	NA	0.52	6.0	0.35	6.41e-9	Acute lymphoblastic leukemia (childhood);
CESC	trans	rs801193	1.000	rs2707856	chr7:66211010	A/T	cg26939375	chr7:64535504	NA	0.66	9.05	0.49	3.22e-17	Aortic root size;
CESC	cis	rs11650494	0.803	rs117801358	chr17:47447950	C/A	cg08112188	chr17:47440006	ZNF652	1.16	7.85	0.43	1.06e-13	Prostate cancer;
CESC	cis	rs4713118	0.513	rs149955	chr6:28036225	G/C	cg17221315	chr6:27791827	HIST1H4J	0.45	5.69	0.33	3.44e-8	Parkinson's disease;
CESC	cis	rs7116495	0.609	rs79889241	chr11:71815585	T/C	cg26138937	chr11:71823887	C11orf51	1.33	8.25	0.45	7.62e-15	Severe influenza A (H1N1) infection;
CESC	trans	rs7615952	0.599	rs7631268	chr3:125755664	T/A	cg07211511	chr3:129823064	LOC729375	-0.59	-6.52	-0.37	3.53e-10	Blood pressure (smoking interaction);
CESC	cis	rs3091242	0.967	rs3093614	chr1:25677844	T/A	cg02931644	chr1:25747376	RHCE	-0.4	-6.55	-0.37	3.02e-10	Erythrocyte sedimentation rate;
CESC	cis	rs4819052	1.000	rs2838847	chr21:46670958	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.89	11.83	0.59	3.37e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs4835473	0.864	rs57648439	chr4:144612672	G/A	cg25736465	chr4:144833511	NA	-0.36	-5.4	-0.31	1.52e-7	Immature fraction of reticulocytes;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg23268322	chr19:50762551	MYH14	0.49	6.6	0.38	2.23e-10	Fibrinogen levels;
CESC	cis	rs10788972	1.000	rs10788972	chr1:54572243	C/A	cg25741118	chr1:54482237	LDLRAD1	-0.24	-5.68	-0.33	3.58e-8	Parkinson disease and lewy body pathology;
CESC	cis	rs875971	0.964	rs160635	chr7:65528918	T/C	cg12463550	chr7:65579703	CRCP	0.57	7.06	0.4	1.5e-11	Aortic root size;
CESC	cis	rs2637266	0.538	rs4379767	chr10:78472596	G/A	cg18941641	chr10:78392320	NA	-0.33	-5.29	-0.31	2.58e-7	Pulmonary function;
CESC	cis	rs4654899	0.965	rs7512116	chr1:21501095	C/A	cg05370193	chr1:21551575	ECE1	0.41	6.22	0.36	1.96e-9	Superior frontal gyrus grey matter volume;
CESC	cis	rs644799	1.000	rs563653	chr11:95561488	T/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.55	6.76	0.38	8.51e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	trans	rs5769765	0.908	rs4074304	chr22:50309446	G/A	cg09872104	chr7:134855509	C7orf49	-0.55	-6.27	-0.36	1.47e-9	Schizophrenia;
CESC	cis	rs55788414	0.932	rs12102728	chr16:81181436	C/T	cg06400318	chr16:81190750	PKD1L2	-0.53	-6.56	-0.37	2.8e-10	Left ventricular obstructive tract defect (maternal effect);
CESC	cis	rs5769765	0.862	rs56377703	chr22:50306940	C/T	cg26441486	chr22:50317300	CRELD2	0.42	5.21	0.3	3.84e-7	Schizophrenia;
CESC	cis	rs4819052	0.800	rs4819045	chr21:46660138	C/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.91	13.24	0.63	4.51e-31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg21790657	chr18:77675478	PQLC1	-0.49	-6.31	-0.36	1.17e-9	Tetralogy of Fallot;
CESC	cis	rs7772486	0.622	rs1292333	chr6:145982344	C/T	cg23711669	chr6:146136114	FBXO30	-0.91	-13.76	-0.65	7.23e-33	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6500395	0.962	rs9936883	chr16:48676443	G/A	cg04672837	chr16:48644449	N4BP1	0.51	6.31	0.36	1.16e-9	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs9322193	0.809	rs9479808	chr6:150072464	A/T	cg07701084	chr6:150067640	NUP43	0.47	6.58	0.37	2.47e-10	Lung cancer;
CESC	trans	rs5756813	1.000	rs5756813	chr22:38175477	A/C	cg19894588	chr14:64061835	NA	-0.48	-6.76	-0.38	8.96e-11	Optic cup area;Vertical cup-disc ratio;
CESC	cis	rs61996546	0.622	rs11639008	chr15:26842107	C/G	cg15066197	chr15:26874202	GABRB3	-0.34	-5.1	-0.3	6.63e-7	Response to methotrexate in juvenile idiopathic arthritis;
CESC	cis	rs7089973	0.604	rs765174	chr10:116601888	C/T	cg25233709	chr10:116636983	FAM160B1	0.38	6.08	0.35	4.13e-9	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs11098499	0.954	rs3733520	chr4:120423480	C/G	cg09160332	chr4:120329925	NA	-0.38	-5.14	-0.3	5.22e-7	Corneal astigmatism;
CESC	trans	rs877282	0.786	rs11253392	chr10:788768	G/A	cg22713356	chr15:30763199	NA	1.32	13.44	0.64	9.25e-32	Uric acid levels;
CESC	cis	rs3204270	0.639	rs79193599	chr17:79651490	C/A	cg26965718	chr17:79658957	HGS	-0.77	-5.22	-0.31	3.54e-7	Dental caries;
CESC	cis	rs9815354	1.000	rs3934103	chr3:41977214	C/T	cg03022575	chr3:42003672	ULK4	-0.46	-5.37	-0.31	1.74e-7	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs916888	0.647	rs199449	chr17:44808902	G/A	cg17911788	chr17:44343683	NA	-0.44	-6.9	-0.39	3.79e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs514406	0.861	rs10888755	chr1:53240829	A/G	cg08736216	chr1:53307985	ZYG11A	0.38	6.62	0.38	2e-10	Monocyte count;
CESC	cis	rs7116495	1.000	rs6592455	chr11:71689541	C/T	cg26138937	chr11:71823887	C11orf51	0.83	6.17	0.35	2.52e-9	Severe influenza A (H1N1) infection;
CESC	cis	rs172166	0.694	rs203884	chr6:28077374	G/T	cg26335602	chr6:28129616	ZNF389	0.4	5.52	0.32	7.96e-8	Cardiac Troponin-T levels;
CESC	cis	rs9916302	0.851	rs11870631	chr17:37645129	C/T	cg20243544	chr17:37824526	PNMT	0.51	6.5	0.37	3.97e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs13191362	0.935	rs34709632	chr6:163048380	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.53	5.37	0.31	1.74e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs28386778	0.704	rs1051688	chr17:62006433	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.95	-15.09	-0.68	1.47e-37	Prudent dietary pattern;
CESC	cis	rs1371867	0.846	rs1788189	chr8:101249762	G/T	cg11906718	chr8:101322791	RNF19A	-0.44	-5.53	-0.32	7.67e-8	Atrioventricular conduction;
CESC	cis	rs4665809	0.549	rs72809635	chr2:26411674	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.02	11.56	0.58	2.78e-25	Gut microbiome composition (summer);
CESC	cis	rs1950626	0.833	rs1951025	chr14:101406022	T/A	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.79	10.67	0.55	2.42e-22	Pelvic organ prolapse (moderate/severe);
CESC	cis	rs80282103	0.618	rs2387299	chr10:1163427	A/G	cg08668510	chr10:1095578	IDI1	0.72	5.84	0.34	1.55e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs6502050	0.764	rs7215277	chr17:80159283	C/A	cg23985595	chr17:80112537	CCDC57	-0.39	-6.24	-0.36	1.76e-9	Life satisfaction;
CESC	cis	rs9790314	0.871	rs336551	chr3:161109720	T/C	cg03342759	chr3:160939853	NMD3	-0.48	-6.68	-0.38	1.37e-10	Morning vs. evening chronotype;
CESC	cis	rs3105593	0.933	rs3131601	chr15:50876942	A/C	cg08437265	chr15:50716283	USP8	0.41	5.26	0.31	2.92e-7	QT interval;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg09302609	chr2:121010281	RALB	-0.46	-6.13	-0.35	3.25e-9	Fibrinogen levels;
CESC	cis	rs6582630	0.555	rs11613249	chr12:38519339	T/C	cg13010199	chr12:38710504	ALG10B	0.49	6.43	0.37	6.06e-10	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs12249377	0.519	rs10785972	chr10:92593800	C/T	cg14313238	chr10:92632228	RPP30	0.42	5.09	0.3	6.8e-7	White matter microstructure (global fractional anisotropy);
CESC	cis	rs7666738	0.715	rs3857216	chr4:99032129	G/T	cg03467027	chr4:99064603	C4orf37	0.49	6.18	0.35	2.44e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10189230	0.967	rs13002861	chr2:222352859	T/G	cg14652038	chr2:222343519	EPHA4	0.37	7.75	0.43	1.97e-13	Urate levels in lean individuals;
CESC	cis	rs8114671	0.562	rs6088653	chr20:33520321	T/C	cg24642439	chr20:33292090	TP53INP2	0.44	5.32	0.31	2.18e-7	Height;
CESC	cis	rs875971	0.545	rs67688847	chr7:65626051	G/A	cg25405998	chr7:65216604	CCT6P1	0.45	5.06	0.3	7.71e-7	Aortic root size;
CESC	cis	rs8072100	0.676	rs9908049	chr17:45502096	G/C	cg08085267	chr17:45401833	C17orf57	-0.52	-6.6	-0.38	2.28e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs8040855	0.627	rs2304418	chr15:85640983	T/C	cg08123816	chr15:85640762	PDE8A	-0.41	-6.16	-0.35	2.7e-9	Bulimia nervosa;
CESC	cis	rs2625529	0.617	rs8557	chr15:72115733	T/C	cg16672083	chr15:72433130	SENP8	-0.48	-7.06	-0.4	1.42e-11	Red blood cell count;
CESC	cis	rs763121	0.853	rs9306329	chr22:39072454	C/T	cg06022373	chr22:39101656	GTPBP1	0.89	14.42	0.66	3.47e-35	Menopause (age at onset);
CESC	cis	rs35110281	0.592	rs6417729	chr21:44967202	A/C	cg21573476	chr21:45109991	RRP1B	-0.42	-5.86	-0.34	1.4e-8	Mean corpuscular volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26820922	chr2:32503023	YIPF4	-0.61	-7.54	-0.42	7.56e-13	Gut microbiome composition (summer);
CESC	cis	rs9916302	0.847	rs7218670	chr17:37500424	G/A	cg07936489	chr17:37558343	FBXL20	0.8	11.69	0.58	9.64e-26	Glomerular filtration rate (creatinine);
CESC	cis	rs2576037	0.526	rs7234570	chr18:44459656	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.42	6.86	0.39	4.72e-11	Personality dimensions;
CESC	cis	rs7666738	0.830	rs10440379	chr4:98902822	G/T	cg03676636	chr4:99064102	C4orf37	0.35	5.21	0.3	3.81e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7818345	0.967	rs4412390	chr8:19270143	A/T	cg11303988	chr8:19266685	CSGALNACT1	-0.32	-5.69	-0.33	3.34e-8	Language performance in older adults (adjusted for episodic memory);
CESC	cis	rs561341	0.825	rs2008368	chr17:30347397	T/C	cg19193384	chr17:30244184	NA	-0.71	-6.43	-0.37	6.05e-10	Hip circumference adjusted for BMI;
CESC	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg06873352	chr17:61820015	STRADA	0.71	12.15	0.6	2.65e-27	Prudent dietary pattern;
CESC	cis	rs11676348	0.846	rs13009946	chr2:219007752	A/C	cg00012203	chr2:219082015	ARPC2	-0.54	-7.03	-0.4	1.73e-11	Ulcerative colitis;
CESC	trans	rs11098499	0.863	rs1010739	chr4:120463471	C/T	cg25214090	chr10:38739885	LOC399744	0.61	8.15	0.45	1.41e-14	Corneal astigmatism;
CESC	cis	rs9660180	1.000	rs9660180	chr1:1723031	G/A	cg05132306	chr1:1846340	CALML6	-0.31	-6.61	-0.38	2.16e-10	Body mass index;
CESC	cis	rs75887402	1.000	rs78557471	chr5:122731890	C/T	cg27033705	chr5:122759302	CEP120	0.81	5.54	0.32	7.3e-8	Breast cancer;
CESC	cis	rs7726839	0.540	rs72707016	chr5:665148	A/G	cg16447950	chr5:562315	NA	-0.62	-6.54	-0.37	3.09e-10	Obesity-related traits;
CESC	cis	rs644799	0.965	rs499076	chr11:95546341	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.53	6.41	0.37	6.77e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs77956314	0.901	rs80001826	chr12:117335652	G/C	cg02017074	chr12:117425053	FBXW8	-0.54	-5.14	-0.3	5.44e-7	Subcortical brain region volumes;Hippocampal volume;
CESC	cis	rs67478160	0.634	rs2368558	chr14:104230518	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.53	-7.73	-0.43	2.26e-13	Schizophrenia;
CESC	trans	rs7178375	0.941	rs35497908	chr15:31224071	C/T	cg04373760	chr16:53404718	NA	0.54	7.26	0.41	4.39e-12	Hypertriglyceridemia;
CESC	cis	rs1448094	0.512	rs6539926	chr12:86244460	G/A	cg19622623	chr12:86230825	RASSF9	-0.46	-5.89	-0.34	1.14e-8	Major depressive disorder;
CESC	cis	rs9300255	0.506	rs11057251	chr12:123791227	A/G	cg05973401	chr12:123451056	ABCB9	-0.45	-5.7	-0.33	3.22e-8	Neutrophil percentage of white cells;
CESC	cis	rs514406	0.505	rs835609	chr1:53170494	T/C	cg16325326	chr1:53192061	ZYG11B	0.9	15.48	0.69	6.2e-39	Monocyte count;
CESC	cis	rs11030122	0.673	rs10767767	chr11:4003678	C/T	cg18678763	chr11:4115507	RRM1	-0.42	-5.57	-0.32	6.34e-8	Mean platelet volume;Platelet distribution width;
CESC	trans	rs1814175	0.647	rs10839394	chr11:49844747	T/C	cg15704280	chr7:45808275	SEPT13	-1.03	-20.57	-0.78	7.78e-57	Height;
CESC	cis	rs116095464	0.558	rs7725227	chr5:233517	G/A	cg20965017	chr5:231967	SDHA	-0.45	-5.05	-0.3	8.18e-7	Breast cancer;
CESC	cis	rs72781680	0.768	rs56339558	chr2:24125234	G/A	cg08917208	chr2:24149416	ATAD2B	0.6	5.95	0.34	8.39e-9	Lymphocyte counts;
CESC	cis	rs2072499	0.554	rs1052067	chr1:156206121	C/T	cg24450063	chr1:156163899	SLC25A44	0.61	7.43	0.42	1.48e-12	Testicular germ cell tumor;
CESC	cis	rs875971	0.862	rs6460307	chr7:66060871	A/G	cg18876405	chr7:65276391	NA	0.5	6.97	0.39	2.45e-11	Aortic root size;
CESC	cis	rs9322193	0.632	rs3828700	chr6:150112169	C/G	cg13206674	chr6:150067644	NUP43	0.42	5.81	0.34	1.76e-8	Lung cancer;
CESC	cis	rs3806933	0.522	rs12521169	chr5:110448313	G/A	cg04022379	chr5:110408740	TSLP	0.47	7.61	0.42	4.93e-13	Eosinophilic esophagitis;
CESC	cis	rs17376456	0.809	rs10476602	chr5:93445255	T/C	cg25358565	chr5:93447407	FAM172A	1.12	11.84	0.59	3.05e-26	Diabetic retinopathy;
CESC	cis	rs1707322	0.638	rs9429095	chr1:46603348	A/C	cg06784218	chr1:46089804	CCDC17	-0.33	-5.3	-0.31	2.48e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs4332037	0.539	rs11762636	chr7:2061111	C/A	cg11693508	chr17:37793320	STARD3	0.66	6.63	0.38	1.84e-10	Bipolar disorder;
CESC	cis	rs853679	0.517	rs17711801	chr6:28092307	C/G	cg19592336	chr6:28129416	ZNF389	0.6	8.08	0.44	2.36e-14	Depression;
CESC	cis	rs1448094	0.838	rs28509446	chr12:86312584	A/C	cg02569458	chr12:86230093	RASSF9	0.36	5.12	0.3	6.01e-7	Major depressive disorder;
CESC	cis	rs1371867	0.810	rs1692004	chr8:101247320	T/C	cg11906718	chr8:101322791	RNF19A	-0.48	-6.12	-0.35	3.36e-9	Atrioventricular conduction;
CESC	cis	rs561341	1.000	rs497479	chr17:30328605	C/T	cg19193384	chr17:30244184	NA	-0.66	-6.37	-0.36	8.42e-10	Hip circumference adjusted for BMI;
CESC	cis	rs59918340	0.728	rs10875467	chr8:142233396	A/C	cg23750338	chr8:142222470	SLC45A4	-0.6	-9.29	-0.5	5.66e-18	Immature fraction of reticulocytes;
CESC	cis	rs9309473	0.904	rs62149783	chr2:73821384	T/A	cg20560298	chr2:73613845	ALMS1	-0.54	-6.85	-0.39	5.25e-11	Metabolite levels;
CESC	cis	rs2797160	1.000	rs2797158	chr6:126009398	G/A	cg05901451	chr6:126070800	HEY2	0.45	6.57	0.37	2.63e-10	Endometrial cancer;
CESC	cis	rs36051895	0.623	rs7023639	chr9:5244058	A/C	cg02405213	chr9:5042618	JAK2	-0.49	-6.03	-0.35	5.51e-9	Pediatric autoimmune diseases;
CESC	cis	rs2929278	0.561	rs2927071	chr15:43919081	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.45	6.8	0.39	6.77e-11	Schizophrenia;
CESC	cis	rs12701220	0.604	rs12702122	chr7:1149494	C/G	cg00990874	chr7:1149470	C7orf50	-0.46	-5.08	-0.3	7.21e-7	Bronchopulmonary dysplasia;
CESC	cis	rs1620921	0.505	rs4708878	chr6:161203026	A/G	cg01280913	chr6:161186852	NA	-0.36	-5.27	-0.31	2.81e-7	Lipoprotein (a) - cholesterol levels;
CESC	cis	rs7762018	1.000	rs6923339	chr6:170128033	T/A	cg13891659	chr6:170190454	C6orf122;C6orf208	0.56	5.6	0.33	5.38e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs6088580	0.570	rs6058057	chr20:33065283	G/A	cg24642439	chr20:33292090	TP53INP2	0.52	6.9	0.39	3.73e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs1707322	0.686	rs1547924	chr1:46085112	C/T	cg06784218	chr1:46089804	CCDC17	0.42	7.37	0.41	2.19e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7216064	0.532	rs3890640	chr17:66053028	C/T	cg07042672	chr17:66097459	LOC651250	0.67	8.94	0.48	7.02e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	trans	rs11992162	0.967	rs7461062	chr8:11831948	T/C	cg15556689	chr8:8085844	FLJ10661	0.54	6.19	0.36	2.33e-9	Monocyte count;
CESC	cis	rs7605827	0.897	rs11892720	chr2:15674267	T/C	cg19274914	chr2:15703543	NA	0.33	5.8	0.34	1.88e-8	Educational attainment (years of education);
CESC	cis	rs7772486	0.875	rs56181683	chr6:146286620	A/G	cg23711669	chr6:146136114	FBXO30	-0.77	-10.96	-0.56	2.61e-23	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6088580	0.619	rs1205335	chr20:32927507	C/T	cg06115741	chr20:33292138	TP53INP2	-0.44	-5.65	-0.33	4.13e-8	Glomerular filtration rate (creatinine);
CESC	trans	rs1814175	0.817	rs4881623	chr11:49804991	C/T	cg15704280	chr7:45808275	SEPT13	-1.02	-19.96	-0.77	1.02e-54	Height;
CESC	cis	rs5758511	0.514	rs5758622	chr22:42563933	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.59	8.74	0.47	2.7e-16	Birth weight;
CESC	cis	rs2832191	0.646	rs2832210	chr21:30508723	T/G	cg08807101	chr21:30365312	RNF160	-0.54	-6.36	-0.36	8.57e-10	Dental caries;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg07870486	chr7:56019566	MRPS17	-0.51	-6.56	-0.37	2.8e-10	Asthma;
CESC	cis	rs9479482	1.000	rs13198863	chr6:150350781	T/G	cg03788504	chr6:150331562	NA	-0.38	-7.07	-0.4	1.38e-11	Alopecia areata;
CESC	cis	rs4148883	0.675	rs10015824	chr4:100074544	C/G	cg13256891	chr4:100009986	ADH5	0.53	7.0	0.4	2.1e-11	Alcohol dependence;
CESC	cis	rs7666738	0.830	rs11940273	chr4:98979965	T/A	cg05340658	chr4:99064831	C4orf37	0.79	12.24	0.6	1.33e-27	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9486715	0.809	rs9486467	chr6:96971803	C/T	cg18709589	chr6:96969512	KIAA0776	0.48	6.7	0.38	1.26e-10	Headache;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg04497927	chr16:84225080	ADAD2	0.49	6.82	0.39	5.97e-11	Fibrinogen levels;
CESC	cis	rs9733	0.569	rs11204691	chr1:150644339	A/T	cg22823121	chr1:150693482	HORMAD1	0.48	7.1	0.4	1.14e-11	Tonsillectomy;
CESC	cis	rs7100689	0.784	rs7082705	chr10:82170856	C/T	cg00277334	chr10:82204260	NA	0.57	7.13	0.4	9.46e-12	Post bronchodilator FEV1;
CESC	cis	rs963731	0.579	rs12471731	chr2:39225171	A/G	cg04010122	chr2:39346883	SOS1	-0.65	-5.86	-0.34	1.34e-8	Corticobasal degeneration;
CESC	cis	rs7678296	1.000	rs73126352	chr4:37215817	G/A	cg06805348	chr4:37245195	KIAA1239	0.47	5.18	0.3	4.37e-7	3-hydroxypropylmercapturic acid levels in smokers;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg14580081	chr19:45873861	ERCC2	-0.41	-6.61	-0.38	2.11e-10	Gambling;
CESC	cis	rs1775715	0.737	rs11817598	chr10:32206259	A/G	cg18675610	chr10:32216311	ARHGAP12	0.35	5.43	0.32	1.27e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs959260	0.557	rs12943902	chr17:73400627	G/C	cg12999837	chr17:73267436	MIF4GD	-0.52	-5.87	-0.34	1.3e-8	Systemic lupus erythematosus;
CESC	cis	rs4986811	1.000	rs4986811	chr11:32451093	T/G	cg27409910	chr11:32454216	WT1	0.48	6.17	0.35	2.59e-9	Rubella-specific interleukin-6 secretion;
CESC	cis	rs7216064	1.000	rs2365764	chr17:65857714	G/A	cg12091567	chr17:66097778	LOC651250	-0.85	-8.71	-0.47	3.45e-16	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs1045714	0.895	rs73043182	chr7:2646005	C/T	cg20813462	chr7:2646259	IQCE	0.63	5.53	0.32	7.86e-8	Urate levels in lean individuals;
CESC	cis	rs5743618	0.537	rs10019853	chr4:38765291	T/C	cg02016764	chr4:38805732	TLR1	-0.34	-5.21	-0.3	3.84e-7	Asthma;Allergic disease (asthma, hay fever or eczema);
CESC	trans	rs7615952	0.641	rs7632497	chr3:125783086	A/C	cg07211511	chr3:129823064	LOC729375	-0.58	-6.52	-0.37	3.56e-10	Blood pressure (smoking interaction);
CESC	cis	rs6681460	0.966	rs10789215	chr1:67151185	C/T	cg02459107	chr1:67143332	SGIP1	-0.37	-5.09	-0.3	6.92e-7	Presence of antiphospholipid antibodies;
CESC	cis	rs6028335	0.674	rs66647661	chr20:37671577	C/T	cg16355469	chr20:37678765	NA	0.52	5.15	0.3	5.19e-7	Alcohol and nicotine co-dependence;
CESC	cis	rs2658782	0.547	rs3020065	chr11:93059899	A/G	cg15737290	chr11:93063684	CCDC67	0.55	7.61	0.42	4.71e-13	Pulmonary function decline;
CESC	cis	rs1185460	1.000	rs1614264	chr11:118942638	A/C	cg23280166	chr11:118938394	VPS11	0.58	7.79	0.43	1.56e-13	Coronary artery disease;
CESC	trans	rs875971	0.660	rs79009421	chr7:66068509	G/C	cg26939375	chr7:64535504	NA	-0.64	-8.64	-0.47	5.37e-16	Aortic root size;
CESC	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	22.1	0.81	4.58e-62	Prudent dietary pattern;
CESC	cis	rs793571	0.502	rs387812	chr15:59074786	T/C	cg05156742	chr15:59063176	FAM63B	0.77	11.12	0.56	8.12e-24	Schizophrenia;
CESC	cis	rs4862750	0.872	rs13143414	chr4:187878213	G/A	cg03647317	chr4:187891568	NA	-0.45	-6.86	-0.39	4.83e-11	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs757081	0.636	rs664382	chr11:17206519	A/T	cg00391031	chr10:72237473	KIAA1274	0.3	6.02	0.35	5.64e-9	Systolic blood pressure;
CESC	cis	rs3087591	0.920	rs11080150	chr17:29629326	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.42	-5.22	-0.31	3.53e-7	Hip circumference;
CESC	trans	rs12339966	0.643	rs2586337	chr9:11680461	G/A	cg03904639	chr13:37677730	CSNK1A1L	0.39	5.99	0.35	6.65e-9	Systolic blood pressure;
CESC	cis	rs7666738	0.830	rs17027058	chr4:98864671	G/A	cg17366294	chr4:99064904	C4orf37	0.55	7.61	0.42	4.8e-13	Colonoscopy-negative controls vs population controls;
CESC	cis	rs362272	0.545	rs2749783	chr4:3326098	A/C	cg14583973	chr4:3374767	RGS12	0.32	5.65	0.33	4.18e-8	Serum sulfate level;
CESC	cis	rs853679	0.517	rs1947862	chr6:28105196	C/T	cg17949981	chr6:28129498	ZNF389	0.48	5.98	0.34	7.1e-9	Depression;
CESC	cis	rs7666738	0.753	rs4699604	chr4:99056353	T/C	cg05340658	chr4:99064831	C4orf37	0.81	12.43	0.61	3.06e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9926296	0.585	rs8045232	chr16:89857548	A/G	cg04287289	chr16:89883240	FANCA	0.88	14.92	0.68	5.91e-37	Vitiligo;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg12014145	chr16:30346812	LOC595101	0.45	6.02	0.35	5.84e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs10129255	0.912	rs6576227	chr14:107186441	A/G	cg23076370	chr14:107095027	NA	-0.48	-6.29	-0.36	1.32e-9	Kawasaki disease;
CESC	cis	rs17253792	0.822	rs10483650	chr14:56145312	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.81	5.68	0.33	3.46e-8	Putamen volume;
CESC	cis	rs1799949	0.894	rs8176160	chr17:41241503	T/C	cg23758822	chr17:41437982	NA	1.0	15.66	0.69	1.44e-39	Menopause (age at onset);
CESC	trans	rs875971	0.522	rs1968127	chr7:66056803	C/T	cg26939375	chr7:64535504	NA	-0.63	-8.52	-0.46	1.24e-15	Aortic root size;
CESC	cis	rs7843479	1.000	rs7843479	chr8:21820813	G/T	cg17168535	chr8:21777572	XPO7	0.53	7.26	0.41	4.2e-12	Mean corpuscular volume;
CESC	cis	rs7945705	0.902	rs1560569	chr11:8939887	C/T	cg09997546	chr11:8931473	C11orf17;ST5	-0.31	-5.11	-0.3	6.05e-7	Hemoglobin concentration;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12451852	chr7:149468989	ZNF467	0.58	6.28	0.36	1.38e-9	Gut microbiome composition (summer);
CESC	cis	rs1023500	0.573	rs4822088	chr22:42470589	G/C	cg04733989	chr22:42467013	NAGA	0.83	12.7	0.62	3.37e-29	Schizophrenia;
CESC	cis	rs4853012	0.887	rs77148265	chr2:74339519	C/T	cg01017244	chr2:74357527	NA	0.62	8.14	0.45	1.51e-14	Gestational age at birth (maternal effect);
CESC	cis	rs514406	0.505	rs835609	chr1:53170494	T/C	cg08736216	chr1:53307985	ZYG11A	-0.4	-6.76	-0.38	8.66e-11	Monocyte count;
CESC	cis	rs2576037	0.526	rs2257027	chr18:44566990	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.69	-10.85	-0.55	6.13e-23	Personality dimensions;
CESC	trans	rs60843830	1.000	rs62114505	chr2:242426	A/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.67	8.35	0.46	3.72e-15	Spherical equivalent (joint analysis main effects and education interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15730116	chr12:76953768	OSBPL8	0.61	7.27	0.41	3.99e-12	Gut microbiome composition (summer);
CESC	cis	rs4819052	0.851	rs2838857	chr21:46681000	A/G	cg11663144	chr21:46675770	NA	-0.51	-7.75	-0.43	2.01e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs6964587	1.000	rs36021614	chr7:91717490	C/G	cg17063962	chr7:91808500	NA	0.54	7.33	0.41	2.71e-12	Breast cancer;
CESC	cis	rs34330	0.562	rs17212236	chr12:12855483	G/C	cg09462578	chr12:12878428	APOLD1	-0.79	-8.38	-0.46	3.09e-15	Systemic lupus erythematosus;
CESC	cis	rs10982213	0.830	rs10081697	chr9:117182605	C/G	cg00969271	chr9:117093052	ORM2	0.41	5.53	0.32	7.75e-8	Interleukin-6 levels;
CESC	cis	rs763121	0.853	rs5750659	chr22:39068789	T/C	cg06022373	chr22:39101656	GTPBP1	0.89	14.42	0.66	3.47e-35	Menopause (age at onset);
CESC	cis	rs2115630	0.645	rs1107179	chr15:85198362	A/C	cg12501888	chr15:85177176	SCAND2	0.47	6.13	0.35	3.17e-9	P wave terminal force;
CESC	cis	rs8005677	1.000	rs1956880	chr14:23394007	A/G	cg25600027	chr14:23388339	RBM23	-0.42	-5.18	-0.3	4.35e-7	Cognitive ability (multi-trait analysis);
CESC	cis	rs12579753	0.879	rs12829053	chr12:82161926	T/A	cg21193143	chr12:82153300	PPFIA2	-0.34	-5.04	-0.3	8.72e-7	Resting heart rate;
CESC	cis	rs644799	0.965	rs549695	chr11:95617788	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.62	7.79	0.43	1.5e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs73110464	0.609	rs6580923	chr12:53358352	A/G	cg25025879	chr12:53359317	NA	-0.61	-8.11	-0.45	1.95e-14	Cancer (pleiotropy);
CESC	cis	rs34734847	0.787	rs7976497	chr12:121135467	T/C	cg26008908	chr12:120799332	MSI1	0.34	5.24	0.31	3.25e-7	Mean corpuscular volume;
CESC	trans	rs4927850	1.000	rs7627706	chr3:195753353	A/C	cg16724585	chr3:197361211	NA	-0.56	-7.2	-0.4	6.32e-12	Pancreatic cancer;
CESC	trans	rs10743315	0.557	rs78983750	chr12:19284967	C/T	cg09562322	chr12:119419143	SRRM4	-0.48	-6.27	-0.36	1.48e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs1894116	0.582	rs11225138	chr11:101993898	C/G	cg03447327	chr11:101977394	NA	-0.57	-5.04	-0.3	8.77e-7	Polycystic ovary syndrome;
CESC	cis	rs1008375	0.931	rs1860592	chr4:17577028	C/G	cg16339924	chr4:17578868	LAP3	0.75	9.8	0.52	1.56e-19	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs1050631	0.623	rs7242481	chr18:33709217	G/A	cg25426722	chr18:33708991	SLC39A6;ELP2	0.59	7.97	0.44	4.65e-14	Esophageal squamous cell cancer (length of survival);
CESC	cis	rs6060717	0.536	rs11699899	chr20:34525646	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.77	-6.96	-0.39	2.72e-11	Hip circumference adjusted for BMI;
CESC	cis	rs9549260	0.620	rs12583418	chr13:41195411	G/A	cg21288729	chr13:41239152	FOXO1	0.63	8.0	0.44	3.79e-14	Red blood cell count;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg15803506	chr10:135125704	ZNF511	0.53	7.36	0.41	2.26e-12	Fibrinogen levels;
CESC	cis	rs8082590	1	rs8082590	chr17:17958402	G/A	cg16928487	chr17:17741425	SREBF1	0.56	9.38	0.5	3e-18	Schizophrenia;
CESC	cis	rs11203032	0.831	rs4078488	chr10:90966546	C/T	cg16672925	chr10:90967113	CH25H	0.72	7.02	0.4	1.86e-11	Heart failure;
CESC	cis	rs875971	0.862	rs1860469	chr7:66106875	A/G	cg18876405	chr7:65276391	NA	-0.47	-6.39	-0.37	7.56e-10	Aortic root size;
CESC	cis	rs7726839	0.794	rs6883536	chr5:599274	G/A	cg09021430	chr5:549028	NA	-0.44	-6.14	-0.35	3.06e-9	Obesity-related traits;
CESC	cis	rs6121246	0.909	rs6060979	chr20:30417522	C/T	cg13852791	chr20:30311386	BCL2L1	0.76	7.78	0.43	1.58e-13	Mean corpuscular hemoglobin;
CESC	trans	rs7615952	0.932	rs13314869	chr3:125644669	G/A	cg07211511	chr3:129823064	LOC729375	-1.13	-15.51	-0.69	4.75e-39	Blood pressure (smoking interaction);
CESC	cis	rs9311474	0.581	rs13621	chr3:52558133	T/C	cg18337363	chr3:52569053	NT5DC2	0.3	5.56	0.32	6.5e-8	Electroencephalogram traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09787254	chr16:74808678	FA2H	0.69	8.04	0.44	3.06e-14	Gut microbiome composition (summer);
CESC	cis	rs875971	0.545	rs73142245	chr7:65691649	A/G	cg25405998	chr7:65216604	CCT6P1	0.5	5.39	0.31	1.58e-7	Aortic root size;
CESC	cis	rs5771069	0.933	rs137848	chr22:50440296	A/G	cg27467552	chr22:50353597	PIM3	-0.49	-7.19	-0.4	6.72e-12	Ulcerative colitis;
CESC	cis	rs950169	0.959	rs12911210	chr15:84792083	A/C	cg17507749	chr15:85114479	UBE2QP1	0.57	6.5	0.37	3.9e-10	Schizophrenia;
CESC	cis	rs9611565	0.659	rs12484228	chr22:41939739	A/G	cg06634786	chr22:41940651	POLR3H	-0.63	-6.6	-0.38	2.2e-10	Vitiligo;
CESC	cis	rs7945705	0.520	rs1984791	chr11:9035027	C/T	cg12365402	chr11:9010492	NRIP3	0.42	6.55	0.37	3.02e-10	Hemoglobin concentration;
CESC	cis	rs9811920	0.535	rs704574	chr3:99483773	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.33	5.4	0.32	1.46e-7	Axial length;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg25528940	chr16:57127044	CPNE2	-0.47	-6.18	-0.35	2.34e-9	Asthma;
CESC	cis	rs3785574	0.962	rs2665840	chr17:61873307	C/T	cg06873352	chr17:61820015	STRADA	-0.47	-6.9	-0.39	3.91e-11	Height;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg23715700	chr19:16188274	TPM4	0.5	6.43	0.37	5.93e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs3796352	1.000	rs2336540	chr3:52974589	G/A	cg12962167	chr3:53033115	SFMBT1	0.6	5.09	0.3	6.95e-7	Immune reponse to smallpox (secreted IL-2);
CESC	cis	rs6570726	0.935	rs446242	chr6:145843866	A/G	cg05347473	chr6:146136440	FBXO30	0.47	6.33	0.36	1.02e-9	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs13082711	0.554	rs7635958	chr3:27385616	A/C	cg02860705	chr3:27208620	NA	0.77	8.7	0.47	3.67e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CESC	cis	rs709400	1.000	rs56660916	chr14:104126137	G/T	cg24130564	chr14:104152367	KLC1	-0.42	-5.41	-0.32	1.44e-7	Body mass index;
CESC	cis	rs7267979	0.773	rs6132821	chr20:25226192	A/G	cg08601574	chr20:25228251	PYGB	0.42	5.81	0.34	1.82e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs1552244	1.000	rs4269070	chr3:10126083	C/G	cg16606324	chr3:10149918	C3orf24	0.43	5.45	0.32	1.12e-7	Alzheimer's disease;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg02040921	chr17:61554411	ACE	-0.41	-6.17	-0.35	2.5e-9	Gambling;
CESC	cis	rs12477438	0.520	rs6756650	chr2:99801800	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.86	15.21	0.68	5.36e-38	Chronic sinus infection;
CESC	cis	rs1799949	1.000	rs67060599	chr17:41255102	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.42	5.77	0.33	2.24e-8	Menopause (age at onset);
CESC	cis	rs6840258	0.943	rs72667748	chr4:87927034	C/T	cg08197287	chr4:87952173	AFF1	-0.41	-5.56	-0.32	6.69e-8	Mean corpuscular volume;Basophil percentage of granulocytes;
CESC	cis	rs853679	0.517	rs9380059	chr6:28132358	A/C	cg19592336	chr6:28129416	ZNF389	0.61	8.03	0.44	3.13e-14	Depression;
CESC	cis	rs8017423	0.630	rs4904678	chr14:90821670	T/C	cg14092571	chr14:90743983	NA	0.45	6.82	0.39	6.23e-11	Mortality in heart failure;
CESC	cis	rs10751667	0.621	rs10794353	chr11:948740	A/G	cg06064525	chr11:970664	AP2A2	-0.5	-9.88	-0.52	8.67e-20	Alzheimer's disease (late onset);
CESC	cis	rs13256369	0.802	rs35382339	chr8:8559255	G/A	cg18904891	chr8:8559673	CLDN23	0.72	7.98	0.44	4.42e-14	Obesity-related traits;
CESC	cis	rs2235642	0.826	rs8053605	chr16:1594158	G/A	cg08296037	chr16:1584118	IFT140;TMEM204	-0.32	-5.26	-0.31	3e-7	Coronary artery disease;
CESC	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.48	-5.2	-0.3	4.05e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs6496667	0.955	rs8039263	chr15:90900597	G/A	cg22089800	chr15:90895588	ZNF774	0.58	5.9	0.34	1.1e-8	Rheumatoid arthritis;
CESC	cis	rs7615952	0.641	rs61048217	chr3:125807905	G/T	cg18479299	chr3:125709523	NA	-0.48	-5.06	-0.3	7.98e-7	Blood pressure (smoking interaction);
CESC	cis	rs3858526	0.796	rs9645652	chr11:5944264	C/T	cg02574844	chr11:5959923	NA	-0.44	-5.5	-0.32	9.15e-8	DNA methylation (variation);
CESC	cis	rs11155671	0.530	rs4458704	chr6:150232879	A/C	cg09699651	chr6:150184138	LRP11	0.41	5.48	0.32	1e-7	Testicular germ cell tumor;
CESC	cis	rs7520050	0.966	rs12405451	chr1:46384326	T/A	cg24296786	chr1:45957014	TESK2	0.44	5.48	0.32	9.94e-8	Red blood cell count;Reticulocyte count;
CESC	cis	rs15676	0.783	rs2417128	chr9:131571756	G/A	cg00228799	chr9:131580591	ENDOG	0.43	5.29	0.31	2.59e-7	Blood metabolite levels;
CESC	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg11494091	chr17:61959527	GH2	0.72	12.11	0.6	3.6e-27	Prudent dietary pattern;
CESC	cis	rs11583043	0.918	rs11581062	chr1:101407519	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.53	-6.19	-0.36	2.23e-9	Ulcerative colitis;Inflammatory bowel disease;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg01740367	chr2:27294264	LOC100128731	0.45	6.05	0.35	5e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs6752107	0.967	rs11680130	chr2:234157258	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.45	6.32	0.36	1.12e-9	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs2404602	0.692	rs4360890	chr15:77173295	G/A	cg26408565	chr15:76604113	ETFA	-0.39	-5.68	-0.33	3.63e-8	Blood metabolite levels;
CESC	cis	rs7618915	0.547	rs11709448	chr3:52647449	T/C	cg18099408	chr3:52552593	STAB1	-0.32	-5.31	-0.31	2.35e-7	Bipolar disorder;
CESC	cis	rs7089973	0.604	rs11196937	chr10:116589500	G/C	cg03647239	chr10:116582469	FAM160B1	0.43	5.29	0.31	2.6e-7	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00026853	chr16:30934156	NCRNA00095	0.6	6.53	0.37	3.26e-10	Gut microbiome composition (summer);
CESC	cis	rs4713118	0.516	rs6931858	chr6:28078411	A/T	cg19592336	chr6:28129416	ZNF389	0.55	7.0	0.4	2.07e-11	Parkinson's disease;
CESC	cis	rs7618501	0.633	rs35065728	chr3:50009176	T/C	cg24308560	chr3:49941425	MST1R	-0.64	-9.33	-0.5	4.29e-18	Intelligence (multi-trait analysis);
CESC	cis	rs7267979	1.000	rs2259926	chr20:25281733	T/C	cg08601574	chr20:25228251	PYGB	0.39	5.57	0.32	6.14e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs9302690	0.557	rs223875	chr16:57506915	C/T	cg27017172	chr16:57497170	POLR2C	0.67	5.93	0.34	9.49e-9	Blood protein levels;
CESC	cis	rs7827545	0.701	rs6577655	chr8:135593725	C/T	cg17885191	chr8:135476712	NA	0.46	5.99	0.35	6.84e-9	Hypertension (SNP x SNP interaction);
CESC	cis	rs4568518	0.619	rs34058374	chr7:18008582	G/A	cg03009463	chr7:17980271	SNX13	0.45	5.86	0.34	1.36e-8	Measles;
CESC	cis	rs798554	0.723	rs798518	chr7:2777825	A/G	cg19346786	chr7:2764209	NA	-0.49	-7.09	-0.4	1.19e-11	Height;
CESC	cis	rs2836974	0.739	rs12482181	chr21:40548852	A/G	cg17971929	chr21:40555470	PSMG1	1.02	15.8	0.7	4.31e-40	Cognitive function;
CESC	cis	rs7586673	0.578	rs6723841	chr2:161879616	G/T	cg21518248	chr2:162101506	NA	0.43	5.53	0.32	7.81e-8	Intelligence (multi-trait analysis);
CESC	cis	rs2050392	0.517	rs589980	chr10:30756385	T/A	cg25182066	chr10:30743637	MAP3K8	-0.52	-7.75	-0.43	2e-13	Inflammatory bowel disease;
CESC	trans	rs1728785	1.000	rs1749792	chr16:68569440	T/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.61	7.47	0.42	1.13e-12	Ulcerative colitis;
CESC	cis	rs3780486	0.846	rs7873903	chr9:33142728	G/A	cg13443165	chr9:33130375	B4GALT1	0.48	6.81	0.39	6.43e-11	IgG glycosylation;
CESC	cis	rs287982	0.935	rs287978	chr2:9970534	T/C	cg10881225	chr2:9984929	TAF1B	-0.41	-5.27	-0.31	2.79e-7	Nonsyndromic cleft lip with cleft palate;
CESC	cis	rs7666738	0.830	rs35865860	chr4:98968822	C/T	cg05340658	chr4:99064831	C4orf37	0.79	12.28	0.6	9.45e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10504229	0.679	rs78941440	chr8:58052095	A/G	cg24829409	chr8:58192753	C8orf71	-0.48	-6.1	-0.35	3.75e-9	Developmental language disorder (linguistic errors);
CESC	trans	rs1814175	0.645	rs7115592	chr11:50013243	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.42	-6.12	-0.35	3.32e-9	Height;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03837726	chr12:119633116	NA	-0.45	-6.38	-0.36	7.65e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs1862618	0.853	rs252909	chr5:56121131	T/C	cg03609598	chr5:56110824	MAP3K1	-0.52	-5.57	-0.32	6.2e-8	Initial pursuit acceleration;
CESC	cis	rs8177253	0.632	rs6782523	chr3:133438917	C/T	cg24879335	chr3:133465180	TF	0.31	5.13	0.3	5.64e-7	Iron status biomarkers;
CESC	cis	rs9837602	1.000	rs62285461	chr3:99767642	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.53	7.51	0.42	8.91e-13	Breast cancer;
CESC	cis	rs6502050	0.835	rs4789744	chr17:80101506	A/C	cg23985595	chr17:80112537	CCDC57	-0.42	-6.57	-0.37	2.72e-10	Life satisfaction;
CESC	cis	rs2479106	0.591	rs7855233	chr9:126328327	C/T	cg16191174	chr9:126692580	DENND1A	-0.37	-5.06	-0.3	8.01e-7	Polycystic ovary syndrome;
CESC	cis	rs9733	0.596	rs72702585	chr1:150696427	G/A	cg04414720	chr1:150670196	GOLPH3L	0.62	8.8	0.48	1.76e-16	Tonsillectomy;
CESC	cis	rs672059	1.000	rs674343	chr1:183162052	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.54	7.05	0.4	1.59e-11	Hypertriglyceridemia;
CESC	cis	rs801193	0.805	rs12532355	chr7:66070584	C/G	cg18252515	chr7:66147081	NA	0.4	5.21	0.3	3.76e-7	Aortic root size;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg13786666	chr9:86536028	KIF27	-0.39	-6.26	-0.36	1.5e-9	Gambling;
CESC	cis	rs2795502	1.000	rs2795497	chr10:43339475	C/A	cg20628663	chr10:43360327	NA	-0.63	-7.47	-0.42	1.16e-12	Blood protein levels;
CESC	cis	rs780096	0.526	rs2010087	chr2:27637235	C/T	cg21248554	chr2:27665150	KRTCAP3	-0.35	-7.3	-0.41	3.41e-12	Total body bone mineral density;
CESC	cis	rs2274273	0.686	rs28631821	chr14:55845987	T/C	cg04306507	chr14:55594613	LGALS3	0.31	6.09	0.35	4.03e-9	Protein biomarker;
CESC	cis	rs8180040	0.681	rs9818382	chr3:47193034	C/T	cg27129171	chr3:47204927	SETD2	0.67	9.81	0.52	1.36e-19	Colorectal cancer;
CESC	cis	rs870825	0.616	rs6810635	chr4:185616859	T/C	cg04058563	chr4:185651563	MLF1IP	0.65	7.08	0.4	1.31e-11	Blood protein levels;
CESC	cis	rs559928	0.556	rs734762	chr11:63912189	G/C	cg18225595	chr11:63971243	STIP1	0.64	5.82	0.34	1.73e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CESC	cis	rs7666738	0.830	rs4699590	chr4:98974030	A/C	cg03467027	chr4:99064603	C4orf37	0.43	5.4	0.31	1.49e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs853679	0.882	rs9468287	chr6:28079741	G/T	cg06606381	chr12:133084897	FBRSL1	-0.67	-6.55	-0.37	2.94e-10	Depression;
CESC	cis	rs5758659	0.652	rs133358	chr22:42442539	A/T	cg05082376	chr22:42548792	NA	-0.37	-5.41	-0.32	1.44e-7	Cognitive function;
CESC	cis	rs2108225	0.872	rs6980029	chr7:107446127	T/C	cg18560240	chr7:107437656	SLC26A3	-0.44	-5.92	-0.34	9.93e-9	Ulcerative colitis;
CESC	cis	rs34779708	0.931	rs11010125	chr10:35502953	A/G	cg03585969	chr10:35415529	CREM	0.75	9.86	0.52	9.85e-20	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs10870270	0.956	rs10870293	chr10:133771413	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.59	-7.63	-0.42	4.22e-13	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs6728642	0.572	rs1320147	chr2:97600626	A/C	cg26665480	chr2:98280029	ACTR1B	0.71	8.61	0.47	6.7e-16	Bipolar disorder lithium response (continuous) or schizophrenia;
CESC	cis	rs854765	0.583	rs11078404	chr17:17820487	A/T	cg16928487	chr17:17741425	SREBF1	-0.56	-9.74	-0.51	2.34e-19	Total body bone mineral density;
CESC	cis	rs938554	0.744	rs7675964	chr4:9941434	C/T	cg00071950	chr4:10020882	SLC2A9	-0.53	-7.38	-0.41	2e-12	Blood metabolite levels;
CESC	cis	rs34779708	0.966	rs57081218	chr10:35434608	A/G	cg03585969	chr10:35415529	CREM	0.75	9.83	0.52	1.2e-19	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs7267979	0.966	rs910996	chr20:25264196	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.88	17.4	0.73	9.43e-46	Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg11259409	chr11:1331124	LOC255512;TOLLIP	-0.44	-6.13	-0.35	3.14e-9	Fibrinogen levels;
CESC	cis	rs2066819	1.000	rs116849218	chr12:56683975	C/T	cg26804944	chr12:56660921	COQ10A	-0.85	-5.19	-0.3	4.22e-7	Psoriasis vulgaris;
CESC	cis	rs8027181	0.804	rs7178130	chr15:72978202	A/G	cg25632853	chr15:73088954	NA	-0.29	-5.11	-0.3	6.14e-7	Triglyceride levels;
CESC	cis	rs1790761	0.505	rs6591256	chr11:67349899	A/G	cg00290607	chr11:67383545	NA	-0.37	-5.57	-0.32	6.31e-8	Mean corpuscular volume;
CESC	cis	rs6502050	0.835	rs7219180	chr17:80079968	C/G	cg23985595	chr17:80112537	CCDC57	0.42	6.56	0.37	2.87e-10	Life satisfaction;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg27571676	chr16:88061218	BANP	0.44	6.01	0.35	6.26e-9	Fibrinogen levels;
CESC	cis	rs1448094	0.511	rs61930074	chr12:86218759	G/C	cg00310523	chr12:86230176	RASSF9	0.37	5.86	0.34	1.41e-8	Major depressive disorder;
CESC	cis	rs12188164	0.965	rs56146525	chr5:442571	A/C	cg21144161	chr5:423903	AHRR	0.37	5.94	0.34	9e-9	Cystic fibrosis severity;
CESC	cis	rs2708240	1.000	rs2708255	chr7:147587614	C/G	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.36	-5.86	-0.34	1.37e-8	QT interval (drug interaction);
CESC	cis	rs6540559	0.546	rs57315825	chr1:210030197	C/T	cg23283495	chr1:209979779	IRF6	0.45	5.05	0.3	8.12e-7	Cleft lip with or without cleft palate;
CESC	cis	rs6582630	0.519	rs8189609	chr12:38281408	A/G	cg26384229	chr12:38710491	ALG10B	0.72	10.26	0.53	5.3e-21	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs7552404	1.000	rs12091720	chr1:76186949	G/A	cg03433033	chr1:76189801	ACADM	0.68	8.05	0.44	2.87e-14	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs1595825	0.786	rs75415672	chr2:198535679	G/A	cg00982548	chr2:198649783	BOLL	-0.49	-5.27	-0.31	2.89e-7	Ulcerative colitis;
CESC	cis	rs863345	0.565	rs2051665	chr1:158507157	A/T	cg12129480	chr1:158549410	OR10X1	-0.35	-7.08	-0.4	1.32e-11	Pneumococcal bacteremia;
CESC	trans	rs3749237	1.000	rs11130216	chr3:49736172	C/A	cg21659725	chr3:3221576	CRBN	0.53	6.3	0.36	1.22e-9	Resting heart rate;
CESC	cis	rs72781680	0.768	rs112139157	chr2:24150783	A/C	cg08917208	chr2:24149416	ATAD2B	0.63	6.24	0.36	1.73e-9	Lymphocyte counts;
CESC	cis	rs13118159	0.872	rs4974605	chr4:1346389	C/G	cg00684032	chr4:1343700	KIAA1530	0.41	6.21	0.36	2.06e-9	Longevity;
CESC	cis	rs798554	0.797	rs1182184	chr7:2872446	G/A	cg18446336	chr7:2847575	GNA12	-0.39	-6.07	-0.35	4.44e-9	Height;
CESC	cis	rs7786808	0.741	rs4909222	chr7:158228095	C/T	cg01191920	chr7:158217561	PTPRN2	0.43	7.76	0.43	1.89e-13	Obesity-related traits;
CESC	cis	rs60154123	0.730	rs652256	chr1:210465017	T/C	cg23283495	chr1:209979779	IRF6	0.41	5.36	0.31	1.79e-7	Coronary artery disease;
CESC	cis	rs9325144	0.560	rs10506127	chr12:39126686	C/G	cg26384229	chr12:38710491	ALG10B	-0.5	-7.31	-0.41	3.18e-12	Morning vs. evening chronotype;
CESC	cis	rs798554	0.683	rs1636264	chr7:2864586	G/T	cg09658497	chr7:2847517	GNA12	-0.37	-5.23	-0.31	3.45e-7	Height;
CESC	cis	rs3126085	0.935	rs3126062	chr1:152272352	G/A	cg03465714	chr1:152285911	FLG	0.46	5.74	0.33	2.54e-8	Atopic dermatitis;
CESC	cis	rs4253772	0.688	rs113928699	chr22:46649344	G/A	cg10541313	chr22:46663664	TTC38	0.74	5.91	0.34	1.02e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs7659604	0.539	rs7686200	chr4:122764553	C/T	cg06713675	chr4:122721982	EXOSC9	-0.52	-7.24	-0.41	4.73e-12	Type 2 diabetes;
CESC	cis	rs875971	0.862	rs801209	chr7:66019390	G/T	cg10691866	chr7:65817282	TPST1	0.33	5.51	0.32	8.51e-8	Aortic root size;
CESC	cis	rs6691722	0.503	rs6656485	chr1:24707685	A/G	cg18323236	chr1:24743029	NIPAL3	0.37	5.46	0.32	1.1e-7	Response to interferon beta in multiple sclerosis;
CESC	cis	rs10078	0.571	rs890977	chr5:476910	T/C	cg08916839	chr5:415575	AHRR	0.6	6.77	0.38	8.3e-11	Fat distribution (HIV);
CESC	cis	rs12477438	0.834	rs6757019	chr2:99676936	T/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-10.57	-0.54	5.22e-22	Chronic sinus infection;
CESC	cis	rs9611565	0.512	rs139561	chr22:42195410	C/T	cg06481639	chr22:41940642	POLR3H	0.57	5.79	0.33	2.01e-8	Vitiligo;
CESC	cis	rs10779751	1.000	rs10779751	chr1:11284336	A/G	cg08854313	chr1:11322531	MTOR	0.79	10.62	0.55	3.5e-22	Body mass index;
CESC	cis	rs425277	0.958	rs262688	chr1:2113565	T/G	cg04315214	chr1:2043799	PRKCZ	-0.37	-5.28	-0.31	2.7e-7	Height;
CESC	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.54	6.73	0.38	1.02e-10	Prudent dietary pattern;
CESC	cis	rs514406	0.825	rs1242328	chr1:53396869	A/G	cg24675658	chr1:53192096	ZYG11B	-0.52	-6.37	-0.36	8.1e-10	Monocyte count;
CESC	cis	rs7666738	0.830	rs28619044	chr4:98789814	G/C	cg03467027	chr4:99064603	C4orf37	0.43	5.47	0.32	1.02e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3091242	0.933	rs11249250	chr1:25767609	G/A	cg02931644	chr1:25747376	RHCE	0.4	6.65	0.38	1.64e-10	Erythrocyte sedimentation rate;
CESC	cis	rs5995756	1.000	rs5995756	chr22:40000313	A/G	cg03390717	chr22:39966585	CACNA1I	-0.31	-5.47	-0.32	1.07e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs2243480	1.000	rs4718317	chr7:65648901	A/G	cg12463550	chr7:65579703	CRCP	-0.76	-6.01	-0.35	6.12e-9	Diabetic kidney disease;
CESC	cis	rs11690935	0.921	rs6710698	chr2:172596078	G/C	cg13550731	chr2:172543902	DYNC1I2	-1.02	-16.95	-0.72	3.83e-44	Schizophrenia;
CESC	cis	rs8072100	0.713	rs11651643	chr17:45483229	A/G	cg25173405	chr17:45401733	C17orf57	-0.44	-5.48	-0.32	9.7e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg07092213	chr7:1199455	ZFAND2A	-0.37	-5.12	-0.3	5.79e-7	Longevity;Endometriosis;
CESC	cis	rs734999	0.588	rs867435	chr1:2523706	C/T	cg20673091	chr1:2541236	MMEL1	0.42	6.76	0.38	8.85e-11	Ulcerative colitis;
CESC	cis	rs17021463	0.902	rs13102926	chr4:95245527	C/T	cg11021082	chr4:95130006	SMARCAD1	0.52	7.84	0.43	1.1e-13	Testicular germ cell tumor;
CESC	cis	rs4629180	0.586	rs57563359	chr2:102125309	A/G	cg04415270	chr2:102091202	RFX8	-0.31	-5.39	-0.31	1.59e-7	Chronic rhinosinusitis with nasal polyps;
CESC	cis	rs11785400	0.793	rs34875149	chr8:143736131	G/A	cg24634471	chr8:143751801	JRK	0.45	5.75	0.33	2.42e-8	Schizophrenia;
CESC	cis	rs2997447	0.748	rs112813126	chr1:26432239	A/T	cg24596570	chr1:26146463	FAM54B;LOC646471	0.62	5.33	0.31	2.07e-7	QRS complex (12-leadsum);
CESC	cis	rs6546550	0.933	rs57278310	chr2:70093647	T/C	cg02498382	chr2:70120550	SNRNP27	-0.35	-6.01	-0.35	6.05e-9	Prevalent atrial fibrillation;
CESC	cis	rs6933660	0.646	rs3816778	chr6:151773353	G/C	cg02564969	chr6:151773285	C6orf211;RMND1	0.66	9.47	0.5	1.61e-18	Menarche (age at onset);
CESC	cis	rs8114671	0.967	rs2065979	chr20:33767690	T/C	cg24642439	chr20:33292090	TP53INP2	0.44	5.26	0.31	2.95e-7	Height;
CESC	cis	rs2354432	0.825	rs10900347	chr1:146800107	G/C	cg25205988	chr1:146714368	CHD1L	1.0	13.23	0.63	5.02e-31	Mitochondrial DNA levels;
CESC	cis	rs7149242	1.000	rs11620937	chr14:101151012	C/G	cg18089426	chr14:101175970	NA	0.4	6.19	0.36	2.26e-9	Platelet count;
CESC	cis	rs7980687	0.662	rs585522	chr12:123550813	A/G	cg00376283	chr12:123451042	ABCB9	0.75	9.26	0.49	7.14e-18	Height;Educational attainment;Head circumference (infant);
CESC	cis	rs746627	0.719	rs35337556	chr17:63863661	A/G	cg07283582	chr17:63770753	CCDC46	-0.34	-5.09	-0.3	6.82e-7	Total body bone mineral density;
CESC	cis	rs2073300	0.609	rs74809795	chr20:23372383	A/C	cg16736954	chr20:23401023	NAPB	0.8	6.25	0.36	1.67e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs1775715	0.870	rs1615256	chr10:32254101	T/C	cg18675610	chr10:32216311	ARHGAP12	0.33	5.14	0.3	5.37e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs798554	0.959	rs798528	chr7:2772431	A/C	cg09658497	chr7:2847517	GNA12	-0.43	-6.24	-0.36	1.75e-9	Height;
CESC	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg18538332	chr22:24372958	LOC391322	-0.84	-13.14	-0.63	1.0500000000000001e-30	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs7772486	0.686	rs9390349	chr6:146054430	T/G	cg23711669	chr6:146136114	FBXO30	-0.86	-12.56	-0.61	1.04e-28	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs904092	0.720	rs1230027	chr4:100183423	T/C	cg12011299	chr4:100065546	ADH4	0.53	6.11	0.35	3.48e-9	Alcohol dependence;
CESC	cis	rs12500824	0.528	rs7677266	chr4:77278251	G/A	cg20311846	chr4:77356250	SHROOM3	0.37	7.07	0.4	1.4e-11	Coronary artery disease;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg03672602	chr19:19754555	GMIP	-0.43	-6.23	-0.36	1.86e-9	Gambling;
CESC	cis	rs2439831	0.850	rs28504496	chr15:44016883	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.68	7.7	0.43	2.77e-13	Lung cancer in ever smokers;
CESC	cis	rs28498503	0.867	rs1841765	chr18:76644636	A/T	cg00806245	chr18:76673096	NA	-0.57	-5.11	-0.3	6.3e-7	Attention function in attention deficit hyperactive disorder;
CESC	cis	rs7927771	0.524	rs12421563	chr11:47780222	G/A	cg18512352	chr11:47633146	NA	-0.35	-5.47	-0.32	1.03e-7	Subjective well-being;
CESC	trans	rs61931739	0.500	rs11053290	chr12:34582392	C/T	cg26384229	chr12:38710491	ALG10B	-0.53	-7.43	-0.42	1.46e-12	Morning vs. evening chronotype;
CESC	cis	rs3749237	0.615	rs6792911	chr3:49429856	C/T	cg07636037	chr3:49044803	WDR6	0.59	8.55	0.47	9.71e-16	Resting heart rate;
CESC	cis	rs3806843	0.568	rs2530232	chr5:140082878	A/G	cg16179182	chr5:140090404	VTRNA1-1	0.4	5.06	0.3	7.67e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs67311347	1.000	rs9874006	chr3:40471596	G/A	cg24209194	chr3:40518798	ZNF619	0.47	6.09	0.35	3.92e-9	Renal cell carcinoma;
CESC	cis	rs9457247	0.663	rs9459845	chr6:167440501	C/G	cg07741184	chr6:167504864	NA	0.34	6.01	0.35	6.21e-9	Crohn's disease;
CESC	cis	rs7772486	0.790	rs9403756	chr6:146257761	C/G	cg23711669	chr6:146136114	FBXO30	-0.87	-12.22	-0.6	1.52e-27	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6121246	0.954	rs7266148	chr20:30431070	G/T	cg13852791	chr20:30311386	BCL2L1	0.74	7.0	0.4	2.1e-11	Mean corpuscular hemoglobin;
CESC	trans	rs55704346	0.566	rs7684466	chr4:25386468	C/T	cg01822600	chr1:245751692	KIF26B	0.42	6.07	0.35	4.43e-9	Tonsillectomy;
CESC	cis	rs17376456	0.542	rs6556833	chr5:93104707	T/C	cg25358565	chr5:93447407	FAM172A	0.47	5.16	0.3	4.73e-7	Diabetic retinopathy;
CESC	cis	rs798554	0.683	rs1182155	chr7:2902890	C/G	cg19717773	chr7:2847554	GNA12	-0.47	-6.68	-0.38	1.39e-10	Height;
CESC	cis	rs5769765	0.730	rs62233964	chr22:50317410	C/G	cg02269571	chr22:50332266	NA	-0.57	-6.56	-0.37	2.82e-10	Schizophrenia;
CESC	cis	rs6542838	0.702	rs4851177	chr2:99535188	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.41	-5.2	-0.3	4.06e-7	Fear of minor pain;
CESC	cis	rs1843834	0.505	rs940317	chr2:225358118	C/T	cg22455342	chr2:225449267	CUL3	0.72	9.92	0.52	6.35e-20	IgE levels in asthmatics (D.p. specific);
CESC	cis	rs6439153	0.933	rs2630262	chr3:128677098	C/T	cg24203234	chr3:128598194	ACAD9	-0.39	-5.15	-0.3	5.07e-7	Pneumococcal bacteremia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14537507	chr5:130970729	RAPGEF6	-0.57	-6.04	-0.35	5.07e-9	Gut microbiome composition (summer);
CESC	cis	rs3858526	0.883	rs11039584	chr11:5935251	C/G	cg13902645	chr11:5959945	NA	-0.66	-8.01	-0.44	3.6e-14	DNA methylation (variation);
CESC	cis	rs9457247	1.000	rs407515	chr6:167407544	G/C	cg07741184	chr6:167504864	NA	0.3	5.52	0.32	8.06e-8	Crohn's disease;
CESC	cis	rs4561483	0.798	rs456325	chr16:12012562	C/G	cg08843971	chr16:11963173	GSPT1	-0.41	-5.59	-0.32	5.65e-8	Testicular germ cell tumor;
CESC	cis	rs3766606	0.505	rs67002863	chr1:7923478	G/A	cg00042356	chr1:8021962	PARK7	0.56	5.47	0.32	1.04e-7	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg08706405	chr16:3724626	TRAP1	0.45	6.15	0.35	2.87e-9	Fibrinogen levels;
CESC	cis	rs7481584	0.624	rs421196	chr11:3048582	T/G	cg25174290	chr11:3078921	CARS	-0.46	-6.4	-0.37	6.86e-10	Calcium levels;
CESC	cis	rs12618769	0.597	rs11901568	chr2:99128621	C/T	cg10123293	chr2:99228465	UNC50	-0.39	-5.21	-0.3	3.8e-7	Bipolar disorder;
CESC	cis	rs3096299	0.658	rs4785679	chr16:89566113	G/T	cg16743903	chr16:89593216	SPG7	-0.5	-6.42	-0.37	6.39e-10	Multiple myeloma (IgH translocation);
CESC	cis	rs1799949	0.864	rs60309406	chr17:41435665	C/T	cg05368731	chr17:41323189	NBR1	0.77	10.55	0.54	5.97e-22	Menopause (age at onset);
CESC	cis	rs796364	0.616	rs1523818	chr2:200684704	G/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.57	5.26	0.31	2.91e-7	Schizophrenia;
CESC	trans	rs7246657	0.943	rs10420754	chr19:37959372	C/G	cg24637308	chr11:6592297	DNHD1	0.54	6.34	0.36	1.01e-9	Coronary artery calcification;
CESC	cis	rs1552244	1.000	rs7622963	chr3:10139825	C/T	cg00149659	chr3:10157352	C3orf10	0.72	9.04	0.49	3.45e-17	Alzheimer's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14645856	chr6:18368844	NA	-0.74	-8.45	-0.46	1.9e-15	Gut microbiome composition (summer);
CESC	cis	rs12142240	0.660	rs72885163	chr1:46807117	C/A	cg10495392	chr1:46806563	NSUN4	0.59	6.34	0.36	9.65e-10	Menopause (age at onset);
CESC	cis	rs514406	0.683	rs6588440	chr1:53209587	C/T	cg08859206	chr1:53392774	SCP2	0.54	6.88	0.39	4.29e-11	Monocyte count;
CESC	cis	rs10751667	0.857	rs7481221	chr11:966813	G/C	cg06064525	chr11:970664	AP2A2	-0.48	-9.29	-0.5	5.99e-18	Alzheimer's disease (late onset);
CESC	cis	rs4835473	0.932	rs34781605	chr4:144706639	G/T	cg25736465	chr4:144833511	NA	-0.33	-5.43	-0.32	1.28e-7	Immature fraction of reticulocytes;
CESC	cis	rs950169	0.922	rs6603022	chr15:84830170	T/C	cg17507749	chr15:85114479	UBE2QP1	-0.55	-6.25	-0.36	1.66e-9	Schizophrenia;
CESC	cis	rs138857	0.515	rs9616373	chr22:50308597	G/A	cg02269571	chr22:50332266	NA	-0.63	-6.15	-0.35	2.91e-9	Mean platelet volume;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg05477027	chr19:46295590	DMWD	-0.41	-6.03	-0.35	5.4e-9	Gambling;
CESC	cis	rs4595586	0.967	rs1400280	chr12:39241240	A/G	cg26384229	chr12:38710491	ALG10B	-0.41	-5.86	-0.34	1.36e-8	Morning vs. evening chronotype;
CESC	cis	rs7811142	0.943	rs28578163	chr7:100044754	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.99	10.56	0.54	5.53e-22	Platelet count;
CESC	cis	rs9916302	0.861	rs752314	chr17:37410700	C/T	cg07936489	chr17:37558343	FBXL20	-0.79	-11.15	-0.57	6.12e-24	Glomerular filtration rate (creatinine);
CESC	cis	rs644799	1.000	rs518919	chr11:95623313	G/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.47	5.52	0.32	8.22e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs881375	0.678	rs10760125	chr9:123662590	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.47	6.83	0.39	5.66e-11	Rheumatoid arthritis;
CESC	trans	rs7246657	0.882	rs59224125	chr19:37963205	T/C	cg24637308	chr11:6592297	DNHD1	0.54	6.34	0.36	1.01e-9	Coronary artery calcification;
CESC	cis	rs6499255	0.951	rs3169315	chr16:69720964	G/A	cg15192750	chr16:69999425	NA	0.42	5.03	0.3	9e-7	IgE levels;
CESC	cis	rs10504229	0.774	rs72650880	chr8:58164727	C/T	cg05313129	chr8:58192883	C8orf71	-0.5	-5.23	-0.31	3.38e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs921968	0.540	rs6746040	chr2:219588890	G/T	cg02176678	chr2:219576539	TTLL4	-0.43	-7.46	-0.42	1.23e-12	Mean corpuscular hemoglobin concentration;
CESC	cis	rs977987	0.778	rs4888412	chr16:75443196	A/G	cg03315344	chr16:75512273	CHST6	0.41	5.86	0.34	1.35e-8	Dupuytren's disease;
CESC	cis	rs7851660	0.967	rs3758248	chr9:100614601	G/A	cg13688889	chr9:100608707	NA	-0.69	-10.57	-0.54	4.92e-22	Strep throat;
CESC	cis	rs514406	0.644	rs928451	chr1:53195800	A/G	cg08736216	chr1:53307985	ZYG11A	0.4	6.33	0.36	1.04e-9	Monocyte count;
CESC	cis	rs15676	0.783	rs10988120	chr9:131564695	G/C	cg00228799	chr9:131580591	ENDOG	-0.49	-6.09	-0.35	3.93e-9	Blood metabolite levels;
CESC	cis	rs72781680	0.752	rs72780185	chr2:24003967	G/A	cg08917208	chr2:24149416	ATAD2B	0.95	8.71	0.47	3.45e-16	Lymphocyte counts;
CESC	cis	rs1670533	0.932	rs2045067	chr4:1052355	C/T	cg04106633	chr4:1044584	NA	0.4	5.16	0.3	4.85e-7	Recombination rate (females);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg02396668	chr19:50528878	VRK3;ZNF473	0.6	8.09	0.45	2.13e-14	Gut microbiota (bacterial taxa);
CESC	trans	rs13098911	0.540	rs34836513	chr3:46046459	G/A	cg10236987	chr1:228114221	WNT9A	0.65	6.48	0.37	4.49e-10	Celiac disease;
CESC	cis	rs4835473	0.932	rs4125545	chr4:144909803	T/C	cg25736465	chr4:144833511	NA	0.42	6.43	0.37	6.02e-10	Immature fraction of reticulocytes;
CESC	cis	rs938554	0.784	rs7682751	chr4:9976294	A/G	cg00071950	chr4:10020882	SLC2A9	0.48	5.68	0.33	3.49e-8	Blood metabolite levels;
CESC	cis	rs873946	0.586	rs61862838	chr10:134572282	C/T	cg26818010	chr10:134567672	INPP5A	-0.93	-11.42	-0.57	7.74e-25	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs6912958	0.712	rs6454638	chr6:88329427	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.34	5.5	0.32	9.08e-8	Monocyte percentage of white cells;
CESC	cis	rs1691799	0.899	rs1168304	chr12:66738667	A/C	cg16791601	chr12:66731901	HELB	-0.75	-13.03	-0.62	2.51e-30	White blood cell count (basophil);
CESC	cis	rs853679	0.517	rs9393894	chr6:28112562	A/G	cg26335602	chr6:28129616	ZNF389	0.53	6.86	0.39	4.94e-11	Depression;
CESC	cis	rs7937682	0.960	rs480293	chr11:111469132	A/C	cg09085632	chr11:111637200	PPP2R1B	-0.9	-12.87	-0.62	9.33e-30	Primary sclerosing cholangitis;
CESC	cis	rs7552404	0.731	rs10873808	chr1:76406767	T/C	cg03433033	chr1:76189801	ACADM	0.64	6.37	0.36	8.15e-10	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs10751667	0.666	rs7395321	chr11:940280	C/T	cg06064525	chr11:970664	AP2A2	-0.5	-10.04	-0.52	2.7e-20	Alzheimer's disease (late onset);
CESC	cis	rs826838	1.000	rs7315028	chr12:38710523	G/A	cg26384229	chr12:38710491	ALG10B	0.83	15.22	0.68	5.18e-38	Heart rate;
CESC	cis	rs67311347	1.000	rs12108041	chr3:40487535	C/T	cg09455208	chr3:40491958	NA	0.49	7.97	0.44	4.72e-14	Renal cell carcinoma;
CESC	cis	rs644799	1.000	rs623191	chr11:95548359	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	9.15	0.49	1.61e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs708547	0.874	rs1713984	chr4:57886493	C/T	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.56	-5.74	-0.33	2.6e-8	Response to bleomycin (chromatid breaks);
CESC	cis	rs2929278	0.589	rs11638972	chr15:44074691	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.52	-6.73	-0.38	1.05e-10	Schizophrenia;
CESC	cis	rs2243480	1.000	rs73142162	chr7:65374296	A/T	cg25894440	chr7:65020034	NA	-0.63	-5.26	-0.31	2.91e-7	Diabetic kidney disease;
CESC	cis	rs1569175	1.000	rs1509830	chr2:200908143	G/A	cg19045956	chr2:200819837	C2orf60;C2orf47	0.64	5.41	0.32	1.44e-7	Response to treatment for acute lymphoblastic leukemia;
CESC	cis	rs10504229	0.953	rs6985942	chr8:58173412	T/C	cg22535103	chr8:58192502	C8orf71	-0.87	-11.17	-0.57	5.43e-24	Developmental language disorder (linguistic errors);
CESC	cis	rs668210	0.793	rs1192184	chr11:65773382	A/G	cg02202077	chr11:65769826	EIF1AD;BANF1	-0.68	-6.75	-0.38	9.22e-11	Cerebrospinal fluid biomarker levels;
CESC	cis	rs10504229	0.683	rs11784908	chr8:58131472	T/C	cg21724239	chr8:58056113	NA	0.58	5.95	0.34	8.29e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs34779708	0.931	rs11010067	chr10:35295431	C/G	cg04310649	chr10:35416472	CREM	0.52	6.32	0.36	1.08e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs3806843	1.000	rs10073974	chr5:140165231	T/C	cg26395211	chr5:140044315	WDR55	-0.43	-5.52	-0.32	8.02e-8	Depressive symptoms (multi-trait analysis);
CESC	cis	rs7605827	0.930	rs10929375	chr2:15684483	A/G	cg19274914	chr2:15703543	NA	0.37	6.7	0.38	1.22e-10	Educational attainment (years of education);
CESC	cis	rs13191362	0.507	rs13212746	chr6:163203092	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.5	5.93	0.34	9.18e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs7772486	0.558	rs9376965	chr6:146130055	G/A	cg23711669	chr6:146136114	FBXO30	0.91	12.25	0.6	1.26e-27	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs933688	1.000	rs6862125	chr5:90724598	T/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.13	13.94	0.65	1.68e-33	Smoking behavior;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg13939297	chr12:104461859	HCFC2	0.4	6.18	0.35	2.35e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs2404602	0.631	rs9646213	chr15:76807672	G/C	cg22467129	chr15:76604101	ETFA	-0.37	-5.52	-0.32	7.96e-8	Blood metabolite levels;
CESC	trans	rs7521492	0.647	rs3856201	chr1:163736341	G/T	cg00842670	chr18:77728011	HSBP1L1	-0.38	-6.05	-0.35	4.93e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs9549367	0.713	rs3024757	chr13:113823186	G/T	cg00898013	chr13:113819073	PROZ	-0.55	-7.42	-0.41	1.59e-12	Platelet distribution width;
CESC	cis	rs17209837	0.607	rs1468615	chr7:87074964	T/C	cg00919237	chr7:87102261	ABCB4	-0.52	-6.03	-0.35	5.4e-9	Gallbladder cancer;
CESC	cis	rs75477785	0.793	rs9919217	chr1:210057532	G/T	cg02304930	chr1:210405566	SERTAD4;C1orf133	-0.96	-6.58	-0.37	2.51e-10	Cleft lip with or without cleft palate;
CESC	cis	rs4780401	0.933	rs7203803	chr16:11812291	A/G	cg01061890	chr16:11836724	TXNDC11	0.38	5.19	0.3	4.1e-7	Rheumatoid arthritis;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg12600695	chr5:137513806	BRD8;KIF20A	0.49	6.28	0.36	1.42e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs7089973	0.604	rs58587374	chr10:116597572	A/G	cg25233709	chr10:116636983	FAM160B1	0.38	5.97	0.34	7.44e-9	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs853679	0.517	rs6922063	chr6:28094366	G/A	cg20151795	chr6:28129481	ZNF389	0.48	6.41	0.37	6.55e-10	Depression;
CESC	cis	rs6460942	0.591	rs4721078	chr7:12334657	T/A	cg02935154	chr7:12443704	VWDE	-0.53	-5.5	-0.32	9.01e-8	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13843727	chr22:41601352	L3MBTL2	0.57	6.22	0.36	1.88e-9	Gut microbiome composition (summer);
CESC	cis	rs9894429	1.000	rs7406003	chr17:79597597	C/T	cg18240062	chr17:79603768	NPLOC4	0.73	10.27	0.53	4.66e-21	Eye color traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13266951	chr7:2013113	MAD1L1	-0.7	-7.91	-0.44	7.05e-14	Gut microbiome composition (summer);
CESC	cis	rs4819052	0.851	rs10470246	chr21:46659017	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.89	13.04	0.63	2.35e-30	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg06873352	chr17:61820015	STRADA	0.72	12.79	0.62	1.64e-29	Prudent dietary pattern;
CESC	cis	rs10089	1.000	rs2898096	chr5:127433214	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.77	10.42	0.54	1.57e-21	Ileal carcinoids;
CESC	cis	rs9948	0.786	rs111237064	chr2:97456578	T/C	cg01990225	chr2:97406019	LMAN2L	-0.93	-7.38	-0.41	2.02e-12	Erectile dysfunction and prostate cancer treatment;
CESC	cis	rs910316	1.000	rs8003506	chr14:75586288	A/C	cg16144293	chr14:75469539	EIF2B2	0.41	5.21	0.3	3.79e-7	Height;
CESC	cis	rs921968	0.528	rs13022583	chr2:219589175	T/C	cg02176678	chr2:219576539	TTLL4	-0.43	-7.59	-0.42	5.51e-13	Mean corpuscular hemoglobin concentration;
CESC	cis	rs7666738	0.830	rs4440224	chr4:99044924	G/A	cg05340658	chr4:99064831	C4orf37	0.82	12.88	0.62	8.44e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2228479	0.850	rs11076623	chr16:89844120	G/T	cg14709524	chr16:89940631	TCF25	0.91	6.72	0.38	1.09e-10	Skin colour saturation;
CESC	cis	rs597539	0.652	rs584108	chr11:68630282	A/T	cg21963583	chr11:68658836	MRPL21	-0.42	-5.91	-0.34	1.07e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs8067354	0.574	rs2531899	chr17:58007193	A/G	cg02344993	chr17:57696989	CLTC	-0.55	-5.67	-0.33	3.67e-8	Hemoglobin concentration;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg09126467	chr6:42796794	KIAA0240	-0.47	-6.04	-0.35	5.21e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs6570726	1.000	rs386678	chr6:145869010	A/G	cg05347473	chr6:146136440	FBXO30	0.45	6.23	0.36	1.83e-9	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs747782	0.585	rs1604655	chr11:48274778	G/A	cg15704280	chr7:45808275	SEPT13	0.69	6.44	0.37	5.65e-10	Intraocular pressure;
CESC	cis	rs3126085	1.000	rs55957623	chr1:152223196	T/A	cg03465714	chr1:152285911	FLG	0.45	5.13	0.3	5.74e-7	Atopic dermatitis;
CESC	cis	rs4665809	1.000	rs10182857	chr2:26344411	C/T	cg08470875	chr2:26401718	FAM59B	-0.47	-5.24	-0.31	3.31e-7	Gut microbiome composition (summer);
CESC	cis	rs1005277	0.579	rs2472181	chr10:38386764	T/C	cg25427524	chr10:38739819	LOC399744	-0.66	-9.5	-0.5	1.29e-18	Extrinsic epigenetic age acceleration;
CESC	cis	rs1552244	0.882	rs7633769	chr3:10020622	C/T	cg08888203	chr3:10149979	C3orf24	0.51	6.33	0.36	1.02e-9	Alzheimer's disease;
CESC	cis	rs12586317	0.547	rs4982236	chr14:35468046	C/G	cg16230307	chr14:35515116	FAM177A1	0.98	10.57	0.54	5.04e-22	Psoriasis;
CESC	cis	rs4925386	0.625	rs3810550	chr20:60912117	C/T	cg06026331	chr20:60912101	LAMA5	0.48	5.05	0.3	8.41e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs7246657	0.943	rs2303131	chr19:37936025	G/A	cg23950597	chr19:37808831	NA	-0.62	-6.3	-0.36	1.26e-9	Coronary artery calcification;
CESC	cis	rs736408	0.660	rs2019065	chr3:52809525	C/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	-0.3	-5.36	-0.31	1.82e-7	Bipolar disorder;
CESC	cis	rs9788333	0.962	rs34853044	chr13:21883784	C/T	cg06138931	chr13:21896616	NA	0.49	6.54	0.37	3.07e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs514406	0.861	rs7518390	chr1:53233374	A/G	cg24675658	chr1:53192096	ZYG11B	0.49	6.31	0.36	1.18e-9	Monocyte count;
CESC	cis	rs9733	0.596	rs34140753	chr1:150642583	T/C	cg09365446	chr1:150670422	GOLPH3L	0.42	5.91	0.34	1.03e-8	Tonsillectomy;
CESC	cis	rs9911578	0.933	rs74370218	chr17:57095212	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.39	-5.05	-0.3	8.2e-7	Intelligence (multi-trait analysis);
CESC	cis	rs9322193	0.962	rs1112730	chr6:150087519	G/A	cg13206674	chr6:150067644	NUP43	0.43	5.98	0.34	7.33e-9	Lung cancer;
CESC	cis	rs7666738	0.716	rs11721453	chr4:99045485	G/T	cg18180107	chr4:99064573	C4orf37	0.41	5.29	0.31	2.51e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1448094	0.872	rs12322940	chr12:86406708	G/C	cg02569458	chr12:86230093	RASSF9	0.33	5.05	0.3	8.33e-7	Major depressive disorder;
CESC	cis	rs11608355	0.545	rs12822974	chr12:109909154	G/T	cg05360138	chr12:110035743	NA	0.81	8.75	0.47	2.52e-16	Neuroticism;
CESC	cis	rs4689388	0.926	rs10937718	chr4:6295217	T/C	cg00701064	chr4:6280414	WFS1	0.68	11.71	0.58	8.68e-26	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs7786877	0.508	rs11765509	chr7:100310990	T/G	cg20848291	chr7:100343083	ZAN	-0.73	-8.95	-0.48	6.21e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs1105228	0.501	rs4709075	chr6:165665299	A/G	cg12582777	chr6:165658423	NA	-0.41	-7.08	-0.4	1.28e-11	Number of pregnancies;Number of children;
CESC	cis	rs7737355	0.812	rs7731773	chr5:130973943	A/G	cg06307176	chr5:131281290	NA	0.38	5.06	0.3	7.77e-7	Life satisfaction;
CESC	cis	rs1005277	0.579	rs1780130	chr10:38485378	T/A	cg25427524	chr10:38739819	LOC399744	-0.7	-10.22	-0.53	7.1e-21	Extrinsic epigenetic age acceleration;
CESC	cis	rs1847202	0.859	rs4566476	chr3:72948995	G/C	cg10804678	chr3:72788309	NA	-0.39	-5.29	-0.31	2.51e-7	Motion sickness;
CESC	cis	rs7662987	0.517	rs2602880	chr4:100040653	C/T	cg13256891	chr4:100009986	ADH5	0.75	8.03	0.44	3.29e-14	Smoking initiation;
CESC	cis	rs28489187	0.706	rs233095	chr1:85824816	T/C	cg16011679	chr1:85725395	C1orf52	0.54	6.21	0.36	2.05e-9	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03552472	chr10:51623769	TIMM23	0.56	6.25	0.36	1.65e-9	Gut microbiome composition (summer);
CESC	cis	rs897080	0.552	rs1067383	chr2:44645911	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.51	6.04	0.35	5.16e-9	Height;
CESC	cis	rs7666738	0.830	rs10470893	chr4:99038756	C/T	cg17366294	chr4:99064904	C4orf37	0.61	8.78	0.47	2.13e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs17253792	0.822	rs75115817	chr14:56069537	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.79	5.91	0.34	1.06e-8	Putamen volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03193865	chr8:145510099	BOP1	-0.65	-7.22	-0.41	5.54e-12	Gut microbiome composition (summer);
CESC	cis	rs4835473	0.714	rs10013005	chr4:144632504	G/A	cg25736465	chr4:144833511	NA	0.4	6.24	0.36	1.74e-9	Immature fraction of reticulocytes;
CESC	cis	rs6540559	1.000	rs2073485	chr1:209962794	G/A	cg21951975	chr1:209979733	IRF6	0.62	9.51	0.5	1.24e-18	Cleft lip with or without cleft palate;
CESC	cis	rs344364	0.511	rs2982447	chr16:1947413	C/T	cg09830162	chr16:1889614	FAHD1;C16orf73	0.57	6.43	0.37	5.87e-10	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs17407555	0.606	rs59871456	chr4:10014441	G/A	cg11266682	chr4:10021025	SLC2A9	-0.51	-6.08	-0.35	4.18e-9	Schizophrenia (age at onset);
CESC	cis	rs4851870	0.834	rs13026762	chr2:106449363	A/G	cg16077055	chr2:106428750	NCK2	-0.39	-5.05	-0.3	8.15e-7	Addiction;
CESC	cis	rs9309473	0.539	rs6732440	chr2:73827099	T/G	cg20560298	chr2:73613845	ALMS1	0.5	7.05	0.4	1.58e-11	Metabolite levels;
CESC	cis	rs2425143	1.000	rs7264414	chr20:34446826	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.78	-7.05	-0.4	1.57e-11	Blood protein levels;
CESC	cis	rs6502050	0.805	rs7225560	chr17:80160884	C/G	cg11859384	chr17:80120422	CCDC57	-0.38	-5.27	-0.31	2.86e-7	Life satisfaction;
CESC	cis	rs2404602	0.692	rs8024476	chr15:76983954	T/C	cg22467129	chr15:76604101	ETFA	-0.34	-5.07	-0.3	7.37e-7	Blood metabolite levels;
CESC	cis	rs2404602	0.692	rs12910734	chr15:77149931	A/G	cg22467129	chr15:76604101	ETFA	-0.34	-5.18	-0.3	4.47e-7	Blood metabolite levels;
CESC	cis	rs6951245	0.832	rs79808627	chr7:1092519	C/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.56	-6.71	-0.38	1.2e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7662987	0.517	rs2602881	chr4:100040695	A/G	cg13256891	chr4:100009986	ADH5	0.75	8.03	0.44	3.29e-14	Smoking initiation;
CESC	cis	rs11971779	0.818	rs12056045	chr7:139025430	C/G	cg07862535	chr7:139043722	LUC7L2	0.52	5.45	0.32	1.17e-7	Diisocyanate-induced asthma;
CESC	cis	rs12681366	0.734	rs716770	chr8:95390921	C/T	cg13257157	chr8:95487014	RAD54B	0.38	5.11	0.3	6.3e-7	Nonsyndromic cleft lip with cleft palate;
CESC	cis	rs10504229	0.773	rs60466370	chr8:58171248	A/C	cg24829409	chr8:58192753	C8orf71	-0.62	-8.61	-0.47	6.73e-16	Developmental language disorder (linguistic errors);
CESC	cis	rs2485892	0.553	rs4844954	chr1:210337043	A/G	cg22029157	chr1:209979665	IRF6	0.51	5.84	0.34	1.55e-8	Manic episodes in bipolar disorder;
CESC	cis	rs3740713	1.000	rs73440610	chr11:18464469	T/C	cg23797887	chr11:18477753	LDHAL6A	-0.53	-5.13	-0.3	5.58e-7	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs6679073	1.000	rs6679073	chr1:205756484	A/C	cg24503407	chr1:205819492	PM20D1	0.37	5.18	0.3	4.39e-7	Prostate-specific antigen levels;
CESC	cis	rs897984	0.646	rs9938088	chr16:30830004	G/A	cg00531865	chr16:30841666	NA	-0.57	-8.42	-0.46	2.4e-15	Dementia with Lewy bodies;
CESC	cis	rs9611565	0.765	rs132914	chr22:41805749	T/C	cg03806693	chr22:41940476	POLR3H	1.04	12.37	0.61	4.76e-28	Vitiligo;
CESC	cis	rs6696846	0.777	rs9651228	chr1:205049383	A/G	cg00857998	chr1:205179979	DSTYK	0.5	6.72	0.38	1.1e-10	Red blood cell count;
CESC	cis	rs62229266	0.740	rs4817759	chr21:37389559	G/A	cg12218747	chr21:37451666	NA	-0.4	-5.65	-0.33	4.06e-8	Mitral valve prolapse;
CESC	cis	rs2404602	0.583	rs12592501	chr15:76554790	C/A	cg26408565	chr15:76604113	ETFA	-0.41	-5.98	-0.34	7.19e-9	Blood metabolite levels;
CESC	cis	rs875971	0.502	rs2946580	chr7:65531842	G/A	cg25405998	chr7:65216604	CCT6P1	-0.51	-5.44	-0.32	1.24e-7	Aortic root size;
CESC	cis	rs208520	0.837	rs208467	chr6:66914837	T/C	cg07460842	chr6:66804631	NA	-0.87	-10.57	-0.54	5.25e-22	Exhaled nitric oxide output;
CESC	cis	rs2842992	0.830	rs752779	chr6:160133957	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.73	9.02	0.48	3.82e-17	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs2742234	0.504	rs7093409	chr10:43740067	A/G	cg15436174	chr10:43711423	RASGEF1A	0.46	5.49	0.32	9.56e-8	Hirschsprung disease;
CESC	cis	rs7666738	0.830	rs2865949	chr4:99039967	A/G	cg03467027	chr4:99064603	C4orf37	0.47	5.98	0.34	7.19e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4948102	0.731	rs6593292	chr7:56043037	G/C	cg09872392	chr7:56161020	PHKG1	-0.46	-7.25	-0.41	4.59e-12	Plasma homocysteine levels (post-methionine load test);
CESC	cis	rs9457247	0.935	rs1794697	chr6:167395410	C/T	cg23791538	chr6:167370224	RNASET2	-0.61	-8.66	-0.47	4.86e-16	Crohn's disease;
CESC	cis	rs11098499	0.754	rs11098502	chr4:120252063	T/A	cg09307838	chr4:120376055	NA	0.77	10.49	0.54	9.15e-22	Corneal astigmatism;
CESC	cis	rs3096299	0.934	rs9927904	chr16:89462847	G/A	cg08392591	chr16:89556376	ANKRD11	0.4	5.17	0.3	4.58e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs17253792	0.822	rs79483507	chr14:56164718	G/T	cg01858014	chr14:56050164	KTN1	-0.97	-7.54	-0.42	7.36e-13	Putamen volume;
CESC	cis	rs1670533	1.000	rs6599279	chr4:1058833	G/A	cg04106633	chr4:1044584	NA	0.4	5.09	0.3	6.69e-7	Recombination rate (females);
CESC	cis	rs12142240	0.730	rs56030283	chr1:46823093	C/G	cg00530320	chr1:46809349	NSUN4	0.6	8.04	0.44	2.96e-14	Menopause (age at onset);
CESC	cis	rs12325245	0.536	rs35908812	chr16:58587426	T/C	cg02549819	chr16:58548995	SETD6	0.96	6.42	0.37	6.42e-10	Schizophrenia;
CESC	cis	rs2425143	1.000	rs4602287	chr20:34368028	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.8	7.75	0.43	1.96e-13	Blood protein levels;
CESC	cis	rs7552404	0.924	rs1146579	chr1:76209792	C/T	cg22875332	chr1:76189707	ACADM	-0.73	-10.23	-0.53	6.21e-21	Blood metabolite levels;Acylcarnitine levels;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg03758523	chr6:151773469	C6orf211;RMND1	-0.48	-6.11	-0.35	3.49e-9	Ulcerative colitis;
CESC	cis	rs393155	0.517	rs330050	chr8:9087679	G/C	cg17143192	chr8:8559678	CLDN23	-0.44	-5.34	-0.31	1.99e-7	Neuroticism;
CESC	cis	rs9311474	0.502	rs4687624	chr3:52563572	C/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.29	5.2	0.3	4.04e-7	Electroencephalogram traits;
CESC	cis	rs6500395	0.735	rs16946340	chr16:48667717	G/A	cg04672837	chr16:48644449	N4BP1	0.45	5.55	0.32	7.01e-8	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs7618915	0.547	rs11177	chr3:52721305	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.5	7.19	0.4	6.47e-12	Bipolar disorder;
CESC	cis	rs12586317	0.547	rs2038254	chr14:35462134	C/T	cg16230307	chr14:35515116	FAM177A1	0.98	10.57	0.54	5.04e-22	Psoriasis;
CESC	cis	rs9322193	0.962	rs6899661	chr6:150139229	T/C	cg13206674	chr6:150067644	NUP43	0.41	5.7	0.33	3.16e-8	Lung cancer;
CESC	cis	rs10504229	0.683	rs16921814	chr8:58107421	A/T	cg02725872	chr8:58115012	NA	-0.43	-6.83	-0.39	5.9e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs2116941	1.000	rs8104426	chr19:10338676	G/T	cg01850179	chr19:10340795	S1PR2	0.6	7.81	0.43	1.37e-13	Pulse pressure;
CESC	cis	rs116095464	0.558	rs59113266	chr5:279965	T/C	cg20965017	chr5:231967	SDHA	-0.46	-5.2	-0.3	4.02e-7	Breast cancer;
CESC	cis	rs2032447	0.714	rs199725	chr6:25953684	A/G	cg03264133	chr6:25882463	NA	-0.45	-6.45	-0.37	5.28e-10	Intelligence (multi-trait analysis);
CESC	cis	rs1620921	0.524	rs7450979	chr6:161186889	A/C	cg01280913	chr6:161186852	NA	0.43	6.47	0.37	4.78e-10	Lipoprotein (a) - cholesterol levels;
CESC	cis	rs854765	0.623	rs9893690	chr17:17753846	A/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.43	-5.64	-0.33	4.46e-8	Total body bone mineral density;
CESC	cis	rs668210	0.793	rs1786172	chr11:65770658	A/G	cg02202077	chr11:65769826	EIF1AD;BANF1	0.7	7.77	0.43	1.72e-13	Cerebrospinal fluid biomarker levels;
CESC	cis	rs733175	0.855	rs10016075	chr4:10006663	G/T	cg00071950	chr4:10020882	SLC2A9	0.56	6.66	0.38	1.6e-10	Psychosis and Alzheimer's disease;
CESC	cis	rs6502050	0.835	rs8073351	chr17:80127625	A/G	cg11859384	chr17:80120422	CCDC57	-0.39	-5.34	-0.31	1.97e-7	Life satisfaction;
CESC	trans	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg13565492	chr6:43139072	SRF	-0.61	-6.51	-0.37	3.65e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2180341	1.000	rs3798852	chr6:127636733	A/G	cg24812749	chr6:127587940	RNF146	1.07	15.48	0.69	6.31e-39	Breast cancer;
CESC	cis	rs7903847	0.646	rs10882924	chr10:99159304	T/A	cg20016023	chr10:99160130	RRP12	-0.3	-5.22	-0.31	3.54e-7	Granulocyte percentage of myeloid white cells;
CESC	cis	rs1048238	0.506	rs12023422	chr1:16187625	G/A	cg21385522	chr1:16154831	NA	0.42	5.26	0.31	2.93e-7	Systolic blood pressure;
CESC	cis	rs7560272	0.538	rs17434634	chr2:73922926	T/A	cg20560298	chr2:73613845	ALMS1	0.45	6.11	0.35	3.58e-9	Schizophrenia;
CESC	cis	rs17826219	0.636	rs79565452	chr17:29142841	T/C	cg19761014	chr17:28927070	LRRC37B2	0.78	6.39	0.37	7.53e-10	Body mass index;
CESC	cis	rs2415984	0.622	rs12434073	chr14:46921265	G/A	cg14871534	chr14:47121158	RPL10L	-0.35	-5.26	-0.31	2.98e-7	Number of children ever born;
CESC	cis	rs2637266	0.935	rs2579771	chr10:78407544	A/G	cg18941641	chr10:78392320	NA	0.44	8.4	0.46	2.76e-15	Pulmonary function;
CESC	cis	rs727505	1.000	rs56356267	chr7:124557549	A/G	cg23710748	chr7:124431027	NA	-0.47	-7.33	-0.41	2.85e-12	Lewy body disease;
CESC	cis	rs9929218	0.551	rs7201437	chr16:68727130	A/C	cg01251360	chr16:68772225	CDH1	-0.22	-5.04	-0.3	8.74e-7	Colorectal cancer;
CESC	trans	rs2018683	0.677	rs2057956	chr7:28973460	G/A	cg19402173	chr7:128379420	CALU	-0.51	-6.61	-0.38	2.09e-10	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CESC	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg23708337	chr7:1209742	NA	0.53	5.34	0.31	1.98e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7680126	0.633	rs28378345	chr4:10209897	A/G	cg00071950	chr4:10020882	SLC2A9	-0.45	-5.08	-0.3	7.16e-7	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	cis	rs73001065	0.551	rs56397647	chr19:19642795	C/T	cg03709012	chr19:19516395	GATAD2A	1.01	7.64	0.43	3.85e-13	LDL cholesterol;
CESC	trans	rs16949788	1.000	rs11071894	chr15:66773733	A/C	cg23949574	chr2:240302855	HDAC4	-0.46	-6.55	-0.37	2.93e-10	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs826838	0.868	rs12322306	chr12:39130021	A/G	cg13010199	chr12:38710504	ALG10B	-0.45	-6.26	-0.36	1.51e-9	Heart rate;
CESC	cis	rs11997175	0.599	rs66474258	chr8:33640225	A/T	ch.8.33884649F	chr8:33765107	NA	0.65	8.35	0.46	3.84e-15	Body mass index;
CESC	cis	rs7635838	0.892	rs9836167	chr3:11493392	C/T	cg00170343	chr3:11313890	ATG7	0.44	6.04	0.35	5.27e-9	HDL cholesterol;
CESC	trans	rs11039798	1.000	rs10838918	chr11:48507449	A/G	cg15704280	chr7:45808275	SEPT13	0.69	6.14	0.35	3.07e-9	Axial length;
CESC	cis	rs6466055	0.604	rs1204078	chr7:104986644	A/T	cg04380332	chr7:105027541	SRPK2	0.43	5.6	0.33	5.33e-8	Schizophrenia;
CESC	trans	rs11098499	0.575	rs907205	chr4:120238664	G/C	cg25214090	chr10:38739885	LOC399744	0.61	8.51	0.46	1.33e-15	Corneal astigmatism;
CESC	cis	rs10504229	0.683	rs11786074	chr8:58133532	A/G	cg24829409	chr8:58192753	C8orf71	-0.58	-7.2	-0.4	6.31e-12	Developmental language disorder (linguistic errors);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg01501135	chr17:16342235	NCRNA00188;SNORD49B;SNORD49A	-0.44	-6.17	-0.35	2.58e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs6502050	0.835	rs12051747	chr17:80114814	T/C	cg23985595	chr17:80112537	CCDC57	-0.41	-6.46	-0.37	4.9e-10	Life satisfaction;
CESC	cis	rs7914558	1.000	rs943036	chr10:104836047	T/C	cg04362960	chr10:104952993	NT5C2	0.48	6.47	0.37	4.65e-10	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs9329289	0.603	rs2458698	chr10:2548452	C/T	cg15501526	chr10:2543763	NA	0.61	9.9	0.52	7.18e-20	Age-related hearing impairment;
CESC	cis	rs7618915	0.571	rs34954168	chr3:52612159	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	6.85	0.39	5.06e-11	Bipolar disorder;
CESC	cis	rs2439831	1.000	rs471229	chr15:43733994	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.84	11.9	0.59	1.84e-26	Lung cancer in ever smokers;
CESC	cis	rs72945132	0.882	rs56368270	chr11:70162590	A/G	cg00319359	chr11:70116639	PPFIA1	0.8	7.52	0.42	8.55e-13	Coronary artery disease;
CESC	cis	rs3858526	0.883	rs10769320	chr11:5932831	G/C	cg02574844	chr11:5959923	NA	-0.41	-5.12	-0.3	6.01e-7	DNA methylation (variation);
CESC	cis	rs921968	0.541	rs832798	chr2:219464810	G/A	cg02176678	chr2:219576539	TTLL4	0.48	8.34	0.46	4.09e-15	Mean corpuscular hemoglobin concentration;
CESC	cis	rs9911578	1.000	rs8071280	chr17:57010225	T/C	cg12560992	chr17:57184187	TRIM37	0.92	15.19	0.68	6.64e-38	Intelligence (multi-trait analysis);
CESC	cis	rs76878669	0.561	rs2279862	chr11:66135179	C/T	cg18002602	chr11:66138449	SLC29A2	0.4	6.68	0.38	1.42e-10	Educational attainment (years of education);
CESC	trans	rs3808502	0.574	rs4841559	chr8:11416885	C/T	cg06636001	chr8:8085503	FLJ10661	-0.51	-6.12	-0.35	3.44e-9	Neuroticism;
CESC	cis	rs60871478	0.578	rs62432900	chr7:826794	G/C	cg27478167	chr7:817139	HEATR2	-0.47	-5.05	-0.3	8.35e-7	Cerebrospinal P-tau181p levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15763497	chr22:18256852	BID	0.64	7.17	0.4	7.49e-12	Gut microbiome composition (summer);
CESC	cis	rs6963495	0.818	rs73192122	chr7:105171471	G/A	cg13798780	chr7:105162888	PUS7	0.77	7.88	0.44	8.3e-14	Bipolar disorder (body mass index interaction);
CESC	cis	rs4654899	0.865	rs12119348	chr1:21484633	C/T	cg05370193	chr1:21551575	ECE1	0.46	7.08	0.4	1.28e-11	Superior frontal gyrus grey matter volume;
CESC	cis	rs2932538	0.883	rs6537740	chr1:113080084	T/G	cg22162597	chr1:113214053	CAPZA1	0.58	6.98	0.39	2.37e-11	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg09529537	chr5:78531947	JMY	0.48	6.37	0.36	8.52e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs727563	0.562	rs5758458	chr22:42154132	G/A	cg17376030	chr22:41985996	PMM1	-0.77	-8.07	-0.44	2.39e-14	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs8078723	0.701	rs2305482	chr17:38140927	A/C	cg17467752	chr17:38218738	THRA	-0.54	-8.09	-0.45	2.16e-14	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CESC	cis	rs9611565	0.559	rs4822048	chr22:41988225	C/T	cg06634786	chr22:41940651	POLR3H	-0.67	-6.46	-0.37	4.85e-10	Vitiligo;
CESC	cis	rs763121	1.000	rs138457	chr22:38898051	T/C	cg06022373	chr22:39101656	GTPBP1	-0.75	-11.64	-0.58	1.47e-25	Menopause (age at onset);
CESC	cis	rs1878047	0.665	rs7249595	chr19:51774613	G/A	cg14884932	chr19:51774451	NA	-0.37	-5.16	-0.3	4.82e-7	Body mass index;
CESC	cis	rs10170846	1.000	rs10170846	chr2:223517705	C/G	cg25565276	chr2:223520875	FARSB	-0.68	-9.8	-0.52	1.47e-19	Schizophrenia (inflammation and infection response interaction);
CESC	cis	rs1348850	0.526	rs6433672	chr2:178378175	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.66	6.02	0.35	5.75e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs727563	0.636	rs2187795	chr22:42092225	C/A	cg17376030	chr22:41985996	PMM1	-0.78	-8.3	-0.45	5.4e-15	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs9341835	0.518	rs2622294	chr6:64218316	T/A	cg03326410	chr6:64151739	NA	0.32	5.15	0.3	5.1e-7	Schizophrenia;
CESC	cis	rs6860806	0.507	rs272878	chr5:131671769	C/T	cg07395648	chr5:131743802	NA	0.42	5.54	0.32	7.34e-8	Breast cancer;
CESC	cis	rs9322193	0.923	rs9478291	chr6:150050570	A/G	cg07701084	chr6:150067640	NUP43	0.48	6.7	0.38	1.28e-10	Lung cancer;
CESC	cis	rs40363	0.645	rs250629	chr16:3525431	C/A	cg05754148	chr16:3507555	NAT15	0.57	8.5	0.46	1.42e-15	Tuberculosis;
CESC	trans	rs634534	0.622	rs1192168	chr11:65730945	T/G	cg17712092	chr4:129076599	LARP1B	0.62	8.29	0.45	5.55e-15	Sum eosinophil basophil counts;Eosinophil counts;
CESC	cis	rs7552404	0.727	rs4949677	chr1:76266662	T/A	cg03433033	chr1:76189801	ACADM	0.62	6.36	0.36	8.72e-10	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs3747547	0.892	rs1976936	chr9:37955433	G/A	cg13774184	chr9:37916125	SHB	-0.68	-5.71	-0.33	3.06e-8	Metabolite levels (Dihydroxy docosatrienoic acid);
CESC	cis	rs9467773	0.595	rs7767847	chr6:26597893	A/T	cg24633756	chr6:26577808	NA	0.38	5.76	0.33	2.28e-8	Intelligence (multi-trait analysis);
CESC	trans	rs7107217	1.000	rs1873872	chr11:129473993	A/T	cg06988368	chr1:147142773	ACP6	0.53	6.78	0.38	7.69e-11	Breast cancer;Type 2 diabetes;
CESC	cis	rs9549260	0.755	rs2755214	chr13:41149345	T/G	cg21288729	chr13:41239152	FOXO1	0.63	7.93	0.44	6.03e-14	Red blood cell count;
CESC	cis	rs2075371	1.000	rs2598292	chr7:133988584	C/G	cg00033643	chr7:134001901	SLC35B4	0.44	5.71	0.33	3.05e-8	Mean platelet volume;
CESC	cis	rs3806843	0.766	rs6848	chr5:140086062	A/T	cg26395211	chr5:140044315	WDR55	0.45	6.03	0.35	5.45e-9	Depressive symptoms (multi-trait analysis);
CESC	cis	rs7786808	0.608	rs7784758	chr7:158214386	A/G	cg09998033	chr7:158218633	PTPRN2	-0.37	-5.65	-0.33	4.14e-8	Obesity-related traits;
CESC	cis	rs6541297	0.645	rs2296065	chr1:230301776	G/A	cg20703242	chr1:230279135	GALNT2	0.56	6.6	0.38	2.29e-10	Coronary artery disease;
CESC	cis	rs10504229	0.683	rs55637580	chr8:58135419	C/T	cg24829409	chr8:58192753	C8orf71	-0.58	-7.2	-0.4	6.31e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs12711979	0.765	rs13028529	chr2:3825467	C/T	cg17052675	chr2:3827356	NA	-0.43	-6.76	-0.38	8.94e-11	Itch intensity from mosquito bite adjusted by bite size;
CESC	cis	rs11098499	0.954	rs11722872	chr4:120233030	G/C	cg09307838	chr4:120376055	NA	0.92	12.74	0.62	2.59e-29	Corneal astigmatism;
CESC	cis	rs78707713	0.512	rs12412776	chr10:71179502	G/A	cg12610070	chr10:71211762	TSPAN15	-0.38	-7.94	-0.44	5.74e-14	Venous thromboembolism;
CESC	cis	rs7605827	0.930	rs6431695	chr2:15539816	T/C	cg19274914	chr2:15703543	NA	0.36	6.55	0.37	2.91e-10	Educational attainment (years of education);
CESC	cis	rs2191566	0.576	rs414402	chr19:44492568	A/G	cg20607764	chr19:44506953	ZNF230	0.45	5.66	0.33	3.96e-8	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs7904368	0.754	rs17139234	chr10:16849732	G/T	cg23933602	chr10:16859644	RSU1	0.66	5.91	0.34	1.07e-8	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
CESC	cis	rs6540559	1.000	rs4844895	chr1:209958580	T/C	cg09509183	chr1:209979624	IRF6	0.47	5.67	0.33	3.78e-8	Cleft lip with or without cleft palate;
CESC	cis	rs10754283	0.934	rs1934043	chr1:90106645	C/T	cg21401794	chr1:90099060	LRRC8C	0.69	9.34	0.5	4.06e-18	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs2839186	0.564	rs4819215	chr21:47623573	G/A	cg00815214	chr21:47717953	NA	-0.43	-6.24	-0.36	1.7e-9	Testicular germ cell tumor;
CESC	cis	rs9649213	0.593	rs1132971	chr7:97921533	A/G	cg24562669	chr7:97807699	LMTK2	0.48	6.8	0.39	6.74e-11	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs10100465	0.596	rs218009	chr8:118716275	A/G	cg20949383	chr7:92465230	CDK6	0.63	6.23	0.36	1.84e-9	Leprosy;
CESC	cis	rs8177253	0.761	rs12490148	chr3:133523973	C/T	cg11941060	chr3:133502564	NA	-0.55	-7.47	-0.42	1.18e-12	Iron status biomarkers;
CESC	cis	rs877282	0.898	rs11253352	chr10:766598	C/A	cg17470449	chr10:769945	NA	0.48	5.39	0.31	1.57e-7	Uric acid levels;
CESC	cis	rs2274273	0.744	rs8011808	chr14:55823344	A/T	cg04306507	chr14:55594613	LGALS3	0.32	6.23	0.36	1.85e-9	Protein biomarker;
CESC	cis	rs9818758	0.607	rs11706052	chr3:49064110	A/G	cg00383909	chr3:49044727	WDR6	0.9	6.12	0.35	3.41e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CESC	cis	rs2836974	0.932	rs6517523	chr21:40557332	T/C	cg11644478	chr21:40555479	PSMG1	1.01	16.32	0.71	6.16e-42	Cognitive function;
CESC	cis	rs1023500	0.505	rs134878	chr22:42663874	A/G	cg04733989	chr22:42467013	NAGA	0.65	9.57	0.51	7.66e-19	Schizophrenia;
CESC	cis	rs7666738	0.830	rs969049	chr4:98988857	C/T	cg05340658	chr4:99064831	C4orf37	0.8	12.42	0.61	3.09e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs12540874	0.698	rs12718574	chr7:50573848	G/C	cg18232548	chr7:50535776	DDC	-0.41	-5.86	-0.34	1.36e-8	Systemic sclerosis;
CESC	cis	rs2404602	0.692	rs4442773	chr15:77031633	T/C	cg26408565	chr15:76604113	ETFA	-0.38	-5.52	-0.32	8.03e-8	Blood metabolite levels;
CESC	cis	rs875971	1.000	rs778706	chr7:65860424	A/G	cg12463550	chr7:65579703	CRCP	0.58	7.41	0.41	1.67e-12	Aortic root size;
CESC	cis	rs9300255	0.510	rs1790086	chr12:123672518	A/G	cg00376283	chr12:123451042	ABCB9	0.72	8.91	0.48	8.62e-17	Neutrophil percentage of white cells;
CESC	cis	rs9649213	0.593	rs7787858	chr7:98009914	T/C	cg21770322	chr7:97807741	LMTK2	0.57	8.63	0.47	5.93e-16	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs997295	0.529	rs12592315	chr15:68040266	A/G	cg05153347	chr5:171434267	FBXW11	0.5	6.48	0.37	4.53e-10	Motion sickness;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12157519	chr9:72874251	SMC5	0.69	7.63	0.42	4.26e-13	Gut microbiome composition (summer);
CESC	cis	rs4665809	1.000	rs17040322	chr2:26351274	G/C	cg22920501	chr2:26401640	FAM59B	-0.67	-8.09	-0.44	2.22e-14	Gut microbiome composition (summer);
CESC	cis	rs55986470	0.817	rs10177049	chr2:239422169	G/T	cg18131467	chr2:239335373	ASB1	-0.58	-5.29	-0.31	2.52e-7	Chronotype;
CESC	cis	rs113835537	0.529	rs11227514	chr11:66286627	G/A	cg24851651	chr11:66362959	CCS	0.43	5.35	0.31	1.87e-7	Airway imaging phenotypes;
CESC	trans	rs13098911	0.540	rs34849862	chr3:46001367	C/A	cg10236987	chr1:228114221	WNT9A	0.57	6.07	0.35	4.38e-9	Celiac disease;
CESC	cis	rs8062405	0.573	rs7187575	chr16:28990101	C/T	cg08761264	chr16:28874980	SH2B1	0.44	5.04	0.3	8.54e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs9322193	0.962	rs2342764	chr6:150156204	G/A	cg13206674	chr6:150067644	NUP43	0.43	5.94	0.34	8.78e-9	Lung cancer;
CESC	cis	rs17539620	0.624	rs74551216	chr6:154840524	T/C	cg20019720	chr6:154832845	CNKSR3	0.44	5.59	0.32	5.6e-8	Lipoprotein (a) levels;
CESC	cis	rs9733	0.596	rs72702573	chr1:150689050	C/T	cg22823121	chr1:150693482	HORMAD1	0.48	7.11	0.4	1.11e-11	Tonsillectomy;
CESC	cis	rs4253772	0.720	rs4253778	chr22:46630634	C/G	cg24881330	chr22:46731750	TRMU	0.73	7.92	0.44	6.56e-14	LDL cholesterol;Cholesterol, total;
CESC	cis	rs6460942	0.915	rs62448594	chr7:12442229	C/G	cg16278512	chr7:12443529	VWDE	-0.5	-5.08	-0.3	7.3e-7	Coronary artery disease;
CESC	cis	rs4843747	0.671	rs72818576	chr16:88111019	C/G	cg17633681	chr16:88106987	BANP	0.79	10.89	0.56	4.68e-23	Menopause (age at onset);
CESC	cis	rs6831352	0.918	rs17218239	chr4:100057020	G/A	cg12011299	chr4:100065546	ADH4	-0.6	-6.62	-0.38	2.04e-10	Alcohol dependence;
CESC	cis	rs9393777	0.513	rs1104871	chr6:26665235	T/G	cg12826209	chr6:26865740	GUSBL1	0.73	8.25	0.45	7.45e-15	Intelligence (multi-trait analysis);
CESC	cis	rs12410462	0.681	rs12401677	chr1:227608577	T/C	cg04117972	chr1:227635322	NA	0.8	7.32	0.41	2.98e-12	Major depressive disorder;
CESC	cis	rs4803468	1.000	rs2241711	chr19:41911980	T/C	cg09537434	chr19:41945824	ATP5SL	-1.09	-19.79	-0.77	3.84e-54	Height;
CESC	cis	rs6964587	0.626	rs9008	chr7:91502407	C/G	cg17063962	chr7:91808500	NA	-0.45	-6.35	-0.36	9.22e-10	Breast cancer;
CESC	cis	rs4629180	1.000	rs11123889	chr2:102107180	G/A	cg04415270	chr2:102091202	RFX8	0.47	7.52	0.42	8.29e-13	Chronic rhinosinusitis with nasal polyps;
CESC	cis	rs9467711	0.606	rs9393707	chr6:26362486	T/C	cg12826209	chr6:26865740	GUSBL1	0.62	5.4	0.32	1.45e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs7219021	1.000	rs7219021	chr17:46840541	A/C	cg16584676	chr17:46985605	UBE2Z	-0.65	-7.29	-0.41	3.64e-12	Schizophrenia or bipolar disorder;
CESC	cis	rs9811920	0.599	rs1688758	chr3:99539890	A/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.48	-5.85	-0.34	1.48e-8	Axial length;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06164187	chr2:242641258	ING5	0.57	6.13	0.35	3.11e-9	Gut microbiome composition (summer);
CESC	cis	rs12042107	0.740	rs10801825	chr1:91206170	C/A	cg13456504	chr1:91191583	NA	-0.33	-5.76	-0.33	2.32e-8	Educational attainment;
CESC	cis	rs870825	0.860	rs60523653	chr4:185604676	T/C	cg04058563	chr4:185651563	MLF1IP	0.54	5.24	0.31	3.27e-7	Blood protein levels;
CESC	cis	rs782590	0.537	rs7575170	chr2:55886780	C/T	cg18811423	chr2:55921094	PNPT1	-0.6	-8.04	-0.44	3.03e-14	Metabolic syndrome;
CESC	cis	rs959260	1.000	rs959260	chr17:73369422	C/T	cg20590849	chr17:73267439	MIF4GD	-0.55	-6.44	-0.37	5.48e-10	Systemic lupus erythematosus;
CESC	cis	rs5758659	0.652	rs133358	chr22:42442539	A/T	cg15557168	chr22:42548783	NA	-0.49	-7.6	-0.42	5.27e-13	Cognitive function;
CESC	trans	rs11098499	0.863	rs1383532	chr4:120434404	A/T	cg25214090	chr10:38739885	LOC399744	-0.7	-9.78	-0.51	1.74e-19	Corneal astigmatism;
CESC	cis	rs12142240	0.698	rs67487250	chr1:46811333	T/C	cg00530320	chr1:46809349	NSUN4	0.58	7.85	0.43	1.05e-13	Menopause (age at onset);
CESC	cis	rs4654899	0.965	rs4654898	chr1:21376383	T/C	cg05370193	chr1:21551575	ECE1	0.36	5.36	0.31	1.85e-7	Superior frontal gyrus grey matter volume;
CESC	trans	rs2388082	0.711	rs12583304	chr13:29967668	C/T	cg18754342	chr12:14849268	GUCY2C	-0.65	-6.0	-0.35	6.63e-9	Insomnia (caffeine-induced);
CESC	cis	rs9649213	0.593	rs6945554	chr7:97972946	T/C	cg00277769	chr7:97922759	BAIAP2L1	-0.33	-5.41	-0.32	1.41e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs4665809	0.549	rs34075014	chr2:26520842	T/C	cg25036284	chr2:26402008	FAM59B	0.7	6.91	0.39	3.51e-11	Gut microbiome composition (summer);
CESC	cis	rs1801251	1.000	rs71421663	chr2:233619131	A/G	cg08000102	chr2:233561755	GIGYF2	0.67	9.48	0.5	1.53e-18	Coronary artery disease;
CESC	cis	rs17666538	0.585	rs1037393	chr8:622634	G/C	cg02524346	chr8:600233	NA	0.84	5.97	0.34	7.53e-9	IgG glycosylation;
CESC	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.89	13.44	0.64	9.54e-32	Prudent dietary pattern;
CESC	cis	rs1957429	0.901	rs7143661	chr14:65378981	G/A	cg23373153	chr14:65346875	NA	0.91	9.83	0.52	1.19e-19	Pediatric areal bone mineral density (radius);
CESC	cis	rs7811142	0.779	rs111312383	chr7:99905325	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.69	5.7	0.33	3.17e-8	Platelet count;
CESC	cis	rs2820292	0.500	rs61824384	chr1:201859213	A/G	cg11586189	chr1:201857591	SHISA4	-0.35	-5.65	-0.33	4.1e-8	Waist circumference;Body mass index (joint analysis main effects and smoking interaction);Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);
CESC	cis	rs1797885	0.510	rs2442802	chr3:12608045	A/C	cg26432171	chr3:12704882	RAF1	-0.4	-5.14	-0.3	5.21e-7	Immature fraction of reticulocytes;
CESC	cis	rs2440129	0.611	rs1042356	chr17:6902743	G/A	cg25987502	chr17:6899865	ALOX12	0.45	7.38	0.41	2.06e-12	Tonsillectomy;
CESC	cis	rs9326248	1.000	rs664971	chr11:117070857	A/G	cg26566898	chr11:117069891	TAGLN	-0.32	-5.31	-0.31	2.37e-7	Blood protein levels;
CESC	cis	rs748404	0.660	rs2249952	chr15:43720533	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	8.13	0.45	1.61e-14	Lung cancer;
CESC	cis	rs9916302	0.904	rs602688	chr17:37439496	C/T	cg00129232	chr17:37814104	STARD3	-0.55	-7.38	-0.41	2.09e-12	Glomerular filtration rate (creatinine);
CESC	cis	rs13253111	0.624	rs13277389	chr8:28100234	G/T	cg26534493	chr8:28060551	NA	0.46	7.15	0.4	8.56e-12	Childhood body mass index;
CESC	cis	rs2235642	0.750	rs2755185	chr16:1645827	A/G	cg03771183	chr16:1608904	IFT140	0.37	5.41	0.32	1.39e-7	Coronary artery disease;
CESC	cis	rs77956314	0.515	rs10850733	chr12:117380961	G/A	cg16111737	chr12:117408163	FBXW8	-0.46	-5.75	-0.33	2.41e-8	Subcortical brain region volumes;Hippocampal volume;
CESC	cis	rs9486715	0.867	rs1127175	chr6:96999725	C/T	cg18709589	chr6:96969512	KIAA0776	-0.46	-6.48	-0.37	4.5e-10	Headache;
CESC	cis	rs11997175	0.545	rs59563980	chr8:33665377	C/T	ch.8.33884649F	chr8:33765107	NA	0.56	7.03	0.4	1.73e-11	Body mass index;
CESC	cis	rs1552244	1.000	rs6442147	chr3:10078247	A/G	cg00166722	chr3:10149974	C3orf24	0.48	6.1	0.35	3.66e-9	Alzheimer's disease;
CESC	cis	rs4689388	0.926	rs4234730	chr4:6296343	A/G	cg25554036	chr4:6271136	WFS1	0.52	8.3	0.45	5.43e-15	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs1878931	0.580	rs4785932	chr16:3410456	C/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.99	15.31	0.69	2.49e-38	Body mass index (adult);
CESC	cis	rs634534	0.622	rs624273	chr11:65712413	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.57	7.36	0.41	2.31e-12	Sum eosinophil basophil counts;Eosinophil counts;
CESC	cis	rs6088580	0.634	rs6142159	chr20:32993035	G/A	cg08999081	chr20:33150536	PIGU	-0.64	-11.25	-0.57	2.81e-24	Glomerular filtration rate (creatinine);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg03454357	chr2:42565216	NA	0.47	6.11	0.35	3.51e-9	Fibrinogen levels;
CESC	cis	rs7615952	0.576	rs2276726	chr3:125826287	C/G	cg02807482	chr3:125708958	NA	-0.42	-5.89	-0.34	1.15e-8	Blood pressure (smoking interaction);
CESC	cis	rs12541635	0.966	rs4734894	chr8:106995313	G/A	cg10147462	chr8:107024639	NA	0.41	5.74	0.33	2.63e-8	Age of smoking initiation;
CESC	cis	rs6502050	0.835	rs9674648	chr17:80096756	A/G	cg23985595	chr17:80112537	CCDC57	-0.4	-6.26	-0.36	1.55e-9	Life satisfaction;
CESC	cis	rs7959452	0.590	rs11177644	chr12:69785748	A/G	cg20891283	chr12:69753455	YEATS4	0.9	15.12	0.68	1.17e-37	Blood protein levels;
CESC	cis	rs854765	0.693	rs11657074	chr17:17770355	G/A	cg09796270	chr17:17721594	SREBF1	-0.45	-6.36	-0.36	8.61e-10	Total body bone mineral density;
CESC	cis	rs963731	0.649	rs297129	chr2:39299271	C/T	cg04010122	chr2:39346883	SOS1	0.7	5.5	0.32	9.03e-8	Corticobasal degeneration;
CESC	cis	rs8060686	0.925	rs9928531	chr16:67833171	T/C	cg26727032	chr16:67993705	SLC12A4	-0.63	-9.17	-0.49	1.4e-17	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs2243480	1.000	rs316315	chr7:65591205	C/T	cg12463550	chr7:65579703	CRCP	-0.68	-6.2	-0.36	2.13e-9	Diabetic kidney disease;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg00491963	chr11:57335356	UBE2L6	-0.39	-6.04	-0.35	5.07e-9	Gambling;
CESC	cis	rs761746	0.672	rs12627933	chr22:32027449	C/T	cg25791279	chr22:32026902	PISD	0.56	5.76	0.33	2.36e-8	Intelligence;
CESC	cis	rs875971	0.895	rs6460300	chr7:65952924	A/G	cg12463550	chr7:65579703	CRCP	0.55	6.87	0.39	4.52e-11	Aortic root size;
CESC	cis	rs1018836	0.631	rs2205158	chr8:91472515	C/T	cg16814680	chr8:91681699	NA	-0.52	-6.92	-0.39	3.38e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs116095464	1.000	rs6555159	chr5:311562	G/A	cg22857025	chr5:266934	NA	-1.24	-10.85	-0.55	6.11e-23	Breast cancer;
CESC	cis	rs798554	0.679	rs1639036	chr7:2885089	G/A	cg04166393	chr7:2884313	GNA12	0.61	8.48	0.46	1.58e-15	Height;
CESC	cis	rs28374715	0.681	rs7168307	chr15:41620534	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.8	-11.98	-0.59	1.03e-26	Ulcerative colitis;
CESC	cis	rs6088580	0.561	rs3761147	chr20:32996689	G/T	cg24642439	chr20:33292090	TP53INP2	-0.51	-6.67	-0.38	1.48e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs2880765	0.835	rs7168860	chr15:86037030	G/A	cg19183879	chr15:85880815	NA	-0.26	-5.29	-0.31	2.51e-7	Coronary artery disease;
CESC	cis	rs2299587	0.553	rs2299580	chr8:17734567	C/A	cg08627089	chr8:17753878	FGL1	-0.4	-5.73	-0.33	2.77e-8	Economic and political preferences;
CESC	cis	rs2249694	0.960	rs6537613	chr10:135412414	T/G	cg20169779	chr10:135381914	SYCE1	-0.41	-5.78	-0.33	2.12e-8	Obesity-related traits;
CESC	cis	rs3806843	0.966	rs2337986	chr5:140160622	C/T	cg26395211	chr5:140044315	WDR55	-0.42	-5.43	-0.32	1.26e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs9487051	0.597	rs351731	chr6:109507842	A/T	cg01475377	chr6:109611718	NA	-0.39	-5.17	-0.3	4.58e-7	Reticulocyte fraction of red cells;
CESC	cis	rs7918232	0.941	rs6482598	chr10:27426375	T/C	cg14240646	chr10:27532245	ACBD5	-0.66	-6.43	-0.37	5.89e-10	Breast cancer;
CESC	cis	rs4665809	0.590	rs11552518	chr2:26455127	G/A	cg04944784	chr2:26401820	FAM59B	0.96	10.5	0.54	8.76e-22	Gut microbiome composition (summer);
CESC	cis	rs2857078	0.720	rs9901595	chr17:42305699	G/A	cg19774624	chr17:42201019	HDAC5	-0.55	-7.41	-0.41	1.75e-12	Red cell distribution width;Reticulocyte count;
CESC	cis	rs796364	0.806	rs56216998	chr2:200944333	G/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.82	-7.29	-0.41	3.5e-12	Schizophrenia;
CESC	cis	rs637571	0.565	rs570387	chr11:65637076	T/C	cg04055107	chr11:65626734	MUS81;CFL1	-0.71	-9.01	-0.48	4.3e-17	Eosinophil percentage of white cells;
CESC	cis	rs1387259	0.929	rs11168484	chr12:48633589	A/C	cg24011408	chr12:48396354	COL2A1	0.43	5.9	0.34	1.11e-8	Obstructive sleep apnea trait (apnea hypopnea index);
CESC	cis	rs7605827	0.930	rs6708288	chr2:15535477	A/G	cg19274914	chr2:15703543	NA	0.36	6.59	0.38	2.3e-10	Educational attainment (years of education);
CESC	cis	rs2963155	0.518	rs864355	chr5:142633229	A/G	cg17617527	chr5:142782415	NR3C1	0.84	7.49	0.42	1.06e-12	Breast cancer;
CESC	cis	rs9487051	0.872	rs9386790	chr6:109608460	G/T	cg01475377	chr6:109611718	NA	0.5	8.31	0.45	5.09e-15	Reticulocyte fraction of red cells;
CESC	cis	rs798554	0.797	rs798494	chr7:2798294	C/A	cg04166393	chr7:2884313	GNA12	0.6	7.73	0.43	2.27e-13	Height;
CESC	trans	rs11039798	0.528	rs10769559	chr11:49032446	T/C	cg15704280	chr7:45808275	SEPT13	0.65	6.96	0.39	2.68e-11	Axial length;
CESC	cis	rs78456975	1.000	rs11899027	chr2:1560414	G/C	cg01028140	chr2:1542097	TPO	-0.5	-5.37	-0.31	1.69e-7	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs684232	0.666	rs2657629	chr17:602261	G/T	cg12384639	chr17:618140	VPS53	0.41	5.45	0.32	1.15e-7	Prostate cancer;
CESC	trans	rs10242455	0.717	rs4646461	chr7:99331473	C/T	cg09045935	chr12:6379348	NA	0.65	6.05	0.35	4.85e-9	Blood metabolite levels;
CESC	cis	rs473651	0.935	rs520765	chr2:239354712	C/T	cg21699342	chr2:239360505	ASB1	0.56	9.65	0.51	4.45e-19	Multiple system atrophy;
CESC	cis	rs7179456	0.610	rs650366	chr15:59061142	A/G	cg05156742	chr15:59063176	FAM63B	0.66	8.94	0.48	6.9e-17	Asperger disorder;
CESC	cis	rs7666738	0.830	rs28451101	chr4:99001190	T/C	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.62e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7259376	0.875	rs6511345	chr19:22537436	T/C	cg02657401	chr19:22469223	NA	-0.26	-5.16	-0.3	4.9e-7	Menopause (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24886033	chr12:10265096	NA	-0.64	-7.53	-0.42	7.8e-13	Gut microbiome composition (summer);
CESC	cis	rs7085104	0.513	rs619824	chr10:104581288	G/T	cg04362960	chr10:104952993	NT5C2	0.51	6.85	0.39	5.05e-11	Immature fraction of reticulocytes;Schizophrenia;
CESC	cis	rs9611565	0.681	rs5751094	chr22:41803279	C/T	cg06481639	chr22:41940642	POLR3H	0.62	6.52	0.37	3.49e-10	Vitiligo;
CESC	cis	rs2295499	0.678	rs12503560	chr4:2714482	T/C	cg27239842	chr4:2403781	ZFYVE28	-0.33	-5.64	-0.33	4.28e-8	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
CESC	trans	rs12107539	1.000	rs3773621	chr3:150996434	A/C	cg05862518	chr17:40277425	RAB5C	-0.48	-6.3	-0.36	1.22e-9	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
CESC	cis	rs72945132	0.882	rs72947078	chr11:70197542	G/T	cg14191688	chr11:70257035	CTTN	0.46	5.41	0.32	1.41e-7	Coronary artery disease;
CESC	cis	rs9549367	0.737	rs9549712	chr13:113902355	G/A	cg18105134	chr13:113819100	PROZ	-0.68	-8.25	-0.45	7.53e-15	Platelet distribution width;
CESC	cis	rs9322193	0.962	rs1112730	chr6:150087519	G/A	cg07701084	chr6:150067640	NUP43	0.44	5.95	0.34	8.59e-9	Lung cancer;
CESC	cis	rs9859260	0.710	rs366268	chr3:195782177	A/G	cg12923728	chr3:195709715	SDHAP1	0.53	6.93	0.39	3.14e-11	Mean corpuscular volume;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg15952933	chr7:1899886	MAD1L1	0.52	7.14	0.4	8.8e-12	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs17253792	0.822	rs76555508	chr14:56071868	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.79	5.91	0.34	1.06e-8	Putamen volume;
CESC	cis	rs1801251	1.000	rs12987513	chr2:233622066	A/G	cg25237894	chr2:233734115	C2orf82	0.44	7.63	0.42	4.32e-13	Coronary artery disease;
CESC	cis	rs10504229	0.609	rs66477547	chr8:58105763	A/C	cg02725872	chr8:58115012	NA	-0.44	-6.87	-0.39	4.53e-11	Developmental language disorder (linguistic errors);
CESC	trans	rs801193	1.000	rs4717319	chr7:66242593	A/G	cg14393609	chr7:65229607	NA	0.47	6.31	0.36	1.17e-9	Aortic root size;
CESC	cis	rs10461617	0.541	rs832575	chr5:56161787	C/T	cg22800045	chr5:56110881	MAP3K1	0.73	7.19	0.4	6.64e-12	Type 2 diabetes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04439696	chr6:36954195	MTCH1	0.61	7.48	0.42	1.08e-12	Gut microbiome composition (summer);
CESC	cis	rs208520	1.000	rs12212063	chr6:66985148	C/A	cg07460842	chr6:66804631	NA	0.77	8.92	0.48	8.09e-17	Exhaled nitric oxide output;
CESC	cis	rs13191362	0.507	rs2846535	chr6:163034019	T/C	cg06582575	chr6:163149167	PACRG;PARK2	-0.5	-6.24	-0.36	1.74e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs514406	0.763	rs6685599	chr1:53213172	G/A	cg24675658	chr1:53192096	ZYG11B	0.54	6.8	0.39	6.96e-11	Monocyte count;
CESC	cis	rs926938	0.527	rs1391484	chr1:115522366	A/G	cg12756093	chr1:115239321	AMPD1	0.45	6.15	0.35	2.84e-9	Autism;
CESC	cis	rs10504229	0.871	rs60342323	chr8:58154899	T/C	cg05313129	chr8:58192883	C8orf71	-0.43	-5.06	-0.3	7.76e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs7267979	0.966	rs2257461	chr20:25265554	A/G	cg08601574	chr20:25228251	PYGB	0.39	5.65	0.33	4.08e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs12824058	0.798	rs4759652	chr12:130808771	C/T	cg26677194	chr12:130822605	PIWIL1	0.5	6.49	0.37	4.23e-10	Menopause (age at onset);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg11087747	chr19:41107377	LTBP4	0.48	6.0	0.35	6.63e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs9790314	1.000	rs336583	chr3:161081981	A/T	cg03342759	chr3:160939853	NMD3	0.47	5.95	0.34	8.63e-9	Morning vs. evening chronotype;
CESC	cis	rs854765	0.547	rs2955355	chr17:17948475	G/A	cg04398451	chr17:18023971	MYO15A	0.71	10.43	0.54	1.44e-21	Total body bone mineral density;
CESC	cis	rs11997175	0.625	rs17698353	chr8:33592241	A/G	ch.8.33884649F	chr8:33765107	NA	0.51	6.29	0.36	1.34e-9	Body mass index;
CESC	cis	rs2243480	1.000	rs422164	chr7:65586605	C/G	cg12463550	chr7:65579703	CRCP	0.73	5.68	0.33	3.5e-8	Diabetic kidney disease;
CESC	cis	rs2204008	0.658	rs11181310	chr12:38315963	C/A	cg13010199	chr12:38710504	ALG10B	0.44	5.62	0.33	4.91e-8	Bladder cancer;
CESC	trans	rs61931739	0.500	rs7979482	chr12:34542877	C/A	cg26384229	chr12:38710491	ALG10B	0.72	10.84	0.55	6.8e-23	Morning vs. evening chronotype;
CESC	cis	rs4819052	0.807	rs7283915	chr21:46671288	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.75	9.88	0.52	8.11e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs7914558	1.000	rs12255047	chr10:104760752	G/A	cg15744005	chr10:104629667	AS3MT	-0.34	-5.51	-0.32	8.56e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10300236	chr14:59950716	C14orf149;JKAMP	0.62	7.12	0.4	9.88e-12	Gut microbiome composition (summer);
CESC	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.65	0.38	1.71e-10	Prudent dietary pattern;
CESC	cis	rs9796	0.621	rs58109657	chr15:41471750	A/G	cg20272979	chr15:41787780	ITPKA	-0.34	-5.18	-0.3	4.46e-7	Menopause (age at onset);
CESC	cis	rs116095464	1.000	rs2015774	chr5:312958	G/T	cg10591111	chr5:226296	SDHA	-0.61	-5.68	-0.33	3.5e-8	Breast cancer;
CESC	cis	rs11677370	0.603	rs11675498	chr2:3850943	G/T	cg17052675	chr2:3827356	NA	-0.43	-5.5	-0.32	8.9e-8	Type 2 diabetes;
CESC	cis	rs6499255	0.951	rs61310815	chr16:69701239	A/T	cg15192750	chr16:69999425	NA	0.45	5.23	0.31	3.53e-7	IgE levels;
CESC	cis	rs6964587	0.869	rs2023784	chr7:91524677	A/G	cg17063962	chr7:91808500	NA	-0.53	-7.0	-0.39	2.11e-11	Breast cancer;
CESC	cis	rs2953174	0.938	rs2975764	chr2:241534381	A/G	cg07929629	chr2:241523174	NA	0.57	5.33	0.31	2.09e-7	Bipolar disorder;
CESC	cis	rs9283706	0.594	rs7717020	chr5:66353322	A/C	cg11590213	chr5:66331682	MAST4	0.39	5.09	0.3	6.9e-7	Coronary artery disease;
CESC	cis	rs1372520	0.684	rs1811442	chr4:90747751	C/T	cg15133208	chr4:90757351	SNCA	-0.4	-5.49	-0.32	9.46e-8	Neuroticism;
CESC	cis	rs6142102	0.580	rs4911139	chr20:32551535	G/A	cg08999081	chr20:33150536	PIGU	0.33	5.04	0.3	8.7e-7	Skin pigmentation;
CESC	cis	rs597539	0.652	rs10792001	chr11:68637737	G/C	cg04772025	chr11:68637568	NA	0.55	6.49	0.37	4.17e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs921968	0.643	rs1344645	chr2:219538019	A/C	cg02176678	chr2:219576539	TTLL4	0.39	6.54	0.37	3.13e-10	Mean corpuscular hemoglobin concentration;
CESC	cis	rs8018808	0.936	rs10140302	chr14:77855693	C/A	cg20045696	chr14:77926864	AHSA1	-0.38	-5.18	-0.3	4.46e-7	Myeloid white cell count;
CESC	cis	rs11048434	0.736	rs11048195	chr12:9105923	A/G	cg23795048	chr12:9217529	LOC144571	0.35	5.4	0.31	1.52e-7	Sjögren's syndrome;
CESC	cis	rs73206853	0.619	rs112148402	chr12:111171493	T/C	cg12870014	chr12:110450643	ANKRD13A	0.73	5.39	0.31	1.53e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs4642101	0.680	rs6442330	chr3:12820501	A/G	cg24848339	chr3:12840334	CAND2	0.41	6.36	0.36	8.71e-10	QRS complex (12-leadsum);
CESC	cis	rs2370759	1.000	rs16933243	chr10:32615135	T/C	cg01819863	chr10:32635814	EPC1	1.16	12.49	0.61	1.86e-28	Sexual dysfunction (female);
CESC	cis	rs2732480	0.577	rs2732481	chr12:48736985	T/G	cg24011408	chr12:48396354	COL2A1	0.44	5.95	0.34	8.54e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.43	-5.73	-0.33	2.74e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs9359856	0.564	rs72913954	chr6:90361589	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.62	-5.7	-0.33	3.12e-8	Bipolar disorder;
CESC	cis	rs896854	0.530	rs10956934	chr8:95992473	C/A	cg09323728	chr8:95962352	TP53INP1	-0.37	-8.0	-0.44	3.92e-14	Type 2 diabetes;
CESC	cis	rs2952156	0.959	rs2941503	chr17:37828745	A/G	cg00129232	chr17:37814104	STARD3	-0.73	-9.76	-0.51	1.96e-19	Asthma;
CESC	cis	rs7246657	0.943	rs7252099	chr19:37933780	G/A	cg23950597	chr19:37808831	NA	-0.61	-6.23	-0.36	1.85e-9	Coronary artery calcification;
CESC	cis	rs13191362	1.000	rs67747005	chr6:163150845	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.69	7.11	0.4	1.11e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18132058	chr10:131567108	NA	-0.55	-6.09	-0.35	4e-9	Gut microbiome composition (summer);
CESC	cis	rs748404	0.697	rs546170	chr15:43564849	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.59	7.8	0.43	1.44e-13	Lung cancer;
CESC	cis	rs7618915	0.501	rs2336149	chr3:52692124	G/A	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.75	0.38	9.1e-11	Bipolar disorder;
CESC	cis	rs514406	0.505	rs12726160	chr1:53175099	A/G	cg08736216	chr1:53307985	ZYG11A	-0.34	-5.69	-0.33	3.44e-8	Monocyte count;
CESC	cis	rs9487051	0.743	rs388526	chr6:109543425	C/G	cg01475377	chr6:109611718	NA	-0.37	-5.35	-0.31	1.92e-7	Reticulocyte fraction of red cells;
CESC	cis	rs17666538	0.585	rs1669615	chr8:616665	T/C	cg07234876	chr8:600039	NA	0.83	5.89	0.34	1.15e-8	IgG glycosylation;
CESC	cis	rs2425143	0.908	rs12480111	chr20:34423186	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-6.11	-0.35	3.47e-9	Blood protein levels;
CESC	cis	rs8016982	0.633	rs72695758	chr14:81720146	T/C	cg01989461	chr14:81687754	GTF2A1	0.71	10.96	0.56	2.67e-23	Schizophrenia;
CESC	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg06877462	chr1:205807181	PM20D1	0.37	5.37	0.31	1.71e-7	Menarche (age at onset);
CESC	cis	rs2860975	0.620	rs7077618	chr10:96793457	T/A	cg09036531	chr10:96991505	NA	-0.35	-5.08	-0.3	7.24e-7	Immune response to smallpox vaccine (IL-6);
CESC	cis	rs9399137	0.507	rs11154791	chr6:135379148	A/G	cg22676075	chr6:135203613	NA	0.53	7.05	0.4	1.52e-11	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	cis	rs7044106	0.718	rs1960421	chr9:123394894	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.76	10.99	0.56	2.18e-23	Hip circumference adjusted for BMI;
CESC	cis	rs9733	0.650	rs4970923	chr1:150608300	A/G	cg17724175	chr1:150552817	MCL1	-0.33	-5.23	-0.31	3.42e-7	Tonsillectomy;
CESC	cis	rs2197308	0.765	rs7295711	chr12:37903631	C/T	cg26384229	chr12:38710491	ALG10B	0.75	11.12	0.56	8.21e-24	Morning vs. evening chronotype;
CESC	cis	rs7659604	0.540	rs13140070	chr4:122713899	C/T	cg19748678	chr4:122722346	EXOSC9	-0.42	-5.26	-0.31	2.99e-7	Type 2 diabetes;
CESC	cis	rs9611565	0.649	rs5751144	chr22:42128097	A/G	cg03806693	chr22:41940476	POLR3H	-0.76	-9.22	-0.49	9.9e-18	Vitiligo;
CESC	cis	rs853679	0.517	rs3173443	chr6:28137027	T/G	cg23281280	chr6:28129359	ZNF389	0.56	7.62	0.42	4.55e-13	Depression;
CESC	cis	rs1218582	0.741	rs11264283	chr1:154869552	A/G	cg06221963	chr1:154839813	KCNN3	-0.67	-11.38	-0.57	1.05e-24	Prostate cancer;
CESC	cis	rs7551222	0.752	rs16853958	chr1:204528344	A/C	cg20240347	chr1:204465584	NA	-0.26	-5.3	-0.31	2.45e-7	Schizophrenia;
CESC	cis	rs854765	0.552	rs6502624	chr17:17847936	G/A	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.54	7.08	0.4	1.28e-11	Total body bone mineral density;
CESC	cis	rs8053891	0.756	rs12708922	chr16:72001629	A/G	cg04254540	chr16:71951199	KIAA0174	-0.41	-5.31	-0.31	2.29e-7	Coronary artery disease;
CESC	cis	rs34779708	0.733	rs7081597	chr10:35546331	G/C	cg04310649	chr10:35416472	CREM	-0.46	-5.28	-0.31	2.76e-7	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs59698941	0.943	rs67462411	chr5:132220031	C/T	cg02081065	chr5:132209139	LEAP2	-0.52	-5.11	-0.3	6.08e-7	Apolipoprotein A-IV levels;
CESC	cis	rs9322193	0.886	rs9718079	chr6:149967083	T/C	cg13206674	chr6:150067644	NUP43	0.41	5.94	0.34	8.98e-9	Lung cancer;
CESC	cis	rs7116495	0.609	rs10736780	chr11:71650241	T/C	cg07596299	chr11:71824057	C11orf51	-0.76	-5.21	-0.3	3.77e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs6502050	0.799	rs6502089	chr17:80169523	G/A	cg11859384	chr17:80120422	CCDC57	-0.37	-5.13	-0.3	5.73e-7	Life satisfaction;
CESC	cis	rs763121	0.853	rs138716	chr22:39146527	C/T	cg06022373	chr22:39101656	GTPBP1	0.88	13.83	0.65	4.02e-33	Menopause (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04724143	chr13:114185494	TMCO3	-0.6	-6.95	-0.39	2.76e-11	Gut microbiome composition (summer);
CESC	cis	rs116095464	0.558	rs10080225	chr5:232175	A/G	cg22496380	chr5:211416	CCDC127	-0.73	-8.37	-0.46	3.25e-15	Breast cancer;
CESC	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg07677032	chr17:61819896	STRADA	0.49	6.59	0.38	2.42e-10	Prudent dietary pattern;
CESC	cis	rs9611565	0.592	rs57102627	chr22:41987627	T/C	cg06634786	chr22:41940651	POLR3H	-0.57	-6.28	-0.36	1.35e-9	Vitiligo;
CESC	cis	rs6952808	0.594	rs3778969	chr7:2139990	A/G	cg23048001	chr7:2026167	MAD1L1	-0.43	-5.57	-0.32	6.34e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs708547	0.836	rs781554	chr4:57717537	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.5	-5.42	-0.32	1.36e-7	Response to bleomycin (chromatid breaks);
CESC	cis	rs1167827	1.000	rs1167827	chr7:75163169	A/G	cg04978709	chr7:75101039	POM121C	0.48	6.91	0.39	3.5e-11	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	trans	rs3942852	0.868	rs7122335	chr11:48106486	C/T	cg15704280	chr7:45808275	SEPT13	-0.68	-7.45	-0.42	1.35e-12	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs4819052	0.851	rs58644915	chr21:46669912	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.74	9.78	0.52	1.7e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs1801251	1.000	rs283486	chr2:233644223	A/G	cg25237894	chr2:233734115	C2orf82	0.46	8.01	0.44	3.67e-14	Coronary artery disease;
CESC	cis	rs9311474	0.508	rs7652191	chr3:52610415	T/C	cg18404041	chr3:52824283	ITIH1	-0.39	-6.78	-0.38	7.71e-11	Electroencephalogram traits;
CESC	cis	rs1461503	0.512	rs4293126	chr11:122804133	A/G	cg27398637	chr11:122830231	C11orf63	0.49	6.9	0.39	3.83e-11	Menarche (age at onset);
CESC	cis	rs3762318	0.756	rs6703475	chr1:67603972	T/C	cg17031739	chr1:67600172	NA	0.53	5.11	0.3	6.16e-7	Leprosy;
CESC	cis	rs7100689	0.725	rs2487074	chr10:82064104	A/G	cg00277334	chr10:82204260	NA	-0.57	-7.14	-0.4	8.97e-12	Post bronchodilator FEV1;
CESC	cis	rs67311347	1.000	rs2276870	chr3:40499182	C/T	cg09455208	chr3:40491958	NA	-0.48	-8.01	-0.44	3.6e-14	Renal cell carcinoma;
CESC	cis	rs1401999	0.510	rs3749438	chr3:183705184	G/A	cg01324343	chr3:183735012	ABCC5	0.36	6.15	0.35	2.77e-9	Anterior chamber depth;
CESC	cis	rs1670533	1.000	rs7673898	chr4:1056569	C/A	cg27284194	chr4:1044797	NA	0.48	6.06	0.35	4.7e-9	Recombination rate (females);
CESC	cis	rs35306767	0.903	rs765867	chr10:869901	G/T	cg20503657	chr10:835505	NA	0.82	8.27	0.45	6.52e-15	Eosinophil percentage of granulocytes;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg06518779	chr13:103452556	BIVM;KDELC1	0.5	6.39	0.37	7.63e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs965469	0.817	rs6037582	chr20:3351696	C/T	cg25506879	chr20:3388711	C20orf194	-0.49	-5.24	-0.31	3.22e-7	IFN-related cytopenia;
CESC	cis	rs9649213	0.593	rs6465678	chr7:98004057	T/C	cg24562669	chr7:97807699	LMTK2	0.48	6.95	0.39	2.81e-11	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs3091242	0.933	rs4649084	chr1:25752617	A/G	cg27572855	chr1:25598939	RHD	0.42	6.98	0.39	2.43e-11	Erythrocyte sedimentation rate;
CESC	cis	rs864537	0.676	rs3108155	chr1:167422057	C/G	cg22356347	chr1:167427500	CD247	-0.39	-8.02	-0.44	3.48e-14	Celiac disease or Rheumatoid arthritis;Celiac disease;
CESC	cis	rs12079745	0.793	rs60011235	chr1:169254727	T/C	cg09363564	chr1:169337483	NME7;BLZF1	-0.94	-6.2	-0.36	2.13e-9	QT interval;
CESC	cis	rs9322193	0.923	rs10782314	chr6:150056663	C/T	cg13206674	chr6:150067644	NUP43	0.43	6.05	0.35	4.94e-9	Lung cancer;
CESC	trans	rs9325144	0.555	rs1825806	chr12:38692547	G/A	cg23762105	chr12:34175262	ALG10	-0.49	-6.56	-0.37	2.76e-10	Morning vs. evening chronotype;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg14843989	chr17:10600751	C17orf48;SCO1	-0.43	-6.11	-0.35	3.59e-9	Fibrinogen levels;
CESC	cis	rs9322193	0.962	rs9689242	chr6:150109106	T/C	cg13206674	chr6:150067644	NUP43	0.42	5.89	0.34	1.19e-8	Lung cancer;
CESC	cis	rs2777491	0.522	rs7169278	chr15:41696932	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.56	-7.77	-0.43	1.72e-13	Ulcerative colitis;
CESC	cis	rs12530845	0.887	rs79100776	chr7:135315817	G/A	cg23117316	chr7:135346802	PL-5283	-0.48	-5.83	-0.34	1.58e-8	Red blood cell traits;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg01688141	chr8:23539808	NKX3-1	0.49	6.27	0.36	1.48e-9	Gut microbiota (bacterial taxa);
CESC	trans	rs4950322	0.563	rs6700783	chr1:146583569	A/T	cg04954894	chr8:38089920	DDHD2	-0.58	-6.34	-0.36	9.9e-10	Protein quantitative trait loci;
CESC	cis	rs7666738	0.830	rs3852123	chr4:98697586	A/G	cg03467027	chr4:99064603	C4orf37	0.43	5.34	0.31	1.98e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10479542	0.929	rs10078796	chr5:178978883	T/A	cg05457628	chr5:178986728	RUFY1	0.51	7.69	0.43	2.8e-13	Lung cancer;
CESC	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	13.7	0.64	1.15e-32	Prudent dietary pattern;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10212537	chr14:93799559	BTBD7;KIAA1409	0.72	8.54	0.46	1.1e-15	Gut microbiome composition (summer);
CESC	trans	rs7107217	1.000	rs1873872	chr11:129473993	A/T	cg18030105	chr11:3396237	ZNF195	-0.48	-6.51	-0.37	3.75e-10	Breast cancer;Type 2 diabetes;
CESC	cis	rs2303759	0.676	rs7248378	chr19:49908144	C/A	cg24324837	chr19:49891574	CCDC155	0.43	5.04	0.3	8.53e-7	Multiple sclerosis;
CESC	cis	rs1799949	1.000	rs4793229	chr17:41418334	C/T	cg23758822	chr17:41437982	NA	-1.06	-16.29	-0.71	8.49e-42	Menopause (age at onset);
CESC	cis	rs1799949	1.000	rs11653069	chr17:41283377	C/T	cg06001716	chr17:41278141	BRCA1;NBR2	0.39	5.26	0.31	3e-7	Menopause (age at onset);
CESC	cis	rs11247915	0.583	rs66569416	chr1:26659737	C/G	cg04990556	chr1:26633338	UBXN11	-0.58	-6.53	-0.37	3.33e-10	Obesity-related traits;
CESC	cis	rs5750830	0.649	rs5750811	chr22:39793066	G/T	cg01416388	chr22:39784598	NA	0.56	6.84	0.39	5.46e-11	Intelligence (multi-trait analysis);
CESC	cis	rs6952808	0.595	rs3778982	chr7:2166233	T/C	cg02951883	chr7:2050386	MAD1L1	-0.46	-5.85	-0.34	1.47e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs9311474	0.508	rs6805156	chr3:52609362	T/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.33	6.0	0.35	6.28e-9	Electroencephalogram traits;
CESC	cis	rs11630290	0.592	rs12324668	chr15:64161786	A/T	cg12036633	chr15:63758958	NA	0.44	5.32	0.31	2.2e-7	Iris characteristics;
CESC	cis	rs10493773	0.609	rs11161656	chr1:86182414	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.44	-6.53	-0.37	3.43e-10	Urate levels in overweight individuals;
CESC	cis	rs9611565	0.512	rs964898	chr22:42142306	C/T	cg03806693	chr22:41940476	POLR3H	-1.19	-13.81	-0.65	4.89e-33	Vitiligo;
CESC	cis	rs896854	0.654	rs896846	chr8:95972453	G/A	cg16049864	chr8:95962084	TP53INP1	-0.65	-11.35	-0.57	1.31e-24	Type 2 diabetes;
CESC	cis	rs897080	0.552	rs1067318	chr2:44634509	A/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	5.91	0.34	1.07e-8	Height;
CESC	cis	rs9911578	1.000	rs2531734	chr17:56550804	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	-0.41	-5.52	-0.32	7.9e-8	Intelligence (multi-trait analysis);
CESC	cis	rs11166629	1.000	rs7003870	chr8:135616586	A/G	cg27224718	chr8:135614730	ZFAT	0.5	6.27	0.36	1.5e-9	Smoking quantity;
CESC	cis	rs2404602	0.647	rs12910081	chr15:77022959	G/C	cg23625390	chr15:77176239	SCAPER	-0.46	-6.5	-0.37	4.05e-10	Blood metabolite levels;
CESC	cis	rs7072216	0.763	rs10883090	chr10:100167236	G/C	cg26618903	chr10:100175079	PYROXD2	-0.37	-5.54	-0.32	7.25e-8	Metabolite levels;
CESC	cis	rs947211	0.950	rs885224	chr1:205753097	A/G	cg26354017	chr1:205819088	PM20D1	0.42	5.32	0.31	2.25e-7	Parkinson's disease;
CESC	cis	rs4835473	0.868	rs7683365	chr4:144920596	G/A	cg25736465	chr4:144833511	NA	-0.46	-6.94	-0.39	2.96e-11	Immature fraction of reticulocytes;
CESC	cis	rs4819052	0.851	rs2236445	chr21:46678453	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.95	14.07	0.65	5.76e-34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs11608355	0.515	rs1045263	chr12:109974191	A/G	cg05360138	chr12:110035743	NA	0.81	8.77	0.47	2.28e-16	Neuroticism;
CESC	trans	rs116095464	0.614	rs62344292	chr5:244630	G/A	cg00938859	chr5:1591904	SDHAP3	0.64	6.98	0.39	2.36e-11	Breast cancer;
CESC	cis	rs67478160	0.679	rs8011109	chr14:104279974	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.51	-7.08	-0.4	1.33e-11	Schizophrenia;
CESC	cis	rs7618915	0.501	rs3733045	chr3:52643307	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	7.77	0.43	1.71e-13	Bipolar disorder;
CESC	cis	rs2806561	0.704	rs2806570	chr1:23527005	C/T	cg12483005	chr1:23474871	LUZP1	-0.42	-6.44	-0.37	5.46e-10	Height;
CESC	cis	rs9311474	0.629	rs13081028	chr3:52555316	G/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.39	-5.65	-0.33	4.12e-8	Electroencephalogram traits;
CESC	cis	rs2066819	1.000	rs2371494	chr12:56728000	G/A	cg26734620	chr12:56694298	CS	0.9	9.04	0.49	3.32e-17	Psoriasis vulgaris;
CESC	cis	rs3768617	0.510	rs1413387	chr1:183096774	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.87	13.4	0.64	1.29e-31	Fuchs's corneal dystrophy;
CESC	cis	rs3768617	0.811	rs12138053	chr1:182979560	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.67	9.18	0.49	1.24e-17	Fuchs's corneal dystrophy;
CESC	cis	rs7577696	0.597	rs212690	chr2:32437631	C/G	cg02381751	chr2:32503542	YIPF4	0.48	5.37	0.31	1.72e-7	Inflammatory biomarkers;
CESC	trans	rs338389	0.934	rs338404	chr15:68251675	T/C	cg10595952	chr5:2097052	NA	-0.36	-6.03	-0.35	5.34e-9	Survival in rectal cancer;
CESC	cis	rs870825	0.550	rs10000507	chr4:185619281	C/T	cg04058563	chr4:185651563	MLF1IP	0.63	7.0	0.4	2.06e-11	Blood protein levels;
CESC	cis	rs1005277	0.579	rs1780146	chr10:38517874	C/A	cg25517755	chr10:38738941	LOC399744	-0.49	-6.38	-0.37	7.75e-10	Extrinsic epigenetic age acceleration;
CESC	cis	rs425277	0.583	rs12059660	chr1:2041461	C/T	cg04315214	chr1:2043799	PRKCZ	0.52	8.83	0.48	1.47e-16	Height;
CESC	trans	rs4335177	0.963	rs6477533	chr9:109364579	C/T	cg12580783	chr12:49362475	WNT10B	0.35	6.58	0.37	2.52e-10	Response to paliperidone in schizophrenia (positive Marder score);
CESC	cis	rs3008870	1.000	rs2182143	chr1:67378936	T/C	cg02640540	chr1:67518911	SLC35D1	0.49	5.21	0.3	3.81e-7	Lymphocyte percentage of white cells;
CESC	cis	rs853679	0.517	rs9380058	chr6:28127444	T/C	cg22143856	chr6:28129313	ZNF389	0.49	6.22	0.36	1.9e-9	Depression;
CESC	cis	rs875971	1.000	rs778722	chr7:65844828	T/C	cg18876405	chr7:65276391	NA	0.5	6.66	0.38	1.61e-10	Aortic root size;
CESC	cis	rs6952808	1.000	rs6952808	chr7:1886535	C/G	cg21782813	chr7:2030301	MAD1L1	0.39	5.44	0.32	1.22e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs2235544	0.542	rs585269	chr1:54469976	C/T	cg25741118	chr1:54482237	LDLRAD1	0.24	5.76	0.33	2.29e-8	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
CESC	cis	rs2760061	0.626	rs2527615	chr1:228119283	A/G	cg02753203	chr1:228287806	NA	-0.5	-7.34	-0.41	2.69e-12	Diastolic blood pressure;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg01042287	chr16:28884343	SH2B1	0.45	6.27	0.36	1.45e-9	Fibrinogen levels;
CESC	cis	rs9815354	0.812	rs17218504	chr3:41987278	A/G	cg03022575	chr3:42003672	ULK4	0.68	6.1	0.35	3.75e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs854765	0.522	rs63721860	chr17:17829576	T/C	cg16928487	chr17:17741425	SREBF1	-0.53	-8.83	-0.48	1.5e-16	Total body bone mineral density;
CESC	cis	rs6912958	0.559	rs242280	chr6:88048714	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.44	7.8	0.43	1.47e-13	Monocyte percentage of white cells;
CESC	cis	rs9858542	0.953	rs3811699	chr3:49396360	T/C	cg07274523	chr3:49395745	GPX1	0.67	8.38	0.46	3.13e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs2370759	1.000	rs78959390	chr10:32616346	C/T	cg18270830	chr10:32634957	EPC1	0.71	6.78	0.38	7.78e-11	Sexual dysfunction (female);
CESC	cis	rs1190552	0.846	rs12883789	chr14:102954621	G/A	cg18135206	chr14:102964638	TECPR2	0.42	5.27	0.31	2.84e-7	Blood protein levels;
CESC	cis	rs4808199	0.901	rs11669516	chr19:19532682	G/A	cg03709012	chr19:19516395	GATAD2A	1.12	13.53	0.64	4.5e-32	Nonalcoholic fatty liver disease;
CESC	cis	rs2243480	1.000	rs13220979	chr7:65363204	G/A	cg18252515	chr7:66147081	NA	-1.01	-9.32	-0.5	4.6e-18	Diabetic kidney disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11446193	chr11:57405815	NA	-0.53	-6.15	-0.35	2.82e-9	Gut microbiome composition (summer);
CESC	cis	rs7474896	0.583	rs10827818	chr10:38000856	T/C	cg00409905	chr10:38381863	ZNF37A	-0.48	-5.59	-0.32	5.65e-8	Obesity (extreme);
CESC	cis	rs12190007	0.508	rs9406321	chr6:169726841	A/T	cg16388071	chr6:169726476	NA	0.56	8.21	0.45	9.58e-15	Obesity-related traits;
CESC	cis	rs9300255	0.722	rs1060105	chr12:123806219	C/T	cg00376283	chr12:123451042	ABCB9	-0.59	-6.26	-0.36	1.51e-9	Neutrophil percentage of white cells;
CESC	cis	rs875971	0.767	rs1695815	chr7:65831344	A/G	cg12463550	chr7:65579703	CRCP	0.59	7.45	0.42	1.29e-12	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03839252	chr13:41240923	FOXO1	0.54	6.07	0.35	4.35e-9	Gut microbiome composition (summer);
CESC	cis	rs25645	0.830	rs3935281	chr17:38188419	C/T	cg17467752	chr17:38218738	THRA	-0.51	-6.65	-0.38	1.63e-10	Myeloid white cell count;
CESC	cis	rs9916302	0.851	rs612209	chr17:37442713	G/C	cg07936489	chr17:37558343	FBXL20	0.78	11.12	0.56	7.9e-24	Glomerular filtration rate (creatinine);
CESC	cis	rs11792861	0.781	rs28361106	chr9:111762385	T/C	cg13535736	chr9:111863775	C9orf5	-0.41	-5.4	-0.31	1.51e-7	Menarche (age at onset);
CESC	cis	rs7666738	0.830	rs10000573	chr4:99048785	G/C	cg24818145	chr4:99064322	C4orf37	0.38	5.04	0.3	8.49e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6502050	0.799	rs7406257	chr17:80089340	G/A	cg01763666	chr17:80159506	CCDC57	-0.37	-5.1	-0.3	6.55e-7	Life satisfaction;
CESC	cis	rs4665809	1.000	rs12471809	chr2:26307140	A/G	cg25036284	chr2:26402008	FAM59B	-0.6	-6.93	-0.39	3.12e-11	Gut microbiome composition (summer);
CESC	cis	rs1005277	0.540	rs1814077	chr10:37992018	G/C	cg00409905	chr10:38381863	ZNF37A	-0.52	-7.09	-0.4	1.23e-11	Extrinsic epigenetic age acceleration;
CESC	cis	rs6933660	0.800	rs3800273	chr6:151759035	G/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.48	-6.22	-0.36	1.95e-9	Menarche (age at onset);
CESC	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg09060608	chr5:178986726	RUFY1	-0.56	-8.79	-0.48	1.95e-16	Lung cancer;
CESC	cis	rs7078219	0.543	rs10786557	chr10:101283328	C/G	cg09788492	chr10:101292477	NKX2-3	0.31	5.9	0.34	1.12e-8	Dental caries;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg05553000	chr11:121163394	SC5DL	-0.45	-6.05	-0.35	5.05e-9	Fibrinogen levels;
CESC	cis	rs11025559	0.716	rs1596376	chr11:20454229	T/C	cg19653624	chr11:20408972	PRMT3	-0.44	-5.08	-0.3	7.14e-7	Pursuit maintenance gain;
CESC	cis	rs17376456	1.000	rs34854140	chr5:93538169	G/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.61	5.21	0.3	3.8e-7	Diabetic retinopathy;
CESC	cis	rs10178094	0.528	rs62175963	chr2:161339964	T/C	cg03641300	chr2:160917029	PLA2R1	-0.48	-6.25	-0.36	1.65e-9	White blood cell count;
CESC	cis	rs7202877	0.561	rs7202083	chr16:75383727	G/T	cg04384234	chr16:75411784	CFDP1	-0.56	-5.63	-0.33	4.68e-8	Type 2 diabetes;Type 1 diabetes;
CESC	cis	rs2440129	0.611	rs11571335	chr17:6904263	C/T	cg05215748	chr17:6898738	ALOX12	0.33	6.8	0.39	7.08e-11	Tonsillectomy;
CESC	cis	rs10794720	0.867	rs78029387	chr10:1138589	C/T	cg08668510	chr10:1095578	IDI1	0.96	5.71	0.33	3.03e-8	Glomerular filtration rate in non diabetics (creatinine);Chronic kidney disease;
CESC	cis	rs3015469	0.671	rs35313842	chr14:51217893	C/T	cg26011998	chr14:51135199	SAV1	0.51	5.89	0.34	1.14e-8	Plasma amyloid beta peptide concentrations (ABx-40);
CESC	cis	rs12188164	0.965	rs72717435	chr5:448202	G/A	cg15813090	chr5:442598	EXOC3;C5orf55	0.42	6.21	0.36	2.06e-9	Cystic fibrosis severity;
CESC	cis	rs208520	0.690	rs207107	chr6:66794385	T/C	cg07460842	chr6:66804631	NA	-1.0	-13.33	-0.63	2.21e-31	Exhaled nitric oxide output;
CESC	cis	rs10876993	0.928	rs1689595	chr12:58056763	C/T	cg18357645	chr12:58087776	OS9	0.64	10.33	0.54	2.96e-21	Celiac disease or Rheumatoid arthritis;
CESC	cis	rs2797160	1.000	rs6904069	chr6:125995134	C/T	cg05901451	chr6:126070800	HEY2	-0.46	-6.63	-0.38	1.87e-10	Endometrial cancer;
CESC	cis	rs6426558	0.502	rs1929858	chr1:227220175	C/A	cg10327440	chr1:227177885	CDC42BPA	0.52	6.31	0.36	1.15e-9	Neutrophil percentage of white cells;
CESC	cis	rs9910055	0.762	rs7213436	chr17:42252163	A/G	cg19774624	chr17:42201019	HDAC5	0.69	10.08	0.53	2e-20	Total body bone mineral density;
CESC	trans	rs10841784	0.958	rs7962263	chr12:21466117	A/G	cg21964798	chr5:1503259	LPCAT1	0.53	6.49	0.37	4.23e-10	Childhood ear infection;
CESC	cis	rs17253792	0.822	rs79747476	chr14:56160485	C/A	cg01858014	chr14:56050164	KTN1	-0.97	-7.53	-0.42	8.03e-13	Putamen volume;
CESC	cis	rs9311474	0.581	rs4687626	chr3:52569098	G/A	cg07507251	chr3:52567010	NT5DC2	0.47	8.73	0.47	2.88e-16	Electroencephalogram traits;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg06866400	chr6:143771904	ADAT2;PEX3	-0.5	-6.5	-0.37	4.02e-10	Ulcerative colitis;
CESC	trans	rs4824093	0.610	rs58671506	chr22:50288983	G/A	cg09872104	chr7:134855509	C7orf49	-0.94	-6.17	-0.35	2.52e-9	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs6460942	0.841	rs62448597	chr7:12449110	G/C	cg13733410	chr7:12443478	VWDE	-0.53	-5.45	-0.32	1.17e-7	Coronary artery disease;
CESC	cis	rs4819052	0.851	rs4819038	chr21:46659393	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.75	9.98	0.52	4.1e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09395855	chr10:120967408	GRK5	0.55	6.14	0.35	2.97e-9	Gut microbiome composition (summer);
CESC	cis	rs2280018	0.581	rs7404524	chr16:15129158	A/G	cg27102117	chr16:15229624	NA	0.51	7.8	0.43	1.47e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs72781680	0.678	rs872169	chr2:24259188	C/G	cg06627628	chr2:24431161	ITSN2	-0.64	-5.96	-0.34	8.16e-9	Lymphocyte counts;
CESC	cis	rs13427251	0.903	rs6746402	chr2:100150443	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.4	-5.29	-0.31	2.55e-7	Chronic sinus infection;
CESC	cis	rs7267979	1.000	rs404394	chr20:25447896	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.86	17.57	0.73	2.33e-46	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7666738	0.830	rs10034619	chr4:98970067	G/C	cg03467027	chr4:99064603	C4orf37	0.42	5.32	0.31	2.25e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6912958	1.000	rs6912958	chr6:88133315	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.41	-6.7	-0.38	1.21e-10	Monocyte percentage of white cells;
CESC	cis	rs9660180	0.967	rs12044597	chr1:1708801	A/G	cg20999797	chr1:1681921	NA	0.27	5.23	0.31	3.43e-7	Body mass index;
CESC	cis	rs6460942	0.915	rs62447638	chr7:12484667	G/A	cg10578991	chr7:12443926	VWDE	-0.48	-5.13	-0.3	5.72e-7	Coronary artery disease;
CESC	cis	rs3026101	0.671	rs9789012	chr17:5301070	C/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.42	5.6	0.33	5.31e-8	Body mass index;
CESC	cis	rs9487051	0.872	rs1320612	chr6:109611990	C/A	cg21918786	chr6:109611834	NA	-0.41	-6.19	-0.36	2.25e-9	Reticulocyte fraction of red cells;
CESC	trans	rs1814175	0.645	rs11040702	chr11:50024827	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.42	-6.13	-0.35	3.1e-9	Height;
CESC	cis	rs2073499	0.872	rs58051625	chr3:50278717	G/C	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.71	5.55	0.32	6.99e-8	Schizophrenia;
CESC	cis	rs10463316	0.608	rs13360453	chr5:150769143	T/C	cg03212797	chr5:150827313	SLC36A1	-0.45	-5.88	-0.34	1.23e-8	Metabolite levels (Pyroglutamine);
CESC	cis	rs9549260	0.753	rs9532562	chr13:41153585	A/G	cg21288729	chr13:41239152	FOXO1	0.49	5.05	0.3	8.38e-7	Red blood cell count;
CESC	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.48	-5.11	-0.3	6.3e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27659478	chr17:73891062	TRIM65	-0.53	-6.29	-0.36	1.3e-9	Gut microbiome composition (summer);
CESC	cis	rs17486696	0.510	rs10009649	chr4:165682980	A/G	cg01215651	chr4:165675138	NA	0.55	6.1	0.35	3.71e-9	Positive affect;
CESC	cis	rs11190604	1.000	rs4919469	chr10:102298855	C/A	cg07080220	chr10:102295463	HIF1AN	0.68	6.27	0.36	1.44e-9	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs760805	0.965	rs11249203	chr1:25258585	G/C	cg22509179	chr1:25234806	RUNX3	-0.6	-8.56	-0.47	9.31e-16	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs9902453	0.933	rs8080343	chr17:28456758	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	7.6	0.42	5.23e-13	Coffee consumption (cups per day);
CESC	cis	rs13108904	0.901	rs7695691	chr4:1304632	A/G	cg16405210	chr4:1374714	KIAA1530	-0.5	-6.26	-0.36	1.58e-9	Obesity-related traits;
CESC	cis	rs9398803	0.723	rs853973	chr6:127068347	A/G	cg19875578	chr6:126661172	C6orf173	-0.42	-5.79	-0.34	2e-8	Male-pattern baldness;
CESC	cis	rs3820068	0.581	rs16851876	chr1:15950628	A/T	cg16988262	chr1:15930761	NA	-0.32	-5.21	-0.31	3.73e-7	Systolic blood pressure;
CESC	cis	rs12477438	0.798	rs1530996	chr2:99584079	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.72	-10.68	-0.55	2.27e-22	Chronic sinus infection;
CESC	cis	rs6912958	0.535	rs242283	chr6:88030931	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.77	11.43	0.57	7.09e-25	Monocyte percentage of white cells;
CESC	cis	rs2481665	0.510	rs2481676	chr1:62627675	C/T	cg18591186	chr1:62594603	INADL	-0.61	-8.34	-0.46	4.03e-15	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs853679	0.517	rs9348793	chr6:28084189	G/A	cg17949981	chr6:28129498	ZNF389	0.45	5.63	0.33	4.71e-8	Depression;
CESC	cis	rs2408955	0.504	rs11168441	chr12:48576054	G/A	cg24011408	chr12:48396354	COL2A1	0.5	7.34	0.41	2.66e-12	Glycated hemoglobin levels;
CESC	cis	rs9649213	0.574	rs6961790	chr7:98007993	C/G	cg08684580	chr7:98029266	BAIAP2L1	-0.35	-5.76	-0.33	2.29e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7552404	0.696	rs10518521	chr1:76461214	G/A	cg10523679	chr1:76189770	ACADM	0.65	5.93	0.34	9.48e-9	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs1153858	0.887	rs7164139	chr15:45670851	G/A	cg14582100	chr15:45693742	SPATA5L1	0.42	5.95	0.34	8.38e-9	Homoarginine levels;
CESC	cis	rs6061231	1.000	rs6061231	chr20:60956917	C/A	cg06197360	chr20:60970103	CABLES2	-0.41	-5.23	-0.31	3.49e-7	Colorectal cancer;
CESC	cis	rs3747547	1.000	rs55979334	chr9:37934702	T/A	cg13774184	chr9:37916125	SHB	-0.7	-6.07	-0.35	4.46e-9	Metabolite levels (Dihydroxy docosatrienoic acid);
CESC	cis	rs1552244	0.882	rs13077641	chr3:10022935	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.76	-9.64	-0.51	4.86e-19	Alzheimer's disease;
CESC	cis	rs7833790	0.724	rs6473311	chr8:82726682	G/A	cg06027949	chr8:82754900	SNX16	-0.44	-5.24	-0.31	3.35e-7	Diastolic blood pressure;
CESC	cis	rs4862750	0.872	rs6852907	chr4:187897094	A/C	cg11301795	chr4:187892539	NA	-0.75	-12.37	-0.61	4.63e-28	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs11792861	0.890	rs3750465	chr9:111900677	T/C	cg13535736	chr9:111863775	C9orf5	-0.5	-6.61	-0.38	2.12e-10	Menarche (age at onset);
CESC	cis	rs3820068	0.705	rs74054769	chr1:15860147	A/C	cg17385448	chr1:15911702	AGMAT	0.38	5.86	0.34	1.37e-8	Systolic blood pressure;
CESC	cis	rs12586317	0.547	rs2273154	chr14:35433187	C/T	cg05294307	chr14:35346193	BAZ1A	-0.5	-5.36	-0.31	1.81e-7	Psoriasis;
CESC	cis	rs11048434	0.636	rs12815310	chr12:9059934	A/G	cg23795048	chr12:9217529	LOC144571	0.32	5.06	0.3	7.96e-7	Sjögren's syndrome;
CESC	cis	rs116095464	0.619	rs2303741	chr5:218356	T/C	cg22496380	chr5:211416	CCDC127	-0.72	-8.57	-0.47	8.59e-16	Breast cancer;
CESC	cis	rs7772486	0.754	rs9386133	chr6:146141213	A/G	cg05347473	chr6:146136440	FBXO30	0.47	6.07	0.35	4.37e-9	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6860806	0.661	rs4705929	chr5:131584178	G/T	cg22638593	chr5:131593259	PDLIM4	0.41	5.33	0.31	2.07e-7	Breast cancer;
CESC	cis	rs4924935	0.851	rs17743944	chr17:18809268	A/G	cg26378065	chr17:18585709	ZNF286B	-0.51	-5.83	-0.34	1.61e-8	Pancreatic cancer;
CESC	cis	rs7666738	0.830	rs17027216	chr4:99009152	G/C	cg03676636	chr4:99064102	C4orf37	0.33	5.16	0.3	4.86e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4964805	0.581	rs7312825	chr12:104188388	G/C	cg02344784	chr12:104178138	NT5DC3	0.46	6.57	0.37	2.73e-10	Attention deficit hyperactivity disorder;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg05924733	chr4:160277162	RAPGEF2	0.42	6.25	0.36	1.64e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs4523957	0.671	rs7223161	chr17:2176181	G/A	cg16513277	chr17:2031491	SMG6	-0.44	-5.06	-0.3	7.84e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs6840258	1.000	rs7695426	chr4:87921277	C/T	cg08197287	chr4:87952173	AFF1	-0.42	-5.66	-0.33	3.97e-8	Mean corpuscular volume;Basophil percentage of granulocytes;
CESC	cis	rs7618915	0.531	rs77146033	chr3:52701501	G/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	5.7	0.33	3.27e-8	Bipolar disorder;
CESC	cis	rs11997175	0.574	rs4370495	chr8:33654819	G/A	ch.8.33884649F	chr8:33765107	NA	0.66	8.38	0.46	3.14e-15	Body mass index;
CESC	cis	rs208520	1.000	rs12190316	chr6:66973365	T/C	cg07460842	chr6:66804631	NA	0.75	8.7	0.47	3.46e-16	Exhaled nitric oxide output;
CESC	trans	rs17307778	0.908	rs10767364	chr11:25358079	T/G	cg22888484	chr20:37075185	SNHG11	-0.63	-6.07	-0.35	4.42e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs796364	0.806	rs6435041	chr2:200867144	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.85	7.55	0.42	7.19e-13	Schizophrenia;
CESC	cis	rs67460515	0.892	rs7647374	chr3:160975576	T/A	cg03342759	chr3:160939853	NMD3	-0.54	-7.73	-0.43	2.18e-13	Parkinson's disease;
CESC	cis	rs2204008	0.687	rs1733404	chr12:38123395	G/T	cg13010199	chr12:38710504	ALG10B	-0.5	-6.16	-0.35	2.73e-9	Bladder cancer;
CESC	cis	rs62229266	0.771	rs62230790	chr21:37388911	A/G	cg12218747	chr21:37451666	NA	-0.44	-6.15	-0.35	2.9e-9	Mitral valve prolapse;
CESC	cis	rs896854	0.596	rs7823059	chr8:95974961	T/C	cg23172400	chr8:95962367	TP53INP1	-0.45	-9.25	-0.49	8.02e-18	Type 2 diabetes;
CESC	cis	rs7666738	0.830	rs13108422	chr4:99059267	G/A	cg17366294	chr4:99064904	C4orf37	0.61	8.61	0.47	6.71e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9487051	0.768	rs9398188	chr6:109526615	G/A	cg01475377	chr6:109611718	NA	-0.44	-6.67	-0.38	1.45e-10	Reticulocyte fraction of red cells;
CESC	cis	rs7829975	0.514	rs2976929	chr8:8258712	T/C	cg06636001	chr8:8085503	FLJ10661	0.5	6.65	0.38	1.67e-10	Mood instability;
CESC	cis	rs1707322	1.000	rs4660889	chr1:46297331	C/T	cg03146154	chr1:46216737	IPP	0.72	9.85	0.52	1.01e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00455883	chr3:73046007	PPP4R2	0.56	7.2	0.4	6.14e-12	Gut microbiome composition (summer);
CESC	cis	rs9818758	0.607	rs3923475	chr3:49055788	G/T	cg00383909	chr3:49044727	WDR6	0.93	6.42	0.37	6.1e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CESC	cis	rs597539	0.652	rs686877	chr11:68637169	G/A	cg04772025	chr11:68637568	NA	0.55	6.49	0.37	4.17e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg01628954	chr18:60190696	ZCCHC2	0.47	6.02	0.35	5.85e-9	Gut microbiota (bacterial taxa);
CESC	trans	rs561341	0.941	rs72825736	chr17:30330286	G/A	cg20587970	chr11:113659929	NA	-1.43	-18.64	-0.75	3.98e-50	Hip circumference adjusted for BMI;
CESC	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg18099408	chr3:52552593	STAB1	-0.34	-6.2	-0.36	2.18e-9	Bipolar disorder;
CESC	cis	rs1348850	0.958	rs4893965	chr2:178463852	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.62	8.62	0.47	6.11e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs79349575	0.783	rs17635252	chr17:47006950	T/C	cg26022315	chr17:47021804	SNF8	0.38	5.11	0.3	6.3e-7	Type 2 diabetes;
CESC	cis	rs2996428	0.667	rs11576900	chr1:3770914	A/G	cg23277830	chr1:3704460	LRRC47	0.35	5.21	0.3	3.85e-7	Red cell distribution width;
CESC	cis	rs365132	1.000	rs2292256	chr5:176333126	C/T	cg16309518	chr5:176445507	NA	-0.41	-6.02	-0.35	5.71e-9	Menarche and menopause (age at onset);Menopause (age at onset);
CESC	cis	rs4604732	0.642	rs4489599	chr1:247635213	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	-0.43	-6.41	-0.37	6.61e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs9583531	0.509	rs9521923	chr13:111405462	C/T	cg24331049	chr13:111365604	ING1	-0.74	-7.05	-0.4	1.53e-11	Coronary artery disease;
CESC	cis	rs5758659	0.652	rs1063392	chr22:42454950	C/T	cg05082376	chr22:42548792	NA	0.36	5.31	0.31	2.3e-7	Cognitive function;
CESC	cis	rs1008375	1.000	rs1008375	chr4:17682834	T/C	cg16339924	chr4:17578868	LAP3	0.51	6.45	0.37	5.25e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs6087990	0.735	rs2424928	chr20:31388636	T/C	cg13636640	chr20:31349939	DNMT3B	0.79	12.91	0.62	6.71e-30	Ulcerative colitis;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg23426587	chr9:21335126	KLHL9	-0.44	-6.35	-0.36	9.19e-10	Gambling;
CESC	cis	rs780096	0.506	rs1647285	chr2:27714511	A/C	cg24768116	chr2:27665128	KRTCAP3	-0.3	-5.64	-0.33	4.33e-8	Total body bone mineral density;
CESC	cis	rs933688	0.877	rs1477349	chr5:90707773	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.99	11.82	0.59	3.43e-26	Smoking behavior;
CESC	cis	rs1707322	0.752	rs8179296	chr1:46143791	G/A	cg03146154	chr1:46216737	IPP	0.82	11.54	0.58	3.18e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs780096	0.546	rs1647284	chr2:27608115	C/T	cg12648201	chr2:27665141	KRTCAP3	-0.34	-6.26	-0.36	1.54e-9	Total body bone mineral density;
CESC	cis	rs7944584	0.588	rs2697923	chr11:47363215	G/T	cg20307385	chr11:47447363	PSMC3	-0.61	-7.45	-0.42	1.31e-12	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CESC	cis	rs1707322	1.000	rs785507	chr1:46541558	C/T	cg06784218	chr1:46089804	CCDC17	-0.35	-5.85	-0.34	1.43e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7917772	0.503	rs11191328	chr10:104305185	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.55	7.54	0.42	7.69e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	trans	rs208520	0.690	rs9345764	chr6:66820597	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.01	-13.01	-0.62	3.07e-30	Exhaled nitric oxide output;
CESC	cis	rs10911232	0.507	rs4651138	chr1:183001312	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.85	13.24	0.63	4.51e-31	Hypertriglyceridemia;
CESC	cis	rs796364	0.806	rs1509832	chr2:200874443	G/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.84	7.71	0.43	2.62e-13	Schizophrenia;
CESC	cis	rs763121	0.853	rs2281019	chr22:39064378	T/A	cg14440974	chr22:39074834	NA	-0.42	-5.82	-0.34	1.69e-8	Menopause (age at onset);
CESC	cis	rs7412746	0.611	rs3768018	chr1:150723747	T/C	cg09365446	chr1:150670422	GOLPH3L	0.39	5.16	0.3	4.94e-7	Melanoma;
CESC	cis	rs1707322	0.927	rs11211194	chr1:46282084	C/T	cg06784218	chr1:46089804	CCDC17	0.33	5.75	0.33	2.42e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs8072100	0.817	rs6505049	chr17:45675781	G/A	cg08085267	chr17:45401833	C17orf57	0.44	5.57	0.32	6.39e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs2273669	0.667	rs7766248	chr6:109347262	C/T	cg05315195	chr6:109294784	ARMC2	-0.67	-6.32	-0.36	1.13e-9	Prostate cancer;
CESC	cis	rs2274273	0.662	rs67958555	chr14:55670866	G/A	cg04306507	chr14:55594613	LGALS3	0.31	5.24	0.31	3.34e-7	Protein biomarker;
CESC	cis	rs7100689	0.646	rs4601708	chr10:82119583	G/T	cg00277334	chr10:82204260	NA	-0.58	-7.76	-0.43	1.84e-13	Post bronchodilator FEV1;
CESC	cis	rs11676348	0.818	rs4674256	chr2:218987893	A/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.46	-6.03	-0.35	5.37e-9	Ulcerative colitis;
CESC	cis	rs2455799	0.573	rs2062824	chr3:15757901	T/C	cg16303742	chr3:15540471	COLQ	-0.39	-6.07	-0.35	4.32e-9	Mean platelet volume;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg08744727	chr4:206112	ZNF876P	-0.53	-6.67	-0.38	1.44e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs1552244	0.882	rs3732966	chr3:10015740	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.86	11.09	0.56	9.7e-24	Alzheimer's disease;
CESC	cis	rs11252926	0.624	rs7085214	chr10:468133	A/G	cg16386425	chr10:429943	DIP2C	-0.46	-5.81	-0.34	1.77e-8	Psychosis in Alzheimer's disease;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg14223017	chr19:2151266	AP3D1	-0.47	-6.12	-0.35	3.28e-9	Ulcerative colitis;
CESC	cis	rs897984	0.542	rs7199949	chr16:31096164	G/C	cg02466173	chr16:30829666	NA	-0.4	-6.75	-0.38	9.46e-11	Dementia with Lewy bodies;
CESC	cis	rs7592578	0.581	rs59109438	chr2:191287683	A/G	cg10560079	chr2:191398806	TMEM194B	-0.6	-5.99	-0.35	6.83e-9	Diastolic blood pressure;
CESC	cis	rs10504229	1.000	rs6987435	chr8:58177334	G/A	cg24829409	chr8:58192753	C8orf71	-0.74	-9.71	-0.51	2.79e-19	Developmental language disorder (linguistic errors);
CESC	cis	rs7124681	0.584	rs4752792	chr11:47815702	G/A	cg20307385	chr11:47447363	PSMC3	-0.58	-8.03	-0.44	3.12e-14	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
CESC	cis	rs2952156	0.883	rs907088	chr17:37833567	G/C	cg00129232	chr17:37814104	STARD3	-0.73	-10.44	-0.54	1.34e-21	Asthma;
CESC	cis	rs11252926	0.550	rs11252134	chr10:442599	G/A	cg03684893	chr10:554711	DIP2C	-0.35	-5.1	-0.3	6.43e-7	Psychosis in Alzheimer's disease;
CESC	cis	rs4243830	0.850	rs2274553	chr1:6586553	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.81	-8.69	-0.47	3.75e-16	Body mass index;
CESC	cis	rs9649213	0.593	rs55825602	chr7:98013039	T/C	cg24562669	chr7:97807699	LMTK2	0.51	7.51	0.42	9.2e-13	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs561341	1.000	rs542132	chr17:30307193	A/T	cg19193384	chr17:30244184	NA	-0.67	-6.36	-0.36	8.74e-10	Hip circumference adjusted for BMI;
CESC	cis	rs7618915	0.571	rs17264436	chr3:52610651	T/A	cg18337363	chr3:52569053	NT5DC2	0.29	5.06	0.3	7.91e-7	Bipolar disorder;
CESC	cis	rs7044106	0.762	rs7044226	chr9:123466328	G/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.69	9.89	0.52	7.9e-20	Hip circumference adjusted for BMI;
CESC	cis	rs9311474	0.508	rs12629701	chr3:52619836	T/C	cg18337363	chr3:52569053	NT5DC2	0.29	5.17	0.3	4.65e-7	Electroencephalogram traits;
CESC	cis	rs1124376	1.000	rs4417886	chr3:20108511	C/T	cg05072819	chr3:20081367	KAT2B	0.62	6.51	0.37	3.68e-10	Bipolar disorder and schizophrenia;
CESC	cis	rs2243480	1.000	rs36068983	chr7:65408991	C/T	cg25894440	chr7:65020034	NA	-0.59	-5.07	-0.3	7.57e-7	Diabetic kidney disease;
CESC	cis	rs4077515	0.934	rs3829111	chr9:139269483	G/A	cg14169450	chr9:139327907	INPP5E	0.36	5.27	0.31	2.85e-7	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs763121	0.853	rs9607566	chr22:39075434	C/G	cg14440974	chr22:39074834	NA	-0.42	-5.77	-0.33	2.19e-8	Menopause (age at onset);
CESC	cis	rs68170813	0.559	rs11769527	chr7:106912948	C/T	cg02696742	chr7:106810147	HBP1	-0.52	-5.09	-0.3	6.84e-7	Coronary artery disease;
CESC	cis	rs4555082	0.834	rs2975217	chr14:105710238	A/C	cg13114125	chr14:105738426	BRF1	-0.8	-9.69	-0.51	3.44e-19	Mean platelet volume;Platelet distribution width;
CESC	cis	rs380904	0.926	rs7842979	chr8:144601896	T/G	cg20583945	chr8:144636462	GSDMD	0.41	5.33	0.31	2.07e-7	Venous thromboembolism (SNP x SNP interaction);
CESC	cis	rs9399135	0.660	rs9376072	chr6:135280519	G/C	cg24558204	chr6:135376177	HBS1L	0.54	7.62	0.42	4.64e-13	Red blood cell count;
CESC	cis	rs4132509	0.592	rs12076373	chr1:243851947	G/C	cg21452805	chr1:244014465	NA	0.51	5.78	0.33	2.07e-8	RR interval (heart rate);
CESC	cis	rs17376456	0.877	rs67066109	chr5:93494101	G/C	cg25358565	chr5:93447407	FAM172A	1.18	11.54	0.58	3.22e-25	Diabetic retinopathy;
CESC	cis	rs4561483	0.801	rs33640	chr16:11986874	C/T	cg08843971	chr16:11963173	GSPT1	-0.55	-8.27	-0.45	6.52e-15	Testicular germ cell tumor;
CESC	cis	rs9322193	0.923	rs9479094	chr6:150046219	C/T	cg13206674	chr6:150067644	NUP43	0.46	6.59	0.38	2.43e-10	Lung cancer;
CESC	cis	rs72781680	1.000	rs72781634	chr2:24199102	C/T	cg08917208	chr2:24149416	ATAD2B	0.9	8.12	0.45	1.8e-14	Lymphocyte counts;
CESC	cis	rs2839186	0.771	rs13049175	chr21:47641326	G/A	cg11766577	chr21:47581405	C21orf56	0.46	6.35	0.36	9.51e-10	Testicular germ cell tumor;
CESC	cis	rs66530629	0.874	rs10903104	chr1:25136713	A/G	cg22509179	chr1:25234806	RUNX3	-0.43	-5.47	-0.32	1.05e-7	Plateletcrit;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21694044	chr22:41215540	SLC25A17	0.6	6.79	0.38	7.39e-11	Gut microbiome composition (summer);
CESC	cis	rs9322193	0.847	rs9383844	chr6:150037404	T/C	cg04369109	chr6:150039330	LATS1	-0.43	-6.19	-0.36	2.31e-9	Lung cancer;
CESC	cis	rs9297145	0.724	rs6958790	chr7:98774738	C/T	cg05967295	chr7:98741636	SMURF1	-0.84	-8.7	-0.47	3.61e-16	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
CESC	cis	rs7772486	0.875	rs1125461	chr6:146417653	C/T	cg05347473	chr6:146136440	FBXO30	0.49	6.43	0.37	6.04e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs10129255	0.500	rs10143242	chr14:107137831	C/T	cg23076370	chr14:107095027	NA	-0.63	-9.58	-0.51	7.37e-19	Kawasaki disease;
CESC	cis	rs116095464	0.558	rs62346526	chr5:220614	T/C	cg10591111	chr5:226296	SDHA	-0.51	-6.35	-0.36	9.22e-10	Breast cancer;
CESC	trans	rs7726839	0.561	rs4957048	chr5:583442	G/A	cg25482853	chr8:67687455	SGK3	0.88	9.24	0.49	8.24e-18	Obesity-related traits;
CESC	cis	rs9911578	1.000	rs2643119	chr17:56827760	G/T	cg12560992	chr17:57184187	TRIM37	0.92	15.09	0.68	1.43e-37	Intelligence (multi-trait analysis);
CESC	cis	rs9325144	0.560	rs1601745	chr12:38647828	G/A	cg13010199	chr12:38710504	ALG10B	-0.45	-6.11	-0.35	3.56e-9	Morning vs. evening chronotype;
CESC	cis	rs875971	0.862	rs11773628	chr7:65982631	G/T	cg18876405	chr7:65276391	NA	-0.5	-6.65	-0.38	1.65e-10	Aortic root size;
CESC	cis	rs4604732	0.642	rs4489599	chr1:247635213	C/T	cg12758973	chr1:247694275	LOC148824;OR2C3	-0.35	-5.28	-0.31	2.74e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs5769765	0.862	rs9616392	chr22:50314705	G/A	cg02269571	chr22:50332266	NA	-0.54	-6.29	-0.36	1.33e-9	Schizophrenia;
CESC	cis	rs7267979	0.844	rs6083824	chr20:25363057	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.79	-14.75	-0.67	2.44e-36	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs561341	1.000	rs8070262	chr17:30262467	A/G	cg13647721	chr17:30228624	UTP6	0.52	5.32	0.31	2.17e-7	Hip circumference adjusted for BMI;
CESC	cis	rs896854	0.684	rs10098778	chr8:95992020	C/T	cg09323728	chr8:95962352	TP53INP1	-0.4	-9.06	-0.49	2.93e-17	Type 2 diabetes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06057208	chr16:30535933	ZNF768	-0.53	-6.35	-0.36	9.51e-10	Gut microbiome composition (summer);
CESC	cis	rs2645424	0.762	rs2294139	chr8:11705442	G/T	cg21281001	chr8:11725306	CTSB	0.48	5.92	0.34	1e-8	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);
CESC	cis	rs12477438	0.953	rs3851334	chr2:99794704	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.75	-8.73	-0.47	3e-16	Chronic sinus infection;
CESC	cis	rs12477438	0.520	rs6712704	chr2:99719687	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.88	15.61	0.69	2.15e-39	Chronic sinus infection;
CESC	cis	rs1559088	0.847	rs10416218	chr19:33599127	T/C	cg17764715	chr19:33622953	WDR88	0.48	6.33	0.36	1.04e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs7072216	0.763	rs10883092	chr10:100167276	A/C	cg26618903	chr10:100175079	PYROXD2	-0.35	-5.33	-0.31	2.1e-7	Metabolite levels;
CESC	cis	rs35110281	0.782	rs6518309	chr21:45047992	C/A	cg21573476	chr21:45109991	RRP1B	-0.55	-7.21	-0.41	5.77e-12	Mean corpuscular volume;
CESC	cis	rs7811142	0.667	rs3873746	chr7:99935097	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.9	10.02	0.52	3.04e-20	Platelet count;
CESC	cis	rs11792861	0.816	rs744980	chr9:111690388	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.52	6.76	0.38	8.95e-11	Menarche (age at onset);
CESC	cis	rs6496667	0.509	rs57962570	chr15:90985596	C/G	cg22089800	chr15:90895588	ZNF774	0.42	5.42	0.32	1.37e-7	Rheumatoid arthritis;
CESC	cis	rs9916302	0.904	rs8065879	chr17:37515978	G/A	cg19468946	chr17:37922297	IKZF3	0.39	5.03	0.3	8.9e-7	Glomerular filtration rate (creatinine);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg11343870	chr11:67888858	CHKA	-0.42	-6.37	-0.36	8.32e-10	Gambling;
CESC	cis	rs1665050	0.534	rs56402153	chr15:59233312	A/G	cg05156742	chr15:59063176	FAM63B	0.48	6.02	0.35	5.95e-9	Atopic dermatitis;
CESC	cis	rs11229555	0.645	rs7116007	chr11:58218701	C/T	cg15696309	chr11:58395628	NA	-0.45	-5.19	-0.3	4.09e-7	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs4604732	0.631	rs10925044	chr1:247627071	A/G	cg12758973	chr1:247694275	LOC148824;OR2C3	0.5	6.33	0.36	1.07e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs9322193	0.923	rs9689084	chr6:149960784	G/A	cg13206674	chr6:150067644	NUP43	0.42	5.99	0.35	6.91e-9	Lung cancer;
CESC	cis	rs9916302	0.904	rs4794813	chr17:37670994	A/T	cg15445000	chr17:37608096	MED1	0.41	6.5	0.37	4e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs3785574	0.962	rs8066463	chr17:61818390	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.81	10.75	0.55	1.32e-22	Height;
CESC	cis	rs10791323	0.538	rs1105494	chr11:133698733	A/C	cg06766960	chr11:133703094	NA	0.38	5.44	0.32	1.23e-7	Childhood ear infection;
CESC	cis	rs6502050	0.697	rs8078634	chr17:80126208	C/T	cg23985595	chr17:80112537	CCDC57	-0.41	-6.42	-0.37	6.33e-10	Life satisfaction;
CESC	cis	rs425277	0.585	rs3107157	chr1:2061969	A/G	cg23803603	chr1:2058230	PRKCZ	-0.34	-5.83	-0.34	1.63e-8	Height;
CESC	cis	rs7666738	0.830	rs4699598	chr4:99019158	C/T	cg17366294	chr4:99064904	C4orf37	0.61	8.76	0.47	2.35e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11785400	0.793	rs1137521	chr8:143739162	C/T	cg10596483	chr8:143751796	JRK	0.41	5.28	0.31	2.64e-7	Schizophrenia;
CESC	cis	rs2180341	0.814	rs9321085	chr6:127735361	T/C	cg24812749	chr6:127587940	RNF146	0.84	12.05	0.59	5.93e-27	Breast cancer;
CESC	cis	rs6951245	0.706	rs1133116	chr7:1195215	A/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.46	5.55	0.32	6.76e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2531992	0.686	rs2041247	chr16:4032581	A/G	cg05927578	chr16:4029543	ADCY9	0.52	7.0	0.39	2.16e-11	Waist circumference;
CESC	trans	rs7246657	0.714	rs12972195	chr19:37752505	T/C	cg24637308	chr11:6592297	DNHD1	0.52	6.0	0.35	6.36e-9	Coronary artery calcification;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg15627031	chr1:45987517	PRDX1	0.47	6.05	0.35	4.92e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs6546537	0.910	rs10779953	chr2:69886757	A/G	cg10773587	chr2:69614142	GFPT1	-0.42	-5.16	-0.3	4.77e-7	Serum thyroid-stimulating hormone levels;
CESC	cis	rs9914578	1.000	rs10459917	chr17:2009752	G/T	cg16513277	chr17:2031491	SMG6	0.53	6.11	0.35	3.5e-9	Body mass index;
CESC	trans	rs3942852	0.568	rs4412719	chr11:48101660	T/A	cg03929089	chr4:120376271	NA	-0.63	-7.78	-0.43	1.64e-13	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs1008375	1.000	rs3846357	chr4:17635887	A/T	cg15017067	chr4:17643749	FAM184B	0.36	5.19	0.3	4.25e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs4722166	0.695	rs7808122	chr7:22798080	A/G	cg05472934	chr7:22766657	IL6	0.62	8.27	0.45	6.75e-15	Lung cancer;
CESC	cis	rs1983891	1.000	rs4714486	chr6:41542417	C/T	cg20194872	chr6:41519635	FOXP4	0.55	7.76	0.43	1.88e-13	Prostate cancer;
CESC	cis	rs4728302	0.869	rs7779370	chr7:133595702	T/C	cg10665199	chr7:133106180	EXOC4	0.39	5.51	0.32	8.43e-8	Intelligence;Intelligence (multi-trait analysis);
CESC	cis	rs16867321	0.950	rs4667223	chr2:181498302	C/G	cg23363182	chr2:181467187	NA	-0.42	-5.49	-0.32	9.38e-8	Obesity;
CESC	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	-0.56	-6.67	-0.38	1.45e-10	Prudent dietary pattern;
CESC	cis	rs643506	0.874	rs680096	chr11:111708668	T/A	cg17089665	chr11:111648010	NA	-0.37	-5.37	-0.31	1.71e-7	Breast cancer;
CESC	cis	rs6060717	0.528	rs73905955	chr20:34332938	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.6	5.25	0.31	3.15e-7	Hip circumference adjusted for BMI;
CESC	cis	rs5417	0.636	rs222851	chr17:7139238	G/A	cg13768953	chr17:7114967	DLG4	-0.37	-5.5	-0.32	9.01e-8	Diastolic blood pressure;
CESC	cis	rs523522	0.926	rs10849766	chr12:121025894	G/A	cg12219531	chr12:120966889	COQ5	0.77	10.04	0.53	2.56e-20	High light scatter reticulocyte count;
CESC	cis	rs8031584	0.541	rs2959037	chr15:31218164	T/C	cg14829155	chr15:31115871	NA	0.74	10.63	0.55	3.3e-22	Huntington's disease progression;
CESC	cis	rs12142240	0.698	rs1135459	chr1:46815930	C/T	cg10495392	chr1:46806563	NSUN4	0.57	6.28	0.36	1.39e-9	Menopause (age at onset);
CESC	cis	rs796364	0.906	rs281784	chr2:200749749	T/A	cg23649088	chr2:200775458	C2orf69	0.55	5.06	0.3	7.77e-7	Schizophrenia;
CESC	cis	rs3733585	0.534	rs7375642	chr4:9955236	A/G	cg00071950	chr4:10020882	SLC2A9	-0.69	-11.31	-0.57	1.83e-24	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg11494091	chr17:61959527	GH2	0.73	12.49	0.61	1.88e-28	Prudent dietary pattern;
CESC	trans	rs2115172	0.836	rs4835799	chr5:122762229	A/G	cg27304813	chr3:120068385	LRRC58	0.49	6.5	0.37	3.99e-10	Weight;
CESC	cis	rs933688	1.000	rs1895448	chr5:90743854	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.04	13.04	0.63	2.37e-30	Smoking behavior;
CESC	cis	rs8067545	0.611	rs11653869	chr17:20197586	T/G	cg13482628	chr17:19912719	NA	-0.42	-5.61	-0.33	5.2e-8	Schizophrenia;
CESC	cis	rs7647973	0.621	rs3774800	chr3:49334768	A/G	cg02487422	chr3:49467188	NICN1	-0.39	-5.03	-0.3	9.15e-7	Menarche (age at onset);
CESC	cis	rs854765	0.693	rs8079418	chr17:17924060	C/T	cg04398451	chr17:18023971	MYO15A	-0.61	-8.85	-0.48	1.32e-16	Total body bone mineral density;
CESC	cis	rs10791323	0.517	rs1120245	chr11:133745290	A/G	cg15485101	chr11:133734466	NA	0.3	5.13	0.3	5.52e-7	Childhood ear infection;
CESC	cis	rs9905704	0.681	rs8081247	chr17:56557837	G/A	cg12560992	chr17:57184187	TRIM37	-0.61	-5.57	-0.32	6.37e-8	Testicular germ cell tumor;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18014247	chr2:220083722	ABCB6	-0.56	-6.23	-0.36	1.83e-9	Gut microbiome composition (summer);
CESC	cis	rs9303401	0.659	rs3809724	chr17:57061238	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.97	11.12	0.56	7.63e-24	Cognitive test performance;
CESC	cis	rs4665809	0.590	rs13387855	chr2:26420708	T/G	cg27170947	chr2:26402098	FAM59B	-0.84	-10.08	-0.53	1.98e-20	Gut microbiome composition (summer);
CESC	cis	rs11997175	0.603	rs7008747	chr8:33834886	G/A	ch.8.33884649F	chr8:33765107	NA	0.44	5.17	0.3	4.73e-7	Body mass index;
CESC	cis	rs873946	0.586	rs12774727	chr10:134569910	T/C	cg26818010	chr10:134567672	INPP5A	-0.94	-11.42	-0.57	7.62e-25	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs2243480	1.000	rs6958420	chr7:65751171	A/G	cg18252515	chr7:66147081	NA	1.41	14.3	0.66	9.43e-35	Diabetic kidney disease;
CESC	cis	rs6893300	0.785	rs12522263	chr5:179176692	T/A	cg14593053	chr5:179126677	CANX	-0.45	-5.07	-0.3	7.62e-7	Resting heart rate;
CESC	cis	rs16973500	0.808	rs61523290	chr16:71943556	A/G	cg09427745	chr16:71932006	KIAA0174	-0.51	-5.26	-0.31	2.95e-7	Response to anti-TNF therapy in rheumatoid arthritis;Attention deficit hyperactivity disorder and conduct disorder;
CESC	cis	rs80130819	0.748	rs7953726	chr12:48611757	A/G	cg05342945	chr12:48394962	COL2A1	-0.48	-5.2	-0.3	4.07e-7	Prostate cancer;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg26602477	chr1:1476845	C1orf70	0.48	6.67	0.38	1.52e-10	Fibrinogen levels;
CESC	cis	rs28374715	0.532	rs316604	chr15:41775221	C/T	cg02330683	chr15:41787940	ITPKA	0.42	5.16	0.3	4.77e-7	Ulcerative colitis;
CESC	cis	rs1799949	0.965	rs8176087	chr17:41270666	C/A	cg23758822	chr17:41437982	NA	1.03	15.39	0.69	1.24e-38	Menopause (age at onset);
CESC	cis	rs7618915	0.547	rs11720432	chr3:52672742	T/C	cg18099408	chr3:52552593	STAB1	-0.32	-5.32	-0.31	2.22e-7	Bipolar disorder;
CESC	cis	rs80282103	0.618	rs74117831	chr10:1145707	A/C	cg08668510	chr10:1095578	IDI1	0.77	6.34	0.36	1e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs13191362	0.872	rs13196631	chr6:163001588	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.88	9.16	0.49	1.46e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs7017914	0.967	rs7018381	chr8:71670117	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.2	-0.3	3.94e-7	Bone mineral density;
CESC	cis	rs854765	0.693	rs9907287	chr17:17774118	C/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.45	-5.84	-0.34	1.52e-8	Total body bone mineral density;
CESC	cis	rs7429990	0.932	rs34025851	chr3:47953733	C/A	cg11946769	chr3:48343235	NME6	0.46	5.62	0.33	4.91e-8	Educational attainment (years of education);
CESC	cis	rs7648466	0.592	rs7616215	chr3:46205686	A/G	cg08033130	chr3:45983597	CXCR6;FYCO1	-0.36	-5.05	-0.3	8.31e-7	Eotaxin levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05694744	chr17:8191820	RANGRF;SLC25A35	-0.59	-6.45	-0.37	5.32e-10	Gut microbiome composition (summer);
CESC	cis	rs3858526	0.796	rs9645652	chr11:5944264	C/T	cg05234568	chr11:5960015	NA	-0.63	-7.46	-0.42	1.2e-12	DNA methylation (variation);
CESC	cis	rs11098499	0.710	rs6851130	chr4:120133712	G/A	cg09307838	chr4:120376055	NA	-0.67	-8.37	-0.46	3.41e-15	Corneal astigmatism;
CESC	cis	rs4268898	0.552	rs7560342	chr2:24371691	T/C	cg20701182	chr2:24300061	SF3B14	-0.39	-5.32	-0.31	2.23e-7	Asthma;
CESC	cis	rs910316	0.737	rs28687415	chr14:75495482	T/C	cg16144293	chr14:75469539	EIF2B2	-0.4	-5.32	-0.31	2.22e-7	Height;
CESC	cis	rs1348850	0.874	rs12996447	chr2:178283592	C/T	cg23306229	chr2:178417860	TTC30B	0.61	7.82	0.43	1.25e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs34172651	0.917	rs35283675	chr16:24820393	A/G	cg06028605	chr16:24865363	SLC5A11	0.39	5.76	0.33	2.27e-8	Intelligence (multi-trait analysis);
CESC	cis	rs911555	0.755	rs4906329	chr14:103942669	A/G	cg24130564	chr14:104152367	KLC1	0.49	6.26	0.36	1.5e-9	Intelligence (multi-trait analysis);
CESC	cis	rs9487051	0.872	rs9386790	chr6:109608460	G/T	cg21918786	chr6:109611834	NA	0.4	6.01	0.35	6.01e-9	Reticulocyte fraction of red cells;
CESC	cis	rs3916	0.794	rs10431384	chr12:121127347	C/T	cg21892295	chr12:121157589	UNC119B	0.36	5.83	0.34	1.59e-8	Urinary metabolites (H-NMR features);
CESC	cis	rs4699052	1.000	rs4699052	chr4:104137790	C/T	cg16532752	chr4:104119610	CENPE	-0.39	-5.41	-0.32	1.42e-7	Testicular germ cell tumor;
CESC	cis	rs804280	0.564	rs4639	chr8:11644751	A/G	cg12395012	chr8:11607386	GATA4	-0.49	-7.3	-0.41	3.33e-12	Myopia (pathological);
CESC	cis	rs57506017	0.585	rs12669919	chr7:12271997	G/A	cg23422036	chr7:12250390	TMEM106B	0.39	5.17	0.3	4.57e-7	Neuroticism;
CESC	cis	rs11958404	1.000	rs9686690	chr5:157412103	C/T	cg05962755	chr5:157440814	NA	0.52	5.95	0.34	8.38e-9	IgG glycosylation;
CESC	cis	rs9811920	0.609	rs10936005	chr3:99674093	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.39	5.28	0.31	2.74e-7	Axial length;
CESC	cis	rs11650494	0.908	rs77338752	chr17:47372328	A/C	cg08112188	chr17:47440006	ZNF652	1.31	8.51	0.46	1.31e-15	Prostate cancer;
CESC	cis	rs734999	0.545	rs10797441	chr1:2551660	T/G	cg18854424	chr1:2615690	NA	0.3	5.88	0.34	1.2e-8	Ulcerative colitis;
CESC	cis	rs4689388	0.853	rs13114527	chr4:6294655	T/G	cg25554036	chr4:6271136	WFS1	0.51	8.37	0.46	3.31e-15	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs9300255	0.602	rs1727294	chr12:123616514	A/G	cg05973401	chr12:123451056	ABCB9	0.52	5.98	0.34	7.22e-9	Neutrophil percentage of white cells;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00144180	chr2:240294362	HDAC4	-0.64	-7.4	-0.41	1.78e-12	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05139434	chr1:41328180	CITED4	0.58	6.74	0.38	1.01e-10	Gut microbiome composition (summer);
CESC	cis	rs597539	0.652	rs611046	chr11:68631704	A/G	cg21963583	chr11:68658836	MRPL21	0.41	5.54	0.32	7.11e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs911555	0.511	rs2296483	chr14:104029792	G/A	cg24130564	chr14:104152367	KLC1	-0.73	-11.9	-0.59	1.91e-26	Intelligence (multi-trait analysis);
CESC	cis	rs6460942	1.000	rs75333414	chr7:12303829	T/A	cg06484146	chr7:12443880	VWDE	-0.68	-7.71	-0.43	2.55e-13	Coronary artery disease;
CESC	cis	rs1552244	0.572	rs3894322	chr3:10168965	G/A	cg00149659	chr3:10157352	C3orf10	0.99	12.05	0.59	6.02e-27	Alzheimer's disease;
CESC	cis	rs1799949	1.000	rs1960605	chr17:41305397	C/T	cg25072359	chr17:41440525	NA	0.43	5.82	0.34	1.68e-8	Menopause (age at onset);
CESC	cis	rs1062177	0.756	rs2915826	chr5:151119963	G/A	cg00977110	chr5:151150581	G3BP1	-0.62	-6.36	-0.36	8.62e-10	Preschool internalizing problems;
CESC	cis	rs7914558	1.000	rs4917996	chr10:104925829	A/C	cg04362960	chr10:104952993	NT5C2	0.47	6.21	0.36	2e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs6938	0.563	rs12917376	chr15:75116167	C/T	cg14664628	chr15:75095509	CSK	-0.69	-9.37	-0.5	3.3e-18	Breast cancer;
CESC	cis	rs1448094	0.512	rs7133591	chr12:86239752	G/C	cg19622623	chr12:86230825	RASSF9	-0.47	-6.09	-0.35	4e-9	Major depressive disorder;
CESC	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg23034840	chr1:205782522	SLC41A1	0.64	7.41	0.41	1.74e-12	Menarche (age at onset);
CESC	cis	rs7474896	0.559	rs1779075	chr10:38167530	C/G	cg25427524	chr10:38739819	LOC399744	0.51	5.79	0.33	2.03e-8	Obesity (extreme);
CESC	cis	rs672059	1.000	rs551569	chr1:183158293	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.54	6.97	0.39	2.51e-11	Hypertriglyceridemia;
CESC	cis	rs853679	0.517	rs4713135	chr6:28039586	G/A	cg12963246	chr6:28129442	ZNF389	0.55	7.21	0.4	5.85e-12	Depression;
CESC	cis	rs864537	0.618	rs1214595	chr1:167427557	G/A	cg09179987	chr1:167433047	CD247	0.53	7.83	0.43	1.17e-13	Celiac disease or Rheumatoid arthritis;Celiac disease;
CESC	cis	rs611744	0.647	rs1379336	chr8:109276606	G/T	cg21045802	chr8:109455806	TTC35	0.5	6.19	0.36	2.34e-9	Dupuytren's disease;
CESC	cis	rs5769765	0.778	rs4574208	chr22:50256738	C/T	cg02269571	chr22:50332266	NA	0.46	6.18	0.36	2.37e-9	Schizophrenia;
CESC	cis	rs10129255	0.957	rs10140904	chr14:107184797	C/T	cg07958169	chr14:107095056	NA	-0.41	-5.67	-0.33	3.72e-8	Kawasaki disease;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg24607948	chr9:100459097	XPA	0.48	6.07	0.35	4.37e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs11864453	0.826	rs2072142	chr16:72132713	C/T	cg01557791	chr16:72042693	DHODH	-0.51	-6.6	-0.38	2.17e-10	Fibrinogen levels;
CESC	cis	rs4746818	1.000	rs10733850	chr10:70959617	C/T	cg11621586	chr10:70884670	VPS26A	0.85	8.42	0.46	2.46e-15	Left atrial antero-posterior diameter;
CESC	cis	rs916888	0.773	rs169201	chr17:44790203	A/G	cg27589368	chr17:43923255	LOC100128977;IMP5	-0.39	-5.24	-0.31	3.28e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs1355223	0.506	rs1828299	chr11:34870418	T/C	cg11622362	chr11:34938112	PDHX;APIP	0.44	5.14	0.3	5.23e-7	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs9902453	0.765	rs2169810	chr17:28167941	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.76	10.01	0.52	3.14e-20	Coffee consumption (cups per day);
CESC	trans	rs12479064	0.604	rs11893359	chr2:99954608	A/G	cg20598333	chr11:3663511	ART5	0.5	6.05	0.35	4.82e-9	Chronic sinus infection;
CESC	cis	rs7223966	0.921	rs2727300	chr17:61965398	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.58	6.89	0.39	3.95e-11	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs2204008	0.744	rs11182316	chr12:38499552	G/A	cg26384229	chr12:38710491	ALG10B	0.72	10.56	0.54	5.58e-22	Bladder cancer;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg15302530	chr7:108210038	THAP5;DNAJB9	0.43	6.16	0.35	2.76e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs7666738	0.830	rs79075162	chr4:98960674	A/T	cg05340658	chr4:99064831	C4orf37	0.8	12.39	0.61	3.96e-28	Colonoscopy-negative controls vs population controls;
CESC	trans	rs7815720	0.866	rs17812918	chr8:118112784	G/A	cg09024962	chr5:132707300	FSTL4	0.56	6.06	0.35	4.63e-9	Intraocular pressure;
CESC	cis	rs8072100	0.713	rs2292346	chr17:45455473	G/A	cg25173405	chr17:45401733	C17orf57	-0.43	-5.42	-0.32	1.36e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	trans	rs9325144	0.555	rs7977200	chr12:38713745	C/T	cg23762105	chr12:34175262	ALG10	-0.48	-6.42	-0.37	6.15e-10	Morning vs. evening chronotype;
CESC	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg11494091	chr17:61959527	GH2	0.72	12.38	0.61	4.46e-28	Prudent dietary pattern;
CESC	cis	rs4780401	0.609	rs35649585	chr16:11813899	G/A	cg01061890	chr16:11836724	TXNDC11	-0.56	-7.58	-0.42	5.69e-13	Rheumatoid arthritis;
CESC	cis	rs3733585	0.699	rs7676733	chr4:9966956	G/A	cg02734326	chr4:10020555	SLC2A9	-0.39	-5.58	-0.32	5.96e-8	Cleft plate (environmental tobacco smoke interaction);
CESC	trans	rs7618501	0.516	rs2856236	chr3:50161717	A/C	cg21659725	chr3:3221576	CRBN	-0.46	-6.31	-0.36	1.15e-9	Intelligence (multi-trait analysis);
CESC	cis	rs11098499	0.820	rs12503082	chr4:120284317	A/G	cg24375607	chr4:120327624	NA	0.42	5.19	0.3	4.19e-7	Corneal astigmatism;
CESC	trans	rs7615952	0.558	rs7641353	chr3:125339879	T/C	cg07211511	chr3:129823064	LOC729375	-0.59	-7.42	-0.41	1.59e-12	Blood pressure (smoking interaction);
CESC	trans	rs3780486	0.801	rs6476398	chr9:33119241	C/T	cg20290983	chr6:43655470	MRPS18A	0.97	17.11	0.72	9.8e-45	IgG glycosylation;
CESC	cis	rs1538970	0.924	rs1494812	chr1:45876999	C/T	cg24296786	chr1:45957014	TESK2	-0.45	-5.22	-0.31	3.64e-7	Platelet count;
CESC	cis	rs832540	0.669	rs832538	chr5:56200016	C/T	cg24549020	chr5:56110836	MAP3K1	0.41	5.08	0.3	7.24e-7	Coronary artery disease;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg10620530	chr9:139922595	C9orf139;ABCA2	0.46	6.57	0.37	2.6e-10	Systemic lupus erythematosus;
CESC	cis	rs2251381	0.808	rs7364112	chr21:30548968	C/A	cg08807101	chr21:30365312	RNF160	0.65	8.07	0.44	2.42e-14	Selective IgA deficiency;
CESC	cis	rs10751667	0.600	rs10751672	chr11:948712	T/C	cg06064525	chr11:970664	AP2A2	-0.5	-9.88	-0.52	8.67e-20	Alzheimer's disease (late onset);
CESC	cis	rs738322	1.000	rs133012	chr22:38570721	G/A	cg25457927	chr22:38595422	NA	-0.3	-5.46	-0.32	1.1e-7	Cutaneous nevi;
CESC	cis	rs12474201	0.894	rs4952842	chr2:46925730	C/A	cg06386533	chr2:46925753	SOCS5	0.91	12.72	0.62	3.09e-29	Height;
CESC	cis	rs9457247	1.000	rs406095	chr6:167409087	C/T	cg25258033	chr6:167368657	RNASET2	0.4	6.14	0.35	2.93e-9	Crohn's disease;
CESC	cis	rs4242434	0.819	rs6558167	chr8:22473850	T/C	cg03733263	chr8:22462867	KIAA1967	0.87	14.4	0.66	4.18e-35	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CESC	cis	rs875971	1.000	rs1565531	chr7:65663113	T/A	cg10691866	chr7:65817282	TPST1	0.33	5.51	0.32	8.45e-8	Aortic root size;
CESC	cis	rs9325144	0.555	rs7968322	chr12:38792348	T/C	cg26384229	chr12:38710491	ALG10B	-0.56	-7.87	-0.44	9.19e-14	Morning vs. evening chronotype;
CESC	cis	rs11718455	0.960	rs35666538	chr3:44004826	A/G	cg08738300	chr3:44038990	NA	0.46	6.12	0.35	3.34e-9	Coronary artery disease;
CESC	cis	rs951366	1.000	rs4951261	chr1:205717823	A/C	cg11965913	chr1:205819406	PM20D1	-0.44	-6.2	-0.36	2.19e-9	Menarche (age at onset);
CESC	cis	rs763121	0.889	rs2267390	chr22:38889657	C/T	cg06544989	chr22:39130855	UNC84B	0.47	7.88	0.44	8.68e-14	Menopause (age at onset);
CESC	cis	rs3126085	0.560	rs11588022	chr1:152316952	A/T	cg03465714	chr1:152285911	FLG	0.46	5.1	0.3	6.44e-7	Atopic dermatitis;
CESC	cis	rs9287719	0.967	rs12692417	chr2:10745718	C/G	cg00105475	chr2:10696890	NA	0.38	5.55	0.32	6.76e-8	Prostate cancer;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg03386556	chr1:113499109	SLC16A1	-0.43	-6.08	-0.35	4.12e-9	Asthma;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg05819912	chr4:170945459	MFAP3L	-0.46	-6.49	-0.37	4.25e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs3942852	0.868	rs11039514	chr11:48109598	A/G	cg15704280	chr7:45808275	SEPT13	-0.65	-7.64	-0.42	4.03e-13	Acute lymphoblastic leukemia (childhood);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg19189965	chr12:123459820	ABCB9;OGFOD2	0.48	6.4	0.37	6.95e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs1048238	0.506	rs6668183	chr1:16173814	G/C	cg22431228	chr1:16359049	CLCNKA	-0.38	-6.68	-0.38	1.43e-10	Systolic blood pressure;
CESC	cis	rs2070488	0.775	rs4371464	chr3:38548021	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.75	-12.0	-0.59	8.82e-27	Electrocardiographic conduction measures;
CESC	cis	rs2710642	0.721	rs1872790	chr2:62890222	T/C	cg17519650	chr2:63277830	OTX1	0.56	6.7	0.38	1.28e-10	LDL cholesterol levels;LDL cholesterol;
CESC	cis	rs7666738	0.830	rs17027216	chr4:99009152	G/C	cg17366294	chr4:99064904	C4orf37	0.6	8.62	0.47	6.37e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4664308	1.000	rs16844715	chr2:160915106	A/G	cg03641300	chr2:160917029	PLA2R1	0.65	9.87	0.52	8.87e-20	Idiopathic membranous nephropathy;
CESC	cis	rs11190604	1.000	rs2295773	chr10:102265815	A/G	cg07080220	chr10:102295463	HIF1AN	0.64	5.88	0.34	1.23e-8	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs10492096	1.000	rs10492096	chr12:6580582	A/G	cg13857086	chr12:6580257	VAMP1	0.69	6.93	0.39	3.19e-11	Hip geometry;
CESC	trans	rs916888	0.647	rs199523	chr17:44848517	C/A	cg22968622	chr17:43663579	NA	-0.76	-9.99	-0.52	3.72e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs11677370	0.603	rs1454242	chr2:3848532	G/A	cg17052675	chr2:3827356	NA	-0.44	-5.68	-0.33	3.56e-8	Type 2 diabetes;
CESC	cis	rs17431357	1.000	rs73230328	chr12:121019639	G/A	cg25045489	chr12:120971538	RNF10	-0.9	-5.23	-0.31	3.44e-7	Insulin resistance/response;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18382947	chr19:51308364	C19orf48	0.58	6.72	0.38	1.1e-10	Gut microbiome composition (summer);
CESC	cis	rs2361718	0.527	rs11150847	chr17:78153130	G/A	cg06718696	chr17:78121285	EIF4A3	0.5	6.78	0.38	7.99e-11	Yeast infection;
CESC	cis	rs6952808	0.624	rs60137119	chr7:2083664	A/G	cg08027265	chr7:2291960	NA	-0.44	-6.69	-0.38	1.29e-10	Bipolar disorder and schizophrenia;
CESC	cis	rs6952808	0.531	rs3778998	chr7:2180753	C/A	cg02951883	chr7:2050386	MAD1L1	-0.45	-5.98	-0.34	7.06e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs6502050	0.835	rs8066284	chr17:80127825	C/T	cg11859384	chr17:80120422	CCDC57	-0.39	-5.34	-0.31	1.97e-7	Life satisfaction;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00271154	chr2:113033418	ZC3H6	-0.69	-8.39	-0.46	3e-15	Gut microbiome composition (summer);
CESC	cis	rs9611565	0.512	rs2899349	chr22:42164660	T/C	cg06634786	chr22:41940651	POLR3H	0.68	6.78	0.38	7.6e-11	Vitiligo;
CESC	cis	rs9831754	1.000	rs9822043	chr3:78352113	T/C	cg06138941	chr3:78371609	NA	-0.77	-8.66	-0.47	4.76e-16	Calcium levels;
CESC	cis	rs61931739	0.500	rs3934517	chr12:34451396	T/C	cg23762105	chr12:34175262	ALG10	-0.4	-5.22	-0.31	3.7e-7	Morning vs. evening chronotype;
CESC	trans	rs561341	0.714	rs473535	chr17:30312365	A/G	cg27661571	chr11:113659931	NA	-0.81	-7.55	-0.42	6.9e-13	Hip circumference adjusted for BMI;
CESC	cis	rs8071789	1.000	rs8071789	chr17:38006333	C/T	cg20243544	chr17:37824526	PNMT	0.53	7.14	0.4	8.83e-12	Selective IgA deficiency;
CESC	cis	rs6502050	0.799	rs11491185	chr17:80151101	C/T	cg11859384	chr17:80120422	CCDC57	-0.38	-5.17	-0.3	4.56e-7	Life satisfaction;
CESC	cis	rs832540	0.931	rs1466008	chr5:56213406	G/C	cg12311346	chr5:56204834	C5orf35	-0.43	-5.43	-0.32	1.25e-7	Coronary artery disease;
CESC	cis	rs4148883	0.615	rs2187483	chr4:100134103	G/T	cg13256891	chr4:100009986	ADH5	-0.44	-5.72	-0.33	2.94e-8	Alcohol dependence;
CESC	cis	rs1707322	0.686	rs1547924	chr1:46085112	C/T	cg03146154	chr1:46216737	IPP	0.79	10.88	0.56	4.78e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7872515	0.775	rs7024583	chr9:94824750	C/T	cg01248375	chr9:94877805	SPTLC1	0.49	5.25	0.31	3.08e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs60871478	0.588	rs56205589	chr7:910419	G/A	cg05535760	chr7:792225	HEATR2	-0.8	-8.26	-0.45	6.78e-15	Cerebrospinal P-tau181p levels;
CESC	cis	rs8072100	0.817	rs9892497	chr17:45545919	G/A	cg08085267	chr17:45401833	C17orf57	-0.58	-7.68	-0.43	3.15e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs3747547	0.818	rs67198935	chr9:37932797	T/G	cg13774184	chr9:37916125	SHB	-0.5	-5.24	-0.31	3.26e-7	Metabolite levels (Dihydroxy docosatrienoic acid);
CESC	cis	rs365132	1.000	rs601923	chr5:176417386	C/G	cg16309518	chr5:176445507	NA	-0.39	-5.73	-0.33	2.68e-8	Menarche and menopause (age at onset);Menopause (age at onset);
CESC	cis	rs2404618	0.593	rs7829532	chr8:1485190	C/A	cg13402656	chr8:1511478	DLGAP2	-0.53	-7.45	-0.42	1.34e-12	Lung cancer;
CESC	cis	rs9649213	0.593	rs6465667	chr7:97957885	G/A	cg00277769	chr7:97922759	BAIAP2L1	-0.33	-5.42	-0.32	1.31e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg06873352	chr17:61820015	STRADA	0.73	12.96	0.62	4.25e-30	Prudent dietary pattern;
CESC	cis	rs35146811	0.586	rs10267231	chr7:99595480	T/C	cg22531904	chr7:99595276	NA	-0.38	-5.04	-0.3	8.84e-7	Coronary artery disease;
CESC	cis	rs55728055	0.661	rs62237845	chr22:32027892	G/A	cg01338084	chr22:32026380	PISD	1.26	8.23	0.45	8.62e-15	Age-related hearing impairment;
CESC	cis	rs7618915	0.570	rs11714088	chr3:52758942	A/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.31	5.49	0.32	9.47e-8	Bipolar disorder;
CESC	cis	rs6121246	0.529	rs6060134	chr20:30176794	A/G	cg13852791	chr20:30311386	BCL2L1	0.57	5.5	0.32	9.14e-8	Mean corpuscular hemoglobin;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg13243329	chr1:212782207	ATF3	-0.48	-6.11	-0.35	3.55e-9	Ulcerative colitis;
CESC	cis	rs17376456	0.825	rs34592268	chr5:93232751	G/C	cg25358565	chr5:93447407	FAM172A	1.1	10.79	0.55	9.8e-23	Diabetic retinopathy;
CESC	cis	rs4713118	0.516	rs4713142	chr6:28106347	T/G	cg20151795	chr6:28129481	ZNF389	0.45	5.92	0.34	9.77e-9	Parkinson's disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg27337021	chr5:139947627	SLC35A4	0.43	6.14	0.35	3.07e-9	Fibrinogen levels;
CESC	cis	rs4665809	0.627	rs1465720	chr2:26412638	G/T	cg22920501	chr2:26401640	FAM59B	-0.85	-9.95	-0.52	5.11e-20	Gut microbiome composition (summer);
CESC	cis	rs11696501	0.688	rs4812955	chr20:44324638	G/C	cg11783356	chr20:44313418	WFDC10B	-0.34	-5.28	-0.31	2.76e-7	Brain structure;
CESC	cis	rs1538970	1.000	rs17395553	chr1:45864761	C/T	cg06784218	chr1:46089804	CCDC17	0.34	5.67	0.33	3.68e-8	Platelet count;
CESC	cis	rs9311474	1.000	rs2276834	chr3:52325759	A/G	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.36	6.63	0.38	1.85e-10	Electroencephalogram traits;
CESC	cis	rs2836974	0.605	rs2836988	chr21:40707975	A/G	cg11644478	chr21:40555479	PSMG1	-0.8	-11.95	-0.59	1.27e-26	Cognitive function;
CESC	cis	rs3733585	0.638	rs7377625	chr4:9953099	T/C	cg11266682	chr4:10021025	SLC2A9	-0.58	-11.05	-0.56	1.39e-23	Cleft plate (environmental tobacco smoke interaction);
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg05875433	chr3:130465895	PIK3R4	-0.49	-6.84	-0.39	5.4e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs798554	0.683	rs1182155	chr7:2902890	C/G	cg18446336	chr7:2847575	GNA12	-0.37	-5.59	-0.32	5.76e-8	Height;
CESC	cis	rs514406	0.668	rs1672911	chr1:53340320	T/C	cg08736216	chr1:53307985	ZYG11A	-0.4	-7.04	-0.4	1.6e-11	Monocyte count;
CESC	cis	rs2637266	0.967	rs7900230	chr10:78366879	A/G	cg18941641	chr10:78392320	NA	0.42	7.87	0.44	8.96e-14	Pulmonary function;
CESC	cis	rs9549260	0.816	rs7337995	chr13:41249040	A/G	cg21288729	chr13:41239152	FOXO1	0.63	7.77	0.43	1.75e-13	Red blood cell count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23057831	chr8:82633454	ZFAND1	0.55	6.06	0.35	4.58e-9	Gut microbiome composition (summer);
CESC	cis	rs7833790	0.963	rs7836040	chr8:82698328	G/A	cg27398817	chr8:82754497	SNX16	-0.53	-6.25	-0.36	1.63e-9	Diastolic blood pressure;
CESC	cis	rs7666738	0.712	rs34043080	chr4:99008748	G/C	cg18180107	chr4:99064573	C4orf37	0.4	5.18	0.3	4.42e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs4906172	0.716	rs8013679	chr14:102506308	A/G	cg17920195	chr4:129149383	NA	0.31	6.17	0.35	2.57e-9	Menopause (age at onset);
CESC	trans	rs11722228	0.522	rs881641	chr4:10133747	G/A	cg26043149	chr18:55253948	FECH	1.01	12.98	0.62	3.9e-30	Gout;Urate levels;Serum uric acid levels;
CESC	cis	rs10504229	0.679	rs17193048	chr8:58055392	G/A	cg02725872	chr8:58115012	NA	-0.44	-5.98	-0.34	7.21e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs2235544	0.513	rs10158824	chr1:54480398	C/G	cg25741118	chr1:54482237	LDLRAD1	0.23	5.87	0.34	1.31e-8	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
CESC	cis	rs763121	0.853	rs5757231	chr22:39071658	C/T	cg06022373	chr22:39101656	GTPBP1	-0.89	-13.81	-0.65	4.77e-33	Menopause (age at onset);
CESC	cis	rs2952156	1.000	rs2934971	chr17:37854507	G/T	cg20243544	chr17:37824526	PNMT	0.61	7.42	0.41	1.61e-12	Asthma;
CESC	cis	rs763121	0.853	rs4821808	chr22:39065739	A/G	cg21395723	chr22:39101663	GTPBP1	0.42	5.27	0.31	2.86e-7	Menopause (age at onset);
CESC	cis	rs644799	1.000	rs566204	chr11:95580926	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.57	6.74	0.38	9.95e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs2404602	0.692	rs67010831	chr15:76965308	T/G	cg26408565	chr15:76604113	ETFA	-0.39	-5.71	-0.33	2.98e-8	Blood metabolite levels;
CESC	cis	rs9815354	0.638	rs73071259	chr3:42001847	G/A	cg03022575	chr3:42003672	ULK4	0.66	5.77	0.33	2.17e-8	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs4665809	1.000	rs1560868	chr2:26281459	A/T	cg27170947	chr2:26402098	FAM59B	0.69	8.1	0.45	2.07e-14	Gut microbiome composition (summer);
CESC	cis	rs7336332	0.598	rs76790205	chr13:28002885	C/T	cg22138327	chr13:27999177	GTF3A	0.64	5.96	0.34	8.09e-9	Weight;
CESC	cis	rs2985684	1.000	rs2985684	chr14:50101682	C/G	cg02151108	chr14:50098012	C14orf104	-0.42	-5.48	-0.32	9.97e-8	Carotid intima media thickness;
CESC	cis	rs4835473	0.900	rs5015759	chr4:144659203	C/G	cg25736465	chr4:144833511	NA	-0.33	-5.2	-0.3	4.04e-7	Immature fraction of reticulocytes;
CESC	cis	rs35110281	0.777	rs7276215	chr21:44990697	A/G	cg04455712	chr21:45112962	RRP1B	0.38	5.6	0.33	5.4e-8	Mean corpuscular volume;
CESC	cis	rs10504229	0.593	rs76922080	chr8:57985837	C/G	cg24829409	chr8:58192753	C8orf71	-0.67	-7.37	-0.41	2.23e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs7618501	0.633	rs12496973	chr3:50002245	T/C	cg24308560	chr3:49941425	MST1R	-0.63	-9.23	-0.49	8.99e-18	Intelligence (multi-trait analysis);
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg05485520	chr3:45883628	LZTFL1	0.49	6.69	0.38	1.29e-10	Systemic lupus erythematosus;
CESC	cis	rs3931020	0.530	rs12125889	chr1:75241971	A/G	cg00121533	chr1:75199117	CRYZ;TYW3	0.54	7.47	0.42	1.2e-12	Resistin levels;
CESC	trans	rs7618501	0.966	rs13063621	chr3:49821625	T/C	cg21659725	chr3:3221576	CRBN	0.83	13.44	0.64	9.18e-32	Intelligence (multi-trait analysis);
CESC	cis	rs12477438	0.765	rs28648058	chr2:99696417	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.64	-8.58	-0.47	7.87e-16	Chronic sinus infection;
CESC	cis	rs7833790	0.724	rs72603871	chr8:82754460	C/G	cg02079420	chr8:82753780	SNX16	-0.53	-8.1	-0.45	2.07e-14	Diastolic blood pressure;
CESC	cis	rs7618915	0.501	rs9917834	chr3:52634619	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.6	8.56	0.47	9.4e-16	Bipolar disorder;
CESC	cis	rs10791323	0.569	rs5019134	chr11:133713082	G/C	cg14349672	chr11:133703707	NA	-0.36	-5.06	-0.3	7.92e-7	Childhood ear infection;
CESC	trans	rs4332037	0.851	rs73050128	chr7:1961882	C/A	cg11693508	chr17:37793320	STARD3	0.7	6.8	0.39	7e-11	Bipolar disorder;
CESC	cis	rs7617773	0.817	rs11710861	chr3:48297560	C/T	cg11946769	chr3:48343235	NME6	0.79	10.54	0.54	6.33e-22	Coronary artery disease;
CESC	cis	rs9788682	1.000	rs34138960	chr15:78831668	A/G	cg06917634	chr15:78832804	PSMA4	-0.55	-6.49	-0.37	4.15e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs57083693	0.500	rs11110751	chr12:101718142	T/C	cg22051763	chr12:101673672	UTP20	-0.44	-5.5	-0.32	8.91e-8	Alcohol dependence (age at onset);
CESC	cis	rs853679	0.517	rs9393901	chr6:28136797	A/G	cg23281280	chr6:28129359	ZNF389	0.56	7.62	0.42	4.55e-13	Depression;
CESC	cis	rs59918340	0.764	rs4961258	chr8:142232878	A/G	cg23750338	chr8:142222470	SLC45A4	-0.6	-9.09	-0.49	2.31e-17	Immature fraction of reticulocytes;
CESC	cis	rs3892630	0.817	rs12609866	chr19:33184412	C/T	cg13157960	chr19:33183277	NUDT19	0.53	5.2	0.3	4.04e-7	Red blood cell traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25433855	chr4:102268622	PPP3CA	-0.61	-7.26	-0.41	4.26e-12	Gut microbiome composition (summer);
CESC	cis	rs7208859	0.623	rs56378576	chr17:29010120	C/T	cg19761014	chr17:28927070	LRRC37B2	0.81	6.67	0.38	1.49e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs10870270	1.000	rs72636963	chr10:133771271	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.87	-12.77	-0.62	2.05e-29	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs6032067	0.850	rs4566421	chr20:43783761	G/T	cg10761708	chr20:43804764	PI3	0.55	5.96	0.34	7.91e-9	Blood protein levels;
CESC	trans	rs9858542	0.953	rs11719996	chr3:49525958	T/C	cg21659725	chr3:3221576	CRBN	-0.55	-6.49	-0.37	4.22e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs34779708	0.931	rs35388511	chr10:35296616	A/G	cg03585969	chr10:35415529	CREM	0.75	9.74	0.51	2.26e-19	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs67311347	0.577	rs11712626	chr3:40259927	G/A	cg09455208	chr3:40491958	NA	0.35	5.5	0.32	8.99e-8	Renal cell carcinoma;
CESC	cis	rs1538970	0.924	rs11211108	chr1:45891152	C/T	cg24296786	chr1:45957014	TESK2	-0.46	-5.3	-0.31	2.41e-7	Platelet count;
CESC	cis	rs34172651	0.517	rs2303083	chr16:24835168	G/A	cg06505273	chr16:24850292	NA	0.5	5.38	0.31	1.66e-7	Intelligence (multi-trait analysis);
CESC	cis	rs12188164	0.610	rs6555242	chr5:416546	A/C	cg26850624	chr5:429559	AHRR	-0.41	-5.97	-0.34	7.41e-9	Cystic fibrosis severity;
CESC	trans	rs11098499	0.954	rs3733520	chr4:120423480	C/G	cg25214090	chr10:38739885	LOC399744	0.71	10.03	0.52	2.81e-20	Corneal astigmatism;
CESC	cis	rs9733	0.744	rs11204737	chr1:150847647	C/T	cg13175981	chr1:150552382	MCL1	0.5	6.82	0.39	5.97e-11	Tonsillectomy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09348431	chr8:144898112	SCRIB	0.6	6.96	0.39	2.69e-11	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02909592	chr3:149181944	NA	-0.62	-7.54	-0.42	7.42e-13	Gut microbiome composition (summer);
CESC	cis	rs8017423	1.000	rs2184281	chr14:90685923	A/G	cg14092571	chr14:90743983	NA	0.53	7.78	0.43	1.63e-13	Mortality in heart failure;
CESC	cis	rs300703	0.655	rs300798	chr2:105917	A/G	cg21211680	chr2:198530	NA	-1.0	-9.26	-0.49	7.45e-18	Blood protein levels;
CESC	cis	rs4144743	0.641	rs67696888	chr17:45355116	A/G	cg18085866	chr17:45331354	ITGB3	-0.58	-5.59	-0.32	5.61e-8	Body mass index;
CESC	cis	rs13108904	0.875	rs73069950	chr4:1276045	C/A	cg00684032	chr4:1343700	KIAA1530	-0.37	-5.13	-0.3	5.61e-7	Obesity-related traits;
CESC	cis	rs3796352	0.892	rs2581807	chr3:53088844	G/A	cg12962167	chr3:53033115	SFMBT1	-0.59	-5.7	-0.33	3.22e-8	Immune reponse to smallpox (secreted IL-2);
CESC	cis	rs7666738	0.830	rs28587201	chr4:98991733	C/T	cg03467027	chr4:99064603	C4orf37	0.44	5.51	0.32	8.65e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs17125944	0.505	rs2295826	chr14:53174923	C/T	cg13660082	chr14:53194042	PSMC6	0.62	5.84	0.34	1.54e-8	Alzheimer's disease (late onset);
CESC	cis	rs1538970	0.924	rs11211117	chr1:45930246	C/T	cg05343316	chr1:45956843	TESK2	0.89	12.12	0.6	3.27e-27	Platelet count;
CESC	cis	rs9768139	0.634	rs56389048	chr7:158121368	T/A	cg24154853	chr7:158122151	PTPRN2	0.44	6.97	0.39	2.53e-11	Calcium levels;
CESC	cis	rs1003719	0.788	rs11911508	chr21:38470504	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.63	8.77	0.47	2.14e-16	Eye color traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00720027	chr8:42249732	VDAC3	0.64	6.99	0.39	2.28e-11	Gut microbiome composition (summer);
CESC	cis	rs9381040	0.701	rs4711658	chr6:41162891	C/T	cg03526776	chr6:41159608	TREML2	-0.32	-6.0	-0.35	6.56e-9	Alzheimer's disease (late onset);
CESC	cis	rs875971	0.545	rs35459055	chr7:65944386	G/A	cg25405998	chr7:65216604	CCT6P1	0.45	5.17	0.3	4.6e-7	Aortic root size;
CESC	cis	rs4727027	0.899	rs7791496	chr7:148863674	C/G	cg23583168	chr7:148888333	NA	-0.81	-12.7	-0.62	3.49e-29	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs7927592	0.956	rs60212556	chr11:68305494	C/T	cg16797656	chr11:68205561	LRP5	0.4	5.51	0.32	8.36e-8	Total body bone mineral density;
CESC	cis	rs4819052	0.851	rs28501512	chr21:46676702	C/T	cg11663144	chr21:46675770	NA	-0.63	-9.75	-0.51	2.19e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs796364	0.806	rs203766	chr2:200902672	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.83	-7.71	-0.43	2.49e-13	Schizophrenia;
CESC	cis	rs5758659	0.904	rs134877	chr22:42662371	C/T	cg15557168	chr22:42548783	NA	-0.51	-8.27	-0.45	6.58e-15	Cognitive function;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20159777	chr1:203296550	NA	0.66	7.22	0.41	5.41e-12	Gut microbiome composition (summer);
CESC	cis	rs9322193	0.923	rs2185352	chr6:150035776	T/G	cg07701084	chr6:150067640	NUP43	0.49	6.91	0.39	3.56e-11	Lung cancer;
CESC	cis	rs7236492	0.627	rs76032846	chr18:77198322	G/A	cg15644404	chr18:77186268	NFATC1	-0.67	-5.06	-0.3	7.67e-7	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs4319547	1.000	rs7309390	chr12:123110422	A/G	cg23029597	chr12:123009494	RSRC2	-0.46	-5.14	-0.3	5.3e-7	Body mass index;
CESC	cis	rs3857067	0.806	rs4693375	chr4:95133241	C/A	cg11021082	chr4:95130006	SMARCAD1	-0.66	-10.02	-0.52	2.93e-20	QT interval;
CESC	trans	rs11992162	0.636	rs4841646	chr8:11798707	C/G	cg15556689	chr8:8085844	FLJ10661	0.52	6.46	0.37	4.98e-10	Monocyte count;
CESC	trans	rs2727020	0.576	rs61885308	chr11:49343363	G/A	cg03929089	chr4:120376271	NA	-0.6	-7.51	-0.42	8.87e-13	Coronary artery disease;
CESC	cis	rs1707322	0.686	rs2991979	chr1:46055858	A/G	cg06784218	chr1:46089804	CCDC17	-0.41	-7.11	-0.4	1.07e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01002995	chr12:8185077	FOXJ2	0.55	6.09	0.35	3.94e-9	Gut microbiome composition (summer);
CESC	cis	rs2404602	0.647	rs12439141	chr15:77095423	T/C	cg23625390	chr15:77176239	SCAPER	-0.4	-5.24	-0.31	3.32e-7	Blood metabolite levels;
CESC	cis	rs4862750	0.758	rs2375915	chr4:187896255	A/C	cg11301795	chr4:187892539	NA	-0.77	-12.15	-0.6	2.73e-27	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs643506	0.874	rs582465	chr11:111668585	C/T	cg17089665	chr11:111648010	NA	-0.38	-5.55	-0.32	7.03e-8	Breast cancer;
CESC	cis	rs6964587	1.000	rs7811873	chr7:91751120	G/A	cg17063962	chr7:91808500	NA	0.58	8.06	0.44	2.57e-14	Breast cancer;
CESC	cis	rs3749237	1.000	rs3749237	chr3:49770032	C/T	cg03060546	chr3:49711283	APEH	0.6	7.29	0.41	3.65e-12	Resting heart rate;
CESC	cis	rs7089973	0.872	rs34683721	chr10:116619849	G/A	cg23260525	chr10:116636907	FAM160B1	0.38	6.42	0.37	6.35e-10	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs8027181	0.682	rs4777546	chr15:73104435	C/T	cg25632853	chr15:73088954	NA	-0.31	-5.41	-0.32	1.43e-7	Triglyceride levels;
CESC	cis	rs8070740	0.592	rs2189338	chr17:5326341	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.58	7.55	0.42	7e-13	Menopause (age at onset);
CESC	cis	rs76419734	0.510	rs3943980	chr4:106676766	G/A	cg24545054	chr4:106630052	GSTCD;INTS12	-0.62	-6.47	-0.37	4.62e-10	Post bronchodilator FEV1;
CESC	cis	rs6974235	0.806	rs42068	chr7:95716570	A/G	cg21022364	chr7:95948586	SLC25A13	0.39	5.56	0.32	6.61e-8	Total body bone mineral density;
CESC	cis	rs11168351	0.927	rs10875716	chr12:48389023	C/T	cg24011408	chr12:48396354	COL2A1	0.54	8.13	0.45	1.69e-14	Bipolar disorder and schizophrenia;
CESC	cis	rs1552244	1.000	rs7610821	chr3:10136150	C/T	cg08888203	chr3:10149979	C3orf24	0.46	6.03	0.35	5.45e-9	Alzheimer's disease;
CESC	cis	rs2228479	0.850	rs62052714	chr16:89857180	T/C	cg06558623	chr16:89946397	TCF25	1.18	9.44	0.5	1.97e-18	Skin colour saturation;
CESC	cis	rs1568889	1.000	rs35343234	chr11:28034379	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.73	9.0	0.48	4.61e-17	Bipolar disorder;
CESC	cis	rs67478160	0.643	rs4900600	chr14:104291839	A/G	cg08213375	chr14:104286397	PPP1R13B	0.54	10.66	0.55	2.59e-22	Schizophrenia;
CESC	cis	rs116095464	0.558	rs9688045	chr5:254035	T/C	cg10591111	chr5:226296	SDHA	-0.51	-6.15	-0.35	2.84e-9	Breast cancer;
CESC	cis	rs919433	0.963	rs13033821	chr2:198173536	T/G	cg03934865	chr2:198174659	NA	-0.42	-5.55	-0.32	6.94e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	trans	rs41357746	0.525	rs57030473	chr15:67776678	A/G	cg05081167	chr6:156967138	NA	0.3	6.18	0.35	2.43e-9	Total body bone mineral density;
CESC	cis	rs694739	0.628	rs11606081	chr11:64137875	T/C	cg23796481	chr11:64053134	BAD;GPR137	0.58	7.09	0.4	1.23e-11	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CESC	trans	rs916888	0.610	rs199452	chr17:44801340	C/T	cg01341218	chr17:43662625	NA	0.52	6.98	0.39	2.34e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs875971	0.660	rs10263935	chr7:66096028	A/G	cg18252515	chr7:66147081	NA	-0.44	-5.74	-0.33	2.52e-8	Aortic root size;
CESC	cis	rs59918340	0.764	rs3824234	chr8:142229370	T/C	cg23750338	chr8:142222470	SLC45A4	0.62	9.26	0.49	7.03e-18	Immature fraction of reticulocytes;
CESC	cis	rs9308731	0.569	rs7585054	chr2:111944927	A/G	cg04202892	chr2:111875749	ACOXL	0.37	5.17	0.3	4.61e-7	Chronic lymphocytic leukemia;
CESC	cis	rs72781680	0.611	rs6720131	chr2:24364736	C/T	cg20701182	chr2:24300061	SF3B14	0.95	10.52	0.54	7.35e-22	Lymphocyte counts;
CESC	cis	rs2017305	0.834	rs12253140	chr10:70780708	G/T	cg01024728	chr10:70782572	NA	0.57	5.41	0.32	1.4e-7	Depression (quantitative trait);
CESC	cis	rs9487051	1.000	rs9487052	chr6:109617086	C/T	cg21918786	chr6:109611834	NA	-0.36	-5.22	-0.31	3.63e-7	Reticulocyte fraction of red cells;
CESC	cis	rs9916302	0.768	rs62077464	chr17:37656056	C/G	cg07936489	chr17:37558343	FBXL20	-0.79	-11.38	-0.57	1.07e-24	Glomerular filtration rate (creatinine);
CESC	cis	rs2836974	0.681	rs8128827	chr21:40710547	C/T	cg11890956	chr21:40555474	PSMG1	1.04	16.54	0.71	1.1e-42	Cognitive function;
CESC	cis	rs7666738	0.830	rs7684646	chr4:99071062	C/T	cg05340658	chr4:99064831	C4orf37	0.82	12.5	0.61	1.73e-28	Colonoscopy-negative controls vs population controls;
CESC	trans	rs7839040	0.698	rs7841608	chr8:82929786	C/G	cg14472086	chr9:107730925	NA	-0.47	-6.28	-0.36	1.38e-9	Response to methotrexate in juvenile idiopathic arthritis;
CESC	cis	rs4566357	0.615	rs2894626	chr2:227916039	T/C	cg11843606	chr2:227700838	RHBDD1	-0.52	-7.01	-0.4	1.92e-11	Coronary artery disease;
CESC	cis	rs1008375	0.932	rs12500947	chr4:17603424	C/T	cg02297831	chr4:17616191	MED28	0.54	6.73	0.38	1.06e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs2439831	0.681	rs540031	chr15:43608855	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.82	12.43	0.61	3.03e-28	Lung cancer in ever smokers;
CESC	cis	rs2228479	0.717	rs2286392	chr16:89809549	A/G	cg00800038	chr16:89945340	TCF25	-0.71	-7.24	-0.41	4.76e-12	Skin colour saturation;
CESC	cis	rs853679	0.517	rs6941992	chr6:28106141	T/C	cg23281280	chr6:28129359	ZNF389	0.59	8.16	0.45	1.34e-14	Depression;
CESC	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	7.83	0.43	1.21e-13	Prudent dietary pattern;
CESC	cis	rs1832871	0.672	rs9456286	chr6:158734315	A/G	cg07165851	chr6:158734300	TULP4	0.6	6.57	0.37	2.63e-10	Height;
CESC	cis	rs12926788	0.546	rs200531	chr16:24756172	G/A	cg06505273	chr16:24850292	NA	-0.53	-6.49	-0.37	4.27e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs3733585	0.699	rs6449158	chr4:9960459	T/C	cg11266682	chr4:10021025	SLC2A9	-0.6	-11.15	-0.57	6.33e-24	Cleft plate (environmental tobacco smoke interaction);
CESC	trans	rs8073060	0.586	rs72828038	chr17:33893908	C/A	cg19694781	chr19:47549865	TMEM160	0.69	6.72	0.38	1.11e-10	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	cis	rs400736	0.740	rs9434981	chr1:8111314	G/C	cg25007680	chr1:8021821	PARK7	0.71	9.97	0.52	4.51e-20	Response to antidepressants and depression;
CESC	cis	rs8078723	0.677	rs8073254	chr17:38149350	C/G	cg17467752	chr17:38218738	THRA	-0.57	-8.58	-0.47	8.38e-16	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CESC	cis	rs1707322	1.000	rs6661500	chr1:46465662	T/C	cg05343316	chr1:45956843	TESK2	0.44	5.29	0.31	2.62e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs35955747	0.934	rs13053245	chr22:31816742	G/C	cg25791279	chr22:32026902	PISD	-0.44	-5.31	-0.31	2.28e-7	Neutrophil count;Sum basophil neutrophil counts;
CESC	cis	rs10479542	0.721	rs6894113	chr5:178974789	G/C	cg21226059	chr5:178986404	RUFY1	0.42	6.12	0.35	3.38e-9	Lung cancer;
CESC	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg24846343	chr22:24311635	DDTL	0.66	11.37	0.57	1.2e-24	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs778371	0.723	rs12105766	chr2:233617647	A/G	cg08000102	chr2:233561755	GIGYF2	0.83	13.68	0.64	1.35e-32	Schizophrenia;
CESC	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	10.12	0.53	1.44e-20	Prudent dietary pattern;
CESC	cis	rs11077998	0.967	rs4789782	chr17:80489323	G/T	cg10255544	chr17:80519551	FOXK2	-0.54	-8.81	-0.48	1.73e-16	Reticulocyte fraction of red cells;
CESC	cis	rs4319547	0.915	rs1473553	chr12:122985057	G/T	cg23029597	chr12:123009494	RSRC2	-0.5	-5.43	-0.32	1.26e-7	Body mass index;
CESC	cis	rs6952808	0.723	rs11766575	chr7:2005747	T/C	cg21782813	chr7:2030301	MAD1L1	0.49	6.84	0.39	5.53e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs933688	0.532	rs973332	chr5:90555129	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.44	-5.11	-0.3	6.1e-7	Smoking behavior;
CESC	cis	rs933688	1.000	rs12654787	chr5:90713259	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.11	12.45	0.61	2.47e-28	Smoking behavior;
CESC	cis	rs6502050	0.835	rs7503225	chr17:80099639	C/A	cg11859384	chr17:80120422	CCDC57	-0.38	-5.11	-0.3	6.21e-7	Life satisfaction;
CESC	cis	rs2635047	0.615	rs9304343	chr18:44720664	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.34	5.13	0.3	5.49e-7	Educational attainment;
CESC	cis	rs875971	0.862	rs7809814	chr7:65615397	G/A	cg18252515	chr7:66147081	NA	0.4	5.13	0.3	5.59e-7	Aortic root size;
CESC	cis	rs10504229	0.679	rs12375445	chr8:58040082	A/G	cg22535103	chr8:58192502	C8orf71	-0.62	-6.85	-0.39	5e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs6942756	0.747	rs691435	chr7:129097352	C/T	cg02491457	chr7:128862824	NA	0.57	7.99	0.44	4.06e-14	White matter hyperintensity burden;
CESC	trans	rs877282	0.629	rs78997110	chr10:764388	A/G	cg22713356	chr15:30763199	NA	1.16	10.88	0.56	5.1e-23	Uric acid levels;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg10163580	chr2:191742848	NA	0.4	6.01	0.35	6.27e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs56235845	0.694	rs9313758	chr5:176773091	T/G	cg17509989	chr5:176798049	RGS14	0.5	6.3	0.36	1.24e-9	Hemoglobin concentration;Hematocrit;
CESC	cis	rs6460942	0.524	rs6948366	chr7:12369905	A/G	cg20607287	chr7:12443886	VWDE	-0.57	-8.19	-0.45	1.1e-14	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23487303	chr19:59086729	MGC2752	0.56	6.02	0.35	5.79e-9	Gut microbiome composition (summer);
CESC	cis	rs780096	0.526	rs3845687	chr2:27689899	T/C	cg22903471	chr2:27725779	GCKR	-0.59	-8.52	-0.46	1.23e-15	Total body bone mineral density;
CESC	cis	rs10129255	0.500	rs6576226	chr14:107186374	G/A	cg23076370	chr14:107095027	NA	-0.65	-9.67	-0.51	3.98e-19	Kawasaki disease;
CESC	cis	rs2072499	0.966	rs1060604	chr1:156184268	T/C	cg06970220	chr1:156163860	SLC25A44	0.39	5.05	0.3	8.14e-7	Testicular germ cell tumor;
CESC	cis	rs9300255	0.596	rs1568427	chr12:123738678	A/G	cg00376283	chr12:123451042	ABCB9	0.66	8.88	0.48	1.02e-16	Neutrophil percentage of white cells;
CESC	cis	rs2290159	0.800	rs2290162	chr3:12647457	A/G	cg23032965	chr3:12705835	RAF1	0.51	5.63	0.33	4.48e-8	Cholesterol, total;
CESC	cis	rs559928	0.606	rs12417635	chr11:63912728	C/T	cg18225595	chr11:63971243	STIP1	0.64	5.82	0.34	1.73e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CESC	cis	rs7618915	0.571	rs2251219	chr3:52584787	C/T	cg05564831	chr3:52568323	NT5DC2	-0.46	-6.64	-0.38	1.79e-10	Bipolar disorder;
CESC	cis	rs7107174	1.000	rs2511177	chr11:77922960	C/T	cg02023728	chr11:77925099	USP35	0.39	5.59	0.32	5.76e-8	Testicular germ cell tumor;
CESC	cis	rs8077889	0.869	rs11713	chr17:41845824	A/G	cg26893861	chr17:41843967	DUSP3	-0.66	-7.77	-0.43	1.71e-13	Triglycerides;
CESC	cis	rs79349575	0.749	rs8182364	chr17:47018025	A/G	cg26022315	chr17:47021804	SNF8	0.39	5.16	0.3	4.94e-7	Type 2 diabetes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21416968	chr1:44441199	ATP6V0B	0.61	7.33	0.41	2.79e-12	Gut microbiome composition (summer);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03900353	chr1:212732456	NA	0.46	6.0	0.35	6.41e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs9902453	0.868	rs9896012	chr17:28470091	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.65	8.29	0.45	5.59e-15	Coffee consumption (cups per day);
CESC	cis	rs7638995	0.878	rs1995665	chr3:69183140	A/C	cg26574240	chr3:69171822	LMOD3	-0.47	-5.11	-0.3	6.04e-7	Alzheimer's disease (late onset);
CESC	cis	rs7811142	1.000	rs6975514	chr7:100056220	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.78	6.81	0.39	6.56e-11	Platelet count;
CESC	cis	rs7937682	0.924	rs875257	chr11:111530453	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.0	-16.56	-0.71	9.02e-43	Primary sclerosing cholangitis;
CESC	cis	rs9549367	0.713	rs3024769	chr13:113825601	A/C	cg18105134	chr13:113819100	PROZ	0.64	8.3	0.45	5.53e-15	Platelet distribution width;
CESC	trans	rs10776614	0.799	rs12358311	chr10:49765337	A/G	cg19218067	chr2:181235115	NA	0.49	6.0	0.35	6.35e-9	Self-employment;
CESC	trans	rs11989744	1.000	rs11989744	chr8:23567463	A/G	cg03492747	chr16:86543808	FOXF1	-0.63	-7.33	-0.41	2.84e-12	Waist-hip ratio;
CESC	cis	rs7617480	0.610	rs4955420	chr3:49208865	A/G	cg03060546	chr3:49711283	APEH	0.59	8.38	0.46	3.15e-15	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CESC	cis	rs1712517	0.566	rs1163073	chr10:105022934	C/T	cg04362960	chr10:104952993	NT5C2	0.45	5.34	0.31	2.01e-7	Migraine;
CESC	cis	rs6733011	0.542	rs6542860	chr2:99679376	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.41	-5.34	-0.31	1.96e-7	Bipolar disorder;
CESC	cis	rs863345	0.808	rs7517316	chr1:158469914	A/T	cg12129480	chr1:158549410	OR10X1	-0.29	-5.56	-0.32	6.42e-8	Pneumococcal bacteremia;
CESC	cis	rs12681288	0.676	rs935820	chr8:1022168	A/G	cg04851639	chr8:1020857	NA	-0.36	-8.01	-0.44	3.65e-14	Schizophrenia;
CESC	cis	rs1062177	0.855	rs6892117	chr5:151264985	C/T	cg12924095	chr5:151150029	G3BP1	-0.39	-5.46	-0.32	1.09e-7	Preschool internalizing problems;
CESC	cis	rs2836974	0.623	rs7280326	chr21:40700408	A/G	cg11644478	chr21:40555479	PSMG1	-0.79	-11.72	-0.58	7.8e-26	Cognitive function;
CESC	cis	rs12142240	0.698	rs6690075	chr1:46819848	G/A	cg10495392	chr1:46806563	NSUN4	0.57	6.27	0.36	1.47e-9	Menopause (age at onset);
CESC	cis	rs147766666	1	rs147766666	chr16:67829763	TAAAC/T	cg26727032	chr16:67993705	SLC12A4	-0.59	-5.63	-0.33	4.48e-8	Hematocrit;Hemoglobin concentration;
CESC	cis	rs9902453	0.845	rs2321493	chr17:28230359	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.65	8.2	0.45	1.05e-14	Coffee consumption (cups per day);
CESC	cis	rs7927771	1.000	rs10838738	chr11:47663049	A/G	cg05585544	chr11:47624801	NA	-0.53	-8.36	-0.46	3.55e-15	Subjective well-being;
CESC	cis	rs2637266	0.967	rs2395407	chr10:78380573	T/A	cg18941641	chr10:78392320	NA	0.43	8.17	0.45	1.28e-14	Pulmonary function;
CESC	cis	rs13191362	1.000	rs34773528	chr6:163088796	G/C	cg14584255	chr6:163149320	PACRG;PARK2	0.64	6.68	0.38	1.44e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs2228479	0.717	rs1800358	chr16:89809319	T/C	cg00800038	chr16:89945340	TCF25	-0.71	-7.24	-0.41	4.76e-12	Skin colour saturation;
CESC	cis	rs4835473	0.932	rs1450235	chr4:144704080	A/G	cg25736465	chr4:144833511	NA	0.43	6.39	0.37	7.62e-10	Immature fraction of reticulocytes;
CESC	cis	rs2154427	0.752	rs79114597	chr21:34200730	C/A	cg21871883	chr21:34145043	C21orf49;C21orf66	0.62	5.15	0.3	5.15e-7	Bilirubin levels;
CESC	cis	rs796364	0.901	rs35572201	chr2:201035093	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.62	-5.95	-0.34	8.43e-9	Schizophrenia;
CESC	cis	rs1348850	0.526	rs9288003	chr2:178446572	T/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.52	5.13	0.3	5.69e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs3784262	0.967	rs4646612	chr15:58265077	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.31	-5.08	-0.3	7.03e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
CESC	cis	rs7191439	0.858	rs7205626	chr16:88780472	T/C	cg27087555	chr16:88793112	FAM38A	-1.15	-9.92	-0.52	6.06e-20	Plateletcrit;
CESC	trans	rs561341	0.941	rs501773	chr17:30314435	T/G	cg27661571	chr11:113659931	NA	-0.72	-7.45	-0.42	1.31e-12	Hip circumference adjusted for BMI;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24875440	chr1:27986375	NA	0.57	6.81	0.39	6.54e-11	Gut microbiome composition (summer);
CESC	cis	rs722599	0.683	rs7160852	chr14:75239424	T/C	cg08847533	chr14:75593920	NEK9	0.5	6.1	0.35	3.79e-9	IgG glycosylation;
CESC	cis	rs6901004	0.688	rs34151782	chr6:111574537	T/A	cg15721981	chr6:111408429	SLC16A10	0.38	5.43	0.32	1.26e-7	Blood metabolite levels;
CESC	cis	rs72627123	0.656	rs117145347	chr14:74564164	T/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.74	5.12	0.3	5.89e-7	Morning vs. evening chronotype;
CESC	cis	rs16866061	0.962	rs72972361	chr2:225341550	G/A	cg12698349	chr2:225449008	CUL3	0.72	10.98	0.56	2.37e-23	Acute graft versus host disease in bone marrow transplantation (recipient effect);
CESC	cis	rs9815354	0.597	rs60690674	chr3:41997811	G/C	cg03022575	chr3:42003672	ULK4	0.64	5.69	0.33	3.42e-8	Pulse pressure;Diastolic blood pressure;
CESC	trans	rs9325144	0.560	rs11182979	chr12:38642562	C/A	cg23762105	chr12:34175262	ALG10	0.48	6.31	0.36	1.16e-9	Morning vs. evening chronotype;
CESC	cis	rs57994353	0.598	rs72775768	chr9:139324574	C/T	cg14019695	chr9:139328340	INPP5E	0.4	5.1	0.3	6.55e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
CESC	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.54	-8.16	-0.45	1.39e-14	Longevity;Endometriosis;
CESC	cis	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg04267008	chr7:1944627	MAD1L1	-0.57	-6.89	-0.39	4.08e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs10056811	0.556	rs57441318	chr5:74379675	T/A	cg03227963	chr5:74354835	NA	0.31	5.07	0.3	7.41e-7	Coronary artery disease;
CESC	cis	rs7680126	0.595	rs17251963	chr4:10142561	A/G	cg11266682	chr4:10021025	SLC2A9	-0.43	-5.5	-0.32	9.1e-8	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	cis	rs9611565	0.765	rs132907	chr22:41801268	A/C	cg03806693	chr22:41940476	POLR3H	1.09	12.57	0.61	9.68e-29	Vitiligo;
CESC	cis	rs11249608	0.548	rs2132671	chr5:178457434	A/G	cg01312482	chr5:178451176	ZNF879	0.46	6.4	0.37	7.07e-10	Pubertal anthropometrics;
CESC	cis	rs7662987	0.517	rs1133485	chr4:100023811	T/A	cg13256891	chr4:100009986	ADH5	0.75	8.03	0.44	3.21e-14	Smoking initiation;
CESC	cis	rs2991971	0.747	rs2492841	chr1:45894891	G/T	cg24296786	chr1:45957014	TESK2	-0.59	-8.09	-0.44	2.2e-14	High light scatter reticulocyte count;
CESC	cis	rs1371867	0.810	rs3020182	chr8:101233008	T/C	cg11906718	chr8:101322791	RNF19A	-0.48	-5.91	-0.34	1.07e-8	Atrioventricular conduction;
CESC	cis	rs12188164	1.000	rs56042615	chr5:437667	G/A	cg26850624	chr5:429559	AHRR	-0.48	-6.63	-0.38	1.85e-10	Cystic fibrosis severity;
CESC	cis	rs780096	0.506	rs1262430	chr2:27673798	T/C	cg24768116	chr2:27665128	KRTCAP3	-0.3	-5.57	-0.32	6.33e-8	Total body bone mineral density;
CESC	cis	rs4132509	0.744	rs7519673	chr1:243993123	A/G	cg21452805	chr1:244014465	NA	0.66	7.16	0.4	7.89e-12	RR interval (heart rate);
CESC	cis	rs7223966	1.000	rs7217982	chr17:61832150	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.56	6.67	0.38	1.48e-10	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs9815354	0.812	rs73073361	chr3:41842926	C/G	cg03022575	chr3:42003672	ULK4	0.7	6.04	0.35	5.26e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs554111	0.660	rs667687	chr1:21072577	A/G	cg04902671	chr1:21058625	SH2D5	-0.42	-5.19	-0.3	4.27e-7	Facial morphology (factor 17, height of vermillion upper lip);
CESC	cis	rs2235642	0.893	rs2076442	chr16:1591112	G/T	cg10465839	chr16:1584050	IFT140;TMEM204	-0.34	-5.48	-0.32	9.76e-8	Coronary artery disease;
CESC	cis	rs561341	0.714	rs7218466	chr17:30263314	A/G	cg13647721	chr17:30228624	UTP6	0.52	5.27	0.31	2.81e-7	Hip circumference adjusted for BMI;
CESC	cis	rs6815814	0.731	rs4504266	chr4:38773754	G/A	cg02016764	chr4:38805732	TLR1	-0.44	-6.08	-0.35	4.24e-9	Breast cancer;
CESC	cis	rs854765	0.647	rs2056842	chr17:18009028	C/T	cg04398451	chr17:18023971	MYO15A	-0.82	-12.2	-0.6	1.77e-27	Total body bone mineral density;
CESC	cis	rs6570726	0.934	rs430003	chr6:145819506	C/T	cg05347473	chr6:146136440	FBXO30	0.49	6.71	0.38	1.2e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs875971	0.798	rs12698522	chr7:65967341	T/C	cg18252515	chr7:66147081	NA	-0.47	-6.11	-0.35	3.53e-9	Aortic root size;
CESC	trans	rs9325144	0.624	rs10783329	chr12:39113951	C/T	cg23762105	chr12:34175262	ALG10	0.47	6.12	0.35	3.31e-9	Morning vs. evening chronotype;
CESC	cis	rs3892630	0.878	rs8108621	chr19:33183291	G/A	cg22980127	chr19:33182716	NUDT19	1.02	11.59	0.58	2.11e-25	Red blood cell traits;
CESC	cis	rs2836974	0.831	rs34592564	chr21:40516288	G/C	cg11890956	chr21:40555474	PSMG1	1.08	16.87	0.72	7e-44	Cognitive function;
CESC	cis	rs7666738	0.830	rs6823718	chr4:99063202	C/T	cg03467027	chr4:99064603	C4orf37	0.48	5.95	0.34	8.67e-9	Colonoscopy-negative controls vs population controls;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg11073833	chr1:153936127	SLC39A1	-0.46	-6.56	-0.37	2.89e-10	Gambling;
CESC	cis	rs10791097	0.608	rs12363140	chr11:130744268	A/C	cg12179176	chr11:130786555	SNX19	0.65	10.05	0.53	2.42e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs2066819	1.000	rs35526714	chr12:56634639	G/C	cg26714650	chr12:56694279	CS	-1.56	-9.55	-0.51	8.89e-19	Psoriasis vulgaris;
CESC	cis	rs3091242	0.809	rs660129	chr1:25727438	C/T	cg03538708	chr1:25844672	NA	-0.4	-5.98	-0.34	7.38e-9	Erythrocyte sedimentation rate;
CESC	cis	rs6120849	0.754	rs6088686	chr20:33623437	C/T	cg24642439	chr20:33292090	TP53INP2	0.68	6.77	0.38	8.46e-11	Protein C levels;
CESC	cis	rs7818688	0.697	rs28399553	chr8:95906794	A/G	cg16049864	chr8:95962084	TP53INP1	0.56	5.46	0.32	1.11e-7	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs17253792	0.822	rs74935793	chr14:56143277	G/A	cg01858014	chr14:56050164	KTN1	-0.97	-7.54	-0.42	7.36e-13	Putamen volume;
CESC	cis	rs4819052	0.851	rs9979545	chr21:46679805	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.45	5.6	0.33	5.26e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs447	0.887	rs6467988	chr7:83756500	C/T	cg22846510	chr7:83753280	SEMA3A	-0.44	-5.38	-0.31	1.64e-7	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs7615952	0.599	rs67566088	chr3:125768973	C/A	cg15145296	chr3:125709740	NA	-0.52	-5.47	-0.32	1.06e-7	Blood pressure (smoking interaction);
CESC	cis	rs9888739	1.000	rs36055763	chr16:31299775	C/T	cg15817542	chr16:31343056	ITGAM	-0.46	-5.2	-0.3	3.95e-7	Systemic lupus erythematosus;
CESC	cis	rs9612	0.950	rs60649310	chr19:44269241	A/G	cg08581076	chr19:44259116	C19orf61	0.48	5.72	0.33	2.84e-8	Exhaled nitric oxide output;
CESC	trans	rs2727020	0.658	rs4980440	chr11:49386017	C/T	cg15704280	chr7:45808275	SEPT13	-0.91	-15.84	-0.7	3.2e-40	Coronary artery disease;
CESC	cis	rs910316	0.763	rs1548807	chr14:75479582	T/G	cg11812906	chr14:75593930	NEK9	0.78	12.56	0.61	1.1e-28	Height;
CESC	cis	rs10504229	0.817	rs55891651	chr8:58167600	C/T	cg22535103	chr8:58192502	C8orf71	-0.84	-11.02	-0.56	1.76e-23	Developmental language disorder (linguistic errors);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04117832	chr2:152685230	ARL5A	0.54	6.43	0.37	5.83e-10	Gut microbiome composition (summer);
CESC	cis	rs7640424	0.649	rs13093976	chr3:107864963	A/C	cg09227934	chr3:107805635	CD47	0.41	5.49	0.32	9.59e-8	Body mass index;
CESC	cis	rs798554	1.000	rs798559	chr7:2758341	T/C	cg09658497	chr7:2847517	GNA12	-0.38	-5.43	-0.32	1.31e-7	Height;
CESC	cis	rs861020	0.527	rs614662	chr1:209962419	C/T	cg22029157	chr1:209979665	IRF6	-0.55	-8.54	-0.46	1.05e-15	Orofacial clefts;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg00630453	chr20:2821369	FAM113A;VPS16	0.46	6.12	0.35	3.34e-9	Systemic lupus erythematosus;
CESC	trans	rs1814175	0.645	rs847630	chr11:49926360	C/T	cg15704280	chr7:45808275	SEPT13	-1.01	-18.94	-0.76	3.64e-51	Height;
CESC	trans	rs12310956	0.532	rs10844715	chr12:33968444	A/G	cg26384229	chr12:38710491	ALG10B	0.45	6.39	0.37	7.33e-10	Morning vs. evening chronotype;
CESC	trans	rs12478296	1.000	rs7420157	chr2:243005204	G/A	cg18288967	chr1:45987694	PRDX1	0.59	6.55	0.37	2.96e-10	Obesity-related traits;
CESC	cis	rs1801251	0.893	rs11687128	chr2:233608901	T/C	cg08000102	chr2:233561755	GIGYF2	0.66	9.34	0.5	4.05e-18	Coronary artery disease;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg15336778	chr2:32853064	TTC27	0.46	6.15	0.35	2.79e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs6089584	0.850	rs6142939	chr20:60627729	A/G	cg13770153	chr20:60521292	NA	-0.5	-6.53	-0.37	3.31e-10	Body mass index;
CESC	cis	rs950776	0.518	rs12910100	chr15:78822667	C/T	cg24631222	chr15:78858424	CHRNA5	-0.42	-5.33	-0.31	2.09e-7	Sudden cardiac arrest;
CESC	cis	rs6061231	0.793	rs2427320	chr20:60976723	A/G	cg22601191	chr20:60968625	CABLES2	0.53	6.48	0.37	4.55e-10	Colorectal cancer;
CESC	cis	rs6502050	0.814	rs9894554	chr17:80073423	C/G	cg23985595	chr17:80112537	CCDC57	0.41	6.38	0.36	7.8e-10	Life satisfaction;
CESC	cis	rs7512552	0.839	rs11590787	chr1:150398531	G/A	cg15654264	chr1:150340011	RPRD2	0.4	5.3	0.31	2.4e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs1552244	0.572	rs7645667	chr3:10157337	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.75	-8.13	-0.45	1.7e-14	Alzheimer's disease;
CESC	cis	rs7618915	0.571	rs17264436	chr3:52610651	T/A	cg05564831	chr3:52568323	NT5DC2	0.46	6.94	0.39	2.93e-11	Bipolar disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22435810	chr17:18164253	SMCR7	0.68	7.66	0.43	3.42e-13	Gut microbiome composition (summer);
CESC	cis	rs662064	0.962	rs660725	chr1:10557544	A/G	cg20482658	chr1:10539492	PEX14	-0.36	-7.09	-0.4	1.24e-11	Asthma;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg11592951	chr7:100472745	SRRT	-0.49	-6.6	-0.38	2.19e-10	Fibrinogen levels;
CESC	cis	rs3780486	0.801	rs3780495	chr9:33125942	A/C	cg13443165	chr9:33130375	B4GALT1	0.47	6.79	0.39	7.28e-11	IgG glycosylation;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03689283	chr3:196668656	NCBP2;LOC152217	0.53	6.99	0.39	2.27e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs116095464	0.558	rs62344345	chr5:257420	C/T	cg12570787	chr5:219185	SDHA;CCDC127	0.51	5.28	0.31	2.76e-7	Breast cancer;
CESC	cis	rs7618501	0.633	rs4688758	chr3:50028385	G/A	cg24308560	chr3:49941425	MST1R	-0.63	-9.02	-0.48	3.95e-17	Intelligence (multi-trait analysis);
CESC	trans	rs4950322	0.580	rs1813002	chr1:146584161	C/G	cg04954894	chr8:38089920	DDHD2	-0.58	-6.28	-0.36	1.4e-9	Protein quantitative trait loci;
CESC	cis	rs801193	0.569	rs2707847	chr7:66202871	C/G	cg11764359	chr7:65958608	NA	0.73	10.55	0.54	5.73e-22	Aortic root size;
CESC	cis	rs9457247	0.534	rs9356551	chr6:167400345	T/C	cg25258033	chr6:167368657	RNASET2	-0.37	-5.44	-0.32	1.2e-7	Crohn's disease;
CESC	cis	rs2243480	0.803	rs35268390	chr7:65416536	C/G	cg25894440	chr7:65020034	NA	-0.59	-5.23	-0.31	3.41e-7	Diabetic kidney disease;
CESC	cis	rs2115630	0.645	rs6496284	chr15:85178270	A/G	cg11189052	chr15:85197271	WDR73	-0.51	-6.78	-0.38	7.61e-11	P wave terminal force;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15503098	chr1:184723524	EDEM3	0.59	6.54	0.37	3.23e-10	Gut microbiome composition (summer);
CESC	cis	rs2635047	0.638	rs2571002	chr18:44665052	T/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.4	5.38	0.31	1.61e-7	Educational attainment;
CESC	cis	rs854765	0.647	rs62073573	chr17:17976354	G/A	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.45	5.63	0.33	4.53e-8	Total body bone mineral density;
CESC	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	22.61	0.81	8.52e-64	Prudent dietary pattern;
CESC	cis	rs7666738	0.830	rs4699600	chr4:99019429	C/G	cg03467027	chr4:99064603	C4orf37	0.46	5.81	0.34	1.8e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6089584	1.000	rs6089581	chr20:60562394	G/A	cg24733560	chr20:60626293	TAF4	0.4	5.77	0.33	2.15e-8	Body mass index;
CESC	cis	rs4973397	0.765	rs13030174	chr2:232271284	A/C	cg09339159	chr2:232260559	B3GNT7	0.51	5.22	0.31	3.56e-7	Anti-saccade response;
CESC	cis	rs2354432	0.607	rs12402309	chr1:146721983	T/A	cg25205988	chr1:146714368	CHD1L	-1.03	-8.98	-0.48	5.06e-17	Mitochondrial DNA levels;
CESC	cis	rs72945132	0.882	rs12099016	chr11:70195161	C/G	cg14191688	chr11:70257035	CTTN	0.41	5.13	0.3	5.6e-7	Coronary artery disease;
CESC	cis	rs1881797	1.000	rs1881797	chr1:247689532	A/G	cg18198730	chr1:247681584	NA	0.56	8.31	0.45	5.01e-15	Acute lymphoblastic leukemia (childhood);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14684917	chr11:62380363	EML3;ROM1	0.59	6.84	0.39	5.61e-11	Gut microbiome composition (summer);
CESC	trans	rs60843830	0.550	rs300751	chr2:209063	A/C	cg06230206	chr11:126456119	KIRREL3	0.37	6.63	0.38	1.85e-10	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs72781680	0.611	rs55868657	chr2:24295385	G/A	cg08917208	chr2:24149416	ATAD2B	0.55	5.22	0.31	3.56e-7	Lymphocyte counts;
CESC	cis	rs818427	0.593	rs448613	chr5:112210966	T/C	cg07820702	chr5:112228657	REEP5	0.41	5.42	0.32	1.35e-7	Total body bone mineral density;
CESC	cis	rs9457247	0.663	rs2237274	chr6:167442995	C/G	cg23791538	chr6:167370224	RNASET2	-0.57	-7.7	-0.43	2.73e-13	Crohn's disease;
CESC	cis	rs9916302	0.904	rs11078897	chr17:37415870	C/T	cg07936489	chr17:37558343	FBXL20	-0.79	-11.07	-0.56	1.19e-23	Glomerular filtration rate (creatinine);
CESC	cis	rs1707322	1.000	rs4660903	chr1:46457601	A/G	cg05343316	chr1:45956843	TESK2	0.44	5.42	0.32	1.36e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs1957429	0.808	rs6573581	chr14:65331955	G/A	cg23373153	chr14:65346875	NA	0.88	9.2	0.49	1.13e-17	Pediatric areal bone mineral density (radius);
CESC	cis	rs59918340	0.738	rs3739235	chr8:142229145	A/G	cg23750338	chr8:142222470	SLC45A4	0.62	9.26	0.49	7.03e-18	Immature fraction of reticulocytes;
CESC	cis	rs1538970	0.851	rs61788285	chr1:45919234	A/C	cg06784218	chr1:46089804	CCDC17	0.35	5.52	0.32	8.19e-8	Platelet count;
CESC	cis	rs11122272	0.668	rs2472261	chr1:231505701	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.49	-6.53	-0.37	3.26e-10	Hemoglobin concentration;
CESC	cis	rs9733	0.596	rs72702570	chr1:150688196	C/T	cg22823121	chr1:150693482	HORMAD1	0.48	7.11	0.4	1.11e-11	Tonsillectomy;
CESC	cis	rs9894429	0.816	rs7406040	chr17:79597583	A/C	cg18240062	chr17:79603768	NPLOC4	0.9	13.2	0.63	6.66e-31	Eye color traits;
CESC	cis	rs17376456	1.000	rs61132622	chr5:93539684	G/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.61	5.21	0.3	3.8e-7	Diabetic retinopathy;
CESC	cis	rs1552244	0.882	rs17081288	chr3:10042113	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.76	-9.68	-0.51	3.46e-19	Alzheimer's disease;
CESC	trans	rs9987353	0.840	rs329994	chr8:9123233	A/G	cg00814883	chr7:100076585	TSC22D4	-0.46	-6.08	-0.35	4.29e-9	Recombination measurement;
CESC	cis	rs798554	1.000	rs798559	chr7:2758341	T/C	cg18446336	chr7:2847575	GNA12	-0.37	-5.63	-0.33	4.5e-8	Height;
CESC	cis	rs6541297	0.703	rs671682	chr1:230313651	C/G	cg20703242	chr1:230279135	GALNT2	-0.43	-5.6	-0.33	5.46e-8	Coronary artery disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg23603076	chr14:24605279	PSME1	-0.46	-6.26	-0.36	1.54e-9	Fibrinogen levels;
CESC	cis	rs425277	1.000	rs262654	chr1:2089526	G/A	cg04315214	chr1:2043799	PRKCZ	-0.39	-5.37	-0.31	1.72e-7	Height;
CESC	cis	rs6570726	0.905	rs406799	chr6:145821837	G/C	cg05347473	chr6:146136440	FBXO30	0.49	6.71	0.38	1.2e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs73206853	0.764	rs56273026	chr12:110901691	A/C	cg12870014	chr12:110450643	ANKRD13A	0.62	5.15	0.3	5.18e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	trans	rs9596009	0.591	rs9595995	chr13:49340625	T/G	cg13176070	chr2:32503943	YIPF4	0.52	6.08	0.35	4.25e-9	Cough in response to angiotensin-converting enzyme inhibitor drugs;
CESC	cis	rs2235544	0.664	rs55766128	chr1:54477726	T/G	cg09175620	chr1:54484536	LDLRAD1	-0.29	-5.09	-0.3	6.64e-7	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
CESC	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg07157834	chr1:205819609	PM20D1	0.79	12.97	0.62	4.05e-30	Menarche (age at onset);
CESC	cis	rs35110281	0.667	rs4819286	chr21:45120121	G/A	cg01579765	chr21:45077557	HSF2BP	-0.54	-9.03	-0.49	3.52e-17	Mean corpuscular volume;
CESC	cis	rs1218582	0.772	rs877343	chr1:154910012	A/G	cg03351412	chr1:154909251	PMVK	0.68	9.09	0.49	2.37e-17	Prostate cancer;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg26996458	chr8:141636297	EIF2C2	0.43	6.0	0.35	6.38e-9	Fibrinogen levels;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg11614198	chr11:47364636	MYBPC3	0.44	6.18	0.35	2.35e-9	Fibrinogen levels;
CESC	cis	rs11583043	0.708	rs1060481	chr1:101546699	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.51	5.44	0.32	1.21e-7	Ulcerative colitis;Inflammatory bowel disease;
CESC	cis	rs3204270	0.714	rs79243595	chr17:79681220	T/C	cg18367735	chr17:79674897	NA	0.74	6.62	0.38	1.99e-10	Dental caries;
CESC	cis	rs950169	0.959	rs66801143	chr15:84736657	C/T	cg17507749	chr15:85114479	UBE2QP1	0.64	7.1	0.4	1.17e-11	Schizophrenia;
CESC	cis	rs933688	0.532	rs997737	chr5:90567031	C/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	-0.43	-5.08	-0.3	7.06e-7	Smoking behavior;
CESC	trans	rs3749237	0.964	rs1799843	chr3:49849723	G/A	cg21659725	chr3:3221576	CRBN	0.53	6.38	0.36	8.01e-10	Resting heart rate;
CESC	trans	rs7980799	0.682	rs4931719	chr12:33602986	G/A	cg26384229	chr12:38710491	ALG10B	-0.56	-8.03	-0.44	3.21e-14	Heart rate;Heart rate variability traits (RMSSD);
CESC	cis	rs6598955	1.000	rs6598955	chr1:26619649	C/T	cg04990556	chr1:26633338	UBXN11	0.81	10.86	0.55	5.7e-23	Obesity-related traits;
CESC	cis	rs8017423	0.967	rs7147809	chr14:90715025	A/G	cg14092571	chr14:90743983	NA	-0.58	-8.72	-0.47	3.01e-16	Mortality in heart failure;
CESC	cis	rs10504229	0.906	rs116341227	chr8:58190532	G/C	cg05313129	chr8:58192883	C8orf71	-0.55	-6.49	-0.37	4.09e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs2797160	0.904	rs1739366	chr6:126007409	T/C	cg05901451	chr6:126070800	HEY2	0.46	6.48	0.37	4.35e-10	Endometrial cancer;
CESC	cis	rs8060686	0.641	rs79577483	chr16:68036939	A/G	cg26727032	chr16:67993705	SLC12A4	-0.51	-5.88	-0.34	1.25e-8	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs875971	0.862	rs937494	chr7:65764678	T/A	cg10691866	chr7:65817282	TPST1	0.31	5.32	0.31	2.25e-7	Aortic root size;
CESC	trans	rs629535	0.859	rs55803226	chr8:70108965	T/C	cg21567404	chr3:27674614	NA	-0.88	-10.23	-0.53	6.38e-21	Dupuytren's disease;
CESC	cis	rs10504229	1.000	rs74546828	chr8:58171678	A/G	cg22535103	chr8:58192502	C8orf71	-1.05	-13.27	-0.63	3.63e-31	Developmental language disorder (linguistic errors);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg12843872	chr7:90894352	FZD1	0.5	6.61	0.38	2.13e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs367943	0.966	rs348947	chr5:112822795	C/G	cg12552261	chr5:112820674	MCC	-0.63	-7.96	-0.44	4.96e-14	Type 2 diabetes;
CESC	cis	rs8077889	0.917	rs4793037	chr17:41914826	C/T	cg26893861	chr17:41843967	DUSP3	0.84	10.56	0.54	5.63e-22	Triglycerides;
CESC	cis	rs4523957	0.890	rs2281727	chr17:2117945	A/G	cg16513277	chr17:2031491	SMG6	-0.63	-8.71	-0.47	3.39e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13457403	chr21:44313401	NDUFV3	0.57	6.48	0.37	4.34e-10	Gut microbiome composition (summer);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg14056620	chr7:44836144	PPIA	-0.49	-6.2	-0.36	2.12e-9	Ulcerative colitis;
CESC	cis	rs12497850	0.627	rs4974078	chr3:49009386	C/T	cg06212747	chr3:49208901	KLHDC8B	0.53	7.21	0.4	5.95e-12	Parkinson's disease;
CESC	cis	rs9902453	0.904	rs4077465	chr17:28300144	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.68	8.99	0.48	4.87e-17	Coffee consumption (cups per day);
CESC	cis	rs8103278	1.000	rs36091860	chr19:46312880	G/A	cg12641515	chr19:46296257	DMWD	-0.52	-5.77	-0.33	2.22e-8	Coronary artery disease;
CESC	cis	rs2777491	0.915	rs8032838	chr15:41605632	G/A	cg02330683	chr15:41787940	ITPKA	0.45	6.56	0.37	2.73e-10	Ulcerative colitis;
CESC	cis	rs9300255	0.602	rs1790098	chr12:123655481	A/C	cg05973401	chr12:123451056	ABCB9	0.54	6.04	0.35	5.31e-9	Neutrophil percentage of white cells;
CESC	cis	rs7808935	0.628	rs12666447	chr7:27937267	C/T	cg05786569	chr7:27702416	HIBADH	0.53	5.83	0.34	1.58e-8	Prostate cancer;
CESC	cis	rs1046896	0.553	rs8073413	chr17:80836005	G/A	cg19046167	chr17:80928561	B3GNTL1	0.48	5.72	0.33	2.84e-8	Glycated hemoglobin levels;
CESC	trans	rs4843747	0.518	rs4072777	chr16:88107030	G/A	cg26811252	chr16:29126840	RRN3P2	0.67	9.46	0.5	1.77e-18	Menopause (age at onset);
CESC	cis	rs12142240	0.731	rs6658556	chr1:46844180	A/C	cg10495392	chr1:46806563	NSUN4	0.55	5.94	0.34	9.08e-9	Menopause (age at onset);
CESC	cis	rs2652822	0.555	rs77171305	chr15:63536230	C/A	cg02713581	chr15:63449717	RPS27L	0.49	6.16	0.35	2.69e-9	Metabolic traits;
CESC	cis	rs55788414	0.932	rs59201365	chr16:81185681	C/G	cg06400318	chr16:81190750	PKD1L2	-0.57	-6.53	-0.37	3.31e-10	Left ventricular obstructive tract defect (maternal effect);
CESC	cis	rs7811142	1.000	rs73161759	chr7:100009994	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.1	10.82	0.55	7.72e-23	Platelet count;
CESC	cis	rs9611565	0.694	rs79008	chr22:41850500	C/T	cg17376030	chr22:41985996	PMM1	0.73	8.03	0.44	3.14e-14	Vitiligo;
CESC	cis	rs7772486	0.754	rs4896839	chr6:146019689	T/G	cg05347473	chr6:146136440	FBXO30	-0.55	-6.66	-0.38	1.6e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6088590	1.000	rs6119516	chr20:33328024	C/T	cg24642439	chr20:33292090	TP53INP2	0.83	11.67	0.58	1.1e-25	Coronary artery disease;
CESC	cis	rs172166	0.694	rs1631552	chr6:28089699	C/A	cg23161317	chr6:28129485	ZNF389	0.4	5.72	0.33	2.81e-8	Cardiac Troponin-T levels;
CESC	cis	rs698761	0.519	rs10427177	chr2:44510179	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.52	5.08	0.3	7.25e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs875971	0.964	rs6945032	chr7:65922486	C/T	cg10691866	chr7:65817282	TPST1	-0.34	-5.62	-0.33	4.93e-8	Aortic root size;
CESC	cis	rs11190604	0.943	rs11190581	chr10:102243387	T/G	cg07080220	chr10:102295463	HIF1AN	0.55	5.44	0.32	1.21e-7	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs1552244	0.882	rs55962400	chr3:10044457	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.83	10.05	0.53	2.43e-20	Alzheimer's disease;
CESC	cis	rs910316	0.763	rs2080201	chr14:75629972	C/T	cg08847533	chr14:75593920	NEK9	-0.87	-14.36	-0.66	5.69e-35	Height;
CESC	cis	rs67311347	0.911	rs6773917	chr3:40469254	G/T	cg09455208	chr3:40491958	NA	0.43	7.34	0.41	2.65e-12	Renal cell carcinoma;
CESC	cis	rs6500395	1.000	rs7197732	chr16:48575878	G/A	cg04672837	chr16:48644449	N4BP1	0.45	5.4	0.31	1.51e-7	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs1413885	0.516	rs9326063	chr1:65835911	T/C	cg14976592	chr1:65886160	LEPROT;LEPR	0.46	5.97	0.34	7.68e-9	Anticoagulant levels;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg15247144	chr16:31213730	PYCARD	0.48	6.06	0.35	4.69e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs3793683	0.928	rs2148666	chr10:134553785	A/G	cg27286337	chr10:134555280	INPP5A	0.91	14.94	0.68	4.94e-37	Migraine;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06722069	chr3:113822382	NA	-0.62	-7.26	-0.41	4.23e-12	Gut microbiome composition (summer);
CESC	trans	rs2727020	0.558	rs1164675	chr11:49325972	C/T	cg03929089	chr4:120376271	NA	0.72	9.89	0.52	7.86e-20	Coronary artery disease;
CESC	cis	rs780096	0.546	rs2293571	chr2:27729480	C/T	cg12648201	chr2:27665141	KRTCAP3	-0.33	-6.08	-0.35	4.17e-9	Total body bone mineral density;
CESC	cis	rs9788333	0.695	rs12871086	chr13:21890224	A/T	cg06138931	chr13:21896616	NA	0.56	7.72	0.43	2.36e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs2295499	0.643	rs35424748	chr4:2669054	T/C	cg27239842	chr4:2403781	ZFYVE28	-0.31	-5.12	-0.3	5.78e-7	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
CESC	cis	rs447735	0.587	rs258336	chr16:89720831	A/C	cg04240660	chr16:89714849	CHMP1A	-0.37	-5.08	-0.3	7.25e-7	Hemoglobin concentration;
CESC	trans	rs7726839	0.526	rs55647623	chr5:567747	T/C	cg25482853	chr8:67687455	SGK3	0.95	10.36	0.54	2.45e-21	Obesity-related traits;
CESC	cis	rs12497850	0.897	rs9884022	chr3:48956862	G/C	cg06212747	chr3:49208901	KLHDC8B	0.68	9.35	0.5	3.77e-18	Parkinson's disease;
CESC	cis	rs523522	0.962	rs4766968	chr12:120947788	G/C	cg12219531	chr12:120966889	COQ5	0.75	9.99	0.52	3.7e-20	High light scatter reticulocyte count;
CESC	cis	rs4713118	0.516	rs4713142	chr6:28106347	T/G	cg12963246	chr6:28129442	ZNF389	0.57	7.78	0.43	1.65e-13	Parkinson's disease;
CESC	cis	rs2742234	0.590	rs2293020	chr10:43692887	A/G	cg15436174	chr10:43711423	RASGEF1A	0.46	5.31	0.31	2.31e-7	Hirschsprung disease;
CESC	cis	rs847577	0.722	rs7790120	chr7:97712831	C/A	cg24562669	chr7:97807699	LMTK2	0.63	10.27	0.53	4.67e-21	Breast cancer;
CESC	cis	rs7680126	0.632	rs6834645	chr4:10150174	G/A	cg11266682	chr4:10021025	SLC2A9	-0.52	-6.56	-0.37	2.77e-10	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	cis	rs727505	1.000	rs28702851	chr7:124442991	G/A	cg23710748	chr7:124431027	NA	-0.47	-7.22	-0.41	5.56e-12	Lewy body disease;
CESC	cis	rs4595586	1.000	rs1523118	chr12:39229699	C/T	cg26384229	chr12:38710491	ALG10B	-0.38	-5.31	-0.31	2.35e-7	Morning vs. evening chronotype;
CESC	cis	rs1577917	0.958	rs11755048	chr6:86514334	A/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.52	-6.47	-0.37	4.58e-10	Response to antipsychotic treatment;
CESC	cis	rs9837602	0.529	rs793494	chr3:99508768	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.59	-9.56	-0.51	8.49e-19	Breast cancer;
CESC	cis	rs4665809	1.000	rs6546744	chr2:26302161	A/G	cg26314531	chr2:26401878	FAM59B	-0.61	-6.93	-0.39	3.18e-11	Gut microbiome composition (summer);
CESC	cis	rs7647973	1.000	rs13322887	chr3:49555583	G/A	cg06212747	chr3:49208901	KLHDC8B	-0.6	-7.97	-0.44	4.76e-14	Menarche (age at onset);
CESC	cis	rs3845702	1.000	rs3738943	chr2:180846743	G/T	cg01881094	chr2:180872142	CWC22	-0.64	-6.78	-0.38	7.99e-11	Schizophrenia;
CESC	cis	rs12900413	0.687	rs12903462	chr15:90304075	C/T	cg24249390	chr15:90295951	MESP1	-0.41	-5.63	-0.33	4.5e-8	Coronary artery aneurysm in Kawasaki disease;
CESC	trans	rs8014204	0.816	rs28426374	chr14:75346740	C/T	cg22117143	chr9:13251431	MPDZ	0.38	6.01	0.35	6.09e-9	Caffeine consumption;
CESC	cis	rs208520	0.754	rs851593	chr6:66875783	C/T	cg07460842	chr6:66804631	NA	1.01	12.99	0.62	3.45e-30	Exhaled nitric oxide output;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12699174	chr1:156024477	ROBLD3;UBQLN4	0.56	6.01	0.35	6.08e-9	Gut microbiome composition (summer);
CESC	cis	rs4237845	0.537	rs2002275	chr12:58283385	A/G	cg02175503	chr12:58329896	NA	0.46	5.72	0.33	2.87e-8	Intelligence (multi-trait analysis);
CESC	cis	rs13095912	1.000	rs35497918	chr3:185310312	C/T	cg11274856	chr3:185301563	NA	0.37	6.05	0.35	5.02e-9	Systolic blood pressure;
CESC	cis	rs6011002	1.000	rs75897888	chr20:62303558	C/G	cg15212369	chr20:62274085	STMN3	-0.57	-5.16	-0.3	4.82e-7	Dental caries;
CESC	cis	rs2228479	0.717	rs1007932	chr16:89838541	C/T	cg04013166	chr16:89971882	TCF25	0.79	8.18	0.45	1.21e-14	Skin colour saturation;
CESC	trans	rs3942852	0.568	rs2904315	chr11:48109948	C/T	cg03929089	chr4:120376271	NA	0.68	8.4	0.46	2.68e-15	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs6433857	0.536	rs12464424	chr2:181349137	A/G	cg23363182	chr2:181467187	NA	-0.4	-5.85	-0.34	1.43e-8	Body mass index;
CESC	cis	rs6500395	1.000	rs7201196	chr16:48674030	C/T	cg04672837	chr16:48644449	N4BP1	0.51	6.31	0.36	1.16e-9	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs7089973	0.604	rs7904188	chr10:116610271	G/C	cg25233709	chr10:116636983	FAM160B1	0.38	6.08	0.35	4.13e-9	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs4555082	0.874	rs760270	chr14:105737785	A/G	cg06808227	chr14:105710500	BRF1	-0.6	-6.93	-0.39	3.25e-11	Mean platelet volume;Platelet distribution width;
CESC	cis	rs6696846	0.729	rs72757512	chr1:205079203	G/A	cg00857998	chr1:205179979	DSTYK	0.54	7.21	0.41	5.81e-12	Red blood cell count;
CESC	trans	rs916888	0.773	rs538628	chr17:44787313	G/C	cg07870213	chr5:140052090	DND1	0.63	6.73	0.38	1.05e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs736408	0.521	rs13074853	chr3:52779801	T/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	5.69	0.33	3.39e-8	Bipolar disorder;
CESC	cis	rs3785574	0.962	rs62077509	chr17:61848973	A/G	cg06420487	chr17:61919686	SMARCD2	0.46	5.52	0.32	8.05e-8	Height;
CESC	cis	rs7826238	0.653	rs2979202	chr8:8344127	T/C	cg15556689	chr8:8085844	FLJ10661	0.51	6.31	0.36	1.18e-9	Systolic blood pressure;
CESC	cis	rs4148883	0.504	rs2000864	chr4:100123776	A/C	cg12011299	chr4:100065546	ADH4	0.48	6.65	0.38	1.71e-10	Alcohol dependence;
CESC	cis	rs2011503	0.882	rs72999030	chr19:19364240	A/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.54	5.73	0.33	2.76e-8	Bipolar disorder;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg12477012	chr1:46049214	NASP	0.5	6.27	0.36	1.46e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs13108904	0.870	rs4974541	chr4:1244037	A/G	cg00684032	chr4:1343700	KIAA1530	0.36	5.4	0.31	1.49e-7	Obesity-related traits;
CESC	cis	rs4237845	0.537	rs12312955	chr12:58265223	A/G	cg00677455	chr12:58241039	CTDSP2	0.78	10.45	0.54	1.23e-21	Intelligence (multi-trait analysis);
CESC	cis	rs9611565	0.625	rs12483991	chr22:41935285	A/G	cg17376030	chr22:41985996	PMM1	0.49	5.66	0.33	3.98e-8	Vitiligo;
CESC	cis	rs4595586	0.545	rs1356265	chr12:39403696	A/G	cg26384229	chr12:38710491	ALG10B	0.54	7.66	0.43	3.57e-13	Morning vs. evening chronotype;
CESC	cis	rs2415984	0.579	rs754962	chr14:46962719	T/C	cg14871534	chr14:47121158	RPL10L	0.35	5.32	0.31	2.24e-7	Number of children ever born;
CESC	cis	rs8180040	0.726	rs4682837	chr3:46999707	C/T	cg27129171	chr3:47204927	SETD2	0.67	9.74	0.51	2.32e-19	Colorectal cancer;
CESC	cis	rs897984	0.568	rs67264578	chr16:30879395	G/A	cg02466173	chr16:30829666	NA	-0.47	-6.87	-0.39	4.6e-11	Dementia with Lewy bodies;
CESC	cis	rs4819052	0.851	rs2838837	chr21:46665988	C/T	cg11663144	chr21:46675770	NA	-0.62	-9.72	-0.51	2.66e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs7937682	0.889	rs3017767	chr11:111508098	A/G	cg22437258	chr11:111473054	SIK2	0.7	9.35	0.5	3.83e-18	Primary sclerosing cholangitis;
CESC	cis	rs72781680	0.898	rs72796154	chr2:23933839	G/A	cg20701182	chr2:24300061	SF3B14	0.77	6.82	0.39	6.04e-11	Lymphocyte counts;
CESC	trans	rs9858542	0.953	rs35115732	chr3:49475155	T/C	cg21659725	chr3:3221576	CRBN	-0.56	-6.63	-0.38	1.86e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs28374715	0.681	rs8037574	chr15:41630770	T/C	cg20272979	chr15:41787780	ITPKA	0.39	5.21	0.3	3.76e-7	Ulcerative colitis;
CESC	cis	rs11190604	1.000	rs9420797	chr10:102331147	C/T	cg07080220	chr10:102295463	HIF1AN	0.59	6.1	0.35	3.84e-9	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs1355223	0.583	rs2956076	chr11:34874124	T/C	cg11058730	chr11:34937778	PDHX;APIP	0.82	12.46	0.61	2.34e-28	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs2836974	0.897	rs11911112	chr21:40528346	A/C	cg17971929	chr21:40555470	PSMG1	1.04	16.44	0.71	2.36e-42	Cognitive function;
CESC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg22081084	chr1:89990230	LRRC8B	-0.44	-6.05	-0.35	5.01e-9	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs5769765	0.773	rs7290751	chr22:50318312	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.63	-6.42	-0.37	6.2e-10	Schizophrenia;
CESC	cis	rs1552244	1.000	rs112509186	chr3:10156533	A/G	cg08888203	chr3:10149979	C3orf24	0.44	5.71	0.33	3.09e-8	Alzheimer's disease;
CESC	trans	rs7088591	0.867	rs58666115	chr10:59735805	C/G	cg10559231	chr5:14188039	TRIO	0.76	6.28	0.36	1.35e-9	Blood pressure;
CESC	cis	rs4862750	0.872	rs9998172	chr4:187898773	T/C	cg11301795	chr4:187892539	NA	-0.75	-12.51	-0.61	1.63e-28	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs963731	0.649	rs6725356	chr2:39238395	C/G	cg04010122	chr2:39346883	SOS1	0.75	5.75	0.33	2.51e-8	Corticobasal degeneration;
CESC	cis	rs60154123	0.554	rs1338290	chr1:210465467	G/A	cg22029157	chr1:209979665	IRF6	0.5	5.92	0.34	9.68e-9	Coronary artery disease;
CESC	cis	rs2109514	0.585	rs3779512	chr7:116171063	T/G	cg04696780	chr7:116139425	CAV2	-0.32	-5.81	-0.34	1.8e-8	Prevalent atrial fibrillation;
CESC	cis	rs2000999	0.778	rs12445401	chr16:72148419	A/G	cg16558253	chr16:72132732	DHX38	-0.54	-6.58	-0.37	2.53e-10	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
CESC	cis	rs7656342	0.622	rs10009838	chr4:9833882	G/A	cg00071950	chr4:10020882	SLC2A9	0.4	5.4	0.31	1.49e-7	Gut microbiota (bacterial taxa);
CESC	cis	rs1707322	0.964	rs1768802	chr1:46547868	A/G	cg06784218	chr1:46089804	CCDC17	-0.33	-5.57	-0.32	6.35e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs3741404	0.665	rs594461	chr11:63872543	A/G	cg18225595	chr11:63971243	STIP1	0.52	6.76	0.38	8.53e-11	Platelet count;
CESC	cis	rs9522267	0.535	rs11069898	chr13:112231512	C/T	cg10483660	chr13:112241077	NA	-0.33	-5.83	-0.34	1.65e-8	Hepatitis;
CESC	cis	rs2243480	1.000	rs6970243	chr7:65388490	C/A	cg12463550	chr7:65579703	CRCP	0.7	5.58	0.32	5.87e-8	Diabetic kidney disease;
CESC	cis	rs7953249	0.656	rs2251468	chr12:121405126	A/C	cg25281562	chr12:121454272	C12orf43	0.45	5.64	0.33	4.35e-8	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
CESC	cis	rs34375054	0.526	rs2343638	chr12:125677122	G/C	cg05341575	chr12:125625032	AACS	-0.36	-5.23	-0.31	3.51e-7	Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs3820068	0.603	rs72645900	chr1:15931980	A/T	cg13390004	chr1:15929781	NA	0.34	5.45	0.32	1.13e-7	Systolic blood pressure;
CESC	cis	rs959260	1.000	rs9900002	chr17:73382018	T/A	cg12999837	chr17:73267436	MIF4GD	-0.48	-5.58	-0.32	5.89e-8	Systemic lupus erythematosus;
CESC	trans	rs66573146	1.000	rs6812391	chr4:6963893	G/A	cg07817883	chr1:32538562	TMEM39B	1.51	9.21	0.49	1.06e-17	Granulocyte percentage of myeloid white cells;
CESC	cis	rs11785400	1.000	rs4297023	chr8:143733307	C/A	cg10596483	chr8:143751796	JRK	0.42	5.53	0.32	7.59e-8	Schizophrenia;
CESC	cis	rs7259376	0.934	rs7253315	chr19:22594439	C/T	cg02657401	chr19:22469223	NA	0.26	5.12	0.3	5.94e-7	Menopause (age at onset);
CESC	cis	rs6502050	0.835	rs12600852	chr17:80104593	G/A	cg23985595	chr17:80112537	CCDC57	-0.42	-6.57	-0.37	2.72e-10	Life satisfaction;
CESC	cis	rs11792861	0.888	rs72607168	chr9:111832192	G/C	cg13535736	chr9:111863775	C9orf5	-0.51	-6.84	-0.39	5.58e-11	Menarche (age at onset);
CESC	cis	rs71335811	1	rs71335811	chr19:49130070	TC/T	cg06677660	chr19:49140777	SEC1;DBP	-0.43	-5.27	-0.31	2.9e-7	Myeloid white cell count;
CESC	cis	rs79057730	0.599	rs4721086	chr7:821123	G/A	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.73	6.83	0.39	5.78e-11	Initial pursuit acceleration;
CESC	cis	rs950173	1.000	rs13000153	chr2:172586067	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.87	-6.48	-0.37	4.53e-10	Hippocampal volume;
CESC	cis	rs6089584	0.893	rs6089306	chr20:60574868	G/A	cg24733560	chr20:60626293	TAF4	0.38	5.46	0.32	1.09e-7	Body mass index;
CESC	cis	rs208520	0.690	rs1738970	chr6:66809491	T/G	cg07460842	chr6:66804631	NA	-0.98	-13.32	-0.63	2.47e-31	Exhaled nitric oxide output;
CESC	cis	rs61931739	0.890	rs1705753	chr12:34144594	C/T	cg19457237	chr12:34500585	NA	-0.36	-5.06	-0.3	7.79e-7	Morning vs. evening chronotype;
CESC	cis	rs798554	0.759	rs1182189	chr7:2869522	G/A	cg09658497	chr7:2847517	GNA12	-0.42	-5.81	-0.34	1.81e-8	Height;
CESC	cis	rs899997	0.862	rs11072787	chr15:78972977	T/C	cg04896959	chr15:78267971	NA	-0.36	-5.23	-0.31	3.47e-7	Coronary artery disease or large artery stroke;
CESC	cis	rs2439831	1.000	rs2256764	chr15:43735763	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.8	9.98	0.52	4.07e-20	Lung cancer in ever smokers;
CESC	cis	rs853679	0.550	rs1233701	chr6:28168726	C/G	cg19592336	chr6:28129416	ZNF389	-0.53	-7.22	-0.41	5.6e-12	Depression;
CESC	cis	rs4072980	0.527	rs11210825	chr1:38446986	G/A	cg18451016	chr1:38461880	NA	0.42	6.4	0.37	6.9e-10	Coronary artery disease;
CESC	cis	rs9911578	0.935	rs9893351	chr17:57023326	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.38	5.05	0.3	8.18e-7	Intelligence (multi-trait analysis);
CESC	cis	rs17486696	0.655	rs62352418	chr4:165680688	T/C	cg01215651	chr4:165675138	NA	0.63	6.64	0.38	1.8e-10	Positive affect;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg06310300	chr7:100076089	TSC22D4	-0.46	-6.94	-0.39	2.93e-11	Gambling;
CESC	cis	rs796364	0.806	rs79897806	chr2:201073968	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.71	-5.91	-0.34	1.07e-8	Schizophrenia;
CESC	cis	rs9916302	0.808	rs12943928	chr17:37611330	G/A	cg07936489	chr17:37558343	FBXL20	-0.81	-11.96	-0.59	1.17e-26	Glomerular filtration rate (creatinine);
CESC	cis	rs6951245	0.744	rs1133122	chr7:1192572	C/A	cg04025307	chr7:1156635	C7orf50	0.42	5.2	0.3	4.09e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs1707322	1.000	rs9793167	chr1:46446800	G/A	cg03146154	chr1:46216737	IPP	0.72	9.82	0.52	1.31e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs853679	0.517	rs9468286	chr6:28079428	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.58	-6.75	-0.38	9.45e-11	Depression;
CESC	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.62	8.09	0.44	2.22e-14	Prudent dietary pattern;
CESC	cis	rs11098499	0.909	rs10026736	chr4:120384322	G/C	cg09307838	chr4:120376055	NA	0.93	12.95	0.62	4.87e-30	Corneal astigmatism;
CESC	cis	rs2180341	0.842	rs9372860	chr6:127546605	G/A	cg27446573	chr6:127587934	RNF146	0.94	11.41	0.57	8.78e-25	Breast cancer;
CESC	cis	rs10751667	0.600	rs1128413	chr11:1010694	C/T	cg20946044	chr11:1010712	AP2A2	-0.51	-6.73	-0.38	1.06e-10	Alzheimer's disease (late onset);
CESC	cis	rs1062177	1.000	rs12654573	chr5:151207473	T/G	cg00977110	chr5:151150581	G3BP1	0.6	6.48	0.37	4.45e-10	Preschool internalizing problems;
CESC	cis	rs2425143	1.000	rs2425093	chr20:34306875	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.63	6.75	0.38	9.35e-11	Blood protein levels;
CESC	cis	rs769267	0.930	rs1063966	chr19:19616742	G/A	cg03709012	chr19:19516395	GATAD2A	1.01	15.89	0.7	2.1e-40	Tonsillectomy;
CESC	trans	rs6073597	1.000	rs6031980	chr20:43714384	C/T	cg06444723	chr6:135376198	HBS1L	0.48	6.47	0.37	4.82e-10	Positive affect;
CESC	cis	rs9926296	0.712	rs258332	chr16:89727683	G/A	cg04287289	chr16:89883240	FANCA	-0.46	-5.64	-0.33	4.4e-8	Vitiligo;
CESC	cis	rs854765	0.583	rs62064158	chr17:17826935	T/C	cg16928487	chr17:17741425	SREBF1	-0.57	-9.74	-0.51	2.41e-19	Total body bone mineral density;
CESC	cis	rs28829049	0.597	rs2296107	chr1:19476649	C/G	cg13387374	chr1:19411106	UBR4	0.44	5.54	0.32	7.13e-8	QRS duration in Tripanosoma cruzi seropositivity;
CESC	cis	rs875971	0.638	rs801205	chr7:66022144	C/A	cg18876405	chr7:65276391	NA	-0.57	-7.75	-0.43	1.97e-13	Aortic root size;
CESC	cis	rs3747547	0.818	rs7027014	chr9:37943571	T/C	cg13774184	chr9:37916125	SHB	-0.55	-5.56	-0.32	6.53e-8	Metabolite levels (Dihydroxy docosatrienoic acid);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg14018420	chr1:21766356	NBPF3	0.5	7.21	0.4	5.78e-12	Gut microbiota (bacterial taxa);
CESC	cis	rs12188164	1.000	rs56104584	chr5:437542	T/C	cg17553881	chr5:443987	EXOC3;C5orf55	-0.34	-5.45	-0.32	1.17e-7	Cystic fibrosis severity;
CESC	cis	rs2439831	0.867	rs2243434	chr15:43689867	A/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.86	13.04	0.63	2.26e-30	Lung cancer in ever smokers;
CESC	cis	rs5769707	0.967	rs2187891	chr22:49994094	C/T	cg20744362	chr22:50050164	C22orf34	0.43	7.08	0.4	1.31e-11	Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs10493773	0.502	rs12061951	chr1:86081453	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.43	-5.7	-0.33	3.14e-8	Urate levels in overweight individuals;
CESC	cis	rs10751667	0.666	rs6597958	chr11:978087	C/T	cg20946044	chr11:1010712	AP2A2	-0.39	-5.4	-0.31	1.48e-7	Alzheimer's disease (late onset);
CESC	cis	rs6066835	0.702	rs2073073	chr20:47269537	A/G	cg18078177	chr20:47281410	PREX1	0.76	5.19	0.3	4.2e-7	Multiple myeloma;
CESC	cis	rs3008870	0.727	rs2755270	chr1:67474503	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.62	8.04	0.44	3.01e-14	Lymphocyte percentage of white cells;
CESC	cis	rs7618915	0.547	rs6976	chr3:52728804	C/T	cg05564831	chr3:52568323	NT5DC2	0.43	6.53	0.37	3.32e-10	Bipolar disorder;
CESC	cis	rs13191362	1.000	rs73016459	chr6:163066323	C/A	cg14584255	chr6:163149320	PACRG;PARK2	0.54	5.6	0.33	5.3e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg17372223	chr3:52568218	NT5DC2	0.45	7.43	0.42	1.51e-12	Bipolar disorder;
CESC	cis	rs2243480	1.000	rs35542501	chr7:65431215	T/C	cg25894440	chr7:65020034	NA	-0.6	-5.31	-0.31	2.38e-7	Diabetic kidney disease;
CESC	cis	rs1215050	0.791	rs503863	chr4:98707663	T/C	cg05340658	chr4:99064831	C4orf37	0.5	6.37	0.36	8.34e-10	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs9309473	0.607	rs10196402	chr2:73572081	A/C	cg20560298	chr2:73613845	ALMS1	-0.47	-6.34	-0.36	9.69e-10	Metabolite levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19881174	chr18:14393244	NA	-0.53	-6.37	-0.36	8.4e-10	Gut microbiome composition (summer);
CESC	cis	rs514406	0.798	rs4351588	chr1:53263826	A/T	cg25767906	chr1:53392781	SCP2	0.51	7.27	0.41	3.98e-12	Monocyte count;
CESC	cis	rs9916302	0.653	rs4239223	chr17:37717004	T/C	cg00129232	chr17:37814104	STARD3	-0.55	-5.69	-0.33	3.39e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs360798	0.512	rs360801	chr2:62955387	C/T	cg17519650	chr2:63277830	OTX1	0.43	5.43	0.32	1.27e-7	Coronary artery disease;
CESC	cis	rs6496667	0.738	rs5020807	chr15:91043188	C/A	cg13834112	chr15:90361639	NA	0.4	5.31	0.31	2.27e-7	Rheumatoid arthritis;
CESC	cis	rs2011503	1.000	rs7252453	chr19:19654117	G/C	cg11584989	chr19:19387371	SF4	0.47	5.71	0.33	3.05e-8	Bipolar disorder;
CESC	cis	rs5753618	0.504	rs9609303	chr22:31896309	C/T	cg00478049	chr22:31556069	RNF185	-0.44	-5.12	-0.3	5.86e-7	Colorectal cancer;
CESC	cis	rs7618915	0.547	rs3755806	chr3:52643685	C/T	cg05564831	chr3:52568323	NT5DC2	-0.45	-6.87	-0.39	4.49e-11	Bipolar disorder;
CESC	cis	rs2777491	0.915	rs28526381	chr15:41621842	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.6	-8.84	-0.48	1.39e-16	Ulcerative colitis;
CESC	cis	rs7818688	0.932	rs6471505	chr8:96028625	G/A	cg16049864	chr8:95962084	TP53INP1	0.6	5.77	0.33	2.25e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs12477438	0.520	rs34766932	chr2:99737273	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.92	15.86	0.7	2.85e-40	Chronic sinus infection;
CESC	cis	rs9486719	1.000	rs2263192	chr6:96873037	C/G	cg18709589	chr6:96969512	KIAA0776	0.53	5.81	0.34	1.75e-8	Migraine;Coronary artery disease;
CESC	cis	rs939658	0.776	rs869672	chr15:79430860	G/A	cg17916960	chr15:79447300	NA	-0.39	-6.33	-0.36	1.07e-9	Refractive error;
CESC	cis	rs8180040	0.654	rs9837343	chr3:47177388	C/T	cg27129171	chr3:47204927	SETD2	0.67	10.16	0.53	1.11e-20	Colorectal cancer;
CESC	cis	rs36051895	0.560	rs1575281	chr9:5219131	T/C	cg02405213	chr9:5042618	JAK2	-0.48	-5.65	-0.33	4.09e-8	Pediatric autoimmune diseases;
CESC	cis	rs7551222	0.716	rs7541589	chr1:204542521	G/A	cg20240347	chr1:204465584	NA	-0.28	-5.64	-0.33	4.38e-8	Schizophrenia;
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg20174699	chr12:50222232	LOC100286844;NCKAP5L	0.43	6.02	0.35	5.93e-9	Vertical cup-disc ratio;
CESC	cis	rs2404602	0.669	rs9788684	chr15:77194838	A/T	cg26408565	chr15:76604113	ETFA	-0.37	-5.36	-0.31	1.79e-7	Blood metabolite levels;
CESC	cis	rs7586879	0.639	rs6722022	chr2:25098859	A/G	cg01884057	chr2:25150051	NA	0.38	7.12	0.4	1.02e-11	Body mass index;
CESC	cis	rs2540647	0.706	rs2518805	chr22:18975587	A/G	cg12798833	chr22:18958832	DGCR5	0.5	5.45	0.32	1.15e-7	Blood metabolite ratios;
CESC	cis	rs6580649	0.941	rs7296913	chr12:48488920	G/A	cg24011408	chr12:48396354	COL2A1	-0.4	-5.05	-0.3	8.15e-7	Lung cancer;
CESC	cis	rs7084402	0.967	rs3001714	chr10:60285494	A/G	cg07615347	chr10:60278583	BICC1	0.61	9.69	0.51	3.28e-19	Refractive error;
CESC	cis	rs875971	0.522	rs2949690	chr7:65483242	C/T	cg06456125	chr7:65229604	NA	-0.45	-5.98	-0.34	7.15e-9	Aortic root size;
CESC	cis	rs3733585	0.673	rs4292332	chr4:9953830	C/A	cg02734326	chr4:10020555	SLC2A9	-0.39	-5.64	-0.33	4.45e-8	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs6429082	0.846	rs2270538	chr1:235602404	G/A	cg26050004	chr1:235667680	B3GALNT2	-0.65	-8.68	-0.47	4.08e-16	Adiposity;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25139596	chr2:24270239	C2orf44	0.58	6.5	0.37	3.89e-10	Gut microbiome composition (summer);
CESC	cis	rs798554	0.797	rs798488	chr7:2802522	T/C	cg19346786	chr7:2764209	NA	-0.49	-7.06	-0.4	1.47e-11	Height;
CESC	cis	rs3733585	0.673	rs4580649	chr4:9948461	G/A	cg00071950	chr4:10020882	SLC2A9	-0.73	-11.98	-0.59	9.94e-27	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs1461503	0.512	rs3816621	chr11:122818311	A/G	cg27398637	chr11:122830231	C11orf63	-0.52	-6.95	-0.39	2.78e-11	Menarche (age at onset);
CESC	cis	rs4268898	0.662	rs9917355	chr2:24433400	C/T	cg20701182	chr2:24300061	SF3B14	0.68	7.16	0.4	7.75e-12	Asthma;
CESC	cis	rs873946	0.648	rs12766166	chr10:134556403	G/C	cg26818010	chr10:134567672	INPP5A	-0.87	-10.61	-0.55	3.9e-22	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs9733	0.596	rs6669369	chr1:150695892	C/T	cg22823121	chr1:150693482	HORMAD1	0.47	6.96	0.39	2.6e-11	Tonsillectomy;
CESC	cis	rs7072216	0.763	rs10748730	chr10:100171440	C/T	cg26618903	chr10:100175079	PYROXD2	-0.38	-5.78	-0.33	2.05e-8	Metabolite levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07094487	chr1:46751642	LRRC41	-0.54	-6.35	-0.36	9.25e-10	Gut microbiome composition (summer);
CESC	cis	rs698833	0.819	rs2340810	chr2:44536546	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	-0.51	-6.43	-0.37	6.01e-10	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs9929218	0.954	rs12599393	chr16:68829021	C/T	cg02972257	chr16:68554789	NA	0.44	5.16	0.3	4.82e-7	Colorectal cancer;
CESC	cis	rs875971	0.508	rs10258739	chr7:66062935	A/T	cg06456125	chr7:65229604	NA	-0.38	-5.22	-0.31	3.56e-7	Aortic root size;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg18885865	chr14:59655267	DAAM1	-0.49	-6.2	-0.36	2.2e-9	Fibrinogen levels;
CESC	cis	rs9443189	1.000	rs1280044	chr6:76522602	A/G	cg01950844	chr6:76311363	SENP6	-0.61	-6.28	-0.36	1.37e-9	Prostate cancer;
CESC	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg06877462	chr1:205807181	PM20D1	0.39	5.51	0.32	8.32e-8	Menarche (age at onset);
CESC	cis	rs10761750	1	rs10761750	chr10:65128619	G/A	cg01631684	chr10:65280961	REEP3	-0.42	-5.17	-0.3	4.55e-7	Vascular endothelial growth factor levels;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg11843188	chr11:102322558	TMEM123	-0.41	-6.25	-0.36	1.62e-9	Gambling;
CESC	cis	rs7249142	0.549	rs2238667	chr19:19282523	G/A	cg27384695	chr19:19271486	LOC729991-MEF2B;MEF2B	0.28	5.12	0.3	5.99e-7	IgG glycosylation;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg20150972	chr6:13574573	SIRT5	-0.46	-6.7	-0.38	1.28e-10	Fibrinogen levels;
CESC	cis	rs514406	0.861	rs7417821	chr1:53295117	A/G	cg24675658	chr1:53192096	ZYG11B	-0.55	-7.54	-0.42	7.34e-13	Monocyte count;
CESC	cis	rs12142240	0.738	rs41293277	chr1:46806550	C/T	cg10495392	chr1:46806563	NSUN4	0.59	6.36	0.36	8.9e-10	Menopause (age at onset);
CESC	cis	rs2777491	0.574	rs28700583	chr15:41714072	C/T	cg20272979	chr15:41787780	ITPKA	0.42	5.18	0.3	4.37e-7	Ulcerative colitis;
CESC	trans	rs1493916	0.905	rs34165207	chr18:31400153	G/A	cg27147174	chr7:100797783	AP1S1	-0.54	-7.32	-0.41	3e-12	Life satisfaction;
CESC	cis	rs7927592	0.956	rs7104877	chr11:68377602	G/T	cg20283391	chr11:68216788	NA	0.46	5.77	0.33	2.26e-8	Total body bone mineral density;
CESC	cis	rs7949030	0.626	rs11231154	chr11:62362293	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.6	8.27	0.45	6.45e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs10504229	1.000	rs79561699	chr8:58170601	A/G	cg24829409	chr8:58192753	C8orf71	-0.75	-9.72	-0.51	2.74e-19	Developmental language disorder (linguistic errors);
CESC	cis	rs710216	0.957	rs841563	chr1:43429520	C/T	cg03128534	chr1:43423976	SLC2A1	0.53	6.13	0.35	3.2e-9	Red cell distribution width;
CESC	cis	rs911555	0.570	rs11625397	chr14:104027557	A/G	cg12935359	chr14:103987150	CKB	0.44	6.87	0.39	4.5e-11	Intelligence (multi-trait analysis);
CESC	trans	rs877282	1.000	rs11253362	chr10:770979	G/T	cg22713356	chr15:30763199	NA	1.26	12.49	0.61	1.82e-28	Uric acid levels;
CESC	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg22535103	chr8:58192502	C8orf71	-0.93	-10.32	-0.54	3.27e-21	Developmental language disorder (linguistic errors);
CESC	cis	rs4771122	0.500	rs1049302	chr13:27998769	T/C	cg01674679	chr13:27998804	GTF3A	0.58	6.74	0.38	9.69e-11	Body mass index;
CESC	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg03188948	chr7:1209495	NA	0.57	6.61	0.38	2.06e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs6860806	0.507	rs272854	chr5:131688017	C/T	cg18758796	chr5:131593413	PDLIM4	0.39	5.25	0.31	3.06e-7	Breast cancer;
CESC	cis	rs933688	1.000	rs2059207	chr5:90731931	C/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.89	11.69	0.58	9.41e-26	Smoking behavior;
CESC	cis	rs2072732	0.861	rs72629493	chr1:2951347	G/A	cg03976712	chr1:2946727	NA	0.33	5.45	0.32	1.17e-7	Plateletcrit;
CESC	cis	rs9649213	0.613	rs10953256	chr7:97951886	G/C	cg08684580	chr7:98029266	BAIAP2L1	-0.35	-5.69	-0.33	3.38e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs6580649	0.941	rs726354	chr12:48500334	G/A	cg05342945	chr12:48394962	COL2A1	0.55	6.35	0.36	9.14e-10	Lung cancer;
CESC	cis	rs9487051	0.837	rs2356817	chr6:109642675	G/A	cg21918786	chr6:109611834	NA	-0.37	-5.39	-0.31	1.54e-7	Reticulocyte fraction of red cells;
CESC	cis	rs10129255	0.518	rs7143784	chr14:107143294	A/G	cg23076370	chr14:107095027	NA	-0.63	-9.65	-0.51	4.43e-19	Kawasaki disease;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg16609818	chr17:41622807	ETV4	-0.39	-6.05	-0.35	4.8e-9	Gambling;
CESC	cis	rs10504229	1.000	rs78953746	chr8:58170608	A/G	cg14926445	chr8:58193284	C8orf71	-0.51	-5.47	-0.32	1.06e-7	Developmental language disorder (linguistic errors);
CESC	trans	rs10241579	1.000	rs28391248	chr7:52771787	C/T	cg18715243	chr8:37658755	GPR124	-0.48	-6.04	-0.35	5.21e-9	Inhibitory control;
CESC	cis	rs6580649	0.941	rs11613485	chr12:48462455	T/C	cg24011408	chr12:48396354	COL2A1	-0.41	-5.27	-0.31	2.86e-7	Lung cancer;
CESC	trans	rs1945213	0.694	rs1384088	chr11:55848713	G/C	cg03929089	chr4:120376271	NA	-0.77	-7.3	-0.41	3.35e-12	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs75477785	1.000	rs10779515	chr1:209987632	G/A	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.84	5.54	0.32	7.21e-8	Cleft lip with or without cleft palate;
CESC	cis	rs9443645	0.901	rs2174743	chr6:79591805	G/A	cg05283184	chr6:79620031	NA	-0.44	-6.64	-0.38	1.74e-10	Intelligence (multi-trait analysis);
CESC	cis	rs2050392	0.544	rs598672	chr10:30742388	C/T	cg18806716	chr10:30721971	MAP3K8	-0.54	-8.2	-0.45	1.02e-14	Inflammatory bowel disease;
CESC	cis	rs9649465	1.000	rs10215466	chr7:123326044	G/T	cg04330084	chr7:123175371	IQUB	-0.38	-5.22	-0.31	3.69e-7	Migraine;
CESC	cis	rs2228479	0.702	rs12600047	chr16:89831630	G/A	cg04013166	chr16:89971882	TCF25	0.77	6.51	0.37	3.84e-10	Skin colour saturation;
CESC	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg22535103	chr8:58192502	C8orf71	-0.92	-10.16	-0.53	1.04e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs2425143	0.730	rs6579259	chr20:34462550	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-6.93	-0.39	3.22e-11	Blood protein levels;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg23939166	chr14:55032812	NA	-0.49	-6.87	-0.39	4.5e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs896854	0.625	rs4735335	chr8:95973327	G/C	cg13393036	chr8:95962371	TP53INP1	-0.48	-10.36	-0.54	2.51e-21	Type 2 diabetes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01402448	chr6:136571605	FAM54A	0.52	6.16	0.35	2.67e-9	Gut microbiome composition (summer);
CESC	cis	rs6570726	0.935	rs367643	chr6:145859602	A/C	cg23711669	chr6:146136114	FBXO30	0.8	11.74	0.58	6.58e-26	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6598955	0.724	rs12732295	chr1:26602251	C/T	cg04990556	chr1:26633338	UBXN11	-0.79	-11.42	-0.57	7.97e-25	Obesity-related traits;
CESC	cis	rs9910055	0.615	rs189049	chr17:42197213	A/C	cg09913183	chr17:42254507	C17orf65;ASB16	-0.69	-9.24	-0.49	8.36e-18	Total body bone mineral density;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg24141078	chr1:32671127	IQCC	-0.42	-6.17	-0.35	2.57e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs8051149	0.688	rs12444670	chr16:87870312	C/T	cg01829163	chr16:87871160	SLC7A5	-0.55	-6.91	-0.39	3.52e-11	Blood metabolite levels;
CESC	cis	rs55883249	0.957	rs62119431	chr2:9750461	G/A	cg23886495	chr2:9695866	ADAM17	0.64	5.76	0.33	2.35e-8	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
CESC	cis	rs6831352	0.819	rs1230158	chr4:99990186	T/C	cg12011299	chr4:100065546	ADH4	0.65	8.15	0.45	1.49e-14	Alcohol dependence;
CESC	cis	rs1552244	0.882	rs55962400	chr3:10044457	C/T	cg00149659	chr3:10157352	C3orf10	0.61	6.61	0.38	2.1e-10	Alzheimer's disease;
CESC	cis	rs2549003	1.000	rs2549005	chr5:131827191	C/T	cg00255919	chr5:131827918	IRF1	0.45	5.69	0.33	3.41e-8	Asthma (sex interaction);
CESC	trans	rs10776614	0.799	rs56058334	chr10:49766777	A/G	cg19218067	chr2:181235115	NA	0.49	6.0	0.35	6.35e-9	Self-employment;
CESC	cis	rs2070997	0.548	rs11244145	chr9:133674088	A/G	cg11464064	chr9:133710261	ABL1	0.63	7.29	0.41	3.66e-12	Response to amphetamines;
CESC	cis	rs2033711	0.840	rs4801590	chr19:58961813	G/C	cg11952622	chr19:58962976	ZNF324B	0.47	6.38	0.37	7.68e-10	Uric acid clearance;
CESC	cis	rs7618915	0.547	rs6768697	chr3:52703615	C/T	cg18099408	chr3:52552593	STAB1	-0.31	-5.19	-0.3	4.19e-7	Bipolar disorder;
CESC	cis	rs11098499	0.863	rs7678400	chr4:120461957	G/A	cg24375607	chr4:120327624	NA	0.44	5.35	0.31	1.89e-7	Corneal astigmatism;
CESC	cis	rs4888262	0.508	rs6564153	chr16:74658723	A/C	cg01733217	chr16:74700730	RFWD3	0.89	12.4	0.61	3.83e-28	Testicular germ cell tumor;
CESC	cis	rs2072732	0.808	rs67758087	chr1:2937031	A/G	cg03976712	chr1:2946727	NA	0.34	5.37	0.31	1.75e-7	Plateletcrit;
CESC	cis	rs2072499	0.554	rs1052067	chr1:156206121	C/T	cg25208724	chr1:156163844	SLC25A44	0.67	8.57	0.47	8.82e-16	Testicular germ cell tumor;
CESC	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.43	5.48	0.32	1.01e-7	Lymphocyte counts;
CESC	cis	rs2839186	0.739	rs2280958	chr21:47642016	C/T	cg10351095	chr21:47802916	PCNT	-0.45	-6.14	-0.35	2.97e-9	Testicular germ cell tumor;
CESC	cis	rs2204008	0.811	rs8189445	chr12:38276295	T/C	cg26384229	chr12:38710491	ALG10B	0.68	9.7	0.51	3.2e-19	Bladder cancer;
CESC	cis	rs9487051	0.872	rs7772602	chr6:109608661	C/G	cg12927641	chr6:109611667	NA	0.42	6.47	0.37	4.6e-10	Reticulocyte fraction of red cells;
CESC	cis	rs10097731	0.908	rs77317991	chr8:82032468	C/T	cg25230327	chr8:82042993	NA	-0.62	-7.14	-0.4	8.86e-12	Serum total protein level;
CESC	cis	rs8020095	0.571	rs7157394	chr14:67562769	G/C	cg19548862	chr14:67692701	FAM71D	-0.48	-5.93	-0.34	9.58e-9	Depression (quantitative trait);
CESC	cis	rs139156536	1	rs139156536	chr17:38164432	TTTTA/T	cg17467752	chr17:38218738	THRA	0.55	7.48	0.42	1.1e-12	Lymphocyte percentage of white cells;
CESC	cis	rs3845702	0.736	rs115569960	chr2:180848214	C/T	cg01881094	chr2:180872142	CWC22	1.05	8.97	0.48	5.61e-17	Schizophrenia;
CESC	cis	rs870825	0.616	rs57316663	chr4:185630011	T/C	cg04058563	chr4:185651563	MLF1IP	0.64	7.05	0.4	1.59e-11	Blood protein levels;
CESC	cis	rs7607369	0.648	rs7582193	chr2:219652532	T/C	cg02176678	chr2:219576539	TTLL4	-0.49	-8.59	-0.47	7.42e-16	Red blood cell count;Amyotrophic lateral sclerosis;
CESC	cis	rs9300255	0.639	rs941306	chr12:123715113	C/T	cg05973401	chr12:123451056	ABCB9	0.5	5.58	0.32	5.95e-8	Neutrophil percentage of white cells;
CESC	cis	rs4862750	0.914	rs11945845	chr4:187874136	T/C	cg10295955	chr4:187884368	NA	-1.0	-17.08	-0.72	1.33e-44	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs854765	0.964	rs12943202	chr17:17994332	T/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.43	-5.68	-0.33	3.61e-8	Total body bone mineral density;
CESC	cis	rs7914558	1.000	rs7920251	chr10:104950197	C/T	cg15744005	chr10:104629667	AS3MT	-0.32	-5.08	-0.3	7.12e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs6733011	0.542	rs6542860	chr2:99679376	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.44	-5.51	-0.32	8.66e-8	Bipolar disorder;
CESC	cis	rs796364	0.664	rs4673660	chr2:200915395	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.63	6.33	0.36	1.03e-9	Schizophrenia;
CESC	cis	rs6665290	0.904	rs3795449	chr1:227181838	T/G	cg10327440	chr1:227177885	CDC42BPA	-1.21	-33.12	-0.9	3.39e-96	Myeloid white cell count;
CESC	cis	rs7945705	0.719	rs2012680	chr11:8996059	G/A	cg09997546	chr11:8931473	C11orf17;ST5	-0.31	-5.16	-0.3	4.96e-7	Hemoglobin concentration;
CESC	cis	rs2014572	0.967	rs11084492	chr19:57756026	A/T	cg12963866	chr19:57752005	ZNF805	-0.49	-6.49	-0.37	4.09e-10	Hyperactive-impulsive symptoms;
CESC	cis	rs2033711	0.870	rs6510152	chr19:58953319	C/T	cg13877915	chr19:58951672	ZNF132	0.4	5.93	0.34	9.18e-9	Uric acid clearance;
CESC	cis	rs6951245	0.832	rs79808627	chr7:1092519	C/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.49	5.64	0.33	4.25e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2380220	0.872	rs7750757	chr6:95997118	A/G	cg04719120	chr6:96025338	MANEA	0.56	5.45	0.32	1.16e-7	Behavioural disinhibition (generation interaction);
CESC	cis	rs72634258	0.786	rs7523335	chr1:8180210	G/A	cg00042356	chr1:8021962	PARK7	0.5	5.43	0.32	1.29e-7	Inflammatory bowel disease;
CESC	cis	rs875971	0.862	rs778707	chr7:65857027	G/A	cg19163074	chr7:65112434	INTS4L2	-0.41	-5.11	-0.3	6.29e-7	Aortic root size;
CESC	cis	rs847577	0.748	rs940430	chr7:97716540	A/G	cg21770322	chr7:97807741	LMTK2	0.64	10.52	0.54	7.29e-22	Breast cancer;
CESC	cis	rs1448094	0.512	rs12305828	chr12:86249153	C/G	cg19622623	chr12:86230825	RASSF9	-0.46	-5.89	-0.34	1.14e-8	Major depressive disorder;
CESC	cis	rs12134245	0.776	rs12125947	chr1:91990487	T/C	cg25838465	chr1:92012736	NA	-0.6	-8.78	-0.47	2.04e-16	Breast cancer;
CESC	cis	rs7829975	0.688	rs13270194	chr8:8378102	T/C	cg06636001	chr8:8085503	FLJ10661	0.51	6.39	0.37	7.48e-10	Mood instability;
CESC	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg01238044	chr22:24384105	GSTT1	-0.46	-5.83	-0.34	1.63e-8	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs2228479	0.867	rs62052187	chr16:89973071	G/A	cg04013166	chr16:89971882	TCF25	0.71	7.01	0.4	1.94e-11	Skin colour saturation;
CESC	cis	rs10504229	0.679	rs72649119	chr8:58040301	T/C	cg22535103	chr8:58192502	C8orf71	-0.62	-6.85	-0.39	5e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs7666738	0.791	rs7660866	chr4:98961335	G/A	cg05340658	chr4:99064831	C4orf37	0.8	12.39	0.61	3.96e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1799949	0.930	rs66499067	chr17:41248484	G/C	cg23758822	chr17:41437982	NA	1.0	14.96	0.68	4.16e-37	Menopause (age at onset);
CESC	cis	rs10463316	0.894	rs6891252	chr5:150762807	G/T	cg03212797	chr5:150827313	SLC36A1	-0.55	-7.15	-0.4	8.53e-12	Metabolite levels (Pyroglutamine);
CESC	cis	rs9388451	0.657	rs4895799	chr6:126052729	C/T	cg05901451	chr6:126070800	HEY2	-0.56	-8.07	-0.44	2.44e-14	Brugada syndrome;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg05790002	chr16:82033681	SDR42E1	0.46	6.31	0.36	1.18e-9	Fibrinogen levels;
CESC	cis	rs9611565	0.592	rs5751139	chr22:42099981	G/C	cg17376030	chr22:41985996	PMM1	-0.78	-8.45	-0.46	1.98e-15	Vitiligo;
CESC	cis	rs1023500	0.505	rs134885	chr22:42673811	C/G	cg04733989	chr22:42467013	NAGA	0.61	9.21	0.49	1.01e-17	Schizophrenia;
CESC	cis	rs2120019	0.938	rs3850093	chr15:75318482	A/G	cg17294928	chr15:75287854	SCAMP5	0.71	7.78	0.43	1.65e-13	Blood trace element (Zn levels);
CESC	cis	rs791888	0.965	rs791876	chr10:89406527	G/A	cg13926569	chr10:89418898	PAPSS2	-0.4	-5.43	-0.32	1.3e-7	Magnesium levels;
CESC	cis	rs10504229	0.565	rs7010503	chr8:58147127	G/A	cg24829409	chr8:58192753	C8orf71	-0.53	-6.91	-0.39	3.55e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs35306767	0.715	rs1250891	chr10:1040159	G/C	cg26597838	chr10:835615	NA	0.68	6.33	0.36	1.04e-9	Eosinophil percentage of granulocytes;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg27158084	chr6:149813350	NA	-0.44	-6.16	-0.35	2.67e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs7208859	0.573	rs11656278	chr17:29075188	C/T	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.79e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs9902453	0.765	rs2628185	chr17:28070107	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.76	-10.2	-0.53	8.08e-21	Coffee consumption (cups per day);
CESC	cis	rs4891159	0.548	rs690414	chr18:74117840	T/C	cg24786174	chr18:74118243	ZNF516	0.85	16.07	0.7	4.75e-41	Longevity;
CESC	cis	rs7666738	0.800	rs13106995	chr4:99028790	A/T	cg05340658	chr4:99064831	C4orf37	0.83	13.1	0.63	1.43e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs62103177	0.810	rs62103197	chr18:77632923	G/A	cg12964065	chr18:77638022	KCNG2	0.58	5.36	0.31	1.78e-7	Opioid sensitivity;
CESC	cis	rs2075371	1.000	rs1421486	chr7:133985196	T/C	cg00033643	chr7:134001901	SLC35B4	0.44	5.71	0.33	3.05e-8	Mean platelet volume;
CESC	trans	rs2727020	0.734	rs1164664	chr11:49295542	T/G	cg15704280	chr7:45808275	SEPT13	0.78	10.35	0.54	2.56e-21	Coronary artery disease;
CESC	cis	rs7618501	0.602	rs2240327	chr3:50113034	C/T	cg24110177	chr3:50126178	RBM5	-0.52	-7.35	-0.41	2.41e-12	Intelligence (multi-trait analysis);
CESC	cis	rs2014572	0.967	rs10418480	chr19:57755055	C/T	cg12963866	chr19:57752005	ZNF805	-0.49	-6.55	-0.37	2.9e-10	Hyperactive-impulsive symptoms;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg12448664	chr15:85143675	ZSCAN2	0.5	6.98	0.39	2.33e-11	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs7818688	0.697	rs76815619	chr8:95981330	G/A	cg16049864	chr8:95962084	TP53INP1	0.55	5.55	0.32	6.92e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs1843834	0.505	rs4674911	chr2:225345254	A/G	cg12698349	chr2:225449008	CUL3	0.61	8.84	0.48	1.33e-16	IgE levels in asthmatics (D.p. specific);
CESC	cis	rs3859192	0.599	rs2302777	chr17:38179492	A/G	cg17344932	chr17:38183730	MED24;SNORD124	0.63	9.55	0.51	9.21e-19	White blood cell count;
CESC	cis	rs67311347	1.000	rs17078813	chr3:40434162	C/T	cg09455208	chr3:40491958	NA	0.5	8.35	0.46	3.82e-15	Renal cell carcinoma;
CESC	cis	rs9318086	0.673	rs7981928	chr13:24435180	T/G	cg25267304	chr13:24462978	PCOTH;MIPEP	0.42	5.72	0.33	2.85e-8	Myopia (pathological);
CESC	cis	rs1620921	0.505	rs1344730	chr6:161204995	G/A	cg01280913	chr6:161186852	NA	-0.4	-6.08	-0.35	4.23e-9	Lipoprotein (a) - cholesterol levels;
CESC	cis	rs6032067	0.704	rs62208374	chr20:43765628	C/T	cg10761708	chr20:43804764	PI3	0.54	6.07	0.35	4.4e-9	Blood protein levels;
CESC	trans	rs57221529	0.766	rs12519469	chr5:581772	A/G	cg25482853	chr8:67687455	SGK3	0.95	9.39	0.5	2.96e-18	Lung disease severity in cystic fibrosis;
CESC	cis	rs5757676	0.858	rs6001585	chr22:39812986	G/T	cg05872129	chr22:39784769	NA	-0.82	-9.32	-0.5	4.71e-18	IgG glycosylation;
CESC	cis	rs9926296	0.548	rs12447465	chr16:89829895	C/T	cg21285383	chr16:89894308	SPIRE2	0.32	5.85	0.34	1.48e-8	Vitiligo;
CESC	cis	rs6952407	1	rs6952407	chr7:66045512	A/G	cg14393609	chr7:65229607	NA	-0.48	-6.24	-0.36	1.75e-9	Cotinine glucuronidation;
CESC	cis	rs7618501	0.633	rs3774733	chr3:50037123	C/G	cg24110177	chr3:50126178	RBM5	-0.54	-7.34	-0.41	2.56e-12	Intelligence (multi-trait analysis);
CESC	trans	rs35110281	0.686	rs162399	chr21:44950020	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.55	7.35	0.41	2.48e-12	Mean corpuscular volume;
CESC	cis	rs9549260	0.755	rs4325426	chr13:41216437	C/A	cg21288729	chr13:41239152	FOXO1	0.65	8.62	0.47	6.27e-16	Red blood cell count;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg21005948	chr18:46065258	KIAA0427	0.44	6.08	0.35	4.13e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs7552404	0.924	rs12136754	chr1:76230232	C/A	cg03433033	chr1:76189801	ACADM	0.73	10.13	0.53	1.39e-20	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs10242455	0.571	rs56167514	chr7:99161347	A/G	cg25640893	chr7:99214727	ZNF498	0.74	5.74	0.33	2.6e-8	Blood metabolite levels;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg09359817	chr16:28503405	CLN3	-0.51	-7.36	-0.41	2.27e-12	Gambling;
CESC	cis	rs853679	0.517	rs55747925	chr6:28044337	T/C	cg23161317	chr6:28129485	ZNF389	0.5	6.31	0.36	1.19e-9	Depression;
CESC	cis	rs11997175	0.574	rs4389890	chr8:33658018	C/T	ch.8.33884649F	chr8:33765107	NA	0.71	9.31	0.5	5.04e-18	Body mass index;
CESC	cis	rs9640161	0.673	rs34489187	chr7:150044379	G/A	cg17279839	chr7:150038598	RARRES2	0.51	6.03	0.35	5.62e-9	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs9611565	0.592	rs9611613	chr22:41961831	T/C	cg17376030	chr22:41985996	PMM1	0.52	5.81	0.34	1.8e-8	Vitiligo;
CESC	cis	rs698833	0.518	rs2033951	chr2:44556298	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.47	5.1	0.3	6.62e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg02725872	chr8:58115012	NA	-0.42	-5.88	-0.34	1.25e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs8141529	0.778	rs5762795	chr22:29182500	C/A	cg02153584	chr22:29168773	CCDC117	0.67	9.68	0.51	3.72e-19	Lymphocyte counts;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17142723	chr17:41324085	NBR1	0.44	6.32	0.36	1.08e-9	Gut microbiome composition (summer);
CESC	cis	rs950776	0.648	rs57945453	chr15:78862845	C/T	cg06917634	chr15:78832804	PSMA4	0.59	7.38	0.41	2.08e-12	Sudden cardiac arrest;
CESC	cis	rs5769765	0.913	rs4824111	chr22:50284305	A/G	cg02269571	chr22:50332266	NA	0.52	6.56	0.37	2.88e-10	Schizophrenia;
CESC	cis	rs459571	0.959	rs461462	chr9:136911272	C/T	cg13789015	chr9:136890014	NCRNA00094	0.52	7.53	0.42	7.86e-13	Platelet distribution width;
CESC	cis	rs11608355	0.545	rs2302707	chr12:109893797	G/A	cg05360138	chr12:110035743	NA	0.82	8.92	0.48	7.93e-17	Neuroticism;
CESC	cis	rs4803468	1.000	rs11880539	chr19:41918949	A/C	cg08639244	chr19:41945921	ATP5SL	0.41	5.19	0.3	4.21e-7	Height;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05262316	chr6:64345491	NA	-0.43	-6.03	-0.35	5.4e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs2842992	1.000	rs2842992	chr6:160071159	G/A	cg11366901	chr6:160182831	ACAT2	0.7	8.21	0.45	9.49e-15	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs17401966	0.931	rs746881	chr1:10346810	C/T	cg15208524	chr1:10270712	KIF1B	-0.45	-5.77	-0.33	2.26e-8	Hepatocellular carcinoma;
CESC	cis	rs7044106	0.762	rs3904197	chr9:123480378	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.82	13.16	0.63	8.79e-31	Hip circumference adjusted for BMI;
CESC	cis	rs763121	0.853	rs5757181	chr22:39013522	G/A	cg06022373	chr22:39101656	GTPBP1	0.83	11.94	0.59	1.35e-26	Menopause (age at onset);
CESC	cis	rs796364	0.760	rs11690371	chr2:200989616	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.76	-6.57	-0.37	2.71e-10	Schizophrenia;
CESC	cis	rs3818285	0.655	rs2475277	chr10:111639730	C/T	cg00817464	chr10:111662876	XPNPEP1	0.48	7.5	0.42	9.91e-13	Superior crus of antihelix expression;
CESC	trans	rs1814175	0.781	rs11040681	chr11:49981654	G/T	cg03929089	chr4:120376271	NA	-0.93	-15.75	-0.7	6.66e-40	Height;
CESC	cis	rs4969178	0.965	rs12451791	chr17:76397343	G/A	cg20026190	chr17:76395443	PGS1	0.49	7.81	0.43	1.34e-13	HDL cholesterol levels;
CESC	cis	rs17253792	0.822	rs76918910	chr14:56058762	T/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.85	6.13	0.35	3.15e-9	Putamen volume;
CESC	cis	rs56114371	0.777	rs200483	chr6:27774824	C/T	cg26587870	chr6:27730563	NA	-0.53	-5.08	-0.3	7.23e-7	Breast cancer;
CESC	cis	rs6942407	0.649	rs6975202	chr7:86860382	C/A	cg02420886	chr7:86849541	C7orf23	0.55	5.2	0.3	3.92e-7	Food allergy;
CESC	cis	rs9815354	0.812	rs57209010	chr3:41854743	A/T	cg03022575	chr3:42003672	ULK4	0.7	6.34	0.36	1.01e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs2066819	1.000	rs1802236	chr12:56679751	A/G	cg26714650	chr12:56694279	CS	-1.52	-10.39	-0.54	1.95e-21	Psoriasis vulgaris;
CESC	cis	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg03188948	chr7:1209495	NA	0.59	5.96	0.34	7.81e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs853679	0.550	rs6901017	chr6:28152583	T/C	cg21251018	chr6:28226885	NKAPL	0.34	5.15	0.3	5.08e-7	Depression;
CESC	cis	rs425277	0.585	rs2222217	chr1:2063164	G/A	cg04315214	chr1:2043799	PRKCZ	0.61	10.33	0.54	3e-21	Height;
CESC	cis	rs4253772	0.591	rs6007732	chr22:46652303	A/T	cg09491104	chr22:46646882	C22orf40	-0.58	-8.79	-0.48	1.88e-16	LDL cholesterol;Cholesterol, total;
CESC	cis	rs2404602	0.692	rs66866130	chr15:77128574	T/C	cg26408565	chr15:76604113	ETFA	-0.37	-5.43	-0.32	1.26e-7	Blood metabolite levels;
CESC	cis	rs12824058	0.831	rs12829373	chr12:130814114	G/C	cg26677194	chr12:130822605	PIWIL1	0.52	6.81	0.39	6.58e-11	Menopause (age at onset);
CESC	cis	rs9649213	0.593	rs6968144	chr7:97915697	G/A	cg21770322	chr7:97807741	LMTK2	0.58	8.64	0.47	5.26e-16	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg23034840	chr1:205782522	SLC41A1	0.67	8.05	0.44	2.78e-14	Menarche (age at onset);
CESC	cis	rs9322193	0.962	rs10214845	chr6:150104260	A/G	cg13206674	chr6:150067644	NUP43	0.42	5.89	0.34	1.19e-8	Lung cancer;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg12121965	chr21:46293563	PTTG1IP	0.44	6.03	0.35	5.63e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs9611565	0.694	rs202616	chr22:41822221	C/G	cg17376030	chr22:41985996	PMM1	-0.76	-8.01	-0.44	3.71e-14	Vitiligo;
CESC	cis	rs17401966	0.894	rs12722830	chr1:10395134	A/G	cg15208524	chr1:10270712	KIF1B	0.43	5.5	0.32	9.01e-8	Hepatocellular carcinoma;
CESC	cis	rs6089584	0.925	rs35683654	chr20:60625401	G/T	cg06108461	chr20:60628389	TAF4	0.82	11.36	0.57	1.29e-24	Body mass index;
CESC	cis	rs2832077	0.527	rs9980449	chr21:30224889	G/C	cg08807101	chr21:30365312	RNF160	-0.66	-8.57	-0.47	8.73e-16	Cognitive test performance;
CESC	trans	rs35110281	0.782	rs1454651	chr21:45012476	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.47	6.21	0.36	2.07e-9	Mean corpuscular volume;
CESC	cis	rs10504229	0.861	rs6990796	chr8:58183097	G/C	cg24829409	chr8:58192753	C8orf71	-0.76	-9.93	-0.52	5.87e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs9549260	0.592	rs9532588	chr13:41302913	G/A	cg21288729	chr13:41239152	FOXO1	0.57	7.13	0.4	9.34e-12	Red blood cell count;
CESC	cis	rs7927771	0.864	rs2293577	chr11:47437202	C/T	cg20307385	chr11:47447363	PSMC3	0.69	8.9	0.48	9.19e-17	Subjective well-being;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22424536	chr5:175792478	ARL10	-0.66	-8.06	-0.44	2.6e-14	Gut microbiome composition (summer);
CESC	cis	rs66530629	0.874	rs6667299	chr1:25158500	T/C	cg22509179	chr1:25234806	RUNX3	-0.44	-5.69	-0.33	3.32e-8	Plateletcrit;
CESC	cis	rs1153858	0.943	rs7402632	chr15:45701913	A/T	cg21132104	chr15:45694354	SPATA5L1	0.87	11.65	0.58	1.36e-25	Homoarginine levels;
CESC	cis	rs1153858	1.000	rs7494956	chr15:45668565	T/C	cg21132104	chr15:45694354	SPATA5L1	0.86	11.62	0.58	1.67e-25	Homoarginine levels;
CESC	cis	rs7044106	0.708	rs10760113	chr9:123474050	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.37	6.01	0.35	5.97e-9	Hip circumference adjusted for BMI;
CESC	cis	rs643506	0.874	rs645411	chr11:111694490	T/C	cg17089665	chr11:111648010	NA	-0.36	-5.18	-0.3	4.3e-7	Breast cancer;
CESC	trans	rs1814175	0.645	rs11040703	chr11:50024961	C/T	cg03929089	chr4:120376271	NA	-0.91	-14.8	-0.67	1.58e-36	Height;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg24607948	chr9:100459097	XPA	-0.42	-6.05	-0.35	4.92e-9	Gambling;
CESC	cis	rs1483890	0.638	rs1564756	chr3:69402489	T/G	cg22125112	chr3:69402811	FRMD4B	-0.38	-5.05	-0.3	8.09e-7	Resting heart rate;
CESC	cis	rs3768617	0.565	rs10752897	chr1:183071024	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.84	13.14	0.63	1.04e-30	Fuchs's corneal dystrophy;
CESC	cis	rs9916302	0.752	rs11078895	chr17:37401051	A/G	cg00129232	chr17:37814104	STARD3	-0.51	-5.34	-0.31	1.99e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs10791097	0.694	rs2155752	chr11:130755998	C/T	cg09137382	chr11:130731461	NA	0.34	5.1	0.3	6.52e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs6499255	1.000	rs7189424	chr16:69782746	G/A	cg15192750	chr16:69999425	NA	0.44	5.43	0.32	1.27e-7	IgE levels;
CESC	cis	rs6460942	0.915	rs6945067	chr7:12444731	A/C	cg19099843	chr7:12443191	VWDE	-0.5	-5.26	-0.31	2.97e-7	Coronary artery disease;
CESC	cis	rs2204008	0.749	rs10880692	chr12:38592918	C/G	cg26384229	chr12:38710491	ALG10B	-0.75	-11.36	-0.57	1.3e-24	Bladder cancer;
CESC	cis	rs796364	0.806	rs74938253	chr2:201008386	T/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.67	-6.43	-0.37	5.87e-10	Schizophrenia;
CESC	cis	rs6500602	0.701	rs8053770	chr16:4539030	T/A	cg08645402	chr16:4508243	NA	0.43	6.69	0.38	1.35e-10	Schizophrenia;
CESC	cis	rs4803468	0.935	rs13346603	chr19:41945837	T/A	cg14132834	chr19:41945861	ATP5SL	0.66	8.19	0.45	1.1e-14	Height;
CESC	cis	rs9309473	0.583	rs6705203	chr2:73574600	T/C	cg20560298	chr2:73613845	ALMS1	-0.45	-5.95	-0.34	8.58e-9	Metabolite levels;
CESC	cis	rs2836974	0.931	rs2735306	chr21:40713134	A/G	cg11644478	chr21:40555479	PSMG1	-0.95	-14.2	-0.66	2.12e-34	Cognitive function;
CESC	cis	rs7246865	0.768	rs8106184	chr19:17159779	A/C	cg19418318	chr19:17219073	MYO9B	0.35	5.63	0.33	4.5e-8	Reticulocyte fraction of red cells;
CESC	cis	rs637571	0.654	rs1058068	chr11:65667796	G/A	cg04055107	chr11:65626734	MUS81;CFL1	0.57	6.82	0.39	6.05e-11	Eosinophil percentage of white cells;
CESC	cis	rs8062405	0.737	rs11861132	chr16:28871860	A/G	cg08761264	chr16:28874980	SH2B1	-0.47	-5.85	-0.34	1.42e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs7666738	0.830	rs10012167	chr4:99048579	T/C	cg17366294	chr4:99064904	C4orf37	0.61	8.78	0.47	2.13e-16	Colonoscopy-negative controls vs population controls;
CESC	trans	rs1285495	0.627	rs10912059	chr1:187354887	C/T	cg06529439	chr2:88991002	RPIA	-0.48	-6.16	-0.35	2.64e-9	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
CESC	cis	rs367615	0.679	rs11241021	chr5:108812090	T/G	cg17395555	chr5:108820864	NA	0.66	11.19	0.57	4.53e-24	Colorectal cancer (SNP x SNP interaction);
CESC	trans	rs931812	1.000	rs4734495	chr8:101917817	C/A	cg20993868	chr7:22813445	NA	0.48	6.58	0.37	2.54e-10	Attention deficit hyperactivity disorder and conduct disorder;
CESC	cis	rs2573652	1.000	rs2573651	chr15:100514109	T/G	cg00587665	chr15:100533223	ADAMTS17	-0.34	-5.44	-0.32	1.21e-7	Height;
CESC	cis	rs651907	0.557	rs34181125	chr3:101490278	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.51	6.85	0.39	5.18e-11	Colorectal cancer;
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg16308174	chr11:70049109	FADD	-0.41	-6.01	-0.35	6.05e-9	Vertical cup-disc ratio;
CESC	cis	rs875971	0.522	rs1701760	chr7:65473688	A/G	cg08632164	chr7:65971372	NA	-0.32	-5.19	-0.3	4.25e-7	Aortic root size;
CESC	cis	rs12541635	0.934	rs1353450	chr8:107035120	A/G	cg10147462	chr8:107024639	NA	-0.38	-5.36	-0.31	1.79e-7	Age of smoking initiation;
CESC	cis	rs8020095	0.528	rs9671368	chr14:67263455	G/A	cg19548862	chr14:67692701	FAM71D	-0.49	-6.01	-0.35	6.17e-9	Depression (quantitative trait);
CESC	cis	rs10911232	0.507	rs10752888	chr1:182993751	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.85	13.21	0.63	5.94e-31	Hypertriglyceridemia;
CESC	cis	rs8062405	1.000	rs7187776	chr16:28857645	A/G	cg08761264	chr16:28874980	SH2B1	-0.47	-6.13	-0.35	3.24e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs9611565	0.921	rs5751080	chr22:41736267	A/G	cg06634786	chr22:41940651	POLR3H	-0.44	-5.03	-0.3	9.13e-7	Vitiligo;
CESC	trans	rs4596713	0.508	rs7862404	chr9:71779903	G/A	cg16512924	chr15:28394682	HERC2	0.48	6.14	0.35	2.95e-9	Headache;
CESC	cis	rs7818345	0.935	rs6983973	chr8:19287867	T/C	cg11303988	chr8:19266685	CSGALNACT1	0.37	6.69	0.38	1.33e-10	Language performance in older adults (adjusted for episodic memory);
CESC	cis	rs2880765	0.835	rs730372	chr15:86038193	G/T	cg19183879	chr15:85880815	NA	0.26	5.32	0.31	2.21e-7	Coronary artery disease;
CESC	cis	rs4253772	0.550	rs6008762	chr22:46736228	T/C	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.61	5.56	0.32	6.49e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs4713118	0.513	rs149955	chr6:28036225	G/C	cg19592336	chr6:28129416	ZNF389	0.45	6.34	0.36	9.91e-10	Parkinson's disease;
CESC	cis	rs10492096	0.947	rs11559082	chr12:6602367	C/T	cg13857086	chr12:6580257	VAMP1	0.6	5.91	0.34	1.04e-8	Hip geometry;
CESC	cis	rs68170813	0.641	rs75639044	chr7:107092631	A/C	cg02696742	chr7:106810147	HBP1	-0.56	-5.19	-0.3	4.1e-7	Coronary artery disease;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg27304813	chr3:120068385	LRRC58	0.55	7.2	0.4	6.38e-12	Gut microbiota (bacterial taxa);
CESC	cis	rs9649213	0.574	rs62479853	chr7:97917158	G/T	cg24562669	chr7:97807699	LMTK2	0.51	7.35	0.41	2.45e-12	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7666738	0.546	rs10007424	chr4:98885450	C/T	cg17366294	chr4:99064904	C4orf37	0.5	6.35	0.36	9.43e-10	Colonoscopy-negative controls vs population controls;
CESC	trans	rs7246657	0.943	rs2126977	chr19:37995747	C/G	cg24637308	chr11:6592297	DNHD1	-0.51	-6.15	-0.35	2.85e-9	Coronary artery calcification;
CESC	cis	rs9322193	0.884	rs7743823	chr6:150170880	A/G	cg09699651	chr6:150184138	LRP11	0.51	6.5	0.37	3.92e-10	Lung cancer;
CESC	cis	rs17666538	0.535	rs4338080	chr8:615598	A/G	cg07234876	chr8:600039	NA	0.81	5.83	0.34	1.62e-8	IgG glycosylation;
CESC	cis	rs6952808	0.656	rs12699646	chr7:2093162	T/G	cg05863683	chr7:1912471	MAD1L1	-0.36	-5.23	-0.31	3.48e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs7605827	0.930	rs2111455	chr2:15549882	C/T	cg19274914	chr2:15703543	NA	0.35	6.27	0.36	1.42e-9	Educational attainment (years of education);
CESC	cis	rs2204008	0.837	rs7315255	chr12:37949279	G/A	cg13010199	chr12:38710504	ALG10B	0.53	6.76	0.38	8.75e-11	Bladder cancer;
CESC	cis	rs826838	0.967	rs1684413	chr12:39128704	G/A	cg13010199	chr12:38710504	ALG10B	-0.45	-6.26	-0.36	1.51e-9	Heart rate;
CESC	cis	rs2836950	0.545	rs4818001	chr21:40575088	T/C	cg11644478	chr21:40555479	PSMG1	-0.55	-7.63	-0.42	4.34e-13	Menarche (age at onset);
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg26035463	chr12:117627651	FBXO21	0.48	6.18	0.35	2.46e-9	Systemic lupus erythematosus;
CESC	cis	rs35110281	0.748	rs1584918	chr21:45042419	C/T	cg01579765	chr21:45077557	HSF2BP	-0.55	-9.2	-0.49	1.12e-17	Mean corpuscular volume;
CESC	cis	rs875971	0.545	rs1909508	chr7:65766353	G/T	cg11764359	chr7:65958608	NA	0.78	10.12	0.53	1.44e-20	Aortic root size;
CESC	cis	rs736408	0.774	rs4687551	chr3:52823448	C/T	cg17372223	chr3:52568218	NT5DC2	-0.37	-5.26	-0.31	2.95e-7	Bipolar disorder;
CESC	cis	rs7312774	0.618	rs7968263	chr12:107330844	C/A	cg16260113	chr12:107380972	MTERFD3	0.79	6.83	0.39	5.68e-11	Severe influenza A (H1N1) infection;
CESC	cis	rs7927771	0.864	rs2293577	chr11:47437202	C/T	cg18512352	chr11:47633146	NA	0.44	6.35	0.36	9.22e-10	Subjective well-being;
CESC	cis	rs9611565	0.512	rs9607842	chr22:42192722	G/A	cg06481639	chr22:41940642	POLR3H	-0.59	-5.91	-0.34	1.08e-8	Vitiligo;
CESC	cis	rs4481887	0.646	rs28421649	chr1:248548122	G/C	cg26353448	chr1:248524236	OR2T4	-0.39	-5.98	-0.34	7.17e-9	Common traits (Other);
CESC	cis	rs9814567	1.000	rs6439484	chr3:134249899	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.45	-6.08	-0.35	4.19e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs7412746	0.658	rs10305704	chr1:150804429	A/C	cg22823121	chr1:150693482	HORMAD1	0.45	6.31	0.36	1.17e-9	Melanoma;
CESC	trans	rs7107217	1.000	rs1873872	chr11:129473993	A/T	cg21932297	chr7:97910808	BRI3	0.5	6.56	0.37	2.79e-10	Breast cancer;Type 2 diabetes;
CESC	cis	rs1862618	0.853	rs252922	chr5:56136343	G/T	cg24531977	chr5:56204891	C5orf35	-0.89	-11.65	-0.58	1.36e-25	Initial pursuit acceleration;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25620125	chr11:61106775	DAK	-0.59	-6.42	-0.37	6.16e-10	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15739904	chr8:125313885	NA	-0.56	-6.32	-0.36	1.12e-9	Gut microbiome composition (summer);
CESC	cis	rs12618769	0.520	rs72821904	chr2:99084882	G/A	cg10123293	chr2:99228465	UNC50	0.39	5.13	0.3	5.6e-7	Bipolar disorder;
CESC	cis	rs56399783	0.901	rs73049305	chr7:2778755	C/T	cg19731401	chr7:2775893	GNA12	0.65	5.89	0.34	1.18e-8	Childhood ear infection;
CESC	cis	rs6504663	0.596	rs7208018	chr17:48557863	C/T	cg03168497	chr17:48586147	MYCBPAP	-0.45	-5.32	-0.31	2.24e-7	Visceral fat;
CESC	cis	rs12497850	0.931	rs13315711	chr3:48986399	A/T	cg02487422	chr3:49467188	NICN1	0.44	5.61	0.33	4.99e-8	Parkinson's disease;
CESC	cis	rs7949030	0.588	rs2509961	chr11:62310909	T/C	cg11742103	chr11:62369870	EML3;MTA2	0.57	8.63	0.47	5.87e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs854765	0.583	rs4413022	chr17:17858280	G/C	cg09796270	chr17:17721594	SREBF1	0.44	6.05	0.35	4.92e-9	Total body bone mineral density;
CESC	cis	rs7617773	0.780	rs34523942	chr3:48342669	C/T	cg11946769	chr3:48343235	NME6	0.83	11.2	0.57	4.23e-24	Coronary artery disease;
CESC	cis	rs6951245	0.872	rs57068908	chr7:1060084	A/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.51	6.15	0.35	2.81e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs4727027	0.933	rs28767030	chr7:148825918	T/G	cg23583168	chr7:148888333	NA	-0.74	-10.89	-0.56	4.6e-23	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs1218582	0.741	rs883718	chr1:154846274	C/T	cg16680214	chr1:154839983	KCNN3	-0.47	-7.44	-0.42	1.41e-12	Prostate cancer;
CESC	cis	rs425277	0.958	rs262639	chr1:2107061	G/T	cg24578937	chr1:2090814	PRKCZ	0.54	9.43	0.5	2.1e-18	Height;
CESC	cis	rs3733585	0.673	rs4560411	chr4:9953361	A/G	cg00071950	chr4:10020882	SLC2A9	-0.69	-11.34	-0.57	1.42e-24	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs2576037	0.583	rs4890698	chr18:44489725	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.39	6.29	0.36	1.29e-9	Personality dimensions;
CESC	cis	rs6460942	0.915	rs62448621	chr7:12459941	G/A	cg17427002	chr7:12443146	VWDE	-0.52	-5.04	-0.3	8.67e-7	Coronary artery disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg15921587	chr2:73144353	EMX1	-0.44	-6.27	-0.36	1.47e-9	Fibrinogen levels;
CESC	cis	rs35110281	0.748	rs9981460	chr21:45030965	T/A	cg21573476	chr21:45109991	RRP1B	-0.5	-6.89	-0.39	3.99e-11	Mean corpuscular volume;
CESC	cis	rs769267	0.895	rs2916073	chr19:19528324	T/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.57	7.41	0.41	1.73e-12	Tonsillectomy;
CESC	cis	rs6547741	1.000	rs13026621	chr2:27807624	G/A	cg27432699	chr2:27873401	GPN1	0.49	6.85	0.39	5.03e-11	Oral cavity cancer;
CESC	cis	rs9733	0.596	rs72702580	chr1:150691285	A/T	cg17724175	chr1:150552817	MCL1	0.45	7.31	0.41	3.23e-12	Tonsillectomy;
CESC	cis	rs1950626	0.623	rs3742401	chr14:101453344	G/A	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.67	8.97	0.48	5.38e-17	Pelvic organ prolapse (moderate/severe);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg00894870	chr1:19578612	MRTO4;KIAA0090	-0.43	-6.15	-0.35	2.88e-9	Gambling;
CESC	cis	rs10751667	0.666	rs10794354	chr11:954615	A/T	cg01483505	chr11:975446	AP2A2	0.37	5.05	0.3	8.3e-7	Alzheimer's disease (late onset);
CESC	cis	rs6751744	0.513	rs6738215	chr2:160453305	C/T	cg08347373	chr2:160653686	CD302	-0.32	-5.3	-0.31	2.49e-7	Dysphagia;
CESC	cis	rs7267979	1.000	rs2424713	chr20:25418482	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.83	15.87	0.7	2.52e-40	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs11792861	0.816	rs2304779	chr9:111670513	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	-0.54	-7.12	-0.4	1.01e-11	Menarche (age at onset);
CESC	cis	rs1552244	0.748	rs113890152	chr3:10085986	A/G	cg00166722	chr3:10149974	C3orf24	0.46	5.9	0.34	1.13e-8	Alzheimer's disease;
CESC	cis	rs6541297	0.887	rs4846906	chr1:230284257	C/A	cg05784532	chr1:230284198	GALNT2	0.52	5.83	0.34	1.64e-8	Coronary artery disease;
CESC	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg07092213	chr7:1199455	ZFAND2A	-0.51	-5.52	-0.32	8.03e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs11645898	0.810	rs72787085	chr16:72182564	C/T	cg14768367	chr16:72042858	DHODH	-0.76	-6.49	-0.37	4.28e-10	Blood protein levels;
CESC	cis	rs1577917	0.771	rs2758844	chr6:86330115	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.55	-7.45	-0.42	1.36e-12	Response to antipsychotic treatment;
CESC	cis	rs9894429	1.000	rs3935543	chr17:79579874	T/C	cg21984481	chr17:79567631	NPLOC4	-0.49	-8.04	-0.44	2.97e-14	Eye color traits;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg11454606	chr11:67888949	CHKA	-0.43	-6.09	-0.35	3.91e-9	Fibrinogen levels;
CESC	cis	rs9905704	0.671	rs4337355	chr17:56950920	C/T	cg12560992	chr17:57184187	TRIM37	0.62	7.85	0.43	1.03e-13	Testicular germ cell tumor;
CESC	cis	rs12325245	0.536	rs8058781	chr16:58653838	G/A	cg02549819	chr16:58548995	SETD6	0.94	6.09	0.35	4.04e-9	Schizophrenia;
CESC	cis	rs2370759	0.891	rs77706860	chr10:32628537	C/T	cg18270830	chr10:32634957	EPC1	0.66	5.63	0.33	4.62e-8	Sexual dysfunction (female);
CESC	cis	rs959260	0.623	rs2164244	chr17:73325244	C/T	cg20590849	chr17:73267439	MIF4GD	-0.43	-5.35	-0.31	1.94e-7	Systemic lupus erythematosus;
CESC	cis	rs9916302	0.904	rs9892055	chr17:37510402	C/T	cg19468946	chr17:37922297	IKZF3	0.4	5.17	0.3	4.69e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg03188948	chr7:1209495	NA	0.71	7.06	0.4	1.5e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs748404	0.697	rs493444	chr15:43566470	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.5	7.8	0.43	1.45e-13	Lung cancer;
CESC	cis	rs992157	0.710	rs56364928	chr2:219059058	G/A	cg00012203	chr2:219082015	ARPC2	0.87	12.47	0.61	2.24e-28	Colorectal cancer;
CESC	cis	rs1448094	0.512	rs7957170	chr12:86243282	A/G	cg19622623	chr12:86230825	RASSF9	-0.46	-5.89	-0.34	1.2e-8	Major depressive disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17561891	chr7:86849173	C7orf23	0.61	6.58	0.37	2.45e-10	Gut microbiome composition (summer);
CESC	cis	rs9908102	0.746	rs73296600	chr17:12903988	G/C	cg26162695	chr17:12921313	ELAC2	0.5	5.49	0.32	9.61e-8	Schizophrenia;
CESC	cis	rs2243480	1.000	rs316307	chr7:65570171	C/T	cg12463550	chr7:65579703	CRCP	0.74	5.74	0.33	2.59e-8	Diabetic kidney disease;
CESC	cis	rs7044106	0.762	rs10818471	chr9:123394045	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.33	5.11	0.3	6.22e-7	Hip circumference adjusted for BMI;
CESC	cis	rs7267979	1.000	rs3761117	chr20:25388070	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.87	-17.84	-0.74	2.71e-47	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs10911232	0.507	rs10911230	chr1:183051118	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.85	13.7	0.64	1.21e-32	Hypertriglyceridemia;
CESC	cis	rs7520050	0.902	rs4626927	chr1:46248645	C/T	cg03146154	chr1:46216737	IPP	-0.49	-6.36	-0.36	8.95e-10	Red blood cell count;Reticulocyte count;
CESC	trans	rs60843830	0.964	rs17713879	chr2:254215	G/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.64	7.95	0.44	5.3e-14	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs17764205	0.777	rs28729385	chr19:3258882	T/C	cg02612712	chr19:3985498	EEF2	0.63	5.17	0.3	4.64e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs2952156	0.920	rs1476278	chr17:37836243	C/T	cg00129232	chr17:37814104	STARD3	-0.78	-11.59	-0.58	2.06e-25	Asthma;
CESC	cis	rs9640161	0.789	rs10952250	chr7:150025966	T/C	cg13722127	chr7:150037890	RARRES2	0.34	5.29	0.31	2.6e-7	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs5758659	0.904	rs134877	chr22:42662371	C/T	cg05082376	chr22:42548792	NA	-0.4	-5.93	-0.34	9.66e-9	Cognitive function;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg26495393	chr16:31473952	ARMC5	0.45	6.44	0.37	5.53e-10	Fibrinogen levels;
CESC	cis	rs4889855	0.530	rs62068346	chr17:78608052	A/G	cg16591659	chr17:78472290	NA	-0.34	-5.49	-0.32	9.53e-8	Fractional excretion of uric acid;
CESC	cis	rs67311347	1.000	rs977652	chr3:40479169	A/G	cg09455208	chr3:40491958	NA	0.47	8.15	0.45	1.46e-14	Renal cell carcinoma;
CESC	cis	rs763121	0.819	rs5757161	chr22:38990662	G/A	cg21395723	chr22:39101663	GTPBP1	0.47	6.19	0.36	2.27e-9	Menopause (age at onset);
CESC	cis	rs66573146	1.000	rs67067921	chr4:6984341	A/T	cg00086871	chr4:6988644	TBC1D14	1.15	6.76	0.38	8.7e-11	Granulocyte percentage of myeloid white cells;
CESC	cis	rs10504229	0.610	rs7011877	chr8:58147181	C/T	cg22535103	chr8:58192502	C8orf71	-0.75	-8.9	-0.48	8.89e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs67311347	1.000	rs2276871	chr3:40499273	C/T	cg09455208	chr3:40491958	NA	0.5	8.49	0.46	1.48e-15	Renal cell carcinoma;
CESC	cis	rs1799949	0.965	rs35954893	chr17:41333786	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.41	5.57	0.32	6.16e-8	Menopause (age at onset);
CESC	cis	rs67311347	1.000	rs11707673	chr3:40450604	C/A	cg24209194	chr3:40518798	ZNF619	0.53	6.52	0.37	3.53e-10	Renal cell carcinoma;
CESC	cis	rs7811142	1.000	rs68116612	chr7:100006493	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.94	10.26	0.53	5.16e-21	Platelet count;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg11914902	chr12:106751322	POLR3B	0.45	6.23	0.36	1.79e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs526821	0.595	rs4938937	chr11:55305507	T/A	cg15704280	chr7:45808275	SEPT13	-0.52	-6.4	-0.37	7.03e-10	Pediatric bone mineral density (spine);
CESC	cis	rs2730245	0.527	rs1188974	chr7:158665748	C/T	cg24397884	chr7:158709396	WDR60	0.77	8.2	0.45	1.03e-14	Height;
CESC	cis	rs7103648	1.000	rs11039225	chr11:47430599	G/A	cg03711944	chr11:47377212	SPI1	-0.31	-5.04	-0.3	8.72e-7	Diastolic blood pressure;Systolic blood pressure;
CESC	trans	rs67340775	0.834	rs13218875	chr6:27884012	C/T	cg06606381	chr12:133084897	FBRSL1	-1.09	-8.62	-0.47	6.27e-16	Lung cancer in ever smokers;
CESC	cis	rs3008870	1.000	rs12044278	chr1:67460977	T/C	cg08660285	chr1:67390436	MIER1;WDR78	-1.06	-15.19	-0.68	6.65e-38	Lymphocyte percentage of white cells;
CESC	cis	rs2303759	0.830	rs7257053	chr19:49894456	C/G	cg22133161	chr19:49891603	CCDC155	0.47	5.3	0.31	2.47e-7	Multiple sclerosis;
CESC	cis	rs6541297	0.699	rs1555290	chr1:230294989	A/C	cg20703242	chr1:230279135	GALNT2	-0.54	-6.24	-0.36	1.72e-9	Coronary artery disease;
CESC	cis	rs34779708	0.966	rs4934540	chr10:35474699	T/C	cg03585969	chr10:35415529	CREM	0.74	9.81	0.52	1.39e-19	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs7592578	0.771	rs1128723	chr2:191366707	A/G	cg10560079	chr2:191398806	TMEM194B	-0.68	-6.07	-0.35	4.3e-9	Diastolic blood pressure;
CESC	cis	rs72772090	0.634	rs72773906	chr5:96092274	C/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.61	-5.58	-0.32	5.79e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs1976403	0.659	rs10799700	chr1:21820968	G/C	cg21906605	chr1:21766650	NBPF3	0.4	5.29	0.31	2.6e-7	Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs916888	0.610	rs199454	chr17:44800110	G/A	cg22968622	chr17:43663579	NA	-0.76	-10.12	-0.53	1.47e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs10876993	0.928	rs2640631	chr12:58067532	A/T	cg18357645	chr12:58087776	OS9	0.61	10.24	0.53	6.11e-21	Celiac disease or Rheumatoid arthritis;
CESC	cis	rs17428076	0.556	rs12692976	chr2:172684403	G/T	cg13550731	chr2:172543902	DYNC1I2	-0.56	-7.43	-0.42	1.46e-12	Myopia;
CESC	cis	rs8141529	0.764	rs5752807	chr22:29223169	A/G	cg15103426	chr22:29168792	CCDC117	0.68	9.65	0.51	4.52e-19	Lymphocyte counts;
CESC	cis	rs71277158	0.688	rs77248289	chr3:169905625	C/T	cg04067573	chr3:169899625	PHC3	0.7	6.72	0.38	1.09e-10	Prostate cancer;
CESC	cis	rs2576037	0.526	rs11082562	chr18:44522671	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.69	10.92	0.56	3.64e-23	Personality dimensions;
CESC	cis	rs9611519	0.761	rs35445172	chr22:41660301	G/A	cg17376030	chr22:41985996	PMM1	0.43	5.04	0.3	8.52e-7	Neuroticism;
CESC	cis	rs1799949	1.000	rs11649954	chr17:41420035	A/G	cg06001716	chr17:41278141	BRCA1;NBR2	0.38	5.17	0.3	4.63e-7	Menopause (age at onset);
CESC	cis	rs875971	0.660	rs7807930	chr7:66087165	C/T	cg06456125	chr7:65229604	NA	-0.4	-5.15	-0.3	4.99e-7	Aortic root size;
CESC	cis	rs4835473	0.736	rs11724009	chr4:144905444	C/A	cg25736465	chr4:144833511	NA	0.41	6.25	0.36	1.65e-9	Immature fraction of reticulocytes;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg01102847	chr14:50053293	RPS29	-0.47	-6.24	-0.36	1.72e-9	Fibrinogen levels;
CESC	trans	rs208520	0.706	rs851601	chr6:66893853	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.91	-11.17	-0.57	5.31e-24	Exhaled nitric oxide output;
CESC	cis	rs6502050	0.835	rs7406220	chr17:80077850	T/C	cg23985595	chr17:80112537	CCDC57	0.42	6.56	0.37	2.87e-10	Life satisfaction;
CESC	cis	rs10504229	1.000	rs66479724	chr8:58188309	T/G	cg05313129	chr8:58192883	C8orf71	-0.57	-6.47	-0.37	4.59e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs7762018	1.000	rs4716378	chr6:170086568	G/C	cg05834625	chr6:170176447	C6orf70	0.62	7.41	0.41	1.7e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs6460942	0.659	rs6969309	chr7:12515847	T/C	cg20607287	chr7:12443886	VWDE	-0.7	-7.58	-0.42	5.83e-13	Coronary artery disease;
CESC	cis	rs10791097	0.609	rs3751039	chr11:130773076	A/G	cg09137382	chr11:130731461	NA	-0.35	-5.27	-0.31	2.89e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs5758659	0.714	rs6002626	chr22:42517989	C/G	cg19513890	chr22:42538836	CYP2D7P1	0.38	5.48	0.32	9.98e-8	Cognitive function;
CESC	cis	rs793571	0.544	rs1427282	chr15:58914326	C/T	cg05156742	chr15:59063176	FAM63B	0.8	11.73	0.58	7.43e-26	Schizophrenia;
CESC	cis	rs6570726	0.875	rs416243	chr6:145868081	A/T	cg23711669	chr6:146136114	FBXO30	0.8	11.78	0.59	4.84e-26	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7666738	0.830	rs10001702	chr4:99065160	T/G	cg05340658	chr4:99064831	C4orf37	0.84	13.04	0.63	2.35e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9858542	0.953	rs67216675	chr3:49493151	G/T	cg07274523	chr3:49395745	GPX1	0.66	8.15	0.45	1.41e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs763121	0.853	rs11704021	chr22:39074716	G/A	cg06022373	chr22:39101656	GTPBP1	0.89	14.32	0.66	7.5e-35	Menopause (age at onset);
CESC	cis	rs17376456	0.825	rs28534784	chr5:93063332	C/A	cg25358565	chr5:93447407	FAM172A	1.09	10.86	0.55	5.92e-23	Diabetic retinopathy;
CESC	cis	rs9325144	0.555	rs7301258	chr12:38706942	C/T	cg26384229	chr12:38710491	ALG10B	0.52	7.39	0.41	1.93e-12	Morning vs. evening chronotype;
CESC	cis	rs459571	0.839	rs2519831	chr9:136886257	T/A	cg13789015	chr9:136890014	NCRNA00094	0.57	8.15	0.45	1.45e-14	Platelet distribution width;
CESC	cis	rs7267979	1.000	rs2027004	chr20:25350618	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.84	-15.92	-0.7	1.72e-40	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs41271473	0.539	rs763519	chr1:228892855	A/G	cg00850481	chr1:228891306	NA	0.45	6.03	0.35	5.46e-9	Chronic lymphocytic leukemia;
CESC	trans	rs7615952	0.534	rs1503072	chr3:125754691	C/T	cg07211511	chr3:129823064	LOC729375	-0.59	-6.52	-0.37	3.53e-10	Blood pressure (smoking interaction);
CESC	cis	rs921968	0.541	rs933995	chr2:219650718	G/A	cg02176678	chr2:219576539	TTLL4	-0.44	-7.81	-0.43	1.3e-13	Mean corpuscular hemoglobin concentration;
CESC	cis	rs1878931	0.501	rs17136359	chr16:3420814	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.76	-10.12	-0.53	1.42e-20	Body mass index (adult);
CESC	cis	rs2985684	0.901	rs2354448	chr14:50098296	G/A	cg02151108	chr14:50098012	C14orf104	-0.42	-5.48	-0.32	9.97e-8	Carotid intima media thickness;
CESC	cis	rs1215050	0.740	rs783945	chr4:99014394	G/A	cg17366294	chr4:99064904	C4orf37	-0.4	-5.26	-0.31	3.01e-7	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs6032067	0.777	rs979641	chr20:43786336	C/T	cg11264863	chr20:43835661	SEMG1	0.5	5.35	0.31	1.86e-7	Blood protein levels;
CESC	cis	rs12472274	0.646	rs34465035	chr2:239114093	C/A	cg17459225	chr2:239074497	NA	0.51	6.01	0.35	6.11e-9	Phospholipid levels (plasma);
CESC	cis	rs3008870	0.958	rs12143044	chr1:67460054	A/T	cg08660285	chr1:67390436	MIER1;WDR78	-1.06	-15.19	-0.68	6.65e-38	Lymphocyte percentage of white cells;
CESC	cis	rs7223966	0.515	rs2727315	chr17:61961458	C/T	cg11494091	chr17:61959527	GH2	0.42	5.73	0.33	2.66e-8	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs2354432	0.556	rs4424557	chr1:146871119	A/G	cg25205988	chr1:146714368	CHD1L	1.02	8.91	0.48	8.56e-17	Mitochondrial DNA levels;
CESC	cis	rs875971	0.545	rs1796219	chr7:66110964	A/G	cg19163074	chr7:65112434	INTS4L2	0.52	5.4	0.31	1.5e-7	Aortic root size;
CESC	cis	rs11864453	0.927	rs1035560	chr16:72032730	T/C	cg01557791	chr16:72042693	DHODH	-0.67	-8.93	-0.48	7.45e-17	Fibrinogen levels;
CESC	cis	rs8018808	0.935	rs11627385	chr14:77936343	T/C	cg20045696	chr14:77926864	AHSA1	0.43	5.9	0.34	1.13e-8	Myeloid white cell count;
CESC	cis	rs2228479	0.557	rs62054639	chr16:89821489	C/T	cg06558623	chr16:89946397	TCF25	1.16	9.28	0.5	6.08e-18	Skin colour saturation;
CESC	cis	rs9399135	0.967	rs2297338	chr6:135375762	G/A	cg24558204	chr6:135376177	HBS1L	0.52	7.19	0.4	6.61e-12	Red blood cell count;
CESC	cis	rs1552244	0.882	rs13089863	chr3:10032259	G/T	cg00166722	chr3:10149974	C3orf24	-0.49	-5.64	-0.33	4.43e-8	Alzheimer's disease;
CESC	cis	rs17125944	0.686	rs76673112	chr14:53366692	T/C	cg00686598	chr14:53173677	PSMC6	0.95	7.15	0.4	8.21e-12	Alzheimer's disease (late onset);
CESC	cis	rs1030877	0.515	rs2576742	chr2:105898822	A/T	cg02079111	chr2:105885981	TGFBRAP1	0.49	6.53	0.37	3.31e-10	Obesity-related traits;
CESC	cis	rs3126085	0.935	rs11204937	chr1:152193851	C/T	cg26876637	chr1:152193138	HRNR	0.46	5.35	0.31	1.89e-7	Atopic dermatitis;
CESC	trans	rs7726839	0.540	rs3749615	chr5:601485	C/T	cg25482853	chr8:67687455	SGK3	1.01	10.04	0.52	2.65e-20	Obesity-related traits;
CESC	cis	rs2235642	0.653	rs7197288	chr16:1654753	C/A	cg03771183	chr16:1608904	IFT140	0.38	5.54	0.32	7.18e-8	Coronary artery disease;
CESC	cis	rs7618501	1.000	rs9872864	chr3:49792023	A/G	cg24308560	chr3:49941425	MST1R	0.52	7.15	0.4	8.43e-12	Intelligence (multi-trait analysis);
CESC	cis	rs8044868	0.530	rs2241411	chr16:72144493	T/C	cg16558253	chr16:72132732	DHX38	-0.39	-6.08	-0.35	4.07e-9	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CESC	cis	rs7520050	0.553	rs2993263	chr1:46021630	A/G	cg05343316	chr1:45956843	TESK2	0.48	6.17	0.35	2.49e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs1799949	0.931	rs34410138	chr17:41279770	A/G	cg25072359	chr17:41440525	NA	0.43	5.84	0.34	1.5e-8	Menopause (age at onset);
CESC	cis	rs1552244	1.000	rs3846177	chr3:10068572	G/T	cg00149659	chr3:10157352	C3orf10	0.74	9.14	0.49	1.63e-17	Alzheimer's disease;
CESC	cis	rs1775715	0.870	rs11008702	chr10:32244818	T/G	cg18675610	chr10:32216311	ARHGAP12	0.33	5.18	0.3	4.44e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs963731	0.649	rs1377860	chr2:39290425	C/G	cg04010122	chr2:39346883	SOS1	0.69	5.69	0.33	3.31e-8	Corticobasal degeneration;
CESC	cis	rs4704187	0.712	rs7701262	chr5:74365986	C/T	cg03227963	chr5:74354835	NA	0.31	5.68	0.33	3.62e-8	Response to amphetamines;
CESC	cis	rs12995491	0.698	rs34352413	chr2:88498754	T/G	cg07952391	chr2:88470173	THNSL2	-0.54	-8.15	-0.45	1.47e-14	Response to metformin (IC50);
CESC	cis	rs4566357	0.615	rs3769645	chr2:227913717	A/G	cg05526886	chr2:227700861	RHBDD1	-0.47	-6.23	-0.36	1.87e-9	Coronary artery disease;
CESC	cis	rs9486715	0.867	rs9386500	chr6:96889845	A/C	cg18709589	chr6:96969512	KIAA0776	0.45	6.29	0.36	1.31e-9	Headache;
CESC	cis	rs6580649	0.941	rs7971668	chr12:48469696	T/C	cg05342945	chr12:48394962	COL2A1	0.5	5.74	0.33	2.59e-8	Lung cancer;
CESC	cis	rs2576037	0.796	rs2576039	chr18:44582148	C/T	cg19077165	chr18:44547161	KATNAL2	0.51	7.13	0.4	9.38e-12	Personality dimensions;
CESC	cis	rs6788895	0.661	rs77431731	chr3:150489911	T/G	cg09723797	chr3:150481914	SIAH2	0.69	5.11	0.3	6.18e-7	Breast cancer;
CESC	cis	rs7937682	0.921	rs1944119	chr11:111436387	A/G	cg22437258	chr11:111473054	SIK2	-0.73	-8.38	-0.46	3.14e-15	Primary sclerosing cholangitis;
CESC	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg07167872	chr1:205819463	PM20D1	0.78	12.16	0.6	2.43e-27	Menarche (age at onset);
CESC	cis	rs2769264	0.505	rs4246526	chr1:151403916	G/T	cg18801370	chr1:151430492	POGZ	0.56	6.88	0.39	4.42e-11	Blood trace element (Cu levels);
CESC	cis	rs9815354	0.812	rs73828254	chr3:41810180	T/A	cg03022575	chr3:42003672	ULK4	0.68	6.06	0.35	4.7e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs7197653	0.748	rs8060690	chr16:68340085	G/T	cg26727032	chr16:67993705	SLC12A4	-0.53	-5.12	-0.3	5.91e-7	Magnesium levels;
CESC	cis	rs7116495	1.000	rs10736786	chr11:71763274	C/T	cg26138937	chr11:71823887	C11orf51	-0.81	-6.47	-0.37	4.6e-10	Severe influenza A (H1N1) infection;
CESC	cis	rs11792861	0.926	rs11787878	chr9:111866749	C/T	cg13535736	chr9:111863775	C9orf5	-0.5	-6.65	-0.38	1.68e-10	Menarche (age at onset);
CESC	cis	rs787274	0.543	rs62576453	chr9:115629921	C/T	cg13803584	chr9:115635662	SNX30	-0.63	-5.9	-0.34	1.1e-8	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs6963495	0.818	rs55922564	chr7:105155890	G/A	cg19920283	chr7:105172520	RINT1	0.69	6.56	0.37	2.85e-10	Bipolar disorder (body mass index interaction);
CESC	cis	rs5753618	0.504	rs9609296	chr22:31891784	T/G	cg13145458	chr22:31556086	RNF185	-0.52	-5.85	-0.34	1.44e-8	Colorectal cancer;
CESC	cis	rs9911578	1.000	rs302859	chr17:56693132	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.27	0.31	2.87e-7	Intelligence (multi-trait analysis);
CESC	cis	rs34172651	0.917	rs1075987	chr16:24794957	G/A	cg06028605	chr16:24865363	SLC5A11	0.35	5.46	0.32	1.11e-7	Intelligence (multi-trait analysis);
CESC	cis	rs2180341	0.680	rs9388554	chr6:127576234	C/G	cg24812749	chr6:127587940	RNF146	0.84	11.79	0.59	4.6e-26	Breast cancer;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg20617676	chr7:123389167	WASL	-0.48	-6.37	-0.36	8.45e-10	Fibrinogen levels;
CESC	cis	rs295140	0.605	rs296818	chr2:201176944	C/T	cg23649088	chr2:200775458	C2orf69	0.46	6.24	0.36	1.73e-9	QT interval;
CESC	cis	rs6662572	0.737	rs7525281	chr1:46267923	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.45	-5.11	-0.3	6.16e-7	Blood protein levels;
CESC	cis	rs617791	0.508	rs2276132	chr11:65770545	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.38	-5.03	-0.3	8.96e-7	Breast cancer;
CESC	cis	rs6061231	1.000	rs6061231	chr20:60956917	C/A	cg24112000	chr20:60950667	NA	-0.57	-7.81	-0.43	1.33e-13	Colorectal cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06074332	chr11:111473729	SIK2	0.57	6.44	0.37	5.49e-10	Gut microbiome composition (summer);
CESC	cis	rs3824867	0.676	rs7104366	chr11:47462115	G/A	cg20307385	chr11:47447363	PSMC3	0.5	6.06	0.35	4.73e-9	Mean corpuscular hemoglobin;
CESC	cis	rs597539	0.617	rs598353	chr11:68635770	C/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.77	9.59	0.51	6.99e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs514406	0.893	rs1242326	chr1:53399104	C/A	cg25767906	chr1:53392781	SCP2	-0.44	-5.5	-0.32	9.08e-8	Monocyte count;
CESC	trans	rs208520	0.754	rs851594	chr6:66876695	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.99	-12.51	-0.61	1.58e-28	Exhaled nitric oxide output;
CESC	cis	rs853679	0.517	rs3757185	chr6:28107776	T/A	cg08968635	chr6:28129556	ZNF389	0.42	5.75	0.33	2.45e-8	Depression;
CESC	cis	rs8044868	0.530	rs12918956	chr16:72224335	A/G	cg01557791	chr16:72042693	DHODH	0.42	5.77	0.33	2.23e-8	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CESC	cis	rs7618915	0.571	rs6798246	chr3:52599922	G/A	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	5.67	0.33	3.7e-8	Bipolar disorder;
CESC	cis	rs1577917	0.771	rs12199873	chr6:86294947	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.56	-7.8	-0.43	1.46e-13	Response to antipsychotic treatment;
CESC	cis	rs847577	0.569	rs12674083	chr7:97696334	C/T	cg21770322	chr7:97807741	LMTK2	0.82	14.51	0.67	1.69e-35	Breast cancer;
CESC	cis	rs9905704	0.846	rs7212271	chr17:56863918	C/T	cg12560992	chr17:57184187	TRIM37	0.62	7.8	0.43	1.45e-13	Testicular germ cell tumor;
CESC	cis	rs6546537	0.562	rs7565783	chr2:69750113	C/T	cg10773587	chr2:69614142	GFPT1	-0.53	-6.66	-0.38	1.54e-10	Serum thyroid-stimulating hormone levels;
CESC	cis	rs514406	0.505	rs269292	chr1:53187911	T/C	cg24675658	chr1:53192096	ZYG11B	-0.5	-6.2	-0.36	2.16e-9	Monocyte count;
CESC	trans	rs6445797	0.788	rs11714608	chr3:56662215	T/C	cg15444621	chr13:113611794	NA	0.33	6.04	0.35	5.18e-9	Gastritis;
CESC	cis	rs7552404	0.731	rs61770556	chr1:76421902	T/C	cg22875332	chr1:76189707	ACADM	0.6	5.66	0.33	3.89e-8	Blood metabolite levels;Acylcarnitine levels;
CESC	trans	rs7937682	0.924	rs7938360	chr11:111539875	A/G	cg18187862	chr3:45730750	SACM1L	0.5	6.36	0.36	8.88e-10	Primary sclerosing cholangitis;
CESC	cis	rs11229555	0.645	rs10896785	chr11:58233395	G/A	cg15696309	chr11:58395628	NA	-0.45	-5.26	-0.31	2.93e-7	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs7296418	0.630	rs28419092	chr12:123812629	G/C	cg00376283	chr12:123451042	ABCB9	0.56	7.64	0.42	3.92e-13	Platelet count;
CESC	cis	rs4665809	0.549	rs62130460	chr2:26472718	T/C	cg27170947	chr2:26402098	FAM59B	0.79	8.45	0.46	1.91e-15	Gut microbiome composition (summer);
CESC	cis	rs6499255	1.000	rs11075733	chr16:69773435	G/T	cg15192750	chr16:69999425	NA	0.51	6.16	0.35	2.75e-9	IgE levels;
CESC	cis	rs28489187	0.730	rs233130	chr1:85795112	T/C	cg16011679	chr1:85725395	C1orf52	0.47	5.6	0.33	5.46e-8	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	cis	rs4862750	0.872	rs6553029	chr4:187876470	G/T	cg22105103	chr4:187893119	NA	-0.44	-5.89	-0.34	1.14e-8	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7937682	0.575	rs7114617	chr11:111768173	A/T	cg22437258	chr11:111473054	SIK2	-0.48	-5.3	-0.31	2.44e-7	Primary sclerosing cholangitis;
CESC	cis	rs17067123	1.000	rs10024135	chr4:180039244	A/G	cg26610307	chr4:180072759	NA	-0.51	-5.35	-0.31	1.91e-7	Response to hepatitis C treatment;
CESC	cis	rs67311347	1.000	rs9874006	chr3:40471596	G/A	cg01475735	chr3:40494733	NA	-0.4	-5.04	-0.3	8.45e-7	Renal cell carcinoma;
CESC	cis	rs858239	0.601	rs7805206	chr7:23160210	C/T	cg23682824	chr7:23144976	KLHL7	0.47	6.3	0.36	1.2e-9	Cerebrospinal fluid biomarker levels;
CESC	cis	rs4253772	0.591	rs9615934	chr22:46682310	C/G	cg09491104	chr22:46646882	C22orf40	-0.53	-5.88	-0.34	1.25e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg03452623	chr4:187889614	NA	-0.93	-18.87	-0.76	6.53e-51	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs36206051	1.000	rs7043056	chr9:90202347	A/G	cg05779585	chr8:1246817	NA	-0.63	-6.16	-0.35	2.65e-9	Night sleep phenotypes;
CESC	cis	rs6088580	0.601	rs6059827	chr20:33016358	C/T	cg06115741	chr20:33292138	TP53INP2	0.48	6.21	0.36	2.09e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs9847710	0.733	rs2581790	chr3:53101780	A/G	cg07507251	chr3:52567010	NT5DC2	-0.33	-5.08	-0.3	7.2e-7	Ulcerative colitis;
CESC	cis	rs7223966	1.000	rs11658329	chr17:61763031	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.45	5.59	0.32	5.68e-8	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs9916302	0.808	rs12947281	chr17:37652210	G/T	cg15445000	chr17:37608096	MED1	0.41	6.76	0.38	8.83e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs7818688	0.858	rs7826196	chr8:96029002	A/G	cg16049864	chr8:95962084	TP53INP1	0.6	5.77	0.33	2.25e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs9486719	1.000	rs4839837	chr6:96908706	G/A	cg06623918	chr6:96969491	KIAA0776	0.88	10.38	0.54	2.16e-21	Migraine;Coronary artery disease;
CESC	cis	rs2228479	0.702	rs62052710	chr16:89854893	C/T	cg04013166	chr16:89971882	TCF25	0.78	6.67	0.38	1.44e-10	Skin colour saturation;
CESC	cis	rs910316	0.692	rs7156586	chr14:75506230	A/T	cg16144293	chr14:75469539	EIF2B2	-0.51	-6.62	-0.38	2.03e-10	Height;
CESC	cis	rs9916302	0.706	rs4795358	chr17:37573065	A/C	cg07936489	chr17:37558343	FBXL20	-0.91	-9.93	-0.52	5.62e-20	Glomerular filtration rate (creatinine);
CESC	cis	rs9287719	0.967	rs6744599	chr2:10747013	C/G	cg00105475	chr2:10696890	NA	-0.38	-5.53	-0.32	7.55e-8	Prostate cancer;
CESC	cis	rs2370759	0.898	rs113412621	chr10:32579306	C/T	cg18270830	chr10:32634957	EPC1	0.73	7.22	0.41	5.35e-12	Sexual dysfunction (female);
CESC	cis	rs7116495	0.881	rs1939243	chr11:71742735	A/G	cg10381502	chr11:71823885	C11orf51	0.64	5.09	0.3	6.87e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs2180341	1.000	rs13218061	chr6:127653758	G/A	cg24812749	chr6:127587940	RNF146	1.07	15.4	0.69	1.16e-38	Breast cancer;
CESC	cis	rs8177253	0.763	rs8177224	chr3:133474003	C/G	cg11941060	chr3:133502564	NA	0.44	5.88	0.34	1.26e-8	Iron status biomarkers;
CESC	cis	rs1005277	0.579	rs1740747	chr10:38520465	G/A	cg25517755	chr10:38738941	LOC399744	-0.44	-5.72	-0.33	2.85e-8	Extrinsic epigenetic age acceleration;
CESC	cis	rs7811142	0.779	rs28680963	chr7:99905475	C/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.03	9.59	0.51	6.65e-19	Platelet count;
CESC	cis	rs2072732	0.821	rs7339938	chr1:2963493	G/C	cg15211996	chr1:2936768	ACTRT2	0.31	5.46	0.32	1.11e-7	Plateletcrit;
CESC	cis	rs10804591	0.848	rs6782700	chr3:129309147	G/A	cg21885638	chr3:129306552	PLXND1	-0.34	-5.22	-0.31	3.63e-7	Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Hip circumference adjusted for BMI;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs7267979	0.789	rs6076347	chr20:25398790	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.68	-11.32	-0.57	1.75e-24	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs12477438	0.520	rs11123762	chr2:99727789	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.88	15.61	0.69	2.15e-39	Chronic sinus infection;
CESC	cis	rs2204008	0.720	rs11181343	chr12:38323616	G/T	cg13010199	chr12:38710504	ALG10B	0.45	5.63	0.33	4.49e-8	Bladder cancer;
CESC	cis	rs7937682	0.924	rs7924683	chr11:111555796	C/A	cg22437258	chr11:111473054	SIK2	0.68	9.01	0.48	4.15e-17	Primary sclerosing cholangitis;
CESC	cis	rs2108225	0.967	rs6466189	chr7:107448516	C/T	cg18560240	chr7:107437656	SLC26A3	-0.38	-5.03	-0.3	8.96e-7	Ulcerative colitis;
CESC	cis	rs11785400	0.890	rs13279182	chr8:143720544	A/G	cg24634471	chr8:143751801	JRK	0.4	5.12	0.3	5.91e-7	Schizophrenia;
CESC	cis	rs10256972	0.684	rs2363279	chr7:1096143	A/G	cg07308232	chr7:1071921	C7orf50	-0.6	-8.38	-0.46	3.2e-15	Longevity;Endometriosis;
CESC	cis	rs703842	1.000	rs3825079	chr12:58203354	C/T	cg18357645	chr12:58087776	OS9	-0.42	-5.9	-0.34	1.12e-8	Multiple sclerosis;
CESC	cis	rs662064	0.962	rs668805	chr1:10544547	A/G	cg20482658	chr1:10539492	PEX14	0.4	8.42	0.46	2.46e-15	Asthma;
CESC	trans	rs6570726	0.791	rs1935612	chr6:145906090	T/A	cg03826317	chr10:25465503	LOC100128811;GPR158	0.31	6.15	0.35	2.8e-9	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2991971	1.000	rs518365	chr1:46010652	A/G	cg05343316	chr1:45956843	TESK2	-0.52	-6.59	-0.38	2.33e-10	High light scatter reticulocyte count;
CESC	cis	rs801193	1.000	rs7788576	chr7:66148302	G/A	cg14393609	chr7:65229607	NA	-0.46	-6.14	-0.35	3.03e-9	Aortic root size;
CESC	cis	rs1552244	0.882	rs3732967	chr3:10015437	T/C	cg00149659	chr3:10157352	C3orf10	0.71	8.4	0.46	2.72e-15	Alzheimer's disease;
CESC	cis	rs2708240	1.000	rs2708240	chr7:147577537	C/T	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.32	-5.29	-0.31	2.51e-7	QT interval (drug interaction);
CESC	cis	rs4268898	0.552	rs11125455	chr2:24374557	C/G	cg06627628	chr2:24431161	ITSN2	0.6	8.23	0.45	8.28e-15	Asthma;
CESC	cis	rs1559088	0.744	rs12972060	chr19:33537096	C/T	cg27124370	chr19:33622961	WDR88	-0.44	-5.5	-0.32	8.93e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs1843834	0.611	rs1058360	chr2:225449242	A/T	cg12698349	chr2:225449008	CUL3	0.61	8.56	0.47	9.55e-16	IgE levels in asthmatics (D.p. specific);
CESC	cis	rs1153858	0.943	rs28605551	chr15:45641720	C/T	cg21132104	chr15:45694354	SPATA5L1	0.82	11.02	0.56	1.72e-23	Homoarginine levels;
CESC	cis	rs9790314	0.875	rs163327	chr3:161062724	A/G	cg03342759	chr3:160939853	NMD3	-0.47	-6.42	-0.37	6.15e-10	Morning vs. evening chronotype;
CESC	cis	rs72792276	1.000	rs72794361	chr5:127435188	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.64	5.12	0.3	5.82e-7	Red cell distribution width;
CESC	cis	rs4853012	0.887	rs2280642	chr2:74358252	T/A	cg19729930	chr2:74357872	NA	0.91	12.88	0.62	8.64e-30	Gestational age at birth (maternal effect);
CESC	cis	rs9399137	0.507	rs6904897	chr6:135382980	T/G	cg24558204	chr6:135376177	HBS1L	0.69	9.56	0.51	8.81e-19	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	cis	rs938554	0.784	rs1071988	chr4:9974638	A/G	cg00071950	chr4:10020882	SLC2A9	-0.47	-5.68	-0.33	3.54e-8	Blood metabolite levels;
CESC	cis	rs6963495	0.818	rs114865717	chr7:105158526	C/T	cg19920283	chr7:105172520	RINT1	0.69	6.56	0.37	2.85e-10	Bipolar disorder (body mass index interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03509671	chr3:101497876	FAM55C	0.57	6.31	0.36	1.19e-9	Gut microbiome composition (summer);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg07956897	chr2:20647393	RHOB	0.4	6.08	0.35	4.17e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs6688613	0.694	rs2075946	chr1:166818566	A/G	ch.1.3259774R	chr1:166827647	TADA1	0.6	6.1	0.35	3.71e-9	Refractive astigmatism;
CESC	cis	rs9457247	1.000	rs409356	chr6:167405226	T/A	cg25258033	chr6:167368657	RNASET2	0.39	5.88	0.34	1.26e-8	Crohn's disease;
CESC	cis	rs1552244	0.882	rs17081288	chr3:10042113	A/G	cg08888203	chr3:10149979	C3orf24	0.48	6.09	0.35	3.99e-9	Alzheimer's disease;
CESC	cis	rs28386778	0.799	rs12450683	chr17:61984299	C/G	cg11494091	chr17:61959527	GH2	0.77	14.79	0.67	1.75e-36	Prudent dietary pattern;
CESC	cis	rs9457247	0.663	rs10946205	chr6:167451311	A/G	cg25258033	chr6:167368657	RNASET2	0.37	5.26	0.31	2.95e-7	Crohn's disease;
CESC	cis	rs2228479	0.850	rs17226966	chr16:89825338	A/G	cg14709524	chr16:89940631	TCF25	0.91	6.75	0.38	9.34e-11	Skin colour saturation;
CESC	cis	rs7927771	0.507	rs7119517	chr11:47675316	T/C	cg20307385	chr11:47447363	PSMC3	0.62	8.8	0.48	1.77e-16	Subjective well-being;
CESC	cis	rs2033711	0.870	rs7408188	chr19:58939389	T/G	cg00825309	chr19:58991885	ZNF446	-0.55	-7.86	-0.43	9.42e-14	Uric acid clearance;
CESC	cis	rs875971	0.798	rs7789615	chr7:65878661	A/G	cg12463550	chr7:65579703	CRCP	0.51	6.41	0.37	6.58e-10	Aortic root size;
CESC	cis	rs72634258	0.891	rs35731977	chr1:8014568	G/A	cg00042356	chr1:8021962	PARK7	0.84	7.07	0.4	1.4e-11	Inflammatory bowel disease;
CESC	cis	rs8114671	0.586	rs6087634	chr20:33413809	G/A	cg24642439	chr20:33292090	TP53INP2	0.44	5.21	0.31	3.72e-7	Height;
CESC	cis	rs2797160	1.000	rs1418951	chr6:125996185	A/G	cg05901451	chr6:126070800	HEY2	-0.45	-6.66	-0.38	1.55e-10	Endometrial cancer;
CESC	cis	rs7267979	0.899	rs6115213	chr20:25550372	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.75	13.02	0.62	2.64e-30	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs9926296	0.605	rs8046243	chr16:89852133	A/G	cg03388025	chr16:89894329	SPIRE2	0.41	7.74	0.43	2.12e-13	Vitiligo;
CESC	cis	rs1799949	0.930	rs56729776	chr17:41422131	C/T	cg25072359	chr17:41440525	NA	0.49	6.53	0.37	3.36e-10	Menopause (age at onset);
CESC	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg21724239	chr8:58056113	NA	0.6	5.45	0.32	1.17e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs7618915	0.547	rs1561337	chr3:52659963	C/T	cg18404041	chr3:52824283	ITIH1	-0.38	-6.3	-0.36	1.24e-9	Bipolar disorder;
CESC	trans	rs8073060	0.586	rs8077826	chr17:34001139	G/A	cg19694781	chr19:47549865	TMEM160	-0.74	-6.91	-0.39	3.64e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	trans	rs7866350	0.604	rs1935389	chr9:100994470	A/G	cg25430849	chr7:99699006	MCM7;AP4M1	0.44	6.16	0.35	2.68e-9	Post-traumatic stress disorder;
CESC	cis	rs4237845	0.537	rs9645819	chr12:58270063	T/C	cg00677455	chr12:58241039	CTDSP2	0.77	10.25	0.53	5.63e-21	Intelligence (multi-trait analysis);
CESC	cis	rs3812762	0.871	rs10734637	chr11:8788225	A/C	cg03980550	chr11:8754370	ST5	0.37	5.43	0.32	1.28e-7	Hypospadias;
CESC	cis	rs2304069	0.954	rs4705408	chr5:149412545	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.9	-11.69	-0.58	1.02e-25	HIV-1 control;
CESC	cis	rs9818758	0.607	rs34580506	chr3:49113713	C/A	cg00383909	chr3:49044727	WDR6	0.92	6.59	0.38	2.35e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg18766056	chr1:39457186	AKIRIN1	-0.53	-6.72	-0.38	1.09e-10	Ulcerative colitis;
CESC	cis	rs7772486	0.790	rs2265474	chr6:146182092	G/A	cg23711669	chr6:146136114	FBXO30	1.03	15.9	0.7	2.01e-40	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7077164	0.960	rs1227777	chr10:71581131	A/G	cg07630274	chr10:71583235	COL13A1	0.41	8.29	0.45	5.83e-15	Non-alcoholic fatty liver disease histology (lobular);
CESC	cis	rs7412746	0.621	rs72704656	chr1:150828307	A/G	cg17724175	chr1:150552817	MCL1	0.4	6.21	0.36	2.04e-9	Melanoma;
CESC	cis	rs798554	1.000	rs798544	chr7:2763102	A/G	cg04166393	chr7:2884313	GNA12	-0.56	-7.17	-0.4	7.57e-12	Height;
CESC	cis	rs7208859	0.673	rs9912122	chr17:29140716	C/A	cg14008862	chr17:28927542	LRRC37B2	0.57	5.43	0.32	1.3e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs7552404	0.921	rs10873685	chr1:76218818	A/C	cg03433033	chr1:76189801	ACADM	0.69	8.34	0.46	4.16e-15	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs2276314	0.857	rs62101376	chr18:33582955	T/C	cg19628046	chr18:33552617	C18orf21	0.47	5.04	0.3	8.63e-7	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs854765	0.693	rs8079321	chr17:17760789	C/T	cg16928487	chr17:17741425	SREBF1	-0.54	-9.63	-0.51	5.09e-19	Total body bone mineral density;
CESC	trans	rs11098499	0.954	rs3890049	chr4:120326283	T/A	cg25214090	chr10:38739885	LOC399744	0.71	9.8	0.52	1.46e-19	Corneal astigmatism;
CESC	cis	rs12791968	1.000	rs10838397	chr11:45009133	A/G	cg11846598	chr11:44996168	LOC221122	0.59	7.98	0.44	4.53e-14	Inhibitory control;
CESC	cis	rs7223966	1.000	rs6504170	chr17:61709168	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.49	-5.88	-0.34	1.21e-8	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs7762018	0.770	rs3823466	chr6:170189926	C/T	cg13891659	chr6:170190454	C6orf122;C6orf208	0.61	6.14	0.35	2.97e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs2075371	0.830	rs12669960	chr7:133931782	A/G	cg00033643	chr7:134001901	SLC35B4	0.41	5.25	0.31	3.2e-7	Mean platelet volume;
CESC	cis	rs66782572	1	rs66782572	chr3:52567617	A/G	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.34	6.49	0.37	4.32e-10	Hemoglobin concentration;
CESC	cis	rs6598955	0.671	rs12086573	chr1:26574330	G/A	cg19743891	chr1:26644573	UBXN11;CD52	0.37	5.19	0.3	4.16e-7	Obesity-related traits;
CESC	cis	rs77106637	1.000	rs76793820	chr11:72619860	G/A	cg03713592	chr11:72463424	ARAP1	1.14	10.34	0.54	2.87e-21	Type 2 diabetes;
CESC	cis	rs17253792	0.731	rs79483151	chr14:56048851	C/T	cg01858014	chr14:56050164	KTN1	-0.99	-7.44	-0.42	1.43e-12	Putamen volume;
CESC	cis	rs1348850	0.567	rs880898	chr2:178532470	C/T	cg23306229	chr2:178417860	TTC30B	0.54	7.16	0.4	8.11e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs9399135	0.660	rs4646868	chr6:135271946	A/G	cg24558204	chr6:135376177	HBS1L	0.6	8.27	0.45	6.5e-15	Red blood cell count;
CESC	cis	rs7833790	0.929	rs28464834	chr8:82797356	A/T	cg07697082	chr8:82753677	SNX16	-0.38	-5.39	-0.31	1.54e-7	Diastolic blood pressure;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27140083	chr15:75230280	COX5A	0.55	6.01	0.35	6.13e-9	Gut microbiome composition (summer);
CESC	cis	rs10911232	0.507	rs10911222	chr1:183047363	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.86	13.6	0.64	2.66e-32	Hypertriglyceridemia;
CESC	cis	rs9911578	1.000	rs9915935	chr17:56843048	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.4	5.29	0.31	2.6e-7	Intelligence (multi-trait analysis);
CESC	cis	rs2066819	0.901	rs773665	chr12:56717466	C/T	cg26734620	chr12:56694298	CS	-0.92	-9.33	-0.5	4.31e-18	Psoriasis vulgaris;
CESC	cis	rs10540	1.000	rs61876334	chr11:487201	T/C	cg21784768	chr11:537496	LRRC56	-0.57	-5.36	-0.31	1.85e-7	Body mass index;
CESC	cis	rs1059312	0.808	rs4760537	chr12:129301299	C/A	cg09035930	chr12:129282057	SLC15A4	0.68	9.02	0.48	4.03e-17	Systemic lupus erythematosus;
CESC	cis	rs5769765	0.955	rs8138687	chr22:50291869	A/G	cg02269571	chr22:50332266	NA	-0.45	-6.05	-0.35	4.98e-9	Schizophrenia;
CESC	cis	rs116095464	0.558	rs60251075	chr5:245292	T/C	cg10591111	chr5:226296	SDHA	-0.52	-6.38	-0.36	7.94e-10	Breast cancer;
CESC	trans	rs3942852	0.806	rs4752893	chr11:48118604	C/T	cg03929089	chr4:120376271	NA	-0.56	-6.38	-0.36	7.84e-10	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs2549003	1.000	rs2549004	chr5:131827825	C/G	cg21138405	chr5:131827807	IRF1	-0.63	-11.3	-0.57	1.97e-24	Asthma (sex interaction);
CESC	cis	rs2841277	0.645	rs28380382	chr14:105410827	C/T	cg15352829	chr14:105391018	PLD4	-0.59	-10.4	-0.54	1.75e-21	Rheumatoid arthritis;
CESC	cis	rs1642645	0.831	rs768613	chr1:42485263	T/C	cg16685388	chr1:42384056	HIVEP3	0.38	5.68	0.33	3.57e-8	Left ventricular obstructive tract defect (maternal effect);
CESC	cis	rs1552244	0.938	rs56274701	chr3:10167790	G/A	cg00166722	chr3:10149974	C3orf24	0.45	5.84	0.34	1.54e-8	Alzheimer's disease;
CESC	cis	rs801193	0.773	rs801207	chr7:66020590	T/C	cg18252515	chr7:66147081	NA	0.39	5.18	0.3	4.4e-7	Aortic root size;
CESC	trans	rs7618501	0.699	rs1317154	chr3:49910084	T/C	cg21659725	chr3:3221576	CRBN	0.59	8.24	0.45	8.11e-15	Intelligence (multi-trait analysis);
CESC	cis	rs4654899	1.000	rs7525438	chr1:21458217	G/A	cg05370193	chr1:21551575	ECE1	0.41	6.2	0.36	2.2e-9	Superior frontal gyrus grey matter volume;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg09755579	chr2:61645972	SNORA70B;USP34	0.4	6.24	0.36	1.74e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs2070488	0.736	rs2070988	chr3:38437835	C/T	cg24069376	chr3:38537580	EXOG	0.37	6.22	0.36	1.89e-9	Electrocardiographic conduction measures;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg27224195	chr8:11324244	FAM167A	-0.45	-6.06	-0.35	4.77e-9	Fibrinogen levels;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg24385632	chr11:16838615	PLEKHA7	0.54	7.25	0.41	4.65e-12	Fibrinogen levels;
CESC	cis	rs67478160	0.654	rs4906365	chr14:104229230	G/C	cg01849466	chr14:104193079	ZFYVE21	-0.48	-6.5	-0.37	3.95e-10	Schizophrenia;
CESC	cis	rs2832191	0.671	rs68101501	chr21:30513229	G/T	cg24692254	chr21:30365293	RNF160	-0.6	-7.63	-0.42	4.31e-13	Dental caries;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg25748441	chr2:202122587	CASP8	-0.49	-6.37	-0.36	8.4e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs1552244	0.882	rs7636817	chr3:10014876	G/T	cg00166722	chr3:10149974	C3orf24	0.49	5.98	0.34	7.37e-9	Alzheimer's disease;
CESC	cis	rs7188697	0.922	rs37041	chr16:58579886	T/C	cg21335942	chr16:58549945	SETD6	0.46	5.4	0.31	1.47e-7	QT interval;
CESC	cis	rs1448094	0.692	rs7958438	chr12:86326141	A/T	cg02569458	chr12:86230093	RASSF9	0.41	5.76	0.33	2.32e-8	Major depressive disorder;
CESC	cis	rs1448094	0.802	rs56391398	chr12:86424114	C/T	cg02569458	chr12:86230093	RASSF9	0.39	5.77	0.33	2.23e-8	Major depressive disorder;
CESC	cis	rs7666738	0.819	rs13120307	chr4:99036100	A/C	cg18180107	chr4:99064573	C4orf37	0.43	5.4	0.31	1.5e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6502050	0.835	rs28640920	chr17:80105151	A/T	cg23985595	chr17:80112537	CCDC57	-0.42	-6.57	-0.37	2.72e-10	Life satisfaction;
CESC	cis	rs7555523	0.887	rs4657471	chr1:165686873	T/C	cg24409356	chr1:165738333	TMCO1	0.89	8.09	0.45	2.14e-14	Intraocular pressure;Glaucoma (high intraocular pressure);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01744729	chr13:113474194	ATP11A	-0.59	-6.63	-0.38	1.92e-10	Gut microbiome composition (summer);
CESC	cis	rs9487051	0.714	rs7744284	chr6:109616218	C/T	cg01475377	chr6:109611718	NA	-0.43	-6.8	-0.39	7.03e-11	Reticulocyte fraction of red cells;
CESC	cis	rs4975709	0.569	rs2077269	chr5:1863506	C/T	cg15595755	chr5:1867978	NA	0.5	8.13	0.45	1.7e-14	Cardiovascular disease risk factors;
CESC	cis	rs1707322	0.964	rs6675259	chr1:46502295	G/A	cg06784218	chr1:46089804	CCDC17	-0.37	-5.97	-0.34	7.75e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs10905099	0.708	rs34463850	chr10:7094084	C/T	cg05230642	chr15:25439252	SNORD115-14	-0.73	-6.17	-0.35	2.6e-9	Orofacial clefts;
CESC	cis	rs4713118	0.662	rs9357060	chr6:28024486	C/G	cg22143856	chr6:28129313	ZNF389	0.42	5.25	0.31	3.16e-7	Parkinson's disease;
CESC	cis	rs4588572	0.643	rs11744479	chr5:77729220	T/G	cg11547950	chr5:77652471	NA	-0.45	-5.6	-0.33	5.32e-8	Triglycerides;
CESC	cis	rs5995756	0.712	rs9611205	chr22:40010521	G/A	cg03390717	chr22:39966585	CACNA1I	-0.31	-5.2	-0.3	3.92e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs13256369	1.000	rs12547721	chr8:8570671	C/T	cg00074818	chr8:8560427	CLDN23	0.34	5.15	0.3	5.12e-7	Obesity-related traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07021777	chr4:88312416	HSD17B11	0.54	6.28	0.36	1.41e-9	Gut microbiome composition (summer);
CESC	cis	rs7772486	0.875	rs969694	chr6:146394655	A/G	cg05347473	chr6:146136440	FBXO30	0.51	7.04	0.4	1.66e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2315504	0.509	rs3760335	chr17:39026061	T/A	cg05063374	chr17:38953512	KRT28	-0.45	-6.34	-0.36	9.66e-10	Height;
CESC	trans	rs9929218	0.520	rs1078621	chr16:68778996	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.85	13.51	0.64	5.58e-32	Colorectal cancer;
CESC	cis	rs561341	1.000	rs530209	chr17:30315287	A/G	cg12193833	chr17:30244370	NA	-0.7	-6.49	-0.37	4.19e-10	Hip circumference adjusted for BMI;
CESC	trans	rs7618501	1.000	rs7648987	chr3:49868455	A/G	cg21659725	chr3:3221576	CRBN	0.82	13.21	0.63	5.87e-31	Intelligence (multi-trait analysis);
CESC	cis	rs694739	0.628	rs617051	chr11:64133638	C/A	cg02228329	chr11:64053129	BAD;GPR137	0.61	7.58	0.42	5.67e-13	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CESC	cis	rs2933343	0.649	rs1683786	chr3:128626952	T/C	cg11901034	chr3:128598214	ACAD9	-0.34	-5.04	-0.3	8.49e-7	IgG glycosylation;
CESC	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg04025307	chr7:1156635	C7orf50	0.55	9.27	0.49	6.93e-18	Longevity;Endometriosis;
CESC	cis	rs561341	1.000	rs497479	chr17:30328605	C/T	cg00745463	chr17:30367425	LRRC37B	-0.82	-7.72	-0.43	2.42e-13	Hip circumference adjusted for BMI;
CESC	cis	rs7923609	0.934	rs7923544	chr10:65182256	T/G	cg01631684	chr10:65280961	REEP3	-0.44	-5.49	-0.32	9.57e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23692589	chr11:67256716	AIP	-0.54	-6.59	-0.38	2.41e-10	Gut microbiome composition (summer);
CESC	cis	rs3126085	0.597	rs12047544	chr1:152169922	C/T	cg03465714	chr1:152285911	FLG	-0.45	-5.53	-0.32	7.5e-8	Atopic dermatitis;
CESC	cis	rs7666738	0.830	rs3852123	chr4:98697586	A/G	cg17366294	chr4:99064904	C4orf37	0.56	7.78	0.43	1.6e-13	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4970966	0.951	rs6665912	chr1:150544093	T/C	cg13175981	chr1:150552382	MCL1	0.54	5.86	0.34	1.39e-8	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs4835473	0.897	rs62337587	chr4:144646992	C/A	cg25736465	chr4:144833511	NA	-0.44	-6.48	-0.37	4.41e-10	Immature fraction of reticulocytes;
CESC	cis	rs6032067	0.925	rs62208424	chr20:43813341	G/A	cg11264863	chr20:43835661	SEMG1	0.49	5.32	0.31	2.21e-7	Blood protein levels;
CESC	cis	rs826838	0.967	rs4768330	chr12:39129399	T/C	cg26384229	chr12:38710491	ALG10B	-0.67	-11.01	-0.56	1.82e-23	Heart rate;
CESC	cis	rs514406	0.644	rs7529978	chr1:53204705	G/A	cg08859206	chr1:53392774	SCP2	0.64	9.35	0.5	3.74e-18	Monocyte count;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg19979643	chr10:6018610	IL15RA	0.47	6.38	0.36	7.94e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs4664308	0.618	rs17830904	chr2:160891688	C/T	cg03641300	chr2:160917029	PLA2R1	0.59	8.57	0.47	8.47e-16	Idiopathic membranous nephropathy;
CESC	cis	rs2576037	0.526	rs1893427	chr18:44434987	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.41	6.86	0.39	4.85e-11	Personality dimensions;
CESC	cis	rs3540	0.574	rs2601205	chr15:90961813	A/G	cg10434728	chr15:90938212	IQGAP1	0.42	7.54	0.42	7.73e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs4689388	0.581	rs1801212	chr4:6302519	C/T	cg25554036	chr4:6271136	WFS1	0.48	6.26	0.36	1.54e-9	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs4718428	0.607	rs66954441	chr7:66369209	T/C	cg18252515	chr7:66147081	NA	-0.45	-5.09	-0.3	6.84e-7	Corneal structure;
CESC	cis	rs7666738	0.830	rs7689495	chr4:98920152	T/C	cg17366294	chr4:99064904	C4orf37	0.57	7.89	0.44	8.07e-14	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6952808	0.582	rs871925	chr7:2047875	G/A	cg05863683	chr7:1912471	MAD1L1	-0.45	-6.67	-0.38	1.48e-10	Bipolar disorder and schizophrenia;
CESC	cis	rs896854	0.967	rs1320164	chr8:95960767	G/A	cg13393036	chr8:95962371	TP53INP1	-0.55	-12.25	-0.6	1.25e-27	Type 2 diabetes;
CESC	cis	rs7618915	0.570	rs2336145	chr3:52629750	A/C	cg05564831	chr3:52568323	NT5DC2	0.46	7.0	0.39	2.13e-11	Bipolar disorder;
CESC	cis	rs4919694	1.000	rs12261040	chr10:104665397	T/C	cg04362960	chr10:104952993	NT5C2	0.74	6.43	0.37	5.8e-10	Arsenic metabolism;
CESC	cis	rs9584850	0.874	rs4584	chr13:99101869	G/C	cg22223119	chr13:99095684	FARP1	-0.37	-5.28	-0.31	2.67e-7	Neuroticism;
CESC	cis	rs7811142	1.000	rs6972167	chr7:100080013	G/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.14	13.23	0.63	5.11e-31	Platelet count;
CESC	cis	rs561341	1.000	rs72823785	chr17:30273784	C/T	cg23018236	chr17:30244563	NA	-0.55	-5.36	-0.31	1.81e-7	Hip circumference adjusted for BMI;
CESC	cis	rs17376456	1.000	rs56046246	chr5:93531545	T/G	cg21475434	chr5:93447410	FAM172A	0.9	7.81	0.43	1.38e-13	Diabetic retinopathy;
CESC	cis	rs67478160	0.643	rs8005225	chr14:104300151	C/T	cg08213375	chr14:104286397	PPP1R13B	-0.53	-10.49	-0.54	9.03e-22	Schizophrenia;
CESC	cis	rs6088590	1.000	rs6119516	chr20:33328024	C/T	cg06115741	chr20:33292138	TP53INP2	0.57	7.12	0.4	9.93e-12	Coronary artery disease;
CESC	cis	rs7134594	0.677	rs2075440	chr12:109859100	C/T	cg19025524	chr12:109796872	NA	0.38	5.5	0.32	9.12e-8	HDL cholesterol;
CESC	cis	rs9302635	0.513	rs35460163	chr16:72177060	C/T	cg01557791	chr16:72042693	DHODH	-0.63	-7.02	-0.4	1.83e-11	Blood protein levels;
CESC	cis	rs763014	0.898	rs35666389	chr16:629458	A/G	cg07256732	chr16:621771	PIGQ	-0.3	-5.11	-0.3	6.07e-7	Height;
CESC	cis	rs11583043	0.958	rs12730160	chr1:101438791	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.5	5.5	0.32	8.95e-8	Ulcerative colitis;Inflammatory bowel disease;
CESC	cis	rs1799949	1.000	rs11654452	chr17:41189383	G/T	cg23758822	chr17:41437982	NA	1.03	14.75	0.67	2.37e-36	Menopause (age at onset);
CESC	cis	rs7666738	0.791	rs4699329	chr4:99056212	G/A	cg18180107	chr4:99064573	C4orf37	0.42	5.36	0.31	1.79e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7312933	0.558	rs1796388	chr12:42785987	G/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.51	-6.85	-0.39	5.05e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs6088580	0.668	rs1205340	chr20:32923871	G/A	cg08999081	chr20:33150536	PIGU	-0.64	-11.04	-0.56	1.46e-23	Glomerular filtration rate (creatinine);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg26270411	chr20:43514327	YWHAB	-0.45	-6.37	-0.36	8.36e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs11030122	0.702	rs2898947	chr11:3977572	G/A	cg18678763	chr11:4115507	RRM1	-0.49	-6.52	-0.37	3.64e-10	Mean platelet volume;Platelet distribution width;
CESC	cis	rs10899021	0.704	rs11236177	chr11:74339067	T/C	cg25880958	chr11:74394337	NA	-0.74	-7.86	-0.43	9.76e-14	Response to metformin (IC50);
CESC	cis	rs2108622	0.727	rs62106158	chr19:15980492	T/G	cg13772218	chr19:15982569	NA	0.3	5.87	0.34	1.27e-8	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CESC	cis	rs2075371	0.674	rs11771785	chr7:134013249	A/G	cg20476274	chr7:133979776	SLC35B4	-0.58	-7.6	-0.42	5.14e-13	Mean platelet volume;
CESC	cis	rs7605378	1.000	rs2689766	chr2:200697539	A/T	cg23649088	chr2:200775458	C2orf69	0.5	6.61	0.38	2.13e-10	Osteoporosis;
CESC	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg06074448	chr4:187884817	NA	0.38	5.37	0.31	1.72e-7	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs514406	0.505	rs835609	chr1:53170494	T/C	cg24675658	chr1:53192096	ZYG11B	-0.52	-6.56	-0.37	2.88e-10	Monocyte count;
CESC	cis	rs637571	0.522	rs538954	chr11:65756808	A/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.43	6.46	0.37	4.93e-10	Eosinophil percentage of white cells;
CESC	cis	rs1580019	0.587	rs10951338	chr7:32560089	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.52	6.73	0.38	1.05e-10	Cognitive ability;
CESC	cis	rs4665809	0.590	rs6730310	chr2:26419470	C/G	cg04944784	chr2:26401820	FAM59B	-0.92	-10.69	-0.55	2.14e-22	Gut microbiome composition (summer);
CESC	cis	rs3762637	0.882	rs56074178	chr3:122180011	C/G	cg24169773	chr3:122142474	KPNA1	-0.54	-6.33	-0.36	1.04e-9	LDL cholesterol levels;
CESC	cis	rs116095464	0.558	rs6881920	chr5:222411	T/C	cg22496380	chr5:211416	CCDC127	-0.72	-8.57	-0.47	8.59e-16	Breast cancer;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg03317280	chr1:228675123	RNF187	-0.5	-6.17	-0.35	2.55e-9	Ulcerative colitis;
CESC	cis	rs780094	0.544	rs780110	chr2:27685388	G/A	cg02592271	chr2:27665507	KRTCAP3	-0.26	-5.63	-0.33	4.6e-8	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
CESC	cis	rs2795502	1.000	rs2795497	chr10:43339475	C/A	cg27426351	chr10:43362370	NA	-0.45	-5.5	-0.32	8.91e-8	Blood protein levels;
CESC	cis	rs5769765	1.000	rs768618	chr22:50286827	G/A	cg02269571	chr22:50332266	NA	-0.46	-6.26	-0.36	1.53e-9	Schizophrenia;
CESC	cis	rs3096299	0.685	rs3803682	chr16:89544636	C/T	cg08392591	chr16:89556376	ANKRD11	0.56	7.63	0.42	4.29e-13	Multiple myeloma (IgH translocation);
CESC	cis	rs2346177	0.554	rs13002880	chr2:46708129	C/G	cg02822958	chr2:46747628	ATP6V1E2	0.45	5.59	0.32	5.7e-8	HDL cholesterol;
CESC	cis	rs854765	0.964	rs72827413	chr17:17988299	C/T	cg04398451	chr17:18023971	MYO15A	0.67	9.39	0.5	2.84e-18	Total body bone mineral density;
CESC	trans	rs2085496	0.764	rs1596751	chr2:193807860	A/G	cg14311088	chr22:40573762	TNRC6B	0.47	6.32	0.36	1.09e-9	Neuroticism;
CESC	cis	rs9911578	1.000	rs7207693	chr17:57016525	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.11	0.3	6.07e-7	Intelligence (multi-trait analysis);
CESC	cis	rs921968	0.565	rs7595901	chr2:219606931	A/G	cg02176678	chr2:219576539	TTLL4	-0.46	-8.15	-0.45	1.46e-14	Mean corpuscular hemoglobin concentration;
CESC	cis	rs3020736	0.500	rs28791586	chr22:42500483	A/G	cg04733989	chr22:42467013	NAGA	-0.79	-12.03	-0.59	6.75e-27	Autism spectrum disorder or schizophrenia;
CESC	cis	rs7666738	0.830	rs3846444	chr4:99032888	T/C	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.58e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs853679	0.517	rs12174753	chr6:28042465	C/G	cg19592336	chr6:28129416	ZNF389	0.6	7.97	0.44	4.69e-14	Depression;
CESC	cis	rs801193	0.569	rs7782587	chr7:66166472	C/T	cg18252515	chr7:66147081	NA	-0.46	-6.24	-0.36	1.71e-9	Aortic root size;
CESC	cis	rs2404602	0.583	rs12898415	chr15:76574232	C/T	cg22467129	chr15:76604101	ETFA	-0.37	-5.66	-0.33	4.01e-8	Blood metabolite levels;
CESC	cis	rs2032447	0.507	rs199748	chr6:25909045	C/G	cg03517284	chr6:25882590	NA	-0.65	-9.09	-0.49	2.38e-17	Intelligence (multi-trait analysis);
CESC	cis	rs6963495	0.585	rs1728653	chr7:105191335	A/G	cg02135003	chr7:105160482	PUS7	-0.38	-5.59	-0.32	5.63e-8	Bipolar disorder (body mass index interaction);
CESC	trans	rs1814175	0.817	rs4405313	chr11:50013636	G/A	cg15704280	chr7:45808275	SEPT13	-1.05	-21.18	-0.79	6.15e-59	Height;
CESC	cis	rs72792276	1.000	rs72794379	chr5:127464965	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.66	5.26	0.31	3.04e-7	Red cell distribution width;
CESC	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg23978390	chr7:1156363	C7orf50	0.59	8.2	0.45	1.04e-14	Longevity;Endometriosis;
CESC	cis	rs9486719	0.895	rs4486019	chr6:96883814	T/C	cg06623918	chr6:96969491	KIAA0776	-0.81	-8.29	-0.45	5.61e-15	Migraine;Coronary artery disease;
CESC	cis	rs7264396	0.635	rs6088971	chr20:34535373	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.81	-11.07	-0.56	1.16e-23	Total cholesterol levels;
CESC	cis	rs1707322	0.682	rs10890334	chr1:46100378	A/T	cg06784218	chr1:46089804	CCDC17	0.4	6.99	0.39	2.23e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg18538332	chr22:24372958	LOC391322	-0.72	-10.45	-0.54	1.26e-21	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs3796619	1.000	rs4974638	chr4:1099201	G/A	cg27284194	chr4:1044797	NA	0.37	5.49	0.32	9.59e-8	Recombination rate (males);
CESC	cis	rs7824557	0.527	rs11785394	chr8:11238029	C/T	cg21775007	chr8:11205619	TDH	-0.5	-6.93	-0.39	3.13e-11	Retinal vascular caliber;
CESC	cis	rs11785693	0.862	rs1156861	chr8:4984434	G/C	cg26367366	chr8:4980734	NA	0.92	8.51	0.46	1.29e-15	Neuroticism (multi-trait analysis);Neuroticism;
CESC	cis	rs1018836	0.923	rs6986088	chr8:91538474	A/C	cg16814680	chr8:91681699	NA	-0.72	-11.04	-0.56	1.4e-23	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs9291683	0.527	rs11727087	chr4:10096020	A/G	cg11266682	chr4:10021025	SLC2A9	0.55	10.48	0.54	9.67e-22	Bone mineral density;
CESC	cis	rs7267979	1.000	rs34645895	chr20:25368373	A/G	cg08601574	chr20:25228251	PYGB	-0.38	-5.55	-0.32	6.88e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs367943	0.712	rs13157609	chr5:112683583	G/A	cg12552261	chr5:112820674	MCC	0.41	5.3	0.31	2.49e-7	Type 2 diabetes;
CESC	cis	rs684232	0.602	rs2543775	chr17:557123	G/A	cg15660573	chr17:549704	VPS53	-0.8	-11.75	-0.59	6.18e-26	Prostate cancer;
CESC	cis	rs11640533	0.901	rs2908790	chr16:53412161	T/C	cg27158636	chr16:53407423	NA	0.38	5.14	0.3	5.39e-7	Intelligence (multi-trait analysis);
CESC	cis	rs6952808	0.756	rs13234214	chr7:1878860	C/T	cg13880726	chr7:1868755	MAD1L1	0.54	7.3	0.41	3.46e-12	Bipolar disorder and schizophrenia;
CESC	cis	rs703842	1.000	rs10877015	chr12:58167788	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.73	9.49	0.5	1.44e-18	Multiple sclerosis;
CESC	cis	rs7267979	1.000	rs2474777	chr20:25272633	A/G	cg08601574	chr20:25228251	PYGB	0.39	5.9	0.34	1.13e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7236492	0.577	rs7236190	chr18:77198217	T/C	cg15644404	chr18:77186268	NFATC1	-0.46	-5.33	-0.31	2.06e-7	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs7662987	0.517	rs2851265	chr4:100029684	A/G	cg12011299	chr4:100065546	ADH4	0.58	6.33	0.36	1.04e-9	Smoking initiation;
CESC	cis	rs9486719	1.000	rs12210146	chr6:96903962	A/G	cg06623918	chr6:96969491	KIAA0776	0.82	8.24	0.45	7.78e-15	Migraine;Coronary artery disease;
CESC	cis	rs6088580	0.634	rs6059856	chr20:33057954	G/C	cg06115741	chr20:33292138	TP53INP2	0.46	5.97	0.34	7.6e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs7072216	0.763	rs942804	chr10:100168499	C/A	cg26618903	chr10:100175079	PYROXD2	-0.36	-5.47	-0.32	1.06e-7	Metabolite levels;
CESC	cis	rs9733	0.744	rs2039590	chr1:150813315	G/A	cg18016565	chr1:150552671	MCL1	-0.35	-5.67	-0.33	3.76e-8	Tonsillectomy;
CESC	cis	rs910316	1.000	rs175425	chr14:75626131	T/C	cg08847533	chr14:75593920	NEK9	-0.97	-17.65	-0.74	1.22e-46	Height;
CESC	cis	rs1552244	0.935	rs35586456	chr3:10116938	A/G	cg08888203	chr3:10149979	C3orf24	0.54	6.78	0.38	7.97e-11	Alzheimer's disease;
CESC	trans	rs4906172	0.773	rs10135238	chr14:102518870	C/T	cg17920195	chr4:129149383	NA	-0.31	-6.01	-0.35	5.97e-9	Menopause (age at onset);
CESC	cis	rs9733	0.596	rs2867300	chr1:150666990	C/G	cg17724175	chr1:150552817	MCL1	0.45	7.24	0.41	4.96e-12	Tonsillectomy;
CESC	cis	rs5758511	0.680	rs56111723	chr22:42664883	T/A	cg00645731	chr22:42541494	CYP2D7P1	0.57	8.59	0.47	7.36e-16	Birth weight;
CESC	cis	rs909341	0.710	rs3848669	chr20:62300811	G/T	cg03999872	chr20:62272968	STMN3	0.53	5.3	0.31	2.5e-7	Atopic dermatitis;
CESC	cis	rs16858210	0.648	rs79478990	chr3:183587094	C/T	cg03417191	chr3:183542750	MAP6D1	-0.46	-5.89	-0.34	1.17e-8	Menopause (age at onset);
CESC	cis	rs4665809	1.000	rs2384321	chr2:26290054	A/G	cg27170947	chr2:26402098	FAM59B	-0.72	-8.31	-0.45	5.18e-15	Gut microbiome composition (summer);
CESC	cis	rs61931739	0.500	rs11053260	chr12:34530215	T/G	cg06521331	chr12:34319734	NA	-0.37	-5.15	-0.3	5.19e-7	Morning vs. evening chronotype;
CESC	cis	rs826838	0.904	rs11612004	chr12:39204282	G/A	cg13010199	chr12:38710504	ALG10B	0.58	8.05	0.44	2.77e-14	Heart rate;
CESC	cis	rs887829	0.588	rs7556676	chr2:234658250	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.5	-6.48	-0.37	4.57e-10	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CESC	cis	rs4975709	0.589	rs4975746	chr5:1861069	G/A	cg14773178	chr5:1868261	NA	0.33	5.88	0.34	1.22e-8	Cardiovascular disease risk factors;
CESC	cis	rs7618915	0.571	rs11130307	chr3:52607682	G/A	cg18337363	chr3:52569053	NT5DC2	0.29	5.03	0.3	8.89e-7	Bipolar disorder;
CESC	cis	rs9916302	0.904	rs12952384	chr17:37669536	T/C	cg15445000	chr17:37608096	MED1	0.41	6.87	0.39	4.66e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs9926296	0.712	rs2437957	chr16:89715648	G/A	cg01097406	chr16:89675127	NA	0.38	5.33	0.31	2.14e-7	Vitiligo;
CESC	cis	rs35306767	0.903	rs11816064	chr10:931176	A/C	cg25019033	chr10:957182	NA	-0.56	-6.18	-0.35	2.42e-9	Eosinophil percentage of granulocytes;
CESC	cis	rs193541	0.632	rs154503	chr5:122204499	G/A	cg19412675	chr5:122181750	SNX24	0.46	5.49	0.32	9.54e-8	Glucose homeostasis traits;
CESC	cis	rs853679	0.882	rs9380069	chr6:28203300	A/G	cg23281280	chr6:28129359	ZNF389	0.55	5.8	0.34	1.85e-8	Depression;
CESC	cis	rs9488822	0.636	rs7745074	chr6:116347432	G/A	cg15226275	chr6:116381976	FRK	0.24	6.2	0.36	2.17e-9	Cholesterol, total;LDL cholesterol;
CESC	cis	rs6089584	0.893	rs6089305	chr20:60571817	T/C	cg24733560	chr20:60626293	TAF4	0.38	5.45	0.32	1.15e-7	Body mass index;
CESC	cis	rs861020	0.527	rs614662	chr1:209962419	C/T	cg23283495	chr1:209979779	IRF6	-0.37	-5.68	-0.33	3.45e-8	Orofacial clefts;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00969680	chr1:113466087	AFARP1;SLC16A1	-0.64	-7.09	-0.4	1.2e-11	Gut microbiome composition (summer);
CESC	cis	rs780096	0.526	rs3845687	chr2:27689899	T/C	cg12648201	chr2:27665141	KRTCAP3	-0.36	-6.64	-0.38	1.76e-10	Total body bone mineral density;
CESC	cis	rs2274273	0.840	rs7159144	chr14:55821324	G/A	cg04306507	chr14:55594613	LGALS3	0.32	6.31	0.36	1.19e-9	Protein biomarker;
CESC	cis	rs4253772	0.530	rs9615958	chr22:46751122	A/G	cg00784671	chr22:46762841	CELSR1	-0.6	-6.28	-0.36	1.36e-9	LDL cholesterol;Cholesterol, total;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg09349940	chr16:22218118	EEF2K	-0.46	-6.08	-0.35	4.16e-9	Asthma;
CESC	cis	rs7552404	0.690	rs12723575	chr1:76335203	T/C	cg10523679	chr1:76189770	ACADM	-0.66	-6.71	-0.38	1.15e-10	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs1008375	1.000	rs10939746	chr4:17684951	A/G	cg02297831	chr4:17616191	MED28	-0.41	-5.28	-0.31	2.67e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17129466	chr19:1848747	REXO1	-0.65	-7.64	-0.42	3.99e-13	Gut microbiome composition (summer);
CESC	cis	rs17490626	0.512	rs12241097	chr10:71216678	T/G	cg12610070	chr10:71211762	TSPAN15	-0.3	-6.33	-0.36	1.07e-9	Thrombosis;
CESC	trans	rs7615952	0.599	rs12496921	chr3:125701948	C/G	cg07211511	chr3:129823064	LOC729375	-0.55	-6.3	-0.36	1.2e-9	Blood pressure (smoking interaction);
CESC	cis	rs7116495	1.000	rs677279	chr11:71770469	G/A	cg10381502	chr11:71823885	C11orf51	-0.67	-5.66	-0.33	3.92e-8	Severe influenza A (H1N1) infection;
CESC	cis	rs4319547	0.915	rs7314638	chr12:122983460	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.66	-7.7	-0.43	2.64e-13	Body mass index;
CESC	cis	rs1008375	0.966	rs10939758	chr4:17698255	C/T	cg04450456	chr4:17643702	FAM184B	0.36	5.05	0.3	8.3e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs3785574	0.962	rs2665835	chr17:61903258	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.57	6.96	0.39	2.69e-11	Height;
CESC	cis	rs3008870	1.000	rs6673462	chr1:67461857	A/C	cg08660285	chr1:67390436	MIER1;WDR78	-1.06	-15.19	-0.68	6.65e-38	Lymphocyte percentage of white cells;
CESC	cis	rs172166	0.694	rs203877	chr6:28048624	T/C	cg23161317	chr6:28129485	ZNF389	0.39	5.48	0.32	1.01e-7	Cardiac Troponin-T levels;
CESC	cis	rs7666738	0.830	rs11947027	chr4:99005941	T/C	cg03467027	chr4:99064603	C4orf37	0.44	5.51	0.32	8.65e-8	Colonoscopy-negative controls vs population controls;
CESC	trans	rs9399401	0.961	rs6909857	chr6:142701158	A/G	cg15730116	chr12:76953768	OSBPL8	-0.42	-6.08	-0.35	4.23e-9	Chronic obstructive pulmonary disease;
CESC	cis	rs9487051	0.646	rs13203365	chr6:109614810	G/T	cg01475377	chr6:109611718	NA	-0.39	-5.27	-0.31	2.79e-7	Reticulocyte fraction of red cells;
CESC	cis	rs9814567	0.964	rs4974480	chr3:134178562	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.37	-5.35	-0.31	1.9e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs763014	1.000	rs763014	chr16:675680	T/C	cg09263875	chr16:632152	PIGQ	0.68	11.71	0.58	8.26e-26	Height;
CESC	cis	rs34779708	0.897	rs11010131	chr10:35513316	A/C	cg04310649	chr10:35416472	CREM	-0.55	-6.38	-0.36	7.93e-10	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs897984	0.568	rs67456613	chr16:30888295	G/A	cg02466173	chr16:30829666	NA	-0.48	-6.81	-0.39	6.53e-11	Dementia with Lewy bodies;
CESC	trans	rs7656342	0.808	rs10003216	chr4:9766749	A/G	cg02276107	chr5:61699841	DIMT1L	-0.54	-6.39	-0.37	7.23e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs7927592	0.956	rs10896334	chr11:68281494	C/T	cg16797656	chr11:68205561	LRP5	0.39	5.38	0.31	1.6e-7	Total body bone mineral density;
CESC	cis	rs2836974	0.899	rs2836957	chr21:40623134	T/C	cg11890956	chr21:40555474	PSMG1	1.16	21.51	0.8	4.52e-60	Cognitive function;
CESC	cis	rs8062405	0.755	rs4787457	chr16:28555400	A/G	cg07382826	chr16:28625726	SULT1A1	0.39	6.39	0.37	7.35e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25011051	chr17:40718249	MLX;COASY	-0.57	-6.85	-0.39	5.24e-11	Gut microbiome composition (summer);
CESC	cis	rs1843834	0.505	rs4674911	chr2:225345254	A/G	cg22509189	chr2:225307070	NA	-0.39	-5.38	-0.31	1.67e-7	IgE levels in asthmatics (D.p. specific);
CESC	cis	rs10752881	1.000	rs10911190	chr1:182979080	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.83	13.29	0.63	3.24e-31	Colorectal cancer;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg22131217	chr17:80348302	NA	0.54	7.4	0.41	1.77e-12	Fibrinogen levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24285721	chr7:44046988	SPDYE1;POLR2J4	-0.59	-7.2	-0.4	6.1e-12	Gut microbiome composition (summer);
CESC	cis	rs7208859	0.573	rs216443	chr17:28931871	A/G	cg13385521	chr17:29058706	SUZ12P	0.71	5.36	0.31	1.83e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	trans	rs11098499	0.874	rs6851169	chr4:120117510	T/C	cg25214090	chr10:38739885	LOC399744	0.61	8.04	0.44	2.91e-14	Corneal astigmatism;
CESC	cis	rs950776	0.506	rs12915366	chr15:78831753	G/A	cg24631222	chr15:78858424	CHRNA5	-0.42	-5.35	-0.31	1.95e-7	Sudden cardiac arrest;
CESC	cis	rs2425143	1.000	rs60646509	chr20:34303409	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.81	-7.35	-0.41	2.49e-12	Blood protein levels;
CESC	cis	rs763014	0.898	rs2017567	chr16:637212	T/C	cg07343612	chr16:622815	PIGQ	-0.55	-8.04	-0.44	3.08e-14	Height;
CESC	cis	rs10899021	0.920	rs11236181	chr11:74345823	A/C	cg25880958	chr11:74394337	NA	-0.77	-8.02	-0.44	3.32e-14	Response to metformin (IC50);
CESC	cis	rs2204008	0.715	rs11495369	chr12:38238673	T/C	cg13010199	chr12:38710504	ALG10B	0.49	6.1	0.35	3.78e-9	Bladder cancer;
CESC	cis	rs7124681	0.584	rs11039448	chr11:47918416	G/T	cg20307385	chr11:47447363	PSMC3	-0.58	-7.99	-0.44	4.23e-14	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25674709	chr12:105724273	C12orf75	0.66	7.54	0.42	7.36e-13	Gut microbiome composition (summer);
CESC	cis	rs3785574	0.962	rs2584630	chr17:61887561	T/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.8	10.66	0.55	2.59e-22	Height;
CESC	cis	rs965469	0.779	rs6051820	chr20:3365301	A/G	cg25506879	chr20:3388711	C20orf194	-0.49	-5.28	-0.31	2.63e-7	IFN-related cytopenia;
CESC	cis	rs2274273	0.935	rs3818451	chr14:55621116	C/G	cg04306507	chr14:55594613	LGALS3	0.28	5.54	0.32	7.17e-8	Protein biomarker;
CESC	cis	rs2836974	0.533	rs418298	chr21:40536654	A/T	cg17971929	chr21:40555470	PSMG1	0.88	12.99	0.62	3.45e-30	Cognitive function;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25464034	chr11:450264	PTDSS2	-0.59	-6.85	-0.39	5.06e-11	Gut microbiome composition (summer);
CESC	cis	rs12893668	0.703	rs12894729	chr14:104035292	G/A	cg24130564	chr14:104152367	KLC1	-0.48	-5.87	-0.34	1.31e-8	Reticulocyte count;
CESC	cis	rs34779708	0.931	rs7079498	chr10:35375344	C/T	cg03585969	chr10:35415529	CREM	0.76	10.2	0.53	8.17e-21	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs11229555	0.874	rs11229512	chr11:58286105	T/C	cg15696309	chr11:58395628	NA	-0.41	-5.03	-0.3	8.87e-7	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs1775715	0.737	rs11817598	chr10:32206259	A/G	cg26784012	chr10:32216390	ARHGAP12	0.39	5.16	0.3	4.96e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs7772486	0.658	rs9403737	chr6:145962193	G/T	cg23711669	chr6:146136114	FBXO30	0.99	14.89	0.68	7.3e-37	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2070997	0.607	rs2314342	chr9:133707362	A/G	cg11464064	chr9:133710261	ABL1	0.68	7.77	0.43	1.79e-13	Response to amphetamines;
CESC	cis	rs34734847	0.871	rs2239760	chr12:121163518	C/A	cg21892295	chr12:121157589	UNC119B	-0.39	-6.18	-0.36	2.38e-9	Mean corpuscular volume;
CESC	cis	rs3857067	0.804	rs6821438	chr4:95091911	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.6	-9.03	-0.48	3.74e-17	QT interval;
CESC	cis	rs763121	0.853	rs3761454	chr22:39066820	C/T	cg06022373	chr22:39101656	GTPBP1	0.87	13.83	0.65	4.07e-33	Menopause (age at onset);
CESC	cis	rs28735056	0.572	rs4799100	chr18:77640207	A/G	cg20368463	chr18:77673604	PQLC1	-0.4	-5.16	-0.3	4.87e-7	Schizophrenia;
CESC	cis	rs2479724	0.846	rs1536702	chr6:41869950	T/A	cg08135965	chr6:41755394	TOMM6	0.44	5.85	0.34	1.46e-8	Menarche (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27327370	chr2:192746685	NA	-0.65	-7.79	-0.43	1.5700000000000001e-13	Gut microbiome composition (summer);
CESC	cis	rs6540559	0.673	rs17015183	chr1:209948711	A/C	cg25204440	chr1:209979598	IRF6	0.6	6.6	0.38	2.24e-10	Cleft lip with or without cleft palate;
CESC	cis	rs875971	1.000	rs4717300	chr7:65947380	T/C	cg10691866	chr7:65817282	TPST1	-0.34	-5.62	-0.33	4.85e-8	Aortic root size;
CESC	trans	rs561341	0.714	rs111760509	chr17:30304320	A/G	cg20587970	chr11:113659929	NA	-1.4	-17.9	-0.74	1.64e-47	Hip circumference adjusted for BMI;
CESC	trans	rs3942852	0.594	rs10769311	chr11:48094009	T/C	cg03929089	chr4:120376271	NA	-0.64	-7.91	-0.44	6.85e-14	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs11295209	1	rs11295209	chr4:120480233	TA/T	cg09307838	chr4:120376055	NA	-0.55	-7.3	-0.41	3.43e-12	Plateletcrit;
CESC	cis	rs34375054	0.526	rs34764657	chr12:125679639	A/G	cg05341575	chr12:125625032	AACS	-0.37	-5.33	-0.31	2.12e-7	Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs7264396	0.673	rs2425163	chr20:34432670	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.85	-11.46	-0.58	5.9e-25	Total cholesterol levels;
CESC	cis	rs9393777	0.513	rs9393737	chr6:26617306	A/G	cg12826209	chr6:26865740	GUSBL1	-0.71	-8.46	-0.46	1.79e-15	Intelligence (multi-trait analysis);
CESC	cis	rs11690935	0.610	rs59844139	chr2:172731983	C/A	cg13550731	chr2:172543902	DYNC1I2	0.5	6.97	0.39	2.48e-11	Schizophrenia;
CESC	cis	rs1775715	0.737	rs2778672	chr10:32122419	T/C	cg18675610	chr10:32216311	ARHGAP12	0.34	5.27	0.31	2.85e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs4713118	0.662	rs149969	chr6:27977737	A/G	cg26335602	chr6:28129616	ZNF389	0.46	6.35	0.36	9.27e-10	Parkinson's disease;
CESC	cis	rs9470366	0.545	rs4711457	chr6:36633160	T/C	cg08179530	chr6:36648295	CDKN1A	-0.62	-8.87	-0.48	1.1e-16	QRS duration;
CESC	cis	rs13191362	0.507	rs2849511	chr6:163139050	C/G	cg06582575	chr6:163149167	PACRG;PARK2	-0.59	-6.94	-0.39	3.07e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs6088590	0.523	rs6088536	chr20:33189106	T/C	cg08999081	chr20:33150536	PIGU	0.68	11.68	0.58	1.07e-25	Coronary artery disease;
CESC	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	13.63	0.64	1.97e-32	Prudent dietary pattern;
CESC	cis	rs36051895	0.664	rs9695933	chr9:5153104	C/T	cg02405213	chr9:5042618	JAK2	-0.54	-6.88	-0.39	4.4e-11	Pediatric autoimmune diseases;
CESC	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.58	0.37	2.49e-10	Prudent dietary pattern;
CESC	cis	rs7552404	0.731	rs11588578	chr1:76400539	T/G	cg03433033	chr1:76189801	ACADM	0.52	5.22	0.31	3.65e-7	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs734999	0.505	rs4278312	chr1:2539555	A/G	cg20673091	chr1:2541236	MMEL1	0.46	7.82	0.43	1.24e-13	Ulcerative colitis;
CESC	cis	rs9503598	0.636	rs6596976	chr6:3466022	C/T	cg00476032	chr6:3446245	SLC22A23	0.35	5.75	0.33	2.45e-8	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
CESC	cis	rs2243480	1.000	rs437889	chr7:65509234	G/A	cg18252515	chr7:66147081	NA	-1.29	-12.52	-0.61	1.5e-28	Diabetic kidney disease;
CESC	cis	rs4450131	0.522	rs4962680	chr10:126358833	C/T	cg20435097	chr10:126320824	FAM53B	0.29	5.18	0.3	4.31e-7	White blood cell count (basophil);
CESC	cis	rs5750830	0.594	rs6001568	chr22:39775786	G/A	cg02038168	chr22:39784481	NA	-0.62	-7.79	-0.43	1.5e-13	Intelligence (multi-trait analysis);
CESC	cis	rs7833986	0.534	rs2458083	chr8:56898785	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.58	7.16	0.4	8.04e-12	Height;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg23104930	chr12:133125882	FBRSL1	0.43	6.23	0.36	1.82e-9	Fibrinogen levels;
CESC	cis	rs9926296	0.581	rs12598477	chr16:89902482	T/C	cg03388025	chr16:89894329	SPIRE2	0.32	5.36	0.31	1.82e-7	Vitiligo;
CESC	cis	rs1256061	0.646	rs1152588	chr14:64688175	G/C	cg21174375	chr14:64681225	SYNE2	0.5	6.44	0.37	5.69e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs9318086	0.687	rs9507182	chr13:24442365	G/A	cg25267304	chr13:24462978	PCOTH;MIPEP	0.43	5.92	0.34	9.83e-9	Myopia (pathological);
CESC	cis	rs6963495	0.745	rs56239334	chr7:105165351	G/A	cg19920283	chr7:105172520	RINT1	0.7	6.66	0.38	1.58e-10	Bipolar disorder (body mass index interaction);
CESC	cis	rs597539	0.652	rs569777	chr11:68706848	G/A	cg18350739	chr11:68623251	NA	-0.44	-6.91	-0.39	3.56e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs9911578	0.967	rs6503893	chr17:57149695	G/A	cg12560992	chr17:57184187	TRIM37	1.02	17.98	0.74	8.31e-48	Intelligence (multi-trait analysis);
CESC	cis	rs7208859	0.524	rs8065744	chr17:29099449	C/T	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.91e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg17178900	chr1:205818956	PM20D1	0.77	12.0	0.59	8.77e-27	Menarche (age at onset);
CESC	cis	rs3820068	0.626	rs11580170	chr1:15909744	C/T	cg17385448	chr1:15911702	AGMAT	0.42	6.64	0.38	1.77e-10	Systolic blood pressure;
CESC	cis	rs60154123	0.615	rs701943	chr1:210425727	A/G	cg22029157	chr1:209979665	IRF6	-0.5	-6.24	-0.36	1.68e-9	Coronary artery disease;
CESC	cis	rs7666738	0.830	rs34244876	chr4:99031336	G/A	cg05340658	chr4:99064831	C4orf37	0.83	13.1	0.63	1.43e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1950626	0.623	rs35947256	chr14:101460366	G/T	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.67	8.48	0.46	1.58e-15	Pelvic organ prolapse (moderate/severe);
CESC	cis	rs11577318	0.853	rs3795684	chr1:26632781	C/T	cg00813993	chr1:26644493	UBXN11;CD52	-0.41	-6.51	-0.37	3.84e-10	Granulocyte percentage of myeloid white cells;
CESC	cis	rs7772486	0.654	rs6906402	chr6:146089307	C/G	cg23711669	chr6:146136114	FBXO30	-0.99	-15.26	-0.68	3.83e-38	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9462846	0.919	rs9462851	chr6:42890602	A/G	cg02353165	chr6:42928485	GNMT	0.43	5.1	0.3	6.62e-7	Blood protein levels;
CESC	trans	rs875971	1.000	rs6961155	chr7:65933295	T/C	cg26939375	chr7:64535504	NA	0.46	6.0	0.35	6.4e-9	Aortic root size;
CESC	cis	rs1862618	0.853	rs832553	chr5:56114786	A/G	cg18230493	chr5:56204884	C5orf35	-0.71	-8.8	-0.48	1.78e-16	Initial pursuit acceleration;
CESC	cis	rs5771069	0.931	rs5771222	chr22:50445704	C/T	cg27467552	chr22:50353597	PIM3	0.5	7.5	0.42	9.87e-13	Ulcerative colitis;
CESC	cis	rs6982240	0.514	rs892362	chr8:142269214	A/G	cg00131261	chr8:142287264	NA	0.51	7.31	0.41	3.24e-12	Tonsillectomy;
CESC	cis	rs72634258	0.554	rs4908694	chr1:7850898	C/T	cg26816564	chr1:7831052	VAMP3	0.66	6.13	0.35	3.21e-9	Inflammatory bowel disease;
CESC	cis	rs3785574	0.924	rs2584641	chr17:61862889	A/G	cg06873352	chr17:61820015	STRADA	0.47	6.9	0.39	3.91e-11	Height;
CESC	cis	rs1559088	0.576	rs7251626	chr19:33578470	C/A	cg27124370	chr19:33622961	WDR88	0.54	7.8	0.43	1.4e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs769267	0.965	rs13964	chr19:19468710	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.63	-8.04	-0.44	3.09e-14	Tonsillectomy;
CESC	cis	rs6495122	0.644	rs62029217	chr15:75261899	C/T	cg09165964	chr15:75287851	SCAMP5	0.49	6.49	0.37	4.14e-10	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
CESC	trans	rs1814175	0.817	rs28679516	chr11:50055998	G/A	cg15704280	chr7:45808275	SEPT13	-1.05	-21.04	-0.79	1.87e-58	Height;
CESC	cis	rs4843747	0.671	rs72818576	chr16:88111019	C/G	cg06374794	chr16:88002281	BANP	0.39	5.11	0.3	6.18e-7	Menopause (age at onset);
CESC	cis	rs7044106	0.791	rs10985009	chr9:123493039	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.87	-14.04	-0.65	7.75e-34	Hip circumference adjusted for BMI;
CESC	trans	rs2230307	0.656	rs568089	chr1:100495392	A/G	cg20664313	chr12:133071297	FBRSL1	-0.63	-6.15	-0.35	2.79e-9	Carotid intima media thickness;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05269546	chr19:50098360	PRR12	-0.63	-6.95	-0.39	2.83e-11	Gut microbiome composition (summer);
CESC	cis	rs7520050	0.931	rs11576305	chr1:46460046	C/T	cg03146154	chr1:46216737	IPP	-0.48	-6.16	-0.35	2.71e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs514406	0.861	rs551435	chr1:53260537	G/T	cg08736216	chr1:53307985	ZYG11A	0.43	7.24	0.41	4.86e-12	Monocyte count;
CESC	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.52	-5.73	-0.33	2.66e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs6496667	0.509	rs6496677	chr15:90990358	A/G	cg22089800	chr15:90895588	ZNF774	0.44	5.68	0.33	3.51e-8	Rheumatoid arthritis;
CESC	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg08027265	chr7:2291960	NA	0.33	5.03	0.3	8.92e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs2439831	0.867	rs28729853	chr15:43673680	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.91	11.14	0.56	6.61e-24	Lung cancer in ever smokers;
CESC	cis	rs6500602	0.592	rs7206782	chr16:4515145	A/C	cg08645402	chr16:4508243	NA	0.43	6.45	0.37	5.38e-10	Schizophrenia;
CESC	cis	rs853679	0.517	rs1904841	chr6:28108085	C/T	cg20151795	chr6:28129481	ZNF389	0.49	6.51	0.37	3.71e-10	Depression;
CESC	cis	rs8180040	0.764	rs13062022	chr3:47169375	G/A	cg27129171	chr3:47204927	SETD2	0.7	10.54	0.54	6.49e-22	Colorectal cancer;
CESC	cis	rs10489202	1.000	rs17556487	chr1:167889094	T/A	cg24449463	chr1:168025552	DCAF6	-0.47	-5.38	-0.31	1.62e-7	Schizophrenia;
CESC	cis	rs9487051	0.872	rs9480922	chr6:109607211	G/A	cg12927641	chr6:109611667	NA	-0.44	-6.83	-0.39	5.89e-11	Reticulocyte fraction of red cells;
CESC	cis	rs796364	1.000	rs1658807	chr2:200767512	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.87	8.68	0.47	4.04e-16	Schizophrenia;
CESC	cis	rs1448094	0.511	rs17279240	chr12:86162550	A/T	cg02569458	chr12:86230093	RASSF9	0.49	7.68	0.43	3.15e-13	Major depressive disorder;
CESC	cis	rs7959452	0.570	rs10878964	chr12:69720691	T/G	cg14784868	chr12:69753453	YEATS4	0.72	10.26	0.53	5.09e-21	Blood protein levels;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg06264303	chr10:38299291	ZNF33A	0.51	6.88	0.39	4.36e-11	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.64	7.44	0.42	1.43e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs820218	0.926	rs820211	chr17:73650686	A/C	cg01592526	chr17:73663357	RECQL5;SAP30BP	-0.41	-5.5	-0.32	8.99e-8	Rotator cuff tears;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg11668448	chr8:124054817	DERL1	-0.5	-6.49	-0.37	4.2e-10	Height;
CESC	cis	rs17711722	0.701	rs55773927	chr7:65337902	T/C	cg18876405	chr7:65276391	NA	0.7	9.76	0.51	2.02e-19	Calcium levels;
CESC	cis	rs372883	0.624	rs1153286	chr21:30684383	A/G	cg24692254	chr21:30365293	RNF160	-0.49	-6.17	-0.35	2.52e-9	Pancreatic cancer;
CESC	cis	rs9660992	0.573	rs12126439	chr1:205200720	C/T	cg00857998	chr1:205179979	DSTYK	0.56	6.88	0.39	4.29e-11	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs1552244	0.882	rs3755782	chr3:10029305	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.76	-9.64	-0.51	4.86e-19	Alzheimer's disease;
CESC	cis	rs9486719	0.741	rs2499799	chr6:96851676	T/C	cg18709589	chr6:96969512	KIAA0776	0.55	5.77	0.33	2.19e-8	Migraine;Coronary artery disease;
CESC	cis	rs4975709	0.610	rs1531994	chr5:1859297	T/C	cg15595755	chr5:1867978	NA	0.55	9.05	0.49	3.23e-17	Cardiovascular disease risk factors;
CESC	cis	rs7618915	0.547	rs2590846	chr3:52692359	C/G	cg05564831	chr3:52568323	NT5DC2	0.44	6.72	0.38	1.09e-10	Bipolar disorder;
CESC	trans	rs11992162	0.560	rs7846248	chr8:11794049	T/A	cg15556689	chr8:8085844	FLJ10661	0.49	6.07	0.35	4.52e-9	Monocyte count;
CESC	trans	rs1545843	0.623	rs11116359	chr12:84791075	A/G	cg03015433	chr16:56623111	MT3	-0.33	-6.02	-0.35	5.66e-9	Major depressive disorder;
CESC	cis	rs10751667	0.600	rs6597948	chr11:1005308	C/T	cg20946044	chr11:1010712	AP2A2	-0.51	-6.93	-0.39	3.23e-11	Alzheimer's disease (late onset);
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg20843052	chr2:61293725	KIAA1841	0.42	6.13	0.35	3.2e-9	Systemic lupus erythematosus;
CESC	cis	rs4975709	0.589	rs1466607	chr5:1864856	A/G	cg10800226	chr5:1850261	NA	0.33	5.33	0.31	2.14e-7	Cardiovascular disease risk factors;
CESC	cis	rs1707322	1.000	rs10890377	chr1:46406594	G/A	cg03146154	chr1:46216737	IPP	0.72	9.82	0.52	1.31e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg20566420	chr12:122327043	PSMD9	0.48	6.21	0.36	2.05e-9	Systemic lupus erythematosus;
CESC	trans	rs6535028	0.803	rs4565134	chr4:135456548	C/T	cg04198210	chr15:74528606	CCDC33	-0.6	-6.14	-0.35	3.07e-9	Response to radiotherapy in prostate cancer (overall toxicity);
CESC	cis	rs9311474	0.508	rs7625743	chr3:52606366	C/G	cg18337363	chr3:52569053	NT5DC2	0.3	5.58	0.32	5.86e-8	Electroencephalogram traits;
CESC	cis	rs3126085	0.935	rs12760382	chr1:152260287	G/T	cg03465714	chr1:152285911	FLG	0.5	5.98	0.34	7.27e-9	Atopic dermatitis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12032620	chr15:43802735	TP53BP1	-0.61	-7.37	-0.41	2.12e-12	Gut microbiome composition (summer);
CESC	cis	rs2996428	0.628	rs6667526	chr1:3774603	G/A	cg13057898	chr1:3703894	LRRC47	0.45	6.14	0.35	3.05e-9	Red cell distribution width;
CESC	cis	rs798554	0.679	rs1639066	chr7:2892972	A/G	cg13628971	chr7:2884303	GNA12	0.63	8.5	0.46	1.42e-15	Height;
CESC	cis	rs13191362	1.000	rs1333963	chr6:163192571	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.05	9.74	0.51	2.3e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs7666738	0.830	rs10049985	chr4:99023517	C/T	cg03676636	chr4:99064102	C4orf37	0.33	5.15	0.3	5.05e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6582630	0.502	rs1915395	chr12:38420726	A/G	cg26384229	chr12:38710491	ALG10B	0.73	10.75	0.55	1.27e-22	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs1707322	1.000	rs7547189	chr1:46319514	C/A	cg06784218	chr1:46089804	CCDC17	0.32	5.57	0.32	6.35e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2933343	0.679	rs789229	chr3:128602526	C/T	cg25356066	chr3:128598488	ACAD9	0.66	9.18	0.49	1.27e-17	IgG glycosylation;
CESC	cis	rs7208859	0.673	rs9895815	chr17:29138033	A/G	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.79e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06714758	chr12:57881796	MARS	0.59	7.04	0.4	1.6e-11	Gut microbiome composition (summer);
CESC	cis	rs9399135	0.967	rs4637662	chr6:135298158	T/C	cg22676075	chr6:135203613	NA	0.52	7.21	0.4	5.94e-12	Red blood cell count;
CESC	trans	rs3942852	0.726	rs10742836	chr11:48175831	G/A	cg03929089	chr4:120376271	NA	-0.66	-7.24	-0.41	4.83e-12	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs2294693	0.679	rs12200923	chr6:40970092	T/G	cg14418226	chr6:40996092	UNC5CL	0.49	5.3	0.31	2.43e-7	Gastric cancer;Non-cardia gastric cancer;
CESC	cis	rs2075371	1.000	rs1421486	chr7:133985196	T/C	cg20476274	chr7:133979776	SLC35B4	0.67	9.79	0.52	1.65e-19	Mean platelet volume;
CESC	cis	rs7552404	0.883	rs77773255	chr1:76217193	G/A	cg22875332	chr1:76189707	ACADM	0.65	7.87	0.44	8.9e-14	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs2274273	0.624	rs7151754	chr14:55788501	C/T	cg04306507	chr14:55594613	LGALS3	0.29	5.1	0.3	6.54e-7	Protein biomarker;
CESC	cis	rs7100689	0.646	rs4357632	chr10:82131783	C/T	cg00277334	chr10:82204260	NA	-0.58	-7.76	-0.43	1.84e-13	Post bronchodilator FEV1;
CESC	cis	rs6812193	0.518	rs77937770	chr4:77193208	A/T	cg20311846	chr4:77356250	SHROOM3	0.3	5.26	0.31	3.01e-7	Parkinson's disease;
CESC	cis	rs2573652	0.722	rs8041337	chr15:100541808	T/C	cg00587665	chr15:100533223	ADAMTS17	-0.4	-6.49	-0.37	4.1e-10	Height;
CESC	cis	rs863345	0.565	rs7551497	chr1:158444925	T/G	cg12129480	chr1:158549410	OR10X1	-0.36	-7.18	-0.4	7.1e-12	Pneumococcal bacteremia;
CESC	cis	rs67311347	1.000	rs4973998	chr3:40460352	C/T	cg24209194	chr3:40518798	ZNF619	0.51	6.26	0.36	1.51e-9	Renal cell carcinoma;
CESC	cis	rs7555523	0.887	rs10918274	chr1:165714416	T/C	cg24409356	chr1:165738333	TMCO1	0.97	8.67	0.47	4.48e-16	Intraocular pressure;Glaucoma (high intraocular pressure);
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg16941144	chr14:45603841	FKBP3;FANCM	-0.46	-6.01	-0.35	6.24e-9	Thyroid stimulating hormone;
CESC	cis	rs3091242	0.967	rs3093614	chr1:25677844	T/A	cg27572855	chr1:25598939	RHD	-0.44	-7.22	-0.41	5.41e-12	Erythrocyte sedimentation rate;
CESC	cis	rs643506	0.845	rs607327	chr11:111695709	C/T	cg09085632	chr11:111637200	PPP2R1B	0.41	5.4	0.31	1.46e-7	Breast cancer;
CESC	cis	rs6493487	0.512	rs17521467	chr15:51214926	T/C	cg02338191	chr15:51200825	AP4E1	0.6	5.57	0.32	6.13e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs7666738	0.830	rs1967977	chr4:98966141	A/G	cg05340658	chr4:99064831	C4orf37	0.8	12.39	0.61	3.96e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs477692	0.673	rs10764889	chr10:131341521	G/A	cg24747557	chr10:131355152	MGMT	-0.39	-5.38	-0.31	1.67e-7	Response to temozolomide;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19041146	chr11:118401536	TMEM25;TTC36	0.62	7.51	0.42	9.27e-13	Gut microbiome composition (summer);
CESC	cis	rs2033711	0.870	rs7259841	chr19:58951123	T/C	cg00825309	chr19:58991885	ZNF446	-0.55	-7.97	-0.44	4.68e-14	Uric acid clearance;
CESC	cis	rs17376456	0.825	rs17314825	chr5:93234937	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.58	5.09	0.3	6.7e-7	Diabetic retinopathy;
CESC	cis	rs3768617	0.811	rs10797828	chr1:183028430	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.66	9.09	0.49	2.4e-17	Fuchs's corneal dystrophy;
CESC	cis	rs7829975	0.742	rs1533058	chr8:8685190	A/G	cg15556689	chr8:8085844	FLJ10661	0.45	5.5	0.32	8.79e-8	Mood instability;
CESC	cis	rs9787249	0.874	rs12094291	chr1:40226046	G/A	cg19912559	chr1:40204330	PPIE	0.4	6.02	0.35	5.65e-9	Blood protein levels;
CESC	cis	rs7659604	0.502	rs28522256	chr4:122709266	C/T	cg19748678	chr4:122722346	EXOSC9	-0.42	-5.26	-0.31	2.97e-7	Type 2 diabetes;
CESC	cis	rs2637266	1.000	rs12414151	chr10:78359041	T/G	cg18941641	chr10:78392320	NA	0.42	7.87	0.44	9.04e-14	Pulmonary function;
CESC	cis	rs10887741	0.646	rs7097212	chr10:89430067	G/A	cg13926569	chr10:89418898	PAPSS2	0.47	7.23	0.41	5.14e-12	Exercise (leisure time);
CESC	cis	rs4819052	0.851	rs2838826	chr21:46655785	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.45	5.36	0.31	1.8e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs3026101	0.671	rs929262	chr17:5312271	A/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.42	5.6	0.33	5.31e-8	Body mass index;
CESC	cis	rs9811920	0.893	rs6798114	chr3:99892825	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.41	6.79	0.38	7.45e-11	Axial length;
CESC	cis	rs7617480	0.648	rs9864243	chr3:48982732	G/A	cg07636037	chr3:49044803	WDR6	0.89	11.66	0.58	1.28e-25	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CESC	cis	rs4713118	0.540	rs469227	chr6:27970705	A/C	cg17221315	chr6:27791827	HIST1H4J	0.43	5.15	0.3	4.98e-7	Parkinson's disease;
CESC	cis	rs769267	0.895	rs1000237	chr19:19518316	T/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.49	6.26	0.36	1.5e-9	Tonsillectomy;
CESC	cis	rs11122272	0.735	rs2486746	chr1:231497324	C/T	cg06096015	chr1:231504339	EGLN1	0.4	5.83	0.34	1.65e-8	Hemoglobin concentration;
CESC	cis	rs4689388	0.853	rs13108780	chr4:6294630	A/G	cg25554036	chr4:6271136	WFS1	0.51	8.37	0.46	3.31e-15	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs9322193	0.923	rs9322197	chr6:149943713	C/A	cg07701084	chr6:150067640	NUP43	0.41	5.67	0.33	3.74e-8	Lung cancer;
CESC	cis	rs7914558	1.000	rs67908413	chr10:104764989	T/C	cg15744005	chr10:104629667	AS3MT	-0.34	-5.54	-0.32	7.28e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs9649213	0.593	rs7787858	chr7:98009914	T/C	cg24562669	chr7:97807699	LMTK2	0.51	7.53	0.42	7.86e-13	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs2576037	0.526	rs4890707	chr18:44497724	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.56	-7.78	-0.43	1.59e-13	Personality dimensions;
CESC	cis	rs9325144	0.723	rs3887436	chr12:39189526	A/C	cg26384229	chr12:38710491	ALG10B	-0.51	-7.23	-0.41	5.23e-12	Morning vs. evening chronotype;
CESC	cis	rs854765	0.623	rs9893690	chr17:17753846	A/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.55	-7.91	-0.44	6.9e-14	Total body bone mineral density;
CESC	cis	rs9486719	0.843	rs976357	chr6:96849679	C/T	cg06623918	chr6:96969491	KIAA0776	0.77	7.27	0.41	4.05e-12	Migraine;Coronary artery disease;
CESC	cis	rs4819052	0.851	rs7276591	chr21:46680156	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.75	10.07	0.53	2.04e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs9487051	0.898	rs882072	chr6:109611806	A/G	cg01475377	chr6:109611718	NA	-0.52	-8.64	-0.47	5.27e-16	Reticulocyte fraction of red cells;
CESC	cis	rs514406	0.825	rs9661082	chr1:53245472	A/T	cg08736216	chr1:53307985	ZYG11A	0.43	7.25	0.41	4.64e-12	Monocyte count;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg16876192	chr8:144550601	ZC3H3	0.52	7.18	0.4	6.83e-12	Fibrinogen levels;
CESC	cis	rs10504229	0.593	rs79615400	chr8:57988740	C/T	cg24829409	chr8:58192753	C8orf71	-0.69	-7.54	-0.42	7.35e-13	Developmental language disorder (linguistic errors);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg13482925	chr10:64028750	RTKN2	0.52	6.51	0.37	3.65e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs1552244	0.882	rs56224841	chr3:10044014	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.74	-9.42	-0.5	2.37e-18	Alzheimer's disease;
CESC	cis	rs2354432	0.556	rs7520661	chr1:146793149	A/G	cg25205988	chr1:146714368	CHD1L	-0.9	-7.67	-0.43	3.18e-13	Mitochondrial DNA levels;
CESC	cis	rs854765	0.604	rs12948749	chr17:17949802	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.5	-6.89	-0.39	4.14e-11	Total body bone mineral density;
CESC	cis	rs60871478	0.636	rs4276575	chr7:900035	C/T	cg15782153	chr7:917662	C7orf20	0.52	5.79	0.34	1.98e-8	Cerebrospinal P-tau181p levels;
CESC	cis	rs116095464	0.558	rs28418643	chr5:240859	A/G	cg22496380	chr5:211416	CCDC127	-0.75	-8.78	-0.47	2.13e-16	Breast cancer;
CESC	cis	rs16866061	1.000	rs72974267	chr2:225454209	T/C	cg12698349	chr2:225449008	CUL3	0.72	10.66	0.55	2.62e-22	Acute graft versus host disease in bone marrow transplantation (recipient effect);
CESC	cis	rs7615952	0.576	rs2276727	chr3:125826243	C/T	cg02807482	chr3:125708958	NA	-0.4	-5.25	-0.31	3.09e-7	Blood pressure (smoking interaction);
CESC	cis	rs9916302	0.752	rs6503513	chr17:37561613	A/G	cg15445000	chr17:37608096	MED1	-0.36	-5.28	-0.31	2.71e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs737337	0.623	rs3826815	chr19:11332505	C/T	cg00586551	chr19:11347513	LOC55908;DOCK6	0.52	5.29	0.31	2.63e-7	HDL cholesterol;HDL cholesterol levels;
CESC	cis	rs4253772	0.530	rs11090875	chr22:46785301	C/T	cg09491104	chr22:46646882	C22orf40	-0.54	-5.23	-0.31	3.44e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs7552404	0.924	rs1694419	chr1:76219801	C/T	cg22875332	chr1:76189707	ACADM	0.68	8.92	0.48	7.66e-17	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs8002861	0.905	rs12875052	chr13:44449368	G/C	cg19180546	chr13:44453867	C13orf31;CCDC122	-0.46	-5.81	-0.34	1.82e-8	Leprosy;
CESC	cis	rs3126085	0.935	rs12729662	chr1:152185750	G/A	cg26876637	chr1:152193138	HRNR	-0.45	-5.09	-0.3	6.95e-7	Atopic dermatitis;
CESC	cis	rs155076	0.711	rs4770129	chr13:21882059	T/G	cg25811766	chr13:21894605	NA	0.56	5.64	0.33	4.32e-8	White matter hyperintensity burden;
CESC	cis	rs9814567	1.000	rs1880376	chr3:134270347	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.45	6.08	0.35	4.21e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs875971	0.522	rs1917563	chr7:65415647	C/T	cg05332525	chr7:65337924	VKORC1L1	-0.48	-5.91	-0.34	1.06e-8	Aortic root size;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg09593402	chr5:96270297	LNPEP	-0.44	-6.24	-0.36	1.7e-9	Gambling;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09688494	chr10:14996222	DCLRE1C	0.55	6.37	0.36	8.39e-10	Gut microbiome composition (summer);
CESC	cis	rs9399135	0.933	rs41294852	chr6:135376379	T/G	cg24558204	chr6:135376177	HBS1L	0.52	7.03	0.4	1.73e-11	Red blood cell count;
CESC	cis	rs9322193	0.923	rs62439842	chr6:149996983	G/A	cg13206674	chr6:150067644	NUP43	0.43	6.15	0.35	2.86e-9	Lung cancer;
CESC	cis	rs1707322	1.000	rs10158032	chr1:46332701	T/C	cg05343316	chr1:45956843	TESK2	0.44	5.5	0.32	9.15e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs3925075	1.000	rs12923297	chr16:31360944	T/C	cg02846316	chr16:31340340	ITGAM	0.42	6.56	0.37	2.87e-10	IgA nephropathy;
CESC	cis	rs875971	0.862	rs2909688	chr7:65841612	C/A	cg18252515	chr7:66147081	NA	-0.46	-6.09	-0.35	4.04e-9	Aortic root size;
CESC	cis	rs1799949	1.000	rs11656097	chr17:41290613	G/T	cg05368731	chr17:41323189	NBR1	0.8	11.27	0.57	2.51e-24	Menopause (age at onset);
CESC	trans	rs11098499	0.954	rs6834796	chr4:120414693	A/C	cg25214090	chr10:38739885	LOC399744	0.72	10.09	0.53	1.85e-20	Corneal astigmatism;
CESC	cis	rs7605827	0.930	rs1997307	chr2:15512588	T/C	cg19274914	chr2:15703543	NA	0.31	5.51	0.32	8.7e-8	Educational attainment (years of education);
CESC	cis	rs4713118	0.586	rs6905516	chr6:28086478	A/G	cg26335602	chr6:28129616	ZNF389	0.53	7.06	0.4	1.48e-11	Parkinson's disease;
CESC	cis	rs7937682	0.924	rs501089	chr11:111502479	G/T	cg22437258	chr11:111473054	SIK2	-0.59	-6.85	-0.39	5e-11	Primary sclerosing cholangitis;
CESC	cis	rs116095464	0.558	rs7731089	chr5:290422	A/C	cg20965017	chr5:231967	SDHA	-0.46	-5.2	-0.3	4.02e-7	Breast cancer;
CESC	cis	rs6460942	0.915	rs75732743	chr7:12454095	C/T	cg02935154	chr7:12443704	VWDE	-0.58	-6.16	-0.35	2.73e-9	Coronary artery disease;
CESC	cis	rs11252926	0.527	rs10904093	chr10:436848	A/G	cg18196295	chr10:418757	DIP2C	-0.53	-7.31	-0.41	3.17e-12	Psychosis in Alzheimer's disease;
CESC	cis	rs7818688	1.000	rs10098453	chr8:96029756	A/G	cg16049864	chr8:95962084	TP53INP1	-0.59	-5.74	-0.33	2.58e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs72781680	0.948	rs72781652	chr2:24213754	G/A	cg20701182	chr2:24300061	SF3B14	0.63	5.58	0.32	6.04e-8	Lymphocyte counts;
CESC	cis	rs4547160	0.606	rs36108998	chr12:63477075	T/C	cg26727693	chr12:63544175	AVPR1A	-0.35	-5.24	-0.31	3.31e-7	Morning vs. evening chronotype;
CESC	cis	rs2836974	0.897	rs2836932	chr21:40546717	G/A	cg11890956	chr21:40555474	PSMG1	1.18	22.66	0.81	6.1e-64	Cognitive function;
CESC	cis	rs10242455	0.867	rs2687145	chr7:99318644	C/T	cg07715041	chr7:99302981	CYP3A7	0.42	5.36	0.31	1.77e-7	Blood metabolite levels;
CESC	cis	rs10129255	0.957	rs10136781	chr14:107188690	G/T	cg07958169	chr14:107095056	NA	-0.4	-5.54	-0.32	7.3e-8	Kawasaki disease;
CESC	cis	rs524281	0.861	rs10896086	chr11:65914764	T/A	cg14036092	chr11:66035641	RAB1B	-0.58	-5.78	-0.33	2.12e-8	Electroencephalogram traits;
CESC	cis	rs7772486	0.720	rs4896844	chr6:146075224	T/C	cg23711669	chr6:146136114	FBXO30	-1.01	-15.7	-0.69	1.03e-39	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs10504229	0.906	rs114810777	chr8:58185298	A/G	cg22535103	chr8:58192502	C8orf71	-1.04	-12.87	-0.62	9.04e-30	Developmental language disorder (linguistic errors);
CESC	cis	rs16854884	0.586	rs13081286	chr3:143723757	A/T	cg06585982	chr3:143692056	C3orf58	0.5	6.79	0.39	7.29e-11	Economic and political preferences (feminism/equality);
CESC	cis	rs62005083	1.000	rs72725929	chr14:74536731	C/T	cg05179529	chr14:74551516	LIN52;ALDH6A1	0.7	5.23	0.31	3.51e-7	Mean corpuscular volume;
CESC	cis	rs911555	0.692	rs7140647	chr14:103893465	A/G	cg24130564	chr14:104152367	KLC1	0.49	6.51	0.37	3.78e-10	Intelligence (multi-trait analysis);
CESC	cis	rs4975616	0.869	rs466502	chr5:1325767	C/T	cg06550200	chr5:1325588	CLPTM1L	0.69	11.11	0.56	8.36e-24	Lung cancer;
CESC	cis	rs79839061	0.610	rs11731387	chr4:851357	C/T	cg07828340	chr4:882639	GAK	0.88	7.17	0.4	7.28e-12	Intelligence (multi-trait analysis);
CESC	cis	rs4975616	0.686	rs37011	chr5:1348798	A/T	cg06550200	chr5:1325588	CLPTM1L	-0.63	-9.49	-0.5	1.42e-18	Lung cancer;
CESC	trans	rs6600671	0.967	rs11249349	chr1:121179169	G/C	cg17023122	chr1:144479586	NA	0.45	6.25	0.36	1.63e-9	Hip geometry;
CESC	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg26338869	chr17:61819248	STRADA	0.69	9.1	0.49	2.2e-17	Prudent dietary pattern;
CESC	cis	rs9916302	0.904	rs68178216	chr17:37526241	A/C	cg00129232	chr17:37814104	STARD3	0.52	6.49	0.37	4.19e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs35110281	0.594	rs230641	chr21:44915441	T/C	cg04455712	chr21:45112962	RRP1B	-0.35	-5.44	-0.32	1.19e-7	Mean corpuscular volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10487699	chr11:57480176	TMX2;MED19	0.53	6.0	0.35	6.35e-9	Gut microbiome composition (summer);
CESC	cis	rs6430585	0.528	rs309159	chr2:136684940	C/T	cg07169764	chr2:136633963	MCM6	1.09	15.21	0.68	5.48e-38	Corneal structure;
CESC	cis	rs921968	0.541	rs4674310	chr2:219318078	T/C	cg02176678	chr2:219576539	TTLL4	-0.53	-9.28	-0.5	6.12e-18	Mean corpuscular hemoglobin concentration;
CESC	cis	rs13256369	0.802	rs11249888	chr8:8564934	T/C	cg00074818	chr8:8560427	CLDN23	0.38	5.46	0.32	1.1e-7	Obesity-related traits;
CESC	cis	rs2380220	0.935	rs7744491	chr6:95994980	T/G	cg15832292	chr6:96025679	MANEA	0.7	6.74	0.38	9.99e-11	Behavioural disinhibition (generation interaction);
CESC	cis	rs6500395	1.000	rs12599028	chr16:48713082	C/A	cg04672837	chr16:48644449	N4BP1	-0.51	-6.53	-0.37	3.33e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs3857536	0.740	rs9354390	chr6:66890162	C/T	cg07460842	chr6:66804631	NA	0.43	5.48	0.32	9.68e-8	Blood trace element (Cu levels);
CESC	cis	rs9488822	0.596	rs6568921	chr6:116373616	C/T	cg05304507	chr6:116381966	FRK	0.23	5.61	0.33	5.1e-8	Cholesterol, total;LDL cholesterol;
CESC	cis	rs3806843	1.000	rs1030164	chr5:140185272	A/G	cg26395211	chr5:140044315	WDR55	-0.42	-5.25	-0.31	3.16e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs17209837	0.607	rs4148816	chr7:87087731	G/A	cg00919237	chr7:87102261	ABCB4	-0.51	-6.58	-0.37	2.45e-10	Gallbladder cancer;
CESC	cis	rs3747547	0.892	rs72726021	chr9:38010435	A/G	cg13774184	chr9:37916125	SHB	-0.73	-6.25	-0.36	1.61e-9	Metabolite levels (Dihydroxy docosatrienoic acid);
CESC	cis	rs28374715	0.578	rs17730888	chr15:41637547	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.03	-16.13	-0.7	2.98e-41	Ulcerative colitis;
CESC	cis	rs6121246	0.559	rs6087771	chr20:30306724	A/G	cg13852791	chr20:30311386	BCL2L1	0.87	11.45	0.58	6.29e-25	Mean corpuscular hemoglobin;
CESC	cis	rs2243480	0.803	rs423187	chr7:65509499	G/C	cg13147721	chr7:65941812	NA	-0.96	-9.02	-0.48	3.98e-17	Diabetic kidney disease;
CESC	cis	rs798554	0.959	rs798528	chr7:2772431	A/C	cg18446336	chr7:2847575	GNA12	-0.4	-6.1	-0.35	3.79e-9	Height;
CESC	cis	rs1707322	0.686	rs3014251	chr1:46077428	G/C	cg03146154	chr1:46216737	IPP	-0.79	-10.71	-0.55	1.73e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs738322	0.967	rs4383	chr22:38570927	C/G	cg25457927	chr22:38595422	NA	-0.3	-5.46	-0.32	1.1e-7	Cutaneous nevi;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27037969	chr12:125549952	AACS	0.64	7.79	0.43	1.5e-13	Gut microbiome composition (summer);
CESC	cis	rs1707322	0.721	rs12037803	chr1:46156492	A/G	cg03146154	chr1:46216737	IPP	0.82	11.54	0.58	3.18e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9811920	0.965	rs9289981	chr3:99868104	A/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.43	7.12	0.4	1.04e-11	Axial length;
CESC	cis	rs2878628	0.650	rs56098033	chr3:52758571	T/A	cg18337363	chr3:52569053	NT5DC2	0.29	5.3	0.31	2.43e-7	Intelligence (multi-trait analysis);
CESC	cis	rs6484504	0.600	rs10835763	chr11:31345574	G/A	cg14844989	chr11:31128820	NA	0.39	5.5	0.32	8.77e-8	Red blood cell count;
CESC	cis	rs36051895	0.589	rs4560849	chr9:5203866	C/G	cg02405213	chr9:5042618	JAK2	-0.49	-5.68	-0.33	3.54e-8	Pediatric autoimmune diseases;
CESC	cis	rs4727027	0.901	rs66800495	chr7:148763702	T/C	cg23583168	chr7:148888333	NA	-0.78	-11.74	-0.59	6.48e-26	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs4727027	0.899	rs6464942	chr7:148826368	T/C	cg23158103	chr7:148848205	ZNF398	-0.4	-6.34	-0.36	9.68e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs9398803	0.965	rs9388489	chr6:126698719	C/T	cg19875578	chr6:126661172	C6orf173	-0.5	-6.96	-0.39	2.74e-11	Male-pattern baldness;
CESC	cis	rs7666738	0.830	rs4699598	chr4:99019158	C/T	cg03467027	chr4:99064603	C4orf37	0.46	5.81	0.34	1.8e-8	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05772935	chr16:1790400	MAPK8IP3	-0.66	-7.2	-0.4	6.03e-12	Gut microbiome composition (summer);
CESC	cis	rs1707322	0.717	rs10890345	chr1:46213927	C/T	cg06784218	chr1:46089804	CCDC17	0.41	7.21	0.41	5.75e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs372883	0.563	rs1153293	chr21:30691325	C/T	cg08807101	chr21:30365312	RNF160	0.45	5.07	0.3	7.48e-7	Pancreatic cancer;
CESC	cis	rs3820068	0.581	rs56128111	chr1:15928948	T/G	cg17385448	chr1:15911702	AGMAT	0.41	6.69	0.38	1.33e-10	Systolic blood pressure;
CESC	cis	rs2243480	1.000	rs313820	chr7:65574466	A/C	cg13147721	chr7:65941812	NA	-0.99	-9.36	-0.5	3.5e-18	Diabetic kidney disease;
CESC	cis	rs36051895	0.530	rs60768043	chr9:5224676	T/G	cg02405213	chr9:5042618	JAK2	-0.54	-6.13	-0.35	3.22e-9	Pediatric autoimmune diseases;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg07790826	chr11:70049435	FADD	-0.48	-6.09	-0.35	4.02e-9	Fibrinogen levels;
CESC	cis	rs10789491	0.767	rs1816730	chr1:47207346	T/C	cg15501359	chr1:47185051	KIAA0494	0.76	7.4	0.41	1.82e-12	Response to hepatitis C treatment;
CESC	cis	rs2072499	0.932	rs2736613	chr1:156196016	T/C	cg25208724	chr1:156163844	SLC25A44	0.94	15.31	0.69	2.4e-38	Testicular germ cell tumor;
CESC	cis	rs4819052	0.851	rs2236443	chr21:46678174	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.88	12.9	0.62	7.34e-30	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs11711311	0.712	rs6795099	chr3:113338782	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.47	6.31	0.36	1.14e-9	IgG glycosylation;
CESC	cis	rs9926296	0.605	rs886951	chr16:89836865	A/G	cg03388025	chr16:89894329	SPIRE2	0.42	8.14	0.45	1.52e-14	Vitiligo;
CESC	cis	rs113835537	0.529	rs11227501	chr11:66274072	T/C	cg22134325	chr11:66188745	NPAS4	0.35	5.57	0.32	6.29e-8	Airway imaging phenotypes;
CESC	cis	rs6598955	0.671	rs12129482	chr1:26623641	C/T	cg19743891	chr1:26644573	UBXN11;CD52	0.37	5.45	0.32	1.18e-7	Obesity-related traits;
CESC	cis	rs853679	0.517	rs4713146	chr6:28111536	A/T	cg20151795	chr6:28129481	ZNF389	0.45	5.7	0.33	3.12e-8	Depression;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg07318050	chr1:233086124	C1orf57	-0.48	-6.9	-0.39	3.87e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs7264396	0.635	rs6058363	chr20:34505054	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.54	6.97	0.39	2.49e-11	Total cholesterol levels;
CESC	cis	rs3733585	0.638	rs28715627	chr4:9958140	T/A	cg00071950	chr4:10020882	SLC2A9	-0.72	-11.7	-0.58	8.89e-26	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs72781680	1.000	rs72781654	chr2:24218099	T/C	cg08917208	chr2:24149416	ATAD2B	0.55	5.38	0.31	1.62e-7	Lymphocyte counts;
CESC	cis	rs4253772	0.550	rs739164	chr22:46684558	C/T	cg09491104	chr22:46646882	C22orf40	0.59	8.75	0.47	2.54e-16	LDL cholesterol;Cholesterol, total;
CESC	cis	rs7618915	0.547	rs2118540	chr3:52629386	T/C	cg18404041	chr3:52824283	ITIH1	-0.4	-6.71	-0.38	1.18e-10	Bipolar disorder;
CESC	cis	rs1799949	0.965	rs799916	chr17:41243190	G/T	cg07153921	chr17:41440717	NA	0.41	5.54	0.32	7.13e-8	Menopause (age at onset);
CESC	cis	rs72781680	0.898	rs10490751	chr2:24001356	A/G	cg08917208	chr2:24149416	ATAD2B	0.95	8.71	0.47	3.45e-16	Lymphocyte counts;
CESC	cis	rs853679	0.517	rs4713137	chr6:28083521	C/G	cg08968635	chr6:28129556	ZNF389	0.4	5.36	0.31	1.84e-7	Depression;
CESC	cis	rs2865126	0.818	rs7227167	chr18:10763007	A/G	cg21165219	chr18:10698044	FAM38B	-0.49	-5.17	-0.3	4.69e-7	Metabolite levels (5-HIAA/ MHPG Ratio);
CESC	cis	rs6540559	1.000	rs6540559	chr1:209982025	G/A	cg22442454	chr1:209979470	IRF6	0.5	6.13	0.35	3.17e-9	Cleft lip with or without cleft palate;
CESC	cis	rs2228479	0.618	rs17233623	chr16:89811209	C/T	cg00800038	chr16:89945340	TCF25	-0.77	-7.17	-0.4	7.39e-12	Skin colour saturation;
CESC	cis	rs873946	0.586	rs57431984	chr10:134567697	C/T	cg27286337	chr10:134555280	INPP5A	0.68	7.69	0.43	2.81e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs4076764	1.000	rs12740984	chr1:163422151	A/G	cg24596788	chr1:163392923	NA	0.49	7.22	0.41	5.38e-12	Motion sickness;
CESC	cis	rs11608355	0.521	rs10850131	chr12:109837052	A/G	cg19025524	chr12:109796872	NA	0.52	7.33	0.41	2.87e-12	Neuroticism;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg15871229	chr10:74451622	CCDC109A	0.46	6.79	0.38	7.47e-11	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs1552244	0.882	rs113268531	chr3:10167069	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.82	-11.61	-0.58	1.83e-25	Alzheimer's disease;
CESC	trans	rs116095464	0.558	rs28636067	chr5:199415	G/A	cg00938859	chr5:1591904	SDHAP3	0.65	6.14	0.35	3.05e-9	Breast cancer;
CESC	cis	rs2576037	0.583	rs4890343	chr18:44540969	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.48	-6.38	-0.37	7.67e-10	Personality dimensions;
CESC	cis	rs10078	0.515	rs890984	chr5:479540	A/G	cg08916839	chr5:415575	AHRR	0.59	6.89	0.39	4.17e-11	Fat distribution (HIV);
CESC	cis	rs3784262	1.000	rs7170896	chr15:58252393	T/A	cg12031962	chr15:58353849	ALDH1A2	-0.31	-5.19	-0.3	4.29e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
CESC	cis	rs6912958	0.712	rs6454640	chr6:88370352	G/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.55	7.46	0.42	1.21e-12	Monocyte percentage of white cells;
CESC	cis	rs7833790	0.963	rs1451997	chr8:82774053	A/T	cg27398817	chr8:82754497	SNX16	0.52	6.12	0.35	3.39e-9	Diastolic blood pressure;
CESC	cis	rs2576037	0.526	rs605487	chr18:44444778	G/C	cg19077165	chr18:44547161	KATNAL2	-0.55	-7.97	-0.44	4.8e-14	Personality dimensions;
CESC	cis	rs911555	0.713	rs10162425	chr14:103931621	C/T	cg09975044	chr14:104007538	NA	0.44	5.49	0.32	9.22e-8	Intelligence (multi-trait analysis);
CESC	cis	rs4595586	0.545	rs6580892	chr12:39370237	G/C	cg26384229	chr12:38710491	ALG10B	0.54	7.53	0.42	7.85e-13	Morning vs. evening chronotype;
CESC	trans	rs78049276	0.512	rs7659823	chr4:148398877	C/G	cg13149281	chr14:23389818	RBM23;PRMT5	-0.74	-10.31	-0.54	3.56e-21	Pulse pressure;
CESC	cis	rs727563	0.555	rs5751136	chr22:42075581	T/A	cg06634786	chr22:41940651	POLR3H	0.56	5.99	0.35	6.82e-9	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs6674176	0.542	rs803675	chr1:44353237	G/A	cg12908607	chr1:44402522	ARTN	-0.39	-5.22	-0.31	3.64e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs7824557	0.628	rs7008205	chr8:11197323	T/G	cg21775007	chr8:11205619	TDH	0.58	9.28	0.5	6.25e-18	Retinal vascular caliber;
CESC	cis	rs2204008	0.591	rs11495396	chr12:38380182	C/T	cg26384229	chr12:38710491	ALG10B	0.73	11.15	0.57	6.25e-24	Bladder cancer;
CESC	cis	rs6570726	0.791	rs11759979	chr6:145918881	C/T	cg05347473	chr6:146136440	FBXO30	0.53	6.85	0.39	5.18e-11	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs4932480	0.522	rs979171	chr15:89755448	A/C	cg24069674	chr6:27230661	NA	-0.42	-6.21	-0.36	2.09e-9	Advanced age-related macular degeneration;Age-related macular degeneration (SNP x mitochondrial G12771A interaction);
CESC	cis	rs9916302	0.904	rs10221223	chr17:37489100	T/G	cg07936489	chr17:37558343	FBXL20	0.77	10.62	0.55	3.6e-22	Glomerular filtration rate (creatinine);
CESC	trans	rs2658782	1.000	rs2019814	chr11:93168885	A/G	cg13657970	chr12:123333035	HIP1R	0.45	6.08	0.35	4.17e-9	Pulmonary function decline;
CESC	cis	rs911555	0.755	rs17841064	chr14:103900609	A/G	cg12935359	chr14:103987150	CKB	-0.57	-8.38	-0.46	3.16e-15	Intelligence (multi-trait analysis);
CESC	cis	rs7000551	0.751	rs2449341	chr8:22390937	C/A	cg12081754	chr8:22256438	SLC39A14	0.41	5.44	0.32	1.22e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CESC	cis	rs7818345	0.512	rs4922028	chr8:19303771	C/T	cg11303988	chr8:19266685	CSGALNACT1	0.32	5.25	0.31	3.09e-7	Language performance in older adults (adjusted for episodic memory);
CESC	cis	rs5997397	0.934	rs6005864	chr22:29157487	A/G	cg15103426	chr22:29168792	CCDC117	-0.49	-6.2	-0.36	2.2e-9	Red cell distribution width;
CESC	cis	rs10504229	0.639	rs56825757	chr8:58106469	A/G	cg02725872	chr8:58115012	NA	-0.43	-6.81	-0.39	6.53e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs5769765	0.865	rs4824108	chr22:50271428	A/G	cg26441486	chr22:50317300	CRELD2	-0.39	-5.5	-0.32	8.72e-8	Schizophrenia;
CESC	cis	rs796364	0.806	rs11684942	chr2:201009136	C/T	cg23649088	chr2:200775458	C2orf69	-0.55	-5.04	-0.3	8.69e-7	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05187422	chr16:89597159	SPG7	-0.51	-6.28	-0.36	1.41e-9	Gut microbiome composition (summer);
CESC	cis	rs9837602	0.882	rs9875664	chr3:99729130	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.49	7.09	0.4	1.2e-11	Breast cancer;
CESC	cis	rs9649213	0.593	rs6465675	chr7:97982103	C/T	cg24562669	chr7:97807699	LMTK2	-0.51	-7.49	-0.42	1.02e-12	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg04724143	chr13:114185494	TMCO3	0.49	6.83	0.39	5.89e-11	Fibrinogen levels;
CESC	cis	rs7903847	0.642	rs9888117	chr10:99159963	C/G	cg20016023	chr10:99160130	RRP12	-0.29	-5.04	-0.3	8.66e-7	Granulocyte percentage of myeloid white cells;
CESC	cis	rs6545883	0.931	rs12713438	chr2:61725501	G/A	cg15711740	chr2:61764176	XPO1	-0.42	-5.28	-0.31	2.64e-7	Tuberculosis;
CESC	cis	rs4665809	0.652	rs11685594	chr2:26402846	A/G	cg27170947	chr2:26402098	FAM59B	-0.82	-9.61	-0.51	6.07e-19	Gut microbiome composition (summer);
CESC	cis	rs9486719	0.895	rs3798294	chr6:97049587	G/A	cg06623918	chr6:96969491	KIAA0776	-0.81	-8.38	-0.46	3.18e-15	Migraine;Coronary artery disease;
CESC	cis	rs2836974	0.544	rs8128919	chr21:40711862	C/T	cg11644478	chr21:40555479	PSMG1	0.61	8.24	0.45	7.75e-15	Cognitive function;
CESC	cis	rs2996428	0.561	rs16824192	chr1:3748605	G/A	cg10555106	chr1:3691387	LOC388588	0.37	5.4	0.31	1.46e-7	Red cell distribution width;
CESC	cis	rs9543976	0.623	rs7317250	chr13:76167141	C/T	cg01531495	chr13:76123901	UCHL3	0.49	5.12	0.3	5.78e-7	Diabetic retinopathy;
CESC	cis	rs76533333	0.564	rs34658917	chr13:113417423	C/T	cg08557188	chr13:113420371	ATP11A	-0.75	-5.12	-0.3	5.83e-7	Red cell distribution width;
CESC	cis	rs478304	0.934	rs603645	chr11:65533000	A/C	cg08755490	chr11:65554678	OVOL1	0.46	6.15	0.35	2.85e-9	Acne (severe);
CESC	cis	rs7811142	0.830	rs11765869	chr7:99964789	T/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.99	9.38	0.5	3.07e-18	Platelet count;
CESC	cis	rs61931739	0.517	rs7139189	chr12:34319757	T/C	cg06521331	chr12:34319734	NA	-0.45	-6.14	-0.35	3.03e-9	Morning vs. evening chronotype;
CESC	cis	rs7312933	0.612	rs10785334	chr12:42620377	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.41	-5.27	-0.31	2.84e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs6662572	0.737	rs9429091	chr1:46513088	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.48	5.41	0.32	1.38e-7	Blood protein levels;
CESC	cis	rs992157	0.710	rs6752254	chr2:219058743	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.65	8.76	0.47	2.32e-16	Colorectal cancer;
CESC	cis	rs78707713	0.560	rs12784882	chr10:71230334	C/G	cg12610070	chr10:71211762	TSPAN15	-0.33	-6.85	-0.39	5.18e-11	Venous thromboembolism;
CESC	cis	rs4319547	0.626	rs12423420	chr12:122938466	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.49	-6.04	-0.35	5.19e-9	Body mass index;
CESC	cis	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg04267008	chr7:1944627	MAD1L1	0.49	6.06	0.35	4.62e-9	Bipolar disorder and schizophrenia;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg26994227	chr5:130971071	RAPGEF6	-0.4	-6.11	-0.35	3.55e-9	Gambling;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12858900	chr10:24909511	ARHGAP21	-0.56	-6.47	-0.37	4.84e-10	Gut microbiome composition (summer);
CESC	cis	rs17401966	0.838	rs7553228	chr1:10350438	G/C	cg15208524	chr1:10270712	KIF1B	0.41	5.32	0.31	2.16e-7	Hepatocellular carcinoma;
CESC	trans	rs1814175	0.587	rs7948538	chr11:50021353	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.41	-6.01	-0.35	6.08e-9	Height;
CESC	cis	rs910316	0.967	rs4903293	chr14:75656568	A/G	cg11812906	chr14:75593930	NEK9	-0.85	-13.81	-0.65	4.82e-33	Height;
CESC	cis	rs7772486	0.754	rs702324	chr6:146008793	A/G	cg05347473	chr6:146136440	FBXO30	-0.5	-6.27	-0.36	1.42e-9	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27656398	chr12:123451108	ABCB9	0.57	6.32	0.36	1.09e-9	Gut microbiome composition (summer);
CESC	cis	rs875971	0.895	rs10447522	chr7:65796074	A/G	cg18252515	chr7:66147081	NA	0.45	5.88	0.34	1.22e-8	Aortic root size;
CESC	cis	rs6831352	0.959	rs4699710	chr4:100051819	C/T	cg21548116	chr4:100009993	ADH5	0.48	5.15	0.3	4.98e-7	Alcohol dependence;
CESC	trans	rs55704346	0.566	rs2292409	chr4:25394221	T/C	cg01822600	chr1:245751692	KIF26B	0.42	6.17	0.35	2.58e-9	Tonsillectomy;
CESC	cis	rs11764590	0.694	rs56072378	chr7:2104364	A/G	cg21782813	chr7:2030301	MAD1L1	-0.41	-5.3	-0.31	2.42e-7	Neuroticism;
CESC	cis	rs6540559	0.673	rs1073150	chr1:210017083	G/A	cg22029157	chr1:209979665	IRF6	0.66	7.44	0.42	1.4e-12	Cleft lip with or without cleft palate;
CESC	cis	rs208520	0.909	rs62414639	chr6:67023706	G/A	cg07460842	chr6:66804631	NA	0.84	8.13	0.45	1.67e-14	Exhaled nitric oxide output;
CESC	cis	rs6570726	0.934	rs9484995	chr6:145781114	T/A	cg05347473	chr6:146136440	FBXO30	-0.4	-5.39	-0.31	1.54e-7	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs12458462	0.787	rs56006341	chr18:77439844	G/T	cg11879182	chr18:77439856	CTDP1	0.86	13.38	0.63	1.54e-31	Monocyte count;
CESC	cis	rs2576037	0.501	rs8089938	chr18:44459497	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.45	7.31	0.41	3.08e-12	Personality dimensions;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11278799	chr20:13765577	ESF1;C20orf7	0.71	8.02	0.44	3.36e-14	Gut microbiome composition (summer);
CESC	cis	rs1799949	0.965	rs11657883	chr17:41330024	T/C	cg23758822	chr17:41437982	NA	1.04	15.71	0.69	9.05e-40	Menopause (age at onset);
CESC	cis	rs61869271	0.797	rs6585313	chr10:116745558	T/A	cg23260525	chr10:116636907	FAM160B1	0.3	5.24	0.31	3.21e-7	Tonsillectomy;
CESC	cis	rs10463316	0.894	rs6579860	chr5:150752338	G/A	cg03212797	chr5:150827313	SLC36A1	-0.52	-6.83	-0.39	5.78e-11	Metabolite levels (Pyroglutamine);
CESC	cis	rs72634258	0.945	rs12748993	chr1:8129507	A/G	cg00042356	chr1:8021962	PARK7	0.83	7.94	0.44	5.61e-14	Inflammatory bowel disease;
CESC	cis	rs2228479	0.850	rs57267516	chr16:89903552	G/A	cg00800038	chr16:89945340	TCF25	-0.83	-6.72	-0.38	1.09e-10	Skin colour saturation;
CESC	cis	rs4803468	0.934	rs11880674	chr19:41889423	A/T	cg09537434	chr19:41945824	ATP5SL	-1.01	-17.8	-0.74	3.78e-47	Height;
CESC	cis	rs28386778	0.700	rs12449555	chr17:62003982	T/A	cg06601766	chr17:61851465	DDX42;CCDC47	-0.55	-6.71	-0.38	1.21e-10	Prudent dietary pattern;
CESC	cis	rs735860	0.726	rs209490	chr6:53179047	C/T	cg10236188	chr6:53219634	NA	0.35	5.23	0.31	3.43e-7	Glaucoma;
CESC	cis	rs9611565	0.694	rs9611591	chr22:41830212	G/A	cg03806693	chr22:41940476	POLR3H	0.77	9.76	0.51	2.07e-19	Vitiligo;
CESC	trans	rs9929218	0.817	rs3114405	chr16:68722377	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.82	-9.91	-0.52	6.54e-20	Colorectal cancer;
CESC	cis	rs875971	1.000	rs1182882	chr7:65562063	C/T	cg25985355	chr7:65971099	NA	0.31	5.06	0.3	7.77e-7	Aortic root size;
CESC	cis	rs1506636	0.927	rs6959270	chr7:123310628	G/A	cg03229431	chr7:123269106	ASB15	-0.51	-6.63	-0.38	1.88e-10	Plateletcrit;Platelet count;
CESC	cis	rs7666738	0.830	rs36028444	chr4:98968635	G/T	cg03467027	chr4:99064603	C4orf37	0.43	5.42	0.32	1.34e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs514406	0.929	rs485631	chr1:53330245	A/G	cg16325326	chr1:53192061	ZYG11B	0.9	14.66	0.67	4.89e-36	Monocyte count;
CESC	cis	rs11722228	0.522	rs62286604	chr4:10131161	A/G	cg14348967	chr4:10160060	NA	-0.4	-5.1	-0.3	6.56e-7	Gout;Urate levels;Serum uric acid levels;
CESC	cis	rs55788414	0.932	rs11649028	chr16:81185326	G/A	cg06400318	chr16:81190750	PKD1L2	0.62	7.11	0.4	1.05e-11	Left ventricular obstructive tract defect (maternal effect);
CESC	cis	rs9348729	1	rs9348729	chr6:26664268	T/C	cg12826209	chr6:26865740	GUSBL1	0.73	8.25	0.45	7.45e-15	Intelligence (multi-trait analysis);
CESC	cis	rs9611565	0.765	rs132909	chr22:41802031	G/A	cg06634786	chr22:41940651	POLR3H	0.71	7.47	0.42	1.16e-12	Vitiligo;
CESC	cis	rs713587	0.967	rs10182181	chr2:25150296	C/T	cg01884057	chr2:25150051	NA	-0.43	-8.27	-0.45	6.53e-15	Body mass index in non-asthmatics;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg11629460	chr3:141457364	RNF7	-0.46	-6.05	-0.35	4.96e-9	Asthma;
CESC	cis	rs8067545	0.611	rs2526476	chr17:20134289	C/T	cg13482628	chr17:19912719	NA	-0.4	-5.33	-0.31	2.09e-7	Schizophrenia;
CESC	cis	rs2486288	0.586	rs12909625	chr15:45572053	C/A	cg21132104	chr15:45694354	SPATA5L1	-0.56	-6.7	-0.38	1.22e-10	Glomerular filtration rate;
CESC	cis	rs2239815	0.515	rs5762829	chr22:29228130	A/G	cg15103426	chr22:29168792	CCDC117	0.5	5.15	0.3	5.12e-7	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
CESC	cis	rs7264396	0.563	rs61191623	chr20:34219987	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.92	-10.16	-0.53	1.07e-20	Total cholesterol levels;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg18264753	chr6:138188625	TNFAIP3	-0.48	-6.67	-0.38	1.5e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs6570726	0.764	rs448258	chr6:145869145	C/A	cg23711669	chr6:146136114	FBXO30	1.02	15.62	0.69	2.01e-39	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2204008	0.846	rs2030416	chr12:38465118	A/G	cg13010199	chr12:38710504	ALG10B	-0.43	-5.6	-0.33	5.44e-8	Bladder cancer;
CESC	cis	rs172166	0.637	rs1225592	chr6:28150242	G/A	cg12963246	chr6:28129442	ZNF389	0.41	6.05	0.35	5e-9	Cardiac Troponin-T levels;
CESC	cis	rs36051895	0.664	rs10116560	chr9:5096433	A/G	cg02405213	chr9:5042618	JAK2	-0.51	-6.17	-0.35	2.61e-9	Pediatric autoimmune diseases;
CESC	cis	rs11690935	0.959	rs3770451	chr2:172668715	T/G	cg13550731	chr2:172543902	DYNC1I2	-0.96	-14.78	-0.67	1.79e-36	Schizophrenia;
CESC	cis	rs453301	0.686	rs6601280	chr8:8909236	A/T	cg15556689	chr8:8085844	FLJ10661	0.46	5.32	0.31	2.18e-7	Joint mobility (Beighton score);
CESC	cis	rs9733	0.715	rs7534124	chr1:150739073	C/T	cg13175981	chr1:150552382	MCL1	0.53	7.24	0.41	4.76e-12	Tonsillectomy;
CESC	cis	rs4253772	0.591	rs6007726	chr22:46650858	A/C	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.69	8.18	0.45	1.16e-14	LDL cholesterol;Cholesterol, total;
CESC	cis	rs959260	1.000	rs7211915	chr17:73379872	A/G	cg20590849	chr17:73267439	MIF4GD	-0.57	-6.73	-0.38	1.07e-10	Systemic lupus erythematosus;
CESC	cis	rs8053891	0.756	rs35800852	chr16:72002105	G/T	cg04254540	chr16:71951199	KIAA0174	-0.44	-5.35	-0.31	1.92e-7	Coronary artery disease;
CESC	cis	rs7927771	0.542	rs6485775	chr11:47773518	A/G	cg05585544	chr11:47624801	NA	-0.32	-5.04	-0.3	8.46e-7	Subjective well-being;
CESC	trans	rs116095464	1.000	rs28416084	chr5:217640	G/A	cg00938859	chr5:1591904	SDHAP3	0.66	6.24	0.36	1.72e-9	Breast cancer;
CESC	cis	rs6499255	1.000	rs12446201	chr16:69815586	T/C	cg15192750	chr16:69999425	NA	0.43	5.35	0.31	1.9e-7	IgE levels;
CESC	cis	rs2267137	0.720	rs2018515	chr22:29818854	C/T	cg07256473	chr22:29710276	RASL10A	0.35	5.09	0.3	6.69e-7	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	cis	rs1552244	1.000	rs4260416	chr3:10125283	C/T	cg00166722	chr3:10149974	C3orf24	0.55	7.17	0.4	7.56e-12	Alzheimer's disease;
CESC	cis	rs703842	0.616	rs10783850	chr12:58229377	T/C	cg00677455	chr12:58241039	CTDSP2	0.72	9.73	0.51	2.43e-19	Multiple sclerosis;
CESC	cis	rs7508679	1.000	rs7508679	chr19:7222832	A/G	cg00428638	chr19:7224713	INSR	0.49	7.77	0.43	1.7e-13	Hypothyroidism;
CESC	cis	rs4523957	0.583	rs2641443	chr17:2036162	G/A	cg16513277	chr17:2031491	SMG6	-0.78	-11.57	-0.58	2.42e-25	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs1728785	0.818	rs1645984	chr16:68628850	T/C	cg02972257	chr16:68554789	NA	-0.68	-7.33	-0.41	2.81e-12	Ulcerative colitis;
CESC	trans	rs9329221	0.617	rs483916	chr8:9793601	A/C	cg06636001	chr8:8085503	FLJ10661	-0.51	-6.28	-0.36	1.39e-9	Neuroticism;
CESC	trans	rs7582180	0.700	rs1437971	chr2:100986964	A/C	cg15313226	chr2:191045668	C2orf88	0.63	6.37	0.36	8.31e-10	Intelligence (multi-trait analysis);
CESC	cis	rs11167764	1.000	rs10057309	chr5:141479870	T/C	cg08523384	chr5:141488047	NDFIP1	-0.36	-5.52	-0.32	8.16e-8	Crohn's disease;
CESC	cis	rs637571	0.544	rs12361552	chr11:65701204	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.46	-6.51	-0.37	3.65e-10	Eosinophil percentage of white cells;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06521774	chr1:38397588	INPP5B	0.58	6.09	0.35	3.95e-9	Gut microbiome composition (summer);
CESC	cis	rs10754283	0.967	rs10801759	chr1:90113745	A/G	cg21401794	chr1:90099060	LRRC8C	0.69	9.34	0.5	4.06e-18	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs2075371	1.000	rs1868783	chr7:133975087	A/G	cg00033643	chr7:134001901	SLC35B4	0.42	5.47	0.32	1.04e-7	Mean platelet volume;
CESC	cis	rs8077577	0.895	rs11078412	chr17:18100618	C/T	cg16794390	chr17:18148240	FLII	-0.44	-6.05	-0.35	4.94e-9	Obesity-related traits;
CESC	cis	rs7666738	0.830	rs2865977	chr4:99017916	C/T	cg17366294	chr4:99064904	C4orf37	0.61	8.76	0.47	2.35e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11123610	0.520	rs66646194	chr2:3720420	G/A	cg19052272	chr2:3704530	ALLC	-0.47	-5.73	-0.33	2.72e-8	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CESC	cis	rs61656020	1	rs61656020	chr16:1882221	C/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.55	-6.39	-0.37	7.55e-10	Ankle injury;
CESC	cis	rs11098499	0.954	rs10008392	chr4:120318839	G/A	cg09307838	chr4:120376055	NA	0.91	12.37	0.61	4.66e-28	Corneal astigmatism;
CESC	cis	rs17125944	0.686	rs6572868	chr14:53325090	C/T	cg00686598	chr14:53173677	PSMC6	-0.67	-5.71	-0.33	3.04e-8	Alzheimer's disease (late onset);
CESC	cis	rs1008375	1.000	rs28552744	chr4:17620165	A/G	cg15017067	chr4:17643749	FAM184B	0.41	6.0	0.35	6.62e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs1799949	1.000	rs35956818	chr17:41422985	T/C	cg06001716	chr17:41278141	BRCA1;NBR2	0.38	5.07	0.3	7.36e-7	Menopause (age at onset);
CESC	cis	rs9649213	0.593	rs3779193	chr7:98028466	T/C	cg08684580	chr7:98029266	BAIAP2L1	-0.35	-5.69	-0.33	3.28e-8	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg01860947	chr19:15442741	NA	-0.51	-6.31	-0.36	1.17e-9	Asthma;
CESC	cis	rs7267979	0.966	rs2500433	chr20:25296335	A/G	cg08601574	chr20:25228251	PYGB	-0.36	-5.13	-0.3	5.74e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs11098499	0.604	rs12642411	chr4:120580525	T/C	cg09307838	chr4:120376055	NA	0.75	9.37	0.5	3.21e-18	Corneal astigmatism;
CESC	cis	rs4665809	0.590	rs7586047	chr2:26447335	A/G	cg08470875	chr2:26401718	FAM59B	-0.75	-7.79	-0.43	1.56e-13	Gut microbiome composition (summer);
CESC	cis	rs1008375	1.000	rs2159583	chr4:17658838	T/C	cg16339924	chr4:17578868	LAP3	0.55	6.93	0.39	3.15e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs8099014	0.861	rs4940703	chr18:56115386	A/G	cg19312305	chr18:56117016	MIR122	-0.26	-5.21	-0.3	3.83e-7	Platelet count;
CESC	cis	rs7223966	1.000	rs7216798	chr17:61740963	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.46	-5.6	-0.33	5.23e-8	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs35110281	0.744	rs162398	chr21:44949285	T/C	cg01579765	chr21:45077557	HSF2BP	-0.56	-9.81	-0.52	1.43e-19	Mean corpuscular volume;
CESC	cis	rs3026101	0.624	rs1058398	chr17:5288760	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	-0.41	-5.68	-0.33	3.46e-8	Body mass index;
CESC	cis	rs3820068	0.705	rs4646087	chr1:15822404	A/G	cg18192808	chr1:15853278	DNAJC16	0.47	5.66	0.33	3.93e-8	Systolic blood pressure;
CESC	cis	rs12142240	0.698	rs12385697	chr1:46818898	T/C	cg00530320	chr1:46809349	NSUN4	0.58	7.89	0.44	8.15e-14	Menopause (age at onset);
CESC	cis	rs941873	0.838	rs2233713	chr10:81107135	A/C	cg08514558	chr10:81106712	PPIF	0.38	6.45	0.37	5.35e-10	Height;
CESC	cis	rs7520050	0.966	rs785471	chr1:46518677	T/C	cg03146154	chr1:46216737	IPP	-0.43	-5.55	-0.32	6.97e-8	Red blood cell count;Reticulocyte count;
CESC	cis	rs875971	0.545	rs1909508	chr7:65766353	G/T	cg25405998	chr7:65216604	CCT6P1	0.44	5.18	0.3	4.3e-7	Aortic root size;
CESC	cis	rs1215050	0.791	rs4699318	chr4:98664370	T/G	cg05340658	chr4:99064831	C4orf37	-0.47	-6.04	-0.35	5.08e-9	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs425277	1.000	rs262676	chr1:2078482	T/A	cg16545954	chr1:2118288	C1orf86	0.33	5.6	0.33	5.35e-8	Height;
CESC	cis	rs7246657	0.943	rs10413602	chr19:37891492	T/C	cg23950597	chr19:37808831	NA	-0.61	-6.19	-0.36	2.31e-9	Coronary artery calcification;
CESC	cis	rs546131	0.928	rs552171	chr11:34830709	G/T	cg06937548	chr11:34938143	PDHX;APIP	0.53	6.55	0.37	3.03e-10	Lung disease severity in cystic fibrosis;
CESC	cis	rs6752107	1.000	rs10165561	chr2:234172915	G/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.48	6.71	0.38	1.19e-10	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs4568518	0.530	rs4493811	chr7:17983369	C/G	cg03009463	chr7:17980271	SNX13	0.39	5.09	0.3	6.75e-7	Measles;
CESC	trans	rs997295	0.529	rs12592315	chr15:68040266	A/G	cg26946276	chr13:31736202	HSPH1	0.48	6.1	0.35	3.73e-9	Motion sickness;
CESC	cis	rs7666738	0.830	rs13124689	chr4:98961182	A/T	cg17366294	chr4:99064904	C4orf37	0.6	8.52	0.46	1.2e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9300255	0.602	rs10846486	chr12:123709927	G/A	cg05973401	chr12:123451056	ABCB9	0.5	5.68	0.33	3.48e-8	Neutrophil percentage of white cells;
CESC	cis	rs4835473	0.932	rs62339581	chr4:144706325	C/T	cg25736465	chr4:144833511	NA	-0.33	-5.43	-0.32	1.28e-7	Immature fraction of reticulocytes;
CESC	cis	rs10504229	0.815	rs75577263	chr8:58188434	A/G	cg05313129	chr8:58192883	C8orf71	-0.55	-6.29	-0.36	1.34e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs12291225	0.545	rs11023187	chr11:14345559	T/G	cg19336497	chr11:14380999	RRAS2	-0.45	-6.67	-0.38	1.48e-10	Sense of smell;
CESC	cis	rs2075371	0.931	rs1646697	chr7:133999930	G/A	cg00033643	chr7:134001901	SLC35B4	0.44	5.59	0.32	5.6e-8	Mean platelet volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23255964	chr5:138862353	TMEM173	-0.56	-6.06	-0.35	4.71e-9	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.830	rs34870112	chr4:99045815	T/G	cg18180107	chr4:99064573	C4orf37	0.41	5.29	0.31	2.51e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs929354	0.772	rs3802125	chr7:156970563	A/C	cg05182265	chr7:156933206	UBE3C	-0.49	-7.28	-0.41	3.85e-12	Body mass index;
CESC	cis	rs644799	1.000	rs596277	chr11:95566886	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.54	6.46	0.37	4.92e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs754466	0.651	rs10824582	chr10:79603688	T/C	cg17075019	chr10:79541650	NA	-0.87	-13.75	-0.65	7.62e-33	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs9814567	1.000	rs9883753	chr3:134247231	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.43	-5.82	-0.34	1.69e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs4072980	0.545	rs10890285	chr1:38453576	A/C	cg18451016	chr1:38461880	NA	-0.41	-5.59	-0.32	5.75e-8	Coronary artery disease;
CESC	cis	rs875971	0.545	rs73152714	chr7:65999628	G/A	cg18876405	chr7:65276391	NA	0.5	5.89	0.34	1.16e-8	Aortic root size;
CESC	cis	rs116095464	0.558	rs10057492	chr5:239503	T/C	cg22857025	chr5:266934	NA	-1.29	-18.85	-0.76	7.29e-51	Breast cancer;
CESC	cis	rs9926296	0.744	rs164747	chr16:89708680	T/G	cg04287289	chr16:89883240	FANCA	-0.45	-5.55	-0.32	7e-8	Vitiligo;
CESC	cis	rs2294693	0.685	rs67525613	chr6:41008956	G/T	cg14418226	chr6:40996092	UNC5CL	0.49	5.34	0.31	2e-7	Gastric cancer;Non-cardia gastric cancer;
CESC	cis	rs10479542	0.549	rs4376229	chr5:179042971	A/G	cg21226059	chr5:178986404	RUFY1	0.39	5.52	0.32	8.22e-8	Lung cancer;
CESC	cis	rs9393777	0.588	rs11967935	chr6:26560672	A/C	cg12826209	chr6:26865740	GUSBL1	0.71	8.5	0.46	1.44e-15	Intelligence (multi-trait analysis);
CESC	cis	rs4727027	0.933	rs12704062	chr7:148827865	G/A	cg23158103	chr7:148848205	ZNF398	-0.41	-6.74	-0.38	9.65e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	trans	rs11039798	0.925	rs10769373	chr11:48531980	T/A	cg15704280	chr7:45808275	SEPT13	0.71	6.6	0.38	2.28e-10	Axial length;
CESC	cis	rs2404602	0.684	rs2047504	chr15:76883516	A/T	cg23625390	chr15:77176239	SCAPER	-0.45	-6.16	-0.35	2.67e-9	Blood metabolite levels;
CESC	cis	rs1538970	0.816	rs11211123	chr1:45957609	G/A	cg24296786	chr1:45957014	TESK2	-0.46	-5.15	-0.3	4.97e-7	Platelet count;
CESC	trans	rs931812	0.895	rs4734493	chr8:101902169	C/T	cg20993868	chr7:22813445	NA	-0.57	-8.66	-0.47	4.66e-16	Attention deficit hyperactivity disorder and conduct disorder;
CESC	cis	rs7811142	1.000	rs11766752	chr7:100073292	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.03	11.71	0.58	8.13e-26	Platelet count;
CESC	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg07677032	chr17:61819896	STRADA	0.44	5.81	0.34	1.81e-8	Prudent dietary pattern;
CESC	cis	rs2439831	0.850	rs524417	chr15:43772374	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.82	11.53	0.58	3.28e-25	Lung cancer in ever smokers;
CESC	cis	rs1707322	0.638	rs1416706	chr1:46602844	G/A	cg06784218	chr1:46089804	CCDC17	-0.33	-5.25	-0.31	3.1e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs10504229	0.595	rs77615399	chr8:58117394	C/G	cg24829409	chr8:58192753	C8orf71	-0.58	-7.2	-0.4	6.31e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs10540	1.000	rs35898083	chr11:484469	C/T	cg21784768	chr11:537496	LRRC56	-0.53	-5.17	-0.3	4.64e-7	Body mass index;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg02836479	chr16:21964489	UQCRC2	-0.48	-6.55	-0.37	3.05e-10	Asthma;
CESC	cis	rs9715521	0.900	rs6551646	chr4:59824827	A/G	cg11281224	chr4:60001000	NA	-0.51	-6.76	-0.38	8.63e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg17095167	chr13:21833918	NA	-0.45	-6.15	-0.35	2.92e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs514406	0.929	rs1672908	chr1:53340885	A/G	cg08736216	chr1:53307985	ZYG11A	-0.42	-6.95	-0.39	2.76e-11	Monocyte count;
CESC	cis	rs2439831	0.867	rs2260160	chr15:43895643	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.66	8.55	0.47	9.65e-16	Lung cancer in ever smokers;
CESC	trans	rs61931739	0.553	rs68124042	chr12:34064431	C/A	cg26384229	chr12:38710491	ALG10B	0.6	8.38	0.46	3.12e-15	Morning vs. evening chronotype;
CESC	cis	rs4665809	0.590	rs1469523	chr2:26474631	T/A	cg27170947	chr2:26402098	FAM59B	0.87	9.85	0.52	1.01e-19	Gut microbiome composition (summer);
CESC	cis	rs533581	0.866	rs4995274	chr16:88970040	T/C	cg16701003	chr16:89028210	CBFA2T3	0.46	6.78	0.38	7.91e-11	Social autistic-like traits;
CESC	cis	rs909002	0.849	rs10753257	chr1:32086089	G/A	cg13919466	chr1:32135498	COL16A1	-0.47	-8.36	-0.46	3.65e-15	Intelligence (multi-trait analysis);
CESC	cis	rs9888739	0.800	rs7193268	chr16:31340997	A/G	cg15817542	chr16:31343056	ITGAM	0.44	6.08	0.35	4.19e-9	Systemic lupus erythematosus;
CESC	cis	rs16854884	1.000	rs16854886	chr3:143781492	A/G	cg06585982	chr3:143692056	C3orf58	0.47	5.23	0.31	3.37e-7	Economic and political preferences (feminism/equality);
CESC	cis	rs11711311	0.955	rs9830102	chr3:113408302	C/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.67	8.96	0.48	5.9e-17	IgG glycosylation;
CESC	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg22520471	chr17:61851767	DDX42;CCDC47	-0.84	-12.56	-0.61	1.1e-28	Prudent dietary pattern;
CESC	cis	rs1799949	0.965	rs7212284	chr17:41205941	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.47	6.72	0.38	1.12e-10	Menopause (age at onset);
CESC	cis	rs10779751	0.770	rs4845853	chr1:11243470	A/G	cg08854313	chr1:11322531	MTOR	0.85	12.53	0.61	1.31e-28	Body mass index;
CESC	cis	rs75804782	0.521	rs55690022	chr2:239407783	C/T	cg18131467	chr2:239335373	ASB1	-0.71	-5.56	-0.32	6.45e-8	Morning vs. evening chronotype;Chronotype;
CESC	cis	rs472402	0.580	rs8192186	chr5:6652009	G/A	cg10789808	chr5:6633262	NSUN2;SRD5A1	-0.54	-7.04	-0.4	1.65e-11	Response to amphetamines;
CESC	cis	rs514406	0.698	rs567880	chr1:53348564	T/G	cg24675658	chr1:53192096	ZYG11B	-0.63	-8.54	-0.46	1.06e-15	Monocyte count;
CESC	cis	rs7666738	0.791	rs7658177	chr4:99035192	T/C	cg03467027	chr4:99064603	C4orf37	0.48	6.05	0.35	4.87e-9	Colonoscopy-negative controls vs population controls;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg18388802	chr22:20004382	ARVCF	-0.48	-6.12	-0.35	3.42e-9	Ulcerative colitis;
CESC	cis	rs6542838	0.704	rs12474283	chr2:99527310	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.41	-5.11	-0.3	6.12e-7	Fear of minor pain;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06684987	chr19:45567721	SFRS16	-0.63	-6.75	-0.38	9.08e-11	Gut microbiome composition (summer);
CESC	cis	rs11078597	0.671	rs1310	chr17:1641715	G/T	cg18436246	chr17:1640651	WDR81	0.62	7.59	0.42	5.36e-13	Serum albumin level;
CESC	cis	rs2455799	0.533	rs924754	chr3:15756215	A/T	cg09340198	chr3:15902540	ANKRD28	-0.33	-5.12	-0.3	6e-7	Mean platelet volume;
CESC	cis	rs75804782	0.521	rs55713398	chr2:239419933	A/G	cg18131467	chr2:239335373	ASB1	-0.68	-5.31	-0.31	2.36e-7	Morning vs. evening chronotype;Chronotype;
CESC	cis	rs5769765	1.000	rs8138941	chr22:50290678	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.45	-5.14	-0.3	5.24e-7	Schizophrenia;
CESC	cis	rs17376456	0.877	rs10078194	chr5:93364310	A/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.6	5.15	0.3	5.06e-7	Diabetic retinopathy;
CESC	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg11494091	chr17:61959527	GH2	0.72	12.33	0.6	6.37e-28	Prudent dietary pattern;
CESC	cis	rs13256369	0.802	rs13256404	chr8:8562974	T/C	cg17143192	chr8:8559678	CLDN23	0.78	8.81	0.48	1.63e-16	Obesity-related traits;
CESC	cis	rs9291683	0.595	rs13145442	chr4:10037261	C/A	cg02734326	chr4:10020555	SLC2A9	0.49	6.83	0.39	5.64e-11	Bone mineral density;
CESC	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg18538332	chr22:24372958	LOC391322	-0.62	-8.69	-0.47	3.73e-16	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs6701037	1.000	rs11585617	chr1:175123186	C/G	cg00321850	chr1:175162397	KIAA0040	-0.42	-5.86	-0.34	1.37e-8	Alcohol dependence;
CESC	cis	rs7264396	0.790	rs6121026	chr20:34266883	A/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.66	7.95	0.44	5.25e-14	Total cholesterol levels;
CESC	cis	rs4843747	0.671	rs28671027	chr16:88116323	G/A	cg03395651	chr16:88107091	BANP	0.45	5.2	0.3	4.07e-7	Menopause (age at onset);
CESC	cis	rs8177253	0.665	rs12639304	chr3:133441594	A/T	cg18769074	chr3:133464867	TF	0.32	5.91	0.34	1.03e-8	Iron status biomarkers;
CESC	cis	rs523522	0.926	rs10774555	chr12:120971978	G/A	cg27279351	chr12:120934652	DYNLL1	0.69	9.11	0.49	2.02e-17	High light scatter reticulocyte count;
CESC	cis	rs938554	0.784	rs11722229	chr4:9980697	C/A	cg11266682	chr4:10021025	SLC2A9	0.36	5.08	0.3	7.18e-7	Blood metabolite levels;
CESC	cis	rs16858210	0.874	rs7618182	chr3:183607003	T/A	cg25686905	chr3:183603175	PARL	-0.34	-6.23	-0.36	1.84e-9	Menopause (age at onset);
CESC	cis	rs992157	0.560	rs6436047	chr2:219108913	A/C	cg00012203	chr2:219082015	ARPC2	0.79	10.82	0.55	7.71e-23	Colorectal cancer;
CESC	cis	rs7385804	0.761	rs1734910	chr7:100309544	A/G	cg16850897	chr7:100343110	ZAN	0.47	6.41	0.37	6.69e-10	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
CESC	trans	rs61931739	0.534	rs2636082	chr12:34061848	T/A	cg26384229	chr12:38710491	ALG10B	0.53	7.25	0.41	4.63e-12	Morning vs. evening chronotype;
CESC	cis	rs1927790	0.727	rs1925122	chr13:96938173	T/C	cg02571835	chr13:96230311	CLDN10	-0.4	-5.75	-0.33	2.49e-8	Body mass index;
CESC	cis	rs12681366	0.592	rs4735291	chr8:95407142	G/C	cg13257157	chr8:95487014	RAD54B	0.43	5.1	0.3	6.52e-7	Nonsyndromic cleft lip with cleft palate;
CESC	trans	rs9987353	0.840	rs329994	chr8:9123233	A/G	cg18393722	chr15:85113863	UBE2QP1	-0.48	-6.55	-0.37	2.93e-10	Recombination measurement;
CESC	cis	rs67478160	0.595	rs8022783	chr14:104245573	T/C	cg08213375	chr14:104286397	PPP1R13B	0.55	11.0	0.56	2.01e-23	Schizophrenia;
CESC	cis	rs6430585	0.528	rs309120	chr2:136708787	G/C	cg07169764	chr2:136633963	MCM6	1.07	15.26	0.68	3.53e-38	Corneal structure;
CESC	cis	rs6484504	0.576	rs11031323	chr11:31245413	T/G	cg14844989	chr11:31128820	NA	-0.43	-5.99	-0.35	6.7e-9	Red blood cell count;
CESC	cis	rs2286503	0.966	rs2286507	chr7:22854760	T/C	cg13679077	chr7:22862647	TOMM7	0.4	5.15	0.3	5.11e-7	Fibrinogen;
CESC	cis	rs67311347	1.000	rs6801185	chr3:40505060	C/T	cg24209194	chr3:40518798	ZNF619	-0.58	-7.88	-0.44	8.41e-14	Renal cell carcinoma;
CESC	cis	rs11608355	0.545	rs61941585	chr12:109905222	C/T	cg05360138	chr12:110035743	NA	0.79	8.25	0.45	7.43e-15	Neuroticism;
CESC	cis	rs12410462	0.901	rs2814090	chr1:227658444	C/G	cg23173402	chr1:227635558	NA	-0.56	-5.75	-0.33	2.44e-8	Major depressive disorder;
CESC	cis	rs4664304	1.000	rs55977890	chr2:160776866	C/T	cg03641300	chr2:160917029	PLA2R1	-0.48	-6.9	-0.39	3.94e-11	Crohn's disease;Inflammatory bowel disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg25152312	chr3:195595803	TNK2	0.47	6.62	0.38	2.03e-10	Fibrinogen levels;
CESC	cis	rs1642645	0.831	rs1327711	chr1:42495949	A/G	cg16685388	chr1:42384056	HIVEP3	0.38	5.71	0.33	3.07e-8	Left ventricular obstructive tract defect (maternal effect);
CESC	cis	rs9790314	0.934	rs455386	chr3:161102495	A/T	cg03342759	chr3:160939853	NMD3	-0.46	-5.95	-0.34	8.51e-9	Morning vs. evening chronotype;
CESC	cis	rs1552244	0.882	rs17050672	chr3:10025463	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.83	9.77	0.51	1.88e-19	Alzheimer's disease;
CESC	cis	rs9910055	0.683	rs7220138	chr17:42254011	C/G	cg19774624	chr17:42201019	HDAC5	-0.82	-12.61	-0.61	7.15e-29	Total body bone mineral density;
CESC	cis	rs9611565	0.659	rs4822035	chr22:41935912	A/G	cg03806693	chr22:41940476	POLR3H	1.17	15.17	0.68	7.83e-38	Vitiligo;
CESC	cis	rs10256972	0.527	rs28671326	chr7:1174973	G/A	cg07308232	chr7:1071921	C7orf50	-0.41	-5.55	-0.32	7.03e-8	Longevity;Endometriosis;
CESC	cis	rs62432291	0.681	rs400477	chr6:159635943	A/C	cg14500486	chr6:159655392	FNDC1	0.55	6.11	0.35	3.62e-9	Joint mobility (Beighton score);
CESC	cis	rs8005677	1.000	rs11157930	chr14:23403171	T/G	cg01529538	chr14:23388837	RBM23	0.5	6.74	0.38	9.9e-11	Cognitive ability (multi-trait analysis);
CESC	cis	rs2836974	0.583	rs9981884	chr21:40585633	G/A	cg11890956	chr21:40555474	PSMG1	0.69	9.49	0.5	1.39e-18	Cognitive function;
CESC	cis	rs5758659	1.000	rs134869	chr22:42652074	G/A	cg04733989	chr22:42467013	NAGA	0.41	5.73	0.33	2.75e-8	Cognitive function;
CESC	cis	rs1707322	0.716	rs6694889	chr1:46101806	A/C	cg05343316	chr1:45956843	TESK2	0.51	6.35	0.36	9.44e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg01704976	chr3:52273381	TWF2	-0.44	-6.28	-0.36	1.4e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs1862618	0.802	rs986049	chr5:56110233	G/A	cg22800045	chr5:56110881	MAP3K1	0.81	10.13	0.53	1.33e-20	Initial pursuit acceleration;
CESC	cis	rs2455799	0.593	rs13085352	chr3:15914845	T/C	cg16303742	chr3:15540471	COLQ	-0.37	-5.67	-0.33	3.7e-8	Mean platelet volume;
CESC	cis	rs1878931	0.624	rs27235	chr16:3439138	G/C	cg22508957	chr16:3507546	NAT15	0.41	5.55	0.32	6.94e-8	Body mass index (adult);
CESC	cis	rs473651	0.904	rs551859	chr2:239371836	T/C	cg18131467	chr2:239335373	ASB1	0.98	18.99	0.76	2.46e-51	Multiple system atrophy;
CESC	cis	rs7666738	0.830	rs11932942	chr4:98998939	T/C	cg05340658	chr4:99064831	C4orf37	0.8	12.44	0.61	2.83e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2120019	1.000	rs12910644	chr15:75358388	A/G	cg09165964	chr15:75287851	SCAMP5	-0.73	-8.47	-0.46	1.7e-15	Blood trace element (Zn levels);
CESC	cis	rs1799949	1.000	rs8176242	chr17:41217874	C/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.43	5.75	0.33	2.4e-8	Menopause (age at onset);
CESC	cis	rs4853012	1.000	rs2280643	chr2:74358286	T/C	cg20891558	chr2:74357851	NA	0.81	11.18	0.57	5.16e-24	Gestational age at birth (maternal effect);
CESC	cis	rs3820068	0.581	rs1547033	chr1:15918988	T/C	cg16988262	chr1:15930761	NA	0.33	5.33	0.31	2.14e-7	Systolic blood pressure;
CESC	trans	rs4771450	0.925	rs7333033	chr13:103978262	G/T	cg08736516	chr4:109541802	LOC285456;RPL34	-0.5	-6.61	-0.38	2.15e-10	Uric acid levels;
CESC	cis	rs8067545	0.750	rs9897246	chr17:19965702	T/G	cg13482628	chr17:19912719	NA	0.38	5.07	0.3	7.57e-7	Schizophrenia;
CESC	cis	rs2228479	0.850	rs2286393	chr16:89809548	C/A	cg00800038	chr16:89945340	TCF25	-0.86	-7.31	-0.41	3.14e-12	Skin colour saturation;
CESC	cis	rs34172651	0.837	rs1978451	chr16:24818286	C/G	cg06028605	chr16:24865363	SLC5A11	0.4	5.95	0.34	8.65e-9	Intelligence (multi-trait analysis);
CESC	cis	rs10754283	0.967	rs7546518	chr1:90109956	C/T	cg21401794	chr1:90099060	LRRC8C	0.69	9.23	0.49	9.05e-18	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs6142102	0.625	rs4911137	chr20:32535463	C/T	cg08999081	chr20:33150536	PIGU	0.34	5.13	0.3	5.49e-7	Skin pigmentation;
CESC	cis	rs10876993	0.890	rs799575	chr12:58069107	A/G	cg18357645	chr12:58087776	OS9	0.63	10.41	0.54	1.65e-21	Celiac disease or Rheumatoid arthritis;
CESC	cis	rs5769765	0.955	rs9616368	chr22:50303533	C/G	cg03033257	chr22:50311977	ALG12;CRELD2	0.52	5.25	0.31	3.11e-7	Schizophrenia;
CESC	cis	rs7408868	1.000	rs6512018	chr19:15282138	T/C	cg14696996	chr19:15285081	NOTCH3	1.11	11.78	0.59	4.93e-26	Pulse pressure;
CESC	cis	rs62064224	0.748	rs72813015	chr17:30693331	T/C	cg24550644	chr17:30846204	MYO1D	-0.35	-5.04	-0.3	8.61e-7	Schizophrenia;
CESC	cis	rs7772486	0.754	rs1415747	chr6:146077249	A/G	cg05347473	chr6:146136440	FBXO30	0.57	7.25	0.41	4.6e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs73072330	1.000	rs17729010	chr3:47912703	A/G	cg04507495	chr3:47563649	NA	-1.01	-7.58	-0.42	5.89e-13	Stem cell growth factor beta levels;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg11287903	chr10:115613834	DCLRE1A;NHLRC2	-0.46	-6.57	-0.37	2.66e-10	Gambling;
CESC	cis	rs4077515	0.967	rs4567159	chr9:139277059	G/A	cg14169450	chr9:139327907	INPP5E	0.39	5.59	0.32	5.6e-8	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14903685	chr15:70391316	TLE3	0.64	7.3	0.41	3.44e-12	Gut microbiome composition (summer);
CESC	cis	rs13064411	0.627	rs9825827	chr3:113182231	T/C	cg18753928	chr3:113234510	CCDC52	-0.46	-5.49	-0.32	9.43e-8	Response to simvastatin treatment (PCSK9 protein level change);
CESC	cis	rs727505	0.607	rs17387591	chr7:124799471	A/G	cg23710748	chr7:124431027	NA	-0.36	-5.43	-0.32	1.3e-7	Lewy body disease;
CESC	cis	rs6831352	0.840	rs35073321	chr4:100053276	G/A	cg13256891	chr4:100009986	ADH5	-0.77	-8.45	-0.46	1.97e-15	Alcohol dependence;
CESC	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg17178900	chr1:205818956	PM20D1	0.77	11.75	0.59	6.14e-26	Menarche (age at onset);
CESC	cis	rs8017423	1.000	rs59052550	chr14:90665098	C/T	cg14092571	chr14:90743983	NA	-0.55	-8.14	-0.45	1.56e-14	Mortality in heart failure;
CESC	cis	rs1008375	1.000	rs1121091	chr4:17676386	A/C	cg02297831	chr4:17616191	MED28	0.45	5.64	0.33	4.42e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs2228479	1.000	rs117406136	chr16:89974605	C/T	cg04013166	chr16:89971882	TCF25	0.76	6.46	0.37	4.89e-10	Skin colour saturation;
CESC	cis	rs11229555	1.000	rs1938598	chr11:58413910	T/C	cg15696309	chr11:58395628	NA	-0.44	-5.69	-0.33	3.39e-8	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CESC	trans	rs3780486	0.505	rs10758194	chr9:33157419	G/T	cg04842962	chr6:43655489	MRPS18A	0.67	10.25	0.53	5.53e-21	IgG glycosylation;
CESC	cis	rs2576037	0.583	rs4890698	chr18:44489725	A/G	cg19077165	chr18:44547161	KATNAL2	-0.62	-9.39	-0.5	2.78e-18	Personality dimensions;
CESC	cis	rs11112613	0.713	rs17037317	chr12:105952058	T/C	cg03607813	chr12:105948248	NA	0.59	7.41	0.41	1.75e-12	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CESC	cis	rs1005277	0.529	rs1780125	chr10:38531376	A/G	cg25517755	chr10:38738941	LOC399744	-0.44	-5.68	-0.33	3.45e-8	Extrinsic epigenetic age acceleration;
CESC	trans	rs875971	0.964	rs9691480	chr7:65944306	A/C	cg26939375	chr7:64535504	NA	0.46	6.0	0.35	6.4e-9	Aortic root size;
CESC	cis	rs7927592	0.513	rs901823	chr11:68205578	T/C	cg16797656	chr11:68205561	LRP5	0.64	10.07	0.53	2.04e-20	Total body bone mineral density;
CESC	cis	rs1799949	0.965	rs11657883	chr17:41330024	T/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.39	5.18	0.3	4.32e-7	Menopause (age at onset);
CESC	cis	rs12545109	0.800	rs1530218	chr8:57407864	C/G	cg09654669	chr8:57350985	NA	-0.56	-6.65	-0.38	1.67e-10	Obesity-related traits;
CESC	cis	rs1461503	0.966	rs11218908	chr11:122841687	A/G	cg27398637	chr11:122830231	C11orf63	-0.55	-8.32	-0.45	4.77e-15	Menarche (age at onset);
CESC	cis	rs6088590	0.610	rs6120663	chr20:33081906	A/C	cg08999081	chr20:33150536	PIGU	-0.63	-10.72	-0.55	1.65e-22	Coronary artery disease;
CESC	cis	rs4253772	0.550	rs6007823	chr22:46706249	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.68	6.55	0.37	2.95e-10	LDL cholesterol;Cholesterol, total;
CESC	cis	rs8044868	0.530	rs2287998	chr16:72059269	C/T	cg16558253	chr16:72132732	DHX38	0.36	5.51	0.32	8.52e-8	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CESC	cis	rs6963495	0.818	rs73190155	chr7:105153535	T/A	cg02135003	chr7:105160482	PUS7	-0.46	-5.55	-0.32	6.92e-8	Bipolar disorder (body mass index interaction);
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg21488398	chr2:70369791	NA	-0.46	-6.18	-0.35	2.34e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7666738	0.830	rs6832209	chr4:98994120	A/G	cg18180107	chr4:99064573	C4orf37	0.4	5.18	0.3	4.42e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6582630	0.572	rs1969363	chr12:38514872	A/G	cg26384229	chr12:38710491	ALG10B	0.43	5.96	0.34	8e-9	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs826838	1.000	rs826889	chr12:39101076	G/A	cg26384229	chr12:38710491	ALG10B	-0.62	-10.2	-0.53	7.78e-21	Heart rate;
CESC	trans	rs9398803	0.897	rs9398804	chr6:126703390	T/A	cg03991309	chr1:68237761	GNG12	-0.42	-6.45	-0.37	5.29e-10	Male-pattern baldness;
CESC	cis	rs2243480	0.901	rs313808	chr7:65499873	T/G	cg12463550	chr7:65579703	CRCP	0.73	5.95	0.34	8.4e-9	Diabetic kidney disease;
CESC	cis	rs28374715	0.662	rs28827035	chr15:41492290	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.82	-10.47	-0.54	1.08e-21	Ulcerative colitis;
CESC	cis	rs12348691	0.503	rs6478423	chr9:100592030	C/T	cg13688889	chr9:100608707	NA	-0.91	-13.31	-0.63	2.78e-31	Alopecia areata;
CESC	cis	rs9660180	0.783	rs1107910	chr1:1692321	C/T	cg13866156	chr1:1669148	SLC35E2	-0.41	-5.7	-0.33	3.22e-8	Body mass index;
CESC	cis	rs12477438	0.765	rs1054042	chr2:99614396	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.64	-9.2	-0.49	1.14e-17	Chronic sinus infection;
CESC	cis	rs8060686	0.623	rs12599178	chr16:68128104	A/G	cg26727032	chr16:67993705	SLC12A4	-0.6	-8.83	-0.48	1.47e-16	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs9733	0.818	rs4970924	chr1:150633079	A/G	cg18016565	chr1:150552671	MCL1	-0.35	-5.83	-0.34	1.61e-8	Tonsillectomy;
CESC	cis	rs344364	0.511	rs2982452	chr16:1949511	G/A	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.55	-6.2	-0.36	2.15e-9	Glomerular filtration rate in chronic kidney disease;
CESC	trans	rs11098499	0.955	rs1397608	chr4:120161744	A/G	cg25214090	chr10:38739885	LOC399744	0.64	8.53	0.46	1.16e-15	Corneal astigmatism;
CESC	trans	rs4950322	0.518	rs61838951	chr1:146587663	T/C	cg04954894	chr8:38089920	DDHD2	-0.58	-6.11	-0.35	3.52e-9	Protein quantitative trait loci;
CESC	cis	rs62432291	0.681	rs435521	chr6:159662638	C/T	cg14500486	chr6:159655392	FNDC1	0.59	6.15	0.35	2.83e-9	Joint mobility (Beighton score);
CESC	cis	rs7296418	0.961	rs1790094	chr12:123586688	T/C	cg00376283	chr12:123451042	ABCB9	0.73	10.52	0.54	7.57e-22	Platelet count;
CESC	cis	rs9399401	0.667	rs6903424	chr6:142699948	A/C	cg04461802	chr6:142623433	GPR126	0.33	5.08	0.3	7.06e-7	Chronic obstructive pulmonary disease;
CESC	cis	rs17384381	0.636	rs11161615	chr1:85906816	A/G	cg16011679	chr1:85725395	C1orf52	-0.54	-5.7	-0.33	3.13e-8	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1538970	0.669	rs3219476	chr1:45802670	A/C	cg05343316	chr1:45956843	TESK2	-0.6	-8.32	-0.46	4.71e-15	Platelet count;
CESC	cis	rs1879734	0.731	rs12405835	chr1:54129732	C/G	cg23596471	chr1:54105337	GLIS1	0.35	5.3	0.31	2.49e-7	Mitral valve prolapse;
CESC	cis	rs9467711	0.559	rs6920256	chr6:26537801	G/A	cg12826209	chr6:26865740	GUSBL1	0.58	5.17	0.3	4.71e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs2243480	0.908	rs2460431	chr7:65622846	A/G	cg18252515	chr7:66147081	NA	1.36	13.62	0.64	2.25e-32	Diabetic kidney disease;
CESC	cis	rs7666738	0.830	rs34892904	chr4:98938097	T/C	cg17366294	chr4:99064904	C4orf37	0.61	8.56	0.47	9.36e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2760061	0.626	rs596208	chr1:228117982	G/C	cg02753203	chr1:228287806	NA	-0.5	-7.24	-0.41	4.83e-12	Diastolic blood pressure;
CESC	cis	rs6964587	1.000	rs12540565	chr7:91633213	T/G	cg17063962	chr7:91808500	NA	0.57	7.92	0.44	6.39e-14	Breast cancer;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg04246357	chr6:158589294	SERAC1;GTF2H5	-0.45	-6.19	-0.36	2.28e-9	Fibrinogen levels;
CESC	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	7.66	0.43	3.42e-13	Prudent dietary pattern;
CESC	cis	rs6860806	0.631	rs4705931	chr5:131588345	T/C	cg22638593	chr5:131593259	PDLIM4	0.41	5.28	0.31	2.71e-7	Breast cancer;
CESC	cis	rs2304069	0.779	rs245080	chr5:149354805	A/G	cg12661370	chr5:149340060	SLC26A2	-0.44	-5.05	-0.3	8.43e-7	HIV-1 control;
CESC	cis	rs4835473	0.932	rs11730929	chr4:144755948	C/T	cg25736465	chr4:144833511	NA	-0.45	-6.75	-0.38	9.22e-11	Immature fraction of reticulocytes;
CESC	cis	rs2361718	0.967	rs2361719	chr17:78103403	A/G	cg27427491	chr17:78079615	GAA	0.34	5.53	0.32	7.54e-8	Yeast infection;
CESC	cis	rs734999	0.588	rs6668149	chr1:2558308	A/C	cg20673091	chr1:2541236	MMEL1	-0.47	-7.84	-0.43	1.11e-13	Ulcerative colitis;
CESC	cis	rs780096	0.526	rs11682621	chr2:27749669	G/A	cg02592271	chr2:27665507	KRTCAP3	-0.28	-5.53	-0.32	7.81e-8	Total body bone mineral density;
CESC	cis	rs6952809	0.532	rs6952152	chr7:2440912	G/A	cg23289794	chr7:2394357	EIF3B	-0.79	-7.29	-0.41	3.64e-12	Multiple sclerosis;
CESC	cis	rs6952808	0.729	rs35797753	chr7:1954914	G/A	cg22963979	chr7:1858916	MAD1L1	-0.38	-5.31	-0.31	2.36e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs853679	0.545	rs35949109	chr6:28025926	T/C	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.87	6.98	0.39	2.41e-11	Depression;
CESC	cis	rs4450798	0.649	rs6808603	chr3:13806359	T/C	cg23332027	chr3:13681764	NA	0.41	5.47	0.32	1.04e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs1448094	0.512	rs10779216	chr12:86240315	A/G	cg00310523	chr12:86230176	RASSF9	-0.35	-5.55	-0.32	7.09e-8	Major depressive disorder;
CESC	cis	rs17376456	0.877	rs9885329	chr5:93380278	G/A	cg21475434	chr5:93447410	FAM172A	0.84	7.15	0.4	8.34e-12	Diabetic retinopathy;
CESC	cis	rs1538970	1.000	rs4660853	chr1:45849090	C/T	cg05343316	chr1:45956843	TESK2	0.84	11.94	0.59	1.41e-26	Platelet count;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg22728371	chr5:32313149	MTMR12	-0.4	-6.3	-0.36	1.21e-9	Gambling;
CESC	cis	rs796364	0.806	rs34381014	chr2:200916403	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.84	-7.75	-0.43	1.94e-13	Schizophrenia;
CESC	cis	rs6736093	0.901	rs34875611	chr2:112763025	G/A	cg12686935	chr2:112915763	FBLN7	-0.43	-5.64	-0.33	4.33e-8	Coronary artery disease;
CESC	cis	rs9311474	0.508	rs12637627	chr3:52619962	G/T	cg07507251	chr3:52567010	NT5DC2	0.33	5.64	0.33	4.31e-8	Electroencephalogram traits;
CESC	cis	rs1609391	0.543	rs6800690	chr3:136623026	G/A	cg15507776	chr3:136538369	TMEM22	0.82	11.97	0.59	1.08e-26	Neuroticism;
CESC	cis	rs12824058	0.831	rs4759653	chr12:130812604	T/C	cg24838063	chr12:130822603	PIWIL1	0.62	8.55	0.47	9.78e-16	Menopause (age at onset);
CESC	cis	rs7617773	0.832	rs6775114	chr3:48182620	G/C	cg11946769	chr3:48343235	NME6	-0.61	-8.18	-0.45	1.18e-14	Coronary artery disease;
CESC	cis	rs7615952	0.673	rs9289270	chr3:125636979	A/T	cg05084668	chr3:125655381	ALG1L	-0.78	-7.65	-0.43	3.65e-13	Blood pressure (smoking interaction);
CESC	cis	rs9937943	0.614	rs35148538	chr16:74613575	G/C	cg01733217	chr16:74700730	RFWD3	0.61	5.2	0.3	4.04e-7	Neutrophil percentage of white cells;
CESC	cis	rs2576037	0.583	rs1465722	chr18:44564499	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.76	-12.55	-0.61	1.16e-28	Personality dimensions;
CESC	cis	rs2380220	0.808	rs2716070	chr6:95912375	T/C	cg15832292	chr6:96025679	MANEA	-0.65	-5.95	-0.34	8.46e-9	Behavioural disinhibition (generation interaction);
CESC	cis	rs617791	0.530	rs7952056	chr11:65744597	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.38	-5.15	-0.3	5.05e-7	Breast cancer;
CESC	cis	rs4664308	0.967	rs56293836	chr2:160910958	T/C	cg03641300	chr2:160917029	PLA2R1	-0.68	-10.17	-0.53	9.82e-21	Idiopathic membranous nephropathy;
CESC	cis	rs2302190	0.941	rs6503865	chr17:56549672	A/C	cg25885038	chr17:56607967	SEPT4	-0.4	-5.41	-0.32	1.44e-7	Vitamin D levels;
CESC	cis	rs7552404	1.000	rs4949879	chr1:76237143	G/A	cg22875332	chr1:76189707	ACADM	0.48	5.56	0.32	6.45e-8	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs6987853	0.761	rs2974322	chr8:42424724	T/C	cg09913449	chr8:42400586	C8orf40	0.46	7.79	0.43	1.53e-13	Mean corpuscular hemoglobin concentration;
CESC	cis	rs35110281	0.627	rs7283362	chr21:44973667	C/G	cg21573476	chr21:45109991	RRP1B	-0.4	-5.5	-0.32	8.96e-8	Mean corpuscular volume;
CESC	cis	rs12188164	0.610	rs6555242	chr5:416546	A/C	cg17553881	chr5:443987	EXOC3;C5orf55	-0.32	-5.54	-0.32	7.35e-8	Cystic fibrosis severity;
CESC	cis	rs7666738	0.830	rs17483521	chr4:98974058	A/T	cg05340658	chr4:99064831	C4orf37	0.8	12.38	0.61	4.42e-28	Colonoscopy-negative controls vs population controls;
CESC	trans	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg10053473	chr17:62856997	LRRC37A3	-0.72	-7.56	-0.42	6.69e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs9916302	0.904	rs585961	chr17:37444036	G/A	cg19468946	chr17:37922297	IKZF3	0.43	5.53	0.32	7.49e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs55794721	0.509	rs6699113	chr1:25777743	C/T	cg02931644	chr1:25747376	RHCE	0.46	7.97	0.44	4.84e-14	Plateletcrit;Mean corpuscular volume;
CESC	cis	rs6456156	0.586	rs6456149	chr6:167463902	T/C	cg07741184	chr6:167504864	NA	0.35	6.1	0.35	3.81e-9	Primary biliary cholangitis;
CESC	cis	rs703842	1.000	rs10877013	chr12:58165085	C/T	cg00677455	chr12:58241039	CTDSP2	0.51	6.67	0.38	1.47e-10	Multiple sclerosis;
CESC	cis	rs66686620	1.000	rs4401244	chr2:69247005	A/G	cg12800200	chr2:69260302	ANTXR1	-0.4	-5.89	-0.34	1.15e-8	Breast cancer;
CESC	cis	rs2439831	0.541	rs12440854	chr15:43610672	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.74	6.24	0.36	1.77e-9	Lung cancer in ever smokers;
CESC	cis	rs698833	0.548	rs1372079	chr2:44543317	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.54	5.51	0.32	8.32e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs453301	0.571	rs2929454	chr8:9083854	A/C	cg17143192	chr8:8559678	CLDN23	-0.47	-5.66	-0.33	3.89e-8	Joint mobility (Beighton score);
CESC	cis	rs708547	0.647	rs1403233	chr4:57885053	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.49	-6.74	-0.38	9.89e-11	Response to bleomycin (chromatid breaks);
CESC	cis	rs3780486	0.846	rs4584234	chr9:33147479	G/A	cg13443165	chr9:33130375	B4GALT1	0.45	6.54	0.37	3.08e-10	IgG glycosylation;
CESC	cis	rs4665809	1.000	rs6720314	chr2:26334852	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.82	-9.22	-0.49	9.78e-18	Gut microbiome composition (summer);
CESC	cis	rs965469	0.895	rs12626130	chr20:3393192	G/T	cg25506879	chr20:3388711	C20orf194	-0.63	-6.42	-0.37	6.37e-10	IFN-related cytopenia;
CESC	trans	rs61931739	0.500	rs11053213	chr12:34466395	G/T	cg26384229	chr12:38710491	ALG10B	0.71	10.64	0.55	3.04e-22	Morning vs. evening chronotype;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg04719816	chr4:529996	PIGG	0.5	6.48	0.37	4.51e-10	Fibrinogen levels;
CESC	cis	rs533581	0.866	rs871756	chr16:88969076	G/C	cg16701003	chr16:89028210	CBFA2T3	0.46	6.3	0.36	1.23e-9	Social autistic-like traits;
CESC	cis	rs10504229	1.000	rs76023408	chr8:58193345	A/G	cg14926445	chr8:58193284	C8orf71	-0.5	-5.45	-0.32	1.18e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs16986825	0.570	rs5752822	chr22:29266025	A/G	cg15103426	chr22:29168792	CCDC117	0.48	5.12	0.3	5.8e-7	Pancreatic cancer;
CESC	cis	rs9929218	1.000	rs12446407	chr16:68804068	G/A	cg02972257	chr16:68554789	NA	0.43	5.18	0.3	4.44e-7	Colorectal cancer;
CESC	cis	rs4481887	0.962	rs10788768	chr1:248456027	G/A	cg00666640	chr1:248458726	OR2T12	0.4	6.62	0.38	1.97e-10	Common traits (Other);
CESC	cis	rs911555	0.692	rs7146215	chr14:103915908	A/G	cg12935359	chr14:103987150	CKB	0.66	9.78	0.52	1.71e-19	Intelligence (multi-trait analysis);
CESC	cis	rs11997175	0.935	rs3903385	chr8:33687399	T/G	ch.8.33884649F	chr8:33765107	NA	0.62	7.75	0.43	1.98e-13	Body mass index;
CESC	cis	rs9768139	0.708	rs10233815	chr7:158114348	C/T	cg06219351	chr7:158114137	PTPRN2	-0.56	-8.96	-0.48	5.77e-17	Calcium levels;
CESC	cis	rs6460942	0.915	rs62448596	chr7:12446869	C/T	cg10578991	chr7:12443926	VWDE	-0.45	-5.09	-0.3	6.83e-7	Coronary artery disease;
CESC	cis	rs12995491	0.731	rs55705009	chr2:88500718	T/G	cg04511125	chr2:88470314	THNSL2	-0.52	-7.7	-0.43	2.76e-13	Response to metformin (IC50);
CESC	cis	rs9311474	0.659	rs7638808	chr3:52572056	C/T	cg05564831	chr3:52568323	NT5DC2	-0.49	-8.21	-0.45	9.82e-15	Electroencephalogram traits;
CESC	cis	rs208520	0.690	rs12213575	chr6:66735989	A/G	cg07460842	chr6:66804631	NA	0.96	12.81	0.62	1.47e-29	Exhaled nitric oxide output;
CESC	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg05313129	chr8:58192883	C8orf71	-0.49	-5.33	-0.31	2.07e-7	Developmental language disorder (linguistic errors);
CESC	trans	rs9467711	0.606	rs12176317	chr6:26372786	A/G	cg06606381	chr12:133084897	FBRSL1	-0.76	-6.89	-0.39	4.1e-11	Autism spectrum disorder or schizophrenia;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg23418198	chr17:4925746	KIF1C	0.41	6.24	0.36	1.68e-9	Fibrinogen levels;
CESC	cis	rs17826219	0.568	rs9907834	chr17:29154013	G/A	cg13385521	chr17:29058706	SUZ12P	0.75	6.0	0.35	6.29e-9	Body mass index;
CESC	cis	rs9322193	0.961	rs2064520	chr6:149924786	A/T	cg13206674	chr6:150067644	NUP43	0.41	5.91	0.34	1.04e-8	Lung cancer;
CESC	cis	rs7000551	0.751	rs2449348	chr8:22359572	C/T	cg12081754	chr8:22256438	SLC39A14	0.41	5.5	0.32	8.87e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CESC	cis	rs3785574	0.582	rs62072238	chr17:61948841	A/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.78	10.11	0.53	1.56e-20	Height;
CESC	trans	rs2727020	0.553	rs7479975	chr11:49581964	C/G	cg03929089	chr4:120376271	NA	-0.78	-11.52	-0.58	3.71e-25	Coronary artery disease;
CESC	cis	rs7044106	0.762	rs1867254	chr9:123429078	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.77	11.25	0.57	2.87e-24	Hip circumference adjusted for BMI;
CESC	cis	rs875971	0.862	rs6460290	chr7:65809106	G/A	cg11764359	chr7:65958608	NA	-0.8	-11.97	-0.59	1.1e-26	Aortic root size;
CESC	trans	rs9325144	0.650	rs6582624	chr12:38733475	A/T	cg23762105	chr12:34175262	ALG10	0.49	6.32	0.36	1.1e-9	Morning vs. evening chronotype;
CESC	cis	rs7208859	0.673	rs2269916	chr17:29233763	A/G	cg19761014	chr17:28927070	LRRC37B2	0.73	5.77	0.33	2.22e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	trans	rs2115172	0.836	rs4835799	chr5:122762229	A/G	cg02576092	chr1:27668556	SYTL1	0.45	6.23	0.36	1.8e-9	Weight;
CESC	cis	rs35110281	0.782	rs1454650	chr21:45012353	C/T	cg04455712	chr21:45112962	RRP1B	0.4	5.98	0.34	7.35e-9	Mean corpuscular volume;
CESC	cis	rs12188164	0.965	rs1056465	chr5:442438	T/A	cg21144161	chr5:423903	AHRR	0.37	6.03	0.35	5.59e-9	Cystic fibrosis severity;
CESC	trans	rs9307551	0.817	rs6852514	chr4:80501913	C/T	cg02747103	chr19:603718	HCN2	-0.41	-6.04	-0.35	5.25e-9	Refractive error;
CESC	cis	rs3785574	0.962	rs13030	chr17:61908556	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.57	7.05	0.4	1.55e-11	Height;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg16209303	chr14:103405847	CDC42BPB	0.45	6.74	0.38	9.93e-11	Fibrinogen levels;
CESC	cis	rs4780401	0.539	rs62040604	chr16:11803641	G/A	cg01061890	chr16:11836724	TXNDC11	-0.58	-7.95	-0.44	5.26e-14	Rheumatoid arthritis;
CESC	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg05064044	chr6:292385	DUSP22	-0.68	-8.67	-0.47	4.36e-16	Menopause (age at onset);
CESC	cis	rs2294693	0.945	rs9381023	chr6:40983281	C/T	cg14418226	chr6:40996092	UNC5CL	-0.49	-5.78	-0.33	2.07e-8	Gastric cancer;Non-cardia gastric cancer;
CESC	cis	rs1878931	0.624	rs1149492	chr16:3445239	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.74	-9.05	-0.49	3.24e-17	Body mass index (adult);
CESC	cis	rs34734847	0.965	rs2005455	chr12:121128699	A/G	cg21892295	chr12:121157589	UNC119B	-0.36	-5.81	-0.34	1.75e-8	Mean corpuscular volume;
CESC	cis	rs1799949	0.864	rs60309406	chr17:41435665	C/T	cg06001716	chr17:41278141	BRCA1;NBR2	0.38	5.08	0.3	7.12e-7	Menopause (age at onset);
CESC	trans	rs274437	0.640	rs62420186	chr6:104819534	G/A	cg04677410	chr11:95846117	MAML2	-0.52	-6.03	-0.35	5.36e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs910316	0.934	rs8006587	chr14:75664939	A/G	cg08847533	chr14:75593920	NEK9	0.9	15.67	0.69	1.24e-39	Height;
CESC	cis	rs4819052	0.851	rs28442024	chr21:46674475	C/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.43	5.46	0.32	1.12e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs2727020	0.576	rs1814175	chr11:49559172	T/C	cg03929089	chr4:120376271	NA	-0.81	-12.23	-0.6	1.44e-27	Coronary artery disease;
CESC	cis	rs6696846	0.630	rs6692706	chr1:205158561	G/T	cg00857998	chr1:205179979	DSTYK	0.56	7.05	0.4	1.53e-11	Red blood cell count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10219037	chr11:111750118	C11orf1;FDXACB1	-0.53	-6.12	-0.35	3.44e-9	Gut microbiome composition (summer);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg00390337	chr16:1798633	MAPK8IP3	0.45	6.26	0.36	1.5e-9	Fibrinogen levels;
CESC	trans	rs73206853	0.841	rs16940885	chr12:110971666	A/G	cg22801913	chr11:47176841	C11orf49	0.5	6.07	0.35	4.47e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs4957048	0.577	rs56294732	chr5:568144	T/C	cg16447950	chr5:562315	NA	-0.66	-7.73	-0.43	2.18e-13	Ulcerative colitis;
CESC	cis	rs11139399	0.650	rs6559638	chr9:84349669	T/A	cg07852945	chr9:84303915	TLE1	0.37	5.61	0.33	5.15e-8	Hippocampal atrophy;
CESC	cis	rs35110281	0.627	rs6518268	chr21:44967448	A/G	cg04455712	chr21:45112962	RRP1B	0.35	5.22	0.31	3.61e-7	Mean corpuscular volume;
CESC	cis	rs926938	0.563	rs360655	chr1:115447867	T/C	cg12756093	chr1:115239321	AMPD1	0.48	6.94	0.39	3e-11	Autism;
CESC	cis	rs2439831	0.681	rs7168940	chr15:43633334	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.89	10.67	0.55	2.46e-22	Lung cancer in ever smokers;
CESC	cis	rs7824557	0.767	rs17797443	chr8:11164012	T/C	cg21775007	chr8:11205619	TDH	0.48	7.0	0.39	2.13e-11	Retinal vascular caliber;
CESC	cis	rs8062405	1.000	rs56404918	chr16:28846840	T/G	cg08761264	chr16:28874980	SH2B1	-0.46	-5.77	-0.33	2.26e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs9549260	0.816	rs7334318	chr13:41217410	C/G	cg21288729	chr13:41239152	FOXO1	0.68	8.81	0.48	1.67e-16	Red blood cell count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02364793	chr5:175964512	RNF44	-0.66	-8.0	-0.44	3.9e-14	Gut microbiome composition (summer);
CESC	cis	rs7617480	0.648	rs9859473	chr3:48837182	A/G	cg07636037	chr3:49044803	WDR6	0.79	10.64	0.55	2.92e-22	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CESC	cis	rs36051895	0.659	rs4495487	chr9:5072798	T/C	cg02405213	chr9:5042618	JAK2	-0.51	-6.19	-0.36	2.28e-9	Pediatric autoimmune diseases;
CESC	cis	rs6714710	0.603	rs956039	chr2:98416848	C/A	cg26665480	chr2:98280029	ACTR1B	0.68	9.4	0.5	2.59e-18	Posterior cortical atrophy and Alzheimer's disease;
CESC	cis	rs11577318	0.853	rs2276712	chr1:26627478	T/C	cg00813993	chr1:26644493	UBXN11;CD52	-0.4	-6.45	-0.37	5.21e-10	Granulocyte percentage of myeloid white cells;
CESC	cis	rs9611565	0.729	rs2413647	chr22:41907148	G/A	cg17376030	chr22:41985996	PMM1	0.76	8.18	0.45	1.22e-14	Vitiligo;
CESC	cis	rs7937682	0.889	rs497111	chr11:111499512	G/A	cg22437258	chr11:111473054	SIK2	0.7	9.18	0.49	1.31e-17	Primary sclerosing cholangitis;
CESC	cis	rs9303401	0.614	rs12948536	chr17:56580413	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.01	12.43	0.61	2.87e-28	Cognitive test performance;
CESC	cis	rs35306767	0.903	rs11815185	chr10:923617	T/A	cg10556349	chr10:835070	NA	0.53	5.24	0.31	3.21e-7	Eosinophil percentage of granulocytes;
CESC	cis	rs4979906	1.000	rs12264636	chr10:79448539	C/G	cg00983440	chr10:79422392	NA	0.5	5.34	0.31	1.99e-7	Mortality in heart failure;
CESC	cis	rs5753037	0.543	rs140126	chr22:30147038	A/G	cg01021169	chr22:30184971	ASCC2	-0.55	-7.83	-0.43	1.17e-13	Type 1 diabetes;
CESC	cis	rs1983170	1.000	rs1983170	chr1:91986482	G/A	cg21854759	chr1:92012499	NA	0.51	5.54	0.32	7.25e-8	Eosinophil percentage of white cells;
CESC	cis	rs561341	1.000	rs548957	chr17:30302411	G/A	cg12193833	chr17:30244370	NA	-0.7	-6.49	-0.37	4.19e-10	Hip circumference adjusted for BMI;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg10647644	chr5:118788352	HSD17B4	0.45	6.02	0.35	5.7e-9	Thyroid stimulating hormone;
CESC	cis	rs11098499	0.954	rs13107475	chr4:120393011	A/T	cg09307838	chr4:120376055	NA	0.95	14.11	0.66	4.2e-34	Corneal astigmatism;
CESC	cis	rs7666738	0.800	rs10028921	chr4:98962630	G/T	cg05340658	chr4:99064831	C4orf37	0.8	12.39	0.61	3.94e-28	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25330243	chr8:102504501	GRHL2	0.56	6.42	0.37	6.12e-10	Gut microbiome composition (summer);
CESC	cis	rs514406	0.823	rs501006	chr1:53368292	T/A	cg25767906	chr1:53392781	SCP2	-0.49	-6.26	-0.36	1.55e-9	Monocyte count;
CESC	cis	rs2439831	0.702	rs7171750	chr15:44025858	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.7	8.06	0.44	2.56e-14	Lung cancer in ever smokers;
CESC	cis	rs514406	0.505	rs425520	chr1:53179805	C/G	cg08859206	chr1:53392774	SCP2	-0.52	-6.8	-0.39	6.9e-11	Monocyte count;
CESC	cis	rs244293	0.760	rs12945393	chr17:53045243	G/A	cg19360675	chr17:53046073	COX11;STXBP4	-0.45	-6.26	-0.36	1.58e-9	Menarche (age at onset);
CESC	cis	rs7927771	0.839	rs7124681	chr11:47529947	C/A	cg18512352	chr11:47633146	NA	-0.46	-7.15	-0.4	8.38e-12	Subjective well-being;
CESC	cis	rs2425143	0.558	rs7274724	chr20:34539466	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.79	-7.1	-0.4	1.13e-11	Blood protein levels;
CESC	cis	rs2758596	0.850	rs2495270	chr1:156181530	A/G	cg25208724	chr1:156163844	SLC25A44	0.66	6.15	0.35	2.87e-9	Paclitaxel disposition in epithelial ovarian cancer;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg24488506	chr11:65667952	FOSL1	-0.46	-6.06	-0.35	4.73e-9	Ulcerative colitis;
CESC	cis	rs35110281	0.807	rs9984002	chr21:45061501	T/C	cg04455712	chr21:45112962	RRP1B	0.39	5.69	0.33	3.31e-8	Mean corpuscular volume;
CESC	cis	rs10479542	0.503	rs12719865	chr5:178993566	C/T	cg22764044	chr5:178986830	RUFY1	0.46	6.66	0.38	1.55e-10	Lung cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26464524	chr7:99699573	MCM7;AP4M1	0.57	6.48	0.37	4.43e-10	Gut microbiome composition (summer);
CESC	cis	rs853679	0.517	rs56364346	chr6:28050762	T/G	cg23281280	chr6:28129359	ZNF389	0.57	7.78	0.43	1.61e-13	Depression;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg13451483	chr19:5720795	TMEM146;LONP1	-0.46	-6.48	-0.37	4.47e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs7188697	0.922	rs37056	chr16:58560877	G/A	cg21335942	chr16:58549945	SETD6	0.46	5.41	0.32	1.4e-7	QT interval;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg25308054	chr19:10676770	KRI1	-0.41	-6.18	-0.35	2.39e-9	Gambling;
CESC	cis	rs9399401	0.601	rs262113	chr6:142824950	T/G	cg03128060	chr6:142623767	GPR126	0.33	5.32	0.31	2.22e-7	Chronic obstructive pulmonary disease;
CESC	cis	rs1707322	0.627	rs3014213	chr1:46045522	T/C	cg03146154	chr1:46216737	IPP	-0.77	-10.4	-0.54	1.77e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs6912958	0.703	rs12207825	chr6:88098292	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.33	5.29	0.31	2.54e-7	Monocyte percentage of white cells;
CESC	cis	rs3733585	0.753	rs12500805	chr4:10017979	C/T	cg00071950	chr4:10020882	SLC2A9	0.87	15.65	0.69	1.54e-39	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs8005677	0.828	rs4981450	chr14:23389304	A/G	cg25600027	chr14:23388339	RBM23	-0.41	-5.06	-0.3	8.03e-7	Cognitive ability (multi-trait analysis);
CESC	cis	rs10949834	0.590	rs1091815	chr7:73489643	G/A	cg07137043	chr7:73588983	EIF4H	0.58	6.53	0.37	3.37e-10	Verbal memory performance (residualized delayed recall change);
CESC	cis	rs6502050	0.835	rs4499294	chr17:80148346	C/T	cg11859384	chr17:80120422	CCDC57	-0.38	-5.17	-0.3	4.56e-7	Life satisfaction;
CESC	cis	rs875971	0.862	rs10256544	chr7:65675128	A/G	cg18876405	chr7:65276391	NA	0.58	8.07	0.44	2.51e-14	Aortic root size;
CESC	cis	rs896854	0.812	rs2340586	chr8:95969261	G/A	cg16049864	chr8:95962084	TP53INP1	-0.67	-12.13	-0.6	3.13e-27	Type 2 diabetes;
CESC	cis	rs6991838	0.584	rs13268343	chr8:66543977	C/T	cg13398993	chr8:66546079	ARMC1	0.46	5.65	0.33	4.19e-8	Intelligence (multi-trait analysis);
CESC	cis	rs7020830	0.931	rs7851239	chr9:37138672	A/G	cg14294708	chr9:37120828	ZCCHC7	-1.15	-18.46	-0.75	1.71e-49	Schizophrenia;
CESC	cis	rs2243480	1.000	rs35432774	chr7:65393019	G/C	cg18252515	chr7:66147081	NA	-1.0	-9.22	-0.49	9.27e-18	Diabetic kidney disease;
CESC	cis	rs1799949	0.965	rs6503726	chr17:41284742	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.48	6.79	0.39	7.21e-11	Menopause (age at onset);
CESC	cis	rs9640161	0.750	rs11538922	chr7:150035183	C/T	cg21361702	chr7:150065534	REPIN1	0.55	5.9	0.34	1.11e-8	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs523522	0.962	rs3759394	chr12:120933173	C/A	cg12219531	chr12:120966889	COQ5	0.75	9.99	0.52	3.7e-20	High light scatter reticulocyte count;
CESC	cis	rs2486288	0.656	rs12440356	chr15:45567529	T/C	cg21132104	chr15:45694354	SPATA5L1	0.62	7.26	0.41	4.26e-12	Glomerular filtration rate;
CESC	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg22907277	chr7:1156413	C7orf50	0.42	5.94	0.34	9.06e-9	Longevity;Endometriosis;
CESC	cis	rs10870270	0.956	rs6557	chr10:133781449	C/T	cg26149184	chr10:133730230	NA	0.38	5.14	0.3	5.32e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs896854	0.967	rs13257021	chr8:95965695	A/G	cg13393036	chr8:95962371	TP53INP1	-0.52	-11.34	-0.57	1.43e-24	Type 2 diabetes;
CESC	trans	rs11039798	0.588	rs6485869	chr11:48576903	G/T	cg15704280	chr7:45808275	SEPT13	0.64	6.64	0.38	1.78e-10	Axial length;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg16798694	chr8:141557712	EIF2C2	0.51	6.61	0.38	2.12e-10	Fibrinogen levels;
CESC	cis	rs9300255	0.544	rs1790100	chr12:123656725	G/T	cg05973401	chr12:123451056	ABCB9	0.5	5.7	0.33	3.19e-8	Neutrophil percentage of white cells;
CESC	cis	rs2280018	0.526	rs1510148	chr16:15167379	T/A	cg07549590	chr16:15018862	NA	-0.61	-9.76	-0.51	2.07e-19	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs10871290	0.730	rs6564097	chr16:74466419	T/C	cg01733217	chr16:74700730	RFWD3	-0.69	-9.24	-0.49	8.21e-18	Breast cancer;
CESC	cis	rs7044106	0.734	rs1981020	chr9:123388464	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.36	5.84	0.34	1.54e-8	Hip circumference adjusted for BMI;
CESC	cis	rs17209837	0.564	rs117373803	chr7:87096783	A/G	cg00919237	chr7:87102261	ABCB4	-0.49	-6.39	-0.37	7.37e-10	Gallbladder cancer;
CESC	cis	rs7618915	0.501	rs2164885	chr3:52731269	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.61	8.78	0.47	2.04e-16	Bipolar disorder;
CESC	cis	rs765787	0.530	rs4775819	chr15:45525966	C/T	cg24006582	chr15:45444508	DUOX1	-0.6	-7.35	-0.41	2.45e-12	Uric acid levels;
CESC	cis	rs274567	0.602	rs272853	chr5:131688561	A/G	cg24060327	chr5:131705240	SLC22A5	-0.71	-9.86	-0.52	1e-19	Blood metabolite levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24714709	chr7:95064397	PON2	0.61	7.25	0.41	4.71e-12	Gut microbiome composition (summer);
CESC	cis	rs6570726	0.875	rs373313	chr6:145857791	T/C	cg23711669	chr6:146136114	FBXO30	0.8	11.74	0.58	6.58e-26	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs12900413	0.603	rs2882677	chr15:90299514	C/T	cg24249390	chr15:90295951	MESP1	-0.4	-5.46	-0.32	1.08e-7	Coronary artery aneurysm in Kawasaki disease;
CESC	cis	rs10927875	0.722	rs6660685	chr1:16346988	A/G	cg21214613	chr1:16344536	HSPB7	0.36	5.17	0.3	4.51e-7	Dilated cardiomyopathy;
CESC	cis	rs11997175	0.574	rs58858314	chr8:33658221	T/C	ch.8.33884649F	chr8:33765107	NA	0.67	8.5	0.46	1.38e-15	Body mass index;
CESC	cis	rs6964587	0.967	rs6465341	chr7:91596121	G/C	cg17063962	chr7:91808500	NA	0.58	7.91	0.44	6.94e-14	Breast cancer;
CESC	cis	rs34891900	0.507	rs1008378	chr22:18207251	T/C	cg19898043	chr22:18121309	BCL2L13	0.58	6.57	0.37	2.6e-10	Sum neutrophil eosinophil counts;
CESC	cis	rs546131	0.928	rs516228	chr11:34838823	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.5	6.5	0.37	3.96e-10	Lung disease severity in cystic fibrosis;
CESC	cis	rs2050392	0.965	rs2265370	chr10:30690581	C/T	cg18806716	chr10:30721971	MAP3K8	-0.4	-5.62	-0.33	4.93e-8	Inflammatory bowel disease;
CESC	cis	rs875971	0.522	rs709604	chr7:65497434	A/G	cg08632164	chr7:65971372	NA	0.32	5.11	0.3	6.05e-7	Aortic root size;
CESC	cis	rs10851478	0.558	rs17478694	chr15:49738542	C/G	cg08060515	chr15:49448048	GALK2;COPS2	0.5	6.25	0.36	1.61e-9	Oral cavity cancer;
CESC	cis	rs36051895	0.659	rs62541538	chr9:5038164	G/A	cg02405213	chr9:5042618	JAK2	-0.47	-5.66	-0.33	3.99e-8	Pediatric autoimmune diseases;
CESC	cis	rs2635047	0.875	rs2251948	chr18:44681356	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.5	6.8	0.39	7.02e-11	Educational attainment;
CESC	cis	rs875971	1.000	rs10257427	chr7:65743208	T/C	cg10691866	chr7:65817282	TPST1	0.33	5.59	0.32	5.54e-8	Aortic root size;
CESC	cis	rs6543140	0.929	rs7602207	chr2:103032366	C/G	cg04239558	chr2:103089729	SLC9A4	0.45	5.76	0.33	2.28e-8	Blood protein levels;
CESC	cis	rs3793683	0.545	rs12784446	chr10:134589094	T/G	cg18305652	chr10:134549665	INPP5A	0.5	7.2	0.4	6.38e-12	Migraine;
CESC	cis	rs2046867	0.818	rs17010195	chr3:72872852	A/G	cg25664220	chr3:72788482	NA	0.38	5.66	0.33	3.86e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg13662628	chr9:127572244	OLFML2A	0.42	6.07	0.35	4.44e-9	Fibrinogen levels;
CESC	cis	rs2204008	0.668	rs1619009	chr12:38120485	G/A	cg26384229	chr12:38710491	ALG10B	-0.43	-5.92	-0.34	9.92e-9	Bladder cancer;
CESC	cis	rs6831352	0.918	rs13138294	chr4:100062675	T/G	cg13256891	chr4:100009986	ADH5	-0.76	-8.4	-0.46	2.83e-15	Alcohol dependence;
CESC	trans	rs17764205	0.929	rs10420340	chr19:3256494	G/A	cg27384338	chr17:2031545	SMG6	-0.64	-6.08	-0.35	4.2e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs9388451	0.626	rs1935983	chr6:126068914	C/T	cg05901451	chr6:126070800	HEY2	-0.61	-9.27	-0.49	6.65e-18	Brugada syndrome;
CESC	cis	rs798554	0.679	rs2527681	chr7:2892384	A/T	cg04166393	chr7:2884313	GNA12	0.62	8.32	0.46	4.69e-15	Height;
CESC	cis	rs501120	0.925	rs494045	chr10:44773498	C/T	cg09554077	chr10:44749378	NA	0.48	5.05	0.3	8.15e-7	Coronary artery disease;Coronary heart disease;
CESC	cis	rs12477438	0.520	rs7604557	chr2:99747829	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.86	15.04	0.68	2.28e-37	Chronic sinus infection;
CESC	cis	rs4727027	0.933	rs757738	chr7:148872351	T/G	cg23583168	chr7:148888333	NA	-0.81	-12.5	-0.61	1.67e-28	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs8077577	0.895	rs16960980	chr17:18100858	C/T	cg16794390	chr17:18148240	FLII	0.45	6.26	0.36	1.57e-9	Obesity-related traits;
CESC	cis	rs17666538	0.636	rs10107345	chr8:603700	G/T	cg02524346	chr8:600233	NA	0.74	6.16	0.35	2.68e-9	IgG glycosylation;
CESC	cis	rs6968419	0.755	rs17138486	chr7:115894403	C/G	cg02561103	chr7:115862891	TES	-0.4	-5.26	-0.31	2.92e-7	Intraocular pressure;
CESC	cis	rs854765	0.583	rs11078406	chr17:17840823	G/T	cg16928487	chr17:17741425	SREBF1	-0.52	-8.83	-0.48	1.51e-16	Total body bone mineral density;
CESC	cis	rs6952808	0.792	rs2056478	chr7:1953897	C/T	cg05863683	chr7:1912471	MAD1L1	0.42	6.27	0.36	1.45e-9	Bipolar disorder and schizophrenia;
CESC	trans	rs1977584	0.725	rs79498729	chr10:45402161	C/T	cg09262100	chr14:103416268	CDC42BPB	0.61	6.14	0.35	3.02e-9	Selective IgA deficiency;
CESC	cis	rs6912958	0.781	rs6454632	chr6:88231824	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.51	-6.77	-0.38	8.38e-11	Monocyte percentage of white cells;
CESC	cis	rs6964587	1.000	rs56072181	chr7:91690457	A/G	cg17063962	chr7:91808500	NA	0.6	8.37	0.46	3.45e-15	Breast cancer;
CESC	cis	rs2228479	1.000	rs117406136	chr16:89974605	C/T	cg14709524	chr16:89940631	TCF25	0.86	6.3	0.36	1.24e-9	Skin colour saturation;
CESC	cis	rs3741404	0.620	rs882147	chr11:63976689	T/A	cg18225595	chr11:63971243	STIP1	0.62	8.65	0.47	4.96e-16	Platelet count;
CESC	cis	rs1375194	0.606	rs17657783	chr2:33814590	A/G	cg04131969	chr2:33951647	MYADML	-0.5	-6.34	-0.36	9.94e-10	Response to antidepressants in depression;
CESC	cis	rs7605827	0.930	rs10201925	chr2:15528742	G/A	cg19274914	chr2:15703543	NA	0.36	6.35	0.36	9.19e-10	Educational attainment (years of education);
CESC	cis	rs4900538	0.821	rs2009575	chr14:102820787	C/T	cg18135206	chr14:102964638	TECPR2	-0.64	-7.68	-0.43	3.18e-13	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	cis	rs6964587	0.869	rs10250641	chr7:91490746	C/T	cg17063962	chr7:91808500	NA	0.54	7.08	0.4	1.27e-11	Breast cancer;
CESC	cis	rs459571	0.959	rs410876	chr9:136893867	C/A	cg13789015	chr9:136890014	NCRNA00094	0.54	7.67	0.43	3.2e-13	Platelet distribution width;
CESC	cis	rs7618915	0.501	rs7624716	chr3:52751534	T/C	cg07507251	chr3:52567010	NT5DC2	0.35	5.94	0.34	8.88e-9	Bipolar disorder;
CESC	cis	rs62064224	0.589	rs9910731	chr17:30784034	A/G	cg18200150	chr17:30822561	MYO1D	0.39	5.07	0.3	7.45e-7	Schizophrenia;
CESC	cis	rs4665809	1.000	rs4233709	chr2:26291493	C/T	cg25036284	chr2:26402008	FAM59B	0.53	6.07	0.35	4.38e-9	Gut microbiome composition (summer);
CESC	cis	rs76419734	0.510	rs4699198	chr4:106645771	G/A	cg24545054	chr4:106630052	GSTCD;INTS12	0.7	8.65	0.47	4.92e-16	Post bronchodilator FEV1;
CESC	cis	rs1799949	1.000	rs8176269	chr17:41213626	G/T	cg23758822	chr17:41437982	NA	1.03	15.15	0.68	8.71e-38	Menopause (age at onset);
CESC	cis	rs9325144	0.555	rs4550281	chr12:38689937	A/G	cg26384229	chr12:38710491	ALG10B	0.58	8.36	0.46	3.71e-15	Morning vs. evening chronotype;
CESC	trans	rs6818288	0.778	rs12503551	chr4:30077431	G/A	cg12528397	chr3:62933670	NA	0.42	6.13	0.35	3.2e-9	Obesity-related traits;
CESC	cis	rs2304069	0.954	rs6579767	chr5:149406271	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.91	11.76	0.59	5.85e-26	HIV-1 control;
CESC	trans	rs916888	0.610	rs199536	chr17:44820425	T/C	cg22433210	chr17:43662623	NA	-0.6	-7.88	-0.44	8.39e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs911555	0.755	rs10144051	chr14:103885931	A/C	cg12935359	chr14:103987150	CKB	-0.56	-8.0	-0.44	3.82e-14	Intelligence (multi-trait analysis);
CESC	cis	rs9910055	0.762	rs184478	chr17:42209751	C/G	cg13607699	chr17:42295918	UBTF	-0.59	-7.75	-0.43	1.99e-13	Total body bone mineral density;
CESC	cis	rs11608355	0.508	rs12817730	chr12:109799330	G/A	cg19025524	chr12:109796872	NA	-0.42	-5.28	-0.31	2.63e-7	Neuroticism;
CESC	cis	rs6546550	0.901	rs6546558	chr2:70145717	C/T	cg02498382	chr2:70120550	SNRNP27	-0.43	-7.41	-0.41	1.65e-12	Prevalent atrial fibrillation;
CESC	cis	rs12142240	0.698	rs6659228	chr1:46811027	C/G	cg10495392	chr1:46806563	NSUN4	0.57	6.29	0.36	1.31e-9	Menopause (age at onset);
CESC	cis	rs7631605	0.875	rs55898028	chr3:37248337	A/G	cg22985146	chr3:37219077	LRRFIP2	-0.35	-5.64	-0.33	4.33e-8	Cerebrospinal P-tau181p levels;
CESC	trans	rs1814175	0.645	rs11040702	chr11:50024827	C/T	cg15704280	chr7:45808275	SEPT13	-1.0	-18.54	-0.75	9.01e-50	Height;
CESC	cis	rs1018836	0.923	rs13267989	chr8:91581648	C/T	cg16814680	chr8:91681699	NA	-0.64	-8.72	-0.47	3.1e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs9790314	0.521	rs13084731	chr3:161086020	G/A	cg04691961	chr3:161091175	C3orf57	-0.37	-5.09	-0.3	6.66e-7	Morning vs. evening chronotype;
CESC	cis	rs1862618	0.853	rs252904	chr5:56118733	A/T	cg24549020	chr5:56110836	MAP3K1	0.66	7.44	0.42	1.37e-12	Initial pursuit acceleration;
CESC	cis	rs113835537	0.529	rs11227495	chr11:66263243	C/T	cg22134325	chr11:66188745	NPAS4	0.37	5.8	0.34	1.93e-8	Airway imaging phenotypes;
CESC	cis	rs2404602	0.583	rs2176623	chr15:76568579	C/T	cg22467129	chr15:76604101	ETFA	-0.38	-5.92	-0.34	1.01e-8	Blood metabolite levels;
CESC	cis	rs6570726	0.764	rs451108	chr6:145844309	T/C	cg05347473	chr6:146136440	FBXO30	0.59	7.6	0.42	5.27e-13	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs3820068	0.705	rs11584398	chr1:15880275	G/A	cg17385448	chr1:15911702	AGMAT	0.36	5.62	0.33	4.77e-8	Systolic blood pressure;
CESC	cis	rs10927875	0.631	rs945418	chr1:16344730	T/C	cg21214613	chr1:16344536	HSPB7	0.37	5.45	0.32	1.15e-7	Dilated cardiomyopathy;
CESC	cis	rs4924935	1.000	rs1737947	chr17:18831432	A/G	cg26378065	chr17:18585709	ZNF286B	-0.49	-5.91	-0.34	1.05e-8	Pancreatic cancer;
CESC	cis	rs2486288	0.554	rs1719235	chr15:45576108	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.62	-7.46	-0.42	1.27e-12	Glomerular filtration rate;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg13860548	chr1:15853252	DNAJC16	-0.43	-6.18	-0.35	2.44e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7552404	1.000	rs9662166	chr1:76235906	C/A	cg22875332	chr1:76189707	ACADM	0.48	5.51	0.32	8.68e-8	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs1008375	0.966	rs3775923	chr4:17585625	T/C	cg15017067	chr4:17643749	FAM184B	0.38	5.04	0.3	8.63e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs5769707	0.609	rs739247	chr22:49996657	T/C	cg05373962	chr22:49881684	NA	-0.35	-5.17	-0.3	4.61e-7	Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs875971	0.862	rs7796162	chr7:65745758	T/C	cg10691866	chr7:65817282	TPST1	0.33	5.5	0.32	8.83e-8	Aortic root size;
CESC	cis	rs9303280	0.806	rs62067034	chr17:38063738	C/T	cg20243544	chr17:37824526	PNMT	0.56	7.37	0.41	2.23e-12	Self-reported allergy;
CESC	trans	rs1909481	0.561	rs894086	chr8:137687996	C/A	cg18579875	chr2:217540128	IGFBP5	-0.71	-6.29	-0.36	1.31e-9	Squamous cell lung carcinoma;
CESC	cis	rs1153858	1.000	rs12439274	chr15:45636667	A/G	cg10760299	chr15:45669010	GATM	0.38	5.22	0.31	3.65e-7	Homoarginine levels;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg21227347	chr9:117374170	C9orf91	0.5	6.57	0.37	2.72e-10	Systemic lupus erythematosus;
CESC	cis	rs1552244	0.882	rs9757159	chr3:10039166	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.85	11.02	0.56	1.64e-23	Alzheimer's disease;
CESC	cis	rs1799949	1.000	rs8176145	chr17:41249094	A/G	cg23758822	chr17:41437982	NA	1.0	15.37	0.69	1.56e-38	Menopause (age at onset);
CESC	cis	rs4909189	1.000	rs62493649	chr7:158135556	C/G	cg24154853	chr7:158122151	PTPRN2	0.46	6.2	0.36	2.22e-9	Response to amphetamines;
CESC	trans	rs61931739	0.857	rs419112	chr12:34130528	A/G	cg26384229	chr12:38710491	ALG10B	0.44	6.05	0.35	5.02e-9	Morning vs. evening chronotype;
CESC	cis	rs10927875	0.541	rs1739843	chr1:16343254	T/C	cg22431228	chr1:16359049	CLCNKA	-0.52	-9.9	-0.52	7.22e-20	Dilated cardiomyopathy;
CESC	cis	rs4642101	0.669	rs1467026	chr3:12830775	G/A	cg24848339	chr3:12840334	CAND2	0.4	6.2	0.36	2.17e-9	QRS complex (12-leadsum);
CESC	cis	rs9399135	0.967	rs9376082	chr6:135346389	T/A	cg22676075	chr6:135203613	NA	0.5	7.17	0.4	7.65e-12	Red blood cell count;
CESC	trans	rs1728785	1.000	rs1182968	chr16:68573945	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.61	7.49	0.42	1.02e-12	Ulcerative colitis;
CESC	cis	rs9487051	0.704	rs1741930	chr6:109519797	T/A	cg01475377	chr6:109611718	NA	-0.37	-5.55	-0.32	6.99e-8	Reticulocyte fraction of red cells;
CESC	cis	rs72781680	0.898	rs72782117	chr2:24026921	G/A	cg08917208	chr2:24149416	ATAD2B	1.13	10.18	0.53	9.42e-21	Lymphocyte counts;
CESC	cis	rs3733585	0.673	rs7377578	chr4:9952775	T/C	cg00071950	chr4:10020882	SLC2A9	-0.69	-11.34	-0.57	1.44e-24	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs4819052	0.851	rs2838834	chr21:46665208	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.75	9.72	0.51	2.78e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs2404602	0.647	rs11634266	chr15:77093461	A/G	cg23625390	chr15:77176239	SCAPER	-0.47	-6.51	-0.37	3.72e-10	Blood metabolite levels;
CESC	cis	rs703842	1.000	rs6581155	chr12:58178162	A/G	cg00677455	chr12:58241039	CTDSP2	0.52	6.86	0.39	4.8e-11	Multiple sclerosis;
CESC	cis	rs6748734	1.000	rs4311055	chr2:241821017	T/C	cg04034577	chr2:241836375	C2orf54	-0.49	-8.43	-0.46	2.18e-15	Urinary metabolites;
CESC	cis	rs79976124	0.879	rs12214948	chr6:66633603	G/A	cg07460842	chr6:66804631	NA	0.72	8.31	0.45	5.13e-15	Type 2 diabetes;
CESC	cis	rs1862618	0.526	rs2591963	chr5:56237135	T/A	cg20203395	chr5:56204925	C5orf35	0.5	5.77	0.33	2.24e-8	Initial pursuit acceleration;
CESC	cis	rs1348850	0.914	rs7591807	chr2:178252986	A/G	cg22681709	chr2:178499509	PDE11A	-0.43	-6.29	-0.36	1.33e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02576381	chr5:159827164	C5orf54	-0.67	-7.88	-0.44	8.77e-14	Gut microbiome composition (summer);
CESC	cis	rs875971	0.964	rs160635	chr7:65528918	T/C	cg11764359	chr7:65958608	NA	0.89	13.06	0.63	1.99e-30	Aortic root size;
CESC	trans	rs1814175	0.645	rs847627	chr11:49927177	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.43	-6.36	-0.36	8.98e-10	Height;
CESC	cis	rs7084402	0.967	rs1626606	chr10:60328088	C/T	cg07615347	chr10:60278583	BICC1	0.59	9.18	0.49	1.26e-17	Refractive error;
CESC	cis	rs1983170	1.000	rs12563578	chr1:91993702	T/C	cg25838465	chr1:92012736	NA	0.46	5.49	0.32	9.64e-8	Eosinophil percentage of white cells;
CESC	cis	rs10463316	0.894	rs3905511	chr5:150768204	G/A	cg03212797	chr5:150827313	SLC36A1	-0.47	-6.15	-0.35	2.86e-9	Metabolite levels (Pyroglutamine);
CESC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg02621907	chr5:93954419	ANKRD32;C5orf36	0.47	6.05	0.35	4.93e-9	Tetralogy of Fallot;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg23333220	chr15:64679825	TRIP4	-0.43	-6.0	-0.35	6.42e-9	Gambling;
CESC	cis	rs853679	0.517	rs4711164	chr6:28115156	C/T	cg22143856	chr6:28129313	ZNF389	0.53	6.71	0.38	1.2e-10	Depression;
CESC	cis	rs2721195	0.654	rs4610795	chr8:145881333	C/T	cg26752003	chr8:145688521	CYHR1	0.46	6.36	0.36	8.99e-10	Age at first birth;
CESC	trans	rs12356475	0.710	rs10822686	chr10:67733250	C/T	cg08839451	chr12:125478775	BRI3BP	0.51	6.16	0.35	2.62e-9	Psoriatic arthritis;
CESC	cis	rs875971	0.862	rs6960446	chr7:65733259	A/G	cg18252515	chr7:66147081	NA	0.44	5.85	0.34	1.48e-8	Aortic root size;
CESC	cis	rs704795	0.836	rs1647281	chr2:27612938	G/C	cg12648201	chr2:27665141	KRTCAP3	-0.34	-6.26	-0.36	1.55e-9	Menopause (age at onset);
CESC	cis	rs8177253	0.665	rs11921527	chr3:133441167	G/A	cg16262614	chr3:133464971	TF	0.3	5.33	0.31	2.11e-7	Iron status biomarkers;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20291513	chr1:207226369	PFKFB2	-0.57	-6.49	-0.37	4.31e-10	Gut microbiome composition (summer);
CESC	cis	rs62064224	0.614	rs9900089	chr17:30772577	C/T	cg18200150	chr17:30822561	MYO1D	0.41	5.26	0.31	2.92e-7	Schizophrenia;
CESC	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg18538332	chr22:24372958	LOC391322	-0.75	-10.94	-0.56	3.01e-23	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs7224737	1.000	rs7214921	chr17:40294025	T/C	cg20291162	chr17:40259547	DHX58	-0.4	-5.48	-0.32	9.96e-8	Fibrinogen levels;
CESC	cis	rs2730245	0.645	rs4909282	chr7:158699797	T/C	cg24397884	chr7:158709396	WDR60	0.68	9.9	0.52	7.06e-20	Height;
CESC	cis	rs9916302	0.768	rs11078900	chr17:37614641	C/T	cg19468946	chr17:37922297	IKZF3	-0.39	-5.13	-0.3	5.47e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs11997175	0.846	rs7388664	chr8:33768773	T/G	ch.8.33884649F	chr8:33765107	NA	0.77	10.29	0.53	4.24e-21	Body mass index;
CESC	cis	rs8072100	0.875	rs4794047	chr17:45763005	A/T	cg08085267	chr17:45401833	C17orf57	0.45	5.99	0.35	6.76e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18537085	chr2:70120936	SNRNP27	-0.55	-6.33	-0.36	1.03e-9	Gut microbiome composition (summer);
CESC	cis	rs1949733	0.628	rs1543246	chr4:8504909	A/T	cg11789530	chr4:8429930	ACOX3	0.65	9.1	0.49	2.17e-17	Response to antineoplastic agents;
CESC	cis	rs1215050	0.791	rs260899	chr4:98707046	G/A	cg05340658	chr4:99064831	C4orf37	0.5	6.4	0.37	7.13e-10	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs9549367	0.713	rs3024776	chr13:113827075	A/G	cg00898013	chr13:113819073	PROZ	0.57	7.97	0.44	4.61e-14	Platelet distribution width;
CESC	cis	rs9911578	1.000	rs9904879	chr17:56864422	G/A	cg05425664	chr17:57184151	TRIM37	-0.49	-6.87	-0.39	4.62e-11	Intelligence (multi-trait analysis);
CESC	cis	rs13191362	1.000	rs35383933	chr6:163002869	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.88	9.16	0.49	1.46e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	trans	rs1814175	0.817	rs7927373	chr11:49957640	A/C	cg03929089	chr4:120376271	NA	-0.93	-15.75	-0.7	6.66e-40	Height;
CESC	cis	rs9611565	0.659	rs17367716	chr22:41913844	A/G	cg06634786	chr22:41940651	POLR3H	-0.63	-6.3	-0.36	1.23e-9	Vitiligo;
CESC	cis	rs1801251	1.000	rs6724117	chr2:233593660	T/G	cg08000102	chr2:233561755	GIGYF2	0.68	9.59	0.51	7.1e-19	Coronary artery disease;
CESC	cis	rs9322193	0.884	rs11155669	chr6:149954637	T/C	cg07701084	chr6:150067640	NUP43	0.45	6.39	0.37	7.37e-10	Lung cancer;
CESC	cis	rs2228479	0.850	rs62056091	chr16:89930414	G/A	cg14709524	chr16:89940631	TCF25	0.87	6.18	0.35	2.43e-9	Skin colour saturation;
CESC	cis	rs17293817	0.914	rs34447234	chr10:1440517	G/A	cg08482957	chr10:1437944	ADARB2	0.36	5.28	0.31	2.75e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs9649465	1.000	rs10270877	chr7:123327860	T/C	cg04330084	chr7:123175371	IQUB	-0.38	-5.16	-0.3	4.75e-7	Migraine;
CESC	cis	rs17376456	0.877	rs10052428	chr5:93476530	T/C	cg25358565	chr5:93447407	FAM172A	1.17	11.51	0.58	3.92e-25	Diabetic retinopathy;
CESC	cis	rs9300255	0.596	rs10773002	chr12:123746961	A/T	cg00376283	chr12:123451042	ABCB9	-0.67	-9.14	-0.49	1.68e-17	Neutrophil percentage of white cells;
CESC	cis	rs6502050	0.698	rs67143649	chr17:80117772	C/G	cg23985595	chr17:80112537	CCDC57	-0.41	-6.47	-0.37	4.81e-10	Life satisfaction;
CESC	cis	rs2732480	0.500	rs7966829	chr12:48615603	G/T	cg24011408	chr12:48396354	COL2A1	0.45	6.23	0.36	1.87e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs7264396	0.790	rs6058297	chr20:34271861	G/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.65	7.81	0.43	1.36e-13	Total cholesterol levels;
CESC	cis	rs920590	0.758	rs35896770	chr8:19665616	G/C	cg01411142	chr8:19674711	INTS10	0.56	6.41	0.37	6.77e-10	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs7666738	0.830	rs1124253	chr4:98949682	C/T	cg05340658	chr4:99064831	C4orf37	0.8	12.48	0.61	2e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6831352	0.879	rs29001208	chr4:100052539	A/C	cg13256891	chr4:100009986	ADH5	-0.77	-8.43	-0.46	2.27e-15	Alcohol dependence;
CESC	cis	rs854765	0.647	rs4365346	chr17:17989373	G/T	cg16928487	chr17:17741425	SREBF1	-0.53	-8.76	-0.47	2.34e-16	Total body bone mineral density;
CESC	cis	rs7980687	0.628	rs1727332	chr12:123718301	C/T	cg05973401	chr12:123451056	ABCB9	0.46	5.63	0.33	4.68e-8	Height;Educational attainment;Head circumference (infant);
CESC	cis	rs1865760	0.566	rs2794720	chr6:26087202	G/C	cg16482183	chr6:26056742	HIST1H1C	0.38	5.11	0.3	6.19e-7	Height;
CESC	cis	rs7116495	1.000	rs542752	chr11:71810644	T/A	cg10381502	chr11:71823885	C11orf51	0.66	5.35	0.31	1.93e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs660899	0.595	rs37458	chr1:44290530	A/G	cg19743044	chr1:44115203	KDM4A	0.47	5.95	0.34	8.62e-9	Hypertension risk in short sleep duration;
CESC	cis	rs7582720	1.000	rs72934764	chr2:203758521	C/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.39	0.41	1.96e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs892961	0.932	rs67719929	chr17:75412605	G/A	cg05865280	chr17:75406074	SEPT9	0.62	12.67	0.61	4.57e-29	Airflow obstruction;
CESC	cis	rs4964805	0.626	rs869993	chr12:104175138	A/T	cg02344784	chr12:104178138	NT5DC3	0.41	5.72	0.33	2.93e-8	Attention deficit hyperactivity disorder;
CESC	cis	rs1799949	1.000	rs2037076	chr17:41305883	G/A	cg23758822	chr17:41437982	NA	1.03	15.83	0.7	3.63e-40	Menopause (age at onset);
CESC	trans	rs66573146	1.000	rs66573146	chr4:6984464	C/G	cg07817883	chr1:32538562	TMEM39B	1.48	9.1	0.49	2.16e-17	Granulocyte percentage of myeloid white cells;
CESC	cis	rs4253772	0.938	rs41427746	chr22:46637239	T/C	cg18190219	chr22:46762943	CELSR1	-0.58	-6.96	-0.39	2.71e-11	LDL cholesterol;Cholesterol, total;
CESC	cis	rs1552244	1.000	rs68067759	chr3:10150535	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.82	-11.0	-0.56	1.9e-23	Alzheimer's disease;
CESC	cis	rs10242455	0.702	rs73711294	chr7:99088714	G/A	cg25640893	chr7:99214727	ZNF498	0.76	5.39	0.31	1.58e-7	Blood metabolite levels;
CESC	cis	rs62344088	1.000	rs6872393	chr5:155854	A/G	cg22857025	chr5:266934	NA	0.97	5.5	0.32	9e-8	Asthma (childhood onset);
CESC	cis	rs3008870	1.000	rs3008858	chr1:67390416	G/C	cg08660285	chr1:67390436	MIER1;WDR78	1.06	15.03	0.68	2.49e-37	Lymphocyte percentage of white cells;
CESC	cis	rs2075371	1.000	rs2075372	chr7:133984432	C/T	cg20476274	chr7:133979776	SLC35B4	0.67	9.79	0.52	1.65e-19	Mean platelet volume;
CESC	cis	rs941873	0.835	rs10762859	chr10:81103370	T/A	cg09469691	chr10:81107165	PPIF	0.56	7.52	0.42	8.38e-13	Height;
CESC	cis	rs6977660	0.598	rs72591445	chr7:19773035	G/A	cg07541023	chr7:19748670	TWISTNB	0.81	7.31	0.41	3.21e-12	Thyroid stimulating hormone;
CESC	cis	rs17384381	0.700	rs11161617	chr1:85913538	A/G	cg16011679	chr1:85725395	C1orf52	0.56	6.49	0.37	4.18e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9287719	0.967	rs2110778	chr2:10748970	A/T	cg00105475	chr2:10696890	NA	0.38	5.57	0.32	6.34e-8	Prostate cancer;
CESC	cis	rs3733585	0.699	rs12498150	chr4:9950537	C/T	cg00071950	chr4:10020882	SLC2A9	-0.71	-11.91	-0.59	1.77e-26	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs7605827	0.893	rs6734024	chr2:15718180	A/G	cg19274914	chr2:15703543	NA	0.35	6.36	0.36	8.56e-10	Educational attainment (years of education);
CESC	cis	rs4076764	0.914	rs12123378	chr1:163377846	C/T	cg24596788	chr1:163392923	NA	-0.53	-7.81	-0.43	1.3e-13	Motion sickness;
CESC	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg07308232	chr7:1071921	C7orf50	0.5	7.11	0.4	1.1e-11	Longevity;Endometriosis;
CESC	cis	rs6815814	0.898	rs1106956	chr4:38889811	A/G	cg02016764	chr4:38805732	TLR1	-0.56	-6.56	-0.37	2.74e-10	Breast cancer;
CESC	cis	rs9818941	0.824	rs11707532	chr3:157801867	T/C	cg08654915	chr3:157813417	NA	0.46	7.53	0.42	8.12e-13	Height;
CESC	cis	rs2832191	0.716	rs2249028	chr21:30365322	G/A	cg08807101	chr21:30365312	RNF160	0.96	14.98	0.68	3.51e-37	Dental caries;
CESC	cis	rs34779708	0.966	rs12773647	chr10:35440327	A/G	cg04310649	chr10:35416472	CREM	-0.5	-6.12	-0.35	3.27e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs870825	0.616	rs4444873	chr4:185628406	A/G	cg04058563	chr4:185651563	MLF1IP	0.65	7.07	0.4	1.36e-11	Blood protein levels;
CESC	cis	rs7191439	0.858	rs6500489	chr16:88772046	T/C	cg02389323	chr16:88786976	FAM38A	0.85	5.95	0.34	8.57e-9	Plateletcrit;
CESC	cis	rs7927771	0.832	rs10769258	chr11:47391039	C/T	cg05585544	chr11:47624801	NA	0.5	7.29	0.41	3.57e-12	Subjective well-being;
CESC	cis	rs9814567	1.000	rs6785027	chr3:134211649	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.44	6.06	0.35	4.53e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs2204008	0.666	rs67792345	chr12:38204698	T/C	cg26384229	chr12:38710491	ALG10B	0.73	10.16	0.53	1.08e-20	Bladder cancer;
CESC	cis	rs921968	0.565	rs6436073	chr2:219618237	A/C	cg02176678	chr2:219576539	TTLL4	-0.43	-7.56	-0.42	6.81e-13	Mean corpuscular hemoglobin concentration;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10328259	chr2:3321226	TSSC1	-0.75	-8.79	-0.48	1.9e-16	Gut microbiome composition (summer);
CESC	cis	rs7546094	1.000	rs12728001	chr1:113076756	T/C	cg22162597	chr1:113214053	CAPZA1	0.35	5.22	0.31	3.63e-7	Platelet distribution width;
CESC	cis	rs7084402	0.902	rs1658417	chr10:60333039	T/C	cg07615347	chr10:60278583	BICC1	0.59	9.23	0.49	9.22e-18	Refractive error;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg15190599	chr6:26156487	HIST1H1E	-0.5	-6.53	-0.37	3.38e-10	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs13108904	0.870	rs2291199	chr4:1244267	A/G	cg00684032	chr4:1343700	KIAA1530	0.43	5.69	0.33	3.33e-8	Obesity-related traits;
CESC	cis	rs10992471	0.756	rs10115222	chr9:95128149	C/T	cg13798575	chr9:95087839	CENPP;NOL8	0.45	5.67	0.33	3.68e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg13476105	chr17:7819425	LOC284023	-0.43	-6.27	-0.36	1.48e-9	Gambling;
CESC	cis	rs7945705	0.818	rs2742552	chr11:8876852	C/T	cg12365402	chr11:9010492	NRIP3	-0.33	-5.25	-0.31	3.05e-7	Hemoglobin concentration;
CESC	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	7.66	0.43	3.42e-13	Prudent dietary pattern;
CESC	cis	rs524281	0.731	rs10791838	chr11:65789854	T/G	cg14036092	chr11:66035641	RAB1B	-0.62	-5.59	-0.32	5.57e-8	Electroencephalogram traits;
CESC	trans	rs11039798	1.000	rs7942284	chr11:48520424	A/G	cg15704280	chr7:45808275	SEPT13	-0.68	-6.22	-0.36	1.96e-9	Axial length;
CESC	cis	rs1799949	1.000	rs4793192	chr17:41204390	T/C	cg05368731	chr17:41323189	NBR1	0.75	10.35	0.54	2.72e-21	Menopause (age at onset);
CESC	cis	rs13191362	1.000	rs13200329	chr6:163004418	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.79	8.26	0.45	6.82e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs61931739	0.500	rs11053194	chr12:34440841	A/G	cg23762105	chr12:34175262	ALG10	-0.4	-5.22	-0.31	3.7e-7	Morning vs. evening chronotype;
CESC	cis	rs6466055	0.692	rs4727621	chr7:105028370	T/C	cg04380332	chr7:105027541	SRPK2	-0.42	-5.37	-0.31	1.74e-7	Schizophrenia;
CESC	cis	rs2742234	0.504	rs10899780	chr10:43725796	T/C	cg07801480	chr10:43725741	RASGEF1A	-0.42	-5.32	-0.31	2.19e-7	Hirschsprung disease;
CESC	cis	rs875971	0.862	rs13536	chr7:66019190	G/A	cg10691866	chr7:65817282	TPST1	0.33	5.51	0.32	8.51e-8	Aortic root size;
CESC	cis	rs651907	0.557	rs7651404	chr3:101393294	C/A	cg12386194	chr3:101231763	SENP7	0.44	5.48	0.32	9.88e-8	Colorectal cancer;
CESC	cis	rs4925386	0.840	rs6143035	chr20:60920700	C/T	cg22633769	chr20:60982531	CABLES2	-0.52	-5.53	-0.32	7.58e-8	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs2354432	0.607	rs9782976	chr1:146825049	A/G	cg25205988	chr1:146714368	CHD1L	0.77	8.2	0.45	1.01e-14	Mitochondrial DNA levels;
CESC	cis	rs11638352	0.661	rs2555382	chr15:44424316	T/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.56	5.29	0.31	2.53e-7	Lipoprotein phospholipase A2 activity in cardiovascular disease;
CESC	cis	rs7267979	1.000	rs6037086	chr20:25306338	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.84	-16.08	-0.7	4.65e-41	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs6460942	0.597	rs10273045	chr7:12519371	T/C	cg06484146	chr7:12443880	VWDE	-0.64	-7.13	-0.4	9.4e-12	Coronary artery disease;
CESC	cis	rs67478160	0.584	rs2295147	chr14:104195664	A/G	cg01849466	chr14:104193079	ZFYVE21	0.56	8.34	0.46	4.02e-15	Schizophrenia;
CESC	cis	rs317689	0.702	rs544696	chr12:69749939	T/C	cg14784868	chr12:69753453	YEATS4	0.74	9.78	0.52	1.72e-19	Response to diuretic therapy;
CESC	cis	rs225245	0.782	rs321618	chr17:33912404	A/G	cg05299278	chr17:33885742	SLFN14	0.38	5.46	0.32	1.08e-7	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
CESC	cis	rs397969	0.596	rs35925051	chr17:19877369	G/A	cg12073167	chr17:19770448	ULK2	-0.49	-5.91	-0.34	1.06e-8	Platelet count;
CESC	cis	rs6964587	0.605	rs6956022	chr7:91553199	A/G	cg17063962	chr7:91808500	NA	-0.45	-6.29	-0.36	1.29e-9	Breast cancer;
CESC	cis	rs6460942	0.915	rs17324858	chr7:12305792	G/T	cg02935154	chr7:12443704	VWDE	-0.4	-5.58	-0.32	5.94e-8	Coronary artery disease;
CESC	cis	rs72781680	0.583	rs6731333	chr2:24113354	C/T	cg08917208	chr2:24149416	ATAD2B	0.6	6.27	0.36	1.44e-9	Lymphocyte counts;
CESC	trans	rs11098499	0.780	rs7692994	chr4:120427489	C/A	cg25214090	chr10:38739885	LOC399744	0.69	9.53	0.51	1.03e-18	Corneal astigmatism;
CESC	trans	rs61931739	0.500	rs10844848	chr12:34409705	A/C	cg13010199	chr12:38710504	ALG10B	0.49	6.33	0.36	1.02e-9	Morning vs. evening chronotype;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg04400940	chr3:150329548	SELT	0.53	6.93	0.39	3.14e-11	Fibrinogen levels;
CESC	cis	rs7666738	0.830	rs9998582	chr4:98938949	T/C	cg17366294	chr4:99064904	C4orf37	0.61	8.56	0.47	9.36e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs67311347	1.000	rs17078511	chr3:40396254	A/G	cg09455208	chr3:40491958	NA	0.53	9.34	0.5	4.14e-18	Renal cell carcinoma;
CESC	cis	rs875971	1.000	rs2220626	chr7:65546062	C/T	cg18876405	chr7:65276391	NA	-0.56	-7.3	-0.41	3.35e-12	Aortic root size;
CESC	cis	rs523522	0.962	rs655530	chr12:121022275	T/C	cg27279351	chr12:120934652	DYNLL1	0.7	9.06	0.49	2.86e-17	High light scatter reticulocyte count;
CESC	cis	rs2228479	0.717	rs12917681	chr16:89810941	C/A	cg14709524	chr16:89940631	TCF25	0.62	5.59	0.33	5.51e-8	Skin colour saturation;
CESC	cis	rs4474465	0.850	rs4945294	chr11:78256864	G/A	cg27205649	chr11:78285834	NARS2	0.42	5.4	0.31	1.49e-7	Alzheimer's disease (survival time);
CESC	cis	rs9916302	0.861	rs9903363	chr17:37499604	C/G	cg15445000	chr17:37608096	MED1	-0.42	-6.87	-0.39	4.46e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs270601	0.770	rs1007602	chr5:131602166	T/C	cg24060327	chr5:131705240	SLC22A5	-0.47	-6.09	-0.35	4.03e-9	Acylcarnitine levels;
CESC	cis	rs9322193	0.884	rs9322210	chr6:150016576	G/A	cg00933542	chr6:150070202	PCMT1	0.29	5.06	0.3	7.82e-7	Lung cancer;
CESC	cis	rs12950390	0.853	rs11079792	chr17:45863311	T/C	cg00777063	chr17:45855553	NA	-0.38	-5.64	-0.33	4.24e-8	IgG glycosylation;
CESC	trans	rs35110281	0.782	rs2051407	chr21:45079245	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.52	6.79	0.38	7.48e-11	Mean corpuscular volume;
CESC	cis	rs11190604	1.000	rs11190601	chr10:102296730	A/G	cg07080220	chr10:102295463	HIF1AN	0.7	6.5	0.37	3.99e-10	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs6460942	0.915	rs72584550	chr7:12304990	G/A	cg02935154	chr7:12443704	VWDE	-0.41	-5.57	-0.32	6.15e-8	Coronary artery disease;
CESC	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg13880726	chr7:1868755	MAD1L1	0.53	7.11	0.4	1.05e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs2243480	0.901	rs2900904	chr7:65204264	C/G	cg13147721	chr7:65941812	NA	-0.88	-8.07	-0.44	2.51e-14	Diabetic kidney disease;
CESC	cis	rs4843747	0.671	rs8062855	chr16:88106941	T/C	cg06374794	chr16:88002281	BANP	0.39	5.16	0.3	4.78e-7	Menopause (age at onset);
CESC	cis	rs9311474	0.607	rs28661185	chr3:52567188	G/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.38	6.85	0.39	5.2e-11	Electroencephalogram traits;
CESC	cis	rs854765	0.547	rs2955355	chr17:17948475	G/A	cg16928487	chr17:17741425	SREBF1	0.57	9.8	0.52	1.45e-19	Total body bone mineral density;
CESC	trans	rs1814175	0.559	rs1818892	chr11:49863084	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.43	-6.26	-0.36	1.51e-9	Height;
CESC	cis	rs7662987	0.517	rs2602858	chr4:100030461	T/C	cg12011299	chr4:100065546	ADH4	0.6	6.56	0.37	2.83e-10	Smoking initiation;
CESC	cis	rs804292	0.695	rs804279	chr8:11623889	A/T	cg26752888	chr8:11627280	NEIL2	0.73	9.41	0.5	2.48e-18	Alcohol dependence;Nicotine use;
CESC	cis	rs732765	0.648	rs8019391	chr14:75409682	T/C	cg06642626	chr14:75180534	FCF1;KIAA0317	-0.37	-5.38	-0.31	1.68e-7	Non-small cell lung cancer;
CESC	cis	rs9291683	0.595	rs3733585	chr4:10036339	A/G	cg11266682	chr4:10021025	SLC2A9	0.7	13.81	0.65	4.81e-33	Bone mineral density;
CESC	cis	rs853679	0.517	rs4713144	chr6:28106790	C/G	cg23281280	chr6:28129359	ZNF389	0.59	8.16	0.45	1.34e-14	Depression;
CESC	cis	rs854765	0.562	rs2955381	chr17:17945500	G/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.62	-8.81	-0.48	1.7e-16	Total body bone mineral density;
CESC	cis	rs12579753	0.917	rs7132732	chr12:82206053	C/G	cg24719984	chr12:82153464	PPFIA2	-0.33	-5.04	-0.3	8.55e-7	Resting heart rate;
CESC	cis	rs6723226	1.000	rs6723226	chr2:32849207	C/T	cg02381751	chr2:32503542	YIPF4	0.69	9.23	0.49	8.95e-18	Intelligence (multi-trait analysis);
CESC	cis	rs11098499	0.820	rs28535956	chr4:120536858	C/T	cg09307838	chr4:120376055	NA	-0.86	-11.86	-0.59	2.69e-26	Corneal astigmatism;
CESC	cis	rs17023223	0.537	rs10923754	chr1:119668640	T/C	cg05756136	chr1:119680316	WARS2	-0.46	-5.64	-0.33	4.42e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CESC	trans	rs17181170	0.553	rs6795510	chr3:87174568	C/T	ch.2.199792288R	chr2:200084043	NA	-0.44	-6.05	-0.35	4.97e-9	Prostate cancer;
CESC	cis	rs7259376	0.875	rs1091182	chr19:22475622	G/A	cg02657401	chr19:22469223	NA	0.26	5.29	0.31	2.52e-7	Menopause (age at onset);
CESC	cis	rs7246865	0.954	rs3745348	chr19:17212410	C/T	cg19418318	chr19:17219073	MYO9B	0.36	6.05	0.35	4.86e-9	Reticulocyte fraction of red cells;
CESC	cis	rs10791323	0.569	rs2187450	chr11:133743792	A/G	cg15485101	chr11:133734466	NA	0.3	5.22	0.31	3.6e-7	Childhood ear infection;
CESC	cis	rs7666738	0.830	rs35915560	chr4:98978649	C/T	cg05340658	chr4:99064831	C4orf37	0.78	11.93	0.59	1.51e-26	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2625529	0.824	rs4777471	chr15:72207804	A/G	cg16672083	chr15:72433130	SENP8	-0.39	-5.09	-0.3	6.78e-7	Red blood cell count;
CESC	cis	rs55823223	0.648	rs936393	chr17:73847613	A/G	cg08125733	chr17:73851984	WBP2	0.89	11.82	0.59	3.46e-26	Psoriasis;
CESC	cis	rs7666738	0.830	rs11935588	chr4:98979862	A/G	cg05340658	chr4:99064831	C4orf37	-0.79	-12.52	-0.61	1.46e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs854765	0.583	rs28428991	chr17:17827649	C/T	cg16928487	chr17:17741425	SREBF1	-0.57	-9.74	-0.51	2.41e-19	Total body bone mineral density;
CESC	cis	rs2243480	1.000	rs466983	chr7:65520496	T/G	cg25894440	chr7:65020034	NA	-0.64	-5.46	-0.32	1.1e-7	Diabetic kidney disease;
CESC	cis	rs6674970	0.518	rs15740	chr1:151040435	G/A	cg03258749	chr1:151040405	MLLT11	-0.45	-6.08	-0.35	4.15e-9	Childhood ear infection;
CESC	cis	rs17253792	0.822	rs17253716	chr14:56153661	G/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.81	5.68	0.33	3.46e-8	Putamen volume;
CESC	cis	rs10504229	0.683	rs2873638	chr8:58114593	G/A	cg21724239	chr8:58056113	NA	0.56	5.76	0.33	2.34e-8	Developmental language disorder (linguistic errors);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19882826	chr6:37787165	ZFAND3	0.57	6.28	0.36	1.4e-9	Gut microbiome composition (summer);
CESC	cis	rs10752881	0.935	rs10911235	chr1:183053746	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.85	13.7	0.64	1.21e-32	Colorectal cancer;
CESC	cis	rs116095464	0.558	rs6879656	chr5:264428	T/C	cg22857025	chr5:266934	NA	-1.32	-15.79	-0.7	4.9e-40	Breast cancer;
CESC	cis	rs3741404	0.825	rs2515241	chr11:63975331	C/T	cg04317338	chr11:64019027	PLCB3	0.47	5.57	0.32	6.34e-8	Platelet count;
CESC	cis	rs17376456	0.825	rs10057130	chr5:93282557	C/T	cg21475434	chr5:93447410	FAM172A	0.77	6.39	0.37	7.61e-10	Diabetic retinopathy;
CESC	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.87	12.72	0.62	2.99e-29	Prudent dietary pattern;
CESC	cis	rs2115536	1.000	rs11637477	chr15:80193295	C/T	cg00225070	chr15:80189496	MTHFS	0.6	8.48	0.46	1.65e-15	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CESC	cis	rs6665290	0.935	rs17600669	chr1:227201871	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.2	-31.15	-0.89	1.43e-90	Myeloid white cell count;
CESC	cis	rs2243480	1.000	rs78803505	chr7:65382572	A/T	cg13147721	chr7:65941812	NA	-0.83	-7.92	-0.44	6.77e-14	Diabetic kidney disease;
CESC	cis	rs3008870	0.755	rs1570838	chr1:67403315	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.63	8.34	0.46	4.16e-15	Lymphocyte percentage of white cells;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg18269826	chr15:101459483	LRRK1	-0.4	-6.05	-0.35	4.93e-9	Fibrinogen levels;
CESC	cis	rs1152591	0.669	rs2978381	chr14:64766652	T/C	cg21174375	chr14:64681225	SYNE2	0.55	7.23	0.41	5.29e-12	Atrial fibrillation;
CESC	cis	rs9916302	0.904	rs11078910	chr17:37671269	G/T	cg20243544	chr17:37824526	PNMT	0.51	6.5	0.37	4.03e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs559928	0.556	rs11607903	chr11:63932140	G/A	cg18225595	chr11:63971243	STIP1	0.69	6.22	0.36	1.88e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CESC	cis	rs853679	0.517	rs4713135	chr6:28039586	G/A	cg23281280	chr6:28129359	ZNF389	0.55	7.31	0.41	3.21e-12	Depression;
CESC	cis	rs7577696	0.597	rs212689	chr2:32437338	G/A	cg02381751	chr2:32503542	YIPF4	0.46	5.16	0.3	4.77e-7	Inflammatory biomarkers;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg08393828	chr14:102228221	PPP2R5C	0.5	6.3	0.36	1.27e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs10887741	0.690	rs4934358	chr10:89439744	C/A	cg13926569	chr10:89418898	PAPSS2	0.35	5.23	0.31	3.39e-7	Exercise (leisure time);
CESC	cis	rs3960554	0.808	rs78587454	chr7:75688672	G/A	cg17325771	chr7:75508891	RHBDD2	-0.36	-5.24	-0.31	3.25e-7	Eotaxin levels;
CESC	cis	rs9311474	0.659	rs1133415	chr3:52575831	G/A	cg05564831	chr3:52568323	NT5DC2	0.48	7.81	0.43	1.32e-13	Electroencephalogram traits;
CESC	cis	rs6032067	0.636	rs7272597	chr20:43908869	T/C	cg10761708	chr20:43804764	PI3	0.38	5.07	0.3	7.6e-7	Blood protein levels;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg21518056	chr19:33183187	NUDT19	-0.48	-6.24	-0.36	1.68e-9	Fibrinogen levels;
CESC	cis	rs8067354	0.540	rs72840315	chr17:58018142	G/C	cg02344993	chr17:57696989	CLTC	0.52	5.52	0.32	8.03e-8	Hemoglobin concentration;
CESC	cis	rs28647808	0.881	rs28461467	chr9:136261288	G/A	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.85	5.74	0.33	2.59e-8	Blood protein levels;
CESC	cis	rs2288073	0.965	rs6545340	chr2:24422269	C/G	cg06627628	chr2:24431161	ITSN2	-0.81	-9.75	-0.51	2.14e-19	Venous thromboembolism (SNP x SNP interaction);
CESC	cis	rs7267979	0.816	rs6037158	chr20:25595466	C/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.78	14.35	0.66	6.13e-35	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs1832871	0.711	rs9457248	chr6:158681204	C/T	cg07165851	chr6:158734300	TULP4	0.59	6.36	0.36	8.84e-10	Height;
CESC	cis	rs6952808	0.609	rs4721190	chr7:1954732	A/G	cg04267008	chr7:1944627	MAD1L1	0.62	7.79	0.43	1.5e-13	Bipolar disorder and schizophrenia;
CESC	cis	rs9916302	0.861	rs7503514	chr17:37669884	G/C	cg00129232	chr17:37814104	STARD3	-0.56	-7.49	-0.42	1e-12	Glomerular filtration rate (creatinine);
CESC	cis	rs1559088	0.545	rs7257431	chr19:33566924	A/G	cg27124370	chr19:33622961	WDR88	0.54	7.51	0.42	9.05e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs1256061	0.603	rs3020445	chr14:64788644	A/G	cg21174375	chr14:64681225	SYNE2	0.54	7.04	0.4	1.62e-11	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg07364676	chr22:29137974	CHEK2;HSCB	-0.41	-6.54	-0.37	3.13e-10	Gambling;
CESC	cis	rs3749237	0.595	rs12489092	chr3:49550914	G/C	cg03060546	chr3:49711283	APEH	0.77	11.8	0.59	4.14e-26	Resting heart rate;
CESC	cis	rs34734847	1.000	rs2948149	chr12:121162854	T/G	cg21892295	chr12:121157589	UNC119B	-0.39	-6.17	-0.35	2.56e-9	Mean corpuscular volume;
CESC	cis	rs7208859	0.623	rs216433	chr17:28921860	T/C	cg19761014	chr17:28927070	LRRC37B2	0.8	7.38	0.41	2.04e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs5769765	0.954	rs910799	chr22:50278568	A/G	cg26441486	chr22:50317300	CRELD2	-0.39	-5.49	-0.32	9.25e-8	Schizophrenia;
CESC	cis	rs412050	0.895	rs6000236	chr22:22296459	A/G	cg17089214	chr22:22089827	YPEL1	0.73	6.94	0.39	2.93e-11	Attention deficit hyperactivity disorder;
CESC	cis	rs73206853	0.841	rs7956963	chr12:110947783	G/A	cg12870014	chr12:110450643	ANKRD13A	0.63	5.22	0.31	3.56e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs6933660	0.646	rs3816778	chr6:151773353	G/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.53	-7.24	-0.41	4.87e-12	Menarche (age at onset);
CESC	cis	rs4919087	0.715	rs34787876	chr10:98999213	T/C	cg25902810	chr10:99078978	FRAT1	-0.46	-5.2	-0.3	4.03e-7	Monocyte count;
CESC	cis	rs9325144	0.647	rs61931899	chr12:38892422	A/G	cg26384229	chr12:38710491	ALG10B	-0.55	-7.65	-0.43	3.64e-13	Morning vs. evening chronotype;
CESC	cis	rs7666738	0.830	rs1025204	chr4:99023441	G/A	cg17366294	chr4:99064904	C4orf37	0.6	8.59	0.47	7.72e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1322639	0.614	rs6900200	chr6:169566173	T/C	cg03254818	chr6:169586852	NA	0.49	5.31	0.31	2.29e-7	Pulse pressure;
CESC	cis	rs6061231	0.837	rs6121558	chr20:60961365	A/G	cg24112000	chr20:60950667	NA	-0.56	-7.0	-0.4	2.04e-11	Colorectal cancer;
CESC	cis	rs3008870	1.000	rs17497828	chr1:67452322	G/A	cg02640540	chr1:67518911	SLC35D1	-0.51	-5.33	-0.31	2.06e-7	Lymphocyte percentage of white cells;
CESC	cis	rs6032067	0.929	rs7344269	chr20:43828668	C/T	cg11264863	chr20:43835661	SEMG1	-0.48	-5.32	-0.31	2.25e-7	Blood protein levels;
CESC	cis	rs34779708	0.931	rs12773169	chr10:35366462	G/C	cg04310649	chr10:35416472	CREM	-0.52	-6.27	-0.36	1.42e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs9303401	0.614	rs35308719	chr17:57163501	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.88	11.1	0.56	9.23e-24	Cognitive test performance;
CESC	cis	rs2549003	1.000	rs10068129	chr5:131821246	A/G	cg02551604	chr5:131831745	NA	0.38	5.26	0.31	3e-7	Asthma (sex interaction);
CESC	cis	rs9911578	0.967	rs6416932	chr17:57148991	G/A	cg05425664	chr17:57184151	TRIM37	-0.53	-7.23	-0.41	5.28e-12	Intelligence (multi-trait analysis);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg01560493	chr5:109024808	MAN2A1	0.47	6.02	0.35	5.66e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs7666738	0.830	rs28795113	chr4:98951331	A/G	cg17366294	chr4:99064904	C4orf37	0.59	8.52	0.46	1.24e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9399135	0.967	rs3756799	chr6:135341011	A/G	cg22676075	chr6:135203613	NA	0.51	7.37	0.41	2.22e-12	Red blood cell count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04932230	chr10:54073878	DKK1	-0.53	-6.91	-0.39	3.67e-11	Gut microbiome composition (summer);
CESC	cis	rs4819052	0.851	rs2838850	chr21:46671445	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.92	13.67	0.64	1.52e-32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs5769765	0.955	rs61136468	chr22:50312679	A/G	cg02269571	chr22:50332266	NA	-0.5	-6.58	-0.37	2.45e-10	Schizophrenia;
CESC	cis	rs2191566	0.960	rs7255315	chr19:44510933	A/T	cg20607764	chr19:44506953	ZNF230	-0.58	-7.63	-0.42	4.31e-13	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs11122272	0.735	rs2491404	chr1:231512127	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.57	-7.82	-0.43	1.29e-13	Hemoglobin concentration;
CESC	cis	rs1707322	0.721	rs11211166	chr1:46157942	G/A	cg06784218	chr1:46089804	CCDC17	0.43	7.63	0.42	4.11e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs736408	0.660	rs2019065	chr3:52809525	C/T	cg18404041	chr3:52824283	ITIH1	0.4	6.78	0.38	7.65e-11	Bipolar disorder;
CESC	cis	rs3785574	0.962	rs8079161	chr17:61808561	C/G	cg07677032	chr17:61819896	STRADA	0.42	5.29	0.31	2.57e-7	Height;
CESC	cis	rs362272	0.545	rs2748447	chr4:3337831	G/A	cg14583973	chr4:3374767	RGS12	0.33	5.78	0.33	2.15e-8	Serum sulfate level;
CESC	cis	rs818427	0.593	rs456531	chr5:112216189	T/C	cg07820702	chr5:112228657	REEP5	-0.39	-5.1	-0.3	6.42e-7	Total body bone mineral density;
CESC	cis	rs7618915	0.501	rs7611731	chr3:52692721	T/C	cg18337363	chr3:52569053	NT5DC2	0.28	5.24	0.31	3.22e-7	Bipolar disorder;
CESC	cis	rs9911578	0.935	rs9911753	chr17:56983174	G/A	cg05425664	chr17:57184151	TRIM37	-0.39	-5.34	-0.31	2.02e-7	Intelligence (multi-trait analysis);
CESC	cis	rs4654899	0.733	rs10442633	chr1:21265097	C/T	cg05370193	chr1:21551575	ECE1	0.38	5.72	0.33	2.83e-8	Superior frontal gyrus grey matter volume;
CESC	cis	rs9902453	0.935	rs9905950	chr17:28431198	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	8.65	0.47	5.09e-16	Coffee consumption (cups per day);
CESC	cis	rs798554	1.000	rs798550	chr7:2760609	A/G	cg04166393	chr7:2884313	GNA12	0.53	6.96	0.39	2.71e-11	Height;
CESC	cis	rs6662572	0.737	rs7413189	chr1:46254330	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.45	-5.03	-0.3	9.07e-7	Blood protein levels;
CESC	cis	rs4665809	0.589	rs4665842	chr2:26448954	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.11	-12.68	-0.61	4.13e-29	Gut microbiome composition (summer);
CESC	cis	rs35123781	1.000	rs585101	chr5:139058454	T/C	cg10513866	chr5:139070639	NA	0.41	5.98	0.34	7.05e-9	Schizophrenia;
CESC	cis	rs7666738	0.830	rs3907021	chr4:99038668	C/T	cg24818145	chr4:99064322	C4orf37	0.38	5.04	0.3	8.49e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2074977	0.500	rs10153493	chr19:3447745	C/T	cg08380311	chr19:3435252	NFIC	-0.39	-5.16	-0.3	4.92e-7	Height;
CESC	cis	rs11997175	0.536	rs10096323	chr8:33776507	T/C	ch.8.33884649F	chr8:33765107	NA	0.54	6.45	0.37	5.25e-10	Body mass index;
CESC	cis	rs10791097	0.694	rs1893018	chr11:130756632	T/C	cg09137382	chr11:130731461	NA	0.35	5.21	0.3	3.81e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs6964587	1.000	rs6960867	chr7:91712698	A/G	cg17063962	chr7:91808500	NA	0.53	7.09	0.4	1.25e-11	Breast cancer;
CESC	cis	rs7223966	1.000	rs8075273	chr17:61728881	G/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.54	-5.5	-0.32	9e-8	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs853679	0.546	rs200954	chr6:27838764	C/G	cg02228804	chr6:27775720	HIST1H2AI;HIST1H2BL	0.63	5.55	0.32	6.79e-8	Depression;
CESC	cis	rs16854884	1.000	rs13068298	chr3:143772247	T/C	cg06585982	chr3:143692056	C3orf58	0.46	5.68	0.33	3.47e-8	Economic and political preferences (feminism/equality);
CESC	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg24829409	chr8:58192753	C8orf71	-0.67	-7.99	-0.44	4.08e-14	Developmental language disorder (linguistic errors);
CESC	cis	rs763014	0.931	rs2071981	chr16:630025	C/G	cg00802000	chr16:706648	WDR90	-0.41	-6.12	-0.35	3.35e-9	Height;
CESC	cis	rs863345	0.967	rs11265030	chr1:158529388	A/G	cg12129480	chr1:158549410	OR10X1	0.33	6.95	0.39	2.8e-11	Pneumococcal bacteremia;
CESC	cis	rs2932538	0.922	rs12406906	chr1:113117900	G/T	cg22162597	chr1:113214053	CAPZA1	-0.51	-6.78	-0.38	7.59e-11	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CESC	cis	rs9297145	0.724	rs62473013	chr7:98762418	G/T	cg05967295	chr7:98741636	SMURF1	0.9	9.34	0.5	4.06e-18	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
CESC	cis	rs4727027	0.705	rs10952803	chr7:148890091	T/G	cg23583168	chr7:148888333	NA	-0.97	-17.53	-0.73	3.38e-46	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs7605827	0.866	rs35237017	chr2:15615704	T/C	cg19274914	chr2:15703543	NA	0.33	5.96	0.34	8.22e-9	Educational attainment (years of education);
CESC	cis	rs4065321	0.609	rs8075668	chr17:38137623	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.4	5.81	0.34	1.75e-8	White blood cell count (basophil);White blood cell count;
CESC	cis	rs1552244	1.000	rs33917318	chr3:10067797	T/C	cg00149659	chr3:10157352	C3orf10	0.74	9.14	0.49	1.63e-17	Alzheimer's disease;
CESC	cis	rs854765	0.522	rs63721860	chr17:17829576	T/C	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.48	6.2	0.36	2.16e-9	Total body bone mineral density;
CESC	cis	rs589448	0.902	rs642786	chr12:69758462	T/C	cg14784868	chr12:69753453	YEATS4	0.89	14.23	0.66	1.66e-34	Cerebrospinal fluid biomarker levels;
CESC	cis	rs12824058	0.831	rs12300308	chr12:130813825	G/A	cg23887609	chr12:130822674	PIWIL1	0.45	5.82	0.34	1.69e-8	Menopause (age at onset);
CESC	cis	rs2832191	0.647	rs11170	chr21:30378090	C/T	cg08807101	chr21:30365312	RNF160	0.9	13.24	0.63	4.68e-31	Dental caries;
CESC	cis	rs6912958	0.712	rs4587138	chr6:88356915	G/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-5.22	-0.31	3.56e-7	Monocyte percentage of white cells;
CESC	cis	rs2283792	0.812	rs5995269	chr22:22289397	G/A	cg17089214	chr22:22089827	YPEL1	0.42	5.04	0.3	8.77e-7	Multiple sclerosis;
CESC	cis	rs9322193	0.923	rs1413654	chr6:150105092	G/A	cg07701084	chr6:150067640	NUP43	0.43	5.85	0.34	1.45e-8	Lung cancer;
CESC	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	10.27	0.53	4.68e-21	Prudent dietary pattern;
CESC	cis	rs1879734	0.731	rs6588487	chr1:54166790	G/A	cg23596471	chr1:54105337	GLIS1	0.35	5.51	0.32	8.39e-8	Mitral valve prolapse;
CESC	cis	rs1475911	0.708	rs8129075	chr21:43523430	G/T	cg19766460	chr21:43528205	UMODL1;C21orf128	0.95	12.87	0.62	9.38e-30	IgG glycosylation;
CESC	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	22.2	0.81	2.11e-62	Prudent dietary pattern;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg07624948	chr16:28962847	NFATC2IP	0.44	6.06	0.35	4.73e-9	Fibrinogen levels;
CESC	cis	rs13272623	0.502	rs268599	chr8:71517401	G/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.21	-0.3	3.77e-7	IgG glycosylation;
CESC	cis	rs6582630	0.519	rs11514056	chr12:38284001	G/T	cg26384229	chr12:38710491	ALG10B	0.65	9.03	0.49	3.55e-17	Drug-induced liver injury (flucloxacillin);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20181887	chr12:123753272	CDK2AP1	-0.49	-6.09	-0.35	4e-9	Gut microbiome composition (summer);
CESC	cis	rs10927875	0.596	rs1806990	chr1:16129377	G/A	cg18973939	chr1:16164122	FLJ37453	0.37	5.58	0.32	6.01e-8	Dilated cardiomyopathy;
CESC	cis	rs250677	1.000	rs36069	chr5:148417253	G/C	cg18129178	chr5:148520854	ABLIM3	-0.49	-5.79	-0.33	2.04e-8	Breast cancer;
CESC	cis	rs12586317	0.534	rs28384418	chr14:35452126	C/A	cg05294307	chr14:35346193	BAZ1A	-0.51	-6.31	-0.36	1.14e-9	Psoriasis;
CESC	cis	rs7212590	0.618	rs59767604	chr17:58041339	C/G	cg20303301	chr17:57937339	TUBD1	-0.54	-5.49	-0.32	9.55e-8	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs7666738	0.830	rs2114426	chr4:98933130	C/T	cg03467027	chr4:99064603	C4orf37	0.46	5.6	0.33	5.39e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs926938	0.527	rs360580	chr1:115462334	A/G	cg12756093	chr1:115239321	AMPD1	0.45	6.28	0.36	1.41e-9	Autism;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg10151248	chr11:66639567	PC	0.46	6.07	0.35	4.3e-9	Fibrinogen levels;
CESC	cis	rs7618915	0.570	rs4687633	chr3:52630548	G/A	cg18099408	chr3:52552593	STAB1	-0.31	-5.16	-0.3	4.75e-7	Bipolar disorder;
CESC	cis	rs6032067	0.929	rs13043296	chr20:43805688	T/C	cg11264863	chr20:43835661	SEMG1	0.51	5.56	0.32	6.5e-8	Blood protein levels;
CESC	cis	rs8077889	0.917	rs8081646	chr17:41893360	T/C	cg26893861	chr17:41843967	DUSP3	0.67	8.03	0.44	3.26e-14	Triglycerides;
CESC	cis	rs7666738	0.830	rs17027198	chr4:98991085	G/C	cg05340658	chr4:99064831	C4orf37	0.8	12.44	0.61	2.83e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6088580	0.634	rs4911422	chr20:32999345	T/C	cg24642439	chr20:33292090	TP53INP2	-0.53	-6.99	-0.39	2.17e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs7552404	0.727	rs1144336	chr1:76277421	C/A	cg10523679	chr1:76189770	ACADM	0.66	7.01	0.4	1.92e-11	Blood metabolite levels;Acylcarnitine levels;
CESC	trans	rs1814175	0.647	rs10769646	chr11:49992204	C/A	cg15704280	chr7:45808275	SEPT13	-1.01	-19.02	-0.76	1.83e-51	Height;
CESC	cis	rs5750830	0.594	rs9611165	chr22:39775250	A/G	cg01416388	chr22:39784598	NA	-0.54	-7.15	-0.4	8.7e-12	Intelligence (multi-trait analysis);
CESC	cis	rs9894429	0.550	rs6565617	chr17:79612333	G/A	cg21984481	chr17:79567631	NPLOC4	-0.35	-5.41	-0.32	1.43e-7	Eye color traits;
CESC	cis	rs9303280	0.806	rs4795399	chr17:38061439	T/C	cg20243544	chr17:37824526	PNMT	0.53	6.87	0.39	4.54e-11	Self-reported allergy;
CESC	cis	rs1577917	1.000	rs7760207	chr6:86721700	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-6.03	-0.35	5.34e-9	Response to antipsychotic treatment;
CESC	cis	rs826838	1.000	rs10880963	chr12:38748408	T/C	cg26384229	chr12:38710491	ALG10B	0.84	14.74	0.67	2.59e-36	Heart rate;
CESC	trans	rs7090925	0.959	rs2454060	chr10:8465041	T/A	cg02275004	chr12:976007	WNK1;HSN2	0.47	6.06	0.35	4.73e-9	Systemic lupus erythematosus;
CESC	cis	rs11785400	0.963	rs6990126	chr8:143728387	T/C	cg10596483	chr8:143751796	JRK	0.41	5.36	0.31	1.78e-7	Schizophrenia;
CESC	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg04234412	chr22:24373322	LOC391322	-0.54	-7.66	-0.43	3.43e-13	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs11871801	0.517	rs6963	chr17:40731597	A/T	cg16308533	chr17:40838983	CNTNAP1	-0.42	-5.41	-0.32	1.39e-7	Crohn's disease;
CESC	cis	rs7618915	0.547	rs68021750	chr3:52624769	G/A	cg18404041	chr3:52824283	ITIH1	-0.39	-6.55	-0.37	2.91e-10	Bipolar disorder;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg00734800	chr3:50388182	TUSC4;CYB561D2	0.5	6.58	0.37	2.48e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs875971	0.862	rs28470208	chr7:65584700	A/G	cg18876405	chr7:65276391	NA	-0.55	-7.37	-0.41	2.17e-12	Aortic root size;
CESC	cis	rs7216064	0.531	rs6504573	chr17:66015963	C/T	cg07042672	chr17:66097459	LOC651250	-0.49	-6.3	-0.36	1.23e-9	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg04025307	chr7:1156635	C7orf50	0.58	10.18	0.53	9.28e-21	Longevity;Endometriosis;
CESC	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.47	-5.64	-0.33	4.35e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs3816788	0.837	rs6557640	chr8:21771731	A/T	cg17168535	chr8:21777572	XPO7	0.63	9.48	0.5	1.55e-18	Lung cancer in ever smokers;
CESC	cis	rs3092073	0.624	rs11906879	chr20:44591324	C/T	cg00981651	chr20:44574847	PCIF1	-0.38	-5.65	-0.33	4.16e-8	Intelligence (multi-trait analysis);
CESC	cis	rs853679	0.517	rs1904840	chr6:28108232	C/T	cg23281280	chr6:28129359	ZNF389	0.59	8.07	0.44	2.52e-14	Depression;
CESC	cis	rs25645	0.771	rs11078936	chr17:38197914	T/C	cg17344932	chr17:38183730	MED24;SNORD124	0.55	7.53	0.42	7.78e-13	Myeloid white cell count;
CESC	cis	rs2985684	1.000	rs2985687	chr14:50100386	T/C	cg02151108	chr14:50098012	C14orf104	-0.42	-5.48	-0.32	9.97e-8	Carotid intima media thickness;
CESC	cis	rs6867032	1.000	rs4975796	chr5:2015520	A/T	cg26168224	chr5:2018326	NA	-0.99	-19.8	-0.77	3.57e-54	Gut microbiome composition (winter);
CESC	cis	rs2251381	0.741	rs2735966	chr21:30538174	G/A	cg08807101	chr21:30365312	RNF160	0.67	8.3	0.45	5.33e-15	Selective IgA deficiency;
CESC	cis	rs889312	0.500	rs832577	chr5:56163787	G/A	cg14703610	chr5:56206110	C5orf35	0.48	6.29	0.36	1.32e-9	Breast cancer;Breast cancer (early onset);
CESC	cis	rs7274811	0.595	rs13045068	chr20:32133484	G/C	cg21523528	chr20:32077966	CBFA2T2	0.63	7.25	0.41	4.68e-12	Height;
CESC	cis	rs11785400	1.000	rs4266629	chr8:143736635	A/G	cg10596483	chr8:143751796	JRK	0.43	5.68	0.33	3.47e-8	Schizophrenia;
CESC	trans	rs12681287	0.547	rs66808088	chr8:87521212	C/T	cg27317242	chr8:23145699	R3HCC1	-0.51	-6.08	-0.35	4.09e-9	Caudate activity during reward;
CESC	cis	rs1008375	0.931	rs2098151	chr4:17577490	T/C	cg16339924	chr4:17578868	LAP3	0.74	9.68	0.51	3.59e-19	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs3815700	1.000	rs10407204	chr19:33097353	C/T	cg24916020	chr19:33096688	ANKRD27	0.59	5.87	0.34	1.28e-8	Eosinophilic esophagitis;
CESC	cis	rs478304	0.514	rs75601653	chr11:65483370	C/G	cg27068330	chr11:65405492	SIPA1	-0.48	-5.54	-0.32	7.15e-8	Acne (severe);
CESC	trans	rs72681920	0.881	rs28364304	chr4:100206912	T/C	cg22948791	chr15:71404101	CT62	-0.54	-6.14	-0.35	2.96e-9	Alcohol dependence;
CESC	cis	rs4237845	0.837	rs7971877	chr12:58287630	T/G	cg00677455	chr12:58241039	CTDSP2	0.42	5.3	0.31	2.39e-7	Intelligence (multi-trait analysis);
CESC	cis	rs6752107	0.901	rs2289477	chr2:234160345	T/G	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.37	5.74	0.33	2.56e-8	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs9910055	0.614	rs12944572	chr17:42245241	T/C	cg19774624	chr17:42201019	HDAC5	-0.9	-14.84	-0.67	1.09e-36	Total body bone mineral density;
CESC	cis	rs10089	1.000	rs73337363	chr5:127483597	A/G	cg19767477	chr5:127420684	SLC12A2	-0.39	-5.18	-0.3	4.42e-7	Ileal carcinoids;
CESC	cis	rs920590	0.758	rs7010174	chr8:19661930	G/C	cg17834443	chr8:19674713	INTS10	0.58	6.53	0.37	3.27e-10	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs1707322	1.000	rs10890378	chr1:46410657	A/G	cg03146154	chr1:46216737	IPP	-0.72	-9.82	-0.52	1.31e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs1729951	0.575	rs361244	chr3:136697506	C/T	cg25687071	chr3:136751404	NA	0.4	5.33	0.31	2.13e-7	Neuroticism;
CESC	cis	rs801193	1.000	rs10252765	chr7:66228732	C/G	cg11764359	chr7:65958608	NA	0.6	7.18	0.4	7.06e-12	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25152312	chr3:195595803	TNK2	-0.59	-6.79	-0.38	7.18e-11	Gut microbiome composition (summer);
CESC	cis	rs3762637	0.823	rs9849013	chr3:122250605	A/G	cg24169773	chr3:122142474	KPNA1	-0.59	-6.85	-0.39	5.26e-11	LDL cholesterol levels;
CESC	cis	rs9858542	0.953	rs1987628	chr3:49399259	G/A	cg03060546	chr3:49711283	APEH	-0.52	-5.96	-0.34	7.89e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs8067545	0.563	rs3850780	chr17:20181902	A/C	cg13482628	chr17:19912719	NA	-0.42	-5.62	-0.33	4.92e-8	Schizophrenia;
CESC	cis	rs12541635	0.966	rs1603363	chr8:107031319	A/G	cg10147462	chr8:107024639	NA	0.39	5.48	0.32	9.71e-8	Age of smoking initiation;
CESC	cis	rs9581857	0.547	rs17753121	chr13:28052613	T/C	cg01674679	chr13:27998804	GTF3A	-0.65	-5.19	-0.3	4.24e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
CESC	cis	rs6598955	0.640	rs4233460	chr1:26633387	A/G	cg04990556	chr1:26633338	UBXN11	-0.79	-11.16	-0.57	5.72e-24	Obesity-related traits;
CESC	cis	rs17826219	0.561	rs4085382	chr17:29071202	T/C	cg13385521	chr17:29058706	SUZ12P	0.74	6.21	0.36	2.01e-9	Body mass index;
CESC	cis	rs3931020	0.530	rs12125889	chr1:75241971	A/G	cg21535942	chr1:75199100	CRYZ;TYW3	0.44	5.86	0.34	1.4e-8	Resistin levels;
CESC	cis	rs9733	0.536	rs6661415	chr1:150635869	G/A	cg04414720	chr1:150670196	GOLPH3L	0.63	9.02	0.48	3.86e-17	Tonsillectomy;
CESC	cis	rs703842	0.616	rs4760171	chr12:58225904	A/G	cg00599273	chr12:58146742	CDK4	0.34	5.16	0.3	4.93e-7	Multiple sclerosis;
CESC	cis	rs11750568	0.967	rs6879226	chr5:178513371	A/G	cg10208897	chr5:178548229	ADAMTS2	0.39	5.45	0.32	1.15e-7	Height;
CESC	cis	rs7586673	0.866	rs7579662	chr2:161915810	G/A	cg21518248	chr2:162101506	NA	0.47	6.27	0.36	1.48e-9	Intelligence (multi-trait analysis);
CESC	trans	rs561341	0.882	rs72825748	chr17:30367396	G/A	cg20587970	chr11:113659929	NA	-1.49	-19.4	-0.77	8.69e-53	Hip circumference adjusted for BMI;
CESC	cis	rs7116495	0.609	rs10501408	chr11:71680590	C/T	cg26138937	chr11:71823887	C11orf51	-1.35	-7.73	-0.43	2.22e-13	Severe influenza A (H1N1) infection;
CESC	trans	rs5758511	0.731	rs5751186	chr22:42349710	G/A	cg15080870	chr19:47770746	CCDC9	-0.5	-6.2	-0.36	2.15e-9	Birth weight;
CESC	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg02018176	chr4:1364513	KIAA1530	-0.56	-7.16	-0.4	8.01e-12	Longevity;
CESC	cis	rs1008375	1.000	rs10032326	chr4:17630717	A/T	cg02297831	chr4:17616191	MED28	0.56	7.03	0.4	1.77e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs60843830	1.000	rs3791220	chr2:227066	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.87	11.66	0.58	1.2e-25	Spherical equivalent (joint analysis main effects and education interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21890848	chr21:27107814	ATP5J;GABPA	0.53	6.6	0.38	2.18e-10	Gut microbiome composition (summer);
CESC	cis	rs765787	0.530	rs12592055	chr15:45514477	C/T	cg24006582	chr15:45444508	DUOX1	0.51	6.25	0.36	1.59e-9	Uric acid levels;
CESC	cis	rs11583043	0.708	rs12734559	chr1:101563001	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.5	5.47	0.32	1.03e-7	Ulcerative colitis;Inflammatory bowel disease;
CESC	cis	rs12148488	0.738	rs4886417	chr15:75330159	T/G	cg14664628	chr15:75095509	CSK	-0.47	-5.71	-0.33	2.97e-8	Caffeine consumption;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg20682991	chr2:74981952	NA	0.45	6.1	0.35	3.64e-9	Fibrinogen levels;
CESC	cis	rs634534	0.562	rs642293	chr11:65730217	G/A	cg02202077	chr11:65769826	EIF1AD;BANF1	0.48	6.51	0.37	3.72e-10	Sum eosinophil basophil counts;Eosinophil counts;
CESC	cis	rs910316	0.712	rs175015	chr14:75457075	A/C	cg16144293	chr14:75469539	EIF2B2	0.41	5.46	0.32	1.11e-7	Height;
CESC	cis	rs938554	0.735	rs11942223	chr4:9962765	T/C	cg11266682	chr4:10021025	SLC2A9	-0.42	-5.61	-0.33	5.17e-8	Blood metabolite levels;
CESC	cis	rs2456568	0.803	rs10831142	chr11:93640781	A/G	cg26875233	chr11:93583750	C11orf90	0.31	5.34	0.31	2.03e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
CESC	cis	rs1670533	0.932	rs6599276	chr4:1056827	T/C	cg04106633	chr4:1044584	NA	0.41	5.21	0.3	3.86e-7	Recombination rate (females);
CESC	cis	rs10876993	0.928	rs1678532	chr12:58055197	T/G	cg18357645	chr12:58087776	OS9	0.6	9.29	0.5	6.03e-18	Celiac disease or Rheumatoid arthritis;
CESC	cis	rs4782309	0.544	rs8060579	chr16:88751667	G/C	cg27087555	chr16:88793112	FAM38A	-1.03	-6.33	-0.36	1.04e-9	Hair color;
CESC	cis	rs965469	0.895	rs6051729	chr20:3290615	A/G	cg25506879	chr20:3388711	C20orf194	-0.55	-5.89	-0.34	1.14e-8	IFN-related cytopenia;
CESC	cis	rs3026101	0.671	rs8077933	chr17:5299674	C/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.42	5.6	0.33	5.31e-8	Body mass index;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg05994294	chr4:1374658	KIAA1530	0.43	6.0	0.35	6.4e-9	Fibrinogen levels;
CESC	cis	rs3733585	0.699	rs6449202	chr4:9974043	T/C	cg00071950	chr4:10020882	SLC2A9	-0.69	-11.29	-0.57	2.13e-24	Cleft plate (environmental tobacco smoke interaction);
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg01484320	chr1:109757057	SARS	-0.46	-6.11	-0.35	3.55e-9	Height;
CESC	cis	rs2952156	0.920	rs1018246	chr17:37835240	C/T	cg19468946	chr17:37922297	IKZF3	-0.39	-5.12	-0.3	5.94e-7	Asthma;
CESC	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.58	0.37	2.49e-10	Prudent dietary pattern;
CESC	cis	rs9916302	0.706	rs582176	chr17:37453999	T/C	cg07936489	chr17:37558343	FBXL20	0.92	10.37	0.54	2.23e-21	Glomerular filtration rate (creatinine);
CESC	cis	rs7520050	0.807	rs12025621	chr1:46228391	G/A	cg03146154	chr1:46216737	IPP	-0.5	-6.6	-0.38	2.2e-10	Red blood cell count;Reticulocyte count;
CESC	cis	rs9487051	0.872	rs1111864	chr6:109611138	A/G	cg12927641	chr6:109611667	NA	-0.43	-6.71	-0.38	1.19e-10	Reticulocyte fraction of red cells;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03774484	chr12:7079822	PHB2;EMG1	0.65	7.88	0.44	8.7e-14	Gut microbiome composition (summer);
CESC	cis	rs2243480	1.000	rs35820085	chr7:65442758	C/T	cg12463550	chr7:65579703	CRCP	0.69	5.5	0.32	9.16e-8	Diabetic kidney disease;
CESC	cis	rs9584850	0.834	rs8481	chr13:99105395	G/A	cg20750642	chr13:99100586	FARP1	-0.38	-5.78	-0.33	2.05e-8	Neuroticism;
CESC	cis	rs7618915	0.547	rs10865973	chr3:52718154	A/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	5.62	0.33	4.81e-8	Bipolar disorder;
CESC	cis	rs7666738	0.791	rs10005118	chr4:99038196	A/C	cg18180107	chr4:99064573	C4orf37	0.41	5.29	0.31	2.55e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4950322	0.857	rs72693002	chr1:146829304	T/A	cg22381352	chr1:146742008	CHD1L	-0.44	-5.08	-0.3	7.24e-7	Protein quantitative trait loci;
CESC	cis	rs478304	0.654	rs7947604	chr11:65442059	G/C	cg27068330	chr11:65405492	SIPA1	-0.46	-5.51	-0.32	8.54e-8	Acne (severe);
CESC	cis	rs2836633	0.894	rs55955614	chr21:40037330	T/G	cg12884169	chr21:40033163	ERG	0.39	6.17	0.35	2.53e-9	Coronary artery disease;
CESC	cis	rs9486719	1.000	rs3798295	chr6:97052164	C/T	cg18709589	chr6:96969512	KIAA0776	-0.53	-5.74	-0.33	2.54e-8	Migraine;Coronary artery disease;
CESC	cis	rs7091068	0.706	rs4919398	chr10:95429162	C/T	cg20715218	chr10:95462985	C10orf4	0.56	5.11	0.3	6.24e-7	Urinary tract infection frequency;
CESC	cis	rs8062405	1.000	rs62036620	chr16:28833097	A/G	cg08761264	chr16:28874980	SH2B1	-0.47	-5.84	-0.34	1.55e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	trans	rs9650657	0.645	rs9969657	chr8:10515278	A/G	cg15556689	chr8:8085844	FLJ10661	0.47	6.08	0.35	4.12e-9	Neuroticism;
CESC	cis	rs10479542	0.549	rs4376229	chr5:179042971	A/G	cg09060608	chr5:178986726	RUFY1	0.45	6.32	0.36	1.12e-9	Lung cancer;
CESC	cis	rs6495122	0.699	rs1378942	chr15:75077367	A/C	cg14664628	chr15:75095509	CSK	0.68	9.37	0.5	3.22e-18	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
CESC	cis	rs854765	0.583	rs12603148	chr17:17865257	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.65	9.42	0.5	2.29e-18	Total body bone mineral density;
CESC	cis	rs2760061	0.505	rs708109	chr1:228190657	C/T	cg02753203	chr1:228287806	NA	0.79	11.5	0.58	4.28e-25	Diastolic blood pressure;
CESC	cis	rs7666738	0.830	rs1111541	chr4:99033860	A/G	cg17366294	chr4:99064904	C4orf37	-0.62	-8.83	-0.48	1.46e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1843834	0.539	rs12694643	chr2:225446603	A/G	cg22455342	chr2:225449267	CUL3	0.67	9.12	0.49	1.92e-17	IgE levels in asthmatics (D.p. specific);
CESC	cis	rs7680126	0.500	rs4697717	chr4:10149784	C/G	cg00071950	chr4:10020882	SLC2A9	-0.6	-6.46	-0.37	5.1e-10	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	cis	rs763121	0.925	rs4821797	chr22:39016182	T/C	cg06544989	chr22:39130855	UNC84B	0.52	9.62	0.51	5.64e-19	Menopause (age at onset);
CESC	cis	rs7584330	0.744	rs72620822	chr2:238379582	C/T	cg14458575	chr2:238380390	NA	0.92	12.91	0.62	6.71e-30	Prostate cancer;
CESC	cis	rs11608355	0.597	rs7300290	chr12:109832545	T/G	cg19025524	chr12:109796872	NA	-0.54	-7.66	-0.43	3.45e-13	Neuroticism;
CESC	cis	rs1448094	0.512	rs7134732	chr12:86241908	T/C	cg02569458	chr12:86230093	RASSF9	0.49	7.24	0.41	4.79e-12	Major depressive disorder;
CESC	cis	rs2243480	1.000	rs34136756	chr7:65381256	A/G	cg18252515	chr7:66147081	NA	-1.06	-9.79	-0.52	1.67e-19	Diabetic kidney disease;
CESC	cis	rs10540	1.000	rs12421457	chr11:505780	T/C	cg03934478	chr11:495069	RNH1	0.54	5.15	0.3	5.16e-7	Body mass index;
CESC	cis	rs727505	0.607	rs66478705	chr7:124789211	C/G	cg23710748	chr7:124431027	NA	-0.4	-6.27	-0.36	1.44e-9	Lewy body disease;
CESC	cis	rs798554	0.836	rs798502	chr7:2789880	G/T	cg13628971	chr7:2884303	GNA12	-0.61	-7.9	-0.44	7.35e-14	Height;
CESC	cis	rs898097	0.841	rs4986136	chr17:80865119	A/G	cg05255149	chr17:80675120	FN3KRP	0.43	5.13	0.3	5.54e-7	Breast cancer;
CESC	cis	rs193541	0.632	rs34714850	chr5:122332695	A/G	cg19412675	chr5:122181750	SNX24	-0.46	-5.38	-0.31	1.67e-7	Glucose homeostasis traits;
CESC	cis	rs5769765	1.000	rs1033665	chr22:50252127	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.47	-5.6	-0.33	5.28e-8	Schizophrenia;
CESC	cis	rs400736	0.602	rs4573544	chr1:8165247	C/T	cg25007680	chr1:8021821	PARK7	-0.58	-7.75	-0.43	2.01e-13	Response to antidepressants and depression;
CESC	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	22.27	0.81	1.17e-62	Prudent dietary pattern;
CESC	cis	rs28386778	0.830	rs7209321	chr17:61855668	A/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.91	13.7	0.64	1.19e-32	Prudent dietary pattern;
CESC	cis	rs8017423	0.967	rs11849641	chr14:90727647	T/C	cg14092571	chr14:90743983	NA	-0.55	-8.17	-0.45	1.24e-14	Mortality in heart failure;
CESC	cis	rs2197308	0.765	rs11182481	chr12:37926019	T/C	cg26384229	chr12:38710491	ALG10B	0.7	10.15	0.53	1.14e-20	Morning vs. evening chronotype;
CESC	cis	rs116095464	0.558	rs73024831	chr5:257192	A/G	cg12570787	chr5:219185	SDHA;CCDC127	0.51	5.28	0.31	2.76e-7	Breast cancer;
CESC	cis	rs7552404	0.889	rs380075	chr1:76106961	T/A	cg22875332	chr1:76189707	ACADM	-0.64	-7.57	-0.42	6.05e-13	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs6546537	1.000	rs17036866	chr2:69857711	T/C	cg10773587	chr2:69614142	GFPT1	-0.61	-7.44	-0.42	1.37e-12	Serum thyroid-stimulating hormone levels;
CESC	cis	rs344364	0.511	rs1742462	chr16:1946062	A/C	cg03013636	chr16:1946785	NA	0.48	6.62	0.38	2.02e-10	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs769267	0.930	rs3794990	chr19:19610030	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.46	5.93	0.34	9.24e-9	Tonsillectomy;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg24834479	chr5:133702818	CDKL3	-0.47	-6.03	-0.35	5.45e-9	Fibrinogen levels;
CESC	cis	rs73206853	0.764	rs56205958	chr12:111027361	G/C	cg12870014	chr12:110450643	ANKRD13A	0.65	5.57	0.32	6.37e-8	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs8031584	0.560	rs7171208	chr15:31198929	A/G	cg19680485	chr15:31195859	MTMR15	0.48	5.89	0.34	1.15e-8	Huntington's disease progression;
CESC	cis	rs617791	0.530	rs10896073	chr11:65762814	T/C	cg09783858	chr11:65769428	EIF1AD;BANF1	0.53	6.37	0.36	8.31e-10	Breast cancer;
CESC	cis	rs9311474	0.508	rs11718420	chr3:52611413	T/C	cg07507251	chr3:52567010	NT5DC2	0.33	5.72	0.33	2.81e-8	Electroencephalogram traits;
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg03330302	chr2:26468406	HADHA;HADHB	-0.4	-6.41	-0.37	6.57e-10	Vertical cup-disc ratio;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg05800758	chr8:101225800	SPAG1	-0.44	-6.39	-0.37	7.4e-10	Gambling;
CESC	cis	rs1008375	1.000	rs114490726	chr4:17680898	T/C	cg16339924	chr4:17578868	LAP3	0.49	6.16	0.35	2.65e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg11407514	chr10:99094219	FRAT2	-0.47	-6.81	-0.39	6.59e-11	Gambling;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12662555	chr3:57742520	SLMAP	0.58	6.1	0.35	3.75e-9	Gut microbiome composition (summer);
CESC	cis	rs1801251	0.896	rs6719061	chr2:233695885	C/T	cg08000102	chr2:233561755	GIGYF2	-0.73	-11.73	-0.58	6.91e-26	Coronary artery disease;
CESC	cis	rs951366	0.903	rs708723	chr1:205739266	C/T	cg07157834	chr1:205819609	PM20D1	0.48	6.96	0.39	2.6e-11	Menarche (age at onset);
CESC	cis	rs6089584	0.507	rs6061999	chr20:60637429	G/A	cg24733560	chr20:60626293	TAF4	0.41	5.97	0.34	7.57e-9	Body mass index;
CESC	cis	rs6570726	0.935	rs415590	chr6:145851244	T/C	cg05347473	chr6:146136440	FBXO30	0.49	6.62	0.38	2.03e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4253772	0.637	rs9627350	chr22:46663017	A/G	cg24881330	chr22:46731750	TRMU	0.85	9.5	0.5	1.3e-18	LDL cholesterol;Cholesterol, total;
CESC	cis	rs9649213	0.593	rs12728	chr7:97922851	C/T	cg21770322	chr7:97807741	LMTK2	0.6	9.15	0.49	1.59e-17	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs7819412	0.540	rs2409725	chr8:11041661	T/C	cg06636001	chr8:8085503	FLJ10661	-0.53	-6.11	-0.35	3.53e-9	Triglycerides;
CESC	cis	rs4319547	0.688	rs10744287	chr12:123077485	T/A	cg05707623	chr12:122985044	ZCCHC8	-0.43	-5.44	-0.32	1.24e-7	Body mass index;
CESC	cis	rs9815354	1.000	rs7616844	chr3:41874343	A/G	cg03022575	chr3:42003672	ULK4	0.45	5.26	0.31	2.97e-7	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs1552244	0.882	rs3755783	chr3:10029289	A/G	cg00166722	chr3:10149974	C3orf24	0.53	6.19	0.36	2.32e-9	Alzheimer's disease;
CESC	cis	rs7937682	0.961	rs11601674	chr11:111634354	C/T	cg22437258	chr11:111473054	SIK2	0.6	6.59	0.38	2.3e-10	Primary sclerosing cholangitis;
CESC	cis	rs4900538	0.855	rs12590993	chr14:102844064	A/G	cg18135206	chr14:102964638	TECPR2	-0.73	-9.31	-0.5	5e-18	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	cis	rs9733	0.791	rs11204693	chr1:150647987	C/T	cg04414720	chr1:150670196	GOLPH3L	-0.37	-5.26	-0.31	3.01e-7	Tonsillectomy;
CESC	cis	rs4237845	0.537	rs11172367	chr12:58272486	T/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.51	5.77	0.33	2.17e-8	Intelligence (multi-trait analysis);
CESC	cis	rs854765	0.534	rs7207461	chr17:17949789	T/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.49	-6.16	-0.35	2.63e-9	Total body bone mineral density;
CESC	cis	rs7662987	0.938	rs28730605	chr4:100001540	C/T	cg13256891	chr4:100009986	ADH5	-0.82	-6.05	-0.35	4.83e-9	Smoking initiation;
CESC	cis	rs5753618	0.607	rs5753621	chr22:31847647	T/C	cg02404636	chr22:31891804	SFI1	0.39	5.23	0.31	3.49e-7	Colorectal cancer;
CESC	cis	rs4253772	0.637	rs9627402	chr22:46702586	C/T	cg24881330	chr22:46731750	TRMU	0.79	6.62	0.38	1.97e-10	LDL cholesterol;Cholesterol, total;
CESC	cis	rs7267979	1.000	rs422424	chr20:25445446	G/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.86	17.57	0.73	2.33e-46	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs6089829	0.925	rs13041507	chr20:61666180	T/C	cg03213289	chr20:61660250	NA	0.39	6.16	0.35	2.7e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs2273669	0.667	rs10457185	chr6:109322477	G/C	cg05315195	chr6:109294784	ARMC2	-0.66	-6.01	-0.35	6.04e-9	Prostate cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25601229	chr1:109618810	TAF13	0.61	6.4	0.37	7.11e-10	Gut microbiome composition (summer);
CESC	cis	rs1008375	1.000	rs2109522	chr4:17658645	T/A	cg16339924	chr4:17578868	LAP3	0.55	6.93	0.39	3.22e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs1059312	0.808	rs12831705	chr12:129294905	G/A	cg09035930	chr12:129282057	SLC15A4	0.68	9.08	0.49	2.61e-17	Systemic lupus erythematosus;
CESC	cis	rs2806561	0.765	rs679591	chr1:23499916	T/C	cg12483005	chr1:23474871	LUZP1	0.39	6.21	0.36	2.05e-9	Height;
CESC	cis	rs2072499	0.865	rs2758603	chr1:156198994	T/C	cg24450063	chr1:156163899	SLC25A44	0.82	12.6	0.61	7.47e-29	Testicular germ cell tumor;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg06370812	chr3:195501042	MUC4	-0.46	-6.38	-0.36	7.77e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs59918340	0.728	rs10112337	chr8:142233573	A/G	cg23750338	chr8:142222470	SLC45A4	-0.61	-9.46	-0.5	1.78e-18	Immature fraction of reticulocytes;
CESC	cis	rs1552244	1.000	rs17032414	chr3:10158302	C/G	cg08888203	chr3:10149979	C3orf24	0.49	6.47	0.37	4.7e-10	Alzheimer's disease;
CESC	cis	rs67478160	0.619	rs8018062	chr14:104281954	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.51	-7.09	-0.4	1.21e-11	Schizophrenia;
CESC	cis	rs62064224	0.714	rs4794915	chr17:30634363	A/G	cg18200150	chr17:30822561	MYO1D	-0.39	-5.31	-0.31	2.32e-7	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00339687	chr1:161348895	NA	-0.49	-6.58	-0.37	2.47e-10	Gut microbiome composition (summer);
CESC	cis	rs1395	0.778	rs724311	chr2:27441645	A/G	cg22903471	chr2:27725779	GCKR	-0.41	-5.09	-0.3	6.92e-7	Blood metabolite levels;
CESC	cis	rs2425143	1.000	rs7273668	chr20:34442731	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.79	-7.16	-0.4	7.86e-12	Blood protein levels;
CESC	trans	rs6445797	0.632	rs11921326	chr3:56664322	C/A	cg15444621	chr13:113611794	NA	0.34	6.1	0.35	3.64e-9	Gastritis;
CESC	cis	rs1511802	0.666	rs28698123	chr4:187123189	C/T	cg24794857	chr4:187113578	CYP4V2	0.45	5.94	0.34	9.1e-9	Blood protein levels;
CESC	cis	rs829883	0.872	rs1641641	chr12:98896018	A/C	cg25150519	chr12:98850993	NA	0.71	9.74	0.51	2.31e-19	Colorectal adenoma (advanced);
CESC	cis	rs3796352	1.000	rs58660500	chr3:53086573	C/T	cg12962167	chr3:53033115	SFMBT1	0.69	6.06	0.35	4.58e-9	Immune reponse to smallpox (secreted IL-2);
CESC	cis	rs1862618	0.853	rs10461617	chr5:56104308	A/G	cg03609598	chr5:56110824	MAP3K1	-0.5	-5.42	-0.32	1.34e-7	Initial pursuit acceleration;
CESC	cis	rs523522	0.962	rs9040	chr12:120900274	C/T	cg12219531	chr12:120966889	COQ5	0.74	9.37	0.5	3.43e-18	High light scatter reticulocyte count;
CESC	cis	rs1256061	0.630	rs1256030	chr14:64747170	A/G	cg21174375	chr14:64681225	SYNE2	0.44	5.77	0.33	2.24e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs2046867	0.862	rs62252362	chr3:72855218	A/G	cg25664220	chr3:72788482	NA	-0.41	-6.06	-0.35	4.56e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CESC	cis	rs2842992	0.915	rs2842985	chr6:160085434	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.67	7.63	0.42	4.23e-13	Age-related macular degeneration (geographic atrophy);
CESC	trans	rs561341	0.663	rs72821936	chr17:30224068	C/G	cg20587970	chr11:113659929	NA	-0.61	-8.13	-0.45	1.69e-14	Hip circumference adjusted for BMI;
CESC	cis	rs1348850	0.874	rs6742951	chr2:178340766	G/C	cg22681709	chr2:178499509	PDE11A	-0.44	-6.16	-0.35	2.67e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs2842992	0.789	rs3818300	chr6:160201677	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.76	9.88	0.52	8.23e-20	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs1904096	0.506	rs114312933	chr4:95216802	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.67	-11.08	-0.56	1.05e-23	Type 2 diabetes;
CESC	cis	rs7949030	1.000	rs7949030	chr11:62394881	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.49	7.87	0.44	8.81e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	trans	rs4662834	0.798	rs12991269	chr2:129490984	G/T	cg12497543	chr10:97515377	ENTPD1	-0.4	-6.63	-0.38	1.82e-10	Response to bleomycin (chromatid breaks);
CESC	cis	rs3858526	0.523	rs10769290	chr11:5886947	T/A	cg02574844	chr11:5959923	NA	-0.47	-7.33	-0.41	2.86e-12	DNA methylation (variation);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22791904	chr19:14273676	LPHN1	-0.62	-6.54	-0.37	3.07e-10	Gut microbiome composition (summer);
CESC	cis	rs1143633	0.579	rs4849132	chr2:113673471	G/A	cg12858261	chr2:113808755	IL1F8	-0.42	-5.11	-0.3	6.05e-7	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs7666738	0.752	rs62318905	chr4:99036103	T/G	cg17366294	chr4:99064904	C4orf37	0.61	8.77	0.47	2.27e-16	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07818830	chr12:76953439	OSBPL8	0.63	7.22	0.41	5.42e-12	Gut microbiome composition (summer);
CESC	cis	rs3741798	1.000	rs17303178	chr12:12485351	G/A	cg08615371	chr12:12503544	MANSC1	0.87	6.35	0.36	9.19e-10	Cerebrospinal fluid biomarker levels;
CESC	cis	rs2204008	0.837	rs10876019	chr12:37985477	C/T	cg13010199	chr12:38710504	ALG10B	0.53	6.61	0.38	2.1e-10	Bladder cancer;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg05644321	chr20:20693493	RALGAPA2	-0.43	-6.01	-0.35	6.26e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs9311474	0.507	rs6787154	chr3:52784416	C/T	cg17372223	chr3:52568218	NT5DC2	0.42	6.41	0.37	6.55e-10	Electroencephalogram traits;
CESC	cis	rs2073300	0.609	rs6137930	chr20:23376732	G/A	cg12062639	chr20:23401060	NAPB	1.07	8.85	0.48	1.29e-16	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs1847202	0.762	rs13093504	chr3:72949855	T/C	cg25664220	chr3:72788482	NA	-0.38	-5.55	-0.32	7.03e-8	Motion sickness;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13932339	chr15:25684205	UBE3A	0.5	6.06	0.35	4.72e-9	Gut microbiome composition (summer);
CESC	cis	rs80130819	0.748	rs10747531	chr12:48632280	A/G	cg05342945	chr12:48394962	COL2A1	-0.48	-5.2	-0.3	4.07e-7	Prostate cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22880820	chr9:35665522	C9orf100	-0.58	-6.39	-0.37	7.36e-10	Gut microbiome composition (summer);
CESC	cis	rs1799949	1.000	rs8176202	chr17:41230228	G/A	cg23758822	chr17:41437982	NA	1.02	15.41	0.69	1.13e-38	Menopause (age at onset);
CESC	cis	rs7772486	0.754	rs2328707	chr6:146053498	G/A	cg05347473	chr6:146136440	FBXO30	-0.56	-7.23	-0.41	5.1e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9323205	0.911	rs60034431	chr14:51622437	C/A	cg23942311	chr14:51606299	NA	-0.45	-5.75	-0.33	2.5e-8	Cancer;
CESC	cis	rs9915657	0.743	rs9894720	chr17:70097607	C/T	cg09344028	chr17:70110421	NA	0.4	7.96	0.44	4.94e-14	Thyroid hormone levels;
CESC	cis	rs7107174	1.000	rs2512538	chr11:77972461	T/G	cg02023728	chr11:77925099	USP35	0.48	6.34	0.36	9.87e-10	Testicular germ cell tumor;
CESC	cis	rs1707322	1.000	rs785517	chr1:46567535	A/T	cg05343316	chr1:45956843	TESK2	-0.47	-5.52	-0.32	7.97e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg27649522	chr12:12877729	APOLD1	-0.46	-6.85	-0.39	5.3e-11	Gambling;
CESC	cis	rs2354432	0.882	rs11576360	chr1:146740576	G/A	cg25205988	chr1:146714368	CHD1L	1.1	15.69	0.69	1.13e-39	Mitochondrial DNA levels;
CESC	cis	rs2346177	0.542	rs13024414	chr2:46687062	G/A	cg02822958	chr2:46747628	ATP6V1E2	0.45	5.63	0.33	4.53e-8	HDL cholesterol;
CESC	cis	rs6952808	0.756	rs13234214	chr7:1878860	C/T	cg04267008	chr7:1944627	MAD1L1	-0.5	-5.98	-0.34	7.07e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs8180040	0.903	rs11710013	chr3:47296921	T/C	cg27129171	chr3:47204927	SETD2	0.66	9.56	0.51	8.61e-19	Colorectal cancer;
CESC	cis	rs1018836	0.632	rs7017630	chr8:91482604	A/G	cg16814680	chr8:91681699	NA	-0.61	-8.36	-0.46	3.55e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs7615952	0.641	rs7632497	chr3:125783086	A/C	cg06494592	chr3:125709126	NA	-0.49	-5.35	-0.31	1.92e-7	Blood pressure (smoking interaction);
CESC	cis	rs17711722	0.675	rs6947132	chr7:65273495	G/A	cg05332525	chr7:65337924	VKORC1L1	-0.52	-6.42	-0.37	6.27e-10	Calcium levels;
CESC	cis	rs798554	0.757	rs1182188	chr7:2869985	T/C	cg09658497	chr7:2847517	GNA12	-0.44	-6.45	-0.37	5.31e-10	Height;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg08265551	chr1:151032119	CDC42SE1;MLLT11	-0.42	-6.07	-0.35	4.39e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs3780486	0.505	rs10813959	chr9:33166234	C/T	cg20290983	chr6:43655470	MRPS18A	-0.72	-11.13	-0.56	7.49e-24	IgG glycosylation;
CESC	cis	rs2705520	0.744	rs1814052	chr3:112231907	C/T	cg09473763	chr3:112282684	SLC35A5	-0.78	-6.1	-0.35	3.72e-9	Asthma (childhood onset);
CESC	cis	rs2228479	0.850	rs62052711	chr16:89855100	C/A	cg14709524	chr16:89940631	TCF25	0.94	7.06	0.4	1.5e-11	Skin colour saturation;
CESC	cis	rs2304069	0.955	rs4288106	chr5:149394872	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.91	11.7	0.58	9.24e-26	HIV-1 control;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg19161053	chr7:99036702	CPSF4;PTCD1	0.48	6.22	0.36	1.91e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs10463316	0.894	rs6579865	chr5:150762335	A/C	cg03212797	chr5:150827313	SLC36A1	-0.46	-6.02	-0.35	5.83e-9	Metabolite levels (Pyroglutamine);
CESC	cis	rs6665290	0.669	rs3768423	chr1:227177293	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.12	-24.44	-0.83	7.56e-70	Myeloid white cell count;
CESC	cis	rs796364	0.806	rs79156935	chr2:200913822	T/G	cg23649088	chr2:200775458	C2orf69	-0.55	-5.05	-0.3	8.29e-7	Schizophrenia;
CESC	cis	rs4835473	0.864	rs35888177	chr4:144888016	G/C	cg25736465	chr4:144833511	NA	0.41	6.27	0.36	1.43e-9	Immature fraction of reticulocytes;
CESC	cis	rs6667605	0.527	rs4422947	chr1:2539590	C/T	cg18854424	chr1:2615690	NA	0.3	6.1	0.35	3.69e-9	Inflammatory bowel disease;Ulcerative colitis;
CESC	cis	rs896854	0.654	rs896847	chr8:95972551	G/A	cg23172400	chr8:95962367	TP53INP1	-0.44	-9.04	-0.49	3.45e-17	Type 2 diabetes;
CESC	cis	rs6500602	0.702	rs2270366	chr16:4558615	A/G	cg08645402	chr16:4508243	NA	-0.55	-9.0	-0.48	4.61e-17	Schizophrenia;
CESC	cis	rs9291683	0.588	rs6844329	chr4:10018544	T/C	cg00071950	chr4:10020882	SLC2A9	0.91	17.5	0.73	4.14e-46	Bone mineral density;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26367235	chr2:239997305	HDAC4	-0.51	-6.1	-0.35	3.69e-9	Gut microbiome composition (summer);
CESC	cis	rs7116495	1.000	rs541022	chr11:71783056	G/A	cg10381502	chr11:71823885	C11orf51	-0.58	-5.16	-0.3	4.85e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs870825	0.698	rs28412823	chr4:185638829	T/C	cg04058563	chr4:185651563	MLF1IP	0.64	7.09	0.4	1.21e-11	Blood protein levels;
CESC	cis	rs2932538	0.922	rs7535636	chr1:113101799	C/T	cg22162597	chr1:113214053	CAPZA1	-0.53	-6.73	-0.38	1.04e-10	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CESC	cis	rs4682868	0.552	rs6771233	chr3:42922697	G/T	cg21365077	chr3:42922735	NA	0.41	5.3	0.31	2.49e-7	Monocyte percentage of white cells;
CESC	trans	rs1814175	0.592	rs1794161	chr11:49898825	A/C	cg15704280	chr7:45808275	SEPT13	-1.0	-18.78	-0.76	1.35e-50	Height;
CESC	cis	rs2070488	0.804	rs13059256	chr3:38504315	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.8	12.69	0.61	3.72e-29	Electrocardiographic conduction measures;
CESC	cis	rs4481887	0.927	rs4551626	chr1:248489128	G/T	cg00666640	chr1:248458726	OR2T12	0.36	6.17	0.35	2.56e-9	Common traits (Other);
CESC	cis	rs172166	0.694	rs203877	chr6:28048624	T/C	cg23281280	chr6:28129359	ZNF389	0.43	6.41	0.37	6.46e-10	Cardiac Troponin-T levels;
CESC	cis	rs11864453	0.514	rs2269918	chr16:72134831	C/A	cg16558253	chr16:72132732	DHX38	-0.54	-8.45	-0.46	1.93e-15	Fibrinogen levels;
CESC	cis	rs2404602	0.692	rs12911174	chr15:77149943	G/A	cg22467129	chr15:76604101	ETFA	-0.34	-5.18	-0.3	4.47e-7	Blood metabolite levels;
CESC	cis	rs11158198	0.738	rs910879	chr14:58571252	T/G	cg15908186	chr14:58618357	C14orf37	0.35	5.28	0.31	2.68e-7	Dementia and core Alzheimer's disease neuropathologic changes;
CESC	cis	rs6842047	0.901	rs2102575	chr4:187131504	G/A	cg23442198	chr4:187126114	CYP4V2	0.72	5.79	0.33	2.03e-8	Blood protein levels;
CESC	cis	rs870825	0.860	rs72689295	chr4:185600930	T/C	cg04058563	chr4:185651563	MLF1IP	0.57	5.29	0.31	2.54e-7	Blood protein levels;
CESC	cis	rs2279817	0.820	rs11203440	chr1:18026352	A/G	cg21791023	chr1:18019539	ARHGEF10L	0.6	8.57	0.47	8.54e-16	Neuroticism;
CESC	cis	rs7659604	0.540	rs4833769	chr4:122672970	A/C	cg19671926	chr4:122722719	EXOSC9	-0.53	-6.53	-0.37	3.4e-10	Type 2 diabetes;
CESC	cis	rs11785693	0.862	rs62491168	chr8:4982290	A/T	cg26367366	chr8:4980734	NA	0.92	8.42	0.46	2.33e-15	Neuroticism (multi-trait analysis);Neuroticism;
CESC	cis	rs1707322	1.000	rs9803784	chr1:46401907	T/C	cg03146154	chr1:46216737	IPP	0.72	9.82	0.52	1.31e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs8177253	0.798	rs9871148	chr3:133507509	T/C	cg01448562	chr3:133502909	NA	-0.56	-7.73	-0.43	2.21e-13	Iron status biomarkers;
CESC	trans	rs7618501	1.000	rs34451146	chr3:49813013	C/T	cg21659725	chr3:3221576	CRBN	0.83	13.55	0.64	3.87e-32	Intelligence (multi-trait analysis);
CESC	cis	rs67311347	1.000	rs4973878	chr3:40407565	C/T	cg01475735	chr3:40494733	NA	-0.4	-5.06	-0.3	7.78e-7	Renal cell carcinoma;
CESC	cis	rs12586317	0.620	rs8021414	chr14:35581480	T/A	cg16230307	chr14:35515116	FAM177A1	0.92	10.08	0.53	1.98e-20	Psoriasis;
CESC	cis	rs9346455	0.554	rs9346457	chr6:72009302	A/T	cg27238071	chr6:71998145	OGFRL1	0.65	6.21	0.36	2.02e-9	Antipsychotic drug-induced weight gain (time interaction);Antipsychotic drug-induced weight gain;
CESC	cis	rs1545257	0.537	rs2249387	chr2:24649801	C/G	cg06627628	chr2:24431161	ITSN2	0.5	6.02	0.35	5.8e-9	Sjögren's syndrome;
CESC	cis	rs1005224	0.853	rs61980778	chr14:76151532	C/T	cg25116370	chr14:76127843	TTLL5;C14orf1	0.43	5.88	0.34	1.21e-8	Large artery stroke;
CESC	trans	rs4335177	0.893	rs6477532	chr9:109364501	T/G	cg12580783	chr12:49362475	WNT10B	-0.32	-6.09	-0.35	3.94e-9	Response to paliperidone in schizophrenia (positive Marder score);
CESC	cis	rs1577917	0.771	rs10944133	chr6:86358984	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.53	-7.08	-0.4	1.33e-11	Response to antipsychotic treatment;
CESC	cis	rs2777491	0.874	rs7161772	chr15:41611066	A/T	cg02330683	chr15:41787940	ITPKA	0.46	6.69	0.38	1.35e-10	Ulcerative colitis;
CESC	cis	rs9611519	0.558	rs8137906	chr22:41442566	A/G	cg03806693	chr22:41940476	POLR3H	-0.51	-6.04	-0.35	5.14e-9	Neuroticism;
CESC	cis	rs9611565	0.649	rs202655	chr22:41841564	G/C	cg17376030	chr22:41985996	PMM1	-0.56	-6.22	-0.36	1.92e-9	Vitiligo;
CESC	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	10.24	0.53	5.92e-21	Prudent dietary pattern;
CESC	cis	rs933688	1.000	rs12656350	chr5:90751343	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.02	10.84	0.55	6.7e-23	Smoking behavior;
CESC	cis	rs1691799	0.899	rs2951656	chr12:66732273	T/G	cg16791601	chr12:66731901	HELB	-0.62	-10.16	-0.53	1.1e-20	White blood cell count (basophil);
CESC	cis	rs870825	0.860	rs72689284	chr4:185596680	A/G	cg04058563	chr4:185651563	MLF1IP	0.57	5.29	0.31	2.54e-7	Blood protein levels;
CESC	cis	rs10504229	0.512	rs117968470	chr8:58014651	C/G	cg05313129	chr8:58192883	C8orf71	-0.5	-5.05	-0.3	8.06e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs7959452	0.868	rs12812860	chr12:69746671	T/C	cg22834771	chr12:69754056	YEATS4	-0.39	-5.24	-0.31	3.2e-7	Blood protein levels;
CESC	trans	rs2867695	0.590	rs11727456	chr4:81181908	C/T	cg02056280	chr3:178866391	PIK3CA	-0.72	-6.17	-0.35	2.6e-9	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CESC	cis	rs11997175	0.967	rs60586868	chr8:33776585	A/G	ch.8.33884649F	chr8:33765107	NA	0.59	7.72	0.43	2.35e-13	Body mass index;
CESC	cis	rs1448094	0.512	rs7313278	chr12:86250263	C/T	cg00310523	chr12:86230176	RASSF9	0.35	5.44	0.32	1.22e-7	Major depressive disorder;
CESC	cis	rs59574136	1	rs59574136	chr7:2036460	T/C	cg04267008	chr7:1944627	MAD1L1	-0.6	-7.44	-0.42	1.4e-12	Autism spectrum disorder or schizophrenia;
CESC	trans	rs2115172	0.836	rs4835799	chr5:122762229	A/G	cg17994379	chr17:43025264	KIF18B	0.46	6.06	0.35	4.74e-9	Weight;
CESC	trans	rs9467711	0.790	rs13195402	chr6:26463575	G/T	cg01620082	chr3:125678407	NA	-0.79	-6.2	-0.36	2.13e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs67478160	0.595	rs1475007	chr14:104297147	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.51	-7.14	-0.4	9.19e-12	Schizophrenia;
CESC	cis	rs2832191	0.967	rs2251377	chr21:30530599	T/C	cg08807101	chr21:30365312	RNF160	0.65	8.66	0.47	4.64e-16	Dental caries;
CESC	cis	rs1062177	0.756	rs2915817	chr5:151115517	T/C	cg12924095	chr5:151150029	G3BP1	-0.45	-5.74	-0.33	2.53e-8	Preschool internalizing problems;
CESC	cis	rs2014572	0.967	rs8111977	chr19:57759158	T/A	cg12963866	chr19:57752005	ZNF805	-0.47	-6.28	-0.36	1.38e-9	Hyperactive-impulsive symptoms;
CESC	cis	rs4563143	0.647	rs117946634	chr19:29256822	G/T	cg04546413	chr19:29218101	NA	0.56	7.77	0.43	1.76e-13	Methadone dose in opioid dependence;
CESC	cis	rs854765	0.718	rs6502629	chr17:17869642	A/G	cg16928487	chr17:17741425	SREBF1	-0.56	-9.26	-0.49	7.4e-18	Total body bone mineral density;
CESC	cis	rs896854	0.902	rs896852	chr8:95960886	G/T	cg09323728	chr8:95962352	TP53INP1	-0.45	-9.86	-0.52	9.98e-20	Type 2 diabetes;
CESC	cis	rs3741151	0.773	rs73544729	chr11:73183418	G/T	cg17517138	chr11:73019481	ARHGEF17	0.95	6.99	0.39	2.29e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs7666738	0.830	rs35752787	chr4:98935202	G/A	cg17366294	chr4:99064904	C4orf37	0.61	8.56	0.47	9.36e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs208520	0.731	rs12206488	chr6:66999917	G/T	cg07460842	chr6:66804631	NA	0.89	9.57	0.51	8.13e-19	Exhaled nitric oxide output;
CESC	cis	rs7208859	0.673	rs61348930	chr17:29221763	C/T	cg19761014	chr17:28927070	LRRC37B2	0.73	5.77	0.33	2.22e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs2425143	0.818	rs6060726	chr20:34555878	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.65	5.58	0.32	6e-8	Blood protein levels;
CESC	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg11905131	chr22:24372483	LOC391322	0.64	8.02	0.44	3.51e-14	Urinary 1,3-butadiene metabolite levels in smokers;
CESC	cis	rs12701220	0.655	rs9638973	chr7:1133678	A/G	cg26769984	chr7:1090371	C7orf50	0.61	6.91	0.39	3.52e-11	Bronchopulmonary dysplasia;
CESC	cis	rs12973672	0.812	rs113185571	chr19:35758929	C/T	cg12095397	chr19:35769544	USF2	0.49	5.83	0.34	1.59e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs2046867	0.818	rs7637138	chr3:72910886	A/G	cg25664220	chr3:72788482	NA	-0.44	-6.39	-0.37	7.45e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CESC	cis	rs9611565	0.512	rs6002474	chr22:42168181	A/G	cg06481639	chr22:41940642	POLR3H	0.6	5.92	0.34	9.88e-9	Vitiligo;
CESC	cis	rs7914558	0.966	rs11191471	chr10:104702050	T/A	cg15744005	chr10:104629667	AS3MT	-0.35	-5.48	-0.32	9.69e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs11969893	0.737	rs1854483	chr6:101378117	G/A	cg12253828	chr6:101329408	ASCC3	0.96	8.17	0.45	1.26e-14	Economic and political preferences (immigration/crime);
CESC	trans	rs6084875	0.641	rs2025116	chr20:4724011	C/T	cg10192164	chr16:30419175	ZNF771	-0.51	-6.18	-0.35	2.44e-9	Systemic lupus erythematosus;
CESC	cis	rs7666738	0.688	rs35739409	chr4:98576934	C/T	cg05340658	chr4:99064831	C4orf37	0.52	5.27	0.31	2.85e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10465746	0.967	rs5028806	chr1:84329295	G/A	cg10977910	chr1:84465055	TTLL7	0.47	6.45	0.37	5.3e-10	Obesity-related traits;
CESC	cis	rs7665939	0.932	rs66626876	chr4:190101569	T/G	cg09826759	chr4:190284978	NA	-0.72	-7.55	-0.42	6.96e-13	Amyotrophic lateral sclerosis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16148674	chr11:14380065	RRAS2	0.59	6.65	0.38	1.62e-10	Gut microbiome composition (summer);
CESC	cis	rs561341	1.000	rs113115092	chr17:30284164	G/A	cg00745463	chr17:30367425	LRRC37B	-0.81	-7.35	-0.41	2.5e-12	Hip circumference adjusted for BMI;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22703791	chr19:1479558	C19orf25	0.52	6.18	0.35	2.47e-9	Gut microbiome composition (summer);
CESC	cis	rs9916302	0.904	rs588193	chr17:37440439	A/C	cg19468946	chr17:37922297	IKZF3	0.41	5.27	0.31	2.87e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs3820068	0.603	rs72647128	chr1:15963908	T/C	cg13390004	chr1:15929781	NA	0.37	5.9	0.34	1.11e-8	Systolic blood pressure;
CESC	cis	rs17166499	0.803	rs73070145	chr7:12898313	T/C	cg12945054	chr7:12841881	NA	0.47	5.07	0.3	7.54e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs3785574	0.638	rs2854182	chr17:61969062	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	7.37	0.41	2.17e-12	Height;
CESC	cis	rs4853012	0.838	rs60705299	chr2:74345370	C/G	cg05776053	chr2:74358815	NA	0.4	5.13	0.3	5.5e-7	Gestational age at birth (maternal effect);
CESC	cis	rs8114671	0.967	rs2069948	chr20:33762489	C/T	cg24642439	chr20:33292090	TP53INP2	0.44	5.37	0.31	1.73e-7	Height;
CESC	cis	rs28374715	0.532	rs11854632	chr15:41682094	A/G	cg18705301	chr15:41695430	NDUFAF1	1.03	16.81	0.72	1.18e-43	Ulcerative colitis;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg25291941	chr8:99129319	POP1;HRSP12	-0.47	-6.33	-0.36	1.05e-9	Fibrinogen levels;
CESC	cis	rs9302635	0.513	rs12928732	chr16:72188683	C/T	cg16558253	chr16:72132732	DHX38	-0.42	-5.08	-0.3	7.08e-7	Blood protein levels;
CESC	cis	rs35110281	0.777	rs7276215	chr21:44990697	A/G	cg21573476	chr21:45109991	RRP1B	-0.45	-6.32	-0.36	1.13e-9	Mean corpuscular volume;
CESC	cis	rs6964587	1.000	rs10235941	chr7:91587050	T/G	cg17063962	chr7:91808500	NA	0.57	7.77	0.43	1.73e-13	Breast cancer;
CESC	cis	rs6121246	0.657	rs74392247	chr20:30241737	C/T	cg13852791	chr20:30311386	BCL2L1	0.83	7.43	0.42	1.53e-12	Mean corpuscular hemoglobin;
CESC	cis	rs4665809	0.838	rs6546780	chr2:26352857	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.65	-7.29	-0.41	3.48e-12	Gut microbiome composition (summer);
CESC	cis	rs2576037	0.526	rs2510444	chr18:44376849	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.7	11.04	0.56	1.49e-23	Personality dimensions;
CESC	cis	rs4665809	0.627	rs13014338	chr2:26463024	C/T	cg22920501	chr2:26401640	FAM59B	0.91	10.33	0.54	3.07e-21	Gut microbiome composition (summer);
CESC	cis	rs7914558	0.933	rs10883814	chr10:104737404	T/C	cg08650961	chr10:104748594	CNNM2	0.32	5.11	0.3	6.27e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs7949030	0.591	rs11231156	chr11:62366454	G/A	cg13298116	chr11:62369859	EML3;MTA2	0.65	9.52	0.5	1.16e-18	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs28374715	0.681	rs7165396	chr15:41586947	T/C	cg02330683	chr15:41787940	ITPKA	0.47	5.65	0.33	4.21e-8	Ulcerative colitis;
CESC	cis	rs3126085	0.877	rs7537633	chr1:152223333	T/G	cg03465714	chr1:152285911	FLG	-0.42	-5.16	-0.3	4.84e-7	Atopic dermatitis;
CESC	cis	rs1256061	0.603	rs1256044	chr14:64734027	G/A	cg23250157	chr14:64679961	SYNE2	0.53	7.64	0.42	4.09e-13	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.55	-6.09	-0.35	3.98e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11153891	chr13:21182994	IFT88	-0.57	-7.45	-0.42	1.32e-12	Gut microbiome composition (summer);
CESC	cis	rs7727544	0.735	rs274568	chr5:131713578	C/T	cg24060327	chr5:131705240	SLC22A5	0.68	9.13	0.49	1.81e-17	Blood metabolite levels;
CESC	cis	rs2836974	0.568	rs414850	chr21:40543337	A/C	cg11890956	chr21:40555474	PSMG1	0.97	16.55	0.71	1.01e-42	Cognitive function;
CESC	cis	rs17818399	0.645	rs35870739	chr2:46784231	A/C	cg26688816	chr2:46740690	ATP6V1E2	-0.49	-5.33	-0.31	2.07e-7	Height;
CESC	cis	rs6690583	0.623	rs7540706	chr1:85534645	A/G	cg22153463	chr1:85462885	MCOLN2	-0.67	-6.6	-0.38	2.18e-10	Serum sulfate level;
CESC	cis	rs853679	0.517	rs9295758	chr6:28120663	C/G	cg26335602	chr6:28129616	ZNF389	0.53	6.82	0.39	6.19e-11	Depression;
CESC	cis	rs8180040	0.701	rs12491473	chr3:46989904	G/A	cg27129171	chr3:47204927	SETD2	-0.63	-8.95	-0.48	6.24e-17	Colorectal cancer;
CESC	cis	rs10504229	0.906	rs7003285	chr8:58173108	A/G	cg22535103	chr8:58192502	C8orf71	-1.05	-13.27	-0.63	3.63e-31	Developmental language disorder (linguistic errors);
CESC	cis	rs6570726	0.935	rs384519	chr6:145846017	C/A	cg05347473	chr6:146136440	FBXO30	0.49	6.62	0.38	1.96e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2180341	0.574	rs13192350	chr6:127677762	G/T	cg24812749	chr6:127587940	RNF146	0.59	7.91	0.44	7.16e-14	Breast cancer;
CESC	cis	rs11718455	0.881	rs17076257	chr3:44006787	C/T	cg08738300	chr3:44038990	NA	0.46	6.13	0.35	3.09e-9	Coronary artery disease;
CESC	cis	rs796364	0.806	rs10445791	chr2:201078307	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.71	-5.94	-0.34	8.97e-9	Schizophrenia;
CESC	cis	rs1862618	0.573	rs185220	chr5:56205357	A/G	cg24531977	chr5:56204891	C5orf35	-0.97	-12.89	-0.62	7.59e-30	Initial pursuit acceleration;
CESC	cis	rs10200159	1.000	rs12616982	chr2:55874811	C/T	cg13617705	chr2:55845095	SMEK2	0.75	5.17	0.3	4.61e-7	Vitiligo;
CESC	trans	rs11098499	0.697	rs35280960	chr4:120257059	G/A	cg25214090	chr10:38739885	LOC399744	0.62	8.45	0.46	1.99e-15	Corneal astigmatism;
CESC	cis	rs472109	0.935	rs378825	chr11:9766932	A/G	cg03108697	chr11:9732066	SWAP70	-0.35	-5.28	-0.31	2.76e-7	Coronary artery disease;
CESC	cis	rs7666738	0.830	rs4392515	chr4:98957431	A/G	cg03467027	chr4:99064603	C4orf37	0.45	5.61	0.33	4.97e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7666738	0.830	rs1349757	chr4:99058763	C/G	cg03467027	chr4:99064603	C4orf37	0.48	5.97	0.34	7.41e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7980687	0.638	rs7299943	chr12:123593485	A/T	cg19016782	chr12:123741754	C12orf65	-0.39	-5.24	-0.31	3.25e-7	Height;Educational attainment;Head circumference (infant);
CESC	cis	rs4076764	0.958	rs12022261	chr1:163398422	A/G	cg06092702	chr1:163392909	NA	-0.41	-5.9	-0.34	1.13e-8	Motion sickness;
CESC	cis	rs7937682	0.883	rs568038	chr11:111432161	A/C	cg22437258	chr11:111473054	SIK2	-0.74	-9.32	-0.5	4.66e-18	Primary sclerosing cholangitis;
CESC	trans	rs10832139	0.553	rs9705260	chr11:13954554	T/A	cg11511669	chr12:131556214	GPR133	0.48	5.99	0.35	6.68e-9	P wave terminal force;
CESC	cis	rs8077577	0.945	rs62073608	chr17:18071448	T/C	cg16794390	chr17:18148240	FLII	0.39	5.17	0.3	4.65e-7	Obesity-related traits;
CESC	cis	rs60871478	0.636	rs6976929	chr7:901382	C/T	cg15782153	chr7:917662	C7orf20	0.52	5.72	0.33	2.91e-8	Cerebrospinal P-tau181p levels;
CESC	cis	rs736408	0.609	rs13095332	chr3:52787242	C/T	cg18404041	chr3:52824283	ITIH1	-0.42	-7.01	-0.4	1.93e-11	Bipolar disorder;
CESC	cis	rs6831352	0.918	rs34805407	chr4:100050786	C/A	cg13256891	chr4:100009986	ADH5	-0.77	-8.43	-0.46	2.27e-15	Alcohol dependence;
CESC	cis	rs2637266	0.967	rs7477607	chr10:78358768	G/T	cg18941641	chr10:78392320	NA	0.42	7.91	0.44	7.15e-14	Pulmonary function;
CESC	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg24739457	chr1:205821442	NA	0.42	5.54	0.32	7.23e-8	Menarche (age at onset);
CESC	cis	rs6032067	0.925	rs13042522	chr20:43829290	G/A	cg11264863	chr20:43835661	SEMG1	0.49	5.37	0.31	1.73e-7	Blood protein levels;
CESC	cis	rs7191700	0.511	rs8058983	chr16:11360849	A/G	cg00044050	chr16:11439710	C16orf75	-0.44	-5.38	-0.31	1.67e-7	Multiple sclerosis;
CESC	cis	rs924607	0.898	rs905193	chr5:635095	T/C	cg09021430	chr5:549028	NA	-0.39	-6.86	-0.39	4.95e-11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg12830829	chr14:51707081	TMX1	-0.45	-6.32	-0.36	1.1e-9	Fibrinogen levels;
CESC	trans	rs10506458	0.834	rs12426860	chr12:63387948	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.33	-17.85	-0.74	2.4e-47	Hemostatic factors and hematological phenotypes;
CESC	cis	rs10751667	0.621	rs10794351	chr11:946228	C/T	cg20946044	chr11:1010712	AP2A2	-0.37	-5.08	-0.3	7.19e-7	Alzheimer's disease (late onset);
CESC	cis	rs1552244	0.816	rs13076197	chr3:10019773	T/C	cg00166722	chr3:10149974	C3orf24	0.49	6.04	0.35	5.3e-9	Alzheimer's disease;
CESC	cis	rs7589728	0.844	rs2363010	chr2:88496399	G/C	cg04511125	chr2:88470314	THNSL2	0.55	5.24	0.31	3.21e-7	Plasma clusterin levels;
CESC	cis	rs1797885	0.510	rs2442820	chr3:12599196	G/C	cg26432171	chr3:12704882	RAF1	-0.42	-5.49	-0.32	9.57e-8	Immature fraction of reticulocytes;
CESC	cis	rs9913156	0.793	rs9916135	chr17:4568115	A/C	cg19197139	chr17:4613644	ARRB2	-0.92	-10.59	-0.55	4.42e-22	Lymphocyte counts;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20203915	chr3:187871836	LPP	0.53	6.23	0.36	1.88e-9	Gut microbiome composition (summer);
CESC	cis	rs9976767	0.608	rs9784208	chr21:43824986	A/G	cg23042151	chr21:43824109	UBASH3A	-0.33	-6.17	-0.35	2.55e-9	Type 1 diabetes;
CESC	cis	rs6580649	0.882	rs7133249	chr12:48456823	C/T	cg05342945	chr12:48394962	COL2A1	0.5	5.85	0.34	1.47e-8	Lung cancer;
CESC	cis	rs6964587	1.000	rs6970277	chr7:91680655	T/C	cg17063962	chr7:91808500	NA	0.54	7.18	0.4	6.85e-12	Breast cancer;
CESC	cis	rs2228479	0.850	rs117880578	chr16:89910230	C/G	cg14709524	chr16:89940631	TCF25	0.88	6.1	0.35	3.82e-9	Skin colour saturation;
CESC	cis	rs6121246	0.909	rs6119729	chr20:30413163	A/G	cg13852791	chr20:30311386	BCL2L1	-0.81	-8.19	-0.45	1.14e-14	Mean corpuscular hemoglobin;
CESC	trans	rs2207136	0.708	rs2746646	chr6:50818239	T/C	cg06522515	chr3:184090630	THPO	-0.38	-6.46	-0.37	4.93e-10	Myopia;
CESC	cis	rs854765	0.619	rs1101727	chr17:18016148	T/C	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.5	6.25	0.36	1.66e-9	Total body bone mineral density;
CESC	cis	rs2835872	0.758	rs1787396	chr21:39036487	A/C	cg06728970	chr21:39037746	KCNJ6	0.3	5.57	0.32	6.36e-8	Electroencephalographic traits in alcoholism;
CESC	cis	rs10493773	0.609	rs11161664	chr1:86185379	C/T	cg17807903	chr1:86174739	ZNHIT6	-0.43	-6.26	-0.36	1.54e-9	Urate levels in overweight individuals;
CESC	cis	rs6991838	0.584	rs7841652	chr8:66518627	T/G	cg13398993	chr8:66546079	ARMC1	-0.46	-5.65	-0.33	4.19e-8	Intelligence (multi-trait analysis);
CESC	cis	rs9487051	0.714	rs9487058	chr6:109631060	A/C	cg21918786	chr6:109611834	NA	-0.39	-5.71	-0.33	3.06e-8	Reticulocyte fraction of red cells;
CESC	cis	rs10484885	0.878	rs17506550	chr6:90508896	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.64	-6.11	-0.35	3.61e-9	QRS interval (sulfonylurea treatment interaction);
CESC	cis	rs372883	0.600	rs1312254	chr21:30695401	A/G	cg08807101	chr21:30365312	RNF160	-0.47	-5.38	-0.31	1.65e-7	Pancreatic cancer;
CESC	cis	rs9611565	0.512	rs964899	chr22:42142386	G/A	cg06481639	chr22:41940642	POLR3H	0.62	6.08	0.35	4.07e-9	Vitiligo;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg09110292	chr10:32217076	ARHGAP12	-0.47	-6.07	-0.35	4.43e-9	Fibrinogen levels;
CESC	cis	rs7474896	0.537	rs2472149	chr10:38262196	A/C	cg25427524	chr10:38739819	LOC399744	0.52	5.92	0.34	1.01e-8	Obesity (extreme);
CESC	cis	rs9309473	0.950	rs11126412	chr2:73887634	A/T	cg20560298	chr2:73613845	ALMS1	-0.58	-7.36	-0.41	2.36e-12	Metabolite levels;
CESC	cis	rs9911578	0.835	rs10853006	chr17:56489076	G/A	cg12560992	chr17:57184187	TRIM37	-0.89	-14.79	-0.67	1.74e-36	Intelligence (multi-trait analysis);
CESC	cis	rs2273669	0.667	rs12196024	chr6:109302258	C/T	cg05315195	chr6:109294784	ARMC2	-0.65	-6.18	-0.35	2.43e-9	Prostate cancer;
CESC	cis	rs2637266	1.000	rs7476937	chr10:78357692	A/T	cg18941641	chr10:78392320	NA	0.44	8.13	0.45	1.71e-14	Pulmonary function;
CESC	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg04025307	chr7:1156635	C7orf50	0.39	5.19	0.3	4.26e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs9796	0.505	rs28665387	chr15:41532869	G/T	cg20272979	chr15:41787780	ITPKA	0.38	5.58	0.32	5.81e-8	Menopause (age at onset);
CESC	cis	rs7615952	0.932	rs11922218	chr3:125631289	C/T	cg05084668	chr3:125655381	ALG1L	-0.47	-5.54	-0.32	7.34e-8	Blood pressure (smoking interaction);
CESC	cis	rs9287719	0.967	rs6432112	chr2:10744874	A/G	cg02196655	chr2:10830764	NOL10	0.36	5.56	0.32	6.43e-8	Prostate cancer;
CESC	cis	rs116095464	0.558	rs9312977	chr5:221916	G/C	cg22857025	chr5:266934	NA	-1.27	-18.89	-0.76	5.51e-51	Breast cancer;
CESC	cis	rs8177179	0.967	rs4994582	chr3:133437566	G/C	cg17775713	chr3:133465469	TF	0.31	5.46	0.32	1.07e-7	Iron status biomarkers (transferrin levels);
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg26206990	chr15:63569719	APH1B	0.42	6.2	0.36	2.12e-9	Thyroid stimulating hormone;
CESC	cis	rs7811142	1.000	rs7794485	chr7:100068936	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.99	9.1	0.49	2.2e-17	Platelet count;
CESC	cis	rs28374715	0.578	rs72739630	chr15:41631064	G/A	cg02330683	chr15:41787940	ITPKA	0.47	5.42	0.32	1.37e-7	Ulcerative colitis;
CESC	cis	rs9611565	0.918	rs9611561	chr22:41757234	C/G	cg06481639	chr22:41940642	POLR3H	-0.69	-7.36	-0.41	2.32e-12	Vitiligo;
CESC	cis	rs701145	0.556	rs357502	chr3:153955950	C/T	cg16511985	chr3:153974050	SGEF	0.46	6.25	0.36	1.62e-9	Coronary artery disease;
CESC	cis	rs597539	0.652	rs579136	chr11:68637476	C/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.77	9.59	0.51	6.99e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs55728055	0.661	rs62237773	chr22:31965054	A/G	cg01338084	chr22:32026380	PISD	1.26	8.23	0.45	8.62e-15	Age-related hearing impairment;
CESC	cis	rs1046896	0.520	rs8074086	chr17:80818460	A/C	cg02398342	chr17:80708632	TBCD;FN3K	0.46	5.53	0.32	7.8e-8	Glycated hemoglobin levels;
CESC	cis	rs7267979	0.903	rs6107015	chr20:25216764	G/A	cg08601574	chr20:25228251	PYGB	0.43	6.04	0.35	5.08e-9	Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs61931739	1.000	rs12305700	chr12:34036332	T/C	cg26384229	chr12:38710491	ALG10B	-0.46	-6.19	-0.36	2.28e-9	Morning vs. evening chronotype;
CESC	cis	rs8114671	0.527	rs2253484	chr20:33405263	A/T	cg07148914	chr20:33460835	GGT7	-0.43	-5.63	-0.33	4.69e-8	Height;
CESC	cis	rs763121	0.853	rs3827357	chr22:39079413	A/G	cg06022373	chr22:39101656	GTPBP1	0.9	14.22	0.66	1.8e-34	Menopause (age at onset);
CESC	cis	rs10540	1.000	rs71487292	chr11:486076	G/A	cg21784768	chr11:537496	LRRC56	-0.56	-5.05	-0.3	8.36e-7	Body mass index;
CESC	cis	rs3785574	1.000	rs3785574	chr17:61763185	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	7.08	0.4	1.26e-11	Height;
CESC	cis	rs7605378	0.528	rs281787	chr2:200784238	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.48	-5.45	-0.32	1.13e-7	Osteoporosis;
CESC	cis	rs875971	0.545	rs17138156	chr7:65714695	C/T	cg25405998	chr7:65216604	CCT6P1	0.45	5.35	0.31	1.92e-7	Aortic root size;
CESC	cis	rs2455799	0.573	rs2455830	chr3:15749213	C/T	cg16303742	chr3:15540471	COLQ	-0.4	-6.21	-0.36	2.03e-9	Mean platelet volume;
CESC	cis	rs1862618	0.641	rs2591954	chr5:56245044	G/C	cg18230493	chr5:56204884	C5orf35	0.61	7.97	0.44	4.79e-14	Initial pursuit acceleration;
CESC	cis	rs3820068	0.705	rs4646110	chr1:15817318	A/T	cg18192808	chr1:15853278	DNAJC16	0.46	5.53	0.32	7.59e-8	Systolic blood pressure;
CESC	cis	rs17376456	0.877	rs12153506	chr5:93360953	T/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.6	5.2	0.3	3.98e-7	Diabetic retinopathy;
CESC	cis	rs79349575	0.783	rs4793995	chr17:47019399	A/C	cg26022315	chr17:47021804	SNF8	0.39	5.16	0.3	4.94e-7	Type 2 diabetes;
CESC	cis	rs7618915	0.547	rs2268027	chr3:52766606	G/A	cg05564831	chr3:52568323	NT5DC2	0.44	6.69	0.38	1.33e-10	Bipolar disorder;
CESC	cis	rs35146811	0.771	rs6465762	chr7:99620554	G/A	cg13334819	chr7:99746414	C7orf59	-0.45	-5.24	-0.31	3.34e-7	Coronary artery disease;
CESC	cis	rs1862618	0.853	rs252922	chr5:56136343	G/T	cg24549020	chr5:56110836	MAP3K1	0.66	7.6	0.42	5.18e-13	Initial pursuit acceleration;
CESC	cis	rs11711311	0.911	rs34337798	chr3:113396704	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.69	8.88	0.48	1e-16	IgG glycosylation;
CESC	trans	rs7824557	0.527	rs2736305	chr8:11237773	T/C	cg15556689	chr8:8085844	FLJ10661	-0.48	-6.0	-0.35	6.55e-9	Retinal vascular caliber;
CESC	cis	rs896854	0.516	rs12679044	chr8:95891356	C/A	cg13393036	chr8:95962371	TP53INP1	-0.39	-7.24	-0.41	4.9e-12	Type 2 diabetes;
CESC	cis	rs6500602	0.727	rs4238849	chr16:4538114	G/A	cg08645402	chr16:4508243	NA	0.58	9.43	0.5	2.19e-18	Schizophrenia;
CESC	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg11905131	chr22:24372483	LOC391322	-0.8	-12.09	-0.6	4.4e-27	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg07677032	chr17:61819896	STRADA	0.45	5.93	0.34	9.64e-9	Prudent dietary pattern;
CESC	cis	rs875971	0.660	rs3764903	chr7:66098482	G/A	cg18876405	chr7:65276391	NA	-0.51	-6.82	-0.39	6.14e-11	Aortic root size;
CESC	cis	rs5753618	0.509	rs5753500	chr22:31578879	A/G	cg13145458	chr22:31556086	RNF185	0.45	5.07	0.3	7.58e-7	Colorectal cancer;
CESC	cis	rs7940866	0.903	rs11222421	chr11:130872351	A/T	cg12179176	chr11:130786555	SNX19	0.65	9.49	0.5	1.39e-18	Schizophrenia;
CESC	cis	rs2370759	1.000	rs77165999	chr10:32577131	T/C	cg01819863	chr10:32635814	EPC1	1.16	13.25	0.63	4.48e-31	Sexual dysfunction (female);
CESC	cis	rs137603	0.644	rs137621	chr22:39710244	G/A	cg01093212	chr22:39715156	SNORD43;RPL3	-0.41	-5.31	-0.31	2.28e-7	Primary biliary cholangitis;
CESC	cis	rs875971	0.505	rs1167385	chr7:65513308	G/A	cg26939375	chr7:64535504	NA	-0.74	-10.63	-0.55	3.13e-22	Aortic root size;
CESC	cis	rs2455799	0.553	rs2262664	chr3:15768097	A/T	cg16303742	chr3:15540471	COLQ	-0.39	-6.24	-0.36	1.76e-9	Mean platelet volume;
CESC	cis	rs4822044	0.560	rs7284839	chr22:42010902	C/T	cg06634786	chr22:41940651	POLR3H	0.61	6.13	0.35	3.21e-9	Cannabis dependence symptom count;
CESC	cis	rs10791097	0.592	rs7116068	chr11:130732739	A/C	cg12179176	chr11:130786555	SNX19	-0.67	-9.91	-0.52	6.72e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	trans	rs7656342	0.808	rs10003216	chr4:9766749	A/G	cg20608709	chr15:58889273	ADAM10	-0.47	-6.28	-0.36	1.36e-9	Gut microbiota (bacterial taxa);
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg04928513	chr20:60717545	PSMA7;SS18L1	-0.46	-6.32	-0.36	1.09e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07940793	chr17:79603854	NPLOC4	0.56	6.8	0.39	6.9e-11	Gut microbiome composition (summer);
CESC	cis	rs7828089	0.504	rs12676477	chr8:22266425	T/C	cg12081754	chr8:22256438	SLC39A14	0.6	8.26	0.45	6.86e-15	Verbal declarative memory;
CESC	cis	rs3859192	0.561	rs12451547	chr17:38181168	T/C	cg17344932	chr17:38183730	MED24;SNORD124	0.6	8.95	0.48	6.49e-17	White blood cell count;
CESC	cis	rs7727544	1.000	rs7727544	chr5:131590534	C/T	cg24060327	chr5:131705240	SLC22A5	-0.41	-5.15	-0.3	5.07e-7	Blood metabolite levels;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg23302558	chr2:182774636	SSFA2	0.39	6.24	0.36	1.69e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs4665809	0.941	rs11126336	chr2:26245931	C/T	cg27170947	chr2:26402098	FAM59B	-0.58	-6.69	-0.38	1.3e-10	Gut microbiome composition (summer);
CESC	cis	rs1862618	0.671	rs28397234	chr5:56248428	T/G	cg24549020	chr5:56110836	MAP3K1	-0.49	-5.87	-0.34	1.29e-8	Initial pursuit acceleration;
CESC	cis	rs2439831	1.000	rs550239	chr15:43720197	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.88	10.61	0.55	3.7e-22	Lung cancer in ever smokers;
CESC	cis	rs367943	0.666	rs10041899	chr5:112724742	A/T	cg12552261	chr5:112820674	MCC	0.4	5.33	0.31	2.12e-7	Type 2 diabetes;
CESC	cis	rs10876993	0.890	rs1082502	chr12:58035706	C/T	cg18357645	chr12:58087776	OS9	0.58	9.07	0.49	2.73e-17	Celiac disease or Rheumatoid arthritis;
CESC	cis	rs597539	0.652	rs611046	chr11:68631704	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.75	8.73	0.47	2.98e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs1862618	0.756	rs13356762	chr5:56110992	G/T	cg03609598	chr5:56110824	MAP3K1	-0.48	-5.22	-0.31	3.53e-7	Initial pursuit acceleration;
CESC	cis	rs752010	0.695	rs10789407	chr1:42106538	G/T	cg06885757	chr1:42089581	HIVEP3	0.49	7.81	0.43	1.37e-13	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs6460942	0.591	rs62448726	chr7:12330881	A/G	cg06484146	chr7:12443880	VWDE	-0.66	-7.27	-0.41	4.01e-12	Coronary artery disease;
CESC	cis	rs9470366	0.883	rs9462207	chr6:36627599	T/C	cg08179530	chr6:36648295	CDKN1A	0.53	6.28	0.36	1.39e-9	QRS duration;
CESC	cis	rs9291683	0.530	rs17246501	chr4:9985710	A/C	cg02734326	chr4:10020555	SLC2A9	0.51	7.66	0.43	3.42e-13	Bone mineral density;
CESC	cis	rs9322193	0.884	rs9688699	chr6:150054816	A/G	cg04369109	chr6:150039330	LATS1	-0.47	-6.56	-0.37	2.75e-10	Lung cancer;
CESC	cis	rs897984	0.806	rs12924903	chr16:30928970	C/T	cg02466173	chr16:30829666	NA	-0.54	-9.34	-0.5	3.98e-18	Dementia with Lewy bodies;
CESC	cis	rs801193	0.591	rs4506088	chr7:66135457	G/A	cg11764359	chr7:65958608	NA	-0.73	-10.43	-0.54	1.48e-21	Aortic root size;
CESC	cis	rs6963495	0.818	rs73192105	chr7:105167945	T/C	cg02135003	chr7:105160482	PUS7	-0.46	-5.45	-0.32	1.13e-7	Bipolar disorder (body mass index interaction);
CESC	cis	rs875971	1.000	rs6958484	chr7:65599446	G/A	cg11764359	chr7:65958608	NA	-0.93	-14.62	-0.67	6.62e-36	Aortic root size;
CESC	cis	rs1799949	0.965	rs4793234	chr17:41436183	A/G	cg23758822	chr17:41437982	NA	1.03	16.1	0.7	3.99e-41	Menopause (age at onset);
CESC	cis	rs12497850	0.931	rs7627404	chr3:48819668	A/C	cg07636037	chr3:49044803	WDR6	1.02	18.44	0.75	2.06e-49	Parkinson's disease;
CESC	cis	rs12142240	0.698	rs112068407	chr1:46822291	T/C	cg10495392	chr1:46806563	NSUN4	0.58	6.32	0.36	1.09e-9	Menopause (age at onset);
CESC	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg07677032	chr17:61819896	STRADA	0.45	5.93	0.34	9.64e-9	Prudent dietary pattern;
CESC	cis	rs1707322	1.000	rs10890353	chr1:46298383	G/T	cg03146154	chr1:46216737	IPP	0.72	9.83	0.52	1.2e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs769267	0.930	rs10414830	chr19:19562332	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.47	5.87	0.34	1.28e-8	Tonsillectomy;
CESC	cis	rs11677416	1.000	rs1304037	chr2:113532236	C/T	cg27083787	chr2:113543245	IL1A	-0.45	-5.77	-0.33	2.25e-8	Response to antipsychotic treatment in schizophrenia (working memory);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24986058	chr14:100812247	WARS	-0.57	-6.24	-0.36	1.76e-9	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.830	rs10017201	chr4:98983561	G/A	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.67e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2404602	0.716	rs284895	chr15:76751225	C/G	cg26408565	chr15:76604113	ETFA	0.4	5.62	0.33	4.94e-8	Blood metabolite levels;
CESC	cis	rs9487051	0.676	rs4383852	chr6:109594475	G/A	cg01475377	chr6:109611718	NA	-0.44	-6.99	-0.39	2.19e-11	Reticulocyte fraction of red cells;
CESC	cis	rs9640161	0.789	rs34311995	chr7:150059255	T/C	cg17279839	chr7:150038598	RARRES2	0.42	5.49	0.32	9.44e-8	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs6502050	0.749	rs7406163	chr17:80086389	C/T	cg11859384	chr17:80120422	CCDC57	0.38	5.13	0.3	5.62e-7	Life satisfaction;
CESC	cis	rs4589502	0.800	rs2035150	chr15:67201794	A/C	cg12317470	chr15:67143691	NA	-0.71	-8.48	-0.46	1.65e-15	Lung cancer (smoking interaction);
CESC	cis	rs7937682	0.564	rs9633937	chr11:111372799	C/T	cg09085632	chr11:111637200	PPP2R1B	0.48	5.67	0.33	3.72e-8	Primary sclerosing cholangitis;
CESC	cis	rs597539	0.652	rs686877	chr11:68637169	G/A	cg06028808	chr11:68637592	NA	0.43	5.12	0.3	5.87e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs597539	0.652	rs11603827	chr11:68719221	C/T	cg04772025	chr11:68637568	NA	0.58	6.54	0.37	3.07e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs17376456	0.825	rs36042718	chr5:93180997	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.6	5.05	0.3	8.28e-7	Diabetic retinopathy;
CESC	cis	rs748404	0.578	rs512628	chr15:43618734	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.6	7.9	0.44	7.7e-14	Lung cancer;
CESC	cis	rs9929218	0.551	rs2274239	chr16:68725783	G/A	cg02972257	chr16:68554789	NA	-0.42	-5.26	-0.31	2.97e-7	Colorectal cancer;
CESC	cis	rs2014572	0.933	rs8109882	chr19:57755618	C/G	cg24459738	chr19:57751996	ZNF805	-0.54	-7.76	-0.43	1.84e-13	Hyperactive-impulsive symptoms;
CESC	cis	rs10751667	0.961	rs6597953	chr11:991099	G/A	cg06064525	chr11:970664	AP2A2	-0.42	-7.08	-0.4	1.27e-11	Alzheimer's disease (late onset);
CESC	cis	rs1218582	0.772	rs4845682	chr1:154877105	T/C	cg06221963	chr1:154839813	KCNN3	-0.66	-11.39	-0.57	1.03e-24	Prostate cancer;
CESC	cis	rs67311347	1.000	rs962847	chr3:40495156	A/G	cg01475735	chr3:40494733	NA	0.47	5.94	0.34	8.79e-9	Renal cell carcinoma;
CESC	cis	rs7412746	0.658	rs12410394	chr1:150860186	G/A	cg17724175	chr1:150552817	MCL1	0.39	5.95	0.34	8.56e-9	Melanoma;
CESC	cis	rs727505	0.909	rs1031958	chr7:124627309	C/T	cg23710748	chr7:124431027	NA	-0.44	-6.86	-0.39	4.95e-11	Lewy body disease;
CESC	cis	rs2075371	0.966	rs722657	chr7:133994956	T/C	cg00033643	chr7:134001901	SLC35B4	0.44	5.6	0.33	5.38e-8	Mean platelet volume;
CESC	trans	rs208520	0.526	rs1385219	chr6:66754476	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.99	19.1	0.76	9.77e-52	Exhaled nitric oxide output;
CESC	cis	rs644799	0.672	rs11021347	chr11:95653494	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.69	9.71	0.51	2.82e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs11638352	1.000	rs11631340	chr15:44286325	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	-0.53	-5.46	-0.32	1.09e-7	Lipoprotein phospholipase A2 activity in cardiovascular disease;
CESC	cis	rs10779751	1.000	rs11121704	chr1:11293959	A/G	cg08854313	chr1:11322531	MTOR	-0.78	-10.72	-0.55	1.63e-22	Body mass index;
CESC	cis	rs7116495	0.867	rs4378421	chr11:71761996	T/C	cg26138937	chr11:71823887	C11orf51	-1.33	-7.65	-0.43	3.76e-13	Severe influenza A (H1N1) infection;
CESC	cis	rs708547	0.671	rs1718863	chr4:57887586	G/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.48	6.68	0.38	1.38e-10	Response to bleomycin (chromatid breaks);
CESC	cis	rs611744	0.647	rs13280487	chr8:109270263	G/C	cg21045802	chr8:109455806	TTC35	0.52	6.45	0.37	5.39e-10	Dupuytren's disease;
CESC	cis	rs2040771	0.770	rs9605962	chr22:19233615	C/T	cg02655711	chr22:19163373	SLC25A1	0.41	6.03	0.35	5.51e-9	Metabolite levels (small molecules and protein measures);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg23262020	chr14:93651423	C14orf109;MOAP1	-0.48	-6.02	-0.35	5.91e-9	Ulcerative colitis;
CESC	cis	rs854765	0.718	rs7224815	chr17:17845800	A/T	cg09796270	chr17:17721594	SREBF1	0.43	5.81	0.34	1.75e-8	Total body bone mineral density;
CESC	cis	rs2243480	1.000	rs313813	chr7:65503500	C/T	cg18252515	chr7:66147081	NA	-1.25	-12.25	-0.6	1.19e-27	Diabetic kidney disease;
CESC	cis	rs875971	0.964	rs697969	chr7:65558478	C/A	cg18876405	chr7:65276391	NA	-0.55	-7.28	-0.41	3.91e-12	Aortic root size;
CESC	cis	rs7116495	0.609	rs4945392	chr11:71694645	C/T	cg10381502	chr11:71823885	C11orf51	-1.19	-7.81	-0.43	1.32e-13	Severe influenza A (H1N1) infection;
CESC	cis	rs644799	0.965	rs534488	chr11:95562327	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	14.27	0.66	1.19e-34	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs172166	0.637	rs1225595	chr6:28151340	A/T	cg12963246	chr6:28129442	ZNF389	0.41	6.05	0.35	5e-9	Cardiac Troponin-T levels;
CESC	cis	rs9811920	0.581	rs793468	chr3:99538346	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.61	-9.88	-0.52	8.43e-20	Axial length;
CESC	cis	rs77216612	0.835	rs56692845	chr12:12887811	C/T	cg24098013	chr12:12878779	APOLD1	0.61	7.57	0.42	6.09e-13	Lymphocyte counts;
CESC	cis	rs10504229	0.906	rs17805439	chr8:58172400	T/C	cg14926445	chr8:58193284	C8orf71	-0.51	-5.47	-0.32	1.03e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs698813	0.789	rs2592195	chr2:44607707	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	5.82	0.34	1.73e-8	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
CESC	cis	rs2658782	1.000	rs2605583	chr11:93164957	T/A	cg15737290	chr11:93063684	CCDC67	0.55	7.02	0.4	1.86e-11	Pulmonary function decline;
CESC	cis	rs6752107	0.782	rs12692254	chr2:234161211	A/T	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.38	5.91	0.34	1.04e-8	Crohn's disease;Inflammatory bowel disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09460159	chr17:30771470	PSMD11	0.65	7.91	0.44	6.86e-14	Gut microbiome composition (summer);
CESC	cis	rs514406	0.861	rs7524476	chr1:53240212	C/T	cg08736216	chr1:53307985	ZYG11A	0.43	7.25	0.41	4.64e-12	Monocyte count;
CESC	cis	rs11252926	0.523	rs816596	chr10:548004	C/T	cg03684893	chr10:554711	DIP2C	-0.45	-6.91	-0.39	3.7e-11	Psychosis in Alzheimer's disease;
CESC	cis	rs34779708	0.897	rs16935880	chr10:35415468	C/G	cg04310649	chr10:35416472	CREM	-0.51	-6.16	-0.35	2.62e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs875971	0.964	rs6945032	chr7:65922486	C/T	cg12463550	chr7:65579703	CRCP	0.56	7.09	0.4	1.2e-11	Aortic root size;
CESC	cis	rs7829975	0.714	rs4841040	chr8:8654527	T/C	cg06636001	chr8:8085503	FLJ10661	0.49	6.38	0.36	8.08e-10	Mood instability;
CESC	cis	rs10504229	0.953	rs114806125	chr8:58182416	C/T	cg24829409	chr8:58192753	C8orf71	-0.63	-8.73	-0.47	3e-16	Developmental language disorder (linguistic errors);
CESC	cis	rs7267979	0.966	rs2261790	chr20:25262789	T/C	cg08601574	chr20:25228251	PYGB	0.39	5.65	0.33	4.08e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs1218582	0.772	rs4845693	chr1:154911257	A/G	cg16680214	chr1:154839983	KCNN3	0.49	7.52	0.42	8.64e-13	Prostate cancer;
CESC	cis	rs6701037	1.000	rs34493921	chr1:175122759	A/G	cg00321850	chr1:175162397	KIAA0040	-0.42	-5.86	-0.34	1.37e-8	Alcohol dependence;
CESC	cis	rs1881797	0.932	rs41305741	chr1:247689543	A/G	cg11166453	chr1:247681781	NA	0.44	5.8	0.34	1.87e-8	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs4450798	0.793	rs62234789	chr3:13750425	G/A	cg23332027	chr3:13681764	NA	0.41	5.5	0.32	9.05e-8	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs875971	0.965	rs697968	chr7:65535033	G/A	cg12463550	chr7:65579703	CRCP	-0.6	-7.4	-0.41	1.78e-12	Aortic root size;
CESC	trans	rs4843747	0.749	rs12102841	chr16:88072574	C/G	cg26811252	chr16:29126840	RRN3P2	-0.68	-10.07	-0.53	2.03e-20	Menopause (age at onset);
CESC	cis	rs2549003	1.000	rs9282761	chr5:131822224	T/C	cg21138405	chr5:131827807	IRF1	0.54	9.32	0.5	4.74e-18	Asthma (sex interaction);
CESC	trans	rs1814175	0.745	rs7483456	chr11:49774613	C/T	cg15704280	chr7:45808275	SEPT13	-1.02	-19.96	-0.77	1.02e-54	Height;
CESC	cis	rs853679	0.517	rs9380057	chr6:28104634	G/T	cg23281280	chr6:28129359	ZNF389	0.59	8.16	0.45	1.34e-14	Depression;
CESC	cis	rs9309473	0.500	rs2421668	chr2:73885096	G/A	cg20560298	chr2:73613845	ALMS1	0.51	7.18	0.4	7.15e-12	Metabolite levels;
CESC	cis	rs10779751	0.734	rs12569242	chr1:11127511	A/C	cg08854313	chr1:11322531	MTOR	0.76	10.11	0.53	1.61e-20	Body mass index;
CESC	cis	rs9322193	0.923	rs62441284	chr6:150072678	C/A	cg13206674	chr6:150067644	NUP43	0.47	6.67	0.38	1.46e-10	Lung cancer;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg12108650	chr18:43678457	ATP5A1	0.49	6.35	0.36	9.34e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs1538970	1.000	rs4660852	chr1:45848931	A/C	cg05343316	chr1:45956843	TESK2	-0.83	-11.98	-0.59	1.02e-26	Platelet count;
CESC	cis	rs7264396	0.635	rs6060710	chr20:34536055	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.6	7.36	0.41	2.35e-12	Total cholesterol levels;
CESC	cis	rs11122272	0.735	rs2491405	chr1:231513431	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.57	-7.82	-0.43	1.29e-13	Hemoglobin concentration;
CESC	cis	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg02951883	chr7:2050386	MAD1L1	-0.41	-5.37	-0.31	1.69e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs1953600	0.540	rs2784773	chr10:81919800	A/G	cg00277334	chr10:82204260	NA	-0.54	-7.49	-0.42	1.06e-12	Sarcoidosis;
CESC	cis	rs9291683	0.566	rs13144709	chr4:10044182	C/T	cg02734326	chr4:10020555	SLC2A9	0.45	6.19	0.36	2.29e-9	Bone mineral density;
CESC	cis	rs1018836	0.923	rs12680211	chr8:91633434	C/T	cg16814680	chr8:91681699	NA	-0.71	-10.18	-0.53	9e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs9322193	0.962	rs4869966	chr6:150084850	A/G	cg13206674	chr6:150067644	NUP43	0.43	5.98	0.34	7.33e-9	Lung cancer;
CESC	cis	rs9682041	0.932	rs9841852	chr3:170067049	C/G	cg11886554	chr3:170076028	SKIL	0.81	7.63	0.42	4.17e-13	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CESC	cis	rs2735413	0.881	rs11150036	chr16:78075687	C/G	cg04733911	chr16:78082701	NA	-0.53	-9.01	-0.48	4.08e-17	Systolic blood pressure (alcohol consumption interaction);
CESC	cis	rs7208859	0.623	rs9911997	chr17:29124648	A/G	cg14008862	chr17:28927542	LRRC37B2	0.65	5.14	0.3	5.34e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs2197308	0.765	rs11182900	chr12:37934009	C/T	cg26384229	chr12:38710491	ALG10B	0.75	11.19	0.57	4.49e-24	Morning vs. evening chronotype;
CESC	cis	rs9457247	1.000	rs413232	chr6:167400972	G/A	cg25258033	chr6:167368657	RNASET2	0.4	5.98	0.34	7.15e-9	Crohn's disease;
CESC	cis	rs7193541	0.585	rs7978	chr16:74486189	T/C	cg01733217	chr16:74700730	RFWD3	-0.91	-14.3	-0.66	9.39e-35	Multiple myeloma;
CESC	cis	rs2191566	0.540	rs436739	chr19:44495553	A/G	cg20607764	chr19:44506953	ZNF230	0.46	5.74	0.33	2.58e-8	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs780096	0.527	rs59644396	chr2:27646083	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.32	-5.99	-0.35	6.8e-9	Total body bone mineral density;
CESC	cis	rs2228479	0.618	rs72477006	chr16:89950299	G/C	cg00800038	chr16:89945340	TCF25	-0.86	-7.47	-0.42	1.17e-12	Skin colour saturation;
CESC	cis	rs7552404	1.000	rs1498315	chr1:76159225	G/A	cg03433033	chr1:76189801	ACADM	0.68	8.14	0.45	1.54e-14	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs7666738	0.962	rs2865986	chr4:99067907	A/G	cg17366294	chr4:99064904	C4orf37	0.54	7.1	0.4	1.11e-11	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7904368	0.806	rs7087360	chr10:16872337	C/A	cg23933602	chr10:16859644	RSU1	0.6	5.74	0.33	2.58e-8	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
CESC	cis	rs7917772	0.502	rs2296584	chr10:104244323	T/A	ch.10.2196322F	chr10:104248062	ACTR1A	0.43	5.25	0.31	3.06e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs11122272	0.735	rs2250734	chr1:231485958	G/A	cg06096015	chr1:231504339	EGLN1	0.4	5.84	0.34	1.5e-8	Hemoglobin concentration;
CESC	cis	rs4969178	0.965	rs4969186	chr17:76398404	C/G	cg20026190	chr17:76395443	PGS1	0.48	7.72	0.43	2.33e-13	HDL cholesterol levels;
CESC	cis	rs2576037	0.526	rs10853544	chr18:44474194	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.44	7.38	0.41	2.11e-12	Personality dimensions;
CESC	cis	rs8099014	0.814	rs9966765	chr18:56116790	C/G	cg19312305	chr18:56117016	MIR122	-0.28	-5.45	-0.32	1.15e-7	Platelet count;
CESC	cis	rs7605378	0.528	rs812760	chr2:200724372	C/T	cg23649088	chr2:200775458	C2orf69	0.72	9.05	0.49	3.22e-17	Osteoporosis;
CESC	cis	rs5769765	0.954	rs6009900	chr22:50236610	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.47	-5.31	-0.31	2.28e-7	Schizophrenia;
CESC	cis	rs634534	0.622	rs1308733	chr11:65720841	T/C	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.62	-8.22	-0.45	9.27e-15	Sum eosinophil basophil counts;Eosinophil counts;
CESC	trans	rs7618501	0.573	rs7634917	chr3:50049299	T/G	cg21659725	chr3:3221576	CRBN	-0.52	-7.33	-0.41	2.83e-12	Intelligence (multi-trait analysis);
CESC	cis	rs72781680	1.000	rs72781643	chr2:24208746	G/A	cg08917208	chr2:24149416	ATAD2B	0.92	8.23	0.45	8.65e-15	Lymphocyte counts;
CESC	cis	rs7193541	0.662	rs8052367	chr16:74658867	G/A	cg01733217	chr16:74700730	RFWD3	1.08	21.41	0.8	1.02e-59	Multiple myeloma;
CESC	cis	rs1044826	0.642	rs295481	chr3:139228811	C/T	cg00490450	chr3:139108681	COPB2	0.45	5.53	0.32	7.84e-8	Obesity-related traits;
CESC	cis	rs977987	0.836	rs7200053	chr16:75474618	C/T	cg03315344	chr16:75512273	CHST6	0.43	6.11	0.35	3.46e-9	Dupuytren's disease;
CESC	cis	rs9916302	0.904	rs10491128	chr17:37551988	G/A	cg00129232	chr17:37814104	STARD3	0.53	6.59	0.38	2.35e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs736408	0.509	rs3774349	chr3:52722335	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	7.18	0.4	7.14e-12	Bipolar disorder;
CESC	cis	rs1348850	0.519	rs4144275	chr2:178523368	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.57	7.04	0.4	1.67e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs71277158	0.688	rs58417766	chr3:169833247	A/G	cg04067573	chr3:169899625	PHC3	0.71	7.06	0.4	1.45e-11	Prostate cancer;
CESC	cis	rs4689592	0.619	rs3796908	chr4:7061378	G/A	cg26116260	chr4:7069785	GRPEL1	0.92	11.99	0.59	9.37e-27	Monocyte percentage of white cells;
CESC	cis	rs1348850	0.651	rs1901826	chr2:178225266	G/A	cg23306229	chr2:178417860	TTC30B	0.54	6.85	0.39	5.2e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	trans	rs12960505	0.506	rs6508235	chr18:51053941	A/G	cg22196977	chr2:128263013	IWS1	-0.44	-6.11	-0.35	3.56e-9	Intelligence (multi-trait analysis);
CESC	cis	rs6667605	0.527	rs4422947	chr1:2539590	C/T	cg20673091	chr1:2541236	MMEL1	0.46	7.9	0.44	7.7e-14	Inflammatory bowel disease;Ulcerative colitis;
CESC	cis	rs13118159	0.742	rs34947293	chr4:1335034	T/C	cg20887711	chr4:1340912	KIAA1530	0.55	7.84	0.43	1.08e-13	Longevity;
CESC	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.45	-6.31	-0.36	1.19e-9	Longevity;Endometriosis;
CESC	cis	rs2842992	0.724	rs4709368	chr6:160204127	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	-0.76	-10.85	-0.55	6.03e-23	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs7107174	0.688	rs881361	chr11:78128047	C/G	cg02023728	chr11:77925099	USP35	0.43	5.48	0.32	1.01e-7	Testicular germ cell tumor;
CESC	cis	rs9487051	0.807	rs7748641	chr6:109592381	C/T	cg12927641	chr6:109611667	NA	-0.41	-6.43	-0.37	6e-10	Reticulocyte fraction of red cells;
CESC	cis	rs3008870	0.959	rs1886686	chr1:67390468	C/G	cg02640540	chr1:67518911	SLC35D1	0.5	5.3	0.31	2.47e-7	Lymphocyte percentage of white cells;
CESC	cis	rs11122272	0.735	rs2790884	chr1:231531932	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.56	-7.66	-0.43	3.45e-13	Hemoglobin concentration;
CESC	cis	rs6460942	0.687	rs74753576	chr7:12463926	G/A	cg16278512	chr7:12443529	VWDE	-0.45	-5.13	-0.3	5.62e-7	Coronary artery disease;
CESC	cis	rs75477785	0.590	rs12354000	chr1:210107020	G/A	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.94	6.89	0.39	4.04e-11	Cleft lip with or without cleft palate;
CESC	cis	rs7927771	0.929	rs66749409	chr11:47568074	C/T	cg20135002	chr11:47629003	NA	-0.39	-5.03	-0.3	9.04e-7	Subjective well-being;
CESC	cis	rs2281558	0.917	rs3787080	chr20:25232604	C/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.57	7.38	0.41	2.02e-12	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;
CESC	cis	rs8002861	0.905	rs12429722	chr13:44412466	T/A	cg19180546	chr13:44453867	C13orf31;CCDC122	-0.41	-5.18	-0.3	4.39e-7	Leprosy;
CESC	trans	rs11098499	0.863	rs3775841	chr4:120425777	A/C	cg25214090	chr10:38739885	LOC399744	0.73	9.99	0.52	3.68e-20	Corneal astigmatism;
CESC	cis	rs9905704	0.624	rs34718875	chr17:57072461	G/A	cg12560992	chr17:57184187	TRIM37	0.65	8.24	0.45	7.83e-15	Testicular germ cell tumor;
CESC	cis	rs9581857	0.556	rs9581861	chr13:28039991	C/T	cg01674679	chr13:27998804	GTF3A	-0.55	-5.89	-0.34	1.17e-8	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
CESC	cis	rs4332037	0.901	rs11767040	chr7:1945468	C/T	cg23422044	chr7:1970798	MAD1L1	-0.53	-5.37	-0.31	1.68e-7	Bipolar disorder;
CESC	cis	rs1218582	0.745	rs1580943	chr1:154865125	G/A	cg06221963	chr1:154839813	KCNN3	-0.66	-11.44	-0.58	6.67e-25	Prostate cancer;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg17424859	chr6:71319002	NA	-0.48	-6.64	-0.38	1.81e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs6430585	0.640	rs3816155	chr2:136552526	A/C	cg07169764	chr2:136633963	MCM6	-1.2	-17.51	-0.73	3.91e-46	Corneal structure;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07970400	chr15:40650285	DISP2	0.6	7.15	0.4	8.56e-12	Gut microbiome composition (summer);
CESC	cis	rs7116495	0.737	rs7101553	chr11:71753903	C/T	cg26138937	chr11:71823887	C11orf51	-1.36	-8.5	-0.46	1.41e-15	Severe influenza A (H1N1) infection;
CESC	cis	rs2415984	0.583	rs2642090	chr14:46968788	C/T	cg14871534	chr14:47121158	RPL10L	0.34	5.21	0.31	3.73e-7	Number of children ever born;
CESC	cis	rs344364	0.636	rs344363	chr16:1972548	C/T	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.56	-5.93	-0.34	9.56e-9	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs2455799	0.613	rs6789076	chr3:15807725	A/T	cg16303742	chr3:15540471	COLQ	0.37	5.94	0.34	8.86e-9	Mean platelet volume;
CESC	trans	rs208520	0.690	rs1776365	chr6:66834474	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-12.94	-0.62	5.07e-30	Exhaled nitric oxide output;
CESC	cis	rs703842	1.000	rs1875124	chr12:58196802	A/G	cg00677455	chr12:58241039	CTDSP2	0.52	6.55	0.37	3.04e-10	Multiple sclerosis;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03399598	chr4:174091002	GALNT7	0.51	6.91	0.39	3.54e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs7246657	0.943	rs1035479	chr19:37893300	G/T	cg23950597	chr19:37808831	NA	0.54	5.91	0.34	1.03e-8	Coronary artery calcification;
CESC	cis	rs4268898	0.527	rs72789910	chr2:24388609	T/G	cg06627628	chr2:24431161	ITSN2	-0.99	-9.69	-0.51	3.3e-19	Asthma;
CESC	cis	rs1062177	0.950	rs59580263	chr5:151269577	T/A	cg12924095	chr5:151150029	G3BP1	0.43	5.32	0.31	2.2e-7	Preschool internalizing problems;
CESC	cis	rs2425143	1.000	rs2425142	chr20:34350346	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.72	6.65	0.38	1.62e-10	Blood protein levels;
CESC	cis	rs2576037	0.899	rs2060417	chr18:44576486	C/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.38	-5.98	-0.34	7.37e-9	Personality dimensions;
CESC	cis	rs9858542	1.000	rs11709525	chr3:49690496	C/T	cg03060546	chr3:49711283	APEH	-0.58	-6.84	-0.39	5.52e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs7188697	0.922	rs173475	chr16:58580530	T/C	cg21335942	chr16:58549945	SETD6	0.46	5.38	0.31	1.61e-7	QT interval;
CESC	cis	rs67311347	0.911	rs58282210	chr3:40417943	C/T	cg24209194	chr3:40518798	ZNF619	0.41	5.08	0.3	7.04e-7	Renal cell carcinoma;
CESC	cis	rs7927771	0.832	rs11601603	chr11:47401171	A/C	cg20307385	chr11:47447363	PSMC3	-0.6	-7.31	-0.41	3.23e-12	Subjective well-being;
CESC	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg04025307	chr7:1156635	C7orf50	0.53	8.9	0.48	9.07e-17	Longevity;Endometriosis;
CESC	cis	rs668210	0.793	rs645571	chr11:65752852	A/T	cg02202077	chr11:65769826	EIF1AD;BANF1	-0.61	-5.63	-0.33	4.58e-8	Cerebrospinal fluid biomarker levels;
CESC	cis	rs9527	0.615	rs10883810	chr10:104727224	A/C	cg04362960	chr10:104952993	NT5C2	0.42	5.28	0.31	2.7e-7	Arsenic metabolism;
CESC	cis	rs7089973	0.624	rs11196940	chr10:116593791	T/G	cg03647239	chr10:116582469	FAM160B1	0.44	5.37	0.31	1.71e-7	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs2033711	0.870	rs7408188	chr19:58939389	T/G	cg11952622	chr19:58962976	ZNF324B	0.46	6.14	0.35	3.08e-9	Uric acid clearance;
CESC	cis	rs10504229	1.000	rs67913746	chr8:58177825	A/G	cg05313129	chr8:58192883	C8orf71	-0.55	-6.37	-0.36	8.42e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs644799	0.582	rs473157	chr11:95596874	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.46	5.95	0.34	8.5e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs9443645	0.901	rs9343860	chr6:79739010	G/A	cg05283184	chr6:79620031	NA	-0.43	-6.62	-0.38	1.97e-10	Intelligence (multi-trait analysis);
CESC	cis	rs796364	0.806	rs6743396	chr2:200860138	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	0.83	7.5	0.42	9.65e-13	Schizophrenia;
CESC	cis	rs2576037	0.796	rs2571032	chr18:44578250	T/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.33	-5.13	-0.3	5.49e-7	Personality dimensions;
CESC	cis	rs208520	0.802	rs208516	chr6:66946119	T/C	cg07460842	chr6:66804631	NA	-0.9	-10.84	-0.55	6.76e-23	Exhaled nitric oxide output;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg19229622	chr11:47291485	MADD	-0.43	-6.03	-0.35	5.41e-9	Gambling;
CESC	cis	rs77106637	0.929	rs77464186	chr11:72460398	A/C	cg03713592	chr11:72463424	ARAP1	1.3	11.1	0.56	9.07e-24	Type 2 diabetes;
CESC	cis	rs910316	1.000	rs10140851	chr14:75512612	G/A	cg11812906	chr14:75593930	NEK9	0.88	14.5	0.67	1.8e-35	Height;
CESC	cis	rs4919694	1.000	rs77827514	chr10:104822009	C/T	cg04362960	chr10:104952993	NT5C2	0.79	7.08	0.4	1.27e-11	Arsenic metabolism;
CESC	cis	rs11123610	0.520	rs35752035	chr2:3721353	G/C	cg10645314	chr2:3704589	ALLC	-0.46	-5.07	-0.3	7.62e-7	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CESC	cis	rs523522	0.962	rs670568	chr12:121021206	C/T	cg12219531	chr12:120966889	COQ5	0.76	10.07	0.53	2.15e-20	High light scatter reticulocyte count;
CESC	cis	rs10504229	1.000	rs67243305	chr8:58174958	G/A	cg24829409	chr8:58192753	C8orf71	-0.76	-9.95	-0.52	5.06e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs4665809	1.000	rs6739061	chr2:26256147	C/T	cg04944784	chr2:26401820	FAM59B	-0.64	-7.32	-0.41	3.04e-12	Gut microbiome composition (summer);
CESC	cis	rs4319547	0.661	rs7398014	chr12:122943980	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.61	-7.0	-0.4	2.06e-11	Body mass index;
CESC	cis	rs11723261	0.582	rs11733927	chr4:166828	A/G	cg12746427	chr4:53362	ZNF718;ZNF595	0.44	5.57	0.32	6.39e-8	Immune response to smallpox vaccine (IL-6);
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg01735503	chr16:69966815	MIR140;WWP2	0.46	7.06	0.4	1.42e-11	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs2549003	1.000	rs17848418	chr5:131821188	C/T	cg21138405	chr5:131827807	IRF1	0.54	9.32	0.5	4.74e-18	Asthma (sex interaction);
CESC	cis	rs921968	0.541	rs490483	chr2:219429052	A/T	cg02176678	chr2:219576539	TTLL4	0.5	8.85	0.48	1.31e-16	Mean corpuscular hemoglobin concentration;
CESC	cis	rs7818688	1.000	rs10097930	chr8:96025735	A/G	cg16049864	chr8:95962084	TP53INP1	0.58	5.69	0.33	3.29e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs12579753	0.692	rs11115064	chr12:82278683	G/A	cg23701643	chr12:82153290	PPFIA2	-0.36	-5.31	-0.31	2.36e-7	Resting heart rate;
CESC	cis	rs832540	0.966	rs33321	chr5:56206073	G/T	cg12311346	chr5:56204834	C5orf35	-0.45	-5.61	-0.33	5.2e-8	Coronary artery disease;
CESC	cis	rs317689	0.718	rs160827	chr12:69770147	G/A	cg20891283	chr12:69753455	YEATS4	0.64	7.46	0.42	1.22e-12	Response to diuretic therapy;
CESC	cis	rs910316	0.763	rs175435	chr14:75612025	A/G	cg16144293	chr14:75469539	EIF2B2	-0.4	-5.25	-0.31	3.19e-7	Height;
CESC	trans	rs7615952	0.611	rs35321002	chr3:125612065	G/C	cg07211511	chr3:129823064	LOC729375	-0.87	-9.05	-0.49	3.1e-17	Blood pressure (smoking interaction);
CESC	cis	rs727505	1.000	rs7791430	chr7:124429953	G/T	cg23710748	chr7:124431027	NA	-0.47	-7.62	-0.42	4.48e-13	Lewy body disease;
CESC	trans	rs7945705	0.905	rs2568054	chr11:8876029	A/G	cg10637292	chr12:52960529	KRT74	0.36	6.2	0.36	2.1e-9	Hemoglobin concentration;
CESC	cis	rs780096	0.526	rs12476704	chr2:27613031	C/A	cg21248554	chr2:27665150	KRTCAP3	-0.31	-6.3	-0.36	1.26e-9	Total body bone mineral density;
CESC	cis	rs7429990	0.965	rs35012836	chr3:47711490	G/A	cg11946769	chr3:48343235	NME6	0.53	5.32	0.31	2.22e-7	Educational attainment (years of education);
CESC	cis	rs10493773	0.532	rs1889919	chr1:86180034	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.42	-6.38	-0.36	7.8e-10	Urate levels in overweight individuals;
CESC	trans	rs1161397	1.000	rs280302	chr6:50622506	C/T	cg15738089	chr13:44542704	NA	-0.67	-6.01	-0.35	6.17e-9	Overweight status;
CESC	cis	rs9814567	0.929	rs1863911	chr3:134205231	C/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.45	-6.22	-0.36	1.92e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs965469	0.779	rs6139092	chr20:3334651	T/C	cg17110299	chr20:3385021	C20orf194	0.43	5.6	0.33	5.48e-8	IFN-related cytopenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01999086	chr20:52824411	PFDN4	0.55	6.64	0.38	1.8e-10	Gut microbiome composition (summer);
CESC	cis	rs4654899	0.865	rs12130664	chr1:21332812	G/T	cg05370193	chr1:21551575	ECE1	0.43	6.55	0.37	3.03e-10	Superior frontal gyrus grey matter volume;
CESC	cis	rs6662572	0.723	rs72677543	chr1:46565329	A/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.46	5.15	0.3	5.06e-7	Blood protein levels;
CESC	cis	rs6775745	0.603	rs6792706	chr3:131783593	G/A	cg12213930	chr3:131751605	CPNE4	0.48	5.46	0.32	1.08e-7	Neutrophil count;
CESC	cis	rs7666738	0.830	rs79075162	chr4:98960674	A/T	cg03676636	chr4:99064102	C4orf37	0.33	5.14	0.3	5.39e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6546550	0.743	rs6731941	chr2:70018496	A/G	cg02498382	chr2:70120550	SNRNP27	-0.36	-6.14	-0.35	3e-9	Prevalent atrial fibrillation;
CESC	cis	rs12477438	0.765	rs1115757	chr2:99660146	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.62	-8.67	-0.47	4.43e-16	Chronic sinus infection;
CESC	cis	rs6952808	0.823	rs58222895	chr7:1885064	G/A	cg13880726	chr7:1868755	MAD1L1	0.54	7.25	0.41	4.45e-12	Bipolar disorder and schizophrenia;
CESC	cis	rs7927592	0.763	rs3740628	chr11:68381415	A/G	cg20283391	chr11:68216788	NA	-0.43	-5.33	-0.31	2.14e-7	Total body bone mineral density;
CESC	cis	rs9354308	0.840	rs17508021	chr6:66569748	G/A	cg07460842	chr6:66804631	NA	0.68	7.68	0.43	3.08e-13	Metabolite levels;
CESC	cis	rs7826238	0.720	rs12546760	chr8:8374836	A/G	cg06636001	chr8:8085503	FLJ10661	-0.41	-5.04	-0.3	8.47e-7	Systolic blood pressure;
CESC	cis	rs9815354	0.556	rs73073276	chr3:42025354	G/A	cg03022575	chr3:42003672	ULK4	0.75	6.64	0.38	1.72e-10	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs763121	0.925	rs17032	chr22:39130843	C/G	cg14440974	chr22:39074834	NA	-0.37	-5.3	-0.31	2.43e-7	Menopause (age at onset);
CESC	cis	rs7666738	0.830	rs17484966	chr4:99014432	T/C	cg18180107	chr4:99064573	C4orf37	0.4	5.3	0.31	2.48e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6831352	0.918	rs29001224	chr4:100047373	G/A	cg12011299	chr4:100065546	ADH4	-0.59	-6.52	-0.37	3.62e-10	Alcohol dependence;
CESC	trans	rs875971	0.508	rs10242423	chr7:66059175	A/G	cg26939375	chr7:64535504	NA	-0.53	-7.37	-0.41	2.22e-12	Aortic root size;
CESC	cis	rs2073499	1.000	rs10510755	chr3:50281168	C/T	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.76	6.0	0.35	6.41e-9	Schizophrenia;
CESC	cis	rs9831754	0.865	rs9842838	chr3:78387904	A/C	cg06138941	chr3:78371609	NA	-0.65	-7.71	-0.43	2.58e-13	Calcium levels;
CESC	trans	rs3942852	0.806	rs11039515	chr11:48119474	A/G	cg03929089	chr4:120376271	NA	0.57	6.45	0.37	5.27e-10	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs1862618	0.525	rs832403	chr5:56265992	G/T	cg24531977	chr5:56204891	C5orf35	0.91	11.41	0.57	8.39e-25	Initial pursuit acceleration;
CESC	trans	rs7246657	0.943	rs6508732	chr19:38000468	C/T	cg24637308	chr11:6592297	DNHD1	0.5	6.03	0.35	5.61e-9	Coronary artery calcification;
CESC	trans	rs1728785	0.892	rs1617749	chr16:68580890	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.64	7.46	0.42	1.26e-12	Ulcerative colitis;
CESC	cis	rs11711311	0.955	rs1048892	chr3:113464859	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.74	10.43	0.54	1.5e-21	IgG glycosylation;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08805662	chr2:70369329	NA	0.6	7.25	0.41	4.63e-12	Gut microbiome composition (summer);
CESC	cis	rs10887741	0.646	rs4244979	chr10:89425507	A/C	cg13926569	chr10:89418898	PAPSS2	0.49	7.8	0.43	1.42e-13	Exercise (leisure time);
CESC	cis	rs2304069	0.507	rs7728264	chr5:149394954	C/G	cg12661370	chr5:149340060	SLC26A2	0.43	5.67	0.33	3.75e-8	HIV-1 control;
CESC	trans	rs57221529	0.766	rs72703026	chr5:572383	G/A	cg25482853	chr8:67687455	SGK3	1.12	10.77	0.55	1.11e-22	Lung disease severity in cystic fibrosis;
CESC	cis	rs2243480	1.000	rs1723269	chr7:65472786	C/G	cg13147721	chr7:65941812	NA	-0.91	-8.73	-0.47	2.87e-16	Diabetic kidney disease;
CESC	cis	rs75804782	0.521	rs72994970	chr2:239426992	G/A	cg18131467	chr2:239335373	ASB1	-0.7	-5.37	-0.31	1.75e-7	Morning vs. evening chronotype;Chronotype;
CESC	trans	rs11574514	1.000	rs8052287	chr16:67865073	C/T	cg08619102	chr4:3765047	NA	-0.71	-6.16	-0.35	2.73e-9	Crohn's disease;
CESC	cis	rs660899	0.857	rs56009633	chr1:44231481	T/C	cg19743044	chr1:44115203	KDM4A	0.42	5.17	0.3	4.68e-7	Hypertension risk in short sleep duration;
CESC	cis	rs74781061	0.929	rs79600165	chr15:74940991	G/A	cg17294928	chr15:75287854	SCAMP5	-0.48	-5.11	-0.3	6.14e-7	Endometriosis;
CESC	cis	rs4665809	0.941	rs11126336	chr2:26245931	C/T	cg22920501	chr2:26401640	FAM59B	-0.66	-7.67	-0.43	3.32e-13	Gut microbiome composition (summer);
CESC	trans	rs1116547	0.600	rs2416281	chr5:112849823	C/T	cg10115368	chr14:100435663	NA	0.52	6.13	0.35	3.21e-9	Cerebral amyloid angiopathy;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg14443077	chr11:68606701	CPT1A	-0.47	-6.02	-0.35	5.81e-9	Ulcerative colitis;
CESC	cis	rs1256061	0.654	rs1256031	chr14:64746179	C/T	cg21174375	chr14:64681225	SYNE2	0.39	5.08	0.3	7.05e-7	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs8005677	1.000	rs1956880	chr14:23394007	A/G	cg01529538	chr14:23388837	RBM23	0.5	6.7	0.38	1.26e-10	Cognitive ability (multi-trait analysis);
CESC	cis	rs10479542	0.766	rs7733389	chr5:178974997	C/T	cg21226059	chr5:178986404	RUFY1	0.4	5.82	0.34	1.65e-8	Lung cancer;
CESC	cis	rs10504229	0.906	rs7842855	chr8:58167718	G/C	cg02725872	chr8:58115012	NA	-0.34	-5.32	-0.31	2.18e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs9354352	0.935	rs9345749	chr6:66699892	G/T	cg07460842	chr6:66804631	NA	-0.43	-5.31	-0.31	2.34e-7	Initial pursuit acceleration in psychotic disorders;
CESC	cis	rs3540	0.920	rs7182658	chr15:91019248	A/T	cg22089800	chr15:90895588	ZNF774	0.44	5.5	0.32	8.77e-8	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs8114671	0.527	rs3736802	chr20:33604042	T/C	cg06115741	chr20:33292138	TP53INP2	-0.44	-5.3	-0.31	2.41e-7	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08109855	chr7:6144399	USP42	0.61	7.39	0.41	1.91e-12	Gut microbiome composition (summer);
CESC	cis	rs72634258	0.842	rs7545745	chr1:8165667	T/A	cg00042356	chr1:8021962	PARK7	-0.46	-5.03	-0.3	8.94e-7	Inflammatory bowel disease;
CESC	cis	rs17253792	0.822	rs13379340	chr14:56050346	C/G	cg01858014	chr14:56050164	KTN1	-0.92	-7.38	-0.41	2.06e-12	Putamen volume;
CESC	cis	rs854765	0.547	rs9894138	chr17:17964345	G/A	cg16928487	chr17:17741425	SREBF1	0.55	9.02	0.48	3.96e-17	Total body bone mineral density;
CESC	cis	rs4665809	0.556	rs4665322	chr2:26434605	C/G	cg27170947	chr2:26402098	FAM59B	-0.89	-10.78	-0.55	1.04e-22	Gut microbiome composition (summer);
CESC	cis	rs4132509	0.744	rs12124113	chr1:243904366	A/G	cg21452805	chr1:244014465	NA	0.61	7.29	0.41	3.56e-12	RR interval (heart rate);
CESC	cis	rs863345	0.564	rs11264988	chr1:158466912	A/G	cg12129480	chr1:158549410	OR10X1	-0.33	-6.46	-0.37	4.99e-10	Pneumococcal bacteremia;
CESC	cis	rs6121246	0.559	rs6119652	chr20:30259445	C/G	cg13852791	chr20:30311386	BCL2L1	0.81	10.53	0.54	6.68e-22	Mean corpuscular hemoglobin;
CESC	trans	rs875971	0.660	rs3764903	chr7:66098482	G/A	cg26939375	chr7:64535504	NA	-0.61	-8.26	-0.45	6.95e-15	Aortic root size;
CESC	cis	rs9487051	0.652	rs6568559	chr6:109592751	C/T	cg01475377	chr6:109611718	NA	-0.44	-6.99	-0.39	2.19e-11	Reticulocyte fraction of red cells;
CESC	cis	rs9611565	0.569	rs188057	chr22:41822305	T/G	cg03806693	chr22:41940476	POLR3H	1.2	14.5	0.67	1.86e-35	Vitiligo;
CESC	cis	rs708547	0.581	rs13121027	chr4:57813369	C/T	cg25525207	chr4:57843836	C4orf14;POLR2B	0.45	5.46	0.32	1.07e-7	Response to bleomycin (chromatid breaks);
CESC	cis	rs12681366	0.762	rs10109060	chr8:95377368	G/A	cg13257157	chr8:95487014	RAD54B	0.38	5.2	0.3	4.01e-7	Nonsyndromic cleft lip with cleft palate;
CESC	cis	rs62432291	0.681	rs439126	chr6:159656632	T/C	cg14500486	chr6:159655392	FNDC1	-0.62	-6.36	-0.36	8.94e-10	Joint mobility (Beighton score);
CESC	cis	rs1707322	0.721	rs4609469	chr1:46117185	C/T	cg06784218	chr1:46089804	CCDC17	0.43	7.48	0.42	1.07e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7772486	0.790	rs6924159	chr6:146267873	A/G	cg23711669	chr6:146136114	FBXO30	-0.94	-13.66	-0.64	1.66e-32	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs10504229	0.679	rs11783965	chr8:58130510	T/G	cg21724239	chr8:58056113	NA	0.58	5.95	0.34	8.29e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs1577917	0.958	rs11756615	chr6:86679835	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.47	-6.08	-0.35	4.29e-9	Response to antipsychotic treatment;
CESC	cis	rs10489525	0.599	rs11102879	chr1:115603504	C/T	cg12756093	chr1:115239321	AMPD1	-0.45	-5.4	-0.31	1.51e-7	Autism;
CESC	cis	rs4919044	0.808	rs835256	chr10:94779550	C/T	cg00487187	chr10:94451625	HHEX	-0.45	-5.05	-0.3	8.21e-7	Coronary artery disease;
CESC	trans	rs10435719	0.902	rs7014580	chr8:11803262	C/G	cg15556689	chr8:8085844	FLJ10661	0.53	6.73	0.38	1.05e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
CESC	cis	rs9611565	0.592	rs5758427	chr22:42099688	A/G	cg06634786	chr22:41940651	POLR3H	0.66	6.76	0.38	8.7e-11	Vitiligo;
CESC	cis	rs9858542	1.000	rs11130213	chr3:49712297	C/T	cg03060546	chr3:49711283	APEH	-0.57	-6.81	-0.39	6.44e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs4780401	0.526	rs12929396	chr16:11774625	C/T	cg01061890	chr16:11836724	TXNDC11	-0.4	-5.1	-0.3	6.58e-7	Rheumatoid arthritis;
CESC	cis	rs9916302	0.861	rs593480	chr17:37453780	A/C	cg19468946	chr17:37922297	IKZF3	0.41	5.26	0.31	3.02e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs10883723	0.810	rs2296582	chr10:104244139	G/T	cg22532475	chr10:104410764	TRIM8	-0.35	-6.2	-0.36	2.14e-9	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs4843747	0.636	rs11117358	chr16:88105053	T/A	cg06915872	chr16:87998081	BANP	0.43	5.19	0.3	4.17e-7	Menopause (age at onset);
CESC	cis	rs514406	0.679	rs545719	chr1:53304922	T/C	cg08736216	chr1:53307985	ZYG11A	-0.4	-7.26	-0.41	4.22e-12	Monocyte count;
CESC	cis	rs4423214	0.559	rs10898228	chr11:71228358	A/T	cg05163923	chr11:71159392	DHCR7	-0.58	-6.26	-0.36	1.58e-9	Vitamin D levels;
CESC	cis	rs3733585	0.605	rs4235355	chr4:10123078	C/A	cg00071950	chr4:10020882	SLC2A9	-0.65	-10.21	-0.53	7.69e-21	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs1018836	0.828	rs12547016	chr8:91563847	T/C	cg16814680	chr8:91681699	NA	-0.63	-9.25	-0.49	7.74e-18	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs9300255	0.830	rs28413626	chr12:123861452	G/A	cg19016782	chr12:123741754	C12orf65	0.5	6.76	0.38	8.53e-11	Neutrophil percentage of white cells;
CESC	cis	rs9611519	0.780	rs9611546	chr22:41698542	C/G	cg17376030	chr22:41985996	PMM1	0.52	5.78	0.33	2.14e-8	Neuroticism;
CESC	cis	rs9818758	0.607	rs67831908	chr3:49313513	T/G	cg00383909	chr3:49044727	WDR6	0.81	6.16	0.35	2.63e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CESC	cis	rs7772486	0.875	rs865913	chr6:146308874	C/T	cg23711669	chr6:146136114	FBXO30	0.9	13.1	0.63	1.45e-30	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs3780486	0.846	rs10813950	chr9:33127640	A/G	cg13443165	chr9:33130375	B4GALT1	-0.43	-6.02	-0.35	5.77e-9	IgG glycosylation;
CESC	cis	rs72781680	0.752	rs56152044	chr2:23927680	A/G	cg08917208	chr2:24149416	ATAD2B	1.05	9.35	0.5	3.89e-18	Lymphocyte counts;
CESC	trans	rs747782	0.528	rs7937670	chr11:48313216	C/T	cg15704280	chr7:45808275	SEPT13	0.68	6.26	0.36	1.5e-9	Intraocular pressure;
CESC	trans	rs916888	0.697	rs199516	chr17:44856485	C/T	cg27125505	chr17:43679177	LOC644172	-0.49	-6.94	-0.39	2.94e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs910316	1.000	rs10138183	chr14:75615227	T/C	cg16144293	chr14:75469539	EIF2B2	-0.39	-5.07	-0.3	7.52e-7	Height;
CESC	cis	rs1957429	0.808	rs1957436	chr14:65348207	T/G	cg23373153	chr14:65346875	NA	0.96	11.49	0.58	4.43e-25	Pediatric areal bone mineral density (radius);
CESC	cis	rs5758511	0.514	rs5758586	chr22:42517471	A/T	cg00645731	chr22:42541494	CYP2D7P1	0.63	9.78	0.52	1.69e-19	Birth weight;
CESC	cis	rs916888	0.773	rs199445	chr17:44817408	C/T	cg17911788	chr17:44343683	NA	-0.61	-8.09	-0.44	2.19e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs7826238	0.564	rs2921053	chr8:8319963	G/C	cg15556689	chr8:8085844	FLJ10661	0.65	8.53	0.46	1.11e-15	Systolic blood pressure;
CESC	cis	rs11122272	0.735	rs2009873	chr1:231499236	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.56	-7.65	-0.43	3.62e-13	Hemoglobin concentration;
CESC	cis	rs1552244	0.572	rs7645759	chr3:10157368	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.8	8.48	0.46	1.59e-15	Alzheimer's disease;
CESC	cis	rs7937682	0.632	rs7112886	chr11:111743232	T/C	cg22437258	chr11:111473054	SIK2	-0.48	-5.32	-0.31	2.2e-7	Primary sclerosing cholangitis;
CESC	cis	rs3793683	0.928	rs2148666	chr10:134553785	A/G	cg26818010	chr10:134567672	INPP5A	-0.46	-5.77	-0.33	2.26e-8	Migraine;
CESC	cis	rs10089	0.953	rs10223203	chr5:127527646	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.69	-9.07	-0.49	2.71e-17	Ileal carcinoids;
CESC	cis	rs853679	0.628	rs9368560	chr6:28159960	T/C	cg23161317	chr6:28129485	ZNF389	0.44	5.4	0.31	1.47e-7	Depression;
CESC	cis	rs7607369	0.536	rs7600248	chr2:219665963	C/T	cg02176678	chr2:219576539	TTLL4	-0.35	-6.21	-0.36	2.09e-9	Red blood cell count;Amyotrophic lateral sclerosis;
CESC	cis	rs10540	1.000	rs61876333	chr11:487136	G/A	cg03934478	chr11:495069	RNH1	0.57	5.24	0.31	3.21e-7	Body mass index;
CESC	cis	rs708547	0.581	rs781661	chr4:57780307	A/G	cg25525207	chr4:57843836	C4orf14;POLR2B	0.43	5.12	0.3	5.97e-7	Response to bleomycin (chromatid breaks);
CESC	trans	rs61931739	0.534	rs7313137	chr12:34010231	T/G	cg26384229	chr12:38710491	ALG10B	0.59	8.21	0.45	9.45e-15	Morning vs. evening chronotype;
CESC	trans	rs1814175	0.817	rs10128730	chr11:50023369	G/T	cg15704280	chr7:45808275	SEPT13	-1.05	-21.18	-0.79	6.15e-59	Height;
CESC	cis	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg07590406	chr3:58292066	RPP14	0.43	5.63	0.33	4.68e-8	Systemic lupus erythematosus;
CESC	cis	rs7208859	0.623	rs9890862	chr17:29125450	C/A	cg14008862	chr17:28927542	LRRC37B2	0.65	5.14	0.3	5.34e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs3820928	0.935	rs113195824	chr2:227769139	A/G	cg05526886	chr2:227700861	RHBDD1	-0.44	-5.75	-0.33	2.41e-8	Pulmonary function;
CESC	cis	rs12220238	0.596	rs11001083	chr10:76370949	T/A	cg19889307	chr10:75911429	ADK;AP3M1	0.55	5.12	0.3	5.85e-7	Soluble interleukin-2 receptor subunit alpha;
CESC	cis	rs2370759	0.945	rs10508773	chr10:32575444	C/T	cg01819863	chr10:32635814	EPC1	1.16	13.25	0.63	4.48e-31	Sexual dysfunction (female);
CESC	cis	rs798554	0.757	rs1182177	chr7:2874540	C/T	cg09658497	chr7:2847517	GNA12	-0.42	-5.92	-0.34	1e-8	Height;
CESC	cis	rs35110281	0.776	rs229357	chr21:44982717	T/C	cg04455712	chr21:45112962	RRP1B	0.36	5.22	0.31	3.58e-7	Mean corpuscular volume;
CESC	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.58	7.33	0.41	2.84e-12	Prudent dietary pattern;
CESC	cis	rs477692	0.692	rs12265758	chr10:131445144	A/G	cg05714579	chr10:131428358	MGMT	-0.6	-8.43	-0.46	2.31e-15	Response to temozolomide;
CESC	cis	rs910316	1.000	rs175436	chr14:75608683	C/G	cg11812906	chr14:75593930	NEK9	-0.88	-15.4	-0.69	1.18e-38	Height;
CESC	cis	rs7017914	0.967	rs13271442	chr8:71585169	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.09	-0.3	6.93e-7	Bone mineral density;
CESC	cis	rs11122272	0.735	rs2790883	chr1:231532726	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.56	-7.62	-0.42	4.55e-13	Hemoglobin concentration;
CESC	trans	rs4665809	1.000	rs750452	chr2:26324995	G/A	cg09258813	chr8:37823409	ADRB3	-0.37	-6.08	-0.35	4.08e-9	Gut microbiome composition (summer);
CESC	cis	rs10540	1.000	rs61876335	chr11:488878	T/C	cg03934478	chr11:495069	RNH1	0.55	5.43	0.32	1.28e-7	Body mass index;
CESC	cis	rs951366	0.649	rs7522056	chr1:205735891	A/G	cg17178900	chr1:205818956	PM20D1	0.54	7.44	0.42	1.42e-12	Menarche (age at onset);
CESC	cis	rs17376456	0.877	rs12716456	chr5:93397557	A/G	cg21475434	chr5:93447410	FAM172A	0.77	6.93	0.39	3.23e-11	Diabetic retinopathy;
CESC	cis	rs11098499	0.863	rs1480940	chr4:120457682	T/C	cg09307838	chr4:120376055	NA	0.92	12.68	0.61	4.22e-29	Corneal astigmatism;
CESC	cis	rs6460942	0.915	rs1595800	chr7:12439816	G/A	cg02935154	chr7:12443704	VWDE	-0.61	-6.93	-0.39	3.11e-11	Coronary artery disease;
CESC	cis	rs748404	0.578	rs4547312	chr15:43632138	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.58	7.4	0.41	1.77e-12	Lung cancer;
CESC	cis	rs863345	0.547	rs10908675	chr1:158504129	A/C	cg12129480	chr1:158549410	OR10X1	-0.34	-6.84	-0.39	5.41e-11	Pneumococcal bacteremia;
CESC	cis	rs9322193	0.884	rs9383865	chr6:150173179	A/G	cg09699651	chr6:150184138	LRP11	0.51	6.43	0.37	5.91e-10	Lung cancer;
CESC	cis	rs2440129	0.611	rs1126667	chr17:6902760	C/T	cg02493798	chr17:6899577	ALOX12	-0.44	-7.82	-0.43	1.24e-13	Tonsillectomy;
CESC	cis	rs875971	0.830	rs809025	chr7:65849819	C/G	cg18876405	chr7:65276391	NA	0.5	6.87	0.39	4.63e-11	Aortic root size;
CESC	cis	rs5750830	0.621	rs5757665	chr22:39821641	A/G	cg11247378	chr22:39784982	NA	-0.62	-9.06	-0.49	2.88e-17	Intelligence (multi-trait analysis);
CESC	cis	rs67311347	1.000	rs9842564	chr3:40405810	A/G	cg09455208	chr3:40491958	NA	-0.43	-7.33	-0.41	2.86e-12	Renal cell carcinoma;
CESC	cis	rs1865721	0.771	rs72975986	chr18:73127649	A/G	cg26385618	chr18:73139727	C18orf62	-0.52	-8.29	-0.45	5.91e-15	Intelligence;
CESC	cis	rs548181	0.611	rs2849225	chr11:125415936	A/G	cg03464685	chr11:125439445	EI24	1.44	11.6	0.58	1.98e-25	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs4566357	0.595	rs2272203	chr2:227914655	C/G	cg05526886	chr2:227700861	RHBDD1	-0.45	-6.02	-0.35	5.83e-9	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15605918	chr19:3501056	DOHH	-0.61	-7.38	-0.41	2.04e-12	Gut microbiome composition (summer);
CESC	cis	rs672059	1.000	rs479994	chr1:183161729	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.54	7.04	0.4	1.62e-11	Hypertriglyceridemia;
CESC	cis	rs72634258	0.786	rs12563704	chr1:8033837	G/A	cg00042356	chr1:8021962	PARK7	0.57	6.06	0.35	4.71e-9	Inflammatory bowel disease;
CESC	cis	rs7296418	0.961	rs1727307	chr12:123575742	A/G	cg05973401	chr12:123451056	ABCB9	0.58	7.36	0.41	2.32e-12	Platelet count;
CESC	cis	rs3741404	0.560	rs12362602	chr11:63908660	G/A	cg05555928	chr11:63887634	MACROD1	0.38	5.61	0.33	5.07e-8	Platelet count;
CESC	cis	rs9863	0.827	rs6488913	chr12:124445569	C/G	cg00084347	chr12:124393913	DNAH10	-0.26	-5.08	-0.3	7.05e-7	White blood cell count;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg13446525	chr9:128170432	NA	-0.43	-6.09	-0.35	4.04e-9	Ulcerative colitis;
CESC	cis	rs4555082	0.830	rs3803319	chr14:105752458	G/A	cg27165867	chr14:105738592	BRF1	-0.49	-5.17	-0.3	4.7e-7	Mean platelet volume;Platelet distribution width;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg07867325	chr3:73159953	NA	0.48	6.92	0.39	3.34e-11	Fibrinogen levels;
CESC	cis	rs9911578	0.835	rs2301867	chr17:56480074	T/A	cg05425664	chr17:57184151	TRIM37	0.44	6.15	0.35	2.81e-9	Intelligence (multi-trait analysis);
CESC	cis	rs1552244	1.000	rs67852463	chr3:10157205	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.86	-12.12	-0.6	3.4e-27	Alzheimer's disease;
CESC	cis	rs9287719	0.934	rs6721510	chr2:10751046	T/C	cg02196655	chr2:10830764	NOL10	-0.38	-5.79	-0.34	1.96e-8	Prostate cancer;
CESC	cis	rs3771570	1.000	rs73018141	chr2:242221570	G/A	cg21155796	chr2:242212141	HDLBP	0.64	5.35	0.31	1.95e-7	Prostate cancer;
CESC	cis	rs7103648	1.000	rs7947450	chr11:47429904	G/A	cg20307385	chr11:47447363	PSMC3	0.94	16.17	0.7	2.26e-41	Diastolic blood pressure;Systolic blood pressure;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14798160	chr4:74718399	PF4V1	-0.56	-6.74	-0.38	1.01e-10	Gut microbiome composition (summer);
CESC	cis	rs7107174	1.000	rs11601590	chr11:78073288	T/G	cg02023728	chr11:77925099	USP35	0.38	5.34	0.31	2.05e-7	Testicular germ cell tumor;
CESC	cis	rs60871478	1.000	rs12531530	chr7:827366	T/C	cg05535760	chr7:792225	HEATR2	0.94	10.69	0.55	2.09e-22	Cerebrospinal P-tau181p levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11489602	chr10:32345426	KIF5B	0.57	6.35	0.36	9.31e-10	Gut microbiome composition (summer);
CESC	cis	rs56399783	0.901	rs6964740	chr7:2819656	C/G	cg19731401	chr7:2775893	GNA12	0.66	6.0	0.35	6.41e-9	Childhood ear infection;
CESC	cis	rs6460942	0.591	rs4721080	chr7:12337785	T/C	cg20607287	chr7:12443886	VWDE	-0.59	-6.52	-0.37	3.54e-10	Coronary artery disease;
CESC	trans	rs73568641	0.546	rs1937637	chr6:154101847	G/A	cg08374472	chr16:87445639	ZCCHC14	-0.46	-6.29	-0.36	1.28e-9	Methadone dose in opioid dependence;
CESC	cis	rs1799949	1.000	rs1799966	chr17:41223094	T/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.45	6.22	0.36	1.9e-9	Menopause (age at onset);
CESC	cis	rs752010	0.523	rs10890158	chr1:42117985	C/T	cg06885757	chr1:42089581	HIVEP3	0.53	8.33	0.46	4.31e-15	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs9393777	0.623	rs9358945	chr6:26472114	C/T	cg12826209	chr6:26865740	GUSBL1	-0.68	-7.36	-0.41	2.32e-12	Intelligence (multi-trait analysis);
CESC	cis	rs1552244	1.000	rs7648104	chr3:10073311	C/A	cg00166722	chr3:10149974	C3orf24	0.46	5.88	0.34	1.21e-8	Alzheimer's disease;
CESC	cis	rs1465370	0.760	rs10263705	chr7:130027633	C/T	cg04743876	chr7:130013617	NA	-0.27	-5.09	-0.3	6.81e-7	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
CESC	cis	rs7223966	1.000	rs11657081	chr17:61792339	C/T	cg11494091	chr17:61959527	GH2	0.39	5.42	0.32	1.34e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs6570726	0.935	rs398060	chr6:145841515	C/T	cg23711669	chr6:146136114	FBXO30	-0.75	-10.84	-0.55	6.64e-23	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg07243700	chr1:100731457	RTCD1	-0.47	-7.35	-0.41	2.44e-12	Vertical cup-disc ratio;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg11906176	chr10:76970489	VDAC2	-0.49	-6.22	-0.36	1.93e-9	Ulcerative colitis;
CESC	cis	rs79349575	0.783	rs62078370	chr17:47026836	G/C	cg26022315	chr17:47021804	SNF8	0.39	5.16	0.3	4.94e-7	Type 2 diabetes;
CESC	cis	rs1062177	1.000	rs2915878	chr5:151149662	A/G	cg12924095	chr5:151150029	G3BP1	0.47	6.0	0.35	6.37e-9	Preschool internalizing problems;
CESC	trans	rs11098499	0.604	rs34278750	chr4:120571136	G/A	cg25214090	chr10:38739885	LOC399744	0.6	7.88	0.44	8.29e-14	Corneal astigmatism;
CESC	cis	rs6728642	0.908	rs11901495	chr2:98017804	A/G	cg26665480	chr2:98280029	ACTR1B	0.81	8.09	0.45	2.15e-14	Bipolar disorder lithium response (continuous) or schizophrenia;
CESC	cis	rs2072732	0.861	rs12033927	chr1:2937550	A/G	cg15211996	chr1:2936768	ACTRT2	0.35	5.29	0.31	2.53e-7	Plateletcrit;
CESC	cis	rs2299587	0.689	rs1847154	chr8:17780338	A/G	cg08627089	chr8:17753878	FGL1	-0.4	-5.27	-0.31	2.8e-7	Economic and political preferences;
CESC	cis	rs731174	0.959	rs7527344	chr1:38191560	C/A	cg12339802	chr1:38156545	C1orf109	-0.55	-6.33	-0.36	1.06e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7927771	0.832	rs935914	chr11:47387599	C/T	cg20307385	chr11:47447363	PSMC3	0.53	6.28	0.36	1.38e-9	Subjective well-being;
CESC	cis	rs1595825	0.891	rs58409972	chr2:198897061	A/T	cg10820045	chr2:198174542	NA	0.42	5.15	0.3	5.04e-7	Ulcerative colitis;
CESC	cis	rs7617773	0.780	rs11718350	chr3:48360992	T/G	cg11946769	chr3:48343235	NME6	0.9	12.38	0.61	4.45e-28	Coronary artery disease;
CESC	trans	rs17508449	0.865	rs113081027	chr1:114118802	C/G	cg23028848	chr11:57092561	TNKS1BP1	-0.8	-6.16	-0.35	2.68e-9	Leprosy;
CESC	cis	rs2832191	1.000	rs2832190	chr21:30488226	G/A	cg24692254	chr21:30365293	RNF160	-0.73	-10.83	-0.55	6.97e-23	Dental caries;
CESC	cis	rs459571	1.000	rs459571	chr9:136912626	C/T	cg13789015	chr9:136890014	NCRNA00094	0.54	7.55	0.42	6.88e-13	Platelet distribution width;
CESC	cis	rs875971	0.862	rs9791712	chr7:66105163	C/G	cg18252515	chr7:66147081	NA	0.5	6.53	0.37	3.31e-10	Aortic root size;
CESC	cis	rs11997175	0.646	rs28785323	chr8:33736104	C/G	ch.8.33884649F	chr8:33765107	NA	0.56	7.05	0.4	1.58e-11	Body mass index;
CESC	cis	rs9916302	0.555	rs12940193	chr17:37652178	T/G	cg07936489	chr17:37558343	FBXL20	-0.81	-12.08	-0.6	4.67e-27	Glomerular filtration rate (creatinine);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15011941	chr7:75948230	NA	-0.52	-6.18	-0.35	2.45e-9	Gut microbiome composition (summer);
CESC	cis	rs8031584	0.678	rs798127	chr15:31117403	T/C	cg08704250	chr15:31115839	NA	0.69	9.23	0.49	9.09e-18	Huntington's disease progression;
CESC	cis	rs9948	1.000	rs72811629	chr2:97519901	T/G	cg01990225	chr2:97406019	LMAN2L	-0.68	-5.05	-0.3	8.28e-7	Erectile dysfunction and prostate cancer treatment;
CESC	cis	rs10883723	0.810	rs2296581	chr10:104242886	G/A	cg22532475	chr10:104410764	TRIM8	-0.34	-5.8	-0.34	1.89e-8	Allergic disease (asthma, hay fever or eczema);
CESC	trans	rs61931739	0.500	rs35391785	chr12:34444478	C/T	cg13010199	chr12:38710504	ALG10B	0.49	6.24	0.36	1.74e-9	Morning vs. evening chronotype;
CESC	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg11494091	chr17:61959527	GH2	0.73	12.76	0.62	2.2e-29	Prudent dietary pattern;
CESC	cis	rs6963495	0.818	rs73190163	chr7:105157294	G/T	cg02135003	chr7:105160482	PUS7	-0.46	-5.55	-0.32	6.92e-8	Bipolar disorder (body mass index interaction);
CESC	cis	rs116095464	0.558	rs73024831	chr5:257192	A/G	cg10591111	chr5:226296	SDHA	-0.51	-6.15	-0.35	2.84e-9	Breast cancer;
CESC	cis	rs60154123	0.772	rs701944	chr1:210417098	G/A	cg23283495	chr1:209979779	IRF6	0.46	5.47	0.32	1.03e-7	Coronary artery disease;
CESC	cis	rs10208940	0.920	rs6714976	chr2:68764873	G/T	cg12452813	chr2:68675892	NA	0.51	5.11	0.3	6.17e-7	Urate levels in lean individuals;
CESC	cis	rs4820539	0.966	rs2267001	chr22:23456696	T/C	cg14186256	chr22:23484241	RTDR1	0.82	14.55	0.67	1.21e-35	Bone mineral density;
CESC	cis	rs10242455	0.867	rs2687136	chr7:99325882	C/T	cg07715041	chr7:99302981	CYP3A7	-0.43	-5.42	-0.32	1.36e-7	Blood metabolite levels;
CESC	cis	rs6582630	0.555	rs7301250	chr12:38596244	G/T	cg26384229	chr12:38710491	ALG10B	0.73	10.91	0.56	4.06e-23	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs4237845	0.611	rs10877036	chr12:58321650	A/G	cg02175503	chr12:58329896	NA	-0.88	-14.43	-0.66	3.18e-35	Intelligence (multi-trait analysis);
CESC	cis	rs12134245	0.719	rs61798831	chr1:91996588	C/T	cg07090678	chr1:91966139	CDC7	0.41	5.53	0.32	7.68e-8	Breast cancer;
CESC	cis	rs854765	0.547	rs2955356	chr17:17964717	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.6	-8.42	-0.46	2.43e-15	Total body bone mineral density;
CESC	cis	rs34779708	0.966	rs12765038	chr10:35416513	G/C	cg04310649	chr10:35416472	CREM	-0.55	-6.8	-0.39	7.1e-11	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs62283056	0.512	rs752854	chr4:6281961	C/T	cg00701064	chr4:6280414	WFS1	0.65	9.21	0.49	1.01e-17	Cisplatin-induced ototoxicity;
CESC	cis	rs10504229	0.679	rs11783965	chr8:58130510	T/G	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs9291683	0.510	rs4318649	chr4:10016815	T/C	cg02734326	chr4:10020555	SLC2A9	0.42	5.76	0.33	2.3e-8	Bone mineral density;
CESC	cis	rs10751667	0.580	rs10751664	chr11:927077	T/G	cg06064525	chr11:970664	AP2A2	-0.52	-10.25	-0.53	5.74e-21	Alzheimer's disease (late onset);
CESC	cis	rs7089973	0.523	rs34170154	chr10:116740959	C/T	cg23260525	chr10:116636907	FAM160B1	0.3	5.24	0.31	3.21e-7	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs11039389	1	rs11039389	chr11:47796062	T/C	cg05585544	chr11:47624801	NA	-0.49	-7.63	-0.42	4.21e-13	Neuroticism;
CESC	cis	rs875971	0.545	rs4718325	chr7:65680310	G/A	cg11764359	chr7:65958608	NA	0.79	8.88	0.48	1.05e-16	Aortic root size;
CESC	cis	rs6088580	0.634	rs6088478	chr20:32971719	T/C	cg08999081	chr20:33150536	PIGU	-0.66	-11.72	-0.58	8.03e-26	Glomerular filtration rate (creatinine);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg08280159	chr8:145504568	BOP1	0.45	6.14	0.35	3.08e-9	Fibrinogen levels;
CESC	cis	rs13108904	0.557	rs1250098	chr4:1238256	A/T	cg20887711	chr4:1340912	KIAA1530	-0.61	-8.28	-0.45	6.08e-15	Obesity-related traits;
CESC	cis	rs9322193	0.962	rs9397022	chr6:150133188	C/T	cg13206674	chr6:150067644	NUP43	0.39	5.51	0.32	8.53e-8	Lung cancer;
CESC	cis	rs7605827	0.930	rs4668904	chr2:15543642	C/G	cg19274914	chr2:15703543	NA	0.31	5.52	0.32	8.05e-8	Educational attainment (years of education);
CESC	cis	rs7811142	1.000	rs66632384	chr7:100018904	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.11	11.1	0.56	9.54e-24	Platelet count;
CESC	cis	rs4819052	0.851	rs2330011	chr21:46658498	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.73	9.9	0.52	7.3e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs1044826	0.642	rs6787649	chr3:139193321	C/T	cg00490450	chr3:139108681	COPB2	0.43	5.33	0.31	2.11e-7	Obesity-related traits;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg14653225	chr1:228003938	PRSS38	-0.41	-6.04	-0.35	5.06e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs7560272	0.669	rs13008860	chr2:73774019	G/A	cg20560298	chr2:73613845	ALMS1	-0.39	-5.49	-0.32	9.3e-8	Schizophrenia;
CESC	cis	rs1538970	0.962	rs9429076	chr1:45819489	A/G	cg05343316	chr1:45956843	TESK2	0.74	9.43	0.5	2.09e-18	Platelet count;
CESC	trans	rs11098499	0.722	rs10006192	chr4:120263022	T/C	cg25214090	chr10:38739885	LOC399744	0.6	8.26	0.45	6.87e-15	Corneal astigmatism;
CESC	cis	rs12142240	0.660	rs72885163	chr1:46807117	C/A	cg00530320	chr1:46809349	NSUN4	0.6	7.98	0.44	4.48e-14	Menopause (age at onset);
CESC	trans	rs526821	0.595	rs565859	chr11:55297367	T/C	cg15704280	chr7:45808275	SEPT13	-0.51	-6.28	-0.36	1.4e-9	Pediatric bone mineral density (spine);
CESC	cis	rs11997175	0.522	rs10954930	chr8:33588352	C/T	ch.8.33884649F	chr8:33765107	NA	0.57	7.4	0.41	1.77e-12	Body mass index;
CESC	cis	rs7959452	0.868	rs10878967	chr12:69740869	T/C	cg22834771	chr12:69754056	YEATS4	-0.39	-5.26	-0.31	2.94e-7	Blood protein levels;
CESC	cis	rs6674176	0.628	rs3828146	chr1:44428715	C/T	cg12908607	chr1:44402522	ARTN	-0.46	-6.61	-0.38	2.08e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs854765	0.583	rs8065563	chr17:17782404	A/G	cg16928487	chr17:17741425	SREBF1	-0.6	-10.35	-0.54	2.67e-21	Total body bone mineral density;
CESC	cis	rs9902453	0.967	rs4325622	chr17:28526475	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	7.68	0.43	3.18e-13	Coffee consumption (cups per day);
CESC	cis	rs863345	0.584	rs10797023	chr1:158497079	T/C	cg12129480	chr1:158549410	OR10X1	-0.35	-6.86	-0.39	4.78e-11	Pneumococcal bacteremia;
CESC	cis	rs1799949	0.860	rs8176279	chr17:41210396	A/C	cg05368731	chr17:41323189	NBR1	0.56	7.59	0.42	5.62e-13	Menopause (age at onset);
CESC	cis	rs2242663	0.798	rs1945302	chr11:66337498	C/T	cg24851651	chr11:66362959	CCS	0.4	5.17	0.3	4.57e-7	Bipolar disorder;
CESC	cis	rs9487051	0.837	rs9480920	chr6:109605322	C/A	cg21918786	chr6:109611834	NA	-0.4	-6.07	-0.35	4.5e-9	Reticulocyte fraction of red cells;
CESC	cis	rs7520050	0.966	rs2486447	chr1:46545724	G/A	cg24296786	chr1:45957014	TESK2	0.41	5.17	0.3	4.57e-7	Red blood cell count;Reticulocyte count;
CESC	cis	rs7949030	0.626	rs11231145	chr11:62328854	G/A	cg13298116	chr11:62369859	EML3;MTA2	0.65	9.65	0.51	4.56e-19	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs7116495	1.000	rs2511076	chr11:71783827	A/G	cg26138937	chr11:71823887	C11orf51	-0.84	-6.79	-0.38	7.37e-11	Severe influenza A (H1N1) infection;
CESC	cis	rs2273669	0.667	rs113477421	chr6:109310268	C/T	cg05315195	chr6:109294784	ARMC2	-0.65	-5.94	-0.34	9.09e-9	Prostate cancer;
CESC	cis	rs62064224	0.560	rs12162135	chr17:30805795	A/C	cg18200150	chr17:30822561	MYO1D	0.64	10.73	0.55	1.51e-22	Schizophrenia;
CESC	cis	rs4588572	0.643	rs9293747	chr5:77705567	A/G	cg11547950	chr5:77652471	NA	-0.46	-6.0	-0.35	6.55e-9	Triglycerides;
CESC	cis	rs79349575	0.811	rs60708039	chr17:46999373	C/G	cg26022315	chr17:47021804	SNF8	0.39	5.18	0.3	4.5e-7	Type 2 diabetes;
CESC	cis	rs708547	0.957	rs2458552	chr4:57773442	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.67	7.33	0.41	2.78e-12	Response to bleomycin (chromatid breaks);
CESC	cis	rs7927592	0.763	rs10896340	chr11:68312645	A/G	cg01657329	chr11:68192670	LRP5	0.48	6.33	0.36	1.05e-9	Total body bone mineral density;
CESC	cis	rs7618915	0.501	rs3774366	chr3:52641255	T/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.3	5.41	0.32	1.38e-7	Bipolar disorder;
CESC	cis	rs7523050	0.643	rs7522324	chr1:109399644	T/C	cg08274380	chr1:109419600	GPSM2	0.83	5.58	0.32	5.89e-8	Fat distribution (HIV);
CESC	cis	rs113835537	0.529	rs11227499	chr11:66272824	A/G	cg22134325	chr11:66188745	NPAS4	0.3	5.12	0.3	5.97e-7	Airway imaging phenotypes;
CESC	cis	rs9913156	0.793	rs72835642	chr17:4573407	T/C	cg19197139	chr17:4613644	ARRB2	0.94	10.57	0.54	4.94e-22	Lymphocyte counts;
CESC	cis	rs7267979	0.934	rs113469203	chr20:25343258	G/A	cg08601574	chr20:25228251	PYGB	-0.38	-5.38	-0.31	1.62e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs6952808	0.543	rs4719436	chr7:2141239	G/A	cg08027265	chr7:2291960	NA	-0.45	-6.93	-0.39	3.12e-11	Bipolar disorder and schizophrenia;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg20247781	chr1:113252666	PPM1J	0.4	6.13	0.35	3.16e-9	Thyroid stimulating hormone;
CESC	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.52	6.32	0.36	1.13e-9	Prudent dietary pattern;
CESC	cis	rs875971	0.929	rs12535036	chr7:65964063	G/T	cg18876405	chr7:65276391	NA	0.48	6.31	0.36	1.16e-9	Aortic root size;
CESC	cis	rs9443189	0.570	rs9341532	chr6:76403674	A/G	cg01950844	chr6:76311363	SENP6	0.88	9.29	0.5	6.05e-18	Prostate cancer;
CESC	trans	rs8056446	0.710	rs8059793	chr16:78189298	A/C	cg17371350	chr17:655677	ELP2P;GEMIN4	0.43	6.06	0.35	4.63e-9	Pulmonary function (smoking interaction);
CESC	cis	rs7584330	0.666	rs72620816	chr2:238353604	C/T	cg14458575	chr2:238380390	NA	0.84	10.63	0.55	3.16e-22	Prostate cancer;
CESC	cis	rs7666738	0.830	rs11097605	chr4:98985167	T/C	cg05340658	chr4:99064831	C4orf37	0.77	11.85	0.59	2.88e-26	Colonoscopy-negative controls vs population controls;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg00196167	chr7:139026058	C7orf55	-0.47	-6.23	-0.36	1.81e-9	Ulcerative colitis;
CESC	cis	rs10504229	1.000	rs112272435	chr8:58170371	A/G	cg22535103	chr8:58192502	C8orf71	-1.05	-12.98	-0.62	3.88e-30	Developmental language disorder (linguistic errors);
CESC	cis	rs9926296	0.712	rs2434872	chr16:89716915	C/G	cg01097406	chr16:89675127	NA	0.38	5.41	0.32	1.42e-7	Vitiligo;
CESC	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.89	13.61	0.64	2.41e-32	Prudent dietary pattern;
CESC	cis	rs72829446	0.530	rs17732878	chr17:7362359	C/T	cg02795151	chr17:7402630	POLR2A	-0.51	-5.45	-0.32	1.16e-7	Androgen levels;
CESC	cis	rs7666738	0.830	rs1834645	chr4:98979593	T/A	cg05340658	chr4:99064831	C4orf37	0.79	12.24	0.6	1.33e-27	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2576037	0.583	rs478820	chr18:44397782	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.35	5.69	0.33	3.38e-8	Personality dimensions;
CESC	cis	rs2072732	0.861	rs12036378	chr1:2955158	G/A	cg15211996	chr1:2936768	ACTRT2	0.34	6.04	0.35	5.27e-9	Plateletcrit;
CESC	cis	rs6502050	0.799	rs8082355	chr17:80120316	A/G	cg11859384	chr17:80120422	CCDC57	-0.39	-5.44	-0.32	1.22e-7	Life satisfaction;
CESC	cis	rs6840360	0.615	rs12503677	chr4:152610543	A/G	cg22705602	chr4:152727874	NA	-0.37	-5.18	-0.3	4.5e-7	Intelligence (multi-trait analysis);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg13172696	chr1:153951646	JTB	-0.34	-6.21	-0.36	2.1e-9	Gambling;
CESC	cis	rs7618915	0.547	rs2268027	chr3:52766606	G/A	cg18099408	chr3:52552593	STAB1	-0.32	-5.17	-0.3	4.69e-7	Bipolar disorder;
CESC	cis	rs57506017	0.565	rs12699333	chr7:12269804	C/T	cg23422036	chr7:12250390	TMEM106B	0.38	5.13	0.3	5.58e-7	Neuroticism;
CESC	cis	rs6543140	0.964	rs4851010	chr2:103056127	A/T	cg04239558	chr2:103089729	SLC9A4	-0.48	-6.07	-0.35	4.3e-9	Blood protein levels;
CESC	cis	rs2204008	0.837	rs11611861	chr12:38357459	A/G	cg13010199	chr12:38710504	ALG10B	0.48	6.06	0.35	4.62e-9	Bladder cancer;
CESC	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg26338869	chr17:61819248	STRADA	0.69	9.2	0.49	1.12e-17	Prudent dietary pattern;
CESC	trans	rs2115172	0.836	rs4835799	chr5:122762229	A/G	cg19850565	chr19:35168394	ZNF302	0.44	6.04	0.35	5.29e-9	Weight;
CESC	cis	rs4727027	0.866	rs10435245	chr7:148816081	C/G	cg23158103	chr7:148848205	ZNF398	-0.41	-6.74	-0.38	9.9e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs1670533	0.932	rs4690347	chr4:1057328	A/G	cg27284194	chr4:1044797	NA	0.48	6.06	0.35	4.7e-9	Recombination rate (females);
CESC	cis	rs1005277	0.522	rs289647	chr10:37968278	A/G	cg25517755	chr10:38738941	LOC399744	-0.38	-5.05	-0.3	8.11e-7	Extrinsic epigenetic age acceleration;
CESC	cis	rs2267137	0.843	rs570731	chr22:29758817	A/G	cg07256473	chr22:29710276	RASL10A	-0.42	-6.49	-0.37	4.21e-10	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	cis	rs4974559	0.501	rs1250129	chr4:1254930	C/T	cg20887711	chr4:1340912	KIAA1530	0.52	5.58	0.32	5.96e-8	Systolic blood pressure;
CESC	cis	rs78456975	0.739	rs11896906	chr2:1519550	A/G	cg01028140	chr2:1542097	TPO	-0.47	-5.29	-0.31	2.56e-7	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs72781680	0.800	rs6718635	chr2:24066183	A/C	cg20701182	chr2:24300061	SF3B14	0.78	6.86	0.39	4.98e-11	Lymphocyte counts;
CESC	cis	rs6502050	0.835	rs8078087	chr17:80113322	T/G	cg11859384	chr17:80120422	CCDC57	-0.39	-5.36	-0.31	1.82e-7	Life satisfaction;
CESC	cis	rs459571	0.715	rs401826	chr9:136890591	C/T	cg13789015	chr9:136890014	NCRNA00094	0.59	8.4	0.46	2.76e-15	Platelet distribution width;
CESC	cis	rs72945132	0.678	rs35733235	chr11:70235595	C/T	cg14191688	chr11:70257035	CTTN	0.41	5.12	0.3	5.9e-7	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14806867	chr13:96329355	DNAJC3	0.55	6.21	0.36	2.04e-9	Gut microbiome composition (summer);
CESC	cis	rs1799949	0.965	rs11658499	chr17:41334749	C/T	cg25072359	chr17:41440525	NA	0.5	6.77	0.38	8.41e-11	Menopause (age at onset);
CESC	cis	rs875971	0.862	rs778702	chr7:65864835	G/A	cg10691866	chr7:65817282	TPST1	-0.32	-5.25	-0.31	3.06e-7	Aortic root size;
CESC	cis	rs7666738	0.830	rs13115356	chr4:98933171	T/C	cg03467027	chr4:99064603	C4orf37	0.46	5.6	0.33	5.39e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7727544	0.684	rs274546	chr5:131699867	A/G	cg24060327	chr5:131705240	SLC22A5	-0.6	-7.58	-0.42	5.85e-13	Blood metabolite levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06516150	chr12:109592528	ACACB	0.62	7.3	0.41	3.36e-12	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23401212	chr20:1099146	PSMF1	0.62	6.8	0.39	6.93e-11	Gut microbiome composition (summer);
CESC	trans	rs7307889	0.793	rs73047652	chr12:6015033	T/G	cg18407955	chr7:158110685	PTPRN2	-0.71	-6.58	-0.37	2.48e-10	Obesity-related traits;
CESC	cis	rs10479542	0.544	rs7706275	chr5:178990305	A/G	cg14820908	chr5:178986412	RUFY1	0.51	7.58	0.42	5.82e-13	Lung cancer;
CESC	cis	rs4730250	0.707	rs257372	chr7:106796977	T/G	cg02696742	chr7:106810147	HBP1	-0.55	-5.18	-0.3	4.44e-7	Osteoarthritis;
CESC	cis	rs7618915	0.547	rs4687638	chr3:52651966	A/C	cg18404041	chr3:52824283	ITIH1	-0.39	-6.54	-0.37	3.08e-10	Bipolar disorder;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg08536481	chr12:123459152	ABCB9;OGFOD2	-0.43	-6.03	-0.35	5.43e-9	Fibrinogen levels;
CESC	cis	rs2204008	0.546	rs11519978	chr12:37998170	C/T	cg26384229	chr12:38710491	ALG10B	0.74	10.87	0.56	5.15e-23	Bladder cancer;
CESC	cis	rs875971	0.545	rs6460276	chr7:65647277	G/A	cg25405998	chr7:65216604	CCT6P1	0.45	5.06	0.3	7.71e-7	Aortic root size;
CESC	cis	rs2228479	0.867	rs2270459	chr16:89979851	A/C	cg00800038	chr16:89945340	TCF25	0.73	7.17	0.4	7.68e-12	Skin colour saturation;
CESC	cis	rs7191700	0.836	rs10163410	chr16:11430615	G/C	cg00044050	chr16:11439710	C16orf75	0.49	5.65	0.33	4.03e-8	Multiple sclerosis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22036008	chr5:122759586	CEP120	-0.52	-6.0	-0.35	6.52e-9	Gut microbiome composition (summer);
CESC	trans	rs161857	0.536	rs257977	chr5:118802221	A/C	cg02306526	chr12:2202821	CACNA1C	0.77	6.48	0.37	4.35e-10	Pyoderma gangrenosum in inflammatory bowel disease;
CESC	cis	rs7662987	0.517	rs2851277	chr4:100022910	G/T	cg12011299	chr4:100065546	ADH4	0.6	6.6	0.38	2.23e-10	Smoking initiation;
CESC	cis	rs72945132	0.941	rs66803755	chr11:70117473	G/A	cg00319359	chr11:70116639	PPFIA1	0.78	7.42	0.41	1.56e-12	Coronary artery disease;
CESC	cis	rs1799949	0.965	rs4793233	chr17:41435437	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	8.59	0.47	7.82e-16	Menopause (age at onset);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg22194305	chr4:2264032	MXD4	0.48	6.07	0.35	4.37e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs1475911	0.708	rs56185023	chr21:43521538	T/C	cg03240473	chr21:43526662	UMODL1;C21orf128	-0.53	-7.13	-0.4	9.27e-12	IgG glycosylation;
CESC	cis	rs853679	0.517	rs67878650	chr6:28142587	G/C	cg18032046	chr6:28092343	ZSCAN16	-0.56	-6.42	-0.37	6.22e-10	Depression;
CESC	cis	rs798554	0.757	rs2644312	chr7:2841164	G/A	cg18446336	chr7:2847575	GNA12	-0.38	-5.72	-0.33	2.81e-8	Height;
CESC	cis	rs2576037	0.526	rs2187092	chr18:44526798	A/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.43	7.2	0.4	6.31e-12	Personality dimensions;
CESC	cis	rs4849845	0.853	rs13386533	chr2:121029586	G/A	cg24070213	chr2:121070622	NA	0.39	5.04	0.3	8.71e-7	Mean platelet volume;
CESC	cis	rs6461049	0.646	rs3778970	chr7:2143208	C/A	cg04267008	chr7:1944627	MAD1L1	-0.61	-7.29	-0.41	3.67e-12	Schizophrenia;
CESC	cis	rs7659604	0.539	rs1507995	chr4:122748308	G/A	cg19748678	chr4:122722346	EXOSC9	0.8	10.05	0.53	2.39e-20	Type 2 diabetes;
CESC	cis	rs1799949	0.965	rs9911630	chr17:41188342	A/G	cg23758822	chr17:41437982	NA	0.95	15.06	0.68	1.95e-37	Menopause (age at onset);
CESC	cis	rs10089	1.000	rs4836369	chr5:127486462	A/G	cg19767477	chr5:127420684	SLC12A2	-0.39	-5.18	-0.3	4.42e-7	Ileal carcinoids;
CESC	cis	rs9815354	0.904	rs9848992	chr3:41875297	C/T	cg03022575	chr3:42003672	ULK4	0.58	6.01	0.35	5.96e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs12791968	0.527	rs4755300	chr11:45013421	C/T	cg11846598	chr11:44996168	LOC221122	0.55	6.14	0.35	2.99e-9	Inhibitory control;
CESC	cis	rs941873	0.900	rs7092536	chr10:81131332	A/C	cg08514558	chr10:81106712	PPIF	0.35	6.14	0.35	3.08e-9	Height;
CESC	cis	rs1799949	1.000	rs8176233	chr17:41219804	T/C	cg06001716	chr17:41278141	BRCA1;NBR2	0.39	5.3	0.31	2.46e-7	Menopause (age at onset);
CESC	cis	rs7945705	0.747	rs2742480	chr11:8993130	A/G	cg12365402	chr11:9010492	NRIP3	-0.47	-7.89	-0.44	7.93e-14	Hemoglobin concentration;
CESC	cis	rs12824058	0.831	rs4759452	chr12:130812799	G/A	cg23887609	chr12:130822674	PIWIL1	0.45	5.82	0.34	1.69e-8	Menopause (age at onset);
CESC	cis	rs1144333	0.655	rs76532097	chr1:76320759	G/C	cg22875332	chr1:76189707	ACADM	0.52	5.08	0.3	7.1e-7	Attention function in attention deficit hyperactive disorder;
CESC	cis	rs4835473	0.838	rs35800634	chr4:144656352	G/A	cg25736465	chr4:144833511	NA	-0.33	-5.3	-0.31	2.48e-7	Immature fraction of reticulocytes;
CESC	cis	rs9926296	0.585	rs8058009	chr16:89856439	G/A	cg04287289	chr16:89883240	FANCA	0.64	8.66	0.47	4.66e-16	Vitiligo;
CESC	cis	rs6502050	0.835	rs62078304	chr17:80085224	G/A	cg23985595	chr17:80112537	CCDC57	0.42	6.53	0.37	3.27e-10	Life satisfaction;
CESC	cis	rs6963495	0.745	rs73190169	chr7:105160500	A/G	cg13798780	chr7:105162888	PUS7	0.78	8.04	0.44	2.99e-14	Bipolar disorder (body mass index interaction);
CESC	cis	rs2573652	1.000	rs2581343	chr15:100514418	C/G	cg09918751	chr15:100517450	ADAMTS17	-0.39	-7.21	-0.4	5.96e-12	Height;
CESC	cis	rs7264396	0.563	rs2425103	chr20:34312329	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.89	-10.78	-0.55	1.03e-22	Total cholesterol levels;
CESC	cis	rs13191362	1.000	rs35449999	chr6:163023465	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.87	9.03	0.49	3.53e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs8133932	0.727	rs2150453	chr21:47253215	C/T	cg14185626	chr21:47401492	COL6A1	-0.46	-5.05	-0.3	8.06e-7	Schizophrenia;
CESC	cis	rs6732160	0.588	rs2043100	chr2:73374096	T/C	cg01422370	chr2:73384389	NA	0.57	9.1	0.49	2.21e-17	Intelligence (multi-trait analysis);
CESC	cis	rs12476592	0.602	rs4671509	chr2:63686004	C/T	cg17519650	chr2:63277830	OTX1	-0.47	-5.29	-0.31	2.52e-7	Childhood ear infection;
CESC	cis	rs1862618	0.853	rs33322	chr5:56175226	A/G	cg22800045	chr5:56110881	MAP3K1	0.82	9.74	0.51	2.29e-19	Initial pursuit acceleration;
CESC	cis	rs7829975	0.777	rs560544	chr8:8637429	G/A	cg06636001	chr8:8085503	FLJ10661	-0.48	-6.27	-0.36	1.48e-9	Mood instability;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15560884	chr1:710097	NA	-0.49	-6.43	-0.37	5.86e-10	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.830	rs6851253	chr4:99029980	A/G	cg17366294	chr4:99064904	C4orf37	0.62	8.95	0.48	6.32e-17	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7605827	0.930	rs13024782	chr2:15700715	A/G	cg19274914	chr2:15703543	NA	0.3	5.45	0.32	1.18e-7	Educational attainment (years of education);
CESC	cis	rs11650494	0.831	rs8065389	chr17:47456064	G/T	cg08112188	chr17:47440006	ZNF652	-0.99	-7.96	-0.44	5.02e-14	Prostate cancer;
CESC	cis	rs7811142	0.830	rs6975660	chr7:99975266	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.93	10.32	0.54	3.22e-21	Platelet count;
CESC	cis	rs1443512	0.812	rs2078098	chr12:54337527	C/A	cg17410650	chr12:54324560	NA	-0.47	-7.97	-0.44	4.79e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
CESC	cis	rs1448094	0.520	rs12304244	chr12:86272823	C/T	cg02569458	chr12:86230093	RASSF9	0.51	7.54	0.42	7.64e-13	Major depressive disorder;
CESC	cis	rs5750830	0.546	rs4821891	chr22:39785381	C/T	cg05872129	chr22:39784769	NA	-0.85	-12.16	-0.6	2.47e-27	Intelligence (multi-trait analysis);
CESC	cis	rs28374715	0.681	rs28687846	chr15:41599902	C/T	cg02330683	chr15:41787940	ITPKA	0.49	5.84	0.34	1.51e-8	Ulcerative colitis;
CESC	cis	rs2820292	0.678	rs4494199	chr1:201884668	C/T	cg11586189	chr1:201857591	SHISA4	0.33	5.84	0.34	1.56e-8	Waist circumference;Body mass index (joint analysis main effects and smoking interaction);Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);
CESC	cis	rs9300255	0.602	rs11057192	chr12:123693420	T/C	cg05973401	chr12:123451056	ABCB9	0.49	5.63	0.33	4.63e-8	Neutrophil percentage of white cells;
CESC	cis	rs7914558	1.000	rs11191539	chr10:104819770	A/G	cg15744005	chr10:104629667	AS3MT	-0.34	-5.49	-0.32	9.49e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs7811142	0.945	rs6955362	chr7:100056166	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.11	11.01	0.56	1.89e-23	Platelet count;
CESC	trans	rs9467711	0.606	rs9379901	chr6:26603866	T/C	cg06606381	chr12:133084897	FBRSL1	-0.78	-7.41	-0.41	1.7e-12	Autism spectrum disorder or schizophrenia;
CESC	cis	rs8067545	0.611	rs9893832	chr17:20038273	A/G	cg13482628	chr17:19912719	NA	0.4	5.37	0.31	1.75e-7	Schizophrenia;
CESC	cis	rs9399135	0.967	rs13191501	chr6:135366880	T/C	cg24558204	chr6:135376177	HBS1L	0.5	6.85	0.39	5.16e-11	Red blood cell count;
CESC	cis	rs892961	0.806	rs312910	chr17:75413961	A/C	cg05865280	chr17:75406074	SEPT9	0.66	14.25	0.66	1.31e-34	Airflow obstruction;
CESC	trans	rs7615952	0.512	rs2979336	chr3:125357470	G/A	cg00769240	chr8:12517080	NA	-0.44	-6.01	-0.35	6.16e-9	Blood pressure (smoking interaction);
CESC	cis	rs13108904	0.837	rs4519749	chr4:1280102	A/G	cg22903657	chr4:1355424	KIAA1530	-0.38	-5.18	-0.3	4.5e-7	Obesity-related traits;
CESC	cis	rs7267979	1.000	rs2258617	chr20:25274318	C/T	cg08601574	chr20:25228251	PYGB	0.39	5.57	0.32	6.14e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7833790	0.963	rs6473312	chr8:82732515	C/A	cg17211192	chr8:82754475	SNX16	-0.7	-8.43	-0.46	2.27e-15	Diastolic blood pressure;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21512817	chr2:216176813	ATIC	0.57	6.59	0.38	2.33e-10	Gut microbiome composition (summer);
CESC	cis	rs61008539	0.815	rs6960062	chr7:884665	A/G	cg10204951	chr7:910479	UNC84A	-0.45	-5.64	-0.33	4.3e-8	Perceived unattractiveness to mosquitoes;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg15556090	chr7:149195153	ZNF746	0.41	6.33	0.36	1.02e-9	Gambling;
CESC	cis	rs2380220	0.541	rs9285413	chr6:96023439	G/A	cg15832292	chr6:96025679	MANEA	0.75	7.83	0.43	1.19e-13	Behavioural disinhibition (generation interaction);
CESC	cis	rs2070488	0.775	rs6599211	chr3:38558830	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.78	-12.57	-0.61	9.53e-29	Electrocardiographic conduction measures;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg09036558	chr16:69973001	WWP2	0.5	6.79	0.38	7.28e-11	Fibrinogen levels;
CESC	cis	rs11696501	0.688	rs6104295	chr20:44326917	C/T	cg11783356	chr20:44313418	WFDC10B	-0.31	-5.08	-0.3	7.02e-7	Brain structure;
CESC	cis	rs17764205	0.929	rs10419626	chr19:3256104	G/T	cg04171554	chr19:2761892	SGTA	-0.55	-5.15	-0.3	4.97e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs270601	0.955	rs273911	chr5:131661526	C/G	cg24060327	chr5:131705240	SLC22A5	-0.76	-10.74	-0.55	1.42e-22	Acylcarnitine levels;
CESC	cis	rs1707322	0.835	rs946525	chr1:46487277	A/T	cg06784218	chr1:46089804	CCDC17	-0.33	-5.6	-0.33	5.27e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2120019	1.000	rs7162900	chr15:75368017	T/C	cg09165964	chr15:75287851	SCAMP5	-0.67	-8.04	-0.44	3.09e-14	Blood trace element (Zn levels);
CESC	cis	rs9837602	1.000	rs35521705	chr3:99716690	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.53	7.24	0.41	4.82e-12	Breast cancer;
CESC	cis	rs7202877	0.656	rs247427	chr16:75439132	T/C	cg04384234	chr16:75411784	CFDP1	0.5	5.78	0.33	2.09e-8	Type 2 diabetes;Type 1 diabetes;
CESC	cis	rs9322193	0.923	rs4869750	chr6:150177132	C/T	cg09699651	chr6:150184138	LRP11	0.52	6.24	0.36	1.71e-9	Lung cancer;
CESC	cis	rs17711722	0.701	rs781145	chr7:65440370	A/C	cg26939375	chr7:64535504	NA	0.76	10.73	0.55	1.49e-22	Calcium levels;
CESC	cis	rs1005277	0.522	rs7072977	chr10:37940440	C/A	cg00409905	chr10:38381863	ZNF37A	-0.49	-6.68	-0.38	1.4e-10	Extrinsic epigenetic age acceleration;
CESC	cis	rs79839061	0.610	rs12651368	chr4:856787	G/A	cg07828340	chr4:882639	GAK	1.09	8.38	0.46	3.15e-15	Intelligence (multi-trait analysis);
CESC	cis	rs2573652	1.000	rs2581358	chr15:100513725	C/G	cg00587665	chr15:100533223	ADAMTS17	-0.34	-5.49	-0.32	9.64e-8	Height;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg13969496	chr9:140095465	C9orf75	-0.46	-6.34	-0.36	9.85e-10	Ulcerative colitis;
CESC	cis	rs2191566	1.000	rs390369	chr19:44506984	C/T	cg20607764	chr19:44506953	ZNF230	0.61	8.1	0.45	2e-14	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs854765	0.583	rs8078105	chr17:17853782	T/C	cg04398451	chr17:18023971	MYO15A	-0.69	-9.72	-0.51	2.77e-19	Total body bone mineral density;
CESC	cis	rs7772486	0.875	rs2814863	chr6:146347299	C/T	cg05347473	chr6:146136440	FBXO30	-0.45	-5.89	-0.34	1.15e-8	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs25645	0.771	rs10445310	chr17:38205396	C/A	cg17467752	chr17:38218738	THRA	-0.53	-6.84	-0.39	5.47e-11	Myeloid white cell count;
CESC	cis	rs17666538	0.585	rs1669733	chr8:606696	C/T	cg23958373	chr8:599963	NA	-0.91	-6.87	-0.39	4.68e-11	IgG glycosylation;
CESC	cis	rs10927875	0.691	rs1048302	chr1:16340879	T/G	cg22431228	chr1:16359049	CLCNKA	-0.48	-7.86	-0.43	9.56e-14	Dilated cardiomyopathy;
CESC	cis	rs4819052	0.807	rs4819047	chr21:46665139	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.91	13.3	0.63	2.96e-31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs10504229	0.679	rs16921688	chr8:58054659	T/C	cg02725872	chr8:58115012	NA	-0.41	-5.95	-0.34	8.38e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs5769707	0.967	rs763126	chr22:49988574	G/T	cg20744362	chr22:50050164	C22orf34	-0.41	-6.75	-0.38	9.28e-11	Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs763121	0.853	rs138713	chr22:39142615	T/C	cg06022373	chr22:39101656	GTPBP1	0.92	16.53	0.71	1.2e-42	Menopause (age at onset);
CESC	cis	rs6580649	0.883	rs7967762	chr12:48420214	C/T	cg24011408	chr12:48396354	COL2A1	-0.42	-5.29	-0.31	2.6e-7	Lung cancer;
CESC	cis	rs7605827	0.866	rs4668917	chr2:15661815	G/C	cg19274914	chr2:15703543	NA	0.36	6.33	0.36	1.07e-9	Educational attainment (years of education);
CESC	cis	rs1218582	0.772	rs4845689	chr1:154885524	A/G	cg03351412	chr1:154909251	PMVK	0.7	9.53	0.51	1.08e-18	Prostate cancer;
CESC	cis	rs651907	0.535	rs34161138	chr3:101510388	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.46	6.05	0.35	4.95e-9	Colorectal cancer;
CESC	cis	rs2637266	0.905	rs2395395	chr10:78360770	A/G	cg18941641	chr10:78392320	NA	0.39	7.19	0.4	6.47e-12	Pulmonary function;
CESC	cis	rs7811142	1.000	rs6962151	chr7:100028484	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.12	12.99	0.62	3.48e-30	Platelet count;
CESC	cis	rs4332037	0.802	rs12113633	chr7:1932936	G/A	cg23422044	chr7:1970798	MAD1L1	-0.58	-6.05	-0.35	5e-9	Bipolar disorder;
CESC	cis	rs145445141	1	rs145445141	chr1:67489169	ATT/A	cg08660285	chr1:67390436	MIER1;WDR78	0.92	10.71	0.55	1.8e-22	Neutrophil percentage of white cells;
CESC	cis	rs2463822	0.764	rs7125402	chr11:62097259	C/T	cg06239285	chr11:62104954	ASRGL1	0.89	8.97	0.48	5.69e-17	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs2066819	1.000	rs11575232	chr12:56744422	G/A	cg26804944	chr12:56660921	COQ10A	-0.83	-5.03	-0.3	9.17e-7	Psoriasis vulgaris;
CESC	cis	rs7186908	0.761	rs34714490	chr16:72177099	G/T	cg16558253	chr16:72132732	DHX38	-0.42	-5.15	-0.3	5.18e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs2204008	0.597	rs4002591	chr12:38133841	A/G	cg13010199	chr12:38710504	ALG10B	0.51	6.39	0.37	7.31e-10	Bladder cancer;
CESC	cis	rs875971	0.862	rs6952182	chr7:65683317	T/G	cg18252515	chr7:66147081	NA	0.46	6.03	0.35	5.53e-9	Aortic root size;
CESC	cis	rs1665050	0.534	rs8028828	chr15:59236052	C/A	cg05156742	chr15:59063176	FAM63B	0.5	6.42	0.37	6.18e-10	Atopic dermatitis;
CESC	cis	rs9910055	0.821	rs4473241	chr17:42281282	G/T	cg10896456	chr17:42255109	ASB16;C17orf65	0.42	5.8	0.34	1.9e-8	Total body bone mineral density;
CESC	cis	rs9322193	0.923	rs9322207	chr6:149978321	G/A	cg07701084	chr6:150067640	NUP43	0.47	6.62	0.38	1.97e-10	Lung cancer;
CESC	cis	rs7127900	0.583	rs11043147	chr11:2234169	C/G	cg25635251	chr11:2234043	NA	0.88	15.7	0.69	1.05e-39	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
CESC	cis	rs769267	0.965	rs2269873	chr19:19392401	T/C	cg03709012	chr19:19516395	GATAD2A	0.96	14.18	0.66	2.35e-34	Tonsillectomy;
CESC	cis	rs2204008	0.774	rs11616004	chr12:38278822	G/A	cg26384229	chr12:38710491	ALG10B	0.72	10.26	0.53	5.3e-21	Bladder cancer;
CESC	cis	rs651907	0.557	rs13069443	chr3:101373305	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.48	6.19	0.36	2.33e-9	Colorectal cancer;
CESC	cis	rs12497850	0.866	rs6791234	chr3:48996137	A/G	cg02487422	chr3:49467188	NICN1	0.46	5.76	0.33	2.38e-8	Parkinson's disease;
CESC	cis	rs116095464	0.558	rs9312956	chr5:201812	T/C	cg22857025	chr5:266934	NA	-1.27	-14.49	-0.66	2e-35	Breast cancer;
CESC	cis	rs5167	0.504	rs7257476	chr19:45453165	C/T	cg20090143	chr19:45452003	APOC2	0.37	6.39	0.37	7.54e-10	Blood protein levels;
CESC	cis	rs1030268	0.640	rs12707092	chr7:133188145	C/G	cg10665199	chr7:133106180	EXOC4	0.5	5.4	0.31	1.51e-7	Intelligence (multi-trait analysis);
CESC	cis	rs11098499	0.863	rs11736416	chr4:120431661	C/T	cg09307838	chr4:120376055	NA	0.93	12.81	0.62	1.5e-29	Corneal astigmatism;
CESC	cis	rs1550582	0.662	rs4909628	chr8:135502380	A/T	cg17885191	chr8:135476712	NA	-0.84	-10.71	-0.55	1.8e-22	Educational attainment;
CESC	cis	rs9291683	0.595	rs35250962	chr4:10048271	C/T	cg00071950	chr4:10020882	SLC2A9	0.85	14.82	0.67	1.3e-36	Bone mineral density;
CESC	cis	rs2576037	0.501	rs8089938	chr18:44459497	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.65	-9.11	-0.49	2.12e-17	Personality dimensions;
CESC	cis	rs801193	1.000	rs4279493	chr7:66226620	C/T	cg11764359	chr7:65958608	NA	0.67	8.72	0.47	3.12e-16	Aortic root size;
CESC	cis	rs72781680	0.611	rs55905755	chr2:24330264	T/C	cg20701182	chr2:24300061	SF3B14	0.94	10.42	0.54	1.55e-21	Lymphocyte counts;
CESC	trans	rs66573146	0.831	rs66645969	chr4:6985614	G/A	cg07817883	chr1:32538562	TMEM39B	1.21	7.99	0.44	4.16e-14	Granulocyte percentage of myeloid white cells;
CESC	cis	rs7945705	0.935	rs11042103	chr11:8888700	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.48	7.76	0.43	1.81e-13	Hemoglobin concentration;
CESC	cis	rs9894429	0.646	rs9902264	chr17:79613828	G/A	cg18240062	chr17:79603768	NPLOC4	0.51	6.76	0.38	8.81e-11	Eye color traits;
CESC	cis	rs4472734	1.000	rs6540834	chr1:214627419	C/T	cg00063699	chr1:214624242	PTPN14	-0.33	-5.05	-0.3	8.33e-7	Height;
CESC	cis	rs7188697	0.882	rs37054	chr16:58558989	C/T	cg21335942	chr16:58549945	SETD6	0.47	5.5	0.32	9.04e-8	QT interval;
CESC	trans	rs11098499	0.865	rs2389809	chr4:120377399	T/C	cg25214090	chr10:38739885	LOC399744	0.7	9.91	0.52	6.89e-20	Corneal astigmatism;
CESC	trans	rs33794	0.623	rs6808026	chr3:45238131	A/G	cg20429833	chr17:6358427	PITPNM3	-0.36	-6.18	-0.35	2.36e-9	Lung function (forced expiratory volume in 1 second);
CESC	cis	rs6424115	0.760	rs2999566	chr1:24051124	A/G	cg10978503	chr1:24200527	CNR2	0.27	5.35	0.31	1.89e-7	Immature fraction of reticulocytes;
CESC	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg24503407	chr1:205819492	PM20D1	0.48	7.28	0.41	3.73e-12	Menarche (age at onset);
CESC	cis	rs9905704	0.918	rs34430710	chr17:56876627	A/T	cg12560992	chr17:57184187	TRIM37	0.6	7.0	0.4	2.08e-11	Testicular germ cell tumor;
CESC	cis	rs1950500	0.545	rs1950501	chr14:24806800	C/G	cg16194253	chr14:24768981	DHRS1;C14orf21	0.5	6.51	0.37	3.73e-10	Height;
CESC	cis	rs2836974	0.897	rs6517513	chr21:40526878	A/G	cg11644478	chr21:40555479	PSMG1	1.04	17.85	0.74	2.41e-47	Cognitive function;
CESC	cis	rs6665290	0.935	rs6659424	chr1:227197875	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.22	-33.72	-0.9	7.52e-98	Myeloid white cell count;
CESC	trans	rs7178375	1.000	rs7178375	chr15:31215935	C/T	cg04373760	chr16:53404718	NA	0.54	6.97	0.39	2.55e-11	Hypertriglyceridemia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21496518	chr3:15374154	SH3BP5	0.51	6.56	0.37	2.87e-10	Gut microbiome composition (summer);
CESC	cis	rs1023500	0.505	rs134899	chr22:42683030	T/G	cg05082376	chr22:42548792	NA	-0.36	-5.33	-0.31	2.08e-7	Schizophrenia;
CESC	cis	rs6952808	0.792	rs4421257	chr7:1955152	T/C	cg05863683	chr7:1912471	MAD1L1	0.37	5.75	0.33	2.47e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs3126085	0.877	rs4456098	chr1:152176034	C/T	cg03465714	chr1:152285911	FLG	-0.47	-5.69	-0.33	3.29e-8	Atopic dermatitis;
CESC	cis	rs56104184	0.668	rs73063523	chr19:49408943	T/C	cg21252483	chr19:49399788	TULP2	-0.52	-5.72	-0.33	2.94e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	cis	rs1707322	0.717	rs1135812	chr1:46095272	T/C	cg06784218	chr1:46089804	CCDC17	0.4	6.97	0.39	2.52e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs6032067	1.000	rs62205501	chr20:43864089	G/A	cg10761708	chr20:43804764	PI3	0.52	6.26	0.36	1.52e-9	Blood protein levels;
CESC	cis	rs7586879	0.593	rs6733224	chr2:25130907	C/T	cg01884057	chr2:25150051	NA	-0.37	-7.04	-0.4	1.64e-11	Body mass index;
CESC	cis	rs9584850	0.574	rs61969454	chr13:99170232	T/C	cg20750642	chr13:99100586	FARP1	-0.37	-5.32	-0.31	2.17e-7	Neuroticism;
CESC	cis	rs4803468	1.000	rs55986560	chr19:41939835	C/T	cg14132834	chr19:41945861	ATP5SL	0.6	7.5	0.42	9.48e-13	Height;
CESC	trans	rs687914	0.710	rs938662	chr2:45864578	A/G	cg07611812	chr8:53627203	RB1CC1	0.63	6.17	0.35	2.53e-9	Diastolic blood pressure;
CESC	cis	rs10256972	0.527	rs28671326	chr7:1174973	G/A	cg04025307	chr7:1156635	C7orf50	0.6	10.46	0.54	1.15e-21	Longevity;Endometriosis;
CESC	cis	rs7100689	0.646	rs10736346	chr10:82134281	A/C	cg00277334	chr10:82204260	NA	-0.57	-7.51	-0.42	9.08e-13	Post bronchodilator FEV1;
CESC	cis	rs7191700	0.644	rs12149160	chr16:11439303	G/T	cg00044050	chr16:11439710	C16orf75	-0.5	-6.3	-0.36	1.24e-9	Multiple sclerosis;
CESC	cis	rs4665809	1.000	rs6546767	chr2:26328746	A/G	cg08470875	chr2:26401718	FAM59B	-0.48	-5.27	-0.31	2.79e-7	Gut microbiome composition (summer);
CESC	cis	rs6674176	0.597	rs4660262	chr1:44382524	G/A	cg13606994	chr1:44402422	ARTN	-0.4	-6.29	-0.36	1.33e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs7584330	0.554	rs77648388	chr2:238431832	G/C	cg14458575	chr2:238380390	NA	0.69	6.48	0.37	4.33e-10	Prostate cancer;
CESC	cis	rs2228479	0.850	rs117880578	chr16:89910230	C/G	cg00800038	chr16:89945340	TCF25	-0.89	-6.89	-0.39	4.13e-11	Skin colour saturation;
CESC	cis	rs6088580	0.567	rs6088520	chr20:33132364	A/G	cg08999081	chr20:33150536	PIGU	-0.64	-10.92	-0.56	3.76e-23	Glomerular filtration rate (creatinine);
CESC	cis	rs35306767	0.855	rs35666723	chr10:867346	A/G	cg20503657	chr10:835505	NA	1.1	10.02	0.52	2.94e-20	Eosinophil percentage of granulocytes;
CESC	cis	rs2404602	0.716	rs2404737	chr15:76872217	T/G	cg22467129	chr15:76604101	ETFA	-0.35	-5.19	-0.3	4.23e-7	Blood metabolite levels;
CESC	cis	rs4835473	0.897	rs55945293	chr4:144625919	A/G	cg25736465	chr4:144833511	NA	-0.36	-5.44	-0.32	1.23e-7	Immature fraction of reticulocytes;
CESC	cis	rs17095355	1.000	rs9630101	chr10:111738451	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.44	-5.2	-0.3	3.98e-7	Biliary atresia;
CESC	cis	rs18122	0.661	rs4671790	chr2:67532139	T/A	cg09028215	chr2:67624308	ETAA1	-0.43	-5.23	-0.31	3.44e-7	Waist-to-hip ratio adjusted for body mass index;
CESC	trans	rs877282	0.947	rs7904978	chr10:768078	C/T	cg22713356	chr15:30763199	NA	1.17	11.73	0.58	7.23e-26	Uric acid levels;
CESC	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg19318889	chr4:1322082	MAEA	0.56	6.71	0.38	1.18e-10	Longevity;
CESC	cis	rs1348850	0.554	rs1374438	chr2:178376684	A/G	cg22681709	chr2:178499509	PDE11A	-0.5	-5.26	-0.31	2.92e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs2839186	0.588	rs7280110	chr21:47619039	G/A	cg12379764	chr21:47803548	PCNT	0.47	6.04	0.35	5.07e-9	Testicular germ cell tumor;
CESC	cis	rs7937682	0.924	rs513425	chr11:111504861	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.99	-16.01	-0.7	8.36e-41	Primary sclerosing cholangitis;
CESC	cis	rs258892	0.947	rs17606	chr5:72184098	C/T	cg21869765	chr5:72125136	TNPO1	0.44	5.57	0.32	6.25e-8	Small cell lung carcinoma;
CESC	cis	rs7824557	0.564	rs2043508	chr8:11227406	G/A	cg21775007	chr8:11205619	TDH	-0.53	-7.77	-0.43	1.76e-13	Retinal vascular caliber;
CESC	cis	rs8114671	0.562	rs6088655	chr20:33527838	A/G	cg24642439	chr20:33292090	TP53INP2	0.43	5.13	0.3	5.54e-7	Height;
CESC	cis	rs3820068	0.655	rs59605679	chr1:15863796	T/G	cg17385448	chr1:15911702	AGMAT	0.36	5.66	0.33	3.96e-8	Systolic blood pressure;
CESC	cis	rs514406	0.929	rs515857	chr1:53336859	A/G	cg16325326	chr1:53192061	ZYG11B	0.75	11.25	0.57	2.93e-24	Monocyte count;
CESC	cis	rs4253772	0.530	rs11090865	chr22:46731689	G/T	cg00784671	chr22:46762841	CELSR1	-0.58	-6.26	-0.36	1.51e-9	LDL cholesterol;Cholesterol, total;
CESC	cis	rs4919687	0.550	rs7907503	chr10:104440050	C/T	cg04362960	chr10:104952993	NT5C2	0.44	5.17	0.3	4.55e-7	Colorectal cancer;
CESC	cis	rs35110281	1.000	rs35110281	chr21:45068947	T/A	cg01579765	chr21:45077557	HSF2BP	-0.55	-9.03	-0.48	3.73e-17	Mean corpuscular volume;
CESC	cis	rs7615952	0.673	rs34209763	chr3:125599595	G/A	cg05084668	chr3:125655381	ALG1L	-0.6	-6.47	-0.37	4.78e-10	Blood pressure (smoking interaction);
CESC	cis	rs15676	0.783	rs3829057	chr9:131567982	A/G	cg00228799	chr9:131580591	ENDOG	0.49	6.2	0.36	2.1e-9	Blood metabolite levels;
CESC	cis	rs7772486	0.790	rs2253880	chr6:146200774	T/C	cg23711669	chr6:146136114	FBXO30	0.9	13.27	0.63	3.71e-31	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4699052	0.963	rs4698890	chr4:104181878	T/C	cg16532752	chr4:104119610	CENPE	-0.45	-6.19	-0.36	2.34e-9	Testicular germ cell tumor;
CESC	cis	rs2576037	0.763	rs2060418	chr18:44576535	A/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.43	5.51	0.32	8.71e-8	Personality dimensions;
CESC	cis	rs7666738	0.830	rs969049	chr4:98988857	C/T	cg17366294	chr4:99064904	C4orf37	0.6	8.59	0.47	7.62e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs17854409	0.881	rs12625401	chr20:61472939	A/T	cg07645718	chr20:61493192	TCFL5	0.8	5.32	0.31	2.26e-7	Obesity-related traits;
CESC	cis	rs769267	0.930	rs2301784	chr19:19390749	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.43	5.33	0.31	2.11e-7	Tonsillectomy;
CESC	cis	rs965513	1.000	rs925488	chr9:100546391	C/T	cg13688889	chr9:100608707	NA	-0.59	-8.35	-0.46	3.72e-15	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
CESC	cis	rs6089584	0.816	rs6061411	chr20:60634716	C/A	cg13770153	chr20:60521292	NA	-0.48	-6.21	-0.36	2e-9	Body mass index;
CESC	cis	rs7267979	1.000	rs4815404	chr20:25301845	T/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.86	-16.91	-0.72	5.15e-44	Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14074042	chr5:159546984	PWWP2A	-0.57	-6.65	-0.38	1.65e-10	Gut microbiome composition (summer);
CESC	cis	rs11676348	0.967	rs4674258	chr2:218990586	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.46	-6.1	-0.35	3.79e-9	Ulcerative colitis;
CESC	trans	rs66573146	1.000	rs55833486	chr4:6978729	C/A	cg07817883	chr1:32538562	TMEM39B	1.28	8.51	0.46	1.31e-15	Granulocyte percentage of myeloid white cells;
CESC	cis	rs1185460	0.967	rs1177562	chr11:118949331	C/T	cg23280166	chr11:118938394	VPS11	0.54	6.93	0.39	3.16e-11	Coronary artery disease;
CESC	cis	rs2180341	0.782	rs6912006	chr6:127722631	C/T	cg27446573	chr6:127587934	RNF146	0.7	9.32	0.5	4.6e-18	Breast cancer;
CESC	cis	rs9611565	0.512	rs5758464	chr22:42171300	A/G	cg03806693	chr22:41940476	POLR3H	0.95	8.47	0.46	1.73e-15	Vitiligo;
CESC	cis	rs4665809	0.652	rs11685594	chr2:26402846	A/G	cg22920501	chr2:26401640	FAM59B	-0.86	-10.03	-0.52	2.73e-20	Gut microbiome composition (summer);
CESC	cis	rs12122100	0.545	rs1984615	chr1:146506206	G/A	cg03526459	chr1:146549940	NA	-0.34	-5.3	-0.31	2.4e-7	HIV-1 control;
CESC	cis	rs11864453	0.713	rs12708926	chr16:72126063	T/C	cg16558253	chr16:72132732	DHX38	-0.56	-8.7	-0.47	3.62e-16	Fibrinogen levels;
CESC	cis	rs61996546	0.622	rs34886387	chr15:26862107	A/T	cg14859324	chr15:26874363	GABRB3	-0.38	-5.19	-0.3	4.11e-7	Response to methotrexate in juvenile idiopathic arthritis;
CESC	cis	rs798766	1.000	rs798741	chr4:1712413	A/G	cg07041428	chr4:1763019	NA	-0.35	-5.11	-0.3	6.05e-7	Bladder cancer;Urinary bladder cancer;
CESC	trans	rs12356475	0.710	rs10822686	chr10:67733250	C/T	cg25065205	chr1:233086286	C1orf57	0.52	6.13	0.35	3.19e-9	Psoriatic arthritis;
CESC	cis	rs7020830	0.894	rs13300951	chr9:37146627	A/G	cg14294708	chr9:37120828	ZCCHC7	1.27	25.54	0.84	2.02e-73	Schizophrenia;
CESC	cis	rs2836974	0.666	rs4624474	chr21:40686327	T/C	cg17971929	chr21:40555470	PSMG1	-0.85	-12.27	-0.6	1.01e-27	Cognitive function;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13719843	chr19:58897798	RPS5	0.66	7.48	0.42	1.09e-12	Gut microbiome composition (summer);
CESC	cis	rs6540556	0.682	rs667681	chr1:209914449	A/G	cg05527609	chr1:210001259	C1orf107	0.63	7.16	0.4	7.78e-12	Red blood cell count;
CESC	cis	rs1499614	1.000	rs2707832	chr7:66136549	C/T	cg13147721	chr7:65941812	NA	-0.92	-8.41	-0.46	2.5e-15	Gout;
CESC	cis	rs854765	0.583	rs11869536	chr17:17826528	T/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.57	8.18	0.45	1.22e-14	Total body bone mineral density;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg00812502	chr22:19109875	DGCR2	-0.43	-6.29	-0.36	1.3e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs853679	0.517	rs4713150	chr6:28136212	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.57	-6.59	-0.38	2.36e-10	Depression;
CESC	cis	rs11264213	0.681	rs116324086	chr1:36287771	A/G	cg27506609	chr1:36549197	TEKT2	0.61	5.04	0.3	8.54e-7	Schizophrenia;
CESC	cis	rs13191362	1.000	rs34066731	chr6:163011047	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.82	8.22	0.45	9.12e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs7178572	0.743	rs62009090	chr15:77837055	T/G	cg22256960	chr15:77711686	NA	-0.54	-7.34	-0.41	2.65e-12	Type 2 diabetes;
CESC	trans	rs11039798	0.588	rs7483361	chr11:48593786	G/A	cg15704280	chr7:45808275	SEPT13	0.6	6.24	0.36	1.69e-9	Axial length;
CESC	cis	rs1801251	0.964	rs7589201	chr2:233724536	A/G	cg08000102	chr2:233561755	GIGYF2	-0.7	-10.05	-0.53	2.42e-20	Coronary artery disease;
CESC	cis	rs7309	0.622	rs4664396	chr2:161901650	C/T	cg08807892	chr2:162101083	NA	-0.41	-5.29	-0.31	2.62e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
CESC	cis	rs875971	0.862	rs801195	chr7:66026115	A/G	cg11764359	chr7:65958608	NA	-0.78	-11.17	-0.57	5.37e-24	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03001504	chr20:17663218	RRBP1	0.59	6.88	0.39	4.42e-11	Gut microbiome composition (summer);
CESC	cis	rs7552404	0.765	rs211717	chr1:76106969	G/A	cg22875332	chr1:76189707	ACADM	-0.64	-7.57	-0.42	6.05e-13	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs7666738	0.830	rs7673385	chr4:99024922	T/G	cg03467027	chr4:99064603	C4orf37	0.48	6.15	0.35	2.83e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs708547	0.836	rs1277287	chr4:57853147	C/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.82	10.58	0.55	4.61e-22	Response to bleomycin (chromatid breaks);
CESC	cis	rs3768617	0.510	rs6424884	chr1:183065904	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.88	14.24	0.66	1.45e-34	Fuchs's corneal dystrophy;
CESC	cis	rs2842992	0.672	rs4708845	chr6:160219601	T/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.78	9.64	0.51	4.81e-19	Age-related macular degeneration (geographic atrophy);
CESC	trans	rs12356475	0.710	rs10822686	chr10:67733250	C/T	cg00828305	chr2:178077190	HNRNPA3	0.51	6.07	0.35	4.48e-9	Psoriatic arthritis;
CESC	trans	rs853679	0.556	rs45509595	chr6:27840926	T/C	cg06606381	chr12:133084897	FBRSL1	-1.11	-8.93	-0.48	7.41e-17	Depression;
CESC	trans	rs650950	0.528	rs646660	chr11:35528452	C/T	cg22087390	chr7:98050531	NA	0.43	6.09	0.35	3.9e-9	Bronchopulmonary dysplasia;
CESC	cis	rs637571	0.522	rs538954	chr11:65756808	A/G	cg02202077	chr11:65769826	EIF1AD;BANF1	0.45	6.03	0.35	5.46e-9	Eosinophil percentage of white cells;
CESC	cis	rs7618915	0.501	rs2159644	chr3:52774530	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.62	8.74	0.47	2.77e-16	Bipolar disorder;
CESC	cis	rs6938	0.534	rs7495739	chr15:75185670	C/T	cg10253484	chr15:75165896	SCAMP2	0.5	6.72	0.38	1.14e-10	Breast cancer;
CESC	cis	rs4665809	0.627	rs35461456	chr2:26482361	C/G	cg25036284	chr2:26402008	FAM59B	0.86	9.36	0.5	3.44e-18	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18269526	chr11:984455	AP2A2	-0.62	-7.28	-0.41	3.76e-12	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10833576	chr5:72861749	UTP15;ANKRA2	-0.55	-6.22	-0.36	1.89e-9	Gut microbiome composition (summer);
CESC	cis	rs977987	0.806	rs2865531	chr16:75390316	T/A	cg03315344	chr16:75512273	CHST6	0.39	5.64	0.33	4.3e-8	Dupuytren's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00747290	chr2:42721154	KCNG3	0.58	6.1	0.35	3.64e-9	Gut microbiome composition (summer);
CESC	cis	rs7937682	0.558	rs7113067	chr11:111692182	G/A	cg09085632	chr11:111637200	PPP2R1B	0.85	10.37	0.54	2.32e-21	Primary sclerosing cholangitis;
CESC	cis	rs2836950	0.527	rs2836948	chr21:40599677	T/C	cg11644478	chr21:40555479	PSMG1	-0.51	-6.94	-0.39	3.01e-11	Menarche (age at onset);
CESC	cis	rs11166629	1.000	rs11166629	chr8:135636964	C/T	cg27224718	chr8:135614730	ZFAT	0.54	6.75	0.38	9.34e-11	Smoking quantity;
CESC	cis	rs1799949	0.965	rs799910	chr17:41279561	G/C	cg23758822	chr17:41437982	NA	0.99	17.46	0.73	5.87e-46	Menopause (age at onset);
CESC	cis	rs9915657	0.870	rs12941066	chr17:70141226	C/T	cg09344028	chr17:70110421	NA	0.34	6.01	0.35	6.13e-9	Thyroid hormone levels;
CESC	cis	rs7923609	1.000	rs7923609	chr10:65133822	A/G	cg01631684	chr10:65280961	REEP3	-0.42	-5.18	-0.3	4.32e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs10791097	0.720	rs7119425	chr11:130733185	C/T	cg12179176	chr11:130786555	SNX19	0.58	8.87	0.48	1.12e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs2228479	1.000	rs117406136	chr16:89974605	C/T	cg06558623	chr16:89946397	TCF25	1.16	9.15	0.49	1.54e-17	Skin colour saturation;
CESC	cis	rs798554	1.000	rs798545	chr7:2762386	C/T	cg19346786	chr7:2764209	NA	-0.51	-7.48	-0.42	1.12e-12	Height;
CESC	cis	rs6724607	1.000	rs11680758	chr2:191446268	T/G	cg21644426	chr2:191273491	MFSD6	0.47	6.48	0.37	4.45e-10	Pulse pressure;
CESC	cis	rs2836974	0.897	rs13049280	chr21:40594656	C/G	cg17971929	chr21:40555470	PSMG1	0.99	13.53	0.64	4.55e-32	Cognitive function;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11224423	chr12:56136943	GDF11	0.57	7.05	0.4	1.58e-11	Gut microbiome composition (summer);
CESC	cis	rs4595586	0.545	rs17546137	chr12:39401124	G/A	cg13010199	chr12:38710504	ALG10B	0.45	5.57	0.32	6.23e-8	Morning vs. evening chronotype;
CESC	cis	rs9322193	0.736	rs3805750	chr6:150112201	G/A	cg13206674	chr6:150067644	NUP43	0.43	6.04	0.35	5.17e-9	Lung cancer;
CESC	cis	rs847577	0.832	rs1799068	chr7:97707069	G/T	cg24562669	chr7:97807699	LMTK2	-0.54	-8.3	-0.45	5.2e-15	Breast cancer;
CESC	cis	rs1670533	1.000	rs6852558	chr4:1059944	C/T	cg27284194	chr4:1044797	NA	0.47	6.07	0.35	4.4e-9	Recombination rate (females);
CESC	cis	rs1552244	1.000	rs7651058	chr3:10066964	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.89	12.17	0.6	2.39e-27	Alzheimer's disease;
CESC	cis	rs9916302	0.706	rs4795385	chr17:37733148	A/G	cg00129232	chr17:37814104	STARD3	0.6	6.11	0.35	3.53e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs4148883	0.675	rs11724783	chr4:100099688	C/A	cg13256891	chr4:100009986	ADH5	0.53	6.93	0.39	3.23e-11	Alcohol dependence;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg12885832	chr12:111843885	SH2B3	-0.4	-6.01	-0.35	5.99e-9	Gambling;
CESC	cis	rs4919694	0.711	rs113361908	chr10:104978126	T/C	cg04362960	chr10:104952993	NT5C2	0.81	6.71	0.38	1.15e-10	Arsenic metabolism;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg27457339	chr12:69004323	RAP1B	0.5	6.44	0.37	5.48e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs6543140	0.964	rs10196334	chr2:103090041	T/C	cg04239558	chr2:103089729	SLC9A4	0.48	6.28	0.36	1.36e-9	Blood protein levels;
CESC	cis	rs7918232	0.830	rs7911024	chr10:27433636	A/C	cg14442939	chr10:27389572	ANKRD26	0.72	6.92	0.39	3.31e-11	Breast cancer;
CESC	cis	rs13108904	0.934	rs13134106	chr4:1302902	A/G	cg22903657	chr4:1355424	KIAA1530	-0.37	-5.13	-0.3	5.63e-7	Obesity-related traits;
CESC	cis	rs10242455	0.702	rs45461000	chr7:99052710	A/G	cg25640893	chr7:99214727	ZNF498	0.72	5.27	0.31	2.78e-7	Blood metabolite levels;
CESC	cis	rs9303401	0.646	rs7217845	chr17:57236900	G/A	cg12560992	chr17:57184187	TRIM37	0.43	5.13	0.3	5.62e-7	Cognitive test performance;
CESC	cis	rs1552244	0.554	rs34883592	chr3:10046165	C/T	cg00149659	chr3:10157352	C3orf10	0.54	6.55	0.37	2.98e-10	Alzheimer's disease;
CESC	cis	rs889312	0.500	rs865570	chr5:56161975	C/T	cg14703610	chr5:56206110	C5orf35	0.48	6.28	0.36	1.38e-9	Breast cancer;Breast cancer (early onset);
CESC	cis	rs854765	0.856	rs2955382	chr17:17947710	C/T	cg04398451	chr17:18023971	MYO15A	0.63	8.9	0.48	9.26e-17	Total body bone mineral density;
CESC	cis	rs9322193	0.923	rs9479494	chr6:150060244	A/G	cg13206674	chr6:150067644	NUP43	0.45	6.5	0.37	3.94e-10	Lung cancer;
CESC	cis	rs1256061	0.654	rs1256031	chr14:64746179	C/T	cg23250157	chr14:64679961	SYNE2	0.47	6.68	0.38	1.43e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	trans	rs9987353	0.840	rs329994	chr8:9123233	A/G	cg26400300	chr15:44829086	EIF3J	-0.45	-6.08	-0.35	4.17e-9	Recombination measurement;
CESC	cis	rs9649213	0.593	rs7458551	chr7:97952167	G/C	cg21770322	chr7:97807741	LMTK2	0.54	8.17	0.45	1.26e-14	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs561341	1.000	rs4795670	chr17:30244839	T/C	cg13647721	chr17:30228624	UTP6	0.7	6.97	0.39	2.47e-11	Hip circumference adjusted for BMI;
CESC	cis	rs875971	0.862	rs6947339	chr7:65888470	T/C	cg11764359	chr7:65958608	NA	0.78	11.31	0.57	1.86e-24	Aortic root size;
CESC	cis	rs57244997	0.544	rs77182940	chr6:162443721	T/C	cg17173639	chr6:162384350	PARK2	-0.52	-5.49	-0.32	9.45e-8	Mosquito bite size;
CESC	cis	rs4835473	0.897	rs13144504	chr4:144628555	T/C	cg25736465	chr4:144833511	NA	-0.45	-6.84	-0.39	5.58e-11	Immature fraction of reticulocytes;
CESC	cis	rs7259376	0.902	rs12978477	chr19:22577709	C/G	cg02657401	chr19:22469223	NA	0.26	5.15	0.3	5.08e-7	Menopause (age at onset);
CESC	cis	rs854765	0.583	rs6502619	chr17:17779704	C/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.52	-7.21	-0.41	5.78e-12	Total body bone mineral density;
CESC	cis	rs6541297	1.000	rs2352723	chr1:230291868	C/T	cg20703242	chr1:230279135	GALNT2	-0.64	-9.16	-0.49	1.46e-17	Coronary artery disease;
CESC	cis	rs34375054	0.573	rs12831151	chr12:125656263	C/T	cg25124228	chr12:125621409	AACS	-0.49	-5.43	-0.32	1.28e-7	Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs910316	0.967	rs4903285	chr14:75609268	A/T	cg11812906	chr14:75593930	NEK9	0.92	16.16	0.7	2.31e-41	Height;
CESC	cis	rs2479106	0.591	rs10760293	chr9:126353327	T/C	cg16191174	chr9:126692580	DENND1A	0.37	5.09	0.3	6.82e-7	Polycystic ovary syndrome;
CESC	cis	rs2204008	0.557	rs11520191	chr12:38197057	T/A	cg13010199	chr12:38710504	ALG10B	0.51	6.45	0.37	5.18e-10	Bladder cancer;
CESC	cis	rs2075371	0.829	rs35897155	chr7:134002711	G/A	cg20476274	chr7:133979776	SLC35B4	0.6	8.4	0.46	2.72e-15	Mean platelet volume;
CESC	cis	rs11785693	0.862	rs73183606	chr8:4986999	C/T	cg26367366	chr8:4980734	NA	0.95	8.7	0.47	3.6e-16	Neuroticism (multi-trait analysis);Neuroticism;
CESC	cis	rs8078723	1.000	rs4795416	chr17:38158133	C/T	cg17467752	chr17:38218738	THRA	0.69	10.55	0.54	5.78e-22	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CESC	cis	rs2439831	1.000	rs2264239	chr15:43765533	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.85	12.48	0.61	1.94e-28	Lung cancer in ever smokers;
CESC	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	7.64	0.43	3.85e-13	Prudent dietary pattern;
CESC	cis	rs7917772	0.636	rs2249845	chr10:104512095	A/G	cg04362960	chr10:104952993	NT5C2	0.44	5.14	0.3	5.33e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg08555112	chr17:48942811	TOB1	0.5	6.57	0.37	2.63e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs7267979	1.000	rs6037086	chr20:25306338	A/G	cg08601574	chr20:25228251	PYGB	-0.36	-5.13	-0.3	5.74e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs3733585	0.673	rs7378340	chr4:9955198	C/T	cg02734326	chr4:10020555	SLC2A9	-0.38	-5.37	-0.31	1.69e-7	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs2075371	1.000	rs2598296	chr7:133992985	C/T	cg00033643	chr7:134001901	SLC35B4	0.44	5.57	0.32	6.31e-8	Mean platelet volume;
CESC	trans	rs7618501	0.602	rs2013208	chr3:50129399	C/T	cg21659725	chr3:3221576	CRBN	-0.5	-6.87	-0.39	4.48e-11	Intelligence (multi-trait analysis);
CESC	cis	rs853679	0.517	rs9357065	chr6:28129580	T/C	cg23161317	chr6:28129485	ZNF389	0.51	6.43	0.37	5.76e-10	Depression;
CESC	cis	rs2710642	0.751	rs10496099	chr2:62805902	T/C	cg17519650	chr2:63277830	OTX1	0.47	5.84	0.34	1.51e-8	LDL cholesterol levels;LDL cholesterol;
CESC	cis	rs7551222	0.752	rs4252677	chr1:204495253	G/A	cg20240347	chr1:204465584	NA	-0.28	-5.66	-0.33	3.86e-8	Schizophrenia;
CESC	cis	rs2688608	0.620	rs12253408	chr10:75495956	G/T	cg23231163	chr10:75533350	FUT11	-0.35	-5.28	-0.31	2.68e-7	Inflammatory bowel disease;
CESC	cis	rs8072100	0.967	rs9894905	chr17:45485982	C/T	cg25173405	chr17:45401733	C17orf57	-0.41	-5.53	-0.32	7.78e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg11965913	chr1:205819406	PM20D1	0.82	13.95	0.65	1.49e-33	Menarche (age at onset);
CESC	cis	rs7100689	0.784	rs7082102	chr10:82104890	A/C	cg09936400	chr10:82049201	MAT1A	0.37	5.53	0.32	7.62e-8	Post bronchodilator FEV1;
CESC	cis	rs2120019	1.000	rs12910644	chr15:75358388	A/G	cg17294928	chr15:75287854	SCAMP5	-0.65	-6.96	-0.39	2.66e-11	Blood trace element (Zn levels);
CESC	cis	rs2549003	1.000	rs6894655	chr5:131818649	T/C	cg00255919	chr5:131827918	IRF1	0.51	8.62	0.47	6.06e-16	Asthma (sex interaction);
CESC	cis	rs684232	0.666	rs366151	chr17:598311	A/C	cg12384639	chr17:618140	VPS53	0.43	5.68	0.33	3.63e-8	Prostate cancer;
CESC	cis	rs7927771	0.524	rs12421563	chr11:47780222	G/A	cg20307385	chr11:47447363	PSMC3	-0.58	-8.01	-0.44	3.54e-14	Subjective well-being;
CESC	trans	rs2075371	0.932	rs1862048	chr7:133978167	C/G	cg11636714	chr8:42128950	IKBKB	0.48	6.09	0.35	3.91e-9	Mean platelet volume;
CESC	cis	rs875971	1.000	rs3981131	chr7:65951677	A/G	cg12463550	chr7:65579703	CRCP	0.54	6.61	0.38	2.07e-10	Aortic root size;
CESC	cis	rs1468333	0.619	rs191968	chr5:137461112	T/C	cg27119451	chr5:137514611	BRD8;KIF20A	0.49	5.1	0.3	6.6e-7	Resting heart rate;
CESC	cis	rs3026101	0.671	rs55662604	chr17:5297457	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.43	5.71	0.33	3.06e-8	Body mass index;
CESC	cis	rs6570726	0.791	rs1509214	chr6:145784606	A/C	cg23711669	chr6:146136114	FBXO30	-0.97	-14.31	-0.66	8.35e-35	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7474896	0.537	rs2749586	chr10:38270214	G/C	cg25427524	chr10:38739819	LOC399744	0.49	5.63	0.33	4.63e-8	Obesity (extreme);
CESC	cis	rs897984	0.806	rs9319588	chr16:30930983	C/T	cg02466173	chr16:30829666	NA	0.49	8.46	0.46	1.82e-15	Dementia with Lewy bodies;
CESC	cis	rs7923609	0.846	rs7896518	chr10:65104500	A/G	cg01631684	chr10:65280961	REEP3	-0.43	-5.33	-0.31	2.1e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs34779708	0.931	rs35317849	chr10:35285721	C/A	cg04310649	chr10:35416472	CREM	-0.49	-5.91	-0.34	1.03e-8	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs7116495	0.609	rs79889241	chr11:71815585	T/C	cg10381502	chr11:71823885	C11orf51	1.08	6.66	0.38	1.56e-10	Severe influenza A (H1N1) infection;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg19244826	chr22:19466934	UFD1L;CDC45L	0.46	6.5	0.37	3.93e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs3091242	0.934	rs686631	chr1:25719599	A/T	cg03538708	chr1:25844672	NA	-0.4	-6.11	-0.35	3.61e-9	Erythrocyte sedimentation rate;
CESC	cis	rs2032447	0.507	rs478349	chr6:25894057	T/C	cg12310025	chr6:25882481	NA	-0.64	-9.52	-0.5	1.16e-18	Intelligence (multi-trait analysis);
CESC	cis	rs9894429	0.624	rs9910935	chr17:79613949	T/C	cg21984481	chr17:79567631	NPLOC4	-0.49	-7.28	-0.41	3.81e-12	Eye color traits;
CESC	cis	rs9584850	0.540	rs61969407	chr13:99119160	C/T	cg20750642	chr13:99100586	FARP1	-0.43	-5.97	-0.34	7.61e-9	Neuroticism;
CESC	cis	rs631288	0.557	rs2354434	chr1:146679428	A/G	cg25205988	chr1:146714368	CHD1L	1.04	6.64	0.38	1.78e-10	PR interval in Tripanosoma cruzi seropositivity;
CESC	cis	rs55788414	0.932	rs9929253	chr16:81181641	C/T	cg06400318	chr16:81190750	PKD1L2	-0.52	-6.18	-0.35	2.41e-9	Left ventricular obstructive tract defect (maternal effect);
CESC	cis	rs12477438	0.520	rs1044575	chr2:99812070	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.92	15.72	0.69	8.5e-40	Chronic sinus infection;
CESC	cis	rs7208859	0.673	rs2470251	chr17:29095061	T/C	cg04154034	chr17:28927549	LRRC37B2	0.56	5.27	0.31	2.89e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs10504229	0.593	rs12155520	chr8:58014318	C/T	cg22535103	chr8:58192502	C8orf71	-0.9	-8.95	-0.48	6.29e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs11792861	0.781	rs11793272	chr9:111762102	G/A	cg05043794	chr9:111880884	C9orf5	-0.38	-6.14	-0.35	2.93e-9	Menarche (age at onset);
CESC	cis	rs7589342	0.899	rs879900	chr2:106494347	A/G	cg16077055	chr2:106428750	NCK2	0.46	6.71	0.38	1.2e-10	Addiction;
CESC	cis	rs2842992	0.672	rs7738253	chr6:160193917	G/T	cg11366901	chr6:160182831	ACAT2	0.88	10.79	0.55	1e-22	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs7178572	0.568	rs12914345	chr15:77670401	A/C	cg22256960	chr15:77711686	NA	-0.53	-6.76	-0.38	8.88e-11	Type 2 diabetes;
CESC	cis	rs910316	0.737	rs175510	chr14:75524839	G/A	cg08847533	chr14:75593920	NEK9	-0.92	-15.88	-0.7	2.27e-40	Height;
CESC	cis	rs12136530	0.593	rs12404783	chr1:19735885	A/C	cg01832549	chr1:19774989	CAPZB	-0.48	-6.3	-0.36	1.25e-9	Lead levels in blood;
CESC	trans	rs9929218	1.000	rs28660361	chr16:68800838	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.63	-8.44	-0.46	2.13e-15	Colorectal cancer;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg09896403	chr22:24110173	CHCHD10	-0.47	-6.13	-0.35	3.22e-9	Asthma;
CESC	cis	rs6899676	0.539	rs16870736	chr6:10878371	C/G	cg17684657	chr6:10886967	SYCP2L	0.47	5.26	0.31	2.99e-7	Menopause (age at onset);
CESC	cis	rs7084402	0.967	rs1649048	chr10:60324282	C/T	cg07615347	chr10:60278583	BICC1	0.61	10.0	0.52	3.54e-20	Refractive error;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17298884	chr22:42343226	CENPM	0.63	7.56	0.42	6.81e-13	Gut microbiome composition (summer);
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg27570636	chr1:214454189	SMYD2	0.47	6.58	0.37	2.53e-10	Systemic lupus erythematosus;
CESC	trans	rs61931739	0.500	rs10844844	chr12:34380350	G/T	cg13010199	chr12:38710504	ALG10B	0.47	6.19	0.36	2.31e-9	Morning vs. evening chronotype;
CESC	cis	rs400736	0.524	rs7540528	chr1:8178624	C/T	cg25007680	chr1:8021821	PARK7	-0.44	-5.43	-0.32	1.27e-7	Response to antidepressants and depression;
CESC	cis	rs7618915	0.571	rs34115864	chr3:52612178	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	6.76	0.38	8.85e-11	Bipolar disorder;
CESC	trans	rs9987353	0.840	rs329994	chr8:9123233	A/G	cg07949612	chr2:69664562	NFU1	-0.47	-6.25	-0.36	1.61e-9	Recombination measurement;
CESC	cis	rs6540559	1.000	rs17015259	chr1:209982923	G/A	cg23283495	chr1:209979779	IRF6	0.51	7.52	0.42	8.25e-13	Cleft lip with or without cleft palate;
CESC	trans	rs1728785	1.000	rs7118	chr16:68600855	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	7.95	0.44	5.4e-14	Ulcerative colitis;
CESC	cis	rs9611565	0.918	rs9538	chr22:41755857	G/T	cg03806693	chr22:41940476	POLR3H	-1.03	-11.8	-0.59	4.22e-26	Vitiligo;
CESC	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.89	13.67	0.64	1.49e-32	Prudent dietary pattern;
CESC	cis	rs61935443	1.000	rs61935443	chr12:95249764	G/C	cg21533806	chr12:95267307	NA	0.52	6.64	0.38	1.8e-10	Schizophrenia;
CESC	cis	rs10754283	0.967	rs10922679	chr1:90100925	T/C	cg21401794	chr1:90099060	LRRC8C	0.7	9.41	0.5	2.54e-18	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs7552404	1.000	rs7513559	chr1:76173744	A/G	cg22875332	chr1:76189707	ACADM	0.63	7.33	0.41	2.78e-12	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs10751667	0.666	rs4074231	chr11:978219	G/C	cg20946044	chr11:1010712	AP2A2	-0.39	-5.4	-0.31	1.48e-7	Alzheimer's disease (late onset);
CESC	cis	rs9768139	0.733	rs56205111	chr7:158121055	T/C	cg24154853	chr7:158122151	PTPRN2	0.43	6.78	0.38	7.65e-11	Calcium levels;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg23912435	chr1:150601613	ENSA	-0.47	-6.97	-0.39	2.49e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs55871839	0.684	rs10108037	chr8:59812337	A/C	cg07426533	chr8:59803705	TOX	-0.47	-7.01	-0.4	1.95e-11	Pneumonia;
CESC	cis	rs12050794	0.636	rs3759902	chr15:72525274	C/G	cg16672083	chr15:72433130	SENP8	0.47	7.03	0.4	1.79e-11	Metabolite levels (HVA/MHPG ratio);
CESC	cis	rs1044826	0.642	rs167187	chr3:139237008	C/T	cg00490450	chr3:139108681	COPB2	-0.45	-5.52	-0.32	8.17e-8	Obesity-related traits;
CESC	cis	rs2832191	0.791	rs28633762	chr21:30500070	C/T	cg24692254	chr21:30365293	RNF160	-0.79	-12.11	-0.6	3.71e-27	Dental caries;
CESC	cis	rs17818399	0.926	rs35350086	chr2:46834036	C/G	cg02822958	chr2:46747628	ATP6V1E2	0.48	5.79	0.33	2.02e-8	Height;
CESC	cis	rs7714584	1.000	rs10058821	chr5:150226385	A/G	cg22134413	chr5:150180641	NA	0.52	5.64	0.33	4.31e-8	Crohn's disease;
CESC	cis	rs1843834	0.539	rs6739735	chr2:225405253	A/G	cg22509189	chr2:225307070	NA	0.4	5.46	0.32	1.11e-7	IgE levels in asthmatics (D.p. specific);
CESC	cis	rs796364	0.760	rs1569178	chr2:201024512	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.78	-6.71	-0.38	1.2e-10	Schizophrenia;
CESC	cis	rs6952808	1.000	rs4721122	chr7:1893311	C/G	cg05863683	chr7:1912471	MAD1L1	0.36	5.21	0.3	3.81e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs7772486	0.754	rs2328709	chr6:146106819	A/G	cg23711669	chr6:146136114	FBXO30	-1.0	-15.18	-0.68	6.78e-38	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs3942852	0.774	rs2279823	chr11:48146092	T/C	cg15704280	chr7:45808275	SEPT13	-0.66	-7.37	-0.41	2.18e-12	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs1799949	0.930	rs2298861	chr17:41176831	G/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.39	5.12	0.3	5.88e-7	Menopause (age at onset);
CESC	cis	rs8077889	0.645	rs1230393	chr17:41842592	A/G	cg26893861	chr17:41843967	DUSP3	-1.09	-22.71	-0.81	3.88e-64	Triglycerides;
CESC	cis	rs4727027	0.727	rs3801980	chr7:148878620	T/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.45	5.37	0.31	1.69e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs559928	0.606	rs76653616	chr11:63936139	T/G	cg18225595	chr11:63971243	STIP1	0.69	6.22	0.36	1.88e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CESC	cis	rs9611565	0.649	rs202614	chr22:41822150	A/C	cg06634786	chr22:41940651	POLR3H	0.71	7.17	0.4	7.6e-12	Vitiligo;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg24393316	chr9:100616469	FOXE1	-0.44	-6.41	-0.37	6.45e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs3105593	0.602	rs7165721	chr15:50942452	C/T	cg08437265	chr15:50716283	USP8	0.4	5.08	0.3	7.11e-7	QT interval;
CESC	cis	rs6088580	0.634	rs4911420	chr20:32998654	A/G	cg08999081	chr20:33150536	PIGU	-0.64	-11.72	-0.58	7.75e-26	Glomerular filtration rate (creatinine);
CESC	cis	rs72781680	0.898	rs72788302	chr2:24107246	C/T	cg20701182	chr2:24300061	SF3B14	0.78	6.93	0.39	3.11e-11	Lymphocyte counts;
CESC	cis	rs5769765	0.862	rs9616381	chr22:50312382	G/A	cg02269571	chr22:50332266	NA	-0.57	-6.99	-0.39	2.29e-11	Schizophrenia;
CESC	cis	rs1023500	0.505	rs134901	chr22:42683520	C/T	cg15557168	chr22:42548783	NA	-0.43	-6.56	-0.37	2.81e-10	Schizophrenia;
CESC	cis	rs1008375	0.932	rs10029173	chr4:17659598	C/T	cg02297831	chr4:17616191	MED28	-0.61	-7.89	-0.44	7.9e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	trans	rs4904167	0.841	rs12878411	chr14:84683539	C/T	cg06870609	chr15:89787223	FANCI	0.46	6.06	0.35	4.73e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs7918232	0.941	rs1775350	chr10:27441973	C/T	cg14240646	chr10:27532245	ACBD5	0.68	6.49	0.37	4.18e-10	Breast cancer;
CESC	cis	rs561341	0.714	rs7218466	chr17:30263314	A/G	cg12193833	chr17:30244370	NA	-0.49	-5.5	-0.32	9.08e-8	Hip circumference adjusted for BMI;
CESC	cis	rs2952156	1.000	rs2934971	chr17:37854507	G/T	cg07936489	chr17:37558343	FBXL20	-0.49	-5.76	-0.33	2.29e-8	Asthma;
CESC	cis	rs9916302	0.904	rs13341996	chr17:37536862	C/T	cg07936489	chr17:37558343	FBXL20	0.81	11.93	0.59	1.5e-26	Glomerular filtration rate (creatinine);
CESC	cis	rs12477438	0.520	rs13009147	chr2:99803998	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.85	15.59	0.69	2.54e-39	Chronic sinus infection;
CESC	cis	rs9611565	0.840	rs2234059	chr22:41777913	T/C	cg17376030	chr22:41985996	PMM1	0.67	7.26	0.41	4.21e-12	Vitiligo;
CESC	cis	rs11997175	0.583	rs17780153	chr8:33789161	A/G	ch.8.33884649F	chr8:33765107	NA	0.45	5.73	0.33	2.78e-8	Body mass index;
CESC	cis	rs947211	0.948	rs863725	chr1:205751196	C/T	cg26354017	chr1:205819088	PM20D1	0.42	5.35	0.31	1.9e-7	Parkinson's disease;
CESC	cis	rs2228479	0.718	rs11645376	chr16:89912281	G/C	cg04013166	chr16:89971882	TCF25	0.72	5.75	0.33	2.41e-8	Skin colour saturation;
CESC	cis	rs10744422	1.000	rs3817094	chr12:123332032	T/C	cg25930673	chr12:123319894	HIP1R	-0.73	-5.73	-0.33	2.68e-8	Schizophrenia;
CESC	cis	rs12042107	0.740	rs10922911	chr1:91205831	C/T	cg13456504	chr1:91191583	NA	-0.33	-5.67	-0.33	3.79e-8	Educational attainment;
CESC	cis	rs769267	0.930	rs4808959	chr19:19572108	T/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.46	5.86	0.34	1.34e-8	Tonsillectomy;
CESC	cis	rs7811142	1.000	rs6972167	chr7:100080013	G/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.03	11.43	0.57	7.31e-25	Platelet count;
CESC	cis	rs2108622	0.727	rs76984410	chr19:15982700	C/T	cg13772218	chr19:15982569	NA	0.29	5.8	0.34	1.85e-8	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CESC	cis	rs7647973	0.621	rs3774800	chr3:49334768	A/G	cg03060546	chr3:49711283	APEH	-0.5	-6.25	-0.36	1.6e-9	Menarche (age at onset);
CESC	cis	rs6598955	0.756	rs10902723	chr1:26568542	T/C	cg04990556	chr1:26633338	UBXN11	-0.78	-11.35	-0.57	1.35e-24	Obesity-related traits;
CESC	cis	rs9611565	0.659	rs28623192	chr22:41940524	A/G	cg06481639	chr22:41940642	POLR3H	-0.61	-6.46	-0.37	4.99e-10	Vitiligo;
CESC	cis	rs367943	0.665	rs4401566	chr5:112963356	A/G	cg12552261	chr5:112820674	MCC	0.44	5.61	0.33	4.97e-8	Type 2 diabetes;
CESC	cis	rs1707322	0.721	rs4564187	chr1:46166861	G/C	cg03146154	chr1:46216737	IPP	0.82	11.54	0.58	3.18e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs853679	0.517	rs9295761	chr6:28147987	A/G	cg12963246	chr6:28129442	ZNF389	0.54	7.16	0.4	7.91e-12	Depression;
CESC	cis	rs2033711	0.870	rs1051500	chr19:58944402	A/G	cg00825309	chr19:58991885	ZNF446	-0.55	-7.86	-0.43	9.77e-14	Uric acid clearance;
CESC	cis	rs765787	0.530	rs11636440	chr15:45535982	C/T	cg24006582	chr15:45444508	DUOX1	-0.59	-7.29	-0.41	3.52e-12	Uric acid levels;
CESC	cis	rs7615952	0.641	rs2365019	chr3:125808135	T/C	cg15145296	chr3:125709740	NA	-0.56	-5.97	-0.34	7.65e-9	Blood pressure (smoking interaction);
CESC	cis	rs11098499	0.820	rs2389885	chr4:120533931	C/T	cg09307838	chr4:120376055	NA	0.84	10.64	0.55	2.99e-22	Corneal astigmatism;
CESC	cis	rs2617583	0.967	rs2652509	chr5:1448247	A/G	cg07151155	chr5:1473589	LPCAT1	-0.34	-5.13	-0.3	5.61e-7	Breast cancer;
CESC	cis	rs3740713	0.920	rs112973292	chr11:18455888	A/C	cg23797887	chr11:18477753	LDHAL6A	-0.53	-5.27	-0.31	2.89e-7	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs2795502	0.882	rs2744095	chr10:43337949	A/T	cg20628663	chr10:43360327	NA	-0.63	-7.43	-0.42	1.5e-12	Blood protein levels;
CESC	cis	rs875971	0.964	rs2277911	chr7:65958625	T/G	cg10691866	chr7:65817282	TPST1	-0.35	-5.62	-0.33	4.9e-8	Aortic root size;
CESC	cis	rs875971	0.895	rs10447522	chr7:65796074	A/G	cg10691866	chr7:65817282	TPST1	0.32	5.42	0.32	1.35e-7	Aortic root size;
CESC	cis	rs7267979	0.966	rs2261794	chr20:25263062	T/G	cg08601574	chr20:25228251	PYGB	0.39	5.65	0.33	4.08e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs9611565	0.559	rs5758412	chr22:42080803	T/A	cg03806693	chr22:41940476	POLR3H	1.09	12.68	0.61	4.09e-29	Vitiligo;
CESC	cis	rs7707921	0.522	rs10065463	chr5:81500280	A/G	cg15871215	chr5:81402204	ATG10	-0.46	-6.55	-0.37	2.9e-10	Breast cancer;
CESC	cis	rs17433710	0.516	rs11805556	chr1:162673946	C/T	cg21140079	chr1:162667252	DDR2	-0.38	-5.04	-0.3	8.65e-7	Dupuytren's disease;
CESC	cis	rs7520050	0.778	rs3014216	chr1:46035760	A/T	cg24296786	chr1:45957014	TESK2	-0.48	-6.18	-0.36	2.37e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs7940866	0.834	rs10894302	chr11:130861994	C/T	cg12179176	chr11:130786555	SNX19	0.69	10.84	0.55	6.65e-23	Schizophrenia;
CESC	cis	rs1215050	0.740	rs6854802	chr4:99065480	A/C	cg05340658	chr4:99064831	C4orf37	0.57	7.49	0.42	1.04e-12	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs2625529	0.526	rs1035744	chr15:72566615	C/T	cg16672083	chr15:72433130	SENP8	0.43	6.49	0.37	4.32e-10	Red blood cell count;
CESC	cis	rs798766	1.000	rs1374469	chr4:1724799	C/T	cg05874882	chr4:1763078	NA	-0.61	-7.94	-0.44	5.92e-14	Bladder cancer;Urinary bladder cancer;
CESC	cis	rs12155623	0.834	rs16939055	chr8:49824013	T/G	cg22283653	chr8:49824208	NA	0.45	6.66	0.38	1.58e-10	Sudden cardiac arrest;
CESC	cis	rs2370759	1.000	rs16933177	chr10:32565705	G/A	cg05361325	chr10:32636312	EPC1	-0.6	-5.49	-0.32	9.48e-8	Sexual dysfunction (female);
CESC	cis	rs8077577	0.895	rs62072464	chr17:18108314	T/C	cg16794390	chr17:18148240	FLII	0.43	5.92	0.34	1.01e-8	Obesity-related traits;
CESC	cis	rs514406	0.679	rs545719	chr1:53304922	T/C	cg24675658	chr1:53192096	ZYG11B	-0.7	-10.15	-0.53	1.15e-20	Monocyte count;
CESC	cis	rs67311347	1.000	rs13073003	chr3:40504326	C/T	cg01475735	chr3:40494733	NA	0.46	5.83	0.34	1.64e-8	Renal cell carcinoma;
CESC	cis	rs10504229	1.000	rs59797486	chr8:58174435	T/C	cg24829409	chr8:58192753	C8orf71	-0.72	-9.91	-0.52	6.72e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs4718428	0.672	rs12530806	chr7:66390724	A/G	cg12165864	chr7:66369176	NA	-0.66	-7.74	-0.43	2.12e-13	Corneal structure;
CESC	trans	rs6084875	0.641	rs4815736	chr20:4722761	G/T	cg10192164	chr16:30419175	ZNF771	-0.5	-6.16	-0.35	2.7e-9	Systemic lupus erythematosus;
CESC	cis	rs2072732	0.808	rs67908307	chr1:2954297	T/C	cg15211996	chr1:2936768	ACTRT2	0.34	6.04	0.35	5.27e-9	Plateletcrit;
CESC	trans	rs12599106	0.584	rs12929704	chr16:34898258	C/A	cg03395511	chr6:291903	DUSP22	-0.7	-8.87	-0.48	1.1e-16	Menopause (age at onset);
CESC	trans	rs11241261	0.520	rs13185767	chr5:113399323	A/G	cg03068319	chr6:17600252	FAM8A1	-0.57	-6.23	-0.36	1.81e-9	Hippocampal sclerosis;
CESC	cis	rs1048238	0.548	rs848217	chr1:16272250	A/G	cg21385522	chr1:16154831	NA	-0.55	-7.35	-0.41	2.4e-12	Systolic blood pressure;
CESC	cis	rs5769707	0.632	rs1476037	chr22:49991377	G/A	cg20744362	chr22:50050164	C22orf34	0.37	5.22	0.31	3.53e-7	Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs35306767	0.761	rs11253559	chr10:1044809	T/C	cg25019033	chr10:957182	NA	-0.57	-5.57	-0.32	6.2e-8	Eosinophil percentage of granulocytes;
CESC	cis	rs8141529	0.509	rs5762864	chr22:29253364	T/C	cg15103426	chr22:29168792	CCDC117	0.63	8.51	0.46	1.29e-15	Lymphocyte counts;
CESC	cis	rs4664308	0.875	rs2124969	chr2:160989486	T/C	cg03641300	chr2:160917029	PLA2R1	-0.65	-9.49	-0.5	1.44e-18	Idiopathic membranous nephropathy;
CESC	cis	rs909002	0.849	rs4949449	chr1:32088534	T/G	cg13919466	chr1:32135498	COL16A1	-0.46	-8.14	-0.45	1.53e-14	Intelligence (multi-trait analysis);
CESC	cis	rs61996546	0.622	rs17560717	chr15:26834211	G/C	cg15066197	chr15:26874202	GABRB3	-0.35	-5.07	-0.3	7.55e-7	Response to methotrexate in juvenile idiopathic arthritis;
CESC	cis	rs10504229	0.511	rs75967910	chr8:58024231	C/G	cg02725872	chr8:58115012	NA	-0.38	-5.1	-0.3	6.54e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs4450798	0.793	rs62234798	chr3:13753974	T/C	cg05589046	chr3:13742034	LOC285375	0.38	5.65	0.33	4.18e-8	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs1348850	0.793	rs6736390	chr2:178480314	T/C	cg23306229	chr2:178417860	TTC30B	0.54	6.6	0.38	2.18e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs9896933	0.832	rs79103992	chr17:80855483	G/A	cg15664640	chr17:80829946	TBCD	-0.53	-5.49	-0.32	9.48e-8	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
CESC	cis	rs1552244	1.000	rs67852463	chr3:10157205	G/C	cg00149659	chr3:10157352	C3orf10	0.71	8.78	0.47	2.09e-16	Alzheimer's disease;
CESC	cis	rs875971	0.545	rs2279757	chr7:65828663	T/C	cg25405998	chr7:65216604	CCT6P1	0.51	5.52	0.32	8.13e-8	Aortic root size;
CESC	cis	rs7216064	0.953	rs4790981	chr17:65921834	A/G	cg12091567	chr17:66097778	LOC651250	-0.73	-8.33	-0.46	4.53e-15	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs7503807	1.000	rs4890056	chr17:78591211	C/T	cg09596252	chr17:78655493	RPTOR	-0.44	-6.38	-0.36	7.82e-10	Obesity;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg13125884	chr15:71408291	CT62	0.44	6.08	0.35	4.28e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs12142240	0.698	rs7525309	chr1:46809025	G/T	cg10495392	chr1:46806563	NSUN4	0.59	6.34	0.36	9.65e-10	Menopause (age at onset);
CESC	cis	rs6460942	0.597	rs4721106	chr7:12535053	T/C	cg06484146	chr7:12443880	VWDE	-0.73	-7.77	-0.43	1.68e-13	Coronary artery disease;
CESC	cis	rs801193	0.904	rs4718403	chr7:66242729	C/G	cg11764359	chr7:65958608	NA	0.67	8.85	0.48	1.24e-16	Aortic root size;
CESC	cis	rs8060686	0.641	rs12447640	chr16:68150527	A/G	cg26727032	chr16:67993705	SLC12A4	-0.54	-6.07	-0.35	4.37e-9	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs9291683	0.588	rs13133766	chr4:10019732	C/T	cg00071950	chr4:10020882	SLC2A9	0.91	17.5	0.73	4.14e-46	Bone mineral density;
CESC	cis	rs295137	0.836	rs1217456	chr2:201092279	C/T	cg23649088	chr2:200775458	C2orf69	0.44	5.77	0.33	2.2e-8	Asthma (bronchodilator response);
CESC	cis	rs34779708	0.966	rs17591857	chr10:35499043	A/G	cg04310649	chr10:35416472	CREM	0.52	6.29	0.36	1.29e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs2066819	1.000	rs77032009	chr12:56679971	A/G	cg26734620	chr12:56694298	CS	1.07	6.58	0.37	2.56e-10	Psoriasis vulgaris;
CESC	cis	rs8031584	0.560	rs7171208	chr15:31198929	A/G	cg08109568	chr15:31115862	NA	0.65	9.21	0.49	1.06e-17	Huntington's disease progression;
CESC	cis	rs11997175	0.545	rs4428637	chr8:33666944	T/G	ch.8.33884649F	chr8:33765107	NA	0.55	6.81	0.39	6.5e-11	Body mass index;
CESC	cis	rs116095464	0.850	rs10055295	chr5:243749	G/A	cg22496380	chr5:211416	CCDC127	-0.74	-8.63	-0.47	5.66e-16	Breast cancer;
CESC	cis	rs8060686	0.641	rs75796305	chr16:68208791	A/G	cg26727032	chr16:67993705	SLC12A4	-0.53	-6.03	-0.35	5.55e-9	HDL cholesterol;Metabolic syndrome;
CESC	trans	rs4332037	0.707	rs73046323	chr7:1882795	G/A	cg11693508	chr17:37793320	STARD3	0.61	6.06	0.35	4.61e-9	Bipolar disorder;
CESC	cis	rs7474896	0.583	rs12776092	chr10:38015795	G/C	cg25427524	chr10:38739819	LOC399744	-0.49	-5.57	-0.32	6.36e-8	Obesity (extreme);
CESC	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg22535103	chr8:58192502	C8orf71	-0.47	-5.85	-0.34	1.46e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs2455799	0.574	rs2455801	chr3:15701857	C/T	cg16303742	chr3:15540471	COLQ	-0.36	-5.59	-0.32	5.55e-8	Mean platelet volume;
CESC	cis	rs858239	0.600	rs6961406	chr7:23134891	C/T	cg23682824	chr7:23144976	KLHL7	0.55	7.61	0.42	4.84e-13	Cerebrospinal fluid biomarker levels;
CESC	cis	rs4820539	1.000	rs3827316	chr22:23468538	T/C	cg14186256	chr22:23484241	RTDR1	0.82	14.67	0.67	4.55e-36	Bone mineral density;
CESC	cis	rs2439831	0.850	rs10438303	chr15:44016417	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.7	7.98	0.44	4.48e-14	Lung cancer in ever smokers;
CESC	cis	rs7116495	0.737	rs7101553	chr11:71753903	C/T	cg10381502	chr11:71823885	C11orf51	-1.18	-7.48	-0.42	1.07e-12	Severe influenza A (H1N1) infection;
CESC	cis	rs2952156	0.920	rs2517955	chr17:37843681	C/T	cg00129232	chr17:37814104	STARD3	-0.81	-11.91	-0.59	1.71e-26	Asthma;
CESC	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg22105103	chr4:187893119	NA	0.49	6.86	0.39	4.89e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs10242455	0.702	rs73713521	chr7:99188649	G/A	cg25640893	chr7:99214727	ZNF498	0.79	5.37	0.31	1.68e-7	Blood metabolite levels;
CESC	cis	rs6424115	1.000	rs974698	chr1:24132785	C/T	cg10978503	chr1:24200527	CNR2	0.28	5.59	0.32	5.65e-8	Immature fraction of reticulocytes;
CESC	cis	rs6582630	0.555	rs10880544	chr12:38473464	G/C	cg13010199	chr12:38710504	ALG10B	0.47	6.11	0.35	3.63e-9	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs12893668	0.628	rs57072546	chr14:104063723	T/C	cg08213375	chr14:104286397	PPP1R13B	0.32	5.06	0.3	7.76e-7	Reticulocyte count;
CESC	cis	rs2479724	0.840	rs10498752	chr6:41768510	T/C	cg08135965	chr6:41755394	TOMM6	-0.43	-5.62	-0.33	4.72e-8	Menarche (age at onset);
CESC	cis	rs6570726	0.935	rs453609	chr6:145812332	T/C	cg23711669	chr6:146136114	FBXO30	0.82	12.07	0.6	5.13e-27	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs801193	1.000	rs13239306	chr7:66136017	T/G	cg26939375	chr7:64535504	NA	-0.58	-7.56	-0.42	6.76e-13	Aortic root size;
CESC	cis	rs7586879	0.638	rs13035244	chr2:25134009	T/C	cg01884057	chr2:25150051	NA	0.36	7.03	0.4	1.8e-11	Body mass index;
CESC	cis	rs4555082	0.681	rs28588570	chr14:105709606	A/T	cg10792982	chr14:105748885	BRF1	0.43	5.8	0.34	1.89e-8	Mean platelet volume;Platelet distribution width;
CESC	cis	rs1775148	1	rs1775148	chr1:205757824	C/T	cg26354017	chr1:205819088	PM20D1	0.51	7.32	0.41	2.96e-12	Prostate cancer;
CESC	cis	rs2342371	0.848	rs7433483	chr3:196217038	C/T	cg15048948	chr3:196158458	UBXN7	-0.43	-5.49	-0.32	9.52e-8	Fat distribution (HIV);
CESC	cis	rs9611565	0.559	rs5751160	chr22:42175695	A/G	cg06634786	chr22:41940651	POLR3H	0.67	6.62	0.38	1.93e-10	Vitiligo;
CESC	cis	rs9467773	1.000	rs1321479	chr6:26501897	C/T	cg20266910	chr6:26577678	NA	-0.31	-5.15	-0.3	5e-7	Intelligence (multi-trait analysis);
CESC	cis	rs651907	0.557	rs11712748	chr3:101383562	G/A	cg12386194	chr3:101231763	SENP7	0.45	5.71	0.33	3.05e-8	Colorectal cancer;
CESC	cis	rs2228479	0.867	rs62052185	chr16:89969254	C/T	cg06558623	chr16:89946397	TCF25	1.08	8.95	0.48	6.51e-17	Skin colour saturation;
CESC	cis	rs9486719	1.000	rs13202675	chr6:97028427	C/T	cg06623918	chr6:96969491	KIAA0776	-0.81	-8.37	-0.46	3.4e-15	Migraine;Coronary artery disease;
CESC	cis	rs798554	0.660	rs1182175	chr7:2875026	C/T	cg13628971	chr7:2884303	GNA12	-0.4	-5.34	-0.31	2.03e-7	Height;
CESC	cis	rs7618915	0.547	rs13085331	chr3:52627486	G/C	cg17372223	chr3:52568218	NT5DC2	0.43	6.43	0.37	5.84e-10	Bipolar disorder;
CESC	cis	rs1499972	0.941	rs62263116	chr3:117622719	T/G	cg07612923	chr3:117604196	NA	0.86	7.52	0.42	8.43e-13	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10582690	chr10:69644422	SIRT1	0.6	7.1	0.4	1.11e-11	Gut microbiome composition (summer);
CESC	cis	rs244293	0.760	rs8069447	chr17:53008873	A/C	cg19360675	chr17:53046073	COX11;STXBP4	-0.48	-6.46	-0.37	5.07e-10	Menarche (age at onset);
CESC	cis	rs853679	0.517	rs4713135	chr6:28039586	G/A	cg20151795	chr6:28129481	ZNF389	0.44	5.54	0.32	7.16e-8	Depression;
CESC	cis	rs4332037	0.539	rs55993248	chr7:2071132	A/G	cg23422044	chr7:1970798	MAD1L1	-0.48	-5.11	-0.3	6.07e-7	Bipolar disorder;
CESC	cis	rs67311347	1.000	rs9857824	chr3:40459412	A/G	cg09455208	chr3:40491958	NA	0.51	8.73	0.47	2.97e-16	Renal cell carcinoma;
CESC	cis	rs5417	0.775	rs222852	chr17:7140606	A/G	cg13768953	chr17:7114967	DLG4	-0.42	-6.52	-0.37	3.58e-10	Diastolic blood pressure;
CESC	cis	rs7208859	0.673	rs423151	chr17:28952286	A/G	cg19761014	chr17:28927070	LRRC37B2	0.8	7.46	0.42	1.24e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs11690935	0.851	rs9808259	chr2:172648974	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.96	-15.02	-0.68	2.52e-37	Schizophrenia;
CESC	cis	rs6952808	0.594	rs3778969	chr7:2139990	A/G	cg02951883	chr7:2050386	MAD1L1	0.47	6.06	0.35	4.77e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs2447097	0.935	rs2447094	chr17:2294048	A/C	cg27406664	chr17:2294951	MNT	0.39	6.49	0.37	4.23e-10	Autism spectrum disorder;
CESC	cis	rs921968	0.613	rs2710251	chr2:219543433	T/C	cg02176678	chr2:219576539	TTLL4	-0.38	-6.47	-0.37	4.74e-10	Mean corpuscular hemoglobin concentration;
CESC	cis	rs5771069	0.897	rs137858	chr22:50445601	T/C	cg27467552	chr22:50353597	PIM3	-0.51	-7.57	-0.42	6.18e-13	Ulcerative colitis;
CESC	cis	rs12497850	1.000	rs4858798	chr3:48727112	C/T	cg06212747	chr3:49208901	KLHDC8B	0.6	8.24	0.45	7.75e-15	Parkinson's disease;
CESC	cis	rs4689388	0.890	rs4689398	chr4:6302199	C/T	cg00701064	chr4:6280414	WFS1	0.73	13.05	0.63	2.19e-30	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs17021463	0.902	rs11097413	chr4:95249286	C/T	cg11021082	chr4:95130006	SMARCAD1	0.56	8.62	0.47	6.2e-16	Testicular germ cell tumor;
CESC	cis	rs10754283	0.935	rs10801756	chr1:90101832	C/T	cg21401794	chr1:90099060	LRRC8C	0.7	9.41	0.5	2.54e-18	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs10504229	0.683	rs7822631	chr8:58130916	C/G	cg21724239	chr8:58056113	NA	0.58	5.95	0.34	8.29e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs8114671	0.836	rs4911461	chr20:33629993	A/C	cg06115741	chr20:33292138	TP53INP2	-0.44	-5.29	-0.31	2.53e-7	Height;
CESC	cis	rs113835537	0.877	rs2275998	chr11:66326581	T/C	cg24851651	chr11:66362959	CCS	0.56	5.71	0.33	2.98e-8	Airway imaging phenotypes;
CESC	cis	rs4629180	0.586	rs7583526	chr2:102124665	G/A	cg21388029	chr2:102003306	CREG2	0.32	5.14	0.3	5.41e-7	Chronic rhinosinusitis with nasal polyps;
CESC	cis	rs854765	0.583	rs7214002	chr17:17852104	G/C	cg04398451	chr17:18023971	MYO15A	-0.72	-10.46	-0.54	1.13e-21	Total body bone mineral density;
CESC	cis	rs72781680	0.848	rs2339926	chr2:24045734	C/G	cg20701182	chr2:24300061	SF3B14	0.63	5.65	0.33	4.21e-8	Lymphocyte counts;
CESC	cis	rs7264396	0.563	rs2425089	chr20:34304036	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.88	-10.64	-0.55	3.06e-22	Total cholesterol levels;
CESC	cis	rs72945132	0.882	rs55915603	chr11:70210067	G/T	cg14191688	chr11:70257035	CTTN	0.44	5.31	0.31	2.37e-7	Coronary artery disease;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg15680989	chr5:1112221	SLC12A7	-0.41	-6.16	-0.35	2.66e-9	Gambling;
CESC	cis	rs1799949	0.501	rs9675035	chr17:41415016	A/T	cg05368731	chr17:41323189	NBR1	0.79	10.96	0.56	2.64e-23	Menopause (age at onset);
CESC	cis	rs2294693	0.530	rs9394761	chr6:41033640	A/C	cg14418226	chr6:40996092	UNC5CL	0.45	5.05	0.3	8.09e-7	Gastric cancer;Non-cardia gastric cancer;
CESC	cis	rs4689388	0.853	rs6817447	chr4:6286847	G/T	cg25554036	chr4:6271136	WFS1	0.56	9.29	0.5	5.92e-18	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs13191362	1.000	rs13214516	chr6:163121583	A/T	cg14584255	chr6:163149320	PACRG;PARK2	0.66	6.73	0.38	1.07e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs7178572	0.568	rs3743479	chr15:77406396	A/G	cg22256960	chr15:77711686	NA	0.54	6.95	0.39	2.86e-11	Type 2 diabetes;
CESC	cis	rs4865169	0.811	rs6841086	chr4:57903268	A/G	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.4	-5.07	-0.3	7.37e-7	Breast cancer;
CESC	cis	rs4665809	0.878	rs35709953	chr2:26334997	G/A	cg04944784	chr2:26401820	FAM59B	0.76	8.13	0.45	1.61e-14	Gut microbiome composition (summer);
CESC	cis	rs7917772	0.636	rs10786708	chr10:104526245	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.44	5.19	0.3	4.17e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs8018808	0.869	rs4369582	chr14:77906389	C/T	cg20045696	chr14:77926864	AHSA1	0.42	5.83	0.34	1.61e-8	Myeloid white cell count;
CESC	cis	rs6933660	0.800	rs13201167	chr6:151773504	T/C	cg02564969	chr6:151773285	C6orf211;RMND1	0.62	8.43	0.46	2.31e-15	Menarche (age at onset);
CESC	cis	rs763121	0.853	rs6001175	chr22:39018334	T/C	cg06544989	chr22:39130855	UNC84B	0.51	9.29	0.5	5.78e-18	Menopause (age at onset);
CESC	trans	rs61931739	0.853	rs7133716	chr12:34041847	G/C	cg26384229	chr12:38710491	ALG10B	-0.46	-6.16	-0.35	2.75e-9	Morning vs. evening chronotype;
CESC	cis	rs1023500	0.573	rs6002592	chr22:42476754	A/C	cg04733989	chr22:42467013	NAGA	-0.83	-12.7	-0.62	3.37e-29	Schizophrenia;
CESC	cis	rs735396	0.770	rs1169314	chr12:121443116	A/G	cg25281562	chr12:121454272	C12orf43	0.51	6.45	0.37	5.17e-10	N-glycan levels;
CESC	cis	rs7666738	0.512	rs1648536	chr4:99019881	G/T	cg05340658	chr4:99064831	C4orf37	-0.59	-7.87	-0.44	8.86e-14	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9443189	0.806	rs9359139	chr6:76487269	C/G	cg01950844	chr6:76311363	SENP6	0.65	6.71	0.38	1.19e-10	Prostate cancer;
CESC	cis	rs7618915	0.570	rs11130319	chr3:52755592	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.49	7.0	0.39	2.13e-11	Bipolar disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00862481	chr16:29998852	TAOK2	-0.63	-7.45	-0.42	1.34e-12	Gut microbiome composition (summer);
CESC	cis	rs875971	0.862	rs2088655	chr7:65795711	T/C	cg11764359	chr7:65958608	NA	-0.79	-11.58	-0.58	2.22e-25	Aortic root size;
CESC	cis	rs9311474	0.713	rs352167	chr3:52238656	C/T	cg18099408	chr3:52552593	STAB1	0.3	5.09	0.3	6.93e-7	Electroencephalogram traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23931027	chr7:2142553	MAD1L1	-0.56	-6.77	-0.38	8.27e-11	Gut microbiome composition (summer);
CESC	cis	rs11683229	0.777	rs12474184	chr2:63253594	A/T	cg17519650	chr2:63277830	OTX1	-0.76	-5.99	-0.35	6.65e-9	Protein quantitative trait loci;
CESC	trans	rs2727020	0.619	rs1164665	chr11:49295630	T/C	cg15704280	chr7:45808275	SEPT13	0.78	10.35	0.54	2.56e-21	Coronary artery disease;
CESC	cis	rs9796	0.636	rs1983400	chr15:41373029	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.43	-6.28	-0.36	1.39e-9	Menopause (age at onset);
CESC	cis	rs11864453	0.612	rs12924413	chr16:72129745	T/C	cg01557791	chr16:72042693	DHODH	-0.43	-5.66	-0.33	3.85e-8	Fibrinogen levels;
CESC	cis	rs4450131	0.522	rs11245328	chr10:126358413	G/A	cg20435097	chr10:126320824	FAM53B	0.29	5.18	0.3	4.31e-7	White blood cell count (basophil);
CESC	cis	rs10791323	0.569	rs2257004	chr11:133712473	C/T	cg06766960	chr11:133703094	NA	-0.38	-5.38	-0.31	1.65e-7	Childhood ear infection;
CESC	cis	rs2456568	0.741	rs9633811	chr11:93628327	A/G	cg26875233	chr11:93583750	C11orf90	0.3	5.15	0.3	5.2e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
CESC	trans	rs2727020	0.658	rs4980431	chr11:49350071	G/T	cg03929089	chr4:120376271	NA	-0.78	-11.96	-0.59	1.21e-26	Coronary artery disease;
CESC	cis	rs875971	0.895	rs4145009	chr7:65726615	T/C	cg11764359	chr7:65958608	NA	-0.82	-12.01	-0.59	8.19e-27	Aortic root size;
CESC	cis	rs34779708	0.966	rs4934732	chr10:35431684	T/C	cg03585969	chr10:35415529	CREM	0.74	9.84	0.52	1.13e-19	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs9926296	0.682	rs645019	chr16:89716883	C/T	cg01097406	chr16:89675127	NA	0.39	5.51	0.32	8.35e-8	Vitiligo;
CESC	cis	rs2952156	0.959	rs2934952	chr17:37832366	G/A	cg20243544	chr17:37824526	PNMT	0.6	7.33	0.41	2.71e-12	Asthma;
CESC	cis	rs13108904	0.967	rs13149715	chr4:1278255	C/A	cg00684032	chr4:1343700	KIAA1530	0.4	5.56	0.32	6.51e-8	Obesity-related traits;
CESC	cis	rs2279817	1.000	rs10888048	chr1:18019742	C/T	cg21791023	chr1:18019539	ARHGEF10L	0.58	8.5	0.46	1.36e-15	Neuroticism;
CESC	cis	rs4563143	0.663	rs5025682	chr19:29238670	A/C	cg04546413	chr19:29218101	NA	0.56	8.14	0.45	1.58e-14	Methadone dose in opioid dependence;
CESC	cis	rs12912251	0.947	rs12898460	chr15:38986813	C/T	cg01338139	chr15:38987640	C15orf53	-0.5	-5.71	-0.33	3.05e-8	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
CESC	cis	rs9487051	0.872	rs9386789	chr6:109603218	A/G	cg12927641	chr6:109611667	NA	-0.43	-6.65	-0.38	1.67e-10	Reticulocyte fraction of red cells;
CESC	cis	rs116095464	0.558	rs10077076	chr5:231940	C/T	cg10591111	chr5:226296	SDHA	-0.52	-6.37	-0.36	8.3e-10	Breast cancer;
CESC	cis	rs8072100	0.967	rs4793842	chr17:45671506	G/A	cg08085267	chr17:45401833	C17orf57	0.4	5.15	0.3	5.18e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs780096	0.546	rs4425043	chr2:27733452	G/A	cg24768116	chr2:27665128	KRTCAP3	-0.33	-5.98	-0.34	7.16e-9	Total body bone mineral density;
CESC	cis	rs7949030	0.626	rs72927213	chr11:62351198	G/C	cg23462726	chr11:62437636	C11orf83;C11orf48	-0.4	-5.24	-0.31	3.23e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs6460942	1.000	rs62448566	chr7:12403662	G/A	cg02935154	chr7:12443704	VWDE	-0.56	-6.1	-0.35	3.8e-9	Coronary artery disease;
CESC	cis	rs7552404	0.690	rs7549863	chr1:76327923	T/C	cg22875332	chr1:76189707	ACADM	-0.62	-6.57	-0.37	2.73e-10	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs5753618	0.561	rs2413049	chr22:31686144	A/G	cg13145458	chr22:31556086	RNF185	0.49	5.48	0.32	9.7e-8	Colorectal cancer;
CESC	cis	rs2932538	0.922	rs12402929	chr1:113072293	G/C	cg22162597	chr1:113214053	CAPZA1	0.56	6.52	0.37	3.58e-10	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CESC	cis	rs1153858	1.000	rs1145074	chr15:45703824	T/A	cg21132104	chr15:45694354	SPATA5L1	0.78	10.3	0.53	3.93e-21	Homoarginine levels;
CESC	cis	rs7666738	0.830	rs11727612	chr4:99001662	T/C	cg05340658	chr4:99064831	C4orf37	0.8	12.44	0.61	2.83e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7666738	0.753	rs7659724	chr4:98944063	C/T	cg03467027	chr4:99064603	C4orf37	0.48	5.95	0.34	8.45e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1552244	1.000	rs9849434	chr3:10133710	A/G	cg08888203	chr3:10149979	C3orf24	-0.5	-6.52	-0.37	3.48e-10	Alzheimer's disease;
CESC	cis	rs7188697	0.646	rs7184114	chr16:58585369	C/A	cg21335942	chr16:58549945	SETD6	-0.49	-6.04	-0.35	5.09e-9	QT interval;
CESC	cis	rs10197940	0.638	rs2288193	chr2:152348842	T/A	cg19508488	chr2:152266495	RIF1	0.53	5.62	0.33	4.74e-8	Lung cancer;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg14462015	chr4:79860507	PAQR3	-0.43	-6.32	-0.36	1.1e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs9311474	1.000	rs7629072	chr3:52305633	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.36	6.58	0.37	2.44e-10	Electroencephalogram traits;
CESC	cis	rs701145	0.556	rs355751	chr3:153971602	T/C	cg16511985	chr3:153974050	SGEF	0.41	5.5	0.32	8.81e-8	Coronary artery disease;
CESC	cis	rs2836950	0.565	rs8130320	chr21:40580258	C/T	cg11644478	chr21:40555479	PSMG1	-0.53	-7.15	-0.4	8.46e-12	Menarche (age at onset);
CESC	cis	rs7178572	1.000	rs11633054	chr15:77747276	A/G	cg22256960	chr15:77711686	NA	-0.57	-7.48	-0.42	1.08e-12	Type 2 diabetes;
CESC	cis	rs425277	1.000	rs421992	chr1:2077260	C/T	cg04315214	chr1:2043799	PRKCZ	-0.38	-5.34	-0.31	2.03e-7	Height;
CESC	cis	rs2836950	0.501	rs2836980	chr21:40687618	G/T	cg11890956	chr21:40555474	PSMG1	-0.65	-9.09	-0.49	2.43e-17	Menarche (age at onset);
CESC	cis	rs7666738	0.830	rs13102652	chr4:99006737	T/G	cg17366294	chr4:99064904	C4orf37	0.6	8.61	0.47	6.47e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1799949	1.000	rs4793192	chr17:41204390	T/C	cg25072359	chr17:41440525	NA	0.45	5.96	0.34	7.83e-9	Menopause (age at onset);
CESC	cis	rs644799	0.965	rs10831426	chr11:95505888	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.71	9.44	0.5	1.99e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs1005224	0.926	rs12892551	chr14:76159902	C/T	cg25116370	chr14:76127843	TTLL5;C14orf1	-0.42	-5.86	-0.34	1.36e-8	Large artery stroke;
CESC	cis	rs4665809	0.549	rs7577896	chr2:26524493	C/T	cg26119090	chr2:26468346	HADHA;HADHB	0.93	9.11	0.49	2.01e-17	Gut microbiome composition (summer);
CESC	cis	rs728616	0.867	rs1923534	chr10:81710485	A/G	cg05935833	chr10:81318306	SFTPA2	-0.51	-5.04	-0.3	8.51e-7	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg00106254	chr7:1943704	MAD1L1	0.48	6.16	0.35	2.69e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs10465746	0.967	rs12748268	chr1:84374438	T/C	cg10977910	chr1:84465055	TTLL7	0.47	6.34	0.36	9.84e-10	Obesity-related traits;
CESC	cis	rs1499972	0.618	rs73168386	chr3:117644339	T/C	cg07612923	chr3:117604196	NA	0.71	6.53	0.37	3.35e-10	Schizophrenia;
CESC	cis	rs3741151	0.773	rs73548688	chr11:73279544	C/T	cg17517138	chr11:73019481	ARHGEF17	1.02	7.54	0.42	7.35e-13	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs7216064	1.000	rs9912084	chr17:65868035	A/C	cg07042672	chr17:66097459	LOC651250	-0.57	-6.57	-0.37	2.69e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs1144333	1.000	rs5745354	chr1:76275178	G/A	cg22875332	chr1:76189707	ACADM	-0.58	-6.02	-0.35	5.91e-9	Attention function in attention deficit hyperactive disorder;
CESC	cis	rs56804039	1.000	rs34154295	chr8:8383477	C/T	cg15556689	chr8:8085844	FLJ10661	-0.48	-5.21	-0.3	3.76e-7	Cervical cancer;
CESC	cis	rs9399135	0.967	rs12527683	chr6:135324534	C/T	cg24558204	chr6:135376177	HBS1L	0.52	7.1	0.4	1.15e-11	Red blood cell count;
CESC	cis	rs35110281	0.667	rs914197	chr21:45117439	A/G	cg21573476	chr21:45109991	RRP1B	-0.55	-7.91	-0.44	6.87e-14	Mean corpuscular volume;
CESC	cis	rs4588572	0.644	rs6882191	chr5:77743098	G/A	cg11547950	chr5:77652471	NA	-0.4	-5.46	-0.32	1.12e-7	Triglycerides;
CESC	cis	rs7511006	1.000	rs7511006	chr22:50676259	T/C	cg16473166	chr22:50639996	SELO	0.5	6.28	0.36	1.39e-9	Obesity-related traits;
CESC	cis	rs4689388	0.853	rs1079216	chr4:6282473	T/C	cg25554036	chr4:6271136	WFS1	0.55	8.68	0.47	4.02e-16	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs780096	0.526	rs3845686	chr2:27655447	T/G	cg24768116	chr2:27665128	KRTCAP3	-0.28	-5.04	-0.3	8.71e-7	Total body bone mineral density;
CESC	cis	rs7215564	0.908	rs4969246	chr17:78740579	G/A	cg11222173	chr17:78748019	RPTOR	0.55	5.04	0.3	8.62e-7	Myopia (pathological);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20047825	chr8:145981074	ZNF251	0.53	6.04	0.35	5.1e-9	Gut microbiome composition (summer);
CESC	cis	rs12188164	0.543	rs2434695	chr5:464177	C/G	cg16584290	chr5:462447	EXOC3	0.46	7.05	0.4	1.51e-11	Cystic fibrosis severity;
CESC	cis	rs2637266	0.905	rs60809084	chr10:78374431	A/C	cg18941641	chr10:78392320	NA	0.4	7.48	0.42	1.06e-12	Pulmonary function;
CESC	cis	rs2742234	0.590	rs2435376	chr10:43684963	A/G	cg15436174	chr10:43711423	RASGEF1A	-0.5	-5.84	-0.34	1.5e-8	Hirschsprung disease;
CESC	cis	rs514406	0.861	rs7526275	chr1:53245849	C/T	cg24675658	chr1:53192096	ZYG11B	0.53	6.73	0.38	1.04e-10	Monocyte count;
CESC	cis	rs7666738	0.830	rs28417577	chr4:99053007	T/C	cg17366294	chr4:99064904	C4orf37	0.61	8.78	0.47	2.13e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9486719	0.948	rs12203657	chr6:96883285	G/A	cg18709589	chr6:96969512	KIAA0776	-0.53	-5.81	-0.34	1.75e-8	Migraine;Coronary artery disease;
CESC	cis	rs78889164	0.956	rs79602905	chr19:33875394	G/T	cg02272751	chr19:33882848	PEPD	-0.54	-7.37	-0.41	2.13e-12	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs208520	0.909	rs55813840	chr6:67012508	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.81	7.68	0.43	3.1400000000000003e-13	Exhaled nitric oxide output;
CESC	cis	rs2243480	1.000	rs58669269	chr7:65951953	T/C	cg18252515	chr7:66147081	NA	-1.41	-14.24	-0.66	1.46e-34	Diabetic kidney disease;
CESC	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg11494091	chr17:61959527	GH2	0.73	12.69	0.61	3.72e-29	Prudent dietary pattern;
CESC	cis	rs17826219	0.706	rs73271850	chr17:29142140	A/G	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.79e-10	Body mass index;
CESC	cis	rs17376456	0.877	rs9314092	chr5:93326362	A/G	cg21475434	chr5:93447410	FAM172A	0.76	6.79	0.38	7.5e-11	Diabetic retinopathy;
CESC	cis	rs6963495	0.818	rs73192115	chr7:105169605	T/A	cg19920283	chr7:105172520	RINT1	0.69	6.54	0.37	3.15e-10	Bipolar disorder (body mass index interaction);
CESC	cis	rs7811142	0.830	rs7341507	chr7:99951315	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.11	11.57	0.58	2.41e-25	Platelet count;
CESC	cis	rs7173419	0.607	rs11637338	chr15:28217259	C/T	cg20906524	chr15:28200668	OCA2	-0.38	-5.25	-0.31	3.07e-7	Eye color;
CESC	cis	rs7772486	0.846	rs866473	chr6:146353414	A/C	cg23711669	chr6:146136114	FBXO30	0.83	12.05	0.6	5.75e-27	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2487048	0.725	rs2422493	chr9:107690995	G/A	cg14470647	chr9:107690075	ABCA1	-0.58	-7.29	-0.41	3.61e-12	Intraocular pressure;
CESC	cis	rs11997175	0.646	rs2006792	chr8:33694423	G/A	ch.8.33884649F	chr8:33765107	NA	0.56	7.34	0.41	2.56e-12	Body mass index;
CESC	cis	rs15676	0.947	rs3115874	chr9:131579338	G/C	cg00228799	chr9:131580591	ENDOG	0.43	5.4	0.31	1.48e-7	Blood metabolite levels;
CESC	cis	rs9902453	0.874	rs11653805	chr17:28378276	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.66	-8.69	-0.47	3.92e-16	Coffee consumption (cups per day);
CESC	cis	rs7666738	0.830	rs58367603	chr4:99015350	T/C	cg05340658	chr4:99064831	C4orf37	0.8	12.51	0.61	1.52e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7927771	0.832	rs7105851	chr11:47383275	T/C	cg18512352	chr11:47633146	NA	0.51	7.28	0.41	3.89e-12	Subjective well-being;
CESC	cis	rs736408	0.608	rs6445534	chr3:52743384	G/A	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	5.75	0.33	2.41e-8	Bipolar disorder;
CESC	cis	rs9549367	0.789	rs9577218	chr13:113894911	A/G	cg18105134	chr13:113819100	PROZ	-0.7	-8.81	-0.48	1.68e-16	Platelet distribution width;
CESC	cis	rs698813	0.851	rs698807	chr2:44701659	G/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.48	5.54	0.32	7.43e-8	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
CESC	cis	rs11122272	0.735	rs2790876	chr1:231536033	C/T	cg06096015	chr1:231504339	EGLN1	0.43	6.08	0.35	4.22e-9	Hemoglobin concentration;
CESC	cis	rs4971059	0.617	rs10908458	chr1:155126948	T/C	cg22049894	chr1:155113146	DPM3	0.47	6.07	0.35	4.4e-9	Breast cancer;
CESC	cis	rs713587	0.563	rs2033655	chr2:25101092	C/T	cg01884057	chr2:25150051	NA	0.31	5.71	0.33	3.05e-8	Body mass index in non-asthmatics;
CESC	cis	rs61931739	0.500	rs7306053	chr12:34510848	T/G	cg06521331	chr12:34319734	NA	-0.37	-5.09	-0.3	6.85e-7	Morning vs. evening chronotype;
CESC	cis	rs35306767	0.761	rs11253557	chr10:1043667	C/T	cg25019033	chr10:957182	NA	-0.55	-5.42	-0.32	1.34e-7	Eosinophil percentage of granulocytes;
CESC	cis	rs7089973	0.604	rs10885620	chr10:116630048	A/T	cg25233709	chr10:116636983	FAM160B1	0.39	6.56	0.37	2.89e-10	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs6690583	0.623	rs12033900	chr1:85478559	T/C	cg22153463	chr1:85462885	MCOLN2	0.79	7.52	0.42	8.55e-13	Serum sulfate level;
CESC	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.46	6.09	0.35	3.89e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16920189	chr15:100105709	MEF2A	0.52	6.12	0.35	3.35e-9	Gut microbiome composition (summer);
CESC	cis	rs875971	1.000	rs6945843	chr7:65734783	G/A	cg10691866	chr7:65817282	TPST1	0.34	5.76	0.33	2.28e-8	Aortic root size;
CESC	cis	rs13191362	0.810	rs35509380	chr6:163053028	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.53	5.24	0.31	3.26e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs7503807	0.905	rs9909449	chr17:78614393	A/G	cg09596252	chr17:78655493	RPTOR	0.52	7.73	0.43	2.3e-13	Obesity;
CESC	cis	rs7539409	0.915	rs4001467	chr1:84275858	A/T	cg10977910	chr1:84465055	TTLL7	-0.56	-5.48	-0.32	9.69e-8	Alzheimer's disease;
CESC	cis	rs514406	0.722	rs7552139	chr1:53387379	G/C	cg25767906	chr1:53392781	SCP2	-0.48	-6.23	-0.36	1.78e-9	Monocyte count;
CESC	trans	rs1994135	0.617	rs2200155	chr12:33734935	G/A	cg26384229	chr12:38710491	ALG10B	0.45	6.5	0.37	4.08e-10	Resting heart rate;
CESC	cis	rs17021463	0.673	rs12646467	chr4:95288819	G/A	cg11021082	chr4:95130006	SMARCAD1	0.5	6.92	0.39	3.3e-11	Testicular germ cell tumor;
CESC	cis	rs4764124	0.646	rs10846062	chr12:14965781	T/C	cg19759883	chr12:14956454	WBP11;C12orf60	0.57	8.45	0.46	1.94e-15	Pubertal anthropometrics;
CESC	cis	rs1577917	1.000	rs1337844	chr6:86677273	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.43	-5.61	-0.33	5.02e-8	Response to antipsychotic treatment;
CESC	cis	rs7666738	0.830	rs11722272	chr4:99000839	C/T	cg03467027	chr4:99064603	C4orf37	0.46	5.61	0.33	5.08e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3806843	0.966	rs1030163	chr5:140185132	G/A	cg26395211	chr5:140044315	WDR55	-0.42	-5.33	-0.31	2.07e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs7589728	1.000	rs7425670	chr2:88522028	C/T	cg04511125	chr2:88470314	THNSL2	0.51	5.04	0.3	8.55e-7	Plasma clusterin levels;
CESC	cis	rs1953600	0.715	rs1079242	chr10:81917708	C/T	cg00277334	chr10:82204260	NA	0.4	5.44	0.32	1.22e-7	Sarcoidosis;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg03158666	chr17:7199744	NA	-0.46	-6.02	-0.35	5.79e-9	Asthma;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19098314	chr17:28804347	GOSR1	-0.58	-7.1	-0.4	1.18e-11	Gut microbiome composition (summer);
CESC	cis	rs10504229	0.871	rs56372514	chr8:58157166	A/G	cg05313129	chr8:58192883	C8orf71	-0.43	-5.11	-0.3	6.19e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs4819052	0.851	rs2838828	chr21:46663423	A/G	cg11663144	chr21:46675770	NA	-0.63	-10.04	-0.53	2.57e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs1348850	0.958	rs1545364	chr2:178462882	G/T	cg23306229	chr2:178417860	TTC30B	0.56	7.42	0.41	1.61e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.55	7.35	0.41	2.52e-12	Lymphocyte counts;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg14574726	chr11:809735	RPLP2	0.46	6.76	0.38	8.74e-11	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs3105593	1.000	rs17645826	chr15:50950141	T/C	cg08437265	chr15:50716283	USP8	0.42	5.36	0.31	1.85e-7	QT interval;
CESC	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.57	7.68	0.43	3.13e-13	Lymphocyte counts;
CESC	cis	rs9916302	0.861	rs2338801	chr17:37490780	G/T	cg19468946	chr17:37922297	IKZF3	0.39	5.09	0.3	6.92e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs7188697	0.809	rs4784956	chr16:58596291	A/C	cg02549819	chr16:58548995	SETD6	0.43	5.4	0.31	1.51e-7	QT interval;
CESC	cis	rs9311474	0.508	rs7625743	chr3:52606366	C/G	cg18099408	chr3:52552593	STAB1	-0.32	-5.42	-0.32	1.37e-7	Electroencephalogram traits;
CESC	cis	rs1801251	0.835	rs1446310	chr2:233683245	G/C	cg08000102	chr2:233561755	GIGYF2	-0.72	-11.29	-0.57	2.1e-24	Coronary artery disease;
CESC	cis	rs666930	0.519	rs532303	chr1:120265444	A/G	cg19096424	chr1:120255104	PHGDH	0.68	7.88	0.44	8.32e-14	Breast cancer;
CESC	cis	rs853679	1.000	rs6901575	chr6:28250984	G/A	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.68	6.91	0.39	3.68e-11	Depression;
CESC	cis	rs10504229	0.775	rs17804888	chr8:58158315	G/T	cg05313129	chr8:58192883	C8orf71	0.51	5.35	0.31	1.91e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs12893668	0.667	rs8017628	chr14:104047428	C/T	cg24130564	chr14:104152367	KLC1	-0.49	-6.23	-0.36	1.78e-9	Reticulocyte count;
CESC	cis	rs2180341	0.814	rs6905553	chr6:127727407	A/G	cg24812749	chr6:127587940	RNF146	0.84	12.05	0.59	5.93e-27	Breast cancer;
CESC	cis	rs765787	0.530	rs4774550	chr15:45542312	C/T	cg24006582	chr15:45444508	DUOX1	-0.57	-6.97	-0.39	2.58e-11	Uric acid levels;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg05518842	chr16:1823291	MRPS34;EME2	0.51	6.77	0.38	8.29e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs832540	0.629	rs3309	chr5:56092779	A/T	cg14703610	chr5:56206110	C5orf35	-0.46	-5.57	-0.32	6.17e-8	Coronary artery disease;
CESC	cis	rs10089	0.953	rs13358455	chr5:127365786	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.76	9.55	0.51	8.83e-19	Ileal carcinoids;
CESC	cis	rs7829975	0.714	rs4841042	chr8:8664622	A/G	cg18904891	chr8:8559673	CLDN23	-0.41	-5.03	-0.3	8.87e-7	Mood instability;
CESC	cis	rs16854884	0.586	rs7611326	chr3:143736374	C/T	cg06585982	chr3:143692056	C3orf58	0.5	6.75	0.38	9.19e-11	Economic and political preferences (feminism/equality);
CESC	cis	rs911555	0.692	rs7146215	chr14:103915908	A/G	cg24130564	chr14:104152367	KLC1	0.5	6.5	0.37	4.05e-10	Intelligence (multi-trait analysis);
CESC	cis	rs11190604	1.000	rs1800662	chr10:102289078	C/A	cg07080220	chr10:102295463	HIF1AN	0.7	6.48	0.37	4.34e-10	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs6570726	0.935	rs429306	chr6:145827016	T/C	cg23711669	chr6:146136114	FBXO30	0.8	12.02	0.59	7.3e-27	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg00630080	chr16:67264248	FHOD1	0.45	6.39	0.37	7.25e-10	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs9649465	0.561	rs631445	chr7:123413707	C/T	cg03229431	chr7:123269106	ASB15	-0.41	-5.53	-0.32	7.63e-8	Migraine;
CESC	cis	rs4819052	1.000	rs13052356	chr21:46663588	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.86	11.17	0.57	5.29e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs7089973	0.604	rs3758603	chr10:116605368	T/C	cg23260525	chr10:116636907	FAM160B1	0.4	7.2	0.4	6.31e-12	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs9443645	0.901	rs9448588	chr6:79590061	T/G	cg05283184	chr6:79620031	NA	-0.43	-6.56	-0.37	2.85e-10	Intelligence (multi-trait analysis);
CESC	cis	rs3096299	0.685	rs4329923	chr16:89560178	C/T	cg16743903	chr16:89593216	SPG7	-0.48	-6.39	-0.37	7.61e-10	Multiple myeloma (IgH translocation);
CESC	cis	rs4689388	0.856	rs10016157	chr4:6294414	T/C	cg14416269	chr4:6271139	WFS1	0.46	7.76	0.43	1.79e-13	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs6998277	1.000	rs62523306	chr8:103640752	C/A	cg10187029	chr8:103597600	NA	0.61	6.88	0.39	4.37e-11	Migraine;
CESC	cis	rs6691722	0.503	rs3765428	chr1:24706113	G/A	cg02336364	chr1:24764700	NIPAL3	0.33	6.8	0.39	6.86e-11	Response to interferon beta in multiple sclerosis;
CESC	cis	rs4523957	0.928	rs216198	chr17:2201735	C/T	cg16513277	chr17:2031491	SMG6	0.57	7.67	0.43	3.23e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs12479064	0.724	rs3792143	chr2:100057020	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.6	-7.06	-0.4	1.45e-11	Chronic sinus infection;
CESC	cis	rs9926296	0.632	rs72807526	chr16:89775946	A/G	cg03388025	chr16:89894329	SPIRE2	-0.31	-5.32	-0.31	2.17e-7	Vitiligo;
CESC	cis	rs7833986	0.534	rs17759244	chr8:57033768	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.57	7.28	0.41	3.83e-12	Height;
CESC	cis	rs1055129	0.655	rs7223416	chr17:73836162	C/G	cg08125733	chr17:73851984	WBP2	0.55	7.58	0.42	6e-13	White matter hyperintensity burden;
CESC	cis	rs1023500	0.507	rs6002600	chr22:42488906	G/A	cg04733989	chr22:42467013	NAGA	-0.79	-12.03	-0.59	6.75e-27	Schizophrenia;
CESC	cis	rs2228479	0.867	rs12919804	chr16:89945369	G/A	cg04013166	chr16:89971882	TCF25	0.77	7.14	0.4	8.86e-12	Skin colour saturation;
CESC	cis	rs1008375	0.902	rs12503164	chr4:17656107	C/T	cg15017067	chr4:17643749	FAM184B	0.36	5.17	0.3	4.73e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs9733	0.519	rs1336899	chr1:150678910	T/C	cg22823121	chr1:150693482	HORMAD1	0.47	7.05	0.4	1.54e-11	Tonsillectomy;
CESC	cis	rs12142240	0.698	rs6679898	chr1:46820589	A/C	cg10495392	chr1:46806563	NSUN4	0.58	6.32	0.36	1.09e-9	Menopause (age at onset);
CESC	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.63	7.15	0.4	8.37e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7264396	0.561	rs6060753	chr20:34598430	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-6.82	-0.39	6.33e-11	Total cholesterol levels;
CESC	cis	rs801193	0.527	rs2707837	chr7:66181073	G/C	cg18252515	chr7:66147081	NA	-0.47	-6.41	-0.37	6.57e-10	Aortic root size;
CESC	cis	rs12956009	0.583	rs16951972	chr18:44898600	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.5	6.49	0.37	4.11e-10	Educational attainment (years of education);
CESC	cis	rs9916302	0.851	rs4794810	chr17:37603774	T/C	cg07936489	chr17:37558343	FBXL20	-0.8	-11.95	-0.59	1.31e-26	Glomerular filtration rate (creatinine);
CESC	cis	rs4704187	0.687	rs10462354	chr5:74453027	T/G	cg03227963	chr5:74354835	NA	0.3	5.5	0.32	8.75e-8	Response to amphetamines;
CESC	cis	rs4689388	0.890	rs4688991	chr4:6302220	C/G	cg14416269	chr4:6271139	WFS1	0.47	7.87	0.44	8.86e-14	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs875971	0.505	rs6955582	chr7:65431686	A/G	cg11764359	chr7:65958608	NA	0.66	8.47	0.46	1.66e-15	Aortic root size;
CESC	cis	rs2797160	1.000	rs6904992	chr6:126016003	G/A	cg05901451	chr6:126070800	HEY2	0.46	6.55	0.37	2.89e-10	Endometrial cancer;
CESC	cis	rs116095464	0.558	rs62347683	chr5:230331	C/T	cg22496380	chr5:211416	CCDC127	-0.74	-8.65	-0.47	5.2e-16	Breast cancer;
CESC	cis	rs7264396	0.563	rs2425103	chr20:34312329	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.64	6.86	0.39	4.8e-11	Total cholesterol levels;
CESC	cis	rs4665809	0.590	rs1865324	chr2:26417533	C/A	cg22920501	chr2:26401640	FAM59B	-0.85	-10.05	-0.53	2.42e-20	Gut microbiome composition (summer);
CESC	cis	rs6088580	0.602	rs6059834	chr20:33019299	A/G	cg08999081	chr20:33150536	PIGU	0.65	11.36	0.57	1.22e-24	Glomerular filtration rate (creatinine);
CESC	cis	rs317689	0.690	rs547827	chr12:69669703	G/A	cg14784868	chr12:69753453	YEATS4	0.47	5.16	0.3	4.75e-7	Response to diuretic therapy;
CESC	cis	rs6840258	1.000	rs72667752	chr4:87939531	G/A	cg08197287	chr4:87952173	AFF1	-0.41	-5.57	-0.32	6.14e-8	Mean corpuscular volume;Basophil percentage of granulocytes;
CESC	cis	rs748404	0.660	rs548704	chr15:43791706	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	8.21	0.45	9.59e-15	Lung cancer;
CESC	cis	rs561341	0.883	rs2074102	chr17:30228884	G/A	cg00745463	chr17:30367425	LRRC37B	-0.64	-6.28	-0.36	1.38e-9	Hip circumference adjusted for BMI;
CESC	cis	rs769267	0.895	rs2905435	chr19:19495954	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.46	-6.05	-0.35	4.83e-9	Tonsillectomy;
CESC	cis	rs6748734	1.000	rs4293565	chr2:241834770	A/G	cg07537917	chr2:241836409	C2orf54	-0.26	-5.72	-0.33	2.95e-8	Urinary metabolites;
CESC	cis	rs4076764	0.846	rs7525724	chr1:163426372	G/A	cg24596788	chr1:163392923	NA	-0.41	-5.81	-0.34	1.76e-8	Motion sickness;
CESC	cis	rs4253772	0.591	rs73886791	chr22:46687212	A/G	cg10231785	chr22:46692440	CN5H6.4;GTSE1	0.55	5.66	0.33	3.89e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs10504229	1.000	rs57624567	chr8:58176995	T/C	cg05313129	chr8:58192883	C8orf71	-0.55	-6.37	-0.36	8.42e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg03188948	chr7:1209495	NA	0.44	5.6	0.33	5.48e-8	Longevity;Endometriosis;
CESC	cis	rs2243480	1.000	rs781157	chr7:65478311	G/A	cg18252515	chr7:66147081	NA	-1.12	-10.8	-0.55	9.01e-23	Diabetic kidney disease;
CESC	cis	rs6582630	0.555	rs8189479	chr12:38308240	C/T	cg26384229	chr12:38710491	ALG10B	-0.44	-5.7	-0.33	3.17e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs4648845	0.777	rs2477689	chr1:2395538	G/C	cg11214544	chr1:2391121	NA	-0.38	-5.99	-0.35	6.83e-9	Schizophrenia;
CESC	cis	rs9733	0.818	rs6694531	chr1:150683512	C/A	cg22823121	chr1:150693482	HORMAD1	-0.41	-6.39	-0.37	7.49e-10	Tonsillectomy;
CESC	cis	rs1799949	1.000	rs33918839	chr17:41329172	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	8.55	0.46	1.01e-15	Menopause (age at onset);
CESC	cis	rs11252926	0.931	rs4881399	chr10:567325	A/G	cg18196295	chr10:418757	DIP2C	0.42	5.05	0.3	8.08e-7	Psychosis in Alzheimer's disease;
CESC	cis	rs12541635	0.966	rs62525734	chr8:106984056	T/C	cg10147462	chr8:107024639	NA	0.41	5.62	0.33	4.88e-8	Age of smoking initiation;
CESC	cis	rs9486719	1.000	rs12190507	chr6:96898265	T/G	cg06623918	chr6:96969491	KIAA0776	-0.81	-8.3	-0.45	5.21e-15	Migraine;Coronary artery disease;
CESC	trans	rs4906172	0.773	rs11844113	chr14:102513596	A/G	cg17920195	chr4:129149383	NA	0.32	6.1	0.35	3.66e-9	Menopause (age at onset);
CESC	cis	rs7772486	0.692	rs2265915	chr6:146194332	A/T	cg23711669	chr6:146136114	FBXO30	1.02	15.84	0.7	3.24e-40	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7116495	0.619	rs7116188	chr11:71841753	A/G	cg10381502	chr11:71823885	C11orf51	0.7	5.7	0.33	3.22e-8	Severe influenza A (H1N1) infection;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22277887	chr6:75994754	TMEM30A	0.52	6.22	0.36	1.91e-9	Gut microbiome composition (summer);
CESC	cis	rs6141600	0.760	rs6060794	chr20:34682864	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.4	-5.52	-0.32	8.06e-8	Height;Hip circumference;
CESC	cis	rs4253772	0.637	rs36125344	chr22:46655779	G/C	cg10541313	chr22:46663664	TTC38	0.74	5.91	0.34	1.05e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs2637266	0.935	rs7393727	chr10:78365977	T/A	cg18941641	chr10:78392320	NA	0.43	8.26	0.45	6.94e-15	Pulmonary function;
CESC	cis	rs4076764	1.000	rs4469696	chr1:163424565	C/T	cg24596788	chr1:163392923	NA	-0.47	-6.89	-0.39	4.15e-11	Motion sickness;
CESC	cis	rs4481887	0.800	rs4278391	chr1:248450495	C/T	cg00666640	chr1:248458726	OR2T12	0.38	6.23	0.36	1.8e-9	Common traits (Other);
CESC	cis	rs8077889	0.703	rs72836567	chr17:41945776	G/A	cg26893861	chr17:41843967	DUSP3	0.74	6.82	0.39	6.31e-11	Triglycerides;
CESC	cis	rs631288	0.793	rs6681716	chr1:146707824	A/C	cg25205988	chr1:146714368	CHD1L	0.77	7.38	0.41	1.99e-12	PR interval in Tripanosoma cruzi seropositivity;
CESC	cis	rs7296418	0.816	rs1790096	chr12:123710364	C/T	cg00376283	chr12:123451042	ABCB9	0.67	9.59	0.51	6.84e-19	Platelet count;
CESC	cis	rs473651	0.935	rs578510	chr2:239343140	C/T	cg18131467	chr2:239335373	ASB1	1.03	21.24	0.79	3.76e-59	Multiple system atrophy;
CESC	cis	rs34734847	0.766	rs3794214	chr12:121168245	C/T	cg21892295	chr12:121157589	UNC119B	0.35	5.71	0.33	3.03e-8	Mean corpuscular volume;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg18014789	chr12:123717788	C12orf65	-0.47	-6.41	-0.37	6.6e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs765787	0.530	rs2413786	chr15:45525394	C/A	cg24006582	chr15:45444508	DUOX1	-0.59	-7.23	-0.41	5.15e-12	Uric acid levels;
CESC	cis	rs597539	0.652	rs513359	chr11:68669496	A/T	cg18350739	chr11:68623251	NA	0.43	6.77	0.38	8.48e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs11792861	0.926	rs72607166	chr9:111821530	A/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.43	5.4	0.31	1.48e-7	Menarche (age at onset);
CESC	cis	rs9611565	0.649	rs5758344	chr22:41817685	G/A	cg03806693	chr22:41940476	POLR3H	1.2	14.5	0.67	1.86e-35	Vitiligo;
CESC	cis	rs2836950	0.585	rs1029004	chr21:40615343	A/G	cg17971929	chr21:40555470	PSMG1	-0.54	-7.0	-0.4	2.04e-11	Menarche (age at onset);
CESC	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg23978390	chr7:1156363	C7orf50	0.42	5.63	0.33	4.49e-8	Longevity;Endometriosis;
CESC	cis	rs9916302	0.851	rs6503502	chr17:37501855	A/G	cg15445000	chr17:37608096	MED1	-0.41	-6.8	-0.39	6.8e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs736801	0.754	rs2706336	chr5:131799961	T/C	cg00255919	chr5:131827918	IRF1	0.35	5.2	0.3	3.91e-7	Breast cancer;Mosquito bite size;
CESC	cis	rs7818688	1.000	rs16917224	chr8:96030110	T/C	cg16049864	chr8:95962084	TP53INP1	0.61	5.74	0.33	2.58e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs9733	0.596	rs2867304	chr1:150630995	G/A	cg09365446	chr1:150670422	GOLPH3L	0.42	5.98	0.34	7.35e-9	Tonsillectomy;
CESC	cis	rs1448094	0.534	rs11613070	chr12:86167544	T/A	cg00310523	chr12:86230176	RASSF9	0.41	6.18	0.36	2.36e-9	Major depressive disorder;
CESC	cis	rs7819412	1.000	rs7819412	chr8:11045161	A/G	cg21775007	chr8:11205619	TDH	0.38	5.36	0.31	1.79e-7	Triglycerides;
CESC	cis	rs2860975	0.905	rs10786182	chr10:96789775	C/T	cg09036531	chr10:96991505	NA	-0.36	-5.23	-0.31	3.42e-7	Immune response to smallpox vaccine (IL-6);
CESC	cis	rs72781680	0.706	rs72794290	chr2:23896106	A/T	cg20701182	chr2:24300061	SF3B14	0.81	7.06	0.4	1.5e-11	Lymphocyte counts;
CESC	cis	rs13385	0.769	rs34994530	chr5:139558669	C/T	cg26211634	chr5:139558579	C5orf32	0.47	5.16	0.3	4.77e-7	Atrial fibrillation;
CESC	cis	rs9311474	0.713	rs352170	chr3:52236077	A/G	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.33	6.0	0.35	6.29e-9	Electroencephalogram traits;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg23098168	chr1:109801427	CELSR2	0.5	7.05	0.4	1.51e-11	Fibrinogen levels;
CESC	trans	rs561341	1.000	rs55959993	chr17:30254771	C/G	cg20587970	chr11:113659929	NA	-1.43	-17.6	-0.73	1.89e-46	Hip circumference adjusted for BMI;
CESC	trans	rs6460942	0.591	rs10262667	chr7:12385391	C/T	cg16269144	chr1:2003326	PRKCZ	0.52	6.26	0.36	1.54e-9	Coronary artery disease;
CESC	cis	rs9948	0.786	rs62152783	chr2:97457389	T/A	cg01990225	chr2:97406019	LMAN2L	-0.92	-7.51	-0.42	9.04e-13	Erectile dysfunction and prostate cancer treatment;
CESC	cis	rs2119480	0.762	rs401084	chr13:111310086	C/G	cg02866700	chr13:111333333	CARS2	-0.37	-5.18	-0.3	4.32e-7	Diastolic blood pressure;
CESC	cis	rs919433	1.000	rs919433	chr2:198166565	G/A	cg03934865	chr2:198174659	NA	-0.45	-6.7	-0.38	1.24e-10	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs3126085	0.560	rs3120665	chr1:152316590	A/G	cg03465714	chr1:152285911	FLG	0.42	5.05	0.3	8.42e-7	Atopic dermatitis;
CESC	cis	rs72781680	1.000	rs12616899	chr2:24165235	A/G	cg08917208	chr2:24149416	ATAD2B	0.94	8.58	0.47	7.87e-16	Lymphocyte counts;
CESC	cis	rs2878628	0.650	rs56098033	chr3:52758571	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	7.95	0.44	5.39e-14	Intelligence (multi-trait analysis);
CESC	trans	rs853679	0.599	rs202906	chr6:28011652	C/T	cg06606381	chr12:133084897	FBRSL1	0.77	7.04	0.4	1.64e-11	Depression;
CESC	cis	rs6674970	0.748	rs56299877	chr1:151115645	C/T	cg11822372	chr1:151115635	SEMA6C	-0.87	-12.11	-0.6	3.82e-27	Childhood ear infection;
CESC	cis	rs9858542	0.953	rs9827021	chr3:49514764	C/A	cg07274523	chr3:49395745	GPX1	0.66	8.05	0.44	2.82e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs7267979	0.966	rs2261795	chr20:25263136	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	18.48	0.75	1.44e-49	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs6582630	0.555	rs11182202	chr12:38476451	C/G	cg26384229	chr12:38710491	ALG10B	0.71	10.82	0.55	7.82e-23	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs7605827	0.930	rs13410044	chr2:15602535	A/G	cg19274914	chr2:15703543	NA	0.36	6.42	0.37	6.2e-10	Educational attainment (years of education);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg19586645	chr17:73266642	MIF4GD	0.53	6.93	0.39	3.16e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs2645694	0.651	rs2703144	chr4:77830505	C/G	cg10057126	chr4:77819792	ANKRD56	0.6	8.46	0.46	1.86e-15	Emphysema distribution in smoking;
CESC	cis	rs2549003	1.000	rs7734334	chr5:131815004	C/A	cg02551604	chr5:131831745	NA	-0.36	-5.08	-0.3	7.22e-7	Asthma (sex interaction);
CESC	cis	rs7552404	0.924	rs1146588	chr1:76229787	C/G	cg03433033	chr1:76189801	ACADM	0.72	10.0	0.52	3.53e-20	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs854765	0.929	rs2955360	chr17:17974887	G/A	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.46	-5.95	-0.34	8.48e-9	Total body bone mineral density;
CESC	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.45	-5.92	-0.34	1e-8	Longevity;Endometriosis;
CESC	cis	rs7089973	0.585	rs7907837	chr10:116610690	G/T	cg23260525	chr10:116636907	FAM160B1	0.43	8.28	0.45	6.14e-15	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs1218582	0.774	rs4845683	chr1:154877407	T/C	cg09359103	chr1:154839909	KCNN3	-0.68	-13.03	-0.62	2.48e-30	Prostate cancer;
CESC	cis	rs854765	0.964	rs854813	chr17:18003845	C/T	cg09796270	chr17:17721594	SREBF1	-0.38	-5.13	-0.3	5.62e-7	Total body bone mineral density;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg11769841	chr22:38795061	LOC400927	0.44	6.51	0.37	3.79e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs10751667	0.961	rs7943115	chr11:973885	T/C	cg06064525	chr11:970664	AP2A2	-0.36	-6.32	-0.36	1.09e-9	Alzheimer's disease (late onset);
CESC	cis	rs8180040	0.620	rs11715121	chr3:47072621	T/A	cg27129171	chr3:47204927	SETD2	-0.66	-9.82	-0.52	1.32e-19	Colorectal cancer;
CESC	cis	rs6502050	0.835	rs4789731	chr17:80145904	C/T	cg11859384	chr17:80120422	CCDC57	-0.38	-5.25	-0.31	3.18e-7	Life satisfaction;
CESC	cis	rs12681288	0.754	rs4735975	chr8:1000470	T/C	cg15309053	chr8:964076	NA	0.32	5.46	0.32	1.11e-7	Schizophrenia;
CESC	cis	rs644799	0.562	rs515546	chr11:95588756	G/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.47	6.06	0.35	4.71e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs7582720	1.000	rs72926782	chr2:203811628	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.36	0.41	2.34e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs708547	0.874	rs1315006	chr4:57858193	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.71	7.63	0.42	4.22e-13	Response to bleomycin (chromatid breaks);
CESC	cis	rs798554	0.959	rs798556	chr7:2759002	C/A	cg18446336	chr7:2847575	GNA12	-0.37	-5.71	-0.33	3e-8	Height;
CESC	cis	rs727563	0.638	rs5996058	chr22:42141452	A/G	cg06634786	chr22:41940651	POLR3H	0.69	6.8	0.39	6.88e-11	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs2380220	0.720	rs9398251	chr6:95984709	C/T	cg15832292	chr6:96025679	MANEA	0.61	6.85	0.39	5.26e-11	Behavioural disinhibition (generation interaction);
CESC	cis	rs722599	0.639	rs12882676	chr14:75272433	A/G	cg08847533	chr14:75593920	NEK9	0.46	5.63	0.33	4.66e-8	IgG glycosylation;
CESC	cis	rs1153858	1.000	rs4395020	chr15:45652889	A/C	cg21132104	chr15:45694354	SPATA5L1	0.86	11.64	0.58	1.49e-25	Homoarginine levels;
CESC	cis	rs17539620	0.624	rs871068	chr6:154837514	C/A	cg17771515	chr6:154831774	CNKSR3	0.59	5.85	0.34	1.43e-8	Lipoprotein (a) levels;
CESC	cis	rs875971	1.000	rs55962648	chr7:65625751	C/G	cg18876405	chr7:65276391	NA	-0.53	-7.16	-0.4	7.93e-12	Aortic root size;
CESC	cis	rs8060686	0.641	rs1074143	chr16:68127278	A/G	cg26727032	chr16:67993705	SLC12A4	-0.54	-6.05	-0.35	4.92e-9	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs9300255	0.739	rs1980252	chr12:123745178	C/G	cg19016782	chr12:123741754	C12orf65	-0.5	-7.26	-0.41	4.23e-12	Neutrophil percentage of white cells;
CESC	cis	rs11864453	0.713	rs7191127	chr16:72123992	G/T	cg01557791	chr16:72042693	DHODH	-0.46	-5.92	-0.34	9.98e-9	Fibrinogen levels;
CESC	cis	rs1218582	0.710	rs9793588	chr1:154878878	C/G	cg24250549	chr1:154909240	PMVK	0.74	11.08	0.56	1.06e-23	Prostate cancer;
CESC	cis	rs116095464	0.558	rs10058428	chr5:235608	A/G	cg12570787	chr5:219185	SDHA;CCDC127	0.5	5.23	0.31	3.39e-7	Breast cancer;
CESC	trans	rs9858542	1.000	rs11718165	chr3:49696797	A/G	cg21659725	chr3:3221576	CRBN	-0.54	-6.47	-0.37	4.79e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs2408955	0.522	rs10875721	chr12:48413593	A/G	cg04545296	chr12:48745243	ZNF641	-0.35	-5.89	-0.34	1.17e-8	Glycated hemoglobin levels;
CESC	cis	rs4319547	0.661	rs10773172	chr12:122939655	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.5	-6.31	-0.36	1.19e-9	Body mass index;
CESC	cis	rs875971	0.571	rs78668714	chr7:65939451	G/A	cg25405998	chr7:65216604	CCT6P1	0.51	5.46	0.32	1.09e-7	Aortic root size;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg01509715	chr16:31073567	ZNF668	0.47	6.12	0.35	3.28e-9	Fibrinogen levels;
CESC	cis	rs4242434	0.854	rs3735893	chr8:22452704	A/G	cg03733263	chr8:22462867	KIAA1967	0.87	14.03	0.65	8.13e-34	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CESC	cis	rs7618915	0.501	rs10865974	chr3:52718280	A/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	-0.36	-6.77	-0.38	8.3e-11	Bipolar disorder;
CESC	cis	rs79349575	0.783	rs4794000	chr17:47022755	C/G	cg26022315	chr17:47021804	SNF8	0.39	5.16	0.3	4.94e-7	Type 2 diabetes;
CESC	cis	rs35110281	0.720	rs162393	chr21:44942692	G/A	cg21573476	chr21:45109991	RRP1B	-0.41	-5.72	-0.33	2.81e-8	Mean corpuscular volume;
CESC	cis	rs2425143	1.000	rs11696369	chr20:34378629	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.8	-7.79	-0.43	1.54e-13	Blood protein levels;
CESC	cis	rs1008375	0.932	rs6449321	chr4:17644472	A/G	cg02297831	chr4:17616191	MED28	0.61	7.82	0.43	1.26e-13	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs9527	0.590	rs3740386	chr10:104931051	C/T	cg04362960	chr10:104952993	NT5C2	0.42	5.25	0.31	3.09e-7	Arsenic metabolism;
CESC	trans	rs4332037	0.552	rs11773627	chr7:2002733	A/G	cg11693508	chr17:37793320	STARD3	0.64	6.49	0.37	4.29e-10	Bipolar disorder;
CESC	cis	rs2952156	0.920	rs9675194	chr17:37833805	A/G	cg20243544	chr17:37824526	PNMT	0.64	8.63	0.47	5.86e-16	Asthma;
CESC	cis	rs3820928	0.874	rs2229813	chr2:227892720	C/T	cg05526886	chr2:227700861	RHBDD1	-0.45	-5.82	-0.34	1.71e-8	Pulmonary function;
CESC	cis	rs4822044	0.561	rs132781	chr22:42046122	T/G	cg06634786	chr22:41940651	POLR3H	0.59	5.93	0.34	9.66e-9	Cannabis dependence symptom count;
CESC	cis	rs7666738	0.753	rs35146453	chr4:98902278	A/G	cg03676636	chr4:99064102	C4orf37	0.34	5.14	0.3	5.27e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2072499	1.000	rs2540173	chr1:156188214	A/G	cg24450063	chr1:156163899	SLC25A44	1.08	21.15	0.79	8.02e-59	Testicular germ cell tumor;
CESC	cis	rs10504229	0.683	rs35889486	chr8:58117749	T/A	cg02725872	chr8:58115012	NA	-0.45	-7.05	-0.4	1.52e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs2979489	0.773	rs2915617	chr8:30272310	C/G	cg26383811	chr8:30366931	RBPMS	0.51	6.48	0.37	4.4e-10	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CESC	cis	rs476633	0.691	rs28568756	chr15:41539371	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.47	-6.94	-0.39	3.01e-11	Glomerular filtration rate (creatinine);
CESC	trans	rs11098499	0.954	rs3733519	chr4:120423448	A/G	cg25214090	chr10:38739885	LOC399744	0.7	9.85	0.52	1.03e-19	Corneal astigmatism;
CESC	cis	rs7274811	0.554	rs35556109	chr20:32133489	G/A	cg21523528	chr20:32077966	CBFA2T2	0.63	7.25	0.41	4.68e-12	Height;
CESC	cis	rs1580019	0.587	rs6951955	chr7:32548761	A/T	cg07520158	chr7:32535189	LSM5;AVL9	0.51	6.39	0.37	7.42e-10	Cognitive ability;
CESC	cis	rs2235642	0.717	rs9937922	chr16:1658154	C/G	cg03771183	chr16:1608904	IFT140	0.4	5.91	0.34	1.04e-8	Coronary artery disease;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg15645344	chr4:165109574	MARCH1	-0.45	-6.13	-0.35	3.21e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs35096708	1.000	rs35096708	chr16:89887249	G/A	cg04287289	chr16:89883240	FANCA	-0.52	-5.81	-0.34	1.76e-8	Skin aging (microtopography measurement);
CESC	cis	rs18122	0.846	rs11885548	chr2:67628593	G/A	cg09028215	chr2:67624308	ETAA1	-0.43	-5.28	-0.31	2.73e-7	Waist-to-hip ratio adjusted for body mass index;
CESC	trans	rs1814175	0.754	rs28663627	chr11:50048829	C/T	cg15704280	chr7:45808275	SEPT13	-1.06	-21.45	-0.8	7.56e-60	Height;
CESC	cis	rs10465746	0.967	rs12140068	chr1:84394286	A/C	cg10977910	chr1:84465055	TTLL7	0.46	6.32	0.36	1.13e-9	Obesity-related traits;
CESC	cis	rs7914558	1.000	rs11191541	chr10:104824199	A/G	cg08650961	chr10:104748594	CNNM2	0.31	5.19	0.3	4.18e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs798554	0.679	rs2533870	chr7:2885274	C/G	cg04166393	chr7:2884313	GNA12	-0.6	-8.23	-0.45	8.48e-15	Height;
CESC	cis	rs6964587	0.692	rs10271430	chr7:91710466	G/C	cg01689657	chr7:91764605	CYP51A1	0.27	5.28	0.31	2.64e-7	Breast cancer;
CESC	cis	rs9970334	0.596	rs709209	chr1:6278414	A/G	cg15892785	chr1:6309343	GPR153	-0.62	-9.02	-0.48	4.04e-17	Resting heart rate;
CESC	cis	rs7772486	0.655	rs2142981	chr6:146071695	G/C	cg05347473	chr6:146136440	FBXO30	-0.57	-7.36	-0.41	2.27e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7666738	0.830	rs10028692	chr4:98962585	C/T	cg03467027	chr4:99064603	C4orf37	0.44	5.57	0.32	6.41e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7914558	1.000	rs1890184	chr10:104748459	A/C	cg15744005	chr10:104629667	AS3MT	-0.34	-5.51	-0.32	8.51e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs12220238	0.730	rs11000899	chr10:75913055	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.65	6.18	0.36	2.35e-9	Soluble interleukin-2 receptor subunit alpha;
CESC	cis	rs6598955	0.670	rs6598942	chr1:26531034	C/T	cg00852783	chr1:26633632	UBXN11	0.41	5.9	0.34	1.09e-8	Obesity-related traits;
CESC	cis	rs62408225	1.000	rs17513415	chr6:90947867	C/T	cg06866423	chr6:90926672	BACH2	0.49	5.9	0.34	1.13e-8	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs10865541	0.571	rs4854187	chr2:3384196	C/G	cg11855769	chr2:3383351	TTC15	-0.44	-5.41	-0.32	1.4e-7	Obesity-related traits;
CESC	cis	rs10089	0.953	rs1036171	chr5:127402798	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.78	10.17	0.53	9.96e-21	Ileal carcinoids;
CESC	cis	rs6500602	0.701	rs4785969	chr16:4536934	A/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.38	5.47	0.32	1.02e-7	Schizophrenia;
CESC	cis	rs4689388	0.581	rs4476672	chr4:6281496	A/G	cg00701064	chr4:6280414	WFS1	0.61	7.51	0.42	8.84e-13	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs858239	0.601	rs4599714	chr7:23168801	C/T	cg23682824	chr7:23144976	KLHL7	0.55	7.73	0.43	2.27e-13	Cerebrospinal fluid biomarker levels;
CESC	cis	rs13118159	0.550	rs4974617	chr4:1373658	T/C	cg20887711	chr4:1340912	KIAA1530	0.84	11.4	0.57	9.5e-25	Longevity;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg01228352	chr3:150329615	SELT	0.47	6.28	0.36	1.37e-9	Fibrinogen levels;
CESC	cis	rs12142240	0.698	rs17361763	chr1:46810670	T/C	cg00530320	chr1:46809349	NSUN4	0.6	7.97	0.44	4.86e-14	Menopause (age at onset);
CESC	cis	rs1538970	0.781	rs10890330	chr1:45920406	G/A	cg03146154	chr1:46216737	IPP	0.47	5.44	0.32	1.23e-7	Platelet count;
CESC	cis	rs7937682	0.632	rs57414412	chr11:111769431	G/A	cg09085632	chr11:111637200	PPP2R1B	0.87	11.02	0.56	1.67e-23	Primary sclerosing cholangitis;
CESC	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg11965913	chr1:205819406	PM20D1	0.83	13.0	0.62	3.29e-30	Menarche (age at onset);
CESC	cis	rs2070488	0.699	rs6599205	chr3:38529440	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.77	11.72	0.58	7.5e-26	Electrocardiographic conduction measures;
CESC	cis	rs4853012	0.941	rs78128123	chr2:74347525	C/T	cg01017244	chr2:74357527	NA	0.77	9.87	0.52	9.02e-20	Gestational age at birth (maternal effect);
CESC	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg09033563	chr22:24373618	LOC391322	0.44	5.77	0.33	2.25e-8	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs9916302	0.851	rs612209	chr17:37442713	G/C	cg20243544	chr17:37824526	PNMT	-0.44	-5.45	-0.32	1.13e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs4253772	0.678	rs9627281	chr22:46644168	A/G	cg09491104	chr22:46646882	C22orf40	-0.56	-8.71	-0.47	3.38e-16	LDL cholesterol;Cholesterol, total;
CESC	cis	rs7412746	0.658	rs10305704	chr1:150804429	A/C	cg04414720	chr1:150670196	GOLPH3L	0.55	7.44	0.42	1.37e-12	Melanoma;
CESC	cis	rs6032067	0.929	rs6032070	chr20:43869795	A/T	cg10761708	chr20:43804764	PI3	0.5	6.06	0.35	4.71e-9	Blood protein levels;
CESC	cis	rs7818688	0.578	rs4355737	chr8:95827173	C/T	cg16049864	chr8:95962084	TP53INP1	0.56	5.65	0.33	4.24e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg26338869	chr17:61819248	STRADA	0.69	9.1	0.49	2.2e-17	Prudent dietary pattern;
CESC	cis	rs2228479	0.850	rs62056102	chr16:89941438	T/C	cg14709524	chr16:89940631	TCF25	0.88	6.44	0.37	5.5e-10	Skin colour saturation;
CESC	cis	rs7937682	0.737	rs682239	chr11:111425105	A/G	cg09085632	chr11:111637200	PPP2R1B	0.75	10.16	0.53	1.1e-20	Primary sclerosing cholangitis;
CESC	trans	rs9929218	1.000	rs28549017	chr16:68758828	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.75	-9.72	-0.51	2.7e-19	Colorectal cancer;
CESC	cis	rs853679	0.550	rs6901017	chr6:28152583	T/C	cg26335602	chr6:28129616	ZNF389	0.49	6.74	0.38	9.99e-11	Depression;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg02470565	chr22:29702866	GAS2L1	-0.48	-6.01	-0.35	6.09e-9	Ulcerative colitis;
CESC	cis	rs1448094	0.654	rs7133797	chr12:86294184	G/C	cg02569458	chr12:86230093	RASSF9	0.36	5.14	0.3	5.46e-7	Major depressive disorder;
CESC	cis	rs9322193	0.962	rs62441335	chr6:150113794	G/A	cg13206674	chr6:150067644	NUP43	0.41	5.78	0.33	2.05e-8	Lung cancer;
CESC	cis	rs4819052	0.851	rs12626188	chr21:46669258	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.73	9.48	0.5	1.53e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs7949030	0.588	rs2512562	chr11:62312156	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.58	8.58	0.47	8.21e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs7903847	0.642	rs11189204	chr10:99164394	C/T	cg20016023	chr10:99160130	RRP12	-0.3	-5.19	-0.3	4.12e-7	Granulocyte percentage of myeloid white cells;
CESC	cis	rs1669338	0.588	rs73009149	chr3:3220473	G/C	cg16797762	chr3:3221439	CRBN	-0.53	-5.18	-0.3	4.5e-7	White matter integrity;
CESC	cis	rs1801251	1.000	rs2675974	chr2:233727071	A/G	cg08000102	chr2:233561755	GIGYF2	0.66	9.67	0.51	3.91e-19	Coronary artery disease;
CESC	cis	rs2742234	0.955	rs2435385	chr10:43665750	A/G	cg15436174	chr10:43711423	RASGEF1A	-0.43	-5.44	-0.32	1.2e-7	Hirschsprung disease;
CESC	cis	rs3020736	0.500	rs6002614	chr22:42501802	G/A	cg15557168	chr22:42548783	NA	0.45	6.51	0.37	3.78e-10	Autism spectrum disorder or schizophrenia;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg27194998	chr19:47217554	PRKD2	-0.51	-6.41	-0.37	6.52e-10	Ulcerative colitis;
CESC	cis	rs722599	0.683	rs8022046	chr14:75278302	G/A	cg11812906	chr14:75593930	NEK9	0.45	5.44	0.32	1.24e-7	IgG glycosylation;
CESC	cis	rs1552244	0.872	rs35988239	chr3:10074145	G/T	cg08888203	chr3:10149979	C3orf24	0.49	5.5	0.32	8.81e-8	Alzheimer's disease;
CESC	cis	rs2576037	0.526	rs3892820	chr18:44479558	A/G	cg19077165	chr18:44547161	KATNAL2	-0.55	-7.89	-0.44	8.21e-14	Personality dimensions;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg23567369	chr14:24036565	AP1G2	-0.48	-6.4	-0.37	6.85e-10	Fibrinogen levels;
CESC	cis	rs62103177	0.810	rs62096746	chr18:77619556	T/A	cg12964065	chr18:77638022	KCNG2	0.58	5.68	0.33	3.5e-8	Opioid sensitivity;
CESC	cis	rs6695640	0.819	rs2800697	chr1:17731751	C/T	cg01904812	chr1:17746340	RCC2	0.36	5.26	0.31	2.97e-7	Mean platelet volume;
CESC	cis	rs6754311	0.509	rs10188066	chr2:136539513	G/A	cg07169764	chr2:136633963	MCM6	-0.72	-9.3	-0.5	5.58e-18	Mosquito bite size;
CESC	cis	rs6063312	0.935	rs6066827	chr20:47341005	T/C	cg18078177	chr20:47281410	PREX1	0.56	5.7	0.33	3.2e-8	Tonometry;
CESC	cis	rs6582630	0.547	rs1589388	chr12:38416025	C/T	cg26384229	chr12:38710491	ALG10B	-0.44	-5.99	-0.35	6.77e-9	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs1879734	0.731	rs10888805	chr1:54160571	A/G	cg23596471	chr1:54105337	GLIS1	0.35	5.66	0.33	3.96e-8	Mitral valve prolapse;
CESC	cis	rs7615952	0.576	rs2276726	chr3:125826287	C/G	cg02772935	chr3:125709198	NA	-0.47	-5.5	-0.32	8.75e-8	Blood pressure (smoking interaction);
CESC	cis	rs4595586	0.545	rs61939641	chr12:39378001	T/C	cg26384229	chr12:38710491	ALG10B	0.54	7.53	0.42	7.85e-13	Morning vs. evening chronotype;
CESC	cis	rs3733418	0.799	rs35680343	chr4:165953134	T/G	cg10852876	chr4:165953100	TRIM60	-0.48	-5.76	-0.33	2.31e-8	Obesity-related traits;
CESC	cis	rs6752107	0.967	rs36001488	chr2:234185267	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.49	6.69	0.38	1.3e-10	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs7666738	0.830	rs10031190	chr4:98908683	C/A	cg03676636	chr4:99064102	C4orf37	0.34	5.14	0.3	5.31e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11122272	0.525	rs2739517	chr1:231537914	C/A	cg06096015	chr1:231504339	EGLN1	0.43	6.08	0.35	4.28e-9	Hemoglobin concentration;
CESC	cis	rs55871839	0.559	rs7834158	chr8:59843813	C/A	cg07426533	chr8:59803705	TOX	0.4	5.28	0.31	2.73e-7	Pneumonia;
CESC	cis	rs4555082	0.834	rs2735822	chr14:105712734	C/T	cg06808227	chr14:105710500	BRF1	-0.51	-5.65	-0.33	4.08e-8	Mean platelet volume;Platelet distribution width;
CESC	cis	rs722599	0.748	rs61978948	chr14:75363369	G/A	cg08847533	chr14:75593920	NEK9	-0.46	-5.49	-0.32	9.57e-8	IgG glycosylation;
CESC	cis	rs4409675	0.576	rs2815707	chr1:28238880	T/C	cg23691781	chr1:28212827	C1orf38	0.28	5.59	0.32	5.61e-8	Corneal astigmatism;
CESC	cis	rs270601	0.955	rs273911	chr5:131661526	C/G	cg07395648	chr5:131743802	NA	-0.43	-5.74	-0.33	2.6e-8	Acylcarnitine levels;
CESC	cis	rs9322193	0.923	rs4870267	chr6:149992708	C/G	cg04369109	chr6:150039330	LATS1	-0.39	-5.38	-0.31	1.63e-7	Lung cancer;
CESC	cis	rs10256972	0.758	rs9801444	chr7:1080444	A/C	cg23978390	chr7:1156363	C7orf50	-0.52	-6.71	-0.38	1.2e-10	Longevity;Endometriosis;
CESC	cis	rs524281	0.861	rs3953856	chr11:65965908	T/A	cg14036092	chr11:66035641	RAB1B	-0.6	-6.1	-0.35	3.77e-9	Electroencephalogram traits;
CESC	cis	rs7666738	0.830	rs1869897	chr4:98730997	C/T	cg17366294	chr4:99064904	C4orf37	0.55	7.43	0.42	1.47e-12	Colonoscopy-negative controls vs population controls;
CESC	cis	rs12618769	0.597	rs12617721	chr2:99083892	G/T	cg10123293	chr2:99228465	UNC50	-0.4	-5.45	-0.32	1.18e-7	Bipolar disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17881958	chr10:50747314	ERCC6	0.61	6.56	0.37	2.79e-10	Gut microbiome composition (summer);
CESC	cis	rs9291683	0.595	rs13145442	chr4:10037261	C/A	cg11266682	chr4:10021025	SLC2A9	0.7	13.8	0.65	5.02e-33	Bone mineral density;
CESC	cis	rs9660992	0.573	rs1172158	chr1:205208948	G/A	cg21643547	chr1:205240462	TMCC2	-0.39	-5.37	-0.31	1.76e-7	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs7648466	0.544	rs2172247	chr3:46214670	T/C	cg08033130	chr3:45983597	CXCR6;FYCO1	0.37	5.16	0.3	4.77e-7	Eotaxin levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22857999	chr1:24127039	GALE	0.58	6.48	0.37	4.53e-10	Gut microbiome composition (summer);
CESC	cis	rs9611565	0.649	rs5758442	chr22:42133060	T/C	cg03806693	chr22:41940476	POLR3H	0.78	9.54	0.51	9.81e-19	Vitiligo;
CESC	cis	rs514406	0.668	rs520281	chr1:53365235	G/C	cg08859206	chr1:53392774	SCP2	-0.65	-9.31	-0.5	5.23e-18	Monocyte count;
CESC	cis	rs7647973	0.626	rs1586827	chr3:49671224	T/C	cg06212747	chr3:49208901	KLHDC8B	0.64	7.69	0.43	2.83e-13	Menarche (age at onset);
CESC	cis	rs1862618	0.853	rs252909	chr5:56121131	T/C	cg12311346	chr5:56204834	C5orf35	-0.74	-8.87	-0.48	1.09e-16	Initial pursuit acceleration;
CESC	cis	rs1862618	0.620	rs189695	chr5:56225769	T/C	cg12311346	chr5:56204834	C5orf35	-0.64	-8.78	-0.47	2.01e-16	Initial pursuit acceleration;
CESC	cis	rs13191362	0.872	rs36069443	chr6:163248701	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.69	6.62	0.38	2e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs6502050	0.799	rs12940433	chr17:80120826	C/T	cg11859384	chr17:80120422	CCDC57	-0.39	-5.34	-0.31	1.98e-7	Life satisfaction;
CESC	cis	rs6674176	0.597	rs12127737	chr1:44402565	G/A	cg13606994	chr1:44402422	ARTN	-0.41	-6.52	-0.37	3.47e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.35	6.8	0.39	6.75e-11	Electroencephalogram traits;
CESC	cis	rs11696501	0.694	rs6130870	chr20:44263263	T/C	cg11783356	chr20:44313418	WFDC10B	-0.34	-5.29	-0.31	2.54e-7	Brain structure;
CESC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg00405494	chr9:7797524	C9orf123	0.51	6.08	0.35	4.23e-9	Lung cancer in ever smokers;
CESC	cis	rs12477438	0.765	rs2309454	chr2:99595418	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.62	-8.67	-0.47	4.43e-16	Chronic sinus infection;
CESC	cis	rs703842	1.000	rs11172351	chr12:58213485	C/T	cg00677455	chr12:58241039	CTDSP2	0.55	7.1	0.4	1.18e-11	Multiple sclerosis;
CESC	cis	rs2304069	0.545	rs12153714	chr5:149395254	A/G	cg12661370	chr5:149340060	SLC26A2	0.43	5.67	0.33	3.75e-8	HIV-1 control;
CESC	cis	rs796364	0.951	rs12620298	chr2:201047184	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.62	-5.91	-0.34	1.05e-8	Schizophrenia;
CESC	cis	rs748404	0.697	rs554001	chr15:43551919	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	8.09	0.44	2.22e-14	Lung cancer;
CESC	cis	rs11078597	0.731	rs12944946	chr17:1649486	C/G	cg18436246	chr17:1640651	WDR81	0.62	7.63	0.42	4.25e-13	Serum albumin level;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09820183	chr1:222886073	C1orf58;AIDA	0.56	6.79	0.38	7.3e-11	Gut microbiome composition (summer);
CESC	cis	rs7786877	0.723	rs73407376	chr7:100215200	C/T	cg16850897	chr7:100343110	ZAN	-0.58	-6.23	-0.36	1.83e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs8014204	0.762	rs10139018	chr14:75274292	T/C	cg08847533	chr14:75593920	NEK9	0.4	5.15	0.3	5.11e-7	Caffeine consumption;
CESC	cis	rs3845702	0.866	rs3914458	chr2:180862606	A/G	cg01881094	chr2:180872142	CWC22	-0.66	-7.11	-0.4	1.05e-11	Schizophrenia;
CESC	cis	rs826838	0.809	rs11169666	chr12:39211300	T/C	cg13010199	chr12:38710504	ALG10B	0.59	8.25	0.45	7.6e-15	Heart rate;
CESC	cis	rs6887276	0.538	rs35897671	chr5:127349745	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.45	-5.56	-0.32	6.52e-8	Height;
CESC	cis	rs9858542	0.953	rs11710037	chr3:49675334	C/G	cg03060546	chr3:49711283	APEH	-0.57	-6.68	-0.38	1.42e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs317689	0.918	rs689415	chr12:69738139	A/G	cg14784868	chr12:69753453	YEATS4	-0.64	-7.26	-0.41	4.35e-12	Response to diuretic therapy;
CESC	cis	rs75477785	0.590	rs79880650	chr1:209913916	A/G	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.84	5.39	0.31	1.54e-7	Cleft lip with or without cleft palate;
CESC	cis	rs1862618	0.511	rs2591952	chr5:56120769	T/A	cg24549020	chr5:56110836	MAP3K1	0.64	7.38	0.41	2.08e-12	Initial pursuit acceleration;
CESC	cis	rs7267979	0.933	rs2387887	chr20:25427081	G/T	cg08601574	chr20:25228251	PYGB	0.38	5.64	0.33	4.4e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs2836974	0.899	rs34978594	chr21:40580003	C/T	cg27266027	chr21:40555129	PSMG1	0.45	5.3	0.31	2.47e-7	Cognitive function;
CESC	cis	rs896854	0.552	rs2515236	chr8:95934907	A/G	cg09323728	chr8:95962352	TP53INP1	0.35	6.18	0.36	2.34e-9	Type 2 diabetes;
CESC	cis	rs6942756	1.000	rs2103232	chr7:128951232	G/T	cg02491457	chr7:128862824	NA	-0.68	-9.28	-0.5	6.2e-18	White matter hyperintensity burden;
CESC	cis	rs7949030	0.626	rs7943191	chr11:62328551	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.6	8.48	0.46	1.58e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg14182682	chr14:57857589	NAA30	-0.45	-6.1	-0.35	3.77e-9	Gut microbiota (bacterial taxa);
CESC	trans	rs116095464	0.681	rs10060016	chr5:241100	T/C	cg00938859	chr5:1591904	SDHAP3	0.64	6.98	0.39	2.36e-11	Breast cancer;
CESC	cis	rs736801	0.808	rs6866614	chr5:131787137	A/G	cg21138405	chr5:131827807	IRF1	0.39	5.66	0.33	3.88e-8	Breast cancer;Mosquito bite size;
CESC	cis	rs6951245	0.744	rs1133122	chr7:1192572	C/A	cg22907277	chr7:1156413	C7orf50	0.47	5.3	0.31	2.48e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs295137	0.798	rs1900706	chr2:201214071	A/C	cg23649088	chr2:200775458	C2orf69	0.41	5.32	0.31	2.26e-7	Asthma (bronchodilator response);
CESC	cis	rs1580019	0.961	rs11768506	chr7:32494788	A/C	cg06627557	chr7:32535165	LSM5;AVL9	0.72	10.07	0.53	2.04e-20	Cognitive ability;
CESC	cis	rs7107174	0.892	rs7115850	chr11:78045071	C/G	cg02023728	chr11:77925099	USP35	0.38	5.45	0.32	1.14e-7	Testicular germ cell tumor;
CESC	cis	rs7580658	0.857	rs17015199	chr2:128094053	A/G	cg10021288	chr2:128175891	PROC	-0.41	-6.37	-0.36	8.11e-10	Protein C levels;
CESC	cis	rs2154427	0.938	rs113791275	chr21:34202806	A/C	cg21871883	chr21:34145043	C21orf49;C21orf66	0.62	5.15	0.3	5.15e-7	Bilirubin levels;
CESC	cis	rs71403859	0.730	rs17347255	chr16:71587225	C/T	cg08717414	chr16:71523259	ZNF19	-0.84	-7.51	-0.42	9.26e-13	Post bronchodilator FEV1;
CESC	cis	rs116095464	0.558	rs10076655	chr5:239464	G/C	cg10591111	chr5:226296	SDHA	-0.51	-6.26	-0.36	1.53e-9	Breast cancer;
CESC	trans	rs3780486	0.846	rs3780490	chr9:33129839	A/G	cg20290983	chr6:43655470	MRPS18A	0.99	18.34	0.75	4.45e-49	IgG glycosylation;
CESC	cis	rs9815354	0.761	rs12186109	chr3:41836920	T/C	cg03022575	chr3:42003672	ULK4	0.7	6.04	0.35	5.26e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs7267979	1.000	rs1047171	chr20:25428786	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.87	18.11	0.74	3e-48	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs714031	0.902	rs4820388	chr22:40070642	C/G	cg21377881	chr22:40064566	CACNA1I	-0.35	-5.75	-0.33	2.49e-8	Schizophrenia;
CESC	trans	rs73242632	1.000	rs12511480	chr4:57748143	C/T	cg16182707	chr12:105478090	ALDH1L2	0.72	6.05	0.35	4.88e-9	Congenital heart disease (maternal effect);
CESC	trans	rs7944735	0.507	rs7114598	chr11:48101766	C/T	cg03929089	chr4:120376271	NA	0.55	6.53	0.37	3.38e-10	Intraocular pressure;
CESC	cis	rs7072216	0.763	rs6584200	chr10:100170037	A/G	cg26618903	chr10:100175079	PYROXD2	-0.37	-5.76	-0.33	2.33e-8	Metabolite levels;
CESC	cis	rs7089973	0.966	rs55711292	chr10:116604870	T/G	cg25233709	chr10:116636983	FAM160B1	0.38	5.49	0.32	9.46e-8	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs6445797	0.662	rs17216671	chr3:56582551	C/G	cg13792233	chr3:56591045	CCDC66	-0.39	-5.11	-0.3	6.19e-7	Gastritis;
CESC	cis	rs7666738	0.791	rs2903151	chr4:99027218	T/C	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.58e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7833790	0.724	rs4739627	chr8:82734657	A/G	cg17211192	chr8:82754475	SNX16	-0.52	-6.64	-0.38	1.73e-10	Diastolic blood pressure;
CESC	trans	rs916888	0.821	rs199512	chr17:44857352	T/C	cg10053473	chr17:62856997	LRRC37A3	0.65	7.33	0.41	2.74e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs7811142	1.000	rs7809801	chr7:100072031	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.03	11.82	0.59	3.55e-26	Platelet count;
CESC	trans	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg10053473	chr17:62856997	LRRC37A3	-0.6	-6.63	-0.38	1.84e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs2842992	0.709	rs1853257	chr6:160212710	C/G	cg11366901	chr6:160182831	ACAT2	0.76	9.51	0.5	1.21e-18	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs9929218	1.000	rs4783570	chr16:68806539	G/T	cg02972257	chr16:68554789	NA	0.43	5.12	0.3	5.89e-7	Colorectal cancer;
CESC	cis	rs40363	0.671	rs4786425	chr16:3537650	A/G	cg00484396	chr16:3507460	NAT15	-0.58	-6.29	-0.36	1.32e-9	Tuberculosis;
CESC	cis	rs77741769	0.571	rs11065324	chr12:121346795	C/G	cg02419362	chr12:121203948	SPPL3	-0.34	-5.5	-0.32	8.83e-8	Mean corpuscular volume;
CESC	cis	rs1046896	0.561	rs8076476	chr17:80861017	A/C	cg02398342	chr17:80708632	TBCD;FN3K	0.43	5.09	0.3	6.66e-7	Glycated hemoglobin levels;
CESC	cis	rs1878931	0.507	rs8054222	chr16:3413477	C/T	cg22508957	chr16:3507546	NAT15	0.38	5.2	0.3	3.96e-7	Body mass index (adult);
CESC	cis	rs7555523	1.000	rs7555523	chr1:165718979	C/A	cg24409356	chr1:165738333	TMCO1	0.92	8.21	0.45	9.56e-15	Intraocular pressure;Glaucoma (high intraocular pressure);
CESC	cis	rs1256061	0.603	rs1256041	chr14:64738029	A/G	cg21174375	chr14:64681225	SYNE2	0.51	6.82	0.39	6.15e-11	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs172166	0.637	rs1225595	chr6:28151340	A/T	cg21251018	chr6:28226885	NKAPL	0.37	6.21	0.36	2.04e-9	Cardiac Troponin-T levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26681016	chr1:43424924	SLC2A1	0.64	7.57	0.42	6.09e-13	Gut microbiome composition (summer);
CESC	cis	rs2425143	0.514	rs8114246	chr20:34581979	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.58	-5.77	-0.33	2.18e-8	Blood protein levels;
CESC	cis	rs6952808	0.929	rs11761270	chr7:1923695	C/T	cg23048001	chr7:2026167	MAD1L1	0.4	5.17	0.3	4.54e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs9902453	0.845	rs116840018	chr17:28232049	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.65	8.2	0.45	1.05e-14	Coffee consumption (cups per day);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04865506	chr17:29422776	NF1	-0.52	-6.03	-0.35	5.47e-9	Gut microbiome composition (summer);
CESC	cis	rs34172651	0.517	rs11647120	chr16:24819806	A/G	cg06505273	chr16:24850292	NA	0.51	6.1	0.35	3.64e-9	Intelligence (multi-trait analysis);
CESC	cis	rs12474201	0.928	rs13025984	chr2:46938789	T/C	cg06386533	chr2:46925753	SOCS5	0.92	12.74	0.62	2.57e-29	Height;
CESC	trans	rs60843830	0.928	rs55742348	chr2:217563	T/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.65	7.99	0.44	4.26e-14	Spherical equivalent (joint analysis main effects and education interaction);
CESC	trans	rs2946505	0.516	rs2954193	chr8:12818373	T/C	cg09851072	chr16:4749498	ANKS3	-0.62	-6.01	-0.35	6.19e-9	Migraine;
CESC	cis	rs6540556	0.769	rs6540553	chr1:209929044	C/G	cg05527609	chr1:210001259	C1orf107	-0.47	-5.73	-0.33	2.7e-8	Red blood cell count;
CESC	cis	rs11920090	0.860	rs7638998	chr3:170741015	A/G	cg09710316	chr3:170744871	SLC2A2	0.43	5.16	0.3	4.81e-7	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
CESC	cis	rs10504229	0.773	rs60466370	chr8:58171248	A/C	cg22535103	chr8:58192502	C8orf71	-0.87	-11.17	-0.57	5.43e-24	Developmental language disorder (linguistic errors);
CESC	cis	rs7223966	1.000	rs16947042	chr17:61766457	T/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.44	-5.35	-0.31	1.9e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs7772486	0.875	rs2492855	chr6:146296926	A/G	cg05347473	chr6:146136440	FBXO30	0.48	6.56	0.37	2.89e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9908102	0.740	rs58700278	chr17:12907128	A/C	cg26162695	chr17:12921313	ELAC2	0.51	5.86	0.34	1.37e-8	Schizophrenia;
CESC	trans	rs11264799	0.765	rs67805319	chr1:157622853	G/A	cg22691776	chr3:15032403	NR2C2	0.33	6.1	0.35	3.7e-9	IgA nephropathy;
CESC	cis	rs4950322	0.570	rs76236344	chr1:146769674	G/A	cg22381352	chr1:146742008	CHD1L	-0.46	-5.05	-0.3	8.32e-7	Protein quantitative trait loci;
CESC	cis	rs2235642	0.928	rs1057610	chr16:1605537	T/C	cg09080909	chr16:1797204	MAPK8IP3	-0.37	-5.08	-0.3	7.16e-7	Coronary artery disease;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg14588027	chr1:212872986	BATF3	-0.39	-5.99	-0.35	6.71e-9	Gambling;
CESC	cis	rs2832191	0.720	rs2832194	chr21:30494250	T/C	cg08807101	chr21:30365312	RNF160	-0.72	-9.88	-0.52	8.63e-20	Dental caries;
CESC	cis	rs853679	0.517	rs9348796	chr6:28126202	A/G	cg23161317	chr6:28129485	ZNF389	0.52	6.48	0.37	4.37e-10	Depression;
CESC	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg26338869	chr17:61819248	STRADA	0.69	9.18	0.49	1.23e-17	Prudent dietary pattern;
CESC	cis	rs2963155	0.518	rs712189	chr5:142631258	C/T	cg17617527	chr5:142782415	NR3C1	0.83	7.26	0.41	4.29e-12	Breast cancer;
CESC	cis	rs9457247	1.000	rs2769354	chr6:167379771	G/T	cg07741184	chr6:167504864	NA	-0.3	-5.38	-0.31	1.62e-7	Crohn's disease;
CESC	cis	rs7666738	0.924	rs13124368	chr4:99039615	T/C	cg03676636	chr4:99064102	C4orf37	0.33	5.12	0.3	5.93e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs35306767	0.668	rs12356612	chr10:1055055	C/T	cg20503657	chr10:835505	NA	0.67	6.11	0.35	3.56e-9	Eosinophil percentage of granulocytes;
CESC	trans	rs11098499	0.644	rs2389880	chr4:120559870	T/A	cg25214090	chr10:38739885	LOC399744	0.64	9.04	0.49	3.3e-17	Corneal astigmatism;
CESC	cis	rs7656342	0.686	rs1401440	chr4:9832512	C/T	cg11266682	chr4:10021025	SLC2A9	0.33	5.26	0.31	3e-7	Gut microbiota (bacterial taxa);
CESC	cis	rs7605827	0.930	rs7608831	chr2:15605029	A/G	cg19274914	chr2:15703543	NA	0.35	6.13	0.35	3.19e-9	Educational attainment (years of education);
CESC	cis	rs3008870	0.917	rs12044492	chr1:67461667	T/C	cg02640540	chr1:67518911	SLC35D1	-0.51	-5.58	-0.32	5.89e-8	Lymphocyte percentage of white cells;
CESC	cis	rs3733585	0.736	rs4543113	chr4:10008305	G/A	cg11266682	chr4:10021025	SLC2A9	0.66	12.55	0.61	1.14e-28	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs1008375	0.966	rs6832387	chr4:17697546	G/T	cg15017067	chr4:17643749	FAM184B	0.37	5.2	0.3	3.95e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs6430585	0.878	rs9677760	chr2:136538939	T/A	cg07169764	chr2:136633963	MCM6	-0.96	-13.08	-0.63	1.64e-30	Corneal structure;
CESC	cis	rs17407555	0.821	rs17198197	chr4:10139157	A/G	cg00071950	chr4:10020882	SLC2A9	0.61	5.49	0.32	9.37e-8	Schizophrenia (age at onset);
CESC	cis	rs3733585	0.725	rs10939636	chr4:9972640	T/G	cg02734326	chr4:10020555	SLC2A9	-0.42	-5.86	-0.34	1.39e-8	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs1023500	0.551	rs133355	chr22:42440285	G/A	cg04733989	chr22:42467013	NAGA	0.8	11.74	0.59	6.47e-26	Schizophrenia;
CESC	cis	rs74181299	0.712	rs2241160	chr2:65291546	A/G	cg05010058	chr2:65284262	CEP68	0.31	5.19	0.3	4.24e-7	Pulse pressure;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04382627	chr10:134351046	INPP5A	0.62	7.12	0.4	1.04e-11	Gut microbiome composition (summer);
CESC	cis	rs7980687	0.628	rs1609520	chr12:123735937	A/G	cg00376283	chr12:123451042	ABCB9	-0.62	-8.06	-0.44	2.66e-14	Height;Educational attainment;Head circumference (infant);
CESC	cis	rs7107174	1.000	rs114142124	chr11:78047537	T/C	cg02023728	chr11:77925099	USP35	0.48	6.16	0.35	2.71e-9	Testicular germ cell tumor;
CESC	cis	rs793571	0.502	rs688756	chr15:59076272	A/C	cg05156742	chr15:59063176	FAM63B	0.78	11.19	0.57	4.54e-24	Schizophrenia;
CESC	cis	rs7267979	0.966	rs6083855	chr20:25405118	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.86	-17.76	-0.74	5.21e-47	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs12701220	0.901	rs12701708	chr7:1090333	C/T	cg26769984	chr7:1090371	C7orf50	0.67	7.83	0.43	1.16e-13	Bronchopulmonary dysplasia;
CESC	cis	rs858239	0.539	rs6461695	chr7:23197784	C/A	cg23682824	chr7:23144976	KLHL7	0.44	5.8	0.34	1.88e-8	Cerebrospinal fluid biomarker levels;
CESC	cis	rs1009170	1.000	rs1009170	chr14:92636713	A/T	cg10324096	chr14:92587714	CPSF2;NDUFB1	-0.46	-5.15	-0.3	5.14e-7	Dialysis-related mortality;
CESC	cis	rs17376456	0.877	rs66696214	chr5:93424533	G/A	cg21475434	chr5:93447410	FAM172A	0.88	7.67	0.43	3.29e-13	Diabetic retinopathy;
CESC	cis	rs9303280	0.806	rs11870965	chr17:38030205	T/A	cg20243544	chr17:37824526	PNMT	0.5	6.43	0.37	5.86e-10	Self-reported allergy;
CESC	cis	rs1949733	0.523	rs62287455	chr4:8544994	A/T	cg11789530	chr4:8429930	ACOX3	-0.56	-7.03	-0.4	1.79e-11	Response to antineoplastic agents;
CESC	cis	rs155076	1.000	rs566364	chr13:21837583	T/C	cg11317459	chr13:21872234	NA	-1.01	-10.78	-0.55	1.07e-22	White matter hyperintensity burden;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg17274881	chr4:79103244	FRAS1	-0.44	-6.26	-0.36	1.53e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs8135665	0.625	rs34385006	chr22:38450291	C/T	cg13116946	chr22:38479732	SLC16A8	0.42	5.14	0.3	5.31e-7	Advanced age-related macular degeneration;Age-related macular degeneration;
CESC	trans	rs9858542	0.953	rs9853683	chr3:49512588	A/G	cg21659725	chr3:3221576	CRBN	-0.55	-6.49	-0.37	4.22e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26220061	chr1:70819839	HHLA3;ANKRD13C	0.57	6.16	0.35	2.75e-9	Gut microbiome composition (summer);
CESC	cis	rs17433780	0.964	rs10493821	chr1:89475135	C/T	cg09516651	chr1:89888402	LOC400759	0.69	9.44	0.5	2.04e-18	Carotid intima media thickness;
CESC	cis	rs875971	0.825	rs59466412	chr7:65565358	A/G	cg11764359	chr7:65958608	NA	-0.78	-10.74	-0.55	1.44e-22	Aortic root size;
CESC	cis	rs1707322	1.000	rs12124847	chr1:46380850	T/A	cg05343316	chr1:45956843	TESK2	0.5	6.07	0.35	4.35e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs1448094	0.511	rs7139088	chr12:86147878	T/C	cg02569458	chr12:86230093	RASSF9	-0.42	-6.44	-0.37	5.67e-10	Major depressive disorder;
CESC	cis	rs4843747	0.803	rs72818522	chr16:88059144	C/T	cg06915872	chr16:87998081	BANP	0.5	5.89	0.34	1.17e-8	Menopause (age at onset);
CESC	cis	rs8072100	0.701	rs2013383	chr17:45791123	T/G	cg08085267	chr17:45401833	C17orf57	-0.43	-5.41	-0.32	1.41e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs9649213	0.593	rs6961438	chr7:98005849	T/C	cg00277769	chr7:97922759	BAIAP2L1	-0.32	-5.32	-0.31	2.25e-7	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs208520	0.754	rs851593	chr6:66875783	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.0	12.55	0.61	1.12e-28	Exhaled nitric oxide output;
CESC	cis	rs4803468	0.763	rs17318596	chr19:41937095	A/G	cg08639244	chr19:41945921	ATP5SL	-0.44	-5.35	-0.31	1.92e-7	Height;
CESC	cis	rs1348850	0.514	rs4893974	chr2:178497026	A/G	cg22681709	chr2:178499509	PDE11A	-0.45	-5.37	-0.31	1.69e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs854765	0.583	rs950966	chr17:17783748	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.53	-7.3	-0.41	3.29e-12	Total body bone mineral density;
CESC	cis	rs854765	0.583	rs5002487	chr17:17832460	A/G	cg09796270	chr17:17721594	SREBF1	0.43	6.12	0.35	3.39e-9	Total body bone mineral density;
CESC	cis	rs4243830	0.850	rs4908911	chr1:6599523	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.86	-7.53	-0.42	7.77e-13	Body mass index;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg08255233	chr6:87607178	NA	-0.43	-6.68	-0.38	1.44e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs6460942	1.000	rs62448565	chr7:12400458	G/A	cg02935154	chr7:12443704	VWDE	-0.56	-6.06	-0.35	4.71e-9	Coronary artery disease;
CESC	cis	rs796364	0.806	rs115717210	chr2:201006247	T/C	cg23649088	chr2:200775458	C2orf69	-0.55	-5.04	-0.3	8.69e-7	Schizophrenia;
CESC	cis	rs763121	0.962	rs6001159	chr22:38966487	A/G	cg06544989	chr22:39130855	UNC84B	0.46	8.25	0.45	7.4e-15	Menopause (age at onset);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg11539992	chr17:74497631	RHBDF2	-0.51	-6.48	-0.37	4.47e-10	Ulcerative colitis;
CESC	cis	rs4689388	0.926	rs1801214	chr4:6303022	C/T	cg00701064	chr4:6280414	WFS1	0.69	12.03	0.59	6.81e-27	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs4604732	0.578	rs12040725	chr1:247644697	T/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.62	8.07	0.44	2.41e-14	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs2985684	0.895	rs3007033	chr14:50103816	T/C	cg02151108	chr14:50098012	C14orf104	-0.42	-5.45	-0.32	1.17e-7	Carotid intima media thickness;
CESC	cis	rs9322193	0.923	rs9800871	chr6:149965676	A/G	cg04369109	chr6:150039330	LATS1	-0.37	-5.08	-0.3	6.98e-7	Lung cancer;
CESC	cis	rs11098499	0.863	rs1010740	chr4:120463409	C/T	cg09307838	chr4:120376055	NA	-0.89	-12.0	-0.59	8.4e-27	Corneal astigmatism;
CESC	cis	rs847577	0.722	rs1013887	chr7:97709345	G/T	cg21770322	chr7:97807741	LMTK2	0.63	10.36	0.54	2.53e-21	Breast cancer;
CESC	cis	rs4604732	0.588	rs7549495	chr1:247627806	G/A	cg12754571	chr1:247694271	LOC148824;OR2C3	0.41	5.09	0.3	6.91e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs3105593	0.605	rs3131562	chr15:50772479	C/T	cg05456662	chr15:50716270	USP8	0.44	5.94	0.34	8.97e-9	QT interval;
CESC	trans	rs1275468	0.798	rs2366987	chr12:75930126	G/A	cg01020758	chr17:39643308	KRT36	-0.44	-6.15	-0.35	2.79e-9	Polycystic ovary syndrome;
CESC	cis	rs17001868	0.568	rs9607702	chr22:40739177	A/G	cg07138101	chr22:40742427	ADSL	0.57	5.38	0.31	1.66e-7	Mammographic density (dense area);
CESC	cis	rs1008375	0.932	rs4698629	chr4:17608884	C/G	cg02297831	chr4:17616191	MED28	0.48	5.39	0.31	1.56e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs7107174	0.901	rs866901	chr11:77926309	C/T	cg02023728	chr11:77925099	USP35	0.47	5.97	0.34	7.71e-9	Testicular germ cell tumor;
CESC	cis	rs8078723	1.000	rs59925331	chr17:38169273	C/G	cg17467752	chr17:38218738	THRA	0.67	9.97	0.52	4.3e-20	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CESC	cis	rs6495122	0.644	rs11630087	chr15:75261673	G/T	cg14664628	chr15:75095509	CSK	-0.53	-6.69	-0.38	1.29e-10	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
CESC	cis	rs35146811	0.520	rs1015538	chr7:99626035	A/G	cg22906224	chr7:99728672	NA	-0.48	-5.73	-0.33	2.7e-8	Coronary artery disease;
CESC	trans	rs35110281	0.748	rs2838324	chr21:44999820	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.56	7.45	0.42	1.29e-12	Mean corpuscular volume;
CESC	cis	rs6662572	0.737	rs7533750	chr1:46558434	G/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.47	5.17	0.3	4.73e-7	Blood protein levels;
CESC	cis	rs9948	0.529	rs62152773	chr2:97448073	T/C	cg01990225	chr2:97406019	LMAN2L	-0.92	-7.51	-0.42	9.04e-13	Erectile dysfunction and prostate cancer treatment;
CESC	cis	rs7336332	0.598	rs12018313	chr13:28012266	C/A	cg01674679	chr13:27998804	GTF3A	-0.58	-5.34	-0.31	2.04e-7	Weight;
CESC	cis	rs12142240	0.660	rs72890715	chr1:46852077	A/G	cg10495392	chr1:46806563	NSUN4	0.56	6.15	0.35	2.86e-9	Menopause (age at onset);
CESC	cis	rs9443189	0.950	rs276698	chr6:76473071	T/C	cg01950844	chr6:76311363	SENP6	0.63	6.19	0.36	2.26e-9	Prostate cancer;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg06130365	chr10:135122020	TUBGCP2;ZNF511	-0.47	-6.33	-0.36	1.02e-9	Fibrinogen levels;
CESC	cis	rs1950626	0.833	rs35151884	chr14:101394196	A/G	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.81	10.85	0.55	5.99e-23	Pelvic organ prolapse (moderate/severe);
CESC	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg11905131	chr22:24372483	LOC391322	-0.74	-10.64	-0.55	2.97e-22	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs1499972	0.941	rs2860308	chr3:117690309	T/G	cg07612923	chr3:117604196	NA	-0.86	-7.19	-0.4	6.63e-12	Schizophrenia;
CESC	cis	rs4713118	0.629	rs203889	chr6:28021775	T/G	cg22143856	chr6:28129313	ZNF389	0.42	5.24	0.31	3.23e-7	Parkinson's disease;
CESC	cis	rs9811920	0.799	rs9832134	chr3:99836722	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.39	5.98	0.34	7.36e-9	Axial length;
CESC	cis	rs2228479	0.850	rs11640209	chr16:89807828	C/A	cg14709524	chr16:89940631	TCF25	0.92	6.97	0.39	2.55e-11	Skin colour saturation;
CESC	cis	rs10504229	0.861	rs116923397	chr8:58185162	T/G	cg05313129	chr8:58192883	C8orf71	-0.55	-6.29	-0.36	1.34e-9	Developmental language disorder (linguistic errors);
CESC	trans	rs7937682	0.924	rs495460	chr11:111504777	G/A	cg18187862	chr3:45730750	SACM1L	0.51	6.47	0.37	4.81e-10	Primary sclerosing cholangitis;
CESC	cis	rs1799949	0.930	rs8176194	chr17:41231221	A/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.42	5.78	0.33	2.14e-8	Menopause (age at onset);
CESC	cis	rs7666738	0.830	rs13145011	chr4:98993410	G/A	cg17366294	chr4:99064904	C4orf37	0.6	8.61	0.47	6.47e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs72627123	0.656	rs117129791	chr14:74520871	G/A	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.78	5.36	0.31	1.81e-7	Morning vs. evening chronotype;
CESC	cis	rs2637266	0.967	rs6480826	chr10:78356154	A/G	cg18941641	chr10:78392320	NA	0.42	7.79	0.43	1.49e-13	Pulmonary function;
CESC	cis	rs2228479	0.850	rs62056068	chr16:89909737	C/T	cg14709524	chr16:89940631	TCF25	0.88	6.1	0.35	3.82e-9	Skin colour saturation;
CESC	cis	rs875971	0.767	rs1643394	chr7:65836094	A/G	cg10691866	chr7:65817282	TPST1	-0.32	-5.27	-0.31	2.87e-7	Aortic root size;
CESC	cis	rs4969178	0.965	rs2292642	chr17:76395430	C/T	cg05887092	chr17:76393375	PGS1	0.58	9.14	0.49	1.64e-17	HDL cholesterol levels;
CESC	cis	rs1355223	0.506	rs11032894	chr11:34865544	T/C	cg11622362	chr11:34938112	PDHX;APIP	0.44	5.29	0.31	2.52e-7	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs9649213	0.593	rs12704989	chr7:98029438	G/T	cg24562669	chr7:97807699	LMTK2	0.53	7.91	0.44	7e-14	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs8103278	0.507	rs522769	chr19:46284520	G/A	cg14061069	chr19:46274453	DMPK	0.51	8.02	0.44	3.46e-14	Coronary artery disease;
CESC	cis	rs5769765	0.773	rs11090920	chr22:50320105	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.54	-5.05	-0.3	8.4e-7	Schizophrenia;
CESC	cis	rs796364	0.806	rs1106400	chr2:201004089	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.67	-6.43	-0.37	5.87e-10	Schizophrenia;
CESC	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg14893161	chr1:205819251	PM20D1	0.98	18.76	0.76	1.49e-50	Menarche (age at onset);
CESC	cis	rs798554	0.757	rs1182178	chr7:2873763	G/A	cg13628971	chr7:2884303	GNA12	0.62	8.04	0.44	2.94e-14	Height;
CESC	cis	rs8017423	0.967	rs11621045	chr14:90714003	C/T	cg14092571	chr14:90743983	NA	-0.58	-8.72	-0.47	3.01e-16	Mortality in heart failure;
CESC	cis	rs6430585	0.528	rs12474975	chr2:136702118	A/T	cg07169764	chr2:136633963	MCM6	1.27	17.82	0.74	3.19e-47	Corneal structure;
CESC	cis	rs7584330	0.518	rs74478860	chr2:238437364	C/G	cg14458575	chr2:238380390	NA	0.72	6.85	0.39	5.03e-11	Prostate cancer;
CESC	cis	rs3096299	0.632	rs4399533	chr16:89539382	G/C	cg00750074	chr16:89608354	SPG7	-0.43	-6.23	-0.36	1.78e-9	Multiple myeloma (IgH translocation);
CESC	cis	rs1003719	0.688	rs2000416	chr21:38540089	T/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.59	-7.7	-0.43	2.7e-13	Eye color traits;
CESC	cis	rs2576037	0.623	rs2576040	chr18:44582027	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.75	-12.21	-0.6	1.7e-27	Personality dimensions;
CESC	cis	rs12681288	0.823	rs12681230	chr8:994422	G/A	cg04851639	chr8:1020857	NA	-0.35	-7.84	-0.43	1.09e-13	Schizophrenia;
CESC	cis	rs9467711	0.606	rs35307327	chr6:26370474	C/T	cg12826209	chr6:26865740	GUSBL1	0.62	5.22	0.31	3.66e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg11494091	chr17:61959527	GH2	0.74	13.02	0.62	2.62e-30	Prudent dietary pattern;
CESC	cis	rs9399137	0.507	rs7745289	chr6:135380327	A/G	cg22676075	chr6:135203613	NA	0.53	7.01	0.4	1.95e-11	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17697381	chr3:148709363	GYG1	0.54	6.2	0.36	2.14e-9	Gut microbiome composition (summer);
CESC	cis	rs12477438	0.765	rs9710648	chr2:99673129	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.64	-8.73	-0.47	2.94e-16	Chronic sinus infection;
CESC	cis	rs853679	0.517	rs55747925	chr6:28044337	T/C	cg23281280	chr6:28129359	ZNF389	0.57	7.78	0.43	1.61e-13	Depression;
CESC	cis	rs10504229	0.953	rs66676208	chr8:58173866	C/T	cg05313129	chr8:58192883	C8orf71	-0.55	-6.37	-0.36	8.42e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs951366	0.649	rs7522056	chr1:205735891	A/G	cg11965913	chr1:205819406	PM20D1	0.46	6.26	0.36	1.53e-9	Menarche (age at onset);
CESC	cis	rs7927771	1.000	rs4752873	chr11:47857520	C/T	cg05585544	chr11:47624801	NA	-0.49	-7.71	-0.43	2.62e-13	Subjective well-being;
CESC	cis	rs6587515	0.748	rs4970970	chr1:150637953	A/C	cg13175981	chr1:150552382	MCL1	0.62	5.67	0.33	3.75e-8	Pericardial adipose tissue adjusted for height and weight;
CESC	cis	rs963731	0.579	rs6739568	chr2:39287550	G/T	cg04010122	chr2:39346883	SOS1	-0.71	-5.67	-0.33	3.76e-8	Corticobasal degeneration;
CESC	cis	rs8177253	1.000	rs8177240	chr3:133477701	T/G	cg11941060	chr3:133502564	NA	-0.45	-6.02	-0.35	5.76e-9	Iron status biomarkers;
CESC	cis	rs28386778	0.700	rs12449555	chr17:62003982	T/A	cg26338869	chr17:61819248	STRADA	-0.65	-8.1	-0.45	2.04e-14	Prudent dietary pattern;
CESC	cis	rs7605827	0.930	rs10189180	chr2:15685949	T/C	cg19274914	chr2:15703543	NA	0.37	6.7	0.38	1.22e-10	Educational attainment (years of education);
CESC	cis	rs4835473	0.932	rs1877235	chr4:144908114	A/G	cg25736465	chr4:144833511	NA	-0.39	-5.95	-0.34	8.51e-9	Immature fraction of reticulocytes;
CESC	cis	rs7481584	1.000	rs12789474	chr11:3024139	T/G	cg25174290	chr11:3078921	CARS	-0.43	-5.43	-0.32	1.27e-7	Calcium levels;
CESC	cis	rs7107174	0.892	rs11237477	chr11:78095069	A/T	cg02023728	chr11:77925099	USP35	0.38	5.19	0.3	4.18e-7	Testicular germ cell tumor;
CESC	cis	rs8072100	0.713	rs4968318	chr17:45451894	G/A	cg25173405	chr17:45401733	C17orf57	-0.42	-5.27	-0.31	2.8e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs12079745	0.793	rs12089602	chr1:169180898	T/A	cg09363564	chr1:169337483	NME7;BLZF1	-1.0	-6.14	-0.35	3e-9	QT interval;
CESC	cis	rs10242455	0.702	rs73403286	chr7:99154865	A/C	cg18809830	chr7:99032528	PTCD1	-0.66	-5.21	-0.3	3.84e-7	Blood metabolite levels;
CESC	cis	rs2839186	0.706	rs2839188	chr21:47692798	C/T	cg12379764	chr21:47803548	PCNT	-0.51	-6.53	-0.37	3.42e-10	Testicular germ cell tumor;
CESC	cis	rs3820928	0.874	rs1054413	chr2:227867719	A/G	cg11843606	chr2:227700838	RHBDD1	0.44	5.61	0.33	5.01e-8	Pulmonary function;
CESC	cis	rs3768617	0.510	rs2296291	chr1:183079509	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.88	14.14	0.66	3.44e-34	Fuchs's corneal dystrophy;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg01399255	chr7:100271274	GNB2	-0.45	-6.38	-0.36	7.73e-10	Fibrinogen levels;
CESC	trans	rs1814175	0.817	rs2866545	chr11:49630824	A/C	cg15704280	chr7:45808275	SEPT13	-1.01	-19.13	-0.76	7.6900000000000007e-52	Height;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg01190323	chr16:2498952	CCNF	0.49	6.77	0.38	8.07e-11	Fibrinogen levels;
CESC	cis	rs12477438	0.520	rs6756650	chr2:99801800	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.84	15.36	0.69	1.63e-38	Chronic sinus infection;
CESC	cis	rs662064	0.748	rs2026792	chr1:10594790	A/G	cg20482658	chr1:10539492	PEX14	0.41	8.38	0.46	3.21e-15	Asthma;
CESC	cis	rs2070997	0.607	rs7037741	chr9:133675110	C/A	cg11464064	chr9:133710261	ABL1	0.62	7.24	0.41	4.73e-12	Response to amphetamines;
CESC	cis	rs9633740	0.578	rs11185951	chr10:82301536	G/C	cg00277334	chr10:82204260	NA	0.57	5.03	0.3	9.18e-7	Post bronchodilator FEV1;
CESC	cis	rs4689388	0.926	rs4343789	chr4:6285228	C/G	cg25554036	chr4:6271136	WFS1	0.57	9.52	0.5	1.15e-18	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs6500395	1.000	rs9937610	chr16:48671274	C/G	cg04672837	chr16:48644449	N4BP1	0.5	6.27	0.36	1.45e-9	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs2070488	0.662	rs7375040	chr3:38469116	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.66	8.73	0.47	2.85e-16	Electrocardiographic conduction measures;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg22839093	chr8:144668199	EEF1D	-0.43	-6.3	-0.36	1.22e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs7927771	1.000	rs4752856	chr11:47648042	C/T	cg18512352	chr11:47633146	NA	-0.63	-9.93	-0.52	5.79e-20	Subjective well-being;
CESC	cis	rs910316	0.503	rs4903273	chr14:75441795	G/A	cg08847533	chr14:75593920	NEK9	-0.7	-10.31	-0.53	3.67e-21	Height;
CESC	cis	rs1568889	0.838	rs6484347	chr11:28040969	G/T	cg06544937	chr11:28130018	METT5D1;KIF18A	-0.77	-12.7	-0.62	3.39e-29	Bipolar disorder;
CESC	cis	rs854765	0.547	rs6502632	chr17:17913057	A/G	cg04398451	chr17:18023971	MYO15A	-0.66	-9.54	-0.51	9.59e-19	Total body bone mineral density;
CESC	cis	rs10744422	0.920	rs3896871	chr12:123333610	G/T	cg25930673	chr12:123319894	HIP1R	-0.73	-5.73	-0.33	2.68e-8	Schizophrenia;
CESC	cis	rs7385804	0.761	rs1734910	chr7:100309544	A/G	cg20848291	chr7:100343083	ZAN	0.48	6.46	0.37	5.08e-10	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
CESC	cis	rs4664304	0.903	rs72957578	chr2:160754133	G/C	cg03641300	chr2:160917029	PLA2R1	-0.48	-6.85	-0.39	5.03e-11	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs9309473	0.519	rs35421685	chr2:73910138	T/C	cg20560298	chr2:73613845	ALMS1	0.49	6.94	0.39	3.06e-11	Metabolite levels;
CESC	cis	rs62064224	0.703	rs62065493	chr17:30822620	C/G	cg25809561	chr17:30822961	MYO1D	0.63	9.17	0.49	1.41e-17	Schizophrenia;
CESC	cis	rs4803455	0.586	rs4803457	chr19:41861359	T/C	cg08477640	chr19:41863820	B9D2	0.49	6.87	0.39	4.65e-11	Migraine;Coronary artery disease;
CESC	cis	rs9916302	0.904	rs57399933	chr17:37551189	A/G	cg07936489	chr17:37558343	FBXL20	0.8	11.5	0.58	4.2e-25	Glomerular filtration rate (creatinine);
CESC	cis	rs7914558	0.966	rs10786724	chr10:104668942	A/G	cg15744005	chr10:104629667	AS3MT	-0.34	-5.46	-0.32	1.09e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs7178909	0.872	rs7179633	chr15:90434877	T/C	cg19708238	chr15:90437601	AP3S2	0.43	6.13	0.35	3.11e-9	Common traits (Other);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03253314	chr19:17445711	ANO8	0.57	6.59	0.38	2.31e-10	Gut microbiome composition (summer);
CESC	cis	rs875971	0.862	rs10240949	chr7:65804417	A/G	cg12463550	chr7:65579703	CRCP	-0.47	-6.08	-0.35	4.28e-9	Aortic root size;
CESC	cis	rs870825	0.616	rs10428373	chr4:185639002	A/T	cg04058563	chr4:185651563	MLF1IP	0.64	7.09	0.4	1.21e-11	Blood protein levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17508018	chr19:40854374	C19orf47;PLD3	-0.69	-8.33	-0.46	4.45e-15	Gut microbiome composition (summer);
CESC	cis	rs9486719	1.000	rs12208124	chr6:97027942	C/T	cg18709589	chr6:96969512	KIAA0776	-0.49	-5.3	-0.31	2.46e-7	Migraine;Coronary artery disease;
CESC	cis	rs1799949	1.000	rs1824889	chr17:41421876	C/G	cg06001716	chr17:41278141	BRCA1;NBR2	0.38	5.17	0.3	4.63e-7	Menopause (age at onset);
CESC	cis	rs2243480	1.000	rs387676	chr7:65598220	C/T	cg18252515	chr7:66147081	NA	-1.41	-14.36	-0.66	5.44e-35	Diabetic kidney disease;
CESC	cis	rs9913156	0.793	rs55974786	chr17:4567564	T/C	cg00122941	chr17:4613640	ARRB2	0.86	10.13	0.53	1.34e-20	Lymphocyte counts;
CESC	cis	rs1865721	0.771	rs7236311	chr18:73137450	A/G	cg26385618	chr18:73139727	C18orf62	-0.53	-8.81	-0.48	1.69e-16	Intelligence;
CESC	cis	rs12142240	0.698	rs1475388	chr1:46816465	G/A	cg00530320	chr1:46809349	NSUN4	0.58	7.89	0.44	8.17e-14	Menopause (age at onset);
CESC	cis	rs262150	0.842	rs2657398	chr7:158784911	T/C	cg12590608	chr7:158785262	NA	0.32	5.46	0.32	1.07e-7	Facial morphology (factor 20);
CESC	cis	rs13242816	1.000	rs2188243	chr7:116109293	G/A	cg04696780	chr7:116139425	CAV2	-0.63	-5.71	-0.33	2.98e-8	P wave duration;
CESC	cis	rs7274811	0.744	rs6141411	chr20:32157934	G/A	cg21523528	chr20:32077966	CBFA2T2	0.45	5.43	0.32	1.25e-7	Height;
CESC	cis	rs6570726	0.791	rs6902404	chr6:145905254	G/A	cg05347473	chr6:146136440	FBXO30	0.48	6.32	0.36	1.08e-9	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.55	-6.09	-0.35	3.98e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs6484504	0.576	rs11031320	chr11:31242545	C/T	cg14844989	chr11:31128820	NA	-0.43	-5.99	-0.35	6.7e-9	Red blood cell count;
CESC	cis	rs4450798	0.793	rs28541501	chr3:13757636	G/T	cg23332027	chr3:13681764	NA	0.38	5.26	0.31	2.99e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs733175	0.857	rs751092	chr4:10005897	C/T	cg00071950	chr4:10020882	SLC2A9	0.51	5.79	0.33	2.03e-8	Psychosis and Alzheimer's disease;
CESC	cis	rs4819052	0.724	rs1304487	chr21:46657283	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.83	-11.88	-0.59	2.17e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs2180341	1.000	rs9321073	chr6:127609691	C/T	cg24812749	chr6:127587940	RNF146	1.06	15.35	0.69	1.74e-38	Breast cancer;
CESC	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.91	13.93	0.65	1.85e-33	Prudent dietary pattern;
CESC	cis	rs7520050	0.933	rs6694340	chr1:46289416	C/T	cg24296786	chr1:45957014	TESK2	0.42	5.42	0.32	1.33e-7	Red blood cell count;Reticulocyte count;
CESC	cis	rs1451375	0.652	rs7779110	chr7:50625651	T/C	cg14593290	chr7:50529359	DDC	0.44	5.37	0.31	1.71e-7	Malaria;
CESC	cis	rs67311347	1.000	rs7631893	chr3:40440869	C/T	cg24209194	chr3:40518798	ZNF619	0.5	6.9	0.39	3.84e-11	Renal cell carcinoma;
CESC	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg22741997	chr17:6900356	ALOX12	0.43	6.84	0.39	5.59e-11	Tonsillectomy;
CESC	cis	rs476633	0.691	rs2164996	chr15:41536624	A/G	cg20272979	chr15:41787780	ITPKA	0.34	5.12	0.3	5.94e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs875971	0.830	rs4718358	chr7:65973668	T/C	cg12463550	chr7:65579703	CRCP	0.55	6.9	0.39	3.78e-11	Aortic root size;
CESC	cis	rs896854	0.654	rs896846	chr8:95972453	G/A	cg23172400	chr8:95962367	TP53INP1	-0.44	-9.04	-0.49	3.45e-17	Type 2 diabetes;
CESC	cis	rs2576037	0.558	rs7244778	chr18:44541915	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.55	-7.65	-0.43	3.81e-13	Personality dimensions;
CESC	cis	rs2576037	0.583	rs680018	chr18:44409167	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.77	12.98	0.62	3.75e-30	Personality dimensions;
CESC	cis	rs1215050	0.740	rs9994227	chr4:98767094	T/G	cg05340658	chr4:99064831	C4orf37	0.53	6.85	0.39	5.29e-11	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs7811142	1.000	rs7803454	chr7:99991548	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.13	10.95	0.56	2.82e-23	Platelet count;
CESC	trans	rs8073060	0.586	rs2428464	chr17:34021994	C/G	cg19694781	chr19:47549865	TMEM160	-0.74	-6.91	-0.39	3.64e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	cis	rs3733585	0.638	rs6449155	chr4:9956547	T/G	cg00071950	chr4:10020882	SLC2A9	-0.7	-11.52	-0.58	3.7e-25	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs10504229	1.000	rs7007805	chr8:58179327	G/A	cg24829409	chr8:58192753	C8orf71	-0.76	-10.0	-0.52	3.53e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs10851478	0.500	rs36023246	chr15:49699311	A/G	cg08060515	chr15:49448048	GALK2;COPS2	0.52	6.63	0.38	1.87e-10	Oral cavity cancer;
CESC	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg01238044	chr22:24384105	GSTT1	0.52	6.63	0.38	1.93e-10	Liver enzyme levels (gamma-glutamyl transferase);
CESC	trans	rs61931739	0.782	rs1197569	chr12:34186733	A/T	cg26384229	chr12:38710491	ALG10B	0.48	6.59	0.38	2.39e-10	Morning vs. evening chronotype;
CESC	cis	rs853679	0.546	rs200950	chr6:27835772	A/G	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.85	7.2	0.4	6.18e-12	Depression;
CESC	cis	rs10504229	1.000	rs57378064	chr8:58169844	C/G	cg22535103	chr8:58192502	C8orf71	-0.87	-11.04	-0.56	1.45e-23	Developmental language disorder (linguistic errors);
CESC	cis	rs853679	0.517	rs4713135	chr6:28039586	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.54	-6.07	-0.35	4.3e-9	Depression;
CESC	cis	rs270601	0.913	rs273916	chr5:131659830	C/A	cg18758796	chr5:131593413	PDLIM4	0.41	5.54	0.32	7.27e-8	Acylcarnitine levels;
CESC	cis	rs2180341	1.000	rs9398838	chr6:127635285	C/T	cg27446573	chr6:127587934	RNF146	1.09	16.38	0.71	3.79e-42	Breast cancer;
CESC	cis	rs7917772	0.503	rs1409310	chr10:104282265	T/C	cg22532475	chr10:104410764	TRIM8	-0.33	-5.67	-0.33	3.77e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs2276314	0.857	rs8087539	chr18:33631537	C/T	cg05985134	chr18:33552581	C18orf21	0.63	7.59	0.42	5.58e-13	Endometriosis;Drug-induced torsades de pointes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19026356	chr22:50624276	TRABD	0.62	7.22	0.41	5.38e-12	Gut microbiome composition (summer);
CESC	trans	rs12599106	0.715	rs34006830	chr16:34878550	C/A	cg01171360	chr6:293285	DUSP22	-0.66	-8.29	-0.45	5.83e-15	Menopause (age at onset);
CESC	cis	rs2180341	1.000	rs3798850	chr6:127613966	C/T	cg24812749	chr6:127587940	RNF146	1.06	15.35	0.69	1.74e-38	Breast cancer;
CESC	cis	rs4728302	0.869	rs6978170	chr7:133603838	C/T	cg10665199	chr7:133106180	EXOC4	0.4	5.56	0.32	6.62e-8	Intelligence;Intelligence (multi-trait analysis);
CESC	cis	rs10791097	0.694	rs4459316	chr11:130756176	T/C	cg12179176	chr11:130786555	SNX19	0.65	10.22	0.53	6.73e-21	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs2929278	0.588	rs688009	chr15:44156302	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.5	6.52	0.37	3.44e-10	Schizophrenia;
CESC	cis	rs6460942	0.556	rs10228123	chr7:12374025	A/C	cg06484146	chr7:12443880	VWDE	-0.51	-7.17	-0.4	7.48e-12	Coronary artery disease;
CESC	cis	rs2933343	0.951	rs789217	chr3:128593201	C/T	cg25356066	chr3:128598488	ACAD9	0.55	6.9	0.39	3.73e-11	IgG glycosylation;
CESC	cis	rs589448	0.902	rs2603090	chr12:69777188	G/A	cg20891283	chr12:69753455	YEATS4	0.97	16.63	0.71	4.93e-43	Cerebrospinal fluid biomarker levels;
CESC	trans	rs9388451	0.559	rs1777210	chr6:126098916	T/G	cg05039488	chr6:79577232	IRAK1BP1	-0.57	-7.45	-0.42	1.28e-12	Brugada syndrome;
CESC	cis	rs9910055	0.676	rs11079983	chr17:42198170	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	0.44	6.59	0.38	2.31e-10	Total body bone mineral density;
CESC	cis	rs7178572	0.568	rs11072643	chr15:77415508	T/A	cg22256960	chr15:77711686	NA	0.52	6.32	0.36	1.1e-9	Type 2 diabetes;
CESC	trans	rs561341	0.609	rs4795659	chr17:30187139	C/G	cg20587970	chr11:113659929	NA	0.57	6.96	0.39	2.65e-11	Hip circumference adjusted for BMI;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04958845	chr8:101170202	SPAG1	0.69	7.87	0.44	9.06e-14	Gut microbiome composition (summer);
CESC	cis	rs4523957	0.928	rs216176	chr17:2168509	G/C	cg16513277	chr17:2031491	SMG6	0.6	8.09	0.45	2.16e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs7662987	0.517	rs2602878	chr4:100039953	T/G	cg13256891	chr4:100009986	ADH5	0.75	8.06	0.44	2.6e-14	Smoking initiation;
CESC	cis	rs8177253	0.761	rs1830084	chr3:133508464	A/T	cg01448562	chr3:133502909	NA	0.58	8.44	0.46	2.06e-15	Iron status biomarkers;
CESC	cis	rs6598955	0.724	rs12132137	chr1:26631243	C/T	cg19743891	chr1:26644573	UBXN11;CD52	-0.27	-5.21	-0.3	3.84e-7	Obesity-related traits;
CESC	cis	rs1552244	1.000	rs6442150	chr3:10122575	T/C	cg00149659	chr3:10157352	C3orf10	0.73	8.73	0.47	2.9e-16	Alzheimer's disease;
CESC	trans	rs877282	0.520	rs12360072	chr10:813082	C/T	cg22713356	chr15:30763199	NA	0.63	7.37	0.41	2.15e-12	Uric acid levels;
CESC	cis	rs9457247	0.612	rs2237273	chr6:167443017	T/C	cg07741184	chr6:167504864	NA	0.33	5.78	0.33	2.04e-8	Crohn's disease;
CESC	cis	rs854765	0.547	rs2955380	chr17:17944349	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.62	-8.81	-0.48	1.7e-16	Total body bone mineral density;
CESC	cis	rs963731	0.571	rs4670270	chr2:39230351	G/A	cg04010122	chr2:39346883	SOS1	-0.69	-5.14	-0.3	5.41e-7	Corticobasal degeneration;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg02396668	chr19:50528878	VRK3;ZNF473	-0.47	-6.86	-0.39	4.98e-11	Gambling;
CESC	cis	rs6964587	1.000	rs12530646	chr7:91588036	A/G	cg17063962	chr7:91808500	NA	-0.56	-7.77	-0.43	1.72e-13	Breast cancer;
CESC	cis	rs611744	0.563	rs7815105	chr8:109298794	C/T	cg21045802	chr8:109455806	TTC35	0.52	6.19	0.36	2.33e-9	Dupuytren's disease;
CESC	cis	rs9309473	1.000	rs13428235	chr2:73633430	G/A	cg20560298	chr2:73613845	ALMS1	-0.51	-6.72	-0.38	1.13e-10	Metabolite levels;
CESC	cis	rs875971	0.545	rs313828	chr7:65552614	T/C	cg19163074	chr7:65112434	INTS4L2	0.52	5.35	0.31	1.87e-7	Aortic root size;
CESC	cis	rs17401966	0.898	rs1396	chr1:10247143	C/A	cg15208524	chr1:10270712	KIF1B	0.51	6.43	0.37	5.92e-10	Hepatocellular carcinoma;
CESC	cis	rs1670533	0.872	rs11727136	chr4:1051804	G/A	cg27284194	chr4:1044797	NA	0.42	5.17	0.3	4.53e-7	Recombination rate (females);
CESC	trans	rs17685	0.753	rs1637039	chr7:75693009	C/T	cg19862616	chr7:65841803	NCRNA00174	0.83	12.37	0.61	4.74e-28	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs6088590	0.687	rs8115656	chr20:33282780	G/C	cg08999081	chr20:33150536	PIGU	0.66	10.88	0.56	5.07e-23	Coronary artery disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg14929913	chr10:1147979	WDR37	0.52	7.05	0.4	1.6e-11	Fibrinogen levels;
CESC	cis	rs6456156	0.586	rs2345753	chr6:167484344	T/A	cg07741184	chr6:167504864	NA	0.37	6.36	0.36	8.83e-10	Primary biliary cholangitis;
CESC	cis	rs344364	0.636	rs344363	chr16:1972548	C/T	cg03013636	chr16:1946785	NA	0.4	5.06	0.3	7.98e-7	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs7267979	0.586	rs11087505	chr20:25196520	T/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.71	11.99	0.59	9.41e-27	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs4727027	0.901	rs6943937	chr7:148869915	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.43	5.3	0.31	2.41e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs9486719	1.000	rs2145535	chr6:97034715	G/A	cg18709589	chr6:96969512	KIAA0776	-0.5	-5.44	-0.32	1.21e-7	Migraine;Coronary artery disease;
CESC	cis	rs5769707	0.609	rs135861	chr22:49998118	A/G	cg05373962	chr22:49881684	NA	-0.35	-5.21	-0.3	3.75e-7	Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs17666538	0.710	rs12716640	chr8:645376	A/C	cg26554054	chr8:600488	NA	0.61	5.36	0.31	1.81e-7	IgG glycosylation;
CESC	cis	rs2439831	0.850	rs2277531	chr15:44069069	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.7	6.79	0.38	7.39e-11	Lung cancer in ever smokers;
CESC	cis	rs9815354	1.000	rs9857175	chr3:41822054	T/G	cg03022575	chr3:42003672	ULK4	0.47	5.16	0.3	4.95e-7	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs7714584	1.000	rs61270113	chr5:150226263	G/A	cg22134413	chr5:150180641	NA	0.52	5.64	0.33	4.31e-8	Crohn's disease;
CESC	cis	rs4555082	0.874	rs3000075	chr14:105713219	C/T	cg06808227	chr14:105710500	BRF1	0.6	7.35	0.41	2.43e-12	Mean platelet volume;Platelet distribution width;
CESC	cis	rs62229266	0.557	rs4817761	chr21:37395556	C/T	cg12218747	chr21:37451666	NA	-0.43	-5.91	-0.34	1.06e-8	Mitral valve prolapse;
CESC	cis	rs7851660	0.809	rs10818241	chr9:100661972	A/G	cg13688889	chr9:100608707	NA	-0.62	-8.87	-0.48	1.11e-16	Strep throat;
CESC	cis	rs1552244	0.572	rs68121641	chr3:10165845	T/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.7	-7.93	-0.44	6.33e-14	Alzheimer's disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg17575087	chr5:154237720	CNOT8	-0.49	-6.48	-0.37	4.52e-10	Fibrinogen levels;
CESC	cis	rs172166	0.694	rs1150666	chr6:28123928	T/C	cg17221315	chr6:27791827	HIST1H4J	0.43	5.47	0.32	1.03e-7	Cardiac Troponin-T levels;
CESC	trans	rs66573146	0.656	rs57454756	chr4:6958582	C/T	cg07817883	chr1:32538562	TMEM39B	1.43	8.7	0.47	3.61e-16	Granulocyte percentage of myeloid white cells;
CESC	cis	rs736408	0.716	rs2239550	chr3:52822509	G/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.35	5.76	0.33	2.35e-8	Bipolar disorder;
CESC	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	10.21	0.53	7.62e-21	Prudent dietary pattern;
CESC	cis	rs6456156	0.586	rs9457261	chr6:167467679	A/G	cg07741184	chr6:167504864	NA	0.36	6.17	0.35	2.48e-9	Primary biliary cholangitis;
CESC	cis	rs860295	0.580	rs6672284	chr1:155277963	C/T	cg02153340	chr1:155202674	NA	-0.36	-5.07	-0.3	7.47e-7	Body mass index;
CESC	cis	rs1862618	0.715	rs6866779	chr5:56090000	G/A	cg18230493	chr5:56204884	C5orf35	-0.72	-8.27	-0.45	6.38e-15	Initial pursuit acceleration;
CESC	cis	rs3859192	0.599	rs34342173	chr17:38161507	T/C	cg17344932	chr17:38183730	MED24;SNORD124	0.61	9.08	0.49	2.59e-17	White blood cell count;
CESC	cis	rs853679	0.550	rs1233707	chr6:28172953	G/A	cg22143856	chr6:28129313	ZNF389	0.45	5.97	0.34	7.71e-9	Depression;
CESC	cis	rs1218582	0.774	rs4845681	chr1:154868055	G/T	cg24250549	chr1:154909240	PMVK	0.62	8.99	0.48	4.74e-17	Prostate cancer;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg17622922	chr11:119187849	MCAM	-0.47	-6.27	-0.36	1.44e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs4713118	0.621	rs4713133	chr6:28034041	T/C	cg23161317	chr6:28129485	ZNF389	0.51	6.38	0.36	7.9e-10	Parkinson's disease;
CESC	cis	rs4629180	0.586	rs2048252	chr2:102138384	C/T	cg04415270	chr2:102091202	RFX8	-0.31	-5.35	-0.31	1.86e-7	Chronic rhinosinusitis with nasal polyps;
CESC	cis	rs7949030	0.591	rs35880596	chr11:62369884	C/G	cg02375832	chr11:62437615	C11orf48	-0.39	-5.45	-0.32	1.15e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs7833790	1.000	rs28696138	chr8:82770794	G/A	cg27398817	chr8:82754497	SNX16	0.56	6.44	0.37	5.68e-10	Diastolic blood pressure;
CESC	cis	rs2735413	0.881	rs12923218	chr16:78080274	C/G	cg04733911	chr16:78082701	NA	-0.54	-9.15	-0.49	1.54e-17	Systolic blood pressure (alcohol consumption interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16181848	chr18:2913135	EMILIN2	-0.62	-7.21	-0.4	5.79e-12	Gut microbiome composition (summer);
CESC	cis	rs8005677	0.962	rs11157931	chr14:23403193	A/C	cg25600027	chr14:23388339	RBM23	-0.43	-5.23	-0.31	3.43e-7	Cognitive ability (multi-trait analysis);
CESC	cis	rs1448094	0.872	rs4919777	chr12:86358491	C/T	cg02569458	chr12:86230093	RASSF9	0.36	5.44	0.32	1.19e-7	Major depressive disorder;
CESC	cis	rs898097	0.528	rs2243523	chr17:80680449	G/T	cg20271620	chr17:80763330	TBCD	0.42	5.51	0.32	8.65e-8	Breast cancer;
CESC	cis	rs208520	0.690	rs207091	chr6:66799847	G/T	cg07460842	chr6:66804631	NA	-1.0	-13.43	-0.64	1.05e-31	Exhaled nitric oxide output;
CESC	cis	rs909674	0.731	rs4821897	chr22:39835587	A/G	cg24399712	chr22:39784796	NA	-0.88	-10.98	-0.56	2.3e-23	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs68170813	0.559	rs7794598	chr7:106826381	C/T	cg02696742	chr7:106810147	HBP1	-0.57	-5.63	-0.33	4.54e-8	Coronary artery disease;
CESC	cis	rs2732480	0.577	rs2634680	chr12:48734564	T/C	cg24011408	chr12:48396354	COL2A1	0.44	5.94	0.34	9.12e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs9925964	0.804	rs4889606	chr16:31011183	C/T	cg02466173	chr16:30829666	NA	-0.36	-5.47	-0.32	1.05e-7	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs6032067	0.777	rs34073275	chr20:43788917	C/T	cg11264863	chr20:43835661	SEMG1	0.5	5.35	0.31	1.86e-7	Blood protein levels;
CESC	cis	rs73001065	0.591	rs2285626	chr19:19467545	C/T	cg03709012	chr19:19516395	GATAD2A	1.03	8.92	0.48	7.63e-17	LDL cholesterol;
CESC	trans	rs561341	0.602	rs114562703	chr17:30233899	G/T	cg20587970	chr11:113659929	NA	-0.64	-8.12	-0.45	1.74e-14	Hip circumference adjusted for BMI;
CESC	cis	rs453301	0.686	rs17702602	chr8:8908596	C/T	cg06636001	chr8:8085503	FLJ10661	-0.44	-5.33	-0.31	2.14e-7	Joint mobility (Beighton score);
CESC	cis	rs1538970	0.884	rs781226	chr1:45872662	T/C	cg24296786	chr1:45957014	TESK2	0.44	5.41	0.32	1.41e-7	Platelet count;
CESC	cis	rs2456568	0.867	rs4753111	chr11:93658410	A/G	cg26875233	chr11:93583750	C11orf90	-0.32	-5.56	-0.32	6.54e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
CESC	cis	rs7100689	0.646	rs11202725	chr10:82136276	A/G	cg00277334	chr10:82204260	NA	-0.57	-7.51	-0.42	9.08e-13	Post bronchodilator FEV1;
CESC	cis	rs9322193	0.923	rs4870267	chr6:149992708	C/G	cg07701084	chr6:150067640	NUP43	0.46	6.45	0.37	5.22e-10	Lung cancer;
CESC	cis	rs10924309	0.882	rs10924306	chr1:245857065	G/A	cg00036263	chr1:245852353	KIF26B	-0.42	-5.09	-0.3	6.65e-7	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
CESC	cis	rs9916302	0.861	rs593480	chr17:37453780	A/C	cg15445000	chr17:37608096	MED1	-0.4	-6.46	-0.37	4.97e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs3767633	0.925	rs10733044	chr1:161903534	A/G	cg09175582	chr1:161736000	ATF6	-0.84	-7.12	-0.4	1.01e-11	IgG glycosylation;
CESC	cis	rs858239	0.632	rs6952947	chr7:23121042	C/G	cg23682824	chr7:23144976	KLHL7	-0.55	-7.75	-0.43	1.96e-13	Cerebrospinal fluid biomarker levels;
CESC	cis	rs7089973	0.604	rs11196937	chr10:116589500	G/C	cg23260525	chr10:116636907	FAM160B1	0.4	7.19	0.4	6.76e-12	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs9488822	0.596	rs13206506	chr6:116324460	A/G	cg26893134	chr6:116381904	FRK	0.22	5.13	0.3	5.7e-7	Cholesterol, total;LDL cholesterol;
CESC	cis	rs561341	0.739	rs8070554	chr17:30216868	A/T	cg13647721	chr17:30228624	UTP6	-0.76	-9.22	-0.49	9.53e-18	Hip circumference adjusted for BMI;
CESC	cis	rs1062177	0.756	rs2964588	chr5:151118386	C/T	cg00977110	chr5:151150581	G3BP1	-0.62	-6.36	-0.36	8.61e-10	Preschool internalizing problems;
CESC	cis	rs7824557	0.602	rs11784544	chr8:11204503	G/C	cg21775007	chr8:11205619	TDH	0.58	8.98	0.48	5.08e-17	Retinal vascular caliber;
CESC	cis	rs60871478	0.898	rs4725241	chr7:796883	C/T	cg05535760	chr7:792225	HEATR2	0.85	10.45	0.54	1.26e-21	Cerebrospinal P-tau181p levels;
CESC	cis	rs10504229	1.000	rs67188507	chr8:58187492	A/T	cg05313129	chr8:58192883	C8orf71	-0.55	-6.28	-0.36	1.4e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs853679	0.513	rs9468296	chr6:28113730	A/G	cg23161317	chr6:28129485	ZNF389	0.5	6.24	0.36	1.69e-9	Depression;
CESC	cis	rs4654899	0.743	rs17409373	chr1:21188871	C/A	cg05370193	chr1:21551575	ECE1	0.39	5.65	0.33	4.12e-8	Superior frontal gyrus grey matter volume;
CESC	cis	rs6088590	0.965	rs6058108	chr20:33288655	A/G	cg08999081	chr20:33150536	PIGU	0.59	9.22	0.49	9.93e-18	Coronary artery disease;
CESC	cis	rs4927850	0.957	rs4927851	chr3:195751853	A/G	cg12923728	chr3:195709715	SDHAP1	-0.68	-9.13	-0.49	1.76e-17	Pancreatic cancer;
CESC	cis	rs1050631	0.592	rs1789527	chr18:33712229	C/G	cg25426722	chr18:33708991	SLC39A6;ELP2	0.52	7.14	0.4	9.15e-12	Esophageal squamous cell cancer (length of survival);
CESC	cis	rs2898681	0.561	rs58577680	chr4:53734294	C/T	cg00791764	chr4:53727839	RASL11B	0.44	5.16	0.3	4.81e-7	Optic nerve measurement (cup area);
CESC	cis	rs4689388	0.926	rs11725494	chr4:6293855	C/T	cg25554036	chr4:6271136	WFS1	0.52	8.45	0.46	1.93e-15	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs10791097	0.694	rs876641	chr11:130752040	A/C	cg12179176	chr11:130786555	SNX19	0.66	10.4	0.54	1.79e-21	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs834811	0.829	rs6980107	chr7:135900757	C/T	cg01726295	chr7:135938950	NA	-0.37	-6.24	-0.36	1.73e-9	Post-traumatic stress disorder;
CESC	cis	rs7666738	0.800	rs1559858	chr4:99024075	A/G	cg18180107	chr4:99064573	C4orf37	0.42	5.41	0.32	1.44e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg07898632	chr15:73345666	NEO1	-0.5	-6.03	-0.35	5.58e-9	Ulcerative colitis;
CESC	cis	rs7216064	0.532	rs3890640	chr17:66053028	C/T	cg12091567	chr17:66097778	LOC651250	0.92	12.28	0.6	9.74e-28	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs7267979	1.000	rs6083825	chr20:25366424	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.88	-18.14	-0.74	2.23e-48	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs116095464	0.558	rs10076655	chr5:239464	G/C	cg22857025	chr5:266934	NA	-1.29	-18.85	-0.76	7.31e-51	Breast cancer;
CESC	cis	rs9324022	0.858	rs1004572	chr14:101178330	G/A	cg18089426	chr14:101175970	NA	0.59	7.51	0.42	9.29e-13	Plateletcrit;
CESC	cis	rs3733585	0.637	rs6850684	chr4:9964380	G/T	cg02734326	chr4:10020555	SLC2A9	-0.44	-6.15	-0.35	2.85e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs2880765	0.835	rs4843063	chr15:86048748	G/T	cg19183879	chr15:85880815	NA	-0.26	-5.29	-0.31	2.52e-7	Coronary artery disease;
CESC	cis	rs1371867	0.846	rs1692007	chr8:101268343	T/C	cg11906718	chr8:101322791	RNF19A	-0.42	-5.47	-0.32	1.06e-7	Atrioventricular conduction;
CESC	cis	rs6089584	0.854	rs6061407	chr20:60622048	A/C	cg06108461	chr20:60628389	TAF4	-0.92	-14.55	-0.67	1.22e-35	Body mass index;
CESC	cis	rs8044868	0.530	rs12932845	chr16:72122765	G/A	cg16558253	chr16:72132732	DHX38	-0.4	-6.23	-0.36	1.79e-9	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CESC	cis	rs2549003	0.966	rs839	chr5:131819126	C/T	cg00255919	chr5:131827918	IRF1	0.51	8.59	0.47	7.76e-16	Asthma (sex interaction);
CESC	cis	rs17376456	0.542	rs10070350	chr5:93103753	C/G	cg25358565	chr5:93447407	FAM172A	0.68	7.25	0.41	4.53e-12	Diabetic retinopathy;
CESC	cis	rs6964587	1.000	rs12536529	chr7:91684086	C/T	cg17063962	chr7:91808500	NA	-0.57	-7.93	-0.44	6.23e-14	Breast cancer;
CESC	cis	rs7219021	0.961	rs9901447	chr17:46872346	C/T	cg16584676	chr17:46985605	UBE2Z	-0.72	-8.09	-0.44	2.23e-14	Schizophrenia or bipolar disorder;
CESC	cis	rs2302729	0.578	rs10774052	chr12:2772171	C/T	cg19945202	chr12:2788847	CACNA1C	-0.49	-7.28	-0.41	3.89e-12	Sleep quality;
CESC	cis	rs4561483	0.624	rs2215928	chr16:11927918	A/T	cg08843971	chr16:11963173	GSPT1	-0.44	-6.16	-0.35	2.72e-9	Testicular germ cell tumor;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg07464025	chr10:13482639	BEND7	-0.46	-6.13	-0.35	3.11e-9	Fibrinogen levels;
CESC	cis	rs4665809	0.878	rs892448	chr2:26366205	A/G	cg04944784	chr2:26401820	FAM59B	-0.7	-8.24	-0.45	8.15e-15	Gut microbiome composition (summer);
CESC	cis	rs61996546	0.622	rs34661562	chr15:26849631	A/G	cg15066197	chr15:26874202	GABRB3	-0.35	-5.19	-0.3	4.1e-7	Response to methotrexate in juvenile idiopathic arthritis;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg10039444	chr14:56233676	RPL13AP3	0.47	7.17	0.4	7.29e-12	Ulcerative colitis;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg05889321	chr10:97416837	ALDH18A1	-0.44	-6.32	-0.36	1.12e-9	Gambling;
CESC	cis	rs10504229	0.679	rs16921683	chr8:58053270	T/C	cg24829409	chr8:58192753	C8orf71	-0.5	-6.27	-0.36	1.43e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs637571	0.546	rs10791827	chr11:65596546	C/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.66	-8.39	-0.46	2.86e-15	Eosinophil percentage of white cells;
CESC	cis	rs1153858	1.000	rs11070457	chr15:45686943	A/C	cg21132104	chr15:45694354	SPATA5L1	0.86	11.67	0.58	1.14e-25	Homoarginine levels;
CESC	cis	rs2404602	0.583	rs12908334	chr15:76581592	C/T	cg22467129	chr15:76604101	ETFA	-0.37	-5.66	-0.33	3.94e-8	Blood metabolite levels;
CESC	cis	rs11122272	0.735	rs2790897	chr1:231491712	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.55	-7.48	-0.42	1.1e-12	Hemoglobin concentration;
CESC	cis	rs4819052	0.851	rs2838833	chr21:46665160	C/T	cg11663144	chr21:46675770	NA	-0.63	-9.94	-0.52	5.62e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs941764	0.965	rs941765	chr14:91841358	G/C	cg10511902	chr14:91842949	CCDC88C	0.54	8.3	0.45	5.2e-15	Breast cancer;
CESC	cis	rs2836974	0.897	rs34035316	chr21:40594023	T/C	cg17971929	chr21:40555470	PSMG1	1.08	16.46	0.71	2e-42	Cognitive function;
CESC	cis	rs9796	0.689	rs692195	chr15:41444894	G/C	cg18705301	chr15:41695430	NDUFAF1	-0.43	-6.36	-0.36	8.97e-10	Menopause (age at onset);
CESC	cis	rs7811142	0.830	rs6955367	chr7:99961194	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.91	10.67	0.55	2.33e-22	Platelet count;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg23819836	chr6:15663134	DTNBP1	-0.48	-6.44	-0.37	5.45e-10	Ulcerative colitis;
CESC	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg18404041	chr3:52824283	ITIH1	-0.38	-6.8	-0.39	6.98e-11	Electroencephalogram traits;
CESC	cis	rs854765	0.583	rs950966	chr17:17783748	A/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.47	-6.05	-0.35	5.01e-9	Total body bone mineral density;
CESC	cis	rs11122272	0.701	rs1009227	chr1:231480507	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-7.23	-0.41	5.18e-12	Hemoglobin concentration;
CESC	cis	rs75804782	0.641	rs3769123	chr2:239349328	C/G	cg18131467	chr2:239335373	ASB1	-0.66	-5.83	-0.34	1.58e-8	Morning vs. evening chronotype;Chronotype;
CESC	cis	rs910316	0.763	rs175014	chr14:75456927	A/G	cg08847533	chr14:75593920	NEK9	-0.86	-14.07	-0.65	6.01e-34	Height;
CESC	cis	rs12586317	0.547	rs10145723	chr14:35460954	G/A	cg05294307	chr14:35346193	BAZ1A	-0.51	-5.48	-0.32	1e-7	Psoriasis;
CESC	cis	rs6582630	0.555	rs7294313	chr12:38323603	G/A	cg26384229	chr12:38710491	ALG10B	-0.42	-5.42	-0.32	1.32e-7	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs3020736	0.500	rs1801311	chr22:42486723	G/A	cg15557168	chr22:42548783	NA	0.45	6.57	0.37	2.72e-10	Autism spectrum disorder or schizophrenia;
CESC	cis	rs1055129	0.682	rs7217432	chr17:73834604	A/G	cg08125733	chr17:73851984	WBP2	0.52	7.21	0.41	5.8e-12	White matter hyperintensity burden;
CESC	cis	rs6963495	0.818	rs73192143	chr7:105202415	A/G	cg13798780	chr7:105162888	PUS7	0.77	7.64	0.42	4.08e-13	Bipolar disorder (body mass index interaction);
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg05335107	chr2:109400084	RANBP2	0.38	6.14	0.35	2.95e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs4253772	0.515	rs7287164	chr22:46781008	T/C	cg00784671	chr22:46762841	CELSR1	-0.66	-6.13	-0.35	3.13e-9	LDL cholesterol;Cholesterol, total;
CESC	cis	rs6089584	0.962	rs6142913	chr20:60566950	A/G	cg24733560	chr20:60626293	TAF4	0.43	6.24	0.36	1.76e-9	Body mass index;
CESC	cis	rs8177253	0.965	rs4854762	chr3:133499063	A/G	cg01448562	chr3:133502909	NA	0.44	6.0	0.35	6.37e-9	Iron status biomarkers;
CESC	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg24642844	chr7:1081250	C7orf50	-0.77	-9.63	-0.51	5.27e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs6952808	0.630	rs4719443	chr7:2161099	A/G	cg05863683	chr7:1912471	MAD1L1	0.43	6.38	0.36	8.03e-10	Bipolar disorder and schizophrenia;
CESC	cis	rs11608355	0.515	rs2270361	chr12:109935894	G/C	cg05360138	chr12:110035743	NA	0.82	8.85	0.48	1.27e-16	Neuroticism;
CESC	cis	rs6484504	0.532	rs2761589	chr11:31311429	C/G	cg14844989	chr11:31128820	NA	0.38	5.34	0.31	2.02e-7	Red blood cell count;
CESC	cis	rs1348850	0.567	rs1527401	chr2:178522104	C/T	cg23306229	chr2:178417860	TTC30B	0.54	7.13	0.4	9.28e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs7666738	0.830	rs34916200	chr4:98851593	C/T	cg17366294	chr4:99064904	C4orf37	0.55	7.72	0.43	2.38e-13	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9486715	0.867	rs9373887	chr6:96957004	C/T	cg18709589	chr6:96969512	KIAA0776	0.46	6.52	0.37	3.49e-10	Headache;
CESC	cis	rs76917914	0.820	rs4743158	chr9:100821275	T/C	cg03040243	chr9:100819229	NANS	0.5	5.6	0.33	5.33e-8	Immature fraction of reticulocytes;
CESC	cis	rs4481887	0.893	rs10788774	chr1:248471712	T/C	cg00666640	chr1:248458726	OR2T12	0.39	6.38	0.37	7.75e-10	Common traits (Other);
CESC	cis	rs57221529	0.825	rs72703051	chr5:582997	G/A	cg16447950	chr5:562315	NA	-0.63	-5.84	-0.34	1.5e-8	Lung disease severity in cystic fibrosis;
CESC	cis	rs801193	0.548	rs2109297	chr7:66122384	G/A	cg12463550	chr7:65579703	CRCP	-0.49	-6.42	-0.37	6.41e-10	Aortic root size;
CESC	cis	rs1008375	1.000	rs7673500	chr4:17621383	C/T	cg16339924	chr4:17578868	LAP3	0.6	7.51	0.42	8.84e-13	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs7605827	0.930	rs7574879	chr2:15698083	C/G	cg19274914	chr2:15703543	NA	0.37	6.58	0.37	2.43e-10	Educational attainment (years of education);
CESC	cis	rs17384381	1.000	rs12140457	chr1:85860170	G/A	cg16011679	chr1:85725395	C1orf52	0.8	8.15	0.45	1.47e-14	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04528624	chr13:60738126	DIAPH3	0.62	6.82	0.39	6.24e-11	Gut microbiome composition (summer);
CESC	cis	rs2439831	0.850	rs2957637	chr15:43951118	C/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.67	7.98	0.44	4.41e-14	Lung cancer in ever smokers;
CESC	cis	rs1008375	0.900	rs1003413	chr4:17582442	C/T	cg02297831	chr4:17616191	MED28	-0.5	-5.74	-0.33	2.59e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs113835537	0.877	rs3867132	chr11:66309269	C/T	cg22134325	chr11:66188745	NPAS4	0.52	5.96	0.34	8.14e-9	Airway imaging phenotypes;
CESC	trans	rs12599106	0.792	rs11648801	chr16:34360980	C/T	cg01516881	chr6:292596	DUSP22	-0.49	-6.45	-0.37	5.17e-10	Menopause (age at onset);
CESC	cis	rs116095464	0.558	rs73029475	chr5:206969	T/C	cg22496380	chr5:211416	CCDC127	-0.95	-10.05	-0.53	2.34e-20	Breast cancer;
CESC	cis	rs9430161	0.611	rs72644043	chr1:11033051	T/A	cg27631724	chr1:11040367	C1orf127	0.38	6.21	0.36	2.02e-9	Ewing sarcoma;
CESC	cis	rs7089973	0.966	rs61867966	chr10:116584362	T/C	cg25233709	chr10:116636983	FAM160B1	0.37	5.3	0.31	2.47e-7	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs72634258	0.945	rs12730860	chr1:8132462	T/C	cg00042356	chr1:8021962	PARK7	0.78	7.36	0.41	2.34e-12	Inflammatory bowel disease;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg06310300	chr7:100076089	TSC22D4	0.44	6.01	0.35	6.1e-9	Systemic lupus erythematosus;
CESC	cis	rs4595586	0.545	rs12826080	chr12:39387772	A/G	cg26384229	chr12:38710491	ALG10B	0.54	7.6	0.42	4.97e-13	Morning vs. evening chronotype;
CESC	cis	rs2072732	0.861	rs56398543	chr1:2950237	G/A	cg15211996	chr1:2936768	ACTRT2	0.34	5.97	0.34	7.52e-9	Plateletcrit;
CESC	cis	rs1348850	0.914	rs1975544	chr2:178465423	G/A	cg23306229	chr2:178417860	TTC30B	0.56	6.72	0.38	1.08e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs1595825	0.891	rs16866980	chr2:198513009	A/C	cg10820045	chr2:198174542	NA	0.4	5.03	0.3	9.19e-7	Ulcerative colitis;
CESC	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.56	-6.94	-0.39	3e-11	Prudent dietary pattern;
CESC	cis	rs870825	0.616	rs36022027	chr4:185639192	C/T	cg04058563	chr4:185651563	MLF1IP	0.64	7.07	0.4	1.39e-11	Blood protein levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17978844	chr19:40854664	PLD3;C19orf47	-0.61	-6.77	-0.38	8.13e-11	Gut microbiome composition (summer);
CESC	cis	rs12540874	0.698	rs3823674	chr7:50571996	C/T	cg18232548	chr7:50535776	DDC	-0.4	-5.7	-0.33	3.26e-8	Systemic sclerosis;
CESC	cis	rs3015497	0.543	rs3015493	chr14:51124353	G/A	cg26011998	chr14:51135199	SAV1	-0.6	-6.3	-0.36	1.26e-9	Mean platelet volume;
CESC	cis	rs9894429	0.608	rs8477	chr17:79618059	C/T	cg18240062	chr17:79603768	NPLOC4	0.51	6.53	0.37	3.32e-10	Eye color traits;
CESC	cis	rs863345	0.604	rs10908674	chr1:158503920	A/T	cg12129480	chr1:158549410	OR10X1	-0.34	-6.84	-0.39	5.41e-11	Pneumococcal bacteremia;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg18342900	chr16:46865048	C16orf87	0.5	6.66	0.38	1.54e-10	Systemic lupus erythematosus;
CESC	cis	rs1552244	1.000	rs9875081	chr3:10083935	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-10.99	-0.56	2.15e-23	Alzheimer's disease;
CESC	cis	rs7666738	0.822	rs979946	chr4:98921235	C/A	cg17366294	chr4:99064904	C4orf37	0.58	8.14	0.45	1.52e-14	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7927771	0.801	rs12798028	chr11:47604639	C/T	cg05585544	chr11:47624801	NA	-0.41	-6.44	-0.37	5.57e-10	Subjective well-being;
CESC	cis	rs501120	0.925	rs492152	chr10:44757677	C/T	cg09554077	chr10:44749378	NA	0.52	6.73	0.38	1.02e-10	Coronary artery disease;Coronary heart disease;
CESC	cis	rs7116495	0.609	rs567026	chr11:71769952	C/T	cg07596299	chr11:71824057	C11orf51	0.85	5.46	0.32	1.07e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs17253792	0.822	rs78824140	chr14:56042715	G/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.84	5.73	0.33	2.76e-8	Putamen volume;
CESC	cis	rs78456975	0.527	rs10184112	chr2:1571112	A/G	cg12573674	chr2:1569213	NA	-0.47	-5.35	-0.31	1.93e-7	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs9926296	0.605	rs6500449	chr16:89856393	T/C	cg21285383	chr16:89894308	SPIRE2	0.32	5.73	0.33	2.66e-8	Vitiligo;
CESC	cis	rs4689592	0.587	rs3822269	chr4:7069901	T/C	cg06697600	chr4:7070879	GRPEL1	-0.51	-7.32	-0.41	2.95e-12	Monocyte percentage of white cells;
CESC	cis	rs2836974	0.584	rs6517535	chr21:40653352	G/C	cg11644478	chr21:40555479	PSMG1	-0.84	-12.62	-0.61	6.4e-29	Cognitive function;
CESC	cis	rs8062405	1.000	rs62036621	chr16:28833299	C/A	cg08761264	chr16:28874980	SH2B1	-0.47	-5.84	-0.34	1.55e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs6558174	0.930	rs12676084	chr8:22493350	C/T	cg03733263	chr8:22462867	KIAA1967	0.47	6.14	0.35	3.03e-9	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15004027	chr11:71823924	C11orf51	0.64	7.39	0.41	1.88e-12	Gut microbiome composition (summer);
CESC	cis	rs1728785	1.000	rs1645928	chr16:68590610	G/T	cg02972257	chr16:68554789	NA	-0.67	-7.61	-0.42	4.84e-13	Ulcerative colitis;
CESC	cis	rs1775715	0.870	rs1755084	chr10:32253709	C/T	cg04359828	chr10:32216031	ARHGAP12	0.36	5.15	0.3	5.14e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs6088580	0.634	rs6088512	chr20:33095891	G/A	cg08999081	chr20:33150536	PIGU	0.65	11.45	0.58	6.19e-25	Glomerular filtration rate (creatinine);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16538604	chr4:2010703	WHSC2	0.63	7.6	0.42	5.18e-13	Gut microbiome composition (summer);
CESC	cis	rs7592578	0.766	rs62182885	chr2:191437024	A/G	cg27211696	chr2:191398769	TMEM194B	-0.62	-5.43	-0.32	1.26e-7	Diastolic blood pressure;
CESC	cis	rs10751667	0.600	rs4076915	chr11:1012464	C/G	cg06064525	chr11:970664	AP2A2	-0.33	-5.58	-0.32	6.04e-8	Alzheimer's disease (late onset);
CESC	cis	rs2404602	0.536	rs12915248	chr15:76765615	A/T	cg26408565	chr15:76604113	ETFA	-0.44	-6.6	-0.38	2.24e-10	Blood metabolite levels;
CESC	cis	rs1413885	0.516	rs1591364	chr1:65842364	T/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.49	6.41	0.37	6.71e-10	Anticoagulant levels;
CESC	cis	rs1475911	1.000	rs34421316	chr21:43513989	C/T	cg19766460	chr21:43528205	UMODL1;C21orf128	0.6	6.74	0.38	9.57e-11	IgG glycosylation;
CESC	trans	rs629535	0.783	rs658407	chr8:70035247	T/C	cg21567404	chr3:27674614	NA	0.93	11.25	0.57	2.83e-24	Dupuytren's disease;
CESC	cis	rs7811142	1.000	rs11559117	chr7:100076614	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.02	11.26	0.57	2.8e-24	Platelet count;
CESC	cis	rs2637266	0.875	rs12783253	chr10:78378108	A/G	cg18941641	chr10:78392320	NA	0.42	7.97	0.44	4.89e-14	Pulmonary function;
CESC	cis	rs7618915	0.547	rs11177	chr3:52721305	G/A	cg07507251	chr3:52567010	NT5DC2	0.41	7.26	0.41	4.17e-12	Bipolar disorder;
CESC	cis	rs1847202	0.859	rs4490296	chr3:72949197	C/A	cg10804678	chr3:72788309	NA	-0.39	-5.25	-0.31	3.19e-7	Motion sickness;
CESC	cis	rs6460942	0.630	rs17670901	chr7:12386622	G/A	cg20607287	chr7:12443886	VWDE	-0.59	-6.42	-0.37	6.19e-10	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17956819	chr17:22191704	NA	-0.51	-7.25	-0.41	4.62e-12	Gut microbiome composition (summer);
CESC	cis	rs4835473	0.838	rs4583708	chr4:144656763	A/G	cg25736465	chr4:144833511	NA	-0.33	-5.21	-0.3	3.82e-7	Immature fraction of reticulocytes;
CESC	cis	rs10242455	0.702	rs112475236	chr7:99044679	A/G	cg18809830	chr7:99032528	PTCD1	-0.62	-5.14	-0.3	5.28e-7	Blood metabolite levels;
CESC	cis	rs11608355	0.545	rs2302705	chr12:109898716	C/T	cg05360138	chr12:110035743	NA	0.82	8.92	0.48	7.93e-17	Neuroticism;
CESC	cis	rs7100689	0.784	rs7895042	chr10:82095276	G/A	cg09936400	chr10:82049201	MAT1A	0.37	5.28	0.31	2.63e-7	Post bronchodilator FEV1;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07701033	chr12:49110781	CCNT1	0.57	6.62	0.38	1.94e-10	Gut microbiome composition (summer);
CESC	cis	rs4718428	0.960	rs6460317	chr7:66390255	A/G	cg12165864	chr7:66369176	NA	-0.47	-5.57	-0.32	6.29e-8	Corneal structure;
CESC	cis	rs7246657	0.943	rs10409204	chr19:37917692	G/A	cg23950597	chr19:37808831	NA	-0.62	-6.35	-0.36	9.22e-10	Coronary artery calcification;
CESC	cis	rs12220238	1.000	rs10824151	chr10:76092179	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.54	5.08	0.3	7.3e-7	Soluble interleukin-2 receptor subunit alpha;
CESC	trans	rs916888	0.821	rs70602	chr17:44859715	T/C	cg23590916	chr17:43697445	MGC57346	-0.6	-6.3	-0.36	1.23e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs35306767	0.903	rs61833260	chr10:975148	T/G	cg25019033	chr10:957182	NA	-0.6	-6.53	-0.37	3.42e-10	Eosinophil percentage of granulocytes;
CESC	cis	rs6973256	0.569	rs9649595	chr7:133385921	G/C	cg10665199	chr7:133106180	EXOC4	0.45	6.2	0.36	2.12e-9	Intelligence (multi-trait analysis);
CESC	cis	rs4722166	0.630	rs4722169	chr7:22785419	C/T	cg05472934	chr7:22766657	IL6	0.86	10.84	0.55	6.66e-23	Lung cancer;
CESC	cis	rs617791	0.530	rs10791835	chr11:65750924	C/A	cg09783858	chr11:65769428	EIF1AD;BANF1	0.53	6.38	0.36	8.01e-10	Breast cancer;
CESC	cis	rs15676	0.783	rs2977995	chr9:131584245	A/G	cg00228799	chr9:131580591	ENDOG	0.55	7.13	0.4	9.74e-12	Blood metabolite levels;
CESC	cis	rs10751667	0.714	rs7395879	chr11:963855	G/C	cg20946044	chr11:1010712	AP2A2	-0.38	-5.35	-0.31	1.92e-7	Alzheimer's disease (late onset);
CESC	cis	rs7481584	0.961	rs729662	chr11:3028140	G/A	cg25174290	chr11:3078921	CARS	-0.44	-5.53	-0.32	7.86e-8	Calcium levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21722680	chr12:64846210	TBK1	-0.59	-6.36	-0.36	8.81e-10	Gut microbiome composition (summer);
CESC	cis	rs1862618	0.853	rs832553	chr5:56114786	A/G	cg12311346	chr5:56204834	C5orf35	-0.7	-8.66	-0.47	4.67e-16	Initial pursuit acceleration;
CESC	cis	rs9487051	0.676	rs1608042	chr6:109595631	G/A	cg21918786	chr6:109611834	NA	-0.38	-5.52	-0.32	8.19e-8	Reticulocyte fraction of red cells;
CESC	cis	rs6860806	0.507	rs582490	chr5:131710095	G/A	cg04518342	chr5:131593106	PDLIM4	-0.36	-5.21	-0.3	3.8e-7	Breast cancer;
CESC	trans	rs3780486	0.846	rs73484568	chr9:33132492	G/A	cg04842962	chr6:43655489	MRPS18A	1.01	19.52	0.77	3.23e-53	IgG glycosylation;
CESC	cis	rs9796	0.870	rs11855248	chr15:41276158	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.47	-7.08	-0.4	1.29e-11	Menopause (age at onset);
CESC	cis	rs1707322	1.000	rs4660905	chr1:46461587	C/T	cg05343316	chr1:45956843	TESK2	-0.44	-5.42	-0.32	1.36e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg22264975	chr6:90121670	RRAGD	-0.49	-6.37	-0.36	8.42e-10	Ulcerative colitis;
CESC	cis	rs896854	0.654	rs1453377	chr8:95969947	C/T	cg26343298	chr8:95960752	TP53INP1	0.35	5.76	0.33	2.29e-8	Type 2 diabetes;
CESC	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-1.17	-22.95	-0.82	6.46e-65	Prudent dietary pattern;
CESC	cis	rs13034020	0.522	rs12998880	chr2:61240882	G/A	cg18625361	chr2:61244694	PEX13;PUS10	0.66	5.9	0.34	1.13e-8	Hodgkin's lymphoma;
CESC	cis	rs10883723	0.810	rs7090276	chr10:104281239	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.55	7.59	0.42	5.46e-13	Allergic disease (asthma, hay fever or eczema);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg10937591	chr1:112532966	KCND3	0.43	6.21	0.36	2.08e-9	Fibrinogen levels;
CESC	cis	rs832540	0.806	rs10039322	chr5:56260259	A/C	cg12311346	chr5:56204834	C5orf35	-0.41	-5.29	-0.31	2.51e-7	Coronary artery disease;
CESC	cis	rs863345	0.967	rs951135	chr1:158531633	A/T	cg12129480	chr1:158549410	OR10X1	0.33	6.71	0.38	1.14e-10	Pneumococcal bacteremia;
CESC	cis	rs16858210	0.874	rs73177525	chr3:183570286	G/C	cg03417191	chr3:183542750	MAP6D1	-0.43	-5.54	-0.32	7.15e-8	Menopause (age at onset);
CESC	cis	rs780096	0.565	rs11681351	chr2:27743423	G/A	cg21248554	chr2:27665150	KRTCAP3	-0.35	-7.15	-0.4	8.37e-12	Total body bone mineral density;
CESC	trans	rs7937682	0.814	rs1784788	chr11:111486136	T/G	cg18187862	chr3:45730750	SACM1L	0.48	6.1	0.35	3.75e-9	Primary sclerosing cholangitis;
CESC	cis	rs1950626	0.532	rs61991120	chr14:101455222	G/A	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.67	8.97	0.48	5.38e-17	Pelvic organ prolapse (moderate/severe);
CESC	trans	rs561341	0.882	rs111484028	chr17:30287701	G/A	cg27661571	chr11:113659931	NA	-0.72	-7.36	-0.41	2.36e-12	Hip circumference adjusted for BMI;
CESC	cis	rs2836974	0.568	rs442972	chr21:40534757	C/T	cg27266027	chr21:40555129	PSMG1	-0.4	-5.13	-0.3	5.5e-7	Cognitive function;
CESC	cis	rs6714710	0.603	rs17489984	chr2:98421364	A/G	cg26665480	chr2:98280029	ACTR1B	0.6	8.26	0.45	6.99e-15	Posterior cortical atrophy and Alzheimer's disease;
CESC	cis	rs4474465	0.833	rs7934912	chr11:78218556	A/T	cg27205649	chr11:78285834	NARS2	0.43	5.29	0.31	2.62e-7	Alzheimer's disease (survival time);
CESC	cis	rs514406	0.505	rs425520	chr1:53179805	C/G	cg08736216	chr1:53307985	ZYG11A	-0.37	-6.19	-0.36	2.27e-9	Monocyte count;
CESC	cis	rs12995491	0.763	rs1914735	chr2:88511953	A/T	cg04511125	chr2:88470314	THNSL2	-0.54	-7.88	-0.44	8.42e-14	Response to metformin (IC50);
CESC	cis	rs7772486	0.754	rs4895682	chr6:146062861	G/A	cg23711669	chr6:146136114	FBXO30	-1.0	-15.05	-0.68	1.98e-37	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7246657	0.943	rs10422967	chr19:37850137	T/C	cg23950597	chr19:37808831	NA	-0.62	-6.3	-0.36	1.26e-9	Coronary artery calcification;
CESC	cis	rs425277	0.538	rs169037	chr1:2095582	G/T	cg23803603	chr1:2058230	PRKCZ	0.3	5.21	0.31	3.73e-7	Height;
CESC	cis	rs1185460	1.000	rs1784305	chr11:118942048	G/A	cg23280166	chr11:118938394	VPS11	0.57	7.83	0.43	1.2e-13	Coronary artery disease;
CESC	cis	rs11785693	0.862	rs62491202	chr8:5001470	C/A	cg26367366	chr8:4980734	NA	0.83	7.77	0.43	1.77e-13	Neuroticism (multi-trait analysis);Neuroticism;
CESC	cis	rs11051970	0.592	rs11051987	chr12:32555406	C/T	cg24626660	chr12:32551988	NA	0.36	5.27	0.31	2.77e-7	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs12130219	0.500	rs1552991	chr1:152165878	C/T	cg09127314	chr1:152161683	NA	0.4	5.11	0.3	6.09e-7	Inflammatory skin disease;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg03325406	chr16:74641227	GLG1	-0.43	-6.04	-0.35	5.13e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs4665809	1.000	rs4665820	chr2:26309150	T/C	cg25036284	chr2:26402008	FAM59B	-0.61	-7.08	-0.4	1.31e-11	Gut microbiome composition (summer);
CESC	cis	rs1348850	0.561	rs57986285	chr2:178468663	C/T	cg23306229	chr2:178417860	TTC30B	0.8	7.71	0.43	2.61e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs1448094	0.511	rs17279338	chr12:86162874	G/A	cg00310523	chr12:86230176	RASSF9	0.35	5.61	0.33	5.01e-8	Major depressive disorder;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg03013188	chr16:2126939	TSC2	0.46	6.03	0.35	5.34e-9	Fibrinogen levels;
CESC	cis	rs7605827	0.930	rs4668926	chr2:15704944	C/T	cg19274914	chr2:15703543	NA	0.3	5.27	0.31	2.86e-7	Educational attainment (years of education);
CESC	cis	rs2276314	0.857	rs56230698	chr18:33628885	A/G	cg19628046	chr18:33552617	C18orf21	0.49	5.38	0.31	1.63e-7	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs7640424	0.649	rs11917909	chr3:107864673	G/A	cg09227934	chr3:107805635	CD47	-0.42	-5.49	-0.32	9.25e-8	Body mass index;
CESC	cis	rs6465657	0.903	rs11767962	chr7:97778576	C/T	cg21770322	chr7:97807741	LMTK2	0.83	13.85	0.65	3.33e-33	Prostate cancer (SNP x SNP interaction);Prostate cancer;
CESC	cis	rs62408225	0.890	rs2134814	chr6:90987512	C/G	cg06866423	chr6:90926672	BACH2	0.45	5.41	0.32	1.42e-7	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	trans	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg13565492	chr6:43139072	SRF	-0.61	-6.51	-0.37	3.65e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs3747547	0.892	rs3763637	chr9:38037956	T/A	cg13774184	chr9:37916125	SHB	-0.68	-5.72	-0.33	2.87e-8	Metabolite levels (Dihydroxy docosatrienoic acid);
CESC	cis	rs11785400	0.762	rs1137522	chr8:143739020	A/C	cg24634471	chr8:143751801	JRK	0.45	5.75	0.33	2.41e-8	Schizophrenia;
CESC	cis	rs12956009	0.518	rs3902716	chr18:44889441	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.52	7.0	0.39	2.11e-11	Educational attainment (years of education);
CESC	trans	rs11722228	0.521	rs62288520	chr4:10099674	G/A	cg26043149	chr18:55253948	FECH	0.92	10.95	0.56	2.93e-23	Gout;Urate levels;Serum uric acid levels;
CESC	cis	rs9486715	0.838	rs9386576	chr6:96954717	C/T	cg06623918	chr6:96969491	KIAA0776	0.93	14.38	0.66	4.75e-35	Headache;
CESC	cis	rs9513627	1.000	rs3928270	chr13:100184268	A/G	cg25919922	chr13:100150906	NA	0.65	5.12	0.3	5.9e-7	Obesity-related traits;
CESC	cis	rs1691799	0.899	rs1168303	chr12:66738586	A/G	cg16791601	chr12:66731901	HELB	-0.75	-13.03	-0.62	2.51e-30	White blood cell count (basophil);
CESC	trans	rs7615952	0.800	rs11915699	chr3:125632684	A/G	cg07211511	chr3:129823064	LOC729375	-1.07	-14.66	-0.67	4.7e-36	Blood pressure (smoking interaction);
CESC	cis	rs11711311	1.000	rs9865965	chr3:113450495	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.72	10.27	0.53	4.81e-21	IgG glycosylation;
CESC	cis	rs7851660	0.967	rs12348691	chr9:100608682	G/A	cg13688889	chr9:100608707	NA	-0.68	-10.61	-0.55	3.8e-22	Strep throat;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg12736146	chr10:116391608	ABLIM1	0.38	6.01	0.35	6.1e-9	Gambling;
CESC	cis	rs72901758	0.768	rs11657271	chr17:76249682	A/T	cg23302638	chr17:76210176	BIRC5	0.45	5.05	0.3	8.29e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
CESC	cis	rs11608355	0.545	rs11612500	chr12:109897136	T/C	cg05360138	chr12:110035743	NA	0.82	8.92	0.48	7.93e-17	Neuroticism;
CESC	cis	rs4835473	0.897	rs4423826	chr4:144913318	A/G	cg25736465	chr4:144833511	NA	0.43	6.43	0.37	6.04e-10	Immature fraction of reticulocytes;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg10384294	chr12:57636980	NA	0.46	6.69	0.38	1.29e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs61931739	0.782	rs1197569	chr12:34186733	A/T	cg19457237	chr12:34500585	NA	-0.37	-5.19	-0.3	4.25e-7	Morning vs. evening chronotype;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg22395299	chr21:47706029	MCM3AP;C21orf57	-0.46	-6.25	-0.36	1.67e-9	Fibrinogen levels;
CESC	cis	rs6964587	0.967	rs4626516	chr7:91807153	G/C	cg17063962	chr7:91808500	NA	0.53	7.13	0.4	9.73e-12	Breast cancer;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg11809123	chr19:1584870	MBD3	0.5	6.41	0.37	6.51e-10	Fibrinogen levels;
CESC	cis	rs10751667	0.600	rs1128413	chr11:1010694	C/T	cg06064525	chr11:970664	AP2A2	-0.37	-6.23	-0.36	1.87e-9	Alzheimer's disease (late onset);
CESC	cis	rs9911578	0.967	rs12603238	chr17:57130785	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.4	-5.09	-0.3	6.91e-7	Intelligence (multi-trait analysis);
CESC	cis	rs1879734	0.521	rs1879731	chr1:54175861	G/A	cg23596471	chr1:54105337	GLIS1	0.32	5.17	0.3	4.7e-7	Mitral valve prolapse;
CESC	cis	rs55883249	1.000	rs10495571	chr2:9736066	A/G	cg23886495	chr2:9695866	ADAM17	0.57	5.41	0.32	1.39e-7	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
CESC	cis	rs2562152	0.654	rs216600	chr16:110165	T/C	cg02949481	chr16:131562	MPG	0.63	6.41	0.37	6.65e-10	Glioblastoma;
CESC	cis	rs9457247	0.508	rs6941355	chr6:167506238	A/G	cg07741184	chr6:167504864	NA	0.34	5.81	0.34	1.78e-8	Crohn's disease;
CESC	cis	rs476633	0.691	rs28409265	chr15:41539404	G/A	cg20272979	chr15:41787780	ITPKA	0.38	5.63	0.33	4.61e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs11098499	0.863	rs3822192	chr4:120445720	A/C	cg09307838	chr4:120376055	NA	0.91	12.34	0.6	5.91e-28	Corneal astigmatism;
CESC	cis	rs736408	0.545	rs6445529	chr3:52662722	T/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.61	8.89	0.48	9.63e-17	Bipolar disorder;
CESC	cis	rs919433	0.926	rs12618567	chr2:198148191	A/T	cg10820045	chr2:198174542	NA	-0.36	-5.17	-0.3	4.67e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs7208859	0.623	rs9891166	chr17:29111902	G/A	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.17e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs4319547	1.000	rs6489071	chr12:123025576	C/G	cg05707623	chr12:122985044	ZCCHC8	-0.57	-6.72	-0.38	1.09e-10	Body mass index;
CESC	cis	rs10789491	1.000	rs1371834	chr1:47176894	G/A	cg15501359	chr1:47185051	KIAA0494	0.77	8.56	0.47	9.21e-16	Response to hepatitis C treatment;
CESC	cis	rs7833790	0.724	rs6473311	chr8:82726682	G/A	cg17211192	chr8:82754475	SNX16	-0.58	-7.38	-0.41	2.04e-12	Diastolic blood pressure;
CESC	cis	rs3026101	0.671	rs1806256	chr17:5314357	A/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.42	5.47	0.32	1.04e-7	Body mass index;
CESC	cis	rs3859192	0.561	rs34453912	chr17:38180352	T/A	cg17344932	chr17:38183730	MED24;SNORD124	0.64	9.62	0.51	5.38e-19	White blood cell count;
CESC	cis	rs9814567	1.000	rs6763093	chr3:134254995	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.45	6.08	0.35	4.21e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs10865397	0.506	rs6546807	chr2:73386212	C/T	cg01422370	chr2:73384389	NA	0.46	7.35	0.41	2.47e-12	Intelligence (multi-trait analysis);
CESC	cis	rs807669	0.524	rs11089258	chr22:19162276	C/T	cg02655711	chr22:19163373	SLC25A1	0.43	6.32	0.36	1.09e-9	Metabolite levels;
CESC	cis	rs4481887	0.893	rs28451623	chr1:248509783	G/A	cg00666640	chr1:248458726	OR2T12	0.35	6.04	0.35	5.22e-9	Common traits (Other);
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg18710692	chr13:20437712	ZMYM5	-0.48	-6.06	-0.35	4.63e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18986332	chr3:33759647	CLASP2	0.55	6.14	0.35	3.08e-9	Gut microbiome composition (summer);
CESC	cis	rs1348850	0.567	rs3770009	chr2:178536544	C/T	cg23306229	chr2:178417860	TTC30B	0.49	5.71	0.33	2.97e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg11494091	chr17:61959527	GH2	0.74	12.87	0.62	8.73e-30	Prudent dietary pattern;
CESC	trans	rs1382269	0.551	rs1461514	chr3:136945045	G/A	cg16900796	chr19:10755136	SLC44A2	-0.42	-6.32	-0.36	1.07e-9	Metabolite levels;
CESC	cis	rs11711311	1.000	rs16861312	chr3:113492402	G/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.71	9.99	0.52	3.74e-20	IgG glycosylation;
CESC	cis	rs12048904	0.595	rs10493937	chr1:101342650	A/T	cg15686842	chr1:101360669	SLC30A7;EXTL2	-0.46	-5.9	-0.34	1.11e-8	Multiple sclerosis;
CESC	cis	rs10489202	1.000	rs2272911	chr1:167936302	C/T	cg24449463	chr1:168025552	DCAF6	-0.46	-5.38	-0.31	1.63e-7	Schizophrenia;
CESC	cis	rs11997175	0.766	rs4273817	chr8:33702686	C/T	ch.8.33884649F	chr8:33765107	NA	0.44	5.64	0.33	4.37e-8	Body mass index;
CESC	cis	rs28489187	0.617	rs233124	chr1:85791658	A/G	cg16011679	chr1:85725395	C1orf52	0.43	5.23	0.31	3.51e-7	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	cis	rs2066819	0.901	rs1274490	chr12:56649601	A/G	cg26714650	chr12:56694279	CS	1.27	16.13	0.7	3.13e-41	Psoriasis vulgaris;
CESC	cis	rs2243480	1.000	rs1499614	chr7:65730798	A/T	cg13147721	chr7:65941812	NA	-0.93	-8.87	-0.48	1.14e-16	Diabetic kidney disease;
CESC	cis	rs3785574	0.962	rs2955235	chr17:61966950	A/C	cg06873352	chr17:61820015	STRADA	0.48	6.83	0.39	5.84e-11	Height;
CESC	cis	rs79976124	0.837	rs74327235	chr6:66648353	T/A	cg07460842	chr6:66804631	NA	0.75	8.76	0.47	2.33e-16	Type 2 diabetes;
CESC	cis	rs9894429	0.646	rs6565612	chr17:79602820	C/T	cg13777783	chr17:79615861	NA	0.37	6.26	0.36	1.55e-9	Eye color traits;
CESC	cis	rs644799	0.965	rs549695	chr11:95617788	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.47	5.69	0.33	3.38e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs6463523	0.933	rs4724821	chr7:762544	C/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.97	15.27	0.68	3.46e-38	Subjective well-being;
CESC	cis	rs561341	1.000	rs8064843	chr17:30245744	A/G	cg12193833	chr17:30244370	NA	-0.55	-6.06	-0.35	4.53e-9	Hip circumference adjusted for BMI;
CESC	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg05313129	chr8:58192883	C8orf71	-0.49	-5.33	-0.31	2.07e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs7666738	1.000	rs7666738	chr4:98968077	C/T	cg03676636	chr4:99064102	C4orf37	0.37	5.67	0.33	3.68e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7666738	0.791	rs10017624	chr4:98984009	G/T	cg05340658	chr4:99064831	C4orf37	0.8	12.42	0.61	3.31e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11690935	0.632	rs12052246	chr2:172895606	G/T	cg13550731	chr2:172543902	DYNC1I2	0.49	6.66	0.38	1.57e-10	Schizophrenia;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg03849780	chr1:7816037	CAMTA1	0.41	6.21	0.36	2.06e-9	Fibrinogen levels;
CESC	cis	rs2637266	0.655	rs846584	chr10:78495419	G/A	cg18941641	chr10:78392320	NA	0.42	7.9	0.44	7.48e-14	Pulmonary function;
CESC	cis	rs3947	1.000	rs709821	chr8:11702594	G/C	cg00262122	chr8:11665843	FDFT1	-0.5	-5.1	-0.3	6.58e-7	Blood protein levels;
CESC	cis	rs7542091	0.748	rs2357231	chr1:210028454	A/C	cg21951975	chr1:209979733	IRF6	-0.41	-7.2	-0.4	6.33e-12	Monobrow;
CESC	cis	rs870825	0.655	rs28555435	chr4:185647300	C/A	cg04058563	chr4:185651563	MLF1IP	0.63	6.96	0.39	2.59e-11	Blood protein levels;
CESC	cis	rs6088590	0.561	rs6088528	chr20:33156742	G/A	cg24642439	chr20:33292090	TP53INP2	0.64	8.54	0.46	1.05e-15	Coronary artery disease;
CESC	cis	rs875971	0.800	rs427557	chr7:65519250	A/G	cg11764359	chr7:65958608	NA	0.89	13.11	0.63	1.31e-30	Aortic root size;
CESC	cis	rs77861329	1.000	rs17051957	chr3:52099441	A/G	cg08692210	chr3:52188851	WDR51A	0.71	6.75	0.38	9.45e-11	Macrophage inflammatory protein 1b levels;
CESC	trans	rs1814175	0.935	rs7925863	chr11:49615802	C/A	cg15704280	chr7:45808275	SEPT13	-1.01	-17.69	-0.74	8.95e-47	Height;
CESC	cis	rs977987	0.872	rs4888422	chr16:75470576	A/G	cg03315344	chr16:75512273	CHST6	0.4	5.91	0.34	1.07e-8	Dupuytren's disease;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg03258011	chr17:54857409	NA	-0.44	-6.2	-0.36	2.18e-9	Gambling;
CESC	cis	rs1707322	0.681	rs12048866	chr1:46117492	T/G	cg05343316	chr1:45956843	TESK2	0.51	6.24	0.36	1.7e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2108225	0.872	rs2051955	chr7:107441154	C/T	cg18560240	chr7:107437656	SLC26A3	-0.41	-5.67	-0.33	3.67e-8	Ulcerative colitis;
CESC	cis	rs965469	0.779	rs6037568	chr20:3333245	C/T	cg17110299	chr20:3385021	C20orf194	0.4	5.25	0.31	3.1e-7	IFN-related cytopenia;
CESC	cis	rs11719291	0.915	rs1048940	chr3:48725707	C/T	cg00383909	chr3:49044727	WDR6	0.85	5.26	0.31	2.96e-7	Cognitive function;
CESC	cis	rs2228479	0.850	rs45524643	chr16:89815824	G/A	cg04013166	chr16:89971882	TCF25	0.77	6.66	0.38	1.58e-10	Skin colour saturation;
CESC	cis	rs4566357	0.615	rs10178260	chr2:227914458	G/T	cg11843606	chr2:227700838	RHBDD1	-0.46	-6.28	-0.36	1.38e-9	Coronary artery disease;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg25825740	chr17:80036910	FASN	0.34	6.35	0.36	9.3e-10	Gambling;
CESC	cis	rs909002	0.830	rs10914460	chr1:32113216	T/C	cg13919466	chr1:32135498	COL16A1	-0.47	-8.63	-0.47	5.6e-16	Intelligence (multi-trait analysis);
CESC	trans	rs9987353	0.840	rs329994	chr8:9123233	A/G	cg01332181	chr19:47290716	SLC1A5	-0.44	-6.06	-0.35	4.66e-9	Recombination measurement;
CESC	cis	rs752010	0.662	rs10890154	chr1:42106740	C/T	cg06885757	chr1:42089581	HIVEP3	0.53	8.29	0.45	5.6e-15	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs6028335	0.674	rs16987712	chr20:37601243	A/G	cg16355469	chr20:37678765	NA	0.52	5.14	0.3	5.28e-7	Alcohol and nicotine co-dependence;
CESC	cis	rs34779708	0.931	rs4351760	chr10:35280254	A/G	cg04310649	chr10:35416472	CREM	-0.5	-6.06	-0.35	4.78e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs7927771	0.965	rs1064608	chr11:47640429	G/C	cg20307385	chr11:47447363	PSMC3	-0.49	-5.98	-0.34	7.21e-9	Subjective well-being;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05800723	chr4:79103126	FRAS1	-0.45	-6.04	-0.35	5.24e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs9910055	0.762	rs227579	chr17:42223134	A/T	cg09913183	chr17:42254507	C17orf65;ASB16	-0.65	-8.68	-0.47	4.16e-16	Total body bone mineral density;
CESC	cis	rs7666738	0.830	rs10007872	chr4:99001904	T/C	cg18180107	chr4:99064573	C4orf37	0.4	5.18	0.3	4.42e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs78456975	0.527	rs11884165	chr2:1561052	A/G	cg26248373	chr2:1572462	NA	-0.58	-6.93	-0.39	3.29e-11	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs12148488	0.816	rs11854975	chr15:75363876	C/T	cg17294928	chr15:75287854	SCAMP5	0.52	6.64	0.38	1.77e-10	Caffeine consumption;
CESC	cis	rs6446731	0.593	rs6446728	chr4:3275650	A/G	cg08886695	chr4:3369023	RGS12	-0.39	-5.62	-0.33	4.77e-8	Mean platelet volume;
CESC	cis	rs2070433	0.800	rs2073380	chr21:47863757	A/C	cg12379764	chr21:47803548	PCNT	0.65	7.24	0.41	4.98e-12	Lymphocyte counts;
CESC	cis	rs2404602	0.716	rs8025134	chr15:76781729	C/T	cg26408565	chr15:76604113	ETFA	-0.43	-6.19	-0.36	2.32e-9	Blood metabolite levels;
CESC	cis	rs2243480	1.000	rs778729	chr7:65824419	T/C	cg12463550	chr7:65579703	CRCP	0.71	5.49	0.32	9.37e-8	Diabetic kidney disease;
CESC	cis	rs6500395	1.000	rs55671623	chr16:48631154	A/G	cg04672837	chr16:48644449	N4BP1	0.51	6.51	0.37	3.71e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs12912251	0.591	rs2624272	chr15:39003409	A/G	cg10631289	chr15:39006617	NA	-0.45	-5.13	-0.3	5.5e-7	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
CESC	cis	rs5850	0.602	rs1005786	chr7:23145837	G/C	cg23682824	chr7:23144976	KLHL7	0.46	6.2	0.36	2.13e-9	Blood protein levels;
CESC	cis	rs7089973	0.966	rs12772800	chr10:116630962	A/G	cg25233709	chr10:116636983	FAM160B1	0.38	5.42	0.32	1.36e-7	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs7264396	0.563	rs17092980	chr20:34289005	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.9	-10.87	-0.56	5.11e-23	Total cholesterol levels;
CESC	cis	rs9649213	0.593	rs6465672	chr7:97963717	C/T	cg24562669	chr7:97807699	LMTK2	-0.49	-7.16	-0.4	8.14e-12	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs11249608	0.548	rs34054398	chr5:178458371	A/G	cg21905437	chr5:178450457	ZNF879	0.58	8.03	0.44	3.12e-14	Pubertal anthropometrics;
CESC	cis	rs9303401	0.614	rs34900851	chr17:56566399	G/A	cg25039879	chr17:56429692	SUPT4H1	0.51	5.08	0.3	7.18e-7	Cognitive test performance;
CESC	cis	rs2710642	0.586	rs62180020	chr2:62819915	C/G	cg17519650	chr2:63277830	OTX1	0.49	6.41	0.37	6.46e-10	LDL cholesterol levels;LDL cholesterol;
CESC	cis	rs2243480	1.000	rs1723269	chr7:65472786	C/G	cg18252515	chr7:66147081	NA	-1.25	-12.29	-0.6	9.28e-28	Diabetic kidney disease;
CESC	cis	rs12145833	0.538	rs61833885	chr1:243397188	C/A	cg02356786	chr1:243265016	LOC731275	0.78	6.34	0.36	9.66e-10	Obesity (early onset extreme);
CESC	cis	rs9322193	0.962	rs3805752	chr6:150116626	C/T	cg04369109	chr6:150039330	LATS1	-0.45	-6.17	-0.35	2.54e-9	Lung cancer;
CESC	cis	rs9291683	0.546	rs4529049	chr4:10045389	C/T	cg02734326	chr4:10020555	SLC2A9	0.45	6.27	0.36	1.46e-9	Bone mineral density;
CESC	cis	rs7296418	0.699	rs11057219	chr12:123750073	T/C	cg00376283	chr12:123451042	ABCB9	0.61	8.4	0.46	2.77e-15	Platelet count;
CESC	cis	rs7246657	0.943	rs1373991	chr19:37838911	T/C	cg23950597	chr19:37808831	NA	-0.55	-6.09	-0.35	3.96e-9	Coronary artery calcification;
CESC	cis	rs9733	0.818	rs7520022	chr1:150659173	C/G	cg13175981	chr1:150552382	MCL1	0.58	8.45	0.46	1.93e-15	Tonsillectomy;
CESC	cis	rs5750830	0.649	rs5750813	chr22:39795228	G/C	cg11247378	chr22:39784982	NA	-0.6	-8.99	-0.48	4.97e-17	Intelligence (multi-trait analysis);
CESC	cis	rs7618915	0.547	rs11130314	chr3:52697082	T/C	cg07507251	chr3:52567010	NT5DC2	0.4	7.1	0.4	1.15e-11	Bipolar disorder;
CESC	cis	rs3096299	0.967	rs11648663	chr16:89466307	C/T	cg02187348	chr16:89574699	SPG7	0.51	6.81	0.39	6.62e-11	Multiple myeloma (IgH translocation);
CESC	cis	rs2243480	1.000	rs2707844	chr7:66059509	G/A	cg18252515	chr7:66147081	NA	-1.39	-14.25	-0.66	1.31e-34	Diabetic kidney disease;
CESC	cis	rs7914558	0.966	rs7921574	chr10:104840970	T/C	cg15744005	chr10:104629667	AS3MT	-0.32	-5.04	-0.3	8.72e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs910316	0.726	rs12882664	chr14:75446778	C/T	cg08847533	chr14:75593920	NEK9	0.91	15.46	0.69	7.14e-39	Height;
CESC	cis	rs1707322	0.752	rs12027622	chr1:46130252	A/C	cg03146154	chr1:46216737	IPP	0.82	11.51	0.58	3.87e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs11250098	0.574	rs7015168	chr8:10772210	G/C	cg27411982	chr8:10470053	RP1L1	-0.43	-5.23	-0.31	3.43e-7	Morning vs. evening chronotype;
CESC	cis	rs1957429	0.808	rs1951492	chr14:65346895	G/A	cg23373153	chr14:65346875	NA	0.96	11.51	0.58	4.06e-25	Pediatric areal bone mineral density (radius);
CESC	cis	rs3105593	1.000	rs2292174	chr15:50924956	A/G	cg08437265	chr15:50716283	USP8	0.41	5.23	0.31	3.37e-7	QT interval;
CESC	cis	rs2485892	0.553	rs4844954	chr1:210337043	A/G	cg23283495	chr1:209979779	IRF6	0.47	5.77	0.33	2.21e-8	Manic episodes in bipolar disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07805240	chr7:8008383	GLCCI1	0.66	8.19	0.45	1.12e-14	Gut microbiome composition (summer);
CESC	cis	rs10791323	0.569	rs5019134	chr11:133713082	G/C	cg06766960	chr11:133703094	NA	-0.4	-5.67	-0.33	3.7e-8	Childhood ear infection;
CESC	cis	rs9479482	0.648	rs912557	chr6:150385977	C/T	cg03788504	chr6:150331562	NA	-0.31	-6.16	-0.35	2.74e-9	Alopecia areata;
CESC	trans	rs7107217	1.000	rs1873872	chr11:129473993	A/T	cg21959181	chr7:150755243	CDK5;SLC4A2	0.45	6.04	0.35	5.2e-9	Breast cancer;Type 2 diabetes;
CESC	cis	rs13064411	0.696	rs13325046	chr3:113104444	C/T	cg18753928	chr3:113234510	CCDC52	-0.47	-5.24	-0.31	3.31e-7	Response to simvastatin treatment (PCSK9 protein level change);
CESC	trans	rs1945213	0.694	rs7106894	chr11:55877315	T/C	cg03929089	chr4:120376271	NA	0.73	6.95	0.39	2.82e-11	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs2742234	0.541	rs61268333	chr10:43721370	G/A	cg07801480	chr10:43725741	RASGEF1A	-0.4	-5.24	-0.31	3.22e-7	Hirschsprung disease;
CESC	trans	rs9929218	0.817	rs3118228	chr16:68710737	T/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.82	-10.44	-0.54	1.35e-21	Colorectal cancer;
CESC	cis	rs7660520	0.524	rs12643521	chr4:183728242	C/G	cg04181038	chr4:183730758	NA	0.63	7.08	0.4	1.26e-11	Pediatric autoimmune diseases;
CESC	cis	rs3008870	1.000	rs2985797	chr1:67431499	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-1.1	-15.07	-0.68	1.75e-37	Lymphocyte percentage of white cells;
CESC	cis	rs2072732	0.904	rs9661525	chr1:2952840	A/C	cg15211996	chr1:2936768	ACTRT2	0.35	6.0	0.35	6.39e-9	Plateletcrit;
CESC	cis	rs8070624	0.543	rs4299203	chr17:17878159	T/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.6	8.13	0.45	1.68e-14	Total body bone mineral density;
CESC	cis	rs4604732	0.631	rs80319072	chr1:247626835	G/A	cg12754571	chr1:247694271	LOC148824;OR2C3	0.44	5.44	0.32	1.21e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	ch.5.2119577R	chr5:115940196	NA	-0.56	-6.24	-0.36	1.71e-9	Gut microbiome composition (summer);
CESC	cis	rs875971	0.862	rs6460306	chr7:66060793	T/C	cg10691866	chr7:65817282	TPST1	0.33	5.49	0.32	9.61e-8	Aortic root size;
CESC	cis	rs10504229	0.834	rs7015674	chr8:58153166	C/T	cg24829409	chr8:58192753	C8orf71	-0.63	-8.28	-0.45	6.05e-15	Developmental language disorder (linguistic errors);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg01811315	chr17:4890515	CAMTA2	-0.5	-6.37	-0.36	8.35e-10	Ulcerative colitis;
CESC	cis	rs873946	0.529	rs12258248	chr10:134573767	A/G	cg26818010	chr10:134567672	INPP5A	-0.85	-10.65	-0.55	2.77e-22	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs2996428	0.667	rs113120570	chr1:3770450	G/C	cg13057898	chr1:3703894	LRRC47	0.45	6.09	0.35	3.87e-9	Red cell distribution width;
CESC	cis	rs3008870	0.755	rs1925410	chr1:67365230	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.63	-8.27	-0.45	6.4e-15	Lymphocyte percentage of white cells;
CESC	cis	rs425277	0.916	rs414777	chr1:2101687	G/A	cg04315214	chr1:2043799	PRKCZ	-0.37	-5.26	-0.31	2.99e-7	Height;
CESC	cis	rs35306767	0.903	rs7914758	chr10:891702	T/C	cg10556349	chr10:835070	NA	0.76	6.35	0.36	9.42e-10	Eosinophil percentage of granulocytes;
CESC	cis	rs1355223	0.506	rs1509659	chr11:34865133	A/G	cg11622362	chr11:34938112	PDHX;APIP	0.44	5.29	0.31	2.52e-7	Systemic lupus erythematosus and Systemic sclerosis;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg22039839	chr20:60777952	NA	-0.47	-6.06	-0.35	4.59e-9	Systemic lupus erythematosus;
CESC	cis	rs13191362	0.935	rs67673890	chr6:163107647	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.04	10.15	0.53	1.18e-20	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs3806843	1.000	rs10053586	chr5:140210760	T/C	cg16179182	chr5:140090404	VTRNA1-1	-0.4	-5.16	-0.3	4.84e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs6691722	0.503	rs6667695	chr1:24707669	G/A	cg02336364	chr1:24764700	NIPAL3	0.32	6.58	0.37	2.48e-10	Response to interferon beta in multiple sclerosis;
CESC	cis	rs7666738	0.830	rs7678250	chr4:98922109	G/A	cg05340658	chr4:99064831	C4orf37	0.82	12.2	0.6	1.81e-27	Colonoscopy-negative controls vs population controls;
CESC	trans	rs9929218	1.000	rs12443730	chr16:68804342	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.61	-8.18	-0.45	1.17e-14	Colorectal cancer;
CESC	cis	rs2439831	1.000	rs690316	chr15:43737880	C/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.81	11.74	0.59	6.47e-26	Lung cancer in ever smokers;
CESC	cis	rs4665809	0.941	rs7602922	chr2:26265782	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.84	-9.27	-0.49	6.81e-18	Gut microbiome composition (summer);
CESC	cis	rs35306767	0.904	rs35667562	chr10:950630	G/A	cg20503657	chr10:835505	NA	1.07	9.84	0.52	1.13e-19	Eosinophil percentage of granulocytes;
CESC	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg14893161	chr1:205819251	PM20D1	0.88	14.7	0.67	3.54e-36	Menarche (age at onset);
CESC	cis	rs36051895	0.530	rs7036833	chr9:5226484	G/A	cg02405213	chr9:5042618	JAK2	-0.58	-6.95	-0.39	2.86e-11	Pediatric autoimmune diseases;
CESC	cis	rs875971	0.862	rs2088653	chr7:65808608	G/A	cg12463550	chr7:65579703	CRCP	-0.48	-6.17	-0.35	2.6e-9	Aortic root size;
CESC	cis	rs8077889	0.871	rs16940243	chr17:41900003	C/G	cg26893861	chr17:41843967	DUSP3	0.77	10.22	0.53	6.78e-21	Triglycerides;
CESC	cis	rs10504229	0.683	rs55660024	chr8:58128943	G/A	cg21724239	chr8:58056113	NA	0.58	5.95	0.34	8.29e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs7666738	0.861	rs10018654	chr4:99002226	A/G	cg17366294	chr4:99064904	C4orf37	0.6	8.6	0.47	7.02e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6952808	0.500	rs3800902	chr7:2144378	C/T	cg08027265	chr7:2291960	NA	-0.45	-6.9	-0.39	3.88e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs4561483	0.843	rs35153773	chr16:11936317	C/T	cg08843971	chr16:11963173	GSPT1	0.54	7.74	0.43	2.1e-13	Testicular germ cell tumor;
CESC	cis	rs561341	1.000	rs113115092	chr17:30284164	G/A	cg19193384	chr17:30244184	NA	-0.68	-6.43	-0.37	5.9e-10	Hip circumference adjusted for BMI;
CESC	cis	rs2439831	0.702	rs3784275	chr15:44091386	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.66	6.51	0.37	3.73e-10	Lung cancer in ever smokers;
CESC	cis	rs6540559	0.673	rs11803382	chr1:209986426	G/A	cg23283495	chr1:209979779	IRF6	0.53	6.17	0.35	2.58e-9	Cleft lip with or without cleft palate;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27308707	chr10:91461150	KIF20B	0.59	6.54	0.37	3.22e-10	Gut microbiome composition (summer);
CESC	cis	rs10242455	0.867	rs2687143	chr7:99320469	C/T	cg07715041	chr7:99302981	CYP3A7	-0.43	-5.42	-0.32	1.36e-7	Blood metabolite levels;
CESC	cis	rs7927771	0.507	rs10838754	chr11:47758532	A/C	cg20307385	chr11:47447363	PSMC3	0.61	8.65	0.47	5.14e-16	Subjective well-being;
CESC	cis	rs2243480	1.000	rs1039664	chr7:65449716	T/G	cg13147721	chr7:65941812	NA	-0.86	-8.36	-0.46	3.7e-15	Diabetic kidney disease;
CESC	cis	rs9640161	0.750	rs3735167	chr7:150039555	C/T	cg17279839	chr7:150038598	RARRES2	0.52	6.07	0.35	4.36e-9	Blood protein levels;Circulating chemerin levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15778497	chr17:80011823	GPS1	-0.46	-6.11	-0.35	3.47e-9	Gut microbiome composition (summer);
CESC	cis	rs9902453	0.904	rs4528633	chr17:28356136	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.67	-8.69	-0.47	3.79e-16	Coffee consumption (cups per day);
CESC	cis	rs34172651	0.583	rs200541	chr16:24733141	A/G	cg04756594	chr16:24857601	SLC5A11	-0.5	-5.81	-0.34	1.82e-8	Intelligence (multi-trait analysis);
CESC	cis	rs12451471	0.559	rs34746710	chr17:78079224	G/A	cg06718696	chr17:78121285	EIF4A3	0.79	9.64	0.51	4.84e-19	Plateletcrit;Mean corpuscular hemoglobin concentration;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg16761550	chr16:3029823	PKMYT1	-0.42	-6.58	-0.37	2.47e-10	Gambling;
CESC	cis	rs3106136	0.933	rs34383543	chr4:95163792	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.45	-6.8	-0.39	6.92e-11	Capecitabine sensitivity;
CESC	cis	rs8177253	0.606	rs6787177	chr3:133450720	C/T	cg24879335	chr3:133465180	TF	0.38	6.48	0.37	4.34e-10	Iron status biomarkers;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg08207256	chr19:10828848	DNM2;MIR638	-0.46	-6.52	-0.37	3.51e-10	Fibrinogen levels;
CESC	cis	rs7264396	0.528	rs3787174	chr20:34487921	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.84	-9.33	-0.5	4.49e-18	Total cholesterol levels;
CESC	cis	rs2933343	0.649	rs2638845	chr3:128587369	A/G	cg25356066	chr3:128598488	ACAD9	0.59	8.35	0.46	3.8e-15	IgG glycosylation;
CESC	cis	rs8072100	1.000	rs4794016	chr17:45725931	T/A	cg08085267	chr17:45401833	C17orf57	0.42	5.57	0.32	6.33e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs6938	0.618	rs12901190	chr15:75231452	T/C	cg09165964	chr15:75287851	SCAMP5	0.49	6.64	0.38	1.81e-10	Breast cancer;
CESC	cis	rs2730245	0.510	rs2788471	chr7:158649786	G/T	cg14689365	chr7:158441557	NCAPG2	0.42	5.21	0.31	3.71e-7	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02176407	chr6:99282754	POU3F2	-0.64	-7.76	-0.43	1.83e-13	Gut microbiome composition (summer);
CESC	cis	rs17539620	0.624	rs62432740	chr6:154836054	C/T	cg20019720	chr6:154832845	CNKSR3	0.46	6.04	0.35	5.16e-9	Lipoprotein (a) levels;
CESC	cis	rs4862750	0.837	rs1863404	chr4:187874654	T/C	cg03452623	chr4:187889614	NA	-0.83	-14.22	-0.66	1.8e-34	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4713118	0.662	rs149970	chr6:27980220	C/T	cg23281280	chr6:28129359	ZNF389	0.45	6.41	0.37	6.46e-10	Parkinson's disease;
CESC	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg23708337	chr7:1209742	NA	0.53	5.34	0.31	1.98e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs1799949	1.000	rs9646417	chr17:41424253	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.6	7.87	0.44	9.16e-14	Menopause (age at onset);
CESC	cis	rs7666738	0.830	rs7657179	chr4:98948569	G/A	cg03467027	chr4:99064603	C4orf37	0.46	5.81	0.34	1.8e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3096299	0.642	rs12934829	chr16:89523349	T/A	cg08392591	chr16:89556376	ANKRD11	0.61	8.29	0.45	5.92e-15	Multiple myeloma (IgH translocation);
CESC	cis	rs11190604	1.000	rs79831012	chr10:102237059	T/C	cg07080220	chr10:102295463	HIF1AN	0.55	5.59	0.33	5.51e-8	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs7605827	0.930	rs3732004	chr2:15713783	C/T	cg19274914	chr2:15703543	NA	0.36	6.51	0.37	3.68e-10	Educational attainment (years of education);
CESC	cis	rs7666738	0.830	rs10009206	chr4:99056900	A/C	cg17366294	chr4:99064904	C4orf37	-0.41	-5.63	-0.33	4.56e-8	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11601239	0.646	rs495498	chr11:105575774	C/T	cg15315312	chr2:176867285	KIAA1715	-0.46	-6.17	-0.35	2.5e-9	Refractive error;
CESC	cis	rs1005277	0.579	rs2472175	chr10:38382901	T/G	cg25427524	chr10:38739819	LOC399744	-0.65	-9.48	-0.5	1.51e-18	Extrinsic epigenetic age acceleration;
CESC	cis	rs11190604	1.000	rs3750629	chr10:102275727	A/G	cg07080220	chr10:102295463	HIF1AN	0.67	6.49	0.37	4.31e-10	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs10504229	1.000	rs17216711	chr8:58170856	T/C	cg24829409	chr8:58192753	C8orf71	-0.76	-10.0	-0.52	3.53e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs6952808	0.717	rs12534679	chr7:1926745	G/A	cg23048001	chr7:2026167	MAD1L1	0.44	5.8	0.34	1.93e-8	Bipolar disorder and schizophrenia;
CESC	trans	rs875971	0.508	rs10950045	chr7:66066373	T/C	cg26939375	chr7:64535504	NA	-0.53	-7.37	-0.41	2.22e-12	Aortic root size;
CESC	cis	rs2576037	0.583	rs4890698	chr18:44489725	A/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.36	5.78	0.33	2.08e-8	Personality dimensions;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg15985338	chr7:6048868	PMS2;AIMP2	-0.4	-6.15	-0.35	2.83e-9	Gambling;
CESC	cis	rs60154123	0.772	rs701944	chr1:210417098	G/A	cg25204440	chr1:209979598	IRF6	0.5	5.08	0.3	7.09e-7	Coronary artery disease;
CESC	cis	rs4865169	0.934	rs3796531	chr4:57850846	A/G	cg25525207	chr4:57843836	C4orf14;POLR2B	0.44	5.77	0.33	2.2e-8	Breast cancer;
CESC	cis	rs7666738	0.861	rs28829607	chr4:98964325	G/C	cg17366294	chr4:99064904	C4orf37	0.6	8.52	0.46	1.2e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9611565	0.592	rs5758406	chr22:42076641	A/G	cg06481639	chr22:41940642	POLR3H	0.6	6.3	0.36	1.21e-9	Vitiligo;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18502306	chr4:8376764	ACOX3	-0.52	-6.07	-0.35	4.51e-9	Gut microbiome composition (summer);
CESC	cis	rs9910055	0.762	rs2631299	chr17:42219773	G/T	cg13607699	chr17:42295918	UBTF	0.63	8.36	0.46	3.49e-15	Total body bone mineral density;
CESC	trans	rs9945268	0.706	rs1452589	chr18:59336601	C/T	cg24536146	chr1:207997166	NA	0.38	6.2	0.36	2.21e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs2836974	0.644	rs2410123	chr21:40700093	C/T	cg11890956	chr21:40555474	PSMG1	-0.93	-15.07	-0.68	1.72e-37	Cognitive function;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg21451265	chr1:97187319	PTBP2	-0.46	-6.14	-0.35	3.05e-9	Ulcerative colitis;
CESC	trans	rs17508449	0.821	rs1419231	chr1:114126218	C/G	cg23028848	chr11:57092561	TNKS1BP1	-0.79	-6.17	-0.35	2.57e-9	Leprosy;
CESC	cis	rs7089973	0.604	rs7914792	chr10:116591391	T/C	cg23260525	chr10:116636907	FAM160B1	0.4	7.19	0.4	6.76e-12	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg20861091	chr8:144881744	SCRIB	0.44	6.63	0.38	1.88e-10	Fibrinogen levels;
CESC	cis	rs7412746	0.658	rs2275235	chr1:150730279	A/G	cg04414720	chr1:150670196	GOLPH3L	0.58	7.56	0.42	6.44e-13	Melanoma;
CESC	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	10.16	0.53	1.09e-20	Prudent dietary pattern;
CESC	cis	rs3820068	0.603	rs927207	chr1:15990552	A/G	cg18133145	chr1:16060689	PLEKHM2	-0.41	-5.22	-0.31	3.64e-7	Systolic blood pressure;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg06090383	chr4:174292579	SAP30	0.51	6.58	0.37	2.48e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs933688	1.000	rs2839728	chr5:90727412	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.1	14.79	0.67	1.76e-36	Smoking behavior;
CESC	cis	rs4665809	0.590	rs6749046	chr2:26429451	C/G	cg22920501	chr2:26401640	FAM59B	0.86	9.98	0.52	3.93e-20	Gut microbiome composition (summer);
CESC	cis	rs13108904	0.967	rs4642180	chr4:1278914	T/C	cg22903657	chr4:1355424	KIAA1530	-0.38	-5.23	-0.31	3.48e-7	Obesity-related traits;
CESC	cis	rs6459788	0.605	rs887628	chr7:157237589	G/A	cg06271696	chr7:157225062	NA	-0.39	-5.45	-0.32	1.13e-7	Epstein-Barr virus copy number in lymphoblastoid cell lines;
CESC	cis	rs736408	0.677	rs1042779	chr3:52821011	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.42	5.68	0.33	3.55e-8	Bipolar disorder;
CESC	cis	rs7116495	0.881	rs7128974	chr11:71677032	C/G	cg26138937	chr11:71823887	C11orf51	0.84	6.8	0.39	6.89e-11	Severe influenza A (H1N1) infection;
CESC	cis	rs7666738	0.830	rs10022389	chr4:99022229	T/C	cg03676636	chr4:99064102	C4orf37	0.33	5.15	0.3	5.05e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2228479	0.681	rs2270461	chr16:89972345	C/T	cg04013166	chr16:89971882	TCF25	-0.74	-9.23	-0.49	8.91e-18	Skin colour saturation;
CESC	cis	rs10479542	0.583	rs4131080	chr5:179044292	G/A	cg21226059	chr5:178986404	RUFY1	0.45	6.49	0.37	4.22e-10	Lung cancer;
CESC	cis	rs6546537	0.550	rs2312202	chr2:69775104	A/C	cg10773587	chr2:69614142	GFPT1	0.4	5.12	0.3	6.02e-7	Serum thyroid-stimulating hormone levels;
CESC	cis	rs7264396	0.836	rs6088880	chr20:34165582	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	0.57	7.05	0.4	1.52e-11	Total cholesterol levels;
CESC	cis	rs6088580	0.634	rs11700221	chr20:32940320	T/C	cg24642439	chr20:33292090	TP53INP2	-0.52	-6.79	-0.38	7.44e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs7833790	0.700	rs7834483	chr8:82704828	A/G	cg23324259	chr8:82754387	SNX16	-0.42	-5.17	-0.3	4.62e-7	Diastolic blood pressure;
CESC	cis	rs35306767	0.903	rs12764024	chr10:922861	A/G	cg26597838	chr10:835615	NA	0.82	8.91	0.48	8.55e-17	Eosinophil percentage of granulocytes;
CESC	cis	rs8177253	0.763	rs12769	chr3:133474328	G/A	cg01448562	chr3:133502909	NA	-0.47	-6.26	-0.36	1.59e-9	Iron status biomarkers;
CESC	cis	rs17345786	1.000	rs7641261	chr3:101279006	C/T	cg12386194	chr3:101231763	SENP7	0.58	6.54	0.37	3.24e-10	Colonoscopy-negative controls vs population controls;
CESC	trans	rs10435719	0.902	rs6601633	chr8:11805173	C/T	cg15556689	chr8:8085844	FLJ10661	-0.53	-6.68	-0.38	1.38e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
CESC	cis	rs2440129	0.611	rs11571335	chr17:6904263	C/T	cg25987502	chr17:6899865	ALOX12	0.45	7.4	0.41	1.86e-12	Tonsillectomy;
CESC	trans	rs1003719	0.715	rs762139	chr21:38568475	A/T	cg05556477	chr5:131705319	SLC22A5	-0.43	-6.09	-0.35	3.98e-9	Eye color traits;
CESC	cis	rs225245	0.765	rs226428	chr17:34049950	C/T	cg05299278	chr17:33885742	SLFN14	-0.37	-5.2	-0.3	3.91e-7	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
CESC	trans	rs2727020	0.521	rs937430	chr11:49542457	A/G	cg15704280	chr7:45808275	SEPT13	0.85	10.76	0.55	1.2e-22	Coronary artery disease;
CESC	cis	rs262150	0.851	rs2527224	chr7:158769198	G/A	cg19418458	chr7:158789849	NA	-0.49	-7.9	-0.44	7.61e-14	Facial morphology (factor 20);
CESC	cis	rs9660180	0.839	rs12040826	chr1:1705287	A/C	cg05132306	chr1:1846340	CALML6	-0.32	-6.73	-0.38	1.03e-10	Body mass index;
CESC	cis	rs2742234	0.910	rs2505505	chr10:43648221	G/T	cg07801480	chr10:43725741	RASGEF1A	0.39	5.65	0.33	4.23e-8	Hirschsprung disease;
CESC	cis	rs6424115	1.000	rs974698	chr1:24132785	C/T	cg15997130	chr1:24165203	NA	0.44	6.22	0.36	1.89e-9	Immature fraction of reticulocytes;
CESC	cis	rs4689592	0.622	rs2276968	chr4:7070118	T/G	cg06697600	chr4:7070879	GRPEL1	-0.59	-8.07	-0.44	2.46e-14	Monocyte percentage of white cells;
CESC	cis	rs1790761	0.587	rs4930430	chr11:67294198	A/G	cg14500267	chr11:67383377	NA	0.31	5.19	0.3	4.09e-7	Mean corpuscular volume;
CESC	cis	rs7659604	0.592	rs56077950	chr4:122721412	C/T	cg19748678	chr4:122722346	EXOSC9	0.76	9.57	0.51	7.84e-19	Type 2 diabetes;
CESC	cis	rs7945705	0.902	rs2012696	chr11:8995818	A/C	cg12365402	chr11:9010492	NRIP3	0.41	6.48	0.37	4.48e-10	Hemoglobin concentration;
CESC	cis	rs11864453	0.713	rs9926156	chr16:72142895	G/C	cg16558253	chr16:72132732	DHX38	-0.55	-8.69	-0.47	3.9e-16	Fibrinogen levels;
CESC	cis	rs2228479	0.557	rs34420680	chr16:89809171	C/T	cg00800038	chr16:89945340	TCF25	-0.9	-7.34	-0.41	2.63e-12	Skin colour saturation;
CESC	cis	rs7666738	0.791	rs7678564	chr4:99057341	A/G	cg03467027	chr4:99064603	C4orf37	0.47	5.9	0.34	1.09e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs34638657	0.872	rs2911423	chr16:82188801	C/T	cg09439754	chr16:82129088	HSD17B2	-0.35	-5.22	-0.31	3.56e-7	Lung adenocarcinoma;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg00910521	chr17:75484950	SEPT9	0.46	6.14	0.35	2.99e-9	Fibrinogen levels;
CESC	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg06601766	chr17:61851465	DDX42;CCDC47	-0.54	-6.77	-0.38	8.1e-11	Prudent dietary pattern;
CESC	cis	rs10876993	0.890	rs774891	chr12:58068571	G/A	cg18357645	chr12:58087776	OS9	0.64	10.4	0.54	1.84e-21	Celiac disease or Rheumatoid arthritis;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg10733145	chr11:60673895	PRPF19	-0.41	-6.13	-0.35	3.09e-9	Gambling;
CESC	cis	rs7918232	0.662	rs10764662	chr10:27300643	T/A	cg14240646	chr10:27532245	ACBD5	-0.49	-5.26	-0.31	2.91e-7	Breast cancer;
CESC	cis	rs4268898	0.662	rs72793967	chr2:24422902	C/T	cg20701182	chr2:24300061	SF3B14	0.68	7.2	0.4	6.23e-12	Asthma;
CESC	cis	rs8062405	0.755	rs17640009	chr16:28595700	A/G	cg07382826	chr16:28625726	SULT1A1	0.4	6.52	0.37	3.55e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs79839061	0.610	rs11733713	chr4:869169	A/G	cg07828340	chr4:882639	GAK	1.07	8.24	0.45	7.96e-15	Intelligence (multi-trait analysis);
CESC	cis	rs2075371	0.897	rs1643102	chr7:133999983	T/A	cg00033643	chr7:134001901	SLC35B4	0.44	5.59	0.32	5.6e-8	Mean platelet volume;
CESC	cis	rs6933660	0.646	rs3816778	chr6:151773353	G/C	cg17179660	chr6:151773299	C6orf211;RMND1	-0.42	-5.47	-0.32	1.05e-7	Menarche (age at onset);
CESC	cis	rs4835473	0.868	rs4350958	chr4:144665809	A/G	cg25736465	chr4:144833511	NA	0.42	6.09	0.35	3.98e-9	Immature fraction of reticulocytes;
CESC	cis	rs769267	0.965	rs2074550	chr19:19387743	A/C	cg03709012	chr19:19516395	GATAD2A	0.96	13.95	0.65	1.59e-33	Tonsillectomy;
CESC	cis	rs7772486	0.790	rs1062068	chr6:146207465	A/G	cg23711669	chr6:146136114	FBXO30	0.94	13.72	0.64	9.92e-33	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6831352	0.918	rs13112733	chr4:100050319	A/T	cg12011299	chr4:100065546	ADH4	-0.59	-6.52	-0.37	3.62e-10	Alcohol dependence;
CESC	cis	rs8067354	0.574	rs1292033	chr17:57990597	A/T	cg02344993	chr17:57696989	CLTC	0.52	5.45	0.32	1.15e-7	Hemoglobin concentration;
CESC	cis	rs2425143	1.000	rs6060639	chr20:34438183	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.66	5.72	0.33	2.88e-8	Blood protein levels;
CESC	cis	rs568617	1.000	rs694994	chr11:65653309	A/G	cg04055107	chr11:65626734	MUS81;CFL1	0.66	6.97	0.39	2.5e-11	Crohn's disease;
CESC	cis	rs1707322	0.964	rs796773	chr1:46564475	C/T	cg03146154	chr1:46216737	IPP	-0.69	-9.13	-0.49	1.84e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7945705	0.846	rs2742540	chr11:8899528	A/G	cg12365402	chr11:9010492	NRIP3	0.33	5.15	0.3	5.08e-7	Hemoglobin concentration;
CESC	cis	rs7666738	0.830	rs4619898	chr4:98959646	G/A	cg03467027	chr4:99064603	C4orf37	0.44	5.56	0.32	6.75e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4974559	0.947	rs28711287	chr4:1346682	G/C	cg02980000	chr4:1222292	CTBP1	0.7	6.44	0.37	5.66e-10	Systolic blood pressure;
CESC	cis	rs225245	0.782	rs225272	chr17:33969911	T/C	cg05299278	chr17:33885742	SLFN14	0.38	5.48	0.32	1e-7	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
CESC	cis	rs561341	1.000	rs8077092	chr17:30281992	T/C	cg00745463	chr17:30367425	LRRC37B	-0.7	-7.02	-0.4	1.9e-11	Hip circumference adjusted for BMI;
CESC	cis	rs514406	0.858	rs574853	chr1:53310959	A/T	cg16325326	chr1:53192061	ZYG11B	0.81	12.79	0.62	1.76e-29	Monocyte count;
CESC	cis	rs950776	0.518	rs28438420	chr15:78836288	A/T	cg24631222	chr15:78858424	CHRNA5	0.4	5.4	0.31	1.51e-7	Sudden cardiac arrest;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg03981592	chr3:86061698	CADM2	0.46	6.54	0.37	3.08e-10	Fibrinogen levels;
CESC	cis	rs35110281	0.592	rs6417729	chr21:44967202	A/C	cg04455712	chr21:45112962	RRP1B	0.34	5.08	0.3	7.2e-7	Mean corpuscular volume;
CESC	cis	rs3820068	0.559	rs6675334	chr1:15923580	A/T	cg16988262	chr1:15930761	NA	0.34	5.46	0.32	1.12e-7	Systolic blood pressure;
CESC	cis	rs9611565	0.921	rs2281332	chr22:41746212	T/C	cg03806693	chr22:41940476	POLR3H	-0.71	-8.5	-0.46	1.39e-15	Vitiligo;
CESC	cis	rs929354	0.772	rs1182365	chr7:157017255	A/T	cg05182265	chr7:156933206	UBE3C	0.5	7.32	0.41	2.97e-12	Body mass index;
CESC	cis	rs11997175	0.583	rs12680755	chr8:33815282	G/A	ch.8.33884649F	chr8:33765107	NA	0.45	5.69	0.33	3.31e-8	Body mass index;
CESC	cis	rs7727544	0.735	rs4705933	chr5:131678412	G/A	cg24060327	chr5:131705240	SLC22A5	-0.67	-9.0	-0.48	4.57e-17	Blood metabolite levels;
CESC	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg11494091	chr17:61959527	GH2	0.72	12.33	0.6	6.37e-28	Prudent dietary pattern;
CESC	cis	rs2836974	0.897	rs1571709	chr21:40553980	T/C	cg11890956	chr21:40555474	PSMG1	1.21	24.48	0.83	5.49e-70	Cognitive function;
CESC	trans	rs4843747	0.708	rs11866437	chr16:88072279	A/G	cg26811252	chr16:29126840	RRN3P2	-0.6	-8.5	-0.46	1.37e-15	Menopause (age at onset);
CESC	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg18402987	chr7:1209562	NA	0.76	7.79	0.43	1.5e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs12545109	0.700	rs2670045	chr8:57393695	A/G	cg09654669	chr8:57350985	NA	-0.57	-7.31	-0.41	3.08e-12	Obesity-related traits;
CESC	trans	rs1814175	0.647	rs10839394	chr11:49844747	T/C	cg03929089	chr4:120376271	NA	-0.92	-15.46	-0.69	6.97e-39	Height;
CESC	cis	rs9899728	0.520	rs12936866	chr17:73052050	A/G	cg27626185	chr17:73056755	KCTD2	-0.95	-8.43	-0.46	2.23e-15	Alzheimer's disease or small vessel stroke;
CESC	trans	rs1814175	0.817	rs11040474	chr11:49708441	G/A	cg15704280	chr7:45808275	SEPT13	-1.02	-19.23	-0.76	3.56e-52	Height;
CESC	cis	rs4665809	0.590	rs1560865	chr2:26452197	C/A	cg26119090	chr2:26468346	HADHA;HADHB	-1.06	-12.34	-0.6	5.85e-28	Gut microbiome composition (summer);
CESC	cis	rs2404602	0.530	rs12915184	chr15:76965922	G/A	cg00316803	chr15:76480434	C15orf27	0.44	5.94	0.34	8.86e-9	Blood metabolite levels;
CESC	cis	rs12477438	1.000	rs17760953	chr2:99859863	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.63	-7.71	-0.43	2.5e-13	Chronic sinus infection;
CESC	cis	rs72781680	1.000	rs963725	chr2:24148231	T/C	cg20701182	chr2:24300061	SF3B14	0.78	6.73	0.38	1.07e-10	Lymphocyte counts;
CESC	cis	rs5758659	0.594	rs739292	chr22:42368857	G/A	cg04733989	chr22:42467013	NAGA	0.44	5.82	0.34	1.72e-8	Cognitive function;
CESC	cis	rs2228479	0.850	rs17233664	chr16:89810628	C/T	cg19635926	chr16:89946313	TCF25	0.66	5.04	0.3	8.52e-7	Skin colour saturation;
CESC	cis	rs7666738	0.830	rs6848404	chr4:98946750	A/G	cg03467027	chr4:99064603	C4orf37	0.46	5.82	0.34	1.74e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9611565	0.659	rs12483998	chr22:41935362	A/G	cg17376030	chr22:41985996	PMM1	0.75	8.07	0.44	2.45e-14	Vitiligo;
CESC	cis	rs8050907	0.590	rs1362627	chr16:4551505	C/G	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.8	5.41	0.32	1.44e-7	Obesity-related traits;
CESC	cis	rs28489187	0.617	rs233118	chr1:85787967	C/T	cg16011679	chr1:85725395	C1orf52	-0.47	-5.79	-0.33	2.03e-8	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	cis	rs780096	0.546	rs7563162	chr2:27631191	C/T	cg24768116	chr2:27665128	KRTCAP3	-0.28	-5.22	-0.31	3.6e-7	Total body bone mineral density;
CESC	cis	rs6662572	0.686	rs72690855	chr1:46266210	G/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.46	5.04	0.3	8.63e-7	Blood protein levels;
CESC	cis	rs1799949	0.501	rs2343819	chr17:41409653	T/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	8.6	0.47	6.99e-16	Menopause (age at onset);
CESC	cis	rs561341	0.714	rs474455	chr17:30312465	A/T	cg12193833	chr17:30244370	NA	-0.58	-5.88	-0.34	1.21e-8	Hip circumference adjusted for BMI;
CESC	cis	rs1881797	1.000	rs66845073	chr1:247688010	C/T	cg05639522	chr1:247681581	NA	0.46	6.02	0.35	5.84e-9	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs11711311	1.000	rs4362695	chr3:113534856	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.56	7.46	0.42	1.25e-12	IgG glycosylation;
CESC	cis	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg05883489	chr16:57334690	NA	-0.39	-5.66	-0.33	3.85e-8	Gambling;
CESC	trans	rs7829975	0.774	rs11775523	chr8:8679176	A/G	cg21775007	chr8:11205619	TDH	0.41	6.04	0.35	5.3e-9	Mood instability;
CESC	cis	rs7208859	0.623	rs56095789	chr17:29060170	A/G	cg13385521	chr17:29058706	SUZ12P	0.81	6.53	0.37	3.28e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs4268898	0.862	rs11125549	chr2:24576240	C/T	cg20701182	chr2:24300061	SF3B14	-0.46	-5.55	-0.32	6.95e-8	Asthma;
CESC	cis	rs10540	1.000	rs61876342	chr11:496193	T/G	cg21784768	chr11:537496	LRRC56	-0.54	-5.1	-0.3	6.36e-7	Body mass index;
CESC	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg02353165	chr6:42928485	GNMT	0.86	13.71	0.64	1.03e-32	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs73206853	0.841	rs9783428	chr12:111068096	C/T	cg12870014	chr12:110450643	ANKRD13A	0.62	5.14	0.3	5.45e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs447	0.943	rs10808306	chr7:83767093	G/A	cg22846510	chr7:83753280	SEMA3A	-0.47	-5.74	-0.33	2.53e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs7267979	0.866	rs2424698	chr20:25256106	C/T	cg08601574	chr20:25228251	PYGB	0.4	5.71	0.33	3.01e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7267979	0.903	rs6050481	chr20:25224580	C/T	cg08601574	chr20:25228251	PYGB	0.44	6.36	0.36	8.57e-10	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs17376456	0.877	rs28418572	chr5:93144161	A/C	cg25358565	chr5:93447407	FAM172A	1.09	10.74	0.55	1.41e-22	Diabetic retinopathy;
CESC	cis	rs5753618	0.509	rs5749229	chr22:31587218	T/C	cg13145458	chr22:31556086	RNF185	0.49	5.52	0.32	7.94e-8	Colorectal cancer;
CESC	trans	rs801193	1.000	rs2055682	chr7:66260289	A/G	cg26939375	chr7:64535504	NA	0.61	7.96	0.44	4.99e-14	Aortic root size;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg09129563	chr1:179198950	ABL2	-0.52	-6.38	-0.36	8.05e-10	Ulcerative colitis;
CESC	cis	rs881375	0.669	rs73541868	chr9:123639264	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.49	7.17	0.4	7.35e-12	Rheumatoid arthritis;
CESC	cis	rs2070488	0.804	rs13092164	chr3:38458533	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.81	13.01	0.62	2.92e-30	Electrocardiographic conduction measures;
CESC	cis	rs1005224	0.864	rs11625011	chr14:76144828	G/A	cg25116370	chr14:76127843	TTLL5;C14orf1	-0.41	-5.65	-0.33	4.13e-8	Large artery stroke;
CESC	cis	rs12410462	0.581	rs12402691	chr1:227543693	G/A	cg10327440	chr1:227177885	CDC42BPA	-0.68	-5.72	-0.33	2.8e-8	Major depressive disorder;
CESC	cis	rs1580019	0.961	rs4357201	chr7:32496333	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.73	10.15	0.53	1.14e-20	Cognitive ability;
CESC	cis	rs561341	0.883	rs1034626	chr17:30219500	C/G	cg13647721	chr17:30228624	UTP6	-0.65	-6.26	-0.36	1.57e-9	Hip circumference adjusted for BMI;
CESC	cis	rs1691799	0.899	rs4762091	chr12:66747863	A/G	cg16791601	chr12:66731901	HELB	-0.79	-14.26	-0.66	1.23e-34	White blood cell count (basophil);
CESC	cis	rs2243480	1.000	rs58062456	chr7:65394852	G/T	cg18252515	chr7:66147081	NA	-1.0	-9.22	-0.49	9.27e-18	Diabetic kidney disease;
CESC	cis	rs2072732	0.706	rs112690788	chr1:2954055	A/G	cg03976712	chr1:2946727	NA	0.34	5.63	0.33	4.57e-8	Plateletcrit;
CESC	cis	rs3540	0.512	rs17263706	chr15:91078803	G/T	cg10434728	chr15:90938212	IQGAP1	0.38	6.48	0.37	4.35e-10	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	trans	rs9534288	0.797	rs2404729	chr13:46617368	C/T	cg11225435	chr1:211849015	NEK2	0.46	6.04	0.35	5.27e-9	Blood protein levels;
CESC	cis	rs7296418	0.961	rs10773921	chr12:123541606	C/T	cg05973401	chr12:123451056	ABCB9	0.58	7.67	0.43	3.25e-13	Platelet count;
CESC	cis	rs929354	1.000	rs8101	chr7:157061474	A/G	cg05182265	chr7:156933206	UBE3C	0.42	5.77	0.33	2.25e-8	Body mass index;
CESC	cis	rs637571	0.522	rs28578718	chr11:65748400	C/A	cg02202077	chr11:65769826	EIF1AD;BANF1	0.45	5.99	0.35	6.79e-9	Eosinophil percentage of white cells;
CESC	cis	rs2075371	0.933	rs1901214	chr7:133945108	C/T	cg11752832	chr7:134001865	SLC35B4	-0.52	-6.66	-0.38	1.57e-10	Mean platelet volume;
CESC	cis	rs34172651	0.517	rs2303084	chr16:24834581	G/C	cg00339695	chr16:24857497	SLC5A11	0.52	6.26	0.36	1.5e-9	Intelligence (multi-trait analysis);
CESC	cis	rs2730245	0.527	rs2657362	chr7:158685095	A/G	cg24397884	chr7:158709396	WDR60	0.85	8.84	0.48	1.41e-16	Height;
CESC	cis	rs7524258	0.868	rs6693725	chr1:7307810	G/T	cg07173049	chr1:7289937	CAMTA1	0.39	6.21	0.36	2.05e-9	Tourette's syndrome or obsessive-compulsive disorder;
CESC	cis	rs9399135	0.935	rs949547	chr6:135343499	C/G	cg22676075	chr6:135203613	NA	0.51	7.36	0.41	2.34e-12	Red blood cell count;
CESC	cis	rs4819052	0.851	rs2877020	chr21:46658742	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.46	5.79	0.34	2e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs712039	0.652	rs1616371	chr17:35773799	A/G	cg16670864	chr17:35848621	DUSP14	0.42	5.31	0.31	2.32e-7	Tuberculosis;
CESC	trans	rs208515	0.525	rs12204706	chr6:66669930	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.87	-11.26	-0.57	2.77e-24	Exhaled nitric oxide levels;
CESC	cis	rs2204008	0.640	rs11520199	chr12:38211026	T/C	cg26384229	chr12:38710491	ALG10B	0.74	10.7	0.55	1.96e-22	Bladder cancer;
CESC	cis	rs790123	1.000	rs2650950	chr3:122382048	C/T	cg17380795	chr3:122379686	NA	0.35	5.19	0.3	4.17e-7	Response to angiotensin II receptor blocker therapy;
CESC	cis	rs17347800	1.000	rs17347800	chr7:18517279	A/G	cg12093519	chr7:19146441	NA	0.64	5.31	0.31	2.34e-7	Stroke;
CESC	cis	rs9911578	0.967	rs2611781	chr17:56703124	C/G	cg05425664	chr17:57184151	TRIM37	-0.5	-7.06	-0.4	1.44e-11	Intelligence (multi-trait analysis);
CESC	cis	rs6546550	0.935	rs13017134	chr2:70090579	C/G	cg02498382	chr2:70120550	SNRNP27	-0.35	-6.07	-0.35	4.29e-9	Prevalent atrial fibrillation;
CESC	cis	rs7520050	0.966	rs61102033	chr1:46382441	G/T	cg24296786	chr1:45957014	TESK2	0.43	5.43	0.32	1.25e-7	Red blood cell count;Reticulocyte count;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg17805752	chr15:40675029	C15orf23	-0.49	-6.22	-0.36	1.88e-9	Ulcerative colitis;
CESC	cis	rs1707322	1.000	rs3922886	chr1:46473902	A/T	cg06784218	chr1:46089804	CCDC17	0.34	5.75	0.33	2.49e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2404602	0.583	rs2176623	chr15:76568579	C/T	cg05617483	chr15:76483344	C15orf27	0.43	5.97	0.34	7.67e-9	Blood metabolite levels;
CESC	cis	rs73110464	0.609	rs11170348	chr12:53355588	A/G	cg05393297	chr12:53359155	NA	-0.71	-10.18	-0.53	9.24e-21	Cancer (pleiotropy);
CESC	cis	rs7851660	0.679	rs7033765	chr9:100591705	A/T	cg13688889	chr9:100608707	NA	0.57	8.86	0.48	1.2e-16	Strep throat;
CESC	cis	rs765787	0.505	rs1648302	chr15:45494238	A/G	cg24006582	chr15:45444508	DUOX1	-0.53	-6.66	-0.38	1.56e-10	Uric acid levels;
CESC	cis	rs933688	0.938	rs7708782	chr5:90718517	T/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.1	12.44	0.61	2.82e-28	Smoking behavior;
CESC	cis	rs9611565	0.579	rs73178621	chr22:41921665	A/G	cg06481639	chr22:41940642	POLR3H	-0.65	-6.66	-0.38	1.54e-10	Vitiligo;
CESC	trans	rs7246657	0.943	rs10405407	chr19:37839164	C/T	cg24637308	chr11:6592297	DNHD1	0.53	6.17	0.35	2.55e-9	Coronary artery calcification;
CESC	cis	rs10242455	0.702	rs73711280	chr7:99039604	C/T	cg18809830	chr7:99032528	PTCD1	-0.63	-5.13	-0.3	5.68e-7	Blood metabolite levels;
CESC	cis	rs6951245	1.000	rs11764748	chr7:1094508	T/C	cg03188948	chr7:1209495	NA	0.57	5.52	0.32	7.89e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs79057730	0.639	rs6463933	chr7:793954	G/A	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.66	5.82	0.34	1.73e-8	Initial pursuit acceleration;
CESC	cis	rs2075371	1.000	rs2598292	chr7:133988584	C/G	cg11752832	chr7:134001865	SLC35B4	0.55	7.23	0.41	5.27e-12	Mean platelet volume;
CESC	cis	rs67311347	1.000	rs7633809	chr3:40517737	A/G	cg01475735	chr3:40494733	NA	0.42	5.24	0.31	3.33e-7	Renal cell carcinoma;
CESC	cis	rs4699052	0.599	rs11938459	chr4:104233989	T/C	cg16532752	chr4:104119610	CENPE	-0.37	-5.23	-0.31	3.45e-7	Testicular germ cell tumor;
CESC	cis	rs1882538	0.538	rs9649587	chr7:133104569	A/C	cg10665199	chr7:133106180	EXOC4	0.6	8.33	0.46	4.47e-15	Intelligence (multi-trait analysis);
CESC	cis	rs7618915	0.501	rs3733041	chr3:52731598	T/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.76	0.38	8.98e-11	Bipolar disorder;
CESC	cis	rs18122	0.846	rs6743811	chr2:67620157	C/A	cg09028215	chr2:67624308	ETAA1	-0.43	-5.41	-0.32	1.39e-7	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs7589342	0.791	rs4438504	chr2:106461035	A/C	cg16077055	chr2:106428750	NCK2	0.51	7.19	0.4	6.6e-12	Addiction;
CESC	cis	rs9908102	0.710	rs8072647	chr17:12914516	T/C	cg26162695	chr17:12921313	ELAC2	0.51	5.47	0.32	1.03e-7	Schizophrenia;
CESC	cis	rs2276314	0.857	rs28435069	chr18:33628475	A/G	cg05985134	chr18:33552581	C18orf21	0.63	7.59	0.42	5.58e-13	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs933688	1.000	rs35712350	chr5:90679519	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.02	14.19	0.66	2.26e-34	Smoking behavior;
CESC	cis	rs6460942	0.908	rs73301032	chr7:12256799	C/G	cg06484146	chr7:12443880	VWDE	-0.55	-5.68	-0.33	3.58e-8	Coronary artery disease;
CESC	cis	rs7100689	0.622	rs1890890	chr10:82090643	A/T	cg00277334	chr10:82204260	NA	-0.6	-7.88	-0.44	8.54e-14	Post bronchodilator FEV1;
CESC	cis	rs7927771	1.000	rs2290850	chr11:47807774	T/C	cg18512352	chr11:47633146	NA	-0.61	-9.7	-0.51	3.18e-19	Subjective well-being;
CESC	cis	rs875971	0.660	rs2013222	chr7:66035936	C/G	cg14393609	chr7:65229607	NA	-0.44	-5.82	-0.34	1.67e-8	Aortic root size;
CESC	cis	rs2439831	0.850	rs28696802	chr15:44140395	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.67	7.46	0.42	1.21e-12	Lung cancer in ever smokers;
CESC	cis	rs896854	0.517	rs10112447	chr8:95955701	C/T	cg13393036	chr8:95962371	TP53INP1	-0.45	-8.26	-0.45	6.81e-15	Type 2 diabetes;
CESC	cis	rs4853012	0.838	rs58759652	chr2:74344902	A/T	cg01017244	chr2:74357527	NA	0.67	9.66	0.51	4.19e-19	Gestational age at birth (maternal effect);
CESC	cis	rs7666738	0.830	rs11947578	chr4:98930462	T/G	cg17366294	chr4:99064904	C4orf37	0.6	8.22	0.45	9.04e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs780096	0.546	rs2911712	chr2:27626945	A/T	cg21248554	chr2:27665150	KRTCAP3	-0.34	-7.05	-0.4	1.54e-11	Total body bone mineral density;
CESC	cis	rs7223966	0.961	rs35844156	chr17:61837568	G/A	cg11494091	chr17:61959527	GH2	0.4	5.3	0.31	2.42e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs9733	0.596	rs1336898	chr1:150665050	G/A	cg17724175	chr1:150552817	MCL1	0.44	7.23	0.41	5.25e-12	Tonsillectomy;
CESC	cis	rs875971	1.000	rs1183245	chr7:65541185	C/T	cg11764359	chr7:65958608	NA	-0.95	-14.12	-0.66	3.94e-34	Aortic root size;
CESC	cis	rs4820539	1.000	rs5759595	chr22:23471624	G/A	cg14186256	chr22:23484241	RTDR1	0.83	15.0	0.68	3.09e-37	Bone mineral density;
CESC	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg18402987	chr7:1209562	NA	0.44	5.74	0.33	2.56e-8	Longevity;Endometriosis;
CESC	cis	rs8103278	0.507	rs8112282	chr19:46265029	C/T	cg12641515	chr19:46296257	DMWD	0.74	9.95	0.52	5e-20	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01908177	chr3:113005203	BOC	-0.52	-6.16	-0.35	2.67e-9	Gut microbiome composition (summer);
CESC	cis	rs9818941	0.824	rs2712318	chr3:157776053	C/T	cg08654915	chr3:157813417	NA	-0.49	-7.64	-0.43	3.87e-13	Height;
CESC	cis	rs4919087	0.926	rs7072078	chr10:99026509	G/A	cg25902810	chr10:99078978	FRAT1	0.67	9.75	0.51	2.23e-19	Monocyte count;
CESC	cis	rs2204008	0.905	rs8189449	chr12:38437377	C/A	cg26384229	chr12:38710491	ALG10B	0.64	9.46	0.5	1.69e-18	Bladder cancer;
CESC	cis	rs4253772	0.530	rs9627387	chr22:46684678	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.78	9.5	0.5	1.27e-18	LDL cholesterol;Cholesterol, total;
CESC	trans	rs11098499	0.754	rs12507565	chr4:120251121	G/A	cg25214090	chr10:38739885	LOC399744	0.62	8.7	0.47	3.58e-16	Corneal astigmatism;
CESC	cis	rs60871478	1.000	rs62432251	chr7:801855	T/G	cg05535760	chr7:792225	HEATR2	0.92	10.51	0.54	7.81e-22	Cerebrospinal P-tau181p levels;
CESC	cis	rs2404602	0.692	rs35395069	chr15:76986334	C/T	cg26408565	chr15:76604113	ETFA	-0.39	-5.56	-0.32	6.68e-8	Blood metabolite levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15162335	chr12:21654546	RECQL;GOLT1B	0.63	6.82	0.39	5.98e-11	Gut microbiome composition (summer);
CESC	cis	rs7618915	0.501	rs34157897	chr3:52716937	T/C	cg07507251	chr3:52567010	NT5DC2	0.32	5.61	0.33	5.12e-8	Bipolar disorder;
CESC	cis	rs9640161	0.789	rs11767409	chr7:150058043	C/T	cg10018233	chr7:150070692	REPIN1	0.39	5.59	0.32	5.7e-8	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs9837602	0.507	rs793453	chr3:99529095	A/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.58	-8.91	-0.48	8.26e-17	Breast cancer;
CESC	cis	rs7618915	0.547	rs13085895	chr3:52678270	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.48	6.9	0.39	3.79e-11	Bipolar disorder;
CESC	cis	rs7666738	0.791	rs10013680	chr4:99023030	G/C	cg17366294	chr4:99064904	C4orf37	0.55	7.57	0.42	6.3e-13	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7223966	1.000	rs11079511	chr17:61858537	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.45	-5.19	-0.3	4.24e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs875971	0.660	rs1860468	chr7:66107252	T/C	cg18876405	chr7:65276391	NA	-0.46	-6.23	-0.36	1.86e-9	Aortic root size;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg06666157	chr19:4791552	FEM1A	0.52	6.87	0.39	4.68e-11	Systemic lupus erythematosus;
CESC	cis	rs61990749	0.597	rs1008988	chr14:78260795	A/G	cg23188588	chr14:78226832	SNW1;C14orf178	0.5	5.17	0.3	4.53e-7	Fibroblast growth factor basic levels;
CESC	trans	rs17685	0.712	rs1637049	chr7:75729975	C/G	cg19862616	chr7:65841803	NCRNA00174	0.86	12.59	0.61	8.1e-29	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs1005277	0.579	rs2474588	chr10:38420870	A/G	cg25427524	chr10:38739819	LOC399744	-0.67	-9.71	-0.51	2.79e-19	Extrinsic epigenetic age acceleration;
CESC	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg06873352	chr17:61820015	STRADA	0.73	13.12	0.63	1.2e-30	Prudent dietary pattern;
CESC	cis	rs9611565	0.765	rs132920	chr22:41810170	T/C	cg17376030	chr22:41985996	PMM1	-0.59	-6.24	-0.36	1.69e-9	Vitiligo;
CESC	cis	rs748404	0.631	rs11070399	chr15:43646347	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.55	8.54	0.46	1.07e-15	Lung cancer;
CESC	cis	rs7618915	0.571	rs2289249	chr3:52597664	G/A	cg07507251	chr3:52567010	NT5DC2	0.43	7.33	0.41	2.73e-12	Bipolar disorder;
CESC	cis	rs11249608	0.548	rs2047354	chr5:178455247	T/C	cg21905437	chr5:178450457	ZNF879	0.6	8.74	0.47	2.75e-16	Pubertal anthropometrics;
CESC	cis	rs12618769	0.597	rs3754880	chr2:99132215	G/C	cg10123293	chr2:99228465	UNC50	0.41	5.44	0.32	1.24e-7	Bipolar disorder;
CESC	cis	rs9549367	0.865	rs3861721	chr13:113906308	C/T	cg18105134	chr13:113819100	PROZ	-0.68	-8.25	-0.45	7.53e-15	Platelet distribution width;
CESC	cis	rs8020095	0.571	rs723432	chr14:67379015	A/C	cg19548862	chr14:67692701	FAM71D	-0.49	-6.07	-0.35	4.46e-9	Depression (quantitative trait);
CESC	cis	rs10504229	0.639	rs72650811	chr8:58115661	G/A	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs1348850	0.872	rs2084233	chr2:178331206	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.89	12.83	0.62	1.21e-29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs2836950	0.565	rs2836945	chr21:40596757	C/T	cg17971929	chr21:40555470	PSMG1	-0.53	-6.8	-0.39	6.76e-11	Menarche (age at onset);
CESC	cis	rs796364	0.774	rs112564437	chr2:201074048	G/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.47	-5.15	-0.3	5.04e-7	Schizophrenia;
CESC	cis	rs6088580	0.505	rs6141503	chr20:33274469	G/A	cg24642439	chr20:33292090	TP53INP2	-0.46	-5.48	-0.32	9.84e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs2011503	1.000	rs77427798	chr19:19652982	T/C	cg11584989	chr19:19387371	SF4	0.58	6.63	0.38	1.87e-10	Bipolar disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17999743	chr8:38239693	WHSC1L1	0.54	6.13	0.35	3.22e-9	Gut microbiome composition (summer);
CESC	cis	rs6500395	0.926	rs1120275	chr16:48598737	T/G	cg04672837	chr16:48644449	N4BP1	0.46	5.54	0.32	7.22e-8	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs1570884	0.516	rs7330830	chr13:50167929	T/A	cg03651054	chr13:50194643	NA	0.31	5.11	0.3	6.14e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
CESC	cis	rs1215050	0.791	rs1605259	chr4:98799732	T/C	cg05340658	chr4:99064831	C4orf37	0.52	6.88	0.39	4.36e-11	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs2625529	0.590	rs8023703	chr15:72504059	G/A	cg16672083	chr15:72433130	SENP8	0.43	6.03	0.35	5.59e-9	Red blood cell count;
CESC	cis	rs7085104	0.632	rs7097872	chr10:104606636	C/T	cg04362960	chr10:104952993	NT5C2	0.5	6.63	0.38	1.83e-10	Immature fraction of reticulocytes;Schizophrenia;
CESC	cis	rs1957429	0.808	rs11158564	chr14:65335082	G/A	cg23373153	chr14:65346875	NA	0.89	9.19	0.49	1.19e-17	Pediatric areal bone mineral density (radius);
CESC	cis	rs2857078	0.772	rs2079008	chr17:42322132	C/A	cg13607699	chr17:42295918	UBTF	-0.76	-10.48	-0.54	1.03e-21	Red cell distribution width;Reticulocyte count;
CESC	cis	rs2425143	1.000	rs8115150	chr20:34397189	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.79	-7.2	-0.4	6.33e-12	Blood protein levels;
CESC	cis	rs1215050	0.755	rs2952911	chr4:98850666	T/C	cg05340658	chr4:99064831	C4orf37	-0.5	-6.59	-0.38	2.32e-10	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs5750830	0.645	rs4821890	chr22:39777523	G/A	cg11247378	chr22:39784982	NA	-0.5	-7.85	-0.43	1.02e-13	Intelligence (multi-trait analysis);
CESC	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg17178900	chr1:205818956	PM20D1	0.8	13.21	0.63	5.93e-31	Menarche (age at onset);
CESC	cis	rs4665809	1.000	rs4665816	chr2:26305094	G/C	cg04944784	chr2:26401820	FAM59B	-0.63	-7.23	-0.41	5.06e-12	Gut microbiome composition (summer);
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg12836313	chr7:156733574	NA	0.44	6.05	0.35	5.04e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7246657	0.943	rs10424574	chr19:37838393	A/G	cg23950597	chr19:37808831	NA	-0.62	-6.3	-0.36	1.26e-9	Coronary artery calcification;
CESC	cis	rs7762018	0.891	rs3749882	chr6:170151766	C/T	cg05834625	chr6:170176447	C6orf70	0.65	7.17	0.4	7.57e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04184623	chr2:217277352	SMARCAL1	0.57	6.97	0.39	2.47e-11	Gut microbiome composition (summer);
CESC	cis	rs6502050	0.761	rs62078754	chr17:80058666	C/T	cg11859384	chr17:80120422	CCDC57	0.39	5.09	0.3	6.86e-7	Life satisfaction;
CESC	cis	rs9457247	1.000	rs2149091	chr6:167372786	C/T	cg25258033	chr6:167368657	RNASET2	-0.41	-6.2	-0.36	2.17e-9	Crohn's disease;
CESC	cis	rs1799949	0.894	rs8176160	chr17:41241503	T/C	cg25072359	chr17:41440525	NA	0.44	6.07	0.35	4.52e-9	Menopause (age at onset);
CESC	cis	rs9362426	0.708	rs9342112	chr6:88092491	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.52	6.31	0.36	1.14e-9	Depressive episodes in bipolar disorder;
CESC	cis	rs7267979	1.000	rs2297497	chr20:25297909	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.89	-17.92	-0.74	1.36e-47	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs9322193	0.962	rs4869731	chr6:150131208	T/C	cg07701084	chr6:150067640	NUP43	0.43	5.8	0.34	1.88e-8	Lung cancer;
CESC	cis	rs2120019	1.000	rs7175720	chr15:75348962	C/G	cg09165964	chr15:75287851	SCAMP5	0.73	8.62	0.47	6.29e-16	Blood trace element (Zn levels);
CESC	cis	rs798554	0.660	rs1182196	chr7:2866478	T/G	cg13628971	chr7:2884303	GNA12	0.4	5.16	0.3	4.91e-7	Height;
CESC	cis	rs7618915	0.501	rs13079063	chr3:52744460	A/G	cg07507251	chr3:52567010	NT5DC2	0.32	5.58	0.32	5.82e-8	Bipolar disorder;
CESC	cis	rs2576037	0.583	rs8096263	chr18:44515216	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.37	5.99	0.35	6.86e-9	Personality dimensions;
CESC	trans	rs9354352	0.935	rs9345749	chr6:66699892	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.51	-6.35	-0.36	9.49e-10	Initial pursuit acceleration in psychotic disorders;
CESC	cis	rs1144713	0.743	rs2668273	chr12:32246494	T/C	cg01321189	chr12:32259338	BICD1	0.42	5.96	0.34	8.16e-9	Obesity-related traits;
CESC	cis	rs6952808	0.531	rs3800922	chr7:2184505	A/G	cg23048001	chr7:2026167	MAD1L1	0.44	5.54	0.32	7.24e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs2243480	1.000	rs59794892	chr7:65415873	G/A	cg18252515	chr7:66147081	NA	-1.04	-9.61	-0.51	6.15e-19	Diabetic kidney disease;
CESC	cis	rs7811142	1.000	rs67315960	chr7:100015124	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.16	11.7	0.58	8.86e-26	Platelet count;
CESC	cis	rs13191362	1.000	rs13202339	chr6:163081812	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.94	9.49	0.5	1.42e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20762182	chr15:69727293	KIF23	-0.68	-7.76	-0.43	1.83e-13	Gut microbiome composition (summer);
CESC	cis	rs35110281	0.744	rs230646	chr21:44918788	A/G	cg21573476	chr21:45109991	RRP1B	-0.38	-5.15	-0.3	5.18e-7	Mean corpuscular volume;
CESC	cis	rs858239	0.600	rs4321896	chr7:23128056	G/A	cg23682824	chr7:23144976	KLHL7	0.54	7.34	0.41	2.63e-12	Cerebrospinal fluid biomarker levels;
CESC	cis	rs477895	0.713	rs12575642	chr11:63979643	G/T	cg04317338	chr11:64019027	PLCB3	0.77	7.82	0.43	1.26e-13	Mean platelet volume;
CESC	cis	rs1267303	0.798	rs1267302	chr1:46990545	G/C	cg25110126	chr1:46999211	NA	-0.78	-9.2	-0.49	1.09e-17	Monobrow;
CESC	cis	rs60843830	1.000	rs62114505	chr2:242426	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.89	11.99	0.59	9.15e-27	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs8177253	0.761	rs35332919	chr3:133519002	T/A	cg24879335	chr3:133465180	TF	0.31	5.13	0.3	5.62e-7	Iron status biomarkers;
CESC	cis	rs7772486	0.686	rs1292336	chr6:145967818	T/C	cg23711669	chr6:146136114	FBXO30	-0.89	-13.32	-0.63	2.51e-31	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7552404	0.727	rs4949677	chr1:76266662	T/A	cg10523679	chr1:76189770	ACADM	0.67	6.74	0.38	9.82e-11	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs2000999	0.514	rs12928056	chr16:72225574	C/A	cg04254540	chr16:71951199	KIAA0174	-0.7	-5.91	-0.34	1.03e-8	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
CESC	trans	rs2530545	0.851	rs2609234	chr7:34688425	G/A	cg14080982	chr15:71736038	THSD4	-0.49	-6.01	-0.35	6.25e-9	IgG glycosylation;
CESC	cis	rs6545883	0.965	rs766447	chr2:61735569	C/T	cg15711740	chr2:61764176	XPO1	-0.42	-5.29	-0.31	2.58e-7	Tuberculosis;
CESC	cis	rs12478296	1.000	rs4973685	chr2:243019089	A/C	cg06360820	chr2:242988706	NA	-0.89	-9.19	-0.49	1.16e-17	Obesity-related traits;
CESC	cis	rs7666738	0.830	rs7696686	chr4:98938445	T/C	cg03467027	chr4:99064603	C4orf37	0.48	5.91	0.34	1.03e-8	Colonoscopy-negative controls vs population controls;
CESC	trans	rs4596713	0.538	rs10781440	chr9:71762766	A/G	cg16512924	chr15:28394682	HERC2	-0.5	-6.32	-0.36	1.11e-9	Headache;
CESC	cis	rs17253792	0.822	rs76201070	chr14:56063604	A/C	cg01858014	chr14:56050164	KTN1	-0.87	-6.75	-0.38	9.11e-11	Putamen volume;
CESC	cis	rs698833	0.886	rs2053454	chr2:44550290	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.58	7.2	0.4	6.12e-12	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs6840258	1.000	rs72667753	chr4:87941012	C/T	cg08197287	chr4:87952173	AFF1	-0.41	-5.52	-0.32	8.12e-8	Mean corpuscular volume;Basophil percentage of granulocytes;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg07545636	chr2:10262820	RRM2	-0.45	-6.22	-0.36	1.97e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs2228479	0.850	rs11641552	chr16:89838700	C/A	cg06558623	chr16:89946397	TCF25	1.17	9.29	0.5	5.84e-18	Skin colour saturation;
CESC	cis	rs1218582	0.772	rs7528532	chr1:154874440	C/T	cg09359103	chr1:154839909	KCNN3	-0.65	-12.33	-0.6	6.58e-28	Prostate cancer;
CESC	cis	rs801193	0.967	rs2707841	chr7:66157020	A/G	cg18876405	chr7:65276391	NA	0.53	7.06	0.4	1.42e-11	Aortic root size;
CESC	cis	rs9611519	0.929	rs9611474	chr22:41434858	G/A	cg03806693	chr22:41940476	POLR3H	-0.57	-5.92	-0.34	1.01e-8	Neuroticism;
CESC	cis	rs7927771	0.542	rs11039336	chr11:47706141	A/G	cg20307385	chr11:47447363	PSMC3	-0.57	-7.85	-0.43	1.02e-13	Subjective well-being;
CESC	cis	rs2380220	0.808	rs72922390	chr6:95934317	G/A	cg15832292	chr6:96025679	MANEA	-0.64	-5.71	-0.33	2.99e-8	Behavioural disinhibition (generation interaction);
CESC	cis	rs9649213	0.593	rs12704989	chr7:98029438	G/T	cg21770322	chr7:97807741	LMTK2	0.56	8.63	0.47	5.86e-16	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs929354	0.742	rs2051877	chr7:157008813	A/T	cg05182265	chr7:156933206	UBE3C	-0.5	-7.29	-0.41	3.54e-12	Body mass index;
CESC	cis	rs7089973	0.604	rs2181563	chr10:116604344	T/C	cg23260525	chr10:116636907	FAM160B1	0.41	7.99	0.44	4.06e-14	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs3785574	0.962	rs2727280	chr17:61918082	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.57	6.75	0.38	9.14e-11	Height;
CESC	cis	rs4481887	1.000	rs7513161	chr1:248453422	A/T	cg00666640	chr1:248458726	OR2T12	0.39	6.51	0.37	3.71e-10	Common traits (Other);
CESC	cis	rs652260	0.663	rs580984	chr19:7881030	C/T	cg26014689	chr19:7917955	EVI5L	-0.4	-5.57	-0.32	6.33e-8	Menarche (age at onset);
CESC	cis	rs909674	0.731	rs6001594	chr22:39837472	C/T	cg24399712	chr22:39784796	NA	-0.83	-10.9	-0.56	4.11e-23	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs7618915	0.571	rs12487445	chr3:52618319	A/C	cg18099408	chr3:52552593	STAB1	-0.34	-5.54	-0.32	7.37e-8	Bipolar disorder;
CESC	cis	rs4563143	0.675	rs73029042	chr19:29267979	A/T	cg14983838	chr19:29218262	NA	0.5	6.16	0.35	2.67e-9	Methadone dose in opioid dependence;
CESC	cis	rs1552244	0.515	rs67342818	chr3:10166406	G/A	cg00149659	chr3:10157352	C3orf10	1.01	12.53	0.61	1.33e-28	Alzheimer's disease;
CESC	cis	rs7100689	0.577	rs1143694	chr10:82040052	C/T	cg09936400	chr10:82049201	MAT1A	-0.41	-6.19	-0.36	2.33e-9	Post bronchodilator FEV1;
CESC	trans	rs561341	0.941	rs4795664	chr17:30233467	C/T	cg20587970	chr11:113659929	NA	-1.09	-13.14	-0.63	1.04e-30	Hip circumference adjusted for BMI;
CESC	cis	rs1862618	0.573	rs1550821	chr5:56242323	C/T	cg24549020	chr5:56110836	MAP3K1	-0.58	-6.28	-0.36	1.37e-9	Initial pursuit acceleration;
CESC	cis	rs514406	0.525	rs269291	chr1:53189297	C/T	cg16325326	chr1:53192061	ZYG11B	0.97	16.59	0.71	7.31e-43	Monocyte count;
CESC	cis	rs7903847	0.642	rs7909345	chr10:99150794	T/C	cg20016023	chr10:99160130	RRP12	-0.3	-5.1	-0.3	6.33e-7	Granulocyte percentage of myeloid white cells;
CESC	cis	rs7772486	0.754	rs697053	chr6:145989807	T/C	cg23711669	chr6:146136114	FBXO30	-1.0	-15.53	-0.69	4.13e-39	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6570726	0.905	rs1355146	chr6:145781741	A/C	cg05347473	chr6:146136440	FBXO30	-0.41	-5.49	-0.32	9.46e-8	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6570726	0.935	rs399169	chr6:145836353	C/A	cg23711669	chr6:146136114	FBXO30	0.8	12.02	0.59	7.3e-27	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2228479	0.850	rs17226973	chr16:89825248	T/C	cg06558623	chr16:89946397	TCF25	1.17	9.38	0.5	3.19e-18	Skin colour saturation;
CESC	cis	rs7552404	0.731	rs1770887	chr1:76401812	A/G	cg22875332	chr1:76189707	ACADM	-0.55	-6.07	-0.35	4.37e-9	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs2425143	1.000	rs17093027	chr20:34319118	A/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.6	5.31	0.31	2.37e-7	Blood protein levels;
CESC	cis	rs3780486	0.505	rs10217267	chr9:33146528	T/C	cg13443165	chr9:33130375	B4GALT1	0.48	7.33	0.41	2.74e-12	IgG glycosylation;
CESC	cis	rs2760061	0.583	rs708123	chr1:228220495	A/G	cg02753203	chr1:228287806	NA	0.83	12.88	0.62	8.61e-30	Diastolic blood pressure;
CESC	cis	rs6460942	0.915	rs6945067	chr7:12444731	A/C	cg17427002	chr7:12443146	VWDE	-0.56	-5.85	-0.34	1.42e-8	Coronary artery disease;
CESC	cis	rs896854	0.517	rs10112447	chr8:95955701	C/T	cg16049864	chr8:95962084	TP53INP1	-0.53	-7.69	-0.43	2.86e-13	Type 2 diabetes;
CESC	cis	rs763014	0.931	rs7192508	chr16:630367	C/T	cg07343612	chr16:622815	PIGQ	-0.58	-8.47	-0.46	1.72e-15	Height;
CESC	cis	rs897984	0.683	rs8050330	chr16:30824970	C/T	cg00531865	chr16:30841666	NA	-0.54	-7.66	-0.43	3.46e-13	Dementia with Lewy bodies;
CESC	trans	rs7618501	1.000	rs11709680	chr3:49745188	C/T	cg21659725	chr3:3221576	CRBN	-0.82	-13.56	-0.64	3.55e-32	Intelligence (multi-trait analysis);
CESC	cis	rs6121246	0.559	rs6060621	chr20:30261562	G/C	cg13852791	chr20:30311386	BCL2L1	0.82	10.64	0.55	3.02e-22	Mean corpuscular hemoglobin;
CESC	cis	rs7666738	0.712	rs34043080	chr4:99008748	G/C	cg17366294	chr4:99064904	C4orf37	0.59	8.43	0.46	2.2e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1048238	0.506	rs10737911	chr1:16167855	C/T	cg21385522	chr1:16154831	NA	-0.46	-6.09	-0.35	3.91e-9	Systolic blood pressure;
CESC	trans	rs61931739	0.517	rs1843738	chr12:34056935	C/T	cg26384229	chr12:38710491	ALG10B	0.6	8.36	0.46	3.68e-15	Morning vs. evening chronotype;
CESC	cis	rs7666738	0.680	rs11726233	chr4:99079773	G/A	cg05340658	chr4:99064831	C4orf37	0.75	10.87	0.56	5.36e-23	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2262909	1.000	rs2359821	chr19:22208314	C/T	cg11619707	chr19:22235551	ZNF257	-0.35	-5.7	-0.33	3.19e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
CESC	cis	rs67460515	0.892	rs35310734	chr3:160943209	T/G	cg03342759	chr3:160939853	NMD3	-0.53	-7.56	-0.42	6.54e-13	Parkinson's disease;
CESC	cis	rs55788414	0.505	rs7190949	chr16:81189583	C/T	cg06400318	chr16:81190750	PKD1L2	0.47	6.56	0.37	2.8e-10	Left ventricular obstructive tract defect (maternal effect);
CESC	cis	rs10088262	0.629	rs7015861	chr8:124795613	C/T	cg02993010	chr8:124780839	FAM91A1	-0.67	-8.48	-0.46	1.56e-15	Pancreatic cancer;
CESC	trans	rs877282	1.000	rs71494928	chr10:769134	A/G	cg22713356	chr15:30763199	NA	1.22	12.0	0.59	8.77e-27	Uric acid levels;
CESC	cis	rs7520050	0.931	rs11211213	chr1:46342517	G/A	cg03146154	chr1:46216737	IPP	-0.48	-6.22	-0.36	1.98e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs2404602	0.536	rs1587381	chr15:76769620	G/A	cg26408565	chr15:76604113	ETFA	-0.43	-6.4	-0.37	7.01e-10	Blood metabolite levels;
CESC	cis	rs34779708	0.966	rs10827487	chr10:35406878	T/A	cg04310649	chr10:35416472	CREM	-0.55	-6.77	-0.38	8.07e-11	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg03188948	chr7:1209495	NA	0.71	7.06	0.4	1.5e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs875971	0.545	rs10261710	chr7:65714189	T/A	cg11764359	chr7:65958608	NA	0.75	8.29	0.45	5.68e-15	Aortic root size;
CESC	cis	rs17345786	0.817	rs11720560	chr3:101328484	C/T	cg12386194	chr3:101231763	SENP7	0.57	6.55	0.37	3e-10	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg03452623	chr4:187889614	NA	-0.88	-15.91	-0.7	1.82e-40	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs3771570	1.000	rs56363214	chr2:242227157	A/G	cg21155796	chr2:242212141	HDLBP	0.62	5.18	0.3	4.34e-7	Prostate cancer;
CESC	cis	rs881375	0.678	rs10739581	chr9:123696871	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.45	6.47	0.37	4.63e-10	Rheumatoid arthritis;
CESC	cis	rs6460942	1.000	rs79659770	chr7:12326371	T/C	cg02935154	chr7:12443704	VWDE	-0.6	-5.95	-0.34	8.36e-9	Coronary artery disease;
CESC	cis	rs3820068	0.603	rs998032	chr1:15989918	T/C	cg18133145	chr1:16060689	PLEKHM2	-0.39	-5.05	-0.3	8.06e-7	Systolic blood pressure;
CESC	cis	rs7613875	0.580	rs6808044	chr3:50136165	A/G	cg24308560	chr3:49941425	MST1R	0.57	7.87	0.44	9.02e-14	Body mass index;
CESC	trans	rs9929218	0.954	rs12599393	chr16:68829021	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.61	-7.99	-0.44	4.18e-14	Colorectal cancer;
CESC	cis	rs12477438	0.559	rs6733285	chr2:99725575	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.8	12.74	0.62	2.5e-29	Chronic sinus infection;
CESC	cis	rs714031	1.000	rs714031	chr22:40070234	C/T	cg21377881	chr22:40064566	CACNA1I	0.33	5.46	0.32	1.09e-7	Schizophrenia;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg11970458	chr16:31213481	PYCARD	-0.45	-6.49	-0.37	4.16e-10	Gambling;
CESC	cis	rs911555	0.511	rs2296483	chr14:104029792	G/A	cg12935359	chr14:103987150	CKB	-0.46	-6.81	-0.39	6.46e-11	Intelligence (multi-trait analysis);
CESC	cis	rs6499255	0.951	rs12232410	chr16:69736851	G/A	cg15192750	chr16:69999425	NA	0.47	5.74	0.33	2.62e-8	IgE levels;
CESC	cis	rs2011503	1.000	rs7256028	chr19:19628240	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.53	5.45	0.32	1.15e-7	Bipolar disorder;
CESC	cis	rs2836974	0.931	rs2836972	chr21:40652142	G/A	cg27266027	chr21:40555129	PSMG1	0.45	5.34	0.31	2.05e-7	Cognitive function;
CESC	cis	rs11718455	0.960	rs13081767	chr3:44004468	T/C	cg08738300	chr3:44038990	NA	0.46	6.07	0.35	4.34e-9	Coronary artery disease;
CESC	cis	rs9388451	0.626	rs1343116	chr6:126069702	C/A	cg05901451	chr6:126070800	HEY2	-0.61	-9.27	-0.49	6.65e-18	Brugada syndrome;
CESC	cis	rs10779751	1.000	rs4845859	chr1:11304873	A/G	cg08854313	chr1:11322531	MTOR	0.8	10.83	0.55	6.99e-23	Body mass index;
CESC	cis	rs875971	0.862	rs801206	chr7:66021966	C/G	cg18876405	chr7:65276391	NA	-0.53	-7.22	-0.41	5.6e-12	Aortic root size;
CESC	cis	rs7296418	0.961	rs1790122	chr12:123606739	G/A	cg05973401	chr12:123451056	ABCB9	0.55	7.08	0.4	1.29e-11	Platelet count;
CESC	cis	rs7208859	0.623	rs9898084	chr17:29082334	C/G	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.17e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs10832963	0.686	rs11024743	chr11:18653712	A/G	cg09201001	chr11:18656081	SPTY2D1	0.83	12.37	0.6	4.94e-28	Breast cancer;
CESC	cis	rs6964587	1.000	rs10245095	chr7:91710845	A/G	cg01689657	chr7:91764605	CYP51A1	0.28	5.08	0.3	7.2e-7	Breast cancer;
CESC	cis	rs4665809	0.652	rs4665832	chr2:26404775	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.06	-12.68	-0.61	3.95e-29	Gut microbiome composition (summer);
CESC	cis	rs2637266	0.703	rs11001861	chr10:78473552	A/C	cg18941641	chr10:78392320	NA	0.39	7.28	0.41	3.8e-12	Pulmonary function;
CESC	cis	rs4253772	0.744	rs4253760	chr22:46622384	T/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.51	5.55	0.32	7.01e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs7267979	1.000	rs2258135	chr20:25272323	C/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	18.62	0.75	4.72e-50	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs807669	0.557	rs712958	chr22:19167409	T/C	cg02655711	chr22:19163373	SLC25A1	0.77	11.28	0.57	2.36e-24	Metabolite levels;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg02081925	chr5:176931394	DOK3	0.48	6.81	0.39	6.34e-11	Fibrinogen levels;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg03872745	chr12:109125505	CORO1C	-0.39	-6.34	-0.36	9.92e-10	Gambling;
CESC	cis	rs3806843	1.000	rs6870764	chr5:140171790	C/T	cg26395211	chr5:140044315	WDR55	-0.41	-5.26	-0.31	2.97e-7	Depressive symptoms (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07934232	chr19:36619082	NA	0.61	6.9	0.39	3.91e-11	Gut microbiome composition (summer);
CESC	cis	rs4819052	0.851	rs2877019	chr21:46658647	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.91	13.22	0.63	5.56e-31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs875971	0.789	rs10260426	chr7:65736042	G/T	cg11764359	chr7:65958608	NA	-0.78	-11.64	-0.58	1.47e-25	Aortic root size;
CESC	cis	rs7824557	0.593	rs11774673	chr8:11191537	T/C	cg21775007	chr8:11205619	TDH	0.55	8.63	0.47	5.8e-16	Retinal vascular caliber;
CESC	cis	rs1256061	0.624	rs1152582	chr14:64692630	G/C	cg23250157	chr14:64679961	SYNE2	0.53	7.53	0.42	8.07e-13	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	trans	rs561341	1.000	rs501312	chr17:30329066	A/G	cg27661571	chr11:113659931	NA	-0.82	-7.6	-0.42	5.24e-13	Hip circumference adjusted for BMI;
CESC	cis	rs55883249	1.000	rs56372340	chr2:9741536	A/G	cg23886495	chr2:9695866	ADAM17	0.61	5.55	0.32	7.08e-8	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
CESC	cis	rs6582630	0.555	rs11504385	chr12:38285085	G/A	cg26384229	chr12:38710491	ALG10B	-0.45	-5.75	-0.33	2.43e-8	Drug-induced liver injury (flucloxacillin);
CESC	trans	rs12356475	0.710	rs10822686	chr10:67733250	C/T	cg23905817	chr15:57884033	GCOM1	0.52	6.37	0.36	8.32e-10	Psoriatic arthritis;
CESC	cis	rs2516839	0.652	rs2774276	chr1:161011716	G/C	cg11161846	chr1:160990452	F11R	-0.44	-6.06	-0.35	4.53e-9	Granulocyte percentage of myeloid white cells;
CESC	cis	rs1005277	0.505	rs10827836	chr10:38215441	A/G	cg00409905	chr10:38381863	ZNF37A	0.57	8.02	0.44	3.52e-14	Extrinsic epigenetic age acceleration;
CESC	cis	rs9900062	0.586	rs12600679	chr17:62687327	T/G	cg02097616	chr17:62675921	NA	0.46	5.63	0.33	4.56e-8	QT interval;
CESC	cis	rs9311474	0.581	rs4687626	chr3:52569098	G/A	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.3	5.34	0.31	2.02e-7	Electroencephalogram traits;
CESC	cis	rs9322193	0.884	rs11155689	chr6:150129606	T/C	cg04369109	chr6:150039330	LATS1	-0.41	-5.54	-0.32	7.2e-8	Lung cancer;
CESC	cis	rs8031584	0.706	rs2177670	chr15:31157751	G/T	cg14298792	chr15:30685198	CHRFAM7A	-0.46	-5.53	-0.32	7.81e-8	Huntington's disease progression;
CESC	cis	rs6460942	0.915	rs2216051	chr7:12304054	G/A	cg02935154	chr7:12443704	VWDE	-0.4	-5.54	-0.32	7.3e-8	Coronary artery disease;
CESC	cis	rs10492096	1.000	rs12427239	chr12:6590626	C/T	cg13857086	chr12:6580257	VAMP1	0.52	5.22	0.31	3.57e-7	Hip geometry;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24722749	chr1:24969476	SRRM1	0.53	6.01	0.35	6.19e-9	Gut microbiome composition (summer);
CESC	trans	rs61931739	0.534	rs11053021	chr12:34111157	C/T	cg26384229	chr12:38710491	ALG10B	0.6	8.45	0.46	1.98e-15	Morning vs. evening chronotype;
CESC	cis	rs4689592	0.523	rs6446565	chr4:7074027	A/G	cg06697600	chr4:7070879	GRPEL1	-0.47	-7.02	-0.4	1.84e-11	Monocyte percentage of white cells;
CESC	cis	rs66530629	0.874	rs6600274	chr1:25162444	T/G	cg22509179	chr1:25234806	RUNX3	-0.42	-5.58	-0.32	6.02e-8	Plateletcrit;
CESC	cis	rs7914558	0.966	rs10450373	chr10:104728616	T/C	cg08650961	chr10:104748594	CNNM2	0.31	5.06	0.3	7.7300000000000005e-07	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs10927875	0.632	rs4661666	chr1:16162471	C/A	cg18973939	chr1:16164122	FLJ37453	0.36	5.5	0.32	9e-8	Dilated cardiomyopathy;
CESC	cis	rs1506636	1.000	rs646753	chr7:123401237	G/T	cg03229431	chr7:123269106	ASB15	0.53	6.98	0.39	2.43e-11	Plateletcrit;Platelet count;
CESC	cis	rs992157	0.767	rs2014615	chr2:219171191	A/G	cg20019365	chr2:219134978	PNKD;AAMP	0.64	8.75	0.47	2.53e-16	Colorectal cancer;
CESC	cis	rs752010	0.714	rs10789403	chr1:42085869	G/A	cg06885757	chr1:42089581	HIVEP3	0.51	8.9	0.48	8.84e-17	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs12926788	0.546	rs200531	chr16:24756172	G/A	cg04756594	chr16:24857601	SLC5A11	-0.45	-5.52	-0.32	8.21e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	trans	rs7819412	0.549	rs28887839	chr8:11000413	C/T	cg06636001	chr8:8085503	FLJ10661	-0.5	-6.0	-0.35	6.55e-9	Triglycerides;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07223164	chr4:109571402	OSTC	-0.53	-6.48	-0.37	4.48e-10	Gut microbiome composition (summer);
CESC	cis	rs2732480	0.517	rs2634676	chr12:48738236	A/G	cg24011408	chr12:48396354	COL2A1	0.44	5.99	0.35	6.99e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs7833790	0.660	rs10091077	chr8:82705464	A/G	cg02079420	chr8:82753780	SNX16	0.52	7.74	0.43	2.04e-13	Diastolic blood pressure;
CESC	cis	rs10883723	0.962	rs10883726	chr10:104236276	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.54	7.34	0.41	2.67e-12	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs8133932	0.654	rs10854474	chr21:47332700	A/G	cg14185626	chr21:47401492	COL6A1	0.46	5.12	0.3	5.88e-7	Schizophrenia;
CESC	cis	rs17376456	1.000	rs9968749	chr5:93509559	A/G	cg21475434	chr5:93447410	FAM172A	0.86	7.71	0.43	2.49e-13	Diabetic retinopathy;
CESC	trans	rs2727020	0.553	rs10839295	chr11:49527345	A/C	cg15704280	chr7:45808275	SEPT13	-0.94	-16.06	-0.7	5.27e-41	Coronary artery disease;
CESC	cis	rs12134245	0.776	rs6688261	chr1:91987034	C/T	cg07090678	chr1:91966139	CDC7	0.39	5.61	0.33	5.02e-8	Breast cancer;
CESC	trans	rs11098499	0.909	rs28571712	chr4:120375980	G/A	cg25214090	chr10:38739885	LOC399744	0.71	9.96	0.52	4.62e-20	Corneal astigmatism;
CESC	cis	rs2288912	0.807	rs7251501	chr19:45455706	C/T	cg09555818	chr19:45449301	APOC2	0.41	6.54	0.37	3.08e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs7599312	0.532	rs16848751	chr2:213389346	A/G	cg20637307	chr2:213403960	ERBB4	0.4	5.51	0.32	8.68e-8	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs2227631	0.505	rs4729662	chr7:100765559	C/T	cg18465962	chr7:100767262	NA	0.49	7.22	0.41	5.67e-12	Plasminogen activator inhibitor type 1 levels (PAI-1);
CESC	cis	rs7618915	0.501	rs2109634	chr3:52752075	T/G	cg07507251	chr3:52567010	NT5DC2	0.35	5.94	0.34	8.88e-9	Bipolar disorder;
CESC	cis	rs763121	0.853	rs5757187	chr22:39021522	A/G	cg14440974	chr22:39074834	NA	0.39	5.29	0.31	2.53e-7	Menopause (age at onset);
CESC	cis	rs8180040	0.701	rs7625067	chr3:47095305	T/C	cg27129171	chr3:47204927	SETD2	0.7	10.49	0.54	9.21e-22	Colorectal cancer;
CESC	cis	rs1577917	1.000	rs12199516	chr6:86726221	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-6.24	-0.36	1.74e-9	Response to antipsychotic treatment;
CESC	cis	rs651907	0.557	rs3094297	chr3:101399260	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	6.99	0.39	2.25e-11	Colorectal cancer;
CESC	cis	rs7666738	0.791	rs13128640	chr4:99003918	A/C	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.62e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs72781680	0.611	rs72783619	chr2:24311607	G/A	cg06627628	chr2:24431161	ITSN2	-0.67	-6.48	-0.37	4.54e-10	Lymphocyte counts;
CESC	cis	rs7605378	0.528	rs281780	chr2:200756331	G/C	cg12253985	chr2:200820533	C2orf60;C2orf47	0.48	5.3	0.31	2.39e-7	Osteoporosis;
CESC	cis	rs3213545	0.700	rs2260445	chr12:121468863	C/A	cg15155738	chr12:121454335	C12orf43	0.5	6.13	0.35	3.13e-9	Subjective well-being;Cardiovascular disease risk factors;
CESC	cis	rs12220238	1.000	rs10824103	chr10:75949415	A/T	cg19889307	chr10:75911429	ADK;AP3M1	0.6	5.06	0.3	7.92e-7	Soluble interleukin-2 receptor subunit alpha;
CESC	cis	rs514406	0.565	rs897732	chr1:53382816	A/C	cg06600287	chr1:53387719	ECHDC2	-0.31	-5.74	-0.33	2.64e-8	Monocyte count;
CESC	cis	rs2980439	0.818	rs2945249	chr8:8094726	G/A	cg15556689	chr8:8085844	FLJ10661	0.66	8.26	0.45	6.9e-15	Neuroticism;
CESC	trans	rs35110281	0.774	rs1003280	chr21:44997322	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.49	6.55	0.37	2.95e-10	Mean corpuscular volume;
CESC	cis	rs769267	0.930	rs892022	chr19:19613381	G/A	cg03709012	chr19:19516395	GATAD2A	1.02	15.58	0.69	2.79e-39	Tonsillectomy;
CESC	cis	rs7666738	0.830	rs17486413	chr4:99060544	G/T	cg18180107	chr4:99064573	C4orf37	0.42	5.23	0.31	3.42e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7811142	0.830	rs6965458	chr7:99973402	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.07	10.49	0.54	9.53e-22	Platelet count;
CESC	cis	rs8077889	1.000	rs4793035	chr17:41887753	C/T	cg26893861	chr17:41843967	DUSP3	0.84	9.77	0.51	1.89e-19	Triglycerides;
CESC	cis	rs7666738	0.830	rs6851253	chr4:99029980	A/G	cg03467027	chr4:99064603	C4orf37	0.49	6.18	0.35	2.44e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11785400	0.928	rs750529	chr8:143744877	G/C	cg24634471	chr8:143751801	JRK	0.47	6.25	0.36	1.61e-9	Schizophrenia;
CESC	trans	rs2727020	0.514	rs4980444	chr11:49550764	T/A	cg15704280	chr7:45808275	SEPT13	-0.94	-16.08	-0.7	4.42e-41	Coronary artery disease;
CESC	cis	rs478304	0.654	rs11227260	chr11:65461158	G/T	cg27068330	chr11:65405492	SIPA1	-0.46	-5.38	-0.31	1.63e-7	Acne (severe);
CESC	cis	rs2742234	0.554	rs1270015	chr10:43698240	G/T	cg07801480	chr10:43725741	RASGEF1A	-0.42	-5.34	-0.31	2.05e-7	Hirschsprung disease;
CESC	cis	rs6685188	0.920	rs6676110	chr1:205662977	G/A	cg26354017	chr1:205819088	PM20D1	-0.4	-5.2	-0.3	4.07e-7	White blood cell count (basophil);Basophil percentage of white cells;
CESC	cis	rs12188164	0.930	rs72717440	chr5:449701	A/T	cg26850624	chr5:429559	AHRR	-0.5	-6.67	-0.38	1.52e-10	Cystic fibrosis severity;
CESC	cis	rs17401966	0.931	rs2236678	chr1:10471789	A/T	cg15208524	chr1:10270712	KIF1B	0.41	5.12	0.3	5.94e-7	Hepatocellular carcinoma;
CESC	cis	rs9911578	1.000	rs12947785	chr17:57045160	A/C	cg05425664	chr17:57184151	TRIM37	-0.5	-6.96	-0.39	2.66e-11	Intelligence (multi-trait analysis);
CESC	cis	rs13108904	0.557	rs1250095	chr4:1239312	C/T	cg19318889	chr4:1322082	MAEA	-0.46	-6.04	-0.35	5.19e-9	Obesity-related traits;
CESC	cis	rs9549367	0.707	rs9549353	chr13:113843427	G/A	cg00898013	chr13:113819073	PROZ	-0.56	-7.55	-0.42	7.02e-13	Platelet distribution width;
CESC	cis	rs9611565	0.659	rs28623192	chr22:41940524	A/G	cg03806693	chr22:41940476	POLR3H	-1.24	-16.8	-0.72	1.25e-43	Vitiligo;
CESC	cis	rs367615	0.704	rs72802966	chr5:108846754	T/G	cg17395555	chr5:108820864	NA	0.61	10.98	0.56	2.33e-23	Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs561341	0.941	rs72825746	chr17:30364610	G/A	cg12193833	chr17:30244370	NA	-0.74	-6.71	-0.38	1.19e-10	Hip circumference adjusted for BMI;
CESC	cis	rs36051895	0.632	rs10815164	chr9:5131312	T/A	cg02405213	chr9:5042618	JAK2	-0.49	-5.86	-0.34	1.35e-8	Pediatric autoimmune diseases;
CESC	cis	rs8051149	0.793	rs12445334	chr16:87871213	G/A	cg01829163	chr16:87871160	SLC7A5	-0.47	-5.48	-0.32	1e-7	Blood metabolite levels;
CESC	cis	rs1005277	0.522	rs9417256	chr10:37976990	A/G	cg25427524	chr10:38739819	LOC399744	-0.66	-9.67	-0.51	3.87e-19	Extrinsic epigenetic age acceleration;
CESC	cis	rs2933343	0.729	rs1680781	chr3:128612830	C/A	cg25356066	chr3:128598488	ACAD9	0.63	8.61	0.47	6.83e-16	IgG glycosylation;
CESC	cis	rs2299587	0.554	rs11778309	chr8:17747433	T/C	cg08627089	chr8:17753878	FGL1	-0.41	-5.87	-0.34	1.33e-8	Economic and political preferences;
CESC	cis	rs9788682	0.706	rs924840	chr15:78731808	A/T	cg24631222	chr15:78858424	CHRNA5	0.64	7.58	0.42	5.73e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs7937682	0.847	rs500163	chr11:111462649	T/G	cg09085632	chr11:111637200	PPP2R1B	-0.9	-12.87	-0.62	9.33e-30	Primary sclerosing cholangitis;
CESC	cis	rs8133932	0.654	rs407651	chr21:47350587	C/T	cg14185626	chr21:47401492	COL6A1	-0.47	-5.34	-0.31	2.04e-7	Schizophrenia;
CESC	cis	rs10504229	1.000	rs73607875	chr8:58173522	T/C	cg14926445	chr8:58193284	C8orf71	-0.51	-5.47	-0.32	1.03e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs727505	0.721	rs17327715	chr7:124760611	G/C	cg23710748	chr7:124431027	NA	-0.37	-6.13	-0.35	3.2e-9	Lewy body disease;
CESC	cis	rs7666738	0.761	rs1456210	chr4:98645932	T/G	cg05340658	chr4:99064831	C4orf37	0.73	10.65	0.55	2.7e-22	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6088580	0.634	rs4142007	chr20:32990050	G/T	cg24642439	chr20:33292090	TP53INP2	-0.52	-6.9	-0.39	3.82e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs761746	0.882	rs5998032	chr22:31928890	T/G	cg25791279	chr22:32026902	PISD	-0.54	-6.15	-0.35	2.79e-9	Intelligence;
CESC	cis	rs1552244	1.000	rs9827740	chr3:10120531	T/C	cg08888203	chr3:10149979	C3orf24	0.55	7.2	0.4	6.16e-12	Alzheimer's disease;
CESC	cis	rs9303401	0.614	rs62084387	chr17:57148027	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.98	11.04	0.56	1.43e-23	Cognitive test performance;
CESC	cis	rs2439831	0.867	rs2251844	chr15:43836478	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.79	8.5	0.46	1.39e-15	Lung cancer in ever smokers;
CESC	cis	rs7666738	0.830	rs2865978	chr4:99017946	G/T	cg18180107	chr4:99064573	C4orf37	0.41	5.39	0.31	1.57e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2294693	0.898	rs6458195	chr6:40972498	A/T	cg14418226	chr6:40996092	UNC5CL	-0.47	-5.75	-0.33	2.42e-8	Gastric cancer;Non-cardia gastric cancer;
CESC	cis	rs11155671	0.530	rs7758020	chr6:150208111	T/C	cg09699651	chr6:150184138	LRP11	0.56	7.79	0.43	1.56e-13	Testicular germ cell tumor;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17748287	chr17:36762518	SRCIN1	0.64	7.2	0.4	6.14e-12	Gut microbiome composition (summer);
CESC	cis	rs854765	0.693	rs12936037	chr17:17777245	A/G	cg16928487	chr17:17741425	SREBF1	0.61	11.07	0.56	1.2e-23	Total body bone mineral density;
CESC	cis	rs7044106	0.762	rs10760110	chr9:123412563	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.65	-8.78	-0.47	2.08e-16	Hip circumference adjusted for BMI;
CESC	cis	rs7772486	0.686	rs9386131	chr6:146121608	G/A	cg23711669	chr6:146136114	FBXO30	0.87	13.02	0.62	2.64e-30	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs1285495	0.627	rs10912059	chr1:187354887	C/T	cg04407233	chr1:10042538	NMNAT1	0.49	6.19	0.36	2.29e-9	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
CESC	trans	rs1728785	1.000	rs1645923	chr16:68581051	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.61	7.49	0.42	1.04e-12	Ulcerative colitis;
CESC	cis	rs748404	0.697	rs554001	chr15:43551919	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.61	8.12	0.45	1.76e-14	Lung cancer;
CESC	cis	rs3617	0.559	rs11915546	chr3:52866845	A/C	cg11645453	chr3:52864694	ITIH4	-0.26	-5.18	-0.3	4.48e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
CESC	cis	rs959260	0.925	rs7207506	chr17:73409410	T/C	cg12999837	chr17:73267436	MIF4GD	-0.47	-5.48	-0.32	9.95e-8	Systemic lupus erythematosus;
CESC	cis	rs9303401	0.659	rs35797125	chr17:56736547	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.04	13.0	0.62	3.27e-30	Cognitive test performance;
CESC	cis	rs1801251	0.778	rs2250654	chr2:233752376	A/T	cg08000102	chr2:233561755	GIGYF2	-0.57	-7.79	-0.43	1.52e-13	Coronary artery disease;
CESC	cis	rs7937682	0.824	rs577044	chr11:111490420	G/T	cg22437258	chr11:111473054	SIK2	0.72	9.81	0.52	1.37e-19	Primary sclerosing cholangitis;
CESC	cis	rs7107174	1.000	rs2510055	chr11:77961912	C/T	cg02023728	chr11:77925099	USP35	0.51	6.76	0.38	8.54e-11	Testicular germ cell tumor;
CESC	cis	rs11405769	1	rs11405769	chr2:63658293	A/AT	cg17519650	chr2:63277830	OTX1	-0.47	-5.25	-0.31	3.09e-7	Childhood ear infection;
CESC	cis	rs10088262	0.629	rs12541177	chr8:124800273	G/T	cg20713898	chr8:124780851	FAM91A1	-0.67	-9.11	-0.49	2.02e-17	Pancreatic cancer;
CESC	cis	rs2228479	0.557	rs11648881	chr16:89862434	T/C	cg00800038	chr16:89945340	TCF25	-0.9	-7.39	-0.41	1.98e-12	Skin colour saturation;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg16189954	chr22:29138267	HSCB;CHEK2	-0.45	-6.02	-0.35	5.87e-9	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24368588	chr20:61903974	ARFGAP1	0.61	7.39	0.41	1.9e-12	Gut microbiome composition (summer);
CESC	cis	rs10504229	0.593	rs16921626	chr8:58040359	C/T	cg22535103	chr8:58192502	C8orf71	-0.67	-7.23	-0.41	5.31e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs6582630	0.519	rs11495724	chr12:38337507	T/C	cg13010199	chr12:38710504	ALG10B	0.47	5.92	0.34	1.01e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs2073300	0.609	rs6137914	chr20:23358364	C/T	cg12062639	chr20:23401060	NAPB	1.08	8.67	0.47	4.32e-16	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs13130787	0.567	rs1438382	chr4:94907750	A/C	cg11021082	chr4:95130006	SMARCAD1	-0.4	-5.64	-0.33	4.3e-8	Colorectal cancer;
CESC	cis	rs1348850	0.874	rs1348848	chr2:178358233	A/C	cg23306229	chr2:178417860	TTC30B	-0.65	-8.33	-0.46	4.51e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	13.67	0.64	1.44e-32	Prudent dietary pattern;
CESC	cis	rs7124681	0.584	rs1471712	chr11:47912150	G/A	cg18512352	chr11:47633146	NA	-0.4	-6.34	-0.36	9.97e-10	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
CESC	cis	rs66573146	0.572	rs66734745	chr4:6948765	T/C	cg26116260	chr4:7069785	GRPEL1	-0.79	-5.25	-0.31	3.06e-7	Granulocyte percentage of myeloid white cells;
CESC	cis	rs4803468	1.000	rs4674	chr19:41930396	A/G	cg08639244	chr19:41945921	ATP5SL	-0.42	-5.07	-0.3	7.34e-7	Height;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg04742505	chr7:72936528	BAZ1B	-0.43	-6.18	-0.35	2.36e-9	Gambling;
CESC	cis	rs748404	0.631	rs2467745	chr15:43722742	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	8.3	0.45	5.47e-15	Lung cancer;
CESC	cis	rs13191362	1.000	rs34138336	chr6:163144929	A/G	cg06582575	chr6:163149167	PACRG;PARK2	1.05	10.33	0.54	2.97e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs9287719	0.967	rs963831	chr2:10745184	T/C	cg02196655	chr2:10830764	NOL10	-0.38	-5.78	-0.33	2.05e-8	Prostate cancer;
CESC	cis	rs926938	0.618	rs6693491	chr1:115371061	A/G	cg12756093	chr1:115239321	AMPD1	-0.45	-6.12	-0.35	3.44e-9	Autism;
CESC	cis	rs7116495	0.609	rs73543643	chr11:71835596	C/T	cg07596299	chr11:71824057	C11orf51	0.79	5.03	0.3	9.07e-7	Severe influenza A (H1N1) infection;
CESC	trans	rs11098499	0.775	rs10029303	chr4:120286755	T/A	cg25214090	chr10:38739885	LOC399744	0.65	9.11	0.49	2.04e-17	Corneal astigmatism;
CESC	cis	rs16854884	0.632	rs4446205	chr3:143682607	A/G	cg06585982	chr3:143692056	C3orf58	0.48	5.92	0.34	1.01e-8	Economic and political preferences (feminism/equality);
CESC	cis	rs3820928	0.874	rs3769646	chr2:227896330	C/T	cg11843606	chr2:227700838	RHBDD1	-0.49	-6.47	-0.37	4.59e-10	Pulmonary function;
CESC	cis	rs12477438	0.798	rs7606635	chr2:99644782	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.64	-8.73	-0.47	2.94e-16	Chronic sinus infection;
CESC	cis	rs7647973	0.566	rs57630346	chr3:49086215	T/C	cg06212747	chr3:49208901	KLHDC8B	0.49	5.47	0.32	1.02e-7	Menarche (age at onset);
CESC	cis	rs55728055	0.661	rs58365021	chr22:32060838	G/C	cg01338084	chr22:32026380	PISD	1.26	8.36	0.46	3.6e-15	Age-related hearing impairment;
CESC	cis	rs736408	0.812	rs2270197	chr3:52824095	T/G	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.31	5.06	0.3	7.83e-7	Bipolar disorder;
CESC	cis	rs7904368	0.806	rs1130684	chr10:16859335	C/G	cg23933602	chr10:16859644	RSU1	0.74	7.53	0.42	8.2e-13	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
CESC	cis	rs10851478	0.872	rs35698479	chr15:49797119	A/G	cg08060515	chr15:49448048	GALK2;COPS2	0.42	5.19	0.3	4.12e-7	Oral cavity cancer;
CESC	cis	rs736408	0.509	rs1108842	chr3:52720080	A/C	cg18099408	chr3:52552593	STAB1	-0.34	-6.21	-0.36	2.06e-9	Bipolar disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	ch.16.692127F	chr16:22223399	EEF2K	-0.64	-7.66	-0.43	3.49e-13	Gut microbiome composition (summer);
CESC	cis	rs10979	0.965	rs7754452	chr6:143889028	G/A	cg25407410	chr6:143891975	LOC285740	-0.61	-9.14	-0.49	1.72e-17	Hypospadias;
CESC	cis	rs13385	0.769	rs4913072	chr5:139608353	T/C	cg26211634	chr5:139558579	C5orf32	0.47	5.16	0.3	4.78e-7	Atrial fibrillation;
CESC	cis	rs2658782	0.789	rs2658773	chr11:93126914	A/G	cg15737290	chr11:93063684	CCDC67	0.49	6.14	0.35	3.01e-9	Pulmonary function decline;
CESC	cis	rs8177253	1.000	rs8177247	chr3:133479499	T/G	cg12373951	chr3:133503437	NA	0.44	6.42	0.37	6.42e-10	Iron status biomarkers;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14373579	chr9:133455264	LOC100272217;FUBP3	0.58	6.65	0.38	1.64e-10	Gut microbiome composition (summer);
CESC	cis	rs4803468	0.935	rs13346603	chr19:41945837	T/A	cg09537434	chr19:41945824	ATP5SL	1.12	21.49	0.8	5.38e-60	Height;
CESC	cis	rs34172651	0.917	rs7202252	chr16:24741686	T/C	cg06028605	chr16:24865363	SLC5A11	-0.42	-6.3	-0.36	1.23e-9	Intelligence (multi-trait analysis);
CESC	cis	rs6063312	1.000	rs11699576	chr20:47349878	A/C	cg18078177	chr20:47281410	PREX1	0.58	5.71	0.33	3.07e-8	Tonometry;
CESC	cis	rs72781680	1.000	rs72781653	chr2:24215633	T/C	cg20701182	chr2:24300061	SF3B14	0.66	5.84	0.34	1.56e-8	Lymphocyte counts;
CESC	cis	rs4588572	0.601	rs6867673	chr5:77779125	A/G	cg11547950	chr5:77652471	NA	-0.48	-6.07	-0.35	4.39e-9	Triglycerides;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07549551	chr6:158487608	SYNJ2	-0.59	-6.76	-0.38	8.99e-11	Gut microbiome composition (summer);
CESC	cis	rs11098499	0.954	rs10006525	chr4:120408931	T/G	cg09160332	chr4:120329925	NA	-0.38	-5.06	-0.3	7.89e-7	Corneal astigmatism;
CESC	cis	rs6736093	0.966	rs11674883	chr2:112713069	C/T	cg12686935	chr2:112915763	FBLN7	0.43	5.44	0.32	1.2e-7	Coronary artery disease;
CESC	cis	rs36051895	0.594	rs10115464	chr9:5144268	C/T	cg02405213	chr9:5042618	JAK2	-0.51	-6.46	-0.37	5.04e-10	Pediatric autoimmune diseases;
CESC	trans	rs629535	0.814	rs652483	chr8:70055083	G/A	cg21567404	chr3:27674614	NA	0.91	10.65	0.55	2.9e-22	Dupuytren's disease;
CESC	cis	rs7998202	0.667	rs99126	chr13:113359336	C/G	cg02820901	chr13:113351484	ATP11A	-0.65	-5.73	-0.33	2.74e-8	Glycated hemoglobin levels;
CESC	cis	rs9300255	0.544	rs1716174	chr12:123660717	T/C	cg00376283	chr12:123451042	ABCB9	0.61	6.2	0.36	2.2e-9	Neutrophil percentage of white cells;
CESC	cis	rs1665050	0.842	rs1665049	chr15:59290652	G/A	cg05156742	chr15:59063176	FAM63B	-0.45	-5.2	-0.3	4.05e-7	Atopic dermatitis;
CESC	cis	rs9399137	0.507	rs11753673	chr6:135316476	T/C	cg24558204	chr6:135376177	HBS1L	0.72	10.08	0.53	1.92e-20	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	cis	rs66573146	0.831	rs1048009	chr4:6988677	G/A	cg00086871	chr4:6988644	TBC1D14	1.21	8.92	0.48	7.85e-17	Granulocyte percentage of myeloid white cells;
CESC	cis	rs11997175	0.574	rs4446694	chr8:33654978	A/G	ch.8.33884649F	chr8:33765107	NA	0.66	8.38	0.46	3.14e-15	Body mass index;
CESC	cis	rs9322193	0.926	rs2342860	chr6:150098777	T/C	cg07701084	chr6:150067640	NUP43	0.42	5.74	0.33	2.61e-8	Lung cancer;
CESC	cis	rs7917772	0.582	rs10748826	chr10:104354804	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.41	5.63	0.33	4.48e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs1152591	0.562	rs1262242	chr14:64653869	C/T	cg23250157	chr14:64679961	SYNE2	0.4	5.71	0.33	2.97e-8	Atrial fibrillation;
CESC	cis	rs1552244	1.000	rs9811771	chr3:10133949	A/G	cg00149659	chr3:10157352	C3orf10	0.71	8.56	0.47	9.48e-16	Alzheimer's disease;
CESC	cis	rs3858526	0.584	rs10769266	chr11:5858460	C/T	cg05234568	chr11:5960015	NA	-0.65	-8.75	-0.47	2.53e-16	DNA methylation (variation);
CESC	cis	rs6860806	0.507	rs273912	chr5:131661349	A/C	cg24060327	chr5:131705240	SLC22A5	0.74	10.22	0.53	6.96e-21	Breast cancer;
CESC	cis	rs6502050	0.761	rs12150321	chr17:80061558	T/C	cg11859384	chr17:80120422	CCDC57	0.38	5.1	0.3	6.51e-7	Life satisfaction;
CESC	cis	rs6088590	1.000	rs910870	chr20:33292893	T/C	cg24642439	chr20:33292090	TP53INP2	0.77	10.33	0.54	2.96e-21	Coronary artery disease;
CESC	cis	rs17209837	0.607	rs2109505	chr7:87079406	T/A	cg00919237	chr7:87102261	ABCB4	-0.53	-6.76	-0.38	8.95e-11	Gallbladder cancer;
CESC	trans	rs9929218	1.000	rs11865026	chr16:68774283	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.75	-9.86	-0.52	9.59e-20	Colorectal cancer;
CESC	cis	rs2228479	0.850	rs62056069	chr16:89912000	C/T	cg06558623	chr16:89946397	TCF25	1.12	8.22	0.45	9.28e-15	Skin colour saturation;
CESC	cis	rs13256369	1.000	rs10088439	chr8:8576699	T/G	cg18904891	chr8:8559673	CLDN23	0.66	7.63	0.42	4.23e-13	Obesity-related traits;
CESC	cis	rs2904967	0.636	rs514076	chr11:64990041	G/C	cg23743554	chr11:65321226	LTBP3	-0.42	-5.36	-0.31	1.79e-7	Mean corpuscular volume;
CESC	cis	rs3091242	0.933	rs35530120	chr1:25785451	A/G	cg12412775	chr1:25698385	RHCE	0.29	5.19	0.3	4.23e-7	Erythrocyte sedimentation rate;
CESC	trans	rs9354308	0.866	rs2814095	chr6:66535706	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.6	6.67	0.38	1.5e-10	Metabolite levels;
CESC	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg06873352	chr17:61820015	STRADA	0.72	12.76	0.62	2.21e-29	Prudent dietary pattern;
CESC	cis	rs3126085	0.877	rs7535536	chr1:152193544	A/G	cg26876637	chr1:152193138	HRNR	0.47	5.43	0.32	1.28e-7	Atopic dermatitis;
CESC	cis	rs858239	0.600	rs1115941	chr7:23137188	C/T	cg23682824	chr7:23144976	KLHL7	0.55	7.72	0.43	2.44e-13	Cerebrospinal fluid biomarker levels;
CESC	cis	rs2204008	0.683	rs12370288	chr12:38127740	G/A	cg26384229	chr12:38710491	ALG10B	0.74	10.55	0.54	5.91e-22	Bladder cancer;
CESC	cis	rs10504229	0.638	rs7826839	chr8:58132075	G/T	cg02725872	chr8:58115012	NA	-0.45	-7.05	-0.4	1.52e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs4561483	0.556	rs11570136	chr16:12058832	T/A	cg08843971	chr16:11963173	GSPT1	-0.43	-5.72	-0.33	2.87e-8	Testicular germ cell tumor;
CESC	cis	rs1862618	0.715	rs6866779	chr5:56090000	G/A	cg22800045	chr5:56110881	MAP3K1	0.85	10.2	0.53	8.13e-21	Initial pursuit acceleration;
CESC	cis	rs9733	0.744	rs12758227	chr1:150844583	C/A	cg13175981	chr1:150552382	MCL1	0.5	6.82	0.39	5.97e-11	Tonsillectomy;
CESC	cis	rs8020095	0.528	rs6573760	chr14:67677375	G/T	cg19548862	chr14:67692701	FAM71D	-0.47	-5.68	-0.33	3.48e-8	Depression (quantitative trait);
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg16196077	chr10:64028521	RTKN2	0.44	6.13	0.35	3.25e-9	Asthma;
CESC	cis	rs1003719	0.788	rs2835589	chr21:38463342	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.63	8.77	0.47	2.14e-16	Eye color traits;
CESC	cis	rs863345	0.565	rs10908671	chr1:158502160	G/A	cg12129480	chr1:158549410	OR10X1	-0.34	-6.84	-0.39	5.41e-11	Pneumococcal bacteremia;
CESC	cis	rs12136530	0.774	rs12140338	chr1:19766430	C/G	cg01832549	chr1:19774989	CAPZB	-0.47	-6.51	-0.37	3.82e-10	Lead levels in blood;
CESC	cis	rs9300255	0.770	rs28683528	chr12:123845351	C/T	cg00376283	chr12:123451042	ABCB9	-0.58	-6.75	-0.38	9.12e-11	Neutrophil percentage of white cells;
CESC	cis	rs1799949	0.965	rs4793234	chr17:41436183	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.4	5.55	0.32	6.85e-8	Menopause (age at onset);
CESC	cis	rs875971	0.862	rs6947339	chr7:65888470	T/C	cg18252515	chr7:66147081	NA	-0.46	-6.05	-0.35	5e-9	Aortic root size;
CESC	cis	rs116095464	0.558	rs10055354	chr5:243794	G/A	cg22857025	chr5:266934	NA	-1.27	-18.37	-0.75	3.49e-49	Breast cancer;
CESC	trans	rs61931739	0.500	rs11053282	chr12:34561151	T/C	cg13010199	chr12:38710504	ALG10B	0.51	6.58	0.37	2.47e-10	Morning vs. evening chronotype;
CESC	cis	rs10129255	0.957	rs10141009	chr14:107184934	A/G	cg07958169	chr14:107095056	NA	-0.42	-5.87	-0.34	1.28e-8	Kawasaki disease;
CESC	cis	rs9894429	1.000	rs7223613	chr17:79574803	C/T	cg18240062	chr17:79603768	NPLOC4	-0.72	-10.27	-0.53	4.71e-21	Eye color traits;
CESC	cis	rs17376456	0.877	rs13165147	chr5:93422214	G/A	cg21475434	chr5:93447410	FAM172A	0.83	7.47	0.42	1.17e-12	Diabetic retinopathy;
CESC	cis	rs10465746	0.780	rs12139191	chr1:84387871	A/C	cg10977910	chr1:84465055	TTLL7	0.5	6.8	0.39	6.77e-11	Obesity-related traits;
CESC	cis	rs9322193	0.962	rs9767122	chr6:150104689	T/G	cg07701084	chr6:150067640	NUP43	0.43	5.85	0.34	1.45e-8	Lung cancer;
CESC	cis	rs9649213	0.593	rs62478200	chr7:97980045	A/G	cg00277769	chr7:97922759	BAIAP2L1	-0.33	-5.41	-0.32	1.41e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs1568889	0.838	rs7952717	chr11:28261658	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.8	13.85	0.65	3.36e-33	Bipolar disorder;
CESC	cis	rs60843830	1.000	rs62114544	chr2:269679	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.88	11.83	0.59	3.33e-26	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs9815354	0.812	rs17215183	chr3:41812334	T/C	cg03022575	chr3:42003672	ULK4	0.7	6.14	0.35	2.98e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs9733	0.596	rs12403255	chr1:150660412	C/T	cg04414720	chr1:150670196	GOLPH3L	0.63	9.11	0.49	2.03e-17	Tonsillectomy;
CESC	cis	rs10479542	0.503	rs12719865	chr5:178993566	C/T	cg21226059	chr5:178986404	RUFY1	0.52	7.8	0.43	1.4e-13	Lung cancer;
CESC	trans	rs1973993	0.691	rs1980683	chr1:96890379	A/G	cg10631902	chr5:14652156	NA	0.59	8.95	0.48	6.56e-17	Weight;
CESC	cis	rs7208859	0.614	rs28758251	chr17:29223312	A/T	cg19761014	chr17:28927070	LRRC37B2	0.73	5.77	0.33	2.22e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs25645	0.830	rs4072639	chr17:38189049	G/A	cg17344932	chr17:38183730	MED24;SNORD124	0.61	8.67	0.47	4.48e-16	Myeloid white cell count;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg23286353	chr2:97523832	ANKRD39	-0.46	-6.1	-0.35	3.83e-9	Ulcerative colitis;
CESC	cis	rs12893668	0.581	rs34843146	chr14:104079864	G/A	cg08213375	chr14:104286397	PPP1R13B	0.33	5.16	0.3	4.79e-7	Reticulocyte count;
CESC	cis	rs2760061	0.569	rs621631	chr1:228114728	A/G	cg02753203	chr1:228287806	NA	-0.5	-7.24	-0.41	4.83e-12	Diastolic blood pressure;
CESC	cis	rs9309473	0.519	rs2421667	chr2:73832459	T/C	cg20560298	chr2:73613845	ALMS1	0.52	7.31	0.41	3.18e-12	Metabolite levels;
CESC	cis	rs12449964	0.524	rs897457	chr17:17572987	A/T	cg04398451	chr17:18023971	MYO15A	0.37	5.05	0.3	8.13e-7	Coronary artery disease or ischemic stroke;
CESC	cis	rs3749237	0.595	rs3870338	chr3:49557051	A/G	cg06212747	chr3:49208901	KLHDC8B	0.47	6.44	0.37	5.58e-10	Resting heart rate;
CESC	trans	rs12310956	0.532	rs7979535	chr12:33947450	A/C	cg26384229	chr12:38710491	ALG10B	-0.58	-8.08	-0.44	2.32e-14	Morning vs. evening chronotype;
CESC	cis	rs67311347	0.956	rs11714871	chr3:40428938	T/G	cg24209194	chr3:40518798	ZNF619	0.47	6.0	0.35	6.55e-9	Renal cell carcinoma;
CESC	trans	rs877282	0.853	rs11595510	chr10:756757	C/G	cg22713356	chr15:30763199	NA	0.91	8.68	0.47	4.21e-16	Uric acid levels;
CESC	trans	rs916888	0.821	rs70600	chr17:44860021	C/T	cg23590916	chr17:43697445	MGC57346	0.62	6.23	0.36	1.87e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs10504229	0.683	rs7459958	chr8:58111905	G/T	cg02725872	chr8:58115012	NA	-0.45	-7.04	-0.4	1.66e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs75804782	0.521	rs72993065	chr2:239409001	C/T	cg18131467	chr2:239335373	ASB1	-0.7	-5.49	-0.32	9.55e-8	Morning vs. evening chronotype;Chronotype;
CESC	cis	rs15676	0.947	rs2759009	chr9:131599008	C/T	cg00228799	chr9:131580591	ENDOG	0.45	5.56	0.32	6.67e-8	Blood metabolite levels;
CESC	cis	rs2797160	0.967	rs28629380	chr6:126004197	A/G	cg05901451	chr6:126070800	HEY2	-0.45	-6.47	-0.37	4.83e-10	Endometrial cancer;
CESC	cis	rs2380220	0.574	rs9374322	chr6:95998994	G/A	cg23517279	chr6:96025343	MANEA	0.54	5.8	0.34	1.85e-8	Behavioural disinhibition (generation interaction);
CESC	cis	rs7666738	0.715	rs61114099	chr4:98931270	C/T	cg03467027	chr4:99064603	C4orf37	0.46	5.6	0.33	5.39e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4555082	0.718	rs2816619	chr14:105732551	G/C	cg27165867	chr14:105738592	BRF1	-0.53	-5.68	-0.33	3.55e-8	Mean platelet volume;Platelet distribution width;
CESC	cis	rs11642862	0.901	rs112190455	chr16:30971437	C/T	cg02466173	chr16:30829666	NA	-0.57	-5.21	-0.3	3.81e-7	Tonsillectomy;
CESC	cis	rs36051895	0.659	rs3780366	chr9:5068596	T/C	cg02405213	chr9:5042618	JAK2	-0.5	-6.18	-0.36	2.37e-9	Pediatric autoimmune diseases;
CESC	cis	rs3820068	0.608	rs11544523	chr1:15904318	C/T	cg17385448	chr1:15911702	AGMAT	0.39	5.96	0.34	8.2e-9	Systolic blood pressure;
CESC	cis	rs34779708	0.931	rs4934710	chr10:35350416	T/C	cg03585969	chr10:35415529	CREM	0.75	9.67	0.51	3.92e-19	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs2108622	0.668	rs62106153	chr19:15978507	C/T	cg13772218	chr19:15982569	NA	0.29	5.69	0.33	3.28e-8	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CESC	cis	rs2280018	0.526	rs2941257	chr16:15166445	T/C	cg27102117	chr16:15229624	NA	0.54	8.13	0.45	1.7e-14	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs7927592	0.731	rs2156463	chr11:68386311	T/C	cg01657329	chr11:68192670	LRP5	-0.47	-6.1	-0.35	3.65e-9	Total body bone mineral density;
CESC	cis	rs11123610	0.520	rs11682697	chr2:3721127	A/G	cg19052272	chr2:3704530	ALLC	-0.47	-5.73	-0.33	2.72e-8	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CESC	cis	rs17826219	0.706	rs609472	chr17:28951427	T/C	cg17105886	chr17:28927953	LRRC37B2	0.64	5.65	0.33	4.15e-8	Body mass index;
CESC	cis	rs9814567	1.000	rs4572812	chr3:134291177	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.45	6.1	0.35	3.71e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs7666738	0.546	rs7699578	chr4:98838893	T/C	cg05340658	chr4:99064831	C4orf37	0.51	5.21	0.3	3.79e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs17125944	0.505	rs3783447	chr14:53191647	G/A	cg13660082	chr14:53194042	PSMC6	-0.64	-5.73	-0.33	2.66e-8	Alzheimer's disease (late onset);
CESC	cis	rs763014	0.898	rs8060585	chr16:635794	C/G	cg00908189	chr16:619842	PIGQ	0.65	9.02	0.48	4.04e-17	Height;
CESC	cis	rs561341	1.000	rs72823787	chr17:30283809	A/T	cg12193833	chr17:30244370	NA	-0.75	-6.92	-0.39	3.36e-11	Hip circumference adjusted for BMI;
CESC	cis	rs12586317	0.547	rs10142667	chr14:35445090	A/G	cg16230307	chr14:35515116	FAM177A1	0.9	10.17	0.53	9.99e-21	Psoriasis;
CESC	cis	rs7666738	0.830	rs1534319	chr4:98964804	T/C	cg05340658	chr4:99064831	C4orf37	0.8	12.39	0.61	3.96e-28	Colonoscopy-negative controls vs population controls;
CESC	trans	rs10510776	0.875	rs11710973	chr3:55217512	C/T	cg21860029	chr14:82000536	SEL1L	0.62	6.18	0.35	2.44e-9	Cancer;
CESC	cis	rs56104184	0.725	rs1466896	chr19:49385253	C/G	cg15549821	chr19:49342101	PLEKHA4	-0.61	-6.24	-0.36	1.72e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	cis	rs1862618	0.853	rs860580	chr5:56149429	G/T	cg03609598	chr5:56110824	MAP3K1	0.48	5.4	0.31	1.5e-7	Initial pursuit acceleration;
CESC	cis	rs17407555	0.779	rs6851524	chr4:10155041	C/A	cg00071950	chr4:10020882	SLC2A9	-0.55	-5.46	-0.32	1.12e-7	Schizophrenia (age at onset);
CESC	cis	rs2120019	0.638	rs12050628	chr15:75333494	G/A	cg00629941	chr15:75287862	SCAMP5	0.54	6.42	0.37	6.39e-10	Blood trace element (Zn levels);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg02957340	chr14:100070899	CCDC85C	-0.5	-6.2	-0.36	2.1e-9	Ulcerative colitis;
CESC	cis	rs4906332	1.000	rs17617307	chr14:103904965	C/G	cg09975044	chr14:104007538	NA	0.47	6.53	0.37	3.32e-10	Coronary artery disease;
CESC	cis	rs10088262	0.629	rs9918907	chr8:124816862	A/G	cg15047889	chr8:124780837	FAM91A1	-0.49	-6.11	-0.35	3.62e-9	Pancreatic cancer;
CESC	cis	rs2204008	0.560	rs4129033	chr12:38301897	A/T	cg26384229	chr12:38710491	ALG10B	-0.44	-5.7	-0.33	3.17e-8	Bladder cancer;
CESC	cis	rs875971	0.895	rs12698520	chr7:65918707	C/A	cg10691866	chr7:65817282	TPST1	-0.34	-5.61	-0.33	5.14e-8	Aortic root size;
CESC	cis	rs1843834	0.505	rs2140508	chr2:225355839	G/T	cg12698349	chr2:225449008	CUL3	0.62	8.74	0.47	2.75e-16	IgE levels in asthmatics (D.p. specific);
CESC	cis	rs2549003	1.000	rs2549007	chr5:131826875	T/C	cg00255919	chr5:131827918	IRF1	-0.58	-10.12	-0.53	1.41e-20	Asthma (sex interaction);
CESC	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	7.71	0.43	2.57e-13	Prudent dietary pattern;
CESC	cis	rs4665809	0.590	rs4665319	chr2:26424583	A/C	cg04944784	chr2:26401820	FAM59B	-0.8	-9.34	-0.5	4.19e-18	Gut microbiome composition (summer);
CESC	cis	rs11098499	0.779	rs7674500	chr4:120303593	C/T	cg24375607	chr4:120327624	NA	0.46	5.55	0.32	6.98e-8	Corneal astigmatism;
CESC	cis	rs1707322	1.000	rs7547284	chr1:46319565	C/G	cg03146154	chr1:46216737	IPP	0.71	9.86	0.52	9.69e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs60154123	0.772	rs701944	chr1:210417098	G/A	cg21951975	chr1:209979733	IRF6	0.5	6.09	0.35	3.87e-9	Coronary artery disease;
CESC	cis	rs13191362	1.000	rs34177053	chr6:163007772	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.82	8.75	0.47	2.56e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs1008375	0.966	rs4698621	chr4:17587565	C/T	cg02297831	chr4:17616191	MED28	0.51	6.26	0.36	1.5e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs9303280	0.806	rs4795399	chr17:38061439	T/C	cg19468946	chr17:37922297	IKZF3	-0.39	-5.2	-0.3	4.07e-7	Self-reported allergy;
CESC	cis	rs2836974	0.897	rs34394827	chr21:40528087	T/C	cg17971929	chr21:40555470	PSMG1	1.04	15.91	0.7	1.8e-40	Cognitive function;
CESC	cis	rs6952809	0.532	rs10272548	chr7:2439467	G/A	cg23289794	chr7:2394357	EIF3B	-0.79	-7.29	-0.41	3.64e-12	Multiple sclerosis;
CESC	cis	rs2576037	0.526	rs2032215	chr18:44439011	A/C	cg19077165	chr18:44547161	KATNAL2	-0.53	-7.61	-0.42	4.89e-13	Personality dimensions;
CESC	trans	rs9467711	0.606	rs9393713	chr6:26373678	C/T	cg06606381	chr12:133084897	FBRSL1	-0.73	-6.91	-0.39	3.57e-11	Autism spectrum disorder or schizophrenia;
CESC	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg18538332	chr22:24372958	LOC391322	-0.7	-9.9	-0.52	7.45e-20	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs8031584	0.697	rs8036176	chr15:31175269	A/G	cg14829155	chr15:31115871	NA	-0.77	-10.1	-0.53	1.69e-20	Huntington's disease progression;
CESC	cis	rs4803468	1.000	rs2241710	chr19:41912092	G/C	cg09537434	chr19:41945824	ATP5SL	-1.09	-19.11	-0.76	9.32e-52	Height;
CESC	cis	rs7089973	0.523	rs7099590	chr10:116749706	G/A	cg23260525	chr10:116636907	FAM160B1	0.3	5.15	0.3	5.12e-7	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs7020830	0.931	rs13288178	chr9:37107799	A/G	cg14294708	chr9:37120828	ZCCHC7	1.27	24.82	0.84	4.28e-71	Schizophrenia;
CESC	cis	rs61935443	0.720	rs10859783	chr12:95285339	A/G	cg21533806	chr12:95267307	NA	0.55	6.71	0.38	1.17e-10	Schizophrenia;
CESC	cis	rs4665809	0.590	rs4665318	chr2:26424517	C/T	cg08470875	chr2:26401718	FAM59B	0.65	6.79	0.38	7.44e-11	Gut microbiome composition (summer);
CESC	cis	rs71403859	0.803	rs8063455	chr16:71599977	G/A	cg08717414	chr16:71523259	ZNF19	-0.81	-7.08	-0.4	1.26e-11	Post bronchodilator FEV1;
CESC	cis	rs597539	0.652	rs592697	chr11:68650064	G/A	cg18350739	chr11:68623251	NA	-0.43	-6.72	-0.38	1.09e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs9467711	0.606	rs68072215	chr6:26377927	T/C	cg14345882	chr6:26364793	BTN3A2	0.64	6.38	0.36	7.8e-10	Autism spectrum disorder or schizophrenia;
CESC	cis	rs2880765	0.835	rs7162502	chr15:86044473	G/T	cg10818794	chr15:86012489	AKAP13	-0.34	-5.22	-0.31	3.68e-7	Coronary artery disease;
CESC	cis	rs1401999	1.000	rs2313217	chr3:183635997	A/G	cg01324343	chr3:183735012	ABCC5	0.63	13.45	0.64	8.71e-32	Anterior chamber depth;
CESC	trans	rs10506458	0.834	rs55966529	chr12:63384114	A/C	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.3	-17.35	-0.73	1.38e-45	Hemostatic factors and hematological phenotypes;
CESC	trans	rs2963826	0.589	rs298091	chr5:58996603	A/T	cg19639873	chr12:49716966	TROAP	0.47	6.03	0.35	5.58e-9	Obesity-related traits;
CESC	cis	rs7918232	0.505	rs788221	chr10:27442247	G/C	cg14240646	chr10:27532245	ACBD5	0.73	5.6	0.33	5.24e-8	Breast cancer;
CESC	cis	rs6460942	0.778	rs74993124	chr7:12462917	A/G	cg17427002	chr7:12443146	VWDE	-0.48	-5.33	-0.31	2.06e-7	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25936770	chr7:122321411	CADPS2	-0.72	-8.75	-0.47	2.48e-16	Gut microbiome composition (summer);
CESC	cis	rs1862618	0.671	rs2591970	chr5:56232595	T/C	cg14703610	chr5:56206110	C5orf35	-0.4	-5.1	-0.3	6.52e-7	Initial pursuit acceleration;
CESC	cis	rs4253772	0.591	rs7291444	chr22:46656246	T/G	cg24881330	chr22:46731750	TRMU	0.85	9.61	0.51	5.92e-19	LDL cholesterol;Cholesterol, total;
CESC	cis	rs2439831	0.681	rs956391	chr15:43617493	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.93	-13.41	-0.64	1.24e-31	Lung cancer in ever smokers;
CESC	cis	rs7714584	1.000	rs11951694	chr5:150254338	G/A	cg22134413	chr5:150180641	NA	0.51	5.92	0.34	9.88e-9	Crohn's disease;
CESC	cis	rs4713118	0.586	rs9468290	chr6:28087674	C/T	cg08968635	chr6:28129556	ZNF389	0.4	5.36	0.31	1.84e-7	Parkinson's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01014486	chr7:2598706	IQCE	0.6	7.24	0.41	4.9e-12	Gut microbiome composition (summer);
CESC	cis	rs2235544	0.565	rs634532	chr1:54468947	G/C	cg25741118	chr1:54482237	LDLRAD1	0.24	5.77	0.33	2.2e-8	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
CESC	cis	rs72781680	0.898	rs6712175	chr2:24023431	T/G	cg20701182	chr2:24300061	SF3B14	0.63	5.65	0.33	4.21e-8	Lymphocyte counts;
CESC	cis	rs3733585	0.673	rs7376505	chr4:9952744	C/A	cg00071950	chr4:10020882	SLC2A9	-0.69	-11.34	-0.57	1.44e-24	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs4561483	0.583	rs11075030	chr16:11976414	C/A	cg08843971	chr16:11963173	GSPT1	0.47	6.57	0.37	2.59e-10	Testicular germ cell tumor;
CESC	cis	rs1559088	0.948	rs3760893	chr19:33597930	C/A	cg27124370	chr19:33622961	WDR88	0.46	6.11	0.35	3.64e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs113835537	0.529	rs3816492	chr11:66297363	C/T	cg22134325	chr11:66188745	NPAS4	0.45	6.75	0.38	9.12e-11	Airway imaging phenotypes;
CESC	cis	rs2933343	0.700	rs1683787	chr3:128627021	C/T	cg24203234	chr3:128598194	ACAD9	-0.41	-5.64	-0.33	4.39e-8	IgG glycosylation;
CESC	cis	rs2637266	1.000	rs7896379	chr10:78366247	C/T	cg18941641	chr10:78392320	NA	0.42	7.87	0.44	8.96e-14	Pulmonary function;
CESC	cis	rs1218582	0.741	rs10908446	chr1:154869559	G/A	cg09359103	chr1:154839909	KCNN3	-0.65	-12.19	-0.6	1.91e-27	Prostate cancer;
CESC	cis	rs7044106	0.708	rs2416760	chr9:123374639	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.36	5.87	0.34	1.31e-8	Hip circumference adjusted for BMI;
CESC	cis	rs2549003	0.966	rs2070730	chr5:131819800	G/A	cg00255919	chr5:131827918	IRF1	0.51	8.59	0.47	7.76e-16	Asthma (sex interaction);
CESC	cis	rs10504229	0.639	rs2318145	chr8:58114867	A/G	cg21724239	chr8:58056113	NA	0.58	5.95	0.34	8.29e-9	Developmental language disorder (linguistic errors);
CESC	trans	rs7824557	0.527	rs11785394	chr8:11238029	C/T	cg15556689	chr8:8085844	FLJ10661	-0.51	-6.03	-0.35	5.45e-9	Retinal vascular caliber;
CESC	cis	rs2952156	0.920	rs2517951	chr17:37853097	C/T	cg07936489	chr17:37558343	FBXL20	-0.58	-7.38	-0.41	2e-12	Asthma;
CESC	trans	rs10486722	0.575	rs11770999	chr7:41812252	C/T	cg16202970	chr6:99283201	POU3F2	-0.48	-6.17	-0.35	2.48e-9	Pit-and-Fissure caries;
CESC	cis	rs763121	0.853	rs138706	chr22:39137834	C/G	cg21395723	chr22:39101663	GTPBP1	0.48	6.59	0.38	2.39e-10	Menopause (age at onset);
CESC	cis	rs172166	0.637	rs1233691	chr6:28153897	T/G	cg18032046	chr6:28092343	ZSCAN16	-0.44	-5.83	-0.34	1.58e-8	Cardiac Troponin-T levels;
CESC	trans	rs2688325	0.520	rs10107710	chr8:3761737	C/T	cg00283030	chr2:132056444	LOC440910	0.32	6.14	0.35	3.08e-9	Menarche (age at onset);
CESC	cis	rs9359856	0.510	rs6454775	chr6:90465000	A/T	cg13799429	chr6:90582589	CASP8AP2	0.69	7.74	0.43	2.11e-13	Bipolar disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02433498	chr17:36904779	PCGF2	0.57	6.13	0.35	3.14e-9	Gut microbiome composition (summer);
CESC	cis	rs1707322	0.827	rs6683274	chr1:46241638	T/G	cg03146154	chr1:46216737	IPP	0.78	10.44	0.54	1.38e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs722599	0.748	rs731952	chr14:75366447	A/G	cg11812906	chr14:75593930	NEK9	0.43	5.2	0.3	3.93e-7	IgG glycosylation;
CESC	cis	rs282587	0.560	rs375527	chr13:113417589	A/G	cg02820901	chr13:113351484	ATP11A	-0.64	-5.33	-0.31	2.09e-7	Glycated hemoglobin levels;
CESC	cis	rs61931739	0.500	rs12829125	chr12:34314789	A/G	cg19457237	chr12:34500585	NA	-0.38	-5.15	-0.3	5.03e-7	Morning vs. evening chronotype;
CESC	cis	rs74181299	0.784	rs2723082	chr2:65289623	C/T	cg05010058	chr2:65284262	CEP68	0.34	5.68	0.33	3.57e-8	Pulse pressure;
CESC	cis	rs2742417	0.603	rs6807438	chr3:45778623	G/A	cg04837898	chr3:45731254	SACM1L	-0.47	-6.2	-0.36	2.19e-9	Response to anti-depressant treatment in major depressive disorder;
CESC	cis	rs6500395	1.000	rs7196823	chr16:48616278	G/A	cg04672837	chr16:48644449	N4BP1	0.51	6.5	0.37	3.95e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs78456975	0.739	rs11891867	chr2:1517894	C/T	cg01028140	chr2:1542097	TPO	-0.51	-5.61	-0.33	5.01e-8	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs9888739	1.000	rs11860650	chr16:31326706	C/T	cg15817542	chr16:31343056	ITGAM	-0.46	-5.46	-0.32	1.11e-7	Systemic lupus erythematosus;
CESC	cis	rs1862618	0.671	rs2591956	chr5:56244604	G/A	cg12311346	chr5:56204834	C5orf35	0.64	8.44	0.46	2.06e-15	Initial pursuit acceleration;
CESC	cis	rs2806561	0.765	rs2776815	chr1:23510584	C/T	cg12483005	chr1:23474871	LUZP1	-0.38	-5.97	-0.34	7.41e-9	Height;
CESC	trans	rs11098499	0.909	rs11098530	chr4:120413154	C/T	cg25214090	chr10:38739885	LOC399744	0.72	10.08	0.53	1.97e-20	Corneal astigmatism;
CESC	cis	rs1799949	1.000	rs33918839	chr17:41329172	T/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.42	5.72	0.33	2.87e-8	Menopause (age at onset);
CESC	cis	rs4835473	0.932	rs62337619	chr4:144663236	C/T	cg25736465	chr4:144833511	NA	-0.42	-6.35	-0.36	9.11e-10	Immature fraction of reticulocytes;
CESC	cis	rs35110281	0.805	rs2838319	chr21:44991901	A/G	cg21573476	chr21:45109991	RRP1B	-0.43	-5.94	-0.34	8.72e-9	Mean corpuscular volume;
CESC	cis	rs6976053	0.541	rs314359	chr7:100411278	T/C	cg03098644	chr7:100410630	EPHB4	-0.51	-6.76	-0.38	8.92e-11	Plasminogen activator inhibitor type 1 levels (PAI-1);
CESC	cis	rs5769765	1.000	rs5769760	chr22:50259696	A/G	cg26441486	chr22:50317300	CRELD2	-0.4	-5.56	-0.32	6.48e-8	Schizophrenia;
CESC	cis	rs3820068	0.603	rs35509554	chr1:15993514	C/T	cg16988262	chr1:15930761	NA	0.33	5.32	0.31	2.2e-7	Systolic blood pressure;
CESC	cis	rs4642101	0.618	rs11128614	chr3:12819212	A/G	cg24848339	chr3:12840334	CAND2	0.4	6.05	0.35	4.93e-9	QRS complex (12-leadsum);
CESC	cis	rs7044106	0.762	rs7357638	chr9:123389204	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.33	5.11	0.3	6.22e-7	Hip circumference adjusted for BMI;
CESC	cis	rs2228479	0.702	rs17177891	chr16:89799950	C/T	cg00800038	chr16:89945340	TCF25	-0.76	-6.19	-0.36	2.29e-9	Skin colour saturation;
CESC	cis	rs6500395	1.000	rs9936454	chr16:48617782	T/G	cg04672837	chr16:48644449	N4BP1	0.51	6.31	0.36	1.14e-9	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs4728302	0.559	rs12707093	chr7:133200817	C/T	cg10665199	chr7:133106180	EXOC4	0.5	6.65	0.38	1.71e-10	Intelligence;Intelligence (multi-trait analysis);
CESC	cis	rs6460942	1.000	rs79659770	chr7:12326371	T/C	cg10578991	chr7:12443926	VWDE	-0.61	-6.33	-0.36	1.04e-9	Coronary artery disease;
CESC	cis	rs9911578	0.935	rs302873	chr17:56769481	C/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.13	0.3	5.66e-7	Intelligence (multi-trait analysis);
CESC	cis	rs2839186	0.739	rs2280958	chr21:47642016	C/T	cg13126279	chr21:47581558	C21orf56	-0.48	-6.54	-0.37	3.09e-10	Testicular germ cell tumor;
CESC	cis	rs1451375	0.572	rs68011952	chr7:50638128	C/T	cg14593290	chr7:50529359	DDC	0.44	5.36	0.31	1.82e-7	Malaria;
CESC	cis	rs55692411	0.537	rs13071931	chr3:50062878	G/A	cg03060546	chr3:49711283	APEH	-0.45	-5.22	-0.31	3.6e-7	Intelligence (multi-trait analysis);
CESC	cis	rs2742234	0.590	rs2742237	chr10:43621323	C/G	cg07801480	chr10:43725741	RASGEF1A	0.42	5.37	0.31	1.69e-7	Hirschsprung disease;
CESC	cis	rs7772486	0.624	rs6930154	chr6:146025662	C/T	cg23711669	chr6:146136114	FBXO30	-0.9	-13.53	-0.64	4.75e-32	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1448094	0.817	rs10779220	chr12:86323543	T/A	cg02569458	chr12:86230093	RASSF9	0.45	6.43	0.37	5.79e-10	Major depressive disorder;
CESC	cis	rs896854	0.846	rs2340584	chr8:95916811	A/G	cg13393036	chr8:95962371	TP53INP1	-0.51	-11.06	-0.56	1.28e-23	Type 2 diabetes;
CESC	cis	rs8062405	0.964	rs62036614	chr16:28824685	T/C	cg08761264	chr16:28874980	SH2B1	-0.45	-5.47	-0.32	1.05e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs2652834	0.851	rs4238370	chr15:63347363	T/G	cg05507819	chr15:63340323	TPM1	0.59	5.9	0.34	1.12e-8	HDL cholesterol;
CESC	cis	rs3136441	1.000	rs2306033	chr11:46897446	G/A	cg25783544	chr11:47291846	MADD	0.55	5.18	0.3	4.43e-7	HDL cholesterol;
CESC	cis	rs710865	0.516	rs12062540	chr1:19529204	A/G	cg13387374	chr1:19411106	UBR4	0.51	7.13	0.4	9.35e-12	Brain structure;
CESC	cis	rs875971	0.522	rs56028712	chr7:65466565	C/T	cg25985355	chr7:65971099	NA	-0.32	-5.29	-0.31	2.61e-7	Aortic root size;
CESC	cis	rs870825	0.860	rs55974219	chr4:185600733	G/A	cg04058563	chr4:185651563	MLF1IP	0.57	5.29	0.31	2.54e-7	Blood protein levels;
CESC	cis	rs7618915	0.571	rs12632381	chr3:52607685	G/A	cg18404041	chr3:52824283	ITIH1	-0.41	-6.78	-0.38	7.61e-11	Bipolar disorder;
CESC	cis	rs9581857	0.725	rs1924074	chr13:28015387	C/G	cg01674679	chr13:27998804	GTF3A	0.68	5.43	0.32	1.3e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg14797243	chr11:68671428	IGHMBP2;MRPL21	-0.49	-7.08	-0.4	1.27e-11	Gambling;
CESC	trans	rs11098499	0.866	rs3756156	chr4:120524841	G/A	cg25214090	chr10:38739885	LOC399744	0.67	9.36	0.5	3.52e-18	Corneal astigmatism;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25411849	chr6:89855994	PM20D2	0.63	7.69	0.43	2.93e-13	Gut microbiome composition (summer);
CESC	cis	rs9611565	0.649	rs5751108	chr22:41858035	T/C	cg06634786	chr22:41940651	POLR3H	0.72	7.39	0.41	1.94e-12	Vitiligo;
CESC	cis	rs7917772	0.560	rs4919664	chr10:104363408	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.42	5.66	0.33	4.02e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs9322193	0.566	rs12528243	chr6:150219627	G/A	cg01145232	chr6:150245071	RAET1G	0.53	6.64	0.38	1.79e-10	Lung cancer;
CESC	cis	rs9815354	0.812	rs55748698	chr3:41805233	G/A	cg03022575	chr3:42003672	ULK4	0.7	6.18	0.35	2.42e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs6580649	0.941	rs17122611	chr12:48458149	C/T	cg05342945	chr12:48394962	COL2A1	0.5	5.85	0.34	1.47e-8	Lung cancer;
CESC	cis	rs2204008	0.567	rs2703685	chr12:38081423	G/C	cg26384229	chr12:38710491	ALG10B	0.44	5.93	0.34	9.45e-9	Bladder cancer;
CESC	cis	rs7918232	0.941	rs788220	chr10:27447205	T/C	cg14442939	chr10:27389572	ANKRD26	-0.68	-6.47	-0.37	4.8e-10	Breast cancer;
CESC	cis	rs2576037	0.583	rs1970668	chr18:44523220	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.77	12.63	0.61	6.21e-29	Personality dimensions;
CESC	cis	rs898097	0.585	rs9893200	chr17:80893028	A/C	cg19046167	chr17:80928561	B3GNTL1	0.39	5.26	0.31	2.93e-7	Breast cancer;
CESC	cis	rs6500395	1.000	rs2354579	chr16:48601521	T/C	cg04672837	chr16:48644449	N4BP1	0.5	6.28	0.36	1.36e-9	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs1008375	0.897	rs1006723	chr4:17618524	G/A	cg02297831	chr4:17616191	MED28	0.6	7.7	0.43	2.71e-13	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs3740713	1.000	rs73438695	chr11:18462101	A/G	cg23797887	chr11:18477753	LDHAL6A	-0.54	-5.28	-0.31	2.63e-7	Amyotrophic lateral sclerosis (sporadic);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg21808837	chr5:176778472	LMAN2	0.46	6.29	0.36	1.33e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs7809950	0.862	rs58391518	chr7:107030787	T/C	cg23024343	chr7:107201750	COG5	-0.42	-5.84	-0.34	1.49e-8	Coronary artery disease;
CESC	cis	rs34172651	0.545	rs9302428	chr16:24717600	C/G	cg06028605	chr16:24865363	SLC5A11	-0.38	-5.98	-0.34	7.39e-9	Intelligence (multi-trait analysis);
CESC	cis	rs4132509	0.779	rs4515770	chr1:243686913	A/G	cg21452805	chr1:244014465	NA	0.41	5.03	0.3	8.93e-7	RR interval (heart rate);
CESC	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg23978390	chr7:1156363	C7orf50	0.6	8.4	0.46	2.68e-15	Longevity;Endometriosis;
CESC	cis	rs6952808	0.931	rs12537430	chr7:1868761	A/G	cg13880726	chr7:1868755	MAD1L1	-0.52	-7.03	-0.4	1.77e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs4665809	0.793	rs6546715	chr2:26261520	G/A	cg08470875	chr2:26401718	FAM59B	-0.48	-5.26	-0.31	2.94e-7	Gut microbiome composition (summer);
CESC	trans	rs1413020	0.660	rs708957	chr20:12771339	C/T	cg19784816	chr3:52812520	ITIH1	0.63	6.05	0.35	4.88e-9	Body mass index (recreational physical activity interaction);
CESC	cis	rs11864453	0.928	rs3213420	chr16:72042433	C/T	cg01557791	chr16:72042693	DHODH	-0.67	-9.27	-0.49	6.64e-18	Fibrinogen levels;
CESC	cis	rs13108904	0.934	rs13149952	chr4:1308437	C/G	cg00684032	chr4:1343700	KIAA1530	0.43	6.12	0.35	3.36e-9	Obesity-related traits;
CESC	cis	rs12824058	0.767	rs4759654	chr12:130815559	A/G	cg23887609	chr12:130822674	PIWIL1	0.45	5.82	0.34	1.69e-8	Menopause (age at onset);
CESC	trans	rs3087243	0.755	rs10490516	chr2:204695788	T/C	cg01841312	chr10:38069945	NA	-0.38	-6.28	-0.36	1.35e-9	Rheumatoid arthritis;Hypothyroidism;Type 1 diabetes;
CESC	cis	rs3096299	0.748	rs2965822	chr16:89444677	A/T	cg16743903	chr16:89593216	SPG7	-0.44	-5.54	-0.32	7.28e-8	Multiple myeloma (IgH translocation);
CESC	cis	rs6456156	0.586	rs12213801	chr6:167474084	T/A	cg23791538	chr6:167370224	RNASET2	-0.52	-6.7	-0.38	1.24e-10	Primary biliary cholangitis;
CESC	cis	rs7762018	1.000	rs4716375	chr6:170071218	A/C	cg13891659	chr6:170190454	C6orf122;C6orf208	0.53	5.41	0.32	1.43e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs11608355	0.521	rs6606704	chr12:109814036	T/C	cg19025524	chr12:109796872	NA	-0.53	-7.76	-0.43	1.83e-13	Neuroticism;
CESC	trans	rs2415984	0.846	rs10146907	chr14:46853617	G/T	cg14945696	chr3:52713679	PBRM1	-0.4	-6.03	-0.35	5.55e-9	Number of children ever born;
CESC	cis	rs896854	0.654	rs4735340	chr8:95976251	A/T	cg13393036	chr8:95962371	TP53INP1	-0.49	-10.52	-0.54	7.38e-22	Type 2 diabetes;
CESC	cis	rs7818688	0.614	rs12056517	chr8:95877285	C/T	cg16049864	chr8:95962084	TP53INP1	0.51	5.28	0.31	2.7e-7	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs1218582	0.772	rs4845693	chr1:154911257	A/G	cg06221963	chr1:154839813	KCNN3	0.65	10.91	0.56	3.88e-23	Prostate cancer;
CESC	cis	rs2730245	0.592	rs2657385	chr7:158649373	A/G	cg14689365	chr7:158441557	NCAPG2	0.45	5.65	0.33	4.04e-8	Height;
CESC	cis	rs9322193	0.923	rs9767652	chr6:150055638	A/T	cg07701084	chr6:150067640	NUP43	0.46	6.25	0.36	1.64e-9	Lung cancer;
CESC	cis	rs1862618	0.671	rs28397234	chr5:56248428	T/G	cg12311346	chr5:56204834	C5orf35	0.64	8.43	0.46	2.26e-15	Initial pursuit acceleration;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg10932289	chr17:55038442	COIL	-0.51	-6.61	-0.38	2.06e-10	Fibrinogen levels;
CESC	cis	rs67311347	1.000	rs7641495	chr3:40494690	T/C	cg09455208	chr3:40491958	NA	-0.48	-8.27	-0.45	6.6e-15	Renal cell carcinoma;
CESC	cis	rs10504229	0.639	rs66667899	chr8:58117065	C/T	cg21724239	chr8:58056113	NA	0.58	5.95	0.34	8.29e-9	Developmental language disorder (linguistic errors);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10832476	chr1:28476863	PTAFR	-0.6	-7.36	-0.41	2.37e-12	Gut microbiome composition (summer);
CESC	cis	rs78456975	1.000	rs111935361	chr2:1554192	C/A	cg26248373	chr2:1572462	NA	-0.58	-5.22	-0.31	3.68e-7	Placebo response in major depressive disorder (% change in symptom score);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg00345621	chr19:1277218	C19orf24	0.48	6.8	0.39	6.75e-11	Fibrinogen levels;
CESC	cis	rs11997175	0.583	rs7464599	chr8:33817572	G/A	ch.8.33884649F	chr8:33765107	NA	0.44	5.39	0.31	1.59e-7	Body mass index;
CESC	cis	rs453301	0.686	rs7017868	chr8:8873293	G/A	cg15556689	chr8:8085844	FLJ10661	-0.47	-5.62	-0.33	4.95e-8	Joint mobility (Beighton score);
CESC	cis	rs78456975	0.941	rs13423300	chr2:1553809	C/A	cg26248373	chr2:1572462	NA	-0.58	-5.48	-0.32	9.71e-8	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs7666738	0.830	rs13138920	chr4:99020786	A/G	cg03467027	chr4:99064603	C4orf37	0.46	5.81	0.34	1.8e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.89	13.34	0.63	2.04e-31	Prudent dietary pattern;
CESC	cis	rs62408225	0.962	rs1604830	chr6:90969221	T/C	cg06866423	chr6:90926672	BACH2	0.45	5.35	0.31	1.9e-7	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs7618915	0.547	rs13085895	chr3:52678270	G/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.3	5.43	0.32	1.27e-7	Bipolar disorder;
CESC	cis	rs10751667	0.643	rs10902244	chr11:949981	A/G	cg20946044	chr11:1010712	AP2A2	-0.39	-5.35	-0.31	1.86e-7	Alzheimer's disease (late onset);
CESC	cis	rs2629540	0.889	rs10901808	chr10:126399159	A/C	cg08799069	chr10:126477246	METTL10	0.59	7.56	0.42	6.73e-13	Cocaine dependence;
CESC	cis	rs7666738	0.830	rs1876192	chr4:98727555	T/C	cg17366294	chr4:99064904	C4orf37	0.56	7.71	0.43	2.56e-13	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2637266	0.783	rs12268496	chr10:78487192	G/A	cg18941641	chr10:78392320	NA	0.42	8.05	0.44	2.88e-14	Pulmonary function;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg08892416	chr16:89800313	ZNF276	0.41	6.13	0.35	3.25e-9	Fibrinogen levels;
CESC	cis	rs7680126	0.585	rs34768406	chr4:10118350	C/A	cg11266682	chr4:10021025	SLC2A9	-0.48	-5.76	-0.33	2.31e-8	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	cis	rs1799949	0.896	rs33933393	chr17:41317432	C/T	cg25072359	chr17:41440525	NA	0.46	6.24	0.36	1.76e-9	Menopause (age at onset);
CESC	cis	rs78366141	0.649	rs7674009	chr4:89683324	C/T	cg01026744	chr4:89619053	NAP1L5;HERC3	-0.68	-5.24	-0.31	3.2e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
CESC	cis	rs698833	1.000	rs698834	chr2:44736957	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.44	5.1	0.3	6.4e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs2637266	0.905	rs2579772	chr10:78406555	A/G	cg18941641	chr10:78392320	NA	0.44	8.55	0.47	9.68e-16	Pulmonary function;
CESC	cis	rs270601	0.909	rs2569265	chr5:131704519	T/C	cg07395648	chr5:131743802	NA	0.39	5.05	0.3	8.31e-7	Acylcarnitine levels;
CESC	cis	rs9733	0.596	rs72702573	chr1:150689050	C/T	cg17724175	chr1:150552817	MCL1	0.45	7.31	0.41	3.23e-12	Tonsillectomy;
CESC	cis	rs10504229	0.593	rs7000752	chr8:58026980	C/G	cg22535103	chr8:58192502	C8orf71	-0.57	-6.51	-0.37	3.67e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs7927771	0.864	rs10838724	chr11:47527052	G/T	cg05585544	chr11:47624801	NA	-0.54	-8.38	-0.46	3.09e-15	Subjective well-being;
CESC	trans	rs61931739	0.500	rs6488222	chr12:34526289	G/A	cg26384229	chr12:38710491	ALG10B	0.71	10.63	0.55	3.31e-22	Morning vs. evening chronotype;
CESC	cis	rs74181299	0.717	rs11893423	chr2:65350949	G/A	cg05010058	chr2:65284262	CEP68	-0.32	-5.19	-0.3	4.14e-7	Pulse pressure;
CESC	cis	rs9443189	0.737	rs2842553	chr6:76456632	A/T	cg01950844	chr6:76311363	SENP6	-0.62	-6.7	-0.38	1.27e-10	Prostate cancer;
CESC	trans	rs1814175	0.645	rs4411280	chr11:49962750	A/G	cg15704280	chr7:45808275	SEPT13	-1.01	-19.0	-0.76	2.27e-51	Height;
CESC	cis	rs6540559	0.673	rs17015309	chr1:210007218	C/T	cg23283495	chr1:209979779	IRF6	0.47	5.24	0.31	3.24e-7	Cleft lip with or without cleft palate;
CESC	cis	rs1707322	1.000	rs1588663	chr1:46548825	G/A	cg03146154	chr1:46216737	IPP	-0.69	-9.04	-0.49	3.51e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs1707322	1.000	rs4660335	chr1:46474718	C/T	cg05343316	chr1:45956843	TESK2	0.48	5.79	0.33	2.03e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs116095464	0.558	rs10077076	chr5:231940	C/T	cg12570787	chr5:219185	SDHA;CCDC127	0.52	5.43	0.32	1.3e-7	Breast cancer;
CESC	cis	rs7223966	1.000	rs7214312	chr17:61870863	A/G	cg11494091	chr17:61959527	GH2	0.38	5.17	0.3	4.56e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs875971	0.862	rs709596	chr7:65825913	A/G	cg18252515	chr7:66147081	NA	-0.41	-5.29	-0.31	2.55e-7	Aortic root size;
CESC	cis	rs11247915	0.501	rs34209692	chr1:26608782	C/T	cg04990556	chr1:26633338	UBXN11	-0.62	-6.88	-0.39	4.24e-11	Obesity-related traits;
CESC	cis	rs7208859	0.623	rs122898	chr17:28905254	C/T	cg13385521	chr17:29058706	SUZ12P	-0.74	-5.59	-0.32	5.64e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs736408	0.570	rs11130327	chr3:52793239	A/G	cg05564831	chr3:52568323	NT5DC2	0.42	6.17	0.35	2.54e-9	Bipolar disorder;
CESC	cis	rs677665	0.537	rs72641835	chr1:9336748	C/T	cg25755851	chr1:9335794	NA	0.95	13.63	0.64	2.08e-32	Eosinophil percentage of white cells;
CESC	cis	rs1799949	1.000	rs12944430	chr17:41330820	C/G	cg05368731	chr17:41323189	NBR1	0.76	10.35	0.54	2.73e-21	Menopause (age at onset);
CESC	cis	rs7020830	0.825	rs7036132	chr9:37317241	A/G	cg14294708	chr9:37120828	ZCCHC7	1.23	22.88	0.81	1.06e-64	Schizophrenia;
CESC	cis	rs7727544	0.735	rs273913	chr5:131661156	A/G	cg24060327	chr5:131705240	SLC22A5	-0.65	-8.4	-0.46	2.78e-15	Blood metabolite levels;
CESC	cis	rs6500602	0.727	rs12443748	chr16:4541831	C/T	cg08645402	chr16:4508243	NA	0.57	9.16	0.49	1.5e-17	Schizophrenia;
CESC	cis	rs10883723	0.810	rs6584508	chr10:104258567	A/G	ch.10.2196322F	chr10:104248062	ACTR1A	0.42	5.09	0.3	6.82e-7	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs8017423	0.967	rs8022531	chr14:90729931	T/C	cg14092571	chr14:90743983	NA	-0.56	-8.38	-0.46	3.07e-15	Mortality in heart failure;
CESC	cis	rs9399135	0.967	rs1041481	chr6:135335063	G/A	cg22676075	chr6:135203613	NA	0.52	7.4	0.41	1.84e-12	Red blood cell count;
CESC	cis	rs71403859	0.614	rs12149533	chr16:71801946	C/T	cg08717414	chr16:71523259	ZNF19	-0.71	-5.96	-0.34	8.03e-9	Post bronchodilator FEV1;
CESC	cis	rs2239547	0.522	rs9831409	chr3:52985711	A/T	cg11645453	chr3:52864694	ITIH4	-0.32	-5.39	-0.31	1.53e-7	Schizophrenia;
CESC	cis	rs6912958	0.559	rs183599	chr6:88061024	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.33	5.46	0.32	1.09e-7	Monocyte percentage of white cells;
CESC	cis	rs9611565	0.840	rs4822025	chr22:41776646	C/G	cg06634786	chr22:41940651	POLR3H	-0.7	-7.43	-0.42	1.53e-12	Vitiligo;
CESC	cis	rs9486719	0.948	rs11152953	chr6:96894305	C/T	cg18709589	chr6:96969512	KIAA0776	-0.53	-5.81	-0.34	1.75e-8	Migraine;Coronary artery disease;
CESC	cis	rs9611565	0.802	rs4822028	chr22:41789408	A/G	cg06481639	chr22:41940642	POLR3H	-0.58	-6.36	-0.36	8.92e-10	Vitiligo;
CESC	cis	rs12824058	0.831	rs4759452	chr12:130812799	G/A	cg26677194	chr12:130822605	PIWIL1	0.52	6.81	0.39	6.58e-11	Menopause (age at onset);
CESC	cis	rs116095464	0.542	rs28650039	chr5:273954	C/A	cg22496380	chr5:211416	CCDC127	-0.75	-8.66	-0.47	4.78e-16	Breast cancer;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg03573187	chr11:62439866	C11orf48	-0.45	-6.55	-0.37	3.04e-10	Gambling;
CESC	cis	rs597539	0.518	rs35093305	chr11:68730729	A/G	cg18350739	chr11:68623251	NA	-0.47	-6.93	-0.39	3.29e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs644799	0.511	rs1016030	chr11:95472693	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.41	5.18	0.3	4.33e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs116095464	0.558	rs7731089	chr5:290422	A/C	cg10591111	chr5:226296	SDHA	-0.53	-6.43	-0.37	6.03e-10	Breast cancer;
CESC	cis	rs10489202	0.632	rs202259	chr1:167962072	G/A	cg24449463	chr1:168025552	DCAF6	-0.43	-5.53	-0.32	7.55e-8	Schizophrenia;
CESC	cis	rs6662572	1.000	rs7517111	chr1:46122140	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.53	5.83	0.34	1.65e-8	Blood protein levels;
CESC	trans	rs747782	0.527	rs75915859	chr11:48232931	C/T	cg15704280	chr7:45808275	SEPT13	0.69	6.34	0.36	1e-9	Intraocular pressure;
CESC	cis	rs17253792	0.915	rs78089630	chr14:56178584	G/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.73	5.13	0.3	5.7e-7	Putamen volume;
CESC	cis	rs4974559	0.947	rs28509315	chr4:1358107	C/T	cg02980000	chr4:1222292	CTBP1	0.75	6.84	0.39	5.52e-11	Systolic blood pressure;
CESC	cis	rs4665809	1.000	rs4665299	chr2:26256840	A/C	cg08470875	chr2:26401718	FAM59B	-0.61	-6.52	-0.37	3.54e-10	Gut microbiome composition (summer);
CESC	cis	rs6446731	0.517	rs2858086	chr4:3270611	A/G	cg08886695	chr4:3369023	RGS12	0.38	5.61	0.33	5.03e-8	Mean platelet volume;
CESC	cis	rs2486288	0.656	rs11632752	chr15:45551140	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.54	-6.55	-0.37	3.03e-10	Glomerular filtration rate;
CESC	cis	rs7208859	0.623	rs73269916	chr17:29096326	A/G	cg13385521	chr17:29058706	SUZ12P	0.81	6.56	0.37	2.85e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs73110464	0.609	rs11170348	chr12:53355588	A/G	cg16329197	chr12:53359506	NA	-0.71	-10.31	-0.53	3.6e-21	Cancer (pleiotropy);
CESC	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.76	6.69	0.38	1.3e-10	Platelet count;
CESC	cis	rs11574514	1.000	rs9928374	chr16:67811930	A/G	cg01866162	chr16:67596514	CTCF	-0.94	-5.88	-0.34	1.26e-8	Crohn's disease;
CESC	cis	rs7167736	0.637	rs2467748	chr15:101206130	A/G	cg09499109	chr15:101097659	NA	0.4	5.06	0.3	7.97e-7	Chin dimples;
CESC	trans	rs2235573	0.551	rs139893	chr22:38393608	G/A	cg19894588	chr14:64061835	NA	0.59	7.71	0.43	2.55e-13	Glioblastoma;Glioma;
CESC	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg07677032	chr17:61819896	STRADA	0.47	6.23	0.36	1.83e-9	Prudent dietary pattern;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg20149956	chr1:249132233	ZNF672	-0.44	-6.01	-0.35	6.23e-9	Ulcerative colitis;
CESC	cis	rs2180341	0.960	rs7766942	chr6:127691323	G/T	cg27446573	chr6:127587934	RNF146	1.05	15.58	0.69	2.65e-39	Breast cancer;
CESC	cis	rs1862618	0.613	rs252889	chr5:56227069	C/A	cg20203395	chr5:56204925	C5orf35	-0.39	-5.27	-0.31	2.86e-7	Initial pursuit acceleration;
CESC	cis	rs6740322	0.895	rs6711966	chr2:43561989	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.58	-6.39	-0.37	7.6e-10	Coronary artery disease;
CESC	cis	rs1775715	0.870	rs11008700	chr10:32236937	A/G	cg18675610	chr10:32216311	ARHGAP12	0.33	5.18	0.3	4.45e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs8072100	0.713	rs8074451	chr17:45477573	C/T	cg25173405	chr17:45401733	C17orf57	-0.44	-5.48	-0.32	9.72e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs56235845	0.694	rs6876677	chr5:176755342	T/C	cg16006841	chr5:176797999	RGS14	0.48	6.19	0.36	2.26e-9	Hemoglobin concentration;Hematocrit;
CESC	cis	rs9796	0.835	rs3100807	chr15:41292206	G/A	cg18705301	chr15:41695430	NDUFAF1	0.43	6.36	0.36	8.58e-10	Menopause (age at onset);
CESC	cis	rs13118159	0.714	rs6843025	chr4:1334418	C/G	cg19318889	chr4:1322082	MAEA	0.46	6.33	0.36	1.04e-9	Longevity;
CESC	cis	rs7772486	0.748	rs2748484	chr6:146333653	C/T	cg23711669	chr6:146136114	FBXO30	0.78	11.1	0.56	8.97e-24	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg11817453	chr19:8464850	RAB11B	0.46	6.25	0.36	1.6e-9	Fibrinogen levels;
CESC	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg23708337	chr7:1209742	NA	0.52	5.14	0.3	5.37e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs6429082	0.715	rs9793740	chr1:235595590	T/C	cg26050004	chr1:235667680	B3GALNT2	-0.53	-6.73	-0.38	1.03e-10	Adiposity;
CESC	cis	rs8002861	0.875	rs12428432	chr13:44464043	A/G	cg19180546	chr13:44453867	C13orf31;CCDC122	-0.47	-6.02	-0.35	5.84e-9	Leprosy;
CESC	cis	rs225245	0.817	rs225299	chr17:33922742	T/C	cg05299278	chr17:33885742	SLFN14	0.37	5.31	0.31	2.27e-7	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
CESC	cis	rs9443645	0.901	rs1538235	chr6:79689450	C/T	cg05283184	chr6:79620031	NA	-0.41	-6.34	-0.36	9.98e-10	Intelligence (multi-trait analysis);
CESC	cis	rs6582630	0.519	rs1607882	chr12:38361657	G/A	cg26384229	chr12:38710491	ALG10B	0.67	9.9	0.52	7.06e-20	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs7605378	0.658	rs4673507	chr2:200710167	G/C	cg17644776	chr2:200775616	C2orf69	0.42	5.44	0.32	1.22e-7	Osteoporosis;
CESC	cis	rs7580658	0.724	rs6712213	chr2:127998230	G/A	cg10021288	chr2:128175891	PROC	-0.4	-6.23	-0.36	1.83e-9	Protein C levels;
CESC	cis	rs1387259	0.929	rs11168484	chr12:48633589	A/C	cg04545296	chr12:48745243	ZNF641	0.41	6.86	0.39	4.97e-11	Obstructive sleep apnea trait (apnea hypopnea index);
CESC	cis	rs1707322	0.963	rs4553121	chr1:46375253	G/A	cg06784218	chr1:46089804	CCDC17	0.32	5.57	0.32	6.35e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg10204999	chr14:103057895	RCOR1	-0.4	-6.24	-0.36	1.71e-9	Gambling;
CESC	cis	rs644799	1.000	rs534497	chr11:95562868	C/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.92	14.05	0.65	6.75e-34	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs60871478	0.704	rs62432895	chr7:822050	C/G	cg27478167	chr7:817139	HEATR2	-0.46	-5.38	-0.31	1.68e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs9303280	0.901	rs12103884	chr17:38045725	C/T	cg20243544	chr17:37824526	PNMT	0.52	6.83	0.39	5.73e-11	Self-reported allergy;
CESC	cis	rs12541635	0.966	rs114386112	chr8:107036340	G/A	cg10147462	chr8:107024639	NA	0.43	6.04	0.35	5.26e-9	Age of smoking initiation;
CESC	cis	rs1568889	0.667	rs16917914	chr11:28459909	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.61	7.57	0.42	6.32e-13	Bipolar disorder;
CESC	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	7.61	0.42	4.89e-13	Prudent dietary pattern;
CESC	cis	rs7395581	0.918	rs7120957	chr11:47340649	A/G	cg25783544	chr11:47291846	MADD	0.61	7.9	0.44	7.43e-14	HDL cholesterol;
CESC	cis	rs9549367	0.789	rs2287251	chr13:113889499	A/G	cg00898013	chr13:113819073	PROZ	-0.5	-6.86	-0.39	4.95e-11	Platelet distribution width;
CESC	cis	rs7833790	0.963	rs10958046	chr8:82729210	A/G	cg02079420	chr8:82753780	SNX16	0.58	7.63	0.42	4.14e-13	Diastolic blood pressure;
CESC	cis	rs7666738	0.830	rs2865980	chr4:99027422	T/G	cg18180107	chr4:99064573	C4orf37	0.42	5.43	0.32	1.29e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs936229	0.626	rs3765066	chr15:75140854	G/A	cg14664628	chr15:75095509	CSK	-0.64	-9.28	-0.5	6.27e-18	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CESC	cis	rs763121	0.853	rs8142098	chr22:39058757	T/G	cg14440974	chr22:39074834	NA	-0.4	-5.5	-0.32	9.03e-8	Menopause (age at onset);
CESC	cis	rs9811920	0.609	rs6765027	chr3:99687730	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.6	-7.21	-0.4	5.96e-12	Axial length;
CESC	cis	rs9287719	0.967	rs728134	chr2:10745187	A/G	cg00105475	chr2:10696890	NA	0.38	5.55	0.32	6.76e-8	Prostate cancer;
CESC	cis	rs798554	0.610	rs2251491	chr7:2852835	T/C	cg09658497	chr7:2847517	GNA12	-0.33	-5.08	-0.3	7.14e-7	Height;
CESC	cis	rs1348850	0.914	rs12469386	chr2:178358281	A/G	cg23306229	chr2:178417860	TTC30B	-0.64	-8.35	-0.46	3.79e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs4555082	0.957	rs2735818	chr14:105714751	A/G	cg27165867	chr14:105738592	BRF1	-0.46	-5.27	-0.31	2.82e-7	Mean platelet volume;Platelet distribution width;
CESC	cis	rs7123876	0.553	rs10898868	chr11:72431679	A/G	cg04827223	chr11:72435913	ARAP1	-0.62	-10.36	-0.54	2.37e-21	Body mass index;
CESC	cis	rs1448094	0.556	rs17345522	chr12:86169929	T/C	cg02569458	chr12:86230093	RASSF9	0.57	8.39	0.46	3e-15	Major depressive disorder;
CESC	cis	rs56104184	0.775	rs55737338	chr19:49403141	A/G	cg21252483	chr19:49399788	TULP2	-0.52	-5.69	-0.33	3.36e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg06873352	chr17:61820015	STRADA	0.72	12.67	0.61	4.43e-29	Prudent dietary pattern;
CESC	cis	rs853679	0.517	rs9380056	chr6:28104476	C/T	cg17949981	chr6:28129498	ZNF389	0.45	5.71	0.33	3.07e-8	Depression;
CESC	cis	rs4481887	0.732	rs6703399	chr1:248416343	T/C	cg00666640	chr1:248458726	OR2T12	0.4	6.53	0.37	3.27e-10	Common traits (Other);
CESC	cis	rs35306767	0.903	rs61833260	chr10:975148	T/G	cg10556349	chr10:835070	NA	0.61	5.86	0.34	1.35e-8	Eosinophil percentage of granulocytes;
CESC	cis	rs317689	0.819	rs317685	chr12:69715457	A/G	cg20891283	chr12:69753455	YEATS4	-0.47	-5.1	-0.3	6.38e-7	Response to diuretic therapy;
CESC	cis	rs4665809	1.000	rs1560868	chr2:26281459	A/T	cg04944784	chr2:26401820	FAM59B	0.74	8.26	0.45	7e-15	Gut microbiome composition (summer);
CESC	cis	rs2302190	0.882	rs7226008	chr17:56644633	T/C	cg25885038	chr17:56607967	SEPT4	-0.4	-5.43	-0.32	1.27e-7	Vitamin D levels;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg26871885	chr11:207525	RIC8A;BET1L	-0.44	-6.08	-0.35	4.1e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs7084402	1.000	rs7917717	chr10:60269100	C/A	cg07615347	chr10:60278583	BICC1	-0.57	-8.73	-0.47	2.82e-16	Refractive error;
CESC	cis	rs4835473	0.750	rs12498381	chr4:144715081	G/A	cg25736465	chr4:144833511	NA	-0.35	-5.83	-0.34	1.59e-8	Immature fraction of reticulocytes;
CESC	cis	rs763014	0.833	rs916415	chr16:632115	G/A	cg00802000	chr16:706648	WDR90	-0.41	-6.12	-0.35	3.33e-9	Height;
CESC	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.54	6.73	0.38	1.02e-10	Prudent dietary pattern;
CESC	cis	rs3096299	0.900	rs2911258	chr16:89480760	A/G	cg08392591	chr16:89556376	ANKRD11	0.42	5.47	0.32	1.03e-7	Multiple myeloma (IgH translocation);
CESC	trans	rs7656342	0.808	rs10003216	chr4:9766749	A/G	cg21086083	chr2:157191261	NA	-0.57	-6.86	-0.39	4.79e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg07677032	chr17:61819896	STRADA	0.45	6.05	0.35	4.97e-9	Prudent dietary pattern;
CESC	cis	rs10242455	0.867	rs2687144	chr7:99318808	C/T	cg07715041	chr7:99302981	CYP3A7	-0.43	-5.42	-0.32	1.36e-7	Blood metabolite levels;
CESC	cis	rs951366	0.903	rs708723	chr1:205739266	C/T	cg11965913	chr1:205819406	PM20D1	0.51	7.64	0.42	4.07e-13	Menarche (age at onset);
CESC	cis	rs752010	0.543	rs7545381	chr1:42044183	T/A	cg06885757	chr1:42089581	HIVEP3	0.46	7.46	0.42	1.28e-12	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs1018836	0.923	rs2105967	chr8:91587522	A/G	cg16814680	chr8:91681699	NA	-0.65	-8.72	-0.47	3.08e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs1348850	0.526	rs2178017	chr2:178374788	G/T	cg23306229	chr2:178417860	TTC30B	0.78	6.93	0.39	3.16e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs11098499	0.954	rs11935596	chr4:120412457	G/C	cg24375607	chr4:120327624	NA	0.46	5.63	0.33	4.52e-8	Corneal astigmatism;
CESC	cis	rs9303401	0.614	rs66480139	chr17:57101538	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.87	10.87	0.56	5.18e-23	Cognitive test performance;
CESC	cis	rs147858478	1	rs147858478	chr5:131682785	CCTGAGTT/C	cg24060327	chr5:131705240	SLC22A5	-0.67	-8.91	-0.48	8.52e-17	High light scatter reticulocyte percentage of red cells;
CESC	cis	rs11997175	0.713	rs4327826	chr8:33654807	T/G	ch.8.33884649F	chr8:33765107	NA	0.57	7.3	0.41	3.26e-12	Body mass index;
CESC	trans	rs7246657	0.882	rs10412043	chr19:37826626	A/C	cg24637308	chr11:6592297	DNHD1	0.53	6.19	0.36	2.22e-9	Coronary artery calcification;
CESC	cis	rs478304	0.651	rs11604451	chr11:65551710	C/T	cg10518572	chr11:65560635	OVOL1	-0.3	-5.69	-0.33	3.38e-8	Acne (severe);
CESC	cis	rs7592578	0.679	rs62181019	chr2:191325414	A/G	cg27211696	chr2:191398769	TMEM194B	-0.53	-5.42	-0.32	1.36e-7	Diastolic blood pressure;
CESC	trans	rs7246760	0.867	rs68041339	chr19:9818851	A/G	cg02900749	chr2:68251473	NA	-0.81	-7.26	-0.41	4.4e-12	Pursuit maintenance gain;
CESC	cis	rs2731664	0.792	rs163199	chr5:176890067	A/G	cg23176889	chr5:176863531	GRK6	-0.61	-10.72	-0.55	1.61e-22	Intelligence (multi-trait analysis);
CESC	cis	rs736408	0.509	rs3774349	chr3:52722335	A/C	cg18099408	chr3:52552593	STAB1	-0.34	-6.3	-0.36	1.22e-9	Bipolar disorder;
CESC	trans	rs7618501	1.000	rs7372730	chr3:49790682	C/G	cg21659725	chr3:3221576	CRBN	-0.83	-13.35	-0.63	1.98e-31	Intelligence (multi-trait analysis);
CESC	cis	rs3733585	0.775	rs13124007	chr4:10043931	G/C	cg00071950	chr4:10020882	SLC2A9	0.81	13.65	0.64	1.7e-32	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs2841277	0.741	rs9672139	chr14:105408182	T/G	cg15352829	chr14:105391018	PLD4	-0.58	-10.02	-0.52	3.07e-20	Rheumatoid arthritis;
CESC	cis	rs4481887	0.861	rs10788778	chr1:248481551	T/C	cg00666640	chr1:248458726	OR2T12	0.41	6.56	0.37	2.84e-10	Common traits (Other);
CESC	cis	rs2425143	1.000	rs7273174	chr20:34350306	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-6.85	-0.39	5.04e-11	Blood protein levels;
CESC	cis	rs4919044	0.740	rs73319304	chr10:94777045	A/G	cg26979504	chr10:94451518	HHEX	-0.47	-5.15	-0.3	5.16e-7	Coronary artery disease;
CESC	cis	rs17539620	0.624	rs62432736	chr6:154834401	A/G	cg20019720	chr6:154832845	CNKSR3	0.48	6.37	0.36	8.3e-10	Lipoprotein (a) levels;
CESC	cis	rs10465746	0.570	rs6658559	chr1:84467412	A/G	cg10977910	chr1:84465055	TTLL7	0.44	5.62	0.33	4.89e-8	Obesity-related traits;
CESC	cis	rs9902453	0.791	rs3115086	chr17:28025949	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.76	10.4	0.54	1.88e-21	Coffee consumption (cups per day);
CESC	cis	rs2228479	0.717	rs17233678	chr16:89809962	T/C	cg14709524	chr16:89940631	TCF25	0.94	7.08	0.4	1.27e-11	Skin colour saturation;
CESC	cis	rs911555	0.755	rs2273702	chr14:103918182	C/G	cg12935359	chr14:103987150	CKB	0.55	7.97	0.44	4.66e-14	Intelligence (multi-trait analysis);
CESC	cis	rs9796	0.689	rs692511	chr15:41446252	A/C	cg12426344	chr15:41135900	SPINT1	-0.24	-5.35	-0.31	1.93e-7	Menopause (age at onset);
CESC	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg07677032	chr17:61819896	STRADA	0.42	5.37	0.31	1.74e-7	Prudent dietary pattern;
CESC	cis	rs897984	0.806	rs10782002	chr16:30946506	A/G	cg00531865	chr16:30841666	NA	0.49	6.71	0.38	1.17e-10	Dementia with Lewy bodies;
CESC	cis	rs12579753	0.917	rs11115058	chr12:82263427	T/C	cg24719984	chr12:82153464	PPFIA2	-0.35	-5.16	-0.3	4.96e-7	Resting heart rate;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14227996	chr4:17616232	MED28	0.57	6.01	0.35	6.28e-9	Gut microbiome composition (summer);
CESC	cis	rs35306767	0.903	rs11253467	chr10:901244	A/G	cg26597838	chr10:835615	NA	0.83	8.76	0.47	2.39e-16	Eosinophil percentage of granulocytes;
CESC	cis	rs1799949	0.965	rs9897425	chr17:41430179	C/G	cg05368731	chr17:41323189	NBR1	0.61	8.44	0.46	2.11e-15	Menopause (age at onset);
CESC	cis	rs11190604	1.000	rs2489043	chr10:102334327	T/C	cg07080220	chr10:102295463	HIF1AN	0.6	5.87	0.34	1.28e-8	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs6991838	0.584	rs73236948	chr8:66521411	T/G	cg13398993	chr8:66546079	ARMC1	-0.46	-5.45	-0.32	1.14e-7	Intelligence (multi-trait analysis);
CESC	cis	rs13191362	1.000	rs73035012	chr6:162997279	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.88	9.16	0.49	1.46e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs9788333	0.962	rs61951450	chr13:21886354	G/A	cg06138931	chr13:21896616	NA	0.47	5.94	0.34	8.88e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs9486715	0.867	rs1127175	chr6:96999725	C/T	cg06623918	chr6:96969491	KIAA0776	-0.84	-12.28	-0.6	9.84e-28	Headache;
CESC	cis	rs7618915	0.508	rs12498066	chr3:52627660	G/A	cg18404041	chr3:52824283	ITIH1	-0.39	-6.55	-0.37	2.91e-10	Bipolar disorder;
CESC	cis	rs3008870	1.000	rs2985824	chr1:67410171	C/T	cg02640540	chr1:67518911	SLC35D1	-0.51	-5.53	-0.32	7.82e-8	Lymphocyte percentage of white cells;
CESC	cis	rs2290159	0.800	rs3773345	chr3:12642945	G/C	cg23032965	chr3:12705835	RAF1	0.5	5.47	0.32	1.05e-7	Cholesterol, total;
CESC	cis	rs7259376	0.902	rs10420380	chr19:22600624	C/T	cg02657401	chr19:22469223	NA	0.26	5.12	0.3	5.79e-7	Menopause (age at onset);
CESC	cis	rs3862260	0.509	rs10923879	chr1:120163831	A/G	cg16322792	chr1:120165303	ZNF697	0.58	10.95	0.56	2.82e-23	Systemic lupus erythematosus;
CESC	cis	rs911555	0.755	rs17841064	chr14:103900609	A/G	cg24130564	chr14:104152367	KLC1	-0.5	-6.68	-0.38	1.43e-10	Intelligence (multi-trait analysis);
CESC	cis	rs7116495	1.000	rs12283462	chr11:71835406	T/G	cg26138937	chr11:71823887	C11orf51	0.8	6.42	0.37	6.17e-10	Severe influenza A (H1N1) infection;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg26877631	chr10:21823297	MLLT10	0.47	6.56	0.37	2.75e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs7789940	0.904	rs73140040	chr7:75936240	C/T	cg10167463	chr7:75959203	YWHAG	-0.44	-5.22	-0.31	3.66e-7	Multiple sclerosis;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg04408576	chr16:1524927	CLCN7	-0.51	-6.52	-0.37	3.48e-10	Ulcerative colitis;
CESC	cis	rs1538970	0.816	rs12029322	chr1:45970446	C/T	cg24296786	chr1:45957014	TESK2	-0.46	-5.15	-0.3	4.97e-7	Platelet count;
CESC	cis	rs11722228	1.000	rs4697695	chr4:9915850	C/T	cg11266682	chr4:10021025	SLC2A9	0.45	7.61	0.42	4.69e-13	Gout;Urate levels;Serum uric acid levels;
CESC	cis	rs7666738	0.791	rs6840669	chr4:99016020	G/T	cg18180107	chr4:99064573	C4orf37	0.4	5.3	0.31	2.48e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7927771	0.864	rs755555	chr11:47431966	C/T	cg20307385	chr11:47447363	PSMC3	-0.64	-7.72	-0.43	2.41e-13	Subjective well-being;
CESC	cis	rs7811142	1.000	rs11763414	chr7:100016844	C/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.78	6.81	0.39	6.5e-11	Platelet count;
CESC	cis	rs3785574	0.962	rs2727331	chr17:61926990	G/T	cg06873352	chr17:61820015	STRADA	0.45	6.57	0.37	2.6e-10	Height;
CESC	cis	rs6952808	1.000	rs4721122	chr7:1893311	C/G	cg13880726	chr7:1868755	MAD1L1	0.52	7.0	0.4	2.07e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs651907	0.557	rs11925001	chr3:101373966	C/T	cg12386194	chr3:101231763	SENP7	0.44	5.38	0.31	1.64e-7	Colorectal cancer;
CESC	cis	rs3096299	0.933	rs3096297	chr16:89453155	T/G	cg00750074	chr16:89608354	SPG7	-0.38	-5.36	-0.31	1.79e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs35306767	0.807	rs34885925	chr10:919032	G/C	cg10556349	chr10:835070	NA	0.76	6.26	0.36	1.54e-9	Eosinophil percentage of granulocytes;
CESC	cis	rs2070488	0.965	rs6599209	chr3:38558197	A/G	cg24069376	chr3:38537580	EXOG	-0.46	-8.5	-0.46	1.42e-15	Electrocardiographic conduction measures;
CESC	cis	rs2576037	0.526	rs10853544	chr18:44474194	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.57	-7.95	-0.44	5.57e-14	Personality dimensions;
CESC	cis	rs12995491	0.933	rs13008732	chr2:88528771	G/A	cg04511125	chr2:88470314	THNSL2	-0.51	-7.35	-0.41	2.42e-12	Response to metformin (IC50);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08007338	chr1:180123948	QSOX1	0.56	6.33	0.36	1.04e-9	Gut microbiome composition (summer);
CESC	cis	rs75477785	1.000	rs17015255	chr1:209982738	C/T	cg02304930	chr1:210405566	SERTAD4;C1orf133	-0.93	-5.84	-0.34	1.51e-8	Cleft lip with or without cleft palate;
CESC	cis	rs4253772	0.530	rs6008662	chr22:46713917	G/A	cg24881330	chr22:46731750	TRMU	0.86	9.19	0.49	1.18e-17	LDL cholesterol;Cholesterol, total;
CESC	cis	rs9926296	0.548	rs12447465	chr16:89829895	C/T	cg03388025	chr16:89894329	SPIRE2	0.41	8.2	0.45	1.06e-14	Vitiligo;
CESC	cis	rs9346455	1.000	rs9360447	chr6:72023223	T/G	cg27238071	chr6:71998145	OGFRL1	0.62	5.58	0.32	6.05e-8	Antipsychotic drug-induced weight gain (time interaction);Antipsychotic drug-induced weight gain;
CESC	cis	rs763014	0.593	rs28455838	chr16:681966	T/C	cg00802000	chr16:706648	WDR90	-0.4	-6.1	-0.35	3.76e-9	Height;
CESC	cis	rs7520050	0.778	rs2991985	chr1:46080530	T/C	cg06784218	chr1:46089804	CCDC17	-0.33	-6.08	-0.35	4.15e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs6121246	0.559	rs6060599	chr20:30257754	T/G	cg13852791	chr20:30311386	BCL2L1	0.8	10.27	0.53	4.64e-21	Mean corpuscular hemoglobin;
CESC	cis	rs7666738	0.830	rs11097608	chr4:99011693	T/C	cg03467027	chr4:99064603	C4orf37	0.46	5.72	0.33	2.91e-8	Colonoscopy-negative controls vs population controls;
CESC	trans	rs629535	0.814	rs56301437	chr8:70108518	C/T	cg21567404	chr3:27674614	NA	-0.87	-10.05	-0.53	2.43e-20	Dupuytren's disease;
CESC	cis	rs2439831	0.702	rs3759791	chr15:44090798	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.69	7.79	0.43	1.52e-13	Lung cancer in ever smokers;
CESC	cis	rs7264396	0.563	rs2050729	chr20:34294409	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	-0.62	-6.65	-0.38	1.71e-10	Total cholesterol levels;
CESC	cis	rs8180040	0.620	rs56217494	chr3:47048452	T/G	cg27129171	chr3:47204927	SETD2	-0.66	-9.61	-0.51	5.83e-19	Colorectal cancer;
CESC	cis	rs6732160	0.684	rs2043095	chr2:73407442	T/C	cg01422370	chr2:73384389	NA	0.45	7.68	0.43	3.02e-13	Intelligence (multi-trait analysis);
CESC	cis	rs9309473	0.948	rs10170849	chr2:73747932	G/A	cg20560298	chr2:73613845	ALMS1	-0.45	-6.04	-0.35	5.24e-9	Metabolite levels;
CESC	cis	rs208515	0.525	rs12204706	chr6:66669930	A/G	cg07460842	chr6:66804631	NA	-0.84	-10.98	-0.56	2.26e-23	Exhaled nitric oxide levels;
CESC	cis	rs561341	0.883	rs7406056	chr17:30220224	C/T	cg00745463	chr17:30367425	LRRC37B	-0.62	-6.24	-0.36	1.68e-9	Hip circumference adjusted for BMI;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03768513	chr22:24552594	CABIN1	0.46	6.16	0.35	2.66e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs7177699	0.557	rs4380028	chr15:79111093	C/T	cg04896959	chr15:78267971	NA	0.32	5.04	0.3	8.54e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg25346583	chr19:16296095	FAM32A	-0.43	-6.26	-0.36	1.55e-9	Gambling;
CESC	cis	rs938554	0.558	rs4697701	chr4:9946095	C/T	cg00071950	chr4:10020882	SLC2A9	-0.51	-6.79	-0.39	7.18e-11	Blood metabolite levels;
CESC	cis	rs11098499	0.954	rs4309825	chr4:120314881	C/T	cg09160332	chr4:120329925	NA	0.38	5.16	0.3	4.82e-7	Corneal astigmatism;
CESC	trans	rs11252926	0.550	rs10795122	chr10:466830	C/T	cg00953403	chr17:74099816	EXOC7	0.53	6.59	0.38	2.3e-10	Psychosis in Alzheimer's disease;
CESC	cis	rs9309473	0.950	rs6546847	chr2:73785358	A/G	cg20560298	chr2:73613845	ALMS1	-0.48	-6.44	-0.37	5.5e-10	Metabolite levels;
CESC	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg07677032	chr17:61819896	STRADA	0.46	6.1	0.35	3.83e-9	Prudent dietary pattern;
CESC	cis	rs7618915	0.533	rs35107891	chr3:52613656	G/C	cg18404041	chr3:52824283	ITIH1	-0.41	-6.78	-0.38	7.75e-11	Bipolar disorder;
CESC	cis	rs9303401	0.659	rs17822735	chr17:56620167	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.03	12.7	0.62	3.54e-29	Cognitive test performance;
CESC	cis	rs7829975	0.714	rs11784052	chr8:8671962	C/T	cg06636001	chr8:8085503	FLJ10661	0.43	5.42	0.32	1.37e-7	Mood instability;
CESC	cis	rs7131987	0.903	rs2194520	chr12:29423712	C/T	cg09582351	chr12:29534625	ERGIC2	-0.33	-5.4	-0.31	1.51e-7	QT interval;
CESC	cis	rs765787	0.530	rs2413782	chr15:45538490	A/C	cg24006582	chr15:45444508	DUOX1	-0.59	-7.32	-0.41	3.04e-12	Uric acid levels;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg17906179	chr3:194991500	C3orf21	-0.41	-6.43	-0.37	5.93e-10	Gambling;
CESC	trans	rs1814175	0.781	rs12286395	chr11:49954062	C/G	cg15704280	chr7:45808275	SEPT13	-1.03	-20.41	-0.78	2.75e-56	Height;
CESC	cis	rs7412746	0.611	rs72704679	chr1:150897477	C/T	cg17724175	chr1:150552817	MCL1	0.33	5.08	0.3	7.11e-7	Melanoma;
CESC	cis	rs11997175	0.766	rs56803376	chr8:33687676	T/C	ch.8.33884649F	chr8:33765107	NA	0.46	5.94	0.34	8.83e-9	Body mass index;
CESC	cis	rs10504229	1.000	rs72650885	chr8:58175131	G/A	cg24829409	chr8:58192753	C8orf71	-0.76	-10.0	-0.52	3.53e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs10504229	0.683	rs7459925	chr8:58111771	G/A	cg02725872	chr8:58115012	NA	-0.45	-7.05	-0.4	1.6e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs7666738	0.791	rs7684521	chr4:99071219	A/G	cg17366294	chr4:99064904	C4orf37	0.61	8.51	0.46	1.3e-15	Colonoscopy-negative controls vs population controls;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg00492233	chr7:135242493	NUP205	0.48	6.06	0.35	4.57e-9	Systemic lupus erythematosus;
CESC	cis	rs10465746	0.967	rs11163861	chr1:84354282	T/C	cg10977910	chr1:84465055	TTLL7	0.48	6.52	0.37	3.63e-10	Obesity-related traits;
CESC	cis	rs35306767	0.953	rs12259801	chr10:959306	C/G	cg26597838	chr10:835615	NA	0.84	9.84	0.52	1.15e-19	Eosinophil percentage of granulocytes;
CESC	cis	rs9611519	0.929	rs12484477	chr22:41429084	G/A	cg03806693	chr22:41940476	POLR3H	-0.58	-6.02	-0.35	5.67e-9	Neuroticism;
CESC	cis	rs2836974	0.644	rs2836982	chr21:40689171	C/A	cg11644478	chr21:40555479	PSMG1	-0.77	-11.36	-0.57	1.25e-24	Cognitive function;
CESC	cis	rs3741151	0.686	rs7112924	chr11:73106408	C/T	cg17517138	chr11:73019481	ARHGEF17	0.82	6.54	0.37	3.21e-10	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs4481887	0.927	rs10749651	chr1:248472930	T/C	cg00666640	chr1:248458726	OR2T12	0.35	5.93	0.34	9.43e-9	Common traits (Other);
CESC	cis	rs116095464	0.558	rs62344300	chr5:246336	A/G	cg22496380	chr5:211416	CCDC127	-0.74	-8.63	-0.47	5.66e-16	Breast cancer;
CESC	cis	rs798766	1.000	rs4865463	chr4:1742400	T/C	cg10756475	chr4:1757242	NA	0.48	6.56	0.37	2.85e-10	Bladder cancer;Urinary bladder cancer;
CESC	cis	rs801193	1.000	rs2707856	chr7:66211010	A/T	cg14393609	chr7:65229607	NA	0.49	6.63	0.38	1.92e-10	Aortic root size;
CESC	cis	rs11871801	0.517	rs645692	chr17:40701073	C/T	cg11629889	chr17:40839022	CNTNAP1	0.4	5.11	0.3	6.07e-7	Crohn's disease;
CESC	cis	rs60871478	1.000	rs4719314	chr7:822523	A/G	cg05535760	chr7:792225	HEATR2	0.81	8.4	0.46	2.8e-15	Cerebrospinal P-tau181p levels;
CESC	cis	rs2479724	0.846	rs2251084	chr6:41838119	T/C	cg08135965	chr6:41755394	TOMM6	0.41	5.5	0.32	9.15e-8	Menarche (age at onset);
CESC	cis	rs801193	0.569	rs2707824	chr7:66189243	A/G	cg11764359	chr7:65958608	NA	0.73	10.55	0.54	5.73e-22	Aortic root size;
CESC	cis	rs11122272	0.735	rs973254	chr1:231521149	T/A	cg06096015	chr1:231504339	EGLN1	0.41	5.85	0.34	1.46e-8	Hemoglobin concentration;
CESC	cis	rs1620921	0.505	rs13216458	chr6:161204262	T/C	cg01280913	chr6:161186852	NA	-0.36	-5.26	-0.31	2.94e-7	Lipoprotein (a) - cholesterol levels;
CESC	cis	rs7666738	0.830	rs62321570	chr4:98984276	G/A	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.67e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2404602	0.735	rs12903874	chr15:76693318	A/T	cg23625390	chr15:77176239	SCAPER	-0.43	-5.9	-0.34	1.12e-8	Blood metabolite levels;
CESC	cis	rs7615952	0.641	rs12491577	chr3:125731131	C/T	cg04553112	chr3:125709451	NA	-0.51	-5.53	-0.32	7.63e-8	Blood pressure (smoking interaction);
CESC	cis	rs703842	1.000	rs1875124	chr12:58196802	A/G	cg18357645	chr12:58087776	OS9	-0.43	-5.98	-0.34	7.09e-9	Multiple sclerosis;
CESC	cis	rs3820928	0.874	rs1949807	chr2:227891861	A/G	cg11843606	chr2:227700838	RHBDD1	-0.48	-6.39	-0.37	7.49e-10	Pulmonary function;
CESC	cis	rs2066819	1.000	rs773664	chr12:56702176	C/T	cg26714650	chr12:56694279	CS	1.28	15.86	0.7	2.7e-40	Psoriasis vulgaris;
CESC	cis	rs4955124	0.558	rs62244392	chr3:32020530	T/C	cg05935571	chr3:32023257	ZNF860;OSBPL10	1.0	8.35	0.46	3.75e-15	Schizophrenia;
CESC	cis	rs61996546	0.622	rs17560717	chr15:26834211	G/C	cg14859324	chr15:26874363	GABRB3	-0.38	-5.12	-0.3	6e-7	Response to methotrexate in juvenile idiopathic arthritis;
CESC	cis	rs763121	0.853	rs5757200	chr22:39043491	T/G	cg14440974	chr22:39074834	NA	-0.4	-5.48	-0.32	9.77e-8	Menopause (age at onset);
CESC	cis	rs7512552	0.839	rs3896342	chr1:150411312	T/C	cg15654264	chr1:150340011	RPRD2	0.39	5.18	0.3	4.42e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs747782	0.702	rs17790804	chr11:47447202	T/C	cg25783544	chr11:47291846	MADD	0.63	5.23	0.31	3.4e-7	Intraocular pressure;
CESC	cis	rs16854884	0.837	rs13083068	chr3:143801642	G/T	cg06585982	chr3:143692056	C3orf58	0.42	5.29	0.31	2.6e-7	Economic and political preferences (feminism/equality);
CESC	cis	rs7301826	0.651	rs7299281	chr12:131303132	G/A	cg11011512	chr12:131303247	STX2	-0.44	-5.36	-0.31	1.81e-7	Plasma plasminogen activator levels;
CESC	cis	rs617791	0.678	rs551659	chr11:65749645	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.74	10.63	0.55	3.14e-22	Breast cancer;
CESC	cis	rs10788264	0.504	rs10749452	chr10:124028141	A/G	cg09507567	chr10:124027408	NA	0.39	5.41	0.32	1.42e-7	Total body bone mineral density;
CESC	cis	rs4927850	1.000	rs7627706	chr3:195753353	A/C	cg00031303	chr3:195681400	NA	0.45	5.65	0.33	4.21e-8	Pancreatic cancer;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04312752	chr5:1801320	NDUFS6;MRPL36	0.52	6.77	0.38	8.46e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs854765	0.623	rs9893690	chr17:17753846	A/T	cg04398451	chr17:18023971	MYO15A	0.66	9.82	0.52	1.33e-19	Total body bone mineral density;
CESC	cis	rs1669338	0.588	rs3864049	chr3:3186719	T/G	cg16797762	chr3:3221439	CRBN	-0.61	-6.42	-0.37	6.21e-10	White matter integrity;
CESC	cis	rs6141600	0.661	rs1001043	chr20:34730674	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.38	-5.14	-0.3	5.21e-7	Height;Hip circumference;
CESC	cis	rs798554	0.731	rs2283779	chr7:2815140	G/A	cg19717773	chr7:2847554	GNA12	-0.56	-8.68	-0.47	4.11e-16	Height;
CESC	cis	rs7618915	0.547	rs3755806	chr3:52643685	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	-0.38	-6.64	-0.38	1.79e-10	Bipolar disorder;
CESC	cis	rs748404	0.631	rs560191	chr15:43767774	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	8.21	0.45	9.59e-15	Lung cancer;
CESC	cis	rs10464366	0.544	rs4540324	chr7:39185299	G/C	cg18850127	chr7:39170497	POU6F2	0.37	5.18	0.3	4.43e-7	IgG glycosylation;
CESC	cis	rs10504229	0.871	rs56048296	chr8:58163781	C/T	cg22535103	chr8:58192502	C8orf71	-0.86	-11.2	-0.57	4.33e-24	Developmental language disorder (linguistic errors);
CESC	cis	rs9640161	0.750	rs4395803	chr7:150025367	A/C	cg10018233	chr7:150070692	REPIN1	0.46	6.99	0.39	2.28e-11	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs9831754	0.704	rs1512492	chr3:78471190	A/C	cg06138941	chr3:78371609	NA	-0.41	-5.37	-0.31	1.72e-7	Calcium levels;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg17774058	chr20:6748719	BMP2	-0.42	-6.11	-0.35	3.59e-9	Height;
CESC	trans	rs4596713	0.508	rs7467352	chr9:71766081	G/A	cg16512924	chr15:28394682	HERC2	0.5	6.38	0.36	7.96e-10	Headache;
CESC	trans	rs1814175	0.715	rs11040586	chr11:49858432	T/A	cg15704280	chr7:45808275	SEPT13	-1.02	-19.98	-0.78	8.73e-55	Height;
CESC	cis	rs3733585	0.648	rs28513781	chr4:9959334	G/C	cg00071950	chr4:10020882	SLC2A9	-0.73	-11.79	-0.59	4.58e-26	Cleft plate (environmental tobacco smoke interaction);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg21416968	chr1:44441199	ATP6V0B	-0.41	-6.33	-0.36	1.06e-9	Gambling;
CESC	cis	rs11098499	0.954	rs11940028	chr4:120411907	T/C	cg09307838	chr4:120376055	NA	0.92	12.96	0.62	4.27e-30	Corneal astigmatism;
CESC	cis	rs4713118	0.586	rs9468290	chr6:28087674	C/T	cg23161317	chr6:28129485	ZNF389	0.51	6.53	0.37	3.44e-10	Parkinson's disease;
CESC	cis	rs2425143	0.643	rs6058324	chr20:34388789	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.79	-7.16	-0.4	7.72e-12	Blood protein levels;
CESC	cis	rs4665809	0.941	rs1470096	chr2:26311482	T/C	cg08470875	chr2:26401718	FAM59B	-0.62	-6.69	-0.38	1.35e-10	Gut microbiome composition (summer);
CESC	cis	rs9584850	0.874	rs3742136	chr13:99102607	C/T	cg22223119	chr13:99095684	FARP1	-0.37	-5.26	-0.31	2.94e-7	Neuroticism;
CESC	cis	rs4665809	1.000	rs4665309	chr2:26335502	T/C	cg27170947	chr2:26402098	FAM59B	-0.59	-7.07	-0.4	1.36e-11	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08541880	chr3:137833983	DZIP1L	0.63	7.22	0.41	5.56e-12	Gut microbiome composition (summer);
CESC	cis	rs8031584	1.000	rs35607976	chr15:31277788	T/C	cg08704250	chr15:31115839	NA	-0.69	-8.45	-0.46	2e-15	Huntington's disease progression;
CESC	cis	rs7827545	1.000	rs7823948	chr8:135566580	G/A	cg17885191	chr8:135476712	NA	0.48	6.28	0.36	1.35e-9	Hypertension (SNP x SNP interaction);
CESC	cis	rs7267979	0.549	rs6138536	chr20:25182648	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.66	10.55	0.54	6.11e-22	Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg05157120	chr14:69727352	GALNTL1	-0.53	-6.3	-0.36	1.26e-9	Lung cancer in ever smokers;
CESC	cis	rs425277	0.583	rs3107151	chr1:2051513	T/G	cg24578937	chr1:2090814	PRKCZ	-0.32	-5.56	-0.32	6.55e-8	Height;
CESC	cis	rs959260	0.623	rs7207618	chr17:73321687	T/C	cg12999837	chr17:73267436	MIF4GD	-0.42	-5.15	-0.3	5.03e-7	Systemic lupus erythematosus;
CESC	cis	rs6690583	0.623	rs12042018	chr1:85436937	T/C	cg22153463	chr1:85462885	MCOLN2	0.77	7.23	0.41	5.04e-12	Serum sulfate level;
CESC	cis	rs2742417	0.587	rs2742375	chr3:45784602	G/A	cg04837898	chr3:45731254	SACM1L	-0.46	-6.02	-0.35	5.82e-9	Response to anti-depressant treatment in major depressive disorder;
CESC	cis	rs2228479	0.850	rs62052660	chr16:89847420	T/A	cg14709524	chr16:89940631	TCF25	0.94	7.07	0.4	1.41e-11	Skin colour saturation;
CESC	cis	rs2797160	0.904	rs1777197	chr6:126007401	G/A	cg05901451	chr6:126070800	HEY2	0.46	6.48	0.37	4.35e-10	Endometrial cancer;
CESC	cis	rs6831352	0.918	rs29001203	chr4:100053091	A/G	cg13256891	chr4:100009986	ADH5	-0.73	-8.31	-0.45	4.94e-15	Alcohol dependence;
CESC	cis	rs7639513	0.767	rs2348201	chr3:12711696	A/G	cg23032965	chr3:12705835	RAF1	0.75	10.39	0.54	2.02e-21	Itch intensity from mosquito bite;
CESC	cis	rs2303759	0.881	rs10412811	chr19:49884495	G/A	cg24324837	chr19:49891574	CCDC155	0.49	5.56	0.32	6.47e-8	Multiple sclerosis;
CESC	cis	rs36051895	0.623	rs2146040	chr9:5260039	C/G	cg02405213	chr9:5042618	JAK2	0.51	6.44	0.37	5.68e-10	Pediatric autoimmune diseases;
CESC	cis	rs929354	0.742	rs3808317	chr7:156944460	A/G	cg05182265	chr7:156933206	UBE3C	-0.5	-7.29	-0.41	3.49e-12	Body mass index;
CESC	cis	rs708547	0.533	rs3806746	chr4:57773330	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.52	-6.66	-0.38	1.59e-10	Response to bleomycin (chromatid breaks);
CESC	cis	rs4713118	0.621	rs4713134	chr6:28034121	T/C	cg22143856	chr6:28129313	ZNF389	0.44	5.49	0.32	9.24e-8	Parkinson's disease;
CESC	cis	rs9926296	0.712	rs258332	chr16:89727683	G/A	cg03605463	chr16:89740564	NA	0.63	7.57	0.42	6.39e-13	Vitiligo;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg04407233	chr1:10042538	NMNAT1	0.48	6.6	0.38	2.28e-10	Fibrinogen levels;
CESC	cis	rs35955747	0.869	rs8143002	chr22:31587191	T/C	cg25791279	chr22:32026902	PISD	-0.48	-5.79	-0.33	2.01e-8	Neutrophil count;Sum basophil neutrophil counts;
CESC	cis	rs9303280	0.685	rs9916765	chr17:38005595	T/C	cg19468946	chr17:37922297	IKZF3	-0.38	-5.31	-0.31	2.33e-7	Self-reported allergy;
CESC	cis	rs3806843	0.868	rs2531349	chr5:140120953	G/A	cg16179182	chr5:140090404	VTRNA1-1	0.38	5.04	0.3	8.79e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs79387448	0.614	rs6719130	chr2:102958236	C/T	cg09003973	chr2:102972529	NA	1.13	8.98	0.48	5.2e-17	Gut microbiota (bacterial taxa);
CESC	cis	rs909674	0.541	rs5750812	chr22:39793079	G/A	cg24399712	chr22:39784796	NA	-0.84	-11.79	-0.59	4.45e-26	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs9488822	0.702	rs12196154	chr6:116327471	T/G	cg15226275	chr6:116381976	FRK	0.25	6.18	0.35	2.39e-9	Cholesterol, total;LDL cholesterol;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg24541279	chr10:71993373	PPA1	-0.49	-6.44	-0.37	5.7e-10	Fibrinogen levels;
CESC	cis	rs1008375	1.000	rs4698635	chr4:17630242	C/A	cg15017067	chr4:17643749	FAM184B	0.41	5.94	0.34	8.84e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs7980687	0.638	rs7299943	chr12:123593485	A/T	cg00376283	chr12:123451042	ABCB9	0.74	8.85	0.48	1.32e-16	Height;Educational attainment;Head circumference (infant);
CESC	cis	rs2996428	0.667	rs16824230	chr1:3766240	A/G	cg13057898	chr1:3703894	LRRC47	0.47	6.77	0.38	8.42e-11	Red cell distribution width;
CESC	cis	rs7927771	0.832	rs67116452	chr11:47385194	G/A	cg05585544	chr11:47624801	NA	-0.49	-7.25	-0.41	4.56e-12	Subjective well-being;
CESC	cis	rs2204008	0.639	rs7311462	chr12:38278130	G/A	cg26384229	chr12:38710491	ALG10B	0.72	10.26	0.53	5.3e-21	Bladder cancer;
CESC	cis	rs72781680	0.678	rs872169	chr2:24259188	C/G	cg08917208	chr2:24149416	ATAD2B	0.66	6.39	0.37	7.45e-10	Lymphocyte counts;
CESC	cis	rs6748734	1.000	rs4675868	chr2:241828542	A/C	cg04034577	chr2:241836375	C2orf54	-0.48	-8.18	-0.45	1.17e-14	Urinary metabolites;
CESC	cis	rs914615	0.508	rs7535292	chr1:155127749	T/C	cg02153340	chr1:155202674	NA	-0.37	-5.51	-0.32	8.71e-8	Urinary albumin-to-creatinine ratio;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg03991333	chr1:2458120	PANK4	-0.44	-6.11	-0.35	3.47e-9	Asthma;
CESC	cis	rs763121	0.819	rs5757126	chr22:38923675	T/C	cg06022373	chr22:39101656	GTPBP1	0.82	11.77	0.59	5.07e-26	Menopause (age at onset);
CESC	cis	rs7927771	0.542	rs7102205	chr11:47745374	C/T	cg18512352	chr11:47633146	NA	0.35	5.41	0.32	1.38e-7	Subjective well-being;
CESC	cis	rs12541635	0.934	rs4734893	chr8:106990275	T/G	cg10147462	chr8:107024639	NA	0.4	5.68	0.33	3.54e-8	Age of smoking initiation;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10500953	chr16:346518	AXIN1	-0.67	-7.94	-0.44	5.94e-14	Gut microbiome composition (summer);
CESC	cis	rs1799949	1.000	rs8176297	chr17:41203325	T/A	cg05368731	chr17:41323189	NBR1	0.75	10.35	0.54	2.72e-21	Menopause (age at onset);
CESC	cis	rs7605827	0.780	rs2287278	chr2:15667771	C/G	cg19274914	chr2:15703543	NA	0.38	6.68	0.38	1.38e-10	Educational attainment (years of education);
CESC	cis	rs7945705	0.967	rs10769968	chr11:8907583	G/C	cg12365402	chr11:9010492	NRIP3	0.34	5.3	0.31	2.42e-7	Hemoglobin concentration;
CESC	cis	rs9443189	0.526	rs775060	chr6:76373567	G/A	cg01950844	chr6:76311363	SENP6	-0.87	-9.27	-0.49	6.59e-18	Prostate cancer;
CESC	cis	rs2463822	1.000	rs2513744	chr11:62077785	C/A	cg06239285	chr11:62104954	ASRGL1	0.98	9.25	0.49	7.5e-18	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs13082711	0.911	rs4973769	chr3:27425746	T/C	cg02860705	chr3:27208620	NA	0.52	6.53	0.37	3.36e-10	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CESC	cis	rs992157	0.710	rs10169718	chr2:219103580	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.69	-9.77	-0.51	1.88e-19	Colorectal cancer;
CESC	cis	rs1707322	1.000	rs10789479	chr1:46352500	T/C	cg05343316	chr1:45956843	TESK2	0.49	5.96	0.34	7.98e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs11098499	0.955	rs1511019	chr4:120166007	T/G	cg24375607	chr4:120327624	NA	0.43	5.21	0.31	3.72e-7	Corneal astigmatism;
CESC	cis	rs28437878	1	rs28437878	chr15:78807872	C/T	cg06917634	chr15:78832804	PSMA4	-0.52	-5.71	-0.33	2.99e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs7618915	0.524	rs10433615	chr3:52638482	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.48	6.8	0.39	6.78e-11	Bipolar disorder;
CESC	cis	rs763121	0.889	rs9607557	chr22:39040279	G/A	cg06544989	chr22:39130855	UNC84B	0.52	9.57	0.51	7.89e-19	Menopause (age at onset);
CESC	cis	rs1008375	1.000	rs2109522	chr4:17658645	T/A	cg02297831	chr4:17616191	MED28	0.53	6.75	0.38	9.49e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs9926296	0.509	rs2159113	chr16:89832083	C/T	cg27121462	chr16:89883253	FANCA	0.59	7.64	0.42	4.1e-13	Vitiligo;
CESC	cis	rs7666738	0.830	rs28451101	chr4:99001190	T/C	cg05340658	chr4:99064831	C4orf37	0.8	12.44	0.61	2.83e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7144547	0.950	rs8004137	chr14:81884857	A/G	cg23690444	chr14:81902736	NA	0.64	6.75	0.38	9.06e-11	Prudent dietary pattern;
CESC	cis	rs8031584	0.958	rs1043742	chr15:31232581	A/C	cg14298792	chr15:30685198	CHRFAM7A	-0.45	-5.36	-0.31	1.81e-7	Huntington's disease progression;
CESC	cis	rs6754311	0.731	rs748841	chr2:136558157	C/T	cg15123519	chr2:136567270	LCT	0.33	5.74	0.33	2.61e-8	Mosquito bite size;
CESC	cis	rs7953249	0.807	rs7970695	chr12:121423376	G/A	cg02403541	chr12:121454288	C12orf43	-0.51	-6.84	-0.39	5.58e-11	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
CESC	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	22.48	0.81	2.38e-63	Prudent dietary pattern;
CESC	cis	rs7267979	0.966	rs6083818	chr20:25346082	G/A	cg08601574	chr20:25228251	PYGB	-0.38	-5.46	-0.32	1.12e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs962856	0.592	rs6546296	chr2:67578422	A/G	cg09028215	chr2:67624308	ETAA1	-0.44	-5.32	-0.31	2.2e-7	Pancreatic cancer;
CESC	cis	rs7116495	0.881	rs598835	chr11:71797727	C/T	cg10381502	chr11:71823885	C11orf51	-0.66	-5.4	-0.31	1.51e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs4665809	1.000	rs3910272	chr2:26287842	T/A	cg27170947	chr2:26402098	FAM59B	-0.72	-8.31	-0.45	5.18e-15	Gut microbiome composition (summer);
CESC	cis	rs898097	0.841	rs55810435	chr17:80836722	G/C	cg19046167	chr17:80928561	B3GNTL1	-0.41	-5.03	-0.3	8.92e-7	Breast cancer;
CESC	cis	rs9303401	0.573	rs34097494	chr17:57171917	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.88	11.1	0.56	8.94e-24	Cognitive test performance;
CESC	cis	rs7618915	0.501	rs3852066	chr3:52621839	C/T	cg18404041	chr3:52824283	ITIH1	-0.38	-6.52	-0.37	3.57e-10	Bipolar disorder;
CESC	cis	rs561341	0.941	rs8081016	chr17:30331751	A/G	cg00745463	chr17:30367425	LRRC37B	-0.83	-7.54	-0.42	7.69e-13	Hip circumference adjusted for BMI;
CESC	trans	rs35110281	0.627	rs11701746	chr21:44975137	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.53	7.11	0.4	1.1e-11	Mean corpuscular volume;
CESC	cis	rs1797081	0.967	rs811912	chr10:16859618	G/C	cg23933602	chr10:16859644	RSU1	1.14	24.21	0.83	4.13e-69	Platelet distribution width;
CESC	cis	rs7552404	0.696	rs1417405	chr1:76457797	T/C	cg10523679	chr1:76189770	ACADM	0.66	6.37	0.36	8.19e-10	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs7795096	0.806	rs10277655	chr7:151540697	T/C	cg17008978	chr7:151542804	PRKAG2	0.39	7.25	0.41	4.53e-12	Bipolar disorder (age of onset and psychotic symptoms);
CESC	cis	rs13191362	1.000	rs35820211	chr6:163046252	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.53	5.94	0.34	9.08e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs10779751	0.690	rs743577	chr1:11119135	G/A	cg08854313	chr1:11322531	MTOR	0.8	10.92	0.56	3.55e-23	Body mass index;
CESC	cis	rs4917385	1	rs4917385	chr10:105003721	T/G	cg04362960	chr10:104952993	NT5C2	0.47	5.56	0.32	6.45e-8	Systemic lupus erythematosus;
CESC	trans	rs4904167	0.737	rs10873355	chr14:84681944	T/C	cg06870609	chr15:89787223	FANCI	0.46	6.06	0.35	4.73e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs13191362	0.935	rs66507030	chr6:162953825	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.8	7.66	0.43	3.61e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs854765	0.522	rs63721860	chr17:17829576	T/C	cg04398451	chr17:18023971	MYO15A	-0.71	-10.41	-0.54	1.66e-21	Total body bone mineral density;
CESC	cis	rs9297145	0.724	rs6954584	chr7:98766930	G/A	cg05967295	chr7:98741636	SMURF1	0.9	9.34	0.5	4.06e-18	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
CESC	cis	rs9911578	1.000	rs9898916	chr17:57048660	C/T	cg12560992	chr17:57184187	TRIM37	0.92	15.24	0.68	4.34e-38	Intelligence (multi-trait analysis);
CESC	cis	rs3540	0.574	rs2526000	chr15:90962626	C/T	cg22089800	chr15:90895588	ZNF774	0.6	7.96	0.44	4.96e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs875971	0.545	rs10950025	chr7:65623933	G/A	cg11764359	chr7:65958608	NA	0.79	9.51	0.5	1.18e-18	Aortic root size;
CESC	cis	rs2276314	0.857	rs28651028	chr18:33638910	G/A	cg19628046	chr18:33552617	C18orf21	0.5	5.66	0.33	3.84e-8	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs780096	0.545	rs2280737	chr2:27589810	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.28	-5.75	-0.33	2.42e-8	Total body bone mineral density;
CESC	cis	rs55871839	0.708	rs7000535	chr8:59804351	T/C	cg07426533	chr8:59803705	TOX	-0.51	-7.39	-0.41	1.95e-12	Pneumonia;
CESC	cis	rs853679	0.517	rs1947863	chr6:28099344	G/A	cg12963246	chr6:28129442	ZNF389	0.57	7.78	0.43	1.65e-13	Depression;
CESC	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg23978390	chr7:1156363	C7orf50	0.5	6.79	0.38	7.43e-11	Longevity;Endometriosis;
CESC	cis	rs6088590	0.965	rs13040449	chr20:33358901	T/A	cg06115741	chr20:33292138	TP53INP2	0.63	7.77	0.43	1.77e-13	Coronary artery disease;
CESC	cis	rs7980687	0.596	rs1727319	chr12:123701353	T/C	cg05973401	chr12:123451056	ABCB9	0.46	5.67	0.33	3.65e-8	Height;Educational attainment;Head circumference (infant);
CESC	cis	rs56104184	0.775	rs56349331	chr19:49403009	T/A	cg15549821	chr19:49342101	PLEKHA4	-0.6	-5.99	-0.35	6.95e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10498100	chr11:121163245	SC5DL	0.52	6.0	0.35	6.37e-9	Gut microbiome composition (summer);
CESC	cis	rs5758659	1.000	rs134902	chr22:42683997	C/T	cg00645731	chr22:42541494	CYP2D7P1	-0.28	-5.03	-0.3	8.85e-7	Cognitive function;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10848882	chr20:39765963	PLCG1	0.56	6.55	0.37	3.02e-10	Gut microbiome composition (summer);
CESC	cis	rs9649213	0.614	rs1006169	chr7:97938443	A/G	cg09267113	chr7:98030324	BAIAP2L1	0.43	5.85	0.34	1.47e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7940866	0.903	rs7940465	chr11:130861339	C/T	cg12179176	chr11:130786555	SNX19	0.63	9.11	0.49	2.05e-17	Schizophrenia;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg09379601	chr19:12992224	DNASE2	-0.47	-6.32	-0.36	1.13e-9	Height;
CESC	cis	rs7223966	1.000	rs2854219	chr17:61942682	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.48	-5.4	-0.31	1.49e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs597539	0.652	rs667989	chr11:68685776	T/A	cg18350739	chr11:68623251	NA	-0.45	-6.93	-0.39	3.15e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs3825199	0.515	rs2072593	chr12:93970026	T/C	cg18151635	chr12:93972918	NA	-0.44	-5.89	-0.34	1.19e-8	Height;
CESC	cis	rs4072980	0.527	rs11210825	chr1:38446986	G/A	cg12658694	chr1:38397304	INPP5B	0.64	9.33	0.5	4.39e-18	Coronary artery disease;
CESC	cis	rs72781680	1.000	rs72781632	chr2:24198342	A/C	cg08917208	chr2:24149416	ATAD2B	1.11	10.02	0.52	3.07e-20	Lymphocyte counts;
CESC	cis	rs2836950	0.501	rs2056844	chr21:40670460	G/C	cg17971929	chr21:40555470	PSMG1	-0.55	-7.12	-0.4	1.01e-11	Menarche (age at onset);
CESC	cis	rs9470366	0.816	rs1321311	chr6:36622900	C/A	cg08179530	chr6:36648295	CDKN1A	0.55	6.59	0.38	2.41e-10	QRS duration;
CESC	cis	rs897080	0.589	rs1085448	chr2:44663805	A/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.45	5.03	0.3	8.86e-7	Height;
CESC	cis	rs17021463	0.902	rs34465979	chr4:95257554	C/A	cg11021082	chr4:95130006	SMARCAD1	0.53	7.88	0.44	8.35e-14	Testicular germ cell tumor;
CESC	trans	rs11722228	0.549	rs62288521	chr4:10099772	G/A	cg26043149	chr18:55253948	FECH	0.92	10.86	0.55	5.93e-23	Gout;Urate levels;Serum uric acid levels;
CESC	cis	rs9354308	0.899	rs2802055	chr6:66545756	T/C	cg07460842	chr6:66804631	NA	0.57	6.4	0.37	6.89e-10	Metabolite levels;
CESC	trans	rs61931739	0.534	rs1608911	chr12:34010249	T/C	cg26384229	chr12:38710491	ALG10B	0.59	8.21	0.45	9.45e-15	Morning vs. evening chronotype;
CESC	cis	rs3091242	0.900	rs669063	chr1:25721154	A/G	cg02931644	chr1:25747376	RHCE	0.47	8.18	0.45	1.17e-14	Erythrocyte sedimentation rate;
CESC	cis	rs6736093	1.000	rs7349221	chr2:112668341	A/G	cg12686935	chr2:112915763	FBLN7	-0.42	-5.37	-0.31	1.72e-7	Coronary artery disease;
CESC	cis	rs9611565	0.694	rs5758365	chr22:41858657	A/G	cg17376030	chr22:41985996	PMM1	-0.73	-7.85	-0.43	1e-13	Vitiligo;
CESC	cis	rs7659604	0.628	rs6838153	chr4:122720999	A/G	cg19748678	chr4:122722346	EXOSC9	0.76	9.57	0.51	7.84e-19	Type 2 diabetes;
CESC	cis	rs7937682	0.562	rs630002	chr11:111377758	G/A	cg22437258	chr11:111473054	SIK2	0.45	5.64	0.33	4.35e-8	Primary sclerosing cholangitis;
CESC	cis	rs11122272	0.701	rs11122273	chr1:231476789	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.45	-6.48	-0.37	4.38e-10	Hemoglobin concentration;
CESC	trans	rs629535	0.862	rs598548	chr8:70032438	C/T	cg21567404	chr3:27674614	NA	0.93	11.25	0.57	2.83e-24	Dupuytren's disease;
CESC	cis	rs910316	1.000	rs7142235	chr14:75559963	T/C	cg11812906	chr14:75593930	NEK9	0.91	15.5	0.69	5.27e-39	Height;
CESC	cis	rs10781543	0.776	rs11145760	chr9:139382594	G/A	cg14019695	chr9:139328340	INPP5E	0.38	5.73	0.33	2.71e-8	Monocyte percentage of white cells;
CESC	cis	rs9811920	0.638	rs793440	chr3:99643176	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.57	7.02	0.4	1.84e-11	Axial length;
CESC	cis	rs8177179	0.967	rs9869311	chr3:133451613	C/T	cg16262614	chr3:133464971	TF	0.43	8.6	0.47	7.12e-16	Iron status biomarkers (transferrin levels);
CESC	cis	rs2953174	0.507	rs2953172	chr2:241525316	C/T	cg03371404	chr2:241525653	CAPN10	-0.56	-6.0	-0.35	6.41e-9	Bipolar disorder;
CESC	cis	rs897080	0.515	rs698818	chr2:44709769	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.48	5.37	0.31	1.72e-7	Height;
CESC	cis	rs7301826	0.627	rs7978987	chr12:131281494	G/A	cg11011512	chr12:131303247	STX2	-0.44	-5.36	-0.31	1.81e-7	Plasma plasminogen activator levels;
CESC	trans	rs9419702	0.806	rs10872832	chr10:133531090	A/G	cg22110973	chr15:91499626	RCCD1	-0.47	-6.23	-0.36	1.78e-9	Survival in rectal cancer;
CESC	cis	rs6952808	0.564	rs55865401	chr7:2145720	G/C	cg21782813	chr7:2030301	MAD1L1	0.47	6.65	0.38	1.64e-10	Bipolar disorder and schizophrenia;
CESC	cis	rs4665809	0.590	rs4665321	chr2:26433801	A/C	cg25036284	chr2:26402008	FAM59B	-0.85	-9.25	-0.49	7.86e-18	Gut microbiome composition (summer);
CESC	cis	rs6565180	1.000	rs11863150	chr16:30385503	C/T	cg17640201	chr16:30407289	ZNF48	0.93	15.58	0.69	2.74e-39	Tonsillectomy;
CESC	cis	rs8070128	0.600	rs8071238	chr17:17900990	T/C	cg16928487	chr17:17741425	SREBF1	-0.5	-8.12	-0.45	1.77e-14	Total body bone mineral density;
CESC	cis	rs6728642	1.000	rs7580504	chr2:97605597	C/G	cg26665480	chr2:98280029	ACTR1B	-0.75	-6.14	-0.35	3.08e-9	Bipolar disorder lithium response (continuous) or schizophrenia;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg02872018	chr2:192746213	NA	-0.42	-6.26	-0.36	1.51e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs4237845	0.591	rs10747788	chr12:58315338	C/T	cg00677455	chr12:58241039	CTDSP2	0.54	6.42	0.37	6.15e-10	Intelligence (multi-trait analysis);
CESC	cis	rs963731	0.522	rs4670907	chr2:39278066	C/T	cg04010122	chr2:39346883	SOS1	-0.75	-5.66	-0.33	3.91e-8	Corticobasal degeneration;
CESC	cis	rs4076764	0.801	rs6698738	chr1:163359918	G/A	cg06092702	chr1:163392909	NA	-0.37	-5.22	-0.31	3.65e-7	Motion sickness;
CESC	cis	rs7927771	0.965	rs12364432	chr11:47902883	G/A	cg20307385	chr11:47447363	PSMC3	-0.45	-5.41	-0.32	1.42e-7	Subjective well-being;
CESC	cis	rs7084402	0.967	rs1623568	chr10:60320446	T/C	cg07615347	chr10:60278583	BICC1	0.63	10.12	0.53	1.48e-20	Refractive error;
CESC	cis	rs9322193	0.923	rs10872651	chr6:150089409	A/T	cg04369109	chr6:150039330	LATS1	-0.46	-6.31	-0.36	1.16e-9	Lung cancer;
CESC	cis	rs6540559	1.000	rs1044516	chr1:209959614	G/T	cg23283495	chr1:209979779	IRF6	0.46	6.62	0.38	1.98e-10	Cleft lip with or without cleft palate;
CESC	cis	rs3820928	0.904	rs6735069	chr2:227893660	A/G	cg05526886	chr2:227700861	RHBDD1	-0.44	-5.47	-0.32	1.03e-7	Pulmonary function;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08187845	chr17:1420199	LOC100306951;INPP5K	0.61	6.94	0.39	3.08e-11	Gut microbiome composition (summer);
CESC	cis	rs12478296	1.000	rs55732177	chr2:243040006	C/T	cg06360820	chr2:242988706	NA	-0.66	-7.52	-0.42	8.51e-13	Obesity-related traits;
CESC	cis	rs7267979	1.000	rs2258617	chr20:25274318	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	18.72	0.75	2.09e-50	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7568458	0.709	rs11895399	chr2:85753806	C/A	cg02493740	chr2:85810744	VAMP5	-0.57	-8.48	-0.46	1.57e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CESC	cis	rs2439831	0.850	rs524417	chr15:43772374	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.9	10.47	0.54	1.08e-21	Lung cancer in ever smokers;
CESC	cis	rs17854409	1.000	rs16983290	chr20:61478894	A/G	cg07645718	chr20:61493192	TCFL5	-0.83	-6.11	-0.35	3.45e-9	Obesity-related traits;
CESC	cis	rs910316	0.699	rs175039	chr14:75468950	G/C	cg08847533	chr14:75593920	NEK9	-0.87	-14.68	-0.67	4.1e-36	Height;
CESC	cis	rs763121	0.853	rs2205802	chr22:39046327	T/C	cg06544989	chr22:39130855	UNC84B	0.5	8.66	0.47	4.63e-16	Menopause (age at onset);
CESC	cis	rs1799949	1.000	rs11653253	chr17:41182662	G/A	cg25072359	chr17:41440525	NA	0.5	6.46	0.37	4.89e-10	Menopause (age at onset);
CESC	cis	rs7267979	1.000	rs2387884	chr20:25379069	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.88	-18.07	-0.74	4.08e-48	Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg23811096	chr1:33502772	AK2	-0.45	-6.11	-0.35	3.61e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs951366	0.538	rs56276813	chr1:205730573	G/T	cg17178900	chr1:205818956	PM20D1	-0.41	-5.2	-0.3	4.06e-7	Menarche (age at onset);
CESC	cis	rs28647808	1.000	rs35348753	chr9:136270070	A/G	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.91	5.71	0.33	3.03e-8	Blood protein levels;
CESC	cis	rs7666738	0.578	rs1989109	chr4:98881246	T/A	cg05340658	chr4:99064831	C4orf37	0.78	11.7	0.58	9.27e-26	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2645694	0.626	rs12502590	chr4:77823642	G/A	cg18351406	chr4:77819688	ANKRD56	0.53	6.57	0.37	2.68e-10	Emphysema distribution in smoking;
CESC	trans	rs11098499	0.775	rs2002049	chr4:120257417	A/G	cg25214090	chr10:38739885	LOC399744	0.64	9.06	0.49	2.97e-17	Corneal astigmatism;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21454386	chr13:114292018	TFDP1	-0.68	-7.85	-0.43	1.04e-13	Gut microbiome composition (summer);
CESC	cis	rs798554	0.836	rs798502	chr7:2789880	G/T	cg04166393	chr7:2884313	GNA12	-0.59	-7.62	-0.42	4.47e-13	Height;
CESC	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	10.38	0.54	2.06e-21	Prudent dietary pattern;
CESC	cis	rs2404602	0.583	rs12908334	chr15:76581592	C/T	cg26408565	chr15:76604113	ETFA	-0.4	-5.93	-0.34	9.44e-9	Blood metabolite levels;
CESC	cis	rs155076	1.000	rs261406	chr13:21855854	G/A	cg11317459	chr13:21872234	NA	-1.06	-11.89	-0.59	1.99e-26	White matter hyperintensity burden;
CESC	cis	rs28374715	0.662	rs111522288	chr15:41480169	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.79	-10.3	-0.53	3.96e-21	Ulcerative colitis;
CESC	cis	rs1707322	1.000	rs1768800	chr1:46549188	A/G	cg06784218	chr1:46089804	CCDC17	-0.33	-5.57	-0.32	6.35e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9309473	0.948	rs10173534	chr2:73813432	C/T	cg20560298	chr2:73613845	ALMS1	-0.54	-7.25	-0.41	4.47e-12	Metabolite levels;
CESC	cis	rs1005277	0.540	rs2224248	chr10:38451886	A/G	cg25517755	chr10:38738941	LOC399744	-0.49	-6.35	-0.36	9.09e-10	Extrinsic epigenetic age acceleration;
CESC	cis	rs9549367	0.789	rs9549708	chr13:113891887	A/G	cg18105134	chr13:113819100	PROZ	-0.66	-7.93	-0.44	6.05e-14	Platelet distribution width;
CESC	cis	rs9467711	0.720	rs9348716	chr6:26375658	G/A	cg12826209	chr6:26865740	GUSBL1	0.64	5.25	0.31	3.2e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs3741151	1.000	rs7949364	chr11:73041077	A/G	cg17517138	chr11:73019481	ARHGEF17	0.63	5.25	0.31	3.19e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs514406	0.621	rs1930306	chr1:53195686	C/G	cg08736216	chr1:53307985	ZYG11A	0.37	5.99	0.35	6.8e-9	Monocyte count;
CESC	cis	rs6831352	0.918	rs29001209	chr4:100052340	C/A	cg13256891	chr4:100009986	ADH5	-0.77	-8.43	-0.46	2.27e-15	Alcohol dependence;
CESC	cis	rs9910055	0.762	rs1135215	chr17:42253519	T/C	cg08499158	chr17:42289980	UBTF	-0.5	-6.32	-0.36	1.1e-9	Total body bone mineral density;
CESC	cis	rs909002	0.819	rs4949457	chr1:32140053	C/T	cg13919466	chr1:32135498	COL16A1	0.39	6.09	0.35	3.87e-9	Intelligence (multi-trait analysis);
CESC	cis	rs1707322	0.827	rs10890347	chr1:46242332	A/T	cg05343316	chr1:45956843	TESK2	-0.48	-5.8	-0.34	1.86e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7809950	0.678	rs7788271	chr7:106985873	A/G	cg23024343	chr7:107201750	COG5	-0.52	-6.73	-0.38	1.02e-10	Coronary artery disease;
CESC	cis	rs4919087	0.810	rs1468069	chr10:98988759	A/C	cg25902810	chr10:99078978	FRAT1	0.61	8.33	0.46	4.42e-15	Monocyte count;
CESC	cis	rs8141529	0.719	rs5762825	chr22:29223642	A/G	cg02153584	chr22:29168773	CCDC117	0.64	9.16	0.49	1.46e-17	Lymphocyte counts;
CESC	cis	rs3916	0.955	rs12828810	chr12:121152017	T/G	cg21892295	chr12:121157589	UNC119B	-0.36	-5.23	-0.31	3.47e-7	Urinary metabolites (H-NMR features);
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg27138088	chr11:842605	TSPAN4;POLR2L	0.52	6.87	0.39	4.62e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs10870270	1.000	rs4880246	chr10:133764064	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.87	-12.78	-0.62	1.87e-29	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs6502050	0.871	rs62079998	chr17:80077245	A/C	cg11859384	chr17:80120422	CCDC57	0.41	5.62	0.33	4.75e-8	Life satisfaction;
CESC	cis	rs8014204	0.967	rs2359240	chr14:75328247	T/C	cg08847533	chr14:75593920	NEK9	-0.47	-5.81	-0.34	1.79e-8	Caffeine consumption;
CESC	cis	rs6580649	0.941	rs60681522	chr12:48464195	T/C	cg05342945	chr12:48394962	COL2A1	0.51	5.91	0.34	1.07e-8	Lung cancer;
CESC	cis	rs4803468	1.000	rs284658	chr19:41929988	G/A	cg14132834	chr19:41945861	ATP5SL	-0.58	-7.12	-0.4	9.92e-12	Height;
CESC	cis	rs17376456	0.877	rs34673483	chr5:93315079	C/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.65	5.62	0.33	4.95e-8	Diabetic retinopathy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01023808	chr7:97857492	TECPR1	-0.57	-6.65	-0.38	1.66e-10	Gut microbiome composition (summer);
CESC	cis	rs10504229	1.000	rs6989060	chr8:58178989	T/G	cg05313129	chr8:58192883	C8orf71	-0.55	-6.37	-0.36	8.42e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs28595532	0.668	rs56410164	chr4:119331625	A/G	cg21605333	chr4:119757512	SEC24D	1.01	5.58	0.32	5.87e-8	Cannabis dependence symptom count;
CESC	cis	rs7246657	0.943	rs28373708	chr19:37976659	C/T	cg23950597	chr19:37808831	NA	-0.58	-6.39	-0.37	7.52e-10	Coronary artery calcification;
CESC	cis	rs13108904	0.901	rs13112706	chr4:1303682	G/T	cg22903657	chr4:1355424	KIAA1530	-0.37	-5.13	-0.3	5.63e-7	Obesity-related traits;
CESC	cis	rs7666738	0.830	rs11735193	chr4:98761900	C/T	cg05340658	chr4:99064831	C4orf37	0.76	11.26	0.57	2.63e-24	Colonoscopy-negative controls vs population controls;
CESC	cis	rs854765	0.603	rs4506967	chr17:17990474	A/C	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.47	5.96	0.34	8.22e-9	Total body bone mineral density;
CESC	cis	rs7560272	0.695	rs780393	chr2:73701669	T/A	cg20560298	chr2:73613845	ALMS1	0.5	7.15	0.4	8.3e-12	Schizophrenia;
CESC	cis	rs2014572	0.967	rs7248000	chr19:57762139	C/T	cg12963866	chr19:57752005	ZNF805	-0.49	-6.6	-0.38	2.28e-10	Hyperactive-impulsive symptoms;
CESC	cis	rs4819052	0.819	rs34818688	chr21:46672416	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.45	5.62	0.33	4.81e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs853679	0.569	rs9348798	chr6:28143011	G/A	cg17949981	chr6:28129498	ZNF389	0.42	5.23	0.31	3.39e-7	Depression;
CESC	cis	rs798554	0.680	rs1713912	chr7:2895784	C/A	cg13628971	chr7:2884303	GNA12	0.62	8.11	0.45	1.84e-14	Height;
CESC	cis	rs6922893	1.000	rs6455393	chr6:71681558	A/G	cg10766373	chr6:71666121	B3GAT2	-0.34	-5.29	-0.31	2.56e-7	Obesity-related traits;
CESC	cis	rs798766	1.000	rs798767	chr4:1734281	A/G	cg05874882	chr4:1763078	NA	-0.59	-7.71	-0.43	2.5e-13	Bladder cancer;Urinary bladder cancer;
CESC	cis	rs7044106	0.537	rs4434680	chr9:123489688	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.75	9.65	0.51	4.31e-19	Hip circumference adjusted for BMI;
CESC	cis	rs5758659	0.622	rs6519298	chr22:42364997	C/T	cg19513890	chr22:42538836	CYP2D7P1	-0.36	-5.13	-0.3	5.73e-7	Cognitive function;
CESC	cis	rs2204008	0.687	rs2320523	chr12:38251397	T/C	cg26384229	chr12:38710491	ALG10B	0.65	9.03	0.49	3.55e-17	Bladder cancer;
CESC	cis	rs1355223	0.752	rs286893	chr11:34674882	C/G	cg11058730	chr11:34937778	PDHX;APIP	0.5	6.51	0.37	3.67e-10	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs4665809	1.000	rs4665306	chr2:26319124	C/T	cg04944784	chr2:26401820	FAM59B	-0.67	-7.65	-0.43	3.71e-13	Gut microbiome composition (summer);
CESC	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	10.13	0.53	1.3e-20	Prudent dietary pattern;
CESC	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.54	6.6	0.38	2.23e-10	Prudent dietary pattern;
CESC	cis	rs9814567	0.964	rs1534028	chr3:134284639	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.45	-6.05	-0.35	4.79e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs2979489	0.891	rs4537262	chr8:30306757	T/A	cg26383811	chr8:30366931	RBPMS	0.84	9.92	0.52	6.18e-20	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CESC	cis	rs7762018	1.000	rs6459657	chr6:170136454	A/G	cg13891659	chr6:170190454	C6orf122;C6orf208	0.61	6.2	0.36	2.12e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs6582630	0.519	rs11520262	chr12:38333051	A/G	cg26384229	chr12:38710491	ALG10B	0.73	10.9	0.56	4.29e-23	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs8017423	0.967	rs2277517	chr14:90722778	G/A	cg14092571	chr14:90743983	NA	-0.55	-8.31	-0.45	5.06e-15	Mortality in heart failure;
CESC	cis	rs1707322	0.686	rs2991987	chr1:46081422	C/G	cg03146154	chr1:46216737	IPP	-0.81	-11.13	-0.56	7.28e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs28493229	0.522	rs2233152	chr19:41281016	C/T	cg21869046	chr19:41225005	ITPKC	0.49	6.39	0.37	7.49e-10	Kawasaki disease;
CESC	cis	rs10751667	1.000	rs10794349	chr11:945678	T/C	cg06064525	chr11:970664	AP2A2	-0.42	-7.63	-0.42	4.21e-13	Alzheimer's disease (late onset);
CESC	cis	rs34779708	0.966	rs11010095	chr10:35395948	A/G	cg03585969	chr10:35415529	CREM	0.78	10.17	0.53	1e-20	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs6912958	0.514	rs7767449	chr6:87887985	A/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.34	-5.4	-0.31	1.5e-7	Monocyte percentage of white cells;
CESC	cis	rs933688	1.000	rs7720132	chr5:90745105	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.15	13.7	0.64	1.17e-32	Smoking behavior;
CESC	cis	rs7312933	0.558	rs1796384	chr12:42780568	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.51	-6.73	-0.38	1.04e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs2742417	1.000	rs2742432	chr3:45737467	G/T	cg10512202	chr3:45649293	LIMD1	0.35	5.06	0.3	7.85e-7	Response to anti-depressant treatment in major depressive disorder;
CESC	cis	rs7592578	0.766	rs12472081	chr2:191398545	G/A	cg10560079	chr2:191398806	TMEM194B	-0.63	-5.32	-0.31	2.21e-7	Diastolic blood pressure;
CESC	cis	rs4713118	0.586	rs9468290	chr6:28087674	C/T	cg20151795	chr6:28129481	ZNF389	0.45	5.87	0.34	1.29e-8	Parkinson's disease;
CESC	cis	rs3126085	0.935	rs10888473	chr1:152220235	G/A	cg03465714	chr1:152285911	FLG	-0.44	-5.34	-0.31	1.96e-7	Atopic dermatitis;
CESC	cis	rs2599510	0.744	rs4952212	chr2:32618493	G/C	cg02381751	chr2:32503542	YIPF4	-0.49	-6.21	-0.36	1.99e-9	Interleukin-18 levels;
CESC	cis	rs1552244	1.000	rs9827740	chr3:10120531	T/C	cg13047869	chr3:10149882	C3orf24	0.4	5.03	0.3	8.89e-7	Alzheimer's disease;
CESC	cis	rs7582720	1.000	rs72928609	chr2:203837573	G/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.36	0.41	2.34e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs1843834	0.898	rs12623277	chr2:225548072	T/G	cg22455342	chr2:225449267	CUL3	0.51	6.55	0.37	3.01e-10	IgE levels in asthmatics (D.p. specific);
CESC	trans	rs4376189	0.681	rs13136101	chr4:186624184	G/A	cg21381065	chr18:49866304	DCC	-0.4	-6.29	-0.36	1.34e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CESC	cis	rs854765	0.520	rs7219324	chr17:17909775	C/T	cg04398451	chr17:18023971	MYO15A	0.6	8.23	0.45	8.57e-15	Total body bone mineral density;
CESC	cis	rs10791097	0.609	rs3751039	chr11:130773076	A/G	cg14779329	chr11:130786720	SNX19	-0.33	-5.32	-0.31	2.19e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs758324	0.898	rs11958749	chr5:131166014	T/C	cg06307176	chr5:131281290	NA	0.42	5.04	0.3	8.69e-7	Alzheimer's disease in APOE e4- carriers;
CESC	cis	rs4454254	1.000	rs4454254	chr8:141060027	C/T	cg06693505	chr8:141057453	TRAPPC9	-0.32	-5.17	-0.3	4.53e-7	Pulse pressure;
CESC	cis	rs17092148	0.636	rs6058107	chr20:33288546	T/C	cg24642439	chr20:33292090	TP53INP2	0.5	5.21	0.31	3.72e-7	Neuroticism;
CESC	cis	rs9325144	0.671	rs35817541	chr12:38975001	T/C	cg26384229	chr12:38710491	ALG10B	-0.53	-7.38	-0.41	2.09e-12	Morning vs. evening chronotype;
CESC	cis	rs3736485	0.932	rs4775946	chr15:51775930	A/G	cg08986416	chr15:51914746	DMXL2	-0.42	-5.54	-0.32	7.22e-8	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs514406	0.755	rs10888754	chr1:53228751	C/G	cg08736216	chr1:53307985	ZYG11A	0.32	5.66	0.33	4e-8	Monocyte count;
CESC	cis	rs11969893	0.649	rs1321204	chr6:101468591	A/G	cg12253828	chr6:101329408	ASCC3	0.63	5.15	0.3	4.97e-7	Economic and political preferences (immigration/crime);
CESC	cis	rs3749237	0.595	rs885592	chr3:49497883	T/G	cg07636037	chr3:49044803	WDR6	0.61	8.86	0.48	1.19e-16	Resting heart rate;
CESC	cis	rs2688608	0.592	rs11000759	chr10:75493726	G/A	cg23231163	chr10:75533350	FUT11	-0.36	-5.42	-0.32	1.36e-7	Inflammatory bowel disease;
CESC	trans	rs61931739	0.620	rs708143	chr12:33719962	A/C	cg26384229	chr12:38710491	ALG10B	0.55	8.21	0.45	9.66e-15	Morning vs. evening chronotype;
CESC	cis	rs847577	0.515	rs10953238	chr7:97676259	C/T	cg21770322	chr7:97807741	LMTK2	0.79	13.74	0.64	8.64e-33	Breast cancer;
CESC	cis	rs7923452	0.688	rs117895480	chr10:30788921	A/G	cg18806716	chr10:30721971	MAP3K8	0.46	5.61	0.33	5.02e-8	Itch intensity from mosquito bite;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg05617300	chr19:59093449	MGC2752	0.47	6.26	0.36	1.55e-9	Fibrinogen levels;
CESC	cis	rs2425143	1.000	rs73902908	chr20:34365112	G/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.69	5.95	0.34	8.54e-9	Blood protein levels;
CESC	cis	rs116095464	0.558	rs57335027	chr5:262907	A/G	cg10591111	chr5:226296	SDHA	-0.52	-6.35	-0.36	9.51e-10	Breast cancer;
CESC	cis	rs9926296	0.581	rs6500457	chr16:89898764	C/G	cg27121462	chr16:89883253	FANCA	-0.55	-6.87	-0.39	4.44e-11	Vitiligo;
CESC	cis	rs17253792	0.731	rs28587929	chr14:56097492	C/T	cg01858014	chr14:56050164	KTN1	-0.83	-7.03	-0.4	1.7e-11	Putamen volume;
CESC	cis	rs2952156	0.920	rs14050	chr17:37828072	C/T	cg07936489	chr17:37558343	FBXL20	-0.55	-6.84	-0.39	5.53e-11	Asthma;
CESC	cis	rs2124969	0.527	rs56040145	chr2:160983850	A/G	cg03641300	chr2:160917029	PLA2R1	-0.56	-5.77	-0.33	2.19e-8	Waist circumference adjusted for body mass index;
CESC	cis	rs7945705	0.714	rs2653570	chr11:8987823	A/G	cg12365402	chr11:9010492	NRIP3	-0.46	-7.82	-0.43	1.23e-13	Hemoglobin concentration;
CESC	cis	rs4819052	0.851	rs2838831	chr21:46664775	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.75	9.95	0.52	5.14e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs9916302	0.904	rs11078898	chr17:37536480	A/G	cg20243544	chr17:37824526	PNMT	-0.51	-6.43	-0.37	5.87e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs9549367	0.789	rs34568744	chr13:113894564	G/T	cg18105134	chr13:113819100	PROZ	-0.66	-7.97	-0.44	4.85e-14	Platelet distribution width;
CESC	cis	rs568617	0.953	rs658938	chr11:65651830	A/G	cg19792802	chr11:65647270	CTSW	-0.35	-5.31	-0.31	2.33e-7	Crohn's disease;
CESC	cis	rs798554	0.683	rs1636264	chr7:2864586	G/T	cg19717773	chr7:2847554	GNA12	-0.52	-7.42	-0.41	1.57e-12	Height;
CESC	cis	rs116095464	0.614	rs78905930	chr5:246560	G/A	cg10591111	chr5:226296	SDHA	-0.51	-6.17	-0.35	2.49e-9	Breast cancer;
CESC	cis	rs1832871	0.672	rs56115227	chr6:158773884	G/A	cg07165851	chr6:158734300	TULP4	0.59	6.35	0.36	9.19e-10	Height;
CESC	cis	rs7568458	0.709	rs1446669	chr2:85762209	T/C	cg02493740	chr2:85810744	VAMP5	-0.58	-8.52	-0.46	1.19e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CESC	cis	rs40363	0.645	rs250627	chr16:3527050	G/A	cg22508957	chr16:3507546	NAT15	0.54	8.53	0.46	1.11e-15	Tuberculosis;
CESC	cis	rs17376456	0.569	rs10057664	chr5:93182274	C/T	cg25358565	chr5:93447407	FAM172A	-0.71	-7.64	-0.43	3.86e-13	Diabetic retinopathy;
CESC	cis	rs4268898	0.662	rs12052954	chr2:24425620	C/T	cg06627628	chr2:24431161	ITSN2	0.94	10.38	0.54	2.18e-21	Asthma;
CESC	cis	rs950169	0.649	rs12905952	chr15:84691261	G/A	cg17507749	chr15:85114479	UBE2QP1	0.58	5.77	0.33	2.21e-8	Schizophrenia;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg12623088	chr15:66585521	DIS3L	-0.49	-6.21	-0.36	2.06e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs7727544	0.642	rs7705189	chr5:131623358	C/T	cg14196790	chr5:131705035	SLC22A5	-0.34	-5.1	-0.3	6.5e-7	Blood metabolite levels;
CESC	cis	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg13284614	chr3:52569169	NT5DC2;LOC440957	-0.35	-5.7	-0.33	3.13e-8	Bipolar disorder;
CESC	cis	rs634534	0.563	rs470192	chr11:65724291	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.45	6.65	0.38	1.71e-10	Sum eosinophil basophil counts;Eosinophil counts;
CESC	cis	rs2599510	0.755	rs67257914	chr2:32804018	G/A	cg02381751	chr2:32503542	YIPF4	0.45	5.46	0.32	1.1e-7	Interleukin-18 levels;
CESC	cis	rs9649213	0.593	rs13246843	chr7:98002661	G/T	cg21770322	chr7:97807741	LMTK2	0.57	8.84	0.48	1.39e-16	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs2836974	0.899	rs2836957	chr21:40623134	T/C	cg27266027	chr21:40555129	PSMG1	0.43	5.13	0.3	5.5e-7	Cognitive function;
CESC	cis	rs2243480	1.000	rs7787230	chr7:65629099	G/A	cg18252515	chr7:66147081	NA	1.36	13.62	0.64	2.25e-32	Diabetic kidney disease;
CESC	cis	rs11190604	0.832	rs2489041	chr10:102333635	G/C	cg07080220	chr10:102295463	HIF1AN	0.64	5.4	0.31	1.5e-7	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg05025164	chr4:1340916	KIAA1530	0.86	11.74	0.59	6.48e-26	Longevity;
CESC	cis	rs2842992	0.872	rs9456440	chr6:160074463	G/T	cg11366901	chr6:160182831	ACAT2	0.78	9.48	0.5	1.56e-18	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs7959452	0.590	rs6581889	chr12:69757429	T/C	cg20891283	chr12:69753455	YEATS4	0.9	14.78	0.67	1.84e-36	Blood protein levels;
CESC	cis	rs10504229	0.683	rs903702	chr8:58128557	T/C	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13470919	chr12:108955320	ISCU;SART3	-0.54	-6.56	-0.37	2.77e-10	Gut microbiome composition (summer);
CESC	cis	rs9467711	0.606	rs9379852	chr6:26357278	A/G	cg14345882	chr6:26364793	BTN3A2	0.59	6.06	0.35	4.66e-9	Autism spectrum disorder or schizophrenia;
CESC	trans	rs687914	0.710	rs938662	chr2:45864578	A/G	cg04297258	chr16:88772664	RNF166;CTU2	0.61	6.14	0.35	2.94e-9	Diastolic blood pressure;
CESC	cis	rs6736093	0.700	rs4848958	chr2:112785775	T/C	cg12686935	chr2:112915763	FBLN7	-0.4	-5.49	-0.32	9.27e-8	Coronary artery disease;
CESC	cis	rs6499255	0.951	rs2361838	chr16:69676086	T/C	cg15192750	chr16:69999425	NA	0.46	5.34	0.31	2.04e-7	IgE levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12926404	chr11:72145533	CLPB	0.57	6.57	0.37	2.6200000000000003e-10	Gut microbiome composition (summer);
CESC	cis	rs9487051	0.676	rs9398193	chr6:109593134	G/T	cg21918786	chr6:109611834	NA	-0.37	-5.41	-0.32	1.39e-7	Reticulocyte fraction of red cells;
CESC	cis	rs763121	0.853	rs3788545	chr22:39065172	A/G	cg21395723	chr22:39101663	GTPBP1	0.43	5.36	0.31	1.77e-7	Menopause (age at onset);
CESC	cis	rs10979	1.000	rs9390112	chr6:143896147	G/A	cg25407410	chr6:143891975	LOC285740	-0.58	-8.64	-0.47	5.28e-16	Hypospadias;
CESC	cis	rs769267	0.965	rs2074550	chr19:19387743	A/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.44	5.35	0.31	1.94e-7	Tonsillectomy;
CESC	cis	rs7855088	1.000	rs7855077	chr9:100742225	C/T	cg13688889	chr9:100608707	NA	-0.37	-5.52	-0.32	8.28e-8	Serum thyroid-stimulating hormone levels;
CESC	cis	rs7618915	0.501	rs3733039	chr3:52719088	C/T	cg18337363	chr3:52569053	NT5DC2	0.29	5.36	0.31	1.85e-7	Bipolar disorder;
CESC	cis	rs9910055	0.639	rs7217858	chr17:42254527	T/G	cg13607699	chr17:42295918	UBTF	0.56	7.08	0.4	1.31e-11	Total body bone mineral density;
CESC	cis	rs28374715	0.662	rs113913466	chr15:41483100	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.8	-10.46	-0.54	1.15e-21	Ulcerative colitis;
CESC	cis	rs12824058	0.831	rs12300308	chr12:130813825	G/A	cg24838063	chr12:130822603	PIWIL1	0.62	8.55	0.47	9.78e-16	Menopause (age at onset);
CESC	cis	rs9660992	0.710	rs1172138	chr1:205246019	G/A	cg21643547	chr1:205240462	TMCC2	-0.46	-6.16	-0.35	2.74e-9	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs2836950	0.501	rs35994303	chr21:40686020	C/T	cg11890956	chr21:40555474	PSMG1	-0.61	-8.26	-0.45	7.14e-15	Menarche (age at onset);
CESC	cis	rs17818399	1.000	rs62136864	chr2:46829124	G/A	cg02822958	chr2:46747628	ATP6V1E2	0.47	5.85	0.34	1.42e-8	Height;
CESC	cis	rs113835537	0.569	rs17496586	chr11:66315512	G/C	cg22134325	chr11:66188745	NPAS4	0.46	6.79	0.38	7.33e-11	Airway imaging phenotypes;
CESC	cis	rs7829975	0.714	rs11777085	chr8:8672429	G/C	cg15556689	chr8:8085844	FLJ10661	0.44	5.55	0.32	6.91e-8	Mood instability;
CESC	trans	rs724568	0.521	rs1430760	chr2:67947592	C/T	cg19718508	chr5:176831858	F12	-0.48	-6.03	-0.35	5.37e-9	Major depressive disorder (broad);
CESC	cis	rs6580649	0.941	rs72644841	chr12:48411987	A/G	cg05342945	chr12:48394962	COL2A1	0.49	5.64	0.33	4.44e-8	Lung cancer;
CESC	cis	rs2070997	0.756	rs3134875	chr9:133710072	G/C	cg11464064	chr9:133710261	ABL1	0.58	5.74	0.33	2.59e-8	Response to amphetamines;
CESC	cis	rs4665809	1.000	rs750450	chr2:26324631	A/G	cg08470875	chr2:26401718	FAM59B	-0.52	-5.8	-0.34	1.93e-8	Gut microbiome composition (summer);
CESC	cis	rs2228479	0.850	rs1800331	chr16:89858417	C/A	cg04013166	chr16:89971882	TCF25	0.77	6.61	0.38	2.05e-10	Skin colour saturation;
CESC	cis	rs3785574	0.962	rs2727331	chr17:61926990	G/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.57	7.02	0.4	1.91e-11	Height;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14064766	chr2:239344455	ASB1	-0.46	-6.03	-0.35	5.5e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs67311347	0.577	rs2371129	chr3:40248393	C/T	cg09455208	chr3:40491958	NA	-0.36	-5.74	-0.33	2.52e-8	Renal cell carcinoma;
CESC	cis	rs12579753	1.000	rs2400979	chr12:82197353	T/C	cg24719984	chr12:82153464	PPFIA2	-0.36	-5.07	-0.3	7.59e-7	Resting heart rate;
CESC	cis	rs3820068	0.581	rs16851876	chr1:15950628	A/T	cg17385448	chr1:15911702	AGMAT	-0.41	-6.68	-0.38	1.4e-10	Systolic blood pressure;
CESC	cis	rs2032447	0.839	rs199750	chr6:26016462	A/G	cg03264133	chr6:25882463	NA	0.47	6.69	0.38	1.32e-10	Intelligence (multi-trait analysis);
CESC	cis	rs1799949	0.965	rs799908	chr17:41278916	A/G	cg23758822	chr17:41437982	NA	0.99	16.77	0.72	1.6700000000000001e-43	Menopause (age at onset);
CESC	cis	rs7927592	0.731	rs11228275	chr11:68303980	G/A	cg01657329	chr11:68192670	LRP5	0.48	6.6	0.38	2.19e-10	Total body bone mineral density;
CESC	cis	rs9913156	0.748	rs55959711	chr17:4562581	C/A	cg00122941	chr17:4613640	ARRB2	0.85	9.99	0.52	3.79e-20	Lymphocyte counts;
CESC	cis	rs13108904	0.870	rs3775092	chr4:1240962	C/G	cg00684032	chr4:1343700	KIAA1530	0.39	5.51	0.32	8.54e-8	Obesity-related traits;
CESC	cis	rs1559088	0.948	rs7247748	chr19:33594023	T/C	cg17764715	chr19:33622953	WDR88	0.49	6.45	0.37	5.37e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs854765	0.583	rs7503334	chr17:17779458	C/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.49	-6.26	-0.36	1.58e-9	Total body bone mineral density;
CESC	cis	rs12190007	0.846	rs9505962	chr6:169726667	A/G	cg16388071	chr6:169726476	NA	0.43	6.06	0.35	4.69e-9	Obesity-related traits;
CESC	cis	rs875971	0.964	rs6978721	chr7:65883204	A/G	cg10691866	chr7:65817282	TPST1	-0.34	-5.47	-0.32	1.06e-7	Aortic root size;
CESC	cis	rs9303280	0.806	rs12232498	chr17:38040363	T/C	cg20243544	chr17:37824526	PNMT	0.5	6.54	0.37	3.21e-10	Self-reported allergy;
CESC	cis	rs1912483	0.505	rs3760372	chr17:45380002	T/C	cg25173405	chr17:45401733	C17orf57	-0.5	-5.78	-0.33	2.09e-8	Coronary artery disease;
CESC	cis	rs873946	0.586	rs12776770	chr10:134564831	T/C	cg06453172	chr10:134556979	INPP5A	-0.39	-5.08	-0.3	7.01e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg11301795	chr4:187892539	NA	-0.74	-11.49	-0.58	4.63e-25	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2625529	0.652	rs1481862	chr15:72245648	G/A	cg16672083	chr15:72433130	SENP8	0.4	6.1	0.35	3.78e-9	Red blood cell count;
CESC	cis	rs9324022	0.790	rs56011271	chr14:101167732	C/T	cg18089426	chr14:101175970	NA	0.56	5.88	0.34	1.25e-8	Plateletcrit;
CESC	cis	rs12586317	0.620	rs2295104	chr14:35579927	A/G	cg16230307	chr14:35515116	FAM177A1	-0.83	-9.13	-0.49	1.76e-17	Psoriasis;
CESC	cis	rs9649213	0.593	rs6947208	chr7:97912204	C/T	cg08684580	chr7:98029266	BAIAP2L1	-0.33	-5.2	-0.3	3.97e-7	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs11098499	0.954	rs11722872	chr4:120233030	G/C	cg25214090	chr10:38739885	LOC399744	0.7	9.63	0.51	5.2e-19	Corneal astigmatism;
CESC	cis	rs1707322	0.752	rs11211171	chr1:46168642	A/G	cg05343316	chr1:45956843	TESK2	0.51	6.32	0.36	1.09e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs12973672	1.000	rs12975284	chr19:35770962	G/C	cg12095397	chr19:35769544	USF2	0.54	7.35	0.41	2.49e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs35306767	0.714	rs67696450	chr10:1090684	C/T	cg26597838	chr10:835615	NA	0.63	5.95	0.34	8.67e-9	Eosinophil percentage of granulocytes;
CESC	cis	rs9487051	0.676	rs7775206	chr6:109597222	A/G	cg01475377	chr6:109611718	NA	-0.45	-7.04	-0.4	1.6e-11	Reticulocyte fraction of red cells;
CESC	cis	rs6740322	1.000	rs11693666	chr2:43562479	A/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.59	6.65	0.38	1.66e-10	Coronary artery disease;
CESC	cis	rs7618915	0.547	rs34215106	chr3:52659124	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	6.88	0.39	4.18e-11	Bipolar disorder;
CESC	cis	rs35306767	0.715	rs17221456	chr10:1037234	T/C	cg25019033	chr10:957182	NA	-0.6	-5.9	-0.34	1.14e-8	Eosinophil percentage of granulocytes;
CESC	cis	rs1775148	1	rs1775148	chr1:205757824	C/T	cg14159672	chr1:205819179	PM20D1	0.48	6.78	0.38	7.83e-11	Prostate cancer;
CESC	cis	rs2228479	0.717	rs34027607	chr16:89808939	T/C	cg04287289	chr16:89883240	FANCA	0.71	6.53	0.37	3.42e-10	Skin colour saturation;
CESC	cis	rs875971	0.792	rs6971752	chr7:65737986	G/A	cg11764359	chr7:65958608	NA	-0.79	-12.0	-0.59	9.01e-27	Aortic root size;
CESC	cis	rs1448094	0.506	rs61930640	chr12:86173333	T/C	cg00310523	chr12:86230176	RASSF9	0.43	6.48	0.37	4.4e-10	Major depressive disorder;
CESC	cis	rs67478160	0.643	rs11626377	chr14:104234357	G/A	cg08213375	chr14:104286397	PPP1R13B	0.55	11.09	0.56	9.71e-24	Schizophrenia;
CESC	trans	rs2727020	0.681	rs2866362	chr11:49379316	A/G	cg15704280	chr7:45808275	SEPT13	-0.87	-14.48	-0.66	2.03e-35	Coronary artery disease;
CESC	cis	rs3815700	0.920	rs10426856	chr19:33096406	A/G	cg24916020	chr19:33096688	ANKRD27	0.61	6.1	0.35	3.64e-9	Eosinophilic esophagitis;
CESC	trans	rs4950322	0.570	rs79810882	chr1:146707223	G/T	cg04954894	chr8:38089920	DDHD2	-0.59	-6.17	-0.35	2.59e-9	Protein quantitative trait loci;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13171016	chr1:40219054	PPIE	-0.65	-7.86	-0.43	9.72e-14	Gut microbiome composition (summer);
CESC	cis	rs344364	0.511	rs1742472	chr16:1953040	A/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.52	-5.87	-0.34	1.29e-8	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs7267979	1.000	rs2258769	chr20:25276680	G/C	cg08601574	chr20:25228251	PYGB	0.39	5.57	0.32	6.14e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs3091242	0.933	rs35148262	chr1:25766623	A/G	cg03538708	chr1:25844672	NA	-0.42	-6.34	-0.36	9.58e-10	Erythrocyte sedimentation rate;
CESC	cis	rs2732480	0.557	rs2732454	chr12:48719677	T/C	cg04545296	chr12:48745243	ZNF641	0.36	6.27	0.36	1.49e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs61008539	0.893	rs11765528	chr7:861952	C/T	cg00475322	chr7:917719	C7orf20	0.44	6.49	0.37	4.2e-10	Perceived unattractiveness to mosquitoes;
CESC	cis	rs10791323	0.569	rs5019134	chr11:133713082	G/C	cg15485101	chr11:133734466	NA	0.4	6.59	0.38	2.34e-10	Childhood ear infection;
CESC	cis	rs9611565	0.694	rs5751107	chr22:41857812	A/G	cg17376030	chr22:41985996	PMM1	-0.74	-7.87	-0.44	9.15e-14	Vitiligo;
CESC	cis	rs9287719	0.967	rs6432119	chr2:10753687	A/T	cg00105475	chr2:10696890	NA	0.38	5.42	0.32	1.34e-7	Prostate cancer;
CESC	cis	rs6570726	0.935	rs387965	chr6:145869366	A/G	cg23711669	chr6:146136114	FBXO30	0.78	11.34	0.57	1.42e-24	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7809950	1.000	rs7778270	chr7:107224667	A/G	cg23024343	chr7:107201750	COG5	0.4	5.58	0.32	5.8e-8	Coronary artery disease;
CESC	cis	rs4472734	0.932	rs6540833	chr1:214627389	T/G	cg00063699	chr1:214624242	PTPN14	-0.33	-5.05	-0.3	8.33e-7	Height;
CESC	cis	rs6860806	0.531	rs274556	chr5:131722075	A/G	cg24060327	chr5:131705240	SLC22A5	0.77	10.88	0.56	4.95e-23	Breast cancer;
CESC	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg05457628	chr5:178986728	RUFY1	0.54	8.23	0.45	8.35e-15	Lung cancer;
CESC	cis	rs7520050	0.931	rs785472	chr1:46518288	T/A	cg03146154	chr1:46216737	IPP	-0.44	-5.72	-0.33	2.88e-8	Red blood cell count;Reticulocyte count;
CESC	cis	rs858239	0.539	rs6955726	chr7:23186691	A/G	cg23682824	chr7:23144976	KLHL7	0.5	6.58	0.37	2.5e-10	Cerebrospinal fluid biomarker levels;
CESC	cis	rs3892630	0.878	rs7246451	chr19:33209614	C/G	cg22980127	chr19:33182716	NUDT19	1.06	11.32	0.57	1.71e-24	Red blood cell traits;
CESC	cis	rs763121	0.819	rs5750658	chr22:39060917	C/T	cg21395723	chr22:39101663	GTPBP1	0.43	5.37	0.31	1.74e-7	Menopause (age at onset);
CESC	cis	rs2952156	0.920	rs732083	chr17:37834367	G/A	cg20243544	chr17:37824526	PNMT	0.62	8.34	0.46	4.13e-15	Asthma;
CESC	cis	rs11583043	0.546	rs6688545	chr1:101590335	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.49	5.43	0.32	1.28e-7	Ulcerative colitis;Inflammatory bowel disease;
CESC	cis	rs17376456	0.877	rs10055340	chr5:93317644	T/C	cg25358565	chr5:93447407	FAM172A	1.07	10.7	0.55	1.86e-22	Diabetic retinopathy;
CESC	cis	rs2243480	1.000	rs313807	chr7:65499481	C/T	cg13147721	chr7:65941812	NA	-0.86	-8.36	-0.46	3.7e-15	Diabetic kidney disease;
CESC	cis	rs4819052	0.851	rs35064782	chr21:46674360	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.47	5.77	0.33	2.19e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs4713118	0.586	rs6905522	chr6:28086479	A/C	cg23281280	chr6:28129359	ZNF389	0.58	7.93	0.44	6.31e-14	Parkinson's disease;
CESC	cis	rs362272	0.505	rs60208975	chr4:3364530	A/G	cg14583973	chr4:3374767	RGS12	0.32	5.57	0.32	6.25e-8	Serum sulfate level;
CESC	cis	rs12476592	0.602	rs2166497	chr2:63800159	C/T	cg17519650	chr2:63277830	OTX1	-0.48	-5.42	-0.32	1.34e-7	Childhood ear infection;
CESC	cis	rs9399137	0.507	rs13209780	chr6:135344795	G/C	cg24558204	chr6:135376177	HBS1L	0.7	9.93	0.52	5.68e-20	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	cis	rs6456156	0.528	rs6936261	chr6:167469676	A/C	cg23791538	chr6:167370224	RNASET2	-0.52	-6.73	-0.38	1.06e-10	Primary biliary cholangitis;
CESC	cis	rs7927771	0.524	rs4752798	chr11:47886364	T/C	cg18512352	chr11:47633146	NA	-0.36	-5.57	-0.32	6.3e-8	Subjective well-being;
CESC	cis	rs9910055	0.529	rs228748	chr17:42174390	G/A	cg13607699	chr17:42295918	UBTF	-0.55	-7.05	-0.4	1.58e-11	Total body bone mineral density;
CESC	cis	rs8141529	0.956	rs469989	chr22:29303595	G/C	cg15103426	chr22:29168792	CCDC117	-0.53	-6.29	-0.36	1.34e-9	Lymphocyte counts;
CESC	cis	rs6502050	0.835	rs3935128	chr17:80113414	T/C	cg11859384	chr17:80120422	CCDC57	-0.39	-5.37	-0.31	1.76e-7	Life satisfaction;
CESC	cis	rs5769765	0.728	rs6520064	chr22:50294469	A/G	cg02269571	chr22:50332266	NA	-0.45	-6.03	-0.35	5.63e-9	Schizophrenia;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg09219196	chr12:53901441	NPFF	-0.45	-6.25	-0.36	1.6e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs2731664	0.792	rs385981	chr5:176886539	C/T	cg23176889	chr5:176863531	GRK6	-0.62	-10.96	-0.56	2.64e-23	Intelligence (multi-trait analysis);
CESC	cis	rs2290159	0.571	rs7637392	chr3:12696433	A/G	cg23032965	chr3:12705835	RAF1	0.53	5.7	0.33	3.12e-8	Cholesterol, total;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg20650035	chr12:29542837	NA	-0.45	-6.36	-0.36	8.68e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs11098499	0.697	rs10020027	chr4:120381879	G/C	cg24375607	chr4:120327624	NA	0.44	5.51	0.32	8.65e-8	Corneal astigmatism;
CESC	cis	rs7219014	1	rs7219014	chr17:37624790	A/G	cg00129232	chr17:37814104	STARD3	-0.51	-6.41	-0.37	6.79e-10	Urinary metabolites;
CESC	cis	rs4148883	0.713	rs3828541	chr4:100042262	A/G	cg12011299	chr4:100065546	ADH4	0.66	9.79	0.52	1.56e-19	Alcohol dependence;
CESC	cis	rs13191362	0.935	rs66923841	chr6:163177317	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.95	8.85	0.48	1.3e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs708547	0.871	rs2687238	chr4:57880474	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.68	7.91	0.44	6.86e-14	Response to bleomycin (chromatid breaks);
CESC	cis	rs738322	0.839	rs9607517	chr22:38596100	G/A	cg17652424	chr22:38574118	PLA2G6	0.3	5.21	0.3	3.84e-7	Cutaneous nevi;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11053272	chr21:42540868	BACE2	0.56	6.0	0.35	6.31e-9	Gut microbiome composition (summer);
CESC	cis	rs796364	0.806	rs1509832	chr2:200874443	G/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.85	7.76	0.43	1.81e-13	Schizophrenia;
CESC	cis	rs514406	0.644	rs1855127	chr1:53199594	A/G	cg27535305	chr1:53392650	SCP2	0.35	6.19	0.36	2.25e-9	Monocyte count;
CESC	cis	rs9309473	0.519	rs6730785	chr2:73642403	A/C	cg20560298	chr2:73613845	ALMS1	0.48	6.82	0.39	6.22e-11	Metabolite levels;
CESC	cis	rs6952808	0.692	rs6950627	chr7:2086672	C/T	cg21782813	chr7:2030301	MAD1L1	0.46	6.45	0.37	5.27e-10	Bipolar disorder and schizophrenia;
CESC	cis	rs11711311	0.955	rs12636536	chr3:113474226	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.72	10.04	0.52	2.67e-20	IgG glycosylation;
CESC	cis	rs172166	0.694	rs1770131	chr6:28086413	C/T	cg26335602	chr6:28129616	ZNF389	0.38	5.53	0.32	7.72e-8	Cardiac Troponin-T levels;
CESC	cis	rs7909074	0.899	rs2026428	chr10:45389452	T/C	cg05187965	chr10:45406764	TMEM72	-0.33	-5.06	-0.3	7.83e-7	Mean corpuscular volume;
CESC	cis	rs2295499	0.673	rs4690016	chr4:2707132	G/A	cg08330972	chr4:2403930	ZFYVE28	-0.32	-5.24	-0.31	3.34e-7	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
CESC	cis	rs7385804	0.766	rs1734909	chr7:100309582	C/G	cg20848291	chr7:100343083	ZAN	0.48	6.46	0.37	5.08e-10	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
CESC	cis	rs1862618	0.853	rs2432195	chr5:56120413	C/T	cg24531977	chr5:56204891	C5orf35	-0.88	-11.52	-0.58	3.54e-25	Initial pursuit acceleration;
CESC	cis	rs7552404	0.627	rs12127049	chr1:76353248	G/A	cg03433033	chr1:76189801	ACADM	0.59	5.78	0.33	2.13e-8	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs1862618	0.853	rs1423620	chr5:56100996	G/T	cg24531977	chr5:56204891	C5orf35	-0.82	-11.08	-0.56	1.05e-23	Initial pursuit acceleration;
CESC	cis	rs1580019	0.961	rs4320456	chr7:32496003	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.73	10.15	0.53	1.14e-20	Cognitive ability;
CESC	cis	rs7267979	1.000	rs2258563	chr20:25273435	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	18.66	0.75	3.33e-50	Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03092607	chr2:96068514	FAHD2A	0.52	6.23	0.36	1.87e-9	Gut microbiome composition (summer);
CESC	cis	rs977987	0.806	rs4888386	chr16:75389740	A/G	cg03315344	chr16:75512273	CHST6	0.41	5.88	0.34	1.21e-8	Dupuytren's disease;
CESC	cis	rs6967414	0.786	rs7804259	chr7:6755448	C/G	cg09896999	chr7:6746977	ZNF12	-0.54	-6.37	-0.36	8.11e-10	Hematocrit;Hemoglobin concentration;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08117032	chr8:38325144	FGFR1	0.52	6.07	0.35	4.48e-9	Gut microbiome composition (summer);
CESC	cis	rs3736485	0.932	rs4774592	chr15:51778879	C/T	cg08986416	chr15:51914746	DMXL2	-0.42	-5.48	-0.32	9.91e-8	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs6991838	0.584	rs61083799	chr8:66487103	C/T	cg13398993	chr8:66546079	ARMC1	-0.46	-5.54	-0.32	7.22e-8	Intelligence (multi-trait analysis);
CESC	cis	rs875971	0.862	rs2088653	chr7:65808608	G/A	cg19163074	chr7:65112434	INTS4L2	0.41	5.18	0.3	4.32e-7	Aortic root size;
CESC	cis	rs9908102	0.740	rs73981611	chr17:12904084	C/T	cg26162695	chr17:12921313	ELAC2	0.5	5.49	0.32	9.61e-8	Schizophrenia;
CESC	cis	rs7666738	0.830	rs34461023	chr4:99023751	C/T	cg03467027	chr4:99064603	C4orf37	0.47	5.96	0.34	8.19e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs853679	0.517	rs4713152	chr6:28137454	G/A	cg23161317	chr6:28129485	ZNF389	0.47	5.89	0.34	1.18e-8	Depression;
CESC	cis	rs2408955	0.521	rs7301003	chr12:48550227	A/G	cg24011408	chr12:48396354	COL2A1	0.5	7.48	0.42	1.12e-12	Glycated hemoglobin levels;
CESC	cis	rs2306032	0.575	rs7111517	chr11:46803708	A/C	cg25783544	chr11:47291846	MADD	-0.43	-5.09	-0.3	6.64e-7	Total body bone mineral density;
CESC	cis	rs654950	0.934	rs654220	chr1:42002556	A/T	cg06885757	chr1:42089581	HIVEP3	-0.65	-10.46	-0.54	1.14e-21	Airway imaging phenotypes;
CESC	cis	rs7937682	0.575	rs34888817	chr11:111756455	C/T	cg22437258	chr11:111473054	SIK2	-0.48	-5.31	-0.31	2.31e-7	Primary sclerosing cholangitis;
CESC	cis	rs875971	0.660	rs1860470	chr7:66103694	G/C	cg06456125	chr7:65229604	NA	-0.38	-5.04	-0.3	8.73e-7	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21275663	chr21:45744644	PFKL	-0.51	-6.12	-0.35	3.33e-9	Gut microbiome composition (summer);
CESC	cis	rs2836950	0.565	rs2150413	chr21:40614878	C/T	cg17971929	chr21:40555470	PSMG1	-0.58	-7.57	-0.42	6.01e-13	Menarche (age at onset);
CESC	cis	rs9905704	0.813	rs304269	chr17:56802059	A/G	cg12560992	chr17:57184187	TRIM37	-0.6	-7.56	-0.42	6.51e-13	Testicular germ cell tumor;
CESC	cis	rs7208859	0.725	rs7342938	chr17:29189830	A/G	cg19761014	chr17:28927070	LRRC37B2	0.57	5.71	0.33	2.96e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs10896135	0.526	rs12795774	chr11:66381517	T/C	cg24851651	chr11:66362959	CCS	-0.54	-7.2	-0.4	6.06e-12	Bipolar disorder;
CESC	cis	rs8180040	0.805	rs17410853	chr3:47363971	G/T	cg27129171	chr3:47204927	SETD2	-0.66	-9.99	-0.52	3.66e-20	Colorectal cancer;
CESC	cis	rs875971	1.000	rs778726	chr7:65828731	C/T	cg10691866	chr7:65817282	TPST1	-0.34	-5.46	-0.32	1.08e-7	Aortic root size;
CESC	cis	rs10504229	0.679	rs16921676	chr8:58052386	G/T	cg22535103	chr8:58192502	C8orf71	-0.69	-7.45	-0.42	1.33e-12	Developmental language disorder (linguistic errors);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg00577969	chr11:122156457	NA	-0.4	-6.51	-0.37	3.7e-10	Gambling;
CESC	cis	rs9811920	0.809	rs4577503	chr3:99657922	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.42	-5.41	-0.32	1.44e-7	Axial length;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg11094161	chr14:57736037	MUDENG;EXOC5	-0.43	-6.31	-0.36	1.15e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs3820928	1.000	rs4675119	chr2:227774635	A/C	cg05526886	chr2:227700861	RHBDD1	-0.39	-5.15	-0.3	5.02e-7	Pulmonary function;
CESC	cis	rs7727544	0.735	rs270605	chr5:131651811	C/T	cg24060327	chr5:131705240	SLC22A5	-0.65	-8.74	-0.47	2.8e-16	Blood metabolite levels;
CESC	cis	rs875971	0.508	rs6947808	chr7:66045082	A/G	cg14393609	chr7:65229607	NA	-0.41	-5.77	-0.33	2.21e-8	Aortic root size;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg04306489	chr17:16593582	CCDC144A	-0.47	-6.37	-0.36	8.48e-10	Thyroid stimulating hormone;
CESC	cis	rs13091206	1	rs13091206	chr3:49238718	A/G	cg07636037	chr3:49044803	WDR6	0.84	10.06	0.53	2.18e-20	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs1448094	0.781	rs7959093	chr12:86335502	C/A	cg02569458	chr12:86230093	RASSF9	0.44	6.29	0.36	1.3e-9	Major depressive disorder;
CESC	cis	rs3793683	0.545	rs12784407	chr10:134589631	A/G	cg26818010	chr10:134567672	INPP5A	-0.91	-11.05	-0.56	1.3e-23	Migraine;
CESC	cis	rs2842992	0.724	rs2273827	chr6:160211339	C/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.77	11.06	0.56	1.26e-23	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs9815354	1.000	rs1612124	chr3:41967893	C/A	cg03022575	chr3:42003672	ULK4	-0.46	-5.37	-0.31	1.76e-7	Pulse pressure;Diastolic blood pressure;
CESC	trans	rs208520	0.690	rs1351867	chr6:66760995	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.94	12.07	0.6	5.01e-27	Exhaled nitric oxide output;
CESC	cis	rs6952808	0.692	rs56727870	chr7:2029940	T/C	cg22963979	chr7:1858916	MAD1L1	-0.38	-5.14	-0.3	5.29e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs875971	0.862	rs4368860	chr7:65608482	C/G	cg11764359	chr7:65958608	NA	-0.78	-11.38	-0.57	1.07e-24	Aortic root size;
CESC	cis	rs35955747	0.870	rs7289189	chr22:31657182	C/T	cg25791279	chr22:32026902	PISD	-0.49	-5.79	-0.34	1.99e-8	Neutrophil count;Sum basophil neutrophil counts;
CESC	cis	rs9325144	0.600	rs12227663	chr12:38734922	C/T	cg26384229	chr12:38710491	ALG10B	-0.56	-7.82	-0.43	1.27e-13	Morning vs. evening chronotype;
CESC	cis	rs2249694	0.960	rs2515642	chr10:135352013	C/T	cg20169779	chr10:135381914	SYCE1	0.4	5.28	0.31	2.76e-7	Obesity-related traits;
CESC	cis	rs7084402	0.565	rs7912792	chr10:60335179	C/T	cg07615347	chr10:60278583	BICC1	0.4	5.83	0.34	1.57e-8	Refractive error;
CESC	trans	rs2727020	0.521	rs10839285	chr11:49496852	T/G	cg03929089	chr4:120376271	NA	0.72	8.84	0.48	1.35e-16	Coronary artery disease;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg08328324	chr8:33370759	C8orf41	0.49	6.78	0.38	8.01e-11	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs4975709	0.610	rs4975704	chr5:1859807	C/A	cg19770292	chr5:1868693	NA	0.3	5.09	0.3	6.71e-7	Cardiovascular disease risk factors;
CESC	cis	rs1215050	0.791	rs10856931	chr4:98819306	C/T	cg05340658	chr4:99064831	C4orf37	0.51	6.62	0.38	1.98e-10	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs6500602	0.627	rs709632	chr16:4587811	C/G	cg08645402	chr16:4508243	NA	-0.4	-6.12	-0.35	3.36e-9	Schizophrenia;
CESC	cis	rs2806561	0.514	rs10917360	chr1:23539010	C/T	cg19743168	chr1:23544995	NA	0.37	5.6	0.33	5.37e-8	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05341670	chr1:54518153	TMEM59;C1orf83	-0.56	-6.31	-0.36	1.19e-9	Gut microbiome composition (summer);
CESC	cis	rs9354352	0.935	rs9354354	chr6:66699333	A/G	cg07460842	chr6:66804631	NA	-0.66	-9.83	-0.52	1.18e-19	Initial pursuit acceleration in psychotic disorders;
CESC	cis	rs2882667	0.858	rs11956159	chr5:138408568	T/C	cg04439458	chr5:138467593	SIL1	-0.36	-5.74	-0.33	2.59e-8	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs1801251	1.000	rs6738386	chr2:233602028	T/C	cg08000102	chr2:233561755	GIGYF2	0.64	9.1	0.49	2.29e-17	Coronary artery disease;
CESC	cis	rs12701220	0.553	rs34062359	chr7:1139076	C/T	cg23978390	chr7:1156363	C7orf50	0.59	5.29	0.31	2.6e-7	Bronchopulmonary dysplasia;
CESC	cis	rs780096	0.587	rs6743819	chr2:27567407	G/T	cg17158414	chr2:27665306	KRTCAP3	-0.32	-6.03	-0.35	5.59e-9	Total body bone mineral density;
CESC	cis	rs1983891	0.673	rs9381083	chr6:41570250	T/A	cg20194872	chr6:41519635	FOXP4	0.44	6.32	0.36	1.09e-9	Prostate cancer;
CESC	cis	rs2433610	1	rs2433610	chr15:45686091	C/T	cg21523688	chr15:45319037	SORD	-0.77	-5.17	-0.3	4.7e-7	Serum metabolite levels;
CESC	cis	rs722599	0.628	rs12896360	chr14:75278181	A/C	cg11812906	chr14:75593930	NEK9	0.42	5.16	0.3	4.83e-7	IgG glycosylation;
CESC	cis	rs8072100	0.713	rs2292346	chr17:45455473	G/A	cg08085267	chr17:45401833	C17orf57	-0.51	-6.49	-0.37	4.12e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg01089395	chr6:139094051	CCDC28A	0.46	6.29	0.36	1.3e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs4466137	0.953	rs6869030	chr5:83007311	C/T	cg16102102	chr5:83017553	HAPLN1	-0.49	-7.05	-0.4	1.56e-11	Prostate cancer;
CESC	cis	rs6968419	0.755	rs2402057	chr7:115897096	C/T	cg02561103	chr7:115862891	TES	0.41	5.28	0.31	2.7e-7	Intraocular pressure;
CESC	cis	rs6938	0.534	rs4886636	chr15:75196176	G/A	cg10253484	chr15:75165896	SCAMP2	-0.53	-7.11	-0.4	1.09e-11	Breast cancer;
CESC	cis	rs12711979	0.509	rs13005405	chr2:3826324	C/T	cg17052675	chr2:3827356	NA	-0.67	-11.05	-0.56	1.35e-23	Itch intensity from mosquito bite adjusted by bite size;
CESC	cis	rs2050392	0.792	rs9338188	chr10:30721963	G/C	cg18806716	chr10:30721971	MAP3K8	-0.41	-5.8	-0.34	1.85e-8	Inflammatory bowel disease;
CESC	cis	rs7412746	0.611	rs111905669	chr1:150777565	T/C	cg22823121	chr1:150693482	HORMAD1	0.47	6.6	0.38	2.22e-10	Melanoma;
CESC	cis	rs8180040	0.966	rs1872164	chr3:47415100	G/A	cg27129171	chr3:47204927	SETD2	-0.64	-10.03	-0.52	2.77e-20	Colorectal cancer;
CESC	cis	rs4237845	0.537	rs10877031	chr12:58266695	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.5	5.62	0.33	4.83e-8	Intelligence (multi-trait analysis);
CESC	cis	rs7542091	0.704	rs9429825	chr1:210052133	C/G	cg21951975	chr1:209979733	IRF6	0.46	8.16	0.45	1.32e-14	Monobrow;
CESC	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.08	20.46	0.78	1.77e-56	Prudent dietary pattern;
CESC	cis	rs748404	0.697	rs473554	chr15:43568207	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	7.83	0.43	1.19e-13	Lung cancer;
CESC	cis	rs477692	0.967	rs496692	chr10:131429100	C/T	cg05714579	chr10:131428358	MGMT	0.51	6.88	0.39	4.41e-11	Response to temozolomide;
CESC	cis	rs896854	0.818	rs896855	chr8:95959808	A/G	cg26343298	chr8:95960752	TP53INP1	0.37	6.1	0.35	3.7e-9	Type 2 diabetes;
CESC	cis	rs17102884	0.506	rs887746	chr14:75403817	C/T	cg08847533	chr14:75593920	NEK9	-0.42	-5.29	-0.31	2.59e-7	Neuroticism;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg17902007	chr13:101184847	A2LD1	0.49	6.61	0.38	2.05e-10	Fibrinogen levels;
CESC	cis	rs2243480	1.000	rs13247184	chr7:65358928	A/G	cg18252515	chr7:66147081	NA	-1.18	-11.4	-0.57	9.2e-25	Diabetic kidney disease;
CESC	cis	rs875971	0.564	rs313804	chr7:65514622	A/G	cg11764359	chr7:65958608	NA	0.88	13.01	0.62	3.05e-30	Aortic root size;
CESC	cis	rs2841277	0.708	rs11851053	chr14:105407208	T/C	cg14403583	chr14:105418241	AHNAK2	-0.57	-7.86	-0.43	9.9e-14	Rheumatoid arthritis;
CESC	cis	rs6582630	0.513	rs1596446	chr12:38282160	C/T	cg26384229	chr12:38710491	ALG10B	-0.66	-9.14	-0.49	1.69e-17	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs2880765	0.743	rs4551990	chr15:86015287	A/C	cg10818794	chr15:86012489	AKAP13	-0.36	-5.61	-0.33	5.16e-8	Coronary artery disease;
CESC	cis	rs2304069	0.954	rs9324638	chr5:149400718	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.82	-9.76	-0.51	2.06e-19	HIV-1 control;
CESC	cis	rs796364	0.951	rs6722092	chr2:201059371	G/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.6	6.1	0.35	3.68e-9	Schizophrenia;
CESC	trans	rs35110281	0.744	rs162396	chr21:44947807	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.49	6.57	0.37	2.65e-10	Mean corpuscular volume;
CESC	cis	rs863345	0.967	rs2317957	chr1:158467487	A/C	cg12129480	chr1:158549410	OR10X1	-0.32	-6.27	-0.36	1.42e-9	Pneumococcal bacteremia;
CESC	cis	rs9322193	0.884	rs9480009	chr6:150079638	A/G	cg13206674	chr6:150067644	NUP43	0.46	6.63	0.38	1.84e-10	Lung cancer;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg23959119	chr19:42806179	PRR19;PAFAH1B3	-0.48	-6.25	-0.36	1.67e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg15042806	chr16:23652268	DCTN5;PALB2	-0.45	-6.5	-0.37	4.04e-10	Gambling;
CESC	cis	rs3741151	1.000	rs7122825	chr11:73061324	C/T	cg17517138	chr11:73019481	ARHGEF17	1.02	6.92	0.39	3.3e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs1153858	1.000	rs3759899	chr15:45655903	T/C	cg14582100	chr15:45693742	SPATA5L1	0.42	5.96	0.34	7.92e-9	Homoarginine levels;
CESC	cis	rs72945132	0.882	rs12278741	chr11:70135742	A/G	cg14191688	chr11:70257035	CTTN	0.41	5.27	0.31	2.9e-7	Coronary artery disease;
CESC	cis	rs1375194	0.606	rs935625	chr2:33811516	C/G	cg04131969	chr2:33951647	MYADML	-0.52	-6.43	-0.37	6.09e-10	Response to antidepressants in depression;
CESC	cis	rs748404	0.660	rs493377	chr15:43773467	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.51	7.9	0.44	7.27e-14	Lung cancer;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg13088374	chr7:43965618	URGCP;UBE2D4	-0.5	-6.0	-0.35	6.42e-9	Ulcerative colitis;
CESC	cis	rs66887589	0.934	rs6817317	chr4:120542827	A/G	cg09307838	chr4:120376055	NA	-0.46	-6.27	-0.36	1.46e-9	Diastolic blood pressure;
CESC	cis	rs7845219	0.544	rs7001535	chr8:95921090	C/G	cg13393036	chr8:95962371	TP53INP1	-0.42	-7.77	-0.43	1.69e-13	Type 2 diabetes;
CESC	cis	rs736408	0.609	rs13095332	chr3:52787242	C/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.31	5.5	0.32	9.14e-8	Bipolar disorder;
CESC	trans	rs4349753	0.663	rs10065677	chr5:144070311	C/T	cg22407458	chr6:35109121	TCP11	0.5	6.28	0.36	1.37e-9	Photic sneeze reflex;
CESC	cis	rs727563	0.648	rs6002406	chr22:41965237	A/T	cg17376030	chr22:41985996	PMM1	0.75	7.88	0.44	8.52e-14	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs12142240	0.692	rs7529674	chr1:46818508	T/C	cg00530320	chr1:46809349	NSUN4	0.58	7.89	0.44	8.15e-14	Menopause (age at onset);
CESC	cis	rs963731	0.649	rs297150	chr2:39326164	C/T	cg04010122	chr2:39346883	SOS1	-0.67	-5.4	-0.31	1.47e-7	Corticobasal degeneration;
CESC	cis	rs34779708	0.931	rs4934719	chr10:35376769	T/C	cg03585969	chr10:35415529	CREM	0.77	10.07	0.53	2.06e-20	Inflammatory bowel disease;Crohn's disease;
CESC	trans	rs875971	0.638	rs6460305	chr7:66060408	G/A	cg26939375	chr7:64535504	NA	-0.64	-8.62	-0.47	6.24e-16	Aortic root size;
CESC	cis	rs1218582	0.774	rs4845681	chr1:154868055	G/T	cg03351412	chr1:154909251	PMVK	0.58	7.66	0.43	3.41e-13	Prostate cancer;
CESC	cis	rs736408	0.609	rs13061423	chr3:52790213	T/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.33	0.36	1.04e-9	Bipolar disorder;
CESC	cis	rs7267979	1.000	rs2482940	chr20:25349830	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.84	-15.92	-0.7	1.72e-40	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs11676348	0.818	rs4674256	chr2:218987893	A/T	cg00012203	chr2:219082015	ARPC2	-0.56	-7.31	-0.41	3.19e-12	Ulcerative colitis;
CESC	cis	rs6831352	0.505	rs11722561	chr4:100088737	T/A	cg12011299	chr4:100065546	ADH4	0.41	5.76	0.33	2.39e-8	Alcohol dependence;
CESC	cis	rs6089584	0.888	rs2146853	chr20:60617908	A/T	cg13770153	chr20:60521292	NA	-0.44	-5.7	-0.33	3.2e-8	Body mass index;
CESC	cis	rs4563143	0.663	rs10406794	chr19:29228056	C/T	cg04546413	chr19:29218101	NA	0.45	6.77	0.38	8.24e-11	Methadone dose in opioid dependence;
CESC	trans	rs459571	0.959	rs392134	chr9:136909008	G/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.66	-8.6	-0.47	7.24e-16	Platelet distribution width;
CESC	cis	rs6540559	0.611	rs6540563	chr1:210019858	C/G	cg23283495	chr1:209979779	IRF6	0.48	5.59	0.32	5.57e-8	Cleft lip with or without cleft palate;
CESC	cis	rs6942756	0.876	rs28636722	chr7:129015151	C/T	cg02491457	chr7:128862824	NA	-0.58	-8.07	-0.44	2.49e-14	White matter hyperintensity burden;
CESC	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg24829409	chr8:58192753	C8orf71	-0.65	-7.36	-0.41	2.29e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs473651	0.935	rs477041	chr2:239355995	C/G	cg18131467	chr2:239335373	ASB1	-1.03	-20.53	-0.78	1.08e-56	Multiple system atrophy;
CESC	cis	rs916888	0.821	rs199505	chr17:44859410	A/G	cg14517863	chr17:44321492	NA	-0.4	-5.16	-0.3	4.79e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs3747547	1.000	rs11790880	chr9:37918219	A/T	cg13774184	chr9:37916125	SHB	-0.73	-6.14	-0.35	2.96e-9	Metabolite levels (Dihydroxy docosatrienoic acid);
CESC	cis	rs2836950	0.565	rs2150414	chr21:40614988	A/G	cg17971929	chr21:40555470	PSMG1	-0.58	-7.54	-0.42	7.55e-13	Menarche (age at onset);
CESC	cis	rs7429990	0.901	rs7431567	chr3:48027832	G/T	cg11946769	chr3:48343235	NME6	-0.5	-6.07	-0.35	4.4e-9	Educational attainment (years of education);
CESC	cis	rs7084402	0.523	rs10740730	chr10:60334939	T/C	cg07615347	chr10:60278583	BICC1	0.4	5.84	0.34	1.53e-8	Refractive error;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg02239891	chr2:214016774	IKZF2	-0.45	-6.04	-0.35	5.09e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs8062405	1.000	rs4788102	chr16:28873398	G/A	cg08761264	chr16:28874980	SH2B1	-0.47	-5.85	-0.34	1.42e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs28489187	0.706	rs12124170	chr1:85811182	A/G	cg16011679	chr1:85725395	C1orf52	0.55	6.37	0.36	8.25e-10	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	cis	rs7224314	1.000	rs8075952	chr17:65381358	C/T	cg01507342	chr17:65387096	PITPNC1	-0.48	-5.68	-0.33	3.45e-8	Diisocyanate-induced asthma;
CESC	cis	rs61931739	0.500	rs7303318	chr12:34467789	T/C	cg23762105	chr12:34175262	ALG10	-0.4	-5.11	-0.3	6.06e-7	Morning vs. evening chronotype;
CESC	cis	rs10927875	0.632	rs1122068	chr1:16127480	G/C	cg05821634	chr1:16164109	FLJ37453	0.35	5.04	0.3	8.77e-7	Dilated cardiomyopathy;
CESC	cis	rs6456156	0.565	rs7750209	chr6:167482895	T/G	cg07741184	chr6:167504864	NA	0.37	6.36	0.36	8.83e-10	Primary biliary cholangitis;
CESC	cis	rs5750830	0.649	rs4821895	chr22:39823015	A/G	cg05872129	chr22:39784769	NA	-0.83	-11.38	-0.57	1.05e-24	Intelligence (multi-trait analysis);
CESC	cis	rs11676348	0.846	rs4674259	chr2:218991005	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.48	-6.25	-0.36	1.61e-9	Ulcerative colitis;
CESC	cis	rs10751667	0.621	rs7394862	chr11:927500	T/C	cg20946044	chr11:1010712	AP2A2	-0.39	-5.26	-0.31	2.96e-7	Alzheimer's disease (late onset);
CESC	cis	rs35082559	1	rs35082559	chr2:23896606	CA/C	cg08917208	chr2:24149416	ATAD2B	0.73	8.0	0.44	3.79e-14	Granulocyte percentage of myeloid white cells;
CESC	cis	rs2236918	0.643	rs3121389	chr1:242020264	C/T	cg17736920	chr1:242011382	EXO1	0.5	6.23	0.36	1.8e-9	Menopause (age at onset);
CESC	cis	rs1178968	1.000	rs757939	chr7:72778108	T/C	cg25889504	chr7:72793014	NA	0.51	5.42	0.32	1.36e-7	Triglyceride levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25425078	chr12:4381777	CCND2	-0.6	-7.64	-0.42	4.02e-13	Gut microbiome composition (summer);
CESC	cis	rs6938	0.618	rs62029167	chr15:75228350	G/A	cg09165964	chr15:75287851	SCAMP5	0.46	6.24	0.36	1.74e-9	Breast cancer;
CESC	cis	rs11122272	0.735	rs2790890	chr1:231514567	C/T	cg06096015	chr1:231504339	EGLN1	0.42	6.11	0.35	3.53e-9	Hemoglobin concentration;
CESC	cis	rs4665809	0.590	rs7582341	chr2:26416301	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.08	-13.24	-0.63	4.53e-31	Gut microbiome composition (summer);
CESC	cis	rs453301	0.653	rs7005133	chr8:8901222	T/G	cg06636001	chr8:8085503	FLJ10661	0.51	6.4	0.37	6.84e-10	Joint mobility (Beighton score);
CESC	cis	rs7927771	0.839	rs59360790	chr11:47669175	T/C	cg18512352	chr11:47633146	NA	-0.46	-7.27	-0.41	4.04e-12	Subjective well-being;
CESC	cis	rs6460942	0.915	rs62448599	chr7:12453764	C/T	cg06484146	chr7:12443880	VWDE	-0.78	-8.78	-0.47	2.01e-16	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07503211	chr7:5402297	TNRC18	-0.56	-6.92	-0.39	3.4e-11	Gut microbiome composition (summer);
CESC	cis	rs965513	1.000	rs965513	chr9:100556109	A/G	cg13688889	chr9:100608707	NA	-0.58	-8.26	-0.45	6.88e-15	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
CESC	cis	rs13253111	0.624	rs7832318	chr8:28110414	A/G	cg26534493	chr8:28060551	NA	0.45	6.84	0.39	5.47e-11	Childhood body mass index;
CESC	cis	rs72627123	0.867	rs73301500	chr14:74473413	T/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.8	5.79	0.34	1.99e-8	Morning vs. evening chronotype;
CESC	cis	rs7618915	1.000	rs34569561	chr3:52287293	T/C	cg17372223	chr3:52568218	NT5DC2	0.38	5.19	0.3	4.14e-7	Bipolar disorder;
CESC	cis	rs919433	0.963	rs2043016	chr2:198146381	C/T	cg10820045	chr2:198174542	NA	-0.44	-6.87	-0.39	4.66e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs2637266	0.807	rs2579762	chr10:78318879	A/C	cg18941641	chr10:78392320	NA	0.33	5.85	0.34	1.41e-8	Pulmonary function;
CESC	cis	rs2228479	0.702	rs17233253	chr16:89828437	A/G	cg00800038	chr16:89945340	TCF25	-0.92	-7.62	-0.42	4.38e-13	Skin colour saturation;
CESC	cis	rs7617773	0.817	rs6796490	chr3:48237104	A/C	cg11946769	chr3:48343235	NME6	0.63	8.7	0.47	3.5e-16	Coronary artery disease;
CESC	cis	rs4865169	0.934	rs3796531	chr4:57850846	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.49	-6.91	-0.39	3.56e-11	Breast cancer;
CESC	cis	rs854765	0.547	rs2955359	chr17:17946730	T/C	cg04398451	chr17:18023971	MYO15A	0.73	10.55	0.54	5.95e-22	Total body bone mineral density;
CESC	cis	rs1707322	0.682	rs28490344	chr1:46197948	C/T	cg03146154	chr1:46216737	IPP	0.82	11.54	0.58	3.18e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs3126085	0.877	rs12133847	chr1:152170101	T/G	cg03465714	chr1:152285911	FLG	-0.45	-5.5	-0.32	8.8e-8	Atopic dermatitis;
CESC	cis	rs7130144	0.541	rs73572221	chr11:130459948	A/G	cg26307797	chr11:130446613	NA	-0.74	-6.36	-0.36	8.72e-10	Urate levels in lean individuals;
CESC	cis	rs6540559	0.611	rs6540563	chr1:210019858	C/G	cg25204440	chr1:209979598	IRF6	0.59	5.92	0.34	9.82e-9	Cleft lip with or without cleft palate;
CESC	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg06873352	chr17:61820015	STRADA	0.71	12.39	0.61	4.07e-28	Prudent dietary pattern;
CESC	cis	rs1568889	1.000	rs7112860	chr11:28151609	C/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.78	10.81	0.55	8.22e-23	Bipolar disorder;
CESC	cis	rs17253792	0.822	rs10136155	chr14:56049129	G/A	cg01858014	chr14:56050164	KTN1	-0.89	-7.05	-0.4	1.58e-11	Putamen volume;
CESC	cis	rs708547	0.599	rs2948348	chr4:57848772	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.59	8.56	0.47	9.53e-16	Response to bleomycin (chromatid breaks);
CESC	cis	rs514406	0.861	rs4926576	chr1:53226775	C/T	cg24675658	chr1:53192096	ZYG11B	0.53	6.78	0.38	7.96e-11	Monocyte count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17461271	chr1:172717683	NA	-0.72	-8.39	-0.46	2.87e-15	Gut microbiome composition (summer);
CESC	cis	rs35306767	0.951	rs61833265	chr10:990143	C/T	cg10556349	chr10:835070	NA	0.54	5.32	0.31	2.2e-7	Eosinophil percentage of granulocytes;
CESC	cis	rs8114671	0.562	rs6120757	chr20:33488771	C/T	cg24642439	chr20:33292090	TP53INP2	0.44	5.32	0.31	2.22e-7	Height;
CESC	cis	rs78456975	1.000	rs13422995	chr2:1553554	C/A	cg26248373	chr2:1572462	NA	-0.57	-5.31	-0.31	2.29e-7	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs1707322	0.691	rs61784803	chr1:46179271	C/A	cg05343316	chr1:45956843	TESK2	-0.51	-6.2	-0.36	2.19e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs617791	0.508	rs1047464	chr11:65769456	A/T	cg04055107	chr11:65626734	MUS81;CFL1	-0.46	-5.28	-0.31	2.65e-7	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21605566	chr1:14075549	PRDM2	-0.6	-6.91	-0.39	3.59e-11	Gut microbiome composition (summer);
CESC	cis	rs2425143	1.000	rs6058303	chr20:34290281	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.77	-7.08	-0.4	1.31e-11	Blood protein levels;
CESC	cis	rs1005277	0.579	rs2505198	chr10:38393183	A/C	cg00409905	chr10:38381863	ZNF37A	-0.52	-7.13	-0.4	9.33e-12	Extrinsic epigenetic age acceleration;
CESC	cis	rs7618915	0.547	rs68021750	chr3:52624769	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	6.77	0.38	8.38e-11	Bipolar disorder;
CESC	cis	rs769267	1.000	rs2074090	chr19:19449686	G/T	cg03709012	chr19:19516395	GATAD2A	-0.96	-14.11	-0.66	4.09e-34	Tonsillectomy;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg25748391	chr11:1330779	TOLLIP;LOC255512	0.46	6.49	0.37	4.24e-10	Thyroid stimulating hormone;
CESC	cis	rs12142240	0.698	rs966907	chr1:46817125	C/G	cg00530320	chr1:46809349	NSUN4	0.58	7.89	0.44	8.17e-14	Menopause (age at onset);
CESC	cis	rs4665809	1.000	rs1371553	chr2:26262948	G/A	cg26314531	chr2:26401878	FAM59B	-0.62	-6.9	-0.39	3.92e-11	Gut microbiome composition (summer);
CESC	cis	rs2842992	1.000	rs2758322	chr6:160075188	G/T	cg11366901	chr6:160182831	ACAT2	0.69	8.21	0.45	9.67e-15	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs6736093	1.000	rs79688911	chr2:112657907	C/T	cg12686935	chr2:112915763	FBLN7	-0.42	-5.17	-0.3	4.56e-7	Coronary artery disease;
CESC	cis	rs8060686	0.641	rs76984161	chr16:68139423	C/A	cg26727032	chr16:67993705	SLC12A4	-0.54	-6.05	-0.35	4.92e-9	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs7592578	0.679	rs62181020	chr2:191325601	A/C	cg10560079	chr2:191398806	TMEM194B	-0.59	-5.69	-0.33	3.43e-8	Diastolic blood pressure;
CESC	cis	rs7811142	1.000	rs2406255	chr7:100053690	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.0	9.19	0.49	1.18e-17	Platelet count;
CESC	cis	rs7666738	0.830	rs6532719	chr4:99043691	A/G	cg17366294	chr4:99064904	C4orf37	0.6	8.51	0.46	1.33e-15	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15005908	chr6:114292723	HDAC2	0.55	6.32	0.36	1.12e-9	Gut microbiome composition (summer);
CESC	cis	rs12893668	0.543	rs12147645	chr14:104100208	T/A	cg08213375	chr14:104286397	PPP1R13B	0.33	5.36	0.31	1.83e-7	Reticulocyte count;
CESC	cis	rs637571	0.522	rs491973	chr11:65727301	A/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.45	6.65	0.38	1.71e-10	Eosinophil percentage of white cells;
CESC	cis	rs12926788	0.546	rs200531	chr16:24756172	G/A	cg02428538	chr16:24856791	SLC5A11	0.47	5.03	0.3	9.12e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg03533382	chr5:126853128	PRRC1	-0.48	-6.91	-0.39	3.54e-11	Gambling;
CESC	cis	rs7084402	0.935	rs7474570	chr10:60343085	C/G	cg07615347	chr10:60278583	BICC1	0.56	8.67	0.47	4.26e-16	Refractive error;
CESC	cis	rs9322193	0.847	rs9383844	chr6:150037404	T/C	cg00933542	chr6:150070202	PCMT1	0.3	5.26	0.31	2.96e-7	Lung cancer;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg03592283	chr3:44666723	ZNF197	-0.42	-6.61	-0.38	2.12e-10	Gambling;
CESC	cis	rs1005277	0.563	rs2800550	chr10:38482929	T/C	cg25517755	chr10:38738941	LOC399744	-0.49	-6.35	-0.36	9.08e-10	Extrinsic epigenetic age acceleration;
CESC	cis	rs2882667	0.756	rs11957953	chr5:138479377	G/T	cg04439458	chr5:138467593	SIL1	-0.38	-5.84	-0.34	1.52e-8	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs62432291	0.614	rs452112	chr6:159658028	A/G	cg14500486	chr6:159655392	FNDC1	-0.61	-6.2	-0.36	2.19e-9	Joint mobility (Beighton score);
CESC	cis	rs4588572	0.643	rs3922654	chr5:77684726	G/A	cg11547950	chr5:77652471	NA	0.45	5.71	0.33	3.06e-8	Triglycerides;
CESC	cis	rs7772486	0.875	rs1331640	chr6:146427250	G/A	cg05347473	chr6:146136440	FBXO30	0.51	6.57	0.37	2.68e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs897080	0.552	rs1067388	chr2:44642482	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	5.89	0.34	1.14e-8	Height;
CESC	cis	rs35110281	0.712	rs162345	chr21:44954155	T/G	cg01579765	chr21:45077557	HSF2BP	-0.53	-9.24	-0.49	8.22e-18	Mean corpuscular volume;
CESC	cis	rs13256369	0.851	rs13256611	chr8:8564341	G/A	cg17143192	chr8:8559678	CLDN23	0.77	8.87	0.48	1.09e-16	Obesity-related traits;
CESC	cis	rs4925325	0.955	rs1776262	chr20:60516023	G/T	cg13770153	chr20:60521292	NA	0.81	11.91	0.59	1.75e-26	Obesity-related traits;
CESC	cis	rs7605827	0.930	rs7595512	chr2:15678368	C/T	cg19274914	chr2:15703543	NA	0.36	6.33	0.36	1.04e-9	Educational attainment (years of education);
CESC	cis	rs9303542	0.625	rs7207109	chr17:46607817	C/T	cg04904318	chr17:46607828	HOXB1	-0.68	-7.42	-0.41	1.62e-12	Ovarian cancer;Epithelial ovarian cancer;
CESC	cis	rs7552404	0.727	rs5745390	chr1:76306591	A/C	cg22875332	chr1:76189707	ACADM	0.63	6.32	0.36	1.11e-9	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs9611565	0.592	rs8779	chr22:42070276	T/C	cg06481639	chr22:41940642	POLR3H	0.57	5.74	0.33	2.58e-8	Vitiligo;
CESC	cis	rs11252926	0.510	rs4881371	chr10:554514	G/A	cg03684893	chr10:554711	DIP2C	-0.47	-7.29	-0.41	3.64e-12	Psychosis in Alzheimer's disease;
CESC	cis	rs9287719	0.578	rs10175555	chr2:10703233	T/C	cg00105475	chr2:10696890	NA	0.41	5.64	0.33	4.3e-8	Prostate cancer;
CESC	cis	rs425277	0.539	rs3128338	chr1:2046786	G/A	cg24578937	chr1:2090814	PRKCZ	-0.35	-6.06	-0.35	4.65e-9	Height;
CESC	cis	rs6674176	0.628	rs3791119	chr1:44431362	C/G	cg13606994	chr1:44402422	ARTN	-0.39	-5.8	-0.34	1.87e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs7772486	0.686	rs1292334	chr6:145968288	A/G	cg23711669	chr6:146136114	FBXO30	0.98	14.83	0.67	1.26e-36	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs11098499	0.954	rs10518331	chr4:120323595	C/T	cg09307838	chr4:120376055	NA	0.94	13.7	0.64	1.18e-32	Corneal astigmatism;
CESC	cis	rs5750830	0.649	rs4821894	chr22:39809820	G/C	cg24399712	chr22:39784796	NA	-0.81	-10.81	-0.55	8.15e-23	Intelligence (multi-trait analysis);
CESC	cis	rs2070433	0.752	rs2839220	chr21:47774330	G/C	cg12379764	chr21:47803548	PCNT	0.65	6.99	0.39	2.24e-11	Lymphocyte counts;
CESC	cis	rs7216064	1.000	rs8074078	chr17:65838743	A/C	cg07042672	chr17:66097459	LOC651250	-0.57	-6.69	-0.38	1.32e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg05863683	chr7:1912471	MAD1L1	0.42	6.21	0.36	2.02e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg05313129	chr8:58192883	C8orf71	-0.49	-5.28	-0.31	2.72e-7	Developmental language disorder (linguistic errors);
CESC	trans	rs60843830	1.000	rs55946380	chr2:268293	A/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.69	8.58	0.47	8.3e-16	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs116095464	0.558	rs28636067	chr5:199415	G/A	cg22857025	chr5:266934	NA	-1.26	-13.82	-0.65	4.44e-33	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20157693	chr1:1419379	ATAD3B	-0.5	-6.4	-0.37	7e-10	Gut microbiome composition (summer);
CESC	cis	rs2777491	0.574	rs2730056	chr15:41735785	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.07	-17.08	-0.72	1.34e-44	Ulcerative colitis;
CESC	cis	rs6460942	0.630	rs62451487	chr7:12390464	G/A	cg02935154	chr7:12443704	VWDE	-0.51	-5.27	-0.31	2.78e-7	Coronary artery disease;
CESC	cis	rs963731	0.579	rs12712630	chr2:39284582	A/G	cg04010122	chr2:39346883	SOS1	-0.7	-5.54	-0.32	7.4e-8	Corticobasal degeneration;
CESC	cis	rs9733	0.519	rs2184833	chr1:150675483	C/T	cg22823121	chr1:150693482	HORMAD1	0.47	7.0	0.39	2.13e-11	Tonsillectomy;
CESC	cis	rs7927771	0.725	rs11570094	chr11:47359706	A/C	cg05585544	chr11:47624801	NA	0.41	5.81	0.34	1.77e-8	Subjective well-being;
CESC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg07185584	chr20:19997881	NAA20	-0.55	-6.07	-0.35	4.38e-9	Lung cancer in ever smokers;
CESC	cis	rs854765	0.583	rs11078404	chr17:17820487	A/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.55	7.34	0.41	2.67e-12	Total body bone mineral density;
CESC	trans	rs9858542	0.953	rs9818590	chr3:49525096	A/G	cg21659725	chr3:3221576	CRBN	-0.54	-6.37	-0.36	8.2e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs959260	1.000	rs4788892	chr17:73391277	A/G	cg12999837	chr17:73267436	MIF4GD	-0.48	-5.54	-0.32	7.21e-8	Systemic lupus erythematosus;
CESC	cis	rs11650494	0.908	rs73340392	chr17:47358308	G/A	cg08112188	chr17:47440006	ZNF652	1.07	7.53	0.42	7.96e-13	Prostate cancer;
CESC	cis	rs1218582	0.510	rs2878411	chr1:154823545	C/T	cg09359103	chr1:154839909	KCNN3	-0.49	-7.75	-0.43	1.92e-13	Prostate cancer;
CESC	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg07677032	chr17:61819896	STRADA	0.45	5.92	0.34	1.01e-8	Prudent dietary pattern;
CESC	cis	rs7666738	0.830	rs3896704	chr4:99034252	C/T	cg03467027	chr4:99064603	C4orf37	0.48	6.05	0.35	4.87e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs853679	0.550	rs1225599	chr6:28165190	C/T	cg20151795	chr6:28129481	ZNF389	0.4	5.39	0.31	1.58e-7	Depression;
CESC	cis	rs4835473	0.932	rs1580002	chr4:144687660	G/A	cg25736465	chr4:144833511	NA	-0.43	-6.5	-0.37	4.07e-10	Immature fraction of reticulocytes;
CESC	cis	rs412050	1.000	rs75599828	chr22:22333062	G/C	cg17089214	chr22:22089827	YPEL1	0.68	5.57	0.32	6.35e-8	Attention deficit hyperactivity disorder;
CESC	cis	rs1957429	0.520	rs17102258	chr14:65332369	G/A	cg23373153	chr14:65346875	NA	-0.76	-5.85	-0.34	1.42e-8	Pediatric areal bone mineral density (radius);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg08448040	chr3:13521693	HDAC11	0.53	6.93	0.39	3.27e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs599083	0.530	rs2508834	chr11:68175354	C/T	cg01657329	chr11:68192670	LRP5	0.45	5.42	0.32	1.37e-7	Bone mineral density (spine);
CESC	cis	rs2370759	0.945	rs10508773	chr10:32575444	C/T	cg18270830	chr10:32634957	EPC1	0.73	7.22	0.41	5.35e-12	Sexual dysfunction (female);
CESC	cis	rs798554	0.660	rs2644274	chr7:2854380	A/T	cg13628971	chr7:2884303	GNA12	0.41	5.41	0.32	1.39e-7	Height;
CESC	cis	rs9926296	0.546	rs9935541	chr16:89905925	G/C	cg04287289	chr16:89883240	FANCA	0.66	8.55	0.46	1.02e-15	Vitiligo;
CESC	cis	rs1729951	0.575	rs361241	chr3:136699561	C/A	cg25687071	chr3:136751404	NA	0.38	5.03	0.3	9.06e-7	Neuroticism;
CESC	cis	rs7618915	0.547	rs11130315	chr3:52697163	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	7.04	0.4	1.62e-11	Bipolar disorder;
CESC	cis	rs7523050	0.730	rs12734623	chr1:109442654	A/G	cg08274380	chr1:109419600	GPSM2	0.91	6.41	0.37	6.51e-10	Fat distribution (HIV);
CESC	cis	rs7666738	0.791	rs2903142	chr4:99040071	C/T	cg18180107	chr4:99064573	C4orf37	0.41	5.29	0.31	2.51e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1552244	0.935	rs7649243	chr3:10089470	T/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.8	-10.21	-0.53	7.17e-21	Alzheimer's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15559398	chr3:179322454	NDUFB5;MRPL47	0.65	7.03	0.4	1.79e-11	Gut microbiome composition (summer);
CESC	cis	rs1005277	0.579	rs176838	chr10:38371899	A/T	cg25517755	chr10:38738941	LOC399744	0.43	5.42	0.32	1.32e-7	Extrinsic epigenetic age acceleration;
CESC	cis	rs7259376	0.936	rs7255829	chr19:22537311	C/T	cg02657401	chr19:22469223	NA	-0.27	-5.29	-0.31	2.63e-7	Menopause (age at onset);
CESC	cis	rs651907	0.535	rs34161138	chr3:101510388	T/C	cg12386194	chr3:101231763	SENP7	0.41	5.11	0.3	6.03e-7	Colorectal cancer;
CESC	cis	rs9322193	0.962	rs35031906	chr6:149998574	T/C	cg07701084	chr6:150067640	NUP43	0.4	5.4	0.31	1.51e-7	Lung cancer;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg09199072	chr6:116692265	DSE	0.46	6.07	0.35	4.49e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs1008375	0.800	rs28754811	chr4:17612312	C/T	cg27347728	chr4:17578864	LAP3	0.46	5.47	0.32	1.03e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs9796	0.745	rs2947493	chr15:41375694	G/A	cg12426344	chr15:41135900	SPINT1	-0.23	-5.1	-0.3	6.45e-7	Menopause (age at onset);
CESC	cis	rs4718428	0.705	rs62465692	chr7:66295745	T/C	cg18252515	chr7:66147081	NA	-0.47	-5.23	-0.31	3.38e-7	Corneal structure;
CESC	cis	rs4665809	0.877	rs35224700	chr2:26298037	T/C	cg27170947	chr2:26402098	FAM59B	0.66	7.37	0.41	2.12e-12	Gut microbiome composition (summer);
CESC	cis	rs7589728	0.563	rs80324973	chr2:88447264	T/G	cg18490616	chr2:88469792	THNSL2	0.55	5.25	0.31	3.06e-7	Plasma clusterin levels;
CESC	cis	rs858239	0.600	rs7341483	chr7:23127657	G/T	cg23682824	chr7:23144976	KLHL7	-0.56	-7.83	-0.43	1.18e-13	Cerebrospinal fluid biomarker levels;
CESC	cis	rs875971	0.545	rs10950027	chr7:65634151	C/T	cg25405998	chr7:65216604	CCT6P1	0.45	5.06	0.3	7.71e-7	Aortic root size;
CESC	cis	rs950776	0.745	rs36045869	chr15:78929498	C/T	cg06917634	chr15:78832804	PSMA4	0.56	6.61	0.38	2.14e-10	Sudden cardiac arrest;
CESC	cis	rs9815354	1.000	rs1716997	chr3:41924333	A/G	cg03022575	chr3:42003672	ULK4	-0.46	-5.37	-0.31	1.75e-7	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs938554	0.513	rs3775946	chr4:9995256	A/G	cg02734326	chr4:10020555	SLC2A9	0.43	5.09	0.3	6.8e-7	Blood metabolite levels;
CESC	cis	rs4713118	0.587	rs61471148	chr6:28037032	T/A	cg20151795	chr6:28129481	ZNF389	0.44	5.34	0.31	1.96e-7	Parkinson's disease;
CESC	trans	rs9831754	1.000	rs9831754	chr3:78353591	A/C	cg06416733	chr12:103344890	NA	0.36	6.15	0.35	2.79e-9	Calcium levels;
CESC	cis	rs2415984	0.579	rs1389606	chr14:46964226	T/C	cg14871534	chr14:47121158	RPL10L	0.35	5.32	0.31	2.24e-7	Number of children ever born;
CESC	cis	rs7937682	0.961	rs1784784	chr11:111483185	C/T	cg22437258	chr11:111473054	SIK2	0.7	9.55	0.51	9.3e-19	Primary sclerosing cholangitis;
CESC	cis	rs7208859	0.623	rs9914499	chr17:29107588	G/A	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.91e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs11190604	1.000	rs3763695	chr10:102269206	A/G	cg07080220	chr10:102295463	HIF1AN	0.67	6.22	0.36	1.91e-9	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs4242434	0.889	rs11785755	chr8:22453223	C/A	cg03733263	chr8:22462867	KIAA1967	0.9	13.45	0.64	8.72e-32	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CESC	cis	rs4450798	0.793	rs28687597	chr3:13757613	T/C	cg05589046	chr3:13742034	LOC285375	0.37	5.23	0.31	3.46e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs7412746	0.571	rs12402939	chr1:150615094	A/C	cg04414720	chr1:150670196	GOLPH3L	0.58	7.89	0.44	7.87e-14	Melanoma;
CESC	cis	rs1218582	0.774	rs4845679	chr1:154861187	G/T	cg09359103	chr1:154839909	KCNN3	-0.68	-12.74	-0.62	2.56e-29	Prostate cancer;
CESC	cis	rs1448094	0.512	rs56082822	chr12:86255475	C/T	cg00310523	chr12:86230176	RASSF9	0.36	5.55	0.32	6.85e-8	Major depressive disorder;
CESC	cis	rs17407555	0.606	rs59871456	chr4:10014441	G/A	cg00071950	chr4:10020882	SLC2A9	-0.6	-6.13	-0.35	3.09e-9	Schizophrenia (age at onset);
CESC	cis	rs7193541	0.640	rs4072222	chr16:74706736	A/C	cg01733217	chr16:74700730	RFWD3	1.03	20.47	0.78	1.73e-56	Multiple myeloma;
CESC	cis	rs2204008	0.774	rs4534658	chr12:38246783	G/A	cg13010199	chr12:38710504	ALG10B	0.46	5.79	0.33	2.02e-8	Bladder cancer;
CESC	cis	rs2228479	0.702	rs12599561	chr16:89894358	C/G	cg04013166	chr16:89971882	TCF25	0.73	5.77	0.33	2.2e-8	Skin colour saturation;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26759515	chr16:67515027	ATP6V0D1	0.63	7.33	0.41	2.76e-12	Gut microbiome composition (summer);
CESC	cis	rs854765	0.583	rs11656840	chr17:17837354	C/T	cg09796270	chr17:17721594	SREBF1	0.43	6.05	0.35	4.89e-9	Total body bone mineral density;
CESC	cis	rs7202877	0.611	rs4888395	chr16:75413715	T/G	cg04384234	chr16:75411784	CFDP1	-0.49	-5.89	-0.34	1.16e-8	Type 2 diabetes;Type 1 diabetes;
CESC	cis	rs539096	0.501	rs713191	chr1:44314553	A/G	cg12908607	chr1:44402522	ARTN	-0.46	-6.6	-0.38	2.26e-10	Intelligence (multi-trait analysis);
CESC	cis	rs1178968	1.000	rs1178968	chr7:72767451	T/C	cg25889504	chr7:72793014	NA	0.5	5.1	0.3	6.62e-7	Triglyceride levels;
CESC	cis	rs4862750	0.872	rs7672831	chr4:187898882	C/T	cg11301795	chr4:187892539	NA	-0.74	-12.36	-0.6	5.13e-28	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs8060686	0.545	rs75229939	chr16:68164949	G/A	cg26727032	chr16:67993705	SLC12A4	-0.5	-5.47	-0.32	1.03e-7	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs7914558	0.966	rs3902934	chr10:104746649	A/G	cg15744005	chr10:104629667	AS3MT	-0.33	-5.26	-0.31	3.02e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs4253772	0.744	rs1134224	chr22:46633371	A/T	cg24881330	chr22:46731750	TRMU	0.74	8.05	0.44	2.75e-14	LDL cholesterol;Cholesterol, total;
CESC	cis	rs1008375	0.898	rs4698623	chr4:17594702	T/C	cg04450456	chr4:17643702	FAM184B	0.37	5.23	0.31	3.44e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs7772486	0.875	rs9373483	chr6:146364194	A/G	cg23711669	chr6:146136114	FBXO30	0.83	12.12	0.6	3.46e-27	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9660180	0.967	rs6664664	chr1:1751264	G/A	cg05132306	chr1:1846340	CALML6	-0.31	-6.57	-0.37	2.6e-10	Body mass index;
CESC	cis	rs2997447	0.802	rs72884792	chr1:26436688	G/C	cg24596570	chr1:26146463	FAM54B;LOC646471	0.62	5.33	0.31	2.07e-7	QRS complex (12-leadsum);
CESC	cis	rs6502050	0.871	rs6502056	chr17:80070912	C/G	cg11859384	chr17:80120422	CCDC57	0.38	5.24	0.31	3.24e-7	Life satisfaction;
CESC	cis	rs4713118	0.662	rs469228	chr6:27970704	A/G	cg12963246	chr6:28129442	ZNF389	0.41	5.56	0.32	6.7e-8	Parkinson's disease;
CESC	cis	rs875971	0.862	rs778702	chr7:65864835	G/A	cg11764359	chr7:65958608	NA	0.81	11.89	0.59	2.11e-26	Aortic root size;
CESC	cis	rs875971	0.862	rs11984115	chr7:65773859	C/T	cg18876405	chr7:65276391	NA	-0.51	-7.1	-0.4	1.15e-11	Aortic root size;
CESC	cis	rs7100689	0.577	rs2185427	chr10:82056667	G/T	cg09936400	chr10:82049201	MAT1A	-0.4	-6.12	-0.35	3.35e-9	Post bronchodilator FEV1;
CESC	cis	rs2439831	0.867	rs3809481	chr15:43662829	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.88	9.41	0.5	2.56e-18	Lung cancer in ever smokers;
CESC	cis	rs796364	0.806	rs77853713	chr2:201006880	A/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.72	-6.48	-0.37	4.47e-10	Schizophrenia;
CESC	trans	rs8073060	0.572	rs1634683	chr17:33941560	G/C	cg19694781	chr19:47549865	TMEM160	-0.69	-6.76	-0.38	8.53e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11342277	chr1:116915598	ATP1A1	0.58	6.49	0.37	4.12e-10	Gut microbiome composition (summer);
CESC	cis	rs10504229	0.679	rs11786328	chr8:58039269	A/G	cg24829409	chr8:58192753	C8orf71	-0.68	-7.41	-0.41	1.68e-12	Developmental language disorder (linguistic errors);
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg16419620	chr12:48214187	HDAC7	-0.41	-6.4	-0.37	6.92e-10	Vertical cup-disc ratio;
CESC	cis	rs1577917	0.771	rs6454486	chr6:86433587	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.36	5.05	0.3	8.36e-7	Response to antipsychotic treatment;
CESC	cis	rs10504229	0.953	rs6991035	chr8:58183374	C/T	cg24829409	chr8:58192753	C8orf71	-0.76	-9.93	-0.52	5.87e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs4808199	0.894	rs9304960	chr19:19465529	G/A	cg03709012	chr19:19516395	GATAD2A	1.14	12.44	0.61	2.65e-28	Nonalcoholic fatty liver disease;
CESC	cis	rs1865721	1.000	rs62089508	chr18:73193344	C/T	cg26385618	chr18:73139727	C18orf62	-0.51	-7.56	-0.42	6.81e-13	Intelligence;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06832064	chr1:150551018	MCL1	0.58	6.25	0.36	1.62e-9	Gut microbiome composition (summer);
CESC	cis	rs8005677	1.000	rs4982709	chr14:23394699	C/T	cg25600027	chr14:23388339	RBM23	-0.42	-5.15	-0.3	5.16e-7	Cognitive ability (multi-trait analysis);
CESC	cis	rs4595586	0.545	rs925828	chr12:39364222	A/G	cg26384229	chr12:38710491	ALG10B	0.54	7.54	0.42	7.28e-13	Morning vs. evening chronotype;
CESC	cis	rs35306767	0.903	rs7067865	chr10:908387	C/T	cg26597838	chr10:835615	NA	0.86	9.05	0.49	3.21e-17	Eosinophil percentage of granulocytes;
CESC	trans	rs34198350	0.687	rs11683689	chr2:48423881	A/C	cg04747634	chr16:71264451	HYDIN	0.61	6.08	0.35	4.18e-9	QT interval in Tripanosoma cruzi seropositivity;
CESC	cis	rs4642101	0.686	rs9822382	chr3:12828828	T/G	cg24848339	chr3:12840334	CAND2	0.35	5.3	0.31	2.48e-7	QRS complex (12-leadsum);
CESC	cis	rs739401	0.611	rs572373	chr11:3055361	T/C	cg25174290	chr11:3078921	CARS	0.55	7.74	0.43	2.14e-13	Longevity;
CESC	cis	rs11577318	0.853	rs7416513	chr1:26647949	G/C	cg00852783	chr1:26633632	UBXN11	0.48	6.61	0.38	2.15e-10	Granulocyte percentage of myeloid white cells;
CESC	cis	rs9888739	0.844	rs41476751	chr16:31335906	T/C	cg15817542	chr16:31343056	ITGAM	-0.42	-5.82	-0.34	1.71e-8	Systemic lupus erythematosus;
CESC	cis	rs2070488	0.861	rs1858740	chr3:38438372	T/C	cg24069376	chr3:38537580	EXOG	0.46	8.17	0.45	1.26e-14	Electrocardiographic conduction measures;
CESC	cis	rs854765	0.583	rs8078583	chr17:17811465	C/T	cg16928487	chr17:17741425	SREBF1	-0.58	-9.9	-0.52	7.14e-20	Total body bone mineral density;
CESC	cis	rs4664304	0.772	rs10183731	chr2:160740989	A/G	cg03641300	chr2:160917029	PLA2R1	0.41	5.72	0.33	2.89e-8	Crohn's disease;Inflammatory bowel disease;
CESC	trans	rs698833	0.669	rs1584885	chr2:44647038	A/C	cg02849725	chr11:114310121	REXO2	-0.45	-6.13	-0.35	3.13e-9	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs9908102	0.740	rs58842254	chr17:12906222	A/G	cg26162695	chr17:12921313	ELAC2	0.46	5.3	0.31	2.43e-7	Schizophrenia;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03093995	chr9:114393414	DNAJC25-GNG10;DNAJC25	0.49	6.19	0.36	2.34e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs13191362	0.507	rs1954806	chr6:163051858	G/C	cg21926612	chr6:163149169	PACRG;PARK2	-0.57	-6.97	-0.39	2.57e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs898097	0.812	rs8065641	chr17:80820259	A/G	cg15664640	chr17:80829946	TBCD	-0.62	-8.98	-0.48	5.17e-17	Breast cancer;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg04282497	chr4:82350883	RASGEF1B	0.56	7.77	0.43	1.73e-13	Fibrinogen levels;
CESC	cis	rs1879734	0.731	rs6661728	chr1:54162471	G/A	cg23596471	chr1:54105337	GLIS1	0.35	5.56	0.32	6.52e-8	Mitral valve prolapse;
CESC	cis	rs7605827	0.930	rs12692264	chr2:15539229	T/A	cg19274914	chr2:15703543	NA	0.34	6.12	0.35	3.44e-9	Educational attainment (years of education);
CESC	cis	rs12618769	0.597	rs3754883	chr2:99129451	T/C	cg10123293	chr2:99228465	UNC50	0.4	5.38	0.31	1.64e-7	Bipolar disorder;
CESC	cis	rs6088580	0.634	rs4911419	chr20:32995873	G/A	cg24642439	chr20:33292090	TP53INP2	-0.53	-6.99	-0.39	2.17e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs2933343	0.621	rs728838	chr3:128589013	A/G	cg24203234	chr3:128598194	ACAD9	0.41	5.72	0.33	2.91e-8	IgG glycosylation;
CESC	cis	rs6696846	0.905	rs12117194	chr1:205040943	C/G	cg00857998	chr1:205179979	DSTYK	-0.48	-6.79	-0.38	7.45e-11	Red blood cell count;
CESC	cis	rs13118159	0.742	rs34947293	chr4:1335034	T/C	cg05025164	chr4:1340916	KIAA1530	0.52	7.3	0.41	3.26e-12	Longevity;
CESC	cis	rs2816062	0.786	rs2745320	chr1:18893592	G/A	cg18795169	chr1:18902165	NA	-0.94	-19.08	-0.76	1.16e-51	Urate levels in lean individuals;
CESC	cis	rs2929278	0.589	rs7174732	chr15:44038463	C/A	cg27015174	chr15:43622946	ADAL;LCMT2	-0.55	-7.28	-0.41	3.82e-12	Schizophrenia;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg20159072	chr3:48936248	SLC25A20	0.46	6.02	0.35	5.79e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs863345	0.604	rs10797018	chr1:158490112	G/A	cg12129480	chr1:158549410	OR10X1	-0.34	-6.85	-0.39	5.17e-11	Pneumococcal bacteremia;
CESC	trans	rs7947523	0.813	rs4999940	chr11:80942337	C/T	cg21227347	chr9:117374170	C9orf91	0.46	6.08	0.35	4.26e-9	Emphysema imaging phenotypes;
CESC	cis	rs7264396	0.790	rs6060582	chr20:34313297	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	-0.64	-7.6	-0.42	4.97e-13	Total cholesterol levels;
CESC	cis	rs2046867	0.818	rs62249860	chr3:72866073	T/G	cg25664220	chr3:72788482	NA	-0.45	-6.62	-0.38	2e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CESC	cis	rs12956009	0.583	rs11663646	chr18:44862895	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.47	-5.98	-0.34	7.27e-9	Educational attainment (years of education);
CESC	cis	rs910316	1.000	rs1047418	chr14:75605792	A/G	cg11812906	chr14:75593930	NEK9	0.89	15.02	0.68	2.58e-37	Height;
CESC	cis	rs11642862	1.000	rs11642603	chr16:30886221	C/G	cg02466173	chr16:30829666	NA	-0.58	-5.67	-0.33	3.72e-8	Tonsillectomy;
CESC	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	21.62	0.8	1.92e-60	Prudent dietary pattern;
CESC	cis	rs4268898	0.662	rs2303297	chr2:24432937	C/T	cg08917208	chr2:24149416	ATAD2B	0.55	5.27	0.31	2.89e-7	Asthma;
CESC	cis	rs6701037	0.566	rs1883102	chr1:175136793	T/A	cg00321850	chr1:175162397	KIAA0040	0.44	6.32	0.36	1.12e-9	Alcohol dependence;
CESC	cis	rs2635047	0.935	rs2635050	chr18:44664131	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.48	6.4	0.37	6.95e-10	Educational attainment;
CESC	cis	rs4780401	0.609	rs16958588	chr16:11819330	G/A	cg01061890	chr16:11836724	TXNDC11	-0.55	-7.56	-0.42	6.67e-13	Rheumatoid arthritis;
CESC	cis	rs72945132	0.882	rs55758686	chr11:70172204	C/T	cg00319359	chr11:70116639	PPFIA1	0.76	7.4	0.41	1.86e-12	Coronary artery disease;
CESC	cis	rs72781680	0.821	rs113014365	chr2:24159903	C/T	cg08917208	chr2:24149416	ATAD2B	0.63	6.24	0.36	1.73e-9	Lymphocyte counts;
CESC	cis	rs9322193	0.923	rs4869812	chr6:149990583	A/G	cg13206674	chr6:150067644	NUP43	0.43	6.17	0.35	2.58e-9	Lung cancer;
CESC	cis	rs1862618	0.620	rs189695	chr5:56225769	T/C	cg20203395	chr5:56204925	C5orf35	-0.39	-5.24	-0.31	3.23e-7	Initial pursuit acceleration;
CESC	cis	rs17253792	0.822	rs10083499	chr14:56066590	T/A	cg01858014	chr14:56050164	KTN1	-0.85	-6.79	-0.38	7.45e-11	Putamen volume;
CESC	cis	rs2243480	1.000	rs35391607	chr7:65360829	G/A	cg18252515	chr7:66147081	NA	-1.01	-9.32	-0.5	4.6e-18	Diabetic kidney disease;
CESC	cis	rs11625487	0.609	rs74063377	chr14:77951431	C/G	cg20045696	chr14:77926864	AHSA1	-0.71	-5.63	-0.33	4.67e-8	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
CESC	cis	rs2625529	0.689	rs12898868	chr15:72112918	A/G	cg16672083	chr15:72433130	SENP8	0.48	7.26	0.41	4.23e-12	Red blood cell count;
CESC	cis	rs920590	0.758	rs17091534	chr8:19670651	C/T	cg01411142	chr8:19674711	INTS10	0.49	5.4	0.31	1.48e-7	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs1642645	0.831	rs11210563	chr1:42494633	G/T	cg16685388	chr1:42384056	HIVEP3	0.37	5.61	0.33	5.2e-8	Left ventricular obstructive tract defect (maternal effect);
CESC	cis	rs1788820	1.000	rs1788820	chr18:21101944	A/G	cg14672496	chr18:21087552	C18orf8	0.5	6.9	0.39	3.93e-11	Body mass index;
CESC	trans	rs2115172	0.836	rs4835799	chr5:122762229	A/G	cg25752527	chr2:136499146	UBXN4	0.45	6.14	0.35	2.92e-9	Weight;
CESC	cis	rs7605827	0.897	rs10084390	chr2:15597662	C/A	cg19274914	chr2:15703543	NA	0.33	5.95	0.34	8.67e-9	Educational attainment (years of education);
CESC	cis	rs910316	1.000	rs175449	chr14:75590846	A/T	cg08847533	chr14:75593920	NEK9	-0.97	-18.7	-0.75	2.51e-50	Height;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05628496	chr17:17991167	DRG2	0.52	6.8	0.39	6.75e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs10504229	0.683	rs11786845	chr8:58133642	T/C	cg21724239	chr8:58056113	NA	0.57	5.87	0.34	1.3e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs4692589	0.965	rs6842442	chr4:170933203	C/T	cg19918862	chr4:170955249	NA	0.37	5.83	0.34	1.59e-8	Anxiety disorder;
CESC	cis	rs7666738	0.716	rs7656233	chr4:99079237	G/A	cg05340658	chr4:99064831	C4orf37	0.75	10.74	0.55	1.38e-22	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2645694	0.626	rs2645709	chr4:77824474	G/A	cg18351406	chr4:77819688	ANKRD56	0.54	6.76	0.38	8.77e-11	Emphysema distribution in smoking;
CESC	cis	rs11711311	1.000	rs3806641	chr3:113465761	T/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.74	10.5	0.54	8.57e-22	IgG glycosylation;
CESC	cis	rs60871478	1.000	rs4720917	chr7:806998	C/G	cg27478167	chr7:817139	HEATR2	-0.46	-5.4	-0.31	1.52e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs28386778	0.701	rs2727337	chr17:61991966	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	-0.81	-11.78	-0.59	4.88e-26	Prudent dietary pattern;
CESC	cis	rs4927850	1.000	rs4927850	chr3:195751630	C/T	cg00031303	chr3:195681400	NA	-0.46	-5.91	-0.34	1.06e-8	Pancreatic cancer;
CESC	cis	rs7647973	0.925	rs9881860	chr3:49352522	A/T	cg06212747	chr3:49208901	KLHDC8B	0.57	7.17	0.4	7.69e-12	Menarche (age at onset);
CESC	cis	rs9733	0.744	rs4970976	chr1:150779524	T/A	cg22823121	chr1:150693482	HORMAD1	-0.4	-6.1	-0.35	3.81e-9	Tonsillectomy;
CESC	cis	rs1878931	0.501	rs9635563	chr16:3416940	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.77	10.42	0.54	1.58e-21	Body mass index (adult);
CESC	cis	rs9457247	0.967	rs447042	chr6:167405435	C/T	cg23791538	chr6:167370224	RNASET2	-0.59	-8.54	-0.46	1.09e-15	Crohn's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22337509	chr1:204093899	SOX13	-0.48	-6.4	-0.37	6.86e-10	Gut microbiome composition (summer);
CESC	cis	rs7772486	0.597	rs1970306	chr6:146154543	A/G	cg23711669	chr6:146136114	FBXO30	0.95	12.44	0.61	2.75e-28	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4716602	0.828	rs10270046	chr7:156159047	T/C	cg04090468	chr7:156181990	NA	0.4	5.15	0.3	5.18e-7	Anti-saccade response;
CESC	cis	rs875971	0.862	rs709609	chr7:65560561	A/G	cg11764359	chr7:65958608	NA	-0.81	-11.13	-0.56	7.19e-24	Aortic root size;
CESC	cis	rs7208859	0.623	rs78071511	chr17:29128154	C/T	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.1e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs897984	0.609	rs4889609	chr16:31026427	A/G	cg00531865	chr16:30841666	NA	-0.4	-5.58	-0.32	5.95e-8	Dementia with Lewy bodies;
CESC	cis	rs113835537	0.529	rs75685325	chr11:66235242	A/G	cg22134325	chr11:66188745	NPAS4	0.43	6.48	0.37	4.41e-10	Airway imaging phenotypes;
CESC	cis	rs7618501	0.573	rs7634917	chr3:50049299	T/G	cg24308560	chr3:49941425	MST1R	0.62	9.01	0.48	4.25e-17	Intelligence (multi-trait analysis);
CESC	cis	rs7904368	0.754	rs12246217	chr10:16853349	G/C	cg23933602	chr10:16859644	RSU1	0.72	6.52	0.37	3.52e-10	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
CESC	cis	rs2637266	0.714	rs11594217	chr10:78385088	G/T	cg18941641	chr10:78392320	NA	-0.35	-5.76	-0.33	2.29e-8	Pulmonary function;
CESC	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg07677032	chr17:61819896	STRADA	0.45	5.91	0.34	1.03e-8	Prudent dietary pattern;
CESC	cis	rs875971	0.862	rs10950043	chr7:65988610	T/C	cg11764359	chr7:65958608	NA	0.79	11.32	0.57	1.67e-24	Aortic root size;
CESC	cis	rs7615952	0.599	rs60847438	chr3:125746005	T/C	cg06494592	chr3:125709126	NA	-0.48	-5.11	-0.3	6.1e-7	Blood pressure (smoking interaction);
CESC	cis	rs875971	0.793	rs460678	chr7:65527200	C/G	cg26939375	chr7:64535504	NA	0.5	6.47	0.37	4.83e-10	Aortic root size;
CESC	cis	rs4727963	0.846	rs10237575	chr7:122706184	A/G	cg03640110	chr7:122635026	TAS2R16	-0.37	-5.7	-0.33	3.11e-8	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
CESC	cis	rs12220238	0.915	rs11000945	chr10:76030739	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.54	5.04	0.3	8.74e-7	Soluble interleukin-2 receptor subunit alpha;
CESC	cis	rs7618915	0.547	rs12496634	chr3:52709259	A/C	cg17372223	chr3:52568218	NT5DC2	0.44	6.61	0.38	2.12e-10	Bipolar disorder;
CESC	cis	rs7107174	1.000	rs72931639	chr11:78036703	C/T	cg02023728	chr11:77925099	USP35	0.51	6.82	0.39	6.24e-11	Testicular germ cell tumor;
CESC	cis	rs1799949	0.965	rs34616041	chr17:41188786	G/A	cg23758822	chr17:41437982	NA	1.03	14.48	0.66	2.1e-35	Menopause (age at onset);
CESC	trans	rs8073060	0.586	rs225292	chr17:33926383	G/A	cg19694781	chr19:47549865	TMEM160	-0.63	-6.92	-0.39	3.31e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	cis	rs2228479	0.850	rs12600051	chr16:89992072	G/T	cg06558623	chr16:89946397	TCF25	1.17	9.0	0.48	4.39e-17	Skin colour saturation;
CESC	cis	rs9951602	0.850	rs56367211	chr18:76677563	G/T	cg00806245	chr18:76673096	NA	0.52	6.24	0.36	1.71e-9	Obesity-related traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01500421	chr5:140070872	HARS2;HARS	0.53	6.24	0.36	1.73e-9	Gut microbiome composition (summer);
CESC	trans	rs8073060	0.586	rs2626625	chr17:34027607	C/G	cg19694781	chr19:47549865	TMEM160	-0.72	-6.47	-0.37	4.69e-10	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	cis	rs910316	0.763	rs175016	chr14:75459633	C/T	cg11812906	chr14:75593930	NEK9	-0.82	-13.27	-0.63	3.75e-31	Height;
CESC	cis	rs10504229	0.683	rs2873638	chr8:58114593	G/A	cg24829409	chr8:58192753	C8orf71	-0.59	-7.34	-0.41	2.64e-12	Developmental language disorder (linguistic errors);
CESC	trans	rs10411161	0.702	rs10403189	chr19:52400673	A/G	cg22319618	chr22:45562946	NUP50	0.78	7.81	0.43	1.37e-13	Breast cancer;
CESC	cis	rs9457247	1.000	rs422694	chr6:167406074	G/T	cg25258033	chr6:167368657	RNASET2	0.39	5.89	0.34	1.15e-8	Crohn's disease;
CESC	cis	rs9733	0.791	rs11204693	chr1:150647987	C/T	cg18016565	chr1:150552671	MCL1	-0.33	-5.57	-0.32	6.22e-8	Tonsillectomy;
CESC	cis	rs514406	0.505	rs269286	chr1:53169018	C/T	cg08736216	chr1:53307985	ZYG11A	0.34	5.9	0.34	1.08e-8	Monocyte count;
CESC	cis	rs4689388	0.609	rs1046319	chr4:6304286	C/T	cg25554036	chr4:6271136	WFS1	0.42	5.56	0.32	6.7e-8	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs3096299	0.967	rs2911253	chr16:89488587	T/G	cg08392591	chr16:89556376	ANKRD11	0.44	5.73	0.33	2.77e-8	Multiple myeloma (IgH translocation);
CESC	cis	rs589448	1.000	rs589448	chr12:69752200	A/G	cg20891283	chr12:69753455	YEATS4	0.99	17.16	0.73	6.54e-45	Cerebrospinal fluid biomarker levels;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	ch.22.1008279F	chr22:48731367	NA	-0.46	-6.35	-0.36	9.18e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs57504626	1	rs57504626	chr19:19720399	C/T	cg03709012	chr19:19516395	GATAD2A	0.92	6.36	0.36	9.03e-10	Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;
CESC	cis	rs9733	0.503	rs7556451	chr1:150913142	A/G	cg17724175	chr1:150552817	MCL1	0.33	5.08	0.3	7.16e-7	Tonsillectomy;
CESC	cis	rs1801251	0.963	rs35362030	chr2:233612845	A/G	cg25237894	chr2:233734115	C2orf82	0.45	7.91	0.44	6.96e-14	Coronary artery disease;
CESC	cis	rs832540	0.656	rs6862118	chr5:56106474	G/A	cg24531977	chr5:56204891	C5orf35	-0.49	-6.01	-0.35	6.13e-9	Coronary artery disease;
CESC	cis	rs1153858	1.000	rs4774578	chr15:45646051	G/A	cg21132104	chr15:45694354	SPATA5L1	0.84	11.4	0.57	9.5e-25	Homoarginine levels;
CESC	cis	rs798554	0.660	rs2527692	chr7:2856533	G/A	cg19717773	chr7:2847554	GNA12	-0.54	-8.57	-0.47	8.85e-16	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23597041	chr15:42840898	LRRC57;HAUS2	0.56	6.22	0.36	1.92e-9	Gut microbiome composition (summer);
CESC	cis	rs7208859	0.623	rs8079891	chr17:29058863	G/A	cg14008862	chr17:28927542	LRRC37B2	0.65	5.12	0.3	5.86e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs8060686	0.641	rs9923710	chr16:68224018	C/T	cg26727032	chr16:67993705	SLC12A4	-0.51	-6.18	-0.36	2.35e-9	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs7412746	0.658	rs4537557	chr1:150734436	A/G	cg04414720	chr1:150670196	GOLPH3L	0.58	7.57	0.42	6.07e-13	Melanoma;
CESC	cis	rs10504229	0.679	rs16920056	chr8:58106218	C/A	cg02725872	chr8:58115012	NA	-0.43	-6.81	-0.39	6.53e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs1200821	0.535	rs1208784	chr10:37768433	A/G	cg25427524	chr10:38739819	LOC399744	-0.41	-5.29	-0.31	2.59e-7	Hemostatic factors and hematological phenotypes;
CESC	cis	rs17125944	0.686	rs2357946	chr14:53345266	G/C	cg00686598	chr14:53173677	PSMC6	-0.6	-5.24	-0.31	3.3e-7	Alzheimer's disease (late onset);
CESC	cis	rs947211	0.846	rs823155	chr1:205762946	T/C	cg14159672	chr1:205819179	PM20D1	0.44	5.73	0.33	2.77e-8	Parkinson's disease;
CESC	cis	rs12681366	0.663	rs2919660	chr8:95470697	C/A	cg13257157	chr8:95487014	RAD54B	0.39	5.34	0.31	2.04e-7	Nonsyndromic cleft lip with cleft palate;
CESC	cis	rs9910055	0.762	rs11080007	chr17:42265442	A/G	cg08499158	chr17:42289980	UBTF	0.42	5.24	0.31	3.22e-7	Total body bone mineral density;
CESC	cis	rs7666738	0.830	rs28810677	chr4:99043193	C/T	cg05340658	chr4:99064831	C4orf37	0.82	12.88	0.62	8.44e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs12325245	0.536	rs35908812	chr16:58587426	T/C	cg05725404	chr16:58534157	NDRG4	-0.61	-5.24	-0.31	3.21e-7	Schizophrenia;
CESC	cis	rs754466	0.651	rs7895188	chr10:79623378	C/G	cg17075019	chr10:79541650	NA	0.85	13.27	0.63	3.61e-31	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs7178572	1.000	rs12904938	chr15:77721225	A/G	cg22256960	chr15:77711686	NA	-0.59	-7.96	-0.44	5e-14	Type 2 diabetes;
CESC	cis	rs739401	0.566	rs7931504	chr11:3026712	C/T	cg08508325	chr11:3079039	CARS	-0.58	-10.87	-0.56	5.22e-23	Longevity;
CESC	cis	rs7208859	0.673	rs73263755	chr17:29198972	A/G	cg19761014	chr17:28927070	LRRC37B2	0.72	5.71	0.33	3.06e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs2075371	1.000	rs2544213	chr7:133982867	G/C	cg20476274	chr7:133979776	SLC35B4	0.67	9.8	0.52	1.46e-19	Mean platelet volume;
CESC	cis	rs1552244	1.000	rs6789156	chr3:10124120	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-10.66	-0.55	2.62e-22	Alzheimer's disease;
CESC	cis	rs30380	0.632	rs27640	chr5:96127905	T/C	cg16492584	chr5:96139282	ERAP1	-0.47	-6.59	-0.38	2.33e-10	Cerebrospinal fluid biomarker levels;
CESC	trans	rs1973993	0.967	rs11165643	chr1:96924097	C/T	cg10631902	chr5:14652156	NA	0.5	6.71	0.38	1.18e-10	Weight;
CESC	cis	rs9796	0.870	rs2412572	chr15:41264426	G/C	cg18705301	chr15:41695430	NDUFAF1	0.43	6.32	0.36	1.12e-9	Menopause (age at onset);
CESC	trans	rs6600671	1.000	rs6600671	chr1:121200490	T/G	cg17023122	chr1:144479586	NA	-0.49	-6.68	-0.38	1.42e-10	Hip geometry;
CESC	cis	rs5753618	0.539	rs2106294	chr22:31645759	C/T	cg13145458	chr22:31556086	RNF185	0.44	5.07	0.3	7.33e-7	Colorectal cancer;
CESC	trans	rs561341	0.883	rs7406056	chr17:30220224	C/T	cg27661571	chr11:113659931	NA	-0.6	-6.15	-0.35	2.83e-9	Hip circumference adjusted for BMI;
CESC	cis	rs9584850	0.874	rs3742136	chr13:99102607	C/T	cg20750642	chr13:99100586	FARP1	-0.38	-5.71	-0.33	3.01e-8	Neuroticism;
CESC	cis	rs61935443	0.666	rs11107780	chr12:95299142	G/A	cg21533806	chr12:95267307	NA	0.48	5.22	0.31	3.55e-7	Schizophrenia;
CESC	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.51	0.37	3.65e-10	Prudent dietary pattern;
CESC	cis	rs10504229	0.639	rs2318146	chr8:58114873	T/G	cg02725872	chr8:58115012	NA	-0.45	-7.05	-0.4	1.52e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs3806843	1.000	rs4404730	chr5:140162610	G/A	cg26395211	chr5:140044315	WDR55	-0.43	-5.59	-0.32	5.59e-8	Depressive symptoms (multi-trait analysis);
CESC	trans	rs11039798	0.512	rs3974936	chr11:49005012	C/T	cg03929089	chr4:120376271	NA	0.61	6.22	0.36	1.88e-9	Axial length;
CESC	cis	rs2929282	1	rs2929282	chr15:44245931	A/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.64	5.37	0.31	1.76e-7	Triglycerides;Triglyceride levels;
CESC	cis	rs1509123	0.609	rs75742091	chr17:6703870	C/T	cg12642237	chr17:6703447	TEKT1	-0.62	-5.08	-0.3	7.26e-7	Blood metabolite levels;
CESC	cis	rs12586317	0.534	rs1568200	chr14:35419592	C/T	cg05294307	chr14:35346193	BAZ1A	-0.57	-6.88	-0.39	4.18e-11	Psoriasis;
CESC	cis	rs6087990	0.701	rs1997797	chr20:31387954	C/G	cg13636640	chr20:31349939	DNMT3B	0.77	12.28	0.6	9.43e-28	Ulcerative colitis;
CESC	cis	rs12142240	0.698	rs10158572	chr1:46822440	G/T	cg10495392	chr1:46806563	NSUN4	0.58	6.32	0.36	1.09e-9	Menopause (age at onset);
CESC	cis	rs9911578	1.000	rs7207693	chr17:57016525	C/T	cg05425664	chr17:57184151	TRIM37	-0.5	-6.83	-0.39	5.73e-11	Intelligence (multi-trait analysis);
CESC	cis	rs208520	0.690	rs2144081	chr6:66824972	G/A	cg07460842	chr6:66804631	NA	-1.01	-13.46	-0.64	8.19e-32	Exhaled nitric oxide output;
CESC	cis	rs10540	0.558	rs12806062	chr11:501429	G/A	cg03576123	chr11:487126	PTDSS2	-1.16	-11.28	-0.57	2.36e-24	Body mass index;
CESC	cis	rs7605827	0.930	rs2111456	chr2:15560118	A/G	cg19274914	chr2:15703543	NA	0.35	6.24	0.36	1.72e-9	Educational attainment (years of education);
CESC	cis	rs10197940	0.624	rs13393122	chr2:152413315	A/G	cg19508488	chr2:152266495	RIF1	0.48	5.26	0.31	2.96e-7	Lung cancer;
CESC	cis	rs6541297	0.887	rs4846906	chr1:230284257	C/A	cg20703242	chr1:230279135	GALNT2	0.65	8.65	0.47	4.89e-16	Coronary artery disease;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg19419581	chr17:79482410	NA	0.51	6.43	0.37	5.88e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs11711311	0.668	rs11718061	chr3:113341826	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	-0.49	-6.47	-0.37	4.73e-10	IgG glycosylation;
CESC	cis	rs7618915	0.501	rs12486554	chr3:52742537	A/T	cg18404041	chr3:52824283	ITIH1	-0.39	-6.43	-0.37	5.97e-10	Bipolar disorder;
CESC	cis	rs6456156	0.586	rs7762156	chr6:167485831	A/T	cg07741184	chr6:167504864	NA	0.37	6.28	0.36	1.39e-9	Primary biliary cholangitis;
CESC	trans	rs1728785	0.901	rs1170438	chr16:68608256	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.67	8.16	0.45	1.4e-14	Ulcerative colitis;
CESC	trans	rs57221529	0.766	rs72706610	chr5:561111	G/A	cg25482853	chr8:67687455	SGK3	1.12	11.92	0.59	1.58e-26	Lung disease severity in cystic fibrosis;
CESC	cis	rs1707322	0.928	rs7527244	chr1:46368772	A/G	cg05343316	chr1:45956843	TESK2	0.43	5.23	0.31	3.41e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs4665809	0.887	rs2384324	chr2:26354239	A/G	cg22920501	chr2:26401640	FAM59B	-0.78	-9.18	-0.49	1.26e-17	Gut microbiome composition (summer);
CESC	cis	rs9549367	0.713	rs9549691	chr13:113861606	A/C	cg18105134	chr13:113819100	PROZ	-0.72	-9.0	-0.48	4.5e-17	Platelet distribution width;
CESC	cis	rs6141600	0.760	rs6060794	chr20:34682864	T/C	cg07747181	chr20:34652970	NA	-0.38	-5.2	-0.3	3.99e-7	Height;Hip circumference;
CESC	cis	rs2367563	1.000	rs8699	chr12:96051883	A/G	cg19013339	chr12:96052514	NTN4	0.36	5.09	0.3	6.73e-7	Allergic dermatitis (nickel);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05152629	chr11:207881	BET1L;RIC8A	-0.62	-7.18	-0.4	7.22e-12	Gut microbiome composition (summer);
CESC	cis	rs9649213	0.574	rs7790229	chr7:97919338	G/A	cg08684580	chr7:98029266	BAIAP2L1	-0.32	-5.09	-0.3	6.87e-7	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg09737499	chr11:126301004	KIRREL3	-0.41	-6.37	-0.36	8.3e-10	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs6695640	0.820	rs2762891	chr1:17750552	T/C	cg01904812	chr1:17746340	RCC2	0.35	5.11	0.3	6.14e-7	Mean platelet volume;
CESC	cis	rs2836974	0.931	rs2735306	chr21:40713134	A/G	cg17971929	chr21:40555470	PSMG1	-0.93	-12.87	-0.62	8.95e-30	Cognitive function;
CESC	cis	rs11083475	0.557	rs2368519	chr19:39259241	C/T	cg26703956	chr19:39260304	NA	-0.35	-6.7	-0.38	1.23e-10	Heart rate;
CESC	trans	rs708224	0.587	rs184469	chr12:32400298	A/G	cg16470816	chr12:58566565	NA	0.37	6.42	0.37	6.33e-10	Pancreatic cancer;
CESC	cis	rs7659604	0.540	rs11934307	chr4:122677514	G/A	cg19671926	chr4:122722719	EXOSC9	0.53	6.7	0.38	1.21e-10	Type 2 diabetes;
CESC	cis	rs6831352	0.879	rs29001212	chr4:100051877	T/C	cg12011299	chr4:100065546	ADH4	-0.59	-6.52	-0.37	3.62e-10	Alcohol dependence;
CESC	cis	rs6088580	0.634	rs6058073	chr20:33116483	T/C	cg24642439	chr20:33292090	TP53INP2	0.51	6.63	0.38	1.89e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs7937682	0.889	rs7948236	chr11:111499933	C/A	cg22437258	chr11:111473054	SIK2	0.69	9.07	0.49	2.75e-17	Primary sclerosing cholangitis;
CESC	cis	rs4523957	0.590	rs9899427	chr17:2063550	A/T	cg16513277	chr17:2031491	SMG6	-0.69	-9.59	-0.51	6.97e-19	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs9486719	1.000	rs4077932	chr6:96905144	C/T	cg18709589	chr6:96969512	KIAA0776	-0.54	-5.97	-0.34	7.42e-9	Migraine;Coronary artery disease;
CESC	cis	rs3096299	0.679	rs3096322	chr16:89441123	A/G	cg02187348	chr16:89574699	SPG7	-0.49	-6.42	-0.37	6.39e-10	Multiple myeloma (IgH translocation);
CESC	cis	rs60154123	0.772	rs664072	chr1:210422160	G/A	cg21951975	chr1:209979733	IRF6	0.47	5.92	0.34	9.94e-9	Coronary artery disease;
CESC	cis	rs28489187	0.660	rs3949301	chr1:85863383	G/A	cg16011679	chr1:85725395	C1orf52	-0.46	-5.55	-0.32	6.87e-8	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	cis	rs9660180	0.875	rs4648727	chr1:1776269	C/A	cg11836949	chr1:1812359	GNB1	-0.37	-5.21	-0.3	3.88e-7	Body mass index;
CESC	cis	rs7089973	0.604	rs765174	chr10:116601888	C/T	cg23260525	chr10:116636907	FAM160B1	0.4	7.2	0.4	6.31e-12	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs2839186	0.770	rs2839984	chr21:47671690	A/G	cg10351095	chr21:47802916	PCNT	-0.48	-6.54	-0.37	3.24e-10	Testicular germ cell tumor;
CESC	cis	rs1707322	0.721	rs61784800	chr1:46178112	A/G	cg06784218	chr1:46089804	CCDC17	-0.42	-7.58	-0.42	5.82e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs6582630	0.598	rs11182207	chr12:38477514	T/C	cg26384229	chr12:38710491	ALG10B	-0.43	-5.85	-0.34	1.44e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs7264396	0.790	rs6060582	chr20:34313297	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.88	11.93	0.59	1.49e-26	Total cholesterol levels;
CESC	cis	rs1816752	1.000	rs7999554	chr13:25009769	C/A	cg02811702	chr13:24901961	NA	0.38	5.62	0.33	4.91e-8	Obesity-related traits;
CESC	cis	rs4780401	0.755	rs2868981	chr16:11765518	T/C	cg01061890	chr16:11836724	TXNDC11	-0.39	-5.07	-0.3	7.41e-7	Rheumatoid arthritis;
CESC	cis	rs9649213	0.593	rs3779193	chr7:98028466	T/C	cg24562669	chr7:97807699	LMTK2	0.53	7.91	0.44	7e-14	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs11792861	0.591	rs2282206	chr9:111746267	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.63	9.56	0.51	8.41e-19	Menarche (age at onset);
CESC	cis	rs1218582	0.772	rs11264282	chr1:154867370	G/A	cg06221963	chr1:154839813	KCNN3	-0.68	-11.73	-0.58	7.43e-26	Prostate cancer;
CESC	cis	rs5769707	0.935	rs1109320	chr22:49989106	G/A	cg20744362	chr22:50050164	C22orf34	0.41	6.87	0.39	4.66e-11	Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs1862618	0.853	rs863840	chr5:56128999	C/G	cg12311346	chr5:56204834	C5orf35	-0.66	-8.0	-0.44	3.92e-14	Initial pursuit acceleration;
CESC	cis	rs8031584	0.958	rs8034856	chr15:31240957	T/C	cg14298792	chr15:30685198	CHRFAM7A	-0.46	-5.51	-0.32	8.59e-8	Huntington's disease progression;
CESC	cis	rs9660992	0.710	rs1668864	chr1:205248799	T/C	cg00857998	chr1:205179979	DSTYK	0.46	5.21	0.3	3.77e-7	Mean corpuscular volume;Mean platelet volume;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg21560157	chr11:71212402	NADSYN1	0.48	6.87	0.39	4.69e-11	Fibrinogen levels;
CESC	cis	rs4555082	0.834	rs1473672	chr14:105721981	G/T	cg06808227	chr14:105710500	BRF1	-0.58	-6.77	-0.38	8.26e-11	Mean platelet volume;Platelet distribution width;
CESC	cis	rs7552404	0.731	rs61770552	chr1:76373050	T/C	cg10523679	chr1:76189770	ACADM	0.64	6.1	0.35	3.73e-9	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs727505	1.000	rs28523990	chr7:124436139	C/T	cg23710748	chr7:124431027	NA	-0.48	-7.83	-0.43	1.21e-13	Lewy body disease;
CESC	cis	rs1008375	0.966	rs6837664	chr4:17697835	G/C	cg04450456	chr4:17643702	FAM184B	0.36	5.04	0.3	8.67e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs7827545	0.545	rs6578228	chr8:135562422	G/A	cg17885191	chr8:135476712	NA	0.54	5.84	0.34	1.56e-8	Hypertension (SNP x SNP interaction);
CESC	cis	rs875971	0.540	rs736270	chr7:65428822	T/C	cg18876405	chr7:65276391	NA	0.69	9.37	0.5	3.34e-18	Aortic root size;
CESC	cis	rs2282802	0.685	rs6889283	chr5:139653439	G/T	cg26211634	chr5:139558579	C5orf32	0.52	7.5	0.42	9.6e-13	Intelligence (multi-trait analysis);
CESC	cis	rs15676	0.783	rs10988121	chr9:131564926	A/T	cg00228799	chr9:131580591	ENDOG	-0.49	-6.09	-0.35	3.93e-9	Blood metabolite levels;
CESC	cis	rs7523050	0.730	rs72984614	chr1:109435848	T/C	cg08274380	chr1:109419600	GPSM2	0.91	6.41	0.37	6.51e-10	Fat distribution (HIV);
CESC	cis	rs765787	0.530	rs10467979	chr15:45521270	G/A	cg24006582	chr15:45444508	DUOX1	-0.57	-6.88	-0.39	4.36e-11	Uric acid levels;
CESC	cis	rs6493487	0.512	rs71471585	chr15:51262700	C/G	cg02338191	chr15:51200825	AP4E1	0.61	5.58	0.32	6.04e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	7.66	0.43	3.4e-13	Prudent dietary pattern;
CESC	cis	rs1371867	0.846	rs1788182	chr8:101334620	C/T	cg11906718	chr8:101322791	RNF19A	0.46	5.91	0.34	1.03e-8	Atrioventricular conduction;
CESC	cis	rs9467711	0.606	rs9379871	chr6:26375854	C/G	cg14345882	chr6:26364793	BTN3A2	0.6	5.99	0.35	6.82e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs9910055	0.529	rs228749	chr17:42174570	A/G	cg13607699	chr17:42295918	UBTF	-0.49	-5.92	-0.34	9.99e-9	Total body bone mineral density;
CESC	cis	rs962856	0.575	rs632700	chr2:67664874	G/A	cg09028215	chr2:67624308	ETAA1	-0.44	-5.36	-0.31	1.84e-7	Pancreatic cancer;
CESC	cis	rs4561483	0.582	rs35063476	chr16:12044301	A/G	cg08843971	chr16:11963173	GSPT1	-0.41	-5.39	-0.31	1.55e-7	Testicular germ cell tumor;
CESC	cis	rs1348850	0.872	rs12991272	chr2:178457339	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.6	7.93	0.44	6.22e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg26354017	chr1:205819088	PM20D1	0.84	13.1	0.63	1.48e-30	Menarche (age at onset);
CESC	cis	rs4713118	0.513	rs149950	chr6:28033039	T/G	cg18032046	chr6:28092343	ZSCAN16	-0.46	-5.96	-0.34	7.97e-9	Parkinson's disease;
CESC	cis	rs7618915	0.501	rs3733045	chr3:52643307	A/G	cg17372223	chr3:52568218	NT5DC2	0.42	6.4	0.37	7.03e-10	Bipolar disorder;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg00734800	chr3:50388182	TUSC4;CYB561D2	0.46	6.21	0.36	2.06e-9	Systemic lupus erythematosus;
CESC	cis	rs7618915	0.547	rs13085331	chr3:52627486	G/C	cg18404041	chr3:52824283	ITIH1	-0.39	-6.55	-0.37	2.91e-10	Bipolar disorder;
CESC	trans	rs6570726	0.791	rs7765687	chr6:145915100	A/C	cg03826317	chr10:25465503	LOC100128811;GPR158	0.3	6.02	0.35	5.89e-9	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs3820928	0.874	rs10210997	chr2:227859108	C/T	cg11843606	chr2:227700838	RHBDD1	-0.45	-5.72	-0.33	2.94e-8	Pulmonary function;
CESC	cis	rs1557765	0.527	rs11024272	chr11:17395760	T/C	cg15432903	chr11:17409602	KCNJ11	0.43	6.3	0.36	1.23e-9	Body mass index;Social communication problems;
CESC	cis	rs2637266	1.000	rs6480824	chr10:78355705	G/A	cg18941641	chr10:78392320	NA	0.42	7.79	0.43	1.49e-13	Pulmonary function;
CESC	cis	rs10791323	0.569	rs10750553	chr11:133740251	T/C	cg15485101	chr11:133734466	NA	0.3	5.12	0.3	5.99e-7	Childhood ear infection;
CESC	cis	rs559928	0.606	rs56311067	chr11:63931607	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.66	5.84	0.34	1.55e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CESC	cis	rs873946	0.517	rs2803990	chr10:134560340	A/G	cg26818010	chr10:134567672	INPP5A	-0.7	-8.77	-0.47	2.19e-16	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs9926296	0.605	rs12599180	chr16:89839306	C/T	cg27121462	chr16:89883253	FANCA	-0.71	-10.7	-0.55	1.88e-22	Vitiligo;
CESC	cis	rs736408	0.522	rs11130310	chr3:52674667	C/T	cg18337363	chr3:52569053	NT5DC2	0.28	5.14	0.3	5.31e-7	Bipolar disorder;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg12445461	chr9:6681608	NA	-0.42	-6.02	-0.35	5.69e-9	Gambling;
CESC	cis	rs13242816	0.881	rs12706091	chr7:116130783	G/C	cg04696780	chr7:116139425	CAV2	-0.61	-5.56	-0.32	6.58e-8	P wave duration;
CESC	cis	rs8038465	0.638	rs12591473	chr15:73967485	A/T	cg15420318	chr15:73925796	NPTN	0.49	7.43	0.42	1.54e-12	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs9359856	0.623	rs1179903	chr6:90321736	G/T	cg13799429	chr6:90582589	CASP8AP2	-0.47	-5.5	-0.32	9.16e-8	Bipolar disorder;
CESC	cis	rs4654899	0.758	rs10218584	chr1:21474480	C/G	cg05370193	chr1:21551575	ECE1	-0.36	-5.4	-0.31	1.47e-7	Superior frontal gyrus grey matter volume;
CESC	trans	rs1814175	0.511	rs61905634	chr11:49819736	G/A	cg03929089	chr4:120376271	NA	-0.91	-15.23	-0.68	4.84e-38	Height;
CESC	cis	rs1355223	0.506	rs7131229	chr11:34869328	A/G	cg11622362	chr11:34938112	PDHX;APIP	-0.43	-5.08	-0.3	7.07e-7	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs2991971	0.903	rs2991973	chr1:46020632	G/A	cg06784218	chr1:46089804	CCDC17	-0.29	-5.07	-0.3	7.56e-7	High light scatter reticulocyte count;
CESC	cis	rs6933660	0.800	rs6931104	chr6:151786177	C/T	cg02564969	chr6:151773285	C6orf211;RMND1	0.6	8.29	0.45	5.79e-15	Menarche (age at onset);
CESC	cis	rs853679	1.000	rs68141011	chr6:28217797	G/T	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.74	7.3	0.41	3.39e-12	Depression;
CESC	cis	rs7208859	0.623	rs11657369	chr17:29136468	G/A	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.1e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs7587476	0.784	rs13026390	chr2:215687075	C/T	cg04004882	chr2:215674386	BARD1	-0.49	-5.53	-0.32	7.73e-8	Neuroblastoma;
CESC	cis	rs1707322	0.963	rs4660900	chr1:46419605	T/C	cg03146154	chr1:46216737	IPP	0.72	9.82	0.52	1.31e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs870825	0.616	rs6552808	chr4:185642865	G/T	cg04058563	chr4:185651563	MLF1IP	0.64	7.1	0.4	1.15e-11	Blood protein levels;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg27345282	chr3:196295526	WDR53;FBXO45	-0.44	-6.48	-0.37	4.49e-10	Gambling;
CESC	cis	rs738322	0.718	rs2899297	chr22:38594668	A/G	cg25457927	chr22:38595422	NA	-0.35	-6.63	-0.38	1.82e-10	Cutaneous nevi;
CESC	cis	rs1163251	0.902	rs640195	chr1:120217650	T/A	cg19096424	chr1:120255104	PHGDH	0.43	5.22	0.31	3.62e-7	Blood metabolite levels;
CESC	cis	rs9611565	0.659	rs4822035	chr22:41935912	A/G	cg06634786	chr22:41940651	POLR3H	0.66	6.98	0.39	2.34e-11	Vitiligo;
CESC	cis	rs853679	0.517	rs9380047	chr6:28037893	G/T	cg12963246	chr6:28129442	ZNF389	0.55	7.26	0.41	4.27e-12	Depression;
CESC	cis	rs2286503	0.752	rs2286504	chr7:22854847	G/T	cg13679077	chr7:22862647	TOMM7	0.51	6.51	0.37	3.78e-10	Fibrinogen;
CESC	cis	rs12497850	0.931	rs9840050	chr3:49133310	A/G	cg06212747	chr3:49208901	KLHDC8B	0.73	9.73	0.51	2.47e-19	Parkinson's disease;
CESC	trans	rs916888	0.610	rs199446	chr17:44813169	G/A	cg22433210	chr17:43662623	NA	-0.6	-7.89	-0.44	8.04e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs6598955	0.670	rs7522905	chr1:26609259	C/T	cg04990556	chr1:26633338	UBXN11	-0.76	-10.79	-0.55	9.37e-23	Obesity-related traits;
CESC	cis	rs1790761	0.587	rs4930431	chr11:67294308	C/T	cg23188684	chr11:67383651	NA	-0.36	-5.69	-0.33	3.27e-8	Mean corpuscular volume;
CESC	cis	rs2073499	1.000	rs79499880	chr3:50259551	A/G	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.7	5.36	0.31	1.84e-7	Schizophrenia;
CESC	cis	rs965469	0.619	rs6037565	chr20:3330308	T/C	cg17110299	chr20:3385021	C20orf194	0.4	5.25	0.31	3.1e-7	IFN-related cytopenia;
CESC	cis	rs5758511	0.689	rs56906457	chr22:42628335	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.53	7.04	0.4	1.63e-11	Birth weight;
CESC	cis	rs9486719	1.000	rs2971603	chr6:97035418	C/T	cg06623918	chr6:96969491	KIAA0776	-0.89	-10.55	-0.54	6.12e-22	Migraine;Coronary artery disease;
CESC	cis	rs7927592	0.913	rs3824850	chr11:68341873	A/G	cg20283391	chr11:68216788	NA	-0.61	-7.29	-0.41	3.48e-12	Total body bone mineral density;
CESC	cis	rs77741769	0.529	rs7137504	chr12:121221628	C/T	cg02419362	chr12:121203948	SPPL3	0.35	5.72	0.33	2.87e-8	Mean corpuscular volume;
CESC	cis	rs6500395	1.000	rs9928051	chr16:48557316	T/A	cg04672837	chr16:48644449	N4BP1	0.45	5.11	0.3	6.18e-7	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs801193	0.569	rs6978178	chr7:66123084	G/A	cg10691866	chr7:65817282	TPST1	0.31	5.34	0.31	2e-7	Aortic root size;
CESC	cis	rs5758659	0.714	rs5758589	chr22:42518382	A/G	cg19513890	chr22:42538836	CYP2D7P1	0.36	5.28	0.31	2.71e-7	Cognitive function;
CESC	cis	rs116095464	0.558	rs7703803	chr5:292311	A/G	cg20965017	chr5:231967	SDHA	-0.48	-5.41	-0.32	1.41e-7	Breast cancer;
CESC	cis	rs7917772	0.582	rs7075269	chr10:104365724	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.41	5.72	0.33	2.8e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs736408	0.609	rs13082960	chr3:52785168	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	6.83	0.39	5.77e-11	Bipolar disorder;
CESC	cis	rs12545109	1.000	rs1975284	chr8:57314663	A/G	cg09654669	chr8:57350985	NA	-0.52	-6.21	-0.36	2.08e-9	Obesity-related traits;
CESC	cis	rs8060686	0.546	rs8047978	chr16:68143598	T/G	cg26727032	chr16:67993705	SLC12A4	-0.59	-8.15	-0.45	1.45e-14	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs6772849	0.930	rs9873888	chr3:128360987	G/A	cg16766828	chr3:128327626	NA	-0.31	-5.03	-0.3	8.89e-7	Monocyte percentage of white cells;Monocyte count;
CESC	cis	rs561341	0.739	rs1978116	chr17:30220978	A/C	cg13647721	chr17:30228624	UTP6	0.79	9.88	0.52	8.14e-20	Hip circumference adjusted for BMI;
CESC	cis	rs2933343	0.700	rs1680779	chr3:128614770	G/A	cg11901034	chr3:128598214	ACAD9	-0.39	-5.53	-0.32	7.53e-8	IgG glycosylation;
CESC	cis	rs9611565	0.506	rs2024567	chr22:41699206	G/C	cg06634786	chr22:41940651	POLR3H	-0.51	-5.53	-0.32	7.85e-8	Vitiligo;
CESC	cis	rs820218	0.886	rs2165634	chr17:73663297	T/G	cg01592526	chr17:73663357	RECQL5;SAP30BP	0.43	5.52	0.32	7.91e-8	Rotator cuff tears;
CESC	cis	rs9911578	1.000	rs12936058	chr17:57017420	T/C	cg05425664	chr17:57184151	TRIM37	-0.5	-6.9	-0.39	3.85e-11	Intelligence (multi-trait analysis);
CESC	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.52	-6.88	-0.39	4.4e-11	Longevity;Endometriosis;
CESC	cis	rs796364	1.000	rs796364	chr2:200716119	C/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.89	8.75	0.47	2.48e-16	Schizophrenia;
CESC	cis	rs12541335	0.639	rs13257108	chr8:22165043	T/C	cg18135555	chr8:22132992	PIWIL2	0.25	5.48	0.32	1.01e-7	Hypertriglyceridemia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01949614	chr16:1359397	UBE2I	0.5	6.04	0.35	5.28e-9	Gut microbiome composition (summer);
CESC	trans	rs35110281	0.837	rs2838342	chr21:45077865	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.51	6.74	0.38	1.01e-10	Mean corpuscular volume;
CESC	cis	rs6141600	0.760	rs2590986	chr20:34686496	C/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.4	5.31	0.31	2.28e-7	Height;Hip circumference;
CESC	cis	rs9868809	0.772	rs9877501	chr3:48718390	C/G	cg06212747	chr3:49208901	KLHDC8B	-0.6	-5.18	-0.3	4.36e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs514406	0.929	rs564273	chr1:53332445	G/C	cg08736216	chr1:53307985	ZYG11A	-0.42	-6.78	-0.38	7.89e-11	Monocyte count;
CESC	cis	rs6502050	0.764	rs35713597	chr17:80119016	C/G	cg11859384	chr17:80120422	CCDC57	-0.38	-5.24	-0.31	3.26e-7	Life satisfaction;
CESC	cis	rs1949733	1.000	rs6837429	chr4:8502374	A/G	cg11789530	chr4:8429930	ACOX3	0.76	10.74	0.55	1.45e-22	Response to antineoplastic agents;
CESC	cis	rs2836974	0.627	rs9981301	chr21:40686078	G/C	cg11890956	chr21:40555474	PSMG1	-0.92	-14.5	-0.67	1.81e-35	Cognitive function;
CESC	cis	rs7208859	0.673	rs216435	chr17:28922737	G/T	cg04154034	chr17:28927549	LRRC37B2	0.66	5.83	0.34	1.57e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs2470135	1	rs2470135	chr15:43995789	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.47	7.13	0.4	9.48e-12	Diastolic blood pressure;
CESC	cis	rs12142240	0.698	rs17357676	chr1:46812444	A/G	cg00530320	chr1:46809349	NSUN4	0.58	7.85	0.43	1.05e-13	Menopause (age at onset);
CESC	cis	rs9902453	0.817	rs55758314	chr17:28173978	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.65	8.22	0.45	9.05e-15	Coffee consumption (cups per day);
CESC	cis	rs4648845	0.579	rs4592207	chr1:2369498	A/G	cg07700843	chr1:2391317	NA	-0.37	-6.55	-0.37	2.94e-10	Schizophrenia;
CESC	cis	rs6088580	0.524	rs1321306	chr20:33266379	T/A	cg24642439	chr20:33292090	TP53INP2	-0.47	-5.48	-0.32	9.79e-8	Glomerular filtration rate (creatinine);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg06285312	chr8:144776160	ZNF707	0.47	6.13	0.35	3.17e-9	Fibrinogen levels;
CESC	cis	rs7845219	0.544	rs6987400	chr8:95921295	T/C	cg09323728	chr8:95962352	TP53INP1	-0.32	-6.23	-0.36	1.8e-9	Type 2 diabetes;
CESC	cis	rs698833	0.926	rs786622	chr2:44606598	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.51	6.56	0.37	2.83e-10	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00832928	chr3:150329458	SELT	-0.71	-8.21	-0.45	9.99e-15	Gut microbiome composition (summer);
CESC	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg06873352	chr17:61820015	STRADA	0.72	12.84	0.62	1.18e-29	Prudent dietary pattern;
CESC	cis	rs6912958	0.712	rs4707383	chr6:88330602	T/A	cg04972856	chr6:88032051	C6orf162;GJB7	-0.3	-5.03	-0.3	8.91e-7	Monocyte percentage of white cells;
CESC	cis	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg18765753	chr7:1198926	ZFAND2A	-0.47	-5.84	-0.34	1.55e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs8067545	0.532	rs12449914	chr17:20003969	T/C	cg12073167	chr17:19770448	ULK2	-0.44	-5.28	-0.31	2.71e-7	Schizophrenia;
CESC	cis	rs748404	0.660	rs542898	chr15:43719392	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	8.13	0.45	1.61e-14	Lung cancer;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg13975730	chr9:139329735	INPP5E	0.45	6.02	0.35	5.78e-9	Fibrinogen levels;
CESC	cis	rs11676348	0.846	rs7607437	chr2:219008392	A/G	cg00012203	chr2:219082015	ARPC2	-0.57	-7.18	-0.4	6.85e-12	Ulcerative colitis;
CESC	cis	rs8031584	0.560	rs1056118	chr15:31203786	G/A	cg08109568	chr15:31115862	NA	0.66	9.24	0.49	8.06e-18	Huntington's disease progression;
CESC	trans	rs12265790	1.000	rs11253674	chr10:15929002	T/C	cg03460745	chr3:171966142	FNDC3B	0.75	6.02	0.35	5.81e-9	Cerebrospinal fluid t-tau:AB1-42 ratio;
CESC	cis	rs9911578	0.967	rs405684	chr17:56777148	T/C	cg12560992	chr17:57184187	TRIM37	0.92	15.4	0.69	1.18e-38	Intelligence (multi-trait analysis);
CESC	cis	rs362272	0.505	rs10155132	chr4:3369500	A/G	cg14583973	chr4:3374767	RGS12	0.31	5.54	0.32	7.35e-8	Serum sulfate level;
CESC	cis	rs1707322	0.721	rs12045096	chr1:46114428	A/G	cg05343316	chr1:45956843	TESK2	0.5	6.12	0.35	3.43e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs11608355	0.597	rs2304548	chr12:109795166	T/G	cg19025524	chr12:109796872	NA	-0.54	-7.99	-0.44	4.03e-14	Neuroticism;
CESC	cis	rs8060686	0.545	rs3815173	chr16:68160289	T/G	cg26727032	chr16:67993705	SLC12A4	-0.5	-5.47	-0.32	1.03e-7	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs12142240	0.621	rs13374968	chr1:46843908	T/G	cg00530320	chr1:46809349	NSUN4	0.6	8.32	0.46	4.75e-15	Menopause (age at onset);
CESC	cis	rs853679	0.517	rs9348797	chr6:28137533	G/C	cg26335602	chr6:28129616	ZNF389	0.52	6.84	0.39	5.58e-11	Depression;
CESC	cis	rs763121	0.853	rs3747172	chr22:39067524	A/G	cg06022373	chr22:39101656	GTPBP1	0.89	14.42	0.66	3.47e-35	Menopause (age at onset);
CESC	cis	rs68170813	0.559	rs6951639	chr7:106817639	A/G	cg02696742	chr7:106810147	HBP1	-0.53	-5.07	-0.3	7.37e-7	Coronary artery disease;
CESC	cis	rs7949030	0.591	rs35880596	chr11:62369884	C/G	cg23462726	chr11:62437636	C11orf83;C11orf48	-0.43	-5.58	-0.32	5.81e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs7762018	1.000	rs4509126	chr6:170068058	A/G	cg13891659	chr6:170190454	C6orf122;C6orf208	0.52	5.34	0.31	2e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03574882	chr7:151574332	PRKAG2	0.6	7.18	0.4	7e-12	Gut microbiome composition (summer);
CESC	cis	rs9815354	0.812	rs56728371	chr3:41999381	T/A	cg03022575	chr3:42003672	ULK4	0.64	5.69	0.33	3.42e-8	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs11098499	0.954	rs12505469	chr4:120249585	C/T	cg24375607	chr4:120327624	NA	0.46	5.64	0.33	4.35e-8	Corneal astigmatism;
CESC	cis	rs12477438	0.520	rs2964969	chr2:99782811	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	15.41	0.69	1.09e-38	Chronic sinus infection;
CESC	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg24642844	chr7:1081250	C7orf50	-0.76	-9.26	-0.49	7.23e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs9322193	0.962	rs9322220	chr6:150104033	G/C	cg07701084	chr6:150067640	NUP43	0.43	5.85	0.34	1.45e-8	Lung cancer;
CESC	cis	rs10751667	0.666	rs7123912	chr11:963936	T/C	cg06064525	chr11:970664	AP2A2	-0.47	-9.32	-0.5	4.88e-18	Alzheimer's disease (late onset);
CESC	cis	rs367943	0.799	rs2115209	chr5:112973494	A/G	cg12552261	chr5:112820674	MCC	0.54	6.14	0.35	3.08e-9	Type 2 diabetes;
CESC	cis	rs7666738	0.830	rs116103936	chr4:98954531	T/C	cg17366294	chr4:99064904	C4orf37	0.6	8.47	0.46	1.72e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs801193	1.000	rs11773829	chr7:66141074	G/A	cg18876405	chr7:65276391	NA	-0.54	-7.11	-0.4	1.11e-11	Aortic root size;
CESC	cis	rs10504229	0.813	rs6999878	chr8:58197243	C/G	cg24829409	chr8:58192753	C8orf71	-0.44	-5.67	-0.33	3.65e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs4076764	0.914	rs4638099	chr1:163365521	A/G	cg06092702	chr1:163392909	NA	0.44	6.49	0.37	4.29e-10	Motion sickness;
CESC	cis	rs9322193	0.962	rs10452626	chr6:150088617	T/C	cg04369109	chr6:150039330	LATS1	-0.39	-5.27	-0.31	2.82e-7	Lung cancer;
CESC	cis	rs35306767	0.903	rs7067865	chr10:908387	C/T	cg10556349	chr10:835070	NA	0.57	5.47	0.32	1.04e-7	Eosinophil percentage of granulocytes;
CESC	cis	rs17039065	0.920	rs73838432	chr4:109434153	A/C	cg16022748	chr4:109541635	LOC285456;RPL34	0.62	5.17	0.3	4.7e-7	Gut microbiome composition (summer);
CESC	cis	rs763014	0.966	rs4984903	chr16:680695	A/G	cg00802000	chr16:706648	WDR90	-0.4	-6.06	-0.35	4.57e-9	Height;
CESC	cis	rs28647808	1.000	rs4962142	chr9:136274883	A/G	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.9	5.73	0.33	2.75e-8	Blood protein levels;
CESC	cis	rs56046484	0.956	rs35204319	chr15:85650477	C/T	cg08123816	chr15:85640762	PDE8A	-0.44	-5.31	-0.31	2.29e-7	Testicular germ cell tumor;
CESC	cis	rs1008375	0.966	rs4698636	chr4:17632834	T/C	cg02297831	chr4:17616191	MED28	0.55	6.95	0.39	2.82e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg26667821	chr1:155099774	EFNA1	0.48	6.34	0.36	9.84e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs4689592	0.503	rs66885632	chr4:7053738	T/C	cg26116260	chr4:7069785	GRPEL1	-0.86	-8.98	-0.48	5.25e-17	Monocyte percentage of white cells;
CESC	cis	rs8072100	0.817	rs7213086	chr17:45752310	C/G	cg08085267	chr17:45401833	C17orf57	-0.4	-5.04	-0.3	8.76e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs5753618	0.539	rs5753596	chr22:31787472	C/T	cg13145458	chr22:31556086	RNF185	0.45	5.57	0.32	6.29e-8	Colorectal cancer;
CESC	cis	rs11190604	0.697	rs12355942	chr10:102201320	T/C	cg07080220	chr10:102295463	HIF1AN	-0.53	-5.38	-0.31	1.66e-7	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs10870270	0.956	rs10430618	chr10:133748996	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.61	-7.93	-0.44	6.27e-14	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs7577696	0.568	rs462878	chr2:32438655	A/G	cg02381751	chr2:32503542	YIPF4	0.46	5.16	0.3	4.77e-7	Inflammatory biomarkers;
CESC	trans	rs3942852	0.868	rs7118232	chr11:48106274	T/C	cg03929089	chr4:120376271	NA	-0.56	-6.13	-0.35	3.19e-9	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs10504229	1.000	rs59797486	chr8:58174435	T/C	cg05313129	chr8:58192883	C8orf71	-0.55	-6.72	-0.38	1.1e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs6582630	0.555	rs11181684	chr12:38388000	T/C	cg26384229	chr12:38710491	ALG10B	0.69	10.49	0.54	8.95e-22	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs9457247	0.967	rs402191	chr6:167405553	T/C	cg23791538	chr6:167370224	RNASET2	-0.59	-8.54	-0.46	1.09e-15	Crohn's disease;
CESC	cis	rs35110281	0.811	rs4819264	chr21:45017349	G/T	cg21573476	chr21:45109991	RRP1B	-0.48	-6.66	-0.38	1.61e-10	Mean corpuscular volume;
CESC	cis	rs6740322	0.895	rs10172375	chr2:43572047	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.65	-7.14	-0.4	8.99e-12	Coronary artery disease;
CESC	cis	rs35955747	0.934	rs5994397	chr22:31826150	G/C	cg25791279	chr22:32026902	PISD	-0.44	-5.29	-0.31	2.53e-7	Neutrophil count;Sum basophil neutrophil counts;
CESC	trans	rs8073060	0.586	rs4796104	chr17:34046832	T/C	cg19694781	chr19:47549865	TMEM160	0.72	6.47	0.37	4.78e-10	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	cis	rs9457247	0.935	rs401260	chr6:167405888	T/C	cg07741184	chr6:167504864	NA	0.29	5.31	0.31	2.32e-7	Crohn's disease;
CESC	cis	rs3020736	0.500	rs2839708	chr22:42500745	A/G	cg04733989	chr22:42467013	NAGA	-0.79	-12.03	-0.59	6.75e-27	Autism spectrum disorder or schizophrenia;
CESC	cis	rs514406	0.825	rs7523761	chr1:53250915	T/C	cg08736216	chr1:53307985	ZYG11A	0.32	5.72	0.33	2.87e-8	Monocyte count;
CESC	cis	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg00106254	chr7:1943704	MAD1L1	-0.51	-6.34	-0.36	9.84e-10	Bipolar disorder and schizophrenia;
CESC	cis	rs514406	0.584	rs7548832	chr1:53193576	A/T	cg08736216	chr1:53307985	ZYG11A	-0.38	-6.0	-0.35	6.43e-9	Monocyte count;
CESC	cis	rs9611565	0.512	rs8141103	chr22:42136930	T/C	cg06481639	chr22:41940642	POLR3H	0.59	5.84	0.34	1.51e-8	Vitiligo;
CESC	cis	rs35110281	0.782	rs7282933	chr21:45046988	A/G	cg21573476	chr21:45109991	RRP1B	-0.5	-6.94	-0.39	3.09e-11	Mean corpuscular volume;
CESC	cis	rs7824557	0.564	rs2736301	chr8:11236413	C/T	cg21775007	chr8:11205619	TDH	-0.54	-8.07	-0.44	2.52e-14	Retinal vascular caliber;
CESC	cis	rs11997175	0.545	rs7818001	chr8:33807682	G/T	ch.8.33884649F	chr8:33765107	NA	0.47	6.0	0.35	6.54e-9	Body mass index;
CESC	cis	rs12220238	0.818	rs115350439	chr10:75899365	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.63	6.15	0.35	2.9e-9	Soluble interleukin-2 receptor subunit alpha;
CESC	cis	rs9311474	0.629	rs13081028	chr3:52555316	G/A	cg25934064	chr3:52569026	NT5DC2	0.26	5.31	0.31	2.27e-7	Electroencephalogram traits;
CESC	cis	rs763121	0.925	rs5750654	chr22:39051428	T/C	cg06022373	chr22:39101656	GTPBP1	0.9	15.29	0.68	2.79e-38	Menopause (age at onset);
CESC	cis	rs4568518	0.619	rs9648238	chr7:18005237	A/G	cg03009463	chr7:17980271	SNX13	0.42	5.54	0.32	7.18e-8	Measles;
CESC	trans	rs79976124	0.842	rs1548154	chr6:66624910	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.73	8.36	0.46	3.49e-15	Type 2 diabetes;
CESC	cis	rs6728642	0.561	rs58984980	chr2:97570759	T/A	cg26665480	chr2:98280029	ACTR1B	-0.58	-5.22	-0.31	3.69e-7	Bipolar disorder lithium response (continuous) or schizophrenia;
CESC	cis	rs2200578	1.000	rs2200578	chr2:99876244	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.48	5.11	0.3	6.16e-7	IgG glycosylation;
CESC	cis	rs597539	0.690	rs615644	chr11:68621806	G/C	cg01988459	chr11:68622903	NA	-0.4	-5.22	-0.31	3.62e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs936229	0.749	rs7497201	chr15:75190690	A/G	cg10253484	chr15:75165896	SCAMP2	-0.44	-5.03	-0.3	9.07e-7	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CESC	cis	rs875971	0.862	rs2088653	chr7:65808608	G/A	cg10691866	chr7:65817282	TPST1	0.32	5.42	0.32	1.35e-7	Aortic root size;
CESC	cis	rs4722585	0.764	rs4259314	chr7:26182214	A/G	cg07876897	chr7:26191696	NFE2L3	-0.42	-5.42	-0.32	1.31e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
CESC	cis	rs36051895	0.632	rs10974979	chr9:5131731	C/A	cg02405213	chr9:5042618	JAK2	-0.49	-5.86	-0.34	1.35e-8	Pediatric autoimmune diseases;
CESC	cis	rs8058578	1.000	rs3747481	chr16:30666367	C/T	cg00531865	chr16:30841666	NA	-0.43	-5.56	-0.32	6.6e-8	Multiple myeloma;
CESC	cis	rs2576037	0.526	rs7234570	chr18:44459656	A/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.32	5.08	0.3	7.02e-7	Personality dimensions;
CESC	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg11965913	chr1:205819406	PM20D1	0.47	7.11	0.4	1.05e-11	Menarche (age at onset);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg09235050	chr20:57599210	TUBB1	0.5	7.36	0.41	2.29e-12	Fibrinogen levels;
CESC	cis	rs7786808	0.705	rs1377373	chr7:158215549	A/C	cg09998033	chr7:158218633	PTPRN2	0.46	7.05	0.4	1.51e-11	Obesity-related traits;
CESC	cis	rs6545883	0.859	rs13004855	chr2:61505072	C/T	cg15711740	chr2:61764176	XPO1	0.39	5.05	0.3	8.17e-7	Tuberculosis;
CESC	cis	rs3820928	1.000	rs3820928	chr2:227773466	A/G	cg05526886	chr2:227700861	RHBDD1	-0.4	-5.34	-0.31	2.05e-7	Pulmonary function;
CESC	cis	rs938554	0.736	rs13125646	chr4:9982330	A/G	cg11266682	chr4:10021025	SLC2A9	0.37	5.09	0.3	6.89e-7	Blood metabolite levels;
CESC	cis	rs1775715	0.870	rs1775731	chr10:32253512	A/G	cg18675610	chr10:32216311	ARHGAP12	0.33	5.14	0.3	5.37e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs4319547	0.695	rs4758662	chr12:122924778	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.54	-6.14	-0.35	2.93e-9	Body mass index;
CESC	cis	rs317689	0.718	rs315130	chr12:69761444	T/C	cg14784868	chr12:69753453	YEATS4	0.64	7.44	0.42	1.36e-12	Response to diuretic therapy;
CESC	cis	rs4713118	0.513	rs1225591	chr6:28148752	G/A	cg26335602	chr6:28129616	ZNF389	0.37	5.29	0.31	2.58e-7	Parkinson's disease;
CESC	cis	rs13191362	1.000	rs35818596	chr6:163001874	C/G	cg06582575	chr6:163149167	PACRG;PARK2	0.83	8.39	0.46	3.02e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs863345	0.604	rs2054993	chr1:158505968	T/G	cg12129480	chr1:158549410	OR10X1	-0.33	-6.61	-0.38	2.11e-10	Pneumococcal bacteremia;
CESC	cis	rs10504229	0.679	rs11783963	chr8:58130496	T/A	cg21724239	chr8:58056113	NA	0.58	5.95	0.34	8.29e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs77106637	0.858	rs117819392	chr11:72514503	C/T	cg04827223	chr11:72435913	ARAP1	-0.57	-5.82	-0.34	1.67e-8	Type 2 diabetes;
CESC	cis	rs9916302	0.718	rs7219909	chr17:37706243	C/T	cg00129232	chr17:37814104	STARD3	-0.57	-7.46	-0.42	1.22e-12	Glomerular filtration rate (creatinine);
CESC	cis	rs11760633	0.672	rs12669620	chr7:1826878	G/C	cg23422044	chr7:1970798	MAD1L1	-0.44	-5.26	-0.31	3.02e-7	Coronary artery disease;
CESC	cis	rs225245	0.791	rs2285742	chr17:34018682	C/T	cg05299278	chr17:33885742	SLFN14	0.4	5.6	0.33	5.35e-8	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
CESC	cis	rs875971	0.862	rs7803416	chr7:65954199	A/G	cg11764359	chr7:65958608	NA	0.96	15.06	0.68	1.89e-37	Aortic root size;
CESC	cis	rs17376456	0.825	rs10064368	chr5:93266396	C/A	cg25358565	chr5:93447407	FAM172A	1.12	10.4	0.54	1.88e-21	Diabetic retinopathy;
CESC	cis	rs2839186	0.732	rs8131458	chr21:47694712	G/A	cg10351095	chr21:47802916	PCNT	-0.5	-6.86	-0.39	4.96e-11	Testicular germ cell tumor;
CESC	cis	rs2274273	0.624	rs8005450	chr14:55799165	A/T	cg04306507	chr14:55594613	LGALS3	0.29	5.11	0.3	6.15e-7	Protein biomarker;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18707867	chr19:3971272	DAPK3	0.54	6.01	0.35	6.08e-9	Gut microbiome composition (summer);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg02986938	chr1:174968958	CACYBP	-0.45	-6.11	-0.35	3.51e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs3096299	0.781	rs2965819	chr16:89501030	G/T	cg02187348	chr16:89574699	SPG7	-0.56	-7.45	-0.42	1.29e-12	Multiple myeloma (IgH translocation);
CESC	cis	rs3762637	1.000	rs9867429	chr3:122232668	T/C	cg24169773	chr3:122142474	KPNA1	-0.6	-6.97	-0.39	2.53e-11	LDL cholesterol levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20121920	chr12:124833935	NCOR2	-0.5	-6.45	-0.37	5.19e-10	Gut microbiome composition (summer);
CESC	cis	rs9649213	0.574	rs7790229	chr7:97919338	G/A	cg24562669	chr7:97807699	LMTK2	0.47	6.61	0.38	2.13e-10	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs2230307	0.536	rs700533	chr1:100483822	A/G	cg24955406	chr1:100503596	HIAT1	0.54	5.44	0.32	1.19e-7	Carotid intima media thickness;
CESC	cis	rs6089584	0.526	rs6089619	chr20:60610916	C/T	cg06108461	chr20:60628389	TAF4	-0.59	-7.88	-0.44	8.57e-14	Body mass index;
CESC	cis	rs921968	0.509	rs626432	chr2:219355658	C/A	cg02176678	chr2:219576539	TTLL4	0.51	9.13	0.49	1.86e-17	Mean corpuscular hemoglobin concentration;
CESC	cis	rs875971	0.545	rs4718325	chr7:65680310	G/A	cg25405998	chr7:65216604	CCT6P1	0.51	5.53	0.32	7.63e-8	Aortic root size;
CESC	cis	rs4132509	0.793	rs10803161	chr1:243990770	T/C	cg21452805	chr1:244014465	NA	0.51	6.35	0.36	9.47e-10	RR interval (heart rate);
CESC	cis	rs2637266	0.756	rs846609	chr10:78551718	A/G	cg18941641	chr10:78392320	NA	0.41	7.93	0.44	6.26e-14	Pulmonary function;
CESC	cis	rs3858526	0.584	rs10769271	chr11:5860572	T/C	cg13902645	chr11:5959945	NA	-0.67	-9.11	-0.49	2.14e-17	DNA methylation (variation);
CESC	cis	rs561341	1.000	rs4795667	chr17:30244443	T/C	cg23018236	chr17:30244563	NA	-0.52	-5.59	-0.32	5.65e-8	Hip circumference adjusted for BMI;
CESC	trans	rs6677604	1.000	rs7519758	chr1:196825287	C/T	cg02859443	chr16:53737878	RPGRIP1L;FTO	-0.62	-6.07	-0.35	4.34e-9	IgA nephropathy;Nephropathy;Blood protein levels;
CESC	cis	rs10411936	1.000	rs11878602	chr19:16555153	A/C	cg10248733	chr19:16607483	C19orf44;CALR3	-0.45	-5.4	-0.31	1.48e-7	White blood cell count;Multiple sclerosis;
CESC	trans	rs12659622	0.703	rs17602097	chr5:15688927	C/T	cg22457238	chr19:58570995	ZNF135	-0.49	-6.25	-0.36	1.59e-9	Obesity-related traits;
CESC	cis	rs4665809	0.590	rs35746418	chr2:26455002	C/G	cg26314531	chr2:26401878	FAM59B	0.85	9.04	0.49	3.44e-17	Gut microbiome composition (summer);
CESC	cis	rs916888	0.773	rs538628	chr17:44787313	G/C	cg27589368	chr17:43923255	LOC100128977;IMP5	-0.38	-5.25	-0.31	3.06e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	trans	rs61931739	0.500	rs1843736	chr12:34012080	C/G	cg26384229	chr12:38710491	ALG10B	0.59	8.21	0.45	9.45e-15	Morning vs. evening chronotype;
CESC	cis	rs1256061	0.603	rs10148269	chr14:64736924	A/G	cg21174375	chr14:64681225	SYNE2	0.51	6.82	0.39	6.15e-11	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18052878	chr11:61276087	LRRC10B	0.53	6.02	0.35	5.89e-9	Gut microbiome composition (summer);
CESC	cis	rs2531992	1.000	rs2531992	chr16:4021734	A/G	cg05927578	chr16:4029543	ADCY9	0.44	5.5	0.32	8.93e-8	Waist circumference;
CESC	cis	rs7116495	0.609	rs7115513	chr11:71664495	T/A	cg07596299	chr11:71824057	C11orf51	-0.76	-5.21	-0.3	3.85e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs3015497	0.789	rs10133849	chr14:51121700	A/G	cg09863266	chr14:51125203	SAV1	-0.36	-5.71	-0.33	3e-8	Mean platelet volume;
CESC	cis	rs473651	0.935	rs559579	chr2:239339501	G/C	cg18131467	chr2:239335373	ASB1	0.94	14.13	0.66	3.57e-34	Multiple system atrophy;
CESC	cis	rs4474465	0.833	rs11606128	chr11:78156960	T/C	cg27205649	chr11:78285834	NARS2	-0.41	-5.16	-0.3	4.79e-7	Alzheimer's disease (survival time);
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg20641355	chr8:90992387	NBN	0.39	6.14	0.35	3.03e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs72945132	0.825	rs72947052	chr11:70188575	A/G	cg00319359	chr11:70116639	PPFIA1	0.76	6.19	0.36	2.3e-9	Coronary artery disease;
CESC	cis	rs2295499	0.700	rs59425183	chr4:2721199	G/A	cg08330972	chr4:2403930	ZFYVE28	-0.33	-5.53	-0.32	7.5e-8	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
CESC	cis	rs1387259	0.929	rs2956703	chr12:48670294	C/T	cg04545296	chr12:48745243	ZNF641	0.42	7.06	0.4	1.47e-11	Obstructive sleep apnea trait (apnea hypopnea index);
CESC	cis	rs6484504	0.576	rs441975	chr11:31233351	C/T	cg14844989	chr11:31128820	NA	-0.43	-6.12	-0.35	3.26e-9	Red blood cell count;
CESC	cis	rs12621445	1	rs12621445	chr2:24154964	C/T	cg08917208	chr2:24149416	ATAD2B	1.12	10.14	0.53	1.21e-20	Immature fraction of reticulocytes;
CESC	cis	rs4629180	0.675	rs908132	chr2:102093096	A/G	cg21388029	chr2:102003306	CREG2	0.32	5.04	0.3	8.68e-7	Chronic rhinosinusitis with nasal polyps;
CESC	cis	rs10870270	1.000	rs72636963	chr10:133771271	C/T	cg26149184	chr10:133730230	NA	0.38	5.16	0.3	4.87e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs7116495	0.609	rs6592457	chr11:71738086	G/C	cg10381502	chr11:71823885	C11orf51	-1.16	-6.94	-0.39	3.1e-11	Severe influenza A (H1N1) infection;
CESC	cis	rs1832871	0.655	rs6920121	chr6:158678504	C/T	cg07165851	chr6:158734300	TULP4	-0.58	-6.32	-0.36	1.12e-9	Height;
CESC	cis	rs2295499	0.782	rs4690053	chr4:2736579	G/C	cg27239842	chr4:2403781	ZFYVE28	-0.32	-5.15	-0.3	5.12e-7	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
CESC	cis	rs12134245	0.747	rs17501512	chr1:92012481	C/G	cg02896835	chr1:92012615	NA	0.49	6.42	0.37	6.41e-10	Breast cancer;
CESC	cis	rs11718455	0.767	rs4682924	chr3:43992760	G/A	cg08738300	chr3:44038990	NA	0.44	5.86	0.34	1.34e-8	Coronary artery disease;
CESC	cis	rs3762637	1.000	rs12633461	chr3:122135897	C/G	cg24169773	chr3:122142474	KPNA1	-0.51	-6.03	-0.35	5.56e-9	LDL cholesterol levels;
CESC	cis	rs60843830	1.000	rs7566279	chr2:281178	C/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.79	10.15	0.53	1.14e-20	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs8020095	0.528	rs6573758	chr14:67667906	A/G	cg19548862	chr14:67692701	FAM71D	-0.47	-5.75	-0.33	2.39e-8	Depression (quantitative trait);
CESC	cis	rs6088580	0.634	rs6059779	chr20:32950325	C/T	cg06115741	chr20:33292138	TP53INP2	-0.44	-5.7	-0.33	3.14e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs7512552	0.839	rs2264418	chr1:150368579	G/A	cg15654264	chr1:150340011	RPRD2	0.4	5.28	0.31	2.65e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs782590	0.967	rs1823893	chr2:55788921	T/C	cg18811423	chr2:55921094	PNPT1	0.77	12.37	0.6	4.82e-28	Metabolic syndrome;
CESC	cis	rs7937682	0.575	rs7107213	chr11:111750430	A/G	cg22437258	chr11:111473054	SIK2	-0.45	-5.05	-0.3	8.14e-7	Primary sclerosing cholangitis;
CESC	cis	rs10924970	0.624	rs12755851	chr1:235477806	G/C	cg26050004	chr1:235667680	B3GALNT2	0.44	5.1	0.3	6.52e-7	Asthma;
CESC	cis	rs7639513	0.767	rs9878151	chr3:12703714	G/C	cg23032965	chr3:12705835	RAF1	0.76	10.61	0.55	3.68e-22	Itch intensity from mosquito bite;
CESC	cis	rs2072732	0.808	rs74048148	chr1:2954031	A/G	cg15211996	chr1:2936768	ACTRT2	0.35	6.02	0.35	5.76e-9	Plateletcrit;
CESC	trans	rs7824557	0.527	rs2572449	chr8:11239137	A/G	cg15556689	chr8:8085844	FLJ10661	0.49	6.28	0.36	1.38e-9	Retinal vascular caliber;
CESC	cis	rs9487051	0.714	rs7744284	chr6:109616218	C/T	cg12927641	chr6:109611667	NA	-0.36	-5.36	-0.31	1.83e-7	Reticulocyte fraction of red cells;
CESC	cis	rs9815354	0.767	rs73830585	chr3:42003698	T/A	cg03022575	chr3:42003672	ULK4	0.66	5.77	0.33	2.17e-8	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs1799949	0.965	rs8176161	chr17:41241390	C/A	cg06001716	chr17:41278141	BRCA1;NBR2	0.38	5.22	0.31	3.62e-7	Menopause (age at onset);
CESC	cis	rs208520	0.690	rs851458	chr6:66813279	T/G	cg07460842	chr6:66804631	NA	-0.98	-13.55	-0.64	3.82e-32	Exhaled nitric oxide output;
CESC	cis	rs7605827	0.930	rs11682580	chr2:15533272	T/C	cg19274914	chr2:15703543	NA	0.36	6.59	0.38	2.3e-10	Educational attainment (years of education);
CESC	cis	rs36093924	0.646	rs5996092	chr22:42344408	A/G	cg15557168	chr22:42548783	NA	0.37	5.39	0.31	1.57e-7	Intelligence;
CESC	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg11494091	chr17:61959527	GH2	0.73	12.58	0.61	8.77e-29	Prudent dietary pattern;
CESC	cis	rs7618915	0.547	rs8906	chr3:52739520	T/C	cg05564831	chr3:52568323	NT5DC2	0.44	6.72	0.38	1.12e-10	Bipolar disorder;
CESC	cis	rs7833986	0.501	rs2976038	chr8:57028864	G/A	cg26371346	chr8:56986568	SNORD54;RPS20	0.57	5.41	0.32	1.42e-7	Height;
CESC	cis	rs2439831	1.000	rs2254321	chr15:43707542	T/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.79	11.67	0.58	1.11e-25	Lung cancer in ever smokers;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg12565914	chr11:47270322	ACP2;NR1H3	0.49	6.19	0.36	2.29e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs9911578	0.933	rs2632508	chr17:56533235	G/A	cg12560992	chr17:57184187	TRIM37	0.91	15.16	0.68	8.27e-38	Intelligence (multi-trait analysis);
CESC	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg12419862	chr22:24373484	LOC391322	-0.7	-9.61	-0.51	6.14e-19	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs7927592	0.956	rs10896334	chr11:68281494	C/T	cg20283391	chr11:68216788	NA	-0.5	-5.99	-0.35	6.77e-9	Total body bone mineral density;
CESC	cis	rs1190552	0.846	rs3783382	chr14:102965437	A/T	cg18135206	chr14:102964638	TECPR2	0.42	5.32	0.31	2.22e-7	Blood protein levels;
CESC	cis	rs55665837	0.559	rs11023210	chr11:14422762	A/G	cg19336497	chr11:14380999	RRAS2	0.35	5.16	0.3	4.9e-7	Vitamin D levels;
CESC	cis	rs7666738	0.830	rs4292341	chr4:98959724	C/T	cg03467027	chr4:99064603	C4orf37	0.41	5.63	0.33	4.48e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9303401	0.632	rs9915267	chr17:57244907	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.56	7.14	0.4	9.15e-12	Cognitive test performance;
CESC	trans	rs7615952	0.932	rs11922218	chr3:125631289	C/T	cg07211511	chr3:129823064	LOC729375	-1.07	-14.34	-0.66	6.43e-35	Blood pressure (smoking interaction);
CESC	cis	rs6456156	0.586	rs2001115	chr6:167486218	A/C	cg23791538	chr6:167370224	RNASET2	-0.5	-6.37	-0.36	8.51e-10	Primary biliary cholangitis;
CESC	cis	rs2235642	0.717	rs9937922	chr16:1658154	C/G	cg03715980	chr16:1756201	MAPK8IP3	0.42	5.61	0.33	5.02e-8	Coronary artery disease;
CESC	cis	rs1448094	0.512	rs12309296	chr12:86241566	T/C	cg19622623	chr12:86230825	RASSF9	-0.47	-6.05	-0.35	4.94e-9	Major depressive disorder;
CESC	trans	rs11039798	0.588	rs12294395	chr11:48476860	C/T	cg15704280	chr7:45808275	SEPT13	0.66	6.84	0.39	5.37e-11	Axial length;
CESC	trans	rs9354308	0.899	rs2814099	chr6:66555130	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.63	7.03	0.4	1.75e-11	Metabolite levels;
CESC	cis	rs8180040	0.966	rs7651762	chr3:47470484	G/A	cg27129171	chr3:47204927	SETD2	-0.63	-9.64	-0.51	4.71e-19	Colorectal cancer;
CESC	trans	rs55704346	0.566	rs2292408	chr4:25394078	A/G	cg01822600	chr1:245751692	KIF26B	0.42	6.17	0.35	2.58e-9	Tonsillectomy;
CESC	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg06873352	chr17:61820015	STRADA	0.72	12.74	0.62	2.58e-29	Prudent dietary pattern;
CESC	cis	rs4253772	0.637	rs6008339	chr22:46650846	C/T	cg10231785	chr22:46692440	CN5H6.4;GTSE1	0.48	5.11	0.3	6.16e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs8002861	0.905	rs12875052	chr13:44449368	G/C	cg14210620	chr13:44453864	C13orf31;CCDC122	-0.44	-5.49	-0.32	9.44e-8	Leprosy;
CESC	cis	rs4253772	0.550	rs9615951	chr22:46728056	C/A	cg18190219	chr22:46762943	CELSR1	-0.62	-6.51	-0.37	3.73e-10	LDL cholesterol;Cholesterol, total;
CESC	cis	rs7618915	0.547	rs62255362	chr3:52699741	C/G	cg05564831	chr3:52568323	NT5DC2	0.44	6.72	0.38	1.08e-10	Bipolar disorder;
CESC	cis	rs12477438	0.520	rs2516835	chr2:99779131	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.77	12.84	0.62	1.16e-29	Chronic sinus infection;
CESC	trans	rs9388451	0.626	rs3799712	chr6:126075103	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.66	-9.3	-0.5	5.38e-18	Brugada syndrome;
CESC	cis	rs7818688	0.697	rs17665737	chr8:95986306	A/G	cg16049864	chr8:95962084	TP53INP1	0.58	5.71	0.33	2.99e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs6540559	0.543	rs664097	chr1:210422179	C/T	cg25204440	chr1:209979598	IRF6	0.47	5.31	0.31	2.33e-7	Cleft lip with or without cleft palate;
CESC	cis	rs1552244	0.515	rs67342818	chr3:10166406	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.78	8.92	0.48	7.63e-17	Alzheimer's disease;
CESC	cis	rs4665809	0.531	rs12987980	chr2:26462093	A/T	cg25036284	chr2:26402008	FAM59B	0.86	9.36	0.5	3.44e-18	Gut microbiome composition (summer);
CESC	cis	rs7089973	0.624	rs10885613	chr10:116589400	G/A	cg25233709	chr10:116636983	FAM160B1	0.38	5.9	0.34	1.12e-8	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs7208859	0.623	rs56018041	chr17:29059985	G/A	cg13385521	chr17:29058706	SUZ12P	0.81	6.53	0.37	3.28e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	trans	rs1814175	0.817	rs1818890	chr11:49856882	T/C	cg03929089	chr4:120376271	NA	-0.91	-15.11	-0.68	1.3e-37	Height;
CESC	cis	rs9322193	0.962	rs6899661	chr6:150139229	T/C	cg05861140	chr6:150128134	PCMT1	-0.37	-5.27	-0.31	2.78e-7	Lung cancer;
CESC	cis	rs72781680	0.752	rs12616649	chr2:23890913	G/A	cg08917208	chr2:24149416	ATAD2B	1.18	10.39	0.54	1.89e-21	Lymphocyte counts;
CESC	cis	rs977987	0.806	rs1544810	chr16:75411163	A/T	cg03315344	chr16:75512273	CHST6	0.4	5.72	0.33	2.88e-8	Dupuytren's disease;
CESC	cis	rs2243480	1.000	rs316315	chr7:65591205	C/T	cg13147721	chr7:65941812	NA	0.8	8.67	0.47	4.4e-16	Diabetic kidney disease;
CESC	cis	rs9311474	0.508	rs17052256	chr3:52593119	A/G	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.31	5.48	0.32	9.87e-8	Electroencephalogram traits;
CESC	cis	rs6088580	0.524	rs2378251	chr20:33276750	C/T	cg08999081	chr20:33150536	PIGU	-0.43	-6.18	-0.35	2.44e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs360798	0.512	rs2710637	chr2:63173450	G/A	cg17519650	chr2:63277830	OTX1	0.52	6.63	0.38	1.87e-10	Coronary artery disease;
CESC	cis	rs300703	0.515	rs364431	chr2:191399	C/A	cg21211680	chr2:198530	NA	0.91	10.48	0.54	1e-21	Blood protein levels;
CESC	cis	rs2066819	1.000	rs74496027	chr12:56726340	C/T	cg26734620	chr12:56694298	CS	0.98	5.95	0.34	8.45e-9	Psoriasis vulgaris;
CESC	cis	rs1927790	0.727	rs4771932	chr13:96950542	G/A	cg02571835	chr13:96230311	CLDN10	-0.36	-5.11	-0.3	6.13e-7	Body mass index;
CESC	cis	rs6963495	0.818	rs55691539	chr7:105165774	T/C	cg19920283	chr7:105172520	RINT1	0.7	6.66	0.38	1.58e-10	Bipolar disorder (body mass index interaction);
CESC	cis	rs9660992	0.710	rs1668867	chr1:205240251	C/T	cg00857998	chr1:205179979	DSTYK	0.46	5.4	0.31	1.51e-7	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs9908102	0.770	rs73298508	chr17:12904223	A/G	cg26162695	chr17:12921313	ELAC2	0.5	5.49	0.32	9.61e-8	Schizophrenia;
CESC	cis	rs4450798	0.602	rs4431090	chr3:13791700	A/C	cg23332027	chr3:13681764	NA	0.4	5.52	0.32	8.21e-8	Bipolar disorder with mood-incongruent psychosis;
CESC	trans	rs11764590	0.694	rs11773643	chr7:2104063	A/G	cg11693508	chr17:37793320	STARD3	0.54	6.1	0.35	3.8e-9	Neuroticism;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22459051	chr7:44058729	POLR2J4	-0.58	-6.32	-0.36	1.13e-9	Gut microbiome composition (summer);
CESC	cis	rs651907	0.557	rs3864012	chr3:101397623	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.51	6.89	0.39	3.98e-11	Colorectal cancer;
CESC	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg14926445	chr8:58193284	C8orf71	-0.54	-5.16	-0.3	4.76e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs35160687	0.644	rs11680025	chr2:86545338	C/T	cg01119172	chr2:86362222	SNORD94;PTCD3	-0.38	-5.29	-0.31	2.57e-7	Night sleep phenotypes;
CESC	cis	rs72949976	0.864	rs10176806	chr2:214022596	T/G	cg08319019	chr2:214017104	IKZF2	-0.46	-5.7	-0.33	3.2e-8	Lung cancer;Squamous cell lung carcinoma;
CESC	cis	rs9611565	0.559	rs5751160	chr22:42175695	A/G	cg06481639	chr22:41940642	POLR3H	0.59	5.76	0.33	2.35e-8	Vitiligo;
CESC	cis	rs6500602	0.648	rs7702	chr16:4560929	G/C	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.35	5.08	0.3	7.22e-7	Schizophrenia;
CESC	cis	rs2658782	0.724	rs1869914	chr11:93112492	C/G	cg15737290	chr11:93063684	CCDC67	0.53	6.9	0.39	3.81e-11	Pulmonary function decline;
CESC	trans	rs4332037	0.851	rs28728306	chr7:1961814	C/A	cg11693508	chr17:37793320	STARD3	0.7	6.8	0.39	7e-11	Bipolar disorder;
CESC	cis	rs2070488	0.699	rs13078966	chr3:38517914	T/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.82	13.35	0.63	2.01e-31	Electrocardiographic conduction measures;
CESC	cis	rs7100689	0.577	rs9420349	chr10:82031160	T/C	cg00277334	chr10:82204260	NA	-0.51	-6.6	-0.38	2.28e-10	Post bronchodilator FEV1;
CESC	cis	rs2625529	0.730	rs2957373	chr15:72340929	T/C	cg16672083	chr15:72433130	SENP8	0.43	6.37	0.36	8.26e-10	Red blood cell count;
CESC	cis	rs12142240	0.698	rs72890727	chr1:46860237	G/A	cg00530320	chr1:46809349	NSUN4	0.6	8.27	0.45	6.54e-15	Menopause (age at onset);
CESC	cis	rs3733585	0.699	rs17245723	chr4:9962218	A/T	cg11266682	chr4:10021025	SLC2A9	-0.6	-11.15	-0.57	6.33e-24	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs9837602	1.000	rs2291495	chr3:99782227	T/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.5	7.11	0.4	1.1e-11	Breast cancer;
CESC	cis	rs4713118	0.587	rs61471148	chr6:28037032	T/A	cg23161317	chr6:28129485	ZNF389	0.53	6.4	0.37	7.05e-10	Parkinson's disease;
CESC	cis	rs8072100	0.667	rs1912485	chr17:45515678	T/G	cg25173405	chr17:45401733	C17orf57	-0.43	-5.43	-0.32	1.26e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	trans	rs561341	0.714	rs111760509	chr17:30304320	A/G	cg27661571	chr11:113659931	NA	-0.82	-7.68	-0.43	3.16e-13	Hip circumference adjusted for BMI;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21959316	chr1:85040158	CTBS	0.67	7.43	0.42	1.54e-12	Gut microbiome composition (summer);
CESC	cis	rs79349575	0.783	rs4793998	chr17:47019899	C/T	cg16584676	chr17:46985605	UBE2Z	0.54	6.67	0.38	1.46e-10	Type 2 diabetes;
CESC	cis	rs3741404	0.560	rs2875748	chr11:63915537	G/A	cg18225595	chr11:63971243	STIP1	-0.48	-6.72	-0.38	1.13e-10	Platelet count;
CESC	cis	rs9902453	0.765	rs2259857	chr17:28097780	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-10.41	-0.54	1.71e-21	Coffee consumption (cups per day);
CESC	cis	rs1218582	0.772	rs7528532	chr1:154874440	C/T	cg06221963	chr1:154839813	KCNN3	-0.66	-11.39	-0.57	1.03e-24	Prostate cancer;
CESC	cis	rs17253792	0.822	rs10147431	chr14:56091841	G/A	cg01858014	chr14:56050164	KTN1	-0.83	-7.03	-0.4	1.7e-11	Putamen volume;
CESC	cis	rs1801251	1.000	rs778166	chr2:233664097	A/T	cg08000102	chr2:233561755	GIGYF2	0.67	9.77	0.51	1.93e-19	Coronary artery disease;
CESC	cis	rs72901758	0.768	rs11657271	chr17:76249682	A/T	cg26068271	chr17:76253126	NA	0.44	6.45	0.37	5.4e-10	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
CESC	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg21724239	chr8:58056113	NA	0.6	5.56	0.32	6.59e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs1568889	0.941	rs35357280	chr11:28322745	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.75	7.67	0.43	3.3e-13	Bipolar disorder;
CESC	cis	rs11711311	1.000	rs9809850	chr3:113429010	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.66	8.98	0.48	5.02e-17	IgG glycosylation;
CESC	cis	rs8114671	0.562	rs4911163	chr20:33470694	C/T	cg07148914	chr20:33460835	GGT7	0.46	6.11	0.35	3.46e-9	Height;
CESC	cis	rs3750965	0.920	rs10896421	chr11:68863048	T/C	cg01403660	chr11:68851641	TPCN2	0.4	5.48	0.32	9.89e-8	Hair color;
CESC	cis	rs7666738	0.830	rs62318470	chr4:98925846	A/C	cg03467027	chr4:99064603	C4orf37	0.46	5.59	0.32	5.78e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3820928	0.904	rs4439949	chr2:227764954	T/G	cg05526886	chr2:227700861	RHBDD1	-0.44	-5.55	-0.32	6.93e-8	Pulmonary function;
CESC	cis	rs7116495	1.000	rs2298456	chr11:71730715	A/T	cg26138937	chr11:71823887	C11orf51	0.76	6.47	0.37	4.63e-10	Severe influenza A (H1N1) infection;
CESC	cis	rs854765	0.647	rs854763	chr17:18010095	C/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.48	6.0	0.35	6.41e-9	Total body bone mineral density;
CESC	cis	rs6963495	0.538	rs55967123	chr7:105163678	C/A	cg13798780	chr7:105162888	PUS7	0.78	8.06	0.44	2.68e-14	Bipolar disorder (body mass index interaction);
CESC	cis	rs4253772	0.575	rs9615979	chr22:46789021	G/T	cg09491104	chr22:46646882	C22orf40	-0.55	-5.04	-0.3	8.54e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs3812762	0.912	rs4929936	chr11:8792622	C/T	cg03980550	chr11:8754370	ST5	-0.39	-5.33	-0.31	2.12e-7	Hypospadias;
CESC	cis	rs67478160	0.654	rs4906365	chr14:104229230	G/C	cg08213375	chr14:104286397	PPP1R13B	0.55	10.87	0.56	5.17e-23	Schizophrenia;
CESC	cis	rs807669	0.505	rs28651174	chr22:19236489	C/T	cg02655711	chr22:19163373	SLC25A1	0.41	6.01	0.35	6.26e-9	Metabolite levels;
CESC	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg01238044	chr22:24384105	GSTT1	-0.67	-8.84	-0.48	1.4e-16	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs3126085	0.877	rs3120672	chr1:152255575	A/G	cg03465714	chr1:152285911	FLG	-0.45	-5.54	-0.32	7.12e-8	Atopic dermatitis;
CESC	cis	rs2274273	0.870	rs7158768	chr14:55763612	A/C	cg04306507	chr14:55594613	LGALS3	0.31	6.09	0.35	4.01e-9	Protein biomarker;
CESC	cis	rs4474465	1.000	rs2373199	chr11:78142982	G/A	cg27205649	chr11:78285834	NARS2	-0.42	-5.1	-0.3	6.41e-7	Alzheimer's disease (survival time);
CESC	cis	rs447735	0.565	rs10852626	chr16:89914633	T/G	cg04287289	chr16:89883240	FANCA	0.58	7.5	0.42	9.56e-13	Hemoglobin concentration;
CESC	trans	rs9929218	0.861	rs3114409	chr16:68732049	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.77	-10.29	-0.53	4.24e-21	Colorectal cancer;
CESC	cis	rs6912958	0.702	rs6906769	chr6:88235949	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-5.08	-0.3	7.21e-7	Monocyte percentage of white cells;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06467587	chr16:15808736	MYH11;NDE1	-0.56	-6.32	-0.36	1.13e-9	Gut microbiome composition (summer);
CESC	trans	rs11098499	0.909	rs7659501	chr4:120371552	G/T	cg25214090	chr10:38739885	LOC399744	0.7	9.92	0.52	6.5e-20	Corneal astigmatism;
CESC	cis	rs42648	0.935	rs42660	chr7:89982522	C/T	cg23697855	chr7:89950296	NA	0.28	5.31	0.31	2.27e-7	Homocysteine levels;
CESC	cis	rs4728302	0.583	rs12707091	chr7:133185749	A/G	cg10665199	chr7:133106180	EXOC4	0.53	7.18	0.4	6.94e-12	Intelligence;Intelligence (multi-trait analysis);
CESC	cis	rs2204008	0.702	rs3849999	chr12:38483498	G/A	cg26384229	chr12:38710491	ALG10B	-0.41	-5.41	-0.32	1.42e-7	Bladder cancer;
CESC	cis	rs4713118	0.662	rs9357060	chr6:28024486	C/G	cg26335602	chr6:28129616	ZNF389	0.44	5.7	0.33	3.25e-8	Parkinson's disease;
CESC	cis	rs2735413	0.918	rs12924772	chr16:78083115	T/C	cg04733911	chr16:78082701	NA	-0.53	-8.89	-0.48	9.44e-17	Systolic blood pressure (alcohol consumption interaction);
CESC	cis	rs6088590	1.000	rs6120747	chr20:33449769	T/C	cg06115741	chr20:33292138	TP53INP2	0.63	7.78	0.43	1.6e-13	Coronary artery disease;
CESC	cis	rs3741151	1.000	rs75004180	chr11:73024739	A/G	cg17517138	chr11:73019481	ARHGEF17	1.12	7.86	0.43	9.43e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs11098499	0.821	rs10032151	chr4:120391628	C/T	cg24375607	chr4:120327624	NA	0.45	5.59	0.32	5.56e-8	Corneal astigmatism;
CESC	cis	rs7927592	0.763	rs10896351	chr11:68386896	G/A	cg01657329	chr11:68192670	LRP5	-0.47	-6.1	-0.35	3.69e-9	Total body bone mineral density;
CESC	cis	rs13266463	0.830	rs6983790	chr8:143406575	A/G	cg06454464	chr8:143427921	TSNARE1	0.41	5.41	0.32	1.41e-7	Schizophrenia;
CESC	cis	rs7635838	0.718	rs2594981	chr3:11380638	C/G	cg00170343	chr3:11313890	ATG7	0.56	8.19	0.45	1.15e-14	HDL cholesterol;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00744550	chr2:242609941	ATG4B	-0.53	-6.13	-0.35	3.12e-9	Gut microbiome composition (summer);
CESC	cis	rs3008870	1.000	rs12137403	chr1:67437043	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-1.03	-14.53	-0.67	1.38e-35	Lymphocyte percentage of white cells;
CESC	cis	rs854765	0.583	rs4341796	chr17:17839024	C/A	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.51	6.57	0.37	2.65e-10	Total body bone mineral density;
CESC	cis	rs9911578	0.835	rs2301867	chr17:56480074	T/A	cg12560992	chr17:57184187	TRIM37	-0.87	-14.52	-0.67	1.57e-35	Intelligence (multi-trait analysis);
CESC	cis	rs2486288	0.656	rs8024620	chr15:45574329	C/T	cg09092052	chr15:45571596	NA	0.44	5.26	0.31	2.98e-7	Glomerular filtration rate;
CESC	cis	rs12545109	0.613	rs10958480	chr8:57278717	A/T	cg09654669	chr8:57350985	NA	-0.46	-5.82	-0.34	1.66e-8	Obesity-related traits;
CESC	cis	rs10911251	0.546	rs12034436	chr1:183114797	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.85	13.23	0.63	5.03e-31	Colorectal cancer;
CESC	cis	rs3733585	0.563	rs881971	chr4:9930962	A/G	cg02734326	chr4:10020555	SLC2A9	-0.4	-5.76	-0.33	2.36e-8	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs11122272	0.735	rs2486743	chr1:231506928	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-7.03	-0.4	1.77e-11	Hemoglobin concentration;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14528254	chr7:5862839	ZNF815	0.6	6.97	0.39	2.47e-11	Gut microbiome composition (summer);
CESC	cis	rs7827545	1.000	rs2119879	chr8:135549042	T/C	cg17885191	chr8:135476712	NA	0.49	6.87	0.39	4.45e-11	Hypertension (SNP x SNP interaction);
CESC	cis	rs11231420	1	rs11231420	chr11:55644734	T/C	cg09684106	chr11:55640291	NA	-0.31	-5.2	-0.3	3.96e-7	Pelvic organ prolapse (moderate/severe);
CESC	cis	rs514406	0.861	rs2448792	chr1:53268313	T/C	cg08859206	chr1:53392774	SCP2	0.56	7.29	0.41	3.54e-12	Monocyte count;
CESC	cis	rs9911578	0.835	rs9788975	chr17:56460800	G/A	cg25039879	chr17:56429692	SUPT4H1	-0.39	-5.23	-0.31	3.39e-7	Intelligence (multi-trait analysis);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg14888445	chr13:101184494	A2LD1	0.49	6.59	0.38	2.34e-10	Fibrinogen levels;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg00872270	chr16:3190814	ZNF213	0.45	6.3	0.36	1.23e-9	Fibrinogen levels;
CESC	cis	rs2777491	0.574	rs1757468	chr15:41743574	T/A	cg18705301	chr15:41695430	NDUFAF1	-1.06	-16.93	-0.72	4.47e-44	Ulcerative colitis;
CESC	cis	rs7959452	0.562	rs11177630	chr12:69767963	G/C	cg22834771	chr12:69754056	YEATS4	-0.48	-6.46	-0.37	4.96e-10	Blood protein levels;
CESC	cis	rs6540556	0.769	rs9430017	chr1:209925058	C/T	cg05527609	chr1:210001259	C1orf107	-0.66	-7.66	-0.43	3.56e-13	Red blood cell count;
CESC	cis	rs1355223	0.583	rs1396881	chr11:34870506	G/T	cg11058730	chr11:34937778	PDHX;APIP	0.82	12.62	0.61	6.79e-29	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs73206853	0.764	rs7314552	chr12:110618890	C/T	cg12870014	chr12:110450643	ANKRD13A	0.65	5.62	0.33	4.79e-8	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs2463822	1.000	rs115395195	chr11:62100353	G/A	cg06239285	chr11:62104954	ASRGL1	-1.1	-9.26	-0.49	7.36e-18	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs3733585	0.699	rs62294332	chr4:9959989	T/C	cg11266682	chr4:10021025	SLC2A9	-0.6	-11.2	-0.57	4.42e-24	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs769267	0.825	rs1469713	chr19:19528806	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.46	6.05	0.35	4.83e-9	Tonsillectomy;
CESC	cis	rs4604732	0.631	rs10925044	chr1:247627071	A/G	cg12754571	chr1:247694271	LOC148824;OR2C3	0.43	5.38	0.31	1.66e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs698813	0.614	rs811494	chr2:44725047	T/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.48	5.23	0.31	3.42e-7	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
CESC	cis	rs4253311	0.593	rs1511802	chr4:187150806	T/C	cg24794857	chr4:187113578	CYP4V2	0.44	5.53	0.32	7.52e-8	Plasma renin activity levels;Circulating chromogranin peptide levels;Blood metabolite levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06096824	chr1:51443952	NA	0.62	6.69	0.38	1.34e-10	Gut microbiome composition (summer);
CESC	cis	rs3768617	1.000	rs3820697	chr1:183100226	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.65	9.05	0.49	3.07e-17	Fuchs's corneal dystrophy;
CESC	cis	rs7552404	1.000	rs4949874	chr1:76161889	T/C	cg22875332	chr1:76189707	ACADM	0.66	7.81	0.43	1.31e-13	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs7666738	0.830	rs7679961	chr4:99000202	C/T	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.62e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs561341	0.660	rs7406043	chr17:30220152	C/G	cg19193384	chr17:30244184	NA	-0.55	-5.82	-0.34	1.65e-8	Hip circumference adjusted for BMI;
CESC	cis	rs838147	0.534	rs2638280	chr19:49209318	G/A	cg21064579	chr19:49206444	FUT2	0.5	6.82	0.39	6e-11	Dietary macronutrient intake;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg27466766	chr8:144679319	EEF1D;TIGD5	-0.49	-6.81	-0.39	6.61e-11	Fibrinogen levels;
CESC	cis	rs17490626	0.568	rs12413529	chr10:71211644	G/T	cg12610070	chr10:71211762	TSPAN15	-0.32	-6.91	-0.39	3.55e-11	Thrombosis;
CESC	cis	rs9399135	0.967	rs4896119	chr6:135293391	C/T	cg22676075	chr6:135203613	NA	0.52	7.12	0.4	9.93e-12	Red blood cell count;
CESC	cis	rs710216	0.957	rs12041787	chr1:43432275	G/C	cg07803811	chr1:43423981	SLC2A1	0.47	5.05	0.3	8.26e-7	Red cell distribution width;
CESC	trans	rs1003719	0.715	rs762139	chr21:38568475	A/T	cg05290708	chr7:140372864	ADCK2	-0.45	-6.1	-0.35	3.76e-9	Eye color traits;
CESC	cis	rs7659604	0.628	rs3828485	chr4:122722368	G/A	cg19748678	chr4:122722346	EXOSC9	0.76	9.57	0.51	7.95e-19	Type 2 diabetes;
CESC	cis	rs950027	0.549	rs12909409	chr15:45608582	T/G	cg21132104	chr15:45694354	SPATA5L1	-0.59	-7.2	-0.4	6.4e-12	Response to fenofibrate (adiponectin levels);
CESC	cis	rs2549003	1.000	rs9282763	chr5:131822133	T/C	cg00255919	chr5:131827918	IRF1	0.51	8.68	0.47	4.19e-16	Asthma (sex interaction);
CESC	cis	rs780096	0.526	rs780107	chr2:27684734	A/G	cg22903471	chr2:27725779	GCKR	-0.52	-7.39	-0.41	1.88e-12	Total body bone mineral density;
CESC	cis	rs2777491	0.957	rs8026197	chr15:41711447	C/T	cg20272979	chr15:41787780	ITPKA	0.45	6.69	0.38	1.3100000000000001e-10	Ulcerative colitis;
CESC	trans	rs1945213	0.694	rs1384088	chr11:55848713	G/C	cg15704280	chr7:45808275	SEPT13	-0.76	-7.3	-0.41	3.45e-12	Acute lymphoblastic leukemia (childhood);
CESC	trans	rs1368304	0.850	rs17107992	chr5:147617065	A/C	cg06836181	chr2:64995545	NA	-0.63	-6.05	-0.35	4.84e-9	IgG glycosylation;
CESC	cis	rs17270561	0.609	rs7754296	chr6:25744878	A/G	cg17691542	chr6:26056736	HIST1H1C	0.4	5.22	0.31	3.55e-7	Iron status biomarkers;
CESC	cis	rs2204008	0.703	rs12818324	chr12:38213871	G/A	cg26384229	chr12:38710491	ALG10B	-0.41	-5.5	-0.32	9.03e-8	Bladder cancer;
CESC	cis	rs4969178	0.965	rs4969179	chr17:76391454	A/C	cg05887092	chr17:76393375	PGS1	0.58	9.11	0.49	2.01e-17	HDL cholesterol levels;
CESC	cis	rs2180341	0.920	rs1073931	chr6:127681762	A/T	cg27446573	chr6:127587934	RNF146	1.06	15.88	0.7	2.39e-40	Breast cancer;
CESC	cis	rs12971120	0.947	rs8084410	chr18:72168486	T/C	cg25817165	chr18:72167213	CNDP2	-0.56	-7.84	-0.43	1.09e-13	Refractive error;
CESC	cis	rs36051895	0.632	rs7036536	chr9:5181610	T/C	cg02405213	chr9:5042618	JAK2	-0.52	-6.72	-0.38	1.11e-10	Pediatric autoimmune diseases;
CESC	cis	rs6570726	0.935	rs379164	chr6:145829093	A/T	cg23711669	chr6:146136114	FBXO30	0.8	12.02	0.59	7.3e-27	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs72781680	1.000	rs72796316	chr2:24132272	T/C	cg08917208	chr2:24149416	ATAD2B	0.93	8.42	0.46	2.35e-15	Lymphocyte counts;
CESC	cis	rs1005277	0.579	rs1780133	chr10:38499509	T/C	cg00409905	chr10:38381863	ZNF37A	-0.52	-7.04	-0.4	1.69e-11	Extrinsic epigenetic age acceleration;
CESC	cis	rs9457247	1.000	rs2149090	chr6:167372764	T/C	cg25258033	chr6:167368657	RNASET2	-0.41	-6.2	-0.36	2.17e-9	Crohn's disease;
CESC	cis	rs9611565	0.525	rs9611548	chr22:41704143	G/T	cg03806693	chr22:41940476	POLR3H	-0.84	-9.48	-0.5	1.53e-18	Vitiligo;
CESC	trans	rs801193	0.935	rs3800820	chr7:66147178	C/T	cg26939375	chr7:64535504	NA	-0.63	-8.5	-0.46	1.4e-15	Aortic root size;
CESC	cis	rs9640161	0.750	rs11764936	chr7:150025915	G/T	cg10018233	chr7:150070692	REPIN1	0.45	6.88	0.39	4.2e-11	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs28489187	0.643	rs1884139	chr1:85845998	G/T	cg16011679	chr1:85725395	C1orf52	0.49	5.8	0.34	1.84e-8	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	cis	rs73001065	0.818	rs10500212	chr19:19723215	C/T	cg03709012	chr19:19516395	GATAD2A	0.92	6.24	0.36	1.7e-9	LDL cholesterol;
CESC	cis	rs1707322	1.000	rs9429186	chr1:46539687	C/T	cg03146154	chr1:46216737	IPP	-0.7	-9.2	-0.49	1.08e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7666738	0.830	rs1405767	chr4:98965295	T/C	cg03467027	chr4:99064603	C4orf37	0.44	5.57	0.32	6.41e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs887829	0.569	rs3821242	chr2:234637803	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.54	-7.47	-0.42	1.2e-12	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CESC	cis	rs2204008	0.774	rs11514062	chr12:38332297	A/C	cg13010199	chr12:38710504	ALG10B	0.42	5.34	0.31	2.02e-7	Bladder cancer;
CESC	cis	rs116095464	0.510	rs10057501	chr5:239545	T/C	cg12570787	chr5:219185	SDHA;CCDC127	0.5	5.21	0.3	3.76e-7	Breast cancer;
CESC	cis	rs6991838	0.584	rs60023200	chr8:66486782	C/T	cg13398993	chr8:66546079	ARMC1	-0.46	-5.54	-0.32	7.22e-8	Intelligence (multi-trait analysis);
CESC	cis	rs6580649	1.000	rs10783227	chr12:48400617	C/T	cg05342945	chr12:48394962	COL2A1	-0.56	-6.78	-0.38	7.56e-11	Lung cancer;
CESC	cis	rs10479542	0.929	rs10078796	chr5:178978883	T/A	cg19626725	chr5:178986131	RUFY1	0.39	6.35	0.36	9.27e-10	Lung cancer;
CESC	cis	rs155076	1.000	rs261407	chr13:21855213	C/A	cg11317459	chr13:21872234	NA	-1.06	-11.89	-0.59	1.99e-26	White matter hyperintensity burden;
CESC	cis	rs6430585	0.702	rs1042712	chr2:136545844	C/G	cg07169764	chr2:136633963	MCM6	-1.19	-17.44	-0.73	7.09e-46	Corneal structure;
CESC	cis	rs2228479	0.850	rs17233448	chr16:89816424	G/T	cg14709524	chr16:89940631	TCF25	0.93	6.94	0.39	3.03e-11	Skin colour saturation;
CESC	cis	rs3741404	0.791	rs7102177	chr11:63909228	T/C	cg18225595	chr11:63971243	STIP1	0.74	10.31	0.53	3.67e-21	Platelet count;
CESC	trans	rs10517270	0.744	rs10028228	chr4:33212652	A/G	cg25767985	chr11:43965591	NA	0.62	6.12	0.35	3.28e-9	Alzheimer's disease (age of onset);
CESC	cis	rs4243830	0.850	rs12563717	chr1:6599557	T/G	cg22792644	chr1:6614718	TAS1R1;NOL9	0.84	7.28	0.41	3.87e-12	Body mass index;
CESC	cis	rs1018836	0.851	rs7014073	chr8:91618548	T/C	cg16814680	chr8:91681699	NA	-0.77	-11.99	-0.59	9.6e-27	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs113835537	0.529	rs11227503	chr11:66275242	G/C	cg22134325	chr11:66188745	NPAS4	0.36	5.66	0.33	3.82e-8	Airway imaging phenotypes;
CESC	cis	rs897984	0.571	rs7184567	chr16:31021078	C/T	cg02466173	chr16:30829666	NA	-0.4	-6.71	-0.38	1.16e-10	Dementia with Lewy bodies;
CESC	cis	rs7829975	0.511	rs1401390	chr8:8136410	C/T	cg15556689	chr8:8085844	FLJ10661	0.54	6.32	0.36	1.13e-9	Mood instability;
CESC	cis	rs1008375	0.868	rs6816286	chr4:17698088	A/G	cg02297831	chr4:17616191	MED28	0.44	5.35	0.31	1.92e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs8017423	0.935	rs11626869	chr14:90788985	A/G	cg14092571	chr14:90743983	NA	0.55	8.47	0.46	1.76e-15	Mortality in heart failure;
CESC	cis	rs616402	0.527	rs10779737	chr1:10580275	C/G	cg07384165	chr1:10488281	NA	-0.49	-7.21	-0.41	5.8e-12	Breast size;
CESC	cis	rs6582630	0.555	rs1906260	chr12:38601013	T/G	cg26384229	chr12:38710491	ALG10B	0.74	11.14	0.56	7.02e-24	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs801193	0.844	rs2244022	chr7:66202430	A/G	cg14393609	chr7:65229607	NA	0.43	6.03	0.35	5.38e-9	Aortic root size;
CESC	cis	rs10896135	0.526	rs1987169	chr11:66448044	A/G	cg24851651	chr11:66362959	CCS	-0.55	-7.27	-0.41	3.98e-12	Bipolar disorder;
CESC	cis	rs7666738	0.830	rs10010223	chr4:99021758	G/A	cg05340658	chr4:99064831	C4orf37	0.82	12.99	0.62	3.34e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4237845	0.537	rs10747786	chr12:58260601	G/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.48	5.37	0.31	1.7e-7	Intelligence (multi-trait analysis);
CESC	cis	rs62158211	0.565	rs57611236	chr2:114103804	A/T	cg17784749	chr2:114082611	LOC440839	0.51	6.34	0.36	1e-9	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;
CESC	cis	rs9584850	0.562	rs17471066	chr13:99164699	A/G	cg20750642	chr13:99100586	FARP1	-0.4	-5.55	-0.32	6.99e-8	Neuroticism;
CESC	cis	rs2108622	0.711	rs12609820	chr19:15978057	T/C	cg13772218	chr19:15982569	NA	0.29	5.69	0.33	3.28e-8	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24954670	chr3:50337092	HYAL3;NAT6	0.55	6.38	0.36	7.84e-10	Gut microbiome composition (summer);
CESC	cis	rs763121	0.853	rs5750672	chr22:39104168	C/T	cg14440974	chr22:39074834	NA	0.38	5.15	0.3	5.06e-7	Menopause (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23676784	chr1:22968681	C1QC	0.59	6.78	0.38	7.79e-11	Gut microbiome composition (summer);
CESC	cis	rs2979489	0.580	rs73245347	chr8:30448213	T/G	cg26383811	chr8:30366931	RBPMS	-0.66	-7.8	-0.43	1.4e-13	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CESC	cis	rs7219021	0.705	rs11079842	chr17:47002762	G/A	cg16584676	chr17:46985605	UBE2Z	-0.62	-7.22	-0.41	5.5e-12	Schizophrenia or bipolar disorder;
CESC	trans	rs7837860	0.588	rs16880580	chr8:89287763	A/G	cg04391754	chr17:18022714	MYO15A	0.52	6.12	0.35	3.35e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs9715521	0.775	rs67846233	chr4:59848576	G/A	cg11281224	chr4:60001000	NA	-0.5	-6.52	-0.37	3.51e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg25184507	chr17:7760147	CYB5D1;LSMD1	0.51	6.52	0.37	3.55e-10	Gut microbiota (bacterial taxa);
CESC	trans	rs116095464	0.558	rs10057626	chr5:239720	T/G	cg00938859	chr5:1591904	SDHAP3	0.64	6.99	0.39	2.27e-11	Breast cancer;
CESC	cis	rs10504229	0.953	rs75585481	chr8:58192202	T/C	cg24829409	chr8:58192753	C8orf71	-0.76	-9.93	-0.52	5.87e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs13631	0.965	rs9411307	chr9:139994947	C/T	cg14289826	chr9:140003911	NA	0.34	6.44	0.37	5.61e-10	Cerebrospinal fluid biomarker levels;
CESC	cis	rs12618769	0.652	rs1062847	chr2:99226173	T/A	cg10123293	chr2:99228465	UNC50	0.4	5.31	0.31	2.33e-7	Bipolar disorder;
CESC	cis	rs6831352	0.760	rs1311616	chr4:100012303	T/G	cg13256891	chr4:100009986	ADH5	0.74	7.97	0.44	4.75e-14	Alcohol dependence;
CESC	cis	rs7044106	0.791	rs2416798	chr9:123480603	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.77	11.39	0.57	1.01e-24	Hip circumference adjusted for BMI;
CESC	cis	rs6500395	0.962	rs9937134	chr16:48577683	T/A	cg04672837	chr16:48644449	N4BP1	0.45	5.43	0.32	1.3e-7	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs8067354	0.831	rs2333617	chr17:57896220	T/A	cg02344993	chr17:57696989	CLTC	-0.48	-6.15	-0.35	2.86e-9	Hemoglobin concentration;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg17484976	chr20:60982411	CABLES2	0.44	6.2	0.36	2.19e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs6430585	0.527	rs1900306	chr2:136416533	G/A	cg07169764	chr2:136633963	MCM6	1.14	12.87	0.62	9.12e-30	Corneal structure;
CESC	cis	rs4819052	0.851	rs7281263	chr21:46695606	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.75	10.02	0.52	2.97e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs748404	0.660	rs690446	chr15:43761264	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.57	7.5	0.42	9.94e-13	Lung cancer;
CESC	cis	rs2243480	0.908	rs55876148	chr7:65379800	G/A	cg18252515	chr7:66147081	NA	-1.18	-10.88	-0.56	5.02e-23	Diabetic kidney disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg20723414	chr7:157207071	DNAJB6	0.48	6.27	0.36	1.46e-9	Fibrinogen levels;
CESC	cis	rs4604732	0.536	rs78019731	chr1:247626430	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.57	7.17	0.4	7.39e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg08132940	chr7:1081526	C7orf50	-0.49	-5.04	-0.3	8.63e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs6598955	0.670	rs7520517	chr1:26556385	A/C	cg19743891	chr1:26644573	UBXN11;CD52	-0.27	-5.16	-0.3	4.86e-7	Obesity-related traits;
CESC	cis	rs7208859	0.623	rs12103440	chr17:29086657	A/G	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.91e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs6866344	0.697	rs11742808	chr5:178131658	G/A	cg10224037	chr5:178157518	ZNF354A	0.67	7.35	0.41	2.46e-12	Neutrophil percentage of white cells;
CESC	cis	rs9611565	0.512	rs5758436	chr22:42124265	C/T	cg03806693	chr22:41940476	POLR3H	1.14	13.61	0.64	2.45e-32	Vitiligo;
CESC	cis	rs11690935	0.788	rs6715929	chr2:172877507	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.62	-8.82	-0.48	1.55e-16	Schizophrenia;
CESC	cis	rs2806561	0.765	rs652783	chr1:23514313	G/T	cg12483005	chr1:23474871	LUZP1	0.38	6.0	0.35	6.44e-9	Height;
CESC	cis	rs6546550	0.743	rs6546548	chr2:70017022	A/G	cg02498382	chr2:70120550	SNRNP27	-0.29	-5.07	-0.3	7.61e-7	Prevalent atrial fibrillation;
CESC	cis	rs898097	0.841	rs4986136	chr17:80865119	A/G	cg15369054	chr17:80825471	TBCD	-0.51	-7.22	-0.41	5.36e-12	Breast cancer;
CESC	cis	rs7809950	0.731	rs2712196	chr7:107128797	G/T	cg23024343	chr7:107201750	COG5	-0.57	-7.42	-0.41	1.55e-12	Coronary artery disease;
CESC	cis	rs36715	0.904	rs36701	chr5:127552529	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.73	7.55	0.42	7.15e-13	Breast cancer;
CESC	cis	rs8180040	0.739	rs11719306	chr3:47184182	G/A	cg27129171	chr3:47204927	SETD2	0.7	10.87	0.56	5.19e-23	Colorectal cancer;
CESC	cis	rs2842992	0.830	rs2495279	chr6:160138796	C/T	cg11366901	chr6:160182831	ACAT2	0.84	11.06	0.56	1.28e-23	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs9430161	0.564	rs12081176	chr1:11034145	T/C	cg27631724	chr1:11040367	C1orf127	0.38	6.21	0.36	2.02e-9	Ewing sarcoma;
CESC	cis	rs453301	0.571	rs2929452	chr8:9084465	G/A	cg15556689	chr8:8085844	FLJ10661	-0.51	-6.39	-0.37	7.51e-10	Joint mobility (Beighton score);
CESC	cis	rs6460942	0.597	rs62449509	chr7:12515013	C/T	cg20607287	chr7:12443886	VWDE	-0.7	-7.61	-0.42	4.88e-13	Coronary artery disease;
CESC	cis	rs1670533	0.746	rs688008	chr4:1082829	T/C	cg27284194	chr4:1044797	NA	0.48	6.07	0.35	4.52e-9	Recombination rate (females);
CESC	cis	rs9768139	0.733	rs56205111	chr7:158121055	T/C	cg06219351	chr7:158114137	PTPRN2	-0.5	-7.84	-0.43	1.1e-13	Calcium levels;
CESC	cis	rs9311474	0.629	rs13081028	chr3:52555316	G/A	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.34	6.47	0.37	4.7e-10	Electroencephalogram traits;
CESC	cis	rs651907	0.535	rs11712309	chr3:101519097	T/C	cg12386194	chr3:101231763	SENP7	0.41	5.11	0.3	6.03e-7	Colorectal cancer;
CESC	cis	rs57221529	0.766	rs12521988	chr5:556421	C/T	cg09021430	chr5:549028	NA	-0.42	-5.26	-0.31	2.92e-7	Lung disease severity in cystic fibrosis;
CESC	cis	rs16854884	0.657	rs10513235	chr3:143698664	T/C	cg06585982	chr3:143692056	C3orf58	0.45	5.62	0.33	4.88e-8	Economic and political preferences (feminism/equality);
CESC	cis	rs2070997	0.607	rs10901284	chr9:133668799	T/C	cg11464064	chr9:133710261	ABL1	0.55	6.28	0.36	1.38e-9	Response to amphetamines;
CESC	cis	rs6952808	0.608	rs6461049	chr7:2017445	C/T	cg21782813	chr7:2030301	MAD1L1	-0.39	-5.48	-0.32	9.92e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs7552404	0.727	rs5745433	chr1:76333163	T/G	cg22875332	chr1:76189707	ACADM	0.64	6.42	0.37	6.23e-10	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs11150038	0.826	rs7203483	chr16:78085836	C/T	cg04733911	chr16:78082701	NA	0.42	5.24	0.31	3.21e-7	Colorectal or endometrial cancer;
CESC	cis	rs1799949	1.000	rs8176145	chr17:41249094	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.67	9.44	0.5	1.97e-18	Menopause (age at onset);
CESC	cis	rs2880765	0.835	rs4536419	chr15:86039471	C/T	cg19183879	chr15:85880815	NA	-0.26	-5.36	-0.31	1.78e-7	Coronary artery disease;
CESC	cis	rs3091242	0.933	rs61775167	chr1:25780893	A/G	cg02931644	chr1:25747376	RHCE	-0.4	-6.7	-0.38	1.27e-10	Erythrocyte sedimentation rate;
CESC	cis	rs863345	0.604	rs11265015	chr1:158503252	G/A	cg12129480	chr1:158549410	OR10X1	-0.35	-6.89	-0.39	4.12e-11	Pneumococcal bacteremia;
CESC	cis	rs55882075	0.634	rs12518476	chr5:179110850	A/G	cg14593053	chr5:179126677	CANX	0.52	6.68	0.38	1.38e-10	Monocyte percentage of white cells;
CESC	cis	rs4919044	0.808	rs2486687	chr10:94778283	T/C	cg00487187	chr10:94451625	HHEX	-0.45	-5.05	-0.3	8.21e-7	Coronary artery disease;
CESC	cis	rs561341	1.000	rs537166	chr17:30326827	C/T	cg19193384	chr17:30244184	NA	-0.61	-6.39	-0.37	7.37e-10	Hip circumference adjusted for BMI;
CESC	cis	rs965469	0.779	rs6051830	chr20:3373397	T/C	cg25506879	chr20:3388711	C20orf194	-0.49	-5.28	-0.31	2.63e-7	IFN-related cytopenia;
CESC	cis	rs1707322	0.656	rs3014210	chr1:46066608	A/G	cg05343316	chr1:45956843	TESK2	-0.54	-6.69	-0.38	1.32e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg06434972	chr7:44122219	POLM	-0.45	-6.56	-0.37	2.78e-10	Gambling;
CESC	trans	rs2727020	0.576	rs12293522	chr11:49558425	T/A	cg03929089	chr4:120376271	NA	-0.85	-13.62	-0.64	2.22e-32	Coronary artery disease;
CESC	cis	rs593982	0.920	rs563427	chr11:65484569	A/G	cg08755490	chr11:65554678	OVOL1	1.17	10.68	0.55	2.27e-22	Atopic dermatitis;
CESC	cis	rs9929218	0.954	rs4420522	chr16:68822971	A/G	cg02972257	chr16:68554789	NA	0.45	5.39	0.31	1.58e-7	Colorectal cancer;
CESC	cis	rs72627509	0.904	rs781663	chr4:57781754	A/G	cg26694713	chr4:57773883	REST	0.57	5.56	0.32	6.47e-8	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CESC	cis	rs9916302	0.851	rs12936646	chr17:37647450	A/T	cg00129232	chr17:37814104	STARD3	-0.57	-7.72	-0.43	2.35e-13	Glomerular filtration rate (creatinine);
CESC	cis	rs7662987	0.517	rs2851286	chr4:100014976	A/G	cg13256891	chr4:100009986	ADH5	-0.82	-8.61	-0.47	6.51e-16	Smoking initiation;
CESC	cis	rs7772486	0.686	rs857877	chr6:145976230	A/C	cg23711669	chr6:146136114	FBXO30	-0.98	-15.19	-0.68	6.34e-38	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs863345	0.564	rs12145401	chr1:158494693	A/G	cg12129480	chr1:158549410	OR10X1	-0.34	-7.02	-0.4	1.84e-11	Pneumococcal bacteremia;
CESC	cis	rs7568458	0.684	rs3731828	chr2:85806266	C/T	cg02493740	chr2:85810744	VAMP5	-0.56	-8.31	-0.45	4.99e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CESC	cis	rs5753618	0.583	rs5753612	chr22:31821479	T/C	cg00478049	chr22:31556069	RNF185	-0.43	-5.11	-0.3	6.22e-7	Colorectal cancer;
CESC	cis	rs13256369	0.851	rs13271698	chr8:8567539	C/A	cg18904891	chr8:8559673	CLDN23	0.67	7.49	0.42	1.01e-12	Obesity-related traits;
CESC	cis	rs801193	1.000	rs2707856	chr7:66211010	A/T	cg06456125	chr7:65229604	NA	0.41	5.37	0.31	1.76e-7	Aortic root size;
CESC	cis	rs7312933	0.558	rs11181501	chr12:42822671	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.5	6.45	0.37	5.25e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs6951245	0.706	rs28522260	chr7:1183964	C/A	cg04025307	chr7:1156635	C7orf50	0.42	5.28	0.31	2.76e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7809799	1.000	rs6465739	chr7:98764248	A/C	cg05967295	chr7:98741636	SMURF1	-0.75	-5.29	-0.31	2.56e-7	Ulcerative colitis;
CESC	cis	rs12188164	0.965	rs11739543	chr5:443676	G/A	cg21144161	chr5:423903	AHRR	0.37	5.98	0.34	7.12e-9	Cystic fibrosis severity;
CESC	cis	rs11249608	0.548	rs17078988	chr5:178459283	A/G	cg21905437	chr5:178450457	ZNF879	0.58	8.06	0.44	2.69e-14	Pubertal anthropometrics;
CESC	cis	rs8177179	0.967	rs4287912	chr3:133437778	A/G	cg17775713	chr3:133465469	TF	0.31	5.59	0.32	5.77e-8	Iron status biomarkers (transferrin levels);
CESC	cis	rs9467711	0.606	rs71557334	chr6:26365913	G/T	cg12826209	chr6:26865740	GUSBL1	0.61	5.17	0.3	4.59e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs4819052	0.851	rs35560973	chr21:46662573	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.87	12.74	0.62	2.53e-29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs870825	0.616	rs28666955	chr4:185631338	A/G	cg04058563	chr4:185651563	MLF1IP	0.64	7.0	0.4	2.05e-11	Blood protein levels;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg16063617	chr5:128430663	ISOC1	-0.52	-6.96	-0.39	2.62e-11	Fibrinogen levels;
CESC	trans	rs10518765	0.786	rs17818441	chr15:54638829	A/G	cg09098624	chr8:11558334	NA	0.56	6.05	0.35	4.98e-9	Select biomarker traits;
CESC	cis	rs4674676	1	rs4674676	chr2:223529112	A/G	cg25565276	chr2:223520875	FARSB	1.06	14.94	0.68	4.85e-37	Chin dimples;
CESC	cis	rs7727544	0.684	rs270602	chr5:131656700	T/C	cg24060327	chr5:131705240	SLC22A5	-0.62	-8.03	-0.44	3.17e-14	Blood metabolite levels;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg01623343	chr16:354374	AXIN1	0.49	6.84	0.39	5.42e-11	Fibrinogen levels;
CESC	cis	rs4979906	1.000	rs4979786	chr10:79444965	T/C	cg00983440	chr10:79422392	NA	-0.48	-5.12	-0.3	5.83e-7	Mortality in heart failure;
CESC	cis	rs9787249	0.957	rs6670841	chr1:40220284	C/G	cg02773041	chr1:40204384	PPIE	0.51	7.24	0.41	4.72e-12	Blood protein levels;
CESC	cis	rs9322193	0.962	rs17673294	chr6:150134993	G/A	cg13206674	chr6:150067644	NUP43	0.43	5.94	0.34	8.74e-9	Lung cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14831746	chr12:49961631	MCRS1	-0.57	-6.66	-0.38	1.61e-10	Gut microbiome composition (summer);
CESC	cis	rs4665809	0.887	rs4665814	chr2:26273687	G/T	cg25036284	chr2:26402008	FAM59B	-0.58	-6.57	-0.37	2.69e-10	Gut microbiome composition (summer);
CESC	cis	rs2576037	0.526	rs607780	chr18:44417456	C/T	cg19077165	chr18:44547161	KATNAL2	-0.53	-7.82	-0.43	1.22e-13	Personality dimensions;
CESC	cis	rs72634258	0.838	rs10489450	chr1:8079301	C/T	cg00042356	chr1:8021962	PARK7	0.82	7.53	0.42	7.8e-13	Inflammatory bowel disease;
CESC	cis	rs9486719	0.895	rs12190520	chr6:96928620	A/C	cg18709589	chr6:96969512	KIAA0776	-0.54	-5.97	-0.34	7.42e-9	Migraine;Coronary artery disease;
CESC	cis	rs4780401	0.728	rs8191335	chr16:11771353	C/A	cg01061890	chr16:11836724	TXNDC11	-0.49	-6.63	-0.38	1.88e-10	Rheumatoid arthritis;
CESC	trans	rs7726839	0.526	rs11960158	chr5:568665	C/T	cg25482853	chr8:67687455	SGK3	0.97	10.85	0.55	6.23e-23	Obesity-related traits;
CESC	cis	rs2286503	0.901	rs2286505	chr7:22854840	G/A	cg13679077	chr7:22862647	TOMM7	0.41	5.21	0.3	3.75e-7	Fibrinogen;
CESC	trans	rs5769765	0.773	rs9616206	chr22:50310847	G/T	cg09872104	chr7:134855509	C7orf49	-0.57	-6.47	-0.37	4.78e-10	Schizophrenia;
CESC	cis	rs733175	0.951	rs6826764	chr4:10030794	C/G	cg00071950	chr4:10020882	SLC2A9	-0.47	-5.38	-0.31	1.6e-7	Psychosis and Alzheimer's disease;
CESC	cis	rs6460942	0.915	rs10488158	chr7:12508894	C/T	cg20607287	chr7:12443886	VWDE	-0.76	-8.53	-0.46	1.16e-15	Coronary artery disease;
CESC	cis	rs9438901	0.592	rs1293259	chr1:25695835	G/A	cg12421513	chr1:25599066	RHD	-0.43	-5.16	-0.3	4.94e-7	Red cell distribution width;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02846228	chr16:31102495	VKORC1	-0.54	-6.38	-0.36	8.05e-10	Gut microbiome composition (summer);
CESC	cis	rs3820068	0.603	rs10492986	chr1:15988702	T/C	cg16988262	chr1:15930761	NA	0.35	5.67	0.33	3.64e-8	Systolic blood pressure;
CESC	cis	rs10882165	0.547	rs4918904	chr10:94961320	A/T	cg00992348	chr10:94926053	NA	0.31	5.48	0.32	9.91e-8	Refractive error;
CESC	cis	rs4253772	0.591	rs113101219	chr22:46659186	C/A	cg00784671	chr22:46762841	CELSR1	-0.51	-5.48	-0.32	9.94e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs514406	0.861	rs1749907	chr1:53259658	C/T	cg24675658	chr1:53192096	ZYG11B	0.53	6.69	0.38	1.29e-10	Monocyte count;
CESC	cis	rs11853189	0.873	rs117636273	chr15:78556895	G/A	cg22935921	chr15:78556834	DNAJA4	0.61	5.1	0.3	6.35e-7	Red cell distribution width;
CESC	cis	rs3785574	0.962	rs8079161	chr17:61808561	C/G	cg06873352	chr17:61820015	STRADA	0.47	6.92	0.39	3.31e-11	Height;
CESC	cis	rs921968	0.565	rs3731876	chr2:219602819	G/A	cg02176678	chr2:219576539	TTLL4	-0.45	-7.81	-0.43	1.36e-13	Mean corpuscular hemoglobin concentration;
CESC	cis	rs2346177	0.542	rs13020043	chr2:46698431	A/T	cg02822958	chr2:46747628	ATP6V1E2	0.45	5.59	0.32	5.67e-8	HDL cholesterol;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg06995880	chr1:61516444	NA	-0.44	-6.28	-0.36	1.4e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs710216	0.843	rs710220	chr1:43415346	G/T	cg03128534	chr1:43423976	SLC2A1	0.59	7.25	0.41	4.55e-12	Red cell distribution width;
CESC	cis	rs62158211	1.000	rs62158211	chr2:114106139	G/T	cg17784749	chr2:114082611	LOC440839	0.72	7.71	0.43	2.57e-13	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;
CESC	cis	rs55794721	0.509	rs11249248	chr1:25753051	T/C	cg03538708	chr1:25844672	NA	-0.41	-6.29	-0.36	1.29e-9	Plateletcrit;Mean corpuscular volume;
CESC	cis	rs12824058	0.831	rs7310433	chr12:130809289	C/T	cg23887609	chr12:130822674	PIWIL1	0.45	5.82	0.34	1.69e-8	Menopause (age at onset);
CESC	cis	rs4588572	0.581	rs4235706	chr5:77644512	G/A	cg11547950	chr5:77652471	NA	0.45	6.03	0.35	5.49e-9	Triglycerides;
CESC	cis	rs6487679	0.526	rs7305336	chr12:9375089	C/A	cg08997352	chr12:9597637	DDX12	-0.51	-5.62	-0.33	4.77e-8	Non-alcoholic fatty liver disease histology (AST);
CESC	cis	rs2832077	0.527	rs2250141	chr21:30241984	A/T	cg03476357	chr21:30257390	N6AMT1	0.46	5.79	0.34	1.94e-8	Cognitive test performance;
CESC	cis	rs9487051	0.676	rs1608041	chr6:109595903	G/A	cg21918786	chr6:109611834	NA	-0.38	-5.52	-0.32	8.19e-8	Reticulocyte fraction of red cells;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg10500953	chr16:346518	AXIN1	0.46	6.37	0.36	8.29e-10	Fibrinogen levels;
CESC	trans	rs802075	0.905	rs2396917	chr6:49635987	G/A	cg06254729	chr2:28550422	BRE	-0.36	-6.13	-0.35	3.15e-9	Bone mineral density (hip) and age at menarche;
CESC	cis	rs7786877	0.626	rs11770389	chr7:100221218	T/G	cg27028030	chr7:100209634	MOSPD3	0.59	5.65	0.33	4.13e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs2929278	0.736	rs2412823	chr15:44227270	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.39	-5.07	-0.3	7.58e-7	Schizophrenia;
CESC	cis	rs3733585	0.673	rs6849729	chr4:9958732	T/C	cg11266682	chr4:10021025	SLC2A9	-0.6	-11.2	-0.57	4.42e-24	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs7116495	1.000	rs560777	chr11:71770602	C/T	cg10381502	chr11:71823885	C11orf51	0.67	5.73	0.33	2.79e-8	Severe influenza A (H1N1) infection;
CESC	cis	rs8018808	0.935	rs11159261	chr14:77921120	A/G	cg20045696	chr14:77926864	AHSA1	0.47	6.59	0.38	2.35e-10	Myeloid white cell count;
CESC	cis	rs1538970	0.781	rs10890330	chr1:45920406	G/A	cg06784218	chr1:46089804	CCDC17	0.35	5.52	0.32	8.19e-8	Platelet count;
CESC	cis	rs13191362	1.000	rs34714518	chr6:163080778	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.62	6.4	0.37	7.19e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs28374715	0.532	rs3204853	chr15:41689166	C/A	cg18705301	chr15:41695430	NDUFAF1	-1.07	-17.69	-0.74	8.95e-47	Ulcerative colitis;
CESC	cis	rs2249625	0.508	rs114505309	chr6:72892383	G/A	cg18830697	chr6:72922368	RIMS1	0.42	5.99	0.35	6.73e-9	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CESC	cis	rs4835473	0.932	rs1450236	chr4:144704222	G/A	cg25736465	chr4:144833511	NA	-0.33	-5.36	-0.31	1.81e-7	Immature fraction of reticulocytes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19769989	chr1:43353266	NA	-0.52	-6.03	-0.35	5.34e-9	Gut microbiome composition (summer);
CESC	trans	rs7819412	0.740	rs11250119	chr8:11037034	C/T	cg06636001	chr8:8085503	FLJ10661	-0.6	-8.14	-0.45	1.53e-14	Triglycerides;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg00187635	chr16:83986795	OSGIN1	0.39	6.04	0.35	5.13e-9	Gambling;
CESC	cis	rs7824557	0.564	rs2572379	chr8:11237480	A/G	cg21775007	chr8:11205619	TDH	-0.54	-7.98	-0.44	4.52e-14	Retinal vascular caliber;
CESC	cis	rs801193	0.569	rs13226966	chr7:66233623	A/G	cg11764359	chr7:65958608	NA	0.7	9.9	0.52	7.02e-20	Aortic root size;
CESC	cis	rs1843834	0.574	rs6436499	chr2:225456551	A/T	cg12698349	chr2:225449008	CUL3	0.55	7.89	0.44	7.83e-14	IgE levels in asthmatics (D.p. specific);
CESC	cis	rs12477438	0.798	rs7570657	chr2:99654281	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.6	-8.45	-0.46	2.02e-15	Chronic sinus infection;
CESC	cis	rs7267979	0.966	rs2257233	chr20:25265984	A/C	cg08601574	chr20:25228251	PYGB	-0.39	-5.59	-0.33	5.51e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs3105593	1.000	rs7167138	chr15:50958998	C/G	cg08437265	chr15:50716283	USP8	0.46	6.07	0.35	4.49e-9	QT interval;
CESC	cis	rs804280	0.525	rs1004712	chr8:11622293	C/T	cg12395012	chr8:11607386	GATA4	-0.37	-5.48	-0.32	9.78e-8	Myopia (pathological);
CESC	cis	rs26868	0.690	rs26835	chr16:2237549	C/T	cg07587117	chr16:2239488	CASKIN1	0.51	9.28	0.5	6.12e-18	Height;
CESC	cis	rs7618501	0.602	rs2301166	chr3:50148305	C/G	cg24110177	chr3:50126178	RBM5	0.53	7.25	0.41	4.51e-12	Intelligence (multi-trait analysis);
CESC	cis	rs6120849	0.754	rs3746446	chr20:33574765	T/C	cg24642439	chr20:33292090	TP53INP2	0.68	6.74	0.38	9.91e-11	Protein C levels;
CESC	cis	rs3733585	0.699	rs6834893	chr4:9959123	C/T	cg02734326	chr4:10020555	SLC2A9	-0.43	-6.01	-0.35	6.1e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg03865041	chr16:71842666	AP1G1	-0.47	-6.5	-0.37	4.05e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs16858210	0.874	rs1879256	chr3:183609061	A/G	cg25686905	chr3:183603175	PARL	-0.33	-5.99	-0.35	6.69e-9	Menopause (age at onset);
CESC	cis	rs6963495	0.818	rs73190161	chr7:105156871	C/T	cg13798780	chr7:105162888	PUS7	0.78	8.04	0.44	2.99e-14	Bipolar disorder (body mass index interaction);
CESC	cis	rs12995491	0.902	rs6737641	chr2:88529471	A/T	cg07952391	chr2:88470173	THNSL2	-0.55	-8.33	-0.46	4.44e-15	Response to metformin (IC50);
CESC	trans	rs561341	0.714	rs55925849	chr17:30253085	C/T	cg20587970	chr11:113659929	NA	-1.43	-17.6	-0.73	1.89e-46	Hip circumference adjusted for BMI;
CESC	cis	rs265548	0.608	rs36690	chr19:17910483	C/T	cg04517722	chr19:17905589	B3GNT3	0.43	5.61	0.33	5.12e-8	Tumor biomarkers;
CESC	cis	rs61931739	0.782	rs451940	chr12:34196005	T/C	cg19457237	chr12:34500585	NA	-0.38	-5.37	-0.31	1.69e-7	Morning vs. evening chronotype;
CESC	cis	rs918629	0.798	rs7705279	chr5:95324375	C/T	cg16656078	chr5:95278638	ELL2	-0.38	-5.52	-0.32	8.22e-8	IgG glycosylation;
CESC	cis	rs6690583	0.623	rs898036	chr1:85521904	A/T	cg11262906	chr1:85462892	MCOLN2	0.54	5.06	0.3	7.79e-7	Serum sulfate level;
CESC	cis	rs854765	0.647	rs6502637	chr17:17986098	A/G	cg16928487	chr17:17741425	SREBF1	-0.53	-8.64	-0.47	5.33e-16	Total body bone mineral density;
CESC	cis	rs6032067	0.852	rs2233882	chr20:43835683	T/A	cg11264863	chr20:43835661	SEMG1	0.48	5.26	0.31	2.99e-7	Blood protein levels;
CESC	cis	rs67478160	0.643	rs4900594	chr14:104251006	C/T	cg08213375	chr14:104286397	PPP1R13B	0.55	10.97	0.56	2.52e-23	Schizophrenia;
CESC	cis	rs7949030	0.523	rs12223627	chr11:62368557	G/C	cg11742103	chr11:62369870	EML3;MTA2	0.56	8.11	0.45	1.94e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs875971	1.000	rs11974219	chr7:65647410	C/T	cg18876405	chr7:65276391	NA	-0.53	-7.18	-0.4	7e-12	Aortic root size;
CESC	cis	rs6089584	0.888	rs6061979	chr20:60617141	C/G	cg13770153	chr20:60521292	NA	-0.44	-5.7	-0.33	3.2e-8	Body mass index;
CESC	cis	rs12540874	0.522	rs4947641	chr7:50489038	C/T	cg18232548	chr7:50535776	DDC	-0.46	-6.67	-0.38	1.49e-10	Systemic sclerosis;
CESC	cis	rs8064299	0.967	rs878905	chr17:72769411	G/A	cg25054828	chr17:72772726	NAT9;TMEM104	0.63	8.98	0.48	5.27e-17	Monocyte count;
CESC	cis	rs7811142	1.000	rs4472444	chr7:100070758	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.95	10.25	0.53	5.58e-21	Platelet count;
CESC	cis	rs896854	0.812	rs2340586	chr8:95969261	G/A	cg26343298	chr8:95960752	TP53INP1	0.37	6.22	0.36	1.96e-9	Type 2 diabetes;
CESC	cis	rs1059312	0.808	rs10847693	chr12:129292006	G/A	cg09035930	chr12:129282057	SLC15A4	0.69	9.2	0.49	1.1e-17	Systemic lupus erythematosus;
CESC	cis	rs7927771	0.524	rs7932703	chr11:47769936	A/C	cg18512352	chr11:47633146	NA	0.34	5.24	0.31	3.22e-7	Subjective well-being;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21394442	chr8:110346440	ENY2;NUDCD1	-0.59	-6.97	-0.39	2.49e-11	Gut microbiome composition (summer);
CESC	cis	rs1003719	0.667	rs73201942	chr21:38475164	G/C	cg10648535	chr21:38446584	PIGP;TTC3	0.53	6.62	0.38	1.99e-10	Eye color traits;
CESC	cis	rs3741404	0.825	rs7111753	chr11:63942189	A/G	cg04317338	chr11:64019027	PLCB3	0.49	5.9	0.34	1.11e-8	Platelet count;
CESC	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.71	0.38	1.2e-10	Prudent dietary pattern;
CESC	cis	rs9649213	0.593	rs2107716	chr7:97944744	G/A	cg00277769	chr7:97922759	BAIAP2L1	-0.35	-5.71	-0.33	2.98e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs9322193	0.962	rs1413655	chr6:150142951	A/G	cg04369109	chr6:150039330	LATS1	-0.43	-5.89	-0.34	1.19e-8	Lung cancer;
CESC	cis	rs36051895	0.695	rs7851556	chr9:5022807	C/T	cg02405213	chr9:5042618	JAK2	-0.46	-5.52	-0.32	7.88e-8	Pediatric autoimmune diseases;
CESC	cis	rs7666738	1.000	rs7666738	chr4:98968077	C/T	cg18180107	chr4:99064573	C4orf37	0.4	5.09	0.3	6.84e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs8060686	0.516	rs9939821	chr16:68167787	T/A	cg26727032	chr16:67993705	SLC12A4	-0.55	-7.65	-0.43	3.84e-13	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs2191566	0.576	rs381759	chr19:44495145	A/G	cg20607764	chr19:44506953	ZNF230	-0.43	-5.36	-0.31	1.78e-7	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs7618915	0.547	rs62253700	chr3:52625019	T/A	cg18404041	chr3:52824283	ITIH1	-0.39	-6.55	-0.37	2.96e-10	Bipolar disorder;
CESC	cis	rs55794721	0.509	rs12027135	chr1:25775733	A/T	cg03538708	chr1:25844672	NA	-0.4	-5.96	-0.34	7.96e-9	Plateletcrit;Mean corpuscular volume;
CESC	cis	rs8071756	1.000	rs11078563	chr17:1576369	A/G	ch.17.72133F	chr17:1577994	PRPF8	-0.49	-5.15	-0.3	5.09e-7	Blood protein levels;
CESC	cis	rs425277	0.917	rs262656	chr1:2088754	A/C	cg16545954	chr1:2118288	C1orf86	0.33	5.47	0.32	1.02e-7	Height;
CESC	cis	rs67478160	0.619	rs10083367	chr14:104314183	C/G	cg08213375	chr14:104286397	PPP1R13B	-0.54	-10.67	-0.55	2.33e-22	Schizophrenia;
CESC	cis	rs2842992	0.724	rs9365097	chr6:160211259	G/A	cg26839252	chr6:160211577	TCP1;MRPL18	0.47	5.86	0.34	1.38e-8	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs752010	0.714	rs2182606	chr1:42082375	T/C	cg12614395	chr1:42085415	HIVEP3	0.3	5.26	0.31	3.01e-7	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs3820068	0.677	rs72643691	chr1:15856251	T/C	cg17385448	chr1:15911702	AGMAT	0.36	5.75	0.33	2.43e-8	Systolic blood pressure;
CESC	cis	rs3740540	0.530	rs2362507	chr10:126290820	A/G	cg04949429	chr10:126290192	LHPP	0.4	5.61	0.33	5.19e-8	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
CESC	cis	rs17376456	0.757	rs1031424	chr5:93139706	G/C	cg25358565	chr5:93447407	FAM172A	1.11	10.66	0.55	2.6e-22	Diabetic retinopathy;
CESC	cis	rs4253772	0.591	rs6008546	chr22:46686377	T/G	cg18190219	chr22:46762943	CELSR1	-0.46	-5.16	-0.3	4.87e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs10465746	0.682	rs882897	chr1:84426049	A/T	cg10977910	chr1:84465055	TTLL7	0.51	6.99	0.39	2.23e-11	Obesity-related traits;
CESC	cis	rs2070488	0.965	rs13097628	chr3:38521156	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.92	16.74	0.72	2.01e-43	Electrocardiographic conduction measures;
CESC	cis	rs17095355	1.000	rs4565840	chr10:111717140	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.44	-5.28	-0.31	2.72e-7	Biliary atresia;
CESC	cis	rs9910055	0.762	rs184478	chr17:42209751	C/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.59	-7.65	-0.43	3.69e-13	Total body bone mineral density;
CESC	cis	rs7666738	0.887	rs34509663	chr4:98982531	C/T	cg03676636	chr4:99064102	C4orf37	0.36	5.36	0.31	1.78e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7267979	1.000	rs4815418	chr20:25382211	T/G	cg08601574	chr20:25228251	PYGB	-0.38	-5.55	-0.32	6.85e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs2074977	0.550	rs11085020	chr19:3446107	C/T	cg08380311	chr19:3435252	NFIC	-0.45	-5.96	-0.34	7.81e-9	Height;
CESC	cis	rs6951245	0.882	rs10256720	chr7:1210825	C/G	cg24642844	chr7:1081250	C7orf50	-0.67	-8.0	-0.44	3.82e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg08130813	chr19:46195655	QPCTL;SNRPD2	-0.42	-6.02	-0.35	5.85e-9	Fibrinogen levels;
CESC	cis	rs875971	0.619	rs2302918	chr7:66000932	A/G	cg11764359	chr7:65958608	NA	0.7	9.18	0.49	1.3e-17	Aortic root size;
CESC	cis	rs35110281	0.811	rs2838337	chr21:45072621	A/C	cg21573476	chr21:45109991	RRP1B	-0.5	-7.01	-0.4	1.95e-11	Mean corpuscular volume;
CESC	cis	rs6088580	0.634	rs1205338	chr20:32925625	C/G	cg24642439	chr20:33292090	TP53INP2	-0.52	-6.79	-0.38	7.53e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs72945132	0.619	rs61887436	chr11:70243337	C/T	cg14191688	chr11:70257035	CTTN	0.5	5.69	0.33	3.39e-8	Coronary artery disease;
CESC	cis	rs644148	0.704	rs2686761	chr19:44989752	T/C	cg15540054	chr19:45004280	ZNF180	-0.58	-6.26	-0.36	1.54e-9	Personality dimensions;
CESC	trans	rs17685	0.796	rs3757594	chr7:75678644	G/A	cg19862616	chr7:65841803	NCRNA00174	-0.82	-11.78	-0.59	5.04e-26	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs4975709	0.959	rs9312959	chr5:1877008	G/A	cg12288994	chr5:1860383	NA	0.37	6.14	0.35	3.01e-9	Cardiovascular disease risk factors;
CESC	cis	rs12134245	0.776	rs12137878	chr1:91973210	G/T	cg02896835	chr1:92012615	NA	-0.51	-6.62	-0.38	1.95e-10	Breast cancer;
CESC	cis	rs15676	0.783	rs7044955	chr9:131567152	C/T	cg00228799	chr9:131580591	ENDOG	-0.49	-6.09	-0.35	3.93e-9	Blood metabolite levels;
CESC	cis	rs9399137	0.507	rs4594969	chr6:135285586	A/T	cg22676075	chr6:135203613	NA	0.53	6.87	0.39	4.46e-11	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	cis	rs11997175	0.935	rs6990082	chr8:33708034	C/A	ch.8.33884649F	chr8:33765107	NA	0.62	7.94	0.44	5.75e-14	Body mass index;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03917423	chr1:156339011	RHBG	0.6	6.75	0.38	9.51e-11	Gut microbiome composition (summer);
CESC	cis	rs7613875	0.600	rs2624832	chr3:50030858	C/T	cg24308560	chr3:49941425	MST1R	-0.58	-8.09	-0.44	2.23e-14	Body mass index;
CESC	cis	rs12681288	0.823	rs2701907	chr8:1003292	A/G	cg04851639	chr8:1020857	NA	-0.29	-6.26	-0.36	1.57e-9	Schizophrenia;
CESC	cis	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg21782813	chr7:2030301	MAD1L1	0.44	6.13	0.35	3.23e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs2070997	0.667	rs2260323	chr9:133700786	C/T	cg11464064	chr9:133710261	ABL1	-0.65	-7.37	-0.41	2.2e-12	Response to amphetamines;
CESC	trans	rs7943203	1.000	rs10890839	chr11:108306236	C/A	cg24643211	chr18:11851603	GNAL;CHMP1B	-0.48	-6.14	-0.35	3.07e-9	Red blood cell count;Mean corpuscular volume;
CESC	cis	rs1801251	0.963	rs7562712	chr2:233606580	A/G	cg08000102	chr2:233561755	GIGYF2	0.66	9.34	0.5	4.05e-18	Coronary artery disease;
CESC	cis	rs1538970	0.962	rs9429160	chr1:45827968	G/T	cg05343316	chr1:45956843	TESK2	0.83	11.22	0.57	3.55e-24	Platelet count;
CESC	cis	rs7481584	0.961	rs12797969	chr11:3019216	C/T	cg25174290	chr11:3078921	CARS	-0.44	-5.4	-0.32	1.46e-7	Calcium levels;
CESC	cis	rs1642645	0.872	rs238675	chr1:42470274	C/T	cg16685388	chr1:42384056	HIVEP3	0.37	5.04	0.3	8.55e-7	Left ventricular obstructive tract defect (maternal effect);
CESC	cis	rs4595586	0.566	rs7135104	chr12:39411086	C/T	cg26384229	chr12:38710491	ALG10B	0.42	6.03	0.35	5.43e-9	Morning vs. evening chronotype;
CESC	cis	rs9937943	0.667	rs12919002	chr16:74612377	A/G	cg01733217	chr16:74700730	RFWD3	0.62	5.53	0.32	7.68e-8	Neutrophil percentage of white cells;
CESC	cis	rs8062405	0.688	rs3924376	chr16:28925978	T/C	cg05966235	chr16:28915196	ATP2A1	-0.4	-5.77	-0.33	2.23e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	trans	rs9914544	0.602	rs4924929	chr17:18714241	G/A	cg04702396	chr17:15466718	FAM18B2	0.52	6.42	0.37	6.21e-10	Educational attainment (years of education);
CESC	cis	rs589448	0.902	rs2603090	chr12:69777188	G/A	cg14784868	chr12:69753453	YEATS4	0.87	13.54	0.64	4.34e-32	Cerebrospinal fluid biomarker levels;
CESC	cis	rs6502050	0.805	rs9898326	chr17:80119582	C/T	cg11859384	chr17:80120422	CCDC57	-0.39	-5.34	-0.31	1.96e-7	Life satisfaction;
CESC	cis	rs9435341	0.965	rs2335077	chr1:107573565	A/G	cg09367891	chr1:107599246	PRMT6	0.61	7.32	0.41	3.01e-12	Facial morphology (factor 21, depth of nasal alae);
CESC	cis	rs2191566	0.960	rs11083733	chr19:44520919	G/C	cg20607764	chr19:44506953	ZNF230	-0.58	-7.58	-0.42	5.8e-13	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs4901869	0.966	rs425764	chr14:59334997	A/G	cg02291164	chr14:59296302	NA	0.44	7.5	0.42	9.74e-13	Panic disorder;
CESC	cis	rs9309473	0.579	rs6728128	chr2:73595982	T/C	cg20560298	chr2:73613845	ALMS1	-0.49	-6.79	-0.39	7.27e-11	Metabolite levels;
CESC	cis	rs2228479	0.850	rs17232630	chr16:89851179	C/T	cg04013166	chr16:89971882	TCF25	0.78	6.68	0.38	1.43e-10	Skin colour saturation;
CESC	trans	rs1814175	0.615	rs11040654	chr11:49939485	T/G	cg15704280	chr7:45808275	SEPT13	-1.01	-18.94	-0.76	3.64e-51	Height;
CESC	cis	rs9649213	0.593	rs1468340	chr7:97987676	T/G	cg21770322	chr7:97807741	LMTK2	0.57	8.84	0.48	1.39e-16	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg16605187	chr1:156252484	TMEM79;SMG5	0.48	6.48	0.37	4.34e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs1008375	1.000	rs3933453	chr4:17636319	A/C	cg16339924	chr4:17578868	LAP3	0.64	8.09	0.44	2.21e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs727563	0.635	rs5751149	chr22:42139501	A/G	cg06481639	chr22:41940642	POLR3H	0.59	5.84	0.34	1.51e-8	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs12474201	0.928	rs12998762	chr2:46938393	A/C	cg06386533	chr2:46925753	SOCS5	0.91	12.52	0.61	1.51e-28	Height;
CESC	cis	rs801193	1.000	rs4717310	chr7:66161007	C/T	cg14393609	chr7:65229607	NA	0.48	6.5	0.37	4e-10	Aortic root size;
CESC	cis	rs12042938	0.600	rs1094655	chr1:231774362	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.41	5.48	0.32	9.81e-8	Neuranatomic and neurocognitive phenotypes;
CESC	cis	rs2066819	1.000	rs2306694	chr12:56680636	C/T	cg26714650	chr12:56694279	CS	1.52	10.39	0.54	1.95e-21	Psoriasis vulgaris;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23112213	chr5:137549144	CDC23	-0.59	-7.18	-0.4	6.86e-12	Gut microbiome composition (summer);
CESC	cis	rs9322193	0.926	rs9383546	chr6:150143879	T/A	cg07701084	chr6:150067640	NUP43	0.42	5.77	0.33	2.22e-8	Lung cancer;
CESC	cis	rs8177253	0.514	rs6790668	chr3:133442481	T/A	cg16262614	chr3:133464971	TF	0.28	5.38	0.31	1.66e-7	Iron status biomarkers;
CESC	cis	rs5753618	0.583	rs5753601	chr22:31798259	G/T	cg02404636	chr22:31891804	SFI1	0.39	5.37	0.31	1.71e-7	Colorectal cancer;
CESC	cis	rs10911251	0.546	rs7473	chr1:183114634	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.86	13.54	0.64	4.24e-32	Colorectal cancer;
CESC	cis	rs1008375	0.866	rs2109518	chr4:17572162	G/A	cg16339924	chr4:17578868	LAP3	0.74	9.62	0.51	5.34e-19	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs4819052	0.851	rs8130285	chr21:46671701	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.75	9.88	0.52	8.11e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs11098499	0.569	rs55845118	chr4:120290913	T/C	cg25214090	chr10:38739885	LOC399744	0.65	9.11	0.49	2.04e-17	Corneal astigmatism;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg22371845	chr8:140718096	NA	0.55	7.2	0.4	6.4e-12	Gut microbiota (bacterial taxa);
CESC	cis	rs2243480	1.000	rs431076	chr7:65600320	A/C	cg18252515	chr7:66147081	NA	-1.42	-14.5	-0.67	1.8e-35	Diabetic kidney disease;
CESC	cis	rs910316	0.967	rs8007539	chr14:75664953	T/C	cg08847533	chr14:75593920	NEK9	-0.93	-16.57	-0.71	8.58e-43	Height;
CESC	cis	rs10899021	0.920	rs61901540	chr11:74314865	A/G	cg25880958	chr11:74394337	NA	-0.76	-7.95	-0.44	5.53e-14	Response to metformin (IC50);
CESC	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg24829409	chr8:58192753	C8orf71	-0.67	-7.99	-0.44	4.08e-14	Developmental language disorder (linguistic errors);
CESC	cis	rs6582630	0.513	rs1596446	chr12:38282160	C/T	cg13010199	chr12:38710504	ALG10B	-0.47	-5.85	-0.34	1.46e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs67311347	1.000	rs9841335	chr3:40475858	G/A	cg01475735	chr3:40494733	NA	-0.4	-5.08	-0.3	7.14e-7	Renal cell carcinoma;
CESC	cis	rs1355223	0.902	rs1588353	chr11:34730814	A/T	cg11058730	chr11:34937778	PDHX;APIP	-0.48	-6.33	-0.36	1.05e-9	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs4665809	1.000	rs750452	chr2:26324995	G/A	cg04944784	chr2:26401820	FAM59B	-0.66	-7.53	-0.42	8.04e-13	Gut microbiome composition (summer);
CESC	cis	rs7647973	0.580	rs2334958	chr3:49252364	C/T	cg06212747	chr3:49208901	KLHDC8B	0.72	10.88	0.56	4.82e-23	Menarche (age at onset);
CESC	cis	rs7666738	0.830	rs10001702	chr4:99065160	T/G	cg18180107	chr4:99064573	C4orf37	0.4	5.14	0.3	5.21e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9297145	0.715	rs62473008	chr7:98751541	A/G	cg05967295	chr7:98741636	SMURF1	0.85	8.66	0.47	4.65e-16	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
CESC	cis	rs7666738	0.830	rs1426665	chr4:99027764	C/T	cg17366294	chr4:99064904	C4orf37	0.61	8.67	0.47	4.35e-16	Colonoscopy-negative controls vs population controls;
CESC	trans	rs2727020	0.688	rs11040338	chr11:49360601	A/G	cg15704280	chr7:45808275	SEPT13	0.87	14.45	0.66	2.59e-35	Coronary artery disease;
CESC	trans	rs1728785	0.901	rs1170437	chr16:68607943	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.67	8.11	0.45	1.92e-14	Ulcerative colitis;
CESC	cis	rs896854	0.714	rs572547	chr8:95966286	A/G	cg23172400	chr8:95962367	TP53INP1	0.4	7.44	0.42	1.38e-12	Type 2 diabetes;
CESC	cis	rs9611565	0.592	rs5751129	chr22:42015765	C/T	cg06634786	chr22:41940651	POLR3H	0.54	5.94	0.34	8.8e-9	Vitiligo;
CESC	cis	rs765787	0.530	rs2554454	chr15:45521536	A/G	cg24006582	chr15:45444508	DUOX1	-0.48	-5.63	-0.33	4.5e-8	Uric acid levels;
CESC	cis	rs6502050	0.731	rs11867299	chr17:80088675	C/A	cg23985595	chr17:80112537	CCDC57	-0.42	-6.6	-0.38	2.18e-10	Life satisfaction;
CESC	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	21.78	0.8	5.33e-61	Prudent dietary pattern;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04939749	chr2:178417898	TTC30B	-0.6	-7.05	-0.4	1.56e-11	Gut microbiome composition (summer);
CESC	cis	rs1348850	0.793	rs13020788	chr2:178480714	C/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.53	6.87	0.39	4.53e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs17401966	0.838	rs12737239	chr1:10323973	C/G	cg15208524	chr1:10270712	KIF1B	0.39	5.07	0.3	7.62e-7	Hepatocellular carcinoma;
CESC	cis	rs7666738	0.830	rs4334758	chr4:98971875	A/G	cg03676636	chr4:99064102	C4orf37	0.34	5.2	0.3	3.93e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9910055	0.659	rs227584	chr17:42225547	A/C	cg10896456	chr17:42255109	ASB16;C17orf65	0.5	7.45	0.42	1.3e-12	Total body bone mineral density;
CESC	cis	rs9911578	0.935	rs9893351	chr17:57023326	G/A	cg12560992	chr17:57184187	TRIM37	0.8	12.5	0.61	1.75e-28	Intelligence (multi-trait analysis);
CESC	cis	rs9325144	0.581	rs2730929	chr12:38942739	T/C	cg13010199	chr12:38710504	ALG10B	-0.51	-7.04	-0.4	1.64e-11	Morning vs. evening chronotype;
CESC	cis	rs6460942	1.000	rs79964328	chr7:12319392	A/C	cg20607287	chr7:12443886	VWDE	-0.79	-8.51	-0.46	1.32e-15	Coronary artery disease;
CESC	cis	rs1799949	1.000	rs4793231	chr17:41427469	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.39	5.27	0.31	2.8e-7	Menopause (age at onset);
CESC	cis	rs71191701	1.000	rs71191701	chr9:139322257	G/C	cg14019695	chr9:139328340	INPP5E	0.4	5.14	0.3	5.37e-7	Myeloid white cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;
CESC	cis	rs61841072	0.961	rs73113549	chr1:243126414	A/G	cg02356786	chr1:243265016	LOC731275	0.4	5.07	0.3	7.42e-7	Schizophrenia;
CESC	trans	rs208520	1.000	rs9453663	chr6:66976077	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.7	7.87	0.44	9.16e-14	Exhaled nitric oxide output;
CESC	cis	rs9926296	0.508	rs1558184	chr16:89842374	T/G	cg27121462	chr16:89883253	FANCA	0.81	12.1	0.6	4e-27	Vitiligo;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07644571	chr22:22307395	PPM1F	0.63	7.78	0.43	1.63e-13	Gut microbiome composition (summer);
CESC	cis	rs798554	0.679	rs11973498	chr7:2886873	C/A	cg18446336	chr7:2847575	GNA12	-0.34	-5.4	-0.31	1.49e-7	Height;
CESC	cis	rs701145	0.556	rs355771	chr3:154039385	G/C	cg16511985	chr3:153974050	SGEF	0.41	5.76	0.33	2.38e-8	Coronary artery disease;
CESC	cis	rs5750830	0.594	rs9611166	chr22:39775268	T/C	cg11247378	chr22:39784982	NA	-0.51	-7.72	-0.43	2.36e-13	Intelligence (multi-trait analysis);
CESC	cis	rs7412746	0.658	rs4970986	chr1:150907955	A/G	cg04414720	chr1:150670196	GOLPH3L	0.52	6.88	0.39	4.32e-11	Melanoma;
CESC	cis	rs10504229	0.683	rs61306359	chr8:58134646	G/A	cg02725872	chr8:58115012	NA	-0.45	-7.05	-0.4	1.52e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs9788682	1.000	rs9788682	chr15:78802586	A/G	cg24631222	chr15:78858424	CHRNA5	-0.82	-10.99	-0.56	2.06e-23	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg22344139	chr1:44435583	DPH2	-0.49	-6.44	-0.37	5.56e-10	Height;
CESC	cis	rs17253792	0.822	rs8007065	chr14:56081272	A/G	cg01858014	chr14:56050164	KTN1	-0.93	-7.33	-0.41	2.71e-12	Putamen volume;
CESC	cis	rs6460942	0.841	rs62448597	chr7:12449110	G/C	cg02935154	chr7:12443704	VWDE	-0.6	-6.82	-0.39	6.02e-11	Coronary artery disease;
CESC	trans	rs1814175	0.817	rs1851858	chr11:49855638	G/A	cg03929089	chr4:120376271	NA	-0.92	-15.77	-0.7	5.68e-40	Height;
CESC	cis	rs10779751	1.000	rs7526649	chr1:11278163	C/T	cg08854313	chr1:11322531	MTOR	0.77	10.45	0.54	1.23e-21	Body mass index;
CESC	cis	rs66573146	0.656	rs56094305	chr4:6956086	C/T	cg00086871	chr4:6988644	TBC1D14	1.05	6.88	0.39	4.25e-11	Granulocyte percentage of myeloid white cells;
CESC	cis	rs10504229	0.636	rs115738451	chr8:58055133	A/T	cg02725872	chr8:58115012	NA	-0.43	-6.2	-0.36	2.16e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs2637266	0.905	rs7076442	chr10:78360480	A/C	cg18941641	chr10:78392320	NA	-0.35	-6.24	-0.36	1.74e-9	Pulmonary function;
CESC	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg23131131	chr22:24373011	LOC391322	-0.71	-9.76	-0.51	2.07e-19	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs9814567	0.896	rs7653880	chr3:134345788	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.42	-5.67	-0.33	3.63e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg15383120	chr6:291909	DUSP22	-0.69	-8.92	-0.48	7.68e-17	Menopause (age at onset);
CESC	cis	rs889312	0.500	rs252906	chr5:56119190	G/T	cg12311346	chr5:56204834	C5orf35	-0.4	-5.16	-0.3	4.91e-7	Breast cancer;Breast cancer (early onset);
CESC	cis	rs2836633	0.929	rs2836602	chr21:40039169	A/T	cg12884169	chr21:40033163	ERG	-0.36	-5.88	-0.34	1.2e-8	Coronary artery disease;
CESC	cis	rs2836974	0.863	rs6517519	chr21:40540245	A/G	cg11890956	chr21:40555474	PSMG1	1.18	22.96	0.82	5.84e-65	Cognitive function;
CESC	cis	rs7618501	0.574	rs6765484	chr3:50041313	C/T	cg24308560	chr3:49941425	MST1R	0.63	9.25	0.49	7.75e-18	Intelligence (multi-trait analysis);
CESC	cis	rs933688	1.000	rs6869717	chr5:90694797	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.99	11.87	0.59	2.36e-26	Smoking behavior;
CESC	cis	rs10465746	0.967	rs11163868	chr1:84397013	T/G	cg10977910	chr1:84465055	TTLL7	0.46	6.29	0.36	1.29e-9	Obesity-related traits;
CESC	cis	rs7312933	0.558	rs1051453	chr12:42852217	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.46	5.92	0.34	9.98e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs9926296	0.605	rs6500453	chr16:89858657	C/G	cg21285383	chr16:89894308	SPIRE2	0.31	5.6	0.33	5.44e-8	Vitiligo;
CESC	cis	rs6545883	0.929	rs6545877	chr2:61741947	T/C	cg15711740	chr2:61764176	XPO1	-0.44	-5.4	-0.31	1.47e-7	Tuberculosis;
CESC	cis	rs9322193	0.962	rs6903998	chr6:150152493	T/C	cg09699651	chr6:150184138	LRP11	0.4	5.18	0.3	4.32e-7	Lung cancer;
CESC	cis	rs1348850	0.668	rs13034886	chr2:178493301	G/T	cg23306229	chr2:178417860	TTC30B	0.54	6.33	0.36	1.02e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs853679	0.517	rs55747925	chr6:28044337	T/C	cg20151795	chr6:28129481	ZNF389	0.44	5.59	0.33	5.5e-8	Depression;
CESC	cis	rs7927592	0.731	rs10896350	chr11:68386373	A/C	cg20283391	chr11:68216788	NA	-0.42	-5.09	-0.3	6.65e-7	Total body bone mineral density;
CESC	cis	rs7666738	0.830	rs6532721	chr4:99048015	G/A	cg18180107	chr4:99064573	C4orf37	0.41	5.29	0.31	2.51e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7429990	0.965	rs777015	chr3:47937072	A/G	cg11946769	chr3:48343235	NME6	0.42	5.27	0.31	2.89e-7	Educational attainment (years of education);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg24830314	chr6:83775579	UBE2CBP	-0.39	-6.16	-0.35	2.62e-9	Gambling;
CESC	cis	rs9768139	0.733	rs13309363	chr7:158122179	C/A	cg27057461	chr7:158136379	PTPRN2	-0.35	-5.43	-0.32	1.27e-7	Calcium levels;
CESC	trans	rs9467711	0.606	rs9393714	chr6:26373740	G/T	cg06606381	chr12:133084897	FBRSL1	-0.76	-7.09	-0.4	1.23e-11	Autism spectrum disorder or schizophrenia;
CESC	cis	rs61776719	0.875	rs10890238	chr1:38445654	A/T	cg26528311	chr1:38462546	FHL3	0.36	5.86	0.34	1.34e-8	Coronary artery disease;
CESC	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg23131131	chr22:24373011	LOC391322	0.56	7.44	0.42	1.4e-12	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs9611565	0.512	rs4820446	chr22:42215684	C/T	cg17376030	chr22:41985996	PMM1	0.76	8.01	0.44	3.63e-14	Vitiligo;
CESC	cis	rs4862750	0.914	rs1991255	chr4:187875340	G/A	cg03452623	chr4:187889614	NA	-0.86	-14.21	-0.66	1.82e-34	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4006360	0.614	rs6416914	chr17:39262850	A/G	cg18442075	chr17:40169520	DNAJC7;NKIRAS2	-0.41	-5.18	-0.3	4.33e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg24829409	chr8:58192753	C8orf71	-0.67	-7.99	-0.44	4.08e-14	Developmental language disorder (linguistic errors);
CESC	cis	rs1030877	0.515	rs3828300	chr2:105901107	G/A	cg02079111	chr2:105885981	TGFBRAP1	-0.51	-6.37	-0.36	8.17e-10	Obesity-related traits;
CESC	cis	rs7116495	0.609	rs4944243	chr11:71674354	T/C	cg18441811	chr11:71824068	C11orf51	-0.81	-5.3	-0.31	2.48e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs6502050	0.799	rs8069827	chr17:80089168	C/T	cg01763666	chr17:80159506	CCDC57	-0.37	-5.1	-0.3	6.55e-7	Life satisfaction;
CESC	cis	rs11608355	0.545	rs2302709	chr12:109893697	A/G	cg05360138	chr12:110035743	NA	0.82	8.92	0.48	7.93e-17	Neuroticism;
CESC	cis	rs736408	0.716	rs2239549	chr3:52823126	C/T	cg17372223	chr3:52568218	NT5DC2	0.43	6.06	0.35	4.63e-9	Bipolar disorder;
CESC	cis	rs6088590	1.000	rs10048849	chr20:33419680	C/T	cg06115741	chr20:33292138	TP53INP2	0.61	7.6	0.42	5.11e-13	Coronary artery disease;
CESC	cis	rs9462846	0.841	rs66541797	chr6:42825942	C/T	cg02353165	chr6:42928485	GNMT	0.47	5.48	0.32	1.01e-7	Blood protein levels;
CESC	cis	rs6429082	0.818	rs291386	chr1:235647050	C/T	cg26050004	chr1:235667680	B3GALNT2	0.61	7.62	0.42	4.63e-13	Adiposity;
CESC	trans	rs2727020	0.595	rs7924311	chr11:49507573	G/A	cg15704280	chr7:45808275	SEPT13	-0.94	-16.43	-0.71	2.51e-42	Coronary artery disease;
CESC	cis	rs780094	0.585	rs3739095	chr2:27556721	C/T	cg02592271	chr2:27665507	KRTCAP3	-0.28	-6.03	-0.35	5.62e-9	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
CESC	cis	rs12824058	0.831	rs4759450	chr12:130812732	G/A	cg26677194	chr12:130822605	PIWIL1	0.51	6.72	0.38	1.13e-10	Menopause (age at onset);
CESC	cis	rs9303401	0.538	rs8078280	chr17:56473132	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.91	10.78	0.55	1.02e-22	Cognitive test performance;
CESC	cis	rs506597	0.850	rs221774	chr7:100298984	A/G	cg10426581	chr7:100472382	SRRT	-0.66	-5.15	-0.3	5.14e-7	Pursuit maintenance gain in psychotic disorders;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg26742440	chr11:73472391	RAB6A	0.48	6.03	0.35	5.41e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs701145	0.556	rs355756	chr3:154021063	G/A	cg16511985	chr3:153974050	SGEF	0.43	6.1	0.35	3.71e-9	Coronary artery disease;
CESC	cis	rs9311474	0.508	rs7625743	chr3:52606366	C/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.6	8.64	0.47	5.42e-16	Electroencephalogram traits;
CESC	cis	rs1003719	0.715	rs7280251	chr21:38567911	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.61	-8.29	-0.45	5.61e-15	Eye color traits;
CESC	cis	rs892961	0.932	rs7216116	chr17:75405078	C/T	cg05865280	chr17:75406074	SEPT9	0.59	10.95	0.56	2.82e-23	Airflow obstruction;
CESC	cis	rs9303401	0.614	rs56284918	chr17:57178838	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.88	11.1	0.56	8.94e-24	Cognitive test performance;
CESC	cis	rs2440129	0.611	rs1126667	chr17:6902760	C/T	cg21237687	chr17:6899380	ALOX12	-0.52	-9.09	-0.49	2.38e-17	Tonsillectomy;
CESC	cis	rs10781543	0.839	rs10870071	chr9:139382184	T/C	cg14169450	chr9:139327907	INPP5E	0.49	7.53	0.42	7.75e-13	Monocyte percentage of white cells;
CESC	cis	rs3820068	0.603	rs59475085	chr1:15911131	G/A	cg17385448	chr1:15911702	AGMAT	0.43	6.67	0.38	1.45e-10	Systolic blood pressure;
CESC	trans	rs28549925	0.590	rs17136920	chr7:16991550	G/A	cg12639933	chr12:57626296	SHMT2	0.95	6.1	0.35	3.83e-9	Congenital heart disease (maternal effect);Conotruncal heart defects (maternal effects);
CESC	cis	rs2066819	1.000	rs79101914	chr12:56729739	A/G	cg26734620	chr12:56694298	CS	0.98	5.95	0.34	8.45e-9	Psoriasis vulgaris;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26239930	chr14:52455994	C14orf166	-0.65	-8.09	-0.45	2.15e-14	Gut microbiome composition (summer);
CESC	cis	rs10504229	0.679	rs17193048	chr8:58055392	G/A	cg21724239	chr8:58056113	NA	0.63	5.77	0.33	2.16e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs5769707	0.967	rs2071904	chr22:50034477	C/T	cg05373962	chr22:49881684	NA	-0.4	-6.91	-0.39	3.65e-11	Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs514406	0.505	rs431459	chr1:53183230	T/G	cg08859206	chr1:53392774	SCP2	-0.54	-7.18	-0.4	7e-12	Monocyte count;
CESC	cis	rs1707322	1.000	rs785469	chr1:46521091	C/T	cg03146154	chr1:46216737	IPP	-0.72	-9.73	-0.51	2.49e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs6540559	0.611	rs6540563	chr1:210019858	C/G	cg21951975	chr1:209979733	IRF6	0.59	7.16	0.4	8.01e-12	Cleft lip with or without cleft palate;
CESC	cis	rs3820928	1.000	rs4673173	chr2:227769493	A/C	cg11843606	chr2:227700838	RHBDD1	-0.44	-5.9	-0.34	1.09e-8	Pulmonary function;
CESC	cis	rs12618769	0.543	rs72819980	chr2:99040522	A/G	cg10123293	chr2:99228465	UNC50	0.41	5.43	0.32	1.27e-7	Bipolar disorder;
CESC	cis	rs11098499	0.657	rs71614442	chr4:120379346	C/T	cg24375607	chr4:120327624	NA	0.45	5.54	0.32	7.19e-8	Corneal astigmatism;
CESC	cis	rs763121	0.853	rs2281021	chr22:39064667	T/C	cg21395723	chr22:39101663	GTPBP1	0.43	5.39	0.31	1.58e-7	Menopause (age at onset);
CESC	cis	rs2439831	0.702	rs8033995	chr15:44013509	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.73	8.48	0.46	1.6e-15	Lung cancer in ever smokers;
CESC	cis	rs3741151	1.000	rs112628073	chr11:73013626	C/T	cg17517138	chr11:73019481	ARHGEF17	1.2	8.42	0.46	2.32e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs6089829	0.855	rs6090203	chr20:61663632	G/A	cg03213289	chr20:61660250	NA	0.39	6.07	0.35	4.42e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs36051895	0.664	rs2274649	chr9:5090934	A/T	cg02405213	chr9:5042618	JAK2	-0.51	-5.94	-0.34	9.11e-9	Pediatric autoimmune diseases;
CESC	cis	rs11122272	0.705	rs2491411	chr1:231533448	C/G	cg06096015	chr1:231504339	EGLN1	0.43	6.15	0.35	2.9e-9	Hemoglobin concentration;
CESC	cis	rs7589342	0.598	rs7602442	chr2:106402795	C/T	cg16077055	chr2:106428750	NCK2	-0.36	-5.17	-0.3	4.61e-7	Addiction;
CESC	trans	rs1814175	0.708	rs10839464	chr11:49981386	T/C	cg15704280	chr7:45808275	SEPT13	-1.01	-19.02	-0.76	1.83e-51	Height;
CESC	cis	rs7666738	0.830	rs10005120	chr4:99038200	A/G	cg03676636	chr4:99064102	C4orf37	0.33	5.12	0.3	5.85e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1552244	0.882	rs35056669	chr3:10014171	C/T	cg08888203	chr3:10149979	C3orf24	0.49	6.07	0.35	4.32e-9	Alzheimer's disease;
CESC	cis	rs9914988	0.943	rs4795459	chr17:27113726	G/C	cg20469991	chr17:27169893	C17orf63	-0.48	-5.25	-0.31	3.18e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CESC	cis	rs9443645	0.901	rs56057971	chr6:79607182	G/A	cg05283184	chr6:79620031	NA	-0.41	-6.38	-0.36	7.79e-10	Intelligence (multi-trait analysis);
CESC	cis	rs12476592	0.602	rs4671516	chr2:63790555	G/T	cg17519650	chr2:63277830	OTX1	-0.48	-5.42	-0.32	1.34e-7	Childhood ear infection;
CESC	cis	rs17253792	0.822	rs77990307	chr14:56070049	T/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.79	5.91	0.34	1.06e-8	Putamen volume;
CESC	cis	rs7192750	0.617	rs9929256	chr16:72040032	A/C	cg14768367	chr16:72042858	DHODH	0.82	6.22	0.36	1.94e-9	LDL cholesterol levels;Total cholesterol levels;
CESC	cis	rs713587	0.713	rs4665276	chr2:25213333	C/T	cg01884057	chr2:25150051	NA	-0.38	-7.17	-0.4	7.39e-12	Body mass index in non-asthmatics;
CESC	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg26338869	chr17:61819248	STRADA	0.68	8.97	0.48	5.62e-17	Prudent dietary pattern;
CESC	cis	rs35306767	0.903	rs12764024	chr10:922861	A/G	cg25019033	chr10:957182	NA	-0.51	-5.69	-0.33	3.3e-8	Eosinophil percentage of granulocytes;
CESC	cis	rs4713118	0.586	rs6905522	chr6:28086479	A/C	cg19592336	chr6:28129416	ZNF389	0.6	7.98	0.44	4.4e-14	Parkinson's disease;
CESC	cis	rs11098499	0.863	rs3775843	chr4:120427844	T/C	cg09307838	chr4:120376055	NA	0.95	13.11	0.63	1.3e-30	Corneal astigmatism;
CESC	cis	rs17407555	0.821	rs17198197	chr4:10139157	A/G	cg11266682	chr4:10021025	SLC2A9	0.53	5.64	0.33	4.44e-8	Schizophrenia (age at onset);
CESC	cis	rs7259376	0.936	rs6511350	chr19:22594697	A/G	cg02657401	chr19:22469223	NA	0.26	5.12	0.3	5.94e-7	Menopause (age at onset);
CESC	cis	rs66887589	0.616	rs11098498	chr4:120187119	T/C	cg09307838	chr4:120376055	NA	0.69	9.61	0.51	5.93e-19	Diastolic blood pressure;
CESC	cis	rs2841277	0.509	rs11850949	chr14:105408827	A/C	cg17340268	chr14:105411764	AHNAK2	-0.53	-6.97	-0.39	2.57e-11	Rheumatoid arthritis;
CESC	cis	rs950169	0.922	rs12911223	chr15:84831671	G/A	cg17507749	chr15:85114479	UBE2QP1	-0.55	-6.25	-0.36	1.66e-9	Schizophrenia;
CESC	cis	rs2404602	0.692	rs56193230	chr15:76934472	C/T	cg22467129	chr15:76604101	ETFA	-0.36	-5.24	-0.31	3.26e-7	Blood metabolite levels;
CESC	cis	rs7605827	0.930	rs1024869	chr2:15549043	G/C	cg19274914	chr2:15703543	NA	0.34	6.12	0.35	3.38e-9	Educational attainment (years of education);
CESC	cis	rs9457247	0.935	rs2149093	chr6:167373045	T/C	cg25258033	chr6:167368657	RNASET2	-0.4	-6.05	-0.35	4.91e-9	Crohn's disease;
CESC	cis	rs2549003	1.000	rs9282762	chr5:131822055	T/C	cg00255919	chr5:131827918	IRF1	0.51	8.68	0.47	4.19e-16	Asthma (sex interaction);
CESC	cis	rs7917772	0.582	rs7087984	chr10:104380686	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.38	5.18	0.3	4.44e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs4243830	0.850	rs12760251	chr1:6601336	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.88	-8.87	-0.48	1.12e-16	Body mass index;
CESC	cis	rs597583	0.715	rs4938399	chr11:117398399	C/T	cg27161313	chr11:117392002	DSCAML1	-0.54	-6.37	-0.36	8.18e-10	Putamen volume;
CESC	cis	rs763121	0.853	rs2064088	chr22:39053382	A/G	cg14440974	chr22:39074834	NA	-0.4	-5.49	-0.32	9.53e-8	Menopause (age at onset);
CESC	cis	rs9649213	0.593	rs6968144	chr7:97915697	G/A	cg24562669	chr7:97807699	LMTK2	0.51	7.35	0.41	2.45e-12	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs72772090	0.539	rs114006288	chr5:96118004	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.57	-5.21	-0.3	3.74e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs826838	0.967	rs73096706	chr12:38860563	G/A	cg26384229	chr12:38710491	ALG10B	0.83	14.35	0.66	6.2e-35	Heart rate;
CESC	cis	rs1185460	0.967	rs1184902	chr11:118945337	A/G	cg23280166	chr11:118938394	VPS11	0.58	7.73	0.43	2.18e-13	Coronary artery disease;
CESC	cis	rs931127	0.505	rs2306362	chr11:65405510	G/T	cg27068330	chr11:65405492	SIPA1	-0.51	-5.58	-0.32	5.94e-8	Systemic lupus erythematosus;
CESC	cis	rs2290159	0.848	rs6771385	chr3:12639419	A/G	cg23032965	chr3:12705835	RAF1	0.49	5.45	0.32	1.14e-7	Cholesterol, total;
CESC	cis	rs12410462	0.681	rs113316536	chr1:227547033	T/G	cg04117972	chr1:227635322	NA	0.62	5.31	0.31	2.27e-7	Major depressive disorder;
CESC	cis	rs1976403	0.659	rs10799699	chr1:21820961	C/T	cg21906605	chr1:21766650	NBPF3	0.41	5.39	0.31	1.59e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs4629180	0.917	rs34217240	chr2:102136682	G/A	cg01388757	chr2:102091195	RFX8	0.41	6.05	0.35	4.87e-9	Chronic rhinosinusitis with nasal polyps;
CESC	cis	rs7296418	0.517	rs73231928	chr12:123724325	T/C	cg00376283	chr12:123451042	ABCB9	0.63	8.78	0.47	2.04e-16	Platelet count;
CESC	cis	rs6426558	0.515	rs7412928	chr1:227332148	C/T	cg10327440	chr1:227177885	CDC42BPA	-0.47	-5.69	-0.33	3.4e-8	Neutrophil percentage of white cells;
CESC	cis	rs28374715	0.662	rs16971558	chr15:41458619	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.79	-10.4	-0.54	1.82e-21	Ulcerative colitis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02260482	chr12:104359603	TDG	0.7	8.3	0.45	5.28e-15	Gut microbiome composition (summer);
CESC	trans	rs875971	1.000	rs35149210	chr7:65929925	T/C	cg26939375	chr7:64535504	NA	0.46	6.0	0.35	6.4e-9	Aortic root size;
CESC	cis	rs1506636	1.000	rs7779099	chr7:123295964	C/T	cg03229431	chr7:123269106	ASB15	-0.53	-6.83	-0.39	5.87e-11	Plateletcrit;Platelet count;
CESC	cis	rs950169	0.614	rs12911536	chr15:84673030	G/T	cg17507749	chr15:85114479	UBE2QP1	0.6	5.93	0.34	9.65e-9	Schizophrenia;
CESC	cis	rs72781680	0.846	rs55770503	chr2:24030126	A/T	cg08917208	chr2:24149416	ATAD2B	0.95	8.71	0.47	3.45e-16	Lymphocyte counts;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22505778	chr3:113822317	NA	-0.68	-7.95	-0.44	5.27e-14	Gut microbiome composition (summer);
CESC	cis	rs1552244	0.882	rs68153882	chr3:10013110	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.74	-9.37	-0.5	3.35e-18	Alzheimer's disease;
CESC	trans	rs78049276	0.736	rs77028772	chr4:148364920	G/A	cg13149281	chr14:23389818	RBM23;PRMT5	-0.62	-6.35	-0.36	9.55e-10	Pulse pressure;
CESC	cis	rs17401966	1.000	rs12734551	chr1:10391536	A/C	cg15208524	chr1:10270712	KIF1B	0.5	6.48	0.37	4.52e-10	Hepatocellular carcinoma;
CESC	cis	rs939658	0.805	rs11630571	chr15:79432992	C/A	cg17916960	chr15:79447300	NA	-0.38	-6.3	-0.36	1.21e-9	Refractive error;
CESC	cis	rs763121	0.853	rs9622833	chr22:39000397	G/A	cg06544989	chr22:39130855	UNC84B	0.49	8.25	0.45	7.34e-15	Menopause (age at onset);
CESC	cis	rs2933343	0.553	rs789212	chr3:128686912	A/C	cg25356066	chr3:128598488	ACAD9	0.56	6.85	0.39	5.2e-11	IgG glycosylation;
CESC	cis	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg18404041	chr3:52824283	ITIH1	0.45	7.25	0.41	4.7e-12	Bipolar disorder;
CESC	cis	rs7943191	0.805	rs12226821	chr11:62369018	C/G	cg11742103	chr11:62369870	EML3;MTA2	0.55	7.97	0.44	4.71e-14	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
CESC	cis	rs412050	0.649	rs117808805	chr22:22246629	C/T	cg17089214	chr22:22089827	YPEL1	0.71	6.13	0.35	3.09e-9	Attention deficit hyperactivity disorder;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg08744097	chr16:1550264	TELO2	0.51	7.11	0.4	1.09e-11	Fibrinogen levels;
CESC	cis	rs11587400	0.574	rs2268696	chr1:115219083	T/A	cg12756093	chr1:115239321	AMPD1	-0.45	-6.18	-0.35	2.42e-9	Autism;
CESC	cis	rs12765878	1.000	rs11191846	chr10:105649813	A/G	cg24587175	chr10:105670608	OBFC1	0.32	5.36	0.31	1.81e-7	Coronary artery disease;
CESC	cis	rs9487051	0.768	rs9480910	chr6:109521707	T/C	cg01475377	chr6:109611718	NA	-0.46	-6.93	-0.39	3.18e-11	Reticulocyte fraction of red cells;
CESC	cis	rs6998277	0.830	rs6468838	chr8:103609336	T/C	cg10187029	chr8:103597600	NA	0.73	9.39	0.5	2.94e-18	Migraine;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg02442526	chr22:46973514	NA	-0.5	-6.49	-0.37	4.14e-10	Fibrinogen levels;
CESC	cis	rs853679	0.517	rs9380059	chr6:28132358	A/C	cg17949981	chr6:28129498	ZNF389	0.45	5.57	0.32	6.26e-8	Depression;
CESC	cis	rs7267979	0.932	rs6132848	chr20:25561645	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.73	12.77	0.62	1.93e-29	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs9300255	0.602	rs1727306	chr12:123665695	A/G	cg00376283	chr12:123451042	ABCB9	0.71	8.71	0.47	3.27e-16	Neutrophil percentage of white cells;
CESC	cis	rs7208859	0.673	rs9913782	chr17:29237384	A/G	cg19761014	chr17:28927070	LRRC37B2	0.71	5.63	0.33	4.48e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15936439	chr13:20767183	GJB2	0.55	6.19	0.36	2.26e-9	Gut microbiome composition (summer);
CESC	cis	rs2274273	0.588	rs7158791	chr14:55828607	A/G	cg04306507	chr14:55594613	LGALS3	0.3	5.26	0.31	2.92e-7	Protein biomarker;
CESC	cis	rs2404602	0.503	rs284909	chr15:76736628	C/T	cg00316803	chr15:76480434	C15orf27	-0.39	-5.88	-0.34	1.25e-8	Blood metabolite levels;
CESC	cis	rs7772486	0.754	rs6910790	chr6:146255330	G/A	cg23711669	chr6:146136114	FBXO30	-0.92	-13.3	-0.63	2.94e-31	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs853679	0.513	rs9468296	chr6:28113730	A/G	cg17949981	chr6:28129498	ZNF389	0.45	5.43	0.32	1.27e-7	Depression;
CESC	cis	rs8027181	0.839	rs8025333	chr15:73025121	A/G	cg25632853	chr15:73088954	NA	0.31	5.46	0.32	1.1e-7	Triglyceride levels;
CESC	cis	rs67397200	0.632	rs11666308	chr19:17437744	T/C	cg22549504	chr19:17448937	GTPBP3	0.51	6.35	0.36	9.42e-10	Breast cancer;Breast Cancer in BRCA1 mutation carriers;Breast cancer (estrogen-receptor negative);
CESC	cis	rs10504229	0.683	rs11786845	chr8:58133642	T/C	cg22535103	chr8:58192502	C8orf71	-0.81	-9.14	-0.49	1.65e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs3780486	0.505	rs10758188	chr9:33123386	C/T	cg13443165	chr9:33130375	B4GALT1	-0.47	-7.06	-0.4	1.49e-11	IgG glycosylation;
CESC	cis	rs9910055	0.529	rs368328	chr17:42170289	G/A	cg13607699	chr17:42295918	UBTF	-0.44	-5.3	-0.31	2.41e-7	Total body bone mineral density;
CESC	cis	rs7772486	0.754	rs10872580	chr6:146140281	C/T	cg05347473	chr6:146136440	FBXO30	-0.57	-7.53	-0.42	8.04e-13	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs12477438	0.684	rs6756880	chr2:99676991	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.62	-8.67	-0.47	4.43e-16	Chronic sinus infection;
CESC	cis	rs11711311	1.000	rs9288983	chr3:113488699	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.68	9.34	0.5	4.24e-18	IgG glycosylation;
CESC	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg03188948	chr7:1209495	NA	0.73	7.02	0.4	1.85e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs72781680	0.716	rs2712056	chr2:23959131	C/T	cg08917208	chr2:24149416	ATAD2B	0.61	5.92	0.34	9.71e-9	Lymphocyte counts;
CESC	cis	rs9457247	0.508	rs9457268	chr6:167503639	A/T	cg07741184	chr6:167504864	NA	0.33	5.73	0.33	2.76e-8	Crohn's disease;
CESC	cis	rs4665809	1.000	rs4665820	chr2:26309150	T/C	cg27170947	chr2:26402098	FAM59B	-0.6	-7.25	-0.41	4.7e-12	Gut microbiome composition (summer);
CESC	cis	rs9522267	0.535	rs4644738	chr13:112235995	G/A	cg10483660	chr13:112241077	NA	-0.33	-5.78	-0.33	2.14e-8	Hepatitis;
CESC	cis	rs116095464	0.558	rs10057626	chr5:239720	T/G	cg22496380	chr5:211416	CCDC127	-0.75	-8.78	-0.47	2.13e-16	Breast cancer;
CESC	cis	rs2011503	0.882	rs4808933	chr19:19363812	T/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.54	5.73	0.33	2.76e-8	Bipolar disorder;
CESC	trans	rs6964833	0.935	rs34630792	chr7:74061197	G/C	cg07504079	chr7:72649617	NCF1B	-0.54	-6.15	-0.35	2.87e-9	Menarche (age at onset);
CESC	cis	rs3820068	0.581	rs16851841	chr1:15922713	A/G	cg13390004	chr1:15929781	NA	0.34	5.3	0.31	2.41e-7	Systolic blood pressure;
CESC	cis	rs875971	0.737	rs7803424	chr7:65880605	T/C	cg10691866	chr7:65817282	TPST1	-0.34	-5.51	-0.32	8.3e-8	Aortic root size;
CESC	cis	rs9487051	0.676	rs6568566	chr6:109596792	G/A	cg21918786	chr6:109611834	NA	-0.38	-5.52	-0.32	8.19e-8	Reticulocyte fraction of red cells;
CESC	cis	rs6502050	0.871	rs8080366	chr17:80067298	A/G	cg23985595	chr17:80112537	CCDC57	0.35	5.44	0.32	1.24e-7	Life satisfaction;
CESC	cis	rs2737618	0.674	rs2258280	chr1:200097648	G/A	cg21825944	chr1:200113062	NR5A2	-0.42	-6.21	-0.36	2.01e-9	Uric acid levels;
CESC	cis	rs13082711	0.911	rs13077400	chr3:27473066	A/G	cg02860705	chr3:27208620	NA	0.5	6.54	0.37	3.15e-10	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CESC	cis	rs2072499	0.695	rs112223391	chr1:156156094	G/A	cg25208724	chr1:156163844	SLC25A44	1.0	12.73	0.62	2.65e-29	Testicular germ cell tumor;
CESC	cis	rs4629180	0.586	rs290773	chr2:102125930	G/A	cg04415270	chr2:102091202	RFX8	0.35	5.91	0.34	1.02e-8	Chronic rhinosinusitis with nasal polyps;
CESC	cis	rs13082711	0.558	rs1844983	chr3:27370203	C/T	cg02860705	chr3:27208620	NA	-0.51	-6.63	-0.38	1.88e-10	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CESC	cis	rs7927771	1.000	rs4752797	chr11:47874364	C/T	cg20307385	chr11:47447363	PSMC3	-0.44	-5.41	-0.32	1.43e-7	Subjective well-being;
CESC	cis	rs514406	0.929	rs562178	chr1:53319562	T/C	cg08859206	chr1:53392774	SCP2	-0.62	-8.41	-0.46	2.57e-15	Monocyte count;
CESC	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.93	10.15	0.53	1.2e-20	Platelet count;
CESC	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.6	0.38	2.17e-10	Prudent dietary pattern;
CESC	cis	rs2836974	0.831	rs34592564	chr21:40516288	G/C	cg11644478	chr21:40555479	PSMG1	0.94	13.54	0.64	4.14e-32	Cognitive function;
CESC	trans	rs744016	0.645	rs5761630	chr22:27006698	A/G	cg26539023	chr1:201369031	LAD1	-0.4	-6.02	-0.35	5.67e-9	RR interval (heart rate);
CESC	trans	rs9325144	0.671	rs7486919	chr12:38767997	A/G	cg10679878	chr6:156759499	NA	-0.34	-6.09	-0.35	4.05e-9	Morning vs. evening chronotype;
CESC	cis	rs9457247	0.967	rs424185	chr6:167410907	C/T	cg25258033	chr6:167368657	RNASET2	0.4	6.14	0.35	2.93e-9	Crohn's disease;
CESC	cis	rs2933343	0.649	rs789214	chr3:128594995	A/G	cg25356066	chr3:128598488	ACAD9	0.63	8.94	0.48	6.95e-17	IgG glycosylation;
CESC	cis	rs6831352	0.842	rs1230156	chr4:99989626	C/T	cg21548116	chr4:100009993	ADH5	0.52	5.43	0.32	1.27e-7	Alcohol dependence;
CESC	cis	rs67478160	0.643	rs7156697	chr14:104211136	G/A	cg08213375	chr14:104286397	PPP1R13B	0.54	10.85	0.55	6.32e-23	Schizophrenia;
CESC	trans	rs7615952	0.688	rs12638240	chr3:125541238	G/A	cg07211511	chr3:129823064	LOC729375	-0.84	-9.55	-0.51	9.43e-19	Blood pressure (smoking interaction);
CESC	cis	rs11190604	0.943	rs11190568	chr10:102224277	C/T	cg07080220	chr10:102295463	HIF1AN	0.58	5.27	0.31	2.81e-7	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs3733585	0.673	rs4235348	chr4:9951968	T/C	cg00071950	chr4:10020882	SLC2A9	-0.69	-11.34	-0.57	1.42e-24	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs12476592	0.571	rs4671505	chr2:63644303	G/T	cg17519650	chr2:63277830	OTX1	-0.47	-5.26	-0.31	2.99e-7	Childhood ear infection;
CESC	cis	rs2180341	0.597	rs11154397	chr6:127646649	G/C	cg24812749	chr6:127587940	RNF146	0.6	8.02	0.44	3.42e-14	Breast cancer;
CESC	cis	rs9322193	0.607	rs12204653	chr6:150213021	C/G	cg01145232	chr6:150245071	RAET1G	0.5	6.22	0.36	1.92e-9	Lung cancer;
CESC	trans	rs11088226	0.581	rs2236430	chr21:33973408	A/G	cg09050820	chr6:167586206	TCP10L2	-0.49	-6.22	-0.36	1.97e-9	Gastritis;
CESC	cis	rs4819052	0.679	rs28623526	chr21:46712324	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.84	12.62	0.61	6.8e-29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs16854884	0.586	rs6782789	chr3:143746691	G/A	cg06585982	chr3:143692056	C3orf58	0.51	6.92	0.39	3.46e-11	Economic and political preferences (feminism/equality);
CESC	cis	rs3806843	0.619	rs2569160	chr5:140028774	T/C	cg16179182	chr5:140090404	VTRNA1-1	0.42	5.45	0.32	1.17e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs858239	0.932	rs858272	chr7:23276785	A/G	cg23682824	chr7:23144976	KLHL7	0.47	6.37	0.36	8.19e-10	Cerebrospinal fluid biomarker levels;
CESC	cis	rs8103278	0.507	rs2041975	chr19:46238555	T/C	cg06577658	chr19:46296270	DMWD	0.42	5.03	0.3	9.2e-7	Coronary artery disease;
CESC	cis	rs7412746	0.611	rs12410869	chr1:150856153	G/T	cg22823121	chr1:150693482	HORMAD1	0.39	5.47	0.32	1.05e-7	Melanoma;
CESC	cis	rs853679	0.517	rs3173443	chr6:28137027	T/G	cg20151795	chr6:28129481	ZNF389	0.41	5.3	0.31	2.46e-7	Depression;
CESC	trans	rs1116547	0.531	rs73247445	chr5:112848230	G/A	cg10115368	chr14:100435663	NA	0.52	6.13	0.35	3.21e-9	Cerebral amyloid angiopathy;
CESC	cis	rs4654899	0.772	rs61778530	chr1:21087363	G/C	cg05370193	chr1:21551575	ECE1	0.34	5.04	0.3	8.63e-7	Superior frontal gyrus grey matter volume;
CESC	cis	rs6061231	0.798	rs2427308	chr20:60969451	C/T	cg22601191	chr20:60968625	CABLES2	0.53	6.24	0.36	1.73e-9	Colorectal cancer;
CESC	cis	rs3741798	0.908	rs61922046	chr12:12495675	A/T	cg08615371	chr12:12503544	MANSC1	0.86	6.13	0.35	3.12e-9	Cerebrospinal fluid biomarker levels;
CESC	cis	rs6893300	0.785	rs6887507	chr5:179186237	A/G	cg14593053	chr5:179126677	CANX	-0.49	-5.79	-0.34	1.94e-8	Resting heart rate;
CESC	cis	rs225245	0.782	rs178649	chr17:33908197	C/G	cg05299278	chr17:33885742	SLFN14	0.36	5.18	0.3	4.4e-7	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
CESC	cis	rs10089	1.000	rs17764954	chr5:127514436	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.76	9.61	0.51	5.97e-19	Ileal carcinoids;
CESC	cis	rs17764205	0.777	rs10424519	chr19:3253532	C/G	cg02612712	chr19:3985498	EEF2	-0.63	-5.17	-0.3	4.69e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs2070488	0.775	rs6599208	chr3:38558104	A/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.78	-12.57	-0.61	9.53e-29	Electrocardiographic conduction measures;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg24528297	chr14:103995361	TRMT61A	-0.43	-6.0	-0.35	6.29e-9	Gambling;
CESC	cis	rs6061231	0.505	rs13037253	chr20:60928724	G/A	cg22307297	chr20:60903441	LAMA5	0.38	5.26	0.31	3.03e-7	Colorectal cancer;
CESC	cis	rs7772486	0.686	rs6933161	chr6:146081369	G/A	cg05347473	chr6:146136440	FBXO30	-0.52	-6.86	-0.39	4.95e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7659604	0.702	rs6826506	chr4:122710865	T/G	cg20573242	chr4:122745356	CCNA2	0.54	6.55	0.37	3.06e-10	Type 2 diabetes;
CESC	cis	rs9287719	0.967	rs12692417	chr2:10745718	C/G	cg02196655	chr2:10830764	NOL10	-0.38	-5.78	-0.33	2.05e-8	Prostate cancer;
CESC	cis	rs2228479	0.850	rs3785281	chr16:89824263	G/C	cg00800038	chr16:89945340	TCF25	-0.92	-7.67	-0.43	3.37e-13	Skin colour saturation;
CESC	cis	rs4908768	0.501	rs7530745	chr1:8557691	A/C	cg00120948	chr1:8484417	RERE	-0.34	-5.29	-0.31	2.61e-7	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
CESC	cis	rs597539	0.652	rs686877	chr11:68637169	G/A	cg18350739	chr11:68623251	NA	-0.46	-7.02	-0.4	1.88e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs561341	1.000	rs564714	chr17:30318404	C/T	cg12193833	chr17:30244370	NA	-0.76	-6.95	-0.39	2.87e-11	Hip circumference adjusted for BMI;
CESC	cis	rs2832077	0.506	rs2832085	chr21:30155258	G/T	cg24692254	chr21:30365293	RNF160	-0.49	-5.86	-0.34	1.34e-8	Cognitive test performance;
CESC	cis	rs1707322	0.752	rs11211146	chr1:46109794	T/C	cg06784218	chr1:46089804	CCDC17	0.4	7.04	0.4	1.69e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs3126085	0.935	rs6587666	chr1:152296863	C/T	cg03465714	chr1:152285911	FLG	0.5	5.71	0.33	2.96e-8	Atopic dermatitis;
CESC	cis	rs950776	0.507	rs12912673	chr15:78810216	T/C	cg24631222	chr15:78858424	CHRNA5	-0.4	-5.09	-0.3	6.79e-7	Sudden cardiac arrest;
CESC	cis	rs7666738	0.861	rs28821920	chr4:98962743	T/C	cg18180107	chr4:99064573	C4orf37	0.4	5.14	0.3	5.26e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg15369419	chr2:207945905	KLF7	0.48	6.3	0.36	1.21e-9	Fibrinogen levels;
CESC	cis	rs4474465	0.790	rs10751295	chr11:78266047	T/A	cg27205649	chr11:78285834	NARS2	0.44	5.65	0.33	4.22e-8	Alzheimer's disease (survival time);
CESC	cis	rs6860806	0.661	rs2136187	chr5:131577894	T/C	cg18301423	chr5:131593218	PDLIM4	0.38	5.54	0.32	7.36e-8	Breast cancer;
CESC	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	10.24	0.53	6.03e-21	Prudent dietary pattern;
CESC	cis	rs7927771	1.000	rs12363232	chr11:47623890	C/T	cg18512352	chr11:47633146	NA	-0.6	-9.08	-0.49	2.54e-17	Subjective well-being;
CESC	cis	rs12497850	0.897	rs6781790	chr3:49044767	C/T	cg07636037	chr3:49044803	WDR6	1.05	19.61	0.77	1.63e-53	Parkinson's disease;
CESC	cis	rs616402	0.527	rs11121581	chr1:10577740	A/G	cg20482658	chr1:10539492	PEX14	-0.29	-5.94	-0.34	8.75e-9	Breast size;
CESC	cis	rs9733	0.596	rs7538493	chr1:150655421	T/C	cg04414720	chr1:150670196	GOLPH3L	0.63	9.01	0.48	4.11e-17	Tonsillectomy;
CESC	cis	rs4665809	0.759	rs62128394	chr2:26364026	T/G	cg27170947	chr2:26402098	FAM59B	0.73	8.33	0.46	4.5e-15	Gut microbiome composition (summer);
CESC	cis	rs4930561	0.714	rs7950452	chr11:67962407	C/A	cg16338278	chr11:67432957	ALDH3B2	0.42	5.27	0.31	2.77e-7	Breast cancer in childhood cancer survivors;IgG glycosylation;
CESC	cis	rs2479724	0.901	rs6458244	chr6:41790455	C/T	cg08135965	chr6:41755394	TOMM6	-0.43	-5.87	-0.34	1.29e-8	Menarche (age at onset);
CESC	cis	rs858239	0.601	rs6969733	chr7:23168377	T/C	cg23682824	chr7:23144976	KLHL7	0.54	7.37	0.41	2.14e-12	Cerebrospinal fluid biomarker levels;
CESC	cis	rs9322193	0.923	rs55849538	chr6:149956466	T/C	cg07701084	chr6:150067640	NUP43	0.42	5.71	0.33	3.08e-8	Lung cancer;
CESC	cis	rs11122272	0.735	rs2749716	chr1:231486908	T/C	cg06096015	chr1:231504339	EGLN1	0.42	6.05	0.35	4.99e-9	Hemoglobin concentration;
CESC	trans	rs801193	0.805	rs12532355	chr7:66070584	C/G	cg26939375	chr7:64535504	NA	-0.54	-7.43	-0.42	1.52e-12	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10451977	chr15:45507901	NA	-0.66	-7.4	-0.41	1.81e-12	Gut microbiome composition (summer);
CESC	trans	rs35110281	0.591	rs86139	chr21:44932802	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.49	6.62	0.38	2.03e-10	Mean corpuscular volume;
CESC	cis	rs2276314	0.857	rs28396546	chr18:33639024	T/C	cg19628046	chr18:33552617	C18orf21	0.5	5.49	0.32	9.61e-8	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs11997175	0.624	rs4733175	chr8:33679744	T/A	ch.8.33884649F	chr8:33765107	NA	0.57	7.4	0.41	1.84e-12	Body mass index;
CESC	cis	rs7552404	0.731	rs931507	chr1:76401577	G/A	cg22875332	chr1:76189707	ACADM	-0.54	-5.79	-0.34	1.94e-8	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs7811142	0.943	rs73403312	chr7:100024153	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.01	9.85	0.52	1.05e-19	Platelet count;
CESC	trans	rs1728785	1.000	rs8058145	chr16:68584090	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.61	7.48	0.42	1.11e-12	Ulcerative colitis;
CESC	cis	rs1348850	0.513	rs6730406	chr2:178492722	C/T	cg22681709	chr2:178499509	PDE11A	-0.41	-5.69	-0.33	3.41e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs7845219	0.544	rs6987400	chr8:95921295	T/C	cg23172400	chr8:95962367	TP53INP1	-0.37	-6.78	-0.38	7.89e-11	Type 2 diabetes;
CESC	cis	rs11792861	0.926	rs72607172	chr9:111876523	A/G	cg05043794	chr9:111880884	C9orf5	-0.42	-6.94	-0.39	3.07e-11	Menarche (age at onset);
CESC	cis	rs514406	0.793	rs12402415	chr1:53218539	G/T	cg25767906	chr1:53392781	SCP2	0.43	5.99	0.35	6.77e-9	Monocyte count;
CESC	cis	rs8067545	0.611	rs12603372	chr17:20181566	C/T	cg13482628	chr17:19912719	NA	0.42	5.54	0.32	7.4e-8	Schizophrenia;
CESC	cis	rs858239	0.670	rs6967526	chr7:23159241	C/A	cg27449745	chr7:23145252	KLHL7	-0.48	-6.31	-0.36	1.16e-9	Cerebrospinal fluid biomarker levels;
CESC	cis	rs9399401	0.601	rs9321870	chr6:142800758	A/T	cg04461802	chr6:142623433	GPR126	0.41	6.24	0.36	1.72e-9	Chronic obstructive pulmonary disease;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg18040997	chr19:47551898	TMEM160	0.48	6.26	0.36	1.54e-9	Systemic lupus erythematosus;
CESC	cis	rs634534	0.561	rs613924	chr11:65769295	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.75	10.97	0.56	2.48e-23	Sum eosinophil basophil counts;Eosinophil counts;
CESC	cis	rs13191362	1.000	rs4260737	chr6:163137746	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.09	11.08	0.56	1.09e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	trans	rs13205180	0.550	rs4711997	chr6:51984771	C/A	cg14179581	chr1:50881502	NA	-0.28	-6.09	-0.35	4.05e-9	Diastolic blood pressure;
CESC	cis	rs35110281	0.840	rs7276633	chr21:45078800	C/T	cg04455712	chr21:45112962	RRP1B	0.39	5.9	0.34	1.08e-8	Mean corpuscular volume;
CESC	cis	rs8031584	0.560	rs1056118	chr15:31203786	G/A	cg08704250	chr15:31115839	NA	0.64	8.95	0.48	6.48e-17	Huntington's disease progression;
CESC	cis	rs7147624	0.882	rs7141367	chr14:65938641	C/T	cg03016385	chr14:66212404	NA	-0.49	-5.11	-0.3	6.05e-7	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs7605378	0.528	rs1704191	chr2:200816393	C/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.5	5.52	0.32	8.07e-8	Osteoporosis;
CESC	cis	rs17209837	0.607	rs45553044	chr7:87085613	A/G	cg00919237	chr7:87102261	ABCB4	-0.51	-6.58	-0.37	2.45e-10	Gallbladder cancer;
CESC	cis	rs12701220	0.948	rs12690826	chr7:1081618	A/G	cg26769984	chr7:1090371	C7orf50	0.66	7.42	0.41	1.57e-12	Bronchopulmonary dysplasia;
CESC	cis	rs3087591	0.960	rs9903754	chr17:29634468	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.41	-5.05	-0.3	8.18e-7	Hip circumference;
CESC	cis	rs367943	0.901	rs171180	chr5:112817093	A/C	cg12552261	chr5:112820674	MCC	-0.62	-7.78	-0.43	1.58e-13	Type 2 diabetes;
CESC	cis	rs8031584	0.958	rs35256769	chr15:31237776	G/A	cg14298792	chr15:30685198	CHRFAM7A	-0.45	-5.39	-0.31	1.55e-7	Huntington's disease progression;
CESC	cis	rs6540559	0.543	rs664097	chr1:210422179	C/T	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.54	6.11	0.35	3.53e-9	Cleft lip with or without cleft palate;
CESC	cis	rs4730250	0.670	rs9641380	chr7:106868151	C/G	cg02696742	chr7:106810147	HBP1	-0.53	-5.08	-0.3	7.18e-7	Osteoarthritis;
CESC	cis	rs2228479	0.850	rs62052212	chr16:89981960	G/A	cg14709524	chr16:89940631	TCF25	0.85	6.08	0.35	4.28e-9	Skin colour saturation;
CESC	cis	rs4853012	0.838	rs61521879	chr2:74346208	T/C	cg19729930	chr2:74357872	NA	0.85	12.96	0.62	4.55e-30	Gestational age at birth (maternal effect);
CESC	cis	rs9611565	0.694	rs5758324	chr22:41787950	G/T	cg06481639	chr22:41940642	POLR3H	-0.43	-5.12	-0.3	5.95e-7	Vitiligo;
CESC	cis	rs7312933	0.670	rs2406568	chr12:42552297	G/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.48	6.25	0.36	1.64e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs6089829	0.692	rs6122349	chr20:61664096	T/C	cg03213289	chr20:61660250	NA	0.42	5.68	0.33	3.57e-8	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg06424138	chr8:102701376	NCALD	0.49	6.35	0.36	9.26e-10	Fibrinogen levels;
CESC	cis	rs17376456	0.877	rs13173952	chr5:93307557	A/T	cg25358565	chr5:93447407	FAM172A	1.08	10.73	0.55	1.54e-22	Diabetic retinopathy;
CESC	cis	rs2836974	0.602	rs2037925	chr21:40699931	C/T	cg11644478	chr21:40555479	PSMG1	-0.8	-11.9	-0.59	1.9e-26	Cognitive function;
CESC	cis	rs317689	0.718	rs315122	chr12:69771073	G/T	cg14784868	chr12:69753453	YEATS4	0.65	7.63	0.42	4.24e-13	Response to diuretic therapy;
CESC	cis	rs4237845	0.591	rs10431506	chr12:58311524	G/A	cg02175503	chr12:58329896	NA	0.8	10.49	0.54	9.11e-22	Intelligence (multi-trait analysis);
CESC	trans	rs747782	0.528	rs4370963	chr11:48433943	C/G	cg15704280	chr7:45808275	SEPT13	0.68	6.21	0.36	2.09e-9	Intraocular pressure;
CESC	trans	rs61931739	0.534	rs10844816	chr12:34248533	C/A	cg26384229	chr12:38710491	ALG10B	0.64	9.16	0.49	1.47e-17	Morning vs. evening chronotype;
CESC	cis	rs10751667	0.666	rs10902249	chr11:958566	C/T	cg20946044	chr11:1010712	AP2A2	0.42	5.94	0.34	8.97e-9	Alzheimer's disease (late onset);
CESC	cis	rs4727027	0.651	rs12704068	chr7:148856153	T/C	cg23158103	chr7:148848205	ZNF398	-0.36	-5.35	-0.31	1.87e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs763014	0.931	rs3752568	chr16:628302	A/G	cg07256732	chr16:621771	PIGQ	-0.3	-5.13	-0.3	5.63e-7	Height;
CESC	cis	rs4949454	0.542	rs10914457	chr1:32094261	A/C	cg13919466	chr1:32135498	COL16A1	0.43	7.13	0.4	9.75e-12	Intelligence (multi-trait analysis);
CESC	cis	rs12477438	0.765	rs6754843	chr2:99680485	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.64	-8.73	-0.47	2.94e-16	Chronic sinus infection;
CESC	cis	rs3105593	1.000	rs3131585	chr15:50845796	C/G	cg08437265	chr15:50716283	USP8	0.41	5.35	0.31	1.94e-7	QT interval;
CESC	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg11494091	chr17:61959527	GH2	-0.68	-11.19	-0.57	4.74e-24	Prudent dietary pattern;
CESC	cis	rs12142240	0.698	rs72677599	chr1:46834251	G/A	cg10495392	chr1:46806563	NSUN4	0.58	6.24	0.36	1.68e-9	Menopause (age at onset);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg12898849	chr1:178511736	C1orf220	-0.46	-6.14	-0.35	3.04e-9	Fibrinogen levels;
CESC	cis	rs9815354	0.812	rs73071304	chr3:41797504	G/C	cg03022575	chr3:42003672	ULK4	0.72	6.35	0.36	9.1e-10	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs597539	0.731	rs664229	chr11:68624483	C/G	cg18350739	chr11:68623251	NA	-0.44	-6.44	-0.37	5.72e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs1799949	0.929	rs799906	chr17:41278116	T/C	cg25072359	chr17:41440525	NA	0.48	7.1	0.4	1.15e-11	Menopause (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04946948	chr11:71196653	NADSYN1	-0.67	-8.11	-0.45	1.87e-14	Gut microbiome composition (summer);
CESC	cis	rs1218582	0.772	rs10908445	chr1:154849590	A/G	cg16680214	chr1:154839983	KCNN3	0.45	7.09	0.4	1.21e-11	Prostate cancer;
CESC	cis	rs344364	0.518	rs1657129	chr16:1945826	G/A	cg03013636	chr16:1946785	NA	0.48	6.62	0.38	2.02e-10	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs873946	0.648	rs12783354	chr10:134557235	T/A	cg18305652	chr10:134549665	INPP5A	0.48	6.75	0.38	9.22e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs2637266	0.967	rs2579760	chr10:78321768	A/C	cg18941641	chr10:78392320	NA	0.4	7.36	0.41	2.38e-12	Pulmonary function;
CESC	cis	rs5769765	0.908	rs138867	chr22:50207703	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.46	5.07	0.3	7.37e-7	Schizophrenia;
CESC	cis	rs1729951	0.575	rs361243	chr3:136697786	C/T	cg04103450	chr3:136751342	NA	0.4	5.35	0.31	1.94e-7	Neuroticism;
CESC	cis	rs8038465	0.622	rs62004587	chr15:73859016	A/C	cg15420318	chr15:73925796	NPTN	0.47	6.55	0.37	2.96e-10	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs1499972	0.887	rs6799997	chr3:117520297	A/C	cg07612923	chr3:117604196	NA	0.72	6.36	0.36	8.93e-10	Schizophrenia;
CESC	cis	rs62064224	0.530	rs8073708	chr17:30680493	T/C	cg18200150	chr17:30822561	MYO1D	0.39	5.14	0.3	5.45e-7	Schizophrenia;
CESC	cis	rs13040088	1.000	rs2295000	chr20:61536938	A/G	cg23096297	chr20:61557774	DIDO1	-0.96	-10.72	-0.55	1.67e-22	Menopause (age at onset);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg23411981	chr14:105940377	CRIP2	-0.45	-6.08	-0.35	4.24e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs6089584	0.854	rs2380146	chr20:60632233	C/T	cg06108461	chr20:60628389	TAF4	-0.89	-14.08	-0.65	5.56e-34	Body mass index;
CESC	cis	rs10911232	0.507	rs10737239	chr1:183030170	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.87	13.57	0.64	3.18e-32	Hypertriglyceridemia;
CESC	cis	rs1862618	0.756	rs13356762	chr5:56110992	G/T	cg12311346	chr5:56204834	C5orf35	-0.7	-8.58	-0.47	8.33e-16	Initial pursuit acceleration;
CESC	cis	rs9467711	0.606	rs2073530	chr6:26375243	T/C	cg14345882	chr6:26364793	BTN3A2	0.63	6.39	0.37	7.52e-10	Autism spectrum disorder or schizophrenia;
CESC	cis	rs1728785	1.000	rs11075680	chr16:68565700	G/C	cg02972257	chr16:68554789	NA	-0.55	-6.37	-0.36	8.21e-10	Ulcerative colitis;
CESC	cis	rs6032067	1.000	rs13041304	chr20:43811697	G/A	cg10761708	chr20:43804764	PI3	0.54	6.5	0.37	3.97e-10	Blood protein levels;
CESC	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.38	5.15	0.3	5.18e-7	Lymphocyte counts;
CESC	cis	rs9513593	0.901	rs7330165	chr13:99889427	C/T	cg21788972	chr13:99853209	UBAC2	-0.59	-6.75	-0.38	9.46e-11	Psoriasis;
CESC	cis	rs35110281	0.744	rs162373	chr21:44927107	C/A	cg21573476	chr21:45109991	RRP1B	0.41	5.9	0.34	1.09e-8	Mean corpuscular volume;
CESC	cis	rs7666738	0.830	rs1534319	chr4:98964804	T/C	cg17366294	chr4:99064904	C4orf37	0.6	8.52	0.46	1.2e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10838687	0.800	rs10838686	chr11:47311367	G/T	cg25783544	chr11:47291846	MADD	0.56	6.44	0.37	5.67e-10	Proinsulin levels;
CESC	cis	rs9868809	0.772	rs9841602	chr3:48713570	A/G	cg03060546	chr3:49711283	APEH	-0.63	-5.6	-0.33	5.46e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs6762	0.748	rs1130663	chr11:837582	G/A	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.76	-10.28	-0.53	4.3e-21	Mean platelet volume;
CESC	cis	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07148535	chr4:100010082	ADH5	0.61	6.57	0.37	2.68e-10	Gut microbiome composition (summer);
CESC	cis	rs4417704	0.525	rs12694990	chr2:241883621	C/G	cg05025159	chr2:241905733	NA	0.35	5.06	0.3	7.71e-7	Joint mobility (Beighton score);
CESC	cis	rs17711722	0.565	rs73372653	chr7:65442795	A/T	cg18876405	chr7:65276391	NA	0.46	5.9	0.34	1.11e-8	Calcium levels;
CESC	cis	rs35306767	0.855	rs34251037	chr10:867884	C/T	cg20503657	chr10:835505	NA	1.09	10.01	0.52	3.32e-20	Eosinophil percentage of granulocytes;
CESC	trans	rs61931739	0.500	rs7977186	chr12:34431486	C/G	cg26384229	chr12:38710491	ALG10B	0.69	10.37	0.54	2.3e-21	Morning vs. evening chronotype;
CESC	cis	rs9916302	0.904	rs2338797	chr17:37548241	G/A	cg00129232	chr17:37814104	STARD3	0.56	7.31	0.41	3.17e-12	Glomerular filtration rate (creatinine);
CESC	cis	rs875971	0.825	rs4587224	chr7:65736182	G/A	cg12463550	chr7:65579703	CRCP	-0.45	-5.72	-0.33	2.86e-8	Aortic root size;
CESC	cis	rs4253772	0.591	rs6008362	chr22:46652737	G/A	cg24881330	chr22:46731750	TRMU	0.89	10.15	0.53	1.19e-20	LDL cholesterol;Cholesterol, total;
CESC	cis	rs2228479	0.717	rs1007932	chr16:89838541	C/T	cg14709524	chr16:89940631	TCF25	0.66	5.51	0.32	8.35e-8	Skin colour saturation;
CESC	cis	rs1670533	1.000	rs10084888	chr4:1053814	G/T	cg27284194	chr4:1044797	NA	0.46	5.86	0.34	1.35e-8	Recombination rate (females);
CESC	cis	rs798554	0.757	rs1182172	chr7:2878103	G/A	cg19717773	chr7:2847554	GNA12	-0.58	-7.89	-0.44	7.78e-14	Height;
CESC	cis	rs3820068	0.603	rs6696286	chr1:15968770	C/T	cg13390004	chr1:15929781	NA	0.38	6.01	0.35	6.03e-9	Systolic blood pressure;
CESC	cis	rs9905704	0.846	rs372648	chr17:56736785	A/C	cg12560992	chr17:57184187	TRIM37	0.62	7.73	0.43	2.17e-13	Testicular germ cell tumor;
CESC	cis	rs473651	0.837	rs563458	chr2:239345613	T/A	cg18131467	chr2:239335373	ASB1	1.01	20.78	0.79	1.41e-57	Multiple system atrophy;
CESC	cis	rs7223966	0.960	rs11659013	chr17:61869559	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.74	0.38	9.84e-11	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs9309711	0.643	rs4535074	chr2:3481637	A/G	cg10845886	chr2:3471009	TTC15	-0.65	-9.01	-0.48	4.18e-17	Neurofibrillary tangles;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg26650007	chr19:14065157	DCAF15;PODNL1	0.38	6.1	0.35	3.8e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs589448	0.900	rs588493	chr12:69751986	G/A	cg14784868	chr12:69753453	YEATS4	0.91	14.57	0.67	1.05e-35	Cerebrospinal fluid biomarker levels;
CESC	cis	rs853679	0.517	rs4713137	chr6:28083521	C/G	cg20151795	chr6:28129481	ZNF389	0.45	5.87	0.34	1.29e-8	Depression;
CESC	cis	rs66887589	0.616	rs1052633	chr4:120215314	A/G	cg09307838	chr4:120376055	NA	0.67	9.36	0.5	3.47e-18	Diastolic blood pressure;
CESC	cis	rs17407555	0.520	rs4292327	chr4:9943700	G/A	cg00071950	chr4:10020882	SLC2A9	-0.59	-6.33	-0.36	1.05e-9	Schizophrenia (age at onset);
CESC	trans	rs35110281	0.811	rs9980185	chr21:45057905	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.54	6.82	0.39	6.32e-11	Mean corpuscular volume;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg04250904	chr19:12623422	ZNF709	0.48	6.79	0.38	7.45e-11	Fibrinogen levels;
CESC	cis	rs4253772	0.591	rs11704614	chr22:46691936	A/G	cg24881330	chr22:46731750	TRMU	0.73	5.24	0.31	3.32e-7	LDL cholesterol;Cholesterol, total;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg02621907	chr5:93954419	ANKRD32;C5orf36	0.46	5.99	0.35	6.65e-9	Gut microbiota (bacterial taxa);
CESC	trans	rs722599	0.748	rs20578	chr14:75367807	C/T	cg00095594	chr1:236228625	NID1	-0.4	-6.19	-0.36	2.31e-9	IgG glycosylation;
CESC	cis	rs2120019	1.000	rs8033837	chr15:75353975	A/C	cg17294928	chr15:75287854	SCAMP5	-0.65	-7.04	-0.4	1.67e-11	Blood trace element (Zn levels);
CESC	cis	rs10751667	0.600	rs1128419	chr11:1010750	G/A	cg06064525	chr11:970664	AP2A2	-0.33	-5.55	-0.32	7.1e-8	Alzheimer's disease (late onset);
CESC	cis	rs7666738	0.791	rs7660866	chr4:98961335	G/A	cg03676636	chr4:99064102	C4orf37	0.33	5.14	0.3	5.39e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9660992	0.710	rs1668873	chr1:205235990	G/A	cg00857998	chr1:205179979	DSTYK	0.46	5.25	0.31	3.08e-7	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs4819052	0.851	rs2236444	chr21:46678226	T/C	cg11663144	chr21:46675770	NA	-0.62	-9.45	-0.5	1.84e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs72634258	0.945	rs6577459	chr1:8100173	G/T	cg00042356	chr1:8021962	PARK7	0.76	6.78	0.38	7.86e-11	Inflammatory bowel disease;
CESC	cis	rs3015497	0.603	rs3015450	chr14:51072713	C/T	cg26011998	chr14:51135199	SAV1	-0.46	-5.22	-0.31	3.6e-7	Mean platelet volume;
CESC	cis	rs4727027	0.704	rs4727031	chr7:148908305	T/C	cg23583168	chr7:148888333	NA	-0.88	-14.24	-0.66	1.49e-34	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs11098499	0.780	rs12504773	chr4:120562149	G/C	cg09307838	chr4:120376055	NA	0.85	11.51	0.58	4.09e-25	Corneal astigmatism;
CESC	cis	rs7666738	0.830	rs4699595	chr4:99012827	A/G	cg03676636	chr4:99064102	C4orf37	0.33	5.16	0.3	4.86e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4555082	0.834	rs2735816	chr14:105721603	C/G	cg06808227	chr14:105710500	BRF1	0.65	7.61	0.42	4.82e-13	Mean platelet volume;Platelet distribution width;
CESC	cis	rs3091242	0.867	rs602052	chr1:25722206	T/C	cg27572855	chr1:25598939	RHD	0.43	7.23	0.41	5.06e-12	Erythrocyte sedimentation rate;
CESC	cis	rs1003719	0.715	rs2835657	chr21:38565064	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.6	-8.18	-0.45	1.19e-14	Eye color traits;
CESC	cis	rs4689388	0.926	rs10937718	chr4:6295217	T/C	cg25554036	chr4:6271136	WFS1	0.51	8.37	0.46	3.31e-15	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs9911578	0.900	rs4793593	chr17:56892699	C/G	cg12560992	chr17:57184187	TRIM37	-0.91	-15.27	-0.68	3.41e-38	Intelligence (multi-trait analysis);
CESC	cis	rs796364	0.616	rs2689765	chr2:200696352	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.56	5.37	0.31	1.74e-7	Schizophrenia;
CESC	cis	rs1577917	1.000	rs12213740	chr6:86656733	A/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.43	-5.61	-0.33	5.17e-8	Response to antipsychotic treatment;
CESC	cis	rs3741404	0.791	rs2282491	chr11:63918373	T/C	cg18225595	chr11:63971243	STIP1	0.68	9.54	0.51	9.82e-19	Platelet count;
CESC	cis	rs2361718	0.521	rs2361724	chr17:78099114	G/A	cg23534315	chr17:78082725	GAA	0.37	5.21	0.3	3.87e-7	Yeast infection;
CESC	cis	rs9906944	0.933	rs35051752	chr17:47089908	G/A	cg16584676	chr17:46985605	UBE2Z	-0.45	-5.09	-0.3	6.8e-7	Intelligence (multi-trait analysis);Body fat percentage;
CESC	cis	rs9863	0.828	rs7311969	chr12:124470333	C/T	cg17562584	chr12:124393655	DNAH10	-0.31	-5.28	-0.31	2.75e-7	White blood cell count;
CESC	cis	rs9296736	1.000	rs9296736	chr6:53924697	A/G	cg04374786	chr6:53939321	C6orf142	0.33	5.09	0.3	6.69e-7	Liver enzyme levels (gamma-glutamyl transferase);
CESC	trans	rs2727020	0.796	rs7131672	chr11:49274421	A/C	cg15704280	chr7:45808275	SEPT13	0.78	10.0	0.52	3.38e-20	Coronary artery disease;
CESC	cis	rs262150	0.851	rs2527224	chr7:158769198	G/A	cg09640425	chr7:158790006	NA	-0.35	-5.25	-0.31	3.16e-7	Facial morphology (factor 20);
CESC	cis	rs17818399	1.000	rs17818399	chr2:46826026	A/C	cg06386533	chr2:46925753	SOCS5	0.49	5.72	0.33	2.91e-8	Height;
CESC	cis	rs1729951	0.575	rs10935213	chr3:136693459	A/G	cg25687071	chr3:136751404	NA	0.4	5.3	0.31	2.47e-7	Neuroticism;
CESC	cis	rs10504229	1.000	rs112272435	chr8:58170371	A/G	cg24829409	chr8:58192753	C8orf71	-0.76	-9.92	-0.52	6.14e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs12701220	0.842	rs10236293	chr7:1032637	G/A	cg26769984	chr7:1090371	C7orf50	0.6	6.84	0.39	5.5e-11	Bronchopulmonary dysplasia;
CESC	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg22535103	chr8:58192502	C8orf71	-0.92	-10.19	-0.53	8.81e-21	Developmental language disorder (linguistic errors);
CESC	cis	rs68170813	0.570	rs7794915	chr7:106849393	C/T	cg02696742	chr7:106810147	HBP1	-0.58	-5.19	-0.3	4.26e-7	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12550816	chr19:47163979	DACT3	0.58	6.88	0.39	4.2e-11	Gut microbiome composition (summer);
CESC	cis	rs7772486	0.790	rs3924498	chr6:146233338	A/T	cg23711669	chr6:146136114	FBXO30	-0.94	-13.73	-0.64	9.31e-33	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs12586317	0.547	rs77262907	chr14:35495734	C/G	cg05294307	chr14:35346193	BAZ1A	-0.51	-5.4	-0.31	1.49e-7	Psoriasis;
CESC	cis	rs2191566	0.959	rs7255623	chr19:44510906	G/C	cg20607764	chr19:44506953	ZNF230	-0.6	-7.8	-0.43	1.4e-13	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs752092	1.000	rs11636578	chr15:101787969	T/C	cg19997662	chr15:101784653	CHSY1	-0.57	-7.73	-0.43	2.24e-13	Corneal structure;
CESC	cis	rs12079745	0.793	rs12067139	chr1:169254507	C/T	cg09363564	chr1:169337483	NME7;BLZF1	-0.94	-6.2	-0.36	2.13e-9	QT interval;
CESC	cis	rs2898681	0.519	rs73814886	chr4:53733251	C/T	cg00791764	chr4:53727839	RASL11B	0.42	5.03	0.3	8.85e-7	Optic nerve measurement (cup area);
CESC	cis	rs200895692	1	rs200895692	chr1:43421956	CGCCTGTAATCCCAG/C	cg12656391	chr1:43425156	SLC2A1	-0.57	-6.36	-0.36	8.67e-10	Monocyte count;
CESC	cis	rs514406	0.929	rs554301	chr1:53321948	A/T	cg08736216	chr1:53307985	ZYG11A	0.4	6.73	0.38	1.07e-10	Monocyte count;
CESC	cis	rs2197308	0.565	rs12809769	chr12:37909968	C/T	cg26384229	chr12:38710491	ALG10B	0.75	11.12	0.56	8.21e-24	Morning vs. evening chronotype;
CESC	cis	rs1707322	0.963	rs10789478	chr1:46350506	C/T	cg05343316	chr1:45956843	TESK2	0.49	5.94	0.34	8.87e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9291683	0.554	rs7668175	chr4:10125782	T/C	cg11266682	chr4:10021025	SLC2A9	-0.48	-8.58	-0.47	8.08e-16	Bone mineral density;
CESC	cis	rs9322193	0.923	rs62439842	chr6:149996983	G/A	cg07701084	chr6:150067640	NUP43	0.45	6.27	0.36	1.42e-9	Lung cancer;
CESC	cis	rs10779751	1.000	rs7524202	chr1:11297762	T/C	cg08854313	chr1:11322531	MTOR	0.79	10.78	0.55	1.06e-22	Body mass index;
CESC	cis	rs3820928	0.874	rs10183633	chr2:227887828	A/G	cg11843606	chr2:227700838	RHBDD1	-0.45	-5.93	-0.34	9.66e-9	Pulmonary function;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg19627653	chr12:133365649	GOLGA3	-0.45	-6.05	-0.35	4.97e-9	Systemic lupus erythematosus;
CESC	cis	rs67311347	1.000	rs2168111	chr3:40395325	T/G	cg09455208	chr3:40491958	NA	0.46	8.08	0.44	2.35e-14	Renal cell carcinoma;
CESC	cis	rs854765	0.551	rs8070748	chr17:17859421	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.59	8.26	0.45	7.24e-15	Total body bone mineral density;
CESC	cis	rs6674176	0.935	rs4314918	chr1:44377503	G/A	cg12908607	chr1:44402522	ARTN	-0.48	-6.67	-0.38	1.52e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs7772486	0.597	rs9285508	chr6:146262697	G/T	cg23711669	chr6:146136114	FBXO30	-0.87	-9.58	-0.51	7.49e-19	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4888262	0.545	rs4243108	chr16:74692453	A/G	cg01733217	chr16:74700730	RFWD3	-0.91	-12.31	-0.6	7.71e-28	Testicular germ cell tumor;
CESC	trans	rs9858542	1.000	rs4283605	chr3:49678651	A/G	cg21659725	chr3:3221576	CRBN	-0.53	-6.38	-0.36	7.75e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs7666738	0.570	rs1869351	chr4:99077286	T/C	cg17366294	chr4:99064904	C4orf37	0.45	6.03	0.35	5.39e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1862618	0.756	rs832548	chr5:56183637	G/C	cg22800045	chr5:56110881	MAP3K1	0.81	9.66	0.51	4.1e-19	Initial pursuit acceleration;
CESC	cis	rs17345786	0.906	rs72944107	chr3:101197190	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.46	-5.12	-0.3	5.81e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2652822	0.525	rs1910094	chr15:63485527	G/C	cg02713581	chr15:63449717	RPS27L	0.5	6.44	0.37	5.72e-10	Metabolic traits;
CESC	cis	rs7927771	0.524	rs11039377	chr11:47789776	C/T	cg20307385	chr11:47447363	PSMC3	0.62	8.69	0.47	3.96e-16	Subjective well-being;
CESC	cis	rs6748734	1.000	rs4675863	chr2:241830763	A/T	cg04034577	chr2:241836375	C2orf54	-0.48	-8.29	-0.45	5.55e-15	Urinary metabolites;
CESC	cis	rs7208859	0.673	rs11649765	chr17:29233888	T/A	cg19761014	chr17:28927070	LRRC37B2	0.73	5.77	0.33	2.22e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs55883249	0.957	rs17453675	chr2:9754407	A/G	cg23886495	chr2:9695866	ADAM17	0.65	5.89	0.34	1.19e-8	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
CESC	cis	rs7923609	0.967	rs7896783	chr10:65162153	G/A	cg01631684	chr10:65280961	REEP3	-0.44	-5.48	-0.32	9.84e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs4699052	0.662	rs6848593	chr4:104250113	G/T	cg16532752	chr4:104119610	CENPE	-0.41	-5.85	-0.34	1.44e-8	Testicular germ cell tumor;
CESC	cis	rs1322639	0.575	rs9294966	chr6:169565318	G/T	cg03254818	chr6:169586852	NA	0.53	5.78	0.33	2.09e-8	Pulse pressure;
CESC	cis	rs11098499	0.954	rs35091806	chr4:120325529	G/A	cg09307838	chr4:120376055	NA	0.94	13.7	0.64	1.18e-32	Corneal astigmatism;
CESC	cis	rs7542091	0.748	rs2357231	chr1:210028454	A/C	cg22029157	chr1:209979665	IRF6	-0.48	-7.75	-0.43	2.03e-13	Monobrow;
CESC	trans	rs9325144	0.555	rs4882279	chr12:38688918	C/A	cg23762105	chr12:34175262	ALG10	-0.46	-6.15	-0.35	2.77e-9	Morning vs. evening chronotype;
CESC	cis	rs72945132	0.825	rs7941965	chr11:70213182	T/C	cg14191688	chr11:70257035	CTTN	0.43	5.38	0.31	1.62e-7	Coronary artery disease;
CESC	cis	rs6580649	0.941	rs60681522	chr12:48464195	T/C	cg24011408	chr12:48396354	COL2A1	-0.41	-5.27	-0.31	2.86e-7	Lung cancer;
CESC	cis	rs9584850	0.609	rs17574495	chr13:99155113	C/T	cg20750642	chr13:99100586	FARP1	-0.4	-5.58	-0.32	5.99e-8	Neuroticism;
CESC	cis	rs9486715	1.000	rs9486725	chr6:97061159	C/T	cg06623918	chr6:96969491	KIAA0776	-0.95	-14.42	-0.66	3.43e-35	Headache;
CESC	cis	rs4975709	0.610	rs1531994	chr5:1859297	T/C	cg19770292	chr5:1868693	NA	0.31	5.19	0.3	4.26e-7	Cardiovascular disease risk factors;
CESC	cis	rs1595825	0.891	rs80178661	chr2:198582442	A/G	cg00982548	chr2:198649783	BOLL	-0.49	-5.28	-0.31	2.69e-7	Ulcerative colitis;
CESC	cis	rs7607369	0.648	rs17470271	chr2:219651995	A/T	cg02176678	chr2:219576539	TTLL4	0.51	9.21	0.49	1.06e-17	Red blood cell count;Amyotrophic lateral sclerosis;
CESC	cis	rs753307	0.676	rs753308	chr19:49518575	C/T	cg20610492	chr19:49520450	LHB	0.36	5.87	0.34	1.27e-8	Blood protein levels;
CESC	cis	rs7945705	0.902	rs11042152	chr11:9020987	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.48	7.83	0.43	1.21e-13	Hemoglobin concentration;
CESC	cis	rs9309711	0.666	rs6723101	chr2:3484443	T/C	cg15541040	chr2:3486749	NA	-0.43	-5.38	-0.31	1.64e-7	Neurofibrillary tangles;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26790879	chr11:58939953	DTX4	0.62	7.06	0.4	1.47e-11	Gut microbiome composition (summer);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg13762887	chr9:131517731	ZER1	0.45	6.59	0.38	2.4e-10	Fibrinogen levels;
CESC	cis	rs7618915	0.501	rs34754793	chr3:52629177	A/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.7	0.38	1.22e-10	Bipolar disorder;
CESC	cis	rs1595825	0.891	rs73054819	chr2:198625744	G/T	cg00982548	chr2:198649783	BOLL	-0.47	-5.08	-0.3	7.12e-7	Ulcerative colitis;
CESC	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg23131131	chr22:24373011	LOC391322	-0.68	-9.31	-0.5	5.2e-18	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs7811142	0.830	rs11765869	chr7:99964789	T/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.07	10.34	0.54	2.91e-21	Platelet count;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg05598539	chr7:128695331	TNPO3;LOC286016	-0.49	-7.04	-0.4	1.68e-11	Gambling;
CESC	cis	rs12497850	0.931	rs9311434	chr3:48884147	T/C	cg06212747	chr3:49208901	KLHDC8B	0.67	9.18	0.49	1.28e-17	Parkinson's disease;
CESC	cis	rs2933343	0.700	rs1680779	chr3:128614770	G/A	cg24203234	chr3:128598194	ACAD9	0.42	5.55	0.32	6.75e-8	IgG glycosylation;
CESC	cis	rs2425143	1.000	rs6058304	chr20:34299851	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.6	5.14	0.3	5.33e-7	Blood protein levels;
CESC	cis	rs11122272	0.735	rs2749708	chr1:231529610	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.56	-7.66	-0.43	3.45e-13	Hemoglobin concentration;
CESC	cis	rs561341	0.883	rs7219239	chr17:30212016	A/G	cg00745463	chr17:30367425	LRRC37B	0.58	5.72	0.33	2.86e-8	Hip circumference adjusted for BMI;
CESC	cis	rs6570726	0.935	rs366621	chr6:145861275	A/G	cg23711669	chr6:146136114	FBXO30	0.79	11.57	0.58	2.41e-25	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs8060686	0.544	rs1124993	chr16:68114626	T/C	cg26727032	chr16:67993705	SLC12A4	-0.56	-6.61	-0.38	2.06e-10	HDL cholesterol;Metabolic syndrome;
CESC	trans	rs10506458	1.000	rs1495013	chr12:63428188	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.33	-17.74	-0.74	6.16e-47	Hemostatic factors and hematological phenotypes;
CESC	cis	rs1865721	0.728	rs8087297	chr18:73136221	T/A	cg26385618	chr18:73139727	C18orf62	-0.49	-7.96	-0.44	5.22e-14	Intelligence;
CESC	cis	rs12477438	0.520	rs6542866	chr2:99764592	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.78	13.4	0.64	1.33e-31	Chronic sinus infection;
CESC	cis	rs35110281	0.811	rs4819264	chr21:45017349	G/T	cg01579765	chr21:45077557	HSF2BP	-0.56	-9.34	-0.5	4.18e-18	Mean corpuscular volume;
CESC	cis	rs477692	0.905	rs509041	chr10:131424948	A/G	cg05714579	chr10:131428358	MGMT	0.58	8.4	0.46	2.66e-15	Response to temozolomide;
CESC	cis	rs12541635	0.739	rs1896915	chr8:107083520	G/T	cg10147462	chr8:107024639	NA	0.36	5.06	0.3	7.86e-7	Age of smoking initiation;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg08647641	chr7:91763896	CYP51A1	-0.46	-6.18	-0.35	2.47e-9	Ulcerative colitis;
CESC	cis	rs4974559	0.947	rs28418481	chr4:1330975	C/G	cg02980000	chr4:1222292	CTBP1	0.64	7.58	0.42	5.76e-13	Systolic blood pressure;
CESC	trans	rs60843830	0.964	rs7584915	chr2:264227	G/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.66	8.3	0.45	5.3e-15	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs853679	0.574	rs1233705	chr6:28166447	C/G	cg17949981	chr6:28129498	ZNF389	0.43	5.58	0.32	5.97e-8	Depression;
CESC	cis	rs3806843	0.733	rs801181	chr5:140092814	C/T	cg26395211	chr5:140044315	WDR55	0.45	6.04	0.35	5.08e-9	Depressive symptoms (multi-trait analysis);
CESC	cis	rs9911578	0.839	rs1871751	chr17:57190368	A/G	cg05425664	chr17:57184151	TRIM37	-0.5	-6.87	-0.39	4.59e-11	Intelligence (multi-trait analysis);
CESC	cis	rs7223966	1.000	rs9895920	chr17:61852719	T/C	cg11494091	chr17:61959527	GH2	0.38	5.32	0.31	2.26e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	trans	rs526821	0.595	rs517627	chr11:55356489	C/T	cg15704280	chr7:45808275	SEPT13	-0.52	-6.55	-0.37	2.99e-10	Pediatric bone mineral density (spine);
CESC	cis	rs3126085	1.000	rs3126092	chr1:152307955	T/A	cg03465714	chr1:152285911	FLG	0.43	5.22	0.31	3.62e-7	Atopic dermatitis;
CESC	cis	rs4862750	0.874	rs6822062	chr4:187895553	T/C	cg03452623	chr4:187889614	NA	-0.89	-16.23	-0.71	1.34e-41	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs863345	0.625	rs4609418	chr1:158464728	C/T	cg12129480	chr1:158549410	OR10X1	-0.35	-6.9	-0.39	3.83e-11	Pneumococcal bacteremia;
CESC	cis	rs2841277	0.708	rs10083490	chr14:105402418	A/G	cg14403583	chr14:105418241	AHNAK2	0.59	8.24	0.45	7.91e-15	Rheumatoid arthritis;
CESC	cis	rs2303745	0.589	rs751599	chr19:17396549	A/G	cg02221750	chr19:17393354	ANKLE1	-0.54	-6.5	-0.37	4.05e-10	Systemic lupus erythematosus;
CESC	cis	rs17376456	0.597	rs10064158	chr5:93095186	C/T	cg25358565	chr5:93447407	FAM172A	0.67	7.16	0.4	7.97e-12	Diabetic retinopathy;
CESC	cis	rs9611565	0.729	rs132902	chr22:41797758	A/G	cg06634786	chr22:41940651	POLR3H	-0.62	-6.85	-0.39	5.17e-11	Vitiligo;
CESC	cis	rs7923609	0.967	rs10761766	chr10:65190327	G/A	cg01631684	chr10:65280961	REEP3	-0.44	-5.48	-0.32	9.84e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs9863706	0.619	rs2118592	chr3:72504654	A/G	cg22685502	chr3:72496851	RYBP	-0.25	-5.28	-0.31	2.69e-7	Height;
CESC	cis	rs7085104	0.660	rs7902804	chr10:104585405	A/T	cg04362960	chr10:104952993	NT5C2	0.47	6.17	0.35	2.48e-9	Immature fraction of reticulocytes;Schizophrenia;
CESC	cis	rs9457247	0.905	rs453184	chr6:167387404	A/C	cg07741184	chr6:167504864	NA	0.31	5.53	0.32	7.87e-8	Crohn's disease;
CESC	cis	rs7762018	0.891	rs73242950	chr6:170144737	C/T	cg05834625	chr6:170176447	C6orf70	0.65	7.37	0.41	2.19e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs7772486	0.686	rs9376956	chr6:145949844	T/C	cg05347473	chr6:146136440	FBXO30	0.53	6.91	0.39	3.53e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4727027	0.800	rs10952796	chr7:148813138	G/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.42	5.23	0.31	3.44e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19871361	chr10:11505280	USP6NL	-0.53	-6.08	-0.35	4.25e-9	Gut microbiome composition (summer);
CESC	cis	rs11792861	0.926	rs75472294	chr9:111804239	G/A	cg13535736	chr9:111863775	C9orf5	-0.5	-6.6	-0.38	2.29e-10	Menarche (age at onset);
CESC	cis	rs4450798	0.649	rs4073434	chr3:13787501	C/T	cg23332027	chr3:13681764	NA	0.38	5.14	0.3	5.41e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs3008870	1.000	rs58680688	chr1:67443751	C/G	cg02640540	chr1:67518911	SLC35D1	-0.52	-5.66	-0.33	3.9e-8	Lymphocyte percentage of white cells;
CESC	cis	rs11098499	0.779	rs80242894	chr4:120375752	G/A	cg24375607	chr4:120327624	NA	0.47	5.89	0.34	1.19e-8	Corneal astigmatism;
CESC	cis	rs7618915	0.547	rs12496476	chr3:52708737	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	6.93	0.39	3.13e-11	Bipolar disorder;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg22295628	chr17:1733433	RPA1;SMYD4	-0.48	-6.15	-0.35	2.9e-9	Ulcerative colitis;
CESC	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg07677032	chr17:61819896	STRADA	0.46	6.08	0.35	4.17e-9	Prudent dietary pattern;
CESC	cis	rs3091242	0.933	rs11802413	chr1:25760920	A/G	cg12412775	chr1:25698385	RHCE	0.28	5.19	0.3	4.26e-7	Erythrocyte sedimentation rate;
CESC	cis	rs477692	0.935	rs554458	chr10:131427372	A/G	cg05714579	chr10:131428358	MGMT	0.6	8.83	0.48	1.43e-16	Response to temozolomide;
CESC	cis	rs2991971	0.934	rs11580609	chr1:45975856	C/G	cg24296786	chr1:45957014	TESK2	0.68	9.37	0.5	3.33e-18	High light scatter reticulocyte count;
CESC	cis	rs875971	0.929	rs778682	chr7:65837934	A/G	cg10691866	chr7:65817282	TPST1	-0.34	-5.46	-0.32	1.08e-7	Aortic root size;
CESC	cis	rs2115630	1.000	rs11854291	chr15:85363708	T/C	cg12501888	chr15:85177176	SCAND2	-0.4	-5.3	-0.31	2.49e-7	P wave terminal force;
CESC	cis	rs7246657	0.943	rs713256	chr19:37865365	C/T	cg23950597	chr19:37808831	NA	-0.62	-6.3	-0.36	1.26e-9	Coronary artery calcification;
CESC	cis	rs9488822	0.636	rs12524932	chr6:116330266	G/A	cg26893134	chr6:116381904	FRK	0.25	6.0	0.35	6.32e-9	Cholesterol, total;LDL cholesterol;
CESC	cis	rs11098499	0.954	rs7656252	chr4:120404268	T/C	cg09307838	chr4:120376055	NA	0.93	13.07	0.63	1.78e-30	Corneal astigmatism;
CESC	cis	rs9611565	0.592	rs5996039	chr22:41981957	A/G	cg06634786	chr22:41940651	POLR3H	-0.57	-6.28	-0.36	1.35e-9	Vitiligo;
CESC	cis	rs13256369	0.901	rs12681298	chr8:8566235	A/G	cg17143192	chr8:8559678	CLDN23	-0.79	-9.63	-0.51	5.02e-19	Obesity-related traits;
CESC	cis	rs7605827	0.930	rs13398393	chr2:15602804	T/G	cg19274914	chr2:15703543	NA	0.37	6.61	0.38	2.16e-10	Educational attainment (years of education);
CESC	cis	rs2120019	0.938	rs8033925	chr15:75311959	A/G	cg17294928	chr15:75287854	SCAMP5	-0.73	-8.69	-0.47	3.87e-16	Blood trace element (Zn levels);
CESC	cis	rs1912483	0.505	rs3760372	chr17:45380002	T/C	cg08085267	chr17:45401833	C17orf57	-0.63	-7.47	-0.42	1.17e-12	Coronary artery disease;
CESC	cis	rs1808579	0.904	rs1788761	chr18:21133084	A/G	cg14672496	chr18:21087552	C18orf8	0.41	5.92	0.34	1e-8	Hip circumference;Body mass index;BMI (adjusted for smoking behaviour);
CESC	cis	rs13108904	0.967	rs4428235	chr4:1278891	C/T	cg00684032	chr4:1343700	KIAA1530	0.4	5.56	0.32	6.51e-8	Obesity-related traits;
CESC	trans	rs7656342	0.808	rs10003216	chr4:9766749	A/G	cg01165297	chr16:475440	RAB11FIP3	-0.51	-6.17	-0.35	2.61e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs12079745	0.793	rs12561922	chr1:169265794	G/A	cg09363564	chr1:169337483	NME7;BLZF1	-1.02	-6.24	-0.36	1.7e-9	QT interval;
CESC	cis	rs2439831	0.681	rs2278859	chr15:43632960	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.85	12.6	0.61	7.52e-29	Lung cancer in ever smokers;
CESC	cis	rs7927592	0.912	rs55767696	chr11:68375120	C/G	cg20283391	chr11:68216788	NA	-0.47	-5.76	-0.33	2.35e-8	Total body bone mineral density;
CESC	cis	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg05863683	chr7:1912471	MAD1L1	0.42	6.24	0.36	1.69e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs2404602	0.583	rs4381566	chr15:76589262	A/G	cg05617483	chr15:76483344	C15orf27	0.39	5.16	0.3	4.9e-7	Blood metabolite levels;
CESC	cis	rs763121	0.853	rs1056610	chr22:39080078	C/T	cg14440974	chr22:39074834	NA	0.36	5.16	0.3	4.76e-7	Menopause (age at onset);
CESC	cis	rs7927771	0.832	rs7924485	chr11:47419129	A/G	cg20307385	chr11:47447363	PSMC3	0.63	7.92	0.44	6.71e-14	Subjective well-being;
CESC	cis	rs6952808	0.595	rs3800916	chr7:2166072	C/T	cg23048001	chr7:2026167	MAD1L1	0.46	5.93	0.34	9.41e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs60733400	0.667	rs4385650	chr1:2499898	G/A	cg18854424	chr1:2615690	NA	0.28	5.4	0.31	1.5e-7	Multiple sclerosis;
CESC	cis	rs911555	0.723	rs4906320	chr14:103876925	T/C	cg12935359	chr14:103987150	CKB	0.6	8.75	0.47	2.59e-16	Intelligence (multi-trait analysis);
CESC	cis	rs9649213	0.593	rs6465675	chr7:97982103	C/T	cg08684580	chr7:98029266	BAIAP2L1	0.35	5.77	0.33	2.19e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7772486	0.754	rs1055212	chr6:146058315	A/T	cg05347473	chr6:146136440	FBXO30	-0.56	-7.15	-0.4	8.5e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs477895	0.653	rs11606544	chr11:63896901	C/T	cg18225595	chr11:63971243	STIP1	0.51	5.13	0.3	5.58e-7	Mean platelet volume;
CESC	cis	rs2769264	0.546	rs12071705	chr1:151430504	G/C	cg18801370	chr1:151430492	POGZ	0.84	10.7	0.55	1.86e-22	Blood trace element (Cu levels);
CESC	cis	rs2050392	0.517	rs593400	chr10:30762088	A/G	cg25182066	chr10:30743637	MAP3K8	0.5	7.22	0.41	5.41e-12	Inflammatory bowel disease;
CESC	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	10.16	0.53	1.12e-20	Prudent dietary pattern;
CESC	cis	rs909674	0.524	rs5757670	chr22:39829736	G/A	cg24399712	chr22:39784796	NA	-0.8	-10.59	-0.55	4.24e-22	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs2228479	0.850	rs62052212	chr16:89981960	G/A	cg06558623	chr16:89946397	TCF25	1.14	8.8	0.48	1.83e-16	Skin colour saturation;
CESC	cis	rs6460942	0.915	rs80345607	chr7:12442249	T/C	cg16278512	chr7:12443529	VWDE	-0.5	-5.08	-0.3	7.3e-7	Coronary artery disease;
CESC	cis	rs10028773	0.700	rs35653026	chr4:120248378	A/G	cg09307838	chr4:120376055	NA	0.74	9.42	0.5	2.28e-18	Educational attainment;
CESC	cis	rs9611565	0.802	rs132916	chr22:41806768	C/G	cg03806693	chr22:41940476	POLR3H	0.77	9.34	0.5	3.97e-18	Vitiligo;
CESC	trans	rs7945705	0.869	rs7925728	chr11:9013002	A/G	cg07894846	chr19:1981143	CSNK1G2	0.39	6.11	0.35	3.61e-9	Hemoglobin concentration;
CESC	cis	rs6460942	0.915	rs1595802	chr7:12439672	C/T	cg20607287	chr7:12443886	VWDE	-0.71	-8.7	-0.47	3.54e-16	Coronary artery disease;
CESC	cis	rs12500824	0.564	rs7660542	chr4:77234758	A/C	cg20311846	chr4:77356250	SHROOM3	-0.38	-6.99	-0.39	2.2e-11	Coronary artery disease;
CESC	cis	rs3820928	0.605	rs4675124	chr2:227802354	G/A	cg05526886	chr2:227700861	RHBDD1	-0.53	-7.21	-0.41	5.72e-12	Pulmonary function;
CESC	trans	rs629535	0.748	rs58675625	chr8:70034924	T/C	cg21567404	chr3:27674614	NA	0.93	11.25	0.57	2.83e-24	Dupuytren's disease;
CESC	cis	rs11779988	0.598	rs13255037	chr8:17911046	A/G	cg18067069	chr8:17937731	ASAH1	-0.4	-5.27	-0.31	2.84e-7	Breast cancer;
CESC	cis	rs9916302	0.861	rs3889368	chr17:37683231	C/T	cg00129232	chr17:37814104	STARD3	-0.59	-7.77	-0.43	1.71e-13	Glomerular filtration rate (creatinine);
CESC	cis	rs910316	0.737	rs175499	chr14:75535927	G/A	cg11812906	chr14:75593930	NEK9	-0.84	-13.56	-0.64	3.55e-32	Height;
CESC	cis	rs6968419	0.755	rs1141470	chr7:115898442	G/C	cg02561103	chr7:115862891	TES	-0.41	-5.42	-0.32	1.37e-7	Intraocular pressure;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg04370476	chr3:49761188	GMPPB	-0.46	-6.4	-0.37	7.17e-10	Fibrinogen levels;
CESC	cis	rs1046896	0.553	rs9893885	chr17:80837107	C/T	cg19046167	chr17:80928561	B3GNTL1	0.48	5.72	0.33	2.84e-8	Glycated hemoglobin levels;
CESC	cis	rs7582720	1.000	rs72932590	chr2:203884308	A/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.36	0.41	2.34e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs4819052	0.851	rs8126930	chr21:46671715	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.71	9.83	0.52	1.19e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg12344600	chr6:89769123	NA	0.43	6.0	0.35	6.41e-9	Fibrinogen levels;
CESC	cis	rs11098499	0.909	rs17046118	chr4:120387496	T/G	cg24375607	chr4:120327624	NA	0.44	5.48	0.32	9.91e-8	Corneal astigmatism;
CESC	cis	rs2425143	1.000	rs2295356	chr20:34252856	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.61	5.14	0.3	5.43e-7	Blood protein levels;
CESC	cis	rs6594499	0.872	rs10045255	chr5:110438357	C/T	cg04022379	chr5:110408740	TSLP	-0.33	-6.02	-0.35	5.81e-9	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs909674	0.865	rs5757682	chr22:39848259	T/G	cg24399712	chr22:39784796	NA	-0.83	-10.24	-0.53	6.16e-21	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs12971120	1.000	rs2278161	chr18:72176083	T/C	cg25817165	chr18:72167213	CNDP2	-0.63	-7.9	-0.44	7.44e-14	Refractive error;
CESC	cis	rs7223966	1.000	rs11657306	chr17:61704822	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	7.2	0.4	6.24e-12	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs1570884	0.516	rs9535268	chr13:50175478	C/A	cg03651054	chr13:50194643	NA	0.31	5.1	0.3	6.6e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
CESC	cis	rs12541335	0.639	rs7834182	chr8:22163112	G/A	cg02788857	chr8:22132959	PIWIL2	0.31	5.49	0.32	9.44e-8	Hypertriglyceridemia;
CESC	cis	rs1421811	0.532	rs72740626	chr5:32692220	G/C	cg16267343	chr5:32710456	NPR3	0.56	6.13	0.35	3.24e-9	Blood pressure;
CESC	cis	rs8072100	0.738	rs9900123	chr17:45549055	T/C	cg25173405	chr17:45401733	C17orf57	-0.45	-5.76	-0.33	2.38e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs2014572	0.967	rs7259978	chr19:57756129	C/T	cg24459738	chr19:57751996	ZNF805	-0.54	-7.74	-0.43	2.08e-13	Hyperactive-impulsive symptoms;
CESC	cis	rs6831352	0.918	rs29001194	chr4:100054844	A/G	cg12011299	chr4:100065546	ADH4	-0.6	-6.62	-0.38	2.04e-10	Alcohol dependence;
CESC	cis	rs3892630	0.878	rs114224536	chr19:33211232	A/G	cg13157960	chr19:33183277	NUDT19	0.55	5.06	0.3	7.79e-7	Red blood cell traits;
CESC	cis	rs853679	0.769	rs7752608	chr6:28301195	A/G	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.78	6.51	0.37	3.69e-10	Depression;
CESC	cis	rs7666738	0.546	rs10007424	chr4:98885450	C/T	cg05340658	chr4:99064831	C4orf37	0.57	7.14	0.4	9.23e-12	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2880765	0.835	rs4526974	chr15:86024284	C/T	cg10818794	chr15:86012489	AKAP13	-0.33	-5.12	-0.3	5.89e-7	Coronary artery disease;
CESC	cis	rs11098499	0.863	rs10004484	chr4:120442428	C/T	cg24375607	chr4:120327624	NA	0.42	5.06	0.3	7.67e-7	Corneal astigmatism;
CESC	cis	rs6546537	0.550	rs4852272	chr2:69776730	C/T	cg10773587	chr2:69614142	GFPT1	-0.51	-6.67	-0.38	1.48e-10	Serum thyroid-stimulating hormone levels;
CESC	trans	rs10411161	0.702	rs7250193	chr19:52385520	C/T	cg22319618	chr22:45562946	NUP50	0.7	7.14	0.4	8.99e-12	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06751603	chr19:11152063	SMARCA4	-0.62	-6.68	-0.38	1.44e-10	Gut microbiome composition (summer);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg09319706	chr4:75024153	MTHFD2L	-0.51	-6.47	-0.37	4.79e-10	Ulcerative colitis;
CESC	cis	rs2576037	0.583	rs616900	chr18:44410849	T/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.32	5.1	0.3	6.39e-7	Personality dimensions;
CESC	cis	rs11677416	1.000	rs1878321	chr2:113544434	A/G	cg27083787	chr2:113543245	IL1A	0.42	5.28	0.31	2.72e-7	Response to antipsychotic treatment in schizophrenia (working memory);
CESC	cis	rs3749237	0.595	rs6784820	chr3:49450864	C/T	cg02487422	chr3:49467188	NICN1	-0.55	-8.01	-0.44	3.62e-14	Resting heart rate;
CESC	cis	rs1152591	0.543	rs1152590	chr14:64681193	C/T	cg21174375	chr14:64681225	SYNE2	0.58	8.47	0.46	1.7e-15	Atrial fibrillation;
CESC	cis	rs35110281	0.633	rs4819292	chr21:45125223	A/G	cg01579765	chr21:45077557	HSF2BP	-0.53	-9.12	-0.49	1.93e-17	Mean corpuscular volume;
CESC	cis	rs9400271	0.632	rs9386784	chr6:109591208	C/A	cg01475377	chr6:109611718	NA	-0.45	-7.02	-0.4	1.9e-11	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
CESC	cis	rs7618915	0.547	rs2590846	chr3:52692359	C/G	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.63	0.38	1.83e-10	Bipolar disorder;
CESC	cis	rs4819052	0.851	rs9753963	chr21:46661437	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.75	9.98	0.52	4.1e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs62064224	0.902	rs35830939	chr17:30627564	A/C	cg25809561	chr17:30822961	MYO1D	0.42	5.54	0.32	7.26e-8	Schizophrenia;
CESC	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.74	10.23	0.53	6.5e-21	Prudent dietary pattern;
CESC	cis	rs7618501	0.635	rs7635002	chr3:49989155	T/G	cg24308560	chr3:49941425	MST1R	-0.64	-9.19	-0.49	1.17e-17	Intelligence (multi-trait analysis);
CESC	cis	rs1957429	0.520	rs7144515	chr14:65333725	G/A	cg23373153	chr14:65346875	NA	-0.76	-5.81	-0.34	1.77e-8	Pediatric areal bone mineral density (radius);
CESC	cis	rs10504229	0.906	rs66480865	chr8:58187100	C/T	cg05313129	chr8:58192883	C8orf71	-0.55	-6.29	-0.36	1.34e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs950776	0.518	rs12903129	chr15:78819606	C/T	cg06917634	chr15:78832804	PSMA4	0.79	12.0	0.59	9.02e-27	Sudden cardiac arrest;
CESC	cis	rs116095464	0.558	rs6869925	chr5:264036	A/G	cg22496380	chr5:211416	CCDC127	-0.74	-8.46	-0.46	1.86e-15	Breast cancer;
CESC	cis	rs4862750	0.872	rs7679956	chr4:187900229	C/T	cg03647317	chr4:187891568	NA	-0.44	-6.92	-0.39	3.31e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6860806	0.661	rs3763112	chr5:131586480	A/G	cg04518342	chr5:131593106	PDLIM4	0.39	5.8	0.34	1.86e-8	Breast cancer;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg21370966	chr3:149771534	NA	0.4	6.29	0.36	1.32e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs7589728	0.858	rs1914734	chr2:88529509	T/C	cg07952391	chr2:88470173	THNSL2	0.44	5.44	0.32	1.22e-7	Plasma clusterin levels;
CESC	cis	rs9318086	0.578	rs2077709	chr13:24476073	A/G	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.44	-6.34	-0.36	9.71e-10	Myopia (pathological);
CESC	cis	rs13102973	0.965	rs4864244	chr4:135866959	A/G	cg14419869	chr4:135874104	NA	0.41	6.52	0.37	3.45e-10	Subjective well-being;
CESC	cis	rs67478160	0.619	rs8018062	chr14:104281954	C/T	cg08213375	chr14:104286397	PPP1R13B	0.54	10.7	0.55	1.97e-22	Schizophrenia;
CESC	cis	rs644799	1.000	rs2508289	chr11:95624669	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.6	7.36	0.41	2.31e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs853679	0.517	rs9393896	chr6:28127703	C/T	cg08968635	chr6:28129556	ZNF389	0.4	5.21	0.3	3.88e-7	Depression;
CESC	cis	rs875971	1.000	rs1183245	chr7:65541185	C/T	cg18876405	chr7:65276391	NA	-0.53	-6.89	-0.39	3.98e-11	Aortic root size;
CESC	cis	rs4713118	0.662	rs149961	chr6:28015569	A/C	cg23161317	chr6:28129485	ZNF389	0.49	6.17	0.35	2.51e-9	Parkinson's disease;
CESC	cis	rs4243830	0.850	rs1010584	chr1:6579843	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.76	-8.23	-0.45	8.77e-15	Body mass index;
CESC	cis	rs2032447	0.670	rs198848	chr6:26106325	A/G	cg18357526	chr6:26021779	HIST1H4A	0.56	7.47	0.42	1.18e-12	Intelligence (multi-trait analysis);
CESC	cis	rs854572	0.870	rs757158	chr7:94955528	C/T	cg04155289	chr7:94953770	PON1	-0.51	-7.04	-0.4	1.61e-11	Paraoxonase activity;
CESC	cis	rs1707322	0.789	rs10789473	chr1:46248131	C/T	cg05343316	chr1:45956843	TESK2	0.47	5.73	0.33	2.75e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs3785574	0.962	rs2727331	chr17:61926990	G/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.1	19.31	0.76	1.74e-52	Height;
CESC	cis	rs8141529	0.764	rs5762854	chr22:29246278	T/C	cg15103426	chr22:29168792	CCDC117	0.7	9.78	0.52	1.7e-19	Lymphocyte counts;
CESC	cis	rs11583043	1.000	rs12567858	chr1:101517688	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.5	5.63	0.33	4.64e-8	Ulcerative colitis;Inflammatory bowel disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07334509	chr8:74361129	STAU2	-0.59	-6.9	-0.39	3.92e-11	Gut microbiome composition (summer);
CESC	cis	rs9322193	0.923	rs9688517	chr6:150061791	T/C	cg04369109	chr6:150039330	LATS1	-0.43	-5.96	-0.34	7.91e-9	Lung cancer;
CESC	cis	rs9611565	0.512	rs2899347	chr22:42158204	T/C	cg06634786	chr22:41940651	POLR3H	0.71	6.94	0.39	3.02e-11	Vitiligo;
CESC	cis	rs79057730	0.527	rs35316052	chr7:802954	C/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.86	7.32	0.41	2.88e-12	Initial pursuit acceleration;
CESC	cis	rs60871478	0.730	rs13222476	chr7:826630	T/C	cg15782153	chr7:917662	C7orf20	-0.49	-5.41	-0.32	1.4e-7	Cerebrospinal P-tau181p levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06191580	chr17:35870477	DUSP14	-0.54	-6.82	-0.39	6.04e-11	Gut microbiome composition (summer);
CESC	cis	rs514406	0.929	rs12145105	chr1:53340564	T/C	cg08736216	chr1:53307985	ZYG11A	-0.43	-7.08	-0.4	1.29e-11	Monocyte count;
CESC	trans	rs4714888	1.000	rs3777562	chr6:45895815	C/T	cg22014887	chr4:2749539	TNIP2	0.84	6.09	0.35	3.95e-9	Age-related macular degeneration;
CESC	trans	rs9325144	0.555	rs7968322	chr12:38792348	T/C	cg10679878	chr6:156759499	NA	-0.33	-6.0	-0.35	6.32e-9	Morning vs. evening chronotype;
CESC	cis	rs7937682	0.663	rs35581942	chr11:111756286	C/T	cg22437258	chr11:111473054	SIK2	-0.5	-5.53	-0.32	7.6e-8	Primary sclerosing cholangitis;
CESC	trans	rs60380162	0.963	rs55838834	chr1:87727640	G/T	cg20163645	chr8:1900353	ARHGEF10	-0.43	-6.03	-0.35	5.48e-9	Loneliness (linear analysis);
CESC	cis	rs8027181	0.839	rs4777532	chr15:73041767	A/G	cg25632853	chr15:73088954	NA	0.31	5.52	0.32	8.02e-8	Triglyceride levels;
CESC	cis	rs2033711	0.870	rs4801583	chr19:58918405	A/G	cg00825309	chr19:58991885	ZNF446	-0.54	-7.89	-0.44	8.09e-14	Uric acid clearance;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg01911186	chr12:12765398	CREBL2	-0.44	-6.41	-0.37	6.8e-10	Gambling;
CESC	cis	rs9291683	0.588	rs3756237	chr4:10013378	G/A	cg02734326	chr4:10020555	SLC2A9	0.52	7.43	0.42	1.5e-12	Bone mineral density;
CESC	cis	rs3747547	0.685	rs11791354	chr9:38125173	G/C	cg13774184	chr9:37916125	SHB	-0.63	-5.19	-0.3	4.17e-7	Metabolite levels (Dihydroxy docosatrienoic acid);
CESC	trans	rs3942852	0.774	rs10838814	chr11:48187178	G/A	cg15704280	chr7:45808275	SEPT13	-0.73	-8.25	-0.45	7.61e-15	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs5769765	0.740	rs2103932	chr22:50272515	A/G	cg02269571	chr22:50332266	NA	0.44	5.98	0.35	7.02e-9	Schizophrenia;
CESC	cis	rs9911578	1.000	rs9911578	chr17:56953147	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.16	0.3	4.87e-7	Intelligence (multi-trait analysis);
CESC	cis	rs9916302	0.731	rs11868030	chr17:37650332	A/G	cg19468946	chr17:37922297	IKZF3	-0.39	-5.08	-0.3	7.08e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs13064411	0.696	rs13066742	chr3:113208423	T/C	cg18753928	chr3:113234510	CCDC52	-0.5	-5.9	-0.34	1.11e-8	Response to simvastatin treatment (PCSK9 protein level change);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25336731	chr2:70520884	SNRPG	0.57	6.74	0.38	1.01e-10	Gut microbiome composition (summer);
CESC	cis	rs4819052	0.851	rs3673	chr21:46681775	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.47	6.07	0.35	4.37e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs12530845	1.000	rs4291212	chr7:135335465	C/T	cg23117316	chr7:135346802	PL-5283	-0.41	-5.21	-0.31	3.72e-7	Red blood cell traits;
CESC	cis	rs1448094	0.511	rs59668915	chr12:86197170	C/T	cg00310523	chr12:86230176	RASSF9	0.38	5.98	0.34	7.37e-9	Major depressive disorder;
CESC	cis	rs6502050	0.799	rs8069827	chr17:80089168	C/T	cg11859384	chr17:80120422	CCDC57	-0.38	-5.14	-0.3	5.31e-7	Life satisfaction;
CESC	cis	rs6424115	0.800	rs4649123	chr1:24197696	A/G	cg10978503	chr1:24200527	CNR2	0.31	6.21	0.36	2e-9	Immature fraction of reticulocytes;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg00974835	chr14:74960278	NPC2;ISCA2	0.49	6.52	0.37	3.62e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs763121	0.853	rs5757213	chr22:39053888	C/T	cg21395723	chr22:39101663	GTPBP1	0.43	5.39	0.31	1.54e-7	Menopause (age at onset);
CESC	cis	rs8017423	0.647	rs12883844	chr14:90820519	T/C	cg14092571	chr14:90743983	NA	0.43	6.55	0.37	2.91e-10	Mortality in heart failure;
CESC	cis	rs4819052	0.851	rs3673	chr21:46681775	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.74	10.14	0.53	1.22e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs4692589	1.000	rs7688417	chr4:170938732	C/T	cg19918862	chr4:170955249	NA	0.36	5.5	0.32	8.93e-8	Anxiety disorder;
CESC	cis	rs881375	0.678	rs4836834	chr9:123665901	T/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.52	7.63	0.42	4.26e-13	Rheumatoid arthritis;
CESC	cis	rs34779708	0.931	rs35126129	chr10:35452141	G/A	cg03585969	chr10:35415529	CREM	0.77	10.27	0.53	4.68e-21	Inflammatory bowel disease;Crohn's disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg09377882	chr17:43139021	NMT1;DCAKD	0.43	6.04	0.35	5.12e-9	Fibrinogen levels;
CESC	cis	rs11098499	0.954	rs10006877	chr4:120242793	C/T	cg24375607	chr4:120327624	NA	0.46	5.6	0.33	5.39e-8	Corneal astigmatism;
CESC	trans	rs8073060	0.544	rs225249	chr17:33942540	T/C	cg19694781	chr19:47549865	TMEM160	-0.71	-6.99	-0.39	2.2e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	cis	rs1707322	1.000	rs3922886	chr1:46473902	A/T	cg05343316	chr1:45956843	TESK2	0.44	5.35	0.31	1.9e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs3812762	0.871	rs2173999	chr11:8778077	G/A	cg03980550	chr11:8754370	ST5	0.37	5.32	0.31	2.22e-7	Hypospadias;
CESC	cis	rs7208859	0.623	rs11651858	chr17:29170718	A/G	cg19761014	chr17:28927070	LRRC37B2	0.72	5.71	0.33	3.06e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg07677032	chr17:61819896	STRADA	0.44	5.81	0.34	1.81e-8	Prudent dietary pattern;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27254601	chr16:29817104	MAZ	-0.56	-6.4	-0.37	7.14e-10	Gut microbiome composition (summer);
CESC	cis	rs514406	0.861	rs12038438	chr1:53230581	A/T	cg24675658	chr1:53192096	ZYG11B	0.54	6.84	0.39	5.57e-11	Monocyte count;
CESC	cis	rs10789491	1.000	rs12794	chr1:47141718	T/C	cg15501359	chr1:47185051	KIAA0494	0.8	8.63	0.47	5.59e-16	Response to hepatitis C treatment;
CESC	cis	rs9640161	0.789	rs34728606	chr7:150054694	G/A	cg17279839	chr7:150038598	RARRES2	0.49	5.78	0.33	2.11e-8	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs17253792	0.822	rs79291233	chr14:56065302	G/C	cg01858014	chr14:56050164	KTN1	-0.96	-7.13	-0.4	9.72e-12	Putamen volume;
CESC	cis	rs929354	0.772	rs1182448	chr7:157021415	G/A	cg05182265	chr7:156933206	UBE3C	0.52	7.62	0.42	4.53e-13	Body mass index;
CESC	cis	rs1499972	1.000	rs1499972	chr3:117719538	A/C	cg07612923	chr3:117604196	NA	-0.77	-5.71	-0.33	3.06e-8	Schizophrenia;
CESC	cis	rs2637266	0.967	rs12254242	chr10:78352934	T/C	cg18941641	chr10:78392320	NA	0.41	7.55	0.42	7.02e-13	Pulmonary function;
CESC	cis	rs9916302	0.800	rs8069451	chr17:37504933	C/T	cg20243544	chr17:37824526	PNMT	0.5	6.25	0.36	1.64e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs35146811	0.586	rs6946168	chr7:99598286	C/T	cg22906224	chr7:99728672	NA	0.44	5.19	0.3	4.24e-7	Coronary artery disease;
CESC	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.56	7.53	0.42	8.02e-13	Lymphocyte counts;
CESC	cis	rs4665809	1.000	rs1030730	chr2:26284143	T/C	cg25036284	chr2:26402008	FAM59B	-0.74	-8.4	-0.46	2.72e-15	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02884346	chr4:6271501	WFS1	0.65	7.83	0.43	1.16e-13	Gut microbiome composition (summer);
CESC	cis	rs2346177	0.542	rs1900591	chr2:46697968	C/T	cg02822958	chr2:46747628	ATP6V1E2	0.43	5.34	0.31	2e-7	HDL cholesterol;
CESC	cis	rs9311474	0.508	rs6788887	chr3:52605005	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.57	7.93	0.44	6.13e-14	Electroencephalogram traits;
CESC	cis	rs6456156	0.806	rs11967165	chr6:167529936	T/C	cg07741184	chr6:167504864	NA	-0.31	-5.12	-0.3	5.75e-7	Primary biliary cholangitis;
CESC	cis	rs17401966	0.931	rs11121545	chr1:10411211	A/G	cg15208524	chr1:10270712	KIF1B	0.4	5.11	0.3	6.13e-7	Hepatocellular carcinoma;
CESC	cis	rs6800768	0.633	rs60635484	chr3:24101328	G/A	cg10674438	chr3:24145617	LOC152024	-0.4	-5.38	-0.31	1.61e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs1568889	0.838	rs11030265	chr11:28296168	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.79	13.35	0.63	1.98e-31	Bipolar disorder;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg17484976	chr20:60982411	CABLES2	-0.38	-6.01	-0.35	6e-9	Gambling;
CESC	cis	rs643506	0.845	rs607327	chr11:111695709	C/T	cg17089665	chr11:111648010	NA	-0.36	-5.19	-0.3	4.21e-7	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14064455	chr7:22862514	TOMM7	0.57	6.22	0.36	1.93e-9	Gut microbiome composition (summer);
CESC	cis	rs4664304	0.966	rs3792198	chr2:160760338	G/A	cg03641300	chr2:160917029	PLA2R1	-0.48	-6.78	-0.38	8.02e-11	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs832540	0.618	rs2548663	chr5:56172778	G/A	cg22800045	chr5:56110881	MAP3K1	0.49	5.83	0.34	1.58e-8	Coronary artery disease;
CESC	cis	rs7116495	1.000	rs1939242	chr11:71753582	C/T	cg26138937	chr11:71823887	C11orf51	-0.71	-5.95	-0.34	8.35e-9	Severe influenza A (H1N1) infection;
CESC	cis	rs6060717	0.536	rs8125393	chr20:34496162	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.75	-6.73	-0.38	1.07e-10	Hip circumference adjusted for BMI;
CESC	cis	rs41271473	0.500	rs4606285	chr1:228887544	G/T	cg00850481	chr1:228891306	NA	-0.44	-6.1	-0.35	3.76e-9	Chronic lymphocytic leukemia;
CESC	cis	rs672059	1.000	rs549844	chr1:183158143	A/G	ch.1.3577855R	chr1:183094577	LAMC1	-0.54	-7.04	-0.4	1.64e-11	Hypertriglyceridemia;
CESC	cis	rs708547	0.830	rs1713983	chr4:57883084	A/G	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.53	-6.19	-0.36	2.34e-9	Response to bleomycin (chromatid breaks);
CESC	cis	rs863345	0.608	rs11265013	chr1:158499625	G/A	cg12129480	chr1:158549410	OR10X1	-0.32	-6.15	-0.35	2.82e-9	Pneumococcal bacteremia;
CESC	cis	rs854765	0.724	rs2955371	chr17:17967397	G/A	cg09796270	chr17:17721594	SREBF1	-0.44	-6.06	-0.35	4.57e-9	Total body bone mineral density;
CESC	cis	rs9549367	0.789	rs6577034	chr13:113879900	T/C	cg00898013	chr13:113819073	PROZ	-0.51	-7.46	-0.42	1.21e-12	Platelet distribution width;
CESC	cis	rs9611565	0.659	rs11090049	chr22:41915329	C/T	cg17376030	chr22:41985996	PMM1	0.76	8.25	0.45	7.51e-15	Vitiligo;
CESC	cis	rs9322193	0.884	rs933055	chr6:150130837	A/G	cg04369109	chr6:150039330	LATS1	-0.41	-5.54	-0.32	7.16e-8	Lung cancer;
CESC	cis	rs2066819	1.000	rs2695782	chr12:56722830	C/T	cg26714650	chr12:56694279	CS	1.34	15.3	0.68	2.7e-38	Psoriasis vulgaris;
CESC	trans	rs4349753	0.663	rs62402074	chr5:144083358	A/C	cg22407458	chr6:35109121	TCP11	0.5	6.31	0.36	1.18e-9	Photic sneeze reflex;
CESC	cis	rs9611565	0.512	rs139571	chr22:42214238	G/A	cg03806693	chr22:41940476	POLR3H	-1.15	-13.11	-0.63	1.33e-30	Vitiligo;
CESC	cis	rs4474465	0.920	rs908002	chr11:78144753	T/A	cg27205649	chr11:78285834	NARS2	-0.41	-5.14	-0.3	5.25e-7	Alzheimer's disease (survival time);
CESC	cis	rs9399135	0.933	rs41294852	chr6:135376379	T/G	cg22676075	chr6:135203613	NA	0.53	7.45	0.42	1.36e-12	Red blood cell count;
CESC	cis	rs7786808	0.608	rs6978352	chr7:158209802	T/C	cg09998033	chr7:158218633	PTPRN2	0.37	5.45	0.32	1.17e-7	Obesity-related traits;
CESC	trans	rs35883536	0.935	rs3904674	chr1:101138932	C/T	cg16931499	chr17:42786676	DBF4B	0.41	6.09	0.35	3.98e-9	Monocyte count;
CESC	cis	rs7264396	0.635	rs7263302	chr20:34545858	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.82	-11.49	-0.58	4.75e-25	Total cholesterol levels;
CESC	cis	rs7666738	0.830	rs115712871	chr4:98954535	A/T	cg03676636	chr4:99064102	C4orf37	0.33	5.11	0.3	6.05e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs921968	0.541	rs578450	chr2:219401237	C/T	cg15547669	chr20:2781122	CPXM1	0.35	6.0	0.35	6.31e-9	Mean corpuscular hemoglobin concentration;
CESC	cis	rs13108904	0.557	rs1250097	chr4:1238338	C/T	cg05025164	chr4:1340916	KIAA1530	-0.64	-8.8	-0.48	1.8e-16	Obesity-related traits;
CESC	cis	rs6502050	0.749	rs7209948	chr17:80086804	T/G	cg11859384	chr17:80120422	CCDC57	0.38	5.11	0.3	6.32e-7	Life satisfaction;
CESC	cis	rs1371867	0.846	rs1660326	chr8:101290447	G/A	cg11906718	chr8:101322791	RNF19A	0.5	6.34	0.36	9.95e-10	Atrioventricular conduction;
CESC	cis	rs1862618	0.671	rs2591958	chr5:56239369	C/G	cg24531977	chr5:56204891	C5orf35	0.69	9.36	0.5	3.49e-18	Initial pursuit acceleration;
CESC	cis	rs9905704	0.718	rs8072379	chr17:56615997	C/A	cg12560992	chr17:57184187	TRIM37	-0.63	-6.02	-0.35	5.95e-9	Testicular germ cell tumor;
CESC	cis	rs2637266	0.703	rs846591	chr10:78506321	A/C	cg18941641	chr10:78392320	NA	0.38	7.49	0.42	1.06e-12	Pulmonary function;
CESC	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.16	11.93	0.59	1.55e-26	Platelet count;
CESC	cis	rs932287	0.536	rs10840160	chr11:9053536	C/T	cg12365402	chr11:9010492	NRIP3	-0.35	-5.39	-0.31	1.57e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs854765	0.583	rs9912895	chr17:17826020	C/T	cg16928487	chr17:17741425	SREBF1	0.55	9.58	0.51	7.61e-19	Total body bone mineral density;
CESC	cis	rs9303401	0.659	rs12600349	chr17:57054245	A/G	cg12560992	chr17:57184187	TRIM37	-0.51	-5.06	-0.3	7.95e-7	Cognitive test performance;
CESC	cis	rs6570726	0.791	rs9373466	chr6:145912016	T/C	cg23711669	chr6:146136114	FBXO30	0.92	13.58	0.64	3.16e-32	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7178572	0.889	rs7177055	chr15:77832762	A/G	cg22256960	chr15:77711686	NA	0.47	6.49	0.37	4.28e-10	Type 2 diabetes;
CESC	cis	rs4975709	0.569	rs1684965	chr5:1865248	A/G	cg10800226	chr5:1850261	NA	0.32	5.21	0.3	3.84e-7	Cardiovascular disease risk factors;
CESC	trans	rs916888	0.773	rs199457	chr17:44795469	C/T	cg22968622	chr17:43663579	NA	1.36	18.72	0.75	2.16e-50	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs62408225	1.000	rs11752685	chr6:90966415	A/C	cg06866423	chr6:90926672	BACH2	0.45	5.43	0.32	1.29e-7	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs7208859	0.623	rs8068645	chr17:29104342	T/A	cg13385521	chr17:29058706	SUZ12P	0.77	6.15	0.35	2.81e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs11098499	0.863	rs13134665	chr4:120426430	T/C	cg09307838	chr4:120376055	NA	0.95	13.07	0.63	1.87e-30	Corneal astigmatism;
CESC	cis	rs7246657	0.943	rs10415937	chr19:37830064	T/G	cg23950597	chr19:37808831	NA	-0.55	-6.09	-0.35	3.96e-9	Coronary artery calcification;
CESC	cis	rs9910055	0.659	rs8079310	chr17:42270291	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.44	6.37	0.36	8.52e-10	Total body bone mineral density;
CESC	cis	rs1707322	1.000	rs10789485	chr1:46407308	C/T	cg06784218	chr1:46089804	CCDC17	0.36	6.01	0.35	5.95e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7560272	0.589	rs34874205	chr2:73875458	G/A	cg20560298	chr2:73613845	ALMS1	0.52	7.23	0.41	5.12e-12	Schizophrenia;
CESC	cis	rs6460942	0.915	rs7803056	chr7:12306913	A/C	cg02935154	chr7:12443704	VWDE	-0.42	-5.58	-0.32	5.91e-8	Coronary artery disease;
CESC	cis	rs2730245	0.592	rs2657385	chr7:158649373	A/G	cg01943577	chr7:158741284	NA	-0.44	-5.77	-0.33	2.19e-8	Height;
CESC	trans	rs11722228	1.000	rs11722228	chr4:9915741	C/T	cg26043149	chr18:55253948	FECH	0.48	6.49	0.37	4.22e-10	Gout;Urate levels;Serum uric acid levels;
CESC	cis	rs4665809	0.590	rs962217	chr2:26438276	T/C	cg08470875	chr2:26401718	FAM59B	-0.74	-7.66	-0.43	3.41e-13	Gut microbiome composition (summer);
CESC	cis	rs9611565	0.659	rs28530678	chr22:41934961	G/C	cg06634786	chr22:41940651	POLR3H	-0.69	-6.71	-0.38	1.17e-10	Vitiligo;
CESC	cis	rs2228479	0.850	rs57267516	chr16:89903552	G/A	cg14709524	chr16:89940631	TCF25	0.75	5.35	0.31	1.95e-7	Skin colour saturation;
CESC	cis	rs28374715	0.662	rs11852419	chr15:41456374	A/T	cg18705301	chr15:41695430	NDUFAF1	0.75	10.38	0.54	2.13e-21	Ulcerative colitis;
CESC	cis	rs17095355	0.786	rs58096078	chr10:111734286	C/G	cg00817464	chr10:111662876	XPNPEP1	-0.45	-5.41	-0.32	1.42e-7	Biliary atresia;
CESC	cis	rs5758659	0.714	rs133376	chr22:42466905	C/T	cg05082376	chr22:42548792	NA	-0.36	-5.21	-0.3	3.85e-7	Cognitive function;
CESC	cis	rs754466	0.651	rs2004382	chr10:79650351	G/C	cg17075019	chr10:79541650	NA	-0.83	-12.1	-0.6	3.96e-27	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs2439831	0.850	rs12441861	chr15:44060883	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.72	6.94	0.39	3.08e-11	Lung cancer in ever smokers;
CESC	cis	rs7208859	0.623	rs28556733	chr17:29083945	T/G	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.91e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs116161686	0.500	rs55871867	chr1:210051029	A/G	cg21951975	chr1:209979733	IRF6	0.56	6.37	0.36	8.42e-10	Coronary artery disease;
CESC	cis	rs854765	0.718	rs12943500	chr17:17790588	C/T	cg09796270	chr17:17721594	SREBF1	-0.43	-5.76	-0.33	2.35e-8	Total body bone mineral density;
CESC	cis	rs2576037	0.583	rs644731	chr18:44426877	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.52	-7.19	-0.4	6.61e-12	Personality dimensions;
CESC	cis	rs5769765	1.000	rs764813	chr22:50286172	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.45	-5.2	-0.3	4.05e-7	Schizophrenia;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg16600432	chr14:64970085	ZBTB1;ZBTB25	-0.43	-6.37	-0.36	8.26e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs7267979	1.000	rs6050602	chr20:25401203	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.87	-18.03	-0.74	5.66e-48	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs6088590	0.561	rs3891369	chr20:33161127	C/T	cg24642439	chr20:33292090	TP53INP2	0.62	8.27	0.45	6.46e-15	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21367838	chr20:47805154	STAU1	0.56	6.42	0.37	6.38e-10	Gut microbiome composition (summer);
CESC	cis	rs3733585	0.699	rs6449202	chr4:9974043	T/C	cg02734326	chr4:10020555	SLC2A9	-0.4	-5.65	-0.33	4.11e-8	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs10129255	0.957	rs12590799	chr14:107187952	G/A	cg23076370	chr14:107095027	NA	-0.48	-6.13	-0.35	3.23e-9	Kawasaki disease;
CESC	cis	rs4853012	0.941	rs7571083	chr2:74342260	C/G	cg19729930	chr2:74357872	NA	0.77	10.48	0.54	9.92e-22	Gestational age at birth (maternal effect);
CESC	cis	rs17539620	0.624	rs12665520	chr6:154835273	C/T	cg17771515	chr6:154831774	CNKSR3	0.57	5.73	0.33	2.73e-8	Lipoprotein (a) levels;
CESC	cis	rs9916302	0.904	rs4795384	chr17:37716771	C/G	cg20243544	chr17:37824526	PNMT	0.51	6.15	0.35	2.82e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs854765	0.583	rs8078105	chr17:17853782	T/C	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.54	7.08	0.4	1.28e-11	Total body bone mineral density;
CESC	cis	rs6088580	0.668	rs1205340	chr20:32923871	G/A	cg24642439	chr20:33292090	TP53INP2	-0.51	-6.66	-0.38	1.53e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs2200578	1.000	rs12053519	chr2:99875018	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.51	5.67	0.33	3.71e-8	IgG glycosylation;
CESC	cis	rs2228479	0.702	rs17233253	chr16:89828437	A/G	cg06558623	chr16:89946397	TCF25	1.17	9.29	0.5	5.76e-18	Skin colour saturation;
CESC	cis	rs12136530	0.744	rs12090885	chr1:19779781	G/A	cg01832549	chr1:19774989	CAPZB	-0.48	-6.95	-0.39	2.8e-11	Lead levels in blood;
CESC	trans	rs7781266	0.790	rs2113565	chr7:133185211	A/G	cg06524120	chr15:77841106	NA	0.34	6.15	0.35	2.91e-9	Educational attainment (college completion);
CESC	cis	rs4835473	0.932	rs17018500	chr4:144746002	A/G	cg25736465	chr4:144833511	NA	-0.34	-5.44	-0.32	1.21e-7	Immature fraction of reticulocytes;
CESC	cis	rs344364	0.511	rs1742473	chr16:1953095	T/C	cg26617929	chr16:1858877	NA	-0.5	-5.21	-0.3	3.74e-7	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs12956009	0.518	rs71352652	chr18:44869536	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.51	6.75	0.38	9.47e-11	Educational attainment (years of education);
CESC	cis	rs1775715	0.737	rs12256714	chr10:32216262	A/G	cg18675610	chr10:32216311	ARHGAP12	-0.36	-5.46	-0.32	1.08e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs651907	0.557	rs7651406	chr3:101393296	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	7.0	0.39	2.15e-11	Colorectal cancer;
CESC	cis	rs67311347	0.955	rs9821036	chr3:40379007	A/G	cg24209194	chr3:40518798	ZNF619	0.42	5.36	0.31	1.82e-7	Renal cell carcinoma;
CESC	cis	rs752010	0.545	rs6600379	chr1:42053497	T/C	cg06885757	chr1:42089581	HIVEP3	0.48	7.59	0.42	5.35e-13	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs17826219	0.568	rs2626985	chr17:29077437	A/G	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.79e-10	Body mass index;
CESC	trans	rs208520	1.000	rs9453671	chr6:66991208	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.77	8.51	0.46	1.34e-15	Exhaled nitric oxide output;
CESC	cis	rs929354	0.772	rs6971896	chr7:156978412	C/T	cg05182265	chr7:156933206	UBE3C	-0.51	-7.5	-0.42	9.58e-13	Body mass index;
CESC	cis	rs3736485	0.966	rs8031903	chr15:51838161	C/T	cg08986416	chr15:51914746	DMXL2	-0.39	-5.03	-0.3	9.11e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs2836974	0.568	rs442972	chr21:40534757	C/T	cg11890956	chr21:40555474	PSMG1	-0.97	-16.63	-0.71	4.94e-43	Cognitive function;
CESC	trans	rs3741489	1.000	rs10161328	chr12:133481884	C/A	cg24132527	chr5:140019269	TMCO6	0.99	6.15	0.35	2.86e-9	Cognitive function;
CESC	cis	rs13082711	0.911	rs11708710	chr3:27457348	A/C	cg02860705	chr3:27208620	NA	0.59	7.39	0.41	1.94e-12	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CESC	cis	rs12971120	0.891	rs2278159	chr18:72178161	T/C	cg26446133	chr18:72167187	CNDP2	-0.74	-9.14	-0.49	1.69e-17	Refractive error;
CESC	cis	rs9403521	1.000	rs6907410	chr6:143995142	A/G	cg18240653	chr6:144019428	PHACTR2	-0.49	-5.57	-0.32	6.22e-8	Obesity-related traits;
CESC	cis	rs941873	0.868	rs1483733	chr10:81130036	A/G	cg09469691	chr10:81107165	PPIF	0.54	7.6	0.42	5.22e-13	Height;
CESC	cis	rs7605827	0.930	rs13001923	chr2:15521264	A/T	cg19274914	chr2:15703543	NA	0.35	6.27	0.36	1.43e-9	Educational attainment (years of education);
CESC	cis	rs7666738	0.830	rs7662948	chr4:99020132	G/C	cg03676636	chr4:99064102	C4orf37	0.34	5.2	0.3	3.93e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs514406	0.584	rs7548832	chr1:53193576	A/T	cg08859206	chr1:53392774	SCP2	-0.59	-7.66	-0.43	3.5e-13	Monocyte count;
CESC	trans	rs8073060	0.586	rs226084	chr17:34019582	T/A	cg19694781	chr19:47549865	TMEM160	-0.74	-6.91	-0.39	3.64e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	cis	rs7666738	0.830	rs10031751	chr4:98939134	G/A	cg03467027	chr4:99064603	C4orf37	0.48	5.91	0.34	1.03e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2806561	0.765	rs1738469	chr1:23511407	G/C	cg12483005	chr1:23474871	LUZP1	0.38	6.04	0.35	5.25e-9	Height;
CESC	cis	rs9914988	0.832	rs4795462	chr17:27130991	C/T	cg20469991	chr17:27169893	C17orf63	-0.48	-5.25	-0.31	3.18e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CESC	cis	rs4819052	0.851	rs2838855	chr21:46680566	C/G	cg20896738	chr21:46707857	POFUT2;LOC642852	-0.46	-5.93	-0.34	9.36e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs17253792	0.915	rs75296402	chr14:56182491	C/T	cg01858014	chr14:56050164	KTN1	-0.9	-7.2	-0.4	6.15e-12	Putamen volume;
CESC	trans	rs2235573	0.625	rs3026677	chr22:38432725	C/G	cg19894588	chr14:64061835	NA	0.48	6.13	0.35	3.14e-9	Glioblastoma;Glioma;
CESC	cis	rs7666738	0.830	rs10017201	chr4:98983561	G/A	cg18180107	chr4:99064573	C4orf37	0.4	5.19	0.3	4.29e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs875971	0.638	rs10249404	chr7:66046724	G/A	cg18876405	chr7:65276391	NA	-0.57	-7.63	-0.42	4.24e-13	Aortic root size;
CESC	cis	rs7084402	0.967	rs1593672	chr10:60294379	T/C	cg07615347	chr10:60278583	BICC1	0.62	9.85	0.52	1.05e-19	Refractive error;
CESC	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-6.15	-0.35	2.85e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg01553388	chr7:158703170	WDR60	0.48	6.13	0.35	3.19e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs13720	0.722	rs163800	chr20:57578508	C/T	cg23907860	chr20:57583709	CTSZ	0.46	5.45	0.32	1.16e-7	Platelet distribution width;
CESC	cis	rs826838	0.967	rs7299170	chr12:38789536	G/A	cg13010199	chr12:38710504	ALG10B	0.6	8.53	0.46	1.1e-15	Heart rate;
CESC	cis	rs1005277	0.602	rs2504142	chr10:38383793	C/T	cg25427524	chr10:38739819	LOC399744	-0.65	-9.48	-0.5	1.51e-18	Extrinsic epigenetic age acceleration;
CESC	cis	rs2286503	0.839	rs2240728	chr7:22852499	C/T	cg13679077	chr7:22862647	TOMM7	0.45	5.77	0.33	2.2e-8	Fibrinogen;
CESC	cis	rs11574514	1.000	rs8058835	chr16:67814865	C/T	cg26727032	chr16:67993705	SLC12A4	-0.58	-5.23	-0.31	3.37e-7	Crohn's disease;
CESC	cis	rs739401	0.595	rs6578304	chr11:2998279	A/G	cg08508325	chr11:3079039	CARS	0.46	8.25	0.45	7.39e-15	Longevity;
CESC	cis	rs2637266	0.685	rs2395427	chr10:78462535	G/A	cg18941641	chr10:78392320	NA	0.4	7.17	0.4	7.65e-12	Pulmonary function;
CESC	cis	rs2880765	0.835	rs12324277	chr15:86041735	G/A	cg10818794	chr15:86012489	AKAP13	-0.33	-5.09	-0.3	6.94e-7	Coronary artery disease;
CESC	cis	rs2066819	1.000	rs2306694	chr12:56680636	C/T	cg26804944	chr12:56660921	COQ10A	0.85	5.19	0.3	4.22e-7	Psoriasis vulgaris;
CESC	cis	rs11122272	0.735	rs2247124	chr1:231493687	A/G	cg06096015	chr1:231504339	EGLN1	0.43	6.13	0.35	3.23e-9	Hemoglobin concentration;
CESC	trans	rs55704346	0.566	rs28656285	chr4:25397026	C/A	cg01822600	chr1:245751692	KIF26B	0.42	6.12	0.35	3.41e-9	Tonsillectomy;
CESC	cis	rs1707322	0.686	rs2050376	chr1:46078630	C/T	cg03146154	chr1:46216737	IPP	0.76	10.41	0.54	1.69e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7605827	0.930	rs4668898	chr2:15511502	T/C	cg19274914	chr2:15703543	NA	0.31	5.51	0.32	8.66e-8	Educational attainment (years of education);
CESC	cis	rs5769765	0.542	rs5769751	chr22:50242733	T/G	cg02269571	chr22:50332266	NA	0.76	6.49	0.37	4.16e-10	Schizophrenia;
CESC	cis	rs6762	0.719	rs28655651	chr11:837121	G/C	cg23754390	chr11:835074	CD151	0.33	5.99	0.35	6.68e-9	Mean platelet volume;
CESC	cis	rs2456568	0.835	rs7936182	chr11:93665532	T/A	cg26875233	chr11:93583750	C11orf90	-0.31	-5.44	-0.32	1.23e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
CESC	cis	rs6426558	0.559	rs2813947	chr1:227459413	G/T	cg10327440	chr1:227177885	CDC42BPA	0.49	6.09	0.35	4.02e-9	Neutrophil percentage of white cells;
CESC	cis	rs11532322	1	rs11532322	chr12:123731423	A/G	cg19016782	chr12:123741754	C12orf65	-0.36	-5.38	-0.31	1.66e-7	Schizophrenia;
CESC	cis	rs11078597	0.731	rs8065251	chr17:1637458	G/A	cg18436246	chr17:1640651	WDR81	0.61	7.43	0.42	1.46e-12	Serum albumin level;
CESC	cis	rs1552244	0.882	rs61429272	chr3:10037320	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.74	-9.37	-0.5	3.42e-18	Alzheimer's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16435601	chr17:65822392	BPTF	0.56	6.16	0.35	2.75e-9	Gut microbiome composition (summer);
CESC	cis	rs1044826	0.667	rs2083336	chr3:139201272	T/G	cg00490450	chr3:139108681	COPB2	0.43	5.34	0.31	2.03e-7	Obesity-related traits;
CESC	cis	rs10504073	0.669	rs341802	chr8:50039313	C/T	cg00325661	chr8:49890786	NA	0.5	7.28	0.41	3.77e-12	Blood metabolite ratios;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg13929079	chr12:49246153	DDX23	-0.43	-6.21	-0.36	2e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs4319547	0.774	rs7959238	chr12:123131498	A/T	cg05707623	chr12:122985044	ZCCHC8	-0.47	-5.7	-0.33	3.26e-8	Body mass index;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21192376	chr14:53020168	GPR137C;TXNDC16	0.6	6.61	0.38	2.13e-10	Gut microbiome composition (summer);
CESC	cis	rs62432291	0.681	rs7757530	chr6:159647929	G/A	cg14500486	chr6:159655392	FNDC1	0.6	6.01	0.35	6.09e-9	Joint mobility (Beighton score);
CESC	cis	rs6815814	0.851	rs9715769	chr4:38774489	A/C	cg02016764	chr4:38805732	TLR1	-0.68	-8.1	-0.45	2.06e-14	Breast cancer;
CESC	cis	rs2980439	0.818	rs2945249	chr8:8094726	G/A	cg06636001	chr8:8085503	FLJ10661	0.63	8.0	0.44	4.01e-14	Neuroticism;
CESC	cis	rs3540	0.574	rs2657946	chr15:90967513	G/C	cg22089800	chr15:90895588	ZNF774	0.62	8.16	0.45	1.36e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs826838	0.585	rs12296822	chr12:38625829	A/T	cg26384229	chr12:38710491	ALG10B	-0.43	-5.65	-0.33	4.09e-8	Heart rate;
CESC	cis	rs6540559	1.000	rs4844895	chr1:209958580	T/C	cg22029157	chr1:209979665	IRF6	0.7	9.83	0.52	1.17e-19	Cleft lip with or without cleft palate;
CESC	cis	rs28830936	1.000	rs4923905	chr15:41909889	G/A	cg11010575	chr15:42129464	JMJD7-PLA2G4B;JMJD7	-0.36	-5.14	-0.3	5.26e-7	Diastolic blood pressure;
CESC	cis	rs9488822	0.651	rs3798228	chr6:116321156	T/C	cg18764771	chr6:116381957	FRK	0.22	5.44	0.32	1.21e-7	Cholesterol, total;LDL cholesterol;
CESC	cis	rs4253772	0.938	rs45550937	chr22:46638128	C/G	cg00784671	chr22:46762841	CELSR1	-0.51	-5.27	-0.31	2.87e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs55728055	0.661	rs16989334	chr22:32016092	A/G	cg01338084	chr22:32026380	PISD	1.15	8.07	0.44	2.41e-14	Age-related hearing impairment;
CESC	trans	rs9987353	0.840	rs329994	chr8:9123233	A/G	cg02284982	chr2:128145269	NA	-0.45	-6.31	-0.36	1.19e-9	Recombination measurement;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg17930852	chr1:45957182	TESK2	0.49	6.21	0.36	2e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs796364	0.616	rs7574313	chr2:200681040	C/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.57	5.23	0.31	3.39e-7	Schizophrenia;
CESC	cis	rs3106136	1.000	rs2664871	chr4:95146281	A/G	cg11021082	chr4:95130006	SMARCAD1	0.45	6.82	0.39	5.98e-11	Capecitabine sensitivity;
CESC	cis	rs2070488	0.804	rs13100195	chr3:38482539	A/G	cg24069376	chr3:38537580	EXOG	0.35	5.99	0.35	6.93e-9	Electrocardiographic conduction measures;
CESC	cis	rs9790314	1.000	rs163328	chr3:161073599	A/G	cg04691961	chr3:161091175	C3orf57	-0.41	-5.22	-0.31	3.68e-7	Morning vs. evening chronotype;
CESC	cis	rs7512552	0.809	rs698923	chr1:150379159	G/A	cg15654264	chr1:150340011	RPRD2	0.4	5.2	0.3	4.06e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.91	13.74	0.64	8.64e-33	Prudent dietary pattern;
CESC	cis	rs854765	0.603	rs4506967	chr17:17990474	A/C	cg04398451	chr17:18023971	MYO15A	-0.75	-11.07	-0.56	1.18e-23	Total body bone mineral density;
CESC	cis	rs3858526	0.920	rs10742832	chr11:5926020	C/G	cg13902645	chr11:5959945	NA	-0.62	-7.3	-0.41	3.35e-12	DNA methylation (variation);
CESC	cis	rs7408868	1.000	rs1548554	chr19:15277938	C/T	cg14696996	chr19:15285081	NOTCH3	1.11	11.94	0.59	1.43e-26	Pulse pressure;
CESC	cis	rs12995491	0.731	rs13019346	chr2:88509321	A/G	cg07952391	chr2:88470173	THNSL2	-0.46	-6.76	-0.38	8.53e-11	Response to metformin (IC50);
CESC	cis	rs829883	0.714	rs249847	chr12:98867716	C/T	cg25150519	chr12:98850993	NA	0.85	14.78	0.67	1.79e-36	Colorectal adenoma (advanced);
CESC	cis	rs2243480	1.000	rs316322	chr7:65611233	G/C	cg13147721	chr7:65941812	NA	-0.97	-9.15	-0.49	1.52e-17	Diabetic kidney disease;
CESC	cis	rs9911578	1.000	rs4793950	chr17:56593111	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	-0.4	-5.31	-0.31	2.38e-7	Intelligence (multi-trait analysis);
CESC	cis	rs1707322	1.000	rs6657720	chr1:46386269	G/A	cg05343316	chr1:45956843	TESK2	0.44	5.42	0.32	1.36e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9733	0.527	rs11204694	chr1:150653391	G/A	cg17724175	chr1:150552817	MCL1	0.42	6.82	0.39	6.06e-11	Tonsillectomy;
CESC	cis	rs6964587	1.000	rs10228800	chr7:91610111	T/G	cg17063962	chr7:91808500	NA	0.57	7.74	0.43	2.11e-13	Breast cancer;
CESC	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg06873352	chr17:61820015	STRADA	0.72	12.67	0.61	4.43e-29	Prudent dietary pattern;
CESC	cis	rs1062177	0.826	rs2915873	chr5:151156658	G/A	cg00977110	chr5:151150581	G3BP1	0.62	6.76	0.38	8.65e-11	Preschool internalizing problems;
CESC	cis	rs7818688	0.614	rs73269199	chr8:95841713	C/T	cg16049864	chr8:95962084	TP53INP1	0.49	5.17	0.3	4.64e-7	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs2228479	0.850	rs2239358	chr16:89827330	C/G	cg00800038	chr16:89945340	TCF25	-0.92	-7.62	-0.42	4.38e-13	Skin colour saturation;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg00748821	chr4:83932227	LIN54	-0.45	-6.03	-0.35	5.37e-9	Height;
CESC	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg23708337	chr7:1209742	NA	0.49	5.36	0.31	1.77e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7072216	0.763	rs733346	chr10:100164325	A/C	cg26618903	chr10:100175079	PYROXD2	-0.35	-5.33	-0.31	2.1e-7	Metabolite levels;
CESC	cis	rs34779708	0.966	rs11010129	chr10:35510822	T/C	cg03585969	chr10:35415529	CREM	0.75	9.46	0.5	1.78e-18	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs13102973	0.965	rs4864240	chr4:135856737	T/C	cg14419869	chr4:135874104	NA	-0.38	-6.02	-0.35	5.82e-9	Subjective well-being;
CESC	cis	rs17345786	0.511	rs1138818	chr3:101399583	C/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.46	5.91	0.34	1.07e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs35306767	0.761	rs11253537	chr10:1010735	G/A	cg25019033	chr10:957182	NA	-0.6	-6.19	-0.36	2.24e-9	Eosinophil percentage of granulocytes;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg16075951	chr14:24899050	CBLN3;KHNYN	-0.47	-6.72	-0.38	1.1e-10	Fibrinogen levels;
CESC	cis	rs1927790	0.727	rs12867783	chr13:96974576	A/T	cg02571835	chr13:96230311	CLDN10	-0.36	-5.21	-0.3	3.83e-7	Body mass index;
CESC	trans	rs4650994	0.525	rs4993304	chr1:178535144	A/G	cg05059571	chr16:84539110	KIAA1609	-0.4	-6.18	-0.35	2.36e-9	HDL cholesterol levels;HDL cholesterol;
CESC	cis	rs2070997	0.667	rs7042528	chr9:133686717	T/G	cg11464064	chr9:133710261	ABL1	0.57	6.36	0.36	8.71e-10	Response to amphetamines;
CESC	cis	rs2836950	0.545	rs8132424	chr21:40584412	A/T	cg11890956	chr21:40555474	PSMG1	0.65	9.2	0.49	1.11e-17	Menarche (age at onset);
CESC	cis	rs9911578	0.935	rs6503878	chr17:56884581	T/G	cg12560992	chr17:57184187	TRIM37	0.92	15.58	0.69	2.71e-39	Intelligence (multi-trait analysis);
CESC	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg26338869	chr17:61819248	STRADA	0.69	9.1	0.49	2.22e-17	Prudent dietary pattern;
CESC	cis	rs4812048	0.901	rs151355	chr20:57607645	G/C	cg14073986	chr20:57617431	SLMO2	0.55	5.79	0.33	2.01e-8	Mean platelet volume;
CESC	cis	rs2276314	0.793	rs77590522	chr18:33629410	C/G	cg05985134	chr18:33552581	C18orf21	0.64	7.27	0.41	4.15e-12	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg26338869	chr17:61819248	STRADA	0.67	8.8	0.48	1.77e-16	Prudent dietary pattern;
CESC	cis	rs7552404	1.000	rs12123977	chr1:76209754	A/G	cg10523679	chr1:76189770	ACADM	-0.69	-7.15	-0.4	8.47e-12	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs3126085	0.825	rs7535078	chr1:152222915	T/C	cg03465714	chr1:152285911	FLG	-0.43	-5.43	-0.32	1.27e-7	Atopic dermatitis;
CESC	cis	rs35146811	0.622	rs6946204	chr7:99589125	T/C	cg14163444	chr7:99595348	NA	-0.39	-5.24	-0.31	3.3e-7	Coronary artery disease;
CESC	cis	rs642803	0.613	rs565427	chr11:65532825	G/A	cg08755490	chr11:65554678	OVOL1	0.43	5.55	0.32	6.76e-8	Urate levels;
CESC	cis	rs12586317	0.547	rs10146699	chr14:35483577	G/A	cg16230307	chr14:35515116	FAM177A1	0.98	10.57	0.54	5.22e-22	Psoriasis;
CESC	cis	rs992157	0.560	rs4674275	chr2:219097738	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.57	-7.45	-0.42	1.29e-12	Colorectal cancer;
CESC	cis	rs853679	0.607	rs201002	chr6:27808192	A/G	cg12740337	chr6:28058973	ZSCAN12L1	0.34	5.04	0.3	8.76e-7	Depression;
CESC	cis	rs7258465	0.965	rs10409003	chr19:18543054	C/T	cg25828334	chr19:18545568	ISYNA1	-0.32	-5.21	-0.3	3.84e-7	Breast cancer;
CESC	cis	rs1729951	0.575	rs35289288	chr3:136680568	C/T	cg25687071	chr3:136751404	NA	0.39	5.17	0.3	4.72e-7	Neuroticism;
CESC	cis	rs2120019	0.938	rs2120020	chr15:75316845	T/C	cg17294928	chr15:75287854	SCAMP5	-0.76	-8.73	-0.47	3e-16	Blood trace element (Zn levels);
CESC	cis	rs9815354	0.812	rs78342280	chr3:41948810	G/A	cg03022575	chr3:42003672	ULK4	0.71	6.45	0.37	5.42e-10	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs965469	1.000	rs2281503	chr20:3263636	G/A	cg25506879	chr20:3388711	C20orf194	-0.55	-5.98	-0.35	7.01e-9	IFN-related cytopenia;
CESC	cis	rs16957304	1.000	rs8050745	chr16:67311767	G/A	cg26727032	chr16:67993705	SLC12A4	-0.54	-5.33	-0.31	2.09e-7	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
CESC	cis	rs9640161	0.871	rs56156367	chr7:150047201	A/T	cg21361702	chr7:150065534	REPIN1	0.48	5.12	0.3	5.96e-7	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs853679	1.000	rs853694	chr6:28279100	A/T	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.68	7.27	0.41	4.07e-12	Depression;
CESC	cis	rs7589342	0.899	rs10185551	chr2:106492201	A/C	cg16077055	chr2:106428750	NCK2	0.47	6.94	0.39	2.94e-11	Addiction;
CESC	cis	rs568617	1.000	rs568617	chr11:65653242	C/T	cg00576331	chr11:65640516	EFEMP2	-0.45	-5.35	-0.31	1.95e-7	Crohn's disease;
CESC	cis	rs2050392	0.894	rs2480277	chr10:30703513	G/T	cg18806716	chr10:30721971	MAP3K8	0.43	6.12	0.35	3.26e-9	Inflammatory bowel disease;
CESC	cis	rs10927875	0.800	rs1627145	chr1:16328116	C/T	cg21214613	chr1:16344536	HSPB7	0.37	5.25	0.31	3.1e-7	Dilated cardiomyopathy;
CESC	cis	rs9911578	1.000	rs12947785	chr17:57045160	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.38	5.08	0.3	7.21e-7	Intelligence (multi-trait analysis);
CESC	cis	rs9611565	0.559	rs132771	chr22:42025350	A/G	cg06634786	chr22:41940651	POLR3H	0.59	6.01	0.35	6.19e-9	Vitiligo;
CESC	cis	rs10504229	0.683	rs10504223	chr8:58140944	G/A	cg22535103	chr8:58192502	C8orf71	-0.8	-9.09	-0.49	2.46e-17	Developmental language disorder (linguistic errors);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04624059	chr7:99063424	ATP5J2	0.49	6.2	0.36	2.21e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs9733	0.596	rs2065900	chr1:150652202	A/G	cg17724175	chr1:150552817	MCL1	0.44	7.21	0.41	5.8e-12	Tonsillectomy;
CESC	cis	rs2294693	0.945	rs9369255	chr6:40989503	T/C	cg14418226	chr6:40996092	UNC5CL	0.53	6.34	0.36	9.61e-10	Gastric cancer;Non-cardia gastric cancer;
CESC	cis	rs6120849	0.754	rs6120788	chr20:33583716	C/T	cg24642439	chr20:33292090	TP53INP2	0.66	6.52	0.37	3.59e-10	Protein C levels;
CESC	cis	rs875971	0.895	rs778700	chr7:65866450	C/T	cg18876405	chr7:65276391	NA	0.5	6.68	0.38	1.43e-10	Aortic root size;
CESC	cis	rs62458065	0.513	rs9655340	chr7:32535920	A/G	cg20159608	chr7:32802032	NA	0.55	6.16	0.35	2.74e-9	Metabolite levels (HVA/MHPG ratio);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg16424138	chr5:14581771	FAM105A	-0.4	-6.23	-0.36	1.86e-9	Gambling;
CESC	cis	rs9913156	0.589	rs7213481	chr17:4547906	C/T	cg19197139	chr17:4613644	ARRB2	0.93	10.3	0.53	3.78e-21	Lymphocyte counts;
CESC	cis	rs116095464	0.558	rs10055993	chr5:264296	A/C	cg22496380	chr5:211416	CCDC127	-0.98	-9.81	-0.52	1.42e-19	Breast cancer;
CESC	cis	rs6952808	0.792	rs12536261	chr7:1953571	G/A	cg21782813	chr7:2030301	MAD1L1	0.42	6.13	0.35	3.12e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs9287719	0.967	rs6709466	chr2:10748257	T/C	cg02196655	chr2:10830764	NOL10	-0.38	-5.79	-0.34	1.96e-8	Prostate cancer;
CESC	trans	rs7628583	0.877	rs12494731	chr3:64082003	G/T	cg08723793	chr12:861752	WNK1	-0.59	-6.02	-0.35	5.81e-9	Parental extreme longevity (95 years and older);
CESC	cis	rs2463822	1.000	rs12279819	chr11:62137245	G/A	cg06239285	chr11:62104954	ASRGL1	-0.96	-8.49	-0.46	1.54e-15	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs637571	0.524	rs674363	chr11:65699134	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.63	-8.23	-0.45	8.45e-15	Eosinophil percentage of white cells;
CESC	cis	rs1707322	1.000	rs1768800	chr1:46549188	A/G	cg03146154	chr1:46216737	IPP	-0.69	-9.04	-0.49	3.51e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg11857246	chr1:11741390	MAD2L2	-0.47	-6.08	-0.35	4.18e-9	Fibrinogen levels;
CESC	cis	rs1949733	1.000	rs6447875	chr4:8503206	T/C	cg11789530	chr4:8429930	ACOX3	0.74	10.46	0.54	1.14e-21	Response to antineoplastic agents;
CESC	cis	rs7662987	0.517	rs2851256	chr4:100039549	G/A	cg13256891	chr4:100009986	ADH5	0.75	8.03	0.44	3.29e-14	Smoking initiation;
CESC	cis	rs4713118	0.662	rs9468274	chr6:28026077	G/T	cg18032046	chr6:28092343	ZSCAN16	-0.54	-6.2	-0.36	2.21e-9	Parkinson's disease;
CESC	cis	rs7833790	0.660	rs7839178	chr8:82763479	A/G	cg07697082	chr8:82753677	SNX16	-0.39	-6.12	-0.35	3.32e-9	Diastolic blood pressure;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02331450	chr3:33155354	CRTAP	0.66	8.14	0.45	1.52e-14	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04158140	chr7:71407448	CALN1	-0.53	-6.09	-0.35	4.03e-9	Gut microbiome composition (summer);
CESC	cis	rs7618915	0.501	rs6617	chr3:52740182	C/G	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.73	0.38	1.07e-10	Bipolar disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03786933	chr16:69760418	NQO1	0.56	6.03	0.35	5.57e-9	Gut microbiome composition (summer);
CESC	trans	rs2727020	0.612	rs603672	chr11:49234566	T/A	cg03929089	chr4:120376271	NA	0.78	11.75	0.59	5.9e-26	Coronary artery disease;
CESC	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg14159672	chr1:205819179	PM20D1	0.79	12.05	0.59	6.01e-27	Menarche (age at onset);
CESC	cis	rs1707322	1.000	rs6429580	chr1:46275648	A/G	cg06784218	chr1:46089804	CCDC17	0.33	5.7	0.33	3.24e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs6987853	0.787	rs2974335	chr8:42417272	C/T	cg09913449	chr8:42400586	C8orf40	0.45	7.44	0.42	1.39e-12	Mean corpuscular hemoglobin concentration;
CESC	cis	rs12042052	1.000	rs6669303	chr1:232912728	G/A	cg00951395	chr1:232941775	KIAA1383	0.7	6.94	0.39	3.02e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CESC	cis	rs7811142	0.830	rs7792959	chr7:99972403	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.74	7.36	0.41	2.29e-12	Platelet count;
CESC	cis	rs7605827	0.930	rs11692377	chr2:15659848	C/T	cg19274914	chr2:15703543	NA	0.36	6.31	0.36	1.18e-9	Educational attainment (years of education);
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg11038604	chr10:14996337	DCLRE1C	-0.47	-6.04	-0.35	5.3e-9	Thyroid stimulating hormone;
CESC	cis	rs1008375	0.966	rs2872957	chr4:17651757	C/A	cg15017067	chr4:17643749	FAM184B	0.38	5.35	0.31	1.86e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs1552244	1.000	rs76041173	chr3:10078695	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.87	12.0	0.59	9.03e-27	Alzheimer's disease;
CESC	cis	rs11122272	0.735	rs11122281	chr1:231519842	A/G	cg06096015	chr1:231504339	EGLN1	0.43	6.11	0.35	3.47e-9	Hemoglobin concentration;
CESC	cis	rs9894429	0.646	rs8080391	chr17:79566319	A/T	cg13777783	chr17:79615861	NA	0.34	5.39	0.31	1.53e-7	Eye color traits;
CESC	cis	rs4665809	1.000	rs750452	chr2:26324995	G/A	cg08470875	chr2:26401718	FAM59B	-0.47	-5.22	-0.31	3.6e-7	Gut microbiome composition (summer);
CESC	cis	rs1023500	0.596	rs133369	chr22:42463814	C/T	cg12850546	chr22:42539477	CYP2D7P1	-0.45	-5.4	-0.31	1.49e-7	Schizophrenia;
CESC	cis	rs6500395	1.000	rs9933329	chr16:48646572	T/C	cg04672837	chr16:48644449	N4BP1	0.5	6.07	0.35	4.3e-9	Response to tocilizumab in rheumatoid arthritis;
CESC	trans	rs2832077	0.527	rs2832116	chr21:30228368	C/A	cg14791747	chr16:20752902	THUMPD1	0.53	7.48	0.42	1.12e-12	Cognitive test performance;
CESC	cis	rs7772486	0.720	rs9403757	chr6:146261271	C/T	cg05347473	chr6:146136440	FBXO30	-0.55	-7.0	-0.39	2.12e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7666738	0.719	rs4699323	chr4:98967484	G/A	cg05340658	chr4:99064831	C4orf37	0.5	5.61	0.33	5.04e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg25192855	chr1:209979283	IRF6	0.32	6.01	0.35	6.04e-9	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
CESC	cis	rs6460942	0.915	rs62447641	chr7:12488764	G/A	cg20607287	chr7:12443886	VWDE	-0.76	-8.61	-0.47	6.79e-16	Coronary artery disease;
CESC	cis	rs4665809	0.590	rs2033317	chr2:26477650	G/A	cg26314531	chr2:26401878	FAM59B	0.85	9.23	0.49	8.65e-18	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.830	rs60994860	chr4:99046753	G/A	cg18180107	chr4:99064573	C4orf37	0.41	5.29	0.31	2.51e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg14893161	chr1:205819251	PM20D1	0.98	18.76	0.76	1.49e-50	Menarche (age at onset);
CESC	cis	rs9902453	0.868	rs11080118	chr17:28475379	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.62	-7.74	-0.43	2.11e-13	Coffee consumption (cups per day);
CESC	cis	rs4853012	0.539	rs9789534	chr2:74362990	A/T	cg05890377	chr2:74357713	NA	0.56	6.58	0.37	2.51e-10	Gestational age at birth (maternal effect);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12733656	chr7:6388695	C7orf70	0.58	6.11	0.35	3.62e-9	Gut microbiome composition (summer);
CESC	cis	rs17253792	0.822	rs76612185	chr14:56037706	T/C	cg01858014	chr14:56050164	KTN1	-0.94	-6.77	-0.38	8.05e-11	Putamen volume;
CESC	cis	rs13108904	0.901	rs6851528	chr4:1296009	G/A	cg16405210	chr4:1374714	KIAA1530	-0.49	-6.2	-0.36	2.2e-9	Obesity-related traits;
CESC	cis	rs5758659	0.652	rs133340	chr22:42417687	A/T	cg04733989	chr22:42467013	NAGA	-0.4	-5.36	-0.31	1.85e-7	Cognitive function;
CESC	cis	rs2797685	1.000	rs2640908	chr1:7889941	C/T	cg04725166	chr1:7887271	PER3	-0.47	-6.42	-0.37	6.44e-10	Crohn's disease;
CESC	cis	rs1552244	0.510	rs13075308	chr3:10034925	G/C	cg00149659	chr3:10157352	C3orf10	0.71	8.45	0.46	2.01e-15	Alzheimer's disease;
CESC	cis	rs7191700	0.674	rs12597893	chr16:11426331	A/G	cg00044050	chr16:11439710	C16orf75	0.46	5.71	0.33	3.02e-8	Multiple sclerosis;
CESC	cis	rs4704187	0.687	rs9293643	chr5:74365053	C/T	cg03227963	chr5:74354835	NA	-0.3	-5.6	-0.33	5.45e-8	Response to amphetamines;
CESC	cis	rs965469	1.000	rs6139068	chr20:3284393	G/A	cg25506879	chr20:3388711	C20orf194	-0.58	-6.15	-0.35	2.79e-9	IFN-related cytopenia;
CESC	cis	rs9291683	0.595	rs13150928	chr4:10052961	G/T	cg02734326	chr4:10020555	SLC2A9	0.48	6.82	0.39	6.29e-11	Bone mineral density;
CESC	cis	rs6912958	0.559	rs242270	chr6:88062190	C/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.71	-10.74	-0.55	1.42e-22	Monocyte percentage of white cells;
CESC	cis	rs2011503	0.882	rs10401714	chr19:19363630	G/A	cg11584989	chr19:19387371	SF4	0.53	6.41	0.37	6.52e-10	Bipolar disorder;
CESC	cis	rs7584330	0.554	rs10178682	chr2:238433818	T/G	cg14458575	chr2:238380390	NA	0.49	5.42	0.32	1.35e-7	Prostate cancer;
CESC	cis	rs7618915	0.501	rs6804145	chr3:52694198	C/T	cg05564831	chr3:52568323	NT5DC2	0.46	7.38	0.41	2.06e-12	Bipolar disorder;
CESC	cis	rs10992471	0.756	rs2516568	chr9:95187380	A/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.45	-5.73	-0.33	2.77e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CESC	cis	rs1799949	0.965	rs9911630	chr17:41188342	A/G	cg25072359	chr17:41440525	NA	0.52	7.53	0.42	8e-13	Menopause (age at onset);
CESC	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.65	7.44	0.42	1.4e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs1153858	1.000	rs4775909	chr15:45643042	T/C	cg14582100	chr15:45693742	SPATA5L1	0.42	6.08	0.35	4.2e-9	Homoarginine levels;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg19942813	chr3:187463496	BCL6	0.44	6.01	0.35	6e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs1395	0.778	rs2580761	chr2:27426362	G/A	cg22903471	chr2:27725779	GCKR	-0.42	-5.21	-0.3	3.81e-7	Blood metabolite levels;
CESC	cis	rs4665809	0.590	rs7579504	chr2:26439995	T/C	cg26314531	chr2:26401878	FAM59B	-0.85	-9.04	-0.49	3.44e-17	Gut microbiome composition (summer);
CESC	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.52	0.37	3.63e-10	Prudent dietary pattern;
CESC	cis	rs1862618	0.853	rs866222	chr5:56184444	T/C	cg12311346	chr5:56204834	C5orf35	-0.74	-8.81	-0.48	1.71e-16	Initial pursuit acceleration;
CESC	cis	rs858239	0.632	rs1985769	chr7:23122506	T/G	cg23682824	chr7:23144976	KLHL7	0.54	7.54	0.42	7.42e-13	Cerebrospinal fluid biomarker levels;
CESC	cis	rs17253792	0.822	rs76055105	chr14:56069127	A/G	cg01858014	chr14:56050164	KTN1	-0.85	-6.99	-0.39	2.22e-11	Putamen volume;
CESC	cis	rs847577	1.000	rs847577	chr7:97694858	T/A	cg24562669	chr7:97807699	LMTK2	-0.64	-10.43	-0.54	1.45e-21	Breast cancer;
CESC	cis	rs9987353	0.544	rs2929470	chr8:9062490	A/G	cg15556689	chr8:8085844	FLJ10661	-0.43	-5.03	-0.3	9.18e-7	Recombination measurement;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01594214	chr6:123110554	SMPDL3A	0.61	7.13	0.4	9.49e-12	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.791	rs2865953	chr4:99040319	C/T	cg03676636	chr4:99064102	C4orf37	0.33	5.12	0.3	5.92e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9486719	0.895	rs34051754	chr6:97007754	A/T	cg06623918	chr6:96969491	KIAA0776	-0.8	-8.3	-0.45	5.39e-15	Migraine;Coronary artery disease;
CESC	cis	rs1950626	0.623	rs4402490	chr14:101445453	A/G	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	-0.67	-9.14	-0.49	1.7e-17	Pelvic organ prolapse (moderate/severe);
CESC	cis	rs6424115	0.830	rs2502994	chr1:24199363	T/C	cg10978503	chr1:24200527	CNR2	0.33	6.63	0.38	1.85e-10	Immature fraction of reticulocytes;
CESC	cis	rs9486719	0.843	rs3849198	chr6:97036539	C/A	cg18709589	chr6:96969512	KIAA0776	-0.5	-5.44	-0.32	1.21e-7	Migraine;Coronary artery disease;
CESC	cis	rs9311474	0.508	rs6786043	chr3:52604861	A/G	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.38	6.93	0.39	3.18e-11	Electroencephalogram traits;
CESC	trans	rs875971	0.964	rs778723	chr7:65829497	T/C	cg26939375	chr7:64535504	NA	0.47	6.14	0.35	3e-9	Aortic root size;
CESC	cis	rs916888	0.779	rs430685	chr17:44859148	T/C	cg01570182	chr17:44337453	NA	-0.88	-10.64	-0.55	2.96e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs10131894	0.611	rs175002	chr14:75436466	C/G	cg11812906	chr14:75593930	NEK9	0.64	9.79	0.52	1.68e-19	Coronary artery disease;
CESC	cis	rs7103648	0.864	rs10769264	chr11:47423340	C/T	cg20307385	chr11:47447363	PSMC3	0.97	16.8	0.72	1.29e-43	Diastolic blood pressure;Systolic blood pressure;
CESC	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.38	5.28	0.31	2.73e-7	Lymphocyte counts;
CESC	cis	rs853679	0.517	rs9380049	chr6:28048535	A/G	cg23161317	chr6:28129485	ZNF389	0.5	6.31	0.36	1.19e-9	Depression;
CESC	cis	rs7843479	0.582	rs11135743	chr8:21803008	A/G	cg17168535	chr8:21777572	XPO7	0.73	12.01	0.59	8.24e-27	Mean corpuscular volume;
CESC	cis	rs17376456	0.757	rs10066431	chr5:93198204	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.63	5.37	0.31	1.74e-7	Diabetic retinopathy;
CESC	cis	rs10851478	0.872	rs55904469	chr15:49789971	G/A	cg08060515	chr15:49448048	GALK2;COPS2	0.42	5.22	0.31	3.56e-7	Oral cavity cancer;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg00692971	chr15:101142510	ASB7;LINS1	-0.47	-6.32	-0.36	1.12e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs3820068	0.581	rs74054797	chr1:15926217	G/A	cg13390004	chr1:15929781	NA	0.35	5.58	0.32	5.83e-8	Systolic blood pressure;
CESC	cis	rs3733585	0.699	rs7699609	chr4:9961059	A/G	cg00071950	chr4:10020882	SLC2A9	-0.73	-11.79	-0.59	4.58e-26	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs12142240	0.698	rs17357621	chr1:46807697	C/T	cg10495392	chr1:46806563	NSUN4	0.59	6.34	0.36	9.65e-10	Menopause (age at onset);
CESC	cis	rs2303759	0.918	rs2288480	chr19:49867016	C/G	cg24324837	chr19:49891574	CCDC155	0.5	5.97	0.34	7.77e-9	Multiple sclerosis;
CESC	cis	rs7843479	0.543	rs10866823	chr8:21781629	C/T	cg17168535	chr8:21777572	XPO7	0.75	12.02	0.59	7.62e-27	Mean corpuscular volume;
CESC	cis	rs1552244	1.000	rs1552244	chr3:10135577	A/G	cg00149659	chr3:10157352	C3orf10	0.72	9.05	0.49	3.14e-17	Alzheimer's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01335785	chr19:7505029	ARHGEF18	-0.55	-6.14	-0.35	2.99e-9	Gut microbiome composition (summer);
CESC	cis	rs11741688	0.557	rs6897783	chr5:178330574	G/A	cg20935368	chr5:178288625	ZNF354B	0.34	5.4	0.32	1.45e-7	Sleep duration;
CESC	cis	rs2404602	0.692	rs7163397	chr15:76940315	A/G	cg26408565	chr15:76604113	ETFA	-0.39	-5.56	-0.32	6.72e-8	Blood metabolite levels;
CESC	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg14893161	chr1:205819251	PM20D1	0.89	15.4	0.69	1.2e-38	Menarche (age at onset);
CESC	cis	rs1008375	1.000	rs3933453	chr4:17636319	A/C	cg02297831	chr4:17616191	MED28	0.6	7.59	0.42	5.34e-13	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs10823500	0.640	rs7077538	chr10:71993094	T/G	cg04118878	chr10:71993077	PPA1	0.53	6.33	0.36	1.02e-9	Blood protein levels;
CESC	cis	rs1218582	0.774	rs4845683	chr1:154877407	T/C	cg16680214	chr1:154839983	KCNN3	-0.51	-8.02	-0.44	3.39e-14	Prostate cancer;
CESC	cis	rs9322193	0.962	rs1112730	chr6:150087519	G/A	cg05861140	chr6:150128134	PCMT1	-0.38	-5.43	-0.32	1.29e-7	Lung cancer;
CESC	cis	rs4423214	1.000	rs2276361	chr11:71169648	A/G	cg05163923	chr11:71159392	DHCR7	0.85	11.46	0.58	5.81e-25	Vitamin D levels;
CESC	cis	rs7680126	0.633	rs55766779	chr4:10287039	C/T	cg11266682	chr4:10021025	SLC2A9	-0.45	-5.69	-0.33	3.42e-8	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	cis	rs4835473	0.770	rs4835096	chr4:144881838	G/C	cg25736465	chr4:144833511	NA	0.39	5.87	0.34	1.31e-8	Immature fraction of reticulocytes;
CESC	cis	rs7474896	0.583	rs7071147	chr10:38003376	T/C	cg25427524	chr10:38739819	LOC399744	-0.48	-5.6	-0.33	5.35e-8	Obesity (extreme);
CESC	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg14159672	chr1:205819179	PM20D1	0.73	10.65	0.55	2.73e-22	Menarche (age at onset);
CESC	cis	rs72781680	0.752	rs72796116	chr2:23913769	C/T	cg20701182	chr2:24300061	SF3B14	0.8	6.89	0.39	3.98e-11	Lymphocyte counts;
CESC	cis	rs3741151	0.686	rs7129990	chr11:73124441	A/G	cg17517138	chr11:73019481	ARHGEF17	0.57	5.45	0.32	1.13e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs2228479	0.557	rs62054639	chr16:89821489	C/T	cg00800038	chr16:89945340	TCF25	-0.91	-7.54	-0.42	7.39e-13	Skin colour saturation;
CESC	cis	rs796364	1.000	rs281788	chr2:200783705	A/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.89	8.76	0.47	2.43e-16	Schizophrenia;
CESC	cis	rs6546550	0.901	rs13028508	chr2:70118427	A/T	cg02498382	chr2:70120550	SNRNP27	0.41	7.26	0.41	4.4e-12	Prevalent atrial fibrillation;
CESC	cis	rs12477438	0.501	rs7349217	chr2:99815146	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.88	15.87	0.7	2.51e-40	Chronic sinus infection;
CESC	cis	rs1568889	1.000	rs58502944	chr11:28060943	C/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.81	10.82	0.55	7.89e-23	Bipolar disorder;
CESC	cis	rs12451471	0.559	rs1042396	chr17:78084769	G/A	cg06718696	chr17:78121285	EIF4A3	0.79	9.46	0.5	1.75e-18	Plateletcrit;Mean corpuscular hemoglobin concentration;
CESC	cis	rs11098499	1.000	rs28374891	chr4:120183550	G/A	cg09307838	chr4:120376055	NA	0.87	11.56	0.58	2.66e-25	Corneal astigmatism;
CESC	cis	rs9640161	0.830	rs6722	chr7:150068933	T/C	cg10018233	chr7:150070692	REPIN1	0.5	9.5	0.5	1.32e-18	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs2070433	0.799	rs7279002	chr21:47910523	C/T	cg12379764	chr21:47803548	PCNT	-0.48	-5.79	-0.34	1.95e-8	Lymphocyte counts;
CESC	cis	rs265548	0.608	rs36690	chr19:17910483	C/T	cg16744531	chr19:17905626	B3GNT3	0.59	8.25	0.45	7.64e-15	Tumor biomarkers;
CESC	cis	rs798554	0.679	rs1636249	chr7:2884283	T/G	cg04166393	chr7:2884313	GNA12	0.61	8.37	0.46	3.4e-15	Height;
CESC	cis	rs7605827	0.930	rs11687702	chr2:15682857	T/C	cg19274914	chr2:15703543	NA	0.37	6.7	0.38	1.22e-10	Educational attainment (years of education);
CESC	cis	rs7091068	0.616	rs1409336	chr10:95479674	T/G	cg20715218	chr10:95462985	C10orf4	0.55	5.55	0.32	6.92e-8	Urinary tract infection frequency;
CESC	cis	rs926938	0.527	rs360681	chr1:115496741	C/G	cg12756093	chr1:115239321	AMPD1	0.44	6.13	0.35	3.24e-9	Autism;
CESC	cis	rs13191362	1.000	rs67042566	chr6:163006541	A/T	cg14584255	chr6:163149320	PACRG;PARK2	0.5	5.19	0.3	4.29e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs7847628	0.550	rs12343516	chr9:123603469	A/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.45	7.87	0.44	8.87e-14	Birth weight;
CESC	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.6	0.38	2.17e-10	Prudent dietary pattern;
CESC	cis	rs6460942	0.915	rs7803051	chr7:12306904	A/T	cg06484146	chr7:12443880	VWDE	-0.47	-6.41	-0.37	6.52e-10	Coronary artery disease;
CESC	cis	rs2204008	0.606	rs1581358	chr12:38391582	G/T	cg13010199	chr12:38710504	ALG10B	0.53	6.42	0.37	6.13e-10	Bladder cancer;
CESC	cis	rs6582630	0.519	rs11495699	chr12:38286219	G/T	cg26384229	chr12:38710491	ALG10B	0.71	9.77	0.51	1.9e-19	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs4718428	0.705	rs4717328	chr7:66352665	T/C	cg25985355	chr7:65971099	NA	-0.35	-5.11	-0.3	6.03e-7	Corneal structure;
CESC	cis	rs644799	0.625	rs1255177	chr11:95471495	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.5	6.94	0.39	2.96e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs7546094	1.000	rs2999155	chr1:113221658	G/A	cg22162597	chr1:113214053	CAPZA1	-0.39	-5.95	-0.34	8.53e-9	Platelet distribution width;
CESC	cis	rs12541635	0.934	rs62527400	chr8:107054229	G/A	cg10147462	chr8:107024639	NA	0.43	6.01	0.35	6.12e-9	Age of smoking initiation;
CESC	cis	rs7927592	0.956	rs7113287	chr11:68372186	A/T	cg20283391	chr11:68216788	NA	-0.47	-5.94	-0.34	8.73e-9	Total body bone mineral density;
CESC	cis	rs6089584	0.566	rs6061963	chr20:60607480	C/G	cg24733560	chr20:60626293	TAF4	0.45	6.66	0.38	1.55e-10	Body mass index;
CESC	cis	rs9322193	0.923	rs9800871	chr6:149965676	A/G	cg13206674	chr6:150067644	NUP43	0.44	6.31	0.36	1.16e-9	Lung cancer;
CESC	trans	rs526821	0.595	rs499446	chr11:55355722	A/G	cg03929089	chr4:120376271	NA	-0.5	-6.07	-0.35	4.33e-9	Pediatric bone mineral density (spine);
CESC	cis	rs11155671	0.530	rs4869763	chr6:150211684	T/C	cg09699651	chr6:150184138	LRP11	0.55	7.64	0.42	3.95e-13	Testicular germ cell tumor;
CESC	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg11905131	chr22:24372483	LOC391322	-0.82	-12.08	-0.6	4.77e-27	Liver enzyme levels (gamma-glutamyl transferase);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg13866129	chr11:62623438	SNORD27;SLC3A2;SNORD28;SNORD25;SNORD26;SNHG1	0.43	6.06	0.35	4.74e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs3820068	0.603	rs56032936	chr1:15970953	T/C	cg13390004	chr1:15929781	NA	0.36	5.74	0.33	2.61e-8	Systolic blood pressure;
CESC	cis	rs763014	0.931	rs2071982	chr16:630405	T/G	cg00908189	chr16:619842	PIGQ	0.67	9.39	0.5	2.81e-18	Height;
CESC	cis	rs4253772	0.614	rs11090859	chr22:46687460	T/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.78	9.17	0.49	1.32e-17	LDL cholesterol;Cholesterol, total;
CESC	cis	rs7084402	0.935	rs10763553	chr10:60274049	C/A	cg07615347	chr10:60278583	BICC1	-0.57	-9.01	-0.48	4.08e-17	Refractive error;
CESC	cis	rs7520050	0.553	rs2993263	chr1:46021630	A/G	cg24296786	chr1:45957014	TESK2	-0.58	-7.71	-0.43	2.58e-13	Red blood cell count;Reticulocyte count;
CESC	cis	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06045062	chr4:100009749	ADH5	0.63	7.54	0.42	7.69e-13	Gut microbiome composition (summer);
CESC	cis	rs644799	1.000	rs644799	chr11:95564259	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.55	6.66	0.38	1.6e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs7833986	0.501	rs2953898	chr8:56980803	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.61	7.55	0.42	6.89e-13	Height;
CESC	cis	rs3008870	0.755	rs1925410	chr1:67365230	C/T	cg02640540	chr1:67518911	SLC35D1	-0.47	-5.71	-0.33	3.03e-8	Lymphocyte percentage of white cells;
CESC	cis	rs4595586	0.505	rs11615603	chr12:39409450	C/G	cg26384229	chr12:38710491	ALG10B	0.54	7.64	0.42	3.96e-13	Morning vs. evening chronotype;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11228005	chr3:197477097	FYTTD1;KIAA0226	0.67	7.39	0.41	1.92e-12	Gut microbiome composition (summer);
CESC	cis	rs1552244	1.000	rs68045038	chr3:10151828	A/G	cg08888203	chr3:10149979	C3orf24	0.45	5.71	0.33	3.04e-8	Alzheimer's disease;
CESC	cis	rs72829446	0.530	rs11869864	chr17:7407766	C/A	cg02795151	chr17:7402630	POLR2A	0.6	6.56	0.37	2.83e-10	Androgen levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09265274	chr17:48585635	MYCBPAP	-0.59	-7.21	-0.4	6.02e-12	Gut microbiome composition (summer);
CESC	cis	rs4629180	0.586	rs1509495	chr2:102134834	C/T	cg04415270	chr2:102091202	RFX8	-0.32	-5.33	-0.31	2.1e-7	Chronic rhinosinusitis with nasal polyps;
CESC	cis	rs6915183	1.000	rs6934656	chr6:166706121	A/G	cg14022523	chr6:166756177	SFT2D1	-0.53	-7.05	-0.4	1.54e-11	Longevity;
CESC	cis	rs10504229	1.000	rs6987435	chr8:58177334	G/A	cg05313129	chr8:58192883	C8orf71	-0.53	-6.13	-0.35	3.11e-9	Developmental language disorder (linguistic errors);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg02951695	chr10:134400351	INPP5A	0.49	6.3	0.36	1.21e-9	Fibrinogen levels;
CESC	cis	rs10905065	0.965	rs10795520	chr10:5764160	G/A	cg11519256	chr10:5708881	ASB13	0.46	6.23	0.36	1.84e-9	Menopause (age at onset);
CESC	cis	rs7208859	0.623	rs9915546	chr17:29132144	G/T	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.79e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs7552404	0.691	rs61770550	chr1:76366966	C/T	cg22875332	chr1:76189707	ACADM	0.58	5.73	0.33	2.66e-8	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs7503807	0.837	rs9915667	chr17:78754340	A/G	cg09596252	chr17:78655493	RPTOR	-0.43	-5.82	-0.34	1.66e-8	Obesity;
CESC	cis	rs7666738	0.546	rs11727151	chr4:98837353	A/C	cg05340658	chr4:99064831	C4orf37	0.52	6.33	0.36	1.04e-9	Colonoscopy-negative controls vs population controls;
CESC	trans	rs6572548	0.504	rs1956082	chr14:49665496	A/C	cg23285320	chr19:36546349	THAP8;WDR62	-0.57	-6.42	-0.37	6.35e-10	Subjective well-being;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10771518	chr10:115439279	CASP7	0.58	6.89	0.39	4.03e-11	Gut microbiome composition (summer);
CESC	cis	rs1799949	1.000	rs1960605	chr17:41305397	C/T	cg06001716	chr17:41278141	BRCA1;NBR2	0.38	5.2	0.3	3.96e-7	Menopause (age at onset);
CESC	cis	rs2760061	0.626	rs591582	chr1:228117360	C/A	cg01973587	chr1:228161476	NA	0.36	5.44	0.32	1.22e-7	Diastolic blood pressure;
CESC	cis	rs798554	0.644	rs1639040	chr7:2884116	G/T	cg13628971	chr7:2884303	GNA12	0.64	8.78	0.47	2.11e-16	Height;
CESC	cis	rs66887589	0.967	rs59516282	chr4:120502016	G/A	cg09307838	chr4:120376055	NA	-0.52	-7.05	-0.4	1.56e-11	Diastolic blood pressure;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg22967283	chr7:4815538	KIAA0415	-0.45	-6.09	-0.35	3.94e-9	Fibrinogen levels;
CESC	cis	rs6032067	0.929	rs17424668	chr20:43809647	C/T	cg11264863	chr20:43835661	SEMG1	-0.48	-5.37	-0.31	1.7e-7	Blood protein levels;
CESC	cis	rs477895	0.713	rs67546972	chr11:63962162	G/A	cg18225595	chr11:63971243	STIP1	0.52	5.19	0.3	4.19e-7	Mean platelet volume;
CESC	cis	rs8062405	0.755	rs4788080	chr16:28558081	C/T	cg01378222	chr16:28622494	SULT1A1	0.3	5.14	0.3	5.27e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs2836974	0.831	rs11911149	chr21:40528375	C/T	cg11890956	chr21:40555474	PSMG1	1.18	24.03	0.83	1.59e-68	Cognitive function;
CESC	cis	rs2839186	0.934	rs13046494	chr21:47707430	A/C	cg10351095	chr21:47802916	PCNT	-0.5	-6.8	-0.39	7.02e-11	Testicular germ cell tumor;
CESC	cis	rs1552244	1.000	rs9834980	chr3:10065528	G/A	cg00149659	chr3:10157352	C3orf10	0.75	9.05	0.49	3.07e-17	Alzheimer's disease;
CESC	cis	rs3096299	0.719	rs2353581	chr16:89518908	T/C	cg02187348	chr16:89574699	SPG7	0.64	8.84	0.48	1.39e-16	Multiple myeloma (IgH translocation);
CESC	cis	rs6570726	0.846	rs371186	chr6:145886971	T/C	cg23711669	chr6:146136114	FBXO30	0.85	12.88	0.62	8.09e-30	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9457247	0.561	rs916331	chr6:167470559	T/G	cg07741184	chr6:167504864	NA	0.38	6.7	0.38	1.22e-10	Crohn's disease;
CESC	trans	rs7618501	0.572	rs4688756	chr3:50040194	T/A	cg21659725	chr3:3221576	CRBN	0.49	6.9	0.39	3.78e-11	Intelligence (multi-trait analysis);
CESC	cis	rs3020736	0.500	rs11090076	chr22:42514190	T/C	cg15557168	chr22:42548783	NA	0.45	6.51	0.37	3.78e-10	Autism spectrum disorder or schizophrenia;
CESC	cis	rs4713118	0.513	rs149955	chr6:28036225	G/C	cg23161317	chr6:28129485	ZNF389	0.38	5.2	0.3	3.97e-7	Parkinson's disease;
CESC	cis	rs3091242	0.836	rs34997029	chr1:25783823	A/G	cg03538708	chr1:25844672	NA	0.4	5.95	0.34	8.36e-9	Erythrocyte sedimentation rate;
CESC	cis	rs12410462	1.000	rs75637482	chr1:227622944	A/T	cg04117972	chr1:227635322	NA	0.62	6.34	0.36	9.91e-10	Major depressive disorder;
CESC	cis	rs1682361	1	rs1682361	chr3:136734014	G/C	cg03617693	chr3:136751559	NA	0.45	6.53	0.37	3.35e-10	Schizophrenia;
CESC	cis	rs72781680	0.898	rs72780125	chr2:24000145	T/C	cg08917208	chr2:24149416	ATAD2B	1.13	10.18	0.53	9.42e-21	Lymphocyte counts;
CESC	cis	rs10870270	1.000	rs6560694	chr10:133773448	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.86	-12.56	-0.61	1.08e-28	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs1538970	0.816	rs3790583	chr1:45956828	C/G	cg24296786	chr1:45957014	TESK2	-0.46	-5.15	-0.3	4.97e-7	Platelet count;
CESC	cis	rs71403859	0.502	rs35981926	chr16:71500755	A/T	cg08717414	chr16:71523259	ZNF19	-1.07	-9.15	-0.49	1.6e-17	Post bronchodilator FEV1;
CESC	cis	rs2072732	0.861	rs12408197	chr1:2951511	C/T	cg03976712	chr1:2946727	NA	0.33	5.45	0.32	1.17e-7	Plateletcrit;
CESC	cis	rs10504229	1.000	rs17805332	chr8:58169798	A/G	cg14926445	chr8:58193284	C8orf71	-0.51	-5.6	-0.33	5.4e-8	Developmental language disorder (linguistic errors);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04189705	chr9:77502517	TRPM6	-0.55	-7.18	-0.4	6.9e-12	Gut microbiome composition (summer);
CESC	cis	rs858239	0.539	rs2141306	chr7:23191664	G/A	cg23682824	chr7:23144976	KLHL7	0.51	6.77	0.38	8.05e-11	Cerebrospinal fluid biomarker levels;
CESC	cis	rs959260	1.000	rs4789184	chr17:73383314	A/G	cg12999837	chr17:73267436	MIF4GD	-0.48	-5.58	-0.32	5.89e-8	Systemic lupus erythematosus;
CESC	cis	rs9581857	0.725	rs9581853	chr13:28016236	T/C	cg01674679	chr13:27998804	GTF3A	-0.69	-5.52	-0.32	7.89e-8	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
CESC	cis	rs4242434	0.889	rs11783129	chr8:22453426	G/A	cg03733263	chr8:22462867	KIAA1967	0.89	14.47	0.66	2.37e-35	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg16143763	chr17:41116517	AARSD1	-0.49	-6.46	-0.37	5.03e-10	Fibrinogen levels;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg26428032	chr11:67387935	NA	0.43	7.08	0.4	1.3e-11	Fibrinogen levels;
CESC	cis	rs17431357	1.000	rs14017	chr12:120941444	T/C	cg25045489	chr12:120971538	RNF10	-0.93	-5.46	-0.32	1.1e-7	Insulin resistance/response;
CESC	cis	rs9733	0.596	rs7538493	chr1:150655421	T/C	cg17724175	chr1:150552817	MCL1	0.44	7.21	0.41	5.8e-12	Tonsillectomy;
CESC	cis	rs35306767	0.904	rs35667562	chr10:950630	G/A	cg26597838	chr10:835615	NA	1.16	11.23	0.57	3.36e-24	Eosinophil percentage of granulocytes;
CESC	cis	rs6952808	0.792	rs4721184	chr7:1950784	T/C	cg04267008	chr7:1944627	MAD1L1	-0.75	-10.01	-0.52	3.22e-20	Bipolar disorder and schizophrenia;
CESC	cis	rs35306767	0.903	rs12250936	chr10:870109	C/T	cg26597838	chr10:835615	NA	0.9	9.51	0.5	1.2e-18	Eosinophil percentage of granulocytes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21036766	chr6:112683796	NA	-0.53	-6.23	-0.36	1.86e-9	Gut microbiome composition (summer);
CESC	cis	rs1005277	0.579	rs1780138	chr10:38501654	A/G	cg25427524	chr10:38739819	LOC399744	-0.73	-10.93	-0.56	3.43e-23	Extrinsic epigenetic age acceleration;
CESC	cis	rs7707921	0.752	rs2406910	chr5:81308719	C/T	cg15871215	chr5:81402204	ATG10	0.47	6.67	0.38	1.5e-10	Breast cancer;
CESC	cis	rs7618915	0.501	rs1468638	chr3:52748058	T/C	cg17372223	chr3:52568218	NT5DC2	0.44	6.62	0.38	1.95e-10	Bipolar disorder;
CESC	cis	rs5760092	0.755	rs915589	chr22:24261004	C/T	cg12419862	chr22:24373484	LOC391322	0.85	10.3	0.53	3.72e-21	Urinary 1,3-butadiene metabolite levels in smokers;
CESC	cis	rs2742234	0.541	rs1879310	chr10:43734775	A/G	cg07801480	chr10:43725741	RASGEF1A	-0.41	-5.39	-0.31	1.58e-7	Hirschsprung disease;
CESC	cis	rs7666738	0.546	rs2098935	chr4:98914376	A/G	cg05340658	chr4:99064831	C4orf37	0.6	7.49	0.42	1.06e-12	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6762	0.719	rs28655651	chr11:837121	G/C	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.68	-8.71	-0.47	3.44e-16	Mean platelet volume;
CESC	cis	rs1046896	0.520	rs9895409	chr17:80902719	C/T	cg19046167	chr17:80928561	B3GNTL1	0.55	6.73	0.38	1.04e-10	Glycated hemoglobin levels;
CESC	cis	rs12530845	1.000	rs6979391	chr7:135328873	C/T	cg23117316	chr7:135346802	PL-5283	-0.41	-5.29	-0.31	2.52e-7	Red blood cell traits;
CESC	cis	rs11098499	0.954	rs6848389	chr4:120402622	A/G	cg09307838	chr4:120376055	NA	0.93	12.91	0.62	6.5e-30	Corneal astigmatism;
CESC	cis	rs6540559	0.611	rs17015226	chr1:209970096	C/G	cg21951975	chr1:209979733	IRF6	0.58	7.22	0.41	5.67e-12	Cleft lip with or without cleft palate;
CESC	cis	rs709400	0.930	rs61996717	chr14:104048571	T/C	cg24130564	chr14:104152367	KLC1	-0.43	-5.07	-0.3	7.4e-7	Body mass index;
CESC	cis	rs9796	0.558	rs7166905	chr15:41514876	G/C	cg18705301	chr15:41695430	NDUFAF1	-0.47	-7.09	-0.4	1.2e-11	Menopause (age at onset);
CESC	cis	rs13095912	0.719	rs7625483	chr3:185297113	T/C	cg11274856	chr3:185301563	NA	0.4	6.09	0.35	4.01e-9	Systolic blood pressure;
CESC	cis	rs12142240	0.660	rs72890715	chr1:46852077	A/G	cg00530320	chr1:46809349	NSUN4	0.6	8.3	0.45	5.19e-15	Menopause (age at onset);
CESC	cis	rs7618915	0.501	rs7622694	chr3:52663882	G/A	cg07507251	chr3:52567010	NT5DC2	0.32	5.57	0.32	6.34e-8	Bipolar disorder;
CESC	cis	rs2228479	0.618	rs34689166	chr16:89860697	C/T	cg06558623	chr16:89946397	TCF25	1.18	9.47	0.5	1.65e-18	Skin colour saturation;
CESC	cis	rs17490626	0.568	rs12413525	chr10:71211721	C/A	cg12610070	chr10:71211762	TSPAN15	-0.32	-6.91	-0.39	3.55e-11	Thrombosis;
CESC	cis	rs7618915	0.547	rs6762813	chr3:52726695	C/T	cg17372223	chr3:52568218	NT5DC2	0.44	6.62	0.38	2.04e-10	Bipolar disorder;
CESC	cis	rs1832871	0.672	rs9456295	chr6:158772078	G/A	cg07165851	chr6:158734300	TULP4	0.58	6.19	0.36	2.31e-9	Height;
CESC	cis	rs2836974	0.897	rs6517513	chr21:40526878	A/G	cg11890956	chr21:40555474	PSMG1	1.18	23.93	0.83	3.5e-68	Cognitive function;
CESC	cis	rs6570726	0.791	rs446362	chr6:145878716	G/T	cg05347473	chr6:146136440	FBXO30	0.57	7.26	0.41	4.21e-12	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg02847760	chr15:40453199	BUB1B	-0.49	-6.23	-0.36	1.81e-9	Ulcerative colitis;
CESC	cis	rs6430585	0.583	rs61253125	chr2:136618178	T/C	cg07169764	chr2:136633963	MCM6	1.29	19.97	0.78	9.47e-55	Corneal structure;
CESC	cis	rs1577917	1.000	rs12192992	chr6:86609915	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-5.9	-0.34	1.13e-8	Response to antipsychotic treatment;
CESC	cis	rs2404602	0.716	rs7174953	chr15:76906847	A/C	cg22467129	chr15:76604101	ETFA	-0.36	-5.28	-0.31	2.7e-7	Blood metabolite levels;
CESC	cis	rs1018836	0.828	rs4734250	chr8:91591239	C/G	cg16814680	chr8:91681699	NA	0.66	9.79	0.52	1.56e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs7607369	0.714	rs55900247	chr2:219618708	T/C	cg02176678	chr2:219576539	TTLL4	-0.5	-8.59	-0.47	7.43e-16	Red blood cell count;Amyotrophic lateral sclerosis;
CESC	cis	rs12822507	0.868	rs12580006	chr12:12789646	C/T	cg09462578	chr12:12878428	APOLD1	-0.44	-5.62	-0.33	4.73e-8	Systemic lupus erythematosus;
CESC	cis	rs933688	0.938	rs7708782	chr5:90718517	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.98	11.78	0.59	5.05e-26	Smoking behavior;
CESC	cis	rs7771547	0.573	rs546353	chr6:36398597	C/A	cg07856975	chr6:36356162	ETV7	0.36	5.38	0.31	1.67e-7	Platelet distribution width;
CESC	cis	rs909002	0.586	rs2297684	chr1:32146764	A/G	cg13919466	chr1:32135498	COL16A1	0.33	5.55	0.32	6.97e-8	Intelligence (multi-trait analysis);
CESC	cis	rs6089829	0.816	rs6062397	chr20:61668268	A/G	cg03213289	chr20:61660250	NA	0.39	6.06	0.35	4.6e-9	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg19343861	chr12:123481935	PITPNM2	0.48	6.32	0.36	1.09e-9	Fibrinogen levels;
CESC	cis	rs854765	0.583	rs9890341	chr17:17823175	G/C	cg16928487	chr17:17741425	SREBF1	-0.57	-9.74	-0.51	2.41e-19	Total body bone mineral density;
CESC	cis	rs736408	0.812	rs1076425	chr3:52825462	A/G	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.38	6.32	0.36	1.13e-9	Bipolar disorder;
CESC	cis	rs854765	0.583	rs4414547	chr17:17859052	G/T	cg04398451	chr17:18023971	MYO15A	-0.69	-9.72	-0.51	2.77e-19	Total body bone mineral density;
CESC	trans	rs1814175	0.650	rs6486000	chr11:49659090	T/A	cg15704280	chr7:45808275	SEPT13	-0.98	-15.6	-0.69	2.26e-39	Height;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg06397424	chr16:15737279	NDE1;KIAA0430	-0.47	-6.34	-0.36	9.72e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs2836974	0.965	rs2836967	chr21:40639102	T/G	cg11644478	chr21:40555479	PSMG1	1.02	16.09	0.7	4.04e-41	Cognitive function;
CESC	cis	rs77741769	0.571	rs73415720	chr12:121344515	T/C	cg02419362	chr12:121203948	SPPL3	0.35	5.6	0.33	5.35e-8	Mean corpuscular volume;
CESC	cis	rs4664308	0.935	rs58354887	chr2:160927112	C/T	cg03641300	chr2:160917029	PLA2R1	-0.67	-9.79	-0.52	1.61e-19	Idiopathic membranous nephropathy;
CESC	cis	rs7246657	0.943	rs9304566	chr19:37845504	T/C	cg23950597	chr19:37808831	NA	-0.62	-6.3	-0.36	1.26e-9	Coronary artery calcification;
CESC	cis	rs4450798	0.649	rs73137996	chr3:13771796	C/A	cg23332027	chr3:13681764	NA	0.38	5.21	0.3	3.81e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs4253772	0.513	rs12171124	chr22:46710693	A/C	cg00784671	chr22:46762841	CELSR1	-0.48	-5.61	-0.33	5.12e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs1005277	0.579	rs2023351	chr10:38378814	A/G	cg25427524	chr10:38739819	LOC399744	-0.66	-9.51	-0.5	1.19e-18	Extrinsic epigenetic age acceleration;
CESC	cis	rs2708240	0.936	rs4140925	chr7:147578597	G/C	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.35	-5.78	-0.33	2.12e-8	QT interval (drug interaction);
CESC	trans	rs7944735	0.545	rs4752805	chr11:48018355	A/G	cg03929089	chr4:120376271	NA	0.56	6.43	0.37	5.85e-10	Intraocular pressure;
CESC	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	7.81	0.43	1.33e-13	Prudent dietary pattern;
CESC	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg02475777	chr4:1388615	CRIPAK	0.71	8.64	0.47	5.57e-16	Longevity;
CESC	cis	rs7818345	0.967	rs7004435	chr8:19282732	G/A	cg11303988	chr8:19266685	CSGALNACT1	0.33	5.83	0.34	1.58e-8	Language performance in older adults (adjusted for episodic memory);
CESC	cis	rs3820068	0.580	rs12760698	chr1:16009814	G/A	cg17385448	chr1:15911702	AGMAT	0.38	5.97	0.34	7.55e-9	Systolic blood pressure;
CESC	cis	rs9611565	0.765	rs9607800	chr22:41784562	A/G	cg06634786	chr22:41940651	POLR3H	-0.72	-7.6	-0.42	5.14e-13	Vitiligo;
CESC	cis	rs4819052	0.851	rs13049337	chr21:46663460	T/G	cg11663144	chr21:46675770	NA	-0.63	-10.04	-0.53	2.57e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs72781680	0.528	rs56258075	chr2:24104256	C/G	cg08917208	chr2:24149416	ATAD2B	0.93	8.63	0.47	5.68e-16	Lymphocyte counts;
CESC	cis	rs897984	0.762	rs4889604	chr16:30985994	G/T	cg00531865	chr16:30841666	NA	0.5	6.8	0.39	6.84e-11	Dementia with Lewy bodies;
CESC	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	10.16	0.53	1.08e-20	Prudent dietary pattern;
CESC	cis	rs7666738	0.962	rs17550217	chr4:98999699	T/A	cg05340658	chr4:99064831	C4orf37	0.6	7.91	0.44	6.96e-14	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7918232	0.941	rs788210	chr10:27476948	T/C	cg14442939	chr10:27389572	ANKRD26	-0.66	-6.44	-0.37	5.58e-10	Breast cancer;
CESC	cis	rs9916302	0.904	rs10432031	chr17:37397852	G/A	cg07936489	chr17:37558343	FBXL20	-0.78	-11.15	-0.57	6.4e-24	Glomerular filtration rate (creatinine);
CESC	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg09177884	chr7:1199841	ZFAND2A	-0.55	-6.16	-0.35	2.67e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs478304	0.651	rs948493	chr11:65552154	C/T	cg27068330	chr11:65405492	SIPA1	-0.48	-5.76	-0.33	2.32e-8	Acne (severe);
CESC	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg12419862	chr22:24373484	LOC391322	-0.84	-12.38	-0.61	4.49e-28	Liver enzyme levels (gamma-glutamyl transferase);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg14400389	chr17:73201327	NUP85	0.45	6.09	0.35	3.95e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs2645424	0.519	rs17154027	chr8:11713852	C/T	cg21281001	chr8:11725306	CTSB	-0.45	-5.51	-0.32	8.29e-8	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);
CESC	cis	rs12477438	0.834	rs1563106	chr2:99701381	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.72	-9.91	-0.52	6.61e-20	Chronic sinus infection;
CESC	cis	rs2836974	0.966	rs7283420	chr21:40666865	T/C	cg27266027	chr21:40555129	PSMG1	0.45	5.13	0.3	5.52e-7	Cognitive function;
CESC	cis	rs796364	0.951	rs971232	chr2:200792881	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.87	8.72	0.47	3.16e-16	Schizophrenia;
CESC	cis	rs2932538	0.922	rs34531155	chr1:113141550	C/T	cg22162597	chr1:113214053	CAPZA1	0.6	7.36	0.41	2.33e-12	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CESC	cis	rs1218582	0.772	rs4845693	chr1:154911257	A/G	cg24250549	chr1:154909240	PMVK	-0.63	-8.8	-0.48	1.84e-16	Prostate cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15340270	chr11:62420901	INTS5	-0.64	-7.66	-0.43	3.48e-13	Gut microbiome composition (summer);
CESC	cis	rs7546094	1.000	rs1001494	chr1:113110619	T/C	cg22162597	chr1:113214053	CAPZA1	0.37	5.67	0.33	3.69e-8	Platelet distribution width;
CESC	cis	rs2832077	0.527	rs2705690	chr21:30239245	T/A	cg03476357	chr21:30257390	N6AMT1	0.48	6.05	0.35	5.02e-9	Cognitive test performance;
CESC	cis	rs72945132	1.000	rs72945127	chr11:70107650	A/G	cg00319359	chr11:70116639	PPFIA1	0.82	7.94	0.44	5.65e-14	Coronary artery disease;
CESC	cis	rs10129255	0.500	rs59939897	chr14:107191651	A/G	cg23076370	chr14:107095027	NA	-0.65	-9.59	-0.51	6.94e-19	Kawasaki disease;
CESC	cis	rs7927771	0.965	rs56400411	chr11:47586376	T/G	cg20135002	chr11:47629003	NA	-0.39	-5.03	-0.3	9.04e-7	Subjective well-being;
CESC	cis	rs1185460	0.967	rs1784459	chr11:118938388	C/A	cg01677386	chr11:118938358	VPS11	-0.44	-5.6	-0.33	5.29e-8	Coronary artery disease;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05093860	chr3:132441075	NPHP3;NCRNA00119	0.54	6.93	0.39	3.15e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs9486719	1.000	rs2205755	chr6:96864704	A/G	cg18709589	chr6:96969512	KIAA0776	0.53	5.81	0.34	1.75e-8	Migraine;Coronary artery disease;
CESC	cis	rs8072100	0.727	rs4794052	chr17:45769236	T/C	cg08085267	chr17:45401833	C17orf57	-0.43	-5.43	-0.32	1.27e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs4810685	0.526	rs6018685	chr20:46410809	A/G	cg08288986	chr20:46415360	SULF2	-0.47	-5.37	-0.31	1.71e-7	Attention deficit hyperactivity disorder (time to onset);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg23039201	chr2:27851887	GPN1;CCDC121	-0.51	-6.84	-0.39	5.44e-11	Ulcerative colitis;
CESC	cis	rs10883723	0.810	rs7912901	chr10:104277440	T/C	ch.10.2196322F	chr10:104248062	ACTR1A	0.42	5.18	0.3	4.34e-7	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs4588572	0.688	rs4590164	chr5:77671870	A/G	cg11547950	chr5:77652471	NA	-0.39	-5.47	-0.32	1.05e-7	Triglycerides;
CESC	cis	rs9443645	0.527	rs2105143	chr6:79742947	G/A	cg05283184	chr6:79620031	NA	-0.38	-5.48	-0.32	1.01e-7	Intelligence (multi-trait analysis);
CESC	cis	rs7666738	0.648	rs33988750	chr4:98985386	T/C	cg03676636	chr4:99064102	C4orf37	0.41	5.11	0.3	6.23e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg26084319	chr14:21905280	CHD8	-0.51	-6.82	-0.39	6e-11	Height;
CESC	cis	rs3768617	0.811	rs4366285	chr1:183013672	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.65	8.89	0.48	9.94e-17	Fuchs's corneal dystrophy;
CESC	cis	rs875971	0.825	rs10281499	chr7:66048966	A/G	cg11764359	chr7:65958608	NA	-0.78	-11.17	-0.57	5.37e-24	Aortic root size;
CESC	cis	rs6974235	0.806	rs42073	chr7:95713880	G/A	cg21022364	chr7:95948586	SLC25A13	0.37	5.35	0.31	1.92e-7	Total body bone mineral density;
CESC	cis	rs10927875	0.550	rs12121918	chr1:16183556	C/A	cg21385522	chr1:16154831	NA	-0.92	-10.54	-0.54	6.39e-22	Dilated cardiomyopathy;
CESC	cis	rs8060686	0.668	rs8046355	chr16:68205214	T/A	cg26727032	chr16:67993705	SLC12A4	-0.56	-7.64	-0.42	4.1e-13	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs2019216	0.564	rs1518053	chr17:21924272	G/T	cg22648282	chr17:21454238	C17orf51	-0.43	-5.67	-0.33	3.72e-8	Pelvic organ prolapse;
CESC	cis	rs611744	0.503	rs13282220	chr8:109263043	T/C	cg21045802	chr8:109455806	TTC35	0.48	5.56	0.32	6.55e-8	Dupuytren's disease;
CESC	cis	rs634534	0.622	rs501353	chr11:65739549	T/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.43	6.44	0.37	5.64e-10	Sum eosinophil basophil counts;Eosinophil counts;
CESC	trans	rs877282	1.000	rs11253367	chr10:773389	G/A	cg22713356	chr15:30763199	NA	1.11	11.3	0.57	2e-24	Uric acid levels;
CESC	cis	rs2197308	0.765	rs7295711	chr12:37903631	C/T	cg13010199	chr12:38710504	ALG10B	0.53	6.76	0.38	8.79e-11	Morning vs. evening chronotype;
CESC	cis	rs7552404	0.924	rs1694419	chr1:76219801	C/T	cg10523679	chr1:76189770	ACADM	0.71	9.2	0.49	1.13e-17	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs7116495	0.609	rs6592447	chr11:71641093	A/T	cg26138937	chr11:71823887	C11orf51	-1.23	-8.55	-0.47	9.86e-16	Severe influenza A (H1N1) infection;
CESC	cis	rs6912958	0.605	rs2754247	chr6:88383571	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.52	-6.91	-0.39	3.62e-11	Monocyte percentage of white cells;
CESC	trans	rs1728785	0.901	rs3087783	chr16:68599668	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.71	8.43	0.46	2.17e-15	Ulcerative colitis;
CESC	cis	rs2573652	0.722	rs968412	chr15:100544512	C/G	cg00587665	chr15:100533223	ADAMTS17	-0.33	-5.22	-0.31	3.56e-7	Height;
CESC	cis	rs9300255	0.739	rs1533703	chr12:123742093	T/G	cg19016782	chr12:123741754	C12orf65	-0.48	-6.9	-0.39	3.71e-11	Neutrophil percentage of white cells;
CESC	cis	rs453301	0.624	rs6987558	chr8:8862521	C/G	cg06636001	chr8:8085503	FLJ10661	0.41	5.43	0.32	1.26e-7	Joint mobility (Beighton score);
CESC	cis	rs34779708	0.966	rs4934734	chr10:35434373	T/C	cg04310649	chr10:35416472	CREM	-0.51	-6.14	-0.35	3.02e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs7116495	0.867	rs510925	chr11:71809500	C/T	cg26138937	chr11:71823887	C11orf51	1.22	7.84	0.43	1.12e-13	Severe influenza A (H1N1) infection;
CESC	cis	rs7760535	0.656	rs1883136	chr6:111907023	G/T	cg22127309	chr6:111907043	TRAF3IP2	-0.51	-7.87	-0.44	8.94e-14	Metabolic traits;
CESC	cis	rs10131894	0.611	rs175000	chr14:75436367	T/C	cg11812906	chr14:75593930	NEK9	-0.66	-10.16	-0.53	1.08e-20	Coronary artery disease;
CESC	cis	rs634534	0.561	rs14157	chr11:65769780	T/G	cg02202077	chr11:65769826	EIF1AD;BANF1	0.47	6.31	0.36	1.14e-9	Sum eosinophil basophil counts;Eosinophil counts;
CESC	cis	rs4319547	0.695	rs4758666	chr12:122902840	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.49	-6.07	-0.35	4.4e-9	Body mass index;
CESC	cis	rs2439831	0.850	rs16977798	chr15:44151948	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.68	7.47	0.42	1.19e-12	Lung cancer in ever smokers;
CESC	cis	rs8177253	1.000	rs8177253	chr3:133480192	A/G	cg12373951	chr3:133503437	NA	-0.43	-6.38	-0.36	7.8e-10	Iron status biomarkers;
CESC	cis	rs1065852	0.526	rs1062753	chr22:42392811	G/A	cg22189786	chr22:42395067	WBP2NL	0.44	5.47	0.32	1.03e-7	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
CESC	cis	rs7197653	0.586	rs55856208	chr16:68324210	A/T	cg26727032	chr16:67993705	SLC12A4	-0.55	-5.39	-0.31	1.57e-7	Magnesium levels;
CESC	cis	rs7959452	0.590	rs10878974	chr12:69781528	C/G	cg20891283	chr12:69753455	YEATS4	0.91	15.03	0.68	2.41e-37	Blood protein levels;
CESC	cis	rs6580649	1.000	rs7132668	chr12:48405860	C/T	cg05342945	chr12:48394962	COL2A1	-0.56	-6.56	-0.37	2.79e-10	Lung cancer;
CESC	cis	rs6540559	0.673	rs17015224	chr1:209968918	G/A	cg21951975	chr1:209979733	IRF6	0.62	7.75	0.43	2.01e-13	Cleft lip with or without cleft palate;
CESC	trans	rs9354308	0.834	rs12212376	chr6:66598879	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.63	7.15	0.4	8.59e-12	Metabolite levels;
CESC	cis	rs2718058	0.692	rs2718041	chr7:37783944	A/G	cg15028436	chr7:37888078	TXNDC3	0.39	5.51	0.32	8.63e-8	Alzheimer's disease (late onset);
CESC	cis	rs7937682	0.921	rs4534611	chr11:111440425	C/G	cg09085632	chr11:111637200	PPP2R1B	-0.89	-12.05	-0.6	5.72e-27	Primary sclerosing cholangitis;
CESC	cis	rs6933660	0.720	rs6914656	chr6:151753421	C/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.86	14.41	0.66	3.84e-35	Menarche (age at onset);
CESC	cis	rs4713118	0.621	rs4713133	chr6:28034041	T/C	cg23281280	chr6:28129359	ZNF389	0.53	7.06	0.4	1.5e-11	Parkinson's disease;
CESC	cis	rs12579753	0.833	rs12579530	chr12:82163930	A/C	cg24719984	chr12:82153464	PPFIA2	-0.36	-5.25	-0.31	3.12e-7	Resting heart rate;
CESC	cis	rs8070740	0.898	rs8074617	chr17:5323989	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.51	6.35	0.36	9.3e-10	Menopause (age at onset);
CESC	cis	rs7312933	0.558	rs11181507	chr12:42844763	T/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.5	6.43	0.37	5.82e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg25447359	chr22:30790057	NA	-0.45	-6.32	-0.36	1.12e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs873946	0.586	rs12259688	chr10:134549628	A/G	cg18305652	chr10:134549665	INPP5A	0.49	7.22	0.41	5.53e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs2637266	1.000	rs7896831	chr10:78366649	A/T	cg18941641	chr10:78392320	NA	0.42	7.87	0.44	8.96e-14	Pulmonary function;
CESC	cis	rs7618501	0.633	rs7621026	chr3:49975334	A/G	cg24308560	chr3:49941425	MST1R	-0.64	-9.35	-0.5	3.91e-18	Intelligence (multi-trait analysis);
CESC	cis	rs875971	0.545	rs1796222	chr7:66057154	T/C	cg25405998	chr7:65216604	CCT6P1	-0.48	-5.19	-0.3	4.24e-7	Aortic root size;
CESC	cis	rs12681288	0.782	rs2123055	chr8:1029500	T/G	cg15309053	chr8:964076	NA	0.37	5.82	0.34	1.68e-8	Schizophrenia;
CESC	cis	rs7927771	0.832	rs11601603	chr11:47401171	A/C	cg18512352	chr11:47633146	NA	-0.51	-7.43	-0.42	1.46e-12	Subjective well-being;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20539961	chr2:106497812	NCK2	-0.58	-6.42	-0.37	6.34e-10	Gut microbiome composition (summer);
CESC	cis	rs769267	0.930	rs9917108	chr19:19572785	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.46	5.94	0.34	8.86e-9	Tonsillectomy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06581840	chr11:113644397	ZW10	0.58	6.22	0.36	1.98e-9	Gut microbiome composition (summer);
CESC	cis	rs16858210	0.874	rs10937153	chr3:183562925	A/G	cg03417191	chr3:183542750	MAP6D1	0.44	5.66	0.33	3.97e-8	Menopause (age at onset);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg04504578	chr17:36831313	C17orf96	0.43	5.99	0.35	6.68e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg06074448	chr4:187884817	NA	0.48	7.49	0.42	1.02e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9430161	0.579	rs11121667	chr1:11038476	C/T	cg27631724	chr1:11040367	C1orf127	0.46	8.39	0.46	3.01e-15	Ewing sarcoma;
CESC	cis	rs8092503	0.904	rs12606230	chr18:52492252	T/C	cg12377874	chr18:52495404	RAB27B	0.37	6.13	0.35	3.13e-9	Childhood body mass index;
CESC	cis	rs11168618	0.626	rs11609074	chr12:48819335	C/A	cg24011408	chr12:48396354	COL2A1	0.36	5.53	0.32	7.49e-8	Adiponectin levels;
CESC	cis	rs897080	0.552	rs1085442	chr2:44635454	C/A	cg04920474	chr2:44395004	PPM1B	0.37	5.12	0.3	5.97e-7	Height;
CESC	cis	rs3733585	0.673	rs4292332	chr4:9953830	C/A	cg11266682	chr4:10021025	SLC2A9	-0.58	-11.0	-0.56	2.04e-23	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs710216	1.000	rs710216	chr1:43428757	A/G	cg03128534	chr1:43423976	SLC2A1	0.54	6.36	0.36	8.78e-10	Red cell distribution width;
CESC	cis	rs1707322	0.752	rs8179402	chr1:46142466	C/A	cg03146154	chr1:46216737	IPP	0.82	11.54	0.58	3.18e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs6088580	0.634	rs6088475	chr20:32964987	T/C	cg06115741	chr20:33292138	TP53INP2	-0.47	-6.02	-0.35	5.66e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs8017423	0.967	rs2282030	chr14:90730265	G/A	cg14092571	chr14:90743983	NA	-0.57	-8.53	-0.46	1.14e-15	Mortality in heart failure;
CESC	cis	rs8077889	0.871	rs72836549	chr17:41904360	G/T	cg26893861	chr17:41843967	DUSP3	0.83	9.9	0.52	7.45e-20	Triglycerides;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04719420	chr1:183441464	SMG7	-0.54	-6.32	-0.36	1.11e-9	Gut microbiome composition (summer);
CESC	cis	rs9815354	0.767	rs6805140	chr3:41995791	A/G	cg03022575	chr3:42003672	ULK4	0.65	5.93	0.34	9.31e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs1218582	0.772	rs4240875	chr1:154885782	G/A	cg09359103	chr1:154839909	KCNN3	-0.66	-12.18	-0.6	2.2e-27	Prostate cancer;
CESC	cis	rs6439153	0.933	rs9822511	chr3:128705567	G/A	cg24203234	chr3:128598194	ACAD9	0.42	5.45	0.32	1.17e-7	Pneumococcal bacteremia;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg26313349	chr1:145589328	NUDT17	-0.42	-6.41	-0.37	6.77e-10	Gambling;
CESC	cis	rs7208859	0.623	rs11657662	chr17:29076347	A/G	cg13385521	chr17:29058706	SUZ12P	-0.87	-6.66	-0.38	1.53e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs11997175	0.574	rs10954931	chr8:33631066	A/T	ch.8.33884649F	chr8:33765107	NA	0.64	8.22	0.45	9.32e-15	Body mass index;
CESC	cis	rs9715521	0.900	rs4860450	chr4:59827819	G/A	cg11281224	chr4:60001000	NA	-0.5	-6.57	-0.37	2.6200000000000003e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs7208859	0.623	rs35916850	chr17:29011173	G/A	cg13385521	chr17:29058706	SUZ12P	0.72	5.63	0.33	4.63e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs9611565	0.921	rs761366	chr22:41744022	C/G	cg06634786	chr22:41940651	POLR3H	-0.63	-6.46	-0.37	5.02e-10	Vitiligo;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20046119	chr8:145981207	ZNF251	-0.52	-6.24	-0.36	1.75e-9	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.830	rs6854994	chr4:98977624	C/G	cg05340658	chr4:99064831	C4orf37	0.79	12.26	0.6	1.12e-27	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27194998	chr19:47217554	PRKD2	0.66	7.55	0.42	7.25e-13	Gut microbiome composition (summer);
CESC	cis	rs1707322	0.752	rs7541962	chr1:46235117	G/A	cg06784218	chr1:46089804	CCDC17	0.39	6.84	0.39	5.31e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs4664308	0.810	rs59019419	chr2:161061287	G/A	cg03641300	chr2:160917029	PLA2R1	-0.63	-9.23	-0.49	8.91e-18	Idiopathic membranous nephropathy;
CESC	cis	rs826838	0.616	rs7966266	chr12:38626138	G/A	cg26384229	chr12:38710491	ALG10B	-0.43	-5.65	-0.33	4.09e-8	Heart rate;
CESC	cis	rs62432291	0.681	rs2932987	chr6:159655673	C/G	cg14500486	chr6:159655392	FNDC1	0.6	6.31	0.36	1.18e-9	Joint mobility (Beighton score);
CESC	cis	rs9303401	0.659	rs12944971	chr17:56988801	A/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.98	10.73	0.55	1.47e-22	Cognitive test performance;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24972377	chr12:122326574	PSMD9	0.61	7.27	0.41	3.95e-12	Gut microbiome composition (summer);
CESC	cis	rs7618915	0.547	rs34017441	chr3:52742413	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	7.21	0.41	5.73e-12	Bipolar disorder;
CESC	cis	rs36051895	0.664	rs3780370	chr9:5095167	A/C	cg02405213	chr9:5042618	JAK2	-0.51	-6.17	-0.35	2.61e-9	Pediatric autoimmune diseases;
CESC	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.63	-9.61	-0.51	6.08e-19	Longevity;Endometriosis;
CESC	cis	rs35146811	0.771	rs1060544	chr7:99613476	C/T	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.49	6.06	0.35	4.59e-9	Coronary artery disease;
CESC	cis	rs3815700	1.000	rs8104328	chr19:33094371	G/A	cg02997394	chr19:33096574	ANKRD27	0.73	7.32	0.41	2.97e-12	Eosinophilic esophagitis;
CESC	cis	rs17376456	0.825	rs17372615	chr5:93124768	C/T	cg21475434	chr5:93447410	FAM172A	0.8	7.22	0.41	5.48e-12	Diabetic retinopathy;
CESC	cis	rs4253772	0.832	rs6008259	chr22:46633782	G/A	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.57	6.51	0.37	3.7e-10	LDL cholesterol;Cholesterol, total;
CESC	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg02018176	chr4:1364513	KIAA1530	0.61	7.94	0.44	5.93e-14	Longevity;
CESC	cis	rs4253772	0.744	rs4253760	chr22:46622384	T/G	cg24881330	chr22:46731750	TRMU	0.64	6.45	0.37	5.33e-10	LDL cholesterol;Cholesterol, total;
CESC	cis	rs57506017	0.585	rs13229988	chr7:12267837	A/G	cg23422036	chr7:12250390	TMEM106B	0.38	5.13	0.3	5.58e-7	Neuroticism;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg12551462	chr6:153304904	FBXO5	-0.5	-6.28	-0.36	1.36e-9	Ulcerative colitis;
CESC	cis	rs6484504	0.576	rs286649	chr11:31230468	C/T	cg14844989	chr11:31128820	NA	-0.42	-5.97	-0.34	7.57e-9	Red blood cell count;
CESC	cis	rs9905704	0.914	rs2643120	chr17:56826949	A/T	cg12560992	chr17:57184187	TRIM37	0.61	7.09	0.4	1.25e-11	Testicular germ cell tumor;
CESC	cis	rs870825	0.616	rs28524599	chr4:185647414	A/G	cg04058563	chr4:185651563	MLF1IP	0.63	6.96	0.39	2.59e-11	Blood protein levels;
CESC	cis	rs9640161	0.830	rs6722	chr7:150068933	T/C	cg21361702	chr7:150065534	REPIN1	0.49	6.48	0.37	4.5e-10	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs941873	0.868	rs2181080	chr10:81121960	A/G	cg09469691	chr10:81107165	PPIF	0.58	7.78	0.43	1.67e-13	Height;
CESC	cis	rs3820068	0.581	rs16851819	chr1:15918739	C/T	cg17385448	chr1:15911702	AGMAT	-0.44	-7.26	-0.41	4.38e-12	Systolic blood pressure;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21623633	chr19:14492003	CD97	0.52	6.29	0.36	1.31e-9	Gut microbiome composition (summer);
CESC	cis	rs7635838	0.785	rs2606738	chr3:11396562	T/C	cg00170343	chr3:11313890	ATG7	0.49	6.89	0.39	4.1e-11	HDL cholesterol;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07050772	chr17:48423262	XYLT2	0.56	6.8	0.39	6.74e-11	Gut microbiome composition (summer);
CESC	cis	rs2072499	0.966	rs2842864	chr1:156159217	G/A	cg06970220	chr1:156163860	SLC25A44	0.39	5.18	0.3	4.32e-7	Testicular germ cell tumor;
CESC	cis	rs780096	0.526	rs12476704	chr2:27613031	C/A	cg02592271	chr2:27665507	KRTCAP3	-0.26	-5.07	-0.3	7.39e-7	Total body bone mineral density;
CESC	cis	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg22963979	chr7:1858916	MAD1L1	-0.43	-5.87	-0.34	1.31e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs6460942	0.597	rs17448193	chr7:12525641	G/A	cg02935154	chr7:12443704	VWDE	-0.55	-5.53	-0.32	7.71e-8	Coronary artery disease;
CESC	cis	rs9611565	0.607	rs132792	chr22:42062822	C/T	cg17376030	chr22:41985996	PMM1	-0.46	-5.39	-0.31	1.53e-7	Vitiligo;
CESC	cis	rs4450798	0.793	rs28581168	chr3:13740488	A/C	cg23332027	chr3:13681764	NA	0.4	5.36	0.31	1.81e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs7618915	0.547	rs34610142	chr3:52708429	G/A	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.31	5.59	0.32	5.58e-8	Bipolar disorder;
CESC	cis	rs3540	0.597	rs12708583	chr15:91050271	C/T	cg22089800	chr15:90895588	ZNF774	0.67	9.44	0.5	2.08e-18	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs1577917	0.739	rs9344532	chr6:86234070	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.56	7.53	0.42	8.17e-13	Response to antipsychotic treatment;
CESC	trans	rs1814175	0.615	rs4545557	chr11:50027329	A/C	cg15704280	chr7:45808275	SEPT13	-1.0	-18.54	-0.75	9.01e-50	Height;
CESC	cis	rs7552404	0.855	rs385897	chr1:76106962	T/C	cg03433033	chr1:76189801	ACADM	-0.67	-7.91	-0.44	7.05e-14	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs793571	0.523	rs7161889	chr15:58983425	C/G	cg05156742	chr15:59063176	FAM63B	0.58	7.77	0.43	1.74e-13	Schizophrenia;
CESC	cis	rs1348850	0.958	rs4893965	chr2:178463852	G/T	cg23306229	chr2:178417860	TTC30B	0.57	7.52	0.42	8.3e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs17293817	0.618	rs58703400	chr10:1430346	A/G	cg04271617	chr10:1416546	ADARB2	0.34	5.27	0.31	2.9e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs2742234	0.955	rs2435384	chr10:43673731	G/T	cg15436174	chr10:43711423	RASGEF1A	-0.42	-5.34	-0.31	2.01e-7	Hirschsprung disease;
CESC	trans	rs7980799	0.772	rs6488162	chr12:33593127	T/C	cg26384229	chr12:38710491	ALG10B	-0.52	-6.85	-0.39	5.26e-11	Heart rate;Heart rate variability traits (RMSSD);
CESC	trans	rs4129059	0.765	rs57047137	chr1:214708900	C/T	cg08158662	chr12:34489995	NA	0.56	6.45	0.37	5.31e-10	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs1915146	0.546	rs9422857	chr10:126861278	C/G	cg17191109	chr10:126851326	NA	0.42	6.76	0.38	8.55e-11	Menarche (age at onset);
CESC	cis	rs2070488	0.804	rs13092164	chr3:38458533	G/A	cg24069376	chr3:38537580	EXOG	0.35	6.02	0.35	5.94e-9	Electrocardiographic conduction measures;
CESC	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.52	-5.94	-0.34	8.89e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs3008870	0.755	rs4486425	chr1:67460791	T/C	cg02640540	chr1:67518911	SLC35D1	-0.46	-5.58	-0.32	5.81e-8	Lymphocyte percentage of white cells;
CESC	cis	rs2074585	0.839	rs11638780	chr15:91041896	G/T	cg10434728	chr15:90938212	IQGAP1	-0.42	-7.64	-0.42	4.06e-13	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
CESC	cis	rs2573652	1.000	rs7163481	chr15:100516916	C/G	cg00587665	chr15:100533223	ADAMTS17	0.32	5.03	0.3	9.08e-7	Height;
CESC	cis	rs34779708	0.733	rs3936503	chr10:35549257	A/G	cg04310649	chr10:35416472	CREM	0.45	5.31	0.31	2.32e-7	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs9611565	0.592	rs5996039	chr22:41981957	A/G	cg06481639	chr22:41940642	POLR3H	-0.56	-6.32	-0.36	1.13e-9	Vitiligo;
CESC	cis	rs896854	0.654	rs896847	chr8:95972551	G/A	cg26343298	chr8:95960752	TP53INP1	0.36	5.96	0.34	7.8e-9	Type 2 diabetes;
CESC	cis	rs7208859	0.623	rs73269913	chr17:29092183	T/C	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.17e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs6693567	0.545	rs2012751	chr1:150438266	T/C	cg09579323	chr1:150459698	TARS2	0.48	6.08	0.35	4.13e-9	Migraine;
CESC	cis	rs1864400	0.645	rs2249005	chr10:43627280	A/G	cg15436174	chr10:43711423	RASGEF1A	-0.49	-5.6	-0.33	5.32e-8	Hirschsprung disease;
CESC	cis	rs7149337	0.805	rs7146561	chr14:51608889	C/G	cg23942311	chr14:51606299	NA	0.48	8.36	0.46	3.56e-15	Cancer;
CESC	cis	rs597539	0.654	rs619727	chr11:68627535	A/G	cg06028808	chr11:68637592	NA	0.45	5.31	0.31	2.37e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs9486719	0.947	rs11153071	chr6:97039741	G/A	cg06623918	chr6:96969491	KIAA0776	-0.79	-8.13	-0.45	1.64e-14	Migraine;Coronary artery disease;
CESC	cis	rs4253772	0.550	rs6008600	chr22:46704676	A/G	cg00784671	chr22:46762841	CELSR1	-0.48	-5.59	-0.32	5.72e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs9815354	0.672	rs12107296	chr3:41892503	C/G	cg03022575	chr3:42003672	ULK4	0.45	5.2	0.3	3.99e-7	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs4253772	0.591	rs9615935	chr22:46686115	T/G	cg24881330	chr22:46731750	TRMU	0.75	5.43	0.32	1.25e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs11997175	0.655	rs72630923	chr8:33662404	C/A	ch.8.33884649F	chr8:33765107	NA	0.47	5.96	0.34	7.88e-9	Body mass index;
CESC	cis	rs9457247	1.000	rs416131	chr6:167406544	A/C	cg07741184	chr6:167504864	NA	-0.32	-5.73	-0.33	2.66e-8	Crohn's disease;
CESC	trans	rs9467711	0.659	rs66941101	chr6:26530376	C/T	cg06606381	chr12:133084897	FBRSL1	-0.93	-7.16	-0.4	8.07e-12	Autism spectrum disorder or schizophrenia;
CESC	cis	rs2072499	0.750	rs10159384	chr1:156160822	C/T	cg24450063	chr1:156163899	SLC25A44	0.98	11.99	0.59	9.64e-27	Testicular germ cell tumor;
CESC	cis	rs6540559	0.543	rs664097	chr1:210422179	C/T	cg21951975	chr1:209979733	IRF6	0.46	6.18	0.35	2.41e-9	Cleft lip with or without cleft palate;
CESC	cis	rs763121	0.785	rs6001203	chr22:39099602	T/C	cg06022373	chr22:39101656	GTPBP1	0.94	17.4	0.73	9.39e-46	Menopause (age at onset);
CESC	cis	rs939658	0.805	rs11631590	chr15:79446199	C/T	cg17916960	chr15:79447300	NA	-0.36	-5.83	-0.34	1.65e-8	Refractive error;
CESC	cis	rs10504229	0.683	rs11786523	chr8:58131319	G/C	cg21724239	chr8:58056113	NA	0.58	5.95	0.34	8.29e-9	Developmental language disorder (linguistic errors);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21962918	chr5:134094454	DDX46	0.59	6.8	0.39	6.91e-11	Gut microbiome composition (summer);
CESC	cis	rs6546537	0.911	rs13027712	chr2:69891367	C/T	cg10773587	chr2:69614142	GFPT1	-0.59	-6.86	-0.39	4.74e-11	Serum thyroid-stimulating hormone levels;
CESC	cis	rs4253772	0.591	rs6008595	chr22:46703860	A/T	cg24881330	chr22:46731750	TRMU	0.86	7.93	0.44	6.15e-14	LDL cholesterol;Cholesterol, total;
CESC	cis	rs4665809	0.878	rs6748745	chr2:26364190	C/T	cg04944784	chr2:26401820	FAM59B	-0.75	-8.97	-0.48	5.69e-17	Gut microbiome composition (summer);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg20593868	chr20:62588672	UCKL1;ZNF512B	-0.38	-6.34	-0.36	1.01e-9	Gambling;
CESC	cis	rs8177253	0.665	rs8177178	chr3:133463272	G/A	cg24879335	chr3:133465180	TF	0.31	5.22	0.31	3.63e-7	Iron status biomarkers;
CESC	cis	rs9309473	1.000	rs13383871	chr2:73631779	T/C	cg20560298	chr2:73613845	ALMS1	-0.53	-6.93	-0.39	3.18e-11	Metabolite levels;
CESC	cis	rs936229	0.705	rs936227	chr15:75131959	A/G	cg14664628	chr15:75095509	CSK	-0.57	-7.51	-0.42	8.83e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CESC	cis	rs989128	0.600	rs73338243	chr17:48631324	T/C	cg24438145	chr17:48624694	SPATA20	0.45	5.31	0.31	2.36e-7	Type 2 diabetes;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg08072980	chr7:50450320	IKZF1	-0.42	-6.15	-0.35	2.88e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs9815354	0.680	rs73075204	chr3:42030392	G/A	cg03022575	chr3:42003672	ULK4	0.75	6.64	0.38	1.72e-10	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs514406	0.861	rs7417821	chr1:53295117	A/G	cg27535305	chr1:53392650	SCP2	-0.31	-5.35	-0.31	1.89e-7	Monocyte count;
CESC	trans	rs11039798	0.920	rs9667596	chr11:48691193	T/C	cg15704280	chr7:45808275	SEPT13	0.7	6.42	0.37	6.38e-10	Axial length;
CESC	cis	rs2549003	0.870	rs61175929	chr5:131821548	C/G	cg02551604	chr5:131831745	NA	-0.37	-5.27	-0.31	2.81e-7	Asthma (sex interaction);
CESC	cis	rs2836974	0.932	rs6517523	chr21:40557332	T/C	cg27266027	chr21:40555129	PSMG1	0.43	5.15	0.3	5.06e-7	Cognitive function;
CESC	cis	rs2404602	0.608	rs17361504	chr15:76601871	A/G	cg22467129	chr15:76604101	ETFA	-0.39	-6.02	-0.35	5.84e-9	Blood metabolite levels;
CESC	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.51	6.31	0.36	1.13e-9	Prudent dietary pattern;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10557320	chr6:12012551	HIVEP1	-0.52	-6.14	-0.35	2.96e-9	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.830	rs1426662	chr4:98990319	C/T	cg03676636	chr4:99064102	C4orf37	0.34	5.21	0.31	3.73e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs875971	0.928	rs6970357	chr7:65968878	T/C	cg18876405	chr7:65276391	NA	0.48	6.31	0.36	1.16e-9	Aortic root size;
CESC	cis	rs832540	0.656	rs2408597	chr5:56098632	G/A	cg24531977	chr5:56204891	C5orf35	-0.47	-5.87	-0.34	1.29e-8	Coronary artery disease;
CESC	cis	rs453301	0.686	rs6748	chr8:8890802	C/T	cg15556689	chr8:8085844	FLJ10661	-0.5	-6.19	-0.36	2.27e-9	Joint mobility (Beighton score);
CESC	cis	rs9916302	0.904	rs8076494	chr17:37516722	A/G	cg15445000	chr17:37608096	MED1	-0.42	-6.66	-0.38	1.57e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs7552404	1.000	rs942270	chr1:76177332	G/A	cg22875332	chr1:76189707	ACADM	0.63	7.34	0.41	2.59e-12	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs9584850	0.874	rs7988959	chr13:99104004	T/C	cg20750642	chr13:99100586	FARP1	-0.4	-6.02	-0.35	5.73e-9	Neuroticism;
CESC	cis	rs2637266	0.935	rs2252661	chr10:78404793	A/G	cg18941641	chr10:78392320	NA	0.45	8.65	0.47	4.94e-16	Pulmonary function;
CESC	cis	rs12979813	0.901	rs10421795	chr19:11344406	C/T	cg00586551	chr19:11347513	LOC55908;DOCK6	0.38	5.31	0.31	2.27e-7	HDL cholesterol;
CESC	cis	rs4727027	0.737	rs10278971	chr7:148780659	A/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.44	5.48	0.32	1.01e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs12142240	0.660	rs112560929	chr1:46822297	A/G	cg00530320	chr1:46809349	NSUN4	0.6	8.04	0.44	2.96e-14	Menopause (age at onset);
CESC	cis	rs6831352	0.819	rs1154401	chr4:100009738	G/C	cg21548116	chr4:100009993	ADH5	0.46	5.19	0.3	4.27e-7	Alcohol dependence;
CESC	cis	rs2836974	0.931	rs8132285	chr21:40655752	T/C	cg11890956	chr21:40555474	PSMG1	1.2	22.3	0.81	9.49e-63	Cognitive function;
CESC	cis	rs3820928	0.874	rs12467261	chr2:227888838	T/C	cg11843606	chr2:227700838	RHBDD1	-0.47	-6.25	-0.36	1.66e-9	Pulmonary function;
CESC	cis	rs2762353	0.779	rs1408273	chr6:25840946	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.4	-5.97	-0.34	7.65e-9	Blood metabolite levels;
CESC	cis	rs6991838	0.584	rs11985628	chr8:66542739	T/C	cg13398993	chr8:66546079	ARMC1	0.46	5.65	0.33	4.19e-8	Intelligence (multi-trait analysis);
CESC	cis	rs2228479	0.702	rs2074903	chr16:89811663	T/C	cg04013166	chr16:89971882	TCF25	0.79	6.78	0.38	7.83e-11	Skin colour saturation;
CESC	cis	rs6541297	0.703	rs652108	chr1:230312704	C/T	cg20703242	chr1:230279135	GALNT2	-0.43	-5.59	-0.32	5.66e-8	Coronary artery disease;
CESC	cis	rs10504229	1.000	rs34616626	chr8:58184650	C/T	cg14926445	chr8:58193284	C8orf71	-0.51	-5.52	-0.32	8.28e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs10504229	0.953	rs75253516	chr8:58171547	C/A	cg14926445	chr8:58193284	C8orf71	-0.5	-5.38	-0.31	1.62e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs12325245	0.536	rs3169293	chr16:58552959	A/G	cg01152986	chr16:58549298	SETD6	0.89	5.38	0.31	1.62e-7	Schizophrenia;
CESC	cis	rs12541335	0.639	rs11779277	chr8:22200683	C/T	cg27266060	chr8:22091797	NA	0.38	7.81	0.43	1.33e-13	Hypertriglyceridemia;
CESC	cis	rs4728302	0.934	rs4129572	chr7:133636888	T/C	cg10665199	chr7:133106180	EXOC4	-0.37	-5.04	-0.3	8.52e-7	Intelligence;Intelligence (multi-trait analysis);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg04127825	chr1:167503222	NA	-0.46	-6.77	-0.38	8.44e-11	Gambling;
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg15433164	chr3:25824899	NGLY1	0.39	6.33	0.36	1.02e-9	Vertical cup-disc ratio;
CESC	cis	rs6089829	0.962	rs9680064	chr20:61666168	G/A	cg08564027	chr20:61660810	NA	0.9	15.37	0.69	1.54e-38	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs12369635	0.929	rs3851667	chr12:129550552	G/T	cg01909103	chr12:129572610	TMEM132D	0.67	6.1	0.35	3.73e-9	Schizophrenia (inflammation and infection response interaction);
CESC	cis	rs2072732	0.861	rs67872056	chr1:2954165	C/T	cg03976712	chr1:2946727	NA	0.33	5.53	0.32	7.83e-8	Plateletcrit;
CESC	cis	rs2425143	1.000	rs2425149	chr20:34359587	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.73	6.75	0.38	9.36e-11	Blood protein levels;
CESC	cis	rs3820068	0.562	rs10927841	chr1:16045261	T/C	cg17385448	chr1:15911702	AGMAT	0.38	5.95	0.34	8.35e-9	Systolic blood pressure;
CESC	cis	rs116095464	0.558	rs2288459	chr5:231143	T/C	cg10591111	chr5:226296	SDHA	-0.51	-6.18	-0.35	2.44e-9	Breast cancer;
CESC	cis	rs1348850	0.608	rs10176632	chr2:178225934	G/T	cg22681709	chr2:178499509	PDE11A	-0.36	-5.33	-0.31	2.12e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs7618915	0.547	rs34017441	chr3:52742413	T/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.31	5.45	0.32	1.15e-7	Bipolar disorder;
CESC	cis	rs7274811	0.625	rs293734	chr20:31924680	T/A	cg21523528	chr20:32077966	CBFA2T2	-0.5	-5.62	-0.33	4.71e-8	Height;
CESC	cis	rs2455799	0.574	rs2102212	chr3:15704223	C/T	cg16303742	chr3:15540471	COLQ	-0.42	-6.58	-0.37	2.48e-10	Mean platelet volume;
CESC	cis	rs12477438	0.501	rs12619780	chr2:99707307	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.79	12.85	0.62	1.04e-29	Chronic sinus infection;
CESC	cis	rs7659604	0.521	rs4833235	chr4:122695136	C/A	cg19671926	chr4:122722719	EXOSC9	0.64	8.55	0.46	1.02e-15	Type 2 diabetes;
CESC	cis	rs7772486	0.754	rs9373476	chr6:146139741	C/G	cg23711669	chr6:146136114	FBXO30	0.97	14.72	0.67	3.09e-36	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7107174	0.681	rs881337	chr11:78128335	G/C	cg02023728	chr11:77925099	USP35	0.43	5.48	0.32	1.01e-7	Testicular germ cell tumor;
CESC	cis	rs7944584	0.545	rs7118178	chr11:47659135	G/A	cg20307385	chr11:47447363	PSMC3	0.8	11.09	0.56	9.91e-24	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CESC	cis	rs3733585	0.588	rs6449154	chr4:9956404	C/T	cg00071950	chr4:10020882	SLC2A9	-0.7	-11.52	-0.58	3.7e-25	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs4253772	0.550	rs6007830	chr22:46711323	C/T	cg09491104	chr22:46646882	C22orf40	-0.49	-5.89	-0.34	1.14e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs9291683	0.546	rs6820188	chr4:10051655	C/T	cg11266682	chr4:10021025	SLC2A9	0.64	12.67	0.61	4.55e-29	Bone mineral density;
CESC	cis	rs910316	1.000	rs10146482	chr14:75574087	C/T	cg08847533	chr14:75593920	NEK9	1.02	20.98	0.79	2.94e-58	Height;
CESC	cis	rs2549003	1.000	rs17848418	chr5:131821188	C/T	cg02551604	chr5:131831745	NA	-0.37	-5.27	-0.31	2.81e-7	Asthma (sex interaction);
CESC	cis	rs425277	0.583	rs1467217	chr1:2045165	G/A	cg23803603	chr1:2058230	PRKCZ	-0.38	-6.9	-0.39	3.81e-11	Height;
CESC	cis	rs780096	0.526	rs4803	chr2:27667297	A/G	cg22903471	chr2:27725779	GCKR	-0.52	-7.39	-0.41	1.88e-12	Total body bone mineral density;
CESC	cis	rs7914558	1.000	rs11191539	chr10:104819770	A/G	cg08650961	chr10:104748594	CNNM2	0.31	5.19	0.3	4.18e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs4665809	1.000	rs1371553	chr2:26262948	G/A	cg22920501	chr2:26401640	FAM59B	-0.7	-8.4	-0.46	2.77e-15	Gut microbiome composition (summer);
CESC	cis	rs739496	0.542	rs7306529	chr12:111780644	A/G	cg10833066	chr12:111807467	FAM109A	0.34	5.24	0.31	3.34e-7	Platelet count;
CESC	cis	rs801193	1.000	rs2659906	chr7:66165310	T/C	cg11764359	chr7:65958608	NA	0.69	9.1	0.49	2.27e-17	Aortic root size;
CESC	trans	rs9929218	0.551	rs2274240	chr16:68725486	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.97	16.37	0.71	4.18e-42	Colorectal cancer;
CESC	cis	rs9322193	0.961	rs9767713	chr6:149909377	T/G	cg13206674	chr6:150067644	NUP43	0.39	5.5	0.32	9.04e-8	Lung cancer;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg09926380	chr3:10052611	LOC401052	0.42	6.27	0.36	1.45e-9	Asthma;
CESC	cis	rs35110281	0.667	rs4819291	chr21:45123139	G/A	cg21573476	chr21:45109991	RRP1B	-0.58	-8.44	-0.46	2.17e-15	Mean corpuscular volume;
CESC	cis	rs763014	0.865	rs710924	chr16:633353	T/C	cg07343612	chr16:622815	PIGQ	-0.57	-8.23	-0.45	8.47e-15	Height;
CESC	trans	rs7395662	0.591	rs4882012	chr11:48560597	T/A	cg00717180	chr2:96193071	NA	-0.45	-6.19	-0.36	2.32e-9	HDL cholesterol;
CESC	cis	rs3733585	0.631	rs3822236	chr4:10119961	T/G	cg11266682	chr4:10021025	SLC2A9	-0.55	-10.3	-0.53	3.87e-21	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs9291683	0.530	rs11723970	chr4:9980462	T/C	cg02734326	chr4:10020555	SLC2A9	0.46	6.92	0.39	3.38e-11	Bone mineral density;
CESC	cis	rs41271473	0.519	rs9660783	chr1:228886880	C/T	cg00850481	chr1:228891306	NA	-0.46	-6.19	-0.36	2.32e-9	Chronic lymphocytic leukemia;
CESC	cis	rs1878931	0.597	rs37816	chr16:3456371	G/A	cg02880119	chr16:3481970	NA	0.43	5.32	0.31	2.24e-7	Body mass index (adult);
CESC	cis	rs9300255	0.543	rs1260294	chr12:123560289	T/C	cg00376283	chr12:123451042	ABCB9	-0.69	-7.14	-0.4	8.92e-12	Neutrophil percentage of white cells;
CESC	trans	rs1814175	0.587	rs7948538	chr11:50021353	A/C	cg15704280	chr7:45808275	SEPT13	-1.0	-18.53	-0.75	9.55e-50	Height;
CESC	cis	rs7818688	0.932	rs6471506	chr8:96028700	T/C	cg16049864	chr8:95962084	TP53INP1	0.6	5.77	0.33	2.25e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs7605827	0.930	rs6718736	chr2:15525875	C/T	cg19274914	chr2:15703543	NA	0.36	6.45	0.37	5.37e-10	Educational attainment (years of education);
CESC	cis	rs7523050	0.643	rs12736534	chr1:109399934	T/C	cg08274380	chr1:109419600	GPSM2	0.83	5.58	0.32	5.89e-8	Fat distribution (HIV);
CESC	trans	rs7849270	1.000	rs10819469	chr9:131882067	G/T	cg05583848	chr6:35265411	DEF6	-0.44	-6.06	-0.35	4.54e-9	Blood metabolite ratios;
CESC	cis	rs801193	1.000	rs4717319	chr7:66242593	A/G	cg18876405	chr7:65276391	NA	0.56	7.48	0.42	1.1e-12	Aortic root size;
CESC	cis	rs7811142	0.775	rs1059129	chr7:99926522	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.94	10.67	0.55	2.43e-22	Platelet count;
CESC	cis	rs1451375	0.652	rs7803440	chr7:50625632	C/T	cg14593290	chr7:50529359	DDC	0.44	5.37	0.31	1.71e-7	Malaria;
CESC	cis	rs6912958	0.967	rs6905947	chr6:88161949	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.61	-8.44	-0.46	2.16e-15	Monocyte percentage of white cells;
CESC	cis	rs12477438	0.765	rs1115756	chr2:99659845	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.62	-8.67	-0.47	4.43e-16	Chronic sinus infection;
CESC	cis	rs11203032	0.831	rs9651424	chr10:90932935	A/G	cg16672925	chr10:90967113	CH25H	0.69	6.48	0.37	4.53e-10	Heart failure;
CESC	cis	rs6088590	0.687	rs6088580	chr20:33285053	G/C	cg24642439	chr20:33292090	TP53INP2	0.68	9.04	0.49	3.51e-17	Coronary artery disease;
CESC	cis	rs637571	0.522	rs606978	chr11:65711517	A/C	cg04055107	chr11:65626734	MUS81;CFL1	0.43	5.27	0.31	2.89e-7	Eosinophil percentage of white cells;
CESC	cis	rs17376456	0.877	rs17083460	chr5:93462354	A/G	cg25358565	chr5:93447407	FAM172A	1.15	11.8	0.59	4.11e-26	Diabetic retinopathy;
CESC	trans	rs427691	0.625	rs845740	chr5:109018902	C/T	cg00054525	chr16:88717587	CYBA	-0.61	-6.33	-0.36	1.06e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs684232	0.583	rs17677436	chr17:520314	T/C	cg12384639	chr17:618140	VPS53	0.43	5.46	0.32	1.12e-7	Prostate cancer;
CESC	cis	rs2963155	0.590	rs258757	chr5:142620736	A/G	cg17617527	chr5:142782415	NR3C1	-0.78	-7.25	-0.41	4.67e-12	Breast cancer;
CESC	cis	rs7851660	0.967	rs12348304	chr9:100611233	T/C	cg13688889	chr9:100608707	NA	-0.68	-10.64	-0.55	3.08e-22	Strep throat;
CESC	cis	rs6502050	0.805	rs56020943	chr17:80105248	C/A	cg23985595	chr17:80112537	CCDC57	-0.42	-6.57	-0.37	2.72e-10	Life satisfaction;
CESC	cis	rs6500395	1.000	rs11644518	chr16:48616789	A/G	cg04672837	chr16:48644449	N4BP1	0.51	6.5	0.37	3.95e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs9487051	0.621	rs351721	chr6:109551109	G/T	cg01475377	chr6:109611718	NA	-0.38	-5.14	-0.3	5.22e-7	Reticulocyte fraction of red cells;
CESC	cis	rs769267	0.965	rs1469712	chr19:19528821	C/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.45	5.92	0.34	1.01e-8	Tonsillectomy;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg21271961	chr1:95285780	SLC44A3	0.48	6.2	0.36	2.2e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs7336332	0.598	rs75439483	chr13:28010512	A/G	cg22138327	chr13:27999177	GTF3A	0.62	5.82	0.34	1.71e-8	Weight;
CESC	cis	rs7552404	0.727	rs4949677	chr1:76266662	T/A	cg22875332	chr1:76189707	ACADM	0.62	6.31	0.36	1.17e-9	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs910316	1.000	rs12889472	chr14:75543979	A/G	cg08847533	chr14:75593920	NEK9	0.99	18.38	0.75	3.34e-49	Height;
CESC	cis	rs9926296	0.605	rs1800287	chr16:89858525	C/G	cg07648498	chr16:89883185	FANCA	0.44	5.56	0.32	6.73e-8	Vitiligo;
CESC	trans	rs4824093	0.610	rs4824113	chr22:50284974	C/T	cg09872104	chr7:134855509	C7orf49	-0.94	-6.17	-0.35	2.52e-9	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs6460942	1.000	rs6970095	chr7:12403840	G/A	cg06484146	chr7:12443880	VWDE	-0.7	-8.15	-0.45	1.5e-14	Coronary artery disease;
CESC	cis	rs8014204	0.544	rs2286913	chr14:75386576	G/A	cg26191576	chr14:75389716	RPS6KL1	-0.39	-5.5	-0.32	8.89e-8	Caffeine consumption;
CESC	cis	rs7580658	0.613	rs12463538	chr2:128196854	G/T	cg10021288	chr2:128175891	PROC	-0.4	-5.93	-0.34	9.32e-9	Protein C levels;
CESC	cis	rs10791323	0.569	rs1944734	chr11:133720077	G/A	cg15485101	chr11:133734466	NA	0.36	5.8	0.34	1.89e-8	Childhood ear infection;
CESC	cis	rs6887276	0.504	rs1003136	chr5:127347815	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.4	5.04	0.3	8.54e-7	Height;
CESC	cis	rs3785574	0.962	rs4968660	chr17:61792221	G/A	cg06420487	chr17:61919686	SMARCD2	0.46	5.53	0.32	7.63e-8	Height;
CESC	cis	rs4835473	0.932	rs34257944	chr4:144657596	A/G	cg25736465	chr4:144833511	NA	-0.33	-5.2	-0.3	3.99e-7	Immature fraction of reticulocytes;
CESC	cis	rs651907	0.557	rs2303474	chr3:101371899	G/T	cg12386194	chr3:101231763	SENP7	0.45	5.52	0.32	8.09e-8	Colorectal cancer;
CESC	cis	rs9549260	0.755	rs9566553	chr13:41174231	A/G	cg21288729	chr13:41239152	FOXO1	0.61	7.67	0.43	3.32e-13	Red blood cell count;
CESC	cis	rs4253772	0.591	rs739165	chr22:46684528	C/T	cg18190219	chr22:46762943	CELSR1	-0.59	-5.61	-0.33	5.16e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs763121	0.853	rs6001182	chr22:39047443	A/G	cg06022373	chr22:39101656	GTPBP1	0.88	13.79	0.65	5.43e-33	Menopause (age at onset);
CESC	cis	rs2652822	0.509	rs7163254	chr15:63439403	G/T	cg02713581	chr15:63449717	RPS27L	0.51	5.61	0.33	4.98e-8	Metabolic traits;
CESC	cis	rs2075371	0.796	rs35440439	chr7:134006094	C/T	cg20476274	chr7:133979776	SLC35B4	0.6	8.33	0.46	4.39e-15	Mean platelet volume;
CESC	cis	rs950776	0.593	rs6495306	chr15:78865893	C/T	cg24631222	chr15:78858424	CHRNA5	0.43	5.41	0.32	1.4e-7	Sudden cardiac arrest;
CESC	cis	rs9549367	0.713	rs3024746	chr13:113821777	G/A	cg00898013	chr13:113819073	PROZ	-0.49	-6.96	-0.39	2.69e-11	Platelet distribution width;
CESC	cis	rs11638352	1.000	rs11854312	chr15:44279709	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	-0.63	-5.6	-0.33	5.48e-8	Lipoprotein phospholipase A2 activity in cardiovascular disease;
CESC	cis	rs2839186	0.596	rs4819217	chr21:47644092	G/T	cg10351095	chr21:47802916	PCNT	-0.43	-5.75	-0.33	2.48e-8	Testicular germ cell tumor;
CESC	cis	rs2576037	0.526	rs2187092	chr18:44526798	A/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.55	-7.55	-0.42	6.89e-13	Personality dimensions;
CESC	cis	rs9611565	0.649	rs202625	chr22:41827082	G/A	cg03806693	chr22:41940476	POLR3H	1.2	14.53	0.67	1.4e-35	Vitiligo;
CESC	cis	rs7811142	0.666	rs28401739	chr7:99905684	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.1	12.2	0.6	1.88e-27	Platelet count;
CESC	cis	rs3092073	0.624	rs11696196	chr20:44574533	C/T	cg00125455	chr20:44574271	PCIF1	0.38	5.96	0.34	8.15e-9	Intelligence (multi-trait analysis);
CESC	cis	rs780096	0.527	rs59644396	chr2:27646083	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.28	-5.7	-0.33	3.17e-8	Total body bone mineral density;
CESC	cis	rs67311347	1.000	rs17078916	chr3:40445438	C/T	cg09455208	chr3:40491958	NA	0.52	8.59	0.47	7.51e-16	Renal cell carcinoma;
CESC	cis	rs8018808	0.905	rs11159259	chr14:77892393	C/T	cg20045696	chr14:77926864	AHSA1	0.42	5.84	0.34	1.55e-8	Myeloid white cell count;
CESC	cis	rs10918270	1.000	rs3795649	chr1:161931562	G/A	cg19735514	chr1:161762739	ATF6	-0.35	-5.19	-0.3	4.16e-7	Parkinson's disease (age of onset);
CESC	cis	rs9649213	0.593	rs6969234	chr7:97987986	T/C	cg21770322	chr7:97807741	LMTK2	0.57	8.84	0.48	1.39e-16	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19742111	chr11:66460113	SPTBN2	-0.62	-7.04	-0.4	1.61e-11	Gut microbiome composition (summer);
CESC	cis	rs9814567	1.000	rs4368544	chr3:134300014	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.45	6.06	0.35	4.58e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs9549260	0.753	rs9549254	chr13:41234763	G/A	cg21288729	chr13:41239152	FOXO1	0.55	5.4	0.31	1.49e-7	Red blood cell count;
CESC	cis	rs28374715	0.532	rs7164211	chr15:41705041	A/T	cg02330683	chr15:41787940	ITPKA	0.44	5.44	0.32	1.2e-7	Ulcerative colitis;
CESC	cis	rs7000551	0.751	rs2449340	chr8:22389900	T/G	cg12081754	chr8:22256438	SLC39A14	0.41	5.54	0.32	7.46e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CESC	cis	rs3820068	0.580	rs34426856	chr1:16006315	C/T	cg13390004	chr1:15929781	NA	0.34	5.18	0.3	4.33e-7	Systolic blood pressure;
CESC	cis	rs7940866	0.809	rs11222410	chr11:130833994	A/G	cg12179176	chr11:130786555	SNX19	0.62	8.55	0.47	9.71e-16	Schizophrenia;
CESC	cis	rs7520050	0.902	rs4626927	chr1:46248645	C/T	cg24296786	chr1:45957014	TESK2	0.44	5.57	0.32	6.14e-8	Red blood cell count;Reticulocyte count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17079530	chr11:117014700	PAFAH1B2	-0.63	-7.44	-0.42	1.43e-12	Gut microbiome composition (summer);
CESC	cis	rs1983170	0.736	rs4484968	chr1:92012005	C/A	cg02896835	chr1:92012615	NA	0.59	6.22	0.36	1.88e-9	Eosinophil percentage of white cells;
CESC	trans	rs11971186	1.000	rs12534101	chr7:126419412	C/A	cg10894441	chr11:111169905	C11orf92;C11orf93	0.47	5.99	0.35	6.66e-9	Chemerin levels;
CESC	cis	rs17376456	0.877	rs10040648	chr5:93490301	G/C	cg21475434	chr5:93447410	FAM172A	0.85	7.58	0.42	5.88e-13	Diabetic retinopathy;
CESC	cis	rs17711722	0.565	rs73372653	chr7:65442795	A/T	cg14393609	chr7:65229607	NA	0.47	6.29	0.36	1.29e-9	Calcium levels;
CESC	cis	rs6502050	0.835	rs9902485	chr17:80093701	C/T	cg11859384	chr17:80120422	CCDC57	-0.38	-5.14	-0.3	5.29e-7	Life satisfaction;
CESC	cis	rs7188697	0.922	rs37039	chr16:58578091	C/T	cg21335942	chr16:58549945	SETD6	0.46	5.48	0.32	1.01e-7	QT interval;
CESC	cis	rs9814567	0.806	rs4535271	chr3:134321669	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.39	-5.13	-0.3	5.64e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	trans	rs11039798	0.623	rs594615	chr11:48402804	T/C	cg15704280	chr7:45808275	SEPT13	-0.69	-6.75	-0.38	9.03e-11	Axial length;
CESC	cis	rs4975616	0.869	rs380286	chr5:1320247	G/A	cg07493874	chr5:1342172	CLPTM1L	-0.41	-7.75	-0.43	2.03e-13	Lung cancer;
CESC	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg23978390	chr7:1156363	C7orf50	0.64	8.91	0.48	8.43e-17	Longevity;Endometriosis;
CESC	cis	rs6502050	0.805	rs7503095	chr17:80107354	G/A	cg23985595	chr17:80112537	CCDC57	-0.42	-6.42	-0.37	6.1e-10	Life satisfaction;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05678175	chr19:59056626	TRIM28	-0.56	-6.36	-0.36	8.78e-10	Gut microbiome composition (summer);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg22586474	chr7:931148	C7orf20	0.5	6.82	0.39	6.04e-11	Fibrinogen levels;
CESC	cis	rs7264396	0.790	rs3787166	chr20:34229072	A/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.55	5.64	0.33	4.26e-8	Total cholesterol levels;
CESC	cis	rs72945132	0.882	rs56368190	chr11:70204328	T/G	cg00319359	chr11:70116639	PPFIA1	0.73	6.96	0.39	2.63e-11	Coronary artery disease;
CESC	trans	rs35110281	0.807	rs4818850	chr21:45028071	T/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.5	6.52	0.37	3.47e-10	Mean corpuscular volume;
CESC	cis	rs2932538	0.922	rs6698030	chr1:113138318	G/A	cg22162597	chr1:113214053	CAPZA1	0.6	7.33	0.41	2.75e-12	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CESC	cis	rs10911232	0.507	rs4129857	chr1:183004547	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.86	13.48	0.64	6.62e-32	Hypertriglyceridemia;
CESC	trans	rs2055011	1.000	rs1491784	chr21:19481664	C/T	cg21339533	chr7:23221367	NUPL2	-0.53	-6.25	-0.36	1.68e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
CESC	cis	rs4665809	0.816	rs2384359	chr2:26371364	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.86	-9.71	-0.51	2.82e-19	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07089834	chr17:79239572	SLC38A10	-0.66	-7.54	-0.42	7.55e-13	Gut microbiome composition (summer);
CESC	cis	rs11958404	0.932	rs72816584	chr5:157433190	G/A	cg05962755	chr5:157440814	NA	0.62	6.56	0.37	2.74e-10	IgG glycosylation;
CESC	cis	rs6137287	0.574	rs11696663	chr20:21065004	C/T	cg13880779	chr20:21376337	NKX2-4	0.33	5.13	0.3	5.47e-7	Height;
CESC	cis	rs7618915	0.571	rs34954168	chr3:52612159	C/T	cg07507251	chr3:52567010	NT5DC2	0.41	7.17	0.4	7.64e-12	Bipolar disorder;
CESC	cis	rs8114671	0.586	rs6087634	chr20:33413809	G/A	cg07148914	chr20:33460835	GGT7	0.42	5.29	0.31	2.63e-7	Height;
CESC	cis	rs6662572	1.000	rs11587982	chr1:46161868	A/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.52	5.46	0.32	1.1e-7	Blood protein levels;
CESC	cis	rs2439831	0.681	rs2242067	chr15:43699303	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.76	9.29	0.5	5.64e-18	Lung cancer in ever smokers;
CESC	trans	rs9951602	0.512	rs8084836	chr18:76647841	A/G	cg02800362	chr5:177631904	HNRNPAB	0.63	8.4	0.46	2.7e-15	Obesity-related traits;
CESC	cis	rs1595825	0.891	rs6733834	chr2:198518709	C/G	cg00982548	chr2:198649783	BOLL	0.47	5.03	0.3	9.03e-7	Ulcerative colitis;
CESC	cis	rs1799949	1.000	rs8176126	chr17:41259049	A/G	cg23758822	chr17:41437982	NA	-1.02	-15.85	-0.7	2.99e-40	Menopause (age at onset);
CESC	cis	rs1862618	0.853	rs1862619	chr5:56098256	T/A	cg18230493	chr5:56204884	C5orf35	-0.66	-8.28	-0.45	6.32e-15	Initial pursuit acceleration;
CESC	cis	rs9311474	0.508	rs1570	chr3:52586682	T/A	cg17372223	chr3:52568218	NT5DC2	0.4	5.94	0.34	8.86e-9	Electroencephalogram traits;
CESC	cis	rs7617773	0.539	rs13069884	chr3:48381148	T/A	cg11946769	chr3:48343235	NME6	0.66	8.34	0.46	4.12e-15	Coronary artery disease;
CESC	cis	rs9733	0.596	rs12086472	chr1:150697710	G/A	cg04414720	chr1:150670196	GOLPH3L	0.62	8.8	0.48	1.76e-16	Tonsillectomy;
CESC	cis	rs1538970	0.962	rs3219472	chr1:45804050	A/G	cg05343316	chr1:45956843	TESK2	-0.83	-10.41	-0.54	1.72e-21	Platelet count;
CESC	cis	rs7833986	0.534	rs2667972	chr8:56906661	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.58	7.09	0.4	1.2e-11	Height;
CESC	cis	rs6570726	0.599	rs4398765	chr6:145935006	C/A	cg05347473	chr6:146136440	FBXO30	0.72	8.95	0.48	6.27e-17	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs12824058	0.831	rs55726136	chr12:130810312	G/A	cg24838063	chr12:130822603	PIWIL1	0.62	8.55	0.47	9.78e-16	Menopause (age at onset);
CESC	cis	rs66887589	0.967	rs7678973	chr4:120511817	T/C	cg09307838	chr4:120376055	NA	-0.53	-7.07	-0.4	1.35e-11	Diastolic blood pressure;
CESC	cis	rs2197308	0.765	rs12370231	chr12:37917881	T/C	cg13010199	chr12:38710504	ALG10B	0.54	6.81	0.39	6.5e-11	Morning vs. evening chronotype;
CESC	cis	rs727563	0.648	rs6002406	chr22:41965237	A/T	cg03806693	chr22:41940476	POLR3H	-1.14	-13.12	-0.63	1.26e-30	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs60843830	1.000	rs10193373	chr2:281886	T/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.87	11.49	0.58	4.68e-25	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs9788682	0.747	rs2915695	chr15:78739471	T/C	cg24631222	chr15:78858424	CHRNA5	-0.63	-7.51	-0.42	9.21e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs56804039	0.895	rs11776995	chr8:8385547	A/G	cg15556689	chr8:8085844	FLJ10661	-0.5	-5.42	-0.32	1.35e-7	Cervical cancer;
CESC	cis	rs12134245	0.747	rs11164929	chr1:92012836	G/C	cg25838465	chr1:92012736	NA	-0.64	-10.07	-0.53	2.12e-20	Breast cancer;
CESC	trans	rs8056446	0.710	rs8059793	chr16:78189298	A/C	cg05022673	chr6:56819429	DST;BEND6	0.46	6.12	0.35	3.44e-9	Pulmonary function (smoking interaction);
CESC	cis	rs1788820	0.717	rs1788823	chr18:21114917	A/G	cg14672496	chr18:21087552	C18orf8	0.43	5.86	0.34	1.37e-8	Body mass index;
CESC	cis	rs367615	0.918	rs10067984	chr5:108872684	C/T	cg17395555	chr5:108820864	NA	0.55	8.2	0.45	1.06e-14	Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs796364	0.806	rs6435040	chr2:200861161	T/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.83	7.49	0.42	1e-12	Schizophrenia;
CESC	cis	rs4423214	1.000	rs12419279	chr11:71139061	T/A	cg05163923	chr11:71159392	DHCR7	0.78	10.47	0.54	1.04e-21	Vitamin D levels;
CESC	cis	rs67311347	1.000	rs2085115	chr3:40497540	G/T	cg24209194	chr3:40518798	ZNF619	0.51	6.07	0.35	4.48e-9	Renal cell carcinoma;
CESC	cis	rs7116495	1.000	rs4945426	chr11:71748146	A/C	cg26138937	chr11:71823887	C11orf51	0.79	6.88	0.39	4.3e-11	Severe influenza A (H1N1) infection;
CESC	cis	rs9399135	0.967	rs2327578	chr6:135329969	C/T	cg22676075	chr6:135203613	NA	0.51	7.23	0.41	5.22e-12	Red blood cell count;
CESC	cis	rs6088580	0.634	rs6142157	chr20:32984172	C/G	cg08999081	chr20:33150536	PIGU	-0.64	-11.25	-0.57	2.81e-24	Glomerular filtration rate (creatinine);
CESC	cis	rs3091242	0.967	rs665372	chr1:25719235	A/C	cg12412775	chr1:25698385	RHCE	-0.33	-5.97	-0.34	7.79e-9	Erythrocyte sedimentation rate;
CESC	cis	rs3733418	0.860	rs35449092	chr4:165949676	C/G	cg10852876	chr4:165953100	TRIM60	-0.47	-5.5	-0.32	8.73e-8	Obesity-related traits;
CESC	cis	rs2836974	0.899	rs34978594	chr21:40580003	C/T	cg11890956	chr21:40555474	PSMG1	1.17	21.83	0.8	3.83e-61	Cognitive function;
CESC	cis	rs801193	1.000	rs6975195	chr7:66124774	T/A	cg14393609	chr7:65229607	NA	-0.45	-6.02	-0.35	5.91e-9	Aortic root size;
CESC	cis	rs2730245	1.000	rs2252502	chr7:158738634	G/C	cg24397884	chr7:158709396	WDR60	-0.89	-13.66	-0.64	1.65e-32	Height;
CESC	cis	rs1707322	0.716	rs6694889	chr1:46101806	A/C	cg03146154	chr1:46216737	IPP	0.81	11.48	0.58	5.05e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs1538970	0.961	rs7543428	chr1:45839643	A/G	cg05343316	chr1:45956843	TESK2	0.84	11.83	0.59	3.26e-26	Platelet count;
CESC	trans	rs2573652	0.755	rs1469830	chr15:100517403	G/T	cg02378063	chr4:22913868	NA	-0.38	-6.0	-0.35	6.28e-9	Height;
CESC	cis	rs360798	0.532	rs12713468	chr2:62983213	G/A	cg17519650	chr2:63277830	OTX1	-0.59	-7.61	-0.42	4.72e-13	Coronary artery disease;
CESC	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg18099408	chr3:52552593	STAB1	-0.43	-8.03	-0.44	3.23e-14	Electroencephalogram traits;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg23712980	chr20:30795555	POFUT1;PLAGL2	-0.49	-6.61	-0.38	2.15e-10	Asthma;
CESC	cis	rs10465746	0.725	rs10127737	chr1:84368642	G/A	cg10977910	chr1:84465055	TTLL7	0.56	7.74	0.43	2.07e-13	Obesity-related traits;
CESC	trans	rs11989744	0.500	rs7844903	chr8:23568464	T/C	cg03492747	chr16:86543808	FOXF1	-0.85	-13.64	-0.64	1.83e-32	Waist-hip ratio;
CESC	cis	rs4141404	0.582	rs5753630	chr22:31861950	A/G	cg00478049	chr22:31556069	RNF185	-0.41	-5.06	-0.3	8.02e-7	Paclitaxel-induced neuropathy;
CESC	cis	rs798554	0.679	rs2527681	chr7:2892384	A/T	cg19717773	chr7:2847554	GNA12	-0.46	-6.47	-0.37	4.83e-10	Height;
CESC	cis	rs4561483	0.801	rs251723	chr16:11953080	G/C	cg08843971	chr16:11963173	GSPT1	-0.56	-8.06	-0.44	2.56e-14	Testicular germ cell tumor;
CESC	cis	rs2273669	0.510	rs11757590	chr6:109370003	T/C	cg05315195	chr6:109294784	ARMC2	-0.67	-6.32	-0.36	1.13e-9	Prostate cancer;
CESC	trans	rs28735056	0.572	rs4799100	chr18:77640207	A/G	cg05926928	chr17:57297772	GDPD1	-0.62	-7.71	-0.43	2.55e-13	Schizophrenia;
CESC	cis	rs9900062	0.560	rs11656678	chr17:62681505	G/A	cg02097616	chr17:62675921	NA	0.44	5.51	0.32	8.34e-8	QT interval;
CESC	cis	rs7173419	0.607	rs12915936	chr15:28223836	A/G	cg20906524	chr15:28200668	OCA2	-0.38	-5.21	-0.31	3.72e-7	Eye color;
CESC	trans	rs524281	0.731	rs12576969	chr11:65802478	A/G	cg03887094	chr16:67198826	HSF4	0.51	6.02	0.35	5.82e-9	Electroencephalogram traits;
CESC	cis	rs6952808	0.630	rs4719443	chr7:2161099	A/G	cg23048001	chr7:2026167	MAD1L1	0.45	5.79	0.33	2.02e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs9625935	0.518	rs5752972	chr22:30250312	A/T	cg01021169	chr22:30184971	ASCC2	0.4	6.31	0.36	1.19e-9	Tonsillectomy;
CESC	cis	rs2463822	0.614	rs117699706	chr11:62161659	T/C	cg06239285	chr11:62104954	ASRGL1	-1.07	-9.26	-0.49	7.43e-18	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs36051895	0.589	rs62543573	chr9:5201675	A/G	cg02405213	chr9:5042618	JAK2	-0.53	-6.18	-0.35	2.45e-9	Pediatric autoimmune diseases;
CESC	trans	rs526821	0.595	rs517627	chr11:55356489	C/T	cg03929089	chr4:120376271	NA	-0.5	-6.07	-0.35	4.33e-9	Pediatric bone mineral density (spine);
CESC	cis	rs8077577	0.747	rs11868708	chr17:18244613	T/C	cg16794390	chr17:18148240	FLII	0.41	6.38	0.36	8.03e-10	Obesity-related traits;
CESC	cis	rs870825	0.655	rs28604350	chr4:185638723	G/A	cg04058563	chr4:185651563	MLF1IP	0.63	6.93	0.39	3.17e-11	Blood protein levels;
CESC	cis	rs7666738	0.830	rs114722517	chr4:99042061	G/A	cg03467027	chr4:99064603	C4orf37	0.47	5.98	0.34	7.19e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7208859	0.623	rs7212991	chr17:29143749	T/C	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.79e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs3768617	0.510	rs12078729	chr1:183060072	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.88	13.97	0.65	1.34e-33	Fuchs's corneal dystrophy;
CESC	cis	rs7267979	0.873	rs6132822	chr20:25228695	C/T	cg08601574	chr20:25228251	PYGB	0.42	5.81	0.34	1.82e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs6500395	0.963	rs6500405	chr16:48690486	C/T	cg04672837	chr16:48644449	N4BP1	-0.51	-6.36	-0.36	8.64e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs5769765	0.955	rs9616204	chr22:50303530	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.54	-5.73	-0.33	2.72e-8	Schizophrenia;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg24173921	chr3:44690229	ZNF35	-0.51	-6.5	-0.37	4.01e-10	Ulcerative colitis;
CESC	cis	rs2342371	0.565	rs11185543	chr3:196215660	G/A	cg15048948	chr3:196158458	UBXN7	-0.39	-5.36	-0.31	1.81e-7	Fat distribution (HIV);
CESC	cis	rs7927771	0.524	rs12362318	chr11:47682671	T/C	cg18512352	chr11:47633146	NA	0.34	5.21	0.31	3.73e-7	Subjective well-being;
CESC	cis	rs1348850	0.958	rs4528793	chr2:178464271	C/T	cg23306229	chr2:178417860	TTC30B	0.57	7.52	0.42	8.3e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs6942756	0.806	rs10257620	chr7:128901429	C/A	cg02491457	chr7:128862824	NA	0.65	9.65	0.51	4.39e-19	White matter hyperintensity burden;
CESC	cis	rs9322193	0.962	rs6903998	chr6:150152493	T/C	cg07701084	chr6:150067640	NUP43	0.43	5.95	0.34	8.47e-9	Lung cancer;
CESC	cis	rs6121246	0.559	rs6121243	chr20:30415094	C/G	cg13852791	chr20:30311386	BCL2L1	0.85	11.11	0.56	8.34e-24	Mean corpuscular hemoglobin;
CESC	cis	rs7635838	0.617	rs346074	chr3:11294310	T/C	cg00170343	chr3:11313890	ATG7	0.59	8.61	0.47	6.6e-16	HDL cholesterol;
CESC	cis	rs12586317	0.576	rs10130047	chr14:35633580	C/A	cg16230307	chr14:35515116	FAM177A1	0.4	5.09	0.3	6.79e-7	Psoriasis;
CESC	cis	rs9790314	1.000	rs336579	chr3:161086610	G/A	cg03342759	chr3:160939853	NMD3	-0.44	-5.61	-0.33	5.11e-8	Morning vs. evening chronotype;
CESC	cis	rs875971	0.862	rs801194	chr7:66028495	T/C	cg18252515	chr7:66147081	NA	0.46	5.96	0.34	8.03e-9	Aortic root size;
CESC	cis	rs3806843	0.771	rs2563334	chr5:140107065	C/G	cg26395211	chr5:140044315	WDR55	0.47	5.95	0.34	8.5e-9	Depressive symptoms (multi-trait analysis);
CESC	cis	rs875971	0.660	rs7807930	chr7:66087165	C/T	cg25985355	chr7:65971099	NA	0.31	5.11	0.3	6.09e-7	Aortic root size;
CESC	cis	rs6740322	0.748	rs6544636	chr2:43487486	C/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.8	-8.73	-0.47	2.84e-16	Coronary artery disease;
CESC	cis	rs7552404	0.731	rs931507	chr1:76401577	G/A	cg10523679	chr1:76189770	ACADM	-0.58	-6.0	-0.35	6.31e-9	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs7618915	0.547	rs62255371	chr3:52747321	A/G	cg17372223	chr3:52568218	NT5DC2	0.44	6.56	0.37	2.88e-10	Bipolar disorder;
CESC	cis	rs300703	0.515	rs300695	chr2:182644	C/A	cg21211680	chr2:198530	NA	-0.91	-10.69	-0.55	2.11e-22	Blood protein levels;
CESC	cis	rs853679	0.550	rs1225598	chr6:28160799	T/G	cg22143856	chr6:28129313	ZNF389	0.44	5.83	0.34	1.57e-8	Depression;
CESC	cis	rs929596	0.561	rs6431625	chr2:234637912	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.62	-8.34	-0.46	4.2e-15	Total bilirubin levels in HIV-1 infection;
CESC	cis	rs55728055	0.661	rs12165609	chr22:32036332	T/C	cg01338084	chr22:32026380	PISD	1.21	8.55	0.47	9.91e-16	Age-related hearing impairment;
CESC	cis	rs1799949	1.000	rs12936831	chr17:41331816	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.59	7.71	0.43	2.62e-13	Menopause (age at onset);
CESC	cis	rs1707322	0.721	rs6697821	chr1:46216722	A/G	cg05343316	chr1:45956843	TESK2	0.51	6.2	0.36	2.19e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs6136813	0.556	rs66649546	chr20:19656150	C/T	cg10180406	chr1:186649877	PTGS2	0.61	6.01	0.35	6.15e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
CESC	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg24101359	chr6:42928495	GNMT	0.59	9.13	0.49	1.84e-17	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs1862618	0.641	rs252893	chr5:56224714	T/C	cg22800045	chr5:56110881	MAP3K1	0.59	7.69	0.43	2.8e-13	Initial pursuit acceleration;
CESC	cis	rs2652822	0.967	rs4775633	chr15:63437746	G/A	cg02713581	chr15:63449717	RPS27L	0.59	7.71	0.43	2.49e-13	Metabolic traits;
CESC	cis	rs7116495	0.609	rs7942626	chr11:71703849	G/A	cg10381502	chr11:71823885	C11orf51	-1.16	-7.94	-0.44	5.77e-14	Severe influenza A (H1N1) infection;
CESC	cis	rs4423214	1.000	rs12793530	chr11:71161656	G/A	cg05163923	chr11:71159392	DHCR7	0.76	10.35	0.54	2.66e-21	Vitamin D levels;
CESC	cis	rs3820928	0.605	rs4281898	chr2:227855493	A/C	cg11843606	chr2:227700838	RHBDD1	-0.5	-6.92	-0.39	3.44e-11	Pulmonary function;
CESC	cis	rs6120849	0.754	rs6120828	chr20:33674460	A/G	cg24642439	chr20:33292090	TP53INP2	0.64	6.48	0.37	4.38e-10	Protein C levels;
CESC	cis	rs10899021	1.000	rs61900636	chr11:74359591	G/T	cg25880958	chr11:74394337	NA	-0.76	-7.25	-0.41	4.55e-12	Response to metformin (IC50);
CESC	cis	rs4665809	1.000	rs6750681	chr2:26329677	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.66	-7.47	-0.42	1.15e-12	Gut microbiome composition (summer);
CESC	cis	rs643506	0.874	rs582465	chr11:111668585	C/T	cg09085632	chr11:111637200	PPP2R1B	0.39	5.12	0.3	5.9e-7	Breast cancer;
CESC	cis	rs11168351	0.864	rs12228750	chr12:48496997	G/A	cg24011408	chr12:48396354	COL2A1	-0.5	-7.58	-0.42	5.74e-13	Bipolar disorder and schizophrenia;
CESC	cis	rs7267979	0.934	rs2261753	chr20:25262291	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	18.61	0.75	5.21e-50	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs1152591	0.811	rs1255984	chr14:64654431	C/T	cg21174375	chr14:64681225	SYNE2	-0.47	-6.31	-0.36	1.17e-9	Atrial fibrillation;
CESC	cis	rs1552244	1.000	rs6442147	chr3:10078247	A/G	cg00149659	chr3:10157352	C3orf10	0.76	9.49	0.5	1.4e-18	Alzheimer's disease;
CESC	cis	rs910316	0.737	rs175072	chr14:75502827	T/C	cg08847533	chr14:75593920	NEK9	-0.91	-16.32	-0.71	6.26e-42	Height;
CESC	cis	rs2072732	0.861	rs12409277	chr1:2957600	A/G	cg03976712	chr1:2946727	NA	0.32	5.55	0.32	7.06e-8	Plateletcrit;
CESC	cis	rs17293817	0.589	rs34788429	chr10:1422208	A/G	cg04271617	chr10:1416546	ADARB2	0.35	5.48	0.32	1e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs2842992	0.830	rs1998365	chr6:160179535	A/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.73	8.91	0.48	8.29e-17	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs1005277	0.579	rs2472174	chr10:38375382	A/G	cg25517755	chr10:38738941	LOC399744	-0.48	-6.22	-0.36	1.94e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs12188164	1.000	rs56042615	chr5:437667	G/A	cg17553881	chr5:443987	EXOC3;C5orf55	-0.34	-5.45	-0.32	1.17e-7	Cystic fibrosis severity;
CESC	cis	rs6952808	1.000	rs4449693	chr7:1884630	G/C	cg13880726	chr7:1868755	MAD1L1	0.53	7.11	0.4	1.08e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs6594499	0.872	rs10043631	chr5:110443228	C/T	cg04022379	chr5:110408740	TSLP	0.33	5.9	0.34	1.1e-8	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs6582630	0.537	rs35336822	chr12:38346251	T/C	cg13010199	chr12:38710504	ALG10B	0.45	5.81	0.34	1.75e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs3820928	0.874	rs10199655	chr2:227892428	T/C	cg11843606	chr2:227700838	RHBDD1	-0.48	-6.4	-0.37	7.05e-10	Pulmonary function;
CESC	cis	rs172166	0.694	rs1631552	chr6:28089699	C/A	cg08968635	chr6:28129556	ZNF389	0.33	5.04	0.3	8.57e-7	Cardiac Troponin-T levels;
CESC	cis	rs853679	0.517	rs3173443	chr6:28137027	T/G	cg22143856	chr6:28129313	ZNF389	0.46	5.83	0.34	1.58e-8	Depression;
CESC	cis	rs4891159	0.790	rs11872411	chr18:74132051	C/T	cg24786174	chr18:74118243	ZNF516	-0.76	-12.06	-0.6	5.35e-27	Longevity;
CESC	cis	rs13385	0.769	rs722437	chr5:139545729	A/T	cg26211634	chr5:139558579	C5orf32	0.47	5.16	0.3	4.77e-7	Atrial fibrillation;
CESC	cis	rs1008375	0.966	rs2098152	chr4:17684392	G/T	cg16339924	chr4:17578868	LAP3	0.51	6.57	0.37	2.67e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs7582720	1.000	rs72934765	chr2:203758551	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.4	0.41	1.85e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs2839186	0.588	rs2839140	chr21:47616080	G/A	cg10351095	chr21:47802916	PCNT	0.43	5.55	0.32	7.02e-8	Testicular germ cell tumor;
CESC	cis	rs4409675	0.576	rs12062621	chr1:28230404	A/G	cg23691781	chr1:28212827	C1orf38	0.28	5.65	0.33	4.16e-8	Corneal astigmatism;
CESC	trans	rs10841784	0.958	rs7962263	chr12:21466117	A/G	cg19907483	chr19:6040198	RFX2	0.5	6.35	0.36	9.44e-10	Childhood ear infection;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg09516144	chr16:15982637	C16orf63	-0.5	-6.2	-0.36	2.1e-9	Ulcerative colitis;
CESC	cis	rs4253772	0.550	rs739164	chr22:46684558	C/T	cg24881330	chr22:46731750	TRMU	-0.84	-8.92	-0.48	7.58e-17	LDL cholesterol;Cholesterol, total;
CESC	cis	rs1953600	0.837	rs2819946	chr10:81951635	G/A	cg00277334	chr10:82204260	NA	0.45	6.26	0.36	1.56e-9	Sarcoidosis;
CESC	trans	rs1545843	0.564	rs2446669	chr12:84888478	G/T	cg03015433	chr16:56623111	MT3	0.34	6.04	0.35	5.19e-9	Major depressive disorder;
CESC	cis	rs1218582	0.772	rs1109815	chr1:154909268	A/G	cg06221963	chr1:154839813	KCNN3	-0.65	-10.78	-0.55	1.09e-22	Prostate cancer;
CESC	cis	rs7618501	0.603	rs72942333	chr3:49986118	T/C	cg24308560	chr3:49941425	MST1R	-0.64	-9.19	-0.49	1.17e-17	Intelligence (multi-trait analysis);
CESC	cis	rs4006360	0.524	rs6503601	chr17:39280487	A/C	cg18442075	chr17:40169520	DNAJC7;NKIRAS2	-0.43	-5.42	-0.32	1.36e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs916888	0.821	rs199509	chr17:44858728	G/A	cg15921436	chr17:44337874	NA	-0.7	-7.95	-0.44	5.35e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs4665809	1.000	rs10048648	chr2:26320315	T/C	cg22920501	chr2:26401640	FAM59B	-0.64	-7.75	-0.43	2.03e-13	Gut microbiome composition (summer);
CESC	cis	rs6570726	0.818	rs952405	chr6:145925952	T/C	cg23711669	chr6:146136114	FBXO30	0.83	12.33	0.6	6.39e-28	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4700695	0.640	rs27083	chr5:65435865	C/T	cg21114390	chr5:65439923	SFRS12	-0.49	-5.88	-0.34	1.21e-8	Facial morphology (factor 19);
CESC	cis	rs4819052	0.851	rs4819040	chr21:46659762	T/C	cg11663144	chr21:46675770	NA	-0.49	-7.59	-0.42	5.62e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs9457247	0.565	rs2239824	chr6:167511799	T/A	cg23791538	chr6:167370224	RNASET2	-0.53	-6.98	-0.39	2.32e-11	Crohn's disease;
CESC	cis	rs4555082	0.834	rs2816623	chr14:105733295	G/A	cg06808227	chr14:105710500	BRF1	-0.56	-6.33	-0.36	1.04e-9	Mean platelet volume;Platelet distribution width;
CESC	cis	rs7811142	1.000	rs4989959	chr7:100032288	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.15	11.48	0.58	4.99e-25	Platelet count;
CESC	cis	rs5758659	0.652	rs133324	chr22:42406371	C/A	cg04733989	chr22:42467013	NAGA	0.44	5.86	0.34	1.37e-8	Cognitive function;
CESC	cis	rs7174348	1	rs7174348	chr15:78792439	G/A	cg24631222	chr15:78858424	CHRNA5	0.63	7.48	0.42	1.07e-12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
CESC	cis	rs2204008	0.744	rs11495519	chr12:38060546	C/A	cg26384229	chr12:38710491	ALG10B	0.74	10.7	0.55	1.96e-22	Bladder cancer;
CESC	cis	rs67478160	0.643	rs3742369	chr14:104251276	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.5	-6.96	-0.39	2.72e-11	Schizophrenia;
CESC	cis	rs35306767	0.671	rs11253473	chr10:906826	A/G	cg20503657	chr10:835505	NA	0.78	7.74	0.43	2.14e-13	Eosinophil percentage of granulocytes;
CESC	cis	rs2718058	0.519	rs2598054	chr7:37884640	C/T	cg15028436	chr7:37888078	TXNDC3	0.52	7.38	0.41	2.01e-12	Alzheimer's disease (late onset);
CESC	cis	rs854765	0.547	rs8069811	chr17:17922280	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.55	7.83	0.43	1.16e-13	Total body bone mineral density;
CESC	cis	rs12497850	0.931	rs6446196	chr3:49004723	A/G	cg06212747	chr3:49208901	KLHDC8B	0.71	9.31	0.5	4.93e-18	Parkinson's disease;
CESC	cis	rs875971	0.893	rs62465470	chr7:65601218	T/C	cg18252515	chr7:66147081	NA	0.4	5.14	0.3	5.38e-7	Aortic root size;
CESC	cis	rs11083475	0.557	rs2368519	chr19:39259241	C/T	cg07905965	chr19:39260460	NA	0.46	7.25	0.41	4.68e-12	Heart rate;
CESC	cis	rs4654899	1.000	rs4654899	chr1:21410231	G/T	cg05370193	chr1:21551575	ECE1	0.38	5.79	0.34	1.97e-8	Superior frontal gyrus grey matter volume;
CESC	cis	rs9486715	0.867	rs4240553	chr6:96965324	T/C	cg06623918	chr6:96969491	KIAA0776	0.95	14.61	0.67	7.22e-36	Headache;
CESC	cis	rs1538970	0.924	rs1007858	chr1:45912005	C/T	cg06784218	chr1:46089804	CCDC17	0.35	5.54	0.32	7.26e-8	Platelet count;
CESC	cis	rs18122	0.781	rs2156717	chr2:67616977	A/T	cg09028215	chr2:67624308	ETAA1	-0.46	-5.55	-0.32	6.91e-8	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs244293	0.965	rs2214980	chr17:53207061	A/G	cg19360675	chr17:53046073	COX11;STXBP4	-0.39	-5.09	-0.3	6.87e-7	Menarche (age at onset);
CESC	cis	rs1559088	0.948	rs10408093	chr19:33597816	T/C	cg27124370	chr19:33622961	WDR88	0.45	5.99	0.35	6.77e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs559928	0.606	rs56207008	chr11:63883215	C/T	cg18225595	chr11:63971243	STIP1	0.63	5.66	0.33	4e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CESC	cis	rs12579753	0.719	rs4418885	chr12:82275845	A/T	cg21193143	chr12:82153300	PPFIA2	-0.35	-5.35	-0.31	1.92e-7	Resting heart rate;
CESC	cis	rs4901847	0.577	rs11158199	chr14:58585354	T/C	cg15908186	chr14:58618357	C14orf37	0.34	5.13	0.3	5.61e-7	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs2479724	0.905	rs2274578	chr6:41888827	C/G	cg17623882	chr6:41773611	USP49	-0.41	-5.84	-0.34	1.5e-8	Menarche (age at onset);
CESC	cis	rs763121	0.651	rs738249	chr22:39037979	T/C	cg06022373	chr22:39101656	GTPBP1	0.86	13.01	0.62	3.03e-30	Menopause (age at onset);
CESC	cis	rs703842	1.000	rs11172349	chr12:58212528	G/A	cg00677455	chr12:58241039	CTDSP2	0.54	6.94	0.39	3.05e-11	Multiple sclerosis;
CESC	cis	rs748404	0.723	rs573169	chr15:43550581	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.62	7.94	0.44	5.82e-14	Lung cancer;
CESC	cis	rs7223966	1.000	rs11657081	chr17:61792339	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	7.36	0.41	2.27e-12	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs7666738	0.830	rs11097606	chr4:99011486	C/T	cg05340658	chr4:99064831	C4orf37	0.8	12.58	0.61	9.12e-29	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6570726	0.764	rs9322028	chr6:145895797	G/T	cg23711669	chr6:146136114	FBXO30	0.97	14.77	0.67	2.05e-36	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27150598	chr12:124325933	DNAH10	-0.51	-6.28	-0.36	1.4e-9	Gut microbiome composition (summer);
CESC	cis	rs6594713	0.717	rs10065790	chr5:112911165	C/T	cg12552261	chr5:112820674	MCC	0.57	5.55	0.32	6.94e-8	Brain cytoarchitecture;
CESC	cis	rs9309473	0.851	rs6546850	chr2:73831147	A/T	cg20560298	chr2:73613845	ALMS1	-0.45	-6.03	-0.35	5.44e-9	Metabolite levels;
CESC	cis	rs2576037	0.562	rs612519	chr18:44379490	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.51	-7.03	-0.4	1.73e-11	Personality dimensions;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20430870	chr10:52487619	NA	-0.63	-7.21	-0.4	5.79e-12	Gut microbiome composition (summer);
CESC	cis	rs734999	0.545	rs9970196	chr1:2574078	T/C	cg20673091	chr1:2541236	MMEL1	-0.49	-8.06	-0.44	2.61e-14	Ulcerative colitis;
CESC	cis	rs9303401	0.614	rs12950028	chr17:56510140	A/G	cg25039879	chr17:56429692	SUPT4H1	0.52	5.44	0.32	1.19e-7	Cognitive test performance;
CESC	cis	rs3785574	0.927	rs2854160	chr17:61977248	C/T	cg07677032	chr17:61819896	STRADA	0.43	5.49	0.32	9.42e-8	Height;
CESC	cis	rs1799949	0.965	rs12950779	chr17:41306523	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.66	9.09	0.49	2.43e-17	Menopause (age at onset);
CESC	cis	rs1950626	0.699	rs12896504	chr14:101467948	A/G	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	-0.84	-10.98	-0.56	2.37e-23	Pelvic organ prolapse (moderate/severe);
CESC	cis	rs2735413	0.846	rs12923626	chr16:78080139	A/C	cg04733911	chr16:78082701	NA	-0.53	-9.01	-0.48	4.13e-17	Systolic blood pressure (alcohol consumption interaction);
CESC	cis	rs9649213	0.593	rs6969234	chr7:97987986	T/C	cg24562669	chr7:97807699	LMTK2	0.51	7.63	0.42	4.29e-13	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs6693567	0.526	rs834239	chr1:150375458	C/A	cg09579323	chr1:150459698	TARS2	0.48	6.01	0.35	6.23e-9	Migraine;
CESC	cis	rs4253772	0.637	rs9627295	chr22:46650100	C/T	cg24881330	chr22:46731750	TRMU	0.89	10.09	0.53	1.86e-20	LDL cholesterol;Cholesterol, total;
CESC	cis	rs728616	0.614	rs56147535	chr10:82027625	G/T	cg27171509	chr10:82033454	MAT1A	-0.41	-5.05	-0.3	8.39e-7	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs10779751	0.881	rs2744815	chr1:11360957	C/T	cg08854313	chr1:11322531	MTOR	0.79	11.54	0.58	3.16e-25	Body mass index;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	ch.8.1993893R	chr8:98864783	LAPTM4B	-0.55	-6.33	-0.36	1.02e-9	Gut microbiome composition (summer);
CESC	cis	rs7259376	0.837	rs1368476	chr19:22586192	A/G	cg02657401	chr19:22469223	NA	0.26	5.12	0.3	5.76e-7	Menopause (age at onset);
CESC	cis	rs2243480	1.000	rs34703416	chr7:65300642	A/G	cg13147721	chr7:65941812	NA	-0.87	-8.59	-0.47	7.36e-16	Diabetic kidney disease;
CESC	cis	rs6598163	0.517	rs10902453	chr12:132297091	G/T	cg22244940	chr12:132335942	MMP17	-0.52	-7.06	-0.4	1.43e-11	Migraine;
CESC	cis	rs9611565	0.512	rs5751148	chr22:42139078	A/G	cg06481639	chr22:41940642	POLR3H	0.59	5.84	0.34	1.51e-8	Vitiligo;
CESC	cis	rs425277	0.628	rs10797427	chr1:2060732	C/T	cg16545954	chr1:2118288	C1orf86	-0.34	-6.64	-0.38	1.73e-10	Height;
CESC	cis	rs344364	0.511	rs1742473	chr16:1953095	T/C	cg03013636	chr16:1946785	NA	0.47	6.37	0.36	8.23e-10	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs698833	0.501	rs35347977	chr2:44506921	C/T	cg04920474	chr2:44395004	PPM1B	0.48	6.88	0.39	4.37e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg02475777	chr4:1388615	CRIPAK	0.73	9.28	0.5	6.07e-18	Longevity;
CESC	cis	rs7552404	1.000	rs7533888	chr1:76160449	A/C	cg10523679	chr1:76189770	ACADM	0.72	8.33	0.46	4.31e-15	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs13385	0.769	rs13175751	chr5:139601097	C/G	cg26211634	chr5:139558579	C5orf32	0.46	5.12	0.3	5.97e-7	Atrial fibrillation;
CESC	cis	rs3754214	0.857	rs9126	chr1:150259400	A/C	cg09579323	chr1:150459698	TARS2	-0.44	-5.56	-0.32	6.43e-8	Cerebrospinal fluid biomarker levels;
CESC	cis	rs4319547	0.656	rs6488951	chr12:122873928	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.54	-6.17	-0.35	2.48e-9	Body mass index;
CESC	cis	rs10870270	0.784	rs10430614	chr10:133748640	C/T	cg08754478	chr10:133766260	PPP2R2D	0.5	6.55	0.37	3.01e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs1975974	1.000	rs4889703	chr17:21721663	T/C	cg18423549	chr17:21743878	NA	-0.51	-7.02	-0.4	1.81e-11	Psoriasis;
CESC	cis	rs2243480	1.000	rs34560516	chr7:65404092	A/T	cg25894440	chr7:65020034	NA	-0.62	-5.16	-0.3	4.73e-7	Diabetic kidney disease;
CESC	cis	rs875971	0.545	rs11767262	chr7:65767224	T/A	cg25405998	chr7:65216604	CCT6P1	0.45	5.35	0.31	1.86e-7	Aortic root size;
CESC	cis	rs9467711	0.606	rs9379899	chr6:26603015	T/A	cg12826209	chr6:26865740	GUSBL1	0.66	5.86	0.34	1.4e-8	Autism spectrum disorder or schizophrenia;
CESC	cis	rs72627123	0.867	rs78496651	chr14:74480070	C/A	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.81	5.36	0.31	1.78e-7	Morning vs. evening chronotype;
CESC	trans	rs4942242	0.663	rs9590779	chr13:44234886	A/G	cg19169023	chr15:41853346	TYRO3	0.66	8.48	0.46	1.57e-15	Response to tocilizumab in rheumatoid arthritis;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg22683624	chr12:133352552	GOLGA3	0.52	6.78	0.38	7.58e-11	Fibrinogen levels;
CESC	cis	rs765787	0.530	rs12323957	chr15:45490773	C/T	cg24006582	chr15:45444508	DUOX1	0.57	6.78	0.38	7.92e-11	Uric acid levels;
CESC	cis	rs763014	1.000	rs7205409	chr16:642610	A/G	cg07343612	chr16:622815	PIGQ	-0.52	-7.52	-0.42	8.53e-13	Height;
CESC	cis	rs8060686	0.641	rs12598274	chr16:68084099	G/A	cg26727032	chr16:67993705	SLC12A4	-0.54	-6.16	-0.35	2.65e-9	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs4919087	0.715	rs2484881	chr10:98998266	C/T	cg25902810	chr10:99078978	FRAT1	-0.46	-5.2	-0.3	4.03e-7	Monocyte count;
CESC	cis	rs10751667	0.666	rs7394427	chr11:970405	G/A	cg20946044	chr11:1010712	AP2A2	-0.39	-5.4	-0.31	1.49e-7	Alzheimer's disease (late onset);
CESC	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg05313129	chr8:58192883	C8orf71	-0.48	-5.27	-0.31	2.89e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs7726839	0.507	rs72703100	chr5:614291	C/T	cg16447950	chr5:562315	NA	-0.58	-5.93	-0.34	9.42e-9	Obesity-related traits;
CESC	cis	rs11098499	0.955	rs11931312	chr4:120159023	T/C	cg24375607	chr4:120327624	NA	0.43	5.21	0.31	3.71e-7	Corneal astigmatism;
CESC	cis	rs875971	0.862	rs9791713	chr7:66105198	C/A	cg11764359	chr7:65958608	NA	-0.74	-10.23	-0.53	6.36e-21	Aortic root size;
CESC	cis	rs1707322	0.717	rs28752166	chr1:46213309	G/A	cg06784218	chr1:46089804	CCDC17	0.41	7.21	0.41	5.75e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs864537	1.000	rs864537	chr1:167411384	A/G	cg09179987	chr1:167433047	CD247	0.36	5.43	0.32	1.26e-7	Celiac disease or Rheumatoid arthritis;Celiac disease;
CESC	cis	rs921968	0.565	rs586194	chr2:219610433	A/G	cg02176678	chr2:219576539	TTLL4	-0.42	-7.44	-0.42	1.43e-12	Mean corpuscular hemoglobin concentration;
CESC	cis	rs11166629	1.000	rs6981735	chr8:135635730	T/C	cg27224718	chr8:135614730	ZFAT	0.55	6.8	0.39	6.9e-11	Smoking quantity;
CESC	cis	rs225245	0.782	rs321617	chr17:33915246	A/G	cg05299278	chr17:33885742	SLFN14	0.37	5.39	0.31	1.6e-7	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
CESC	cis	rs2836950	0.545	rs2836940	chr21:40588696	T/C	cg11644478	chr21:40555479	PSMG1	-0.51	-6.94	-0.39	3.03e-11	Menarche (age at onset);
CESC	cis	rs5769707	0.656	rs135875	chr22:50012419	T/G	cg20744362	chr22:50050164	C22orf34	0.35	5.12	0.3	5.92e-7	Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs514406	0.679	rs11585495	chr1:53244331	T/C	cg16325326	chr1:53192061	ZYG11B	-0.53	-7.96	-0.44	5.13e-14	Monocyte count;
CESC	cis	rs1371867	0.846	rs1660312	chr8:101330634	C/G	cg11906718	chr8:101322791	RNF19A	0.53	6.76	0.38	8.54e-11	Atrioventricular conduction;
CESC	cis	rs77216612	0.840	rs11055030	chr12:12878349	G/C	cg24098013	chr12:12878779	APOLD1	0.56	6.86	0.39	4.78e-11	Lymphocyte counts;
CESC	cis	rs708547	0.647	rs1403233	chr4:57885053	C/T	cg25525207	chr4:57843836	C4orf14;POLR2B	0.43	5.56	0.32	6.56e-8	Response to bleomycin (chromatid breaks);
CESC	cis	rs4237845	0.788	rs6581157	chr12:58288793	C/T	cg00677455	chr12:58241039	CTDSP2	0.63	7.68	0.43	3.1400000000000003e-13	Intelligence (multi-trait analysis);
CESC	cis	rs17711722	0.510	rs11767457	chr7:65290615	C/T	cg14393609	chr7:65229607	NA	0.47	6.21	0.36	2e-9	Calcium levels;
CESC	cis	rs875971	0.862	rs801209	chr7:66019390	G/T	cg11764359	chr7:65958608	NA	-0.78	-11.22	-0.57	3.73e-24	Aortic root size;
CESC	cis	rs362272	0.545	rs2749782	chr4:3339761	A/G	cg14583973	chr4:3374767	RGS12	0.34	5.92	0.34	1.01e-8	Serum sulfate level;
CESC	trans	rs11722228	0.522	rs12503195	chr4:10082772	T/C	cg26043149	chr18:55253948	FECH	0.51	6.72	0.38	1.13e-10	Gout;Urate levels;Serum uric acid levels;
CESC	cis	rs854765	0.565	rs4072738	chr17:17884547	A/C	cg16928487	chr17:17741425	SREBF1	-0.48	-8.15	-0.45	1.43e-14	Total body bone mineral density;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg21490161	chr5:180647246	NA	0.48	6.46	0.37	5.01e-10	Fibrinogen levels;
CESC	cis	rs6867032	1.000	rs2129471	chr5:2016236	C/G	cg26168224	chr5:2018326	NA	0.96	19.64	0.77	1.3e-53	Gut microbiome composition (winter);
CESC	cis	rs2075371	1.000	rs2075371	chr7:133984127	A/G	cg11752832	chr7:134001865	SLC35B4	0.54	6.93	0.39	3.22e-11	Mean platelet volume;
CESC	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-6.21	-0.36	2.01e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs11098499	0.865	rs9994730	chr4:120381564	A/C	cg24375607	chr4:120327624	NA	0.45	5.51	0.32	8.64e-8	Corneal astigmatism;
CESC	cis	rs7296418	0.663	rs4553407	chr12:123750748	G/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.32	-5.12	-0.3	6.01e-7	Platelet count;
CESC	cis	rs12477438	0.520	rs13018891	chr2:99755099	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	15.46	0.69	7.45e-39	Chronic sinus infection;
CESC	cis	rs6502050	0.835	rs6502068	chr17:80112223	C/T	cg23985595	chr17:80112537	CCDC57	-0.42	-6.65	-0.38	1.62e-10	Life satisfaction;
CESC	cis	rs875971	0.862	rs10950043	chr7:65988610	T/C	cg12463550	chr7:65579703	CRCP	0.51	6.36	0.36	8.66e-10	Aortic root size;
CESC	cis	rs4836694	0.574	rs67899211	chr9:132935614	G/A	cg13414629	chr9:132935646	FREQ	0.43	5.37	0.31	1.75e-7	Alzheimer's disease (cognitive decline);
CESC	cis	rs1218582	0.772	rs906593	chr1:154885255	G/A	cg16680214	chr1:154839983	KCNN3	-0.44	-6.79	-0.38	7.4e-11	Prostate cancer;
CESC	cis	rs6430585	0.527	rs2278731	chr2:136396300	T/C	cg07169764	chr2:136633963	MCM6	1.03	11.87	0.59	2.4e-26	Corneal structure;
CESC	cis	rs2243480	1.000	rs13235972	chr7:65883605	C/T	cg12463550	chr7:65579703	CRCP	0.71	5.49	0.32	9.37e-8	Diabetic kidney disease;
CESC	trans	rs8026198	0.568	rs1678984	chr15:42616332	T/G	cg13954090	chr10:73533106	CDH23;C10orf54	-0.69	-6.02	-0.35	5.7e-9	Fibrinogen levels;
CESC	cis	rs1055129	0.681	rs7221792	chr17:73834690	T/G	cg02397686	chr17:73851076	WBP2	0.35	5.12	0.3	5.79e-7	White matter hyperintensity burden;
CESC	cis	rs1797081	0.646	rs7090256	chr10:16851949	T/G	cg23933602	chr10:16859644	RSU1	0.87	12.75	0.62	2.26e-29	Platelet distribution width;
CESC	cis	rs875971	1.000	rs778694	chr7:65871558	A/G	cg10691866	chr7:65817282	TPST1	-0.34	-5.51	-0.32	8.3e-8	Aortic root size;
CESC	cis	rs10540	1.000	rs61876336	chr11:489537	C/T	cg21784768	chr11:537496	LRRC56	-0.57	-5.38	-0.31	1.65e-7	Body mass index;
CESC	cis	rs4253772	0.550	rs55926596	chr22:46682955	C/T	cg00784671	chr22:46762841	CELSR1	-0.61	-5.98	-0.34	7.22e-9	LDL cholesterol;Cholesterol, total;
CESC	cis	rs10911232	0.507	rs10797821	chr1:183012559	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.87	13.67	0.64	1.52e-32	Hypertriglyceridemia;
CESC	cis	rs7020830	0.931	rs6476613	chr9:37084340	A/G	cg14294708	chr9:37120828	ZCCHC7	1.22	23.54	0.82	6.97e-67	Schizophrenia;
CESC	trans	rs10506458	0.915	rs998505	chr12:63400018	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.34	-18.35	-0.75	4.19e-49	Hemostatic factors and hematological phenotypes;
CESC	cis	rs780096	0.546	rs1528533	chr2:27595756	G/C	cg21248554	chr2:27665150	KRTCAP3	-0.34	-7.22	-0.41	5.5e-12	Total body bone mineral density;
CESC	cis	rs736408	0.812	rs9324	chr3:52825585	T/C	cg18404041	chr3:52824283	ITIH1	-0.49	-8.13	-0.45	1.61e-14	Bipolar disorder;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg25341937	chr6:17706893	NUP153	-0.46	-6.44	-0.37	5.63e-10	Fibrinogen levels;
CESC	cis	rs9322193	0.923	rs10747276	chr6:150079875	G/A	cg07701084	chr6:150067640	NUP43	0.47	6.73	0.38	1.06e-10	Lung cancer;
CESC	cis	rs1707322	0.752	rs11211147	chr1:46110094	A/G	cg03146154	chr1:46216737	IPP	0.82	11.48	0.58	5.01e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2439831	0.850	rs11070408	chr15:44034788	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.7	7.97	0.44	4.82e-14	Lung cancer in ever smokers;
CESC	trans	rs17181170	0.574	rs56378315	chr3:87206488	G/C	ch.2.199792288R	chr2:200084043	NA	-0.46	-6.1	-0.35	3.78e-9	Prostate cancer;
CESC	cis	rs748404	0.690	rs2924369	chr15:43777985	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	-0.5	-7.74	-0.43	2.06e-13	Lung cancer;
CESC	cis	rs4722166	0.532	rs4719711	chr7:22755688	A/G	cg05472934	chr7:22766657	IL6	-0.52	-6.86	-0.39	4.96e-11	Lung cancer;
CESC	trans	rs9870718	0.541	rs35613967	chr3:36245304	T/C	cg17530152	chr10:90692333	NA	0.56	6.1	0.35	3.83e-9	Asthma;
CESC	trans	rs6456042	0.893	rs3127440	chr6:166558950	C/T	cg01261503	chr17:62493599	POLG2	-0.44	-6.36	-0.36	8.89e-10	Asthma;
CESC	cis	rs2760061	0.819	rs708112	chr1:228192452	G/A	cg02753203	chr1:228287806	NA	0.52	7.7	0.43	2.71e-13	Diastolic blood pressure;
CESC	cis	rs7560272	0.538	rs2001436	chr2:73928965	A/T	cg20560298	chr2:73613845	ALMS1	0.46	6.35	0.36	9.43e-10	Schizophrenia;
CESC	cis	rs6952407	1	rs6952407	chr7:66045512	A/G	cg06456125	chr7:65229604	NA	-0.43	-5.44	-0.32	1.21e-7	Cotinine glucuronidation;
CESC	cis	rs9322193	0.847	rs12210605	chr6:150138403	A/G	cg07701084	chr6:150067640	NUP43	0.43	5.71	0.33	3.1e-8	Lung cancer;
CESC	cis	rs17095355	0.901	rs6584964	chr10:111759160	G/C	cg00817464	chr10:111662876	XPNPEP1	-0.48	-5.6	-0.33	5.27e-8	Biliary atresia;
CESC	cis	rs2404602	0.716	rs67888330	chr15:76752483	A/G	cg22467129	chr15:76604101	ETFA	-0.38	-5.81	-0.34	1.81e-8	Blood metabolite levels;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03084103	chr4:38869707	MIR574;FAM114A1	-0.41	-6.02	-0.35	5.79e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs2180341	0.782	rs6912196	chr6:127722732	C/G	cg24812749	chr6:127587940	RNF146	0.83	11.9	0.59	1.86e-26	Breast cancer;
CESC	cis	rs9309473	1.000	rs6755241	chr2:73641364	C/T	cg20560298	chr2:73613845	ALMS1	-0.53	-7.01	-0.4	2.03e-11	Metabolite levels;
CESC	cis	rs9325144	0.555	rs1813392	chr12:38692203	C/T	cg26384229	chr12:38710491	ALG10B	-0.58	-8.31	-0.45	5.07e-15	Morning vs. evening chronotype;
CESC	cis	rs3733585	0.624	rs76574510	chr4:9953252	T/A	cg00071950	chr4:10020882	SLC2A9	-0.69	-11.34	-0.57	1.42e-24	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs7107174	1.000	rs7939352	chr11:78003151	G/A	cg27205649	chr11:78285834	NARS2	-0.4	-5.04	-0.3	8.5e-7	Testicular germ cell tumor;
CESC	cis	rs9911578	1.000	rs7215808	chr17:56940742	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.38	5.07	0.3	7.54e-7	Intelligence (multi-trait analysis);
CESC	cis	rs116095464	0.558	rs3213838	chr5:223890	G/C	cg22496380	chr5:211416	CCDC127	-0.74	-8.72	-0.47	3.15e-16	Breast cancer;
CESC	cis	rs3092073	0.624	rs34293711	chr20:44587186	C/T	cg00125455	chr20:44574271	PCIF1	0.35	5.8	0.34	1.84e-8	Intelligence (multi-trait analysis);
CESC	trans	rs17764205	0.777	rs17696630	chr19:3261995	A/G	cg03776506	chr16:30581384	ZNF688	0.8	6.45	0.37	5.25e-10	Bipolar disorder and schizophrenia;
CESC	cis	rs6740322	0.748	rs6544634	chr2:43471528	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.77	-8.83	-0.48	1.49e-16	Coronary artery disease;
CESC	cis	rs2228479	0.867	rs34272502	chr16:89949000	G/C	cg04013166	chr16:89971882	TCF25	0.77	7.14	0.4	8.86e-12	Skin colour saturation;
CESC	cis	rs9300255	0.782	rs12809602	chr12:123768916	T/G	cg19016782	chr12:123741754	C12orf65	0.43	5.31	0.31	2.34e-7	Neutrophil percentage of white cells;
CESC	cis	rs2425143	1.000	rs17093026	chr20:34318911	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	-0.61	-5.37	-0.31	1.77e-7	Blood protein levels;
CESC	cis	rs8031584	1.000	rs35607976	chr15:31277788	T/C	cg08109568	chr15:31115862	NA	-0.75	-9.43	-0.5	2.12e-18	Huntington's disease progression;
CESC	cis	rs7618915	0.501	rs12486554	chr3:52742537	A/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.38	6.71	0.38	1.15e-10	Bipolar disorder;
CESC	cis	rs7084402	0.967	rs1582827	chr10:60297102	T/C	cg07615347	chr10:60278583	BICC1	0.6	9.42	0.5	2.35e-18	Refractive error;
CESC	cis	rs7772486	0.790	rs6570724	chr6:146151283	T/C	cg05347473	chr6:146136440	FBXO30	0.55	7.26	0.41	4.4e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.65	7.41	0.41	1.72e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs875971	0.862	rs10224872	chr7:65759773	T/A	cg10691866	chr7:65817282	TPST1	0.31	5.32	0.31	2.25e-7	Aortic root size;
CESC	cis	rs4580814	0.869	rs4535497	chr5:1107428	G/T	cg18655438	chr5:1077845	SLC12A7	0.37	5.38	0.31	1.66e-7	Mean corpuscular hemoglobin concentration;
CESC	cis	rs7208859	0.623	rs56325146	chr17:29151024	T/C	cg19761014	chr17:28927070	LRRC37B2	0.72	6.08	0.35	4.21e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs2228479	0.850	rs17226980	chr16:89825065	G/A	cg06558623	chr16:89946397	TCF25	1.17	9.38	0.5	3.19e-18	Skin colour saturation;
CESC	cis	rs7408868	0.764	rs45504393	chr19:15277010	A/G	cg14696996	chr19:15285081	NOTCH3	1.11	11.51	0.58	3.92e-25	Pulse pressure;
CESC	cis	rs7044106	0.791	rs10985001	chr9:123484232	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.81	13.03	0.63	2.43e-30	Hip circumference adjusted for BMI;
CESC	cis	rs2576037	0.526	rs3892820	chr18:44479558	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.7	10.7	0.55	1.95e-22	Personality dimensions;
CESC	cis	rs4253772	0.575	rs74879643	chr22:46660014	T/C	cg18190219	chr22:46762943	CELSR1	-0.56	-5.43	-0.32	1.29e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs4423214	1.000	rs12278461	chr11:71182185	C/T	cg05163923	chr11:71159392	DHCR7	0.82	10.82	0.55	7.9399999999999994e-23	Vitamin D levels;
CESC	cis	rs10129255	0.500	rs7157975	chr14:107212287	G/A	cg07958169	chr14:107095056	NA	-0.54	-8.28	-0.45	6.02e-15	Kawasaki disease;
CESC	cis	rs6570726	0.967	rs9497316	chr6:145792387	G/T	cg05347473	chr6:146136440	FBXO30	-0.4	-5.48	-0.32	9.96e-8	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs875971	0.516	rs6945322	chr7:65336056	T/C	cg14393609	chr7:65229607	NA	0.52	7.08	0.4	1.3e-11	Aortic root size;
CESC	cis	rs3793683	0.928	rs10781585	chr10:134553369	C/A	cg27286337	chr10:134555280	INPP5A	-0.92	-15.17	-0.68	7.5e-38	Migraine;
CESC	cis	rs7618915	0.571	rs12632381	chr3:52607685	G/A	cg18099408	chr3:52552593	STAB1	-0.33	-5.45	-0.32	1.17e-7	Bipolar disorder;
CESC	cis	rs514406	0.830	rs533935	chr1:53308807	T/C	cg25767906	chr1:53392781	SCP2	-0.45	-5.84	-0.34	1.49e-8	Monocyte count;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg09429435	chr19:12914994	NA	0.46	6.0	0.35	6.47e-9	Fibrinogen levels;
CESC	cis	rs9916302	0.861	rs3889368	chr17:37683231	C/T	cg15445000	chr17:37608096	MED1	0.4	6.56	0.37	2.79e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs2594989	0.943	rs77630528	chr3:11314041	A/G	cg00170343	chr3:11313890	ATG7	0.58	5.13	0.3	5.47e-7	Circulating chemerin levels;
CESC	cis	rs6674970	0.541	rs2902811	chr1:151010521	G/C	cg03258749	chr1:151040405	MLLT11	-0.41	-5.45	-0.32	1.13e-7	Childhood ear infection;
CESC	cis	rs9815354	0.812	rs73081372	chr3:41917993	C/T	cg03022575	chr3:42003672	ULK4	0.66	5.78	0.33	2.09e-8	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs875971	0.638	rs801216	chr7:66011667	T/C	cg11764359	chr7:65958608	NA	-0.72	-9.68	-0.51	3.48e-19	Aortic root size;
CESC	cis	rs2933343	0.700	rs789239	chr3:128633808	T/C	cg25356066	chr3:128598488	ACAD9	0.58	7.95	0.44	5.32e-14	IgG glycosylation;
CESC	cis	rs12887734	0.546	rs12886637	chr14:104222892	A/G	cg08213375	chr14:104286397	PPP1R13B	-0.41	-6.87	-0.39	4.65e-11	Schizophrenia;Autism spectrum disorder or schizophrenia;
CESC	cis	rs7077164	1.000	rs1227776	chr10:71580893	G/A	cg07630274	chr10:71583235	COL13A1	-0.39	-7.65	-0.43	3.62e-13	Non-alcoholic fatty liver disease histology (lobular);
CESC	cis	rs2274273	0.588	rs9919923	chr14:55813899	A/G	cg04306507	chr14:55594613	LGALS3	0.29	5.13	0.3	5.66e-7	Protein biomarker;
CESC	cis	rs2439831	0.850	rs544122	chr15:43775732	A/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.81	10.65	0.55	2.78e-22	Lung cancer in ever smokers;
CESC	cis	rs2120019	0.608	rs8042558	chr15:75320433	G/T	cg17294928	chr15:75287854	SCAMP5	-0.73	-9.09	-0.49	2.31e-17	Blood trace element (Zn levels);
CESC	cis	rs561341	1.000	rs72823787	chr17:30283809	A/T	cg19193384	chr17:30244184	NA	-0.71	-6.63	-0.38	1.92e-10	Hip circumference adjusted for BMI;
CESC	cis	rs4819052	1.000	rs4818769	chr21:46667451	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.89	11.73	0.58	7.11e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs9467711	0.659	rs13216828	chr6:26373507	G/A	cg14345882	chr6:26364793	BTN3A2	0.61	6.45	0.37	5.32e-10	Autism spectrum disorder or schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07181902	chr2:85829892	TMEM150A	0.71	7.72	0.43	2.35e-13	Gut microbiome composition (summer);
CESC	cis	rs9457247	0.730	rs9459841	chr6:167431949	G/A	cg23791538	chr6:167370224	RNASET2	-0.52	-7.15	-0.4	8.6e-12	Crohn's disease;
CESC	cis	rs1018836	1.000	rs1018836	chr8:91570362	A/G	cg16814680	chr8:91681699	NA	-0.6	-8.39	-0.46	2.97e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs12900413	0.562	rs11631438	chr15:90300620	C/T	cg24249390	chr15:90295951	MESP1	-0.41	-5.46	-0.32	1.12e-7	Coronary artery aneurysm in Kawasaki disease;
CESC	cis	rs909674	0.514	rs7423	chr22:39781429	C/T	cg01416388	chr22:39784598	NA	-0.49	-6.5	-0.37	3.93e-10	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs10504229	0.683	rs73603874	chr8:58108340	G/A	cg22535103	chr8:58192502	C8orf71	-0.77	-8.76	-0.47	2.37e-16	Developmental language disorder (linguistic errors);
CESC	cis	rs2279817	0.818	rs34421778	chr1:17984859	C/G	cg21791023	chr1:18019539	ARHGEF10L	-0.66	-7.97	-0.44	4.73e-14	Neuroticism;
CESC	cis	rs9611565	0.729	rs202654	chr22:41841034	G/A	cg03806693	chr22:41940476	POLR3H	0.77	9.9	0.52	7.28e-20	Vitiligo;
CESC	cis	rs873946	0.586	rs57431984	chr10:134567697	C/T	cg18305652	chr10:134549665	INPP5A	0.45	6.26	0.36	1.53e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs6674176	0.597	rs9326136	chr1:44390392	A/G	cg23954153	chr1:44402353	ARTN	0.36	5.83	0.34	1.63e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs6912958	0.712	rs7755167	chr6:88338752	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-6.72	-0.38	1.09e-10	Monocyte percentage of white cells;
CESC	cis	rs8002861	0.905	rs12873099	chr13:44396247	G/A	cg19180546	chr13:44453867	C13orf31;CCDC122	-0.45	-5.58	-0.32	6.02e-8	Leprosy;
CESC	cis	rs6088580	0.634	rs6088478	chr20:32971719	T/C	cg24642439	chr20:33292090	TP53INP2	-0.52	-6.9	-0.39	3.82e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs6120849	0.901	rs6060278	chr20:33753262	T/C	cg24642439	chr20:33292090	TP53INP2	0.58	6.31	0.36	1.18e-9	Protein C levels;
CESC	cis	rs793571	0.544	rs12912699	chr15:58917021	T/C	cg05156742	chr15:59063176	FAM63B	0.79	11.47	0.58	5.31e-25	Schizophrenia;
CESC	cis	rs7224314	1.000	rs62084077	chr17:65386837	G/A	cg01507342	chr17:65387096	PITPNC1	-0.47	-5.72	-0.33	2.83e-8	Diisocyanate-induced asthma;
CESC	cis	rs9322193	0.923	rs11155683	chr6:150100477	T/C	cg04369109	chr6:150039330	LATS1	-0.39	-5.35	-0.31	1.93e-7	Lung cancer;
CESC	cis	rs7714584	0.793	rs2161363	chr5:150182079	G/C	cg22134413	chr5:150180641	NA	0.62	5.79	0.34	1.96e-8	Crohn's disease;
CESC	cis	rs1707322	0.928	rs61785614	chr1:46446047	A/G	cg05343316	chr1:45956843	TESK2	0.44	5.42	0.32	1.36e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs6811802	1	rs6811802	chr4:78932838	G/C	cg07207937	chr4:78783799	MRPL1	-0.83	-8.89	-0.48	9.66e-17	Left ventricular obstructive tract defect (inherited effect);
CESC	cis	rs6736093	0.966	rs34705448	chr2:112730089	C/T	cg12686935	chr2:112915763	FBLN7	-0.44	-5.72	-0.33	2.86e-8	Coronary artery disease;
CESC	trans	rs748404	0.631	rs6493084	chr15:43647627	A/G	cg24053811	chr14:70265306	SLC10A1	0.43	6.06	0.35	4.72e-9	Lung cancer;
CESC	trans	rs2391518	0.639	rs2969003	chr4:130781879	A/T	cg04981619	chr2:43328122	NA	0.38	6.0	0.35	6.59e-9	Body mass index;
CESC	cis	rs514406	0.505	rs6688064	chr1:53165609	C/T	cg16325326	chr1:53192061	ZYG11B	0.94	16.56	0.71	9.15e-43	Monocyte count;
CESC	cis	rs4423214	0.840	rs1790343	chr11:71177207	T/C	cg05163923	chr11:71159392	DHCR7	-0.65	-7.55	-0.42	6.91e-13	Vitamin D levels;
CESC	cis	rs6963495	1.000	rs6963495	chr7:105166853	T/C	cg13798780	chr7:105162888	PUS7	0.73	6.59	0.38	2.34e-10	Bipolar disorder (body mass index interaction);
CESC	cis	rs12142240	0.698	rs17357676	chr1:46812444	A/G	cg10495392	chr1:46806563	NSUN4	0.57	6.29	0.36	1.33e-9	Menopause (age at onset);
CESC	cis	rs1178968	1.000	rs6460041	chr7:72757671	A/G	cg25889504	chr7:72793014	NA	0.48	5.08	0.3	7.22e-7	Triglyceride levels;
CESC	cis	rs660498	0.507	rs11015783	chr10:27729745	A/G	cg25705717	chr10:27608719	NA	0.49	5.84	0.34	1.49e-8	Asthma (childhood onset);
CESC	cis	rs875971	0.505	rs1723275	chr7:65504633	G/C	cg18876405	chr7:65276391	NA	-0.66	-9.1	-0.49	2.16e-17	Aortic root size;
CESC	cis	rs9790314	1.000	rs9846756	chr3:160983809	A/C	cg04691961	chr3:161091175	C3orf57	-0.41	-5.22	-0.31	3.56e-7	Morning vs. evening chronotype;
CESC	cis	rs4253772	0.591	rs113101219	chr22:46659186	C/A	cg24881330	chr22:46731750	TRMU	0.8	6.6	0.38	2.24e-10	LDL cholesterol;Cholesterol, total;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04672650	chr10:96943563	NA	0.53	6.4	0.37	7.13e-10	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.830	rs13148324	chr4:98833616	G/A	cg05340658	chr4:99064831	C4orf37	0.72	10.37	0.54	2.25e-21	Colonoscopy-negative controls vs population controls;
CESC	cis	rs514406	0.861	rs7518390	chr1:53233374	A/G	cg08736216	chr1:53307985	ZYG11A	0.39	6.68	0.38	1.42e-10	Monocyte count;
CESC	cis	rs2549003	1.000	rs2070726	chr5:131821738	C/A	cg02551604	chr5:131831745	NA	-0.37	-5.27	-0.31	2.81e-7	Asthma (sex interaction);
CESC	cis	rs2836950	0.565	rs2150413	chr21:40614878	C/T	cg11890956	chr21:40555474	PSMG1	-0.67	-9.25	-0.49	7.56e-18	Menarche (age at onset);
CESC	cis	rs7845219	0.544	rs7015841	chr8:95920193	A/C	cg09323728	chr8:95962352	TP53INP1	-0.34	-6.59	-0.38	2.41e-10	Type 2 diabetes;
CESC	cis	rs1642645	0.757	rs6600394	chr1:42472453	T/C	cg16685388	chr1:42384056	HIVEP3	0.37	5.6	0.33	5.26e-8	Left ventricular obstructive tract defect (maternal effect);
CESC	cis	rs3105593	1.000	rs3131589	chr15:50841053	G/C	cg08437265	chr15:50716283	USP8	0.43	5.53	0.32	7.62e-8	QT interval;
CESC	cis	rs2795502	1.000	rs2744090	chr10:43339614	G/C	cg20628663	chr10:43360327	NA	-0.63	-7.47	-0.42	1.16e-12	Blood protein levels;
CESC	cis	rs10129255	0.957	rs6576228	chr14:107186640	A/G	cg07958169	chr14:107095056	NA	-0.42	-5.88	-0.34	1.26e-8	Kawasaki disease;
CESC	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg03188948	chr7:1209495	NA	0.72	6.91	0.39	3.61e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg25586305	chr2:234281690	DGKD	0.45	6.01	0.35	6.09e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs524281	0.861	rs7942894	chr11:65976525	T/C	cg14036092	chr11:66035641	RAB1B	-0.5	-5.38	-0.31	1.64e-7	Electroencephalogram traits;
CESC	cis	rs6866344	0.697	rs11748495	chr5:178130000	A/G	cg03877680	chr5:178157825	ZNF354A	-0.75	-8.59	-0.47	7.68e-16	Neutrophil percentage of white cells;
CESC	cis	rs4654899	0.865	rs7541923	chr1:21403582	G/C	cg05370193	chr1:21551575	ECE1	0.43	6.61	0.38	2.05e-10	Superior frontal gyrus grey matter volume;
CESC	cis	rs5758659	0.714	rs133376	chr22:42466905	C/T	cg19513890	chr22:42538836	CYP2D7P1	-0.38	-5.62	-0.33	4.73e-8	Cognitive function;
CESC	cis	rs4713118	0.662	rs149947	chr6:27972433	A/T	cg22143856	chr6:28129313	ZNF389	0.41	5.22	0.31	3.64e-7	Parkinson's disease;
CESC	cis	rs7666738	0.830	rs13139024	chr4:99020700	C/T	cg03467027	chr4:99064603	C4orf37	0.46	5.81	0.34	1.8e-8	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18900838	chr17:28804337	GOSR1	-0.63	-7.39	-0.41	1.92e-12	Gut microbiome composition (summer);
CESC	cis	rs9303401	0.573	rs35104446	chr17:57180234	A/C	cg12560992	chr17:57184187	TRIM37	0.51	5.28	0.31	2.68e-7	Cognitive test performance;
CESC	cis	rs9457247	0.663	rs12526548	chr6:167431147	C/T	cg07741184	chr6:167504864	NA	0.34	6.12	0.35	3.27e-9	Crohn's disease;
CESC	cis	rs11122272	0.701	rs971533	chr1:231522097	T/C	cg06096015	chr1:231504339	EGLN1	0.43	6.18	0.35	2.46e-9	Hemoglobin concentration;
CESC	cis	rs769267	0.859	rs2916076	chr19:19545990	T/C	cg03709012	chr19:19516395	GATAD2A	1.01	16.05	0.7	5.61e-41	Tonsillectomy;
CESC	cis	rs8062405	1.000	rs62037369	chr16:28883841	C/T	cg08761264	chr16:28874980	SH2B1	-0.45	-5.49	-0.32	9.61e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs67311347	1.000	rs66841330	chr3:40531123	G/A	cg09455208	chr3:40491958	NA	0.46	7.34	0.41	2.69e-12	Renal cell carcinoma;
CESC	cis	rs9894429	0.646	rs7406522	chr17:79615396	G/T	cg13777783	chr17:79615861	NA	-0.34	-5.75	-0.33	2.49e-8	Eye color traits;
CESC	cis	rs9733	0.519	rs11807450	chr1:150677719	C/T	cg09365446	chr1:150670422	GOLPH3L	0.39	5.35	0.31	1.92e-7	Tonsillectomy;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg09068198	chr2:65357064	RAB1A	0.48	6.19	0.36	2.25e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs35306767	0.855	rs12771179	chr10:872347	A/G	cg20503657	chr10:835505	NA	1.09	10.01	0.52	3.32e-20	Eosinophil percentage of granulocytes;
CESC	cis	rs1670533	0.818	rs643484	chr4:1085826	A/G	cg27284194	chr4:1044797	NA	0.48	6.17	0.35	2.6e-9	Recombination rate (females);
CESC	cis	rs13191362	1.000	rs34344906	chr6:162993378	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.86	8.98	0.48	5.03e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs56104184	0.775	rs56317021	chr19:49395960	C/T	cg21252483	chr19:49399788	TULP2	-0.53	-5.72	-0.33	2.94e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	cis	rs8072100	0.817	rs9892497	chr17:45545919	G/A	cg25173405	chr17:45401733	C17orf57	-0.47	-6.16	-0.35	2.68e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs7412746	0.611	rs752376	chr1:150941381	C/T	cg17724175	chr1:150552817	MCL1	0.33	5.18	0.3	4.49e-7	Melanoma;
CESC	cis	rs7914558	0.966	rs10786725	chr10:104682357	T/C	cg04362960	chr10:104952993	NT5C2	0.43	5.54	0.32	7.17e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs875971	0.862	rs12698526	chr7:65969105	T/C	cg10691866	chr7:65817282	TPST1	-0.33	-5.42	-0.32	1.34e-7	Aortic root size;
CESC	cis	rs780096	0.526	rs1406295	chr2:27689700	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.29	-5.79	-0.34	2e-8	Total body bone mineral density;
CESC	cis	rs736408	0.609	rs13082208	chr3:52781539	T/G	cg18404041	chr3:52824283	ITIH1	-0.42	-7.13	-0.4	9.59e-12	Bipolar disorder;
CESC	cis	rs4689388	0.853	rs11729672	chr4:6293838	A/G	cg25554036	chr4:6271136	WFS1	0.51	8.37	0.46	3.31e-15	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs62103177	0.810	rs62103195	chr18:77629693	T/C	cg12964065	chr18:77638022	KCNG2	0.59	5.51	0.32	8.57e-8	Opioid sensitivity;
CESC	cis	rs780096	0.546	rs4425043	chr2:27733452	G/A	cg22903471	chr2:27725779	GCKR	-0.56	-7.62	-0.42	4.62e-13	Total body bone mineral density;
CESC	cis	rs3091242	0.933	rs35403885	chr1:25784551	G/A	cg12412775	chr1:25698385	RHCE	0.28	5.12	0.3	5.94e-7	Erythrocyte sedimentation rate;
CESC	cis	rs9326248	0.817	rs1242127	chr11:117076564	A/G	cg11861562	chr11:117069780	TAGLN	-0.31	-5.38	-0.31	1.64e-7	Blood protein levels;
CESC	cis	rs6598955	0.543	rs3795689	chr1:26560366	C/G	cg04990556	chr1:26633338	UBXN11	0.84	9.59	0.51	6.82e-19	Obesity-related traits;
CESC	cis	rs10097731	1.000	rs10097731	chr8:82027672	G/T	cg25230327	chr8:82042993	NA	-0.61	-6.99	-0.39	2.27e-11	Serum total protein level;
CESC	cis	rs12410462	0.681	rs4614224	chr1:227574966	C/T	cg04117972	chr1:227635322	NA	0.75	6.22	0.36	1.93e-9	Major depressive disorder;
CESC	cis	rs28498503	0.867	rs28536126	chr18:76649586	G/A	cg00806245	chr18:76673096	NA	-0.52	-5.31	-0.31	2.29e-7	Attention function in attention deficit hyperactive disorder;
CESC	cis	rs1891275	0.513	rs1539041	chr10:93577141	T/G	cg12805727	chr10:93557676	TNKS2	0.49	5.68	0.33	3.58e-8	Intelligence (multi-trait analysis);
CESC	cis	rs7671266	0.668	rs6834055	chr4:10158511	A/T	cg00071950	chr4:10020882	SLC2A9	-0.55	-5.97	-0.34	7.54e-9	Cardiovascular disease risk factors;
CESC	trans	rs11098499	0.629	rs28369518	chr4:120271630	T/C	cg25214090	chr10:38739885	LOC399744	0.6	8.3	0.45	5.33e-15	Corneal astigmatism;
CESC	cis	rs6840258	1.000	rs56390363	chr4:87943087	G/A	cg08197287	chr4:87952173	AFF1	-0.41	-5.47	-0.32	1.02e-7	Mean corpuscular volume;Basophil percentage of granulocytes;
CESC	cis	rs7107174	1.000	rs2510040	chr11:77944548	T/A	cg02023728	chr11:77925099	USP35	0.53	7.08	0.4	1.26e-11	Testicular germ cell tumor;
CESC	cis	rs116095464	0.558	rs56081398	chr5:247318	C/T	cg22857025	chr5:266934	NA	-1.29	-14.08	-0.65	5.3e-34	Breast cancer;
CESC	cis	rs7520050	0.553	rs2993263	chr1:46021630	A/G	cg03146154	chr1:46216737	IPP	0.48	6.32	0.36	1.12e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs875971	0.862	rs1695820	chr7:65844563	G/A	cg11764359	chr7:65958608	NA	0.81	11.89	0.59	2.11e-26	Aortic root size;
CESC	cis	rs7647973	1.000	rs2312462	chr3:49601255	A/G	cg07636037	chr3:49044803	WDR6	0.61	8.73	0.47	2.98e-16	Menarche (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21528136	chr17:73901016	MRPL38	0.56	6.43	0.37	5.93e-10	Gut microbiome composition (summer);
CESC	cis	rs7089973	0.604	rs2420069	chr10:116605103	A/G	cg03647239	chr10:116582469	FAM160B1	0.43	5.35	0.31	1.94e-7	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs963731	0.579	rs1454226	chr2:39246862	A/G	cg04010122	chr2:39346883	SOS1	-0.72	-5.37	-0.31	1.7e-7	Corticobasal degeneration;
CESC	trans	rs3780486	0.522	rs10217770	chr9:33146393	C/A	cg20290983	chr6:43655470	MRPS18A	0.73	11.18	0.57	4.97e-24	IgG glycosylation;
CESC	cis	rs769267	0.965	rs13964	chr19:19468710	C/G	cg03709012	chr19:19516395	GATAD2A	-0.98	-14.29	-0.66	1.02e-34	Tonsillectomy;
CESC	cis	rs6963495	0.818	rs818619	chr7:105172505	A/T	cg19920283	chr7:105172520	RINT1	0.72	8.05	0.44	2.75e-14	Bipolar disorder (body mass index interaction);
CESC	cis	rs896854	0.738	rs481887	chr8:95967838	A/G	cg13393036	chr8:95962371	TP53INP1	0.47	9.03	0.49	3.59e-17	Type 2 diabetes;
CESC	cis	rs826838	1.000	rs6582619	chr12:38729904	A/G	cg13010199	chr12:38710504	ALG10B	0.62	8.73	0.47	2.87e-16	Heart rate;
CESC	cis	rs4689388	0.889	rs4629534	chr4:6294124	G/T	cg00701064	chr4:6280414	WFS1	0.69	11.74	0.58	6.7e-26	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00139389	chr7:150741207	ABCB8	-0.58	-6.1	-0.35	3.64e-9	Gut microbiome composition (summer);
CESC	cis	rs898097	0.578	rs9906163	chr17:80908174	T/C	cg19046167	chr17:80928561	B3GNTL1	0.41	5.48	0.32	9.72e-8	Breast cancer;
CESC	cis	rs561341	1.000	rs15654	chr17:30326360	A/C	cg23018236	chr17:30244563	NA	-0.52	-5.11	-0.3	6.12e-7	Hip circumference adjusted for BMI;
CESC	cis	rs6089584	0.853	rs1740367	chr20:60574834	C/T	cg13770153	chr20:60521292	NA	-0.5	-6.17	-0.35	2.54e-9	Body mass index;
CESC	cis	rs801193	0.613	rs2659900	chr7:66184443	G/C	cg10691866	chr7:65817282	TPST1	-0.35	-5.95	-0.34	8.45e-9	Aortic root size;
CESC	cis	rs992157	0.717	rs3817266	chr2:219142594	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.67	-8.69	-0.47	3.72e-16	Colorectal cancer;
CESC	cis	rs7666738	0.830	rs17027102	chr4:98919221	A/G	cg03467027	chr4:99064603	C4orf37	-0.41	-5.13	-0.3	5.52e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs919433	0.889	rs12693816	chr2:198208420	T/A	cg20885578	chr2:198174922	NA	-0.38	-5.06	-0.3	7.87e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs9486719	0.656	rs4839826	chr6:96853616	A/G	cg18709589	chr6:96969512	KIAA0776	-0.44	-5.25	-0.31	3.09e-7	Migraine;Coronary artery disease;
CESC	cis	rs2576037	0.583	rs2156049	chr18:44455717	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.52	-7.14	-0.4	8.75e-12	Personality dimensions;
CESC	cis	rs798554	0.797	rs798493	chr7:2798731	A/G	cg09658497	chr7:2847517	GNA12	-0.42	-5.85	-0.34	1.44e-8	Height;
CESC	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg06873352	chr17:61820015	STRADA	0.72	12.93	0.62	5.79e-30	Prudent dietary pattern;
CESC	cis	rs66569888	0.754	rs6719028	chr2:106895212	T/C	cg15412446	chr2:106886593	NA	0.68	8.02	0.44	3.34e-14	Facial morphology (factor 23);
CESC	cis	rs75887402	1.000	rs10519724	chr5:122712563	G/A	cg27033705	chr5:122759302	CEP120	0.93	6.19	0.36	2.28e-9	Breast cancer;
CESC	cis	rs7246657	0.943	rs7408563	chr19:37808585	G/C	cg23950597	chr19:37808831	NA	-0.6	-6.4	-0.37	6.98e-10	Coronary artery calcification;
CESC	cis	rs7811142	0.887	rs35111986	chr7:100000274	C/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.09	10.91	0.56	3.82e-23	Platelet count;
CESC	cis	rs6089829	0.962	rs9679865	chr20:61666132	C/G	cg03213289	chr20:61660250	NA	0.39	6.16	0.35	2.7e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs11098499	0.863	rs10009626	chr4:120470005	T/C	cg24375607	chr4:120327624	NA	0.44	5.36	0.31	1.84e-7	Corneal astigmatism;
CESC	cis	rs11893307	0.507	rs1465304	chr2:191585398	A/G	cg10560079	chr2:191398806	TMEM194B	-0.45	-5.59	-0.32	5.55e-8	Mean platelet volume;
CESC	cis	rs11122272	0.735	rs11122279	chr1:231519804	A/G	cg06096015	chr1:231504339	EGLN1	0.43	6.11	0.35	3.47e-9	Hemoglobin concentration;
CESC	cis	rs9611565	0.722	rs202635	chr22:41809637	C/T	cg06481639	chr22:41940642	POLR3H	0.62	6.52	0.37	3.49e-10	Vitiligo;
CESC	cis	rs10737909	1.000	rs10803369	chr1:15550525	G/T	cg21012057	chr1:15538911	TMEM51	-0.43	-6.09	-0.35	3.98e-9	Migraine;
CESC	cis	rs4689388	0.824	rs4467645	chr4:6294305	C/T	cg14416269	chr4:6271139	WFS1	0.46	7.76	0.43	1.79e-13	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs2204008	0.627	rs11176531	chr12:38152166	T/G	cg26384229	chr12:38710491	ALG10B	0.73	10.02	0.52	3.02e-20	Bladder cancer;
CESC	cis	rs875971	0.895	rs7788984	chr7:65915616	A/G	cg11764359	chr7:65958608	NA	0.97	15.58	0.69	2.77e-39	Aortic root size;
CESC	cis	rs9649213	0.593	rs34534766	chr7:97920871	G/C	cg24562669	chr7:97807699	LMTK2	0.48	6.8	0.39	6.74e-11	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11913218	chr1:10754156	CASZ1	0.52	6.0	0.35	6.52e-9	Gut microbiome composition (summer);
CESC	cis	rs6496667	0.533	rs7172909	chr15:90991416	C/T	cg10434728	chr15:90938212	IQGAP1	0.31	5.45	0.32	1.13e-7	Rheumatoid arthritis;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg10824722	chr1:206506826	NA	-0.47	-6.95	-0.39	2.87e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs9911578	0.967	rs4598970	chr17:57076893	T/A	cg12560992	chr17:57184187	TRIM37	-0.99	-16.91	-0.72	5.06e-44	Intelligence (multi-trait analysis);
CESC	cis	rs6502050	0.799	rs7502533	chr17:80109778	A/G	cg23985595	chr17:80112537	CCDC57	-0.42	-6.57	-0.37	2.72e-10	Life satisfaction;
CESC	cis	rs853679	0.517	rs9357065	chr6:28129580	T/C	cg22143856	chr6:28129313	ZNF389	0.49	6.18	0.35	2.47e-9	Depression;
CESC	cis	rs8013055	0.898	rs8014913	chr14:105977313	T/C	cg23356831	chr14:105996513	TMEM121	0.37	5.13	0.3	5.53e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
CESC	cis	rs11969893	0.850	rs9498414	chr6:101322976	C/T	cg12253828	chr6:101329408	ASCC3	0.92	7.84	0.43	1.12e-13	Economic and political preferences (immigration/crime);
CESC	cis	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg02951883	chr7:2050386	MAD1L1	-0.44	-5.62	-0.33	4.93e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs1799949	0.930	rs1554063	chr17:41287145	T/C	cg05368731	chr17:41323189	NBR1	0.6	8.37	0.46	3.43e-15	Menopause (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24601517	chr6:5004202	RPP40	0.56	6.32	0.36	1.12e-9	Gut microbiome composition (summer);
CESC	cis	rs1862618	0.671	rs2591957	chr5:56243146	A/T	cg18230493	chr5:56204884	C5orf35	0.61	7.98	0.44	4.33e-14	Initial pursuit acceleration;
CESC	cis	rs898097	0.812	rs55794221	chr17:80849003	G/A	cg08704611	chr17:80376099	HEXDC;C17orf101	-0.45	-5.16	-0.3	4.79e-7	Breast cancer;
CESC	cis	rs796364	0.950	rs188146	chr2:200750444	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.87	8.64	0.47	5.23e-16	Schizophrenia;
CESC	cis	rs9291683	0.618	rs13137343	chr4:10043028	C/A	cg00071950	chr4:10020882	SLC2A9	0.83	14.41	0.66	3.63e-35	Bone mineral density;
CESC	cis	rs42648	0.870	rs7783199	chr7:89999305	G/A	cg23697855	chr7:89950296	NA	-0.27	-5.12	-0.3	5.74e-7	Homocysteine levels;
CESC	cis	rs748404	0.560	rs2255663	chr15:43829008	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.48	-7.34	-0.41	2.67e-12	Lung cancer;
CESC	cis	rs17666538	0.710	rs11987001	chr8:630755	T/C	cg07234876	chr8:600039	NA	0.78	5.48	0.32	1.01e-7	IgG glycosylation;
CESC	cis	rs7524258	0.835	rs2412150	chr1:7303343	A/C	cg07173049	chr1:7289937	CAMTA1	0.42	6.24	0.36	1.74e-9	Tourette's syndrome or obsessive-compulsive disorder;
CESC	cis	rs6088580	0.634	rs4911423	chr20:32999386	T/A	cg06115741	chr20:33292138	TP53INP2	-0.47	-6.03	-0.35	5.36e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs7255436	0.965	rs11666003	chr19:8452102	G/A	cg16745616	chr19:8428856	ANGPTL4	-0.36	-5.49	-0.32	9.22e-8	HDL cholesterol;
CESC	cis	rs9399137	0.507	rs56164974	chr6:135288716	C/T	cg24558204	chr6:135376177	HBS1L	0.7	9.61	0.51	5.91e-19	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	cis	rs17362650	0.653	rs12474647	chr2:9554280	A/T	cg12832956	chr2:9616023	IAH1	-0.57	-6.63	-0.38	1.89e-10	Alcohol dependence (age at onset);
CESC	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg24101359	chr6:42928495	GNMT	0.62	9.51	0.5	1.22e-18	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs7107174	1.000	rs2510047	chr11:77988668	C/T	cg02023728	chr11:77925099	USP35	-0.35	-5.18	-0.3	4.45e-7	Testicular germ cell tumor;
CESC	cis	rs6032067	0.598	rs2741500	chr20:43944958	G/T	cg10761708	chr20:43804764	PI3	0.44	5.32	0.31	2.17e-7	Blood protein levels;
CESC	cis	rs561341	1.000	rs4795668	chr17:30244554	G/A	cg00745463	chr17:30367425	LRRC37B	-0.6	-5.81	-0.34	1.8e-8	Hip circumference adjusted for BMI;
CESC	cis	rs7264396	0.635	rs6121073	chr20:34457513	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.63	7.4	0.41	1.75e-12	Total cholesterol levels;
CESC	cis	rs597583	0.664	rs4938395	chr11:117384673	C/T	cg27161313	chr11:117392002	DSCAML1	0.5	6.22	0.36	1.93e-9	Putamen volume;
CESC	cis	rs60871478	1.000	rs62432252	chr7:802886	C/G	cg27478167	chr7:817139	HEATR2	-0.49	-5.35	-0.31	1.87e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg23131131	chr22:24373011	LOC391322	-0.65	-8.86	-0.48	1.15e-16	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs11785400	1.000	rs11780221	chr8:143748215	T/A	cg10596483	chr8:143751796	JRK	0.44	5.72	0.33	2.8e-8	Schizophrenia;
CESC	cis	rs6952808	0.798	rs28970524	chr7:1927484	C/T	cg05863683	chr7:1912471	MAD1L1	0.5	7.75	0.43	2.02e-13	Bipolar disorder and schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07491375	chr4:71705274	GRSF1	0.56	7.11	0.4	1.06e-11	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17099683	chr14:96969243	PAPOLA	-0.58	-6.42	-0.37	6.18e-10	Gut microbiome composition (summer);
CESC	cis	rs926938	0.584	rs1299780	chr1:115366014	G/A	cg12756093	chr1:115239321	AMPD1	0.45	6.04	0.35	5.1e-9	Autism;
CESC	cis	rs477895	0.838	rs1058735	chr11:64000410	C/G	cg18225595	chr11:63971243	STIP1	0.53	5.57	0.32	6.17e-8	Mean platelet volume;
CESC	cis	rs10504229	0.683	rs11786074	chr8:58133532	A/G	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs35740288	0.539	rs34362339	chr15:86337628	C/T	cg20737812	chr15:86336631	KLHL25	-0.42	-5.28	-0.31	2.71e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
CESC	cis	rs9811920	0.609	rs793460	chr3:99615733	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.64	10.11	0.53	1.53e-20	Axial length;
CESC	cis	rs7660520	0.557	rs76004373	chr4:183731011	C/G	cg04526738	chr4:183727387	NA	0.7	6.58	0.37	2.5e-10	Pediatric autoimmune diseases;
CESC	cis	rs4713118	0.629	rs203890	chr6:28022248	T/C	cg12963246	chr6:28129442	ZNF389	0.49	6.35	0.36	9.29e-10	Parkinson's disease;
CESC	cis	rs67311347	0.911	rs6775936	chr3:40377399	T/G	cg24209194	chr3:40518798	ZNF619	0.42	5.36	0.31	1.83e-7	Renal cell carcinoma;
CESC	trans	rs875971	1.000	rs11971949	chr7:65626014	A/G	cg26939375	chr7:64535504	NA	-0.47	-6.16	-0.35	2.69e-9	Aortic root size;
CESC	cis	rs3820928	0.874	rs10207404	chr2:227794420	T/C	cg05526886	chr2:227700861	RHBDD1	-0.4	-5.12	-0.3	5.87e-7	Pulmonary function;
CESC	cis	rs5758659	0.652	rs4822084	chr22:42435868	A/G	cg04733989	chr22:42467013	NAGA	-0.44	-5.92	-0.34	9.79e-9	Cognitive function;
CESC	cis	rs113835537	0.877	rs3867132	chr11:66309269	C/T	cg24851651	chr11:66362959	CCS	0.61	5.52	0.32	8.26e-8	Airway imaging phenotypes;
CESC	cis	rs2425143	0.908	rs75331436	chr20:34391052	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.68	5.93	0.34	9.19e-9	Blood protein levels;
CESC	cis	rs35306767	0.903	rs34270014	chr10:904666	T/C	cg25019033	chr10:957182	NA	-0.59	-6.32	-0.36	1.08e-9	Eosinophil percentage of granulocytes;
CESC	cis	rs780096	0.526	rs1260341	chr2:27663215	T/A	cg02592271	chr2:27665507	KRTCAP3	-0.29	-5.79	-0.34	2e-8	Total body bone mineral density;
CESC	cis	rs11514810	1.000	rs9648620	chr7:1427980	T/C	cg24899294	chr7:1481343	MICALL2	-0.62	-5.37	-0.31	1.74e-7	Executive inhibition (Stroop WIT and CIT) in attention deficit hyperactivity disorder;
CESC	cis	rs6496667	1.000	rs7182544	chr15:90897480	G/C	cg22089800	chr15:90895588	ZNF774	0.57	5.76	0.33	2.27e-8	Rheumatoid arthritis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18228282	chr17:46703908	HOXB9	0.52	6.27	0.36	1.47e-9	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.830	rs10000573	chr4:99048785	G/C	cg17366294	chr4:99064904	C4orf37	0.61	8.78	0.47	2.13e-16	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16352085	chr1:859719	SAMD11	0.61	6.41	0.37	6.72e-10	Gut microbiome composition (summer);
CESC	cis	rs7116495	0.737	rs7126838	chr11:71826237	A/G	cg10381502	chr11:71823885	C11orf51	0.65	5.45	0.32	1.15e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs10504229	1.000	rs116444534	chr8:58181915	A/G	cg05313129	chr8:58192883	C8orf71	-0.47	-5.42	-0.32	1.35e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs79057730	0.599	rs112891948	chr7:816059	C/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.91	7.83	0.43	1.15e-13	Initial pursuit acceleration;
CESC	cis	rs7959452	0.557	rs7980883	chr12:69778914	C/T	cg22834771	chr12:69754056	YEATS4	-0.48	-6.46	-0.37	4.87e-10	Blood protein levels;
CESC	cis	rs875971	0.830	rs427575	chr7:65519219	A/G	cg12463550	chr7:65579703	CRCP	0.57	7.15	0.4	8.68e-12	Aortic root size;
CESC	cis	rs801193	0.935	rs2659916	chr7:66151352	C/G	cg25985355	chr7:65971099	NA	-0.31	-5.04	-0.3	8.47e-7	Aortic root size;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04260516	chr14:24630327	IRF9	0.51	6.57	0.37	2.66e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs708547	0.915	rs28605409	chr4:57766261	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.67	7.33	0.41	2.78e-12	Response to bleomycin (chromatid breaks);
CESC	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg19678392	chr7:94953810	PON1	-0.48	-7.73	-0.43	2.31e-13	Paraoxonase activity;
CESC	cis	rs2228479	0.867	rs62056110	chr16:89946388	A/C	cg14709524	chr16:89940631	TCF25	0.74	5.75	0.33	2.43e-8	Skin colour saturation;
CESC	cis	rs7216064	0.953	rs1966410	chr17:65837215	T/C	cg12091567	chr17:66097778	LOC651250	-0.8	-9.08	-0.49	2.62e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs72781680	1.000	rs72796339	chr2:24143063	T/C	cg20701182	chr2:24300061	SF3B14	0.63	5.67	0.33	3.79e-8	Lymphocyte counts;
CESC	cis	rs1552244	0.872	rs115331527	chr3:10154504	G/A	cg00166722	chr3:10149974	C3orf24	0.49	6.28	0.36	1.35e-9	Alzheimer's disease;
CESC	cis	rs6815814	0.950	rs55903115	chr4:38786474	C/A	cg02016764	chr4:38805732	TLR1	-0.64	-7.93	-0.44	6.35e-14	Breast cancer;
CESC	cis	rs7618915	0.571	rs34954168	chr3:52612159	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.38	6.79	0.39	7.14e-11	Bipolar disorder;
CESC	cis	rs2836974	0.931	rs2836968	chr21:40642386	A/G	cg11644478	chr21:40555479	PSMG1	1.05	16.84	0.72	9.02e-44	Cognitive function;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02469457	chr2:242254758	SEPT2;HDLBP	0.59	6.38	0.36	7.83e-10	Gut microbiome composition (summer);
CESC	cis	rs1552244	1.000	rs9875081	chr3:10083935	G/A	cg08888203	chr3:10149979	C3orf24	0.47	6.03	0.35	5.4e-9	Alzheimer's disease;
CESC	cis	rs36051895	0.695	rs60221565	chr9:5029077	T/G	cg02405213	chr9:5042618	JAK2	-0.49	-5.78	-0.33	2.05e-8	Pediatric autoimmune diseases;
CESC	cis	rs7084402	0.967	rs1649030	chr10:60279830	G/A	cg07615347	chr10:60278583	BICC1	-0.59	-9.45	-0.5	1.83e-18	Refractive error;
CESC	cis	rs9322193	0.962	rs4380763	chr6:149999222	A/G	cg07701084	chr6:150067640	NUP43	0.46	6.3	0.36	1.24e-9	Lung cancer;
CESC	cis	rs6500395	1.000	rs1558817	chr16:48730722	G/A	cg04672837	chr16:48644449	N4BP1	0.47	5.58	0.32	6.02e-8	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs7264396	0.563	rs2425116	chr20:34323553	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.63	6.86	0.39	4.77e-11	Total cholesterol levels;
CESC	cis	rs208520	0.739	rs1935894	chr6:66891434	A/G	cg07460842	chr6:66804631	NA	-0.93	-11.85	-0.59	2.81e-26	Exhaled nitric oxide output;
CESC	cis	rs754466	0.580	rs10824576	chr10:79566040	G/C	cg17075019	chr10:79541650	NA	-0.82	-13.42	-0.64	1.14e-31	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs7412746	0.658	rs10888397	chr1:150886752	A/G	cg18016565	chr1:150552671	MCL1	-0.33	-5.07	-0.3	7.34e-7	Melanoma;
CESC	cis	rs7615952	0.576	rs4646748	chr3:125826329	G/A	cg02807482	chr3:125708958	NA	-0.39	-5.08	-0.3	7.17e-7	Blood pressure (smoking interaction);
CESC	cis	rs8049040	0.609	rs7188858	chr16:71468895	T/C	cg08717414	chr16:71523259	ZNF19	-0.56	-6.39	-0.37	7.37e-10	Blood protein levels;
CESC	cis	rs72781680	1.000	rs7355559	chr2:24256946	G/T	cg20701182	chr2:24300061	SF3B14	-0.74	-7.36	-0.41	2.37e-12	Lymphocyte counts;
CESC	cis	rs7949030	0.626	rs61296092	chr11:62320838	T/C	cg11742103	chr11:62369870	EML3;MTA2	0.65	9.81	0.52	1.35e-19	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs9611565	0.512	rs2899347	chr22:42158204	T/C	cg06481639	chr22:41940642	POLR3H	0.62	6.06	0.35	4.65e-9	Vitiligo;
CESC	cis	rs6831352	0.703	rs3133152	chr4:100031721	C/G	cg13256891	chr4:100009986	ADH5	0.69	8.13	0.45	1.61e-14	Alcohol dependence;
CESC	cis	rs9611565	0.659	rs1810461	chr22:41927820	G/A	cg03806693	chr22:41940476	POLR3H	-1.21	-15.69	-0.69	1.07e-39	Vitiligo;
CESC	cis	rs7617773	0.780	rs13085251	chr3:48340045	C/T	cg11946769	chr3:48343235	NME6	0.89	12.11	0.6	3.63e-27	Coronary artery disease;
CESC	cis	rs3096299	0.754	rs2965816	chr16:89514183	G/T	cg02187348	chr16:89574699	SPG7	-0.64	-9.02	-0.48	3.94e-17	Multiple myeloma (IgH translocation);
CESC	cis	rs2032447	0.670	rs198845	chr6:26107790	A/C	cg03517284	chr6:25882590	NA	-0.42	-5.81	-0.34	1.8e-8	Intelligence (multi-trait analysis);
CESC	cis	rs9911578	0.967	rs57869245	chr17:57106630	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	-0.4	-5.25	-0.31	3.12e-7	Intelligence (multi-trait analysis);
CESC	cis	rs12220238	1.000	rs10824075	chr10:75880254	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.65	6.42	0.37	6.1e-10	Soluble interleukin-2 receptor subunit alpha;
CESC	cis	rs12369635	1.000	rs12372807	chr12:129561332	C/T	cg01909103	chr12:129572610	TMEM132D	-0.65	-5.95	-0.34	8.64e-9	Schizophrenia (inflammation and infection response interaction);
CESC	cis	rs1801251	1.000	rs7578299	chr2:233573469	G/T	cg25237894	chr2:233734115	C2orf82	0.5	8.49	0.46	1.45e-15	Coronary artery disease;
CESC	cis	rs10504229	0.683	rs16921817	chr8:58107563	A/T	cg22535103	chr8:58192502	C8orf71	-0.77	-8.76	-0.47	2.37e-16	Developmental language disorder (linguistic errors);
CESC	cis	rs9937943	0.721	rs8059315	chr16:74506447	C/G	cg01733217	chr16:74700730	RFWD3	0.62	5.69	0.33	3.37e-8	Neutrophil percentage of white cells;
CESC	trans	rs3741489	1.000	rs2062162	chr12:133432744	C/T	cg24132527	chr5:140019269	TMCO6	1.19	8.86	0.48	1.16e-16	Cognitive function;
CESC	cis	rs2228479	0.867	rs57940434	chr16:89975496	G/A	cg04013166	chr16:89971882	TCF25	0.7	6.91	0.39	3.7e-11	Skin colour saturation;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg22792938	chr2:228337242	AGFG1	-0.41	-6.64	-0.38	1.81e-10	Gambling;
CESC	cis	rs10905065	0.827	rs10752111	chr10:5837286	T/C	cg11519256	chr10:5708881	ASB13	0.44	6.12	0.35	3.39e-9	Menopause (age at onset);
CESC	cis	rs7811142	0.830	rs76798830	chr7:99952828	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.09	10.29	0.53	4.06e-21	Platelet count;
CESC	cis	rs9649213	0.593	rs7812180	chr7:97969140	A/G	cg24562669	chr7:97807699	LMTK2	-0.6	-8.38	-0.46	3.18e-15	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs9911578	1.000	rs304299	chr17:56838472	C/G	cg12560992	chr17:57184187	TRIM37	0.92	15.29	0.68	2.77e-38	Intelligence (multi-trait analysis);
CESC	cis	rs9733	0.818	rs12403609	chr1:150676485	T/C	cg04414720	chr1:150670196	GOLPH3L	-0.37	-5.2	-0.3	4.06e-7	Tonsillectomy;
CESC	cis	rs258892	0.895	rs16901131	chr5:72054836	C/T	cg21869765	chr5:72125136	TNPO1	-0.42	-5.32	-0.31	2.2e-7	Small cell lung carcinoma;
CESC	cis	rs67478160	0.572	rs8016014	chr14:104293798	G/C	cg08213375	chr14:104286397	PPP1R13B	0.52	10.42	0.54	1.54e-21	Schizophrenia;
CESC	cis	rs3092073	0.624	rs3848719	chr20:44596545	G/A	cg00981651	chr20:44574847	PCIF1	0.38	5.59	0.33	5.51e-8	Intelligence (multi-trait analysis);
CESC	cis	rs7267979	0.966	rs2151144	chr20:25414924	G/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.84	-16.22	-0.71	1.47e-41	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs3820068	0.581	rs16851851	chr1:15929628	C/G	cg16988262	chr1:15930761	NA	0.35	5.65	0.33	4.18e-8	Systolic blood pressure;
CESC	trans	rs7307889	0.793	rs10161529	chr12:6013122	G/A	cg18407955	chr7:158110685	PTPRN2	-0.72	-6.67	-0.38	1.45e-10	Obesity-related traits;
CESC	cis	rs2797160	0.967	rs2747715	chr6:126007719	A/T	cg05901451	chr6:126070800	HEY2	0.45	6.53	0.37	3.4e-10	Endometrial cancer;
CESC	cis	rs950776	0.518	rs11630349	chr15:78824608	C/T	cg24631222	chr15:78858424	CHRNA5	-0.42	-5.33	-0.31	2.09e-7	Sudden cardiac arrest;
CESC	cis	rs7412746	0.634	rs7521592	chr1:150821691	A/C	cg22823121	chr1:150693482	HORMAD1	0.44	6.15	0.35	2.85e-9	Melanoma;
CESC	cis	rs2276314	0.857	rs59649576	chr18:33616075	G/T	cg19628046	chr18:33552617	C18orf21	0.53	5.97	0.34	7.5e-9	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs832540	0.552	rs252924	chr5:56205643	A/G	cg14703610	chr5:56206110	C5orf35	0.42	5.22	0.31	3.54e-7	Coronary artery disease;
CESC	cis	rs7811142	1.000	rs7783159	chr7:100017454	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.94	9.59	0.51	6.76e-19	Platelet count;
CESC	cis	rs9837602	0.810	rs9854260	chr3:99850212	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.39	5.04	0.3	8.6e-7	Breast cancer;
CESC	cis	rs2797160	0.967	rs1739355	chr6:126018114	A/G	cg05901451	chr6:126070800	HEY2	0.45	6.38	0.36	7.82e-10	Endometrial cancer;
CESC	cis	rs1178968	0.901	rs7783232	chr7:72765171	C/G	cg25889504	chr7:72793014	NA	0.48	5.11	0.3	6.25e-7	Triglyceride levels;
CESC	cis	rs10411936	0.626	rs8113060	chr19:16596795	G/C	cg10248733	chr19:16607483	C19orf44;CALR3	0.58	6.9	0.39	3.75e-11	White blood cell count;Multiple sclerosis;
CESC	cis	rs25645	0.760	rs11870683	chr17:38129841	T/A	cg17467752	chr17:38218738	THRA	-0.42	-5.47	-0.32	1.06e-7	Myeloid white cell count;
CESC	cis	rs7039377	0.513	rs7854134	chr9:38672523	C/T	cg14625731	chr9:38672608	NA	-0.42	-5.53	-0.32	7.62e-8	Obesity-related traits;
CESC	cis	rs4819052	0.885	rs28576202	chr21:46674684	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.47	5.88	0.34	1.23e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs45535039	1.000	rs10892342	chr11:119135814	T/C	cg16724696	chr11:118992527	HINFP	0.4	5.11	0.3	6.21e-7	Plateletcrit;
CESC	cis	rs763121	0.853	rs2281021	chr22:39064667	T/C	cg06022373	chr22:39101656	GTPBP1	0.88	13.95	0.65	1.51e-33	Menopause (age at onset);
CESC	cis	rs9837602	1.000	rs17379739	chr3:99724792	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.48	7.04	0.4	1.66e-11	Breast cancer;
CESC	cis	rs12477438	0.520	rs13012481	chr2:99754290	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.86	15.92	0.7	1.72e-40	Chronic sinus infection;
CESC	trans	rs3741578	0.702	rs10506348	chr12:57331370	A/G	cg14720773	chr17:17603531	RAI1	0.47	6.21	0.36	2.02e-9	Asthma;
CESC	cis	rs2299587	0.897	rs3850744	chr8:17784203	A/G	cg08627089	chr8:17753878	FGL1	-0.36	-5.04	-0.3	8.69e-7	Economic and political preferences;
CESC	cis	rs2070488	0.775	rs1073506	chr3:38566235	G/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.72	-10.94	-0.56	3.14e-23	Electrocardiographic conduction measures;
CESC	cis	rs3733585	0.699	rs6823361	chr4:9963127	A/G	cg00071950	chr4:10020882	SLC2A9	-0.73	-11.91	-0.59	1.82e-26	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs34638657	0.673	rs67661146	chr16:82199669	G/A	cg09439754	chr16:82129088	HSD17B2	-0.37	-6.42	-0.37	6.31e-10	Lung adenocarcinoma;
CESC	cis	rs1499614	0.522	rs13247442	chr7:66188858	T/C	cg13147721	chr7:65941812	NA	-0.86	-6.2	-0.36	2.1e-9	Gout;
CESC	cis	rs7089973	0.604	rs11196924	chr10:116571796	A/C	cg23260525	chr10:116636907	FAM160B1	-0.35	-6.0	-0.35	6.45e-9	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs801193	0.660	rs10950049	chr7:66230860	T/C	cg10691866	chr7:65817282	TPST1	-0.37	-6.17	-0.35	2.5e-9	Aortic root size;
CESC	cis	rs7666738	0.546	rs10461174	chr4:98698293	G/A	cg05340658	chr4:99064831	C4orf37	0.54	6.56	0.37	2.81e-10	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9660992	0.573	rs1172159	chr1:205207512	T/C	cg00857998	chr1:205179979	DSTYK	0.56	6.94	0.39	2.95e-11	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs6032067	0.704	rs62208390	chr20:43794844	A/C	cg10761708	chr20:43804764	PI3	0.56	6.55	0.37	3.01e-10	Blood protein levels;
CESC	cis	rs853679	0.517	rs9393898	chr6:28130376	G/T	cg17949981	chr6:28129498	ZNF389	0.47	5.86	0.34	1.37e-8	Depression;
CESC	cis	rs8060686	0.641	rs8060893	chr16:68191608	A/T	cg26727032	chr16:67993705	SLC12A4	-0.53	-6.02	-0.35	5.67e-9	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs5757673	1	rs5757673	chr22:39837920	T/C	cg24399712	chr22:39784796	NA	-0.87	-10.71	-0.55	1.79e-22	Post bronchodilator FEV1;
CESC	cis	rs10504229	0.683	rs58438731	chr8:58134790	C/T	cg21724239	chr8:58056113	NA	0.58	5.95	0.34	8.29e-9	Developmental language disorder (linguistic errors);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg03142634	chr7:45151369	TBRG4	-0.46	-6.12	-0.35	3.31e-9	Fibrinogen levels;
CESC	cis	rs116095464	0.558	rs62347678	chr5:227496	A/G	cg22857025	chr5:266934	NA	-1.26	-18.2	-0.75	1.38e-48	Breast cancer;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg10255097	chr10:114711603	TCF7L2	-0.47	-6.9	-0.39	3.77e-11	Gambling;
CESC	cis	rs4665809	0.590	rs1560865	chr2:26452197	C/A	cg04944784	chr2:26401820	FAM59B	-0.96	-10.83	-0.55	7.34e-23	Gut microbiome composition (summer);
CESC	cis	rs6087990	0.735	rs2424922	chr20:31386449	T/C	cg13636640	chr20:31349939	DNMT3B	0.8	13.01	0.62	2.87e-30	Ulcerative colitis;
CESC	cis	rs7312774	0.618	rs57361179	chr12:107337483	T/C	cg16260113	chr12:107380972	MTERFD3	0.82	7.53	0.42	8.11e-13	Severe influenza A (H1N1) infection;
CESC	cis	rs763014	1.000	rs763014	chr16:675680	T/C	cg00802000	chr16:706648	WDR90	-0.43	-6.55	-0.37	2.94e-10	Height;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg23428725	chr14:36278532	RALGAPA1	-0.46	-6.2	-0.36	2.14e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs875971	0.520	rs12666485	chr7:65625122	T/C	cg18876405	chr7:65276391	NA	0.51	5.96	0.34	8.21e-9	Aortic root size;
CESC	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-6.15	-0.35	2.85e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs11078597	0.614	rs62090057	chr17:1645526	C/T	cg18436246	chr17:1640651	WDR81	0.62	7.59	0.42	5.36e-13	Serum albumin level;
CESC	cis	rs6120849	0.707	rs3746444	chr20:33578251	A/G	cg24642439	chr20:33292090	TP53INP2	0.67	6.72	0.38	1.12e-10	Protein C levels;
CESC	cis	rs11190604	1.000	rs4919472	chr10:102315864	T/A	cg07080220	chr10:102295463	HIF1AN	0.64	6.08	0.35	4.28e-9	Palmitoleic acid (16:1n-7) levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26230390	chr2:203130314	NOP58	0.53	6.2	0.36	2.2e-9	Gut microbiome composition (summer);
CESC	cis	rs7429990	0.965	rs1550914	chr3:47995168	A/C	cg11946769	chr3:48343235	NME6	0.45	5.59	0.32	5.78e-8	Educational attainment (years of education);
CESC	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	7.7	0.43	2.77e-13	Prudent dietary pattern;
CESC	cis	rs17125944	0.505	rs28568967	chr14:53223060	A/G	cg00686598	chr14:53173677	PSMC6	1.35	11.65	0.58	1.3e-25	Alzheimer's disease (late onset);
CESC	cis	rs1153858	1.000	rs1049503	chr15:45653707	T/C	cg21132104	chr15:45694354	SPATA5L1	0.85	11.64	0.58	1.47e-25	Homoarginine levels;
CESC	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg07167872	chr1:205819463	PM20D1	0.75	12.71	0.62	3.22e-29	Menarche (age at onset);
CESC	cis	rs10504229	0.861	rs6990796	chr8:58183097	G/C	cg22535103	chr8:58192502	C8orf71	-1.05	-13.08	-0.63	1.71e-30	Developmental language disorder (linguistic errors);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04466995	chr11:65421839	RELA	-0.56	-6.73	-0.38	1.05e-10	Gut microbiome composition (summer);
CESC	cis	rs17608059	1.000	rs17608059	chr17:13910549	C/T	cg11395062	chr17:14139857	CDRT15	0.5	5.88	0.34	1.23e-8	Temperament;
CESC	cis	rs6430585	0.528	rs309158	chr2:136680534	A/G	cg07169764	chr2:136633963	MCM6	1.08	16.51	0.71	1.41e-42	Corneal structure;
CESC	cis	rs1218582	0.740	rs1977879	chr1:154879743	G/A	cg03351412	chr1:154909251	PMVK	0.69	9.38	0.5	3.14e-18	Prostate cancer;
CESC	cis	rs12618769	0.652	rs7595120	chr2:99231805	C/G	cg10123293	chr2:99228465	UNC50	0.4	5.27	0.31	2.79e-7	Bipolar disorder;
CESC	cis	rs4713118	0.662	rs149969	chr6:27977737	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.54	-6.66	-0.38	1.57e-10	Parkinson's disease;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg26566046	chr12:80083628	PAWR	-0.4	-6.25	-0.36	1.64e-9	Gambling;
CESC	cis	rs7640424	0.649	rs35710439	chr3:107913059	C/A	cg09227934	chr3:107805635	CD47	-0.45	-5.67	-0.33	3.73e-8	Body mass index;
CESC	cis	rs1552244	0.882	rs6796419	chr3:10040812	G/A	cg00166722	chr3:10149974	C3orf24	0.5	6.2	0.36	2.2e-9	Alzheimer's disease;
CESC	cis	rs2050392	1.000	rs2183176	chr10:30698544	C/T	cg18806716	chr10:30721971	MAP3K8	0.43	6.26	0.36	1.51e-9	Inflammatory bowel disease;
CESC	cis	rs1005277	0.540	rs289638	chr10:37923731	G/A	cg00409905	chr10:38381863	ZNF37A	-0.48	-6.58	-0.37	2.57e-10	Extrinsic epigenetic age acceleration;
CESC	cis	rs854765	0.647	rs2974999	chr17:17997547	T/G	cg16928487	chr17:17741425	SREBF1	-0.53	-8.7	-0.47	3.61e-16	Total body bone mineral density;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg17882028	chr5:140070892	HARS;HARS2	-0.45	-6.06	-0.35	4.71e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs959260	1.000	rs9909076	chr17:73384809	G/T	cg20590849	chr17:73267439	MIF4GD	-0.58	-6.86	-0.39	4.77e-11	Systemic lupus erythematosus;
CESC	trans	rs10905099	0.708	rs7084114	chr10:7097364	T/C	cg05230642	chr15:25439252	SNORD115-14	-0.73	-6.17	-0.35	2.6e-9	Orofacial clefts;
CESC	cis	rs7542091	0.579	rs34638782	chr1:210032055	C/G	cg22029157	chr1:209979665	IRF6	0.36	5.16	0.3	4.8e-7	Monobrow;
CESC	cis	rs7605827	0.930	rs1019358	chr2:15524042	A/G	cg19274914	chr2:15703543	NA	0.35	6.27	0.36	1.43e-9	Educational attainment (years of education);
CESC	cis	rs10883723	0.962	rs1056738	chr10:104236481	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.54	7.34	0.41	2.67e-12	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs7777754	0.512	rs11238131	chr7:50538589	T/C	cg14593290	chr7:50529359	DDC	-0.38	-5.38	-0.31	1.61e-7	Response to zileuton treatment in asthma (FEV1 change interaction);
CESC	cis	rs798766	1.000	rs798719	chr4:1698183	C/T	cg10756475	chr4:1757242	NA	0.43	5.67	0.33	3.75e-8	Bladder cancer;Urinary bladder cancer;
CESC	cis	rs6088590	1.000	rs6088590	chr20:33313566	T/C	cg24642439	chr20:33292090	TP53INP2	0.83	11.61	0.58	1.81e-25	Coronary artery disease;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg07508260	chr11:111742291	ALG9	-0.5	-6.72	-0.38	1.09e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs3785574	0.962	rs57553639	chr17:61848499	C/T	cg06873352	chr17:61820015	STRADA	0.48	7.07	0.4	1.37e-11	Height;
CESC	cis	rs7666738	0.800	rs13106995	chr4:99028790	A/T	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.58e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs12136530	0.593	rs881246	chr1:19733255	C/A	cg01832549	chr1:19774989	CAPZB	-0.48	-6.33	-0.36	1.05e-9	Lead levels in blood;
CESC	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	-0.5	-6.29	-0.36	1.31e-9	Prudent dietary pattern;
CESC	cis	rs2070433	0.559	rs11089057	chr21:47721228	T/A	cg12379764	chr21:47803548	PCNT	0.58	6.21	0.36	2.03e-9	Lymphocyte counts;
CESC	trans	rs561341	1.000	rs521919	chr17:30298039	G/T	cg27661571	chr11:113659931	NA	-0.69	-6.94	-0.39	2.95e-11	Hip circumference adjusted for BMI;
CESC	cis	rs10794720	0.748	rs11250275	chr10:1171823	A/G	cg08668510	chr10:1095578	IDI1	-0.68	-5.11	-0.3	6.3e-7	Glomerular filtration rate in non diabetics (creatinine);Chronic kidney disease;
CESC	cis	rs597539	0.654	rs655816	chr11:68626405	A/G	cg21963583	chr11:68658836	MRPL21	0.42	5.75	0.33	2.47e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs75477785	0.590	rs4844938	chr1:210180988	T/A	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.92	6.23	0.36	1.82e-9	Cleft lip with or without cleft palate;
CESC	cis	rs4423214	0.650	rs2186777	chr11:71219803	C/A	cg24826892	chr11:71159390	DHCR7	0.5	5.65	0.33	4.07e-8	Vitamin D levels;
CESC	cis	rs9649213	0.593	rs1468341	chr7:97987696	G/A	cg21770322	chr7:97807741	LMTK2	0.58	8.86	0.48	1.18e-16	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg25274881	chr12:49761165	SPATS2	-0.43	-6.08	-0.35	4.16e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs116979167	0.575	rs67661063	chr7:105187259	T/G	cg19920283	chr7:105172520	RINT1	0.51	5.8	0.34	1.91e-8	Bipolar disorder (body mass index interaction);
CESC	cis	rs6089829	0.962	rs1060490	chr20:61665871	A/G	cg03213289	chr20:61660250	NA	0.39	6.16	0.35	2.7e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs727563	0.593	rs5758461	chr22:42162189	G/C	cg06634786	chr22:41940651	POLR3H	0.71	7.03	0.4	1.75e-11	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs2075371	1.000	rs2241334	chr7:133979225	C/G	cg00033643	chr7:134001901	SLC35B4	0.42	5.41	0.32	1.41e-7	Mean platelet volume;
CESC	cis	rs765787	0.530	rs28815867	chr15:45526805	G/C	cg24006582	chr15:45444508	DUOX1	-0.59	-7.23	-0.41	5.15e-12	Uric acid levels;
CESC	cis	rs898097	0.578	rs8069697	chr17:80908110	T/C	cg15664640	chr17:80829946	TBCD	0.42	6.07	0.35	4.3e-9	Breast cancer;
CESC	cis	rs11785400	1.000	rs11785400	chr8:143730456	C/T	cg24634471	chr8:143751801	JRK	0.45	5.89	0.34	1.15e-8	Schizophrenia;
CESC	cis	rs6032067	0.538	rs6017489	chr20:43731932	C/T	cg10761708	chr20:43804764	PI3	0.45	5.22	0.31	3.53e-7	Blood protein levels;
CESC	cis	rs7949030	0.626	rs7124057	chr11:62334096	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.65	9.8	0.52	1.49e-19	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs2576037	0.583	rs512699	chr18:44374681	C/T	cg19077165	chr18:44547161	KATNAL2	0.6	9.22	0.49	9.27e-18	Personality dimensions;
CESC	cis	rs9486719	0.948	rs2499817	chr6:96878321	C/T	cg06623918	chr6:96969491	KIAA0776	0.81	8.29	0.45	5.61e-15	Migraine;Coronary artery disease;
CESC	cis	rs2842992	0.830	rs2495279	chr6:160138796	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.73	9.02	0.48	3.82e-17	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs9733	0.519	rs12095002	chr1:150649249	G/A	cg22823121	chr1:150693482	HORMAD1	0.48	7.09	0.4	1.21e-11	Tonsillectomy;
CESC	cis	rs2243480	1.000	rs56016656	chr7:65383481	C/T	cg25894440	chr7:65020034	NA	-0.62	-5.16	-0.3	4.73e-7	Diabetic kidney disease;
CESC	cis	rs2250402	0.510	rs6492926	chr15:40325829	T/G	cg10636054	chr15:40330586	SRP14	1.03	7.47	0.42	1.13e-12	Corneal curvature;
CESC	cis	rs561341	0.714	rs7218466	chr17:30263314	A/G	cg00745463	chr17:30367425	LRRC37B	-0.48	-5.21	-0.3	3.74e-7	Hip circumference adjusted for BMI;
CESC	cis	rs9623117	1.000	rs6001728	chr22:40434757	A/G	cg05033341	chr22:40419857	FAM83F	-0.38	-5.03	-0.3	8.97e-7	Prostate cancer (SNP x SNP interaction);Prostate cancer;
CESC	cis	rs2294693	0.947	rs9349176	chr6:40989525	C/T	cg14418226	chr6:40996092	UNC5CL	0.52	6.5	0.37	4.04e-10	Gastric cancer;Non-cardia gastric cancer;
CESC	cis	rs11711311	0.784	rs13081931	chr3:113349928	G/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.41	5.21	0.3	3.75e-7	IgG glycosylation;
CESC	cis	rs10242455	0.702	rs78218664	chr7:99154381	C/A	cg25640893	chr7:99214727	ZNF498	0.79	5.62	0.33	4.84e-8	Blood metabolite levels;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg19138250	chr10:69524126	NA	0.47	6.39	0.37	7.28e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs12477438	0.765	rs6754843	chr2:99680485	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.62	-8.67	-0.47	4.43e-16	Chronic sinus infection;
CESC	cis	rs1941023	0.503	rs10750936	chr11:60144180	G/A	cg08716584	chr11:60157161	MS4A7	-0.57	-9.51	-0.5	1.18e-18	Congenital heart disease (maternal effect);
CESC	cis	rs7131987	0.903	rs10843367	chr12:29408380	G/A	cg09582351	chr12:29534625	ERGIC2	-0.36	-5.67	-0.33	3.66e-8	QT interval;
CESC	cis	rs2115536	1.000	rs7163338	chr15:80198408	C/G	cg00225070	chr15:80189496	MTHFS	0.55	7.45	0.42	1.3e-12	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CESC	cis	rs3749237	0.636	rs1568662	chr3:49521263	A/G	cg06212747	chr3:49208901	KLHDC8B	0.48	6.38	0.36	7.79e-10	Resting heart rate;
CESC	cis	rs8177179	0.967	rs10935085	chr3:133459735	C/T	cg24879335	chr3:133465180	TF	0.45	8.61	0.47	6.73e-16	Iron status biomarkers (transferrin levels);
CESC	cis	rs2882667	0.824	rs13189485	chr5:138475401	C/T	cg04439458	chr5:138467593	SIL1	-0.36	-5.52	-0.32	7.93e-8	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs7116495	0.609	rs2508860	chr11:71805052	C/T	cg26138937	chr11:71823887	C11orf51	1.29	7.99	0.44	4.16e-14	Severe influenza A (H1N1) infection;
CESC	cis	rs727505	0.563	rs73227531	chr7:124800221	T/A	cg23710748	chr7:124431027	NA	-0.4	-6.13	-0.35	3.13e-9	Lewy body disease;
CESC	cis	rs2549003	0.966	rs2706385	chr5:131831766	T/G	cg00255919	chr5:131827918	IRF1	-0.57	-9.72	-0.51	2.75e-19	Asthma (sex interaction);
CESC	trans	rs79976124	0.797	rs74995761	chr6:66640216	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.73	8.29	0.45	5.56e-15	Type 2 diabetes;
CESC	cis	rs2439831	1.000	rs2245054	chr15:43751909	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.89	10.57	0.54	5.08e-22	Lung cancer in ever smokers;
CESC	cis	rs10504229	0.953	rs78089850	chr8:58171557	A/G	cg14926445	chr8:58193284	C8orf71	-0.5	-5.38	-0.31	1.62e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs6933660	0.646	rs9397410	chr6:151770503	C/T	cg17179660	chr6:151773299	C6orf211;RMND1	-0.42	-5.45	-0.32	1.13e-7	Menarche (age at onset);
CESC	cis	rs7828089	0.582	rs7825938	chr8:22266866	G/A	cg12081754	chr8:22256438	SLC39A14	0.63	8.91	0.48	8.53e-17	Verbal declarative memory;
CESC	trans	rs10002492	0.666	rs1481185	chr4:12580757	A/G	cg25106635	chr16:2510001	C16orf59	0.5	6.27	0.36	1.46e-9	IgG glycosylation;
CESC	cis	rs5769707	0.967	rs2051626	chr22:50008973	G/A	cg20744362	chr22:50050164	C22orf34	0.47	8.12	0.45	1.8e-14	Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs17711722	0.523	rs313812	chr7:65505043	T/C	cg14393609	chr7:65229607	NA	-0.47	-6.56	-0.37	2.86e-10	Calcium levels;
CESC	cis	rs6061231	0.544	rs2427314	chr20:60973666	C/T	cg22601191	chr20:60968625	CABLES2	0.38	5.2	0.3	4.07e-7	Colorectal cancer;
CESC	cis	rs8014204	0.762	rs10138360	chr14:75293386	A/G	cg08847533	chr14:75593920	NEK9	-0.39	-5.06	-0.3	7.94e-7	Caffeine consumption;
CESC	cis	rs7312933	0.558	rs1669886	chr12:42838240	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.5	-6.67	-0.38	1.45e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs7833986	0.501	rs2719259	chr8:56941630	A/G	cg26371346	chr8:56986568	SNORD54;RPS20	0.57	5.27	0.31	2.81e-7	Height;
CESC	cis	rs4253772	0.514	rs11704878	chr22:46714664	C/T	cg24881330	chr22:46731750	TRMU	0.79	6.02	0.35	5.79e-9	LDL cholesterol;Cholesterol, total;
CESC	cis	rs875971	0.617	rs810400	chr7:66022889	G/C	cg18876405	chr7:65276391	NA	-0.57	-7.75	-0.43	1.97e-13	Aortic root size;
CESC	cis	rs2836633	0.929	rs58120977	chr21:40037346	C/T	cg12884169	chr21:40033163	ERG	0.39	6.17	0.35	2.53e-9	Coronary artery disease;
CESC	cis	rs11098499	0.644	rs2389880	chr4:120559870	T/A	cg09307838	chr4:120376055	NA	0.73	9.59	0.51	7.04e-19	Corneal astigmatism;
CESC	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg03188948	chr7:1209495	NA	0.7	6.57	0.37	2.65e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs61931739	0.929	rs2389274	chr12:34075149	T/C	cg26384229	chr12:38710491	ALG10B	-0.47	-6.61	-0.38	2.16e-10	Morning vs. evening chronotype;
CESC	cis	rs853679	0.517	rs9295761	chr6:28147987	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.56	-6.43	-0.37	5.9e-10	Depression;
CESC	cis	rs3820928	0.904	rs4129884	chr2:227820943	G/A	cg11843606	chr2:227700838	RHBDD1	-0.43	-5.68	-0.33	3.57e-8	Pulmonary function;
CESC	cis	rs6840258	1.000	rs56201818	chr4:87952633	T/C	cg08197287	chr4:87952173	AFF1	-0.39	-5.3	-0.31	2.39e-7	Mean corpuscular volume;Basophil percentage of granulocytes;
CESC	cis	rs910316	0.783	rs11850751	chr14:75590113	A/T	cg08847533	chr14:75593920	NEK9	1.0	18.45	0.75	1.83e-49	Height;
CESC	cis	rs2425143	0.915	rs74355238	chr20:34441541	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.67	6.06	0.35	4.6e-9	Blood protein levels;
CESC	cis	rs34779708	0.931	rs11010083	chr10:35351531	C/G	cg04310649	chr10:35416472	CREM	-0.52	-6.21	-0.36	2.07e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs3749237	0.557	rs7631908	chr3:49425707	T/G	cg02487422	chr3:49467188	NICN1	0.55	7.99	0.44	4.23e-14	Resting heart rate;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04217776	chr1:173794059	CENPL;DARS2	0.58	6.15	0.35	2.78e-9	Gut microbiome composition (summer);
CESC	cis	rs6540559	0.611	rs926347	chr1:209965193	T/C	cg23283495	chr1:209979779	IRF6	0.55	6.3	0.36	1.24e-9	Cleft lip with or without cleft palate;
CESC	trans	rs1814175	0.803	rs11040451	chr11:49650639	C/T	cg15704280	chr7:45808275	SEPT13	-1.0	-17.65	-0.74	1.25e-46	Height;
CESC	cis	rs5769765	1.000	rs4824112	chr22:50284345	A/G	cg02269571	chr22:50332266	NA	-0.52	-6.56	-0.37	2.88e-10	Schizophrenia;
CESC	cis	rs4853012	0.838	rs72911122	chr2:74344119	C/G	cg05776053	chr2:74358815	NA	0.41	5.12	0.3	5.76e-7	Gestational age at birth (maternal effect);
CESC	cis	rs10208940	0.920	rs12713643	chr2:68724129	C/G	cg12452813	chr2:68675892	NA	0.52	5.24	0.31	3.26e-7	Urate levels in lean individuals;
CESC	cis	rs9583531	0.600	rs9555724	chr13:111354110	C/T	cg15841412	chr13:111365552	ING1	-0.44	-5.96	-0.34	8.22e-9	Coronary artery disease;
CESC	trans	rs7824557	0.564	rs2736293	chr8:11234613	T/A	cg06636001	chr8:8085503	FLJ10661	-0.48	-6.0	-0.35	6.44e-9	Retinal vascular caliber;
CESC	cis	rs9911578	0.692	rs412000	chr17:56709058	G/C	cg05425664	chr17:57184151	TRIM37	-0.4	-5.47	-0.32	1.05e-7	Intelligence (multi-trait analysis);
CESC	cis	rs7811142	1.000	rs73161762	chr7:100014846	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.08	9.66	0.51	4.01e-19	Platelet count;
CESC	cis	rs4911259	0.533	rs6058931	chr20:31471012	C/T	cg13636640	chr20:31349939	DNMT3B	-0.51	-6.94	-0.39	3.05e-11	Inflammatory bowel disease;
CESC	cis	rs11166629	1.000	rs894349	chr8:135638055	T/C	cg27224718	chr8:135614730	ZFAT	0.55	6.77	0.38	8.28e-11	Smoking quantity;
CESC	cis	rs9303401	0.580	rs12603808	chr17:56578508	T/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.98	10.76	0.55	1.19e-22	Cognitive test performance;
CESC	cis	rs6500602	0.648	rs7702	chr16:4560929	G/C	cg08645402	chr16:4508243	NA	0.44	6.43	0.37	5.76e-10	Schizophrenia;
CESC	cis	rs2072732	0.861	rs67289919	chr1:2954208	G/A	cg15211996	chr1:2936768	ACTRT2	0.34	6.04	0.35	5.27e-9	Plateletcrit;
CESC	cis	rs9908102	0.740	rs73981621	chr17:12914832	C/T	cg26162695	chr17:12921313	ELAC2	0.52	5.67	0.33	3.69e-8	Schizophrenia;
CESC	cis	rs1728785	1.000	rs1728780	chr16:68567642	G/C	cg02972257	chr16:68554789	NA	-0.55	-6.36	-0.36	8.6e-10	Ulcerative colitis;
CESC	cis	rs57502260	0.704	rs72936570	chr11:68307139	A/G	cg20283391	chr11:68216788	NA	-0.71	-5.78	-0.33	2.1e-8	Total body bone mineral density (age 45-60);
CESC	cis	rs561341	1.000	rs530209	chr17:30315287	A/G	cg00745463	chr17:30367425	LRRC37B	-0.78	-7.09	-0.4	1.2e-11	Hip circumference adjusted for BMI;
CESC	cis	rs3096299	0.933	rs2965939	chr16:89493043	G/A	cg08392591	chr16:89556376	ANKRD11	0.47	6.04	0.35	5.28e-9	Multiple myeloma (IgH translocation);
CESC	cis	rs1878931	0.580	rs7194596	chr16:3404408	T/A	cg00484396	chr16:3507460	NAT15	-0.36	-5.54	-0.32	7.37e-8	Body mass index (adult);
CESC	cis	rs10129255	0.518	rs12590732	chr14:107187851	C/T	cg23076370	chr14:107095027	NA	0.65	9.84	0.52	1.14e-19	Kawasaki disease;
CESC	cis	rs1003719	0.715	rs2835649	chr21:38552230	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.62	8.38	0.46	3.2e-15	Eye color traits;
CESC	cis	rs858239	0.539	rs6461694	chr7:23187779	G/A	cg23682824	chr7:23144976	KLHL7	0.46	5.85	0.34	1.45e-8	Cerebrospinal fluid biomarker levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25346720	chr7:73184981	CLDN3	0.56	6.33	0.36	1.07e-9	Gut microbiome composition (summer);
CESC	cis	rs853679	0.517	rs4711164	chr6:28115156	C/T	cg17949981	chr6:28129498	ZNF389	0.45	5.49	0.32	9.35e-8	Depression;
CESC	cis	rs17826219	0.706	rs8075107	chr17:29106649	C/A	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.91e-10	Body mass index;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg24512544	chr8:141588943	EIF2C2	0.5	6.77	0.38	8.14e-11	Fibrinogen levels;
CESC	cis	rs2841277	0.770	rs10149193	chr14:105403474	C/T	cg15352829	chr14:105391018	PLD4	-0.6	-10.53	-0.54	6.87e-22	Rheumatoid arthritis;
CESC	cis	rs7666738	0.830	rs11941844	chr4:99042722	A/T	cg18180107	chr4:99064573	C4orf37	0.41	5.29	0.31	2.51e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1577917	1.000	rs12199784	chr6:86726808	C/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-6.03	-0.35	5.34e-9	Response to antipsychotic treatment;
CESC	cis	rs7582720	1.000	rs79642273	chr2:203830851	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.36	0.41	2.34e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs2710642	0.815	rs6545971	chr2:63074986	A/T	cg17519650	chr2:63277830	OTX1	0.59	7.72	0.43	2.4e-13	LDL cholesterol levels;LDL cholesterol;
CESC	cis	rs6952808	0.931	rs12537430	chr7:1868761	A/G	cg23102388	chr7:1867652	MAD1L1	0.36	5.54	0.32	7.34e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs889398	0.802	rs8050414	chr16:69886813	T/A	cg09409435	chr16:70099608	PDXDC2	0.41	5.07	0.3	7.55e-7	Body mass index;
CESC	cis	rs7208859	0.673	rs73265624	chr17:29232066	G/A	cg19761014	chr17:28927070	LRRC37B2	0.73	5.77	0.33	2.22e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs68170813	0.559	rs76843318	chr7:106863173	A/G	cg02696742	chr7:106810147	HBP1	-0.52	-5.09	-0.3	6.89e-7	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12066592	chr14:34931026	C14orf147	0.55	6.1	0.35	3.68e-9	Gut microbiome composition (summer);
CESC	cis	rs763121	0.853	rs4821810	chr22:39072098	C/G	cg21395723	chr22:39101663	GTPBP1	0.49	6.73	0.38	1.07e-10	Menopause (age at onset);
CESC	cis	rs1670533	1.000	rs6857085	chr4:1095920	C/A	cg04106633	chr4:1044584	NA	-0.4	-5.18	-0.3	4.5e-7	Recombination rate (females);
CESC	cis	rs2228479	0.681	rs4287569	chr16:89957815	A/G	cg04013166	chr16:89971882	TCF25	0.72	8.95	0.48	6.37e-17	Skin colour saturation;
CESC	cis	rs4148883	0.645	rs2851264	chr4:100029715	C/T	cg13256891	chr4:100009986	ADH5	0.54	7.11	0.4	1.07e-11	Alcohol dependence;
CESC	cis	rs858239	0.670	rs3807452	chr7:23162081	C/T	cg27449745	chr7:23145252	KLHL7	0.49	6.63	0.38	1.9e-10	Cerebrospinal fluid biomarker levels;
CESC	cis	rs7666738	0.830	rs115279324	chr4:99042114	T/C	cg18180107	chr4:99064573	C4orf37	0.4	5.2	0.3	4.08e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7726839	0.507	rs56282020	chr5:596701	T/C	cg16447950	chr5:562315	NA	-0.59	-6.01	-0.35	6.18e-9	Obesity-related traits;
CESC	cis	rs2228479	0.867	rs57492102	chr16:89975572	A/G	cg04013166	chr16:89971882	TCF25	0.7	6.91	0.39	3.7e-11	Skin colour saturation;
CESC	cis	rs8114671	0.839	rs6142290	chr20:33654672	A/C	cg24642439	chr20:33292090	TP53INP2	-0.47	-5.7	-0.33	3.19e-8	Height;
CESC	cis	rs17253792	0.822	rs75991559	chr14:56092419	A/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.79	5.91	0.34	1.06e-8	Putamen volume;
CESC	cis	rs826838	0.967	rs1719852	chr12:39128531	A/G	cg13010199	chr12:38710504	ALG10B	-0.44	-5.97	-0.34	7.74e-9	Heart rate;
CESC	cis	rs13102973	0.864	rs7442176	chr4:135899575	C/A	cg14419869	chr4:135874104	NA	-0.34	-5.18	-0.3	4.49e-7	Subjective well-being;
CESC	cis	rs1178968	1.000	rs757938	chr7:72778573	A/G	cg25889504	chr7:72793014	NA	0.49	5.26	0.31	2.91e-7	Triglyceride levels;
CESC	cis	rs12497850	0.931	rs4974082	chr3:48999323	G/A	cg02487422	chr3:49467188	NICN1	0.43	5.53	0.32	7.78e-8	Parkinson's disease;
CESC	cis	rs6540559	1.000	rs6696825	chr1:209982372	A/G	cg09509183	chr1:209979624	IRF6	0.47	5.9	0.34	1.08e-8	Cleft lip with or without cleft palate;
CESC	cis	rs9858542	1.000	rs13316695	chr3:49684917	C/G	cg03060546	chr3:49711283	APEH	-0.59	-6.94	-0.39	2.96e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs3733585	0.699	rs7657340	chr4:9966772	A/T	cg00071950	chr4:10020882	SLC2A9	-0.7	-11.44	-0.57	6.82e-25	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs9921222	0.509	rs3743883	chr16:404750	T/C	cg26944245	chr16:421049	TMEM8A;MRPL28	0.48	7.75	0.43	1.99e-13	Bone mineral density (spine);Bone mineral density;
CESC	trans	rs7246760	0.867	rs61011126	chr19:9814421	A/C	cg02900749	chr2:68251473	NA	-0.86	-7.65	-0.43	3.79e-13	Pursuit maintenance gain;
CESC	cis	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg15921436	chr17:44337874	NA	0.78	9.07	0.49	2.84e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs6691722	0.583	rs7532539	chr1:24694427	A/G	cg02336364	chr1:24764700	NIPAL3	0.28	5.68	0.33	3.59e-8	Response to interferon beta in multiple sclerosis;
CESC	cis	rs11240408	1	rs11240408	chr1:205264536	A/T	cg21643547	chr1:205240462	TMCC2	0.51	7.47	0.42	1.14e-12	Platelet count;
CESC	cis	rs2050392	0.517	rs603072	chr10:30755778	C/T	cg18806716	chr10:30721971	MAP3K8	0.53	8.06	0.44	2.57e-14	Inflammatory bowel disease;
CESC	cis	rs7666738	0.830	rs1349757	chr4:99058763	C/G	cg05340658	chr4:99064831	C4orf37	0.81	12.43	0.61	3.07e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs8092503	1.000	rs11152003	chr18:52476469	A/G	cg12377874	chr18:52495404	RAB27B	0.38	6.27	0.36	1.46e-9	Childhood body mass index;
CESC	cis	rs17818399	0.533	rs4384837	chr2:46789514	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.41	5.3	0.31	2.44e-7	Height;
CESC	cis	rs11098499	0.863	rs3822194	chr4:120471648	A/G	cg09307838	chr4:120376055	NA	0.9	12.48	0.61	1.95e-28	Corneal astigmatism;
CESC	cis	rs9359856	0.564	rs72915946	chr6:90447924	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.61	-5.59	-0.32	5.75e-8	Bipolar disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21521250	chr18:43753889	C18orf25	0.53	6.02	0.35	5.8e-9	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.830	rs11725477	chr4:98803266	G/T	cg24818145	chr4:99064322	C4orf37	0.4	5.18	0.3	4.34e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1801251	1.000	rs283469	chr2:233656997	G/T	cg08000102	chr2:233561755	GIGYF2	0.66	9.49	0.5	1.46e-18	Coronary artery disease;
CESC	cis	rs6120849	0.754	rs6120790	chr20:33599090	A/T	cg06115741	chr20:33292138	TP53INP2	0.53	5.11	0.3	6.15e-7	Protein C levels;
CESC	cis	rs2070488	0.766	rs6808093	chr3:38498160	T/C	cg24069376	chr3:38537580	EXOG	0.33	5.59	0.32	5.58e-8	Electrocardiographic conduction measures;
CESC	cis	rs4242434	0.854	rs4872007	chr8:22538879	G/A	cg03733263	chr8:22462867	KIAA1967	-0.94	-13.23	-0.63	5.15e-31	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CESC	cis	rs9818758	0.607	rs67060340	chr3:48915321	C/T	cg00383909	chr3:49044727	WDR6	0.9	6.78	0.38	7.86e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CESC	cis	rs12900413	0.687	rs13343248	chr15:90311226	A/T	cg24249390	chr15:90295951	MESP1	-0.4	-5.5	-0.32	9.05e-8	Coronary artery aneurysm in Kawasaki disease;
CESC	cis	rs11166629	1.000	rs2315838	chr8:135645968	C/T	cg27224718	chr8:135614730	ZFAT	0.49	6.3	0.36	1.26e-9	Smoking quantity;
CESC	cis	rs6460942	0.555	rs7803268	chr7:12306793	G/A	cg10578991	chr7:12443926	VWDE	-0.59	-6.16	-0.35	2.63e-9	Coronary artery disease;
CESC	cis	rs7811142	1.000	rs66632384	chr7:100018904	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.08	10.67	0.55	2.41e-22	Platelet count;
CESC	cis	rs40363	0.645	rs6501177	chr16:3523681	C/T	cg05754148	chr16:3507555	NAT15	0.57	8.57	0.47	8.86e-16	Tuberculosis;
CESC	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg07157834	chr1:205819609	PM20D1	0.72	11.05	0.56	1.35e-23	Menarche (age at onset);
CESC	trans	rs650950	0.528	rs646660	chr11:35528452	C/T	cg19586661	chr11:66079705	NA	0.45	6.13	0.35	3.11e-9	Bronchopulmonary dysplasia;
CESC	cis	rs4909189	1.000	rs62493649	chr7:158135556	C/G	cg06219351	chr7:158114137	PTPRN2	-0.6	-8.1	-0.45	2e-14	Response to amphetamines;
CESC	cis	rs2011503	1.000	rs45631651	chr19:19638743	A/G	cg11584989	chr19:19387371	SF4	0.61	7.03	0.4	1.79e-11	Bipolar disorder;
CESC	cis	rs2839186	0.933	rs4818832	chr21:47708634	C/T	cg10351095	chr21:47802916	PCNT	-0.5	-6.8	-0.39	7.02e-11	Testicular germ cell tumor;
CESC	cis	rs2839186	0.706	rs2839188	chr21:47692798	C/T	cg13012494	chr21:47604986	C21orf56	0.45	5.64	0.33	4.32e-8	Testicular germ cell tumor;
CESC	cis	rs61008539	0.893	rs11765528	chr7:861952	C/T	cg05535760	chr7:792225	HEATR2	-0.39	-5.03	-0.3	9.07e-7	Perceived unattractiveness to mosquitoes;
CESC	cis	rs2204008	0.522	rs117743143	chr12:38030824	C/T	cg26384229	chr12:38710491	ALG10B	0.54	7.63	0.42	4.16e-13	Bladder cancer;
CESC	cis	rs1878931	0.501	rs28735976	chr16:3418419	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.77	10.42	0.54	1.58e-21	Body mass index (adult);
CESC	cis	rs7605827	0.930	rs11893272	chr2:15613796	C/T	cg19274914	chr2:15703543	NA	0.38	6.75	0.38	9.33e-11	Educational attainment (years of education);
CESC	cis	rs7923609	0.967	rs2393966	chr10:65134814	T/G	cg01631684	chr10:65280961	REEP3	-0.42	-5.18	-0.3	4.35e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7527798	0.592	rs6657161	chr1:207847128	C/T	cg21110645	chr1:207815933	NA	-0.33	-5.63	-0.33	4.66e-8	Erythrocyte sedimentation rate;
CESC	cis	rs72627123	0.656	rs4646864	chr14:74526703	G/A	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.78	5.36	0.31	1.81e-7	Morning vs. evening chronotype;
CESC	cis	rs2735413	0.875	rs8053987	chr16:78084834	G/A	cg04733911	chr16:78082701	NA	0.54	9.15	0.49	1.57e-17	Systolic blood pressure (alcohol consumption interaction);
CESC	cis	rs7208859	0.673	rs450585	chr17:28951039	G/A	cg17105886	chr17:28927953	LRRC37B2	0.61	5.44	0.32	1.19e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs911555	0.692	rs7145753	chr14:103866100	G/A	cg12935359	chr14:103987150	CKB	0.59	8.63	0.47	5.97e-16	Intelligence (multi-trait analysis);
CESC	cis	rs3733585	0.699	rs12498956	chr4:9950705	G/T	cg02734326	chr4:10020555	SLC2A9	-0.4	-5.68	-0.33	3.49e-8	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.6	6.69	0.38	1.3e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs72634258	0.842	rs6577463	chr1:8169485	T/G	cg00042356	chr1:8021962	PARK7	-0.56	-5.99	-0.35	6.97e-9	Inflammatory bowel disease;
CESC	cis	rs258324	0.790	rs2162944	chr16:89717670	G/C	cg04240660	chr16:89714849	CHMP1A	-0.55	-5.3	-0.31	2.39e-7	Height;
CESC	cis	rs35146811	0.807	rs10228764	chr7:99608029	A/G	cg14163444	chr7:99595348	NA	-0.39	-5.14	-0.3	5.32e-7	Coronary artery disease;
CESC	cis	rs9549260	0.564	rs7998086	chr13:41268924	T/C	cg21288729	chr13:41239152	FOXO1	0.58	7.43	0.42	1.48e-12	Red blood cell count;
CESC	cis	rs963731	0.579	rs2168042	chr2:39273536	C/T	cg04010122	chr2:39346883	SOS1	-0.68	-5.33	-0.31	2.1e-7	Corticobasal degeneration;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04738447	chr16:708575	WDR90	-0.58	-6.31	-0.36	1.14e-9	Gut microbiome composition (summer);
CESC	cis	rs1707322	0.896	rs946528	chr1:46485562	C/T	cg03146154	chr1:46216737	IPP	-0.71	-9.65	-0.51	4.43e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs3820068	0.603	rs59558854	chr1:15971399	T/G	cg17385448	chr1:15911702	AGMAT	0.42	6.75	0.38	9.26e-11	Systolic blood pressure;
CESC	cis	rs514406	0.679	rs61768344	chr1:53229274	G/A	cg16325326	chr1:53192061	ZYG11B	-0.54	-8.02	-0.44	3.49e-14	Monocyte count;
CESC	cis	rs2228479	0.850	rs17226666	chr16:89835401	G/A	cg14709524	chr16:89940631	TCF25	0.91	6.74	0.38	1e-10	Skin colour saturation;
CESC	cis	rs2836974	0.899	rs35774464	chr21:40580169	G/A	cg11644478	chr21:40555479	PSMG1	0.96	13.84	0.65	3.74e-33	Cognitive function;
CESC	cis	rs7107174	1.000	rs2292573	chr11:78053139	A/G	cg02023728	chr11:77925099	USP35	0.38	5.4	0.31	1.47e-7	Testicular germ cell tumor;
CESC	cis	rs684232	0.602	rs331014	chr17:532103	C/T	cg12384639	chr17:618140	VPS53	0.41	5.31	0.31	2.36e-7	Prostate cancer;
CESC	cis	rs9322193	0.962	rs10452626	chr6:150088617	T/C	cg05861140	chr6:150128134	PCMT1	-0.38	-5.43	-0.32	1.29e-7	Lung cancer;
CESC	cis	rs72781680	0.898	rs72780123	chr2:23996009	G/A	cg08917208	chr2:24149416	ATAD2B	0.95	8.71	0.47	3.45e-16	Lymphocyte counts;
CESC	cis	rs2242194	0.816	rs6671688	chr1:154994265	T/C	cg09359103	chr1:154839909	KCNN3	-0.41	-6.62	-0.38	2.01e-10	Schizophrenia;
CESC	cis	rs9937943	0.667	rs35126294	chr16:74651005	T/C	cg01733217	chr16:74700730	RFWD3	0.6	5.64	0.33	4.45e-8	Neutrophil percentage of white cells;
CESC	cis	rs1552244	0.572	rs41464050	chr3:10158393	A/G	cg00149659	chr3:10157352	C3orf10	0.95	11.38	0.57	1.05e-24	Alzheimer's disease;
CESC	cis	rs3733585	0.673	rs6840802	chr4:9965633	C/G	cg00071950	chr4:10020882	SLC2A9	0.73	11.3	0.57	1.93e-24	Cleft plate (environmental tobacco smoke interaction);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg09744376	chr3:53080176	SFMBT1	-0.43	-6.05	-0.35	4.83e-9	Fibrinogen levels;
CESC	cis	rs7666738	0.830	rs13139078	chr4:99020774	C/T	cg05340658	chr4:99064831	C4orf37	0.82	12.99	0.62	3.34e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1862618	0.525	rs832403	chr5:56265992	G/T	cg18230493	chr5:56204884	C5orf35	0.68	7.88	0.44	8.77e-14	Initial pursuit acceleration;
CESC	cis	rs7618915	0.524	rs35249778	chr3:52661640	G/C	cg05564831	chr3:52568323	NT5DC2	0.44	6.83	0.39	5.68e-11	Bipolar disorder;
CESC	cis	rs3540	0.554	rs12443252	chr15:91064690	C/T	cg10434728	chr15:90938212	IQGAP1	-0.41	-7.07	-0.4	1.37e-11	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	trans	rs11764590	0.715	rs11760737	chr7:2104055	T/C	cg11693508	chr17:37793320	STARD3	0.67	6.38	0.36	8.07e-10	Neuroticism;
CESC	cis	rs6952808	0.756	rs12537348	chr7:1948172	C/G	cg08027265	chr7:2291960	NA	-0.33	-5.06	-0.3	7.8e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs13118159	0.550	rs4974614	chr4:1373489	A/G	cg01939980	chr4:1354348	KIAA1530	0.43	5.08	0.3	7e-7	Longevity;
CESC	cis	rs1421811	0.606	rs981001	chr5:32721545	G/A	cg16267343	chr5:32710456	NPR3	0.54	5.85	0.34	1.42e-8	Blood pressure;
CESC	cis	rs5758659	0.652	rs5758553	chr22:42431429	G/A	cg05082376	chr22:42548792	NA	-0.38	-5.59	-0.32	5.78e-8	Cognitive function;
CESC	cis	rs1005277	0.540	rs1987431	chr10:37988887	T/C	cg00409905	chr10:38381863	ZNF37A	-0.51	-7.12	-0.4	9.95e-12	Extrinsic epigenetic age acceleration;
CESC	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg02725872	chr8:58115012	NA	-0.41	-5.82	-0.34	1.69e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs875971	1.000	rs11974264	chr7:65647582	C/G	cg18876405	chr7:65276391	NA	-0.52	-7.03	-0.4	1.71e-11	Aortic root size;
CESC	cis	rs6933660	0.800	rs9383900	chr6:151782816	A/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.53	-7.07	-0.4	1.35e-11	Menarche (age at onset);
CESC	cis	rs1552244	0.872	rs35988239	chr3:10074145	G/T	cg00149659	chr3:10157352	C3orf10	0.63	6.44	0.37	5.66e-10	Alzheimer's disease;
CESC	cis	rs7762018	1.000	rs73242927	chr6:170129573	T/A	cg05834625	chr6:170176447	C6orf70	0.66	7.76	0.43	1.9e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs8180040	0.654	rs11714373	chr3:47214817	G/A	cg27129171	chr3:47204927	SETD2	-0.68	-9.97	-0.52	4.2e-20	Colorectal cancer;
CESC	cis	rs9616064	0.506	rs2073275	chr22:47070432	G/C	cg05621596	chr22:47072043	GRAMD4	-0.74	-11.13	-0.56	7.47e-24	Urate levels in obese individuals;
CESC	cis	rs2658782	0.756	rs3019223	chr11:93084182	G/A	cg15737290	chr11:93063684	CCDC67	0.59	7.43	0.42	1.52e-12	Pulmonary function decline;
CESC	cis	rs875971	0.862	rs4718330	chr7:65715243	G/A	cg11764359	chr7:65958608	NA	-0.78	-11.64	-0.58	1.45e-25	Aortic root size;
CESC	cis	rs8072100	0.713	rs8074451	chr17:45477573	C/T	cg08085267	chr17:45401833	C17orf57	-0.53	-6.64	-0.38	1.77e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs3768617	0.565	rs10752901	chr1:183089327	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.87	13.49	0.64	6.22e-32	Fuchs's corneal dystrophy;
CESC	cis	rs9303401	0.614	rs8081058	chr17:57160513	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.92	11.49	0.58	4.47e-25	Cognitive test performance;
CESC	cis	rs796364	0.789	rs176008	chr2:200814720	A/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.89	8.87	0.48	1.08e-16	Schizophrenia;
CESC	cis	rs12220238	1.000	rs10824098	chr10:75943579	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.6	5.75	0.33	2.43e-8	Soluble interleukin-2 receptor subunit alpha;
CESC	cis	rs875971	0.830	rs6950137	chr7:65976610	G/A	cg11764359	chr7:65958608	NA	0.81	11.74	0.58	6.73e-26	Aortic root size;
CESC	cis	rs898097	0.841	rs8180	chr17:80901036	C/G	cg05255149	chr17:80675120	FN3KRP	0.45	5.39	0.31	1.58e-7	Breast cancer;
CESC	cis	rs2228479	0.867	rs2270459	chr16:89979851	A/C	cg06558623	chr16:89946397	TCF25	-0.87	-8.01	-0.44	3.6e-14	Skin colour saturation;
CESC	cis	rs6691722	0.503	rs4140519	chr1:24708304	C/T	cg02336364	chr1:24764700	NIPAL3	0.32	6.55	0.37	2.91e-10	Response to interferon beta in multiple sclerosis;
CESC	cis	rs7618915	0.501	rs62253740	chr3:52684128	A/T	cg07507251	chr3:52567010	NT5DC2	0.32	5.56	0.32	6.75e-8	Bipolar disorder;
CESC	cis	rs870825	0.616	rs7674952	chr4:185622327	A/C	cg04058563	chr4:185651563	MLF1IP	0.64	7.05	0.4	1.59e-11	Blood protein levels;
CESC	cis	rs854765	0.647	rs854767	chr17:18018263	A/C	cg16928487	chr17:17741425	SREBF1	0.45	7.11	0.4	1.07e-11	Total body bone mineral density;
CESC	cis	rs7520050	0.931	rs6688365	chr1:46329884	G/C	cg24296786	chr1:45957014	TESK2	0.43	5.41	0.32	1.4e-7	Red blood cell count;Reticulocyte count;
CESC	trans	rs12891047	1.000	rs7160196	chr14:68265744	C/T	cg12499123	chr5:10250085	CCT5;FAM173B	0.51	6.06	0.35	4.6e-9	Amyotrophic lateral sclerosis (sporadic);
CESC	trans	rs1814175	0.645	rs1721996	chr11:49915527	G/A	cg15704280	chr7:45808275	SEPT13	-1.01	-18.94	-0.76	3.64e-51	Height;
CESC	cis	rs6952808	0.692	rs6950627	chr7:2086672	C/T	cg08027265	chr7:2291960	NA	-0.39	-5.87	-0.34	1.29e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs67311347	1.000	rs9842564	chr3:40405810	A/G	cg24209194	chr3:40518798	ZNF619	-0.45	-5.81	-0.34	1.76e-8	Renal cell carcinoma;
CESC	cis	rs1218582	0.774	rs12036859	chr1:154859940	A/C	cg09359103	chr1:154839909	KCNN3	0.66	12.27	0.6	1.03e-27	Prostate cancer;
CESC	cis	rs6964587	1.000	rs10245095	chr7:91710845	A/G	cg17063962	chr7:91808500	NA	0.55	7.68	0.43	3.06e-13	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03779880	chr21:44395779	PKNOX1	0.61	7.12	0.4	1.01e-11	Gut microbiome composition (summer);
CESC	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg24846343	chr22:24311635	DDTL	-0.48	-7.69	-0.43	2.98e-13	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs4805272	0.512	rs4805279	chr19:29336966	A/G	cg12756686	chr19:29218302	NA	0.41	5.32	0.31	2.17e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
CESC	cis	rs11098499	0.754	rs878376	chr4:120237702	G/A	cg09307838	chr4:120376055	NA	0.81	10.96	0.56	2.61e-23	Corneal astigmatism;
CESC	cis	rs9611565	0.512	rs715498	chr22:42148467	G/A	cg17376030	chr22:41985996	PMM1	-0.78	-8.23	-0.45	8.32e-15	Vitiligo;
CESC	cis	rs6860806	0.661	rs6871350	chr5:131580220	A/G	cg09877947	chr5:131593287	PDLIM4	0.47	6.15	0.35	2.86e-9	Breast cancer;
CESC	cis	rs796364	0.806	rs74266490	chr2:201005995	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.72	-6.48	-0.37	4.47e-10	Schizophrenia;
CESC	trans	rs208520	0.633	rs7738469	chr6:66807446	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.99	-12.78	-0.62	1.78e-29	Exhaled nitric oxide output;
CESC	cis	rs2070488	0.931	rs6599212	chr3:38558906	T/C	cg24069376	chr3:38537580	EXOG	-0.46	-8.45	-0.46	1.91e-15	Electrocardiographic conduction measures;
CESC	cis	rs10256972	0.621	rs10951594	chr7:1088607	C/G	cg23978390	chr7:1156363	C7orf50	0.47	6.41	0.37	6.75e-10	Longevity;Endometriosis;
CESC	cis	rs1691799	0.899	rs1168329	chr12:66731864	C/A	cg16791601	chr12:66731901	HELB	-0.79	-14.29	-0.66	9.69e-35	White blood cell count (basophil);
CESC	cis	rs60871478	1.000	rs7795258	chr7:795227	A/G	cg05535760	chr7:792225	HEATR2	0.85	10.7	0.55	1.91e-22	Cerebrospinal P-tau181p levels;
CESC	cis	rs9300255	0.550	rs10772997	chr12:123719880	C/A	cg19016782	chr12:123741754	C12orf65	-0.36	-5.3	-0.31	2.45e-7	Neutrophil percentage of white cells;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg03353863	chr19:52618714	ZNF616	0.48	6.04	0.35	5.14e-9	Fibrinogen levels;
CESC	cis	rs9291683	0.588	rs34501273	chr4:9996996	C/T	cg11266682	chr4:10021025	SLC2A9	0.66	13.36	0.63	1.79e-31	Bone mineral density;
CESC	cis	rs7666738	0.830	rs62321598	chr4:99014237	C/T	cg18180107	chr4:99064573	C4orf37	0.4	5.3	0.31	2.48e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7937682	0.889	rs10749984	chr11:111492861	T/C	cg09085632	chr11:111637200	PPP2R1B	-0.95	-14.6	-0.67	8.26e-36	Primary sclerosing cholangitis;
CESC	cis	rs2836974	0.965	rs6517538	chr21:40656242	C/T	cg27266027	chr21:40555129	PSMG1	0.43	5.11	0.3	6.04e-7	Cognitive function;
CESC	cis	rs3015497	0.603	rs2356453	chr14:51049648	C/T	cg26011998	chr14:51135199	SAV1	-0.46	-5.25	-0.31	3.2e-7	Mean platelet volume;
CESC	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg21724239	chr8:58056113	NA	0.6	5.56	0.32	6.59e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs115344852	0.598	rs2191035	chr6:28434943	A/G	cg14547644	chr6:28411285	ZSCAN23	-0.32	-5.07	-0.3	7.31e-7	Epithelial ovarian cancer;
CESC	cis	rs28386778	0.734	rs12946669	chr17:62006007	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.95	14.87	0.67	9.16e-37	Prudent dietary pattern;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg10044839	chr6:13487863	GFOD1;C6orf114	-0.51	-6.4	-0.37	7.07e-10	Ulcerative colitis;
CESC	cis	rs698813	0.763	rs786615	chr2:44590608	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	5.9	0.34	1.1e-8	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
CESC	cis	rs778371	0.522	rs10205801	chr2:233597196	G/A	cg08000102	chr2:233561755	GIGYF2	0.8	13.08	0.63	1.72e-30	Schizophrenia;
CESC	cis	rs4665809	1.000	rs6546728	chr2:26276531	G/C	cg25036284	chr2:26402008	FAM59B	-0.74	-8.4	-0.46	2.72e-15	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23540748	chr19:8455165	RAB11B	0.56	6.27	0.36	1.44e-9	Gut microbiome composition (summer);
CESC	cis	rs826838	0.967	rs11183022	chr12:38652519	G/A	cg13010199	chr12:38710504	ALG10B	0.59	8.31	0.45	4.93e-15	Heart rate;
CESC	trans	rs61931739	0.500	rs11053189	chr12:34433455	G/A	cg13010199	chr12:38710504	ALG10B	0.49	6.3	0.36	1.24e-9	Morning vs. evening chronotype;
CESC	cis	rs853679	0.517	rs1904840	chr6:28108232	C/T	cg08968635	chr6:28129556	ZNF389	0.41	5.53	0.32	7.61e-8	Depression;
CESC	cis	rs7552404	0.924	rs1611823	chr1:76221706	T/G	cg03433033	chr1:76189801	ACADM	0.71	9.78	0.52	1.68e-19	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs1003719	0.715	rs2835639	chr21:38537016	G/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.59	-7.98	-0.44	4.49e-14	Eye color traits;
CESC	trans	rs7839040	0.698	rs7825067	chr8:82929707	T/C	cg14472086	chr9:107730925	NA	-0.48	-6.33	-0.36	1.03e-9	Response to methotrexate in juvenile idiopathic arthritis;
CESC	cis	rs35306767	0.951	rs55742421	chr10:961037	A/C	cg26597838	chr10:835615	NA	0.98	10.69	0.55	2.06e-22	Eosinophil percentage of granulocytes;
CESC	cis	rs7208859	0.623	rs9897728	chr17:29108804	A/G	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.17e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs1799949	0.965	rs8176193	chr17:41231516	C/T	cg05368731	chr17:41323189	NBR1	0.78	11.15	0.57	6.28e-24	Menopause (age at onset);
CESC	cis	rs7193541	0.684	rs9929496	chr16:74668473	G/A	cg05580060	chr16:74700937	RFWD3	-0.48	-6.26	-0.36	1.57e-9	Multiple myeloma;
CESC	cis	rs9611565	0.729	rs505533	chr22:41864216	A/C	cg06634786	chr22:41940651	POLR3H	0.45	5.31	0.31	2.3e-7	Vitiligo;
CESC	cis	rs2243480	1.000	rs35735127	chr7:65300423	G/T	cg18252515	chr7:66147081	NA	-1.01	-9.72	-0.51	2.6e-19	Diabetic kidney disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00861839	chr18:23670297	SS18	-0.55	-6.27	-0.36	1.48e-9	Gut microbiome composition (summer);
CESC	cis	rs911555	0.655	rs10141157	chr14:104018105	T/C	cg24130564	chr14:104152367	KLC1	-0.58	-8.27	-0.45	6.5e-15	Intelligence (multi-trait analysis);
CESC	cis	rs9787249	0.957	rs11206754	chr1:40216234	A/G	cg19912559	chr1:40204330	PPIE	0.44	6.76	0.38	8.9e-11	Blood protein levels;
CESC	cis	rs738322	0.935	rs133014	chr22:38571087	T/G	cg25457927	chr22:38595422	NA	-0.3	-5.46	-0.32	1.1e-7	Cutaneous nevi;
CESC	cis	rs4919044	0.688	rs59539045	chr10:94776594	C/A	cg16508068	chr10:94451736	HHEX	-0.5	-5.49	-0.32	9.61e-8	Coronary artery disease;
CESC	cis	rs9549367	0.789	rs2302757	chr13:113909339	A/G	cg00898013	chr13:113819073	PROZ	-0.56	-7.74	-0.43	2.08e-13	Platelet distribution width;
CESC	trans	rs877282	0.755	rs2486579	chr10:785647	G/A	cg22713356	chr15:30763199	NA	1.09	11.81	0.59	3.82e-26	Uric acid levels;
CESC	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg06873352	chr17:61820015	STRADA	0.71	12.16	0.6	2.5e-27	Prudent dietary pattern;
CESC	trans	rs89107	0.549	rs4945623	chr6:118980556	G/C	cg15017278	chr16:127449	MPG	-0.32	-6.0	-0.35	6.53e-9	Cardiac structure and function;
CESC	cis	rs7412746	0.634	rs72704658	chr1:150833010	T/C	cg09365446	chr1:150670422	GOLPH3L	0.39	5.13	0.3	5.7e-7	Melanoma;
CESC	cis	rs2294693	0.945	rs9369252	chr6:40986028	C/T	cg14418226	chr6:40996092	UNC5CL	-0.57	-6.67	-0.38	1.48e-10	Gastric cancer;Non-cardia gastric cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14136810	chr15:40213326	GPR176	0.55	6.52	0.37	3.49e-10	Gut microbiome composition (summer);
CESC	cis	rs7317038	0.745	rs75590443	chr13:114015421	A/T	cg24344662	chr13:114018021	GRTP1	-0.5	-6.19	-0.36	2.27e-9	Mean platelet volume;
CESC	cis	rs4919087	0.923	rs11189037	chr10:98974707	C/G	cg25902810	chr10:99078978	FRAT1	0.67	9.67	0.51	3.88e-19	Monocyte count;
CESC	cis	rs7659604	0.539	rs3217771	chr4:122739483	G/A	cg06713675	chr4:122721982	EXOSC9	-0.51	-7.02	-0.4	1.9e-11	Type 2 diabetes;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg05205664	chr11:73694566	UCP2	-0.46	-6.11	-0.35	3.47e-9	Asthma;
CESC	cis	rs7829975	0.502	rs7820738	chr8:8702607	C/G	cg17143192	chr8:8559678	CLDN23	-0.42	-5.03	-0.3	9.02e-7	Mood instability;
CESC	trans	rs1223629	1.000	rs11187800	chr10:95936892	A/G	cg16346422	chr11:2920819	SLC22A18;SLC22A18AS	0.67	6.02	0.35	5.67e-9	Glucose homeostasis traits;
CESC	cis	rs1799949	1.000	rs8176289	chr17:41206056	T/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.41	5.6	0.33	5.36e-8	Menopause (age at onset);
CESC	cis	rs7208859	0.673	rs11650305	chr17:29229361	A/C	cg19761014	chr17:28927070	LRRC37B2	0.64	5.32	0.31	2.2e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs6073597	1.000	rs6031980	chr20:43714384	C/T	cg26270411	chr20:43514327	YWHAB	-0.35	-5.08	-0.3	7.27e-7	Positive affect;
CESC	cis	rs116095464	0.558	rs9312977	chr5:221916	G/C	cg22496380	chr5:211416	CCDC127	-0.72	-8.57	-0.47	8.59e-16	Breast cancer;
CESC	cis	rs3768617	0.510	rs6666259	chr1:183102855	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.88	14.27	0.66	1.19e-34	Fuchs's corneal dystrophy;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg14405528	chr22:47372700	TBC1D22A	0.49	6.57	0.37	2.59e-10	Fibrinogen levels;
CESC	cis	rs13256369	1.000	rs10103769	chr8:8573036	G/T	cg17143192	chr8:8559678	CLDN23	0.74	8.83	0.48	1.51e-16	Obesity-related traits;
CESC	cis	rs9549367	0.774	rs9549696	chr13:113875062	C/T	cg18105134	chr13:113819100	PROZ	-0.69	-8.91	-0.48	8.28e-17	Platelet distribution width;
CESC	cis	rs1775715	0.870	rs1615256	chr10:32254101	T/C	cg04359828	chr10:32216031	ARHGAP12	0.35	5.17	0.3	4.72e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs8114671	0.662	rs3761143	chr20:33545745	C/T	cg07148914	chr20:33460835	GGT7	0.42	5.38	0.31	1.64e-7	Height;
CESC	cis	rs2718058	0.639	rs2597270	chr7:37762014	A/G	cg15028436	chr7:37888078	TXNDC3	-0.44	-6.24	-0.36	1.69e-9	Alzheimer's disease (late onset);
CESC	cis	rs425277	1.000	rs262654	chr1:2089526	G/A	cg16545954	chr1:2118288	C1orf86	0.33	5.52	0.32	7.93e-8	Height;
CESC	cis	rs3931020	0.508	rs4145871	chr1:75218704	C/T	cg10128416	chr1:75198403	TYW3;CRYZ	0.44	5.34	0.31	1.97e-7	Resistin levels;
CESC	cis	rs8042849	1	rs8042849	chr15:78817929	C/T	cg18825076	chr15:78729989	IREB2	0.43	5.58	0.32	5.91e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Parental lifespan;Post bronchodilator FEV1/FVC ratio in COPD;
CESC	cis	rs7412746	0.611	rs1889741	chr1:150869045	T/C	cg22823121	chr1:150693482	HORMAD1	0.36	5.1	0.3	6.36e-7	Melanoma;
CESC	cis	rs9614461	0.826	rs9614649	chr22:45746097	C/A	cg01808030	chr22:45809952	RIBC2;SMC1B	0.67	7.24	0.41	4.83e-12	Tonsillectomy;
CESC	trans	rs7824557	0.527	rs4631425	chr8:11239054	C/T	cg06636001	chr8:8085503	FLJ10661	-0.48	-6.23	-0.36	1.83e-9	Retinal vascular caliber;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07580707	chr3:14220061	XPC;LSM3	0.56	6.71	0.38	1.19e-10	Gut microbiome composition (summer);
CESC	cis	rs12476592	0.571	rs10171223	chr2:63687700	A/G	cg17519650	chr2:63277830	OTX1	-0.48	-5.41	-0.32	1.39e-7	Childhood ear infection;
CESC	cis	rs6502050	0.835	rs8077926	chr17:80117315	C/A	cg23985595	chr17:80112537	CCDC57	-0.41	-6.47	-0.37	4.81e-10	Life satisfaction;
CESC	cis	rs739401	0.611	rs450817	chr11:3056712	A/G	cg05729581	chr11:3078854	CARS	-0.38	-5.08	-0.3	7.26e-7	Longevity;
CESC	cis	rs3105593	0.575	rs3098174	chr15:50778853	C/T	cg08437265	chr15:50716283	USP8	0.49	6.41	0.37	6.65e-10	QT interval;
CESC	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg04025307	chr7:1156635	C7orf50	0.5	8.5	0.46	1.36e-15	Longevity;Endometriosis;
CESC	cis	rs7680126	0.596	rs10020887	chr4:10140751	C/G	cg11266682	chr4:10021025	SLC2A9	-0.46	-5.95	-0.34	8.27e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	cis	rs4474465	0.688	rs4275650	chr11:78284822	T/A	cg27205649	chr11:78285834	NARS2	0.47	6.17	0.35	2.6e-9	Alzheimer's disease (survival time);
CESC	cis	rs4812048	0.689	rs151357	chr20:57609055	A/G	cg14073986	chr20:57617431	SLMO2	0.54	5.18	0.3	4.3e-7	Mean platelet volume;
CESC	cis	rs4594175	1.000	rs4594175	chr14:51606541	C/A	cg23942311	chr14:51606299	NA	0.39	5.96	0.34	8.22e-9	Cancer;
CESC	cis	rs977987	0.931	rs8057084	chr16:75492706	G/T	cg03315344	chr16:75512273	CHST6	-0.52	-7.49	-0.42	1.03e-12	Dupuytren's disease;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg06149389	chr14:77499875	NA	0.48	6.04	0.35	5.08e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs7659604	0.540	rs10004284	chr4:122699222	A/T	cg19671926	chr4:122722719	EXOSC9	0.66	9.02	0.48	3.96e-17	Type 2 diabetes;
CESC	cis	rs1862618	0.573	rs1550821	chr5:56242323	C/T	cg24531977	chr5:56204891	C5orf35	1.0	13.11	0.63	1.35e-30	Initial pursuit acceleration;
CESC	cis	rs916888	0.779	rs430685	chr17:44859148	T/C	cg14517863	chr17:44321492	NA	-0.4	-5.17	-0.3	4.56e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs6089584	0.566	rs6061972	chr20:60610245	C/T	cg23463467	chr20:60627584	TAF4	0.35	5.06	0.3	7.99e-7	Body mass index;
CESC	cis	rs727563	0.636	rs2413653	chr22:42106996	T/C	cg06634786	chr22:41940651	POLR3H	0.67	6.72	0.38	1.12e-10	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs4604732	0.642	rs10925047	chr1:247640143	A/C	cg12758973	chr1:247694275	LOC148824;OR2C3	0.35	5.11	0.3	6.11e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs727563	0.562	rs5758458	chr22:42154132	G/A	cg06634786	chr22:41940651	POLR3H	0.7	7.03	0.4	1.8e-11	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs10504229	0.683	rs16921843	chr8:58113338	T/C	cg24829409	chr8:58192753	C8orf71	-0.59	-7.32	-0.41	2.94e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs7666738	0.800	rs28427190	chr4:98989106	A/G	cg17366294	chr4:99064904	C4orf37	0.6	8.59	0.47	7.62e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs367943	0.799	rs10478135	chr5:112976905	C/A	cg12552261	chr5:112820674	MCC	0.54	6.14	0.35	2.99e-9	Type 2 diabetes;
CESC	cis	rs1448094	0.717	rs7137122	chr12:86290702	T/C	cg02569458	chr12:86230093	RASSF9	0.38	5.49	0.32	9.45e-8	Major depressive disorder;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg06583696	chr2:26101536	ASXL2	-0.49	-7.15	-0.4	8.32e-12	Gambling;
CESC	cis	rs72634258	0.554	rs12723500	chr1:7857374	G/C	cg26816564	chr1:7831052	VAMP3	0.68	6.12	0.35	3.32e-9	Inflammatory bowel disease;
CESC	cis	rs208515	0.556	rs12214562	chr6:66681011	T/A	cg07460842	chr6:66804631	NA	0.86	10.87	0.56	5.19e-23	Exhaled nitric oxide levels;
CESC	cis	rs2276314	0.857	rs6507157	chr18:33631703	A/C	cg05985134	chr18:33552581	C18orf21	0.62	7.16	0.4	8.06e-12	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs2228479	0.850	rs62052711	chr16:89855100	C/A	cg06558623	chr16:89946397	TCF25	1.18	9.44	0.5	1.97e-18	Skin colour saturation;
CESC	cis	rs7953249	0.564	rs1183910	chr12:121420807	G/A	cg25281562	chr12:121454272	C12orf43	0.55	6.58	0.37	2.53e-10	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
CESC	cis	rs7666738	0.830	rs1426666	chr4:99030887	A/G	cg05340658	chr4:99064831	C4orf37	0.83	13.1	0.63	1.43e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6089584	0.566	rs2181589	chr20:60622817	C/T	cg23463467	chr20:60627584	TAF4	-0.35	-5.1	-0.3	6.56e-7	Body mass index;
CESC	cis	rs748404	0.578	rs576557	chr15:43597737	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.63	8.4	0.46	2.68e-15	Lung cancer;
CESC	cis	rs9611565	0.512	rs132767	chr22:42009520	C/T	cg17376030	chr22:41985996	PMM1	0.74	8.34	0.46	4.24e-15	Vitiligo;
CESC	cis	rs1862618	0.802	rs2591949	chr5:56132627	T/C	cg22800045	chr5:56110881	MAP3K1	0.83	9.98	0.52	3.92e-20	Initial pursuit acceleration;
CESC	cis	rs7811142	1.000	rs60844404	chr7:100080474	A/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.87	9.04	0.49	3.44e-17	Platelet count;
CESC	cis	rs2243480	1.000	rs316317	chr7:65613637	G/T	cg18252515	chr7:66147081	NA	-1.41	-14.48	-0.66	2.11e-35	Diabetic kidney disease;
CESC	cis	rs4925325	0.955	rs1776262	chr20:60516023	G/T	cg18761221	chr20:60518478	NA	-0.53	-7.68	-0.43	3.04e-13	Obesity-related traits;
CESC	cis	rs9926296	0.572	rs2079671	chr16:89884981	T/C	cg27121462	chr16:89883253	FANCA	0.62	8.02	0.44	3.5e-14	Vitiligo;
CESC	cis	rs12142240	0.698	rs6703374	chr1:46862332	C/G	cg10495392	chr1:46806563	NSUN4	0.56	6.17	0.35	2.61e-9	Menopause (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25959527	chr3:195163920	ACAP2	0.58	6.21	0.36	2.05e-9	Gut microbiome composition (summer);
CESC	cis	rs3793683	0.965	rs3829131	chr10:134564627	A/G	cg26818010	chr10:134567672	INPP5A	0.51	6.3	0.36	1.2e-9	Migraine;
CESC	cis	rs67311347	0.956	rs9817233	chr3:40425618	G/T	cg09455208	chr3:40491958	NA	0.49	8.1	0.45	1.99e-14	Renal cell carcinoma;
CESC	cis	rs7524258	0.835	rs7543228	chr1:7306538	G/C	cg07173049	chr1:7289937	CAMTA1	0.36	5.62	0.33	4.83e-8	Tourette's syndrome or obsessive-compulsive disorder;
CESC	cis	rs7666738	0.753	rs10004827	chr4:99037953	A/C	cg03676636	chr4:99064102	C4orf37	0.33	5.12	0.3	6.01e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6089829	0.962	rs6062777	chr20:61663748	G/A	cg08564027	chr20:61660810	NA	0.9	15.42	0.69	9.97e-39	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs208520	0.770	rs2153941	chr6:66885521	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.92	-11.49	-0.58	4.62e-25	Exhaled nitric oxide output;
CESC	cis	rs881375	0.715	rs10760119	chr9:123646060	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	6.09	0.35	4.05e-9	Rheumatoid arthritis;
CESC	cis	rs2576037	0.899	rs7233515	chr18:44585955	A/G	cg19077165	chr18:44547161	KATNAL2	-0.49	-6.67	-0.38	1.51e-10	Personality dimensions;
CESC	cis	rs35110281	0.626	rs162389	chr21:44936227	T/C	cg21573476	chr21:45109991	RRP1B	-0.35	-5.15	-0.3	5.01e-7	Mean corpuscular volume;
CESC	cis	rs2204008	0.811	rs2139752	chr12:38370398	C/T	cg13010199	chr12:38710504	ALG10B	0.49	6.26	0.36	1.57e-9	Bladder cancer;
CESC	cis	rs67460515	0.892	rs35100811	chr3:161084046	A/C	cg03342759	chr3:160939853	NMD3	-0.55	-7.74	-0.43	2.15e-13	Parkinson's disease;
CESC	cis	rs763014	0.966	rs4144003	chr16:645968	C/T	cg09263875	chr16:632152	PIGQ	0.68	11.71	0.58	8.63e-26	Height;
CESC	cis	rs514406	0.895	rs1925673	chr1:53326984	T/G	cg08736216	chr1:53307985	ZYG11A	-0.42	-7.0	-0.4	2.05e-11	Monocyte count;
CESC	cis	rs875971	0.862	rs10276077	chr7:65728411	A/G	cg10691866	chr7:65817282	TPST1	0.32	5.36	0.31	1.79e-7	Aortic root size;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg21810621	chr11:1331345	LOC255512;TOLLIP	-0.5	-6.49	-0.37	4.22e-10	Ulcerative colitis;
CESC	trans	rs7938889	0.517	rs505689	chr11:95930072	A/G	cg20372048	chr12:82752172	CCDC59;C12orf26	0.45	5.99	0.35	6.71e-9	Methadone dose in opioid dependence;
CESC	cis	rs7044106	0.791	rs2416798	chr9:123480603	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.33	5.16	0.3	4.84e-7	Hip circumference adjusted for BMI;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16902244	chr1:24117464	LYPLA2	-0.54	-6.47	-0.37	4.78e-10	Gut microbiome composition (summer);
CESC	trans	rs1945213	0.694	rs1384099	chr11:55866040	A/C	cg03929089	chr4:120376271	NA	0.73	6.92	0.39	3.43e-11	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs9640161	0.830	rs17173681	chr7:150059414	A/G	cg10018233	chr7:150070692	REPIN1	-0.37	-5.78	-0.33	2.14e-8	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs9322193	0.923	rs2342765	chr6:150180009	C/G	cg13206674	chr6:150067644	NUP43	0.39	5.34	0.31	2.02e-7	Lung cancer;
CESC	cis	rs228769	0.673	rs375677	chr17:42108974	A/C	cg19774624	chr17:42201019	HDAC5	0.54	6.12	0.35	3.39e-9	Bone mineral density (hip);Bone mineral density (spine);
CESC	cis	rs13108904	0.517	rs13128825	chr4:1334007	G/A	cg13395646	chr4:1353034	KIAA1530	-0.49	-6.32	-0.36	1.08e-9	Obesity-related traits;
CESC	cis	rs4730250	0.707	rs3729877	chr7:106787065	T/G	cg02696742	chr7:106810147	HBP1	0.56	5.3	0.31	2.47e-7	Osteoarthritis;
CESC	cis	rs9611565	0.506	rs4822020	chr22:41700203	C/T	cg06481639	chr22:41940642	POLR3H	-0.52	-5.74	-0.33	2.57e-8	Vitiligo;
CESC	cis	rs3733585	0.673	rs4697914	chr4:9952266	G/A	cg00071950	chr4:10020882	SLC2A9	-0.69	-11.34	-0.57	1.42e-24	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs738322	0.967	rs6001038	chr22:38570585	A/G	cg17652424	chr22:38574118	PLA2G6	-0.34	-6.04	-0.35	5.08e-9	Cutaneous nevi;
CESC	cis	rs362272	0.545	rs3135146	chr4:3307638	C/G	cg08886695	chr4:3369023	RGS12	0.41	5.58	0.32	6e-8	Serum sulfate level;
CESC	cis	rs6580649	0.941	rs6580651	chr12:48429933	A/T	cg05342945	chr12:48394962	COL2A1	0.51	5.87	0.34	1.3e-8	Lung cancer;
CESC	cis	rs6570726	0.935	rs367612	chr6:145828987	A/G	cg23711669	chr6:146136114	FBXO30	0.76	11.31	0.57	1.84e-24	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs11690935	0.851	rs7573003	chr2:172741415	T/A	cg13550731	chr2:172543902	DYNC1I2	-0.84	-12.82	-0.62	1.36e-29	Schizophrenia;
CESC	cis	rs11514810	1.000	rs7812242	chr7:1431747	C/T	cg24899294	chr7:1481343	MICALL2	-0.65	-5.36	-0.31	1.79e-7	Executive inhibition (Stroop WIT and CIT) in attention deficit hyperactivity disorder;
CESC	cis	rs694739	0.536	rs11231740	chr11:64046641	C/T	cg24431193	chr11:63883947	FLRT1;MACROD1	-0.42	-5.8	-0.34	1.89e-8	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CESC	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg11494091	chr17:61959527	GH2	0.73	12.56	0.61	1.04e-28	Prudent dietary pattern;
CESC	cis	rs67478160	0.634	rs2295140	chr14:104216293	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.54	-7.89	-0.44	7.99e-14	Schizophrenia;
CESC	cis	rs1059312	0.932	rs11059916	chr12:129287609	C/A	cg09035930	chr12:129282057	SLC15A4	0.78	10.94	0.56	3.13e-23	Systemic lupus erythematosus;
CESC	cis	rs9926296	0.546	rs6500442	chr16:89828862	T/C	cg27121462	chr16:89883253	FANCA	0.76	11.18	0.57	5.09e-24	Vitiligo;
CESC	cis	rs7296418	0.961	rs1790106	chr12:123591596	G/T	cg05973401	chr12:123451056	ABCB9	0.57	7.51	0.42	9.17e-13	Platelet count;
CESC	cis	rs2732480	0.538	rs2468943	chr12:48747249	G/T	cg24011408	chr12:48396354	COL2A1	-0.37	-5.08	-0.3	6.97e-7	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs2836974	0.897	rs2836923	chr21:40524236	T/C	cg17971929	chr21:40555470	PSMG1	1.03	15.23	0.68	4.85e-38	Cognitive function;
CESC	cis	rs2463822	0.583	rs72917379	chr11:62026112	T/C	cg06239285	chr11:62104954	ASRGL1	-1.05	-7.91	-0.44	7.04e-14	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs362272	0.524	rs881816	chr4:3365366	A/G	cg08886695	chr4:3369023	RGS12	-0.43	-5.86	-0.34	1.35e-8	Serum sulfate level;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10985993	chr2:166810260	TTC21B	0.6	7.14	0.4	9.14e-12	Gut microbiome composition (summer);
CESC	cis	rs6570726	0.577	rs399502	chr6:145805874	A/G	cg23711669	chr6:146136114	FBXO30	0.95	12.72	0.62	2.95e-29	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7086627	0.515	rs10887900	chr10:82210265	A/G	cg00277334	chr10:82204260	NA	-0.89	-14.86	-0.67	9.67e-37	Post bronchodilator FEV1;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23497857	chr14:24685372	MDP1	-0.65	-8.14	-0.45	1.53e-14	Gut microbiome composition (summer);
CESC	cis	rs1801251	1.000	rs283474	chr2:233654627	A/G	cg08000102	chr2:233561755	GIGYF2	0.68	9.74	0.51	2.4e-19	Coronary artery disease;
CESC	cis	rs35306767	0.903	rs17159950	chr10:875287	T/G	cg25019033	chr10:957182	NA	-0.59	-6.23	-0.36	1.86e-9	Eosinophil percentage of granulocytes;
CESC	cis	rs116095464	0.558	rs9312979	chr5:222057	A/C	cg22496380	chr5:211416	CCDC127	-0.96	-10.08	-0.53	1.95e-20	Breast cancer;
CESC	cis	rs6952808	1.000	rs12540579	chr7:1882227	C/A	cg04267008	chr7:1944627	MAD1L1	-0.59	-7.26	-0.41	4.18e-12	Bipolar disorder and schizophrenia;
CESC	cis	rs7267979	0.866	rs437635	chr20:25456888	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.78	14.78	0.67	1.87e-36	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7829975	0.535	rs17683510	chr8:8500724	A/G	cg06636001	chr8:8085503	FLJ10661	0.4	5.2	0.3	3.98e-7	Mood instability;
CESC	cis	rs397969	0.596	rs12453720	chr17:19895202	A/G	cg12073167	chr17:19770448	ULK2	0.46	5.39	0.31	1.55e-7	Platelet count;
CESC	cis	rs1862618	0.573	rs832532	chr5:56221938	T/C	cg24549020	chr5:56110836	MAP3K1	0.57	6.18	0.35	2.45e-9	Initial pursuit acceleration;
CESC	cis	rs597539	0.654	rs7107137	chr11:68623712	A/G	cg01988459	chr11:68622903	NA	-0.41	-5.3	-0.31	2.4e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg04234412	chr22:24373322	LOC391322	-0.62	-9.19	-0.49	1.18e-17	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs17428041	0.521	rs13255951	chr8:21722998	T/C	cg17168535	chr8:21777572	XPO7	-0.44	-5.83	-0.34	1.61e-8	Neuropathic pain in type 2 diabetes;
CESC	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg24829409	chr8:58192753	C8orf71	-0.67	-7.99	-0.44	4.08e-14	Developmental language disorder (linguistic errors);
CESC	cis	rs694739	0.628	rs617051	chr11:64133638	C/A	cg23796481	chr11:64053134	BAD;GPR137	0.56	6.87	0.39	4.63e-11	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CESC	cis	rs116095464	0.558	rs6866776	chr5:264495	C/T	cg12570787	chr5:219185	SDHA;CCDC127	0.53	5.49	0.32	9.44e-8	Breast cancer;
CESC	cis	rs56104184	0.775	rs56317021	chr19:49395960	C/T	cg15549821	chr19:49342101	PLEKHA4	-0.58	-5.8	-0.34	1.9e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	cis	rs7312774	0.618	rs61061573	chr12:107372758	T/C	cg16260113	chr12:107380972	MTERFD3	0.95	7.37	0.41	2.16e-12	Severe influenza A (H1N1) infection;
CESC	cis	rs3741151	1.000	rs3741151	chr11:73020846	G/T	cg17517138	chr11:73019481	ARHGEF17	1.16	8.06	0.44	2.63e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs4713118	0.616	rs9348789	chr6:28025486	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.54	-6.2	-0.36	2.21e-9	Parkinson's disease;
CESC	cis	rs12801636	0.739	rs12790427	chr11:65384727	C/T	cg01685242	chr11:65405760	SIPA1	0.46	5.07	0.3	7.63e-7	Coronary artery disease;HDL cholesterol;HDL cholesterol levels;
CESC	cis	rs3749237	0.595	rs2878298	chr3:49406080	T/C	cg07636037	chr3:49044803	WDR6	0.62	8.99	0.48	4.79e-17	Resting heart rate;
CESC	cis	rs2282802	0.617	rs10477348	chr5:139666906	A/T	cg26211634	chr5:139558579	C5orf32	0.5	7.08	0.4	1.28e-11	Intelligence (multi-trait analysis);
CESC	cis	rs1728785	1.000	rs7195979	chr16:68586801	G/A	cg02972257	chr16:68554789	NA	-0.66	-7.38	-0.41	2.03e-12	Ulcerative colitis;
CESC	cis	rs4253772	0.637	rs8135997	chr22:46651366	G/A	cg24881330	chr22:46731750	TRMU	0.89	10.09	0.53	1.86e-20	LDL cholesterol;Cholesterol, total;
CESC	cis	rs709400	0.663	rs17617941	chr14:103953032	T/C	cg12935359	chr14:103987150	CKB	-0.57	-8.39	-0.46	2.88e-15	Body mass index;
CESC	cis	rs6163	0.588	rs12763284	chr10:104508202	C/T	cg04362960	chr10:104952993	NT5C2	-0.37	-5.14	-0.3	5.37e-7	Waist circumference;Hip circumference;
CESC	cis	rs6426558	0.537	rs689094	chr1:227308909	G/A	cg10327440	chr1:227177885	CDC42BPA	0.46	5.77	0.33	2.19e-8	Neutrophil percentage of white cells;
CESC	cis	rs748404	0.697	rs475227	chr15:43546446	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.61	8.07	0.44	2.39e-14	Lung cancer;
CESC	cis	rs12618769	0.652	rs13402379	chr2:99209314	G/A	cg10123293	chr2:99228465	UNC50	0.39	5.1	0.3	6.61e-7	Bipolar disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09847284	chr11:45907071	MAPK8IP1	0.67	7.28	0.41	3.77e-12	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17282910	chr5:89825494	LYSMD3	-0.54	-6.04	-0.35	5.28e-9	Gut microbiome composition (summer);
CESC	cis	rs514406	0.668	rs520281	chr1:53365235	G/C	cg25767906	chr1:53392781	SCP2	-0.52	-7.16	-0.4	7.76e-12	Monocyte count;
CESC	cis	rs7903847	0.642	rs7896100	chr10:99156994	C/T	cg20016023	chr10:99160130	RRP12	-0.3	-5.19	-0.3	4.18e-7	Granulocyte percentage of myeloid white cells;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg17358899	chr7:148580458	EZH2	-0.48	-6.77	-0.38	8.09e-11	Gambling;
CESC	cis	rs11122272	0.701	rs2486725	chr1:231540288	G/C	cg06096015	chr1:231504339	EGLN1	0.42	6.05	0.35	4.97e-9	Hemoglobin concentration;
CESC	trans	rs2963826	0.589	rs298091	chr5:58996603	A/T	cg06508976	chr9:131940586	IER5L	0.46	6.18	0.35	2.43e-9	Obesity-related traits;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg19731367	chr10:95256484	CEP55	-0.49	-7.18	-0.4	6.88e-12	Fibrinogen levels;
CESC	trans	rs11098499	0.863	rs1480939	chr4:120456927	T/C	cg25214090	chr10:38739885	LOC399744	0.7	9.62	0.51	5.47e-19	Corneal astigmatism;
CESC	cis	rs1862618	0.802	rs832560	chr5:56124423	T/A	cg03609598	chr5:56110824	MAP3K1	-0.51	-5.5	-0.32	9.11e-8	Initial pursuit acceleration;
CESC	cis	rs8044868	0.606	rs7189591	chr16:72099011	G/T	cg16558253	chr16:72132732	DHX38	-0.41	-6.44	-0.37	5.61e-10	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CESC	cis	rs4975709	0.838	rs4975753	chr5:1880865	T/C	cg17650747	chr5:1873721	NA	0.38	5.19	0.3	4.24e-7	Cardiovascular disease risk factors;
CESC	cis	rs372883	0.506	rs2832300	chr21:30749315	A/G	cg24692254	chr21:30365293	RNF160	0.47	5.89	0.34	1.14e-8	Pancreatic cancer;
CESC	cis	rs561341	1.000	rs4795670	chr17:30244839	T/C	cg12193833	chr17:30244370	NA	-0.58	-6.22	-0.36	1.95e-9	Hip circumference adjusted for BMI;
CESC	trans	rs61931739	0.534	rs10844840	chr12:34364517	C/T	cg26384229	chr12:38710491	ALG10B	0.68	10.06	0.53	2.22e-20	Morning vs. evening chronotype;
CESC	cis	rs1670533	1.000	rs652063	chr4:1084137	T/C	cg04106633	chr4:1044584	NA	0.4	5.08	0.3	6.98e-7	Recombination rate (females);
CESC	trans	rs116095464	0.558	rs9312956	chr5:201812	T/C	cg00938859	chr5:1591904	SDHAP3	0.62	6.01	0.35	6.17e-9	Breast cancer;
CESC	cis	rs35306767	0.903	rs11253492	chr10:936873	T/C	cg26597838	chr10:835615	NA	0.91	9.95	0.52	5.15e-20	Eosinophil percentage of granulocytes;
CESC	cis	rs8072100	0.764	rs4794371	chr17:45627693	G/C	cg08085267	chr17:45401833	C17orf57	0.4	5.22	0.31	3.64e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs7927771	0.524	rs9633830	chr11:47849470	T/G	cg18512352	chr11:47633146	NA	0.35	5.33	0.31	2.05e-7	Subjective well-being;
CESC	cis	rs116095464	0.558	rs6866632	chr5:264429	C/G	cg22857025	chr5:266934	NA	-1.29	-16.06	-0.7	5.35e-41	Breast cancer;
CESC	cis	rs7927771	0.800	rs12146565	chr11:47398963	G/A	cg05585544	chr11:47624801	NA	-0.49	-7.12	-0.4	1.03e-11	Subjective well-being;
CESC	cis	rs55894533	0.597	rs2645408	chr8:11746358	A/G	cg21281001	chr8:11725306	CTSB	0.48	5.82	0.34	1.69e-8	Leprosy;
CESC	trans	rs2282526	0.615	rs463738	chr21:44921166	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.49	-6.18	-0.35	2.35e-9	Mean corpuscular hemoglobin;
CESC	cis	rs1371867	0.839	rs1788186	chr8:101335686	T/C	cg11906718	chr8:101322791	RNF19A	0.46	5.91	0.34	1.03e-8	Atrioventricular conduction;
CESC	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	13.66	0.64	1.57e-32	Prudent dietary pattern;
CESC	cis	rs3818285	0.632	rs536343	chr10:111632879	T/C	cg00817464	chr10:111662876	XPNPEP1	0.44	6.7	0.38	1.21e-10	Superior crus of antihelix expression;
CESC	cis	rs7937682	0.632	rs4935811	chr11:111679262	C/T	cg09085632	chr11:111637200	PPP2R1B	0.85	10.45	0.54	1.21e-21	Primary sclerosing cholangitis;
CESC	cis	rs7089973	0.872	rs34064819	chr10:116621154	C/A	cg23260525	chr10:116636907	FAM160B1	0.38	6.35	0.36	9.27e-10	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs9309473	1.000	rs11893881	chr2:73824373	T/A	cg20560298	chr2:73613845	ALMS1	-0.54	-7.01	-0.4	2e-11	Metabolite levels;
CESC	cis	rs6424115	1.000	rs2256179	chr1:24132305	A/G	cg15997130	chr1:24165203	NA	-0.42	-5.8	-0.34	1.89e-8	Immature fraction of reticulocytes;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg19318450	chr21:34852305	TMEM50B	-0.48	-6.04	-0.35	5.1e-9	Ulcerative colitis;
CESC	cis	rs72781680	1.000	rs72798408	chr2:24181845	G/C	cg08917208	chr2:24149416	ATAD2B	1.11	10.02	0.52	3.07e-20	Lymphocyte counts;
CESC	cis	rs12900413	0.687	rs28435184	chr15:90306732	T/C	cg24249390	chr15:90295951	MESP1	-0.42	-5.69	-0.33	3.34e-8	Coronary artery aneurysm in Kawasaki disease;
CESC	cis	rs7772486	0.902	rs1125462	chr6:146417832	A/G	cg23711669	chr6:146136114	FBXO30	0.73	10.72	0.55	1.59e-22	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs896854	0.714	rs6471503	chr8:95990283	G/A	cg09323728	chr8:95962352	TP53INP1	-0.41	-8.98	-0.48	5.27e-17	Type 2 diabetes;
CESC	cis	rs9611519	0.780	rs2235852	chr22:41661154	G/T	cg03806693	chr22:41940476	POLR3H	-0.55	-6.43	-0.37	5.78e-10	Neuroticism;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg14837817	chr8:144692253	PYCRL	-0.46	-6.05	-0.35	4.9e-9	Asthma;
CESC	cis	rs9611565	0.512	rs5758439	chr22:42131762	C/T	cg03806693	chr22:41940476	POLR3H	1.16	13.59	0.64	2.85e-32	Vitiligo;
CESC	cis	rs2072732	0.821	rs60287244	chr1:2943668	A/G	cg15211996	chr1:2936768	ACTRT2	0.35	5.74	0.33	2.65e-8	Plateletcrit;
CESC	cis	rs9399135	0.967	rs4896121	chr6:135293645	T/C	cg22676075	chr6:135203613	NA	0.52	7.12	0.4	1e-11	Red blood cell count;
CESC	cis	rs7833986	0.501	rs72653986	chr8:57035048	T/C	cg26371346	chr8:56986568	SNORD54;RPS20	0.57	5.41	0.32	1.42e-7	Height;
CESC	cis	rs10129255	0.500	rs6576231	chr14:107191930	T/C	cg07958169	chr14:107095056	NA	-0.54	-8.32	-0.46	4.65e-15	Kawasaki disease;
CESC	cis	rs3762637	1.000	rs12638866	chr3:122194382	T/C	cg24169773	chr3:122142474	KPNA1	-0.54	-6.33	-0.36	1.04e-9	LDL cholesterol levels;
CESC	cis	rs67478160	0.595	rs12879501	chr14:104272634	G/T	cg01849466	chr14:104193079	ZFYVE21	-0.5	-7.07	-0.4	1.39e-11	Schizophrenia;
CESC	cis	rs4665809	0.589	rs4665841	chr2:26448950	G/A	cg27170947	chr2:26402098	FAM59B	-0.89	-10.77	-0.55	1.17e-22	Gut microbiome composition (summer);
CESC	cis	rs2070488	0.965	rs7372849	chr3:38524328	G/C	cg24069376	chr3:38537580	EXOG	0.47	8.57	0.47	8.51e-16	Electrocardiographic conduction measures;
CESC	cis	rs736408	0.608	rs6445534	chr3:52743384	G/A	cg18337363	chr3:52569053	NT5DC2	0.28	5.2	0.3	3.94e-7	Bipolar disorder;
CESC	cis	rs7872515	0.887	rs7029539	chr9:94864322	A/G	cg01248375	chr9:94877805	SPTLC1	0.56	6.1	0.35	3.81e-9	Bipolar disorder and schizophrenia;
CESC	trans	rs7618501	1.000	rs60205400	chr3:49800272	C/T	cg21659725	chr3:3221576	CRBN	0.83	13.56	0.64	3.67e-32	Intelligence (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01945625	chr16:1437845	NA	-0.54	-6.48	-0.37	4.33e-10	Gut microbiome composition (summer);
CESC	cis	rs7208859	0.623	rs56378576	chr17:29010120	C/T	cg14008862	chr17:28927542	LRRC37B2	0.73	5.82	0.34	1.67e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs13191362	1.000	rs13210756	chr6:163009030	T/A	cg14584255	chr6:163149320	PACRG;PARK2	0.49	5.36	0.31	1.82e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.58	7.5	0.42	9.93e-13	Prudent dietary pattern;
CESC	cis	rs561341	0.709	rs8068049	chr17:30183857	T/C	cg19193384	chr17:30244184	NA	0.57	5.31	0.31	2.37e-7	Hip circumference adjusted for BMI;
CESC	trans	rs1814175	0.781	rs12286395	chr11:49954062	C/G	cg03929089	chr4:120376271	NA	-0.93	-15.75	-0.7	6.66e-40	Height;
CESC	cis	rs17253792	0.822	rs76164147	chr14:56140369	T/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.81	5.68	0.33	3.46e-8	Putamen volume;
CESC	cis	rs1642645	0.872	rs7550500	chr1:42505522	T/C	cg16685388	chr1:42384056	HIVEP3	0.4	5.87	0.34	1.31e-8	Left ventricular obstructive tract defect (maternal effect);
CESC	cis	rs4654899	1.000	rs7543126	chr1:21406088	T/G	cg05370193	chr1:21551575	ECE1	0.37	5.56	0.32	6.48e-8	Superior frontal gyrus grey matter volume;
CESC	cis	rs2760061	0.603	rs697762	chr1:228192410	G/A	cg02753203	chr1:228287806	NA	0.72	11.27	0.57	2.57e-24	Diastolic blood pressure;
CESC	cis	rs2116941	1.000	rs7250265	chr19:10339818	G/C	cg01850179	chr19:10340795	S1PR2	-0.59	-7.61	-0.42	4.9e-13	Pulse pressure;
CESC	trans	rs2963826	0.589	rs298091	chr5:58996603	A/T	cg09311052	chr1:154531418	UBE2Q1	0.49	6.62	0.38	2e-10	Obesity-related traits;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg22546437	chr19:47987707	KPTN	-0.49	-6.09	-0.35	3.89e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs6028335	0.674	rs6028234	chr20:37607869	A/C	cg16355469	chr20:37678765	NA	0.51	5.09	0.3	6.82e-7	Alcohol and nicotine co-dependence;
CESC	cis	rs7432375	0.609	rs835637	chr3:136673157	A/T	cg15507776	chr3:136538369	TMEM22	0.56	7.17	0.4	7.5e-12	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg13852536	chr9:32567045	NDUFB6	0.54	7.67	0.43	3.22e-13	Fibrinogen levels;
CESC	cis	rs9322193	0.923	rs14314	chr6:150141531	A/C	cg05861140	chr6:150128134	PCMT1	-0.37	-5.35	-0.31	1.91e-7	Lung cancer;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg12897370	chr6:155055079	RBM16	-0.49	-6.15	-0.35	2.8e-9	Ulcerative colitis;
CESC	cis	rs4665809	1.000	rs6546736	chr2:26293878	C/T	cg27170947	chr2:26402098	FAM59B	0.56	6.87	0.39	4.58e-11	Gut microbiome composition (summer);
CESC	trans	rs8073060	0.586	rs225300	chr17:33922428	C/T	cg19694781	chr19:47549865	TMEM160	-0.72	-6.95	-0.39	2.85e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	cis	rs36051895	0.623	rs2208685	chr9:5251758	T/C	cg02405213	chr9:5042618	JAK2	-0.53	-6.27	-0.36	1.43e-9	Pediatric autoimmune diseases;
CESC	cis	rs7254114	0.645	rs57681847	chr19:11300648	G/T	cg02815516	chr19:11306319	KANK2	-0.38	-5.85	-0.34	1.44e-8	Immature fraction of reticulocytes;
CESC	cis	rs7296418	0.885	rs1790104	chr12:123709409	C/T	cg05973401	chr12:123451056	ABCB9	0.51	6.63	0.38	1.88e-10	Platelet count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13499067	chr11:10879629	ZBED5	0.63	7.11	0.4	1.11e-11	Gut microbiome composition (summer);
CESC	trans	rs61931739	0.500	rs12146843	chr12:34451738	T/G	cg26384229	chr12:38710491	ALG10B	0.54	7.5	0.42	9.79e-13	Morning vs. evening chronotype;
CESC	trans	rs7615952	0.800	rs13086460	chr3:125646417	C/T	cg07211511	chr3:129823064	LOC729375	-1.14	-15.22	-0.68	5.24e-38	Blood pressure (smoking interaction);
CESC	cis	rs9660992	0.573	rs4400674	chr1:205218425	A/C	cg00857998	chr1:205179979	DSTYK	-0.56	-6.84	-0.39	5.5e-11	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs10754283	0.967	rs10737708	chr1:90119804	A/G	cg21401794	chr1:90099060	LRRC8C	0.66	8.77	0.47	2.18e-16	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	-0.53	-6.48	-0.37	4.48e-10	Prudent dietary pattern;
CESC	cis	rs2204008	0.540	rs3908193	chr12:38410907	G/T	cg26384229	chr12:38710491	ALG10B	-0.45	-6.09	-0.35	4.05e-9	Bladder cancer;
CESC	cis	rs6964587	1.000	rs9784993	chr7:91672403	G/A	cg17063962	chr7:91808500	NA	0.59	8.15	0.45	1.48e-14	Breast cancer;
CESC	cis	rs6542838	0.611	rs1976766	chr2:99522754	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.42	-5.23	-0.31	3.53e-7	Fear of minor pain;
CESC	cis	rs9902453	0.967	rs12450956	chr17:28529025	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.57	7.06	0.4	1.43e-11	Coffee consumption (cups per day);
CESC	cis	rs72781680	0.898	rs12620558	chr2:23936022	G/A	cg08917208	chr2:24149416	ATAD2B	1.1	10.15	0.53	1.18e-20	Lymphocyte counts;
CESC	cis	rs2281558	0.833	rs12480853	chr20:25522959	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.55	7.61	0.42	4.83e-13	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;
CESC	cis	rs9649213	0.593	rs6961438	chr7:98005849	T/C	cg24562669	chr7:97807699	LMTK2	0.51	7.53	0.42	7.86e-13	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs28735056	0.903	rs56185453	chr18:77638297	A/G	cg05926928	chr17:57297772	GDPD1	-0.62	-7.79	-0.43	1.49e-13	Schizophrenia;
CESC	cis	rs12142240	0.698	rs12385695	chr1:46819021	A/G	cg00530320	chr1:46809349	NSUN4	0.58	7.89	0.44	8.15e-14	Menopause (age at onset);
CESC	cis	rs9905704	0.624	rs6503891	chr17:57065924	A/C	cg12560992	chr17:57184187	TRIM37	0.66	8.09	0.44	2.21e-14	Testicular germ cell tumor;
CESC	cis	rs1609391	0.561	rs9817967	chr3:136629490	G/A	cg15507776	chr3:136538369	TMEM22	0.81	11.89	0.59	2.08e-26	Neuroticism;
CESC	cis	rs798554	0.731	rs2283779	chr7:2815140	G/A	cg13628971	chr7:2884303	GNA12	0.39	5.07	0.3	7.49e-7	Height;
CESC	cis	rs3820068	0.603	rs7537618	chr1:15977682	G/A	cg17385448	chr1:15911702	AGMAT	0.43	7.04	0.4	1.66e-11	Systolic blood pressure;
CESC	cis	rs7584330	0.740	rs11891348	chr2:238440449	T/G	cg14458575	chr2:238380390	NA	0.71	10.15	0.53	1.19e-20	Prostate cancer;
CESC	cis	rs9660992	0.674	rs1151784	chr1:205232447	C/T	cg00857998	chr1:205179979	DSTYK	0.47	5.35	0.31	1.87e-7	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs644799	0.965	rs11021310	chr11:95502106	A/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.72	9.53	0.51	1.05e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs61774743	0.557	rs4660192	chr1:41842350	C/T	cg08462924	chr1:41848221	NA	0.4	5.43	0.32	1.27e-7	Intelligence (multi-trait analysis);
CESC	cis	rs3008870	1.000	rs12740884	chr1:67459855	C/A	cg02640540	chr1:67518911	SLC35D1	-0.51	-5.58	-0.32	5.89e-8	Lymphocyte percentage of white cells;
CESC	cis	rs13191362	0.938	rs35211042	chr6:162998703	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.79	8.31	0.45	5.17e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs11048434	0.761	rs12827988	chr12:9130287	A/G	cg23795048	chr12:9217529	LOC144571	0.34	5.05	0.3	8.31e-7	Sjögren's syndrome;
CESC	cis	rs228437	1.000	rs985121	chr6:134930893	C/T	cg24504307	chr6:134963096	NA	0.55	5.93	0.34	9.31e-9	Melanoma;
CESC	cis	rs4253772	0.591	rs11704586	chr22:46685274	T/C	cg24881330	chr22:46731750	TRMU	0.75	5.43	0.32	1.25e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs6952808	0.630	rs4719443	chr7:2161099	A/G	cg21782813	chr7:2030301	MAD1L1	0.51	7.2	0.4	6.27e-12	Bipolar disorder and schizophrenia;
CESC	cis	rs7949030	0.626	rs7943191	chr11:62328551	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.66	9.93	0.52	5.98e-20	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg17146150	chr15:56657437	TEX9	0.48	6.05	0.35	5.03e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs9911578	1.000	rs8071280	chr17:57010225	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.13	0.3	5.67e-7	Intelligence (multi-trait analysis);
CESC	trans	rs11098499	0.691	rs10028773	chr4:120265259	C/G	cg25214090	chr10:38739885	LOC399744	-0.58	-7.81	-0.43	1.31e-13	Corneal astigmatism;
CESC	cis	rs12497850	0.864	rs4279134	chr3:49156676	A/G	cg07636037	chr3:49044803	WDR6	1.05	18.48	0.75	1.44e-49	Parkinson's disease;
CESC	cis	rs11997175	0.653	rs7817167	chr8:33633088	A/C	ch.8.33884649F	chr8:33765107	NA	0.55	6.86	0.39	4.88e-11	Body mass index;
CESC	cis	rs4808199	0.948	rs11085261	chr19:19462606	G/A	cg03709012	chr19:19516395	GATAD2A	1.08	12.28	0.6	9.85e-28	Nonalcoholic fatty liver disease;
CESC	cis	rs5750830	0.594	rs1010169	chr22:39778167	C/T	cg11247378	chr22:39784982	NA	0.63	9.48	0.5	1.53e-18	Intelligence (multi-trait analysis);
CESC	cis	rs8031584	0.706	rs798084	chr15:31126935	C/T	cg08109568	chr15:31115862	NA	-0.68	-9.22	-0.49	9.92e-18	Huntington's disease progression;
CESC	cis	rs1552244	1.000	rs67134728	chr3:10151431	G/C	cg00166722	chr3:10149974	C3orf24	0.45	5.63	0.33	4.62e-8	Alzheimer's disease;
CESC	cis	rs1707322	1.000	rs3922886	chr1:46473902	A/T	cg03146154	chr1:46216737	IPP	0.73	9.95	0.52	5.12e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17645130	chr1:115053969	TRIM33	0.57	6.46	0.37	5.03e-10	Gut microbiome composition (summer);
CESC	cis	rs28386778	0.830	rs7209321	chr17:61855668	A/C	cg26338869	chr17:61819248	STRADA	0.7	9.25	0.49	7.94e-18	Prudent dietary pattern;
CESC	cis	rs7520050	0.933	rs12045165	chr1:46256022	C/A	cg24296786	chr1:45957014	TESK2	0.44	5.64	0.33	4.37e-8	Red blood cell count;Reticulocyte count;
CESC	cis	rs561341	0.609	rs2051810	chr17:30195841	C/T	cg13647721	chr17:30228624	UTP6	-0.74	-8.55	-0.46	9.94e-16	Hip circumference adjusted for BMI;
CESC	trans	rs35110281	0.744	rs230646	chr21:44918788	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.53	7.1	0.4	1.12e-11	Mean corpuscular volume;
CESC	cis	rs1799949	0.929	rs12937015	chr17:41307473	A/C	cg23758822	chr17:41437982	NA	1.03	16.08	0.7	4.57e-41	Menopause (age at onset);
CESC	cis	rs10905065	1.000	rs2380199	chr10:5803689	C/T	cg11519256	chr10:5708881	ASB13	0.38	5.08	0.3	7.12e-7	Menopause (age at onset);
CESC	cis	rs7666738	0.830	rs7662218	chr4:98983126	T/G	cg03676636	chr4:99064102	C4orf37	0.33	5.1	0.3	6.58e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs8005677	1.000	rs8014936	chr14:23375145	A/G	cg25600027	chr14:23388339	RBM23	-0.41	-5.04	-0.3	8.45e-7	Cognitive ability (multi-trait analysis);
CESC	cis	rs4555082	0.957	rs2816608	chr14:105718407	A/G	cg06808227	chr14:105710500	BRF1	0.43	5.43	0.32	1.26e-7	Mean platelet volume;Platelet distribution width;
CESC	cis	rs7084402	0.967	rs11817440	chr10:60272369	T/C	cg07615347	chr10:60278583	BICC1	-0.57	-8.87	-0.48	1.12e-16	Refractive error;
CESC	cis	rs6461049	0.519	rs3778992	chr7:2175313	C/G	cg05863683	chr7:1912471	MAD1L1	0.38	5.63	0.33	4.63e-8	Schizophrenia;
CESC	cis	rs832540	0.695	rs702686	chr5:56201350	A/G	cg12311346	chr5:56204834	C5orf35	-0.6	-7.95	-0.44	5.23e-14	Coronary artery disease;
CESC	cis	rs7208859	0.573	rs73267872	chr17:29067207	T/C	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.14e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs3008870	0.755	rs2815363	chr1:67497221	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-0.6	-7.93	-0.44	6.25e-14	Lymphocyte percentage of white cells;
CESC	cis	rs7208859	0.573	rs11654035	chr17:29136426	T/C	cg14008862	chr17:28927542	LRRC37B2	0.69	5.37	0.31	1.7e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs76419734	0.510	rs2544402	chr4:106687733	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	-0.61	-6.29	-0.36	1.31e-9	Post bronchodilator FEV1;
CESC	cis	rs425277	0.628	rs3107147	chr1:2048729	G/A	cg19257562	chr1:2043853	PRKCZ	0.4	6.55	0.37	2.99e-10	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13652281	chr17:80393504	HEXDC	-0.5	-6.15	-0.35	2.82e-9	Gut microbiome composition (summer);
CESC	cis	rs11098499	0.722	rs17595727	chr4:120262074	C/T	cg09307838	chr4:120376055	NA	-0.75	-9.99	-0.52	3.85e-20	Corneal astigmatism;
CESC	cis	rs1843834	0.539	rs3912999	chr2:225390089	C/T	cg22509189	chr2:225307070	NA	-0.41	-5.29	-0.31	2.51e-7	IgE levels in asthmatics (D.p. specific);
CESC	cis	rs9300255	0.602	rs1106241	chr12:123627016	T/C	cg00376283	chr12:123451042	ABCB9	0.7	8.58	0.47	8.2e-16	Neutrophil percentage of white cells;
CESC	cis	rs113835537	0.877	rs77239910	chr11:66329639	G/A	cg22134325	chr11:66188745	NPAS4	0.52	6.0	0.35	6.58e-9	Airway imaging phenotypes;
CESC	cis	rs25645	0.830	rs3935281	chr17:38188419	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.61	8.68	0.47	4.23e-16	Myeloid white cell count;
CESC	cis	rs9815354	0.716	rs73087368	chr3:41930379	A/G	cg03022575	chr3:42003672	ULK4	0.71	6.44	0.37	5.46e-10	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs5769765	0.671	rs138832	chr22:50178082	A/G	cg26441486	chr22:50317300	CRELD2	0.4	5.2	0.3	3.96e-7	Schizophrenia;
CESC	cis	rs2425143	1.000	rs57963833	chr20:34344225	T/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.67	5.92	0.34	1.01e-8	Blood protein levels;
CESC	cis	rs3820928	1.000	rs6752707	chr2:227766822	C/G	cg05526886	chr2:227700861	RHBDD1	-0.43	-5.63	-0.33	4.53e-8	Pulmonary function;
CESC	cis	rs7618915	0.532	rs13060675	chr3:52674300	T/G	cg07507251	chr3:52567010	NT5DC2	0.4	7.11	0.4	1.1e-11	Bipolar disorder;
CESC	cis	rs9303401	0.614	rs34683543	chr17:56520036	C/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.95	11.71	0.58	8.62e-26	Cognitive test performance;
CESC	cis	rs6540556	0.678	rs11119330	chr1:209889659	A/G	cg05527609	chr1:210001259	C1orf107	-0.68	-7.38	-0.41	2.11e-12	Red blood cell count;
CESC	cis	rs7666738	0.830	rs7662389	chr4:99019892	G/A	cg05340658	chr4:99064831	C4orf37	0.82	12.9	0.62	7.31e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs798554	0.797	rs798486	chr7:2803037	A/G	cg13628971	chr7:2884303	GNA12	0.65	8.39	0.46	2.85e-15	Height;
CESC	trans	rs9987353	0.840	rs329994	chr8:9123233	A/G	cg22377913	chr1:26758610	DHDDS	-0.49	-6.05	-0.35	5e-9	Recombination measurement;
CESC	cis	rs6456156	0.586	rs9457266	chr6:167482555	T/C	cg23791538	chr6:167370224	RNASET2	-0.51	-6.44	-0.37	5.67e-10	Primary biliary cholangitis;
CESC	cis	rs4253772	0.938	rs14842	chr22:46639457	A/T	cg18190219	chr22:46762943	CELSR1	-0.61	-5.82	-0.34	1.66e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs17253792	0.822	rs28681420	chr14:56088403	G/T	cg01858014	chr14:56050164	KTN1	-0.85	-6.99	-0.39	2.22e-11	Putamen volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07195508	chr1:67390935	MIER1;WDR78	0.59	6.27	0.36	1.46e-9	Gut microbiome composition (summer);
CESC	cis	rs6088580	0.634	rs6088488	chr20:32992631	T/C	cg24642439	chr20:33292090	TP53INP2	-0.52	-6.9	-0.39	3.82e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs7524258	0.901	rs11120884	chr1:7305361	C/A	cg07173049	chr1:7289937	CAMTA1	0.37	5.69	0.33	3.32e-8	Tourette's syndrome or obsessive-compulsive disorder;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg00529053	chr6:158589440	GTF2H5;SERAC1	-0.48	-6.28	-0.36	1.38e-9	Ulcerative colitis;
CESC	cis	rs34779708	0.966	rs11592567	chr10:35409369	C/T	cg03585969	chr10:35415529	CREM	0.77	10.1	0.53	1.71e-20	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs35110281	0.782	rs4818856	chr21:45043495	A/G	cg04455712	chr21:45112962	RRP1B	0.4	5.93	0.34	9.32e-9	Mean corpuscular volume;
CESC	cis	rs10129255	0.642	rs11624918	chr14:107120688	T/C	cg23076370	chr14:107095027	NA	-0.54	-7.11	-0.4	1.05e-11	Kawasaki disease;
CESC	cis	rs921968	0.541	rs3731867	chr2:219472734	G/A	cg02176678	chr2:219576539	TTLL4	-0.53	-9.13	-0.49	1.85e-17	Mean corpuscular hemoglobin concentration;
CESC	cis	rs9457247	0.565	rs12178491	chr6:167512474	C/T	cg23791538	chr6:167370224	RNASET2	-0.54	-7.03	-0.4	1.73e-11	Crohn's disease;
CESC	cis	rs2732480	0.557	rs2732484	chr12:48737245	A/C	cg04545296	chr12:48745243	ZNF641	0.44	7.22	0.41	5.44e-12	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs2836974	0.897	rs36113648	chr21:40555497	G/A	cg27266027	chr21:40555129	PSMG1	0.47	5.63	0.33	4.62e-8	Cognitive function;
CESC	cis	rs933688	1.000	rs10041402	chr5:90738948	A/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.11	14.03	0.65	8.31e-34	Smoking behavior;
CESC	cis	rs59918340	0.764	rs2304282	chr8:142229543	A/G	cg23750338	chr8:142222470	SLC45A4	0.61	9.16	0.49	1.45e-17	Immature fraction of reticulocytes;
CESC	cis	rs62158211	0.691	rs1964463	chr2:114069021	C/T	cg17784749	chr2:114082611	LOC440839	-0.66	-7.45	-0.42	1.36e-12	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;
CESC	cis	rs801193	0.967	rs2707849	chr7:66152712	T/C	cg06456125	chr7:65229604	NA	0.4	5.23	0.31	3.51e-7	Aortic root size;
CESC	cis	rs7100689	0.622	rs1340379	chr10:82121455	G/A	cg00277334	chr10:82204260	NA	-0.58	-7.76	-0.43	1.84e-13	Post bronchodilator FEV1;
CESC	trans	rs7839040	0.698	rs10504746	chr8:82928476	C/A	cg14472086	chr9:107730925	NA	-0.47	-6.33	-0.36	1.02e-9	Response to methotrexate in juvenile idiopathic arthritis;
CESC	cis	rs801193	1.000	rs2707850	chr7:66203870	G/T	cg11764359	chr7:65958608	NA	0.69	9.1	0.49	2.27e-17	Aortic root size;
CESC	cis	rs921968	0.565	rs1079177	chr2:219605929	G/A	cg02176678	chr2:219576539	TTLL4	-0.46	-8.21	-0.45	9.84e-15	Mean corpuscular hemoglobin concentration;
CESC	trans	rs875971	0.964	rs778708	chr7:65856319	T/C	cg26939375	chr7:64535504	NA	0.47	6.14	0.35	3.07e-9	Aortic root size;
CESC	cis	rs2806561	0.704	rs6680974	chr1:23376233	A/G	cg12483005	chr1:23474871	LUZP1	0.34	5.22	0.31	3.61e-7	Height;
CESC	cis	rs727505	0.721	rs11536526	chr7:124749441	G/A	cg23710748	chr7:124431027	NA	-0.38	-6.26	-0.36	1.54e-9	Lewy body disease;
CESC	trans	rs2727020	0.521	rs2088526	chr11:49531968	G/A	cg15704280	chr7:45808275	SEPT13	0.82	9.96	0.52	4.58e-20	Coronary artery disease;
CESC	cis	rs1059312	1.000	rs3825180	chr12:129279242	A/G	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.73	10.1	0.53	1.74e-20	Systemic lupus erythematosus;
CESC	cis	rs4819052	0.851	rs914214	chr21:46697820	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.93	13.95	0.65	1.55e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs1728785	0.688	rs698729	chr16:68624205	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.65	7.72	0.43	2.35e-13	Ulcerative colitis;
CESC	cis	rs6570726	0.935	rs384453	chr6:145815145	G/C	cg23711669	chr6:146136114	FBXO30	0.82	12.29	0.6	8.74e-28	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9902453	0.808	rs76515799	chr17:28169491	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	8.37	0.46	3.33e-15	Coffee consumption (cups per day);
CESC	cis	rs4237845	0.742	rs6650219	chr12:58289100	T/C	cg00677455	chr12:58241039	CTDSP2	0.44	5.78	0.33	2.09e-8	Intelligence (multi-trait analysis);
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg13819485	chr11:118868642	CCDC84	0.48	6.42	0.37	6.2e-10	Systemic lupus erythematosus;
CESC	cis	rs9926296	0.572	rs2376878	chr16:89885161	G/A	cg27121462	chr16:89883253	FANCA	0.61	8.1	0.45	2.06e-14	Vitiligo;
CESC	cis	rs614226	0.872	rs12307148	chr12:120903179	T/C	cg27489772	chr12:121021490	NA	-0.5	-5.1	-0.3	6.48e-7	Type 1 diabetes nephropathy;
CESC	cis	rs4654899	1.000	rs6669102	chr1:21355543	A/G	cg05370193	chr1:21551575	ECE1	0.4	6.14	0.35	2.95e-9	Superior frontal gyrus grey matter volume;
CESC	cis	rs17253792	0.822	rs80174205	chr14:56058694	T/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.84	5.62	0.33	4.81e-8	Putamen volume;
CESC	cis	rs2235544	0.588	rs664758	chr1:54461263	C/T	cg25741118	chr1:54482237	LDLRAD1	0.24	6.0	0.35	6.31e-9	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
CESC	cis	rs911555	0.755	rs4143998	chr14:103955247	T/C	cg09975044	chr14:104007538	NA	0.43	5.28	0.31	2.68e-7	Intelligence (multi-trait analysis);
CESC	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.75	10.62	0.55	3.37e-22	Prudent dietary pattern;
CESC	cis	rs7191439	0.790	rs8060966	chr16:88777329	A/G	cg27087555	chr16:88793112	FAM38A	-0.92	-7.61	-0.42	4.75e-13	Plateletcrit;
CESC	cis	rs9796	0.621	rs691702	chr15:41474399	C/G	cg12386646	chr15:41787261	ITPKA	0.33	5.08	0.3	7.11e-7	Menopause (age at onset);
CESC	cis	rs6933660	0.646	rs3816778	chr6:151773353	G/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.87	15.14	0.68	9.75e-38	Menarche (age at onset);
CESC	cis	rs847577	0.569	rs35101190	chr7:97695888	G/A	cg24562669	chr7:97807699	LMTK2	0.78	13.23	0.63	5.22e-31	Breast cancer;
CESC	trans	rs6934970	0.556	rs62414949	chr6:112986802	T/G	cg05146922	chr2:10634174	NA	-0.37	-6.17	-0.35	2.53e-9	Bipolar disorder (body mass index interaction);
CESC	cis	rs7923609	0.967	rs3956912	chr10:65205881	C/T	cg01631684	chr10:65280961	REEP3	-0.43	-5.39	-0.31	1.55e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs9916302	0.706	rs8069074	chr17:37685401	C/T	cg00129232	chr17:37814104	STARD3	0.49	5.05	0.3	8.34e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs875971	0.862	rs2420611	chr7:65999320	A/G	cg10691866	chr7:65817282	TPST1	-0.33	-5.39	-0.31	1.58e-7	Aortic root size;
CESC	cis	rs1976403	0.659	rs10799701	chr1:21820990	A/G	cg21906605	chr1:21766650	NBPF3	0.39	5.15	0.3	5.13e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs4727027	0.782	rs10245343	chr7:148796333	T/C	cg23583168	chr7:148888333	NA	-0.72	-9.39	-0.5	2.92e-18	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs3806843	0.735	rs801183	chr5:140091115	C/T	cg16179182	chr5:140090404	VTRNA1-1	-0.42	-5.58	-0.32	5.9e-8	Depressive symptoms (multi-trait analysis);
CESC	cis	rs2072510	0.569	rs7970524	chr12:96390152	A/G	cg09636302	chr12:96389483	HAL	-0.47	-5.87	-0.34	1.3e-8	Metabolite levels (small molecules and protein measures);
CESC	cis	rs3825932	1.000	rs3825932	chr15:79235446	A/G	cg25744700	chr15:79237217	CTSH	0.46	6.25	0.36	1.6e-9	Type 1 diabetes;
CESC	cis	rs2180341	1.000	rs2144743	chr6:127633810	A/T	cg27446573	chr6:127587934	RNF146	1.09	16.38	0.71	3.79e-42	Breast cancer;
CESC	cis	rs67311347	0.866	rs9826419	chr3:40352051	G/A	cg09455208	chr3:40491958	NA	0.46	7.61	0.42	4.93e-13	Renal cell carcinoma;
CESC	cis	rs2404602	0.709	rs11072591	chr15:76649562	A/G	cg23625390	chr15:77176239	SCAPER	0.41	5.66	0.33	3.94e-8	Blood metabolite levels;
CESC	cis	rs208520	0.690	rs207118	chr6:66788948	T/A	cg07460842	chr6:66804631	NA	-1.0	-13.33	-0.63	2.21e-31	Exhaled nitric oxide output;
CESC	cis	rs6942756	1.000	rs1473236	chr7:128880831	G/T	cg02491457	chr7:128862824	NA	-0.69	-9.9	-0.52	7.04e-20	White matter hyperintensity burden;
CESC	cis	rs9649465	0.561	rs609953	chr7:123422444	T/A	cg03229431	chr7:123269106	ASB15	0.42	5.69	0.33	3.28e-8	Migraine;
CESC	cis	rs6963495	0.818	rs6955796	chr7:105170321	T/G	cg02135003	chr7:105160482	PUS7	-0.46	-5.5	-0.32	9.1e-8	Bipolar disorder (body mass index interaction);
CESC	cis	rs7811142	1.000	rs11761784	chr7:100039970	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.03	11.56	0.58	2.62e-25	Platelet count;
CESC	cis	rs9768139	0.524	rs7779175	chr7:158136918	C/T	cg06219351	chr7:158114137	PTPRN2	0.53	7.26	0.41	4.21e-12	Calcium levels;
CESC	cis	rs9902453	0.967	rs8067576	chr17:28444254	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	7.73	0.43	2.21e-13	Coffee consumption (cups per day);
CESC	cis	rs1707322	1.000	rs12133129	chr1:46373348	C/T	cg05343316	chr1:45956843	TESK2	0.44	5.55	0.32	7.05e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg01238044	chr22:24384105	GSTT1	-0.66	-8.67	-0.47	4.41e-16	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs681343	1.000	rs492602	chr19:49206417	A/G	cg21064579	chr19:49206444	FUT2	0.52	7.39	0.41	1.98e-12	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
CESC	cis	rs7618915	0.547	rs11709448	chr3:52647449	T/C	cg05564831	chr3:52568323	NT5DC2	0.45	6.76	0.38	8.65e-11	Bipolar disorder;
CESC	cis	rs2836974	0.865	rs34778912	chr21:40667037	T/G	cg27266027	chr21:40555129	PSMG1	0.44	5.18	0.3	4.48e-7	Cognitive function;
CESC	cis	rs1348850	0.539	rs1453371	chr2:178227862	T/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.66	8.94	0.48	6.68e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs7727544	0.606	rs11950562	chr5:131652529	A/C	cg14196790	chr5:131705035	SLC22A5	0.41	6.29	0.36	1.34e-9	Blood metabolite levels;
CESC	cis	rs6430585	0.528	rs12464050	chr2:136663110	G/T	cg07169764	chr2:136633963	MCM6	1.23	16.56	0.71	8.67e-43	Corneal structure;
CESC	cis	rs10504229	0.683	rs7464038	chr8:58111908	T/C	cg21724239	chr8:58056113	NA	0.58	5.93	0.34	9.17e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs1790761	0.520	rs7124513	chr11:67395714	C/T	cg00290607	chr11:67383545	NA	-0.38	-5.33	-0.31	2.09e-7	Mean corpuscular volume;
CESC	cis	rs1552244	0.554	rs4488814	chr3:10002400	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.66	-9.18	-0.49	1.25e-17	Alzheimer's disease;
CESC	cis	rs6545883	0.929	rs2593627	chr2:61618574	T/C	cg15711740	chr2:61764176	XPO1	0.39	5.03	0.3	9.02e-7	Tuberculosis;
CESC	cis	rs6088590	0.561	rs11167239	chr20:33140472	G/A	cg24642439	chr20:33292090	TP53INP2	0.61	8.15	0.45	1.5e-14	Coronary artery disease;
CESC	cis	rs10504229	1.000	rs17216648	chr8:58169429	C/T	cg22535103	chr8:58192502	C8orf71	-1.05	-13.2	-0.63	6.43e-31	Developmental language disorder (linguistic errors);
CESC	cis	rs6060717	0.536	rs11699815	chr20:34543125	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.79	-7.11	-0.4	1.1e-11	Hip circumference adjusted for BMI;
CESC	cis	rs6087990	0.735	rs6087420	chr20:31359391	G/A	cg13636640	chr20:31349939	DNMT3B	0.79	13.4	0.64	1.27e-31	Ulcerative colitis;
CESC	cis	rs1552244	1.000	rs9845756	chr3:10067548	G/C	cg00166722	chr3:10149974	C3orf24	0.5	6.31	0.36	1.19e-9	Alzheimer's disease;
CESC	cis	rs858239	0.670	rs6967526	chr7:23159241	C/A	cg23682824	chr7:23144976	KLHL7	0.48	6.69	0.38	1.33e-10	Cerebrospinal fluid biomarker levels;
CESC	cis	rs3026101	0.671	rs28437236	chr17:5319214	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.4	5.22	0.31	3.64e-7	Body mass index;
CESC	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	10.25	0.53	5.39e-21	Prudent dietary pattern;
CESC	cis	rs7618915	0.501	rs6804145	chr3:52694198	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.75	0.38	9.1e-11	Bipolar disorder;
CESC	cis	rs3741151	0.881	rs79623427	chr11:73094896	C/T	cg17517138	chr11:73019481	ARHGEF17	0.98	6.98	0.39	2.4e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs12477438	0.798	rs1349779	chr2:99645055	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-10.6	-0.55	4.17e-22	Chronic sinus infection;
CESC	cis	rs898097	0.510	rs10445242	chr17:80891666	G/T	cg10494973	chr17:80897199	TBCD	-0.47	-5.88	-0.34	1.24e-8	Breast cancer;
CESC	cis	rs6831352	0.918	rs13112176	chr4:100055825	G/A	cg13256891	chr4:100009986	ADH5	-0.77	-8.45	-0.46	1.97e-15	Alcohol dependence;
CESC	trans	rs11039798	0.623	rs584851	chr11:48416321	A/G	cg15704280	chr7:45808275	SEPT13	-0.68	-6.25	-0.36	1.61e-9	Axial length;
CESC	cis	rs7927771	1.000	rs35902101	chr11:47795169	C/T	cg18512352	chr11:47633146	NA	-0.61	-9.59	-0.51	6.7e-19	Subjective well-being;
CESC	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.48	-5.08	-0.3	7.1e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs4253772	0.678	rs1053332	chr22:46640179	A/G	cg24881330	chr22:46731750	TRMU	0.75	8.28	0.45	6.28e-15	LDL cholesterol;Cholesterol, total;
CESC	cis	rs1005277	0.579	rs2472183	chr10:38392495	T/G	cg00409905	chr10:38381863	ZNF37A	-0.47	-6.3	-0.36	1.24e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs10504229	0.679	rs11783444	chr8:58131267	A/G	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs6714710	0.603	rs2044459	chr2:98447004	T/C	cg26665480	chr2:98280029	ACTR1B	0.6	8.23	0.45	8.31e-15	Posterior cortical atrophy and Alzheimer's disease;
CESC	cis	rs35306767	0.855	rs61830900	chr10:871481	C/G	cg26597838	chr10:835615	NA	1.18	11.47	0.58	5.21e-25	Eosinophil percentage of granulocytes;
CESC	cis	rs909674	0.690	rs1972280	chr22:39831986	T/A	cg02038168	chr22:39784481	NA	-0.66	-8.65	-0.47	5.03e-16	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs2404602	0.692	rs34478400	chr15:76923510	C/T	cg22467129	chr15:76604101	ETFA	-0.36	-5.32	-0.31	2.25e-7	Blood metabolite levels;
CESC	cis	rs10851478	0.872	rs12902960	chr15:49925041	T/C	cg08060515	chr15:49448048	GALK2;COPS2	0.42	5.2	0.3	3.95e-7	Oral cavity cancer;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg02111299	chr17:17068273	MPRIP	0.42	6.0	0.35	6.4e-9	Fibrinogen levels;
CESC	cis	rs17376456	0.877	rs10476598	chr5:93367281	C/T	cg25358565	chr5:93447407	FAM172A	-1.1	-11.03	-0.56	1.54e-23	Diabetic retinopathy;
CESC	cis	rs7259376	0.905	rs1975172	chr19:22534603	A/G	cg02657401	chr19:22469223	NA	-0.28	-5.42	-0.32	1.34e-7	Menopause (age at onset);
CESC	cis	rs6570726	0.791	rs9403729	chr6:145907007	C/T	cg23711669	chr6:146136114	FBXO30	0.99	15.01	0.68	2.93e-37	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2576037	0.899	rs12955429	chr18:44585484	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.51	6.48	0.37	4.48e-10	Personality dimensions;
CESC	cis	rs1008375	0.966	rs2872957	chr4:17651757	C/A	cg04450456	chr4:17643702	FAM184B	0.36	5.06	0.3	7.87e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg05313129	chr8:58192883	C8orf71	-0.49	-5.36	-0.31	1.8e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs2742234	0.541	rs7098236	chr10:43740508	T/C	cg07801480	chr10:43725741	RASGEF1A	-0.41	-5.21	-0.3	3.75e-7	Hirschsprung disease;
CESC	cis	rs79057730	0.599	rs6951032	chr7:794092	C/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.87	7.2	0.4	6.39e-12	Initial pursuit acceleration;
CESC	cis	rs4141404	0.851	rs9606833	chr22:31750013	T/C	cg13145458	chr22:31556086	RNF185	-0.58	-6.16	-0.35	2.68e-9	Paclitaxel-induced neuropathy;
CESC	cis	rs7666738	0.791	rs7665273	chr4:98997413	C/A	cg18180107	chr4:99064573	C4orf37	0.4	5.23	0.31	3.41e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9733	0.818	rs4970926	chr1:150673684	T/C	cg18016565	chr1:150552671	MCL1	-0.35	-5.82	-0.34	1.73e-8	Tonsillectomy;
CESC	cis	rs763121	0.853	rs5750659	chr22:39068789	T/C	cg06544989	chr22:39130855	UNC84B	0.5	8.88	0.48	1.05e-16	Menopause (age at onset);
CESC	cis	rs921968	0.643	rs2278529	chr2:219502132	C/T	cg02176678	chr2:219576539	TTLL4	0.35	6.13	0.35	3.16e-9	Mean corpuscular hemoglobin concentration;
CESC	cis	rs875971	0.964	rs778708	chr7:65856319	T/C	cg12463550	chr7:65579703	CRCP	0.59	7.52	0.42	8.29e-13	Aortic root size;
CESC	cis	rs875971	0.545	rs75577046	chr7:65958716	A/G	cg25405998	chr7:65216604	CCT6P1	0.46	5.11	0.3	6.26e-7	Aortic root size;
CESC	cis	rs473651	0.935	rs515412	chr2:239345394	A/T	cg21699342	chr2:239360505	ASB1	0.46	7.59	0.42	5.56e-13	Multiple system atrophy;
CESC	cis	rs8114671	0.562	rs725521	chr20:33516071	T/C	cg07148914	chr20:33460835	GGT7	0.46	6.13	0.35	3.19e-9	Height;
CESC	trans	rs9325144	0.555	rs2387855	chr12:38687964	T/G	cg23762105	chr12:34175262	ALG10	-0.46	-6.15	-0.35	2.77e-9	Morning vs. evening chronotype;
CESC	cis	rs2070488	0.804	rs13063978	chr3:38476538	A/G	cg24069376	chr3:38537580	EXOG	0.35	5.92	0.34	9.72e-9	Electrocardiographic conduction measures;
CESC	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg24829409	chr8:58192753	C8orf71	-0.69	-7.68	-0.43	3.13e-13	Developmental language disorder (linguistic errors);
CESC	cis	rs7666738	0.830	rs10470951	chr4:99037051	G/A	cg24818145	chr4:99064322	C4orf37	0.38	5.04	0.3	8.81e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs853679	0.546	rs200981	chr6:27833174	A/G	cg26587870	chr6:27730563	NA	-0.59	-5.26	-0.31	3e-7	Depression;
CESC	cis	rs8133932	0.654	rs425232	chr21:47346525	G/T	cg14185626	chr21:47401492	COL6A1	-0.48	-5.33	-0.31	2.07e-7	Schizophrenia;
CESC	cis	rs7089973	0.604	rs7897937	chr10:116591318	A/G	cg23260525	chr10:116636907	FAM160B1	0.4	7.19	0.4	6.76e-12	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs514406	0.683	rs6588440	chr1:53209587	C/T	cg24675658	chr1:53192096	ZYG11B	0.6	7.55	0.42	7.13e-13	Monocyte count;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg05714672	chr3:15469004	METTL6;EAF1	-0.4	-6.02	-0.35	5.94e-9	Gambling;
CESC	cis	rs738322	0.839	rs9607517	chr22:38596100	G/A	cg25457927	chr22:38595422	NA	0.35	6.58	0.37	2.47e-10	Cutaneous nevi;
CESC	cis	rs12188164	0.965	rs1056465	chr5:442438	T/A	cg15813090	chr5:442598	EXOC3;C5orf55	0.42	6.29	0.36	1.31e-9	Cystic fibrosis severity;
CESC	cis	rs9811920	0.809	rs6440967	chr3:99722396	G/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.43	7.18	0.4	7.21e-12	Axial length;
CESC	cis	rs3087591	0.879	rs59015798	chr17:29580882	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.44	-5.09	-0.3	6.75e-7	Hip circumference;
CESC	cis	rs4925386	0.840	rs6143036	chr20:60921721	C/A	cg22307297	chr20:60903441	LAMA5	0.4	5.38	0.31	1.62e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs6502050	0.835	rs11077971	chr17:80090629	A/G	cg11859384	chr17:80120422	CCDC57	-0.38	-5.16	-0.3	4.95e-7	Life satisfaction;
CESC	cis	rs367943	0.712	rs7734061	chr5:112700175	A/G	cg12552261	chr5:112820674	MCC	0.42	5.54	0.32	7.2e-8	Type 2 diabetes;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg07156929	chr6:34856927	ANKS1A;TAF11	-0.46	-6.05	-0.35	4.79e-9	Ulcerative colitis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01027365	chr2:191184571	HIBCH	0.59	6.92	0.39	3.34e-11	Gut microbiome composition (summer);
CESC	cis	rs916888	0.773	rs169201	chr17:44790203	A/G	cg15921436	chr17:44337874	NA	0.74	7.76	0.43	1.82e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs2072499	0.966	rs2842869	chr1:156160696	A/G	cg06970220	chr1:156163860	SLC25A44	0.39	5.18	0.3	4.32e-7	Testicular germ cell tumor;
CESC	trans	rs9987353	0.840	rs329994	chr8:9123233	A/G	cg21271767	chr15:63449808	RPS27L	-0.47	-6.23	-0.36	1.82e-9	Recombination measurement;
CESC	cis	rs2439831	0.557	rs13329084	chr15:44151063	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.7	-6.98	-0.39	2.43e-11	Lung cancer in ever smokers;
CESC	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg11494091	chr17:61959527	GH2	0.73	12.49	0.61	1.88e-28	Prudent dietary pattern;
CESC	cis	rs8070740	0.617	rs1058115	chr17:5323269	A/G	cg25236894	chr17:5323110	RPAIN;NUP88	-0.54	-7.39	-0.41	1.95e-12	Menopause (age at onset);
CESC	cis	rs2404602	0.692	rs7163397	chr15:76940315	A/G	cg22467129	chr15:76604101	ETFA	-0.35	-5.15	-0.3	5.1e-7	Blood metabolite levels;
CESC	cis	rs5753037	0.653	rs131271	chr22:30151582	A/G	cg01021169	chr22:30184971	ASCC2	-0.44	-6.2	-0.36	2.12e-9	Type 1 diabetes;
CESC	cis	rs832540	0.629	rs10940512	chr5:56082094	G/C	cg22800045	chr5:56110881	MAP3K1	0.51	6.16	0.35	2.73e-9	Coronary artery disease;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg15120237	chr17:7747620	KDM6B	-0.47	-6.73	-0.38	1.02e-10	Gambling;
CESC	cis	rs17376456	0.877	rs34673483	chr5:93315079	C/A	cg25358565	chr5:93447407	FAM172A	1.1	10.7	0.55	1.98e-22	Diabetic retinopathy;
CESC	cis	rs344364	0.511	rs911392	chr16:1947259	A/G	cg03013636	chr16:1946785	NA	0.46	6.4	0.37	7.09e-10	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs116095464	0.558	rs7713524	chr5:276200	C/T	cg12570787	chr5:219185	SDHA;CCDC127	-0.53	-5.63	-0.33	4.62e-8	Breast cancer;
CESC	cis	rs9486719	0.857	rs9285393	chr6:97020917	C/A	cg06623918	chr6:96969491	KIAA0776	-0.75	-8.14	-0.45	1.51e-14	Migraine;Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25430995	chr10:73611082	PSAP	0.55	6.5	0.37	3.89e-10	Gut microbiome composition (summer);
CESC	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg06873352	chr17:61820015	STRADA	0.74	13.19	0.63	7.17e-31	Prudent dietary pattern;
CESC	cis	rs17376456	0.825	rs6877030	chr5:93201841	C/A	cg21475434	chr5:93447410	FAM172A	0.84	7.45	0.42	1.35e-12	Diabetic retinopathy;
CESC	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg22907277	chr7:1156413	C7orf50	0.45	5.11	0.3	6.12e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs4268898	0.560	rs78711174	chr2:24496531	G/A	cg20701182	chr2:24300061	SF3B14	0.62	6.64	0.38	1.81e-10	Asthma;
CESC	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg24503407	chr1:205819492	PM20D1	0.92	16.78	0.72	1.49e-43	Menarche (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04050850	chr2:219536800	STK36;RNF25	0.53	6.1	0.35	3.75e-9	Gut microbiome composition (summer);
CESC	cis	rs2228479	0.702	rs17226841	chr16:89828484	C/T	cg00800038	chr16:89945340	TCF25	-0.92	-7.62	-0.42	4.38e-13	Skin colour saturation;
CESC	trans	rs561341	1.000	rs554078	chr17:30330109	A/C	cg27661571	chr11:113659931	NA	-0.87	-8.03	-0.44	3.16e-14	Hip circumference adjusted for BMI;
CESC	cis	rs35110281	0.693	rs2251253	chr21:45092257	T/A	cg04455712	chr21:45112962	RRP1B	0.46	7.4	0.41	1.77e-12	Mean corpuscular volume;
CESC	trans	rs208520	0.837	rs208489	chr6:66927584	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.85	-9.9	-0.52	7.1e-20	Exhaled nitric oxide output;
CESC	cis	rs61841072	1.000	rs61841073	chr1:243129519	A/G	cg02356786	chr1:243265016	LOC731275	0.41	5.26	0.31	2.97e-7	Schizophrenia;
CESC	cis	rs7927771	0.965	rs1064608	chr11:47640429	G/C	cg18512352	chr11:47633146	NA	-0.63	-10.06	-0.53	2.25e-20	Subjective well-being;
CESC	cis	rs6540559	0.673	rs6694552	chr1:209976459	A/C	cg21951975	chr1:209979733	IRF6	0.62	7.75	0.43	2.01e-13	Cleft lip with or without cleft palate;
CESC	cis	rs9549260	0.560	rs61963353	chr13:41327301	C/T	cg21288729	chr13:41239152	FOXO1	0.63	5.24	0.31	3.36e-7	Red blood cell count;
CESC	cis	rs6541297	1.000	rs4846909	chr1:230285372	G/A	cg20703242	chr1:230279135	GALNT2	0.72	11.12	0.56	8.03e-24	Coronary artery disease;
CESC	cis	rs10905065	1.000	rs10795488	chr10:5755207	C/A	cg11519256	chr10:5708881	ASB13	0.43	5.59	0.32	5.52e-8	Menopause (age at onset);
CESC	cis	rs12079745	0.793	rs3766094	chr1:169288264	T/A	cg09363564	chr1:169337483	NME7;BLZF1	-1.0	-5.7	-0.33	3.17e-8	QT interval;
CESC	cis	rs35123781	1.000	rs34510678	chr5:139064835	C/T	cg10513866	chr5:139070639	NA	0.39	5.75	0.33	2.41e-8	Schizophrenia;
CESC	cis	rs7552404	0.924	rs1858536	chr1:76161595	G/T	cg03433033	chr1:76189801	ACADM	0.7	9.38	0.5	2.99e-18	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs12136530	0.774	rs10442635	chr1:19775492	C/T	cg01832549	chr1:19774989	CAPZB	0.4	5.81	0.34	1.75e-8	Lead levels in blood;
CESC	cis	rs853679	0.517	rs9357061	chr6:28051772	A/G	cg12963246	chr6:28129442	ZNF389	0.55	7.35	0.41	2.46e-12	Depression;
CESC	trans	rs9325144	0.560	rs7980358	chr12:38640396	C/G	cg23762105	chr12:34175262	ALG10	-0.48	-6.25	-0.36	1.63e-9	Morning vs. evening chronotype;
CESC	cis	rs748404	0.601	rs489964	chr15:43517554	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	-0.43	-5.18	-0.3	4.34e-7	Lung cancer;
CESC	cis	rs2836974	0.897	rs68090597	chr21:40535633	A/G	cg17971929	chr21:40555470	PSMG1	1.04	16.4	0.71	3.38e-42	Cognitive function;
CESC	cis	rs4891159	0.548	rs660342	chr18:74130896	C/G	cg24786174	chr18:74118243	ZNF516	0.83	15.82	0.7	3.9e-40	Longevity;
CESC	cis	rs514406	0.505	rs395169	chr1:53174071	G/A	cg08736216	chr1:53307985	ZYG11A	-0.39	-6.42	-0.37	6.21e-10	Monocyte count;
CESC	cis	rs8005677	1.000	rs4981446	chr14:23381413	A/G	cg25600027	chr14:23388339	RBM23	-0.43	-5.33	-0.31	2.08e-7	Cognitive ability (multi-trait analysis);
CESC	trans	rs1814175	0.817	rs4881623	chr11:49804991	C/T	cg03929089	chr4:120376271	NA	-0.9	-14.97	-0.68	4.06e-37	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05606948	chr13:24408286	MIPEP	-0.6	-6.46	-0.37	4.98e-10	Gut microbiome composition (summer);
CESC	cis	rs631288	0.793	rs894473	chr1:146687789	A/G	cg25205988	chr1:146714368	CHD1L	1.17	6.69	0.38	1.34e-10	PR interval in Tripanosoma cruzi seropositivity;
CESC	trans	rs11098499	0.863	rs34868248	chr4:120442430	A/G	cg25214090	chr10:38739885	LOC399744	0.7	9.63	0.51	5.06e-19	Corneal astigmatism;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15793417	chr19:38573135	SIPA1L3	-0.56	-6.7	-0.38	1.23e-10	Gut microbiome composition (summer);
CESC	cis	rs2073300	0.609	rs2281428	chr20:23400050	C/T	cg12062639	chr20:23401060	NAPB	1.08	8.41	0.46	2.6e-15	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	trans	rs2207136	0.868	rs9381906	chr6:50830691	G/T	cg06522515	chr3:184090630	THPO	-0.38	-6.63	-0.38	1.9e-10	Myopia;
CESC	cis	rs9682041	0.696	rs11927807	chr3:170096623	A/G	cg11886554	chr3:170076028	SKIL	0.7	6.46	0.37	4.94e-10	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CESC	cis	rs208520	0.690	rs7764570	chr6:66827600	G/C	cg07460842	chr6:66804631	NA	-0.84	-11.39	-0.57	9.72e-25	Exhaled nitric oxide output;
CESC	cis	rs10504229	0.683	rs11775506	chr8:58133639	G/T	cg22535103	chr8:58192502	C8orf71	-0.81	-9.14	-0.49	1.65e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs6463523	0.898	rs66892628	chr7:759374	T/A	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.96	14.73	0.67	2.83e-36	Subjective well-being;
CESC	cis	rs1475911	0.708	rs8129075	chr21:43523430	G/T	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.55	-8.53	-0.46	1.18e-15	IgG glycosylation;
CESC	cis	rs4843747	0.671	rs72818577	chr16:88111181	G/A	cg17633681	chr16:88106987	BANP	0.76	10.48	0.54	1.02e-21	Menopause (age at onset);
CESC	cis	rs9486715	0.867	rs1855533	chr6:97050265	T/C	cg18709589	chr6:96969512	KIAA0776	-0.45	-6.21	-0.36	2.05e-9	Headache;
CESC	cis	rs644799	1.000	rs611020	chr11:95567905	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.55	6.49	0.37	4.26e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs10870270	1.000	rs9971066	chr10:133788233	G/A	cg26149184	chr10:133730230	NA	0.4	5.42	0.32	1.35e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs6754311	0.731	rs2322660	chr2:136557319	A/G	cg07169764	chr2:136633963	MCM6	0.67	8.2	0.45	1.03e-14	Mosquito bite size;
CESC	cis	rs7178909	0.872	rs61345389	chr15:90435885	T/C	cg19708238	chr15:90437601	AP3S2	0.43	6.23	0.36	1.86e-9	Common traits (Other);
CESC	cis	rs6060717	0.653	rs2590962	chr20:34615363	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-7.86	-0.43	9.46e-14	Hip circumference adjusted for BMI;
CESC	cis	rs9611565	0.659	rs56319767	chr22:41933837	G/A	cg06481639	chr22:41940642	POLR3H	-0.62	-6.41	-0.37	6.55e-10	Vitiligo;
CESC	cis	rs4927850	0.709	rs6765762	chr3:195652851	G/A	cg01181863	chr3:195395398	SDHAP2	-0.69	-7.75	-0.43	1.94e-13	Pancreatic cancer;
CESC	cis	rs10461617	0.531	rs2662033	chr5:56213410	T/G	cg20203395	chr5:56204925	C5orf35	-0.43	-5.21	-0.3	3.87e-7	Type 2 diabetes;
CESC	cis	rs4713118	0.662	rs9468276	chr6:28027688	A/C	cg12963246	chr6:28129442	ZNF389	0.5	6.4	0.37	6.93e-10	Parkinson's disease;
CESC	cis	rs11997175	0.624	rs4355732	chr8:33676920	A/C	ch.8.33884649F	chr8:33765107	NA	0.58	7.4	0.41	1.85e-12	Body mass index;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg04141094	chr2:54785178	SPTBN1	-0.45	-6.07	-0.35	4.5e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs7666738	0.830	rs4699600	chr4:99019429	C/G	cg03676636	chr4:99064102	C4orf37	0.33	5.15	0.3	5.05e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6952809	0.516	rs6952959	chr7:2440722	C/T	cg23289794	chr7:2394357	EIF3B	-0.79	-7.29	-0.41	3.64e-12	Multiple sclerosis;
CESC	cis	rs5167	0.506	rs7257916	chr19:45482884	T/C	cg09555818	chr19:45449301	APOC2	-0.47	-6.99	-0.39	2.26e-11	Blood protein levels;
CESC	cis	rs9916302	0.861	rs8081033	chr17:37506650	A/G	cg15445000	chr17:37608096	MED1	-0.41	-6.81	-0.39	6.37e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs2032447	0.802	rs199755	chr6:25990367	G/A	cg18357526	chr6:26021779	HIST1H4A	0.7	9.42	0.5	2.24e-18	Intelligence (multi-trait analysis);
CESC	cis	rs7937682	0.564	rs10891277	chr11:111373103	A/G	cg09085632	chr11:111637200	PPP2R1B	0.45	5.45	0.32	1.15e-7	Primary sclerosing cholangitis;
CESC	cis	rs4665809	0.590	rs13016807	chr2:26496186	G/C	cg26119090	chr2:26468346	HADHA;HADHB	1.1	12.44	0.61	2.67e-28	Gut microbiome composition (summer);
CESC	cis	rs8031584	1.000	rs35607976	chr15:31277788	T/C	cg14298792	chr15:30685198	CHRFAM7A	-0.46	-5.16	-0.3	4.81e-7	Huntington's disease progression;
CESC	cis	rs73110464	0.609	rs4919752	chr12:53359229	G/C	cg14581129	chr12:53358946	NA	-0.58	-7.84	-0.43	1.07e-13	Cancer (pleiotropy);
CESC	cis	rs9640161	0.830	rs7800196	chr7:150061534	C/G	cg27494647	chr7:150038898	RARRES2	0.42	5.9	0.34	1.1e-8	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs7615952	0.641	rs7640158	chr3:125808011	G/A	cg06494592	chr3:125709126	NA	-0.51	-5.51	-0.32	8.32e-8	Blood pressure (smoking interaction);
CESC	cis	rs863345	0.967	rs12080815	chr1:158533140	A/G	cg12129480	chr1:158549410	OR10X1	-0.31	-6.6	-0.38	2.22e-10	Pneumococcal bacteremia;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg15008879	chr10:22292810	DNAJC1	0.52	6.75	0.38	9.45e-11	Gut microbiota (bacterial taxa);
CESC	trans	rs9856151	1.000	rs13063979	chr3:131564741	G/T	cg07970948	chr7:149543165	ZNF862	-0.47	-6.02	-0.35	5.73e-9	Body mass index;
CESC	trans	rs1814175	0.817	rs10839401	chr11:49876144	C/T	cg03929089	chr4:120376271	NA	-0.9	-14.88	-0.67	8.24e-37	Height;
CESC	cis	rs6598955	0.671	rs58038522	chr1:26582713	C/T	cg19743891	chr1:26644573	UBXN11;CD52	0.37	5.19	0.3	4.16e-7	Obesity-related traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23561934	chr2:121199920	NA	0.57	6.39	0.37	7.25e-10	Gut microbiome composition (summer);
CESC	cis	rs898097	0.841	rs11656358	chr17:80853956	G/A	cg15369054	chr17:80825471	TBCD	0.57	7.96	0.44	5.16e-14	Breast cancer;
CESC	cis	rs8070740	1.000	rs4790772	chr17:5330959	C/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.56	6.77	0.38	8.23e-11	Menopause (age at onset);
CESC	cis	rs9733	0.596	rs72702523	chr1:150650425	G/T	cg22823121	chr1:150693482	HORMAD1	0.48	7.09	0.4	1.21e-11	Tonsillectomy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03800765	chr3:11313984	ATG7	0.56	6.14	0.35	3.02e-9	Gut microbiome composition (summer);
CESC	cis	rs77741769	0.571	rs11065300	chr12:121298512	G/C	cg02419362	chr12:121203948	SPPL3	0.34	5.59	0.32	5.6e-8	Mean corpuscular volume;
CESC	cis	rs1499972	0.938	rs2925312	chr3:117720473	C/T	cg07612923	chr3:117604196	NA	-0.77	-5.71	-0.33	3.06e-8	Schizophrenia;
CESC	cis	rs9868809	0.881	rs7631574	chr3:48663046	A/G	cg07636037	chr3:49044803	WDR6	0.62	5.71	0.33	3e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs933688	1.000	rs6867219	chr5:90718008	T/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.1	12.44	0.61	2.82e-28	Smoking behavior;
CESC	cis	rs2731664	0.756	rs4976695	chr5:176862963	T/A	cg23176889	chr5:176863531	GRK6	-0.64	-10.92	-0.56	3.67e-23	Intelligence (multi-trait analysis);
CESC	cis	rs7772486	0.846	rs9373482	chr6:146363123	A/C	cg23711669	chr6:146136114	FBXO30	0.85	12.56	0.61	1.02e-28	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs116988415	0.584	rs2269306	chr14:65245417	A/G	cg25083366	chr14:65239357	SPTB	-0.67	-5.04	-0.3	8.56e-7	Daytime sleep phenotypes;
CESC	cis	rs34779708	0.931	rs4934697	chr10:35287192	C/T	cg04310649	chr10:35416472	CREM	-0.49	-5.91	-0.34	1.03e-8	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs17023223	0.508	rs12096448	chr1:119683390	G/A	cg05756136	chr1:119680316	WARS2	-0.45	-5.42	-0.32	1.31e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CESC	cis	rs2204008	0.777	rs11179774	chr12:38219559	A/C	cg13010199	chr12:38710504	ALG10B	0.53	6.65	0.38	1.69e-10	Bladder cancer;
CESC	cis	rs13191362	0.935	rs34268859	chr6:162934731	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.73	6.4	0.37	6.88e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs9902453	0.845	rs10853135	chr17:28188675	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.65	8.21	0.45	9.9e-15	Coffee consumption (cups per day);
CESC	cis	rs853679	0.517	rs9393891	chr6:28079160	C/T	cg26335602	chr6:28129616	ZNF389	0.53	7.06	0.4	1.48e-11	Depression;
CESC	cis	rs7586673	1.000	rs16845584	chr2:161923830	C/T	cg22496339	chr2:162101262	NA	-0.51	-6.71	-0.38	1.2e-10	Intelligence (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26773803	chr7:148958927	ZNF783	0.55	6.51	0.37	3.7e-10	Gut microbiome composition (summer);
CESC	trans	rs10242455	0.571	rs45593341	chr7:99304911	C/A	cg09045935	chr12:6379348	NA	0.78	6.33	0.36	1.07e-9	Blood metabolite levels;
CESC	cis	rs8005677	1.000	rs1043209	chr14:23373986	A/G	cg01529538	chr14:23388837	RBM23	-0.53	-7.13	-0.4	9.35e-12	Cognitive ability (multi-trait analysis);
CESC	cis	rs12048904	0.595	rs2295280	chr1:101342497	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.66	9.55	0.51	9.28e-19	Multiple sclerosis;
CESC	cis	rs1799949	1.000	rs33945274	chr17:41280073	G/A	cg25072359	chr17:41440525	NA	0.43	5.78	0.33	2.04e-8	Menopause (age at onset);
CESC	cis	rs9303401	0.659	rs34426768	chr17:56683385	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.02	11.73	0.58	7.25e-26	Cognitive test performance;
CESC	cis	rs798554	0.959	rs798558	chr7:2758935	T/G	cg09658497	chr7:2847517	GNA12	-0.39	-5.53	-0.32	7.81e-8	Height;
CESC	cis	rs962856	0.756	rs4671800	chr2:67622348	T/C	cg09028215	chr2:67624308	ETAA1	-0.44	-5.6	-0.33	5.35e-8	Pancreatic cancer;
CESC	trans	rs35110281	0.627	rs7283362	chr21:44973667	C/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.53	7.11	0.4	1.09e-11	Mean corpuscular volume;
CESC	cis	rs8114671	0.562	rs6087653	chr20:33522054	T/C	cg07148914	chr20:33460835	GGT7	0.46	6.13	0.35	3.19e-9	Height;
CESC	cis	rs910316	1.000	rs11623413	chr14:75588824	C/T	cg08847533	chr14:75593920	NEK9	-0.98	-17.76	-0.74	5e-47	Height;
CESC	cis	rs72781680	1.000	rs55773155	chr2:24255081	A/G	cg08917208	chr2:24149416	ATAD2B	1.06	8.75	0.47	2.62e-16	Lymphocyte counts;
CESC	cis	rs9399135	0.967	rs7773126	chr6:135318390	A/G	cg22676075	chr6:135203613	NA	0.5	6.87	0.39	4.48e-11	Red blood cell count;
CESC	cis	rs963731	0.579	rs1454220	chr2:39277108	G/A	cg04010122	chr2:39346883	SOS1	-0.71	-5.66	-0.33	3.89e-8	Corticobasal degeneration;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10083149	chr2:3321068	TSSC1	-0.64	-7.44	-0.42	1.43e-12	Gut microbiome composition (summer);
CESC	cis	rs728616	0.764	rs56122289	chr10:81746027	G/A	cg05935833	chr10:81318306	SFTPA2	-0.54	-5.16	-0.3	4.93e-7	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs11608355	0.515	rs7976796	chr12:109928013	C/T	cg05360138	chr12:110035743	NA	0.81	8.75	0.47	2.52e-16	Neuroticism;
CESC	cis	rs7772486	0.790	rs9497431	chr6:146248177	T/C	cg05347473	chr6:146136440	FBXO30	-0.55	-7.03	-0.4	1.78e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs16957304	1.000	rs16957304	chr16:67334969	C/T	cg01866162	chr16:67596514	CTCF	-0.73	-5.2	-0.3	3.9e-7	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
CESC	cis	rs7647973	0.580	rs2117938	chr3:49263850	A/G	cg03060546	chr3:49711283	APEH	-0.51	-6.94	-0.39	3.07e-11	Menarche (age at onset);
CESC	cis	rs875971	0.929	rs12673810	chr7:65923853	T/A	cg11764359	chr7:65958608	NA	0.97	15.5	0.69	5.25e-39	Aortic root size;
CESC	cis	rs72781680	0.898	rs56216411	chr2:23934533	G/A	cg08917208	chr2:24149416	ATAD2B	1.1	10.15	0.53	1.18e-20	Lymphocyte counts;
CESC	cis	rs7666738	0.830	rs13113899	chr4:99050422	T/C	cg05340658	chr4:99064831	C4orf37	0.8	12.27	0.6	1.03e-27	Colonoscopy-negative controls vs population controls;
CESC	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg06877462	chr1:205807181	PM20D1	0.39	5.82	0.34	1.69e-8	Menarche (age at onset);
CESC	cis	rs28647808	1.000	rs28690644	chr9:136269669	A/G	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.9	5.73	0.33	2.75e-8	Blood protein levels;
CESC	cis	rs858239	0.539	rs4295546	chr7:23191021	C/T	cg23682824	chr7:23144976	KLHL7	0.49	6.46	0.37	5.12e-10	Cerebrospinal fluid biomarker levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23396974	chr7:45151349	TBRG4	0.58	6.31	0.36	1.19e-9	Gut microbiome composition (summer);
CESC	cis	rs959260	1.000	rs4789181	chr17:73374640	T/A	cg12999837	chr17:73267436	MIF4GD	-0.51	-5.8	-0.34	1.91e-8	Systemic lupus erythematosus;
CESC	cis	rs10927875	0.541	rs1048237	chr1:16341733	T/C	cg22431228	chr1:16359049	CLCNKA	-0.52	-9.9	-0.52	7.22e-20	Dilated cardiomyopathy;
CESC	trans	rs1814175	0.791	rs11040513	chr11:49778153	G/C	cg03929089	chr4:120376271	NA	-0.9	-14.97	-0.68	4.06e-37	Height;
CESC	cis	rs11098499	0.865	rs28634456	chr4:120375778	A/G	cg09307838	chr4:120376055	NA	0.93	13.29	0.63	3.24e-31	Corneal astigmatism;
CESC	cis	rs7412746	0.563	rs3768013	chr1:150815411	G/A	cg17724175	chr1:150552817	MCL1	0.33	5.23	0.31	3.44e-7	Melanoma;
CESC	cis	rs17376456	1.000	rs12187701	chr5:93522290	A/G	cg21475434	chr5:93447410	FAM172A	0.9	7.81	0.43	1.38e-13	Diabetic retinopathy;
CESC	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg09033563	chr22:24373618	LOC391322	-0.52	-7.07	-0.4	1.36e-11	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs274567	0.501	rs274571	chr5:131712125	A/G	cg07395648	chr5:131743802	NA	0.41	5.35	0.31	1.86e-7	Blood metabolite levels;
CESC	cis	rs12477438	0.765	rs62154861	chr2:99590235	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.73	-10.26	-0.53	5.33e-21	Chronic sinus infection;
CESC	cis	rs3760982	0.565	rs8104300	chr19:44293144	T/C	cg11993925	chr19:44307056	LYPD5	0.32	5.39	0.31	1.57e-7	Breast cancer (estrogen-receptor negative);Breast cancer;
CESC	cis	rs34638657	0.827	rs3829548	chr16:82206238	C/G	cg07918374	chr16:82182319	MPHOSPH6	-0.62	-7.49	-0.42	1.06e-12	Lung adenocarcinoma;
CESC	cis	rs2415984	0.600	rs61993295	chr14:46932614	T/C	cg14871534	chr14:47121158	RPL10L	-0.34	-5.14	-0.3	5.44e-7	Number of children ever born;
CESC	cis	rs7216064	1.000	rs6504555	chr17:65940727	A/G	cg12091567	chr17:66097778	LOC651250	0.71	8.07	0.44	2.47e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs4481887	0.893	rs4244186	chr1:248493319	A/G	cg00666640	chr1:248458726	OR2T12	0.36	6.17	0.35	2.56e-9	Common traits (Other);
CESC	cis	rs9649213	0.593	rs35983874	chr7:97916461	C/T	cg00277769	chr7:97922759	BAIAP2L1	-0.35	-5.73	-0.33	2.72e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs67460515	0.892	rs11718905	chr3:161051793	G/A	cg03342759	chr3:160939853	NMD3	-0.52	-7.26	-0.41	4.28e-12	Parkinson's disease;
CESC	cis	rs7618915	0.501	rs35526119	chr3:52749334	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.53	7.88	0.44	8.44e-14	Bipolar disorder;
CESC	cis	rs17376456	0.877	rs2290937	chr5:93356515	A/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.6	5.55	0.32	6.89e-8	Diabetic retinopathy;
CESC	cis	rs9611565	0.545	rs5758432	chr22:42111693	T/C	cg06481639	chr22:41940642	POLR3H	0.62	6.06	0.35	4.57e-9	Vitiligo;
CESC	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg27532560	chr4:187881888	NA	-0.4	-6.14	-0.35	2.92e-9	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2011503	0.941	rs56278919	chr19:19367190	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.5	5.06	0.3	7.87e-7	Bipolar disorder;
CESC	cis	rs9467773	0.595	rs7767847	chr6:26597893	A/T	cg20266910	chr6:26577678	NA	0.35	5.85	0.34	1.44e-8	Intelligence (multi-trait analysis);
CESC	cis	rs4601790	0.601	rs66864335	chr11:65390803	G/A	cg06492744	chr11:65406254	SIPA1	0.42	5.09	0.3	6.67e-7	Blood pressure (age interaction);
CESC	cis	rs7666738	0.753	rs7657644	chr4:99057734	T/A	cg03467027	chr4:99064603	C4orf37	0.48	5.98	0.35	7.02e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6831352	0.918	rs35662508	chr4:100050974	C/G	cg12011299	chr4:100065546	ADH4	-0.59	-6.52	-0.37	3.62e-10	Alcohol dependence;
CESC	cis	rs7255436	0.965	rs7249624	chr19:8446135	G/A	cg10174797	chr19:8464628	RAB11B	0.41	5.96	0.34	8.11e-9	HDL cholesterol;
CESC	cis	rs3820928	0.874	rs10166456	chr2:227900113	G/A	cg11843606	chr2:227700838	RHBDD1	-0.48	-6.43	-0.37	5.78e-10	Pulmonary function;
CESC	cis	rs9527	0.615	rs11191401	chr10:104573403	A/G	cg04362960	chr10:104952993	NT5C2	0.45	5.32	0.31	2.2e-7	Arsenic metabolism;
CESC	cis	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg22127309	chr6:111907043	TRAF3IP2	-0.34	-5.38	-0.31	1.66e-7	Metabolic traits;
CESC	cis	rs11123610	0.520	rs35482526	chr2:3720707	C/G	cg19052272	chr2:3704530	ALLC	-0.5	-5.83	-0.34	1.64e-8	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CESC	cis	rs34779708	0.966	rs35146199	chr10:35460939	T/C	cg04310649	chr10:35416472	CREM	-0.51	-6.2	-0.36	2.13e-9	Inflammatory bowel disease;Crohn's disease;
CESC	trans	rs3780486	1.000	rs10813951	chr9:33128021	C/T	cg20290983	chr6:43655470	MRPS18A	-0.86	-12.61	-0.61	6.96e-29	IgG glycosylation;
CESC	cis	rs7412746	0.621	rs7518156	chr1:150945794	A/C	cg04414720	chr1:150670196	GOLPH3L	0.45	5.92	0.34	1.01e-8	Melanoma;
CESC	cis	rs881375	0.654	rs10760126	chr9:123662618	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.52	7.63	0.42	4.26e-13	Rheumatoid arthritis;
CESC	trans	rs9929218	0.954	rs4552018	chr16:68822854	T/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.62	-8.13	-0.45	1.69e-14	Colorectal cancer;
CESC	cis	rs4780401	0.933	rs12926451	chr16:11819569	A/C	cg01061890	chr16:11836724	TXNDC11	0.4	5.32	0.31	2.26e-7	Rheumatoid arthritis;
CESC	cis	rs911186	0.740	rs6938200	chr6:27231150	A/G	cg12292205	chr6:26970375	C6orf41	-0.57	-5.99	-0.35	6.8e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs2635047	0.811	rs9965170	chr18:44788274	C/T	cg24371990	chr18:44770781	NA	0.39	6.31	0.36	1.14e-9	Educational attainment;
CESC	cis	rs10899021	1.000	rs11236190	chr11:74366755	G/T	cg25880958	chr11:74394337	NA	-0.79	-6.51	-0.37	3.71e-10	Response to metformin (IC50);
CESC	cis	rs7937682	0.855	rs571462	chr11:111487106	C/G	cg22437258	chr11:111473054	SIK2	0.72	9.66	0.51	4.24e-19	Primary sclerosing cholangitis;
CESC	cis	rs12458462	0.892	rs2242174	chr18:77458037	T/C	cg23301140	chr18:77439876	CTDP1	0.56	7.5	0.42	9.67e-13	Monocyte count;
CESC	cis	rs7666738	0.800	rs11941885	chr4:99072921	A/C	cg05340658	chr4:99064831	C4orf37	0.85	12.97	0.62	4.01e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1799949	1.000	rs2175957	chr17:41286822	T/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.66	9.22	0.49	9.73e-18	Menopause (age at onset);
CESC	cis	rs897984	0.609	rs732173	chr16:31050023	C/A	cg02466173	chr16:30829666	NA	-0.44	-7.68	-0.43	3.08e-13	Dementia with Lewy bodies;
CESC	cis	rs963731	0.579	rs1377863	chr2:39238854	T/C	cg04010122	chr2:39346883	SOS1	-0.59	-5.23	-0.31	3.39e-7	Corticobasal degeneration;
CESC	cis	rs11792861	0.926	rs12686736	chr9:111888739	A/G	cg05043794	chr9:111880884	C9orf5	-0.43	-7.08	-0.4	1.3e-11	Menarche (age at onset);
CESC	cis	rs763014	0.966	rs7198877	chr16:661439	A/G	cg07343612	chr16:622815	PIGQ	-0.56	-8.17	-0.45	1.28e-14	Height;
CESC	cis	rs3825932	0.961	rs11856301	chr15:79232330	T/C	cg25744700	chr15:79237217	CTSH	0.48	6.58	0.37	2.45e-10	Type 1 diabetes;
CESC	cis	rs2243480	1.000	rs313799	chr7:65494330	A/G	cg13147721	chr7:65941812	NA	-0.86	-8.36	-0.46	3.7e-15	Diabetic kidney disease;
CESC	cis	rs6142102	0.602	rs2300209	chr20:32643100	T/C	cg08999081	chr20:33150536	PIGU	0.33	5.13	0.3	5.64e-7	Skin pigmentation;
CESC	cis	rs7927771	0.524	rs4539273	chr11:47694699	C/T	cg18512352	chr11:47633146	NA	-0.37	-5.73	-0.33	2.74e-8	Subjective well-being;
CESC	cis	rs2204008	0.660	rs2874343	chr12:38239096	C/T	cg26384229	chr12:38710491	ALG10B	0.73	10.35	0.54	2.55e-21	Bladder cancer;
CESC	trans	rs1728785	0.901	rs933713	chr16:68581378	C/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.61	7.49	0.42	1.04e-12	Ulcerative colitis;
CESC	cis	rs853679	0.517	rs4711164	chr6:28115156	C/T	cg20151795	chr6:28129481	ZNF389	0.46	5.83	0.34	1.65e-8	Depression;
CESC	trans	rs11098499	0.691	rs9995716	chr4:120264996	T/C	cg25214090	chr10:38739885	LOC399744	0.6	8.26	0.45	6.87e-15	Corneal astigmatism;
CESC	cis	rs8070624	0.502	rs12951376	chr17:17752809	C/T	cg04398451	chr17:18023971	MYO15A	-0.58	-7.73	-0.43	2.18e-13	Total body bone mineral density;
CESC	cis	rs2282802	0.685	rs2337081	chr5:139642414	A/C	cg26211634	chr5:139558579	C5orf32	0.53	7.66	0.43	3.55e-13	Intelligence (multi-trait analysis);
CESC	cis	rs1401999	0.966	rs2292998	chr3:183663833	T/C	cg01324343	chr3:183735012	ABCC5	0.63	13.49	0.64	6.42e-32	Anterior chamber depth;
CESC	cis	rs2012796	0.661	rs59969857	chr14:81841579	A/G	cg02996355	chr14:81879375	NA	0.62	7.59	0.42	5.34e-13	Night sleep phenotypes;
CESC	cis	rs4423214	0.879	rs1792283	chr11:71135136	T/C	cg05163923	chr11:71159392	DHCR7	-0.59	-6.82	-0.39	6e-11	Vitamin D levels;
CESC	cis	rs10504229	0.683	rs56208052	chr8:58130207	A/T	cg02725872	chr8:58115012	NA	-0.45	-7.05	-0.4	1.52e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs1580019	0.813	rs2044839	chr7:32500805	A/C	cg06627557	chr7:32535165	LSM5;AVL9	0.9	12.81	0.62	1.49e-29	Cognitive ability;
CESC	cis	rs10256972	0.786	rs3735686	chr7:1062527	G/A	cg04025307	chr7:1156635	C7orf50	0.46	7.33	0.41	2.78e-12	Longevity;Endometriosis;
CESC	cis	rs4727027	0.754	rs917124	chr7:148851213	C/T	cg23158103	chr7:148848205	ZNF398	-0.35	-5.22	-0.31	3.65e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	trans	rs35110281	0.565	rs7278003	chr21:44966069	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.59	8.09	0.45	2.12e-14	Mean corpuscular volume;
CESC	trans	rs916888	0.821	rs199505	chr17:44859410	A/G	cg01341218	chr17:43662625	NA	-0.85	-10.25	-0.53	5.55e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs2072732	0.904	rs2993481	chr1:2973433	A/T	cg03976712	chr1:2946727	NA	0.32	5.2	0.3	3.99e-7	Plateletcrit;
CESC	cis	rs597539	0.690	rs497149	chr11:68626639	A/T	cg18350739	chr11:68623251	NA	-0.44	-6.45	-0.37	5.25e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs4242434	0.927	rs35952885	chr8:22491622	T/G	cg03733263	chr8:22462867	KIAA1967	0.98	14.23	0.66	1.6e-34	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01380634	chr19:4046108	ZBTB7A	-0.54	-6.44	-0.37	5.44e-10	Gut microbiome composition (summer);
CESC	cis	rs10504229	0.679	rs73681882	chr8:58030038	A/G	cg24829409	chr8:58192753	C8orf71	-0.46	-5.93	-0.34	9.43e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs597539	0.731	rs664229	chr11:68624483	C/G	cg21963583	chr11:68658836	MRPL21	0.42	5.73	0.33	2.78e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs1005277	0.603	rs1998062	chr10:38457652	G/C	cg00409905	chr10:38381863	ZNF37A	-0.45	-5.96	-0.34	8.1e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs12950390	0.853	rs8071192	chr17:45856141	A/G	cg00777063	chr17:45855553	NA	-0.4	-5.8	-0.34	1.84e-8	IgG glycosylation;
CESC	cis	rs2749592	0.505	rs7915670	chr10:37870212	T/C	cg00409905	chr10:38381863	ZNF37A	0.43	5.7	0.33	3.24e-8	Age-related hearing impairment (SNP x SNP interaction);
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg17482927	chr17:63133259	RGS9	0.47	6.3	0.36	1.21e-9	Systemic lupus erythematosus;
CESC	cis	rs7666738	0.830	rs13129503	chr4:98987892	T/C	cg03467027	chr4:99064603	C4orf37	0.44	5.54	0.32	7.12e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs8177253	1.000	rs1525892	chr3:133484712	C/T	cg11941060	chr3:133502564	NA	-0.46	-6.46	-0.37	5.02e-10	Iron status biomarkers;
CESC	cis	rs9487051	0.872	rs9487038	chr6:109610152	T/C	cg01475377	chr6:109611718	NA	-0.51	-8.36	-0.46	3.66e-15	Reticulocyte fraction of red cells;
CESC	cis	rs8180040	0.620	rs11709660	chr3:47074927	G/A	cg27129171	chr3:47204927	SETD2	-0.66	-9.82	-0.52	1.32e-19	Colorectal cancer;
CESC	cis	rs1003719	0.762	rs34273703	chr21:38475019	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.63	8.77	0.47	2.14e-16	Eye color traits;
CESC	cis	rs9649213	0.593	rs6949718	chr7:97924483	G/A	cg00277769	chr7:97922759	BAIAP2L1	-0.33	-5.4	-0.31	1.46e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs10504229	0.683	rs7459958	chr8:58111905	G/T	cg24829409	chr8:58192753	C8orf71	-0.59	-7.32	-0.41	2.94e-12	Developmental language disorder (linguistic errors);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg23411318	chr17:27939327	ANKRD13B	0.46	6.14	0.35	3.09e-9	Fibrinogen levels;
CESC	cis	rs735396	1.000	rs1169306	chr12:121438311	C/T	cg25281562	chr12:121454272	C12orf43	0.4	5.17	0.3	4.6e-7	N-glycan levels;
CESC	cis	rs12586317	0.547	rs28589276	chr14:35478865	A/G	cg16230307	chr14:35515116	FAM177A1	0.98	10.57	0.54	5.04e-22	Psoriasis;
CESC	cis	rs6570726	0.935	rs12663205	chr6:145818378	G/A	cg05347473	chr6:146136440	FBXO30	0.49	6.71	0.38	1.2e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs12928939	0.517	rs8049508	chr16:71978313	C/T	cg03805757	chr16:71968109	PKD1L3	-0.56	-6.33	-0.36	1.04e-9	Post bronchodilator FEV1;
CESC	cis	rs909674	0.818	rs5750833	chr22:39843091	C/A	cg24399712	chr22:39784796	NA	-0.83	-10.98	-0.56	2.21e-23	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs597539	0.652	rs501799	chr11:68631240	G/T	cg04772025	chr11:68637568	NA	0.51	6.18	0.36	2.36e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs2842992	0.789	rs7758895	chr6:160193465	T/C	cg27503950	chr6:160024002	NA	0.35	5.08	0.3	7.22e-7	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs8112211	0.816	rs80248244	chr19:38841714	A/C	cg14299480	chr19:38876666	GGN	-0.43	-5.28	-0.31	2.74e-7	Blood protein levels;
CESC	cis	rs13130787	0.606	rs13134681	chr4:94943706	C/T	cg11021082	chr4:95130006	SMARCAD1	0.42	5.88	0.34	1.25e-8	Colorectal cancer;
CESC	cis	rs4662945	0.525	rs28819474	chr2:130264623	T/C	cg05962382	chr2:130345044	NA	-0.47	-7.06	-0.4	1.47e-11	Response to cytidine analogues (gemcitabine);
CESC	cis	rs1008375	0.966	rs11737844	chr4:17697421	A/C	cg15017067	chr4:17643749	FAM184B	0.37	5.2	0.3	3.95e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs1949733	1.000	rs2631745	chr4:8490530	T/C	cg11789530	chr4:8429930	ACOX3	-0.79	-11.25	-0.57	2.91e-24	Response to antineoplastic agents;
CESC	trans	rs3784262	0.669	rs3784257	chr15:58262974	C/T	cg20199333	chr11:46740790	F2	0.37	6.11	0.35	3.62e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
CESC	cis	rs10911363	0.573	rs2761580	chr1:183516989	A/T	cg09173681	chr1:183549694	NCF2	0.52	7.67	0.43	3.24e-13	Systemic lupus erythematosus;
CESC	cis	rs7666738	0.830	rs7664169	chr4:99037859	C/T	cg03467027	chr4:99064603	C4orf37	-0.47	-5.95	-0.34	8.44e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs798554	0.797	rs798487	chr7:2802943	G/A	cg04166393	chr7:2884313	GNA12	0.6	7.6	0.42	5.22e-13	Height;
CESC	trans	rs7726839	0.540	rs7558	chr5:660491	C/T	cg25482853	chr8:67687455	SGK3	0.98	10.12	0.53	1.43e-20	Obesity-related traits;
CESC	cis	rs2204008	0.505	rs11182550	chr12:38570061	A/T	cg26384229	chr12:38710491	ALG10B	0.47	6.8	0.39	6.95e-11	Bladder cancer;
CESC	cis	rs17666538	0.585	rs10090260	chr8:608034	T/C	cg23958373	chr8:599963	NA	0.85	6.57	0.37	2.69e-10	IgG glycosylation;
CESC	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg23708337	chr7:1209742	NA	0.54	5.4	0.31	1.48e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs4561483	0.831	rs2018199	chr16:11940968	C/T	cg08843971	chr16:11963173	GSPT1	-0.38	-5.37	-0.31	1.68e-7	Testicular germ cell tumor;
CESC	cis	rs6543140	0.964	rs6543136	chr2:103065547	G/A	cg04239558	chr2:103089729	SLC9A4	0.43	5.39	0.31	1.54e-7	Blood protein levels;
CESC	cis	rs72848980	0.512	rs61151381	chr10:105370496	C/G	cg00126946	chr10:105363258	SH3PXD2A	0.6	8.53	0.46	1.14e-15	White matter hyperintensity burden;
CESC	trans	rs2727020	0.513	rs10839307	chr11:49609843	A/C	cg03929089	chr4:120376271	NA	-0.85	-13.4	-0.64	1.35e-31	Coronary artery disease;
CESC	cis	rs7666738	0.830	rs13110498	chr4:98959150	G/A	cg03467027	chr4:99064603	C4orf37	0.44	5.54	0.32	7.16e-8	Colonoscopy-negative controls vs population controls;
CESC	trans	rs2066819	1.000	rs808919	chr12:56647911	C/G	cg23245485	chr12:6484219	SCNN1A	-0.42	-6.0	-0.35	6.62e-9	Psoriasis vulgaris;
CESC	trans	rs8073060	0.614	rs225279	chr17:33974214	A/G	cg19694781	chr19:47549865	TMEM160	-0.73	-7.03	-0.4	1.79e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-6.21	-0.36	2.01e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs8027181	0.617	rs4777541	chr15:73082240	C/T	cg25632853	chr15:73088954	NA	0.36	5.86	0.34	1.37e-8	Triglyceride levels;
CESC	cis	rs2842992	0.830	rs2758312	chr6:160153452	G/A	cg26839252	chr6:160211577	TCP1;MRPL18	0.46	5.46	0.32	1.12e-7	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs34779708	0.966	rs7077242	chr10:35481965	A/C	cg03585969	chr10:35415529	CREM	-0.75	-9.82	-0.52	1.3e-19	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs1799949	1.000	rs8176296	chr17:41203591	T/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.41	5.6	0.33	5.36e-8	Menopause (age at onset);
CESC	cis	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg17971929	chr21:40555470	PSMG1	-0.5	-6.26	-0.36	1.55e-9	Cognitive function;
CESC	cis	rs9329289	0.603	rs2458698	chr10:2548452	C/T	cg18171855	chr10:2543474	NA	0.39	5.75	0.33	2.49e-8	Age-related hearing impairment;
CESC	cis	rs731174	0.959	rs11264092	chr1:38190625	T/C	cg12339802	chr1:38156545	C1orf109	-0.54	-6.29	-0.36	1.31e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs6952808	0.692	rs59619245	chr7:2068630	C/T	cg04267008	chr7:1944627	MAD1L1	-0.65	-8.02	-0.44	3.47e-14	Bipolar disorder and schizophrenia;
CESC	cis	rs2273669	0.667	rs12210444	chr6:109305743	T/C	cg05315195	chr6:109294784	ARMC2	-0.65	-6.08	-0.35	4.15e-9	Prostate cancer;
CESC	cis	rs9549260	0.604	rs9532587	chr13:41302694	A/T	cg21288729	chr13:41239152	FOXO1	0.57	5.14	0.3	5.42e-7	Red blood cell count;
CESC	cis	rs1348850	0.645	rs13431091	chr2:178434615	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.6	6.3	0.36	1.26e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs9649213	0.593	rs3779194	chr7:98010277	A/G	cg00277769	chr7:97922759	BAIAP2L1	-0.32	-5.32	-0.31	2.25e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs2594989	0.895	rs2606759	chr3:11349494	T/C	cg00170343	chr3:11313890	ATG7	0.56	5.14	0.3	5.26e-7	Circulating chemerin levels;
CESC	cis	rs11696501	0.739	rs6104250	chr20:44251479	C/T	cg11783356	chr20:44313418	WFDC10B	-0.35	-5.42	-0.32	1.35e-7	Brain structure;
CESC	cis	rs10089	1.000	rs72794401	chr5:127517626	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.77	9.64	0.51	4.67e-19	Ileal carcinoids;
CESC	cis	rs1059312	0.808	rs2170989	chr12:129291317	T/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.82	12.04	0.59	6.48e-27	Systemic lupus erythematosus;
CESC	cis	rs12450688	1	rs12450688	chr17:38144229	G/A	cg17467752	chr17:38218738	THRA	-0.56	-8.22	-0.45	8.91e-15	Sum eosinophil basophil counts;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg26828131	chr1:249106207	SH3BP5L	0.49	6.29	0.36	1.29e-9	Fibrinogen levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06320606	chr5:60139941	ELOVL7	0.63	7.64	0.42	3.86e-13	Gut microbiome composition (summer);
CESC	cis	rs6546550	0.901	rs6721891	chr2:70146121	A/G	cg02498382	chr2:70120550	SNRNP27	-0.41	-7.36	-0.41	2.35e-12	Prevalent atrial fibrillation;
CESC	cis	rs67478160	0.644	rs7159810	chr14:104294117	T/G	cg01849466	chr14:104193079	ZFYVE21	-0.51	-7.1	-0.4	1.12e-11	Schizophrenia;
CESC	cis	rs1008375	0.932	rs6449315	chr4:17590219	A/G	cg27347728	chr4:17578864	LAP3	0.49	5.63	0.33	4.53e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs9640161	0.659	rs11974980	chr7:150009838	C/T	cg10018233	chr7:150070692	REPIN1	0.46	7.32	0.41	2.89e-12	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs9457247	0.967	rs2769355	chr6:167380493	G/A	cg07741184	chr6:167504864	NA	-0.3	-5.38	-0.31	1.65e-7	Crohn's disease;
CESC	cis	rs7618915	0.571	rs6778844	chr3:52596398	C/T	cg18099408	chr3:52552593	STAB1	0.36	5.93	0.34	9.21e-9	Bipolar disorder;
CESC	cis	rs1003719	0.788	rs1155785	chr21:38447939	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.62	8.64	0.47	5.56e-16	Eye color traits;
CESC	cis	rs916888	0.773	rs199451	chr17:44801784	G/A	cg15921436	chr17:44337874	NA	0.74	7.81	0.43	1.35e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs72781680	0.898	rs113522526	chr2:24018476	C/T	cg08917208	chr2:24149416	ATAD2B	0.95	8.55	0.46	1.03e-15	Lymphocyte counts;
CESC	trans	rs116095464	0.558	rs73024831	chr5:257192	A/G	cg00938859	chr5:1591904	SDHAP3	0.63	6.77	0.38	8.35e-11	Breast cancer;
CESC	cis	rs1957429	0.901	rs3813423	chr14:65347475	C/A	cg23373153	chr14:65346875	NA	0.96	11.49	0.58	4.43e-25	Pediatric areal bone mineral density (radius);
CESC	cis	rs2721195	0.874	rs2721173	chr8:145744429	C/T	cg11211951	chr8:145729740	GPT	0.43	7.63	0.42	4.3e-13	Age at first birth;
CESC	cis	rs896854	1.000	rs896854	chr8:95960511	T/C	cg09323728	chr8:95962352	TP53INP1	-0.45	-9.86	-0.52	9.98e-20	Type 2 diabetes;
CESC	cis	rs6502050	0.871	rs62079994	chr17:80076516	T/C	cg11859384	chr17:80120422	CCDC57	0.4	5.5	0.32	8.88e-8	Life satisfaction;
CESC	cis	rs1062177	0.855	rs6884630	chr5:151268997	A/T	cg12924095	chr5:151150029	G3BP1	0.41	5.53	0.32	7.54e-8	Preschool internalizing problems;
CESC	cis	rs6938	0.618	rs11638130	chr15:75183935	G/A	cg14664628	chr15:75095509	CSK	-0.52	-6.85	-0.39	5.26e-11	Breast cancer;
CESC	cis	rs10751667	0.643	rs7396046	chr11:937176	T/C	cg06064525	chr11:970664	AP2A2	-0.5	-10.04	-0.52	2.7e-20	Alzheimer's disease (late onset);
CESC	cis	rs6570726	0.791	rs370112	chr6:145859853	T/G	cg05347473	chr6:146136440	FBXO30	0.57	7.3	0.41	3.36e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.54	6.65	0.38	1.7e-10	Prudent dietary pattern;
CESC	cis	rs16854884	0.632	rs34071449	chr3:143662861	C/T	cg06585982	chr3:143692056	C3orf58	0.53	6.6	0.38	2.26e-10	Economic and political preferences (feminism/equality);
CESC	cis	rs854765	0.583	rs6502622	chr17:17834691	A/G	cg04398451	chr17:18023971	MYO15A	-0.67	-9.75	-0.51	2.19e-19	Total body bone mineral density;
CESC	cis	rs9611565	0.802	rs73176692	chr22:41785735	G/A	cg03806693	chr22:41940476	POLR3H	-1.06	-12.46	-0.61	2.35e-28	Vitiligo;
CESC	cis	rs1790761	0.667	rs598811	chr11:67311676	C/T	cg24690094	chr11:67383802	NA	0.35	5.74	0.33	2.59e-8	Mean corpuscular volume;
CESC	cis	rs769267	1.000	rs2074090	chr19:19449686	G/T	cg15052019	chr19:19431593	KIAA0892;SF4	-0.41	-5.2	-0.3	3.93e-7	Tonsillectomy;
CESC	cis	rs736408	0.509	rs13083798	chr3:52649748	A/G	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.34	6.68	0.38	1.42e-10	Bipolar disorder;
CESC	cis	rs10788264	0.569	rs3901289	chr10:124027433	T/C	cg09507567	chr10:124027408	NA	0.43	6.64	0.38	1.75e-10	Total body bone mineral density;
CESC	cis	rs9916302	0.904	rs55660616	chr17:37684990	C/A	cg07936489	chr17:37558343	FBXL20	-0.8	-11.57	-0.58	2.46e-25	Glomerular filtration rate (creatinine);
CESC	cis	rs9649213	0.593	rs7797943	chr7:97946902	T/C	cg08684580	chr7:98029266	BAIAP2L1	-0.35	-5.74	-0.33	2.57e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs34779708	0.897	rs4934527	chr10:35281118	T/A	cg04310649	chr10:35416472	CREM	-0.52	-6.37	-0.36	8.48e-10	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs977987	0.806	rs2903033	chr16:75389606	T/A	cg03315344	chr16:75512273	CHST6	0.4	5.83	0.34	1.61e-8	Dupuytren's disease;
CESC	cis	rs7949030	0.626	rs71490390	chr11:62329185	A/G	cg23462726	chr11:62437636	C11orf83;C11orf48	-0.39	-5.12	-0.3	5.79e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs7818345	1.000	rs6984145	chr8:19294111	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.35	6.32	0.36	1.12e-9	Language performance in older adults (adjusted for episodic memory);
CESC	cis	rs9649213	0.593	rs13246725	chr7:97914898	C/G	cg21770322	chr7:97807741	LMTK2	0.55	8.08	0.44	2.32e-14	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs853679	0.517	rs2275508	chr6:28094731	T/C	cg17949981	chr6:28129498	ZNF389	0.48	6.14	0.35	3.05e-9	Depression;
CESC	cis	rs67478160	0.634	rs941475	chr14:104240618	A/C	cg01849466	chr14:104193079	ZFYVE21	-0.53	-7.8	-0.43	1.41e-13	Schizophrenia;
CESC	cis	rs7208859	0.673	rs9891413	chr17:29208209	G/C	cg19761014	chr17:28927070	LRRC37B2	0.72	5.71	0.33	3.06e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs713587	0.571	rs2918630	chr2:25314186	A/G	cg10045137	chr2:25383940	POMC	-0.34	-5.08	-0.3	7.05e-7	Body mass index in non-asthmatics;
CESC	trans	rs7615952	0.512	rs4646765	chr3:125820707	G/A	cg07211511	chr3:129823064	LOC729375	-0.57	-6.28	-0.36	1.38e-9	Blood pressure (smoking interaction);
CESC	cis	rs13191362	0.507	rs1954806	chr6:163051858	G/C	cg06582575	chr6:163149167	PACRG;PARK2	-0.51	-6.09	-0.35	3.91e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04740264	chr16:3632588	BTBD12	-0.55	-6.28	-0.36	1.37e-9	Gut microbiome composition (summer);
CESC	cis	rs10504229	1.000	rs66840104	chr8:58190001	C/T	cg14926445	chr8:58193284	C8orf71	-0.51	-5.52	-0.32	8.28e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs763121	0.819	rs5757133	chr22:38947835	A/G	cg06022373	chr22:39101656	GTPBP1	-0.79	-11.61	-0.58	1.83e-25	Menopause (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24623068	chr5:154317667	GEMIN5	0.68	7.96	0.44	5e-14	Gut microbiome composition (summer);
CESC	cis	rs9311474	0.508	rs11720243	chr3:52618018	T/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	5.87	0.34	1.27e-8	Electroencephalogram traits;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg18247177	chr17:7745472	KDM6B	0.48	6.19	0.36	2.31e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs6912958	0.712	rs6454638	chr6:88329427	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.51	6.79	0.38	7.55e-11	Monocyte percentage of white cells;
CESC	cis	rs1707322	1.000	rs4134387	chr1:46395158	A/T	cg06784218	chr1:46089804	CCDC17	0.36	6.01	0.35	5.95e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9486719	0.948	rs6920913	chr6:96874297	A/G	cg18709589	chr6:96969512	KIAA0776	0.49	5.55	0.32	6.82e-8	Migraine;Coronary artery disease;
CESC	cis	rs36051895	0.664	rs12340866	chr9:5094185	G/A	cg02405213	chr9:5042618	JAK2	-0.51	-6.17	-0.35	2.61e-9	Pediatric autoimmune diseases;
CESC	cis	rs67311347	1.000	rs1047855	chr3:40468896	A/G	cg24209194	chr3:40518798	ZNF619	-0.54	-6.69	-0.38	1.3e-10	Renal cell carcinoma;
CESC	cis	rs7618915	0.547	rs2289250	chr3:52682946	A/C	cg05564831	chr3:52568323	NT5DC2	-0.46	-7.14	-0.4	8.9e-12	Bipolar disorder;
CESC	cis	rs7208859	0.673	rs999798	chr17:29158840	A/G	cg19761014	chr17:28927070	LRRC37B2	0.59	6.03	0.35	5.62e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs4665809	0.816	rs2384359	chr2:26371364	T/C	cg26314531	chr2:26401878	FAM59B	-0.78	-8.82	-0.48	1.6e-16	Gut microbiome composition (summer);
CESC	cis	rs1580019	0.713	rs2122632	chr7:32524686	A/G	cg06627557	chr7:32535165	LSM5;AVL9	-1.01	-16.42	-0.71	2.93e-42	Cognitive ability;
CESC	cis	rs875971	0.862	rs778736	chr7:65813848	C/T	cg18876405	chr7:65276391	NA	0.53	7.27	0.41	4.11e-12	Aortic root size;
CESC	trans	rs12310956	0.532	rs1525897	chr12:33941033	C/T	cg26384229	chr12:38710491	ALG10B	0.57	7.99	0.44	4.13e-14	Morning vs. evening chronotype;
CESC	cis	rs7666738	0.783	rs10028584	chr4:98962404	C/T	cg05340658	chr4:99064831	C4orf37	0.8	12.17	0.6	2.3e-27	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7582180	0.700	rs1437971	chr2:100986964	A/C	cg16145071	chr2:101727897	TBC1D8	-0.5	-5.31	-0.31	2.35e-7	Intelligence (multi-trait analysis);
CESC	cis	rs7618501	1.000	rs11709680	chr3:49745188	C/T	cg24308560	chr3:49941425	MST1R	0.51	6.95	0.39	2.87e-11	Intelligence (multi-trait analysis);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg10042178	chr1:87794589	LMO4	-0.45	-6.25	-0.36	1.66e-9	Gambling;
CESC	trans	rs11992162	0.967	rs10112888	chr8:11830208	G/C	cg15556689	chr8:8085844	FLJ10661	0.54	6.44	0.37	5.7e-10	Monocyte count;
CESC	cis	rs244293	0.795	rs12940239	chr17:53068930	A/G	cg19360675	chr17:53046073	COX11;STXBP4	-0.47	-6.14	-0.35	3.07e-9	Menarche (age at onset);
CESC	cis	rs11166927	0.967	rs56343024	chr8:140803580	G/A	cg16909799	chr8:140841666	TRAPPC9	0.62	8.98	0.48	5.1e-17	Pediatric non-alcoholic fatty liver disease activity score;
CESC	cis	rs1799949	1.000	rs33945274	chr17:41280073	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.67	9.34	0.5	3.98e-18	Menopause (age at onset);
CESC	cis	rs2645694	0.651	rs2703128	chr4:77819187	C/G	cg18351406	chr4:77819688	ANKRD56	0.53	6.45	0.37	5.2e-10	Emphysema distribution in smoking;
CESC	cis	rs3785574	0.962	rs62077509	chr17:61848973	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.11	19.58	0.77	2.06e-53	Height;
CESC	cis	rs7927771	0.524	rs11039419	chr11:47851354	C/T	cg18512352	chr11:47633146	NA	0.34	5.29	0.31	2.55e-7	Subjective well-being;
CESC	cis	rs11031096	0.727	rs2268168	chr11:4142069	C/T	cg18678763	chr11:4115507	RRM1	-0.46	-6.32	-0.36	1.12e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	cis	rs2412208	0.509	rs7546792	chr1:7124346	C/T	cg20434152	chr1:7120926	CAMTA1	-0.36	-5.81	-0.34	1.75e-8	Survival in sporadic amyotrophic lateral sclerosis;
CESC	cis	rs793571	0.662	rs964285	chr15:59170964	A/G	cg05156742	chr15:59063176	FAM63B	-0.52	-6.95	-0.39	2.84e-11	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00995911	chr19:45004602	ZNF180	0.59	7.23	0.41	5.06e-12	Gut microbiome composition (summer);
CESC	cis	rs896854	0.654	rs28716845	chr8:95974485	A/G	cg26343298	chr8:95960752	TP53INP1	0.36	5.98	0.34	7.06e-9	Type 2 diabetes;
CESC	cis	rs250677	1.000	rs40525	chr5:148432932	G/T	cg18129178	chr5:148520854	ABLIM3	0.45	5.04	0.3	8.78e-7	Breast cancer;
CESC	cis	rs12701220	0.520	rs7803208	chr7:1162084	C/T	cg23978390	chr7:1156363	C7orf50	0.61	7.4	0.41	1.82e-12	Bronchopulmonary dysplasia;
CESC	cis	rs3741151	1.000	rs60924672	chr11:73098724	A/C	cg17517138	chr11:73019481	ARHGEF17	0.98	7.01	0.4	1.99e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs2406342	0.528	rs75536638	chr18:74499060	G/T	cg16472389	chr18:74514291	NA	0.45	5.15	0.3	5.11e-7	Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin);
CESC	cis	rs4604732	0.574	rs111928142	chr1:247625229	G/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	7.52	0.42	8.51e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg12419862	chr22:24373484	LOC391322	-0.8	-11.73	-0.58	7.06e-26	Liver enzyme levels (gamma-glutamyl transferase);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00356213	chr9:35103430	STOML2	-0.58	-6.81	-0.39	6.35e-11	Gut microbiome composition (summer);
CESC	cis	rs9926296	0.632	rs2011925	chr16:89814064	T/G	cg27121462	chr16:89883253	FANCA	0.58	7.01	0.4	1.98e-11	Vitiligo;
CESC	cis	rs7412746	0.611	rs11204748	chr1:150927369	G/T	cg04414720	chr1:150670196	GOLPH3L	0.45	6.02	0.35	5.91e-9	Melanoma;
CESC	cis	rs854765	0.619	rs4561528	chr17:17979099	C/T	cg09796270	chr17:17721594	SREBF1	0.42	5.75	0.33	2.48e-8	Total body bone mineral density;
CESC	cis	rs9469578	1.000	rs9469580	chr6:33715837	A/G	cg18708504	chr6:33715942	IP6K3	-0.61	-7.43	-0.42	1.52e-12	Phosphorus levels;
CESC	cis	rs3008870	1.000	rs3008888	chr1:67368965	C/T	cg08660285	chr1:67390436	MIER1;WDR78	1.02	14.11	0.65	4.39e-34	Lymphocyte percentage of white cells;
CESC	cis	rs3091242	0.836	rs34997029	chr1:25783823	A/G	cg27572855	chr1:25598939	RHD	-0.46	-7.68	-0.43	3.17e-13	Erythrocyte sedimentation rate;
CESC	cis	rs7551222	0.691	rs4951077	chr1:204482262	G/A	cg20240347	chr1:204465584	NA	-0.28	-5.65	-0.33	4.03e-8	Schizophrenia;
CESC	cis	rs9322193	0.923	rs2342765	chr6:150180009	C/G	cg07701084	chr6:150067640	NUP43	0.39	5.16	0.3	4.78e-7	Lung cancer;
CESC	cis	rs7552404	1.000	rs6593585	chr1:76140273	G/A	cg10523679	chr1:76189770	ACADM	0.72	8.33	0.46	4.38e-15	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs11264213	0.901	rs645123	chr1:36458075	T/C	cg27506609	chr1:36549197	TEKT2	0.49	5.15	0.3	5.03e-7	Schizophrenia;
CESC	cis	rs12900413	0.603	rs11629982	chr15:90300272	G/A	cg24249390	chr15:90295951	MESP1	-0.4	-5.38	-0.31	1.61e-7	Coronary artery aneurysm in Kawasaki disease;
CESC	cis	rs9733	0.596	rs6661872	chr1:150628357	C/G	cg17724175	chr1:150552817	MCL1	0.44	7.21	0.41	5.75e-12	Tonsillectomy;
CESC	cis	rs6963495	0.932	rs55700120	chr7:105148460	G/T	cg19920283	chr7:105172520	RINT1	0.66	6.28	0.36	1.36e-9	Bipolar disorder (body mass index interaction);
CESC	cis	rs9486719	1.000	rs12208449	chr6:96903253	A/G	cg18709589	chr6:96969512	KIAA0776	0.52	5.64	0.33	4.45e-8	Migraine;Coronary artery disease;
CESC	cis	rs4862750	0.872	rs1991254	chr4:187875375	T/G	cg10295955	chr4:187884368	NA	-1.01	-16.88	-0.72	6.4e-44	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1879734	0.731	rs6691833	chr1:54159079	C/G	cg23596471	chr1:54105337	GLIS1	0.35	5.67	0.33	3.77e-8	Mitral valve prolapse;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19886106	chr8:144776541	ZNF707	-0.53	-6.25	-0.36	1.66e-9	Gut microbiome composition (summer);
CESC	cis	rs6963495	0.769	rs11556986	chr7:105177041	A/T	cg13798780	chr7:105162888	PUS7	0.73	7.98	0.44	4.55e-14	Bipolar disorder (body mass index interaction);
CESC	cis	rs9322193	0.923	rs1572229	chr6:150064977	T/A	cg13206674	chr6:150067644	NUP43	0.45	6.44	0.37	5.7e-10	Lung cancer;
CESC	cis	rs193541	0.593	rs1035372	chr5:122169448	C/A	cg19412675	chr5:122181750	SNX24	0.45	5.22	0.31	3.63e-7	Glucose homeostasis traits;
CESC	cis	rs6089584	0.606	rs6089599	chr20:60576992	A/G	cg24733560	chr20:60626293	TAF4	-0.45	-6.8	-0.39	6.95e-11	Body mass index;
CESC	cis	rs9479482	0.967	rs763574	chr6:150349415	G/C	cg03788504	chr6:150331562	NA	-0.38	-7.1	-0.4	1.13e-11	Alopecia areata;
CESC	cis	rs35110281	0.837	rs2838340	chr21:45076373	A/G	cg04455712	chr21:45112962	RRP1B	0.39	6.09	0.35	3.85e-9	Mean corpuscular volume;
CESC	cis	rs62244186	0.520	rs2372828	chr3:44784949	A/G	cg15225532	chr3:44803084	KIF15;KIAA1143	-0.49	-6.47	-0.37	4.72e-10	Depressive symptoms;
CESC	cis	rs4819052	0.851	rs4819043	chr21:46660078	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.74	9.89	0.52	7.86e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs2842992	0.830	rs1853259	chr6:160147441	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	-0.69	-8.96	-0.48	5.78e-17	Age-related macular degeneration (geographic atrophy);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg21511036	chr2:227663538	IRS1	0.45	6.13	0.35	3.23e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs17818399	0.653	rs34050156	chr2:46777646	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.48	5.83	0.34	1.65e-8	Height;
CESC	cis	rs9911578	1.000	rs2611782	chr17:56717956	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.27	0.31	2.87e-7	Intelligence (multi-trait analysis);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg16349277	chr4:83323642	NA	-0.47	-6.56	-0.37	2.83e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs7149337	0.836	rs12588488	chr14:51660217	C/A	cg23942311	chr14:51606299	NA	0.45	7.8	0.43	1.45e-13	Cancer;
CESC	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.55	-6.13	-0.35	3.19e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs9916302	0.904	rs801426	chr17:37441109	C/T	cg07936489	chr17:37558343	FBXL20	0.75	10.64	0.55	2.9e-22	Glomerular filtration rate (creatinine);
CESC	cis	rs7582720	0.945	rs2351524	chr2:203880992	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	-0.78	-7.13	-0.4	9.69e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs7666738	0.830	rs35235971	chr4:98999833	G/T	cg03467027	chr4:99064603	C4orf37	0.44	5.51	0.32	8.65e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6089584	0.816	rs6061410	chr20:60625329	A/G	cg24733560	chr20:60626293	TAF4	0.47	6.72	0.38	1.09e-10	Body mass index;
CESC	trans	rs7618501	0.603	rs72942333	chr3:49986118	T/C	cg21659725	chr3:3221576	CRBN	0.55	7.6	0.42	5.29e-13	Intelligence (multi-trait analysis);
CESC	trans	rs3780486	0.846	rs10971419	chr9:33124161	T/C	cg20290983	chr6:43655470	MRPS18A	0.99	18.4	0.75	2.85e-49	IgG glycosylation;
CESC	cis	rs7605378	0.528	rs281787	chr2:200784238	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.51	-5.91	-0.34	1.02e-8	Osteoporosis;
CESC	cis	rs4523957	0.583	rs1565763	chr17:2055300	T/C	cg16513277	chr17:2031491	SMG6	-0.76	-11.02	-0.56	1.68e-23	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs854765	0.551	rs8070748	chr17:17859421	A/G	cg16928487	chr17:17741425	SREBF1	-0.57	-9.57	-0.51	7.66e-19	Total body bone mineral density;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14607407	chr21:34638535	IL10RB	-0.59	-6.54	-0.37	3.06e-10	Gut microbiome composition (summer);
CESC	cis	rs9611565	0.512	rs7291736	chr22:42124874	C/A	cg03806693	chr22:41940476	POLR3H	1.14	13.61	0.64	2.45e-32	Vitiligo;
CESC	cis	rs7666738	0.830	rs7664340	chr4:99037820	C/T	cg18180107	chr4:99064573	C4orf37	0.4	5.2	0.3	4.08e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs910316	1.000	rs12889309	chr14:75593902	C/T	cg16144293	chr14:75469539	EIF2B2	-0.39	-5.08	-0.3	7.04e-7	Height;
CESC	cis	rs7605827	0.930	rs11684395	chr2:15530870	A/G	cg19274914	chr2:15703543	NA	0.35	6.2	0.36	2.12e-9	Educational attainment (years of education);
CESC	cis	rs4727027	1.000	rs4727027	chr7:148869277	C/T	cg23583168	chr7:148888333	NA	-0.8	-12.42	-0.61	3.23e-28	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs2109514	0.650	rs12531767	chr7:116129005	T/A	cg12739419	chr7:116140593	CAV2	-0.38	-6.77	-0.38	8.45e-11	Prevalent atrial fibrillation;
CESC	trans	rs3780486	0.846	rs10813948	chr9:33121570	G/A	cg20290983	chr6:43655470	MRPS18A	0.98	18.13	0.74	2.59e-48	IgG glycosylation;
CESC	cis	rs6570726	0.935	rs382910	chr6:145865941	G/A	cg05347473	chr6:146136440	FBXO30	0.46	6.16	0.35	2.72e-9	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7927771	0.524	rs7943464	chr11:47886639	T/A	cg18512352	chr11:47633146	NA	0.35	5.43	0.32	1.29e-7	Subjective well-being;
CESC	cis	rs2836974	0.666	rs4818015	chr21:40675493	A/C	cg11890956	chr21:40555474	PSMG1	0.96	15.73	0.69	7.86e-40	Cognitive function;
CESC	cis	rs6429082	0.967	rs704710	chr1:235621026	A/G	cg26050004	chr1:235667680	B3GALNT2	0.47	6.34	0.36	1e-9	Adiposity;
CESC	cis	rs1552244	0.808	rs7615088	chr3:10035896	A/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.74	-9.37	-0.5	3.42e-18	Alzheimer's disease;
CESC	cis	rs72945132	0.882	rs7932431	chr11:70166059	A/T	cg00319359	chr11:70116639	PPFIA1	0.78	7.75	0.43	1.98e-13	Coronary artery disease;
CESC	cis	rs2075371	0.835	rs1646724	chr7:134001875	T/G	cg20476274	chr7:133979776	SLC35B4	0.64	9.07	0.49	2.71e-17	Mean platelet volume;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg25372841	chr8:145675454	CYHR1	0.48	6.84	0.39	5.61e-11	Fibrinogen levels;
CESC	cis	rs896854	0.624	rs9297949	chr8:95969445	A/C	cg26343298	chr8:95960752	TP53INP1	0.36	5.95	0.34	8.49e-9	Type 2 diabetes;
CESC	trans	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg13565492	chr6:43139072	SRF	-0.74	-8.72	-0.47	3.11e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs57143961	1	rs57143961	chr19:16533225	C/CT	cg10248733	chr19:16607483	C19orf44;CALR3	-0.62	-6.65	-0.38	1.64e-10	Lymphocyte percentage of white cells;
CESC	cis	rs2842992	0.715	rs2277073	chr6:160182749	G/A	cg11366901	chr6:160182831	ACAT2	0.82	10.5	0.54	8.86e-22	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs9549260	0.683	rs35594717	chr13:41240783	G/A	cg21288729	chr13:41239152	FOXO1	0.57	5.55	0.32	7.09e-8	Red blood cell count;
CESC	cis	rs425277	0.583	rs925905	chr1:2044037	T/C	cg16545954	chr1:2118288	C1orf86	-0.32	-6.08	-0.35	4.14e-9	Height;
CESC	cis	rs4909189	0.915	rs11773551	chr7:158136146	C/T	cg06219351	chr7:158114137	PTPRN2	-0.58	-7.18	-0.4	6.86e-12	Response to amphetamines;
CESC	trans	rs7618501	0.635	rs34080578	chr3:50026029	A/C	cg21659725	chr3:3221576	CRBN	0.53	7.37	0.41	2.19e-12	Intelligence (multi-trait analysis);
CESC	cis	rs3762637	1.000	rs7617042	chr3:122190985	C/T	cg24169773	chr3:122142474	KPNA1	-0.54	-6.33	-0.36	1.04e-9	LDL cholesterol levels;
CESC	cis	rs11785400	0.793	rs7459963	chr8:143737129	C/T	cg24634471	chr8:143751801	JRK	0.46	5.94	0.34	9.01e-9	Schizophrenia;
CESC	cis	rs17376456	0.504	rs7702649	chr5:93065149	C/A	cg25358565	chr5:93447407	FAM172A	0.67	7.24	0.41	4.89e-12	Diabetic retinopathy;
CESC	cis	rs7666738	0.791	rs10033994	chr4:98969582	C/T	cg17366294	chr4:99064904	C4orf37	0.59	8.43	0.46	2.22e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs780096	0.506	rs1647265	chr2:27692261	A/G	cg22903471	chr2:27725779	GCKR	-0.52	-7.39	-0.41	1.88e-12	Total body bone mineral density;
CESC	cis	rs7412746	0.587	rs3849279	chr1:150944707	T/C	cg22823121	chr1:150693482	HORMAD1	0.36	5.04	0.3	8.54e-7	Melanoma;
CESC	cis	rs7727544	0.709	rs272852	chr5:131688767	G/A	cg07395648	chr5:131743802	NA	-0.4	-5.3	-0.31	2.48e-7	Blood metabolite levels;
CESC	cis	rs826838	0.967	rs12823908	chr12:38845686	T/C	cg13010199	chr12:38710504	ALG10B	0.6	8.53	0.46	1.18e-15	Heart rate;
CESC	cis	rs6088590	0.561	rs6087600	chr20:33157217	T/C	cg24642439	chr20:33292090	TP53INP2	0.62	8.42	0.46	2.42e-15	Coronary artery disease;
CESC	trans	rs875971	1.000	rs778726	chr7:65828731	C/T	cg26939375	chr7:64535504	NA	0.47	6.06	0.35	4.66e-9	Aortic root size;
CESC	cis	rs4423214	0.802	rs2276358	chr11:71184498	G/A	cg05163923	chr11:71159392	DHCR7	-0.68	-7.76	-0.43	1.82e-13	Vitamin D levels;
CESC	cis	rs13118159	0.836	rs2293630	chr4:1342521	G/A	cg16405210	chr4:1374714	KIAA1530	-0.7	-9.68	-0.51	3.46e-19	Longevity;
CESC	trans	rs561341	0.825	rs2008368	chr17:30347397	T/C	cg20587970	chr11:113659929	NA	-1.47	-18.13	-0.74	2.44e-48	Hip circumference adjusted for BMI;
CESC	cis	rs3091242	0.933	rs7541095	chr1:25761291	T/C	cg27572855	chr1:25598939	RHD	0.43	7.2	0.4	6.13e-12	Erythrocyte sedimentation rate;
CESC	cis	rs2929278	0.617	rs11070410	chr15:44057045	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.56	-7.54	-0.42	7.29e-13	Schizophrenia;
CESC	cis	rs7918232	0.505	rs788221	chr10:27442247	G/C	cg14442939	chr10:27389572	ANKRD26	-0.66	-5.03	-0.3	8.92e-7	Breast cancer;
CESC	cis	rs7949030	0.588	rs2509982	chr11:62312318	C/T	cg02375832	chr11:62437615	C11orf48	-0.36	-5.27	-0.31	2.83e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs12477438	0.666	rs10179910	chr2:99658503	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.57	-7.83	-0.43	1.19e-13	Chronic sinus infection;
CESC	cis	rs4722166	0.598	rs4722178	chr7:22798650	T/C	cg05472934	chr7:22766657	IL6	0.43	5.79	0.34	1.97e-8	Lung cancer;
CESC	cis	rs514406	0.793	rs12081018	chr1:53217542	C/A	cg24675658	chr1:53192096	ZYG11B	0.57	7.82	0.43	1.23e-13	Monocyte count;
CESC	cis	rs7666738	0.747	rs2865955	chr4:99040518	A/C	cg03676636	chr4:99064102	C4orf37	0.33	5.12	0.3	5.93e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11792861	0.851	rs4542004	chr9:111814478	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.5	6.75	0.38	9.43e-11	Menarche (age at onset);
CESC	cis	rs7843479	0.601	rs11781959	chr8:21841863	C/G	cg17168535	chr8:21777572	XPO7	0.73	11.87	0.59	2.35e-26	Mean corpuscular volume;
CESC	cis	rs12368653	0.840	rs10877020	chr12:58188014	G/A	cg00677455	chr12:58241039	CTDSP2	-0.47	-6.16	-0.35	2.67e-9	Multiple sclerosis;
CESC	cis	rs17253792	0.822	rs17746033	chr14:56061837	G/A	cg01858014	chr14:56050164	KTN1	-0.87	-6.75	-0.38	9.11e-11	Putamen volume;
CESC	cis	rs1322639	0.614	rs6925950	chr6:169563958	A/G	cg03254818	chr6:169586852	NA	0.48	5.22	0.31	3.57e-7	Pulse pressure;
CESC	cis	rs2228479	0.681	rs3212346	chr16:89982358	G/A	cg00800038	chr16:89945340	TCF25	-0.63	-6.6	-0.38	2.19e-10	Skin colour saturation;
CESC	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	7.83	0.43	1.17e-13	Prudent dietary pattern;
CESC	cis	rs2439831	0.867	rs2447196	chr15:43893818	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.82	-8.56	-0.47	9.6e-16	Lung cancer in ever smokers;
CESC	cis	rs896854	0.818	rs13262110	chr8:95926890	C/T	cg23172400	chr8:95962367	TP53INP1	-0.44	-9.16	-0.49	1.49e-17	Type 2 diabetes;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg09302448	chr16:67562672	FAM65A	0.51	7.04	0.4	1.6e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs35306767	0.855	rs56222464	chr10:867535	C/G	cg10556349	chr10:835070	NA	0.76	6.39	0.37	7.22e-10	Eosinophil percentage of granulocytes;
CESC	cis	rs561341	1.000	rs4795669	chr17:30244701	C/T	cg13647721	chr17:30228624	UTP6	0.59	5.28	0.31	2.69e-7	Hip circumference adjusted for BMI;
CESC	cis	rs2243480	1.000	rs10807702	chr7:65767843	C/T	cg12463550	chr7:65579703	CRCP	0.77	5.93	0.34	9.18e-9	Diabetic kidney disease;
CESC	cis	rs875971	0.522	rs4718286	chr7:65292764	A/G	cg11987759	chr7:65425863	GUSB	-0.48	-6.62	-0.38	1.93e-10	Aortic root size;
CESC	cis	rs787274	1.000	rs1711739	chr9:115464474	G/A	cg13803584	chr9:115635662	SNX30	0.52	5.14	0.3	5.29e-7	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs9322193	0.923	rs66516768	chr6:149993135	C/T	cg00933542	chr6:150070202	PCMT1	0.31	5.42	0.32	1.33e-7	Lung cancer;
CESC	cis	rs7618915	0.524	rs2028216	chr3:52680823	C/T	cg05564831	chr3:52568323	NT5DC2	0.45	6.78	0.38	7.87e-11	Bipolar disorder;
CESC	cis	rs2180341	0.814	rs6940933	chr6:127732740	C/G	cg27446573	chr6:127587934	RNF146	0.83	11.83	0.59	3.26e-26	Breast cancer;
CESC	cis	rs2243480	1.000	rs34192067	chr7:65887657	C/A	cg13147721	chr7:65941812	NA	-0.95	-8.95	-0.48	6.27e-17	Diabetic kidney disease;
CESC	cis	rs9311474	0.508	rs17052256	chr3:52593119	A/G	cg05564831	chr3:52568323	NT5DC2	0.47	7.33	0.41	2.81e-12	Electroencephalogram traits;
CESC	cis	rs7772486	0.686	rs6570701	chr6:145954090	A/G	cg23711669	chr6:146136114	FBXO30	0.91	13.45	0.64	8.62e-32	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1620921	0.505	rs1549741	chr6:161204783	G/T	cg01280913	chr6:161186852	NA	-0.36	-5.27	-0.31	2.81e-7	Lipoprotein (a) - cholesterol levels;
CESC	cis	rs10779751	0.960	rs2076657	chr1:11318763	C/G	cg08854313	chr1:11322531	MTOR	0.91	14.45	0.66	2.77e-35	Body mass index;
CESC	cis	rs9549367	0.601	rs558869	chr13:113849932	G/T	cg00898013	chr13:113819073	PROZ	0.45	6.84	0.39	5.48e-11	Platelet distribution width;
CESC	cis	rs9325144	0.505	rs6582691	chr12:38806894	T/C	cg26384229	chr12:38710491	ALG10B	-0.67	-11.36	-0.57	1.23e-24	Morning vs. evening chronotype;
CESC	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.58	7.51	0.42	9.06e-13	Prudent dietary pattern;
CESC	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg23034840	chr1:205782522	SLC41A1	0.66	7.89	0.44	8.02e-14	Menarche (age at onset);
CESC	cis	rs11077773	1.000	rs11077773	chr17:73060073	C/T	cg27626185	chr17:73056755	KCTD2	0.57	6.0	0.35	6.39e-9	Information processing speed;
CESC	cis	rs6089584	0.854	rs6061985	chr20:60622362	T/C	cg13770153	chr20:60521292	NA	-0.44	-5.7	-0.33	3.2e-8	Body mass index;
CESC	cis	rs10089	1.000	rs3805606	chr5:127470813	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.74	-9.78	-0.51	1.74e-19	Ileal carcinoids;
CESC	cis	rs7903847	0.642	rs3814553	chr10:99155984	G/A	cg20016023	chr10:99160130	RRP12	-0.3	-5.16	-0.3	4.77e-7	Granulocyte percentage of myeloid white cells;
CESC	cis	rs56399783	0.803	rs17132665	chr7:2802173	T/C	cg19731401	chr7:2775893	GNA12	0.63	5.59	0.33	5.51e-8	Childhood ear infection;
CESC	cis	rs9322193	0.923	rs9479094	chr6:150046219	C/T	cg04369109	chr6:150039330	LATS1	-0.41	-5.81	-0.34	1.82e-8	Lung cancer;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg04486506	chr20:62577863	UCKL1	0.45	6.46	0.37	5.05e-10	Fibrinogen levels;
CESC	cis	rs13315871	0.929	rs13082278	chr3:58318224	A/G	cg20936604	chr3:58311152	NA	-0.51	-5.13	-0.3	5.57e-7	Cholesterol, total;
CESC	cis	rs13191362	1.000	rs73035021	chr6:163000716	C/A	cg06582575	chr6:163149167	PACRG;PARK2	0.83	8.39	0.46	3.02e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs7116495	0.529	rs575871	chr11:71778822	A/G	cg26138937	chr11:71823887	C11orf51	-0.92	-6.95	-0.39	2.9100000000000002e-11	Severe influenza A (H1N1) infection;
CESC	cis	rs8031584	0.541	rs2955777	chr15:31219788	A/C	cg19680485	chr15:31195859	MTMR15	0.5	6.05	0.35	4.83e-9	Huntington's disease progression;
CESC	cis	rs10504229	0.595	rs36081958	chr8:58117505	C/G	cg22535103	chr8:58192502	C8orf71	-0.8	-9.03	-0.49	3.55e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs2086824	0.702	rs3114896	chr16:89393562	C/T	cg08822215	chr16:89438651	ANKRD11	0.39	5.51	0.32	8.31e-8	Multiple myeloma (IgH translocation);
CESC	cis	rs2839186	0.596	rs4819217	chr21:47644092	G/T	cg00612595	chr21:47717864	NA	-0.37	-5.21	-0.3	3.81e-7	Testicular germ cell tumor;
CESC	cis	rs798554	0.610	rs2248390	chr7:2855594	T/C	cg04166393	chr7:2884313	GNA12	0.39	5.14	0.3	5.3e-7	Height;
CESC	cis	rs875971	0.545	rs73376401	chr7:65639828	G/A	cg19163074	chr7:65112434	INTS4L2	-0.46	-5.05	-0.3	8.17e-7	Aortic root size;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg19313758	chr11:64889193	FAU;MRPL49	0.49	6.42	0.37	6.34e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs3820928	0.874	rs6717168	chr2:227901342	C/T	cg11843606	chr2:227700838	RHBDD1	-0.46	-6.12	-0.35	3.36e-9	Pulmonary function;
CESC	cis	rs11792861	0.926	rs72607163	chr9:111803128	G/T	cg14384093	chr9:111878565	C9orf5	-0.41	-5.12	-0.3	5.85e-7	Menarche (age at onset);
CESC	cis	rs1545257	0.537	rs4581852	chr2:24638256	C/A	cg06627628	chr2:24431161	ITSN2	-0.48	-5.88	-0.34	1.21e-8	Sjögren's syndrome;
CESC	cis	rs713587	0.776	rs3731623	chr2:25163783	T/C	cg01884057	chr2:25150051	NA	0.39	7.38	0.41	1.99e-12	Body mass index in non-asthmatics;
CESC	cis	rs11711311	0.868	rs13091621	chr3:113481977	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.59	7.77	0.43	1.71e-13	IgG glycosylation;
CESC	cis	rs9649213	0.574	rs3801251	chr7:98027618	T/C	cg21770322	chr7:97807741	LMTK2	0.56	8.63	0.47	5.86e-16	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs10870270	0.957	rs7074604	chr10:133740373	G/C	cg17892150	chr10:133769511	PPP2R2D	-0.86	-12.69	-0.61	3.83e-29	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs853679	0.542	rs2295594	chr6:28053097	G/A	cg17949981	chr6:28129498	ZNF389	0.45	5.62	0.33	4.9e-8	Depression;
CESC	cis	rs835154	0.900	rs835153	chr5:14877474	A/G	cg18064842	chr5:14874549	NA	-0.34	-5.21	-0.31	3.71e-7	Blood metabolite levels;
CESC	cis	rs672059	1.000	rs483783	chr1:183162152	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.55	7.22	0.41	5.37e-12	Hypertriglyceridemia;
CESC	cis	rs7666738	0.830	rs35644814	chr4:98886111	G/C	cg17366294	chr4:99064904	C4orf37	0.55	7.65	0.43	3.72e-13	Colonoscopy-negative controls vs population controls;
CESC	trans	rs561341	1.000	rs560132	chr17:30320019	C/T	cg27661571	chr11:113659931	NA	-0.87	-8.01	-0.44	3.71e-14	Hip circumference adjusted for BMI;
CESC	cis	rs6032067	0.929	rs45461302	chr20:43805274	G/A	cg10761708	chr20:43804764	PI3	0.53	6.33	0.36	1.04e-9	Blood protein levels;
CESC	cis	rs3091242	1.000	rs646867	chr1:25709258	A/C	cg27572855	chr1:25598939	RHD	0.44	7.23	0.41	5.28e-12	Erythrocyte sedimentation rate;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg06745235	chr1:180471494	ACBD6	0.48	6.73	0.38	1.06e-10	Systemic lupus erythematosus;
CESC	cis	rs3806843	0.966	rs4141841	chr5:140203432	C/T	cg26395211	chr5:140044315	WDR55	-0.44	-5.49	-0.32	9.2e-8	Depressive symptoms (multi-trait analysis);
CESC	cis	rs780096	0.506	rs2950834	chr2:27627366	G/A	cg24768116	chr2:27665128	KRTCAP3	-0.28	-5.32	-0.31	2.17e-7	Total body bone mineral density;
CESC	cis	rs703842	1.000	rs703842	chr12:58162739	C/T	cg00599273	chr12:58146742	CDK4	-0.33	-5.05	-0.3	8.12e-7	Multiple sclerosis;
CESC	cis	rs1552244	0.572	rs58223482	chr3:10169746	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.67	-7.6	-0.42	5.23e-13	Alzheimer's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21652505	chr19:40023540	EID2B	0.57	6.64	0.38	1.77e-10	Gut microbiome composition (summer);
CESC	cis	rs72945132	0.882	rs58039907	chr11:70183336	C/T	cg00319359	chr11:70116639	PPFIA1	0.72	6.97	0.39	2.51e-11	Coronary artery disease;
CESC	cis	rs1153858	0.943	rs11070454	chr15:45680252	C/T	cg21132104	chr15:45694354	SPATA5L1	0.86	11.62	0.58	1.67e-25	Homoarginine levels;
CESC	cis	rs3859192	0.577	rs25645	chr17:38173143	G/A	cg17467752	chr17:38218738	THRA	-0.45	-5.94	-0.34	8.9e-9	White blood cell count;
CESC	cis	rs6547741	1.000	rs6749052	chr2:27772879	A/T	cg21248554	chr2:27665150	KRTCAP3	0.25	5.24	0.31	3.28e-7	Oral cavity cancer;
CESC	cis	rs9987353	0.566	rs34389718	chr8:9065525	A/G	cg15556689	chr8:8085844	FLJ10661	-0.53	-6.19	-0.36	2.22e-9	Recombination measurement;
CESC	cis	rs5758511	0.514	rs5751240	chr22:42595258	G/C	cg00645731	chr22:42541494	CYP2D7P1	0.59	8.88	0.48	1.02e-16	Birth weight;
CESC	cis	rs9287719	0.967	rs6719701	chr2:10748283	G/A	cg00105475	chr2:10696890	NA	0.38	5.57	0.32	6.34e-8	Prostate cancer;
CESC	cis	rs4423214	0.959	rs12800438	chr11:71171003	G/A	cg05163923	chr11:71159392	DHCR7	0.83	11.29	0.57	2.17e-24	Vitamin D levels;
CESC	cis	rs7267979	1.000	rs6050542	chr20:25318879	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.89	-18.7	-0.75	2.52e-50	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs853679	0.517	rs9368555	chr6:28108967	T/C	cg22143856	chr6:28129313	ZNF389	0.51	6.55	0.37	3e-10	Depression;
CESC	trans	rs9325144	0.600	rs61931871	chr12:38829889	G/A	cg23762105	chr12:34175262	ALG10	0.47	6.09	0.35	3.93e-9	Morning vs. evening chronotype;
CESC	cis	rs6952808	1.000	rs6952808	chr7:1886535	C/G	cg20295408	chr7:1910781	MAD1L1	-0.4	-5.03	-0.3	9.13e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs12142240	0.698	rs6683192	chr1:46830257	C/T	cg10495392	chr1:46806563	NSUN4	0.58	6.3	0.36	1.24e-9	Menopause (age at onset);
CESC	cis	rs1559088	1.000	rs7245404	chr19:33550589	C/T	cg27124370	chr19:33622961	WDR88	0.42	5.34	0.31	1.99e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09279412	chr7:101459283	CUX1	0.56	6.55	0.37	2.96e-10	Gut microbiome composition (summer);
CESC	cis	rs7618915	0.547	rs4687638	chr3:52651966	A/C	cg17372223	chr3:52568218	NT5DC2	0.42	6.29	0.36	1.32e-9	Bipolar disorder;
CESC	cis	rs1218582	0.741	rs10908447	chr1:154869742	C/T	cg16680214	chr1:154839983	KCNN3	-0.5	-7.67	-0.43	3.27e-13	Prostate cancer;
CESC	cis	rs7560272	0.695	rs10190002	chr2:73794054	C/T	cg20560298	chr2:73613845	ALMS1	-0.5	-7.17	-0.4	7.49e-12	Schizophrenia;
CESC	cis	rs7402982	0.934	rs8028620	chr15:99202875	C/T	cg03437748	chr15:99193247	IGF1R	0.73	11.64	0.58	1.49e-25	Birth weight;
CESC	cis	rs17253792	0.822	rs7145064	chr14:56088860	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.71	5.03	0.3	9.02e-7	Putamen volume;
CESC	cis	rs7824557	0.628	rs11994376	chr8:11202960	G/A	cg21775007	chr8:11205619	TDH	0.58	8.89	0.48	9.39e-17	Retinal vascular caliber;
CESC	cis	rs875971	0.862	rs801209	chr7:66019390	G/T	cg19163074	chr7:65112434	INTS4L2	0.42	5.25	0.31	3.18e-7	Aortic root size;
CESC	cis	rs7647973	1.000	rs3866330	chr3:49582994	T/C	cg06212747	chr3:49208901	KLHDC8B	0.6	8.13	0.45	1.66e-14	Menarche (age at onset);
CESC	cis	rs7555523	0.887	rs4657477	chr1:165736175	C/T	cg24409356	chr1:165738333	TMCO1	1.01	8.98	0.48	5.17e-17	Intraocular pressure;Glaucoma (high intraocular pressure);
CESC	cis	rs1552244	0.572	rs57268864	chr3:10164233	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.68	-7.55	-0.42	6.87e-13	Alzheimer's disease;
CESC	cis	rs7621025	0.542	rs71336078	chr3:136489602	G/A	cg15507776	chr3:136538369	TMEM22	-0.77	-7.16	-0.4	8.06e-12	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
CESC	cis	rs2795502	1.000	rs2744092	chr10:43339343	T/C	cg20628663	chr10:43360327	NA	-0.63	-7.47	-0.42	1.16e-12	Blood protein levels;
CESC	cis	rs148734725	1	rs148734725	chr3:49406708	G/A	cg03060546	chr3:49711283	APEH	-0.54	-6.1	-0.35	3.73e-9	Educational attainment (college completion);
CESC	cis	rs9399401	0.667	rs12213892	chr6:142702234	A/G	cg03128060	chr6:142623767	GPR126	0.37	6.5	0.37	4e-10	Chronic obstructive pulmonary disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11315179	chr8:103876601	AZIN1	0.57	6.35	0.36	9.23e-10	Gut microbiome composition (summer);
CESC	cis	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg06181531	chr16:57023355	NLRC5	0.34	5.15	0.3	5.14e-7	Gambling;
CESC	cis	rs9733	0.621	rs6669122	chr1:150591732	A/G	cg18016565	chr1:150552671	MCL1	-0.43	-7.2	-0.4	6.08e-12	Tonsillectomy;
CESC	cis	rs854765	0.693	rs12936037	chr17:17777245	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.5	-6.96	-0.39	2.63e-11	Total body bone mineral density;
CESC	cis	rs7615952	0.576	rs2276727	chr3:125826243	C/T	cg18479299	chr3:125709523	NA	-0.48	-5.24	-0.31	3.29e-7	Blood pressure (smoking interaction);
CESC	cis	rs9733	0.596	rs1415148	chr1:150705755	G/A	cg17724175	chr1:150552817	MCL1	0.45	7.31	0.41	3.17e-12	Tonsillectomy;
CESC	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg08219700	chr8:58056026	NA	0.41	5.38	0.31	1.62e-7	Developmental language disorder (linguistic errors);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20526205	chr7:96339258	SHFM1	0.58	6.51	0.37	3.7e-10	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.830	rs1813251	chr4:98921170	A/G	cg17366294	chr4:99064904	C4orf37	0.57	7.89	0.44	8.07e-14	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7091068	0.616	rs4322326	chr10:95483382	A/T	cg20715218	chr10:95462985	C10orf4	0.49	5.04	0.3	8.66e-7	Urinary tract infection frequency;
CESC	cis	rs11677416	1.000	rs1800587	chr2:113542960	C/T	cg27083787	chr2:113543245	IL1A	0.41	5.23	0.31	3.53e-7	Response to antipsychotic treatment in schizophrenia (working memory);
CESC	cis	rs6728642	1.000	rs113934577	chr2:97888047	G/A	cg26665480	chr2:98280029	ACTR1B	-0.92	-6.97	-0.39	2.47e-11	Bipolar disorder lithium response (continuous) or schizophrenia;
CESC	cis	rs9913156	0.793	rs8074545	chr17:4567337	C/G	cg00122941	chr17:4613640	ARRB2	-0.82	-9.66	-0.51	4.06e-19	Lymphocyte counts;
CESC	cis	rs3087591	1.000	rs7216033	chr17:29574642	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.46	-5.82	-0.34	1.69e-8	Hip circumference;
CESC	cis	rs8180040	0.726	rs4078466	chr3:47126543	C/T	cg27129171	chr3:47204927	SETD2	0.72	11.05	0.56	1.37e-23	Colorectal cancer;
CESC	cis	rs2839186	0.709	rs2839176	chr21:47678173	A/G	cg13012494	chr21:47604986	C21orf56	0.48	6.29	0.36	1.32e-9	Testicular germ cell tumor;
CESC	cis	rs9902453	0.845	rs7209622	chr17:28256807	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.76	10.2	0.53	7.85e-21	Coffee consumption (cups per day);
CESC	cis	rs6540559	0.673	rs17015309	chr1:210007218	C/T	cg21951975	chr1:209979733	IRF6	0.58	6.68	0.38	1.39e-10	Cleft lip with or without cleft palate;
CESC	cis	rs4700695	0.719	rs1643415	chr5:65447087	T/C	cg21114390	chr5:65439923	SFRS12	-0.49	-6.04	-0.35	5.09e-9	Facial morphology (factor 19);
CESC	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.64	7.45	0.42	1.33e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs798554	0.591	rs1713913	chr7:2895627	C/T	cg18446336	chr7:2847575	GNA12	-0.31	-5.05	-0.3	8.06e-7	Height;
CESC	cis	rs875971	0.660	rs10263935	chr7:66096028	A/G	cg21092303	chr7:65958667	NA	-0.4	-5.21	-0.3	3.81e-7	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19594360	chr1:151255303	ZNF687	0.56	6.57	0.37	2.73e-10	Gut microbiome composition (summer);
CESC	cis	rs2109514	0.902	rs7810505	chr7:116111078	G/T	cg12739419	chr7:116140593	CAV2	-0.38	-6.83	-0.39	5.8200000000000003e-11	Prevalent atrial fibrillation;
CESC	cis	rs1218582	0.741	rs4339857	chr1:154888962	A/G	cg09359103	chr1:154839909	KCNN3	-0.65	-12.24	-0.6	1.38e-27	Prostate cancer;
CESC	cis	rs2760061	0.626	rs592736	chr1:228116831	A/G	cg02753203	chr1:228287806	NA	-0.51	-7.71	-0.43	2.57e-13	Diastolic blood pressure;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25277630	chr1:53662708	CPT2	-0.53	-6.15	-0.35	2.82e-9	Gut microbiome composition (summer);
CESC	cis	rs7044106	0.718	rs1981021	chr9:123388393	T/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.8	12.55	0.61	1.17e-28	Hip circumference adjusted for BMI;
CESC	cis	rs9611565	0.592	rs5996038	chr22:41965300	T/C	cg06634786	chr22:41940651	POLR3H	-0.62	-6.75	-0.38	9.16e-11	Vitiligo;
CESC	cis	rs7714584	0.793	rs12653039	chr5:150252631	G/A	cg22134413	chr5:150180641	NA	0.63	6.38	0.36	7.8e-10	Crohn's disease;
CESC	cis	rs9926296	0.632	rs7184315	chr16:89799373	C/G	cg03388025	chr16:89894329	SPIRE2	-0.3	-5.17	-0.3	4.55e-7	Vitiligo;
CESC	cis	rs10883723	0.810	rs1056857	chr10:104240003	C/T	cg22532475	chr10:104410764	TRIM8	-0.34	-5.75	-0.33	2.48e-8	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs1448094	0.556	rs17279916	chr12:86170647	G/A	cg00310523	chr12:86230176	RASSF9	0.42	6.35	0.36	9.52e-10	Major depressive disorder;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg02748427	chr1:92764574	RPAP2;GLMN	-0.49	-6.59	-0.38	2.34e-10	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs6912958	0.712	rs6908386	chr6:88354746	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-5.22	-0.31	3.56e-7	Monocyte percentage of white cells;
CESC	cis	rs1448094	0.512	rs6539925	chr12:86244358	A/G	cg00310523	chr12:86230176	RASSF9	0.35	5.38	0.31	1.67e-7	Major depressive disorder;
CESC	cis	rs1538970	0.924	rs11211118	chr1:45930270	A/C	cg06784218	chr1:46089804	CCDC17	0.34	5.45	0.32	1.14e-7	Platelet count;
CESC	cis	rs1018836	0.886	rs4734246	chr8:91569028	A/C	cg16814680	chr8:91681699	NA	-0.72	-10.29	-0.53	4.01e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs2204008	0.604	rs2320521	chr12:38253789	A/G	cg13010199	chr12:38710504	ALG10B	0.48	6.04	0.35	5.23e-9	Bladder cancer;
CESC	cis	rs7666738	0.753	rs1830230	chr4:99026186	G/C	cg17366294	chr4:99064904	C4orf37	0.62	8.95	0.48	6.32e-17	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9911578	1.000	rs1472288	chr17:56910720	G/A	cg12560992	chr17:57184187	TRIM37	0.94	15.75	0.7	6.57e-40	Intelligence (multi-trait analysis);
CESC	cis	rs11785693	0.865	rs7815144	chr8:4970788	G/T	cg26367366	chr8:4980734	NA	-0.68	-6.47	-0.37	4.62e-10	Neuroticism (multi-trait analysis);Neuroticism;
CESC	cis	rs2243480	1.000	rs160652	chr7:65538431	A/G	cg18252515	chr7:66147081	NA	-1.37	-13.35	-0.63	1.91e-31	Diabetic kidney disease;
CESC	cis	rs10129255	0.646	rs55995061	chr14:107207547	A/G	cg23076370	chr14:107095027	NA	-0.62	-8.49	-0.46	1.45e-15	Kawasaki disease;
CESC	cis	rs763014	0.931	rs7199839	chr16:636126	T/C	cg07343612	chr16:622815	PIGQ	-0.55	-7.99	-0.44	4.25e-14	Height;
CESC	cis	rs4604732	0.536	rs12037221	chr1:247631212	T/C	cg12758973	chr1:247694275	LOC148824;OR2C3	0.48	5.96	0.34	7.9e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs2777491	1.000	rs11631770	chr15:41737059	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.64	-9.62	-0.51	5.41e-19	Ulcerative colitis;
CESC	cis	rs7945705	0.902	rs10743095	chr11:8936984	T/C	cg09997546	chr11:8931473	C11orf17;ST5	0.32	5.29	0.31	2.58e-7	Hemoglobin concentration;
CESC	cis	rs6546550	0.933	rs6546555	chr2:70135760	A/G	cg02498382	chr2:70120550	SNRNP27	-0.39	-6.82	-0.39	5.98e-11	Prevalent atrial fibrillation;
CESC	cis	rs4243830	0.850	rs1064835	chr1:6585539	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	0.65	6.57	0.37	2.68e-10	Body mass index;
CESC	trans	rs208520	0.661	rs704519	chr6:66801136	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.99	-12.8	-0.62	1.63e-29	Exhaled nitric oxide output;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg01830674	chr2:219433148	RQCD1;USP37	0.48	6.49	0.37	4.12e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs6963495	0.818	rs56268110	chr7:105166712	T/C	cg02135003	chr7:105160482	PUS7	-0.46	-5.51	-0.32	8.38e-8	Bipolar disorder (body mass index interaction);
CESC	cis	rs3008870	0.755	rs2815374	chr1:67507387	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.65	8.39	0.46	2.95e-15	Lymphocyte percentage of white cells;
CESC	cis	rs2070488	1.000	rs2268757	chr3:38505853	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.94	17.63	0.73	1.48e-46	Electrocardiographic conduction measures;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg16902244	chr1:24117464	LYPLA2	0.45	6.47	0.37	4.81e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs281302	0.621	rs421853	chr15:47744331	C/T	cg15377044	chr10:47688638	ANTXRL	-0.43	-6.2	-0.36	2.1e-9	Educational attainment (years of education);Cognitive ability (multi-trait analysis);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg14112570	chr9:131644312	CCBL1;LRRC8A	-0.44	-6.14	-0.35	3.03e-9	Fibrinogen levels;
CESC	cis	rs5758659	0.652	rs1063392	chr22:42454950	C/T	cg19513890	chr22:42538836	CYP2D7P1	0.39	5.92	0.34	9.92e-9	Cognitive function;
CESC	cis	rs933688	1.000	rs332544	chr5:90778848	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.94	11.49	0.58	4.76e-25	Smoking behavior;
CESC	cis	rs684232	0.644	rs2657613	chr17:623902	T/C	cg15660573	chr17:549704	VPS53	-0.65	-8.83	-0.48	1.47e-16	Prostate cancer;
CESC	cis	rs9039	1.000	rs17567434	chr16:9221447	C/G	cg08831531	chr16:9218945	NA	-0.53	-7.02	-0.4	1.87e-11	Menopause (age at onset);
CESC	cis	rs9549367	0.826	rs9549713	chr13:113905308	G/T	cg00898013	chr13:113819073	PROZ	-0.53	-7.21	-0.41	5.74e-12	Platelet distribution width;
CESC	cis	rs644799	0.710	rs11021309	chr11:95501898	C/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.77	11.59	0.58	2.21e-25	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs4900538	0.855	rs1190537	chr14:102887816	C/T	cg18135206	chr14:102964638	TECPR2	-0.75	-9.5	-0.5	1.29e-18	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	cis	rs12497850	0.543	rs6446218	chr3:49075513	A/T	cg06212747	chr3:49208901	KLHDC8B	0.7	9.05	0.49	3.26e-17	Parkinson's disease;
CESC	cis	rs4253772	0.701	rs9627280	chr22:46643964	T/C	cg09491104	chr22:46646882	C22orf40	-0.56	-8.71	-0.47	3.38e-16	LDL cholesterol;Cholesterol, total;
CESC	cis	rs10465746	0.570	rs11163887	chr1:84474718	C/T	cg10977910	chr1:84465055	TTLL7	0.43	5.46	0.32	1.12e-7	Obesity-related traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06362048	chr16:15051589	NA	-0.61	-7.04	-0.4	1.6e-11	Gut microbiome composition (summer);
CESC	cis	rs9905704	0.560	rs2450509	chr17:56446150	T/C	cg12560992	chr17:57184187	TRIM37	0.64	5.49	0.32	9.54e-8	Testicular germ cell tumor;
CESC	cis	rs61008539	0.893	rs11765528	chr7:861952	C/T	cg15782153	chr7:917662	C7orf20	0.46	6.63	0.38	1.89e-10	Perceived unattractiveness to mosquitoes;
CESC	cis	rs7660520	0.524	rs4862100	chr4:183732709	G/T	cg04526738	chr4:183727387	NA	0.7	6.47	0.37	4.61e-10	Pediatric autoimmune diseases;
CESC	cis	rs9322193	0.962	rs10452626	chr6:150088617	T/C	cg13206674	chr6:150067644	NUP43	0.43	5.98	0.34	7.33e-9	Lung cancer;
CESC	cis	rs1847505	0.716	rs7321236	chr13:61516730	C/T	cg14094164	chr13:61491000	NA	0.36	5.33	0.31	2.06e-7	Polychlorinated biphenyl levels;
CESC	cis	rs35123781	0.654	rs356443	chr5:139077829	G/C	cg10513866	chr5:139070639	NA	0.42	5.83	0.34	1.6e-8	Schizophrenia;
CESC	cis	rs1665050	0.534	rs4600408	chr15:59246800	T/C	cg05156742	chr15:59063176	FAM63B	0.49	6.15	0.35	2.92e-9	Atopic dermatitis;
CESC	cis	rs3785574	1.000	rs7223257	chr17:61787684	T/C	cg07677032	chr17:61819896	STRADA	0.42	5.41	0.32	1.44e-7	Height;
CESC	cis	rs2180341	0.842	rs7739679	chr6:127545428	G/A	cg27446573	chr6:127587934	RNF146	0.96	11.83	0.59	3.2e-26	Breast cancer;
CESC	cis	rs7301826	0.610	rs7961690	chr12:131296880	G/T	cg11011512	chr12:131303247	STX2	-0.45	-5.49	-0.32	9.37e-8	Plasma plasminogen activator levels;
CESC	cis	rs6546550	0.901	rs7419837	chr2:70146625	T/C	cg02498382	chr2:70120550	SNRNP27	-0.41	-7.26	-0.41	4.34e-12	Prevalent atrial fibrillation;
CESC	cis	rs17001868	0.568	rs9611325	chr22:40782490	G/A	cg07138101	chr22:40742427	ADSL	0.59	5.78	0.33	2.09e-8	Mammographic density (dense area);
CESC	cis	rs514406	0.722	rs7552139	chr1:53387379	G/C	cg24675658	chr1:53192096	ZYG11B	-0.56	-6.98	-0.39	2.36e-11	Monocyte count;
CESC	cis	rs1580019	0.665	rs34147895	chr7:32531796	G/C	cg06627557	chr7:32535165	LSM5;AVL9	1.02	16.48	0.71	1.73e-42	Cognitive ability;
CESC	cis	rs801193	0.967	rs2420827	chr7:66147101	G/A	cg14393609	chr7:65229607	NA	-0.4	-5.2	-0.3	3.97e-7	Aortic root size;
CESC	cis	rs2749592	0.550	rs9733309	chr10:37882405	G/A	cg00409905	chr10:38381863	ZNF37A	0.43	5.79	0.33	2.02e-8	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs7786877	0.723	rs10487157	chr7:100214487	C/G	cg27028030	chr7:100209634	MOSPD3	0.57	5.58	0.32	6.04e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs1348850	0.914	rs1374437	chr2:178363423	T/C	cg22681709	chr2:178499509	PDE11A	-0.43	-6.31	-0.36	1.2e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs10979	0.597	rs9403515	chr6:143908013	A/G	cg25407410	chr6:143891975	LOC285740	-0.49	-6.31	-0.36	1.16e-9	Hypospadias;
CESC	cis	rs1707322	1.000	rs11211236	chr1:46443767	C/A	cg03146154	chr1:46216737	IPP	0.72	9.82	0.52	1.31e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9611565	0.512	rs2899347	chr22:42158204	T/C	cg17376030	chr22:41985996	PMM1	-0.79	-8.18	-0.45	1.18e-14	Vitiligo;
CESC	cis	rs2070488	0.965	rs2051215	chr3:38560345	A/G	cg24069376	chr3:38537580	EXOG	-0.44	-8.24	-0.45	7.75e-15	Electrocardiographic conduction measures;
CESC	cis	rs9916302	0.821	rs11078916	chr17:37746307	T/C	cg15445000	chr17:37608096	MED1	0.34	5.17	0.3	4.63e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs962856	0.619	rs6714988	chr2:67595789	A/G	cg09028215	chr2:67624308	ETAA1	-0.44	-5.31	-0.31	2.37e-7	Pancreatic cancer;
CESC	cis	rs7647973	0.848	rs4292260	chr3:49148890	T/C	cg06212747	chr3:49208901	KLHDC8B	0.55	6.36	0.36	8.72e-10	Menarche (age at onset);
CESC	cis	rs897984	0.645	rs58726213	chr16:31044683	A/G	cg02466173	chr16:30829666	NA	-0.41	-7.03	-0.4	1.73e-11	Dementia with Lewy bodies;
CESC	cis	rs9894429	0.966	rs6565605	chr17:79589359	C/T	cg21984481	chr17:79567631	NPLOC4	-0.44	-7.08	-0.4	1.26e-11	Eye color traits;
CESC	trans	rs10208443	0.647	rs10203930	chr2:72340402	C/T	cg04832019	chr5:28928735	NA	-0.45	-6.05	-0.35	4.81e-9	Colorectal adenoma (advanced);
CESC	cis	rs9768139	0.733	rs13309408	chr7:158122261	C/T	cg25566285	chr7:158114605	PTPRN2	0.48	7.79	0.43	1.48e-13	Calcium levels;
CESC	cis	rs9658691	0.607	rs9658766	chr10:90771612	G/A	cg03111039	chr10:90751583	FAS;ACTA2	-0.61	-5.34	-0.31	2e-7	Mosquito bite size;
CESC	trans	rs9467711	0.606	rs9348726	chr6:26605206	G/A	cg01620082	chr3:125678407	NA	-0.62	-6.25	-0.36	1.59e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs2404602	0.692	rs4641709	chr15:77047736	C/T	cg22467129	chr15:76604101	ETFA	0.35	5.29	0.31	2.53e-7	Blood metabolite levels;
CESC	cis	rs9584850	0.794	rs17574433	chr13:99138057	A/G	cg22223119	chr13:99095684	FARP1	0.4	5.86	0.34	1.4e-8	Neuroticism;
CESC	cis	rs1552244	1.000	rs35993975	chr3:10067794	A/G	cg00149659	chr3:10157352	C3orf10	0.67	7.44	0.42	1.43e-12	Alzheimer's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00978910	chr1:172502140	C1orf9	0.57	6.44	0.37	5.74e-10	Gut microbiome composition (summer);
CESC	cis	rs2576037	0.526	rs509647	chr18:44383675	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.66	9.87	0.52	9.16e-20	Personality dimensions;
CESC	cis	rs7552404	0.924	rs7550974	chr1:76204185	A/G	cg03433033	chr1:76189801	ACADM	0.76	10.66	0.55	2.64e-22	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs1983891	1.000	rs9381080	chr6:41527698	G/C	cg20194872	chr6:41519635	FOXP4	0.56	8.09	0.45	2.16e-14	Prostate cancer;
CESC	cis	rs10540	0.818	rs12806089	chr11:501468	G/A	cg21784768	chr11:537496	LRRC56	-0.54	-5.08	-0.3	7.13e-7	Body mass index;
CESC	cis	rs17376456	1.000	rs13154249	chr5:93550508	C/T	cg21475434	chr5:93447410	FAM172A	0.86	7.53	0.42	7.93e-13	Diabetic retinopathy;
CESC	cis	rs4819052	0.851	rs7275468	chr21:46656499	C/A	cg11663144	chr21:46675770	NA	-0.49	-7.23	-0.41	5.1e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs2295359	1.000	rs11465754	chr1:67631431	A/G	cg17031739	chr1:67600172	NA	0.37	5.04	0.3	8.77e-7	Psoriasis;
CESC	cis	rs10875746	0.729	rs11168355	chr12:48410978	A/G	cg24011408	chr12:48396354	COL2A1	0.42	5.13	0.3	5.74e-7	Longevity (90 years and older);
CESC	cis	rs6964587	1.000	rs9690208	chr7:91735613	T/A	cg17063962	chr7:91808500	NA	0.55	7.54	0.42	7.58e-13	Breast cancer;
CESC	cis	rs7267979	0.966	rs2261720	chr20:25260641	T/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	18.61	0.75	5.21e-50	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs9303401	0.646	rs7213269	chr17:57237796	C/T	cg12560992	chr17:57184187	TRIM37	0.43	5.13	0.3	5.62e-7	Cognitive test performance;
CESC	cis	rs11077998	0.840	rs9894993	chr17:80481088	T/C	cg10255544	chr17:80519551	FOXK2	0.52	8.6	0.47	7.06e-16	Reticulocyte fraction of red cells;
CESC	cis	rs12410462	0.681	rs4486420	chr1:227572321	T/A	cg04117972	chr1:227635322	NA	0.74	6.17	0.35	2.52e-9	Major depressive disorder;
CESC	cis	rs9303401	0.614	rs35308719	chr17:57163501	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.92	11.43	0.57	7.38e-25	Cognitive test performance;
CESC	cis	rs35110281	0.616	rs2236666	chr21:45109856	T/C	cg01579765	chr21:45077557	HSF2BP	-0.53	-8.58	-0.47	8.21e-16	Mean corpuscular volume;
CESC	cis	rs1799949	1.000	rs2175957	chr17:41286822	T/G	cg23758822	chr17:41437982	NA	1.02	15.61	0.69	2.04e-39	Menopause (age at onset);
CESC	cis	rs4665809	0.590	rs13019536	chr2:26526978	C/A	cg26314531	chr2:26401878	FAM59B	-0.49	-5.38	-0.31	1.66e-7	Gut microbiome composition (summer);
CESC	cis	rs3845702	1.000	rs3768839	chr2:180835992	G/A	cg01881094	chr2:180872142	CWC22	-0.64	-6.76	-0.38	8.55e-11	Schizophrenia;
CESC	cis	rs6032067	1.000	rs6017519	chr20:43854677	C/T	cg10761708	chr20:43804764	PI3	0.5	6.15	0.35	2.83e-9	Blood protein levels;
CESC	cis	rs7130144	0.541	rs28875239	chr11:130459571	A/G	cg26307797	chr11:130446613	NA	-0.74	-6.35	-0.36	9.2e-10	Urate levels in lean individuals;
CESC	cis	rs17711722	0.522	rs6957759	chr7:65271785	A/G	cg02869306	chr7:64672164	INTS4L1	-0.33	-5.24	-0.31	3.3e-7	Calcium levels;
CESC	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.6	-7.95	-0.44	5.42e-14	Prudent dietary pattern;
CESC	cis	rs939574	1.000	rs11689596	chr2:220093423	T/G	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-0.63	-6.26	-0.36	1.53e-9	Platelet distribution width;
CESC	cis	rs11676348	0.755	rs6436026	chr2:218951738	T/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.41	-5.48	-0.32	9.9e-8	Ulcerative colitis;
CESC	cis	rs7945705	0.747	rs2568045	chr11:9004060	T/C	cg14711859	chr11:8959438	ASCL3	0.31	5.09	0.3	6.89e-7	Hemoglobin concentration;
CESC	cis	rs1003719	0.788	rs9981226	chr21:38452127	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.62	8.63	0.47	5.94e-16	Eye color traits;
CESC	cis	rs2688608	0.592	rs7076585	chr10:75503692	T/C	cg23231163	chr10:75533350	FUT11	-0.37	-5.57	-0.32	6.38e-8	Inflammatory bowel disease;
CESC	cis	rs367943	0.965	rs463249	chr5:112797430	A/C	cg12552261	chr5:112820674	MCC	-0.61	-7.57	-0.42	6.33e-13	Type 2 diabetes;
CESC	cis	rs938554	0.571	rs7696092	chr4:10025320	C/A	cg00071950	chr4:10020882	SLC2A9	0.71	8.77	0.47	2.19e-16	Blood metabolite levels;
CESC	cis	rs61990749	0.597	rs1477260	chr14:78256818	G/C	cg23188588	chr14:78226832	SNW1;C14orf178	0.5	5.14	0.3	5.27e-7	Fibroblast growth factor basic levels;
CESC	cis	rs875971	0.798	rs57739047	chr7:65972566	A/T	cg10691866	chr7:65817282	TPST1	-0.32	-5.25	-0.31	3.16e-7	Aortic root size;
CESC	cis	rs896854	0.654	rs16893776	chr8:95973604	C/T	cg16049864	chr8:95962084	TP53INP1	-0.63	-10.8	-0.55	9.14e-23	Type 2 diabetes;
CESC	cis	rs425277	0.583	rs925905	chr1:2044037	T/C	cg19257562	chr1:2043853	PRKCZ	0.39	6.35	0.36	9.47e-10	Height;
CESC	cis	rs947211	0.846	rs708726	chr1:205762139	G/T	cg11965913	chr1:205819406	PM20D1	-0.38	-5.16	-0.3	4.89e-7	Parkinson's disease;
CESC	cis	rs2243480	0.711	rs2420172	chr7:65635341	T/C	cg18252515	chr7:66147081	NA	1.36	13.62	0.64	2.25e-32	Diabetic kidney disease;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg17697381	chr3:148709363	GYG1	-0.45	-6.25	-0.36	1.62e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs6866344	0.697	rs11748497	chr5:178130012	C/G	cg03877680	chr5:178157825	ZNF354A	0.76	8.68	0.47	4.16e-16	Neutrophil percentage of white cells;
CESC	cis	rs8062405	0.755	rs55792032	chr16:28599411	A/G	cg01378222	chr16:28622494	SULT1A1	0.31	5.24	0.31	3.28e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	trans	rs7246760	0.867	rs59616842	chr19:9792245	G/A	cg02900749	chr2:68251473	NA	-0.85	-7.53	-0.42	8.04e-13	Pursuit maintenance gain;
CESC	cis	rs4253772	0.550	rs9615951	chr22:46728056	C/A	cg09491104	chr22:46646882	C22orf40	-0.54	-6.11	-0.35	3.62e-9	LDL cholesterol;Cholesterol, total;
CESC	cis	rs4594175	0.847	rs17252303	chr14:51632246	C/T	cg23942311	chr14:51606299	NA	0.37	5.53	0.32	7.79e-8	Cancer;
CESC	cis	rs2228479	0.717	rs34027607	chr16:89808939	T/C	cg00800038	chr16:89945340	TCF25	-0.71	-7.24	-0.41	4.76e-12	Skin colour saturation;
CESC	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg03188948	chr7:1209495	NA	0.7	7.31	0.41	3.1e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs8073060	0.586	rs225303	chr17:33922149	A/G	cg19694781	chr19:47549865	TMEM160	0.69	6.82	0.39	6.13e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	cis	rs1559088	0.895	rs7246562	chr19:33546088	T/G	cg27124370	chr19:33622961	WDR88	0.48	5.89	0.34	1.17e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs798554	0.704	rs798512	chr7:2782592	C/G	cg19717773	chr7:2847554	GNA12	-0.55	-8.64	-0.47	5.3e-16	Height;
CESC	cis	rs801193	1.000	rs2707850	chr7:66203870	G/T	cg18876405	chr7:65276391	NA	0.54	7.28	0.41	3.88e-12	Aortic root size;
CESC	cis	rs7432375	0.610	rs56695781	chr3:136510601	G/T	cg15507776	chr3:136538369	TMEM22	0.6	8.03	0.44	3.19e-14	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg22331096	chr8:128749328	MYC	-0.45	-6.2	-0.36	2.11e-9	Fibrinogen levels;
CESC	cis	rs4665809	0.590	rs13019536	chr2:26526978	C/A	cg27170947	chr2:26402098	FAM59B	-0.6	-7.11	-0.4	1.08e-11	Gut microbiome composition (summer);
CESC	cis	rs8177253	1.000	rs8177248	chr3:133479626	C/T	cg01448562	chr3:133502909	NA	-0.45	-6.22	-0.36	1.92e-9	Iron status biomarkers;
CESC	cis	rs17331151	0.573	rs13080929	chr3:52885112	A/C	cg04865290	chr3:52927548	TMEM110	-0.5	-5.31	-0.31	2.3e-7	Immune reponse to smallpox (secreted IL-2);
CESC	cis	rs12042938	0.600	rs1094656	chr1:231773675	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.42	5.38	0.31	1.67e-7	Neuranatomic and neurocognitive phenotypes;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg00699235	chr12:49962218	MCRS1	-0.47	-6.24	-0.36	1.75e-9	Height;
CESC	cis	rs2549003	1.000	rs2549003	chr5:131829297	A/G	cg02551604	chr5:131831745	NA	-0.37	-5.31	-0.31	2.3e-7	Asthma (sex interaction);
CESC	cis	rs2239908	0.718	rs241776	chr17:26644308	C/T	cg10494684	chr17:26645200	TMEM97	0.37	5.12	0.3	5.85e-7	Blood protein levels;
CESC	cis	rs3820928	0.934	rs1366756	chr2:227772038	G/A	cg05526886	chr2:227700861	RHBDD1	-0.42	-5.54	-0.32	7.19e-8	Pulmonary function;
CESC	cis	rs2204008	0.805	rs11514348	chr12:38243427	T/C	cg13010199	chr12:38710504	ALG10B	0.51	6.3	0.36	1.24e-9	Bladder cancer;
CESC	cis	rs2858942	0.602	rs1211375	chr16:240280	G/T	cg00126636	chr16:237282	NA	0.44	6.29	0.36	1.3e-9	Mean corpuscular hemoglobin;
CESC	cis	rs7560272	0.723	rs62153184	chr2:73773869	G/C	cg20560298	chr2:73613845	ALMS1	-0.51	-7.31	-0.41	3.21e-12	Schizophrenia;
CESC	cis	rs1707322	1.000	rs11211217	chr1:46348229	C/G	cg03146154	chr1:46216737	IPP	0.71	9.86	0.52	9.69e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs6736093	0.796	rs13001162	chr2:112805997	C/T	cg12686935	chr2:112915763	FBLN7	-0.45	-5.93	-0.34	9.41e-9	Coronary artery disease;
CESC	cis	rs6541297	0.703	rs627702	chr1:230324119	A/G	cg20703242	chr1:230279135	GALNT2	0.38	5.13	0.3	5.74e-7	Coronary artery disease;
CESC	cis	rs10464366	0.571	rs4723825	chr7:39157627	G/C	cg18850127	chr7:39170497	POU6F2	0.39	5.51	0.32	8.29e-8	IgG glycosylation;
CESC	cis	rs2836974	0.739	rs12482181	chr21:40548852	A/G	cg11890956	chr21:40555474	PSMG1	1.15	22.11	0.81	4.18e-62	Cognitive function;
CESC	cis	rs7927771	0.832	rs10838704	chr11:47424717	T/C	cg18512352	chr11:47633146	NA	-0.55	-7.83	-0.43	1.15e-13	Subjective well-being;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16712549	chr7:39773156	LOC349114	0.59	6.35	0.36	9.26e-10	Gut microbiome composition (summer);
CESC	cis	rs9858542	0.953	rs34363169	chr3:49537712	G/A	cg07274523	chr3:49395745	GPX1	0.66	8.05	0.44	2.78e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs9910055	0.659	rs227580	chr17:42223068	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	-0.5	-7.43	-0.42	1.53e-12	Total body bone mineral density;
CESC	cis	rs769267	0.895	rs2905435	chr19:19495954	G/A	cg03709012	chr19:19516395	GATAD2A	-0.99	-15.8	-0.7	4.37e-40	Tonsillectomy;
CESC	cis	rs17826219	0.500	rs2874724	chr17:29072433	T/C	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.79e-10	Body mass index;
CESC	cis	rs8092503	0.951	rs1833281	chr18:52498801	C/G	cg12377874	chr18:52495404	RAB27B	0.37	6.19	0.36	2.23e-9	Childhood body mass index;
CESC	cis	rs798554	0.796	rs2533884	chr7:2836848	T/G	cg09658497	chr7:2847517	GNA12	-0.41	-5.68	-0.33	3.53e-8	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11367502	chr7:22862612	TOMM7	-0.59	-6.65	-0.38	1.71e-10	Gut microbiome composition (summer);
CESC	cis	rs1799949	0.965	rs799908	chr17:41278916	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	7.87	0.44	8.99e-14	Menopause (age at onset);
CESC	cis	rs4722166	0.597	rs2069845	chr7:22770149	G/A	cg05472934	chr7:22766657	IL6	0.66	9.07	0.49	2.79e-17	Lung cancer;
CESC	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg03452623	chr4:187889614	NA	-0.88	-16.16	-0.7	2.39e-41	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs11608355	0.618	rs60819157	chr12:109795766	G/A	cg19025524	chr12:109796872	NA	-0.53	-7.65	-0.43	3.83e-13	Neuroticism;
CESC	cis	rs3820068	0.581	rs6666373	chr1:15939884	A/T	cg17385448	chr1:15911702	AGMAT	0.41	6.59	0.38	2.42e-10	Systolic blood pressure;
CESC	cis	rs1538970	0.924	rs11211111	chr1:45908782	C/T	cg05343316	chr1:45956843	TESK2	0.89	12.04	0.59	6.22e-27	Platelet count;
CESC	cis	rs7618915	0.547	rs34610878	chr3:52759169	G/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	6.83	0.39	5.96e-11	Bipolar disorder;
CESC	cis	rs10484885	0.680	rs72921943	chr6:90581542	A/C	cg13799429	chr6:90582589	CASP8AP2	-0.9	-11.56	-0.58	2.77e-25	QRS interval (sulfonylurea treatment interaction);
CESC	cis	rs13108904	0.935	rs11247984	chr4:1292811	G/A	cg00684032	chr4:1343700	KIAA1530	0.39	5.45	0.32	1.15e-7	Obesity-related traits;
CESC	cis	rs2295499	0.754	rs12499320	chr4:2703081	C/T	cg08330972	chr4:2403930	ZFYVE28	-0.35	-5.65	-0.33	4.07e-8	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
CESC	cis	rs6088590	0.735	rs6088618	chr20:33409350	G/A	cg24642439	chr20:33292090	TP53INP2	0.71	9.4	0.5	2.72e-18	Coronary artery disease;
CESC	cis	rs7666738	0.753	rs11097607	chr4:99011640	C/T	cg05340658	chr4:99064831	C4orf37	0.8	12.48	0.61	1.97e-28	Colonoscopy-negative controls vs population controls;
CESC	trans	rs7734156	0.500	rs6878067	chr5:115700721	C/G	cg17756860	chr4:110510374	CCDC109B	0.42	5.99	0.35	6.67e-9	IgG glycosylation;
CESC	cis	rs853679	0.569	rs9348798	chr6:28143011	G/A	cg23281280	chr6:28129359	ZNF389	0.56	7.61	0.42	4.91e-13	Depression;
CESC	cis	rs11098499	0.955	rs35434465	chr4:120169378	C/G	cg24375607	chr4:120327624	NA	0.44	5.25	0.31	3.14e-7	Corneal astigmatism;
CESC	cis	rs4423214	0.918	rs11233789	chr11:71181085	A/G	cg05163923	chr11:71159392	DHCR7	0.82	10.84	0.55	6.81e-23	Vitamin D levels;
CESC	trans	rs11098499	0.866	rs6857892	chr4:120282696	G/T	cg25214090	chr10:38739885	LOC399744	0.65	9.11	0.49	2.04e-17	Corneal astigmatism;
CESC	trans	rs726288	1.000	rs75164680	chr10:81686133	A/G	cg22160595	chr7:72769274	FKBP6	0.97	6.11	0.35	3.52e-9	Rheumatoid arthritis;
CESC	cis	rs7927771	0.832	rs4752990	chr11:47410393	G/A	cg18512352	chr11:47633146	NA	-0.53	-7.95	-0.44	5.27e-14	Subjective well-being;
CESC	cis	rs1008375	0.900	rs10019460	chr4:17686337	T/C	cg16339924	chr4:17578868	LAP3	-0.58	-7.01	-0.4	1.92e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs9527	0.590	rs1541213	chr10:104885330	A/G	cg04362960	chr10:104952993	NT5C2	0.44	5.54	0.32	7.12e-8	Arsenic metabolism;
CESC	cis	rs4523957	0.579	rs57130712	chr17:2089035	A/G	cg16513277	chr17:2031491	SMG6	-0.64	-8.86	-0.48	1.16e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs546131	0.928	rs483976	chr11:34840167	C/G	cg06937548	chr11:34938143	PDHX;APIP	0.52	6.41	0.37	6.63e-10	Lung disease severity in cystic fibrosis;
CESC	trans	rs2099077	0.867	rs77180512	chr5:102795939	C/G	cg07434438	chr16:72961899	ZFHX3	0.49	6.67	0.38	1.5e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs12079745	0.793	rs78277513	chr1:169414777	A/C	cg09363564	chr1:169337483	NME7;BLZF1	-1.11	-6.44	-0.37	5.56e-10	QT interval;
CESC	cis	rs17826219	0.568	rs59858012	chr17:29078582	C/T	cg19761014	chr17:28927070	LRRC37B2	0.88	6.51	0.37	3.71e-10	Body mass index;
CESC	cis	rs4727027	0.745	rs10952801	chr7:148864757	T/C	cg23583168	chr7:148888333	NA	-0.81	-12.7	-0.62	3.49e-29	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs875971	0.825	rs10281499	chr7:66048966	A/G	cg18876405	chr7:65276391	NA	-0.53	-7.25	-0.41	4.64e-12	Aortic root size;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg02948236	chr16:66864732	NAE1	-0.44	-6.39	-0.37	7.43e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs2963155	0.518	rs853179	chr5:142634773	G/T	cg17617527	chr5:142782415	NR3C1	0.88	7.89	0.44	7.84e-14	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14569778	chr17:28952111	LRRC37B2	-0.53	-7.05	-0.4	1.57e-11	Gut microbiome composition (summer);
CESC	cis	rs9905704	0.918	rs302858	chr17:56692800	G/T	cg12560992	chr17:57184187	TRIM37	0.59	7.02	0.4	1.86e-11	Testicular germ cell tumor;
CESC	cis	rs7666738	0.716	rs11721453	chr4:99045485	G/T	cg17366294	chr4:99064904	C4orf37	0.61	8.78	0.47	2.13e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7216064	0.906	rs78452260	chr17:65848522	G/T	cg12091567	chr17:66097778	LOC651250	-0.84	-8.47	-0.46	1.68e-15	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs4665809	0.590	rs13387855	chr2:26420708	T/G	cg22920501	chr2:26401640	FAM59B	-0.86	-10.17	-0.53	1.03e-20	Gut microbiome composition (summer);
CESC	cis	rs8180040	0.701	rs7617689	chr3:46996442	C/T	cg27129171	chr3:47204927	SETD2	-0.66	-9.51	-0.5	1.18e-18	Colorectal cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20719122	chr6:35523700	NA	-0.57	-6.46	-0.37	5.07e-10	Gut microbiome composition (summer);
CESC	cis	rs244293	0.965	rs171513	chr17:53190426	A/G	cg19360675	chr17:53046073	COX11;STXBP4	-0.39	-5.06	-0.3	7.95e-7	Menarche (age at onset);
CESC	cis	rs754466	0.606	rs3740250	chr10:79580101	C/T	cg17075019	chr10:79541650	NA	-0.87	-13.65	-0.64	1.81e-32	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs40363	0.671	rs4786425	chr16:3537650	A/G	cg05754148	chr16:3507555	NAT15	-0.64	-6.12	-0.35	3.34e-9	Tuberculosis;
CESC	cis	rs9457247	0.967	rs2149084	chr6:167370988	G/C	cg25258033	chr6:167368657	RNASET2	-0.41	-6.12	-0.35	3.35e-9	Crohn's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26345216	chr11:117747030	FXYD6	-0.55	-6.31	-0.36	1.19e-9	Gut microbiome composition (summer);
CESC	cis	rs2370759	1.000	rs11597888	chr10:32635834	G/A	cg05361325	chr10:32636312	EPC1	-0.56	-5.21	-0.3	3.82e-7	Sexual dysfunction (female);
CESC	cis	rs1005277	0.579	rs2505257	chr10:38372664	A/G	cg25427524	chr10:38739819	LOC399744	-0.66	-9.52	-0.5	1.15e-18	Extrinsic epigenetic age acceleration;
CESC	cis	rs1862618	0.671	rs2591958	chr5:56239369	C/G	cg24549020	chr5:56110836	MAP3K1	-0.5	-6.24	-0.36	1.76e-9	Initial pursuit acceleration;
CESC	cis	rs72945132	0.714	rs72947077	chr11:70197431	A/G	cg14191688	chr11:70257035	CTTN	0.45	5.31	0.31	2.29e-7	Coronary artery disease;
CESC	cis	rs9309473	0.519	rs2421583	chr2:73898785	C/G	cg20560298	chr2:73613845	ALMS1	0.53	7.23	0.41	5.11e-12	Metabolite levels;
CESC	cis	rs10752881	1.000	rs10797807	chr1:182978873	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.83	13.29	0.63	3.24e-31	Colorectal cancer;
CESC	cis	rs2075371	1.000	rs1421484	chr7:133979795	T/C	cg11752832	chr7:134001865	SLC35B4	0.55	7.21	0.4	6.03e-12	Mean platelet volume;
CESC	cis	rs4555082	0.874	rs11622166	chr14:105759763	C/A	cg06808227	chr14:105710500	BRF1	-0.49	-5.28	-0.31	2.72e-7	Mean platelet volume;Platelet distribution width;
CESC	cis	rs2644899	0.859	rs2545757	chr19:41297302	A/G	cg10585486	chr19:41304133	EGLN2	-0.36	-5.06	-0.3	7.81e-7	Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.46	6.02	0.35	5.72e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07100957	chr19:58982330	ZNF324	-0.59	-7.36	-0.41	2.28e-12	Gut microbiome composition (summer);
CESC	cis	rs7044106	0.537	rs4434680	chr9:123489688	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.65	8.1	0.45	2.07e-14	Hip circumference adjusted for BMI;
CESC	cis	rs4975709	0.610	rs1531994	chr5:1859297	T/C	cg14773178	chr5:1868261	NA	0.34	5.96	0.34	7.89e-9	Cardiovascular disease risk factors;
CESC	cis	rs11122272	0.735	rs2486745	chr1:231505717	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.57	-7.82	-0.43	1.23e-13	Hemoglobin concentration;
CESC	cis	rs12545109	0.879	rs2670015	chr8:57376607	T/A	cg09654669	chr8:57350985	NA	-0.57	-6.67	-0.38	1.46e-10	Obesity-related traits;
CESC	cis	rs2228479	0.850	rs79244293	chr16:89896220	T/C	cg14709524	chr16:89940631	TCF25	0.85	5.79	0.34	1.98e-8	Skin colour saturation;
CESC	cis	rs2354432	1.000	rs2354432	chr1:146693229	C/T	cg25205988	chr1:146714368	CHD1L	1.12	12.27	0.6	1.07e-27	Mitochondrial DNA levels;
CESC	cis	rs60871478	1.000	rs62432250	chr7:801792	C/G	cg27478167	chr7:817139	HEATR2	-0.5	-5.94	-0.34	9.02e-9	Cerebrospinal P-tau181p levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00567190	chr1:211556508	C1orf97	-0.55	-6.67	-0.38	1.47e-10	Gut microbiome composition (summer);
CESC	cis	rs9948	0.655	rs2280356	chr2:97366324	C/T	cg01990225	chr2:97406019	LMAN2L	0.85	7.66	0.43	3.59e-13	Erectile dysfunction and prostate cancer treatment;
CESC	cis	rs977987	0.771	rs8048527	chr16:75422054	C/A	cg03315344	chr16:75512273	CHST6	0.4	5.75	0.33	2.45e-8	Dupuytren's disease;
CESC	cis	rs1557765	0.527	rs2018218	chr11:17390855	A/G	cg15432903	chr11:17409602	KCNJ11	0.43	6.25	0.36	1.64e-9	Body mass index;Social communication problems;
CESC	cis	rs3091242	0.902	rs36003018	chr1:25784318	A/G	cg03538708	chr1:25844672	NA	0.38	5.82	0.34	1.66e-8	Erythrocyte sedimentation rate;
CESC	cis	rs9611565	0.649	rs79005	chr22:41835544	G/A	cg06634786	chr22:41940651	POLR3H	0.58	6.31	0.36	1.14e-9	Vitiligo;
CESC	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.48	-5.2	-0.3	4.05e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.43	-5.68	-0.33	3.61e-8	Longevity;Endometriosis;
CESC	cis	rs7577696	0.597	rs17011801	chr2:32298072	A/T	cg02381751	chr2:32503542	YIPF4	-0.42	-5.05	-0.3	8.32e-7	Inflammatory biomarkers;
CESC	cis	rs7799006	0.527	rs73039284	chr7:2221583	C/G	cg05863683	chr7:1912471	MAD1L1	0.36	5.04	0.3	8.49e-7	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs4604732	0.588	rs4925551	chr1:247631724	T/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.52	6.44	0.37	5.54e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs2415984	0.629	rs7158003	chr14:46919042	T/C	cg14871534	chr14:47121158	RPL10L	0.33	5.12	0.3	5.89e-7	Number of children ever born;
CESC	cis	rs1728785	0.688	rs698718	chr16:68560185	A/G	cg02972257	chr16:68554789	NA	-0.55	-6.38	-0.36	7.91e-10	Ulcerative colitis;
CESC	cis	rs3796352	0.892	rs2581807	chr3:53088844	G/A	cg15956490	chr3:53032818	SFMBT1	-0.58	-5.34	-0.31	2.02e-7	Immune reponse to smallpox (secreted IL-2);
CESC	cis	rs4843747	0.605	rs4072779	chr16:88107290	C/T	cg17633681	chr16:88106987	BANP	0.76	10.51	0.54	8.01e-22	Menopause (age at onset);
CESC	cis	rs11098499	0.738	rs28408407	chr4:120376030	C/G	cg09307838	chr4:120376055	NA	0.95	13.84	0.65	3.83e-33	Corneal astigmatism;
CESC	cis	rs35306767	0.951	rs12777021	chr10:967270	T/C	cg10556349	chr10:835070	NA	0.63	6.16	0.35	2.76e-9	Eosinophil percentage of granulocytes;
CESC	cis	rs4665809	1.000	rs12475854	chr2:26267375	G/A	cg04944784	chr2:26401820	FAM59B	-0.64	-7.3	-0.41	3.46e-12	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03232484	chr7:93633800	BET1	-0.65	-7.85	-0.43	1e-13	Gut microbiome composition (summer);
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg21808837	chr5:176778472	LMAN2	-0.49	-6.49	-0.37	4.24e-10	Asthma;
CESC	cis	rs875971	0.862	rs4718383	chr7:66108409	T/C	cg12463550	chr7:65579703	CRCP	-0.5	-6.41	-0.37	6.59e-10	Aortic root size;
CESC	cis	rs875971	0.522	rs709604	chr7:65497434	A/G	cg05332525	chr7:65337924	VKORC1L1	-0.5	-6.12	-0.35	3.44e-9	Aortic root size;
CESC	cis	rs7789940	1.000	rs758944	chr7:75953297	G/T	cg10167463	chr7:75959203	YWHAG	-0.55	-6.92	-0.39	3.49e-11	Multiple sclerosis;
CESC	cis	rs6952808	0.689	rs871924	chr7:2047845	A/G	cg04267008	chr7:1944627	MAD1L1	-0.56	-6.59	-0.38	2.37e-10	Bipolar disorder and schizophrenia;
CESC	cis	rs28673728	0.868	rs28380108	chr1:38409103	G/C	cg17077180	chr1:38461687	NA	0.46	6.9	0.39	3.83e-11	Red cell distribution width;
CESC	cis	rs11098499	0.954	rs13133522	chr4:120324424	A/T	cg24375607	chr4:120327624	NA	0.47	5.89	0.34	1.14e-8	Corneal astigmatism;
CESC	cis	rs6732160	0.613	rs59979991	chr2:73384422	G/A	cg01422370	chr2:73384389	NA	0.56	8.65	0.47	5.08e-16	Intelligence (multi-trait analysis);
CESC	cis	rs7762018	0.891	rs4716343	chr6:170143817	C/G	cg05834625	chr6:170176447	C6orf70	0.64	7.17	0.4	7.47e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs2841277	0.616	rs1048257	chr14:105404384	T/C	cg15352829	chr14:105391018	PLD4	-0.6	-10.3	-0.53	3.96e-21	Rheumatoid arthritis;
CESC	cis	rs36051895	0.603	rs10123980	chr9:5130363	T/C	cg02405213	chr9:5042618	JAK2	-0.49	-6.13	-0.35	3.15e-9	Pediatric autoimmune diseases;
CESC	cis	rs10504229	0.593	rs17192845	chr8:58053339	C/T	cg02725872	chr8:58115012	NA	-0.41	-5.49	-0.32	9.22e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs853679	0.517	rs9468292	chr6:28095355	G/A	cg22143856	chr6:28129313	ZNF389	0.51	6.62	0.38	2e-10	Depression;
CESC	cis	rs9649213	0.593	rs35535338	chr7:97962319	C/T	cg08684580	chr7:98029266	BAIAP2L1	-0.36	-5.91	-0.34	1.05e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs12142240	0.698	rs1057534	chr1:46815880	A/C	cg10495392	chr1:46806563	NSUN4	0.57	6.28	0.36	1.39e-9	Menopause (age at onset);
CESC	cis	rs73001065	0.901	rs8107974	chr19:19388500	A/T	cg03709012	chr19:19516395	GATAD2A	0.86	5.57	0.32	6.3e-8	LDL cholesterol;
CESC	cis	rs7131987	0.868	rs11050151	chr12:29403008	T/A	cg09582351	chr12:29534625	ERGIC2	-0.34	-5.45	-0.32	1.14e-7	QT interval;
CESC	cis	rs7551222	0.752	rs4252718	chr1:204512195	A/T	cg20240347	chr1:204465584	NA	0.27	5.48	0.32	9.92e-8	Schizophrenia;
CESC	cis	rs6754311	0.731	rs2164210	chr2:136580287	T/C	cg07169764	chr2:136633963	MCM6	-0.66	-7.98	-0.44	4.39e-14	Mosquito bite size;
CESC	cis	rs3858526	0.508	rs10838734	chr11:5876325	T/G	cg02574844	chr11:5959923	NA	-0.43	-5.66	-0.33	3.96e-8	DNA methylation (variation);
CESC	cis	rs9322193	0.923	rs9322207	chr6:149978321	G/A	cg13206674	chr6:150067644	NUP43	0.44	6.42	0.37	6.24e-10	Lung cancer;
CESC	cis	rs875971	0.862	rs11773628	chr7:65982631	G/T	cg12463550	chr7:65579703	CRCP	-0.49	-6.05	-0.35	4.83e-9	Aortic root size;
CESC	cis	rs6570726	0.967	rs450973	chr6:145863065	C/A	cg23711669	chr6:146136114	FBXO30	0.73	10.52	0.54	7.61e-22	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs1814175	0.817	rs10839397	chr11:49857074	C/T	cg03929089	chr4:120376271	NA	-0.91	-15.11	-0.68	1.3e-37	Height;
CESC	cis	rs79057730	0.599	rs4721086	chr7:821123	G/A	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.71	6.66	0.38	1.56e-10	Initial pursuit acceleration;
CESC	cis	rs763121	0.853	rs6001204	chr22:39100239	T/C	cg06544989	chr22:39130855	UNC84B	0.52	9.9	0.52	7.02e-20	Menopause (age at onset);
CESC	cis	rs826838	1.000	rs11609286	chr12:38875511	A/G	cg26384229	chr12:38710491	ALG10B	-0.82	-14.2	-0.66	2e-34	Heart rate;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11530293	chr8:54935097	TCEA1	0.59	6.44	0.37	5.69e-10	Gut microbiome composition (summer);
CESC	cis	rs7937682	0.883	rs542831	chr11:111471392	T/A	cg09085632	chr11:111637200	PPP2R1B	-0.93	-13.56	-0.64	3.46e-32	Primary sclerosing cholangitis;
CESC	cis	rs10504229	0.683	rs66893068	chr8:58144238	A/G	cg24829409	chr8:58192753	C8orf71	-0.54	-6.79	-0.39	7.19e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs7666738	0.830	rs13138051	chr4:99050367	C/T	cg03676636	chr4:99064102	C4orf37	0.33	5.12	0.3	5.93e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs12478296	0.591	rs4973646	chr2:243001373	C/T	cg06360820	chr2:242988706	NA	0.59	7.5	0.42	9.62e-13	Obesity-related traits;
CESC	cis	rs2380220	0.541	rs72928273	chr6:96079360	C/T	cg23517279	chr6:96025343	MANEA	-0.55	-5.38	-0.31	1.6e-7	Behavioural disinhibition (generation interaction);
CESC	cis	rs9322193	0.884	rs9688858	chr6:149959047	C/A	cg07701084	chr6:150067640	NUP43	0.42	5.73	0.33	2.67e-8	Lung cancer;
CESC	cis	rs870825	0.616	rs28500698	chr4:185627746	A/C	cg04058563	chr4:185651563	MLF1IP	0.64	7.05	0.4	1.59e-11	Blood protein levels;
CESC	cis	rs875971	0.825	rs28480509	chr7:66099224	A/G	cg19163074	chr7:65112434	INTS4L2	0.43	5.4	0.31	1.5e-7	Aortic root size;
CESC	cis	rs801193	0.839	rs12534943	chr7:66070520	A/G	cg18252515	chr7:66147081	NA	0.4	5.21	0.3	3.77e-7	Aortic root size;
CESC	cis	rs853679	0.517	rs9468298	chr6:28122345	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.61	-6.96	-0.39	2.6e-11	Depression;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00405494	chr9:7797524	C9orf123	-0.55	-6.32	-0.36	1.08e-9	Gut microbiome composition (summer);
CESC	cis	rs2070433	0.948	rs2839304	chr21:47952650	C/G	cg12379764	chr21:47803548	PCNT	-0.62	-7.08	-0.4	1.27e-11	Lymphocyte counts;
CESC	cis	rs990171	0.607	rs3917246	chr2:102775164	T/C	cg22835712	chr2:102737379	NA	0.42	5.7	0.33	3.18e-8	Lymphocyte counts;
CESC	cis	rs472402	0.623	rs7707877	chr5:6635946	C/G	cg10789808	chr5:6633262	NSUN2;SRD5A1	-0.47	-6.26	-0.36	1.51e-9	Response to amphetamines;
CESC	cis	rs9487051	0.872	rs9386791	chr6:109608497	C/T	cg21918786	chr6:109611834	NA	-0.4	-6.01	-0.35	6.17e-9	Reticulocyte fraction of red cells;
CESC	cis	rs12142240	0.698	rs1057534	chr1:46815880	A/C	cg00530320	chr1:46809349	NSUN4	0.58	7.89	0.44	8.17e-14	Menopause (age at onset);
CESC	cis	rs2836974	0.865	rs7282624	chr21:40667040	C/T	cg17971929	chr21:40555470	PSMG1	1.04	15.58	0.69	2.81e-39	Cognitive function;
CESC	cis	rs116979167	0.575	rs818470	chr7:105165350	A/C	cg19920283	chr7:105172520	RINT1	0.48	5.41	0.32	1.39e-7	Bipolar disorder (body mass index interaction);
CESC	cis	rs1005277	0.505	rs10827836	chr10:38215441	A/G	cg25517755	chr10:38738941	LOC399744	0.39	5.04	0.3	8.48e-7	Extrinsic epigenetic age acceleration;
CESC	cis	rs736408	0.509	rs13083798	chr3:52649748	A/G	cg18337363	chr3:52569053	NT5DC2	0.29	5.75	0.33	2.5e-8	Bipolar disorder;
CESC	cis	rs614226	0.935	rs3887875	chr12:120895749	A/G	cg27489772	chr12:121021490	NA	-0.5	-5.1	-0.3	6.48e-7	Type 1 diabetes nephropathy;
CESC	cis	rs7824557	0.510	rs1435274	chr8:11235910	G/A	cg21775007	chr8:11205619	TDH	-0.54	-8.05	-0.44	2.9e-14	Retinal vascular caliber;
CESC	trans	rs6089829	0.855	rs4809459	chr20:61661345	C/T	cg23505145	chr19:12996616	KLF1	0.52	6.7	0.38	1.24e-10	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7100689	0.725	rs2487074	chr10:82064104	A/G	cg09936400	chr10:82049201	MAT1A	0.36	5.13	0.3	5.74e-7	Post bronchodilator FEV1;
CESC	cis	rs7560272	0.501	rs6755500	chr2:73942233	C/T	cg20560298	chr2:73613845	ALMS1	0.43	6.06	0.35	4.77e-9	Schizophrenia;
CESC	cis	rs7208859	0.623	rs6505207	chr17:29076571	T/C	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.79e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs2295499	0.610	rs2239726	chr4:2697089	A/C	cg27239842	chr4:2403781	ZFYVE28	-0.31	-5.29	-0.31	2.55e-7	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
CESC	cis	rs13272623	0.502	rs268594	chr8:71513130	C/T	cg23757474	chr8:71581111	LACTB2;XKR9	0.42	5.21	0.3	3.89e-7	IgG glycosylation;
CESC	cis	rs3768617	0.811	rs6674729	chr1:183059143	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.67	9.27	0.49	6.9e-18	Fuchs's corneal dystrophy;
CESC	cis	rs9527	0.615	rs1556960	chr10:104726673	A/G	cg04362960	chr10:104952993	NT5C2	0.42	5.25	0.31	3.14e-7	Arsenic metabolism;
CESC	cis	rs933688	1.000	rs61612071	chr5:90741470	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.1	12.13	0.6	3.17e-27	Smoking behavior;
CESC	cis	rs11190604	1.000	rs2495747	chr10:102328247	C/T	cg07080220	chr10:102295463	HIF1AN	0.56	5.43	0.32	1.31e-7	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs7631605	0.870	rs6775008	chr3:37179031	A/G	cg22985146	chr3:37219077	LRRFIP2	-0.32	-5.14	-0.3	5.27e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs7537052	0.669	rs4652903	chr1:36642858	C/T	cg24686825	chr1:36642396	MAP7D1	-0.57	-8.29	-0.45	5.68e-15	Schizophrenia;
CESC	cis	rs875971	0.862	rs10278014	chr7:66051264	C/T	cg11764359	chr7:65958608	NA	-0.78	-11.17	-0.57	5.37e-24	Aortic root size;
CESC	cis	rs9640161	0.659	rs11974980	chr7:150009838	C/T	cg21361702	chr7:150065534	REPIN1	0.54	6.29	0.36	1.3e-9	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs8072100	0.744	rs34537623	chr17:45530203	A/G	cg25173405	chr17:45401733	C17orf57	-0.42	-5.59	-0.32	5.75e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs796364	0.806	rs203766	chr2:200902672	T/C	cg23649088	chr2:200775458	C2orf69	-0.57	-5.24	-0.31	3.23e-7	Schizophrenia;
CESC	cis	rs7666738	1.000	rs13116475	chr4:99054843	C/T	cg03676636	chr4:99064102	C4orf37	-0.4	-5.82	-0.34	1.68e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2559856	0.967	rs2695290	chr12:102087844	A/G	cg12213457	chr12:102090980	CHPT1	0.34	5.13	0.3	5.59e-7	Blood protein levels;
CESC	cis	rs2380220	0.541	rs72928273	chr6:96079360	C/T	cg04719120	chr6:96025338	MANEA	-0.64	-6.74	-0.38	1.01e-10	Behavioural disinhibition (generation interaction);
CESC	cis	rs1580019	0.539	rs11769109	chr7:32571352	A/G	cg06627557	chr7:32535165	LSM5;AVL9	1.06	18.93	0.76	3.76e-51	Cognitive ability;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20175760	chr8:125486985	RNF139	0.54	6.15	0.35	2.92e-9	Gut microbiome composition (summer);
CESC	cis	rs9902453	0.791	rs9904051	chr17:28244122	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.68	8.87	0.48	1.08e-16	Coffee consumption (cups per day);
CESC	cis	rs9287719	0.967	rs10454738	chr2:10742049	G/A	cg00105475	chr2:10696890	NA	0.39	5.64	0.33	4.44e-8	Prostate cancer;
CESC	cis	rs6032067	0.777	rs13037651	chr20:43782230	C/G	cg10761708	chr20:43804764	PI3	0.56	6.55	0.37	3.01e-10	Blood protein levels;
CESC	cis	rs2273669	0.667	rs76732622	chr6:109318280	A/T	cg05315195	chr6:109294784	ARMC2	-0.66	-5.71	-0.33	3.03e-8	Prostate cancer;
CESC	cis	rs1048238	0.506	rs12039892	chr1:16167974	A/G	cg22431228	chr1:16359049	CLCNKA	-0.35	-6.1	-0.35	3.76e-9	Systolic blood pressure;
CESC	cis	rs757110	0.770	rs2051772	chr11:17389850	G/A	cg15432903	chr11:17409602	KCNJ11	0.58	8.14	0.45	1.5e-14	Type 2 diabetes;
CESC	cis	rs4665809	0.590	rs6749046	chr2:26429451	C/G	cg08470875	chr2:26401718	FAM59B	0.73	7.81	0.43	1.37e-13	Gut microbiome composition (summer);
CESC	cis	rs1008375	0.966	rs1860591	chr4:17577329	A/G	cg02297831	chr4:17616191	MED28	0.45	5.51	0.32	8.4e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs238295	0.805	rs6053499	chr20:5542546	C/T	cg24001556	chr20:5591874	RP5-1022P6.2	-0.46	-5.49	-0.32	9.48e-8	Occipital cortical area (total cortical area interaction);
CESC	cis	rs9815354	0.812	rs17218264	chr3:41975847	C/T	cg03022575	chr3:42003672	ULK4	-0.73	-6.33	-0.36	1.02e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs1950626	0.699	rs12880855	chr14:101468382	C/T	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.82	10.28	0.53	4.42e-21	Pelvic organ prolapse (moderate/severe);
CESC	cis	rs9300255	0.544	rs1790130	chr12:123701270	A/C	cg05973401	chr12:123451056	ABCB9	0.49	5.63	0.33	4.65e-8	Neutrophil percentage of white cells;
CESC	trans	rs4332037	0.539	rs56180486	chr7:2050747	C/T	cg11693508	chr17:37793320	STARD3	0.68	6.8	0.39	7.12e-11	Bipolar disorder;
CESC	trans	rs1814175	0.646	rs61904497	chr11:49883449	A/T	cg11707556	chr5:10655725	ANKRD33B	-0.43	-6.27	-0.36	1.42e-9	Height;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg04669830	chr20:1306048	SDCBP2	-0.47	-6.0	-0.35	6.36e-9	Fibrinogen levels;
CESC	cis	rs4563143	0.663	rs2218396	chr19:29236392	C/T	cg04546413	chr19:29218101	NA	0.48	7.53	0.42	7.81e-13	Methadone dose in opioid dependence;
CESC	cis	rs6089829	0.962	rs9679865	chr20:61666132	C/G	cg16240275	chr20:61666158	NCRNA00029	0.5	8.96	0.48	6.1e-17	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs4689388	0.926	rs11725500	chr4:6293919	C/G	cg14416269	chr4:6271139	WFS1	0.46	7.76	0.43	1.79e-13	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs3204270	0.684	rs62080212	chr17:79642500	G/A	cg18367735	chr17:79674897	NA	0.62	5.34	0.31	2e-7	Dental caries;
CESC	cis	rs2243480	1.000	rs316326	chr7:65609453	T/C	cg12463550	chr7:65579703	CRCP	0.75	5.84	0.34	1.56e-8	Diabetic kidney disease;
CESC	cis	rs1983891	1.000	rs1983891	chr6:41536427	A/G	cg20194872	chr6:41519635	FOXP4	-0.54	-7.75	-0.43	1.91e-13	Prostate cancer;
CESC	cis	rs9300255	0.596	rs10732573	chr12:123743883	G/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.33	-5.04	-0.3	8.7e-7	Neutrophil percentage of white cells;
CESC	cis	rs916888	0.610	rs199536	chr17:44820425	T/C	cg17911788	chr17:44343683	NA	0.43	6.78	0.38	7.61e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs2777491	0.957	rs8027626	chr15:41711514	T/G	cg02330683	chr15:41787940	ITPKA	0.48	7.01	0.4	2.03e-11	Ulcerative colitis;
CESC	cis	rs501120	1.000	rs479596	chr10:44760473	C/T	cg09554077	chr10:44749378	NA	0.54	6.01	0.35	6.28e-9	Coronary artery disease;Coronary heart disease;
CESC	cis	rs826838	0.967	rs6580726	chr12:39108623	T/C	cg26384229	chr12:38710491	ALG10B	-0.63	-10.23	-0.53	6.29e-21	Heart rate;
CESC	cis	rs2425143	0.818	rs2378414	chr20:34534374	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.65	5.58	0.32	6.02e-8	Blood protein levels;
CESC	cis	rs2933343	0.859	rs789247	chr3:128580585	C/A	cg25356066	chr3:128598488	ACAD9	0.56	7.08	0.4	1.26e-11	IgG glycosylation;
CESC	cis	rs3741151	1.000	rs74795285	chr11:73033387	A/G	cg17517138	chr11:73019481	ARHGEF17	0.98	7.03	0.4	1.72e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg07496882	chr10:112631570	LOC282997;PDCD4	-0.39	-6.11	-0.35	3.54e-9	Gambling;
CESC	cis	rs698813	0.573	rs6544750	chr2:44490780	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	5.63	0.33	4.62e-8	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
CESC	cis	rs1552244	0.935	rs41520445	chr3:10153141	A/C	cg00149659	chr3:10157352	C3orf10	-0.74	-9.41	-0.5	2.42e-18	Alzheimer's disease;
CESC	cis	rs3020736	0.500	rs1801311	chr22:42486723	G/A	cg04733989	chr22:42467013	NAGA	-0.79	-12.03	-0.59	6.75e-27	Autism spectrum disorder or schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11427898	chr15:38544983	SPRED1	0.59	6.45	0.37	5.16e-10	Gut microbiome composition (summer);
CESC	cis	rs8016982	0.633	rs4363794	chr14:81674327	C/A	cg01989461	chr14:81687754	GTF2A1	0.71	10.37	0.54	2.35e-21	Schizophrenia;
CESC	trans	rs7980799	0.933	rs11052705	chr12:33588388	T/C	cg26384229	chr12:38710491	ALG10B	-0.53	-7.19	-0.4	6.53e-12	Heart rate;Heart rate variability traits (RMSSD);
CESC	cis	rs13095912	1.000	rs13100229	chr3:185343200	C/T	cg11274856	chr3:185301563	NA	0.34	5.49	0.32	9.47e-8	Systolic blood pressure;
CESC	cis	rs713587	0.875	rs6746013	chr2:25143649	C/G	cg01884057	chr2:25150051	NA	0.42	7.97	0.44	4.79e-14	Body mass index in non-asthmatics;
CESC	cis	rs7843479	0.526	rs34802507	chr8:21773853	C/T	cg17168535	chr8:21777572	XPO7	0.66	9.78	0.51	1.76e-19	Mean corpuscular volume;
CESC	cis	rs4561483	0.801	rs33631	chr16:11995387	G/C	cg08843971	chr16:11963173	GSPT1	-0.55	-8.04	-0.44	3.03e-14	Testicular germ cell tumor;
CESC	cis	rs6952808	0.929	rs12667688	chr7:1931030	C/T	cg02951883	chr7:2050386	MAD1L1	-0.52	-6.84	-0.39	5.42e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs7666738	0.830	rs35951881	chr4:98999474	A/C	cg18180107	chr4:99064573	C4orf37	0.4	5.23	0.31	3.41e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs921968	0.540	rs10190250	chr2:219457731	C/T	cg02176678	chr2:219576539	TTLL4	-0.52	-9.12	-0.49	1.94e-17	Mean corpuscular hemoglobin concentration;
CESC	cis	rs7794273	0.723	rs2588638	chr7:18844596	C/T	cg13420273	chr7:18810212	HDAC9	0.37	5.12	0.3	5.91e-7	Night sleep phenotypes;
CESC	cis	rs7274811	0.711	rs291697	chr20:31985248	T/C	cg21523528	chr20:32077966	CBFA2T2	-0.49	-5.66	-0.33	3.98e-8	Height;
CESC	cis	rs11247915	0.561	rs12750420	chr1:26608649	G/A	cg00852783	chr1:26633632	UBXN11	0.41	5.12	0.3	5.9e-7	Obesity-related traits;
CESC	cis	rs2625529	0.627	rs12898585	chr15:72473928	T/C	cg16672083	chr15:72433130	SENP8	-0.39	-5.25	-0.31	3.16e-7	Red blood cell count;
CESC	cis	rs754466	0.580	rs2289311	chr10:79565655	G/A	cg17075019	chr10:79541650	NA	-0.83	-12.74	-0.62	2.47e-29	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs2070488	0.804	rs13092539	chr3:38458725	G/A	cg24069376	chr3:38537580	EXOG	0.35	6.01	0.35	6.11e-9	Electrocardiographic conduction measures;
CESC	cis	rs853679	0.550	rs1150689	chr6:28165099	T/C	cg20151795	chr6:28129481	ZNF389	0.39	5.25	0.31	3.17e-7	Depression;
CESC	cis	rs9611565	0.625	rs12483991	chr22:41935285	A/G	cg06481639	chr22:41940642	POLR3H	-0.5	-5.69	-0.33	3.37e-8	Vitiligo;
CESC	cis	rs7020830	0.931	rs1388978	chr9:37144062	G/T	cg14294708	chr9:37120828	ZCCHC7	1.14	21.7	0.8	9.94e-61	Schizophrenia;
CESC	cis	rs12142240	0.698	rs28578741	chr1:46825176	T/C	cg00530320	chr1:46809349	NSUN4	0.6	8.04	0.44	2.96e-14	Menopause (age at onset);
CESC	cis	rs11690935	0.851	rs10174055	chr2:172858214	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.8	-10.87	-0.56	5.4e-23	Schizophrenia;
CESC	cis	rs6088580	0.634	rs4911423	chr20:32999386	T/A	cg08999081	chr20:33150536	PIGU	-0.65	-11.34	-0.57	1.5e-24	Glomerular filtration rate (creatinine);
CESC	cis	rs875971	1.000	rs1144894	chr7:65542894	A/G	cg18876405	chr7:65276391	NA	-0.53	-6.89	-0.39	3.98e-11	Aortic root size;
CESC	cis	rs79349575	0.715	rs999474	chr17:46987665	G/A	cg16584676	chr17:46985605	UBE2Z	-0.71	-9.25	-0.49	8.03e-18	Type 2 diabetes;
CESC	cis	rs4727963	0.846	rs953563	chr7:122714001	A/C	cg03640110	chr7:122635026	TAS2R16	-0.36	-5.64	-0.33	4.46e-8	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
CESC	cis	rs9303280	0.806	rs62067034	chr17:38063738	C/T	cg19468946	chr17:37922297	IKZF3	-0.41	-5.53	-0.32	7.55e-8	Self-reported allergy;
CESC	cis	rs7843479	0.544	rs7839925	chr8:21792983	G/C	cg17168535	chr8:21777572	XPO7	0.7	11.35	0.57	1.4e-24	Mean corpuscular volume;
CESC	cis	rs1801251	1.000	rs71421663	chr2:233619131	A/G	cg25237894	chr2:233734115	C2orf82	0.45	7.9	0.44	7.6e-14	Coronary artery disease;
CESC	cis	rs6502050	0.835	rs6502079	chr17:80124454	T/A	cg11859384	chr17:80120422	CCDC57	-0.39	-5.34	-0.31	1.98e-7	Life satisfaction;
CESC	cis	rs9796	0.663	rs11853192	chr15:41368515	G/A	cg12426344	chr15:41135900	SPINT1	-0.24	-5.28	-0.31	2.69e-7	Menopause (age at onset);
CESC	cis	rs826838	0.935	rs3886109	chr12:39189243	C/T	cg26384229	chr12:38710491	ALG10B	0.78	13.13	0.63	1.09e-30	Heart rate;
CESC	cis	rs763121	0.853	rs6519120	chr22:38991393	A/C	cg21395723	chr22:39101663	GTPBP1	-0.44	-5.33	-0.31	2.14e-7	Menopause (age at onset);
CESC	cis	rs8014204	0.657	rs2884668	chr14:75281576	T/A	cg08847533	chr14:75593920	NEK9	0.4	5.25	0.31	3.13e-7	Caffeine consumption;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16075951	chr14:24899050	CBLN3;KHNYN	0.56	6.53	0.37	3.37e-10	Gut microbiome composition (summer);
CESC	cis	rs2367563	0.927	rs2367562	chr12:96057213	G/A	cg19013339	chr12:96052514	NTN4	0.36	5.19	0.3	4.22e-7	Allergic dermatitis (nickel);
CESC	trans	rs6084875	0.538	rs2093389	chr20:4723262	T/C	cg10192164	chr16:30419175	ZNF771	-0.51	-6.18	-0.35	2.44e-9	Systemic lupus erythematosus;
CESC	cis	rs7666738	0.830	rs2865980	chr4:99027422	T/G	cg24818145	chr4:99064322	C4orf37	0.39	5.09	0.3	6.95e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs861020	0.771	rs1962735	chr1:210012102	A/G	cg05527609	chr1:210001259	C1orf107	0.89	12.02	0.59	7.35e-27	Orofacial clefts;
CESC	trans	rs2764766	0.789	rs245313	chr5:127165481	A/G	cg15764593	chr10:829463	NA	0.4	6.27	0.36	1.46e-9	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21028292	chr3:129158769	IFT122;MBD4	0.56	6.65	0.38	1.65e-10	Gut microbiome composition (summer);
CESC	trans	rs7944735	0.817	rs747782	chr11:47940925	A/G	cg15704280	chr7:45808275	SEPT13	0.56	6.07	0.35	4.45e-9	Intraocular pressure;
CESC	cis	rs7772486	0.846	rs1331636	chr6:146338826	T/C	cg05347473	chr6:146136440	FBXO30	0.52	6.71	0.38	1.17e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs12220238	1.000	rs12220238	chr10:75952670	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.64	5.45	0.32	1.16e-7	Soluble interleukin-2 receptor subunit alpha;
CESC	cis	rs9487051	0.933	rs5005289	chr6:109617673	C/G	cg21918786	chr6:109611834	NA	-0.35	-5.03	-0.3	8.9e-7	Reticulocyte fraction of red cells;
CESC	cis	rs4713118	0.662	rs149901	chr6:27965503	C/T	cg17949981	chr6:28129498	ZNF389	0.39	5.1	0.3	6.36e-7	Parkinson's disease;
CESC	cis	rs10504229	1.000	rs77857677	chr8:58170131	G/A	cg05313129	chr8:58192883	C8orf71	-0.55	-6.29	-0.36	1.31e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs4142995	0.962	rs1917368	chr7:17911752	G/T	cg03009463	chr7:17980271	SNX13	-0.37	-5.04	-0.3	8.51e-7	HDL cholesterol;HDL cholesterol levels;
CESC	trans	rs7937682	0.889	rs542424	chr11:111477698	T/C	cg18187862	chr3:45730750	SACM1L	0.48	6.1	0.35	3.71e-9	Primary sclerosing cholangitis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10937591	chr1:112532966	KCND3	-0.54	-6.32	-0.36	1.08e-9	Gut microbiome composition (summer);
CESC	cis	rs1799949	0.965	rs34616041	chr17:41188786	G/A	cg05368731	chr17:41323189	NBR1	0.77	10.06	0.53	2.31e-20	Menopause (age at onset);
CESC	cis	rs1552244	1.000	rs35741213	chr3:10087661	A/G	cg00166722	chr3:10149974	C3orf24	0.51	6.31	0.36	1.19e-9	Alzheimer's disease;
CESC	cis	rs854765	0.583	rs6502619	chr17:17779704	C/G	cg04398451	chr17:18023971	MYO15A	0.64	8.99	0.48	4.72e-17	Total body bone mineral density;
CESC	cis	rs2075371	1.000	rs2598297	chr7:133993001	T/G	cg11752832	chr7:134001865	SLC35B4	0.55	7.12	0.4	1.03e-11	Mean platelet volume;
CESC	cis	rs7103648	0.735	rs3824869	chr11:47378245	T/C	cg20307385	chr11:47447363	PSMC3	-0.9	-12.82	-0.62	1.39e-29	Diastolic blood pressure;Systolic blood pressure;
CESC	cis	rs763121	0.853	rs9607566	chr22:39075434	C/G	cg06544989	chr22:39130855	UNC84B	0.52	9.08	0.49	2.57e-17	Menopause (age at onset);
CESC	cis	rs4642101	0.793	rs56082700	chr3:12833833	T/C	cg05775895	chr3:12838266	CAND2	0.36	5.4	0.31	1.49e-7	QRS complex (12-leadsum);
CESC	cis	rs11785400	1.000	rs13266249	chr8:143732433	A/C	cg24634471	chr8:143751801	JRK	0.46	6.05	0.35	4.84e-9	Schizophrenia;
CESC	cis	rs7666738	0.830	rs13138051	chr4:99050367	C/T	cg24818145	chr4:99064322	C4orf37	0.38	5.04	0.3	8.49e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs514406	0.929	rs1672908	chr1:53340885	A/G	cg25767906	chr1:53392781	SCP2	-0.49	-6.21	-0.36	2.04e-9	Monocyte count;
CESC	trans	rs1728785	0.901	rs1645934	chr16:68564490	T/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.61	7.42	0.41	1.57e-12	Ulcerative colitis;
CESC	cis	rs1633360	1	rs1633360	chr12:58108052	C/T	cg18357645	chr12:58087776	OS9	0.55	9.25	0.49	8e-18	Rheumatoid arthritis;
CESC	cis	rs694739	1.000	rs11231757	chr11:64106317	C/T	cg23796481	chr11:64053134	BAD;GPR137	0.67	8.68	0.47	4.13e-16	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CESC	cis	rs6674176	0.542	rs3011225	chr1:44319373	G/A	cg12908607	chr1:44402522	ARTN	-0.4	-5.48	-0.32	9.78e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs13095912	0.962	rs12374077	chr3:185317674	G/C	cg11274856	chr3:185301563	NA	0.36	5.87	0.34	1.33e-8	Systolic blood pressure;
CESC	cis	rs1552244	1.000	rs7615764	chr3:10082592	C/T	cg00149659	chr3:10157352	C3orf10	0.76	9.52	0.5	1.17e-18	Alzheimer's disease;
CESC	cis	rs6665290	0.904	rs11587443	chr1:227187896	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.21	-32.66	-0.89	6.96e-95	Myeloid white cell count;
CESC	cis	rs9291683	0.566	rs13115776	chr4:10040189	C/G	cg02734326	chr4:10020555	SLC2A9	0.46	6.33	0.36	1.02e-9	Bone mineral density;
CESC	cis	rs11792861	0.591	rs7044275	chr9:111717138	T/C	cg13535736	chr9:111863775	C9orf5	-0.39	-5.72	-0.33	2.88e-8	Menarche (age at onset);
CESC	cis	rs7613875	0.620	rs7634441	chr3:50071677	G/A	cg24110177	chr3:50126178	RBM5	0.58	8.14	0.45	1.55e-14	Body mass index;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04039414	chr16:27280154	NSMCE1	0.58	6.35	0.36	9.38e-10	Gut microbiome composition (summer);
CESC	cis	rs3820068	0.603	rs6429769	chr1:15968610	C/G	cg17385448	chr1:15911702	AGMAT	0.4	6.77	0.38	8.36e-11	Systolic blood pressure;
CESC	cis	rs3916	0.641	rs7964786	chr12:121132100	C/T	cg00257296	chr12:120799373	MSI1	0.35	5.38	0.31	1.67e-7	Urinary metabolites (H-NMR features);
CESC	cis	rs1552244	1.000	rs3846177	chr3:10068572	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-10.79	-0.55	9.49e-23	Alzheimer's disease;
CESC	cis	rs7511006	0.798	rs11703673	chr22:50652427	A/G	cg16473166	chr22:50639996	SELO	-0.49	-5.59	-0.32	5.55e-8	Obesity-related traits;
CESC	cis	rs2228479	0.702	rs78331410	chr16:89917775	C/T	cg00800038	chr16:89945340	TCF25	-0.91	-6.93	-0.39	3.21e-11	Skin colour saturation;
CESC	cis	rs425277	0.606	rs262653	chr1:2090095	T/G	cg24578937	chr1:2090814	PRKCZ	0.36	6.52	0.37	3.48e-10	Height;
CESC	cis	rs2243480	1.000	rs462853	chr7:65558167	G/C	cg18252515	chr7:66147081	NA	-1.39	-13.81	-0.65	4.83e-33	Diabetic kidney disease;
CESC	cis	rs941408	0.515	rs1640262	chr19:2779134	C/T	cg02580895	chr19:2754563	NA	0.47	6.55	0.37	2.94e-10	Total cholesterol levels;
CESC	cis	rs9611565	0.694	rs202641	chr22:41833116	C/T	cg06634786	chr22:41940651	POLR3H	0.56	6.12	0.35	3.39e-9	Vitiligo;
CESC	cis	rs2228479	0.618	rs34689166	chr16:89860697	C/T	cg19635926	chr16:89946313	TCF25	0.68	5.17	0.3	4.65e-7	Skin colour saturation;
CESC	cis	rs9908102	0.740	rs733890	chr17:12918054	C/T	cg26162695	chr17:12921313	ELAC2	0.54	5.91	0.34	1.06e-8	Schizophrenia;
CESC	cis	rs9902453	0.808	rs76039587	chr17:28233760	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.65	8.2	0.45	1.05e-14	Coffee consumption (cups per day);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23203684	chr5:76326465	AGGF1	0.53	6.03	0.35	5.51e-9	Gut microbiome composition (summer);
CESC	cis	rs2730245	0.527	rs2527197	chr7:158735260	G/A	cg24397884	chr7:158709396	WDR60	-0.86	-9.09	-0.49	2.37e-17	Height;
CESC	cis	rs2075371	1.000	rs2504	chr7:133979545	A/T	cg00033643	chr7:134001901	SLC35B4	0.42	5.38	0.31	1.61e-7	Mean platelet volume;
CESC	trans	rs12356475	0.710	rs10822686	chr10:67733250	C/T	cg19524972	chr12:121647936	P2RX4	0.53	6.26	0.36	1.52e-9	Psoriatic arthritis;
CESC	cis	rs514406	0.929	rs564273	chr1:53332445	G/C	cg16325326	chr1:53192061	ZYG11B	0.83	12.87	0.62	8.73e-30	Monocyte count;
CESC	cis	rs3806843	0.966	rs2563265	chr5:140137005	C/T	cg26395211	chr5:140044315	WDR55	0.45	5.79	0.34	1.97e-8	Depressive symptoms (multi-trait analysis);
CESC	cis	rs9926296	0.568	rs1230	chr16:89804855	A/G	cg21285383	chr16:89894308	SPIRE2	-0.28	-5.05	-0.3	8.36e-7	Vitiligo;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24723716	chr1:244998845	FAM36A	0.59	6.11	0.35	3.47e-9	Gut microbiome composition (summer);
CESC	cis	rs2576037	0.526	rs10853544	chr18:44474194	T/C	cg19077165	chr18:44547161	KATNAL2	-0.55	-8.14	-0.45	1.51e-14	Personality dimensions;
CESC	cis	rs13108904	0.650	rs3796618	chr4:1349602	T/A	cg00684032	chr4:1343700	KIAA1530	0.36	5.18	0.3	4.32e-7	Obesity-related traits;
CESC	cis	rs9790314	0.875	rs459515	chr3:161092351	T/C	cg03342759	chr3:160939853	NMD3	-0.41	-5.4	-0.31	1.49e-7	Morning vs. evening chronotype;
CESC	cis	rs9911578	0.874	rs302874	chr17:56767996	A/G	cg12560992	chr17:57184187	TRIM37	0.94	15.2	0.68	6.12e-38	Intelligence (multi-trait analysis);
CESC	cis	rs9911578	1.000	rs302859	chr17:56693132	C/T	cg05425664	chr17:57184151	TRIM37	-0.51	-7.21	-0.4	6.03e-12	Intelligence (multi-trait analysis);
CESC	cis	rs75477785	1.000	rs12563527	chr1:210054211	G/A	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.8	5.19	0.3	4.2e-7	Cleft lip with or without cleft palate;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg24336590	chr1:120396074	NA	0.5	6.98	0.39	2.34e-11	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs1799949	1.000	rs9646417	chr17:41424253	G/A	cg25072359	chr17:41440525	NA	0.48	6.35	0.36	9.3e-10	Menopause (age at onset);
CESC	cis	rs17376456	0.825	rs17314762	chr5:93231200	C/T	cg21475434	chr5:93447410	FAM172A	0.82	6.99	0.39	2.2e-11	Diabetic retinopathy;
CESC	cis	rs6066835	0.572	rs12329434	chr20:47260191	T/C	cg18078177	chr20:47281410	PREX1	0.67	5.03	0.3	8.94e-7	Multiple myeloma;
CESC	trans	rs1728785	1.000	rs1170442	chr16:68574064	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.61	7.49	0.42	1.04e-12	Ulcerative colitis;
CESC	trans	rs7246760	1.000	rs56754106	chr19:9937789	T/A	cg02900749	chr2:68251473	NA	-0.82	-6.85	-0.39	5.23e-11	Pursuit maintenance gain;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg12784848	chr8:23081957	TNFRSF10A	-0.48	-6.07	-0.35	4.39e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	trans	rs7107217	1.000	rs1873872	chr11:129473993	A/T	cg20962211	chr2:183580829	DNAJC10	0.5	6.59	0.38	2.32e-10	Breast cancer;Type 2 diabetes;
CESC	cis	rs736801	0.780	rs2188962	chr5:131770805	C/T	cg21138405	chr5:131827807	IRF1	-0.36	-5.23	-0.31	3.37e-7	Breast cancer;Mosquito bite size;
CESC	cis	rs7100689	0.646	rs7899791	chr10:82091950	A/T	cg00277334	chr10:82204260	NA	-0.6	-7.96	-0.44	4.91e-14	Post bronchodilator FEV1;
CESC	cis	rs873946	0.564	rs12242672	chr10:134555609	A/T	cg18305652	chr10:134549665	INPP5A	0.5	7.58	0.42	5.94e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs950776	0.518	rs28438420	chr15:78836288	A/T	cg06917634	chr15:78832804	PSMA4	-0.68	-10.17	-0.53	9.91e-21	Sudden cardiac arrest;
CESC	trans	rs208520	0.770	rs1342960	chr6:66883514	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.92	-11.49	-0.58	4.62e-25	Exhaled nitric oxide output;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08697244	chr7:6487510	DAGLB	0.55	6.01	0.35	6.15e-9	Gut microbiome composition (summer);
CESC	cis	rs7692995	1.000	rs16896312	chr4:18030853	C/T	cg08925142	chr4:18023851	LCORL	-0.43	-5.03	-0.3	9e-7	Height;
CESC	cis	rs2247341	0.965	rs2854917	chr4:1720550	T/C	cg07465881	chr4:1713556	SLBP	-0.53	-6.58	-0.37	2.51e-10	Hip circumference adjusted for BMI;Height;
CESC	cis	rs1008375	1.000	rs3815414	chr4:17606659	A/G	cg02297831	chr4:17616191	MED28	-0.49	-6.18	-0.35	2.43e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs9324022	0.656	rs72698711	chr14:101167563	C/T	cg18089426	chr14:101175970	NA	0.56	5.88	0.34	1.25e-8	Plateletcrit;
CESC	cis	rs1559088	0.749	rs10405757	chr19:33616526	C/A	cg17764715	chr19:33622953	WDR88	0.45	5.85	0.34	1.45e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs644799	0.710	rs3017756	chr11:95537358	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.76	10.93	0.56	3.47e-23	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs7116495	0.609	rs7113520	chr11:71691946	G/A	cg07596299	chr11:71824057	C11orf51	-0.87	-5.46	-0.32	1.08e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs11719291	0.833	rs11713694	chr3:48833615	G/T	cg00383909	chr3:49044727	WDR6	0.92	6.66	0.38	1.62e-10	Cognitive function;
CESC	cis	rs9902453	0.967	rs1906451	chr17:28515479	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	7.44	0.42	1.38e-12	Coffee consumption (cups per day);
CESC	cis	rs1790761	0.587	rs7934075	chr11:67295949	T/C	cg24690094	chr11:67383802	NA	-0.34	-5.91	-0.34	1.05e-8	Mean corpuscular volume;
CESC	cis	rs1707322	0.929	rs785513	chr1:46538320	T/C	cg06784218	chr1:46089804	CCDC17	-0.35	-5.93	-0.34	9.27e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs3026101	0.624	rs1065483	chr17:5284770	C/T	cg24500398	chr17:5266808	RABEP1	-0.41	-5.92	-0.34	9.97e-9	Body mass index;
CESC	cis	rs477692	1.000	rs506274	chr10:131409392	T/A	cg05714579	chr10:131428358	MGMT	0.49	6.54	0.37	3.2e-10	Response to temozolomide;
CESC	cis	rs7560272	0.512	rs12998980	chr2:73930726	A/C	cg20560298	chr2:73613845	ALMS1	0.46	6.35	0.36	9.43e-10	Schizophrenia;
CESC	cis	rs8077577	0.747	rs62072511	chr17:18193157	G/A	cg16794390	chr17:18148240	FLII	0.41	6.45	0.37	5.26e-10	Obesity-related traits;
CESC	cis	rs1927790	0.637	rs7337506	chr13:96936978	G/A	cg02571835	chr13:96230311	CLDN10	-0.39	-5.51	-0.32	8.55e-8	Body mass index;
CESC	cis	rs7674212	0.570	rs2251634	chr4:104082349	C/T	cg16532752	chr4:104119610	CENPE	-0.45	-6.18	-0.36	2.37e-9	Type 2 diabetes;
CESC	cis	rs4481887	0.927	rs10888344	chr1:248446655	T/C	cg00666640	chr1:248458726	OR2T12	0.37	6.47	0.37	4.71e-10	Common traits (Other);
CESC	cis	rs7250872	0.568	rs749109	chr19:1819736	G/A	cg05970437	chr19:1864622	KLF16	0.49	5.7	0.33	3.2e-8	Bipolar disorder;
CESC	cis	rs642803	0.613	rs489574	chr11:65542739	C/T	cg02870584	chr11:65547924	DKFZp761E198	0.54	6.83	0.39	5.85e-11	Urate levels;
CESC	cis	rs4665809	1.000	rs13030858	chr2:26315451	G/A	cg22920501	chr2:26401640	FAM59B	-0.67	-8.12	-0.45	1.72e-14	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26010175	chr3:135969053	PCCB	0.61	7.05	0.4	1.59e-11	Gut microbiome composition (summer);
CESC	cis	rs910316	1.000	rs12897094	chr14:75579416	C/T	cg08847533	chr14:75593920	NEK9	1.0	19.67	0.77	9.95e-54	Height;
CESC	trans	rs73660619	0.818	rs3943652	chr8:3084216	C/T	cg21503148	chr8:786831	NA	0.55	6.09	0.35	3.85e-9	Alzheimer's disease (cognitive decline);
CESC	cis	rs1728785	0.901	rs933713	chr16:68581378	C/A	cg02972257	chr16:68554789	NA	-0.55	-6.31	-0.36	1.17e-9	Ulcerative colitis;
CESC	cis	rs6598955	0.671	rs6658935	chr1:26568912	G/A	cg19743891	chr1:26644573	UBXN11;CD52	0.38	5.44	0.32	1.21e-7	Obesity-related traits;
CESC	cis	rs977987	0.843	rs10871312	chr16:75486202	C/T	cg03315344	chr16:75512273	CHST6	0.46	6.53	0.37	3.27e-10	Dupuytren's disease;
CESC	cis	rs6570726	0.526	rs9376928	chr6:145724403	T/G	cg23711669	chr6:146136114	FBXO30	-0.53	-7.12	-0.4	1.01e-11	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs7726839	0.540	rs72703080	chr5:595238	A/G	cg25482853	chr8:67687455	SGK3	1.01	8.93	0.48	7.38e-17	Obesity-related traits;
CESC	cis	rs7524258	1.000	rs7524258	chr1:7292229	T/C	cg07173049	chr1:7289937	CAMTA1	0.41	6.47	0.37	4.67e-10	Tourette's syndrome or obsessive-compulsive disorder;
CESC	cis	rs6461049	0.638	rs1859993	chr7:2183702	A/G	cg23048001	chr7:2026167	MAD1L1	0.44	5.9	0.34	1.11e-8	Schizophrenia;
CESC	cis	rs12681288	0.676	rs2701927	chr8:995886	G/A	cg04851639	chr8:1020857	NA	-0.35	-7.48	-0.42	1.12e-12	Schizophrenia;
CESC	trans	rs877282	0.891	rs34652870	chr10:772218	T/C	cg22713356	chr15:30763199	NA	1.26	12.75	0.62	2.39e-29	Uric acid levels;
CESC	cis	rs736408	0.677	rs2286798	chr3:52821177	G/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.42	-5.79	-0.33	2.02e-8	Bipolar disorder;
CESC	cis	rs7264396	0.676	rs6060729	chr20:34557004	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.77	-10.29	-0.53	4.22e-21	Total cholesterol levels;
CESC	cis	rs910316	0.967	rs2268619	chr14:75640354	C/G	cg08847533	chr14:75593920	NEK9	-0.92	-15.1	-0.68	1.37e-37	Height;
CESC	cis	rs4909189	1.000	rs4909189	chr7:158136986	A/T	cg25566285	chr7:158114605	PTPRN2	-0.45	-6.22	-0.36	1.93e-9	Response to amphetamines;
CESC	cis	rs7917772	0.582	rs4919665	chr10:104366042	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.42	-5.79	-0.34	1.97e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs2439831	0.867	rs2584702	chr15:43684914	C/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.91	11.14	0.56	6.61e-24	Lung cancer in ever smokers;
CESC	cis	rs9443645	0.901	rs1538233	chr6:79743735	G/T	cg05283184	chr6:79620031	NA	-0.43	-6.84	-0.39	5.35e-11	Intelligence (multi-trait analysis);
CESC	cis	rs6121246	0.908	rs17093657	chr20:30428894	G/A	cg13852791	chr20:30311386	BCL2L1	0.75	7.48	0.42	1.09e-12	Mean corpuscular hemoglobin;
CESC	cis	rs9811920	0.609	rs13317017	chr3:99665521	A/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.58	-7.0	-0.39	2.14e-11	Axial length;
CESC	trans	rs1667255	0.830	rs2034404	chr18:29156302	A/G	cg08619119	chr6:13575098	SIRT5	0.52	6.56	0.37	2.75e-10	Retinol levels;
CESC	cis	rs3126085	0.935	rs4511113	chr1:152222192	G/A	cg03465714	chr1:152285911	FLG	-0.42	-5.17	-0.3	4.56e-7	Atopic dermatitis;
CESC	cis	rs7666738	0.830	rs13106434	chr4:98991651	T/A	cg05340658	chr4:99064831	C4orf37	0.8	12.44	0.61	2.83e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7020830	0.898	rs506981	chr9:37351348	A/T	cg14294708	chr9:37120828	ZCCHC7	-1.0	-17.3	-0.73	2.23e-45	Schizophrenia;
CESC	cis	rs12497850	0.543	rs6446218	chr3:49075513	A/T	cg07636037	chr3:49044803	WDR6	1.07	19.04	0.76	1.57e-51	Parkinson's disease;
CESC	cis	rs7772486	0.658	rs9403737	chr6:145962193	G/T	cg05347473	chr6:146136440	FBXO30	0.56	7.17	0.4	7.56e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs116095464	0.558	rs59113266	chr5:279965	T/C	cg10591111	chr5:226296	SDHA	-0.53	-6.43	-0.37	6.03e-10	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12857652	chr6:64289969	PTP4A1	-0.67	-7.85	-0.43	1.05e-13	Gut microbiome composition (summer);
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg17967426	chr5:168006763	PANK3	-0.53	-7.04	-0.4	1.63e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs6570726	0.935	rs380433	chr6:145859601	A/T	cg23711669	chr6:146136114	FBXO30	0.8	11.74	0.58	6.58e-26	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7267979	0.933	rs6138571	chr20:25435388	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.86	17.57	0.73	2.33e-46	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs476633	0.691	rs6492997	chr15:41541171	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.47	-6.78	-0.38	7.93e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs2735413	0.914	rs2262658	chr16:78060267	A/G	cg04733911	chr16:78082701	NA	-0.45	-7.04	-0.4	1.69e-11	Systolic blood pressure (alcohol consumption interaction);
CESC	trans	rs6951245	0.507	rs11976805	chr7:1138716	C/T	cg13565492	chr6:43139072	SRF	-0.6	-7.26	-0.41	4.42e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2243480	1.000	rs313803	chr7:65514731	G/A	cg18252515	chr7:66147081	NA	-1.25	-12.55	-0.61	1.18e-28	Diabetic kidney disease;
CESC	cis	rs9902453	0.933	rs7224199	chr17:28523726	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.58	7.34	0.41	2.67e-12	Coffee consumption (cups per day);
CESC	cis	rs2191566	0.959	rs7256345	chr19:44510905	T/G	cg20607764	chr19:44506953	ZNF230	-0.6	-7.8	-0.43	1.4e-13	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs6460942	0.841	rs6968277	chr7:12443795	C/A	cg20607287	chr7:12443886	VWDE	-0.68	-9.85	-0.52	1.04e-19	Coronary artery disease;
CESC	cis	rs847577	0.630	rs3801294	chr7:97822210	G/A	cg21770322	chr7:97807741	LMTK2	0.86	14.68	0.67	4.05e-36	Breast cancer;
CESC	cis	rs6580649	0.783	rs1635526	chr12:48396785	C/T	cg05342945	chr12:48394962	COL2A1	-0.54	-6.54	-0.37	3.07e-10	Lung cancer;
CESC	trans	rs561341	0.505	rs548298	chr17:30297494	C/A	cg27661571	chr11:113659931	NA	-0.72	-7.36	-0.41	2.36e-12	Hip circumference adjusted for BMI;
CESC	cis	rs9916302	0.904	rs7208274	chr17:37513796	C/T	cg07936489	chr17:37558343	FBXL20	0.82	11.93	0.59	1.54e-26	Glomerular filtration rate (creatinine);
CESC	cis	rs35306767	0.855	rs34318754	chr10:890714	G/A	cg20503657	chr10:835505	NA	1.1	9.65	0.51	4.39e-19	Eosinophil percentage of granulocytes;
CESC	cis	rs1707322	1.000	rs11211244	chr1:46456673	G/A	cg06784218	chr1:46089804	CCDC17	0.33	5.63	0.33	4.7e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7520050	0.933	rs9787208	chr1:46314616	C/A	cg24296786	chr1:45957014	TESK2	0.42	5.42	0.32	1.33e-7	Red blood cell count;Reticulocyte count;
CESC	cis	rs11098499	0.954	rs7436506	chr4:120393769	T/C	cg24375607	chr4:120327624	NA	0.45	5.74	0.33	2.61e-8	Corneal astigmatism;
CESC	cis	rs643506	0.874	rs663511	chr11:111710034	T/C	cg09085632	chr11:111637200	PPP2R1B	0.42	5.38	0.31	1.61e-7	Breast cancer;
CESC	cis	rs12347191	0.500	rs907578	chr9:100622883	A/G	cg13688889	chr9:100608707	NA	-0.89	-13.0	-0.62	3.11e-30	Orofacial clefts;
CESC	cis	rs1552244	1.000	rs33917318	chr3:10067797	T/C	cg08888203	chr3:10149979	C3orf24	0.49	6.29	0.36	1.3e-9	Alzheimer's disease;
CESC	cis	rs9457247	0.624	rs9457260	chr6:167466665	C/T	cg07741184	chr6:167504864	NA	0.37	6.49	0.37	4.2e-10	Crohn's disease;
CESC	cis	rs9910055	0.659	rs186603	chr17:42207884	C/T	cg08499158	chr17:42289980	UBTF	0.49	6.16	0.35	2.69e-9	Total body bone mineral density;
CESC	cis	rs9916302	0.851	rs2338795	chr17:37399364	T/G	cg07936489	chr17:37558343	FBXL20	-0.79	-11.25	-0.57	3.02e-24	Glomerular filtration rate (creatinine);
CESC	cis	rs7131987	0.903	rs67150462	chr12:29393325	T/C	cg09582351	chr12:29534625	ERGIC2	-0.32	-5.1	-0.3	6.58e-7	QT interval;
CESC	cis	rs6570726	0.577	rs399502	chr6:145805874	A/G	cg05347473	chr6:146136440	FBXO30	0.74	9.49	0.5	1.41e-18	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7267979	1.000	rs2259873	chr20:25280781	A/G	cg08601574	chr20:25228251	PYGB	0.39	5.57	0.32	6.14e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7772486	0.875	rs2814871	chr6:146312274	G/T	cg05347473	chr6:146136440	FBXO30	0.53	7.1	0.4	1.18e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs8064299	0.574	rs1879455	chr17:72774738	C/G	cg25054828	chr17:72772726	NAT9;TMEM104	0.83	13.9	0.65	2.3e-33	Monocyte count;
CESC	cis	rs9815354	0.951	rs9849393	chr3:41875369	G/C	cg03022575	chr3:42003672	ULK4	0.58	6.01	0.35	5.96e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs909674	0.690	rs5750825	chr22:39831278	A/G	cg02038168	chr22:39784481	NA	-0.66	-8.52	-0.46	1.24e-15	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs7095944	0.614	rs11245354	chr10:126450125	C/A	cg08799069	chr10:126477246	METTL10	-0.35	-5.15	-0.3	5.19e-7	Asthma;
CESC	cis	rs7794273	0.821	rs2520343	chr7:18843808	C/A	cg13420273	chr7:18810212	HDAC9	0.37	5.22	0.31	3.55e-7	Night sleep phenotypes;
CESC	cis	rs55794721	0.509	rs2982358	chr1:25745204	G/T	cg12412775	chr1:25698385	RHCE	-0.29	-5.13	-0.3	5.68e-7	Plateletcrit;Mean corpuscular volume;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg10545644	chr17:40719582	MLX	-0.38	-6.11	-0.35	3.52e-9	Gambling;
CESC	cis	rs2228479	0.850	rs17233567	chr16:89813821	G/A	cg14709524	chr16:89940631	TCF25	0.95	7.1	0.4	1.18e-11	Skin colour saturation;
CESC	cis	rs9486715	0.867	rs7451950	chr6:96879974	T/C	cg18709589	chr6:96969512	KIAA0776	0.45	6.46	0.37	5.05e-10	Headache;
CESC	cis	rs698813	0.674	rs11680456	chr2:44497544	C/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.48	5.34	0.31	2e-7	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
CESC	cis	rs2486288	0.656	rs10519018	chr15:45549265	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.55	-6.71	-0.38	1.2e-10	Glomerular filtration rate;
CESC	cis	rs1218582	0.772	rs877343	chr1:154910012	A/G	cg06221963	chr1:154839813	KCNN3	-0.66	-11.12	-0.56	8.2e-24	Prostate cancer;
CESC	cis	rs17384381	1.000	rs12123745	chr1:85884772	T/C	cg16011679	chr1:85725395	C1orf52	0.74	7.58	0.42	5.98e-13	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs911555	0.755	rs9671414	chr14:103967299	C/T	cg09975044	chr14:104007538	NA	-0.47	-5.53	-0.32	7.53e-8	Intelligence (multi-trait analysis);
CESC	trans	rs12356475	0.710	rs10822686	chr10:67733250	C/T	cg09140281	chr5:131563492	P4HA2	0.52	6.41	0.37	6.66e-10	Psoriatic arthritis;
CESC	cis	rs34779708	0.966	rs2045915	chr10:35418616	G/C	cg03585969	chr10:35415529	CREM	0.77	10.03	0.52	2.75e-20	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs2072499	0.865	rs2758608	chr1:156202860	A/T	cg25208724	chr1:156163844	SLC25A44	0.84	13.27	0.63	3.75e-31	Testicular germ cell tumor;
CESC	cis	rs1697139	0.583	rs17289614	chr5:66541592	G/A	cg11553311	chr5:66541588	NA	0.38	5.37	0.31	1.75e-7	Breast cancer;
CESC	cis	rs10411936	1.000	rs10411936	chr19:16548375	C/T	cg10248733	chr19:16607483	C19orf44;CALR3	-0.5	-6.02	-0.35	5.81e-9	White blood cell count;Multiple sclerosis;
CESC	cis	rs3820068	0.608	rs58140482	chr1:16043979	A/G	cg17385448	chr1:15911702	AGMAT	0.38	6.08	0.35	4.28e-9	Systolic blood pressure;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg06471548	chr7:192006	FAM20C	-0.5	-6.74	-0.38	9.92e-11	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs4253772	0.938	rs10154348	chr22:46638159	C/A	cg00784671	chr22:46762841	CELSR1	-0.51	-5.27	-0.31	2.87e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs4836694	0.574	rs67899211	chr9:132935614	G/A	cg05251000	chr9:132935664	FREQ	0.43	5.68	0.33	3.47e-8	Alzheimer's disease (cognitive decline);
CESC	cis	rs5750830	0.649	rs4384886	chr22:39793766	C/T	cg11247378	chr22:39784982	NA	-0.64	-9.68	-0.51	3.5e-19	Intelligence (multi-trait analysis);
CESC	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg07677032	chr17:61819896	STRADA	0.45	5.97	0.34	7.74e-9	Prudent dietary pattern;
CESC	cis	rs7965445	0.803	rs61937080	chr12:131929054	C/A	cg08164151	chr12:131118432	NA	0.63	5.15	0.3	5.11e-7	Mortality in heart failure;
CESC	cis	rs7666738	0.830	rs13125537	chr4:98978428	A/G	cg05340658	chr4:99064831	C4orf37	0.79	12.26	0.6	1.12e-27	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1784581	0.588	rs9885762	chr6:162411954	G/A	cg17173639	chr6:162384350	PARK2	0.58	8.71	0.47	3.3e-16	Itch intensity from mosquito bite;
CESC	cis	rs2839186	0.770	rs2839171	chr21:47673247	C/T	cg14789911	chr21:47582049	C21orf56	0.35	5.18	0.3	4.36e-7	Testicular germ cell tumor;
CESC	cis	rs67478160	0.619	rs1187416	chr14:104311465	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.51	-7.18	-0.4	7.24e-12	Schizophrenia;
CESC	cis	rs8067354	0.645	rs2102507	chr17:57875907	A/G	cg13753209	chr17:57696993	CLTC	0.66	8.34	0.46	4.12e-15	Hemoglobin concentration;
CESC	cis	rs7666738	0.830	rs28618180	chr4:98912184	A/C	cg03467027	chr4:99064603	C4orf37	0.44	5.37	0.31	1.73e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs698813	0.572	rs13424464	chr2:44482263	A/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.48	5.41	0.32	1.41e-7	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
CESC	cis	rs637571	0.522	rs542332	chr11:65744421	C/T	cg02202077	chr11:65769826	EIF1AD;BANF1	0.45	6.05	0.35	5.01e-9	Eosinophil percentage of white cells;
CESC	cis	rs7772486	0.686	rs9485019	chr6:146046381	C/G	cg05347473	chr6:146136440	FBXO30	-0.53	-6.99	-0.39	2.21e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7267979	0.933	rs11699203	chr20:25435169	G/C	cg08601574	chr20:25228251	PYGB	0.37	5.31	0.31	2.31e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7605827	0.930	rs12692267	chr2:15572834	A/G	cg19274914	chr2:15703543	NA	-0.32	-5.93	-0.34	9.24e-9	Educational attainment (years of education);
CESC	cis	rs473651	1.000	rs473651	chr2:239335401	A/C	cg18131467	chr2:239335373	ASB1	1.04	20.93	0.79	4.5e-58	Multiple system atrophy;
CESC	cis	rs6061231	0.561	rs67072353	chr20:60940702	G/A	cg24112000	chr20:60950667	NA	-0.59	-6.16	-0.35	2.66e-9	Colorectal cancer;
CESC	trans	rs7178375	0.941	rs4779796	chr15:31208050	C/T	cg04373760	chr16:53404718	NA	0.53	7.2	0.4	6.18e-12	Hypertriglyceridemia;
CESC	cis	rs6685188	0.920	rs10751444	chr1:205662144	A/G	cg14893161	chr1:205819251	PM20D1	-0.47	-6.47	-0.37	4.7e-10	White blood cell count (basophil);Basophil percentage of white cells;
CESC	cis	rs1387259	0.929	rs11168460	chr12:48597365	A/G	cg04545296	chr12:48745243	ZNF641	0.4	6.74	0.38	9.66e-11	Obstructive sleep apnea trait (apnea hypopnea index);
CESC	cis	rs17253792	0.822	rs28481586	chr14:56053863	C/G	cg01858014	chr14:56050164	KTN1	-0.82	-6.45	-0.37	5.37e-10	Putamen volume;
CESC	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg08946332	chr17:6899888	ALOX12	0.44	6.43	0.37	5.99e-10	Tonsillectomy;
CESC	cis	rs4803468	0.967	rs13344547	chr19:41945848	G/T	cg14132834	chr19:41945861	ATP5SL	0.6	7.5	0.42	9.48e-13	Height;
CESC	cis	rs4588572	0.601	rs10942855	chr5:77737529	G/A	cg11547950	chr5:77652471	NA	-0.44	-5.54	-0.32	7.21e-8	Triglycerides;
CESC	cis	rs6582630	0.555	rs7969922	chr12:38529491	C/T	cg13010199	chr12:38710504	ALG10B	0.46	5.95	0.34	8.41e-9	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs7586673	0.857	rs16845580	chr2:161920884	T/C	cg08807892	chr2:162101083	NA	0.45	6.1	0.35	3.83e-9	Intelligence (multi-trait analysis);
CESC	cis	rs7267979	1.000	rs2257982	chr20:25269630	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	18.61	0.75	5.02e-50	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs709400	0.526	rs11622835	chr14:103967504	G/A	cg12935359	chr14:103987150	CKB	-0.63	-6.89	-0.39	4.02e-11	Body mass index;
CESC	cis	rs12618769	0.597	rs3769737	chr2:99088873	C/G	cg10123293	chr2:99228465	UNC50	-0.39	-5.13	-0.3	5.6e-7	Bipolar disorder;
CESC	trans	rs10743315	0.643	rs75189071	chr12:19329505	C/T	cg09562322	chr12:119419143	SRRM4	-0.49	-6.18	-0.35	2.45e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs2243480	0.908	rs2460431	chr7:65622846	A/G	cg12463550	chr7:65579703	CRCP	-0.73	-5.71	-0.33	3.1e-8	Diabetic kidney disease;
CESC	cis	rs10504229	0.683	rs66730544	chr8:58127280	A/T	cg21724239	chr8:58056113	NA	0.57	5.76	0.33	2.29e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.5	-6.31	-0.36	1.18e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs4727963	0.869	rs10953973	chr7:122793182	T/C	cg03640110	chr7:122635026	TAS2R16	0.33	5.11	0.3	6.2e-7	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
CESC	cis	rs2836950	0.501	rs11702505	chr21:40700614	G/T	cg11890956	chr21:40555474	PSMG1	-0.67	-9.42	-0.5	2.35e-18	Menarche (age at onset);
CESC	cis	rs8060686	0.844	rs7196076	chr16:67887494	T/A	cg26727032	chr16:67993705	SLC12A4	-0.55	-5.63	-0.33	4.53e-8	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs1975974	0.872	rs66502681	chr17:21722119	T/A	cg18423549	chr17:21743878	NA	-0.51	-7.02	-0.4	1.81e-11	Psoriasis;
CESC	cis	rs6500395	0.926	rs1039344	chr16:48577569	A/G	cg04672837	chr16:48644449	N4BP1	0.45	5.43	0.32	1.3e-7	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs425277	1.000	rs55826501	chr1:2059143	G/A	cg04315214	chr1:2043799	PRKCZ	-0.43	-5.95	-0.34	8.56e-9	Height;
CESC	cis	rs8058578	0.832	rs3812999	chr16:30773605	G/T	cg02466173	chr16:30829666	NA	-0.41	-6.68	-0.38	1.43e-10	Multiple myeloma;
CESC	cis	rs11792861	0.962	rs3829084	chr9:111801724	C/G	cg14384093	chr9:111878565	C9orf5	0.42	5.26	0.31	2.93e-7	Menarche (age at onset);
CESC	cis	rs10871290	0.881	rs3863439	chr16:74470644	T/C	cg01733217	chr16:74700730	RFWD3	-0.67	-8.98	-0.48	5.28e-17	Breast cancer;
CESC	cis	rs739401	0.611	rs401707	chr11:3050965	T/C	cg08508325	chr11:3079039	CARS	-0.56	-10.89	-0.56	4.52e-23	Longevity;
CESC	cis	rs9291683	0.551	rs2276961	chr4:10022981	C/T	cg00071950	chr4:10020882	SLC2A9	0.89	17.02	0.72	2.12e-44	Bone mineral density;
CESC	cis	rs7944584	0.511	rs10838725	chr11:47557871	T/C	cg10504702	chr11:47789108	FNBP4	0.42	5.2	0.3	4.01e-7	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg24429881	chr1:166809343	POGK	-0.45	-6.08	-0.35	4.24e-9	Fibrinogen levels;
CESC	cis	rs1371867	0.846	rs1692006	chr8:101252462	C/T	cg11906718	chr8:101322791	RNF19A	-0.45	-5.64	-0.33	4.46e-8	Atrioventricular conduction;
CESC	cis	rs7772486	0.774	rs6930181	chr6:146180974	A/T	cg23711669	chr6:146136114	FBXO30	-0.7	-10.36	-0.54	2.37e-21	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs13108904	0.901	rs13112706	chr4:1303682	G/T	cg00684032	chr4:1343700	KIAA1530	0.41	5.72	0.33	2.95e-8	Obesity-related traits;
CESC	cis	rs2635047	0.967	rs1119005	chr18:44725605	A/G	cg19077165	chr18:44547161	KATNAL2	-0.46	-6.26	-0.36	1.54e-9	Educational attainment;
CESC	cis	rs4927850	0.723	rs7630825	chr3:195753740	T/C	cg01181863	chr3:195395398	SDHAP2	-0.55	-6.66	-0.38	1.53e-10	Pancreatic cancer;
CESC	cis	rs9487051	0.872	rs9487042	chr6:109610443	T/G	cg21918786	chr6:109611834	NA	-0.4	-6.01	-0.35	6.17e-9	Reticulocyte fraction of red cells;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00173170	chr1:214779122	CENPF	-0.56	-6.61	-0.38	2.08e-10	Gut microbiome composition (summer);
CESC	cis	rs34779708	0.931	rs9663401	chr10:35278849	G/T	cg04310649	chr10:35416472	CREM	-0.5	-5.97	-0.34	7.61e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs853679	0.513	rs13437444	chr6:28070998	C/T	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.56	5.5	0.32	8.88e-8	Depression;
CESC	cis	rs10504229	0.861	rs67966192	chr8:58188172	A/C	cg24829409	chr8:58192753	C8orf71	-0.62	-8.61	-0.47	6.43e-16	Developmental language disorder (linguistic errors);
CESC	cis	rs10504229	1.000	rs112272435	chr8:58170371	A/G	cg05313129	chr8:58192883	C8orf71	-0.55	-6.29	-0.36	1.31e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs763014	0.898	rs8060921	chr16:635988	C/A	cg00802000	chr16:706648	WDR90	-0.41	-6.19	-0.36	2.26e-9	Height;
CESC	cis	rs7264396	0.635	rs6058375	chr20:34531997	T/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.55	6.67	0.38	1.53e-10	Total cholesterol levels;
CESC	cis	rs1843834	0.539	rs12694643	chr2:225446603	A/G	cg22509189	chr2:225307070	NA	-0.41	-5.59	-0.32	5.63e-8	IgE levels in asthmatics (D.p. specific);
CESC	cis	rs2928148	0.522	rs11858278	chr15:41416276	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.76	-9.87	-0.52	9.03e-20	Glomerular filtration rate in non diabetics (creatinine);
CESC	cis	rs11122272	0.735	rs2739518	chr1:231537633	C/T	cg06096015	chr1:231504339	EGLN1	0.42	6.07	0.35	4.33e-9	Hemoglobin concentration;
CESC	cis	rs10242455	0.571	rs11734	chr7:99229768	C/G	cg07338983	chr7:99679036	ZNF3	-0.63	-5.04	-0.3	8.69e-7	Blood metabolite levels;
CESC	cis	rs13106227	0.576	rs10031136	chr4:77407344	A/G	cg20311846	chr4:77356250	SHROOM3	-0.31	-6.04	-0.35	5.26e-9	Eosinophilic esophagitis (pediatric);
CESC	cis	rs7208859	0.623	rs9899268	chr17:29150255	T/C	cg13385521	chr17:29058706	SUZ12P	0.8	6.42	0.37	6.22e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs514406	0.861	rs6588443	chr1:53250650	G/A	cg24675658	chr1:53192096	ZYG11B	0.53	6.68	0.38	1.43e-10	Monocyte count;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg11310125	chr2:113239311	TTL	-0.46	-6.57	-0.37	2.68e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs801193	0.904	rs4718405	chr7:66254646	A/G	cg11764359	chr7:65958608	NA	0.68	8.53	0.46	1.15e-15	Aortic root size;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg23260799	chr11:451101	PTDSS2	0.54	7.0	0.4	2.08e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs9486719	1.000	rs13202675	chr6:97028427	C/T	cg18709589	chr6:96969512	KIAA0776	-0.5	-5.43	-0.32	1.28e-7	Migraine;Coronary artery disease;
CESC	cis	rs4975616	0.869	rs466502	chr5:1325767	C/T	cg07493874	chr5:1342172	CLPTM1L	0.41	7.95	0.44	5.54e-14	Lung cancer;
CESC	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg11494091	chr17:61959527	GH2	0.74	12.57	0.61	9.52e-29	Prudent dietary pattern;
CESC	cis	rs2066819	0.892	rs112931321	chr12:56667894	C/T	cg26734620	chr12:56694298	CS	1.07	6.56	0.37	2.85e-10	Psoriasis vulgaris;
CESC	cis	rs919433	0.889	rs787998	chr2:198216092	A/G	cg10820045	chr2:198174542	NA	0.4	6.05	0.35	4.95e-9	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs752010	0.967	rs10890153	chr1:42102060	C/A	cg06885757	chr1:42089581	HIVEP3	0.5	8.07	0.44	2.49e-14	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs2050392	0.517	rs7096279	chr10:30759608	C/T	cg25182066	chr10:30743637	MAP3K8	-0.52	-7.65	-0.43	3.71e-13	Inflammatory bowel disease;
CESC	cis	rs2235642	0.826	rs8053605	chr16:1594158	G/A	cg07639376	chr16:1584516	IFT140;TMEM204	-0.32	-5.21	-0.3	3.88e-7	Coronary artery disease;
CESC	cis	rs796364	0.950	rs56155997	chr2:200768491	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.95	-7.48	-0.42	1.09e-12	Schizophrenia;
CESC	cis	rs6933660	0.536	rs3800274	chr6:151759192	T/G	cg14262678	chr6:151773367	RMND1;C6orf211	0.58	7.19	0.4	6.66e-12	Menarche (age at onset);
CESC	cis	rs72781680	0.846	rs72782114	chr2:24025740	G/A	cg20701182	chr2:24300061	SF3B14	0.63	5.62	0.33	4.86e-8	Lymphocyte counts;
CESC	cis	rs11098499	0.863	rs6534139	chr4:120449456	A/G	cg09307838	chr4:120376055	NA	-0.91	-12.17	-0.6	2.32e-27	Corneal astigmatism;
CESC	cis	rs11853189	0.938	rs113594982	chr15:78557392	C/T	cg22935921	chr15:78556834	DNAJA4	0.61	5.1	0.3	6.35e-7	Red cell distribution width;
CESC	cis	rs798554	0.757	rs1182172	chr7:2878103	G/A	cg18446336	chr7:2847575	GNA12	-0.4	-5.75	-0.33	2.45e-8	Height;
CESC	cis	rs7809950	0.678	rs2395868	chr7:106897500	C/T	cg23024343	chr7:107201750	COG5	0.54	7.09	0.4	1.24e-11	Coronary artery disease;
CESC	cis	rs1552244	0.882	rs13084194	chr3:10031492	T/A	cg00149659	chr3:10157352	C3orf10	0.61	6.61	0.38	2.1e-10	Alzheimer's disease;
CESC	cis	rs9467711	0.516	rs1324087	chr6:25841408	A/G	cg21479132	chr6:26055353	NA	-0.61	-6.47	-0.37	4.69e-10	Autism spectrum disorder or schizophrenia;
CESC	cis	rs6964587	1.000	rs12537846	chr7:91721581	C/T	cg17063962	chr7:91808500	NA	-0.58	-7.87	-0.44	8.99e-14	Breast cancer;
CESC	cis	rs13191362	1.000	rs7764785	chr6:163009967	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.87	8.98	0.48	5.33e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs9987353	0.566	rs13260067	chr8:9071033	A/G	cg06636001	chr8:8085503	FLJ10661	-0.54	-6.46	-0.37	4.99e-10	Recombination measurement;
CESC	cis	rs7551222	0.752	rs4328119	chr1:204564986	C/T	cg20240347	chr1:204465584	NA	-0.26	-5.39	-0.31	1.57e-7	Schizophrenia;
CESC	cis	rs7149337	0.805	rs2999361	chr14:51605358	G/A	cg23942311	chr14:51606299	NA	0.48	8.34	0.46	4.23e-15	Cancer;
CESC	cis	rs6912958	0.781	rs4707379	chr6:88310623	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-6.69	-0.38	1.35e-10	Monocyte percentage of white cells;
CESC	cis	rs7582720	1.000	rs114393235	chr2:203795987	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.38	0.41	1.99e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs9560113	0.573	rs1888304	chr13:112242454	A/G	cg10483660	chr13:112241077	NA	0.44	7.31	0.41	3.18e-12	Menarche (age at onset);
CESC	cis	rs5753037	0.547	rs140134	chr22:30163332	G/A	cg01021169	chr22:30184971	ASCC2	-0.57	-8.56	-0.47	9.24e-16	Type 1 diabetes;
CESC	cis	rs10504229	0.954	rs114134184	chr8:58181969	G/A	cg05313129	chr8:58192883	C8orf71	-0.55	-6.29	-0.36	1.34e-9	Developmental language disorder (linguistic errors);
CESC	trans	rs1814175	0.645	rs7123448	chr11:49764865	T/G	cg15704280	chr7:45808275	SEPT13	-1.0	-17.38	-0.73	1.13e-45	Height;
CESC	cis	rs875971	0.825	rs1860472	chr7:66082723	T/C	cg12463550	chr7:65579703	CRCP	-0.53	-6.74	-0.38	9.87e-11	Aortic root size;
CESC	cis	rs13118159	0.934	rs4974608	chr4:1356780	C/T	cg00684032	chr4:1343700	KIAA1530	0.35	5.45	0.32	1.17e-7	Longevity;
CESC	cis	rs8103278	0.507	rs62111759	chr19:46296230	A/T	cg20908204	chr19:46285434	DMPK	0.35	5.58	0.32	6.09e-8	Coronary artery disease;
CESC	cis	rs698833	0.780	rs11124986	chr2:44508835	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.52	6.61	0.38	2.11e-10	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs2050392	0.624	rs303447	chr10:30728464	T/C	cg25182066	chr10:30743637	MAP3K8	-0.45	-5.91	-0.34	1.04e-8	Inflammatory bowel disease;
CESC	cis	rs763014	0.931	rs3752568	chr16:628302	A/G	cg09263875	chr16:632152	PIGQ	0.67	11.07	0.56	1.14e-23	Height;
CESC	trans	rs1814175	0.935	rs7479914	chr11:49661351	T/C	cg03929089	chr4:120376271	NA	-0.87	-13.36	-0.63	1.83e-31	Height;
CESC	cis	rs7927771	1.000	rs4752856	chr11:47648042	C/T	cg05585544	chr11:47624801	NA	-0.53	-8.38	-0.46	3.1e-15	Subjective well-being;
CESC	cis	rs4919044	0.808	rs835256	chr10:94779550	C/T	cg26979504	chr10:94451518	HHEX	-0.47	-5.15	-0.3	5.16e-7	Coronary artery disease;
CESC	cis	rs2180341	1.000	rs6569477	chr6:127589302	T/A	cg24812749	chr6:127587940	RNF146	1.06	15.28	0.68	3.03e-38	Breast cancer;
CESC	cis	rs7552404	1.000	rs7524467	chr1:76194054	C/G	cg10523679	chr1:76189770	ACADM	0.7	8.12	0.45	1.73e-14	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs1008375	0.932	rs13109475	chr4:17677565	C/G	cg16339924	chr4:17578868	LAP3	-0.57	-6.87	-0.39	4.5e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs875971	0.862	rs11763189	chr7:65983529	G/A	cg11764359	chr7:65958608	NA	0.8	11.64	0.58	1.39e-25	Aortic root size;
CESC	cis	rs3845702	0.736	rs12693214	chr2:180825685	G/A	cg01881094	chr2:180872142	CWC22	-1.06	-9.19	-0.49	1.18e-17	Schizophrenia;
CESC	cis	rs2279817	1.000	rs2354290	chr1:18019861	A/G	cg21791023	chr1:18019539	ARHGEF10L	0.55	8.17	0.45	1.27e-14	Neuroticism;
CESC	cis	rs5758659	0.652	rs133305	chr22:42395960	C/T	cg04733989	chr22:42467013	NAGA	0.44	5.81	0.34	1.78e-8	Cognitive function;
CESC	cis	rs6973256	0.569	rs6944149	chr7:133381365	A/C	cg10665199	chr7:133106180	EXOC4	0.45	6.11	0.35	3.54e-9	Intelligence (multi-trait analysis);
CESC	cis	rs9926296	0.632	rs4785717	chr16:89801133	A/G	cg04287289	chr16:89883240	FANCA	0.65	8.79	0.48	1.88e-16	Vitiligo;
CESC	cis	rs514406	0.607	rs6696940	chr1:53203427	C/T	cg08736216	chr1:53307985	ZYG11A	0.4	6.45	0.37	5.35e-10	Monocyte count;
CESC	cis	rs9487051	0.837	rs2356817	chr6:109642675	G/A	cg12927641	chr6:109611667	NA	-0.4	-5.92	-0.34	1e-8	Reticulocyte fraction of red cells;
CESC	cis	rs6460942	1.000	rs6460938	chr7:12406808	T/G	cg06484146	chr7:12443880	VWDE	-0.8	-9.02	-0.48	3.94e-17	Coronary artery disease;
CESC	cis	rs10242455	0.867	rs1818797	chr7:99296195	G/A	cg07715041	chr7:99302981	CYP3A7	-0.44	-5.56	-0.32	6.73e-8	Blood metabolite levels;
CESC	trans	rs916888	0.821	rs199506	chr17:44859031	A/G	cg22433210	chr17:43662623	NA	-0.91	-10.49	-0.54	9.15e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs2882667	0.754	rs11746434	chr5:138435303	A/G	cg04439458	chr5:138467593	SIL1	-0.41	-6.37	-0.36	8.13e-10	Age-related hearing impairment (SNP x SNP interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08317834	chr8:26148868	PPP2R2A	0.55	6.84	0.39	5.51e-11	Gut microbiome composition (summer);
CESC	cis	rs17001868	0.568	rs55769635	chr22:40790101	G/A	cg07138101	chr22:40742427	ADSL	0.52	5.32	0.31	2.17e-7	Mammographic density (dense area);
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg14093289	chr19:33622866	WDR88	-0.5	-6.36	-0.36	8.66e-10	Asthma;
CESC	cis	rs4319547	0.915	rs7316734	chr12:123117425	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.59	-6.95	-0.39	2.76e-11	Body mass index;
CESC	trans	rs3008870	0.583	rs2031495	chr1:67421714	G/T	cg19754094	chr2:74055942	STAMBP	0.62	6.0	0.35	6.49e-9	Lymphocyte percentage of white cells;
CESC	cis	rs9488822	0.636	rs11153592	chr6:116330574	T/C	cg26893134	chr6:116381904	FRK	0.25	6.0	0.35	6.32e-9	Cholesterol, total;LDL cholesterol;
CESC	cis	rs9583531	0.600	rs7986286	chr13:111357207	A/G	cg15841412	chr13:111365552	ING1	0.5	6.51	0.37	3.78e-10	Coronary artery disease;
CESC	cis	rs2842992	0.915	rs2842958	chr6:160108425	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.65	7.85	0.43	1.05e-13	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs11190604	1.000	rs2489047	chr10:102347028	A/G	cg07080220	chr10:102295463	HIF1AN	0.52	5.07	0.3	7.52e-7	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs6693567	0.565	rs4926395	chr1:150405298	T/C	cg09579323	chr1:150459698	TARS2	0.46	5.89	0.34	1.15e-8	Migraine;
CESC	cis	rs1372520	0.564	rs356197	chr4:90682750	G/A	cg15133208	chr4:90757351	SNCA	0.43	5.12	0.3	5.78e-7	Neuroticism;
CESC	cis	rs9486715	1.000	rs2273621	chr6:97058553	A/G	cg18709589	chr6:96969512	KIAA0776	-0.46	-6.33	-0.36	1.04e-9	Headache;
CESC	cis	rs2404602	0.684	rs11072600	chr15:76867915	T/C	cg23625390	chr15:77176239	SCAPER	-0.44	-6.14	-0.35	3.01e-9	Blood metabolite levels;
CESC	cis	rs9311474	0.508	rs3796353	chr3:52593230	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.49	7.15	0.4	8.44e-12	Electroencephalogram traits;
CESC	cis	rs13096760	1	rs13096760	chr3:49476806	T/C	cg06212747	chr3:49208901	KLHDC8B	0.49	6.7	0.38	1.21e-10	Intelligence (multi-trait analysis);
CESC	cis	rs9733	0.596	rs6686525	chr1:150635811	C/T	cg22823121	chr1:150693482	HORMAD1	0.48	7.12	0.4	1.02e-11	Tonsillectomy;
CESC	cis	rs644799	0.544	rs1254935	chr11:95631470	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.52	6.69	0.38	1.29e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs6121246	0.609	rs6060843	chr20:30297047	G/C	cg13852791	chr20:30311386	BCL2L1	0.82	10.57	0.54	5.11e-22	Mean corpuscular hemoglobin;
CESC	cis	rs2295499	0.643	rs3733215	chr4:2698364	C/T	cg08330972	chr4:2403930	ZFYVE28	-0.31	-5.1	-0.3	6.62e-7	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
CESC	cis	rs9487051	0.872	rs6924815	chr6:109612344	A/G	cg12927641	chr6:109611667	NA	-0.43	-6.75	-0.38	9.5e-11	Reticulocyte fraction of red cells;
CESC	cis	rs875971	0.545	rs6460298	chr7:65907770	T/C	cg18876405	chr7:65276391	NA	0.5	5.81	0.34	1.75e-8	Aortic root size;
CESC	cis	rs17376456	0.825	rs17372649	chr5:93126096	C/G	cg25358565	chr5:93447407	FAM172A	1.11	10.66	0.55	2.6e-22	Diabetic retinopathy;
CESC	cis	rs1728785	0.901	rs1728787	chr16:68593042	G/C	cg02972257	chr16:68554789	NA	-0.59	-6.7	-0.38	1.23e-10	Ulcerative colitis;
CESC	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg01238044	chr22:24384105	GSTT1	0.74	10.18	0.53	8.97e-21	Liver enzyme levels (gamma-glutamyl transferase);
CESC	trans	rs561341	0.941	rs7215147	chr17:30266711	G/A	cg27661571	chr11:113659931	NA	-0.57	-6.42	-0.37	6.14e-10	Hip circumference adjusted for BMI;
CESC	cis	rs561341	0.825	rs2008368	chr17:30347397	T/C	cg12193833	chr17:30244370	NA	-0.73	-6.51	-0.37	3.83e-10	Hip circumference adjusted for BMI;
CESC	cis	rs9902453	0.967	rs12602258	chr17:28317657	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.64	8.08	0.44	2.36e-14	Coffee consumption (cups per day);
CESC	cis	rs11122272	0.735	rs2790892	chr1:231512771	G/A	cg06096015	chr1:231504339	EGLN1	0.43	6.18	0.35	2.46e-9	Hemoglobin concentration;
CESC	cis	rs79349575	0.679	rs9894239	chr17:46997959	C/T	cg16584676	chr17:46985605	UBE2Z	-0.71	-9.25	-0.49	8.03e-18	Type 2 diabetes;
CESC	trans	rs10488821	0.953	rs1458727	chr11:30517996	C/T	cg04407762	chr4:113442791	NA	-0.45	-6.61	-0.38	2.07e-10	QRS complex (12-leadsum);
CESC	cis	rs7546094	0.967	rs1032312	chr1:113112746	G/A	cg22162597	chr1:113214053	CAPZA1	0.37	5.67	0.33	3.69e-8	Platelet distribution width;
CESC	trans	rs1459104	0.778	rs12797173	chr11:55506548	C/T	cg10201141	chr12:7032793	ENO2;ATN1	-0.74	-6.46	-0.37	4.88e-10	Body mass index;
CESC	cis	rs2839186	0.616	rs4819213	chr21:47619300	G/A	cg12379764	chr21:47803548	PCNT	0.47	6.04	0.35	5.07e-9	Testicular germ cell tumor;
CESC	cis	rs4713118	0.621	rs9368548	chr6:28034737	A/G	cg23161317	chr6:28129485	ZNF389	0.51	6.32	0.36	1.08e-9	Parkinson's disease;
CESC	cis	rs8114671	0.869	rs66535333	chr20:33656666	G/A	cg24642439	chr20:33292090	TP53INP2	-0.47	-5.7	-0.33	3.19e-8	Height;
CESC	cis	rs9486719	0.741	rs976356	chr6:96849437	T/A	cg06623918	chr6:96969491	KIAA0776	0.77	7.27	0.41	4.05e-12	Migraine;Coronary artery disease;
CESC	cis	rs6089829	0.925	rs11086152	chr20:61664656	T/C	cg03213289	chr20:61660250	NA	0.39	6.07	0.35	4.42e-9	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26447919	chr20:17949531	C20orf72;SNX5	0.56	6.47	0.37	4.61e-10	Gut microbiome composition (summer);
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg27434890	chr6:135517041	MYB	0.4	6.23	0.36	1.81e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs7811142	1.000	rs67163493	chr7:100023838	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.16	11.71	0.58	8.43e-26	Platelet count;
CESC	cis	rs8062405	1.000	rs11861174	chr16:28871989	A/G	cg08761264	chr16:28874980	SH2B1	-0.47	-5.85	-0.34	1.42e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs7660520	0.524	rs4862101	chr4:183733177	T/C	cg04181038	chr4:183730758	NA	0.64	6.96	0.39	2.71e-11	Pediatric autoimmune diseases;
CESC	cis	rs763121	0.853	rs1569492	chr22:38975511	A/G	cg06022373	chr22:39101656	GTPBP1	-0.72	-11.35	-0.57	1.39e-24	Menopause (age at onset);
CESC	cis	rs734999	0.545	rs12730932	chr1:2559589	T/G	cg18854424	chr1:2615690	NA	-0.3	-5.88	-0.34	1.2e-8	Ulcerative colitis;
CESC	cis	rs9733	0.744	rs11204725	chr1:150742700	T/C	cg22823121	chr1:150693482	HORMAD1	-0.39	-5.83	-0.34	1.63e-8	Tonsillectomy;
CESC	cis	rs2439831	1.000	rs690436	chr15:43761205	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.85	12.48	0.61	1.94e-28	Lung cancer in ever smokers;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg27152661	chr10:99052555	ARHGAP19	-0.48	-6.63	-0.38	1.84e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs2066819	1.000	rs78121408	chr12:56684798	C/T	cg26804944	chr12:56660921	COQ10A	-0.85	-5.19	-0.3	4.22e-7	Psoriasis vulgaris;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27135125	chr7:23510082	IGF2BP3	0.56	6.41	0.37	6.8e-10	Gut microbiome composition (summer);
CESC	cis	rs853679	0.517	rs9393884	chr6:28046789	A/G	cg17949981	chr6:28129498	ZNF389	0.49	6.18	0.35	2.4e-9	Depression;
CESC	cis	rs2228479	0.557	rs62054639	chr16:89821489	C/T	cg14709524	chr16:89940631	TCF25	0.93	6.94	0.39	3.03e-11	Skin colour saturation;
CESC	cis	rs875971	0.545	rs11767262	chr7:65767224	T/A	cg18876405	chr7:65276391	NA	0.47	5.71	0.33	3.05e-8	Aortic root size;
CESC	cis	rs4417704	0.551	rs6753109	chr2:241877597	C/T	cg05025159	chr2:241905733	NA	-0.35	-5.18	-0.3	4.39e-7	Joint mobility (Beighton score);
CESC	cis	rs752010	1.000	rs4999015	chr1:42093547	G/A	cg06885757	chr1:42089581	HIVEP3	0.5	8.22	0.45	9.25e-15	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs1915146	0.546	rs2681919	chr10:126859029	A/G	cg05090351	chr10:126851162	NA	0.6	9.24	0.49	8.52e-18	Menarche (age at onset);
CESC	cis	rs2963155	0.518	rs72801054	chr5:142687742	T/C	cg17617527	chr5:142782415	NR3C1	0.79	6.76	0.38	8.65e-11	Breast cancer;
CESC	cis	rs6430585	0.583	rs12472293	chr2:136648077	T/C	cg07169764	chr2:136633963	MCM6	1.3	20.37	0.78	3.82e-56	Corneal structure;
CESC	cis	rs763121	0.925	rs9611008	chr22:39098787	T/C	cg21395723	chr22:39101663	GTPBP1	0.44	5.89	0.34	1.19e-8	Menopause (age at onset);
CESC	cis	rs3780486	0.522	rs1328898	chr9:33163271	A/G	cg13443165	chr9:33130375	B4GALT1	0.48	7.29	0.41	3.61e-12	IgG glycosylation;
CESC	cis	rs10129255	0.719	rs7156660	chr14:107129187	T/C	cg07958169	chr14:107095056	NA	-0.41	-6.01	-0.35	6.26e-9	Kawasaki disease;
CESC	cis	rs12079745	0.793	rs12074013	chr1:169133621	C/T	cg09363564	chr1:169337483	NME7;BLZF1	-1.07	-6.67	-0.38	1.52e-10	QT interval;
CESC	cis	rs7680126	0.596	rs12503603	chr4:10313757	T/G	cg11266682	chr4:10021025	SLC2A9	-0.43	-5.29	-0.31	2.54e-7	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	cis	rs7474896	0.583	rs12783272	chr10:38024885	T/G	cg00409905	chr10:38381863	ZNF37A	-0.48	-5.2	-0.3	4.06e-7	Obesity (extreme);
CESC	cis	rs2878628	0.596	rs57039206	chr3:52758570	T/A	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	5.81	0.34	1.79e-8	Intelligence (multi-trait analysis);
CESC	cis	rs798554	0.757	rs2533882	chr7:2846894	G/T	cg13628971	chr7:2884303	GNA12	0.64	8.03	0.44	3.22e-14	Height;
CESC	cis	rs922182	0.599	rs34409256	chr15:64270314	G/T	cg24729988	chr15:64271149	DAPK2	-0.48	-6.86	-0.39	4.91e-11	Blood protein levels;
CESC	cis	rs9287719	0.967	rs7592691	chr2:10737426	A/G	cg02196655	chr2:10830764	NOL10	-0.37	-5.72	-0.33	2.87e-8	Prostate cancer;
CESC	cis	rs2952156	0.920	rs2952152	chr17:37832735	T/C	cg20243544	chr17:37824526	PNMT	0.62	7.95	0.44	5.42e-14	Asthma;
CESC	cis	rs4728302	0.869	rs6966403	chr7:133614421	A/C	cg10665199	chr7:133106180	EXOC4	-0.39	-5.35	-0.31	1.87e-7	Intelligence;Intelligence (multi-trait analysis);
CESC	cis	rs34779708	0.966	rs4934735	chr10:35496730	C/T	cg04310649	chr10:35416472	CREM	0.49	5.91	0.34	1.07e-8	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs4604732	0.527	rs60444724	chr1:247623164	T/G	cg12754571	chr1:247694271	LOC148824;OR2C3	0.42	5.27	0.31	2.9e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs8060686	0.516	rs2290700	chr16:68288983	T/G	cg26727032	chr16:67993705	SLC12A4	-0.55	-7.2	-0.4	6.16e-12	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs769267	0.930	rs4808964	chr19:19603692	A/C	cg17414380	chr19:19431394	KIAA0892;SF4	-0.47	-5.9	-0.34	1.13e-8	Tonsillectomy;
CESC	cis	rs9527	0.590	rs7920868	chr10:104795409	C/T	cg04362960	chr10:104952993	NT5C2	0.42	5.44	0.32	1.24e-7	Arsenic metabolism;
CESC	cis	rs2952156	0.920	rs907090	chr17:37833632	T/C	cg00129232	chr17:37814104	STARD3	-0.74	-10.58	-0.55	4.66e-22	Asthma;
CESC	cis	rs514406	0.698	rs567880	chr1:53348564	T/G	cg08736216	chr1:53307985	ZYG11A	-0.39	-6.7	-0.38	1.23e-10	Monocyte count;
CESC	cis	rs6893300	0.961	rs730012	chr5:179220638	A/C	cg14593053	chr5:179126677	CANX	-0.51	-5.66	-0.33	3.92e-8	Resting heart rate;
CESC	cis	rs847577	0.677	rs951988	chr7:97762474	C/G	cg21770322	chr7:97807741	LMTK2	-0.5	-7.3	-0.41	3.36e-12	Breast cancer;
CESC	cis	rs2797685	0.755	rs41402249	chr1:7822723	C/G	cg04725166	chr1:7887271	PER3	0.45	5.21	0.3	3.84e-7	Crohn's disease;
CESC	cis	rs9796	0.636	rs1983400	chr15:41373029	T/C	cg12426344	chr15:41135900	SPINT1	-0.23	-5.1	-0.3	6.45e-7	Menopause (age at onset);
CESC	cis	rs6121246	0.567	rs6058197	chr20:30194899	A/G	cg13852791	chr20:30311386	BCL2L1	0.58	5.56	0.32	6.65e-8	Mean corpuscular hemoglobin;
CESC	cis	rs7296418	0.961	rs7957096	chr12:123544878	A/G	cg00376283	chr12:123451042	ABCB9	0.78	11.46	0.58	5.84e-25	Platelet count;
CESC	cis	rs662064	0.962	rs607941	chr1:10539543	C/T	cg20482658	chr1:10539492	PEX14	-0.42	-8.64	-0.47	5.55e-16	Asthma;
CESC	cis	rs10851478	0.590	rs12591300	chr15:49704741	A/G	cg08060515	chr15:49448048	GALK2;COPS2	-0.56	-7.09	-0.4	1.18e-11	Oral cavity cancer;
CESC	cis	rs4906332	1.000	rs35224956	chr14:103900481	A/G	cg09975044	chr14:104007538	NA	0.47	6.49	0.37	4.16e-10	Coronary artery disease;
CESC	cis	rs7851660	0.844	rs12342417	chr9:100639065	G/A	cg13688889	chr9:100608707	NA	-0.61	-8.69	-0.47	3.77e-16	Strep throat;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20138264	chr17:48585640	MYCBPAP	-0.6	-6.83	-0.39	5.83e-11	Gut microbiome composition (summer);
CESC	cis	rs761746	0.882	rs4820978	chr22:31912119	G/A	cg25791279	chr22:32026902	PISD	-0.49	-5.52	-0.32	7.93e-8	Intelligence;
CESC	cis	rs2228479	0.850	rs62056063	chr16:89903680	C/T	cg14709524	chr16:89940631	TCF25	0.88	6.1	0.35	3.82e-9	Skin colour saturation;
CESC	cis	rs910316	0.737	rs108621	chr14:75480637	T/C	cg11812906	chr14:75593930	NEK9	-0.79	-12.68	-0.61	4.02e-29	Height;
CESC	cis	rs12497850	0.897	rs7373778	chr3:48836392	C/G	cg03060546	chr3:49711283	APEH	0.45	5.46	0.32	1.08e-7	Parkinson's disease;
CESC	cis	rs10256972	0.527	rs2949170	chr7:1216438	A/G	cg23978390	chr7:1156363	C7orf50	0.58	7.68	0.43	3.12e-13	Longevity;Endometriosis;
CESC	cis	rs472109	0.565	rs441293	chr11:9786136	T/C	cg03108697	chr11:9732066	SWAP70	-0.36	-5.15	-0.3	5.18e-7	Coronary artery disease;
CESC	cis	rs9311474	0.713	rs352165	chr3:52242902	A/G	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.29	5.26	0.31	2.93e-7	Electroencephalogram traits;
CESC	cis	rs7937682	0.961	rs552387	chr11:111490047	T/G	cg22437258	chr11:111473054	SIK2	0.72	9.81	0.52	1.37e-19	Primary sclerosing cholangitis;
CESC	cis	rs2573652	0.657	rs2573668	chr15:100541776	C/T	cg00587665	chr15:100533223	ADAMTS17	0.35	5.48	0.32	1.01e-7	Height;
CESC	cis	rs875971	0.830	rs6967708	chr7:65657313	A/T	cg12463550	chr7:65579703	CRCP	-0.49	-6.21	-0.36	2.06e-9	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04779640	chr3:108307951	DZIP3;KIAA1524	-0.55	-6.75	-0.38	9.56e-11	Gut microbiome composition (summer);
CESC	cis	rs2806561	0.734	rs7548692	chr1:23354877	T/A	cg12483005	chr1:23474871	LUZP1	0.35	5.29	0.31	2.58e-7	Height;
CESC	cis	rs2408955	0.521	rs1476607	chr12:48524804	A/G	cg04545296	chr12:48745243	ZNF641	-0.36	-6.19	-0.36	2.27e-9	Glycated hemoglobin levels;
CESC	cis	rs524023	0.874	rs7102344	chr11:64396569	A/T	cg07220939	chr11:64358617	SLC22A12	-0.36	-5.45	-0.32	1.17e-7	Urate levels in obese individuals;
CESC	cis	rs10791097	0.690	rs12284487	chr11:130729705	T/C	cg09137382	chr11:130731461	NA	0.39	5.69	0.33	3.36e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs1799949	1.000	rs4793191	chr17:41204377	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.64	8.65	0.47	4.88e-16	Menopause (age at onset);
CESC	cis	rs3785574	0.582	rs62072238	chr17:61948841	A/T	cg07677032	chr17:61819896	STRADA	0.45	5.69	0.33	3.36e-8	Height;
CESC	cis	rs7301826	0.651	rs1554807	chr12:131280417	C/T	cg11011512	chr12:131303247	STX2	-0.5	-6.15	-0.35	2.88e-9	Plasma plasminogen activator levels;
CESC	cis	rs7666738	0.830	rs6854902	chr4:99033416	T/G	cg17366294	chr4:99064904	C4orf37	0.62	8.95	0.48	6.32e-17	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6032067	0.929	rs56168207	chr20:43803971	C/T	cg11264863	chr20:43835661	SEMG1	0.51	5.58	0.32	5.85e-8	Blood protein levels;
CESC	trans	rs11098499	0.863	rs13140391	chr4:120503437	A/G	cg25214090	chr10:38739885	LOC399744	0.66	8.85	0.48	1.28e-16	Corneal astigmatism;
CESC	cis	rs6088580	0.634	rs6087580	chr20:32992592	A/G	cg06115741	chr20:33292138	TP53INP2	-0.49	-6.42	-0.37	6.13e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg05313129	chr8:58192883	C8orf71	-0.49	-5.28	-0.31	2.72e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs6537837	1.000	rs3525	chr1:110136846	T/A	cg05049280	chr1:110155535	GNAT2	0.38	5.3	0.31	2.42e-7	Major depressive disorder;
CESC	cis	rs2635047	0.967	rs9960264	chr18:44606996	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.56	7.64	0.42	3.98e-13	Educational attainment;
CESC	cis	rs2228479	0.850	rs3785281	chr16:89824263	G/C	cg14709524	chr16:89940631	TCF25	0.91	6.75	0.38	9.34e-11	Skin colour saturation;
CESC	cis	rs7552404	1.000	rs28602663	chr1:76235355	C/T	cg10523679	chr1:76189770	ACADM	0.55	6.21	0.36	2.04e-9	Blood metabolite levels;Acylcarnitine levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12475106	chr4:503275	PIGG	-0.68	-7.59	-0.42	5.63e-13	Gut microbiome composition (summer);
CESC	cis	rs4604732	0.631	rs11490199	chr1:247625737	A/G	cg12754571	chr1:247694271	LOC148824;OR2C3	0.44	5.44	0.32	1.21e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs12530845	0.945	rs73725433	chr7:135313251	C/T	cg23117316	chr7:135346802	PL-5283	-0.44	-5.6	-0.33	5.48e-8	Red blood cell traits;
CESC	cis	rs34172651	0.517	rs200526	chr16:24760511	C/T	cg00339695	chr16:24857497	SLC5A11	-0.5	-6.57	-0.37	2.58e-10	Intelligence (multi-trait analysis);
CESC	cis	rs11264213	0.901	rs631202	chr1:36449099	G/C	cg27506609	chr1:36549197	TEKT2	0.49	5.19	0.3	4.1e-7	Schizophrenia;
CESC	cis	rs853679	0.542	rs9393892	chr6:28081394	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.57	-6.62	-0.38	1.93e-10	Depression;
CESC	cis	rs4594175	0.926	rs4349056	chr14:51625819	A/G	cg23942311	chr14:51606299	NA	0.39	5.9	0.34	1.1e-8	Cancer;
CESC	cis	rs9911578	1.000	rs12453459	chr17:56624291	C/T	cg12560992	chr17:57184187	TRIM37	-0.93	-15.59	-0.69	2.43e-39	Intelligence (multi-trait analysis);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg19268579	chr10:43904406	HNRNPF	-0.48	-6.81	-0.39	6.65e-11	Fibrinogen levels;
CESC	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg23708337	chr7:1209742	NA	0.53	5.34	0.31	1.98e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2839186	0.500	rs13052701	chr21:47660045	A/T	cg00815214	chr21:47717953	NA	-0.48	-6.6	-0.38	2.17e-10	Testicular germ cell tumor;
CESC	trans	rs1814175	0.645	rs1722000	chr11:49917928	A/C	cg15704280	chr7:45808275	SEPT13	-1.01	-18.94	-0.76	3.64e-51	Height;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg09912005	chr4:123300640	ADAD1	0.5	6.61	0.38	2.07e-10	Fibrinogen levels;
CESC	trans	rs970548	0.657	rs11239572	chr10:46088061	C/T	cg16175941	chr6:154779103	CNKSR3	-0.56	-6.52	-0.37	3.59e-10	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
CESC	cis	rs2012796	1.000	rs10450939	chr14:81825202	A/T	cg02996355	chr14:81879375	NA	0.5	5.86	0.34	1.34e-8	Night sleep phenotypes;
CESC	cis	rs1003719	0.708	rs3787788	chr21:38502804	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-8.47	-0.46	1.69e-15	Eye color traits;
CESC	cis	rs3771570	1.000	rs59536819	chr2:242272388	A/G	cg21155796	chr2:242212141	HDLBP	0.6	5.04	0.3	8.44e-7	Prostate cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14036097	chr4:190862158	FRG1	0.57	6.89	0.39	3.94e-11	Gut microbiome composition (summer);
CESC	cis	rs10918270	1.000	rs10918270	chr1:161915501	G/A	cg19735514	chr1:161762739	ATF6	-0.37	-5.35	-0.31	1.94e-7	Parkinson's disease (age of onset);
CESC	cis	rs9322193	0.962	rs2275046	chr6:150157001	A/G	cg13206674	chr6:150067644	NUP43	0.42	5.81	0.34	1.8e-8	Lung cancer;
CESC	cis	rs7399018	0.739	rs6580811	chr12:51612501	T/C	cg20712883	chr12:51590929	POU6F1	0.47	5.57	0.32	6.33e-8	Cisplatin-induced ototoxicity;
CESC	cis	rs7412746	0.658	rs4970986	chr1:150907955	A/G	cg17724175	chr1:150552817	MCL1	0.38	5.9	0.34	1.13e-8	Melanoma;
CESC	cis	rs2294693	0.947	rs10456496	chr6:40988840	A/G	cg14769373	chr6:40998127	UNC5CL	0.4	5.91	0.34	1.02e-8	Gastric cancer;Non-cardia gastric cancer;
CESC	cis	rs9287719	0.967	rs7570118	chr2:10718007	G/T	cg00105475	chr2:10696890	NA	0.4	5.79	0.33	2.02e-8	Prostate cancer;
CESC	trans	rs61931739	0.500	rs34080094	chr12:34547952	G/A	cg13010199	chr12:38710504	ALG10B	0.5	6.51	0.37	3.79e-10	Morning vs. evening chronotype;
CESC	cis	rs13191362	0.507	rs2849540	chr6:163094522	G/A	cg06582575	chr6:163149167	PACRG;PARK2	-0.62	-7.25	-0.41	4.71e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs1185460	0.967	rs1177563	chr11:118949083	C/T	cg01677386	chr11:118938358	VPS11	-0.43	-5.56	-0.32	6.57e-8	Coronary artery disease;
CESC	cis	rs7412746	0.611	rs10888394	chr1:150749913	C/T	cg09365446	chr1:150670422	GOLPH3L	0.4	5.26	0.31	3.03e-7	Melanoma;
CESC	cis	rs514406	0.895	rs1925673	chr1:53326984	T/G	cg08859206	chr1:53392774	SCP2	-0.64	-8.55	-0.47	9.9e-16	Monocyte count;
CESC	cis	rs35110281	0.511	rs2298562	chr21:45085236	A/G	cg21573476	chr21:45109991	RRP1B	-0.54	-8.07	-0.44	2.41e-14	Mean corpuscular volume;
CESC	cis	rs6752107	1.000	rs12994971	chr2:234178453	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.47	6.36	0.36	8.89e-10	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs7680126	0.596	rs4698009	chr4:10284993	A/G	cg00071950	chr4:10020882	SLC2A9	-0.45	-5.15	-0.3	5.14e-7	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	cis	rs561341	1.000	rs72823787	chr17:30283809	A/T	cg00745463	chr17:30367425	LRRC37B	-0.85	-7.68	-0.43	3.12e-13	Hip circumference adjusted for BMI;
CESC	cis	rs6686643	0.762	rs9333432	chr1:165611159	A/G	cg19407955	chr1:165599744	MGST3	-0.54	-5.68	-0.33	3.55e-8	Total ventricular volume;
CESC	cis	rs2073300	1.000	rs74273799	chr20:23444492	T/C	cg12062639	chr20:23401060	NAPB	0.91	6.41	0.37	6.71e-10	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs9921222	0.509	rs3743883	chr16:404750	T/C	cg10349874	chr16:420996	TMEM8A;MRPL28	-0.38	-5.21	-0.3	3.79e-7	Bone mineral density (spine);Bone mineral density;
CESC	trans	rs427691	0.625	rs845733	chr5:109023401	A/G	cg00054525	chr16:88717587	CYBA	-0.58	-6.37	-0.36	8.16e-10	Autism spectrum disorder or schizophrenia;
CESC	cis	rs8077577	0.895	rs62072465	chr17:18114494	C/G	cg16794390	chr17:18148240	FLII	0.41	5.63	0.33	4.55e-8	Obesity-related traits;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg06821919	chr20:16710653	SNRPB2	-0.5	-6.62	-0.38	2.01e-10	Ulcerative colitis;
CESC	cis	rs10905065	0.766	rs11598374	chr10:5826986	T/C	cg11519256	chr10:5708881	ASB13	-0.39	-5.15	-0.3	4.97e-7	Menopause (age at onset);
CESC	cis	rs3092073	0.669	rs11697323	chr20:44551579	C/T	cg00125455	chr20:44574271	PCIF1	0.38	6.06	0.35	4.7e-9	Intelligence (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25094149	chr1:32253906	NA	-0.61	-7.54	-0.42	7.61e-13	Gut microbiome composition (summer);
CESC	cis	rs1707322	1.000	rs4660318	chr1:46334876	A/G	cg06784218	chr1:46089804	CCDC17	0.32	5.57	0.32	6.35e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs12142240	0.698	rs6667861	chr1:46815749	T/C	cg10495392	chr1:46806563	NSUN4	0.57	6.28	0.36	1.39e-9	Menopause (age at onset);
CESC	cis	rs8141529	0.636	rs5762799	chr22:29187380	G/T	cg02153584	chr22:29168773	CCDC117	0.47	5.13	0.3	5.59e-7	Lymphocyte counts;
CESC	cis	rs7822232	1.000	rs7822232	chr8:145145687	A/C	cg06495924	chr8:145149574	CYC1	-0.83	-7.44	-0.42	1.42e-12	Blood metabolite levels;
CESC	cis	rs798554	0.660	rs2283783	chr7:2855326	G/A	cg13628971	chr7:2884303	GNA12	0.39	5.11	0.3	6.31e-7	Height;
CESC	cis	rs11677416	1.000	rs1516789	chr2:113531024	C/T	cg27083787	chr2:113543245	IL1A	0.5	6.28	0.36	1.35e-9	Response to antipsychotic treatment in schizophrenia (working memory);
CESC	cis	rs7107174	0.901	rs11237487	chr11:78126754	G/C	cg02023728	chr11:77925099	USP35	0.44	5.64	0.33	4.28e-8	Testicular germ cell tumor;
CESC	cis	rs4319547	0.956	rs10744275	chr12:123048618	A/G	cg23029597	chr12:123009494	RSRC2	-0.51	-5.44	-0.32	1.22e-7	Body mass index;
CESC	cis	rs17376456	0.877	rs10076052	chr5:93317762	C/T	cg25358565	chr5:93447407	FAM172A	1.07	10.61	0.55	3.7e-22	Diabetic retinopathy;
CESC	cis	rs3733585	0.638	rs6414766	chr4:9956474	G/A	cg00071950	chr4:10020882	SLC2A9	-0.7	-11.45	-0.58	6.33e-25	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs11711311	1.000	rs12637066	chr3:113527574	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.72	10.17	0.53	1.02e-20	IgG glycosylation;
CESC	cis	rs3087591	1.000	rs2051506	chr17:29699860	T/A	cg24425628	chr17:29625626	OMG;NF1	-0.46	-5.86	-0.34	1.38e-8	Hip circumference;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08355537	chr1:245026452	HNRNPU	0.62	6.7	0.38	1.27e-10	Gut microbiome composition (summer);
CESC	cis	rs7274811	0.744	rs34489266	chr20:32223040	A/G	cg21523528	chr20:32077966	CBFA2T2	0.64	7.44	0.42	1.41e-12	Height;
CESC	cis	rs6580649	0.941	rs57054831	chr12:48486892	C/T	cg24011408	chr12:48396354	COL2A1	-0.4	-5.04	-0.3	8.67e-7	Lung cancer;
CESC	trans	rs12659622	0.850	rs17601883	chr5:15675883	G/A	cg22457238	chr19:58570995	ZNF135	-0.51	-6.01	-0.35	6.11e-9	Obesity-related traits;
CESC	cis	rs1862618	0.853	rs6885541	chr5:56110857	G/C	cg22800045	chr5:56110881	MAP3K1	0.84	10.35	0.54	2.56e-21	Initial pursuit acceleration;
CESC	cis	rs13108904	0.521	rs4974609	chr4:1356924	A/C	cg13395646	chr4:1353034	KIAA1530	0.46	5.98	0.35	7.03e-9	Obesity-related traits;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg26316544	chr3:52188418	WDR51A	-0.47	-6.51	-0.37	3.82e-10	Fibrinogen levels;
CESC	cis	rs72634258	0.945	rs17523802	chr1:8021740	G/A	cg00042356	chr1:8021962	PARK7	0.71	6.91	0.39	3.59e-11	Inflammatory bowel disease;
CESC	cis	rs3768617	0.510	rs10797835	chr1:183072908	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.88	14.27	0.66	1.19e-34	Fuchs's corneal dystrophy;
CESC	cis	rs7089973	0.604	rs2420069	chr10:116605103	A/G	cg25233709	chr10:116636983	FAM160B1	0.38	6.08	0.35	4.13e-9	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs10870270	0.913	rs4880326	chr10:133745547	C/A	cg26149184	chr10:133730230	NA	0.37	5.09	0.3	6.85e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs2576037	0.583	rs578451	chr18:44404525	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.76	12.39	0.61	3.92e-28	Personality dimensions;
CESC	cis	rs4919694	1.000	rs77505796	chr10:104647774	A/T	cg04362960	chr10:104952993	NT5C2	0.76	6.03	0.35	5.63e-9	Arsenic metabolism;
CESC	cis	rs1832871	0.711	rs9459918	chr6:158703604	A/C	cg07165851	chr6:158734300	TULP4	0.6	6.45	0.37	5.23e-10	Height;
CESC	cis	rs13118159	0.801	rs7664474	chr4:1329116	T/A	cg16405210	chr4:1374714	KIAA1530	-0.59	-8.14	-0.45	1.56e-14	Longevity;
CESC	cis	rs7044106	0.708	rs10760113	chr9:123474050	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.85	13.79	0.65	5.58e-33	Hip circumference adjusted for BMI;
CESC	cis	rs10129255	0.556	rs8010005	chr14:107186226	A/G	cg23076370	chr14:107095027	NA	-0.65	-9.62	-0.51	5.59e-19	Kawasaki disease;
CESC	cis	rs875971	0.862	rs13226170	chr7:65999298	G/A	cg12463550	chr7:65579703	CRCP	0.51	6.36	0.36	8.66e-10	Aortic root size;
CESC	trans	rs4689592	0.513	rs3857178	chr4:7066516	G/A	cg07817883	chr1:32538562	TMEM39B	-0.53	-6.09	-0.35	3.89e-9	Monocyte percentage of white cells;
CESC	cis	rs2721195	0.719	rs4925812	chr8:145808035	C/T	cg15320075	chr8:145703422	NA	0.46	6.03	0.35	5.56e-9	Age at first birth;
CESC	cis	rs769267	0.965	rs2074296	chr19:19373689	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.55	6.81	0.39	6.44e-11	Tonsillectomy;
CESC	cis	rs9790314	0.543	rs1349352	chr3:161118486	C/T	cg03342759	chr3:160939853	NMD3	-0.44	-5.71	-0.33	2.99e-8	Morning vs. evening chronotype;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg11333835	chr1:23495430	LUZP1	0.43	6.14	0.35	3.01e-9	Fibrinogen levels;
CESC	trans	rs55704346	0.566	rs12509787	chr4:25385512	C/T	cg01822600	chr1:245751692	KIF26B	0.43	6.26	0.36	1.55e-9	Tonsillectomy;
CESC	cis	rs523516	0.645	rs16525	chr17:37321605	C/T	cg20555674	chr17:37321631	ARL5C	0.38	6.35	0.36	9.36e-10	IgG glycosylation;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26782824	chr11:82867961	PCF11	-0.56	-6.64	-0.38	1.76e-10	Gut microbiome composition (summer);
CESC	cis	rs35110281	0.755	rs4819270	chr21:45020919	G/A	cg01579765	chr21:45077557	HSF2BP	-0.55	-9.22	-0.49	9.75e-18	Mean corpuscular volume;
CESC	cis	rs75920871	0.589	rs115787357	chr11:117064506	T/G	cg01368799	chr11:117014884	PAFAH1B2	-0.8	-5.72	-0.33	2.94e-8	Subjective well-being;
CESC	cis	rs6951245	0.515	rs78461900	chr7:1007033	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.6	-5.54	-0.32	7.41e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs6736093	0.965	rs4264571	chr2:112674149	T/C	cg12686935	chr2:112915763	FBLN7	-0.41	-5.18	-0.3	4.49e-7	Coronary artery disease;
CESC	cis	rs4423214	1.000	rs1044482	chr11:71155171	C/T	cg05163923	chr11:71159392	DHCR7	0.88	12.71	0.62	3.28e-29	Vitamin D levels;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg21959316	chr1:85040158	CTBS	-0.48	-6.35	-0.36	9.29e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs10771431	0.935	rs1988852	chr12:9372862	G/A	cg00504896	chr12:9437009	LOC642846	-0.41	-5.45	-0.32	1.15e-7	Breast size;
CESC	cis	rs6496667	0.532	rs2601207	chr15:90963542	C/G	cg22089800	chr15:90895588	ZNF774	-0.43	-5.44	-0.32	1.18e-7	Rheumatoid arthritis;
CESC	cis	rs3760982	0.585	rs67648499	chr19:44294055	G/A	cg11993925	chr19:44307056	LYPD5	0.34	5.84	0.34	1.56e-8	Breast cancer (estrogen-receptor negative);Breast cancer;
CESC	cis	rs6484504	0.576	rs2616792	chr11:31324298	T/G	cg14844989	chr11:31128820	NA	0.39	5.47	0.32	1.04e-7	Red blood cell count;
CESC	cis	rs9815354	0.638	rs73073302	chr3:42029879	T/C	cg03022575	chr3:42003672	ULK4	0.75	6.64	0.38	1.72e-10	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs7408868	1.000	rs2074617	chr19:15276055	C/G	cg14696996	chr19:15285081	NOTCH3	1.12	11.59	0.58	2.09e-25	Pulse pressure;
CESC	cis	rs3916	0.955	rs2066938	chr12:121160615	A/G	cg21892295	chr12:121157589	UNC119B	-0.36	-5.26	-0.31	2.96e-7	Urinary metabolites (H-NMR features);
CESC	cis	rs9858542	0.953	rs9814873	chr3:49454112	A/G	cg07274523	chr3:49395745	GPX1	0.61	7.92	0.44	6.75e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs201673768	1	rs201673768	chr12:48699606	TGTTTTGTTTTG/T	cg24011408	chr12:48396354	COL2A1	0.42	6.68	0.38	1.42e-10	Platelet count;
CESC	cis	rs9787249	0.957	rs1046988	chr1:40219065	A/G	cg19912559	chr1:40204330	PPIE	-0.41	-6.27	-0.36	1.44e-9	Blood protein levels;
CESC	cis	rs9649213	0.555	rs67132564	chr7:98014900	T/A	cg21770322	chr7:97807741	LMTK2	0.55	8.34	0.46	4.02e-15	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs4689592	0.513	rs2358718	chr4:7068743	A/C	cg19539972	chr4:7069911	GRPEL1	-0.66	-8.23	-0.45	8.59e-15	Monocyte percentage of white cells;
CESC	cis	rs9733	0.818	rs12403609	chr1:150676485	T/C	cg22823121	chr1:150693482	HORMAD1	-0.41	-6.3	-0.36	1.24e-9	Tonsillectomy;
CESC	cis	rs7605827	0.930	rs6723785	chr2:15688314	T/C	cg19274914	chr2:15703543	NA	0.37	6.7	0.38	1.22e-10	Educational attainment (years of education);
CESC	cis	rs3096299	0.685	rs3803681	chr16:89544756	C/T	cg16743903	chr16:89593216	SPG7	-0.42	-5.42	-0.32	1.31e-7	Multiple myeloma (IgH translocation);
CESC	trans	rs4332037	0.539	rs55988458	chr7:2059761	G/A	cg11693508	chr17:37793320	STARD3	0.66	6.63	0.38	1.84e-10	Bipolar disorder;
CESC	cis	rs17023223	0.537	rs61806983	chr1:119731524	G/C	cg05756136	chr1:119680316	WARS2	-0.47	-5.69	-0.33	3.34e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CESC	cis	rs11871801	0.517	rs10454087	chr17:40735641	C/T	cg14558262	chr17:40713999	COASY	0.51	5.89	0.34	1.19e-8	Crohn's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17198369	chr8:144883931	SCRIB	-0.52	-6.07	-0.35	4.37e-9	Gut microbiome composition (summer);
CESC	cis	rs9611565	0.729	rs203320	chr22:41913477	T/C	cg17376030	chr22:41985996	PMM1	0.43	5.14	0.3	5.39e-7	Vitiligo;
CESC	cis	rs67340775	0.541	rs200979	chr6:27852357	G/A	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.54	5.08	0.3	7.08e-7	Lung cancer in ever smokers;
CESC	cis	rs9715521	0.935	rs62301184	chr4:59836168	A/G	cg11281224	chr4:60001000	NA	-0.5	-6.45	-0.37	5.19e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	trans	rs12750249	0.658	rs4148045	chr1:94947655	A/G	cg15462887	chr11:27744049	BDNF	-0.46	-6.06	-0.35	4.56e-9	IgG glycosylation;
CESC	cis	rs6831352	0.918	rs29001202	chr4:100053782	T/A	cg13256891	chr4:100009986	ADH5	-0.77	-8.49	-0.46	1.5e-15	Alcohol dependence;
CESC	cis	rs2576037	0.523	rs4890705	chr18:44509758	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.36	5.81	0.34	1.74e-8	Personality dimensions;
CESC	cis	rs1552244	0.882	rs13075842	chr3:10055813	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.75	-9.48	-0.5	1.49e-18	Alzheimer's disease;
CESC	cis	rs113835537	0.529	rs4542420	chr11:66277610	G/C	cg22134325	chr11:66188745	NPAS4	0.36	5.66	0.33	3.82e-8	Airway imaging phenotypes;
CESC	cis	rs7605827	0.930	rs6710456	chr2:15669939	C/T	cg19274914	chr2:15703543	NA	-0.32	-5.78	-0.33	2.14e-8	Educational attainment (years of education);
CESC	cis	rs9733	0.596	rs6587518	chr1:150661787	T/C	cg09365446	chr1:150670422	GOLPH3L	0.43	6.02	0.35	5.89e-9	Tonsillectomy;
CESC	cis	rs7216064	0.953	rs58141639	chr17:65864902	C/T	cg07042672	chr17:66097459	LOC651250	-0.54	-5.59	-0.32	5.61e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs10823500	1.000	rs10823500	chr10:72005190	A/G	cg04118878	chr10:71993077	PPA1	0.45	5.5	0.32	9.13e-8	Blood protein levels;
CESC	cis	rs2652834	0.904	rs2937859	chr15:63366282	C/T	cg05507819	chr15:63340323	TPM1	0.68	7.16	0.4	8.17e-12	HDL cholesterol;
CESC	cis	rs7527798	0.592	rs960086	chr1:207827069	A/G	cg21110645	chr1:207815933	NA	-0.33	-5.87	-0.34	1.31e-8	Erythrocyte sedimentation rate;
CESC	cis	rs9733	0.519	rs7521898	chr1:150707596	G/A	cg17724175	chr1:150552817	MCL1	0.45	7.41	0.41	1.71e-12	Tonsillectomy;
CESC	cis	rs4595586	0.505	rs12823590	chr12:39399750	A/T	cg13010199	chr12:38710504	ALG10B	0.42	5.07	0.3	7.58e-7	Morning vs. evening chronotype;
CESC	cis	rs7618915	0.547	rs2118540	chr3:52629386	T/C	cg07507251	chr3:52567010	NT5DC2	0.41	7.15	0.4	8.25e-12	Bipolar disorder;
CESC	cis	rs35110281	0.667	rs9941787	chr21:45116042	A/G	cg04455712	chr21:45112962	RRP1B	0.49	7.37	0.41	2.19e-12	Mean corpuscular volume;
CESC	cis	rs425277	0.565	rs61775448	chr1:2045376	A/G	cg24578937	chr1:2090814	PRKCZ	-0.34	-6.01	-0.35	5.99e-9	Height;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg23469219	chr7:128116967	METTL2B	-0.53	-7.01	-0.4	1.94e-11	Fibrinogen levels;
CESC	cis	rs73001065	0.818	rs73004966	chr19:19716558	C/T	cg03709012	chr19:19516395	GATAD2A	0.94	6.55	0.37	2.96e-10	LDL cholesterol;
CESC	cis	rs77972916	0.505	rs6736400	chr2:43500804	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.61	-5.88	-0.34	1.2e-8	Granulocyte percentage of myeloid white cells;
CESC	cis	rs6066835	0.572	rs6066804	chr20:47262322	G/A	cg18078177	chr20:47281410	PREX1	0.69	5.14	0.3	5.45e-7	Multiple myeloma;
CESC	cis	rs1801251	1.000	rs6714245	chr2:233580505	T/C	cg08000102	chr2:233561755	GIGYF2	0.67	9.05	0.49	3.1e-17	Coronary artery disease;
CESC	cis	rs7408868	1.000	rs757472	chr19:15273221	T/C	cg14696996	chr19:15285081	NOTCH3	1.02	10.91	0.56	3.94e-23	Pulse pressure;
CESC	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg11494091	chr17:61959527	GH2	0.68	11.47	0.58	5.36e-25	Prudent dietary pattern;
CESC	cis	rs1348850	0.626	rs1901825	chr2:178225331	A/T	cg22681709	chr2:178499509	PDE11A	-0.38	-5.73	-0.33	2.73e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs6460942	0.511	rs13245890	chr7:12543134	A/C	cg20607287	chr7:12443886	VWDE	-0.7	-7.34	-0.41	2.7e-12	Coronary artery disease;
CESC	cis	rs9925964	0.687	rs12917722	chr16:30948397	A/G	cg02466173	chr16:30829666	NA	0.37	5.56	0.32	6.6e-8	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs7666738	0.716	rs9994641	chr4:99101605	C/T	cg17366294	chr4:99064904	C4orf37	0.55	7.28	0.41	3.77e-12	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7666738	0.830	rs11727612	chr4:99001662	T/C	cg18180107	chr4:99064573	C4orf37	0.4	5.23	0.31	3.41e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7208859	0.623	rs7219361	chr17:29080393	G/A	cg13385521	chr17:29058706	SUZ12P	0.81	6.57	0.37	2.73e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs7508	0.694	rs7830490	chr8:17922414	A/G	cg18067069	chr8:17937731	ASAH1	-0.4	-5.47	-0.32	1.05e-7	Atrial fibrillation;
CESC	cis	rs9291683	0.546	rs6829727	chr4:10051672	A/C	cg02734326	chr4:10020555	SLC2A9	0.44	6.14	0.35	3.03e-9	Bone mineral density;
CESC	cis	rs67311347	1.000	rs6801185	chr3:40505060	C/T	cg01475735	chr3:40494733	NA	0.44	5.68	0.33	3.47e-8	Renal cell carcinoma;
CESC	cis	rs7100689	0.599	rs946892	chr10:82127551	C/T	cg00277334	chr10:82204260	NA	-0.58	-7.63	-0.42	4.2e-13	Post bronchodilator FEV1;
CESC	cis	rs13114435	0.723	rs13148414	chr4:183817674	C/G	cg00486011	chr4:183851557	NA	-0.36	-5.55	-0.32	7.06e-8	Obesity-related traits;
CESC	cis	rs8062405	0.895	rs62036658	chr16:28850371	T/G	cg08761264	chr16:28874980	SH2B1	-0.44	-5.39	-0.31	1.58e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs2274273	1.000	rs7493394	chr14:55617755	A/T	cg04306507	chr14:55594613	LGALS3	0.28	5.26	0.31	2.94e-7	Protein biomarker;
CESC	cis	rs4665809	0.590	rs7260	chr2:26413917	C/T	cg22920501	chr2:26401640	FAM59B	-0.84	-10.28	-0.53	4.45e-21	Gut microbiome composition (summer);
CESC	cis	rs36051895	0.659	rs62541556	chr9:5049092	G/T	cg02405213	chr9:5042618	JAK2	-0.48	-5.79	-0.34	1.96e-8	Pediatric autoimmune diseases;
CESC	cis	rs12121840	0.790	rs74120755	chr1:165520392	A/T	cg16553119	chr1:165599451	MGST3	-0.45	-5.07	-0.3	7.64e-7	Interleukin-1-receptor antagonist levels;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg11621667	chr7:39662995	RALA	-0.44	-6.22	-0.36	1.96e-9	Fibrinogen levels;
CESC	cis	rs10927875	0.619	rs1806991	chr1:16129441	T/C	cg21385522	chr1:16154831	NA	-0.76	-10.68	-0.55	2.15e-22	Dilated cardiomyopathy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00881440	chr7:2595255	C7orf27	0.52	6.07	0.35	4.42e-9	Gut microbiome composition (summer);
CESC	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg18402987	chr7:1209562	NA	0.75	7.76	0.43	1.88e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs4975709	0.569	rs4975743	chr5:1859941	G/T	cg15595755	chr5:1867978	NA	0.53	8.63	0.47	5.92e-16	Cardiovascular disease risk factors;
CESC	cis	rs7208859	0.623	rs11656844	chr17:29060597	G/T	cg13385521	chr17:29058706	SUZ12P	0.81	6.53	0.37	3.28e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21845580	chr12:53472882	SPRYD3	0.61	6.7	0.38	1.22e-10	Gut microbiome composition (summer);
CESC	cis	rs10791323	0.628	rs10750543	chr11:133718467	G/A	cg06766960	chr11:133703094	NA	-0.35	-5.11	-0.3	6.03e-7	Childhood ear infection;
CESC	cis	rs4843747	0.636	rs4075597	chr16:88107590	C/A	cg06915872	chr16:87998081	BANP	0.46	5.47	0.32	1.07e-7	Menopause (age at onset);
CESC	cis	rs1401999	0.690	rs6768149	chr3:183636195	T/C	cg01324343	chr3:183735012	ABCC5	0.46	8.94	0.48	6.6e-17	Anterior chamber depth;
CESC	cis	rs12586317	0.547	rs28569331	chr14:35473584	T/C	cg16230307	chr14:35515116	FAM177A1	0.98	10.57	0.54	5.04e-22	Psoriasis;
CESC	cis	rs9640161	0.789	rs34495356	chr7:150057791	A/G	cg10018233	chr7:150070692	REPIN1	0.39	5.51	0.32	8.63e-8	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs4665809	0.590	rs3806514	chr2:26466772	C/T	cg08470875	chr2:26401718	FAM59B	0.76	8.06	0.44	2.69e-14	Gut microbiome composition (summer);
CESC	cis	rs9612	1.000	rs1058	chr19:44268325	C/G	cg08581076	chr19:44259116	C19orf61	0.5	5.87	0.34	1.27e-8	Exhaled nitric oxide output;
CESC	cis	rs1691799	0.867	rs1168338	chr12:66759369	T/C	cg16791601	chr12:66731901	HELB	-0.78	-13.96	-0.65	1.46e-33	White blood cell count (basophil);
CESC	cis	rs10484885	0.824	rs72921954	chr6:90586656	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.8	-7.65	-0.43	3.69e-13	QRS interval (sulfonylurea treatment interaction);
CESC	cis	rs9287719	0.967	rs10203664	chr2:10752377	T/C	cg00105475	chr2:10696890	NA	0.38	5.42	0.32	1.34e-7	Prostate cancer;
CESC	cis	rs9916302	0.555	rs12940193	chr17:37652178	T/G	cg00129232	chr17:37814104	STARD3	-0.56	-7.49	-0.42	1.02e-12	Glomerular filtration rate (creatinine);
CESC	cis	rs8114671	0.662	rs6088664	chr20:33551100	G/A	cg24642439	chr20:33292090	TP53INP2	0.42	5.05	0.3	8.2e-7	Height;
CESC	cis	rs965513	0.965	rs10759944	chr9:100556972	A/G	cg13688889	chr9:100608707	NA	-0.58	-8.26	-0.45	6.88e-15	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
CESC	cis	rs9457247	0.765	rs10455982	chr6:167448728	C/T	cg07741184	chr6:167504864	NA	0.36	6.48	0.37	4.57e-10	Crohn's disease;
CESC	cis	rs911555	0.755	rs11627446	chr14:103946450	G/C	cg24130564	chr14:104152367	KLC1	-0.5	-6.55	-0.37	2.94e-10	Intelligence (multi-trait analysis);
CESC	cis	rs7904368	0.754	rs7076955	chr10:16852781	G/A	cg14835575	chr10:16859367	RSU1	0.48	5.1	0.3	6.4e-7	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
CESC	cis	rs11098499	0.955	rs1551	chr4:120158500	T/G	cg09307838	chr4:120376055	NA	0.87	11.52	0.58	3.6e-25	Corneal astigmatism;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13379827	chr1:65468782	NA	0.57	6.35	0.36	9.13e-10	Gut microbiome composition (summer);
CESC	cis	rs113835537	0.559	rs11227498	chr11:66269714	A/G	cg22134325	chr11:66188745	NPAS4	0.37	5.78	0.33	2.11e-8	Airway imaging phenotypes;
CESC	cis	rs8044995	0.706	rs73612697	chr16:68162016	G/A	cg26727032	chr16:67993705	SLC12A4	-0.49	-5.41	-0.32	1.43e-7	Schizophrenia;
CESC	cis	rs7216064	0.954	rs9907491	chr17:65949993	G/A	cg07042672	chr17:66097459	LOC651250	0.62	7.67	0.43	3.21e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs1371867	0.817	rs1788179	chr8:101333345	A/G	cg11906718	chr8:101322791	RNF19A	0.53	6.86	0.39	4.86e-11	Atrioventricular conduction;
CESC	cis	rs798554	0.607	rs1182151	chr7:2909225	C/G	cg04166393	chr7:2884313	GNA12	0.59	6.78	0.38	7.85e-11	Height;
CESC	cis	rs6598955	0.585	rs6659822	chr1:26626408	C/A	cg19743891	chr1:26644573	UBXN11;CD52	0.35	5.12	0.3	5.89e-7	Obesity-related traits;
CESC	cis	rs713587	0.571	rs2438679	chr2:25317653	C/T	cg10045137	chr2:25383940	POMC	-0.34	-5.03	-0.3	9.15e-7	Body mass index in non-asthmatics;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg19222080	chr17:61523511	CYB561	-0.45	-6.22	-0.36	1.9e-9	Fibrinogen levels;
CESC	cis	rs7618915	0.501	rs7624716	chr3:52751534	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.6	8.47	0.46	1.74e-15	Bipolar disorder;
CESC	cis	rs17401966	0.931	rs1555849	chr1:10400602	G/T	cg15208524	chr1:10270712	KIF1B	-0.41	-5.27	-0.31	2.87e-7	Hepatocellular carcinoma;
CESC	cis	rs853679	0.517	rs35227624	chr6:28132726	A/G	cg19592336	chr6:28129416	ZNF389	0.61	8.03	0.44	3.13e-14	Depression;
CESC	cis	rs11785400	0.793	rs4467920	chr8:143736846	C/T	cg24634471	chr8:143751801	JRK	0.46	5.91	0.34	1.06e-8	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13522835	chr17:61905166	FTSJ3;PSMC5	0.55	6.01	0.35	6.2e-9	Gut microbiome composition (summer);
CESC	cis	rs4821897	0.514	rs739141	chr22:39824450	A/G	cg24399712	chr22:39784796	NA	0.69	9.48	0.5	1.47e-18	IgG glycosylation;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05062814	chr6:39083007	C6orf64	0.52	6.24	0.36	1.69e-9	Gut microbiome composition (summer);
CESC	cis	rs7660520	0.557	rs76004373	chr4:183731011	C/G	cg04181038	chr4:183730758	NA	0.63	6.91	0.39	3.55e-11	Pediatric autoimmune diseases;
CESC	cis	rs921968	0.519	rs72966020	chr2:219642620	C/G	cg02176678	chr2:219576539	TTLL4	-0.5	-8.51	-0.46	1.34e-15	Mean corpuscular hemoglobin concentration;
CESC	cis	rs651907	0.557	rs62284199	chr3:101478531	T/G	cg12386194	chr3:101231763	SENP7	0.41	5.12	0.3	5.89e-7	Colorectal cancer;
CESC	cis	rs6540556	0.906	rs6540554	chr1:209932297	A/T	cg23920097	chr1:209922102	NA	0.35	5.24	0.31	3.25e-7	Red blood cell count;
CESC	cis	rs5167	0.504	rs4803779	chr19:45456497	T/C	cg09555818	chr19:45449301	APOC2	0.41	6.54	0.37	3.08e-10	Blood protein levels;
CESC	cis	rs853679	0.517	rs9380049	chr6:28048535	A/G	cg12963246	chr6:28129442	ZNF389	0.55	7.35	0.41	2.46e-12	Depression;
CESC	cis	rs9910055	1.000	rs9895423	chr17:42285740	T/C	cg13607699	chr17:42295918	UBTF	0.61	7.01	0.4	1.93e-11	Total body bone mineral density;
CESC	cis	rs911555	0.519	rs8014069	chr14:104004311	A/C	cg24130564	chr14:104152367	KLC1	-0.47	-6.58	-0.37	2.52e-10	Intelligence (multi-trait analysis);
CESC	cis	rs8078723	1.000	rs8070454	chr17:38160754	C/T	cg17467752	chr17:38218738	THRA	0.69	10.55	0.54	5.78e-22	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CESC	cis	rs2573652	0.722	rs11852383	chr15:100542765	C/T	cg00587665	chr15:100533223	ADAMTS17	-0.38	-6.0	-0.35	6.3e-9	Height;
CESC	cis	rs782590	0.967	rs6545506	chr2:55798108	A/G	cg18811423	chr2:55921094	PNPT1	-0.77	-12.45	-0.61	2.48e-28	Metabolic syndrome;
CESC	cis	rs7959452	0.536	rs4761237	chr12:69776461	C/G	cg22834771	chr12:69754056	YEATS4	-0.48	-6.37	-0.36	8.22e-10	Blood protein levels;
CESC	cis	rs9811920	0.609	rs812657	chr3:99566329	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.63	-10.36	-0.54	2.45e-21	Axial length;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18451310	chr22:42017231	PPPDE2;XRCC6	-0.68	-8.35	-0.46	3.74e-15	Gut microbiome composition (summer);
CESC	cis	rs8077577	0.708	rs2290503	chr17:18135753	T/C	cg16794390	chr17:18148240	FLII	-0.45	-6.69	-0.38	1.33e-10	Obesity-related traits;
CESC	cis	rs782590	0.620	rs4322879	chr2:55797033	G/T	cg18811423	chr2:55921094	PNPT1	-0.62	-8.26	-0.45	7.09e-15	Metabolic syndrome;
CESC	cis	rs10540	0.558	rs12806062	chr11:501429	G/A	cg03352830	chr11:487213	PTDSS2	0.76	7.2	0.4	6.21e-12	Body mass index;
CESC	trans	rs4843747	0.749	rs13333619	chr16:88072076	C/T	cg26811252	chr16:29126840	RRN3P2	0.73	10.49	0.54	9.35e-22	Menopause (age at onset);
CESC	cis	rs2439831	0.681	rs540388	chr15:43606494	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.91	10.73	0.55	1.49e-22	Lung cancer in ever smokers;
CESC	cis	rs7666738	0.830	rs10028692	chr4:98962585	C/T	cg03676636	chr4:99064102	C4orf37	0.33	5.14	0.3	5.39e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4434138	0.683	rs13063160	chr3:52602274	T/C	cg07507251	chr3:52567010	NT5DC2	0.32	5.64	0.33	4.4e-8	Intelligence (multi-trait analysis);
CESC	cis	rs1215050	0.740	rs783945	chr4:99014394	G/A	cg05340658	chr4:99064831	C4orf37	-0.57	-7.68	-0.43	3.05e-13	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs1008375	0.863	rs10003291	chr4:17600728	A/C	cg16339924	chr4:17578868	LAP3	0.76	9.5	0.5	1.31e-18	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg23978390	chr7:1156363	C7orf50	0.51	6.68	0.38	1.41e-10	Longevity;Endometriosis;
CESC	cis	rs4927850	0.723	rs7630825	chr3:195753740	T/C	cg12923728	chr3:195709715	SDHAP1	-0.68	-9.28	-0.5	6.46e-18	Pancreatic cancer;
CESC	cis	rs2204008	0.754	rs11181643	chr12:38380553	G/A	cg13010199	chr12:38710504	ALG10B	0.47	6.02	0.35	5.68e-9	Bladder cancer;
CESC	cis	rs4665809	1.000	rs11678157	chr2:26321526	T/C	cg25036284	chr2:26402008	FAM59B	-0.57	-6.58	-0.37	2.57e-10	Gut microbiome composition (summer);
CESC	cis	rs11711311	1.000	rs9879760	chr3:113457948	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.72	10.27	0.53	4.81e-21	IgG glycosylation;
CESC	cis	rs2440129	0.611	rs11571335	chr17:6904263	C/T	cg03762994	chr17:6899332	ALOX12	0.4	7.03	0.4	1.77e-11	Tonsillectomy;
CESC	cis	rs9381040	1.000	rs9381040	chr6:41154650	C/T	cg03526776	chr6:41159608	TREML2	0.39	6.5	0.37	4.03e-10	Alzheimer's disease (late onset);
CESC	cis	rs11583043	1.000	rs11583043	chr1:101466054	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.53	5.89	0.34	1.17e-8	Ulcerative colitis;Inflammatory bowel disease;
CESC	cis	rs9611565	0.559	rs6002408	chr22:41967870	C/T	cg06481639	chr22:41940642	POLR3H	-0.57	-6.18	-0.35	2.4e-9	Vitiligo;
CESC	cis	rs897984	0.542	rs7294	chr16:31102321	A/G	cg02466173	chr16:30829666	NA	0.42	7.24	0.41	4.91e-12	Dementia with Lewy bodies;
CESC	cis	rs8114671	0.562	rs6058120	chr20:33402829	A/G	cg08999081	chr20:33150536	PIGU	0.4	5.64	0.33	4.3e-8	Height;
CESC	cis	rs7927592	0.672	rs10501398	chr11:68331715	C/G	cg16797656	chr11:68205561	LRP5	-0.5	-7.85	-0.43	1.03e-13	Total body bone mineral density;
CESC	cis	rs861020	0.527	rs614662	chr1:209962419	C/T	cg21951975	chr1:209979733	IRF6	-0.49	-8.15	-0.45	1.46e-14	Orofacial clefts;
CESC	cis	rs6540556	0.859	rs12079960	chr1:209937168	A/C	cg05527609	chr1:210001259	C1orf107	-0.48	-6.05	-0.35	4.95e-9	Red blood cell count;
CESC	trans	rs9850225	0.719	rs4856616	chr3:80466481	A/C	cg18067127	chr19:3767310	MRPL54	0.38	6.09	0.35	4.04e-9	Erectile dysfunction in type 1 diabetes;
CESC	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg24846343	chr22:24311635	DDTL	0.68	11.41	0.57	8.24e-25	Liver enzyme levels (gamma-glutamyl transferase);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg00219956	chr16:30794205	ZNF629	-0.45	-6.18	-0.35	2.43e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs3091242	0.933	rs11249251	chr1:25770188	C/G	cg12412775	chr1:25698385	RHCE	-0.28	-5.13	-0.3	5.65e-7	Erythrocyte sedimentation rate;
CESC	cis	rs896854	0.517	rs2013597	chr8:95951807	G/A	cg13393036	chr8:95962371	TP53INP1	-0.46	-8.3	-0.45	5.34e-15	Type 2 diabetes;
CESC	cis	rs2842992	0.724	rs15982	chr6:160199687	T/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.76	10.81	0.55	8.12e-23	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs1799949	1.000	rs2298862	chr17:41176688	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	8.16	0.45	1.32e-14	Menopause (age at onset);
CESC	cis	rs2361718	0.603	rs12951255	chr17:78085597	A/G	cg14949292	chr17:78079608	GAA	-0.33	-5.08	-0.3	6.97e-7	Yeast infection;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg17808901	chr3:39093368	WDR48	0.5	6.47	0.37	4.59e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs35110281	0.607	rs4819212	chr21:44977455	G/A	cg04455712	chr21:45112962	RRP1B	0.35	5.09	0.3	6.86e-7	Mean corpuscular volume;
CESC	cis	rs67397200	0.590	rs12327712	chr19:17424947	T/G	cg22549504	chr19:17448937	GTPBP3	0.49	6.14	0.35	2.92e-9	Breast cancer;Breast Cancer in BRCA1 mutation carriers;Breast cancer (estrogen-receptor negative);
CESC	cis	rs8177179	0.967	rs9869311	chr3:133451613	C/T	cg24879335	chr3:133465180	TF	0.47	9.11	0.49	2.14e-17	Iron status biomarkers (transferrin levels);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17208363	chr15:41851964	TYRO3	-0.56	-6.2	-0.36	2.21e-9	Gut microbiome composition (summer);
CESC	cis	rs854765	0.575	rs7207821	chr17:17891781	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.63	9.08	0.49	2.57e-17	Total body bone mineral density;
CESC	cis	rs12136530	0.593	rs12136926	chr1:19710794	G/A	cg01832549	chr1:19774989	CAPZB	-0.36	-5.33	-0.31	2.08e-7	Lead levels in blood;
CESC	cis	rs7584330	0.695	rs77922291	chr2:238366317	T/G	cg14458575	chr2:238380390	NA	0.62	8.43	0.46	2.19e-15	Prostate cancer;
CESC	cis	rs898097	0.812	rs7406011	chr17:80829980	C/T	cg05255149	chr17:80675120	FN3KRP	-0.46	-5.32	-0.31	2.17e-7	Breast cancer;
CESC	cis	rs67366981	1.000	rs17105547	chr14:77698358	G/A	cg22824376	chr14:77648248	TMEM63C	0.68	5.72	0.33	2.9e-8	Obsessive-compulsive symptoms;
CESC	cis	rs1862618	0.671	rs252897	chr5:56223000	G/A	cg20203395	chr5:56204925	C5orf35	-0.4	-5.21	-0.3	3.79e-7	Initial pursuit acceleration;
CESC	cis	rs2274273	0.967	rs11622740	chr14:55617844	G/A	cg04306507	chr14:55594613	LGALS3	0.28	5.23	0.31	3.42e-7	Protein biomarker;
CESC	cis	rs2625529	0.730	rs4511483	chr15:72138590	G/A	cg16672083	chr15:72433130	SENP8	-0.4	-5.93	-0.34	9.45e-9	Red blood cell count;
CESC	cis	rs854765	0.547	rs2955353	chr17:17948979	T/C	cg04398451	chr17:18023971	MYO15A	0.73	10.55	0.54	5.95e-22	Total body bone mineral density;
CESC	cis	rs3126085	0.877	rs4415568	chr1:152181207	G/A	cg03465714	chr1:152285911	FLG	-0.43	-5.16	-0.3	4.81e-7	Atopic dermatitis;
CESC	cis	rs2637266	1.000	rs7897348	chr10:78359620	G/A	cg18941641	chr10:78392320	NA	0.42	7.87	0.44	9.04e-14	Pulmonary function;
CESC	cis	rs6540556	0.769	rs12030655	chr1:209922123	G/T	cg05527609	chr1:210001259	C1orf107	-0.48	-5.8	-0.34	1.85e-8	Red blood cell count;
CESC	cis	rs1003719	0.586	rs2298685	chr21:38533390	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.59	-8.06	-0.44	2.72e-14	Eye color traits;
CESC	cis	rs35110281	0.811	rs1122873	chr21:45044672	G/C	cg04455712	chr21:45112962	RRP1B	0.39	5.72	0.33	2.86e-8	Mean corpuscular volume;
CESC	cis	rs17407555	1.000	rs17407555	chr4:10274994	A/G	cg11266682	chr4:10021025	SLC2A9	-0.48	-5.94	-0.34	8.93e-9	Schizophrenia (age at onset);
CESC	cis	rs929354	0.742	rs7806775	chr7:156947199	A/G	cg05182265	chr7:156933206	UBE3C	-0.5	-7.18	-0.4	7.24e-12	Body mass index;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg17297071	chr21:26934424	MIR155HG	0.45	6.34	0.36	1e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06564473	chr11:601660	PHRF1	-0.57	-7.24	-0.41	4.77e-12	Gut microbiome composition (summer);
CESC	cis	rs2625529	0.730	rs2957737	chr15:72265410	A/G	cg16672083	chr15:72433130	SENP8	0.41	5.96	0.34	8.23e-9	Red blood cell count;
CESC	cis	rs9308433	0.529	rs867445	chr1:214502230	C/G	cg06198575	chr1:214491504	SMYD2	0.48	5.78	0.33	2.1e-8	IgG glycosylation;
CESC	cis	rs7666738	0.830	rs6854919	chr4:98947326	C/T	cg03467027	chr4:99064603	C4orf37	0.44	5.39	0.31	1.52e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7508	0.668	rs10087428	chr8:17918454	G/T	cg18067069	chr8:17937731	ASAH1	-0.4	-5.21	-0.3	3.88e-7	Atrial fibrillation;
CESC	cis	rs847577	0.748	rs55784506	chr7:97718201	G/A	cg24562669	chr7:97807699	LMTK2	0.63	10.23	0.53	6.29e-21	Breast cancer;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg08889949	chr3:49044473	P4HTM;WDR6	-0.46	-6.12	-0.35	3.37e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs4466137	0.909	rs4466136	chr5:82985576	T/G	cg16102102	chr5:83017553	HAPLN1	-0.41	-6.18	-0.35	2.44e-9	Prostate cancer;
CESC	cis	rs2842992	0.958	rs2758318	chr6:160069637	C/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.68	7.98	0.44	4.34e-14	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs748404	0.587	rs9920879	chr15:43639770	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.54	8.4	0.46	2.66e-15	Lung cancer;
CESC	cis	rs735396	1.000	rs1169313	chr12:121442670	C/T	cg02403541	chr12:121454288	C12orf43	-0.62	-8.97	-0.48	5.62e-17	N-glycan levels;
CESC	cis	rs9611565	0.546	rs2092274	chr22:42123737	A/G	cg06634786	chr22:41940651	POLR3H	0.66	6.7	0.38	1.24e-10	Vitiligo;
CESC	cis	rs4132509	0.696	rs12023642	chr1:243767826	T/G	cg21452805	chr1:244014465	NA	0.64	6.83	0.39	5.74e-11	RR interval (heart rate);
CESC	cis	rs7586879	0.616	rs10203386	chr2:25136866	T/A	cg01884057	chr2:25150051	NA	0.37	6.82	0.39	6.11e-11	Body mass index;
CESC	trans	rs12599106	0.680	rs34728702	chr16:34896584	A/G	cg01516881	chr6:292596	DUSP22	-0.84	-11.26	-0.57	2.69e-24	Menopause (age at onset);
CESC	trans	rs17508449	0.819	rs79220465	chr1:114171341	A/T	cg23028848	chr11:57092561	TNKS1BP1	-0.75	-6.1	-0.35	3.7e-9	Leprosy;
CESC	trans	rs11098499	0.754	rs878376	chr4:120237702	G/A	cg25214090	chr10:38739885	LOC399744	0.64	8.86	0.48	1.19e-16	Corneal astigmatism;
CESC	cis	rs2404602	0.692	rs1471780	chr15:77026526	T/C	cg22467129	chr15:76604101	ETFA	-0.34	-5.16	-0.3	4.84e-7	Blood metabolite levels;
CESC	cis	rs7122539	0.603	rs508443	chr11:66509369	C/T	cg24851651	chr11:66362959	CCS	-0.49	-6.96	-0.39	2.63e-11	HIV-1 susceptibility;
CESC	cis	rs1729951	0.575	rs16844325	chr3:136678161	C/G	cg03617693	chr3:136751559	NA	0.37	5.21	0.3	3.77e-7	Neuroticism;
CESC	cis	rs1707322	0.893	rs9919275	chr1:46441360	A/C	cg03146154	chr1:46216737	IPP	0.72	9.82	0.52	1.31e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs8111998	0.826	rs4932774	chr19:22766593	G/T	cg19914732	chr19:22715077	NA	-0.37	-5.18	-0.3	4.45e-7	Corneal structure;
CESC	cis	rs910316	0.737	rs175048	chr14:75479894	A/T	cg11812906	chr14:75593930	NEK9	-0.8	-13.2	-0.63	6.54e-31	Height;
CESC	trans	rs7937682	0.889	rs10749984	chr11:111492861	T/C	cg18187862	chr3:45730750	SACM1L	0.48	6.01	0.35	6.26e-9	Primary sclerosing cholangitis;
CESC	cis	rs9399135	0.967	rs6915770	chr6:135369214	G/A	cg24558204	chr6:135376177	HBS1L	0.51	6.99	0.39	2.27e-11	Red blood cell count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21853250	chr8:681212	ERICH1	0.58	6.32	0.36	1.08e-9	Gut microbiome composition (summer);
CESC	cis	rs9287719	0.967	rs2884233	chr2:10745303	G/A	cg02196655	chr2:10830764	NOL10	-0.38	-5.78	-0.33	2.05e-8	Prostate cancer;
CESC	cis	rs1799949	0.965	rs8067269	chr17:41235799	C/T	cg07153921	chr17:41440717	NA	-0.38	-5.19	-0.3	4.23e-7	Menopause (age at onset);
CESC	cis	rs1878047	0.702	rs12972903	chr19:51775738	C/T	cg14884932	chr19:51774451	NA	-0.37	-5.16	-0.3	4.87e-7	Body mass index;
CESC	cis	rs7552404	0.690	rs11161620	chr1:76255228	A/G	cg22875332	chr1:76189707	ACADM	-0.62	-6.27	-0.36	1.47e-9	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs3736485	0.934	rs28393906	chr15:51867605	T/A	cg08986416	chr15:51914746	DMXL2	-0.4	-5.12	-0.3	5.86e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs12500824	0.564	rs34078673	chr4:77232408	A/G	cg20311846	chr4:77356250	SHROOM3	0.4	7.77	0.43	1.71e-13	Coronary artery disease;
CESC	cis	rs853679	0.569	rs9348798	chr6:28143011	G/A	cg19592336	chr6:28129416	ZNF389	0.59	7.78	0.43	1.63e-13	Depression;
CESC	cis	rs57244997	0.725	rs73785320	chr6:162439590	A/C	cg17173639	chr6:162384350	PARK2	-0.46	-5.27	-0.31	2.78e-7	Mosquito bite size;
CESC	trans	rs208520	1.000	rs12189683	chr6:66977716	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.83	-9.32	-0.5	4.61e-18	Exhaled nitric oxide output;
CESC	cis	rs4423214	1.000	rs4944956	chr11:71167765	C/T	cg24826892	chr11:71159390	DHCR7	0.44	5.08	0.3	7.05e-7	Vitamin D levels;
CESC	cis	rs9649213	0.593	rs6465664	chr7:97921834	A/G	cg24562669	chr7:97807699	LMTK2	0.48	6.8	0.39	6.74e-11	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7914558	0.966	rs10786727	chr10:104698523	G/A	cg15744005	chr10:104629667	AS3MT	-0.35	-5.48	-0.32	9.76e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs3858526	0.584	rs10769274	chr11:5866925	T/C	cg05234568	chr11:5960015	NA	-0.64	-9.02	-0.48	3.81e-17	DNA methylation (variation);
CESC	cis	rs7666738	0.791	rs1593571	chr4:98963763	T/C	cg03676636	chr4:99064102	C4orf37	0.34	5.15	0.3	5.01e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2732480	0.577	rs2634691	chr12:48708259	G/T	cg04545296	chr12:48745243	ZNF641	0.43	7.3	0.41	3.34e-12	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs9549260	0.712	rs9532564	chr13:41160579	C/G	cg21288729	chr13:41239152	FOXO1	0.55	5.04	0.3	8.81e-7	Red blood cell count;
CESC	cis	rs4862750	0.872	rs6830426	chr4:187897270	T/A	cg03452623	chr4:187889614	NA	-0.88	-16.15	-0.7	2.59e-41	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs13191362	0.507	rs2023036	chr6:163122736	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.53	6.38	0.37	7.67e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg06697439	chr19:59031463	ZBTB45	-0.43	-6.01	-0.35	6.27e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs2997447	0.761	rs61776596	chr1:26454968	T/C	cg24596570	chr1:26146463	FAM54B;LOC646471	0.59	5.16	0.3	4.76e-7	QRS complex (12-leadsum);
CESC	cis	rs1153858	0.621	rs1719237	chr15:45579822	G/A	cg21132104	chr15:45694354	SPATA5L1	0.75	9.05	0.49	3.22e-17	Homoarginine levels;
CESC	cis	rs66887589	0.934	rs41464847	chr4:120532401	A/G	cg09307838	chr4:120376055	NA	-0.46	-6.17	-0.35	2.55e-9	Diastolic blood pressure;
CESC	cis	rs11734570	0.581	rs79354477	chr4:38597448	C/T	cg18361445	chr4:38666374	KLF3;FLJ13197	0.6	7.34	0.41	2.7e-12	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs881375	0.934	rs1468671	chr9:123657502	C/G	cg14580859	chr9:123691850	NA	0.29	5.15	0.3	5.17e-7	Rheumatoid arthritis;
CESC	cis	rs9916302	0.706	rs2879259	chr17:37410892	C/G	cg07936489	chr17:37558343	FBXL20	-0.94	-10.92	-0.56	3.58e-23	Glomerular filtration rate (creatinine);
CESC	cis	rs6952808	0.862	rs4721135	chr7:1912222	A/G	cg13880726	chr7:1868755	MAD1L1	0.44	6.03	0.35	5.39e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs1874326	0.504	rs7793703	chr7:138113421	T/G	cg18008034	chr7:138118925	NA	-0.41	-5.22	-0.31	3.63e-7	Quantitative traits;
CESC	cis	rs9329221	0.512	rs7843924	chr8:9976540	C/T	cg21625330	chr8:9911636	MSRA	-0.41	-5.26	-0.31	3.04e-7	Neuroticism;
CESC	cis	rs7267979	0.966	rs2482923	chr20:25308981	T/C	cg08601574	chr20:25228251	PYGB	-0.36	-5.06	-0.3	7.89e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs6163	0.727	rs284854	chr10:104574562	T/G	cg04362960	chr10:104952993	NT5C2	-0.49	-6.78	-0.38	7.89e-11	Waist circumference;Hip circumference;
CESC	cis	rs870825	0.616	rs4610378	chr4:185624220	C/T	cg04058563	chr4:185651563	MLF1IP	-0.63	-7.46	-0.42	1.24e-12	Blood protein levels;
CESC	cis	rs4950322	0.857	rs7522219	chr1:146838619	T/C	cg22381352	chr1:146742008	CHD1L	-0.45	-5.19	-0.3	4.12e-7	Protein quantitative trait loci;
CESC	trans	rs3780486	0.713	rs3780489	chr9:33129844	G/T	cg20290983	chr6:43655470	MRPS18A	0.99	18.34	0.75	4.45e-49	IgG glycosylation;
CESC	cis	rs597539	0.652	rs1249474	chr11:68654774	C/T	cg21963583	chr11:68658836	MRPL21	0.37	5.41	0.32	1.39e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs9640161	0.742	rs2159235	chr7:150017228	T/C	cg10018233	chr7:150070692	REPIN1	0.45	7.22	0.41	5.48e-12	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs798554	0.757	rs2533882	chr7:2846894	G/T	cg09658497	chr7:2847517	GNA12	-0.43	-5.87	-0.34	1.27e-8	Height;
CESC	cis	rs12545109	0.807	rs13263281	chr8:57346582	C/A	cg09654669	chr8:57350985	NA	-0.51	-6.48	-0.37	4.41e-10	Obesity-related traits;
CESC	cis	rs4665809	0.590	rs13016300	chr2:26468365	G/C	cg08470875	chr2:26401718	FAM59B	0.75	7.79	0.43	1.49e-13	Gut microbiome composition (summer);
CESC	cis	rs10504073	0.669	rs818560	chr8:50035417	C/T	cg00325661	chr8:49890786	NA	0.51	7.5	0.42	9.61e-13	Blood metabolite ratios;
CESC	cis	rs7267979	0.833	rs4619688	chr20:25244101	C/G	cg08601574	chr20:25228251	PYGB	0.42	5.92	0.34	1.01e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs2204008	0.754	rs11181244	chr12:38302454	T/C	cg13010199	chr12:38710504	ALG10B	0.45	5.65	0.33	4.06e-8	Bladder cancer;
CESC	cis	rs7940866	0.774	rs2162059	chr11:130831224	C/T	cg12179176	chr11:130786555	SNX19	0.67	10.28	0.53	4.38e-21	Schizophrenia;
CESC	cis	rs10504229	0.683	rs61241336	chr8:58106585	A/G	cg21724239	chr8:58056113	NA	0.57	5.9	0.34	1.08e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs9303401	0.659	rs7225896	chr17:56637337	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.01	11.43	0.57	7.19e-25	Cognitive test performance;
CESC	cis	rs4665809	0.590	rs35615763	chr2:26468778	C/G	cg26314531	chr2:26401878	FAM59B	0.85	9.04	0.49	3.44e-17	Gut microbiome composition (summer);
CESC	cis	rs2836950	0.501	rs2836984	chr21:40700949	A/C	cg11890956	chr21:40555474	PSMG1	-0.66	-9.23	-0.49	9.1e-18	Menarche (age at onset);
CESC	cis	rs2050392	0.624	rs303436	chr10:30731893	G/T	cg25182066	chr10:30743637	MAP3K8	-0.44	-5.78	-0.33	2.07e-8	Inflammatory bowel disease;
CESC	cis	rs1020064	0.636	rs2576750	chr2:105916635	A/T	cg02079111	chr2:105885981	TGFBRAP1	0.39	5.2	0.3	3.96e-7	AIDS;
CESC	cis	rs6964587	0.626	rs10243083	chr7:91552530	G/A	cg17063962	chr7:91808500	NA	-0.45	-6.29	-0.36	1.29e-9	Breast cancer;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg10891888	chr12:46765615	SLC38A2	0.48	6.78	0.38	7.87e-11	Gut microbiota (bacterial taxa);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14378659	chr8:8860465	ERI1	0.69	7.83	0.43	1.2e-13	Gut microbiome composition (summer);
CESC	cis	rs8049040	0.609	rs9940485	chr16:71486105	C/T	cg08717414	chr16:71523259	ZNF19	-0.58	-6.66	-0.38	1.57e-10	Blood protein levels;
CESC	cis	rs9325144	0.647	rs34963631	chr12:38912260	T/A	cg26384229	chr12:38710491	ALG10B	-0.56	-7.75	-0.43	2.02e-13	Morning vs. evening chronotype;
CESC	cis	rs11969893	0.850	rs9791284	chr6:101353886	G/A	cg12253828	chr6:101329408	ASCC3	0.91	6.53	0.37	3.33e-10	Economic and political preferences (immigration/crime);
CESC	cis	rs7829975	0.742	rs882462	chr8:8678530	G/A	cg06636001	chr8:8085503	FLJ10661	0.45	5.83	0.34	1.58e-8	Mood instability;
CESC	cis	rs9649465	0.967	rs6950373	chr7:123361773	C/T	cg04330084	chr7:123175371	IQUB	-0.39	-5.23	-0.31	3.47e-7	Migraine;
CESC	cis	rs7666738	0.800	rs2865988	chr4:99067807	T/C	cg05340658	chr4:99064831	C4orf37	0.83	12.82	0.62	1.36e-29	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4664308	0.710	rs13001911	chr2:161020703	G/C	cg03641300	chr2:160917029	PLA2R1	-0.54	-7.75	-0.43	2.01e-13	Idiopathic membranous nephropathy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24047259	chr14:65347275	NA	0.53	6.28	0.36	1.35e-9	Gut microbiome composition (summer);
CESC	cis	rs12048904	0.505	rs11166508	chr1:101233511	A/G	cg15686842	chr1:101360669	SLC30A7;EXTL2	-0.56	-6.35	-0.36	9.23e-10	Multiple sclerosis;
CESC	trans	rs17764205	0.568	rs72987040	chr19:3251116	C/A	cg02013146	chr16:89452259	ANKRD11	-0.77	-6.05	-0.35	5.04e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs1552244	0.882	rs6443279	chr3:10053599	C/A	cg00149659	chr3:10157352	C3orf10	0.69	8.03	0.44	3.14e-14	Alzheimer's disease;
CESC	cis	rs4629180	0.675	rs13388183	chr2:102111912	A/G	cg04415270	chr2:102091202	RFX8	-0.31	-5.45	-0.32	1.18e-7	Chronic rhinosinusitis with nasal polyps;
CESC	cis	rs4970988	0.556	rs2280078	chr1:150600181	C/T	cg04414720	chr1:150670196	GOLPH3L	-0.5	-6.55	-0.37	2.93e-10	Urate levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07151560	chr1:111991897	WDR77;ATP5F1	0.53	6.0	0.35	6.36e-9	Gut microbiome composition (summer);
CESC	cis	rs1862618	0.671	rs906631	chr5:56245803	C/G	cg24549020	chr5:56110836	MAP3K1	-0.52	-6.46	-0.37	4.87e-10	Initial pursuit acceleration;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg05922971	chr5:43121458	ZNF131	-0.42	-6.06	-0.35	4.54e-9	Fibrinogen levels;
CESC	cis	rs8180040	0.967	rs17411375	chr3:47395135	C/T	cg27129171	chr3:47204927	SETD2	-0.68	-10.45	-0.54	1.24e-21	Colorectal cancer;
CESC	cis	rs12579753	0.719	rs10862377	chr12:82270172	C/T	cg23701643	chr12:82153290	PPFIA2	-0.36	-5.29	-0.31	2.57e-7	Resting heart rate;
CESC	trans	rs10028773	0.568	rs6838457	chr4:120267367	A/G	cg25214090	chr10:38739885	LOC399744	0.59	8.14	0.45	1.55e-14	Educational attainment;
CESC	cis	rs10504229	0.545	rs56394419	chr8:58128982	T/C	cg24829409	chr8:58192753	C8orf71	-0.58	-7.2	-0.4	6.31e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs35306767	0.903	rs12763396	chr10:927357	C/A	cg25019033	chr10:957182	NA	-0.55	-6.18	-0.36	2.38e-9	Eosinophil percentage of granulocytes;
CESC	cis	rs9790314	1.000	rs336589	chr3:161080358	C/T	cg03342759	chr3:160939853	NMD3	-0.45	-5.97	-0.34	7.5e-9	Morning vs. evening chronotype;
CESC	cis	rs12541635	0.677	rs7460291	chr8:107057861	A/G	cg10147462	chr8:107024639	NA	0.43	6.41	0.37	6.55e-10	Age of smoking initiation;
CESC	cis	rs9916302	0.851	rs11078904	chr17:37650569	G/A	cg00129232	chr17:37814104	STARD3	-0.54	-7.14	-0.4	9.08e-12	Glomerular filtration rate (creatinine);
CESC	cis	rs4481887	0.927	rs4472779	chr1:248474603	G/A	cg00666640	chr1:248458726	OR2T12	0.34	5.89	0.34	1.18e-8	Common traits (Other);
CESC	cis	rs10751667	0.666	rs10902247	chr11:953686	G/A	cg06064525	chr11:970664	AP2A2	-0.48	-9.52	-0.5	1.15e-18	Alzheimer's disease (late onset);
CESC	cis	rs7552404	0.731	rs12078299	chr1:76365764	T/A	cg10523679	chr1:76189770	ACADM	0.63	6.03	0.35	5.41e-9	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs9487051	0.700	rs9400266	chr6:109596193	T/A	cg01475377	chr6:109611718	NA	-0.45	-7.04	-0.4	1.6e-11	Reticulocyte fraction of red cells;
CESC	cis	rs977987	0.806	rs2865530	chr16:75414376	G/T	cg03315344	chr16:75512273	CHST6	0.4	5.73	0.33	2.78e-8	Dupuytren's disease;
CESC	cis	rs3087591	1.000	rs2525578	chr17:29711411	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.49	-6.09	-0.35	4.05e-9	Hip circumference;
CESC	cis	rs367615	0.506	rs2914680	chr5:108787146	A/G	cg17395555	chr5:108820864	NA	-0.6	-10.07	-0.53	2.11e-20	Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs17376456	0.825	rs36042718	chr5:93180997	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.63	5.37	0.31	1.74e-7	Diabetic retinopathy;
CESC	cis	rs6690583	0.623	rs898036	chr1:85521904	A/T	cg22488158	chr1:85528044	WDR63	0.58	5.57	0.32	6.27e-8	Serum sulfate level;
CESC	cis	rs7520050	0.966	rs12144263	chr1:46352446	G/A	cg24296786	chr1:45957014	TESK2	0.43	5.41	0.32	1.42e-7	Red blood cell count;Reticulocyte count;
CESC	trans	rs6479874	0.831	rs2456758	chr10:52738018	A/G	cg02905881	chr2:48009730	MSH6	0.79	6.19	0.36	2.26e-9	Migraine;
CESC	cis	rs4604732	0.631	rs1106720	chr1:247624681	T/C	cg12758973	chr1:247694275	LOC148824;OR2C3	0.51	6.36	0.36	8.65e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs5753618	0.504	rs9609296	chr22:31891784	T/G	cg02404636	chr22:31891804	SFI1	0.42	5.44	0.32	1.23e-7	Colorectal cancer;
CESC	cis	rs1878931	0.543	rs1129568	chr16:3483475	G/A	cg22508957	chr16:3507546	NAT15	-0.42	-6.13	-0.35	3.23e-9	Body mass index (adult);
CESC	cis	rs8180040	1.000	rs295442	chr3:47335881	A/C	cg27129171	chr3:47204927	SETD2	0.64	9.57	0.51	7.8e-19	Colorectal cancer;
CESC	cis	rs17021463	0.673	rs57939388	chr4:95282365	A/G	cg11021082	chr4:95130006	SMARCAD1	0.5	6.91	0.39	3.66e-11	Testicular germ cell tumor;
CESC	cis	rs616402	0.527	rs589151	chr1:10567711	C/T	cg17425144	chr1:10567563	PEX14	0.38	6.09	0.35	4.02e-9	Breast size;
CESC	cis	rs4665809	0.878	rs6720312	chr2:26364934	A/G	cg27170947	chr2:26402098	FAM59B	0.64	7.8	0.43	1.39e-13	Gut microbiome composition (summer);
CESC	cis	rs853679	0.517	rs9348794	chr6:28117757	T/A	cg23161317	chr6:28129485	ZNF389	0.52	6.48	0.37	4.48e-10	Depression;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17008164	chr15:31507824	NA	0.6	7.02	0.4	1.87e-11	Gut microbiome composition (summer);
CESC	trans	rs853679	0.599	rs149949	chr6:28011516	T/C	cg06606381	chr12:133084897	FBRSL1	-0.74	-6.49	-0.37	4.27e-10	Depression;
CESC	cis	rs1129187	0.837	rs4714634	chr6:42901120	G/A	cg14338887	chr6:42928500	GNMT	0.37	5.26	0.31	2.93e-7	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs35306767	0.903	rs12249828	chr10:894838	C/T	cg20503657	chr10:835505	NA	0.76	7.88	0.44	8.52e-14	Eosinophil percentage of granulocytes;
CESC	cis	rs6500395	0.962	rs1039341	chr16:48574869	C/T	cg04672837	chr16:48644449	N4BP1	0.45	5.4	0.31	1.51e-7	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs2354432	0.556	rs2883319	chr1:146838177	A/G	cg25205988	chr1:146714368	CHD1L	-1.02	-8.38	-0.46	3.08e-15	Mitochondrial DNA levels;
CESC	cis	rs597539	0.652	rs513359	chr11:68669496	A/T	cg01988459	chr11:68622903	NA	0.4	5.68	0.33	3.54e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs116095464	0.558	rs6872854	chr5:209038	G/T	cg22857025	chr5:266934	NA	-1.25	-18.53	-0.75	9.96e-50	Breast cancer;
CESC	cis	rs863345	0.901	rs2213947	chr1:158445699	A/G	cg12129480	chr1:158549410	OR10X1	-0.31	-6.07	-0.35	4.42e-9	Pneumococcal bacteremia;
CESC	cis	rs7618915	0.508	rs13065851	chr3:52644836	T/A	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.36	6.3	0.36	1.23e-9	Bipolar disorder;
CESC	cis	rs10484885	0.715	rs2585013	chr6:90553402	T/G	cg13799429	chr6:90582589	CASP8AP2	-0.86	-10.96	-0.56	2.66e-23	QRS interval (sulfonylurea treatment interaction);
CESC	cis	rs35306767	0.855	rs55697724	chr10:885622	T/C	cg10556349	chr10:835070	NA	0.76	6.35	0.36	9.42e-10	Eosinophil percentage of granulocytes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19230709	chr19:4933046	UHRF1	-0.63	-6.92	-0.39	3.35e-11	Gut microbiome composition (summer);
CESC	cis	rs9318086	0.712	rs66683041	chr13:24442090	T/A	cg25267304	chr13:24462978	PCOTH;MIPEP	0.6	6.82	0.39	6.2e-11	Myopia (pathological);
CESC	cis	rs6933660	0.665	rs6921042	chr6:151732385	T/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.66	9.32	0.5	4.58e-18	Menarche (age at onset);
CESC	cis	rs7267979	0.586	rs6050432	chr20:25184028	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.66	10.78	0.55	1.07e-22	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs561341	0.689	rs578635	chr17:30289897	A/C	cg23018236	chr17:30244563	NA	-0.38	-5.1	-0.3	6.62e-7	Hip circumference adjusted for BMI;
CESC	cis	rs9911578	0.967	rs302843	chr17:56727986	C/T	cg12560992	chr17:57184187	TRIM37	0.93	15.58	0.69	2.6e-39	Intelligence (multi-trait analysis);
CESC	cis	rs9291683	0.679	rs3756225	chr4:10094133	G/C	cg00071950	chr4:10020882	SLC2A9	-0.59	-9.59	-0.51	7.06e-19	Bone mineral density;
CESC	cis	rs6032067	0.925	rs62208424	chr20:43813341	G/A	cg10761708	chr20:43804764	PI3	0.53	6.38	0.36	7.98e-10	Blood protein levels;
CESC	cis	rs4803468	1.000	rs2569754	chr19:41936734	A/G	cg14132834	chr19:41945861	ATP5SL	-0.69	-8.69	-0.47	3.72e-16	Height;
CESC	cis	rs9399137	0.507	rs11759062	chr6:135381248	A/C	cg24558204	chr6:135376177	HBS1L	0.69	9.52	0.5	1.12e-18	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	cis	rs4909189	1.000	rs71547530	chr7:158135503	A/G	cg25566285	chr7:158114605	PTPRN2	0.43	5.42	0.32	1.36e-7	Response to amphetamines;
CESC	trans	rs208520	0.690	rs1563929	chr6:66702108	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.97	12.46	0.61	2.35e-28	Exhaled nitric oxide output;
CESC	cis	rs7520050	0.966	rs34102169	chr1:46424864	G/T	cg03146154	chr1:46216737	IPP	-0.47	-6.1	-0.35	3.74e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs13256369	0.802	rs11249887	chr8:8562184	T/C	cg00074818	chr8:8560427	CLDN23	0.36	5.22	0.31	3.64e-7	Obesity-related traits;
CESC	trans	rs1814175	0.669	rs12364577	chr11:49707361	A/C	cg15704280	chr7:45808275	SEPT13	-0.84	-11.66	-0.58	1.23e-25	Height;
CESC	cis	rs60843830	1.000	rs56321614	chr2:268191	G/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.88	12.15	0.6	2.6e-27	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs7666738	0.830	rs10440379	chr4:98902822	G/T	cg03467027	chr4:99064603	C4orf37	0.42	5.11	0.3	6.18e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9611565	0.840	rs9607799	chr22:41777558	A/G	cg06634786	chr22:41940651	POLR3H	-0.68	-7.28	-0.41	3.87e-12	Vitiligo;
CESC	cis	rs30380	0.632	rs26489	chr5:96133427	C/T	cg16492584	chr5:96139282	ERAP1	-0.49	-6.84	-0.39	5.49e-11	Cerebrospinal fluid biomarker levels;
CESC	cis	rs7666738	0.830	rs2903152	chr4:99067992	A/G	cg17366294	chr4:99064904	C4orf37	0.61	8.5	0.46	1.41e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2281845	0.507	rs12025414	chr1:201100496	A/G	cg06714761	chr1:201096289	NA	0.44	6.83	0.39	5.8200000000000003e-11	Permanent tooth development;
CESC	trans	rs7246760	0.867	rs2287843	chr19:9769913	G/A	cg02900749	chr2:68251473	NA	-0.85	-7.53	-0.42	8.04e-13	Pursuit maintenance gain;
CESC	cis	rs977987	0.806	rs4993969	chr16:75411521	A/T	cg03315344	chr16:75512273	CHST6	0.38	5.5	0.32	8.89e-8	Dupuytren's disease;
CESC	cis	rs4555082	0.750	rs2816650	chr14:105708343	C/T	cg06808227	chr14:105710500	BRF1	-0.51	-5.78	-0.33	2.08e-8	Mean platelet volume;Platelet distribution width;
CESC	cis	rs5750830	0.595	rs4821892	chr22:39795683	G/C	cg24399712	chr22:39784796	NA	-0.83	-11.47	-0.58	5.45e-25	Intelligence (multi-trait analysis);
CESC	cis	rs7919006	1.000	rs6480766	chr10:76803880	G/A	cg01390419	chr10:76803856	DUPD1	0.39	5.56	0.32	6.59e-8	Weight;
CESC	cis	rs7618501	0.933	rs3811695	chr3:49761613	C/T	cg24308560	chr3:49941425	MST1R	0.51	7.05	0.4	1.58e-11	Intelligence (multi-trait analysis);
CESC	cis	rs250677	0.687	rs384979	chr5:148459267	C/T	cg12140854	chr5:148520817	ABLIM3	0.41	5.13	0.3	5.52e-7	Breast cancer;
CESC	cis	rs7633770	0.805	rs11130098	chr3:46661926	A/G	cg11219411	chr3:46661640	NA	-0.47	-7.42	-0.41	1.63e-12	Coronary artery disease;
CESC	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg14926445	chr8:58193284	C8orf71	-0.54	-5.16	-0.3	4.76e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs7914558	0.966	rs12571568	chr10:104891396	C/G	cg04362960	chr10:104952993	NT5C2	0.46	5.92	0.34	9.98e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs2243480	0.522	rs12698511	chr7:65474919	G/T	cg25894440	chr7:65020034	NA	-0.78	-5.63	-0.33	4.69e-8	Diabetic kidney disease;
CESC	cis	rs7666738	0.791	rs13125277	chr4:99009922	T/G	cg18180107	chr4:99064573	C4orf37	0.4	5.3	0.31	2.48e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6963495	0.818	rs55922564	chr7:105155890	G/A	cg02135003	chr7:105160482	PUS7	-0.46	-5.55	-0.32	6.92e-8	Bipolar disorder (body mass index interaction);
CESC	cis	rs9894429	1.000	rs7209180	chr17:79581519	C/A	cg21984481	chr17:79567631	NPLOC4	-0.49	-8.04	-0.44	2.97e-14	Eye color traits;
CESC	cis	rs736408	0.609	rs2268025	chr3:52795224	A/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.3	5.16	0.3	4.78e-7	Bipolar disorder;
CESC	cis	rs7618915	0.547	rs13069481	chr3:52666866	C/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.31	5.43	0.32	1.24e-7	Bipolar disorder;
CESC	cis	rs10949662	1.000	rs10949662	chr7:157534105	A/G	cg11757124	chr7:157526947	PTPRN2	0.43	5.09	0.3	6.69e-7	Intelligence (multi-trait analysis);
CESC	cis	rs2576037	0.561	rs513775	chr18:44396334	T/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.32	5.03	0.3	8.86e-7	Personality dimensions;
CESC	cis	rs6460942	0.915	rs62448620	chr7:12458170	C/T	cg02935154	chr7:12443704	VWDE	-0.58	-6.16	-0.35	2.73e-9	Coronary artery disease;
CESC	trans	rs5756813	0.754	rs34848977	chr22:38165587	G/A	cg19894588	chr14:64061835	NA	-0.71	-8.82	-0.48	1.52e-16	Optic cup area;Vertical cup-disc ratio;
CESC	cis	rs1577917	0.727	rs9444361	chr6:86400900	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.54	7.41	0.41	1.69e-12	Response to antipsychotic treatment;
CESC	cis	rs2066819	1.000	rs2371454	chr12:56647243	A/G	cg26734620	chr12:56694298	CS	-1.07	-6.58	-0.37	2.56e-10	Psoriasis vulgaris;
CESC	cis	rs1448094	0.512	rs7303330	chr12:86255123	G/A	cg00310523	chr12:86230176	RASSF9	0.36	5.55	0.32	6.85e-8	Major depressive disorder;
CESC	cis	rs4819052	0.679	rs2838860	chr21:46684904	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.69	9.47	0.5	1.67e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs6570726	1.000	rs6570699	chr6:145920732	G/A	cg23711669	chr6:146136114	FBXO30	0.67	9.61	0.51	5.87e-19	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs3857067	1.000	rs1509940	chr4:95018758	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.52	-8.04	-0.44	3.05e-14	QT interval;
CESC	cis	rs950027	0.549	rs1719250	chr15:45609773	A/G	cg21132104	chr15:45694354	SPATA5L1	0.61	7.38	0.41	2.06e-12	Response to fenofibrate (adiponectin levels);
CESC	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg23708337	chr7:1209742	NA	0.5	5.57	0.32	6.3e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17280624	chr4:129208725	PGRMC2	-0.61	-7.05	-0.4	1.59e-11	Gut microbiome composition (summer);
CESC	cis	rs2832191	0.679	rs2705659	chr21:30363908	G/C	cg08807101	chr21:30365312	RNF160	0.96	14.93	0.68	5.23e-37	Dental caries;
CESC	cis	rs367943	1.000	rs348925	chr5:112817533	T/A	cg12552261	chr5:112820674	MCC	-0.62	-7.78	-0.43	1.58e-13	Type 2 diabetes;
CESC	cis	rs7809950	1.000	rs2057837	chr7:107222725	C/G	cg23024343	chr7:107201750	COG5	0.4	5.54	0.32	7.44e-8	Coronary artery disease;
CESC	cis	rs35306767	0.903	rs34270014	chr10:904666	T/C	cg10556349	chr10:835070	NA	0.56	5.32	0.31	2.16e-7	Eosinophil percentage of granulocytes;
CESC	cis	rs2797160	1.000	rs1418948	chr6:126007018	C/T	cg05901451	chr6:126070800	HEY2	0.45	6.54	0.37	3.11e-10	Endometrial cancer;
CESC	cis	rs10905065	0.833	rs6602259	chr10:5844628	C/T	cg11519256	chr10:5708881	ASB13	0.43	5.99	0.35	6.82e-9	Menopause (age at onset);
CESC	cis	rs597539	0.652	rs546382	chr11:68704264	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.81	10.75	0.55	1.29e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs4654899	0.680	rs12407731	chr1:21254789	C/T	cg05370193	chr1:21551575	ECE1	0.34	5.22	0.31	3.64e-7	Superior frontal gyrus grey matter volume;
CESC	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	7.54	0.42	7.65e-13	Prudent dietary pattern;
CESC	cis	rs6088580	0.634	rs6141465	chr20:32967314	T/C	cg06115741	chr20:33292138	TP53INP2	-0.47	-6.08	-0.35	4.22e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs10504229	1.000	rs17217047	chr8:58180296	G/A	cg22535103	chr8:58192502	C8orf71	-1.05	-13.27	-0.63	3.63e-31	Developmental language disorder (linguistic errors);
CESC	cis	rs9916302	0.718	rs10445306	chr17:37591422	A/G	cg20243544	chr17:37824526	PNMT	0.52	6.53	0.37	3.3e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs240110	0.539	rs6934256	chr6:101338728	G/A	cg09795085	chr6:101329169	ASCC3	0.46	6.0	0.35	6.5e-9	Neuroticism;
CESC	cis	rs4803468	1.000	rs11883104	chr19:41923799	T/C	cg08639244	chr19:41945921	ATP5SL	-0.41	-5.03	-0.3	9.08e-7	Height;
CESC	cis	rs854765	0.583	rs8075965	chr17:17853180	A/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.57	8.07	0.44	2.47e-14	Total body bone mineral density;
CESC	cis	rs4718428	0.705	rs13231140	chr7:66361618	C/G	cg18252515	chr7:66147081	NA	-0.46	-5.17	-0.3	4.51e-7	Corneal structure;
CESC	cis	rs3091242	0.933	rs1534954	chr1:25761924	A/T	cg03538708	chr1:25844672	NA	-0.42	-6.33	-0.36	1.07e-9	Erythrocyte sedimentation rate;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12141457	chr10:126182012	LHPP	-0.55	-6.11	-0.35	3.55e-9	Gut microbiome composition (summer);
CESC	cis	rs2303745	0.589	rs751599	chr19:17396549	A/G	cg04248312	chr19:17393744	ANKLE1	-0.86	-12.84	-0.62	1.15e-29	Systemic lupus erythematosus;
CESC	cis	rs9487051	0.708	rs378447	chr6:109526823	G/A	cg01475377	chr6:109611718	NA	-0.44	-6.67	-0.38	1.45e-10	Reticulocyte fraction of red cells;
CESC	cis	rs875971	0.545	rs73376394	chr7:65637681	C/T	cg18876405	chr7:65276391	NA	0.5	5.98	0.34	7.33e-9	Aortic root size;
CESC	cis	rs9457247	0.967	rs443570	chr6:167389925	G/A	cg25258033	chr6:167368657	RNASET2	0.39	5.77	0.33	2.19e-8	Crohn's disease;
CESC	cis	rs1790761	0.501	rs4930210	chr11:67404726	G/T	cg00290607	chr11:67383545	NA	-0.44	-6.77	-0.38	8.09e-11	Mean corpuscular volume;
CESC	cis	rs12497850	0.931	rs7430501	chr3:48890119	C/T	cg03060546	chr3:49711283	APEH	0.44	5.38	0.31	1.61e-7	Parkinson's disease;
CESC	cis	rs7618915	0.501	rs2079929	chr3:52765646	C/T	cg05564831	chr3:52568323	NT5DC2	0.44	6.84	0.39	5.53e-11	Bipolar disorder;
CESC	cis	rs7937682	0.632	rs11608193	chr11:111732215	T/C	cg22437258	chr11:111473054	SIK2	-0.49	-5.38	-0.31	1.64e-7	Primary sclerosing cholangitis;
CESC	cis	rs11264213	0.901	rs72661636	chr1:36426483	T/C	cg27506609	chr1:36549197	TEKT2	0.67	5.55	0.32	6.97e-8	Schizophrenia;
CESC	cis	rs9788682	1.000	rs12438181	chr15:78812098	G/A	cg06917634	chr15:78832804	PSMA4	-0.57	-6.59	-0.38	2.39e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs911555	0.755	rs1116095	chr14:103931879	A/G	cg12935359	chr14:103987150	CKB	0.66	9.68	0.51	3.48e-19	Intelligence (multi-trait analysis);
CESC	cis	rs9457247	0.624	rs17524252	chr6:167466978	T/G	cg07741184	chr6:167504864	NA	0.37	6.49	0.37	4.2e-10	Crohn's disease;
CESC	cis	rs4132509	0.895	rs6674314	chr1:243920895	A/G	cg21452805	chr1:244014465	NA	0.42	5.26	0.31	2.9e-7	RR interval (heart rate);
CESC	cis	rs6912958	0.712	rs7746465	chr6:88348996	T/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-6.72	-0.38	1.09e-10	Monocyte percentage of white cells;
CESC	cis	rs7666738	0.830	rs11097582	chr4:98772201	G/A	cg03467027	chr4:99064603	C4orf37	0.43	5.47	0.32	1.02e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs597539	0.617	rs672853	chr11:68636362	G/A	cg18350739	chr11:68623251	NA	-0.48	-6.99	-0.39	2.22e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	trans	rs1857353	0.520	rs17567748	chr1:75701159	A/G	cg14377739	chr9:139699037	KIAA1984;LOC100131193	-0.78	-6.38	-0.36	7.95e-10	Whole-brain volume (Alzheimer's disease interaction);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg09606015	chr3:182511586	ATP11B	-0.46	-6.58	-0.37	2.51e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs2243480	1.000	rs465359	chr7:65558164	C/T	cg18252515	chr7:66147081	NA	-1.39	-13.81	-0.65	4.83e-33	Diabetic kidney disease;
CESC	cis	rs36051895	0.695	rs11794708	chr9:5023441	G/A	cg02405213	chr9:5042618	JAK2	-0.5	-5.63	-0.33	4.66e-8	Pediatric autoimmune diseases;
CESC	trans	rs79976124	0.879	rs17432710	chr6:66621744	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.75	8.58	0.47	7.94e-16	Type 2 diabetes;
CESC	cis	rs4713118	0.629	rs203890	chr6:28022248	T/C	cg19592336	chr6:28129416	ZNF389	0.53	6.84	0.39	5.4e-11	Parkinson's disease;
CESC	trans	rs208520	0.690	rs12213575	chr6:66735989	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.95	12.22	0.6	1.51e-27	Exhaled nitric oxide output;
CESC	cis	rs5753618	0.555	rs5749291	chr22:31907523	C/G	cg02404636	chr22:31891804	SFI1	0.43	5.9	0.34	1.08e-8	Colorectal cancer;
CESC	cis	rs9660180	0.935	rs9786942	chr1:1759213	A/G	cg17747265	chr1:1875780	NA	-0.57	-9.25	-0.49	7.58e-18	Body mass index;
CESC	cis	rs4588572	0.643	rs10440686	chr5:77688331	A/G	cg11547950	chr5:77652471	NA	0.45	5.71	0.33	3.06e-8	Triglycerides;
CESC	cis	rs854765	0.583	rs4553680	chr17:17857722	A/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.49	6.22	0.36	1.97e-9	Total body bone mineral density;
CESC	cis	rs4604732	0.578	rs12038656	chr1:247623816	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.55	6.86	0.39	4.77e-11	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs2576037	0.899	rs2060417	chr18:44576486	C/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.63	-9.12	-0.49	1.9e-17	Personality dimensions;
CESC	cis	rs3020736	0.500	rs5996109	chr22:42493098	A/G	cg15557168	chr22:42548783	NA	0.45	6.57	0.37	2.72e-10	Autism spectrum disorder or schizophrenia;
CESC	cis	rs11098499	0.954	rs878373	chr4:120237484	A/T	cg24375607	chr4:120327624	NA	0.46	5.6	0.33	5.42e-8	Corneal astigmatism;
CESC	cis	rs3741404	0.537	rs1123251	chr11:63917601	G/T	cg26318627	chr11:63887540	MACROD1	0.33	5.08	0.3	7.24e-7	Platelet count;
CESC	cis	rs7586879	0.616	rs6722587	chr2:25132192	C/A	cg01884057	chr2:25150051	NA	0.36	7.02	0.4	1.82e-11	Body mass index;
CESC	trans	rs10743315	0.557	rs77194694	chr12:19354075	A/G	cg09562322	chr12:119419143	SRRM4	-0.47	-6.01	-0.35	6.01e-9	Gut microbiota (bacterial taxa);
CESC	trans	rs208520	0.526	rs7776413	chr6:66783241	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.1	-24.14	-0.83	7.13e-69	Exhaled nitric oxide output;
CESC	cis	rs977987	0.645	rs34904236	chr16:75498253	G/T	cg03315344	chr16:75512273	CHST6	0.52	7.64	0.42	3.9e-13	Dupuytren's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02138756	chr12:685505	NINJ2	0.53	6.1	0.35	3.78e-9	Gut microbiome composition (summer);
CESC	cis	rs9322193	0.923	rs9689599	chr6:149953109	A/C	cg13206674	chr6:150067644	NUP43	0.43	6.27	0.36	1.44e-9	Lung cancer;
CESC	cis	rs11792861	0.926	rs72607163	chr9:111803128	G/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.48	6.03	0.35	5.57e-9	Menarche (age at onset);
CESC	cis	rs9905704	0.718	rs62083527	chr17:56667853	T/C	cg12560992	chr17:57184187	TRIM37	0.64	5.98	0.34	7.36e-9	Testicular germ cell tumor;
CESC	cis	rs13118159	0.934	rs4974553	chr4:1356911	G/A	cg16405210	chr4:1374714	KIAA1530	-0.5	-6.69	-0.38	1.34e-10	Longevity;
CESC	cis	rs2228479	0.702	rs62056100	chr16:89939753	C/T	cg14709524	chr16:89940631	TCF25	0.88	6.36	0.36	8.79e-10	Skin colour saturation;
CESC	cis	rs13082711	0.911	rs923941	chr3:27458914	A/G	cg02860705	chr3:27208620	NA	0.58	7.29	0.41	3.49e-12	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CESC	cis	rs7116495	0.737	rs7101553	chr11:71753903	C/T	cg07596299	chr11:71824057	C11orf51	-0.85	-5.35	-0.31	1.89e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs4853012	0.941	rs78128123	chr2:74347525	C/T	cg19729930	chr2:74357872	NA	0.93	12.29	0.6	8.99e-28	Gestational age at birth (maternal effect);
CESC	cis	rs7772486	0.727	rs10223508	chr6:146285205	C/T	cg23711669	chr6:146136114	FBXO30	-0.8	-10.95	-0.56	2.86e-23	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7666738	0.830	rs13328042	chr4:99055406	A/G	cg03676636	chr4:99064102	C4orf37	0.34	5.17	0.3	4.55e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7208859	0.623	rs11651857	chr17:28926362	G/T	cg19761014	chr17:28927070	LRRC37B2	0.85	6.59	0.38	2.33e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs9916302	0.861	rs11078912	chr17:37671490	A/G	cg19468946	chr17:37922297	IKZF3	-0.4	-5.45	-0.32	1.17e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg24829409	chr8:58192753	C8orf71	-0.67	-8.18	-0.45	1.19e-14	Developmental language disorder (linguistic errors);
CESC	cis	rs3126085	0.935	rs4845426	chr1:152195359	A/G	cg03465714	chr1:152285911	FLG	-0.44	-5.43	-0.32	1.25e-7	Atopic dermatitis;
CESC	cis	rs17711722	0.565	rs73372653	chr7:65442795	A/T	cg07424592	chr7:64974309	NA	-0.4	-5.71	-0.33	2.95e-8	Calcium levels;
CESC	cis	rs2933343	0.700	rs883602	chr3:128653952	A/G	cg11901034	chr3:128598214	ACAD9	-0.36	-5.3	-0.31	2.38e-7	IgG glycosylation;
CESC	cis	rs9796	0.866	rs66818965	chr15:41402279	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.42	-6.23	-0.36	1.78e-9	Menopause (age at onset);
CESC	cis	rs10504229	0.906	rs114810777	chr8:58185298	A/G	cg05313129	chr8:58192883	C8orf71	-0.54	-6.24	-0.36	1.76e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs3771570	1.000	rs62186400	chr2:242226700	A/G	cg21155796	chr2:242212141	HDLBP	0.62	5.19	0.3	4.18e-7	Prostate cancer;
CESC	cis	rs909674	0.734	rs5757675	chr22:39838892	G/T	cg02038168	chr22:39784481	NA	-0.66	-8.55	-0.47	9.78e-16	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs2262909	0.853	rs56207853	chr19:22292357	C/T	cg11619707	chr19:22235551	ZNF257	0.34	5.56	0.32	6.54e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
CESC	cis	rs2997447	0.761	rs55960411	chr1:26437741	G/C	cg24596570	chr1:26146463	FAM54B;LOC646471	0.62	5.33	0.31	2.07e-7	QRS complex (12-leadsum);
CESC	cis	rs228769	0.543	rs170634	chr17:42175821	C/A	cg13607699	chr17:42295918	UBTF	-0.59	-7.76	-0.43	1.82e-13	Bone mineral density (hip);Bone mineral density (spine);
CESC	cis	rs4713118	0.621	rs9368548	chr6:28034737	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.54	-5.98	-0.34	7.07e-9	Parkinson's disease;
CESC	cis	rs4974559	0.895	rs10004411	chr4:1354306	T/G	cg02980000	chr4:1222292	CTBP1	0.63	6.21	0.36	2.06e-9	Systolic blood pressure;
CESC	cis	rs4604732	0.536	rs10925056	chr1:247650472	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.61	8.04	0.44	3.06e-14	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs7937682	0.737	rs542275	chr11:111431614	C/T	cg22437258	chr11:111473054	SIK2	0.64	8.2	0.45	1.04e-14	Primary sclerosing cholangitis;
CESC	cis	rs9937943	0.720	rs112685216	chr16:74609517	G/A	cg01733217	chr16:74700730	RFWD3	0.62	5.53	0.32	7.68e-8	Neutrophil percentage of white cells;
CESC	cis	rs2522056	1.000	rs2706381	chr5:131810619	C/T	cg24060327	chr5:131705240	SLC22A5	0.59	6.68	0.38	1.38e-10	Lymphocyte counts;Fibrinogen;
CESC	cis	rs4423214	1.000	rs1981412	chr11:71138710	T/C	cg05163923	chr11:71159392	DHCR7	0.78	10.47	0.54	1.04e-21	Vitamin D levels;
CESC	cis	rs8067354	1.000	rs8067354	chr17:57821430	G/A	cg02344993	chr17:57696989	CLTC	0.49	6.31	0.36	1.14e-9	Hemoglobin concentration;
CESC	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg14893161	chr1:205819251	PM20D1	0.87	14.89	0.68	7.26e-37	Menarche (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23010568	chr17:568212	VPS53	-0.53	-6.42	-0.37	6.1e-10	Gut microbiome composition (summer);
CESC	cis	rs9814567	0.929	rs9855013	chr3:134240414	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.45	-6.08	-0.35	4.26e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs10504229	0.679	rs7839948	chr8:58130607	A/G	cg24829409	chr8:58192753	C8orf71	-0.58	-7.2	-0.4	6.31e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs10791323	0.604	rs2250025	chr11:133710914	G/A	cg15485101	chr11:133734466	NA	0.41	6.54	0.37	3.09e-10	Childhood ear infection;
CESC	cis	rs4629180	0.538	rs6746761	chr2:102122390	G/T	cg21388029	chr2:102003306	CREG2	0.32	5.24	0.31	3.33e-7	Chronic rhinosinusitis with nasal polyps;
CESC	cis	rs4969178	0.930	rs11077363	chr17:76397309	C/T	cg20026190	chr17:76395443	PGS1	0.49	7.81	0.43	1.34e-13	HDL cholesterol levels;
CESC	cis	rs4237845	0.611	rs10877036	chr12:58321650	A/G	cg00677455	chr12:58241039	CTDSP2	-0.43	-5.58	-0.32	6.03e-8	Intelligence (multi-trait analysis);
CESC	cis	rs17666538	0.535	rs896522	chr8:616991	A/G	cg23958373	chr8:599963	NA	0.83	6.1	0.35	3.7e-9	IgG glycosylation;
CESC	trans	rs7618501	1.000	rs2271961	chr3:49878113	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.59	-8.5	-0.46	1.4e-15	Intelligence (multi-trait analysis);
CESC	cis	rs2011503	0.941	rs6511027	chr19:19391851	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.52	5.4	0.31	1.48e-7	Bipolar disorder;
CESC	cis	rs8018808	0.967	rs10133896	chr14:77853806	C/T	cg20045696	chr14:77926864	AHSA1	-0.38	-5.18	-0.3	4.46e-7	Myeloid white cell count;
CESC	cis	rs9916302	0.706	rs6503504	chr17:37514412	A/G	cg07936489	chr17:37558343	FBXL20	0.89	9.69	0.51	3.45e-19	Glomerular filtration rate (creatinine);
CESC	cis	rs9611565	0.659	rs9607812	chr22:41941243	G/A	cg03806693	chr22:41940476	POLR3H	-1.24	-16.78	-0.72	1.44e-43	Vitiligo;
CESC	cis	rs3820928	0.934	rs16822890	chr2:227761477	G/A	cg11843606	chr2:227700838	RHBDD1	-0.42	-5.72	-0.33	2.92e-8	Pulmonary function;
CESC	cis	rs7666738	0.719	rs4699323	chr4:98967484	G/A	cg03676636	chr4:99064102	C4orf37	0.41	5.49	0.32	9.57e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6933660	0.745	rs9397405	chr6:151736084	G/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.87	14.29	0.66	1e-34	Menarche (age at onset);
CESC	cis	rs763121	0.925	rs4821815	chr22:39105707	G/A	cg21395723	chr22:39101663	GTPBP1	0.45	6.08	0.35	4.28e-9	Menopause (age at onset);
CESC	cis	rs4665809	1.000	rs2384321	chr2:26290054	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.83	-9.25	-0.49	7.55e-18	Gut microbiome composition (summer);
CESC	cis	rs244293	0.730	rs12945579	chr17:53022714	A/T	cg19360675	chr17:53046073	COX11;STXBP4	-0.44	-5.85	-0.34	1.48e-8	Menarche (age at onset);
CESC	cis	rs17021463	0.645	rs12651347	chr4:95334650	G/A	cg11021082	chr4:95130006	SMARCAD1	0.48	6.25	0.36	1.62e-9	Testicular germ cell tumor;
CESC	cis	rs10504229	0.683	rs2005392	chr8:58106896	T/C	cg21724239	chr8:58056113	NA	0.57	5.9	0.34	1.08e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs34779708	0.931	rs35136660	chr10:35385973	C/A	cg03585969	chr10:35415529	CREM	0.77	10.07	0.53	2.06e-20	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs6486730	1.000	rs6486730	chr12:129275027	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.39	-5.46	-0.32	1.08e-7	Systemic lupus erythematosus;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg03047724	chr7:139477895	TBXAS1;HIPK2	-0.45	-6.05	-0.35	4.95e-9	Fibrinogen levels;
CESC	cis	rs6460942	0.915	rs17541242	chr7:12459068	A/G	cg20607287	chr7:12443886	VWDE	-0.79	-9.27	-0.49	6.78e-18	Coronary artery disease;
CESC	cis	rs597539	0.617	rs669659	chr11:68635623	G/C	cg01988459	chr11:68622903	NA	-0.38	-5.14	-0.3	5.45e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs478304	0.651	rs11227281	chr11:65496558	T/C	cg10518572	chr11:65560635	OVOL1	-0.33	-6.61	-0.38	2.09e-10	Acne (severe);
CESC	cis	rs3820068	0.603	rs3795763	chr1:15959977	C/T	cg16988262	chr1:15930761	NA	0.34	5.48	0.32	9.82e-8	Systolic blood pressure;
CESC	cis	rs769267	0.930	rs2301784	chr19:19390749	G/A	cg03709012	chr19:19516395	GATAD2A	0.96	14.18	0.66	2.35e-34	Tonsillectomy;
CESC	cis	rs2841277	0.802	rs2841269	chr14:105386149	C/G	cg14403583	chr14:105418241	AHNAK2	-0.54	-7.3	-0.41	3.35e-12	Rheumatoid arthritis;
CESC	cis	rs7412746	0.611	rs10888395	chr1:150762171	C/T	cg04414720	chr1:150670196	GOLPH3L	0.55	7.08	0.4	1.27e-11	Melanoma;
CESC	cis	rs684232	0.602	rs394747	chr17:562495	C/G	cg12384639	chr17:618140	VPS53	-0.42	-5.47	-0.32	1.02e-7	Prostate cancer;
CESC	cis	rs4523957	0.859	rs9891227	chr17:2164311	G/A	cg16513277	chr17:2031491	SMG6	-0.6	-8.18	-0.45	1.22e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs2073300	0.609	rs6137917	chr20:23360369	G/A	cg16736954	chr20:23401023	NAPB	0.8	6.09	0.35	3.89e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs1023500	0.551	rs61665536	chr22:42512613	A/G	cg15557168	chr22:42548783	NA	0.45	6.51	0.37	3.78e-10	Schizophrenia;
CESC	cis	rs8060686	0.641	rs76419201	chr16:68153553	G/A	cg26727032	chr16:67993705	SLC12A4	-0.54	-6.05	-0.35	5.04e-9	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs2011503	0.941	rs2074302	chr19:19381728	G/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.51	5.18	0.3	4.38e-7	Bipolar disorder;
CESC	cis	rs193541	0.632	rs39821	chr5:122295472	T/C	cg19412675	chr5:122181750	SNX24	0.45	5.34	0.31	2.03e-7	Glucose homeostasis traits;
CESC	cis	rs3956705	0.762	rs13437980	chr7:32997749	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.46	5.39	0.31	1.56e-7	Red cell distribution width;
CESC	cis	rs7618915	0.547	rs62253703	chr3:52632357	T/C	cg07507251	chr3:52567010	NT5DC2	0.41	7.11	0.4	1.05e-11	Bipolar disorder;
CESC	cis	rs875971	0.862	rs4236208	chr7:65749078	C/T	cg18252515	chr7:66147081	NA	0.4	5.2	0.3	4e-7	Aortic root size;
CESC	cis	rs11098499	0.691	rs9995716	chr4:120264996	T/C	cg09307838	chr4:120376055	NA	0.75	9.88	0.52	8.38e-20	Corneal astigmatism;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24542046	chr7:102782124	NAPEPLD;RPL19P12	-0.49	-6.14	-0.35	3.02e-9	Gut microbiome composition (summer);
CESC	cis	rs796364	0.616	rs6710393	chr2:200697246	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.65	6.36	0.36	9.05e-10	Schizophrenia;
CESC	cis	rs4141404	0.757	rs5749272	chr22:31830351	C/T	cg13145458	chr22:31556086	RNF185	0.49	6.07	0.35	4.33e-9	Paclitaxel-induced neuropathy;
CESC	cis	rs12824058	0.831	rs12322456	chr12:130813594	A/G	cg26677194	chr12:130822605	PIWIL1	0.53	6.98	0.39	2.31e-11	Menopause (age at onset);
CESC	cis	rs2440129	0.611	rs434473	chr17:6904934	A/G	cg22741997	chr17:6900356	ALOX12	-0.46	-7.12	-0.4	1.03e-11	Tonsillectomy;
CESC	cis	rs7188697	0.922	rs37055	chr16:58560775	C/T	cg02549819	chr16:58548995	SETD6	-0.42	-5.23	-0.31	3.45e-7	QT interval;
CESC	cis	rs796364	0.568	rs11890894	chr2:201072055	C/T	cg23649088	chr2:200775458	C2orf69	0.49	5.72	0.33	2.81e-8	Schizophrenia;
CESC	cis	rs6695640	0.819	rs2762887	chr1:17731440	A/G	cg01904812	chr1:17746340	RCC2	0.35	5.18	0.3	4.32e-7	Mean platelet volume;
CESC	cis	rs1003719	0.788	rs2835584	chr21:38460338	A/T	cg10648535	chr21:38446584	PIGP;TTC3	0.62	8.68	0.47	4.19e-16	Eye color traits;
CESC	cis	rs7582720	1.000	rs115953525	chr2:203744445	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.39	0.41	1.96e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	trans	rs561341	0.883	rs1034627	chr17:30219569	C/T	cg27661571	chr11:113659931	NA	-0.63	-6.89	-0.39	4e-11	Hip circumference adjusted for BMI;
CESC	trans	rs7107217	1.000	rs1873872	chr11:129473993	A/T	cg00747290	chr2:42721154	KCNG3	0.48	6.02	0.35	5.88e-9	Breast cancer;Type 2 diabetes;
CESC	trans	rs11098499	0.954	rs3733524	chr4:120423729	T/C	cg25214090	chr10:38739885	LOC399744	0.7	9.61	0.51	6.02e-19	Corneal astigmatism;
CESC	cis	rs1878931	0.580	rs3848355	chr16:3407489	A/C	cg22508957	chr16:3507546	NAT15	-0.37	-5.31	-0.31	2.31e-7	Body mass index (adult);
CESC	cis	rs2440129	0.611	rs434473	chr17:6904934	A/G	cg03760483	chr17:6899297	ALOX12	-0.37	-6.28	-0.36	1.4e-9	Tonsillectomy;
CESC	cis	rs6860806	0.631	rs7736284	chr5:131588151	T/C	cg04518342	chr5:131593106	PDLIM4	0.41	6.21	0.36	2.08e-9	Breast cancer;
CESC	cis	rs6964587	0.692	rs7807490	chr7:91773359	A/G	cg01689657	chr7:91764605	CYP51A1	0.27	5.24	0.31	3.24e-7	Breast cancer;
CESC	cis	rs2795502	1.000	rs2185717	chr10:43343875	G/A	cg20628663	chr10:43360327	NA	0.61	7.23	0.41	5.03e-12	Blood protein levels;
CESC	cis	rs798502	0.522	rs7790322	chr7:2830498	C/T	cg19346786	chr7:2764209	NA	-0.43	-6.48	-0.37	4.51e-10	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Inflammatory bowel disease;Waist circumference adjusted for BMI in non-smokers;Ulcerative colitis;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
CESC	cis	rs10927875	0.722	rs6660685	chr1:16346988	A/G	cg22431228	chr1:16359049	CLCNKA	-0.5	-8.33	-0.46	4.4e-15	Dilated cardiomyopathy;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg06766273	chr11:62521983	ZBTB3	-0.48	-7.13	-0.4	9.64e-12	Gambling;
CESC	cis	rs9467711	0.606	rs2073527	chr6:26374978	T/C	cg12826209	chr6:26865740	GUSBL1	0.65	5.35	0.31	1.88e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs3806843	0.735	rs778596	chr5:140037272	G/A	cg16179182	chr5:140090404	VTRNA1-1	0.39	5.1	0.3	6.44e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs7552404	1.000	rs4949876	chr1:76173377	C/T	cg03433033	chr1:76189801	ACADM	0.68	8.14	0.45	1.54e-14	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs514406	0.505	rs269290	chr1:53167027	A/T	cg27535305	chr1:53392650	SCP2	-0.33	-5.42	-0.32	1.31e-7	Monocyte count;
CESC	cis	rs2576037	0.526	rs7240239	chr18:44460037	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.73	11.64	0.58	1.46e-25	Personality dimensions;
CESC	cis	rs7666738	0.791	rs6851549	chr4:99029827	G/A	cg17366294	chr4:99064904	C4orf37	0.62	8.98	0.48	5.15e-17	Colonoscopy-negative controls vs population controls;
CESC	cis	rs79349575	0.783	rs9747646	chr17:47016882	C/T	cg26022315	chr17:47021804	SNF8	0.39	5.16	0.3	4.94e-7	Type 2 diabetes;
CESC	cis	rs2070997	0.607	rs9695221	chr9:133660295	A/G	cg11464064	chr9:133710261	ABL1	0.56	6.65	0.38	1.68e-10	Response to amphetamines;
CESC	cis	rs10504229	0.683	rs903702	chr8:58128557	T/C	cg21724239	chr8:58056113	NA	0.58	5.95	0.34	8.29e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs881375	0.678	rs9886724	chr9:123665019	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.52	7.66	0.43	3.56e-13	Rheumatoid arthritis;
CESC	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg14159672	chr1:205819179	PM20D1	0.48	6.94	0.39	3.01e-11	Menarche (age at onset);
CESC	cis	rs597539	0.652	rs478647	chr11:68700424	C/T	cg01988459	chr11:68622903	NA	-0.45	-6.43	-0.37	5.81e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs35306767	0.761	rs12770910	chr10:1050318	A/G	cg20503657	chr10:835505	NA	0.69	6.31	0.36	1.19e-9	Eosinophil percentage of granulocytes;
CESC	cis	rs3087591	0.922	rs757383	chr17:29596045	C/G	cg24425628	chr17:29625626	OMG;NF1	0.42	5.14	0.3	5.26e-7	Hip circumference;
CESC	cis	rs7659604	0.518	rs17452156	chr4:122733623	T/C	cg20573242	chr4:122745356	CCNA2	0.62	7.46	0.42	1.22e-12	Type 2 diabetes;
CESC	cis	rs9303401	0.614	rs35057477	chr17:57097064	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.98	12.37	0.61	4.77e-28	Cognitive test performance;
CESC	cis	rs1030877	0.515	rs2679893	chr2:105909554	A/G	cg02079111	chr2:105885981	TGFBRAP1	0.47	6.21	0.36	2.08e-9	Obesity-related traits;
CESC	cis	rs5769765	0.908	rs4824109	chr22:50271460	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	0.44	5.07	0.3	7.31e-7	Schizophrenia;
CESC	cis	rs9311474	1.000	rs6445358	chr3:52308845	C/G	cg18099408	chr3:52552593	STAB1	-0.3	-5.24	-0.31	3.35e-7	Electroencephalogram traits;
CESC	cis	rs6728642	0.572	rs13403225	chr2:97600827	A/G	cg26665480	chr2:98280029	ACTR1B	-0.69	-8.45	-0.46	1.95e-15	Bipolar disorder lithium response (continuous) or schizophrenia;
CESC	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg14159672	chr1:205819179	PM20D1	0.68	10.79	0.55	9.86e-23	Monocyte percentage of white cells;
CESC	cis	rs2404602	0.669	rs17464903	chr15:77195486	A/G	cg22467129	chr15:76604101	ETFA	-0.36	-5.48	-0.32	1e-7	Blood metabolite levels;
CESC	cis	rs34172651	0.517	rs2547040	chr16:24736408	G/C	cg04756594	chr16:24857601	SLC5A11	-0.48	-5.77	-0.33	2.22e-8	Intelligence (multi-trait analysis);
CESC	cis	rs2228479	0.850	rs17226428	chr16:89842884	T/A	cg14709524	chr16:89940631	TCF25	0.9	6.7	0.38	1.25e-10	Skin colour saturation;
CESC	cis	rs35306767	0.903	rs12778891	chr10:950130	T/A	cg26597838	chr10:835615	NA	0.91	9.79	0.52	1.66e-19	Eosinophil percentage of granulocytes;
CESC	cis	rs6912958	0.684	rs2787893	chr6:88387359	C/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.53	-7.08	-0.4	1.31e-11	Monocyte percentage of white cells;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18767321	chr22:39096505	JOSD1	0.67	7.86	0.43	9.98e-14	Gut microbiome composition (summer);
CESC	trans	rs561341	0.941	rs2428338	chr17:30299629	T/C	cg27661571	chr11:113659931	NA	-0.69	-6.97	-0.39	2.54e-11	Hip circumference adjusted for BMI;
CESC	cis	rs7618915	0.547	rs62253733	chr3:52653414	A/G	cg07507251	chr3:52567010	NT5DC2	0.41	7.2	0.4	6.38e-12	Bipolar disorder;
CESC	cis	rs12137294	0.829	rs1172154	chr1:205220639	T/G	cg21643547	chr1:205240462	TMCC2	-0.34	-5.46	-0.32	1.1e-7	Red cell distribution width;
CESC	cis	rs2204008	0.728	rs12369538	chr12:38443942	C/T	cg13010199	chr12:38710504	ALG10B	0.46	5.9	0.34	1.1e-8	Bladder cancer;
CESC	cis	rs1862618	0.641	rs252893	chr5:56224714	T/C	cg24549020	chr5:56110836	MAP3K1	0.46	5.67	0.33	3.64e-8	Initial pursuit acceleration;
CESC	cis	rs6963495	0.818	rs73190187	chr7:105164401	A/T	cg02135003	chr7:105160482	PUS7	-0.47	-5.59	-0.33	5.51e-8	Bipolar disorder (body mass index interaction);
CESC	cis	rs61869271	0.871	rs6585309	chr10:116730337	A/G	cg23260525	chr10:116636907	FAM160B1	-0.29	-5.21	-0.31	3.73e-7	Tonsillectomy;
CESC	cis	rs2235642	0.592	rs743963	chr16:1657350	A/T	cg03771183	chr16:1608904	IFT140	0.39	5.45	0.32	1.14e-7	Coronary artery disease;
CESC	cis	rs2760061	0.545	rs1745423	chr1:228224153	G/T	cg18477163	chr1:228402036	OBSCN	-0.31	-5.31	-0.31	2.31e-7	Diastolic blood pressure;
CESC	cis	rs10504229	1.000	rs67705655	chr8:58177688	G/A	cg22535103	chr8:58192502	C8orf71	-1.05	-13.27	-0.63	3.63e-31	Developmental language disorder (linguistic errors);
CESC	cis	rs9916302	0.706	rs4516267	chr17:37471482	G/T	cg07936489	chr17:37558343	FBXL20	0.92	10.37	0.54	2.23e-21	Glomerular filtration rate (creatinine);
CESC	cis	rs514406	0.893	rs499195	chr1:53344907	C/T	cg16325326	chr1:53192061	ZYG11B	0.89	14.86	0.67	9.59e-37	Monocyte count;
CESC	cis	rs67311347	1.000	rs4973989	chr3:40451543	C/T	cg24209194	chr3:40518798	ZNF619	0.5	6.13	0.35	3.1e-9	Renal cell carcinoma;
CESC	cis	rs72781680	0.560	rs72781698	chr2:24271506	C/T	cg06627628	chr2:24431161	ITSN2	-0.65	-6.09	-0.35	3.92e-9	Lymphocyte counts;
CESC	cis	rs897984	0.762	rs11150601	chr16:30977799	G/A	cg02466173	chr16:30829666	NA	0.47	7.92	0.44	6.36e-14	Dementia with Lewy bodies;
CESC	cis	rs9311474	0.508	rs4687629	chr3:52615227	G/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.33	6.0	0.35	6.5e-9	Electroencephalogram traits;
CESC	cis	rs6460942	1.000	rs17668923	chr7:12302873	A/T	cg02935154	chr7:12443704	VWDE	-0.51	-5.53	-0.32	7.73e-8	Coronary artery disease;
CESC	cis	rs1790761	0.520	rs7124513	chr11:67395714	C/T	cg14500267	chr11:67383377	NA	-0.35	-5.53	-0.32	7.74e-8	Mean corpuscular volume;
CESC	cis	rs6032067	0.852	rs6032053	chr20:43829935	G/T	cg11264863	chr20:43835661	SEMG1	0.48	5.29	0.31	2.56e-7	Blood protein levels;
CESC	cis	rs1552244	0.554	rs7638846	chr3:10048601	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.57	-7.44	-0.42	1.37e-12	Alzheimer's disease;
CESC	cis	rs6665290	0.904	rs1343744	chr1:227183022	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.17	-26.61	-0.85	8.35e-77	Myeloid white cell count;
CESC	cis	rs763014	0.898	rs8060585	chr16:635794	C/G	cg09263875	chr16:632152	PIGQ	0.68	11.61	0.58	1.81e-25	Height;
CESC	cis	rs4849845	0.849	rs3889224	chr2:121024419	A/G	cg24070213	chr2:121070622	NA	0.39	5.04	0.3	8.71e-7	Mean platelet volume;
CESC	cis	rs611744	0.870	rs685358	chr8:109161413	T/C	cg21045802	chr8:109455806	TTC35	0.47	5.8	0.34	1.92e-8	Dupuytren's disease;
CESC	cis	rs7666738	0.830	rs6843777	chr4:98866635	T/A	cg17366294	chr4:99064904	C4orf37	0.54	7.36	0.41	2.3e-12	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6714710	0.580	rs11692470	chr2:98520564	T/C	cg26665480	chr2:98280029	ACTR1B	0.6	8.14	0.45	1.57e-14	Posterior cortical atrophy and Alzheimer's disease;
CESC	cis	rs10791097	0.694	rs4457753	chr11:130755575	A/G	cg12179176	chr11:130786555	SNX19	0.65	10.12	0.53	1.49e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs17711722	0.675	rs6947132	chr7:65273495	G/A	cg06456125	chr7:65229604	NA	-0.44	-5.77	-0.33	2.23e-8	Calcium levels;
CESC	cis	rs2635047	0.811	rs12956009	chr18:44768024	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.45	5.95	0.34	8.42e-9	Educational attainment;
CESC	trans	rs1728785	1.000	rs698712	chr16:68561879	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.59	7.23	0.41	5.24e-12	Ulcerative colitis;
CESC	cis	rs13382862	0.823	rs12710743	chr2:20880714	T/C	cg12334488	chr2:20871173	GDF7	-0.37	-5.58	-0.32	5.86e-8	Abdominal aortic aneurysm;
CESC	cis	rs1153858	1.000	rs1719247	chr15:45620985	C/T	cg21132104	chr15:45694354	SPATA5L1	0.78	10.38	0.54	2.12e-21	Homoarginine levels;
CESC	cis	rs11122272	0.735	rs2749717	chr1:231489353	G/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.47	-6.27	-0.36	1.48e-9	Hemoglobin concentration;
CESC	cis	rs1799949	1.000	rs12952790	chr17:41299607	A/G	cg05368731	chr17:41323189	NBR1	0.8	11.27	0.57	2.51e-24	Menopause (age at onset);
CESC	cis	rs2576037	0.526	rs1789152	chr18:44433092	G/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.32	5.16	0.3	4.85e-7	Personality dimensions;
CESC	trans	rs17116334	1.000	rs17116334	chr11:113961762	C/T	cg12368752	chr11:117800233	TMPRSS13	0.32	6.28	0.36	1.37e-9	Conduct disorder (maternal expressed emotions interaction);
CESC	cis	rs79387448	0.638	rs116055209	chr2:103032189	C/T	cg09003973	chr2:102972529	NA	0.97	7.69	0.43	2.98e-13	Gut microbiota (bacterial taxa);
CESC	cis	rs36051895	0.658	rs10974914	chr9:5014332	C/T	cg02405213	chr9:5042618	JAK2	-0.46	-5.72	-0.33	2.82e-8	Pediatric autoimmune diseases;
CESC	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	7.61	0.42	4.95e-13	Prudent dietary pattern;
CESC	cis	rs1003719	0.762	rs3787780	chr21:38462614	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.63	8.62	0.47	6.19e-16	Eye color traits;
CESC	cis	rs2635047	0.638	rs16954999	chr18:44610718	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.4	5.53	0.32	7.48e-8	Educational attainment;
CESC	cis	rs6967414	0.786	rs6948965	chr7:6758547	G/A	cg00387323	chr7:6746715	ZNF12	0.61	5.77	0.33	2.21e-8	Hematocrit;Hemoglobin concentration;
CESC	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.65	0.38	1.71e-10	Prudent dietary pattern;
CESC	trans	rs1421898	0.685	rs6556362	chr5:158157593	A/T	cg19069039	chr12:52238665	NA	-0.51	-6.07	-0.35	4.31e-9	Inflammatory skin disease;
CESC	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	22.02	0.8	8.62e-62	Prudent dietary pattern;
CESC	cis	rs897984	0.609	rs17839567	chr16:31057945	A/G	cg00531865	chr16:30841666	NA	-0.38	-5.43	-0.32	1.29e-7	Dementia with Lewy bodies;
CESC	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg26338869	chr17:61819248	STRADA	0.73	9.65	0.51	4.47e-19	Prudent dietary pattern;
CESC	cis	rs7527798	0.592	rs960088	chr1:207827067	A/C	cg21110645	chr1:207815933	NA	-0.33	-5.87	-0.34	1.31e-8	Erythrocyte sedimentation rate;
CESC	cis	rs801193	0.569	rs7782587	chr7:66166472	C/T	cg11764359	chr7:65958608	NA	0.74	10.72	0.55	1.66e-22	Aortic root size;
CESC	cis	rs2243480	1.000	rs35421653	chr7:65363429	C/A	cg12463550	chr7:65579703	CRCP	0.7	5.42	0.32	1.33e-7	Diabetic kidney disease;
CESC	cis	rs910316	0.935	rs175076	chr14:75505486	A/G	cg11812906	chr14:75593930	NEK9	-0.86	-14.27	-0.66	1.16e-34	Height;
CESC	cis	rs524023	0.629	rs480617	chr11:64478320	C/T	cg07220939	chr11:64358617	SLC22A12	-0.34	-5.11	-0.3	6.05e-7	Urate levels in obese individuals;
CESC	cis	rs1538970	0.774	rs67683090	chr1:45977803	T/G	cg06784218	chr1:46089804	CCDC17	0.37	5.9	0.34	1.11e-8	Platelet count;
CESC	cis	rs2066819	1.000	rs11575232	chr12:56744422	G/A	cg26734620	chr12:56694298	CS	0.98	5.94	0.34	8.73e-9	Psoriasis vulgaris;
CESC	cis	rs12926788	0.689	rs1862450	chr16:24856775	A/G	cg00339695	chr16:24857497	SLC5A11	-0.49	-6.04	-0.35	5.17e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs2299587	0.545	rs12543739	chr8:17756229	C/T	cg08627089	chr8:17753878	FGL1	-0.38	-5.52	-0.32	8.01e-8	Economic and political preferences;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03361557	chr19:19774500	ATP13A1	0.55	6.82	0.39	6.3e-11	Gut microbiome composition (summer);
CESC	cis	rs7264396	0.563	rs2425094	chr20:34306974	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.63	6.75	0.38	9.35e-11	Total cholesterol levels;
CESC	cis	rs6701037	1.000	rs12747817	chr1:175118895	C/T	cg00321850	chr1:175162397	KIAA0040	-0.42	-5.91	-0.34	1.02e-8	Alcohol dependence;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg04013959	chr19:16739443	MED26	-0.51	-6.3	-0.36	1.21e-9	Asthma;
CESC	cis	rs17253792	0.822	rs76264681	chr14:56060447	T/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.85	6.13	0.35	3.15e-9	Putamen volume;
CESC	cis	rs72945132	0.825	rs58532402	chr11:70189491	C/T	cg14191688	chr11:70257035	CTTN	0.41	5.13	0.3	5.6e-7	Coronary artery disease;
CESC	cis	rs761746	0.881	rs12484606	chr22:31937476	C/T	cg25791279	chr22:32026902	PISD	-0.52	-6.01	-0.35	6.1e-9	Intelligence;
CESC	cis	rs9595066	0.627	rs4942287	chr13:44734696	C/T	cg04068111	chr13:44716778	NA	0.4	5.59	0.33	5.51e-8	Schizophrenia;
CESC	cis	rs6952808	0.689	rs11771625	chr7:2050401	C/T	cg05863683	chr7:1912471	MAD1L1	0.48	7.08	0.4	1.29e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs2404602	0.583	rs3759853	chr15:76587777	C/T	cg22467129	chr15:76604101	ETFA	-0.37	-5.64	-0.33	4.4e-8	Blood metabolite levels;
CESC	cis	rs36051895	0.623	rs10120337	chr9:5243511	G/A	cg02405213	chr9:5042618	JAK2	-0.6	-7.21	-0.41	5.78e-12	Pediatric autoimmune diseases;
CESC	cis	rs13191362	1.000	rs67747005	chr6:163150845	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.71	7.37	0.41	2.11e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs4948102	0.731	rs7800001	chr7:56072010	T/C	cg09872392	chr7:56161020	PHKG1	-0.42	-6.46	-0.37	4.96e-10	Plasma homocysteine levels (post-methionine load test);
CESC	cis	rs6430585	0.527	rs6753232	chr2:136436317	C/T	cg07169764	chr2:136633963	MCM6	-1.02	-11.43	-0.57	7.47e-25	Corneal structure;
CESC	cis	rs3733585	0.664	rs28602527	chr4:9958327	G/A	cg11266682	chr4:10021025	SLC2A9	-0.6	-11.2	-0.57	4.42e-24	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs763121	0.819	rs5750658	chr22:39060917	C/T	cg14440974	chr22:39074834	NA	-0.4	-5.5	-0.32	9.03e-8	Menopause (age at onset);
CESC	cis	rs597539	0.731	rs664229	chr11:68624483	C/G	cg01988459	chr11:68622903	NA	-0.4	-5.25	-0.31	3.13e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs13095912	0.925	rs11924016	chr3:185307879	A/T	cg11274856	chr3:185301563	NA	0.37	5.83	0.34	1.57e-8	Systolic blood pressure;
CESC	trans	rs7672847	0.547	rs72974775	chr4:170524429	G/C	cg19308436	chr1:237949471	RYR2	0.57	6.33	0.36	1.04e-9	Subjective well-being;
CESC	cis	rs9393777	0.623	rs9358948	chr6:26483806	G/A	cg12826209	chr6:26865740	GUSBL1	0.65	6.85	0.39	5.16e-11	Intelligence (multi-trait analysis);
CESC	cis	rs3008870	1.000	rs2815351	chr1:67477980	A/G	cg02640540	chr1:67518911	SLC35D1	0.48	5.27	0.31	2.77e-7	Lymphocyte percentage of white cells;
CESC	cis	rs4588572	0.643	rs1560195	chr5:77701913	A/G	cg11547950	chr5:77652471	NA	0.46	5.95	0.34	8.49e-9	Triglycerides;
CESC	cis	rs7762018	1.000	rs6904601	chr6:170131905	T/G	cg13891659	chr6:170190454	C6orf122;C6orf208	0.58	6.0	0.35	6.55e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs589448	0.538	rs622656	chr12:69753595	C/T	cg20891283	chr12:69753455	YEATS4	0.77	10.24	0.53	5.78e-21	Cerebrospinal fluid biomarker levels;
CESC	cis	rs4888262	0.545	rs7193959	chr16:74664969	T/A	cg01733217	chr16:74700730	RFWD3	0.92	12.54	0.61	1.21e-28	Testicular germ cell tumor;
CESC	cis	rs2243480	1.000	rs7795242	chr7:65390094	T/C	cg18252515	chr7:66147081	NA	-1.0	-9.22	-0.49	9.27e-18	Diabetic kidney disease;
CESC	cis	rs12477438	0.520	rs7605843	chr2:99811894	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.91	15.7	0.69	1.04e-39	Chronic sinus infection;
CESC	cis	rs10751667	0.714	rs7933889	chr11:972270	C/T	cg06064525	chr11:970664	AP2A2	-0.47	-9.13	-0.49	1.87e-17	Alzheimer's disease (late onset);
CESC	cis	rs10504229	0.906	rs903718	chr8:58167726	A/G	cg24829409	chr8:58192753	C8orf71	-0.62	-8.39	-0.46	3.01e-15	Developmental language disorder (linguistic errors);
CESC	cis	rs1348850	0.519	rs4144275	chr2:178523368	C/T	cg22681709	chr2:178499509	PDE11A	-0.49	-7.08	-0.4	1.29e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26547359	chr10:16859530	RSU1	0.68	8.08	0.44	2.33e-14	Gut microbiome composition (summer);
CESC	cis	rs12530845	1.000	rs77068811	chr7:135334571	A/G	cg23117316	chr7:135346802	PL-5283	-0.4	-5.15	-0.3	4.98e-7	Red blood cell traits;
CESC	cis	rs13266463	0.830	rs7014552	chr8:143410423	A/G	cg06454464	chr8:143427921	TSNARE1	0.4	5.27	0.31	2.8e-7	Schizophrenia;
CESC	cis	rs1862618	0.671	rs2591970	chr5:56232595	T/C	cg18230493	chr5:56204884	C5orf35	0.61	8.27	0.45	6.7e-15	Initial pursuit acceleration;
CESC	cis	rs2777491	0.957	rs6493002	chr15:41709195	C/G	cg20272979	chr15:41787780	ITPKA	0.45	6.66	0.38	1.54e-10	Ulcerative colitis;
CESC	cis	rs9902453	0.934	rs7211246	chr17:28485762	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	7.67	0.43	3.35e-13	Coffee consumption (cups per day);
CESC	trans	rs6073597	1.000	rs6031980	chr20:43714384	C/T	cg16618282	chr3:47018402	CCDC12	0.42	6.03	0.35	5.41e-9	Positive affect;
CESC	cis	rs7618501	1.000	rs11130219	chr3:49752427	C/T	cg24308560	chr3:49941425	MST1R	0.5	6.94	0.39	3.08e-11	Intelligence (multi-trait analysis);
CESC	cis	rs7666738	0.830	rs10031292	chr4:99056877	A/G	cg03467027	chr4:99064603	C4orf37	0.48	6.21	0.36	2.02e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs57083693	0.536	rs10745911	chr12:101695105	T/C	cg22051763	chr12:101673672	UTP20	-0.44	-5.5	-0.32	8.8e-8	Alcohol dependence (age at onset);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg16242888	chr9:34179479	UBAP1	-0.45	-6.42	-0.37	6.37e-10	Gambling;
CESC	cis	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg14665389	chr10:114710815	TCF7L2	0.45	5.36	0.31	1.78e-7	Breast cancer;
CESC	cis	rs11785400	1.000	rs6997670	chr8:143737915	G/A	cg24634471	chr8:143751801	JRK	0.47	6.21	0.36	2e-9	Schizophrenia;
CESC	cis	rs4713118	0.588	rs200994	chr6:27813813	A/C	cg26587870	chr6:27730563	NA	0.43	5.57	0.32	6.12e-8	Parkinson's disease;
CESC	cis	rs172166	0.694	rs1770131	chr6:28086413	C/T	cg23281280	chr6:28129359	ZNF389	0.43	6.41	0.37	6.55e-10	Cardiac Troponin-T levels;
CESC	cis	rs4423214	0.959	rs12793224	chr11:71168710	G/A	cg05163923	chr11:71159392	DHCR7	0.77	10.41	0.54	1.69e-21	Vitamin D levels;
CESC	trans	rs3942852	0.524	rs7118665	chr11:48078427	C/A	cg15704280	chr7:45808275	SEPT13	0.77	9.66	0.51	4.23e-19	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs7091068	0.616	rs10748611	chr10:95482761	A/C	cg20715218	chr10:95462985	C10orf4	0.5	5.29	0.31	2.5e-7	Urinary tract infection frequency;
CESC	cis	rs4409675	0.576	rs6564	chr1:28212975	A/G	cg23691781	chr1:28212827	C1orf38	-0.29	-5.69	-0.33	3.31e-8	Corneal astigmatism;
CESC	cis	rs863345	0.584	rs1342949	chr1:158463295	C/T	cg12129480	chr1:158549410	OR10X1	-0.35	-6.97	-0.39	2.46e-11	Pneumococcal bacteremia;
CESC	cis	rs926392	0.572	rs6129157	chr20:37672247	G/T	cg16355469	chr20:37678765	NA	0.54	6.53	0.37	3.31e-10	Dialysis-related mortality;
CESC	cis	rs5167	0.506	rs11669173	chr19:45492559	G/A	cg09555818	chr19:45449301	APOC2	-0.44	-6.55	-0.37	2.92e-10	Blood protein levels;
CESC	cis	rs11676348	0.846	rs4674257	chr2:218988774	A/G	cg00012203	chr2:219082015	ARPC2	-0.56	-7.31	-0.41	3.19e-12	Ulcerative colitis;
CESC	cis	rs4713118	0.586	rs6905522	chr6:28086479	A/C	cg23161317	chr6:28129485	ZNF389	0.51	6.53	0.37	3.44e-10	Parkinson's disease;
CESC	cis	rs1577917	0.958	rs12207374	chr6:86656645	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.45	-5.86	-0.34	1.4e-8	Response to antipsychotic treatment;
CESC	cis	rs4819052	1.000	rs2297285	chr21:46705621	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.85	-10.36	-0.54	2.52e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs898097	0.841	rs55810435	chr17:80836722	G/C	cg05483915	chr17:80145575	CCDC57	0.43	5.23	0.31	3.48e-7	Breast cancer;
CESC	cis	rs1348850	0.872	rs4893959	chr2:178400204	G/A	cg23306229	chr2:178417860	TTC30B	0.63	7.84	0.43	1.08e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs13082711	0.911	rs11718991	chr3:27452944	A/G	cg02860705	chr3:27208620	NA	0.59	7.39	0.41	1.94e-12	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CESC	cis	rs4450798	0.739	rs3856823	chr3:13742350	A/G	cg05589046	chr3:13742034	LOC285375	0.34	5.47	0.32	1.05e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs1707322	0.682	rs3014241	chr1:46087879	A/G	cg03146154	chr1:46216737	IPP	-0.81	-11.24	-0.57	3.26e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg03389907	chr1:54954187	NA	-0.42	-6.06	-0.35	4.72e-9	Gambling;
CESC	cis	rs3845702	0.736	rs72958863	chr2:180808144	C/T	cg01881094	chr2:180872142	CWC22	1.04	8.75	0.47	2.56e-16	Schizophrenia;
CESC	cis	rs478304	0.651	rs948494	chr11:65552118	G/A	cg27068330	chr11:65405492	SIPA1	-0.48	-5.76	-0.33	2.32e-8	Acne (severe);
CESC	cis	rs62432291	0.681	rs431205	chr6:159662499	A/G	cg14500486	chr6:159655392	FNDC1	-0.58	-5.82	-0.34	1.69e-8	Joint mobility (Beighton score);
CESC	cis	rs703842	1.000	rs1875124	chr12:58196802	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.71	8.96	0.48	5.78e-17	Multiple sclerosis;
CESC	trans	rs4332037	0.539	rs3823624	chr7:2110346	T/C	cg11693508	chr17:37793320	STARD3	0.67	6.79	0.38	7.32e-11	Bipolar disorder;
CESC	cis	rs9457247	1.000	rs2757047	chr6:167374489	C/T	cg07741184	chr6:167504864	NA	-0.3	-5.44	-0.32	1.19e-7	Crohn's disease;
CESC	trans	rs6499129	0.571	rs9940665	chr16:67289841	C/T	cg17013778	chr10:135130084	NA	-0.75	-6.17	-0.35	2.56e-9	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs1215050	0.791	rs165241	chr4:98681112	C/T	cg05340658	chr4:99064831	C4orf37	0.47	6.04	0.35	5.08e-9	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs1878931	0.535	rs10852706	chr16:3412582	G/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.73	9.08	0.49	2.54e-17	Body mass index (adult);
CESC	cis	rs12200560	0.505	rs4839849	chr6:97076673	T/C	cg06623918	chr6:96969491	KIAA0776	0.5	6.42	0.37	6.42e-10	Coronary heart disease;
CESC	cis	rs7666738	0.830	rs7673385	chr4:99024922	T/G	cg05340658	chr4:99064831	C4orf37	0.81	12.59	0.61	8.13e-29	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg07308232	chr7:1071921	C7orf50	-0.59	-8.46	-0.46	1.88e-15	Longevity;Endometriosis;
CESC	cis	rs8180040	0.726	rs4682844	chr3:46982737	T/C	cg27129171	chr3:47204927	SETD2	-0.64	-9.04	-0.49	3.43e-17	Colorectal cancer;
CESC	cis	rs736408	0.511	rs12637632	chr3:52708073	A/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.38	6.7	0.38	1.23e-10	Bipolar disorder;
CESC	cis	rs4604732	0.631	rs76761880	chr1:247626377	T/A	cg12758973	chr1:247694275	LOC148824;OR2C3	0.51	6.36	0.36	8.65e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs6089584	0.861	rs2180302	chr20:60576369	A/G	cg06108461	chr20:60628389	TAF4	-0.84	-12.48	-0.61	1.92e-28	Body mass index;
CESC	cis	rs7107174	1.000	rs1318241	chr11:77930792	C/T	cg02023728	chr11:77925099	USP35	0.52	6.68	0.38	1.38e-10	Testicular germ cell tumor;
CESC	cis	rs6424115	0.965	rs2502986	chr1:24135292	G/T	cg15997130	chr1:24165203	NA	0.43	5.94	0.34	9.1e-9	Immature fraction of reticulocytes;
CESC	cis	rs2991971	0.810	rs2036021	chr1:45901370	G/A	cg24296786	chr1:45957014	TESK2	0.59	8.38	0.46	3.24e-15	High light scatter reticulocyte count;
CESC	cis	rs7818688	1.000	rs28378156	chr8:96027127	C/T	cg16049864	chr8:95962084	TP53INP1	0.6	5.77	0.33	2.25e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg12506980	chr3:20227397	SGOL1	-0.47	-6.32	-0.36	1.07e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs4835473	0.932	rs11721700	chr4:144745417	G/C	cg25736465	chr4:144833511	NA	-0.35	-5.43	-0.32	1.28e-7	Immature fraction of reticulocytes;
CESC	cis	rs10504229	0.679	rs16921687	chr8:58053514	T/C	cg24829409	chr8:58192753	C8orf71	-0.5	-6.27	-0.36	1.43e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs9899728	0.539	rs12938889	chr17:73039929	A/C	cg27626185	chr17:73056755	KCTD2	0.97	8.53	0.46	1.14e-15	Alzheimer's disease or small vessel stroke;
CESC	cis	rs9443645	0.901	rs9443622	chr6:79582790	C/T	cg05283184	chr6:79620031	NA	-0.43	-6.56	-0.37	2.85e-10	Intelligence (multi-trait analysis);
CESC	cis	rs17253792	0.822	rs113350960	chr14:56087713	G/A	cg01858014	chr14:56050164	KTN1	-0.83	-7.03	-0.4	1.7e-11	Putamen volume;
CESC	cis	rs2072732	0.861	rs77840846	chr1:2968983	G/C	cg15211996	chr1:2936768	ACTRT2	0.33	5.21	0.3	3.74e-7	Plateletcrit;
CESC	trans	rs1814175	0.935	rs28586931	chr11:49693872	G/A	cg03929089	chr4:120376271	NA	-0.87	-13.35	-0.63	1.93e-31	Height;
CESC	cis	rs854765	0.647	rs2974998	chr17:17995619	A/G	cg16928487	chr17:17741425	SREBF1	-0.53	-8.7	-0.47	3.48e-16	Total body bone mineral density;
CESC	cis	rs6952808	0.689	rs1107591	chr7:2041638	G/A	cg22963979	chr7:1858916	MAD1L1	-0.38	-5.27	-0.31	2.81e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs7772486	0.790	rs6917135	chr6:146152426	T/C	cg05347473	chr6:146136440	FBXO30	0.55	7.26	0.41	4.4e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9443645	0.869	rs10943585	chr6:79502409	G/C	cg05283184	chr6:79620031	NA	-0.43	-6.67	-0.38	1.52e-10	Intelligence (multi-trait analysis);
CESC	cis	rs4604732	0.631	rs12039642	chr1:247624898	A/G	cg12758973	chr1:247694275	LOC148824;OR2C3	0.51	6.36	0.36	8.65e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs3785574	1.000	rs3785574	chr17:61763185	T/C	cg06420487	chr17:61919686	SMARCD2	0.48	5.54	0.32	7.15e-8	Height;
CESC	cis	rs854765	0.693	rs9907287	chr17:17774118	C/T	cg16928487	chr17:17741425	SREBF1	0.55	9.59	0.51	7.06e-19	Total body bone mineral density;
CESC	cis	rs3008870	0.755	rs10749766	chr1:67376921	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.64	8.41	0.46	2.52e-15	Lymphocyte percentage of white cells;
CESC	cis	rs13256369	0.826	rs7846050	chr8:8575669	A/G	cg18904891	chr8:8559673	CLDN23	0.67	7.92	0.44	6.42e-14	Obesity-related traits;
CESC	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg23131131	chr22:24373011	LOC391322	-0.69	-9.69	-0.51	3.38e-19	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs9858542	0.953	rs9827021	chr3:49514764	C/A	cg03060546	chr3:49711283	APEH	-0.55	-6.28	-0.36	1.34e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs875971	0.862	rs2088655	chr7:65795711	T/C	cg18876405	chr7:65276391	NA	-0.53	-7.27	-0.41	4.11e-12	Aortic root size;
CESC	cis	rs208520	0.690	rs12202805	chr6:66703903	A/G	cg07460842	chr6:66804631	NA	-0.94	-13.0	-0.62	3.26e-30	Exhaled nitric oxide output;
CESC	cis	rs1797081	0.542	rs2603796	chr10:16871456	C/T	cg23933602	chr10:16859644	RSU1	0.72	10.3	0.53	3.93e-21	Platelet distribution width;
CESC	cis	rs2425143	1.000	rs17093026	chr20:34318911	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.73	6.78	0.38	7.95e-11	Blood protein levels;
CESC	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg18402987	chr7:1209562	NA	0.75	7.5	0.42	9.63e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs11122272	0.701	rs2790887	chr1:231523724	G/C	cg06096015	chr1:231504339	EGLN1	0.43	6.18	0.35	2.46e-9	Hemoglobin concentration;
CESC	cis	rs10504229	0.683	rs35889486	chr8:58117749	T/A	cg24829409	chr8:58192753	C8orf71	-0.58	-7.2	-0.4	6.31e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs7542091	0.635	rs985431	chr1:210043948	A/T	cg09509183	chr1:209979624	IRF6	0.4	5.78	0.33	2.12e-8	Monobrow;
CESC	cis	rs1348850	0.574	rs4893834	chr2:178442288	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.52	-5.13	-0.3	5.66e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs7089973	0.624	rs17586888	chr10:116598121	T/C	cg25233709	chr10:116636983	FAM160B1	0.38	5.97	0.34	7.44e-9	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs9905704	0.718	rs193391	chr17:56672944	T/C	cg12560992	chr17:57184187	TRIM37	0.64	5.98	0.34	7.36e-9	Testicular germ cell tumor;
CESC	cis	rs6540559	0.673	rs7550857	chr1:209956542	C/A	cg25204440	chr1:209979598	IRF6	0.65	6.65	0.38	1.67e-10	Cleft lip with or without cleft palate;
CESC	cis	rs11785400	1.000	rs4736342	chr8:143735190	A/G	cg10596483	chr8:143751796	JRK	0.43	5.51	0.32	8.49e-8	Schizophrenia;
CESC	cis	rs7786877	0.723	rs11764045	chr7:100212754	C/T	cg16850897	chr7:100343110	ZAN	-0.56	-5.87	-0.34	1.29e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	trans	rs16958440	1.000	rs60228288	chr18:44640412	G/A	cg19380001	chr1:50889427	DMRTA2	-0.88	-6.07	-0.35	4.47e-9	Sitting height ratio;
CESC	cis	rs4971059	0.654	rs10157801	chr1:155120012	A/G	cg22049894	chr1:155113146	DPM3	0.43	5.68	0.33	3.5e-8	Breast cancer;
CESC	cis	rs7772486	0.686	rs9403746	chr6:146103768	C/A	cg05347473	chr6:146136440	FBXO30	-0.53	-6.93	-0.39	3.25e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs72781680	0.898	rs72788214	chr2:24087621	A/C	cg20701182	chr2:24300061	SF3B14	0.62	5.68	0.33	3.54e-8	Lymphocyte counts;
CESC	cis	rs11168618	0.626	rs11514105	chr12:48820934	G/C	cg24011408	chr12:48396354	COL2A1	0.36	5.53	0.32	7.49e-8	Adiponectin levels;
CESC	cis	rs7580658	0.864	rs4150454	chr2:128038544	T/C	cg10021288	chr2:128175891	PROC	-0.39	-6.24	-0.36	1.74e-9	Protein C levels;
CESC	cis	rs807669	0.869	rs1061325	chr22:19184095	T/C	cg02655711	chr22:19163373	SLC25A1	0.44	6.76	0.38	8.99e-11	Metabolite levels;
CESC	cis	rs7833986	0.501	rs2976012	chr8:56974343	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.61	7.55	0.42	6.89e-13	Height;
CESC	cis	rs8031584	0.541	rs2955797	chr15:31210981	A/G	cg14829155	chr15:31115871	NA	0.72	10.47	0.54	1.05e-21	Huntington's disease progression;
CESC	trans	rs11148252	0.532	rs9536185	chr13:53179801	G/A	cg18335740	chr13:41363409	SLC25A15	0.56	7.46	0.42	1.27e-12	Lewy body disease;
CESC	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg01238044	chr22:24384105	GSTT1	-0.51	-6.42	-0.37	6.25e-10	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs1448094	0.817	rs11117115	chr12:86331021	A/G	cg02569458	chr12:86230093	RASSF9	0.45	6.43	0.37	5.79e-10	Major depressive disorder;
CESC	cis	rs7605378	0.528	rs1704190	chr2:200760629	G/A	cg23649088	chr2:200775458	C2orf69	0.74	9.34	0.5	4.04e-18	Osteoporosis;
CESC	cis	rs17376456	0.825	rs10064368	chr5:93266396	C/A	cg21475434	chr5:93447410	FAM172A	0.74	6.16	0.35	2.67e-9	Diabetic retinopathy;
CESC	cis	rs116095464	0.558	rs6962	chr5:256509	G/A	cg22857025	chr5:266934	NA	-1.28	-15.48	-0.69	6.35e-39	Breast cancer;
CESC	cis	rs727505	0.954	rs1383748	chr7:124638201	A/T	cg23710748	chr7:124431027	NA	-0.44	-6.9	-0.39	3.88e-11	Lewy body disease;
CESC	cis	rs2898681	0.642	rs11538878	chr4:53728524	T/C	cg21521518	chr4:53727714	RASL11B	0.36	5.17	0.3	4.6e-7	Optic nerve measurement (cup area);
CESC	cis	rs9488822	0.651	rs3798228	chr6:116321156	T/C	cg05304507	chr6:116381966	FRK	0.26	6.56	0.37	2.82e-10	Cholesterol, total;LDL cholesterol;
CESC	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg02071572	chr4:1403502	NA	-0.37	-5.69	-0.33	3.36e-8	Longevity;
CESC	cis	rs7267979	0.844	rs6076343	chr20:25376663	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.79	-14.54	-0.67	1.28e-35	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs761746	0.960	rs5753686	chr22:31947948	G/A	cg25791279	chr22:32026902	PISD	0.49	5.61	0.33	5.09e-8	Intelligence;
CESC	cis	rs916888	0.773	rs199439	chr17:44793503	A/G	cg27589368	chr17:43923255	LOC100128977;IMP5	-0.38	-5.26	-0.31	3.01e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg16132339	chr22:24313637	DDTL;DDT	0.41	6.35	0.36	9.31e-10	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs10871290	0.650	rs12600126	chr16:74489732	A/T	cg01733217	chr16:74700730	RFWD3	-0.69	-9.37	-0.5	3.29e-18	Breast cancer;
CESC	cis	rs8114671	0.586	rs6087634	chr20:33413809	G/A	cg08999081	chr20:33150536	PIGU	0.39	5.41	0.32	1.4e-7	Height;
CESC	trans	rs1373453	0.808	rs77141535	chr12:70070304	T/G	cg19702771	chr4:82058885	PRKG2	0.75	6.12	0.35	3.4e-9	Orofacial clefts;
CESC	cis	rs7336332	0.569	rs7988412	chr13:28000282	C/T	cg22138327	chr13:27999177	GTF3A	0.66	6.48	0.37	4.53e-10	Weight;
CESC	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg18538332	chr22:24372958	LOC391322	-0.71	-10.2	-0.53	7.94e-21	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs10540	1.000	rs61876334	chr11:487201	T/C	cg03576123	chr11:487126	PTDSS2	-1.08	-10.51	-0.54	7.9e-22	Body mass index;
CESC	cis	rs367943	0.698	rs7728525	chr5:112972215	C/G	cg12552261	chr5:112820674	MCC	0.44	5.63	0.33	4.63e-8	Type 2 diabetes;
CESC	cis	rs6831352	0.879	rs1984362	chr4:100070973	G/A	cg12011299	chr4:100065546	ADH4	-0.56	-6.0	-0.35	6.4e-9	Alcohol dependence;
CESC	cis	rs4699052	0.662	rs6825489	chr4:104250184	T/C	cg16532752	chr4:104119610	CENPE	-0.41	-5.85	-0.34	1.44e-8	Testicular germ cell tumor;
CESC	cis	rs962856	0.575	rs644032	chr2:67659656	C/A	cg09028215	chr2:67624308	ETAA1	-0.41	-5.06	-0.3	7.68e-7	Pancreatic cancer;
CESC	cis	rs854765	0.618	rs9908017	chr17:17774422	C/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.5	-6.73	-0.38	1.02e-10	Total body bone mineral density;
CESC	cis	rs7927771	0.832	rs11601173	chr11:47401058	A/G	cg05585544	chr11:47624801	NA	-0.48	-7.04	-0.4	1.67e-11	Subjective well-being;
CESC	trans	rs2727020	0.757	rs7924526	chr11:49267043	G/A	cg03929089	chr4:120376271	NA	0.75	9.68	0.51	3.66e-19	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18732869	chr19:6739680	TRIP10	0.58	6.72	0.38	1.14e-10	Gut microbiome composition (summer);
CESC	cis	rs4253772	1.000	rs4253772	chr22:46627603	C/T	cg00784671	chr22:46762841	CELSR1	-0.56	-5.06	-0.3	8.02e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs7811142	0.720	rs112622797	chr7:99917416	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.87	7.08	0.4	1.28e-11	Platelet count;
CESC	cis	rs7264396	1.000	rs224418	chr20:34142527	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.55	-7.04	-0.4	1.65e-11	Total cholesterol levels;
CESC	trans	rs4950322	0.580	rs4950371	chr1:146585825	C/T	cg04954894	chr8:38089920	DDHD2	-0.58	-6.12	-0.35	3.31e-9	Protein quantitative trait loci;
CESC	cis	rs425277	0.565	rs2480711	chr1:2111376	A/G	cg24578937	chr1:2090814	PRKCZ	0.33	5.87	0.34	1.31e-8	Height;
CESC	cis	rs2635047	0.967	rs12960378	chr18:44614090	A/C	cg19077165	chr18:44547161	KATNAL2	-0.48	-6.64	-0.38	1.78e-10	Educational attainment;
CESC	cis	rs929354	0.772	rs3802117	chr7:156987000	C/T	cg05182265	chr7:156933206	UBE3C	-0.51	-7.5	-0.42	9.58e-13	Body mass index;
CESC	cis	rs9910055	0.530	rs2269906	chr17:42294337	G/T	cg13607699	chr17:42295918	UBTF	-0.8	-12.25	-0.6	1.23e-27	Total body bone mineral density;
CESC	cis	rs9287719	0.967	rs6721739	chr2:10751246	G/T	cg00105475	chr2:10696890	NA	-0.38	-5.48	-0.32	9.71e-8	Prostate cancer;
CESC	trans	rs916888	0.773	rs199534	chr17:44824213	T/G	cg27125505	chr17:43679177	LOC644172	0.47	6.14	0.35	3.08e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs1538970	0.962	rs7544178	chr1:45819069	C/T	cg05343316	chr1:45956843	TESK2	0.81	11.05	0.56	1.38e-23	Platelet count;
CESC	cis	rs2440129	0.611	rs434473	chr17:6904934	A/G	cg08946332	chr17:6899888	ALOX12	-0.47	-6.59	-0.38	2.42e-10	Tonsillectomy;
CESC	cis	rs910316	1.000	rs2300601	chr14:75639571	A/G	cg11812906	chr14:75593930	NEK9	0.86	13.72	0.64	9.57e-33	Height;
CESC	cis	rs9359856	0.564	rs72915903	chr6:90420190	A/C	cg13799429	chr6:90582589	CASP8AP2	-0.66	-6.62	-0.38	1.95e-10	Bipolar disorder;
CESC	cis	rs6433857	0.594	rs736019	chr2:181526568	A/C	cg23363182	chr2:181467187	NA	0.44	6.12	0.35	3.43e-9	Body mass index;
CESC	cis	rs3820068	0.581	rs2861387	chr1:15951296	G/A	cg16988262	chr1:15930761	NA	0.33	5.21	0.31	3.73e-7	Systolic blood pressure;
CESC	cis	rs6460942	0.915	rs6460907	chr7:12304449	G/A	cg20607287	chr7:12443886	VWDE	-0.41	-5.96	-0.34	7.94e-9	Coronary artery disease;
CESC	cis	rs2710642	0.821	rs2710639	chr2:63138963	C/T	cg17519650	chr2:63277830	OTX1	0.45	5.52	0.32	8.2e-8	LDL cholesterol levels;LDL cholesterol;
CESC	cis	rs9611565	0.592	rs80477	chr22:42001183	C/T	cg17376030	chr22:41985996	PMM1	-0.5	-5.48	-0.32	1.01e-7	Vitiligo;
CESC	cis	rs9303401	0.615	rs35288118	chr17:56600748	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.98	11.09	0.56	1.02e-23	Cognitive test performance;
CESC	cis	rs6912958	0.935	rs2179844	chr6:88165773	C/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.32	-5.3	-0.31	2.44e-7	Monocyte percentage of white cells;
CESC	cis	rs950169	1.000	rs12915234	chr15:84758301	G/A	cg17507749	chr15:85114479	UBE2QP1	0.64	7.04	0.4	1.64e-11	Schizophrenia;
CESC	cis	rs887829	0.569	rs4663963	chr2:234650193	T/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.5	-6.58	-0.37	2.54e-10	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CESC	cis	rs9926296	0.656	rs2376881	chr16:89827011	C/G	cg27121462	chr16:89883253	FANCA	0.54	6.6	0.38	2.26e-10	Vitiligo;
CESC	trans	rs3780486	0.846	rs10813954	chr9:33137596	A/C	cg20290983	chr6:43655470	MRPS18A	0.98	18.17	0.74	1.8e-48	IgG glycosylation;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg05673432	chr3:15919505	NA	0.51	6.56	0.37	2.75e-10	Fibrinogen levels;
CESC	cis	rs965469	1.000	rs6051708	chr20:3262493	A/G	cg25506879	chr20:3388711	C20orf194	-0.57	-5.88	-0.34	1.24e-8	IFN-related cytopenia;
CESC	cis	rs9649213	0.531	rs35216698	chr7:97896175	C/T	cg08684580	chr7:98029266	BAIAP2L1	-0.33	-5.15	-0.3	5.15e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7772486	0.712	rs6570726	chr6:146159460	T/C	cg05347473	chr6:146136440	FBXO30	0.46	6.48	0.37	4.39e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9291683	0.588	rs3756236	chr4:10013463	T/A	cg00071950	chr4:10020882	SLC2A9	0.91	17.5	0.73	4.16e-46	Bone mineral density;
CESC	cis	rs9811920	0.809	rs7649349	chr3:99725629	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.48	-7.99	-0.44	4.26e-14	Axial length;
CESC	cis	rs739401	0.611	rs7109088	chr11:3027485	G/T	cg08508325	chr11:3079039	CARS	-0.57	-10.83	-0.55	7.32e-23	Longevity;
CESC	cis	rs7188861	0.768	rs1646025	chr16:11379938	A/G	cg01510278	chr16:11456238	NA	0.34	5.23	0.31	3.45e-7	HDL cholesterol;
CESC	cis	rs4664308	0.618	rs17830940	chr2:160891768	T/C	cg03641300	chr2:160917029	PLA2R1	-0.59	-8.54	-0.46	1.04e-15	Idiopathic membranous nephropathy;
CESC	cis	rs561341	1.000	rs550264	chr17:30317540	G/T	cg00745463	chr17:30367425	LRRC37B	-0.8	-7.25	-0.41	4.55e-12	Hip circumference adjusted for BMI;
CESC	cis	rs36051895	0.632	rs10118930	chr9:5148278	C/T	cg02405213	chr9:5042618	JAK2	-0.53	-6.79	-0.39	7.2e-11	Pediatric autoimmune diseases;
CESC	cis	rs7666738	0.830	rs13112037	chr4:98976986	A/T	cg03467027	chr4:99064603	C4orf37	0.43	5.4	0.31	1.49e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs36051895	0.593	rs12340303	chr9:5176147	C/T	cg02405213	chr9:5042618	JAK2	-0.51	-6.5	-0.37	4.02e-10	Pediatric autoimmune diseases;
CESC	cis	rs9911578	0.967	rs4932693	chr17:57110327	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	-0.39	-5.04	-0.3	8.43e-7	Intelligence (multi-trait analysis);
CESC	cis	rs2243480	0.803	rs35480979	chr7:65357084	A/G	cg12463550	chr7:65579703	CRCP	0.68	5.73	0.33	2.72e-8	Diabetic kidney disease;
CESC	cis	rs1256061	0.654	rs1256033	chr14:64745399	A/G	cg23250157	chr14:64679961	SYNE2	0.47	6.63	0.38	1.88e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs4664293	1.000	rs6745766	chr2:160454795	G/A	cg08347373	chr2:160653686	CD302	-0.34	-5.47	-0.32	1.06e-7	Monocyte percentage of white cells;
CESC	cis	rs11608355	0.515	rs12822282	chr12:109923207	G/A	cg05360138	chr12:110035743	NA	0.81	8.75	0.47	2.52e-16	Neuroticism;
CESC	cis	rs9818941	0.824	rs1574064	chr3:157801204	C/G	cg08654915	chr3:157813417	NA	-0.43	-7.34	-0.41	2.58e-12	Height;
CESC	cis	rs1448094	0.549	rs12308898	chr12:86233678	G/A	cg02569458	chr12:86230093	RASSF9	0.52	7.41	0.41	1.67e-12	Major depressive disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10226922	chr1:153895448	GATAD2B	0.54	6.16	0.35	2.67e-9	Gut microbiome composition (summer);
CESC	cis	rs8114671	0.836	rs2038504	chr20:33648187	T/C	cg06115741	chr20:33292138	TP53INP2	-0.43	-5.15	-0.3	5.03e-7	Height;
CESC	cis	rs2236918	0.710	rs1776159	chr1:242018583	C/G	cg17736920	chr1:242011382	EXO1	0.56	7.16	0.4	8.01e-12	Menopause (age at onset);
CESC	cis	rs9399137	0.507	rs7768278	chr6:135274957	T/C	cg22676075	chr6:135203613	NA	0.53	6.83	0.39	5.83e-11	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	cis	rs116095464	0.558	rs7736600	chr5:231337	A/C	cg22857025	chr5:266934	NA	-1.28	-18.2	-0.75	1.47e-48	Breast cancer;
CESC	cis	rs875971	0.862	rs11760844	chr7:65739883	C/G	cg12463550	chr7:65579703	CRCP	-0.45	-5.72	-0.33	2.86e-8	Aortic root size;
CESC	cis	rs208520	0.690	rs1885100	chr6:66871047	C/G	cg07460842	chr6:66804631	NA	-0.99	-13.52	-0.64	4.76e-32	Exhaled nitric oxide output;
CESC	cis	rs73019876	0.901	rs2666453	chr19:22129287	A/G	cg11619707	chr19:22235551	ZNF257	-0.29	-5.45	-0.32	1.15e-7	Testicular germ cell tumor;
CESC	cis	rs919433	0.750	rs788012	chr2:198229856	A/T	cg20885578	chr2:198174922	NA	0.4	5.2	0.3	4.09e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs1218582	0.710	rs9793588	chr1:154878878	C/G	cg09359103	chr1:154839909	KCNN3	-0.65	-12.31	-0.6	7.76e-28	Prostate cancer;
CESC	cis	rs9911578	0.835	rs10853006	chr17:56489076	G/A	cg05425664	chr17:57184151	TRIM37	0.46	6.35	0.36	9.56e-10	Intelligence (multi-trait analysis);
CESC	cis	rs8112211	0.834	rs3178327	chr19:38798086	T/C	cg14299480	chr19:38876666	GGN	-0.38	-5.1	-0.3	6.56e-7	Blood protein levels;
CESC	cis	rs6951245	0.744	rs10275401	chr7:1213943	A/C	cg07092213	chr7:1199455	ZFAND2A	-0.48	-5.04	-0.3	8.48e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg01085137	chr16:48278085	LONP2	-0.45	-6.05	-0.35	4.9e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs11098499	0.954	rs11734241	chr4:120416872	A/G	cg09307838	chr4:120376055	NA	0.93	13.06	0.63	2.03e-30	Corneal astigmatism;
CESC	cis	rs1008375	0.932	rs6814465	chr4:17659034	C/T	cg02297831	chr4:17616191	MED28	0.63	8.03	0.44	3.3e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs6088580	0.570	rs6058057	chr20:33065283	G/A	cg06115741	chr20:33292138	TP53INP2	0.47	6.09	0.35	4.03e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs735396	0.770	rs2464196	chr12:121435427	G/A	cg02403541	chr12:121454288	C12orf43	0.73	10.33	0.54	2.99e-21	N-glycan levels;
CESC	cis	rs4718428	0.705	rs4717331	chr7:66378886	C/T	cg18252515	chr7:66147081	NA	-0.45	-5.09	-0.3	6.82e-7	Corneal structure;
CESC	cis	rs12477438	0.765	rs7605734	chr2:99644068	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.62	-8.67	-0.47	4.43e-16	Chronic sinus infection;
CESC	cis	rs7666738	0.753	rs9991512	chr4:99007205	T/C	cg03467027	chr4:99064603	C4orf37	0.44	5.51	0.32	8.65e-8	Colonoscopy-negative controls vs population controls;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg05904283	chr16:716021	WDR90	0.46	6.26	0.36	1.56e-9	Fibrinogen levels;
CESC	cis	rs17021463	0.555	rs7664979	chr4:95325397	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.43	-5.82	-0.34	1.65e-8	Testicular germ cell tumor;
CESC	cis	rs10791097	0.703	rs11222360	chr11:130730871	C/T	cg09137382	chr11:130731461	NA	0.39	5.99	0.35	6.65e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs9549367	0.713	rs2146750	chr13:113822530	A/G	cg00898013	chr13:113819073	PROZ	0.45	6.0	0.35	6.52e-9	Platelet distribution width;
CESC	cis	rs9612	1.000	rs8105041	chr19:44258458	A/G	cg08581076	chr19:44259116	C19orf61	0.52	6.19	0.36	2.33e-9	Exhaled nitric oxide output;
CESC	cis	rs9389248	0.690	rs6569982	chr6:135256495	C/G	cg24558204	chr6:135376177	HBS1L	0.66	9.54	0.51	9.64e-19	High light scatter reticulocyte percentage of red cells;
CESC	cis	rs1707322	1.000	rs785467	chr1:46521559	A/T	cg05343316	chr1:45956843	TESK2	-0.49	-5.89	-0.34	1.19e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs8018808	0.935	rs11159263	chr14:77930188	G/C	cg20045696	chr14:77926864	AHSA1	0.43	5.9	0.34	1.13e-8	Myeloid white cell count;
CESC	cis	rs11123610	0.520	rs66646194	chr2:3720420	G/A	cg10645314	chr2:3704589	ALLC	-0.46	-5.09	-0.3	6.83e-7	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CESC	cis	rs1475911	1.000	rs34421316	chr21:43513989	C/T	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.4	-5.78	-0.33	2.08e-8	IgG glycosylation;
CESC	cis	rs2742234	0.518	rs2505514	chr10:43633248	A/G	cg07801480	chr10:43725741	RASGEF1A	0.44	5.51	0.32	8.67e-8	Hirschsprung disease;
CESC	cis	rs5753037	0.754	rs41158	chr22:30405983	A/G	cg01021169	chr22:30184971	ASCC2	-0.37	-5.8	-0.34	1.84e-8	Type 1 diabetes;
CESC	cis	rs6762	0.719	rs1130698	chr11:838542	C/T	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.69	-9.14	-0.49	1.68e-17	Mean platelet volume;
CESC	cis	rs977987	0.778	rs4888426	chr16:75476451	G/A	cg03315344	chr16:75512273	CHST6	0.43	6.13	0.35	3.23e-9	Dupuytren's disease;
CESC	cis	rs2836950	0.545	rs11701805	chr21:40618683	T/C	cg17971929	chr21:40555470	PSMG1	-0.58	-7.4	-0.41	1.79e-12	Menarche (age at onset);
CESC	cis	rs4268898	1.000	rs10165445	chr2:24441698	C/T	cg20701182	chr2:24300061	SF3B14	-0.43	-5.28	-0.31	2.67e-7	Asthma;
CESC	cis	rs72945132	0.769	rs3781645	chr11:70190374	T/C	cg00319359	chr11:70116639	PPFIA1	0.71	6.87	0.39	4.68e-11	Coronary artery disease;
CESC	cis	rs265548	0.646	rs36692	chr19:17906839	C/T	cg16024904	chr19:17905718	B3GNT3	0.41	5.55	0.32	6.96e-8	Tumor biomarkers;
CESC	cis	rs9457247	0.663	rs12526548	chr6:167431147	C/T	cg23791538	chr6:167370224	RNASET2	-0.54	-7.26	-0.41	4.27e-12	Crohn's disease;
CESC	cis	rs854765	0.927	rs12943914	chr17:17980671	A/G	cg04398451	chr17:18023971	MYO15A	-0.65	-9.38	-0.5	3.06e-18	Total body bone mineral density;
CESC	cis	rs7618915	0.501	rs6617	chr3:52740182	C/G	cg18337363	chr3:52569053	NT5DC2	0.29	5.29	0.31	2.62e-7	Bipolar disorder;
CESC	cis	rs7666738	0.830	rs17486413	chr4:99060544	G/T	cg17366294	chr4:99064904	C4orf37	0.6	8.29	0.45	5.78e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs896854	0.936	rs10108430	chr8:95961794	C/T	cg09323728	chr8:95962352	TP53INP1	-0.43	-9.53	-0.51	1.07e-18	Type 2 diabetes;
CESC	cis	rs858239	0.539	rs3950345	chr7:23191114	T/C	cg23682824	chr7:23144976	KLHL7	0.51	6.77	0.38	8.05e-11	Cerebrospinal fluid biomarker levels;
CESC	cis	rs73206853	0.764	rs73205079	chr12:110599953	C/T	cg12870014	chr12:110450643	ANKRD13A	0.65	5.62	0.33	4.79e-8	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs9325144	0.534	rs1843887	chr12:38692380	T/C	cg26384229	chr12:38710491	ALG10B	0.59	8.76	0.47	2.33e-16	Morning vs. evening chronotype;
CESC	cis	rs6952808	0.578	rs6949478	chr7:1841342	A/G	cg04267008	chr7:1944627	MAD1L1	0.45	5.17	0.3	4.53e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs2242116	0.592	rs2290545	chr3:46967040	C/T	cg27129171	chr3:47204927	SETD2	0.47	5.31	0.31	2.36e-7	Birth weight;
CESC	cis	rs8077577	0.895	rs16960983	chr17:18104568	A/T	cg16794390	chr17:18148240	FLII	0.38	5.12	0.3	5.95e-7	Obesity-related traits;
CESC	cis	rs7666738	0.830	rs9998803	chr4:99002519	C/T	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.62e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs748404	0.697	rs530188	chr15:43545314	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.51	8.01	0.44	3.59e-14	Lung cancer;
CESC	cis	rs8077889	1.000	rs17742905	chr17:41891143	C/A	cg26893861	chr17:41843967	DUSP3	0.82	9.77	0.51	1.89e-19	Triglycerides;
CESC	cis	rs9916302	0.707	rs11078903	chr17:37631924	G/A	cg15445000	chr17:37608096	MED1	0.41	6.77	0.38	8.24e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs2273669	0.667	rs7759014	chr6:109351125	A/G	cg05315195	chr6:109294784	ARMC2	-0.67	-6.32	-0.36	1.13e-9	Prostate cancer;
CESC	cis	rs3106136	0.901	rs17623135	chr4:95213091	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.45	-6.73	-0.38	1.02e-10	Capecitabine sensitivity;
CESC	cis	rs3096299	0.874	rs3102342	chr16:89451575	T/C	cg16743903	chr16:89593216	SPG7	-0.4	-5.1	-0.3	6.48e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs1218582	0.772	rs1976559	chr1:154879788	A/T	cg16680214	chr1:154839983	KCNN3	-0.44	-6.69	-0.38	1.28e-10	Prostate cancer;
CESC	cis	rs74181299	0.750	rs1420185	chr2:65315903	A/G	cg05010058	chr2:65284262	CEP68	0.31	5.19	0.3	4.11e-7	Pulse pressure;
CESC	cis	rs7772486	0.686	rs9403739	chr6:146015357	A/G	cg05347473	chr6:146136440	FBXO30	-0.57	-7.17	-0.4	7.53e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4595586	0.563	rs2388178	chr12:39364366	T/G	cg26384229	chr12:38710491	ALG10B	0.54	7.54	0.42	7.28e-13	Morning vs. evening chronotype;
CESC	cis	rs12926788	0.689	rs7186308	chr16:24848471	A/G	cg06028605	chr16:24865363	SLC5A11	0.47	6.7	0.38	1.26e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs936229	0.861	rs7180484	chr15:75115416	G/T	cg14664628	chr15:75095509	CSK	1.03	16.93	0.72	4.22e-44	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CESC	cis	rs10504229	0.683	rs2101864	chr8:58113226	C/T	cg24829409	chr8:58192753	C8orf71	-0.59	-7.32	-0.41	2.94e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs1023500	0.505	rs134887	chr22:42674239	A/G	cg15557168	chr22:42548783	NA	-0.4	-6.09	-0.35	3.97e-9	Schizophrenia;
CESC	cis	rs1799949	1.000	rs8176220	chr17:41222462	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.45	6.22	0.36	1.9e-9	Menopause (age at onset);
CESC	cis	rs796364	0.760	rs55906940	chr2:201049386	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.72	-6.04	-0.35	5.34e-9	Schizophrenia;
CESC	cis	rs1707322	1.000	rs4390216	chr1:46266456	C/T	cg03146154	chr1:46216737	IPP	0.71	9.86	0.52	9.77e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs12973672	1.000	rs10410675	chr19:35768828	T/C	cg12095397	chr19:35769544	USF2	0.54	7.35	0.41	2.49e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs9916302	0.706	rs8075737	chr17:37727316	C/T	cg07936489	chr17:37558343	FBXL20	0.94	11.48	0.58	4.98e-25	Glomerular filtration rate (creatinine);
CESC	cis	rs2228479	1.000	rs62052180	chr16:89963289	C/G	cg14709524	chr16:89940631	TCF25	0.72	5.45	0.32	1.16e-7	Skin colour saturation;
CESC	cis	rs2952156	1.000	rs2643194	chr17:37853048	C/T	cg00129232	chr17:37814104	STARD3	-0.68	-8.53	-0.46	1.15e-15	Asthma;
CESC	cis	rs11608355	0.508	rs12822899	chr12:109800978	A/G	cg19025524	chr12:109796872	NA	-0.43	-5.37	-0.31	1.76e-7	Neuroticism;
CESC	trans	rs2965280	0.793	rs11879050	chr19:34823233	G/T	cg05799317	chr6:165723796	C6orf118	0.81	6.0	0.35	6.45e-9	Colorectal cancer;
CESC	cis	rs4561483	0.831	rs8052900	chr16:11940390	T/C	cg08843971	chr16:11963173	GSPT1	0.38	5.09	0.3	6.71e-7	Testicular germ cell tumor;
CESC	cis	rs3733585	0.588	rs6449154	chr4:9956404	C/T	cg11266682	chr4:10021025	SLC2A9	-0.59	-11.16	-0.57	5.9e-24	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs12220238	0.822	rs7919517	chr10:76111355	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.54	5.21	0.3	3.89e-7	Soluble interleukin-2 receptor subunit alpha;
CESC	cis	rs7618501	0.633	rs2526748	chr3:50080439	A/G	cg24110177	chr3:50126178	RBM5	0.53	7.42	0.41	1.6e-12	Intelligence (multi-trait analysis);
CESC	cis	rs9905704	0.647	rs9898048	chr17:57108543	C/T	cg12560992	chr17:57184187	TRIM37	0.56	6.93	0.39	3.25e-11	Testicular germ cell tumor;
CESC	cis	rs12369635	1.000	rs11060121	chr12:129564206	C/T	cg01909103	chr12:129572610	TMEM132D	-0.68	-5.96	-0.34	8.2e-9	Schizophrenia (inflammation and infection response interaction);
CESC	cis	rs8141529	0.956	rs469989	chr22:29303595	G/C	cg02153584	chr22:29168773	CCDC117	-0.46	-5.45	-0.32	1.18e-7	Lymphocyte counts;
CESC	cis	rs9584850	0.718	rs6491427	chr13:99113166	A/G	cg22223119	chr13:99095684	FARP1	-0.37	-5.3	-0.31	2.44e-7	Neuroticism;
CESC	cis	rs2066819	1.000	rs78495928	chr12:56635080	G/C	cg26734620	chr12:56694298	CS	1.05	6.75	0.38	9.35e-11	Psoriasis vulgaris;
CESC	cis	rs36051895	0.659	rs7045342	chr9:5183892	T/C	cg02405213	chr9:5042618	JAK2	-0.54	-6.51	-0.37	3.81e-10	Pediatric autoimmune diseases;
CESC	cis	rs9443189	0.570	rs6931578	chr6:76272310	C/T	cg01950844	chr6:76311363	SENP6	0.88	9.38	0.5	3e-18	Prostate cancer;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg00416492	chr6:14211855	NA	-0.44	-6.24	-0.36	1.72e-9	Gambling;
CESC	cis	rs2455799	0.613	rs2654654	chr3:15789242	C/T	cg09340198	chr3:15902540	ANKRD28	-0.33	-5.16	-0.3	4.94e-7	Mean platelet volume;
CESC	cis	rs9457247	1.000	rs415890	chr6:167406633	C/G	cg07741184	chr6:167504864	NA	-0.3	-5.34	-0.31	2.04e-7	Crohn's disease;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg26673286	chr19:49458596	BAX	0.49	6.19	0.36	2.24e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs5756813	0.754	rs8137848	chr22:38185994	T/G	cg19894588	chr14:64061835	NA	-0.64	-8.24	-0.45	7.83e-15	Optic cup area;Vertical cup-disc ratio;
CESC	cis	rs9905704	0.633	rs2680694	chr17:56469869	T/C	cg12560992	chr17:57184187	TRIM37	-0.61	-5.75	-0.33	2.49e-8	Testicular germ cell tumor;
CESC	cis	rs68170813	0.559	rs77671232	chr7:106939202	A/G	cg02696742	chr7:106810147	HBP1	-0.54	-5.26	-0.31	2.98e-7	Coronary artery disease;
CESC	cis	rs35306767	0.715	rs17293580	chr10:1034895	T/C	cg20503657	chr10:835505	NA	0.73	6.43	0.37	5.79e-10	Eosinophil percentage of granulocytes;
CESC	cis	rs7264396	0.563	rs2425079	chr20:34298191	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.88	-10.64	-0.55	3.06e-22	Total cholesterol levels;
CESC	cis	rs763121	0.853	rs7289855	chr22:39042221	G/T	cg06022373	chr22:39101656	GTPBP1	0.88	13.45	0.64	8.75e-32	Menopause (age at onset);
CESC	cis	rs853679	0.517	rs9368553	chr6:28082265	T/C	cg12963246	chr6:28129442	ZNF389	0.56	7.63	0.42	4.26e-13	Depression;
CESC	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg09033563	chr22:24373618	LOC391322	-0.43	-5.59	-0.32	5.66e-8	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs4713118	0.662	rs149947	chr6:27972433	A/T	cg26335602	chr6:28129616	ZNF389	0.46	6.09	0.35	3.87e-9	Parkinson's disease;
CESC	cis	rs3857067	0.806	rs72665627	chr4:95111824	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.6	-9.12	-0.49	1.97e-17	QT interval;
CESC	cis	rs2979489	0.945	rs11992441	chr8:30313649	A/G	cg26383811	chr8:30366931	RBPMS	0.82	10.01	0.52	3.21e-20	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CESC	cis	rs9905704	0.846	rs304268	chr17:56799907	T/C	cg12560992	chr17:57184187	TRIM37	0.62	7.78	0.43	1.6e-13	Testicular germ cell tumor;
CESC	cis	rs116095464	0.558	rs6555058	chr5:226376	C/T	cg22857025	chr5:266934	NA	1.25	17.78	0.74	4.46e-47	Breast cancer;
CESC	trans	rs10242455	0.702	rs73711294	chr7:99088714	G/A	cg09045935	chr12:6379348	NA	0.88	6.81	0.39	6.62e-11	Blood metabolite levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15265785	chr3:156877897	CCNL1	0.56	6.76	0.38	8.52e-11	Gut microbiome composition (summer);
CESC	cis	rs9902453	0.817	rs1842026	chr17:28188111	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.65	8.21	0.45	9.9e-15	Coffee consumption (cups per day);
CESC	cis	rs875971	0.862	rs28491091	chr7:65669064	G/T	cg11764359	chr7:65958608	NA	-0.77	-10.96	-0.56	2.63e-23	Aortic root size;
CESC	cis	rs6696846	0.777	rs6664397	chr1:205051871	C/T	cg00857998	chr1:205179979	DSTYK	0.5	6.72	0.38	1.1e-10	Red blood cell count;
CESC	cis	rs7927592	0.701	rs12226585	chr11:68257861	A/T	cg20283391	chr11:68216788	NA	0.47	6.08	0.35	4.18e-9	Total body bone mineral density;
CESC	cis	rs7236492	0.532	rs8090536	chr18:77195553	C/T	cg15644404	chr18:77186268	NFATC1	-0.49	-5.57	-0.32	6.16e-8	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs9399135	0.967	rs6569990	chr6:135365818	C/T	cg22676075	chr6:135203613	NA	0.5	7.06	0.4	1.49e-11	Red blood cell count;
CESC	cis	rs769267	0.930	rs6909	chr19:19619542	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.47	6.05	0.35	5.05e-9	Tonsillectomy;
CESC	cis	rs12477438	0.520	rs1453563	chr2:99720267	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.8	12.74	0.62	2.5e-29	Chronic sinus infection;
CESC	cis	rs798766	1.000	rs3752749	chr4:1737262	T/C	cg05874882	chr4:1763078	NA	-0.56	-7.28	-0.41	3.86e-12	Bladder cancer;Urinary bladder cancer;
CESC	cis	rs6120849	1.000	rs6120849	chr20:33730387	C/T	cg24642439	chr20:33292090	TP53INP2	0.66	7.05	0.4	1.57e-11	Protein C levels;
CESC	cis	rs13191362	1.000	rs35092540	chr6:163090778	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.64	6.68	0.38	1.44e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11702503	chr19:6215254	MLLT1	-0.65	-7.34	-0.41	2.6e-12	Gut microbiome composition (summer);
CESC	cis	rs116095464	0.558	rs10076655	chr5:239464	G/C	cg12570787	chr5:219185	SDHA;CCDC127	0.51	5.32	0.31	2.18e-7	Breast cancer;
CESC	trans	rs1814175	0.817	rs80244685	chr11:49763292	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.43	-6.05	-0.35	4.99e-9	Height;
CESC	cis	rs12360000	0.797	rs12768776	chr10:1901587	C/T	cg26364871	chr10:1889757	NA	-0.39	-5.16	-0.3	4.81e-7	Metabolite levels (Dihydroxy docosatrienoic acid);
CESC	cis	rs2857078	0.772	rs4793086	chr17:42320751	C/T	cg13607699	chr17:42295918	UBTF	-0.77	-10.62	-0.55	3.61e-22	Red cell distribution width;Reticulocyte count;
CESC	cis	rs6963495	0.818	rs73192143	chr7:105202415	A/G	cg19920283	chr7:105172520	RINT1	0.68	6.27	0.36	1.47e-9	Bipolar disorder (body mass index interaction);
CESC	cis	rs4076764	0.914	rs4638099	chr1:163365521	A/G	cg24596788	chr1:163392923	NA	0.52	7.65	0.43	3.66e-13	Motion sickness;
CESC	cis	rs4704187	0.640	rs1600075	chr5:74418304	G/A	cg03227963	chr5:74354835	NA	0.31	5.7	0.33	3.22e-8	Response to amphetamines;
CESC	cis	rs10465746	0.704	rs6667468	chr1:84479507	G/A	cg10977910	chr1:84465055	TTLL7	0.41	5.09	0.3	6.72e-7	Obesity-related traits;
CESC	cis	rs9682041	0.569	rs11914970	chr3:170112307	T/G	cg11886554	chr3:170076028	SKIL	0.57	5.72	0.33	2.82e-8	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CESC	cis	rs4819052	0.851	rs2838845	chr21:46670812	A/G	cg11663144	chr21:46675770	NA	-0.61	-9.5	-0.5	1.27e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg00419759	chr1:114301964	PHTF1	0.5	6.47	0.37	4.71e-10	Systemic lupus erythematosus;
CESC	cis	rs7208859	0.623	rs11652631	chr17:29060766	A/G	cg13385521	chr17:29058706	SUZ12P	0.81	6.53	0.37	3.28e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	trans	rs1814175	0.585	rs4881661	chr11:50000117	A/G	cg03929089	chr4:120376271	NA	-0.91	-14.65	-0.67	5.08e-36	Height;
CESC	cis	rs6460942	1.000	rs6460942	chr7:12420989	T/C	cg10578991	chr7:12443926	VWDE	-0.49	-5.53	-0.32	7.51e-8	Coronary artery disease;
CESC	trans	rs11722228	0.522	rs73212817	chr4:10064011	T/C	cg26043149	chr18:55253948	FECH	0.88	10.22	0.53	6.8e-21	Gout;Urate levels;Serum uric acid levels;
CESC	cis	rs875971	0.545	rs316324	chr7:65610614	A/G	cg19163074	chr7:65112434	INTS4L2	0.46	5.05	0.3	8.07e-7	Aortic root size;
CESC	cis	rs3733585	0.699	rs6449176	chr4:9967843	G/A	cg02734326	chr4:10020555	SLC2A9	-0.39	-5.58	-0.32	5.96e-8	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs7680126	0.585	rs34768406	chr4:10118350	C/A	cg00071950	chr4:10020882	SLC2A9	-0.58	-6.05	-0.35	4.9e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	cis	rs3096299	0.781	rs2965819	chr16:89501030	G/T	cg08822215	chr16:89438651	ANKRD11	0.35	5.3	0.31	2.49e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs17433780	0.808	rs7541867	chr1:89513537	G/A	cg09516651	chr1:89888402	LOC400759	0.7	10.7	0.55	1.94e-22	Carotid intima media thickness;
CESC	cis	rs7666738	0.830	rs28810677	chr4:99043193	C/T	cg18180107	chr4:99064573	C4orf37	0.41	5.29	0.31	2.51e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg22535103	chr8:58192502	C8orf71	-0.92	-10.19	-0.53	8.81e-21	Developmental language disorder (linguistic errors);
CESC	cis	rs2425143	1.000	rs4504072	chr20:34448773	G/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.65	5.62	0.33	4.72e-8	Blood protein levels;
CESC	cis	rs921968	0.643	rs711186	chr2:219346102	A/G	cg02176678	chr2:219576539	TTLL4	-0.39	-6.81	-0.39	6.53e-11	Mean corpuscular hemoglobin concentration;
CESC	cis	rs2228479	0.850	rs62052660	chr16:89847420	T/A	cg06558623	chr16:89946397	TCF25	1.17	9.37	0.5	3.31e-18	Skin colour saturation;
CESC	cis	rs6500395	0.925	rs6500396	chr16:48625458	A/T	cg04672837	chr16:48644449	N4BP1	0.51	6.5	0.37	3.95e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs116095464	0.510	rs55750776	chr5:230467	T/C	cg12570787	chr5:219185	SDHA;CCDC127	0.53	5.69	0.33	3.34e-8	Breast cancer;
CESC	cis	rs9858542	1.000	rs9812791	chr3:49682311	G/A	cg07274523	chr3:49395745	GPX1	0.67	8.56	0.47	9.19e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs2730245	0.527	rs2036582	chr7:158701708	A/T	cg24397884	chr7:158709396	WDR60	0.68	7.16	0.4	8.17e-12	Height;
CESC	cis	rs2576037	0.583	rs501062	chr18:44411135	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.33	5.26	0.31	2.9e-7	Personality dimensions;
CESC	cis	rs4450131	0.522	rs2272005	chr10:126402100	C/T	cg20435097	chr10:126320824	FAM53B	0.28	5.08	0.3	7.28e-7	White blood cell count (basophil);
CESC	cis	rs35955747	0.738	rs2012451	chr22:31844373	A/C	cg25791279	chr22:32026902	PISD	-0.43	-5.33	-0.31	2.11e-7	Neutrophil count;Sum basophil neutrophil counts;
CESC	cis	rs9430161	0.579	rs10864486	chr1:11040979	A/G	cg27631724	chr1:11040367	C1orf127	0.44	7.61	0.42	4.72e-13	Ewing sarcoma;
CESC	cis	rs2735413	0.881	rs4888727	chr16:78077038	T/C	cg04733911	chr16:78082701	NA	-0.53	-9.01	-0.48	4.08e-17	Systolic blood pressure (alcohol consumption interaction);
CESC	cis	rs72781680	0.752	rs7578606	chr2:23902360	T/C	cg08917208	chr2:24149416	ATAD2B	1.17	10.72	0.55	1.61e-22	Lymphocyte counts;
CESC	cis	rs10504229	1.000	rs61998259	chr8:58192290	T/C	cg24829409	chr8:58192753	C8orf71	-0.76	-9.93	-0.52	5.87e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs5758659	0.652	rs133303	chr22:42395242	C/G	cg04733989	chr22:42467013	NAGA	0.42	5.59	0.32	5.71e-8	Cognitive function;
CESC	cis	rs514406	0.793	rs12081018	chr1:53217542	C/A	cg16325326	chr1:53192061	ZYG11B	-0.72	-11.9	-0.59	1.88e-26	Monocyte count;
CESC	cis	rs7666738	0.830	rs11723283	chr4:99001617	C/T	cg03467027	chr4:99064603	C4orf37	0.44	5.51	0.32	8.65e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11190604	1.000	rs2495754	chr10:102324812	C/T	cg07080220	chr10:102295463	HIF1AN	0.63	5.98	0.34	7.11e-9	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs7539409	0.651	rs969724	chr1:84300712	T/G	cg10977910	chr1:84465055	TTLL7	0.8	7.62	0.42	4.64e-13	Alzheimer's disease;
CESC	cis	rs2836950	0.520	rs2836966	chr21:40637521	A/G	cg11644478	chr21:40555479	PSMG1	-0.54	-7.14	-0.4	9.04e-12	Menarche (age at onset);
CESC	cis	rs4642101	0.765	rs3901665	chr3:12824610	C/A	cg05775895	chr3:12838266	CAND2	0.39	6.0	0.35	6.55e-9	QRS complex (12-leadsum);
CESC	cis	rs763121	0.962	rs1980455	chr22:38925719	A/C	cg06544989	chr22:39130855	UNC84B	0.44	7.91	0.44	7.2e-14	Menopause (age at onset);
CESC	cis	rs3858526	0.883	rs10769326	chr11:5934358	C/T	cg13902645	chr11:5959945	NA	-0.55	-6.56	-0.37	2.87e-10	DNA methylation (variation);
CESC	trans	rs9929218	1.000	rs4500718	chr16:68754312	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.72	-9.46	-0.5	1.72e-18	Colorectal cancer;
CESC	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.54	6.69	0.38	1.3100000000000001e-10	Prudent dietary pattern;
CESC	cis	rs853679	0.713	rs200991	chr6:27815494	A/C	cg20933634	chr6:27740509	NA	-0.52	-5.95	-0.34	8.45e-9	Depression;
CESC	cis	rs1546924	0.692	rs197374	chr1:112289983	C/T	cg23955903	chr1:112298873	DDX20;C1orf183	0.42	5.52	0.32	8.09e-8	Body mass index;
CESC	cis	rs17376456	0.825	rs13357713	chr5:93145423	T/C	cg25358565	chr5:93447407	FAM172A	1.11	10.65	0.55	2.72e-22	Diabetic retinopathy;
CESC	cis	rs4664304	0.802	rs17830307	chr2:160871799	T/C	cg03641300	chr2:160917029	PLA2R1	-0.53	-7.47	-0.42	1.2e-12	Crohn's disease;Inflammatory bowel disease;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg06429195	chr3:16646582	DAZL	0.47	6.28	0.36	1.39e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs6951245	0.706	rs28522260	chr7:1183964	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.48	-5.86	-0.34	1.34e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2742417	0.935	rs2673028	chr3:45759654	A/G	cg10512202	chr3:45649293	LIMD1	0.35	5.04	0.3	8.62e-7	Response to anti-depressant treatment in major depressive disorder;
CESC	cis	rs7692995	0.844	rs16895971	chr4:17884986	A/G	cg08925142	chr4:18023851	LCORL	-0.46	-5.07	-0.3	7.32e-7	Height;
CESC	cis	rs7178572	0.633	rs4886877	chr15:77838535	C/G	cg22256960	chr15:77711686	NA	-0.59	-7.65	-0.43	3.74e-13	Type 2 diabetes;
CESC	cis	rs4862750	0.832	rs6836426	chr4:187897837	T/G	cg03647317	chr4:187891568	NA	-0.44	-6.42	-0.37	6.16e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs932287	0.666	rs10840161	chr11:9053824	G/A	cg12365402	chr11:9010492	NRIP3	0.37	6.16	0.35	2.71e-9	Colonoscopy-negative controls vs population controls;
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg13355623	chr17:26898935	PIGS	-0.43	-6.36	-0.36	8.61e-10	Vertical cup-disc ratio;
CESC	cis	rs6500395	0.962	rs9921737	chr16:48589873	G/T	cg04672837	chr16:48644449	N4BP1	0.46	5.61	0.33	5.16e-8	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs6540559	1.000	rs2073485	chr1:209962794	G/A	cg10074409	chr1:209979377	IRF6	0.38	5.99	0.35	6.7e-9	Cleft lip with or without cleft palate;
CESC	trans	rs61931739	0.500	rs9919726	chr12:34510783	A/G	cg26384229	chr12:38710491	ALG10B	0.54	7.55	0.42	7.05e-13	Morning vs. evening chronotype;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06917548	chr19:16643283	CHERP	-0.57	-6.57	-0.37	2.65e-10	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11664809	chr8:146126282	ZNF250	-0.6	-7.1	-0.4	1.13e-11	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.785	rs11944120	chr4:99079932	A/C	cg05340658	chr4:99064831	C4orf37	0.61	7.11	0.4	1.1e-11	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4680748	0.661	rs6800659	chr3:28270669	A/G	cg15038811	chr3:28283857	CMC1	-0.36	-5.41	-0.32	1.41e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs1728785	0.901	rs12929568	chr16:68596689	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.57	7.08	0.4	1.3e-11	Ulcerative colitis;
CESC	cis	rs6736093	0.966	rs13003919	chr2:112753950	A/G	cg12686935	chr2:112915763	FBLN7	0.42	5.44	0.32	1.22e-7	Coronary artery disease;
CESC	cis	rs7605827	0.930	rs2010881	chr2:15624646	T/A	cg19274914	chr2:15703543	NA	0.36	6.49	0.37	4.08e-10	Educational attainment (years of education);
CESC	cis	rs2576037	0.526	rs626217	chr18:44429182	T/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.41	6.86	0.39	4.74e-11	Personality dimensions;
CESC	cis	rs8005677	1.000	rs8016061	chr14:23375809	A/G	cg01529538	chr14:23388837	RBM23	0.51	6.99	0.39	2.25e-11	Cognitive ability (multi-trait analysis);
CESC	cis	rs1878931	0.513	rs35160989	chr16:3405506	G/A	cg22508957	chr16:3507546	NAT15	-0.36	-5.22	-0.31	3.66e-7	Body mass index (adult);
CESC	cis	rs1799949	1.000	rs34059614	chr17:41303071	C/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.42	5.76	0.33	2.3e-8	Menopause (age at onset);
CESC	cis	rs763121	0.853	rs5757162	chr22:38993370	C/T	cg06544989	chr22:39130855	UNC84B	0.5	8.26	0.45	6.86e-15	Menopause (age at onset);
CESC	cis	rs4664308	1.000	rs6759836	chr2:160912802	C/T	cg03641300	chr2:160917029	PLA2R1	-0.67	-10.16	-0.53	1.11e-20	Idiopathic membranous nephropathy;
CESC	trans	rs1945213	0.694	rs12222077	chr11:55848116	T/A	cg03929089	chr4:120376271	NA	0.76	7.26	0.41	4.31e-12	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs7264396	0.635	rs6060696	chr20:34522060	C/T	cg17201900	chr20:34330562	RBM39	0.49	5.13	0.3	5.62e-7	Total cholesterol levels;
CESC	cis	rs873946	0.564	rs2803992	chr10:134550882	T/C	cg18305652	chr10:134549665	INPP5A	0.49	7.55	0.42	6.96e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs10504229	1.000	rs57261109	chr8:58172152	C/T	cg24829409	chr8:58192753	C8orf71	-0.76	-10.0	-0.52	3.53e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs6547741	1.000	rs13026621	chr2:27807624	G/A	cg21248554	chr2:27665150	KRTCAP3	0.25	5.08	0.3	7.23e-7	Oral cavity cancer;
CESC	trans	rs4129059	0.765	rs57047137	chr1:214708900	C/T	cg08821431	chr12:34491090	NA	0.63	6.97	0.39	2.54e-11	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs4332037	0.552	rs11773627	chr7:2002733	A/G	cg23422044	chr7:1970798	MAD1L1	-0.48	-5.21	-0.31	3.73e-7	Bipolar disorder;
CESC	cis	rs6582630	0.519	rs8189549	chr12:38245752	A/G	cg26384229	chr12:38710491	ALG10B	0.71	10.11	0.53	1.52e-20	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs9549367	0.789	rs9577220	chr13:113908294	T/A	cg00898013	chr13:113819073	PROZ	-0.52	-7.45	-0.42	1.31e-12	Platelet distribution width;
CESC	cis	rs6032067	0.777	rs13037651	chr20:43782230	C/G	cg11264863	chr20:43835661	SEMG1	0.5	5.35	0.31	1.86e-7	Blood protein levels;
CESC	cis	rs7395581	0.959	rs59663860	chr11:47276350	G/C	cg25783544	chr11:47291846	MADD	0.6	7.8	0.43	1.47e-13	HDL cholesterol;
CESC	cis	rs67311347	1.000	rs13095055	chr3:40505666	G/T	cg24209194	chr3:40518798	ZNF619	-0.58	-7.88	-0.44	8.41e-14	Renal cell carcinoma;
CESC	cis	rs35306767	0.903	rs10508208	chr10:910983	C/T	cg26597838	chr10:835615	NA	0.83	9.08	0.49	2.65e-17	Eosinophil percentage of granulocytes;
CESC	cis	rs938554	0.692	rs6449213	chr4:9994215	A/G	cg11266682	chr4:10021025	SLC2A9	-0.48	-6.15	-0.35	2.83e-9	Blood metabolite levels;
CESC	cis	rs1568889	0.838	rs7943538	chr11:28288955	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.76	12.47	0.61	2.16e-28	Bipolar disorder;
CESC	cis	rs875971	0.505	rs1167386	chr7:65513096	G/A	cg06456125	chr7:65229604	NA	-0.48	-6.34	-0.36	9.96e-10	Aortic root size;
CESC	cis	rs6665290	0.935	rs1929863	chr1:227195728	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.23	-34.09	-0.9	6.84e-99	Myeloid white cell count;
CESC	cis	rs736408	0.609	rs2268025	chr3:52795224	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.47	6.51	0.37	3.85e-10	Bipolar disorder;
CESC	cis	rs7727544	0.684	rs272874	chr5:131675046	A/G	cg24060327	chr5:131705240	SLC22A5	0.53	5.44	0.32	1.21e-7	Blood metabolite levels;
CESC	cis	rs875971	0.628	rs6974355	chr7:65841981	A/G	cg11764359	chr7:65958608	NA	0.66	8.2	0.45	1.03e-14	Aortic root size;
CESC	cis	rs748404	0.660	rs689767	chr15:43722077	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	8.13	0.45	1.61e-14	Lung cancer;
CESC	cis	rs2836950	0.501	rs4818019	chr21:40694456	T/A	cg11890956	chr21:40555474	PSMG1	-0.65	-8.96	-0.48	5.97e-17	Menarche (age at onset);
CESC	cis	rs11264213	0.681	rs79419570	chr1:36210279	G/A	cg27506609	chr1:36549197	TEKT2	0.64	5.32	0.31	2.21e-7	Schizophrenia;
CESC	cis	rs643506	0.874	rs10789849	chr11:111716070	A/C	cg17089665	chr11:111648010	NA	-0.38	-5.58	-0.32	5.97e-8	Breast cancer;
CESC	cis	rs1005277	0.579	rs2504148	chr10:38400788	A/G	cg00409905	chr10:38381863	ZNF37A	-0.47	-6.22	-0.36	1.91e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs2066819	1.000	rs2066808	chr12:56737973	A/G	cg26714650	chr12:56694279	CS	-1.22	-14.6	-0.67	8.06e-36	Psoriasis vulgaris;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg25680105	chr8:82434497	NA	0.5	6.37	0.36	8.32e-10	Fibrinogen levels;
CESC	cis	rs35275482	0.607	rs2965331	chr15:60113632	A/G	cg11160654	chr15:60369068	NA	0.34	5.05	0.3	8.14e-7	Gut microbiota (bacterial taxa);
CESC	cis	rs748404	0.697	rs491804	chr15:43560825	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.6	7.71	0.43	2.46e-13	Lung cancer;
CESC	cis	rs10504229	0.609	rs66477547	chr8:58105763	A/C	cg22535103	chr8:58192502	C8orf71	-0.77	-8.78	-0.47	2.12e-16	Developmental language disorder (linguistic errors);
CESC	cis	rs3740713	1.000	rs73438690	chr11:18461214	A/C	cg23797887	chr11:18477753	LDHAL6A	-0.54	-5.28	-0.31	2.63e-7	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs12541635	0.934	rs10955407	chr8:107020648	G/A	cg10147462	chr8:107024639	NA	0.41	5.94	0.34	8.76e-9	Age of smoking initiation;
CESC	cis	rs875971	0.767	rs12668005	chr7:65909021	T/C	cg18252515	chr7:66147081	NA	-0.47	-6.14	-0.35	3.09e-9	Aortic root size;
CESC	cis	rs7615952	0.641	rs12488180	chr3:125782236	C/T	cg15145296	chr3:125709740	NA	-0.49	-5.42	-0.32	1.31e-7	Blood pressure (smoking interaction);
CESC	cis	rs17253792	0.822	rs17683656	chr14:56053361	C/T	cg01858014	chr14:56050164	KTN1	0.86	6.8	0.39	6.73e-11	Putamen volume;
CESC	cis	rs11958404	0.932	rs72816571	chr5:157429759	C/T	cg05962755	chr5:157440814	NA	0.62	6.53	0.37	3.41e-10	IgG glycosylation;
CESC	cis	rs4919694	0.908	rs11191523	chr10:104792400	A/G	cg04362960	chr10:104952993	NT5C2	0.77	6.69	0.38	1.34e-10	Arsenic metabolism;
CESC	cis	rs2479724	0.792	rs7739064	chr6:41834037	C/A	cg08135965	chr6:41755394	TOMM6	0.4	5.46	0.32	1.07e-7	Menarche (age at onset);
CESC	cis	rs5769765	0.955	rs9616204	chr22:50303530	T/C	cg03033257	chr22:50311977	ALG12;CRELD2	0.52	5.25	0.31	3.11e-7	Schizophrenia;
CESC	cis	rs6964587	1.000	rs2888851	chr7:91648341	G/A	cg17063962	chr7:91808500	NA	0.58	8.02	0.44	3.36e-14	Breast cancer;
CESC	cis	rs7605378	0.964	rs2689763	chr2:200689555	G/A	cg23649088	chr2:200775458	C2orf69	0.53	6.88	0.39	4.19e-11	Osteoporosis;
CESC	cis	rs17376456	0.825	rs55724660	chr5:93276636	A/G	cg21475434	chr5:93447410	FAM172A	0.77	6.36	0.36	8.6e-10	Diabetic retinopathy;
CESC	cis	rs2836974	0.568	rs4816620	chr21:40613786	A/G	cg17971929	chr21:40555470	PSMG1	-0.85	-12.37	-0.6	4.79e-28	Cognitive function;
CESC	cis	rs6952809	0.504	rs1978169	chr7:2434522	G/A	cg25507518	chr7:2405875	EIF3B	0.44	5.04	0.3	8.58e-7	Multiple sclerosis;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg21940081	chr2:131103235	IMP4	0.49	6.42	0.37	6.18e-10	Fibrinogen levels;
CESC	trans	rs2727020	0.554	rs7111711	chr11:49557880	G/A	cg15704280	chr7:45808275	SEPT13	-0.82	-9.94	-0.52	5.55e-20	Coronary artery disease;
CESC	cis	rs3820068	0.608	rs10927840	chr1:16045250	A/G	cg13390004	chr1:15929781	NA	0.34	5.23	0.31	3.48e-7	Systolic blood pressure;
CESC	cis	rs12597458	0.763	rs3213422	chr16:72042682	A/C	cg16558253	chr16:72132732	DHX38	0.41	5.82	0.34	1.66e-8	Prostate cancer;
CESC	cis	rs921968	0.565	rs35358516	chr2:219625723	A/C	cg02176678	chr2:219576539	TTLL4	-0.45	-7.83	-0.43	1.15e-13	Mean corpuscular hemoglobin concentration;
CESC	cis	rs854765	0.647	rs854808	chr17:18006634	C/T	cg16928487	chr17:17741425	SREBF1	-0.54	-8.8	-0.48	1.78e-16	Total body bone mineral density;
CESC	cis	rs35306767	0.903	rs35370435	chr10:898205	T/C	cg10556349	chr10:835070	NA	0.75	6.28	0.36	1.34e-9	Eosinophil percentage of granulocytes;
CESC	cis	rs9796	0.621	rs2899013	chr15:41492283	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.45	-6.61	-0.38	2.13e-10	Menopause (age at onset);
CESC	cis	rs6695640	0.820	rs2800686	chr1:17763312	C/T	cg01904812	chr1:17746340	RCC2	-0.35	-5.15	-0.3	5.12e-7	Mean platelet volume;
CESC	cis	rs9300255	0.639	rs1716171	chr12:123716376	C/T	cg19016782	chr12:123741754	C12orf65	-0.5	-7.1	-0.4	1.18e-11	Neutrophil percentage of white cells;
CESC	cis	rs3733585	0.673	rs6449156	chr4:9956712	G/C	cg11266682	chr4:10021025	SLC2A9	-0.58	-10.84	-0.55	6.77e-23	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs10771431	1.000	rs10771431	chr12:9380859	C/T	cg08997352	chr12:9597637	DDX12	-0.61	-8.1	-0.45	2e-14	Breast size;
CESC	cis	rs1395	0.744	rs1122227	chr2:27544285	C/T	cg22903471	chr2:27725779	GCKR	-0.51	-6.25	-0.36	1.66e-9	Blood metabolite levels;
CESC	trans	rs11722228	0.522	rs2241468	chr4:10113905	G/A	cg26043149	chr18:55253948	FECH	0.99	11.73	0.58	7.34e-26	Gout;Urate levels;Serum uric acid levels;
CESC	cis	rs72615157	0.539	rs2261360	chr7:99692993	G/T	cg22004693	chr7:99632812	ZKSCAN1	0.43	5.41	0.32	1.44e-7	Lung function (FEV1/FVC);
CESC	cis	rs12410462	0.681	rs12401677	chr1:227608577	T/C	cg23173402	chr1:227635558	NA	0.74	6.78	0.38	7.82e-11	Major depressive disorder;
CESC	cis	rs2576037	0.583	rs501882	chr18:44411066	A/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.34	5.39	0.31	1.59e-7	Personality dimensions;
CESC	cis	rs10489202	1.000	rs7538581	chr1:167979347	A/G	cg24449463	chr1:168025552	DCAF6	-0.45	-5.18	-0.3	4.45e-7	Schizophrenia;
CESC	cis	rs7772486	0.790	rs2249147	chr6:146184999	T/C	cg05347473	chr6:146136440	FBXO30	0.55	7.21	0.4	5.88e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2839186	0.709	rs2839176	chr21:47678173	A/G	cg13126279	chr21:47581558	C21orf56	-0.51	-6.91	-0.39	3.64e-11	Testicular germ cell tumor;
CESC	cis	rs7914558	0.966	rs3977751	chr10:104920232	A/G	cg04362960	chr10:104952993	NT5C2	0.45	5.88	0.34	1.21e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs11190604	1.000	rs12355721	chr10:102244911	C/T	cg07080220	chr10:102295463	HIF1AN	0.55	5.44	0.32	1.21e-7	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs12479064	0.724	rs737094	chr2:100089078	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.53	-6.07	-0.35	4.53e-9	Chronic sinus infection;
CESC	cis	rs9388451	0.805	rs1028481	chr6:126106573	G/T	cg05901451	chr6:126070800	HEY2	-0.63	-9.17	-0.49	1.35e-17	Brugada syndrome;
CESC	cis	rs698813	0.604	rs1596009	chr2:44492102	G/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	5.6	0.33	5.26e-8	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
CESC	cis	rs8002861	0.905	rs12430629	chr13:44415919	T/A	cg19180546	chr13:44453867	C13orf31;CCDC122	-0.41	-5.2	-0.3	4.01e-7	Leprosy;
CESC	cis	rs3858526	0.514	rs4595572	chr11:5864045	T/G	cg25319279	chr11:5960081	NA	-0.35	-5.47	-0.32	1.02e-7	DNA methylation (variation);
CESC	cis	rs9640161	0.830	rs17173682	chr7:150059602	A/G	cg10018233	chr7:150070692	REPIN1	0.36	5.63	0.33	4.57e-8	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs2228479	0.850	rs62056102	chr16:89941438	T/C	cg00800038	chr16:89945340	TCF25	-0.94	-7.79	-0.43	1.52e-13	Skin colour saturation;
CESC	trans	rs12599106	0.715	rs34006830	chr16:34878550	C/A	cg01516881	chr6:292596	DUSP22	-0.84	-10.82	-0.55	7.53e-23	Menopause (age at onset);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg24343413	chr1:151735844	OAZ3;MRPL9	-0.37	-6.17	-0.35	2.57e-9	Gambling;
CESC	cis	rs10504229	1.000	rs61998259	chr8:58192290	T/C	cg05313129	chr8:58192883	C8orf71	-0.55	-6.29	-0.36	1.34e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs4555082	0.645	rs2816605	chr14:105715515	C/T	cg27165867	chr14:105738592	BRF1	-0.51	-5.4	-0.31	1.46e-7	Mean platelet volume;Platelet distribution width;
CESC	cis	rs916888	0.738	rs199515	chr17:44856641	C/G	cg17911788	chr17:44343683	NA	0.54	7.56	0.42	6.81e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs7264396	0.635	rs6121102	chr20:34544274	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.57	6.97	0.39	2.48e-11	Total cholesterol levels;
CESC	cis	rs7385804	0.761	rs504141	chr7:100309125	G/A	cg16850897	chr7:100343110	ZAN	0.47	6.41	0.37	6.69e-10	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
CESC	cis	rs4948102	0.686	rs11771788	chr7:56158040	T/C	cg09872392	chr7:56161020	PHKG1	-0.47	-7.49	-0.42	1.05e-12	Plasma homocysteine levels (post-methionine load test);
CESC	cis	rs5769765	0.908	rs9616216	chr22:50318927	T/C	cg02269571	chr22:50332266	NA	-0.55	-6.42	-0.37	6.1e-10	Schizophrenia;
CESC	cis	rs7474896	0.515	rs2749582	chr10:38275284	A/G	cg25427524	chr10:38739819	LOC399744	0.49	5.63	0.33	4.63e-8	Obesity (extreme);
CESC	cis	rs11098499	0.754	rs12510269	chr4:120241646	A/G	cg09307838	chr4:120376055	NA	0.79	10.62	0.55	3.55e-22	Corneal astigmatism;
CESC	trans	rs3780486	0.505	rs959749	chr9:33147858	T/C	cg20290983	chr6:43655470	MRPS18A	0.73	11.46	0.58	5.66e-25	IgG glycosylation;
CESC	cis	rs4315565	0.688	rs4608564	chr2:69266804	C/T	cg12800200	chr2:69260302	ANTXR1	-0.4	-5.58	-0.32	5.88e-8	Height;
CESC	cis	rs739401	0.611	rs401707	chr11:3050965	T/C	cg25174290	chr11:3078921	CARS	0.55	7.58	0.42	5.71e-13	Longevity;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg07292445	chr17:27055725	NEK8	-0.44	-6.12	-0.35	3.28e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7223966	1.000	rs7223672	chr17:61720565	T/C	cg11494091	chr17:61959527	GH2	0.38	5.06	0.3	7.81e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs8099014	0.906	rs4940696	chr18:56106596	C/T	cg19312305	chr18:56117016	MIR122	0.26	5.15	0.3	5.02e-7	Platelet count;
CESC	cis	rs7618501	0.635	rs34080578	chr3:50026029	A/C	cg24110177	chr3:50126178	RBM5	-0.52	-7.06	-0.4	1.42e-11	Intelligence (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03981592	chr3:86061698	CADM2	-0.58	-6.83	-0.39	5.78e-11	Gut microbiome composition (summer);
CESC	cis	rs9788682	0.747	rs2568497	chr15:78721397	G/T	cg24631222	chr15:78858424	CHRNA5	-0.61	-7.04	-0.4	1.67e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs12134245	0.776	rs13447526	chr1:91983174	A/G	cg07090678	chr1:91966139	CDC7	-0.44	-5.84	-0.34	1.49e-8	Breast cancer;
CESC	cis	rs4595586	0.655	rs11831502	chr12:39310127	A/T	cg26384229	chr12:38710491	ALG10B	0.42	6.11	0.35	3.51e-9	Morning vs. evening chronotype;
CESC	cis	rs34638657	0.656	rs2911429	chr16:82203443	T/C	cg09439754	chr16:82129088	HSD17B2	-0.36	-5.93	-0.34	9.32e-9	Lung adenocarcinoma;
CESC	cis	rs798554	0.836	rs798490	chr7:2801542	C/T	cg19346786	chr7:2764209	NA	-0.48	-7.08	-0.4	1.31e-11	Height;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg19309549	chr1:100435460	SLC35A3	0.48	6.16	0.35	2.65e-9	Systemic lupus erythematosus;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13598790	chr5:55007947	SLC38A9	0.61	7.13	0.4	9.62e-12	Gut microbiome composition (summer);
CESC	cis	rs1799949	1.000	rs16942	chr17:41244000	T/C	cg25072359	chr17:41440525	NA	0.44	6.04	0.35	5.21e-9	Menopause (age at onset);
CESC	cis	rs9926296	0.632	rs9935559	chr16:89800529	C/T	cg04287289	chr16:89883240	FANCA	-0.64	-8.44	-0.46	2.15e-15	Vitiligo;
CESC	cis	rs1355223	0.507	rs11032903	chr11:34876176	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.55	-6.59	-0.38	2.37e-10	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs7192380	0.630	rs2965749	chr16:69771914	C/T	cg15192750	chr16:69999425	NA	-0.37	-5.11	-0.3	6.03e-7	Sjögren's syndrome;
CESC	cis	rs1707322	0.682	rs10890335	chr1:46100394	G/C	cg06784218	chr1:46089804	CCDC17	0.4	6.99	0.39	2.23e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs911555	0.511	rs8007489	chr14:104054572	A/G	cg12935359	chr14:103987150	CKB	0.43	6.48	0.37	4.35e-10	Intelligence (multi-trait analysis);
CESC	cis	rs7927592	0.913	rs7104345	chr11:68316772	G/A	cg20283391	chr11:68216788	NA	-0.61	-7.36	-0.41	2.26e-12	Total body bone mineral density;
CESC	cis	rs11690935	0.879	rs908671	chr2:172690265	C/G	cg13550731	chr2:172543902	DYNC1I2	-0.96	-14.1	-0.65	4.75e-34	Schizophrenia;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg15951691	chr7:150065937	REPIN1	0.48	5.99	0.35	6.66e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs9611519	0.507	rs12484525	chr22:41443877	G/C	cg03806693	chr22:41940476	POLR3H	-0.5	-5.99	-0.35	6.73e-9	Neuroticism;
CESC	cis	rs748404	0.660	rs690446	chr15:43761264	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	8.21	0.45	9.59e-15	Lung cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06807593	chr18:51795886	POLI	0.59	6.25	0.36	1.65e-9	Gut microbiome composition (summer);
CESC	cis	rs3741151	0.686	rs73546735	chr11:73256797	C/T	cg17517138	chr11:73019481	ARHGEF17	1.05	7.72	0.43	2.46e-13	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23932593	chr6:133135524	RPS12;SNORD101	0.52	6.19	0.36	2.24e-9	Gut microbiome composition (summer);
CESC	cis	rs4665809	0.816	rs2384359	chr2:26371364	T/C	cg25036284	chr2:26402008	FAM59B	-0.83	-9.85	-0.52	1.01e-19	Gut microbiome composition (summer);
CESC	cis	rs2933343	0.621	rs789249	chr3:128578453	T/C	cg24203234	chr3:128598194	ACAD9	0.41	5.66	0.33	4e-8	IgG glycosylation;
CESC	cis	rs4713118	0.527	rs9461433	chr6:28095172	C/T	cg08968635	chr6:28129556	ZNF389	0.41	5.51	0.32	8.4e-8	Parkinson's disease;
CESC	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg18538332	chr22:24372958	LOC391322	-0.78	-11.72	-0.58	7.97e-26	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs10979	1.000	rs12212011	chr6:143894694	C/A	cg25407410	chr6:143891975	LOC285740	-0.61	-9.2	-0.49	1.13e-17	Hypospadias;
CESC	cis	rs2797160	1.000	rs1739377	chr6:126012236	T/C	cg05901451	chr6:126070800	HEY2	0.46	6.63	0.38	1.87e-10	Endometrial cancer;
CESC	cis	rs853679	0.517	rs7755442	chr6:28039015	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.53	-6.09	-0.35	3.91e-9	Depression;
CESC	cis	rs7084402	0.967	rs1649059	chr10:60312599	T/C	cg07615347	chr10:60278583	BICC1	0.61	9.6	0.51	6.58e-19	Refractive error;
CESC	cis	rs11630290	0.736	rs2197259	chr15:64154156	T/C	cg12036633	chr15:63758958	NA	0.52	5.64	0.33	4.32e-8	Iris characteristics;
CESC	cis	rs9868809	0.772	rs9809222	chr3:48714411	C/T	cg03060546	chr3:49711283	APEH	-0.67	-5.73	-0.33	2.68e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs6831352	0.703	rs2602862	chr4:100033221	A/G	cg13256891	chr4:100009986	ADH5	0.69	8.13	0.45	1.61e-14	Alcohol dependence;
CESC	cis	rs4950322	0.857	rs55790545	chr1:146838364	C/A	cg22381352	chr1:146742008	CHD1L	-0.45	-5.19	-0.3	4.12e-7	Protein quantitative trait loci;
CESC	cis	rs13108904	0.775	rs2279282	chr4:1216033	G/C	cg16405210	chr4:1374714	KIAA1530	-0.45	-5.48	-0.32	1.01e-7	Obesity-related traits;
CESC	cis	rs9905704	0.881	rs12942879	chr17:56861253	G/A	cg12560992	chr17:57184187	TRIM37	0.61	7.15	0.4	8.7e-12	Testicular germ cell tumor;
CESC	cis	rs9640161	0.789	rs28439010	chr7:150046276	C/T	cg17279839	chr7:150038598	RARRES2	0.49	5.92	0.34	9.88e-9	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs9487051	0.837	rs1915834	chr6:109597624	C/A	cg01475377	chr6:109611718	NA	-0.51	-8.56	-0.47	9.09e-16	Reticulocyte fraction of red cells;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24000912	chr8:8082819	NA	-0.49	-6.57	-0.37	2.73e-10	Gut microbiome composition (summer);
CESC	cis	rs3858526	0.959	rs11039540	chr11:5928334	C/T	cg13902645	chr11:5959945	NA	-0.61	-7.19	-0.4	6.77e-12	DNA methylation (variation);
CESC	cis	rs2243480	1.000	rs410128	chr7:65603173	C/T	cg18252515	chr7:66147081	NA	-1.4	-13.69	-0.64	1.22e-32	Diabetic kidney disease;
CESC	cis	rs796364	0.806	rs35200468	chr2:201110368	G/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.7	-6.31	-0.36	1.14e-9	Schizophrenia;
CESC	cis	rs853679	0.517	rs7755442	chr6:28039015	T/C	cg23161317	chr6:28129485	ZNF389	0.5	6.31	0.36	1.19e-9	Depression;
CESC	cis	rs1799949	1.000	rs11656097	chr17:41290613	G/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.67	9.36	0.5	3.44e-18	Menopause (age at onset);
CESC	cis	rs1153858	1.000	rs66528868	chr15:45668547	A/C	cg14582100	chr15:45693742	SPATA5L1	0.42	5.95	0.34	8.38e-9	Homoarginine levels;
CESC	cis	rs7666738	0.830	rs60994860	chr4:99046753	G/A	cg03676636	chr4:99064102	C4orf37	0.33	5.12	0.3	5.93e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9814567	1.000	rs9876658	chr3:134179453	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.35	5.03	0.3	9.23e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs9291683	0.546	rs13146686	chr4:10034933	A/G	cg00071950	chr4:10020882	SLC2A9	0.77	12.79	0.62	1.73e-29	Bone mineral density;
CESC	cis	rs977987	0.778	rs12929908	chr16:75462071	C/T	cg03315344	chr16:75512273	CHST6	0.41	5.91	0.34	1.07e-8	Dupuytren's disease;
CESC	cis	rs13256369	0.901	rs4841015	chr8:8567140	C/G	cg17143192	chr8:8559678	CLDN23	0.71	8.18	0.45	1.16e-14	Obesity-related traits;
CESC	cis	rs7103648	0.897	rs2278890	chr11:47399602	G/A	cg20307385	chr11:47447363	PSMC3	0.95	14.26	0.66	1.26e-34	Diastolic blood pressure;Systolic blood pressure;
CESC	cis	rs9303280	0.776	rs9891174	chr17:38031802	T/A	cg19468946	chr17:37922297	IKZF3	-0.4	-5.31	-0.31	2.28e-7	Self-reported allergy;
CESC	cis	rs11657217	0.638	rs4313839	chr17:77698619	C/T	cg06901238	chr17:77706717	ENPP7	-0.44	-6.43	-0.37	6.08e-10	Diastolic blood pressure response to hydrochlorothiazide in hypertension;
CESC	cis	rs6964587	0.626	rs6951795	chr7:91543764	T/C	cg17063962	chr7:91808500	NA	-0.46	-6.64	-0.38	1.8e-10	Breast cancer;
CESC	cis	rs7605827	0.930	rs12991640	chr2:15505789	T/C	cg19274914	chr2:15703543	NA	0.32	5.76	0.33	2.33e-8	Educational attainment (years of education);
CESC	cis	rs7666738	0.830	rs13134216	chr4:98919765	C/T	cg17366294	chr4:99064904	C4orf37	0.57	7.96	0.44	4.98e-14	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4704187	0.687	rs10051422	chr5:74502573	G/A	cg03227963	chr5:74354835	NA	0.28	5.18	0.3	4.33e-7	Response to amphetamines;
CESC	cis	rs9916302	0.861	rs7503514	chr17:37669884	G/C	cg07936489	chr17:37558343	FBXL20	-0.8	-11.82	-0.59	3.49e-26	Glomerular filtration rate (creatinine);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08242217	chr21:40752130	WRB	0.55	6.29	0.36	1.34e-9	Gut microbiome composition (summer);
CESC	cis	rs916888	0.821	rs199507	chr17:44858855	A/G	cg14517863	chr17:44321492	NA	-0.4	-5.16	-0.3	4.82e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs17666538	0.585	rs4448252	chr8:615597	A/G	cg02524346	chr8:600233	NA	0.83	6.05	0.35	4.92e-9	IgG glycosylation;
CESC	cis	rs2404602	0.735	rs11637490	chr15:76759565	A/G	cg23625390	chr15:77176239	SCAPER	-0.42	-5.81	-0.34	1.83e-8	Blood metabolite levels;
CESC	cis	rs2075371	0.933	rs2544201	chr7:133963561	C/G	cg20476274	chr7:133979776	SLC35B4	0.69	10.36	0.54	2.5e-21	Mean platelet volume;
CESC	cis	rs477692	0.637	rs10829598	chr10:131319774	C/G	cg24747557	chr10:131355152	MGMT	-0.37	-5.09	-0.3	6.87e-7	Response to temozolomide;
CESC	cis	rs8133932	0.654	rs402039	chr21:47358809	A/G	cg14185626	chr21:47401492	COL6A1	-0.46	-5.19	-0.3	4.22e-7	Schizophrenia;
CESC	cis	rs3617	0.573	rs9880978	chr3:52923251	C/G	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.3	5.23	0.31	3.48e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
CESC	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg27094323	chr7:1216898	NA	-0.38	-5.18	-0.3	4.49e-7	Longevity;Endometriosis;
CESC	cis	rs2832191	0.597	rs8127842	chr21:30516461	G/A	cg08807101	chr21:30365312	RNF160	-0.56	-6.41	-0.37	6.63e-10	Dental caries;
CESC	cis	rs11098499	0.863	rs1480936	chr4:120462861	C/T	cg24375607	chr4:120327624	NA	0.44	5.31	0.31	2.31e-7	Corneal astigmatism;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10018778	chr12:58138402	TSPAN31	-0.61	-6.93	-0.39	3.16e-11	Gut microbiome composition (summer);
CESC	cis	rs6088765	0.606	rs2425024	chr20:33844938	G/T	cg08999081	chr20:33150536	PIGU	-0.4	-5.86	-0.34	1.34e-8	Ulcerative colitis;
CESC	cis	rs11864453	0.826	rs8062041	chr16:72088964	C/T	cg01557791	chr16:72042693	DHODH	-0.61	-7.91	-0.44	6.83e-14	Fibrinogen levels;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg05380570	chr1:17866686	ARHGEF10L	-0.43	-6.07	-0.35	4.38e-9	Asthma;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02237855	chr2:74329332	TET3	-0.74	-8.51	-0.46	1.28e-15	Gut microbiome composition (summer);
CESC	cis	rs2933343	0.649	rs789219	chr3:128592520	G/A	cg24203234	chr3:128598194	ACAD9	0.43	5.91	0.34	1.04e-8	IgG glycosylation;
CESC	cis	rs6540559	1.000	rs2235372	chr1:209960436	A/G	cg12034118	chr1:209979487	IRF6	-0.46	-5.61	-0.33	5.13e-8	Cleft lip with or without cleft palate;
CESC	cis	rs7799006	0.606	rs7792045	chr7:2316852	C/T	cg08027265	chr7:2291960	NA	-0.57	-9.39	-0.5	2.97e-18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs9788682	1.000	rs61204066	chr15:78815298	G/A	cg24631222	chr15:78858424	CHRNA5	0.76	9.69	0.51	3.35e-19	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs116095464	0.558	rs7356561	chr5:284381	G/C	cg12570787	chr5:219185	SDHA;CCDC127	0.52	5.41	0.32	1.38e-7	Breast cancer;
CESC	cis	rs769267	0.629	rs7245672	chr19:19699963	T/C	cg03709012	chr19:19516395	GATAD2A	-0.65	-7.87	-0.44	8.95e-14	Tonsillectomy;
CESC	cis	rs4722166	0.597	rs1554606	chr7:22768707	T/G	cg05265849	chr7:22767390	IL6	0.41	5.69	0.33	3.32e-8	Lung cancer;
CESC	cis	rs4665809	0.590	rs4665321	chr2:26433801	A/C	cg04944784	chr2:26401820	FAM59B	-0.95	-10.38	-0.54	2.13e-21	Gut microbiome composition (summer);
CESC	cis	rs763121	0.889	rs1837988	chr22:38901094	A/G	cg06544989	chr22:39130855	UNC84B	0.45	7.36	0.41	2.26e-12	Menopause (age at onset);
CESC	cis	rs13256369	1.000	rs883648	chr8:8569521	A/G	cg18904891	chr8:8559673	CLDN23	0.68	7.73	0.43	2.27e-13	Obesity-related traits;
CESC	cis	rs67311347	0.713	rs9861194	chr3:40309225	C/T	cg09455208	chr3:40491958	NA	0.44	7.36	0.41	2.38e-12	Renal cell carcinoma;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg25946722	chr6:105307729	HACE1	-0.42	-6.07	-0.35	4.42e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs4803468	1.000	rs1473248	chr19:41923314	C/T	cg08639244	chr19:41945921	ATP5SL	0.41	5.03	0.3	9.08e-7	Height;
CESC	cis	rs933688	1.000	rs11950530	chr5:90688740	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.11	12.36	0.6	5.17e-28	Smoking behavior;
CESC	cis	rs8067545	0.611	rs9902032	chr17:20015178	G/C	cg13482628	chr17:19912719	NA	0.41	5.34	0.31	2e-7	Schizophrenia;
CESC	cis	rs7520050	0.966	rs785491	chr1:46583418	G/A	cg03146154	chr1:46216737	IPP	-0.43	-5.57	-0.32	6.33e-8	Red blood cell count;Reticulocyte count;
CESC	cis	rs7613875	0.600	rs2856237	chr3:50158774	A/G	cg24110177	chr3:50126178	RBM5	0.59	8.32	0.46	4.75e-15	Body mass index;
CESC	cis	rs7264396	0.580	rs6119655	chr20:34412049	G/A	cg17201900	chr20:34330562	RBM39	0.52	5.2	0.3	3.98e-7	Total cholesterol levels;
CESC	trans	rs9693444	0.898	rs4732697	chr8:29519861	A/G	cg01766191	chr11:57103423	SSRP1	-0.45	-6.64	-0.38	1.77e-10	Breast cancer;
CESC	cis	rs6461049	0.800	rs2398706	chr7:2156338	A/T	cg04267008	chr7:1944627	MAD1L1	-0.48	-5.67	-0.33	3.68e-8	Schizophrenia;
CESC	cis	rs801193	1.000	rs3857688	chr7:66127806	G/A	cg06456125	chr7:65229604	NA	-0.39	-5.09	-0.3	6.82e-7	Aortic root size;
CESC	cis	rs3820068	0.603	rs3766163	chr1:15986547	T/C	cg18133145	chr1:16060689	PLEKHM2	-0.4	-5.21	-0.3	3.86e-7	Systolic blood pressure;
CESC	cis	rs4423214	0.840	rs1792233	chr11:71182179	G/A	cg05163923	chr11:71159392	DHCR7	-0.65	-7.66	-0.43	3.55e-13	Vitamin D levels;
CESC	cis	rs938554	0.779	rs7442295	chr4:9966380	A/G	cg00071950	chr4:10020882	SLC2A9	-0.47	-5.55	-0.32	7.04e-8	Blood metabolite levels;
CESC	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg01238044	chr22:24384105	GSTT1	0.48	6.03	0.35	5.47e-9	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs4568518	0.710	rs6966083	chr7:18016544	G/T	cg03009463	chr7:17980271	SNX13	0.44	5.76	0.33	2.3e-8	Measles;
CESC	trans	rs4245128	0.930	rs9666469	chr11:112787696	C/G	cg10894232	chr8:11772343	NA	0.37	6.04	0.35	5.15e-9	Life satisfaction;
CESC	cis	rs3733585	0.631	rs4697924	chr4:10124239	A/G	cg00071950	chr4:10020882	SLC2A9	-0.63	-9.18	-0.49	1.25e-17	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs10883723	0.810	rs10786669	chr10:104256094	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.54	7.43	0.42	1.49e-12	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs13106227	0.550	rs11723732	chr4:77370557	A/G	cg27417997	chr4:77356416	SHROOM3	-0.33	-5.08	-0.3	7.19e-7	Eosinophilic esophagitis (pediatric);
CESC	cis	rs2439831	0.850	rs544122	chr15:43775732	A/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.89	9.72	0.51	2.7e-19	Lung cancer in ever smokers;
CESC	cis	rs829661	0.947	rs829665	chr2:30724701	T/A	cg07150166	chr2:30669952	LCLAT1	0.86	7.36	0.41	2.38e-12	Midgestational circulating levels of PBDEs (fetal genetic effect);
CESC	cis	rs4076764	0.957	rs4443867	chr1:163434917	T/C	cg24596788	chr1:163392923	NA	-0.47	-6.88	-0.39	4.18e-11	Motion sickness;
CESC	cis	rs3820068	0.603	rs67349836	chr1:15966176	T/C	cg13390004	chr1:15929781	NA	0.36	5.66	0.33	3.95e-8	Systolic blood pressure;
CESC	cis	rs796364	0.806	rs74724807	chr2:201005109	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.75	-6.83	-0.39	5.71e-11	Schizophrenia;
CESC	cis	rs7208859	0.623	rs55811708	chr17:29104731	G/T	cg19761014	chr17:28927070	LRRC37B2	0.75	6.17	0.35	2.49e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs4727027	0.704	rs7784122	chr7:148904624	A/G	cg23583168	chr7:148888333	NA	0.95	16.99	0.72	2.7e-44	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg11494091	chr17:61959527	GH2	0.72	12.37	0.61	4.59e-28	Prudent dietary pattern;
CESC	cis	rs10504229	1.000	rs72650885	chr8:58175131	G/A	cg14926445	chr8:58193284	C8orf71	-0.51	-5.47	-0.32	1.03e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs9902453	1.000	rs4350617	chr17:28423088	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	7.93	0.44	6.25e-14	Coffee consumption (cups per day);
CESC	cis	rs61931739	0.500	rs7963282	chr12:34535255	A/C	cg06521331	chr12:34319734	NA	-0.37	-5.15	-0.3	5.19e-7	Morning vs. evening chronotype;
CESC	trans	rs1814175	0.817	rs11040700	chr11:50023832	C/T	cg03929089	chr4:120376271	NA	-0.94	-16.01	-0.7	7.75e-41	Height;
CESC	cis	rs514406	0.861	rs2477741	chr1:53265278	A/G	cg16325326	chr1:53192061	ZYG11B	-0.9	-15.33	-0.69	2.02e-38	Monocyte count;
CESC	cis	rs7618915	0.571	rs1961959	chr3:52585760	G/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	6.6	0.38	2.27e-10	Bipolar disorder;
CESC	cis	rs10504229	1.000	rs74546828	chr8:58171678	A/G	cg14926445	chr8:58193284	C8orf71	-0.51	-5.47	-0.32	1.03e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs2859741	0.967	rs535876	chr1:37484052	C/G	cg09363841	chr1:37513479	NA	-0.61	-9.61	-0.51	5.8e-19	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
CESC	cis	rs898097	0.756	rs11655103	chr17:80813467	T/C	cg15369054	chr17:80825471	TBCD	0.58	8.17	0.45	1.24e-14	Breast cancer;
CESC	cis	rs6061231	0.631	rs2427318	chr20:60975727	G/T	cg23531748	chr20:60969906	CABLES2	0.39	5.41	0.32	1.41e-7	Colorectal cancer;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg16973203	chr2:230876010	FBXO36	0.41	6.07	0.35	4.51e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs2878628	0.650	rs56098033	chr3:52758571	T/A	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	5.81	0.34	1.79e-8	Intelligence (multi-trait analysis);
CESC	cis	rs2075371	0.644	rs1643041	chr7:134012211	C/T	cg20476274	chr7:133979776	SLC35B4	0.51	6.63	0.38	1.87e-10	Mean platelet volume;
CESC	cis	rs637571	0.522	rs538954	chr11:65756808	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.73	10.61	0.55	3.86e-22	Eosinophil percentage of white cells;
CESC	trans	rs8073060	0.586	rs8074800	chr17:33979148	A/G	cg19694781	chr19:47549865	TMEM160	0.67	7.05	0.4	1.51e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04215179	chr7:23719682	C7orf46	0.55	6.53	0.37	3.42e-10	Gut microbiome composition (summer);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg25547957	chr6:73972768	KHDC1	-0.51	-6.28	-0.36	1.4e-9	Ulcerative colitis;
CESC	cis	rs2228479	0.702	rs62053702	chr16:89860688	G/T	cg00800038	chr16:89945340	TCF25	-0.9	-7.49	-0.42	1.01e-12	Skin colour saturation;
CESC	cis	rs1538970	0.924	rs12097497	chr1:45880669	C/T	cg06784218	chr1:46089804	CCDC17	0.33	5.36	0.31	1.85e-7	Platelet count;
CESC	cis	rs3736485	0.966	rs7182977	chr15:51854130	C/G	cg08986416	chr15:51914746	DMXL2	-0.4	-5.13	-0.3	5.5e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs287982	0.800	rs9973905	chr2:9960855	G/C	cg10881225	chr2:9984929	TAF1B	0.41	5.25	0.31	3.05e-7	Nonsyndromic cleft lip with cleft palate;
CESC	cis	rs9640161	0.636	rs56190213	chr7:150025720	T/C	cg17279839	chr7:150038598	RARRES2	0.5	5.91	0.34	1.04e-8	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs11098499	0.909	rs28571712	chr4:120375980	G/A	cg09307838	chr4:120376055	NA	0.92	12.73	0.62	2.68e-29	Corneal astigmatism;
CESC	cis	rs13108904	0.557	rs1250095	chr4:1239312	C/T	cg02475777	chr4:1388615	CRIPAK	-0.46	-5.98	-0.34	7.12e-9	Obesity-related traits;
CESC	cis	rs7107174	1.000	rs2511158	chr11:77973980	C/T	cg02023728	chr11:77925099	USP35	0.48	6.34	0.36	9.87e-10	Testicular germ cell tumor;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25605771	chr1:44466601	SLC6A9	-0.63	-6.97	-0.39	2.53e-11	Gut microbiome composition (summer);
CESC	cis	rs5753037	0.702	rs140100	chr22:30128240	C/T	cg01021169	chr22:30184971	ASCC2	-0.46	-6.17	-0.35	2.55e-9	Type 1 diabetes;
CESC	cis	rs9916302	0.652	rs9903269	chr17:37742383	A/T	cg07936489	chr17:37558343	FBXL20	-0.87	-8.8	-0.48	1.82e-16	Glomerular filtration rate (creatinine);
CESC	cis	rs2841277	0.802	rs2841269	chr14:105386149	C/G	cg17340268	chr14:105411764	AHNAK2	-0.52	-6.85	-0.39	5.2e-11	Rheumatoid arthritis;
CESC	cis	rs11098499	0.909	rs28884220	chr4:120307211	A/G	cg09307838	chr4:120376055	NA	0.92	12.66	0.61	4.96e-29	Corneal astigmatism;
CESC	trans	rs916888	0.610	rs199454	chr17:44800110	G/A	cg22433210	chr17:43662623	NA	-0.58	-7.35	-0.41	2.52e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs7666738	0.830	rs6854594	chr4:99065312	A/T	cg05340658	chr4:99064831	C4orf37	0.84	12.86	0.62	1.01e-29	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1003719	0.680	rs2835670	chr21:38581114	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.6	-8.07	-0.44	2.45e-14	Eye color traits;
CESC	cis	rs116095464	0.558	rs62347678	chr5:227496	A/G	cg22496380	chr5:211416	CCDC127	-0.72	-8.45	-0.46	1.92e-15	Breast cancer;
CESC	cis	rs9611565	0.659	rs28623192	chr22:41940524	A/G	cg17376030	chr22:41985996	PMM1	0.69	7.53	0.42	8.22e-13	Vitiligo;
CESC	cis	rs4919694	1.000	rs11191545	chr10:104829793	C/T	cg04362960	chr10:104952993	NT5C2	0.76	6.71	0.38	1.19e-10	Arsenic metabolism;
CESC	cis	rs3806843	0.518	rs2563310	chr5:140015741	A/G	cg26395211	chr5:140044315	WDR55	0.41	5.19	0.3	4.13e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs644799	0.710	rs12273579	chr11:95524421	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.77	11.14	0.56	6.71e-24	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs9796	0.689	rs8032195	chr15:41448790	G/A	cg20272979	chr15:41787780	ITPKA	0.34	5.14	0.3	5.42e-7	Menopause (age at onset);
CESC	cis	rs7512552	0.780	rs2794681	chr1:150321951	C/T	cg15654264	chr1:150340011	RPRD2	0.39	5.12	0.3	5.94e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg25936770	chr7:122321411	CADPS2	0.47	6.55	0.37	2.89e-10	Fibrinogen levels;
CESC	trans	rs2727020	0.729	rs2299650	chr11:49174007	A/C	cg03929089	chr4:120376271	NA	-0.78	-11.88	-0.59	2.2e-26	Coronary artery disease;
CESC	cis	rs1534166	0.647	rs9853615	chr3:133519981	C/T	cg12373951	chr3:133503437	NA	0.35	5.26	0.31	3.04e-7	Alcohol consumption (transferrin glycosylation);
CESC	cis	rs9487051	0.676	rs1608044	chr6:109594076	T/C	cg12927641	chr6:109611667	NA	-0.37	-5.57	-0.32	6.16e-8	Reticulocyte fraction of red cells;
CESC	cis	rs708547	0.581	rs6554400	chr4:57805306	A/C	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.52	-7.03	-0.4	1.71e-11	Response to bleomycin (chromatid breaks);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg19268579	chr10:43904406	HNRNPF	-0.47	-6.01	-0.35	5.97e-9	Ulcerative colitis;
CESC	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.65	0.38	1.71e-10	Prudent dietary pattern;
CESC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg19757253	chr2:32853039	TTC27	-0.52	-6.22	-0.36	1.97e-9	Lung cancer in ever smokers;
CESC	cis	rs12042938	0.935	rs1094657	chr1:231773407	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.45	6.18	0.35	2.39e-9	Neuranatomic and neurocognitive phenotypes;
CESC	cis	rs546131	0.928	rs558967	chr11:34827168	T/A	cg11058730	chr11:34937778	PDHX;APIP	0.46	5.82	0.34	1.65e-8	Lung disease severity in cystic fibrosis;
CESC	cis	rs6088580	0.634	rs6579165	chr20:32994715	A/G	cg08999081	chr20:33150536	PIGU	-0.65	-11.29	-0.57	2.22e-24	Glomerular filtration rate (creatinine);
CESC	cis	rs6088590	1.000	rs11698977	chr20:33449691	C/T	cg08999081	chr20:33150536	PIGU	0.58	8.91	0.48	8.59e-17	Coronary artery disease;
CESC	trans	rs61931739	0.517	rs1586409	chr12:34046614	C/A	cg26384229	chr12:38710491	ALG10B	0.53	7.22	0.41	5.44e-12	Morning vs. evening chronotype;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg12536451	chr10:99496852	ZFYVE27	0.5	6.75	0.38	9.24e-11	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg04234412	chr22:24373322	LOC391322	-0.63	-9.2	-0.49	1.11e-17	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs4604732	0.588	rs7552443	chr1:247628583	G/T	cg12758973	chr1:247694275	LOC148824;OR2C3	0.48	6.01	0.35	6.07e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs9911578	0.933	rs2531726	chr17:56522533	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.38	-5.14	-0.3	5.35e-7	Intelligence (multi-trait analysis);
CESC	cis	rs36051895	0.632	rs12349918	chr9:5125250	A/G	cg02405213	chr9:5042618	JAK2	-0.54	-6.47	-0.37	4.66e-10	Pediatric autoimmune diseases;
CESC	cis	rs4660261	0.561	rs11210934	chr1:44369435	G/A	cg12908607	chr1:44402522	ARTN	-0.49	-7.52	-0.42	8.28e-13	Intelligence (multi-trait analysis);
CESC	cis	rs6032067	0.673	rs36019441	chr20:43892401	G/A	cg10761708	chr20:43804764	PI3	0.41	5.14	0.3	5.43e-7	Blood protein levels;
CESC	cis	rs1348850	0.567	rs3770005	chr2:178528874	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.52	6.95	0.39	2.88e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs4665809	0.590	rs62128455	chr2:26466530	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.1	12.68	0.61	4e-29	Gut microbiome composition (summer);
CESC	cis	rs12188164	0.582	rs72700694	chr5:483267	T/C	cg15813090	chr5:442598	EXOC3;C5orf55	0.4	5.64	0.33	4.32e-8	Cystic fibrosis severity;
CESC	cis	rs933688	0.556	rs4916855	chr5:90596345	T/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	-0.52	-6.22	-0.36	1.89e-9	Smoking behavior;
CESC	cis	rs1348850	0.914	rs10170667	chr2:178336878	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.89	12.75	0.62	2.42e-29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs4843747	0.671	rs13334603	chr16:88116016	T/C	cg03395651	chr16:88107091	BANP	0.45	5.12	0.3	5.76e-7	Menopause (age at onset);
CESC	cis	rs4689388	0.581	rs1801212	chr4:6302519	C/T	cg00701064	chr4:6280414	WFS1	0.55	7.0	0.4	2.05e-11	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs9911578	1.000	rs9901181	chr17:56964271	C/T	cg05425664	chr17:57184151	TRIM37	-0.5	-6.95	-0.39	2.9100000000000002e-11	Intelligence (multi-trait analysis);
CESC	cis	rs4654899	0.802	rs10916903	chr1:21247944	T/C	cg05370193	chr1:21551575	ECE1	0.39	5.63	0.33	4.62e-8	Superior frontal gyrus grey matter volume;
CESC	cis	rs9916302	0.904	rs1966916	chr17:37425238	T/G	cg20243544	chr17:37824526	PNMT	0.46	5.76	0.33	2.31e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs858239	0.669	rs10950940	chr7:23196816	C/T	cg27449745	chr7:23145252	KLHL7	0.41	5.22	0.31	3.6e-7	Cerebrospinal fluid biomarker levels;
CESC	cis	rs11098499	0.863	rs13140391	chr4:120503437	A/G	cg09307838	chr4:120376055	NA	0.95	12.98	0.62	3.72e-30	Corneal astigmatism;
CESC	cis	rs938554	0.736	rs4475146	chr4:9946656	C/A	cg00071950	chr4:10020882	SLC2A9	-0.51	-5.95	-0.34	8.36e-9	Blood metabolite levels;
CESC	cis	rs926938	0.618	rs360624	chr1:115409476	A/C	cg12756093	chr1:115239321	AMPD1	0.51	7.34	0.41	2.61e-12	Autism;
CESC	cis	rs2404602	0.669	rs17367297	chr15:77158026	A/C	cg22467129	chr15:76604101	ETFA	-0.35	-5.27	-0.31	2.8e-7	Blood metabolite levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17513182	chr1:153894941	GATAD2B	0.57	6.19	0.36	2.26e-9	Gut microbiome composition (summer);
CESC	cis	rs2836974	0.644	rs7281853	chr21:40693490	A/G	cg11644478	chr21:40555479	PSMG1	-0.75	-10.59	-0.55	4.51e-22	Cognitive function;
CESC	cis	rs7613875	0.620	rs2526747	chr3:50082914	C/G	cg24308560	chr3:49941425	MST1R	-0.5	-6.87	-0.39	4.66e-11	Body mass index;
CESC	cis	rs10883723	0.518	rs10786679	chr10:104315667	C/T	ch.10.2196322F	chr10:104248062	ACTR1A	0.46	5.61	0.33	5.12e-8	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs12936587	0.535	rs6502615	chr17:17612023	C/T	cg04398451	chr17:18023971	MYO15A	0.38	5.15	0.3	5.19e-7	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
CESC	cis	rs6540559	1.000	rs2235372	chr1:209960436	A/G	cg10074409	chr1:209979377	IRF6	-0.37	-5.87	-0.34	1.32e-8	Cleft lip with or without cleft palate;
CESC	cis	rs868036	1.000	rs1026731	chr15:68095018	G/A	cg08079166	chr15:68083412	MAP2K5	0.44	6.94	0.39	2.94e-11	Restless legs syndrome;
CESC	cis	rs6584283	0.846	rs7917446	chr10:101286207	T/C	cg09788492	chr10:101292477	NKX2-3	0.33	6.15	0.35	2.87e-9	Ulcerative colitis;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg00093436	chr1:36172279	NA	-0.4	-6.1	-0.35	3.66e-9	Gambling;
CESC	cis	rs11997175	0.587	rs72612118	chr8:33695225	T/C	ch.8.33884649F	chr8:33765107	NA	0.56	7.33	0.41	2.82e-12	Body mass index;
CESC	cis	rs11030122	0.673	rs4910597	chr11:4094923	G/A	cg18678763	chr11:4115507	RRM1	-0.53	-6.97	-0.39	2.51e-11	Mean platelet volume;Platelet distribution width;
CESC	cis	rs7923609	0.967	rs2393977	chr10:65247609	A/C	cg01631684	chr10:65280961	REEP3	-0.43	-5.4	-0.31	1.49e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs1018697	0.518	rs2790914	chr10:104568018	C/T	cg04362960	chr10:104952993	NT5C2	-0.58	-6.42	-0.37	6.35e-10	Colorectal adenoma (advanced);
CESC	trans	rs9329221	0.537	rs6995859	chr8:9975709	T/A	cg06636001	chr8:8085503	FLJ10661	0.49	6.2	0.36	2.18e-9	Neuroticism;
CESC	cis	rs9796	0.621	rs2928142	chr15:41470449	T/C	cg18705301	chr15:41695430	NDUFAF1	0.44	6.46	0.37	4.86e-10	Menopause (age at onset);
CESC	cis	rs2576037	0.583	rs2571028	chr18:44561100	C/G	cg19077165	chr18:44547161	KATNAL2	0.65	10.03	0.52	2.79e-20	Personality dimensions;
CESC	cis	rs1707322	0.721	rs4415615	chr1:46132109	C/T	cg06784218	chr1:46089804	CCDC17	0.41	7.12	0.4	1.04e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs1593	0.734	rs4862670	chr4:187145423	A/T	cg09526685	chr4:187126073	CYP4V2	0.61	5.03	0.3	9e-7	Activated partial thromboplastin time;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg04407147	chr2:160606257	MARCH7	0.41	6.38	0.36	7.79e-10	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs9815354	1.000	rs73081353	chr3:41906448	T/A	cg03022575	chr3:42003672	ULK4	0.57	5.88	0.34	1.2e-8	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs8067545	1.000	rs28807825	chr17:19942850	G/A	cg13482628	chr17:19912719	NA	0.43	5.78	0.33	2.07e-8	Schizophrenia;
CESC	cis	rs765787	0.530	rs1706764	chr15:45524256	T/A	cg24006582	chr15:45444508	DUOX1	-0.58	-7.08	-0.4	1.26e-11	Uric acid levels;
CESC	cis	rs9611565	0.694	rs2142505	chr22:41820541	A/G	cg03806693	chr22:41940476	POLR3H	1.21	14.54	0.67	1.31e-35	Vitiligo;
CESC	cis	rs4819052	0.851	rs8134392	chr21:46663790	A/G	cg11663144	chr21:46675770	NA	0.63	9.94	0.52	5.51e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15322430	chr1:40157251	HPCAL4	0.58	6.39	0.37	7.23e-10	Gut microbiome composition (summer);
CESC	cis	rs9894429	1.000	rs12948099	chr17:79600799	C/G	cg21984481	chr17:79567631	NPLOC4	-0.49	-7.96	-0.44	4.9e-14	Eye color traits;
CESC	cis	rs6587515	0.901	rs12045807	chr1:150584834	C/T	cg13175981	chr1:150552382	MCL1	0.59	5.62	0.33	4.75e-8	Pericardial adipose tissue adjusted for height and weight;
CESC	cis	rs1506636	0.720	rs633590	chr7:123442156	G/A	cg03229431	chr7:123269106	ASB15	0.39	5.19	0.3	4.15e-7	Plateletcrit;Platelet count;
CESC	cis	rs9926296	0.585	rs1800337	chr16:89845194	A/G	cg03388025	chr16:89894329	SPIRE2	0.41	7.8	0.43	1.45e-13	Vitiligo;
CESC	cis	rs769267	0.930	rs10282	chr19:19619317	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.48	6.05	0.35	4.83e-9	Tonsillectomy;
CESC	cis	rs5750830	0.621	rs5757665	chr22:39821641	A/G	cg01416388	chr22:39784598	NA	-0.58	-7.11	-0.4	1.1e-11	Intelligence (multi-trait analysis);
CESC	cis	rs6952808	1.000	rs6957894	chr7:1887362	G/A	cg05863683	chr7:1912471	MAD1L1	0.37	5.49	0.32	9.51e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs11958404	0.719	rs72818153	chr5:157487035	T/C	cg05962755	chr5:157440814	NA	0.63	7.31	0.41	3.13e-12	IgG glycosylation;
CESC	cis	rs9911578	1.000	rs3744109	chr17:56594197	C/T	cg12560992	chr17:57184187	TRIM37	-0.93	-15.59	-0.69	2.43e-39	Intelligence (multi-trait analysis);
CESC	cis	rs2845885	0.793	rs56241103	chr11:63882364	C/T	cg24431193	chr11:63883947	FLRT1;MACROD1	0.81	9.49	0.5	1.39e-18	Body mass index;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16411216	chr1:9340507	NA	0.55	6.23	0.36	1.8e-9	Gut microbiome composition (summer);
CESC	cis	rs7918232	0.830	rs7915902	chr10:27410734	T/C	cg14240646	chr10:27532245	ACBD5	-0.66	-6.43	-0.37	5.89e-10	Breast cancer;
CESC	cis	rs9733	0.569	rs11588404	chr1:150688529	C/A	cg17724175	chr1:150552817	MCL1	0.45	7.31	0.41	3.23e-12	Tonsillectomy;
CESC	cis	rs72781680	1.000	rs74704838	chr2:24158270	C/A	cg20701182	chr2:24300061	SF3B14	0.65	5.81	0.34	1.79e-8	Lymphocyte counts;
CESC	cis	rs7680126	0.536	rs3796841	chr4:10007904	C/T	cg00071950	chr4:10020882	SLC2A9	0.58	5.75	0.33	2.41e-8	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	cis	rs1577917	1.000	rs10944169	chr6:86683036	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.47	-6.07	-0.35	4.5e-9	Response to antipsychotic treatment;
CESC	cis	rs709400	0.663	rs10141388	chr14:103939679	A/G	cg12935359	chr14:103987150	CKB	-0.47	-6.87	-0.39	4.58e-11	Body mass index;
CESC	cis	rs3733585	0.699	rs28610447	chr4:9971517	T/C	cg00071950	chr4:10020882	SLC2A9	-0.69	-11.32	-0.57	1.7e-24	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs4819052	0.851	rs2838831	chr21:46664775	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.48	5.97	0.34	7.58e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs116095464	0.558	rs56127718	chr5:270273	G/T	cg20965017	chr5:231967	SDHA	-0.48	-5.44	-0.32	1.22e-7	Breast cancer;
CESC	cis	rs6570726	0.791	rs414297	chr6:145887556	C/T	cg05347473	chr6:146136440	FBXO30	0.54	7.09	0.4	1.24e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7296418	0.699	rs11057254	chr12:123794581	A/C	cg00376283	chr12:123451042	ABCB9	0.57	7.82	0.43	1.23e-13	Platelet count;
CESC	trans	rs9325144	0.723	rs3887436	chr12:39189526	A/C	cg23762105	chr12:34175262	ALG10	0.45	6.14	0.35	3.01e-9	Morning vs. evening chronotype;
CESC	cis	rs921968	0.643	rs833083	chr2:219336959	A/T	cg02176678	chr2:219576539	TTLL4	-0.39	-6.99	-0.39	2.26e-11	Mean corpuscular hemoglobin concentration;
CESC	cis	rs2463822	1.000	rs2513074	chr11:62100880	A/C	cg06239285	chr11:62104954	ASRGL1	0.89	8.97	0.48	5.69e-17	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs2228479	0.867	rs57492102	chr16:89975572	A/G	cg06558623	chr16:89946397	TCF25	0.9	7.89	0.44	7.95e-14	Skin colour saturation;
CESC	cis	rs9908102	0.740	rs73298506	chr17:12904119	G/A	cg26162695	chr17:12921313	ELAC2	0.5	5.49	0.32	9.61e-8	Schizophrenia;
CESC	cis	rs11098499	0.909	rs28668716	chr4:120309875	T/C	cg24375607	chr4:120327624	NA	0.46	5.55	0.32	6.98e-8	Corneal astigmatism;
CESC	cis	rs9911578	1.000	rs12952832	chr17:56906254	T/C	cg05425664	chr17:57184151	TRIM37	-0.5	-6.92	-0.39	3.44e-11	Intelligence (multi-trait analysis);
CESC	cis	rs7666738	0.830	rs11097606	chr4:99011486	C/T	cg18180107	chr4:99064573	C4orf37	0.41	5.39	0.31	1.53e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2425143	0.908	rs6060632	chr20:34422601	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-6.14	-0.35	3.05e-9	Blood protein levels;
CESC	cis	rs12079745	0.590	rs12095526	chr1:169401827	A/G	cg09363564	chr1:169337483	NME7;BLZF1	-1.26	-7.33	-0.41	2.72e-12	QT interval;
CESC	cis	rs9488822	0.636	rs12201275	chr6:116314563	C/G	cg05304507	chr6:116381966	FRK	0.24	6.26	0.36	1.53e-9	Cholesterol, total;LDL cholesterol;
CESC	cis	rs7618915	0.508	rs7628578	chr3:52628321	A/T	cg17372223	chr3:52568218	NT5DC2	0.42	6.42	0.37	6.09e-10	Bipolar disorder;
CESC	cis	rs728616	0.867	rs4387301	chr10:81736399	C/T	cg05935833	chr10:81318306	SFTPA2	-0.51	-5.04	-0.3	8.51e-7	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs763014	0.838	rs4984670	chr16:641044	A/G	cg07597022	chr16:675116	RAB40C	-0.31	-5.03	-0.3	8.85e-7	Height;
CESC	cis	rs6570726	0.791	rs9376945	chr6:145828080	T/A	cg05347473	chr6:146136440	FBXO30	0.59	7.56	0.42	6.43e-13	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs10504229	0.683	rs67035623	chr8:58139963	G/T	cg22535103	chr8:58192502	C8orf71	-0.8	-9.09	-0.49	2.46e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs7666738	0.800	rs11941885	chr4:99072921	A/C	cg18180107	chr4:99064573	C4orf37	0.42	5.23	0.31	3.45e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4835473	0.932	rs7690428	chr4:144706553	A/G	cg25736465	chr4:144833511	NA	-0.33	-5.43	-0.32	1.28e-7	Immature fraction of reticulocytes;
CESC	cis	rs1552244	1.000	rs67006488	chr3:10152993	T/C	cg00149659	chr3:10157352	C3orf10	0.72	9.05	0.49	3.26e-17	Alzheimer's disease;
CESC	cis	rs67311347	1.000	rs9874499	chr3:40441908	C/T	cg24209194	chr3:40518798	ZNF619	0.43	5.42	0.32	1.35e-7	Renal cell carcinoma;
CESC	cis	rs62064224	0.554	rs9901737	chr17:30681354	C/G	cg18200150	chr17:30822561	MYO1D	0.38	5.11	0.3	6.22e-7	Schizophrenia;
CESC	cis	rs9815354	0.723	rs61182696	chr3:42032511	C/T	cg03022575	chr3:42003672	ULK4	0.75	6.64	0.38	1.72e-10	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs769267	0.895	rs2916074	chr19:19530270	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.48	6.11	0.35	3.49e-9	Tonsillectomy;
CESC	cis	rs12476592	0.602	rs10168545	chr2:63734284	C/A	cg17519650	chr2:63277830	OTX1	-0.48	-5.59	-0.32	5.6e-8	Childhood ear infection;
CESC	cis	rs6540559	0.808	rs11119358	chr1:210042456	T/C	cg25204440	chr1:209979598	IRF6	0.67	7.93	0.44	6.35e-14	Cleft lip with or without cleft palate;
CESC	cis	rs6570726	0.791	rs6570693	chr6:145910841	C/T	cg23711669	chr6:146136114	FBXO30	0.92	13.58	0.64	3.16e-32	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1707322	0.638	rs1707302	chr1:46600917	A/G	cg06784218	chr1:46089804	CCDC17	-0.32	-5.16	-0.3	4.84e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs208520	0.526	rs1385219	chr6:66754476	C/T	cg07460842	chr6:66804631	NA	1.01	21.14	0.79	8.4e-59	Exhaled nitric oxide output;
CESC	cis	rs1577917	1.000	rs12207305	chr6:86723502	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-6.03	-0.35	5.34e-9	Response to antipsychotic treatment;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg14393411	chr19:13067586	GADD45GIP1	0.5	6.75	0.38	9.21e-11	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs732765	0.602	rs2359192	chr14:75410523	A/C	cg06642626	chr14:75180534	FCF1;KIAA0317	0.36	5.31	0.31	2.37e-7	Non-small cell lung cancer;
CESC	cis	rs8180040	0.726	rs11130110	chr3:47000606	T/C	cg27129171	chr3:47204927	SETD2	0.66	9.63	0.51	4.97e-19	Colorectal cancer;
CESC	cis	rs6964587	0.967	rs28399886	chr7:91638451	A/G	cg17063962	chr7:91808500	NA	0.58	8.01	0.44	3.65e-14	Breast cancer;
CESC	cis	rs9325144	0.577	rs12314639	chr12:39119869	T/C	cg26384229	chr12:38710491	ALG10B	-0.54	-7.43	-0.42	1.48e-12	Morning vs. evening chronotype;
CESC	cis	rs5758659	1.000	rs134882	chr22:42670965	A/G	cg15557168	chr22:42548783	NA	-0.5	-8.05	-0.44	2.74e-14	Cognitive function;
CESC	cis	rs7208859	0.623	rs28627615	chr17:29145817	G/C	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.1e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs7937682	1.000	rs7128353	chr11:111538875	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.98	-15.54	-0.69	3.81e-39	Primary sclerosing cholangitis;
CESC	cis	rs5763662	1.000	rs34474867	chr22:30563301	C/T	cg21388335	chr22:29999516	NF2	-0.74	-5.04	-0.3	8.8e-7	LDL cholesterol levels;LDL cholesterol;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11587315	chr1:223254976	NA	0.6	6.88	0.39	4.33e-11	Gut microbiome composition (summer);
CESC	cis	rs2625529	0.652	rs2957735	chr15:72265173	T/C	cg16672083	chr15:72433130	SENP8	0.46	6.78	0.38	7.68e-11	Red blood cell count;
CESC	trans	rs61931739	0.500	rs7311302	chr12:34557211	T/C	cg26384229	chr12:38710491	ALG10B	0.53	7.41	0.41	1.74e-12	Morning vs. evening chronotype;
CESC	cis	rs8077889	1.000	rs2342310	chr17:41866199	T/C	cg26893861	chr17:41843967	DUSP3	0.85	9.86	0.52	1e-19	Triglycerides;
CESC	cis	rs4253772	0.530	rs9615958	chr22:46751122	A/G	cg24881330	chr22:46731750	TRMU	0.75	5.75	0.33	2.46e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs17711722	0.522	rs4642526	chr7:65216742	G/T	cg26939375	chr7:64535504	NA	0.66	9.52	0.5	1.17e-18	Calcium levels;
CESC	cis	rs2836974	0.965	rs9941894	chr21:40634058	C/T	cg11644478	chr21:40555479	PSMG1	0.95	14.21	0.66	1.96e-34	Cognitive function;
CESC	cis	rs1570884	0.516	rs9316462	chr13:50176321	A/G	cg08779649	chr13:50194554	NA	0.39	6.71	0.38	1.17e-10	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
CESC	cis	rs2066819	0.901	rs1274490	chr12:56649601	A/G	cg26316697	chr12:56727976	PAN2	-0.7	-6.79	-0.39	7.22e-11	Psoriasis vulgaris;
CESC	cis	rs7267979	0.549	rs11698185	chr20:25181998	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.66	10.57	0.54	4.93e-22	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs1799949	1.000	rs1824889	chr17:41421876	C/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.4	5.42	0.32	1.32e-7	Menopause (age at onset);
CESC	cis	rs875971	0.862	rs11984115	chr7:65773859	C/T	cg19163074	chr7:65112434	INTS4L2	0.41	5.24	0.31	3.26e-7	Aortic root size;
CESC	cis	rs910316	0.763	rs2080201	chr14:75629972	C/T	cg11812906	chr14:75593930	NEK9	-0.79	-12.24	-0.6	1.36e-27	Height;
CESC	cis	rs722599	0.683	rs17102847	chr14:75324780	A/G	cg11812906	chr14:75593930	NEK9	-0.46	-5.68	-0.33	3.46e-8	IgG glycosylation;
CESC	cis	rs4253772	0.575	rs9615364	chr22:46797503	G/A	cg24881330	chr22:46731750	TRMU	0.67	5.27	0.31	2.76e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs10504229	0.906	rs7003276	chr8:58173089	A/T	cg24829409	chr8:58192753	C8orf71	-0.75	-9.95	-0.52	5.19e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs11711311	1.000	rs12736	chr3:113530211	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.68	9.39	0.5	2.79e-18	IgG glycosylation;
CESC	cis	rs11190604	1.000	rs10883493	chr10:102208188	A/T	cg07080220	chr10:102295463	HIF1AN	0.55	5.51	0.32	8.5e-8	Palmitoleic acid (16:1n-7) levels;
CESC	trans	rs17536732	0.685	rs79983181	chr4:162859282	C/A	cg12177677	chr2:158300475	CYTIP	-0.63	-6.2	-0.36	2.17e-9	Risky sexual behaviors (alcohol dependence interaction);
CESC	cis	rs10504229	0.683	rs56211106	chr8:58113497	A/G	cg02725872	chr8:58115012	NA	-0.45	-7.04	-0.4	1.66e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs4561483	0.549	rs33657	chr16:11969724	G/C	cg08843971	chr16:11963173	GSPT1	-0.53	-7.56	-0.42	6.61e-13	Testicular germ cell tumor;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00098451	chr1:16370634	CLCNKB	-0.56	-7.29	-0.41	3.62e-12	Gut microbiome composition (summer);
CESC	cis	rs10504229	1.000	rs61998258	chr8:58192284	T/C	cg14926445	chr8:58193284	C8orf71	-0.51	-5.52	-0.32	8.28e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs4835473	0.932	rs17763107	chr4:144749665	A/G	cg25736465	chr4:144833511	NA	-0.45	-6.75	-0.38	9.22e-11	Immature fraction of reticulocytes;
CESC	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg19318889	chr4:1322082	MAEA	0.59	7.05	0.4	1.53e-11	Longevity;
CESC	cis	rs6912958	1.000	rs6937823	chr6:88160386	G/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.6	-8.32	-0.45	4.79e-15	Monocyte percentage of white cells;
CESC	cis	rs4955124	0.558	rs62244396	chr3:32023779	T/C	cg05935571	chr3:32023257	ZNF860;OSBPL10	0.99	7.96	0.44	5.07e-14	Schizophrenia;
CESC	cis	rs1005277	0.579	rs176886	chr10:38403974	C/T	cg00409905	chr10:38381863	ZNF37A	-0.48	-6.39	-0.37	7.55e-10	Extrinsic epigenetic age acceleration;
CESC	cis	rs2243480	0.901	rs58207111	chr7:65486723	C/T	cg13147721	chr7:65941812	NA	-0.86	-8.36	-0.46	3.7e-15	Diabetic kidney disease;
CESC	trans	rs116095464	0.558	rs1971229	chr5:268187	A/G	cg00938859	chr5:1591904	SDHAP3	0.63	6.77	0.38	8.38e-11	Breast cancer;
CESC	cis	rs4888262	0.526	rs4887772	chr16:74537591	C/T	cg01733217	chr16:74700730	RFWD3	0.81	11.32	0.57	1.68e-24	Testicular germ cell tumor;
CESC	cis	rs12325245	0.536	rs35832551	chr16:58591444	G/T	cg02549819	chr16:58548995	SETD6	0.96	6.42	0.37	6.42e-10	Schizophrenia;
CESC	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg14820908	chr5:178986412	RUFY1	0.5	7.84	0.43	1.12e-13	Lung cancer;
CESC	cis	rs2842992	0.915	rs2758350	chr6:160118056	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.64	8.08	0.44	2.36e-14	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs7666738	0.822	rs17484018	chr4:98988960	G/A	cg17366294	chr4:99064904	C4orf37	0.6	8.59	0.47	7.62e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs13256369	0.802	rs13280101	chr8:8562773	G/A	cg17143192	chr8:8559678	CLDN23	0.77	8.67	0.47	4.32e-16	Obesity-related traits;
CESC	cis	rs7727544	0.606	rs10060615	chr5:131708877	T/C	cg14196790	chr5:131705035	SLC22A5	0.36	5.44	0.32	1.18e-7	Blood metabolite levels;
CESC	cis	rs10751667	0.643	rs10794352	chr11:946294	T/C	cg06064525	chr11:970664	AP2A2	-0.49	-9.82	-0.52	1.26e-19	Alzheimer's disease (late onset);
CESC	cis	rs9905704	0.918	rs186221	chr17:56695967	C/T	cg12560992	chr17:57184187	TRIM37	0.59	6.98	0.39	2.34e-11	Testicular germ cell tumor;
CESC	cis	rs1941023	0.503	rs7952244	chr11:60132164	G/A	cg08716584	chr11:60157161	MS4A7	-0.55	-8.95	-0.48	6.42e-17	Congenital heart disease (maternal effect);
CESC	cis	rs1538970	0.924	rs2088100	chr1:45877575	C/T	cg24296786	chr1:45957014	TESK2	-0.45	-5.22	-0.31	3.64e-7	Platelet count;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg10113582	chr4:905918	GAK	0.45	6.06	0.35	4.6e-9	Fibrinogen levels;
CESC	cis	rs10479542	1.000	rs10479542	chr5:178981241	T/A	cg09060608	chr5:178986726	RUFY1	0.51	7.79	0.43	1.5700000000000001e-13	Lung cancer;
CESC	cis	rs9527	1.000	rs9527	chr10:104623578	C/T	cg04362960	chr10:104952993	NT5C2	0.51	5.48	0.32	9.8e-8	Arsenic metabolism;
CESC	cis	rs3096299	0.719	rs12934708	chr16:89523790	C/T	cg08822215	chr16:89438651	ANKRD11	-0.34	-5.11	-0.3	6.26e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs72634258	0.554	rs4562654	chr1:7934423	A/T	cg00042356	chr1:8021962	PARK7	0.6	5.95	0.34	8.6e-9	Inflammatory bowel disease;
CESC	cis	rs5769707	0.616	rs135869	chr22:50008366	T/C	cg20744362	chr22:50050164	C22orf34	0.38	5.26	0.31	2.97e-7	Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs116095464	0.558	rs6555055	chr5:226160	A/C	cg12570787	chr5:219185	SDHA;CCDC127	0.52	5.58	0.32	5.88e-8	Breast cancer;
CESC	cis	rs1552244	1.000	rs67569278	chr3:10149893	T/C	cg08888203	chr3:10149979	C3orf24	0.42	5.1	0.3	6.38e-7	Alzheimer's disease;
CESC	cis	rs12464559	0.522	rs11676866	chr2:152628858	G/C	cg01189475	chr2:152685088	ARL5A	0.72	7.17	0.4	7.48e-12	Response to cognitive-behavioural therapy in anxiety disorder;
CESC	cis	rs2637266	0.935	rs12259550	chr10:78352843	A/G	cg18941641	chr10:78392320	NA	0.41	7.55	0.42	7.02e-13	Pulmonary function;
CESC	cis	rs8060686	0.920	rs2292316	chr16:67861134	C/G	cg26727032	chr16:67993705	SLC12A4	0.58	6.39	0.37	7.27e-10	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs861020	0.630	rs657861	chr1:210006884	C/G	cg05527609	chr1:210001259	C1orf107	0.72	9.41	0.5	2.51e-18	Orofacial clefts;
CESC	cis	rs9926296	0.533	rs9938865	chr16:89867797	A/G	cg27121462	chr16:89883253	FANCA	0.82	12.35	0.6	5.75e-28	Vitiligo;
CESC	cis	rs13095912	1.000	rs10937226	chr3:185302885	G/A	cg11274856	chr3:185301563	NA	0.35	5.7	0.33	3.24e-8	Systolic blood pressure;
CESC	cis	rs959260	0.925	rs9901434	chr17:73388770	A/G	cg12999837	chr17:73267436	MIF4GD	-0.51	-5.74	-0.33	2.57e-8	Systemic lupus erythematosus;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg18046570	chr17:26368374	NLK	0.46	6.44	0.37	5.6e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs6691722	0.503	rs3765427	chr1:24705567	G/A	cg18323236	chr1:24743029	NIPAL3	0.39	5.7	0.33	3.12e-8	Response to interferon beta in multiple sclerosis;
CESC	cis	rs2836950	0.545	rs2297256	chr21:40558421	C/T	cg11644478	chr21:40555479	PSMG1	-0.5	-6.82	-0.39	6.23e-11	Menarche (age at onset);
CESC	cis	rs2243480	1.000	rs316322	chr7:65611233	G/C	cg18252515	chr7:66147081	NA	-1.41	-14.47	-0.66	2.25e-35	Diabetic kidney disease;
CESC	cis	rs11255291	0.668	rs4749169	chr10:7737661	G/C	cg26051552	chr10:7670683	ITIH5	0.36	5.15	0.3	5e-7	Ovarian reserve;
CESC	cis	rs4889855	0.530	rs4477776	chr17:78581765	G/A	cg16591659	chr17:78472290	NA	-0.31	-5.15	-0.3	5.08e-7	Fractional excretion of uric acid;
CESC	cis	rs10504229	0.953	rs72650891	chr8:58179697	T/G	cg22535103	chr8:58192502	C8orf71	-1.05	-13.27	-0.63	3.63e-31	Developmental language disorder (linguistic errors);
CESC	cis	rs6952808	0.594	rs3778965	chr7:2138296	G/A	cg21782813	chr7:2030301	MAD1L1	0.49	7.01	0.4	1.98e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs9896933	0.723	rs7224189	chr17:80782227	C/T	cg20578329	chr17:80767326	TBCD	-0.61	-6.69	-0.38	1.35e-10	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
CESC	cis	rs1707322	1.000	rs10890381	chr1:46451771	T/G	cg03146154	chr1:46216737	IPP	0.78	10.77	0.55	1.17e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs650950	0.528	rs646660	chr11:35528452	C/T	cg26859690	chr20:3869672	PANK2	0.46	6.25	0.36	1.63e-9	Bronchopulmonary dysplasia;
CESC	cis	rs9902453	0.836	rs62070337	chr17:28466257	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.62	8.02	0.44	3.41e-14	Coffee consumption (cups per day);
CESC	cis	rs4835473	0.838	rs56033497	chr4:144713494	A/T	cg25736465	chr4:144833511	NA	-0.36	-5.86	-0.34	1.4e-8	Immature fraction of reticulocytes;
CESC	cis	rs10045504	0.502	rs17456198	chr5:38732005	A/G	cg15396434	chr5:38725168	NA	-0.66	-6.41	-0.37	6.49e-10	Night sleep phenotypes;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg15312298	chr8:127570908	FAM84B	-0.43	-6.01	-0.35	6.09e-9	Height;
CESC	cis	rs7927771	0.524	rs10838775	chr11:47856382	C/G	cg18512352	chr11:47633146	NA	0.35	5.39	0.31	1.53e-7	Subjective well-being;
CESC	cis	rs7267979	0.844	rs2474780	chr20:25285835	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.79	14.56	0.67	1.07e-35	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs1707322	1.000	rs10890360	chr1:46338444	C/T	cg05343316	chr1:45956843	TESK2	0.44	5.55	0.32	7.05e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7666738	0.830	rs72882693	chr4:98960804	T/A	cg17366294	chr4:99064904	C4orf37	0.6	8.52	0.46	1.2e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs17407555	0.821	rs55851451	chr4:10139189	G/A	cg00071950	chr4:10020882	SLC2A9	-0.62	-5.6	-0.33	5.37e-8	Schizophrenia (age at onset);
CESC	cis	rs4975709	0.589	rs4975745	chr5:1861058	G/C	cg14773178	chr5:1868261	NA	0.32	5.58	0.32	6e-8	Cardiovascular disease risk factors;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21159473	chr9:15510228	PSIP1	0.57	6.92	0.39	3.33e-11	Gut microbiome composition (summer);
CESC	cis	rs1862618	0.853	rs832582	chr5:56177743	G/A	cg22800045	chr5:56110881	MAP3K1	0.81	9.74	0.51	2.33e-19	Initial pursuit acceleration;
CESC	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.55	-6.1	-0.35	3.69e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs8114671	0.527	rs3736802	chr20:33604042	T/C	cg24642439	chr20:33292090	TP53INP2	-0.5	-6.2	-0.36	2.2e-9	Height;
CESC	cis	rs597539	0.652	rs592697	chr11:68650064	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.77	10.1	0.53	1.71e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg14677014	chr10:15001504	MEIG1	-0.46	-6.19	-0.36	2.23e-9	Fibrinogen levels;
CESC	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	10.58	0.55	4.6e-22	Prudent dietary pattern;
CESC	cis	rs9911578	1.000	rs437732	chr17:56675861	A/C	cg12560992	chr17:57184187	TRIM37	0.93	15.58	0.69	2.6e-39	Intelligence (multi-trait analysis);
CESC	cis	rs7666738	0.830	rs13137808	chr4:99047095	T/C	cg18180107	chr4:99064573	C4orf37	0.41	5.29	0.31	2.51e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2361718	0.568	rs1042397	chr17:78092063	G/A	cg27427491	chr17:78079615	GAA	-0.37	-5.71	-0.33	3.09e-8	Yeast infection;
CESC	cis	rs710216	0.917	rs1681859	chr1:43411829	G/A	cg07803811	chr1:43423981	SLC2A1	0.49	5.19	0.3	4.12e-7	Red cell distribution width;
CESC	cis	rs2380220	0.541	rs9285413	chr6:96023439	G/A	cg04719120	chr6:96025338	MANEA	0.65	6.94	0.39	3.08e-11	Behavioural disinhibition (generation interaction);
CESC	cis	rs1348850	0.567	rs880898	chr2:178532470	C/T	cg22681709	chr2:178499509	PDE11A	-0.48	-7.75	-0.43	1.95e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs875971	0.862	rs1167399	chr7:65561877	G/A	cg18876405	chr7:65276391	NA	-0.57	-7.55	-0.42	6.85e-13	Aortic root size;
CESC	cis	rs9859260	0.744	rs557527	chr3:195780709	G/A	cg12923728	chr3:195709715	SDHAP1	0.54	6.96	0.39	2.68e-11	Mean corpuscular volume;
CESC	cis	rs7589342	0.628	rs9646959	chr2:106412191	A/G	cg16077055	chr2:106428750	NCK2	-0.52	-6.57	-0.37	2.71e-10	Addiction;
CESC	cis	rs892961	0.932	rs7224116	chr17:75413177	A/G	cg05865280	chr17:75406074	SEPT9	0.62	12.67	0.61	4.57e-29	Airflow obstruction;
CESC	cis	rs672059	0.513	rs572977	chr1:183164991	C/G	cg05929019	chr1:183155154	LAMC2	-0.29	-5.37	-0.31	1.71e-7	Hypertriglyceridemia;
CESC	cis	rs7917772	0.508	rs2252147	chr10:104467774	G/A	cg04362960	chr10:104952993	NT5C2	-0.46	-5.04	-0.3	8.82e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs864537	0.646	rs1723016	chr1:167433056	T/C	cg22356347	chr1:167427500	CD247	-0.37	-7.65	-0.43	3.84e-13	Celiac disease or Rheumatoid arthritis;Celiac disease;
CESC	cis	rs8064299	0.655	rs734232	chr17:72765731	C/T	cg25054828	chr17:72772726	NAT9;TMEM104	0.49	6.24	0.36	1.7e-9	Monocyte count;
CESC	cis	rs2108225	0.934	rs2301989	chr7:107443871	G/A	cg18560240	chr7:107437656	SLC26A3	-0.37	-5.13	-0.3	5.61e-7	Ulcerative colitis;
CESC	cis	rs7726839	0.540	rs72703079	chr5:595173	T/C	cg16447950	chr5:562315	NA	-0.6	-6.08	-0.35	4.21e-9	Obesity-related traits;
CESC	cis	rs9300255	0.544	rs1727310	chr12:123660510	A/G	cg00376283	chr12:123451042	ABCB9	0.61	6.17	0.35	2.57e-9	Neutrophil percentage of white cells;
CESC	cis	rs875971	0.895	rs1974769	chr7:65950614	G/A	cg11764359	chr7:65958608	NA	0.96	15.03	0.68	2.41e-37	Aortic root size;
CESC	trans	rs11098499	0.863	rs10004484	chr4:120442428	C/T	cg25214090	chr10:38739885	LOC399744	0.71	9.82	0.52	1.35e-19	Corneal astigmatism;
CESC	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg26338869	chr17:61819248	STRADA	0.69	9.47	0.5	1.66e-18	Prudent dietary pattern;
CESC	cis	rs10949834	0.540	rs810552	chr7:73489298	A/G	cg07137043	chr7:73588983	EIF4H	0.59	7.05	0.4	1.59e-11	Verbal memory performance (residualized delayed recall change);
CESC	cis	rs9931543	0.504	rs4784650	chr16:56306640	A/G	cg02433656	chr16:56322654	GNAO1	0.39	5.06	0.3	7.68e-7	Subjective well-being;
CESC	cis	rs7666738	0.830	rs6854902	chr4:99033416	T/G	cg03467027	chr4:99064603	C4orf37	0.49	6.18	0.35	2.44e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1559088	0.573	rs1270591	chr19:33622942	C/T	cg27124370	chr19:33622961	WDR88	-0.52	-7.35	-0.41	2.41e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs372883	0.554	rs10154065	chr21:30749480	G/C	cg24692254	chr21:30365293	RNF160	0.51	6.38	0.37	7.69e-10	Pancreatic cancer;
CESC	cis	rs7659604	0.540	rs11098643	chr4:122701507	C/A	cg19748678	chr4:122722346	EXOSC9	-0.43	-5.36	-0.31	1.84e-7	Type 2 diabetes;
CESC	cis	rs367943	0.966	rs348924	chr5:112817930	T/G	cg12552261	chr5:112820674	MCC	-0.62	-7.78	-0.43	1.58e-13	Type 2 diabetes;
CESC	cis	rs425277	0.565	rs61775448	chr1:2045376	A/G	cg04315214	chr1:2043799	PRKCZ	0.62	11.23	0.57	3.43e-24	Height;
CESC	cis	rs2267137	0.836	rs2283855	chr22:29796775	T/C	cg07256473	chr22:29710276	RASL10A	0.39	5.57	0.32	6.1e-8	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	cis	rs4588572	0.643	rs6453396	chr5:77785387	T/C	cg11547950	chr5:77652471	NA	-0.48	-6.09	-0.35	3.93e-9	Triglycerides;
CESC	cis	rs2439831	0.867	rs6493082	chr15:43634808	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.83	12.31	0.6	7.84e-28	Lung cancer in ever smokers;
CESC	cis	rs11645898	0.622	rs4788463	chr16:72223716	G/T	cg14768367	chr16:72042858	DHODH	-0.67	-5.04	-0.3	8.59e-7	Blood protein levels;
CESC	cis	rs875971	0.895	rs3857684	chr7:65938158	G/C	cg10691866	chr7:65817282	TPST1	-0.34	-5.65	-0.33	4.03e-8	Aortic root size;
CESC	cis	rs9388451	0.839	rs10457469	chr6:126083658	G/A	cg05901451	chr6:126070800	HEY2	-0.63	-8.86	-0.48	1.22e-16	Brugada syndrome;
CESC	cis	rs11167764	1.000	rs3761757	chr5:141488219	A/C	cg08523384	chr5:141488047	NDFIP1	-0.37	-5.43	-0.32	1.25e-7	Crohn's disease;
CESC	cis	rs637571	0.522	rs503524	chr11:65751764	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.44	6.61	0.38	2.11e-10	Eosinophil percentage of white cells;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg03368399	chr8:22102556	POLR3D;MIR320A	-0.38	-6.21	-0.36	1.99e-9	Gambling;
CESC	cis	rs757110	0.834	rs1002226	chr11:17405617	C/T	cg11839944	chr11:17409644	KCNJ11	0.39	5.38	0.31	1.66e-7	Type 2 diabetes;
CESC	cis	rs9768139	0.524	rs7779175	chr7:158136918	C/T	cg25566285	chr7:158114605	PTPRN2	-0.45	-6.23	-0.36	1.77e-9	Calcium levels;
CESC	cis	rs637571	0.544	rs617791	chr11:65702523	C/G	cg04055107	chr11:65626734	MUS81;CFL1	0.54	6.73	0.38	1.06e-10	Eosinophil percentage of white cells;
CESC	cis	rs4969178	0.965	rs16971105	chr17:76393975	G/T	cg20026190	chr17:76395443	PGS1	0.47	7.58	0.42	5.9e-13	HDL cholesterol levels;
CESC	cis	rs713587	0.563	rs7591460	chr2:25103967	A/C	cg01884057	chr2:25150051	NA	0.33	6.3	0.36	1.24e-9	Body mass index in non-asthmatics;
CESC	cis	rs6540559	0.673	rs17015183	chr1:209948711	A/C	cg23283495	chr1:209979779	IRF6	0.46	5.66	0.33	3.89e-8	Cleft lip with or without cleft palate;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06211794	chr20:48330587	B4GALT5	0.66	7.73	0.43	2.3e-13	Gut microbiome composition (summer);
CESC	cis	rs12136530	0.681	rs6426798	chr1:19719728	C/T	cg01832549	chr1:19774989	CAPZB	-0.4	-5.74	-0.33	2.53e-8	Lead levels in blood;
CESC	cis	rs2842992	0.672	rs7738253	chr6:160193917	G/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.77	9.64	0.51	4.76e-19	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs9733	0.596	rs6692960	chr1:150695965	G/A	cg17724175	chr1:150552817	MCL1	0.45	7.31	0.41	3.17e-12	Tonsillectomy;
CESC	cis	rs864745	0.579	rs849336	chr7:28224053	A/G	cg23620719	chr7:28220237	JAZF1	-0.44	-5.2	-0.3	3.91e-7	Crohn's disease;Type 2 diabetes;
CESC	cis	rs7666738	0.753	rs10033138	chr4:98981922	A/C	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.67e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9611565	0.694	rs202639	chr22:41856137	T/A	cg17376030	chr22:41985996	PMM1	-0.73	-7.85	-0.43	1e-13	Vitiligo;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg24340029	chr9:136039283	GBGT1	-0.35	-6.0	-0.35	6.34e-9	Gambling;
CESC	cis	rs2235544	0.565	rs620907	chr1:54468166	T/G	cg25741118	chr1:54482237	LDLRAD1	0.24	5.82	0.34	1.72e-8	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
CESC	cis	rs11608355	0.545	rs1073779	chr12:109894721	C/T	cg05360138	chr12:110035743	NA	0.82	8.92	0.48	7.93e-17	Neuroticism;
CESC	cis	rs11190604	1.000	rs10509744	chr10:102271579	C/T	cg07080220	chr10:102295463	HIF1AN	0.66	6.13	0.35	3.24e-9	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs8017423	0.967	rs11844225	chr14:90726676	G/A	cg14092571	chr14:90743983	NA	-0.55	-8.29	-0.45	5.82e-15	Mortality in heart failure;
CESC	cis	rs10949834	0.793	rs810532	chr7:73505188	A/G	cg07137043	chr7:73588983	EIF4H	-0.68	-7.39	-0.41	1.89e-12	Verbal memory performance (residualized delayed recall change);
CESC	cis	rs4563143	0.514	rs73029081	chr19:29295583	C/G	cg14983838	chr19:29218262	NA	0.5	5.52	0.32	8.22e-8	Methadone dose in opioid dependence;
CESC	cis	rs6815814	0.950	rs67206233	chr4:38807853	T/C	cg02016764	chr4:38805732	TLR1	-0.63	-7.26	-0.41	4.22e-12	Breast cancer;
CESC	cis	rs4727027	0.901	rs4727019	chr7:148822266	A/G	cg23158103	chr7:148848205	ZNF398	-0.41	-6.47	-0.37	4.71e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg07092213	chr7:1199455	ZFAND2A	-0.46	-6.35	-0.36	9.42e-10	Longevity;Endometriosis;
CESC	cis	rs4481887	1.000	rs4916124	chr1:248466495	T/C	cg00666640	chr1:248458726	OR2T12	0.39	6.37	0.36	8.47e-10	Common traits (Other);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg05007375	chr14:92588364	NDUFB1;CPSF2	-0.43	-6.26	-0.36	1.51e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs4523957	0.579	rs903162	chr17:2092200	C/T	cg16513277	chr17:2031491	SMG6	-0.61	-8.48	-0.46	1.59e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs3820068	0.608	rs7519899	chr1:16045579	A/G	cg13390004	chr1:15929781	NA	0.34	5.21	0.3	3.79e-7	Systolic blood pressure;
CESC	cis	rs6537837	0.838	rs71657105	chr1:110114122	G/A	cg05049280	chr1:110155535	GNAT2	0.38	5.39	0.31	1.55e-7	Major depressive disorder;
CESC	trans	rs3942852	0.606	rs10734561	chr11:48097480	C/T	cg15704280	chr7:45808275	SEPT13	-0.61	-7.51	-0.42	8.79e-13	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	7.83	0.43	1.17e-13	Prudent dietary pattern;
CESC	cis	rs6545883	1.000	rs778762	chr2:61782921	G/T	cg15711740	chr2:61764176	XPO1	-0.42	-5.14	-0.3	5.46e-7	Tuberculosis;
CESC	cis	rs6690583	0.623	rs893620	chr1:85425821	T/C	cg22488158	chr1:85528044	WDR63	0.57	5.5	0.32	8.98e-8	Serum sulfate level;
CESC	cis	rs727505	0.754	rs55859595	chr7:124783083	G/T	cg23710748	chr7:124431027	NA	-0.38	-6.2	-0.36	2.14e-9	Lewy body disease;
CESC	cis	rs6674176	0.569	rs34830883	chr1:44405339	T/C	cg13606994	chr1:44402422	ARTN	-0.39	-6.06	-0.35	4.68e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs7923609	1.000	rs1935	chr10:64927823	C/G	cg01631684	chr10:65280961	REEP3	-0.46	-5.71	-0.33	3.06e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7927771	1.000	rs1317149	chr11:47486885	C/T	cg05585544	chr11:47624801	NA	-0.52	-7.82	-0.43	1.27e-13	Subjective well-being;
CESC	cis	rs6540556	0.723	rs6679099	chr1:209895852	T/G	cg05527609	chr1:210001259	C1orf107	-0.66	-7.32	-0.41	2.95e-12	Red blood cell count;
CESC	cis	rs7267979	1.000	rs6115140	chr20:25285507	C/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.86	16.82	0.72	1.06e-43	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7552404	0.824	rs1251077	chr1:76189745	C/G	cg03433033	chr1:76189801	ACADM	-0.8	-12.71	-0.62	3.18e-29	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs9858542	0.953	rs9837341	chr3:49664767	A/G	cg07274523	chr3:49395745	GPX1	0.68	8.7	0.47	3.66e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs7666738	0.830	rs9996098	chr4:98867740	T/C	cg17366294	chr4:99064904	C4orf37	0.54	7.48	0.42	1.1e-12	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7208859	0.623	rs55724095	chr17:29153058	A/G	cg13385521	chr17:29058706	SUZ12P	0.75	5.95	0.34	8.3e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs7107174	1.000	rs2511171	chr11:77930935	G/A	cg02023728	chr11:77925099	USP35	0.52	6.76	0.38	8.53e-11	Testicular germ cell tumor;
CESC	cis	rs35110281	0.782	rs2838329	chr21:45023329	T/C	cg04455712	chr21:45112962	RRP1B	0.39	5.76	0.33	2.31e-8	Mean corpuscular volume;
CESC	cis	rs4450798	0.793	rs9855726	chr3:13741475	T/A	cg23332027	chr3:13681764	NA	0.41	5.45	0.32	1.12e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs7474896	0.609	rs11011336	chr10:37985316	A/G	cg00409905	chr10:38381863	ZNF37A	-0.47	-5.47	-0.32	1.06e-7	Obesity (extreme);
CESC	cis	rs6088590	0.561	rs6088527	chr20:33155841	C/T	cg24642439	chr20:33292090	TP53INP2	0.63	8.5	0.46	1.36e-15	Coronary artery disease;
CESC	cis	rs6942756	1.000	rs6974155	chr7:128914545	C/G	cg02491457	chr7:128862824	NA	-0.7	-10.36	-0.54	2.47e-21	White matter hyperintensity burden;
CESC	cis	rs478304	0.651	rs7110576	chr11:65512057	T/G	cg10518572	chr11:65560635	OVOL1	-0.32	-6.53	-0.37	3.33e-10	Acne (severe);
CESC	cis	rs2304069	0.954	rs2276983	chr5:149424966	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.84	10.86	0.55	5.76e-23	HIV-1 control;
CESC	cis	rs360798	0.532	rs189671	chr2:62959308	T/A	cg17519650	chr2:63277830	OTX1	-0.55	-6.94	-0.39	2.96e-11	Coronary artery disease;
CESC	cis	rs752092	0.894	rs8043243	chr15:101771453	C/T	cg19997662	chr15:101784653	CHSY1	-0.46	-5.98	-0.34	7.3e-9	Corneal structure;
CESC	cis	rs9322193	0.884	rs2342858	chr6:150127103	C/T	cg05861140	chr6:150128134	PCMT1	-0.37	-5.34	-0.31	2.02e-7	Lung cancer;
CESC	cis	rs780096	0.565	rs780104	chr2:27677691	G/A	cg22903471	chr2:27725779	GCKR	-0.52	-7.39	-0.41	1.88e-12	Total body bone mineral density;
CESC	cis	rs4971059	0.654	rs4971078	chr1:155129023	A/G	cg22049894	chr1:155113146	DPM3	0.47	6.07	0.35	4.4e-9	Breast cancer;
CESC	cis	rs2286503	0.780	rs2240727	chr7:22852512	C/T	cg13679077	chr7:22862647	TOMM7	0.52	6.58	0.37	2.57e-10	Fibrinogen;
CESC	cis	rs6088580	0.634	rs6120666	chr20:33090718	A/G	cg06115741	chr20:33292138	TP53INP2	0.45	5.8	0.34	1.9e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs9790314	0.628	rs1599381	chr3:160867680	G/A	cg03342759	chr3:160939853	NMD3	-0.42	-5.86	-0.34	1.4e-8	Morning vs. evening chronotype;
CESC	cis	rs7223966	0.655	rs6504165	chr17:61630076	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.48	5.66	0.33	3.92e-8	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs4689388	0.853	rs1079214	chr4:6282157	T/C	cg14416269	chr4:6271139	WFS1	0.46	7.45	0.42	1.35e-12	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs28489187	0.617	rs233097	chr1:85825473	G/C	cg16011679	chr1:85725395	C1orf52	0.45	5.31	0.31	2.35e-7	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	cis	rs4927850	1.000	rs10881564	chr3:195750326	C/T	cg12923728	chr3:195709715	SDHAP1	-0.67	-8.79	-0.48	1.88e-16	Pancreatic cancer;
CESC	cis	rs4689592	0.503	rs3857180	chr4:7073899	T/G	cg19539972	chr4:7069911	GRPEL1	-0.69	-6.88	-0.39	4.34e-11	Monocyte percentage of white cells;
CESC	cis	rs61931739	0.500	rs11519123	chr12:34436478	A/G	cg06521331	chr12:34319734	NA	-0.37	-5.12	-0.3	5.98e-7	Morning vs. evening chronotype;
CESC	cis	rs9322193	0.923	rs9800736	chr6:149982417	A/G	cg00933542	chr6:150070202	PCMT1	0.29	5.11	0.3	6.31e-7	Lung cancer;
CESC	cis	rs7301826	0.560	rs12829294	chr12:131309972	A/G	cg11011512	chr12:131303247	STX2	-0.45	-5.49	-0.32	9.37e-8	Plasma plasminogen activator levels;
CESC	cis	rs12725198	1.000	rs12725198	chr1:16080171	A/G	cg18133145	chr1:16060689	PLEKHM2	0.5	5.53	0.32	7.81e-8	Cardiac Troponin-T levels;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg09828580	chr10:103868007	LDB1	0.45	6.44	0.37	5.53e-10	Fibrinogen levels;
CESC	cis	rs3785574	0.962	rs57553639	chr17:61848499	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	7.29	0.41	3.54e-12	Height;
CESC	cis	rs2073300	0.609	rs6137919	chr20:23363163	T/C	cg16736954	chr20:23401023	NAPB	0.8	6.09	0.35	3.89e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs5769765	0.955	rs8135963	chr22:50301476	T/C	cg26441486	chr22:50317300	CRELD2	0.4	5.38	0.31	1.6e-7	Schizophrenia;
CESC	cis	rs10504229	0.562	rs2014516	chr8:58128288	C/A	cg02725872	chr8:58115012	NA	-0.45	-7.05	-0.4	1.52e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs1506636	1.000	rs652497	chr7:123423671	G/T	cg03229431	chr7:123269106	ASB15	0.49	6.59	0.38	2.41e-10	Plateletcrit;Platelet count;
CESC	cis	rs11122272	0.705	rs2572260	chr1:231486189	T/C	cg06096015	chr1:231504339	EGLN1	0.43	6.21	0.36	2.03e-9	Hemoglobin concentration;
CESC	cis	rs10256972	0.758	rs9801444	chr7:1080444	A/C	cg04025307	chr7:1156635	C7orf50	-0.45	-6.94	-0.39	3.01e-11	Longevity;Endometriosis;
CESC	cis	rs36051895	0.664	rs4593605	chr9:5107278	C/A	cg02405213	chr9:5042618	JAK2	-0.49	-6.04	-0.35	5.3e-9	Pediatric autoimmune diseases;
CESC	cis	rs1707322	0.789	rs10789473	chr1:46248131	C/T	cg03146154	chr1:46216737	IPP	0.8	11.14	0.56	6.98e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs13064411	0.627	rs9872168	chr3:113233132	A/C	cg18753928	chr3:113234510	CCDC52	-0.48	-5.72	-0.33	2.92e-8	Response to simvastatin treatment (PCSK9 protein level change);
CESC	cis	rs9311474	0.539	rs12489828	chr3:52567014	G/T	cg25934064	chr3:52569026	NT5DC2	0.25	5.25	0.31	3.08e-7	Electroencephalogram traits;
CESC	cis	rs477692	0.699	rs509017	chr10:131367174	T/G	cg24747557	chr10:131355152	MGMT	-0.37	-5.1	-0.3	6.56e-7	Response to temozolomide;
CESC	cis	rs7618915	0.547	rs11130313	chr3:52676190	A/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.3	5.43	0.32	1.27e-7	Bipolar disorder;
CESC	cis	rs62064224	0.791	rs11653160	chr17:30717222	A/G	cg25809561	chr17:30822961	MYO1D	0.59	8.31	0.45	4.87e-15	Schizophrenia;
CESC	cis	rs9457247	0.510	rs6456151	chr6:167471851	A/C	cg07741184	chr6:167504864	NA	0.36	6.21	0.36	2.01e-9	Crohn's disease;
CESC	cis	rs9389248	0.500	rs116273677	chr6:135339135	A/C	cg24558204	chr6:135376177	HBS1L	0.52	7.18	0.4	7.17e-12	High light scatter reticulocyte percentage of red cells;
CESC	cis	rs2836974	0.965	rs9941894	chr21:40634058	C/T	cg27266027	chr21:40555129	PSMG1	0.48	5.73	0.33	2.74e-8	Cognitive function;
CESC	cis	rs3749237	0.595	rs10865955	chr3:49499829	G/A	cg06212747	chr3:49208901	KLHDC8B	0.49	6.6	0.38	2.26e-10	Resting heart rate;
CESC	cis	rs3026101	0.624	rs60116755	chr17:5303215	G/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.42	5.6	0.33	5.31e-8	Body mass index;
CESC	cis	rs9486715	0.867	rs4839842	chr6:96955387	A/T	cg06623918	chr6:96969491	KIAA0776	0.93	14.38	0.66	4.75e-35	Headache;
CESC	cis	rs67311347	1.000	rs28536038	chr3:40496382	A/C	cg24209194	chr3:40518798	ZNF619	0.5	6.11	0.35	3.59e-9	Renal cell carcinoma;
CESC	cis	rs854765	0.583	rs12603148	chr17:17865257	C/T	cg16928487	chr17:17741425	SREBF1	-0.52	-8.66	-0.47	4.86e-16	Total body bone mineral density;
CESC	cis	rs875971	0.651	rs313829	chr7:65552497	A/G	cg05332525	chr7:65337924	VKORC1L1	-0.45	-5.18	-0.3	4.41e-7	Aortic root size;
CESC	cis	rs7617773	0.817	rs3731534	chr3:48211777	C/T	cg11946769	chr3:48343235	NME6	0.88	11.37	0.57	1.18e-24	Coronary artery disease;
CESC	cis	rs7666738	0.753	rs7657644	chr4:99057734	T/A	cg03676636	chr4:99064102	C4orf37	0.34	5.1	0.3	6.47e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2011503	0.943	rs2965195	chr19:19463032	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.51	-5.17	-0.3	4.66e-7	Bipolar disorder;
CESC	cis	rs10504229	0.593	rs80174614	chr8:58024631	G/A	cg24829409	chr8:58192753	C8orf71	-0.5	-6.08	-0.35	4.13e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs4319547	0.656	rs4997380	chr12:122838956	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.45	-5.25	-0.31	3.06e-7	Body mass index;
CESC	cis	rs801193	0.935	rs2286683	chr7:66129843	G/A	cg25985355	chr7:65971099	NA	0.32	5.23	0.31	3.53e-7	Aortic root size;
CESC	cis	rs7927771	1.000	rs12418852	chr11:47868853	C/G	cg20307385	chr11:47447363	PSMC3	-0.49	-6.0	-0.35	6.54e-9	Subjective well-being;
CESC	cis	rs9443645	0.775	rs9359359	chr6:79700980	T/C	cg05283184	chr6:79620031	NA	-0.38	-5.9	-0.34	1.13e-8	Intelligence (multi-trait analysis);
CESC	cis	rs4472734	0.863	rs5028966	chr1:214618908	C/A	cg00063699	chr1:214624242	PTPN14	-0.34	-5.28	-0.31	2.68e-7	Height;
CESC	cis	rs7618915	0.501	rs2289247	chr3:52727257	C/T	cg18404041	chr3:52824283	ITIH1	-0.36	-5.97	-0.34	7.76e-9	Bipolar disorder;
CESC	cis	rs9911578	1.000	rs2531732	chr17:56548420	T/A	cg02118635	chr17:56770003	RAD51C;TEX14	-0.41	-5.52	-0.32	7.9e-8	Intelligence (multi-trait analysis);
CESC	cis	rs2996428	0.643	rs6424056	chr1:3722486	G/A	cg22529645	chr1:3704559	LRRC47	0.4	5.12	0.3	6.01e-7	Red cell distribution width;
CESC	cis	rs916888	0.610	rs199444	chr17:44818276	T/C	cg17911788	chr17:44343683	NA	-0.43	-6.79	-0.39	7.27e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs2858942	0.575	rs2858011	chr16:247938	C/T	cg00126636	chr16:237282	NA	-0.45	-6.16	-0.35	2.75e-9	Mean corpuscular hemoglobin;
CESC	cis	rs1153858	1.000	rs66714503	chr15:45648038	G/C	cg14582100	chr15:45693742	SPATA5L1	0.42	5.95	0.34	8.45e-9	Homoarginine levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02239082	chr19:48972844	CYTH2	0.66	7.99	0.44	4.06e-14	Gut microbiome composition (summer);
CESC	cis	rs7843479	1.000	rs1032094	chr8:21820479	A/T	cg17168535	chr8:21777572	XPO7	0.49	6.73	0.38	1.03e-10	Mean corpuscular volume;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg13483603	chr12:113344754	OAS1	0.43	6.12	0.35	3.41e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs6089584	0.893	rs6089305	chr20:60571817	T/C	cg13770153	chr20:60521292	NA	-0.48	-6.37	-0.36	8.11e-10	Body mass index;
CESC	cis	rs4555082	0.756	rs76863138	chr14:105736379	C/T	cg27165867	chr14:105738592	BRF1	-0.57	-6.06	-0.35	4.74e-9	Mean platelet volume;Platelet distribution width;
CESC	cis	rs4689388	0.929	rs1046320	chr4:6304344	C/T	cg25554036	chr4:6271136	WFS1	0.52	8.44	0.46	2.12e-15	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs6500395	1.000	rs4493038	chr16:48683920	A/G	cg04672837	chr16:48644449	N4BP1	0.51	6.36	0.36	8.64e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs11690935	0.655	rs12052995	chr2:172537212	A/G	cg13550731	chr2:172543902	DYNC1I2	0.59	8.3	0.45	5.24e-15	Schizophrenia;
CESC	cis	rs6580649	0.941	rs58046797	chr12:48487619	T/C	cg24011408	chr12:48396354	COL2A1	-0.4	-5.04	-0.3	8.67e-7	Lung cancer;
CESC	cis	rs2228479	0.850	rs11641147	chr16:89813589	C/T	cg04013166	chr16:89971882	TCF25	0.79	6.78	0.38	7.83e-11	Skin colour saturation;
CESC	cis	rs9733	0.744	rs4970976	chr1:150779524	T/A	cg18016565	chr1:150552671	MCL1	-0.36	-5.93	-0.34	9.63e-9	Tonsillectomy;
CESC	cis	rs4665809	0.590	rs4665318	chr2:26424517	C/T	cg22920501	chr2:26401640	FAM59B	0.8	9.08	0.49	2.61e-17	Gut microbiome composition (summer);
CESC	cis	rs57083693	0.518	rs6538980	chr12:101692966	A/G	cg22051763	chr12:101673672	UTP20	-0.44	-5.51	-0.32	8.71e-8	Alcohol dependence (age at onset);
CESC	cis	rs7666738	0.716	rs13136721	chr4:99085602	G/A	cg17366294	chr4:99064904	C4orf37	0.54	7.24	0.41	5.01e-12	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg03188948	chr7:1209495	NA	0.71	7.06	0.4	1.5e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs6952808	0.531	rs4721441	chr7:2184060	A/G	cg23048001	chr7:2026167	MAD1L1	0.41	5.46	0.32	1.11e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs3857067	1.000	rs3857067	chr4:95026434	A/T	cg11021082	chr4:95130006	SMARCAD1	-0.54	-8.29	-0.45	5.72e-15	QT interval;
CESC	cis	rs4689388	0.929	rs1046320	chr4:6304344	C/T	cg00701064	chr4:6280414	WFS1	0.66	10.99	0.56	2.16e-23	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs2051211	0.895	rs2300670	chr3:38555815	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.62	-7.13	-0.4	9.69e-12	QRS duration;
CESC	cis	rs1005277	0.579	rs2474572	chr10:38385316	A/G	cg25517755	chr10:38738941	LOC399744	-0.44	-5.75	-0.33	2.43e-8	Extrinsic epigenetic age acceleration;
CESC	cis	rs2249625	0.545	rs2496487	chr6:72875226	G/C	cg18830697	chr6:72922368	RIMS1	-0.48	-7.16	-0.4	7.86e-12	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg04405926	chr1:150208726	ANP32E	0.45	6.14	0.35	3.03e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs2760061	0.626	rs2527614	chr1:228126470	A/G	cg02753203	chr1:228287806	NA	-0.5	-7.22	-0.41	5.54e-12	Diastolic blood pressure;
CESC	cis	rs6662572	1.000	rs1053941	chr1:46084383	G/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.5	5.55	0.32	6.81e-8	Blood protein levels;
CESC	cis	rs7582720	0.945	rs72936875	chr2:203791912	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.38	0.41	1.99e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs4888262	0.545	rs58136167	chr16:74700628	G/A	cg01733217	chr16:74700730	RFWD3	0.9	12.8	0.62	1.6e-29	Testicular germ cell tumor;
CESC	trans	rs2727020	0.554	rs7111711	chr11:49557880	G/A	cg03929089	chr4:120376271	NA	-0.7	-7.93	-0.44	6.31e-14	Coronary artery disease;
CESC	trans	rs826838	0.654	rs7977738	chr12:38722460	G/A	cg23762105	chr12:34175262	ALG10	-0.46	-6.03	-0.35	5.55e-9	Heart rate;
CESC	cis	rs1568889	1.000	rs12797689	chr11:28076042	C/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.7	8.15	0.45	1.44e-14	Bipolar disorder;
CESC	cis	rs7618915	0.571	rs67539070	chr3:52711974	T/C	cg07507251	chr3:52567010	NT5DC2	0.4	7.1	0.4	1.14e-11	Bipolar disorder;
CESC	cis	rs3093024	0.935	rs10946216	chr6:167538897	T/C	cg07741184	chr6:167504864	NA	-0.33	-5.56	-0.32	6.49e-8	Rheumatoid arthritis;
CESC	cis	rs2880765	0.545	rs17553734	chr15:86013059	C/G	cg10818794	chr15:86012489	AKAP13	0.37	5.11	0.3	6.09e-7	Coronary artery disease;
CESC	cis	rs727505	0.754	rs56056794	chr7:124783027	C/T	cg23710748	chr7:124431027	NA	-0.38	-6.2	-0.36	2.14e-9	Lewy body disease;
CESC	cis	rs155076	1.000	rs2478824	chr13:21844144	G/C	cg11317459	chr13:21872234	NA	-1.01	-11.12	-0.56	7.88e-24	White matter hyperintensity burden;
CESC	cis	rs7666738	0.830	rs3846445	chr4:99032939	T/A	cg03467027	chr4:99064603	C4orf37	0.49	6.18	0.35	2.44e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs8103278	0.507	rs3745802	chr19:46271177	G/T	cg14061069	chr19:46274453	DMPK	0.51	8.19	0.45	1.11e-14	Coronary artery disease;
CESC	cis	rs4423214	1.000	rs732934	chr11:71186476	G/A	cg05163923	chr11:71159392	DHCR7	0.8	10.68	0.55	2.29e-22	Vitamin D levels;
CESC	cis	rs7552404	0.807	rs2066183	chr1:76153745	A/G	cg03433033	chr1:76189801	ACADM	0.7	9.38	0.5	2.99e-18	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.64	7.21	0.41	5.71e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs916888	0.773	rs199443	chr17:44819565	C/T	cg01341218	chr17:43662625	NA	0.92	11.18	0.57	5.1900000000000004e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs2228479	0.850	rs11076619	chr16:89831243	C/A	cg04013166	chr16:89971882	TCF25	0.78	6.69	0.38	1.3e-10	Skin colour saturation;
CESC	cis	rs7666738	0.830	rs28417577	chr4:99053007	T/C	cg18180107	chr4:99064573	C4orf37	0.41	5.29	0.31	2.51e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3126085	0.877	rs868304	chr1:152178568	G/A	cg26876637	chr1:152193138	HRNR	0.48	5.44	0.32	1.21e-7	Atopic dermatitis;
CESC	cis	rs4253772	0.550	rs739164	chr22:46684558	C/T	cg10231785	chr22:46692440	CN5H6.4;GTSE1	-0.61	-6.42	-0.37	6.38e-10	LDL cholesterol;Cholesterol, total;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg25365794	chr17:8022404	ALOXE3	0.47	6.19	0.36	2.26e-9	Systemic lupus erythematosus;
CESC	cis	rs853679	0.517	rs4713143	chr6:28106759	A/C	cg19592336	chr6:28129416	ZNF389	0.61	8.24	0.45	8.13e-15	Depression;
CESC	cis	rs7618915	0.501	rs13060048	chr3:52598608	G/A	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.67	0.38	1.47e-10	Bipolar disorder;
CESC	cis	rs9584850	0.874	rs7988959	chr13:99104004	T/C	cg22223119	chr13:99095684	FARP1	-0.38	-5.33	-0.31	2.06e-7	Neuroticism;
CESC	cis	rs2980439	0.818	rs2948294	chr8:8094961	A/G	cg06636001	chr8:8085503	FLJ10661	0.61	7.84	0.43	1.11e-13	Neuroticism;
CESC	cis	rs35160687	0.623	rs2276625	chr2:86481835	A/G	cg01119172	chr2:86362222	SNORD94;PTCD3	0.41	5.49	0.32	9.61e-8	Night sleep phenotypes;
CESC	cis	rs2066819	1.000	rs41363748	chr12:56696056	C/T	cg26714650	chr12:56694279	CS	1.5	10.42	0.54	1.53e-21	Psoriasis vulgaris;
CESC	cis	rs909002	0.789	rs3817398	chr1:32119431	C/T	cg13919466	chr1:32135498	COL16A1	0.44	7.95	0.44	5.54e-14	Intelligence (multi-trait analysis);
CESC	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg18538332	chr22:24372958	LOC391322	-0.76	-11.21	-0.57	4.11e-24	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs1506636	0.889	rs619075	chr7:123426317	A/T	cg03229431	chr7:123269106	ASB15	0.5	6.65	0.38	1.71e-10	Plateletcrit;Platelet count;
CESC	cis	rs910316	0.967	rs2024653	chr14:75595154	G/A	cg11812906	chr14:75593930	NEK9	0.89	15.03	0.68	2.4e-37	Height;
CESC	cis	rs568617	0.716	rs17854357	chr11:65601560	G/C	cg04055107	chr11:65626734	MUS81;CFL1	1.0	8.35	0.46	3.71e-15	Crohn's disease;
CESC	cis	rs782590	0.935	rs2627779	chr2:55892356	A/G	cg18811423	chr2:55921094	PNPT1	0.79	12.54	0.61	1.25e-28	Metabolic syndrome;
CESC	cis	rs3960554	0.599	rs56090527	chr7:75762125	A/C	cg17325771	chr7:75508891	RHBDD2	-0.34	-5.23	-0.31	3.5e-7	Eotaxin levels;
CESC	cis	rs295140	0.605	rs295149	chr2:201175244	A/G	cg23649088	chr2:200775458	C2orf69	-0.43	-5.72	-0.33	2.9e-8	QT interval;
CESC	cis	rs11098499	0.866	rs12513310	chr4:120288039	T/A	cg24375607	chr4:120327624	NA	0.42	5.19	0.3	4.19e-7	Corneal astigmatism;
CESC	cis	rs863345	0.604	rs10797020	chr1:158490324	A/G	cg12129480	chr1:158549410	OR10X1	-0.34	-6.85	-0.39	5.17e-11	Pneumococcal bacteremia;
CESC	cis	rs13256369	0.802	rs2280560	chr8:8560602	C/T	cg00074818	chr8:8560427	CLDN23	0.36	5.22	0.31	3.68e-7	Obesity-related traits;
CESC	cis	rs7927771	0.965	rs35985502	chr11:47847428	G/A	cg18512352	chr11:47633146	NA	-0.6	-9.57	-0.51	8.16e-19	Subjective well-being;
CESC	trans	rs1814175	0.676	rs11040647	chr11:49935947	A/C	cg15704280	chr7:45808275	SEPT13	-1.01	-18.94	-0.76	3.64e-51	Height;
CESC	cis	rs9899728	0.764	rs9660	chr17:73038746	A/G	cg27626185	chr17:73056755	KCTD2	-0.56	-5.64	-0.33	4.28e-8	Alzheimer's disease or small vessel stroke;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08477215	chr7:75072259	POM121C	-0.62	-7.53	-0.42	8.09e-13	Gut microbiome composition (summer);
CESC	cis	rs1045902	0.967	rs10207625	chr2:73464808	T/C	cg01422370	chr2:73384389	NA	0.43	7.29	0.41	3.57e-12	Intelligence (multi-trait analysis);
CESC	trans	rs9325144	0.602	rs10785590	chr12:38694145	C/T	cg23762105	chr12:34175262	ALG10	-0.49	-6.56	-0.37	2.76e-10	Morning vs. evening chronotype;
CESC	cis	rs909002	0.849	rs2271933	chr1:32092525	C/T	cg13919466	chr1:32135498	COL16A1	0.46	8.21	0.45	9.83e-15	Intelligence (multi-trait analysis);
CESC	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg11494091	chr17:61959527	GH2	0.76	13.29	0.63	3.18e-31	Prudent dietary pattern;
CESC	cis	rs763014	0.966	rs4984675	chr16:670117	T/C	cg09781414	chr16:715207	WDR90	-0.35	-5.34	-0.31	1.95e-7	Height;
CESC	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg09177884	chr7:1199841	ZFAND2A	-0.52	-6.74	-0.38	9.71e-11	Longevity;Endometriosis;
CESC	cis	rs9790314	1.000	rs189270	chr3:161063504	T/C	cg03342759	chr3:160939853	NMD3	-0.5	-6.54	-0.37	3.13e-10	Morning vs. evening chronotype;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09770068	chr12:52294251	NA	-0.55	-6.8	-0.39	7.12e-11	Gut microbiome composition (summer);
CESC	cis	rs780096	0.546	rs1528533	chr2:27595756	G/C	cg24768116	chr2:27665128	KRTCAP3	-0.31	-5.96	-0.34	8.08e-9	Total body bone mineral density;
CESC	cis	rs477692	0.544	rs12251589	chr10:131417354	C/A	cg24747557	chr10:131355152	MGMT	0.43	5.93	0.34	9.25e-9	Response to temozolomide;
CESC	cis	rs10870270	1.000	rs7077744	chr10:133770201	C/T	cg26149184	chr10:133730230	NA	0.38	5.14	0.3	5.22e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs7618915	0.571	rs17264436	chr3:52610651	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.47	6.57	0.37	2.63e-10	Bipolar disorder;
CESC	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg27094323	chr7:1216898	NA	-0.43	-6.03	-0.35	5.61e-9	Longevity;Endometriosis;
CESC	cis	rs1008375	1.000	rs3733579	chr4:17694943	A/G	cg16339924	chr4:17578868	LAP3	0.57	7.11	0.4	1.06e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs11098499	0.863	rs3775854	chr4:120471971	C/T	cg24375607	chr4:120327624	NA	0.45	5.5	0.32	9.09e-8	Corneal astigmatism;
CESC	cis	rs7826238	0.502	rs10503377	chr8:8378422	C/T	cg15556689	chr8:8085844	FLJ10661	0.45	5.5	0.32	8.8e-8	Systolic blood pressure;
CESC	cis	rs6540559	0.932	rs764093	chr1:209983331	A/G	cg09509183	chr1:209979624	IRF6	0.51	6.42	0.37	6.24e-10	Cleft lip with or without cleft palate;
CESC	cis	rs61996546	0.622	rs56031087	chr15:26847834	A/C	cg15066197	chr15:26874202	GABRB3	-0.35	-5.19	-0.3	4.1e-7	Response to methotrexate in juvenile idiopathic arthritis;
CESC	cis	rs9815354	0.812	rs17283243	chr3:41914792	C/T	cg03022575	chr3:42003672	ULK4	0.7	6.18	0.36	2.38e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs9649213	0.593	rs35983874	chr7:97916461	C/T	cg21770322	chr7:97807741	LMTK2	0.55	8.1	0.45	2.02e-14	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs769267	0.930	rs6511038	chr19:19607564	A/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.59	7.48	0.42	1.1e-12	Tonsillectomy;
CESC	cis	rs7124681	0.546	rs7941399	chr11:47890421	A/T	cg20307385	chr11:47447363	PSMC3	0.63	8.82	0.48	1.52e-16	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
CESC	cis	rs17023223	0.537	rs4590715	chr1:119750201	C/T	cg05756136	chr1:119680316	WARS2	-0.48	-5.79	-0.33	2.03e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CESC	cis	rs4689388	0.824	rs6446482	chr4:6295693	C/G	cg14416269	chr4:6271139	WFS1	0.46	7.71	0.43	2.6e-13	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs2370759	0.898	rs113412621	chr10:32579306	C/T	cg01819863	chr10:32635814	EPC1	1.16	13.25	0.63	4.48e-31	Sexual dysfunction (female);
CESC	cis	rs1005277	0.540	rs7903942	chr10:37929276	C/T	cg25427524	chr10:38739819	LOC399744	0.62	8.98	0.48	5.15e-17	Extrinsic epigenetic age acceleration;
CESC	cis	rs6460942	0.915	rs62448623	chr7:12464122	A/G	cg06484146	chr7:12443880	VWDE	-0.78	-9.14	-0.49	1.68e-17	Coronary artery disease;
CESC	cis	rs10851478	0.842	rs34146550	chr15:49790877	T/C	cg08060515	chr15:49448048	GALK2;COPS2	0.42	5.19	0.3	4.12e-7	Oral cavity cancer;
CESC	cis	rs9611519	0.780	rs2235849	chr22:41653540	T/G	cg03806693	chr22:41940476	POLR3H	-0.56	-6.56	-0.37	2.75e-10	Neuroticism;
CESC	trans	rs12356475	0.710	rs10822686	chr10:67733250	C/T	cg15717258	chr5:140537705	PCDHB17	-0.47	-6.64	-0.38	1.78e-10	Psoriatic arthritis;
CESC	cis	rs4654899	1.000	rs6426660	chr1:21361640	A/G	cg05370193	chr1:21551575	ECE1	0.39	5.85	0.34	1.47e-8	Superior frontal gyrus grey matter volume;
CESC	cis	rs7296418	0.961	rs4148863	chr12:123569375	A/G	cg00376283	chr12:123451042	ABCB9	0.74	10.75	0.55	1.3e-22	Platelet count;
CESC	cis	rs1832871	0.683	rs9459852	chr6:158687250	T/G	cg07165851	chr6:158734300	TULP4	0.59	6.23	0.36	1.87e-9	Height;
CESC	cis	rs1055129	0.560	rs2608880	chr17:73938957	C/T	cg08125733	chr17:73851984	WBP2	0.5	6.74	0.38	9.73e-11	White matter hyperintensity burden;
CESC	cis	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg08027265	chr7:2291960	NA	-0.36	-5.48	-0.32	1.01e-7	Bipolar disorder and schizophrenia;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg16866257	chr17:61905183	FTSJ3;PSMC5	0.49	6.2	0.36	2.18e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs28830936	0.510	rs7174099	chr15:42099059	A/G	cg11010575	chr15:42129464	JMJD7-PLA2G4B;JMJD7	-0.32	-5.05	-0.3	8.06e-7	Diastolic blood pressure;
CESC	cis	rs769267	0.930	rs4808955	chr19:19552413	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.56	6.89	0.39	4.14e-11	Tonsillectomy;
CESC	cis	rs17666538	0.636	rs10107345	chr8:603700	G/T	cg07234876	chr8:600039	NA	0.79	6.63	0.38	1.83e-10	IgG glycosylation;
CESC	cis	rs1218582	0.772	rs4845690	chr1:154886817	C/T	cg24250549	chr1:154909240	PMVK	-0.76	-11.29	-0.57	2.19e-24	Prostate cancer;
CESC	cis	rs9916302	0.808	rs6503515	chr17:37606433	G/T	cg19468946	chr17:37922297	IKZF3	-0.39	-5.08	-0.3	7.08e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs9611565	0.694	rs202628	chr22:41849513	A/G	cg06481639	chr22:41940642	POLR3H	-0.56	-6.14	-0.35	2.93e-9	Vitiligo;
CESC	cis	rs2075371	0.611	rs35428392	chr7:134019645	G/A	cg20476274	chr7:133979776	SLC35B4	0.55	7.38	0.41	2.01e-12	Mean platelet volume;
CESC	cis	rs7592578	0.771	rs4258824	chr2:191395027	C/T	cg10560079	chr2:191398806	TMEM194B	-0.55	-5.04	-0.3	8.66e-7	Diastolic blood pressure;
CESC	cis	rs10504229	0.817	rs55891651	chr8:58167600	C/T	cg05313129	chr8:58192883	C8orf71	-0.46	-5.85	-0.34	1.46e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs9790314	0.521	rs13084746	chr3:161086038	G/A	cg03342759	chr3:160939853	NMD3	-0.41	-5.74	-0.33	2.52e-8	Morning vs. evening chronotype;
CESC	cis	rs6089584	0.830	rs4925331	chr20:60580174	T/C	cg06108461	chr20:60628389	TAF4	-0.81	-11.72	-0.58	7.56e-26	Body mass index;
CESC	cis	rs1799949	0.965	rs35521261	chr17:41313612	A/G	cg25072359	chr17:41440525	NA	0.46	6.12	0.35	3.4e-9	Menopause (age at onset);
CESC	cis	rs2282802	0.635	rs397463	chr5:139584275	C/G	cg26211634	chr5:139558579	C5orf32	-0.5	-7.41	-0.41	1.68e-12	Intelligence (multi-trait analysis);
CESC	cis	rs4253772	0.591	rs11703848	chr22:46685131	A/G	cg24881330	chr22:46731750	TRMU	0.75	5.43	0.32	1.25e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs2635047	0.512	rs9962436	chr18:44599109	A/G	cg19077165	chr18:44547161	KATNAL2	-0.42	-5.91	-0.34	1.07e-8	Educational attainment;
CESC	cis	rs141759085	1	rs141759085	chr16:530967	A/G	cg00676925	chr16:540266	RAB11FIP3	-0.65	-7.38	-0.41	2.03e-12	Platelet count;
CESC	cis	rs143000161	1	rs143000161	chr2:165710540	A/T	cg03182029	chr2:165697222	COBLL1	0.72	5.64	0.33	4.36e-8	Heschl's gyrus morphology;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04135372	chr2:99061383	INPP4A	0.46	6.46	0.37	4.89e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs9863	0.861	rs7958691	chr12:124440743	G/T	cg17562584	chr12:124393655	DNAH10	0.32	5.56	0.32	6.59e-8	White blood cell count;
CESC	cis	rs853679	0.517	rs1904840	chr6:28108232	C/T	cg17949981	chr6:28129498	ZNF389	0.44	5.53	0.32	7.84e-8	Depression;
CESC	trans	rs6934970	0.860	rs4354190	chr6:112981624	T/C	cg05146922	chr2:10634174	NA	-0.36	-6.01	-0.35	5.97e-9	Bipolar disorder (body mass index interaction);
CESC	cis	rs6087990	0.584	rs6058897	chr20:31398105	G/T	cg13636640	chr20:31349939	DNMT3B	-0.73	-11.61	-0.58	1.86e-25	Ulcerative colitis;
CESC	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.55	-6.09	-0.35	3.98e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7555523	0.779	rs6662839	chr1:165722646	T/G	cg24409356	chr1:165738333	TMCO1	0.97	8.67	0.47	4.48e-16	Intraocular pressure;Glaucoma (high intraocular pressure);
CESC	cis	rs9715521	0.900	rs72634620	chr4:59822396	C/T	cg11281224	chr4:60001000	NA	-0.51	-6.67	-0.38	1.45e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs7772486	0.686	rs1337841	chr6:146059487	A/G	cg23711669	chr6:146136114	FBXO30	-0.89	-13.12	-0.63	1.2e-30	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs8017423	0.647	rs12882575	chr14:90820454	C/G	cg14092571	chr14:90743983	NA	0.43	6.55	0.37	2.91e-10	Mortality in heart failure;
CESC	cis	rs6540559	0.673	rs114467813	chr1:210017785	G/A	cg21951975	chr1:209979733	IRF6	0.6	6.65	0.38	1.63e-10	Cleft lip with or without cleft palate;
CESC	cis	rs2549003	1.000	rs2070725	chr5:131821788	C/T	cg02551604	chr5:131831745	NA	-0.37	-5.27	-0.31	2.81e-7	Asthma (sex interaction);
CESC	cis	rs72792276	1.000	rs56657382	chr5:127387338	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.68	5.24	0.31	3.26e-7	Red cell distribution width;
CESC	cis	rs11958404	0.932	rs72816543	chr5:157416464	A/G	cg05962755	chr5:157440814	NA	0.62	6.64	0.38	1.74e-10	IgG glycosylation;
CESC	cis	rs10504229	0.683	rs10504221	chr8:58140256	A/G	cg02725872	chr8:58115012	NA	-0.45	-7.12	-0.4	1.02e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs9916302	0.904	rs8079355	chr17:37473018	G/A	cg20243544	chr17:37824526	PNMT	-0.46	-5.66	-0.33	3.97e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs2404602	0.598	rs11855999	chr15:76627333	A/C	cg06336613	chr15:77223807	RCN2	0.41	5.09	0.3	6.72e-7	Blood metabolite levels;
CESC	cis	rs225245	0.782	rs321599	chr17:33905745	C/T	cg05299278	chr17:33885742	SLFN14	0.38	5.46	0.32	1.08e-7	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
CESC	cis	rs116095464	0.558	rs2288458	chr5:231260	C/T	cg22857025	chr5:266934	NA	-1.28	-18.2	-0.75	1.47e-48	Breast cancer;
CESC	cis	rs4423214	0.592	rs10898234	chr11:71236684	A/G	cg05163923	chr11:71159392	DHCR7	-0.55	-5.89	-0.34	1.17e-8	Vitamin D levels;
CESC	cis	rs6089584	0.586	rs4925216	chr20:60599923	G/A	cg06108461	chr20:60628389	TAF4	-0.58	-7.7	-0.43	2.68e-13	Body mass index;
CESC	cis	rs4919694	1.000	rs112809537	chr10:104670346	C/T	cg04362960	chr10:104952993	NT5C2	0.78	6.58	0.37	2.5e-10	Arsenic metabolism;
CESC	trans	rs1814175	0.817	rs10839318	chr11:49657511	G/C	cg15704280	chr7:45808275	SEPT13	-1.04	-20.31	-0.78	6.22e-56	Height;
CESC	cis	rs1218582	0.772	rs4845688	chr1:154884142	T/C	cg03351412	chr1:154909251	PMVK	0.7	9.54	0.51	9.98e-19	Prostate cancer;
CESC	cis	rs9649213	0.593	rs6947340	chr7:97912241	A/G	cg00277769	chr7:97922759	BAIAP2L1	0.32	5.34	0.31	2.05e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs2797160	1.000	rs1777183	chr6:126011995	A/C	cg05901451	chr6:126070800	HEY2	0.46	6.55	0.37	2.91e-10	Endometrial cancer;
CESC	cis	rs7267979	1.000	rs397119	chr20:25440187	C/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.82	15.9	0.7	1.91e-40	Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09019002	chr7:102715232	ARMC10;FBXL13	0.62	7.68	0.43	3.18e-13	Gut microbiome composition (summer);
CESC	trans	rs17685	0.558	rs60787921	chr7:75792844	C/A	cg19862616	chr7:65841803	NCRNA00174	0.84	12.03	0.59	6.77e-27	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs6502050	0.799	rs8082355	chr17:80120316	A/G	cg23985595	chr17:80112537	CCDC57	-0.41	-6.54	-0.37	3.21e-10	Life satisfaction;
CESC	cis	rs1005277	0.579	rs1780136	chr10:38501453	A/G	cg00409905	chr10:38381863	ZNF37A	-0.52	-7.04	-0.4	1.69e-11	Extrinsic epigenetic age acceleration;
CESC	cis	rs9911578	1.000	rs999431	chr17:56854441	A/G	cg12560992	chr17:57184187	TRIM37	0.92	15.2	0.68	6.06e-38	Intelligence (multi-trait analysis);
CESC	cis	rs10465746	0.725	rs1359331	chr1:84360301	C/A	cg10977910	chr1:84465055	TTLL7	0.56	7.74	0.43	2.07e-13	Obesity-related traits;
CESC	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg24642844	chr7:1081250	C7orf50	-0.75	-9.03	-0.49	3.61e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs4474465	0.850	rs4387376	chr11:78257662	T/C	cg27205649	chr11:78285834	NARS2	0.42	5.4	0.31	1.49e-7	Alzheimer's disease (survival time);
CESC	cis	rs3015497	0.603	rs1494178	chr14:51072210	A/C	cg26011998	chr14:51135199	SAV1	-0.46	-5.22	-0.31	3.6e-7	Mean platelet volume;
CESC	cis	rs854765	0.583	rs7503334	chr17:17779458	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.52	-7.21	-0.41	5.78e-12	Total body bone mineral density;
CESC	cis	rs10870270	1.000	rs11146354	chr10:133774757	A/G	cg17892150	chr10:133769511	PPP2R2D	-0.86	-12.56	-0.61	1.08e-28	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs7412746	0.658	rs3768015	chr1:150812954	C/T	cg09365446	chr1:150670422	GOLPH3L	0.4	5.45	0.32	1.14e-7	Melanoma;
CESC	cis	rs4423214	0.840	rs1123007	chr11:71185357	G/A	cg05163923	chr11:71159392	DHCR7	-0.7	-7.97	-0.44	4.79e-14	Vitamin D levels;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg04371633	chr14:65381025	CHURC1	-0.46	-6.34	-0.36	9.89e-10	Height;
CESC	cis	rs4689388	0.750	rs10001190	chr4:6284633	C/T	cg25554036	chr4:6271136	WFS1	-0.49	-7.36	-0.41	2.25e-12	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs9467773	0.587	rs9467722	chr6:26352566	T/C	cg14345882	chr6:26364793	BTN3A2	0.29	5.06	0.3	7.96e-7	Intelligence (multi-trait analysis);
CESC	cis	rs870825	0.616	rs4437299	chr4:185643223	T/A	cg04058563	chr4:185651563	MLF1IP	0.64	7.1	0.4	1.15e-11	Blood protein levels;
CESC	cis	rs854765	0.547	rs28537385	chr17:17902135	G/A	cg04398451	chr17:18023971	MYO15A	-0.71	-10.42	-0.54	1.54e-21	Total body bone mineral density;
CESC	cis	rs7592578	0.679	rs62181020	chr2:191325601	A/C	cg27211696	chr2:191398769	TMEM194B	-0.59	-5.9	-0.34	1.13e-8	Diastolic blood pressure;
CESC	cis	rs6714710	0.603	rs11692010	chr2:98397301	C/T	cg26665480	chr2:98280029	ACTR1B	0.56	7.87	0.44	8.84e-14	Posterior cortical atrophy and Alzheimer's disease;
CESC	cis	rs2262909	0.925	rs73019900	chr19:22286680	G/A	cg11619707	chr19:22235551	ZNF257	0.34	5.58	0.32	6.06e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
CESC	cis	rs13191362	0.935	rs7767254	chr6:162954674	T/G	cg21926612	chr6:163149169	PACRG;PARK2	0.79	7.79	0.43	1.52e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs853679	0.517	rs9380050	chr6:28048538	A/G	cg23281280	chr6:28129359	ZNF389	0.57	7.78	0.43	1.61e-13	Depression;
CESC	cis	rs9287719	0.578	rs13425171	chr2:10731966	C/G	cg00105475	chr2:10696890	NA	0.39	5.27	0.31	2.83e-7	Prostate cancer;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg05645997	chr2:108443466	LOC729121;RGPD4	0.53	7.38	0.41	2.08e-12	Fibrinogen levels;
CESC	cis	rs8002861	0.727	rs9525850	chr13:44402100	C/T	cg19180546	chr13:44453867	C13orf31;CCDC122	-0.4	-5.13	-0.3	5.7e-7	Leprosy;
CESC	cis	rs2299587	0.554	rs2073565	chr8:17743649	T/C	cg08627089	chr8:17753878	FGL1	-0.4	-5.76	-0.33	2.37e-8	Economic and political preferences;
CESC	trans	rs916888	0.610	rs199444	chr17:44818276	T/C	cg01341218	chr17:43662625	NA	0.56	7.5	0.42	9.66e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs709400	0.859	rs942863	chr14:104021268	C/T	cg12935359	chr14:103987150	CKB	-0.49	-6.3	-0.36	1.21e-9	Body mass index;
CESC	cis	rs7949030	0.523	rs12223627	chr11:62368557	G/C	cg23462726	chr11:62437636	C11orf83;C11orf48	-0.44	-5.87	-0.34	1.33e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs8072100	0.666	rs9913014	chr17:45460189	C/T	cg25173405	chr17:45401733	C17orf57	-0.43	-5.42	-0.32	1.36e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs514406	0.861	rs4926577	chr1:53226788	C/A	cg08859206	chr1:53392774	SCP2	0.53	7.09	0.4	1.19e-11	Monocyte count;
CESC	cis	rs703842	1.000	rs3825079	chr12:58203354	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.71	9.12	0.49	1.96e-17	Multiple sclerosis;
CESC	cis	rs5753618	0.539	rs2228619	chr22:31663842	C/G	cg00478049	chr22:31556069	RNF185	0.45	5.16	0.3	4.89e-7	Colorectal cancer;
CESC	cis	rs2243480	0.706	rs6460257	chr7:65196780	C/T	cg18252515	chr7:66147081	NA	-0.56	-5.61	-0.33	5.16e-8	Diabetic kidney disease;
CESC	cis	rs898097	0.691	rs7222745	chr17:80907253	C/T	cg15369054	chr17:80825471	TBCD	0.37	5.28	0.31	2.69e-7	Breast cancer;
CESC	cis	rs2795502	1.000	rs2744090	chr10:43339614	G/C	cg27426351	chr10:43362370	NA	-0.45	-5.5	-0.32	8.91e-8	Blood protein levels;
CESC	cis	rs7107174	0.892	rs2512548	chr11:77962116	A/G	cg02023728	chr11:77925099	USP35	0.45	6.36	0.36	8.61e-10	Testicular germ cell tumor;
CESC	cis	rs2115536	0.935	rs11854390	chr15:80224817	C/T	cg11839771	chr15:80205821	ST20	-0.35	-5.09	-0.3	6.8e-7	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CESC	cis	rs9486719	1.000	rs12201449	chr6:96959382	C/T	cg06623918	chr6:96969491	KIAA0776	-0.8	-8.21	-0.45	9.67e-15	Migraine;Coronary artery disease;
CESC	cis	rs1707322	1.000	rs11211200	chr1:46288352	A/G	cg06784218	chr1:46089804	CCDC17	0.31	5.34	0.31	2e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2073300	0.609	rs6137931	chr20:23376875	G/C	cg12062639	chr20:23401060	NAPB	1.07	8.85	0.48	1.29e-16	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs2075371	0.674	rs11771785	chr7:134013249	A/G	cg11752832	chr7:134001865	SLC35B4	-0.43	-5.05	-0.3	8.14e-7	Mean platelet volume;
CESC	cis	rs832540	0.519	rs10036895	chr5:56273693	G/A	cg12311346	chr5:56204834	C5orf35	-0.44	-5.44	-0.32	1.19e-7	Coronary artery disease;
CESC	cis	rs1707322	1.000	rs4134387	chr1:46395158	A/T	cg05343316	chr1:45956843	TESK2	0.5	6.13	0.35	3.11e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9876781	0.530	rs11708617	chr3:48396309	C/T	cg11946769	chr3:48343235	NME6	0.4	5.25	0.31	3.13e-7	Longevity;
CESC	cis	rs12477438	0.520	rs13035311	chr2:99717322	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.88	15.55	0.69	3.41e-39	Chronic sinus infection;
CESC	cis	rs7666738	0.830	rs3846443	chr4:99032666	G/A	cg03467027	chr4:99064603	C4orf37	0.48	6.06	0.35	4.54e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs754466	0.606	rs11002315	chr10:79617385	T/G	cg17075019	chr10:79541650	NA	-0.87	-13.72	-0.64	1.01e-32	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs7927771	1.000	rs12419692	chr11:47624714	A/C	cg05585544	chr11:47624801	NA	0.49	7.64	0.42	4.01e-13	Subjective well-being;
CESC	cis	rs8067354	0.574	rs1292050	chr17:57965169	T/C	cg02344993	chr17:57696989	CLTC	0.53	5.56	0.32	6.43e-8	Hemoglobin concentration;
CESC	cis	rs3026101	0.624	rs62072673	chr17:5317669	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.4	5.12	0.3	5.75e-7	Body mass index;
CESC	cis	rs7666738	0.830	rs7664305	chr4:99037691	G/A	cg18180107	chr4:99064573	C4orf37	0.41	5.29	0.31	2.52e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs8103278	0.507	rs2041975	chr19:46238555	T/C	cg14061069	chr19:46274453	DMPK	0.51	8.12	0.45	1.76e-14	Coronary artery disease;
CESC	cis	rs733175	0.855	rs6853437	chr4:10005435	A/G	cg11266682	chr4:10021025	SLC2A9	-0.38	-5.2	-0.3	3.91e-7	Psychosis and Alzheimer's disease;
CESC	cis	rs7259376	0.905	rs116632927	chr19:22562520	C/T	cg02657401	chr19:22469223	NA	-0.26	-5.18	-0.3	4.47e-7	Menopause (age at onset);
CESC	cis	rs13191362	0.872	rs73020362	chr6:163005737	A/C	cg06582575	chr6:163149167	PACRG;PARK2	0.82	8.29	0.45	5.87e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs2576037	0.507	rs2571019	chr18:44585287	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.73	-11.55	-0.58	2.97e-25	Personality dimensions;
CESC	cis	rs514406	0.798	rs4351588	chr1:53263826	A/T	cg08736216	chr1:53307985	ZYG11A	0.35	6.17	0.35	2.52e-9	Monocyte count;
CESC	cis	rs96067	0.711	rs272827	chr1:36627191	C/T	cg24686825	chr1:36642396	MAP7D1	0.64	8.2	0.45	1.05e-14	Corneal structure;
CESC	cis	rs4604732	0.631	rs7546720	chr1:247627229	G/A	cg12754571	chr1:247694271	LOC148824;OR2C3	0.44	5.44	0.32	1.21e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs28489187	0.706	rs18582	chr1:85794819	A/G	cg16011679	chr1:85725395	C1orf52	0.48	5.83	0.34	1.62e-8	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	cis	rs412050	1.000	rs239919	chr22:22313128	C/T	cg17089214	chr22:22089827	YPEL1	0.64	5.93	0.34	9.33e-9	Attention deficit hyperactivity disorder;
CESC	cis	rs10504229	1.000	rs67344620	chr8:58187537	C/A	cg14926445	chr8:58193284	C8orf71	-0.51	-5.52	-0.32	8.28e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs826838	1.000	rs7299124	chr12:39002661	T/C	cg26384229	chr12:38710491	ALG10B	0.82	14.29	0.66	1.01e-34	Heart rate;
CESC	cis	rs7917772	0.604	rs7908249	chr10:104373300	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.39	5.41	0.32	1.43e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs1448094	0.511	rs59668915	chr12:86197170	C/T	cg19622623	chr12:86230825	RASSF9	-0.47	-6.05	-0.35	5.05e-9	Major depressive disorder;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg05214047	chr5:56112645	MAP3K1	-0.44	-6.42	-0.37	6.11e-10	Gambling;
CESC	cis	rs7937682	0.889	rs479667	chr11:111484034	C/T	cg22437258	chr11:111473054	SIK2	0.71	9.61	0.51	6.16e-19	Primary sclerosing cholangitis;
CESC	cis	rs2979489	0.891	rs17551512	chr8:30330109	A/G	cg26383811	chr8:30366931	RBPMS	-0.83	-9.92	-0.52	6.32e-20	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CESC	cis	rs9916302	0.851	rs11870631	chr17:37645129	C/T	cg19468946	chr17:37922297	IKZF3	-0.39	-5.08	-0.3	7.08e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs950169	0.810	rs62029594	chr15:84955252	T/C	cg17507749	chr15:85114479	UBE2QP1	0.59	6.54	0.37	3.11e-10	Schizophrenia;
CESC	cis	rs6714710	0.603	rs11679828	chr2:98517626	G/A	cg26665480	chr2:98280029	ACTR1B	0.6	8.14	0.45	1.57e-14	Posterior cortical atrophy and Alzheimer's disease;
CESC	cis	rs763121	0.853	rs5750668	chr22:39079964	T/C	cg21395723	chr22:39101663	GTPBP1	0.43	5.29	0.31	2.55e-7	Menopause (age at onset);
CESC	cis	rs72781680	1.000	rs17711825	chr2:24124578	A/G	cg20701182	chr2:24300061	SF3B14	0.62	5.58	0.32	5.85e-8	Lymphocyte counts;
CESC	cis	rs898097	0.841	rs55810435	chr17:80836722	G/C	cg05255149	chr17:80675120	FN3KRP	-0.45	-5.23	-0.31	3.49e-7	Breast cancer;
CESC	cis	rs1552244	1.000	rs6793396	chr3:10110927	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	11.94	0.59	1.43e-26	Alzheimer's disease;
CESC	cis	rs2072732	0.756	rs7514166	chr1:2949607	G/C	cg15211996	chr1:2936768	ACTRT2	0.35	6.12	0.35	3.42e-9	Plateletcrit;
CESC	cis	rs7666738	0.830	rs11727612	chr4:99001662	T/C	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.62e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7927771	1.000	rs4752797	chr11:47874364	C/T	cg05585544	chr11:47624801	NA	-0.45	-6.93	-0.39	3.15e-11	Subjective well-being;
CESC	cis	rs2932538	0.922	rs6537744	chr1:113096746	C/G	cg22162597	chr1:113214053	CAPZA1	0.56	7.02	0.4	1.82e-11	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CESC	cis	rs75477785	0.590	rs4844501	chr1:210104598	A/G	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.94	6.89	0.39	4.04e-11	Cleft lip with or without cleft palate;
CESC	cis	rs921968	0.541	rs588770	chr2:219494638	T/C	cg02176678	chr2:219576539	TTLL4	0.43	7.47	0.42	1.14e-12	Mean corpuscular hemoglobin concentration;
CESC	cis	rs11098499	0.954	rs17006190	chr4:120418838	C/G	cg09307838	chr4:120376055	NA	0.92	12.86	0.62	9.72e-30	Corneal astigmatism;
CESC	cis	rs2764980	1.000	rs2764980	chr10:3284007	C/T	cg11630169	chr10:3283847	NA	0.37	5.24	0.31	3.21e-7	Attention deficit hyperactivity disorder and conduct disorder;
CESC	cis	rs6430585	0.591	rs309118	chr2:136746224	G/C	cg07169764	chr2:136633963	MCM6	1.12	16.81	0.72	1.2e-43	Corneal structure;
CESC	cis	rs4563143	0.577	rs73025093	chr19:29254618	T/G	cg04546413	chr19:29218101	NA	0.56	7.91	0.44	6.84e-14	Methadone dose in opioid dependence;
CESC	cis	rs7100689	0.784	rs10749562	chr10:82108253	G/T	cg09936400	chr10:82049201	MAT1A	0.37	5.28	0.31	2.73e-7	Post bronchodilator FEV1;
CESC	cis	rs1552244	0.882	rs55808392	chr3:10054681	C/T	cg08888203	chr3:10149979	C3orf24	0.48	6.08	0.35	4.18e-9	Alzheimer's disease;
CESC	cis	rs13191362	1.000	rs2156257	chr6:163100710	G/T	cg06582575	chr6:163149167	PACRG;PARK2	1.02	10.2	0.53	7.92e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg12393716	chr11:62495049	TTC9C;HNRNPUL2	0.52	7.2	0.4	6.18e-12	Systemic lupus erythematosus;
CESC	cis	rs863345	0.967	rs1342944	chr1:158512923	T/C	cg12129480	chr1:158549410	OR10X1	-0.32	-6.48	-0.37	4.53e-10	Pneumococcal bacteremia;
CESC	cis	rs6547741	0.935	rs12714204	chr2:27787540	T/C	cg27432699	chr2:27873401	GPN1	0.48	6.84	0.39	5.6e-11	Oral cavity cancer;
CESC	cis	rs6815814	0.768	rs2013740	chr4:38891737	A/G	cg02016764	chr4:38805732	TLR1	-0.51	-6.97	-0.39	2.55e-11	Breast cancer;
CESC	cis	rs9457247	0.555	rs2247325	chr6:167369992	A/G	cg23791538	chr6:167370224	RNASET2	0.66	9.47	0.5	1.64e-18	Crohn's disease;
CESC	cis	rs7666738	0.830	rs7664340	chr4:99037820	C/T	cg17366294	chr4:99064904	C4orf37	0.6	8.5	0.46	1.41e-15	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11098499	0.754	rs10518300	chr4:120249499	G/T	cg25214090	chr10:38739885	LOC399744	-0.59	-8.03	-0.44	3.2e-14	Corneal astigmatism;
CESC	cis	rs1847202	0.826	rs1979884	chr3:72948515	T/C	cg25664220	chr3:72788482	NA	-0.37	-5.49	-0.32	9.43e-8	Motion sickness;
CESC	cis	rs4853012	0.941	rs78128123	chr2:74347525	C/T	cg20891558	chr2:74357851	NA	0.82	10.24	0.53	5.88e-21	Gestational age at birth (maternal effect);
CESC	cis	rs34779708	0.931	rs7923217	chr10:35309589	A/G	cg03585969	chr10:35415529	CREM	0.76	10.11	0.53	1.57e-20	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs9902453	0.740	rs2244247	chr17:28110174	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-10.34	-0.54	2.82e-21	Coffee consumption (cups per day);
CESC	cis	rs11638352	0.661	rs2706488	chr15:44389897	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.61	-5.66	-0.33	3.84e-8	Lipoprotein phospholipase A2 activity in cardiovascular disease;
CESC	cis	rs727563	0.593	rs132770	chr22:42017264	A/G	cg06634786	chr22:41940651	POLR3H	0.61	5.99	0.35	6.94e-9	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg06601766	chr17:61851465	DDX42;CCDC47	-0.49	-6.19	-0.36	2.31e-9	Prudent dietary pattern;
CESC	cis	rs2404602	0.662	rs908817	chr15:76639191	G/A	cg23625390	chr15:77176239	SCAPER	-0.44	-5.99	-0.35	6.98e-9	Blood metabolite levels;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg09444120	chr8:107227878	NA	-0.44	-6.11	-0.35	3.53e-9	Asthma;
CESC	cis	rs250677	0.687	rs2963484	chr5:148451127	A/T	cg18129178	chr5:148520854	ABLIM3	-0.51	-5.84	-0.34	1.54e-8	Breast cancer;
CESC	cis	rs6087990	0.965	rs2424904	chr20:31352316	T/C	cg13636640	chr20:31349939	DNMT3B	0.92	16.25	0.71	1.16e-41	Ulcerative colitis;
CESC	cis	rs10479542	0.784	rs7702303	chr5:178986436	G/A	cg09060608	chr5:178986726	RUFY1	0.56	8.69	0.47	3.87e-16	Lung cancer;
CESC	cis	rs7811142	0.945	rs6955362	chr7:100056166	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.78	6.81	0.39	6.56e-11	Platelet count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09719331	chr20:44486197	ZSWIM3;ACOT8	-0.5	-6.13	-0.35	3.17e-9	Gut microbiome composition (summer);
CESC	cis	rs1580019	0.563	rs34201720	chr7:32568935	G/A	cg07520158	chr7:32535189	LSM5;AVL9	0.52	6.61	0.38	2.16e-10	Cognitive ability;
CESC	cis	rs13191362	0.507	rs2803083	chr6:163111199	A/C	cg06582575	chr6:163149167	PACRG;PARK2	0.61	7.3	0.41	3.27e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	trans	rs853679	0.505	rs200992	chr6:27814677	A/G	cg06606381	chr12:133084897	FBRSL1	-0.86	-7.85	-0.43	1.03e-13	Depression;
CESC	cis	rs2295499	0.754	rs3864117	chr4:2626569	G/A	cg27239842	chr4:2403781	ZFYVE28	-0.34	-5.65	-0.33	4.05e-8	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
CESC	cis	rs6912958	0.712	rs4707383	chr6:88330602	T/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.5	-6.74	-0.38	1.01e-10	Monocyte percentage of white cells;
CESC	cis	rs4665809	0.793	rs6546715	chr2:26261520	G/A	cg26314531	chr2:26401878	FAM59B	-0.6	-6.79	-0.38	7.45e-11	Gut microbiome composition (summer);
CESC	cis	rs9733	0.596	rs11204687	chr1:150629880	C/A	cg04414720	chr1:150670196	GOLPH3L	0.63	9.04	0.49	3.47e-17	Tonsillectomy;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg03413328	chr12:8851234	RIMKLB	0.46	6.18	0.35	2.36e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs5753618	0.504	rs5753659	chr22:31893613	A/G	cg02404636	chr22:31891804	SFI1	0.41	5.21	0.31	3.73e-7	Colorectal cancer;
CESC	cis	rs3020736	0.500	rs6002623	chr22:42513761	G/A	cg04733989	chr22:42467013	NAGA	-0.78	-11.9	-0.59	1.87e-26	Autism spectrum disorder or schizophrenia;
CESC	cis	rs7193541	0.684	rs4887783	chr16:74700743	G/C	cg01733217	chr16:74700730	RFWD3	1.09	22.56	0.81	1.32e-63	Multiple myeloma;
CESC	cis	rs6714710	0.627	rs11680883	chr2:98472610	T/C	cg26665480	chr2:98280029	ACTR1B	0.68	9.13	0.49	1.75e-17	Posterior cortical atrophy and Alzheimer's disease;
CESC	cis	rs17376456	0.778	rs10440717	chr5:93424852	C/A	cg25358565	chr5:93447407	FAM172A	1.14	11.74	0.58	6.72e-26	Diabetic retinopathy;
CESC	cis	rs1788820	0.917	rs1788826	chr18:21154024	G/A	cg14672496	chr18:21087552	C18orf8	0.54	7.36	0.41	2.32e-12	Body mass index;
CESC	cis	rs8031584	0.918	rs34331396	chr15:31248736	C/G	cg14829155	chr15:31115871	NA	-0.73	-9.8	-0.52	1.51e-19	Huntington's disease progression;
CESC	cis	rs7666738	0.830	rs1869082	chr4:98841254	T/A	cg17366294	chr4:99064904	C4orf37	0.52	7.14	0.4	9e-12	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4595586	0.655	rs7953715	chr12:39325539	T/C	cg26384229	chr12:38710491	ALG10B	0.41	5.93	0.34	9.53e-9	Morning vs. evening chronotype;
CESC	cis	rs2055729	0.507	rs814424	chr8:9942924	C/T	cg21625330	chr8:9911636	MSRA	0.5	5.77	0.33	2.26e-8	Multiple myeloma (hyperdiploidy);
CESC	cis	rs2836974	0.897	rs2836927	chr21:40543216	T/C	cg11890956	chr21:40555474	PSMG1	1.18	22.82	0.81	1.7600000000000002e-64	Cognitive function;
CESC	cis	rs7666738	0.791	rs7658177	chr4:99035192	T/C	cg05340658	chr4:99064831	C4orf37	0.83	12.92	0.62	5.86e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2243480	1.000	rs1796220	chr7:66062100	C/T	cg12463550	chr7:65579703	CRCP	0.74	5.83	0.34	1.61e-8	Diabetic kidney disease;
CESC	cis	rs7666738	0.791	rs2081622	chr4:98927369	T/C	cg17366294	chr4:99064904	C4orf37	0.6	8.23	0.45	8.65e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7917772	0.503	rs7093285	chr10:104374815	G/C	ch.10.2196322F	chr10:104248062	ACTR1A	0.46	5.38	0.31	1.66e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs3796352	1.000	rs35174175	chr3:53041509	T/C	cg12962167	chr3:53033115	SFMBT1	0.65	5.17	0.3	4.52e-7	Immune reponse to smallpox (secreted IL-2);
CESC	cis	rs4665809	0.590	rs1122972	chr2:26418788	A/C	cg08470875	chr2:26401718	FAM59B	-0.73	-7.96	-0.44	4.94e-14	Gut microbiome composition (summer);
CESC	cis	rs12545109	0.765	rs2576594	chr8:57412126	T/G	cg09654669	chr8:57350985	NA	-0.53	-6.23	-0.36	1.84e-9	Obesity-related traits;
CESC	cis	rs3768617	0.510	rs7549768	chr1:183097382	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.89	14.27	0.66	1.13e-34	Fuchs's corneal dystrophy;
CESC	cis	rs2276314	0.857	rs7237599	chr18:33639396	T/C	cg05985134	chr18:33552581	C18orf21	0.62	7.54	0.42	7.57e-13	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs11249608	0.789	rs1969025	chr5:178425192	A/G	cg21905437	chr5:178450457	ZNF879	0.53	7.11	0.4	1.11e-11	Pubertal anthropometrics;
CESC	cis	rs9595066	0.627	rs4942290	chr13:44757339	C/T	cg04068111	chr13:44716778	NA	-0.44	-5.59	-0.32	5.7e-8	Schizophrenia;
CESC	cis	rs2075371	0.829	rs11770764	chr7:134003308	T/C	cg00033643	chr7:134001901	SLC35B4	0.42	5.28	0.31	2.73e-7	Mean platelet volume;
CESC	cis	rs6062302	0.522	rs11696202	chr20:62246292	G/C	cg06363034	chr20:62225388	GMEB2	-0.5	-6.35	-0.36	9.49e-10	Glioblastoma;
CESC	cis	rs10911232	0.507	rs10732271	chr1:183025898	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.87	13.5	0.64	5.97e-32	Hypertriglyceridemia;
CESC	cis	rs12477438	0.520	rs34252185	chr2:99737646	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	15.18	0.68	6.85e-38	Chronic sinus infection;
CESC	cis	rs763121	0.853	rs4821808	chr22:39065739	A/G	cg14440974	chr22:39074834	NA	-0.41	-5.59	-0.32	5.61e-8	Menopause (age at onset);
CESC	cis	rs909002	0.925	rs7524405	chr1:32108579	A/C	cg13919466	chr1:32135498	COL16A1	0.48	8.51	0.46	1.27e-15	Intelligence (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16662489	chr10:14541114	NA	-0.52	-6.11	-0.35	3.64e-9	Gut microbiome composition (summer);
CESC	cis	rs561341	0.700	rs8079471	chr17:30218317	A/G	cg13647721	chr17:30228624	UTP6	0.81	10.14	0.53	1.28e-20	Hip circumference adjusted for BMI;
CESC	cis	rs2721195	0.967	rs10108150	chr8:145687475	A/G	cg17328964	chr8:145687451	CYHR1	0.41	5.98	0.34	7.19e-9	Age at first birth;
CESC	cis	rs10504229	0.683	rs2088217	chr8:58113124	C/T	cg24829409	chr8:58192753	C8orf71	-0.59	-7.32	-0.41	2.94e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs4819052	0.807	rs28715237	chr21:46673768	C/G	cg11663144	chr21:46675770	NA	-0.63	-9.74	-0.51	2.3e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs2576037	0.796	rs2576038	chr18:44582200	C/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.33	-5.16	-0.3	4.9e-7	Personality dimensions;
CESC	cis	rs2274273	0.870	rs3783650	chr14:55848972	A/C	cg04306507	chr14:55594613	LGALS3	0.31	6.09	0.35	4.04e-9	Protein biomarker;
CESC	cis	rs9611565	0.512	rs139573	chr22:42214785	G/A	cg17376030	chr22:41985996	PMM1	0.77	8.15	0.45	1.47e-14	Vitiligo;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg04148091	chr16:81348876	GAN	0.55	7.26	0.41	4.43e-12	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs2576037	0.796	rs2576038	chr18:44582200	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.45	5.87	0.34	1.33e-8	Personality dimensions;
CESC	cis	rs1185460	0.967	rs1784460	chr11:118938371	A/T	cg23280166	chr11:118938394	VPS11	-0.64	-9.58	-0.51	7.25e-19	Coronary artery disease;
CESC	cis	rs753778	0.570	rs6578154	chr8:142210057	G/A	cg18755752	chr8:142205143	DENND3	-0.63	-9.19	-0.49	1.2e-17	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27559595	chr15:79237381	CTSH	0.68	8.22	0.45	8.99e-15	Gut microbiome composition (summer);
CESC	cis	rs4665809	1.000	rs4233710	chr2:26291565	G/A	cg08470875	chr2:26401718	FAM59B	-0.62	-6.69	-0.38	1.35e-10	Gut microbiome composition (summer);
CESC	cis	rs854765	0.547	rs4925135	chr17:17952868	T/C	cg04398451	chr17:18023971	MYO15A	0.73	10.55	0.54	5.95e-22	Total body bone mineral density;
CESC	cis	rs1008375	1.000	rs28545485	chr4:17645376	C/T	cg02297831	chr4:17616191	MED28	0.53	6.71	0.38	1.2e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs7615952	0.576	rs17523380	chr3:125802874	C/T	cg15145296	chr3:125709740	NA	-0.55	-6.63	-0.38	1.91e-10	Blood pressure (smoking interaction);
CESC	trans	rs12356475	0.710	rs10822686	chr10:67733250	C/T	cg27010136	chr7:1131122	GPER;C7orf50	-0.51	-6.37	-0.36	8.45e-10	Psoriatic arthritis;
CESC	cis	rs9682041	0.932	rs1525362	chr3:170070702	C/T	cg11886554	chr3:170076028	SKIL	0.82	6.83	0.39	5.75e-11	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CESC	cis	rs769267	0.965	rs2074299	chr19:19380646	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	7.36	0.41	2.29e-12	Tonsillectomy;
CESC	cis	rs7635838	0.892	rs754015	chr3:11493945	T/C	cg00170343	chr3:11313890	ATG7	0.45	6.14	0.35	2.98e-9	HDL cholesterol;
CESC	cis	rs644799	1.000	rs472231	chr11:95532166	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.53	6.41	0.37	6.77e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs2952156	0.876	rs903504	chr17:37829570	C/G	cg07936489	chr17:37558343	FBXL20	-0.59	-7.52	-0.42	8.39e-13	Asthma;
CESC	cis	rs11711311	0.736	rs2278941	chr3:113350508	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.6	7.63	0.42	4.25e-13	IgG glycosylation;
CESC	cis	rs4665809	1.000	rs4665299	chr2:26256840	A/C	cg04944784	chr2:26401820	FAM59B	-0.79	-8.77	-0.47	2.26e-16	Gut microbiome composition (summer);
CESC	cis	rs1552244	0.882	rs13099136	chr3:10031431	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.73	-9.22	-0.49	9.33e-18	Alzheimer's disease;
CESC	cis	rs4253772	0.530	rs6008623	chr22:46710024	G/A	cg09491104	chr22:46646882	C22orf40	-0.49	-5.84	-0.34	1.53e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs738322	0.935	rs133014	chr22:38571087	T/G	cg17652424	chr22:38574118	PLA2G6	-0.34	-6.04	-0.35	5.08e-9	Cutaneous nevi;
CESC	cis	rs2408955	0.541	rs11168428	chr12:48547128	A/G	cg24011408	chr12:48396354	COL2A1	-0.49	-7.31	-0.41	3.2e-12	Glycated hemoglobin levels;
CESC	cis	rs4819052	0.851	rs1999334	chr21:46670457	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.42	5.25	0.31	3.06e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs9359856	0.600	rs11961825	chr6:90482250	T/A	cg13799429	chr6:90582589	CASP8AP2	-0.64	-6.06	-0.35	4.56e-9	Bipolar disorder;
CESC	cis	rs1552244	1.000	rs6772315	chr3:10113644	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.8	-10.46	-0.54	1.15e-21	Alzheimer's disease;
CESC	cis	rs10504229	0.683	rs2088217	chr8:58113124	C/T	cg21724239	chr8:58056113	NA	0.58	5.93	0.34	9.45e-9	Developmental language disorder (linguistic errors);
CESC	trans	rs11039798	0.623	rs588700	chr11:48449889	T/C	cg15704280	chr7:45808275	SEPT13	-0.69	-6.7	-0.38	1.26e-10	Axial length;
CESC	cis	rs9300255	0.664	rs7306755	chr12:123767929	G/A	cg00376283	chr12:123451042	ABCB9	-0.62	-6.4	-0.37	7.02e-10	Neutrophil percentage of white cells;
CESC	cis	rs35306767	0.903	rs11253504	chr10:956046	A/G	cg26597838	chr10:835615	NA	0.98	10.69	0.55	2.06e-22	Eosinophil percentage of granulocytes;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg00222982	chr11:125439225	EI24	-0.39	-6.12	-0.35	3.37e-9	Gambling;
CESC	cis	rs2479724	0.870	rs3747753	chr6:41753380	G/T	cg17623882	chr6:41773611	USP49	0.42	5.99	0.35	6.95e-9	Menarche (age at onset);
CESC	cis	rs6952808	0.929	rs12667688	chr7:1931030	C/T	cg00106254	chr7:1943704	MAD1L1	-0.49	-6.04	-0.35	5.23e-9	Bipolar disorder and schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13263114	chr17:37857070	ERBB2	-0.52	-6.21	-0.36	2.09e-9	Gut microbiome composition (summer);
CESC	cis	rs959260	1.000	rs7211915	chr17:73379872	A/G	cg12999837	chr17:73267436	MIF4GD	-0.48	-5.58	-0.32	5.89e-8	Systemic lupus erythematosus;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg03069383	chr2:18741691	RDH14	-0.46	-6.0	-0.35	6.59e-9	Ulcerative colitis;
CESC	cis	rs2228479	0.850	rs12597299	chr16:89822364	C/A	cg04013166	chr16:89971882	TCF25	0.77	6.66	0.38	1.58e-10	Skin colour saturation;
CESC	cis	rs896854	0.540	rs2011567	chr8:95971920	G/A	cg13393036	chr8:95962371	TP53INP1	-0.47	-9.97	-0.52	4.26e-20	Type 2 diabetes;
CESC	cis	rs9911578	1.000	rs1057068	chr17:56598439	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	-0.39	-5.27	-0.31	2.79e-7	Intelligence (multi-trait analysis);
CESC	cis	rs4699052	0.662	rs6848091	chr4:104250101	A/G	cg16532752	chr4:104119610	CENPE	-0.41	-5.85	-0.34	1.43e-8	Testicular germ cell tumor;
CESC	trans	rs3749237	1.000	rs2307021	chr3:49765483	C/G	cg21659725	chr3:3221576	CRBN	0.55	6.62	0.38	1.93e-10	Resting heart rate;
CESC	cis	rs4481887	0.830	rs6686474	chr1:248477116	A/C	cg00666640	chr1:248458726	OR2T12	0.36	5.98	0.34	7.16e-9	Common traits (Other);
CESC	trans	rs9929218	1.000	rs7186084	chr16:68816260	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.54	6.92	0.39	3.38e-11	Colorectal cancer;
CESC	cis	rs916888	0.821	rs199504	chr17:44861003	C/T	cg14517863	chr17:44321492	NA	-0.41	-5.15	-0.3	5.15e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs1862618	0.802	rs42769	chr5:56144152	G/A	cg22800045	chr5:56110881	MAP3K1	0.81	9.96	0.52	4.58e-20	Initial pursuit acceleration;
CESC	cis	rs3796352	0.892	rs9756317	chr3:53088815	T/C	cg07884673	chr3:53033167	SFMBT1	-0.64	-6.12	-0.35	3.42e-9	Immune reponse to smallpox (secreted IL-2);
CESC	cis	rs4595586	0.545	rs11615718	chr12:39395335	A/G	cg26384229	chr12:38710491	ALG10B	0.54	7.64	0.42	3.96e-13	Morning vs. evening chronotype;
CESC	cis	rs8060686	0.641	rs75909028	chr16:68089578	A/C	cg26727032	chr16:67993705	SLC12A4	-0.55	-6.15	-0.35	2.9e-9	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs1878931	0.582	rs27238	chr16:3441223	G/A	cg02880119	chr16:3481970	NA	0.42	5.26	0.31	2.94e-7	Body mass index (adult);
CESC	cis	rs1775715	0.678	rs2778649	chr10:32146803	C/G	cg18675610	chr10:32216311	ARHGAP12	0.35	5.51	0.32	8.38e-8	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs2455799	0.613	rs4467435	chr3:15791671	A/G	cg09340198	chr3:15902540	ANKRD28	-0.33	-5.16	-0.3	4.94e-7	Mean platelet volume;
CESC	cis	rs34172651	0.517	rs11642954	chr16:24824248	G/A	cg04756594	chr16:24857601	SLC5A11	0.45	5.38	0.31	1.68e-7	Intelligence (multi-trait analysis);
CESC	cis	rs72781680	1.000	rs6710426	chr2:24159288	A/G	cg20701182	chr2:24300061	SF3B14	0.65	5.81	0.34	1.79e-8	Lymphocyte counts;
CESC	cis	rs67311347	1.000	rs7634375	chr3:40431946	C/T	cg09455208	chr3:40491958	NA	0.49	7.91	0.44	6.79e-14	Renal cell carcinoma;
CESC	cis	rs7666738	0.830	rs1426663	chr4:98990092	T/G	cg03467027	chr4:99064603	C4orf37	0.44	5.51	0.32	8.53e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs853679	0.517	rs9368555	chr6:28108967	T/C	cg23281280	chr6:28129359	ZNF389	0.59	8.07	0.44	2.52e-14	Depression;
CESC	cis	rs7605827	0.930	rs2058868	chr2:15679609	A/T	cg19274914	chr2:15703543	NA	0.37	6.7	0.38	1.22e-10	Educational attainment (years of education);
CESC	cis	rs6500602	0.893	rs8061742	chr16:4489436	T/C	cg08645402	chr16:4508243	NA	0.38	5.36	0.31	1.84e-7	Schizophrenia;
CESC	cis	rs6952808	0.689	rs11771625	chr7:2050401	C/T	cg08027265	chr7:2291960	NA	-0.35	-5.07	-0.3	7.38e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs17376456	1.000	rs34854140	chr5:93538169	G/A	cg21475434	chr5:93447410	FAM172A	0.86	7.69	0.43	2.82e-13	Diabetic retinopathy;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg10538454	chr17:48238843	NA	-0.5	-6.61	-0.38	2.1e-10	Fibrinogen levels;
CESC	cis	rs131805	0.794	rs131813	chr22:50961169	A/G	cg25309564	chr22:51001381	C22orf41	0.67	6.94	0.39	3.03e-11	Granulocyte percentage of myeloid white cells;
CESC	trans	rs5752128	1	rs5752128	chr22:25718623	T/C	cg18115658	chr5:138720490	SLC23A1	0.52	6.44	0.37	5.6e-10	Monokine induced by gamma interferon levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16142977	chr19:3985688	EEF2	-0.62	-7.33	-0.41	2.84e-12	Gut microbiome composition (summer);
CESC	cis	rs2204008	0.754	rs11514074	chr12:38401128	C/T	cg13010199	chr12:38710504	ALG10B	0.54	6.83	0.39	5.71e-11	Bladder cancer;
CESC	trans	rs8073060	0.586	rs72829927	chr17:34049992	A/G	cg19694781	chr19:47549865	TMEM160	0.72	6.47	0.37	4.78e-10	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	cis	rs3820068	0.603	rs3795763	chr1:15959977	C/T	cg17385448	chr1:15911702	AGMAT	0.41	6.69	0.38	1.3100000000000001e-10	Systolic blood pressure;
CESC	cis	rs4604732	0.631	rs80319072	chr1:247626835	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.57	7.17	0.4	7.39e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs1971256	0.500	rs1971255	chr6:151816094	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	-0.61	-5.92	-0.34	9.71e-9	Endometriosis;
CESC	cis	rs7666738	0.830	rs3852122	chr4:98697400	T/C	cg17366294	chr4:99064904	C4orf37	0.57	7.83	0.43	1.21e-13	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18948967	chr14:52119097	FRMD6	0.54	6.17	0.35	2.6e-9	Gut microbiome composition (summer);
CESC	cis	rs2742234	0.541	rs10793422	chr10:43703874	G/A	cg07801480	chr10:43725741	RASGEF1A	-0.42	-5.37	-0.31	1.73e-7	Hirschsprung disease;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03232484	chr7:93633800	BET1	-0.44	-6.21	-0.36	2.07e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs2191566	0.960	rs12232810	chr19:44525122	A/G	cg20607764	chr19:44506953	ZNF230	-0.58	-7.58	-0.42	5.8e-13	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs7552404	0.727	rs11161626	chr1:76260837	C/T	cg03433033	chr1:76189801	ACADM	0.63	6.47	0.37	4.6e-10	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs644799	1.000	rs632388	chr11:95563775	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.55	6.76	0.38	8.51e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs477895	0.838	rs35090903	chr11:64000598	C/T	cg04317338	chr11:64019027	PLCB3	0.9	10.09	0.53	1.82e-20	Mean platelet volume;
CESC	cis	rs9612	0.948	rs189408	chr19:44268006	T/C	cg08581076	chr19:44259116	C19orf61	0.44	5.26	0.31	2.93e-7	Exhaled nitric oxide output;
CESC	cis	rs8060686	0.545	rs9931987	chr16:68256639	G/A	cg26727032	chr16:67993705	SLC12A4	-0.46	-5.4	-0.32	1.45e-7	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs7130144	0.541	rs56097840	chr11:130462749	C/T	cg26307797	chr11:130446613	NA	-0.74	-6.5	-0.37	3.95e-10	Urate levels in lean individuals;
CESC	cis	rs1371867	0.846	rs1788206	chr8:101306966	A/G	cg11906718	chr8:101322791	RNF19A	0.54	6.93	0.39	3.24e-11	Atrioventricular conduction;
CESC	cis	rs7618915	0.570	rs11714088	chr3:52758942	A/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.49	0.37	4.1e-10	Bipolar disorder;
CESC	cis	rs7296418	0.922	rs1790134	chr12:123697898	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.32	-5.07	-0.3	7.34e-7	Platelet count;
CESC	cis	rs36051895	0.659	rs12348771	chr9:5083634	T/C	cg02405213	chr9:5042618	JAK2	-0.55	-6.66	-0.38	1.58e-10	Pediatric autoimmune diseases;
CESC	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg26338869	chr17:61819248	STRADA	0.7	9.28	0.5	6.1e-18	Prudent dietary pattern;
CESC	trans	rs4906172	0.898	rs10135027	chr14:102497772	A/G	cg17920195	chr4:129149383	NA	0.33	6.52	0.37	3.6e-10	Menopause (age at onset);
CESC	cis	rs854765	0.583	rs9913724	chr17:17819101	A/G	cg04398451	chr17:18023971	MYO15A	-0.67	-9.74	-0.51	2.33e-19	Total body bone mineral density;
CESC	cis	rs10857712	0.950	rs7906765	chr10:135225460	G/T	cg01444801	chr10:135216882	MTG1	-0.45	-5.32	-0.31	2.24e-7	Systemic lupus erythematosus;
CESC	cis	rs644799	1.000	rs593665	chr11:95574302	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.94	13.75	0.65	7.53e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs9790314	0.521	rs1376122	chr3:161087857	A/G	cg03342759	chr3:160939853	NMD3	-0.41	-5.74	-0.33	2.52e-8	Morning vs. evening chronotype;
CESC	cis	rs2795502	0.873	rs3123753	chr10:43404899	C/T	cg27426351	chr10:43362370	NA	0.49	6.03	0.35	5.54e-9	Blood protein levels;
CESC	cis	rs6952808	0.689	rs58227534	chr7:2046328	A/G	cg23048001	chr7:2026167	MAD1L1	0.48	6.26	0.36	1.57e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs8020095	0.571	rs7156119	chr14:67650115	C/T	cg19548862	chr14:67692701	FAM71D	-0.46	-5.53	-0.32	7.72e-8	Depression (quantitative trait);
CESC	cis	rs7219021	0.669	rs35584414	chr17:47022727	C/G	cg16584676	chr17:46985605	UBE2Z	-0.64	-7.14	-0.4	9.18e-12	Schizophrenia or bipolar disorder;
CESC	cis	rs9486719	0.948	rs6920913	chr6:96874297	A/G	cg06623918	chr6:96969491	KIAA0776	0.9	10.2	0.53	8.21e-21	Migraine;Coronary artery disease;
CESC	cis	rs7829975	0.840	rs555617	chr8:8592845	C/G	cg06636001	chr8:8085503	FLJ10661	-0.46	-5.96	-0.34	8.13e-9	Mood instability;
CESC	cis	rs523522	0.923	rs1048830	chr12:120882217	G/T	cg27279351	chr12:120934652	DYNLL1	0.65	7.94	0.44	5.74e-14	High light scatter reticulocyte count;
CESC	cis	rs6701037	0.748	rs2685	chr1:175127771	A/G	cg00321850	chr1:175162397	KIAA0040	0.4	5.76	0.33	2.37e-8	Alcohol dependence;
CESC	cis	rs8180040	1.000	rs1076394	chr3:47322781	G/A	cg27129171	chr3:47204927	SETD2	-0.66	-10.07	-0.53	2.14e-20	Colorectal cancer;
CESC	trans	rs57221529	0.600	rs11750269	chr5:666270	G/A	cg25482853	chr8:67687455	SGK3	1.03	10.1	0.53	1.7e-20	Lung disease severity in cystic fibrosis;
CESC	cis	rs7586879	0.551	rs7565460	chr2:25130073	C/T	cg01884057	chr2:25150051	NA	0.37	7.08	0.4	1.27e-11	Body mass index;
CESC	cis	rs7589342	0.895	rs2033008	chr2:106502585	T/A	cg14210321	chr2:106509881	NCK2	-0.47	-5.37	-0.31	1.75e-7	Addiction;
CESC	cis	rs875971	0.660	rs79009421	chr7:66068509	G/C	cg14393609	chr7:65229607	NA	-0.47	-6.28	-0.36	1.39e-9	Aortic root size;
CESC	cis	rs7769051	0.522	rs34688576	chr6:133118214	C/T	cg22852734	chr6:133119734	C6orf192	1.06	7.13	0.4	9.46e-12	Type 2 diabetes nephropathy;
CESC	cis	rs2637266	1.000	rs2637270	chr10:78336901	C/T	cg18941641	chr10:78392320	NA	0.41	7.62	0.42	4.6e-13	Pulmonary function;
CESC	cis	rs8072100	0.738	rs9900123	chr17:45549055	T/C	cg08085267	chr17:45401833	C17orf57	-0.54	-6.85	-0.39	5.15e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs3845702	0.736	rs2678936	chr2:180872179	G/C	cg01881094	chr2:180872142	CWC22	1.11	10.12	0.53	1.45e-20	Schizophrenia;
CESC	trans	rs801193	1.000	rs2707836	chr7:66160435	A/C	cg26939375	chr7:64535504	NA	0.64	8.77	0.47	2.19e-16	Aortic root size;
CESC	cis	rs75804782	0.641	rs6715311	chr2:239363321	A/G	cg18131467	chr2:239335373	ASB1	-0.68	-5.65	-0.33	4.08e-8	Morning vs. evening chronotype;Chronotype;
CESC	cis	rs1799949	0.859	rs11657004	chr17:41442751	A/G	cg23758822	chr17:41437982	NA	0.98	17.37	0.73	1.23e-45	Menopause (age at onset);
CESC	cis	rs72781680	0.533	rs34668726	chr2:23895901	C/G	cg20701182	chr2:24300061	SF3B14	0.74	6.96	0.39	2.61e-11	Lymphocyte counts;
CESC	cis	rs2505675	0.665	rs234932	chr6:2220520	C/T	cg16550324	chr6:2245327	GMDS	0.41	5.19	0.3	4.19e-7	Tuberculosis;
CESC	cis	rs7089973	0.624	rs17586888	chr10:116598121	T/C	cg03647239	chr10:116582469	FAM160B1	0.44	5.55	0.32	6.83e-8	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs6728642	0.908	rs10207116	chr2:98018281	G/A	cg26665480	chr2:98280029	ACTR1B	-0.81	-7.49	-0.42	1e-12	Bipolar disorder lithium response (continuous) or schizophrenia;
CESC	cis	rs11958404	0.932	rs72816580	chr5:157432221	A/T	cg05962755	chr5:157440814	NA	0.62	6.56	0.37	2.74e-10	IgG glycosylation;
CESC	cis	rs1448094	0.512	rs7133591	chr12:86239752	G/C	cg00310523	chr12:86230176	RASSF9	0.34	5.43	0.32	1.27e-7	Major depressive disorder;
CESC	trans	rs7824557	0.564	rs7834572	chr8:11236685	C/T	cg06636001	chr8:8085503	FLJ10661	-0.49	-6.15	-0.35	2.9e-9	Retinal vascular caliber;
CESC	cis	rs4803468	1.000	rs284663	chr19:41932612	C/T	cg14132834	chr19:41945861	ATP5SL	-0.68	-8.4	-0.46	2.68e-15	Height;
CESC	cis	rs35306767	0.953	rs12357633	chr10:957246	C/T	cg26597838	chr10:835615	NA	0.98	10.69	0.55	2.06e-22	Eosinophil percentage of granulocytes;
CESC	cis	rs4808199	0.895	rs12981405	chr19:19651577	C/T	cg03709012	chr19:19516395	GATAD2A	1.0	9.88	0.52	8.15e-20	Nonalcoholic fatty liver disease;
CESC	cis	rs2836950	0.501	rs2070865	chr21:40715519	C/T	cg17971929	chr21:40555470	PSMG1	-0.51	-6.31	-0.36	1.16e-9	Menarche (age at onset);
CESC	cis	rs9322193	0.962	rs9505974	chr6:150100430	C/T	cg09699651	chr6:150184138	LRP11	0.4	5.1	0.3	6.34e-7	Lung cancer;
CESC	cis	rs9549367	0.789	rs2025247	chr13:113882564	C/G	cg00898013	chr13:113819073	PROZ	-0.49	-6.73	-0.38	1.05e-10	Platelet distribution width;
CESC	cis	rs4704187	0.687	rs6453112	chr5:74389901	A/C	cg03227963	chr5:74354835	NA	0.32	5.92	0.34	9.97e-9	Response to amphetamines;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07371452	chr16:139780	C16orf35	-0.55	-5.99	-0.35	6.71e-9	Gut microbiome composition (summer);
CESC	cis	rs1348850	0.526	rs1345138	chr2:178387100	A/T	cg23306229	chr2:178417860	TTC30B	0.78	6.92	0.39	3.32e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs1552244	0.882	rs61429272	chr3:10037320	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.85	11.02	0.56	1.64e-23	Alzheimer's disease;
CESC	cis	rs9303401	0.659	rs12600349	chr17:57054245	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	-1.01	-12.41	-0.61	3.56e-28	Cognitive test performance;
CESC	cis	rs9814567	0.752	rs6779326	chr3:134330027	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.4	-5.09	-0.3	6.84e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs76878669	0.561	rs6591215	chr11:66170611	A/C	cg18002602	chr11:66138449	SLC29A2	-0.3	-5.1	-0.3	6.39e-7	Educational attainment (years of education);
CESC	cis	rs858239	0.601	rs6461702	chr7:23249273	C/G	cg23682824	chr7:23144976	KLHL7	0.44	5.63	0.33	4.51e-8	Cerebrospinal fluid biomarker levels;
CESC	cis	rs17253792	0.731	rs28587929	chr14:56097492	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.77	5.98	0.34	7.23e-9	Putamen volume;
CESC	cis	rs875971	0.545	rs12671152	chr7:65776127	G/T	cg18876405	chr7:65276391	NA	0.5	5.54	0.32	7.2e-8	Aortic root size;
CESC	cis	rs7659604	0.518	rs17452156	chr4:122733623	T/C	cg19748678	chr4:122722346	EXOSC9	0.78	9.69	0.51	3.45e-19	Type 2 diabetes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15995771	chr1:59250858	JUN	0.57	6.25	0.36	1.6e-9	Gut microbiome composition (summer);
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg03066081	chr17:77784036	NA	0.49	6.61	0.38	2.11e-10	Systemic lupus erythematosus;
CESC	cis	rs951366	1.000	rs951366	chr1:205685352	C/T	cg14159672	chr1:205819179	PM20D1	0.43	5.93	0.34	9.36e-9	Menarche (age at onset);
CESC	cis	rs2456568	0.709	rs1546400	chr11:93639203	G/A	cg26875233	chr11:93583750	C11orf90	0.3	5.27	0.31	2.77e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
CESC	cis	rs7208859	0.623	rs6505207	chr17:29076571	T/C	cg14008862	chr17:28927542	LRRC37B2	0.65	5.14	0.3	5.34e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs11785400	0.793	rs4403386	chr8:143736770	C/G	cg10596483	chr8:143751796	JRK	0.43	5.41	0.32	1.37e-7	Schizophrenia;
CESC	cis	rs7656342	0.686	rs10031303	chr4:9841690	A/T	cg11266682	chr4:10021025	SLC2A9	0.33	5.22	0.31	3.55e-7	Gut microbiota (bacterial taxa);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11844697	chr17:80935769	B3GNTL1	-0.53	-6.07	-0.35	4.3e-9	Gut microbiome composition (summer);
CESC	cis	rs155076	0.666	rs2015241	chr13:21888254	A/G	cg25811766	chr13:21894605	NA	0.58	5.83	0.34	1.59e-8	White matter hyperintensity burden;
CESC	cis	rs875971	0.545	rs801199	chr7:66025273	A/G	cg25405998	chr7:65216604	CCT6P1	-0.46	-5.22	-0.31	3.71e-7	Aortic root size;
CESC	cis	rs1832871	0.672	rs9457362	chr6:158772052	C/T	cg07165851	chr6:158734300	TULP4	0.58	6.19	0.36	2.31e-9	Height;
CESC	cis	rs8050907	0.744	rs1362625	chr16:4526310	G/C	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.9	6.28	0.36	1.39e-9	Obesity-related traits;
CESC	cis	rs916888	0.610	rs199452	chr17:44801340	C/T	cg01570182	chr17:44337453	NA	0.63	8.63	0.47	5.75e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs10927875	0.632	rs4661667	chr1:16162731	C/T	cg21385522	chr1:16154831	NA	-1.02	-16.92	-0.72	4.74e-44	Dilated cardiomyopathy;
CESC	cis	rs7129220	0.588	rs72860548	chr11:10128679	C/G	cg01453529	chr11:10209919	SBF2	-0.47	-5.37	-0.31	1.7e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CESC	cis	rs2014572	0.967	rs7248000	chr19:57762139	C/T	cg24459738	chr19:57751996	ZNF805	-0.56	-7.97	-0.44	4.64e-14	Hyperactive-impulsive symptoms;
CESC	cis	rs4268898	0.662	rs35624938	chr2:24576651	T/C	cg20701182	chr2:24300061	SF3B14	0.65	6.93	0.39	3.15e-11	Asthma;
CESC	cis	rs4911259	0.552	rs2014837	chr20:31461082	C/T	cg13636640	chr20:31349939	DNMT3B	0.57	7.97	0.44	4.66e-14	Inflammatory bowel disease;
CESC	cis	rs6088813	1.000	rs6088821	chr20:33987576	G/A	cg14752227	chr20:34000481	UQCC	-0.4	-5.08	-0.3	7.17e-7	Height;
CESC	cis	rs6736093	0.966	rs870763	chr2:112745481	C/T	cg12686935	chr2:112915763	FBLN7	0.43	5.62	0.33	4.9e-8	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15289517	chr15:65809633	DPP8	0.56	6.55	0.37	3.04e-10	Gut microbiome composition (summer);
CESC	cis	rs10504229	1.000	rs68076606	chr8:58191271	A/G	cg22535103	chr8:58192502	C8orf71	-1.05	-13.08	-0.63	1.71e-30	Developmental language disorder (linguistic errors);
CESC	cis	rs916888	0.773	rs199448	chr17:44809001	A/G	cg27589368	chr17:43923255	LOC100128977;IMP5	-0.38	-5.35	-0.31	1.89e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs1448094	0.512	rs1349063	chr12:86264237	C/T	cg19622623	chr12:86230825	RASSF9	-0.47	-6.06	-0.35	4.65e-9	Major depressive disorder;
CESC	cis	rs17253792	0.558	rs10083353	chr14:56066370	G/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.85	6.09	0.35	4.01e-9	Putamen volume;
CESC	cis	rs2108622	0.727	rs7253684	chr19:15981126	C/T	cg13772218	chr19:15982569	NA	0.3	5.87	0.34	1.27e-8	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CESC	cis	rs4253772	0.591	rs6520010	chr22:46721223	G/A	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.78	9.23	0.49	8.88e-18	LDL cholesterol;Cholesterol, total;
CESC	cis	rs4972806	0.849	rs2071581	chr2:177026148	G/T	cg13092806	chr2:177043255	NA	0.46	6.72	0.38	1.12e-10	IgG glycosylation;
CESC	cis	rs75477785	1.000	rs10489343	chr1:209984824	G/T	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.92	6.04	0.35	5.06e-9	Cleft lip with or without cleft palate;
CESC	cis	rs1799949	1.000	rs35070007	chr17:41316747	C/G	cg05368731	chr17:41323189	NBR1	-0.61	-8.42	-0.46	2.36e-15	Menopause (age at onset);
CESC	cis	rs2576037	0.526	rs11082562	chr18:44522671	T/C	cg19077165	chr18:44547161	KATNAL2	-0.53	-7.75	-0.43	1.94e-13	Personality dimensions;
CESC	cis	rs17401966	0.838	rs4846197	chr1:10282166	G/A	cg15208524	chr1:10270712	KIF1B	0.41	5.23	0.31	3.43e-7	Hepatocellular carcinoma;
CESC	cis	rs1348850	0.914	rs6710575	chr2:178377311	C/T	cg22681709	chr2:178499509	PDE11A	-0.39	-5.47	-0.32	1.02e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs7216064	0.684	rs8182243	chr17:66018505	T/C	cg07042672	chr17:66097459	LOC651250	0.61	7.95	0.44	5.31e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs7000551	0.715	rs7828610	chr8:22307326	C/T	cg12081754	chr8:22256438	SLC39A14	0.44	5.91	0.34	1.07e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CESC	cis	rs55692411	0.537	rs71326904	chr3:49991060	C/T	cg24110177	chr3:50126178	RBM5	-0.43	-5.1	-0.3	6.39e-7	Intelligence (multi-trait analysis);
CESC	trans	rs8135828	0.770	rs2188120	chr22:29920819	A/C	cg00674024	chr14:102829918	TECPR2;CINP	0.56	6.36	0.36	8.76e-10	Lipid traits;
CESC	cis	rs965469	0.779	rs6037541	chr20:3287704	G/C	cg25506879	chr20:3388711	C20orf194	-0.48	-5.31	-0.31	2.36e-7	IFN-related cytopenia;
CESC	cis	rs7659604	0.605	rs1396080	chr4:122740454	T/G	cg20573242	chr4:122745356	CCNA2	0.75	10.17	0.53	1e-20	Type 2 diabetes;
CESC	cis	rs2011503	1.000	rs34067609	chr19:19653524	G/A	cg11584989	chr19:19387371	SF4	0.58	6.67	0.38	1.52e-10	Bipolar disorder;
CESC	cis	rs798766	1.000	rs2236786	chr4:1719294	T/C	cg05874882	chr4:1763078	NA	0.61	7.32	0.41	3.06e-12	Bladder cancer;Urinary bladder cancer;
CESC	cis	rs2243480	1.000	rs316322	chr7:65611233	G/C	cg12463550	chr7:65579703	CRCP	0.74	5.79	0.33	2.02e-8	Diabetic kidney disease;
CESC	cis	rs854765	0.583	rs4244602	chr17:17841456	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.53	7.27	0.41	3.96e-12	Total body bone mineral density;
CESC	cis	rs8049040	0.609	rs16972805	chr16:71478249	A/G	cg08717414	chr16:71523259	ZNF19	0.64	7.25	0.41	4.65e-12	Blood protein levels;
CESC	cis	rs763121	0.853	rs5757253	chr22:39104320	C/T	cg21395723	chr22:39101663	GTPBP1	0.5	6.82	0.39	6.16e-11	Menopause (age at onset);
CESC	cis	rs2243480	0.708	rs35310401	chr7:65390359	A/G	cg12463550	chr7:65579703	CRCP	0.7	5.58	0.32	5.87e-8	Diabetic kidney disease;
CESC	cis	rs7940866	0.903	rs10750457	chr11:130850277	T/C	cg12179176	chr11:130786555	SNX19	0.59	8.43	0.46	2.23e-15	Schizophrenia;
CESC	cis	rs7267979	1.000	rs6050631	chr20:25431749	C/T	cg08601574	chr20:25228251	PYGB	0.38	5.57	0.32	6.24e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs763121	0.853	rs2413545	chr22:39092524	C/T	cg06544989	chr22:39130855	UNC84B	0.5	8.24	0.45	8.07e-15	Menopause (age at onset);
CESC	cis	rs12618769	0.597	rs17504774	chr2:99135627	A/G	cg10123293	chr2:99228465	UNC50	-0.38	-5.16	-0.3	4.92e-7	Bipolar disorder;
CESC	cis	rs9291683	0.507	rs6849273	chr4:10021595	C/T	cg02734326	chr4:10020555	SLC2A9	0.42	5.84	0.34	1.52e-8	Bone mineral density;
CESC	trans	rs11770686	0.967	rs4728289	chr7:75348505	C/T	cg16600432	chr14:64970085	ZBTB1;ZBTB25	-0.39	-6.02	-0.35	5.82e-9	Essential tremor;
CESC	cis	rs1799949	0.965	rs7212284	chr17:41205941	A/G	cg05368731	chr17:41323189	NBR1	0.54	7.43	0.42	1.52e-12	Menopause (age at onset);
CESC	cis	rs10206020	0.885	rs13411553	chr2:1574018	A/G	cg26248373	chr2:1572462	NA	-0.58	-6.78	-0.38	7.78e-11	IgG glycosylation;
CESC	cis	rs4604732	0.812	rs6663238	chr1:247624971	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	-0.39	-5.42	-0.32	1.31e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs9814567	1.000	rs7433663	chr3:134235790	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.45	-6.08	-0.35	4.09e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs1008375	0.966	rs2098152	chr4:17684392	G/T	cg02297831	chr4:17616191	MED28	0.44	5.64	0.33	4.43e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs1153858	1.000	rs10519022	chr15:45663684	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.43	-6.1	-0.35	3.81e-9	Homoarginine levels;
CESC	cis	rs738322	0.967	rs133013	chr22:38570912	C/T	cg17652424	chr22:38574118	PLA2G6	-0.34	-6.04	-0.35	5.08e-9	Cutaneous nevi;
CESC	trans	rs1116547	0.531	rs7707443	chr5:112790219	C/T	cg10115368	chr14:100435663	NA	0.5	6.01	0.35	6.04e-9	Cerebral amyloid angiopathy;
CESC	cis	rs2072499	0.966	rs2842864	chr1:156159217	G/A	cg24450063	chr1:156163899	SLC25A44	1.11	23.64	0.82	3.21e-67	Testicular germ cell tumor;
CESC	cis	rs12681288	0.823	rs4735974	chr8:1000218	T/G	cg04851639	chr8:1020857	NA	-0.32	-7.17	-0.4	7.66e-12	Schizophrenia;
CESC	cis	rs11785693	0.862	rs17351027	chr8:4987098	A/G	cg26367366	chr8:4980734	NA	-0.61	-5.95	-0.34	8.47e-9	Neuroticism (multi-trait analysis);Neuroticism;
CESC	cis	rs7828089	0.934	rs12544427	chr8:22263115	C/T	cg13512537	chr8:22265999	SLC39A14	0.37	5.31	0.31	2.31e-7	Verbal declarative memory;
CESC	cis	rs12130219	1.000	rs12130219	chr1:152162106	A/G	cg17718321	chr1:152188247	HRNR	0.41	5.45	0.32	1.18e-7	Inflammatory skin disease;
CESC	cis	rs832540	0.931	rs2591960	chr5:56238811	A/T	cg14703610	chr5:56206110	C5orf35	-0.45	-5.46	-0.32	1.07e-7	Coronary artery disease;
CESC	cis	rs962856	0.575	rs1486134	chr2:67639769	G/T	cg09028215	chr2:67624308	ETAA1	-0.41	-5.1	-0.3	6.58e-7	Pancreatic cancer;
CESC	cis	rs9814567	1.000	rs2373865	chr3:134291556	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.45	6.1	0.35	3.71e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs4925386	1.000	rs6121990	chr20:60919263	G/A	cg24112000	chr20:60950667	NA	0.51	7.59	0.42	5.58e-13	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs11792861	0.816	rs113624314	chr9:111689953	G/A	cg13535736	chr9:111863775	C9orf5	-0.46	-6.08	-0.35	4.28e-9	Menarche (age at onset);
CESC	cis	rs10751667	0.621	rs11246345	chr11:934924	T/C	cg20946044	chr11:1010712	AP2A2	-0.4	-5.43	-0.32	1.26e-7	Alzheimer's disease (late onset);
CESC	cis	rs72781680	1.000	rs72796359	chr2:24160545	T/C	cg20701182	chr2:24300061	SF3B14	0.78	6.82	0.39	5.98e-11	Lymphocyte counts;
CESC	cis	rs711245	0.573	rs7570763	chr2:36800589	A/C	cg15105969	chr2:36825350	FEZ2	-0.45	-5.18	-0.3	4.37e-7	Height;
CESC	cis	rs561341	1.000	rs1557731	chr17:30321567	T/G	cg19193384	chr17:30244184	NA	-0.61	-6.39	-0.37	7.37e-10	Hip circumference adjusted for BMI;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25371038	chr22:22337141	TOP3B	0.68	7.3	0.41	3.35e-12	Gut microbiome composition (summer);
CESC	cis	rs798502	0.522	rs7790322	chr7:2830498	C/T	cg18446336	chr7:2847575	GNA12	-0.44	-7.38	-0.41	2.04e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Inflammatory bowel disease;Waist circumference adjusted for BMI in non-smokers;Ulcerative colitis;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
CESC	cis	rs1008375	0.897	rs6820164	chr4:17630115	G/A	cg16339924	chr4:17578868	LAP3	0.71	9.08	0.49	2.58e-17	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs72772090	0.539	rs55996659	chr5:96114150	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.63	-5.68	-0.33	3.57e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	trans	rs921968	0.541	rs581013	chr2:219432040	G/T	cg15547669	chr20:2781122	CPXM1	0.36	6.01	0.35	5.97e-9	Mean corpuscular hemoglobin concentration;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25940730	chr4:16228647	TAPT1;FLJ39653	0.57	6.39	0.37	7.57e-10	Gut microbiome composition (summer);
CESC	cis	rs2228479	0.850	rs11642010	chr16:89845111	T/C	cg14709524	chr16:89940631	TCF25	0.75	5.07	0.3	7.38e-7	Skin colour saturation;
CESC	cis	rs9916302	0.851	rs6503502	chr17:37501855	A/G	cg07936489	chr17:37558343	FBXL20	0.8	11.69	0.58	9.64e-26	Glomerular filtration rate (creatinine);
CESC	cis	rs704	0.605	rs2071379	chr17:26695832	A/G	cg10342447	chr17:26645325	TMEM97	-0.42	-6.04	-0.35	5.17e-9	Osteoprotegerin levels;
CESC	cis	rs748404	0.660	rs2439845	chr15:43722610	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.57	7.62	0.42	4.42e-13	Lung cancer;
CESC	cis	rs4243830	0.737	rs11581831	chr1:6609958	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.85	-8.42	-0.46	2.37e-15	Body mass index;
CESC	cis	rs1570884	0.857	rs9535263	chr13:50137363	T/A	cg08779649	chr13:50194554	NA	0.32	5.2	0.3	3.93e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
CESC	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg27094323	chr7:1216898	NA	-0.37	-5.36	-0.31	1.81e-7	Longevity;Endometriosis;
CESC	cis	rs4665809	0.838	rs6546780	chr2:26352857	T/C	cg26314531	chr2:26401878	FAM59B	-0.61	-6.85	-0.39	5.02e-11	Gut microbiome composition (summer);
CESC	cis	rs2806561	0.808	rs1413974	chr1:23347125	C/T	cg12483005	chr1:23474871	LUZP1	-0.35	-5.41	-0.32	1.43e-7	Height;
CESC	cis	rs367943	0.712	rs9326887	chr5:112728581	T/A	cg12552261	chr5:112820674	MCC	0.38	5.08	0.3	7.02e-7	Type 2 diabetes;
CESC	cis	rs7179456	0.547	rs6494035	chr15:59015888	C/G	cg05156742	chr15:59063176	FAM63B	0.57	7.3	0.41	3.33e-12	Asperger disorder;
CESC	cis	rs4718428	0.672	rs13241598	chr7:66300652	A/G	cg18252515	chr7:66147081	NA	-0.47	-5.24	-0.31	3.23e-7	Corneal structure;
CESC	cis	rs2228479	0.850	rs62054601	chr16:89811751	C/G	cg04013166	chr16:89971882	TCF25	0.78	6.74	0.38	9.93e-11	Skin colour saturation;
CESC	cis	rs752010	0.746	rs11210499	chr1:42089703	C/T	cg12614395	chr1:42085415	HIVEP3	-0.31	-5.31	-0.31	2.28e-7	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs10504229	0.639	rs17331850	chr8:58113538	G/T	cg21724239	chr8:58056113	NA	0.58	5.93	0.34	9.45e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs10465746	0.846	rs9700285	chr1:84336685	G/A	cg10977910	chr1:84465055	TTLL7	0.48	6.5	0.37	3.92e-10	Obesity-related traits;
CESC	cis	rs727563	0.636	rs2413653	chr22:42106996	T/C	cg06481639	chr22:41940642	POLR3H	0.6	6.04	0.35	5.18e-9	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs698833	0.886	rs786654	chr2:44581007	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.46	5.8	0.34	1.84e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs1475911	0.708	rs11701371	chr21:43523972	C/G	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.46	-7.18	-0.4	7.07e-12	IgG glycosylation;
CESC	cis	rs6696846	0.765	rs11577406	chr1:205065733	G/T	cg00857998	chr1:205179979	DSTYK	0.56	7.36	0.41	2.27e-12	Red blood cell count;
CESC	cis	rs10883723	0.810	rs12265877	chr10:104247247	C/G	cg22532475	chr10:104410764	TRIM8	-0.34	-5.72	-0.33	2.86e-8	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs1371867	0.875	rs1660344	chr8:101324659	A/G	cg11906718	chr8:101322791	RNF19A	0.54	6.93	0.39	3.1e-11	Atrioventricular conduction;
CESC	cis	rs11098499	0.569	rs55845118	chr4:120290913	T/C	cg09307838	chr4:120376055	NA	0.87	12.16	0.6	2.41e-27	Corneal astigmatism;
CESC	cis	rs72781680	0.611	rs56113233	chr2:24341085	A/C	cg06627628	chr2:24431161	ITSN2	-0.66	-6.24	-0.36	1.69e-9	Lymphocyte counts;
CESC	cis	rs4953318	0.619	rs13406773	chr2:46362868	T/C	cg12428440	chr2:46370979	PRKCE	0.49	6.59	0.38	2.31e-10	Red blood cell count;Hematocrit;Red blood cell traits;
CESC	cis	rs6088580	0.713	rs1884669	chr20:33171287	G/A	cg06115741	chr20:33292138	TP53INP2	0.51	6.51	0.37	3.71e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs17253792	0.822	rs80321745	chr14:56162947	T/A	cg01858014	chr14:56050164	KTN1	-0.97	-7.54	-0.42	7.36e-13	Putamen volume;
CESC	cis	rs35306767	0.855	rs12771179	chr10:872347	A/G	cg10556349	chr10:835070	NA	0.76	6.39	0.37	7.22e-10	Eosinophil percentage of granulocytes;
CESC	cis	rs8067354	0.645	rs2645467	chr17:57854783	C/T	cg02344993	chr17:57696989	CLTC	0.67	8.32	0.46	4.71e-15	Hemoglobin concentration;
CESC	cis	rs742614	0.533	rs6059499	chr20:32447920	C/T	cg06304546	chr20:32448765	NA	0.47	6.01	0.35	5.96e-9	Stearic acid (18:0) levels;
CESC	cis	rs7608623	0.679	rs4665652	chr2:24250023	G/A	cg20701182	chr2:24300061	SF3B14	-0.4	-5.34	-0.31	2.01e-7	Obesity-related traits;
CESC	cis	rs10276381	0.579	rs73072539	chr7:28146255	C/G	cg23620719	chr7:28220237	JAZF1	0.65	5.19	0.3	4.13e-7	Crohn's disease;
CESC	cis	rs208520	0.821	rs9363572	chr6:67012231	C/T	cg07460842	chr6:66804631	NA	0.84	8.13	0.45	1.67e-14	Exhaled nitric oxide output;
CESC	cis	rs7607369	0.714	rs4674338	chr2:219647487	A/G	cg02176678	chr2:219576539	TTLL4	0.46	8.14	0.45	1.51e-14	Red blood cell count;Amyotrophic lateral sclerosis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21099326	chr8:27168591	TRIM35;PTK2B	0.57	6.57	0.37	2.67e-10	Gut microbiome composition (summer);
CESC	trans	rs7618501	0.722	rs9853458	chr3:49783211	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.58	-8.4	-0.46	2.71e-15	Intelligence (multi-trait analysis);
CESC	cis	rs4835473	0.932	rs1450250	chr4:144653026	A/G	cg25736465	chr4:144833511	NA	0.37	5.67	0.33	3.72e-8	Immature fraction of reticulocytes;
CESC	trans	rs9467711	0.606	rs68112369	chr6:26365759	T/C	cg06606381	chr12:133084897	FBRSL1	-0.77	-6.97	-0.39	2.57e-11	Autism spectrum disorder or schizophrenia;
CESC	cis	rs1862618	0.853	rs1559282	chr5:56099375	T/A	cg18230493	chr5:56204884	C5orf35	-0.66	-8.28	-0.45	6.32e-15	Initial pursuit acceleration;
CESC	cis	rs11252926	0.599	rs11252213	chr10:454694	C/T	cg18196295	chr10:418757	DIP2C	0.52	7.06	0.4	1.49e-11	Psychosis in Alzheimer's disease;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg06825833	chr13:111566802	ANKRD10	0.51	6.57	0.37	2.66e-10	Gut microbiota (bacterial taxa);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg24294857	chr1:20812821	CAMK2N1	-0.43	-6.18	-0.35	2.46e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs6952808	0.792	rs13224989	chr7:1953766	C/G	cg21782813	chr7:2030301	MAD1L1	0.4	5.83	0.34	1.57e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs72781680	0.611	rs2303287	chr2:24302246	A/G	cg06627628	chr2:24431161	ITSN2	0.68	6.46	0.37	4.88e-10	Lymphocyte counts;
CESC	cis	rs10791323	0.582	rs2851120	chr11:133708065	A/G	cg15485101	chr11:133734466	NA	0.37	6.26	0.36	1.55e-9	Childhood ear infection;
CESC	cis	rs116095464	0.558	rs56298907	chr5:283280	C/A	cg22496380	chr5:211416	CCDC127	-0.99	-10.19	-0.53	8.71e-21	Breast cancer;
CESC	cis	rs9584850	0.718	rs6491427	chr13:99113166	A/G	cg20750642	chr13:99100586	FARP1	-0.39	-5.91	-0.34	1.05e-8	Neuroticism;
CESC	cis	rs34172651	0.517	rs874484	chr16:24803242	T/C	cg04756594	chr16:24857601	SLC5A11	0.5	5.82	0.34	1.7e-8	Intelligence (multi-trait analysis);
CESC	cis	rs59698941	0.943	rs997633	chr5:132219304	A/T	cg02081065	chr5:132209139	LEAP2	-0.52	-5.11	-0.3	6.08e-7	Apolipoprotein A-IV levels;
CESC	cis	rs34734847	0.750	rs3915	chr12:121176679	C/T	cg21892295	chr12:121157589	UNC119B	-0.34	-5.29	-0.31	2.53e-7	Mean corpuscular volume;
CESC	cis	rs7726839	0.794	rs10053310	chr5:595661	C/G	cg16447950	chr5:562315	NA	-0.49	-5.75	-0.33	2.39e-8	Obesity-related traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11923054	chr4:4250051	TMEM128	-0.57	-6.71	-0.38	1.17e-10	Gut microbiome composition (summer);
CESC	cis	rs898097	0.841	rs9896263	chr17:80902741	A/G	cg15369054	chr17:80825471	TBCD	-0.47	-6.74	-0.38	1.01e-10	Breast cancer;
CESC	cis	rs9611519	0.780	rs9611546	chr22:41698542	C/G	cg03806693	chr22:41940476	POLR3H	-0.78	-8.82	-0.48	1.58e-16	Neuroticism;
CESC	cis	rs3126085	0.867	rs36033453	chr1:152221226	T/G	cg03465714	chr1:152285911	FLG	0.45	5.37	0.31	1.73e-7	Atopic dermatitis;
CESC	cis	rs2625529	0.652	rs2930069	chr15:72226977	G/A	cg16672083	chr15:72433130	SENP8	0.41	6.24	0.36	1.72e-9	Red blood cell count;
CESC	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	22.27	0.81	1.17e-62	Prudent dietary pattern;
CESC	cis	rs7851660	0.772	rs6478471	chr9:100664382	A/G	cg13688889	chr9:100608707	NA	-0.62	-8.83	-0.48	1.5e-16	Strep throat;
CESC	cis	rs1729951	0.575	rs12494558	chr3:136678781	C/G	cg03617693	chr3:136751559	NA	0.38	5.33	0.31	2.08e-7	Neuroticism;
CESC	cis	rs4713118	0.662	rs149900	chr6:28014597	C/T	cg26335602	chr6:28129616	ZNF389	0.45	5.57	0.32	6.23e-8	Parkinson's disease;
CESC	cis	rs11650494	0.908	rs77247327	chr17:47411493	T/C	cg08112188	chr17:47440006	ZNF652	1.31	8.52	0.46	1.22e-15	Prostate cancer;
CESC	cis	rs5769707	0.967	rs9616701	chr22:50025546	G/A	cg05373962	chr22:49881684	NA	-0.39	-6.81	-0.39	6.45e-11	Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs863345	0.967	rs12121983	chr1:158510273	A/G	cg12129480	chr1:158549410	OR10X1	-0.32	-6.59	-0.38	2.3e-10	Pneumococcal bacteremia;
CESC	cis	rs16866061	1.000	rs72974203	chr2:225408430	G/A	cg12698349	chr2:225449008	CUL3	0.74	11.36	0.57	1.3e-24	Acute graft versus host disease in bone marrow transplantation (recipient effect);
CESC	cis	rs3785574	0.962	rs58131426	chr17:61854375	T/C	cg06420487	chr17:61919686	SMARCD2	0.47	5.59	0.32	5.68e-8	Height;
CESC	cis	rs7071206	0.947	rs1877998	chr10:79411740	C/T	cg00983440	chr10:79422392	NA	-0.66	-7.97	-0.44	4.74e-14	Bone mineral density;
CESC	cis	rs10540	1.000	rs71487296	chr11:500282	G/A	cg03576123	chr11:487126	PTDSS2	-1.11	-11.13	-0.56	7.09e-24	Body mass index;
CESC	cis	rs9611565	0.659	rs116959331	chr22:41932774	A/G	cg06481639	chr22:41940642	POLR3H	-0.61	-6.39	-0.37	7.34e-10	Vitiligo;
CESC	cis	rs7267979	1.000	rs2257420	chr20:25275890	C/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	18.72	0.75	2.09e-50	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs921968	0.541	rs620596	chr2:219462419	G/A	cg02176678	chr2:219576539	TTLL4	0.48	8.45	0.46	2e-15	Mean corpuscular hemoglobin concentration;
CESC	cis	rs7618915	0.501	rs62253740	chr3:52684128	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	7.86	0.43	9.89e-14	Bipolar disorder;
CESC	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.61	0.38	2.05e-10	Prudent dietary pattern;
CESC	cis	rs7843479	0.965	rs733543	chr8:21835465	A/G	cg17168535	chr8:21777572	XPO7	0.51	7.2	0.4	6.27e-12	Mean corpuscular volume;
CESC	cis	rs7208859	0.673	rs1347359	chr17:28914529	T/C	cg19761014	chr17:28927070	LRRC37B2	0.79	7.2	0.4	6.08e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs4665809	0.590	rs72809668	chr2:26467653	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.1	12.68	0.61	4e-29	Gut microbiome composition (summer);
CESC	cis	rs7615952	0.932	rs13314869	chr3:125644669	G/A	cg05084668	chr3:125655381	ALG1L	-0.52	-6.14	-0.35	3.02e-9	Blood pressure (smoking interaction);
CESC	cis	rs703842	0.928	rs724834	chr12:58180416	G/C	cg00677455	chr12:58241039	CTDSP2	0.52	6.57	0.37	2.68e-10	Multiple sclerosis;
CESC	cis	rs3931020	0.530	rs6668736	chr1:75234550	C/T	cg10128416	chr1:75198403	TYW3;CRYZ	0.48	6.5	0.37	4.07e-10	Resistin levels;
CESC	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg03188948	chr7:1209495	NA	0.7	6.78	0.38	7.86e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs854765	0.619	rs4561528	chr17:17979099	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.61	8.64	0.47	5.5e-16	Total body bone mineral density;
CESC	cis	rs3126085	0.935	rs12409762	chr1:152175398	G/A	cg03465714	chr1:152285911	FLG	0.49	5.98	0.34	7.36e-9	Atopic dermatitis;
CESC	cis	rs10504229	0.683	rs11787247	chr8:58131528	G/T	cg24829409	chr8:58192753	C8orf71	-0.58	-7.2	-0.4	6.31e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs2735413	0.881	rs12919672	chr16:78082760	C/G	cg04733911	chr16:78082701	NA	-0.53	-8.89	-0.48	9.44e-17	Systolic blood pressure (alcohol consumption interaction);
CESC	cis	rs453301	0.686	rs11787026	chr8:8902371	A/T	cg15556689	chr8:8085844	FLJ10661	0.47	5.9	0.34	1.1e-8	Joint mobility (Beighton score);
CESC	cis	rs4660306	0.614	rs781057	chr1:45936017	C/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.47	5.2	0.3	3.91e-7	Homocysteine levels;
CESC	cis	rs853679	0.713	rs200991	chr6:27815494	A/C	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	-0.55	-5.63	-0.33	4.62e-8	Depression;
CESC	cis	rs2243480	1.000	rs56016656	chr7:65383481	C/T	cg13147721	chr7:65941812	NA	-0.88	-8.15	-0.45	1.47e-14	Diabetic kidney disease;
CESC	cis	rs2820292	0.619	rs41299585	chr1:201853165	G/T	cg06775570	chr1:201857621	SHISA4	-0.33	-5.31	-0.31	2.32e-7	Waist circumference;Body mass index (joint analysis main effects and smoking interaction);Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);
CESC	cis	rs2760061	0.583	rs3094911	chr1:228210179	A/G	cg02753203	chr1:228287806	NA	0.76	11.42	0.57	7.89e-25	Diastolic blood pressure;
CESC	cis	rs710865	0.627	rs10799710	chr1:19483209	A/G	cg13387374	chr1:19411106	UBR4	0.55	7.48	0.42	1.08e-12	Brain structure;
CESC	cis	rs2239547	0.522	rs6445550	chr3:52983434	G/A	cg11645453	chr3:52864694	ITIH4	0.32	5.33	0.31	2.06e-7	Schizophrenia;
CESC	cis	rs28386778	0.769	rs6504179	chr17:61812995	T/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.56	0.37	2.83e-10	Prudent dietary pattern;
CESC	cis	rs2991971	0.810	rs2356413	chr1:45914048	A/T	cg05343316	chr1:45956843	TESK2	0.59	8.4	0.46	2.68e-15	High light scatter reticulocyte count;
CESC	cis	rs9291683	0.526	rs6827785	chr4:10018205	C/T	cg00071950	chr4:10020882	SLC2A9	0.82	13.82	0.65	4.37e-33	Bone mineral density;
CESC	cis	rs9611565	0.694	rs7285041	chr22:41829149	G/T	cg06481639	chr22:41940642	POLR3H	0.63	6.29	0.36	1.27e-9	Vitiligo;
CESC	cis	rs72781680	0.799	rs2712084	chr2:24003051	A/G	cg08917208	chr2:24149416	ATAD2B	0.61	5.99	0.35	6.76e-9	Lymphocyte counts;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg11498079	chr5:173043766	BOD1	-0.48	-6.57	-0.37	2.6200000000000003e-10	Fibrinogen levels;
CESC	cis	rs763014	0.931	rs2071982	chr16:630405	T/G	cg00802000	chr16:706648	WDR90	-0.42	-6.36	-0.36	8.74e-10	Height;
CESC	cis	rs9910055	0.762	rs184478	chr17:42209751	C/G	cg19774624	chr17:42201019	HDAC5	0.71	10.48	0.54	1.01e-21	Total body bone mineral density;
CESC	cis	rs72781680	0.752	rs72796138	chr2:23926233	C/T	cg20701182	chr2:24300061	SF3B14	0.79	7.0	0.39	2.12e-11	Lymphocyte counts;
CESC	cis	rs12887734	0.546	rs12886637	chr14:104222892	A/G	cg01849466	chr14:104193079	ZFYVE21	0.43	5.48	0.32	9.92e-8	Schizophrenia;Autism spectrum disorder or schizophrenia;
CESC	cis	rs722599	0.748	rs55707505	chr14:75362552	T/C	cg08847533	chr14:75593920	NEK9	-0.47	-5.72	-0.33	2.88e-8	IgG glycosylation;
CESC	cis	rs7659604	0.605	rs67772833	chr4:122723106	G/A	cg19671926	chr4:122722719	EXOSC9	-0.51	-6.1	-0.35	3.65e-9	Type 2 diabetes;
CESC	cis	rs1501550	0.541	rs11119666	chr1:211201592	G/A	cg23086161	chr1:211307217	KCNH1	-0.33	-5.15	-0.3	5.1e-7	Circulating vasoactive peptide levels;
CESC	cis	rs798554	0.757	rs1182171	chr7:2878510	A/G	cg18446336	chr7:2847575	GNA12	-0.36	-5.43	-0.32	1.29e-7	Height;
CESC	cis	rs78456975	0.628	rs13426896	chr2:1554768	C/T	cg01028140	chr2:1542097	TPO	-0.47	-5.29	-0.31	2.6e-7	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs6089584	0.528	rs881994	chr20:60623931	G/A	cg06108461	chr20:60628389	TAF4	-0.6	-8.03	-0.44	3.26e-14	Body mass index;
CESC	cis	rs4713118	0.621	rs9295756	chr6:28033396	G/T	cg19592336	chr6:28129416	ZNF389	0.57	7.41	0.41	1.68e-12	Parkinson's disease;
CESC	cis	rs3096299	0.566	rs4129126	chr16:89561475	A/C	cg08392591	chr16:89556376	ANKRD11	0.42	5.09	0.3	6.66e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs9916302	0.904	rs4795359	chr17:37573146	C/T	cg15445000	chr17:37608096	MED1	0.41	6.74	0.38	9.67e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs2760061	0.599	rs849903	chr1:228137659	T/C	cg01973587	chr1:228161476	NA	0.37	5.64	0.33	4.43e-8	Diastolic blood pressure;
CESC	cis	rs4243830	0.850	rs12410405	chr1:6581283	C/G	cg22792644	chr1:6614718	TAS1R1;NOL9	0.86	9.39	0.5	2.85e-18	Body mass index;
CESC	cis	rs9790314	1.000	rs9790314	chr3:161019558	T/C	cg03342759	chr3:160939853	NMD3	-0.5	-6.9	-0.39	3.8e-11	Morning vs. evening chronotype;
CESC	cis	rs8020095	0.571	rs10138865	chr14:67606802	C/T	cg19548862	chr14:67692701	FAM71D	-0.48	-5.7	-0.33	3.12e-8	Depression (quantitative trait);
CESC	cis	rs11098499	0.909	rs7659501	chr4:120371552	G/T	cg09307838	chr4:120376055	NA	0.94	13.7	0.64	1.18e-32	Corneal astigmatism;
CESC	cis	rs6540559	1.000	rs7522250	chr1:209962539	T/C	cg10074409	chr1:209979377	IRF6	0.37	5.98	0.35	7.05e-9	Cleft lip with or without cleft palate;
CESC	cis	rs1348850	0.789	rs13027959	chr2:178275887	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.75	10.73	0.55	1.57e-22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs9733	0.628	rs11807409	chr1:150683423	C/T	cg04414720	chr1:150670196	GOLPH3L	0.62	8.86	0.48	1.21e-16	Tonsillectomy;
CESC	cis	rs7552404	0.731	rs17650138	chr1:76398887	C/T	cg03433033	chr1:76189801	ACADM	-0.63	-6.01	-0.35	6.27e-9	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs853679	0.517	rs4713146	chr6:28111536	A/T	cg23281280	chr6:28129359	ZNF389	0.59	7.91	0.44	7.14e-14	Depression;
CESC	cis	rs6933660	0.665	rs6921042	chr6:151732385	T/C	cg02564969	chr6:151773285	C6orf211;RMND1	0.64	8.72	0.47	3.02e-16	Menarche (age at onset);
CESC	cis	rs858239	0.676	rs274032	chr7:23374559	C/G	cg23682824	chr7:23144976	KLHL7	0.45	6.04	0.35	5.24e-9	Cerebrospinal fluid biomarker levels;
CESC	trans	rs561341	0.941	rs17780080	chr17:30343146	G/A	cg20587970	chr11:113659929	NA	-1.5	-18.59	-0.75	5.81e-50	Hip circumference adjusted for BMI;
CESC	cis	rs9905704	0.846	rs11079356	chr17:56864242	C/A	cg12560992	chr17:57184187	TRIM37	0.62	7.8	0.43	1.45e-13	Testicular germ cell tumor;
CESC	cis	rs7666738	0.830	rs4699603	chr4:99056172	T/C	cg17366294	chr4:99064904	C4orf37	0.62	8.85	0.48	1.3e-16	Colonoscopy-negative controls vs population controls;
CESC	trans	rs66573146	0.656	rs41410847	chr4:6957332	C/T	cg07817883	chr1:32538562	TMEM39B	0.89	7.36	0.41	2.29e-12	Granulocyte percentage of myeloid white cells;
CESC	trans	rs2018683	0.768	rs10282015	chr7:29022138	G/A	cg19402173	chr7:128379420	CALU	-0.6	-7.48	-0.42	1.13e-12	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CESC	cis	rs1218582	0.774	rs4845683	chr1:154877407	T/C	cg24250549	chr1:154909240	PMVK	0.62	8.68	0.47	4.03e-16	Prostate cancer;
CESC	cis	rs8031584	0.706	rs2177670	chr15:31157751	G/T	cg08704250	chr15:31115839	NA	-0.68	-9.07	-0.49	2.76e-17	Huntington's disease progression;
CESC	cis	rs12824058	0.831	rs11616174	chr12:130814503	A/G	cg26677194	chr12:130822605	PIWIL1	0.52	6.81	0.39	6.58e-11	Menopause (age at onset);
CESC	cis	rs763121	0.853	rs5757231	chr22:39071658	C/T	cg14440974	chr22:39074834	NA	0.45	6.2	0.36	2.15e-9	Menopause (age at onset);
CESC	cis	rs36051895	0.632	rs7038813	chr9:5177685	A/G	cg02405213	chr9:5042618	JAK2	-0.51	-6.55	-0.37	2.91e-10	Pediatric autoimmune diseases;
CESC	cis	rs6775745	0.654	rs2141572	chr3:131788366	G/A	cg12213930	chr3:131751605	CPNE4	0.46	5.25	0.31	3.08e-7	Neutrophil count;
CESC	cis	rs1801251	1.000	rs1446308	chr2:233639309	T/C	cg08000102	chr2:233561755	GIGYF2	0.66	9.35	0.5	3.7e-18	Coronary artery disease;
CESC	cis	rs7605378	1.000	rs10194076	chr2:200677663	T/C	cg23649088	chr2:200775458	C2orf69	0.5	6.45	0.37	5.39e-10	Osteoporosis;
CESC	cis	rs9811920	0.609	rs793462	chr3:99616461	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.59	7.22	0.41	5.61e-12	Axial length;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05922971	chr5:43121458	ZNF131	0.6	7.34	0.41	2.64e-12	Gut microbiome composition (summer);
CESC	trans	rs11696739	1.000	rs11696739	chr20:1600925	A/G	cg13912702	chr13:113520917	ATP11A	0.47	6.11	0.35	3.49e-9	Mean platelet volume;
CESC	cis	rs9457247	0.765	rs9457249	chr6:167426438	A/G	cg07741184	chr6:167504864	NA	0.35	6.44	0.37	5.64e-10	Crohn's disease;
CESC	cis	rs9948	1.000	rs59244622	chr2:97501632	C/T	cg01990225	chr2:97406019	LMAN2L	-0.69	-5.03	-0.3	8.93e-7	Erectile dysfunction and prostate cancer treatment;
CESC	cis	rs11792861	0.926	rs118011482	chr9:111770626	G/C	cg13535736	chr9:111863775	C9orf5	-0.49	-6.35	-0.36	9.42e-10	Menarche (age at onset);
CESC	cis	rs365132	1.000	rs402511	chr5:176434440	G/A	cg16309518	chr5:176445507	NA	-0.37	-5.35	-0.31	1.9e-7	Menarche and menopause (age at onset);Menopause (age at onset);
CESC	cis	rs4665809	0.531	rs3892649	chr2:26457267	T/G	cg25036284	chr2:26402008	FAM59B	0.86	9.36	0.5	3.44e-18	Gut microbiome composition (summer);
CESC	cis	rs35306767	0.953	rs10904583	chr10:983498	T/C	cg10556349	chr10:835070	NA	0.51	5.43	0.32	1.3e-7	Eosinophil percentage of granulocytes;
CESC	cis	rs4665809	0.590	rs35656275	chr2:26494695	G/C	cg04944784	chr2:26401820	FAM59B	0.93	10.26	0.53	5.24e-21	Gut microbiome composition (summer);
CESC	cis	rs524281	0.861	rs11227410	chr11:65873396	G/C	cg14036092	chr11:66035641	RAB1B	-0.62	-6.35	-0.36	9.06e-10	Electroencephalogram traits;
CESC	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg06877462	chr1:205807181	PM20D1	0.37	5.34	0.31	1.98e-7	Menarche (age at onset);
CESC	trans	rs61931739	0.749	rs11053093	chr12:34231095	A/G	cg26384229	chr12:38710491	ALG10B	0.49	6.73	0.38	1.02e-10	Morning vs. evening chronotype;
CESC	cis	rs933688	0.532	rs13164949	chr5:90538489	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	-0.45	-5.16	-0.3	4.73e-7	Smoking behavior;
CESC	cis	rs6088580	0.634	rs6088502	chr20:33037644	A/T	cg24642439	chr20:33292090	TP53INP2	0.51	6.74	0.38	9.69e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs875971	0.660	rs10281080	chr7:66042441	T/C	cg06456125	chr7:65229604	NA	-0.4	-5.15	-0.3	5.11e-7	Aortic root size;
CESC	cis	rs12900413	0.603	rs2351493	chr15:90299536	A/G	cg24249390	chr15:90295951	MESP1	-0.38	-5.08	-0.3	7.22e-7	Coronary artery aneurysm in Kawasaki disease;
CESC	cis	rs2944591	0.505	rs2592118	chr2:233792425	C/T	cg11972305	chr2:233791962	NGEF	-0.38	-6.18	-0.35	2.41e-9	Autism spectrum disorder or schizophrenia;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg01953317	chr2:55642894	CCDC88A	0.44	6.88	0.39	4.35e-11	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs7335046	0.536	rs61970284	chr13:99918771	C/T	cg21788972	chr13:99853209	UBAC2	-0.43	-5.4	-0.31	1.49e-7	Basal cell carcinoma;
CESC	cis	rs914615	0.552	rs7556304	chr1:155139509	T/C	cg02153340	chr1:155202674	NA	-0.37	-5.39	-0.31	1.56e-7	Urinary albumin-to-creatinine ratio;
CESC	cis	rs7267979	1.000	rs4815426	chr20:25405186	A/C	cg08601574	chr20:25228251	PYGB	-0.37	-5.39	-0.31	1.53e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs1448094	0.765	rs4919773	chr12:86337559	C/T	cg02569458	chr12:86230093	RASSF9	0.45	6.34	0.36	9.64e-10	Major depressive disorder;
CESC	cis	rs651907	0.535	rs34263427	chr3:101507805	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.46	6.01	0.35	6.09e-9	Colorectal cancer;
CESC	cis	rs4975709	0.610	rs4975706	chr5:1860365	G/T	cg10800226	chr5:1850261	NA	0.34	5.62	0.33	4.84e-8	Cardiovascular disease risk factors;
CESC	cis	rs1050631	1.000	rs1785919	chr18:33691964	G/A	cg25426722	chr18:33708991	SLC39A6;ELP2	0.44	5.7	0.33	3.22e-8	Esophageal squamous cell cancer (length of survival);
CESC	cis	rs10911232	0.560	rs6697320	chr1:183037377	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.82	12.63	0.61	6.02e-29	Hypertriglyceridemia;
CESC	cis	rs6963495	0.818	rs73192105	chr7:105167945	T/C	cg19920283	chr7:105172520	RINT1	0.68	6.44	0.37	5.53e-10	Bipolar disorder (body mass index interaction);
CESC	cis	rs826838	0.933	rs980573	chr12:39127811	T/C	cg13010199	chr12:38710504	ALG10B	-0.45	-6.26	-0.36	1.51e-9	Heart rate;
CESC	cis	rs8031584	0.958	rs11293	chr15:31234981	G/A	cg14298792	chr15:30685198	CHRFAM7A	-0.46	-5.44	-0.32	1.2e-7	Huntington's disease progression;
CESC	cis	rs662064	0.748	rs2506892	chr1:10598216	G/A	cg20482658	chr1:10539492	PEX14	0.41	8.41	0.46	2.64e-15	Asthma;
CESC	cis	rs7618915	0.501	rs2079929	chr3:52765646	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	8.23	0.45	8.74e-15	Bipolar disorder;
CESC	cis	rs7666738	0.830	rs2865977	chr4:99017916	C/T	cg03467027	chr4:99064603	C4orf37	0.46	5.81	0.34	1.8e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1862618	0.853	rs832554	chr5:56115036	A/G	cg24531977	chr5:56204891	C5orf35	-0.9	-11.69	-0.58	1.01e-25	Initial pursuit acceleration;
CESC	cis	rs6831352	0.918	rs1042365	chr4:100045500	G/T	cg12011299	chr4:100065546	ADH4	-0.59	-6.72	-0.38	1.09e-10	Alcohol dependence;
CESC	cis	rs9486719	1.000	rs12530462	chr6:97053514	C/T	cg06623918	chr6:96969491	KIAA0776	-0.82	-8.43	-0.46	2.29e-15	Migraine;Coronary artery disease;
CESC	trans	rs9467711	0.606	rs9379855	chr6:26364930	C/T	cg06606381	chr12:133084897	FBRSL1	0.74	7.28	0.41	3.86e-12	Autism spectrum disorder or schizophrenia;
CESC	trans	rs11098499	0.687	rs71610270	chr4:120287436	A/G	cg25214090	chr10:38739885	LOC399744	0.65	9.11	0.49	2.04e-17	Corneal astigmatism;
CESC	cis	rs853679	0.517	rs56364346	chr6:28050762	T/G	cg19592336	chr6:28129416	ZNF389	0.6	7.97	0.44	4.69e-14	Depression;
CESC	cis	rs875971	0.545	rs7810213	chr7:65946579	G/C	cg11764359	chr7:65958608	NA	0.82	9.18	0.49	1.27e-17	Aortic root size;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg02205181	chr10:104154811	NFKB2	0.46	6.21	0.36	2.08e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs10504229	1.000	rs73607874	chr8:58173433	G/C	cg24829409	chr8:58192753	C8orf71	-0.76	-10.0	-0.52	3.53e-20	Developmental language disorder (linguistic errors);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05924212	chr2:30455114	LBH	-0.57	-6.58	-0.37	2.52e-10	Gut microbiome composition (summer);
CESC	cis	rs1552244	0.572	rs6783705	chr3:10164783	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.79	8.79	0.47	1.98e-16	Alzheimer's disease;
CESC	cis	rs854765	0.547	rs2955372	chr17:17970229	T/C	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.49	-6.2	-0.36	2.1e-9	Total body bone mineral density;
CESC	cis	rs11638352	0.661	rs2114422	chr15:44420244	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	-0.56	-5.29	-0.31	2.53e-7	Lipoprotein phospholipase A2 activity in cardiovascular disease;
CESC	cis	rs780096	0.565	rs11681351	chr2:27743423	G/A	cg02592271	chr2:27665507	KRTCAP3	-0.3	-6.02	-0.35	5.84e-9	Total body bone mineral density;
CESC	cis	rs1044826	0.642	rs7624321	chr3:139220159	C/A	cg00490450	chr3:139108681	COPB2	0.45	5.53	0.32	7.8e-8	Obesity-related traits;
CESC	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.6	0.38	2.17e-10	Prudent dietary pattern;
CESC	cis	rs12410462	0.581	rs6675521	chr1:227544702	C/T	cg04117972	chr1:227635322	NA	0.62	5.31	0.31	2.27e-7	Major depressive disorder;
CESC	trans	rs916888	0.821	rs199513	chr17:44856932	A/G	cg07870213	chr5:140052090	DND1	-0.6	-6.8	-0.39	7.02e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs10751667	1.000	rs6597972	chr11:928402	C/T	cg20946044	chr11:1010712	AP2A2	-0.42	-5.53	-0.32	7.87e-8	Alzheimer's disease (late onset);
CESC	cis	rs916888	0.773	rs199534	chr17:44824213	T/G	cg01570182	chr17:44337453	NA	0.91	10.31	0.53	3.6e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs9649213	0.593	rs7803372	chr7:97992257	A/G	cg08684580	chr7:98029266	BAIAP2L1	-0.36	-5.86	-0.34	1.4e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7116495	1.000	rs7124000	chr11:71754338	T/C	cg26138937	chr11:71823887	C11orf51	-0.71	-6.19	-0.36	2.33e-9	Severe influenza A (H1N1) infection;
CESC	cis	rs2952156	0.920	rs732084	chr17:37834357	A/C	cg00129232	chr17:37814104	STARD3	-0.73	-10.6	-0.55	4.07e-22	Asthma;
CESC	cis	rs365132	1.000	rs353490	chr5:176433063	C/T	cg16309518	chr5:176445507	NA	-0.37	-5.35	-0.31	1.9e-7	Menarche and menopause (age at onset);Menopause (age at onset);
CESC	cis	rs6502050	0.799	rs34795957	chr17:80118013	G/A	cg23985595	chr17:80112537	CCDC57	-0.41	-6.47	-0.37	4.81e-10	Life satisfaction;
CESC	cis	rs10791097	0.694	rs4436551	chr11:130755739	A/G	cg09137382	chr11:130731461	NA	-0.37	-5.66	-0.33	3.87e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00114383	chr16:28962172	NFATC2IP	-0.52	-6.26	-0.36	1.52e-9	Gut microbiome composition (summer);
CESC	cis	rs2197308	0.765	rs11182992	chr12:37935572	G/C	cg26384229	chr12:38710491	ALG10B	0.75	11.15	0.57	6.28e-24	Morning vs. evening chronotype;
CESC	cis	rs9660992	0.710	rs4951184	chr1:205240659	A/T	cg00857998	chr1:205179979	DSTYK	0.43	5.03	0.3	9.21e-7	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs933688	1.000	rs2059207	chr5:90731931	C/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.08	13.94	0.65	1.63e-33	Smoking behavior;
CESC	cis	rs2836974	0.932	rs73221193	chr21:40554693	C/T	cg17971929	chr21:40555470	PSMG1	1.06	16.48	0.71	1.79e-42	Cognitive function;
CESC	cis	rs11122272	0.735	rs2011357	chr1:231480208	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.48	-6.41	-0.37	6.56e-10	Hemoglobin concentration;
CESC	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg21280719	chr6:42927975	GNMT	-0.29	-6.47	-0.37	4.76e-10	Alzheimer's disease in APOE e4+ carriers;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg07274998	chr10:126107781	OAT	-0.43	-6.25	-0.36	1.67e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs5769765	0.773	rs9616208	chr22:50313359	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.58	-6.14	-0.35	3e-9	Schizophrenia;
CESC	trans	rs35146811	0.735	rs858505	chr7:99819577	G/A	cg13215871	chr17:75784724	NA	-0.34	-6.33	-0.36	1.07e-9	Coronary artery disease;
CESC	cis	rs7937682	0.847	rs11213948	chr11:111464401	G/A	cg22437258	chr11:111473054	SIK2	0.71	9.19	0.49	1.16e-17	Primary sclerosing cholangitis;
CESC	cis	rs6076065	0.748	rs2236023	chr20:23373043	A/C	cg11657817	chr20:23433608	CST11	0.4	6.11	0.35	3.46e-9	Facial morphology (factor 15, philtrum width);
CESC	cis	rs4523957	0.928	rs12453323	chr17:2160214	T/C	cg16513277	chr17:2031491	SMG6	0.6	8.18	0.45	1.22e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	trans	rs3749237	0.964	rs2352967	chr3:49871641	C/T	cg21659725	chr3:3221576	CRBN	0.54	6.4	0.37	7.12e-10	Resting heart rate;
CESC	cis	rs3617	0.625	rs7652667	chr3:52866535	C/A	cg07507251	chr3:52567010	NT5DC2	-0.32	-5.43	-0.32	1.27e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
CESC	cis	rs2710642	0.721	rs1038572	chr2:62902019	G/T	cg17519650	chr2:63277830	OTX1	0.58	6.88	0.39	4.23e-11	LDL cholesterol levels;LDL cholesterol;
CESC	cis	rs7264396	0.790	rs6121020	chr20:34252006	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.65	7.81	0.43	1.36e-13	Total cholesterol levels;
CESC	cis	rs6570726	0.935	rs422540	chr6:145837815	G/T	cg23711669	chr6:146136114	FBXO30	0.8	12.02	0.59	7.3e-27	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs10411161	0.702	rs8113768	chr19:52383938	C/T	cg22319618	chr22:45562946	NUP50	-0.7	-6.78	-0.38	7.84e-11	Breast cancer;
CESC	cis	rs829883	0.659	rs11109524	chr12:98939172	G/A	cg25150519	chr12:98850993	NA	-0.64	-7.87	-0.44	8.8e-14	Colorectal adenoma (advanced);
CESC	cis	rs6493487	0.512	rs8032550	chr15:51178313	A/C	cg02338191	chr15:51200825	AP4E1	0.6	5.58	0.32	5.79e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs6547741	1.000	rs11127071	chr2:27838058	C/A	cg27432699	chr2:27873401	GPN1	0.49	6.93	0.39	3.21e-11	Oral cavity cancer;
CESC	cis	rs2228479	0.717	rs11644967	chr16:89806614	T/A	cg06558623	chr16:89946397	TCF25	0.81	7.38	0.41	2e-12	Skin colour saturation;
CESC	cis	rs4975709	0.610	rs1531994	chr5:1859297	T/C	cg17650747	chr5:1873721	NA	0.44	6.06	0.35	4.62e-9	Cardiovascular disease risk factors;
CESC	cis	rs10870270	0.957	rs3829156	chr10:133789386	C/G	cg17892150	chr10:133769511	PPP2R2D	-0.84	-12.23	-0.6	1.43e-27	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs7264396	0.561	rs6142474	chr20:34574914	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.63	6.97	0.39	2.45e-11	Total cholesterol levels;
CESC	cis	rs7818688	0.614	rs60171840	chr8:95832520	C/A	cg16049864	chr8:95962084	TP53INP1	0.55	5.64	0.33	4.28e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs6460942	0.597	rs17544637	chr7:12521871	T/C	cg06484146	chr7:12443880	VWDE	-0.64	-7.13	-0.4	9.4e-12	Coronary artery disease;
CESC	cis	rs4819052	0.851	rs8127834	chr21:46696109	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.92	13.55	0.64	3.83e-32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs9303401	0.538	rs35454383	chr17:56475599	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.87	9.33	0.5	4.31e-18	Cognitive test performance;
CESC	cis	rs2070488	0.775	rs2070489	chr3:38519424	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.8	12.57	0.61	1.01e-28	Electrocardiographic conduction measures;
CESC	cis	rs7923609	0.967	rs7082470	chr10:65277026	G/A	cg01631684	chr10:65280961	REEP3	-0.44	-5.47	-0.32	1.05e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs6547741	1.000	rs6718128	chr2:27833752	A/G	cg27432699	chr2:27873401	GPN1	-0.48	-6.83	-0.39	5.64e-11	Oral cavity cancer;
CESC	cis	rs75887402	0.744	rs2303720	chr5:122682334	A/G	cg27033705	chr5:122759302	CEP120	-0.84	-6.36	-0.36	8.95e-10	Breast cancer;
CESC	cis	rs2985684	1.000	rs2147712	chr14:50091684	G/A	cg02151108	chr14:50098012	C14orf104	-0.45	-5.85	-0.34	1.43e-8	Carotid intima media thickness;
CESC	cis	rs910316	0.737	rs108622	chr14:75481908	A/G	cg11812906	chr14:75593930	NEK9	-0.81	-13.05	-0.63	2.11e-30	Height;
CESC	cis	rs208515	0.525	rs12193034	chr6:66677866	C/T	cg07460842	chr6:66804631	NA	0.86	10.87	0.56	5.19e-23	Exhaled nitric oxide levels;
CESC	cis	rs1878931	0.559	rs1968055	chr16:3392053	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.71	8.92	0.48	7.73e-17	Body mass index (adult);
CESC	cis	rs4713118	0.662	rs9468275	chr6:28026136	G/T	cg23161317	chr6:28129485	ZNF389	0.49	6.19	0.36	2.28e-9	Parkinson's disease;
CESC	cis	rs8099014	0.906	rs4940695	chr18:56106483	T/G	cg19312305	chr18:56117016	MIR122	-0.29	-5.58	-0.32	6.08e-8	Platelet count;
CESC	cis	rs9596863	0.950	rs1379827	chr13:54395414	A/C	ch.13.53330881F	chr13:54432880	NA	0.66	5.36	0.31	1.84e-7	Epilepsy and lamotrigine-induced maculopapular eruptions;
CESC	trans	rs17227506	0.538	rs71522360	chr8:13463811	A/G	cg19797304	chr14:24732234	TGM1	-0.4	-6.23	-0.36	1.78e-9	Nonsyndromic cleft lip with cleft palate;
CESC	cis	rs4665809	0.567	rs6546848	chr2:26444414	G/C	cg27170947	chr2:26402098	FAM59B	-0.87	-10.16	-0.53	1.05e-20	Gut microbiome composition (summer);
CESC	cis	rs7772486	0.558	rs62435775	chr6:146136415	G/C	cg23711669	chr6:146136114	FBXO30	0.92	12.35	0.6	5.59e-28	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs10788264	0.504	rs4751886	chr10:124020396	T/C	cg09507567	chr10:124027408	NA	0.42	5.73	0.33	2.77e-8	Total body bone mineral density;
CESC	cis	rs807669	0.548	rs885978	chr22:19198226	A/G	cg02655711	chr22:19163373	SLC25A1	0.79	11.96	0.59	1.24e-26	Metabolite levels;
CESC	trans	rs113577745	0.673	rs17364519	chr2:10142819	A/G	cg12379383	chr15:96896940	NA	-0.59	-6.11	-0.35	3.53e-9	Breast cancer;
CESC	trans	rs9858542	0.953	rs7623659	chr3:49414791	C/T	cg21659725	chr3:3221576	CRBN	-0.54	-6.47	-0.37	4.62e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs7617773	0.817	rs34225441	chr3:48308891	T/A	cg11946769	chr3:48343235	NME6	0.87	11.65	0.58	1.3e-25	Coronary artery disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg19275838	chr7:45115588	CCM2	0.48	6.42	0.37	6.17e-10	Fibrinogen levels;
CESC	cis	rs11785400	1.000	rs13265663	chr8:143732255	A/C	cg10596483	chr8:143751796	JRK	0.41	5.39	0.31	1.56e-7	Schizophrenia;
CESC	cis	rs6912958	0.547	rs451089	chr6:88041859	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.74	11.37	0.57	1.18e-24	Monocyte percentage of white cells;
CESC	cis	rs7666738	0.830	rs28622458	chr4:98916651	A/G	cg03467027	chr4:99064603	C4orf37	0.43	5.22	0.31	3.57e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs60843830	1.000	rs3828165	chr2:220889	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.88	11.57	0.58	2.48e-25	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs1865721	1.000	rs8091890	chr18:73197242	T/C	cg26385618	chr18:73139727	C18orf62	-0.51	-7.54	-0.42	7.49e-13	Intelligence;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02532014	chr15:85114169	UBE2QP1	-0.54	-6.42	-0.37	6.25e-10	Gut microbiome composition (summer);
CESC	cis	rs2576037	0.583	rs9954336	chr18:44465945	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.35	5.57	0.32	6.32e-8	Personality dimensions;
CESC	cis	rs597539	0.652	rs674654	chr11:68698762	G/T	cg04772025	chr11:68637568	NA	0.53	6.44	0.37	5.59e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs4243830	0.850	rs10779787	chr1:6599755	C/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.86	-7.53	-0.42	7.77e-13	Body mass index;
CESC	cis	rs6460942	0.818	rs73299043	chr7:12251595	C/G	cg20607287	chr7:12443886	VWDE	-0.54	-5.53	-0.32	7.51e-8	Coronary artery disease;
CESC	cis	rs12291225	0.585	rs10832246	chr11:14380828	G/A	cg19336497	chr11:14380999	RRAS2	-0.45	-6.59	-0.38	2.32e-10	Sense of smell;
CESC	cis	rs7937682	0.921	rs12806479	chr11:111443192	G/C	cg22437258	chr11:111473054	SIK2	-0.66	-7.16	-0.4	7.79e-12	Primary sclerosing cholangitis;
CESC	cis	rs1975974	0.539	rs58796614	chr17:21733767	C/T	cg18423549	chr17:21743878	NA	-0.61	-8.75	-0.47	2.48e-16	Psoriasis;
CESC	cis	rs7666738	0.830	rs116103936	chr4:98954531	T/C	cg03676636	chr4:99064102	C4orf37	0.33	5.11	0.3	6.05e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4700695	0.719	rs27084	chr5:65435286	G/A	cg21114390	chr5:65439923	SFRS12	-0.48	-5.74	-0.33	2.54e-8	Facial morphology (factor 19);
CESC	cis	rs654950	0.934	rs665223	chr1:42000654	A/T	cg06885757	chr1:42089581	HIVEP3	-0.64	-10.2	-0.53	7.82e-21	Airway imaging phenotypes;
CESC	cis	rs10206020	0.921	rs4072986	chr2:1547734	C/G	cg26248373	chr2:1572462	NA	-0.58	-6.59	-0.38	2.38e-10	IgG glycosylation;
CESC	cis	rs7044106	0.762	rs1886337	chr9:123443776	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.81	12.82	0.62	1.3e-29	Hip circumference adjusted for BMI;
CESC	cis	rs2075371	0.865	rs2544172	chr7:133931338	T/C	cg11752832	chr7:134001865	SLC35B4	0.51	6.56	0.37	2.87e-10	Mean platelet volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22393360	chr14:81902974	NA	0.58	6.27	0.36	1.42e-9	Gut microbiome composition (summer);
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg24722365	chr1:10270654	KIF1B	-0.46	-6.24	-0.36	1.75e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs9916302	0.808	rs12947281	chr17:37652210	G/T	cg00129232	chr17:37814104	STARD3	-0.54	-7.14	-0.4	9.08e-12	Glomerular filtration rate (creatinine);
CESC	cis	rs9287719	0.967	rs7566767	chr2:10754663	T/C	cg00105475	chr2:10696890	NA	0.38	5.4	0.31	1.5e-7	Prostate cancer;
CESC	cis	rs9595066	0.715	rs9567366	chr13:44682973	A/C	cg04068111	chr13:44716778	NA	0.39	5.56	0.32	6.71e-8	Schizophrenia;
CESC	cis	rs2439831	0.867	rs2260160	chr15:43895643	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.78	8.59	0.47	7.41e-16	Lung cancer in ever smokers;
CESC	cis	rs896854	0.875	rs4735333	chr8:95955074	G/A	cg13393036	chr8:95962371	TP53INP1	-0.52	-11.64	-0.58	1.41e-25	Type 2 diabetes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27612744	chr5:16465883	ZNF622	0.57	6.48	0.37	4.58e-10	Gut microbiome composition (summer);
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg12951224	chr8:38126910	PPAPDC1B	-0.47	-6.26	-0.36	1.51e-9	Height;
CESC	cis	rs3762637	1.000	rs11932	chr3:122141135	A/G	cg24169773	chr3:122142474	KPNA1	0.52	6.38	0.36	7.77e-10	LDL cholesterol levels;
CESC	cis	rs35306767	0.668	rs12784928	chr10:1083617	A/C	cg26597838	chr10:835615	NA	0.51	5.4	0.31	1.47e-7	Eosinophil percentage of granulocytes;
CESC	cis	rs7666738	0.830	rs10021709	chr4:99030587	G/A	cg24818145	chr4:99064322	C4orf37	0.39	5.09	0.3	6.95e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9611519	0.780	rs1535048	chr22:41684093	C/T	cg17376030	chr22:41985996	PMM1	0.47	5.29	0.31	2.61e-7	Neuroticism;
CESC	cis	rs1559088	0.649	rs4528686	chr19:33556074	A/G	cg17764715	chr19:33622953	WDR88	0.46	5.73	0.33	2.7e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs1790761	0.501	rs4930210	chr11:67404726	G/T	cg14500267	chr11:67383377	NA	-0.31	-5.35	-0.31	1.9e-7	Mean corpuscular volume;
CESC	cis	rs1023500	0.573	rs133378	chr22:42467695	G/C	cg04733989	chr22:42467013	NAGA	0.79	12.0	0.59	8.9e-27	Schizophrenia;
CESC	cis	rs10791323	0.536	rs4937842	chr11:133734542	C/G	cg15485101	chr11:133734466	NA	-0.4	-7.09	-0.4	1.21e-11	Childhood ear infection;
CESC	cis	rs9611565	0.546	rs2092274	chr22:42123737	A/G	cg17376030	chr22:41985996	PMM1	-0.72	-7.79	-0.43	1.55e-13	Vitiligo;
CESC	cis	rs7762018	0.882	rs4716342	chr6:170137959	A/G	cg13891659	chr6:170190454	C6orf122;C6orf208	0.61	5.87	0.34	1.31e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs3857536	0.813	rs1029399	chr6:66952476	G/C	cg07460842	chr6:66804631	NA	-0.42	-5.11	-0.3	6.32e-7	Blood trace element (Cu levels);
CESC	cis	rs10751667	0.857	rs6597961	chr11:976677	T/C	cg20946044	chr11:1010712	AP2A2	-0.42	-5.6	-0.33	5.23e-8	Alzheimer's disease (late onset);
CESC	cis	rs7149337	0.837	rs4296182	chr14:51662167	A/C	cg23942311	chr14:51606299	NA	0.4	6.73	0.38	1.06e-10	Cancer;
CESC	cis	rs2644899	0.750	rs2604869	chr19:41283693	G/A	cg24958765	chr19:41283667	RAB4B	0.59	6.56	0.37	2.73e-10	Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs4654899	0.714	rs12123093	chr1:21114416	C/T	cg05370193	chr1:21551575	ECE1	0.34	5.05	0.3	8.36e-7	Superior frontal gyrus grey matter volume;
CESC	cis	rs477692	0.583	rs12415589	chr10:131428336	C/G	cg26102564	chr10:131424627	MGMT	-0.35	-5.22	-0.31	3.59e-7	Response to temozolomide;
CESC	trans	rs2727020	0.530	rs7113153	chr11:49457957	G/A	cg03929089	chr4:120376271	NA	-0.67	-7.52	-0.42	8.71e-13	Coronary artery disease;
CESC	cis	rs7666738	0.830	rs4443295	chr4:99044935	G/A	cg03467027	chr4:99064603	C4orf37	0.47	5.96	0.34	8.08e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2865126	0.743	rs1941551	chr18:10744620	G/T	cg21165219	chr18:10698044	FAM38B	-0.52	-5.42	-0.32	1.31e-7	Metabolite levels (5-HIAA/ MHPG Ratio);
CESC	cis	rs4975709	0.610	rs1531994	chr5:1859297	T/C	cg10800226	chr5:1850261	NA	0.36	5.9	0.34	1.13e-8	Cardiovascular disease risk factors;
CESC	cis	rs875971	0.792	rs6971752	chr7:65737986	G/A	cg10691866	chr7:65817282	TPST1	0.31	5.37	0.31	1.75e-7	Aortic root size;
CESC	cis	rs12497850	0.931	rs4072859	chr3:49032205	G/C	cg02487422	chr3:49467188	NICN1	0.46	5.74	0.33	2.54e-8	Parkinson's disease;
CESC	cis	rs11723261	0.582	rs7679573	chr4:151605	G/C	cg12746427	chr4:53362	ZNF718;ZNF595	0.47	6.15	0.35	2.91e-9	Immune response to smallpox vaccine (IL-6);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg02896403	chr1:155231989	SCAMP3	-0.48	-6.52	-0.37	3.6e-10	Fibrinogen levels;
CESC	cis	rs7789940	0.951	rs73140055	chr7:75975777	A/T	cg10167463	chr7:75959203	YWHAG	-0.54	-6.8	-0.39	6.91e-11	Multiple sclerosis;
CESC	cis	rs12200560	0.505	rs984520	chr6:97076454	A/G	cg06623918	chr6:96969491	KIAA0776	-0.49	-6.22	-0.36	1.89e-9	Coronary heart disease;
CESC	cis	rs919433	1.000	rs112572902	chr2:198175179	G/C	cg03934865	chr2:198174659	NA	-0.48	-7.4	-0.41	1.83e-12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	trans	rs6572548	0.504	rs1956082	chr14:49665496	A/C	cg17308151	chr11:8703888	RPL27A	-0.54	-6.02	-0.35	5.81e-9	Subjective well-being;
CESC	cis	rs1005277	0.505	rs7069702	chr10:38247359	G/T	cg00409905	chr10:38381863	ZNF37A	0.57	8.02	0.44	3.47e-14	Extrinsic epigenetic age acceleration;
CESC	cis	rs5769765	0.908	rs9616376	chr22:50310829	A/G	cg26441486	chr22:50317300	CRELD2	0.42	5.24	0.31	3.33e-7	Schizophrenia;
CESC	cis	rs9457247	1.000	rs405553	chr6:167395058	A/G	cg07741184	chr6:167504864	NA	0.31	5.53	0.32	7.87e-8	Crohn's disease;
CESC	cis	rs2731664	0.792	rs465670	chr5:176877624	C/T	cg23176889	chr5:176863531	GRK6	-0.63	-11.03	-0.56	1.52e-23	Intelligence (multi-trait analysis);
CESC	trans	rs11992162	0.597	rs6996342	chr8:11784541	C/T	cg15556689	chr8:8085844	FLJ10661	-0.5	-6.08	-0.35	4.21e-9	Monocyte count;
CESC	cis	rs7618915	0.571	rs2251219	chr3:52584787	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.47	-5.78	-0.33	2.1e-8	Bipolar disorder;
CESC	cis	rs2204008	0.689	rs1581357	chr12:38391479	C/G	cg13010199	chr12:38710504	ALG10B	0.47	5.91	0.34	1.03e-8	Bladder cancer;
CESC	cis	rs6461049	0.646	rs3778970	chr7:2143208	C/A	cg02951883	chr7:2050386	MAD1L1	-0.45	-5.81	-0.34	1.77e-8	Schizophrenia;
CESC	cis	rs748404	0.631	rs560191	chr15:43767774	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.57	7.5	0.42	9.94e-13	Lung cancer;
CESC	cis	rs1799949	0.602	rs4600503	chr17:41414324	C/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	8.6	0.47	6.99e-16	Menopause (age at onset);
CESC	cis	rs8062405	1.000	rs62036616	chr16:28826307	A/G	cg08761264	chr16:28874980	SH2B1	-0.43	-5.31	-0.31	2.32e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs274567	0.501	rs272855	chr5:131687175	C/T	cg07395648	chr5:131743802	NA	-0.4	-5.16	-0.3	4.79e-7	Blood metabolite levels;
CESC	cis	rs9549260	0.569	rs117615233	chr13:41309223	G/A	cg21288729	chr13:41239152	FOXO1	0.58	5.26	0.31	2.92e-7	Red blood cell count;
CESC	cis	rs12995491	0.731	rs13019346	chr2:88509321	A/G	cg14558114	chr2:88469736	THNSL2	-0.43	-6.17	-0.35	2.54e-9	Response to metformin (IC50);
CESC	cis	rs589448	0.902	rs315134	chr12:69762713	G/A	cg20891283	chr12:69753455	YEATS4	0.98	16.88	0.72	6.73e-44	Cerebrospinal fluid biomarker levels;
CESC	cis	rs7666738	0.830	rs13148324	chr4:98833616	G/A	cg17366294	chr4:99064904	C4orf37	0.54	7.42	0.41	1.61e-12	Colonoscopy-negative controls vs population controls;
CESC	cis	rs8027181	0.839	rs7176235	chr15:72999104	A/G	cg25632853	chr15:73088954	NA	0.3	5.26	0.31	3.04e-7	Triglyceride levels;
CESC	cis	rs3733585	0.673	rs6814664	chr4:9956228	C/T	cg02734326	chr4:10020555	SLC2A9	-0.41	-5.87	-0.34	1.32e-8	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.55	-6.13	-0.35	3.19e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs524281	0.861	rs471484	chr11:65955144	A/G	cg14036092	chr11:66035641	RAB1B	-0.49	-5.5	-0.32	9.06e-8	Electroencephalogram traits;
CESC	cis	rs921968	0.541	rs58650092	chr2:219304851	C/A	cg02176678	chr2:219576539	TTLL4	-0.47	-8.22	-0.45	9.4e-15	Mean corpuscular hemoglobin concentration;
CESC	cis	rs7666738	0.830	rs17558151	chr4:99048699	T/C	cg18180107	chr4:99064573	C4orf37	0.4	5.2	0.3	4.08e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7829975	0.659	rs4382480	chr8:8721473	C/T	cg15556689	chr8:8085844	FLJ10661	0.49	6.09	0.35	3.93e-9	Mood instability;
CESC	cis	rs10129255	0.500	rs1974468	chr14:107142166	A/G	cg07470598	chr14:107239068	NA	0.38	5.42	0.32	1.34e-7	Kawasaki disease;
CESC	cis	rs8103278	0.507	rs4802276	chr19:46260748	T/C	cg12641515	chr19:46296257	DMWD	0.81	10.79	0.55	9.66e-23	Coronary artery disease;
CESC	cis	rs4665809	0.549	rs72809635	chr2:26411674	G/A	cg08470875	chr2:26401718	FAM59B	0.67	6.99	0.39	2.28e-11	Gut microbiome composition (summer);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg09287164	chr2:220462681	STK11IP	-0.45	-6.57	-0.37	2.61e-10	Gut microbiota (bacterial taxa);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00995584	chr10:75757877	VCL	0.55	6.21	0.36	2.04e-9	Gut microbiome composition (summer);
CESC	cis	rs3785574	0.962	rs2727329	chr17:61924566	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.79	10.32	0.54	3.26e-21	Height;
CESC	cis	rs72781680	1.000	rs72796357	chr2:24160131	A/G	cg20701182	chr2:24300061	SF3B14	0.66	5.88	0.34	1.25e-8	Lymphocyte counts;
CESC	cis	rs9311474	0.713	rs352169	chr3:52236762	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.32	5.82	0.34	1.72e-8	Electroencephalogram traits;
CESC	cis	rs7584330	0.910	rs12465081	chr2:238401784	A/G	cg14458575	chr2:238380390	NA	0.55	8.1	0.45	1.99e-14	Prostate cancer;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg03771185	chr4:775700	NA	-0.48	-6.19	-0.36	2.24e-9	Height;
CESC	cis	rs9790314	0.936	rs336572	chr3:161068014	G/A	cg03342759	chr3:160939853	NMD3	-0.42	-5.65	-0.33	4.08e-8	Morning vs. evening chronotype;
CESC	cis	rs832540	0.931	rs832534	chr5:56213672	G/A	cg14703610	chr5:56206110	C5orf35	0.55	7.24	0.41	4.82e-12	Coronary artery disease;
CESC	cis	rs910316	0.712	rs175074	chr14:75504454	G/A	cg16144293	chr14:75469539	EIF2B2	0.4	5.36	0.31	1.8e-7	Height;
CESC	cis	rs34779708	0.966	rs12782948	chr10:35450607	G/A	cg04310649	chr10:35416472	CREM	-0.55	-6.85	-0.39	5.16e-11	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs72781680	0.716	rs2675363	chr2:24080003	G/C	cg08917208	chr2:24149416	ATAD2B	0.54	5.49	0.32	9.3e-8	Lymphocyte counts;
CESC	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg03188948	chr7:1209495	NA	0.7	6.71	0.38	1.17e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs4474465	0.920	rs12222907	chr11:78219726	C/T	cg27205649	chr11:78285834	NARS2	0.44	5.28	0.31	2.69e-7	Alzheimer's disease (survival time);
CESC	cis	rs1023500	0.551	rs2854837	chr22:42458481	G/A	cg15557168	chr22:42548783	NA	-0.4	-5.56	-0.32	6.75e-8	Schizophrenia;
CESC	cis	rs7949030	0.626	rs7124057	chr11:62334096	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.59	8.25	0.45	7.72e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs9733	0.544	rs2867302	chr1:150653650	T/C	cg09365446	chr1:150670422	GOLPH3L	0.42	5.9	0.34	1.09e-8	Tonsillectomy;
CESC	cis	rs7267979	1.000	rs6037121	chr20:25428311	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.87	18.11	0.74	3e-48	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs597539	0.652	rs622082	chr11:68703959	A/G	cg21963583	chr11:68658836	MRPL21	0.39	5.66	0.33	3.86e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg18342900	chr16:46865048	C16orf87	0.49	6.28	0.36	1.39e-9	Gut microbiota (bacterial taxa);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10132348	chr4:6784379	KIAA0232	0.67	7.9	0.44	7.63e-14	Gut microbiome composition (summer);
CESC	cis	rs11711311	0.822	rs9850256	chr3:113408382	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.52	6.68	0.38	1.42e-10	IgG glycosylation;
CESC	trans	rs9949291	0.565	rs60236554	chr18:61362259	A/G	cg18704691	chr1:221052468	HLX	-0.39	-6.11	-0.35	3.46e-9	Eosinophil percentage of white cells;
CESC	trans	rs7819412	0.594	rs7460507	chr8:10969075	C/T	cg15556689	chr8:8085844	FLJ10661	-0.49	-6.22	-0.36	1.95e-9	Triglycerides;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg16701105	chr15:66084815	DENND4A	-0.47	-6.17	-0.35	2.51e-9	Asthma;
CESC	cis	rs8060686	0.623	rs255049	chr16:68013471	T/C	cg26727032	chr16:67993705	SLC12A4	-0.58	-8.27	-0.45	6.54e-15	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg22535103	chr8:58192502	C8orf71	-0.92	-10.16	-0.53	1.04e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs950776	0.518	rs12594391	chr15:78816240	A/G	cg24631222	chr15:78858424	CHRNA5	-0.4	-5.18	-0.3	4.45e-7	Sudden cardiac arrest;
CESC	cis	rs7618915	0.508	rs11717043	chr3:52656092	A/T	cg07507251	chr3:52567010	NT5DC2	0.4	6.98	0.39	2.43e-11	Bipolar disorder;
CESC	cis	rs35110281	0.548	rs2838350	chr21:45109972	T/C	cg01579765	chr21:45077557	HSF2BP	-0.51	-8.4	-0.46	2.7e-15	Mean corpuscular volume;
CESC	cis	rs6460942	0.591	rs7800823	chr7:12378697	G/T	cg02935154	chr7:12443704	VWDE	-0.4	-5.99	-0.35	6.76e-9	Coronary artery disease;
CESC	cis	rs9487051	1.000	rs1341271	chr6:109617542	A/T	cg01475377	chr6:109611718	NA	-0.42	-6.43	-0.37	6e-10	Reticulocyte fraction of red cells;
CESC	cis	rs9549367	0.762	rs9549694	chr13:113870510	G/A	cg00898013	chr13:113819073	PROZ	-0.53	-7.88	-0.44	8.46e-14	Platelet distribution width;
CESC	cis	rs8031584	0.678	rs798125	chr15:31116800	C/T	cg14298792	chr15:30685198	CHRFAM7A	0.46	5.59	0.33	5.51e-8	Huntington's disease progression;
CESC	cis	rs965469	0.779	rs6037571	chr20:3334322	C/T	cg17110299	chr20:3385021	C20orf194	0.4	5.24	0.31	3.22e-7	IFN-related cytopenia;
CESC	cis	rs4764487	0.735	rs2159521	chr12:6349328	A/G	cg08284733	chr12:6341482	CD9	0.42	6.17	0.35	2.54e-9	Mean platelet volume;
CESC	cis	rs8044868	0.541	rs7202268	chr16:72086746	A/G	cg16558253	chr16:72132732	DHX38	-0.41	-6.4	-0.37	7.21e-10	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CESC	cis	rs9522267	0.535	rs9522302	chr13:112236874	C/T	cg10483660	chr13:112241077	NA	-0.33	-5.78	-0.33	2.14e-8	Hepatitis;
CESC	cis	rs1707322	1.000	rs10890375	chr1:46406581	G/A	cg03146154	chr1:46216737	IPP	0.72	9.82	0.52	1.31e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9300255	0.537	rs2695482	chr12:123623174	C/T	cg00376283	chr12:123451042	ABCB9	0.7	8.58	0.47	8.2e-16	Neutrophil percentage of white cells;
CESC	cis	rs11048434	0.649	rs11613650	chr12:9060396	T/C	cg23795048	chr12:9217529	LOC144571	0.36	5.69	0.33	3.32e-8	Sjögren's syndrome;
CESC	cis	rs8067354	0.645	rs56236317	chr17:57822125	C/T	cg02344993	chr17:57696989	CLTC	0.68	8.07	0.44	2.5e-14	Hemoglobin concentration;
CESC	cis	rs6570726	0.791	rs12208019	chr6:145935572	T/C	cg05347473	chr6:146136440	FBXO30	0.58	7.43	0.42	1.48e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6460942	0.915	rs62447642	chr7:12489147	T/C	cg06484146	chr7:12443880	VWDE	-0.77	-8.63	-0.47	5.59e-16	Coronary artery disease;
CESC	cis	rs9768139	0.903	rs28503558	chr7:158119568	C/T	cg25566285	chr7:158114605	PTPRN2	-0.52	-8.82	-0.48	1.51e-16	Calcium levels;
CESC	cis	rs2204008	0.689	rs1581357	chr12:38391479	C/G	cg26384229	chr12:38710491	ALG10B	0.72	10.54	0.54	6.34e-22	Bladder cancer;
CESC	cis	rs1707322	0.691	rs61784803	chr1:46179271	C/A	cg03146154	chr1:46216737	IPP	-0.82	-11.54	-0.58	3.18e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs4979906	1.000	rs7098023	chr10:79449665	A/C	cg07817648	chr10:79422355	NA	-0.49	-5.8	-0.34	1.88e-8	Mortality in heart failure;
CESC	cis	rs6540559	0.673	rs7525951	chr1:210018306	C/T	cg25204440	chr1:209979598	IRF6	-0.53	-5.32	-0.31	2.22e-7	Cleft lip with or without cleft palate;
CESC	cis	rs7296418	0.630	rs7974099	chr12:123771475	A/G	cg00376283	chr12:123451042	ABCB9	0.59	7.94	0.44	5.64e-14	Platelet count;
CESC	cis	rs116095464	0.558	rs2288458	chr5:231260	C/T	cg10591111	chr5:226296	SDHA	-0.51	-6.18	-0.35	2.44e-9	Breast cancer;
CESC	cis	rs6912958	0.535	rs242283	chr6:88030931	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.51	9.05	0.49	3.09e-17	Monocyte percentage of white cells;
CESC	cis	rs4727027	0.901	rs12671341	chr7:148805282	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.42	5.25	0.31	3.12e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs7020830	0.931	rs13295115	chr9:37157964	T/G	cg14294708	chr9:37120828	ZCCHC7	1.24	23.33	0.82	3.31e-66	Schizophrenia;
CESC	cis	rs11249608	0.590	rs36051170	chr5:178447971	T/C	cg01312482	chr5:178451176	ZNF879	-0.41	-5.63	-0.33	4.59e-8	Pubertal anthropometrics;
CESC	cis	rs9611565	0.659	rs1810460	chr22:41927700	C/T	cg17376030	chr22:41985996	PMM1	0.68	7.58	0.42	5.82e-13	Vitiligo;
CESC	cis	rs561341	1.000	rs554078	chr17:30330109	A/C	cg12193833	chr17:30244370	NA	-0.76	-6.98	-0.39	2.3e-11	Hip circumference adjusted for BMI;
CESC	cis	rs597539	0.652	rs557625	chr11:68634722	G/A	cg06028808	chr11:68637592	NA	0.43	5.12	0.3	5.87e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs752092	0.894	rs8036083	chr15:101767822	T/G	cg19997662	chr15:101784653	CHSY1	-0.42	-5.68	-0.33	3.58e-8	Corneal structure;
CESC	cis	rs4891159	0.660	rs4891160	chr18:74102135	C/T	cg24786174	chr18:74118243	ZNF516	0.66	10.28	0.53	4.41e-21	Longevity;
CESC	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg22907277	chr7:1156413	C7orf50	0.43	6.04	0.35	5.09e-9	Longevity;Endometriosis;
CESC	cis	rs10504229	1.000	rs66479724	chr8:58188309	T/G	cg14926445	chr8:58193284	C8orf71	-0.51	-5.42	-0.32	1.37e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs919433	0.783	rs788011	chr2:198230771	A/G	cg03934865	chr2:198174659	NA	0.43	6.21	0.36	2.01e-9	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs637571	0.522	rs550435	chr11:65732651	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.73	10.63	0.55	3.36e-22	Eosinophil percentage of white cells;
CESC	cis	rs734999	0.505	rs10910108	chr1:2539532	A/G	cg18854424	chr1:2615690	NA	0.29	5.87	0.34	1.29e-8	Ulcerative colitis;
CESC	cis	rs67460515	0.500	rs9832109	chr3:160723364	T/C	cg03342759	chr3:160939853	NMD3	-0.43	-5.4	-0.32	1.45e-7	Parkinson's disease;
CESC	cis	rs933688	1.000	rs6867091	chr5:90734333	C/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.84	11.02	0.56	1.72e-23	Smoking behavior;
CESC	cis	rs3785574	0.962	rs4968660	chr17:61792221	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.8	10.74	0.55	1.38e-22	Height;
CESC	cis	rs4728302	0.869	rs10231102	chr7:133573310	G/A	cg10665199	chr7:133106180	EXOC4	0.39	5.36	0.31	1.84e-7	Intelligence;Intelligence (multi-trait analysis);
CESC	cis	rs854765	0.964	rs854810	chr17:18006421	G/C	cg09796270	chr17:17721594	SREBF1	-0.38	-5.13	-0.3	5.62e-7	Total body bone mineral density;
CESC	cis	rs67311347	0.956	rs9822870	chr3:40514890	A/C	cg09455208	chr3:40491958	NA	-0.48	-8.23	-0.45	8.51e-15	Renal cell carcinoma;
CESC	cis	rs4268898	0.636	rs72787385	chr2:24585820	G/A	cg06627628	chr2:24431161	ITSN2	-1.03	-11.63	-0.58	1.53e-25	Asthma;
CESC	cis	rs9303401	0.659	rs35928756	chr17:56702652	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.04	13.0	0.62	3.27e-30	Cognitive test performance;
CESC	cis	rs1707322	1.000	rs10890375	chr1:46406581	G/A	cg06784218	chr1:46089804	CCDC17	0.33	5.63	0.33	4.7e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs6967414	0.681	rs2881352	chr7:6753511	T/A	cg00387323	chr7:6746715	ZNF12	0.65	6.12	0.35	3.39e-9	Hematocrit;Hemoglobin concentration;
CESC	cis	rs9302635	0.513	rs8061282	chr16:72155938	C/T	cg01557791	chr16:72042693	DHODH	-0.57	-6.65	-0.38	1.66e-10	Blood protein levels;
CESC	cis	rs9400271	0.609	rs9386782	chr6:109588643	G/T	cg01475377	chr6:109611718	NA	-0.46	-7.18	-0.4	7.24e-12	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
CESC	cis	rs8180040	0.739	rs12488225	chr3:47235107	G/A	cg27129171	chr3:47204927	SETD2	0.68	10.33	0.54	3.02e-21	Colorectal cancer;
CESC	cis	rs7666738	0.546	rs10026181	chr4:98814118	C/T	cg17366294	chr4:99064904	C4orf37	-0.46	-5.52	-0.32	8.01e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7312933	0.501	rs7296357	chr12:42729891	T/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.49	-6.37	-0.36	8.5e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs11098499	0.820	rs28394116	chr4:120524283	T/G	cg09307838	chr4:120376055	NA	0.88	12.11	0.6	3.6e-27	Corneal astigmatism;
CESC	cis	rs4835473	0.932	rs1375987	chr4:144700775	G/C	cg25736465	chr4:144833511	NA	-0.33	-5.23	-0.31	3.48e-7	Immature fraction of reticulocytes;
CESC	cis	rs9811920	0.742	rs2316263	chr3:99900096	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.38	5.95	0.34	8.5e-9	Axial length;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg25622317	chr11:1002295	AP2A2	0.4	6.24	0.36	1.71e-9	Fibrinogen levels;
CESC	cis	rs4964805	0.526	rs934845	chr12:104185257	T/G	cg02344784	chr12:104178138	NT5DC3	0.48	6.91	0.39	3.55e-11	Attention deficit hyperactivity disorder;
CESC	cis	rs9914988	0.943	rs4262997	chr17:27129562	A/G	cg20469991	chr17:27169893	C17orf63	-0.48	-5.25	-0.31	3.18e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CESC	cis	rs7130144	0.541	rs57898590	chr11:130462913	G/A	cg26307797	chr11:130446613	NA	-0.74	-6.5	-0.37	3.95e-10	Urate levels in lean individuals;
CESC	cis	rs2625529	0.529	rs7183055	chr15:72377048	C/T	cg16672083	chr15:72433130	SENP8	0.46	7.12	0.4	1.03e-11	Red blood cell count;
CESC	trans	rs10009321	1.000	rs4525996	chr4:130246216	C/G	cg05721189	chr3:14308081	NA	-0.48	-6.04	-0.35	5.25e-9	Neurofibrillary tangles;
CESC	cis	rs684232	0.602	rs416662	chr17:535699	A/G	cg12384639	chr17:618140	VPS53	0.41	5.28	0.31	2.7e-7	Prostate cancer;
CESC	cis	rs780096	0.565	rs8179252	chr2:27746832	A/C	cg22903471	chr2:27725779	GCKR	-0.52	-7.39	-0.41	1.93e-12	Total body bone mineral density;
CESC	cis	rs8031584	0.541	rs2955777	chr15:31219788	A/C	cg14829155	chr15:31115871	NA	0.74	10.59	0.55	4.45e-22	Huntington's disease progression;
CESC	cis	rs6952808	0.601	rs3778978	chr7:2159817	A/G	cg05863683	chr7:1912471	MAD1L1	0.38	5.54	0.32	7.31e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs9322193	0.886	rs17672976	chr6:150097343	T/A	cg04369109	chr6:150039330	LATS1	-0.39	-5.34	-0.31	2.01e-7	Lung cancer;
CESC	cis	rs897984	0.572	rs112906665	chr16:31040139	T/C	cg00531865	chr16:30841666	NA	-0.38	-5.36	-0.31	1.84e-7	Dementia with Lewy bodies;
CESC	cis	rs1152591	1.000	rs2738413	chr14:64679960	A/G	cg21174375	chr14:64681225	SYNE2	0.46	6.23	0.36	1.84e-9	Atrial fibrillation;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg22032789	chr5:149512529	PDGFRB	-0.38	-6.0	-0.35	6.54e-9	Gambling;
CESC	cis	rs4555082	0.874	rs28822720	chr14:105746282	T/C	cg27165867	chr14:105738592	BRF1	-0.55	-6.22	-0.36	1.98e-9	Mean platelet volume;Platelet distribution width;
CESC	cis	rs9790314	0.791	rs6809256	chr3:161026513	G/A	cg03342759	chr3:160939853	NMD3	-0.51	-7.32	-0.41	2.89e-12	Morning vs. evening chronotype;
CESC	trans	rs9467711	0.606	rs9379863	chr6:26372427	A/G	cg06606381	chr12:133084897	FBRSL1	-0.76	-6.89	-0.39	4.1e-11	Autism spectrum disorder or schizophrenia;
CESC	cis	rs13191362	1.000	rs35092540	chr6:163090778	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.99	10.2	0.53	8.22e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	trans	rs837841	0.864	rs1660903	chr2:130046679	C/G	cg26516701	chr12:53845683	PCBP2	-0.55	-7.06	-0.4	1.44e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
CESC	cis	rs10504229	0.679	rs17800895	chr8:58050085	A/G	cg14926445	chr8:58193284	C8orf71	-0.53	-5.04	-0.3	8.54e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs1046896	0.520	rs8074086	chr17:80818460	A/C	cg02711726	chr17:80685570	FN3KRP	-0.44	-5.73	-0.33	2.72e-8	Glycated hemoglobin levels;
CESC	cis	rs778371	0.958	rs2675968	chr2:233736244	A/G	cg08000102	chr2:233561755	GIGYF2	0.82	13.33	0.63	2.3e-31	Schizophrenia;
CESC	cis	rs116095464	0.614	rs62344339	chr5:252995	T/G	cg22857025	chr5:266934	NA	-1.29	-18.21	-0.75	1.29e-48	Breast cancer;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg04580897	chr3:39448698	SNORA6;RPSA	-0.47	-6.28	-0.36	1.36e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs2635047	0.566	rs8092050	chr18:44796323	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.39	5.07	0.3	7.35e-7	Educational attainment;
CESC	cis	rs2415984	0.622	rs12437018	chr14:46937149	A/G	cg14871534	chr14:47121158	RPL10L	-0.34	-5.17	-0.3	4.55e-7	Number of children ever born;
CESC	cis	rs6748734	1.000	rs4344931	chr2:241818527	A/C	cg07537917	chr2:241836409	C2orf54	-0.25	-5.36	-0.31	1.84e-7	Urinary metabolites;
CESC	cis	rs2274273	1.000	rs7140872	chr14:55612744	C/T	cg04306507	chr14:55594613	LGALS3	0.28	5.26	0.31	2.94e-7	Protein biomarker;
CESC	cis	rs3806843	0.832	rs2531360	chr5:140116664	G/A	cg26395211	chr5:140044315	WDR55	0.44	5.79	0.33	2.02e-8	Depressive symptoms (multi-trait analysis);
CESC	cis	rs2072438	0.503	rs4837810	chr9:123881199	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.38	5.44	0.32	1.19e-7	Rheumatoid arthritis;
CESC	trans	rs2727020	0.894	rs1917328	chr11:49359606	G/A	cg03929089	chr4:120376271	NA	-0.64	-7.48	-0.42	1.13e-12	Coronary artery disease;
CESC	cis	rs2282802	0.660	rs6873248	chr5:139683762	A/G	cg26211634	chr5:139558579	C5orf32	-0.48	-7.0	-0.39	2.14e-11	Intelligence (multi-trait analysis);
CESC	cis	rs13256369	0.802	rs13280101	chr8:8562773	G/A	cg00074818	chr8:8560427	CLDN23	0.36	5.17	0.3	4.58e-7	Obesity-related traits;
CESC	cis	rs13242816	1.000	rs62471184	chr7:116090300	G/A	cg04696780	chr7:116139425	CAV2	-0.63	-5.64	-0.33	4.39e-8	P wave duration;
CESC	cis	rs4253772	0.591	rs11705624	chr22:46685380	C/T	cg10541313	chr22:46663664	TTC38	0.72	5.15	0.3	5.01e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs7772486	0.790	rs9376970	chr6:146241472	A/C	cg05347473	chr6:146136440	FBXO30	-0.56	-7.4	-0.41	1.82e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1401999	0.966	rs2139560	chr3:183653869	A/G	cg01324343	chr3:183735012	ABCC5	0.66	14.04	0.65	7.57e-34	Anterior chamber depth;
CESC	cis	rs3026101	0.671	rs8077472	chr17:5299359	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.42	5.6	0.33	5.31e-8	Body mass index;
CESC	cis	rs875971	0.508	rs10258739	chr7:66062935	A/T	cg11764359	chr7:65958608	NA	-0.53	-7.1	-0.4	1.13e-11	Aortic root size;
CESC	cis	rs9788333	0.888	rs35880230	chr13:21885972	A/G	cg23743428	chr13:21893420	NA	-0.38	-6.1	-0.35	3.69e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs2901656	0.677	rs2269615	chr1:172415451	C/T	cg03748243	chr1:172413542	C1orf105;PIGC	0.52	8.0	0.44	3.88e-14	Red cell distribution width;Platelet distribution width;
CESC	cis	rs10779751	1.000	rs2300094	chr1:11266044	C/T	cg08854313	chr1:11322531	MTOR	0.91	14.32	0.66	7.99e-35	Body mass index;
CESC	cis	rs714031	0.934	rs2235342	chr22:40068853	T/C	cg21377881	chr22:40064566	CACNA1I	-0.32	-5.16	-0.3	4.96e-7	Schizophrenia;
CESC	cis	rs7605827	0.897	rs6734288	chr2:15526222	T/G	cg19274914	chr2:15703543	NA	0.35	6.27	0.36	1.43e-9	Educational attainment (years of education);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg02250553	chr10:134511404	INPP5A	0.49	6.47	0.37	4.78e-10	Fibrinogen levels;
CESC	cis	rs9322193	0.736	rs3828701	chr6:150112199	C/T	cg04369109	chr6:150039330	LATS1	-0.4	-5.47	-0.32	1.04e-7	Lung cancer;
CESC	cis	rs10979	1.000	rs9403504	chr6:143885430	G/A	cg25407410	chr6:143891975	LOC285740	-0.62	-9.51	-0.5	1.21e-18	Hypospadias;
CESC	cis	rs11608355	0.545	rs7139106	chr12:109908640	G/A	cg05360138	chr12:110035743	NA	0.81	8.75	0.47	2.52e-16	Neuroticism;
CESC	cis	rs4819052	0.580	rs419322	chr21:46551702	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.52	5.6	0.33	5.39e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs13130787	0.802	rs10030952	chr4:94938117	C/T	cg11021082	chr4:95130006	SMARCAD1	0.38	5.1	0.3	6.56e-7	Colorectal cancer;
CESC	cis	rs8180040	0.620	rs749511	chr3:47035735	A/C	cg27129171	chr3:47204927	SETD2	-0.67	-9.95	-0.52	5.18e-20	Colorectal cancer;
CESC	cis	rs1448094	0.512	rs61930137	chr12:86242930	C/T	cg00310523	chr12:86230176	RASSF9	0.35	5.44	0.32	1.21e-7	Major depressive disorder;
CESC	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg24642844	chr7:1081250	C7orf50	-0.77	-9.63	-0.51	5.27e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00298675	chr2:73612788	ALMS1	0.57	6.45	0.37	5.4e-10	Gut microbiome composition (summer);
CESC	cis	rs1799949	0.965	rs11658499	chr17:41334749	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.59	7.71	0.43	2.62e-13	Menopause (age at onset);
CESC	cis	rs7589342	0.899	rs10185551	chr2:106492201	A/C	cg14210321	chr2:106509881	NCK2	-0.48	-5.61	-0.33	5.2100000000000003e-08	Addiction;
CESC	cis	rs4906332	1.000	rs10459573	chr14:103925457	A/C	cg09975044	chr14:104007538	NA	0.47	6.45	0.37	5.25e-10	Coronary artery disease;
CESC	cis	rs6831352	0.918	rs35784540	chr4:100061692	T/A	cg12011299	chr4:100065546	ADH4	-0.6	-6.61	-0.38	2.09e-10	Alcohol dependence;
CESC	cis	rs7917772	0.536	rs17783771	chr10:104410736	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.58	7.1	0.4	1.12e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs2262909	0.962	rs12609368	chr19:22263996	T/C	cg11619707	chr19:22235551	ZNF257	0.34	5.44	0.32	1.24e-7	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
CESC	cis	rs9322193	0.607	rs7764677	chr6:150227333	C/T	cg01145232	chr6:150245071	RAET1G	0.51	6.63	0.38	1.88e-10	Lung cancer;
CESC	cis	rs1728785	1.000	rs1645936	chr16:68563743	A/G	cg02972257	chr16:68554789	NA	-0.49	-5.93	-0.34	9.24e-9	Ulcerative colitis;
CESC	cis	rs72945132	0.882	rs61260732	chr11:70162145	G/A	cg00319359	chr11:70116639	PPFIA1	0.78	7.71	0.43	2.52e-13	Coronary artery disease;
CESC	cis	rs9300255	0.602	rs10846486	chr12:123709927	G/A	cg00376283	chr12:123451042	ABCB9	0.7	8.89	0.48	9.66e-17	Neutrophil percentage of white cells;
CESC	cis	rs6426558	0.537	rs7512409	chr1:227484038	A/G	cg10327440	chr1:227177885	CDC42BPA	-0.41	-5.24	-0.31	3.24e-7	Neutrophil percentage of white cells;
CESC	cis	rs7267979	0.966	rs2257233	chr20:25265984	A/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.9	-18.45	-0.75	1.86e-49	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs847577	0.609	rs6465658	chr7:97816638	C/G	cg21770322	chr7:97807741	LMTK2	0.83	13.36	0.63	1.74e-31	Breast cancer;
CESC	cis	rs11690935	0.959	rs2674484	chr2:172574612	G/A	cg13550731	chr2:172543902	DYNC1I2	-0.96	-14.77	-0.67	2.06e-36	Schizophrenia;
CESC	cis	rs6500395	1.000	rs9931737	chr16:48623539	C/T	cg04672837	chr16:48644449	N4BP1	0.52	6.64	0.38	1.81e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs9457247	1.000	rs421214	chr6:167396629	A/G	cg25258033	chr6:167368657	RNASET2	0.4	5.95	0.34	8.36e-9	Crohn's disease;
CESC	cis	rs7165102	1.000	rs590958	chr15:65735707	T/G	cg11441148	chr15:65824328	PTPLAD1	0.33	5.48	0.32	1e-7	Mean corpuscular hemoglobin;
CESC	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg03188948	chr7:1209495	NA	0.73	7.05	0.4	1.54e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7772486	0.790	rs9399571	chr6:146282061	A/G	cg05347473	chr6:146136440	FBXO30	-0.56	-7.11	-0.4	1.09e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2180341	0.521	rs12203812	chr6:127617816	A/T	cg24812749	chr6:127587940	RNF146	0.49	6.36	0.36	8.77e-10	Breast cancer;
CESC	cis	rs6724607	1.000	rs28452331	chr2:191471847	C/T	cg21644426	chr2:191273491	MFSD6	-0.49	-6.68	-0.38	1.42e-10	Pulse pressure;
CESC	cis	rs13336428	0.730	rs28653458	chr16:1525850	T/C	cg26690334	chr16:1524521	CLCN7	-0.37	-5.35	-0.31	1.87e-7	Bone mineral density;
CESC	cis	rs12893668	0.703	rs55751606	chr14:104028806	G/A	cg08213375	chr14:104286397	PPP1R13B	0.32	5.04	0.3	8.58e-7	Reticulocyte count;
CESC	cis	rs1534166	0.601	rs13324779	chr3:133510413	G/A	cg12373951	chr3:133503437	NA	-0.35	-5.26	-0.31	2.9e-7	Alcohol consumption (transferrin glycosylation);
CESC	cis	rs12478296	0.685	rs35577962	chr2:242993575	A/G	cg06360820	chr2:242988706	NA	-0.81	-9.49	-0.5	1.38e-18	Obesity-related traits;
CESC	cis	rs8062405	1.000	rs56358680	chr16:28843118	A/G	cg08761264	chr16:28874980	SH2B1	-0.45	-5.67	-0.33	3.78e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs826838	0.967	rs4768329	chr12:39129394	T/C	cg26384229	chr12:38710491	ALG10B	-0.67	-11.01	-0.56	1.82e-23	Heart rate;
CESC	cis	rs12134245	0.747	rs17501512	chr1:92012481	C/G	cg25838465	chr1:92012736	NA	0.6	8.88	0.48	1.07e-16	Breast cancer;
CESC	trans	rs9929218	0.529	rs17715450	chr16:68729785	C/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.86	13.93	0.65	1.8e-33	Colorectal cancer;
CESC	cis	rs2842992	0.872	rs2758315	chr6:160158640	T/C	cg11366901	chr6:160182831	ACAT2	0.82	10.61	0.55	3.82e-22	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs7927771	1.000	rs7947730	chr11:47786184	C/T	cg05585544	chr11:47624801	NA	-0.5	-7.88	-0.44	8.28e-14	Subjective well-being;
CESC	cis	rs12134245	0.776	rs6688261	chr1:91987034	C/T	cg02896835	chr1:92012615	NA	-0.57	-7.98	-0.44	4.45e-14	Breast cancer;
CESC	cis	rs916888	0.647	rs199523	chr17:44848517	C/A	cg01570182	chr17:44337453	NA	-0.65	-8.65	-0.47	5.14e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs6499255	0.857	rs8060588	chr16:69656500	A/G	cg15192750	chr16:69999425	NA	0.51	5.87	0.34	1.33e-8	IgE levels;
CESC	cis	rs6860806	0.661	rs3763112	chr5:131586480	A/G	cg12564285	chr5:131593104	PDLIM4	0.37	5.57	0.32	6.26e-8	Breast cancer;
CESC	cis	rs1364705	1.000	rs13262685	chr8:120226145	A/G	cg09273054	chr8:120220131	MAL2	0.5	5.71	0.33	3.05e-8	Hippocampal atrophy;
CESC	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.34	6.74	0.38	9.81e-11	Bipolar disorder;
CESC	cis	rs875971	0.862	rs801195	chr7:66026115	A/G	cg12463550	chr7:65579703	CRCP	-0.5	-6.34	-0.36	9.71e-10	Aortic root size;
CESC	cis	rs3008870	1.000	rs12740884	chr1:67459855	C/A	cg08660285	chr1:67390436	MIER1;WDR78	-1.06	-15.19	-0.68	6.65e-38	Lymphocyte percentage of white cells;
CESC	cis	rs4900538	0.787	rs11704	chr14:102808655	C/G	cg18135206	chr14:102964638	TECPR2	0.69	8.36	0.46	3.51e-15	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	cis	rs7726839	1.000	rs7726839	chr5:618586	A/G	cg03128945	chr5:622914	CEP72	-0.39	-5.29	-0.31	2.59e-7	Obesity-related traits;
CESC	cis	rs10242455	0.702	rs45451992	chr7:99041416	C/A	cg18809830	chr7:99032528	PTCD1	-0.93	-5.77	-0.33	2.19e-8	Blood metabolite levels;
CESC	cis	rs11674184	0.525	rs4669755	chr2:11748585	A/C	cg07314298	chr2:11723111	GREB1	0.57	8.17	0.45	1.25e-14	Endometriosis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24531267	chr20:34043122	CEP250	0.62	7.19	0.4	6.5e-12	Gut microbiome composition (summer);
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg16139199	chr18:19180362	ESCO1	0.53	7.85	0.43	1.02e-13	Systemic lupus erythematosus;
CESC	cis	rs4843747	0.708	rs11866437	chr16:88072279	A/G	cg06915872	chr16:87998081	BANP	-0.45	-5.63	-0.33	4.6e-8	Menopause (age at onset);
CESC	cis	rs9916302	0.904	rs2338797	chr17:37548241	G/A	cg15445000	chr17:37608096	MED1	-0.41	-6.75	-0.38	9.08e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs1448094	0.512	rs12314274	chr12:86249196	A/G	cg19622623	chr12:86230825	RASSF9	-0.44	-5.61	-0.33	4.98e-8	Major depressive disorder;
CESC	cis	rs9487051	0.714	rs7744284	chr6:109616218	C/T	cg21918786	chr6:109611834	NA	-0.38	-5.55	-0.32	6.89e-8	Reticulocyte fraction of red cells;
CESC	cis	rs897984	0.537	rs8045637	chr16:30818662	C/T	cg02466173	chr16:30829666	NA	-0.6	-11.78	-0.59	4.82e-26	Dementia with Lewy bodies;
CESC	cis	rs4862750	0.914	rs1991255	chr4:187875340	G/A	cg06074448	chr4:187884817	NA	-0.37	-5.22	-0.31	3.6e-7	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4843747	0.636	rs11864872	chr16:88105966	A/G	cg06915872	chr16:87998081	BANP	0.44	5.25	0.31	3.11e-7	Menopause (age at onset);
CESC	cis	rs67079557	1	rs67079557	chr15:75930300	ATAATAAG/A	cg20655648	chr15:75932815	IMP3	0.53	6.55	0.37	3.06e-10	Breast cancer;
CESC	cis	rs1215050	0.740	rs10025482	chr4:99053277	T/C	cg05340658	chr4:99064831	C4orf37	0.61	8.27	0.45	6.57e-15	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs10927875	0.965	rs3961710	chr1:16313172	C/T	cg21385522	chr1:16154831	NA	-0.77	-9.68	-0.51	3.51e-19	Dilated cardiomyopathy;
CESC	cis	rs875971	0.862	rs778734	chr7:65814849	C/G	cg10691866	chr7:65817282	TPST1	-0.31	-5.25	-0.31	3.18e-7	Aortic root size;
CESC	cis	rs798502	0.541	rs2644307	chr7:2832973	G/A	cg04166393	chr7:2884313	GNA12	0.43	5.73	0.33	2.75e-8	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Inflammatory bowel disease;Waist circumference adjusted for BMI in non-smokers;Ulcerative colitis;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
CESC	cis	rs6088580	0.634	rs4911151	chr20:32932273	T/C	cg06115741	chr20:33292138	TP53INP2	-0.44	-5.65	-0.33	4.16e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs1799949	1.000	rs11651341	chr17:41428061	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.65	9.04	0.49	3.33e-17	Menopause (age at onset);
CESC	trans	rs35110281	0.806	rs1454649	chr21:45032982	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.56	7.25	0.41	4.58e-12	Mean corpuscular volume;
CESC	cis	rs9399135	0.967	rs9376077	chr6:135299713	C/G	cg24558204	chr6:135376177	HBS1L	0.5	6.66	0.38	1.58e-10	Red blood cell count;
CESC	cis	rs8078723	0.738	rs4065321	chr17:38143548	C/T	cg17467752	chr17:38218738	THRA	-0.56	-8.48	-0.46	1.63e-15	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CESC	cis	rs6445797	0.632	rs9842283	chr3:56609469	G/T	cg13792233	chr3:56591045	CCDC66	0.39	5.13	0.3	5.61e-7	Gastritis;
CESC	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	13.49	0.64	6.45e-32	Prudent dietary pattern;
CESC	cis	rs35110281	0.667	rs7282405	chr21:45123611	C/G	cg01579765	chr21:45077557	HSF2BP	-0.54	-9.3	-0.5	5.56e-18	Mean corpuscular volume;
CESC	cis	rs909002	0.849	rs3753611	chr1:32082486	C/T	cg13919466	chr1:32135498	COL16A1	-0.46	-8.05	-0.44	2.89e-14	Intelligence (multi-trait analysis);
CESC	cis	rs8114671	0.562	rs1018447	chr20:33401707	A/G	cg07148914	chr20:33460835	GGT7	-0.42	-5.64	-0.33	4.29e-8	Height;
CESC	cis	rs4237845	0.537	rs11172369	chr12:58280592	T/C	cg02175503	chr12:58329896	NA	0.5	5.92	0.34	9.68e-9	Intelligence (multi-trait analysis);
CESC	cis	rs2806561	0.808	rs4654834	chr1:23364919	T/C	cg12483005	chr1:23474871	LUZP1	-0.33	-5.36	-0.31	1.8e-7	Height;
CESC	cis	rs9660180	0.868	rs12567685	chr1:1806647	T/C	cg17747265	chr1:1875780	NA	-0.6	-9.81	-0.52	1.42e-19	Body mass index;
CESC	cis	rs2842992	0.789	rs6908680	chr6:160218209	G/T	cg11366901	chr6:160182831	ACAT2	0.76	9.31	0.5	4.95e-18	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs644799	0.930	rs631099	chr11:95563482	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	14.27	0.66	1.19e-34	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs7044106	0.762	rs1886337	chr9:123443776	G/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.69	10.09	0.53	1.84e-20	Hip circumference adjusted for BMI;
CESC	cis	rs875971	0.660	rs13224319	chr7:66007363	A/G	cg25985355	chr7:65971099	NA	-0.32	-5.28	-0.31	2.71e-7	Aortic root size;
CESC	cis	rs2836633	0.929	rs11702165	chr21:40035313	C/T	cg05519781	chr21:40033154	ERG	0.79	13.91	0.65	2.1e-33	Coronary artery disease;
CESC	cis	rs365132	0.818	rs6879982	chr5:176351330	A/T	cg16309518	chr5:176445507	NA	-0.37	-5.39	-0.31	1.59e-7	Menarche and menopause (age at onset);Menopause (age at onset);
CESC	cis	rs11122272	0.735	rs2749711	chr1:231537543	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.55	-7.44	-0.42	1.38e-12	Hemoglobin concentration;
CESC	cis	rs896854	0.654	rs28716845	chr8:95974485	A/G	cg13393036	chr8:95962371	TP53INP1	-0.49	-10.52	-0.54	7.38e-22	Type 2 diabetes;
CESC	cis	rs4919687	0.550	rs11191372	chr10:104462187	T/C	cg04362960	chr10:104952993	NT5C2	0.45	5.36	0.31	1.82e-7	Colorectal cancer;
CESC	cis	rs561341	0.883	rs886224	chr17:30229902	T/C	cg13647721	chr17:30228624	UTP6	0.59	5.34	0.31	1.99e-7	Hip circumference adjusted for BMI;
CESC	cis	rs7258465	1.000	rs2303695	chr19:18562624	C/T	cg25828334	chr19:18545568	ISYNA1	-0.32	-5.16	-0.3	4.81e-7	Breast cancer;
CESC	cis	rs9611565	0.921	rs4822021	chr22:41726053	G/A	cg06481639	chr22:41940642	POLR3H	-0.59	-6.39	-0.37	7.32e-10	Vitiligo;
CESC	cis	rs6963495	0.818	rs73190155	chr7:105153535	T/A	cg19920283	chr7:105172520	RINT1	0.69	6.56	0.37	2.85e-10	Bipolar disorder (body mass index interaction);
CESC	cis	rs6444746	1.000	rs2008918	chr3:193499512	A/G	cg22553634	chr3:193489233	NA	-0.47	-5.53	-0.32	7.78e-8	Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
CESC	cis	rs796364	0.625	rs13035260	chr2:201132377	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.49	-5.14	-0.3	5.38e-7	Schizophrenia;
CESC	cis	rs6860806	0.507	rs2631371	chr5:131703691	G/A	cg24060327	chr5:131705240	SLC22A5	0.76	10.57	0.54	5.15e-22	Breast cancer;
CESC	cis	rs10504229	0.953	rs66676208	chr8:58173866	C/T	cg22535103	chr8:58192502	C8orf71	-1.05	-13.27	-0.63	3.63e-31	Developmental language disorder (linguistic errors);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg24608144	chr20:62398219	ZBTB46	0.58	7.71	0.43	2.55e-13	Fibrinogen levels;
CESC	cis	rs644799	1.000	rs560854	chr11:95584905	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.67	8.18	0.45	1.16e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs2243480	1.000	rs13237037	chr7:65997882	T/C	cg18252515	chr7:66147081	NA	-1.4	-14.3	-0.66	9.38e-35	Diabetic kidney disease;
CESC	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg23708337	chr7:1209742	NA	0.55	5.41	0.32	1.41e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7520050	0.807	rs3013595	chr1:46153203	G/A	cg24296786	chr1:45957014	TESK2	-0.48	-6.14	-0.35	2.96e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs11723261	0.582	rs11735742	chr4:142550	C/T	cg12746427	chr4:53362	ZNF718;ZNF595	-0.46	-6.0	-0.35	6.48e-9	Immune response to smallpox vaccine (IL-6);
CESC	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg05552183	chr6:42928497	GNMT	0.8	13.69	0.64	1.23e-32	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs7772486	0.727	rs2235481	chr6:146056848	T/C	cg23711669	chr6:146136114	FBXO30	-0.91	-12.26	-0.6	1.1e-27	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27169379	chr21:43274834	PRDM15	-0.6	-6.44	-0.37	5.65e-10	Gut microbiome composition (summer);
CESC	trans	rs4650994	0.525	rs2493858	chr1:178541210	A/G	cg05059571	chr16:84539110	KIAA1609	-0.39	-6.01	-0.35	5.99e-9	HDL cholesterol levels;HDL cholesterol;
CESC	cis	rs7267979	1.000	rs4815424	chr20:25390284	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.84	-16.35	-0.71	4.94e-42	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs36051895	0.664	rs3780371	chr9:5095191	T/A	cg02405213	chr9:5042618	JAK2	-0.51	-6.17	-0.35	2.61e-9	Pediatric autoimmune diseases;
CESC	cis	rs2303745	0.589	rs11086065	chr19:17395003	A/G	cg22549504	chr19:17448937	GTPBP3	0.5	5.56	0.32	6.74e-8	Systemic lupus erythematosus;
CESC	cis	rs1971256	0.500	rs9479050	chr6:151806338	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.61	5.62	0.33	4.85e-8	Endometriosis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26088104	chr5:43515152	C5orf34	-0.53	-6.21	-0.36	2e-9	Gut microbiome composition (summer);
CESC	cis	rs4319547	0.794	rs61954972	chr12:123074167	T/G	cg05707623	chr12:122985044	ZCCHC8	-0.58	-6.75	-0.38	9.5e-11	Body mass index;
CESC	cis	rs1387259	0.929	rs2634666	chr12:48663670	G/T	cg24011408	chr12:48396354	COL2A1	0.43	6.07	0.35	4.46e-9	Obstructive sleep apnea trait (apnea hypopnea index);
CESC	trans	rs60180747	1.000	rs35510028	chr15:66612079	C/G	cg01218494	chr17:71160864	SSTR2	0.45	6.03	0.35	5.59e-9	Testicular germ cell tumor;
CESC	cis	rs12438659	1	rs12438659	chr15:78824924	G/A	cg24631222	chr15:78858424	CHRNA5	0.76	9.6	0.51	6.48e-19	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs7772486	0.875	rs2777483	chr6:146329235	A/G	cg05347473	chr6:146136440	FBXO30	0.53	6.96	0.39	2.7e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2540647	0.908	rs2540654	chr22:18973671	C/T	cg12798833	chr22:18958832	DGCR5	0.73	7.34	0.41	2.56e-12	Blood metabolite ratios;
CESC	cis	rs34891900	0.507	rs2008085	chr22:18204316	T/G	cg19898043	chr22:18121309	BCL2L13	0.57	6.78	0.38	7.99e-11	Sum neutrophil eosinophil counts;
CESC	cis	rs863345	0.584	rs10908676	chr1:158506163	C/G	cg12129480	chr1:158549410	OR10X1	-0.33	-6.54	-0.37	3.17e-10	Pneumococcal bacteremia;
CESC	cis	rs4072980	0.545	rs7528185	chr1:38452059	C/T	cg12658694	chr1:38397304	INPP5B	-0.61	-7.96	-0.44	5.03e-14	Coronary artery disease;
CESC	cis	rs11098499	0.909	rs71614422	chr4:120359340	G/A	cg09307838	chr4:120376055	NA	0.95	13.68	0.64	1.38e-32	Corneal astigmatism;
CESC	cis	rs1801251	1.000	rs12990821	chr2:233617585	C/G	cg08000102	chr2:233561755	GIGYF2	0.67	9.48	0.5	1.53e-18	Coronary artery disease;
CESC	cis	rs10504229	1.000	rs68076606	chr8:58191271	A/G	cg14926445	chr8:58193284	C8orf71	-0.51	-5.52	-0.32	8.28e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs2304069	0.545	rs11167492	chr5:149403101	G/A	cg12661370	chr5:149340060	SLC26A2	0.43	5.62	0.33	4.77e-8	HIV-1 control;
CESC	cis	rs7659604	0.540	rs11098643	chr4:122701507	C/A	cg19671926	chr4:122722719	EXOSC9	0.65	8.61	0.47	6.55e-16	Type 2 diabetes;
CESC	trans	rs4957048	0.891	rs11960196	chr5:568857	C/A	cg25482853	chr8:67687455	SGK3	0.97	10.84	0.55	6.55e-23	Ulcerative colitis;
CESC	cis	rs3091242	0.933	rs11249250	chr1:25767609	G/A	cg03538708	chr1:25844672	NA	-0.39	-5.93	-0.34	9.62e-9	Erythrocyte sedimentation rate;
CESC	cis	rs769267	0.629	rs7245672	chr19:19699963	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	-0.42	-5.03	-0.3	9.08e-7	Tonsillectomy;
CESC	cis	rs6502050	0.835	rs4789678	chr17:80101078	C/T	cg11859384	chr17:80120422	CCDC57	-0.38	-5.15	-0.3	5.06e-7	Life satisfaction;
CESC	cis	rs769267	0.965	rs2017964	chr19:19387149	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	7.34	0.41	2.56e-12	Tonsillectomy;
CESC	cis	rs2836974	0.897	rs8132419	chr21:40527827	C/T	cg27266027	chr21:40555129	PSMG1	0.48	5.82	0.34	1.68e-8	Cognitive function;
CESC	cis	rs274567	0.501	rs2631368	chr5:131705297	T/G	cg04518342	chr5:131593106	PDLIM4	-0.36	-5.05	-0.3	8.21e-7	Blood metabolite levels;
CESC	cis	rs7100689	0.577	rs4934038	chr10:82057334	C/A	cg09936400	chr10:82049201	MAT1A	0.4	6.04	0.35	5.32e-9	Post bronchodilator FEV1;
CESC	cis	rs58785573	0.624	rs2126526	chr4:38618689	A/G	cg18361445	chr4:38666374	KLF3;FLJ13197	0.41	5.34	0.31	1.96e-7	Lymphocyte percentage of white cells;
CESC	cis	rs9682041	0.825	rs6785326	chr3:170095145	T/C	cg11886554	chr3:170076028	SKIL	1.05	8.52	0.46	1.25e-15	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CESC	cis	rs7116495	1.000	rs2511114	chr11:71792147	T/C	cg10381502	chr11:71823885	C11orf51	-0.7	-5.7	-0.33	3.19e-8	Severe influenza A (H1N1) infection;
CESC	cis	rs7833790	1.000	rs7460277	chr8:82709777	T/C	cg17211192	chr8:82754475	SNX16	-0.7	-8.37	-0.46	3.35e-15	Diastolic blood pressure;
CESC	cis	rs514406	0.644	rs928451	chr1:53195800	A/G	cg08859206	chr1:53392774	SCP2	0.56	7.11	0.4	1.1e-11	Monocyte count;
CESC	cis	rs798554	0.759	rs798495	chr7:2797267	T/C	cg19717773	chr7:2847554	GNA12	-0.56	-7.94	-0.44	5.68e-14	Height;
CESC	cis	rs854765	0.583	rs4925126	chr17:17798633	C/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.46	5.93	0.34	9.52e-9	Total body bone mineral density;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19413799	chr1:32645788	TXLNA	0.57	6.73	0.38	1.07e-10	Gut microbiome composition (summer);
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg14705778	chr4:174254825	HMGB2	0.48	6.29	0.36	1.27e-9	Thyroid stimulating hormone;
CESC	cis	rs748404	0.697	rs555001	chr15:43545728	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.61	7.86	0.43	9.6e-14	Lung cancer;
CESC	cis	rs8141529	0.764	rs5752809	chr22:29225500	G/A	cg02153584	chr22:29168773	CCDC117	0.64	9.16	0.49	1.46e-17	Lymphocyte counts;
CESC	cis	rs7116495	1.000	rs517837	chr11:71802359	A/G	cg26138937	chr11:71823887	C11orf51	-0.86	-7.03	-0.4	1.75e-11	Severe influenza A (H1N1) infection;
CESC	cis	rs614226	0.935	rs7137953	chr12:120894685	C/T	cg27489772	chr12:121021490	NA	-0.5	-5.1	-0.3	6.48e-7	Type 1 diabetes nephropathy;
CESC	cis	rs6584283	0.875	rs1548962	chr10:101289735	C/G	cg09788492	chr10:101292477	NKX2-3	-0.32	-5.86	-0.34	1.35e-8	Ulcerative colitis;
CESC	cis	rs6740322	0.895	rs28456986	chr2:43553321	A/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.7	-7.43	-0.42	1.52e-12	Coronary artery disease;
CESC	cis	rs6860806	0.631	rs6863548	chr5:131575920	G/A	cg09877947	chr5:131593287	PDLIM4	0.45	5.96	0.34	7.83e-9	Breast cancer;
CESC	cis	rs2239547	0.618	rs4687658	chr3:52860366	C/G	cg11645453	chr3:52864694	ITIH4	0.32	5.89	0.34	1.15e-8	Schizophrenia;
CESC	cis	rs72829446	0.530	rs7217492	chr17:7396049	C/G	cg02795151	chr17:7402630	POLR2A	0.58	6.04	0.35	5.08e-9	Androgen levels;
CESC	cis	rs6138458	1.000	rs227658	chr20:24932028	A/G	cg06937882	chr20:24974362	C20orf3	-0.35	-5.11	-0.3	6.15e-7	Blood protein levels;
CESC	cis	rs61931739	0.571	rs4001689	chr12:34243271	C/T	cg19457237	chr12:34500585	NA	-0.38	-5.38	-0.31	1.61e-7	Morning vs. evening chronotype;
CESC	cis	rs9581857	0.579	rs3759433	chr13:27997999	C/T	cg01674679	chr13:27998804	GTF3A	-0.58	-6.05	-0.35	4.82e-9	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
CESC	cis	rs853679	0.569	rs9348798	chr6:28143011	G/A	cg12963246	chr6:28129442	ZNF389	0.54	7.18	0.4	6.92e-12	Depression;
CESC	cis	rs933688	1.000	rs6867219	chr5:90718008	T/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.98	11.78	0.59	5.05e-26	Smoking behavior;
CESC	cis	rs17711722	0.585	rs6942660	chr7:65302406	C/T	cg14393609	chr7:65229607	NA	0.52	6.97	0.39	2.47e-11	Calcium levels;
CESC	cis	rs798554	0.757	rs1182187	chr7:2870454	T/G	cg09658497	chr7:2847517	GNA12	-0.42	-5.96	-0.34	8.2e-9	Height;
CESC	cis	rs2033711	0.755	rs4801587	chr19:58936679	C/A	cg26874164	chr19:58962979	ZNF324B	0.52	7.02	0.4	1.81e-11	Uric acid clearance;
CESC	cis	rs7811142	0.887	rs111972532	chr7:100069088	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.14	11.04	0.56	1.49e-23	Platelet count;
CESC	cis	rs7246657	0.943	rs7246993	chr19:37890154	C/T	cg23950597	chr19:37808831	NA	-0.61	-6.19	-0.36	2.31e-9	Coronary artery calcification;
CESC	cis	rs3733585	0.664	rs28602527	chr4:9958327	G/A	cg00071950	chr4:10020882	SLC2A9	-0.73	-11.79	-0.59	4.58e-26	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs35110281	0.591	rs86138	chr21:44932398	G/A	cg21573476	chr21:45109991	RRP1B	-0.39	-5.62	-0.33	4.71e-8	Mean corpuscular volume;
CESC	cis	rs763121	0.853	rs5757181	chr22:39013522	G/A	cg06544989	chr22:39130855	UNC84B	0.49	7.99	0.44	4.07e-14	Menopause (age at onset);
CESC	cis	rs3857067	0.967	rs5019896	chr4:95035751	C/T	cg11021082	chr4:95130006	SMARCAD1	0.51	7.76	0.43	1.82e-13	QT interval;
CESC	cis	rs965513	0.524	rs6478413	chr9:100582024	A/G	cg13688889	chr9:100608707	NA	-0.53	-7.69	-0.43	2.87e-13	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
CESC	cis	rs9300255	0.679	rs12817892	chr12:123728702	G/A	cg00376283	chr12:123451042	ABCB9	-0.63	-6.54	-0.37	3.21e-10	Neutrophil percentage of white cells;
CESC	cis	rs6502050	0.805	rs9915071	chr17:80119138	T/C	cg23985595	chr17:80112537	CCDC57	-0.41	-6.57	-0.37	2.6200000000000003e-10	Life satisfaction;
CESC	cis	rs9815354	0.857	rs9852020	chr3:41830206	G/A	cg03022575	chr3:42003672	ULK4	0.7	6.04	0.35	5.26e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs875971	0.929	rs778682	chr7:65837934	A/G	cg12463550	chr7:65579703	CRCP	0.59	7.45	0.42	1.29e-12	Aortic root size;
CESC	cis	rs2072732	0.861	rs66693767	chr1:2955930	A/G	cg03976712	chr1:2946727	NA	0.33	5.53	0.32	7.83e-8	Plateletcrit;
CESC	cis	rs7772486	0.727	rs12190966	chr6:146146820	T/G	cg23711669	chr6:146136114	FBXO30	0.88	12.62	0.61	6.34e-29	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1499614	1.000	rs2659903	chr7:66180931	G/A	cg18252515	chr7:66147081	NA	-1.42	-14.62	-0.67	6.69e-36	Gout;
CESC	cis	rs2996428	0.709	rs12127399	chr1:3721609	G/A	cg13057898	chr1:3703894	LRRC47	0.47	6.46	0.37	4.86e-10	Red cell distribution width;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05697969	chr19:590413	HCN2	0.51	6.17	0.35	2.59e-9	Gut microbiome composition (summer);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg02923393	chr16:1543003	TELO2	0.52	6.78	0.38	7.95e-11	Gut microbiota (bacterial taxa);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg00575769	chr8:22079255	PHYHIP	0.46	6.06	0.35	4.74e-9	Fibrinogen levels;
CESC	trans	rs6445797	0.821	rs57800049	chr3:56665015	A/T	cg15444621	chr13:113611794	NA	0.33	6.15	0.35	2.85e-9	Gastritis;
CESC	cis	rs2204008	0.807	rs4123933	chr12:37973539	G/A	cg26384229	chr12:38710491	ALG10B	0.74	10.84	0.55	6.46e-23	Bladder cancer;
CESC	cis	rs6089584	0.566	rs55881457	chr20:60608424	G/A	cg06108461	chr20:60628389	TAF4	-0.62	-8.21	-0.45	9.98e-15	Body mass index;
CESC	cis	rs7192750	0.652	rs152828	chr16:72123886	T/C	cg14768367	chr16:72042858	DHODH	0.7	5.57	0.32	6.23e-8	LDL cholesterol levels;Total cholesterol levels;
CESC	cis	rs36051895	0.659	rs57204002	chr9:5062610	T/C	cg02405213	chr9:5042618	JAK2	-0.49	-5.96	-0.34	7.96e-9	Pediatric autoimmune diseases;
CESC	cis	rs12220238	1.000	rs6480723	chr10:75966366	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.6	5.45	0.32	1.13e-7	Soluble interleukin-2 receptor subunit alpha;
CESC	cis	rs72945132	1.000	rs56913804	chr11:70114673	G/A	cg14191688	chr11:70257035	CTTN	0.41	5.04	0.3	8.65e-7	Coronary artery disease;
CESC	cis	rs9911578	0.967	rs7503190	chr17:57184162	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.07	0.3	7.47e-7	Intelligence (multi-trait analysis);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg20769334	chr22:50913335	SBF1	-0.44	-6.59	-0.38	2.43e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs60843830	1.000	rs56167434	chr2:282137	G/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.87	11.53	0.58	3.43e-25	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs763121	0.853	rs5757213	chr22:39053888	C/T	cg14440974	chr22:39074834	NA	-0.4	-5.49	-0.32	9.53e-8	Menopause (age at onset);
CESC	cis	rs193541	0.632	rs30023	chr5:122285299	T/G	cg19412675	chr5:122181750	SNX24	0.46	5.49	0.32	9.32e-8	Glucose homeostasis traits;
CESC	cis	rs1707322	0.752	rs61784793	chr1:46149285	G/A	cg06784218	chr1:46089804	CCDC17	0.41	7.21	0.41	5.75e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs4835473	0.897	rs7657088	chr4:144623030	G/A	cg25736465	chr4:144833511	NA	-0.35	-5.24	-0.31	3.23e-7	Immature fraction of reticulocytes;
CESC	cis	rs1003719	0.788	rs2835576	chr21:38457393	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.62	8.67	0.47	4.41e-16	Eye color traits;
CESC	cis	rs1707322	0.721	rs10749856	chr1:46164846	A/T	cg06784218	chr1:46089804	CCDC17	0.43	7.58	0.42	5.65e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs67311347	0.826	rs9863679	chr3:40439614	G/A	cg24209194	chr3:40518798	ZNF619	0.52	6.48	0.37	4.46e-10	Renal cell carcinoma;
CESC	cis	rs3733585	0.699	rs6815001	chr4:9958662	G/C	cg11266682	chr4:10021025	SLC2A9	-0.6	-11.2	-0.57	4.42e-24	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs9905704	0.918	rs4132924	chr17:56937653	C/T	cg12560992	chr17:57184187	TRIM37	0.61	7.05	0.4	1.54e-11	Testicular germ cell tumor;
CESC	cis	rs2573652	1.000	rs2581341	chr15:100514494	T/C	cg00587665	chr15:100533223	ADAMTS17	-0.36	-5.65	-0.33	4.06e-8	Height;
CESC	cis	rs763121	0.853	rs5757204	chr22:39046700	A/C	cg06544989	chr22:39130855	UNC84B	0.5	8.66	0.47	4.63e-16	Menopause (age at onset);
CESC	cis	rs832540	0.656	rs702689	chr5:56177443	G/A	cg24531977	chr5:56204891	C5orf35	-0.48	-5.88	-0.34	1.26e-8	Coronary artery disease;
CESC	cis	rs7560272	0.538	rs4852972	chr2:73916672	C/T	cg20560298	chr2:73613845	ALMS1	0.45	6.14	0.35	3.03e-9	Schizophrenia;
CESC	cis	rs11098499	0.866	rs6824111	chr4:120285968	T/A	cg24375607	chr4:120327624	NA	0.42	5.19	0.3	4.19e-7	Corneal astigmatism;
CESC	cis	rs9611519	0.894	rs4821990	chr22:41438710	A/C	cg03806693	chr22:41940476	POLR3H	-0.55	-5.82	-0.34	1.65e-8	Neuroticism;
CESC	cis	rs7666738	0.830	rs13138920	chr4:99020786	A/G	cg03676636	chr4:99064102	C4orf37	0.33	5.15	0.3	5.05e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs858239	0.601	rs6971002	chr7:23172304	C/G	cg23682824	chr7:23144976	KLHL7	0.55	7.57	0.42	6.22e-13	Cerebrospinal fluid biomarker levels;
CESC	cis	rs56235845	0.964	rs4075958	chr5:176784512	A/G	cg17509989	chr5:176798049	RGS14	-0.75	-8.4	-0.46	2.71e-15	Hemoglobin concentration;Hematocrit;
CESC	cis	rs3820068	0.581	rs72645888	chr1:15929922	C/A	cg13390004	chr1:15929781	NA	0.35	5.58	0.32	5.83e-8	Systolic blood pressure;
CESC	cis	rs7223966	1.000	rs6504170	chr17:61709168	C/T	cg11494091	chr17:61959527	GH2	0.41	5.84	0.34	1.53e-8	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs2836950	0.545	rs2836940	chr21:40588696	T/C	cg11890956	chr21:40555474	PSMG1	-0.61	-8.44	-0.46	2.16e-15	Menarche (age at onset);
CESC	cis	rs4268898	0.931	rs60716082	chr2:24526265	T/A	cg06627628	chr2:24431161	ITSN2	-0.71	-8.6	-0.47	7.33e-16	Asthma;
CESC	cis	rs7618915	0.547	rs2286800	chr3:52778051	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.49	6.97	0.39	2.44e-11	Bipolar disorder;
CESC	cis	rs1801251	0.656	rs10211596	chr2:233699415	C/T	cg08000102	chr2:233561755	GIGYF2	-0.73	-11.94	-0.59	1.42e-26	Coronary artery disease;
CESC	cis	rs853679	0.517	rs9357061	chr6:28051772	A/G	cg20151795	chr6:28129481	ZNF389	0.44	5.59	0.33	5.5e-8	Depression;
CESC	cis	rs9733	0.628	rs72700895	chr1:150626029	C/T	cg18016565	chr1:150552671	MCL1	0.33	5.13	0.3	5.67e-7	Tonsillectomy;
CESC	cis	rs400736	0.896	rs225126	chr1:8090615	A/G	cg25007680	chr1:8021821	PARK7	0.71	10.05	0.53	2.34e-20	Response to antidepressants and depression;
CESC	cis	rs7089973	0.604	rs11196929	chr10:116582080	G/C	cg25233709	chr10:116636983	FAM160B1	0.34	5.31	0.31	2.31e-7	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	trans	rs3780486	0.505	rs7868663	chr9:33141229	A/G	cg20290983	chr6:43655470	MRPS18A	0.76	12.2	0.6	1.82e-27	IgG glycosylation;
CESC	cis	rs2836974	0.568	rs2836969	chr21:40648265	G/A	cg11890956	chr21:40555474	PSMG1	-0.97	-15.94	-0.7	1.46e-40	Cognitive function;
CESC	cis	rs12497850	0.864	rs4279134	chr3:49156676	A/G	cg06212747	chr3:49208901	KLHDC8B	0.74	9.86	0.52	9.48e-20	Parkinson's disease;
CESC	cis	rs4253772	0.550	rs11703564	chr22:46722194	G/A	cg00784671	chr22:46762841	CELSR1	-0.56	-5.69	-0.33	3.35e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs4141404	0.640	rs9606854	chr22:31930567	C/T	cg02404636	chr22:31891804	SFI1	0.44	5.33	0.31	2.13e-7	Paclitaxel-induced neuropathy;
CESC	cis	rs7267979	0.509	rs6115218	chr20:25566485	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.57	8.11	0.45	1.88e-14	Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22762088	chr20:33581493	MYH7B	-0.5	-6.06	-0.35	4.55e-9	Gut microbiome composition (summer);
CESC	trans	rs916888	0.773	rs199451	chr17:44801784	G/A	cg07870213	chr5:140052090	DND1	0.64	6.75	0.38	9.18e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs11031096	0.711	rs10835694	chr11:4178757	G/C	cg18678763	chr11:4115507	RRM1	-0.43	-5.95	-0.34	8.38e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	cis	rs2953174	1.000	rs2953176	chr2:241520754	T/A	cg07929629	chr2:241523174	NA	0.62	5.82	0.34	1.73e-8	Bipolar disorder;
CESC	cis	rs1707322	0.613	rs1473840	chr1:46601197	A/G	cg03146154	chr1:46216737	IPP	-0.61	-7.28	-0.41	3.76e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs4466137	0.830	rs6886695	chr5:82994293	T/A	cg16102102	chr5:83017553	HAPLN1	-0.42	-6.15	-0.35	2.81e-9	Prostate cancer;
CESC	cis	rs12142240	0.698	rs56344958	chr1:46814518	G/A	cg00530320	chr1:46809349	NSUN4	0.58	7.89	0.44	8.17e-14	Menopause (age at onset);
CESC	cis	rs10540	0.558	rs12806062	chr11:501429	G/A	cg03934478	chr11:495069	RNH1	0.56	5.27	0.31	2.88e-7	Body mass index;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22212156	chr20:32031449	SNTA1	0.59	6.71	0.38	1.19e-10	Gut microbiome composition (summer);
CESC	cis	rs1218582	0.772	rs1109815	chr1:154909268	A/G	cg03351412	chr1:154909251	PMVK	0.69	9.15	0.49	1.62e-17	Prostate cancer;
CESC	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.54	6.73	0.38	1.05e-10	Prudent dietary pattern;
CESC	cis	rs12497850	0.966	rs6792510	chr3:48723302	G/C	cg03060546	chr3:49711283	APEH	0.44	5.39	0.31	1.58e-7	Parkinson's disease;
CESC	cis	rs7666738	0.830	rs7657982	chr4:99044015	G/A	cg18180107	chr4:99064573	C4orf37	0.4	5.09	0.3	6.96e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs34375054	0.738	rs10773145	chr12:125625603	C/T	cg25124228	chr12:125621409	AACS	0.6	8.24	0.45	7.8e-15	Post bronchodilator FEV1/FVC ratio;
CESC	trans	rs4709783	0.738	rs9364708	chr6:164309316	A/G	cg26167625	chr4:7770639	AFAP1;LOC84740	0.42	6.0	0.35	6.58e-9	Parental longevity (mother's age at death);
CESC	trans	rs829883	1.000	rs249839	chr12:98872364	T/C	cg04550079	chr16:67212681	KIAA0895L	-0.38	-6.2	-0.36	2.1e-9	Colorectal adenoma (advanced);
CESC	cis	rs780096	0.545	rs2280737	chr2:27589810	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.33	-6.96	-0.39	2.62e-11	Total body bone mineral density;
CESC	cis	rs7819412	0.521	rs11777887	chr8:11036799	C/G	cg21775007	chr8:11205619	TDH	0.39	5.07	0.3	7.32e-7	Triglycerides;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg24058025	chr1:44412156	IPO13	-0.5	-6.09	-0.35	3.95e-9	Ulcerative colitis;
CESC	cis	rs7666738	0.791	rs1559860	chr4:99024422	C/T	cg18180107	chr4:99064573	C4orf37	0.42	5.43	0.32	1.29e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3820068	0.603	rs56032936	chr1:15970953	T/C	cg18133145	chr1:16060689	PLEKHM2	-0.39	-5.04	-0.3	8.81e-7	Systolic blood pressure;
CESC	cis	rs7727544	0.716	rs2089855	chr5:131573529	A/G	cg14196790	chr5:131705035	SLC22A5	0.4	5.68	0.33	3.53e-8	Blood metabolite levels;
CESC	cis	rs11630290	0.592	rs1912049	chr15:64155606	G/T	cg12036633	chr15:63758958	NA	0.45	5.45	0.32	1.13e-7	Iris characteristics;
CESC	cis	rs2404602	0.608	rs12911035	chr15:76606591	T/C	cg26408565	chr15:76604113	ETFA	-0.42	-6.16	-0.35	2.64e-9	Blood metabolite levels;
CESC	cis	rs9858542	1.000	rs9836291	chr3:49697459	G/A	cg03060546	chr3:49711283	APEH	-0.58	-6.9	-0.39	3.87e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs9914544	1.000	rs7223231	chr17:18811846	C/T	cg26378065	chr17:18585709	ZNF286B	0.46	6.03	0.35	5.61e-9	Educational attainment (years of education);
CESC	cis	rs3806843	0.657	rs2563283	chr5:140105978	C/A	cg26395211	chr5:140044315	WDR55	0.47	6.05	0.35	4.82e-9	Depressive symptoms (multi-trait analysis);
CESC	cis	rs2645694	0.626	rs2703143	chr4:77830441	A/G	cg10057126	chr4:77819792	ANKRD56	0.6	8.45	0.46	1.91e-15	Emphysema distribution in smoking;
CESC	cis	rs12765878	1.000	rs35223321	chr10:105646395	C/T	cg24587175	chr10:105670608	OBFC1	0.32	5.22	0.31	3.58e-7	Coronary artery disease;
CESC	cis	rs1178968	1.000	rs4717756	chr7:72765458	C/G	cg25889504	chr7:72793014	NA	-0.47	-5.07	-0.3	7.47e-7	Triglyceride levels;
CESC	cis	rs911555	0.755	rs6575988	chr14:103900827	G/T	cg12935359	chr14:103987150	CKB	0.52	7.62	0.42	4.4e-13	Intelligence (multi-trait analysis);
CESC	cis	rs367615	0.704	rs7726991	chr5:108847434	C/T	cg17395555	chr5:108820864	NA	0.63	11.15	0.57	6.1e-24	Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs9811920	0.609	rs793463	chr3:99620252	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.59	7.22	0.41	5.61e-12	Axial length;
CESC	cis	rs2204008	0.713	rs11173567	chr12:38089375	T/C	cg26384229	chr12:38710491	ALG10B	0.65	8.86	0.48	1.23e-16	Bladder cancer;
CESC	cis	rs704795	0.836	rs1083865	chr2:27620827	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.29	-5.49	-0.32	9.46e-8	Menopause (age at onset);
CESC	cis	rs4563143	0.675	rs73029049	chr19:29275534	C/A	cg12667521	chr19:29218732	NA	0.48	6.4	0.37	6.97e-10	Methadone dose in opioid dependence;
CESC	cis	rs561341	0.883	rs7406056	chr17:30220224	C/T	cg19193384	chr17:30244184	NA	-0.55	-5.82	-0.34	1.65e-8	Hip circumference adjusted for BMI;
CESC	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.59	-7.36	-0.41	2.29e-12	Prudent dietary pattern;
CESC	cis	rs4665809	0.590	rs35746418	chr2:26455002	C/G	cg22920501	chr2:26401640	FAM59B	0.91	10.33	0.54	3.07e-21	Gut microbiome composition (summer);
CESC	cis	rs2243480	1.000	rs1267820	chr7:66050295	C/G	cg12463550	chr7:65579703	CRCP	0.72	5.62	0.33	4.87e-8	Diabetic kidney disease;
CESC	cis	rs3617	0.573	rs9850563	chr3:52912214	G/A	cg11645453	chr3:52864694	ITIH4	-0.28	-5.65	-0.33	4.13e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
CESC	cis	rs1552244	0.882	rs2030564	chr3:10039044	A/G	cg00166722	chr3:10149974	C3orf24	0.48	5.98	0.34	7.12e-9	Alzheimer's disease;
CESC	cis	rs9911578	1.000	rs4398153	chr17:56968181	T/C	cg05425664	chr17:57184151	TRIM37	0.49	6.71	0.38	1.19e-10	Intelligence (multi-trait analysis);
CESC	cis	rs698833	0.710	rs1441048	chr2:44511929	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.43	5.27	0.31	2.8e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs10870270	0.956	rs11146425	chr10:133734261	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.62	-8.06	-0.44	2.63e-14	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs56235845	0.665	rs4976685	chr5:176766177	C/T	cg17509989	chr5:176798049	RGS14	-0.52	-6.89	-0.39	4.16e-11	Hemoglobin concentration;Hematocrit;
CESC	cis	rs113835537	0.597	rs10896129	chr11:66338300	T/C	cg22134325	chr11:66188745	NPAS4	0.37	5.56	0.32	6.61e-8	Airway imaging phenotypes;
CESC	cis	rs6484504	0.600	rs12796587	chr11:31266443	T/C	cg14844989	chr11:31128820	NA	-0.41	-5.82	-0.34	1.73e-8	Red blood cell count;
CESC	cis	rs868036	0.645	rs4776972	chr15:68083436	A/C	cg08079166	chr15:68083412	MAP2K5	0.43	5.88	0.34	1.23e-8	Restless legs syndrome;
CESC	trans	rs916888	0.821	rs199512	chr17:44857352	T/C	cg23590916	chr17:43697445	MGC57346	-0.61	-6.51	-0.37	3.66e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs12497850	0.931	rs9840684	chr3:48893780	T/C	cg02487422	chr3:49467188	NICN1	0.4	5.15	0.3	5.11e-7	Parkinson's disease;
CESC	cis	rs1552244	0.572	rs113406084	chr3:10170190	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.77	8.79	0.48	1.96e-16	Alzheimer's disease;
CESC	cis	rs5750830	0.594	rs9611165	chr22:39775250	A/G	cg24399712	chr22:39784796	NA	-0.77	-11.05	-0.56	1.34e-23	Intelligence (multi-trait analysis);
CESC	cis	rs832540	0.629	rs6888317	chr5:56093307	A/G	cg24531977	chr5:56204891	C5orf35	0.48	5.78	0.33	2.09e-8	Coronary artery disease;
CESC	cis	rs7833790	0.963	rs6473312	chr8:82732515	C/A	cg02079420	chr8:82753780	SNX16	0.57	7.64	0.42	3.93e-13	Diastolic blood pressure;
CESC	cis	rs6060717	0.529	rs6060535	chr20:34235522	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.83	-7.54	-0.42	7.43e-13	Hip circumference adjusted for BMI;
CESC	cis	rs6685188	0.920	rs10751444	chr1:205662144	A/G	cg26354017	chr1:205819088	PM20D1	-0.41	-5.42	-0.32	1.31e-7	White blood cell count (basophil);Basophil percentage of white cells;
CESC	cis	rs6484504	0.553	rs7113880	chr11:31279557	A/G	cg14844989	chr11:31128820	NA	-0.37	-5.25	-0.31	3.12e-7	Red blood cell count;
CESC	cis	rs2836950	0.805	rs2836961	chr21:40627020	A/C	cg11890956	chr21:40555474	PSMG1	-0.62	-7.96	-0.44	4.92e-14	Menarche (age at onset);
CESC	cis	rs2836950	0.565	rs2836931	chr21:40546569	T/G	cg17971929	chr21:40555470	PSMG1	-0.6	-8.02	-0.44	3.31e-14	Menarche (age at onset);
CESC	cis	rs4629180	0.544	rs7595274	chr2:102140086	T/C	cg04415270	chr2:102091202	RFX8	-0.31	-5.36	-0.31	1.81e-7	Chronic rhinosinusitis with nasal polyps;
CESC	cis	rs2576037	0.526	rs2257027	chr18:44566990	A/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.42	-6.98	-0.39	2.33e-11	Personality dimensions;
CESC	cis	rs3213545	0.700	rs2260399	chr12:121469653	C/T	cg15155738	chr12:121454335	C12orf43	0.51	6.23	0.36	1.79e-9	Subjective well-being;Cardiovascular disease risk factors;
CESC	cis	rs4268898	0.529	rs4426488	chr2:24372815	A/G	cg06627628	chr2:24431161	ITSN2	0.6	8.23	0.45	8.28e-15	Asthma;
CESC	cis	rs34779708	0.733	rs7087099	chr10:35541982	C/T	cg03585969	chr10:35415529	CREM	0.56	6.48	0.37	4.34e-10	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs2839186	0.619	rs2187118	chr21:47611310	C/T	cg12516959	chr21:47718080	NA	-0.38	-5.32	-0.31	2.22e-7	Testicular germ cell tumor;
CESC	cis	rs1799949	0.929	rs799906	chr17:41278116	T/C	cg05368731	chr17:41323189	NBR1	0.6	8.36	0.46	3.63e-15	Menopause (age at onset);
CESC	cis	rs72781680	0.566	rs6713979	chr2:23899876	A/G	cg08917208	chr2:24149416	ATAD2B	0.7	6.86	0.39	4.99e-11	Lymphocyte counts;
CESC	cis	rs2777491	0.957	rs8026197	chr15:41711447	C/T	cg02330683	chr15:41787940	ITPKA	0.48	7.12	0.4	1.01e-11	Ulcerative colitis;
CESC	cis	rs8112211	0.834	rs11881305	chr19:38804218	A/G	cg14299480	chr19:38876666	GGN	-0.43	-5.85	-0.34	1.46e-8	Blood protein levels;
CESC	trans	rs1973993	0.903	rs2038646	chr1:96940371	C/G	cg10631902	chr5:14652156	NA	0.5	6.7	0.38	1.28e-10	Weight;
CESC	cis	rs10504229	0.638	rs7826839	chr8:58132075	G/T	cg24829409	chr8:58192753	C8orf71	-0.58	-7.2	-0.4	6.31e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs875971	0.545	rs10950029	chr7:65634321	A/C	cg18876405	chr7:65276391	NA	0.51	5.91	0.34	1.04e-8	Aortic root size;
CESC	cis	rs9788682	0.624	rs518425	chr15:78883813	A/G	cg24631222	chr15:78858424	CHRNA5	0.67	8.24	0.45	7.82e-15	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs12155623	0.619	rs17641604	chr8:49842784	C/T	cg22283653	chr8:49824208	NA	0.36	5.44	0.32	1.19e-7	Sudden cardiac arrest;
CESC	cis	rs9811920	0.609	rs6440938	chr3:99652092	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.59	-7.22	-0.41	5.61e-12	Axial length;
CESC	cis	rs6500395	1.000	rs11641458	chr16:48670845	C/T	cg04672837	chr16:48644449	N4BP1	0.51	6.43	0.37	6.06e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	trans	rs3008706	0.790	rs2987040	chr9:16002275	G/C	cg09705784	chr17:76565232	DNAH17	0.56	6.01	0.35	6.16e-9	Bilirubin levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04386144	chr6:43970475	C6orf223	0.74	8.35	0.46	3.8e-15	Gut microbiome composition (summer);
CESC	cis	rs2439831	0.702	rs2467402	chr15:44024490	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	-0.58	-6.15	-0.35	2.81e-9	Lung cancer in ever smokers;
CESC	cis	rs2404602	0.647	rs11631959	chr15:77040048	T/C	cg23625390	chr15:77176239	SCAPER	-0.47	-6.52	-0.37	3.54e-10	Blood metabolite levels;
CESC	cis	rs2625529	0.617	rs2929509	chr15:72239272	T/C	cg16672083	chr15:72433130	SENP8	0.4	6.04	0.35	5.3300000000000004e-09	Red blood cell count;
CESC	cis	rs2635047	0.530	rs4986228	chr18:44595259	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.45	5.81	0.34	1.82e-8	Educational attainment;
CESC	cis	rs9309473	0.500	rs2421664	chr2:73858881	C/T	cg20560298	chr2:73613845	ALMS1	0.49	6.88	0.39	4.43e-11	Metabolite levels;
CESC	cis	rs17376456	0.877	rs10050465	chr5:93349963	C/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.61	5.2	0.3	3.97e-7	Diabetic retinopathy;
CESC	cis	rs7552404	1.000	rs72686191	chr1:76218319	G/T	cg22875332	chr1:76189707	ACADM	0.59	6.78	0.38	7.6e-11	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs763121	0.853	rs5750627	chr22:38982321	A/G	cg06544989	chr22:39130855	UNC84B	0.5	9.13	0.49	1.8e-17	Menopause (age at onset);
CESC	trans	rs35110281	0.782	rs1584917	chr21:45042365	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.52	6.87	0.39	4.49e-11	Mean corpuscular volume;
CESC	cis	rs698813	0.604	rs10865200	chr2:44482884	G/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.49	5.59	0.32	5.78e-8	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
CESC	cis	rs425277	0.539	rs3128337	chr1:2045882	A/G	cg04315214	chr1:2043799	PRKCZ	0.64	11.39	0.57	9.85e-25	Height;
CESC	cis	rs3026101	0.671	rs3944127	chr17:5297766	C/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.43	5.68	0.33	3.57e-8	Body mass index;
CESC	cis	rs12973672	1.000	rs2280747	chr19:35770064	C/T	cg12095397	chr19:35769544	USF2	0.54	7.35	0.41	2.49e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs916888	0.610	rs199452	chr17:44801340	C/T	cg17911788	chr17:44343683	NA	-0.44	-7.03	-0.4	1.77e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs1580019	0.568	rs2122633	chr7:32523870	G/T	cg07520158	chr7:32535189	LSM5;AVL9	0.52	6.41	0.37	6.82e-10	Cognitive ability;
CESC	cis	rs10504229	1.000	rs73607871	chr8:58173007	T/C	cg14926445	chr8:58193284	C8orf71	-0.51	-5.47	-0.32	1.03e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs6500602	0.673	rs4786513	chr16:4576423	T/C	cg08645402	chr16:4508243	NA	0.39	6.03	0.35	5.36e-9	Schizophrenia;
CESC	cis	rs12530845	0.673	rs4073627	chr7:135312572	A/G	cg23117316	chr7:135346802	PL-5283	0.52	6.16	0.35	2.68e-9	Red blood cell traits;
CESC	cis	rs2832077	0.527	rs2738953	chr21:30238363	G/C	cg08807101	chr21:30365312	RNF160	0.53	6.54	0.37	3.13e-10	Cognitive test performance;
CESC	cis	rs2243480	1.000	rs58669269	chr7:65951953	T/C	cg13147721	chr7:65941812	NA	-0.94	-8.74	-0.47	2.71e-16	Diabetic kidney disease;
CESC	cis	rs6570726	0.935	rs12663204	chr6:145818373	G/A	cg23711669	chr6:146136114	FBXO30	0.81	12.04	0.59	6.44e-27	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs916888	0.610	rs199446	chr17:44813169	G/A	cg17911788	chr17:44343683	NA	0.43	6.87	0.39	4.55e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg07113549	chr3:98312651	CPOX	-0.42	-6.05	-0.35	4.93e-9	Gambling;
CESC	cis	rs2228479	0.717	rs1800358	chr16:89809319	T/C	cg27121462	chr16:89883253	FANCA	0.63	5.51	0.32	8.36e-8	Skin colour saturation;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21300382	chr19:13248092	NACC1	-0.55	-6.29	-0.36	1.29e-9	Gut microbiome composition (summer);
CESC	cis	rs2439831	0.571	rs689883	chr15:43812596	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.8	8.57	0.47	8.59e-16	Lung cancer in ever smokers;
CESC	cis	rs10504229	0.683	rs66893068	chr8:58144238	A/G	cg22535103	chr8:58192502	C8orf71	-0.76	-8.74	-0.47	2.65e-16	Developmental language disorder (linguistic errors);
CESC	cis	rs12425451	0.552	rs10848765	chr12:3141495	C/T	cg05389053	chr12:3131226	TEAD4	0.52	6.17	0.35	2.48e-9	Narcolepsy with cataplexy;
CESC	cis	rs40363	0.723	rs8060367	chr16:3537919	C/A	cg05754148	chr16:3507555	NAT15	-0.63	-6.18	-0.35	2.46e-9	Tuberculosis;
CESC	cis	rs7618915	0.571	rs34115864	chr3:52612178	A/G	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	5.71	0.33	2.98e-8	Bipolar disorder;
CESC	cis	rs7474896	0.515	rs624359	chr10:38299132	T/C	cg00409905	chr10:38381863	ZNF37A	0.46	5.15	0.3	5.06e-7	Obesity (extreme);
CESC	cis	rs761746	0.960	rs5753734	chr22:32028721	A/C	cg25791279	chr22:32026902	PISD	0.55	6.66	0.38	1.55e-10	Intelligence;
CESC	cis	rs60154123	0.730	rs689248	chr1:210463122	A/G	cg25204440	chr1:209979598	IRF6	-0.47	-5.27	-0.31	2.87e-7	Coronary artery disease;
CESC	cis	rs11122272	0.735	rs2486737	chr1:231520523	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.57	-7.82	-0.43	1.29e-13	Hemoglobin concentration;
CESC	cis	rs7605827	0.930	rs11903302	chr2:15706286	C/T	cg19274914	chr2:15703543	NA	0.34	5.96	0.34	8.13e-9	Educational attainment (years of education);
CESC	cis	rs4665809	1.000	rs4665809	chr2:26251361	C/T	cg08470875	chr2:26401718	FAM59B	0.47	5.1	0.3	6.57e-7	Gut microbiome composition (summer);
CESC	cis	rs7662987	0.517	rs1377689	chr4:100021787	A/G	cg13256891	chr4:100009986	ADH5	0.75	8.03	0.44	3.21e-14	Smoking initiation;
CESC	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg24101359	chr6:42928495	GNMT	0.56	7.93	0.44	6.17e-14	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs2635047	0.625	rs1836259	chr18:44732389	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.4	5.42	0.32	1.31e-7	Educational attainment;
CESC	cis	rs34734847	0.766	rs3794214	chr12:121168245	C/T	cg26008908	chr12:120799332	MSI1	-0.33	-5.19	-0.3	4.21e-7	Mean corpuscular volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25428156	chr4:119556601	NA	-0.58	-8.42	-0.46	2.42e-15	Gut microbiome composition (summer);
CESC	cis	rs8170	0.603	rs11086068	chr19:17420165	T/C	cg04749549	chr19:17459798	NA	-0.34	-5.56	-0.32	6.61e-8	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
CESC	cis	rs9543976	0.623	rs7139740	chr13:76166942	C/T	cg01531495	chr13:76123901	UCHL3	0.5	5.03	0.3	9.04e-7	Diabetic retinopathy;
CESC	cis	rs67311347	0.955	rs6782746	chr3:40510592	A/G	cg01475735	chr3:40494733	NA	0.41	5.17	0.3	4.71e-7	Renal cell carcinoma;
CESC	cis	rs1153858	1.000	rs8032904	chr15:45651309	C/T	cg21132104	chr15:45694354	SPATA5L1	0.85	11.57	0.58	2.4e-25	Homoarginine levels;
CESC	trans	rs1814175	0.533	rs4528310	chr11:49983106	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.43	-6.24	-0.36	1.75e-9	Height;
CESC	cis	rs2066819	1.000	rs744051	chr12:56667298	C/T	cg26734620	chr12:56694298	CS	-1.0	-6.49	-0.37	4.12e-10	Psoriasis vulgaris;
CESC	cis	rs7044106	1.000	rs7044106	chr9:123494062	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.72	8.55	0.46	1.02e-15	Hip circumference adjusted for BMI;
CESC	cis	rs9612	0.718	rs346532	chr19:44248878	A/G	cg08581076	chr19:44259116	C19orf61	0.46	5.56	0.32	6.54e-8	Exhaled nitric oxide output;
CESC	cis	rs1799949	0.965	rs799917	chr17:41244936	G/A	cg23758822	chr17:41437982	NA	0.97	17.29	0.73	2.39e-45	Menopause (age at onset);
CESC	cis	rs832540	0.931	rs2591960	chr5:56238811	A/T	cg24531977	chr5:56204891	C5orf35	0.57	6.87	0.39	4.44e-11	Coronary artery disease;
CESC	cis	rs1267303	0.642	rs1267301	chr1:46992853	C/G	cg25110126	chr1:46999211	NA	-1.04	-10.98	-0.56	2.23e-23	Monobrow;
CESC	cis	rs72781680	0.756	rs2712059	chr2:24020539	T/C	cg08917208	chr2:24149416	ATAD2B	0.61	5.99	0.35	6.76e-9	Lymphocyte counts;
CESC	cis	rs3096299	0.702	rs2086825	chr16:89471542	C/T	cg00750074	chr16:89608354	SPG7	-0.39	-5.36	-0.31	1.81e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs17711722	0.522	rs6957759	chr7:65271785	A/G	cg18876405	chr7:65276391	NA	0.48	6.48	0.37	4.51e-10	Calcium levels;
CESC	trans	rs11039798	1.000	rs11039904	chr11:48682597	T/A	cg15704280	chr7:45808275	SEPT13	0.7	6.38	0.36	7.68e-10	Axial length;
CESC	cis	rs3749237	0.555	rs7637665	chr3:49552295	T/C	cg03060546	chr3:49711283	APEH	0.76	11.62	0.58	1.73e-25	Resting heart rate;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17709466	chr12:56618184	OBFC2B	0.61	6.31	0.36	1.16e-9	Gut microbiome composition (summer);
CESC	cis	rs7918232	1.000	rs6482595	chr10:27380261	A/G	cg14442939	chr10:27389572	ANKRD26	-0.57	-6.03	-0.35	5.51e-9	Breast cancer;
CESC	cis	rs9403521	1.000	rs116980222	chr6:143998987	C/T	cg18240653	chr6:144019428	PHACTR2	-0.48	-5.36	-0.31	1.81e-7	Obesity-related traits;
CESC	cis	rs9926296	0.744	rs154656	chr16:89708003	T/A	cg27121462	chr16:89883253	FANCA	-0.44	-5.31	-0.31	2.37e-7	Vitiligo;
CESC	cis	rs250677	1.000	rs36080	chr5:148430451	A/G	cg18129178	chr5:148520854	ABLIM3	-0.48	-5.56	-0.32	6.72e-8	Breast cancer;
CESC	cis	rs561341	1.000	rs550264	chr17:30317540	G/T	cg12193833	chr17:30244370	NA	-0.72	-6.64	-0.38	1.78e-10	Hip circumference adjusted for BMI;
CESC	cis	rs7618915	0.547	rs13085895	chr3:52678270	G/C	cg17372223	chr3:52568218	NT5DC2	0.43	6.51	0.37	3.76e-10	Bipolar disorder;
CESC	cis	rs17854409	0.764	rs8116995	chr20:61475824	A/G	cg07645718	chr20:61493192	TCFL5	0.79	5.68	0.33	3.48e-8	Obesity-related traits;
CESC	cis	rs34779708	0.766	rs7897088	chr10:35551567	G/T	cg03585969	chr10:35415529	CREM	0.54	6.14	0.35	2.99e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs17401966	0.964	rs34215045	chr1:10361679	G/A	cg15208524	chr1:10270712	KIF1B	0.51	6.55	0.37	2.91e-10	Hepatocellular carcinoma;
CESC	cis	rs926938	0.841	rs11588144	chr1:115239355	G/A	cg12756093	chr1:115239321	AMPD1	-0.72	-11.49	-0.58	4.71e-25	Autism;
CESC	cis	rs34779708	0.733	rs4444023	chr10:35548354	G/A	cg03585969	chr10:35415529	CREM	0.55	6.37	0.36	8.28e-10	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs4975709	0.589	rs4975745	chr5:1861058	G/C	cg12288994	chr5:1860383	NA	0.43	7.13	0.4	9.62e-12	Cardiovascular disease risk factors;
CESC	cis	rs6831352	0.819	rs2851274	chr4:100025866	G/C	cg12011299	chr4:100065546	ADH4	0.65	8.28	0.45	6.2e-15	Alcohol dependence;
CESC	cis	rs9322193	0.962	rs4870048	chr6:150155460	A/G	cg07701084	chr6:150067640	NUP43	0.4	5.26	0.31	2.97e-7	Lung cancer;
CESC	cis	rs6597981	0.592	rs10902218	chr11:743813	C/T	cg01741372	chr11:783889	NA	-0.55	-8.24	-0.45	8.17e-15	Breast cancer;
CESC	cis	rs7927771	1.000	rs12787330	chr11:47812311	C/T	cg18512352	chr11:47633146	NA	-0.6	-9.57	-0.51	8.16e-19	Subjective well-being;
CESC	trans	rs9467711	0.606	rs9379900	chr6:26603811	A/C	cg01620082	chr3:125678407	NA	-0.64	-6.33	-0.36	1.03e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs4704187	0.663	rs56012051	chr5:74551828	A/G	cg03227963	chr5:74354835	NA	0.29	5.43	0.32	1.27e-7	Response to amphetamines;
CESC	cis	rs7666738	0.822	rs28512427	chr4:98919029	G/A	cg03467027	chr4:99064603	C4orf37	0.44	5.32	0.31	2.18e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs1814175	0.619	rs10769623	chr11:49865926	C/T	cg03929089	chr4:120376271	NA	-0.88	-14.39	-0.66	4.31e-35	Height;
CESC	cis	rs17253792	0.822	rs12100753	chr14:56042870	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.8	5.93	0.34	9.48e-9	Putamen volume;
CESC	cis	rs250677	1.000	rs36082	chr5:148428844	C/G	cg18129178	chr5:148520854	ABLIM3	-0.5	-5.43	-0.32	1.3e-7	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18568647	chr15:90174826	KIF7	-0.66	-8.05	-0.44	2.76e-14	Gut microbiome composition (summer);
CESC	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg03452623	chr4:187889614	NA	-0.89	-14.8	-0.67	1.53e-36	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7727544	0.684	rs2516788	chr5:131715565	G/C	cg07395648	chr5:131743802	NA	0.45	5.93	0.34	9.66e-9	Blood metabolite levels;
CESC	cis	rs2191566	0.691	rs56182773	chr19:44588325	G/T	cg20607764	chr19:44506953	ZNF230	-0.4	-5.31	-0.31	2.28e-7	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs7666738	0.606	rs10006454	chr4:99080361	G/A	cg05340658	chr4:99064831	C4orf37	0.65	8.94	0.48	6.63e-17	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2239547	0.657	rs4687672	chr3:52880543	G/A	cg11645453	chr3:52864694	ITIH4	0.33	6.12	0.35	3.3e-9	Schizophrenia;
CESC	cis	rs763014	0.931	rs10903017	chr16:627920	T/C	cg00802000	chr16:706648	WDR90	-0.42	-6.36	-0.36	8.74e-10	Height;
CESC	cis	rs8060686	0.516	rs7187202	chr16:68273895	T/C	cg26727032	chr16:67993705	SLC12A4	-0.53	-7.01	-0.4	2.01e-11	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs12681288	0.676	rs2701913	chr8:999982	A/T	cg04851639	chr8:1020857	NA	-0.32	-6.79	-0.38	7.37e-11	Schizophrenia;
CESC	cis	rs4268898	0.552	rs35331966	chr2:24367828	C/T	cg06627628	chr2:24431161	ITSN2	0.59	8.19	0.45	1.15e-14	Asthma;
CESC	cis	rs8111998	0.826	rs4932777	chr19:22766764	C/T	cg19914732	chr19:22715077	NA	-0.37	-5.18	-0.3	4.45e-7	Corneal structure;
CESC	cis	rs6502050	0.835	rs9904520	chr17:80100117	T/C	cg11859384	chr17:80120422	CCDC57	-0.38	-5.11	-0.3	6.21e-7	Life satisfaction;
CESC	cis	rs2440129	0.611	rs1126667	chr17:6902760	C/T	cg25987502	chr17:6899865	ALOX12	-0.41	-6.66	-0.38	1.55e-10	Tonsillectomy;
CESC	cis	rs858239	0.669	rs1990365	chr7:23115966	T/C	cg27449745	chr7:23145252	KLHL7	-0.49	-6.39	-0.37	7.54e-10	Cerebrospinal fluid biomarker levels;
CESC	cis	rs2274273	0.686	rs11624679	chr14:55624244	G/A	cg04306507	chr14:55594613	LGALS3	0.31	5.26	0.31	2.99e-7	Protein biomarker;
CESC	cis	rs854765	1.000	rs854765	chr17:18012730	T/C	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.46	-5.6	-0.33	5.44e-8	Total body bone mineral density;
CESC	cis	rs10927875	0.722	rs945425	chr1:16348412	T/C	cg21385522	chr1:16154831	NA	0.59	6.95	0.39	2.89e-11	Dilated cardiomyopathy;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg26947572	chr2:10442852	HPCAL1	-0.45	-6.11	-0.35	3.48e-9	Fibrinogen levels;
CESC	cis	rs1799949	0.965	rs7223952	chr17:41194885	T/C	cg25072359	chr17:41440525	NA	0.51	7.39	0.41	1.91e-12	Menopause (age at onset);
CESC	cis	rs1552244	1.000	rs67006488	chr3:10152993	T/C	cg00166722	chr3:10149974	C3orf24	0.47	6.05	0.35	4.96e-9	Alzheimer's disease;
CESC	cis	rs4853012	0.838	rs6715351	chr2:74346119	G/A	cg01017244	chr2:74357527	NA	0.71	10.57	0.54	4.91e-22	Gestational age at birth (maternal effect);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg10717766	chr19:5134118	KDM4B	0.45	6.23	0.36	1.78e-9	Fibrinogen levels;
CESC	cis	rs763121	0.853	rs5750662	chr22:39072472	G/A	cg06544989	chr22:39130855	UNC84B	0.5	8.88	0.48	1.05e-16	Menopause (age at onset);
CESC	trans	rs8073060	0.586	rs6505485	chr17:33996102	C/T	cg19694781	chr19:47549865	TMEM160	-0.74	-6.49	-0.37	4.23e-10	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	cis	rs10791097	0.694	rs10791103	chr11:130757161	G/A	cg09137382	chr11:130731461	NA	0.37	5.58	0.32	6.01e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs8141529	0.636	rs5762799	chr22:29187380	G/T	cg15103426	chr22:29168792	CCDC117	0.48	5.11	0.3	6.09e-7	Lymphocyte counts;
CESC	cis	rs9916302	0.904	rs1966916	chr17:37425238	T/G	cg15445000	chr17:37608096	MED1	0.4	6.45	0.37	5.35e-10	Glomerular filtration rate (creatinine);
CESC	trans	rs453301	0.624	rs330056	chr8:9089695	A/T	cg15556689	chr8:8085844	FLJ10661	-0.53	-6.6	-0.38	2.25e-10	Joint mobility (Beighton score);
CESC	trans	rs10242455	0.571	rs45527841	chr7:99310965	C/T	cg09045935	chr12:6379348	NA	0.76	6.38	0.36	7.87e-10	Blood metabolite levels;
CESC	cis	rs763121	0.853	rs10135	chr22:39082174	C/T	cg21395723	chr22:39101663	GTPBP1	-0.48	-6.44	-0.37	5.45e-10	Menopause (age at onset);
CESC	cis	rs1538970	0.781	rs12049503	chr1:46021556	G/T	cg06784218	chr1:46089804	CCDC17	0.37	5.83	0.34	1.61e-8	Platelet count;
CESC	cis	rs2070677	0.597	rs1410898	chr10:135295455	G/T	cg20169779	chr10:135381914	SYCE1	0.42	5.4	0.32	1.46e-7	Gout;
CESC	cis	rs2204008	0.683	rs7305703	chr12:38138381	T/C	cg13010199	chr12:38710504	ALG10B	0.49	5.99	0.35	6.72e-9	Bladder cancer;
CESC	cis	rs4919694	1.000	rs77969925	chr10:104649357	C/T	cg04362960	chr10:104952993	NT5C2	0.74	6.45	0.37	5.32e-10	Arsenic metabolism;
CESC	cis	rs1062177	1.000	rs2964571	chr5:151171256	C/T	cg00977110	chr5:151150581	G3BP1	0.66	7.11	0.4	1.06e-11	Preschool internalizing problems;
CESC	cis	rs2228479	0.681	rs10153055	chr16:89965842	C/T	cg04013166	chr16:89971882	TCF25	0.71	8.56	0.47	9.33e-16	Skin colour saturation;
CESC	cis	rs9611565	0.918	rs73176685	chr22:41781094	C/G	cg03806693	chr22:41940476	POLR3H	-0.99	-11.88	-0.59	2.25e-26	Vitiligo;
CESC	cis	rs854765	0.547	rs9896837	chr17:17924868	A/G	cg04398451	chr17:18023971	MYO15A	-0.67	-9.46	-0.5	1.75e-18	Total body bone mineral density;
CESC	cis	rs12618769	0.597	rs1587835	chr2:99041269	A/C	cg10123293	chr2:99228465	UNC50	0.39	5.1	0.3	6.52e-7	Bipolar disorder;
CESC	cis	rs4523957	0.855	rs9896535	chr17:2133205	C/T	cg16513277	chr17:2031491	SMG6	-0.63	-8.99	-0.48	4.73e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs1451375	0.572	rs896309	chr7:50545022	A/G	cg14593290	chr7:50529359	DDC	-0.54	-6.6	-0.38	2.25e-10	Malaria;
CESC	cis	rs1707322	0.686	rs2050376	chr1:46078630	C/T	cg05343316	chr1:45956843	TESK2	0.5	6.13	0.35	3.17e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs1008375	0.900	rs12650220	chr4:17595365	A/T	cg02297831	chr4:17616191	MED28	0.46	5.72	0.33	2.82e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs6685188	0.920	rs6676110	chr1:205662977	G/A	cg07157834	chr1:205819609	PM20D1	-0.41	-5.51	-0.32	8.62e-8	White blood cell count (basophil);Basophil percentage of white cells;
CESC	cis	rs6951245	0.832	rs79808627	chr7:1092519	C/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.52	-5.85	-0.34	1.41e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs898097	0.578	rs6502021	chr17:80907728	T/C	cg15369054	chr17:80825471	TBCD	-0.37	-5.42	-0.32	1.34e-7	Breast cancer;
CESC	cis	rs853679	0.546	rs17695758	chr6:27837183	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.75	-5.22	-0.31	3.68e-7	Depression;
CESC	cis	rs1448094	0.511	rs2405623	chr12:86153466	G/A	cg02569458	chr12:86230093	RASSF9	-0.42	-6.46	-0.37	4.89e-10	Major depressive disorder;
CESC	cis	rs4523957	0.614	rs1563966	chr17:2095954	A/G	cg16513277	chr17:2031491	SMG6	0.56	7.34	0.41	2.68e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs7246657	0.943	rs7253091	chr19:37967214	C/T	cg23950597	chr19:37808831	NA	-0.57	-6.22	-0.36	1.96e-9	Coronary artery calcification;
CESC	cis	rs11958404	0.932	rs72816550	chr5:157418457	A/T	cg05962755	chr5:157440814	NA	0.58	6.53	0.37	3.31e-10	IgG glycosylation;
CESC	cis	rs853679	0.517	rs6932109	chr6:28078303	A/G	cg19592336	chr6:28129416	ZNF389	-0.63	-8.8	-0.48	1.82e-16	Depression;
CESC	cis	rs7914558	0.869	rs10883842	chr10:104941589	C/T	cg15744005	chr10:104629667	AS3MT	-0.31	-5.04	-0.3	8.72e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs737337	0.623	rs4804154	chr19:11334179	C/T	cg00586551	chr19:11347513	LOC55908;DOCK6	0.54	5.66	0.33	4.02e-8	HDL cholesterol;HDL cholesterol levels;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg11891431	chr5:178209272	NA	-0.38	-6.0	-0.35	6.55e-9	Systemic lupus erythematosus;
CESC	cis	rs780096	0.546	rs2293572	chr2:27728777	C/G	cg12648201	chr2:27665141	KRTCAP3	0.3	5.32	0.31	2.19e-7	Total body bone mineral density;
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg14172412	chr1:87797008	LMO4	-0.44	-6.58	-0.37	2.54e-10	Vertical cup-disc ratio;
CESC	cis	rs1862618	0.671	rs2591956	chr5:56244604	G/A	cg24531977	chr5:56204891	C5orf35	0.69	9.25	0.49	8.04e-18	Initial pursuit acceleration;
CESC	cis	rs941408	0.515	rs1005556	chr19:2778543	G/T	cg00079169	chr19:2811669	THOP1	0.39	5.44	0.32	1.19e-7	Total cholesterol levels;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg26583560	chr16:896768	NA	0.37	6.04	0.35	5.1e-9	Fibrinogen levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22233523	chr18:44497604	PIAS2	0.66	7.78	0.43	1.59e-13	Gut microbiome composition (summer);
CESC	cis	rs6933660	0.800	rs963193	chr6:151789355	G/T	cg02564969	chr6:151773285	C6orf211;RMND1	-0.61	-8.46	-0.46	1.83e-15	Menarche (age at onset);
CESC	cis	rs10752881	1.000	rs12133714	chr1:182988252	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.84	13.3	0.63	2.79e-31	Colorectal cancer;
CESC	cis	rs751837	0.518	rs17101146	chr14:103463599	A/G	cg10087771	chr14:103399429	CDC42BPB	-0.59	-5.42	-0.32	1.35e-7	Large B-cell lymphoma;
CESC	cis	rs2228479	0.850	rs12596934	chr16:89841605	T/G	cg14709524	chr16:89940631	TCF25	0.91	6.74	0.38	1e-10	Skin colour saturation;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14477673	chr9:6835001	KDM4C	-0.59	-6.75	-0.38	9.23e-11	Gut microbiome composition (summer);
CESC	cis	rs6860806	0.531	rs270607	chr5:131649186	A/G	cg24060327	chr5:131705240	SLC22A5	-0.73	-10.13	-0.53	1.36e-20	Breast cancer;
CESC	cis	rs6088590	0.901	rs6087631	chr20:33403509	T/C	cg24642439	chr20:33292090	TP53INP2	0.84	11.74	0.58	6.85e-26	Coronary artery disease;
CESC	cis	rs826838	1.000	rs10875717	chr12:38911174	T/C	cg26384229	chr12:38710491	ALG10B	0.82	14.52	0.67	1.49e-35	Heart rate;
CESC	trans	rs877282	0.682	rs2265092	chr10:780293	C/T	cg22713356	chr15:30763199	NA	-0.55	-6.02	-0.35	5.89e-9	Uric acid levels;
CESC	cis	rs2637266	0.967	rs12246605	chr10:78352994	G/A	cg18941641	chr10:78392320	NA	0.42	7.79	0.43	1.49e-13	Pulmonary function;
CESC	trans	rs35110281	0.774	rs141521	chr21:44963686	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.48	6.37	0.36	8.35e-10	Mean corpuscular volume;
CESC	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg10150615	chr22:24372951	LOC391322	-0.49	-6.29	-0.36	1.32e-9	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs7666738	0.830	rs10021044	chr4:99002488	A/T	cg03467027	chr4:99064603	C4orf37	0.44	5.51	0.32	8.65e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9399135	0.967	rs7750300	chr6:135350950	C/G	cg22676075	chr6:135203613	NA	0.5	7.12	0.4	1.04e-11	Red blood cell count;
CESC	cis	rs6546537	0.550	rs4241252	chr2:69777065	C/A	cg10773587	chr2:69614142	GFPT1	-0.44	-5.73	-0.33	2.74e-8	Serum thyroid-stimulating hormone levels;
CESC	cis	rs2276314	0.947	rs3898595	chr18:33565885	T/A	cg19628046	chr18:33552617	C18orf21	0.55	6.03	0.35	5.49e-9	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs7772486	0.686	rs9497395	chr6:146013592	A/G	cg23711669	chr6:146136114	FBXO30	-0.89	-12.51	-0.61	1.62e-28	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs80130819	0.688	rs10783233	chr12:48590899	C/G	cg07561017	chr12:48398056	COL2A1	0.39	5.29	0.31	2.62e-7	Prostate cancer;
CESC	cis	rs12701220	0.522	rs868833	chr7:1054973	C/G	cg04025307	chr7:1156635	C7orf50	0.37	5.57	0.32	6.18e-8	Bronchopulmonary dysplasia;
CESC	cis	rs344364	0.511	rs1742468	chr16:1950243	C/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.55	-6.2	-0.36	2.15e-9	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	10.16	0.53	1.09e-20	Prudent dietary pattern;
CESC	cis	rs6500602	0.893	rs6500598	chr16:4470964	G/T	cg08645402	chr16:4508243	NA	0.37	5.25	0.31	3.17e-7	Schizophrenia;
CESC	cis	rs10883723	0.810	rs10883728	chr10:104269301	A/G	cg22532475	chr10:104410764	TRIM8	0.34	5.74	0.33	2.62e-8	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs4268898	0.662	rs9784114	chr2:24437517	C/T	cg20701182	chr2:24300061	SF3B14	0.68	7.16	0.4	7.75e-12	Asthma;
CESC	cis	rs116095464	0.558	rs10036253	chr5:238519	A/C	cg22857025	chr5:266934	NA	-1.29	-18.85	-0.76	7.29e-51	Breast cancer;
CESC	cis	rs796364	0.951	rs7565005	chr2:201013277	A/G	cg23649088	chr2:200775458	C2orf69	-0.58	-5.92	-0.34	9.75e-9	Schizophrenia;
CESC	cis	rs7212590	0.618	rs56142307	chr17:57878149	A/G	cg20303301	chr17:57937339	TUBD1	-0.54	-5.22	-0.31	3.66e-7	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg14183313	chr9:130007677	NA	-0.46	-6.12	-0.35	3.28e-9	Fibrinogen levels;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg02904235	chr14:91527369	RPS6KA5	-0.55	-6.88	-0.39	4.43e-11	Asthma;
CESC	cis	rs5753618	0.555	rs5749291	chr22:31907523	C/G	cg13145458	chr22:31556086	RNF185	-0.48	-5.68	-0.33	3.51e-8	Colorectal cancer;
CESC	cis	rs6540559	0.611	rs926347	chr1:209965193	T/C	cg22029157	chr1:209979665	IRF6	0.77	8.52	0.46	1.23e-15	Cleft lip with or without cleft palate;
CESC	cis	rs2730245	0.510	rs2788471	chr7:158649786	G/T	cg24397884	chr7:158709396	WDR60	0.68	9.86	0.52	1e-19	Height;
CESC	cis	rs780096	1.000	rs780096	chr2:27741072	C/G	cg21248554	chr2:27665150	KRTCAP3	-0.26	-5.1	-0.3	6.52e-7	Total body bone mineral density;
CESC	cis	rs9488822	0.676	rs873879	chr6:116391259	A/G	cg26893134	chr6:116381904	FRK	0.25	6.24	0.36	1.71e-9	Cholesterol, total;LDL cholesterol;
CESC	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	10.4	0.54	1.84e-21	Prudent dietary pattern;
CESC	cis	rs4253772	0.637	rs8135997	chr22:46651366	G/A	cg09491104	chr22:46646882	C22orf40	-0.59	-9.15	-0.49	1.58e-17	LDL cholesterol;Cholesterol, total;
CESC	cis	rs4665809	1.000	rs2289022	chr2:26350136	G/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.67	-7.53	-0.42	7.92e-13	Gut microbiome composition (summer);
CESC	cis	rs9768139	0.634	rs56389048	chr7:158121368	T/A	cg25566285	chr7:158114605	PTPRN2	0.5	8.19	0.45	1.11e-14	Calcium levels;
CESC	cis	rs853679	0.517	rs9468292	chr6:28095355	G/A	cg17949981	chr6:28129498	ZNF389	0.44	5.58	0.32	5.97e-8	Depression;
CESC	cis	rs1218582	0.628	rs12130132	chr1:154880386	C/T	cg09359103	chr1:154839909	KCNN3	-0.56	-9.62	-0.51	5.59e-19	Prostate cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14093526	chr11:134094620	VPS26B;NCAPD3	0.53	6.52	0.37	3.6e-10	Gut microbiome composition (summer);
CESC	cis	rs56046484	0.956	rs35045545	chr15:85664951	A/G	cg08123816	chr15:85640762	PDE8A	-0.5	-6.19	-0.36	2.23e-9	Testicular germ cell tumor;
CESC	cis	rs3733585	0.673	rs9993410	chr4:9951264	C/T	cg11266682	chr4:10021025	SLC2A9	-0.59	-11.11	-0.56	8.58e-24	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs9660180	1.000	rs9660180	chr1:1723031	G/A	cg23982607	chr1:1823379	GNB1	-0.76	-12.19	-0.6	2.02e-27	Body mass index;
CESC	cis	rs9486715	1.000	rs9486715	chr6:97059769	A/C	cg18709589	chr6:96969512	KIAA0776	-0.46	-6.4	-0.37	6.94e-10	Headache;
CESC	cis	rs12497850	0.864	rs4521268	chr3:49137904	G/T	cg07636037	chr3:49044803	WDR6	1.05	18.71	0.75	2.36e-50	Parkinson's disease;
CESC	cis	rs7811142	0.779	rs111312383	chr7:99905325	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.14	10.97	0.56	2.56e-23	Platelet count;
CESC	cis	rs4566357	0.595	rs6707286	chr2:227911400	A/G	cg11843606	chr2:227700838	RHBDD1	-0.47	-6.49	-0.37	4.32e-10	Coronary artery disease;
CESC	cis	rs6732160	0.624	rs10865397	chr2:73358292	C/T	cg01422370	chr2:73384389	NA	0.33	5.45	0.32	1.16e-7	Intelligence (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03632145	chr6:24403130	MRS2	0.57	6.38	0.36	7.78e-10	Gut microbiome composition (summer);
CESC	cis	rs9309473	0.519	rs1815027	chr2:73831840	T/C	cg20560298	chr2:73613845	ALMS1	0.49	7.07	0.4	1.39e-11	Metabolite levels;
CESC	cis	rs6456156	0.792	rs2039321	chr6:167516299	C/T	cg07741184	chr6:167504864	NA	0.36	6.39	0.37	7.38e-10	Primary biliary cholangitis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09284707	chr11:107799080	RAB39	0.46	6.59	0.38	2.41e-10	Gut microbiome composition (summer);
CESC	cis	rs7618915	0.547	rs4687548	chr3:52666650	A/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.5	0.37	3.95e-10	Bipolar disorder;
CESC	cis	rs7666738	0.800	rs2865987	chr4:99067852	A/C	cg17366294	chr4:99064904	C4orf37	0.62	8.54	0.46	1.04e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7560272	0.723	rs6744697	chr2:73765438	T/C	cg20560298	chr2:73613845	ALMS1	-0.49	-6.92	-0.39	3.47e-11	Schizophrenia;
CESC	cis	rs853679	0.517	rs4713137	chr6:28083521	C/G	cg12963246	chr6:28129442	ZNF389	0.56	7.63	0.42	4.26e-13	Depression;
CESC	cis	rs6545883	1.000	rs778763	chr2:61785639	C/G	cg15711740	chr2:61764176	XPO1	-0.43	-5.2	-0.3	3.98e-7	Tuberculosis;
CESC	cis	rs9916302	0.784	rs4795382	chr17:37700860	A/G	cg07936489	chr17:37558343	FBXL20	-0.8	-11.62	-0.58	1.73e-25	Glomerular filtration rate (creatinine);
CESC	cis	rs898097	0.585	rs9892342	chr17:80893029	C/T	cg19046167	chr17:80928561	B3GNTL1	0.39	5.26	0.31	2.93e-7	Breast cancer;
CESC	cis	rs56399783	0.614	rs55776032	chr7:2762255	T/C	cg19731401	chr7:2775893	GNA12	0.63	5.33	0.31	2.11e-7	Childhood ear infection;
CESC	cis	rs853679	0.517	rs9348794	chr6:28117757	T/A	cg08968635	chr6:28129556	ZNF389	0.41	5.28	0.31	2.68e-7	Depression;
CESC	cis	rs12476592	0.543	rs12105140	chr2:63797218	A/G	cg17519650	chr2:63277830	OTX1	-0.49	-5.45	-0.32	1.16e-7	Childhood ear infection;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07494914	chr16:46461571	NA	-0.52	-6.03	-0.35	5.4e-9	Gut microbiome composition (summer);
CESC	cis	rs9840812	0.610	rs34967300	chr3:136268818	A/G	cg15507776	chr3:136538369	TMEM22	-0.5	-5.33	-0.31	2.08e-7	Fibrinogen levels;
CESC	cis	rs7914558	0.901	rs1926034	chr10:104829102	G/A	cg04362960	chr10:104952993	NT5C2	0.46	6.18	0.35	2.39e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs916888	0.773	rs199447	chr17:44812188	C/T	cg01570182	chr17:44337453	NA	0.88	9.87	0.52	8.81e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs524023	0.914	rs526338	chr11:64418900	G/A	cg07220939	chr11:64358617	SLC22A12	-0.36	-5.45	-0.32	1.17e-7	Urate levels in obese individuals;
CESC	cis	rs9303401	0.614	rs12950028	chr17:56510140	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.96	11.77	0.59	5.09e-26	Cognitive test performance;
CESC	cis	rs2742234	0.590	rs1254965	chr10:43689853	C/T	cg07801480	chr10:43725741	RASGEF1A	-0.41	-5.29	-0.31	2.56e-7	Hirschsprung disease;
CESC	cis	rs6582630	0.502	rs11182760	chr12:38606273	A/T	cg26384229	chr12:38710491	ALG10B	0.74	11.15	0.57	6.39e-24	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs17376456	0.825	rs34967135	chr5:93221785	G/A	cg21475434	chr5:93447410	FAM172A	0.79	7.07	0.4	1.38e-11	Diabetic retinopathy;
CESC	cis	rs7635838	0.859	rs6768611	chr3:11434465	G/A	cg00170343	chr3:11313890	ATG7	0.44	5.6	0.33	5.34e-8	HDL cholesterol;
CESC	cis	rs651907	0.557	rs13077925	chr3:101488181	T/A	cg12386194	chr3:101231763	SENP7	0.41	5.16	0.3	4.92e-7	Colorectal cancer;
CESC	cis	rs2603127	0.768	rs6769587	chr3:108502836	A/C	cg03329597	chr3:108125523	MYH15	0.58	5.15	0.3	5.2e-7	Hemostatic factors and hematological phenotypes;
CESC	cis	rs9911578	0.967	rs1588322	chr17:56990099	T/C	cg12560992	chr17:57184187	TRIM37	0.93	15.26	0.68	3.55e-38	Intelligence (multi-trait analysis);
CESC	cis	rs7116495	0.881	rs1892921	chr11:71702138	G/A	cg26138937	chr11:71823887	C11orf51	-0.81	-6.87	-0.39	4.57e-11	Severe influenza A (H1N1) infection;
CESC	cis	rs7586673	1.000	rs16845584	chr2:161923830	C/T	cg21518248	chr2:162101506	NA	-0.47	-6.39	-0.37	7.63e-10	Intelligence (multi-trait analysis);
CESC	cis	rs10754283	0.967	rs2390763	chr1:90105688	A/G	cg21401794	chr1:90099060	LRRC8C	0.69	9.34	0.5	4.06e-18	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs35079454	1	rs35079454	chr1:85780863	AG/A	cg16011679	chr1:85725395	C1orf52	0.52	6.16	0.35	2.67e-9	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7945705	0.719	rs2012680	chr11:8996059	G/A	cg12365402	chr11:9010492	NRIP3	-0.47	-7.97	-0.44	4.86e-14	Hemoglobin concentration;
CESC	cis	rs561341	1.000	rs510264	chr17:30323414	A/G	cg23018236	chr17:30244563	NA	-0.55	-5.3	-0.31	2.42e-7	Hip circumference adjusted for BMI;
CESC	cis	rs13191362	0.507	rs2846519	chr6:163045463	G/A	cg21926612	chr6:163149169	PACRG;PARK2	-0.52	-6.53	-0.37	3.33e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs40363	0.645	rs1690446	chr16:3519009	T/C	cg21433313	chr16:3507492	NAT15	0.5	7.85	0.43	1.02e-13	Tuberculosis;
CESC	cis	rs2797160	0.547	rs9388442	chr6:125972608	G/C	cg05901451	chr6:126070800	HEY2	-0.38	-5.27	-0.31	2.83e-7	Endometrial cancer;
CESC	cis	rs5769765	0.954	rs910799	chr22:50278568	A/G	cg02269571	chr22:50332266	NA	0.45	6.14	0.35	2.97e-9	Schizophrenia;
CESC	cis	rs2637266	0.739	rs2579736	chr10:78427688	G/A	cg18941641	chr10:78392320	NA	0.41	7.51	0.42	9.03e-13	Pulmonary function;
CESC	cis	rs9549367	0.789	rs12584008	chr13:113881228	C/T	cg18105134	chr13:113819100	PROZ	-0.66	-8.19	-0.45	1.12e-14	Platelet distribution width;
CESC	cis	rs6691722	0.506	rs11587667	chr1:24715435	C/G	cg02336364	chr1:24764700	NIPAL3	0.32	6.4	0.37	7.05e-10	Response to interferon beta in multiple sclerosis;
CESC	cis	rs9457247	1.000	rs430293	chr6:167404958	A/G	cg25258033	chr6:167368657	RNASET2	0.39	5.88	0.34	1.26e-8	Crohn's disease;
CESC	cis	rs4835473	0.932	rs34525847	chr4:144656123	T/C	cg25736465	chr4:144833511	NA	-0.34	-5.45	-0.32	1.15e-7	Immature fraction of reticulocytes;
CESC	cis	rs778371	0.748	rs2675953	chr2:233749565	G/C	cg08000102	chr2:233561755	GIGYF2	-0.82	-13.22	-0.63	5.6e-31	Schizophrenia;
CESC	cis	rs77216612	0.840	rs11055030	chr12:12878349	G/C	cg09462578	chr12:12878428	APOLD1	-1.01	-15.36	-0.69	1.66e-38	Lymphocyte counts;
CESC	trans	rs11971186	0.793	rs1361987	chr7:126489310	T/A	cg10894441	chr11:111169905	C11orf92;C11orf93	-0.48	-6.3	-0.36	1.22e-9	Chemerin levels;
CESC	cis	rs7542091	0.635	rs985431	chr1:210043948	A/T	cg21951975	chr1:209979733	IRF6	0.47	8.25	0.45	7.51e-15	Monobrow;
CESC	cis	rs13108904	0.870	rs4974577	chr4:1266046	G/A	cg00684032	chr4:1343700	KIAA1530	0.42	5.89	0.34	1.16e-8	Obesity-related traits;
CESC	cis	rs6459804	1.000	rs6459806	chr7:157510483	C/G	cg05731713	chr7:157510257	PTPRN2	0.41	6.98	0.39	2.3e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs17021463	0.902	rs2016483	chr4:95229039	A/T	cg11021082	chr4:95130006	SMARCAD1	-0.61	-9.66	-0.51	4.01e-19	Testicular germ cell tumor;
CESC	cis	rs7267979	0.934	rs2257464	chr20:25265872	C/T	cg08601574	chr20:25228251	PYGB	0.39	5.65	0.33	4.08e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs6752107	1.000	rs12994971	chr2:234178453	C/T	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.39	5.81	0.34	1.76e-8	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs6701037	0.681	rs6664840	chr1:175128726	A/G	cg00321850	chr1:175162397	KIAA0040	-0.42	-6.14	-0.35	3.03e-9	Alcohol dependence;
CESC	trans	rs17536732	0.685	rs41461449	chr4:162858888	A/C	cg12177677	chr2:158300475	CYTIP	0.62	6.19	0.36	2.3e-9	Risky sexual behaviors (alcohol dependence interaction);
CESC	cis	rs2228479	0.850	rs62054601	chr16:89811751	C/G	cg14709524	chr16:89940631	TCF25	0.89	6.6	0.38	2.22e-10	Skin colour saturation;
CESC	cis	rs13095912	0.962	rs1568664	chr3:185312231	T/C	cg11274856	chr3:185301563	NA	0.36	5.78	0.33	2.11e-8	Systolic blood pressure;
CESC	cis	rs6912958	0.535	rs448580	chr6:88040399	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.78	11.18	0.57	4.88e-24	Monocyte percentage of white cells;
CESC	cis	rs11098499	0.954	rs1480931	chr4:120395809	G/T	cg24375607	chr4:120327624	NA	0.43	5.34	0.31	2e-7	Corneal astigmatism;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07997682	chr22:41418886	NA	-0.72	-9.27	-0.49	6.8e-18	Gut microbiome composition (summer);
CESC	cis	rs763121	0.853	rs5750621	chr22:38956166	C/T	cg14440974	chr22:39074834	NA	-0.4	-5.27	-0.31	2.82e-7	Menopause (age at onset);
CESC	cis	rs5769765	0.819	rs9616379	chr22:50312035	C/T	cg26441486	chr22:50317300	CRELD2	0.42	5.24	0.31	3.33e-7	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08517072	chr5:141258709	PCDH1	-0.55	-6.73	-0.38	1.05e-10	Gut microbiome composition (summer);
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg12857786	chr4:83934023	LIN54	-0.53	-7.05	-0.4	1.53e-11	Height;
CESC	cis	rs9443645	0.901	rs1960542	chr6:79566643	C/T	cg05283184	chr6:79620031	NA	-0.44	-6.84	-0.39	5.47e-11	Intelligence (multi-trait analysis);
CESC	cis	rs734999	0.545	rs7368072	chr1:2556125	C/T	cg20673091	chr1:2541236	MMEL1	0.48	8.03	0.44	3.11e-14	Ulcerative colitis;
CESC	cis	rs12142240	0.698	rs1053628	chr1:46827769	C/T	cg00530320	chr1:46809349	NSUN4	0.6	8.01	0.44	3.75e-14	Menopause (age at onset);
CESC	cis	rs3126085	0.935	rs10888483	chr1:152252789	T/A	cg03465714	chr1:152285911	FLG	0.49	5.43	0.32	1.24e-7	Atopic dermatitis;
CESC	cis	rs2204008	0.654	rs1290325	chr12:38152910	C/T	cg26384229	chr12:38710491	ALG10B	-0.51	-7.18	-0.4	6.82e-12	Bladder cancer;
CESC	cis	rs6546550	0.904	rs3771537	chr2:70038792	A/C	cg02498382	chr2:70120550	SNRNP27	-0.36	-6.29	-0.36	1.29e-9	Prevalent atrial fibrillation;
CESC	cis	rs35306767	0.761	rs12359796	chr10:1021479	G/C	cg20503657	chr10:835505	NA	0.74	6.69	0.38	1.28e-10	Eosinophil percentage of granulocytes;
CESC	cis	rs6009527	0.752	rs7286232	chr22:49568490	A/G	cg12746016	chr22:49560550	NA	0.4	6.88	0.39	4.4e-11	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);
CESC	cis	rs8060686	0.516	rs8044995	chr16:68189340	G/A	cg26727032	chr16:67993705	SLC12A4	-0.55	-7.63	-0.42	4.17e-13	HDL cholesterol;Metabolic syndrome;
CESC	trans	rs1814175	0.588	rs10839463	chr11:49971643	A/G	cg03929089	chr4:120376271	NA	-0.92	-15.24	-0.68	4.38e-38	Height;
CESC	cis	rs6540559	1.000	rs12070337	chr1:209992127	G/A	cg21951975	chr1:209979733	IRF6	0.66	9.95	0.52	5.01e-20	Cleft lip with or without cleft palate;
CESC	cis	rs9796	0.621	rs2899013	chr15:41492283	G/T	cg20272979	chr15:41787780	ITPKA	0.35	5.23	0.31	3.5e-7	Menopause (age at onset);
CESC	cis	rs2952156	0.959	rs2941504	chr17:37830900	A/G	cg07936489	chr17:37558343	FBXL20	-0.5	-6.04	-0.35	5.14e-9	Asthma;
CESC	cis	rs13191362	0.935	rs66962088	chr6:162963891	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.81	7.71	0.43	2.49e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs1003719	0.591	rs9636914	chr21:38589732	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.48	6.11	0.35	3.63e-9	Eye color traits;
CESC	cis	rs9649213	0.593	rs6465672	chr7:97963717	C/T	cg00277769	chr7:97922759	BAIAP2L1	0.33	5.5	0.32	9.17e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg11494091	chr17:61959527	GH2	-0.8	-15.09	-0.68	1.42e-37	Prudent dietary pattern;
CESC	cis	rs9393777	0.513	rs9368447	chr6:26646674	A/C	cg12292205	chr6:26970375	C6orf41	-0.53	-5.84	-0.34	1.53e-8	Intelligence (multi-trait analysis);
CESC	cis	rs10504229	0.861	rs59873610	chr8:58172290	T/A	cg24829409	chr8:58192753	C8orf71	-0.75	-9.96	-0.52	4.74e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs9467711	0.606	rs9379863	chr6:26372427	A/G	cg14345882	chr6:26364793	BTN3A2	0.6	6.21	0.36	2.07e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs6032067	0.929	rs17424696	chr20:43810734	G/A	cg11264863	chr20:43835661	SEMG1	0.49	5.33	0.31	2.06e-7	Blood protein levels;
CESC	cis	rs7666738	0.830	rs2903150	chr4:99027184	T/C	cg18180107	chr4:99064573	C4orf37	0.42	5.43	0.32	1.29e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg11494091	chr17:61959527	GH2	-0.71	-12.41	-0.61	3.42e-28	Prudent dietary pattern;
CESC	cis	rs724767	1.000	rs724767	chr3:193722330	C/T	cg01524723	chr3:193718032	NA	-0.64	-6.52	-0.37	3.5e-10	Estradiol plasma levels (breast cancer);
CESC	cis	rs7520050	0.966	rs12021587	chr1:46472759	G/T	cg03146154	chr1:46216737	IPP	-0.46	-5.87	-0.34	1.31e-8	Red blood cell count;Reticulocyte count;
CESC	cis	rs2637266	0.756	rs846631	chr10:78536928	T/G	cg18941641	chr10:78392320	NA	0.41	8.21	0.45	1.01e-14	Pulmonary function;
CESC	cis	rs10510653	0.522	rs62244401	chr3:32033509	G/A	cg05935571	chr3:32023257	ZNF860;OSBPL10	0.98	7.16	0.4	8.14e-12	Schizophrenia;
CESC	cis	rs7945705	0.967	rs10840148	chr11:8923528	C/T	cg09997546	chr11:8931473	C11orf17;ST5	0.38	6.0	0.35	6.57e-9	Hemoglobin concentration;
CESC	cis	rs2070433	1.000	rs11701310	chr21:47962836	G/C	cg12379764	chr21:47803548	PCNT	0.6	6.99	0.39	2.19e-11	Lymphocyte counts;
CESC	cis	rs875971	0.862	rs12537823	chr7:65720884	C/T	cg11764359	chr7:65958608	NA	0.8	12.03	0.59	6.98e-27	Aortic root size;
CESC	cis	rs425277	0.606	rs377283	chr1:2075570	T/C	cg04315214	chr1:2043799	PRKCZ	-0.46	-7.35	-0.41	2.5e-12	Height;
CESC	cis	rs10129255	0.518	rs8009612	chr14:107185749	G/T	cg23076370	chr14:107095027	NA	-0.67	-10.03	-0.52	2.81e-20	Kawasaki disease;
CESC	cis	rs8027181	0.617	rs6495017	chr15:73089625	T/A	cg25632853	chr15:73088954	NA	-0.38	-5.44	-0.32	1.24e-7	Triglyceride levels;
CESC	cis	rs11958404	0.932	rs11950297	chr5:157419938	T/G	cg05962755	chr5:157440814	NA	0.63	6.75	0.38	9.02e-11	IgG glycosylation;
CESC	cis	rs829883	0.659	rs11109520	chr12:98928646	C/T	cg25150519	chr12:98850993	NA	0.65	8.0	0.44	3.78e-14	Colorectal adenoma (advanced);
CESC	cis	rs1218582	0.772	rs4240875	chr1:154885782	G/A	cg24250549	chr1:154909240	PMVK	0.74	10.98	0.56	2.38e-23	Prostate cancer;
CESC	cis	rs7216064	1.000	rs4791299	chr17:65930937	A/G	cg12091567	chr17:66097778	LOC651250	-0.72	-8.28	-0.45	6.01e-15	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg15604190	chr1:6052593	NPHP4	-0.5	-6.1	-0.35	3.75e-9	Lung cancer in ever smokers;
CESC	cis	rs2012796	0.957	rs8016255	chr14:81816121	C/G	cg02996355	chr14:81879375	NA	0.49	5.68	0.33	3.53e-8	Night sleep phenotypes;
CESC	cis	rs875971	1.000	rs1167612	chr7:65567976	C/A	cg11764359	chr7:65958608	NA	-0.95	-14.42	-0.66	3.33e-35	Aortic root size;
CESC	cis	rs244293	0.795	rs11079151	chr17:53095366	G/A	cg19360675	chr17:53046073	COX11;STXBP4	0.4	5.11	0.3	6.18e-7	Menarche (age at onset);
CESC	cis	rs73206853	0.563	rs1107652	chr12:111176213	A/G	cg12870014	chr12:110450643	ANKRD13A	0.66	5.92	0.34	1e-8	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs1448094	0.511	rs10863083	chr12:86226739	C/A	cg19622623	chr12:86230825	RASSF9	-0.45	-5.91	-0.34	1.06e-8	Major depressive disorder;
CESC	cis	rs853679	0.517	rs4713143	chr6:28106759	A/C	cg23281280	chr6:28129359	ZNF389	0.59	8.16	0.45	1.34e-14	Depression;
CESC	trans	rs875971	1.000	rs10215948	chr7:65747786	G/A	cg26939375	chr7:64535504	NA	-0.45	-6.06	-0.35	4.54e-9	Aortic root size;
CESC	cis	rs7264396	0.790	rs1040695	chr20:34244829	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.65	7.82	0.43	1.25e-13	Total cholesterol levels;
CESC	cis	rs6062302	0.522	rs13043255	chr20:62218916	C/G	cg09650180	chr20:62225654	GMEB2	-0.81	-9.29	-0.5	5.66e-18	Glioblastoma;
CESC	cis	rs9911578	0.904	rs7209253	chr17:56908987	C/T	cg12560992	chr17:57184187	TRIM37	0.94	15.75	0.7	6.57e-40	Intelligence (multi-trait analysis);
CESC	cis	rs3733585	0.673	rs9994266	chr4:9954450	C/T	cg11266682	chr4:10021025	SLC2A9	-0.6	-11.54	-0.58	3.03e-25	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs561341	0.941	rs8066558	chr17:30272879	G/T	cg19193384	chr17:30244184	NA	-0.63	-6.55	-0.37	3.01e-10	Hip circumference adjusted for BMI;
CESC	cis	rs113835537	0.529	rs57691879	chr11:66236604	C/T	cg24851651	chr11:66362959	CCS	0.47	5.83	0.34	1.62e-8	Airway imaging phenotypes;
CESC	cis	rs12477438	1.000	rs17760953	chr2:99859863	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.73	-8.78	-0.47	2.13e-16	Chronic sinus infection;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg20099018	chr17:40169396	DNAJC7;NKIRAS2	0.48	6.4	0.37	6.9e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs2075371	1.000	rs2598294	chr7:133991690	C/T	cg20476274	chr7:133979776	SLC35B4	0.67	9.79	0.52	1.65e-19	Mean platelet volume;
CESC	cis	rs1797885	1.000	rs2589673	chr3:12516501	T/C	cg26432171	chr3:12704882	RAF1	-0.5	-6.47	-0.37	4.75e-10	Immature fraction of reticulocytes;
CESC	cis	rs6964587	0.773	rs38793	chr7:92027187	A/G	cg17063962	chr7:91808500	NA	-0.56	-7.19	-0.4	6.44e-12	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06208661	chr6:26660150	ZNF322A	-0.58	-6.2	-0.36	2.2e-9	Gut microbiome composition (summer);
CESC	cis	rs3110496	0.685	rs550818	chr17:27901975	A/G	cg00032419	chr17:27895566	TP53I13	0.52	5.43	0.32	1.3e-7	Height;
CESC	cis	rs425277	0.606	rs3128339	chr1:2046938	G/T	cg19257562	chr1:2043853	PRKCZ	0.41	6.72	0.38	1.08e-10	Height;
CESC	cis	rs2806561	0.704	rs636940	chr1:23522967	A/T	cg12483005	chr1:23474871	LUZP1	0.43	6.55	0.37	2.93e-10	Height;
CESC	cis	rs225245	0.817	rs225284	chr17:33933006	A/C	cg05299278	chr17:33885742	SLFN14	0.39	5.51	0.32	8.59e-8	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
CESC	cis	rs7618501	0.521	rs11130222	chr3:49901060	A/T	cg24110177	chr3:50126178	RBM5	-0.51	-6.73	-0.38	1.06e-10	Intelligence (multi-trait analysis);
CESC	cis	rs12530845	1.000	rs6979439	chr7:135329004	A/G	cg23117316	chr7:135346802	PL-5283	-0.41	-5.29	-0.31	2.52e-7	Red blood cell traits;
CESC	cis	rs4721295	0.573	rs3779000	chr7:2181628	G/A	cg05863683	chr7:1912471	MAD1L1	0.4	5.84	0.34	1.49e-8	Schizophrenia, schizoaffective disorder or bipolar disorder;
CESC	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg23131131	chr22:24373011	LOC391322	0.7	9.57	0.51	8.02e-19	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs6582630	0.502	rs7311700	chr12:38463232	T/A	cg13010199	chr12:38710504	ALG10B	0.53	6.74	0.38	9.64e-11	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs2991971	1.000	rs2934859	chr1:46017836	C/T	cg05343316	chr1:45956843	TESK2	-0.48	-6.08	-0.35	4.21e-9	High light scatter reticulocyte count;
CESC	cis	rs4888262	0.526	rs7205258	chr16:74642539	C/T	cg01733217	chr16:74700730	RFWD3	0.86	12.18	0.6	2.06e-27	Testicular germ cell tumor;
CESC	cis	rs7312774	0.881	rs7297923	chr12:107305573	T/C	cg16260113	chr12:107380972	MTERFD3	0.64	6.08	0.35	4.15e-9	Severe influenza A (H1N1) infection;
CESC	cis	rs1448094	0.511	rs61930579	chr12:86157044	G/A	cg02569458	chr12:86230093	RASSF9	0.51	7.69	0.43	2.85e-13	Major depressive disorder;
CESC	cis	rs4849845	0.678	rs3896632	chr2:121023496	C/T	cg24070213	chr2:121070622	NA	0.45	6.48	0.37	4.45e-10	Mean platelet volume;
CESC	cis	rs561341	0.883	rs886224	chr17:30229902	T/C	cg00745463	chr17:30367425	LRRC37B	-0.64	-6.26	-0.36	1.57e-9	Hip circumference adjusted for BMI;
CESC	cis	rs8114671	0.562	rs4911449	chr20:33512236	T/G	cg07148914	chr20:33460835	GGT7	0.45	5.9	0.34	1.09e-8	Height;
CESC	trans	rs9325144	0.560	rs11182952	chr12:38636278	C/A	cg23762105	chr12:34175262	ALG10	0.48	6.31	0.36	1.16e-9	Morning vs. evening chronotype;
CESC	cis	rs9457247	0.935	rs9348211	chr6:167375173	G/C	cg07741184	chr6:167504864	NA	-0.3	-5.38	-0.31	1.66e-7	Crohn's disease;
CESC	cis	rs1322639	0.614	rs6908401	chr6:169564716	A/C	cg03254818	chr6:169586852	NA	-0.49	-5.45	-0.32	1.14e-7	Pulse pressure;
CESC	cis	rs2635047	1.000	rs2277717	chr18:44702718	C/A	cg19077165	chr18:44547161	KATNAL2	-0.45	-6.12	-0.35	3.31e-9	Educational attainment;
CESC	cis	rs9811920	0.809	rs793475	chr3:99543764	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.43	-7.02	-0.4	1.9e-11	Axial length;
CESC	cis	rs7666738	0.830	rs11726604	chr4:99000969	T/C	cg18180107	chr4:99064573	C4orf37	0.4	5.23	0.31	3.41e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg27588902	chr6:42928151	GNMT	-0.27	-5.09	-0.3	6.92e-7	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs7618915	0.547	rs11714419	chr3:52628816	A/G	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.41	7.34	0.41	2.62e-12	Bipolar disorder;
CESC	cis	rs873946	0.586	rs12774727	chr10:134569910	T/C	cg27286337	chr10:134555280	INPP5A	0.68	7.69	0.43	2.81e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs7666738	0.830	rs17550610	chr4:99008273	T/C	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.62e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs875971	0.825	rs6951503	chr7:65718936	T/G	cg18252515	chr7:66147081	NA	0.44	5.78	0.33	2.14e-8	Aortic root size;
CESC	cis	rs2075371	0.501	rs1646652	chr7:134024515	A/T	cg20476274	chr7:133979776	SLC35B4	0.4	5.2	0.3	3.98e-7	Mean platelet volume;
CESC	cis	rs2072499	1.000	rs2241108	chr1:156181007	C/G	cg24450063	chr1:156163899	SLC25A44	1.07	22.09	0.8	5.03e-62	Testicular germ cell tumor;
CESC	cis	rs1729951	0.546	rs12054218	chr3:136677496	C/G	cg25687071	chr3:136751404	NA	0.39	5.23	0.31	3.44e-7	Neuroticism;
CESC	cis	rs11997175	0.550	rs7459534	chr8:33836623	G/C	ch.8.33884649F	chr8:33765107	NA	0.59	7.16	0.4	7.74e-12	Body mass index;
CESC	trans	rs7615952	0.932	rs13086087	chr3:125646281	A/C	cg07211511	chr3:129823064	LOC729375	-1.13	-15.07	-0.68	1.8e-37	Blood pressure (smoking interaction);
CESC	cis	rs2617583	0.904	rs2937639	chr5:1443728	A/G	cg07151155	chr5:1473589	LPCAT1	-0.35	-5.37	-0.31	1.72e-7	Breast cancer;
CESC	cis	rs412050	0.512	rs79497006	chr22:22254137	G/A	cg17089214	chr22:22089827	YPEL1	0.75	5.14	0.3	5.4e-7	Attention deficit hyperactivity disorder;
CESC	cis	rs3733585	0.673	rs4447861	chr4:9953940	C/T	cg00071950	chr4:10020882	SLC2A9	-0.69	-11.34	-0.57	1.42e-24	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs7089973	0.604	rs11196941	chr10:116596258	A/G	cg25233709	chr10:116636983	FAM160B1	0.38	5.98	0.34	7.26e-9	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs35110281	0.693	rs11089093	chr21:45121161	C/T	cg04455712	chr21:45112962	RRP1B	0.5	7.58	0.42	5.84e-13	Mean corpuscular volume;
CESC	cis	rs14403	1.000	rs12134270	chr1:243662668	T/G	cg21452805	chr1:244014465	NA	0.46	5.42	0.32	1.31e-7	Schizophrenia;
CESC	cis	rs854765	0.647	rs7212447	chr17:17987067	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.61	8.67	0.47	4.44e-16	Total body bone mineral density;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07154196	chr1:29214064	EPB41	0.57	6.45	0.37	5.15e-10	Gut microbiome composition (summer);
CESC	cis	rs9660180	0.875	rs4648727	chr1:1776269	C/A	cg13866156	chr1:1669148	SLC35E2	0.41	5.45	0.32	1.16e-7	Body mass index;
CESC	cis	rs6547741	0.935	rs4666004	chr2:27855052	T/A	cg21248554	chr2:27665150	KRTCAP3	0.26	5.31	0.31	2.34e-7	Oral cavity cancer;
CESC	cis	rs826838	0.651	rs1843896	chr12:38612913	G/C	cg26384229	chr12:38710491	ALG10B	0.55	8.11	0.45	1.93e-14	Heart rate;
CESC	cis	rs7959452	0.640	rs12370042	chr12:69692420	C/G	cg20891283	chr12:69753455	YEATS4	0.77	11.34	0.57	1.43e-24	Blood protein levels;
CESC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg07775675	chr17:74379922	SPHK1	-0.46	-6.11	-0.35	3.55e-9	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs4704187	0.663	rs6897274	chr5:74426103	T/A	cg03227963	chr5:74354835	NA	0.31	5.68	0.33	3.52e-8	Response to amphetamines;
CESC	cis	rs832540	0.519	rs10036895	chr5:56273693	G/A	cg14703610	chr5:56206110	C5orf35	0.52	6.76	0.38	8.68e-11	Coronary artery disease;
CESC	cis	rs2304069	0.954	rs216127	chr5:149428890	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.92	11.75	0.59	6.29e-26	HIV-1 control;
CESC	cis	rs796364	0.951	rs59695400	chr2:201021325	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.63	-6.41	-0.37	6.74e-10	Schizophrenia;
CESC	cis	rs72772090	0.539	rs56120748	chr5:96110622	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.6	-5.03	-0.3	8.86e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs72945132	0.882	rs17853270	chr11:70200529	C/T	cg00319359	chr11:70116639	PPFIA1	0.78	7.27	0.41	3.99e-12	Coronary artery disease;
CESC	cis	rs7786808	0.741	rs7789415	chr7:158227617	C/T	cg01191920	chr7:158217561	PTPRN2	-0.41	-7.31	-0.41	3.1e-12	Obesity-related traits;
CESC	cis	rs2535633	0.631	rs11915851	chr3:53096047	C/T	cg07507251	chr3:52567010	NT5DC2	0.35	5.19	0.3	4.13e-7	Body mass index;
CESC	cis	rs4975709	0.589	rs4975744	chr5:1860049	A/G	cg10800226	chr5:1850261	NA	0.34	5.68	0.33	3.55e-8	Cardiovascular disease risk factors;
CESC	cis	rs4604732	0.578	rs12038656	chr1:247623816	A/G	cg12754571	chr1:247694271	LOC148824;OR2C3	0.41	5.1	0.3	6.5e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs4819052	0.765	rs2838868	chr21:46714641	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	-0.56	-6.48	-0.37	4.47e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs11640734	0.609	rs11647746	chr16:89806343	C/A	cg04013166	chr16:89971882	TCF25	0.78	8.27	0.45	6.77e-15	Interleukin-17 levels;
CESC	cis	rs637571	0.584	rs594689	chr11:65635559	G/A	cg26695010	chr11:65641043	EFEMP2	0.59	7.37	0.41	2.14e-12	Eosinophil percentage of white cells;
CESC	cis	rs7408868	1.000	rs7249525	chr19:15277309	G/A	cg14696996	chr19:15285081	NOTCH3	1.11	11.39	0.57	1.03e-24	Pulse pressure;
CESC	cis	rs7107174	1.000	rs4944195	chr11:78003499	T/C	cg02023728	chr11:77925099	USP35	0.5	6.69	0.38	1.33e-10	Testicular germ cell tumor;
CESC	trans	rs7246760	1.000	rs17849496	chr19:9922223	G/A	cg02900749	chr2:68251473	NA	-0.83	-7.08	-0.4	1.3e-11	Pursuit maintenance gain;
CESC	cis	rs2439831	0.850	rs7179388	chr15:44123945	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.7	7.36	0.41	2.32e-12	Lung cancer in ever smokers;
CESC	cis	rs7089973	0.604	rs1359079	chr10:116582502	A/G	cg25233709	chr10:116636983	FAM160B1	0.35	5.47	0.32	1.05e-7	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs2109514	0.902	rs926197	chr7:116118330	A/C	cg12739419	chr7:116140593	CAV2	0.34	6.26	0.36	1.53e-9	Prevalent atrial fibrillation;
CESC	cis	rs9611565	0.512	rs139572	chr22:42214532	C/T	cg06481639	chr22:41940642	POLR3H	-0.53	-5.11	-0.3	6.3e-7	Vitiligo;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22580712	chr15:99191230	NA	-0.59	-6.79	-0.38	7.36e-11	Gut microbiome composition (summer);
CESC	cis	rs3736485	0.934	rs4143721	chr15:51866781	A/G	cg08986416	chr15:51914746	DMXL2	-0.4	-5.12	-0.3	5.86e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs60515486	0.527	rs10769255	chr11:47367371	C/T	cg25783544	chr11:47291846	MADD	0.62	6.14	0.35	2.99e-9	Lymphocyte counts;
CESC	cis	rs7560272	0.501	rs10191988	chr2:73947787	A/G	cg20560298	chr2:73613845	ALMS1	0.42	5.68	0.33	3.57e-8	Schizophrenia;
CESC	cis	rs8017423	0.935	rs3737035	chr14:90745422	T/C	cg14092571	chr14:90743983	NA	0.56	8.5	0.46	1.42e-15	Mortality in heart failure;
CESC	cis	rs4689388	0.926	rs1801214	chr4:6303022	C/T	cg14416269	chr4:6271139	WFS1	0.47	7.91	0.44	7.13e-14	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs7824557	0.564	rs13274106	chr8:11233958	A/G	cg21775007	chr8:11205619	TDH	-0.52	-7.67	-0.43	3.23e-13	Retinal vascular caliber;
CESC	cis	rs2576037	0.526	rs3892820	chr18:44479558	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.45	7.4	0.41	1.77e-12	Personality dimensions;
CESC	cis	rs490234	0.616	rs2648318	chr9:128163447	T/C	cg14078157	chr9:128172775	NA	-0.3	-5.22	-0.31	3.56e-7	Mean arterial pressure;
CESC	cis	rs7503807	0.967	rs12939549	chr17:78611724	C/T	cg09596252	chr17:78655493	RPTOR	-0.5	-7.35	-0.41	2.4e-12	Obesity;
CESC	cis	rs12190007	0.547	rs3006184	chr6:169805128	C/T	cg15038512	chr6:170123185	PHF10	-0.48	-6.81	-0.39	6.6e-11	Obesity-related traits;
CESC	cis	rs9322193	1.000	rs9767077	chr6:150109615	T/A	cg13206674	chr6:150067644	NUP43	0.42	5.89	0.34	1.19e-8	Lung cancer;
CESC	cis	rs7085104	0.572	rs284858	chr10:104573936	T/C	cg04362960	chr10:104952993	NT5C2	-0.47	-6.17	-0.35	2.58e-9	Immature fraction of reticulocytes;Schizophrenia;
CESC	trans	rs875971	0.617	rs810400	chr7:66022889	G/C	cg26939375	chr7:64535504	NA	-0.64	-8.7	-0.47	3.62e-16	Aortic root size;
CESC	cis	rs3106136	0.967	rs66581998	chr4:95196901	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.48	-7.19	-0.4	6.65e-12	Capecitabine sensitivity;
CESC	cis	rs58235267	0.656	rs13410889	chr2:63087778	T/C	cg17519650	chr2:63277830	OTX1	0.65	9.15	0.49	1.54e-17	Prostate-specific antigen levels (conditioned on lead SNPs);
CESC	cis	rs4925386	0.681	rs2427294	chr20:60927257	G/A	cg22633769	chr20:60982531	CABLES2	0.54	5.68	0.33	3.55e-8	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CESC	trans	rs9329221	0.506	rs17689674	chr8:9981854	C/A	cg15556689	chr8:8085844	FLJ10661	0.51	6.18	0.35	2.45e-9	Neuroticism;
CESC	trans	rs2727020	0.786	rs10839263	chr11:49354462	A/G	cg03929089	chr4:120376271	NA	-0.64	-7.4	-0.41	1.82e-12	Coronary artery disease;
CESC	cis	rs873946	0.648	rs35417213	chr10:134553749	A/G	cg18305652	chr10:134549665	INPP5A	0.48	7.05	0.4	1.54e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs9649213	0.593	rs11760930	chr7:97915789	G/A	cg00277769	chr7:97922759	BAIAP2L1	-0.36	-5.74	-0.33	2.54e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7178909	0.831	rs1910587	chr15:90440487	A/C	cg19708238	chr15:90437601	AP3S2	0.46	6.52	0.37	3.52e-10	Common traits (Other);
CESC	cis	rs1707322	1.000	rs4660903	chr1:46457601	A/G	cg03146154	chr1:46216737	IPP	0.72	9.82	0.52	1.31e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs11039798	0.623	rs635632	chr11:48399532	T/C	cg15704280	chr7:45808275	SEPT13	-0.69	-6.75	-0.38	9.03e-11	Axial length;
CESC	trans	rs9561428	0.850	rs7319499	chr13:94419894	T/G	cg17039369	chr21:46341006	ITGB2	0.5	6.11	0.35	3.5e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs9926296	0.605	rs8047486	chr16:89854025	A/T	cg03388025	chr16:89894329	SPIRE2	0.4	7.51	0.42	9.13e-13	Vitiligo;
CESC	cis	rs875971	0.798	rs7789615	chr7:65878661	A/G	cg10691866	chr7:65817282	TPST1	-0.33	-5.43	-0.32	1.3e-7	Aortic root size;
CESC	cis	rs10504229	0.683	rs7817188	chr8:58129549	C/T	cg21724239	chr8:58056113	NA	0.58	5.95	0.34	8.29e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs6912958	1.000	rs9294379	chr6:88152535	C/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.33	-5.36	-0.31	1.81e-7	Monocyte percentage of white cells;
CESC	cis	rs6500395	1.000	rs7184144	chr16:48606077	C/T	cg04672837	chr16:48644449	N4BP1	0.52	6.51	0.37	3.72e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs751728	1.000	rs3806108	chr6:33767579	C/G	cg15252951	chr6:33757062	LEMD2	0.47	6.02	0.35	5.76e-9	Crohn's disease;
CESC	cis	rs12893668	0.572	rs4900591	chr14:104154878	G/A	cg24130564	chr14:104152367	KLC1	-0.48	-6.36	-0.36	8.88e-10	Reticulocyte count;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg24686684	chr20:48330546	B4GALT5	-0.47	-6.12	-0.35	3.32e-9	Ulcerative colitis;
CESC	cis	rs9811920	0.514	rs1287283	chr3:99515750	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.56	-8.51	-0.46	1.35e-15	Axial length;
CESC	cis	rs2000999	0.515	rs2854956	chr16:72115238	A/T	cg01557791	chr16:72042693	DHODH	-0.57	-7.5	-0.42	9.36e-13	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
CESC	cis	rs12130219	0.500	rs1552991	chr1:152165878	C/T	cg25272121	chr1:152190972	HRNR	-0.41	-6.0	-0.35	6.32e-9	Inflammatory skin disease;
CESC	cis	rs920590	0.684	rs59565447	chr8:19668430	A/T	cg01411142	chr8:19674711	INTS10	0.55	6.1	0.35	3.65e-9	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs7582720	1.000	rs72936834	chr2:203771260	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.39	0.41	1.96e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	trans	rs2090104	0.739	rs7663339	chr4:128481449	T/C	cg21894728	chr21:47453656	NA	-0.4	-6.01	-0.35	6.22e-9	IgG glycosylation;
CESC	cis	rs798554	0.634	rs6978692	chr7:2857411	C/T	cg13628971	chr7:2884303	GNA12	0.43	5.79	0.34	1.96e-8	Height;
CESC	cis	rs7586673	1.000	rs7586673	chr2:161923520	C/A	cg16506815	chr2:162101123	NA	0.43	5.89	0.34	1.16e-8	Intelligence (multi-trait analysis);
CESC	cis	rs11864453	0.826	rs8062041	chr16:72088964	C/T	cg16558253	chr16:72132732	DHX38	-0.56	-8.42	-0.46	2.4e-15	Fibrinogen levels;
CESC	cis	rs798554	0.757	rs1182185	chr7:2872233	A/G	cg18446336	chr7:2847575	GNA12	-0.34	-5.4	-0.31	1.49e-7	Height;
CESC	cis	rs3733585	0.577	rs5014939	chr4:9953253	T/A	cg00071950	chr4:10020882	SLC2A9	-0.69	-11.34	-0.57	1.42e-24	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs941873	0.772	rs1892498	chr10:81103862	A/G	cg08514558	chr10:81106712	PPIF	0.33	5.61	0.33	5.02e-8	Height;
CESC	cis	rs936229	0.749	rs8031937	chr15:75181121	A/G	cg10253484	chr15:75165896	SCAMP2	-0.45	-5.14	-0.3	5.28e-7	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CESC	cis	rs7044106	0.762	rs10739570	chr9:123381222	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.69	9.89	0.52	7.98e-20	Hip circumference adjusted for BMI;
CESC	cis	rs921968	0.565	rs6436072	chr2:219598095	C/T	cg02176678	chr2:219576539	TTLL4	-0.45	-8.06	-0.44	2.61e-14	Mean corpuscular hemoglobin concentration;
CESC	cis	rs4319547	0.656	rs10744209	chr12:122931568	G/A	cg23029597	chr12:123009494	RSRC2	-0.45	-5.08	-0.3	7.04e-7	Body mass index;
CESC	cis	rs13191362	1.000	rs35820211	chr6:163046252	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.84	9.06	0.49	2.98e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	trans	rs7615952	0.932	rs7630077	chr3:125649676	T/C	cg07211511	chr3:129823064	LOC729375	-1.07	-14.03	-0.65	8.08e-34	Blood pressure (smoking interaction);
CESC	cis	rs35110281	0.782	rs9981790	chr21:45045052	G/C	cg21573476	chr21:45109991	RRP1B	-0.47	-6.6	-0.38	2.19e-10	Mean corpuscular volume;
CESC	cis	rs7833986	0.501	rs72653981	chr8:57027814	G/A	cg26371346	chr8:56986568	SNORD54;RPS20	0.57	5.41	0.32	1.42e-7	Height;
CESC	cis	rs748404	0.690	rs2244981	chr15:43752751	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.57	7.49	0.42	1.01e-12	Lung cancer;
CESC	cis	rs425277	0.628	rs10797427	chr1:2060732	C/T	cg12718519	chr1:2058417	PRKCZ	-0.24	-5.16	-0.3	4.91e-7	Height;
CESC	cis	rs7116495	0.609	rs501308	chr11:71581325	C/G	cg26138937	chr11:71823887	C11orf51	1.15	7.68	0.43	3.09e-13	Severe influenza A (H1N1) infection;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg22704915	chr10:73079101	SLC29A3	-0.5	-6.56	-0.37	2.81e-10	Fibrinogen levels;
CESC	cis	rs35306767	0.953	rs11253520	chr10:975961	C/G	cg26597838	chr10:835615	NA	-0.46	-5.83	-0.34	1.57e-8	Eosinophil percentage of granulocytes;
CESC	cis	rs17001868	0.568	rs9611315	chr22:40736900	A/T	cg07138101	chr22:40742427	ADSL	0.57	5.38	0.31	1.66e-7	Mammographic density (dense area);
CESC	cis	rs16917546	1.000	rs7094595	chr10:64415413	T/A	cg03961010	chr10:64397487	ZNF365	-0.38	-6.22	-0.36	1.91e-9	Basal cell carcinoma;
CESC	trans	rs11159647	0.636	rs12431785	chr14:84729859	T/G	cg19838074	chr2:242149865	ANO7	0.41	6.01	0.35	6.27e-9	Alzheimer's disease;
CESC	trans	rs629535	0.814	rs62513378	chr8:70095788	G/C	cg21567404	chr3:27674614	NA	-0.86	-9.86	-0.52	9.8e-20	Dupuytren's disease;
CESC	cis	rs11958404	0.932	rs11950881	chr5:157410550	C/T	cg05962755	chr5:157440814	NA	0.56	6.16	0.35	2.74e-9	IgG glycosylation;
CESC	cis	rs2180341	0.618	rs12529077	chr6:127634244	G/T	cg27446573	chr6:127587934	RNF146	0.62	8.56	0.47	9.22e-16	Breast cancer;
CESC	cis	rs2573652	0.755	rs6598286	chr15:100515985	G/T	cg09918751	chr15:100517450	ADAMTS17	-0.43	-8.48	-0.46	1.63e-15	Height;
CESC	cis	rs7762018	1.000	rs73242927	chr6:170129573	T/A	cg13891659	chr6:170190454	C6orf122;C6orf208	0.56	5.6	0.33	5.38e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs4665809	1.000	rs6704930	chr2:26325705	G/A	cg26314531	chr2:26401878	FAM59B	-0.61	-6.85	-0.39	5.26e-11	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.830	rs13108705	chr4:99044438	T/C	cg18180107	chr4:99064573	C4orf37	0.41	5.29	0.31	2.51e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3749237	0.595	rs1050088	chr3:49570882	C/T	cg03060546	chr3:49711283	APEH	-0.73	-10.88	-0.56	4.83e-23	Resting heart rate;
CESC	cis	rs35306767	0.903	rs35637113	chr10:874149	G/C	cg10556349	chr10:835070	NA	0.62	5.93	0.34	9.61e-9	Eosinophil percentage of granulocytes;
CESC	cis	rs6674176	0.518	rs917294	chr1:44249485	A/G	cg12908607	chr1:44402522	ARTN	-0.4	-5.4	-0.31	1.5e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs2243480	1.000	rs34637256	chr7:65360131	G/A	cg13147721	chr7:65941812	NA	-0.85	-8.15	-0.45	1.41e-14	Diabetic kidney disease;
CESC	cis	rs9393777	0.513	rs9295702	chr6:26634040	T/C	cg12826209	chr6:26865740	GUSBL1	0.75	8.82	0.48	1.62e-16	Intelligence (multi-trait analysis);
CESC	cis	rs3857067	0.772	rs4692999	chr4:95107644	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.6	-9.05	-0.49	3.25e-17	QT interval;
CESC	cis	rs4906332	0.811	rs2296487	chr14:103996205	T/C	cg04998671	chr14:104000505	TRMT61A	-0.47	-5.63	-0.33	4.58e-8	Coronary artery disease;
CESC	cis	rs10128251	0.746	rs9424194	chr10:5724073	A/G	cg24097872	chr10:5724021	NA	0.38	5.55	0.32	6.76e-8	Childhood ear infection;
CESC	cis	rs7274811	0.711	rs291698	chr20:31982250	A/T	cg21523528	chr20:32077966	CBFA2T2	-0.45	-5.32	-0.31	2.21e-7	Height;
CESC	cis	rs8031584	0.678	rs4779497	chr15:31151365	T/A	cg14829155	chr15:31115871	NA	-0.76	-10.62	-0.55	3.5e-22	Huntington's disease progression;
CESC	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	7.83	0.43	1.17e-13	Prudent dietary pattern;
CESC	cis	rs13118159	0.934	rs4974553	chr4:1356911	G/A	cg20887711	chr4:1340912	KIAA1530	0.5	6.95	0.39	2.76e-11	Longevity;
CESC	cis	rs75804782	0.557	rs3769118	chr2:239342542	C/G	cg18131467	chr2:239335373	ASB1	-0.69	-6.69	-0.38	1.35e-10	Morning vs. evening chronotype;Chronotype;
CESC	cis	rs616402	0.527	rs589151	chr1:10567711	C/T	cg20482658	chr1:10539492	PEX14	-0.28	-5.84	-0.34	1.54e-8	Breast size;
CESC	trans	rs7088969	0.627	rs6585460	chr10:119552567	C/T	cg11827998	chr14:105995685	TMEM121	-0.41	-6.02	-0.35	5.83e-9	Homeostasis model assessment of beta-cell function (dietary factor interaction);
CESC	cis	rs644799	0.763	rs2950521	chr11:95536870	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.54	6.61	0.38	2.07e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg11970458	chr16:31213481	PYCARD	0.49	6.38	0.36	7.83e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs644799	0.965	rs534488	chr11:95562327	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.55	6.76	0.38	8.51e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs875971	0.522	rs6960048	chr7:65408039	A/G	cg14393609	chr7:65229607	NA	0.53	7.23	0.41	5.11e-12	Aortic root size;
CESC	trans	rs1814175	0.588	rs10466497	chr11:49864381	A/T	cg15704280	chr7:45808275	SEPT13	-1.0	-18.47	-0.75	1.63e-49	Height;
CESC	cis	rs3026101	0.671	rs1806249	chr17:5311143	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.42	5.6	0.33	5.28e-8	Body mass index;
CESC	trans	rs208520	0.690	rs3843513	chr6:66836797	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-12.94	-0.62	5.29e-30	Exhaled nitric oxide output;
CESC	cis	rs1448094	0.512	rs7313035	chr12:86250100	C/G	cg00310523	chr12:86230176	RASSF9	0.35	5.44	0.32	1.22e-7	Major depressive disorder;
CESC	cis	rs4819052	0.851	rs13050359	chr21:46672671	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.75	9.93	0.52	5.7e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs66573146	0.831	rs56081162	chr4:6989718	C/T	cg00086871	chr4:6988644	TBC1D14	1.18	7.59	0.42	5.52e-13	Granulocyte percentage of myeloid white cells;
CESC	cis	rs853679	0.542	rs2295594	chr6:28053097	G/A	cg12963246	chr6:28129442	ZNF389	0.55	7.35	0.41	2.46e-12	Depression;
CESC	cis	rs1707322	0.716	rs10890342	chr1:46157087	C/T	cg06784218	chr1:46089804	CCDC17	0.41	7.21	0.41	5.75e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs7837860	0.588	rs28630437	chr8:89298359	A/G	cg04391754	chr17:18022714	MYO15A	0.53	6.14	0.35	2.98e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs9768139	0.733	rs921617	chr7:158118198	A/G	cg25566285	chr7:158114605	PTPRN2	0.49	8.13	0.45	1.64e-14	Calcium levels;
CESC	cis	rs7824557	0.564	rs7821459	chr8:11236681	T/G	cg21775007	chr8:11205619	TDH	-0.54	-8.07	-0.44	2.52e-14	Retinal vascular caliber;
CESC	cis	rs9487051	0.676	rs7775206	chr6:109597222	A/G	cg12927641	chr6:109611667	NA	-0.37	-5.5	-0.32	8.91e-8	Reticulocyte fraction of red cells;
CESC	trans	rs1814175	0.645	rs1851853	chr11:49953434	C/T	cg03929089	chr4:120376271	NA	-0.92	-15.24	-0.68	4.38e-38	Height;
CESC	cis	rs2180341	1.000	rs9388561	chr6:127634921	C/T	cg27446573	chr6:127587934	RNF146	1.09	16.38	0.71	3.79e-42	Breast cancer;
CESC	cis	rs7923452	0.938	rs34930615	chr10:30761051	G/A	cg18806716	chr10:30721971	MAP3K8	0.5	6.0	0.35	6.45e-9	Itch intensity from mosquito bite;
CESC	cis	rs875971	0.862	rs13232191	chr7:65986648	A/G	cg10691866	chr7:65817282	TPST1	-0.33	-5.39	-0.31	1.58e-7	Aortic root size;
CESC	cis	rs2249694	0.503	rs9418982	chr10:135320622	C/T	cg20169779	chr10:135381914	SYCE1	0.41	5.4	0.31	1.49e-7	Obesity-related traits;
CESC	cis	rs10789491	1.000	rs11211342	chr1:47163098	T/C	cg15501359	chr1:47185051	KIAA0494	0.79	8.81	0.48	1.66e-16	Response to hepatitis C treatment;
CESC	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg20887711	chr4:1340912	KIAA1530	-0.84	-11.42	-0.57	8.04e-25	Longevity;
CESC	cis	rs3091242	0.804	rs631133	chr1:25724146	T/C	cg27572855	chr1:25598939	RHD	0.42	6.97	0.39	2.49e-11	Erythrocyte sedimentation rate;
CESC	cis	rs2303759	1.000	rs2303759	chr19:49869051	T/G	cg24324837	chr19:49891574	CCDC155	0.5	5.97	0.34	7.77e-9	Multiple sclerosis;
CESC	cis	rs965469	0.779	rs2236109	chr20:3286439	C/A	cg25506879	chr20:3388711	C20orf194	-0.47	-5.23	-0.31	3.51e-7	IFN-related cytopenia;
CESC	cis	rs875971	0.638	rs7793569	chr7:66116633	T/G	cg14393609	chr7:65229607	NA	-0.45	-6.02	-0.35	5.91e-9	Aortic root size;
CESC	cis	rs4891159	0.757	rs11665018	chr18:74123589	C/T	cg24786174	chr18:74118243	ZNF516	-0.72	-11.28	-0.57	2.31e-24	Longevity;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16526961	chr12:43965849	NA	-0.6	-7.71	-0.43	2.59e-13	Gut microbiome composition (summer);
CESC	trans	rs116095464	0.614	rs62344339	chr5:252995	T/G	cg00938859	chr5:1591904	SDHAP3	0.63	6.77	0.38	8.35e-11	Breast cancer;
CESC	cis	rs7219021	0.739	rs1800632	chr17:46970509	G/A	cg16584676	chr17:46985605	UBE2Z	-0.64	-7.31	-0.41	3.24e-12	Schizophrenia or bipolar disorder;
CESC	trans	rs9325144	0.600	rs7312522	chr12:38730423	A/G	cg23762105	chr12:34175262	ALG10	-0.45	-6.01	-0.35	6.11e-9	Morning vs. evening chronotype;
CESC	cis	rs4862750	0.872	rs6836781	chr4:187899701	G/A	cg10295955	chr4:187884368	NA	-1.08	-23.01	-0.82	4.07e-65	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1448094	0.512	rs11117061	chr12:86250916	G/A	cg02569458	chr12:86230093	RASSF9	0.53	7.76	0.43	1.89e-13	Major depressive disorder;
CESC	cis	rs2952156	0.959	rs2952151	chr17:37828496	T/C	cg00129232	chr17:37814104	STARD3	-0.74	-9.86	-0.52	9.77e-20	Asthma;
CESC	cis	rs1799949	1.000	rs8176273	chr17:41211653	A/G	cg05368731	chr17:41323189	NBR1	0.75	9.96	0.52	4.62e-20	Menopause (age at onset);
CESC	cis	rs425277	0.606	rs12082939	chr1:2078922	C/T	cg04315214	chr1:2043799	PRKCZ	-0.44	-7.18	-0.4	7.17e-12	Height;
CESC	cis	rs3106136	0.546	rs2664881	chr4:95143484	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.7	-11.56	-0.58	2.74e-25	Capecitabine sensitivity;
CESC	cis	rs1256061	0.646	rs1256056	chr14:64712626	A/G	cg23250157	chr14:64679961	SYNE2	0.51	7.36	0.41	2.3e-12	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs7703051	0.775	rs7702895	chr5:74612893	G/A	cg03227963	chr5:74354835	NA	0.28	5.1	0.3	6.48e-7	LDL cholesterol;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
CESC	cis	rs888194	0.934	rs3742015	chr12:110017125	T/C	cg19025524	chr12:109796872	NA	-0.35	-5.24	-0.31	3.3e-7	Neuroticism;
CESC	cis	rs9908102	0.746	rs8071456	chr17:12914458	C/A	cg26162695	chr17:12921313	ELAC2	0.52	5.66	0.33	4.01e-8	Schizophrenia;
CESC	trans	rs9330316	0.609	rs7579996	chr2:110371692	C/A	cg02059952	chr17:8384595	MYH10	-0.49	-6.06	-0.35	4.66e-9	Schizophrenia;
CESC	cis	rs9311474	1.000	rs1060330	chr3:52288945	T/C	cg18099408	chr3:52552593	STAB1	-0.32	-5.4	-0.31	1.46e-7	Electroencephalogram traits;
CESC	cis	rs9457247	1.000	rs10946199	chr6:167404492	G/A	cg25258033	chr6:167368657	RNASET2	0.39	5.9	0.34	1.13e-8	Crohn's disease;
CESC	cis	rs1552244	0.554	rs7638846	chr3:10048601	A/G	cg00149659	chr3:10157352	C3orf10	0.53	6.5	0.37	3.93e-10	Alzheimer's disease;
CESC	cis	rs11190604	1.000	rs74650218	chr10:102293830	C/T	cg07080220	chr10:102295463	HIF1AN	0.7	6.48	0.37	4.34e-10	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs807669	0.903	rs1780640	chr22:19174597	C/T	cg02655711	chr22:19163373	SLC25A1	0.97	15.0	0.68	2.98e-37	Metabolite levels;
CESC	cis	rs798554	0.797	rs798493	chr7:2798731	A/G	cg13628971	chr7:2884303	GNA12	0.61	7.69	0.43	2.95e-13	Height;
CESC	cis	rs2243480	0.901	rs57126451	chr7:65416306	T/C	cg25894440	chr7:65020034	NA	-0.63	-5.53	-0.32	7.48e-8	Diabetic kidney disease;
CESC	cis	rs7149337	0.869	rs7159770	chr14:51691835	G/A	cg23942311	chr14:51606299	NA	0.47	7.77	0.43	1.78e-13	Cancer;
CESC	cis	rs9584850	0.874	rs3742137	chr13:99102449	C/T	cg22223119	chr13:99095684	FARP1	-0.37	-5.22	-0.31	3.63e-7	Neuroticism;
CESC	cis	rs7666738	0.579	rs7672718	chr4:98645122	A/G	cg17366294	chr4:99064904	C4orf37	0.53	6.6	0.38	2.26e-10	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11958404	0.858	rs72818142	chr5:157474934	C/T	cg05962755	chr5:157440814	NA	0.62	7.22	0.41	5.45e-12	IgG glycosylation;
CESC	cis	rs6426558	0.502	rs6697665	chr1:227474665	T/C	cg10327440	chr1:227177885	CDC42BPA	0.48	6.02	0.35	5.76e-9	Neutrophil percentage of white cells;
CESC	cis	rs61996546	0.622	rs34916314	chr15:26833559	A/G	cg14859324	chr15:26874363	GABRB3	-0.38	-5.1	-0.3	6.45e-7	Response to methotrexate in juvenile idiopathic arthritis;
CESC	cis	rs713587	0.713	rs1982200	chr2:25205427	C/T	cg01884057	chr2:25150051	NA	-0.37	-6.94	-0.39	2.96e-11	Body mass index in non-asthmatics;
CESC	cis	rs12545109	0.800	rs2670055	chr8:57421575	T/C	cg09654669	chr8:57350985	NA	-0.45	-6.11	-0.35	3.5e-9	Obesity-related traits;
CESC	cis	rs3733585	0.579	rs4235353	chr4:10122934	C/T	cg00071950	chr4:10020882	SLC2A9	-0.65	-9.64	-0.51	4.77e-19	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs6662572	0.806	rs11211133	chr1:45991079	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.53	5.85	0.34	1.48e-8	Blood protein levels;
CESC	cis	rs6502050	0.835	rs4789731	chr17:80145904	C/T	cg23985595	chr17:80112537	CCDC57	-0.41	-6.48	-0.37	4.56e-10	Life satisfaction;
CESC	cis	rs2243480	1.000	rs313814	chr7:65503293	C/A	cg25894440	chr7:65020034	NA	-0.62	-5.24	-0.31	3.26e-7	Diabetic kidney disease;
CESC	cis	rs7666738	0.830	rs13138059	chr4:99050430	A/G	cg17366294	chr4:99064904	C4orf37	0.61	8.68	0.47	4.24e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7208859	0.673	rs4131618	chr17:29204801	C/T	cg19761014	chr17:28927070	LRRC37B2	0.63	5.27	0.31	2.88e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg17004975	chr10:81743287	NA	0.43	6.43	0.37	6.06e-10	Fibrinogen levels;
CESC	cis	rs9399135	0.967	rs6902438	chr6:135336587	C/T	cg22676075	chr6:135203613	NA	0.52	7.42	0.41	1.61e-12	Red blood cell count;
CESC	cis	rs7772486	0.597	rs2485631	chr6:146190077	G/C	cg23711669	chr6:146136114	FBXO30	0.94	12.32	0.6	7.27e-28	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs12477438	0.765	rs2309520	chr2:99570477	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.61	8.58	0.47	8.15e-16	Chronic sinus infection;
CESC	cis	rs2412488	0.853	rs12507739	chr4:54352768	C/T	cg22241045	chr4:54363911	LNX1	0.38	5.29	0.31	2.54e-7	DNA methylation (variation);
CESC	cis	rs7617773	0.780	rs11706277	chr3:48360433	A/G	cg20734569	chr3:48348370	SPINK8	-0.4	-5.37	-0.31	1.69e-7	Coronary artery disease;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg27337021	chr5:139947627	SLC35A4	0.46	6.01	0.35	5.98e-9	Ulcerative colitis;
CESC	cis	rs9443645	0.527	rs9359360	chr6:79702796	C/T	cg05283184	chr6:79620031	NA	-0.36	-5.17	-0.3	4.64e-7	Intelligence (multi-trait analysis);
CESC	cis	rs1799949	1.000	rs35956818	chr17:41422985	T/C	cg25072359	chr17:41440525	NA	0.45	6.03	0.35	5.61e-9	Menopause (age at onset);
CESC	cis	rs7937682	0.960	rs480293	chr11:111469132	A/C	cg22437258	chr11:111473054	SIK2	0.71	9.19	0.49	1.16e-17	Primary sclerosing cholangitis;
CESC	cis	rs6460942	0.915	rs62448623	chr7:12464122	A/G	cg10578991	chr7:12443926	VWDE	-0.5	-5.52	-0.32	7.93e-8	Coronary artery disease;
CESC	cis	rs2274273	0.840	rs2341622	chr14:55737243	C/A	cg04306507	chr14:55594613	LGALS3	0.29	5.59	0.33	5.51e-8	Protein biomarker;
CESC	trans	rs7824557	0.547	rs2409745	chr8:11076635	G/T	cg15556689	chr8:8085844	FLJ10661	0.49	6.15	0.35	2.8e-9	Retinal vascular caliber;
CESC	cis	rs2380220	0.574	rs7766765	chr6:95997362	G/A	cg04719120	chr6:96025338	MANEA	0.47	5.39	0.31	1.6e-7	Behavioural disinhibition (generation interaction);
CESC	cis	rs561341	1.000	rs72823789	chr17:30284084	G/A	cg12193833	chr17:30244370	NA	-0.76	-6.94	-0.39	2.92e-11	Hip circumference adjusted for BMI;
CESC	cis	rs4689592	0.513	rs4689586	chr4:7067413	A/G	cg26116260	chr4:7069785	GRPEL1	0.99	14.35	0.66	5.85e-35	Monocyte percentage of white cells;
CESC	cis	rs1400745	0.718	rs1200414	chr14:35330893	G/A	cg16230307	chr14:35515116	FAM177A1	0.45	5.2	0.3	4.05e-7	Monocyte count;
CESC	cis	rs909674	0.662	rs2899318	chr22:39837625	A/G	cg01416388	chr22:39784598	NA	-0.62	-7.64	-0.42	4.05e-13	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs1707322	0.752	rs12024590	chr1:46127496	A/C	cg06784218	chr1:46089804	CCDC17	0.41	7.12	0.4	1.04e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9733	0.650	rs11204684	chr1:150608894	A/G	cg18016565	chr1:150552671	MCL1	-0.42	-6.96	-0.39	2.64e-11	Tonsillectomy;
CESC	cis	rs1348850	0.914	rs4893950	chr2:178304885	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.88	12.63	0.61	5.96e-29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs2243480	1.000	rs56985706	chr7:65394562	C/T	cg12463550	chr7:65579703	CRCP	0.7	5.7	0.33	3.21e-8	Diabetic kidney disease;
CESC	cis	rs780096	0.546	rs1260320	chr2:27722416	A/G	cg17158414	chr2:27665306	KRTCAP3	0.32	6.14	0.35	2.98e-9	Total body bone mineral density;
CESC	cis	rs1568889	0.592	rs11828877	chr11:28384030	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.54	5.33	0.31	2.1e-7	Bipolar disorder;
CESC	cis	rs7089973	0.966	rs12772800	chr10:116630962	A/G	cg23260525	chr10:116636907	FAM160B1	0.37	6.08	0.35	4.22e-9	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg19552494	chr11:60674271	PRPF19	-0.43	-6.03	-0.35	5.56e-9	Gambling;
CESC	cis	rs8031584	0.678	rs36047941	chr15:31159235	A/G	cg08109568	chr15:31115862	NA	-0.71	-9.63	-0.51	5.02e-19	Huntington's disease progression;
CESC	cis	rs30380	0.632	rs27434	chr5:96129512	A/G	cg16492584	chr5:96139282	ERAP1	-0.48	-6.82	-0.39	6.04e-11	Cerebrospinal fluid biomarker levels;
CESC	cis	rs4819052	0.851	rs12626188	chr21:46669258	A/G	cg11663144	chr21:46675770	NA	-0.64	-10.11	-0.53	1.55e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs763121	0.853	rs1043441	chr22:39130964	C/T	cg06022373	chr22:39101656	GTPBP1	0.89	14.59	0.67	8.89e-36	Menopause (age at onset);
CESC	cis	rs2070488	0.965	rs7372386	chr3:38484175	C/G	cg24069376	chr3:38537580	EXOG	0.46	8.19	0.45	1.15e-14	Electrocardiographic conduction measures;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	ch.14.1124768F	chr14:75910539	JDP2	-0.66	-8.3	-0.45	5.3e-15	Gut microbiome composition (summer);
CESC	cis	rs7818688	1.000	rs10110635	chr8:96025069	C/A	cg16049864	chr8:95962084	TP53INP1	0.6	5.76	0.33	2.31e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs4654899	0.796	rs77366434	chr1:21520069	C/T	cg05370193	chr1:21551575	ECE1	0.45	7.03	0.4	1.76e-11	Superior frontal gyrus grey matter volume;
CESC	cis	rs9894429	0.716	rs7405578	chr17:79588306	C/A	cg21984481	chr17:79567631	NPLOC4	-0.57	-9.34	-0.5	4.18e-18	Eye color traits;
CESC	cis	rs611744	0.839	rs672552	chr8:109164223	A/G	cg21045802	chr8:109455806	TTC35	0.45	5.49	0.32	9.39e-8	Dupuytren's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10082991	chr5:175964280	RNF44	-0.64	-7.4	-0.41	1.78e-12	Gut microbiome composition (summer);
CESC	cis	rs17253792	0.822	rs9323289	chr14:56106784	G/C	cg01858014	chr14:56050164	KTN1	-0.85	-7.03	-0.4	1.73e-11	Putamen volume;
CESC	cis	rs9902453	1.000	rs4239227	chr17:28389103	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.62	-7.87	-0.44	9.09e-14	Coffee consumption (cups per day);
CESC	cis	rs6879260	1.000	rs7725605	chr5:179732678	T/G	cg23248424	chr5:179741104	GFPT2	-0.7	-9.8	-0.52	1.47e-19	Height;
CESC	cis	rs9581857	0.547	rs9579087	chr13:28059780	G/A	cg01674679	chr13:27998804	GTF3A	-0.64	-5.34	-0.31	2.03e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
CESC	cis	rs514406	0.505	rs374662	chr1:53164549	C/A	cg24675658	chr1:53192096	ZYG11B	-0.52	-6.6	-0.38	2.19e-10	Monocyte count;
CESC	cis	rs4253772	0.638	rs6007845	chr22:46718417	A/T	cg18190219	chr22:46762943	CELSR1	0.4	5.27	0.31	2.86e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs3091242	0.933	rs9438904	chr1:25756860	T/C	cg03538708	chr1:25844672	NA	-0.41	-6.25	-0.36	1.67e-9	Erythrocyte sedimentation rate;
CESC	cis	rs62005083	1.000	rs55714624	chr14:74483344	C/A	cg05179529	chr14:74551516	LIN52;ALDH6A1	0.69	5.12	0.3	6.01e-7	Mean corpuscular volume;
CESC	cis	rs7824557	0.767	rs2164273	chr8:11168499	A/G	cg21775007	chr8:11205619	TDH	0.47	6.79	0.39	7.18e-11	Retinal vascular caliber;
CESC	cis	rs8111998	0.826	rs16999362	chr19:22764825	A/C	cg19914732	chr19:22715077	NA	-0.37	-5.09	-0.3	6.68e-7	Corneal structure;
CESC	trans	rs11098499	0.954	rs12507964	chr4:120413061	T/A	cg25214090	chr10:38739885	LOC399744	0.72	10.08	0.53	1.97e-20	Corneal astigmatism;
CESC	cis	rs208520	0.770	rs2224422	chr6:66883993	G/A	cg07460842	chr6:66804631	NA	-0.94	-12.15	-0.6	2.75e-27	Exhaled nitric oxide output;
CESC	cis	rs7617773	0.817	rs13094727	chr3:48323489	G/A	cg11946769	chr3:48343235	NME6	0.88	11.71	0.58	8.57e-26	Coronary artery disease;
CESC	cis	rs1003719	0.715	rs9974494	chr21:38566566	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.61	-8.27	-0.45	6.41e-15	Eye color traits;
CESC	cis	rs933688	0.938	rs7720235	chr5:90659329	A/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.19	16.79	0.72	1.39e-43	Smoking behavior;
CESC	cis	rs9926296	0.585	rs6500450	chr16:89858024	A/G	cg27121462	chr16:89883253	FANCA	0.74	10.32	0.54	3.3e-21	Vitiligo;
CESC	cis	rs9815354	1.000	rs1716669	chr3:41908681	A/G	cg03022575	chr3:42003672	ULK4	0.44	5.16	0.3	4.85e-7	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs7662987	0.517	rs2602883	chr4:100040914	A/T	cg13256891	chr4:100009986	ADH5	0.74	7.89	0.44	7.94e-14	Smoking initiation;
CESC	cis	rs7264396	0.563	rs6060558	chr20:34271092	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.9	-9.83	-0.52	1.23e-19	Total cholesterol levels;
CESC	cis	rs7301826	0.651	rs7971046	chr12:131286807	G/A	cg11011512	chr12:131303247	STX2	0.47	5.85	0.34	1.48e-8	Plasma plasminogen activator levels;
CESC	cis	rs28374715	0.532	rs28584379	chr15:41670408	C/G	cg18705301	chr15:41695430	NDUFAF1	-1.08	-17.72	-0.74	7.19e-47	Ulcerative colitis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14899563	chr17:80656473	RAB40B	0.66	7.8	0.43	1.4e-13	Gut microbiome composition (summer);
CESC	cis	rs681343	1.000	rs516246	chr19:49206172	C/T	cg21064579	chr19:49206444	FUT2	0.52	7.35	0.41	2.4e-12	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
CESC	cis	rs3820068	0.603	rs6660234	chr1:15962590	T/C	cg16988262	chr1:15930761	NA	0.34	5.48	0.32	9.82e-8	Systolic blood pressure;
CESC	cis	rs7561273	0.609	rs10189243	chr2:24293756	C/T	cg20701182	chr2:24300061	SF3B14	0.45	6.03	0.35	5.41e-9	Quantitative traits;
CESC	cis	rs1552244	1.000	rs6781811	chr3:10121922	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	0.85	12.03	0.59	6.76e-27	Alzheimer's disease;
CESC	cis	rs3820068	0.705	rs4646109	chr1:15817319	T/C	cg17385448	chr1:15911702	AGMAT	0.41	6.43	0.37	5.93e-10	Systolic blood pressure;
CESC	cis	rs12142240	0.698	rs79490411	chr1:46813568	G/A	cg00530320	chr1:46809349	NSUN4	0.58	7.45	0.42	1.31e-12	Menopause (age at onset);
CESC	cis	rs13385	0.769	rs9042	chr5:139625347	A/C	cg26211634	chr5:139558579	C5orf32	0.49	5.36	0.31	1.86e-7	Atrial fibrillation;
CESC	cis	rs34779708	0.801	rs12246600	chr10:35538121	A/C	cg03585969	chr10:35415529	CREM	0.57	6.57	0.37	2.6200000000000003e-10	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs561341	1.000	rs55959993	chr17:30254771	C/G	cg19193384	chr17:30244184	NA	-0.7	-6.41	-0.37	6.77e-10	Hip circumference adjusted for BMI;
CESC	cis	rs477692	0.699	rs471357	chr10:131389373	C/G	cg05714579	chr10:131428358	MGMT	0.47	6.16	0.35	2.74e-9	Response to temozolomide;
CESC	cis	rs8077889	0.826	rs60085355	chr17:41847415	T/C	cg26893861	chr17:41843967	DUSP3	0.74	8.79	0.48	1.87e-16	Triglycerides;
CESC	cis	rs3796352	1.000	rs13072457	chr3:53102389	G/A	cg12962167	chr3:53033115	SFMBT1	0.7	6.17	0.35	2.6e-9	Immune reponse to smallpox (secreted IL-2);
CESC	cis	rs2985684	0.841	rs2281836	chr14:50065717	G/C	cg10008539	chr14:50087325	RPL36AL;MGAT2	-0.45	-5.35	-0.31	1.92e-7	Carotid intima media thickness;
CESC	cis	rs3096299	0.933	rs2965823	chr16:89454924	G/A	cg08392591	chr16:89556376	ANKRD11	0.4	5.1	0.3	6.46e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs11122272	0.735	rs2250704	chr1:231486647	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-7.06	-0.4	1.44e-11	Hemoglobin concentration;
CESC	cis	rs55728055	0.661	rs7293143	chr22:32013365	A/G	cg01338084	chr22:32026380	PISD	-1.03	-7.29	-0.41	3.65e-12	Age-related hearing impairment;
CESC	cis	rs7666738	0.830	rs62318470	chr4:98925846	A/C	cg05340658	chr4:99064831	C4orf37	0.82	12.2	0.6	1.81e-27	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6460942	0.908	rs73677573	chr7:12283598	G/A	cg20607287	chr7:12443886	VWDE	-0.57	-6.07	-0.35	4.48e-9	Coronary artery disease;
CESC	cis	rs7116495	0.786	rs1573501	chr11:71735693	C/T	cg18441811	chr11:71824068	C11orf51	-0.86	-5.19	-0.3	4.21e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs36051895	0.589	rs7869015	chr9:5199750	C/T	cg02405213	chr9:5042618	JAK2	-0.58	-7.15	-0.4	8.26e-12	Pediatric autoimmune diseases;
CESC	cis	rs1048257	0.553	rs2819421	chr14:105408811	A/G	cg14403583	chr14:105418241	AHNAK2	-0.57	-7.87	-0.44	9.27e-14	Systemic lupus erythematosus;
CESC	cis	rs12188164	0.965	rs72717435	chr5:448202	G/A	cg17553881	chr5:443987	EXOC3;C5orf55	-0.38	-6.13	-0.35	3.15e-9	Cystic fibrosis severity;
CESC	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.53	7.26	0.41	4.23e-12	Lymphocyte counts;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg08907850	chr10:1094976	IDI1	-0.43	-6.29	-0.36	1.29e-9	Gambling;
CESC	cis	rs116095464	0.558	rs61689490	chr5:224904	T/C	cg22496380	chr5:211416	CCDC127	-0.74	-8.72	-0.47	3.15e-16	Breast cancer;
CESC	cis	rs9828933	1.000	rs1060897	chr3:63997872	C/T	cg16258503	chr3:63850278	ATXN7;THOC7	0.53	5.78	0.33	2.07e-8	Type 2 diabetes;
CESC	cis	rs734999	0.588	rs4648562	chr1:2535613	C/A	cg20673091	chr1:2541236	MMEL1	0.43	7.16	0.4	7.78e-12	Ulcerative colitis;
CESC	trans	rs7672847	0.547	rs73864703	chr4:170434337	C/A	cg19308436	chr1:237949471	RYR2	0.64	6.86	0.39	4.99e-11	Subjective well-being;
CESC	cis	rs2033711	0.870	rs11669741	chr19:58960481	C/T	cg13877915	chr19:58951672	ZNF132	-0.35	-5.32	-0.31	2.16e-7	Uric acid clearance;
CESC	cis	rs66573146	0.831	rs6851488	chr4:6987412	C/T	cg00086871	chr4:6988644	TBC1D14	1.11	8.24	0.45	8.17e-15	Granulocyte percentage of myeloid white cells;
CESC	cis	rs11722228	0.522	rs7662229	chr4:10133014	A/T	cg14348967	chr4:10160060	NA	-0.39	-5.06	-0.3	7.9e-7	Gout;Urate levels;Serum uric acid levels;
CESC	cis	rs854765	0.583	rs4534911	chr17:17852330	A/G	cg04398451	chr17:18023971	MYO15A	-0.7	-9.67	-0.51	3.92e-19	Total body bone mineral density;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg26820922	chr2:32503023	YIPF4	-0.47	-6.79	-0.38	7.37e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs9393777	0.513	rs9379893	chr6:26584668	A/G	cg12826209	chr6:26865740	GUSBL1	-0.63	-7.18	-0.4	7.13e-12	Intelligence (multi-trait analysis);
CESC	cis	rs8044868	0.586	rs7190994	chr16:72099241	T/A	cg01557791	chr16:72042693	DHODH	-0.43	-5.89	-0.34	1.17e-8	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CESC	cis	rs7481584	0.962	rs11603638	chr11:2990526	G/A	cg25174290	chr11:3078921	CARS	-0.51	-6.24	-0.36	1.75e-9	Calcium levels;
CESC	cis	rs1355223	0.902	rs680727	chr11:34704446	A/C	cg11058730	chr11:34937778	PDHX;APIP	0.49	6.62	0.38	1.99e-10	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs2832191	0.740	rs6516890	chr21:30476812	T/A	cg08807101	chr21:30365312	RNF160	0.76	11.01	0.56	1.88e-23	Dental caries;
CESC	cis	rs3026101	0.587	rs8066000	chr17:5310033	C/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.42	5.6	0.33	5.31e-8	Body mass index;
CESC	cis	rs2742234	0.541	rs61845684	chr10:43744983	T/C	cg15436174	chr10:43711423	RASGEF1A	0.46	5.33	0.31	2.14e-7	Hirschsprung disease;
CESC	cis	rs2637266	1.000	rs4979784	chr10:78355476	T/A	cg18941641	chr10:78392320	NA	0.42	7.79	0.43	1.49e-13	Pulmonary function;
CESC	cis	rs597539	0.616	rs72945243	chr11:68633358	T/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.76	9.54	0.51	1e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs4144743	0.941	rs10438782	chr17:45323892	G/A	cg18085866	chr17:45331354	ITGB3	-0.66	-7.64	-0.43	3.87e-13	Body mass index;
CESC	cis	rs4555082	0.874	rs28822720	chr14:105746282	T/C	cg10792982	chr14:105748885	BRF1	0.43	5.67	0.33	3.65e-8	Mean platelet volume;Platelet distribution width;
CESC	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg05552183	chr6:42928497	GNMT	0.75	11.18	0.57	4.84e-24	Alzheimer's disease in APOE e4+ carriers;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg27304813	chr3:120068385	LRRC58	-0.45	-5.99	-0.35	6.64e-9	Height;
CESC	cis	rs1348850	0.914	rs1374437	chr2:178363423	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.86	12.28	0.6	9.65e-28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs4692589	0.802	rs1480542	chr4:170953614	C/T	cg19918862	chr4:170955249	NA	0.43	6.62	0.38	2e-10	Anxiety disorder;
CESC	trans	rs11039798	0.660	rs717897	chr11:48375604	A/G	cg15704280	chr7:45808275	SEPT13	-0.62	-6.13	-0.35	3.22e-9	Axial length;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16555184	chr1:149982714	OTUD7B	0.61	6.76	0.38	8.66e-11	Gut microbiome composition (summer);
CESC	cis	rs875971	1.000	rs12533997	chr7:65965377	A/G	cg18876405	chr7:65276391	NA	0.49	6.51	0.37	3.76e-10	Aortic root size;
CESC	cis	rs2066819	1.000	rs2066818	chr12:56753822	C/A	cg26714650	chr12:56694279	CS	-1.39	-9.05	-0.49	3.12e-17	Psoriasis vulgaris;
CESC	cis	rs1577917	1.000	rs1995688	chr6:86632319	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.42	-5.53	-0.32	7.75e-8	Response to antipsychotic treatment;
CESC	cis	rs1552244	1.000	rs112509186	chr3:10156533	A/G	cg00149659	chr3:10157352	C3orf10	0.7	8.47	0.46	1.68e-15	Alzheimer's disease;
CESC	cis	rs9311474	0.508	rs12629701	chr3:52619836	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.49	7.13	0.4	9.67e-12	Electroencephalogram traits;
CESC	cis	rs6460942	0.749	rs74834695	chr7:12464779	G/A	cg10578991	chr7:12443926	VWDE	-0.5	-5.52	-0.32	7.93e-8	Coronary artery disease;
CESC	cis	rs4843747	0.671	rs28465438	chr16:88103714	G/A	cg17633681	chr16:88106987	BANP	0.71	9.35	0.5	3.79e-18	Menopause (age at onset);
CESC	cis	rs870825	0.616	rs28463742	chr4:185611005	G/A	cg04058563	chr4:185651563	MLF1IP	0.67	7.38	0.41	2.09e-12	Blood protein levels;
CESC	cis	rs864537	0.646	rs1773542	chr1:167432949	T/C	cg09179987	chr1:167433047	CD247	0.53	8.2	0.45	1.07e-14	Celiac disease or Rheumatoid arthritis;Celiac disease;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg14457132	chr6:7389888	CAGE1;RIOK1	-0.48	-6.0	-0.35	6.56e-9	Ulcerative colitis;
CESC	cis	rs10870270	1.000	rs7078692	chr10:133775370	T/A	cg08754478	chr10:133766260	PPP2R2D	-0.59	-7.57	-0.42	6.29e-13	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	trans	rs7618501	1.000	rs11716575	chr3:49744890	A/G	cg21659725	chr3:3221576	CRBN	-0.82	-13.57	-0.64	3.35e-32	Intelligence (multi-trait analysis);
CESC	cis	rs4535700	0.504	rs66528253	chr7:55996763	C/T	cg09872392	chr7:56161020	PHKG1	0.41	5.86	0.34	1.41e-8	Macular telangiectasia type 2;
CESC	trans	rs561341	1.000	rs72823785	chr17:30273784	C/T	cg20587970	chr11:113659929	NA	-1.44	-18.65	-0.75	3.63e-50	Hip circumference adjusted for BMI;
CESC	cis	rs2011503	1.000	rs1036215	chr19:19657198	C/T	cg11584989	chr19:19387371	SF4	0.56	5.96	0.34	8.06e-9	Bipolar disorder;
CESC	cis	rs1799949	1.000	rs11653069	chr17:41283377	C/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.45	6.31	0.36	1.17e-9	Menopause (age at onset);
CESC	cis	rs11871801	1.000	rs78594996	chr17:40570109	A/G	cg21433558	chr17:40837037	CNTNAP1	0.46	5.12	0.3	5.77e-7	Crohn's disease;
CESC	cis	rs561341	0.629	rs7216107	chr17:30224419	G/A	cg13647721	chr17:30228624	UTP6	0.73	9.24	0.49	8.1e-18	Hip circumference adjusted for BMI;
CESC	cis	rs6570726	0.791	rs436156	chr6:145874873	A/G	cg05347473	chr6:146136440	FBXO30	0.57	7.21	0.4	5.99e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7831492	0.564	rs6981979	chr8:41612255	C/T	cg17182837	chr8:41585554	ANK1	-0.42	-6.42	-0.37	6.25e-10	Colorectal cancer;
CESC	cis	rs2898290	0.540	rs12677146	chr8:11450737	C/G	cg21775007	chr8:11205619	TDH	-0.46	-6.7	-0.38	1.25e-10	Systolic blood pressure;
CESC	cis	rs4665809	1.000	rs2384321	chr2:26290054	A/G	cg26314531	chr2:26401878	FAM59B	-0.77	-8.56	-0.47	9.38e-16	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14413721	chr9:86322043	UBQLN1	-0.59	-6.6	-0.38	2.25e-10	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.830	rs35915560	chr4:98978649	C/T	cg03676636	chr4:99064102	C4orf37	0.33	5.15	0.3	5.16e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7980687	0.628	rs1727332	chr12:123718301	C/T	cg19016782	chr12:123741754	C12orf65	-0.37	-5.49	-0.32	9.58e-8	Height;Educational attainment;Head circumference (infant);
CESC	cis	rs2836974	0.565	rs2836939	chr21:40578546	C/T	cg17971929	chr21:40555470	PSMG1	0.71	7.24	0.41	4.94e-12	Cognitive function;
CESC	cis	rs735396	1.000	rs1169311	chr12:121440731	C/T	cg25281562	chr12:121454272	C12orf43	0.39	5.08	0.3	7.26e-7	N-glycan levels;
CESC	cis	rs1124769	0.871	rs2619695	chr15:51160090	C/G	cg21246271	chr15:51200259	AP4E1	0.54	5.15	0.3	5.16e-7	Cognitive performance;
CESC	cis	rs8103278	0.864	rs2070737	chr19:46282890	A/T	cg14061069	chr19:46274453	DMPK	-0.4	-5.44	-0.32	1.22e-7	Coronary artery disease;
CESC	cis	rs736408	0.677	rs1042779	chr3:52821011	A/G	cg17372223	chr3:52568218	NT5DC2	0.39	5.6	0.33	5.45e-8	Bipolar disorder;
CESC	cis	rs9733	0.596	rs72702580	chr1:150691285	A/T	cg22823121	chr1:150693482	HORMAD1	0.48	7.11	0.4	1.11e-11	Tonsillectomy;
CESC	cis	rs62005083	1.000	rs56073585	chr14:74490045	C/T	cg05179529	chr14:74551516	LIN52;ALDH6A1	0.69	5.12	0.3	6.01e-7	Mean corpuscular volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14748682	chr11:6624841	ILK;RRP8	0.61	6.52	0.37	3.45e-10	Gut microbiome composition (summer);
CESC	cis	rs36051895	0.623	rs7043634	chr9:5263146	G/A	cg02405213	chr9:5042618	JAK2	-0.55	-6.72	-0.38	1.1e-10	Pediatric autoimmune diseases;
CESC	cis	rs854765	0.964	rs854813	chr17:18003845	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.46	-6.09	-0.35	3.92e-9	Total body bone mineral density;
CESC	cis	rs3008870	1.000	rs12117131	chr1:67451922	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-1.04	-14.57	-0.67	9.76e-36	Lymphocyte percentage of white cells;
CESC	cis	rs60871478	1.000	rs62432253	chr7:802928	A/G	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.62	6.09	0.35	3.88e-9	Cerebrospinal P-tau181p levels;
CESC	cis	rs9611565	0.694	rs7285041	chr22:41829149	G/T	cg06634786	chr22:41940651	POLR3H	0.71	7.08	0.4	1.28e-11	Vitiligo;
CESC	cis	rs2228479	0.717	rs2286392	chr16:89809549	A/G	cg06558623	chr16:89946397	TCF25	0.79	7.45	0.42	1.32e-12	Skin colour saturation;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05446253	chr17:73498127	CASKIN2	-0.53	-6.03	-0.35	5.34e-9	Gut microbiome composition (summer);
CESC	cis	rs826838	1.000	rs11168676	chr12:38977304	A/G	cg26384229	chr12:38710491	ALG10B	0.82	14.24	0.66	1.47e-34	Heart rate;
CESC	cis	rs4975709	0.610	rs4975706	chr5:1860365	G/T	cg17650747	chr5:1873721	NA	0.41	5.69	0.33	3.31e-8	Cardiovascular disease risk factors;
CESC	trans	rs10751667	0.961	rs7480178	chr11:927108	T/C	cg00159523	chr10:114713187	TCF7L2	-0.41	-6.13	-0.35	3.1e-9	Alzheimer's disease (late onset);
CESC	cis	rs769267	0.965	rs2023882	chr19:19405405	T/C	cg03709012	chr19:19516395	GATAD2A	0.95	13.98	0.65	1.22e-33	Tonsillectomy;
CESC	cis	rs7188861	0.813	rs1794021	chr16:11377234	G/A	cg01510278	chr16:11456238	NA	0.33	5.18	0.3	4.49e-7	HDL cholesterol;
CESC	cis	rs35110281	0.633	rs2329593	chr21:45121987	T/C	cg21573476	chr21:45109991	RRP1B	-0.56	-8.01	-0.44	3.56e-14	Mean corpuscular volume;
CESC	cis	rs12579753	0.917	rs76240969	chr12:82195236	C/A	cg24719984	chr12:82153464	PPFIA2	-0.33	-5.04	-0.3	8.55e-7	Resting heart rate;
CESC	cis	rs959260	1.000	rs2033608	chr17:73367208	T/C	cg12999837	chr17:73267436	MIF4GD	-0.51	-5.73	-0.33	2.73e-8	Systemic lupus erythematosus;
CESC	cis	rs736408	0.609	rs13095332	chr3:52787242	C/T	cg05564831	chr3:52568323	NT5DC2	0.45	6.78	0.38	7.86e-11	Bipolar disorder;
CESC	cis	rs12995491	1.000	rs12995491	chr2:88527414	C/T	cg18490616	chr2:88469792	THNSL2	0.51	7.69	0.43	2.86e-13	Response to metformin (IC50);
CESC	cis	rs9611565	0.765	rs132905	chr22:41799106	C/A	cg06634786	chr22:41940651	POLR3H	0.71	7.51	0.42	9.15e-13	Vitiligo;
CESC	cis	rs12681288	0.792	rs4735972	chr8:998618	A/C	cg04851639	chr8:1020857	NA	-0.29	-6.55	-0.37	2.9e-10	Schizophrenia;
CESC	cis	rs7618915	0.547	rs62253733	chr3:52653414	A/G	cg18099408	chr3:52552593	STAB1	-0.32	-5.19	-0.3	4.2e-7	Bipolar disorder;
CESC	cis	rs514406	0.708	rs546334	chr1:53326210	T/C	cg08859206	chr1:53392774	SCP2	-0.67	-9.86	-0.52	9.57e-20	Monocyte count;
CESC	cis	rs11642862	1.000	rs75231191	chr16:30788601	C/T	cg02466173	chr16:30829666	NA	-0.59	-5.92	-0.34	9.76e-9	Tonsillectomy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12037538	chr1:25664880	TMEM50A	-0.66	-7.52	-0.42	8.47e-13	Gut microbiome composition (summer);
CESC	cis	rs6088580	0.561	rs3761147	chr20:32996689	G/T	cg06115741	chr20:33292138	TP53INP2	-0.45	-5.72	-0.33	2.85e-8	Glomerular filtration rate (creatinine);
CESC	trans	rs10838801	1	rs10838801	chr11:48098280	G/A	cg15704280	chr7:45808275	SEPT13	-0.71	-9.29	-0.5	6.03e-18	Height;
CESC	trans	rs73568641	0.583	rs73572674	chr6:154098476	A/G	cg08374472	chr16:87445639	ZCCHC14	-0.45	-6.13	-0.35	3.22e-9	Methadone dose in opioid dependence;
CESC	cis	rs9487051	0.676	rs9374077	chr6:109600194	C/T	cg01475377	chr6:109611718	NA	-0.43	-6.82	-0.39	6.19e-11	Reticulocyte fraction of red cells;
CESC	cis	rs6461049	0.638	rs1859993	chr7:2183702	A/G	cg02951883	chr7:2050386	MAD1L1	-0.41	-5.44	-0.32	1.18e-7	Schizophrenia;
CESC	cis	rs9868809	0.772	rs12107418	chr3:48689787	A/G	cg07636037	chr3:49044803	WDR6	-0.73	-6.57	-0.37	2.71e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs1882538	0.901	rs35284403	chr7:132948884	T/C	cg10665199	chr7:133106180	EXOC4	0.51	6.23	0.36	1.82e-9	Intelligence (multi-trait analysis);
CESC	cis	rs7131987	0.903	rs11050163	chr12:29420398	C/T	cg09582351	chr12:29534625	ERGIC2	-0.33	-5.51	-0.32	8.63e-8	QT interval;
CESC	cis	rs7980687	0.627	rs1727325	chr12:123698332	G/C	cg00376283	chr12:123451042	ABCB9	0.7	8.83	0.48	1.41e-16	Height;Educational attainment;Head circumference (infant);
CESC	cis	rs6691722	0.543	rs12034846	chr1:24699589	G/A	cg02336364	chr1:24764700	NIPAL3	0.35	7.07	0.4	1.41e-11	Response to interferon beta in multiple sclerosis;
CESC	cis	rs4803468	0.967	rs892044	chr19:41903671	A/G	cg14132834	chr19:41945861	ATP5SL	-0.61	-7.74	-0.43	2.09e-13	Height;
CESC	cis	rs62084913	0.511	rs895690	chr17:72784649	C/T	cg25054828	chr17:72772726	NAT9;TMEM104	0.52	7.32	0.41	3.03e-12	Breast cancer;
CESC	cis	rs597539	0.552	rs6591360	chr11:68718669	G/T	cg21963583	chr11:68658836	MRPL21	0.4	5.66	0.33	3.88e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs853679	0.550	rs1150692	chr6:28173957	A/G	cg19592336	chr6:28129416	ZNF389	0.51	6.92	0.39	3.39e-11	Depression;
CESC	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.54	6.73	0.38	1.02e-10	Prudent dietary pattern;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24557248	chr1:155990769	SSR2	0.63	7.19	0.4	6.63e-12	Gut microbiome composition (summer);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg12655452	chr1:77685094	PIGK	-0.49	-6.42	-0.37	6.42e-10	Fibrinogen levels;
CESC	cis	rs9733	0.525	rs11584184	chr1:150695689	A/T	cg18016565	chr1:150552671	MCL1	0.34	5.28	0.31	2.67e-7	Tonsillectomy;
CESC	cis	rs2274273	0.638	rs11622636	chr14:55647840	C/T	cg04306507	chr14:55594613	LGALS3	0.31	5.3	0.31	2.42e-7	Protein biomarker;
CESC	cis	rs7107770	0.739	rs4936994	chr11:125081440	G/C	cg27629782	chr11:125073726	PKNOX2	0.34	5.06	0.3	7.96e-7	Photic sneeze reflex;
CESC	cis	rs7267979	1.000	rs6115140	chr20:25285507	C/A	cg08601574	chr20:25228251	PYGB	0.37	5.2	0.3	3.93e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs12971120	1.000	rs734559	chr18:72179579	G/A	cg26446133	chr18:72167187	CNDP2	-0.75	-9.67	-0.51	3.83e-19	Refractive error;
CESC	cis	rs733592	0.507	rs7304428	chr12:48494275	T/G	cg04545296	chr12:48745243	ZNF641	-0.29	-5.37	-0.31	1.69e-7	Plateletcrit;
CESC	trans	rs4689592	0.503	rs59640165	chr4:7051661	G/A	cg07817883	chr1:32538562	TMEM39B	0.68	6.45	0.37	5.33e-10	Monocyte percentage of white cells;
CESC	cis	rs9926296	0.632	rs1800286	chr16:89869761	T/C	cg27121462	chr16:89883253	FANCA	0.56	6.57	0.37	2.66e-10	Vitiligo;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg10205151	chr7:931109	C7orf20	0.48	6.43	0.37	6.01e-10	Fibrinogen levels;
CESC	cis	rs227584	0.663	rs3180912	chr17:42259463	A/G	cg19774624	chr17:42201019	HDAC5	-0.67	-10.02	-0.52	3.09e-20	Bone mineral density (hip);Bone mineral density;
CESC	cis	rs6723226	0.766	rs398290	chr2:32503526	T/C	cg02381751	chr2:32503542	YIPF4	0.9	12.99	0.62	3.45e-30	Intelligence (multi-trait analysis);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg07610776	chr16:1832675	SPSB3;NUBP2	-0.42	-6.13	-0.35	3.22e-9	Gambling;
CESC	cis	rs2836950	0.565	rs7278297	chr21:40625752	A/C	cg11890956	chr21:40555474	PSMG1	-0.65	-8.96	-0.48	5.81e-17	Menarche (age at onset);
CESC	cis	rs748404	0.631	rs4296223	chr15:43645246	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.6	7.78	0.43	1.64e-13	Lung cancer;
CESC	cis	rs6693567	0.565	rs12093148	chr1:150265173	G/A	cg09579323	chr1:150459698	TARS2	-0.48	-5.93	-0.34	9.32e-9	Migraine;
CESC	cis	rs4243830	0.522	rs11122086	chr1:6601246	T/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.99	-9.93	-0.52	5.89e-20	Body mass index;
CESC	cis	rs7666738	0.830	rs1405767	chr4:98965295	T/C	cg05340658	chr4:99064831	C4orf37	0.8	12.39	0.61	3.96e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs514406	0.644	rs7552663	chr1:53204352	C/T	cg16325326	chr1:53192061	ZYG11B	-0.7	-11.18	-0.57	4.87e-24	Monocyte count;
CESC	cis	rs4664304	0.629	rs62175466	chr2:160852308	C/T	cg03641300	chr2:160917029	PLA2R1	-0.43	-5.8	-0.34	1.86e-8	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs9486715	0.867	rs3860243	chr6:96905303	T/G	cg06623918	chr6:96969491	KIAA0776	0.93	14.55	0.67	1.23e-35	Headache;
CESC	cis	rs734999	0.505	rs60687045	chr1:2539603	G/A	cg18854424	chr1:2615690	NA	0.29	5.69	0.33	3.33e-8	Ulcerative colitis;
CESC	trans	rs1814175	0.645	rs1851845	chr11:49982396	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.43	-6.26	-0.36	1.53e-9	Height;
CESC	cis	rs832540	0.519	rs10039338	chr5:56260363	C/T	cg12311346	chr5:56204834	C5orf35	0.45	5.85	0.34	1.48e-8	Coronary artery disease;
CESC	cis	rs6142102	0.517	rs6142046	chr20:32514061	C/T	cg08999081	chr20:33150536	PIGU	0.34	5.25	0.31	3.06e-7	Skin pigmentation;
CESC	cis	rs4481887	1.000	rs6697863	chr1:248495588	G/A	cg00666640	chr1:248458726	OR2T12	0.41	6.57	0.37	2.64e-10	Common traits (Other);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16900589	chr2:238617188	LRRFIP1	-0.55	-6.0	-0.35	6.57e-9	Gut microbiome composition (summer);
CESC	cis	rs367943	0.712	rs6594707	chr5:112700503	C/T	cg12552261	chr5:112820674	MCC	0.42	5.59	0.32	5.75e-8	Type 2 diabetes;
CESC	cis	rs870825	0.616	rs4386643	chr4:185624281	A/T	cg04058563	chr4:185651563	MLF1IP	0.64	7.05	0.4	1.59e-11	Blood protein levels;
CESC	cis	rs875971	0.658	rs432667	chr7:65514633	A/G	cg26939375	chr7:64535504	NA	0.48	6.19	0.36	2.32e-9	Aortic root size;
CESC	cis	rs3008870	1.000	rs3008873	chr1:67425770	G/A	cg08660285	chr1:67390436	MIER1;WDR78	1.06	15.19	0.68	6.65e-38	Lymphocyte percentage of white cells;
CESC	cis	rs9487051	0.872	rs7772602	chr6:109608661	C/G	cg01475377	chr6:109611718	NA	0.5	8.25	0.45	7.57e-15	Reticulocyte fraction of red cells;
CESC	cis	rs7772486	0.875	rs9322048	chr6:146400439	A/G	cg05347473	chr6:146136440	FBXO30	0.51	7.03	0.4	1.78e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6089584	0.925	rs35683654	chr20:60625401	G/T	cg24733560	chr20:60626293	TAF4	-0.44	-6.06	-0.35	4.69e-9	Body mass index;
CESC	cis	rs6088590	1.000	rs2076668	chr20:33437621	G/A	cg06115741	chr20:33292138	TP53INP2	0.61	7.68	0.43	3.01e-13	Coronary artery disease;
CESC	cis	rs2404602	0.532	rs284892	chr15:76721037	A/G	cg00316803	chr15:76480434	C15orf27	-0.35	-5.28	-0.31	2.71e-7	Blood metabolite levels;
CESC	cis	rs78456975	1.000	rs55761535	chr2:1561450	A/G	cg26248373	chr2:1572462	NA	-0.59	-5.73	-0.33	2.74e-8	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs9649465	1.000	rs2299985	chr7:123369044	T/C	cg04330084	chr7:123175371	IQUB	-0.38	-5.13	-0.3	5.55e-7	Migraine;
CESC	cis	rs13082711	0.911	rs923940	chr3:27459341	C/G	cg02860705	chr3:27208620	NA	0.53	6.8	0.39	7.04e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CESC	cis	rs7666738	0.830	rs1025204	chr4:99023441	G/A	cg18180107	chr4:99064573	C4orf37	0.42	5.44	0.32	1.2e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4237845	0.844	rs4630335	chr12:58302258	A/G	cg00677455	chr12:58241039	CTDSP2	0.56	7.38	0.41	2.09e-12	Intelligence (multi-trait analysis);
CESC	cis	rs864537	0.618	rs2988277	chr1:167431352	A/G	cg09179987	chr1:167433047	CD247	-0.56	-8.49	-0.46	1.49e-15	Celiac disease or Rheumatoid arthritis;Celiac disease;
CESC	cis	rs13256369	0.802	rs13281933	chr8:8562665	C/A	cg18904891	chr8:8559673	CLDN23	0.69	7.74	0.43	2.13e-13	Obesity-related traits;
CESC	cis	rs1800469	1.000	rs2241712	chr19:41869756	C/T	cg09537434	chr19:41945824	ATP5SL	-0.67	-8.31	-0.45	5.12e-15	Colorectal cancer;
CESC	cis	rs2072732	0.808	rs67758087	chr1:2937031	A/G	cg15211996	chr1:2936768	ACTRT2	0.34	5.6	0.33	5.36e-8	Plateletcrit;
CESC	cis	rs3806843	0.706	rs2563302	chr5:140079051	T/C	cg16179182	chr5:140090404	VTRNA1-1	0.39	5.03	0.3	9.22e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs8067354	0.789	rs4622571	chr17:57884397	T/A	cg13753209	chr17:57696993	CLTC	0.47	6.5	0.37	3.9e-10	Hemoglobin concentration;
CESC	cis	rs9611565	0.649	rs202655	chr22:41841564	G/C	cg03806693	chr22:41940476	POLR3H	1.13	15.27	0.68	3.52e-38	Vitiligo;
CESC	cis	rs9649213	0.593	rs736754	chr7:97931559	C/T	cg08684580	chr7:98029266	BAIAP2L1	-0.35	-5.68	-0.33	3.49e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7918232	0.941	rs4749228	chr10:27433618	C/T	cg14442939	chr10:27389572	ANKRD26	-0.72	-6.71	-0.38	1.16e-10	Breast cancer;
CESC	cis	rs2075671	0.903	rs11520986	chr7:100276994	A/G	cg20848291	chr7:100343083	ZAN	-0.81	-10.52	-0.54	7.29e-22	Other erythrocyte phenotypes;
CESC	cis	rs9911578	1.000	rs9892062	chr17:56976981	G/A	cg05425664	chr17:57184151	TRIM37	-0.5	-6.81	-0.39	6.5500000000000006e-11	Intelligence (multi-trait analysis);
CESC	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg06873352	chr17:61820015	STRADA	0.73	12.96	0.62	4.25e-30	Prudent dietary pattern;
CESC	cis	rs4973397	0.601	rs2034412	chr2:232288061	C/G	cg09339159	chr2:232260559	B3GNT7	-0.47	-5.62	-0.33	4.91e-8	Anti-saccade response;
CESC	cis	rs2243480	1.000	rs313813	chr7:65503500	C/T	cg13147721	chr7:65941812	NA	-0.87	-8.22	-0.45	8.94e-15	Diabetic kidney disease;
CESC	cis	rs6499255	0.904	rs60010276	chr16:69674805	C/T	cg15192750	chr16:69999425	NA	0.46	5.34	0.31	2.04e-7	IgE levels;
CESC	cis	rs35110281	0.837	rs2838342	chr21:45077865	G/A	cg01579765	chr21:45077557	HSF2BP	-0.58	-10.02	-0.52	3.09e-20	Mean corpuscular volume;
CESC	cis	rs6951245	0.872	rs11768895	chr7:1063691	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.45	5.14	0.3	5.44e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs4819052	0.851	rs13052312	chr21:46662359	T/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.46	5.81	0.34	1.81e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs1707322	1.000	rs10890380	chr1:46449469	A/G	cg03146154	chr1:46216737	IPP	0.75	10.29	0.53	4.13e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs6424115	0.867	rs2501432	chr1:24201920	T/C	cg10978503	chr1:24200527	CNR2	0.33	6.6	0.38	2.2e-10	Immature fraction of reticulocytes;
CESC	trans	rs7716219	0.731	rs7704138	chr5:54944262	C/T	cg20755408	chr12:498145	KDM5A;CCDC77	-0.39	-6.0	-0.35	6.44e-9	Height;
CESC	cis	rs12711979	0.765	rs7559461	chr2:3818623	G/A	cg17052675	chr2:3827356	NA	-0.42	-6.45	-0.37	5.34e-10	Itch intensity from mosquito bite adjusted by bite size;
CESC	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg07308232	chr7:1071921	C7orf50	-0.45	-6.34	-0.36	9.83e-10	Longevity;Endometriosis;
CESC	cis	rs7089973	0.872	rs35622181	chr10:116631976	C/T	cg23260525	chr10:116636907	FAM160B1	0.37	6.15	0.35	2.84e-9	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs75477785	1.000	rs2235377	chr1:209975392	T/C	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.88	5.74	0.33	2.62e-8	Cleft lip with or without cleft palate;
CESC	cis	rs910316	0.935	rs175422	chr14:75627319	T/A	cg11812906	chr14:75593930	NEK9	-0.87	-14.35	-0.66	5.82e-35	Height;
CESC	cis	rs7044106	0.791	rs10985000	chr9:123484115	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.7	10.3	0.53	3.82e-21	Hip circumference adjusted for BMI;
CESC	cis	rs478304	0.651	rs10896038	chr11:65505528	G/C	cg27068330	chr11:65405492	SIPA1	-0.45	-5.46	-0.32	1.08e-7	Acne (severe);
CESC	trans	rs427691	0.625	rs372062	chr5:109010527	G/A	cg00054525	chr16:88717587	CYBA	-0.61	-6.8	-0.39	7.05e-11	Autism spectrum disorder or schizophrenia;
CESC	cis	rs2243480	0.901	rs57126451	chr7:65416306	T/C	cg13147721	chr7:65941812	NA	-0.87	-8.57	-0.47	8.79e-16	Diabetic kidney disease;
CESC	cis	rs2835872	0.758	rs1787394	chr21:39036176	C/A	cg06728970	chr21:39037746	KCNJ6	0.3	5.57	0.32	6.2e-8	Electroencephalographic traits in alcoholism;
CESC	cis	rs736408	0.677	rs678	chr3:52820981	A/T	cg07507251	chr3:52567010	NT5DC2	0.37	5.98	0.34	7.16e-9	Bipolar disorder;
CESC	cis	rs3858526	0.917	rs9284148	chr11:5973185	G/C	cg05234568	chr11:5960015	NA	-0.52	-5.92	-0.34	9.79e-9	DNA methylation (variation);
CESC	cis	rs8031584	0.706	rs2177670	chr15:31157751	G/T	cg14829155	chr15:31115871	NA	-0.76	-10.54	-0.54	6.55e-22	Huntington's disease progression;
CESC	trans	rs35110281	0.591	rs162366	chr21:44935383	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.48	-6.53	-0.37	3.41e-10	Mean corpuscular volume;
CESC	cis	rs4713118	0.662	rs156744	chr6:27967274	G/A	cg12963246	chr6:28129442	ZNF389	0.5	6.58	0.37	2.51e-10	Parkinson's disease;
CESC	cis	rs636291	0.500	rs655271	chr1:10536635	G/A	cg07384165	chr1:10488281	NA	-0.58	-8.61	-0.47	6.84e-16	Prostate cancer;
CESC	cis	rs7793919	0.691	rs4077986	chr7:4766676	A/G	cg09789173	chr7:4769017	FOXK1	0.63	9.17	0.49	1.34e-17	Mosquito bite size;
CESC	cis	rs2274273	0.905	rs17128183	chr14:55579513	C/T	cg04306507	chr14:55594613	LGALS3	-0.31	-6.31	-0.36	1.15e-9	Protein biomarker;
CESC	cis	rs9430161	0.645	rs12081186	chr1:11034195	T/C	cg27631724	chr1:11040367	C1orf127	0.38	6.21	0.36	2.02e-9	Ewing sarcoma;
CESC	cis	rs6952808	0.630	rs1860832	chr7:2161849	G/A	cg08027265	chr7:2291960	NA	-0.45	-6.99	-0.39	2.21e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs9790314	0.586	rs1839491	chr3:161126429	C/A	cg03342759	chr3:160939853	NMD3	-0.45	-5.77	-0.33	2.21e-8	Morning vs. evening chronotype;
CESC	cis	rs1552244	0.882	rs13062917	chr3:10017032	T/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.87	11.29	0.57	2.21e-24	Alzheimer's disease;
CESC	cis	rs17376456	0.877	rs67066109	chr5:93494101	G/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.61	5.04	0.3	8.6e-7	Diabetic retinopathy;
CESC	cis	rs727563	0.594	rs132807	chr22:42071584	T/C	cg17376030	chr22:41985996	PMM1	-0.79	-8.55	-0.47	9.65e-16	Crohn's disease;Inflammatory bowel disease;
CESC	trans	rs11039798	0.620	rs10838833	chr11:48238880	C/T	cg15704280	chr7:45808275	SEPT13	0.71	6.65	0.38	1.68e-10	Axial length;
CESC	cis	rs561341	0.783	rs512698	chr17:30292507	G/T	cg00745463	chr17:30367425	LRRC37B	-0.81	-7.36	-0.41	2.38e-12	Hip circumference adjusted for BMI;
CESC	cis	rs9467160	1.000	rs6922631	chr6:24438734	G/A	cg20631270	chr6:24437470	GPLD1	0.42	5.18	0.3	4.49e-7	Liver enzyme levels;
CESC	cis	rs2842992	0.915	rs2842980	chr6:160100116	A/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.65	7.47	0.42	1.17e-12	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs6933660	0.760	rs6904364	chr6:151754273	T/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.62	8.55	0.46	1.02e-15	Menarche (age at onset);
CESC	cis	rs2228479	0.850	rs11644526	chr16:89898660	C/T	cg06558623	chr16:89946397	TCF25	1.12	8.22	0.45	9.28e-15	Skin colour saturation;
CESC	cis	rs9287719	0.967	rs2110776	chr2:10748810	A/G	cg00105475	chr2:10696890	NA	0.38	5.57	0.32	6.34e-8	Prostate cancer;
CESC	cis	rs7412746	0.611	rs11803940	chr1:150685835	A/G	cg09365446	chr1:150670422	GOLPH3L	0.4	5.7	0.33	3.11e-8	Melanoma;
CESC	cis	rs10857712	0.754	rs2297032	chr10:135234580	C/T	cg01444801	chr10:135216882	MTG1	-0.46	-5.24	-0.31	3.29e-7	Systemic lupus erythematosus;
CESC	cis	rs2228479	0.850	rs2302162	chr16:89845287	A/G	cg00800038	chr16:89945340	TCF25	-0.92	-7.65	-0.43	3.63e-13	Skin colour saturation;
CESC	cis	rs8077577	0.945	rs62073609	chr17:18071843	T/C	cg16794390	chr17:18148240	FLII	0.4	5.26	0.31	3.04e-7	Obesity-related traits;
CESC	trans	rs78049276	0.736	rs73855814	chr4:148397751	G/T	cg13149281	chr14:23389818	RBM23;PRMT5	-0.64	-6.73	-0.38	1.02e-10	Pulse pressure;
CESC	cis	rs1375194	0.509	rs62150473	chr2:33822320	G/A	cg04131969	chr2:33951647	MYADML	-0.53	-6.71	-0.38	1.21e-10	Response to antidepressants in depression;
CESC	cis	rs2282802	0.685	rs11745502	chr5:139558808	G/A	cg26211634	chr5:139558579	C5orf32	-0.48	-7.04	-0.4	1.68e-11	Intelligence (multi-trait analysis);
CESC	cis	rs7631605	0.875	rs56180213	chr3:37109633	C/A	cg22985146	chr3:37219077	LRRFIP2	-0.32	-5.08	-0.3	7.09e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs72772090	0.539	rs11135480	chr5:96110582	T/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.6	-5.03	-0.3	8.86e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs4835473	0.932	rs35947975	chr4:144700122	G/A	cg25736465	chr4:144833511	NA	-0.33	-5.23	-0.31	3.48e-7	Immature fraction of reticulocytes;
CESC	cis	rs1707322	0.928	rs10732844	chr1:46372688	T/C	cg03146154	chr1:46216737	IPP	0.71	9.86	0.52	9.69e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9910055	0.530	rs11656758	chr17:42301541	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.35	5.14	0.3	5.27e-7	Total body bone mineral density;
CESC	cis	rs2576037	0.526	rs2051292	chr18:44484372	C/G	cg19077165	chr18:44547161	KATNAL2	-0.54	-7.54	-0.42	7.52e-13	Personality dimensions;
CESC	cis	rs6732160	0.845	rs11894833	chr2:73388418	G/T	cg01422370	chr2:73384389	NA	-0.43	-7.35	-0.41	2.43e-12	Intelligence (multi-trait analysis);
CESC	cis	rs10979	1.000	rs10979	chr6:143890039	G/A	cg25407410	chr6:143891975	LOC285740	-0.61	-9.14	-0.49	1.72e-17	Hypospadias;
CESC	cis	rs8038465	0.516	rs8037836	chr15:73859855	G/A	cg15420318	chr15:73925796	NPTN	0.55	8.05	0.44	2.75e-14	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs9487051	0.735	rs1146246	chr6:109519741	C/T	cg01475377	chr6:109611718	NA	-0.37	-5.55	-0.32	6.99e-8	Reticulocyte fraction of red cells;
CESC	cis	rs7124681	0.584	rs7950674	chr11:47871017	T/C	cg18512352	chr11:47633146	NA	0.35	5.45	0.32	1.17e-7	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
CESC	cis	rs514406	0.505	rs395169	chr1:53174071	G/A	cg27535305	chr1:53392650	SCP2	-0.34	-5.56	-0.32	6.66e-8	Monocyte count;
CESC	cis	rs6032067	0.777	rs2868237	chr20:43794189	C/T	cg10761708	chr20:43804764	PI3	0.56	6.55	0.37	3.01e-10	Blood protein levels;
CESC	cis	rs2273669	0.667	rs2273668	chr6:109323519	G/T	cg05315195	chr6:109294784	ARMC2	-0.66	-6.01	-0.35	6.04e-9	Prostate cancer;
CESC	cis	rs977987	0.843	rs4887820	chr16:75397287	C/T	cg03315344	chr16:75512273	CHST6	0.39	5.63	0.33	4.61e-8	Dupuytren's disease;
CESC	cis	rs1372520	0.684	rs2583979	chr4:90750588	A/T	cg15133208	chr4:90757351	SNCA	-0.4	-5.37	-0.31	1.71e-7	Neuroticism;
CESC	trans	rs4596713	0.538	rs4592105	chr9:71754305	T/G	cg16512924	chr15:28394682	HERC2	0.5	6.27	0.36	1.43e-9	Headache;
CESC	cis	rs10979	0.679	rs9403510	chr6:143892174	C/T	cg25407410	chr6:143891975	LOC285740	-0.55	-7.7	-0.43	2.68e-13	Hypospadias;
CESC	cis	rs7592578	0.825	rs12477369	chr2:191455624	G/T	cg27211696	chr2:191398769	TMEM194B	0.56	5.1	0.3	6.48e-7	Diastolic blood pressure;
CESC	cis	rs10214930	0.647	rs7791369	chr7:27912080	C/T	cg05786569	chr7:27702416	HIBADH	0.44	5.2	0.3	4.05e-7	Hypospadias;
CESC	cis	rs2066819	1.000	rs77853814	chr12:56687572	G/T	cg26714650	chr12:56694279	CS	-1.44	-9.83	-0.52	1.25e-19	Psoriasis vulgaris;
CESC	cis	rs9611565	0.546	rs739129	chr22:42118249	G/A	cg06481639	chr22:41940642	POLR3H	0.59	5.95	0.34	8.35e-9	Vitiligo;
CESC	cis	rs941873	0.805	rs10824747	chr10:81118464	T/C	cg08514558	chr10:81106712	PPIF	0.35	5.92	0.34	9.89e-9	Height;
CESC	cis	rs7666738	0.606	rs7663216	chr4:99088385	A/C	cg05340658	chr4:99064831	C4orf37	0.64	9.0	0.48	4.38e-17	Colonoscopy-negative controls vs population controls;
CESC	cis	rs447	1.000	rs7783472	chr7:83751882	G/A	cg22846510	chr7:83753280	SEMA3A	-0.45	-5.67	-0.33	3.8e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs2304069	0.779	rs245050	chr5:149346960	C/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.72	-9.33	-0.5	4.38e-18	HIV-1 control;
CESC	cis	rs6693567	0.545	rs12049177	chr1:150474337	G/A	cg09579323	chr1:150459698	TARS2	0.45	5.54	0.32	7.24e-8	Migraine;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg27200190	chr17:35766714	ACACA;TADA2A	-0.46	-6.33	-0.36	1.05e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs11614062	0.761	rs11107115	chr12:93972987	A/G	cg18151635	chr12:93972918	NA	-0.45	-5.92	-0.34	9.99e-9	Height;
CESC	cis	rs7267979	0.816	rs1044573	chr20:25206654	A/G	cg08601574	chr20:25228251	PYGB	0.37	5.28	0.31	2.71e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7666738	0.830	rs28728124	chr4:99001116	G/T	cg03467027	chr4:99064603	C4orf37	0.44	5.51	0.32	8.65e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2440129	0.611	rs1126667	chr17:6902760	C/T	cg03760483	chr17:6899297	ALOX12	-0.43	-7.84	-0.43	1.08e-13	Tonsillectomy;
CESC	cis	rs78456975	0.506	rs6756310	chr2:1549809	A/G	cg01028140	chr2:1542097	TPO	-0.47	-5.93	-0.34	9.62e-9	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs736801	0.729	rs1050152	chr5:131676320	C/T	cg21138405	chr5:131827807	IRF1	-0.36	-5.13	-0.3	5.71e-7	Breast cancer;Mosquito bite size;
CESC	cis	rs1005277	0.579	rs1780146	chr10:38517874	C/A	cg25427524	chr10:38739819	LOC399744	-0.71	-10.42	-0.54	1.54e-21	Extrinsic epigenetic age acceleration;
CESC	cis	rs7714584	1.000	rs2004711	chr5:150225068	C/T	cg22134413	chr5:150180641	NA	0.52	5.64	0.33	4.31e-8	Crohn's disease;
CESC	cis	rs4660306	0.961	rs4660862	chr1:45955056	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.61	-7.69	-0.43	2.86e-13	Homocysteine levels;
CESC	cis	rs2074585	0.802	rs2589940	chr15:90931363	C/T	cg22089800	chr15:90895588	ZNF774	0.68	9.5	0.5	1.35e-18	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
CESC	cis	rs61931739	0.534	rs35056575	chr12:34142914	A/T	cg19457237	chr12:34500585	NA	-0.38	-5.16	-0.3	4.82e-7	Morning vs. evening chronotype;
CESC	cis	rs3768617	0.510	rs1413389	chr1:183096668	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.89	14.39	0.66	4.39e-35	Fuchs's corneal dystrophy;
CESC	cis	rs7100689	0.556	rs3120976	chr10:82025682	C/A	cg09936400	chr10:82049201	MAT1A	0.35	5.17	0.3	4.62e-7	Post bronchodilator FEV1;
CESC	cis	rs2404602	0.669	rs8036703	chr15:76951040	A/G	cg22467129	chr15:76604101	ETFA	-0.35	-5.18	-0.3	4.46e-7	Blood metabolite levels;
CESC	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.64	7.52	0.42	8.66e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs875971	0.545	rs12670811	chr7:65823019	C/A	cg11764359	chr7:65958608	NA	0.8	9.75	0.51	2.17e-19	Aortic root size;
CESC	cis	rs12477438	0.798	rs4622780	chr2:99631760	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.72	-10.25	-0.53	5.55e-21	Chronic sinus infection;
CESC	cis	rs7828089	0.504	rs12676477	chr8:22266425	T/C	cg23129673	chr8:22266227	SLC39A14	0.35	5.17	0.3	4.64e-7	Verbal declarative memory;
CESC	cis	rs875971	0.522	rs4502988	chr7:65297746	A/G	cg14393609	chr7:65229607	NA	0.52	7.08	0.4	1.33e-11	Aortic root size;
CESC	trans	rs9329221	0.683	rs4598253	chr8:9890304	A/T	cg15556689	chr8:8085844	FLJ10661	-0.56	-7.35	-0.41	2.5e-12	Neuroticism;
CESC	cis	rs9911578	0.867	rs4793941	chr17:56472366	G/A	cg12560992	chr17:57184187	TRIM37	-0.87	-14.37	-0.66	5.07e-35	Intelligence (multi-trait analysis);
CESC	cis	rs7017914	0.934	rs7814274	chr8:71570411	C/T	cg23757474	chr8:71581111	LACTB2;XKR9	0.41	5.22	0.31	3.58e-7	Bone mineral density;
CESC	cis	rs1552244	0.810	rs4019706	chr3:10112862	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-11.04	-0.56	1.41e-23	Alzheimer's disease;
CESC	cis	rs7084402	0.935	rs10740732	chr10:60352888	G/A	cg07615347	chr10:60278583	BICC1	0.54	8.25	0.45	7.48e-15	Refractive error;
CESC	cis	rs10979	0.597	rs9496684	chr6:143908687	C/A	cg25407410	chr6:143891975	LOC285740	-0.49	-6.57	-0.37	2.58e-10	Hypospadias;
CESC	cis	rs1707322	1.000	rs10890381	chr1:46451771	T/G	cg05343316	chr1:45956843	TESK2	0.5	6.13	0.35	3.11e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs17253792	0.545	rs12886406	chr14:56027605	G/A	cg01858014	chr14:56050164	KTN1	-0.88	-6.42	-0.37	6.21e-10	Putamen volume;
CESC	cis	rs11785400	0.793	rs4567014	chr8:143737690	G/C	cg10596483	chr8:143751796	JRK	0.43	5.41	0.32	1.37e-7	Schizophrenia;
CESC	trans	rs11098499	0.954	rs1546505	chr4:120241224	A/G	cg25214090	chr10:38739885	LOC399744	0.71	9.9	0.52	7.1e-20	Corneal astigmatism;
CESC	cis	rs9300255	0.596	rs10734900	chr12:123743445	G/A	cg00376283	chr12:123451042	ABCB9	0.66	8.97	0.48	5.43e-17	Neutrophil percentage of white cells;
CESC	cis	rs10504229	0.683	rs16921814	chr8:58107421	A/T	cg21724239	chr8:58056113	NA	0.58	6.07	0.35	4.37e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs3008870	1.000	rs2755245	chr1:67487964	C/G	cg02640540	chr1:67518911	SLC35D1	0.47	5.14	0.3	5.3e-7	Lymphocyte percentage of white cells;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05556477	chr5:131705319	SLC22A5	0.47	6.08	0.35	4.2e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs10129255	1.000	rs10129407	chr14:107176199	G/C	cg23076370	chr14:107095027	NA	-0.42	-5.03	-0.3	9.05e-7	Kawasaki disease;
CESC	cis	rs801193	1.000	rs13239306	chr7:66136017	T/G	cg11987759	chr7:65425863	GUSB	0.38	5.1	0.3	6.48e-7	Aortic root size;
CESC	cis	rs9916302	0.904	rs4795355	chr17:37427382	C/T	cg15445000	chr17:37608096	MED1	0.39	6.38	0.36	7.82e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs10489202	1.000	rs12407660	chr1:167954363	C/T	cg24449463	chr1:168025552	DCAF6	-0.46	-5.34	-0.31	2.02e-7	Schizophrenia;
CESC	cis	rs9916302	0.904	rs4795355	chr17:37427382	C/T	cg07936489	chr17:37558343	FBXL20	-0.78	-11.38	-0.57	1.08e-24	Glomerular filtration rate (creatinine);
CESC	cis	rs6424115	0.830	rs1106	chr1:24200772	C/G	cg10978503	chr1:24200527	CNR2	0.33	6.62	0.38	1.93e-10	Immature fraction of reticulocytes;
CESC	cis	rs28386778	0.701	rs2727337	chr17:61991966	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	-0.46	-5.61	-0.33	5.06e-8	Prudent dietary pattern;
CESC	cis	rs3796352	0.892	rs9756317	chr3:53088815	T/C	cg15956490	chr3:53032818	SFMBT1	-0.58	-5.34	-0.31	2.02e-7	Immune reponse to smallpox (secreted IL-2);
CESC	cis	rs748404	0.697	rs564946	chr15:43556272	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	7.85	0.43	1.01e-13	Lung cancer;
CESC	trans	rs8073060	0.586	rs188959	chr17:34021307	C/A	cg19694781	chr19:47549865	TMEM160	-0.74	-6.91	-0.39	3.64e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	cis	rs2228479	0.717	rs9282682	chr16:89805794	A/G	cg14709524	chr16:89940631	TCF25	0.56	5.06	0.3	7.85e-7	Skin colour saturation;
CESC	cis	rs7589728	0.563	rs79892776	chr2:88470593	G/A	cg04511125	chr2:88470314	THNSL2	0.69	6.76	0.38	8.71e-11	Plasma clusterin levels;
CESC	cis	rs2243480	1.000	rs35542501	chr7:65431215	T/C	cg13147721	chr7:65941812	NA	-0.86	-8.55	-0.47	9.73e-16	Diabetic kidney disease;
CESC	cis	rs875971	0.540	rs736270	chr7:65428822	T/C	cg06456125	chr7:65229604	NA	0.44	5.67	0.33	3.71e-8	Aortic root size;
CESC	cis	rs11252926	0.550	rs10904148	chr10:454551	G/T	cg03684893	chr10:554711	DIP2C	-0.37	-5.36	-0.31	1.79e-7	Psychosis in Alzheimer's disease;
CESC	cis	rs9430161	0.611	rs12081181	chr1:11034165	T/G	cg27631724	chr1:11040367	C1orf127	0.37	5.92	0.34	1.01e-8	Ewing sarcoma;
CESC	cis	rs7665939	1.000	rs72727637	chr4:190106678	G/T	cg09826759	chr4:190284978	NA	-0.86	-7.15	-0.4	8.52e-12	Amyotrophic lateral sclerosis;
CESC	cis	rs7618915	0.508	rs12498066	chr3:52627660	G/A	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.59	0.38	2.35e-10	Bipolar disorder;
CESC	trans	rs3942852	0.696	rs4597030	chr11:48176573	G/A	cg03929089	chr4:120376271	NA	-0.66	-7.24	-0.41	4.83e-12	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs1005277	0.638	rs1005278	chr10:38218748	G/A	cg00409905	chr10:38381863	ZNF37A	0.4	5.16	0.3	4.78e-7	Extrinsic epigenetic age acceleration;
CESC	cis	rs965469	0.671	rs6139076	chr20:3305210	T/C	cg25506879	chr20:3388711	C20orf194	-0.49	-5.36	-0.31	1.79e-7	IFN-related cytopenia;
CESC	cis	rs4819052	0.851	rs4818768	chr21:46659818	T/A	cg11663144	chr21:46675770	NA	-0.63	-10.02	-0.52	3.12e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	7.61	0.42	4.95e-13	Prudent dietary pattern;
CESC	cis	rs9926296	0.568	rs1230	chr16:89804855	A/G	cg03388025	chr16:89894329	SPIRE2	-0.38	-7.34	-0.41	2.6e-12	Vitiligo;
CESC	cis	rs13118159	0.550	rs4974617	chr4:1373658	T/C	cg02475777	chr4:1388615	CRIPAK	0.71	8.99	0.48	4.82e-17	Longevity;
CESC	cis	rs9457247	0.765	rs10484531	chr6:167454434	G/A	cg07741184	chr6:167504864	NA	0.36	6.56	0.37	2.74e-10	Crohn's disease;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg01764079	chr8:144718741	ZNF623	-0.46	-6.29	-0.36	1.32e-9	Asthma;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02073954	chr6:28193080	ZNF193	0.64	7.27	0.41	3.97e-12	Gut microbiome composition (summer);
CESC	cis	rs6540559	0.932	rs764093	chr1:209983331	A/G	cg22029157	chr1:209979665	IRF6	0.69	10.12	0.53	1.44e-20	Cleft lip with or without cleft palate;
CESC	trans	rs2727020	0.702	rs609054	chr11:49219725	C/G	cg15704280	chr7:45808275	SEPT13	0.85	13.98	0.65	1.19e-33	Coronary artery disease;
CESC	cis	rs4819052	0.851	rs2236443	chr21:46678174	T/C	cg11663144	chr21:46675770	NA	-0.47	-7.06	-0.4	1.5e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs11190604	1.000	rs11190578	chr10:102238953	C/T	cg07080220	chr10:102295463	HIF1AN	0.56	5.59	0.32	5.61e-8	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs7000551	0.638	rs2469771	chr8:22376627	T/C	cg12081754	chr8:22256438	SLC39A14	0.4	5.35	0.31	1.88e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CESC	cis	rs1448094	0.512	rs11117061	chr12:86250916	G/A	cg19622623	chr12:86230825	RASSF9	-0.42	-5.23	-0.31	3.51e-7	Major depressive disorder;
CESC	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.42	-5.35	-0.31	1.91e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs853679	0.517	rs9295759	chr6:28124469	C/T	cg12963246	chr6:28129442	ZNF389	0.58	7.62	0.42	4.61e-13	Depression;
CESC	cis	rs807669	0.903	rs1018764	chr22:19172006	T/C	cg02655711	chr22:19163373	SLC25A1	0.97	15.0	0.68	3.01e-37	Metabolite levels;
CESC	cis	rs10791323	0.569	rs10736608	chr11:133740048	C/T	cg15485101	chr11:133734466	NA	0.3	5.18	0.3	4.45e-7	Childhood ear infection;
CESC	cis	rs11098499	0.754	rs11732087	chr4:120239831	A/G	cg09307838	chr4:120376055	NA	0.79	10.63	0.55	3.17e-22	Corneal astigmatism;
CESC	cis	rs4563143	0.675	rs55849754	chr19:29279665	G/A	cg12667521	chr19:29218732	NA	0.48	6.19	0.36	2.22e-9	Methadone dose in opioid dependence;
CESC	cis	rs7772486	0.875	rs2814863	chr6:146347299	C/T	cg23711669	chr6:146136114	FBXO30	-0.79	-11.35	-0.57	1.37e-24	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2228479	0.850	rs17233455	chr16:89816407	A/G	cg06558623	chr16:89946397	TCF25	1.16	9.28	0.5	6.08e-18	Skin colour saturation;
CESC	cis	rs7267979	1.000	rs2482927	chr20:25327151	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.83	-15.72	-0.69	8.65e-40	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs1784581	0.588	rs7451121	chr6:162412344	A/G	cg17173639	chr6:162384350	PARK2	0.56	8.43	0.46	2.21e-15	Itch intensity from mosquito bite;
CESC	cis	rs2637266	0.783	rs2588333	chr10:78538952	A/G	cg18941641	chr10:78392320	NA	0.39	7.75	0.43	1.99e-13	Pulmonary function;
CESC	cis	rs270601	0.770	rs932019	chr5:131599370	T/C	cg22638593	chr5:131593259	PDLIM4	0.39	5.07	0.3	7.56e-7	Acylcarnitine levels;
CESC	cis	rs9487051	0.768	rs463916	chr6:109520538	A/G	cg01475377	chr6:109611718	NA	-0.45	-6.81	-0.39	6.35e-11	Reticulocyte fraction of red cells;
CESC	cis	rs10129255	0.912	rs8009135	chr14:107185767	A/G	cg23076370	chr14:107095027	NA	-0.49	-6.26	-0.36	1.56e-9	Kawasaki disease;
CESC	trans	rs2842169	0.558	rs11597150	chr10:128292604	A/G	cg10374248	chr10:99083645	NA	-0.74	-6.28	-0.36	1.41e-9	Response to radiotherapy in prostate cancer (overall toxicity);
CESC	cis	rs7560272	0.538	rs1806683	chr2:73939812	C/T	cg20560298	chr2:73613845	ALMS1	-0.41	-5.62	-0.33	4.81e-8	Schizophrenia;
CESC	cis	rs1691799	0.899	rs1168293	chr12:66733904	G/A	cg16791601	chr12:66731901	HELB	-0.62	-9.95	-0.52	4.98e-20	White blood cell count (basophil);
CESC	cis	rs7246657	0.765	rs7247259	chr19:37851090	T/C	cg23950597	chr19:37808831	NA	-0.55	-6.09	-0.35	3.96e-9	Coronary artery calcification;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21348586	chr8:141461100	TRAPPC9	-0.59	-6.92	-0.39	3.37e-11	Gut microbiome composition (summer);
CESC	cis	rs3857536	0.813	rs9354403	chr6:66943426	A/G	cg07460842	chr6:66804631	NA	-0.41	-5.28	-0.31	2.71e-7	Blood trace element (Cu levels);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg06901790	chr16:31712112	C16orf67	-0.51	-6.73	-0.38	1.03e-10	Fibrinogen levels;
CESC	cis	rs2439831	0.867	rs2245715	chr15:43818052	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.72	9.43	0.5	2.23e-18	Lung cancer in ever smokers;
CESC	cis	rs1799949	1.000	rs36036395	chr17:41181297	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	8.16	0.45	1.32e-14	Menopause (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11611950	chr6:24667276	ACOT13;TTRAP	0.53	6.05	0.35	4.89e-9	Gut microbiome composition (summer);
CESC	cis	rs12681366	0.734	rs4735292	chr8:95408731	C/T	cg13257157	chr8:95487014	RAD54B	0.37	5.04	0.3	8.46e-7	Nonsyndromic cleft lip with cleft palate;
CESC	cis	rs35146811	0.555	rs2527898	chr7:99534030	C/G	cg22531904	chr7:99595276	NA	-0.4	-5.04	-0.3	8.8e-7	Coronary artery disease;
CESC	cis	rs6762477	0.505	rs17304079	chr3:50085153	A/G	cg24308560	chr3:49941425	MST1R	-0.55	-6.76	-0.38	8.93e-11	Menarche (age at onset);
CESC	cis	rs13082711	0.911	rs2370995	chr3:27428216	C/T	cg02860705	chr3:27208620	NA	0.52	6.49	0.37	4.14e-10	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CESC	cis	rs9359856	0.636	rs4706345	chr6:90301565	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.46	-5.2	-0.3	3.93e-7	Bipolar disorder;
CESC	cis	rs1865721	0.682	rs1561080	chr18:73145847	A/G	cg26385618	chr18:73139727	C18orf62	-0.46	-7.43	-0.42	1.48e-12	Intelligence;
CESC	cis	rs34779708	0.733	rs11010146	chr10:35541561	T/A	cg03585969	chr10:35415529	CREM	0.56	6.42	0.37	6.15e-10	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs77972916	0.536	rs6751209	chr2:43588302	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.51	-5.17	-0.3	4.57e-7	Granulocyte percentage of myeloid white cells;
CESC	cis	rs10752881	1.000	rs12126434	chr1:182988414	A/G	ch.1.3577855R	chr1:183094577	LAMC1	-0.86	-13.62	-0.64	2.2e-32	Colorectal cancer;
CESC	cis	rs853679	0.517	rs56310871	chr6:28044482	A/G	cg26335602	chr6:28129616	ZNF389	0.53	7.05	0.4	1.55e-11	Depression;
CESC	cis	rs11645898	0.810	rs72787060	chr16:72105371	T/C	cg14768367	chr16:72042858	DHODH	-0.77	-6.17	-0.35	2.48e-9	Blood protein levels;
CESC	cis	rs4819052	0.851	rs28442024	chr21:46674475	C/A	cg11663144	chr21:46675770	NA	-0.56	-8.8	-0.48	1.82e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs8067545	0.750	rs4925072	chr17:19956899	C/T	cg13482628	chr17:19912719	NA	-0.38	-5.08	-0.3	7.27e-7	Schizophrenia;
CESC	cis	rs12822507	0.868	rs61915599	chr12:12768409	A/G	cg04607235	chr12:12878440	APOLD1	-0.49	-6.11	-0.35	3.56e-9	Systemic lupus erythematosus;
CESC	cis	rs75477785	1.000	rs78355191	chr1:210042077	C/T	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.82	5.27	0.31	2.79e-7	Cleft lip with or without cleft palate;
CESC	cis	rs7727544	0.581	rs10075801	chr5:131677642	A/G	cg14196790	chr5:131705035	SLC22A5	0.36	5.42	0.32	1.33e-7	Blood metabolite levels;
CESC	cis	rs7635838	0.617	rs2606731	chr3:11291615	A/C	cg00170343	chr3:11313890	ATG7	0.62	8.68	0.47	4.01e-16	HDL cholesterol;
CESC	cis	rs11112613	0.713	rs11112592	chr12:105951702	C/T	cg03607813	chr12:105948248	NA	-0.57	-7.09	-0.4	1.2e-11	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CESC	cis	rs112158604	1	rs112158604	chr1:150696792	TCTTCTGCAG/T	cg22823121	chr1:150693482	HORMAD1	-0.41	-6.29	-0.36	1.33e-9	Lymphocyte counts;
CESC	cis	rs7592578	0.771	rs62181034	chr2:191354963	C/A	cg10560079	chr2:191398806	TMEM194B	-0.63	-5.62	-0.33	4.81e-8	Diastolic blood pressure;
CESC	cis	rs116095464	0.558	rs6874745	chr5:264527	A/G	cg22857025	chr5:266934	NA	-1.3	-18.55	-0.75	8.05e-50	Breast cancer;
CESC	cis	rs7703051	0.901	rs4604177	chr5:74808880	C/T	cg03227963	chr5:74354835	NA	0.3	5.36	0.31	1.85e-7	LDL cholesterol;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
CESC	cis	rs8060686	0.545	rs12597573	chr16:68167521	A/C	cg26727032	chr16:67993705	SLC12A4	0.5	5.46	0.32	1.11e-7	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs875971	0.862	rs1167399	chr7:65561877	G/A	cg12463550	chr7:65579703	CRCP	-0.54	-6.65	-0.38	1.65e-10	Aortic root size;
CESC	cis	rs7577696	0.626	rs212754	chr2:32421628	A/G	cg02381751	chr2:32503542	YIPF4	0.45	5.41	0.32	1.4e-7	Inflammatory biomarkers;
CESC	cis	rs1008375	1.000	rs6449323	chr4:17683916	A/T	cg02297831	chr4:17616191	MED28	0.45	5.51	0.32	8.62e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs12887734	0.524	rs4900599	chr14:104283444	G/T	cg01849466	chr14:104193079	ZFYVE21	-0.44	-5.62	-0.33	4.74e-8	Schizophrenia;Autism spectrum disorder or schizophrenia;
CESC	cis	rs367615	0.591	rs4530812	chr5:108858587	A/C	cg17395555	chr5:108820864	NA	-0.43	-6.93	-0.39	3.29e-11	Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs9902453	0.838	rs9646438	chr17:28209091	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	8.08	0.44	2.31e-14	Coffee consumption (cups per day);
CESC	cis	rs6496667	0.557	rs2589951	chr15:90958392	T/C	cg10434728	chr15:90938212	IQGAP1	0.31	5.5	0.32	9.17e-8	Rheumatoid arthritis;
CESC	cis	rs250677	0.687	rs40522	chr5:148442295	G/A	cg18129178	chr5:148520854	ABLIM3	-0.51	-5.87	-0.34	1.33e-8	Breast cancer;
CESC	cis	rs896854	0.517	rs9643353	chr8:95957063	A/G	cg16049864	chr8:95962084	TP53INP1	0.54	7.92	0.44	6.44e-14	Type 2 diabetes;
CESC	trans	rs2727020	0.595	rs10769583	chr11:49483193	G/A	cg03929089	chr4:120376271	NA	-0.85	-13.45	-0.64	8.77e-32	Coronary artery disease;
CESC	cis	rs9787249	0.915	rs58589165	chr1:40213670	A/T	cg19912559	chr1:40204330	PPIE	0.42	6.48	0.37	4.37e-10	Blood protein levels;
CESC	cis	rs7020830	1.000	rs7020830	chr9:37085184	A/T	cg14294708	chr9:37120828	ZCCHC7	1.22	23.54	0.82	6.97e-67	Schizophrenia;
CESC	cis	rs67478160	0.619	rs3742365	chr14:104198251	A/G	cg08213375	chr14:104286397	PPP1R13B	0.47	9.08	0.49	2.53e-17	Schizophrenia;
CESC	cis	rs769267	0.965	rs2074296	chr19:19373689	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.42	5.06	0.3	7.71e-7	Tonsillectomy;
CESC	cis	rs7829975	0.711	rs12682352	chr8:8646246	A/G	cg15556689	chr8:8085844	FLJ10661	0.52	6.68	0.38	1.43e-10	Mood instability;
CESC	cis	rs1467026	0.719	rs17037220	chr3:12818103	A/G	cg24848339	chr3:12840334	CAND2	0.42	6.64	0.38	1.76e-10	P wave duration;
CESC	cis	rs4727027	0.870	rs11524138	chr7:148799125	G/A	cg23583168	chr7:148888333	NA	-0.78	-12.16	-0.6	2.45e-27	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs4919694	1.000	rs76255497	chr10:104651955	T/C	cg04362960	chr10:104952993	NT5C2	0.74	6.45	0.37	5.32e-10	Arsenic metabolism;
CESC	cis	rs941873	0.868	rs12780295	chr10:81115438	G/A	cg11057378	chr10:81107060	PPIF	0.32	5.24	0.31	3.25e-7	Height;
CESC	trans	rs10841784	0.959	rs34249976	chr12:21469942	T/C	cg00566759	chr18:28682345	DSC2	0.48	6.4	0.37	6.85e-10	Childhood ear infection;
CESC	cis	rs68170813	0.559	rs4730223	chr7:106814234	A/T	cg02696742	chr7:106810147	HBP1	0.55	5.31	0.31	2.28e-7	Coronary artery disease;
CESC	cis	rs4076764	0.958	rs11580702	chr1:163385523	C/G	cg06092702	chr1:163392909	NA	-0.4	-5.89	-0.34	1.18e-8	Motion sickness;
CESC	cis	rs12477438	1.000	rs6542873	chr2:99824965	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.62	-7.37	-0.41	2.12e-12	Chronic sinus infection;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg19519331	chr10:91403645	PANK1	-0.44	-6.12	-0.35	3.26e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs9311474	0.508	rs3796353	chr3:52593230	C/T	cg18099408	chr3:52552593	STAB1	-0.36	-6.02	-0.35	5.76e-9	Electroencephalogram traits;
CESC	cis	rs17376456	0.569	rs7736892	chr5:93205597	G/A	cg21475434	chr5:93447410	FAM172A	-0.52	-5.25	-0.31	3.13e-7	Diabetic retinopathy;
CESC	cis	rs2952156	0.920	rs1565920	chr17:37831613	G/A	cg20243544	chr17:37824526	PNMT	0.64	8.3	0.45	5.36e-15	Asthma;
CESC	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg22105103	chr4:187893119	NA	0.51	7.69	0.43	2.88e-13	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1941023	0.503	rs4939350	chr11:60136243	C/G	cg08716584	chr11:60157161	MS4A7	-0.54	-8.74	-0.47	2.67e-16	Congenital heart disease (maternal effect);
CESC	cis	rs36051895	0.659	rs12337134	chr9:5061578	G/A	cg02405213	chr9:5042618	JAK2	-0.5	-6.13	-0.35	3.19e-9	Pediatric autoimmune diseases;
CESC	cis	rs1005277	0.603	rs1998062	chr10:38457652	G/C	cg25427524	chr10:38739819	LOC399744	-0.68	-9.78	-0.51	1.74e-19	Extrinsic epigenetic age acceleration;
CESC	cis	rs9325144	0.581	rs2653758	chr12:38946233	G/T	cg13010199	chr12:38710504	ALG10B	-0.39	-5.18	-0.3	4.47e-7	Morning vs. evening chronotype;
CESC	cis	rs1552244	1.000	rs57631744	chr3:10118962	T/C	cg08888203	chr3:10149979	C3orf24	0.55	7.2	0.4	6.16e-12	Alzheimer's disease;
CESC	cis	rs2573652	1.000	rs11634977	chr15:100516472	G/A	cg09918751	chr15:100517450	ADAMTS17	-0.4	-7.73	-0.43	2.29e-13	Height;
CESC	cis	rs6952808	0.564	rs73038441	chr7:2139286	T/C	cg04267008	chr7:1944627	MAD1L1	-0.6	-7.25	-0.41	4.44e-12	Bipolar disorder and schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19901191	chr1:33005091	ZBTB8A	0.58	6.45	0.37	5.22e-10	Gut microbiome composition (summer);
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg10316662	chr8:93156389	NA	-0.48	-6.49	-0.37	4.31e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs9796	0.870	rs7169375	chr15:41311046	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.45	-6.79	-0.38	7.49e-11	Menopause (age at onset);
CESC	cis	rs3126085	1.000	rs3126085	chr1:152300817	G/A	cg03465714	chr1:152285911	FLG	0.43	5.22	0.31	3.62e-7	Atopic dermatitis;
CESC	cis	rs4665809	1.000	rs4665306	chr2:26319124	C/T	cg08470875	chr2:26401718	FAM59B	-0.47	-5.22	-0.31	3.55e-7	Gut microbiome composition (summer);
CESC	cis	rs7208859	0.623	rs73267858	chr17:29059737	A/G	cg19761014	chr17:28927070	LRRC37B2	0.76	6.25	0.36	1.66e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs1050631	0.592	rs1789548	chr18:33724296	G/A	cg25426722	chr18:33708991	SLC39A6;ELP2	0.53	7.16	0.4	7.87e-12	Esophageal squamous cell cancer (length of survival);
CESC	cis	rs765787	0.530	rs55920042	chr15:45541577	G/A	cg24006582	chr15:45444508	DUOX1	-0.59	-7.32	-0.41	3.04e-12	Uric acid levels;
CESC	cis	rs7208859	0.623	rs7208441	chr17:29143863	C/T	cg13385521	chr17:29058706	SUZ12P	0.82	6.57	0.37	2.6200000000000003e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg05290695	chr8:119634602	SAMD12	0.4	6.34	0.36	9.65e-10	Gambling;
CESC	cis	rs7923609	1.000	rs12355784	chr10:65121565	G/T	cg01631684	chr10:65280961	REEP3	-0.42	-5.29	-0.31	2.59e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs79349575	0.681	rs56080003	chr17:47019049	A/T	cg16584676	chr17:46985605	UBE2Z	0.54	6.67	0.38	1.46e-10	Type 2 diabetes;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg23333220	chr15:64679825	TRIP4	-0.56	-7.46	-0.42	1.2e-12	Height;
CESC	cis	rs11690935	0.959	rs11904009	chr2:172627343	T/G	cg13550731	chr2:172543902	DYNC1I2	-0.97	-14.95	-0.68	4.66e-37	Schizophrenia;
CESC	cis	rs460214	0.528	rs4817954	chr21:40023857	C/T	cg05519781	chr21:40033154	ERG	-0.45	-5.58	-0.32	6.08e-8	Response to cognitive-behavioural therapy in anxiety disorder;
CESC	cis	rs4713118	0.662	rs464312	chr6:27967591	T/A	cg19592336	chr6:28129416	ZNF389	0.47	6.44	0.37	5.49e-10	Parkinson's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03885022	chr7:92158293	C7orf64;PEX1	-0.6	-7.06	-0.4	1.49e-11	Gut microbiome composition (summer);
CESC	cis	rs2243480	0.901	rs58207111	chr7:65486723	C/T	cg18252515	chr7:66147081	NA	-1.13	-10.9	-0.56	4.18e-23	Diabetic kidney disease;
CESC	cis	rs3820068	0.581	rs16851851	chr1:15929628	C/G	cg13390004	chr1:15929781	NA	0.35	5.58	0.32	5.83e-8	Systolic blood pressure;
CESC	cis	rs9911578	1.000	rs9898626	chr17:56698219	C/G	cg05425664	chr17:57184151	TRIM37	-0.51	-7.21	-0.4	6.03e-12	Intelligence (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23204345	chr6:108882184	FOXO3	0.6	6.87	0.39	4.5e-11	Gut microbiome composition (summer);
CESC	cis	rs2486288	0.656	rs11631021	chr15:45556829	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.63	-7.54	-0.42	7.58e-13	Glomerular filtration rate;
CESC	cis	rs2011503	1.000	rs58074958	chr19:19570555	G/C	cg11584989	chr19:19387371	SF4	0.62	7.22	0.41	5.54e-12	Bipolar disorder;
CESC	cis	rs2070488	0.965	rs1984312	chr3:38538466	G/T	cg24069376	chr3:38537580	EXOG	-0.43	-7.87	-0.44	9.09e-14	Electrocardiographic conduction measures;
CESC	trans	rs7726839	0.540	rs72703079	chr5:595173	T/C	cg25482853	chr8:67687455	SGK3	1.04	10.11	0.53	1.55e-20	Obesity-related traits;
CESC	cis	rs9583531	0.689	rs6492308	chr13:111377829	T/C	cg15841412	chr13:111365552	ING1	0.45	5.6	0.33	5.46e-8	Coronary artery disease;
CESC	cis	rs11098499	0.754	rs11724409	chr4:120252361	A/G	cg09307838	chr4:120376055	NA	0.77	10.49	0.54	9.15e-22	Corneal astigmatism;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05135541	chr1:150039387	VPS45	0.62	7.48	0.42	1.07e-12	Gut microbiome composition (summer);
CESC	cis	rs72901758	0.768	rs11650317	chr17:76251306	A/T	cg23302638	chr17:76210176	BIRC5	0.47	5.06	0.3	7.71e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
CESC	cis	rs2463822	1.000	rs2463825	chr11:62094493	G/A	cg06239285	chr11:62104954	ASRGL1	0.89	8.97	0.48	5.69e-17	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs1801251	1.000	rs1947105	chr2:233721455	A/G	cg08000102	chr2:233561755	GIGYF2	0.71	10.38	0.54	2.12e-21	Coronary artery disease;
CESC	cis	rs7615952	0.512	rs4646765	chr3:125820707	G/A	cg02807482	chr3:125708958	NA	-0.39	-5.11	-0.3	6.29e-7	Blood pressure (smoking interaction);
CESC	cis	rs11078597	0.731	rs12937244	chr17:1646317	T/C	cg18436246	chr17:1640651	WDR81	0.62	7.59	0.42	5.36e-13	Serum albumin level;
CESC	cis	rs3762637	1.000	rs9836309	chr3:122135195	G/A	cg24169773	chr3:122142474	KPNA1	-0.51	-6.03	-0.35	5.56e-9	LDL cholesterol levels;
CESC	cis	rs7666738	0.830	rs4699589	chr4:98973889	A/G	cg05340658	chr4:99064831	C4orf37	0.79	12.26	0.6	1.12e-27	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12759997	chr1:54518742	TMEM59;C1orf83	0.68	7.86	0.43	9.88e-14	Gut microbiome composition (summer);
CESC	cis	rs7085104	0.700	rs743572	chr10:104597152	A/G	cg15744005	chr10:104629667	AS3MT	-0.34	-5.32	-0.31	2.17e-7	Immature fraction of reticulocytes;Schizophrenia;
CESC	cis	rs16973500	0.808	rs72801786	chr16:71955085	C/T	cg09427745	chr16:71932006	KIAA0174	-0.52	-5.3	-0.31	2.39e-7	Response to anti-TNF therapy in rheumatoid arthritis;Attention deficit hyperactivity disorder and conduct disorder;
CESC	cis	rs36051895	0.659	rs1159782	chr9:5078117	T/C	cg02405213	chr9:5042618	JAK2	-0.51	-6.18	-0.35	2.45e-9	Pediatric autoimmune diseases;
CESC	cis	rs7618915	0.501	rs34157897	chr3:52716937	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.61	8.82	0.48	1.53e-16	Bipolar disorder;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg09686635	chr1:210001418	C1orf107	-0.48	-6.45	-0.37	5.28e-10	Thyroid stimulating hormone;
CESC	cis	rs8177253	0.965	rs4854760	chr3:133498741	C/T	cg12373951	chr3:133503437	NA	-0.36	-5.36	-0.31	1.79e-7	Iron status biomarkers;
CESC	cis	rs938554	0.570	rs7696983	chr4:9995829	A/C	cg00071950	chr4:10020882	SLC2A9	0.67	7.76	0.43	1.81e-13	Blood metabolite levels;
CESC	cis	rs854765	0.603	rs4506967	chr17:17990474	A/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.6	8.56	0.47	9.59e-16	Total body bone mineral density;
CESC	cis	rs9300255	0.568	rs1627724	chr12:123638580	T/A	cg05973401	chr12:123451056	ABCB9	0.5	5.79	0.34	1.98e-8	Neutrophil percentage of white cells;
CESC	cis	rs6543140	0.855	rs4851591	chr2:103077423	T/C	cg04239558	chr2:103089729	SLC9A4	0.47	6.16	0.35	2.64e-9	Blood protein levels;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg04838709	chr14:21151782	ANG;RNASE4	0.47	6.65	0.38	1.68e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs870825	0.860	rs60022249	chr4:185600772	T/C	cg04058563	chr4:185651563	MLF1IP	0.52	5.13	0.3	5.69e-7	Blood protein levels;
CESC	cis	rs4665809	0.590	rs962217	chr2:26438276	T/C	cg27170947	chr2:26402098	FAM59B	-0.87	-9.81	-0.52	1.41e-19	Gut microbiome composition (summer);
CESC	cis	rs9611565	0.729	rs202654	chr22:41841034	G/A	cg06481639	chr22:41940642	POLR3H	0.42	5.03	0.3	9e-7	Vitiligo;
CESC	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.55	-6.13	-0.35	3.19e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs847577	0.646	rs10270222	chr7:97781799	C/T	cg21770322	chr7:97807741	LMTK2	-0.5	-7.34	-0.41	2.65e-12	Breast cancer;
CESC	cis	rs7078219	0.714	rs10883363	chr10:101287580	C/T	cg09788492	chr10:101292477	NKX2-3	0.31	5.03	0.3	8.88e-7	Dental caries;
CESC	cis	rs11155671	0.530	rs2342767	chr6:150209717	C/G	cg09699651	chr6:150184138	LRP11	0.54	7.56	0.42	6.82e-13	Testicular germ cell tumor;
CESC	cis	rs7666738	0.753	rs1830230	chr4:99026186	G/C	cg24818145	chr4:99064322	C4orf37	0.39	5.09	0.3	6.95e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4423214	1.000	rs7944926	chr11:71165625	A/G	cg05163923	chr11:71159392	DHCR7	0.76	10.16	0.53	1.05e-20	Vitamin D levels;
CESC	cis	rs3767633	0.502	rs2499845	chr1:161933066	G/C	cg09175582	chr1:161736000	ATF6	0.48	5.17	0.3	4.72e-7	IgG glycosylation;
CESC	cis	rs8071756	1.000	rs8076644	chr17:1574548	T/C	ch.17.72133F	chr17:1577994	PRPF8	0.49	5.31	0.31	2.36e-7	Blood protein levels;
CESC	cis	rs4713118	0.513	rs183244	chr6:28031838	C/A	cg23161317	chr6:28129485	ZNF389	0.38	5.33	0.31	2.07e-7	Parkinson's disease;
CESC	trans	rs7246657	0.943	rs1035479	chr19:37893300	G/T	cg24637308	chr11:6592297	DNHD1	-0.55	-6.32	-0.36	1.1e-9	Coronary artery calcification;
CESC	cis	rs875971	1.000	rs6958484	chr7:65599446	G/A	cg12463550	chr7:65579703	CRCP	-0.56	-7.23	-0.41	5.19e-12	Aortic root size;
CESC	cis	rs523522	0.892	rs4767916	chr12:121024032	T/C	cg12219531	chr12:120966889	COQ5	0.76	10.1	0.53	1.68e-20	High light scatter reticulocyte count;
CESC	cis	rs12477438	0.520	rs4340581	chr2:99725025	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	15.18	0.68	6.85e-38	Chronic sinus infection;
CESC	cis	rs8072100	0.713	rs2136750	chr17:45456100	A/G	cg08085267	chr17:45401833	C17orf57	-0.52	-6.54	-0.37	3.11e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs2651899	0.865	rs2817126	chr1:3083246	T/G	cg22674798	chr1:3096360	PRDM16	0.34	6.57	0.37	2.72e-10	Migraine;
CESC	cis	rs7809799	1.000	rs2395048	chr7:98765552	T/C	cg05967295	chr7:98741636	SMURF1	-0.77	-5.41	-0.32	1.37e-7	Ulcerative colitis;
CESC	cis	rs9611565	0.921	rs761366	chr22:41744022	C/G	cg17376030	chr22:41985996	PMM1	0.56	5.85	0.34	1.42e-8	Vitiligo;
CESC	cis	rs9611519	0.780	rs9611546	chr22:41698542	C/G	cg06634786	chr22:41940651	POLR3H	-0.5	-5.36	-0.31	1.83e-7	Neuroticism;
CESC	cis	rs1144333	0.850	rs1251274	chr1:76288587	T/C	cg10523679	chr1:76189770	ACADM	-0.56	-5.28	-0.31	2.65e-7	Attention function in attention deficit hyperactive disorder;
CESC	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	13.67	0.64	1.44e-32	Prudent dietary pattern;
CESC	cis	rs9457247	1.000	rs421214	chr6:167396629	A/G	cg23791538	chr6:167370224	RNASET2	-0.6	-8.48	-0.46	1.57e-15	Crohn's disease;
CESC	cis	rs7618915	0.501	rs2336146	chr3:52626646	A/G	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	5.83	0.34	1.59e-8	Bipolar disorder;
CESC	cis	rs9322193	0.923	rs9404048	chr6:149937324	C/T	cg07701084	chr6:150067640	NUP43	0.44	6.06	0.35	4.63e-9	Lung cancer;
CESC	trans	rs748404	0.676	rs4401024	chr15:43650335	C/T	cg24053811	chr14:70265306	SLC10A1	0.43	6.01	0.35	6.15e-9	Lung cancer;
CESC	cis	rs5750830	0.649	rs4384886	chr22:39793766	C/T	cg02038168	chr22:39784481	NA	-0.63	-8.12	-0.45	1.71e-14	Intelligence (multi-trait analysis);
CESC	cis	rs4713118	0.629	rs172165	chr6:28020814	T/G	cg23161317	chr6:28129485	ZNF389	0.49	6.17	0.35	2.49e-9	Parkinson's disease;
CESC	cis	rs9811920	0.609	rs704583	chr3:99643693	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.64	10.11	0.53	1.53e-20	Axial length;
CESC	cis	rs1799949	1.000	rs1824889	chr17:41421876	C/G	cg05368731	chr17:41323189	NBR1	0.79	10.92	0.56	3.52e-23	Menopause (age at onset);
CESC	cis	rs9549367	0.713	rs2480949	chr13:113853149	T/C	cg18105134	chr13:113819100	PROZ	0.55	7.17	0.4	7.52e-12	Platelet distribution width;
CESC	cis	rs12048904	0.647	rs7528268	chr1:101329295	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.84	11.38	0.57	1.04e-24	Multiple sclerosis;
CESC	cis	rs6831352	1.000	rs1126673	chr4:100045616	C/T	cg12011299	chr4:100065546	ADH4	0.7	8.55	0.47	9.67e-16	Alcohol dependence;
CESC	cis	rs2070488	0.699	rs13078966	chr3:38517914	T/G	cg24069376	chr3:38537580	EXOG	0.36	6.09	0.35	4.04e-9	Electrocardiographic conduction measures;
CESC	cis	rs11696501	0.739	rs6073821	chr20:44251791	A/G	cg11783356	chr20:44313418	WFDC10B	-0.35	-5.42	-0.32	1.35e-7	Brain structure;
CESC	cis	rs6541297	0.703	rs611701	chr1:230324173	C/T	cg20703242	chr1:230279135	GALNT2	-0.4	-5.26	-0.31	2.96e-7	Coronary artery disease;
CESC	cis	rs11098499	0.865	rs11098513	chr4:120316075	A/G	cg09307838	chr4:120376055	NA	0.92	12.35	0.6	5.56e-28	Corneal astigmatism;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24451422	chr1:23751210	TCEA3	0.59	6.43	0.37	5.95e-10	Gut microbiome composition (summer);
CESC	cis	rs2227631	1.000	rs2227631	chr7:100769538	A/G	cg08053846	chr7:100769605	SERPINE1	-0.42	-5.9	-0.34	1.11e-8	Plasminogen activator inhibitor type 1 levels (PAI-1);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg17533847	chr17:77812622	CBX4	0.48	6.23	0.36	1.83e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs2180341	0.842	rs9372860	chr6:127546605	G/A	cg24812749	chr6:127587940	RNF146	0.9	10.7	0.55	1.95e-22	Breast cancer;
CESC	cis	rs1728785	0.901	rs1728797	chr16:68570989	A/T	cg02972257	chr16:68554789	NA	-0.55	-6.34	-0.36	9.7e-10	Ulcerative colitis;
CESC	cis	rs6430585	0.527	rs1446586	chr2:136407445	C/T	cg07169764	chr2:136633963	MCM6	-1.03	-12.54	-0.61	1.21e-28	Corneal structure;
CESC	cis	rs3096299	0.685	rs4329923	chr16:89560178	C/T	cg08392591	chr16:89556376	ANKRD11	0.55	7.5	0.42	9.86e-13	Multiple myeloma (IgH translocation);
CESC	cis	rs7618501	0.633	rs9861216	chr3:50059339	A/G	cg24110177	chr3:50126178	RBM5	0.53	7.55	0.42	7.24e-13	Intelligence (multi-trait analysis);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg17817474	chr15:90809403	NGRN	-0.43	-6.31	-0.36	1.17e-9	Gambling;
CESC	cis	rs854765	0.964	rs2230316	chr17:17997209	C/T	cg04398451	chr17:18023971	MYO15A	0.68	9.06	0.49	2.91e-17	Total body bone mineral density;
CESC	cis	rs3747547	0.818	rs16934640	chr9:37943164	C/T	cg13774184	chr9:37916125	SHB	-0.54	-5.58	-0.32	5.79e-8	Metabolite levels (Dihydroxy docosatrienoic acid);
CESC	cis	rs9309473	0.519	rs12991161	chr2:73871371	G/A	cg20560298	chr2:73613845	ALMS1	0.51	7.13	0.4	9.62e-12	Metabolite levels;
CESC	cis	rs2730245	0.618	rs859781	chr7:158661758	G/A	cg14689365	chr7:158441557	NCAPG2	0.42	5.18	0.3	4.35e-7	Height;
CESC	cis	rs1707322	1.000	rs1707338	chr1:46511981	T/G	cg06784218	chr1:46089804	CCDC17	-0.33	-5.65	-0.33	4.08e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs17711722	0.523	rs365896	chr7:65510697	A/G	cg04775059	chr7:64541387	NA	-0.41	-5.08	-0.3	7.07e-7	Calcium levels;
CESC	cis	rs6860806	0.661	rs2171247	chr5:131580234	G/T	cg22638593	chr5:131593259	PDLIM4	0.39	5.06	0.3	7.78e-7	Breast cancer;
CESC	cis	rs7845219	0.544	rs4735331	chr8:95917958	C/T	cg23172400	chr8:95962367	TP53INP1	-0.38	-7.08	-0.4	1.3e-11	Type 2 diabetes;
CESC	cis	rs6121246	0.567	rs6060344	chr20:30207316	A/G	cg13852791	chr20:30311386	BCL2L1	0.57	5.29	0.31	2.54e-7	Mean corpuscular hemoglobin;
CESC	cis	rs1799949	0.896	rs33933393	chr17:41317432	C/T	cg05368731	chr17:41323189	NBR1	0.79	11.1	0.56	9.39e-24	Menopause (age at onset);
CESC	cis	rs7714584	1.000	rs10041072	chr5:150259642	A/G	cg22134413	chr5:150180641	NA	0.49	5.38	0.31	1.68e-7	Crohn's disease;
CESC	cis	rs7635838	0.892	rs9823197	chr3:11503133	A/T	cg00170343	chr3:11313890	ATG7	0.42	5.67	0.33	3.64e-8	HDL cholesterol;
CESC	cis	rs2637266	1.000	rs7101318	chr10:78379780	T/C	cg18941641	chr10:78392320	NA	0.43	8.11	0.45	1.86e-14	Pulmonary function;
CESC	cis	rs941873	0.805	rs10824747	chr10:81118464	T/C	cg11057378	chr10:81107060	PPIF	0.36	5.7	0.33	3.22e-8	Height;
CESC	cis	rs9329289	0.851	rs61835719	chr10:2543390	A/G	cg18171855	chr10:2543474	NA	0.35	5.26	0.31	2.9e-7	Age-related hearing impairment;
CESC	trans	rs17764205	0.777	rs112570652	chr19:3255789	G/A	cg03776506	chr16:30581384	ZNF688	-0.78	-6.03	-0.35	5.44e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs10744422	1.000	rs7972447	chr12:123354545	C/G	cg25930673	chr12:123319894	HIP1R	-0.65	-5.1	-0.3	6.44e-7	Schizophrenia;
CESC	cis	rs7618915	0.571	rs7623199	chr3:52605974	C/T	cg05564831	chr3:52568323	NT5DC2	0.46	6.93	0.39	3.15e-11	Bipolar disorder;
CESC	cis	rs35146811	0.844	rs13223792	chr7:99675659	T/G	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.45	5.89	0.34	1.16e-8	Coronary artery disease;
CESC	cis	rs4722166	0.630	rs7781534	chr7:22778592	A/C	cg05472934	chr7:22766657	IL6	0.87	10.94	0.56	3.06e-23	Lung cancer;
CESC	cis	rs561341	1.000	rs7216102	chr17:30259450	A/G	cg12193833	chr17:30244370	NA	-0.47	-5.41	-0.32	1.38e-7	Hip circumference adjusted for BMI;
CESC	cis	rs7762018	0.607	rs6907814	chr6:170058206	G/A	cg19338460	chr6:170058176	WDR27	-0.84	-7.07	-0.4	1.39e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs74181299	0.892	rs2249105	chr2:65287896	C/T	cg05010058	chr2:65284262	CEP68	-0.33	-5.82	-0.34	1.68e-8	Pulse pressure;
CESC	cis	rs6582630	0.519	rs1607882	chr12:38361657	G/A	cg13010199	chr12:38710504	ALG10B	0.43	5.48	0.32	9.9e-8	Drug-induced liver injury (flucloxacillin);
CESC	trans	rs3942852	0.910	rs10742831	chr11:48119691	G/A	cg15704280	chr7:45808275	SEPT13	-0.62	-6.74	-0.38	1e-10	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs6690583	0.623	rs11588160	chr1:85444226	T/G	cg22153463	chr1:85462885	MCOLN2	0.75	7.17	0.4	7.47e-12	Serum sulfate level;
CESC	cis	rs9916302	0.851	rs9909064	chr17:37500434	G/T	cg20243544	chr17:37824526	PNMT	-0.47	-5.94	-0.34	9.04e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs7100689	0.784	rs10736341	chr10:82061206	C/G	cg09936400	chr10:82049201	MAT1A	0.37	5.3	0.31	2.41e-7	Post bronchodilator FEV1;
CESC	cis	rs9457247	1.000	rs408918	chr6:167399282	G/T	cg25258033	chr6:167368657	RNASET2	0.4	6.04	0.35	5.12e-9	Crohn's disease;
CESC	cis	rs992157	0.798	rs7587220	chr2:219160864	C/A	cg00012203	chr2:219082015	ARPC2	-0.74	-9.46	-0.5	1.7e-18	Colorectal cancer;
CESC	cis	rs9318086	0.648	rs9507184	chr13:24473642	T/C	cg25267304	chr13:24462978	PCOTH;MIPEP	0.44	6.27	0.36	1.44e-9	Myopia (pathological);
CESC	cis	rs9341808	0.718	rs9294171	chr6:80839815	C/T	cg08355045	chr6:80787529	NA	0.34	5.41	0.32	1.41e-7	Sitting height ratio;
CESC	cis	rs7264396	0.635	rs6060688	chr20:34516731	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.75	10.38	0.54	2.12e-21	Total cholesterol levels;
CESC	cis	rs2228479	0.702	rs11076620	chr16:89831520	A/T	cg14709524	chr16:89940631	TCF25	0.91	6.74	0.38	1e-10	Skin colour saturation;
CESC	cis	rs4237845	0.816	rs61935769	chr12:58294344	G/A	cg02175503	chr12:58329896	NA	0.64	7.73	0.43	2.3e-13	Intelligence (multi-trait analysis);
CESC	trans	rs7618501	0.633	rs2856234	chr3:50139142	A/G	cg21659725	chr3:3221576	CRBN	-0.49	-6.75	-0.38	9.22e-11	Intelligence (multi-trait analysis);
CESC	cis	rs873946	0.504	rs3829132	chr10:134579044	A/C	cg26818010	chr10:134567672	INPP5A	-0.86	-10.64	-0.55	3.04e-22	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs12325245	0.536	rs71375919	chr16:58547522	C/T	cg05725404	chr16:58534157	NDRG4	-0.63	-5.44	-0.32	1.22e-7	Schizophrenia;
CESC	cis	rs17711722	0.727	rs2658585	chr7:65461941	A/T	cg18876405	chr7:65276391	NA	0.72	10.04	0.52	2.67e-20	Calcium levels;
CESC	cis	rs9388451	1.000	rs9388451	chr6:126090377	A/G	cg05901451	chr6:126070800	HEY2	-0.64	-9.12	-0.49	1.9e-17	Brugada syndrome;
CESC	trans	rs1493916	1.000	rs12457802	chr18:31389865	A/G	cg27147174	chr7:100797783	AP1S1	0.5	6.83	0.39	5.71e-11	Life satisfaction;
CESC	cis	rs6460942	0.597	rs12699381	chr7:12527026	G/A	cg06484146	chr7:12443880	VWDE	-0.71	-7.7	-0.43	2.7e-13	Coronary artery disease;
CESC	cis	rs1862618	0.853	rs252919	chr5:56124111	T/C	cg22800045	chr5:56110881	MAP3K1	0.84	10.23	0.53	6.66e-21	Initial pursuit acceleration;
CESC	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	7.7	0.43	2.77e-13	Prudent dietary pattern;
CESC	cis	rs7267979	1.000	rs404394	chr20:25447896	A/G	cg08601574	chr20:25228251	PYGB	0.37	5.31	0.31	2.31e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7582720	1.000	rs72936842	chr2:203773686	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.39	0.41	1.96e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs9443645	0.901	rs9352667	chr6:79572296	A/G	cg05283184	chr6:79620031	NA	0.44	6.82	0.39	6.32e-11	Intelligence (multi-trait analysis);
CESC	cis	rs9814567	1.000	rs9985356	chr3:134232920	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.42	6.17	0.35	2.56e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs9318086	0.600	rs9507185	chr13:24473734	G/A	cg25267304	chr13:24462978	PCOTH;MIPEP	0.44	6.28	0.36	1.35e-9	Myopia (pathological);
CESC	cis	rs7666738	0.716	rs2865982	chr4:99031661	T/G	cg17366294	chr4:99064904	C4orf37	0.62	8.95	0.48	6.32e-17	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2204008	0.715	rs11525003	chr12:38332359	G/A	cg13010199	chr12:38710504	ALG10B	0.48	6.11	0.35	3.53e-9	Bladder cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20117626	chr22:32150034	DEPDC5	0.59	7.27	0.41	4.17e-12	Gut microbiome composition (summer);
CESC	cis	rs13108904	0.935	rs3755920	chr4:1243617	T/C	cg16405210	chr4:1374714	KIAA1530	-0.42	-5.69	-0.33	3.39e-8	Obesity-related traits;
CESC	cis	rs17253792	0.822	rs78615025	chr14:56168012	G/A	cg01858014	chr14:56050164	KTN1	-0.97	-7.54	-0.42	7.36e-13	Putamen volume;
CESC	cis	rs7666738	0.519	rs11732209	chr4:98801643	A/G	cg17366294	chr4:99064904	C4orf37	0.49	6.09	0.35	3.92e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9457247	0.646	rs239934	chr6:167412048	G/A	cg07741184	chr6:167504864	NA	0.29	5.26	0.31	2.98e-7	Crohn's disease;
CESC	cis	rs826838	0.967	rs11168299	chr12:38902028	G/T	cg26384229	chr12:38710491	ALG10B	0.82	14.52	0.67	1.49e-35	Heart rate;
CESC	cis	rs2303759	0.676	rs7248378	chr19:49908144	C/A	cg22590775	chr19:49891494	CCDC155	0.52	6.11	0.35	3.47e-9	Multiple sclerosis;
CESC	cis	rs1707322	0.928	rs6681068	chr1:46398382	G/A	cg06784218	chr1:46089804	CCDC17	0.33	5.63	0.33	4.7e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24189559	chr3:12851674	CAND2	0.59	7.24	0.41	4.79e-12	Gut microbiome composition (summer);
CESC	cis	rs13191362	1.000	rs36042757	chr6:163004744	A/C	cg06582575	chr6:163149167	PACRG;PARK2	0.79	8.26	0.45	6.82e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs6942756	0.806	rs2694572	chr7:128911721	A/G	cg02491457	chr7:128862824	NA	0.65	9.51	0.5	1.23e-18	White matter hyperintensity burden;
CESC	cis	rs8020095	0.571	rs9323483	chr14:67239607	C/T	cg19548862	chr14:67692701	FAM71D	-0.5	-6.2	-0.36	2.13e-9	Depression (quantitative trait);
CESC	cis	rs6089584	0.566	rs2146852	chr20:60616492	T/G	cg06108461	chr20:60628389	TAF4	-0.63	-8.37	-0.46	3.37e-15	Body mass index;
CESC	cis	rs7847628	0.587	rs1060817	chr9:123583192	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.82	13.32	0.63	2.43e-31	Birth weight;
CESC	cis	rs2425143	0.558	rs7274724	chr20:34539466	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.65	5.59	0.32	5.74e-8	Blood protein levels;
CESC	cis	rs7615952	0.576	rs2276726	chr3:125826287	C/G	cg04553112	chr3:125709451	NA	-0.55	-6.36	-0.36	8.75e-10	Blood pressure (smoking interaction);
CESC	cis	rs6952808	1.000	rs6953693	chr7:1886388	C/G	cg22963979	chr7:1858916	MAD1L1	-0.38	-5.15	-0.3	5e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs1799949	0.965	rs8176161	chr17:41241390	C/A	cg05368731	chr17:41323189	NBR1	0.78	11.14	0.56	6.78e-24	Menopause (age at onset);
CESC	cis	rs9911578	1.000	rs9892795	chr17:57023054	G/C	cg12560992	chr17:57184187	TRIM37	0.92	15.18	0.68	7.1e-38	Intelligence (multi-trait analysis);
CESC	cis	rs16866061	1.000	rs10498163	chr2:225434445	A/G	cg12698349	chr2:225449008	CUL3	0.75	11.51	0.58	4.07e-25	Acute graft versus host disease in bone marrow transplantation (recipient effect);
CESC	cis	rs4253772	0.515	rs6008591	chr22:46703664	T/C	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.66	6.5	0.37	4.07e-10	LDL cholesterol;Cholesterol, total;
CESC	cis	rs896854	0.846	rs2340584	chr8:95916811	A/G	cg16049864	chr8:95962084	TP53INP1	-0.68	-12.14	-0.6	2.91e-27	Type 2 diabetes;
CESC	cis	rs1256061	0.624	rs1152582	chr14:64692630	G/C	cg21174375	chr14:64681225	SYNE2	0.49	6.48	0.37	4.42e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs317689	0.819	rs317685	chr12:69715457	A/G	cg14784868	chr12:69753453	YEATS4	-0.48	-5.2	-0.3	3.92e-7	Response to diuretic therapy;
CESC	cis	rs7385804	0.796	rs221801	chr7:100290031	C/A	cg20848291	chr7:100343083	ZAN	0.55	7.38	0.41	2.05e-12	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
CESC	cis	rs9457247	0.663	rs1894603	chr6:167434686	C/T	cg07741184	chr6:167504864	NA	-0.33	-5.81	-0.34	1.83e-8	Crohn's disease;
CESC	cis	rs4950322	0.570	rs72691033	chr1:146732921	C/T	cg16700924	chr1:146552102	NA	-0.41	-5.12	-0.3	5.98e-7	Protein quantitative trait loci;
CESC	cis	rs2447097	0.935	rs2447094	chr17:2294048	A/C	cg04477101	chr17:2275030	SGSM2	0.34	5.03	0.3	8.91e-7	Autism spectrum disorder;
CESC	cis	rs11252926	0.562	rs11252792	chr10:544369	G/A	cg03684893	chr10:554711	DIP2C	0.37	5.57	0.32	6.32e-8	Psychosis in Alzheimer's disease;
CESC	trans	rs650950	0.528	rs646660	chr11:35528452	C/T	cg09041756	chr7:5570314	ACTB	0.46	6.01	0.35	6.12e-9	Bronchopulmonary dysplasia;
CESC	cis	rs8062405	0.824	rs7191618	chr16:28565667	C/G	cg07382826	chr16:28625726	SULT1A1	0.31	5.05	0.3	8.11e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs28489187	0.683	rs1498373	chr1:85790633	G/A	cg16011679	chr1:85725395	C1orf52	0.54	6.29	0.36	1.31e-9	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	trans	rs1945213	0.625	rs7128190	chr11:55858550	A/T	cg03929089	chr4:120376271	NA	0.77	7.35	0.41	2.48e-12	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs2658782	0.826	rs1975820	chr11:93081815	G/A	cg15737290	chr11:93063684	CCDC67	0.6	7.57	0.42	6.32e-13	Pulmonary function decline;
CESC	cis	rs7662987	0.540	rs2851278	chr4:100021253	G/C	cg13256891	chr4:100009986	ADH5	0.75	8.06	0.44	2.6e-14	Smoking initiation;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08585351	chr13:22178326	EFHA1	0.57	6.78	0.38	7.59e-11	Gut microbiome composition (summer);
CESC	cis	rs651907	0.513	rs34963630	chr3:101504817	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.46	6.18	0.35	2.43e-9	Colorectal cancer;
CESC	cis	rs2637266	0.579	rs10824424	chr10:78321443	A/G	cg18941641	chr10:78392320	NA	0.33	5.11	0.3	6.22e-7	Pulmonary function;
CESC	cis	rs853679	0.517	rs9380055	chr6:28081629	A/G	cg26335602	chr6:28129616	ZNF389	0.53	7.06	0.4	1.48e-11	Depression;
CESC	cis	rs8141529	0.702	rs469992	chr22:29314899	T/C	cg15103426	chr22:29168792	CCDC117	-0.61	-7.81	-0.43	1.33e-13	Lymphocyte counts;
CESC	trans	rs1545843	0.623	rs4326842	chr12:84797890	C/A	cg03015433	chr16:56623111	MT3	-0.34	-6.14	-0.35	3.04e-9	Major depressive disorder;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg16328610	chr6:83777335	DOPEY1	-0.5	-6.13	-0.35	3.14e-9	Ulcerative colitis;
CESC	cis	rs477692	0.905	rs570967	chr10:131421330	T/G	cg05714579	chr10:131428358	MGMT	0.55	7.89	0.44	7.86e-14	Response to temozolomide;
CESC	cis	rs9660180	0.837	rs915292	chr1:1792157	A/C	cg05132306	chr1:1846340	CALML6	-0.3	-6.24	-0.36	1.77e-9	Body mass index;
CESC	cis	rs9649465	1.000	rs11765478	chr7:123362872	A/C	cg04330084	chr7:123175371	IQUB	-0.38	-5.13	-0.3	5.55e-7	Migraine;
CESC	cis	rs888194	0.714	rs7308864	chr12:109871179	A/G	cg19025524	chr12:109796872	NA	-0.35	-5.21	-0.3	3.84e-7	Neuroticism;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg27071285	chr11:62559100	TMEM223	-0.5	-6.24	-0.36	1.74e-9	Asthma;
CESC	cis	rs807669	0.903	rs762527	chr22:19183470	A/G	cg02655711	chr22:19163373	SLC25A1	0.97	15.0	0.68	2.98e-37	Metabolite levels;
CESC	cis	rs8067545	1.000	rs4925066	chr17:19915292	A/G	cg13482628	chr17:19912719	NA	0.43	5.81	0.34	1.78e-8	Schizophrenia;
CESC	cis	rs1401999	0.628	rs6798870	chr3:183740350	G/A	cg01324343	chr3:183735012	ABCC5	0.54	10.75	0.55	1.28e-22	Anterior chamber depth;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg18796520	chr12:4758272	NDUFA9	0.48	6.02	0.35	5.73e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs933688	1.000	rs6865495	chr5:90746424	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.92	12.03	0.59	6.82e-27	Smoking behavior;
CESC	cis	rs7188697	0.922	rs7186997	chr16:58603348	A/G	cg02549819	chr16:58548995	SETD6	0.43	5.4	0.31	1.51e-7	QT interval;
CESC	cis	rs7188697	0.885	rs246194	chr16:58573901	G/A	cg21335942	chr16:58549945	SETD6	0.46	5.36	0.31	1.84e-7	QT interval;
CESC	cis	rs75804782	0.641	rs72983853	chr2:239324210	C/T	cg18131467	chr2:239335373	ASB1	-0.69	-5.73	-0.33	2.75e-8	Morning vs. evening chronotype;Chronotype;
CESC	cis	rs9911578	0.874	rs302865	chr17:56756977	A/G	cg05425664	chr17:57184151	TRIM37	-0.52	-7.2	-0.4	6.21e-12	Intelligence (multi-trait analysis);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg23709988	chr14:23772096	PPP1R3E	-0.46	-6.44	-0.37	5.58e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs950776	0.616	rs647041	chr15:78880481	T/C	cg24631222	chr15:78858424	CHRNA5	0.46	5.74	0.33	2.65e-8	Sudden cardiac arrest;
CESC	cis	rs1862618	0.853	rs863840	chr5:56128999	C/G	cg18230493	chr5:56204884	C5orf35	-0.67	-8.08	-0.44	2.36e-14	Initial pursuit acceleration;
CESC	cis	rs12142240	0.698	rs1475389	chr1:46816429	T/C	cg00530320	chr1:46809349	NSUN4	0.58	7.89	0.44	8.17e-14	Menopause (age at onset);
CESC	trans	rs9833726	0.799	rs13325775	chr3:86137307	C/G	cg10416071	chr15:75628863	COMMD4	0.59	6.12	0.35	3.37e-9	Breast cancer;
CESC	cis	rs9611565	0.569	rs6002328	chr22:41710034	T/C	cg06481639	chr22:41940642	POLR3H	-0.47	-5.41	-0.32	1.37e-7	Vitiligo;
CESC	cis	rs1008375	0.932	rs4698626	chr4:17605821	G/C	cg02297831	chr4:17616191	MED28	0.52	6.61	0.38	2.1e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs832540	0.931	rs2662040	chr5:56246610	A/G	cg14703610	chr5:56206110	C5orf35	-0.52	-6.88	-0.39	4.41e-11	Coronary artery disease;
CESC	cis	rs8067545	0.532	rs35915823	chr17:19973397	A/G	cg12073167	chr17:19770448	ULK2	-0.43	-5.21	-0.3	3.88e-7	Schizophrenia;
CESC	cis	rs9611565	0.918	rs9611561	chr22:41757234	C/G	cg06634786	chr22:41940651	POLR3H	-0.66	-6.76	-0.38	8.78e-11	Vitiligo;
CESC	cis	rs672059	0.513	rs572977	chr1:183164991	C/G	cg01949993	chr1:183155116	LAMC2	-0.29	-5.26	-0.31	2.91e-7	Hypertriglyceridemia;
CESC	cis	rs2991971	0.747	rs2492841	chr1:45894891	G/T	cg05343316	chr1:45956843	TESK2	0.61	8.6	0.47	6.97e-16	High light scatter reticulocyte count;
CESC	cis	rs2439831	0.681	rs825739	chr15:43592428	T/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.89	13.39	0.64	1.43e-31	Lung cancer in ever smokers;
CESC	cis	rs9649213	0.593	rs7795176	chr7:97978287	A/C	cg21770322	chr7:97807741	LMTK2	0.57	8.84	0.48	1.39e-16	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs847577	0.630	rs2132276	chr7:97826340	G/A	cg24562669	chr7:97807699	LMTK2	0.83	13.83	0.65	4.09e-33	Breast cancer;
CESC	cis	rs10504229	0.683	rs35244711	chr8:58117762	T/G	cg21724239	chr8:58056113	NA	0.58	5.95	0.34	8.29e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs4713118	0.662	rs9468274	chr6:28026077	G/T	cg19592336	chr6:28129416	ZNF389	0.54	6.94	0.39	3e-11	Parkinson's disease;
CESC	cis	rs72634258	0.503	rs34177663	chr1:7833228	A/G	cg26816564	chr1:7831052	VAMP3	0.69	6.39	0.37	7.6e-10	Inflammatory bowel disease;
CESC	cis	rs11098499	0.863	rs1552092	chr4:120488496	C/T	cg09307838	chr4:120376055	NA	0.91	12.68	0.61	4e-29	Corneal astigmatism;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg01008097	chr4:110267632	NA	-0.34	-6.07	-0.35	4.51e-9	Thyroid stimulating hormone;
CESC	cis	rs5753037	0.676	rs6006267	chr22:30216982	C/A	cg01021169	chr22:30184971	ASCC2	-0.47	-6.64	-0.38	1.74e-10	Type 1 diabetes;
CESC	cis	rs9915657	0.660	rs982534	chr17:70081366	T/G	cg09344028	chr17:70110421	NA	0.38	6.95	0.39	2.89e-11	Thyroid hormone levels;
CESC	cis	rs7116495	1.000	rs659513	chr11:71812411	C/T	cg10381502	chr11:71823885	C11orf51	0.72	6.21	0.36	2.06e-9	Severe influenza A (H1N1) infection;
CESC	cis	rs9916302	0.706	rs12947506	chr17:37707592	A/G	cg07936489	chr17:37558343	FBXL20	-0.97	-11.4	-0.57	9.06e-25	Glomerular filtration rate (creatinine);
CESC	cis	rs12893668	0.572	rs4900591	chr14:104154878	G/A	cg08213375	chr14:104286397	PPP1R13B	0.33	5.41	0.32	1.42e-7	Reticulocyte count;
CESC	trans	rs10489896	0.541	rs2065143	chr1:234568613	T/C	cg23817893	chr11:86085932	CCDC81	-0.45	-6.21	-0.36	2.04e-9	Cognitive test performance;
CESC	cis	rs10504229	0.683	rs16921823	chr8:58108612	G/C	cg21724239	chr8:58056113	NA	0.57	5.9	0.34	1.08e-8	Developmental language disorder (linguistic errors);
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg17422500	chr1:249152952	ZNF692	-0.41	-6.28	-0.36	1.36e-9	Vertical cup-disc ratio;
CESC	cis	rs2439831	1.000	rs2253708	chr15:43797273	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.85	12.03	0.59	7.01e-27	Lung cancer in ever smokers;
CESC	cis	rs10752881	0.935	rs10911197	chr1:182995399	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.84	13.19	0.63	6.74e-31	Colorectal cancer;
CESC	cis	rs7259376	0.905	rs7258446	chr19:22550341	A/T	cg02657401	chr19:22469223	NA	-0.25	-5.05	-0.3	8.18e-7	Menopause (age at onset);
CESC	cis	rs12497850	0.931	rs6446205	chr3:49035211	C/T	cg02487422	chr3:49467188	NICN1	0.4	5.04	0.3	8.72e-7	Parkinson's disease;
CESC	cis	rs9929218	1.000	rs12930371	chr16:68802936	A/G	cg02972257	chr16:68554789	NA	-0.44	-5.26	-0.31	2.92e-7	Colorectal cancer;
CESC	cis	rs2204008	0.683	rs11522927	chr12:38137537	C/T	cg26384229	chr12:38710491	ALG10B	0.75	10.66	0.55	2.52e-22	Bladder cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16442450	chr15:69111511	ANP32A	0.55	6.64	0.38	1.79e-10	Gut microbiome composition (summer);
CESC	cis	rs17253792	0.571	rs112129578	chr14:56028415	T/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.82	5.41	0.32	1.38e-7	Putamen volume;
CESC	cis	rs651907	0.535	rs4342086	chr3:101503765	G/A	cg12386194	chr3:101231763	SENP7	0.41	5.16	0.3	4.78e-7	Colorectal cancer;
CESC	cis	rs2439831	0.867	rs16957630	chr15:43642780	A/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.9	10.37	0.54	2.22e-21	Lung cancer in ever smokers;
CESC	cis	rs11098499	0.954	rs13151285	chr4:120314741	C/A	cg09307838	chr4:120376055	NA	0.92	12.66	0.61	4.96e-29	Corneal astigmatism;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg13724827	chr9:126030353	STRBP	0.5	6.67	0.38	1.52e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs9926296	0.712	rs2437957	chr16:89715648	G/A	cg03605463	chr16:89740564	NA	0.66	7.87	0.44	9.23e-14	Vitiligo;
CESC	trans	rs9929218	0.954	rs7198799	chr16:68818390	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.65	-8.5	-0.46	1.44e-15	Colorectal cancer;
CESC	cis	rs9399401	0.961	rs1342060	chr6:142663177	T/C	cg03128060	chr6:142623767	GPR126	0.26	5.07	0.3	7.44e-7	Chronic obstructive pulmonary disease;
CESC	cis	rs4604732	0.631	rs34443739	chr1:247626913	A/G	cg12758973	chr1:247694275	LOC148824;OR2C3	0.51	6.36	0.36	8.65e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs1552244	0.510	rs13075308	chr3:10034925	G/C	cg00166722	chr3:10149974	C3orf24	0.48	5.92	0.34	9.76e-9	Alzheimer's disease;
CESC	cis	rs6987853	0.933	rs6980507	chr8:42383084	A/G	cg09913449	chr8:42400586	C8orf40	0.38	6.03	0.35	5.38e-9	Mean corpuscular hemoglobin concentration;
CESC	trans	rs9858542	1.000	rs2172252	chr3:49678307	A/T	cg21659725	chr3:3221576	CRBN	-0.53	-6.39	-0.37	7.25e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs8031584	0.541	rs2955777	chr15:31219788	A/C	cg08109568	chr15:31115862	NA	0.68	9.49	0.5	1.38e-18	Huntington's disease progression;
CESC	cis	rs9487051	0.676	rs6913093	chr6:109636205	T/C	cg01475377	chr6:109611718	NA	-0.45	-7.05	-0.4	1.6e-11	Reticulocyte fraction of red cells;
CESC	cis	rs2836974	0.897	rs13049280	chr21:40594656	C/G	cg11890956	chr21:40555474	PSMG1	1.12	18.25	0.75	9.24e-49	Cognitive function;
CESC	cis	rs11792861	0.781	rs11793272	chr9:111762102	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.52	6.7	0.38	1.23e-10	Menarche (age at onset);
CESC	cis	rs9325144	0.534	rs4882350	chr12:38686979	A/G	cg26384229	chr12:38710491	ALG10B	0.58	8.59	0.47	7.74e-16	Morning vs. evening chronotype;
CESC	cis	rs4604732	0.574	rs111928142	chr1:247625229	G/T	cg12754571	chr1:247694271	LOC148824;OR2C3	0.44	5.51	0.32	8.54e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs60843830	1.000	rs2290911	chr2:224919	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.86	11.39	0.57	9.82e-25	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs55728055	0.661	rs8139560	chr22:32003798	C/T	cg01338084	chr22:32026380	PISD	1.22	8.02	0.44	3.48e-14	Age-related hearing impairment;
CESC	cis	rs3106136	0.837	rs2289186	chr4:95255637	T/G	cg11021082	chr4:95130006	SMARCAD1	0.39	5.58	0.32	6.03e-8	Capecitabine sensitivity;
CESC	trans	rs1814175	0.645	rs1851857	chr11:49855589	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.43	-6.28	-0.36	1.35e-9	Height;
CESC	cis	rs9905704	0.624	rs11652761	chr17:56986095	C/T	cg12560992	chr17:57184187	TRIM37	0.62	7.6	0.42	4.98e-13	Testicular germ cell tumor;
CESC	cis	rs1552244	0.882	rs7633769	chr3:10020622	C/T	cg00149659	chr3:10157352	C3orf10	0.71	8.29	0.45	5.85e-15	Alzheimer's disease;
CESC	cis	rs1707322	0.964	rs6675259	chr1:46502295	G/A	cg05343316	chr1:45956843	TESK2	-0.49	-5.66	-0.33	3.83e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs6940638	0.688	rs9393791	chr6:27132529	C/G	cg12292205	chr6:26970375	C6orf41	-0.41	-5.44	-0.32	1.22e-7	Intelligence (multi-trait analysis);
CESC	cis	rs6500395	1.000	rs2354578	chr16:48593298	T/C	cg04672837	chr16:48644449	N4BP1	0.51	6.36	0.36	8.56e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs10416265	0.527	rs11084699	chr19:33538393	A/T	cg27124370	chr19:33622961	WDR88	0.54	7.38	0.41	1.99e-12	Bone properties (heel);
CESC	trans	rs12356475	0.710	rs10822686	chr10:67733250	C/T	cg10731192	chr6:35436023	RPL10A	0.51	6.17	0.35	2.5e-9	Psoriatic arthritis;
CESC	cis	rs9858542	0.953	rs6803222	chr3:49665976	T/G	cg07274523	chr3:49395745	GPX1	0.68	8.59	0.47	7.34e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs13118159	0.934	rs4974553	chr4:1356911	G/A	cg00684032	chr4:1343700	KIAA1530	0.34	5.16	0.3	4.89e-7	Longevity;
CESC	cis	rs9768139	0.901	rs56113702	chr7:158117938	C/T	cg25566285	chr7:158114605	PTPRN2	-0.52	-8.87	-0.48	1.1e-16	Calcium levels;
CESC	trans	rs921968	0.541	rs687747	chr2:219399627	T/C	cg15547669	chr20:2781122	CPXM1	0.35	6.0	0.35	6.31e-9	Mean corpuscular hemoglobin concentration;
CESC	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	10.13	0.53	1.35e-20	Prudent dietary pattern;
CESC	cis	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03900664	chr4:99917553	METAP1	0.47	5.03	0.3	9.06e-7	Gut microbiome composition (summer);
CESC	cis	rs6062302	0.522	rs2282157	chr20:62227180	C/G	cg06363034	chr20:62225388	GMEB2	-0.52	-6.6	-0.38	2.21e-10	Glioblastoma;
CESC	cis	rs796364	0.951	rs3098341	chr2:200792498	G/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.86	8.47	0.46	1.75e-15	Schizophrenia;
CESC	cis	rs3087591	0.960	rs2952976	chr17:29486152	G/A	cg24425628	chr17:29625626	OMG;NF1	0.41	5.13	0.3	5.71e-7	Hip circumference;
CESC	cis	rs559928	0.606	rs11231710	chr11:63925743	A/G	cg18225595	chr11:63971243	STIP1	0.65	5.97	0.34	7.73e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CESC	cis	rs7119	0.717	rs10519167	chr15:77723027	G/T	cg17802220	chr15:77601643	NA	-0.53	-7.36	-0.41	2.31e-12	Type 2 diabetes;
CESC	cis	rs17270561	0.583	rs12662869	chr6:25784481	A/C	cg17691542	chr6:26056736	HIST1H1C	-0.47	-6.31	-0.36	1.19e-9	Iron status biomarkers;
CESC	cis	rs34172651	0.583	rs4787649	chr16:24700215	C/T	cg04756594	chr16:24857601	SLC5A11	-0.53	-6.79	-0.38	7.37e-11	Intelligence (multi-trait analysis);
CESC	cis	rs2075371	1.000	rs7486	chr7:133975183	A/G	cg20476274	chr7:133979776	SLC35B4	0.68	10.07	0.53	2.09e-20	Mean platelet volume;
CESC	cis	rs12618769	0.652	rs72823796	chr2:99227812	C/T	cg10123293	chr2:99228465	UNC50	0.4	5.21	0.31	3.72e-7	Bipolar disorder;
CESC	cis	rs4268898	0.686	rs2042468	chr2:24398446	A/T	cg06627628	chr2:24431161	ITSN2	0.54	7.25	0.41	4.45e-12	Asthma;
CESC	cis	rs5769765	1.000	rs5770728	chr22:50259984	G/A	cg02269571	chr22:50332266	NA	0.46	6.24	0.36	1.76e-9	Schizophrenia;
CESC	cis	rs10276381	0.786	rs10272155	chr7:28246989	A/G	cg23620719	chr7:28220237	JAZF1	0.74	7.68	0.43	3.18e-13	Crohn's disease;
CESC	cis	rs7666738	0.606	rs13108868	chr4:99083753	C/T	cg24818145	chr4:99064322	C4orf37	0.39	5.13	0.3	5.73e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6500395	1.000	rs4785536	chr16:48712980	C/T	cg04672837	chr16:48644449	N4BP1	-0.51	-6.53	-0.37	3.33e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs9900062	0.507	rs7225993	chr17:62708284	C/G	cg02097616	chr17:62675921	NA	0.44	5.54	0.32	7.19e-8	QT interval;
CESC	cis	rs2439831	0.850	rs60883262	chr15:44076503	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.68	7.83	0.43	1.17e-13	Lung cancer in ever smokers;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11713664	chr1:202995853	NA	0.54	6.42	0.37	6.25e-10	Gut microbiome composition (summer);
CESC	cis	rs7264396	0.790	rs12480622	chr20:34234620	T/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.59	6.45	0.37	5.14e-10	Total cholesterol levels;
CESC	cis	rs7615952	0.641	rs60839048	chr3:125807938	G/A	cg06494592	chr3:125709126	NA	-0.51	-5.51	-0.32	8.32e-8	Blood pressure (smoking interaction);
CESC	cis	rs6062302	0.522	rs6089929	chr20:62219679	C/T	cg06363034	chr20:62225388	GMEB2	-0.52	-6.6	-0.38	2.22e-10	Glioblastoma;
CESC	cis	rs4563143	0.675	rs56322221	chr19:29270349	A/T	cg04546413	chr19:29218101	NA	0.56	7.91	0.44	6.84e-14	Methadone dose in opioid dependence;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24480577	chr20:62169334	PTK6	0.56	6.82	0.39	6.16e-11	Gut microbiome composition (summer);
CESC	cis	rs7202877	0.706	rs2059257	chr16:75396376	G/A	cg04384234	chr16:75411784	CFDP1	-0.47	-5.78	-0.33	2.13e-8	Type 2 diabetes;Type 1 diabetes;
CESC	cis	rs3768617	0.510	rs4651142	chr1:183097386	A/T	ch.1.3577855R	chr1:183094577	LAMC1	0.89	14.27	0.66	1.13e-34	Fuchs's corneal dystrophy;
CESC	cis	rs2816062	0.813	rs2816057	chr1:18902257	G/C	cg18795169	chr1:18902165	NA	-0.94	-17.58	-0.73	2.19e-46	Urate levels in lean individuals;
CESC	cis	rs9611565	0.840	rs3788584	chr22:41779073	T/A	cg17376030	chr22:41985996	PMM1	0.66	7.2	0.4	6.32e-12	Vitiligo;
CESC	cis	rs698833	0.962	rs1067386	chr2:44644257	G/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.47	5.91	0.34	1.02e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	trans	rs17638544	0.881	rs7326472	chr13:42979951	C/T	cg01287592	chr8:142139839	DENND3	0.72	6.09	0.35	3.85e-9	Bone mineral density;
CESC	cis	rs9457247	1.000	rs408040	chr6:167398903	A/T	cg23791538	chr6:167370224	RNASET2	-0.59	-8.41	-0.46	2.56e-15	Crohn's disease;
CESC	cis	rs11997175	0.562	rs58955533	chr8:33829692	C/T	ch.8.33884649F	chr8:33765107	NA	0.46	5.8	0.34	1.86e-8	Body mass index;
CESC	cis	rs2075371	1.000	rs1421486	chr7:133985196	T/C	cg11752832	chr7:134001865	SLC35B4	0.55	7.23	0.41	5.27e-12	Mean platelet volume;
CESC	cis	rs9308433	0.529	rs6660335	chr1:214501855	C/T	cg06198575	chr1:214491504	SMYD2	0.43	5.18	0.3	4.35e-7	IgG glycosylation;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22065367	chr18:60382639	PHLPP1	0.58	6.37	0.36	8.48e-10	Gut microbiome composition (summer);
CESC	cis	rs17376456	0.877	rs7734897	chr5:93305402	G/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.64	5.63	0.33	4.56e-8	Diabetic retinopathy;
CESC	cis	rs6540559	1.000	rs6659367	chr1:209982408	G/T	cg23283495	chr1:209979779	IRF6	0.51	7.52	0.42	8.25e-13	Cleft lip with or without cleft palate;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg04095345	chr6:34857663	ANKS1A	-0.43	-6.11	-0.35	3.45e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	trans	rs61931739	0.500	rs11053274	chr12:34547605	G/A	cg26384229	chr12:38710491	ALG10B	0.71	10.51	0.54	8.1e-22	Morning vs. evening chronotype;
CESC	cis	rs7618915	0.501	rs13079063	chr3:52744460	A/G	cg05564831	chr3:52568323	NT5DC2	0.45	7.15	0.4	8.3e-12	Bipolar disorder;
CESC	cis	rs7847628	0.666	rs2031974	chr9:123527521	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.51	6.12	0.35	3.41e-9	Birth weight;
CESC	cis	rs2603127	0.768	rs6797831	chr3:108463025	G/A	cg03329597	chr3:108125523	MYH15	0.6	5.42	0.32	1.33e-7	Hemostatic factors and hematological phenotypes;
CESC	cis	rs9815354	0.812	rs10510731	chr3:41853310	C/T	cg03022575	chr3:42003672	ULK4	0.7	6.32	0.36	1.08e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs7395581	0.918	rs326214	chr11:47298360	G/A	cg25783544	chr11:47291846	MADD	-0.57	-7.59	-0.42	5.46e-13	HDL cholesterol;
CESC	cis	rs853679	0.517	rs4713152	chr6:28137454	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.57	-6.59	-0.38	2.36e-10	Depression;
CESC	cis	rs12325245	0.536	rs35908812	chr16:58587426	T/C	cg01152986	chr16:58549298	SETD6	0.89	5.4	0.32	1.45e-7	Schizophrenia;
CESC	cis	rs428668	0.523	rs3926389	chr5:150677806	C/T	cg11125805	chr5:150678162	SLC36A3	0.71	11.3	0.57	1.99e-24	Skin aging (microtopography measurement);
CESC	cis	rs7520050	0.931	rs7526678	chr1:46374159	A/G	cg03146154	chr1:46216737	IPP	-0.48	-6.19	-0.36	2.33e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs9322193	0.962	rs2342861	chr6:150098697	C/T	cg05861140	chr6:150128134	PCMT1	-0.36	-5.16	-0.3	4.89e-7	Lung cancer;
CESC	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg10819733	chr22:24237672	NA	0.39	5.57	0.32	6.25e-8	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs9325144	0.600	rs12297194	chr12:38735803	A/G	cg26384229	chr12:38710491	ALG10B	-0.54	-7.83	-0.43	1.14e-13	Morning vs. evening chronotype;
CESC	cis	rs7666738	0.830	rs969048	chr4:98988921	T/C	cg18180107	chr4:99064573	C4orf37	0.4	5.2	0.3	3.92e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs5769765	0.773	rs9616383	chr22:50313014	T/C	cg09872104	chr7:134855509	C7orf49	-0.55	-6.31	-0.36	1.19e-9	Schizophrenia;
CESC	cis	rs425277	0.500	rs908744	chr1:2038893	G/A	cg13918804	chr1:2043761	PRKCZ	0.27	5.26	0.31	3e-7	Height;
CESC	cis	rs34421088	0.678	rs35726503	chr8:11591916	A/T	cg13293535	chr8:11597251	GATA4	0.3	5.7	0.33	3.26e-8	Neuroticism;
CESC	cis	rs858239	0.862	rs1728292	chr7:23263474	C/G	cg23682824	chr7:23144976	KLHL7	0.43	5.77	0.33	2.16e-8	Cerebrospinal fluid biomarker levels;
CESC	cis	rs12497850	0.897	rs6446252	chr3:48911125	C/T	cg06212747	chr3:49208901	KLHDC8B	0.66	8.74	0.47	2.71e-16	Parkinson's disease;
CESC	cis	rs2228479	0.867	rs12930056	chr16:89946649	C/A	cg00800038	chr16:89945340	TCF25	-0.88	-7.85	-0.43	1.01e-13	Skin colour saturation;
CESC	cis	rs7927771	1.000	rs4752873	chr11:47857520	C/T	cg18512352	chr11:47633146	NA	-0.6	-9.57	-0.51	8.16e-19	Subjective well-being;
CESC	cis	rs62283056	0.636	rs62283057	chr4:6276805	C/T	cg00701064	chr4:6280414	WFS1	-0.58	-5.34	-0.31	1.95e-7	Cisplatin-induced ototoxicity;
CESC	cis	rs875971	0.545	rs10950025	chr7:65623933	G/A	cg18876405	chr7:65276391	NA	0.51	5.96	0.34	8.21e-9	Aortic root size;
CESC	cis	rs9902453	1.000	rs9891871	chr17:28370191	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.62	-7.84	-0.43	1.09e-13	Coffee consumption (cups per day);
CESC	cis	rs7084402	0.967	rs2917949	chr10:60329166	G/A	cg07615347	chr10:60278583	BICC1	0.59	9.18	0.49	1.26e-17	Refractive error;
CESC	cis	rs1475911	1.000	rs17114359	chr21:43510437	A/C	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.41	-5.88	-0.34	1.22e-8	IgG glycosylation;
CESC	cis	rs2353275	0.655	rs7080866	chr10:88152150	C/T	cg07322936	chr10:88137208	NA	1.04	6.26	0.36	1.54e-9	Asthma (childhood onset);Asthma;
CESC	cis	rs1862618	0.671	rs28397234	chr5:56248428	T/G	cg24531977	chr5:56204891	C5orf35	0.71	9.52	0.5	1.11e-18	Initial pursuit acceleration;
CESC	cis	rs7084402	0.529	rs7912116	chr10:60335389	G/C	cg07615347	chr10:60278583	BICC1	0.4	5.83	0.34	1.57e-8	Refractive error;
CESC	cis	rs7044106	0.762	rs4142158	chr9:123410819	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.33	5.08	0.3	7.23e-7	Hip circumference adjusted for BMI;
CESC	cis	rs2012796	0.785	rs61986593	chr14:81840659	G/A	cg02996355	chr14:81879375	NA	0.67	8.11	0.45	1.91e-14	Night sleep phenotypes;
CESC	cis	rs2836974	0.653	rs8130556	chr21:40516872	C/T	cg27266027	chr21:40555129	PSMG1	0.43	5.08	0.3	7.22e-7	Cognitive function;
CESC	cis	rs12681366	0.537	rs10956914	chr8:95483723	G/T	cg13257157	chr8:95487014	RAD54B	-0.43	-5.25	-0.31	3.11e-7	Nonsyndromic cleft lip with cleft palate;
CESC	cis	rs12477438	0.765	rs2309521	chr2:99592069	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.64	-8.73	-0.47	2.94e-16	Chronic sinus infection;
CESC	cis	rs116095464	0.558	rs2288457	chr5:231270	C/T	cg12570787	chr5:219185	SDHA;CCDC127	0.5	5.22	0.31	3.68e-7	Breast cancer;
CESC	cis	rs763014	0.833	rs916415	chr16:632115	G/A	cg00908189	chr16:619842	PIGQ	0.67	9.34	0.5	4.24e-18	Height;
CESC	cis	rs4665809	0.525	rs4665324	chr2:26447147	A/C	cg25036284	chr2:26402008	FAM59B	-0.86	-9.36	-0.5	3.44e-18	Gut microbiome composition (summer);
CESC	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg24642844	chr7:1081250	C7orf50	-0.74	-8.9	-0.48	8.74e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs9926296	0.528	rs4785721	chr16:89839997	G/A	cg07648498	chr16:89883185	FANCA	0.46	5.62	0.33	4.84e-8	Vitiligo;
CESC	cis	rs344364	0.511	rs1742462	chr16:1946062	A/C	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.55	-6.2	-0.36	2.15e-9	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs2637266	1.000	rs1907317	chr10:78337849	C/A	cg18941641	chr10:78392320	NA	0.42	7.61	0.42	4.9e-13	Pulmonary function;
CESC	cis	rs7851660	0.967	rs13288000	chr9:100608980	A/G	cg13688889	chr9:100608707	NA	-0.69	-10.7	-0.55	1.96e-22	Strep throat;
CESC	cis	rs3091242	0.933	rs932372	chr1:25755014	G/A	cg03538708	chr1:25844672	NA	-0.42	-6.4	-0.37	6.9e-10	Erythrocyte sedimentation rate;
CESC	cis	rs736408	0.545	rs6445529	chr3:52662722	T/A	cg18099408	chr3:52552593	STAB1	-0.3	-5.09	-0.3	6.67e-7	Bipolar disorder;
CESC	cis	rs735396	0.770	rs1169315	chr12:121443753	T/G	cg25281562	chr12:121454272	C12orf43	0.52	6.5	0.37	3.91e-10	N-glycan levels;
CESC	cis	rs561341	1.000	rs117029332	chr17:30266085	C/G	cg00745463	chr17:30367425	LRRC37B	-0.83	-7.62	-0.42	4.42e-13	Hip circumference adjusted for BMI;
CESC	cis	rs6495122	0.699	rs1378941	chr15:75080150	C/A	cg09165964	chr15:75287851	SCAMP5	0.4	5.23	0.31	3.46e-7	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
CESC	trans	rs2727020	0.521	rs11039902	chr11:48679467	A/G	cg00717180	chr2:96193071	NA	-0.44	-6.01	-0.35	6e-9	Coronary artery disease;
CESC	cis	rs977987	0.815	rs11646677	chr16:75408981	T/C	cg03315344	chr16:75512273	CHST6	0.4	5.73	0.33	2.78e-8	Dupuytren's disease;
CESC	cis	rs6831352	0.918	rs7689753	chr4:100055575	A/G	cg12011299	chr4:100065546	ADH4	-0.6	-6.62	-0.38	2.04e-10	Alcohol dependence;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26880806	chr2:98262454	COX5B	0.58	6.09	0.35	3.86e-9	Gut microbiome composition (summer);
CESC	cis	rs2439831	1.000	rs2444032	chr15:43755346	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.83	11.98	0.59	1.04e-26	Lung cancer in ever smokers;
CESC	trans	rs6951245	0.608	rs10252234	chr7:1114381	C/T	cg13565492	chr6:43139072	SRF	-0.54	-6.07	-0.35	4.44e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs820218	0.926	rs820206	chr17:73641714	G/A	cg01592526	chr17:73663357	RECQL5;SAP30BP	0.42	5.48	0.32	9.69e-8	Rotator cuff tears;
CESC	cis	rs2228479	0.702	rs3819574	chr16:89826630	G/A	cg06558623	chr16:89946397	TCF25	1.17	9.29	0.5	5.76e-18	Skin colour saturation;
CESC	cis	rs6714710	0.603	rs35255677	chr2:98567820	G/A	cg26665480	chr2:98280029	ACTR1B	0.59	8.04	0.44	2.97e-14	Posterior cortical atrophy and Alzheimer's disease;
CESC	cis	rs9863	0.861	rs3789967	chr12:124447339	T/G	cg00084347	chr12:124393913	DNAH10	0.27	5.3	0.31	2.46e-7	White blood cell count;
CESC	cis	rs1799949	1.000	rs11658754	chr17:41292739	G/A	cg25072359	chr17:41440525	NA	0.43	5.83	0.34	1.61e-8	Menopause (age at onset);
CESC	cis	rs60871478	0.786	rs55899111	chr7:827843	C/G	cg15782153	chr7:917662	C7orf20	0.48	5.29	0.31	2.57e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs7223966	1.000	rs8075257	chr17:61728750	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	7.16	0.4	8.13e-12	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs12220238	0.915	rs10824074	chr10:75876457	T/A	cg19889307	chr10:75911429	ADK;AP3M1	0.66	6.56	0.37	2.83e-10	Soluble interleukin-2 receptor subunit alpha;
CESC	cis	rs501120	1.000	rs607760	chr10:44756236	A/G	cg09554077	chr10:44749378	NA	0.53	6.85	0.39	5.25e-11	Coronary artery disease;Coronary heart disease;
CESC	cis	rs7833790	0.926	rs72686467	chr8:82758929	T/G	cg07697082	chr8:82753677	SNX16	-0.39	-5.32	-0.31	2.19e-7	Diastolic blood pressure;
CESC	cis	rs10752881	0.743	rs10737244	chr1:183098417	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.89	14.39	0.66	4.39e-35	Colorectal cancer;
CESC	cis	rs11696501	0.688	rs8123346	chr20:44309987	A/T	cg11783356	chr20:44313418	WFDC10B	-0.33	-5.25	-0.31	3.07e-7	Brain structure;
CESC	cis	rs1046896	0.503	rs12947062	chr17:80686370	A/G	cg02711726	chr17:80685570	FN3KRP	0.6	9.12	0.49	1.91e-17	Glycated hemoglobin levels;
CESC	cis	rs8017423	0.904	rs11848894	chr14:90723660	C/A	cg14092571	chr14:90743983	NA	-0.55	-8.31	-0.45	5.06e-15	Mortality in heart failure;
CESC	cis	rs11958404	0.932	rs113494689	chr5:157428078	G/T	cg05962755	chr5:157440814	NA	0.59	6.45	0.37	5.28e-10	IgG glycosylation;
CESC	cis	rs6460942	0.915	rs62447642	chr7:12489147	T/C	cg20607287	chr7:12443886	VWDE	-0.77	-8.71	-0.47	3.35e-16	Coronary artery disease;
CESC	cis	rs4253772	0.637	rs9627350	chr22:46663017	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.68	8.04	0.44	3.08e-14	LDL cholesterol;Cholesterol, total;
CESC	cis	rs941408	0.515	rs1005556	chr19:2778543	G/T	cg02580895	chr19:2754563	NA	-0.48	-6.7	-0.38	1.27e-10	Total cholesterol levels;
CESC	cis	rs3087591	0.887	rs12150521	chr17:29595108	C/T	cg24425628	chr17:29625626	OMG;NF1	0.47	6.04	0.35	5.07e-9	Hip circumference;
CESC	cis	rs2652822	0.935	rs2292038	chr15:63449680	C/G	cg02713581	chr15:63449717	RPS27L	-0.59	-7.72	-0.43	2.41e-13	Metabolic traits;
CESC	cis	rs228769	0.562	rs228779	chr17:42091213	A/G	cg19774624	chr17:42201019	HDAC5	0.51	5.66	0.33	3.93e-8	Bone mineral density (hip);Bone mineral density (spine);
CESC	cis	rs11649653	0.502	rs4889490	chr16:30823047	A/C	cg00531865	chr16:30841666	NA	-0.43	-5.49	-0.32	9.52e-8	Triglycerides;
CESC	cis	rs2795502	1.000	rs1852959	chr10:43359636	T/C	cg27426351	chr10:43362370	NA	0.49	6.09	0.35	4.06e-9	Blood protein levels;
CESC	cis	rs853679	0.517	rs9393885	chr6:28050009	A/T	cg23281280	chr6:28129359	ZNF389	0.57	7.78	0.43	1.61e-13	Depression;
CESC	cis	rs9457247	0.967	rs1211447	chr6:167381979	C/T	cg23791538	chr6:167370224	RNASET2	-0.6	-8.65	-0.47	5.12e-16	Crohn's disease;
CESC	cis	rs2463822	1.000	rs72921501	chr11:62115622	A/T	cg06239285	chr11:62104954	ASRGL1	-0.99	-8.49	-0.46	1.48e-15	Chronic obstructive pulmonary disease-related biomarkers;
CESC	trans	rs629535	0.814	rs78813708	chr8:70073977	A/G	cg21567404	chr3:27674614	NA	0.86	10.06	0.53	2.32e-20	Dupuytren's disease;
CESC	cis	rs9300255	0.602	rs1616131	chr12:123619838	G/A	cg00376283	chr12:123451042	ABCB9	0.71	8.71	0.47	3.37e-16	Neutrophil percentage of white cells;
CESC	cis	rs2228479	0.702	rs11076621	chr16:89837927	A/G	cg00800038	chr16:89945340	TCF25	-0.92	-7.64	-0.42	4.02e-13	Skin colour saturation;
CESC	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg07092213	chr7:1199455	ZFAND2A	-0.42	-5.75	-0.33	2.48e-8	Longevity;Endometriosis;
CESC	cis	rs853679	0.517	rs4713141	chr6:28101678	G/C	cg22143856	chr6:28129313	ZNF389	0.52	6.76	0.38	8.79e-11	Depression;
CESC	cis	rs897984	0.609	rs11862744	chr16:31057800	G/A	cg02466173	chr16:30829666	NA	-0.39	-6.77	-0.38	8.15e-11	Dementia with Lewy bodies;
CESC	cis	rs2070997	0.607	rs4504691	chr9:133663852	T/C	cg11464064	chr9:133710261	ABL1	0.58	6.8	0.39	6.9e-11	Response to amphetamines;
CESC	cis	rs7618915	0.501	rs35526119	chr3:52749334	C/T	cg18404041	chr3:52824283	ITIH1	-0.4	-6.76	-0.38	8.51e-11	Bipolar disorder;
CESC	cis	rs12142240	0.698	rs17357635	chr1:46808668	G/A	cg00530320	chr1:46809349	NSUN4	0.6	7.98	0.44	4.48e-14	Menopause (age at onset);
CESC	cis	rs7208859	0.623	rs7220999	chr17:29149298	C/T	cg19761014	chr17:28927070	LRRC37B2	0.79	6.47	0.37	4.6e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs2354432	0.505	rs72691009	chr1:146708397	C/T	cg25205988	chr1:146714368	CHD1L	-1.02	-8.03	-0.44	3.16e-14	Mitochondrial DNA levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14518868	chr12:69864352	FRS2	0.53	6.16	0.35	2.71e-9	Gut microbiome composition (summer);
CESC	cis	rs4899260	0.911	rs194713	chr14:69295469	T/C	cg03189333	chr14:69283534	NA	0.47	5.13	0.3	5.5e-7	Celiac disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26071963	chr14:88945568	PTPN21	-0.58	-6.43	-0.37	5.99e-10	Gut microbiome composition (summer);
CESC	cis	rs1008375	1.000	rs17507481	chr4:17620066	A/G	cg15017067	chr4:17643749	FAM184B	0.41	5.82	0.34	1.7e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs902774	0.515	rs2363635	chr12:53354622	T/C	cg14581129	chr12:53358946	NA	-0.52	-7.01	-0.4	2.01e-11	Prostate cancer;
CESC	cis	rs4925386	1.000	rs4925389	chr20:60922512	G/A	cg24112000	chr20:60950667	NA	0.51	7.42	0.41	1.62e-12	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CESC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg15254786	chr2:207630414	MDH1B;FASTKD2	0.47	6.16	0.35	2.75e-9	Tetralogy of Fallot;
CESC	cis	rs4604732	0.527	rs60444724	chr1:247623164	T/G	cg12758973	chr1:247694275	LOC148824;OR2C3	0.51	6.46	0.37	5.02e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs5753618	0.583	rs8141150	chr22:31800336	C/T	cg13145458	chr22:31556086	RNF185	-0.49	-5.83	-0.34	1.62e-8	Colorectal cancer;
CESC	cis	rs9311474	0.508	rs3796353	chr3:52593230	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.57	7.87	0.44	8.87e-14	Electroencephalogram traits;
CESC	cis	rs77956314	0.515	rs10850733	chr12:117380961	G/A	cg02017074	chr12:117425053	FBXW8	0.8	8.81	0.48	1.69e-16	Subcortical brain region volumes;Hippocampal volume;
CESC	cis	rs453301	0.653	rs2956244	chr8:8885166	A/G	cg15556689	chr8:8085844	FLJ10661	0.49	6.3	0.36	1.22e-9	Joint mobility (Beighton score);
CESC	trans	rs1667255	0.830	rs2034404	chr18:29156302	A/G	cg15908398	chr12:112037868	ATXN2	0.5	6.4	0.37	7.03e-10	Retinol levels;
CESC	cis	rs72781680	0.559	rs72796103	chr2:23900382	G/A	cg20701182	chr2:24300061	SF3B14	0.8	6.92	0.39	3.33e-11	Lymphocyte counts;
CESC	cis	rs965513	1.000	rs7030241	chr9:100550375	T/A	cg13688889	chr9:100608707	NA	-0.6	-8.62	-0.47	6.31e-16	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
CESC	cis	rs911555	0.755	rs12436729	chr14:103929889	G/C	cg24130564	chr14:104152367	KLC1	0.49	6.32	0.36	1.11e-9	Intelligence (multi-trait analysis);
CESC	cis	rs9916302	0.784	rs34473775	chr17:37396201	G/T	cg15445000	chr17:37608096	MED1	0.4	6.47	0.37	4.81e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs17641971	0.684	rs4873310	chr8:49990006	A/T	cg00325661	chr8:49890786	NA	0.39	5.5	0.32	8.94e-8	Blood metabolite levels;
CESC	cis	rs887829	0.569	rs10179091	chr2:234657983	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.48	-6.02	-0.35	5.88e-9	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CESC	cis	rs2637266	0.935	rs7921790	chr10:78368253	T/C	cg18941641	chr10:78392320	NA	0.43	8.26	0.45	6.94e-15	Pulmonary function;
CESC	cis	rs7512552	0.646	rs1694367	chr1:150329469	T/A	cg15654264	chr1:150340011	RPRD2	0.39	5.24	0.31	3.25e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs17711722	0.727	rs781151	chr7:65479878	T/C	cg11764359	chr7:65958608	NA	0.6	7.4	0.41	1.85e-12	Calcium levels;
CESC	cis	rs694739	1.000	rs1783521	chr11:64106291	T/C	cg23796481	chr11:64053134	BAD;GPR137	0.66	8.5	0.46	1.36e-15	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CESC	cis	rs2732480	0.537	rs1061986	chr12:48736439	T/C	cg04545296	chr12:48745243	ZNF641	0.44	7.22	0.41	5.44e-12	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs13118159	0.801	rs7664474	chr4:1329116	T/A	cg19318889	chr4:1322082	MAEA	0.43	5.96	0.34	8.03e-9	Longevity;
CESC	cis	rs9322193	0.923	rs9383812	chr6:150033491	C/T	cg00933542	chr6:150070202	PCMT1	0.3	5.26	0.31	2.96e-7	Lung cancer;
CESC	cis	rs7223966	1.000	rs7211213	chr17:61769456	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.47	-5.76	-0.33	2.37e-8	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs9611565	0.559	rs7290990	chr22:41964357	C/A	cg03806693	chr22:41940476	POLR3H	-0.97	-12.07	-0.6	4.96e-27	Vitiligo;
CESC	cis	rs7618915	0.508	rs7628578	chr3:52628321	A/T	cg18099408	chr3:52552593	STAB1	-0.3	-5.14	-0.3	5.45e-7	Bipolar disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26216002	chr1:10093067	UBE4B	-0.53	-6.14	-0.35	2.96e-9	Gut microbiome composition (summer);
CESC	cis	rs8072100	0.713	rs9807106	chr17:45457102	G/T	cg08085267	chr17:45401833	C17orf57	-0.51	-6.49	-0.37	4.12e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	trans	rs2727020	0.636	rs10839275	chr11:49438962	T/A	cg03929089	chr4:120376271	NA	-0.81	-12.55	-0.61	1.11e-28	Coronary artery disease;
CESC	cis	rs911555	0.755	rs35233301	chr14:103885291	A/G	cg24130564	chr14:104152367	KLC1	0.49	6.36	0.36	9e-10	Intelligence (multi-trait analysis);
CESC	trans	rs1814175	0.588	rs1794144	chr11:49918233	A/G	cg03929089	chr4:120376271	NA	-0.92	-15.2	-0.68	6e-38	Height;
CESC	cis	rs4888262	0.508	rs7189123	chr16:74540097	C/A	cg01733217	chr16:74700730	RFWD3	0.81	11.31	0.57	1.89e-24	Testicular germ cell tumor;
CESC	trans	rs9858542	0.903	rs9875617	chr3:49634696	G/A	cg21659725	chr3:3221576	CRBN	-0.53	-6.46	-0.37	4.86e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs2635047	0.638	rs2571006	chr18:44718515	G/T	cg24371990	chr18:44770781	NA	0.32	5.06	0.3	7.89e-7	Educational attainment;
CESC	trans	rs1814175	0.645	rs1721995	chr11:49915488	A/G	cg03929089	chr4:120376271	NA	-0.89	-14.83	-0.67	1.17e-36	Height;
CESC	cis	rs2933343	0.621	rs789242	chr3:128585707	T/C	cg24203234	chr3:128598194	ACAD9	0.38	5.14	0.3	5.33e-7	IgG glycosylation;
CESC	cis	rs12541635	0.639	rs10955408	chr8:107020789	G/A	cg10147462	chr8:107024639	NA	0.47	7.08	0.4	1.27e-11	Age of smoking initiation;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg18756868	chr18:19284803	ABHD3	-0.49	-6.13	-0.35	3.24e-9	Ulcerative colitis;
CESC	cis	rs6665290	0.904	rs2297418	chr1:227192579	A/C	cg10327440	chr1:227177885	CDC42BPA	-1.22	-32.59	-0.89	1.07e-94	Myeloid white cell count;
CESC	cis	rs55823223	0.648	rs936394	chr17:73852008	C/A	cg08125733	chr17:73851984	WBP2	0.91	11.81	0.59	3.71e-26	Psoriasis;
CESC	cis	rs4595586	0.756	rs7137139	chr12:39364013	C/T	cg26384229	chr12:38710491	ALG10B	0.42	6.05	0.35	4.8e-9	Morning vs. evening chronotype;
CESC	cis	rs1023500	0.573	rs133377	chr22:42466950	C/T	cg15557168	chr22:42548783	NA	-0.45	-6.3	-0.36	1.26e-9	Schizophrenia;
CESC	cis	rs2455799	0.573	rs2470523	chr3:15768091	G/C	cg16303742	chr3:15540471	COLQ	-0.39	-6.24	-0.36	1.76e-9	Mean platelet volume;
CESC	cis	rs9549367	0.713	rs4907598	chr13:113861385	C/T	cg18105134	chr13:113819100	PROZ	0.55	7.39	0.41	1.87e-12	Platelet distribution width;
CESC	cis	rs4953076	0.573	rs7595470	chr2:44402467	A/G	cg04920474	chr2:44395004	PPM1B	0.55	7.09	0.4	1.23e-11	Height;
CESC	cis	rs6540559	0.611	rs61747285	chr1:210004332	G/A	cg22029157	chr1:209979665	IRF6	0.71	7.61	0.42	4.72e-13	Cleft lip with or without cleft palate;
CESC	cis	rs7851660	0.809	rs7034249	chr9:100653821	C/T	cg13688889	chr9:100608707	NA	-0.63	-8.96	-0.48	5.96e-17	Strep throat;
CESC	cis	rs6484504	0.625	rs796341	chr11:31414151	G/A	cg14844989	chr11:31128820	NA	0.39	5.58	0.32	6.03e-8	Red blood cell count;
CESC	cis	rs3096299	1.000	rs3096299	chr16:89448663	G/A	cg16743903	chr16:89593216	SPG7	-0.42	-5.36	-0.31	1.82e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs919433	0.889	rs787998	chr2:198216092	A/G	cg03934865	chr2:198174659	NA	0.45	6.81	0.39	6.4e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs933688	1.000	rs1964292	chr5:90743608	T/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.1	12.13	0.6	3.17e-27	Smoking behavior;
CESC	cis	rs7208859	0.524	rs8069400	chr17:29075967	G/T	cg19761014	chr17:28927070	LRRC37B2	0.81	6.64	0.38	1.81e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs10045504	0.502	rs17352898	chr5:38745498	C/T	cg15396434	chr5:38725168	NA	-0.73	-6.82	-0.39	6.32e-11	Night sleep phenotypes;
CESC	cis	rs1559088	0.576	rs7251626	chr19:33578470	C/A	cg17764715	chr19:33622953	WDR88	0.59	8.48	0.46	1.61e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07853919	chr18:77711868	PQLC1	0.55	7.01	0.4	1.97e-11	Gut microbiome composition (summer);
CESC	trans	rs35110281	0.626	rs162367	chr21:44934857	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.44	6.11	0.35	3.58e-9	Mean corpuscular volume;
CESC	trans	rs2016266	0.929	rs7486393	chr12:53652885	C/T	cg08421126	chr2:43019854	HAAO	-0.46	-6.1	-0.35	3.83e-9	Bone mineral density (spine);Bone mineral density;
CESC	cis	rs9815354	1.000	rs9823254	chr3:41894768	G/C	cg03022575	chr3:42003672	ULK4	0.58	5.94	0.34	9.04e-9	Pulse pressure;Diastolic blood pressure;
CESC	trans	rs57221529	0.766	rs72703065	chr5:588123	C/A	cg25482853	chr8:67687455	SGK3	1.01	9.99	0.52	3.67e-20	Lung disease severity in cystic fibrosis;
CESC	cis	rs6912958	0.500	rs2025486	chr6:87796886	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.63	-7.84	-0.43	1.12e-13	Monocyte percentage of white cells;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08467400	chr7:44646271	OGDH	0.69	7.91	0.44	6.94e-14	Gut microbiome composition (summer);
CESC	cis	rs2816062	0.813	rs2816053	chr1:18895819	A/G	cg18795169	chr1:18902165	NA	-0.91	-17.81	-0.74	3.44e-47	Urate levels in lean individuals;
CESC	cis	rs7811142	1.000	rs28490152	chr7:100020982	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.86	9.12	0.49	1.95e-17	Platelet count;
CESC	cis	rs6831352	0.801	rs2602897	chr4:100046293	A/T	cg12011299	chr4:100065546	ADH4	0.59	6.52	0.37	3.62e-10	Alcohol dependence;
CESC	cis	rs9311474	0.508	rs12637627	chr3:52619962	G/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	5.73	0.33	2.7e-8	Electroencephalogram traits;
CESC	cis	rs5769765	0.704	rs138837	chr22:50180714	A/G	cg02269571	chr22:50332266	NA	-0.46	-5.94	-0.34	9.04e-9	Schizophrenia;
CESC	cis	rs977987	0.843	rs4888415	chr16:75448921	C/T	cg03315344	chr16:75512273	CHST6	0.42	6.11	0.35	3.62e-9	Dupuytren's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21150049	chr12:50677498	LIMA1	0.56	6.68	0.38	1.42e-10	Gut microbiome composition (summer);
CESC	cis	rs6582630	0.519	rs12582285	chr12:38298753	C/T	cg26384229	chr12:38710491	ALG10B	0.7	10.34	0.54	2.92e-21	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs853679	0.517	rs4713137	chr6:28083521	C/G	cg17949981	chr6:28129498	ZNF389	0.45	5.63	0.33	4.71e-8	Depression;
CESC	cis	rs62432291	0.681	rs404461	chr6:159640709	T/C	cg14500486	chr6:159655392	FNDC1	0.57	5.73	0.33	2.68e-8	Joint mobility (Beighton score);
CESC	cis	rs1124376	0.935	rs9855900	chr3:20147172	C/T	cg05072819	chr3:20081367	KAT2B	0.47	5.14	0.3	5.39e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs12497850	0.864	rs3212	chr3:49145741	T/C	cg06212747	chr3:49208901	KLHDC8B	0.74	9.72	0.51	2.73e-19	Parkinson's disease;
CESC	cis	rs2985684	0.948	rs11623263	chr14:50083295	A/G	cg02151108	chr14:50098012	C14orf104	-0.41	-5.4	-0.31	1.51e-7	Carotid intima media thickness;
CESC	cis	rs4595586	0.679	rs1878228	chr12:39355595	T/C	cg26384229	chr12:38710491	ALG10B	0.42	6.07	0.35	4.3e-9	Morning vs. evening chronotype;
CESC	trans	rs7618501	0.633	rs2526751	chr3:50064867	T/C	cg21659725	chr3:3221576	CRBN	-0.53	-7.45	-0.42	1.33e-12	Intelligence (multi-trait analysis);
CESC	cis	rs728616	0.867	rs116994688	chr10:81738137	G/C	cg05935833	chr10:81318306	SFTPA2	-0.52	-5.06	-0.3	7.72e-7	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs6963495	0.818	rs6973974	chr7:105170629	C/T	cg19920283	chr7:105172520	RINT1	0.69	6.54	0.37	3.15e-10	Bipolar disorder (body mass index interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00322698	chr6:41069048	NFYA;LOC221442	-0.62	-7.0	-0.4	2.09e-11	Gut microbiome composition (summer);
CESC	cis	rs9393777	0.513	rs9348728	chr6:26634436	G/A	cg14345882	chr6:26364793	BTN3A2	0.41	5.35	0.31	1.94e-7	Intelligence (multi-trait analysis);
CESC	cis	rs34779708	0.766	rs7913451	chr10:35551525	T/C	cg03585969	chr10:35415529	CREM	0.54	6.14	0.35	2.99e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs2228479	0.850	rs11644526	chr16:89898660	C/T	cg00800038	chr16:89945340	TCF25	-0.89	-6.89	-0.39	4.13e-11	Skin colour saturation;
CESC	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg23131131	chr22:24373011	LOC391322	0.64	8.8	0.48	1.76e-16	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs7582720	0.943	rs72932559	chr2:203847382	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.36	0.41	2.34e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg05694744	chr17:8191820	RANGRF;SLC25A35	-0.49	-6.44	-0.37	5.66e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs2204008	0.837	rs11612125	chr12:38213212	C/T	cg26384229	chr12:38710491	ALG10B	0.74	10.7	0.55	1.96e-22	Bladder cancer;
CESC	cis	rs7647973	0.580	rs11130184	chr3:49229930	C/T	cg02487422	chr3:49467188	NICN1	0.38	5.17	0.3	4.51e-7	Menarche (age at onset);
CESC	cis	rs6952808	0.893	rs35487994	chr7:1920171	G/A	cg05863683	chr7:1912471	MAD1L1	0.45	6.75	0.38	9.09e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs5769765	1.000	rs768619	chr22:50287266	C/T	cg02269571	chr22:50332266	NA	-0.46	-6.26	-0.36	1.53e-9	Schizophrenia;
CESC	cis	rs959260	1.000	rs959260	chr17:73369422	C/T	cg12999837	chr17:73267436	MIF4GD	-0.47	-5.5	-0.32	8.8e-8	Systemic lupus erythematosus;
CESC	cis	rs2769264	0.546	rs12047617	chr1:151392597	G/A	cg18801370	chr1:151430492	POGZ	0.55	6.9	0.39	3.8e-11	Blood trace element (Cu levels);
CESC	cis	rs992157	0.835	rs4674283	chr2:219144254	G/A	cg00012203	chr2:219082015	ARPC2	-0.76	-9.55	-0.51	9.45e-19	Colorectal cancer;
CESC	cis	rs10504229	0.683	rs16921831	chr8:58111142	G/A	cg02725872	chr8:58115012	NA	-0.45	-7.04	-0.4	1.66e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs1670533	1.000	rs6837145	chr4:1071067	T/C	cg27284194	chr4:1044797	NA	0.45	5.76	0.33	2.27e-8	Recombination rate (females);
CESC	cis	rs4665809	0.590	rs2289019	chr2:26420809	G/C	cg27170947	chr2:26402098	FAM59B	-0.84	-10.08	-0.53	1.98e-20	Gut microbiome composition (summer);
CESC	trans	rs7246760	0.867	rs2336089	chr19:9849972	C/T	cg02900749	chr2:68251473	NA	-0.84	-7.32	-0.41	2.99e-12	Pursuit maintenance gain;
CESC	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg26338869	chr17:61819248	STRADA	0.67	8.66	0.47	4.55e-16	Prudent dietary pattern;
CESC	cis	rs3749237	0.576	rs3877784	chr3:49539417	C/T	cg07636037	chr3:49044803	WDR6	0.61	8.81	0.48	1.66e-16	Resting heart rate;
CESC	cis	rs748404	0.578	rs552701	chr15:43613810	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.6	8.0	0.44	3.9e-14	Lung cancer;
CESC	trans	rs2727020	0.688	rs11040338	chr11:49360601	A/G	cg03929089	chr4:120376271	NA	0.79	11.98	0.59	1.01e-26	Coronary artery disease;
CESC	cis	rs2075371	1.000	rs2075371	chr7:133984127	A/G	cg20476274	chr7:133979776	SLC35B4	0.66	9.48	0.5	1.52e-18	Mean platelet volume;
CESC	cis	rs12410462	0.681	rs6682883	chr1:227635598	G/A	cg04117972	chr1:227635322	NA	0.75	6.71	0.38	1.18e-10	Major depressive disorder;
CESC	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg24846343	chr22:24311635	DDTL	-0.65	-11.02	-0.56	1.66e-23	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs55879323	1	rs55879323	chr1:152168740	C/T	cg26879891	chr1:152191343	HRNR	-0.42	-6.57	-0.37	2.71e-10	Inflammatory skin disease;
CESC	cis	rs4975616	0.714	rs37007	chr5:1352372	G/C	cg26373071	chr5:1325741	CLPTM1L	0.45	7.11	0.4	1.1e-11	Lung cancer;
CESC	cis	rs736408	0.716	rs2239550	chr3:52822509	G/C	cg18337363	chr3:52569053	NT5DC2	0.31	5.24	0.31	3.31e-7	Bipolar disorder;
CESC	cis	rs875971	0.619	rs10278371	chr7:66051540	C/A	cg14393609	chr7:65229607	NA	-0.48	-6.31	-0.36	1.18e-9	Aortic root size;
CESC	cis	rs599083	0.573	rs3018713	chr11:68390986	A/G	cg16797656	chr11:68205561	LRP5	0.49	7.44	0.42	1.4e-12	Bone mineral density (spine);
CESC	cis	rs4689388	0.750	rs10755148	chr4:6295064	A/G	cg00701064	chr4:6280414	WFS1	0.65	9.71	0.51	2.92e-19	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs7618915	0.547	rs68021750	chr3:52624769	G/A	cg07507251	chr3:52567010	NT5DC2	0.4	6.96	0.39	2.7e-11	Bipolar disorder;
CESC	cis	rs12995491	0.933	rs12995212	chr2:88527184	C/T	cg14558114	chr2:88469736	THNSL2	-0.47	-6.71	-0.38	1.2e-10	Response to metformin (IC50);
CESC	cis	rs10256972	0.528	rs7784607	chr7:1178694	A/G	cg07308232	chr7:1071921	C7orf50	-0.42	-5.66	-0.33	3.97e-8	Longevity;Endometriosis;
CESC	cis	rs875971	0.502	rs1796227	chr7:66087019	G/C	cg18876405	chr7:65276391	NA	-0.48	-5.4	-0.31	1.47e-7	Aortic root size;
CESC	trans	rs17685	0.753	rs11982200	chr7:75714883	T/C	cg19862616	chr7:65841803	NCRNA00174	0.87	12.7	0.62	3.58e-29	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs4665809	0.590	rs35656275	chr2:26494695	G/C	cg25036284	chr2:26402008	FAM59B	0.83	9.07	0.49	2.67e-17	Gut microbiome composition (summer);
CESC	cis	rs258892	0.895	rs463250	chr5:72144463	G/C	cg21869765	chr5:72125136	TNPO1	0.43	5.43	0.32	1.26e-7	Small cell lung carcinoma;
CESC	cis	rs6430585	0.759	rs4954623	chr2:136535876	G/A	cg07169764	chr2:136633963	MCM6	-1.17	-16.7	-0.72	2.81e-43	Corneal structure;
CESC	cis	rs71277158	0.688	rs2255256	chr3:169785903	G/A	cg04067573	chr3:169899625	PHC3	0.72	7.1	0.4	1.16e-11	Prostate cancer;
CESC	cis	rs2032447	0.839	rs199751	chr6:26015583	T/C	cg18357526	chr6:26021779	HIST1H4A	0.77	10.81	0.55	8.06e-23	Intelligence (multi-trait analysis);
CESC	cis	rs7188697	0.922	rs37053	chr16:58558707	T/C	cg21335942	chr16:58549945	SETD6	0.47	5.5	0.32	9.04e-8	QT interval;
CESC	cis	rs6951245	0.872	rs11768895	chr7:1063691	T/C	cg24642844	chr7:1081250	C7orf50	-0.65	-8.14	-0.45	1.54e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2952156	0.920	rs732083	chr17:37834367	G/A	cg07936489	chr17:37558343	FBXL20	-0.61	-8.16	-0.45	1.39e-14	Asthma;
CESC	cis	rs34779708	0.931	rs11597483	chr10:35285117	A/G	cg03585969	chr10:35415529	CREM	0.77	10.3	0.53	3.84e-21	Inflammatory bowel disease;Crohn's disease;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg11437374	chr5:169010780	CCDC99	-0.45	-6.3	-0.36	1.24e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs2880765	0.835	rs4536419	chr15:86039471	C/T	cg10818794	chr15:86012489	AKAP13	-0.35	-5.46	-0.32	1.07e-7	Coronary artery disease;
CESC	trans	rs7726839	0.574	rs11739866	chr5:636299	C/T	cg25482853	chr8:67687455	SGK3	1.0	9.64	0.51	4.75e-19	Obesity-related traits;
CESC	cis	rs9611565	0.802	rs4822028	chr22:41789408	A/G	cg06634786	chr22:41940651	POLR3H	-0.63	-6.86	-0.39	4.77e-11	Vitiligo;
CESC	cis	rs7267979	0.873	rs6115093	chr20:25210730	C/T	cg08601574	chr20:25228251	PYGB	0.44	6.12	0.35	3.41e-9	Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg12958836	chr12:8185024	FOXJ2	-0.42	-6.0	-0.35	6.45e-9	Asthma;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12616745	chr2:191273000	MFSD6	0.53	6.04	0.35	5.3e-9	Gut microbiome composition (summer);
CESC	cis	rs17376456	1.000	rs17323433	chr5:93551028	G/A	cg25358565	chr5:93447407	FAM172A	1.15	11.09	0.56	1.02e-23	Diabetic retinopathy;
CESC	cis	rs9916302	0.904	rs2168785	chr17:37407135	C/T	cg15445000	chr17:37608096	MED1	0.41	6.76	0.38	8.81e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs12134245	0.719	rs61798831	chr1:91996588	C/T	cg25838465	chr1:92012736	NA	-0.62	-8.93	-0.48	7.55e-17	Breast cancer;
CESC	cis	rs875971	0.522	rs34973832	chr7:65396204	A/G	cg11764359	chr7:65958608	NA	0.67	8.62	0.47	6.29e-16	Aortic root size;
CESC	trans	rs35110281	0.713	rs1378079	chr21:45011187	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.46	6.13	0.35	3.22e-9	Mean corpuscular volume;
CESC	cis	rs4629710	0.645	rs34601891	chr6:131551238	C/T	cg12606694	chr6:131520996	AKAP7	0.48	5.92	0.34	9.77e-9	Multiple myeloma (IgH translocation);
CESC	trans	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg13565492	chr6:43139072	SRF	-0.72	-8.79	-0.48	1.98e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs116095464	0.558	rs11959126	chr5:283880	T/G	cg22496380	chr5:211416	CCDC127	-0.74	-8.46	-0.46	1.77e-15	Breast cancer;
CESC	trans	rs12265790	1.000	rs11253673	chr10:15928921	G/A	cg03460745	chr3:171966142	FNDC3B	0.75	6.02	0.35	5.81e-9	Cerebrospinal fluid t-tau:AB1-42 ratio;
CESC	cis	rs116095464	0.558	rs13357299	chr5:242211	T/C	cg20965017	chr5:231967	SDHA	-0.45	-5.18	-0.3	4.46e-7	Breast cancer;
CESC	cis	rs2066819	1.000	rs76430365	chr12:56699993	A/C	cg26714650	chr12:56694279	CS	-1.48	-9.9	-0.52	7.03e-20	Psoriasis vulgaris;
CESC	cis	rs1023500	0.505	rs134899	chr22:42683030	T/G	cg15557168	chr22:42548783	NA	-0.44	-6.85	-0.39	5.27e-11	Schizophrenia;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg10671167	chr7:39988923	CDK13	0.5	6.79	0.38	7.42e-11	Systemic lupus erythematosus;
CESC	cis	rs9322193	0.886	rs12525871	chr6:150097018	A/G	cg13206674	chr6:150067644	NUP43	0.41	5.74	0.33	2.62e-8	Lung cancer;
CESC	cis	rs875971	0.862	rs10274883	chr7:66116091	C/T	cg12463550	chr7:65579703	CRCP	-0.49	-6.42	-0.37	6.41e-10	Aortic root size;
CESC	cis	rs875971	0.522	rs4502988	chr7:65297746	A/G	cg26939375	chr7:64535504	NA	0.76	10.85	0.55	6.19e-23	Aortic root size;
CESC	cis	rs2836974	0.966	rs7283516	chr21:40690537	A/G	cg22974920	chr21:40686053	BRWD1	0.48	5.47	0.32	1.06e-7	Cognitive function;
CESC	cis	rs7772486	0.738	rs2246334	chr6:146183635	G/A	cg23711669	chr6:146136114	FBXO30	1.0	14.88	0.67	8.44e-37	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs61931739	0.517	rs11053063	chr12:34181011	C/T	cg19457237	chr12:34500585	NA	-0.39	-5.39	-0.31	1.53e-7	Morning vs. evening chronotype;
CESC	cis	rs477692	0.692	rs7905095	chr10:131448143	C/T	cg05714579	chr10:131428358	MGMT	-0.59	-8.34	-0.46	3.98e-15	Response to temozolomide;
CESC	cis	rs2806561	0.704	rs667330	chr1:23515257	A/G	cg12483005	chr1:23474871	LUZP1	0.38	6.0	0.35	6.44e-9	Height;
CESC	cis	rs5753618	0.509	rs4820951	chr22:31586248	G/A	cg13145458	chr22:31556086	RNF185	0.49	5.52	0.32	7.94e-8	Colorectal cancer;
CESC	cis	rs910316	0.763	rs13712	chr14:75483812	T/C	cg08847533	chr14:75593920	NEK9	0.92	16.82	0.72	1.12e-43	Height;
CESC	cis	rs643506	1.000	rs1788955	chr11:111630998	C/G	cg17089665	chr11:111648010	NA	-0.37	-5.22	-0.31	3.55e-7	Breast cancer;
CESC	cis	rs1008375	0.931	rs6449310	chr4:17575530	T/C	cg16339924	chr4:17578868	LAP3	0.74	9.66	0.51	4.03e-19	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs1707322	0.752	rs11211168	chr1:46163647	C/T	cg05343316	chr1:45956843	TESK2	0.51	6.26	0.36	1.54e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7618915	0.501	rs13085775	chr3:52678370	C/T	cg18337363	chr3:52569053	NT5DC2	0.28	5.13	0.3	5.53e-7	Bipolar disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22998610	chr11:62538411	TAF6L	0.56	6.86	0.39	4.94e-11	Gut microbiome composition (summer);
CESC	cis	rs514406	0.893	rs1242315	chr1:53417181	A/G	cg24675658	chr1:53192096	ZYG11B	-0.53	-6.4	-0.37	6.86e-10	Monocyte count;
CESC	cis	rs6089584	0.816	rs6061411	chr20:60634716	C/A	cg23262073	chr20:60523788	NA	-0.38	-5.15	-0.3	5.03e-7	Body mass index;
CESC	cis	rs950169	0.919	rs12915589	chr15:84734464	T/C	cg17507749	chr15:85114479	UBE2QP1	0.64	7.1	0.4	1.17e-11	Schizophrenia;
CESC	cis	rs10504229	0.683	rs16921810	chr8:58106067	A/G	cg21724239	chr8:58056113	NA	0.57	5.9	0.34	1.08e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs4481887	1.000	rs4306162	chr1:248468509	C/T	cg00666640	chr1:248458726	OR2T12	0.39	6.36	0.36	8.71e-10	Common traits (Other);
CESC	cis	rs7635838	0.859	rs9875414	chr3:11453559	A/G	cg00170343	chr3:11313890	ATG7	0.42	5.55	0.32	6.87e-8	HDL cholesterol;
CESC	cis	rs11792861	0.926	rs58795279	chr9:111851902	A/T	cg05043794	chr9:111880884	C9orf5	-0.41	-6.86	-0.39	4.76e-11	Menarche (age at onset);
CESC	cis	rs798554	0.797	rs2107964	chr7:2863574	G/A	cg19717773	chr7:2847554	GNA12	-0.56	-7.74	-0.43	2.11e-13	Height;
CESC	cis	rs9322193	0.887	rs9767113	chr6:150039293	T/C	cg04369109	chr6:150039330	LATS1	-0.43	-5.97	-0.34	7.5e-9	Lung cancer;
CESC	cis	rs9911578	1.000	rs9901181	chr17:56964271	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.17	0.3	4.64e-7	Intelligence (multi-trait analysis);
CESC	cis	rs2075371	0.966	rs1646676	chr7:133999267	G/A	cg20476274	chr7:133979776	SLC35B4	0.65	9.4	0.5	2.63e-18	Mean platelet volume;
CESC	cis	rs2055729	0.591	rs6987670	chr8:9883177	C/T	cg21625330	chr8:9911636	MSRA	-0.5	-6.39	-0.37	7.63e-10	Multiple myeloma (hyperdiploidy);
CESC	cis	rs7508	0.521	rs4377998	chr8:17923339	C/T	cg18067069	chr8:17937731	ASAH1	-0.4	-5.71	-0.33	2.95e-8	Atrial fibrillation;
CESC	cis	rs6142102	0.625	rs6142061	chr20:32548335	A/G	cg08999081	chr20:33150536	PIGU	0.34	5.1	0.3	6.35e-7	Skin pigmentation;
CESC	cis	rs10751667	1.000	rs12798036	chr11:947585	T/C	cg20946044	chr11:1010712	AP2A2	-0.42	-5.68	-0.33	3.61e-8	Alzheimer's disease (late onset);
CESC	cis	rs951366	0.649	rs7522056	chr1:205735891	A/G	cg14893161	chr1:205819251	PM20D1	0.5	6.76	0.38	8.77e-11	Menarche (age at onset);
CESC	trans	rs11088226	0.645	rs2833904	chr21:33941089	T/C	cg09050820	chr6:167586206	TCP10L2	0.82	7.6	0.42	5.16e-13	Gastritis;
CESC	cis	rs4654899	0.833	rs3816454	chr1:21191416	T/G	cg05370193	chr1:21551575	ECE1	-0.37	-5.36	-0.31	1.77e-7	Superior frontal gyrus grey matter volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03553080	chr16:88697695	ZC3H18	-0.53	-6.23	-0.36	1.79e-9	Gut microbiome composition (summer);
CESC	cis	rs7949030	0.653	rs2849030	chr11:62366986	G/A	cg23462726	chr11:62437636	C11orf83;C11orf48	0.41	5.41	0.32	1.4e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs2274273	0.638	rs3825614	chr14:55729387	G/A	cg04306507	chr14:55594613	LGALS3	0.3	5.04	0.3	8.61e-7	Protein biomarker;
CESC	cis	rs3820928	0.904	rs4414671	chr2:227816200	T/A	cg05526886	chr2:227700861	RHBDD1	-0.44	-5.68	-0.33	3.56e-8	Pulmonary function;
CESC	cis	rs4604732	0.527	rs7546805	chr1:247627259	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.57	7.2	0.4	6.34e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs4853012	0.793	rs6707619	chr2:74344656	G/A	cg20891558	chr2:74357851	NA	0.82	11.92	0.59	1.58e-26	Gestational age at birth (maternal effect);
CESC	cis	rs11155671	0.530	rs7764376	chr6:150210344	A/G	cg09699651	chr6:150184138	LRP11	0.55	7.7	0.43	2.78e-13	Testicular germ cell tumor;
CESC	cis	rs2742234	0.590	rs2505557	chr10:43666016	C/T	cg15436174	chr10:43711423	RASGEF1A	-0.51	-5.84	-0.34	1.54e-8	Hirschsprung disease;
CESC	cis	rs11122272	0.735	rs2486729	chr1:231535584	C/T	cg06096015	chr1:231504339	EGLN1	0.43	6.12	0.35	3.39e-9	Hemoglobin concentration;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg21167072	chr6:90539455	CASP8AP2	0.45	6.17	0.35	2.55e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs9325144	0.554	rs7960616	chr12:39096664	T/A	cg26384229	chr12:38710491	ALG10B	-0.5	-7.04	-0.4	1.6e-11	Morning vs. evening chronotype;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg00990635	chr19:19745667	GMIP	0.47	6.15	0.35	2.9e-9	Fibrinogen levels;
CESC	cis	rs10791323	0.628	rs1893850	chr11:133705356	T/C	cg15485101	chr11:133734466	NA	0.4	6.6	0.38	2.21e-10	Childhood ear infection;
CESC	cis	rs4835473	0.864	rs13145791	chr4:144656841	T/C	cg25736465	chr4:144833511	NA	-0.33	-5.17	-0.3	4.65e-7	Immature fraction of reticulocytes;
CESC	cis	rs4665809	0.590	rs5001914	chr2:26415429	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.08	-13.27	-0.63	3.74e-31	Gut microbiome composition (summer);
CESC	cis	rs1355223	0.872	rs7116409	chr11:34751007	T/G	cg11058730	chr11:34937778	PDHX;APIP	-0.47	-6.12	-0.35	3.3e-9	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs2477686	0.526	rs2477690	chr1:2395563	G/A	cg02275930	chr1:2372054	NA	-0.5	-8.02	-0.44	3.35e-14	Non-obstructive azoospermia;
CESC	cis	rs2731664	0.792	rs335468	chr5:176892349	A/G	cg23176889	chr5:176863531	GRK6	0.64	11.34	0.57	1.52e-24	Intelligence (multi-trait analysis);
CESC	cis	rs7927771	0.832	rs1317164	chr11:47419757	G/T	cg20307385	chr11:47447363	PSMC3	-0.62	-7.61	-0.42	4.69e-13	Subjective well-being;
CESC	cis	rs2832191	0.791	rs7283853	chr21:30498515	G/A	cg08807101	chr21:30365312	RNF160	-0.72	-9.88	-0.52	8.5e-20	Dental caries;
CESC	cis	rs11252926	0.563	rs10795103	chr10:451849	C/A	cg16386425	chr10:429943	DIP2C	-0.57	-7.24	-0.41	4.97e-12	Psychosis in Alzheimer's disease;
CESC	cis	rs35955747	0.777	rs5997895	chr22:31566173	T/G	cg25791279	chr22:32026902	PISD	-0.42	-5.1	-0.3	6.35e-7	Neutrophil count;Sum basophil neutrophil counts;
CESC	cis	rs10129255	0.500	rs6576229	chr14:107186773	G/A	cg23076370	chr14:107095027	NA	-0.66	-10.03	-0.52	2.9e-20	Kawasaki disease;
CESC	cis	rs9430161	0.579	rs7542158	chr1:11040193	G/A	cg27631724	chr1:11040367	C1orf127	0.44	7.63	0.42	4.18e-13	Ewing sarcoma;
CESC	cis	rs72781680	0.898	rs72780111	chr2:23991146	G/A	cg08917208	chr2:24149416	ATAD2B	0.95	8.71	0.47	3.45e-16	Lymphocyte counts;
CESC	cis	rs6580649	0.843	rs3803184	chr12:48398002	G/C	cg05342945	chr12:48394962	COL2A1	-0.55	-6.61	-0.38	2.16e-10	Lung cancer;
CESC	trans	rs61931739	0.500	rs56404399	chr12:34543101	A/G	cg26384229	chr12:38710491	ALG10B	0.72	10.84	0.55	6.43e-23	Morning vs. evening chronotype;
CESC	cis	rs1153858	1.000	rs11858495	chr15:45637662	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.75	-9.34	-0.5	4.19e-18	Homoarginine levels;
CESC	cis	rs1218582	0.741	rs883718	chr1:154846274	C/T	cg24250549	chr1:154909240	PMVK	0.64	9.28	0.5	6.44e-18	Prostate cancer;
CESC	cis	rs72901758	0.768	rs76962230	chr17:76251920	A/G	cg26068271	chr17:76253126	NA	0.46	6.47	0.37	4.69e-10	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
CESC	cis	rs10927875	0.619	rs12121764	chr1:16138059	A/T	cg21385522	chr1:16154831	NA	-0.75	-10.77	-0.55	1.16e-22	Dilated cardiomyopathy;
CESC	cis	rs12145833	0.538	rs4658547	chr1:243391131	T/G	cg02356786	chr1:243265016	LOC731275	-0.79	-6.57	-0.37	2.71e-10	Obesity (early onset extreme);
CESC	cis	rs4664304	0.710	rs9636280	chr2:160717852	C/T	cg03641300	chr2:160917029	PLA2R1	-0.42	-5.57	-0.32	6.19e-8	Crohn's disease;Inflammatory bowel disease;
CESC	trans	rs10242455	0.557	rs59672032	chr7:99058697	T/C	cg09045935	chr12:6379348	NA	0.9	7.78	0.43	1.67e-13	Blood metabolite levels;
CESC	cis	rs9303401	0.538	rs8078280	chr17:56473132	A/G	cg12560992	chr17:57184187	TRIM37	0.51	5.17	0.3	4.71e-7	Cognitive test performance;
CESC	cis	rs2073499	0.872	rs41291724	chr3:50294066	C/G	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.72	5.88	0.34	1.21e-8	Schizophrenia;
CESC	cis	rs7264396	0.508	rs6060739	chr20:34567592	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.7	-8.91	-0.48	8.56e-17	Total cholesterol levels;
CESC	cis	rs1018836	0.828	rs2105968	chr8:91591825	A/G	cg16814680	chr8:91681699	NA	-0.68	-9.99	-0.52	3.84e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg03188948	chr7:1209495	NA	0.73	7.02	0.4	1.85e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg10556830	chr5:68462986	CCNB1	-0.42	-6.06	-0.35	4.55e-9	Gambling;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00004979	chr12:111885466	SH2B3	-0.5	-6.23	-0.36	1.79e-9	Gut microbiome composition (summer);
CESC	cis	rs7940866	0.874	rs10894306	chr11:130873882	A/C	cg12179176	chr11:130786555	SNX19	0.68	9.96	0.52	4.78e-20	Schizophrenia;
CESC	cis	rs360798	0.512	rs2430388	chr2:63106784	T/C	cg17519650	chr2:63277830	OTX1	0.55	7.07	0.4	1.39e-11	Coronary artery disease;
CESC	cis	rs155076	0.702	rs482731	chr13:21846075	G/A	cg11317459	chr13:21872234	NA	-1.04	-11.45	-0.58	6.22e-25	White matter hyperintensity burden;
CESC	cis	rs597539	0.652	rs660614	chr11:68659488	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.79	10.1	0.53	1.68e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg19321730	chr11:63996766	NUDT22;DNAJC4	0.47	6.66	0.38	1.55e-10	Fibrinogen levels;
CESC	cis	rs2180341	1.000	rs9398837	chr6:127635217	G/A	cg27446573	chr6:127587934	RNF146	1.09	16.38	0.71	3.79e-42	Breast cancer;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg12588476	chr7:99647494	ZSCAN21	-0.5	-6.43	-0.37	5.85e-10	Ulcerative colitis;
CESC	cis	rs1832871	0.672	rs62437399	chr6:158784251	C/A	cg07165851	chr6:158734300	TULP4	0.56	5.49	0.32	9.27e-8	Height;
CESC	cis	rs780096	0.526	rs780112	chr2:27665361	C/G	cg17158414	chr2:27665306	KRTCAP3	-0.32	-5.97	-0.34	7.45e-9	Total body bone mineral density;
CESC	cis	rs7512552	0.809	rs9436108	chr1:150360930	A/G	cg15654264	chr1:150340011	RPRD2	0.4	5.28	0.31	2.65e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CESC	trans	rs6951245	0.706	rs1133116	chr7:1195215	A/C	cg13565492	chr6:43139072	SRF	-0.59	-6.09	-0.35	4.01e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs1062177	0.855	rs1346489	chr5:151266534	C/T	cg00977110	chr5:151150581	G3BP1	0.54	6.22	0.36	1.89e-9	Preschool internalizing problems;
CESC	cis	rs4474465	0.850	rs4441045	chr11:78220436	G/T	cg27205649	chr11:78285834	NARS2	0.44	5.27	0.31	2.83e-7	Alzheimer's disease (survival time);
CESC	cis	rs425277	0.583	rs10910046	chr1:2041155	C/T	cg04315214	chr1:2043799	PRKCZ	0.54	9.38	0.5	3.02e-18	Height;
CESC	cis	rs10504229	1.000	rs34616626	chr8:58184650	C/T	cg22535103	chr8:58192502	C8orf71	-1.05	-13.08	-0.63	1.71e-30	Developmental language disorder (linguistic errors);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22918914	chr5:6378597	MED10	-0.51	-6.22	-0.36	1.93e-9	Gut microbiome composition (summer);
CESC	cis	rs2576037	0.562	rs13381557	chr18:44513371	A/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.32	5.13	0.3	5.57e-7	Personality dimensions;
CESC	cis	rs3096299	0.685	rs4785675	chr16:89539974	T/C	cg08392591	chr16:89556376	ANKRD11	0.6	8.15	0.45	1.47e-14	Multiple myeloma (IgH translocation);
CESC	cis	rs9311474	0.607	rs11711421	chr3:52561779	C/T	cg18337363	chr3:52569053	NT5DC2	0.3	5.57	0.32	6.28e-8	Electroencephalogram traits;
CESC	cis	rs35160687	0.644	rs57270703	chr2:86516873	T/C	cg01119172	chr2:86362222	SNORD94;PTCD3	-0.38	-5.1	-0.3	6.57e-7	Night sleep phenotypes;
CESC	cis	rs853679	0.517	rs9380056	chr6:28104476	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.55	-6.39	-0.37	7.41e-10	Depression;
CESC	cis	rs7705819	1.000	rs6887996	chr5:172870964	A/T	cg14746387	chr5:172879299	NA	0.37	5.07	0.3	7.44e-7	Stroke;
CESC	trans	rs1814175	0.765	rs1722003	chr11:49895896	G/A	cg15704280	chr7:45808275	SEPT13	-1.03	-20.88	-0.79	6.44e-58	Height;
CESC	cis	rs4906332	1.000	rs8012127	chr14:103942762	G/A	cg09975044	chr14:104007538	NA	0.47	6.39	0.37	7.49e-10	Coronary artery disease;
CESC	cis	rs10883723	0.810	rs7092622	chr10:104249919	T/G	ch.10.2196322F	chr10:104248062	ACTR1A	0.42	5.1	0.3	6.33e-7	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs1862618	0.671	rs173763	chr5:56225418	G/A	cg24549020	chr5:56110836	MAP3K1	0.47	5.82	0.34	1.66e-8	Initial pursuit acceleration;
CESC	cis	rs1707322	0.827	rs12125508	chr1:46246010	A/G	cg06784218	chr1:46089804	CCDC17	0.36	6.14	0.35	3e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs17826219	0.500	rs57005940	chr17:29066329	C/G	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.1e-10	Body mass index;
CESC	cis	rs7959452	0.640	rs4761233	chr12:69722880	T/C	cg22834771	chr12:69754056	YEATS4	-0.39	-5.07	-0.3	7.31e-7	Blood protein levels;
CESC	cis	rs2191566	0.960	rs367209	chr19:44506249	A/G	cg20607764	chr19:44506953	ZNF230	0.6	7.98	0.44	4.5e-14	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs425277	1.000	rs262670	chr1:2082458	C/T	cg04315214	chr1:2043799	PRKCZ	-0.38	-5.3	-0.31	2.42e-7	Height;
CESC	cis	rs854765	0.647	rs7212447	chr17:17987067	G/A	cg16928487	chr17:17741425	SREBF1	-0.53	-8.68	-0.47	4.24e-16	Total body bone mineral density;
CESC	cis	rs12545109	0.800	rs2670028	chr8:57423673	G/A	cg09654669	chr8:57350985	NA	-0.45	-5.84	-0.34	1.5e-8	Obesity-related traits;
CESC	cis	rs8077889	0.700	rs28571770	chr17:41904066	A/T	cg26893861	chr17:41843967	DUSP3	0.74	9.39	0.5	2.82e-18	Triglycerides;
CESC	cis	rs6866344	0.697	rs17184344	chr5:178129281	A/G	cg10224037	chr5:178157518	ZNF354A	0.69	7.75	0.43	1.96e-13	Neutrophil percentage of white cells;
CESC	cis	rs9467711	0.606	rs12174639	chr6:26373121	G/A	cg12826209	chr6:26865740	GUSBL1	0.62	5.31	0.31	2.31e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs9868809	0.772	rs12107252	chr3:48691316	T/C	cg07636037	chr3:49044803	WDR6	-0.72	-6.6	-0.38	2.26e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs4523957	0.614	rs2316512	chr17:2064710	A/T	cg16513277	chr17:2031491	SMG6	-0.72	-10.2	-0.53	8.12e-21	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs1448094	0.791	rs10863124	chr12:86352548	A/T	cg02569458	chr12:86230093	RASSF9	0.4	5.99	0.35	6.8e-9	Major depressive disorder;
CESC	cis	rs11048434	0.698	rs10842537	chr12:9066158	T/C	cg23795048	chr12:9217529	LOC144571	0.36	5.71	0.33	2.99e-8	Sjögren's syndrome;
CESC	cis	rs7552404	0.731	rs1770887	chr1:76401812	A/G	cg10523679	chr1:76189770	ACADM	-0.58	-6.24	-0.36	1.73e-9	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg06873352	chr17:61820015	STRADA	-0.73	-12.95	-0.62	4.86e-30	Prudent dietary pattern;
CESC	cis	rs7959452	1.000	rs2168029	chr12:69734641	A/C	cg22834771	chr12:69754056	YEATS4	-0.43	-5.59	-0.32	5.53e-8	Blood protein levels;
CESC	cis	rs7223966	1.000	rs11079508	chr17:61750066	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.44	-5.16	-0.3	4.73e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs5758659	0.652	rs133349	chr22:42428727	A/T	cg04733989	chr22:42467013	NAGA	0.47	6.62	0.38	2e-10	Cognitive function;
CESC	cis	rs4523957	0.928	rs422632	chr17:2162049	G/A	cg16513277	chr17:2031491	SMG6	0.6	8.18	0.45	1.22e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs7918232	0.882	rs788237	chr10:27457932	C/T	cg14442939	chr10:27389572	ANKRD26	-0.67	-6.43	-0.37	5.92e-10	Breast cancer;
CESC	cis	rs6088590	0.561	rs6059918	chr20:33150503	C/T	cg08999081	chr20:33150536	PIGU	0.69	12.05	0.59	5.92e-27	Coronary artery disease;
CESC	cis	rs9916302	0.861	rs4795376	chr17:37669043	T/C	cg20243544	chr17:37824526	PNMT	0.48	6.1	0.35	3.71e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs1005277	0.540	rs116205409	chr10:38478970	G/A	cg25427524	chr10:38739819	LOC399744	-0.7	-10.24	-0.53	6.01e-21	Extrinsic epigenetic age acceleration;
CESC	cis	rs9649213	0.593	rs7789380	chr7:97956180	G/A	cg24562669	chr7:97807699	LMTK2	0.48	7.08	0.4	1.31e-11	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs27434	0.510	rs27038	chr5:96112954	A/G	cg16492584	chr5:96139282	ERAP1	-0.48	-5.84	-0.34	1.52e-8	Ankylosing spondylitis;
CESC	cis	rs7631605	0.905	rs7649344	chr3:37006396	C/T	cg22985146	chr3:37219077	LRRFIP2	0.35	5.43	0.32	1.27e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs8005677	1.000	rs4981446	chr14:23381413	A/G	cg01529538	chr14:23388837	RBM23	0.51	6.87	0.39	4.64e-11	Cognitive ability (multi-trait analysis);
CESC	cis	rs7666738	0.716	rs6817529	chr4:99023213	T/C	cg17366294	chr4:99064904	C4orf37	0.61	8.76	0.47	2.35e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1862618	0.853	rs2113078	chr5:56087190	C/T	cg18230493	chr5:56204884	C5orf35	-0.71	-8.21	-0.45	9.61e-15	Initial pursuit acceleration;
CESC	cis	rs2708240	0.539	rs2538994	chr7:147574509	C/T	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.42	-6.36	-0.36	8.59e-10	QT interval (drug interaction);
CESC	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg05064044	chr6:292385	DUSP22	-0.69	-8.96	-0.48	6.05e-17	Menopause (age at onset);
CESC	cis	rs3820928	0.692	rs17416354	chr2:227770844	A/G	cg05526886	chr2:227700861	RHBDD1	-0.56	-7.4	-0.41	1.85e-12	Pulmonary function;
CESC	cis	rs7666738	0.830	rs732299	chr4:98995389	C/T	cg03467027	chr4:99064603	C4orf37	0.43	5.4	0.31	1.49e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4835473	0.932	rs1973608	chr4:144834210	A/C	cg25736465	chr4:144833511	NA	0.42	6.4	0.37	6.94e-10	Immature fraction of reticulocytes;
CESC	cis	rs12142240	0.698	rs10158130	chr1:46822600	T/C	cg10495392	chr1:46806563	NSUN4	0.58	6.32	0.36	1.09e-9	Menopause (age at onset);
CESC	cis	rs6964587	0.967	rs34344935	chr7:91835436	G/A	cg17063962	chr7:91808500	NA	0.58	7.81	0.43	1.35e-13	Breast cancer;
CESC	cis	rs77861329	0.925	rs72964042	chr3:52088485	A/C	cg08692210	chr3:52188851	WDR51A	0.81	7.23	0.41	5.25e-12	Macrophage inflammatory protein 1b levels;
CESC	cis	rs780096	0.527	rs12471703	chr2:27738854	C/T	cg22903471	chr2:27725779	GCKR	-0.56	-7.71	-0.43	2.59e-13	Total body bone mineral density;
CESC	cis	rs2439831	1.000	rs690263	chr15:43704465	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.87	10.58	0.55	4.62e-22	Lung cancer in ever smokers;
CESC	cis	rs17376456	0.825	rs6874766	chr5:93213807	C/G	cg21475434	chr5:93447410	FAM172A	-0.83	-7.09	-0.4	1.2e-11	Diabetic retinopathy;
CESC	trans	rs35110281	0.591	rs230642	chr21:44915533	A/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.5	-7.08	-0.4	1.29e-11	Mean corpuscular volume;
CESC	cis	rs8067354	0.645	rs2173120	chr17:57892640	A/T	cg13753209	chr17:57696993	CLTC	0.56	6.3	0.36	1.21e-9	Hemoglobin concentration;
CESC	cis	rs4555082	0.874	rs2735828	chr14:105710486	C/A	cg06808227	chr14:105710500	BRF1	-0.61	-7.38	-0.41	2.01e-12	Mean platelet volume;Platelet distribution width;
CESC	cis	rs6690583	0.623	rs893618	chr1:85513770	C/T	cg22153463	chr1:85462885	MCOLN2	0.74	7.68	0.43	3.05e-13	Serum sulfate level;
CESC	cis	rs9611565	0.559	rs5758412	chr22:42080803	T/A	cg17376030	chr22:41985996	PMM1	-0.79	-8.55	-0.47	9.65e-16	Vitiligo;
CESC	cis	rs6500395	1.000	rs1872654	chr16:48671050	C/T	cg04672837	chr16:48644449	N4BP1	0.51	6.43	0.37	6.06e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	-0.53	-6.69	-0.38	1.33e-10	Prudent dietary pattern;
CESC	cis	rs6952808	0.895	rs4513875	chr7:1928159	C/T	cg00106254	chr7:1943704	MAD1L1	-0.5	-6.22	-0.36	1.88e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs36051895	0.626	rs9695934	chr9:5153108	C/G	cg02405213	chr9:5042618	JAK2	-0.54	-6.88	-0.39	4.4e-11	Pediatric autoimmune diseases;
CESC	cis	rs7772486	0.603	rs2223411	chr6:146028767	T/C	cg23711669	chr6:146136114	FBXO30	-0.92	-12.44	-0.61	2.84e-28	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4642101	0.512	rs9813960	chr3:12818205	A/G	cg24848339	chr3:12840334	CAND2	0.43	6.96	0.39	2.7e-11	QRS complex (12-leadsum);
CESC	cis	rs7818688	0.653	rs11786088	chr8:95836140	C/T	cg16049864	chr8:95962084	TP53INP1	0.54	5.7	0.33	3.15e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs736408	0.609	rs13095332	chr3:52787242	C/T	cg18099408	chr3:52552593	STAB1	-0.33	-5.34	-0.31	2.02e-7	Bipolar disorder;
CESC	trans	rs561341	1.000	rs537166	chr17:30326827	C/T	cg20587970	chr11:113659929	NA	-1.13	-14.25	-0.66	1.39e-34	Hip circumference adjusted for BMI;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg21941105	chr19:10491405	TYK2	0.47	6.14	0.35	3.08e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg18483322	chr2:97523826	ANKRD39	0.42	6.0	0.35	6.6e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs7044106	0.762	rs10760115	chr9:123476952	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.82	13.0	0.62	3.26e-30	Hip circumference adjusted for BMI;
CESC	cis	rs761746	0.921	rs12171042	chr22:32011225	T/C	cg25791279	chr22:32026902	PISD	0.57	6.67	0.38	1.49e-10	Intelligence;
CESC	cis	rs5753618	0.583	rs5753631	chr22:31863022	A/C	cg02404636	chr22:31891804	SFI1	0.39	5.29	0.31	2.59e-7	Colorectal cancer;
CESC	cis	rs3796352	1.000	rs11714876	chr3:53101640	C/G	cg12962167	chr3:53033115	SFMBT1	-0.62	-5.65	-0.33	4.09e-8	Immune reponse to smallpox (secreted IL-2);
CESC	cis	rs61931739	0.500	rs12146843	chr12:34451738	T/G	cg23762105	chr12:34175262	ALG10	-0.4	-5.22	-0.31	3.7e-7	Morning vs. evening chronotype;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg02837703	chr11:67236413	TMEM134	-0.45	-6.13	-0.35	3.22e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs4835473	0.932	rs28668841	chr4:144903683	A/T	cg25736465	chr4:144833511	NA	-0.43	-6.49	-0.37	4.21e-10	Immature fraction of reticulocytes;
CESC	cis	rs208520	1.000	rs12192261	chr6:66985268	A/G	cg07460842	chr6:66804631	NA	0.87	10.14	0.53	1.25e-20	Exhaled nitric oxide output;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25075503	chr6:89673509	RNGTT	0.52	6.01	0.35	5.96e-9	Gut microbiome composition (summer);
CESC	cis	rs6831352	0.918	rs13127153	chr4:100058121	C/T	cg13256891	chr4:100009986	ADH5	-0.77	-8.49	-0.46	1.5e-15	Alcohol dependence;
CESC	cis	rs644799	0.610	rs1255179	chr11:95472097	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.43	5.98	0.34	7.37e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs6860806	0.661	rs6890009	chr5:131580033	G/T	cg22638593	chr5:131593259	PDLIM4	0.4	5.04	0.3	8.6e-7	Breast cancer;
CESC	cis	rs7618501	0.933	rs6809431	chr3:49804119	A/G	cg24308560	chr3:49941425	MST1R	-0.52	-7.18	-0.4	7.15e-12	Intelligence (multi-trait analysis);
CESC	cis	rs7605827	0.930	rs4668921	chr2:15672071	T/C	cg19274914	chr2:15703543	NA	0.39	6.93	0.39	3.15e-11	Educational attainment (years of education);
CESC	cis	rs7659604	0.560	rs769238	chr4:122744942	G/A	cg19748678	chr4:122722346	EXOSC9	0.79	10.03	0.52	2.85e-20	Type 2 diabetes;
CESC	cis	rs595982	0.559	rs17206714	chr19:49362001	T/A	cg15549821	chr19:49342101	PLEKHA4	-0.69	-7.74	-0.43	2.11e-13	Red cell distribution width;
CESC	cis	rs2576037	0.796	rs2576043	chr18:44573476	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.6	-8.52	-0.46	1.19e-15	Personality dimensions;
CESC	cis	rs9659323	0.539	rs1750331	chr1:119494973	A/G	cg05756136	chr1:119680316	WARS2	-0.45	-6.17	-0.35	2.56e-9	Body mass index;
CESC	cis	rs863345	0.836	rs10908652	chr1:158453924	C/T	cg12129480	chr1:158549410	OR10X1	-0.3	-5.97	-0.34	7.47e-9	Pneumococcal bacteremia;
CESC	cis	rs9858542	1.000	rs9882740	chr3:49702484	T/C	cg03060546	chr3:49711283	APEH	-0.57	-6.8	-0.39	7.07e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs9549260	0.755	rs17061503	chr13:41246758	A/G	cg21288729	chr13:41239152	FOXO1	-0.67	-8.27	-0.45	6.49e-15	Red blood cell count;
CESC	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg23708337	chr7:1209742	NA	0.55	5.42	0.32	1.33e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs9611565	0.765	rs202659	chr22:41811620	T/C	cg17376030	chr22:41985996	PMM1	-0.59	-6.24	-0.36	1.69e-9	Vitiligo;
CESC	cis	rs704	0.605	rs2227736	chr17:26693231	G/C	cg10494684	chr17:26645200	TMEM97	-0.38	-5.32	-0.31	2.25e-7	Osteoprotegerin levels;
CESC	cis	rs722599	0.639	rs2193596	chr14:75234101	A/C	cg11812906	chr14:75593930	NEK9	0.45	5.17	0.3	4.52e-7	IgG glycosylation;
CESC	cis	rs137699	1.000	rs2049986	chr22:39756854	C/G	cg24399712	chr22:39784796	NA	0.39	5.29	0.31	2.54e-7	IgG glycosylation;
CESC	cis	rs2274273	0.840	rs7153110	chr14:55820628	A/G	cg04306507	chr14:55594613	LGALS3	0.32	6.26	0.36	1.58e-9	Protein biomarker;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg24862861	chr10:976594	NA	-0.45	-6.01	-0.35	6.23e-9	Height;
CESC	cis	rs4808199	0.947	rs2099333	chr19:19605963	C/T	cg03709012	chr19:19516395	GATAD2A	1.15	13.01	0.62	3.04e-30	Nonalcoholic fatty liver disease;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg05898482	chr7:152373203	XRCC2	-0.46	-6.24	-0.36	1.72e-9	Asthma;
CESC	cis	rs2777491	0.957	rs316614	chr15:41746625	A/G	cg20272979	chr15:41787780	ITPKA	0.44	6.5	0.37	4.02e-10	Ulcerative colitis;
CESC	cis	rs3806843	0.676	rs2245643	chr5:140029780	C/T	cg26395211	chr5:140044315	WDR55	0.52	6.81	0.39	6.4e-11	Depressive symptoms (multi-trait analysis);
CESC	cis	rs2276314	0.857	rs62101394	chr18:33592299	C/T	cg19628046	chr18:33552617	C18orf21	0.51	5.76	0.33	2.3e-8	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs72634258	0.786	rs9434991	chr1:8178708	G/C	cg00042356	chr1:8021962	PARK7	0.5	5.39	0.31	1.55e-7	Inflammatory bowel disease;
CESC	cis	rs60843830	1.000	rs55946380	chr2:268293	A/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.78	10.02	0.52	2.91e-20	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs17023223	0.537	rs66715579	chr1:119725432	G/A	cg05756136	chr1:119680316	WARS2	-0.47	-5.69	-0.33	3.34e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CESC	cis	rs17666538	0.535	rs168062	chr8:632444	T/A	cg07234876	chr8:600039	NA	0.8	5.98	0.34	7.33e-9	IgG glycosylation;
CESC	cis	rs17253792	0.915	rs28375514	chr14:56179941	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.73	5.13	0.3	5.7e-7	Putamen volume;
CESC	cis	rs9581857	0.579	rs75326986	chr13:27997758	C/T	cg01674679	chr13:27998804	GTF3A	-0.66	-5.49	-0.32	9.61e-8	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
CESC	cis	rs2204008	0.837	rs11168504	chr12:37964922	G/T	cg13010199	chr12:38710504	ALG10B	0.52	6.51	0.37	3.74e-10	Bladder cancer;
CESC	cis	rs2479724	1.000	rs2479724	chr6:41890982	T/C	cg08135965	chr6:41755394	TOMM6	0.37	5.07	0.3	7.6e-7	Menarche (age at onset);
CESC	cis	rs2243480	1.000	rs2465120	chr7:65620974	C/G	cg13147721	chr7:65941812	NA	-0.97	-9.19	-0.49	1.2e-17	Diabetic kidney disease;
CESC	cis	rs7572263	0.724	rs12986551	chr2:209052303	T/C	cg23998903	chr2:209048830	C2orf80	-0.39	-5.14	-0.3	5.4e-7	Glioma;Non-glioblastoma glioma;
CESC	cis	rs10857712	0.904	rs7918164	chr10:135223323	G/A	cg01444801	chr10:135216882	MTG1	-0.47	-5.67	-0.33	3.75e-8	Systemic lupus erythematosus;
CESC	cis	rs1799949	1.000	rs12516	chr17:41196408	G/A	cg05368731	chr17:41323189	NBR1	0.76	10.52	0.54	7.29e-22	Menopause (age at onset);
CESC	cis	rs7100689	0.577	rs2236569	chr10:82043576	G/A	cg09936400	chr10:82049201	MAT1A	0.4	6.16	0.35	2.72e-9	Post bronchodilator FEV1;
CESC	cis	rs1348850	0.567	rs880899	chr2:178532416	A/G	cg23306229	chr2:178417860	TTC30B	0.54	7.16	0.4	8.11e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs9611565	0.694	rs106860	chr22:41840407	C/T	cg17376030	chr22:41985996	PMM1	0.77	8.3	0.45	5.53e-15	Vitiligo;
CESC	cis	rs11098499	0.697	rs11941899	chr4:120382758	C/A	cg24375607	chr4:120327624	NA	0.45	5.52	0.32	8.05e-8	Corneal astigmatism;
CESC	cis	rs4665809	0.525	rs10865402	chr2:26535383	A/G	cg26314531	chr2:26401878	FAM59B	-0.44	-5.06	-0.3	7.91e-7	Gut microbiome composition (summer);
CESC	cis	rs897080	0.552	rs1067392	chr2:44639097	G/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.51	5.97	0.34	7.74e-9	Height;
CESC	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg07092213	chr7:1199455	ZFAND2A	-0.5	-5.18	-0.3	4.36e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2836974	0.897	rs2836973	chr21:40654928	A/G	cg27266027	chr21:40555129	PSMG1	0.48	5.71	0.33	2.99e-8	Cognitive function;
CESC	cis	rs2073300	0.609	rs6137919	chr20:23363163	T/C	cg12062639	chr20:23401060	NAPB	1.08	8.67	0.47	4.32e-16	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs2777491	0.957	rs3743038	chr15:41694743	C/T	cg02330683	chr15:41787940	ITPKA	0.48	7.1	0.4	1.14e-11	Ulcerative colitis;
CESC	trans	rs722599	0.748	rs2300599	chr14:75359441	A/G	cg00095594	chr1:236228625	NID1	-0.39	-6.01	-0.35	6.01e-9	IgG glycosylation;
CESC	cis	rs9894429	0.966	rs10871499	chr17:79589006	G/A	cg18240062	chr17:79603768	NPLOC4	0.73	10.36	0.54	2.38e-21	Eye color traits;
CESC	cis	rs7267979	1.000	rs2500418	chr20:25382268	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.84	-15.95	-0.7	1.31e-40	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7927771	0.965	rs56400411	chr11:47586376	T/G	cg05585544	chr11:47624801	NA	-0.52	-8.03	-0.44	3.23e-14	Subjective well-being;
CESC	cis	rs9549260	0.755	rs12585875	chr13:41199531	A/G	cg21288729	chr13:41239152	FOXO1	0.64	8.26	0.45	7.14e-15	Red blood cell count;
CESC	cis	rs4924935	0.851	rs966811	chr17:18830287	G/A	cg26378065	chr17:18585709	ZNF286B	-0.47	-5.3	-0.31	2.39e-7	Pancreatic cancer;
CESC	cis	rs25645	0.800	rs11078935	chr17:38192137	T/G	cg17467752	chr17:38218738	THRA	-0.55	-7.09	-0.4	1.24e-11	Myeloid white cell count;
CESC	cis	rs870825	0.616	rs2090590	chr4:185647850	A/C	cg04058563	chr4:185651563	MLF1IP	0.63	6.96	0.39	2.59e-11	Blood protein levels;
CESC	cis	rs9487051	0.676	rs9400268	chr6:109600550	C/T	cg21918786	chr6:109611834	NA	-0.39	-5.74	-0.33	2.55e-8	Reticulocyte fraction of red cells;
CESC	cis	rs1003719	0.646	rs2835672	chr21:38581234	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.61	-8.22	-0.45	8.86e-15	Eye color traits;
CESC	cis	rs910316	0.737	rs424120	chr14:75482828	G/T	cg08847533	chr14:75593920	NEK9	-0.9	-15.43	-0.69	9.04e-39	Height;
CESC	cis	rs875971	0.545	rs1638735	chr7:66095738	C/T	cg19163074	chr7:65112434	INTS4L2	-0.46	-5.18	-0.3	4.47e-7	Aortic root size;
CESC	cis	rs6570726	0.791	rs1509213	chr6:145783360	G/A	cg05347473	chr6:146136440	FBXO30	-0.55	-7.13	-0.4	9.41e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs798554	0.718	rs1636247	chr7:2881917	A/G	cg09658497	chr7:2847517	GNA12	-0.38	-5.37	-0.31	1.72e-7	Height;
CESC	cis	rs9399401	0.710	rs12190271	chr6:142681409	A/G	cg03128060	chr6:142623767	GPR126	-0.4	-6.87	-0.39	4.55e-11	Chronic obstructive pulmonary disease;
CESC	cis	rs10791323	0.517	rs1120247	chr11:133745180	T/G	cg15485101	chr11:133734466	NA	0.3	5.13	0.3	5.52e-7	Childhood ear infection;
CESC	cis	rs904092	0.720	rs1230028	chr4:100182886	C/G	cg12011299	chr4:100065546	ADH4	0.53	6.11	0.35	3.48e-9	Alcohol dependence;
CESC	cis	rs17666538	0.585	rs336437	chr8:636251	A/C	cg23958373	chr8:599963	NA	0.81	6.15	0.35	2.91e-9	IgG glycosylation;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg24228800	chr13:113863762	CUL4A;PCID2	-0.46	-6.08	-0.35	4.14e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs6860806	0.661	rs6890009	chr5:131580033	G/T	cg04518342	chr5:131593106	PDLIM4	0.4	5.94	0.34	8.79e-9	Breast cancer;
CESC	cis	rs4970988	0.787	rs1532770	chr1:150725335	G/T	cg22823121	chr1:150693482	HORMAD1	0.45	6.24	0.36	1.76e-9	Urate levels;
CESC	cis	rs7582720	1.000	rs72926796	chr2:203827480	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.36	0.41	2.34e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs4555082	0.834	rs2816607	chr14:105718385	A/T	cg13114125	chr14:105738426	BRF1	-0.88	-10.73	-0.55	1.49e-22	Mean platelet volume;Platelet distribution width;
CESC	cis	rs10504229	0.683	rs903702	chr8:58128557	T/C	cg24829409	chr8:58192753	C8orf71	-0.58	-7.2	-0.4	6.31e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs6831352	0.840	rs17817868	chr4:100060623	C/T	cg13256891	chr4:100009986	ADH5	-0.75	-8.21	-0.45	9.89e-15	Alcohol dependence;
CESC	cis	rs873946	0.648	rs1543593	chr10:134553185	A/T	cg18305652	chr10:134549665	INPP5A	0.47	6.64	0.38	1.79e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs10504229	0.512	rs77289815	chr8:57995242	A/G	cg24829409	chr8:58192753	C8orf71	-0.67	-6.26	-0.36	1.56e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs116095464	0.558	rs2288459	chr5:231143	T/C	cg22857025	chr5:266934	NA	-1.28	-18.2	-0.75	1.47e-48	Breast cancer;
CESC	trans	rs10411161	0.702	rs11879336	chr19:52389627	C/T	cg22319618	chr22:45562946	NUP50	-0.79	-7.76	-0.43	1.81e-13	Breast cancer;
CESC	cis	rs4595586	0.525	rs7972595	chr12:39338000	G/A	cg26384229	chr12:38710491	ALG10B	0.64	9.0	0.48	4.59e-17	Morning vs. evening chronotype;
CESC	cis	rs12474201	0.963	rs3829835	chr2:46925789	C/T	cg06386533	chr2:46925753	SOCS5	0.92	12.79	0.62	1.66e-29	Height;
CESC	cis	rs514406	0.698	rs522259	chr1:53365481	A/G	cg08859206	chr1:53392774	SCP2	-0.68	-9.87	-0.52	9.2e-20	Monocyte count;
CESC	cis	rs13385	0.769	rs7727069	chr5:139573265	A/G	cg26211634	chr5:139558579	C5orf32	0.47	5.28	0.31	2.75e-7	Atrial fibrillation;
CESC	cis	rs9926296	0.605	rs8047486	chr16:89854025	A/T	cg04287289	chr16:89883240	FANCA	0.87	14.3	0.66	8.95e-35	Vitiligo;
CESC	cis	rs11252926	0.537	rs61836851	chr10:447231	T/C	cg16386425	chr10:429943	DIP2C	-0.56	-7.23	-0.41	5.02e-12	Psychosis in Alzheimer's disease;
CESC	cis	rs9341808	0.500	rs2322629	chr6:80811540	C/T	cg08355045	chr6:80787529	NA	0.37	5.51	0.32	8.3e-8	Sitting height ratio;
CESC	cis	rs1348850	0.526	rs935426	chr2:178369433	T/C	cg23306229	chr2:178417860	TTC30B	0.8	7.39	0.41	1.96e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs9399135	0.967	rs4896122	chr6:135295081	T/C	cg22676075	chr6:135203613	NA	0.52	7.21	0.4	5.94e-12	Red blood cell count;
CESC	trans	rs1814175	0.817	rs1615305	chr11:49895222	T/A	cg15704280	chr7:45808275	SEPT13	-1.03	-20.9	-0.79	5.71e-58	Height;
CESC	cis	rs3857067	0.806	rs4693002	chr4:95115302	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.58	-8.57	-0.47	8.86e-16	QT interval;
CESC	cis	rs7762018	1.000	rs4716378	chr6:170086568	G/C	cg13891659	chr6:170190454	C6orf122;C6orf208	0.53	5.52	0.32	8.28e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs7078219	0.505	rs4129132	chr10:101284637	T/G	cg09788492	chr10:101292477	NKX2-3	0.33	6.35	0.36	9.52e-10	Dental caries;
CESC	cis	rs4654899	0.802	rs17416732	chr1:21256368	T/C	cg05370193	chr1:21551575	ECE1	0.38	5.51	0.32	8.58e-8	Superior frontal gyrus grey matter volume;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg10579840	chr8:99306110	NIPAL2	-0.48	-6.24	-0.36	1.69e-9	Height;
CESC	cis	rs977987	0.806	rs17696696	chr16:75393352	G/T	cg03315344	chr16:75512273	CHST6	-0.4	-5.67	-0.33	3.65e-8	Dupuytren's disease;
CESC	cis	rs3096299	0.933	rs2965938	chr16:89491336	C/T	cg02187348	chr16:89574699	SPG7	0.59	8.01	0.44	3.73e-14	Multiple myeloma (IgH translocation);
CESC	cis	rs6942756	1.000	rs6971917	chr7:128976919	G/A	cg02491457	chr7:128862824	NA	-0.68	-9.24	-0.49	8.31e-18	White matter hyperintensity burden;
CESC	cis	rs644799	0.544	rs1727165	chr11:95521648	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.49	6.47	0.37	4.68e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	trans	rs9354308	0.899	rs2802056	chr6:66546219	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.6	6.62	0.38	1.93e-10	Metabolite levels;
CESC	cis	rs72829446	0.530	rs11869899	chr17:7407915	C/T	cg02795151	chr17:7402630	POLR2A	0.61	6.59	0.38	2.32e-10	Androgen levels;
CESC	cis	rs2857078	0.720	rs9901595	chr17:42305699	G/A	cg09913183	chr17:42254507	C17orf65;ASB16	0.41	5.1	0.3	6.35e-7	Red cell distribution width;Reticulocyte count;
CESC	cis	rs5760092	0.618	rs4461358	chr22:24260106	T/C	cg24846343	chr22:24311635	DDTL	-0.45	-6.39	-0.37	7.51e-10	Urinary 1,3-butadiene metabolite levels in smokers;
CESC	cis	rs8092503	1.000	rs3764513	chr18:52495089	A/G	cg12377874	chr18:52495404	RAB27B	0.37	6.14	0.35	3.02e-9	Childhood body mass index;
CESC	cis	rs11864453	0.826	rs2240243	chr16:72137561	A/G	cg16558253	chr16:72132732	DHX38	0.63	9.99	0.52	3.84e-20	Fibrinogen levels;
CESC	cis	rs5769765	0.773	rs9616206	chr22:50310847	G/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.56	-5.93	-0.34	9.34e-9	Schizophrenia;
CESC	trans	rs1814175	0.935	rs10839317	chr11:49657228	A/C	cg15704280	chr7:45808275	SEPT13	-1.01	-17.87	-0.74	2.03e-47	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11939075	chr4:83956728	COPS4	-0.61	-6.82	-0.39	6.29e-11	Gut microbiome composition (summer);
CESC	cis	rs4819052	0.851	rs9753963	chr21:46661437	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.46	5.79	0.34	2e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs457287	0.772	rs691772	chr9:4825117	C/T	cg20099147	chr19:56652066	ZNF444	0.5	6.05	0.35	5.04e-9	Platelet count;
CESC	cis	rs6570726	0.791	rs1280276	chr6:145892350	A/C	cg23711669	chr6:146136114	FBXO30	1.0	15.28	0.68	3.05e-38	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6831352	0.819	rs13832	chr4:99993075	C/A	cg12011299	chr4:100065546	ADH4	0.68	8.5	0.46	1.35e-15	Alcohol dependence;
CESC	trans	rs9467711	0.659	rs35680819	chr6:26455814	T/C	cg01620082	chr3:125678407	NA	-0.81	-6.27	-0.36	1.44e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs6088813	1.000	rs6087703	chr20:33996433	T/C	cg14752227	chr20:34000481	UQCC	-0.4	-5.08	-0.3	7.17e-7	Height;
CESC	cis	rs6088580	0.634	rs4258875	chr20:32924895	C/A	cg08999081	chr20:33150536	PIGU	-0.64	-11.02	-0.56	1.75e-23	Glomerular filtration rate (creatinine);
CESC	cis	rs1784581	0.569	rs9365357	chr6:162414913	A/G	cg17173639	chr6:162384350	PARK2	0.58	8.71	0.47	3.3e-16	Itch intensity from mosquito bite;
CESC	cis	rs1552244	1.000	rs35993975	chr3:10067794	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.86	10.69	0.55	2.05e-22	Alzheimer's disease;
CESC	cis	rs5760092	0.755	rs4585126	chr22:24270005	T/C	cg09033563	chr22:24373618	LOC391322	0.45	5.53	0.32	7.63e-8	Urinary 1,3-butadiene metabolite levels in smokers;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20545551	chr22:18560636	PEX26	0.68	7.37	0.41	2.24e-12	Gut microbiome composition (summer);
CESC	cis	rs11683229	0.704	rs13027462	chr2:63154816	A/G	cg17519650	chr2:63277830	OTX1	-0.66	-5.47	-0.32	1.04e-7	Protein quantitative trait loci;
CESC	cis	rs9815354	0.812	rs73071330	chr3:41810553	T/G	cg03022575	chr3:42003672	ULK4	0.68	6.06	0.35	4.7e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs67311347	0.955	rs6773383	chr3:40377412	A/T	cg09455208	chr3:40491958	NA	0.45	7.9	0.44	7.28e-14	Renal cell carcinoma;
CESC	trans	rs9951602	0.512	rs8085719	chr18:76649111	A/G	cg02800362	chr5:177631904	HNRNPAB	0.65	8.62	0.47	6.15e-16	Obesity-related traits;
CESC	cis	rs881375	0.967	rs10733648	chr9:123700779	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.38	5.05	0.3	8.12e-7	Rheumatoid arthritis;
CESC	cis	rs7116495	0.609	rs73543612	chr11:71820350	C/T	cg26138937	chr11:71823887	C11orf51	1.29	7.98	0.44	4.34e-14	Severe influenza A (H1N1) infection;
CESC	cis	rs9487051	0.698	rs4301336	chr6:109650140	A/T	cg01475377	chr6:109611718	NA	0.39	5.29	0.31	2.5e-7	Reticulocyte fraction of red cells;
CESC	cis	rs8018808	0.935	rs7146595	chr14:77932017	A/C	cg20045696	chr14:77926864	AHSA1	0.43	5.9	0.34	1.13e-8	Myeloid white cell count;
CESC	cis	rs1218582	0.596	rs906595	chr1:154822907	C/T	cg03351412	chr1:154909251	PMVK	0.51	6.1	0.35	3.81e-9	Prostate cancer;
CESC	cis	rs2130392	0.926	rs7679215	chr4:185635311	C/T	cg21366198	chr4:185655624	MLF1IP	0.46	6.55	0.37	3.01e-10	Kawasaki disease;
CESC	trans	rs61931739	0.500	rs11836198	chr12:34552782	T/C	cg26384229	chr12:38710491	ALG10B	0.53	7.39	0.41	1.9e-12	Morning vs. evening chronotype;
CESC	cis	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg21782813	chr7:2030301	MAD1L1	0.41	5.72	0.33	2.9e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs9790314	0.905	rs1154701	chr3:161008025	T/A	cg03342759	chr3:160939853	NMD3	-0.46	-6.12	-0.35	3.41e-9	Morning vs. evening chronotype;
CESC	cis	rs13095912	0.752	rs13092283	chr3:185338005	T/C	cg11274856	chr3:185301563	NA	0.37	5.51	0.32	8.61e-8	Systolic blood pressure;
CESC	cis	rs7618915	0.531	rs77146033	chr3:52701501	G/T	cg05564831	chr3:52568323	NT5DC2	0.44	6.72	0.38	1.08e-10	Bipolar disorder;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg19419581	chr17:79482410	NA	-0.47	-6.68	-0.38	1.36e-10	Gambling;
CESC	cis	rs9399401	0.626	rs3817928	chr6:142750516	A/G	cg04461802	chr6:142623433	GPR126	0.39	5.69	0.33	3.29e-8	Chronic obstructive pulmonary disease;
CESC	cis	rs4730250	0.708	rs74983157	chr7:106823951	A/G	cg02696742	chr7:106810147	HBP1	-0.53	-5.07	-0.3	7.37e-7	Osteoarthritis;
CESC	cis	rs894734	0.567	rs7138907	chr12:54324576	C/T	cg12374095	chr12:54320830	NA	-0.42	-5.93	-0.34	9.48e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
CESC	cis	rs853679	0.517	rs4711165	chr6:28115184	T/G	cg12963246	chr6:28129442	ZNF389	0.59	7.68	0.43	3e-13	Depression;
CESC	cis	rs7107174	0.901	rs10899500	chr11:78125246	A/G	cg02023728	chr11:77925099	USP35	0.45	5.83	0.34	1.58e-8	Testicular germ cell tumor;
CESC	cis	rs1018836	0.699	rs13271657	chr8:91474599	C/G	cg16814680	chr8:91681699	NA	-0.54	-7.09	-0.4	1.2e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs10751667	0.643	rs7394524	chr11:933865	T/C	cg20946044	chr11:1010712	AP2A2	-0.4	-5.43	-0.32	1.26e-7	Alzheimer's disease (late onset);
CESC	cis	rs2486288	0.656	rs7171312	chr15:45570225	C/G	cg09092052	chr15:45571596	NA	0.45	5.33	0.31	2.14e-7	Glomerular filtration rate;
CESC	cis	rs10911232	0.507	rs10797820	chr1:183011366	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.87	13.67	0.64	1.52e-32	Hypertriglyceridemia;
CESC	cis	rs1862618	0.802	rs194058	chr5:56188977	G/A	cg20203395	chr5:56204925	C5orf35	-0.43	-5.06	-0.3	7.66e-7	Initial pursuit acceleration;
CESC	cis	rs9902453	0.902	rs4075014	chr17:28305674	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.64	8.08	0.44	2.36e-14	Coffee consumption (cups per day);
CESC	cis	rs2180341	0.814	rs9385424	chr6:127726796	A/G	cg24812749	chr6:127587940	RNF146	0.84	12.05	0.59	5.93e-27	Breast cancer;
CESC	cis	rs597539	0.616	rs10896386	chr11:68722694	C/T	cg18350739	chr11:68623251	NA	-0.48	-7.14	-0.4	9.06e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg06877860	chr20:55043471	C20orf43	-0.5	-6.09	-0.35	4.01e-9	Ulcerative colitis;
CESC	cis	rs3820068	0.603	rs932602	chr1:15986087	A/G	cg17385448	chr1:15911702	AGMAT	0.44	7.31	0.41	3.13e-12	Systolic blood pressure;
CESC	cis	rs7666738	0.753	rs1527520	chr4:98929164	A/G	cg03467027	chr4:99064603	C4orf37	0.46	5.59	0.32	5.78e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7605827	0.930	rs3805102	chr2:15518312	G/A	cg19274914	chr2:15703543	NA	0.35	6.11	0.35	3.61e-9	Educational attainment (years of education);
CESC	cis	rs5757676	1.000	rs5757676	chr22:39841700	T/C	cg11247378	chr22:39784982	NA	-0.6	-7.16	-0.4	8.03e-12	IgG glycosylation;
CESC	cis	rs763014	0.898	rs1981484	chr16:630710	A/G	cg07256732	chr16:621771	PIGQ	-0.31	-5.38	-0.31	1.61e-7	Height;
CESC	cis	rs1707322	0.682	rs10890335	chr1:46100394	G/C	cg03146154	chr1:46216737	IPP	0.81	11.48	0.58	5.05e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7552404	1.000	rs4949879	chr1:76237143	G/A	cg10523679	chr1:76189770	ACADM	0.55	6.17	0.35	2.53e-9	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs2011503	1.000	rs11085264	chr19:19621780	A/G	cg11584989	chr19:19387371	SF4	0.61	7.06	0.4	1.45e-11	Bipolar disorder;
CESC	cis	rs7809950	0.724	rs1858888	chr7:107046062	T/A	cg23024343	chr7:107201750	COG5	-0.59	-7.45	-0.42	1.35e-12	Coronary artery disease;
CESC	cis	rs7078219	0.505	rs4409764	chr10:101284237	T/G	cg09788492	chr10:101292477	NKX2-3	0.34	6.42	0.37	6.25e-10	Dental caries;
CESC	cis	rs4689388	0.581	rs11727100	chr4:6281458	A/C	cg00701064	chr4:6280414	WFS1	0.61	7.51	0.42	8.84e-13	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs9581857	0.512	rs9581866	chr13:28063176	G/A	cg01674679	chr13:27998804	GTF3A	-0.64	-5.36	-0.31	1.8e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
CESC	cis	rs7666738	0.830	rs10025174	chr4:98914172	A/G	cg05340658	chr4:99064831	C4orf37	0.75	10.74	0.55	1.42e-22	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21679509	chr7:28219613	JAZF1	0.51	6.32	0.36	1.13e-9	Gut microbiome composition (summer);
CESC	cis	rs6540556	0.723	rs6672256	chr1:209894043	A/T	cg23920097	chr1:209922102	NA	0.42	5.19	0.3	4.13e-7	Red blood cell count;
CESC	cis	rs1707322	0.752	rs61784793	chr1:46149285	G/A	cg05343316	chr1:45956843	TESK2	0.51	6.32	0.36	1.09e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs35306767	0.903	rs35957139	chr10:884889	C/T	cg26597838	chr10:835615	NA	1.18	11.37	0.57	1.12e-24	Eosinophil percentage of granulocytes;
CESC	trans	rs10743315	0.557	rs16915108	chr12:19290406	T/C	cg09562322	chr12:119419143	SRRM4	-0.48	-6.18	-0.35	2.4e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs2832191	0.967	rs2832216	chr21:30521921	C/T	cg08807101	chr21:30365312	RNF160	0.68	9.35	0.5	3.88e-18	Dental caries;
CESC	cis	rs2050392	0.517	rs2771242	chr10:30762973	C/T	cg25182066	chr10:30743637	MAP3K8	-0.49	-6.87	-0.39	4.44e-11	Inflammatory bowel disease;
CESC	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg06877462	chr1:205807181	PM20D1	0.39	5.84	0.34	1.51e-8	Menarche (age at onset);
CESC	cis	rs4727027	0.933	rs6961605	chr7:148870108	G/A	cg23583168	chr7:148888333	NA	-0.8	-12.19	-0.6	1.96e-27	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.52	6.43	0.37	6.07e-10	Prudent dietary pattern;
CESC	cis	rs6542838	0.641	rs12712042	chr2:99534401	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.47	-5.95	-0.34	8.33e-9	Fear of minor pain;
CESC	cis	rs3749237	0.595	rs2878298	chr3:49406080	T/C	cg06212747	chr3:49208901	KLHDC8B	0.53	7.21	0.4	5.85e-12	Resting heart rate;
CESC	cis	rs6570726	0.791	rs6918814	chr6:145906028	G/A	cg05347473	chr6:146136440	FBXO30	0.55	7.37	0.41	2.13e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1642645	0.757	rs3845574	chr1:42476574	C/A	cg16685388	chr1:42384056	HIVEP3	0.38	5.68	0.33	3.57e-8	Left ventricular obstructive tract defect (maternal effect);
CESC	cis	rs1552244	1.000	rs6768102	chr3:10149380	A/G	cg00149659	chr3:10157352	C3orf10	0.73	8.73	0.47	2.94e-16	Alzheimer's disease;
CESC	cis	rs6963495	0.745	rs73192153	chr7:105212418	A/T	cg02135003	chr7:105160482	PUS7	-0.48	-5.51	-0.32	8.52e-8	Bipolar disorder (body mass index interaction);
CESC	cis	rs116095464	0.558	rs62347683	chr5:230331	C/T	cg20965017	chr5:231967	SDHA	-0.45	-5.08	-0.3	7.29e-7	Breast cancer;
CESC	cis	rs921968	0.643	rs508157	chr2:219435288	G/A	cg02176678	chr2:219576539	TTLL4	0.41	7.08	0.4	1.27e-11	Mean corpuscular hemoglobin concentration;
CESC	cis	rs910316	1.000	rs7303	chr14:75520065	T/C	cg08847533	chr14:75593920	NEK9	0.99	18.49	0.75	1.4e-49	Height;
CESC	trans	rs877282	0.733	rs7092976	chr10:756358	G/A	cg22713356	chr15:30763199	NA	0.93	8.39	0.46	3e-15	Uric acid levels;
CESC	cis	rs1865721	1.000	rs11659761	chr18:73186974	A/G	cg26385618	chr18:73139727	C18orf62	-0.53	-7.94	-0.44	5.65e-14	Intelligence;
CESC	cis	rs4568518	0.710	rs12699930	chr7:18012258	T/C	cg03009463	chr7:17980271	SNX13	0.46	6.0	0.35	6.38e-9	Measles;
CESC	cis	rs7296418	0.961	rs11608811	chr12:123529056	A/G	cg05973401	chr12:123451056	ABCB9	0.6	7.85	0.43	1.01e-13	Platelet count;
CESC	cis	rs4601790	0.601	rs4930295	chr11:65390554	C/G	cg24147428	chr11:65409760	SIPA1	-0.41	-5.84	-0.34	1.49e-8	Blood pressure (age interaction);
CESC	cis	rs8177253	0.829	rs9813689	chr3:133514822	C/T	cg01448562	chr3:133502909	NA	-0.56	-7.78	-0.43	1.66e-13	Iron status biomarkers;
CESC	cis	rs6570726	0.577	rs867056	chr6:145784805	A/C	cg23711669	chr6:146136114	FBXO30	-0.93	-12.62	-0.61	6.62e-29	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2072732	0.861	rs67630839	chr1:2951989	C/T	cg15211996	chr1:2936768	ACTRT2	0.33	5.61	0.33	4.97e-8	Plateletcrit;
CESC	cis	rs6570726	0.935	rs9390329	chr6:145828026	T/C	cg05347473	chr6:146136440	FBXO30	0.44	5.99	0.35	6.71e-9	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs57506017	0.585	rs7809700	chr7:12267734	G/A	cg23422036	chr7:12250390	TMEM106B	0.38	5.13	0.3	5.58e-7	Neuroticism;
CESC	cis	rs9818941	0.824	rs2712325	chr3:157787473	G/C	cg08654915	chr3:157813417	NA	-0.45	-7.3	-0.41	3.41e-12	Height;
CESC	cis	rs7524258	0.835	rs75096060	chr1:7270248	G/C	cg07173049	chr1:7289937	CAMTA1	0.37	5.61	0.33	5.15e-8	Tourette's syndrome or obsessive-compulsive disorder;
CESC	cis	rs6879260	1.000	rs7706951	chr5:179733407	C/T	cg02891314	chr5:179741120	GFPT2	-0.58	-7.86	-0.43	1e-13	Height;
CESC	cis	rs1005277	0.522	rs1208767	chr10:38042295	G/T	cg00409905	chr10:38381863	ZNF37A	-0.5	-6.82	-0.39	6.2e-11	Extrinsic epigenetic age acceleration;
CESC	cis	rs919433	1.000	rs1560277	chr2:198187903	C/T	cg10820045	chr2:198174542	NA	0.39	5.72	0.33	2.91e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs7666738	0.830	rs116103936	chr4:98954531	T/C	cg03467027	chr4:99064603	C4orf37	0.45	5.61	0.33	4.97e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11690935	0.550	rs4280427	chr2:172813218	G/A	cg13550731	chr2:172543902	DYNC1I2	0.46	6.37	0.36	8.38e-10	Schizophrenia;
CESC	cis	rs10504229	0.600	rs6987243	chr8:58115406	T/C	cg21724239	chr8:58056113	NA	0.57	5.84	0.34	1.49e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs11098499	0.863	rs1155576	chr4:120450159	A/C	cg09307838	chr4:120376055	NA	0.9	12.26	0.6	1.15e-27	Corneal astigmatism;
CESC	cis	rs16895831	0.519	rs62414629	chr6:42598898	G/A	cg10605015	chr6:42532144	UBR2	-0.52	-5.91	-0.34	1.07e-8	Granulocyte percentage of myeloid white cells;Neutrophil percentage of white cells;Eosinophil percentage of white cells;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Neutrophil count;Sum basophil neutrophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
CESC	cis	rs11048434	0.661	rs34791180	chr12:9110919	T/C	cg23795048	chr12:9217529	LOC144571	0.35	5.36	0.31	1.78e-7	Sjögren's syndrome;
CESC	cis	rs7044106	0.791	rs735109	chr9:123488879	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.85	13.76	0.65	7.24e-33	Hip circumference adjusted for BMI;
CESC	cis	rs763014	0.931	rs2071981	chr16:630025	C/G	cg00908189	chr16:619842	PIGQ	0.66	9.26	0.49	7.42e-18	Height;
CESC	cis	rs7923609	1.000	rs4379723	chr10:64963449	T/C	cg01631684	chr10:65280961	REEP3	-0.45	-5.56	-0.32	6.51e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg25187967	chr11:77024606	NA	0.49	6.9	0.39	3.93e-11	Fibrinogen levels;
CESC	cis	rs1448094	0.511	rs4559760	chr12:86149414	G/A	cg02569458	chr12:86230093	RASSF9	-0.42	-6.44	-0.37	5.67e-10	Major depressive disorder;
CESC	cis	rs9733	0.596	rs72702585	chr1:150696427	G/A	cg17724175	chr1:150552817	MCL1	0.45	7.31	0.41	3.17e-12	Tonsillectomy;
CESC	cis	rs1023500	0.573	rs13057094	chr22:42470317	T/C	cg04733989	chr22:42467013	NAGA	0.8	11.49	0.58	4.5e-25	Schizophrenia;
CESC	cis	rs875971	0.545	rs316305	chr7:65617971	G/A	cg18876405	chr7:65276391	NA	-0.51	-5.96	-0.34	8.21e-9	Aortic root size;
CESC	cis	rs3733585	0.753	rs12500805	chr4:10017979	C/T	cg11266682	chr4:10021025	SLC2A9	0.69	13.9	0.65	2.39e-33	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs4862750	0.872	rs6830426	chr4:187897270	T/A	cg07414643	chr4:187882934	NA	0.55	7.99	0.44	4.15e-14	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs28647808	1.000	rs28489061	chr9:136270319	T/C	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.9	5.73	0.33	2.75e-8	Blood protein levels;
CESC	cis	rs2011503	1.000	rs61744761	chr19:19656615	C/T	cg11584989	chr19:19387371	SF4	0.56	6.26	0.36	1.55e-9	Bipolar disorder;
CESC	cis	rs7772486	0.875	rs969694	chr6:146394655	A/G	cg23711669	chr6:146136114	FBXO30	0.77	11.48	0.58	4.79e-25	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7552404	1.000	rs211723	chr1:76103030	C/T	cg10523679	chr1:76189770	ACADM	-0.65	-7.22	-0.41	5.56e-12	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs12586317	0.547	rs74243586	chr14:35477325	C/T	cg05294307	chr14:35346193	BAZ1A	-0.51	-5.45	-0.32	1.16e-7	Psoriasis;
CESC	cis	rs644799	1.000	rs7749	chr11:95565789	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.94	14.0	0.65	1.01e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs1008375	1.000	rs555	chr4:17625658	A/G	cg16339924	chr4:17578868	LAP3	0.56	6.97	0.39	2.49e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs9479482	0.967	rs61730071	chr6:150342232	G/A	cg03788504	chr6:150331562	NA	-0.35	-6.93	-0.39	3.15e-11	Alopecia areata;
CESC	cis	rs7542091	0.704	rs1883331	chr1:210043483	A/G	cg23283495	chr1:209979779	IRF6	0.35	5.8	0.34	1.84e-8	Monobrow;
CESC	cis	rs7085104	0.552	rs11191414	chr10:104601565	A/T	cg04362960	chr10:104952993	NT5C2	0.5	6.62	0.38	2e-10	Immature fraction of reticulocytes;Schizophrenia;
CESC	cis	rs15676	0.783	rs10819442	chr9:131564750	C/G	cg00228799	chr9:131580591	ENDOG	-0.49	-6.09	-0.35	3.93e-9	Blood metabolite levels;
CESC	cis	rs9896933	0.775	rs79299098	chr17:80830944	G/A	cg19500275	chr17:80737654	TBCD	0.62	5.88	0.34	1.23e-8	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
CESC	cis	rs10870270	0.830	rs11146269	chr10:133761820	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.58	-7.54	-0.42	7.44e-13	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs2228479	0.850	rs12598316	chr16:89916600	C/A	cg14709524	chr16:89940631	TCF25	0.87	5.91	0.34	1.04e-8	Skin colour saturation;
CESC	cis	rs77972916	0.536	rs7562101	chr2:43592756	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.5	-5.12	-0.3	5.76e-7	Granulocyte percentage of myeloid white cells;
CESC	cis	rs9308731	0.644	rs3789064	chr2:111915322	T/C	cg04202892	chr2:111875749	ACOXL	0.44	6.34	0.36	1.01e-9	Chronic lymphocytic leukemia;
CESC	cis	rs11581903	0.568	rs11205978	chr1:53076057	G/A	cg19751897	chr1:52520827	TXNDC12;BTF3L4	0.73	5.47	0.32	1.06e-7	Joint mobility (Beighton score);
CESC	cis	rs796364	0.539	rs6738494	chr2:200697058	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	0.64	6.22	0.36	1.97e-9	Schizophrenia;
CESC	cis	rs8050907	0.744	rs80031922	chr16:4538185	C/T	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.89	5.66	0.33	3.84e-8	Obesity-related traits;
CESC	cis	rs9815354	0.767	rs73071337	chr3:41822518	G/C	cg03022575	chr3:42003672	ULK4	0.7	6.2	0.36	2.11e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs9611565	0.694	rs9611591	chr22:41830212	G/A	cg17376030	chr22:41985996	PMM1	-0.42	-5.1	-0.3	6.56e-7	Vitiligo;
CESC	cis	rs4803468	1.000	rs17318666	chr19:41940342	T/G	cg08639244	chr19:41945921	ATP5SL	0.43	5.33	0.31	2.07e-7	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04158115	chr1:36863305	LSM10	0.62	7.07	0.4	1.42e-11	Gut microbiome composition (summer);
CESC	cis	rs10927875	0.632	rs1122068	chr1:16127480	G/C	cg18973939	chr1:16164122	FLJ37453	0.37	5.52	0.32	8.2e-8	Dilated cardiomyopathy;
CESC	cis	rs1799949	1.000	rs4793231	chr17:41427469	A/G	cg05368731	chr17:41323189	NBR1	0.76	10.38	0.54	2.05e-21	Menopause (age at onset);
CESC	trans	rs16949788	1.000	rs41315964	chr15:66779698	C/T	cg23949574	chr2:240302855	HDAC4	0.44	6.0	0.35	6.53e-9	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs7818688	0.653	rs16893774	chr8:95895976	C/G	cg16049864	chr8:95962084	TP53INP1	-0.51	-5.14	-0.3	5.47e-7	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs1552244	1.000	rs6789156	chr3:10124120	C/T	cg00149659	chr3:10157352	C3orf10	0.73	8.5	0.46	1.35e-15	Alzheimer's disease;
CESC	cis	rs7927592	0.956	rs7116899	chr11:68385535	G/T	cg20283391	chr11:68216788	NA	-0.48	-5.82	-0.34	1.69e-8	Total body bone mineral density;
CESC	cis	rs2204008	0.837	rs12370891	chr12:37984531	A/G	cg26384229	chr12:38710491	ALG10B	0.74	10.84	0.55	6.46e-23	Bladder cancer;
CESC	cis	rs9287719	0.747	rs1534400	chr2:10696833	T/C	cg00105475	chr2:10696890	NA	0.44	6.69	0.38	1.29e-10	Prostate cancer;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg22966973	chr7:35077753	DPY19L1	-0.53	-6.47	-0.37	4.82e-10	Ulcerative colitis;
CESC	cis	rs763014	0.898	rs35666389	chr16:629458	A/G	cg07343612	chr16:622815	PIGQ	-0.58	-8.41	-0.46	2.55e-15	Height;
CESC	trans	rs61931739	0.927	rs12315970	chr12:34038535	A/G	cg26384229	chr12:38710491	ALG10B	-0.47	-6.26	-0.36	1.51e-9	Morning vs. evening chronotype;
CESC	cis	rs7249142	0.506	rs8101388	chr19:19293938	A/C	cg27384695	chr19:19271486	LOC729991-MEF2B;MEF2B	0.29	5.1	0.3	6.51e-7	IgG glycosylation;
CESC	cis	rs7659604	0.702	rs61217486	chr4:122693973	T/C	cg06713675	chr4:122721982	EXOSC9	-0.43	-6.05	-0.35	5.01e-9	Type 2 diabetes;
CESC	cis	rs17253792	0.822	rs76264681	chr14:56060447	T/C	cg01858014	chr14:56050164	KTN1	-0.87	-6.75	-0.38	9.11e-11	Putamen volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09214955	chr7:139025759	C7orf55	-0.53	-6.1	-0.35	3.83e-9	Gut microbiome composition (summer);
CESC	cis	rs8177253	0.965	rs4854762	chr3:133499063	A/G	cg11941060	chr3:133502564	NA	0.4	5.27	0.31	2.77e-7	Iron status biomarkers;
CESC	cis	rs4820294	1.000	rs62236668	chr22:38063870	G/A	cg21798802	chr22:38057573	PDXP	0.46	7.99	0.44	4.16e-14	Fat distribution (HIV);
CESC	cis	rs651907	0.535	rs11716558	chr3:101528481	T/C	cg12386194	chr3:101231763	SENP7	0.41	5.11	0.3	6.03e-7	Colorectal cancer;
CESC	cis	rs6088590	0.965	rs6120730	chr20:33385102	G/C	cg06115741	chr20:33292138	TP53INP2	0.62	7.52	0.42	8.73e-13	Coronary artery disease;
CESC	cis	rs11718455	0.960	rs11921995	chr3:44017301	C/A	cg08738300	chr3:44038990	NA	0.48	6.07	0.35	4.32e-9	Coronary artery disease;
CESC	cis	rs9549367	0.713	rs9549352	chr13:113833221	A/G	cg00898013	chr13:113819073	PROZ	-0.55	-7.5	-0.42	9.59e-13	Platelet distribution width;
CESC	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	7.71	0.43	2.57e-13	Prudent dietary pattern;
CESC	cis	rs1008375	0.900	rs1003413	chr4:17582442	C/T	cg27347728	chr4:17578864	LAP3	-0.48	-5.42	-0.32	1.34e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs9399137	0.507	rs7748708	chr6:135275142	G/A	cg22676075	chr6:135203613	NA	0.54	6.88	0.39	4.31e-11	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	cis	rs12497850	0.931	rs9876848	chr3:48844059	G/A	cg02487422	chr3:49467188	NICN1	0.4	5.08	0.3	6.98e-7	Parkinson's disease;
CESC	cis	rs7666738	0.830	rs13108705	chr4:99044438	T/C	cg03676636	chr4:99064102	C4orf37	0.33	5.12	0.3	5.93e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6688613	0.694	rs3820387	chr1:166820284	A/T	cg07049167	chr1:166818506	POGK	0.51	6.27	0.36	1.47e-9	Refractive astigmatism;
CESC	cis	rs7666738	0.830	rs4472144	chr4:98956494	G/A	cg03676636	chr4:99064102	C4orf37	0.33	5.03	0.3	9.1e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04490136	chr11:34073216	CAPRIN1	0.56	6.15	0.35	2.86e-9	Gut microbiome composition (summer);
CESC	cis	rs5997397	0.967	rs5762777	chr22:29150044	T/C	cg02153584	chr22:29168773	CCDC117	0.54	7.41	0.41	1.65e-12	Red cell distribution width;
CESC	cis	rs9300255	0.739	rs4759415	chr12:123743674	C/T	cg19016782	chr12:123741754	C12orf65	0.5	7.24	0.41	4.8e-12	Neutrophil percentage of white cells;
CESC	cis	rs8114671	0.562	rs6088646	chr20:33505937	T/C	cg07148914	chr20:33460835	GGT7	0.45	5.9	0.34	1.09e-8	Height;
CESC	cis	rs597539	0.652	rs501799	chr11:68631240	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.77	10.0	0.52	3.59e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs10781543	0.775	rs10870194	chr9:139327034	A/G	cg14169450	chr9:139327907	INPP5E	0.54	8.21	0.45	9.94e-15	Monocyte percentage of white cells;
CESC	cis	rs7259376	0.807	rs7254434	chr19:22500033	G/A	cg02657401	chr19:22469223	NA	-0.26	-5.27	-0.31	2.84e-7	Menopause (age at onset);
CESC	cis	rs1552244	0.882	rs3732967	chr3:10015437	T/C	cg08888203	chr3:10149979	C3orf24	0.49	6.17	0.35	2.49e-9	Alzheimer's disease;
CESC	cis	rs4819052	0.800	rs4819045	chr21:46660138	C/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.46	5.79	0.34	2e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs780096	0.526	rs1647276	chr2:27688601	C/T	cg21248554	chr2:27665150	KRTCAP3	-0.36	-7.38	-0.41	2.02e-12	Total body bone mineral density;
CESC	cis	rs901683	1.000	rs34566829	chr10:45973598	G/T	cg16031567	chr10:46195673	NA	-0.75	-5.04	-0.3	8.78e-7	Red blood cell traits;Mean corpuscular volume;
CESC	cis	rs7267979	1.000	rs3002702	chr20:25268920	T/C	cg08601574	chr20:25228251	PYGB	0.4	5.74	0.33	2.64e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs8044868	0.530	rs2550870	chr16:72070129	C/T	cg01557791	chr16:72042693	DHODH	-0.45	-6.26	-0.36	1.54e-9	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CESC	cis	rs7223966	1.000	rs8069687	chr17:61883023	C/T	cg11494091	chr17:61959527	GH2	-0.38	-5.18	-0.3	4.41e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs17253792	0.822	rs75555677	chr14:56096429	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.79	5.91	0.34	1.06e-8	Putamen volume;
CESC	cis	rs4699052	0.625	rs11097808	chr4:104263130	G/A	cg16532752	chr4:104119610	CENPE	-0.42	-5.99	-0.35	6.75e-9	Testicular germ cell tumor;
CESC	cis	rs57677839	1	rs57677839	chr11:17028189	G/A	cg15378786	chr11:17036137	PLEKHA7	1.1	19.7	0.77	7.94e-54	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17973889	chr20:2644865	IDH3B	0.57	6.19	0.36	2.33e-9	Gut microbiome composition (summer);
CESC	cis	rs2645694	0.626	rs2645708	chr4:77822682	G/A	cg18351406	chr4:77819688	ANKRD56	0.52	6.44	0.37	5.65e-10	Emphysema distribution in smoking;
CESC	cis	rs4594175	0.926	rs4243570	chr14:51624243	C/T	cg23942311	chr14:51606299	NA	0.39	5.93	0.34	9.29e-9	Cancer;
CESC	cis	rs79349575	0.783	rs2088139	chr17:47000110	C/T	cg26022315	chr17:47021804	SNF8	0.39	5.3	0.31	2.5e-7	Type 2 diabetes;
CESC	cis	rs1559088	0.947	rs7259879	chr19:33549462	T/C	cg17764715	chr19:33622953	WDR88	0.46	5.74	0.33	2.57e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs372883	0.613	rs1153289	chr21:30686212	G/T	cg24692254	chr21:30365293	RNF160	-0.53	-6.83	-0.39	5.77e-11	Pancreatic cancer;
CESC	cis	rs35110281	0.782	rs1584917	chr21:45042365	A/G	cg21573476	chr21:45109991	RRP1B	-0.49	-6.88	-0.39	4.4e-11	Mean corpuscular volume;
CESC	cis	rs8103278	0.507	rs7246377	chr19:46292259	G/A	cg12641515	chr19:46296257	DMWD	0.78	10.2	0.53	7.99e-21	Coronary artery disease;
CESC	cis	rs854765	0.663	rs4925120	chr17:17754633	C/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.5	-6.67	-0.38	1.48e-10	Total body bone mineral density;
CESC	cis	rs7927771	0.690	rs35496532	chr11:47450338	C/T	cg18512352	chr11:47633146	NA	-0.51	-7.27	-0.41	4.03e-12	Subjective well-being;
CESC	cis	rs875971	0.522	rs1701760	chr7:65473688	A/G	cg05332525	chr7:65337924	VKORC1L1	0.49	6.1	0.35	3.67e-9	Aortic root size;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg16713009	chr19:44223436	IRGC	0.42	6.06	0.35	4.76e-9	Fibrinogen levels;
CESC	cis	rs921968	0.643	rs3931102	chr2:219520405	C/T	cg02176678	chr2:219576539	TTLL4	0.44	7.82	0.43	1.29e-13	Mean corpuscular hemoglobin concentration;
CESC	cis	rs9911578	1.000	rs2079703	chr17:56603978	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	-0.41	-5.53	-0.32	7.63e-8	Intelligence (multi-trait analysis);
CESC	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg22907277	chr7:1156413	C7orf50	0.45	6.36	0.36	8.57e-10	Longevity;Endometriosis;
CESC	cis	rs28489187	0.505	rs7525786	chr1:85884076	C/T	cg16011679	chr1:85725395	C1orf52	-0.42	-5.11	-0.3	6.27e-7	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg04254159	chr8:66701461	PDE7A	0.37	6.17	0.35	2.5e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs56104184	0.775	rs56146968	chr19:49398847	A/G	cg21252483	chr19:49399788	TULP2	-0.52	-5.64	-0.33	4.45e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	cis	rs4819052	1.000	rs9984901	chr21:46663952	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.83	10.32	0.54	3.36e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg22535103	chr8:58192502	C8orf71	-0.92	-10.22	-0.53	6.79e-21	Developmental language disorder (linguistic errors);
CESC	cis	rs4975616	0.773	rs414965	chr5:1324121	G/A	cg26373071	chr5:1325741	CLPTM1L	0.44	6.9	0.39	3.85e-11	Lung cancer;
CESC	cis	rs9649213	0.537	rs6465663	chr7:97918883	C/G	cg00277769	chr7:97922759	BAIAP2L1	-0.35	-5.69	-0.33	3.29e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs2425143	1.000	rs6060524	chr20:34221155	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.88	-7.96	-0.44	5.22e-14	Blood protein levels;
CESC	cis	rs561341	1.000	rs7210970	chr17:30262169	G/A	cg00745463	chr17:30367425	LRRC37B	-0.49	-5.29	-0.31	2.57e-7	Hip circumference adjusted for BMI;
CESC	cis	rs709400	1.000	rs58133129	chr14:104104759	A/G	cg24130564	chr14:104152367	KLC1	-0.42	-5.37	-0.31	1.73e-7	Body mass index;
CESC	cis	rs1448094	0.512	rs11117061	chr12:86250916	G/A	cg00310523	chr12:86230176	RASSF9	0.37	5.71	0.33	3.06e-8	Major depressive disorder;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg23981150	chr1:161111090	NA	-0.49	-6.72	-0.38	1.09e-10	Asthma;
CESC	cis	rs8060686	0.920	rs2292318	chr16:67985706	C/T	cg26727032	chr16:67993705	SLC12A4	-0.56	-6.18	-0.36	2.36e-9	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs818427	0.820	rs712666	chr5:112227939	T/C	cg07820702	chr5:112228657	REEP5	-0.42	-5.24	-0.31	3.32e-7	Total body bone mineral density;
CESC	cis	rs7216064	0.953	rs4790905	chr17:65863350	C/A	cg12091567	chr17:66097778	LOC651250	-0.8	-9.03	-0.49	3.62e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs9325144	0.647	rs11169258	chr12:39113040	C/T	cg26384229	chr12:38710491	ALG10B	-0.53	-7.47	-0.42	1.14e-12	Morning vs. evening chronotype;
CESC	cis	rs4930103	0.935	rs4930110	chr11:2026701	G/C	cg23202291	chr11:1979235	NA	0.37	5.3	0.31	2.5e-7	DNA methylation (parent-of-origin);DNA methylation (variation);
CESC	cis	rs2991971	0.933	rs12568144	chr1:45965307	G/A	cg05343316	chr1:45956843	TESK2	-0.5	-6.51	-0.37	3.79e-10	High light scatter reticulocyte count;
CESC	cis	rs1348850	0.872	rs4893959	chr2:178400204	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.78	10.75	0.55	1.28e-22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs710865	0.541	rs2273046	chr1:19566296	C/T	cg13387374	chr1:19411106	UBR4	-0.49	-5.88	-0.34	1.21e-8	Brain structure;
CESC	cis	rs11583043	0.668	rs6681915	chr1:101558521	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.51	5.54	0.32	7.3e-8	Ulcerative colitis;Inflammatory bowel disease;
CESC	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg07157834	chr1:205819609	PM20D1	0.7	10.53	0.54	6.73e-22	Menarche (age at onset);
CESC	cis	rs80130819	0.688	rs7313023	chr12:48584179	T/C	cg07561017	chr12:48398056	COL2A1	0.39	5.19	0.3	4.22e-7	Prostate cancer;
CESC	cis	rs12705054	1.000	rs17161618	chr7:98801704	A/G	cg08595433	chr7:98102096	NA	0.44	5.57	0.32	6.34e-8	Facial emotion recognition (sad faces);
CESC	cis	rs8013055	0.846	rs12717698	chr14:105979015	G/A	cg23356831	chr14:105996513	TMEM121	0.38	5.2	0.3	4.03e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
CESC	cis	rs9486719	0.948	rs2499813	chr6:96875338	T/C	cg18709589	chr6:96969512	KIAA0776	0.53	5.81	0.34	1.76e-8	Migraine;Coronary artery disease;
CESC	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.55	0.37	2.98e-10	Prudent dietary pattern;
CESC	cis	rs4566357	0.615	rs12328876	chr2:227918899	G/T	cg11843606	chr2:227700838	RHBDD1	-0.54	-7.02	-0.4	1.84e-11	Coronary artery disease;
CESC	cis	rs2637266	0.669	rs2395426	chr10:78462328	T/C	cg18941641	chr10:78392320	NA	0.38	6.66	0.38	1.56e-10	Pulmonary function;
CESC	cis	rs78456975	0.527	rs11886696	chr2:1567841	A/G	cg26248373	chr2:1572462	NA	-0.57	-6.52	-0.37	3.61e-10	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs9910055	0.593	rs58392387	chr17:42297889	A/G	cg08499158	chr17:42289980	UBTF	-0.49	-6.04	-0.35	5.06e-9	Total body bone mineral density;
CESC	cis	rs1862618	0.853	rs252910	chr5:56192983	G/A	cg24549020	chr5:56110836	MAP3K1	0.63	6.69	0.38	1.3100000000000001e-10	Initial pursuit acceleration;
CESC	cis	rs9435341	0.930	rs2232015	chr1:107599258	A/T	cg09367891	chr1:107599246	PRMT6	0.7	8.42	0.46	2.38e-15	Facial morphology (factor 21, depth of nasal alae);
CESC	cis	rs72634030	0.510	rs2641244	chr17:5140385	T/C	cg24500398	chr17:5266808	RABEP1	-0.63	-5.13	-0.3	5.67e-7	Rheumatoid arthritis;
CESC	cis	rs9549367	0.713	rs3024743	chr13:113821430	C/T	cg18105134	chr13:113819100	PROZ	-0.65	-8.04	-0.44	2.96e-14	Platelet distribution width;
CESC	cis	rs10887741	0.646	rs4934355	chr10:89425411	G/A	cg13926569	chr10:89418898	PAPSS2	0.52	8.18	0.45	1.22e-14	Exercise (leisure time);
CESC	cis	rs9811920	0.638	rs7629426	chr3:99652577	C/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.4	5.38	0.31	1.67e-7	Axial length;
CESC	cis	rs875971	0.543	rs801191	chr7:66032955	G/A	cg18876405	chr7:65276391	NA	-0.54	-7.59	-0.42	5.49e-13	Aortic root size;
CESC	cis	rs870825	0.616	rs12498890	chr4:185636096	C/G	cg04058563	chr4:185651563	MLF1IP	-0.63	-7.07	-0.4	1.37e-11	Blood protein levels;
CESC	cis	rs2370759	0.945	rs3740237	chr10:32557592	G/C	cg01819863	chr10:32635814	EPC1	1.15	9.68	0.51	3.48e-19	Sexual dysfunction (female);
CESC	cis	rs7937682	0.575	rs12808601	chr11:111776066	G/A	cg09085632	chr11:111637200	PPP2R1B	0.94	13.08	0.63	1.67e-30	Primary sclerosing cholangitis;
CESC	cis	rs3785574	0.962	rs4968660	chr17:61792221	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.58	7.23	0.41	5.29e-12	Height;
CESC	cis	rs1062177	1.000	rs2016409	chr5:151126324	G/T	cg12924095	chr5:151150029	G3BP1	-0.48	-5.84	-0.34	1.53e-8	Preschool internalizing problems;
CESC	cis	rs7520050	0.966	rs785481	chr1:46554518	G/A	cg03146154	chr1:46216737	IPP	-0.44	-5.69	-0.33	3.34e-8	Red blood cell count;Reticulocyte count;
CESC	cis	rs2997447	0.846	rs61775428	chr1:26409126	G/C	cg24596570	chr1:26146463	FAM54B;LOC646471	0.62	5.23	0.31	3.44e-7	QRS complex (12-leadsum);
CESC	cis	rs9660992	0.573	rs7531256	chr1:205191202	T/G	cg00857998	chr1:205179979	DSTYK	0.54	6.63	0.38	1.93e-10	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs1008375	0.897	rs3733577	chr4:17649233	T/G	cg02297831	chr4:17616191	MED28	0.61	7.82	0.43	1.26e-13	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs7618915	0.524	rs2028216	chr3:52680823	C/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.31	5.56	0.32	6.67e-8	Bipolar disorder;
CESC	cis	rs7586673	0.578	rs6723841	chr2:161879616	G/T	cg08807892	chr2:162101083	NA	0.4	5.09	0.3	6.64e-7	Intelligence (multi-trait analysis);
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg08748207	chr12:46777589	NA	-0.45	-6.09	-0.35	3.89e-9	Height;
CESC	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg21237687	chr17:6899380	ALOX12	0.51	8.9	0.48	9.29e-17	Tonsillectomy;
CESC	cis	rs4665809	0.938	rs4665822	chr2:26312555	C/G	cg25036284	chr2:26402008	FAM59B	-0.58	-6.73	-0.38	1.04e-10	Gut microbiome composition (summer);
CESC	cis	rs8017423	0.630	rs12589687	chr14:90819570	C/G	cg14092571	chr14:90743983	NA	0.44	6.62	0.38	1.93e-10	Mortality in heart failure;
CESC	cis	rs7927592	0.913	rs10896330	chr11:68254998	A/G	cg16797656	chr11:68205561	LRP5	0.41	5.66	0.33	3.96e-8	Total body bone mineral density;
CESC	cis	rs5753618	0.555	rs9609304	chr22:31897795	T/C	cg13145458	chr22:31556086	RNF185	-0.53	-6.2	-0.36	2.11e-9	Colorectal cancer;
CESC	cis	rs453301	0.571	rs2929305	chr8:9085217	G/A	cg15556689	chr8:8085844	FLJ10661	-0.52	-6.59	-0.38	2.31e-10	Joint mobility (Beighton score);
CESC	cis	rs853679	0.517	rs9468298	chr6:28122345	A/G	cg19592336	chr6:28129416	ZNF389	0.61	7.97	0.44	4.74e-14	Depression;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14510504	chr13:77566830	CLN5	-0.54	-6.38	-0.36	7.65e-10	Gut microbiome composition (summer);
CESC	trans	rs7839040	0.672	rs1507095	chr8:82927310	A/T	cg14472086	chr9:107730925	NA	-0.47	-6.33	-0.36	1.02e-9	Response to methotrexate in juvenile idiopathic arthritis;
CESC	cis	rs6088580	0.524	rs6088570	chr20:33268295	T/C	cg08999081	chr20:33150536	PIGU	-0.44	-6.19	-0.36	2.32e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs1799949	0.965	rs8176130	chr17:41258043	C/T	cg23758822	chr17:41437982	NA	1.01	15.76	0.7	6.41e-40	Menopause (age at onset);
CESC	cis	rs2842992	0.915	rs2842985	chr6:160085434	C/T	cg11366901	chr6:160182831	ACAT2	0.81	9.81	0.52	1.44e-19	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs1062177	1.000	rs892006	chr5:151180890	G/T	cg00977110	chr5:151150581	G3BP1	0.66	7.27	0.41	4.05e-12	Preschool internalizing problems;
CESC	cis	rs6500395	1.000	rs3848322	chr16:48620964	C/A	cg04672837	chr16:48644449	N4BP1	0.52	6.56	0.37	2.82e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs5750830	0.649	rs5750814	chr22:39797987	T/C	cg05872129	chr22:39784769	NA	-0.84	-11.68	-0.58	1.03e-25	Intelligence (multi-trait analysis);
CESC	cis	rs35306767	0.761	rs11253558	chr10:1043983	T/C	cg20503657	chr10:835505	NA	0.7	6.33	0.36	1.02e-9	Eosinophil percentage of granulocytes;
CESC	cis	rs67311347	1.000	rs72861689	chr3:40435890	A/G	cg09455208	chr3:40491958	NA	0.42	7.11	0.4	1.1e-11	Renal cell carcinoma;
CESC	cis	rs7666738	0.753	rs10029372	chr4:98859002	T/C	cg17366294	chr4:99064904	C4orf37	0.54	7.48	0.42	1.1e-12	Colonoscopy-negative controls vs population controls;
CESC	cis	rs736408	0.540	rs4687637	chr3:52634092	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.36	6.43	0.37	6.02e-10	Bipolar disorder;
CESC	cis	rs2952156	0.684	rs881844	chr17:37810218	C/G	cg00129232	chr17:37814104	STARD3	-0.8	-11.79	-0.59	4.6e-26	Asthma;
CESC	cis	rs1878931	0.543	rs1129568	chr16:3483475	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.98	15.31	0.69	2.38e-38	Body mass index (adult);
CESC	cis	rs67478160	0.619	rs12878682	chr14:104233627	G/C	cg08213375	chr14:104286397	PPP1R13B	0.55	11.09	0.56	9.71e-24	Schizophrenia;
CESC	trans	rs7715474	0.706	rs7728674	chr5:120097719	G/C	cg12384126	chr1:185285600	IVNS1ABP	-0.46	-6.02	-0.35	5.66e-9	Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs11792861	0.888	rs75543406	chr9:111816903	A/T	cg05043794	chr9:111880884	C9orf5	-0.39	-6.4	-0.37	6.82e-10	Menarche (age at onset);
CESC	cis	rs514406	0.621	rs1930306	chr1:53195686	C/G	cg24675658	chr1:53192096	ZYG11B	0.68	8.64	0.47	5.45e-16	Monocyte count;
CESC	cis	rs10949834	0.504	rs77541100	chr7:73555605	C/T	cg07137043	chr7:73588983	EIF4H	-0.64	-6.94	-0.39	2.98e-11	Verbal memory performance (residualized delayed recall change);
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg17164693	chr10:124913828	BUB3	-0.47	-6.16	-0.35	2.65e-9	Height;
CESC	cis	rs965469	0.948	rs6139079	chr20:3314374	C/T	cg25506879	chr20:3388711	C20orf194	0.49	5.28	0.31	2.71e-7	IFN-related cytopenia;
CESC	cis	rs863345	0.604	rs12064489	chr1:158499449	T/C	cg12129480	chr1:158549410	OR10X1	-0.34	-6.84	-0.39	5.41e-11	Pneumococcal bacteremia;
CESC	cis	rs11031096	0.503	rs67065286	chr11:4105273	A/C	cg18678763	chr11:4115507	RRM1	-0.53	-7.13	-0.4	9.42e-12	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	cis	rs7395581	0.959	rs901746	chr11:47260319	A/G	cg25783544	chr11:47291846	MADD	0.56	7.2	0.4	6.35e-12	HDL cholesterol;
CESC	cis	rs763121	0.853	rs6001185	chr22:39052155	G/A	cg06022373	chr22:39101656	GTPBP1	0.88	13.91	0.65	2.06e-33	Menopause (age at onset);
CESC	cis	rs2952156	0.920	rs2934953	chr17:37832315	T/A	cg20243544	chr17:37824526	PNMT	0.6	7.35	0.41	2.46e-12	Asthma;
CESC	cis	rs2425143	1.000	rs8124505	chr20:34307247	C/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.61	5.28	0.31	2.7e-7	Blood protein levels;
CESC	cis	rs9733	0.791	rs11204693	chr1:150647987	C/T	cg22823121	chr1:150693482	HORMAD1	-0.38	-5.95	-0.34	8.59e-9	Tonsillectomy;
CESC	cis	rs35110281	0.837	rs7279958	chr21:45016016	C/A	cg04455712	chr21:45112962	RRP1B	0.39	5.88	0.34	1.24e-8	Mean corpuscular volume;
CESC	cis	rs7959452	0.535	rs10878953	chr12:69674187	A/G	cg14784868	chr12:69753453	YEATS4	0.66	9.07	0.49	2.78e-17	Blood protein levels;
CESC	cis	rs12477438	0.798	rs4622780	chr2:99631760	C/G	cg08885076	chr2:99613938	TSGA10	-0.38	-5.06	-0.3	7.82e-7	Chronic sinus infection;
CESC	cis	rs7659604	0.702	rs6815790	chr4:122695385	A/C	cg06713675	chr4:122721982	EXOSC9	-0.43	-6.13	-0.35	3.16e-9	Type 2 diabetes;
CESC	cis	rs4689388	0.889	rs10026334	chr4:6294607	G/A	cg14416269	chr4:6271139	WFS1	0.46	7.76	0.43	1.79e-13	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs2243480	1.000	rs7787230	chr7:65629099	G/A	cg12463550	chr7:65579703	CRCP	-0.73	-5.71	-0.33	3.1e-8	Diabetic kidney disease;
CESC	cis	rs4835473	0.900	rs67600034	chr4:144655823	C/A	cg25736465	chr4:144833511	NA	-0.33	-5.22	-0.31	3.68e-7	Immature fraction of reticulocytes;
CESC	cis	rs2932538	0.922	rs11102508	chr1:113141175	T/C	cg22162597	chr1:113214053	CAPZA1	0.49	6.48	0.37	4.46e-10	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06538998	chr16:28503160	CLN3	0.54	6.82	0.39	6.01e-11	Gut microbiome composition (summer);
CESC	cis	rs10887741	0.646	rs11202499	chr10:89433211	C/G	cg13926569	chr10:89418898	PAPSS2	0.46	6.86	0.39	4.96e-11	Exercise (leisure time);
CESC	cis	rs74181299	0.964	rs2540949	chr2:65284231	A/T	cg05010058	chr2:65284262	CEP68	0.34	6.14	0.35	2.99e-9	Pulse pressure;
CESC	cis	rs17666538	0.792	rs7820788	chr8:601846	C/T	cg07234876	chr8:600039	NA	0.83	6.53	0.37	3.39e-10	IgG glycosylation;
CESC	cis	rs7923609	0.967	rs10761752	chr10:65160321	T/C	cg01631684	chr10:65280961	REEP3	-0.43	-5.41	-0.32	1.41e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs34172651	0.517	rs2303083	chr16:24835168	G/A	cg06028605	chr16:24865363	SLC5A11	0.55	7.29	0.41	3.51e-12	Intelligence (multi-trait analysis);
CESC	cis	rs7692995	1.000	rs73098848	chr4:17941027	G/C	cg08925142	chr4:18023851	LCORL	-0.46	-5.29	-0.31	2.59e-7	Height;
CESC	cis	rs4853012	0.775	rs12465641	chr2:74337715	A/G	cg19729930	chr2:74357872	NA	-0.72	-10.19	-0.53	8.94e-21	Gestational age at birth (maternal effect);
CESC	cis	rs13102973	0.965	rs6838419	chr4:135875682	T/C	cg14419869	chr4:135874104	NA	-0.37	-5.78	-0.33	2.06e-8	Subjective well-being;
CESC	cis	rs1018836	0.847	rs4735225	chr8:91569100	G/C	cg16814680	chr8:91681699	NA	-0.72	-10.29	-0.53	4.01e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs208520	0.779	rs208451	chr6:66906155	G/A	cg07460842	chr6:66804631	NA	-0.86	-10.11	-0.53	1.55e-20	Exhaled nitric oxide output;
CESC	cis	rs8058578	0.945	rs885107	chr16:30672719	T/C	cg00531865	chr16:30841666	NA	-0.44	-5.88	-0.34	1.25e-8	Multiple myeloma;
CESC	cis	rs7937682	0.961	rs7119563	chr11:111543916	T/A	cg09085632	chr11:111637200	PPP2R1B	1.02	13.65	0.64	1.69e-32	Primary sclerosing cholangitis;
CESC	cis	rs589448	0.902	rs315113	chr12:69786543	G/T	cg20891283	chr12:69753455	YEATS4	-0.85	-13.98	-0.65	1.18e-33	Cerebrospinal fluid biomarker levels;
CESC	cis	rs3768617	0.510	rs10752895	chr1:183068505	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.88	14.25	0.66	1.3600000000000001e-34	Fuchs's corneal dystrophy;
CESC	cis	rs447	1.000	rs2067693	chr7:83759570	C/T	cg22846510	chr7:83753280	SEMA3A	-0.44	-5.38	-0.31	1.64e-7	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs12155623	0.619	rs11775403	chr8:49877323	A/T	cg22283653	chr8:49824208	NA	0.36	5.34	0.31	2.04e-7	Sudden cardiac arrest;
CESC	cis	rs11792861	0.619	rs2289481	chr9:111712924	G/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.62	9.52	0.5	1.17e-18	Menarche (age at onset);
CESC	cis	rs2243480	1.000	rs2177703	chr7:65391717	C/A	cg18252515	chr7:66147081	NA	-1.0	-9.22	-0.49	9.27e-18	Diabetic kidney disease;
CESC	cis	rs9814567	1.000	rs12637751	chr3:134266124	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.45	6.08	0.35	4.21e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs35110281	0.667	rs4819288	chr21:45120173	C/G	cg21573476	chr21:45109991	RRP1B	-0.56	-7.99	-0.44	4.19e-14	Mean corpuscular volume;
CESC	cis	rs6484504	0.532	rs12222329	chr11:31274340	T/C	cg14844989	chr11:31128820	NA	-0.41	-5.69	-0.33	3.43e-8	Red blood cell count;
CESC	cis	rs6032067	0.852	rs17333180	chr20:43803708	C/A	cg11264863	chr20:43835661	SEMG1	0.5	5.41	0.32	1.41e-7	Blood protein levels;
CESC	cis	rs919433	1.000	rs1346649	chr2:198166117	C/A	cg03934865	chr2:198174659	NA	-0.45	-6.82	-0.39	6.16e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs4665809	1.000	rs7588802	chr2:26277789	A/G	cg08470875	chr2:26401718	FAM59B	-0.55	-6.0	-0.35	6.49e-9	Gut microbiome composition (summer);
CESC	cis	rs1348850	0.872	rs4893825	chr2:178298687	A/G	cg22681709	chr2:178499509	PDE11A	-0.38	-5.26	-0.31	2.98e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs7216064	1.000	rs9913471	chr17:65874495	C/T	cg12091567	chr17:66097778	LOC651250	-0.81	-9.16	-0.49	1.48e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs11785400	0.963	rs6990126	chr8:143728387	T/C	cg24634471	chr8:143751801	JRK	0.45	5.84	0.34	1.5e-8	Schizophrenia;
CESC	cis	rs7829975	0.514	rs2976926	chr8:8261624	T/C	cg15556689	chr8:8085844	FLJ10661	0.59	7.71	0.43	2.59e-13	Mood instability;
CESC	cis	rs875971	0.545	rs17138149	chr7:65693180	A/G	cg11764359	chr7:65958608	NA	0.76	9.55	0.51	9.29e-19	Aortic root size;
CESC	cis	rs9815354	0.761	rs73079307	chr3:41862273	A/C	cg03022575	chr3:42003672	ULK4	0.69	6.07	0.35	4.53e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs9486719	0.843	rs2499789	chr6:96844510	T/C	cg18709589	chr6:96969512	KIAA0776	0.55	5.64	0.33	4.26e-8	Migraine;Coronary artery disease;
CESC	cis	rs5769765	0.908	rs4074304	chr22:50309446	G/A	cg26441486	chr22:50317300	CRELD2	0.42	5.24	0.31	3.33e-7	Schizophrenia;
CESC	cis	rs3820068	0.580	rs12760698	chr1:16009814	G/A	cg18133145	chr1:16060689	PLEKHM2	-0.4	-5.05	-0.3	8.31e-7	Systolic blood pressure;
CESC	cis	rs8114671	0.562	rs4911450	chr20:33512406	C/T	cg07148914	chr20:33460835	GGT7	0.52	6.8	0.39	6.88e-11	Height;
CESC	cis	rs4689592	0.546	rs2359012	chr4:7066053	A/C	cg26116260	chr4:7069785	GRPEL1	0.98	14.45	0.66	2.76e-35	Monocyte percentage of white cells;
CESC	cis	rs7147624	0.882	rs1956008	chr14:66085429	G/T	cg03016385	chr14:66212404	NA	-0.52	-5.26	-0.31	3.01e-7	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs561341	1.000	rs546519	chr17:30297682	T/G	cg00745463	chr17:30367425	LRRC37B	-0.7	-7.02	-0.4	1.85e-11	Hip circumference adjusted for BMI;
CESC	cis	rs1707322	0.752	rs12047629	chr1:46162802	G/A	cg03146154	chr1:46216737	IPP	0.82	11.53	0.58	3.39e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs4727027	0.933	rs1044358	chr7:148879951	C/A	cg23158103	chr7:148848205	ZNF398	-0.41	-6.54	-0.37	3.15e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs10197940	0.901	rs2290367	chr2:152266731	T/A	cg19508488	chr2:152266495	RIF1	0.62	8.28	0.45	6.1e-15	Lung cancer;
CESC	cis	rs17376456	0.877	rs13156865	chr5:93390908	C/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.62	5.36	0.31	1.81e-7	Diabetic retinopathy;
CESC	cis	rs60871478	0.578	rs62432900	chr7:826794	G/C	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.57	5.61	0.33	4.98e-8	Cerebrospinal P-tau181p levels;
CESC	cis	rs2280018	0.526	rs2966128	chr16:15153389	G/T	cg27102117	chr16:15229624	NA	0.53	7.89	0.44	7.75e-14	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs875971	0.862	rs778702	chr7:65864835	G/A	cg18876405	chr7:65276391	NA	0.5	6.87	0.39	4.63e-11	Aortic root size;
CESC	cis	rs13118159	0.778	rs12650998	chr4:1338832	T/C	cg20887711	chr4:1340912	KIAA1530	0.45	6.07	0.35	4.4e-9	Longevity;
CESC	cis	rs2243480	0.614	rs34032527	chr7:65565141	C/G	cg18252515	chr7:66147081	NA	-1.39	-13.81	-0.65	4.83e-33	Diabetic kidney disease;
CESC	cis	rs9916302	0.904	rs8065963	chr17:37681332	C/T	cg15445000	chr17:37608096	MED1	0.42	6.99	0.39	2.21e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs798766	1.000	rs4865463	chr4:1742400	T/C	cg05874882	chr4:1763078	NA	-0.58	-8.03	-0.44	3.23e-14	Bladder cancer;Urinary bladder cancer;
CESC	cis	rs6991838	0.551	rs7007505	chr8:66533954	C/G	cg13398993	chr8:66546079	ARMC1	0.46	5.65	0.33	4.19e-8	Intelligence (multi-trait analysis);
CESC	cis	rs6460942	0.915	rs7803051	chr7:12306904	A/T	cg02935154	chr7:12443704	VWDE	-0.42	-5.58	-0.32	5.91e-8	Coronary artery disease;
CESC	cis	rs17253792	0.822	rs76612185	chr14:56037706	T/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.86	5.67	0.33	3.75e-8	Putamen volume;
CESC	cis	rs1538970	0.924	rs12037201	chr1:45941349	G/T	cg05343316	chr1:45956843	TESK2	0.9	12.39	0.61	4.15e-28	Platelet count;
CESC	cis	rs9916302	0.904	rs801419	chr17:37466327	A/G	cg00129232	chr17:37814104	STARD3	0.51	6.35	0.36	9.57e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs9916302	0.904	rs585961	chr17:37444036	G/A	cg15445000	chr17:37608096	MED1	-0.42	-6.81	-0.39	6.69e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs12545109	0.800	rs1467124	chr8:57418862	T/G	cg09654669	chr8:57350985	NA	-0.45	-6.27	-0.36	1.47e-9	Obesity-related traits;
CESC	cis	rs6496667	0.865	rs7171617	chr15:90904858	G/A	cg22089800	chr15:90895588	ZNF774	0.55	5.58	0.32	5.8e-8	Rheumatoid arthritis;
CESC	cis	rs13385	0.769	rs6878006	chr5:139595751	T/C	cg26211634	chr5:139558579	C5orf32	0.46	5.13	0.3	5.68e-7	Atrial fibrillation;
CESC	cis	rs7833790	0.685	rs13255262	chr8:82728024	T/G	cg07697082	chr8:82753677	SNX16	0.41	6.22	0.36	1.92e-9	Diastolic blood pressure;
CESC	cis	rs2836974	0.568	rs377098	chr21:40535216	G/A	cg27266027	chr21:40555129	PSMG1	-0.4	-5.13	-0.3	5.63e-7	Cognitive function;
CESC	cis	rs9596863	1.000	rs9536557	chr13:54433190	A/G	ch.13.53330881F	chr13:54432880	NA	-0.63	-5.37	-0.31	1.74e-7	Epilepsy and lamotrigine-induced maculopapular eruptions;
CESC	cis	rs6693567	0.545	rs7553647	chr1:150472666	C/T	cg09579323	chr1:150459698	TARS2	0.47	5.73	0.33	2.76e-8	Migraine;
CESC	cis	rs2251381	0.778	rs2471947	chr21:30534219	G/T	cg24692254	chr21:30365293	RNF160	0.77	10.32	0.54	3.25e-21	Selective IgA deficiency;
CESC	trans	rs698833	0.669	rs1584885	chr2:44647038	A/C	cg02851237	chr16:84650990	COTL1	-0.46	-6.07	-0.35	4.39e-9	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs3540	0.554	rs12900987	chr15:91071776	T/C	cg22089800	chr15:90895588	ZNF774	-0.64	-8.42	-0.46	2.39e-15	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs9733	0.621	rs6669122	chr1:150591732	A/G	cg17724175	chr1:150552817	MCL1	-0.33	-5.38	-0.31	1.6e-7	Tonsillectomy;
CESC	cis	rs7107174	0.892	rs11601195	chr11:78073501	A/G	cg02023728	chr11:77925099	USP35	0.47	6.23	0.36	1.82e-9	Testicular germ cell tumor;
CESC	cis	rs3008870	0.958	rs12143044	chr1:67460054	A/T	cg02640540	chr1:67518911	SLC35D1	-0.51	-5.58	-0.32	5.89e-8	Lymphocyte percentage of white cells;
CESC	cis	rs4665809	1.000	rs1550382	chr2:26266877	T/G	cg08470875	chr2:26401718	FAM59B	-0.48	-5.23	-0.31	3.44e-7	Gut microbiome composition (summer);
CESC	cis	rs4787484	1.000	rs7189750	chr16:29911416	G/A	cg01827781	chr16:29875145	LOC440356;CDIPT	0.36	5.05	0.3	8.21e-7	Response to taxane treatment (placlitaxel);
CESC	cis	rs1879734	0.731	rs7512093	chr1:54163207	T/G	cg23596471	chr1:54105337	GLIS1	0.33	5.41	0.32	1.38e-7	Mitral valve prolapse;
CESC	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	13.72	0.64	9.9e-33	Prudent dietary pattern;
CESC	cis	rs9403521	1.000	rs12208927	chr6:143993634	A/G	cg21026257	chr6:143998961	PHACTR2	0.49	5.34	0.31	2.05e-7	Obesity-related traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14328907	chr9:125590265	PDCL	0.58	6.52	0.37	3.58e-10	Gut microbiome composition (summer);
CESC	cis	rs1005277	0.579	rs1621040	chr10:38497232	T/C	cg00409905	chr10:38381863	ZNF37A	-0.51	-6.91	-0.39	3.63e-11	Extrinsic epigenetic age acceleration;
CESC	cis	rs9309473	0.898	rs11126404	chr2:73796924	T/A	cg20560298	chr2:73613845	ALMS1	-0.48	-6.51	-0.37	3.74e-10	Metabolite levels;
CESC	cis	rs7811142	0.943	rs28660238	chr7:100023308	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.9	9.78	0.51	1.73e-19	Platelet count;
CESC	trans	rs2121875	0.667	rs10043545	chr5:44220474	T/A	cg07292773	chr6:156718177	NA	-0.47	-6.01	-0.35	6.16e-9	Prostate cancer;
CESC	trans	rs12599106	0.584	rs12929704	chr16:34898258	C/A	cg01516881	chr6:292596	DUSP22	-0.84	-11.29	-0.57	2.11e-24	Menopause (age at onset);
CESC	cis	rs17253792	0.822	rs17253744	chr14:56161950	C/G	cg01858014	chr14:56050164	KTN1	-0.98	-7.55	-0.42	6.95e-13	Putamen volume;
CESC	cis	rs10504229	1.000	rs60454728	chr8:58173781	G/A	cg05313129	chr8:58192883	C8orf71	-0.55	-6.37	-0.36	8.42e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs12477438	0.520	rs4851188	chr2:99745898	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.78	13.4	0.64	1.33e-31	Chronic sinus infection;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14410072	chr9:139838381	C8G;FBXW5	0.56	6.55	0.37	3.06e-10	Gut microbiome composition (summer);
CESC	cis	rs6831352	1.000	rs6532798	chr4:100054827	C/T	cg12011299	chr4:100065546	ADH4	0.69	8.57	0.47	8.82e-16	Alcohol dependence;
CESC	cis	rs2991971	1.000	rs518365	chr1:46010652	A/G	cg03146154	chr1:46216737	IPP	-0.44	-5.5	-0.32	8.79e-8	High light scatter reticulocyte count;
CESC	cis	rs7116495	0.609	rs6592457	chr11:71738086	G/C	cg07596299	chr11:71824057	C11orf51	-0.85	-5.06	-0.3	7.92e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs910316	0.712	rs175037	chr14:75465038	T/C	cg16144293	chr14:75469539	EIF2B2	0.41	5.43	0.32	1.24e-7	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10681125	chr19:18316102	RAB3A	-0.56	-6.42	-0.37	6.13e-10	Gut microbiome composition (summer);
CESC	cis	rs1552244	1.000	rs9824585	chr3:10114802	T/C	cg08888203	chr3:10149979	C3orf24	0.53	6.83	0.39	5.8200000000000003e-11	Alzheimer's disease;
CESC	cis	rs9910055	0.529	rs228766	chr17:42186813	A/G	cg13607699	chr17:42295918	UBTF	-0.45	-5.49	-0.32	9.28e-8	Total body bone mineral density;
CESC	cis	rs2276314	1.000	rs62101367	chr18:33550884	C/T	cg19628046	chr18:33552617	C18orf21	0.6	6.7	0.38	1.28e-10	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs71277158	0.688	rs2287478	chr3:169788105	A/C	cg04067573	chr3:169899625	PHC3	0.72	7.1	0.4	1.16e-11	Prostate cancer;
CESC	cis	rs4604732	0.578	rs12038656	chr1:247623816	A/G	cg12758973	chr1:247694275	LOC148824;OR2C3	0.49	6.04	0.35	5.16e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12444081	chr17:16521159	NA	-0.66	-7.9	-0.44	7.47e-14	Gut microbiome composition (summer);
CESC	cis	rs7772486	0.790	rs2256998	chr6:146207657	A/C	cg23711669	chr6:146136114	FBXO30	0.92	13.35	0.63	1.96e-31	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1034435	0.755	rs5768680	chr22:48892919	T/C	cg05992904	chr22:48892994	FAM19A5	-0.57	-9.8	-0.52	1.53e-19	Late-onset Alzheimer's disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg11122301	chr12:122255844	SETD1B	0.46	6.15	0.35	2.91e-9	Fibrinogen levels;
CESC	cis	rs6690583	1.000	rs2304641	chr1:85513398	C/T	cg11262906	chr1:85462892	MCOLN2	0.51	5.28	0.31	2.71e-7	Serum sulfate level;
CESC	cis	rs10885582	0.781	rs10159857	chr10:116294870	C/A	cg17056676	chr10:116301354	ABLIM1	-0.28	-5.14	-0.3	5.47e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs12912251	0.500	rs2643204	chr15:39007171	C/T	cg10631289	chr15:39006617	NA	-0.49	-5.31	-0.31	2.27e-7	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
CESC	cis	rs4568518	0.616	rs13223642	chr7:18004975	C/T	cg03009463	chr7:17980271	SNX13	0.43	5.66	0.33	3.88e-8	Measles;
CESC	cis	rs7267979	0.903	rs1118963	chr20:25247449	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.82	15.08	0.68	1.65e-37	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs3026101	0.671	rs3026128	chr17:5293962	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.43	5.68	0.33	3.57e-8	Body mass index;
CESC	cis	rs829883	0.934	rs249814	chr12:98892964	A/G	cg25150519	chr12:98850993	NA	0.71	9.74	0.51	2.31e-19	Colorectal adenoma (advanced);
CESC	cis	rs977987	0.800	rs4888378	chr16:75332041	A/G	cg03315344	chr16:75512273	CHST6	0.38	5.47	0.32	1.06e-7	Dupuytren's disease;
CESC	cis	rs6500395	0.928	rs2080509	chr16:48690915	T/C	cg04672837	chr16:48644449	N4BP1	-0.51	-6.37	-0.36	8.27e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs1008375	0.932	rs6841784	chr4:17626418	G/A	cg02297831	chr4:17616191	MED28	0.63	7.97	0.44	4.82e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12575136	chr18:32820987	ZNF397	0.53	6.25	0.36	1.6e-9	Gut microbiome composition (summer);
CESC	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg14159672	chr1:205819179	PM20D1	-0.72	-9.63	-0.51	5.21e-19	Menarche (age at onset);
CESC	cis	rs950776	0.706	rs11636753	chr15:78928946	G/T	cg06917634	chr15:78832804	PSMA4	0.51	6.44	0.37	5.49e-10	Sudden cardiac arrest;
CESC	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg03188948	chr7:1209495	NA	0.69	7.66	0.43	3.45e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs3845702	0.736	rs6722147	chr2:180829704	G/A	cg01881094	chr2:180872142	CWC22	-1.06	-9.19	-0.49	1.18e-17	Schizophrenia;
CESC	cis	rs7178572	0.568	rs12909924	chr15:77551445	T/G	cg22256960	chr15:77711686	NA	-0.53	-6.78	-0.38	7.79e-11	Type 2 diabetes;
CESC	cis	rs12928939	0.517	rs9940234	chr16:71964805	C/T	cg03805757	chr16:71968109	PKD1L3	-0.56	-6.37	-0.36	8.44e-10	Post bronchodilator FEV1;
CESC	cis	rs172166	0.637	rs1071893	chr6:28167635	G/C	cg19592336	chr6:28129416	ZNF389	0.43	6.21	0.36	2.05e-9	Cardiac Troponin-T levels;
CESC	cis	rs13191362	1.000	rs34773528	chr6:163088796	G/C	cg18825119	chr6:163149453	PACRG;PARK2	0.51	5.07	0.3	7.6e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs13191362	1.000	rs34398656	chr6:162999612	G/T	cg14584255	chr6:163149320	PACRG;PARK2	0.49	5.34	0.31	2.01e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs684232	0.623	rs391002	chr17:535441	T/G	cg15660573	chr17:549704	VPS53	-0.8	-11.72	-0.58	7.73e-26	Prostate cancer;
CESC	cis	rs10504229	1.000	rs66870803	chr8:58180022	G/C	cg24829409	chr8:58192753	C8orf71	-0.76	-10.0	-0.52	3.53e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs4704187	0.687	rs4447963	chr5:74376309	A/C	cg03227963	chr5:74354835	NA	0.32	5.95	0.34	8.68e-9	Response to amphetamines;
CESC	cis	rs798554	0.959	rs798558	chr7:2758935	T/G	cg19346786	chr7:2764209	NA	-0.46	-6.72	-0.38	1.14e-10	Height;
CESC	cis	rs7584330	0.554	rs13431733	chr2:238430275	A/G	cg14458575	chr2:238380390	NA	0.48	5.3	0.31	2.4e-7	Prostate cancer;
CESC	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg24829409	chr8:58192753	C8orf71	-0.67	-8.18	-0.45	1.19e-14	Developmental language disorder (linguistic errors);
CESC	cis	rs3096299	0.967	rs28575874	chr16:89469890	C/T	cg16743903	chr16:89593216	SPG7	-0.41	-5.2	-0.3	4.03e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs748404	0.660	rs2439846	chr15:43740970	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	8.23	0.45	8.36e-15	Lung cancer;
CESC	cis	rs7615952	0.599	rs2333408	chr3:125732098	G/A	cg04553112	chr3:125709451	NA	-0.48	-5.38	-0.31	1.65e-7	Blood pressure (smoking interaction);
CESC	cis	rs9818758	0.607	rs12715434	chr3:49295025	G/C	cg00383909	chr3:49044727	WDR6	0.8	6.18	0.36	2.36e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CESC	cis	rs1218582	0.744	rs6674853	chr1:154892753	G/C	cg06221963	chr1:154839813	KCNN3	-0.66	-10.93	-0.56	3.29e-23	Prostate cancer;
CESC	cis	rs11098499	0.909	rs9994810	chr4:120381590	A/G	cg09307838	chr4:120376055	NA	0.96	13.95	0.65	1.6e-33	Corneal astigmatism;
CESC	cis	rs763121	0.853	rs35522482	chr22:39063015	C/A	cg06022373	chr22:39101656	GTPBP1	0.88	13.95	0.65	1.51e-33	Menopause (age at onset);
CESC	cis	rs8177179	0.967	rs10935085	chr3:133459735	C/T	cg17775713	chr3:133465469	TF	0.33	5.85	0.34	1.44e-8	Iron status biomarkers (transferrin levels);
CESC	cis	rs909674	0.818	rs5757681	chr22:39845547	A/G	cg11247378	chr22:39784982	NA	-0.6	-8.25	-0.45	7.72e-15	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs2235544	0.579	rs1537321	chr1:54482236	C/A	cg09175620	chr1:54484536	LDLRAD1	-0.3	-5.49	-0.32	9.48e-8	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
CESC	cis	rs736408	0.509	rs3774349	chr3:52722335	A/C	cg18404041	chr3:52824283	ITIH1	-0.35	-6.36	-0.36	8.79e-10	Bipolar disorder;
CESC	cis	rs10256972	0.685	rs10263665	chr7:1110628	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.45	-5.64	-0.33	4.44e-8	Longevity;Endometriosis;
CESC	cis	rs4836694	0.574	rs3824542	chr9:132936132	C/T	cg05251000	chr9:132935664	FREQ	0.48	6.16	0.35	2.68e-9	Alzheimer's disease (cognitive decline);
CESC	cis	rs10242455	0.571	rs11972210	chr7:99206943	A/C	cg25640893	chr7:99214727	ZNF498	0.74	5.69	0.33	3.4e-8	Blood metabolite levels;
CESC	cis	rs7264396	0.676	rs58372200	chr20:34555445	C/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.52	6.18	0.36	2.37e-9	Total cholesterol levels;
CESC	cis	rs853679	0.550	rs1233704	chr6:28166923	A/G	cg17949981	chr6:28129498	ZNF389	-0.39	-5.15	-0.3	5.2e-7	Depression;
CESC	cis	rs801193	0.569	rs13226966	chr7:66233623	A/G	cg10691866	chr7:65817282	TPST1	-0.33	-5.64	-0.33	4.41e-8	Aortic root size;
CESC	cis	rs668210	0.739	rs1151511	chr11:65756283	A/G	cg02202077	chr11:65769826	EIF1AD;BANF1	0.69	7.56	0.42	6.56e-13	Cerebrospinal fluid biomarker levels;
CESC	cis	rs763121	0.819	rs5757160	chr22:38989646	T/C	cg06544989	chr22:39130855	UNC84B	0.5	9.21	0.49	1e-17	Menopause (age at onset);
CESC	cis	rs12188164	0.965	rs11739543	chr5:443676	G/A	cg26850624	chr5:429559	AHRR	-0.5	-6.67	-0.38	1.52e-10	Cystic fibrosis severity;
CESC	cis	rs2440129	0.611	rs434473	chr17:6904934	A/G	cg19294448	chr17:6900799	ALOX12	-0.33	-5.23	-0.31	3.41e-7	Tonsillectomy;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg13825663	chr2:96873994	STARD7	-0.45	-6.0	-0.35	6.56e-9	Fibrinogen levels;
CESC	cis	rs7552404	0.961	rs1767458	chr1:76219155	A/G	cg22875332	chr1:76189707	ACADM	0.7	9.65	0.51	4.56e-19	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs5498	0.809	rs2075742	chr19:10401607	G/C	cg22910295	chr19:10403862	ICAM5	0.42	5.93	0.34	9.22e-9	Lymphocyte counts;Soluble ICAM-1;Blood protein levels;
CESC	cis	rs9309473	0.898	rs10185080	chr2:73797507	C/A	cg20560298	chr2:73613845	ALMS1	-0.54	-7.11	-0.4	1.1e-11	Metabolite levels;
CESC	cis	rs7208859	0.623	rs216436	chr17:28922900	G/A	cg14008862	chr17:28927542	LRRC37B2	0.76	5.62	0.33	4.85e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs2425143	1.000	rs56904633	chr20:34400757	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.79	-7.2	-0.4	6.33e-12	Blood protein levels;
CESC	cis	rs1008375	0.966	rs1476836	chr4:17585014	G/C	cg27347728	chr4:17578864	LAP3	0.46	5.49	0.32	9.24e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs6736093	0.966	rs13020304	chr2:112741535	A/G	cg12686935	chr2:112915763	FBLN7	-0.42	-5.45	-0.32	1.17e-7	Coronary artery disease;
CESC	cis	rs3936840	0.539	rs3742441	chr14:102970581	C/G	cg18135206	chr14:102964638	TECPR2	0.4	5.07	0.3	7.37e-7	Plateletcrit;
CESC	cis	rs1316952	0.667	rs76411891	chr12:124388236	A/G	cg00084347	chr12:124393913	DNAH10	0.4	5.55	0.32	6.78e-8	Visceral adipose tissue adjusted for BMI;Visceral adipose tissue/subcutaneous adipose tissue ratio;
CESC	cis	rs1552244	0.882	rs66559400	chr3:10012551	G/A	cg00149659	chr3:10157352	C3orf10	0.7	8.25	0.45	7.27e-15	Alzheimer's disease;
CESC	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	10.31	0.54	3.45e-21	Prudent dietary pattern;
CESC	cis	rs8092503	1.000	rs2009198	chr18:52480795	A/G	cg12377874	chr18:52495404	RAB27B	0.38	6.2	0.36	2.13e-9	Childhood body mass index;
CESC	cis	rs7917772	0.636	rs7088981	chr10:104520423	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.44	-5.1	-0.3	6.44e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg03188948	chr7:1209495	NA	0.53	5.98	0.35	7.04e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs6460942	0.731	rs7799372	chr7:12233784	T/A	cg06484146	chr7:12443880	VWDE	-0.47	-5.22	-0.31	3.54e-7	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03425468	chr1:155164676	MIR92B	0.59	7.12	0.4	1e-11	Gut microbiome composition (summer);
CESC	cis	rs11098499	0.909	rs11723757	chr4:120299669	C/T	cg09307838	chr4:120376055	NA	0.92	12.66	0.61	4.96e-29	Corneal astigmatism;
CESC	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg06873352	chr17:61820015	STRADA	0.72	12.61	0.61	7.14e-29	Prudent dietary pattern;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10024446	chr10:22048429	DNAJC1	-0.58	-6.13	-0.35	3.1e-9	Gut microbiome composition (summer);
CESC	cis	rs644799	1.000	rs644799	chr11:95564259	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.69	8.85	0.48	1.3e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs6752107	0.967	rs10210302	chr2:234158839	C/T	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.35	5.46	0.32	1.11e-7	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs7225537	0.559	rs3744138	chr17:17045861	C/T	cg20098446	chr17:17120238	FLCN	0.33	5.13	0.3	5.68e-7	Mean platelet volume;
CESC	cis	rs10131894	0.611	rs175000	chr14:75436367	T/C	cg08847533	chr14:75593920	NEK9	-0.76	-12.23	-0.6	1.43e-27	Coronary artery disease;
CESC	cis	rs514406	0.861	rs2065477	chr1:53250213	C/T	cg08736216	chr1:53307985	ZYG11A	-0.42	-7.07	-0.4	1.34e-11	Monocyte count;
CESC	cis	rs13067593	1.000	rs67563589	chr3:188564574	G/C	cg17809494	chr3:188572244	LPP	0.35	5.13	0.3	5.74e-7	Immune reponse to smallpox (secreted IFN-alpha);
CESC	cis	rs870825	0.616	rs61653735	chr4:185630025	G/A	cg04058563	chr4:185651563	MLF1IP	0.64	7.02	0.4	1.86e-11	Blood protein levels;
CESC	cis	rs9303401	0.625	rs34963822	chr17:56988424	C/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.99	12.05	0.59	5.91e-27	Cognitive test performance;
CESC	cis	rs1707322	0.752	rs28438704	chr1:46170544	G/A	cg06784218	chr1:46089804	CCDC17	0.43	7.58	0.42	5.65e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs17116334	1.000	rs17116334	chr11:113961762	C/T	cg21254083	chr11:119598909	PVRL1	0.56	6.48	0.37	4.52e-10	Conduct disorder (maternal expressed emotions interaction);
CESC	cis	rs7208859	0.623	rs76633166	chr17:29113365	C/T	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.1e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs8067354	0.645	rs2102507	chr17:57875907	A/G	cg02344993	chr17:57696989	CLTC	0.67	8.28	0.45	6.3e-15	Hemoglobin concentration;
CESC	cis	rs1005277	0.579	rs2472182	chr10:38388865	T/C	cg00409905	chr10:38381863	ZNF37A	-0.47	-6.3	-0.36	1.23e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs763014	0.966	rs4984904	chr16:680809	C/G	cg07256732	chr16:621771	PIGQ	-0.31	-5.38	-0.31	1.67e-7	Height;
CESC	cis	rs910316	0.712	rs175074	chr14:75504454	G/A	cg11812906	chr14:75593930	NEK9	-0.8	-13.04	-0.63	2.33e-30	Height;
CESC	trans	rs11039798	0.925	rs7482967	chr11:48613527	T/A	cg15704280	chr7:45808275	SEPT13	0.65	6.28	0.36	1.39e-9	Axial length;
CESC	cis	rs11608355	0.705	rs6663	chr12:109886603	G/A	cg05360138	chr12:110035743	NA	0.53	5.9	0.34	1.08e-8	Neuroticism;
CESC	cis	rs6500395	0.890	rs9936445	chr16:48617754	T/G	cg04672837	chr16:48644449	N4BP1	0.47	5.82	0.34	1.72e-8	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs761746	0.672	rs2236033	chr22:32001050	A/G	cg25791279	chr22:32026902	PISD	-0.55	-5.78	-0.33	2.1e-8	Intelligence;
CESC	cis	rs7772486	0.902	rs2144476	chr6:146322484	G/A	cg23711669	chr6:146136114	FBXO30	0.72	10.34	0.54	2.76e-21	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2734839	0.964	rs1107162	chr11:113289037	A/G	cg14159747	chr11:113255604	NA	-0.34	-5.84	-0.34	1.51e-8	Information processing speed;
CESC	cis	rs72627123	0.867	rs58102735	chr14:74467531	G/A	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.79	5.74	0.33	2.6e-8	Morning vs. evening chronotype;
CESC	cis	rs875971	0.830	rs587360	chr7:65522698	C/A	cg12463550	chr7:65579703	CRCP	0.57	7.22	0.41	5.6e-12	Aortic root size;
CESC	cis	rs514406	0.763	rs9988539	chr1:53213884	T/C	cg08859206	chr1:53392774	SCP2	0.54	7.12	0.4	1.03e-11	Monocyte count;
CESC	cis	rs1728785	0.892	rs4783562	chr16:68562963	A/G	cg02972257	chr16:68554789	NA	-0.62	-7.02	-0.4	1.83e-11	Ulcerative colitis;
CESC	cis	rs9814567	0.964	rs9815983	chr3:134222507	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.43	-5.98	-0.34	7.14e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg17514098	chr12:125302114	SCARB1	-0.49	-6.23	-0.36	1.84e-9	Tetralogy of Fallot;
CESC	cis	rs16866061	1.000	rs1568750	chr2:225342597	A/T	cg12698349	chr2:225449008	CUL3	0.73	11.05	0.56	1.37e-23	Acute graft versus host disease in bone marrow transplantation (recipient effect);
CESC	trans	rs2018683	1.000	rs4719963	chr7:29011064	A/G	cg19402173	chr7:128379420	CALU	0.65	9.23	0.49	8.86e-18	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CESC	cis	rs11718455	0.960	rs11720974	chr3:43999111	G/C	cg08738300	chr3:44038990	NA	0.46	6.22	0.36	1.96e-9	Coronary artery disease;
CESC	cis	rs6502050	0.835	rs3088177	chr17:80111724	A/G	cg11859384	chr17:80120422	CCDC57	-0.39	-5.28	-0.31	2.7e-7	Life satisfaction;
CESC	cis	rs35306767	0.716	rs34487581	chr10:897201	G/A	cg20503657	chr10:835505	NA	1.09	9.88	0.52	8.32e-20	Eosinophil percentage of granulocytes;
CESC	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg02475777	chr4:1388615	CRIPAK	0.72	9.28	0.5	6.11e-18	Longevity;
CESC	cis	rs727563	0.638	rs4820443	chr22:42193913	A/G	cg17376030	chr22:41985996	PMM1	0.73	8.0	0.44	3.9e-14	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs561341	0.941	rs4795664	chr17:30233467	C/T	cg12193833	chr17:30244370	NA	-0.61	-6.18	-0.36	2.36e-9	Hip circumference adjusted for BMI;
CESC	cis	rs79976124	0.842	rs74881738	chr6:66621825	T/G	cg07460842	chr6:66804631	NA	0.72	8.33	0.46	4.49e-15	Type 2 diabetes;
CESC	cis	rs4665809	0.590	rs1865324	chr2:26417533	C/A	cg04944784	chr2:26401820	FAM59B	-0.93	-10.76	-0.55	1.26e-22	Gut microbiome composition (summer);
CESC	cis	rs17023223	0.537	rs61319010	chr1:119743011	T/A	cg05756136	chr1:119680316	WARS2	-0.47	-5.59	-0.32	5.56e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CESC	cis	rs7100689	0.646	rs7903701	chr10:82129268	T/C	cg00277334	chr10:82204260	NA	-0.58	-7.76	-0.43	1.84e-13	Post bronchodilator FEV1;
CESC	cis	rs7312933	0.703	rs10880259	chr12:42558003	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.47	6.17	0.35	2.57e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs2295499	0.700	rs59425183	chr4:2721199	G/A	cg27239842	chr4:2403781	ZFYVE28	-0.3	-5.17	-0.3	4.53e-7	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
CESC	cis	rs8060686	0.565	rs8044328	chr16:68146859	G/C	cg26727032	chr16:67993705	SLC12A4	-0.52	-6.3	-0.36	1.24e-9	HDL cholesterol;Metabolic syndrome;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg10755512	chr3:44666543	ZNF197	-0.52	-6.09	-0.35	3.85e-9	Ulcerative colitis;
CESC	cis	rs2011503	0.941	rs4808944	chr19:19426613	A/C	cg11584989	chr19:19387371	SF4	0.67	8.03	0.44	3.2e-14	Bipolar disorder;
CESC	cis	rs9916302	0.629	rs9972882	chr17:37807698	A/C	cg20243544	chr17:37824526	PNMT	0.54	6.39	0.37	7.57e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs1832871	0.711	rs9459954	chr6:158709345	G/T	cg07165851	chr6:158734300	TULP4	0.56	6.29	0.36	1.27e-9	Height;
CESC	cis	rs3126085	1.000	rs12567463	chr1:152180128	T/A	cg03465714	chr1:152285911	FLG	0.43	5.04	0.3	8.56e-7	Atopic dermatitis;
CESC	cis	rs477692	0.549	rs7098548	chr10:131455028	A/G	cg05714579	chr10:131428358	MGMT	-0.41	-5.58	-0.32	5.97e-8	Response to temozolomide;
CESC	cis	rs1941023	0.584	rs7935082	chr11:60155000	T/C	cg08716584	chr11:60157161	MS4A7	-0.6	-10.18	-0.53	9e-21	Congenital heart disease (maternal effect);
CESC	cis	rs7980687	0.628	rs2851443	chr12:123694250	C/T	cg00376283	chr12:123451042	ABCB9	0.67	9.21	0.49	1.02e-17	Height;Educational attainment;Head circumference (infant);
CESC	cis	rs9309473	1.000	rs10175180	chr2:73673123	C/T	cg20560298	chr2:73613845	ALMS1	-0.46	-6.22	-0.36	1.95e-9	Metabolite levels;
CESC	cis	rs7786808	0.615	rs4909209	chr7:158194329	C/T	cg01191920	chr7:158217561	PTPRN2	-0.32	-5.43	-0.32	1.29e-7	Obesity-related traits;
CESC	cis	rs1799949	1.000	rs33945274	chr17:41280073	G/A	cg23758822	chr17:41437982	NA	1.02	15.6	0.69	2.35e-39	Menopause (age at onset);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg01413268	chr19:51602462	CTU1	0.4	6.54	0.37	3.2e-10	Fibrinogen levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10599693	chr2:24300242	SF3B14	0.7	8.21	0.45	9.88e-15	Gut microbiome composition (summer);
CESC	cis	rs9787249	0.957	rs7548120	chr1:40204424	A/T	cg02773041	chr1:40204384	PPIE	0.54	7.73	0.43	2.17e-13	Blood protein levels;
CESC	cis	rs2236918	0.687	rs1776176	chr1:242012554	C/T	cg17736920	chr1:242011382	EXO1	0.58	7.48	0.42	1.08e-12	Menopause (age at onset);
CESC	trans	rs66573146	0.656	rs66517061	chr4:6935163	C/G	cg07817883	chr1:32538562	TMEM39B	1.2	6.85	0.39	5.26e-11	Granulocyte percentage of myeloid white cells;
CESC	cis	rs2455799	0.613	rs7614204	chr3:15792748	A/G	cg16303742	chr3:15540471	COLQ	-0.39	-6.14	-0.35	3.01e-9	Mean platelet volume;
CESC	cis	rs2635047	0.811	rs12962421	chr18:44787498	A/G	cg24371990	chr18:44770781	NA	0.41	6.53	0.37	3.34e-10	Educational attainment;
CESC	cis	rs523522	0.962	rs55848094	chr12:120966659	G/A	cg27279351	chr12:120934652	DYNLL1	0.69	9.11	0.49	2.02e-17	High light scatter reticulocyte count;
CESC	cis	rs12348691	0.503	rs10739513	chr9:100592705	C/T	cg13688889	chr9:100608707	NA	-0.91	-13.3	-0.63	2.87e-31	Alopecia areata;
CESC	cis	rs7618915	0.547	rs12496476	chr3:52708737	A/G	cg17372223	chr3:52568218	NT5DC2	0.44	6.57	0.37	2.69e-10	Bipolar disorder;
CESC	cis	rs17023223	0.537	rs3934789	chr1:119683063	G/A	cg05756136	chr1:119680316	WARS2	-0.45	-5.45	-0.32	1.17e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CESC	cis	rs1568889	1.000	rs12803655	chr11:28060785	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.78	10.96	0.56	2.77e-23	Bipolar disorder;
CESC	trans	rs61931739	0.929	rs3912551	chr12:34076696	C/T	cg26384229	chr12:38710491	ALG10B	-0.47	-6.61	-0.38	2.16e-10	Morning vs. evening chronotype;
CESC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg06333435	chr8:22102724	POLR3D;MIR320A	0.44	6.07	0.35	4.36e-9	Intelligence (multi-trait analysis);
CESC	cis	rs6691722	0.503	rs3765431	chr1:24706410	T/C	cg02336364	chr1:24764700	NIPAL3	0.33	6.8	0.39	6.86e-11	Response to interferon beta in multiple sclerosis;
CESC	cis	rs2777491	1.000	rs7168177	chr15:41715585	A/G	cg02330683	chr15:41787940	ITPKA	0.48	7.09	0.4	1.21e-11	Ulcerative colitis;
CESC	cis	rs2154427	0.752	rs79114597	chr21:34200730	C/A	cg03746930	chr21:34165763	C21orf62;C21orf49	-0.53	-5.32	-0.31	2.17e-7	Bilirubin levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19260885	chr1:113162159	ST7L;CAPZA1	0.56	6.2	0.36	2.2e-9	Gut microbiome composition (summer);
CESC	trans	rs3780486	0.846	rs10758192	chr9:33131651	G/A	cg04842962	chr6:43655489	MRPS18A	1.01	19.64	0.77	1.24e-53	IgG glycosylation;
CESC	cis	rs8177253	1.000	rs1358023	chr3:133484393	T/C	cg11941060	chr3:133502564	NA	-0.47	-6.5	-0.37	4e-10	Iron status biomarkers;
CESC	cis	rs501120	1.000	rs579058	chr10:44755104	A/G	cg09554077	chr10:44749378	NA	0.52	6.89	0.39	3.96e-11	Coronary artery disease;Coronary heart disease;
CESC	cis	rs6835098	1.000	rs1054496	chr4:174089080	A/G	cg08422745	chr4:174089978	GALNT7	-0.78	-10.7	-0.55	1.89e-22	Dementia and core Alzheimer's disease neuropathologic changes;
CESC	cis	rs7095944	0.614	rs7099316	chr10:126469005	G/A	cg08799069	chr10:126477246	METTL10	-0.36	-5.22	-0.31	3.53e-7	Asthma;
CESC	cis	rs11098499	0.566	rs17051356	chr4:120585308	C/T	cg09307838	chr4:120376055	NA	0.71	8.87	0.48	1.07e-16	Corneal astigmatism;
CESC	cis	rs2841277	0.708	rs10083496	chr14:105402786	G/A	cg21017887	chr14:105400489	NA	0.42	6.87	0.39	4.54e-11	Rheumatoid arthritis;
CESC	cis	rs9660992	0.710	rs7367930	chr1:205235512	A/G	cg00857998	chr1:205179979	DSTYK	0.47	5.37	0.31	1.69e-7	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs3126085	0.935	rs12742573	chr1:152260103	A/C	cg03465714	chr1:152285911	FLG	0.5	5.75	0.33	2.47e-8	Atopic dermatitis;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg16864825	chr17:37183552	NA	0.42	6.0	0.35	6.48e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.43	-5.73	-0.33	2.74e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7116495	0.609	rs10751191	chr11:71680920	C/T	cg26138937	chr11:71823887	C11orf51	-1.25	-7.99	-0.44	4.19e-14	Severe influenza A (H1N1) infection;
CESC	cis	rs2730245	0.569	rs1188955	chr7:158690866	A/G	cg24397884	chr7:158709396	WDR60	0.66	9.39	0.5	2.79e-18	Height;
CESC	cis	rs3749237	0.595	rs6784820	chr3:49450864	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.51	-6.96	-0.39	2.67e-11	Resting heart rate;
CESC	cis	rs11690935	0.921	rs7594711	chr2:172895637	T/G	cg13550731	chr2:172543902	DYNC1I2	-0.9	-12.2	-0.6	1.82e-27	Schizophrenia;
CESC	cis	rs7824557	0.734	rs2293856	chr8:11177447	C/T	cg21775007	chr8:11205619	TDH	0.5	7.22	0.41	5.58e-12	Retinal vascular caliber;
CESC	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	10.31	0.54	3.43e-21	Prudent dietary pattern;
CESC	cis	rs6598955	0.671	rs11247910	chr1:26645666	G/A	cg19743891	chr1:26644573	UBXN11;CD52	0.35	5.09	0.3	6.68e-7	Obesity-related traits;
CESC	cis	rs694739	0.536	rs11231740	chr11:64046641	C/T	cg02228329	chr11:64053129	BAD;GPR137	-0.46	-5.67	-0.33	3.67e-8	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CESC	cis	rs7818345	0.967	rs4549789	chr8:19284015	C/A	cg11303988	chr8:19266685	CSGALNACT1	0.35	6.42	0.37	6.41e-10	Language performance in older adults (adjusted for episodic memory);
CESC	cis	rs7772486	0.875	rs9403770	chr6:146423334	C/T	cg23711669	chr6:146136114	FBXO30	0.86	12.72	0.62	2.98e-29	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg04381043	chr16:89341467	ANKRD11	0.48	6.48	0.37	4.34e-10	Fibrinogen levels;
CESC	cis	rs9443645	0.901	rs9361488	chr6:79782874	T/C	cg05283184	chr6:79620031	NA	-0.44	-6.8	-0.39	6.75e-11	Intelligence (multi-trait analysis);
CESC	cis	rs4819052	0.851	rs2838826	chr21:46655785	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.71	8.87	0.48	1.09e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs3736485	0.844	rs8041197	chr15:51865877	T/C	cg08986416	chr15:51914746	DMXL2	-0.4	-5.07	-0.3	7.63e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs8062405	0.723	rs113208333	chr16:28606160	G/T	cg07382826	chr16:28625726	SULT1A1	0.4	6.5	0.37	4.06e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs35306767	0.761	rs11253540	chr10:1011958	C/T	cg25019033	chr10:957182	NA	0.59	6.12	0.35	3.41e-9	Eosinophil percentage of granulocytes;
CESC	trans	rs2085496	0.764	rs1596751	chr2:193807860	A/G	cg26594331	chr5:178053244	CLK4	0.47	6.07	0.35	4.4e-9	Neuroticism;
CESC	cis	rs7208859	0.623	rs9894709	chr17:29078454	G/A	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.17e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg27549887	chr15:48623952	DUT	-0.54	-7.19	-0.4	6.46e-12	Ulcerative colitis;
CESC	cis	rs9715521	0.868	rs12650159	chr4:59818550	C/T	cg11281224	chr4:60001000	NA	-0.52	-6.72	-0.38	1.13e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs736408	0.609	rs2336545	chr3:52787603	C/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	-0.34	-6.13	-0.35	3.25e-9	Bipolar disorder;
CESC	cis	rs55823223	0.648	rs936393	chr17:73847613	A/G	cg02397686	chr17:73851076	WBP2	0.56	7.18	0.4	6.83e-12	Psoriasis;
CESC	cis	rs6795744	0.901	rs112911837	chr3:13906925	C/T	cg14375111	chr3:14165186	TMEM43;CHCHD4	-0.52	-5.05	-0.3	8.25e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs4253772	0.591	rs6007740	chr22:46654323	A/G	cg09491104	chr22:46646882	C22orf40	0.56	8.65	0.47	5.19e-16	LDL cholesterol;Cholesterol, total;
CESC	cis	rs977987	0.836	rs8055974	chr16:75470986	C/G	cg03315344	chr16:75512273	CHST6	0.42	6.07	0.35	4.42e-9	Dupuytren's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09423610	chr7:902986	UNC84A	-0.55	-6.31	-0.36	1.16e-9	Gut microbiome composition (summer);
CESC	cis	rs4803468	1.000	rs284655	chr19:41928765	C/T	cg08639244	chr19:41945921	ATP5SL	-0.42	-5.11	-0.3	6.32e-7	Height;
CESC	cis	rs9916302	0.904	rs602688	chr17:37439496	C/T	cg07936489	chr17:37558343	FBXL20	-0.77	-11.31	-0.57	1.84e-24	Glomerular filtration rate (creatinine);
CESC	cis	rs3741151	1.000	rs75007932	chr11:73080336	G/A	cg17517138	chr11:73019481	ARHGEF17	0.97	6.53	0.37	3.3e-10	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs710216	0.957	rs710215	chr1:43429105	T/C	cg03128534	chr1:43423976	SLC2A1	0.53	6.09	0.35	4.06e-9	Red cell distribution width;
CESC	cis	rs875971	1.000	rs778710	chr7:65854834	T/C	cg10691866	chr7:65817282	TPST1	-0.34	-5.51	-0.32	8.3e-8	Aortic root size;
CESC	cis	rs6460942	0.749	rs79221452	chr7:12202897	T/C	cg20607287	chr7:12443886	VWDE	-0.56	-5.38	-0.31	1.64e-7	Coronary artery disease;
CESC	cis	rs769267	0.930	rs2301786	chr19:19413947	A/G	cg03709012	chr19:19516395	GATAD2A	0.95	13.92	0.65	1.92e-33	Tonsillectomy;
CESC	cis	rs933688	1.000	rs61612071	chr5:90741470	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.15	13.7	0.64	1.17e-32	Smoking behavior;
CESC	cis	rs12477438	0.798	rs9308816	chr2:99637230	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.7	-10.25	-0.53	5.39e-21	Chronic sinus infection;
CESC	cis	rs36715	0.953	rs2617613	chr5:127552589	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.44	5.12	0.3	5.83e-7	Breast cancer;
CESC	cis	rs1943345	0.686	rs10898088	chr11:82874970	G/A	cg07047830	chr11:82868014	PCF11	0.59	7.9	0.44	7.61e-14	Obesity-related traits;
CESC	cis	rs7640424	0.649	rs13094403	chr3:107930210	G/T	cg09227934	chr3:107805635	CD47	-0.45	-5.82	-0.34	1.66e-8	Body mass index;
CESC	cis	rs9287719	0.967	rs6735074	chr2:10734766	G/T	cg00105475	chr2:10696890	NA	-0.37	-5.39	-0.31	1.55e-7	Prostate cancer;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg02786269	chr8:140927326	TRAPPC9	0.51	6.56	0.37	2.73e-10	Fibrinogen levels;
CESC	cis	rs3125734	0.633	rs10740068	chr10:63982254	A/C	cg09941381	chr10:64027924	RTKN2	-0.31	-5.09	-0.3	6.96e-7	Rheumatoid arthritis;
CESC	cis	rs7044106	0.791	rs12554440	chr9:123485333	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.37	5.86	0.34	1.35e-8	Hip circumference adjusted for BMI;
CESC	cis	rs7546094	1.000	rs2932536	chr1:113202417	G/A	cg22162597	chr1:113214053	CAPZA1	-0.39	-6.01	-0.35	6.14e-9	Platelet distribution width;
CESC	cis	rs11122272	0.735	rs10489610	chr1:231517765	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.57	-7.82	-0.43	1.29e-13	Hemoglobin concentration;
CESC	cis	rs17125944	0.505	rs17125762	chr14:53289288	A/G	cg00686598	chr14:53173677	PSMC6	1.39	10.01	0.52	3.3e-20	Alzheimer's disease (late onset);
CESC	cis	rs72945132	0.882	rs58039907	chr11:70183336	C/T	cg14191688	chr11:70257035	CTTN	0.43	5.47	0.32	1.04e-7	Coronary artery disease;
CESC	cis	rs3781458	0.803	rs7088656	chr10:126324077	G/A	cg20435097	chr10:126320824	FAM53B	0.3	5.67	0.33	3.65e-8	Male-pattern baldness;
CESC	cis	rs798554	0.607	rs1182151	chr7:2909225	C/G	cg18446336	chr7:2847575	GNA12	-0.4	-5.52	-0.32	8.23e-8	Height;
CESC	cis	rs4713118	0.662	rs9468277	chr6:28028390	C/A	cg23281280	chr6:28129359	ZNF389	0.5	6.56	0.37	2.75e-10	Parkinson's disease;
CESC	cis	rs7607369	0.536	rs11892469	chr2:219669488	A/T	cg02176678	chr2:219576539	TTLL4	-0.36	-6.16	-0.35	2.75e-9	Red blood cell count;Amyotrophic lateral sclerosis;
CESC	trans	rs9858542	0.953	rs6809216	chr3:49412559	G/A	cg21659725	chr3:3221576	CRBN	-0.54	-6.47	-0.37	4.62e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs1552244	0.810	rs6809572	chr3:10100145	G/A	cg00166722	chr3:10149974	C3orf24	0.53	6.52	0.37	3.49e-10	Alzheimer's disease;
CESC	cis	rs6424115	0.830	rs2503000	chr1:24197898	C/G	cg10978503	chr1:24200527	CNR2	0.34	6.72	0.38	1.11e-10	Immature fraction of reticulocytes;
CESC	cis	rs1862618	0.853	rs252919	chr5:56124111	T/C	cg18230493	chr5:56204884	C5orf35	-0.72	-8.57	-0.47	8.6e-16	Initial pursuit acceleration;
CESC	cis	rs9611565	0.659	rs9611610	chr22:41949259	A/G	cg06634786	chr22:41940651	POLR3H	-0.73	-7.55	-0.42	6.84e-13	Vitiligo;
CESC	trans	rs17081231	0.590	rs17081545	chr13:67165163	A/T	cg20557801	chr15:68121177	LBXCOR1	-0.68	-6.2	-0.36	2.13e-9	Obesity;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg10029411	chr13:50746245	FAM10A4	-0.47	-6.71	-0.38	1.2e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs2243480	1.000	rs6460260	chr7:65215455	T/C	cg18252515	chr7:66147081	NA	1.26	11.9	0.59	1.98e-26	Diabetic kidney disease;
CESC	cis	rs9322193	0.924	rs9498382	chr6:149932118	A/G	cg07701084	chr6:150067640	NUP43	0.44	6.26	0.36	1.5e-9	Lung cancer;
CESC	cis	rs7274811	0.516	rs3213141	chr20:32274380	G/A	cg21523528	chr20:32077966	CBFA2T2	0.58	5.92	0.34	9.99e-9	Height;
CESC	cis	rs35110281	0.807	rs9976441	chr21:45046591	G/A	cg01579765	chr21:45077557	HSF2BP	-0.58	-9.94	-0.52	5.28e-20	Mean corpuscular volume;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg24663683	chr5:39721720	NA	-0.52	-7.09	-0.4	1.23e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs72781680	0.898	rs72796171	chr2:23942667	G/C	cg20701182	chr2:24300061	SF3B14	0.69	6.2	0.36	2.18e-9	Lymphocyte counts;
CESC	cis	rs9443645	0.835	rs1044309	chr6:79646575	A/G	cg05283184	chr6:79620031	NA	-0.43	-6.5	-0.37	3.94e-10	Intelligence (multi-trait analysis);
CESC	cis	rs1008375	0.686	rs34338142	chr4:17626174	T/A	cg16339924	chr4:17578868	LAP3	0.63	8.03	0.44	3.19e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs2046867	0.862	rs6788139	chr3:72835630	A/G	cg25664220	chr3:72788482	NA	0.39	5.21	0.3	3.81e-7	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CESC	cis	rs11249608	0.548	rs7707587	chr5:178462590	G/C	cg01312482	chr5:178451176	ZNF879	-0.45	-6.09	-0.35	3.85e-9	Pubertal anthropometrics;
CESC	cis	rs7659604	0.502	rs13104233	chr4:122672473	T/C	cg19671926	chr4:122722719	EXOSC9	0.53	6.61	0.38	2.09e-10	Type 2 diabetes;
CESC	cis	rs425277	0.606	rs16824792	chr1:2039521	G/T	cg04315214	chr1:2043799	PRKCZ	0.54	9.38	0.5	3.1e-18	Height;
CESC	cis	rs7927771	0.832	rs10769258	chr11:47391039	C/T	cg18512352	chr11:47633146	NA	0.5	7.15	0.4	8.63e-12	Subjective well-being;
CESC	cis	rs7618915	0.501	rs2289247	chr3:52727257	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.34	5.96	0.34	8e-9	Bipolar disorder;
CESC	cis	rs4555082	0.874	rs2816621	chr14:105732762	A/T	cg13114125	chr14:105738426	BRF1	-0.9	-11.19	-0.57	4.61e-24	Mean platelet volume;Platelet distribution width;
CESC	cis	rs62064224	0.791	rs2344977	chr17:30720573	C/G	cg09324608	chr17:30823087	MYO1D	0.47	7.03	0.4	1.78e-11	Schizophrenia;
CESC	cis	rs7568458	0.684	rs7608074	chr2:85809703	T/G	cg02493740	chr2:85810744	VAMP5	-0.56	-8.24	-0.45	8.01e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CESC	cis	rs36051895	0.632	rs62541899	chr9:5143291	C/T	cg02405213	chr9:5042618	JAK2	-0.5	-6.07	-0.35	4.52e-9	Pediatric autoimmune diseases;
CESC	cis	rs4835473	0.932	rs7687151	chr4:144702834	C/T	cg25736465	chr4:144833511	NA	-0.33	-5.25	-0.31	3.18e-7	Immature fraction of reticulocytes;
CESC	cis	rs34891900	0.507	rs2535707	chr22:18181869	C/T	cg19898043	chr22:18121309	BCL2L13	-0.58	-7.04	-0.4	1.62e-11	Sum neutrophil eosinophil counts;
CESC	cis	rs4722166	0.630	rs4722168	chr7:22779002	G/A	cg05472934	chr7:22766657	IL6	0.87	10.94	0.56	3.06e-23	Lung cancer;
CESC	cis	rs13392177	0.660	rs12988046	chr2:219073804	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.52	-6.44	-0.37	5.46e-10	Pyoderma gangrenosum in inflammatory bowel disease;
CESC	cis	rs11264213	0.591	rs408986	chr1:36551895	C/T	cg27506609	chr1:36549197	TEKT2	0.69	6.94	0.39	3.03e-11	Schizophrenia;
CESC	cis	rs35849525	0.814	rs7635601	chr3:50044006	A/T	cg03060546	chr3:49711283	APEH	-0.47	-5.63	-0.33	4.56e-8	Intelligence (multi-trait analysis);
CESC	cis	rs1055129	0.560	rs2608880	chr17:73938957	C/T	cg02678768	chr17:74002944	EVPL	0.38	5.25	0.31	3.07e-7	White matter hyperintensity burden;
CESC	cis	rs916888	0.773	rs199447	chr17:44812188	C/T	cg15921436	chr17:44337874	NA	0.75	8.04	0.44	3.04e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs7665147	1	rs7665147	chr4:57767327	T/A	cg26694713	chr4:57773883	REST	0.58	5.67	0.33	3.77e-8	Platelet count;
CESC	cis	rs10883723	0.775	rs2296579	chr10:104241375	A/G	ch.10.2196322F	chr10:104248062	ACTR1A	0.43	5.22	0.31	3.57e-7	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs12142240	0.698	rs17413694	chr1:46818416	A/C	cg10495392	chr1:46806563	NSUN4	0.57	6.27	0.36	1.47e-9	Menopause (age at onset);
CESC	cis	rs9788721	0.630	rs77681598	chr15:78906103	C/A	cg06917634	chr15:78832804	PSMA4	-0.55	-7.25	-0.41	4.54e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
CESC	trans	rs11098499	0.954	rs6847248	chr4:120225955	A/G	cg25214090	chr10:38739885	LOC399744	0.72	9.5	0.5	1.33e-18	Corneal astigmatism;
CESC	cis	rs9583531	0.550	rs7985098	chr13:111386416	G/A	cg15841412	chr13:111365552	ING1	0.53	7.08	0.4	1.3e-11	Coronary artery disease;
CESC	cis	rs1348850	0.514	rs4893974	chr2:178497026	A/G	cg23306229	chr2:178417860	TTC30B	0.62	6.2	0.36	2.11e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs4975709	0.569	rs931509	chr5:1858821	A/T	cg15595755	chr5:1867978	NA	0.5	7.79	0.43	1.53e-13	Cardiovascular disease risk factors;
CESC	cis	rs9581857	0.579	rs2780341	chr13:27996401	C/T	cg22138327	chr13:27999177	GTF3A	-0.65	-5.46	-0.32	1.12e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
CESC	cis	rs7772486	0.875	rs6930975	chr6:146387111	C/T	cg05347473	chr6:146136440	FBXO30	0.5	6.88	0.39	4.28e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs909674	0.690	rs1972280	chr22:39831986	T/A	cg11247378	chr22:39784982	NA	-0.58	-8.63	-0.47	5.83e-16	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs1008375	0.872	rs2315552	chr4:17627294	A/G	cg02297831	chr4:17616191	MED28	0.55	6.97	0.39	2.51e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg22535103	chr8:58192502	C8orf71	-0.96	-9.81	-0.52	1.45e-19	Developmental language disorder (linguistic errors);
CESC	cis	rs2439831	0.702	rs3759791	chr15:44090798	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.73	6.87	0.39	4.58e-11	Lung cancer in ever smokers;
CESC	cis	rs1153858	1.000	rs1049508	chr15:45653592	A/G	cg21132104	chr15:45694354	SPATA5L1	0.76	10.2	0.53	8.01e-21	Homoarginine levels;
CESC	cis	rs10463316	0.894	rs12153347	chr5:150765471	C/T	cg03212797	chr5:150827313	SLC36A1	-0.46	-6.04	-0.35	5.23e-9	Metabolite levels (Pyroglutamine);
CESC	cis	rs2180341	0.960	rs9398842	chr6:127674662	T/C	cg24812749	chr6:127587940	RNF146	1.05	15.15	0.68	9.37e-38	Breast cancer;
CESC	cis	rs7927771	0.832	rs11605672	chr11:47413733	A/G	cg25783544	chr11:47291846	MADD	-0.44	-5.06	-0.3	8e-7	Subjective well-being;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg05323904	chr16:691677	FAM195A	0.48	6.25	0.36	1.67e-9	Systemic lupus erythematosus;
CESC	cis	rs6540559	0.543	rs672819	chr1:210436404	T/A	cg25204440	chr1:209979598	IRF6	0.49	5.14	0.3	5.43e-7	Cleft lip with or without cleft palate;
CESC	cis	rs597539	0.615	rs583182	chr11:68678634	C/T	cg18350739	chr11:68623251	NA	-0.48	-7.53	-0.42	7.98e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs9640161	0.750	rs59211922	chr7:150023790	T/G	cg10018233	chr7:150070692	REPIN1	0.45	7.41	0.41	1.72e-12	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs2415984	0.562	rs4306423	chr14:46915671	G/A	cg14871534	chr14:47121158	RPL10L	0.42	5.94	0.34	9e-9	Number of children ever born;
CESC	cis	rs6088580	0.524	rs6088570	chr20:33268295	T/C	cg24642439	chr20:33292090	TP53INP2	-0.45	-5.3	-0.31	2.38e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs9303401	0.538	rs3785493	chr17:56472119	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.9	-9.5	-0.5	1.3e-18	Cognitive test performance;
CESC	cis	rs7605827	0.930	rs12692261	chr2:15511967	T/G	cg19274914	chr2:15703543	NA	0.31	5.5	0.32	8.99e-8	Educational attainment (years of education);
CESC	cis	rs2070997	0.607	rs2261468	chr9:133708873	T/C	cg11464064	chr9:133710261	ABL1	0.68	8.07	0.44	2.52e-14	Response to amphetamines;
CESC	cis	rs1008375	1.000	rs13106338	chr4:17676871	G/T	cg16339924	chr4:17578868	LAP3	-0.59	-7.1	-0.4	1.13e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs12477438	0.520	rs10865029	chr2:99718298	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.86	15.87	0.7	2.48e-40	Chronic sinus infection;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg14527942	chr3:10276383	IRAK2	0.42	6.35	0.36	9.14e-10	Fibrinogen levels;
CESC	cis	rs2243480	1.000	rs73142162	chr7:65374296	A/T	cg18252515	chr7:66147081	NA	-1.23	-11.49	-0.58	4.61e-25	Diabetic kidney disease;
CESC	cis	rs9649213	0.593	rs3801255	chr7:98000929	C/T	cg08684580	chr7:98029266	BAIAP2L1	-0.35	-5.8	-0.34	1.85e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs8114671	0.562	rs6088636	chr20:33469746	C/T	cg24642439	chr20:33292090	TP53INP2	0.43	5.21	0.3	3.79e-7	Height;
CESC	cis	rs7208859	0.673	rs9896095	chr17:29187497	A/G	cg19761014	chr17:28927070	LRRC37B2	0.63	5.27	0.31	2.88e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs739401	0.611	rs2301140	chr11:3022629	C/T	cg08508325	chr11:3079039	CARS	-0.49	-8.42	-0.46	2.38e-15	Longevity;
CESC	cis	rs4665809	1.000	rs12475854	chr2:26267375	G/A	cg27170947	chr2:26402098	FAM59B	-0.58	-6.89	-0.39	4.08e-11	Gut microbiome composition (summer);
CESC	cis	rs1552244	0.554	rs17050705	chr3:10046398	G/C	cg00149659	chr3:10157352	C3orf10	0.54	6.55	0.37	2.98e-10	Alzheimer's disease;
CESC	cis	rs4566357	1.000	rs6436649	chr2:227923952	A/G	cg11843606	chr2:227700838	RHBDD1	-0.42	-5.37	-0.31	1.72e-7	Coronary artery disease;
CESC	cis	rs6060717	0.536	rs6060669	chr20:34480557	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.75	-6.89	-0.39	4e-11	Hip circumference adjusted for BMI;
CESC	cis	rs6500395	1.000	rs1420704	chr16:48716902	C/T	cg04672837	chr16:48644449	N4BP1	-0.51	-6.53	-0.37	3.33e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs11190604	1.000	rs17746014	chr10:102315354	T/C	cg07080220	chr10:102295463	HIF1AN	0.64	6.08	0.35	4.28e-9	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs4727963	0.846	rs1525487	chr7:122710189	G/T	cg03640110	chr7:122635026	TAS2R16	-0.38	-5.89	-0.34	1.15e-8	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
CESC	cis	rs748404	0.660	rs693510	chr15:43714625	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.58	7.68	0.43	3.04e-13	Lung cancer;
CESC	cis	rs9611565	0.559	rs132771	chr22:42025350	A/G	cg17376030	chr22:41985996	PMM1	-0.8	-9.14	-0.49	1.64e-17	Vitiligo;
CESC	cis	rs896854	1.000	rs7003387	chr8:95961979	C/G	cg26343298	chr8:95960752	TP53INP1	0.37	5.94	0.34	8.73e-9	Type 2 diabetes;
CESC	cis	rs5750830	0.546	rs4821891	chr22:39785381	C/T	cg24399712	chr22:39784796	NA	-0.83	-11.77	-0.59	5.37e-26	Intelligence (multi-trait analysis);
CESC	trans	rs875971	0.660	rs801190	chr7:66033033	C/T	cg26939375	chr7:64535504	NA	-0.64	-8.8	-0.48	1.77e-16	Aortic root size;
CESC	cis	rs9488822	0.676	rs12202641	chr6:116314634	A/G	cg15226275	chr6:116381976	FRK	-0.25	-6.37	-0.36	8.17e-10	Cholesterol, total;LDL cholesterol;
CESC	cis	rs1799949	1.000	rs11649954	chr17:41420035	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.64	8.68	0.47	4.11e-16	Menopause (age at onset);
CESC	cis	rs4803468	0.967	rs11670583	chr19:41920440	A/T	cg09537434	chr19:41945824	ATP5SL	-1.08	-18.9	-0.76	4.86e-51	Height;
CESC	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	7.52	0.42	8.58e-13	Prudent dietary pattern;
CESC	cis	rs2191566	0.664	rs62115489	chr19:44578585	A/G	cg20607764	chr19:44506953	ZNF230	-0.44	-5.59	-0.32	5.7e-8	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs7584330	0.554	rs6740722	chr2:238393288	T/C	cg14458575	chr2:238380390	NA	0.7	6.14	0.35	2.99e-9	Prostate cancer;
CESC	cis	rs11792861	0.926	rs12683988	chr9:111867290	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.41	5.15	0.3	5.08e-7	Menarche (age at onset);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg23956071	chr17:4710044	PLD2	-0.48	-6.34	-0.36	9.65e-10	Ulcerative colitis;
CESC	cis	rs1448094	0.544	rs56330110	chr12:86166666	A/G	cg00310523	chr12:86230176	RASSF9	0.4	6.0	0.35	6.34e-9	Major depressive disorder;
CESC	cis	rs28595532	0.748	rs55949457	chr4:119336174	A/G	cg21605333	chr4:119757512	SEC24D	0.94	5.82	0.34	1.7e-8	Cannabis dependence symptom count;
CESC	cis	rs916888	0.773	rs199445	chr17:44817408	C/T	cg27589368	chr17:43923255	LOC100128977;IMP5	-0.39	-5.46	-0.32	1.11e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs367943	0.966	rs455435	chr5:112799412	T/C	cg12552261	chr5:112820674	MCC	-0.62	-7.85	-0.43	1.05e-13	Type 2 diabetes;
CESC	cis	rs10504229	1.000	rs17805332	chr8:58169798	A/G	cg22535103	chr8:58192502	C8orf71	-1.04	-13.38	-0.63	1.56e-31	Developmental language disorder (linguistic errors);
CESC	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg03188948	chr7:1209495	NA	0.72	6.93	0.39	3.15e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs875971	0.862	rs6971059	chr7:66067032	A/G	cg12463550	chr7:65579703	CRCP	-0.53	-6.77	-0.38	8.05e-11	Aortic root size;
CESC	cis	rs2836974	0.836	rs1041440	chr21:40627325	C/T	cg17971929	chr21:40555470	PSMG1	1.07	16.28	0.71	8.83e-42	Cognitive function;
CESC	cis	rs2637266	0.749	rs4979831	chr10:78457588	G/T	cg18941641	chr10:78392320	NA	0.4	7.33	0.41	2.74e-12	Pulmonary function;
CESC	cis	rs2559856	1.000	rs2695284	chr12:102089318	A/G	cg12213457	chr12:102090980	CHPT1	0.36	5.48	0.32	9.99e-8	Blood protein levels;
CESC	cis	rs3785574	0.924	rs2584641	chr17:61862889	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.8	10.6	0.55	4.05e-22	Height;
CESC	cis	rs933688	0.536	rs332537	chr5:90794973	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	-0.62	-5.97	-0.34	7.61e-9	Smoking behavior;
CESC	trans	rs55704346	0.566	rs17605267	chr4:25395674	C/A	cg01822600	chr1:245751692	KIF26B	0.42	6.17	0.35	2.58e-9	Tonsillectomy;
CESC	cis	rs7149337	0.780	rs4369569	chr14:51689181	C/G	cg23942311	chr14:51606299	NA	-0.52	-8.82	-0.48	1.55e-16	Cancer;
CESC	cis	rs4132509	0.793	rs10927046	chr1:243801190	T/C	cg21452805	chr1:244014465	NA	0.61	6.46	0.37	4.94e-10	RR interval (heart rate);
CESC	cis	rs9549260	0.755	rs2755219	chr13:41169625	A/G	cg21288729	chr13:41239152	FOXO1	0.61	7.67	0.43	3.32e-13	Red blood cell count;
CESC	cis	rs875971	0.895	rs4145009	chr7:65726615	T/C	cg12463550	chr7:65579703	CRCP	-0.47	-5.83	-0.34	1.58e-8	Aortic root size;
CESC	cis	rs10791097	0.677	rs11222359	chr11:130730648	A/G	cg12179176	chr11:130786555	SNX19	0.56	8.12	0.45	1.72e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs1862618	0.671	rs832531	chr5:56228401	A/G	cg12311346	chr5:56204834	C5orf35	-0.64	-8.94	-0.48	7.05e-17	Initial pursuit acceleration;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04190776	chr16:89614921	SPG7	-0.68	-7.86	-0.43	9.82e-14	Gut microbiome composition (summer);
CESC	cis	rs4076764	0.958	rs6691127	chr1:163384831	T/C	cg06092702	chr1:163392909	NA	-0.4	-5.82	-0.34	1.73e-8	Motion sickness;
CESC	cis	rs654950	0.806	rs10749832	chr1:42041806	C/T	cg06885757	chr1:42089581	HIVEP3	0.64	10.41	0.54	1.7e-21	Airway imaging phenotypes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10130314	chr10:71993273	PPA1	0.73	8.68	0.47	4.06e-16	Gut microbiome composition (summer);
CESC	cis	rs4253772	0.530	rs6008616	chr22:46707954	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.67	6.51	0.37	3.73e-10	LDL cholesterol;Cholesterol, total;
CESC	cis	rs11122272	0.735	rs2246645	chr1:231497393	T/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.56	-7.76	-0.43	1.87e-13	Hemoglobin concentration;
CESC	cis	rs798554	1.000	rs798554	chr7:2759795	C/T	cg13628971	chr7:2884303	GNA12	0.59	7.67	0.43	3.35e-13	Height;
CESC	cis	rs10504229	0.861	rs67042991	chr8:58191749	G/C	cg22535103	chr8:58192502	C8orf71	-1.05	-13.08	-0.63	1.71e-30	Developmental language disorder (linguistic errors);
CESC	cis	rs4282054	0.631	rs13081155	chr3:52732429	A/G	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.39	7.52	0.42	8.66e-13	Cognitive function;
CESC	cis	rs853679	0.550	rs1237875	chr6:28173010	A/G	cg23161317	chr6:28129485	ZNF389	-0.44	-5.6	-0.33	5.36e-8	Depression;
CESC	cis	rs7937682	0.564	rs11600652	chr11:111754368	A/T	cg09085632	chr11:111637200	PPP2R1B	0.92	12.04	0.59	6.56e-27	Primary sclerosing cholangitis;
CESC	cis	rs589448	0.902	rs528974	chr12:69765918	A/T	cg20891283	chr12:69753455	YEATS4	0.98	16.88	0.72	6.74e-44	Cerebrospinal fluid biomarker levels;
CESC	cis	rs9303280	0.806	rs9909593	chr17:37970149	C/T	cg20243544	chr17:37824526	PNMT	-0.51	-6.87	-0.39	4.53e-11	Self-reported allergy;
CESC	cis	rs6088590	1.000	rs6119530	chr20:33403930	A/G	cg06115741	chr20:33292138	TP53INP2	0.62	7.52	0.42	8.6e-13	Coronary artery disease;
CESC	cis	rs28374715	0.578	rs8036026	chr15:41630499	C/G	cg02330683	chr15:41787940	ITPKA	0.48	5.65	0.33	4.21e-8	Ulcerative colitis;
CESC	cis	rs1475911	1.000	rs1475911	chr21:43513480	A/C	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.43	-6.17	-0.35	2.59e-9	IgG glycosylation;
CESC	cis	rs853679	0.542	rs9393892	chr6:28081394	A/G	cg12963246	chr6:28129442	ZNF389	0.59	8.0	0.44	3.89e-14	Depression;
CESC	cis	rs34172651	0.517	rs2303083	chr16:24835168	G/A	cg00339695	chr16:24857497	SLC5A11	0.54	6.33	0.36	1.04e-9	Intelligence (multi-trait analysis);
CESC	cis	rs4927850	1.000	rs4927850	chr3:195751630	C/T	cg12923728	chr3:195709715	SDHAP1	0.68	9.25	0.49	7.57e-18	Pancreatic cancer;
CESC	cis	rs9915657	0.773	rs9896360	chr17:70099469	C/G	cg09344028	chr17:70110421	NA	0.39	7.66	0.43	3.57e-13	Thyroid hormone levels;
CESC	cis	rs7666738	0.609	rs28833816	chr4:98868866	T/C	cg17366294	chr4:99064904	C4orf37	0.52	6.68	0.38	1.36e-10	Colonoscopy-negative controls vs population controls;
CESC	cis	rs854765	0.686	rs8065497	chr17:17782649	A/G	cg09796270	chr17:17721594	SREBF1	-0.43	-5.77	-0.33	2.21e-8	Total body bone mineral density;
CESC	cis	rs9322193	0.923	rs62441303	chr6:150088683	A/G	cg07701084	chr6:150067640	NUP43	0.44	5.95	0.34	8.59e-9	Lung cancer;
CESC	cis	rs9905704	0.846	rs302878	chr17:56762964	G/A	cg12560992	chr17:57184187	TRIM37	0.62	7.79	0.43	1.53e-13	Testicular germ cell tumor;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18493449	chr17:74467972	RHBDF2	-0.55	-6.16	-0.35	2.69e-9	Gut microbiome composition (summer);
CESC	cis	rs1862618	0.802	rs832547	chr5:56183941	C/G	cg03609598	chr5:56110824	MAP3K1	-0.51	-5.32	-0.31	2.22e-7	Initial pursuit acceleration;
CESC	cis	rs4835473	0.932	rs17018238	chr4:144703890	A/T	cg25736465	chr4:144833511	NA	-0.32	-5.16	-0.3	4.85e-7	Immature fraction of reticulocytes;
CESC	cis	rs6087990	0.899	rs4911262	chr20:31393352	G/A	cg13636640	chr20:31349939	DNMT3B	0.92	15.76	0.7	6.03e-40	Ulcerative colitis;
CESC	cis	rs1348850	0.507	rs10186934	chr2:178425998	T/C	cg23306229	chr2:178417860	TTC30B	0.7	5.59	0.32	5.72e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs753778	0.602	rs9792	chr8:142205237	C/T	cg18755752	chr8:142205143	DENND3	0.69	10.31	0.54	3.54e-21	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	trans	rs2075371	0.932	rs1862048	chr7:133978167	C/G	cg18939928	chr19:1407468	DAZAP1	0.47	6.06	0.35	4.56e-9	Mean platelet volume;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg10083149	chr2:3321068	TSSC1	0.45	6.12	0.35	3.3e-9	Fibrinogen levels;
CESC	cis	rs2832191	0.933	rs2832236	chr21:30547602	C/T	cg24692254	chr21:30365293	RNF160	-0.65	-9.49	-0.5	1.39e-18	Dental caries;
CESC	cis	rs847577	0.677	rs1495525	chr7:97826232	G/A	cg21770322	chr7:97807741	LMTK2	-0.52	-7.44	-0.42	1.44e-12	Breast cancer;
CESC	cis	rs4604732	0.631	rs75320597	chr1:247626751	T/G	cg12754571	chr1:247694271	LOC148824;OR2C3	0.44	5.44	0.32	1.21e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs60154123	0.505	rs1319435	chr1:210047618	C/T	cg25204440	chr1:209979598	IRF6	-0.68	-6.31	-0.36	1.2e-9	Coronary artery disease;
CESC	cis	rs40363	0.680	rs4010628	chr16:3529779	G/A	cg22508957	chr16:3507546	NAT15	0.7	7.5	0.42	9.39e-13	Tuberculosis;
CESC	cis	rs3749237	0.615	rs6792911	chr3:49429856	C/T	cg02487422	chr3:49467188	NICN1	0.53	7.71	0.43	2.55e-13	Resting heart rate;
CESC	cis	rs10242455	0.571	rs6955162	chr7:99184400	T/G	cg18809830	chr7:99032528	PTCD1	-0.75	-5.25	-0.31	3.12e-7	Blood metabolite levels;
CESC	cis	rs5769765	0.955	rs8138687	chr22:50291869	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.45	-5.2	-0.3	4.01e-7	Schizophrenia;
CESC	cis	rs3736485	0.966	rs8042221	chr15:51774613	A/G	cg08986416	chr15:51914746	DMXL2	-0.42	-5.54	-0.32	7.22e-8	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs11098499	0.779	rs7699346	chr4:120310542	C/T	cg09307838	chr4:120376055	NA	0.93	12.77	0.62	2.01e-29	Corneal astigmatism;
CESC	cis	rs35306767	0.859	rs11817793	chr10:878895	C/T	cg25019033	chr10:957182	NA	-0.61	-6.67	-0.38	1.48e-10	Eosinophil percentage of granulocytes;
CESC	cis	rs9303401	0.625	rs66508449	chr17:56691034	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.01	12.49	0.61	1.91e-28	Cognitive test performance;
CESC	cis	rs1413885	0.549	rs10889546	chr1:65851759	G/A	cg14976592	chr1:65886160	LEPROT;LEPR	0.48	6.32	0.36	1.13e-9	Anticoagulant levels;
CESC	cis	rs11792861	0.555	rs4978767	chr9:111762925	C/T	cg13535736	chr9:111863775	C9orf5	-0.39	-5.59	-0.32	5.77e-8	Menarche (age at onset);
CESC	cis	rs11190604	0.945	rs2495735	chr10:102338609	G/A	cg07080220	chr10:102295463	HIF1AN	0.57	5.84	0.34	1.51e-8	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs10744422	1.000	rs897386	chr12:123341289	A/C	cg25930673	chr12:123319894	HIP1R	-0.69	-5.43	-0.32	1.28e-7	Schizophrenia;
CESC	cis	rs763121	0.853	rs3761454	chr22:39066820	C/T	cg21395723	chr22:39101663	GTPBP1	0.42	5.33	0.31	2.15e-7	Menopause (age at onset);
CESC	cis	rs5758511	0.680	rs1107554	chr22:42667594	C/G	cg00645731	chr22:42541494	CYP2D7P1	0.58	8.88	0.48	1.02e-16	Birth weight;
CESC	cis	rs11871801	1.000	rs7223784	chr17:40577580	A/C	cg21433558	chr17:40837037	CNTNAP1	0.45	5.04	0.3	8.46e-7	Crohn's disease;
CESC	cis	rs523522	0.962	rs4766966	chr12:120942911	G/C	cg12219531	chr12:120966889	COQ5	0.75	9.95	0.52	5.02e-20	High light scatter reticulocyte count;
CESC	cis	rs11997175	0.574	rs4364597	chr8:33653729	G/C	ch.8.33884649F	chr8:33765107	NA	0.66	8.38	0.46	3.14e-15	Body mass index;
CESC	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.49	-6.28	-0.36	1.38e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg19705215	chr14:61747501	TMEM30B	-0.44	-6.02	-0.35	5.93e-9	Ulcerative colitis;
CESC	cis	rs7618915	0.547	rs13069481	chr3:52666866	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	6.98	0.39	2.38e-11	Bipolar disorder;
CESC	cis	rs62012628	0.527	rs12438008	chr15:79084680	C/T	cg22753661	chr15:79092743	ADAMTS7	-0.44	-5.75	-0.33	2.4e-8	Diastolic blood pressure;
CESC	cis	rs769267	0.930	rs3794990	chr19:19610030	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.47	5.84	0.34	1.51e-8	Tonsillectomy;
CESC	cis	rs9649465	0.967	rs2299986	chr7:123369539	T/C	cg04330084	chr7:123175371	IQUB	-0.38	-5.13	-0.3	5.59e-7	Migraine;
CESC	cis	rs9303401	0.614	rs12947982	chr17:57140301	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.9	11.19	0.57	4.72e-24	Cognitive test performance;
CESC	cis	rs644799	0.601	rs662168	chr11:95586982	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.58	8.31	0.45	5.15e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs12604637	0.536	rs16953742	chr18:8555808	C/T	ch.18.196065F	chr18:8819933	KIAA0802	-0.77	-5.21	-0.3	3.74e-7	Colorectal cancer;
CESC	cis	rs875971	0.516	rs6945322	chr7:65336056	T/C	cg11987759	chr7:65425863	GUSB	-0.48	-6.51	-0.37	3.74e-10	Aortic root size;
CESC	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg07167872	chr1:205819463	PM20D1	0.75	12.43	0.61	3.05e-28	Menarche (age at onset);
CESC	cis	rs6088590	1.000	rs2295354	chr20:33356541	T/C	cg08999081	chr20:33150536	PIGU	0.61	9.39	0.5	2.97e-18	Coronary artery disease;
CESC	cis	rs4629180	0.606	rs13390891	chr2:102111943	T/C	cg21388029	chr2:102003306	CREG2	0.32	5.17	0.3	4.65e-7	Chronic rhinosinusitis with nasal polyps;
CESC	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.89	13.55	0.64	3.99e-32	Prudent dietary pattern;
CESC	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg10862848	chr6:42927986	GNMT	-0.29	-7.09	-0.4	1.2e-11	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs9308433	0.529	rs17022608	chr1:214500907	A/C	cg06198575	chr1:214491504	SMYD2	0.5	6.01	0.35	6.23e-9	IgG glycosylation;
CESC	cis	rs854765	0.583	rs4553680	chr17:17857722	A/G	cg04398451	chr17:18023971	MYO15A	-0.67	-9.28	-0.5	6.3e-18	Total body bone mineral density;
CESC	cis	rs10256972	0.621	rs10951594	chr7:1088607	C/G	cg04025307	chr7:1156635	C7orf50	0.45	7.44	0.42	1.41e-12	Longevity;Endometriosis;
CESC	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg07431429	chr13:21750645	MRP63;SKA3	0.46	6.6	0.38	2.18e-10	Myopia (pathological);
CESC	cis	rs4822044	0.568	rs1883370	chr22:42143740	C/A	cg06481639	chr22:41940642	POLR3H	0.58	5.71	0.33	3.05e-8	Cannabis dependence symptom count;
CESC	cis	rs929354	0.772	rs2023975	chr7:157012096	G/A	cg05182265	chr7:156933206	UBE3C	-0.52	-7.61	-0.42	4.91e-13	Body mass index;
CESC	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg26338869	chr17:61819248	STRADA	0.69	9.21	0.49	1.04e-17	Prudent dietary pattern;
CESC	cis	rs17039065	0.920	rs59486913	chr4:109384333	T/C	cg16022748	chr4:109541635	LOC285456;RPL34	0.6	5.1	0.3	6.35e-7	Gut microbiome composition (summer);
CESC	cis	rs17407555	0.606	rs73229818	chr4:10019884	C/T	cg11266682	chr4:10021025	SLC2A9	-0.51	-6.08	-0.35	4.18e-9	Schizophrenia (age at onset);
CESC	cis	rs12134040	0.646	rs12734378	chr1:236511354	A/G	cg21399712	chr1:236511386	NA	0.37	5.13	0.3	5.47e-7	Urate levels (BMI interaction);
CESC	cis	rs55794721	0.509	rs7554255	chr1:25778106	C/T	cg27572855	chr1:25598939	RHD	0.49	8.31	0.45	4.97e-15	Plateletcrit;Mean corpuscular volume;
CESC	cis	rs2286503	0.780	rs2286506	chr7:22854815	T/C	cg13679077	chr7:22862647	TOMM7	0.51	6.51	0.37	3.78e-10	Fibrinogen;
CESC	cis	rs8018808	0.935	rs760257	chr14:77935145	G/A	cg20045696	chr14:77926864	AHSA1	0.43	5.91	0.34	1.08e-8	Myeloid white cell count;
CESC	cis	rs8049040	0.586	rs13333985	chr16:71550853	T/C	cg08717414	chr16:71523259	ZNF19	-0.62	-6.78	-0.38	7.92e-11	Blood protein levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24541279	chr10:71993373	PPA1	0.62	6.83	0.39	5.85e-11	Gut microbiome composition (summer);
CESC	cis	rs1949733	0.701	rs2688222	chr4:8473735	C/A	cg11789530	chr4:8429930	ACOX3	0.65	7.49	0.42	1.01e-12	Response to antineoplastic agents;
CESC	cis	rs754466	0.580	rs10430529	chr10:79582623	C/A	cg17075019	chr10:79541650	NA	-0.88	-13.79	-0.65	5.74e-33	Liver enzyme levels (gamma-glutamyl transferase);
CESC	trans	rs650950	0.528	rs646660	chr11:35528452	C/T	cg16988008	chr11:108463728	EXPH5	0.45	6.16	0.35	2.68e-9	Bronchopulmonary dysplasia;
CESC	cis	rs10540	1.000	rs12419716	chr11:503385	C/G	cg03352830	chr11:487213	PTDSS2	0.74	7.21	0.4	5.99e-12	Body mass index;
CESC	cis	rs4727027	0.704	rs12537763	chr7:148903984	G/A	cg23158103	chr7:148848205	ZNF398	-0.31	-5.04	-0.3	8.44e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs1862618	0.671	rs2591966	chr5:56233688	T/G	cg18230493	chr5:56204884	C5orf35	0.59	8.03	0.44	3.23e-14	Initial pursuit acceleration;
CESC	cis	rs12142240	0.628	rs56126529	chr1:46808860	C/T	cg10495392	chr1:46806563	NSUN4	0.59	6.34	0.36	9.65e-10	Menopause (age at onset);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg22345911	chr17:80231263	CSNK1D	-0.47	-6.86	-0.39	4.8e-11	Fibrinogen levels;
CESC	cis	rs13108904	0.967	rs1732107	chr4:1276758	G/A	cg22903657	chr4:1355424	KIAA1530	0.41	5.59	0.32	5.69e-8	Obesity-related traits;
CESC	cis	rs1862618	0.802	rs33327	chr5:56142693	T/G	cg03609598	chr5:56110824	MAP3K1	-0.53	-5.62	-0.33	4.78e-8	Initial pursuit acceleration;
CESC	cis	rs9811920	0.638	rs793503	chr3:99588070	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.38	-5.05	-0.3	8.29e-7	Axial length;
CESC	cis	rs7618915	0.571	rs6798246	chr3:52599922	G/A	cg05564831	chr3:52568323	NT5DC2	0.46	6.93	0.39	3.15e-11	Bipolar disorder;
CESC	cis	rs478304	0.593	rs4645933	chr11:65485120	C/T	cg27068330	chr11:65405492	SIPA1	-0.44	-5.07	-0.3	7.43e-7	Acne (severe);
CESC	cis	rs864537	0.676	rs2056626	chr1:167420425	T/G	cg09179987	chr1:167433047	CD247	0.51	7.66	0.43	3.45e-13	Celiac disease or Rheumatoid arthritis;Celiac disease;
CESC	cis	rs8067545	0.693	rs8066150	chr17:19886948	G/A	cg13482628	chr17:19912719	NA	0.4	5.06	0.3	7.98e-7	Schizophrenia;
CESC	cis	rs4819052	1.000	rs13052356	chr21:46663588	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.82	10.38	0.54	2.04e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs67478160	0.643	rs4906369	chr14:104242458	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.52	-7.2	-0.4	6.3e-12	Schizophrenia;
CESC	cis	rs10504229	1.000	rs17805656	chr8:58180318	T/C	cg22535103	chr8:58192502	C8orf71	-1.05	-13.27	-0.63	3.63e-31	Developmental language disorder (linguistic errors);
CESC	cis	rs7223966	1.000	rs61360320	chr17:61800392	C/T	cg11494091	chr17:61959527	GH2	0.38	5.17	0.3	4.56e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	trans	rs629535	0.767	rs72654070	chr8:70079369	G/A	cg21567404	chr3:27674614	NA	-0.89	-10.61	-0.55	3.89e-22	Dupuytren's disease;
CESC	cis	rs6460942	0.908	rs6948654	chr7:12418546	T/A	cg10578991	chr7:12443926	VWDE	-0.47	-5.42	-0.32	1.34e-7	Coronary artery disease;
CESC	cis	rs7223966	1.000	rs3817181	chr17:61776538	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.52	6.13	0.35	3.21e-9	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs10028773	0.506	rs12374346	chr4:120281705	G/A	cg09307838	chr4:120376055	NA	0.87	12.16	0.6	2.41e-27	Educational attainment;
CESC	cis	rs854765	0.583	rs4257260	chr17:17857003	A/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.54	7.08	0.4	1.28e-11	Total body bone mineral density;
CESC	cis	rs5753618	0.561	rs4141404	chr22:31675185	A/C	cg13145458	chr22:31556086	RNF185	0.51	5.68	0.33	3.46e-8	Colorectal cancer;
CESC	cis	rs6088590	1.000	rs2378256	chr20:33292127	G/C	cg06115741	chr20:33292138	TP53INP2	0.61	7.45	0.42	1.34e-12	Coronary artery disease;
CESC	cis	rs919433	0.963	rs4850786	chr2:198178608	A/G	cg03934865	chr2:198174659	NA	0.43	5.9	0.34	1.09e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	trans	rs983392	0.679	rs10736701	chr11:60031476	C/T	cg13921652	chr1:144931966	PDE4DIP	0.48	6.15	0.35	2.91e-9	Alzheimer's disease (late onset);
CESC	cis	rs2011503	0.943	rs79370636	chr19:19614289	G/A	cg11584989	chr19:19387371	SF4	0.62	7.13	0.4	9.66e-12	Bipolar disorder;
CESC	cis	rs9457247	1.000	rs448060	chr6:167382622	A/G	cg23791538	chr6:167370224	RNASET2	-0.6	-8.65	-0.47	5.12e-16	Crohn's disease;
CESC	cis	rs3858526	0.584	rs10734559	chr11:5861788	A/C	cg13902645	chr11:5959945	NA	-0.65	-8.98	-0.48	5.31e-17	DNA methylation (variation);
CESC	cis	rs1552244	0.882	rs13077641	chr3:10022935	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.87	11.29	0.57	2.21e-24	Alzheimer's disease;
CESC	cis	rs425277	0.527	rs3107144	chr1:2045380	C/A	cg19257562	chr1:2043853	PRKCZ	0.38	6.38	0.37	7.7e-10	Height;
CESC	cis	rs7617773	0.539	rs13087050	chr3:48392800	C/T	cg11946769	chr3:48343235	NME6	0.6	7.53	0.42	7.97e-13	Coronary artery disease;
CESC	cis	rs10461617	0.541	rs860581	chr5:56150537	A/G	cg24531977	chr5:56204891	C5orf35	-0.82	-8.05	-0.44	2.72e-14	Type 2 diabetes;
CESC	cis	rs35306767	0.855	rs55708963	chr10:925712	C/A	cg20503657	chr10:835505	NA	1.06	10.03	0.52	2.79e-20	Eosinophil percentage of granulocytes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16098064	chr2:43823287	THADA	0.56	6.57	0.37	2.63e-10	Gut microbiome composition (summer);
CESC	cis	rs4563143	0.675	rs55976444	chr19:29265214	G/C	cg14983838	chr19:29218262	NA	0.5	6.16	0.35	2.67e-9	Methadone dose in opioid dependence;
CESC	cis	rs6502050	0.634	rs11077973	chr17:80095191	C/T	cg11859384	chr17:80120422	CCDC57	-0.38	-5.14	-0.3	5.29e-7	Life satisfaction;
CESC	cis	rs60871478	0.735	rs4721501	chr7:862166	G/T	cg13798912	chr7:905769	UNC84A	-0.59	-5.82	-0.34	1.73e-8	Cerebrospinal P-tau181p levels;
CESC	trans	rs208520	0.909	rs58958359	chr6:67021381	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.81	7.68	0.43	3.1400000000000003e-13	Exhaled nitric oxide output;
CESC	cis	rs741677	0.507	rs2075443	chr17:465775	G/A	cg15660573	chr17:549704	VPS53	0.56	7.01	0.4	1.98e-11	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
CESC	cis	rs9894429	0.646	rs9902264	chr17:79613828	G/A	cg13777783	chr17:79615861	NA	-0.36	-6.04	-0.35	5.09e-9	Eye color traits;
CESC	cis	rs17608059	0.524	rs9897978	chr17:13900256	G/T	cg11395062	chr17:14139857	CDRT15	-0.48	-5.84	-0.34	1.49e-8	Temperament;
CESC	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.65	7.41	0.41	1.72e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs10504229	1.000	rs59275611	chr8:58195191	G/A	cg05313129	chr8:58192883	C8orf71	-0.59	-6.66	-0.38	1.6e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs67460515	0.563	rs6794882	chr3:160851849	G/A	cg03342759	chr3:160939853	NMD3	-0.52	-6.73	-0.38	1.02e-10	Parkinson's disease;
CESC	cis	rs10504229	0.683	rs7835498	chr8:58129780	A/C	cg21724239	chr8:58056113	NA	0.58	5.95	0.34	8.29e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs801193	0.569	rs13242290	chr7:66121885	G/A	cg12463550	chr7:65579703	CRCP	-0.49	-6.42	-0.37	6.36e-10	Aortic root size;
CESC	trans	rs2018683	0.584	rs4722880	chr7:28999197	C/T	cg19402173	chr7:128379420	CALU	-0.58	-7.07	-0.4	1.36e-11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CESC	cis	rs8092503	1.000	rs12965081	chr18:52479039	G/A	cg12377874	chr18:52495404	RAB27B	0.38	6.27	0.36	1.46e-9	Childhood body mass index;
CESC	cis	rs7927771	0.864	rs2053979	chr11:47439444	A/G	cg05585544	chr11:47624801	NA	-0.47	-6.88	-0.39	4.42e-11	Subjective well-being;
CESC	cis	rs9300255	0.639	rs941306	chr12:123715113	C/T	cg00376283	chr12:123451042	ABCB9	0.72	8.84	0.48	1.34e-16	Neutrophil percentage of white cells;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02046226	chr10:121410475	BAG3	-0.63	-7.31	-0.41	3.08e-12	Gut microbiome composition (summer);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg15946545	chr13:41345183	MRPS31	0.49	6.19	0.36	2.23e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05899741	chr4:43901084	NA	-0.4	-6.35	-0.36	9.51e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs36051895	0.632	rs9657576	chr9:5183028	T/G	cg02405213	chr9:5042618	JAK2	-0.53	-6.82	-0.39	6.16e-11	Pediatric autoimmune diseases;
CESC	trans	rs2727020	0.619	rs1829979	chr11:49436875	T/G	cg15704280	chr7:45808275	SEPT13	-0.81	-9.74	-0.51	2.41e-19	Coronary artery disease;
CESC	cis	rs926938	0.557	rs6667218	chr1:115238982	G/A	cg12756093	chr1:115239321	AMPD1	-0.49	-6.14	-0.35	2.94e-9	Autism;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg16489582	chr16:28223388	XPO6	0.43	6.1	0.35	3.65e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs6938	0.618	rs62029167	chr15:75228350	G/A	cg14664628	chr15:75095509	CSK	-0.55	-7.17	-0.4	7.52e-12	Breast cancer;
CESC	cis	rs55871839	0.708	rs6651298	chr8:59808307	C/G	cg07426533	chr8:59803705	TOX	-0.47	-6.74	-0.38	1.01e-10	Pneumonia;
CESC	cis	rs7089973	0.604	rs11196941	chr10:116596258	A/G	cg03647239	chr10:116582469	FAM160B1	0.44	5.54	0.32	7.14e-8	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs597539	0.652	rs513615	chr11:68705504	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.79	9.58	0.51	7.12e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg10585161	chr5:115420544	COMMD10	-0.45	-6.18	-0.35	2.41e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	trans	rs2727020	0.617	rs7102702	chr11:49401125	T/G	cg15704280	chr7:45808275	SEPT13	-0.82	-10.68	-0.55	2.29e-22	Coronary artery disease;
CESC	cis	rs6061231	1.000	rs11696991	chr20:60959694	G/T	cg22633769	chr20:60982531	CABLES2	0.46	5.16	0.3	4.93e-7	Colorectal cancer;
CESC	cis	rs2836950	0.565	rs4816617	chr21:40540690	T/C	cg17971929	chr21:40555470	PSMG1	-0.54	-6.98	-0.39	2.39e-11	Menarche (age at onset);
CESC	cis	rs7208859	0.623	rs2035494	chr17:29130393	T/G	cg14008862	chr17:28927542	LRRC37B2	0.65	5.14	0.3	5.34e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	trans	rs66887589	0.616	rs6843509	chr4:120220196	G/A	cg25214090	chr10:38739885	LOC399744	0.43	6.04	0.35	5.13e-9	Diastolic blood pressure;
CESC	trans	rs10242455	0.717	rs2687133	chr7:99332083	C/T	cg09045935	chr12:6379348	NA	-0.58	-6.08	-0.35	4.15e-9	Blood metabolite levels;
CESC	cis	rs8070740	0.898	rs9303192	chr17:5324836	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.51	6.35	0.36	9.3e-10	Menopause (age at onset);
CESC	cis	rs2180341	1.000	rs6569478	chr6:127598619	G/A	cg24812749	chr6:127587940	RNF146	1.06	15.23	0.68	4.52e-38	Breast cancer;
CESC	cis	rs35110281	0.805	rs8131005	chr21:45041954	T/C	cg01579765	chr21:45077557	HSF2BP	-0.51	-8.79	-0.47	1.98e-16	Mean corpuscular volume;
CESC	cis	rs7216064	0.700	rs4791295	chr17:65997317	G/A	cg12091567	chr17:66097778	LOC651250	-0.82	-9.07	-0.49	2.67e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs6570726	0.935	rs419854	chr6:145844085	A/C	cg23711669	chr6:146136114	FBXO30	0.79	11.85	0.59	2.77e-26	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs13385	0.769	rs7722986	chr5:139617386	G/A	cg26211634	chr5:139558579	C5orf32	0.48	5.27	0.31	2.79e-7	Atrial fibrillation;
CESC	cis	rs12477438	0.765	rs2309521	chr2:99592069	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.62	-8.67	-0.47	4.43e-16	Chronic sinus infection;
CESC	cis	rs1862618	0.853	rs866222	chr5:56184444	T/C	cg18230493	chr5:56204884	C5orf35	-0.73	-8.57	-0.47	8.93e-16	Initial pursuit acceleration;
CESC	cis	rs9916302	0.851	rs6503502	chr17:37501855	A/G	cg20243544	chr17:37824526	PNMT	-0.47	-5.94	-0.34	9.04e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs7589728	0.563	rs79892776	chr2:88470593	G/A	cg07952391	chr2:88470173	THNSL2	0.63	6.17	0.35	2.55e-9	Plasma clusterin levels;
CESC	cis	rs6977660	0.652	rs12673842	chr7:19747437	T/C	cg05791153	chr7:19748676	TWISTNB	0.78	6.75	0.38	9.56e-11	Thyroid stimulating hormone;
CESC	cis	rs12893668	0.603	rs61637848	chr14:104096031	C/T	cg08213375	chr14:104286397	PPP1R13B	0.33	5.46	0.32	1.07e-7	Reticulocyte count;
CESC	cis	rs780096	0.587	rs10205219	chr2:27568565	T/C	cg22903471	chr2:27725779	GCKR	-0.45	-6.26	-0.36	1.53e-9	Total body bone mineral density;
CESC	cis	rs2576037	0.583	rs4890698	chr18:44489725	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.79	13.19	0.63	6.86e-31	Personality dimensions;
CESC	cis	rs67311347	1.000	rs897117	chr3:40437294	C/T	cg24209194	chr3:40518798	ZNF619	-0.41	-5.42	-0.32	1.34e-7	Renal cell carcinoma;
CESC	cis	rs7666738	0.830	rs7689495	chr4:98920152	T/C	cg03467027	chr4:99064603	C4orf37	0.43	5.32	0.31	2.17e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2262909	0.962	rs11673195	chr19:22313814	T/C	cg11619707	chr19:22235551	ZNF257	0.33	5.31	0.31	2.35e-7	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
CESC	cis	rs9291683	0.597	rs11722989	chr4:10126139	A/G	cg11266682	chr4:10021025	SLC2A9	-0.46	-8.32	-0.45	4.84e-15	Bone mineral density;
CESC	cis	rs7937682	0.632	rs4936834	chr11:111764017	T/A	cg22437258	chr11:111473054	SIK2	-0.5	-5.53	-0.32	7.78e-8	Primary sclerosing cholangitis;
CESC	cis	rs9926296	0.682	rs645019	chr16:89716883	C/T	cg27121462	chr16:89883253	FANCA	-0.49	-5.82	-0.34	1.69e-8	Vitiligo;
CESC	cis	rs10754283	0.967	rs6428559	chr1:90099036	C/T	cg21401794	chr1:90099060	LRRC8C	0.7	9.26	0.49	7.18e-18	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs4819052	0.807	rs1075788	chr21:46666564	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.73	9.9	0.52	7.25e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs9322193	0.923	rs9371207	chr6:150179223	A/G	cg07701084	chr6:150067640	NUP43	0.41	5.37	0.31	1.72e-7	Lung cancer;
CESC	cis	rs9311474	0.508	rs6788887	chr3:52605005	T/C	cg18337363	chr3:52569053	NT5DC2	0.29	5.26	0.31	3.02e-7	Electroencephalogram traits;
CESC	cis	rs6598955	0.670	rs6598942	chr1:26531034	C/T	cg04990556	chr1:26633338	UBXN11	-0.75	-10.55	-0.54	5.96e-22	Obesity-related traits;
CESC	cis	rs941873	0.868	rs2181080	chr10:81121960	A/G	cg08514558	chr10:81106712	PPIF	0.36	6.15	0.35	2.77e-9	Height;
CESC	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg26338869	chr17:61819248	STRADA	0.73	9.64	0.51	4.77e-19	Prudent dietary pattern;
CESC	cis	rs9649213	0.531	rs35216698	chr7:97896175	C/T	cg24562669	chr7:97807699	LMTK2	0.52	7.41	0.41	1.7e-12	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs832540	0.519	rs10036895	chr5:56273693	G/A	cg24531977	chr5:56204891	C5orf35	-0.42	-5.23	-0.31	3.53e-7	Coronary artery disease;
CESC	cis	rs10504229	0.516	rs7821160	chr8:57986281	C/T	cg24829409	chr8:58192753	C8orf71	0.36	5.18	0.3	4.35e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs4819052	0.851	rs4819040	chr21:46659762	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.79	11.46	0.58	5.94e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs7267979	0.932	rs446649	chr20:25467359	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.75	14.46	0.66	2.46e-35	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs2836974	0.931	rs2776307	chr21:40713833	C/G	cg11890956	chr21:40555474	PSMG1	-1.01	-15.8	-0.7	4.48e-40	Cognitive function;
CESC	cis	rs3008870	0.727	rs4582760	chr1:67464394	G/A	cg08660285	chr1:67390436	MIER1;WDR78	-0.63	-8.34	-0.46	4.02e-15	Lymphocyte percentage of white cells;
CESC	cis	rs9291683	0.610	rs993173	chr4:10323935	T/C	cg11266682	chr4:10021025	SLC2A9	-0.49	-8.6	-0.47	7.15e-16	Bone mineral density;
CESC	cis	rs7412746	0.611	rs66847267	chr1:150875173	C/A	cg04414720	chr1:150670196	GOLPH3L	0.44	5.84	0.34	1.49e-8	Melanoma;
CESC	cis	rs55692411	0.537	rs71326904	chr3:49991060	C/T	cg03060546	chr3:49711283	APEH	-0.47	-5.43	-0.32	1.3e-7	Intelligence (multi-trait analysis);
CESC	cis	rs12973672	1.000	rs10421768	chr19:35772899	A/G	cg12095397	chr19:35769544	USF2	0.51	7.12	0.4	1.01e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs7216064	1.000	rs3935969	chr17:65881959	A/G	cg07042672	chr17:66097459	LOC651250	-0.57	-6.54	-0.37	3.09e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs9291683	0.566	rs13144709	chr4:10044182	C/T	cg00071950	chr4:10020882	SLC2A9	0.81	13.65	0.64	1.7e-32	Bone mineral density;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg05542295	chr17:55162876	AKAP1	-0.42	-6.06	-0.35	4.55e-9	Gambling;
CESC	cis	rs9926296	0.533	rs10852623	chr16:89865242	T/C	cg03388025	chr16:89894329	SPIRE2	0.4	7.89	0.44	7.74e-14	Vitiligo;
CESC	cis	rs11676348	0.791	rs4133195	chr2:218951245	A/G	cg20019365	chr2:219134978	PNKD;AAMP	0.4	5.42	0.32	1.33e-7	Ulcerative colitis;
CESC	cis	rs4237845	0.636	rs11172371	chr12:58286188	C/T	cg00677455	chr12:58241039	CTDSP2	0.74	9.25	0.49	7.78e-18	Intelligence (multi-trait analysis);
CESC	cis	rs6087990	0.899	rs4911110	chr20:31392366	C/T	cg13636640	chr20:31349939	DNMT3B	-0.89	-15.81	-0.7	4.09e-40	Ulcerative colitis;
CESC	cis	rs875971	1.000	rs778694	chr7:65871558	A/G	cg12463550	chr7:65579703	CRCP	0.59	7.52	0.42	8.29e-13	Aortic root size;
CESC	cis	rs3820068	0.705	rs72645808	chr1:15870118	G/C	cg17385448	chr1:15911702	AGMAT	0.4	6.03	0.35	5.62e-9	Systolic blood pressure;
CESC	cis	rs2075371	0.796	rs1978504	chr7:134006933	C/T	cg11752832	chr7:134001865	SLC35B4	-0.52	-6.61	-0.38	2.15e-10	Mean platelet volume;
CESC	trans	rs208520	0.690	rs10944872	chr6:66708239	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.9	11.55	0.58	2.9e-25	Exhaled nitric oxide output;
CESC	cis	rs40363	0.645	rs6501177	chr16:3523681	C/T	cg00484396	chr16:3507460	NAT15	0.44	7.27	0.41	4.08e-12	Tuberculosis;
CESC	cis	rs6061231	0.631	rs2427318	chr20:60975727	G/T	cg24112000	chr20:60950667	NA	-0.54	-8.45	-0.46	1.94e-15	Colorectal cancer;
CESC	cis	rs193541	0.632	rs119449	chr5:122283741	T/G	cg19412675	chr5:122181750	SNX24	0.48	5.59	0.32	5.57e-8	Glucose homeostasis traits;
CESC	cis	rs7666738	0.830	rs10021709	chr4:99030587	G/A	cg18180107	chr4:99064573	C4orf37	0.42	5.43	0.32	1.29e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs660498	0.507	rs34773871	chr10:27727645	G/A	cg11203244	chr10:27609286	NA	0.38	5.09	0.3	6.82e-7	Asthma (childhood onset);
CESC	cis	rs15676	0.783	rs7860949	chr9:131586883	C/T	cg00228799	chr9:131580591	ENDOG	-0.55	-7.07	-0.4	1.41e-11	Blood metabolite levels;
CESC	cis	rs1707322	0.656	rs2991981	chr1:46057144	A/G	cg03146154	chr1:46216737	IPP	-0.75	-10.01	-0.52	3.19e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9549367	0.789	rs2287244	chr13:113887173	C/G	cg18105134	chr13:113819100	PROZ	0.59	7.38	0.41	2.03e-12	Platelet distribution width;
CESC	cis	rs7845219	0.544	rs34208552	chr8:95908067	C/G	cg09323728	chr8:95962352	TP53INP1	-0.34	-6.53	-0.37	3.36e-10	Type 2 diabetes;
CESC	cis	rs2046867	0.862	rs62251657	chr3:72832076	C/T	cg25664220	chr3:72788482	NA	-0.44	-6.22	-0.36	1.9e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CESC	cis	rs10256972	0.786	rs3735686	chr7:1062527	G/A	cg23978390	chr7:1156363	C7orf50	0.52	6.89	0.39	4.14e-11	Longevity;Endometriosis;
CESC	cis	rs4969178	0.622	rs11657987	chr17:76387363	G/T	cg05887092	chr17:76393375	PGS1	0.66	10.94	0.56	3.05e-23	HDL cholesterol levels;
CESC	cis	rs4523957	0.647	rs12950603	chr17:2194937	T/A	cg16513277	chr17:2031491	SMG6	0.6	8.1	0.45	1.97e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs704795	0.867	rs7566052	chr2:27628635	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.28	-5.62	-0.33	4.88e-8	Menopause (age at onset);
CESC	cis	rs6547741	1.000	rs1972669	chr2:27767107	T/G	cg21248554	chr2:27665150	KRTCAP3	0.24	5.06	0.3	7.83e-7	Oral cavity cancer;
CESC	cis	rs10883723	0.773	rs715439	chr10:104257809	A/C	ch.10.2196322F	chr10:104248062	ACTR1A	0.42	5.08	0.3	6.99e-7	Allergic disease (asthma, hay fever or eczema);
CESC	trans	rs55704346	0.566	rs13434763	chr4:25388590	T/C	cg01822600	chr1:245751692	KIF26B	0.42	6.17	0.35	2.58e-9	Tonsillectomy;
CESC	cis	rs4900538	0.821	rs12586673	chr14:102827643	C/T	cg18135206	chr14:102964638	TECPR2	-0.72	-8.71	-0.47	3.32e-16	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	cis	rs742614	0.533	rs2747541	chr20:32418772	G/T	cg06304546	chr20:32448765	NA	-0.42	-5.38	-0.31	1.67e-7	Stearic acid (18:0) levels;
CESC	cis	rs7618915	0.547	rs34610878	chr3:52759169	G/C	cg05564831	chr3:52568323	NT5DC2	0.44	6.58	0.37	2.57e-10	Bipolar disorder;
CESC	cis	rs1143633	0.530	rs4538207	chr2:113701863	G/T	cg12858261	chr2:113808755	IL1F8	0.45	5.47	0.32	1.03e-7	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs9443189	0.570	rs775072	chr6:76377998	G/A	cg01950844	chr6:76311363	SENP6	-0.87	-9.27	-0.49	6.59e-18	Prostate cancer;
CESC	trans	rs2727020	0.576	rs11040223	chr11:49034633	G/T	cg15704280	chr7:45808275	SEPT13	-0.57	-6.94	-0.39	3.04e-11	Coronary artery disease;
CESC	cis	rs1729951	0.546	rs12054408	chr3:136677645	T/C	cg04103450	chr3:136751342	NA	0.4	5.28	0.31	2.66e-7	Neuroticism;
CESC	cis	rs7618501	0.966	rs7372966	chr3:49788969	T/C	cg24308560	chr3:49941425	MST1R	0.51	6.95	0.39	2.89e-11	Intelligence (multi-trait analysis);
CESC	cis	rs873946	0.517	rs7071784	chr10:134559980	T/C	cg18305652	chr10:134549665	INPP5A	0.5	7.59	0.42	5.45e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs881375	0.678	rs7021049	chr9:123683982	G/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.44	6.21	0.36	2.04e-9	Rheumatoid arthritis;
CESC	cis	rs6939532	0.517	rs733528	chr6:26374903	A/G	cg14345882	chr6:26364793	BTN3A2	0.38	6.0	0.35	6.37e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs9612	0.718	rs173202	chr19:44253588	C/T	cg08581076	chr19:44259116	C19orf61	0.46	5.71	0.33	3e-8	Exhaled nitric oxide output;
CESC	cis	rs2559856	1.000	rs2695285	chr12:102089043	G/A	cg15068132	chr12:102092402	CHPT1	-0.43	-5.71	-0.33	3.02e-8	Blood protein levels;
CESC	cis	rs10465746	0.570	rs2147950	chr1:84465545	C/T	cg10977910	chr1:84465055	TTLL7	0.45	5.85	0.34	1.41e-8	Obesity-related traits;
CESC	cis	rs10744422	0.858	rs4759389	chr12:123308615	A/G	cg25930673	chr12:123319894	HIP1R	-0.65	-5.23	-0.31	3.4e-7	Schizophrenia;
CESC	cis	rs3091242	1.000	rs3091242	chr1:25674785	C/T	cg03538708	chr1:25844672	NA	-0.36	-5.29	-0.31	2.62e-7	Erythrocyte sedimentation rate;
CESC	cis	rs10504073	0.647	rs10105794	chr8:50012793	G/C	cg00325661	chr8:49890786	NA	0.5	7.68	0.43	3.16e-13	Blood metabolite ratios;
CESC	cis	rs6866344	0.697	rs62392831	chr5:178134365	A/G	cg10224037	chr5:178157518	ZNF354A	0.67	7.34	0.41	2.64e-12	Neutrophil percentage of white cells;
CESC	cis	rs9926296	0.568	rs4420527	chr16:89814188	C/T	cg04287289	chr16:89883240	FANCA	-0.92	-16.4	-0.71	3.2e-42	Vitiligo;
CESC	cis	rs2842992	0.830	rs2025189	chr6:160137518	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.73	9.02	0.48	3.82e-17	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs1008375	0.932	rs6857678	chr4:17696964	A/T	cg04450456	chr4:17643702	FAM184B	0.36	5.15	0.3	5.16e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs597539	0.617	rs598353	chr11:68635770	C/A	cg01988459	chr11:68622903	NA	-0.39	-5.21	-0.3	3.76e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs9311474	0.597	rs13303	chr3:52558008	T/C	cg07507251	chr3:52567010	NT5DC2	0.47	9.07	0.49	2.67e-17	Electroencephalogram traits;
CESC	cis	rs947211	0.950	rs1775145	chr1:205756143	C/A	cg17178900	chr1:205818956	PM20D1	0.38	5.12	0.3	5.81e-7	Parkinson's disease;
CESC	cis	rs59918340	0.548	rs10102728	chr8:142205964	G/A	cg23750338	chr8:142222470	SLC45A4	0.42	5.97	0.34	7.43e-9	Immature fraction of reticulocytes;
CESC	cis	rs698833	0.780	rs9309115	chr2:44510146	A/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.52	6.17	0.35	2.61e-9	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs1448094	0.512	rs7299285	chr12:86244959	A/T	cg19622623	chr12:86230825	RASSF9	-0.46	-5.89	-0.34	1.14e-8	Major depressive disorder;
CESC	cis	rs9457247	0.646	rs239934	chr6:167412048	G/A	cg25258033	chr6:167368657	RNASET2	0.39	6.01	0.35	6.04e-9	Crohn's disease;
CESC	cis	rs1862618	0.853	rs10461617	chr5:56104308	A/G	cg22800045	chr5:56110881	MAP3K1	0.8	10.05	0.53	2.5e-20	Initial pursuit acceleration;
CESC	cis	rs4888262	0.526	rs4887776	chr16:74635632	A/G	cg01733217	chr16:74700730	RFWD3	0.86	11.84	0.59	2.98e-26	Testicular germ cell tumor;
CESC	cis	rs2274273	0.805	rs10131926	chr14:55713246	T/C	cg04306507	chr14:55594613	LGALS3	0.29	5.83	0.34	1.65e-8	Protein biomarker;
CESC	cis	rs7786808	0.615	rs1563066	chr7:158194935	A/C	cg09998033	chr7:158218633	PTPRN2	-0.39	-5.65	-0.33	4.05e-8	Obesity-related traits;
CESC	cis	rs9303401	0.659	rs62081316	chr17:56781499	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.05	12.77	0.62	1.94e-29	Cognitive test performance;
CESC	cis	rs2075371	1.000	rs2598288	chr7:133977304	A/T	cg20476274	chr7:133979776	SLC35B4	0.68	10.07	0.53	2.09e-20	Mean platelet volume;
CESC	cis	rs12477438	0.798	rs6736064	chr2:99658201	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.75	-10.87	-0.56	5.17e-23	Chronic sinus infection;
CESC	cis	rs7811142	1.000	rs11773661	chr7:100073069	G/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.11	11.01	0.56	1.89e-23	Platelet count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02764006	chr17:65029280	CACNG4	-0.51	-6.38	-0.36	8.01e-10	Gut microbiome composition (summer);
CESC	cis	rs116095464	0.558	rs6866632	chr5:264429	C/G	cg22496380	chr5:211416	CCDC127	-0.82	-8.86	-0.48	1.18e-16	Breast cancer;
CESC	cis	rs2243480	0.901	rs73148097	chr7:65431787	A/C	cg12463550	chr7:65579703	CRCP	0.69	5.5	0.32	9.16e-8	Diabetic kidney disease;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg12187437	chr12:66524584	LLPH	-0.44	-6.33	-0.36	1.04e-9	Gambling;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25824265	chr7:132766817	CHCHD3	0.59	6.43	0.37	5.85e-10	Gut microbiome composition (summer);
CESC	cis	rs10752881	0.933	rs2027086	chr1:183057933	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.85	13.71	0.64	1.08e-32	Colorectal cancer;
CESC	cis	rs1355223	0.867	rs11821793	chr11:34681462	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.49	-6.41	-0.37	6.59e-10	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs12220238	1.000	rs10824128	chr10:76007903	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.62	6.1	0.35	3.7e-9	Soluble interleukin-2 receptor subunit alpha;
CESC	trans	rs650950	0.528	rs646660	chr11:35528452	C/T	cg19491415	chr10:32217948	ARHGAP12	0.43	6.07	0.35	4.32e-9	Bronchopulmonary dysplasia;
CESC	cis	rs7647973	0.769	rs4974081	chr3:49070499	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.47	-5.59	-0.32	5.75e-8	Menarche (age at onset);
CESC	cis	rs4727963	0.777	rs7781708	chr7:122719076	G/T	cg03640110	chr7:122635026	TAS2R16	-0.35	-5.36	-0.31	1.82e-7	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
CESC	cis	rs7772486	0.875	rs1412080	chr6:146417304	T/C	cg05347473	chr6:146136440	FBXO30	0.5	6.87	0.39	4.66e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6598955	0.724	rs3924934	chr1:26644079	A/G	cg04990556	chr1:26633338	UBXN11	-0.72	-9.8	-0.52	1.49e-19	Obesity-related traits;
CESC	cis	rs1218582	0.741	rs10908444	chr1:154840287	G/A	cg09359103	chr1:154839909	KCNN3	-0.67	-12.81	-0.62	1.45e-29	Prostate cancer;
CESC	cis	rs997295	0.520	rs4776971	chr15:68081097	C/A	cg08079166	chr15:68083412	MAP2K5	0.4	6.42	0.37	6.19e-10	Motion sickness;
CESC	cis	rs4654899	0.802	rs3767247	chr1:21227338	T/C	cg05370193	chr1:21551575	ECE1	0.39	5.63	0.33	4.63e-8	Superior frontal gyrus grey matter volume;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg04995826	chr11:43333458	API5	-0.41	-6.09	-0.35	3.97e-9	Gambling;
CESC	cis	rs2070488	0.775	rs13098946	chr3:38517784	C/G	cg24069376	chr3:38537580	EXOG	0.35	5.88	0.34	1.22e-8	Electrocardiographic conduction measures;
CESC	cis	rs1552244	0.882	rs13077641	chr3:10022935	G/A	cg00149659	chr3:10157352	C3orf10	0.71	8.4	0.46	2.72e-15	Alzheimer's disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg09662798	chr17:73498302	CASKIN2	0.41	6.17	0.35	2.5e-9	Fibrinogen levels;
CESC	cis	rs10751667	1.000	rs10902246	chr11:953674	T/C	cg20946044	chr11:1010712	AP2A2	-0.41	-5.48	-0.32	9.89e-8	Alzheimer's disease (late onset);
CESC	cis	rs2273669	0.667	rs78383792	chr6:109312498	A/G	cg05315195	chr6:109294784	ARMC2	-0.66	-6.28	-0.36	1.36e-9	Prostate cancer;
CESC	cis	rs7666738	0.819	rs13120307	chr4:99036100	A/C	cg03467027	chr4:99064603	C4orf37	0.48	5.92	0.34	9.73e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3733585	0.699	rs10001964	chr4:9959275	C/T	cg00071950	chr4:10020882	SLC2A9	-0.73	-11.83	-0.59	3.28e-26	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs7811142	0.830	rs11768967	chr7:99967644	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.93	10.91	0.56	4.02e-23	Platelet count;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg12091641	chr8:145180933	NA	0.45	6.49	0.37	4.16e-10	Fibrinogen levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23143233	chr20:57465864	GNAS	-0.56	-6.16	-0.35	2.68e-9	Gut microbiome composition (summer);
CESC	cis	rs7085104	0.700	rs10786712	chr10:104596396	A/G	cg04362960	chr10:104952993	NT5C2	-0.48	-6.09	-0.35	4e-9	Immature fraction of reticulocytes;Schizophrenia;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg17983724	chr7:72298804	TYW1B;SBDSP	-0.45	-6.17	-0.35	2.5e-9	Fibrinogen levels;
CESC	cis	rs4665809	1.000	rs4665299	chr2:26256840	A/C	cg26314531	chr2:26401878	FAM59B	-0.75	-8.29	-0.45	5.77e-15	Gut microbiome composition (summer);
CESC	cis	rs57506017	0.585	rs6460897	chr7:12252741	T/G	cg23422036	chr7:12250390	TMEM106B	0.38	5.12	0.3	5.83e-7	Neuroticism;
CESC	cis	rs4835473	0.900	rs10025455	chr4:144919570	C/G	cg25736465	chr4:144833511	NA	-0.46	-6.94	-0.39	2.96e-11	Immature fraction of reticulocytes;
CESC	cis	rs2072499	0.966	rs2842865	chr1:156159532	G/A	cg25208724	chr1:156163844	SLC25A44	1.01	18.98	0.76	2.67e-51	Testicular germ cell tumor;
CESC	cis	rs60871478	0.636	rs4721834	chr7:896142	C/T	cg15782153	chr7:917662	C7orf20	0.52	5.72	0.33	2.91e-8	Cerebrospinal P-tau181p levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00737992	chr20:55098859	GCNT7;C20orf106	-0.51	-6.08	-0.35	4.2e-9	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24261754	chr3:193310895	OPA1	0.62	6.72	0.38	1.12e-10	Gut microbiome composition (summer);
CESC	cis	rs703842	1.000	rs6581155	chr12:58178162	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.71	9.33	0.5	4.47e-18	Multiple sclerosis;
CESC	cis	rs4889855	0.556	rs4508465	chr17:78543368	G/A	cg16591659	chr17:78472290	NA	0.38	6.32	0.36	1.08e-9	Fractional excretion of uric acid;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg23486179	chr3:49466665	NICN1	-0.47	-6.2	-0.36	2.19e-9	Fibrinogen levels;
CESC	cis	rs875971	0.862	rs778734	chr7:65814849	C/G	cg18876405	chr7:65276391	NA	0.51	7.02	0.4	1.9e-11	Aortic root size;
CESC	cis	rs9911578	0.967	rs12603238	chr17:57130785	C/T	cg05425664	chr17:57184151	TRIM37	0.53	7.36	0.41	2.26e-12	Intelligence (multi-trait analysis);
CESC	cis	rs6762	0.748	rs5030780	chr11:838110	C/T	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.7	-9.75	-0.51	2.1e-19	Mean platelet volume;
CESC	cis	rs6460942	0.915	rs72584550	chr7:12304990	G/A	cg06484146	chr7:12443880	VWDE	-0.4	-5.59	-0.32	5.57e-8	Coronary artery disease;
CESC	cis	rs1451375	0.617	rs880029	chr7:50569927	G/C	cg14593290	chr7:50529359	DDC	-0.53	-6.67	-0.38	1.48e-10	Malaria;
CESC	cis	rs4434138	0.568	rs6414569	chr3:52708075	A/T	cg17372223	chr3:52568218	NT5DC2	0.42	6.34	0.36	1e-9	Intelligence (multi-trait analysis);
CESC	cis	rs7647973	1.000	rs6805609	chr3:49471522	C/G	cg06212747	chr3:49208901	KLHDC8B	-0.55	-6.45	-0.37	5.2400000000000005e-10	Menarche (age at onset);
CESC	cis	rs72781680	0.898	rs72780191	chr2:24007122	T/C	cg08917208	chr2:24149416	ATAD2B	1.13	10.18	0.53	9.42e-21	Lymphocyte counts;
CESC	cis	rs1552244	0.882	rs13064570	chr3:9997545	G/C	cg00149659	chr3:10157352	C3orf10	0.62	7.37	0.41	2.2e-12	Alzheimer's disease;
CESC	cis	rs8067545	1.000	rs8065337	chr17:19941879	C/A	cg13482628	chr17:19912719	NA	0.43	5.72	0.33	2.9e-8	Schizophrenia;
CESC	cis	rs1448094	0.512	rs7970081	chr12:86243392	G/T	cg02569458	chr12:86230093	RASSF9	0.49	7.22	0.41	5.67e-12	Major depressive disorder;
CESC	cis	rs4077515	0.935	rs3088081	chr9:139270149	A/G	cg14169450	chr9:139327907	INPP5E	0.41	5.88	0.34	1.24e-8	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg07925619	chr17:39913753	JUP	0.44	6.0	0.35	6.58e-9	Fibrinogen levels;
CESC	cis	rs7246657	1.000	rs34544865	chr19:37801242	G/C	cg23950597	chr19:37808831	NA	-0.63	-5.85	-0.34	1.47e-8	Coronary artery calcification;
CESC	cis	rs12956009	0.518	rs10164267	chr18:44820032	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.45	-5.95	-0.34	8.24e-9	Educational attainment (years of education);
CESC	cis	rs4746818	0.793	rs2008541	chr10:70860599	A/G	cg11621586	chr10:70884670	VPS26A	0.83	8.65	0.47	5.14e-16	Left atrial antero-posterior diameter;
CESC	cis	rs11711311	1.000	rs13061150	chr3:113506734	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.59	7.83	0.43	1.14e-13	IgG glycosylation;
CESC	cis	rs72781680	0.559	rs72796103	chr2:23900382	G/A	cg08917208	chr2:24149416	ATAD2B	1.17	10.72	0.55	1.61e-22	Lymphocyte counts;
CESC	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg07677032	chr17:61819896	STRADA	0.45	6.05	0.35	4.97e-9	Prudent dietary pattern;
CESC	cis	rs2836974	0.965	rs34578707	chr21:40675167	G/A	cg17971929	chr21:40555470	PSMG1	1.01	13.92	0.65	1.92e-33	Cognitive function;
CESC	cis	rs3762318	1.000	rs3762318	chr1:67597119	A/G	cg17031739	chr1:67600172	NA	-0.55	-6.21	-0.36	2.07e-9	Leprosy;
CESC	cis	rs524281	0.861	rs11227409	chr11:65870938	A/G	cg14036092	chr11:66035641	RAB1B	-0.62	-6.29	-0.36	1.27e-9	Electroencephalogram traits;
CESC	cis	rs2658782	0.789	rs3019206	chr11:93111073	A/G	cg15737290	chr11:93063684	CCDC67	0.52	6.73	0.38	1.04e-10	Pulmonary function decline;
CESC	cis	rs7296418	0.961	rs4148863	chr12:123569375	A/G	cg05973401	chr12:123451056	ABCB9	0.59	7.84	0.43	1.12e-13	Platelet count;
CESC	cis	rs9549367	0.713	rs556990	chr13:113845059	T/C	cg00898013	chr13:113819073	PROZ	0.46	6.89	0.39	4.03e-11	Platelet distribution width;
CESC	trans	rs1908814	0.516	rs35391955	chr8:11796728	A/C	cg15556689	chr8:8085844	FLJ10661	0.52	6.44	0.37	5.68e-10	Neuroticism;
CESC	cis	rs1008375	0.898	rs7670500	chr4:17586957	A/G	cg02297831	chr4:17616191	MED28	0.51	6.18	0.35	2.44e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs2836974	0.830	rs2735309	chr21:40715313	C/T	cg11644478	chr21:40555479	PSMG1	0.93	13.51	0.64	5.27e-32	Cognitive function;
CESC	cis	rs12497850	0.931	rs9311434	chr3:48884147	T/C	cg07636037	chr3:49044803	WDR6	0.99	18.11	0.74	3.06e-48	Parkinson's disease;
CESC	cis	rs12474201	0.507	rs6714451	chr2:47017743	G/C	cg06386533	chr2:46925753	SOCS5	0.48	6.29	0.36	1.3e-9	Height;
CESC	trans	rs1814175	0.645	rs1874969	chr11:49826700	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.42	-6.25	-0.36	1.64e-9	Height;
CESC	cis	rs5758659	1.000	rs134900	chr22:42683343	C/G	cg05082376	chr22:42548792	NA	-0.36	-5.51	-0.32	8.44e-8	Cognitive function;
CESC	cis	rs9916302	0.808	rs12948906	chr17:37644854	C/T	cg20243544	chr17:37824526	PNMT	0.5	6.37	0.36	8.22e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs2016266	0.859	rs10783575	chr12:53742885	C/T	cg26875137	chr12:53738046	NA	-0.37	-5.49	-0.32	9.17e-8	Bone mineral density (spine);Bone mineral density;
CESC	cis	rs7772486	0.875	rs6570738	chr6:146412695	G/A	cg05347473	chr6:146136440	FBXO30	0.5	6.87	0.39	4.66e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4253772	0.591	rs739165	chr22:46684528	C/T	cg24881330	chr22:46731750	TRMU	0.77	5.78	0.33	2.15e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs524281	0.861	rs6591208	chr11:65949689	A/C	cg14036092	chr11:66035641	RAB1B	-0.58	-5.91	-0.34	1.07e-8	Electroencephalogram traits;
CESC	cis	rs2249625	0.874	rs2463745	chr6:72876135	A/G	cg18830697	chr6:72922368	RIMS1	-0.4	-5.86	-0.34	1.36e-8	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CESC	cis	rs12579753	1.000	rs17749267	chr12:82178308	A/G	cg23701643	chr12:82153290	PPFIA2	0.37	5.14	0.3	5.44e-7	Resting heart rate;
CESC	cis	rs8031584	0.678	rs4779496	chr15:31151054	A/G	cg08109568	chr15:31115862	NA	-0.72	-9.73	-0.51	2.44e-19	Huntington's disease progression;
CESC	cis	rs722599	0.715	rs11851433	chr14:75339450	C/T	cg08847533	chr14:75593920	NEK9	0.47	6.02	0.35	5.74e-9	IgG glycosylation;
CESC	cis	rs9596863	1.000	rs9591538	chr13:54407573	A/C	ch.13.53330881F	chr13:54432880	NA	0.66	5.25	0.31	3.08e-7	Epilepsy and lamotrigine-induced maculopapular eruptions;
CESC	cis	rs17608059	0.679	rs9898056	chr17:13951966	C/G	cg27005118	chr17:13972210	COX10	-0.37	-5.62	-0.33	4.93e-8	Temperament;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24434368	chr7:116593263	ST7;ST7OT4;ST7OT1	-0.58	-7.04	-0.4	1.64e-11	Gut microbiome composition (summer);
CESC	trans	rs10411161	0.702	rs892039	chr19:52396541	G/A	cg22319618	chr22:45562946	NUP50	-0.77	-7.77	-0.43	1.78e-13	Breast cancer;
CESC	cis	rs2273669	0.667	rs75671532	chr6:109341298	A/G	cg05315195	chr6:109294784	ARMC2	-0.67	-6.32	-0.36	1.13e-9	Prostate cancer;
CESC	trans	rs79976124	0.837	rs11751994	chr6:66644028	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.72	8.26	0.45	6.99e-15	Type 2 diabetes;
CESC	cis	rs9911578	0.967	rs6503893	chr17:57149695	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.39	5.06	0.3	8.02e-7	Intelligence (multi-trait analysis);
CESC	cis	rs71327718	1	rs71327718	chr3:125592857	C/G	cg05084668	chr3:125655381	ALG1L	-0.77	-7.79	-0.43	1.55e-13	Metabolite levels (HVA/5-HIAA ratio);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22610194	chr7:77045539	PION	0.57	6.18	0.35	2.45e-9	Gut microbiome composition (summer);
CESC	cis	rs11214589	0.774	rs7107223	chr11:113255574	A/T	cg14159747	chr11:113255604	NA	0.37	6.88	0.39	4.2e-11	Neuroticism;
CESC	cis	rs1707322	1.000	rs12403666	chr1:46431621	G/A	cg06784218	chr1:46089804	CCDC17	0.33	5.67	0.33	3.8e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs8177253	0.761	rs1830084	chr3:133508464	A/T	cg24879335	chr3:133465180	TF	-0.31	-5.05	-0.3	8.16e-7	Iron status biomarkers;
CESC	cis	rs10463316	0.747	rs10077700	chr5:150768324	A/T	cg03212797	chr5:150827313	SLC36A1	-0.45	-5.88	-0.34	1.24e-8	Metabolite levels (Pyroglutamine);
CESC	cis	rs1799949	1.000	rs34572725	chr17:41428666	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.65	9.04	0.49	3.33e-17	Menopause (age at onset);
CESC	cis	rs8141529	0.664	rs5762861	chr22:29250505	T/G	cg02153584	chr22:29168773	CCDC117	0.52	6.47	0.37	4.59e-10	Lymphocyte counts;
CESC	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg07677032	chr17:61819896	STRADA	0.45	5.96	0.34	8.19e-9	Prudent dietary pattern;
CESC	cis	rs854765	0.547	rs2955359	chr17:17946730	T/C	cg09796270	chr17:17721594	SREBF1	-0.38	-5.07	-0.3	7.66e-7	Total body bone mineral density;
CESC	cis	rs9311474	0.508	rs11718420	chr3:52611413	T/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	5.89	0.34	1.18e-8	Electroencephalogram traits;
CESC	cis	rs1538970	0.884	rs61788261	chr1:45899114	G/A	cg03146154	chr1:46216737	IPP	0.44	5.11	0.3	6.13e-7	Platelet count;
CESC	cis	rs4065321	0.522	rs3744245	chr17:38146542	C/G	cg17467752	chr17:38218738	THRA	-0.45	-5.91	-0.34	1.04e-8	White blood cell count (basophil);White blood cell count;
CESC	cis	rs4689592	0.503	rs11937667	chr4:7057037	C/G	cg19539972	chr4:7069911	GRPEL1	-0.76	-7.49	-0.42	9.98e-13	Monocyte percentage of white cells;
CESC	cis	rs11711311	1.000	rs10212375	chr3:113471336	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.59	7.81	0.43	1.33e-13	IgG glycosylation;
CESC	cis	rs780096	0.526	rs3845687	chr2:27689899	T/C	cg24768116	chr2:27665128	KRTCAP3	-0.29	-5.35	-0.31	1.89e-7	Total body bone mineral density;
CESC	cis	rs7071206	0.853	rs57420220	chr10:79428886	C/T	cg23888215	chr10:79422304	NA	-0.53	-5.68	-0.33	3.5e-8	Bone mineral density;
CESC	cis	rs1395	0.744	rs62130714	chr2:27532870	A/G	cg22903471	chr2:27725779	GCKR	-0.48	-5.74	-0.33	2.57e-8	Blood metabolite levels;
CESC	cis	rs6714710	0.603	rs717417	chr2:98416850	T/G	cg26665480	chr2:98280029	ACTR1B	0.68	9.4	0.5	2.59e-18	Posterior cortical atrophy and Alzheimer's disease;
CESC	cis	rs2404602	0.692	rs35195096	chr15:76938447	C/T	cg22467129	chr15:76604101	ETFA	-0.35	-5.21	-0.3	3.89e-7	Blood metabolite levels;
CESC	cis	rs1559088	0.895	rs7246562	chr19:33546088	T/G	cg17764715	chr19:33622953	WDR88	0.5	6.04	0.35	5.08e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs7188697	0.922	rs246258	chr16:58579274	A/G	cg02549819	chr16:58548995	SETD6	0.4	5.03	0.3	8.98e-7	QT interval;
CESC	cis	rs6500395	1.000	rs11076578	chr16:48714520	C/G	cg04672837	chr16:48644449	N4BP1	-0.51	-6.53	-0.37	3.33e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs9457247	0.967	rs376097	chr6:167410878	A/G	cg25258033	chr6:167368657	RNASET2	0.4	6.14	0.35	2.93e-9	Crohn's disease;
CESC	cis	rs2991971	0.869	rs2453404	chr1:46014735	A/G	cg05343316	chr1:45956843	TESK2	-0.51	-6.5	-0.37	3.93e-10	High light scatter reticulocyte count;
CESC	cis	rs4665809	0.590	rs72809668	chr2:26467653	C/T	cg04944784	chr2:26401820	FAM59B	0.96	10.55	0.54	5.79e-22	Gut microbiome composition (summer);
CESC	cis	rs9379850	0.527	rs9393704	chr6:26358775	T/C	cg12826209	chr6:26865740	GUSBL1	0.61	5.17	0.3	4.52e-7	Intelligence (multi-trait analysis);
CESC	cis	rs2354432	0.607	rs7516430	chr1:146767062	A/G	cg25205988	chr1:146714368	CHD1L	-0.96	-10.35	-0.54	2.56e-21	Mitochondrial DNA levels;
CESC	cis	rs6540559	0.740	rs2064163	chr1:210048819	G/T	cg21951975	chr1:209979733	IRF6	0.53	8.71	0.47	3.44e-16	Cleft lip with or without cleft palate;
CESC	cis	rs6570726	1.000	rs374464	chr6:145846679	A/C	cg23711669	chr6:146136114	FBXO30	0.76	11.22	0.57	3.63e-24	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs595982	0.527	rs73061656	chr19:49372355	G/A	cg15549821	chr19:49342101	PLEKHA4	-0.65	-6.96	-0.39	2.63e-11	Red cell distribution width;
CESC	cis	rs4423214	0.840	rs1790344	chr11:71176897	A/G	cg05163923	chr11:71159392	DHCR7	-0.65	-7.55	-0.42	6.91e-13	Vitamin D levels;
CESC	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.41	-5.26	-0.31	2.98e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2573652	1.000	rs2573650	chr15:100514097	A/G	cg00587665	chr15:100533223	ADAMTS17	0.32	5.05	0.3	8.08e-7	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17446216	chr1:32480239	KHDRBS1	-0.58	-7.22	-0.41	5.64e-12	Gut microbiome composition (summer);
CESC	cis	rs3820068	0.581	rs72645889	chr1:15930251	T/G	cg13390004	chr1:15929781	NA	0.35	5.58	0.32	5.83e-8	Systolic blood pressure;
CESC	cis	rs3859192	0.599	rs2270401	chr17:38176256	A/T	cg17467752	chr17:38218738	THRA	-0.44	-5.8	-0.34	1.93e-8	White blood cell count;
CESC	cis	rs910316	0.934	rs8016330	chr14:75657507	G/T	cg11812906	chr14:75593930	NEK9	-0.84	-13.95	-0.65	1.57e-33	Height;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg15309264	chr2:58274034	VRK2	0.48	6.13	0.35	3.2e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs798502	0.522	rs7790322	chr7:2830498	C/T	cg19717773	chr7:2847554	GNA12	-0.63	-10.09	-0.53	1.75e-20	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Inflammatory bowel disease;Waist circumference adjusted for BMI in non-smokers;Ulcerative colitis;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
CESC	cis	rs501120	0.657	rs646890	chr10:44741710	C/T	cg09554077	chr10:44749378	NA	0.43	5.19	0.3	4.27e-7	Coronary artery disease;Coronary heart disease;
CESC	cis	rs367615	0.512	rs246105	chr5:108672946	C/T	cg17395555	chr5:108820864	NA	0.48	7.88	0.44	8.54e-14	Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs9560113	0.509	rs4771758	chr13:112201573	C/G	cg10483660	chr13:112241077	NA	0.42	7.19	0.4	6.68e-12	Menarche (age at onset);
CESC	cis	rs6570726	0.935	rs401888	chr6:145831535	A/G	cg05347473	chr6:146136440	FBXO30	0.49	6.69	0.38	1.3100000000000001e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2073300	0.609	rs6137929	chr20:23376357	G/A	cg16736954	chr20:23401023	NAPB	0.8	6.25	0.36	1.67e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs1957429	0.634	rs7143541	chr14:65419777	G/T	cg23373153	chr14:65346875	NA	-0.78	-7.97	-0.44	4.89e-14	Pediatric areal bone mineral density (radius);
CESC	cis	rs6582630	0.622	rs11182005	chr12:38441292	G/A	cg26384229	chr12:38710491	ALG10B	-0.44	-5.95	-0.34	8.28e-9	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs5753037	0.676	rs737945	chr22:30202774	G/C	cg01021169	chr22:30184971	ASCC2	-0.46	-6.44	-0.37	5.61e-10	Type 1 diabetes;
CESC	cis	rs7084402	0.967	rs1427199	chr10:60274941	C/T	cg07615347	chr10:60278583	BICC1	-0.57	-8.96	-0.48	6.01e-17	Refractive error;
CESC	cis	rs9457247	1.000	rs422562	chr6:167406318	A/G	cg07741184	chr6:167504864	NA	0.31	5.59	0.33	5.5e-8	Crohn's disease;
CESC	cis	rs9388451	0.839	rs9401845	chr6:126104118	A/G	cg05901451	chr6:126070800	HEY2	-0.63	-9.23	-0.49	8.85e-18	Brugada syndrome;
CESC	trans	rs116095464	0.558	rs7725227	chr5:233517	G/A	cg00938859	chr5:1591904	SDHAP3	0.64	7.04	0.4	1.68e-11	Breast cancer;
CESC	cis	rs992157	0.835	rs2271543	chr2:219142491	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.67	-8.69	-0.47	3.72e-16	Colorectal cancer;
CESC	cis	rs6964587	0.900	rs7783674	chr7:91784212	T/A	cg17063962	chr7:91808500	NA	0.58	8.19	0.45	1.13e-14	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27326469	chr22:47133964	CERK	0.56	6.65	0.38	1.63e-10	Gut microbiome composition (summer);
CESC	cis	rs9322193	0.567	rs7747457	chr6:150213502	T/A	cg09699651	chr6:150184138	LRP11	0.54	7.44	0.42	1.38e-12	Lung cancer;
CESC	trans	rs11098499	0.754	rs28643450	chr4:120245242	G/A	cg25214090	chr10:38739885	LOC399744	0.62	8.71	0.47	3.41e-16	Corneal astigmatism;
CESC	cis	rs7949030	0.626	rs7930896	chr11:62325272	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.64	9.7	0.51	3.09e-19	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs4330281	0.740	rs4611850	chr3:17798649	A/C	cg20981856	chr3:17787350	NA	0.36	5.36	0.31	1.81e-7	Schizophrenia;
CESC	cis	rs9487051	0.872	rs4601178	chr6:109611246	C/T	cg12927641	chr6:109611667	NA	-0.43	-6.78	-0.38	7.62e-11	Reticulocyte fraction of red cells;
CESC	cis	rs12926788	0.689	rs7186308	chr16:24848471	A/G	cg00339695	chr16:24857497	SLC5A11	0.52	6.85	0.39	5.05e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs2842992	0.830	rs2758312	chr6:160153452	G/A	cg11366901	chr6:160182831	ACAT2	0.82	10.61	0.55	3.82e-22	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs2735413	0.914	rs2707604	chr16:78054853	A/G	cg04733911	chr16:78082701	NA	-0.44	-6.58	-0.37	2.44e-10	Systolic blood pressure (alcohol consumption interaction);
CESC	cis	rs7605827	0.930	rs7601661	chr2:15597409	A/G	cg19274914	chr2:15703543	NA	0.32	5.67	0.33	3.71e-8	Educational attainment (years of education);
CESC	cis	rs1707322	1.000	rs4074225	chr1:46392364	G/C	cg05343316	chr1:45956843	TESK2	0.5	6.13	0.35	3.11e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18509271	chr14:77494952	C14orf4	0.58	6.22	0.36	1.95e-9	Gut microbiome composition (summer);
CESC	cis	rs1983170	0.736	rs745731	chr1:92011467	G/T	cg02896835	chr1:92012615	NA	0.59	6.22	0.36	1.88e-9	Eosinophil percentage of white cells;
CESC	cis	rs7726839	0.540	rs7434	chr5:660804	A/G	cg16447950	chr5:562315	NA	0.61	6.66	0.38	1.57e-10	Obesity-related traits;
CESC	cis	rs9311474	0.569	rs7614981	chr3:52566914	G/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.37	-5.41	-0.32	1.39e-7	Electroencephalogram traits;
CESC	cis	rs12142240	0.698	rs12385696	chr1:46818836	A/G	cg10495392	chr1:46806563	NSUN4	0.56	6.22	0.36	1.93e-9	Menopause (age at onset);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg10880863	chr7:132937862	EXOC4	0.47	6.11	0.35	3.57e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs12479064	0.724	rs112900993	chr2:99948805	C/G	cg09787394	chr2:99771194	LIPT1;TSGA10	0.48	5.06	0.3	7.78e-7	Chronic sinus infection;
CESC	cis	rs1799949	1.000	rs2292595	chr17:41290674	G/C	cg06001716	chr17:41278141	BRCA1;NBR2	0.39	5.26	0.31	3e-7	Menopause (age at onset);
CESC	cis	rs2415984	0.579	rs8010773	chr14:46956863	T/C	cg14871534	chr14:47121158	RPL10L	-0.36	-5.45	-0.32	1.15e-7	Number of children ever born;
CESC	cis	rs4604732	0.631	rs1106719	chr1:247624713	A/G	cg12758973	chr1:247694275	LOC148824;OR2C3	-0.5	-6.44	-0.37	5.56e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs9611565	0.559	rs7290991	chr22:41964361	C/G	cg17376030	chr22:41985996	PMM1	0.53	5.88	0.34	1.25e-8	Vitiligo;
CESC	cis	rs1707322	0.752	rs11211146	chr1:46109794	T/C	cg03146154	chr1:46216737	IPP	0.82	11.48	0.58	5.01e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7107174	1.000	rs2511187	chr11:77985849	T/A	cg02023728	chr11:77925099	USP35	0.47	6.49	0.37	4.19e-10	Testicular germ cell tumor;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15606692	chr11:124669480	C11orf61	-0.59	-7.1	-0.4	1.15e-11	Gut microbiome composition (summer);
CESC	cis	rs7071206	0.947	rs10509391	chr10:79422369	G/A	cg00983440	chr10:79422392	NA	-0.69	-8.22	-0.45	9.07e-15	Bone mineral density;
CESC	cis	rs17854409	0.764	rs12625513	chr20:61475661	G/A	cg07645718	chr20:61493192	TCFL5	0.94	5.03	0.3	9.14e-7	Obesity-related traits;
CESC	trans	rs673604	0.505	rs676614	chr1:36107510	G/T	cg11639397	chr19:46010716	VASP	0.59	6.44	0.37	5.63e-10	Endometrial cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01248421	chr18:32924572	ZNF24	-0.6	-7.08	-0.4	1.32e-11	Gut microbiome composition (summer);
CESC	cis	rs6089584	0.606	rs2144674	chr20:60576579	G/A	cg24733560	chr20:60626293	TAF4	0.44	6.57	0.37	2.65e-10	Body mass index;
CESC	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg11494091	chr17:61959527	GH2	0.73	12.52	0.61	1.41e-28	Prudent dietary pattern;
CESC	cis	rs2985684	0.846	rs10150624	chr14:50051565	A/G	cg04989706	chr14:50066350	PPIL5	-0.45	-5.05	-0.3	8.24e-7	Carotid intima media thickness;
CESC	cis	rs2204008	0.652	rs11520002	chr12:38022179	G/T	cg13010199	chr12:38710504	ALG10B	0.54	6.63	0.38	1.87e-10	Bladder cancer;
CESC	cis	rs1425132	0.805	rs718015	chr7:37563478	G/T	cg15028436	chr7:37888078	TXNDC3	-0.31	-5.2	-0.3	4.09e-7	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
CESC	cis	rs722599	0.748	rs3742783	chr14:75377008	C/T	cg08847533	chr14:75593920	NEK9	-0.45	-5.37	-0.31	1.72e-7	IgG glycosylation;
CESC	cis	rs7267979	1.000	rs7018	chr20:25278261	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.85	16.94	0.72	3.97e-44	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs68170813	0.559	rs7779062	chr7:106880195	T/A	cg02696742	chr7:106810147	HBP1	-0.52	-5.13	-0.3	5.57e-7	Coronary artery disease;
CESC	cis	rs17431357	0.867	rs117548673	chr12:120968889	G/A	cg25045489	chr12:120971538	RNF10	-0.93	-5.46	-0.32	1.1e-7	Insulin resistance/response;
CESC	cis	rs854765	0.583	rs11650649	chr17:17790319	C/A	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.48	-6.2	-0.36	2.14e-9	Total body bone mineral density;
CESC	cis	rs1348850	0.634	rs1534304	chr2:178489264	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.48	5.37	0.31	1.74e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs7772486	0.875	rs854145	chr6:146349650	C/T	cg05347473	chr6:146136440	FBXO30	0.48	6.27	0.36	1.46e-9	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7666738	0.791	rs2903142	chr4:99040071	C/T	cg05340658	chr4:99064831	C4orf37	0.82	12.88	0.62	8.44e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs757110	0.866	rs5215	chr11:17408630	C/T	cg01153817	chr11:17409509	KCNJ11	0.35	5.1	0.3	6.53e-7	Type 2 diabetes;
CESC	cis	rs7833790	0.632	rs6415653	chr8:82702536	A/G	cg27398817	chr8:82754497	SNX16	-0.42	-5.32	-0.31	2.24e-7	Diastolic blood pressure;
CESC	cis	rs4243830	0.850	rs4908558	chr1:6584101	A/G	cg05709478	chr1:6581295	PLEKHG5	-0.47	-5.17	-0.3	4.72e-7	Body mass index;
CESC	cis	rs1003719	0.680	rs2187577	chr21:38533341	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.59	-7.94	-0.44	5.62e-14	Eye color traits;
CESC	cis	rs4253772	0.550	rs6008613	chr22:46707924	G/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.67	6.51	0.37	3.73e-10	LDL cholesterol;Cholesterol, total;
CESC	cis	rs5758659	0.714	rs6002626	chr22:42517989	C/G	cg04733989	chr22:42467013	NAGA	-0.4	-5.41	-0.32	1.39e-7	Cognitive function;
CESC	cis	rs1348850	0.914	rs10497503	chr2:178371739	G/T	cg23306229	chr2:178417860	TTC30B	0.67	8.82	0.48	1.59e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs4819052	1.000	rs3746980	chr21:46711580	C/T	cg11663144	chr21:46675770	NA	-0.49	-6.62	-0.38	1.99e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs9926296	0.512	rs11076626	chr16:89865103	T/A	cg07648498	chr16:89883185	FANCA	0.49	6.21	0.36	2.01e-9	Vitiligo;
CESC	cis	rs780096	0.505	rs12475426	chr2:27599132	G/A	cg12648201	chr2:27665141	KRTCAP3	-0.33	-6.09	-0.35	3.86e-9	Total body bone mineral density;
CESC	cis	rs11098499	0.955	rs1397608	chr4:120161744	A/G	cg24375607	chr4:120327624	NA	0.43	5.24	0.31	3.34e-7	Corneal astigmatism;
CESC	cis	rs634534	0.622	rs531612	chr11:65705432	C/T	cg26695010	chr11:65641043	EFEMP2	0.47	5.9	0.34	1.12e-8	Sum eosinophil basophil counts;Eosinophil counts;
CESC	cis	rs875971	0.545	rs2420612	chr7:66001812	G/A	cg25405998	chr7:65216604	CCT6P1	0.49	5.26	0.31	2.97e-7	Aortic root size;
CESC	trans	rs3942852	0.568	rs10769313	chr11:48097466	A/G	cg15704280	chr7:45808275	SEPT13	-0.72	-9.39	-0.5	2.86e-18	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs7412746	0.611	rs2271076	chr1:150916657	C/T	cg22823121	chr1:150693482	HORMAD1	0.36	5.12	0.3	5.88e-7	Melanoma;
CESC	cis	rs801193	0.569	rs2659908	chr7:66160822	G/A	cg12463550	chr7:65579703	CRCP	0.49	6.35	0.36	9.51e-10	Aortic root size;
CESC	cis	rs727563	0.594	rs5758408	chr22:42077737	A/C	cg06481639	chr22:41940642	POLR3H	0.57	5.74	0.33	2.58e-8	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs55794721	0.509	rs11249248	chr1:25753051	T/C	cg02931644	chr1:25747376	RHCE	0.38	6.37	0.36	8.43e-10	Plateletcrit;Mean corpuscular volume;
CESC	cis	rs9921192	0.967	rs3747571	chr16:4323983	A/G	cg00021532	chr16:4324280	TFAP4	0.9	13.94	0.65	1.69e-33	Prostate-specific antigen levels;
CESC	cis	rs5498	0.869	rs2569702	chr19:10403947	A/G	cg08845333	chr19:10403403	ICAM5	0.4	5.51	0.32	8.48e-8	Lymphocyte counts;Soluble ICAM-1;Blood protein levels;
CESC	cis	rs7666738	0.716	rs35195511	chr4:98859660	G/A	cg03467027	chr4:99064603	C4orf37	0.42	5.17	0.3	4.56e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7772486	0.840	rs2474355	chr6:146312540	C/G	cg23711669	chr6:146136114	FBXO30	0.9	13.07	0.63	1.79e-30	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2953145	0.568	rs2975752	chr2:241521327	A/G	cg07929629	chr2:241523174	NA	0.57	7.23	0.41	5.03e-12	Bipolar disorder;
CESC	cis	rs7666738	0.830	rs6819047	chr4:98866902	G/A	cg17366294	chr4:99064904	C4orf37	0.55	7.72	0.43	2.38e-13	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1552244	0.832	rs3732968	chr3:10013273	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.77	-9.88	-0.52	8.65e-20	Alzheimer's disease;
CESC	cis	rs1348850	0.668	rs12618542	chr2:178494520	A/G	cg22681709	chr2:178499509	PDE11A	-0.46	-6.28	-0.36	1.41e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs636291	0.517	rs11121579	chr1:10541824	G/C	cg07384165	chr1:10488281	NA	-0.58	-8.51	-0.46	1.33e-15	Prostate cancer;
CESC	cis	rs4700695	0.668	rs253214	chr5:65499401	A/G	cg21114390	chr5:65439923	SFRS12	-0.49	-5.98	-0.34	7.07e-9	Facial morphology (factor 19);
CESC	cis	rs7474896	0.559	rs1208779	chr10:38077729	A/C	cg25427524	chr10:38739819	LOC399744	-0.47	-5.24	-0.31	3.34e-7	Obesity (extreme);
CESC	cis	rs921968	0.612	rs496908	chr2:219357742	A/T	cg02176678	chr2:219576539	TTLL4	0.44	7.69	0.43	2.92e-13	Mean corpuscular hemoglobin concentration;
CESC	cis	rs4665809	1.000	rs4665306	chr2:26319124	C/T	cg27170947	chr2:26402098	FAM59B	-0.59	-7.1	-0.4	1.13e-11	Gut microbiome composition (summer);
CESC	cis	rs3806933	0.522	rs12515367	chr5:110447853	A/G	cg04022379	chr5:110408740	TSLP	0.46	7.39	0.41	1.98e-12	Eosinophilic esophagitis;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg04267851	chr20:377134	TRIB3	0.47	6.8	0.39	6.93e-11	Fibrinogen levels;
CESC	cis	rs2274273	1.000	rs3742566	chr14:55595839	T/A	cg04306507	chr14:55594613	LGALS3	0.28	5.28	0.31	2.63e-7	Protein biomarker;
CESC	trans	rs6089829	0.962	rs6062777	chr20:61663748	G/A	cg23505145	chr19:12996616	KLF1	0.52	6.74	0.38	1e-10	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs10504229	0.953	rs114853497	chr8:58176176	A/T	cg22535103	chr8:58192502	C8orf71	-1.05	-13.27	-0.63	3.63e-31	Developmental language disorder (linguistic errors);
CESC	cis	rs7845219	0.597	rs7002058	chr8:95873993	G/C	cg09323728	chr8:95962352	TP53INP1	-0.26	-5.09	-0.3	6.67e-7	Type 2 diabetes;
CESC	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg24642844	chr7:1081250	C7orf50	-0.75	-8.99	-0.48	4.94e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2576037	0.583	rs9947131	chr18:44534769	G/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.48	-6.39	-0.37	7.49e-10	Personality dimensions;
CESC	trans	rs13098911	0.540	rs34324101	chr3:46000728	T/G	cg10236987	chr1:228114221	WNT9A	0.57	6.07	0.35	4.38e-9	Celiac disease;
CESC	cis	rs11577318	0.796	rs4625269	chr1:26626967	C/A	cg19743891	chr1:26644573	UBXN11;CD52	-0.28	-5.11	-0.3	6.05e-7	Granulocyte percentage of myeloid white cells;
CESC	cis	rs34779708	0.966	rs7070427	chr10:35485689	A/T	cg04310649	chr10:35416472	CREM	-0.52	-6.34	-0.36	9.86e-10	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs8060686	0.641	rs36086450	chr16:68046996	A/C	cg26727032	chr16:67993705	SLC12A4	-0.54	-6.15	-0.35	2.78e-9	HDL cholesterol;Metabolic syndrome;
CESC	trans	rs35110281	0.712	rs1454648	chr21:45053815	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.54	7.08	0.4	1.32e-11	Mean corpuscular volume;
CESC	cis	rs858239	0.600	rs28646184	chr7:23139595	T/C	cg23682824	chr7:23144976	KLHL7	0.55	7.73	0.43	2.23e-13	Cerebrospinal fluid biomarker levels;
CESC	cis	rs6831352	0.918	rs2851249	chr4:100044822	T/C	cg13256891	chr4:100009986	ADH5	0.74	8.21	0.45	9.57e-15	Alcohol dependence;
CESC	cis	rs3126085	0.877	rs4845742	chr1:152183949	G/A	cg03465714	chr1:152285911	FLG	-0.43	-5.16	-0.3	4.81e-7	Atopic dermatitis;
CESC	cis	rs7613875	0.600	rs7061	chr3:50114515	C/T	cg24110177	chr3:50126178	RBM5	0.52	6.99	0.39	2.2e-11	Body mass index;
CESC	cis	rs1552244	1.000	rs6781811	chr3:10121922	A/G	cg00149659	chr3:10157352	C3orf10	-0.73	-9.15	-0.49	1.59e-17	Alzheimer's disease;
CESC	cis	rs7980687	0.574	rs10744149	chr12:123708490	T/A	cg00376283	chr12:123451042	ABCB9	0.68	8.46	0.46	1.81e-15	Height;Educational attainment;Head circumference (infant);
CESC	cis	rs7786877	0.723	rs62482239	chr7:100217810	C/T	cg27028030	chr7:100209634	MOSPD3	0.56	5.49	0.32	9.51e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs854765	0.583	rs6502619	chr17:17779704	C/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.49	-6.26	-0.36	1.58e-9	Total body bone mineral density;
CESC	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	22.27	0.81	1.17e-62	Prudent dietary pattern;
CESC	cis	rs425277	0.606	rs424079	chr1:2071340	C/A	cg23803603	chr1:2058230	PRKCZ	-0.31	-5.25	-0.31	3.14e-7	Height;
CESC	cis	rs9788682	0.747	rs8042374	chr15:78908032	A/G	cg24631222	chr15:78858424	CHRNA5	0.78	9.59	0.51	6.67e-19	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs2832077	0.506	rs2832081	chr21:30152992	A/C	cg24692254	chr21:30365293	RNF160	0.5	6.13	0.35	3.22e-9	Cognitive test performance;
CESC	cis	rs7617480	0.648	rs4974083	chr3:49000626	A/G	cg06212747	chr3:49208901	KLHDC8B	0.49	5.34	0.31	1.99e-7	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CESC	cis	rs4555082	0.834	rs2735819	chr14:105713449	C/T	cg06808227	chr14:105710500	BRF1	-0.51	-5.78	-0.33	2.13e-8	Mean platelet volume;Platelet distribution width;
CESC	cis	rs920590	0.721	rs67989257	chr8:19660278	G/A	cg03894339	chr8:19674705	INTS10	0.64	7.31	0.41	3.24e-12	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs2710642	0.721	rs12328837	chr2:62896544	G/A	cg17519650	chr2:63277830	OTX1	0.57	7.06	0.4	1.46e-11	LDL cholesterol levels;LDL cholesterol;
CESC	cis	rs11645898	0.748	rs72787042	chr16:72067522	A/G	cg14768367	chr16:72042858	DHODH	-0.84	-6.92	-0.39	3.43e-11	Blood protein levels;
CESC	cis	rs17125944	0.686	rs7149638	chr14:53346931	T/C	cg00686598	chr14:53173677	PSMC6	-0.61	-5.36	-0.31	1.84e-7	Alzheimer's disease (late onset);
CESC	cis	rs9322193	0.923	rs10872651	chr6:150089409	A/T	cg09699651	chr6:150184138	LRP11	0.4	5.04	0.3	8.58e-7	Lung cancer;
CESC	cis	rs60871478	1.000	rs12531530	chr7:827366	T/C	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.58	5.69	0.33	3.34e-8	Cerebrospinal P-tau181p levels;
CESC	cis	rs6952808	0.531	rs1107351	chr7:2177093	G/A	cg08027265	chr7:2291960	NA	-0.48	-7.49	-0.42	1.04e-12	Bipolar disorder and schizophrenia;
CESC	cis	rs1799949	1.000	rs4793189	chr17:41190715	G/A	cg23758822	chr17:41437982	NA	1.03	14.77	0.67	2.05e-36	Menopause (age at onset);
CESC	trans	rs9325144	0.555	rs7968322	chr12:38792348	T/C	cg23762105	chr12:34175262	ALG10	0.46	6.09	0.35	4e-9	Morning vs. evening chronotype;
CESC	cis	rs938554	0.612	rs7669607	chr4:9997801	C/T	cg00071950	chr4:10020882	SLC2A9	-0.59	-7.38	-0.41	2.06e-12	Blood metabolite levels;
CESC	trans	rs7615952	0.866	rs6438949	chr3:125650064	G/C	cg07211511	chr3:129823064	LOC729375	-1.09	-14.38	-0.66	4.86e-35	Blood pressure (smoking interaction);
CESC	cis	rs7618915	0.571	rs7623199	chr3:52605974	C/T	cg18337363	chr3:52569053	NT5DC2	0.29	5.03	0.3	8.89e-7	Bipolar disorder;
CESC	cis	rs7246865	0.510	rs34833670	chr19:17172983	T/C	cg16202187	chr19:17186497	HAUS8;MYO9B	0.48	6.28	0.36	1.38e-9	Reticulocyte fraction of red cells;
CESC	cis	rs10504229	1.000	rs66731170	chr8:58187895	C/G	cg24829409	chr8:58192753	C8orf71	-0.76	-9.93	-0.52	5.87e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs12701220	0.655	rs7784403	chr7:1153077	G/A	cg26769984	chr7:1090371	C7orf50	0.54	6.18	0.35	2.47e-9	Bronchopulmonary dysplasia;
CESC	cis	rs769267	0.929	rs2965180	chr19:19491973	T/C	cg03709012	chr19:19516395	GATAD2A	-0.99	-15.45	-0.69	7.62e-39	Tonsillectomy;
CESC	cis	rs7827545	1.000	rs7832857	chr8:135565477	A/G	cg17885191	chr8:135476712	NA	0.48	6.28	0.36	1.39e-9	Hypertension (SNP x SNP interaction);
CESC	cis	rs698833	0.518	rs4953085	chr2:44554724	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.55	5.83	0.34	1.57e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs12681366	0.734	rs10102496	chr8:95398181	G/A	cg13257157	chr8:95487014	RAD54B	0.38	5.14	0.3	5.22e-7	Nonsyndromic cleft lip with cleft palate;
CESC	cis	rs9399401	0.710	rs7765770	chr6:142687305	C/T	cg03128060	chr6:142623767	GPR126	0.37	6.51	0.37	3.66e-10	Chronic obstructive pulmonary disease;
CESC	cis	rs7618915	0.547	rs2336542	chr3:52710636	A/G	cg05564831	chr3:52568323	NT5DC2	0.43	6.65	0.38	1.71e-10	Bipolar disorder;
CESC	cis	rs2576037	0.901	rs2571021	chr18:44583498	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.45	5.91	0.34	1.04e-8	Personality dimensions;
CESC	cis	rs780096	0.526	rs1647276	chr2:27688601	C/T	cg12648201	chr2:27665141	KRTCAP3	-0.35	-6.56	-0.37	2.79e-10	Total body bone mineral density;
CESC	cis	rs11155671	0.530	rs4870080	chr6:150202644	T/C	cg09699651	chr6:150184138	LRP11	0.57	7.71	0.43	2.57e-13	Testicular germ cell tumor;
CESC	cis	rs7208859	0.524	rs73263982	chr17:28920624	T/C	cg17105886	chr17:28927953	LRRC37B2	0.61	5.4	0.31	1.47e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs9929218	0.954	rs34097984	chr16:68824148	T/G	cg02972257	chr16:68554789	NA	0.45	5.38	0.31	1.66e-7	Colorectal cancer;
CESC	cis	rs951366	1.000	rs4951261	chr1:205717823	A/C	cg24503407	chr1:205819492	PM20D1	-0.44	-6.03	-0.35	5.37e-9	Menarche (age at onset);
CESC	cis	rs9916302	0.706	rs12950186	chr17:37393395	A/C	cg07936489	chr17:37558343	FBXL20	-0.93	-10.49	-0.54	9.21e-22	Glomerular filtration rate (creatinine);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26407100	chr8:11726043	CTSB	-0.59	-6.53	-0.37	3.32e-10	Gut microbiome composition (summer);
CESC	cis	rs698813	0.674	rs7590224	chr2:44501209	T/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.45	5.07	0.3	7.5e-7	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
CESC	cis	rs12928939	0.517	rs10852507	chr16:71971900	G/A	cg03805757	chr16:71968109	PKD1L3	-0.57	-6.49	-0.37	4.16e-10	Post bronchodilator FEV1;
CESC	trans	rs11039798	0.511	rs2047812	chr11:48162042	A/G	cg15704280	chr7:45808275	SEPT13	-0.7	-7.05	-0.4	1.52e-11	Axial length;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg02315113	chr1:173684045	KLHL20	-0.46	-6.35	-0.36	9.27e-10	Height;
CESC	cis	rs60843830	1.000	rs7595075	chr2:264019	C/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.89	12.12	0.6	3.46e-27	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs9733	0.596	rs12089731	chr1:150647798	T/C	cg22823121	chr1:150693482	HORMAD1	0.48	7.1	0.4	1.14e-11	Tonsillectomy;
CESC	cis	rs2243480	0.908	rs313822	chr7:65573939	G/A	cg25894440	chr7:65020034	NA	-0.61	-5.04	-0.3	8.52e-7	Diabetic kidney disease;
CESC	cis	rs9303542	0.625	rs9905940	chr17:46614102	A/C	cg04904318	chr17:46607828	HOXB1	0.49	5.35	0.31	1.95e-7	Ovarian cancer;Epithelial ovarian cancer;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg14949694	chr7:66367000	NA	0.51	6.86	0.39	4.91e-11	Fibrinogen levels;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg14702927	chr19:46366445	FOXA3;SYMPK	-0.49	-6.65	-0.38	1.65e-10	Fibrinogen levels;
CESC	cis	rs1538970	0.781	rs12049503	chr1:46021556	G/T	cg03146154	chr1:46216737	IPP	0.49	5.59	0.32	5.62e-8	Platelet count;
CESC	cis	rs870825	0.929	rs2310102	chr4:185595141	C/G	cg04058563	chr4:185651563	MLF1IP	-0.52	-5.15	-0.3	5.03e-7	Blood protein levels;
CESC	cis	rs4665809	0.887	rs4665825	chr2:26333100	A/G	cg08470875	chr2:26401718	FAM59B	-0.47	-5.24	-0.31	3.31e-7	Gut microbiome composition (summer);
CESC	cis	rs45535039	1.000	rs3794073	chr11:119146129	T/C	cg16724696	chr11:118992527	HINFP	0.43	5.42	0.32	1.31e-7	Plateletcrit;
CESC	cis	rs7959452	0.649	rs4761239	chr12:69776886	T/A	cg14784868	chr12:69753453	YEATS4	0.83	12.69	0.61	3.9e-29	Blood protein levels;
CESC	cis	rs2933343	0.729	rs813945	chr3:128660937	A/G	cg24203234	chr3:128598194	ACAD9	0.4	5.43	0.32	1.24e-7	IgG glycosylation;
CESC	cis	rs2273669	0.667	rs12197912	chr6:109338147	C/T	cg05315195	chr6:109294784	ARMC2	-0.67	-6.32	-0.36	1.13e-9	Prostate cancer;
CESC	cis	rs1801251	1.000	rs6437074	chr2:233712296	C/T	cg25237894	chr2:233734115	C2orf82	-0.46	-8.07	-0.44	2.53e-14	Coronary artery disease;
CESC	cis	rs8067545	0.935	rs7209734	chr17:19988543	C/A	cg13482628	chr17:19912719	NA	0.46	6.28	0.36	1.36e-9	Schizophrenia;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg22690212	chr1:145438435	TXNIP	-0.49	-6.46	-0.37	5.07e-10	Fibrinogen levels;
CESC	cis	rs117623576	0.590	rs2988084	chr10:32398653	C/T	cg03047570	chr10:32398778	NA	0.4	5.26	0.31	2.98e-7	Anti-saccade response;
CESC	cis	rs13082711	0.516	rs13084067	chr3:27358935	A/T	cg02860705	chr3:27208620	NA	0.57	6.92	0.39	3.44e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CESC	cis	rs12545109	0.613	rs6998873	chr8:57299697	A/G	cg09654669	chr8:57350985	NA	0.56	6.42	0.37	6.14e-10	Obesity-related traits;
CESC	cis	rs2242194	0.844	rs11264295	chr1:154987526	C/T	cg06221963	chr1:154839813	KCNN3	-0.37	-5.41	-0.32	1.38e-7	Schizophrenia;
CESC	cis	rs2635047	0.542	rs2668768	chr18:44783447	A/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.32	5.06	0.3	7.93e-7	Educational attainment;
CESC	cis	rs28830936	0.510	rs2412640	chr15:42124082	C/T	cg17847044	chr15:42102381	MAPKBP1	0.41	6.82	0.39	6.21e-11	Diastolic blood pressure;
CESC	cis	rs7917772	0.536	rs17783771	chr10:104410736	C/T	ch.10.2196322F	chr10:104248062	ACTR1A	0.51	5.56	0.32	6.58e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs3741151	0.892	rs7105681	chr11:73059341	G/A	cg17517138	chr11:73019481	ARHGEF17	0.63	5.32	0.31	2.18e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs9910055	0.659	rs721769	chr17:42261588	T/G	cg19774624	chr17:42201019	HDAC5	-0.89	-14.51	-0.67	1.63e-35	Total body bone mineral density;
CESC	cis	rs78889164	0.956	rs999503	chr19:33851730	C/T	cg02272751	chr19:33882848	PEPD	-0.5	-6.43	-0.37	5.81e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs35306767	0.903	rs10508208	chr10:910983	C/T	cg20503657	chr10:835505	NA	0.74	7.62	0.42	4.46e-13	Eosinophil percentage of granulocytes;
CESC	cis	rs2228479	0.850	rs12597296	chr16:89822331	C/T	cg06558623	chr16:89946397	TCF25	1.16	9.28	0.5	6.08e-18	Skin colour saturation;
CESC	cis	rs875971	0.545	rs2420612	chr7:66001812	G/A	cg18876405	chr7:65276391	NA	0.48	5.3	0.31	2.47e-7	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11120115	chr7:98649861	SMURF1	-0.59	-6.43	-0.37	5.77e-10	Gut microbiome composition (summer);
CESC	cis	rs2953174	1.000	rs2975754	chr2:241522634	G/A	cg07929629	chr2:241523174	NA	0.63	6.11	0.35	3.49e-9	Bipolar disorder;
CESC	cis	rs854765	0.647	rs854814	chr17:18003648	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.62	8.83	0.48	1.51e-16	Total body bone mineral density;
CESC	cis	rs17095355	1.000	rs11194920	chr10:111695412	G/T	cg00817464	chr10:111662876	XPNPEP1	-0.45	-5.25	-0.31	3.18e-7	Biliary atresia;
CESC	cis	rs7107174	1.000	rs10899476	chr11:78051794	A/G	cg02023728	chr11:77925099	USP35	0.47	6.23	0.36	1.82e-9	Testicular germ cell tumor;
CESC	trans	rs17685	0.593	rs56265719	chr7:75796269	C/T	cg19862616	chr7:65841803	NCRNA00174	0.79	11.08	0.56	1.09e-23	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs10392	0.516	rs4141892	chr20:37590758	T/C	cg27552599	chr20:37590471	DHX35	0.38	5.76	0.33	2.37e-8	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
CESC	cis	rs6500395	0.775	rs8050844	chr16:48665696	A/G	cg04672837	chr16:48644449	N4BP1	0.49	6.27	0.36	1.46e-9	Response to tocilizumab in rheumatoid arthritis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24937796	chr17:45918691	SCRN2	0.59	6.54	0.37	3.15e-10	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01382281	chr19:56104340	FIZ1	-0.59	-6.43	-0.37	5.94e-10	Gut microbiome composition (summer);
CESC	cis	rs2243480	1.000	rs778729	chr7:65824419	T/C	cg18252515	chr7:66147081	NA	-1.39	-14.18	-0.66	2.5e-34	Diabetic kidney disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01604348	chr19:54663591	LENG1	-0.56	-6.43	-0.37	5.99e-10	Gut microbiome composition (summer);
CESC	cis	rs1008375	1.000	rs7654345	chr4:17691796	A/G	cg16339924	chr4:17578868	LAP3	0.63	7.67	0.43	3.27e-13	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs965469	0.708	rs80050989	chr20:3297881	A/G	cg25506879	chr20:3388711	C20orf194	-0.49	-5.39	-0.31	1.59e-7	IFN-related cytopenia;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg14851846	chr7:99716985	TAF6;CNPY4	-0.4	-6.01	-0.35	6.01e-9	Gambling;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg18001435	chr13:111291955	CARKD	0.53	7.73	0.43	2.21e-13	Fibrinogen levels;
CESC	cis	rs4665809	0.590	rs1049987	chr2:26413817	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.07	12.72	0.62	3.02e-29	Gut microbiome composition (summer);
CESC	cis	rs9611565	0.527	rs73178638	chr22:41942904	T/C	cg06634786	chr22:41940651	POLR3H	-0.69	-6.78	-0.38	7.77e-11	Vitiligo;
CESC	cis	rs4665809	0.531	rs12990692	chr2:26464939	C/T	cg04944784	chr2:26401820	FAM59B	0.96	10.83	0.55	7.34e-23	Gut microbiome composition (summer);
CESC	cis	rs8017423	0.647	rs10132599	chr14:90815342	C/T	cg14092571	chr14:90743983	NA	0.43	6.62	0.38	1.93e-10	Mortality in heart failure;
CESC	cis	rs12586317	0.620	rs76293361	chr14:35570889	G/A	cg16230307	chr14:35515116	FAM177A1	0.92	9.84	0.52	1.12e-19	Psoriasis;
CESC	cis	rs1707322	0.716	rs28370457	chr1:46172062	C/T	cg03146154	chr1:46216737	IPP	0.82	11.53	0.58	3.39e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7202877	0.610	rs8053632	chr16:75364940	C/T	cg04384234	chr16:75411784	CFDP1	-0.45	-5.37	-0.31	1.68e-7	Type 2 diabetes;Type 1 diabetes;
CESC	trans	rs916888	0.821	rs199504	chr17:44861003	C/T	cg10053473	chr17:62856997	LRRC37A3	0.69	7.65	0.43	3.82e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs8031584	0.958	rs34909055	chr15:31284170	C/T	cg14298792	chr15:30685198	CHRFAM7A	-0.44	-5.23	-0.31	3.52e-7	Huntington's disease progression;
CESC	cis	rs80282103	0.618	rs59377495	chr10:1157019	C/T	cg08668510	chr10:1095578	IDI1	0.74	6.04	0.35	5.2e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs875971	0.862	rs3926380	chr7:66080645	G/T	cg10691866	chr7:65817282	TPST1	0.33	5.53	0.32	7.81e-8	Aortic root size;
CESC	cis	rs875971	0.508	rs10242423	chr7:66059175	A/G	cg18252515	chr7:66147081	NA	0.39	5.2	0.3	4.09e-7	Aortic root size;
CESC	cis	rs2204008	0.774	rs10400552	chr12:38393577	C/G	cg13010199	chr12:38710504	ALG10B	0.47	5.88	0.34	1.25e-8	Bladder cancer;
CESC	cis	rs6502050	0.769	rs9904237	chr17:80119664	G/A	cg23985595	chr17:80112537	CCDC57	-0.41	-6.57	-0.37	2.6e-10	Life satisfaction;
CESC	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg02725872	chr8:58115012	NA	-0.42	-5.74	-0.33	2.62e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs9325144	0.647	rs7957185	chr12:38909710	G/A	cg26384229	chr12:38710491	ALG10B	-0.55	-7.73	-0.43	2.2e-13	Morning vs. evening chronotype;
CESC	cis	rs10504229	0.683	rs6998040	chr8:58110155	G/T	cg21724239	chr8:58056113	NA	-0.59	-5.9	-0.34	1.08e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs854765	0.647	rs2974999	chr17:17997547	T/G	cg04398451	chr17:18023971	MYO15A	-0.77	-11.4	-0.57	8.88e-25	Total body bone mineral density;
CESC	cis	rs6537837	1.000	rs2301229	chr1:110136678	C/T	cg05049280	chr1:110155535	GNAT2	0.38	5.3	0.31	2.42e-7	Major depressive disorder;
CESC	cis	rs12900413	0.673	rs35308090	chr15:90308026	G/T	cg24249390	chr15:90295951	MESP1	-0.42	-5.69	-0.33	3.37e-8	Coronary artery aneurysm in Kawasaki disease;
CESC	cis	rs2204008	0.777	rs2049130	chr12:38444837	G/A	cg26384229	chr12:38710491	ALG10B	0.64	9.46	0.5	1.69e-18	Bladder cancer;
CESC	trans	rs10841784	1.000	rs10841789	chr12:21467666	A/C	cg00566759	chr18:28682345	DSC2	0.48	6.37	0.36	8.16e-10	Childhood ear infection;
CESC	cis	rs2075371	0.933	rs2544182	chr7:133949793	C/T	cg20476274	chr7:133979776	SLC35B4	0.64	9.22	0.49	9.9e-18	Mean platelet volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15650170	chr7:150783791	AGAP3	0.61	6.84	0.39	5.39e-11	Gut microbiome composition (summer);
CESC	cis	rs34779708	0.733	rs61449529	chr10:35543914	T/C	cg03585969	chr10:35415529	CREM	0.56	6.54	0.37	3.22e-10	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs1008375	0.902	rs6844984	chr4:17651304	C/G	cg15017067	chr4:17643749	FAM184B	0.39	5.47	0.32	1.02e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10353388	chr11:93474820	C11orf54;TAF1D	0.55	6.33	0.36	1.02e-9	Gut microbiome composition (summer);
CESC	cis	rs9902453	1.000	rs55971458	chr17:28427016	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	7.94	0.44	5.85e-14	Coffee consumption (cups per day);
CESC	cis	rs1552244	1.000	rs2160869	chr3:10079255	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.88	12.05	0.59	5.93e-27	Alzheimer's disease;
CESC	cis	rs16854884	0.657	rs35877644	chr3:143701755	A/G	cg06585982	chr3:143692056	C3orf58	0.48	6.2	0.36	2.11e-9	Economic and political preferences (feminism/equality);
CESC	cis	rs523522	0.962	rs10744752	chr12:120900554	T/G	cg12219531	chr12:120966889	COQ5	0.74	9.31	0.5	5.13e-18	High light scatter reticulocyte count;
CESC	cis	rs7572263	0.724	rs7579275	chr2:209053080	A/C	cg23998903	chr2:209048830	C2orf80	-0.39	-5.4	-0.31	1.47e-7	Glioma;Non-glioblastoma glioma;
CESC	cis	rs853679	0.542	rs9393892	chr6:28081394	A/G	cg20151795	chr6:28129481	ZNF389	0.48	6.24	0.36	1.73e-9	Depression;
CESC	cis	rs8067545	0.750	rs11871651	chr17:19997425	T/C	cg13482628	chr17:19912719	NA	0.41	5.52	0.32	7.93e-8	Schizophrenia;
CESC	cis	rs3761847	0.500	rs10760132	chr9:123739993	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.39	5.16	0.3	4.86e-7	Rheumatoid arthritis;
CESC	cis	rs910316	0.737	rs175055	chr14:75488946	T/G	cg15467112	chr14:75489610	MLH3	-0.33	-5.14	-0.3	5.25e-7	Height;
CESC	cis	rs7904368	0.707	rs12253979	chr10:16853415	T/C	cg23933602	chr10:16859644	RSU1	0.74	7.11	0.4	1.05e-11	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
CESC	cis	rs2836974	0.644	rs2836986	chr21:40702136	A/C	cg11644478	chr21:40555479	PSMG1	-0.78	-11.54	-0.58	3.11e-25	Cognitive function;
CESC	cis	rs4727027	0.933	rs28767030	chr7:148825918	T/G	cg23158103	chr7:148848205	ZNF398	-0.4	-6.34	-0.36	9.68e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs11677416	1.000	rs3783559	chr2:113529837	A/G	cg27083787	chr2:113543245	IL1A	0.43	5.37	0.31	1.73e-7	Response to antipsychotic treatment in schizophrenia (working memory);
CESC	cis	rs2742234	0.590	rs2435376	chr10:43684963	A/G	cg07801480	chr10:43725741	RASGEF1A	0.41	5.29	0.31	2.56e-7	Hirschsprung disease;
CESC	cis	rs12618769	0.572	rs4851141	chr2:99112966	A/C	cg10123293	chr2:99228465	UNC50	0.39	5.13	0.3	5.6e-7	Bipolar disorder;
CESC	cis	rs6570726	0.935	rs425717	chr6:145838620	A/T	cg23711669	chr6:146136114	FBXO30	0.8	12.02	0.59	7.3e-27	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7772486	0.521	rs9485017	chr6:146023326	C/T	cg23711669	chr6:146136114	FBXO30	0.8	10.85	0.55	6.3e-23	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs864643	0.678	rs500507	chr3:39534377	C/T	cg21413947	chr1:165329957	NA	0.42	6.05	0.35	4.92e-9	Attention deficit hyperactivity disorder;
CESC	cis	rs698813	0.604	rs58667148	chr2:44481443	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.48	5.38	0.31	1.62e-7	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
CESC	cis	rs8099014	0.861	rs6566974	chr18:56131156	A/G	cg19312305	chr18:56117016	MIR122	-0.27	-5.27	-0.31	2.81e-7	Platelet count;
CESC	cis	rs9359856	0.564	rs41273329	chr6:90393483	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.62	-5.73	-0.33	2.7e-8	Bipolar disorder;
CESC	cis	rs8020095	0.528	rs2319777	chr14:67810033	C/T	cg19548862	chr14:67692701	FAM71D	-0.45	-5.3	-0.31	2.41e-7	Depression (quantitative trait);
CESC	cis	rs9527	0.590	rs7089680	chr10:104802071	C/T	cg04362960	chr10:104952993	NT5C2	-0.42	-5.38	-0.31	1.66e-7	Arsenic metabolism;
CESC	cis	rs2985684	0.948	rs6572592	chr14:50080871	G/A	cg10008539	chr14:50087325	RPL36AL;MGAT2	-0.47	-5.61	-0.33	5.18e-8	Carotid intima media thickness;
CESC	cis	rs7818688	0.697	rs11781397	chr8:95974506	G/T	cg16049864	chr8:95962084	TP53INP1	0.57	5.73	0.33	2.79e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs8141529	0.748	rs6519766	chr22:29269991	A/G	cg15103426	chr22:29168792	CCDC117	-0.61	-8.32	-0.46	4.64e-15	Lymphocyte counts;
CESC	cis	rs6724607	1.000	rs4321393	chr2:191452899	G/T	cg10560079	chr2:191398806	TMEM194B	0.5	7.11	0.4	1.08e-11	Pulse pressure;
CESC	cis	rs17021463	0.902	rs10516950	chr4:95254730	C/T	cg11021082	chr4:95130006	SMARCAD1	0.52	8.09	0.45	2.11e-14	Testicular germ cell tumor;
CESC	cis	rs7618915	0.571	rs1961958	chr3:52585990	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.45	6.23	0.36	1.83e-9	Bipolar disorder;
CESC	cis	rs3540	0.514	rs2601194	chr15:90937051	T/A	cg22089800	chr15:90895588	ZNF774	0.66	8.91	0.48	8.58e-17	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs5753618	0.504	rs9606848	chr22:31901867	G/A	cg13145458	chr22:31556086	RNF185	-0.48	-5.69	-0.33	3.28e-8	Colorectal cancer;
CESC	cis	rs853679	0.550	rs1233707	chr6:28172953	G/A	cg12963246	chr6:28129442	ZNF389	0.51	7.07	0.4	1.36e-11	Depression;
CESC	cis	rs6570726	0.791	rs407887	chr6:145843759	C/T	cg05347473	chr6:146136440	FBXO30	0.58	7.44	0.42	1.39e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs12048904	0.619	rs10875346	chr1:101328083	T/C	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.64	7.51	0.42	9.22e-13	Multiple sclerosis;
CESC	cis	rs7091068	0.518	rs4144097	chr10:95432480	A/C	cg20715218	chr10:95462985	C10orf4	0.45	5.79	0.34	1.96e-8	Urinary tract infection frequency;
CESC	cis	rs2243480	1.000	rs2177703	chr7:65391717	C/A	cg12463550	chr7:65579703	CRCP	0.7	5.7	0.33	3.21e-8	Diabetic kidney disease;
CESC	cis	rs36051895	0.632	rs62541959	chr9:5175687	G/C	cg02405213	chr9:5042618	JAK2	-0.48	-5.5	-0.32	8.93e-8	Pediatric autoimmune diseases;
CESC	cis	rs2797160	1.000	rs1578794	chr6:126015469	T/C	cg05901451	chr6:126070800	HEY2	0.46	6.55	0.37	2.89e-10	Endometrial cancer;
CESC	cis	rs9457247	1.000	rs2149090	chr6:167372764	T/C	cg23791538	chr6:167370224	RNASET2	0.6	8.49	0.46	1.53e-15	Crohn's disease;
CESC	cis	rs9303401	0.614	rs12948536	chr17:56580413	G/T	cg12560992	chr17:57184187	TRIM37	0.52	5.08	0.3	7.01e-7	Cognitive test performance;
CESC	cis	rs864537	0.584	rs7523907	chr1:167427247	A/G	cg09179987	chr1:167433047	CD247	0.43	6.58	0.37	2.51e-10	Celiac disease or Rheumatoid arthritis;Celiac disease;
CESC	cis	rs9640161	0.658	rs74348353	chr7:150053655	C/A	cg21361702	chr7:150065534	REPIN1	0.61	6.73	0.38	1.05e-10	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs7746199	0.736	rs58616630	chr6:27474715	A/G	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.85	5.83	0.34	1.61e-8	Gait speed in old age;Autism spectrum disorder or schizophrenia;
CESC	cis	rs3793683	0.597	rs2182620	chr10:134590715	C/T	cg26818010	chr10:134567672	INPP5A	-0.91	-11.2	-0.57	4.4e-24	Migraine;
CESC	cis	rs875971	0.928	rs6970357	chr7:65968878	T/C	cg12463550	chr7:65579703	CRCP	0.56	7.07	0.4	1.39e-11	Aortic root size;
CESC	cis	rs864537	0.646	rs2995091	chr1:167434277	T/C	cg09179987	chr1:167433047	CD247	0.56	8.37	0.46	3.4e-15	Celiac disease or Rheumatoid arthritis;Celiac disease;
CESC	cis	rs1153858	1.000	rs2467863	chr15:45641880	G/A	cg14582100	chr15:45693742	SPATA5L1	0.42	5.93	0.34	9.4e-9	Homoarginine levels;
CESC	cis	rs875971	0.862	rs9791712	chr7:66105163	C/G	cg19163074	chr7:65112434	INTS4L2	0.43	5.37	0.31	1.71e-7	Aortic root size;
CESC	cis	rs4986811	1.000	rs5030172	chr11:32449274	G/C	cg27409910	chr11:32454216	WT1	0.46	5.79	0.33	2.02e-8	Rubella-specific interleukin-6 secretion;
CESC	cis	rs2952156	0.920	rs2247862	chr17:37829129	A/G	cg07936489	chr17:37558343	FBXL20	-0.5	-6.1	-0.35	3.69e-9	Asthma;
CESC	cis	rs875971	0.522	rs1917563	chr7:65415647	C/T	cg26939375	chr7:64535504	NA	-0.75	-10.67	-0.55	2.46e-22	Aortic root size;
CESC	cis	rs9948	0.521	rs62156206	chr2:97357108	G/A	cg01990225	chr2:97406019	LMAN2L	-0.92	-7.06	-0.4	1.46e-11	Erectile dysfunction and prostate cancer treatment;
CESC	cis	rs10504073	0.584	rs10957337	chr8:49959027	G/T	cg00325661	chr8:49890786	NA	0.59	8.65	0.47	5.19e-16	Blood metabolite ratios;
CESC	cis	rs4665809	0.590	rs35727620	chr2:26458364	G/A	cg25036284	chr2:26402008	FAM59B	0.86	9.4	0.5	2.74e-18	Gut microbiome composition (summer);
CESC	cis	rs10208940	0.764	rs6546420	chr2:68799454	G/A	cg12452813	chr2:68675892	NA	0.52	5.18	0.3	4.47e-7	Urate levels in lean individuals;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05989775	chr11:2906934	CDKN1C	0.62	7.45	0.42	1.31e-12	Gut microbiome composition (summer);
CESC	cis	rs1348850	0.608	rs2364845	chr2:178226240	T/C	cg22681709	chr2:178499509	PDE11A	-0.38	-5.73	-0.33	2.73e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs910316	0.503	rs12894709	chr14:75441734	G/A	cg08847533	chr14:75593920	NEK9	0.75	11.51	0.58	3.86e-25	Height;
CESC	cis	rs12541635	0.739	rs7833595	chr8:107089603	G/T	cg10147462	chr8:107024639	NA	-0.38	-5.44	-0.32	1.2e-7	Age of smoking initiation;
CESC	trans	rs13160161	0.533	rs13179322	chr5:38986557	A/G	cg09550024	chr10:96698366	CYP2C9	-0.46	-6.05	-0.35	5.05e-9	Obesity-related traits;
CESC	cis	rs9388451	0.626	rs3734637	chr6:126081319	G/T	cg05901451	chr6:126070800	HEY2	-0.59	-8.89	-0.48	9.86e-17	Brugada syndrome;
CESC	cis	rs11122272	0.735	rs2491403	chr1:231511185	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.57	-7.82	-0.43	1.29e-13	Hemoglobin concentration;
CESC	cis	rs35306767	0.903	rs35370435	chr10:898205	T/C	cg20503657	chr10:835505	NA	1.09	9.88	0.52	8.32e-20	Eosinophil percentage of granulocytes;
CESC	cis	rs2075371	1.000	rs2544221	chr7:133993014	G/C	cg11752832	chr7:134001865	SLC35B4	0.57	7.41	0.41	1.74e-12	Mean platelet volume;
CESC	cis	rs1878931	0.858	rs3760083	chr16:3450052	C/T	cg00484396	chr16:3507460	NAT15	0.38	5.92	0.34	1.02e-8	Body mass index (adult);
CESC	cis	rs7264396	0.570	rs6060717	chr20:34544647	T/C	cg17201900	chr20:34330562	RBM39	0.5	5.21	0.3	3.88e-7	Total cholesterol levels;
CESC	cis	rs116095464	0.558	rs9654453	chr5:299621	T/C	cg22496380	chr5:211416	CCDC127	-0.99	-10.2	-0.53	8.02e-21	Breast cancer;
CESC	cis	rs722599	0.651	rs12887044	chr14:75255659	C/T	cg08847533	chr14:75593920	NEK9	0.49	6.01	0.35	6.21e-9	IgG glycosylation;
CESC	cis	rs1552244	1.000	rs9820598	chr3:10117912	C/G	cg13047869	chr3:10149882	C3orf24	0.4	5.03	0.3	8.89e-7	Alzheimer's disease;
CESC	cis	rs896854	0.714	rs572547	chr8:95966286	A/G	cg09323728	chr8:95962352	TP53INP1	0.36	6.98	0.39	2.32e-11	Type 2 diabetes;
CESC	cis	rs4930103	0.534	rs2063550	chr11:1979223	G/C	cg23202291	chr11:1979235	NA	0.43	6.25	0.36	1.66e-9	DNA methylation (parent-of-origin);DNA methylation (variation);
CESC	cis	rs1003719	1.000	rs1003719	chr21:38491095	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.65	8.87	0.48	1.12e-16	Eye color traits;
CESC	cis	rs2108622	0.683	rs6512067	chr19:15982951	G/T	cg13772218	chr19:15982569	NA	0.3	5.85	0.34	1.42e-8	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CESC	trans	rs3087243	0.755	rs2162606	chr2:204705157	G/C	cg01841312	chr10:38069945	NA	-0.38	-6.3	-0.36	1.23e-9	Rheumatoid arthritis;Hypothyroidism;Type 1 diabetes;
CESC	cis	rs10504229	1.000	rs75037501	chr8:58170136	T/G	cg22535103	chr8:58192502	C8orf71	-1.05	-12.98	-0.62	3.88e-30	Developmental language disorder (linguistic errors);
CESC	cis	rs6493487	0.512	rs35114758	chr15:51371419	C/G	cg02338191	chr15:51200825	AP4E1	0.58	5.42	0.32	1.35e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs250677	0.522	rs998304	chr5:148382365	C/A	cg18129178	chr5:148520854	ABLIM3	-0.46	-5.14	-0.3	5.39e-7	Breast cancer;
CESC	cis	rs9487051	1.000	rs11757567	chr6:109614713	G/A	cg01475377	chr6:109611718	NA	-0.42	-6.43	-0.37	6.01e-10	Reticulocyte fraction of red cells;
CESC	cis	rs8002861	0.905	rs12430629	chr13:44415919	T/A	cg14210620	chr13:44453864	C13orf31;CCDC122	-0.42	-5.41	-0.32	1.41e-7	Leprosy;
CESC	cis	rs6502050	0.835	rs66531647	chr17:80089022	G/T	cg01763666	chr17:80159506	CCDC57	-0.37	-5.1	-0.3	6.55e-7	Life satisfaction;
CESC	cis	rs7666738	1.000	rs2865983	chr4:99033352	C/T	cg17366294	chr4:99064904	C4orf37	0.54	7.22	0.41	5.38e-12	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2380220	0.872	rs66723559	chr6:95956338	T/C	cg15832292	chr6:96025679	MANEA	-0.64	-5.66	-0.33	3.83e-8	Behavioural disinhibition (generation interaction);
CESC	cis	rs1862618	0.754	rs252899	chr5:56188569	G/C	cg24549020	chr5:56110836	MAP3K1	0.6	6.64	0.38	1.75e-10	Initial pursuit acceleration;
CESC	cis	rs873946	0.586	rs61862838	chr10:134572282	C/T	cg18305652	chr10:134549665	INPP5A	0.44	6.15	0.35	2.85e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs3858526	0.642	rs55732658	chr11:5894602	A/C	cg05234568	chr11:5960015	NA	-0.51	-6.1	-0.35	3.71e-9	DNA methylation (variation);
CESC	cis	rs477895	1.000	rs12785488	chr11:64107521	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.61	5.03	0.3	9.08e-7	Mean platelet volume;
CESC	cis	rs372883	0.648	rs2832296	chr21:30741454	C/T	cg08807101	chr21:30365312	RNF160	-0.44	-5.14	-0.3	5.34e-7	Pancreatic cancer;
CESC	cis	rs644148	0.902	rs12982159	chr19:44964300	C/T	cg15540054	chr19:45004280	ZNF180	-0.69	-8.35	-0.46	3.86e-15	Personality dimensions;
CESC	cis	rs11785693	0.862	rs7009771	chr8:4990189	C/T	cg26367366	chr8:4980734	NA	0.63	6.29	0.36	1.33e-9	Neuroticism (multi-trait analysis);Neuroticism;
CESC	cis	rs55728055	0.661	rs8142821	chr22:31941240	A/C	cg01338084	chr22:32026380	PISD	1.26	8.11	0.45	1.91e-14	Age-related hearing impairment;
CESC	cis	rs2425143	0.730	rs6060626	chr20:34415073	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.73	-6.2	-0.36	2.14e-9	Blood protein levels;
CESC	cis	rs7216064	1.000	rs56404791	chr17:65893019	T/G	cg07042672	chr17:66097459	LOC651250	-0.62	-7.65	-0.43	3.74e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs72781680	0.799	rs17508218	chr2:23976536	C/T	cg20701182	chr2:24300061	SF3B14	0.63	5.54	0.32	7.13e-8	Lymphocyte counts;
CESC	cis	rs7811142	0.943	rs73403312	chr7:100024153	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.78	6.87	0.39	4.46e-11	Platelet count;
CESC	trans	rs324780	0.544	rs3103500	chr12:83888032	A/G	cg22140261	chr22:42466895	NAGA	0.47	6.03	0.35	5.38e-9	Vertical cup-disc ratio;
CESC	cis	rs17666538	0.585	rs1669733	chr8:606696	C/T	cg02524346	chr8:600233	NA	-0.91	-6.74	-0.38	9.72e-11	IgG glycosylation;
CESC	cis	rs6687430	0.526	rs7555790	chr1:10613167	A/G	cg07384165	chr1:10488281	NA	0.47	6.64	0.38	1.74e-10	Hand grip strength;
CESC	cis	rs7666738	0.830	rs13112131	chr4:98976784	G/A	cg05340658	chr4:99064831	C4orf37	0.79	12.26	0.6	1.12e-27	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7666738	0.830	rs11942114	chr4:99066261	C/G	cg05340658	chr4:99064831	C4orf37	0.82	12.56	0.61	1.09e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2273669	0.667	rs74582170	chr6:109312689	C/T	cg05315195	chr6:109294784	ARMC2	-0.66	-6.28	-0.36	1.36e-9	Prostate cancer;
CESC	cis	rs7085104	0.700	rs6163	chr10:104596924	C/A	cg15744005	chr10:104629667	AS3MT	-0.35	-5.44	-0.32	1.23e-7	Immature fraction of reticulocytes;Schizophrenia;
CESC	cis	rs56046484	0.871	rs12900736	chr15:85558140	C/T	cg08123816	chr15:85640762	PDE8A	-0.5	-5.94	-0.34	9.11e-9	Testicular germ cell tumor;
CESC	cis	rs2342371	0.883	rs11185542	chr3:196187927	G/C	cg15048948	chr3:196158458	UBXN7	-0.49	-6.52	-0.37	3.56e-10	Fat distribution (HIV);
CESC	cis	rs752010	0.714	rs7515948	chr1:42079046	T/G	cg06885757	chr1:42089581	HIVEP3	0.51	8.71	0.47	3.32e-16	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs10771431	0.738	rs11049697	chr12:9385339	T/C	cg08997352	chr12:9597637	DDX12	-0.77	-10.22	-0.53	6.96e-21	Breast size;
CESC	cis	rs67311347	1.000	rs13073003	chr3:40504326	C/T	cg24209194	chr3:40518798	ZNF619	-0.58	-7.8	-0.43	1.41e-13	Renal cell carcinoma;
CESC	cis	rs798554	0.759	rs798495	chr7:2797267	T/C	cg13628971	chr7:2884303	GNA12	0.61	7.63	0.42	4.13e-13	Height;
CESC	cis	rs5769765	0.908	rs9616211	chr22:50317676	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.63	-6.44	-0.37	5.53e-10	Schizophrenia;
CESC	cis	rs7811142	0.830	rs28495773	chr7:99943583	A/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.15	11.99	0.59	9.47e-27	Platelet count;
CESC	cis	rs11785400	0.793	rs7000765	chr8:143722457	G/A	cg24634471	chr8:143751801	JRK	0.41	5.13	0.3	5.59e-7	Schizophrenia;
CESC	cis	rs2439831	0.867	rs689616	chr15:43761901	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.83	12.17	0.6	2.26e-27	Lung cancer in ever smokers;
CESC	cis	rs9443645	0.901	rs4147183	chr6:79557046	C/G	cg05283184	chr6:79620031	NA	-0.44	-6.88	-0.39	4.39e-11	Intelligence (multi-trait analysis);
CESC	trans	rs7839040	0.662	rs7812509	chr8:82931291	C/G	cg14472086	chr9:107730925	NA	-0.48	-6.45	-0.37	5.4e-10	Response to methotrexate in juvenile idiopathic arthritis;
CESC	cis	rs2120019	1.000	rs7162900	chr15:75368017	T/C	cg17294928	chr15:75287854	SCAMP5	-0.59	-6.7	-0.38	1.28e-10	Blood trace element (Zn levels);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08118649	chr12:99038419	APAF1;IKBIP	0.6	6.57	0.37	2.64e-10	Gut microbiome composition (summer);
CESC	cis	rs6901004	0.935	rs9487602	chr6:111560946	C/T	cg15721981	chr6:111408429	SLC16A10	0.39	5.88	0.34	1.25e-8	Blood metabolite levels;
CESC	cis	rs7267979	1.000	rs6083813	chr20:25337671	A/G	cg08601574	chr20:25228251	PYGB	-0.38	-5.55	-0.32	6.85e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs9549260	0.569	rs73174811	chr13:41315998	T/G	cg21288729	chr13:41239152	FOXO1	0.64	5.8	0.34	1.91e-8	Red blood cell count;
CESC	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.66	-8.88	-0.48	1e-16	Longevity;Endometriosis;
CESC	cis	rs7520050	0.778	rs2088102	chr1:46032974	T/C	cg06784218	chr1:46089804	CCDC17	-0.34	-5.95	-0.34	8.46e-9	Red blood cell count;Reticulocyte count;
CESC	trans	rs6084875	0.641	rs2093388	chr20:4724219	A/G	cg10192164	chr16:30419175	ZNF771	-0.51	-6.18	-0.35	2.46e-9	Systemic lupus erythematosus;
CESC	cis	rs12780046	0.572	rs2796764	chr10:100960710	T/C	cg27143070	chr10:101087766	CNNM1	0.39	5.66	0.33	3.94e-8	Non-glioblastoma glioma;
CESC	cis	rs35123781	1.000	rs600848	chr5:139057270	T/C	cg10513866	chr5:139070639	NA	0.37	5.37	0.31	1.75e-7	Schizophrenia;
CESC	cis	rs62432291	0.681	rs436277	chr6:159634142	G/A	cg14500486	chr6:159655392	FNDC1	0.57	5.99	0.35	6.78e-9	Joint mobility (Beighton score);
CESC	cis	rs4481887	0.927	rs10888340	chr1:248440381	C/T	cg00666640	chr1:248458726	OR2T12	0.41	6.81	0.39	6.41e-11	Common traits (Other);
CESC	cis	rs539096	0.540	rs3011219	chr1:44306120	A/G	cg13606994	chr1:44402422	ARTN	-0.34	-5.1	-0.3	6.42e-7	Intelligence (multi-trait analysis);
CESC	cis	rs7607369	0.618	rs62193298	chr2:219655211	T/G	cg02176678	chr2:219576539	TTLL4	-0.47	-8.21	-0.45	9.61e-15	Red blood cell count;Amyotrophic lateral sclerosis;
CESC	cis	rs853679	0.542	rs9380063	chr6:28137853	A/G	cg23161317	chr6:28129485	ZNF389	0.48	5.97	0.34	7.7e-9	Depression;
CESC	cis	rs875971	0.789	rs28815324	chr7:65565776	A/T	cg18876405	chr7:65276391	NA	-0.55	-6.01	-0.35	6.19e-9	Aortic root size;
CESC	cis	rs6460942	0.597	rs4721105	chr7:12534881	C/T	cg20607287	chr7:12443886	VWDE	-0.72	-7.71	-0.43	2.51e-13	Coronary artery disease;
CESC	cis	rs9926296	0.712	rs2434872	chr16:89716915	C/G	cg04287289	chr16:89883240	FANCA	-0.48	-5.89	-0.34	1.16e-8	Vitiligo;
CESC	cis	rs765787	0.530	rs7167731	chr15:45510900	T/C	cg24006582	chr15:45444508	DUOX1	0.52	6.34	0.36	9.88e-10	Uric acid levels;
CESC	cis	rs801193	1.000	rs17566701	chr7:66193183	T/C	cg14393609	chr7:65229607	NA	0.42	5.47	0.32	1.05e-7	Aortic root size;
CESC	cis	rs1862618	0.853	rs861283	chr5:56184610	C/T	cg03609598	chr5:56110824	MAP3K1	-0.51	-5.32	-0.31	2.22e-7	Initial pursuit acceleration;
CESC	cis	rs61931739	0.534	rs11053131	chr12:34282109	A/G	cg06521331	chr12:34319734	NA	-0.43	-6.01	-0.35	6.16e-9	Morning vs. evening chronotype;
CESC	cis	rs6687430	0.532	rs17035305	chr1:10616505	C/A	cg20482658	chr1:10539492	PEX14	0.39	8.06	0.44	2.69e-14	Hand grip strength;
CESC	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.87	12.45	0.61	2.52e-28	Prudent dietary pattern;
CESC	cis	rs3749237	0.595	rs3870338	chr3:49557051	A/G	cg02487422	chr3:49467188	NICN1	0.56	8.22	0.45	9.05e-15	Resting heart rate;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19224713	chr8:119634283	SAMD12	0.55	6.33	0.36	1.03e-9	Gut microbiome composition (summer);
CESC	cis	rs67478160	0.634	rs2368559	chr14:104230535	C/T	cg08213375	chr14:104286397	PPP1R13B	0.46	9.0	0.48	4.6e-17	Schizophrenia;
CESC	trans	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg13565492	chr6:43139072	SRF	-0.73	-8.6	-0.47	7.12e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs4975616	0.804	rs459961	chr5:1337106	T/A	cg06550200	chr5:1325588	CLPTM1L	-0.68	-10.37	-0.54	2.33e-21	Lung cancer;
CESC	trans	rs1443125	0.901	rs16903272	chr8:129631541	A/G	cg18172051	chr1:29189940	OPRD1	0.56	6.04	0.35	5.06e-9	Perceived unattractiveness to mosquitoes;
CESC	cis	rs17253792	0.822	rs80085988	chr14:56096173	A/G	cg01858014	chr14:56050164	KTN1	-0.85	-6.99	-0.39	2.22e-11	Putamen volume;
CESC	cis	rs9811920	0.638	rs793474	chr3:99544380	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.63	10.34	0.54	2.93e-21	Axial length;
CESC	cis	rs12497850	0.931	rs7647813	chr3:48833348	G/T	cg02487422	chr3:49467188	NICN1	0.39	5.05	0.3	8.06e-7	Parkinson's disease;
CESC	cis	rs72781680	1.000	rs72781663	chr2:24221694	C/G	cg20701182	chr2:24300061	SF3B14	0.65	5.68	0.33	3.52e-8	Lymphocyte counts;
CESC	cis	rs9303401	0.614	rs62084384	chr17:57126842	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.98	12.19	0.6	1.95e-27	Cognitive test performance;
CESC	cis	rs7949030	0.596	rs71490394	chr11:62370155	G/A	cg13298116	chr11:62369859	EML3;MTA2	0.65	9.46	0.5	1.75e-18	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	trans	rs1814175	0.740	rs10839439	chr11:49918240	C/T	cg15704280	chr7:45808275	SEPT13	-1.03	-20.27	-0.78	8.31e-56	Height;
CESC	cis	rs684232	0.602	rs2160955	chr17:560604	T/C	cg12384639	chr17:618140	VPS53	0.42	5.38	0.31	1.61e-7	Prostate cancer;
CESC	cis	rs10089	0.953	rs17164427	chr5:127361736	C/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.74	-9.89	-0.52	7.84e-20	Ileal carcinoids;
CESC	cis	rs7089973	0.604	rs7903663	chr10:116609904	G/A	cg25233709	chr10:116636983	FAM160B1	0.38	6.14	0.35	3.07e-9	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs854765	0.583	rs9904163	chr17:17830553	C/T	cg09796270	chr17:17721594	SREBF1	0.43	6.05	0.35	4.93e-9	Total body bone mineral density;
CESC	cis	rs7178572	1.000	rs34591043	chr15:77713586	A/G	cg22256960	chr15:77711686	NA	-0.58	-7.92	-0.44	6.36e-14	Type 2 diabetes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26735824	chr11:121163657	SC5DL	0.59	6.9	0.39	3.84e-11	Gut microbiome composition (summer);
CESC	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg09033563	chr22:24373618	LOC391322	-0.4	-5.27	-0.31	2.79e-7	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs4423214	1.000	rs2852853	chr11:71150217	C/T	cg05163923	chr11:71159392	DHCR7	0.71	9.5	0.5	1.31e-18	Vitamin D levels;
CESC	cis	rs2050392	0.894	rs303430	chr10:30706235	C/A	cg25182066	chr10:30743637	MAP3K8	-0.4	-5.36	-0.31	1.77e-7	Inflammatory bowel disease;
CESC	cis	rs79057730	0.599	rs4333501	chr7:803244	C/T	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.85	7.34	0.41	2.57e-12	Initial pursuit acceleration;
CESC	cis	rs11792861	0.855	rs72607165	chr9:111814498	C/T	cg05043794	chr9:111880884	C9orf5	-0.39	-6.4	-0.37	6.82e-10	Menarche (age at onset);
CESC	cis	rs1707322	0.963	rs4630155	chr1:46257110	G/C	cg05343316	chr1:45956843	TESK2	0.51	6.25	0.36	1.59e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs34172651	0.583	rs200541	chr16:24733141	A/G	cg00339695	chr16:24857497	SLC5A11	-0.53	-6.58	-0.37	2.56e-10	Intelligence (multi-trait analysis);
CESC	cis	rs796364	0.806	rs76568708	chr2:200929531	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.86	-7.87	-0.44	9.02e-14	Schizophrenia;
CESC	cis	rs10931896	0.531	rs295118	chr2:201144004	C/T	cg23649088	chr2:200775458	C2orf69	0.53	7.38	0.41	2.06e-12	Systolic blood pressure;
CESC	cis	rs2901656	1.000	rs2901656	chr1:172434812	C/T	cg03748243	chr1:172413542	C1orf105;PIGC	0.41	6.41	0.37	6.45e-10	Red cell distribution width;Platelet distribution width;
CESC	cis	rs514406	0.893	rs522287	chr1:53365493	C/T	cg24675658	chr1:53192096	ZYG11B	-0.56	-6.9	-0.39	3.75e-11	Monocyte count;
CESC	cis	rs2832191	0.755	rs55671430	chr21:30492421	G/C	cg24692254	chr21:30365293	RNF160	-0.79	-12.11	-0.6	3.54e-27	Dental caries;
CESC	cis	rs4566357	1.000	rs4296417	chr2:227921941	G/A	cg11843606	chr2:227700838	RHBDD1	-0.41	-5.27	-0.31	2.77e-7	Coronary artery disease;
CESC	cis	rs7618915	0.547	rs4687636	chr3:52633929	G/A	cg18099408	chr3:52552593	STAB1	-0.32	-5.36	-0.31	1.78e-7	Bipolar disorder;
CESC	cis	rs875971	0.862	rs7796162	chr7:65745758	T/C	cg18876405	chr7:65276391	NA	-0.51	-7.01	-0.4	1.94e-11	Aortic root size;
CESC	cis	rs72945132	0.882	rs4567496	chr11:70193208	A/T	cg00319359	chr11:70116639	PPFIA1	0.82	7.36	0.41	2.35e-12	Coronary artery disease;
CESC	cis	rs6502050	0.835	rs9891962	chr17:80153594	T/C	cg23985595	chr17:80112537	CCDC57	-0.39	-6.19	-0.36	2.23e-9	Life satisfaction;
CESC	cis	rs1728785	0.591	rs10775305	chr16:68656460	A/G	cg02972257	chr16:68554789	NA	-0.63	-7.02	-0.4	1.86e-11	Ulcerative colitis;
CESC	cis	rs4450798	0.649	rs9878907	chr3:13791196	T/C	cg23332027	chr3:13681764	NA	0.38	5.13	0.3	5.63e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs7944584	1.000	rs7944584	chr11:47336320	A/T	cg20307385	chr11:47447363	PSMC3	0.69	8.04	0.44	3.02e-14	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CESC	cis	rs3733585	0.638	rs7377625	chr4:9953099	T/C	cg00071950	chr4:10020882	SLC2A9	-0.69	-11.27	-0.57	2.44e-24	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs5758511	0.680	rs5758688	chr22:42662501	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.58	8.76	0.47	2.43e-16	Birth weight;
CESC	cis	rs7589342	0.801	rs13031068	chr2:106455021	A/G	cg16077055	chr2:106428750	NCK2	0.49	6.99	0.39	2.27e-11	Addiction;
CESC	cis	rs4713118	0.662	rs156744	chr6:27967274	G/A	cg22143856	chr6:28129313	ZNF389	0.42	5.34	0.31	1.98e-7	Parkinson's disease;
CESC	cis	rs1451375	0.652	rs7803788	chr7:50625898	A/G	cg14593290	chr7:50529359	DDC	-0.44	-5.28	-0.31	2.65e-7	Malaria;
CESC	cis	rs7666738	0.753	rs10004827	chr4:99037953	A/C	cg24818145	chr4:99064322	C4orf37	0.38	5.04	0.3	8.81e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4953076	0.573	rs7602070	chr2:44388614	G/A	cg04920474	chr2:44395004	PPM1B	0.51	6.36	0.36	9.01e-10	Height;
CESC	cis	rs2243480	0.808	rs12698508	chr7:65411958	A/T	cg25894440	chr7:65020034	NA	-0.63	-5.26	-0.31	2.91e-7	Diabetic kidney disease;
CESC	cis	rs709400	0.628	rs11622320	chr14:103912194	A/T	cg12935359	chr14:103987150	CKB	-0.57	-8.42	-0.46	2.43e-15	Body mass index;
CESC	cis	rs514406	0.505	rs835609	chr1:53170494	T/C	cg08859206	chr1:53392774	SCP2	-0.6	-8.02	-0.44	3.43e-14	Monocyte count;
CESC	cis	rs5743618	0.537	rs11466661	chr4:38774482	G/T	cg02016764	chr4:38805732	TLR1	-0.32	-5.04	-0.3	8.7e-7	Asthma;Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs79839061	0.610	rs73207794	chr4:872020	T/C	cg07828340	chr4:882639	GAK	1.07	8.28	0.45	6.23e-15	Intelligence (multi-trait analysis);
CESC	cis	rs11785693	0.819	rs6994891	chr8:4989856	T/A	cg26367366	chr8:4980734	NA	0.94	8.56	0.47	9.04e-16	Neuroticism (multi-trait analysis);Neuroticism;
CESC	cis	rs13256369	0.853	rs13256216	chr8:8577883	C/T	cg17143192	chr8:8559678	CLDN23	0.7	7.73	0.43	2.25e-13	Obesity-related traits;
CESC	cis	rs1943345	0.642	rs11233500	chr11:82881407	C/T	cg07047830	chr11:82868014	PCF11	-0.61	-8.39	-0.46	2.87e-15	Obesity-related traits;
CESC	cis	rs11958404	0.932	rs112993559	chr5:157414712	A/C	cg05962755	chr5:157440814	NA	0.62	6.72	0.38	1.08e-10	IgG glycosylation;
CESC	cis	rs7833790	0.700	rs7834483	chr8:82704828	A/G	cg02079420	chr8:82753780	SNX16	0.52	7.77	0.43	1.71e-13	Diastolic blood pressure;
CESC	cis	rs2050392	0.517	rs687036	chr10:30761249	G/A	cg25182066	chr10:30743637	MAP3K8	-0.49	-6.93	-0.39	3.24e-11	Inflammatory bowel disease;
CESC	cis	rs1577917	1.000	rs13196930	chr6:86652245	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.49	-6.33	-0.36	1.04e-9	Response to antipsychotic treatment;
CESC	cis	rs9443645	0.838	rs9350800	chr6:79729489	A/C	cg05283184	chr6:79620031	NA	-0.44	-6.79	-0.39	7.19e-11	Intelligence (multi-trait analysis);
CESC	cis	rs12887734	0.546	rs12885509	chr14:104273325	T/C	cg08213375	chr14:104286397	PPP1R13B	0.41	6.84	0.39	5.38e-11	Schizophrenia;Autism spectrum disorder or schizophrenia;
CESC	cis	rs17023223	0.537	rs12083510	chr1:119746620	T/G	cg05756136	chr1:119680316	WARS2	-0.48	-5.7	-0.33	3.25e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CESC	cis	rs10504229	1.000	rs66886949	chr8:58187613	A/G	cg22535103	chr8:58192502	C8orf71	-1.05	-13.08	-0.63	1.71e-30	Developmental language disorder (linguistic errors);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg04558166	chr1:210001279	C1orf107	-0.45	-7.38	-0.41	2.06e-12	Gambling;
CESC	cis	rs6831352	0.918	rs17218288	chr4:100058030	A/T	cg13256891	chr4:100009986	ADH5	-0.77	-8.46	-0.46	1.82e-15	Alcohol dependence;
CESC	cis	rs1005277	0.505	rs200910	chr10:38108176	C/T	cg00409905	chr10:38381863	ZNF37A	-0.55	-7.63	-0.42	4.18e-13	Extrinsic epigenetic age acceleration;
CESC	trans	rs11098499	0.913	rs68128210	chr4:120137819	T/G	cg25214090	chr10:38739885	LOC399744	0.63	8.33	0.46	4.44e-15	Corneal astigmatism;
CESC	cis	rs7932354	0.528	rs4752952	chr11:47082858	T/C	cg25783544	chr11:47291846	MADD	-0.41	-5.47	-0.32	1.05e-7	Bone mineral density (hip);Bone mineral density;
CESC	cis	rs7071206	0.947	rs10824560	chr10:79416901	C/T	cg00983440	chr10:79422392	NA	-0.67	-8.17	-0.45	1.3e-14	Bone mineral density;
CESC	cis	rs3733585	0.648	rs7376155	chr4:9952588	C/T	cg02734326	chr4:10020555	SLC2A9	-0.39	-5.64	-0.33	4.45e-8	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs1707322	0.752	rs6703748	chr1:46095976	G/A	cg03146154	chr1:46216737	IPP	0.81	11.43	0.57	7.16e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7412746	0.658	rs10888397	chr1:150886752	A/G	cg17724175	chr1:150552817	MCL1	-0.39	-6.12	-0.35	3.28e-9	Melanoma;
CESC	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg10295955	chr4:187884368	NA	-1.08	-23.01	-0.82	4.07e-65	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6032067	1.000	rs35284867	chr20:43845836	A/T	cg11264863	chr20:43835661	SEMG1	0.48	5.19	0.3	4.24e-7	Blood protein levels;
CESC	cis	rs2742417	0.603	rs2742371	chr3:45782763	G/A	cg04837898	chr3:45731254	SACM1L	-0.46	-6.04	-0.35	5.31e-9	Response to anti-depressant treatment in major depressive disorder;
CESC	cis	rs7552404	1.000	rs437298	chr1:76113770	T/C	cg03433033	chr1:76189801	ACADM	-0.62	-7.15	-0.4	8.57e-12	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs796364	1.000	rs11895190	chr2:200838613	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.86	-8.67	-0.47	4.32e-16	Schizophrenia;
CESC	cis	rs7811142	0.830	rs77861211	chr7:99962096	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.1	11.77	0.59	5.44e-26	Platelet count;
CESC	cis	rs514406	0.823	rs501006	chr1:53368292	T/A	cg24675658	chr1:53192096	ZYG11B	-0.56	-6.9	-0.39	3.75e-11	Monocyte count;
CESC	cis	rs1784581	0.802	rs7768986	chr6:162427890	G/C	cg17173639	chr6:162384350	PARK2	0.61	9.55	0.51	9.38e-19	Itch intensity from mosquito bite;
CESC	cis	rs67257959	0.708	rs1979261	chr19:17193518	C/T	cg16202187	chr19:17186497	HAUS8;MYO9B	-0.46	-5.58	-0.32	6.04e-8	Selective IgA deficiency;
CESC	cis	rs9311474	0.581	rs13621	chr3:52558133	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.37	5.26	0.31	3.03e-7	Electroencephalogram traits;
CESC	cis	rs4319547	1.000	rs7295397	chr12:123116209	C/T	cg23029597	chr12:123009494	RSRC2	-0.49	-5.37	-0.31	1.74e-7	Body mass index;
CESC	cis	rs4843747	0.605	rs28399183	chr16:88107277	G/A	cg03395651	chr16:88107091	BANP	0.45	5.26	0.31	2.98e-7	Menopause (age at onset);
CESC	cis	rs9733	0.596	rs12077833	chr1:150674333	C/T	cg17724175	chr1:150552817	MCL1	0.44	7.23	0.41	5.25e-12	Tonsillectomy;
CESC	cis	rs4727027	0.835	rs11767810	chr7:148774433	T/A	cg23158103	chr7:148848205	ZNF398	-0.41	-6.53	-0.37	3.38e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs9733	0.596	rs12085275	chr1:150650265	T/C	cg09365446	chr1:150670422	GOLPH3L	0.42	5.9	0.34	1.09e-8	Tonsillectomy;
CESC	cis	rs7811142	1.000	rs11763511	chr7:100081944	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.97	10.28	0.53	4.51e-21	Platelet count;
CESC	cis	rs3126085	0.935	rs11204980	chr1:152296191	G/C	cg03465714	chr1:152285911	FLG	0.5	5.71	0.33	2.96e-8	Atopic dermatitis;
CESC	cis	rs17711722	0.727	rs35850374	chr7:65357776	A/G	cg05332525	chr7:65337924	VKORC1L1	0.51	6.35	0.36	9.52e-10	Calcium levels;
CESC	cis	rs2836974	0.965	rs8130984	chr21:40639966	A/C	cg11890956	chr21:40555474	PSMG1	1.16	20.96	0.79	3.6e-58	Cognitive function;
CESC	cis	rs4243830	1.000	rs11811007	chr1:6584657	T/C	cg22792644	chr1:6614718	TAS1R1;NOL9	0.69	5.88	0.34	1.24e-8	Body mass index;
CESC	cis	rs2806561	0.704	rs664301	chr1:23522522	C/T	cg12483005	chr1:23474871	LUZP1	0.43	6.55	0.37	2.93e-10	Height;
CESC	trans	rs11098499	0.615	rs28551750	chr4:120264901	C/T	cg25214090	chr10:38739885	LOC399744	0.6	8.26	0.45	6.87e-15	Corneal astigmatism;
CESC	cis	rs9479482	0.935	rs5017315	chr6:150333574	C/T	cg03788504	chr6:150331562	NA	-0.35	-7.05	-0.4	1.54e-11	Alopecia areata;
CESC	cis	rs34526934	0.608	rs7591820	chr2:177028144	G/T	cg14324370	chr2:177042789	NA	-0.5	-6.1	-0.35	3.65e-9	Obstructive sleep apnea trait (apnea hypopnea index);
CESC	cis	rs68170813	0.559	rs3801959	chr7:106955666	A/G	cg02696742	chr7:106810147	HBP1	-0.54	-5.17	-0.3	4.72e-7	Coronary artery disease;
CESC	cis	rs8103278	0.507	rs62111759	chr19:46296230	A/T	cg02376097	chr19:46275166	DMPK	0.38	5.64	0.33	4.26e-8	Coronary artery disease;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg22328890	chr16:68298258	SLC7A6	0.5	6.83	0.39	5.71e-11	Systemic lupus erythematosus;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg24555065	chr12:6977392	TPI1	-0.47	-6.22	-0.36	1.92e-9	Height;
CESC	cis	rs2274273	0.638	rs58269011	chr14:55684388	A/G	cg04306507	chr14:55594613	LGALS3	0.31	5.26	0.31	3.03e-7	Protein biomarker;
CESC	cis	rs208520	0.837	rs208486	chr6:66926255	A/T	cg07460842	chr6:66804631	NA	-0.88	-10.55	-0.54	6.07e-22	Exhaled nitric oxide output;
CESC	trans	rs637571	0.676	rs1151523	chr11:65665200	C/T	cg17712092	chr4:129076599	LARP1B	-0.75	-10.22	-0.53	6.83e-21	Eosinophil percentage of white cells;
CESC	cis	rs6448317	0.539	rs13113895	chr4:24932077	T/C	cg21108841	chr4:24914750	CCDC149	-0.57	-8.04	-0.44	3e-14	Heschl's gyrus morphology;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg20708961	chr19:22235256	ZNF257	0.42	6.31	0.36	1.2e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs9479482	1.000	rs9479481	chr6:150357944	A/G	cg03788504	chr6:150331562	NA	-0.38	-7.22	-0.41	5.37e-12	Alopecia areata;
CESC	cis	rs10078	0.510	rs2278248	chr5:469570	G/T	cg08916839	chr5:415575	AHRR	0.51	6.01	0.35	6.26e-9	Fat distribution (HIV);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09228562	chr1:182808478	DHX9	0.54	6.17	0.35	2.56e-9	Gut microbiome composition (summer);
CESC	cis	rs9815354	0.812	rs4434125	chr3:42004681	A/G	cg03022575	chr3:42003672	ULK4	0.65	5.73	0.33	2.75e-8	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs950169	0.650	rs12902052	chr15:85125838	A/T	cg17507749	chr15:85114479	UBE2QP1	0.54	6.09	0.35	3.99e-9	Schizophrenia;
CESC	cis	rs116095464	0.558	rs1971229	chr5:268187	A/G	cg20965017	chr5:231967	SDHA	-0.48	-5.43	-0.32	1.25e-7	Breast cancer;
CESC	cis	rs7762018	0.655	rs2184194	chr6:170148394	C/T	cg13891659	chr6:170190454	C6orf122;C6orf208	0.67	6.53	0.37	3.28e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs75477785	0.590	rs10863789	chr1:209987919	T/C	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.92	6.04	0.35	5.06e-9	Cleft lip with or without cleft palate;
CESC	cis	rs4713118	0.662	rs9468271	chr6:28024570	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.52	-6.03	-0.35	5.5e-9	Parkinson's disease;
CESC	cis	rs514406	0.505	rs437954	chr1:53173321	C/G	cg08736216	chr1:53307985	ZYG11A	-0.4	-6.55	-0.37	2.93e-10	Monocyte count;
CESC	cis	rs2235642	0.891	rs2281231	chr16:1601879	A/G	cg03771183	chr16:1608904	IFT140	0.4	5.84	0.34	1.52e-8	Coronary artery disease;
CESC	cis	rs561341	0.883	rs4795661	chr17:30201774	T/A	cg12193833	chr17:30244370	NA	0.54	5.46	0.32	1.09e-7	Hip circumference adjusted for BMI;
CESC	cis	rs12497850	0.931	rs28642807	chr3:48926816	A/G	cg07636037	chr3:49044803	WDR6	1.03	19.1	0.76	1e-51	Parkinson's disease;
CESC	cis	rs875971	0.862	rs2088655	chr7:65795711	T/C	cg10691866	chr7:65817282	TPST1	0.32	5.42	0.32	1.35e-7	Aortic root size;
CESC	trans	rs2797160	0.967	rs4897151	chr6:125993202	T/G	cg05039488	chr6:79577232	IRAK1BP1	-0.45	-6.01	-0.35	6.16e-9	Endometrial cancer;
CESC	cis	rs9916302	0.861	rs11658219	chr17:37709782	G/A	cg07936489	chr17:37558343	FBXL20	-0.81	-11.66	-0.58	1.27e-25	Glomerular filtration rate (creatinine);
CESC	cis	rs769267	0.931	rs15622	chr19:19468734	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	-0.5	-6.23	-0.36	1.78e-9	Tonsillectomy;
CESC	cis	rs9926296	0.568	rs4420527	chr16:89814188	C/T	cg27121462	chr16:89883253	FANCA	-0.81	-12.17	-0.6	2.33e-27	Vitiligo;
CESC	cis	rs6500602	0.929	rs6500603	chr16:4497537	G/C	cg08645402	chr16:4508243	NA	0.46	6.96	0.39	2.72e-11	Schizophrenia;
CESC	cis	rs853679	0.569	rs9348798	chr6:28143011	G/A	cg26335602	chr6:28129616	ZNF389	0.52	6.85	0.39	5.22e-11	Depression;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg15543284	chr2:54785307	SPTBN1	-0.45	-6.12	-0.35	3.31e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs1008375	1.000	rs555	chr4:17625658	A/G	cg02297831	chr4:17616191	MED28	0.54	6.9	0.39	3.75e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs9912789	0.807	rs9896850	chr17:79191726	C/T	cg14413466	chr17:79170920	AZI1	-0.44	-6.72	-0.38	1.12e-10	Frontotemporal dementia;
CESC	cis	rs4727963	0.811	rs7458859	chr7:122711358	C/T	cg03640110	chr7:122635026	TAS2R16	0.37	5.87	0.34	1.33e-8	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
CESC	cis	rs61861422	0.516	rs12412216	chr10:134393338	C/T	cg26818010	chr10:134567672	INPP5A	-0.59	-5.45	-0.32	1.15e-7	Primary sclerosing cholangitis;
CESC	cis	rs8050907	0.744	rs8063084	chr16:4536555	C/T	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.71	5.05	0.3	8.06e-7	Obesity-related traits;
CESC	cis	rs1018836	0.923	rs4734266	chr8:91628147	C/T	cg16814680	chr8:91681699	NA	-0.72	-9.98	-0.52	3.92e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs1986734	0.619	rs13106413	chr4:77418698	G/T	cg20311846	chr4:77356250	SHROOM3	-0.27	-5.47	-0.32	1.06e-7	Eosinophilic esophagitis (pediatric);Metabolite levels (small molecules and protein measures);
CESC	cis	rs10751667	0.580	rs7395515	chr11:1005160	C/T	cg06064525	chr11:970664	AP2A2	-0.32	-5.5	-0.32	9.11e-8	Alzheimer's disease (late onset);
CESC	cis	rs7659604	0.540	rs4833775	chr4:122716826	T/C	cg19671926	chr4:122722719	EXOSC9	0.67	8.93	0.48	7.16e-17	Type 2 diabetes;
CESC	cis	rs965469	1.000	rs6051713	chr20:3265779	C/T	cg25506879	chr20:3388711	C20orf194	0.51	5.47	0.32	1.04e-7	IFN-related cytopenia;
CESC	cis	rs7772486	0.846	rs6908063	chr6:146403618	T/C	cg05347473	chr6:146136440	FBXO30	0.48	6.59	0.38	2.4e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs736408	0.562	rs12497998	chr3:52793602	C/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.31	5.49	0.32	9.27e-8	Bipolar disorder;
CESC	cis	rs2797160	1.000	rs61299898	chr6:126007651	G/C	cg05901451	chr6:126070800	HEY2	0.45	6.53	0.37	3.43e-10	Endometrial cancer;
CESC	cis	rs35110281	0.837	rs2838343	chr21:45078035	C/T	cg04455712	chr21:45112962	RRP1B	0.41	6.09	0.35	3.89e-9	Mean corpuscular volume;
CESC	cis	rs4253772	0.591	rs9615934	chr22:46682310	C/G	cg00784671	chr22:46762841	CELSR1	-0.56	-6.04	-0.35	5.06e-9	LDL cholesterol;Cholesterol, total;
CESC	cis	rs1707322	1.000	rs6672115	chr1:46272879	T/C	cg03146154	chr1:46216737	IPP	0.78	10.71	0.55	1.78e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg24642844	chr7:1081250	C7orf50	-0.77	-9.63	-0.51	5.27e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs748404	0.697	rs475261	chr15:43546456	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.61	7.86	0.43	9.6e-14	Lung cancer;
CESC	cis	rs7618915	0.571	rs2289249	chr3:52597664	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	6.62	0.38	1.93e-10	Bipolar disorder;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg05397629	chr11:3848986	RHOG	0.43	6.12	0.35	3.37e-9	Fibrinogen levels;
CESC	cis	rs9549260	0.564	rs9577107	chr13:41271676	A/T	cg21288729	chr13:41239152	FOXO1	0.59	7.68	0.43	2.99e-13	Red blood cell count;
CESC	trans	rs9329221	0.683	rs525726	chr8:9887797	G/C	cg15556689	chr8:8085844	FLJ10661	-0.54	-7.05	-0.4	1.54e-11	Neuroticism;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg00788375	chr19:7745377	TRAPPC5	-0.39	-6.47	-0.37	4.72e-10	Gambling;
CESC	cis	rs1008375	0.932	rs13127157	chr4:17618049	A/G	cg02297831	chr4:17616191	MED28	-0.64	-7.7	-0.43	2.75e-13	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05226292	chr8:71520850	TRAM1	0.58	7.03	0.4	1.77e-11	Gut microbiome composition (summer);
CESC	cis	rs780096	0.526	rs780102	chr2:27659491	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.32	-5.97	-0.34	7.45e-9	Total body bone mineral density;
CESC	trans	rs877282	0.898	rs71489279	chr10:760510	T/C	cg22713356	chr15:30763199	NA	1.14	11.28	0.57	2.37e-24	Uric acid levels;
CESC	cis	rs62432291	0.681	rs1699442	chr6:159655918	A/C	cg14500486	chr6:159655392	FNDC1	0.6	5.98	0.34	7.22e-9	Joint mobility (Beighton score);
CESC	cis	rs4803468	1.000	rs166925	chr19:41926098	T/C	cg14132834	chr19:41945861	ATP5SL	-0.67	-8.35	-0.46	3.83e-15	Height;
CESC	cis	rs9287719	0.934	rs4371336	chr2:10755723	C/A	cg02196655	chr2:10830764	NOL10	-0.37	-5.69	-0.33	3.39e-8	Prostate cancer;
CESC	cis	rs832540	0.931	rs1445996	chr5:56235548	C/T	cg24531977	chr5:56204891	C5orf35	0.4	5.03	0.3	9.23e-7	Coronary artery disease;
CESC	cis	rs2991971	1.000	rs2934859	chr1:46017836	C/T	cg24296786	chr1:45957014	TESK2	0.63	8.21	0.45	9.97e-15	High light scatter reticulocyte count;
CESC	cis	rs3806843	0.750	rs2563285	chr5:140126137	T/C	cg16179182	chr5:140090404	VTRNA1-1	0.39	5.1	0.3	6.59e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs6582630	0.584	rs12832156	chr12:38419435	C/T	cg26384229	chr12:38710491	ALG10B	-0.42	-5.52	-0.32	8.2e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs853679	0.517	rs4713145	chr6:28106827	T/C	cg08968635	chr6:28129556	ZNF389	0.42	5.72	0.33	2.86e-8	Depression;
CESC	cis	rs1570884	0.516	rs2146144	chr13:50170245	C/T	cg03651054	chr13:50194643	NA	0.31	5.08	0.3	7.07e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
CESC	cis	rs853679	0.517	rs17774663	chr6:28120898	G/A	cg20151795	chr6:28129481	ZNF389	0.46	5.81	0.34	1.76e-8	Depression;
CESC	cis	rs769267	0.899	rs3934667	chr19:19431423	T/G	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.41	-5.24	-0.31	3.25e-7	Tonsillectomy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08195029	chr19:9695212	ZNF121	0.55	6.0	0.35	6.3e-9	Gut microbiome composition (summer);
CESC	trans	rs916888	0.773	rs199457	chr17:44795469	C/T	cg01341218	chr17:43662625	NA	0.92	10.64	0.55	3.07e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs9910055	0.531	rs6503490	chr17:42246656	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.72	9.89	0.52	7.62e-20	Total body bone mineral density;
CESC	cis	rs3540	0.574	rs2657947	chr15:90968977	C/T	cg10434728	chr15:90938212	IQGAP1	-0.4	-7.05	-0.4	1.52e-11	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs17608059	0.710	rs8080167	chr17:13949828	G/A	cg11395062	chr17:14139857	CDRT15	0.48	6.27	0.36	1.45e-9	Temperament;
CESC	cis	rs116095464	0.850	rs6896163	chr5:303686	A/G	cg22857025	chr5:266934	NA	-1.2	-10.61	-0.55	3.75e-22	Breast cancer;
CESC	trans	rs9929218	0.861	rs4783667	chr16:68752878	C/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.79	-10.48	-0.54	1.03e-21	Colorectal cancer;
CESC	cis	rs7666738	0.830	rs13124127	chr4:98990729	G/A	cg05340658	chr4:99064831	C4orf37	0.78	11.87	0.59	2.5e-26	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9287719	0.601	rs12692412	chr2:10720054	A/G	cg00105475	chr2:10696890	NA	-0.39	-5.42	-0.32	1.36e-7	Prostate cancer;
CESC	cis	rs425277	0.628	rs262668	chr1:2082602	A/G	cg24578937	chr1:2090814	PRKCZ	0.38	6.62	0.38	2.03e-10	Height;
CESC	cis	rs6460942	0.915	rs62447642	chr7:12489147	T/C	cg10578991	chr7:12443926	VWDE	-0.49	-5.22	-0.31	3.59e-7	Coronary artery disease;
CESC	cis	rs2294693	0.945	rs9369253	chr6:40986538	A/G	cg14418226	chr6:40996092	UNC5CL	0.54	6.44	0.37	5.51e-10	Gastric cancer;Non-cardia gastric cancer;
CESC	cis	rs6728861	1	rs6728861	chr2:203873743	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.83	7.17	0.4	7.34e-12	Coronary artery disease;
CESC	trans	rs7944735	0.507	rs17198607	chr11:48028343	A/C	cg15704280	chr7:45808275	SEPT13	-0.71	-6.41	-0.37	6.71e-10	Intraocular pressure;
CESC	trans	rs11039798	0.588	rs11039818	chr11:48562120	C/T	cg03929089	chr4:120376271	NA	0.6	6.12	0.35	3.35e-9	Axial length;
CESC	cis	rs4771122	0.500	rs1049302	chr13:27998769	T/C	cg22138327	chr13:27999177	GTF3A	-0.88	-11.9	-0.59	1.96e-26	Body mass index;
CESC	cis	rs2204008	0.623	rs1607878	chr12:38376000	A/G	cg26384229	chr12:38710491	ALG10B	0.67	9.88	0.52	8.42e-20	Bladder cancer;
CESC	cis	rs6088580	0.608	rs8114616	chr20:32969092	G/T	cg06115741	chr20:33292138	TP53INP2	-0.46	-5.9	-0.34	1.09e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.48	-7.15	-0.4	8.52e-12	Longevity;Endometriosis;
CESC	cis	rs7927771	1.000	rs7927771	chr11:47781306	A/G	cg18512352	chr11:47633146	NA	-0.61	-9.64	-0.51	4.87e-19	Subjective well-being;
CESC	cis	rs193541	0.632	rs30036	chr5:122278260	A/G	cg19412675	chr5:122181750	SNX24	0.42	5.03	0.3	9.19e-7	Glucose homeostasis traits;
CESC	cis	rs616402	0.527	rs2274985	chr1:10573867	G/A	cg07384165	chr1:10488281	NA	-0.58	-8.57	-0.47	8.45e-16	Breast size;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg19862918	chr17:40761350	FAM134C;TUBG1	-0.49	-6.11	-0.35	3.59e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs6860806	0.507	rs270606	chr5:131650867	A/G	cg07395648	chr5:131743802	NA	-0.46	-6.12	-0.35	3.41e-9	Breast cancer;
CESC	cis	rs6963495	0.818	rs73190181	chr7:105162907	A/C	cg13798780	chr7:105162888	PUS7	0.78	8.04	0.44	2.99e-14	Bipolar disorder (body mass index interaction);
CESC	cis	rs9309711	0.770	rs13409323	chr2:3488184	C/T	cg10845886	chr2:3471009	TTC15	-0.84	-11.56	-0.58	2.71e-25	Neurofibrillary tangles;
CESC	cis	rs1552244	1.000	rs66838678	chr3:10150350	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.82	-10.94	-0.56	3.04e-23	Alzheimer's disease;
CESC	cis	rs2637266	0.703	rs846593	chr10:78504258	T/C	cg18941641	chr10:78392320	NA	0.38	7.53	0.42	7.77e-13	Pulmonary function;
CESC	cis	rs2979489	0.533	rs62505280	chr8:30448124	C/T	cg26383811	chr8:30366931	RBPMS	-0.66	-7.8	-0.43	1.4e-13	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CESC	cis	rs4319547	0.774	rs7307233	chr12:123124301	C/G	cg23029597	chr12:123009494	RSRC2	-0.45	-5.2	-0.3	4.02e-7	Body mass index;
CESC	cis	rs1355223	0.902	rs448016	chr11:34706593	A/C	cg11058730	chr11:34937778	PDHX;APIP	0.5	6.79	0.38	7.5e-11	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs763121	0.853	rs6001214	chr22:39149155	C/T	cg06022373	chr22:39101656	GTPBP1	0.92	15.76	0.7	6.4e-40	Menopause (age at onset);
CESC	cis	rs4910157	1	rs4910157	chr11:8941215	A/G	cg12365402	chr11:9010492	NRIP3	0.37	5.76	0.33	2.32e-8	Tonsillectomy;
CESC	cis	rs2204008	0.837	rs11181857	chr12:38413255	C/G	cg13010199	chr12:38710504	ALG10B	0.42	5.52	0.32	8.24e-8	Bladder cancer;
CESC	cis	rs875971	0.522	rs9530	chr7:65425894	A/G	cg06456125	chr7:65229604	NA	0.42	5.28	0.31	2.74e-7	Aortic root size;
CESC	cis	rs4665809	1.000	rs6720314	chr2:26334852	G/A	cg27170947	chr2:26402098	FAM59B	-0.71	-8.27	-0.45	6.5e-15	Gut microbiome composition (summer);
CESC	cis	rs13191362	1.000	rs36007635	chr6:163009335	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.5	5.19	0.3	4.29e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs11098499	0.691	rs9996494	chr4:120238880	C/A	cg09307838	chr4:120376055	NA	0.78	10.46	0.54	1.15e-21	Corneal astigmatism;
CESC	cis	rs9487051	0.807	rs7748641	chr6:109592381	C/T	cg01475377	chr6:109611718	NA	-0.51	-8.56	-0.47	9.01e-16	Reticulocyte fraction of red cells;
CESC	cis	rs9611565	0.592	rs5758405	chr22:42076381	C/A	cg03806693	chr22:41940476	POLR3H	1.01	11.96	0.59	1.19e-26	Vitiligo;
CESC	cis	rs10823500	0.674	rs7089860	chr10:71992848	C/G	cg02100629	chr10:71892760	AIFM2	-0.35	-5.52	-0.32	7.91e-8	Blood protein levels;
CESC	cis	rs798554	0.759	rs1636255	chr7:2892804	A/C	cg09658497	chr7:2847517	GNA12	0.37	5.27	0.31	2.79e-7	Height;
CESC	cis	rs7927592	0.763	rs10896340	chr11:68312645	A/G	cg16797656	chr11:68205561	LRP5	-0.48	-7.41	-0.41	1.7e-12	Total body bone mineral density;
CESC	cis	rs2839186	0.933	rs56955294	chr21:47708953	A/G	cg10351095	chr21:47802916	PCNT	-0.5	-6.69	-0.38	1.35e-10	Testicular germ cell tumor;
CESC	cis	rs8027181	0.839	rs7176223	chr15:73077742	T/G	cg25632853	chr15:73088954	NA	0.31	5.48	0.32	1e-7	Triglyceride levels;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg09242721	chr3:3168535	TRNT1	-0.45	-6.1	-0.35	3.73e-9	Fibrinogen levels;
CESC	cis	rs7605827	0.930	rs7596951	chr2:15513473	G/C	cg19274914	chr2:15703543	NA	0.32	5.56	0.32	6.52e-8	Educational attainment (years of education);
CESC	cis	rs2576037	0.899	rs2576035	chr18:44587654	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.37	-5.65	-0.33	4.09e-8	Personality dimensions;
CESC	cis	rs72848980	0.512	rs12359556	chr10:105390677	C/T	cg00126946	chr10:105363258	SH3PXD2A	0.59	8.47	0.46	1.66e-15	White matter hyperintensity burden;
CESC	cis	rs4927850	1.000	rs7625570	chr3:195747398	A/G	cg01181863	chr3:195395398	SDHAP2	-0.47	-5.45	-0.32	1.15e-7	Pancreatic cancer;
CESC	cis	rs12545109	0.800	rs2118260	chr8:57393481	T/C	cg09654669	chr8:57350985	NA	-0.54	-6.56	-0.37	2.86e-10	Obesity-related traits;
CESC	cis	rs7264396	0.635	rs6121073	chr20:34457513	G/A	cg17201900	chr20:34330562	RBM39	0.52	5.3	0.31	2.44e-7	Total cholesterol levels;
CESC	cis	rs7561273	0.609	rs10197527	chr2:24352398	A/C	cg20701182	chr2:24300061	SF3B14	0.46	6.01	0.35	6.27e-9	Quantitative traits;
CESC	trans	rs916888	0.821	rs199512	chr17:44857352	T/C	cg07870213	chr5:140052090	DND1	-0.61	-6.87	-0.39	4.47e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs7666738	0.830	rs10049985	chr4:99023517	C/T	cg18180107	chr4:99064573	C4orf37	0.41	5.39	0.31	1.57e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2836974	0.584	rs7276774	chr21:40628725	T/G	cg11890956	chr21:40555474	PSMG1	-0.98	-15.85	-0.7	2.96e-40	Cognitive function;
CESC	cis	rs4862750	0.872	rs6553029	chr4:187876470	G/T	cg06074448	chr4:187884817	NA	0.38	5.18	0.3	4.33e-7	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1144333	1.000	rs5745343	chr1:76273805	A/G	cg03433033	chr1:76189801	ACADM	-0.51	-5.41	-0.32	1.41e-7	Attention function in attention deficit hyperactive disorder;
CESC	cis	rs950776	0.518	rs4887062	chr15:78837801	G/A	cg06917634	chr15:78832804	PSMA4	-0.76	-11.22	-0.57	3.72e-24	Sudden cardiac arrest;
CESC	cis	rs9311474	0.713	rs352165	chr3:52242902	A/G	cg07507251	chr3:52567010	NT5DC2	0.35	6.25	0.36	1.67e-9	Electroencephalogram traits;
CESC	cis	rs72634258	0.519	rs4908487	chr1:7937437	C/T	cg00042356	chr1:8021962	PARK7	0.6	5.73	0.33	2.72e-8	Inflammatory bowel disease;
CESC	trans	rs11098499	0.866	rs12374352	chr4:120281977	C/T	cg25214090	chr10:38739885	LOC399744	0.65	9.11	0.49	2.04e-17	Corneal astigmatism;
CESC	cis	rs67460515	0.892	rs7648279	chr3:160979646	G/A	cg03342759	chr3:160939853	NMD3	-0.54	-7.71	-0.43	2.55e-13	Parkinson's disease;
CESC	cis	rs9837602	0.938	rs17393059	chr3:99761908	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.49	7.14	0.4	8.96e-12	Breast cancer;
CESC	cis	rs6484504	0.576	rs11031324	chr11:31250299	T/C	cg14844989	chr11:31128820	NA	-0.42	-5.94	-0.34	9.07e-9	Red blood cell count;
CESC	cis	rs6582630	0.555	rs10880421	chr12:38423015	C/T	cg26384229	chr12:38710491	ALG10B	0.72	10.51	0.54	7.9e-22	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs7130144	0.541	rs7110730	chr11:130457867	C/T	cg26307797	chr11:130446613	NA	-0.8	-6.52	-0.37	3.61e-10	Urate levels in lean individuals;
CESC	cis	rs847577	0.609	rs6977321	chr7:97774859	A/G	cg21770322	chr7:97807741	LMTK2	0.84	14.14	0.66	3.26e-34	Breast cancer;
CESC	cis	rs7618915	0.547	rs12486847	chr3:52691112	T/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.38	6.66	0.38	1.54e-10	Bipolar disorder;
CESC	cis	rs365132	0.875	rs2962842	chr5:176338955	A/G	cg16309518	chr5:176445507	NA	-0.39	-5.66	-0.33	3.95e-8	Menarche and menopause (age at onset);Menopause (age at onset);
CESC	cis	rs6724607	1.000	rs6434402	chr2:191469322	C/T	cg27211696	chr2:191398769	TMEM194B	-0.5	-7.58	-0.42	5.86e-13	Pulse pressure;
CESC	cis	rs3733585	0.673	rs4560411	chr4:9953361	A/G	cg02734326	chr4:10020555	SLC2A9	-0.39	-5.64	-0.33	4.45e-8	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg24846343	chr22:24311635	DDTL	0.64	11.14	0.56	6.74e-24	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs4727963	0.811	rs1404837	chr7:122696659	A/T	cg03640110	chr7:122635026	TAS2R16	0.37	5.81	0.34	1.76e-8	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
CESC	cis	rs1707322	0.721	rs12043945	chr1:46106922	T/A	cg03146154	chr1:46216737	IPP	0.82	11.48	0.58	4.81e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs10256972	0.967	rs4723338	chr7:1036241	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.41	-5.13	-0.3	5.62e-7	Longevity;Endometriosis;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg15564865	chr6:4021423	PRPF4B	0.47	6.15	0.35	2.79e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs77741769	0.571	rs1542859	chr12:121336766	A/G	cg02419362	chr12:121203948	SPPL3	0.35	5.6	0.33	5.35e-8	Mean corpuscular volume;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg14872693	chr11:65190203	NEAT1	-0.43	-6.02	-0.35	5.69e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs1862618	0.853	rs861283	chr5:56184610	C/T	cg24549020	chr5:56110836	MAP3K1	0.66	7.45	0.42	1.29e-12	Initial pursuit acceleration;
CESC	cis	rs6540559	0.611	rs926347	chr1:209965193	T/C	cg25204440	chr1:209979598	IRF6	0.66	6.52	0.37	3.63e-10	Cleft lip with or without cleft palate;
CESC	cis	rs9325144	0.555	rs61929925	chr12:38698828	C/A	cg26384229	chr12:38710491	ALG10B	-0.6	-8.5	-0.46	1.43e-15	Morning vs. evening chronotype;
CESC	cis	rs9611565	0.546	rs34077262	chr22:42061639	A/G	cg06481639	chr22:41940642	POLR3H	0.59	6.51	0.37	3.8e-10	Vitiligo;
CESC	cis	rs7267979	0.844	rs6132824	chr20:25238173	T/C	cg08601574	chr20:25228251	PYGB	0.42	5.81	0.34	1.77e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs6502050	0.835	rs4523985	chr17:80154466	C/A	cg23985595	chr17:80112537	CCDC57	-0.39	-6.24	-0.36	1.77e-9	Life satisfaction;
CESC	cis	rs6089829	0.962	rs4997812	chr20:61663153	T/G	cg08564027	chr20:61660810	NA	0.92	15.61	0.69	2.2e-39	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs9926296	0.681	rs12923946	chr16:89821080	C/T	cg04287289	chr16:89883240	FANCA	0.62	8.04	0.44	3.07e-14	Vitiligo;
CESC	cis	rs9583531	0.574	rs61971615	chr13:111353111	C/T	cg15841412	chr13:111365552	ING1	-0.5	-6.38	-0.36	7.91e-10	Coronary artery disease;
CESC	cis	rs2292864	0.764	rs35265764	chr17:45363546	G/T	cg18085866	chr17:45331354	ITGB3	-0.63	-5.46	-0.32	1.09e-7	Left atrial antero-posterior diameter;
CESC	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.57	-7.48	-0.42	1.1e-12	Longevity;Endometriosis;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg08262876	chr10:102757026	LZTS2	0.46	6.26	0.36	1.57e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	20.88	0.79	6.44e-58	Prudent dietary pattern;
CESC	cis	rs61931739	0.500	rs11053140	chr12:34316122	T/C	cg19457237	chr12:34500585	NA	-0.37	-5.06	-0.3	7.75e-7	Morning vs. evening chronotype;
CESC	cis	rs9322193	0.884	rs7450246	chr6:150023653	C/T	cg00933542	chr6:150070202	PCMT1	0.29	5.15	0.3	5e-7	Lung cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24848437	chr7:2645542	IQCE	-0.51	-6.04	-0.35	5.06e-9	Gut microbiome composition (summer);
CESC	cis	rs4835473	0.932	rs10030428	chr4:144683852	C/T	cg25736465	chr4:144833511	NA	0.33	5.22	0.31	3.71e-7	Immature fraction of reticulocytes;
CESC	cis	rs2836974	0.602	rs2037925	chr21:40699931	C/T	cg17971929	chr21:40555470	PSMG1	-0.86	-12.5	-0.61	1.69e-28	Cognitive function;
CESC	cis	rs4689388	0.824	rs4467645	chr4:6294305	C/T	cg25554036	chr4:6271136	WFS1	0.51	8.37	0.46	3.31e-15	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17472953	chr4:130014042	SCLT1;C4orf33	-0.57	-6.84	-0.39	5.5e-11	Gut microbiome composition (summer);
CESC	cis	rs8177253	1.000	rs6762719	chr3:133480817	A/G	cg11941060	chr3:133502564	NA	-0.49	-6.81	-0.39	6.41e-11	Iron status biomarkers;
CESC	cis	rs2046867	0.818	rs6789061	chr3:72888690	C/T	cg25664220	chr3:72788482	NA	-0.46	-6.35	-0.36	9.09e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CESC	cis	rs798554	0.567	rs2527695	chr7:2858267	T/G	cg13628971	chr7:2884303	GNA12	0.42	5.68	0.33	3.5e-8	Height;
CESC	cis	rs12477438	0.765	rs72957180	chr2:99694452	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-10.57	-0.54	5.22e-22	Chronic sinus infection;
CESC	cis	rs2303759	0.918	rs2288480	chr19:49867016	C/G	cg22590775	chr19:49891494	CCDC155	0.58	6.97	0.39	2.46e-11	Multiple sclerosis;
CESC	cis	rs11214589	0.905	rs1078	chr11:113241877	C/T	cg14159747	chr11:113255604	NA	0.33	5.86	0.34	1.35e-8	Neuroticism;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12227505	chr17:78194145	SLC26A11;SGSH	0.54	6.45	0.37	5.32e-10	Gut microbiome composition (summer);
CESC	cis	rs6430585	0.583	rs6728946	chr2:136635343	C/G	cg07169764	chr2:136633963	MCM6	1.31	20.8	0.79	1.22e-57	Corneal structure;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16278828	chr15:75648574	MAN2C1	-0.55	-6.92	-0.39	3.45e-11	Gut microbiome composition (summer);
CESC	cis	rs7959452	0.535	rs11615712	chr12:69619736	A/T	cg14784868	chr12:69753453	YEATS4	-0.66	-9.17	-0.49	1.34e-17	Blood protein levels;
CESC	cis	rs7666738	0.791	rs28858828	chr4:98950442	C/G	cg03467027	chr4:99064603	C4orf37	0.45	5.67	0.33	3.69e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs703842	0.616	rs10877024	chr12:58226709	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.58	6.88	0.39	4.37e-11	Multiple sclerosis;
CESC	cis	rs2806561	0.780	rs12117752	chr1:23360223	T/C	cg12483005	chr1:23474871	LUZP1	-0.34	-5.37	-0.31	1.71e-7	Height;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg10971895	chr1:201438445	PHLDA3	-0.49	-6.04	-0.35	5.07e-9	Ulcerative colitis;
CESC	cis	rs1707322	0.686	rs3014239	chr1:46089801	G/A	cg05343316	chr1:45956843	TESK2	-0.52	-6.4	-0.37	7.03e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg05062679	chr10:94000186	CPEB3	0.47	6.53	0.37	3.35e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs6500602	0.627	rs6500610	chr16:4529613	A/G	cg08645402	chr16:4508243	NA	0.42	5.92	0.34	1.01e-8	Schizophrenia;
CESC	cis	rs28647808	1.000	rs4962145	chr9:136275188	A/G	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.9	5.73	0.33	2.75e-8	Blood protein levels;
CESC	cis	rs7980687	0.506	rs1611973	chr12:123622731	C/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.32	-5.07	-0.3	7.48e-7	Height;Educational attainment;Head circumference (infant);
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg00529697	chr5:75013131	C5orf37	0.41	6.15	0.35	2.87e-9	Vertical cup-disc ratio;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg20594226	chr2:87035716	CD8A	-0.5	-6.39	-0.37	7.25e-10	Ulcerative colitis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09538139	chr9:127532208	NR6A1	-0.56	-6.55	-0.37	3.04e-10	Gut microbiome composition (summer);
CESC	cis	rs17376456	0.877	rs17315943	chr5:93442830	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.6	5.11	0.3	6.27e-7	Diabetic retinopathy;
CESC	cis	rs6502050	0.731	rs34796376	chr17:80116635	G/T	cg11859384	chr17:80120422	CCDC57	-0.38	-5.17	-0.3	4.51e-7	Life satisfaction;
CESC	cis	rs11674184	0.743	rs12470971	chr2:11725241	A/G	cg07314298	chr2:11723111	GREB1	0.65	10.02	0.52	3.02e-20	Endometriosis;
CESC	cis	rs7116495	0.881	rs673478	chr11:71799104	G/A	cg26138937	chr11:71823887	C11orf51	-0.87	-7.06	-0.4	1.42e-11	Severe influenza A (H1N1) infection;
CESC	cis	rs12477438	0.520	rs4347885	chr2:99804007	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.78	12.28	0.6	9.55e-28	Chronic sinus infection;
CESC	cis	rs4853012	0.838	rs4452177	chr2:74345206	A/G	cg19729930	chr2:74357872	NA	0.85	12.84	0.62	1.15e-29	Gestational age at birth (maternal effect);
CESC	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg18765753	chr7:1198926	ZFAND2A	-0.39	-5.62	-0.33	4.77e-8	Longevity;Endometriosis;
CESC	cis	rs3820928	0.874	rs11685983	chr2:227799853	A/G	cg05526886	chr2:227700861	RHBDD1	-0.39	-5.07	-0.3	7.46e-7	Pulmonary function;
CESC	cis	rs9346455	0.568	rs9354994	chr6:72030632	C/T	cg27238071	chr6:71998145	OGFRL1	0.55	5.21	0.3	3.81e-7	Antipsychotic drug-induced weight gain (time interaction);Antipsychotic drug-induced weight gain;
CESC	trans	rs61931739	0.500	rs11053236	chr12:34507962	C/G	cg13010199	chr12:38710504	ALG10B	0.5	6.42	0.37	6.3e-10	Morning vs. evening chronotype;
CESC	cis	rs4625783	0.583	rs11077974	chr17:80095193	A/G	cg01763666	chr17:80159506	CCDC57	-0.37	-5.1	-0.3	6.61e-7	Blood metabolite levels;
CESC	cis	rs1256061	0.624	rs1152586	chr14:64690784	T/C	cg21174375	chr14:64681225	SYNE2	0.49	6.43	0.37	5.95e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg24511898	chr2:242576823	ATG4B;THAP4	0.46	6.3	0.36	1.26e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs10479542	0.766	rs7733389	chr5:178974997	C/T	cg00080972	chr5:178986291	RUFY1	0.37	5.61	0.33	5.16e-8	Lung cancer;
CESC	cis	rs34779708	0.931	rs35388511	chr10:35296616	A/G	cg04310649	chr10:35416472	CREM	-0.49	-5.93	-0.34	9.63e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs17384381	0.634	rs11801146	chr1:85915374	C/T	cg16011679	chr1:85725395	C1orf52	0.66	6.65	0.38	1.63e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6424115	0.800	rs4649123	chr1:24197696	A/G	cg15997130	chr1:24165203	NA	0.4	5.25	0.31	3.1e-7	Immature fraction of reticulocytes;
CESC	cis	rs155076	0.666	rs9509640	chr13:21872880	T/C	cg25811766	chr13:21894605	NA	0.54	5.41	0.32	1.39e-7	White matter hyperintensity burden;
CESC	cis	rs72627123	0.867	rs74395411	chr14:74478584	T/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.73	5.63	0.33	4.49e-8	Morning vs. evening chronotype;
CESC	cis	rs1552244	1.000	rs9881859	chr3:10072814	A/T	cg00166722	chr3:10149974	C3orf24	0.5	6.31	0.36	1.19e-9	Alzheimer's disease;
CESC	cis	rs28386778	0.704	rs1051688	chr17:62006433	G/C	cg06873352	chr17:61820015	STRADA	-0.6	-9.63	-0.51	5.11e-19	Prudent dietary pattern;
CESC	trans	rs7937682	0.889	rs1789359	chr11:111475995	T/A	cg18187862	chr3:45730750	SACM1L	0.48	6.11	0.35	3.49e-9	Primary sclerosing cholangitis;
CESC	cis	rs870825	0.550	rs35981185	chr4:185639720	A/C	cg04058563	chr4:185651563	MLF1IP	0.64	7.09	0.4	1.21e-11	Blood protein levels;
CESC	cis	rs7833986	0.501	rs72653917	chr8:56892844	T/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.58	7.16	0.4	8.04e-12	Height;
CESC	trans	rs6089829	1.000	rs6089829	chr20:61669036	C/T	cg23505145	chr19:12996616	KLF1	-0.54	-7.03	-0.4	1.7e-11	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7551222	0.752	rs11240754	chr1:204477977	A/G	cg20240347	chr1:204465584	NA	-0.28	-5.61	-0.33	5.15e-8	Schizophrenia;
CESC	cis	rs7847628	0.587	rs1060817	chr9:123583192	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.45	7.78	0.43	1.61e-13	Birth weight;
CESC	cis	rs9911578	0.967	rs302842	chr17:56728102	C/G	cg12560992	chr17:57184187	TRIM37	0.93	15.58	0.69	2.6e-39	Intelligence (multi-trait analysis);
CESC	cis	rs4819052	0.807	rs7283915	chr21:46671288	T/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.45	5.59	0.32	5.76e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs6762	0.692	rs7928925	chr11:839155	G/A	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.68	-8.44	-0.46	2.13e-15	Mean platelet volume;
CESC	cis	rs7937682	0.575	rs7107213	chr11:111750430	A/G	cg09085632	chr11:111637200	PPP2R1B	0.92	12.4	0.61	3.78e-28	Primary sclerosing cholangitis;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg07355262	chr7:5347698	TNRC18	-0.39	-6.01	-0.35	6.09e-9	Gut microbiota (bacterial taxa);
CESC	trans	rs11098499	0.863	rs7669520	chr4:120515278	T/C	cg25214090	chr10:38739885	LOC399744	0.68	9.26	0.49	7.05e-18	Corneal astigmatism;
CESC	cis	rs1018836	0.886	rs10283086	chr8:91616651	G/A	cg16814680	chr8:91681699	NA	-0.76	-11.84	-0.59	3.08e-26	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs17376456	0.825	rs10075217	chr5:93176774	C/G	cg25358565	chr5:93447407	FAM172A	1.06	10.37	0.54	2.34e-21	Diabetic retinopathy;
CESC	cis	rs1006703	0.544	rs35443604	chr17:3833972	G/A	cg06463185	chr17:3833770	ATP2A3	-0.54	-5.89	-0.34	1.18e-8	Glucose homeostasis traits;
CESC	cis	rs1729951	0.545	rs1097288	chr3:136693721	C/T	cg25687071	chr3:136751404	NA	0.39	5.19	0.3	4.27e-7	Neuroticism;
CESC	cis	rs7560272	0.501	rs4852978	chr2:73943110	G/A	cg20560298	chr2:73613845	ALMS1	0.41	5.69	0.33	3.43e-8	Schizophrenia;
CESC	cis	rs2075371	1.000	rs2598291	chr7:133988313	C/G	cg20476274	chr7:133979776	SLC35B4	0.67	9.8	0.52	1.45e-19	Mean platelet volume;
CESC	cis	rs9308731	0.556	rs10166773	chr2:111936935	G/T	cg04202892	chr2:111875749	ACOXL	0.37	5.18	0.3	4.34e-7	Chronic lymphocytic leukemia;
CESC	cis	rs9814567	1.000	rs7433991	chr3:134312292	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.4	-5.44	-0.32	1.21e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs7959452	0.640	rs12370042	chr12:69692420	C/G	cg14784868	chr12:69753453	YEATS4	0.74	10.68	0.55	2.15e-22	Blood protein levels;
CESC	cis	rs11098499	0.954	rs7687843	chr4:120421211	C/T	cg24375607	chr4:120327624	NA	0.46	5.64	0.33	4.3e-8	Corneal astigmatism;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg11884792	chr2:192542902	OBFC2A	-0.46	-6.05	-0.35	4.99e-9	Asthma;
CESC	cis	rs3806843	0.735	rs778595	chr5:140036681	G/A	cg26395211	chr5:140044315	WDR55	0.48	6.19	0.36	2.27e-9	Depressive symptoms (multi-trait analysis);
CESC	cis	rs2832191	0.903	rs11700687	chr21:30486767	A/G	cg24692254	chr21:30365293	RNF160	-0.73	-10.87	-0.56	5.11e-23	Dental caries;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg09138430	chr7:44084267	DBNL	-0.46	-6.05	-0.35	4.98e-9	Ulcerative colitis;
CESC	cis	rs35110281	0.807	rs28840140	chr21:45039163	T/C	cg21573476	chr21:45109991	RRP1B	-0.46	-6.38	-0.37	7.77e-10	Mean corpuscular volume;
CESC	cis	rs6688363	0.943	rs1016732	chr1:160086968	A/G	cg22802111	chr1:160068614	IGSF8	0.52	5.17	0.3	4.65e-7	Response to antipsychotic treatment;
CESC	cis	rs881375	0.933	rs4837804	chr9:123705304	C/G	cg14580859	chr9:123691850	NA	0.28	5.12	0.3	5.88e-7	Rheumatoid arthritis;
CESC	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg24642844	chr7:1081250	C7orf50	-0.76	-9.26	-0.49	7.23e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs875971	1.000	rs6961717	chr7:65587537	C/T	cg11764359	chr7:65958608	NA	-0.93	-14.62	-0.67	6.62e-36	Aortic root size;
CESC	trans	rs61931739	0.534	rs11053047	chr12:34161084	C/T	cg26384229	chr12:38710491	ALG10B	0.64	9.08	0.49	2.54e-17	Morning vs. evening chronotype;
CESC	cis	rs8064299	0.967	rs3744208	chr17:72767565	A/G	cg25054828	chr17:72772726	NAT9;TMEM104	0.65	9.3	0.5	5.28e-18	Monocyte count;
CESC	cis	rs1728785	0.901	rs12929568	chr16:68596689	A/G	cg02972257	chr16:68554789	NA	-0.51	-6.05	-0.35	4.98e-9	Ulcerative colitis;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg09928813	chr16:30794679	ZNF629	0.48	6.73	0.38	1.06e-10	Fibrinogen levels;
CESC	cis	rs45535039	1.000	rs11217194	chr11:119097568	T/C	cg16724696	chr11:118992527	HINFP	0.42	5.28	0.31	2.69e-7	Plateletcrit;
CESC	cis	rs34172651	0.517	rs36113933	chr16:24838862	A/G	cg06505273	chr16:24850292	NA	0.54	6.51	0.37	3.66e-10	Intelligence (multi-trait analysis);
CESC	cis	rs9329289	0.888	rs11251273	chr10:2540300	G/C	cg15501526	chr10:2543763	NA	0.63	11.27	0.57	2.43e-24	Age-related hearing impairment;
CESC	cis	rs854765	0.583	rs8073001	chr17:17831716	A/C	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.53	-6.98	-0.39	2.41e-11	Total body bone mineral density;
CESC	cis	rs425277	1.000	rs381664	chr1:2088104	A/G	cg24578937	chr1:2090814	PRKCZ	0.55	9.47	0.5	1.63e-18	Height;
CESC	trans	rs2727020	0.930	rs1164688	chr11:49290604	C/G	cg15704280	chr7:45808275	SEPT13	0.8	11.17	0.57	5.5e-24	Coronary artery disease;
CESC	cis	rs2880765	0.835	rs2170735	chr15:86043485	G/A	cg19183879	chr15:85880815	NA	-0.25	-5.1	-0.3	6.47e-7	Coronary artery disease;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg06348081	chr3:182511312	ATP11B	-0.49	-6.27	-0.36	1.45e-9	Asthma;
CESC	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg12419862	chr22:24373484	LOC391322	-0.9	-13.91	-0.65	2.15e-33	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs72781680	0.898	rs72798041	chr2:23953076	T/C	cg20701182	chr2:24300061	SF3B14	0.77	6.7	0.38	1.28e-10	Lymphocyte counts;
CESC	cis	rs10197940	0.624	rs6724796	chr2:152412813	C/T	cg06191203	chr2:152266755	RIF1	-0.44	-5.56	-0.32	6.44e-8	Lung cancer;
CESC	cis	rs412050	0.502	rs8136405	chr22:22148021	A/C	cg17089214	chr22:22089827	YPEL1	0.69	5.8	0.34	1.85e-8	Attention deficit hyperactivity disorder;
CESC	cis	rs16854884	0.526	rs7643341	chr3:143726980	C/T	cg01302019	chr3:143689584	C3orf58	-0.38	-5.94	-0.34	9.06e-9	Economic and political preferences (feminism/equality);
CESC	cis	rs7833790	0.660	rs67666182	chr8:82772037	A/G	cg02079420	chr8:82753780	SNX16	-0.53	-8.2	-0.45	1.01e-14	Diastolic blood pressure;
CESC	cis	rs9303401	0.527	rs34835800	chr17:56764990	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.03	12.47	0.61	2.14e-28	Cognitive test performance;
CESC	cis	rs7811142	0.830	rs6948685	chr7:99970188	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.69	6.11	0.35	3.54e-9	Platelet count;
CESC	cis	rs1355223	0.867	rs2281908	chr11:34683578	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.48	-6.25	-0.36	1.61e-9	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs4665809	0.941	rs2289021	chr2:26362515	A/C	cg08470875	chr2:26401718	FAM59B	0.48	5.74	0.33	2.59e-8	Gut microbiome composition (summer);
CESC	cis	rs61931739	0.817	rs10772144	chr12:34242463	A/C	cg19457237	chr12:34500585	NA	-0.42	-5.79	-0.33	2.01e-8	Morning vs. evening chronotype;
CESC	cis	rs1707322	0.682	rs28508523	chr1:46189625	G/A	cg06784218	chr1:46089804	CCDC17	0.42	7.58	0.42	5.82e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs453301	0.571	rs330054	chr8:9088291	G/A	cg17143192	chr8:8559678	CLDN23	-0.44	-5.34	-0.31	1.99e-7	Joint mobility (Beighton score);
CESC	cis	rs35146811	0.844	rs4729576	chr7:99692594	G/A	cg13334819	chr7:99746414	C7orf59	-0.44	-5.19	-0.3	4.13e-7	Coronary artery disease;
CESC	cis	rs7829975	0.617	rs4841071	chr8:8791144	G/T	cg06636001	chr8:8085503	FLJ10661	0.41	5.18	0.3	4.46e-7	Mood instability;
CESC	cis	rs4889855	0.578	rs7216808	chr17:78484187	A/G	cg16591659	chr17:78472290	NA	-0.51	-7.57	-0.42	6.27e-13	Fractional excretion of uric acid;
CESC	cis	rs7851660	0.874	rs7868534	chr9:100632606	G/A	cg13688889	chr9:100608707	NA	-0.6	-8.55	-0.47	9.84e-16	Strep throat;
CESC	cis	rs1506636	0.708	rs7788702	chr7:123237421	C/T	cg03229431	chr7:123269106	ASB15	0.38	5.13	0.3	5.71e-7	Plateletcrit;Platelet count;
CESC	cis	rs798554	0.679	rs1636250	chr7:2884433	T/C	cg13628971	chr7:2884303	GNA12	0.64	8.78	0.47	2.11e-16	Height;
CESC	cis	rs9303401	0.659	rs12952325	chr17:56899371	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.01	12.68	0.61	4.11e-29	Cognitive test performance;
CESC	cis	rs3091242	0.933	rs34006994	chr1:25780668	C/T	cg27572855	chr1:25598939	RHD	-0.43	-7.24	-0.41	4.99e-12	Erythrocyte sedimentation rate;
CESC	cis	rs9733	0.570	rs951281	chr1:150691122	A/C	cg18016565	chr1:150552671	MCL1	0.35	5.36	0.31	1.86e-7	Tonsillectomy;
CESC	cis	rs9910055	0.762	rs184478	chr17:42209751	C/G	cg10896456	chr17:42255109	ASB16;C17orf65	-0.41	-6.06	-0.35	4.7e-9	Total body bone mineral density;
CESC	cis	rs8072100	0.790	rs1962307	chr17:45707871	A/G	cg08085267	chr17:45401833	C17orf57	-0.45	-5.65	-0.33	4.17e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs798554	0.704	rs798513	chr7:2782493	C/T	cg19717773	chr7:2847554	GNA12	-0.55	-8.64	-0.47	5.3e-16	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11204671	chr14:24583351	DCAF11	0.53	6.05	0.35	5.02e-9	Gut microbiome composition (summer);
CESC	trans	rs10242455	0.702	rs73403290	chr7:99157828	C/T	cg09045935	chr12:6379348	NA	0.92	7.54	0.42	7.67e-13	Blood metabolite levels;
CESC	cis	rs28498503	0.573	rs9945815	chr18:76654224	A/G	cg00806245	chr18:76673096	NA	-0.69	-5.66	-0.33	3.92e-8	Attention function in attention deficit hyperactive disorder;
CESC	cis	rs965469	0.947	rs6051773	chr20:3330382	C/G	cg25506879	chr20:3388711	C20orf194	-0.54	-5.78	-0.33	2.14e-8	IFN-related cytopenia;
CESC	cis	rs6952808	0.689	rs12668156	chr7:2019875	G/A	cg08027265	chr7:2291960	NA	-0.4	-5.81	-0.34	1.78e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg02353165	chr6:42928485	GNMT	0.81	12.31	0.6	7.7e-28	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs9346455	0.614	rs1322759	chr6:72013023	A/G	cg27238071	chr6:71998145	OGFRL1	0.64	6.17	0.35	2.52e-9	Antipsychotic drug-induced weight gain (time interaction);Antipsychotic drug-induced weight gain;
CESC	cis	rs9768139	0.708	rs921616	chr7:158117960	A/G	cg06219351	chr7:158114137	PTPRN2	-0.5	-7.84	-0.43	1.1e-13	Calcium levels;
CESC	trans	rs12681287	0.547	rs9942793	chr8:87509091	C/T	cg27317242	chr8:23145699	R3HCC1	-0.53	-6.35	-0.36	9.05e-10	Caudate activity during reward;
CESC	cis	rs12130219	1.000	rs34428306	chr1:152184316	G/C	cg17718321	chr1:152188247	HRNR	0.41	5.53	0.32	7.77e-8	Inflammatory skin disease;
CESC	cis	rs7666738	0.830	rs6832568	chr4:98994061	G/A	cg17366294	chr4:99064904	C4orf37	0.6	8.61	0.47	6.47e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs80282103	0.618	rs11250249	chr10:1116999	T/C	cg08668510	chr10:1095578	IDI1	0.83	5.06	0.3	7.71e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs1729951	0.575	rs35289288	chr3:136680568	C/T	cg04103450	chr3:136751342	NA	0.4	5.28	0.31	2.67e-7	Neuroticism;
CESC	cis	rs7107174	1.000	rs2510048	chr11:77987464	T/C	cg02023728	chr11:77925099	USP35	0.48	6.63	0.38	1.82e-10	Testicular germ cell tumor;
CESC	cis	rs875971	1.000	rs6961717	chr7:65587537	C/T	cg18876405	chr7:65276391	NA	-0.5	-6.78	-0.38	7.91e-11	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00746487	chr13:99293520	NA	-0.54	-6.29	-0.36	1.3e-9	Gut microbiome composition (summer);
CESC	cis	rs1670533	1.000	rs652063	chr4:1084137	T/C	cg27284194	chr4:1044797	NA	0.48	6.17	0.35	2.6e-9	Recombination rate (females);
CESC	cis	rs1256061	0.646	rs1256059	chr14:64710417	A/G	cg21174375	chr14:64681225	SYNE2	0.49	6.68	0.38	1.43e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs7666738	0.830	rs7678911	chr4:99057430	C/T	cg17366294	chr4:99064904	C4orf37	0.62	8.84	0.48	1.34e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4555082	0.834	rs1473672	chr14:105721981	G/T	cg10792982	chr14:105748885	BRF1	0.41	5.26	0.31	2.96e-7	Mean platelet volume;Platelet distribution width;
CESC	cis	rs7000551	0.681	rs2461488	chr8:22371858	G/A	cg12081754	chr8:22256438	SLC39A14	0.38	5.11	0.3	6.32e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CESC	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg10150615	chr22:24372951	LOC391322	-0.61	-8.37	-0.46	3.35e-15	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs832540	0.618	rs2548663	chr5:56172778	G/A	cg24531977	chr5:56204891	C5orf35	-0.5	-6.01	-0.35	6.01e-9	Coronary artery disease;
CESC	cis	rs959260	1.000	rs4789193	chr17:73404796	A/T	cg12999837	chr17:73267436	MIF4GD	0.48	5.46	0.32	1.07e-7	Systemic lupus erythematosus;
CESC	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg21856205	chr7:94953877	PON1	-0.43	-6.97	-0.39	2.59e-11	Paraoxonase activity;
CESC	cis	rs4561483	0.801	rs40311	chr16:11963190	C/G	cg08843971	chr16:11963173	GSPT1	0.57	8.58	0.47	7.98e-16	Testicular germ cell tumor;
CESC	cis	rs12079745	0.590	rs12065030	chr1:169258201	A/G	cg09363564	chr1:169337483	NME7;BLZF1	0.91	5.87	0.34	1.29e-8	QT interval;
CESC	cis	rs780096	0.526	rs1647267	chr2:27651054	A/T	cg24768116	chr2:27665128	KRTCAP3	-0.3	-5.57	-0.32	6.2e-8	Total body bone mineral density;
CESC	cis	rs8020095	0.528	rs6573724	chr14:67240565	T/C	cg19548862	chr14:67692701	FAM71D	-0.49	-5.97	-0.34	7.66e-9	Depression (quantitative trait);
CESC	cis	rs4423214	0.840	rs4435028	chr11:71183690	C/A	cg05163923	chr11:71159392	DHCR7	-0.68	-7.76	-0.43	1.82e-13	Vitamin D levels;
CESC	cis	rs2594989	0.943	rs2594970	chr3:11400877	C/T	cg00170343	chr3:11313890	ATG7	0.55	5.03	0.3	9.09e-7	Circulating chemerin levels;
CESC	cis	rs4555082	0.874	rs2816612	chr14:105723103	C/T	cg06808227	chr14:105710500	BRF1	-0.58	-6.77	-0.38	8.26e-11	Mean platelet volume;Platelet distribution width;
CESC	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg09033563	chr22:24373618	LOC391322	-0.45	-5.76	-0.33	2.29e-8	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs7666738	0.761	rs13136913	chr4:98998031	C/T	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.62e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6933660	0.800	rs9383900	chr6:151782816	A/C	cg02564969	chr6:151773285	C6orf211;RMND1	0.62	8.49	0.46	1.51e-15	Menarche (age at onset);
CESC	trans	rs982100	0.596	rs933759	chr2:118469325	C/T	cg24863536	chr7:75889570	SRRM3	0.76	6.07	0.35	4.35e-9	Alzheimer disease and age of onset;
CESC	cis	rs8017423	0.967	rs61592400	chr14:90703252	T/C	cg14092571	chr14:90743983	NA	-0.57	-8.44	-0.46	2.09e-15	Mortality in heart failure;
CESC	cis	rs6812193	0.518	rs7662031	chr4:77205338	T/C	cg20311846	chr4:77356250	SHROOM3	-0.31	-5.58	-0.32	5.82e-8	Parkinson's disease;
CESC	trans	rs7615952	0.512	rs2979351	chr3:125363599	C/T	cg21747405	chr11:67723411	NA	-0.44	-6.69	-0.38	1.3100000000000001e-10	Blood pressure (smoking interaction);
CESC	cis	rs9916302	0.904	rs801420	chr17:37466103	C/G	cg19468946	chr17:37922297	IKZF3	0.41	5.22	0.31	3.59e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs8180040	0.966	rs2291298	chr3:47555142	C/A	cg27129171	chr3:47204927	SETD2	0.59	8.48	0.46	1.57e-15	Colorectal cancer;
CESC	cis	rs1355223	0.902	rs12801509	chr11:34747336	G/T	cg11058730	chr11:34937778	PDHX;APIP	-0.47	-6.08	-0.35	4.14e-9	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs853679	0.545	rs35949109	chr6:28025926	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.67	-5.12	-0.3	5.9e-7	Depression;
CESC	cis	rs8017423	1.000	rs2183189	chr14:90670057	A/G	cg14092571	chr14:90743983	NA	-0.56	-8.28	-0.45	5.95e-15	Mortality in heart failure;
CESC	cis	rs4423214	0.840	rs1792224	chr11:71176141	C/T	cg05163923	chr11:71159392	DHCR7	-0.65	-7.55	-0.42	6.91e-13	Vitamin D levels;
CESC	cis	rs769267	0.930	rs4808208	chr19:19650096	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.47	5.87	0.34	1.31e-8	Tonsillectomy;
CESC	cis	rs9311474	0.713	rs352165	chr3:52242902	A/G	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.32	5.75	0.33	2.47e-8	Electroencephalogram traits;
CESC	cis	rs7647973	0.710	rs2029591	chr3:49646981	C/T	cg13072238	chr3:49761600	GMPPB	0.51	5.93	0.34	9.53e-9	Menarche (age at onset);
CESC	cis	rs9649213	0.593	rs6955647	chr7:98004562	T/C	cg24562669	chr7:97807699	LMTK2	0.48	7.01	0.4	1.98e-11	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs11514810	1.000	rs9648619	chr7:1427949	G/T	cg24899294	chr7:1481343	MICALL2	-0.69	-5.78	-0.33	2.07e-8	Executive inhibition (Stroop WIT and CIT) in attention deficit hyperactivity disorder;
CESC	cis	rs7044106	0.762	rs1547267	chr9:123408736	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.33	5.14	0.3	5.26e-7	Hip circumference adjusted for BMI;
CESC	cis	rs6540556	0.608	rs7548781	chr1:209915795	A/G	cg05527609	chr1:210001259	C1orf107	0.57	6.67	0.38	1.5e-10	Red blood cell count;
CESC	cis	rs9488822	0.636	rs10872142	chr6:116369052	C/A	cg26893134	chr6:116381904	FRK	0.25	6.08	0.35	4.07e-9	Cholesterol, total;LDL cholesterol;
CESC	cis	rs79349575	0.721	rs9904645	chr17:46969665	A/T	cg16584676	chr17:46985605	UBE2Z	0.54	6.62	0.38	2.03e-10	Type 2 diabetes;
CESC	cis	rs1707322	0.717	rs1135850	chr1:46093692	G/A	cg03146154	chr1:46216737	IPP	0.79	11.05	0.56	1.36e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs7618501	0.633	rs6771546	chr3:49968572	T/C	cg21659725	chr3:3221576	CRBN	0.49	6.8	0.39	6.8e-11	Intelligence (multi-trait analysis);
CESC	trans	rs3942852	0.712	rs2174129	chr11:48108557	A/C	cg15704280	chr7:45808275	SEPT13	-0.73	-8.8	-0.48	1.75e-16	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg15112475	chr7:1198522	ZFAND2A	-0.38	-5.96	-0.34	8.22e-9	Longevity;Endometriosis;
CESC	cis	rs10504229	0.683	rs55807014	chr8:58131801	T/C	cg02725872	chr8:58115012	NA	-0.45	-7.05	-0.4	1.52e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs274567	0.501	rs272856	chr5:131687081	G/C	cg18758796	chr5:131593413	PDLIM4	0.38	5.07	0.3	7.43e-7	Blood metabolite levels;
CESC	cis	rs6598955	0.670	rs10794525	chr1:26537193	C/A	cg04990556	chr1:26633338	UBXN11	-0.75	-10.63	-0.55	3.15e-22	Obesity-related traits;
CESC	cis	rs9487051	0.768	rs351742	chr6:109527325	C/T	cg01475377	chr6:109611718	NA	0.43	6.44	0.37	5.44e-10	Reticulocyte fraction of red cells;
CESC	cis	rs7193541	0.684	rs9923145	chr16:74686166	G/A	cg01733217	chr16:74700730	RFWD3	1.05	20.17	0.78	1.79e-55	Multiple myeloma;
CESC	cis	rs2228479	0.702	rs11076621	chr16:89837927	A/G	cg04013166	chr16:89971882	TCF25	0.78	6.69	0.38	1.3e-10	Skin colour saturation;
CESC	cis	rs832540	0.669	rs832538	chr5:56200016	C/T	cg12311346	chr5:56204834	C5orf35	-0.57	-7.57	-0.42	6.09e-13	Coronary artery disease;
CESC	trans	rs7937682	0.924	rs875257	chr11:111530453	A/G	cg18187862	chr3:45730750	SACM1L	0.48	6.08	0.35	4.15e-9	Primary sclerosing cholangitis;
CESC	cis	rs78366141	0.536	rs78517451	chr4:89650437	C/A	cg01026744	chr4:89619053	NAP1L5;HERC3	0.86	5.39	0.31	1.56e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
CESC	cis	rs9911578	0.967	rs12944948	chr17:56951474	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.17	0.3	4.57e-7	Intelligence (multi-trait analysis);
CESC	cis	rs9287719	0.967	rs1541573	chr2:10773385	T/G	cg02196655	chr2:10830764	NOL10	-0.36	-5.36	-0.31	1.79e-7	Prostate cancer;
CESC	cis	rs1707322	0.963	rs4508055	chr1:46257731	A/T	cg03146154	chr1:46216737	IPP	0.8	11.02	0.56	1.72e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2901656	0.502	rs9425602	chr1:172383686	T/A	cg03748243	chr1:172413542	C1orf105;PIGC	-0.38	-5.18	-0.3	4.43e-7	Red cell distribution width;Platelet distribution width;
CESC	cis	rs6963495	0.818	rs75116202	chr7:105160059	C/T	cg19920283	chr7:105172520	RINT1	0.69	6.56	0.37	2.85e-10	Bipolar disorder (body mass index interaction);
CESC	cis	rs7312774	0.881	rs79048355	chr12:107311169	G/T	cg16260113	chr12:107380972	MTERFD3	0.64	6.08	0.35	4.08e-9	Severe influenza A (H1N1) infection;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg14633757	chr17:80231324	CSNK1D	-0.47	-6.36	-0.36	8.78e-10	Fibrinogen levels;
CESC	cis	rs2836974	0.831	rs34294410	chr21:40555160	C/G	cg11644478	chr21:40555479	PSMG1	1.04	16.98	0.72	2.99e-44	Cognitive function;
CESC	cis	rs67311347	0.910	rs7651204	chr3:40512835	C/T	cg24209194	chr3:40518798	ZNF619	-0.53	-6.88	-0.39	4.25e-11	Renal cell carcinoma;
CESC	cis	rs11098499	0.722	rs28713555	chr4:120251995	C/T	cg09307838	chr4:120376055	NA	0.77	10.49	0.54	9.15e-22	Corneal astigmatism;
CESC	cis	rs1552244	0.935	rs11926481	chr3:10142102	G/T	cg00166722	chr3:10149974	C3orf24	0.46	5.94	0.34	9.04e-9	Alzheimer's disease;
CESC	cis	rs672059	1.000	rs510642	chr1:183162776	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.56	7.17	0.4	7.56e-12	Hypertriglyceridemia;
CESC	cis	rs8070624	0.502	rs12951376	chr17:17752809	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.45	5.93	0.34	9.52e-9	Total body bone mineral density;
CESC	cis	rs6088580	0.584	rs2378203	chr20:32993846	A/T	cg24642439	chr20:33292090	TP53INP2	-0.53	-6.98	-0.39	2.31e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs11760633	0.607	rs11760284	chr7:1827569	C/T	cg23422044	chr7:1970798	MAD1L1	-0.43	-5.14	-0.3	5.27e-7	Coronary artery disease;
CESC	cis	rs41271951	0.558	rs79671334	chr1:151115887	C/G	cg11822372	chr1:151115635	SEMA6C	-0.87	-6.23	-0.36	1.83e-9	Blood protein levels;
CESC	cis	rs9549260	0.876	rs9549258	chr13:41248026	T/C	cg21288729	chr13:41239152	FOXO1	0.62	5.89	0.34	1.15e-8	Red blood cell count;
CESC	cis	rs5753618	0.504	rs5753661	chr22:31899797	C/A	cg00478049	chr22:31556069	RNF185	-0.46	-5.53	-0.32	7.55e-8	Colorectal cancer;
CESC	cis	rs736408	0.562	rs12497998	chr3:52793602	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.53	7.73	0.43	2.19e-13	Bipolar disorder;
CESC	cis	rs7845219	0.544	rs4735330	chr8:95917770	A/C	cg16049864	chr8:95962084	TP53INP1	-0.49	-7.22	-0.41	5.48e-12	Type 2 diabetes;
CESC	cis	rs722599	0.748	rs17102884	chr14:75374899	C/T	cg08847533	chr14:75593920	NEK9	-0.45	-5.47	-0.32	1.02e-7	IgG glycosylation;
CESC	trans	rs8073060	0.586	rs226087	chr17:34017652	T/C	cg19694781	chr19:47549865	TMEM160	-0.74	-6.91	-0.39	3.64e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	cis	rs4253772	0.591	rs6007795	chr22:46686792	C/G	cg10231785	chr22:46692440	CN5H6.4;GTSE1	0.55	5.66	0.33	3.89e-8	LDL cholesterol;Cholesterol, total;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg09225973	chr6:150232183	NA	-0.46	-6.45	-0.37	5.35e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs35110281	0.666	rs2838348	chr21:45107285	C/G	cg01579765	chr21:45077557	HSF2BP	0.51	8.54	0.46	1.09e-15	Mean corpuscular volume;
CESC	cis	rs4862750	0.872	rs6811837	chr4:187898162	G/A	cg10295955	chr4:187884368	NA	-1.08	-23.24	-0.82	6.56e-66	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs116095464	0.558	rs73029475	chr5:206969	T/C	cg16372103	chr5:203701	NA	0.49	5.29	0.31	2.6e-7	Breast cancer;
CESC	cis	rs1707322	1.000	rs6675222	chr1:46326576	G/T	cg03146154	chr1:46216737	IPP	0.72	9.91	0.52	6.71e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7618915	0.570	rs11130312	chr3:52675055	A/C	cg18404041	chr3:52824283	ITIH1	-0.39	-6.55	-0.37	2.91e-10	Bipolar disorder;
CESC	cis	rs9400271	0.632	rs6899616	chr6:109584885	A/G	cg01475377	chr6:109611718	NA	-0.45	-7.04	-0.4	1.6e-11	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg10211485	chr17:655108	ELP2P;GEMIN4	-0.45	-6.13	-0.35	3.18e-9	Asthma;
CESC	cis	rs2688608	0.592	rs11814282	chr10:75490217	T/C	cg23231163	chr10:75533350	FUT11	-0.35	-5.27	-0.31	2.81e-7	Inflammatory bowel disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08914378	chr7:98923334	ARPC1A	0.58	7.09	0.4	1.25e-11	Gut microbiome composition (summer);
CESC	trans	rs1814175	0.519	rs10839291	chr11:49514321	G/A	cg03929089	chr4:120376271	NA	0.68	7.7	0.43	2.66e-13	Height;
CESC	cis	rs6879260	1.000	rs7730585	chr5:179733440	T/C	cg02891314	chr5:179741120	GFPT2	-0.58	-7.86	-0.43	1e-13	Height;
CESC	cis	rs801193	1.000	rs3857688	chr7:66127806	G/A	cg18876405	chr7:65276391	NA	-0.54	-7.06	-0.4	1.46e-11	Aortic root size;
CESC	cis	rs10504229	0.595	rs76447299	chr8:58117395	A/G	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs3768617	0.510	rs3818417	chr1:183079376	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.88	14.14	0.66	3.44e-34	Fuchs's corneal dystrophy;
CESC	trans	rs66573146	1.000	rs66519732	chr4:6990569	C/G	cg07817883	chr1:32538562	TMEM39B	1.33	7.93	0.44	6.25e-14	Granulocyte percentage of myeloid white cells;
CESC	cis	rs8028182	0.636	rs8029112	chr15:75808972	T/C	cg20655648	chr15:75932815	IMP3	0.48	5.91	0.34	1.06e-8	Sudden cardiac arrest;
CESC	cis	rs2742234	0.955	rs1800861	chr10:43613843	G/T	cg15436174	chr10:43711423	RASGEF1A	-0.4	-5.11	-0.3	6.04e-7	Hirschsprung disease;
CESC	cis	rs10504229	0.679	rs7840100	chr8:58036662	T/G	cg24829409	chr8:58192753	C8orf71	-0.46	-5.83	-0.34	1.59e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs1538970	0.961	rs4660854	chr1:45854087	A/T	cg05343316	chr1:45956843	TESK2	0.8	11.55	0.58	2.96e-25	Platelet count;
CESC	cis	rs11098499	0.954	rs28685688	chr4:120420334	T/C	cg24375607	chr4:120327624	NA	0.46	5.61	0.33	5.16e-8	Corneal astigmatism;
CESC	trans	rs7937682	0.889	rs497111	chr11:111499512	G/A	cg18187862	chr3:45730750	SACM1L	0.51	6.5	0.37	3.97e-10	Primary sclerosing cholangitis;
CESC	cis	rs9549260	0.564	rs4245402	chr13:41287540	C/T	cg21288729	chr13:41239152	FOXO1	0.58	7.81	0.43	1.36e-13	Red blood cell count;
CESC	cis	rs6952808	0.825	rs34296663	chr7:1935245	C/T	cg05863683	chr7:1912471	MAD1L1	0.45	6.87	0.39	4.55e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs4588572	0.643	rs1019739	chr5:77770241	G/C	cg11547950	chr5:77652471	NA	-0.45	-5.63	-0.33	4.53e-8	Triglycerides;
CESC	cis	rs748404	0.697	rs546722	chr15:43580819	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.54	8.49	0.46	1.51e-15	Lung cancer;
CESC	cis	rs11098499	0.691	rs10010355	chr4:120261043	A/G	cg09307838	chr4:120376055	NA	0.76	10.31	0.54	3.54e-21	Corneal astigmatism;
CESC	cis	rs11997175	0.646	rs7005018	chr8:33700210	A/G	ch.8.33884649F	chr8:33765107	NA	0.56	7.34	0.41	2.56e-12	Body mass index;
CESC	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	21.08	0.79	1.35e-58	Prudent dietary pattern;
CESC	trans	rs7319075	0.657	rs9533543	chr13:44173400	A/G	cg03952484	chr1:149899818	SF3B4	0.5	6.19	0.36	2.3e-9	Photic sneeze reflex;
CESC	cis	rs7811142	0.830	rs73401443	chr7:99977582	T/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.09	12.96	0.62	4.51e-30	Platelet count;
CESC	cis	rs7618915	0.501	rs3774366	chr3:52641255	T/C	cg18099408	chr3:52552593	STAB1	-0.3	-5.05	-0.3	8.22e-7	Bipolar disorder;
CESC	cis	rs1055129	0.516	rs7218498	chr17:73931847	C/G	cg08125733	chr17:73851984	WBP2	0.51	7.05	0.4	1.51e-11	White matter hyperintensity burden;
CESC	cis	rs2066819	1.000	rs11575231	chr12:56744445	T/C	cg26734620	chr12:56694298	CS	0.98	5.94	0.34	8.73e-9	Psoriasis vulgaris;
CESC	cis	rs7666738	0.830	rs28485415	chr4:99060340	G/A	cg05340658	chr4:99064831	C4orf37	0.83	12.91	0.62	6.52e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7089973	0.604	rs61596353	chr10:116597763	T/C	cg03647239	chr10:116582469	FAM160B1	0.44	5.55	0.32	6.83e-8	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs875971	0.522	rs4718285	chr7:65292005	A/G	cg18876405	chr7:65276391	NA	0.7	9.83	0.52	1.18e-19	Aortic root size;
CESC	cis	rs933688	1.000	rs1895448	chr5:90743854	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.9	11.74	0.58	6.72e-26	Smoking behavior;
CESC	cis	rs1003719	0.667	rs8127148	chr21:38481292	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.61	8.02	0.44	3.44e-14	Eye color traits;
CESC	cis	rs1421811	0.606	rs62369523	chr5:32713365	T/G	cg16267343	chr5:32710456	NPR3	0.57	6.16	0.35	2.73e-9	Blood pressure;
CESC	cis	rs454510	0.726	rs376910	chr1:120181277	A/C	cg16322792	chr1:120165303	ZNF697	-0.4	-6.62	-0.38	2.04e-10	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
CESC	cis	rs854572	0.870	rs757158	chr7:94955528	C/T	cg17330251	chr7:94953956	PON1	-0.65	-9.86	-0.52	9.59e-20	Paraoxonase activity;
CESC	cis	rs7520050	0.966	rs11211241	chr1:46452683	T/A	cg24296786	chr1:45957014	TESK2	0.44	5.5	0.32	8.98e-8	Red blood cell count;Reticulocyte count;
CESC	cis	rs9479482	0.678	rs3903885	chr6:150364128	G/A	cg03788504	chr6:150331562	NA	-0.36	-6.99	-0.39	2.17e-11	Alopecia areata;
CESC	cis	rs854765	0.506	rs7210400	chr17:17949957	C/T	cg16928487	chr17:17741425	SREBF1	0.57	9.8	0.52	1.45e-19	Total body bone mineral density;
CESC	cis	rs1784581	0.588	rs9346894	chr6:162430763	T/C	cg17173639	chr6:162384350	PARK2	0.56	8.46	0.46	1.87e-15	Itch intensity from mosquito bite;
CESC	cis	rs1983891	0.643	rs3800284	chr6:41558365	G/C	cg20194872	chr6:41519635	FOXP4	0.45	6.3	0.36	1.22e-9	Prostate cancer;
CESC	cis	rs10479542	0.892	rs7723230	chr5:178980474	T/C	cg22764044	chr5:178986830	RUFY1	0.45	6.78	0.38	7.76e-11	Lung cancer;
CESC	cis	rs3749237	0.576	rs4241406	chr3:49600426	C/T	cg03060546	chr3:49711283	APEH	0.77	11.73	0.58	7.34e-26	Resting heart rate;
CESC	cis	rs7666738	1.000	rs2865983	chr4:99033352	C/T	cg05340658	chr4:99064831	C4orf37	0.69	9.46	0.5	1.69e-18	Colonoscopy-negative controls vs population controls;
CESC	cis	rs55788414	0.932	rs8048115	chr16:81182554	T/C	cg06400318	chr16:81190750	PKD1L2	-0.59	-7.02	-0.4	1.84e-11	Left ventricular obstructive tract defect (maternal effect);
CESC	cis	rs12681366	0.647	rs12545262	chr8:95405041	C/T	cg13257157	chr8:95487014	RAD54B	0.39	5.21	0.3	3.82e-7	Nonsyndromic cleft lip with cleft palate;
CESC	cis	rs11792861	0.816	rs2275637	chr9:111696043	C/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.53	6.77	0.38	8.2e-11	Menarche (age at onset);
CESC	cis	rs1005277	0.579	rs2472175	chr10:38382901	T/G	cg00409905	chr10:38381863	ZNF37A	-0.45	-6.0	-0.35	6.61e-9	Extrinsic epigenetic age acceleration;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg22584335	chr2:27806067	ZNF512	-0.41	-6.07	-0.35	4.4e-9	Gambling;
CESC	cis	rs2455799	0.613	rs4685260	chr3:15832417	C/T	cg16303742	chr3:15540471	COLQ	-0.41	-6.22	-0.36	1.88e-9	Mean platelet volume;
CESC	cis	rs1552244	1.000	rs61052895	chr3:10147516	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.82	-11.0	-0.56	1.9e-23	Alzheimer's disease;
CESC	cis	rs2075371	0.966	rs2544225	chr7:133995838	A/C	cg00033643	chr7:134001901	SLC35B4	0.44	5.71	0.33	2.99e-8	Mean platelet volume;
CESC	cis	rs3820928	0.874	rs1917123	chr2:227889783	T/G	cg05526886	chr2:227700861	RHBDD1	-0.41	-5.12	-0.3	5.78e-7	Pulmonary function;
CESC	cis	rs950169	0.881	rs34117475	chr15:85108443	T/C	cg17507749	chr15:85114479	UBE2QP1	0.55	6.18	0.35	2.42e-9	Schizophrenia;
CESC	cis	rs2842992	0.724	rs9365097	chr6:160211259	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.77	11.05	0.56	1.35e-23	Age-related macular degeneration (geographic atrophy);
CESC	trans	rs9929218	0.581	rs7203337	chr16:68774800	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.88	14.99	0.68	3.36e-37	Colorectal cancer;
CESC	cis	rs1005277	0.557	rs1854563	chr10:38434961	G/A	cg00409905	chr10:38381863	ZNF37A	-0.45	-5.96	-0.34	7.89e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs896854	0.654	rs896847	chr8:95972551	G/A	cg13393036	chr8:95962371	TP53INP1	-0.48	-10.36	-0.54	2.51e-21	Type 2 diabetes;
CESC	cis	rs9837602	1.000	rs35669453	chr3:99766063	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.54	7.56	0.42	6.43e-13	Breast cancer;
CESC	cis	rs4727963	0.792	rs2402627	chr7:122728102	T/C	cg03640110	chr7:122635026	TAS2R16	0.4	6.29	0.36	1.3e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
CESC	cis	rs769267	0.930	rs10422819	chr19:19643028	C/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.46	5.76	0.33	2.3e-8	Tonsillectomy;
CESC	cis	rs597539	0.652	rs559032	chr11:68710847	G/T	cg18350739	chr11:68623251	NA	-0.44	-6.98	-0.39	2.31e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs6493487	0.512	rs2414054	chr15:51129827	A/G	cg02338191	chr15:51200825	AP4E1	0.51	5.19	0.3	4.29e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs34891900	0.507	rs738133	chr22:18205557	C/T	cg19898043	chr22:18121309	BCL2L13	0.56	6.73	0.38	1.02e-10	Sum neutrophil eosinophil counts;
CESC	cis	rs10479542	0.766	rs7733389	chr5:178974997	C/T	cg22764044	chr5:178986830	RUFY1	0.38	5.49	0.32	9.45e-8	Lung cancer;
CESC	cis	rs9926296	0.609	rs4785710	chr16:89796756	C/T	cg04287289	chr16:89883240	FANCA	-0.64	-8.66	-0.47	4.86e-16	Vitiligo;
CESC	cis	rs10276381	0.892	rs7786444	chr7:28154384	C/T	cg23620719	chr7:28220237	JAZF1	0.59	6.27	0.36	1.5e-9	Crohn's disease;
CESC	cis	rs7927771	0.697	rs11039307	chr11:47611152	C/T	cg20307385	chr11:47447363	PSMC3	-0.42	-5.18	-0.3	4.36e-7	Subjective well-being;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg17578755	chr11:1299291	TOLLIP	0.38	6.11	0.35	3.48e-9	Fibrinogen levels;
CESC	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg07677032	chr17:61819896	STRADA	0.45	5.92	0.34	1.01e-8	Prudent dietary pattern;
CESC	cis	rs2576037	0.526	rs649076	chr18:44414614	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.71	11.36	0.57	1.22e-24	Personality dimensions;
CESC	cis	rs2439831	0.867	rs2245176	chr15:43750762	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.89	10.57	0.54	5.08e-22	Lung cancer in ever smokers;
CESC	cis	rs7605827	0.930	rs2160692	chr2:15637496	C/G	cg19274914	chr2:15703543	NA	0.36	6.32	0.36	1.13e-9	Educational attainment (years of education);
CESC	cis	rs67311347	1.000	rs6599102	chr3:40468406	G/A	cg09455208	chr3:40491958	NA	0.44	7.5	0.42	9.61e-13	Renal cell carcinoma;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23373626	chr5:141031295	FCHSD1	-0.62	-6.67	-0.38	1.53e-10	Gut microbiome composition (summer);
CESC	cis	rs9291683	0.588	rs12647117	chr4:10022059	T/C	cg11266682	chr4:10021025	SLC2A9	0.7	14.67	0.67	4.52e-36	Bone mineral density;
CESC	cis	rs7264396	0.790	rs6060516	chr20:34214368	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.65	7.65	0.43	3.84e-13	Total cholesterol levels;
CESC	cis	rs2204008	0.837	rs7301679	chr12:37989629	T/C	cg26384229	chr12:38710491	ALG10B	-0.55	-7.8	-0.43	1.39e-13	Bladder cancer;
CESC	trans	rs5756813	0.754	rs4821708	chr22:38164106	C/T	cg19894588	chr14:64061835	NA	-0.69	-9.22	-0.49	9.91e-18	Optic cup area;Vertical cup-disc ratio;
CESC	cis	rs6088580	0.634	rs6059850	chr20:33044784	C/G	cg24642439	chr20:33292090	TP53INP2	0.53	7.1	0.4	1.11e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs9911578	0.967	rs405684	chr17:56777148	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.38	5.15	0.3	5.01e-7	Intelligence (multi-trait analysis);
CESC	cis	rs637571	0.522	rs12792888	chr11:65761446	C/T	cg04055107	chr11:65626734	MUS81;CFL1	0.43	5.31	0.31	2.36e-7	Eosinophil percentage of white cells;
CESC	cis	rs2839186	0.587	rs35679325	chr21:47640980	A/G	cg00815214	chr21:47717953	NA	0.36	5.31	0.31	2.36e-7	Testicular germ cell tumor;
CESC	cis	rs10791097	0.547	rs1050078	chr11:130746146	T/C	cg12179176	chr11:130786555	SNX19	0.68	10.08	0.53	1.97e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs10089	0.951	rs1864923	chr5:127420843	G/C	cg19767477	chr5:127420684	SLC12A2	-0.41	-5.52	-0.32	7.88e-8	Ileal carcinoids;
CESC	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg11494091	chr17:61959527	GH2	0.71	11.59	0.58	2.1e-25	Prudent dietary pattern;
CESC	cis	rs4595586	0.545	rs6580889	chr12:39369742	T/C	cg26384229	chr12:38710491	ALG10B	0.49	7.0	0.4	2.1e-11	Morning vs. evening chronotype;
CESC	cis	rs7809799	1.000	rs10266364	chr7:98764779	T/C	cg05967295	chr7:98741636	SMURF1	-0.77	-5.41	-0.32	1.37e-7	Ulcerative colitis;
CESC	cis	rs8031584	0.958	rs11293	chr15:31234981	G/A	cg08704250	chr15:31115839	NA	-0.63	-8.07	-0.44	2.48e-14	Huntington's disease progression;
CESC	trans	rs11039798	0.528	rs10839208	chr11:49030456	C/T	cg15704280	chr7:45808275	SEPT13	0.66	7.08	0.4	1.3e-11	Axial length;
CESC	cis	rs6584283	0.713	rs1332100	chr10:101301346	C/T	cg09788492	chr10:101292477	NKX2-3	-0.3	-5.17	-0.3	4.54e-7	Ulcerative colitis;
CESC	cis	rs9902453	0.900	rs56195309	chr17:28453753	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	8.01	0.44	3.58e-14	Coffee consumption (cups per day);
CESC	cis	rs11587400	0.656	rs6689415	chr1:115107469	G/T	cg12756093	chr1:115239321	AMPD1	0.44	6.14	0.35	2.94e-9	Autism;
CESC	cis	rs35110281	0.805	rs4818855	chr21:45038951	C/T	cg04455712	chr21:45112962	RRP1B	0.4	6.2	0.36	2.16e-9	Mean corpuscular volume;
CESC	cis	rs9828933	0.938	rs7617036	chr3:64002995	G/A	cg16258503	chr3:63850278	ATXN7;THOC7	-0.52	-5.21	-0.3	3.74e-7	Type 2 diabetes;
CESC	cis	rs7165102	1.000	rs12906196	chr15:65884888	T/C	cg11441148	chr15:65824328	PTPLAD1	0.32	5.39	0.31	1.53e-7	Mean corpuscular hemoglobin;
CESC	cis	rs858239	0.601	rs764533	chr7:23153875	C/T	cg23682824	chr7:23144976	KLHL7	0.54	7.44	0.42	1.45e-12	Cerebrospinal fluid biomarker levels;
CESC	cis	rs12410462	1.000	rs12410462	chr1:227667790	A/G	cg04117972	chr1:227635322	NA	-0.66	-6.58	-0.37	2.56e-10	Major depressive disorder;
CESC	cis	rs769267	0.895	rs1858999	chr19:19497669	C/G	cg03709012	chr19:19516395	GATAD2A	-0.99	-15.04	-0.68	2.25e-37	Tonsillectomy;
CESC	cis	rs9790314	0.846	rs9815222	chr3:160994897	C/T	cg03342759	chr3:160939853	NMD3	-0.51	-7.37	-0.41	2.23e-12	Morning vs. evening chronotype;
CESC	cis	rs847577	0.550	rs12670686	chr7:97708397	A/G	cg21770322	chr7:97807741	LMTK2	0.82	14.54	0.67	1.31e-35	Breast cancer;
CESC	cis	rs7100689	0.622	rs7082093	chr10:82134954	T/G	cg00277334	chr10:82204260	NA	-0.58	-7.52	-0.42	8.77e-13	Post bronchodilator FEV1;
CESC	cis	rs1153858	1.000	rs4775907	chr15:45638647	G/A	cg14582100	chr15:45693742	SPATA5L1	0.42	6.08	0.35	4.2e-9	Homoarginine levels;
CESC	cis	rs11676348	0.774	rs4672870	chr2:218941916	C/T	cg00012203	chr2:219082015	ARPC2	-0.46	-5.73	-0.33	2.71e-8	Ulcerative colitis;
CESC	cis	rs643506	1.000	rs643506	chr11:111636627	T/G	cg17089665	chr11:111648010	NA	-0.36	-5.05	-0.3	8.24e-7	Breast cancer;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg22004443	chr2:10953237	PDIA6	-0.44	-6.2	-0.36	2.18e-9	Asthma;
CESC	cis	rs9910055	0.659	rs6503488	chr17:42246158	T/G	cg08499158	chr17:42289980	UBTF	-0.53	-6.66	-0.38	1.59e-10	Total body bone mineral density;
CESC	cis	rs40363	0.645	rs250630	chr16:3524242	C/T	cg22508957	chr16:3507546	NAT15	0.57	9.5	0.5	1.31e-18	Tuberculosis;
CESC	cis	rs2070677	0.935	rs4335491	chr10:135422460	T/G	cg20169779	chr10:135381914	SYCE1	-0.74	-9.88	-0.52	8.58e-20	Gout;
CESC	cis	rs116095464	0.558	rs57335027	chr5:262907	A/G	cg22496380	chr5:211416	CCDC127	-0.74	-8.46	-0.46	1.86e-15	Breast cancer;
CESC	cis	rs9611565	0.649	rs202655	chr22:41841564	G/C	cg06634786	chr22:41940651	POLR3H	0.58	6.31	0.36	1.14e-9	Vitiligo;
CESC	cis	rs2732480	0.500	rs2732461	chr12:48692802	C/A	cg24011408	chr12:48396354	COL2A1	0.42	5.86	0.34	1.4e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs1218582	0.596	rs11264275	chr1:154825270	G/T	cg16680214	chr1:154839983	KCNN3	0.36	5.34	0.31	2.02e-7	Prostate cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05636869	chr5:52777880	FST	0.55	6.02	0.35	5.73e-9	Gut microbiome composition (summer);
CESC	cis	rs3785574	0.962	rs2584623	chr17:61906679	G/A	cg06873352	chr17:61820015	STRADA	0.47	6.81	0.39	6.42e-11	Height;
CESC	cis	rs7130144	0.541	rs73572230	chr11:130460843	G/A	cg26307797	chr11:130446613	NA	-0.8	-6.53	-0.37	3.43e-10	Urate levels in lean individuals;
CESC	cis	rs17666538	0.710	rs7834337	chr8:655828	A/G	cg02524346	chr8:600233	NA	0.83	6.81	0.39	6.47e-11	IgG glycosylation;
CESC	cis	rs514406	0.679	rs499239	chr1:53310594	A/G	cg16325326	chr1:53192061	ZYG11B	0.61	9.29	0.5	5.81e-18	Monocyte count;
CESC	cis	rs8072100	0.840	rs4968319	chr17:45464967	A/G	cg25173405	chr17:45401733	C17orf57	-0.43	-5.62	-0.33	4.91e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs1005277	0.579	rs2472182	chr10:38388865	T/C	cg25427524	chr10:38739819	LOC399744	-0.66	-9.5	-0.5	1.29e-18	Extrinsic epigenetic age acceleration;
CESC	cis	rs7666738	0.791	rs7678564	chr4:99057341	A/G	cg03676636	chr4:99064102	C4orf37	0.34	5.12	0.3	5.96e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs75477785	0.590	rs72649937	chr1:210205055	C/G	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.91	6.32	0.36	1.09e-9	Cleft lip with or without cleft palate;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07988989	chr2:120981274	TMEM185B	-0.63	-7.16	-0.4	7.81e-12	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02468154	chr11:43755634	HSD17B12	-0.5	-6.15	-0.35	2.88e-9	Gut microbiome composition (summer);
CESC	cis	rs9291683	0.588	rs2240724	chr4:10021290	G/C	cg00071950	chr4:10020882	SLC2A9	0.89	17.23	0.73	3.88e-45	Bone mineral density;
CESC	cis	rs4689388	0.782	rs4262051	chr4:6281775	G/A	cg00701064	chr4:6280414	WFS1	0.72	11.88	0.59	2.22e-26	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs6460942	0.915	rs10267801	chr7:12451931	G/A	cg17427002	chr7:12443146	VWDE	-0.46	-5.1	-0.3	6.52e-7	Coronary artery disease;
CESC	cis	rs1941023	0.584	rs2233253	chr11:60157166	C/T	cg08716584	chr11:60157161	MS4A7	-0.6	-10.18	-0.53	9e-21	Congenital heart disease (maternal effect);
CESC	cis	rs977987	0.806	rs12917651	chr16:75466696	G/T	cg03315344	chr16:75512273	CHST6	0.41	5.94	0.34	8.69e-9	Dupuytren's disease;
CESC	cis	rs4849845	0.584	rs3896630	chr2:121037018	A/G	cg24070213	chr2:121070622	NA	0.43	6.33	0.36	1.07e-9	Mean platelet volume;
CESC	cis	rs11792861	0.926	rs118011482	chr9:111770626	G/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.49	6.18	0.35	2.4e-9	Menarche (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22442180	chr1:1684399	NADK	-0.48	-6.07	-0.35	4.53e-9	Gut microbiome composition (summer);
CESC	cis	rs7208859	0.623	rs8079891	chr17:29058863	G/A	cg19761014	chr17:28927070	LRRC37B2	0.76	6.25	0.36	1.66e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs9649213	0.593	rs1468338	chr7:97951118	T/C	cg00277769	chr7:97922759	BAIAP2L1	-0.34	-5.61	-0.33	4.97e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7666738	0.712	rs11731393	chr4:98859070	G/C	cg17366294	chr4:99064904	C4orf37	0.57	5.87	0.34	1.3e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9911578	0.967	rs7502208	chr17:57165097	G/A	cg05425664	chr17:57184151	TRIM37	-0.52	-7.23	-0.41	5.23e-12	Intelligence (multi-trait analysis);
CESC	cis	rs66573146	0.831	rs67602077	chr4:7024244	A/G	cg12726927	chr4:7941431	AFAP1	-0.88	-5.19	-0.3	4.26e-7	Granulocyte percentage of myeloid white cells;
CESC	cis	rs9311474	0.607	rs4234633	chr3:52557038	C/T	cg05564831	chr3:52568323	NT5DC2	0.45	7.04	0.4	1.68e-11	Electroencephalogram traits;
CESC	cis	rs35306767	0.903	rs11253475	chr10:907262	C/A	cg26597838	chr10:835615	NA	0.86	8.97	0.48	5.53e-17	Eosinophil percentage of granulocytes;
CESC	trans	rs116095464	0.558	rs62347678	chr5:227496	A/G	cg00938859	chr5:1591904	SDHAP3	0.61	6.75	0.38	9.06e-11	Breast cancer;
CESC	cis	rs35110281	0.506	rs13051661	chr21:45111518	A/T	cg01579765	chr21:45077557	HSF2BP	-0.53	-8.87	-0.48	1.12e-16	Mean corpuscular volume;
CESC	cis	rs4423214	0.765	rs2002064	chr11:71163420	A/G	cg05163923	chr11:71159392	DHCR7	-0.63	-7.38	-0.41	2.01e-12	Vitamin D levels;
CESC	cis	rs7666738	0.830	rs9999200	chr4:99030690	A/C	cg17366294	chr4:99064904	C4orf37	0.62	8.95	0.48	6.32e-17	Colonoscopy-negative controls vs population controls;
CESC	cis	rs67460515	0.563	rs13256	chr3:160796505	G/A	cg03342759	chr3:160939853	NMD3	-0.51	-6.25	-0.36	1.65e-9	Parkinson's disease;
CESC	cis	rs3809863	0.646	rs9899121	chr17:45395144	C/T	cg25173405	chr17:45401733	C17orf57	-0.54	-6.99	-0.39	2.17e-11	Glaucoma (primary open-angle);
CESC	cis	rs2282802	0.685	rs10051345	chr5:139670932	C/G	cg26211634	chr5:139558579	C5orf32	-0.49	-7.03	-0.4	1.72e-11	Intelligence (multi-trait analysis);
CESC	cis	rs9399135	0.967	rs9389253	chr6:135329755	T/C	cg22676075	chr6:135203613	NA	0.51	7.23	0.41	5.22e-12	Red blood cell count;
CESC	cis	rs524281	1.000	rs475805	chr11:65848738	G/A	cg14036092	chr11:66035641	RAB1B	0.53	6.04	0.35	5.32e-9	Electroencephalogram traits;
CESC	cis	rs4148883	0.651	rs2851301	chr4:100010127	C/T	cg13256891	chr4:100009986	ADH5	0.53	6.87	0.39	4.44e-11	Alcohol dependence;
CESC	trans	rs11039798	0.623	rs6485879	chr11:48587984	G/T	cg15704280	chr7:45808275	SEPT13	0.61	6.16	0.35	2.65e-9	Axial length;
CESC	cis	rs514406	0.679	rs12563825	chr1:53238324	G/T	cg25767906	chr1:53392781	SCP2	0.5	7.37	0.41	2.22e-12	Monocyte count;
CESC	cis	rs9898189	1	rs9898189	chr17:80480516	C/G	cg10255544	chr17:80519551	FOXK2	0.37	5.46	0.32	1.07e-7	Red cell distribution width;
CESC	cis	rs4547160	0.821	rs951359	chr12:63482309	G/A	cg26727693	chr12:63544175	AVPR1A	-0.41	-5.67	-0.33	3.74e-8	Morning vs. evening chronotype;
CESC	cis	rs3749237	0.595	rs7621003	chr3:49411404	T/C	cg02487422	chr3:49467188	NICN1	0.55	7.98	0.44	4.56e-14	Resting heart rate;
CESC	cis	rs11638352	0.661	rs2412855	chr15:44340480	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	-0.65	-6.0	-0.35	6.43e-9	Lipoprotein phospholipase A2 activity in cardiovascular disease;
CESC	cis	rs7937682	0.889	rs487985	chr11:111517908	G/A	cg22437258	chr11:111473054	SIK2	0.7	9.35	0.5	3.83e-18	Primary sclerosing cholangitis;
CESC	cis	rs7772486	0.558	rs9497403	chr6:146054695	T/G	cg23711669	chr6:146136114	FBXO30	-0.92	-12.44	-0.61	2.84e-28	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2425143	1.000	rs6058311	chr20:34321895	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.8	-7.51	-0.42	9.02e-13	Blood protein levels;
CESC	cis	rs1003719	0.680	rs2835620	chr21:38505581	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-8.47	-0.46	1.69e-15	Eye color traits;
CESC	cis	rs898097	0.841	rs9896263	chr17:80902741	A/G	cg10494973	chr17:80897199	TBCD	-0.44	-5.3	-0.31	2.41e-7	Breast cancer;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg11118681	chr3:39149366	TTC21A;GORASP1	-0.48	-6.16	-0.35	2.65e-9	Ulcerative colitis;
CESC	cis	rs3858526	0.584	rs10769270	chr11:5860563	T/C	cg05234568	chr11:5960015	NA	-0.65	-8.8	-0.48	1.77e-16	DNA methylation (variation);
CESC	cis	rs2952156	0.684	rs1877031	chr17:37814080	G/A	cg20243544	chr17:37824526	PNMT	0.65	8.75	0.47	2.47e-16	Asthma;
CESC	cis	rs2243480	1.000	rs35825738	chr7:65318027	A/G	cg12463550	chr7:65579703	CRCP	0.68	5.73	0.33	2.72e-8	Diabetic kidney disease;
CESC	cis	rs4319547	0.688	rs10847242	chr12:123079020	T/G	cg05707623	chr12:122985044	ZCCHC8	-0.43	-5.36	-0.31	1.77e-7	Body mass index;
CESC	cis	rs6502050	0.835	rs35070385	chr17:80128447	G/A	cg11859384	chr17:80120422	CCDC57	-0.39	-5.34	-0.31	1.97e-7	Life satisfaction;
CESC	cis	rs1008375	1.000	rs4698648	chr4:17692715	C/G	cg02297831	chr4:17616191	MED28	0.46	5.62	0.33	4.91e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs77106637	1.000	rs11605166	chr11:72669777	T/C	cg04827223	chr11:72435913	ARAP1	-0.54	-5.71	-0.33	3.08e-8	Type 2 diabetes;
CESC	cis	rs2075371	0.863	rs1646635	chr7:134006728	T/C	cg00033643	chr7:134001901	SLC35B4	0.42	5.42	0.32	1.36e-7	Mean platelet volume;
CESC	cis	rs875971	1.000	rs1981798	chr7:65954903	G/T	cg18876405	chr7:65276391	NA	0.49	6.38	0.36	7.93e-10	Aortic root size;
CESC	cis	rs2777491	0.957	rs16971798	chr15:41657144	A/T	cg18705301	chr15:41695430	NDUFAF1	0.58	8.67	0.47	4.41e-16	Ulcerative colitis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05522145	chr7:53255065	NA	-0.53	-6.45	-0.37	5.41e-10	Gut microbiome composition (summer);
CESC	cis	rs7777484	0.500	rs757787	chr7:2836355	G/A	cg19717773	chr7:2847554	GNA12	-0.68	-11.76	-0.59	5.77e-26	Height;
CESC	cis	rs6089584	0.816	rs744778	chr20:60631365	A/G	cg06108461	chr20:60628389	TAF4	-0.92	-14.34	-0.66	6.58e-35	Body mass index;
CESC	cis	rs7927771	1.000	rs7927771	chr11:47781306	A/G	cg20307385	chr11:47447363	PSMC3	-0.51	-6.23	-0.36	1.79e-9	Subjective well-being;
CESC	cis	rs5750830	0.621	rs5750810	chr22:39792943	A/G	cg05872129	chr22:39784769	NA	-0.8	-11.24	-0.57	3.28e-24	Intelligence (multi-trait analysis);
CESC	cis	rs35110281	0.805	rs3788062	chr21:44991159	C/T	cg21573476	chr21:45109991	RRP1B	-0.43	-5.96	-0.34	8.16e-9	Mean corpuscular volume;
CESC	cis	rs3733585	0.699	rs6844316	chr4:9958977	A/G	cg11266682	chr4:10021025	SLC2A9	-0.6	-11.2	-0.57	4.42e-24	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs11168618	0.567	rs12372687	chr12:48811799	G/T	cg24011408	chr12:48396354	COL2A1	0.36	5.68	0.33	3.52e-8	Adiponectin levels;
CESC	cis	rs9649213	0.537	rs6971825	chr7:97979548	C/T	cg00277769	chr7:97922759	BAIAP2L1	-0.33	-5.41	-0.32	1.41e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs9311474	0.607	rs4687625	chr3:52563718	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.69	0.38	1.3100000000000001e-10	Electroencephalogram traits;
CESC	cis	rs10911232	0.507	rs3934697	chr1:183027512	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.87	13.49	0.64	6.27e-32	Hypertriglyceridemia;
CESC	cis	rs75804782	0.641	rs1030786	chr2:239361150	A/G	cg18131467	chr2:239335373	ASB1	-0.7	-5.88	-0.34	1.26e-8	Morning vs. evening chronotype;Chronotype;
CESC	cis	rs4332037	0.624	rs11764337	chr7:1892309	A/G	cg23422044	chr7:1970798	MAD1L1	0.49	5.5	0.32	8.94e-8	Bipolar disorder;
CESC	cis	rs2456568	0.803	rs10831138	chr11:93640468	T/C	cg26875233	chr11:93583750	C11orf90	-0.29	-5.06	-0.3	7.7e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
CESC	cis	rs10751667	0.961	rs7396670	chr11:929269	A/G	cg01483505	chr11:975446	AP2A2	0.39	5.07	0.3	7.63e-7	Alzheimer's disease (late onset);
CESC	cis	rs6570726	1.000	rs374464	chr6:145846679	A/C	cg05347473	chr6:146136440	FBXO30	0.42	5.63	0.33	4.5e-8	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2832191	0.716	rs2692625	chr21:30446360	C/G	cg24692254	chr21:30365293	RNF160	0.99	17.29	0.73	2.32e-45	Dental caries;
CESC	cis	rs870825	0.616	rs9715644	chr4:185632965	C/T	cg04058563	chr4:185651563	MLF1IP	0.63	6.89	0.39	3.95e-11	Blood protein levels;
CESC	cis	rs7208859	0.673	rs56846352	chr17:29119188	C/T	cg13385521	chr17:29058706	SUZ12P	0.59	5.49	0.32	9.51e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs4819052	0.807	rs4819047	chr21:46665139	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.76	10.08	0.53	1.99e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs6460942	1.000	rs118083671	chr7:12466036	C/T	cg02935154	chr7:12443704	VWDE	-0.58	-6.16	-0.35	2.73e-9	Coronary artery disease;
CESC	cis	rs10089	1.000	rs10060390	chr5:127452947	C/T	cg19767477	chr5:127420684	SLC12A2	-0.4	-5.32	-0.31	2.18e-7	Ileal carcinoids;
CESC	cis	rs4665809	1.000	rs1030730	chr2:26284143	T/C	cg08470875	chr2:26401718	FAM59B	-0.62	-6.71	-0.38	1.2e-10	Gut microbiome composition (summer);
CESC	cis	rs13242816	1.000	rs2191499	chr7:116138599	C/T	cg04696780	chr7:116139425	CAV2	-0.61	-5.51	-0.32	8.44e-8	P wave duration;
CESC	trans	rs3741404	0.665	rs12418535	chr11:63910980	A/G	cg15268290	chr11:83690587	DLG2	0.43	6.04	0.35	5.23e-9	Platelet count;
CESC	cis	rs78456975	1.000	rs10208340	chr2:1563100	G/A	cg01028140	chr2:1542097	TPO	-0.5	-5.35	-0.31	1.89e-7	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs597539	0.617	rs669659	chr11:68635623	G/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.76	9.46	0.5	1.71e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs6456156	0.792	rs7775443	chr6:167513252	A/C	cg07741184	chr6:167504864	NA	-0.39	-7.0	-0.39	2.13e-11	Primary biliary cholangitis;
CESC	cis	rs7178572	0.962	rs1022172	chr15:77793359	A/G	cg22256960	chr15:77711686	NA	-0.58	-7.68	-0.43	3.02e-13	Type 2 diabetes;
CESC	cis	rs11792861	0.926	rs72607169	chr9:111832471	A/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.42	5.26	0.31	3.04e-7	Menarche (age at onset);
CESC	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg03188948	chr7:1209495	NA	0.61	6.98	0.39	2.32e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg13672103	chr12:57985290	PIP4K2C	-0.42	-6.07	-0.35	4.36e-9	Gambling;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05214679	chr19:36630902	CAPNS1	0.54	6.23	0.36	1.82e-9	Gut microbiome composition (summer);
CESC	cis	rs12497850	0.931	rs7623023	chr3:48914238	G/A	cg03060546	chr3:49711283	APEH	0.45	5.75	0.33	2.44e-8	Parkinson's disease;
CESC	cis	rs6120849	0.951	rs55670307	chr20:33720494	T/C	cg24642439	chr20:33292090	TP53INP2	0.62	6.49	0.37	4.3e-10	Protein C levels;
CESC	cis	rs3106136	0.967	rs11722476	chr4:95170839	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.46	-6.76	-0.38	8.54e-11	Capecitabine sensitivity;
CESC	cis	rs10504229	0.953	rs6990806	chr8:58183113	G/A	cg05313129	chr8:58192883	C8orf71	-0.55	-6.29	-0.36	1.34e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs6570726	0.935	rs369458	chr6:145812809	A/G	cg23711669	chr6:146136114	FBXO30	0.83	12.23	0.6	1.41e-27	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs12900413	0.562	rs2118849	chr15:90302399	G/T	cg24249390	chr15:90295951	MESP1	-0.4	-5.37	-0.31	1.75e-7	Coronary artery aneurysm in Kawasaki disease;
CESC	cis	rs7772486	0.875	rs2180192	chr6:146322284	T/C	cg05347473	chr6:146136440	FBXO30	0.52	6.7	0.38	1.25e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6540559	0.611	rs17015226	chr1:209970096	C/G	cg25204440	chr1:209979598	IRF6	0.6	6.23	0.36	1.86e-9	Cleft lip with or without cleft palate;
CESC	cis	rs4654899	0.802	rs7517642	chr1:21252696	T/C	cg05370193	chr1:21551575	ECE1	0.38	5.51	0.32	8.58e-8	Superior frontal gyrus grey matter volume;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg13296916	chr12:117348627	FBXW8	0.53	6.98	0.39	2.37e-11	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs36051895	0.623	rs1555476	chr9:5233054	T/C	cg02405213	chr9:5042618	JAK2	-0.58	-6.32	-0.36	1.12e-9	Pediatric autoimmune diseases;
CESC	cis	rs1475911	1.000	rs1475911	chr21:43513480	A/C	cg19766460	chr21:43528205	UMODL1;C21orf128	0.59	6.63	0.38	1.82e-10	IgG glycosylation;
CESC	cis	rs4689592	0.554	rs3951346	chr4:7073321	C/T	cg19539972	chr4:7069911	GRPEL1	0.75	10.0	0.52	3.44e-20	Monocyte percentage of white cells;
CESC	cis	rs1178968	1.000	rs7802062	chr7:72757812	T/C	cg25889504	chr7:72793014	NA	0.48	5.08	0.3	7.22e-7	Triglyceride levels;
CESC	cis	rs8114671	0.527	rs6060068	chr20:33415820	T/A	cg24642439	chr20:33292090	TP53INP2	0.46	5.45	0.32	1.14e-7	Height;
CESC	cis	rs7216064	0.861	rs62084252	chr17:65879578	G/C	cg07042672	chr17:66097459	LOC651250	-0.62	-7.3	-0.41	3.34e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs6598163	0.712	rs10751695	chr12:132291061	A/C	cg02426739	chr12:132285352	NA	0.37	5.27	0.31	2.86e-7	Migraine;
CESC	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.61	0.38	2.05e-10	Prudent dietary pattern;
CESC	cis	rs6460942	1.000	rs77010200	chr7:12290724	G/A	cg20607287	chr7:12443886	VWDE	-0.74	-7.82	-0.43	1.24e-13	Coronary artery disease;
CESC	cis	rs684232	0.602	rs401592	chr17:551316	T/C	cg15660573	chr17:549704	VPS53	-0.8	-11.67	-0.58	1.16e-25	Prostate cancer;
CESC	cis	rs13108904	0.935	rs4974575	chr4:1252028	A/G	cg16405210	chr4:1374714	KIAA1530	-0.44	-5.87	-0.34	1.33e-8	Obesity-related traits;
CESC	cis	rs1448094	0.512	rs7313278	chr12:86250263	C/T	cg19622623	chr12:86230825	RASSF9	-0.46	-5.93	-0.34	9.45e-9	Major depressive disorder;
CESC	cis	rs9291683	0.551	rs62295971	chr4:9978142	G/A	cg11266682	chr4:10021025	SLC2A9	0.61	12.55	0.61	1.12e-28	Bone mineral density;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14288281	chr1:1093457	NA	0.55	6.18	0.35	2.45e-9	Gut microbiome composition (summer);
CESC	cis	rs854765	0.547	rs4072739	chr17:17884660	G/A	cg04398451	chr17:18023971	MYO15A	-0.6	-8.63	-0.47	5.68e-16	Total body bone mineral density;
CESC	cis	rs870825	0.616	rs6844588	chr4:185644517	T/G	cg04058563	chr4:185651563	MLF1IP	0.63	6.96	0.39	2.59e-11	Blood protein levels;
CESC	cis	rs1879734	0.731	rs11206195	chr1:54164156	T/C	cg23596471	chr1:54105337	GLIS1	0.33	5.45	0.32	1.17e-7	Mitral valve prolapse;
CESC	cis	rs2952156	0.959	rs1495101	chr17:37832103	C/A	cg20243544	chr17:37824526	PNMT	0.6	7.38	0.41	2.01e-12	Asthma;
CESC	cis	rs4704187	0.687	rs13360638	chr5:74433258	G/A	cg03227963	chr5:74354835	NA	0.3	5.46	0.32	1.07e-7	Response to amphetamines;
CESC	cis	rs7618915	0.524	rs2028216	chr3:52680823	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.38	6.69	0.38	1.33e-10	Bipolar disorder;
CESC	cis	rs67311347	1.000	rs9857824	chr3:40459412	A/G	cg24209194	chr3:40518798	ZNF619	0.5	6.3	0.36	1.21e-9	Renal cell carcinoma;
CESC	cis	rs4975709	0.589	rs4975747	chr5:1862836	G/A	cg10800226	chr5:1850261	NA	0.33	5.34	0.31	2.04e-7	Cardiovascular disease risk factors;
CESC	cis	rs6580649	0.941	rs4589362	chr12:48478664	T/C	cg05342945	chr12:48394962	COL2A1	0.5	5.74	0.33	2.59e-8	Lung cancer;
CESC	cis	rs425277	0.539	rs3128338	chr1:2046786	G/A	cg19257562	chr1:2043853	PRKCZ	0.41	6.72	0.38	1.08e-10	Height;
CESC	cis	rs514406	0.644	rs4926928	chr1:53210163	G/T	cg16325326	chr1:53192061	ZYG11B	0.95	16.94	0.72	4.11e-44	Monocyte count;
CESC	cis	rs3540	0.512	rs17263706	chr15:91078803	G/T	cg22089800	chr15:90895588	ZNF774	0.61	7.91	0.44	6.88e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs977987	0.806	rs4146809	chr16:75415775	A/G	cg03315344	chr16:75512273	CHST6	-0.4	-5.83	-0.34	1.56e-8	Dupuytren's disease;
CESC	cis	rs10791097	0.694	rs4456262	chr11:130755813	C/T	cg12179176	chr11:130786555	SNX19	-0.69	-9.76	-0.51	1.95e-19	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs12142240	0.698	rs17357683	chr1:46815378	C/T	cg10495392	chr1:46806563	NSUN4	0.57	6.28	0.36	1.39e-9	Menopause (age at onset);
CESC	cis	rs780096	0.546	rs2911712	chr2:27626945	A/T	cg24768116	chr2:27665128	KRTCAP3	-0.28	-5.35	-0.31	1.92e-7	Total body bone mineral density;
CESC	cis	rs1799949	0.965	rs799916	chr17:41243190	G/T	cg25072359	chr17:41440525	NA	-0.49	-7.39	-0.41	1.92e-12	Menopause (age at onset);
CESC	cis	rs4819052	0.851	rs8131143	chr21:46671646	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.74	-9.92	-0.52	6.35e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs7814319	0.966	rs10955069	chr8:97253788	C/T	cg20787634	chr8:97240163	UQCRB	-0.6	-7.96	-0.44	5.1e-14	Lung function (FVC);
CESC	cis	rs763121	0.962	rs2071887	chr22:38879010	A/T	cg14440974	chr22:39074834	NA	-0.39	-5.42	-0.32	1.37e-7	Menopause (age at onset);
CESC	trans	rs4950322	0.570	rs72691012	chr1:146711400	G/C	cg04954894	chr8:38089920	DDHD2	-0.6	-6.38	-0.36	7.74e-10	Protein quantitative trait loci;
CESC	cis	rs798554	0.757	rs2644312	chr7:2841164	G/A	cg13628971	chr7:2884303	GNA12	0.65	8.32	0.45	4.79e-15	Height;
CESC	cis	rs10504229	0.595	rs77615399	chr8:58117394	C/G	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs13272623	0.502	rs268601	chr8:71518548	C/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.44	-5.55	-0.32	7.08e-8	IgG glycosylation;
CESC	cis	rs2286503	0.752	rs59538378	chr7:22877097	G/A	cg13679077	chr7:22862647	TOMM7	0.58	7.49	0.42	1.05e-12	Fibrinogen;
CESC	trans	rs11252926	0.527	rs10904093	chr10:436848	A/G	cg00953403	chr17:74099816	EXOC7	-0.56	-7.2	-0.4	6.38e-12	Psychosis in Alzheimer's disease;
CESC	cis	rs2074585	0.806	rs8033813	chr15:90999715	A/T	cg10434728	chr15:90938212	IQGAP1	0.41	7.32	0.41	3.03e-12	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
CESC	cis	rs71403859	0.803	rs7203606	chr16:71590511	A/C	cg08717414	chr16:71523259	ZNF19	-0.79	-7.11	-0.4	1.09e-11	Post bronchodilator FEV1;
CESC	trans	rs561341	1.000	rs542132	chr17:30307193	A/T	cg27661571	chr11:113659931	NA	-0.83	-7.76	-0.43	1.9e-13	Hip circumference adjusted for BMI;
CESC	cis	rs12190007	0.514	rs2984462	chr6:169843903	A/T	cg15038512	chr6:170123185	PHF10	-0.52	-7.37	-0.41	2.16e-12	Obesity-related traits;
CESC	cis	rs2635047	0.905	rs7504798	chr18:44610879	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.48	6.54	0.37	3.21e-10	Educational attainment;
CESC	cis	rs6582630	0.555	rs34145279	chr12:38405588	T/C	cg13010199	chr12:38710504	ALG10B	0.54	6.87	0.39	4.7e-11	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs1808579	0.904	rs1652344	chr18:21128857	T/C	cg14672496	chr18:21087552	C18orf8	0.43	6.05	0.35	4.82e-9	Hip circumference;Body mass index;BMI (adjusted for smoking behaviour);
CESC	cis	rs950027	0.620	rs1153855	chr15:45660758	C/G	cg21132104	chr15:45694354	SPATA5L1	0.67	8.55	0.46	1.01e-15	Response to fenofibrate (adiponectin levels);
CESC	cis	rs9303542	0.559	rs12946931	chr17:46614080	T/C	cg04904318	chr17:46607828	HOXB1	-0.6	-5.74	-0.33	2.54e-8	Ovarian cancer;Epithelial ovarian cancer;
CESC	cis	rs4555082	0.830	rs2735812	chr14:105727575	A/G	cg13114125	chr14:105738426	BRF1	-0.83	-10.25	-0.53	5.5e-21	Mean platelet volume;Platelet distribution width;
CESC	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg13126279	chr21:47581558	C21orf56	-0.49	-6.68	-0.38	1.43e-10	Testicular germ cell tumor;
CESC	cis	rs6662572	0.737	rs56316933	chr1:46266725	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.46	5.04	0.3	8.63e-7	Blood protein levels;
CESC	trans	rs7937682	0.924	rs6589244	chr11:111534333	T/C	cg18187862	chr3:45730750	SACM1L	0.48	6.0	0.35	6.32e-9	Primary sclerosing cholangitis;
CESC	cis	rs9768139	0.733	rs35016950	chr7:158118710	C/A	cg06219351	chr7:158114137	PTPRN2	-0.49	-7.5	-0.42	9.58e-13	Calcium levels;
CESC	cis	rs6142102	0.625	rs6142056	chr20:32541155	T/C	cg08999081	chr20:33150536	PIGU	0.34	5.12	0.3	5.84e-7	Skin pigmentation;
CESC	trans	rs2963826	0.589	rs298091	chr5:58996603	A/T	cg20662616	chr2:30454643	LBH	0.46	6.24	0.36	1.73e-9	Obesity-related traits;
CESC	cis	rs3096299	0.967	rs2911255	chr16:89487137	C/T	cg02034447	chr16:89574710	SPG7	0.41	5.18	0.3	4.4e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs1062177	1.000	rs2915887	chr5:151205504	C/T	cg00977110	chr5:151150581	G3BP1	0.63	6.62	0.38	2.01e-10	Preschool internalizing problems;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg23260255	chr3:187871479	LPP	0.48	6.11	0.35	3.47e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs9287719	0.967	rs6761678	chr2:10746341	T/C	cg00105475	chr2:10696890	NA	0.38	5.55	0.32	6.76e-8	Prostate cancer;
CESC	cis	rs7618915	0.501	rs3733041	chr3:52731598	T/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	5.86	0.34	1.41e-8	Bipolar disorder;
CESC	cis	rs6575793	0.553	rs7154024	chr14:101031710	G/T	cg18516195	chr14:101012996	BEGAIN	0.43	5.28	0.31	2.63e-7	Menarche (age at onset);
CESC	cis	rs11245387	0.564	rs7915429	chr10:126510089	T/C	cg08799069	chr10:126477246	METTL10	-0.55	-6.52	-0.37	3.64e-10	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
CESC	cis	rs2816062	0.813	rs2816044	chr1:18892826	A/G	cg18795169	chr1:18902165	NA	-0.91	-17.5	-0.73	4.31e-46	Urate levels in lean individuals;
CESC	cis	rs9389248	0.690	rs6939543	chr6:135255143	A/G	cg24558204	chr6:135376177	HBS1L	-0.63	-8.71	-0.47	3.23e-16	High light scatter reticulocyte percentage of red cells;
CESC	cis	rs16910800	0.689	rs7101737	chr11:23165031	C/T	cg20040320	chr11:23191996	NA	-0.65	-6.17	-0.35	2.51e-9	Cancer;
CESC	cis	rs854765	0.663	rs12941550	chr17:17753828	C/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.47	-6.57	-0.37	2.67e-10	Total body bone mineral density;
CESC	cis	rs274567	0.599	rs11242110	chr5:131743777	A/C	cg24060327	chr5:131705240	SLC22A5	0.5	6.42	0.37	6.12e-10	Blood metabolite levels;
CESC	cis	rs7246865	0.954	rs1060367	chr19:17215202	G/A	cg19418318	chr19:17219073	MYO9B	0.36	6.03	0.35	5.63e-9	Reticulocyte fraction of red cells;
CESC	cis	rs11190604	1.000	rs7079136	chr10:102292709	T/C	cg07080220	chr10:102295463	HIF1AN	0.7	6.48	0.37	4.34e-10	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs523522	0.962	rs2168319	chr12:120933217	C/T	cg27279351	chr12:120934652	DYNLL1	0.68	8.7	0.47	3.6e-16	High light scatter reticulocyte count;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg26106524	chr19:19517029	GATAD2A	0.47	6.36	0.36	9.03e-10	Gut microbiota (bacterial taxa);
CESC	trans	rs35110281	0.659	rs11702544	chr21:45091861	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.45	6.05	0.35	4.83e-9	Mean corpuscular volume;
CESC	cis	rs875971	0.545	rs4718348	chr7:65906576	A/G	cg18876405	chr7:65276391	NA	0.51	5.89	0.34	1.18e-8	Aortic root size;
CESC	cis	rs4566357	0.595	rs10206912	chr2:227921095	A/T	cg11843606	chr2:227700838	RHBDD1	-0.52	-7.3	-0.41	3.33e-12	Coronary artery disease;
CESC	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg19318889	chr4:1322082	MAEA	0.59	7.02	0.4	1.91e-11	Longevity;
CESC	cis	rs8063160	0.799	rs1805007	chr16:89986117	A/G	cg07984980	chr16:89898383	SPIRE2	-0.9	-6.11	-0.35	3.45e-9	Red vs non-red hair color;Light vs. dark hair color;Brown vs. non-brown hair color;
CESC	cis	rs796364	0.951	rs281769	chr2:200809709	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.83	8.38	0.46	3.17e-15	Schizophrenia;
CESC	cis	rs2228479	0.541	rs13335395	chr16:89952843	T/A	cg00800038	chr16:89945340	TCF25	-0.62	-6.76	-0.38	8.88e-11	Skin colour saturation;
CESC	cis	rs4423214	0.840	rs1629220	chr11:71174553	C/T	cg05163923	chr11:71159392	DHCR7	-0.65	-7.55	-0.42	6.91e-13	Vitamin D levels;
CESC	cis	rs9287719	0.967	rs6432120	chr2:10753771	C/T	cg02196655	chr2:10830764	NOL10	-0.37	-5.69	-0.33	3.39e-8	Prostate cancer;
CESC	cis	rs2836974	0.897	rs1571709	chr21:40553980	T/C	cg27266027	chr21:40555129	PSMG1	0.46	5.58	0.32	6.08e-8	Cognitive function;
CESC	cis	rs734999	0.588	rs3748818	chr1:2525660	G/A	cg18854424	chr1:2615690	NA	0.27	5.06	0.3	7.78e-7	Ulcerative colitis;
CESC	cis	rs806215	0.901	rs989100	chr7:127220918	T/C	cg25922125	chr7:127225783	GCC1	-0.5	-5.69	-0.33	3.31e-8	Type 2 diabetes;
CESC	cis	rs10927875	0.722	rs6696912	chr1:16338474	T/C	cg21214613	chr1:16344536	HSPB7	0.37	5.34	0.31	2.03e-7	Dilated cardiomyopathy;
CESC	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg24642844	chr7:1081250	C7orf50	-0.77	-9.63	-0.51	5.27e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs6456156	0.819	rs9457273	chr6:167520749	A/T	cg07741184	chr6:167504864	NA	-0.39	-7.0	-0.39	2.13e-11	Primary biliary cholangitis;
CESC	trans	rs3942852	0.910	rs10742829	chr11:48115837	C/T	cg15704280	chr7:45808275	SEPT13	0.63	7.08	0.4	1.31e-11	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs7552404	0.883	rs7513363	chr1:76143443	A/G	cg22875332	chr1:76189707	ACADM	0.69	9.21	0.49	1.01e-17	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs7188697	0.922	rs37041	chr16:58579886	T/C	cg02549819	chr16:58548995	SETD6	-0.43	-5.35	-0.31	1.9e-7	QT interval;
CESC	cis	rs2576037	0.526	rs2156050	chr18:44455873	A/G	cg19077165	chr18:44547161	KATNAL2	-0.54	-7.94	-0.44	5.81e-14	Personality dimensions;
CESC	cis	rs898097	0.578	rs2380173	chr17:80909157	G/T	cg10494973	chr17:80897199	TBCD	0.53	6.93	0.39	3.11e-11	Breast cancer;
CESC	cis	rs4819052	0.851	rs2330011	chr21:46658498	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.45	5.68	0.33	3.6e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs2594989	1.000	rs2606752	chr3:11360170	A/G	cg00170343	chr3:11313890	ATG7	0.59	5.18	0.3	4.42e-7	Circulating chemerin levels;
CESC	cis	rs826838	1.000	rs826851	chr12:39112639	A/G	cg13010199	chr12:38710504	ALG10B	-0.48	-6.58	-0.37	2.53e-10	Heart rate;
CESC	cis	rs1707322	0.686	rs2275085	chr1:46085852	C/T	cg06784218	chr1:46089804	CCDC17	-0.42	-7.26	-0.41	4.44e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2797685	0.898	rs3753503	chr1:7841971	G/A	cg04725166	chr1:7887271	PER3	-0.45	-6.09	-0.35	4e-9	Crohn's disease;
CESC	cis	rs992157	0.697	rs13384682	chr2:219069137	G/A	cg00012203	chr2:219082015	ARPC2	0.86	12.41	0.61	3.6e-28	Colorectal cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17436946	chr4:39699568	UBE2K	0.57	6.42	0.37	6.44e-10	Gut microbiome composition (summer);
CESC	cis	rs514406	0.861	rs503296	chr1:53283088	A/G	cg08859206	chr1:53392774	SCP2	0.55	7.28	0.41	3.86e-12	Monocyte count;
CESC	cis	rs4665809	0.590	rs62128457	chr2:26467347	C/A	cg08470875	chr2:26401718	FAM59B	0.75	7.79	0.43	1.49e-13	Gut microbiome composition (summer);
CESC	cis	rs12476592	0.571	rs4671512	chr2:63753095	A/G	cg17519650	chr2:63277830	OTX1	-0.47	-5.36	-0.31	1.83e-7	Childhood ear infection;
CESC	cis	rs1348850	0.598	rs1405717	chr2:178500101	G/T	cg23306229	chr2:178417860	TTC30B	0.6	7.53	0.42	7.93e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs2710642	0.962	rs2058567	chr2:63091426	T/C	cg17519650	chr2:63277830	OTX1	0.49	6.18	0.36	2.36e-9	LDL cholesterol levels;LDL cholesterol;
CESC	cis	rs7666738	0.830	rs921521	chr4:98838339	A/G	cg05340658	chr4:99064831	C4orf37	0.71	10.13	0.53	1.34e-20	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7124681	0.528	rs74608150	chr11:47696214	A/T	cg18512352	chr11:47633146	NA	0.34	5.25	0.31	3.15e-7	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
CESC	cis	rs6032067	0.777	rs116517830	chr20:43784872	G/A	cg11264863	chr20:43835661	SEMG1	0.5	5.35	0.31	1.89e-7	Blood protein levels;
CESC	cis	rs7020830	0.931	rs13297576	chr9:37142189	A/C	cg14294708	chr9:37120828	ZCCHC7	1.25	25.19	0.84	2.66e-72	Schizophrenia;
CESC	cis	rs7264396	0.790	rs2425096	chr20:34308588	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.85	-11.52	-0.58	3.56e-25	Total cholesterol levels;
CESC	cis	rs12048904	0.595	rs10493937	chr1:101342650	A/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.65	-9.39	-0.5	2.83e-18	Multiple sclerosis;
CESC	cis	rs34172651	0.917	rs2343606	chr16:24793741	C/T	cg06028605	chr16:24865363	SLC5A11	0.41	6.22	0.36	1.94e-9	Intelligence (multi-trait analysis);
CESC	cis	rs6963495	0.818	rs73190149	chr7:105152793	C/T	cg02135003	chr7:105160482	PUS7	-0.46	-5.5	-0.32	9.08e-8	Bipolar disorder (body mass index interaction);
CESC	cis	rs8077577	1.000	rs62073606	chr17:18069142	G/A	cg16794390	chr17:18148240	FLII	0.47	6.04	0.35	5.22e-9	Obesity-related traits;
CESC	trans	rs3780486	0.813	rs3780488	chr9:33133812	T/C	cg20290983	chr6:43655470	MRPS18A	0.99	17.78	0.74	4.34e-47	IgG glycosylation;
CESC	cis	rs2439831	0.681	rs956391	chr15:43617493	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.88	-9.72	-0.51	2.77e-19	Lung cancer in ever smokers;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg03648789	chr2:38304037	CYP1B1	-0.49	-6.43	-0.37	5.82e-10	Ulcerative colitis;
CESC	cis	rs10752881	0.935	rs10797834	chr1:183048749	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.86	13.61	0.64	2.32e-32	Colorectal cancer;
CESC	cis	rs1983170	1.000	rs483532	chr1:91980447	A/G	cg02896835	chr1:92012615	NA	-0.53	-6.1	-0.35	3.8e-9	Eosinophil percentage of white cells;
CESC	cis	rs929596	0.785	rs17862875	chr2:234649302	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.68	-8.31	-0.45	5.09e-15	Total bilirubin levels in HIV-1 infection;
CESC	trans	rs1814175	0.817	rs10839351	chr11:49758153	C/T	cg15704280	chr7:45808275	SEPT13	-1.03	-19.89	-0.77	1.79e-54	Height;
CESC	cis	rs2011503	1.000	rs4808962	chr19:19579557	A/G	cg11584989	chr19:19387371	SF4	0.62	7.22	0.41	5.54e-12	Bipolar disorder;
CESC	cis	rs6502050	0.634	rs11077973	chr17:80095191	C/T	cg01763666	chr17:80159506	CCDC57	-0.37	-5.1	-0.3	6.61e-7	Life satisfaction;
CESC	cis	rs7098414	0.511	rs4934134	chr10:82160582	C/T	cg00277334	chr10:82204260	NA	-0.52	-7.68	-0.43	3.1400000000000003e-13	Post bronchodilator FEV1;
CESC	cis	rs796364	0.760	rs2881594	chr2:201026183	T/A	cg23649088	chr2:200775458	C2orf69	-0.6	-5.16	-0.3	4.78e-7	Schizophrenia;
CESC	cis	rs2985684	0.894	rs7152110	chr14:50018218	T/C	cg02151108	chr14:50098012	C14orf104	-0.39	-5.09	-0.3	6.78e-7	Carotid intima media thickness;
CESC	cis	rs4595586	0.525	rs17467376	chr12:39377551	T/G	cg13010199	chr12:38710504	ALG10B	0.44	5.51	0.32	8.37e-8	Morning vs. evening chronotype;
CESC	cis	rs11577318	0.853	rs11803933	chr1:26629465	G/C	cg00852783	chr1:26633632	UBXN11	0.5	6.99	0.39	2.17e-11	Granulocyte percentage of myeloid white cells;
CESC	cis	rs262150	1.000	rs262150	chr7:158777934	G/A	cg19418458	chr7:158789849	NA	-0.48	-7.58	-0.42	5.94e-13	Facial morphology (factor 20);
CESC	cis	rs1552244	1.000	rs68045038	chr3:10151828	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.89	12.23	0.6	1.42e-27	Alzheimer's disease;
CESC	cis	rs477692	0.905	rs7905466	chr10:131438937	A/T	cg05714579	chr10:131428358	MGMT	-0.57	-8.14	-0.45	1.57e-14	Response to temozolomide;
CESC	cis	rs1707322	0.691	rs61784799	chr1:46177748	A/G	cg05343316	chr1:45956843	TESK2	-0.51	-6.32	-0.36	1.09e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7552167	0.925	rs11249020	chr1:24512804	A/G	cg01960748	chr1:24522592	NA	-0.42	-5.34	-0.31	2.01e-7	Psoriasis vulgaris;
CESC	cis	rs10504229	1.000	rs17217082	chr8:58180918	G/A	cg05313129	chr8:58192883	C8orf71	-0.55	-6.37	-0.36	8.42e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs3015497	0.753	rs4643225	chr14:51122205	G/C	cg09863266	chr14:51125203	SAV1	-0.35	-5.4	-0.31	1.51e-7	Mean platelet volume;
CESC	cis	rs4423214	1.000	rs12422045	chr11:71154820	C/T	cg24826892	chr11:71159390	DHCR7	0.45	5.32	0.31	2.25e-7	Vitamin D levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00185004	chr17:55752472	MSI2	-0.59	-6.9	-0.39	3.8e-11	Gut microbiome composition (summer);
CESC	cis	rs1862618	0.853	rs190414	chr5:56116772	C/A	cg12311346	chr5:56204834	C5orf35	-0.71	-8.58	-0.47	8.07e-16	Initial pursuit acceleration;
CESC	cis	rs11122272	0.735	rs1076804	chr1:231498460	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.56	-7.65	-0.43	3.62e-13	Hemoglobin concentration;
CESC	cis	rs1153858	1.000	rs4775937	chr15:45678614	C/A	cg14582100	chr15:45693742	SPATA5L1	0.42	5.95	0.34	8.38e-9	Homoarginine levels;
CESC	cis	rs559928	0.556	rs734762	chr11:63912189	G/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.68	6.06	0.35	4.55e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CESC	cis	rs9611565	0.512	rs139560	chr22:42194962	A/G	cg03806693	chr22:41940476	POLR3H	-1.13	-13.58	-0.64	3.04e-32	Vitiligo;
CESC	trans	rs3942852	0.868	rs58407618	chr11:48104167	T/G	cg15704280	chr7:45808275	SEPT13	-0.61	-6.84	-0.39	5.37e-11	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs35110281	0.743	rs230640	chr21:44914815	A/T	cg01579765	chr21:45077557	HSF2BP	0.51	8.7	0.47	3.61e-16	Mean corpuscular volume;
CESC	cis	rs9308731	0.623	rs6708784	chr2:111927379	A/G	cg04202892	chr2:111875749	ACOXL	0.42	5.93	0.34	9.43e-9	Chronic lymphocytic leukemia;
CESC	cis	rs10924309	0.889	rs10802247	chr1:245858508	G/A	cg00036263	chr1:245852353	KIF26B	-0.41	-5.18	-0.3	4.4e-7	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
CESC	cis	rs11764590	0.756	rs17132130	chr7:2108036	G/C	cg21782813	chr7:2030301	MAD1L1	-0.4	-5.07	-0.3	7.46e-7	Neuroticism;
CESC	cis	rs4689388	0.926	rs11732178	chr4:6292643	G/C	cg25554036	chr4:6271136	WFS1	0.52	8.51	0.46	1.34e-15	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs2549003	0.966	rs10072571	chr5:131816711	A/C	cg21138405	chr5:131827807	IRF1	0.54	9.24	0.49	8.12e-18	Asthma (sex interaction);
CESC	cis	rs8028182	0.636	rs7171507	chr15:75737287	T/C	cg20655648	chr15:75932815	IMP3	0.49	6.04	0.35	5.28e-9	Sudden cardiac arrest;
CESC	cis	rs3857067	0.806	rs10008044	chr4:95092850	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.61	-9.04	-0.49	3.47e-17	QT interval;
CESC	trans	rs877282	0.853	rs7079450	chr10:755932	T/A	cg22713356	chr15:30763199	NA	0.93	8.39	0.46	3e-15	Uric acid levels;
CESC	cis	rs593982	0.925	rs603509	chr11:65507605	C/T	cg08755490	chr11:65554678	OVOL1	-1.27	-19.88	-0.77	1.83e-54	Atopic dermatitis;
CESC	cis	rs9302635	0.513	rs8044555	chr16:72152755	T/C	cg16558253	chr16:72132732	DHX38	-0.46	-6.04	-0.35	5.19e-9	Blood protein levels;
CESC	cis	rs6121246	0.909	rs6060633	chr20:30263317	G/T	cg13852791	chr20:30311386	BCL2L1	0.77	8.18	0.45	1.17e-14	Mean corpuscular hemoglobin;
CESC	cis	rs4253772	0.530	rs9627387	chr22:46684678	A/G	cg18190219	chr22:46762943	CELSR1	-0.46	-6.01	-0.35	6.25e-9	LDL cholesterol;Cholesterol, total;
CESC	cis	rs796364	0.760	rs74993507	chr2:201068684	C/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.82	-6.63	-0.38	1.86e-10	Schizophrenia;
CESC	cis	rs875971	0.789	rs10260426	chr7:65736042	G/T	cg10691866	chr7:65817282	TPST1	0.33	5.55	0.32	6.96e-8	Aortic root size;
CESC	cis	rs7940866	0.646	rs10894293	chr11:130824213	C/T	cg12179176	chr11:130786555	SNX19	-0.61	-8.46	-0.46	1.87e-15	Schizophrenia;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg00593699	chr11:472782	PTDSS2	0.51	7.16	0.4	7.99e-12	Fibrinogen levels;
CESC	cis	rs9309473	1.000	rs6724782	chr2:73679990	T/A	cg20560298	chr2:73613845	ALMS1	-0.46	-6.17	-0.35	2.53e-9	Metabolite levels;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg19273467	chr1:32110819	PEF1	0.48	6.21	0.36	2.03e-9	Systemic lupus erythematosus;
CESC	cis	rs3806843	0.900	rs2337984	chr5:140136811	G/A	cg16179182	chr5:140090404	VTRNA1-1	0.42	5.43	0.32	1.3e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs6570726	0.935	rs397418	chr6:145842362	C/T	cg23711669	chr6:146136114	FBXO30	0.79	11.78	0.59	4.77e-26	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1005277	0.602	rs1740743	chr10:38519222	C/T	cg25517755	chr10:38738941	LOC399744	-0.44	-5.72	-0.33	2.85e-8	Extrinsic epigenetic age acceleration;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg18179305	chr5:89705894	CETN3	-0.48	-6.79	-0.38	7.33e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs477895	1.000	rs7939107	chr11:64034773	C/T	cg04317338	chr11:64019027	PLCB3	0.7	5.96	0.34	8.22e-9	Mean platelet volume;
CESC	cis	rs17376456	0.877	rs9314101	chr5:93461593	A/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.62	5.44	0.32	1.23e-7	Diabetic retinopathy;
CESC	cis	rs4665809	0.887	rs2384324	chr2:26354239	A/G	cg04944784	chr2:26401820	FAM59B	-0.79	-8.87	-0.48	1.09e-16	Gut microbiome composition (summer);
CESC	cis	rs12618769	0.652	rs3754872	chr2:99223925	A/T	cg10123293	chr2:99228465	UNC50	0.41	5.35	0.31	1.88e-7	Bipolar disorder;
CESC	cis	rs2295499	0.678	rs12503560	chr4:2714482	T/C	cg08330972	chr4:2403930	ZFYVE28	-0.32	-5.28	-0.31	2.66e-7	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
CESC	cis	rs11098499	0.738	rs34566984	chr4:120361270	G/A	cg24375607	chr4:120327624	NA	0.47	5.89	0.34	1.14e-8	Corneal astigmatism;
CESC	cis	rs1707322	1.000	rs7539800	chr1:46262129	C/G	cg03146154	chr1:46216737	IPP	-0.78	-10.71	-0.55	1.78e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs704795	0.836	rs1647281	chr2:27612938	G/C	cg22903471	chr2:27725779	GCKR	-0.5	-7.08	-0.4	1.32e-11	Menopause (age at onset);
CESC	cis	rs17854409	0.881	rs1046784	chr20:61472808	G/C	cg07645718	chr20:61493192	TCFL5	0.81	5.37	0.31	1.69e-7	Obesity-related traits;
CESC	cis	rs2486288	0.656	rs11637920	chr15:45550905	T/C	cg21132104	chr15:45694354	SPATA5L1	-0.54	-6.55	-0.37	3.03e-10	Glomerular filtration rate;
CESC	cis	rs477895	0.713	rs882146	chr11:63976699	G/A	cg04317338	chr11:64019027	PLCB3	0.89	9.26	0.49	6.99e-18	Mean platelet volume;
CESC	cis	rs875971	0.862	rs10224872	chr7:65759773	T/A	cg11764359	chr7:65958608	NA	-0.8	-12.02	-0.59	7.52e-27	Aortic root size;
CESC	cis	rs7659604	0.539	rs2063165	chr4:122750005	A/G	cg19748678	chr4:122722346	EXOSC9	0.8	10.1	0.53	1.66e-20	Type 2 diabetes;
CESC	cis	rs9611565	0.694	rs202664	chr22:41813886	C/T	cg06481639	chr22:41940642	POLR3H	0.59	6.25	0.36	1.61e-9	Vitiligo;
CESC	cis	rs2290159	0.800	rs9809947	chr3:12655944	T/C	cg23032965	chr3:12705835	RAF1	0.55	6.04	0.35	5.13e-9	Cholesterol, total;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23084309	chr19:6280164	MLLT1	0.55	6.28	0.36	1.35e-9	Gut microbiome composition (summer);
CESC	cis	rs7247513	0.930	rs34321000	chr19:12713088	C/T	cg01871581	chr19:12707946	ZNF490	-0.89	-15.12	-0.68	1.12e-37	Bipolar disorder;
CESC	trans	rs66573146	0.572	rs66819208	chr4:6946128	A/G	cg07817883	chr1:32538562	TMEM39B	1.25	8.66	0.47	4.59e-16	Granulocyte percentage of myeloid white cells;
CESC	cis	rs425277	0.606	rs3128295	chr1:2068480	C/T	cg23803603	chr1:2058230	PRKCZ	-0.31	-5.24	-0.31	3.2e-7	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19612890	chr12:131356591	RAN	0.54	6.0	0.35	6.36e-9	Gut microbiome composition (summer);
CESC	cis	rs7605827	0.836	rs9287659	chr2:15595755	C/T	cg19274914	chr2:15703543	NA	0.33	5.97	0.34	7.72e-9	Educational attainment (years of education);
CESC	cis	rs9911578	0.967	rs12603238	chr17:57130785	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.4	-5.19	-0.3	4.23e-7	Intelligence (multi-trait analysis);
CESC	cis	rs959260	0.623	rs7207618	chr17:73321687	T/C	cg20590849	chr17:73267439	MIF4GD	-0.44	-5.38	-0.31	1.63e-7	Systemic lupus erythematosus;
CESC	cis	rs4689592	0.503	rs3857180	chr4:7073899	T/G	cg26116260	chr4:7069785	GRPEL1	-0.87	-9.28	-0.5	6.45e-18	Monocyte percentage of white cells;
CESC	cis	rs703842	0.964	rs2014886	chr12:58177437	C/T	cg00677455	chr12:58241039	CTDSP2	0.52	6.62	0.38	2.03e-10	Multiple sclerosis;
CESC	cis	rs561341	0.943	rs508566	chr17:30289861	G/C	cg00745463	chr17:30367425	LRRC37B	-0.81	-7.19	-0.4	6.78e-12	Hip circumference adjusted for BMI;
CESC	cis	rs8114671	0.562	rs2889861	chr20:33405664	C/T	cg06115741	chr20:33292138	TP53INP2	0.44	5.41	0.32	1.41e-7	Height;
CESC	cis	rs16858210	0.874	rs34113436	chr3:183573836	G/A	cg03417191	chr3:183542750	MAP6D1	-0.4	-5.11	-0.3	6.11e-7	Menopause (age at onset);
CESC	cis	rs2070433	0.539	rs2839314	chr21:47961067	A/G	cg12379764	chr21:47803548	PCNT	0.62	8.21	0.45	9.85e-15	Lymphocyte counts;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg00459447	chr7:108210006	THAP5;DNAJB9	-0.45	-6.07	-0.35	4.3e-9	Ulcerative colitis;
CESC	cis	rs1218582	0.772	rs2335408	chr1:154915977	G/A	cg16680214	chr1:154839983	KCNN3	-0.48	-7.31	-0.41	3.09e-12	Prostate cancer;
CESC	trans	rs12681287	0.517	rs34596274	chr8:87517679	C/T	cg27317242	chr8:23145699	R3HCC1	-0.52	-6.13	-0.35	3.12e-9	Caudate activity during reward;
CESC	cis	rs832540	0.519	rs10940518	chr5:56270794	C/T	cg12311346	chr5:56204834	C5orf35	-0.45	-5.62	-0.33	4.74e-8	Coronary artery disease;
CESC	cis	rs7216064	0.773	rs74541577	chr17:65853651	C/T	cg07042672	chr17:66097459	LOC651250	-0.54	-5.62	-0.33	4.77e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs11676348	0.729	rs13013361	chr2:218947515	A/T	cg00012203	chr2:219082015	ARPC2	-0.5	-6.37	-0.36	8.46e-10	Ulcerative colitis;
CESC	trans	rs1814175	0.647	rs4881649	chr11:49845560	A/G	cg15704280	chr7:45808275	SEPT13	-0.81	-11.37	-0.57	1.15e-24	Height;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg12232852	chr3:69129018	UBA3	0.51	6.69	0.38	1.34e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs875971	0.895	rs4718349	chr7:65909011	C/G	cg12463550	chr7:65579703	CRCP	0.57	7.19	0.4	6.54e-12	Aortic root size;
CESC	trans	rs4650994	0.507	rs12141152	chr1:178514165	C/T	cg05059571	chr16:84539110	KIAA1609	-0.4	-6.22	-0.36	1.93e-9	HDL cholesterol levels;HDL cholesterol;
CESC	cis	rs3733585	0.579	rs4235353	chr4:10122934	C/T	cg02734326	chr4:10020555	SLC2A9	-0.37	-5.03	-0.3	8.89e-7	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs4594175	0.926	rs116372620	chr14:51599682	T/C	cg23942311	chr14:51606299	NA	0.4	6.02	0.35	5.87e-9	Cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26542412	chr1:92350568	TGFBR3	-0.62	-7.59	-0.42	5.31e-13	Gut microbiome composition (summer);
CESC	cis	rs344364	0.511	rs911391	chr16:1947016	C/A	cg03013636	chr16:1946785	NA	0.48	6.62	0.38	2.02e-10	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs7247513	1.000	rs8104385	chr19:12700284	G/A	cg01871581	chr19:12707946	ZNF490	-0.88	-15.42	-0.69	9.87e-39	Bipolar disorder;
CESC	cis	rs72781680	0.611	rs7596820	chr2:24335036	G/C	cg06627628	chr2:24431161	ITSN2	-0.67	-6.51	-0.37	3.7e-10	Lymphocyte counts;
CESC	cis	rs2932538	0.922	rs112363416	chr1:113107543	T/C	cg22162597	chr1:113214053	CAPZA1	0.6	7.33	0.41	2.75e-12	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CESC	cis	rs35110281	0.744	rs162373	chr21:44927107	C/A	cg01579765	chr21:45077557	HSF2BP	0.52	9.13	0.49	1.86e-17	Mean corpuscular volume;
CESC	cis	rs4665809	0.838	rs2243834	chr2:26357748	A/C	cg26314531	chr2:26401878	FAM59B	0.57	6.58	0.37	2.5e-10	Gut microbiome composition (summer);
CESC	cis	rs6831352	0.760	rs1311616	chr4:100012303	T/G	cg12011299	chr4:100065546	ADH4	0.61	6.71	0.38	1.17e-10	Alcohol dependence;
CESC	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	7.83	0.43	1.17e-13	Prudent dietary pattern;
CESC	cis	rs11690935	0.959	rs11897196	chr2:172585595	G/A	cg13550731	chr2:172543902	DYNC1I2	-0.97	-14.97	-0.68	4e-37	Schizophrenia;
CESC	cis	rs3008870	0.959	rs4655658	chr1:67389608	C/T	cg02640540	chr1:67518911	SLC35D1	0.47	5.05	0.3	8.1e-7	Lymphocyte percentage of white cells;
CESC	cis	rs6724607	1.000	rs13410230	chr2:191446252	A/G	cg10560079	chr2:191398806	TMEM194B	0.47	6.77	0.38	8.47e-11	Pulse pressure;
CESC	cis	rs17711722	0.727	rs1880555	chr7:65432567	T/C	cg26939375	chr7:64535504	NA	0.76	10.88	0.56	5.07e-23	Calcium levels;
CESC	trans	rs7944735	0.786	rs7123436	chr11:48013484	G/A	cg15704280	chr7:45808275	SEPT13	0.64	6.51	0.37	3.79e-10	Intraocular pressure;
CESC	cis	rs2637266	0.678	rs2583060	chr10:78558893	C/T	cg18941641	chr10:78392320	NA	0.4	7.57	0.42	6.04e-13	Pulmonary function;
CESC	cis	rs55788414	1.000	rs67345347	chr16:81185125	G/C	cg06400318	chr16:81190750	PKD1L2	-0.61	-6.81	-0.39	6.38e-11	Left ventricular obstructive tract defect (maternal effect);
CESC	cis	rs1008375	1.000	rs7697889	chr4:17617961	G/T	cg04450456	chr4:17643702	FAM184B	0.4	5.69	0.33	3.35e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs7412746	0.658	rs12405726	chr1:150956128	G/A	cg04414720	chr1:150670196	GOLPH3L	0.51	6.64	0.38	1.79e-10	Melanoma;
CESC	cis	rs12476592	0.602	rs10865338	chr2:63732509	A/G	cg17519650	chr2:63277830	OTX1	-0.47	-5.4	-0.31	1.46e-7	Childhood ear infection;
CESC	cis	rs7772486	0.875	rs1929523	chr6:146339989	T/A	cg05347473	chr6:146136440	FBXO30	0.52	6.71	0.38	1.17e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4253772	0.513	rs6008700	chr22:46722560	C/T	cg09491104	chr22:46646882	C22orf40	-0.55	-7.99	-0.44	4.14e-14	LDL cholesterol;Cholesterol, total;
CESC	cis	rs1799949	0.773	rs2137990	chr17:41317896	T/A	cg25072359	chr17:41440525	NA	-0.49	-7.21	-0.41	5.7e-12	Menopause (age at onset);
CESC	cis	rs1371867	0.875	rs1788168	chr8:101324960	G/T	cg11906718	chr8:101322791	RNF19A	0.46	5.92	0.34	1.02e-8	Atrioventricular conduction;
CESC	cis	rs11864453	0.560	rs6499561	chr16:72148404	A/G	cg16558253	chr16:72132732	DHX38	-0.54	-8.58	-0.47	8.07e-16	Fibrinogen levels;
CESC	cis	rs6460942	0.597	rs12699388	chr7:12536336	T/C	cg02935154	chr7:12443704	VWDE	-0.57	-5.7	-0.33	3.23e-8	Coronary artery disease;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg06131143	chr2:48757612	NA	-0.42	-6.05	-0.35	4.82e-9	Asthma;
CESC	cis	rs875971	0.862	rs2420611	chr7:65999320	A/G	cg19163074	chr7:65112434	INTS4L2	-0.43	-5.34	-0.31	2e-7	Aortic root size;
CESC	trans	rs9858542	1.000	rs9823546	chr3:49705512	T/A	cg21659725	chr3:3221576	CRBN	-0.53	-6.6	-0.38	2.27e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs10743315	0.557	rs77194694	chr12:19354075	A/G	cg02471346	chr12:19282374	PLEKHA5	0.7	5.25	0.31	3.2e-7	Gut microbiota (bacterial taxa);
CESC	cis	rs1865721	1.000	rs62089511	chr18:73197629	C/T	cg26385618	chr18:73139727	C18orf62	-0.51	-7.54	-0.42	7.49e-13	Intelligence;
CESC	cis	rs1005277	0.579	rs932538	chr10:38381314	T/C	cg25427524	chr10:38739819	LOC399744	-0.69	-10.3	-0.53	3.72e-21	Extrinsic epigenetic age acceleration;
CESC	cis	rs8031584	0.958	rs1043742	chr15:31232581	A/C	cg08704250	chr15:31115839	NA	-0.61	-7.86	-0.43	9.71e-14	Huntington's disease progression;
CESC	cis	rs62432291	0.681	rs420054	chr6:159655084	C/G	cg14500486	chr6:159655392	FNDC1	-0.6	-5.92	-0.34	9.83e-9	Joint mobility (Beighton score);
CESC	trans	rs7656342	0.808	rs10003216	chr4:9766749	A/G	cg16329901	chr2:220094343	ATG9A;ANKZF1	-0.52	-6.34	-0.36	1e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs1348850	1.000	rs1348850	chr2:178418575	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.7	9.45	0.5	1.89e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs1023500	0.573	rs133370	chr22:42465260	T/C	cg04733989	chr22:42467013	NAGA	0.79	12.05	0.59	5.98e-27	Schizophrenia;
CESC	trans	rs208520	0.802	rs4710315	chr6:66887594	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.92	-11.49	-0.58	4.62e-25	Exhaled nitric oxide output;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg13709765	chr18:3451484	TGIF1	-0.46	-6.21	-0.36	2.02e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs2836950	0.545	rs8132143	chr21:40584258	A/T	cg11890956	chr21:40555474	PSMG1	-0.66	-9.44	-0.5	1.99e-18	Menarche (age at onset);
CESC	cis	rs763121	0.853	rs35522482	chr22:39063015	C/A	cg14440974	chr22:39074834	NA	-0.42	-5.82	-0.34	1.69e-8	Menopause (age at onset);
CESC	cis	rs6912958	0.781	rs7761814	chr6:88188309	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.43	-5.82	-0.34	1.68e-8	Monocyte percentage of white cells;
CESC	cis	rs4950322	0.748	rs17356680	chr1:146826644	C/T	cg22381352	chr1:146742008	CHD1L	-0.47	-5.04	-0.3	8.64e-7	Protein quantitative trait loci;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11066750	chr2:120125096	C2orf76;DBI	0.58	6.73	0.38	1.07e-10	Gut microbiome composition (summer);
CESC	cis	rs1218582	0.772	rs6669791	chr1:154845484	G/T	cg03351412	chr1:154909251	PMVK	0.65	8.71	0.47	3.36e-16	Prostate cancer;
CESC	cis	rs7615952	0.932	rs13065725	chr3:125632289	C/A	cg05084668	chr3:125655381	ALG1L	-0.49	-5.61	-0.33	5.14e-8	Blood pressure (smoking interaction);
CESC	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg24642844	chr7:1081250	C7orf50	-0.62	-8.1	-0.45	1.97e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2274273	0.638	rs17672364	chr14:55705904	G/T	cg04306507	chr14:55594613	LGALS3	0.31	5.15	0.3	5.01e-7	Protein biomarker;
CESC	cis	rs1799949	1.000	rs11079056	chr17:41300799	C/A	cg05368731	chr17:41323189	NBR1	0.8	11.27	0.57	2.51e-24	Menopause (age at onset);
CESC	cis	rs7582720	1.000	rs72934738	chr2:203740861	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.32	0.41	3.04e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs28830936	0.966	rs17678552	chr15:42066190	T/C	cg17847044	chr15:42102381	MAPKBP1	-0.34	-5.08	-0.3	7.07e-7	Diastolic blood pressure;
CESC	cis	rs4835473	0.897	rs35162238	chr4:144614671	A/G	cg25736465	chr4:144833511	NA	-0.36	-5.45	-0.32	1.17e-7	Immature fraction of reticulocytes;
CESC	cis	rs6545883	0.831	rs9309336	chr2:61763165	T/C	cg15711740	chr2:61764176	XPO1	-0.44	-5.34	-0.31	1.95e-7	Tuberculosis;
CESC	cis	rs2717559	0.542	rs34147336	chr8:143884869	A/G	cg17252645	chr8:143867129	LY6D	-0.32	-5.47	-0.32	1.06e-7	Urinary tract infection frequency;
CESC	cis	rs7917772	0.503	rs746552	chr10:104342501	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.53	7.47	0.42	1.15e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs853679	0.517	rs9380060	chr6:28132603	G/A	cg23161317	chr6:28129485	ZNF389	0.52	6.48	0.37	4.37e-10	Depression;
CESC	cis	rs9910055	0.639	rs7217858	chr17:42254527	T/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.74	10.2	0.53	8.14e-21	Total body bone mineral density;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13195218	chr1:223900468	CAPN2	0.55	6.19	0.36	2.23e-9	Gut microbiome composition (summer);
CESC	cis	rs8060686	0.641	rs9674047	chr16:68045046	G/A	cg26727032	chr16:67993705	SLC12A4	-0.53	-6.48	-0.37	4.39e-10	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs2651899	0.902	rs1624023	chr1:3079337	C/T	cg22674798	chr1:3096360	PRDM16	0.38	7.42	0.41	1.56e-12	Migraine;
CESC	cis	rs6912958	0.667	rs7746545	chr6:88090225	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.5	8.46	0.46	1.84e-15	Monocyte percentage of white cells;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg05979741	chr2:110873485	MALL	-0.45	-6.07	-0.35	4.31e-9	Height;
CESC	cis	rs6541297	0.699	rs966333	chr1:230305477	T/C	cg20703242	chr1:230279135	GALNT2	0.62	6.93	0.39	3.14e-11	Coronary artery disease;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg05306856	chr1:89357390	GTF2B	-0.43	-6.26	-0.36	1.5e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs769267	1.000	rs2074090	chr19:19449686	G/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.64	-8.23	-0.45	8.51e-15	Tonsillectomy;
CESC	cis	rs367943	1.000	rs191553	chr5:112823659	A/G	cg12552261	chr5:112820674	MCC	-0.63	-7.96	-0.44	4.96e-14	Type 2 diabetes;
CESC	cis	rs9649213	0.555	rs6956686	chr7:97997945	T/C	cg00277769	chr7:97922759	BAIAP2L1	-0.33	-5.45	-0.32	1.17e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs28830936	1.000	rs9672360	chr15:41912411	T/C	cg11010575	chr15:42129464	JMJD7-PLA2G4B;JMJD7	-0.36	-5.08	-0.3	6.99e-7	Diastolic blood pressure;
CESC	cis	rs2845885	1.000	rs11231698	chr11:63877163	C/T	cg24431193	chr11:63883947	FLRT1;MACROD1	0.88	7.33	0.41	2.72e-12	Body mass index;
CESC	cis	rs8072100	0.544	rs9284377	chr17:45386412	C/T	cg08085267	chr17:45401833	C17orf57	-0.53	-6.72	-0.38	1.11e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg24642844	chr7:1081250	C7orf50	-0.77	-9.41	-0.5	2.48e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs34172651	0.917	rs200532	chr16:24756148	C/T	cg06028605	chr16:24865363	SLC5A11	-0.35	-5.49	-0.32	9.48e-8	Intelligence (multi-trait analysis);
CESC	trans	rs208520	0.690	rs12198297	chr6:66714665	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.95	12.36	0.6	5.09e-28	Exhaled nitric oxide output;
CESC	cis	rs7772486	0.790	rs4314514	chr6:146260010	A/G	cg05347473	chr6:146136440	FBXO30	-0.55	-7.0	-0.39	2.12e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6942756	1.000	rs67997229	chr7:128957366	G/C	cg02491457	chr7:128862824	NA	-0.67	-9.07	-0.49	2.8e-17	White matter hyperintensity burden;
CESC	cis	rs6598955	0.724	rs10902737	chr1:26635716	G/A	cg00852783	chr1:26633632	UBXN11	0.43	6.24	0.36	1.76e-9	Obesity-related traits;
CESC	cis	rs7666738	0.830	rs13119913	chr4:98977983	G/T	cg03676636	chr4:99064102	C4orf37	0.33	5.12	0.3	5.91e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7520050	0.966	rs6661910	chr1:46290632	A/T	cg03146154	chr1:46216737	IPP	-0.47	-6.12	-0.35	3.29e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs6867032	0.958	rs4975795	chr5:2015390	G/A	cg26168224	chr5:2018326	NA	0.96	19.34	0.77	1.46e-52	Gut microbiome composition (winter);
CESC	cis	rs2842992	0.830	rs752779	chr6:160133957	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.69	9.01	0.48	4.25e-17	Age-related macular degeneration (geographic atrophy);
CESC	trans	rs3780486	1.000	rs10813957	chr9:33153527	G/T	cg04842962	chr6:43655489	MRPS18A	0.93	13.03	0.62	2.49e-30	IgG glycosylation;
CESC	cis	rs2430386	1.000	rs2430386	chr2:63178111	C/T	cg17519650	chr2:63277830	OTX1	0.58	8.18	0.45	1.16e-14	Prostate cancer;
CESC	trans	rs12599106	0.584	rs12929704	chr16:34898258	C/A	cg26668828	chr6:292823	DUSP22	-0.71	-9.3	-0.5	5.31e-18	Menopause (age at onset);
CESC	cis	rs9291683	0.632	rs11734786	chr4:10041499	A/C	cg02734326	chr4:10020555	SLC2A9	0.47	6.53	0.37	3.29e-10	Bone mineral density;
CESC	cis	rs926938	0.618	rs3121506	chr1:115363207	T/G	cg12756093	chr1:115239321	AMPD1	0.43	5.83	0.34	1.58e-8	Autism;
CESC	cis	rs12477438	0.765	rs6735801	chr2:99657995	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.62	-8.67	-0.47	4.43e-16	Chronic sinus infection;
CESC	cis	rs568617	1.000	rs656980	chr11:65656282	G/A	cg00576331	chr11:65640516	EFEMP2	-0.45	-5.35	-0.31	1.95e-7	Crohn's disease;
CESC	cis	rs7103648	0.966	rs896817	chr11:47394305	A/G	cg20307385	chr11:47447363	PSMC3	-0.94	-14.48	-0.66	2.09e-35	Diastolic blood pressure;Systolic blood pressure;
CESC	cis	rs13242816	1.000	rs12672717	chr7:116128270	G/A	cg04696780	chr7:116139425	CAV2	-0.61	-5.56	-0.32	6.58e-8	P wave duration;
CESC	cis	rs959260	1.000	rs2033607	chr17:73367288	A/G	cg20590849	chr17:73267439	MIF4GD	-0.53	-6.46	-0.37	5.01e-10	Systemic lupus erythematosus;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg14816013	chr12:56618154	OBFC2B	-0.41	-6.01	-0.35	6.25e-9	Gambling;
CESC	cis	rs28374715	0.578	rs10518717	chr15:41623368	C/G	cg20272979	chr15:41787780	ITPKA	0.45	5.35	0.31	1.89e-7	Ulcerative colitis;
CESC	cis	rs11168351	0.591	rs4258439	chr12:48468652	A/G	cg04545296	chr12:48745243	ZNF641	-0.29	-5.44	-0.32	1.18e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs10242455	0.867	rs2037498	chr7:99311550	G/A	cg07715041	chr7:99302981	CYP3A7	-0.43	-5.42	-0.32	1.36e-7	Blood metabolite levels;
CESC	cis	rs9916302	0.706	rs801427	chr17:37436711	A/G	cg07936489	chr17:37558343	FBXL20	-0.92	-10.41	-0.54	1.65e-21	Glomerular filtration rate (creatinine);
CESC	cis	rs780096	0.506	rs1728922	chr2:27644464	A/C	cg24768116	chr2:27665128	KRTCAP3	-0.29	-5.36	-0.31	1.82e-7	Total body bone mineral density;
CESC	cis	rs9649213	0.593	rs6969234	chr7:97987986	T/C	cg00277769	chr7:97922759	BAIAP2L1	-0.33	-5.41	-0.32	1.41e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs4566357	0.615	rs2272204	chr2:227915601	G/T	cg11843606	chr2:227700838	RHBDD1	-0.51	-6.99	-0.39	2.29e-11	Coronary artery disease;
CESC	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg27094323	chr7:1216898	NA	-0.39	-5.53	-0.32	7.74e-8	Longevity;Endometriosis;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg26011156	chr1:156183096	PMF1	0.47	6.12	0.35	3.32e-9	Systemic lupus erythematosus;
CESC	cis	rs6598955	0.671	rs17163749	chr1:26568165	A/G	cg19743891	chr1:26644573	UBXN11;CD52	0.38	5.38	0.31	1.68e-7	Obesity-related traits;
CESC	trans	rs34132583	0.614	rs74847445	chr4:146367961	A/G	cg20655644	chr15:79254454	RASGRF1	0.69	6.14	0.35	2.94e-9	Hippocampal sclerosis;
CESC	cis	rs2228479	0.702	rs12599561	chr16:89894358	C/G	cg00800038	chr16:89945340	TCF25	-0.89	-6.88	-0.39	4.34e-11	Skin colour saturation;
CESC	cis	rs12122100	0.507	rs1925343	chr1:146505535	A/T	cg03526459	chr1:146549940	NA	-0.36	-5.78	-0.33	2.1e-8	HIV-1 control;
CESC	cis	rs11650494	0.831	rs11650886	chr17:47449193	G/A	cg08112188	chr17:47440006	ZNF652	1.07	7.52	0.42	8.54e-13	Prostate cancer;
CESC	cis	rs796364	0.951	rs13029537	chr2:200998950	T/C	cg23649088	chr2:200775458	C2orf69	-0.52	-5.09	-0.3	6.77e-7	Schizophrenia;
CESC	cis	rs1862618	0.671	rs2255726	chr5:56243128	T/C	cg24549020	chr5:56110836	MAP3K1	-0.5	-6.23	-0.36	1.87e-9	Initial pursuit acceleration;
CESC	cis	rs10504229	0.683	rs56211106	chr8:58113497	A/G	cg21724239	chr8:58056113	NA	0.58	5.93	0.34	9.45e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs4862750	0.872	rs9998173	chr4:187898778	T/A	cg06074448	chr4:187884817	NA	-0.37	-5.45	-0.32	1.16e-7	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7216064	1.000	rs8067892	chr17:65837983	A/G	cg12091567	chr17:66097778	LOC651250	-0.8	-9.08	-0.49	2.62e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs870825	0.616	rs7678864	chr4:185635158	C/T	cg04058563	chr4:185651563	MLF1IP	0.63	6.89	0.39	3.95e-11	Blood protein levels;
CESC	cis	rs72781680	1.000	rs17762102	chr2:24085606	A/G	cg08917208	chr2:24149416	ATAD2B	0.92	8.46	0.46	1.78e-15	Lymphocyte counts;
CESC	cis	rs9894429	0.608	rs7406219	chr17:79609410	G/T	cg18240062	chr17:79603768	NPLOC4	0.54	7.05	0.4	1.56e-11	Eye color traits;
CESC	cis	rs3796352	1.000	rs7622420	chr3:53111069	A/G	cg07884673	chr3:53033167	SFMBT1	0.5	5.31	0.31	2.3e-7	Immune reponse to smallpox (secreted IL-2);
CESC	cis	rs6952808	0.689	rs12668156	chr7:2019875	G/A	cg05863683	chr7:1912471	MAD1L1	0.41	5.93	0.34	9.29e-9	Bipolar disorder and schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05318600	chr7:6695121	NA	-0.56	-6.25	-0.36	1.63e-9	Gut microbiome composition (summer);
CESC	cis	rs7586879	0.639	rs7580081	chr2:25097072	G/C	cg01884057	chr2:25150051	NA	0.38	7.4	0.41	1.85e-12	Body mass index;
CESC	cis	rs854765	0.547	rs8075189	chr17:17901946	C/G	cg09796270	chr17:17721594	SREBF1	0.39	5.47	0.32	1.06e-7	Total body bone mineral density;
CESC	cis	rs875971	0.545	rs3936065	chr7:65790564	C/T	cg25405998	chr7:65216604	CCT6P1	0.52	5.79	0.34	1.99e-8	Aortic root size;
CESC	cis	rs344364	0.511	rs56077812	chr16:1948870	T/G	cg03013636	chr16:1946785	NA	0.48	6.62	0.38	2.02e-10	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs9287719	0.967	rs9679581	chr2:10751736	G/A	cg02196655	chr2:10830764	NOL10	-0.38	-5.79	-0.34	1.96e-8	Prostate cancer;
CESC	cis	rs7714584	1.000	rs7705542	chr5:150228318	G/A	cg22134413	chr5:150180641	NA	0.52	5.64	0.33	4.31e-8	Crohn's disease;
CESC	cis	rs2288912	0.838	rs7251503	chr19:45455715	C/G	cg13119609	chr19:45449297	APOC2	0.49	8.03	0.44	3.23e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs6800768	0.604	rs75990679	chr3:24155774	G/C	cg10674438	chr3:24145617	LOC152024	-0.46	-6.04	-0.35	5.08e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs2865126	0.743	rs1941550	chr18:10747590	T/C	cg21165219	chr18:10698044	FAM38B	-0.51	-5.16	-0.3	4.83e-7	Metabolite levels (5-HIAA/ MHPG Ratio);
CESC	cis	rs1577917	0.958	rs11754330	chr6:86455070	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.53	-6.89	-0.39	4.05e-11	Response to antipsychotic treatment;
CESC	cis	rs801193	0.967	rs3800823	chr7:66147110	C/A	cg14393609	chr7:65229607	NA	-0.42	-5.49	-0.32	9.38e-8	Aortic root size;
CESC	cis	rs1707322	1.000	rs4660896	chr1:46372416	A/G	cg05343316	chr1:45956843	TESK2	0.44	5.55	0.32	7.05e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7267979	0.932	rs6115215	chr20:25562500	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.73	12.77	0.62	1.93e-29	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs16854884	0.586	rs6796460	chr3:143756367	G/A	cg06585982	chr3:143692056	C3orf58	0.48	6.6	0.38	2.28e-10	Economic and political preferences (feminism/equality);
CESC	cis	rs2075671	0.855	rs62483567	chr7:100286435	G/A	cg20848291	chr7:100343083	ZAN	-0.8	-10.07	-0.53	2.04e-20	Other erythrocyte phenotypes;
CESC	cis	rs4819052	0.851	rs58644915	chr21:46669912	T/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.44	5.48	0.32	9.98e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs9325144	0.624	rs7309400	chr12:39150369	G/C	cg26384229	chr12:38710491	ALG10B	-0.52	-7.12	-0.4	1.02e-11	Morning vs. evening chronotype;
CESC	cis	rs7267979	0.966	rs2227892	chr20:25264814	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	18.61	0.75	5.02e-50	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs2842992	1.000	rs2758322	chr6:160075188	G/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.68	8.01	0.44	3.59e-14	Age-related macular degeneration (geographic atrophy);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07204069	chr17:72772514	TMEM104;NAT9	0.53	6.12	0.35	3.32e-9	Gut microbiome composition (summer);
CESC	trans	rs61931739	0.534	rs814669	chr12:34102459	C/T	cg26384229	chr12:38710491	ALG10B	0.52	7.06	0.4	1.45e-11	Morning vs. evening chronotype;
CESC	cis	rs4835473	0.932	rs4835278	chr4:144709586	T/C	cg25736465	chr4:144833511	NA	-0.33	-5.35	-0.31	1.87e-7	Immature fraction of reticulocytes;
CESC	cis	rs12042052	0.590	rs72752167	chr1:232922414	G/A	cg00951395	chr1:232941775	KIAA1383	0.71	6.48	0.37	4.51e-10	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CESC	cis	rs2979489	0.699	rs17554116	chr8:30419334	C/T	cg26383811	chr8:30366931	RBPMS	-0.75	-8.98	-0.48	5.12e-17	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CESC	cis	rs317689	0.819	rs317667	chr12:69703754	G/T	cg14784868	chr12:69753453	YEATS4	0.49	5.22	0.31	3.68e-7	Response to diuretic therapy;
CESC	cis	rs1552244	0.816	rs13059144	chr3:10010197	A/C	cg08888203	chr3:10149979	C3orf24	0.48	6.0	0.35	6.49e-9	Alzheimer's disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg27003951	chr16:11350045	SOCS1	-0.46	-6.46	-0.37	5.12e-10	Fibrinogen levels;
CESC	cis	rs12142240	0.698	rs57267378	chr1:46816644	A/G	cg00530320	chr1:46809349	NSUN4	0.58	7.89	0.44	8.17e-14	Menopause (age at onset);
CESC	cis	rs5753037	0.754	rs4820824	chr22:30360915	G/A	cg01021169	chr22:30184971	ASCC2	-0.38	-5.91	-0.34	1.02e-8	Type 1 diabetes;
CESC	cis	rs1008375	0.932	rs6857678	chr4:17696964	A/T	cg02297831	chr4:17616191	MED28	0.44	5.4	0.32	1.45e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs9287719	0.967	rs2110776	chr2:10748810	A/G	cg02196655	chr2:10830764	NOL10	-0.38	-5.79	-0.34	1.96e-8	Prostate cancer;
CESC	cis	rs9733	0.650	rs2048558	chr1:150571730	A/G	cg17724175	chr1:150552817	MCL1	-0.33	-5.35	-0.31	1.9e-7	Tonsillectomy;
CESC	cis	rs7959452	0.719	rs57954211	chr12:69748397	C/A	cg20891283	chr12:69753455	YEATS4	0.84	13.12	0.63	1.24e-30	Blood protein levels;
CESC	cis	rs6831352	0.918	rs13140423	chr4:100050400	T/C	cg13256891	chr4:100009986	ADH5	-0.77	-8.43	-0.46	2.27e-15	Alcohol dependence;
CESC	cis	rs4820539	0.933	rs2267004	chr22:23459863	G/A	cg14186256	chr22:23484241	RTDR1	0.81	14.18	0.66	2.33e-34	Bone mineral density;
CESC	cis	rs6062302	0.522	rs3787112	chr20:62222411	G/A	cg06363034	chr20:62225388	GMEB2	-0.52	-6.73	-0.38	1.05e-10	Glioblastoma;
CESC	trans	rs2121875	0.667	rs1550939	chr5:44221712	A/G	cg07292773	chr6:156718177	NA	-0.47	-6.03	-0.35	5.62e-9	Prostate cancer;
CESC	cis	rs1153858	1.000	rs28679834	chr15:45616206	C/T	cg14582100	chr15:45693742	SPATA5L1	0.39	5.47	0.32	1.02e-7	Homoarginine levels;
CESC	cis	rs425277	0.539	rs3107142	chr1:2044542	T/C	cg23803603	chr1:2058230	PRKCZ	-0.34	-5.79	-0.34	1.97e-8	Height;
CESC	cis	rs9287719	0.967	rs7570118	chr2:10718007	G/T	cg02196655	chr2:10830764	NOL10	-0.37	-5.64	-0.33	4.43e-8	Prostate cancer;
CESC	cis	rs7617773	0.817	rs4131361	chr3:48328812	T/C	cg11946769	chr3:48343235	NME6	0.8	10.89	0.56	4.71e-23	Coronary artery disease;
CESC	cis	rs7772486	0.720	rs4896837	chr6:146014168	C/T	cg05347473	chr6:146136440	FBXO30	-0.52	-6.29	-0.36	1.32e-9	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2439831	1.000	rs689781	chr15:43792097	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.83	12.17	0.6	2.26e-27	Lung cancer in ever smokers;
CESC	cis	rs1003719	0.788	rs7276917	chr21:38451334	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.62	8.63	0.47	5.94e-16	Eye color traits;
CESC	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg06074448	chr4:187884817	NA	-0.38	-5.43	-0.32	1.27e-7	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7429990	0.965	rs4858871	chr3:47953405	A/C	cg11946769	chr3:48343235	NME6	0.42	5.13	0.3	5.71e-7	Educational attainment (years of education);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06103301	chr3:23987730	NR1D2	0.61	7.15	0.4	8.38e-12	Gut microbiome composition (summer);
CESC	cis	rs8027181	0.958	rs4776614	chr15:73082468	C/G	cg25632853	chr15:73088954	NA	0.37	6.37	0.36	8.47e-10	Triglyceride levels;
CESC	cis	rs1008375	0.843	rs59112113	chr4:17685336	A/T	cg02297831	chr4:17616191	MED28	0.41	5.23	0.31	3.5e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs9916302	0.847	rs7218670	chr17:37500424	G/A	cg19468946	chr17:37922297	IKZF3	0.4	5.22	0.31	3.56e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs2243480	1.000	rs4718309	chr7:65627764	G/C	cg12463550	chr7:65579703	CRCP	-0.73	-5.71	-0.33	3.1e-8	Diabetic kidney disease;
CESC	cis	rs1050631	0.592	rs1010955	chr18:33710610	T/C	cg25426722	chr18:33708991	SLC39A6;ELP2	0.59	8.19	0.45	1.15e-14	Esophageal squamous cell cancer (length of survival);
CESC	cis	rs7208859	0.623	rs11658022	chr17:29085359	A/T	cg19761014	chr17:28927070	LRRC37B2	0.79	6.28	0.36	1.37e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs10791323	0.569	rs10750542	chr11:133713436	T/C	cg06766960	chr11:133703094	NA	-0.41	-5.87	-0.34	1.28e-8	Childhood ear infection;
CESC	cis	rs2976388	0.556	rs4736300	chr8:143829269	C/T	cg24634471	chr8:143751801	JRK	-0.45	-5.06	-0.3	7.96e-7	Urinary tract infection frequency;
CESC	cis	rs9660180	0.620	rs34298494	chr1:1663402	A/C	cg13866156	chr1:1669148	SLC35E2	0.49	6.43	0.37	5.98e-10	Body mass index;
CESC	cis	rs367943	0.666	rs10064031	chr5:112970924	C/G	cg12552261	chr5:112820674	MCC	0.44	5.63	0.33	4.63e-8	Type 2 diabetes;
CESC	cis	rs8072100	0.738	rs9895509	chr17:45549618	A/T	cg08085267	chr17:45401833	C17orf57	0.52	6.65	0.38	1.67e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs7116495	1.000	rs12293885	chr11:71816092	T/A	cg26138937	chr11:71823887	C11orf51	0.85	6.85	0.39	5.03e-11	Severe influenza A (H1N1) infection;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26386643	chr15:74753645	UBL7	0.55	6.02	0.35	5.81e-9	Gut microbiome composition (summer);
CESC	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg18337363	chr3:52569053	NT5DC2	0.34	6.66	0.38	1.61e-10	Electroencephalogram traits;
CESC	cis	rs672059	0.513	rs572977	chr1:183164991	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.51	6.42	0.37	6.1e-10	Hypertriglyceridemia;
CESC	cis	rs947211	0.846	rs708726	chr1:205762139	G/T	cg14159672	chr1:205819179	PM20D1	-0.43	-5.85	-0.34	1.46e-8	Parkinson's disease;
CESC	cis	rs9811920	0.609	rs6765027	chr3:99687730	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.64	-10.1	-0.53	1.73e-20	Axial length;
CESC	cis	rs7772486	0.875	rs2748502	chr6:146298239	A/G	cg05347473	chr6:146136440	FBXO30	0.53	7.12	0.4	1.02e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9287719	0.967	rs4669593	chr2:10701908	C/T	cg00105475	chr2:10696890	NA	0.39	5.71	0.33	3.1e-8	Prostate cancer;
CESC	cis	rs4909189	1.000	rs62493651	chr7:158135592	T/C	cg24154853	chr7:158122151	PTPRN2	0.46	6.2	0.36	2.22e-9	Response to amphetamines;
CESC	cis	rs9322193	0.962	rs9478848	chr6:150146216	G/T	cg13206674	chr6:150067644	NUP43	0.39	5.5	0.32	9.12e-8	Lung cancer;
CESC	cis	rs6433857	0.505	rs1542036	chr2:181350009	A/C	cg23363182	chr2:181467187	NA	-0.41	-5.94	-0.34	9.11e-9	Body mass index;
CESC	cis	rs6461049	0.765	rs4719431	chr7:2140312	T/C	cg04267008	chr7:1944627	MAD1L1	-0.47	-5.65	-0.33	4.05e-8	Schizophrenia;
CESC	cis	rs9790314	0.967	rs7623206	chr3:160971518	G/A	cg04691961	chr3:161091175	C3orf57	-0.4	-5.08	-0.3	7.19e-7	Morning vs. evening chronotype;
CESC	cis	rs6912958	0.781	rs6940150	chr6:88287114	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-6.58	-0.37	2.55e-10	Monocyte percentage of white cells;
CESC	cis	rs2228479	0.850	rs45567439	chr16:89814604	G/A	cg14709524	chr16:89940631	TCF25	0.93	6.94	0.39	3.03e-11	Skin colour saturation;
CESC	cis	rs9322193	0.923	rs9800580	chr6:149953981	C/T	cg13206674	chr6:150067644	NUP43	0.43	6.27	0.36	1.44e-9	Lung cancer;
CESC	cis	rs4803468	1.000	rs4803468	chr19:41922352	A/G	cg14132834	chr19:41945861	ATP5SL	-0.68	-8.41	-0.46	2.55e-15	Height;
CESC	cis	rs2439831	1.000	rs2439850	chr15:43784854	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.88	10.25	0.53	5.49e-21	Lung cancer in ever smokers;
CESC	trans	rs12599106	0.707	rs2163977	chr16:34916134	A/G	cg05064044	chr6:292385	DUSP22	-0.6	-7.44	-0.42	1.37e-12	Menopause (age at onset);
CESC	cis	rs6480314	0.656	rs2394459	chr10:69981436	C/T	cg06988349	chr10:69991859	ATOH7	0.32	5.11	0.3	6.22e-7	Optic nerve measurement (disc area);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12344600	chr6:89769123	NA	-0.66	-7.96	-0.44	5.17e-14	Gut microbiome composition (summer);
CESC	cis	rs4642101	0.793	rs56082700	chr3:12833833	T/C	cg24848339	chr3:12840334	CAND2	0.34	5.24	0.31	3.28e-7	QRS complex (12-leadsum);
CESC	cis	rs13191362	1.000	rs35820211	chr6:163046252	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.89	9.93	0.52	5.96e-20	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs12545109	0.876	rs4738494	chr8:57327438	G/T	cg09654669	chr8:57350985	NA	-0.58	-7.07	-0.4	1.37e-11	Obesity-related traits;
CESC	cis	rs9420	0.961	rs71484461	chr11:57488890	G/A	cg19752551	chr11:57585705	CTNND1	-0.36	-5.07	-0.3	7.55e-7	Schizophrenia;
CESC	cis	rs887829	0.569	rs4399719	chr2:234666461	T/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.48	-6.16	-0.35	2.62e-9	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CESC	cis	rs2594989	0.943	rs2454500	chr3:11500103	C/T	cg00170343	chr3:11313890	ATG7	0.56	5.1	0.3	6.55e-7	Circulating chemerin levels;
CESC	cis	rs8017423	0.967	rs4904657	chr14:90721600	A/G	cg14092571	chr14:90743983	NA	-0.55	-8.25	-0.45	7.71e-15	Mortality in heart failure;
CESC	cis	rs9733	0.596	rs12086472	chr1:150697710	G/A	cg18016565	chr1:150552671	MCL1	0.34	5.28	0.31	2.67e-7	Tonsillectomy;
CESC	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg05313129	chr8:58192883	C8orf71	-0.48	-5.27	-0.31	2.89e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs2576037	0.583	rs541634	chr18:44420271	C/G	cg19077165	chr18:44547161	KATNAL2	-0.6	-9.11	-0.49	2.13e-17	Personality dimensions;
CESC	cis	rs863345	0.564	rs11265014	chr1:158503221	T/C	cg12129480	chr1:158549410	OR10X1	-0.35	-6.89	-0.39	4.12e-11	Pneumococcal bacteremia;
CESC	cis	rs9291683	0.609	rs3796836	chr4:10011345	A/G	cg02734326	chr4:10020555	SLC2A9	0.5	7.27	0.41	4.15e-12	Bone mineral density;
CESC	cis	rs10504229	0.683	rs1495866	chr8:58141128	T/C	cg21724239	chr8:58056113	NA	0.58	5.95	0.34	8.37e-9	Developmental language disorder (linguistic errors);
CESC	trans	rs61931739	0.517	rs12367881	chr12:34175508	T/C	cg26384229	chr12:38710491	ALG10B	0.66	9.12	0.49	1.89e-17	Morning vs. evening chronotype;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg03031583	chr16:21964721	UQCRC2	-0.47	-6.69	-0.38	1.3e-10	Gambling;
CESC	cis	rs12142240	0.959	rs12137934	chr1:46728913	A/G	cg00530320	chr1:46809349	NSUN4	0.54	6.81	0.39	6.47e-11	Menopause (age at onset);
CESC	cis	rs2842992	0.789	rs2342446	chr6:160220687	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.76	9.9	0.52	7.05e-20	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs9300255	0.722	rs11830103	chr12:123823546	A/G	cg00376283	chr12:123451042	ABCB9	-0.58	-6.75	-0.38	9.12e-11	Neutrophil percentage of white cells;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg22833807	chr22:36925177	EIF3D	-0.48	-7.05	-0.4	1.59e-11	Gambling;
CESC	cis	rs1707322	1.000	rs4606257	chr1:46307268	G/A	cg05343316	chr1:45956843	TESK2	0.49	5.94	0.34	8.87e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7210086	1.000	rs7210086	chr17:70641698	A/C	cg04206342	chr17:70636940	NA	-0.35	-5.81	-0.34	1.79e-8	Ulcerative colitis;
CESC	cis	rs7666738	0.819	rs62318904	chr4:99036101	A/T	cg18180107	chr4:99064573	C4orf37	0.43	5.4	0.31	1.5e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs684232	0.583	rs4968094	chr17:507120	A/T	cg12384639	chr17:618140	VPS53	0.43	5.57	0.32	6.3e-8	Prostate cancer;
CESC	cis	rs7666738	0.830	rs10021044	chr4:99002488	A/T	cg18180107	chr4:99064573	C4orf37	0.4	5.23	0.31	3.41e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4713118	0.662	rs149946	chr6:27970031	A/C	cg23281280	chr6:28129359	ZNF389	-0.52	-6.88	-0.39	4.4e-11	Parkinson's disease;
CESC	cis	rs959260	0.858	rs2053156	chr17:73378440	G/T	cg12999837	chr17:73267436	MIF4GD	-0.48	-5.57	-0.32	6.3e-8	Systemic lupus erythematosus;
CESC	cis	rs7666738	0.962	rs13147921	chr4:99069296	C/G	cg18180107	chr4:99064573	C4orf37	0.43	5.07	0.3	7.33e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs68170813	0.523	rs11762152	chr7:106811374	G/A	cg02696742	chr7:106810147	HBP1	-0.58	-5.75	-0.33	2.45e-8	Coronary artery disease;
CESC	cis	rs7927592	0.956	rs11228251	chr11:68244558	G/T	cg20283391	chr11:68216788	NA	-0.5	-6.4	-0.37	7e-10	Total body bone mineral density;
CESC	cis	rs9815354	1.000	rs6763829	chr3:41897046	A/G	cg03022575	chr3:42003672	ULK4	0.45	5.2	0.3	3.99e-7	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg07167872	chr1:205819463	PM20D1	0.79	12.48	0.61	2.06e-28	Menarche (age at onset);
CESC	cis	rs7560272	0.588	rs4852965	chr2:73911169	T/C	cg20560298	chr2:73613845	ALMS1	0.49	6.88	0.39	4.23e-11	Schizophrenia;
CESC	trans	rs11098499	0.954	rs6822679	chr4:120402702	A/C	cg25214090	chr10:38739885	LOC399744	0.72	10.21	0.53	7.58e-21	Corneal astigmatism;
CESC	cis	rs225245	0.755	rs226441	chr17:34033072	C/T	cg05299278	chr17:33885742	SLFN14	0.38	5.43	0.32	1.27e-7	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
CESC	cis	rs3087591	0.887	rs2905796	chr17:29537586	G/A	cg24425628	chr17:29625626	OMG;NF1	0.42	5.03	0.3	9.22e-7	Hip circumference;
CESC	cis	rs10832963	1.000	rs10832962	chr11:18656271	C/T	cg20219074	chr11:18656078	SPTY2D1	0.8	11.7	0.58	9.24e-26	Breast cancer;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg14161438	chr18:72920197	ZADH2	0.48	6.78	0.38	7.81e-11	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.55	0.37	2.91e-10	Prudent dietary pattern;
CESC	cis	rs2836974	0.644	rs2836982	chr21:40689171	C/A	cg17971929	chr21:40555470	PSMG1	-0.84	-12.15	-0.6	2.69e-27	Cognitive function;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg02196227	chr4:89080292	ABCG2	0.42	6.16	0.35	2.69e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs1348850	0.567	rs3770011	chr2:178537890	C/T	cg23306229	chr2:178417860	TTC30B	0.51	6.16	0.35	2.68e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	trans	rs11098499	0.780	rs7680914	chr4:120563053	A/G	cg25214090	chr10:38739885	LOC399744	0.68	9.47	0.5	1.66e-18	Corneal astigmatism;
CESC	cis	rs1475911	0.708	rs56185023	chr21:43521538	T/C	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.46	-7.17	-0.4	7.32e-12	IgG glycosylation;
CESC	cis	rs34779708	0.931	rs35848945	chr10:35287561	G/T	cg04310649	chr10:35416472	CREM	-0.48	-5.78	-0.33	2.07e-8	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs10504229	1.000	rs7007805	chr8:58179327	G/A	cg14926445	chr8:58193284	C8orf71	-0.51	-5.47	-0.32	1.03e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs10751667	0.666	rs7943140	chr11:973824	T/C	cg20946044	chr11:1010712	AP2A2	-0.39	-5.32	-0.31	2.24e-7	Alzheimer's disease (late onset);
CESC	cis	rs17407555	0.647	rs55811736	chr4:10014221	G/A	cg11266682	chr4:10021025	SLC2A9	-0.51	-6.08	-0.35	4.18e-9	Schizophrenia (age at onset);
CESC	cis	rs1348850	0.574	rs13431105	chr2:178434674	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.63	5.39	0.31	1.57e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg15232450	chr3:4345438	SETMAR	-0.41	-6.1	-0.35	3.66e-9	Gambling;
CESC	cis	rs9733	0.519	rs12095002	chr1:150649249	G/A	cg04414720	chr1:150670196	GOLPH3L	0.63	9.01	0.48	4.11e-17	Tonsillectomy;
CESC	cis	rs73206853	0.841	rs28480627	chr12:110834659	T/C	cg12870014	chr12:110450643	ANKRD13A	0.63	5.23	0.31	3.48e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs8002861	0.754	rs7330760	chr13:44403088	A/T	cg19180546	chr13:44453867	C13orf31;CCDC122	-0.39	-5.12	-0.3	6.01e-7	Leprosy;
CESC	cis	rs10789491	1.000	rs1545206	chr1:47185082	C/G	cg15501359	chr1:47185051	KIAA0494	0.82	9.02	0.48	3.92e-17	Response to hepatitis C treatment;
CESC	cis	rs2295499	0.673	rs55688738	chr4:2704628	G/C	cg27239842	chr4:2403781	ZFYVE28	-0.33	-5.54	-0.32	7.32e-8	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
CESC	cis	rs1580019	0.523	rs9791770	chr7:32582252	C/A	cg07520158	chr7:32535189	LSM5;AVL9	0.52	6.45	0.37	5.36e-10	Cognitive ability;
CESC	cis	rs4654899	1.000	rs6659152	chr1:21355841	C/G	cg05370193	chr1:21551575	ECE1	0.4	6.14	0.35	3.03e-9	Superior frontal gyrus grey matter volume;
CESC	cis	rs11718455	0.960	rs13083325	chr3:44005333	T/C	cg08738300	chr3:44038990	NA	0.46	6.12	0.35	3.34e-9	Coronary artery disease;
CESC	cis	rs4665809	1.000	rs4665821	chr2:26309949	A/C	cg25036284	chr2:26402008	FAM59B	-0.58	-6.73	-0.38	1.04e-10	Gut microbiome composition (summer);
CESC	cis	rs10129255	0.785	rs10150044	chr14:107183934	T/A	cg23076370	chr14:107095027	NA	-0.47	-6.15	-0.35	2.81e-9	Kawasaki disease;
CESC	cis	rs1983170	0.778	rs906241	chr1:92012154	G/T	cg21854759	chr1:92012499	NA	-0.52	-5.71	-0.33	3.02e-8	Eosinophil percentage of white cells;
CESC	cis	rs4727027	0.901	rs11760293	chr7:148811725	A/G	cg23583168	chr7:148888333	NA	-0.79	-12.22	-0.6	1.51e-27	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs523522	0.892	rs4767916	chr12:121024032	T/C	cg27279351	chr12:120934652	DYNLL1	0.69	8.86	0.48	1.2e-16	High light scatter reticulocyte count;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg03925809	chr19:6393419	GTF2F1	0.47	6.6	0.38	2.22e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs4237845	0.804	rs11172372	chr12:58286273	T/C	cg02175503	chr12:58329896	NA	0.62	8.94	0.48	6.68e-17	Intelligence (multi-trait analysis);
CESC	cis	rs12451471	0.637	rs7567	chr17:78093549	G/T	cg24585782	chr17:78113791	EIF4A3	-0.61	-7.91	-0.44	6.83e-14	Plateletcrit;Mean corpuscular hemoglobin concentration;
CESC	cis	rs7762018	0.556	rs78233989	chr6:170102041	C/G	cg19338460	chr6:170058176	WDR27	-1.04	-8.47	-0.46	1.75e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs4713118	0.513	rs9368547	chr6:28028067	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.46	-5.92	-0.34	1e-8	Parkinson's disease;
CESC	cis	rs17711722	0.701	rs781145	chr7:65440370	A/C	cg14393609	chr7:65229607	NA	0.52	6.98	0.39	2.33e-11	Calcium levels;
CESC	cis	rs7084402	0.934	rs1658471	chr10:60291911	A/T	cg07615347	chr10:60278583	BICC1	0.6	9.41	0.5	2.54e-18	Refractive error;
CESC	cis	rs7809950	0.678	rs2107317	chr7:106899685	T/C	cg23024343	chr7:107201750	COG5	-0.54	-6.86	-0.39	4.86e-11	Coronary artery disease;
CESC	cis	rs9649213	0.593	rs3801264	chr7:97950620	A/G	cg24562669	chr7:97807699	LMTK2	0.48	7.1	0.4	1.13e-11	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs611744	0.538	rs13257548	chr8:109273185	G/A	cg21045802	chr8:109455806	TTC35	0.56	6.95	0.39	2.89e-11	Dupuytren's disease;
CESC	cis	rs2243480	0.522	rs12698511	chr7:65474919	G/T	cg13147721	chr7:65941812	NA	-0.84	-6.4	-0.37	6.86e-10	Diabetic kidney disease;
CESC	cis	rs477692	0.905	rs576560	chr10:131420697	C/A	cg05714579	chr10:131428358	MGMT	0.55	7.88	0.44	8.39e-14	Response to temozolomide;
CESC	cis	rs9611565	0.592	rs5996038	chr22:41965300	T/C	cg17376030	chr22:41985996	PMM1	0.54	5.98	0.35	7.02e-9	Vitiligo;
CESC	cis	rs909002	0.800	rs11589306	chr1:32082822	C/G	cg13919466	chr1:32135498	COL16A1	-0.46	-8.26	-0.45	6.82e-15	Intelligence (multi-trait analysis);
CESC	cis	rs17376456	0.757	rs6859757	chr5:93206042	C/T	cg21475434	chr5:93447410	FAM172A	0.86	7.46	0.42	1.2e-12	Diabetic retinopathy;
CESC	cis	rs6570726	0.791	rs405206	chr6:145836873	C/A	cg23711669	chr6:146136114	FBXO30	1.02	15.96	0.7	1.2e-40	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7772486	0.875	rs2224121	chr6:146343214	G/A	cg05347473	chr6:146136440	FBXO30	0.49	6.36	0.36	8.84e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs763121	0.853	rs35565791	chr22:39063011	C/A	cg14440974	chr22:39074834	NA	-0.42	-5.82	-0.34	1.69e-8	Menopause (age at onset);
CESC	cis	rs6570726	0.935	rs447818	chr6:145868996	C/T	cg05347473	chr6:146136440	FBXO30	0.46	6.16	0.35	2.72e-9	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs920590	0.684	rs59259846	chr8:19669468	C/G	cg01411142	chr8:19674711	INTS10	0.56	6.19	0.36	2.24e-9	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs9900062	1.000	rs2521879	chr17:62742678	A/G	cg02598441	chr17:62777298	LOC146880	-0.5	-5.27	-0.31	2.87e-7	QT interval;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20149956	chr1:249132233	ZNF672	0.55	6.71	0.38	1.18e-10	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13520342	chr11:18230799	LOC494141	-0.43	-6.1	-0.35	3.72e-9	Gut microbiome composition (summer);
CESC	cis	rs1707322	0.752	rs11211145	chr1:46108491	A/C	cg05343316	chr1:45956843	TESK2	0.47	5.39	0.31	1.57e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9660992	0.674	rs72745219	chr1:205262271	G/A	cg00857998	chr1:205179979	DSTYK	0.49	5.51	0.32	8.52e-8	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs10876993	0.928	rs2928053	chr12:58063475	T/C	cg18357645	chr12:58087776	OS9	0.64	10.4	0.54	1.75e-21	Celiac disease or Rheumatoid arthritis;
CESC	cis	rs2204008	0.811	rs11520277	chr12:38359611	G/A	cg13010199	chr12:38710504	ALG10B	0.45	5.77	0.33	2.24e-8	Bladder cancer;
CESC	cis	rs7833790	0.963	rs28823280	chr8:82777716	G/A	cg02079420	chr8:82753780	SNX16	-0.58	-7.74	-0.43	2.15e-13	Diastolic blood pressure;
CESC	cis	rs7639513	0.767	rs7617041	chr3:12709167	A/G	cg23032965	chr3:12705835	RAF1	0.76	10.86	0.55	5.83e-23	Itch intensity from mosquito bite;
CESC	cis	rs12950390	0.853	rs12450729	chr17:45855363	A/G	cg00777063	chr17:45855553	NA	-0.39	-5.74	-0.33	2.62e-8	IgG glycosylation;
CESC	cis	rs10883723	0.810	rs10748823	chr10:104274465	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.55	7.58	0.42	5.73e-13	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs1801251	1.000	rs1801251	chr2:233633460	G/A	cg25237894	chr2:233734115	C2orf82	0.45	7.9	0.44	7.6e-14	Coronary artery disease;
CESC	cis	rs561341	0.941	rs17780086	chr17:30343282	G/A	cg19193384	chr17:30244184	NA	-0.7	-6.34	-0.36	9.87e-10	Hip circumference adjusted for BMI;
CESC	trans	rs8060598	0.548	rs4785453	chr16:50842162	C/T	cg00849365	chr16:5074999	NAGPA	-0.38	-6.16	-0.35	2.71e-9	Leprosy;
CESC	cis	rs7666738	0.830	rs13148913	chr4:99009732	C/T	cg17366294	chr4:99064904	C4orf37	0.6	8.62	0.47	6.37e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2073300	0.609	rs6137938	chr20:23389127	C/G	cg16736954	chr20:23401023	NAPB	0.76	6.0	0.35	6.44e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs6460942	1.000	rs17274870	chr7:12406221	G/T	cg02935154	chr7:12443704	VWDE	-0.57	-5.89	-0.34	1.16e-8	Coronary artery disease;
CESC	cis	rs17826219	0.636	rs12946563	chr17:29103166	C/G	cg13385521	chr17:29058706	SUZ12P	0.77	6.15	0.35	2.81e-9	Body mass index;
CESC	trans	rs5756813	0.754	rs762982	chr22:38144235	A/G	cg19894588	chr14:64061835	NA	0.66	7.67	0.43	3.21e-13	Optic cup area;Vertical cup-disc ratio;
CESC	cis	rs4665809	1.000	rs11126375	chr2:26344787	G/A	cg04944784	chr2:26401820	FAM59B	-0.66	-7.62	-0.42	4.62e-13	Gut microbiome composition (summer);
CESC	cis	rs4434138	0.594	rs7653028	chr3:52763000	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	8.38	0.46	3.05e-15	Intelligence (multi-trait analysis);
CESC	cis	rs4969178	0.965	rs12451715	chr17:76397334	A/C	cg20026190	chr17:76395443	PGS1	0.49	7.81	0.43	1.34e-13	HDL cholesterol levels;
CESC	cis	rs1552244	1.000	rs2272125	chr3:10138069	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.84	-11.65	-0.58	1.38e-25	Alzheimer's disease;
CESC	cis	rs6831352	0.840	rs17817868	chr4:100060623	C/T	cg12011299	chr4:100065546	ADH4	-0.59	-6.59	-0.38	2.35e-10	Alcohol dependence;
CESC	cis	rs4727027	0.522	rs6956736	chr7:148893472	G/C	cg23583168	chr7:148888333	NA	-0.81	-10.14	-0.53	1.28e-20	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs992157	0.560	rs6436048	chr2:219109033	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.58	7.26	0.41	4.4e-12	Colorectal cancer;
CESC	cis	rs4835937	0.670	rs10064559	chr5:127329683	C/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.56	5.08	0.3	7.26e-7	Cancer;
CESC	cis	rs6952808	0.931	rs12537479	chr7:1868995	A/G	cg04267008	chr7:1944627	MAD1L1	0.55	6.72	0.38	1.11e-10	Bipolar disorder and schizophrenia;
CESC	cis	rs896854	0.818	rs896855	chr8:95959808	A/G	cg09323728	chr8:95962352	TP53INP1	-0.43	-9.53	-0.51	1.07e-18	Type 2 diabetes;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg19155557	chr3:41240643	CTNNB1	-0.52	-7.34	-0.41	2.61e-12	Gut microbiota (bacterial taxa);
CESC	cis	rs9581857	0.579	rs76657892	chr13:27997604	A/G	cg22138327	chr13:27999177	GTF3A	0.64	5.43	0.32	1.26e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
CESC	cis	rs2842992	0.830	rs1853259	chr6:160147441	A/G	cg11366901	chr6:160182831	ACAT2	-0.84	-10.96	-0.56	2.59e-23	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs1707322	0.758	rs10789474	chr1:46250040	G/T	cg06784218	chr1:46089804	CCDC17	0.37	6.34	0.36	1e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg21314839	chr13:114782035	RASA3	0.44	6.29	0.36	1.31e-9	Fibrinogen levels;
CESC	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.89	13.47	0.64	7.58e-32	Prudent dietary pattern;
CESC	cis	rs9457247	0.565	rs2239823	chr6:167512131	T/C	cg23791538	chr6:167370224	RNASET2	-0.54	-7.06	-0.4	1.48e-11	Crohn's disease;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg09698166	chr20:21106763	PLK1S1	-0.42	-6.3	-0.36	1.21e-9	Gambling;
CESC	cis	rs1461503	0.932	rs10892944	chr11:122843895	T/C	cg27398637	chr11:122830231	C11orf63	-0.55	-8.26	-0.45	7.22e-15	Menarche (age at onset);
CESC	cis	rs7666738	0.830	rs9884501	chr4:98893721	A/C	cg17366294	chr4:99064904	C4orf37	0.55	7.59	0.42	5.41e-13	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3785574	0.962	rs62077509	chr17:61848973	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.81	10.76	0.55	1.2e-22	Height;
CESC	cis	rs854765	0.964	rs854810	chr17:18006421	G/C	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.47	-5.98	-0.34	7.09e-9	Total body bone mineral density;
CESC	cis	rs9322193	0.886	rs9767555	chr6:149968158	T/C	cg13206674	chr6:150067644	NUP43	0.37	5.18	0.3	4.36e-7	Lung cancer;
CESC	cis	rs17293817	0.618	rs35057480	chr10:1430947	A/T	cg04271617	chr10:1416546	ADARB2	0.33	5.05	0.3	8.1e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs7811142	0.830	rs6955367	chr7:99961194	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.08	14.1	0.65	4.76e-34	Platelet count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01849047	chr16:3646322	BTBD12	-0.52	-6.14	-0.35	3.07e-9	Gut microbiome composition (summer);
CESC	cis	rs4899260	0.779	rs4899261	chr14:69283375	C/T	cg03189333	chr14:69283534	NA	-0.44	-5.03	-0.3	8.88e-7	Celiac disease;
CESC	cis	rs763121	0.853	rs4821816	chr22:39113134	G/A	cg14440974	chr22:39074834	NA	-0.35	-5.13	-0.3	5.71e-7	Menopause (age at onset);
CESC	cis	rs34779708	0.966	rs4934734	chr10:35434373	T/C	cg03585969	chr10:35415529	CREM	0.75	9.84	0.52	1.09e-19	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs7923609	1.000	rs10761723	chr10:64955581	C/T	cg01631684	chr10:65280961	REEP3	-0.45	-5.56	-0.32	6.51e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg02621907	chr5:93954419	ANKRD32;C5orf36	-0.46	-6.74	-0.38	1e-10	Gambling;
CESC	cis	rs909002	0.742	rs12032291	chr1:32129041	A/G	cg13919466	chr1:32135498	COL16A1	0.43	7.47	0.42	1.19e-12	Intelligence (multi-trait analysis);
CESC	cis	rs1552244	0.706	rs279545	chr3:9972493	A/G	cg08888203	chr3:10149979	C3orf24	0.41	5.77	0.33	2.15e-8	Alzheimer's disease;
CESC	cis	rs11098499	0.954	rs56270433	chr4:120406030	C/T	cg24375607	chr4:120327624	NA	0.45	5.52	0.32	8.1e-8	Corneal astigmatism;
CESC	cis	rs3857067	0.806	rs6532471	chr4:95108584	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.6	-9.05	-0.49	3.25e-17	QT interval;
CESC	cis	rs7927771	0.507	rs10838759	chr11:47785347	T/C	cg18512352	chr11:47633146	NA	0.34	5.3	0.31	2.38e-7	Subjective well-being;
CESC	cis	rs4665809	1.000	rs4665823	chr2:26312723	A/G	cg22920501	chr2:26401640	FAM59B	-0.66	-7.93	-0.44	6.28e-14	Gut microbiome composition (summer);
CESC	cis	rs12618769	0.652	rs4851146	chr2:99237439	A/G	cg10123293	chr2:99228465	UNC50	0.42	5.58	0.32	6.08e-8	Bipolar disorder;
CESC	trans	rs5756813	0.754	rs5750495	chr22:38179120	T/A	cg19894588	chr14:64061835	NA	0.67	8.47	0.46	1.76e-15	Optic cup area;Vertical cup-disc ratio;
CESC	cis	rs875971	1.000	rs11974264	chr7:65647582	C/G	cg11764359	chr7:65958608	NA	-0.92	-14.66	-0.67	5e-36	Aortic root size;
CESC	cis	rs1048257	0.553	rs2819421	chr14:105408811	A/G	cg15352829	chr14:105391018	PLD4	-0.58	-9.88	-0.52	8.19e-20	Systemic lupus erythematosus;
CESC	trans	rs10895547	0.527	rs559828	chr11:103790829	C/T	cg23613023	chr12:115353932	NA	-0.38	-6.22	-0.36	1.96e-9	LDL cholesterol;
CESC	cis	rs1348850	0.958	rs11684320	chr2:178456346	T/C	cg23306229	chr2:178417860	TTC30B	0.57	7.44	0.42	1.43e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs7666738	0.830	rs4699580	chr4:98930673	T/C	cg03467027	chr4:99064603	C4orf37	0.46	5.6	0.33	5.39e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3862030	0.720	rs7341995	chr10:104223831	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.38	-5.23	-0.31	3.51e-7	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
CESC	cis	rs10781543	0.817	rs1128874	chr9:139323424	T/C	cg14169450	chr9:139327907	INPP5E	0.55	8.62	0.47	6.16e-16	Monocyte percentage of white cells;
CESC	cis	rs780096	0.565	rs8179252	chr2:27746832	A/C	cg12648201	chr2:27665141	KRTCAP3	-0.31	-5.76	-0.33	2.37e-8	Total body bone mineral density;
CESC	cis	rs847577	0.609	rs11768309	chr7:97773812	G/T	cg24562669	chr7:97807699	LMTK2	0.85	14.61	0.67	7.13e-36	Breast cancer;
CESC	cis	rs113835537	0.529	rs11227511	chr11:66281244	A/C	cg24851651	chr11:66362959	CCS	0.43	5.38	0.31	1.63e-7	Airway imaging phenotypes;
CESC	trans	rs11098499	1.000	rs11726229	chr4:120211580	C/T	cg25214090	chr10:38739885	LOC399744	0.68	9.37	0.5	3.4e-18	Corneal astigmatism;
CESC	cis	rs11098499	0.863	rs3733525	chr4:120447048	A/G	cg09307838	chr4:120376055	NA	0.92	12.61	0.61	7.4e-29	Corneal astigmatism;
CESC	cis	rs10504229	0.683	rs10504225	chr8:58145121	A/T	cg24829409	chr8:58192753	C8orf71	-0.54	-6.79	-0.39	7.19e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs853679	0.517	rs4713135	chr6:28039586	G/A	cg08968635	chr6:28129556	ZNF389	0.39	5.14	0.3	5.33e-7	Depression;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg03239202	chr2:68694299	FBXO48;APLF	0.49	6.09	0.35	4e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs7520050	0.751	rs2230657	chr1:46073489	G/A	cg24296786	chr1:45957014	TESK2	0.47	5.78	0.33	2.05e-8	Red blood cell count;Reticulocyte count;
CESC	cis	rs1799949	0.965	rs4793204	chr17:41279298	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.67	9.34	0.5	3.98e-18	Menopause (age at onset);
CESC	cis	rs13256369	1.000	rs7004438	chr8:8574379	C/T	cg17143192	chr8:8559678	CLDN23	0.74	8.73	0.47	2.86e-16	Obesity-related traits;
CESC	cis	rs7129220	0.512	rs2119991	chr11:10226268	A/G	cg01453529	chr11:10209919	SBF2	-0.47	-5.79	-0.33	2.01e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CESC	trans	rs12599106	0.707	rs2163977	chr16:34916134	A/G	cg01171360	chr6:293285	DUSP22	-0.63	-8.12	-0.45	1.81e-14	Menopause (age at onset);
CESC	cis	rs12497850	0.931	rs7628719	chr3:48995487	C/T	cg06212747	chr3:49208901	KLHDC8B	0.73	10.06	0.53	2.28e-20	Parkinson's disease;
CESC	cis	rs950776	0.518	rs12902493	chr15:78819275	C/G	cg06917634	chr15:78832804	PSMA4	0.76	11.15	0.57	6.26e-24	Sudden cardiac arrest;
CESC	cis	rs1552244	1.000	rs12374115	chr3:10134766	A/G	cg08888203	chr3:10149979	C3orf24	-0.43	-5.71	-0.33	3.08e-8	Alzheimer's disease;
CESC	cis	rs1451375	0.794	rs11238133	chr7:50542914	A/C	cg18232548	chr7:50535776	DDC	-0.42	-5.34	-0.31	2e-7	Malaria;
CESC	cis	rs12477438	0.798	rs17708218	chr2:99696284	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.72	-10.79	-0.55	9.43e-23	Chronic sinus infection;
CESC	cis	rs910316	0.737	rs175055	chr14:75488946	T/G	cg16144293	chr14:75469539	EIF2B2	0.4	5.36	0.31	1.81e-7	Height;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg21702128	chr5:142784721	NR3C1	-0.44	-6.21	-0.36	2.03e-9	Gambling;
CESC	cis	rs7481584	0.962	rs11024759	chr11:2982092	T/C	cg25174290	chr11:3078921	CARS	-0.49	-5.94	-0.34	8.74e-9	Calcium levels;
CESC	cis	rs875971	0.862	rs13232191	chr7:65986648	A/G	cg19163074	chr7:65112434	INTS4L2	-0.43	-5.34	-0.31	2e-7	Aortic root size;
CESC	cis	rs765787	0.530	rs2554455	chr15:45521304	T/C	cg24006582	chr15:45444508	DUOX1	-0.57	-6.88	-0.39	4.36e-11	Uric acid levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12126796	chr10:123687380	ATE1	0.64	7.01	0.4	2.02e-11	Gut microbiome composition (summer);
CESC	trans	rs11098499	0.818	rs12498599	chr4:120468503	C/T	cg25214090	chr10:38739885	LOC399744	0.67	9.21	0.49	1.05e-17	Corneal astigmatism;
CESC	cis	rs6484504	0.553	rs413067	chr11:31223497	T/C	cg14844989	chr11:31128820	NA	-0.42	-5.96	-0.34	7.83e-9	Red blood cell count;
CESC	cis	rs2282802	0.685	rs2337082	chr5:139649201	G/A	cg26211634	chr5:139558579	C5orf32	0.52	7.49	0.42	1.05e-12	Intelligence (multi-trait analysis);
CESC	cis	rs7191700	0.836	rs28502009	chr16:11426541	G/A	cg00044050	chr16:11439710	C16orf75	0.48	5.65	0.33	4.2e-8	Multiple sclerosis;
CESC	cis	rs1218582	0.596	rs11264275	chr1:154825270	G/T	cg03351412	chr1:154909251	PMVK	-0.49	-6.11	-0.35	3.45e-9	Prostate cancer;
CESC	cis	rs8141529	0.732	rs5762815	chr22:29205076	A/G	cg02153584	chr22:29168773	CCDC117	0.68	9.65	0.51	4.34e-19	Lymphocyte counts;
CESC	trans	rs9325144	0.555	rs7960411	chr12:38703019	A/G	cg23762105	chr12:34175262	ALG10	0.49	6.38	0.36	7.75e-10	Morning vs. evening chronotype;
CESC	trans	rs9325144	0.723	rs1586373	chr12:39181582	G/A	cg23762105	chr12:34175262	ALG10	0.45	6.14	0.35	3.01e-9	Morning vs. evening chronotype;
CESC	cis	rs2354432	0.607	rs1530336	chr1:146685121	G/A	cg25205988	chr1:146714368	CHD1L	1.15	8.65	0.47	4.98e-16	Mitochondrial DNA levels;
CESC	cis	rs7927771	0.864	rs755554	chr11:47432034	G/C	cg05585544	chr11:47624801	NA	0.41	6.06	0.35	4.76e-9	Subjective well-being;
CESC	cis	rs950169	0.922	rs4842946	chr15:84942331	G/A	cg17507749	chr15:85114479	UBE2QP1	0.59	6.52	0.37	3.46e-10	Schizophrenia;
CESC	cis	rs9815354	0.627	rs80120812	chr3:42021760	C/T	cg03022575	chr3:42003672	ULK4	0.75	6.64	0.38	1.72e-10	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg05863683	chr7:1912471	MAD1L1	0.37	5.39	0.31	1.56e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs9611565	0.625	rs9607819	chr22:41958862	C/G	cg03806693	chr22:41940476	POLR3H	-1.07	-13.69	-0.64	1.25e-32	Vitiligo;
CESC	cis	rs763121	0.853	rs5750649	chr22:39036769	T/C	cg06022373	chr22:39101656	GTPBP1	0.95	17.36	0.73	1.37e-45	Menopause (age at onset);
CESC	cis	rs9926296	0.609	rs4785709	chr16:89796665	G/A	cg27121462	chr16:89883253	FANCA	-0.58	-7.04	-0.4	1.62e-11	Vitiligo;
CESC	cis	rs501120	0.925	rs1746049	chr10:44776310	C/T	cg09554077	chr10:44749378	NA	0.57	6.56	0.37	2.84e-10	Coronary artery disease;Coronary heart disease;
CESC	cis	rs6912958	0.781	rs9450712	chr6:88193175	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.44	-5.92	-0.34	1e-8	Monocyte percentage of white cells;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg24027378	chr17:46103806	COPZ2	-0.42	-6.06	-0.35	4.67e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs1832871	0.711	rs9457264	chr6:158689367	G/A	cg07165851	chr6:158734300	TULP4	0.59	6.23	0.36	1.87e-9	Height;
CESC	cis	rs67311347	1.000	rs12630072	chr3:40517190	T/G	cg24209194	chr3:40518798	ZNF619	0.5	6.15	0.35	2.84e-9	Renal cell carcinoma;
CESC	cis	rs4665809	0.652	rs6727974	chr2:26524639	A/G	cg04944784	chr2:26401820	FAM59B	0.64	7.09	0.4	1.24e-11	Gut microbiome composition (summer);
CESC	cis	rs763512	0.504	rs58201617	chr17:35865451	G/T	cg16670864	chr17:35848621	DUSP14	0.46	5.76	0.33	2.35e-8	3-hydroxypropylmercapturic acid levels in smokers;
CESC	cis	rs854765	0.718	rs6502629	chr17:17869642	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.48	6.28	0.36	1.39e-9	Total body bone mineral density;
CESC	cis	rs798554	1.000	rs798544	chr7:2763102	A/G	cg19346786	chr7:2764209	NA	0.51	7.51	0.42	8.81e-13	Height;
CESC	cis	rs7914558	0.966	rs11191471	chr10:104702050	T/A	cg08650961	chr10:104748594	CNNM2	0.32	5.06	0.3	7.88e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs3733585	0.605	rs4235355	chr4:10123078	C/A	cg11266682	chr4:10021025	SLC2A9	-0.57	-10.59	-0.55	4.39e-22	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs9911578	1.000	rs654778	chr17:56736473	A/C	cg05425664	chr17:57184151	TRIM37	-0.51	-7.21	-0.4	6.03e-12	Intelligence (multi-trait analysis);
CESC	cis	rs62005083	1.000	rs72725916	chr14:74508858	A/G	cg05179529	chr14:74551516	LIN52;ALDH6A1	0.7	5.22	0.31	3.68e-7	Mean corpuscular volume;
CESC	cis	rs9527	0.637	rs12219247	chr10:104613361	A/G	cg04362960	chr10:104952993	NT5C2	0.51	6.36	0.36	8.64e-10	Arsenic metabolism;
CESC	cis	rs10791323	0.572	rs4412766	chr11:133742811	A/C	cg15485101	chr11:133734466	NA	0.32	5.5	0.32	8.87e-8	Childhood ear infection;
CESC	cis	rs2204008	0.728	rs12369538	chr12:38443942	C/T	cg26384229	chr12:38710491	ALG10B	0.69	10.28	0.53	4.42e-21	Bladder cancer;
CESC	cis	rs7223966	1.000	rs9899788	chr17:61756384	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.58	7.42	0.41	1.55e-12	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs763121	0.853	rs5757203	chr22:39044152	G/C	cg21395723	chr22:39101663	GTPBP1	0.43	5.33	0.31	2.09e-7	Menopause (age at onset);
CESC	cis	rs9916302	0.851	rs7225096	chr17:37664443	T/C	cg19468946	chr17:37922297	IKZF3	-0.39	-5.08	-0.3	7.08e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs7044106	0.762	rs7044226	chr9:123466328	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.79	12.22	0.6	1.56e-27	Hip circumference adjusted for BMI;
CESC	cis	rs7666738	0.830	rs34870112	chr4:99045815	T/G	cg03467027	chr4:99064603	C4orf37	0.47	5.98	0.34	7.19e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1941023	0.584	rs2014121	chr11:60156297	T/C	cg08716584	chr11:60157161	MS4A7	-0.6	-10.18	-0.53	9e-21	Congenital heart disease (maternal effect);
CESC	cis	rs34779708	0.733	rs12249814	chr10:35542757	T/C	cg04310649	chr10:35416472	CREM	-0.47	-5.39	-0.31	1.59e-7	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs1152591	0.524	rs1255991	chr14:64661642	G/A	cg21174375	chr14:64681225	SYNE2	0.55	7.84	0.43	1.13e-13	Atrial fibrillation;
CESC	cis	rs9929218	1.000	rs17772363	chr16:68788909	G/T	cg02972257	chr16:68554789	NA	0.53	6.08	0.35	4.07e-9	Colorectal cancer;
CESC	trans	rs208520	0.690	rs2144081	chr6:66824972	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.01	-12.92	-0.62	5.99e-30	Exhaled nitric oxide output;
CESC	cis	rs2070488	0.775	rs11926767	chr3:38527913	A/G	cg24069376	chr3:38537580	EXOG	-0.33	-5.47	-0.32	1.05e-7	Electrocardiographic conduction measures;
CESC	cis	rs853679	0.517	rs9393901	chr6:28136797	A/G	cg22143856	chr6:28129313	ZNF389	0.46	5.83	0.34	1.58e-8	Depression;
CESC	cis	rs798554	0.679	rs2533870	chr7:2885274	C/G	cg19717773	chr7:2847554	GNA12	0.42	6.19	0.36	2.25e-9	Height;
CESC	cis	rs854765	0.647	rs854770	chr17:18019048	A/G	cg16928487	chr17:17741425	SREBF1	-0.46	-7.29	-0.41	3.49e-12	Total body bone mineral density;
CESC	cis	rs2228479	0.557	rs34420680	chr16:89809171	C/T	cg14709524	chr16:89940631	TCF25	0.94	6.97	0.39	2.46e-11	Skin colour saturation;
CESC	cis	rs727563	0.636	rs2413653	chr22:42106996	T/C	cg17376030	chr22:41985996	PMM1	-0.78	-8.43	-0.46	2.23e-15	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs5769765	1.000	rs5770742	chr22:50270309	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	0.46	5.32	0.31	2.21e-7	Schizophrenia;
CESC	cis	rs6991838	0.584	rs14213	chr8:66514954	C/T	cg13398993	chr8:66546079	ARMC1	0.45	5.39	0.31	1.58e-7	Intelligence (multi-trait analysis);
CESC	cis	rs10876993	0.855	rs1689601	chr12:58049557	G/A	cg18357645	chr12:58087776	OS9	0.6	9.28	0.5	6.25e-18	Celiac disease or Rheumatoid arthritis;
CESC	cis	rs6674176	0.628	rs12145999	chr1:44428632	C/T	cg13606994	chr1:44402422	ARTN	-0.38	-5.64	-0.33	4.28e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs1552244	0.935	rs6805869	chr3:10119917	T/C	cg08888203	chr3:10149979	C3orf24	0.55	7.2	0.4	6.16e-12	Alzheimer's disease;
CESC	cis	rs7412746	0.658	rs7528773	chr1:150915875	G/A	cg22823121	chr1:150693482	HORMAD1	0.4	5.7	0.33	3.2e-8	Melanoma;
CESC	cis	rs2710642	0.564	rs9989741	chr2:62828377	T/A	cg17519650	chr2:63277830	OTX1	0.48	6.38	0.36	7.95e-10	LDL cholesterol levels;LDL cholesterol;
CESC	trans	rs2085496	0.764	rs1596751	chr2:193807860	A/G	ch.12.74620632F	chr12:76334365	NA	0.47	6.21	0.36	2.01e-9	Neuroticism;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22416051	chr7:157455196	PTPRN2	-0.48	-6.49	-0.37	4.2e-10	Gut microbiome composition (summer);
CESC	cis	rs55728055	0.661	rs9619215	chr22:32042732	A/G	cg01338084	chr22:32026380	PISD	1.06	7.93	0.44	6.25e-14	Age-related hearing impairment;
CESC	cis	rs4713118	0.527	rs35949862	chr6:28115367	A/G	cg12963246	chr6:28129442	ZNF389	0.59	7.68	0.43	3e-13	Parkinson's disease;
CESC	cis	rs7208859	0.623	rs6505207	chr17:29076571	T/C	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.1e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs9815354	0.904	rs73073368	chr3:41843391	A/G	cg03022575	chr3:42003672	ULK4	0.7	6.04	0.35	5.26e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs977987	0.843	rs28655617	chr16:75489642	G/A	cg03315344	chr16:75512273	CHST6	0.44	6.4	0.37	7.1e-10	Dupuytren's disease;
CESC	cis	rs4595586	0.545	rs1607042	chr12:39368028	A/G	cg26384229	chr12:38710491	ALG10B	0.54	7.53	0.42	7.85e-13	Morning vs. evening chronotype;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg03402994	chr4:984131	SLC26A1;IDUA	0.45	6.19	0.36	2.25e-9	Fibrinogen levels;
CESC	trans	rs2388082	1.000	rs75787187	chr13:29962905	G/T	cg18754342	chr12:14849268	GUCY2C	-0.66	-6.18	-0.35	2.44e-9	Insomnia (caffeine-induced);
CESC	cis	rs2303759	0.918	rs1054770	chr19:49878115	G/A	cg22590775	chr19:49891494	CCDC155	0.59	7.01	0.4	2e-11	Multiple sclerosis;
CESC	cis	rs2286503	0.752	rs6461669	chr7:22858066	T/G	cg13679077	chr7:22862647	TOMM7	0.52	6.72	0.38	1.11e-10	Fibrinogen;
CESC	cis	rs4253772	0.530	rs715518	chr22:46754177	C/G	cg24881330	chr22:46731750	TRMU	0.8	5.71	0.33	3.03e-8	LDL cholesterol;Cholesterol, total;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg01736252	chr1:55181557	TTC4	-0.4	-6.3	-0.36	1.26e-9	Gambling;
CESC	cis	rs742614	0.533	rs6059496	chr20:32446931	T/C	cg06304546	chr20:32448765	NA	-0.49	-6.22	-0.36	1.92e-9	Stearic acid (18:0) levels;
CESC	cis	rs7772486	0.764	rs7762562	chr6:146158994	T/C	cg23711669	chr6:146136114	FBXO30	0.99	14.93	0.68	5.61e-37	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9894429	0.809	rs9889642	chr17:79591762	T/C	cg13777783	chr17:79615861	NA	-0.35	-5.79	-0.34	1.98e-8	Eye color traits;
CESC	cis	rs35110281	0.782	rs1584917	chr21:45042365	A/G	cg04455712	chr21:45112962	RRP1B	0.4	6.09	0.35	3.98e-9	Mean corpuscular volume;
CESC	trans	rs16949788	1.000	rs41306345	chr15:66782048	C/T	cg23949574	chr2:240302855	HDAC4	0.44	6.0	0.35	6.53e-9	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs4853012	0.838	rs2177707	chr2:74356850	A/G	cg19729930	chr2:74357872	NA	0.91	12.88	0.62	8.64e-30	Gestational age at birth (maternal effect);
CESC	cis	rs9815354	1.000	rs1016669	chr3:41894440	T/C	cg03022575	chr3:42003672	ULK4	0.45	5.23	0.31	3.48e-7	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs7208859	0.623	rs9893422	chr17:29111715	A/G	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.91e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs17666538	0.585	rs4735812	chr8:607766	C/G	cg23958373	chr8:599963	NA	0.81	5.88	0.34	1.26e-8	IgG glycosylation;
CESC	cis	rs9640161	0.789	rs60283368	chr7:150023258	G/A	cg21361702	chr7:150065534	REPIN1	0.46	5.4	0.31	1.46e-7	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs1775715	0.644	rs2799022	chr10:32137198	C/T	cg18675610	chr10:32216311	ARHGAP12	0.33	5.09	0.3	6.66e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg14893161	chr1:205819251	PM20D1	0.88	14.21	0.66	1.84e-34	Menarche (age at onset);
CESC	cis	rs3106136	0.967	rs35670996	chr4:95199479	C/G	cg11021082	chr4:95130006	SMARCAD1	-0.47	-7.13	-0.4	9.29e-12	Capecitabine sensitivity;
CESC	cis	rs34779708	0.966	rs10827491	chr10:35427395	G/A	cg03585969	chr10:35415529	CREM	0.76	10.3	0.53	3.72e-21	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs801193	0.569	rs10950050	chr7:66239588	A/C	cg12463550	chr7:65579703	CRCP	0.44	5.75	0.33	2.48e-8	Aortic root size;
CESC	cis	rs2302777	0.507	rs9889716	chr17:38108298	A/G	cg17467752	chr17:38218738	THRA	0.41	5.11	0.3	6.17e-7	Multiple myeloma (hyperdiploidy);
CESC	cis	rs6933660	0.720	rs6913515	chr6:151753470	G/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.83	13.61	0.64	2.37e-32	Menarche (age at onset);
CESC	cis	rs4891159	0.584	rs690397	chr18:74117767	C/T	cg24786174	chr18:74118243	ZNF516	0.85	16.07	0.7	4.75e-41	Longevity;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01554580	chr3:47324306	KIF9;KLHL18	0.56	6.02	0.35	5.7e-9	Gut microbiome composition (summer);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg00291003	chr10:75541506	CHCHD1	0.45	6.1	0.35	3.78e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs7084402	0.967	rs1658438	chr10:60326583	A/G	cg07615347	chr10:60278583	BICC1	-0.61	-9.62	-0.51	5.36e-19	Refractive error;
CESC	cis	rs4970988	0.556	rs6681426	chr1:150586971	G/A	cg17724175	chr1:150552817	MCL1	-0.51	-8.12	-0.45	1.73e-14	Urate levels;
CESC	cis	rs2243480	1.000	rs313832	chr7:65550891	G/T	cg13147721	chr7:65941812	NA	-1.02	-9.75	-0.51	2.11e-19	Diabetic kidney disease;
CESC	cis	rs853679	0.517	rs4713145	chr6:28106827	T/C	cg26335602	chr6:28129616	ZNF389	0.54	7.2	0.4	6.09e-12	Depression;
CESC	cis	rs4969178	1.000	rs4969178	chr17:76388202	C/T	cg20026190	chr17:76395443	PGS1	-0.4	-6.3	-0.36	1.21e-9	HDL cholesterol levels;
CESC	cis	rs9902453	0.765	rs1531553	chr17:28066752	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.76	-10.21	-0.53	7.5e-21	Coffee consumption (cups per day);
CESC	cis	rs9611565	0.659	rs9611602	chr22:41908405	T/C	cg06481639	chr22:41940642	POLR3H	-0.62	-6.44	-0.37	5.63e-10	Vitiligo;
CESC	cis	rs2836950	0.805	rs2836961	chr21:40627020	A/C	cg11644478	chr21:40555479	PSMG1	-0.53	-6.76	-0.38	8.71e-11	Menarche (age at onset);
CESC	cis	rs7527798	0.592	rs10746386	chr1:207855095	C/T	cg21110645	chr1:207815933	NA	-0.33	-5.86	-0.34	1.33e-8	Erythrocyte sedimentation rate;
CESC	cis	rs12477438	0.605	rs4585080	chr2:99557327	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.63	-8.91	-0.48	8.15e-17	Chronic sinus infection;
CESC	cis	rs2295499	0.715	rs2282766	chr4:2658327	G/A	cg08330972	chr4:2403930	ZFYVE28	-0.32	-5.22	-0.31	3.58e-7	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
CESC	cis	rs11785400	0.793	rs3735993	chr8:143741170	G/A	cg10596483	chr8:143751796	JRK	0.42	5.23	0.31	3.39e-7	Schizophrenia;
CESC	trans	rs2155929	0.627	rs9304531	chr18:26605972	C/T	cg25413575	chr17:80870577	TBCD	-0.39	-6.06	-0.35	4.66e-9	Temperament (bipolar disorder);
CESC	cis	rs769267	0.896	rs7250893	chr19:19625547	A/G	cg03709012	chr19:19516395	GATAD2A	1.0	15.82	0.7	3.95e-40	Tonsillectomy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17168242	chr1:149982704	OTUD7B	0.66	7.72	0.43	2.36e-13	Gut microbiome composition (summer);
CESC	cis	rs2576037	0.583	rs9954336	chr18:44465945	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.79	13.17	0.63	7.92e-31	Personality dimensions;
CESC	cis	rs875971	0.545	rs2420456	chr7:65745606	T/G	cg11764359	chr7:65958608	NA	0.8	9.99	0.52	3.86e-20	Aortic root size;
CESC	trans	rs7839040	0.698	rs12548655	chr8:82932088	A/G	cg14472086	chr9:107730925	NA	-0.48	-6.45	-0.37	5.4e-10	Response to methotrexate in juvenile idiopathic arthritis;
CESC	trans	rs2727020	0.553	rs4980447	chr11:49591662	T/C	cg03929089	chr4:120376271	NA	-0.71	-8.18	-0.45	1.21e-14	Coronary artery disease;
CESC	cis	rs9486715	0.838	rs9386576	chr6:96954717	C/T	cg18709589	chr6:96969512	KIAA0776	0.46	6.48	0.37	4.41e-10	Headache;
CESC	cis	rs10743315	0.643	rs17505214	chr12:19307139	A/G	cg02471346	chr12:19282374	PLEKHA5	0.78	5.94	0.34	9.04e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs1790761	0.505	rs17593068	chr11:67350932	G/T	cg14500267	chr11:67383377	NA	-0.31	-5.12	-0.3	5.81e-7	Mean corpuscular volume;
CESC	cis	rs34938134	0.686	rs7541633	chr1:245503899	C/G	cg15057323	chr1:245496060	KIF26B	0.4	5.12	0.3	5.79e-7	Daytime sleep phenotypes;
CESC	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg03188948	chr7:1209495	NA	0.7	6.88	0.39	4.39e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs17125944	0.615	rs12590862	chr14:53297008	A/G	cg00686598	chr14:53173677	PSMC6	-0.69	-5.97	-0.34	7.62e-9	Alzheimer's disease (late onset);
CESC	cis	rs4589502	1.000	rs2414925	chr15:67129986	A/G	cg12317470	chr15:67143691	NA	0.67	5.62	0.33	4.71e-8	Lung cancer (smoking interaction);
CESC	trans	rs11039798	0.623	rs7294273	chr11:48705374	T/C	cg15704280	chr7:45808275	SEPT13	0.65	6.5	0.37	4.05e-10	Axial length;
CESC	cis	rs9733	0.519	rs72704603	chr1:150707992	C/T	cg17724175	chr1:150552817	MCL1	0.43	6.96	0.39	2.67e-11	Tonsillectomy;
CESC	cis	rs116095464	0.558	rs62344345	chr5:257420	C/T	cg10591111	chr5:226296	SDHA	-0.51	-6.15	-0.35	2.84e-9	Breast cancer;
CESC	cis	rs1799949	0.965	rs8176198	chr17:41230537	A/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.42	5.63	0.33	4.54e-8	Menopause (age at onset);
CESC	cis	rs6982240	0.514	rs72681579	chr8:142263074	G/A	cg00131261	chr8:142287264	NA	-0.53	-7.39	-0.41	1.97e-12	Tonsillectomy;
CESC	cis	rs782590	0.967	rs35504023	chr2:55806503	C/T	cg18811423	chr2:55921094	PNPT1	-0.77	-12.36	-0.6	5.23e-28	Metabolic syndrome;
CESC	cis	rs2242194	0.816	rs2242193	chr1:154995503	A/G	cg12436631	chr1:155007014	DCST1;DCST2	-0.46	-8.08	-0.44	2.37e-14	Schizophrenia;
CESC	cis	rs10504229	0.680	rs16921675	chr8:58052082	A/G	cg22535103	chr8:58192502	C8orf71	-0.63	-7.09	-0.4	1.25e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs4862750	0.872	rs7671914	chr4:187878165	A/G	cg07414643	chr4:187882934	NA	0.59	8.57	0.47	8.61e-16	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs11098499	0.909	rs28555550	chr4:120211040	C/G	cg25214090	chr10:38739885	LOC399744	0.68	9.37	0.5	3.4e-18	Corneal astigmatism;
CESC	cis	rs7296418	0.961	rs11613937	chr12:123520071	C/T	cg00376283	chr12:123451042	ABCB9	0.77	11.23	0.57	3.44e-24	Platelet count;
CESC	cis	rs2073300	0.609	rs3746737	chr20:23424638	C/T	cg16736954	chr20:23401023	NAPB	0.73	5.23	0.31	3.38e-7	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs7524258	0.868	rs1304711	chr1:7270320	G/T	cg07173049	chr1:7289937	CAMTA1	-0.39	-5.81	-0.34	1.77e-8	Tourette's syndrome or obsessive-compulsive disorder;
CESC	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.41	-5.17	-0.3	4.71e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs265548	0.646	rs36689	chr19:17910639	A/G	cg00024989	chr19:17902242	NA	0.44	7.52	0.42	8.31e-13	Tumor biomarkers;
CESC	cis	rs2777491	0.874	rs7161772	chr15:41611066	A/T	cg20272979	chr15:41787780	ITPKA	0.36	5.16	0.3	4.84e-7	Ulcerative colitis;
CESC	cis	rs2243480	1.000	rs160652	chr7:65538431	A/G	cg13147721	chr7:65941812	NA	-1.02	-9.64	-0.51	4.9e-19	Diabetic kidney disease;
CESC	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg10295955	chr4:187884368	NA	-1.08	-22.71	-0.81	3.93e-64	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2439831	0.681	rs2242067	chr15:43699303	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.9	9.42	0.5	2.25e-18	Lung cancer in ever smokers;
CESC	cis	rs2273669	0.667	rs12212402	chr6:109306681	T/C	cg05315195	chr6:109294784	ARMC2	-0.65	-6.08	-0.35	4.15e-9	Prostate cancer;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg00810945	chr16:21964237	UQCRC2	-0.47	-6.33	-0.36	1.03e-9	Height;
CESC	cis	rs514406	0.798	rs4351588	chr1:53263826	A/T	cg16325326	chr1:53192061	ZYG11B	-0.63	-9.58	-0.51	7.64e-19	Monocyte count;
CESC	cis	rs6964587	1.000	rs2285333	chr7:91667692	T/G	cg17063962	chr7:91808500	NA	0.6	8.31	0.45	4.96e-15	Breast cancer;
CESC	cis	rs7618915	0.547	rs11130317	chr3:52731483	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	6.96	0.39	2.64e-11	Bipolar disorder;
CESC	cis	rs9611565	0.512	rs1983576	chr22:42166486	G/A	cg03806693	chr22:41940476	POLR3H	1.18	13.88	0.65	2.76e-33	Vitiligo;
CESC	cis	rs2439831	0.850	rs28413881	chr15:44174099	G/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.61	5.19	0.3	4.12e-7	Lung cancer in ever smokers;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg23029715	chr19:42363959	RPS19	-0.45	-6.32	-0.36	1.13e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs763014	0.931	rs59476302	chr16:629006	C/T	cg07256732	chr16:621771	PIGQ	-0.3	-5.18	-0.3	4.3e-7	Height;
CESC	cis	rs4819052	1.000	rs13053002	chr21:46677854	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.84	10.79	0.55	9.54e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg25802871	chr7:2282184	FTSJ2;NUDT1	-0.47	-6.73	-0.38	1.04e-10	Gambling;
CESC	cis	rs2204008	0.603	rs4397954	chr12:38089157	T/C	cg13010199	chr12:38710504	ALG10B	0.53	6.43	0.37	5.77e-10	Bladder cancer;
CESC	cis	rs854765	0.663	rs12941550	chr17:17753828	C/A	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.5	-6.72	-0.38	1.1e-10	Total body bone mineral density;
CESC	cis	rs4253772	0.614	rs11090859	chr22:46687460	T/G	cg07012999	chr22:46692446	CN5H6.4;GTSE1	0.52	5.34	0.31	2.04e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs2228479	0.557	rs11641726	chr16:89891619	G/A	cg04013166	chr16:89971882	TCF25	0.73	5.77	0.33	2.2e-8	Skin colour saturation;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22377913	chr1:26758610	DHDDS	0.64	6.89	0.39	4.13e-11	Gut microbiome composition (summer);
CESC	trans	rs7618501	0.633	rs12496973	chr3:50002245	T/C	cg21659725	chr3:3221576	CRBN	0.49	6.79	0.38	7.26e-11	Intelligence (multi-trait analysis);
CESC	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg02353165	chr6:42928485	GNMT	0.85	13.12	0.63	1.23e-30	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs7772486	0.754	rs6570718	chr6:146088443	T/G	cg23711669	chr6:146136114	FBXO30	-0.99	-15.07	-0.68	1.76e-37	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6899676	0.539	rs16870736	chr6:10878371	C/G	cg03320827	chr6:10887367	SYCP2L	0.51	5.89	0.34	1.14e-8	Menopause (age at onset);
CESC	cis	rs9660992	0.590	rs1779411	chr1:205238530	C/T	cg21643547	chr1:205240462	TMCC2	-0.47	-6.34	-0.36	1.01e-9	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs6690583	1.000	rs6690464	chr1:85466369	A/G	cg22153463	chr1:85462885	MCOLN2	-0.77	-9.26	-0.49	7.39e-18	Serum sulfate level;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22748698	chr17:7146447	GABARAP	0.56	6.6	0.38	2.26e-10	Gut microbiome composition (summer);
CESC	cis	rs875971	0.825	rs28480509	chr7:66099224	A/G	cg10691866	chr7:65817282	TPST1	0.31	5.22	0.31	3.55e-7	Aortic root size;
CESC	cis	rs7582720	1.000	rs72936326	chr2:204054141	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.84	7.17	0.4	7.7e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs11252926	0.650	rs4880678	chr10:490472	G/A	cg18196295	chr10:418757	DIP2C	0.41	5.54	0.32	7.31e-8	Psychosis in Alzheimer's disease;
CESC	cis	rs8017423	0.935	rs716122	chr14:90792313	A/C	cg14092571	chr14:90743983	NA	0.54	8.19	0.45	1.11e-14	Mortality in heart failure;
CESC	cis	rs710865	1.000	rs710866	chr1:19568722	G/C	cg13387374	chr1:19411106	UBR4	0.56	7.44	0.42	1.44e-12	Brain structure;
CESC	cis	rs2227631	0.505	rs12530730	chr7:100758591	T/A	cg18465962	chr7:100767262	NA	0.56	9.16	0.49	1.51e-17	Plasminogen activator inhibitor type 1 levels (PAI-1);
CESC	cis	rs11122272	0.766	rs1435166	chr1:231502310	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.58	-8.04	-0.44	2.95e-14	Hemoglobin concentration;
CESC	cis	rs2274273	0.870	rs1109170	chr14:55785788	A/C	cg04306507	chr14:55594613	LGALS3	0.31	6.07	0.35	4.34e-9	Protein biomarker;
CESC	cis	rs7223966	0.960	rs2319990	chr17:61705397	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.45	-5.37	-0.31	1.75e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs7618915	0.547	rs12496476	chr3:52708737	A/G	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.66	0.38	1.54e-10	Bipolar disorder;
CESC	cis	rs2303759	0.709	rs2278405	chr19:49812403	A/C	cg22307029	chr19:49891270	CCDC155	-0.55	-5.96	-0.34	8.11e-9	Multiple sclerosis;
CESC	cis	rs1215050	0.791	rs968854	chr4:98837863	T/C	cg05340658	chr4:99064831	C4orf37	0.5	6.44	0.37	5.57e-10	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs4925386	0.840	rs8124907	chr20:60913127	A/G	cg22633769	chr20:60982531	CABLES2	0.52	5.52	0.32	8.23e-8	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs12136530	0.593	rs10917443	chr1:19724079	A/C	cg01832549	chr1:19774989	CAPZB	-0.43	-6.21	-0.36	2.09e-9	Lead levels in blood;
CESC	cis	rs2732480	0.500	rs7297824	chr12:48598650	T/C	cg24011408	chr12:48396354	COL2A1	0.43	6.11	0.35	3.5e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs4688759	0.719	rs73079018	chr3:49875327	T/C	cg00383909	chr3:49044727	WDR6	0.85	5.49	0.32	9.46e-8	Blood protein levels;
CESC	cis	rs67460515	0.892	rs6780536	chr3:161058726	T/C	cg03342759	chr3:160939853	NMD3	-0.54	-7.86	-0.43	9.59e-14	Parkinson's disease;
CESC	cis	rs5769707	0.967	rs17182154	chr22:49990470	A/G	cg05373962	chr22:49881684	NA	-0.36	-6.18	-0.35	2.44e-9	Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs6426558	0.537	rs6682642	chr1:227244600	G/T	cg10327440	chr1:227177885	CDC42BPA	0.45	5.78	0.33	2.08e-8	Neutrophil percentage of white cells;
CESC	cis	rs10927875	0.562	rs10803401	chr1:16147377	G/A	cg21385522	chr1:16154831	NA	-1.02	-16.41	-0.71	2.97e-42	Dilated cardiomyopathy;
CESC	cis	rs863345	1.000	rs863353	chr1:158541270	C/A	cg12129480	chr1:158549410	OR10X1	-0.32	-6.46	-0.37	5.08e-10	Pneumococcal bacteremia;
CESC	trans	rs875971	0.638	rs10249404	chr7:66046724	G/A	cg26939375	chr7:64535504	NA	-0.63	-8.52	-0.46	1.25e-15	Aortic root size;
CESC	cis	rs4713118	0.516	rs4713142	chr6:28106347	T/G	cg22143856	chr6:28129313	ZNF389	0.52	6.77	0.38	8.31e-11	Parkinson's disease;
CESC	cis	rs4629710	0.645	rs35561719	chr6:131551244	G/A	cg12606694	chr6:131520996	AKAP7	0.48	5.92	0.34	9.77e-9	Multiple myeloma (IgH translocation);
CESC	cis	rs9894429	1.000	rs9747349	chr17:79584297	C/T	cg18240062	chr17:79603768	NPLOC4	0.72	10.27	0.53	4.71e-21	Eye color traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07160044	chr13:24735301	SPATA13;MIR2276	0.61	7.26	0.41	4.22e-12	Gut microbiome composition (summer);
CESC	cis	rs478304	0.651	rs11227279	chr11:65495211	G/A	cg10518572	chr11:65560635	OVOL1	-0.32	-6.19	-0.36	2.31e-9	Acne (severe);
CESC	cis	rs9303401	0.659	rs12602389	chr17:56779778	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.05	12.77	0.62	1.94e-29	Cognitive test performance;
CESC	trans	rs875971	0.895	rs778700	chr7:65866450	C/T	cg26939375	chr7:64535504	NA	0.47	6.06	0.35	4.77e-9	Aortic root size;
CESC	trans	rs11098499	0.779	rs10016060	chr4:120298412	A/G	cg25214090	chr10:38739885	LOC399744	0.68	9.2	0.49	1.14e-17	Corneal astigmatism;
CESC	cis	rs875971	0.895	rs4145009	chr7:65726615	T/C	cg18876405	chr7:65276391	NA	-0.54	-7.41	-0.41	1.7e-12	Aortic root size;
CESC	cis	rs6459804	0.844	rs76501205	chr7:157508941	A/T	cg05731713	chr7:157510257	PTPRN2	0.4	6.55	0.37	2.93e-10	Bipolar disorder and schizophrenia;
CESC	cis	rs780096	0.546	rs1528533	chr2:27595756	G/C	cg17158414	chr2:27665306	KRTCAP3	-0.32	-6.22	-0.36	1.98e-9	Total body bone mineral density;
CESC	cis	rs938554	0.736	rs11734219	chr4:9977154	C/T	cg00071950	chr4:10020882	SLC2A9	0.48	5.68	0.33	3.49e-8	Blood metabolite levels;
CESC	cis	rs3733585	0.726	rs4306953	chr4:9955776	G/A	cg00071950	chr4:10020882	SLC2A9	-0.69	-11.31	-0.57	1.83e-24	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg05313129	chr8:58192883	C8orf71	-0.48	-5.27	-0.31	2.89e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs941408	1.000	rs1736180	chr19:2796021	C/T	cg06609049	chr19:2785107	THOP1	0.74	10.87	0.56	5.35e-23	Total cholesterol levels;
CESC	cis	rs1865721	1.000	rs72977890	chr18:73198776	C/A	cg26385618	chr18:73139727	C18orf62	-0.52	-7.73	-0.43	2.26e-13	Intelligence;
CESC	cis	rs6570726	0.935	rs390252	chr6:145856896	A/G	cg05347473	chr6:146136440	FBXO30	0.48	6.44	0.37	5.7e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9303401	0.659	rs34878689	chr17:56694330	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.0	11.58	0.58	2.27e-25	Cognitive test performance;
CESC	cis	rs1879734	0.773	rs7518284	chr1:54150890	A/T	cg23596471	chr1:54105337	GLIS1	0.33	5.24	0.31	3.27e-7	Mitral valve prolapse;
CESC	cis	rs3733585	0.699	rs10017674	chr4:9967053	T/C	cg02734326	chr4:10020555	SLC2A9	-0.39	-5.58	-0.32	5.96e-8	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs1865760	0.566	rs9358904	chr6:26068566	C/T	cg16482183	chr6:26056742	HIST1H1C	0.4	5.4	0.31	1.49e-7	Height;
CESC	cis	rs12971120	0.891	rs4891558	chr18:72170359	A/G	cg26446133	chr18:72167187	CNDP2	-0.76	-9.29	-0.5	6.04e-18	Refractive error;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg16830545	chr17:17120324	FLCN	-0.45	-6.03	-0.35	5.46e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs13082711	0.863	rs77135084	chr3:27423549	A/C	cg02860705	chr3:27208620	NA	0.58	7.2	0.4	6.4e-12	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg09015484	chr9:96929106	NA	0.46	6.4	0.37	7.15e-10	Systemic lupus erythematosus;
CESC	cis	rs9487051	0.639	rs2884012	chr6:109598221	C/T	cg01475377	chr6:109611718	NA	-0.45	-7.04	-0.4	1.6e-11	Reticulocyte fraction of red cells;
CESC	cis	rs6951245	0.572	rs73264028	chr7:1045455	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.61	-5.44	-0.32	1.23e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7666738	0.830	rs6532723	chr4:99052147	A/T	cg18180107	chr4:99064573	C4orf37	0.41	5.29	0.31	2.51e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9457247	0.534	rs1130033	chr6:167385623	C/T	cg25258033	chr6:167368657	RNASET2	0.37	5.14	0.3	5.31e-7	Crohn's disease;
CESC	cis	rs3820068	0.581	rs72645864	chr1:15921153	C/T	cg16988262	chr1:15930761	NA	0.35	5.63	0.33	4.6e-8	Systolic blood pressure;
CESC	cis	rs523522	1.000	rs1563333	chr12:120934407	C/T	cg27279351	chr12:120934652	DYNLL1	0.69	8.94	0.48	6.79e-17	High light scatter reticulocyte count;
CESC	cis	rs4689592	0.523	rs6446565	chr4:7074027	A/G	cg26116260	chr4:7069785	GRPEL1	0.96	13.91	0.65	2.11e-33	Monocyte percentage of white cells;
CESC	cis	rs6952808	0.531	rs3779003	chr7:2184902	C/T	cg04267008	chr7:1944627	MAD1L1	-0.59	-7.05	-0.4	1.58e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs4268898	0.552	rs12621083	chr2:24367540	C/T	cg06627628	chr2:24431161	ITSN2	0.59	8.19	0.45	1.12e-14	Asthma;
CESC	cis	rs7666738	0.830	rs11731478	chr4:99001686	A/G	cg05340658	chr4:99064831	C4orf37	0.8	12.44	0.61	2.83e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9911578	1.000	rs11079365	chr17:56945430	T/C	cg05425664	chr17:57184151	TRIM37	-0.5	-6.96	-0.39	2.6e-11	Intelligence (multi-trait analysis);
CESC	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg07157834	chr1:205819609	PM20D1	0.73	10.38	0.54	2.17e-21	Menarche (age at onset);
CESC	cis	rs4604732	0.527	rs12031949	chr1:247624463	G/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.58	7.26	0.41	4.23e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs9660992	0.624	rs72745217	chr1:205261482	C/G	cg21643547	chr1:205240462	TMCC2	-0.47	-6.25	-0.36	1.6e-9	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs3820068	0.581	rs59991988	chr1:15950552	T/A	cg16988262	chr1:15930761	NA	0.34	5.47	0.32	1.04e-7	Systolic blood pressure;
CESC	cis	rs561341	1.000	rs8077092	chr17:30281992	T/C	cg19193384	chr17:30244184	NA	-0.62	-6.45	-0.37	5.21e-10	Hip circumference adjusted for BMI;
CESC	cis	rs4481887	0.861	rs6681336	chr1:248482756	C/T	cg00666640	chr1:248458726	OR2T12	0.34	5.64	0.33	4.3e-8	Common traits (Other);
CESC	cis	rs6496932	0.563	rs2344083	chr15:85897432	T/C	cg19183879	chr15:85880815	NA	-0.34	-6.16	-0.35	2.76e-9	Central corneal thickness;Corneal structure;
CESC	cis	rs2742234	0.910	rs2505513	chr10:43633537	C/G	cg07801480	chr10:43725741	RASGEF1A	0.39	5.64	0.33	4.27e-8	Hirschsprung disease;
CESC	cis	rs6938	0.597	rs11856413	chr15:75199892	A/G	cg14664628	chr15:75095509	CSK	-0.53	-6.93	-0.39	3.29e-11	Breast cancer;
CESC	cis	rs801193	0.569	rs2659907	chr7:66164032	G/A	cg18876405	chr7:65276391	NA	0.44	6.08	0.35	4.21e-9	Aortic root size;
CESC	cis	rs4808199	0.948	rs8108647	chr19:19427623	A/G	cg03709012	chr19:19516395	GATAD2A	1.08	11.69	0.58	9.9e-26	Nonalcoholic fatty liver disease;
CESC	cis	rs6460942	1.000	rs75333414	chr7:12303829	T/A	cg02935154	chr7:12443704	VWDE	-0.52	-5.52	-0.32	8.01e-8	Coronary artery disease;
CESC	cis	rs9291683	0.935	rs1860910	chr4:10275470	T/G	cg11266682	chr4:10021025	SLC2A9	0.47	8.4	0.46	2.71e-15	Bone mineral density;
CESC	cis	rs524281	0.731	rs6591203	chr11:65806229	G/A	cg14036092	chr11:66035641	RAB1B	0.5	5.08	0.3	7.08e-7	Electroencephalogram traits;
CESC	cis	rs2073300	0.609	rs17757442	chr20:23421101	A/G	cg12062639	chr20:23401060	NAPB	-1.06	-8.8	-0.48	1.81e-16	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs7618915	0.501	rs1468638	chr3:52748058	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.6	8.47	0.46	1.69e-15	Bipolar disorder;
CESC	cis	rs4862750	0.872	rs7672831	chr4:187898882	C/T	cg03452623	chr4:187889614	NA	-0.88	-16.39	-0.71	3.66e-42	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg00804338	chr13:114239234	TFDP1	-0.4	-6.09	-0.35	4.05e-9	Fibrinogen levels;
CESC	cis	rs11711311	0.955	rs9881563	chr3:113414031	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	-0.65	-8.83	-0.48	1.45e-16	IgG glycosylation;
CESC	trans	rs7246657	0.882	rs4803539	chr19:37897522	A/C	cg24637308	chr11:6592297	DNHD1	0.54	6.3	0.36	1.21e-9	Coronary artery calcification;
CESC	cis	rs35306767	0.714	rs7075188	chr10:1088746	G/T	cg26597838	chr10:835615	NA	-0.48	-5.28	-0.31	2.74e-7	Eosinophil percentage of granulocytes;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg14898140	chr17:66031871	KPNA2	-0.48	-6.62	-0.38	1.99e-10	Fibrinogen levels;
CESC	cis	rs763121	0.853	rs5757193	chr22:39034867	A/G	cg14440974	chr22:39074834	NA	0.41	5.43	0.32	1.27e-7	Menopause (age at onset);
CESC	cis	rs9287719	0.967	rs6759740	chr2:10747271	A/G	cg02196655	chr2:10830764	NOL10	-0.38	-5.79	-0.34	1.96e-8	Prostate cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18313530	chr11:111749763	C11orf1;FDXACB1	0.6	6.99	0.39	2.26e-11	Gut microbiome composition (summer);
CESC	cis	rs4665809	0.590	rs35532350	chr2:26441605	T/C	cg04944784	chr2:26401820	FAM59B	-0.96	-10.55	-0.54	5.79e-22	Gut microbiome composition (summer);
CESC	cis	rs8044868	0.586	rs8182213	chr16:72080005	C/T	cg16558253	chr16:72132732	DHX38	-0.4	-6.32	-0.36	1.12e-9	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CESC	cis	rs4642101	0.765	rs9871991	chr3:12827525	C/A	cg05775895	chr3:12838266	CAND2	0.38	5.69	0.33	3.31e-8	QRS complex (12-leadsum);
CESC	trans	rs11098499	0.863	rs1552095	chr4:120460306	A/G	cg25214090	chr10:38739885	LOC399744	0.69	9.12	0.49	2e-17	Corneal astigmatism;
CESC	cis	rs6951245	0.744	rs1133122	chr7:1192572	C/A	cg07092213	chr7:1199455	ZFAND2A	-0.49	-5.17	-0.3	4.65e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs533581	0.844	rs548591	chr16:88974516	A/G	cg16701003	chr16:89028210	CBFA2T3	0.55	8.27	0.45	6.73e-15	Social autistic-like traits;
CESC	cis	rs9908102	0.710	rs41494747	chr17:12914920	A/G	cg26162695	chr17:12921313	ELAC2	0.52	6.0	0.35	6.29e-9	Schizophrenia;
CESC	trans	rs875971	1.000	rs2077593	chr7:65892530	A/G	cg26939375	chr7:64535504	NA	0.47	6.05	0.35	4.96e-9	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21167072	chr6:90539455	CASP8AP2	-0.56	-6.29	-0.36	1.34e-9	Gut microbiome composition (summer);
CESC	cis	rs7605827	0.930	rs6753645	chr2:15539556	G/C	cg19274914	chr2:15703543	NA	0.36	6.55	0.37	2.91e-10	Educational attainment (years of education);
CESC	cis	rs3780486	0.846	rs10124479	chr9:33136233	T/G	cg13443165	chr9:33130375	B4GALT1	0.46	6.78	0.38	7.98e-11	IgG glycosylation;
CESC	cis	rs2228479	0.850	rs1108063	chr16:89893983	A/G	cg14709524	chr16:89940631	TCF25	0.89	6.42	0.37	6.21e-10	Skin colour saturation;
CESC	cis	rs9894429	0.869	rs9748184	chr17:79596280	A/G	cg21984481	chr17:79567631	NPLOC4	-0.49	-7.86	-0.43	9.77e-14	Eye color traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05534213	chr10:43932466	ZNF487	0.55	6.23	0.36	1.83e-9	Gut microbiome composition (summer);
CESC	cis	rs9527	0.622	rs12779263	chr10:104886533	G/T	cg04362960	chr10:104952993	NT5C2	0.46	5.54	0.32	7.43e-8	Arsenic metabolism;
CESC	cis	rs12541635	0.677	rs2163124	chr8:107058862	G/T	cg10147462	chr8:107024639	NA	0.48	7.19	0.4	6.78e-12	Age of smoking initiation;
CESC	cis	rs6502050	0.736	rs12150322	chr17:80061582	T/G	cg11859384	chr17:80120422	CCDC57	0.38	5.1	0.3	6.51e-7	Life satisfaction;
CESC	cis	rs962856	0.575	rs661435	chr2:67654113	A/G	cg09028215	chr2:67624308	ETAA1	0.46	5.59	0.32	5.67e-8	Pancreatic cancer;
CESC	cis	rs2243480	0.764	rs2460423	chr7:65601216	A/T	cg18252515	chr7:66147081	NA	-1.41	-14.46	-0.66	2.54e-35	Diabetic kidney disease;
CESC	trans	rs12310956	0.532	rs7967627	chr12:33974669	G/T	cg26384229	chr12:38710491	ALG10B	0.51	6.98	0.39	2.42e-11	Morning vs. evening chronotype;
CESC	cis	rs12824058	0.831	rs1390849	chr12:130811547	A/G	cg26677194	chr12:130822605	PIWIL1	0.52	6.81	0.39	6.58e-11	Menopause (age at onset);
CESC	cis	rs6812193	0.518	rs28597785	chr4:77188288	G/C	cg20311846	chr4:77356250	SHROOM3	0.28	5.14	0.3	5.41e-7	Parkinson's disease;
CESC	cis	rs35110281	0.782	rs9981790	chr21:45045052	G/C	cg04455712	chr21:45112962	RRP1B	0.42	6.36	0.36	8.8e-10	Mean corpuscular volume;
CESC	cis	rs6496667	0.510	rs16944405	chr15:90975517	A/G	cg22089800	chr15:90895588	ZNF774	0.5	6.36	0.36	8.64e-10	Rheumatoid arthritis;
CESC	cis	rs7605827	0.930	rs4133515	chr2:15696655	A/G	cg19274914	chr2:15703543	NA	0.37	6.48	0.37	4.42e-10	Educational attainment (years of education);
CESC	cis	rs763121	0.815	rs12168758	chr22:38997269	C/G	cg06022373	chr22:39101656	GTPBP1	0.8	12.95	0.62	4.88e-30	Menopause (age at onset);
CESC	cis	rs4713675	0.565	rs4713659	chr6:33667839	A/G	cg14003231	chr6:33640908	ITPR3	0.34	6.04	0.35	5.08e-9	Plateletcrit;
CESC	cis	rs7772486	0.597	rs9386136	chr6:146158300	A/T	cg05347473	chr6:146136440	FBXO30	0.75	9.51	0.5	1.19e-18	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4925325	0.876	rs6089560	chr20:60517325	T/G	cg13770153	chr20:60521292	NA	-0.84	-12.35	-0.6	5.54e-28	Obesity-related traits;
CESC	cis	rs6089829	0.855	rs6090205	chr20:61665269	A/G	cg08564027	chr20:61660810	NA	0.9	15.37	0.69	1.54e-38	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs10504229	0.609	rs56289889	chr8:58116276	G/C	cg21724239	chr8:58056113	NA	0.58	5.95	0.34	8.29e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs7937682	0.883	rs512669	chr11:111467893	G/A	cg22437258	chr11:111473054	SIK2	0.71	9.19	0.49	1.16e-17	Primary sclerosing cholangitis;
CESC	cis	rs208520	0.690	rs12201156	chr6:66720874	G/T	cg07460842	chr6:66804631	NA	0.94	12.59	0.61	8.06e-29	Exhaled nitric oxide output;
CESC	cis	rs11098499	0.866	rs9991221	chr4:120292107	G/C	cg09307838	chr4:120376055	NA	0.87	12.16	0.6	2.41e-27	Corneal astigmatism;
CESC	cis	rs763121	0.819	rs4560233	chr22:38982442	A/T	cg14440974	chr22:39074834	NA	-0.39	-5.24	-0.31	3.33e-7	Menopause (age at onset);
CESC	cis	rs2576037	0.526	rs658756	chr18:44431832	A/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.33	5.38	0.31	1.66e-7	Personality dimensions;
CESC	cis	rs72901758	0.768	rs55782477	chr17:76250703	G/C	cg26068271	chr17:76253126	NA	0.46	6.6	0.38	2.25e-10	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
CESC	cis	rs524023	0.914	rs11606370	chr11:64378452	C/A	cg07220939	chr11:64358617	SLC22A12	-0.35	-5.35	-0.31	1.94e-7	Urate levels in obese individuals;
CESC	cis	rs28374715	0.733	rs9568	chr15:41573612	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.89	-12.61	-0.61	7.18e-29	Ulcerative colitis;
CESC	cis	rs2629540	0.765	rs11245387	chr10:126537825	C/T	cg08799069	chr10:126477246	METTL10	-0.53	-7.49	-0.42	1.04e-12	Cocaine dependence;
CESC	cis	rs597539	0.652	rs514296	chr11:68654182	G/T	cg21963583	chr11:68658836	MRPL21	0.39	5.75	0.33	2.47e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs1577917	1.000	rs6936048	chr6:86702608	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.45	-5.79	-0.33	2.02e-8	Response to antipsychotic treatment;
CESC	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	10.31	0.53	3.63e-21	Prudent dietary pattern;
CESC	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.67	0.38	1.45e-10	Prudent dietary pattern;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25752797	chr13:25670228	PABPC3	-0.52	-7.08	-0.4	1.3e-11	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.753	rs13122897	chr4:98936185	C/A	cg03467027	chr4:99064603	C4orf37	0.48	5.91	0.34	1.03e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2835872	0.758	rs1709820	chr21:39035971	A/C	cg06728970	chr21:39037746	KCNJ6	0.3	5.58	0.32	5.99e-8	Electroencephalographic traits in alcoholism;
CESC	cis	rs9527	0.571	rs7096249	chr10:104618524	G/A	cg04362960	chr10:104952993	NT5C2	0.47	6.04	0.35	5.12e-9	Arsenic metabolism;
CESC	cis	rs2425143	1.000	rs733609	chr20:34393074	A/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.68	5.93	0.34	9.19e-9	Blood protein levels;
CESC	trans	rs1814175	0.645	rs6486022	chr11:49776137	A/G	cg15704280	chr7:45808275	SEPT13	-0.99	-17.45	-0.73	6.41e-46	Height;
CESC	cis	rs1448094	0.512	rs1349063	chr12:86264237	C/T	cg02569458	chr12:86230093	RASSF9	0.48	7.23	0.41	5.05e-12	Major depressive disorder;
CESC	cis	rs2303759	0.881	rs10412811	chr19:49884495	G/A	cg22307029	chr19:49891270	CCDC155	0.71	8.2	0.45	1.06e-14	Multiple sclerosis;
CESC	cis	rs11785400	0.762	rs7007349	chr8:143722673	T/C	cg10596483	chr8:143751796	JRK	0.42	5.35	0.31	1.86e-7	Schizophrenia;
CESC	cis	rs7208859	0.562	rs216408	chr17:28907757	C/G	cg04154034	chr17:28927549	LRRC37B2	-0.7	-6.45	-0.37	5.3e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg12614633	chr1:22110289	USP48	-0.48	-6.72	-0.38	1.12e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs832540	1.000	rs252913	chr5:56195846	C/T	cg14703610	chr5:56206110	C5orf35	-0.52	-7.03	-0.4	1.75e-11	Coronary artery disease;
CESC	cis	rs7666738	0.791	rs10856933	chr4:98958542	C/A	cg17366294	chr4:99064904	C4orf37	0.6	8.47	0.46	1.72e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6061231	0.624	rs8668	chr20:60964064	C/T	cg15674680	chr20:60982522	CABLES2	-0.48	-6.07	-0.35	4.5e-9	Colorectal cancer;
CESC	cis	rs6963495	0.818	rs818621	chr7:105173029	T/C	cg19920283	chr7:105172520	RINT1	0.72	7.94	0.44	5.6e-14	Bipolar disorder (body mass index interaction);
CESC	cis	rs12545109	0.800	rs2609979	chr8:57390066	G/A	cg09654669	chr8:57350985	NA	-0.57	-7.21	-0.41	5.71e-12	Obesity-related traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12672205	chr22:39101803	GTPBP1	0.56	6.25	0.36	1.59e-9	Gut microbiome composition (summer);
CESC	cis	rs10876993	0.855	rs10877007	chr12:58100058	T/A	cg18357645	chr12:58087776	OS9	0.63	10.47	0.54	1.11e-21	Celiac disease or Rheumatoid arthritis;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg05508478	chr11:9482677	ZNF143	0.45	6.03	0.35	5.49e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs6569992	0.636	rs55683605	chr6:135487107	C/T	cg22676075	chr6:135203613	NA	0.56	5.45	0.32	1.14e-7	Red blood cell traits;
CESC	cis	rs11792861	0.926	rs77567374	chr9:111835034	T/C	cg05043794	chr9:111880884	C9orf5	-0.4	-6.51	-0.37	3.67e-10	Menarche (age at onset);
CESC	cis	rs1799949	1.000	rs12516	chr17:41196408	G/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.41	5.68	0.33	3.49e-8	Menopause (age at onset);
CESC	cis	rs7703051	0.760	rs34341	chr5:74934009	A/T	cg03227963	chr5:74354835	NA	-0.28	-5.11	-0.3	6.15e-7	LDL cholesterol;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
CESC	cis	rs172166	0.694	rs203877	chr6:28048624	T/C	cg20151795	chr6:28129481	ZNF389	0.35	5.06	0.3	7.95e-7	Cardiac Troponin-T levels;
CESC	cis	rs7917772	0.546	rs10883743	chr10:104338389	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.41	5.61	0.33	5.05e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs2836974	0.897	rs2836927	chr21:40543216	T/C	cg27266027	chr21:40555129	PSMG1	0.46	5.59	0.32	5.69e-8	Cognitive function;
CESC	cis	rs5769765	0.954	rs5769762	chr22:50264042	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	0.46	5.32	0.31	2.21e-7	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16207528	chr7:48964051	CDC14C	-0.62	-7.62	-0.42	4.59e-13	Gut microbiome composition (summer);
CESC	cis	rs7615952	0.576	rs2276729	chr3:125826214	G/A	cg06494592	chr3:125709126	NA	-0.5	-5.66	-0.33	3.89e-8	Blood pressure (smoking interaction);
CESC	cis	rs1707322	1.000	rs1768801	chr1:46549137	C/G	cg06784218	chr1:46089804	CCDC17	-0.33	-5.57	-0.32	6.35e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs1808579	0.874	rs1788817	chr18:21097460	A/G	cg14672496	chr18:21087552	C18orf8	0.45	6.48	0.37	4.35e-10	Hip circumference;Body mass index;BMI (adjusted for smoking behaviour);
CESC	cis	rs651907	0.557	rs11917569	chr3:101355063	G/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.46	5.84	0.34	1.56e-8	Colorectal cancer;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg20203792	chr4:20701925	PACRGL	-0.46	-6.23	-0.36	1.87e-9	Height;
CESC	cis	rs1862618	0.573	rs2034245	chr5:56243685	T/C	cg20203395	chr5:56204925	C5orf35	0.51	5.83	0.34	1.6e-8	Initial pursuit acceleration;
CESC	cis	rs9487051	0.676	rs9400267	chr6:109600164	T/C	cg12927641	chr6:109611667	NA	-0.36	-5.28	-0.31	2.66e-7	Reticulocyte fraction of red cells;
CESC	cis	rs6500395	0.962	rs9937568	chr16:48612361	C/T	cg04672837	chr16:48644449	N4BP1	-0.44	-5.34	-0.31	2.04e-7	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs7927771	0.524	rs12785949	chr11:47729770	C/T	cg20307385	chr11:47447363	PSMC3	0.62	8.6	0.47	7.23e-16	Subjective well-being;
CESC	cis	rs7811142	0.830	rs11761253	chr7:99939321	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.91	8.88	0.48	1.02e-16	Platelet count;
CESC	cis	rs896854	1.000	rs13255935	chr8:95965685	C/A	cg13393036	chr8:95962371	TP53INP1	-0.54	-11.91	-0.59	1.74e-26	Type 2 diabetes;
CESC	cis	rs10242455	0.702	rs73405247	chr7:99159174	C/G	cg18809830	chr7:99032528	PTCD1	-0.66	-5.21	-0.3	3.84e-7	Blood metabolite levels;
CESC	cis	rs9583531	0.600	rs7330080	chr13:111367115	C/T	cg15841412	chr13:111365552	ING1	0.47	6.27	0.36	1.48e-9	Coronary artery disease;
CESC	cis	rs6582630	0.555	rs4601853	chr12:38435569	G/A	cg26384229	chr12:38710491	ALG10B	0.69	10.57	0.54	5e-22	Drug-induced liver injury (flucloxacillin);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg00822591	chr3:16306489	DPH3;OXNAD1	-0.52	-6.98	-0.39	2.38e-11	Fibrinogen levels;
CESC	cis	rs868036	0.609	rs28742003	chr15:68127769	C/T	cg24579218	chr15:68104479	NA	-0.39	-5.47	-0.32	1.05e-7	Restless legs syndrome;
CESC	cis	rs4242434	0.747	rs6986550	chr8:22467870	T/A	cg03733263	chr8:22462867	KIAA1967	0.88	14.76	0.67	2.2e-36	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CESC	cis	rs3892630	0.588	rs7248798	chr19:33303684	G/T	cg22980127	chr19:33182716	NUDT19	1.15	15.15	0.68	8.77e-38	Red blood cell traits;
CESC	cis	rs2282802	0.660	rs7726176	chr5:139547971	T/A	cg26211634	chr5:139558579	C5orf32	-0.46	-6.65	-0.38	1.65e-10	Intelligence (multi-trait analysis);
CESC	cis	rs1862618	0.756	rs9292125	chr5:56107200	C/T	cg18230493	chr5:56204884	C5orf35	-0.7	-8.55	-0.47	9.85e-16	Initial pursuit acceleration;
CESC	cis	rs12681288	0.676	rs17740799	chr8:1014327	C/T	cg04851639	chr8:1020857	NA	0.35	7.54	0.42	7.43e-13	Schizophrenia;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg10705503	chr12:102513685	C12orf48;NUP37	-0.4	-6.15	-0.35	2.89e-9	Gambling;
CESC	cis	rs854765	0.647	rs4426402	chr17:17977926	C/T	cg09796270	chr17:17721594	SREBF1	-0.38	-5.1	-0.3	6.41e-7	Total body bone mineral density;
CESC	cis	rs2841277	0.708	rs10083374	chr14:105402994	T/C	cg19901468	chr14:105411992	AHNAK2	-0.6	-8.68	-0.47	4.07e-16	Rheumatoid arthritis;
CESC	cis	rs4268898	0.552	rs11125444	chr2:24367205	G/T	cg06627628	chr2:24431161	ITSN2	0.59	8.19	0.45	1.12e-14	Asthma;
CESC	cis	rs3020736	0.500	rs4147638	chr22:42487900	G/A	cg04733989	chr22:42467013	NAGA	-0.83	-12.68	-0.61	3.98e-29	Autism spectrum disorder or schizophrenia;
CESC	cis	rs2180341	1.000	rs6910763	chr6:127630925	T/C	cg27446573	chr6:127587934	RNF146	1.09	16.33	0.71	5.73e-42	Breast cancer;
CESC	cis	rs1552244	0.882	rs28366039	chr3:10028988	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.82	9.57	0.51	8.02e-19	Alzheimer's disease;
CESC	cis	rs801193	0.805	rs12532355	chr7:66070584	C/G	cg19163074	chr7:65112434	INTS4L2	0.43	5.49	0.32	9.47e-8	Aortic root size;
CESC	cis	rs2859741	0.546	rs2133910	chr1:37478785	G/T	cg09363841	chr1:37513479	NA	-0.49	-7.17	-0.4	7.42e-12	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg22335246	chr12:120763591	PLA2G1B	0.49	6.92	0.39	3.49e-11	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs2933343	1.000	rs1683776	chr3:128622760	G/T	cg25356066	chr3:128598488	ACAD9	0.59	7.16	0.4	7.76e-12	IgG glycosylation;
CESC	trans	rs4332037	0.851	rs34040190	chr7:1920356	G/A	cg11693508	chr17:37793320	STARD3	0.68	6.43	0.37	5.94e-10	Bipolar disorder;
CESC	cis	rs6831352	0.918	rs17817958	chr4:100061245	A/C	cg12011299	chr4:100065546	ADH4	0.53	5.62	0.33	4.89e-8	Alcohol dependence;
CESC	cis	rs2404602	0.692	rs35138393	chr15:76977617	G/A	cg22467129	chr15:76604101	ETFA	-0.34	-5.15	-0.3	5.13e-7	Blood metabolite levels;
CESC	cis	rs2290159	0.898	rs2290160	chr3:12633083	A/G	cg23032965	chr3:12705835	RAF1	0.49	5.48	0.32	9.8e-8	Cholesterol, total;
CESC	cis	rs3829251	0.786	rs7103591	chr11:71237619	T/C	cg05163923	chr11:71159392	DHCR7	-0.54	-5.61	-0.33	5.1e-8	Vitamin D levels;
CESC	cis	rs270601	0.739	rs3900945	chr5:131592870	T/C	cg24060327	chr5:131705240	SLC22A5	-0.49	-6.26	-0.36	1.56e-9	Acylcarnitine levels;
CESC	cis	rs11122272	0.701	rs2486725	chr1:231540288	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.55	-7.47	-0.42	1.14e-12	Hemoglobin concentration;
CESC	cis	rs875971	0.660	rs801193	chr7:66030612	A/C	cg25985355	chr7:65971099	NA	0.32	5.38	0.31	1.63e-7	Aortic root size;
CESC	cis	rs6582630	0.598	rs10880614	chr12:38509766	G/A	cg26384229	chr12:38710491	ALG10B	-0.41	-5.44	-0.32	1.23e-7	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs735396	0.595	rs1169279	chr12:121455873	C/T	cg15155738	chr12:121454335	C12orf43	0.45	5.24	0.31	3.31e-7	N-glycan levels;
CESC	cis	rs7208859	0.623	rs9915566	chr17:29132158	G/A	cg14008862	chr17:28927542	LRRC37B2	0.65	5.14	0.3	5.34e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs2228479	0.717	rs17233678	chr16:89809962	T/C	cg19635926	chr16:89946313	TCF25	0.66	5.04	0.3	8.52e-7	Skin colour saturation;
CESC	cis	rs9868809	0.542	rs9873726	chr3:48712367	C/T	cg07636037	chr3:49044803	WDR6	-0.61	-5.53	-0.32	7.82e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs7044106	0.791	rs4836829	chr9:123482747	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.36	5.87	0.34	1.3e-8	Hip circumference adjusted for BMI;
CESC	cis	rs9948	0.655	rs78424221	chr2:97410399	A/G	cg01990225	chr2:97406019	LMAN2L	-0.98	-7.35	-0.41	2.39e-12	Erectile dysfunction and prostate cancer treatment;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00482020	chr16:25026850	ARHGAP17	0.58	7.09	0.4	1.25e-11	Gut microbiome composition (summer);
CESC	cis	rs9858542	0.953	rs34588335	chr3:49407660	G/C	cg07274523	chr3:49395745	GPX1	0.68	8.49	0.46	1.55e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	trans	rs1493916	0.905	rs4799727	chr18:31393095	T/G	cg27147174	chr7:100797783	AP1S1	-0.52	-6.92	-0.39	3.32e-11	Life satisfaction;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg07473634	chr13:113647389	MCF2L	-0.38	-6.06	-0.35	4.62e-9	Gut microbiota (bacterial taxa);
CESC	trans	rs12310956	0.515	rs11052934	chr12:33970381	T/C	cg26384229	chr12:38710491	ALG10B	0.45	6.21	0.36	1.99e-9	Morning vs. evening chronotype;
CESC	cis	rs3749237	0.615	rs6792911	chr3:49429856	C/T	cg03060546	chr3:49711283	APEH	0.75	11.32	0.57	1.71e-24	Resting heart rate;
CESC	cis	rs9325144	0.671	rs7486919	chr12:38767997	A/G	cg26384229	chr12:38710491	ALG10B	-0.56	-7.9	-0.44	7.48e-14	Morning vs. evening chronotype;
CESC	cis	rs9467711	0.659	rs34605993	chr6:26454363	C/T	cg14345882	chr6:26364793	BTN3A2	0.67	5.41	0.32	1.42e-7	Autism spectrum disorder or schizophrenia;
CESC	trans	rs916888	0.738	rs199515	chr17:44856641	C/G	cg01341218	chr17:43662625	NA	-0.86	-10.99	-0.56	2.19e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs2749592	0.550	rs9733309	chr10:37882405	G/A	cg25427524	chr10:38739819	LOC399744	0.55	7.65	0.43	3.64e-13	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs854765	0.565	rs4072738	chr17:17884547	A/C	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.5	6.69	0.38	1.3100000000000001e-10	Total body bone mineral density;
CESC	cis	rs7714584	1.000	rs76548544	chr5:150223515	T/A	cg22134413	chr5:150180641	NA	0.53	5.75	0.33	2.47e-8	Crohn's disease;
CESC	cis	rs10203711	0.966	rs4998692	chr2:239564772	T/G	cg14580085	chr2:239553406	NA	0.34	5.16	0.3	4.74e-7	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs77741769	0.571	rs34009825	chr12:121326183	A/G	cg02419362	chr12:121203948	SPPL3	0.34	5.58	0.32	5.97e-8	Mean corpuscular volume;
CESC	cis	rs2304069	0.779	rs245080	chr5:149354805	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.71	-9.1	-0.49	2.23e-17	HIV-1 control;
CESC	trans	rs1814175	0.645	rs847632	chr11:49926097	C/T	cg03929089	chr4:120376271	NA	-0.89	-14.83	-0.67	1.17e-36	Height;
CESC	cis	rs9894429	0.646	rs12948797	chr17:79617384	G/A	cg18240062	chr17:79603768	NPLOC4	0.48	6.12	0.35	3.28e-9	Eye color traits;
CESC	cis	rs9399401	0.626	rs4304190	chr6:142778912	A/G	cg03128060	chr6:142623767	GPR126	0.3	5.03	0.3	8.92e-7	Chronic obstructive pulmonary disease;
CESC	cis	rs10927875	0.894	rs10927878	chr1:16319957	C/T	cg21214613	chr1:16344536	HSPB7	-0.38	-5.78	-0.33	2.1e-8	Dilated cardiomyopathy;
CESC	cis	rs9322193	0.884	rs7743823	chr6:150170880	A/G	cg13206674	chr6:150067644	NUP43	0.38	5.12	0.3	5.87e-7	Lung cancer;
CESC	cis	rs35306767	0.714	rs10508206	chr10:1075777	A/C	cg20503657	chr10:835505	NA	0.5	5.13	0.3	5.68e-7	Eosinophil percentage of granulocytes;
CESC	cis	rs35146811	0.586	rs10267231	chr7:99595480	T/C	cg14163444	chr7:99595348	NA	-0.39	-5.11	-0.3	6.28e-7	Coronary artery disease;
CESC	cis	rs4853012	0.941	rs78128123	chr2:74347525	C/T	cg05890377	chr2:74357713	NA	0.78	9.11	0.49	2.07e-17	Gestational age at birth (maternal effect);
CESC	cis	rs2439831	0.850	rs3736180	chr15:44106624	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.66	5.97	0.34	7.58e-9	Lung cancer in ever smokers;
CESC	cis	rs116095464	0.558	rs6878061	chr5:223072	A/G	cg22496380	chr5:211416	CCDC127	-0.72	-8.57	-0.47	8.59e-16	Breast cancer;
CESC	cis	rs9916302	0.645	rs1053651	chr17:37822311	A/C	cg00129232	chr17:37814104	STARD3	-0.75	-10.23	-0.53	6.33e-21	Glomerular filtration rate (creatinine);
CESC	cis	rs12142240	0.698	rs77185326	chr1:46818417	T/C	cg00530320	chr1:46809349	NSUN4	0.58	7.89	0.44	8.15e-14	Menopause (age at onset);
CESC	cis	rs7020830	0.867	rs1339553	chr9:37266123	C/G	cg14294708	chr9:37120828	ZCCHC7	1.21	22.97	0.82	5.23e-65	Schizophrenia;
CESC	cis	rs9916302	0.706	rs7503377	chr17:37708841	A/G	cg07936489	chr17:37558343	FBXL20	-0.98	-10.93	-0.56	3.28e-23	Glomerular filtration rate (creatinine);
CESC	cis	rs61008539	0.815	rs6960062	chr7:884665	A/G	cg00934597	chr7:893267	UNC84A	-0.53	-7.19	-0.4	6.66e-12	Perceived unattractiveness to mosquitoes;
CESC	cis	rs1862618	0.641	rs170733	chr5:56249251	A/G	cg12311346	chr5:56204834	C5orf35	0.65	8.47	0.46	1.68e-15	Initial pursuit acceleration;
CESC	cis	rs4975709	0.610	rs4975705	chr5:1860359	T/C	cg12288994	chr5:1860383	NA	0.42	7.0	0.4	2.04e-11	Cardiovascular disease risk factors;
CESC	cis	rs7917772	0.503	rs11191330	chr10:104306160	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.56	7.87	0.44	9.28e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs4604732	0.631	rs12039596	chr1:247624766	A/G	cg12758973	chr1:247694275	LOC148824;OR2C3	0.51	6.36	0.36	8.65e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs12497850	0.931	rs13316620	chr3:49045355	T/C	cg06212747	chr3:49208901	KLHDC8B	0.68	8.98	0.48	5.01e-17	Parkinson's disease;
CESC	cis	rs8177253	1.000	rs6439439	chr3:133481498	G/T	cg11941060	chr3:133502564	NA	-0.48	-6.64	-0.38	1.79e-10	Iron status biomarkers;
CESC	cis	rs7312933	0.531	rs2406674	chr12:42720150	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.48	-6.4	-0.37	7.09e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs11864453	0.713	rs2241412	chr16:72144284	A/G	cg01557791	chr16:72042693	DHODH	-0.48	-6.35	-0.36	9.29e-10	Fibrinogen levels;
CESC	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg27588902	chr6:42928151	GNMT	0.29	5.52	0.32	8.05e-8	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs3947	0.906	rs709822	chr8:11702313	C/G	cg00262122	chr8:11665843	FDFT1	-0.48	-5.36	-0.31	1.82e-7	Blood protein levels;
CESC	cis	rs7552404	1.000	rs4559448	chr1:76203456	A/G	cg10523679	chr1:76189770	ACADM	0.73	8.74	0.47	2.81e-16	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs10504229	1.000	rs58382845	chr8:58169851	A/C	cg22535103	chr8:58192502	C8orf71	-1.04	-12.83	-0.62	1.26e-29	Developmental language disorder (linguistic errors);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19329146	chr7:30544921	GGCT	0.66	7.35	0.41	2.47e-12	Gut microbiome composition (summer);
CESC	cis	rs34779708	0.897	rs4934716	chr10:35369299	A/G	cg04310649	chr10:35416472	CREM	-0.52	-6.4	-0.37	7.03e-10	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs1950626	0.751	rs12883799	chr14:101396850	A/C	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.8	10.73	0.55	1.57e-22	Pelvic organ prolapse (moderate/severe);
CESC	cis	rs644799	0.622	rs1255167	chr11:95500213	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.64	8.59	0.47	7.64e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg23708337	chr7:1209742	NA	0.53	5.34	0.31	1.98e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs6694270	0.529	rs4076925	chr1:19113026	C/T	cg19637330	chr1:19110922	NA	0.55	7.02	0.4	1.91e-11	Drug-induced liver injury (nitrofurantoin);
CESC	cis	rs6545883	0.965	rs9989775	chr2:61761774	A/G	cg15711740	chr2:61764176	XPO1	-0.44	-5.37	-0.31	1.73e-7	Tuberculosis;
CESC	cis	rs6426558	0.514	rs3754418	chr1:227348473	T/C	cg10327440	chr1:227177885	CDC42BPA	-0.46	-5.72	-0.33	2.86e-8	Neutrophil percentage of white cells;
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg18044720	chr4:87857031	AFF1	-0.43	-6.05	-0.35	4.9e-9	Vertical cup-disc ratio;
CESC	cis	rs2180341	1.000	rs2038378	chr6:127590400	C/T	cg24812749	chr6:127587940	RNF146	1.06	15.28	0.68	3.03e-38	Breast cancer;
CESC	cis	rs2075671	0.810	rs12531792	chr7:100280624	G/A	cg16850897	chr7:100343110	ZAN	-0.7	-8.9	-0.48	9.03e-17	Other erythrocyte phenotypes;
CESC	cis	rs6502050	0.777	rs6502058	chr17:80082500	A/C	cg23985595	chr17:80112537	CCDC57	0.42	6.55	0.37	2.99e-10	Life satisfaction;
CESC	cis	rs13118159	0.836	rs2293630	chr4:1342521	G/A	cg02018176	chr4:1364513	KIAA1530	0.5	7.0	0.39	2.14e-11	Longevity;
CESC	cis	rs2730245	0.636	rs2657382	chr7:158650941	G/A	cg01943577	chr7:158741284	NA	-0.41	-5.25	-0.31	3.07e-7	Height;
CESC	cis	rs9911578	1.000	rs12936058	chr17:57017420	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.14	0.3	5.41e-7	Intelligence (multi-trait analysis);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg08039701	chr5:74063125	NSA2;GFM2	-0.36	-6.08	-0.35	4.25e-9	Gambling;
CESC	cis	rs6933660	0.720	rs6936936	chr6:151753395	A/G	cg02564969	chr6:151773285	C6orf211;RMND1	0.61	8.46	0.46	1.89e-15	Menarche (age at onset);
CESC	cis	rs1153858	1.000	rs10519022	chr15:45663684	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.86	-11.63	-0.58	1.6e-25	Homoarginine levels;
CESC	cis	rs9902453	0.765	rs8079209	chr17:28186773	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	8.77	0.47	2.28e-16	Coffee consumption (cups per day);
CESC	cis	rs7818345	1.000	rs12675717	chr8:19293177	G/A	cg11303988	chr8:19266685	CSGALNACT1	0.35	6.31	0.36	1.17e-9	Language performance in older adults (adjusted for episodic memory);
CESC	cis	rs7824557	0.583	rs2736306	chr8:11239762	A/T	cg21775007	chr8:11205619	TDH	0.5	7.52	0.42	8.43e-13	Retinal vascular caliber;
CESC	cis	rs875971	1.000	rs4718357	chr7:65960878	A/G	cg10691866	chr7:65817282	TPST1	-0.34	-5.59	-0.32	5.57e-8	Aortic root size;
CESC	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg22535103	chr8:58192502	C8orf71	-0.96	-9.81	-0.52	1.45e-19	Developmental language disorder (linguistic errors);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15464645	chr15:28380110	HERC2	-0.61	-6.63	-0.38	1.85e-10	Gut microbiome composition (summer);
CESC	cis	rs244293	0.831	rs11079149	chr17:53095046	A/G	cg19360675	chr17:53046073	COX11;STXBP4	0.4	5.11	0.3	6.18e-7	Menarche (age at onset);
CESC	cis	rs56804039	1.000	rs11780966	chr8:8383396	T/G	cg15556689	chr8:8085844	FLJ10661	-0.49	-5.31	-0.31	2.27e-7	Cervical cancer;
CESC	cis	rs10743315	0.778	rs10841184	chr12:19370768	T/G	cg02471346	chr12:19282374	PLEKHA5	-0.48	-5.2	-0.3	4.07e-7	Gut microbiota (bacterial taxa);
CESC	cis	rs9388451	0.874	rs1159974	chr6:126090277	C/T	cg10911889	chr6:126070802	HEY2	-0.39	-5.26	-0.31	3e-7	Brugada syndrome;
CESC	cis	rs8103278	0.507	rs7246377	chr19:46292259	G/A	cg06577658	chr19:46296270	DMWD	0.49	5.75	0.33	2.45e-8	Coronary artery disease;
CESC	cis	rs2456568	0.548	rs4753113	chr11:93660974	G/A	cg26875233	chr11:93583750	C11orf90	-0.32	-5.66	-0.33	3.88e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
CESC	cis	rs10992471	0.575	rs1152759	chr9:95129359	T/C	cg13798575	chr9:95087839	CENPP;NOL8	0.4	5.04	0.3	8.5e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CESC	cis	rs8114671	0.562	rs6120758	chr20:33492523	C/T	cg06115741	chr20:33292138	TP53INP2	0.48	5.79	0.34	1.97e-8	Height;
CESC	cis	rs6952808	0.531	rs3778991	chr7:2172455	G/A	cg04267008	chr7:1944627	MAD1L1	-0.57	-6.84	-0.39	5.61e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs7618915	0.571	rs6762457	chr3:52609157	G/A	cg07507251	chr3:52567010	NT5DC2	0.41	7.12	0.4	1.02e-11	Bipolar disorder;
CESC	cis	rs9311474	0.508	rs11720243	chr3:52618018	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.5	7.32	0.41	2.95e-12	Electroencephalogram traits;
CESC	cis	rs875971	0.545	rs12671152	chr7:65776127	G/T	cg25405998	chr7:65216604	CCT6P1	0.51	5.54	0.32	7.38e-8	Aortic root size;
CESC	cis	rs2404602	0.716	rs4886817	chr15:76877702	C/T	cg26408565	chr15:76604113	ETFA	-0.4	-5.65	-0.33	4.24e-8	Blood metabolite levels;
CESC	cis	rs4568518	0.710	rs13230836	chr7:18013895	A/T	cg03009463	chr7:17980271	SNX13	0.47	6.29	0.36	1.33e-9	Measles;
CESC	cis	rs6912958	1.000	rs9294380	chr6:88152667	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.33	-5.36	-0.31	1.81e-7	Monocyte percentage of white cells;
CESC	cis	rs761746	0.921	rs761747	chr22:32001835	C/A	cg25791279	chr22:32026902	PISD	0.58	6.85	0.39	5.13e-11	Intelligence;
CESC	cis	rs12579753	0.879	rs7971664	chr12:82264101	T/C	cg24719984	chr12:82153464	PPFIA2	-0.35	-5.16	-0.3	4.96e-7	Resting heart rate;
CESC	cis	rs2228479	0.702	rs17233441	chr16:89817998	C/G	cg19635926	chr16:89946313	TCF25	0.67	5.09	0.3	6.82e-7	Skin colour saturation;
CESC	cis	rs2243480	0.901	rs778732	chr7:65822360	C/T	cg12463550	chr7:65579703	CRCP	0.71	5.39	0.31	1.57e-7	Diabetic kidney disease;
CESC	trans	rs61931739	0.500	rs3922568	chr12:34560107	A/C	cg26384229	chr12:38710491	ALG10B	0.53	7.4	0.41	1.81e-12	Morning vs. evening chronotype;
CESC	cis	rs6662572	0.906	rs76438782	chr1:46240425	C/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.45	5.2	0.3	3.91e-7	Blood protein levels;
CESC	cis	rs5769765	0.954	rs5770709	chr22:50245196	G/T	cg02269571	chr22:50332266	NA	0.45	6.04	0.35	5.28e-9	Schizophrenia;
CESC	cis	rs35110281	0.807	rs2838326	chr21:45014315	C/T	cg04455712	chr21:45112962	RRP1B	0.39	6.12	0.35	3.44e-9	Mean corpuscular volume;
CESC	cis	rs3126085	0.935	rs4534386	chr1:152251714	A/G	cg03465714	chr1:152285911	FLG	-0.46	-5.75	-0.33	2.42e-8	Atopic dermatitis;
CESC	cis	rs35110281	0.693	rs2838344	chr21:45089877	C/T	cg21573476	chr21:45109991	RRP1B	-0.53	-8.01	-0.44	3.68e-14	Mean corpuscular volume;
CESC	cis	rs651907	0.557	rs11917682	chr3:101355427	G/A	cg12386194	chr3:101231763	SENP7	0.44	5.37	0.31	1.71e-7	Colorectal cancer;
CESC	cis	rs2836950	0.501	rs11088470	chr21:40689162	A/G	cg17971929	chr21:40555470	PSMG1	-0.6	-7.82	-0.43	1.24e-13	Menarche (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07017209	chr1:220263177	BPNT1	0.65	7.79	0.43	1.5700000000000001e-13	Gut microbiome composition (summer);
CESC	cis	rs3741404	0.609	rs666497	chr11:63869821	G/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.72	10.02	0.52	2.95e-20	Platelet count;
CESC	cis	rs9467711	0.606	rs9379901	chr6:26603866	T/C	cg12826209	chr6:26865740	GUSBL1	0.66	5.86	0.34	1.4e-8	Autism spectrum disorder or schizophrenia;
CESC	cis	rs9303401	0.614	rs2240719	chr17:56582477	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.01	12.14	0.6	2.94e-27	Cognitive test performance;
CESC	cis	rs9287719	0.967	rs7355649	chr2:10748094	C/A	cg00105475	chr2:10696890	NA	0.38	5.42	0.32	1.36e-7	Prostate cancer;
CESC	cis	rs11718455	0.960	rs11920021	chr3:44000856	T/C	cg08738300	chr3:44038990	NA	0.46	6.14	0.35	3.03e-9	Coronary artery disease;
CESC	cis	rs6032067	0.929	rs17334064	chr20:43839197	T/C	cg11264863	chr20:43835661	SEMG1	0.48	5.26	0.31	2.98e-7	Blood protein levels;
CESC	trans	rs1945213	0.694	rs7116741	chr11:55862620	C/T	cg03929089	chr4:120376271	NA	0.77	7.35	0.41	2.48e-12	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs2073300	0.609	rs6137939	chr20:23390206	C/T	cg12062639	chr20:23401060	NAPB	-1.05	-9.01	-0.48	4.22e-17	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs854765	0.647	rs854814	chr17:18003648	G/A	cg09796270	chr17:17721594	SREBF1	0.38	5.15	0.3	5.05e-7	Total body bone mineral density;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg24109975	chr19:59055787	TRIM28	-0.45	-6.11	-0.35	3.59e-9	Ulcerative colitis;
CESC	cis	rs9611565	0.659	rs1569516	chr22:41910244	C/T	cg06481639	chr22:41940642	POLR3H	-0.64	-6.58	-0.37	2.54e-10	Vitiligo;
CESC	cis	rs1957429	0.808	rs7149922	chr14:65334541	C/T	cg23373153	chr14:65346875	NA	0.89	9.19	0.49	1.19e-17	Pediatric areal bone mineral density (radius);
CESC	cis	rs367943	0.698	rs10046061	chr5:112976533	A/G	cg12552261	chr5:112820674	MCC	0.43	5.46	0.32	1.09e-7	Type 2 diabetes;
CESC	cis	rs4664308	0.618	rs3792192	chr2:160886875	G/A	cg03641300	chr2:160917029	PLA2R1	-0.59	-8.54	-0.46	1.06e-15	Idiopathic membranous nephropathy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25588969	chr20:25388199	GINS1	0.59	6.35	0.36	9.45e-10	Gut microbiome composition (summer);
CESC	cis	rs2380220	0.541	rs72928277	chr6:96079745	G/T	cg23517279	chr6:96025343	MANEA	-0.55	-5.38	-0.31	1.6e-7	Behavioural disinhibition (generation interaction);
CESC	cis	rs7666738	0.830	rs28594127	chr4:99001121	T/G	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.62e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2286503	0.780	rs12113458	chr7:22855628	G/T	cg11367502	chr7:22862612	TOMM7	0.4	5.32	0.31	2.26e-7	Fibrinogen;
CESC	cis	rs9611565	0.921	rs8137373	chr22:41729216	A/G	cg17376030	chr22:41985996	PMM1	-0.52	-5.68	-0.33	3.63e-8	Vitiligo;
CESC	cis	rs7089973	0.584	rs6585300	chr10:116639889	A/C	cg03647239	chr10:116582469	FAM160B1	0.46	5.97	0.34	7.42e-9	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs116095464	0.558	rs6874745	chr5:264527	A/G	cg20965017	chr5:231967	SDHA	-0.48	-5.43	-0.32	1.25e-7	Breast cancer;
CESC	cis	rs6754311	0.597	rs2278544	chr2:136546110	A/G	cg07169764	chr2:136633963	MCM6	-0.74	-9.4	-0.5	2.65e-18	Mosquito bite size;
CESC	cis	rs875971	1.000	rs7792762	chr7:66004138	T/C	cg11764359	chr7:65958608	NA	0.93	14.69	0.67	3.92e-36	Aortic root size;
CESC	cis	rs73001065	0.901	rs73004926	chr19:19671266	C/T	cg03709012	chr19:19516395	GATAD2A	0.97	5.93	0.34	9.39e-9	LDL cholesterol;
CESC	cis	rs6860806	0.661	rs2136188	chr5:131577514	A/G	cg22638593	chr5:131593259	PDLIM4	-0.41	-5.36	-0.31	1.82e-7	Breast cancer;
CESC	cis	rs6964587	0.869	rs11769726	chr7:91485231	A/G	cg17063962	chr7:91808500	NA	-0.5	-6.56	-0.37	2.77e-10	Breast cancer;
CESC	cis	rs12188164	0.965	rs72717435	chr5:448202	G/A	cg26850624	chr5:429559	AHRR	-0.49	-6.62	-0.38	1.98e-10	Cystic fibrosis severity;
CESC	cis	rs208520	0.609	rs208436	chr6:66897470	G/A	cg07460842	chr6:66804631	NA	-0.7	-8.83	-0.48	1.47e-16	Exhaled nitric oxide output;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23496400	chr2:17721775	VSNL1	0.51	6.97	0.39	2.5e-11	Gut microbiome composition (summer);
CESC	trans	rs1116547	0.501	rs67020702	chr5:112897619	A/G	cg10115368	chr14:100435663	NA	0.5	6.1	0.35	3.72e-9	Cerebral amyloid angiopathy;
CESC	cis	rs6662572	0.950	rs111971542	chr1:46235998	A/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.49	5.34	0.31	2.04e-7	Blood protein levels;
CESC	cis	rs734999	0.588	rs2764841	chr1:2529360	G/A	cg20673091	chr1:2541236	MMEL1	-0.44	-7.5	-0.42	9.48e-13	Ulcerative colitis;
CESC	cis	rs1580019	0.587	rs34488151	chr7:32548146	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.51	6.39	0.37	7.42e-10	Cognitive ability;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15233126	chr3:40566533	ZNF621	0.6	7.34	0.41	2.57e-12	Gut microbiome composition (summer);
CESC	cis	rs12911832	0.701	rs452698	chr15:59105571	A/G	cg05156742	chr15:59063176	FAM63B	0.72	10.04	0.52	2.61e-20	Schizophrenia;
CESC	trans	rs7839040	0.698	rs13273019	chr8:82925431	T/C	cg14472086	chr9:107730925	NA	-0.47	-6.33	-0.36	1.02e-9	Response to methotrexate in juvenile idiopathic arthritis;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg07132517	chr11:842517	TSPAN4;POLR2L	-0.48	-6.23	-0.36	1.83e-9	Ulcerative colitis;
CESC	cis	rs17711722	0.523	rs313812	chr7:65505043	T/C	cg11764359	chr7:65958608	NA	-0.48	-6.06	-0.35	4.55e-9	Calcium levels;
CESC	cis	rs9914988	0.887	rs12947735	chr17:27156866	A/T	cg20469991	chr17:27169893	C17orf63	-0.48	-5.25	-0.31	3.18e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09026875	chr17:60501189	METTL2A	0.64	7.88	0.44	8.32e-14	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08663669	chr6:70506547	LMBRD1	-0.6	-7.24	-0.41	4.76e-12	Gut microbiome composition (summer);
CESC	cis	rs7107174	1.000	rs948662	chr11:77979829	A/G	cg02023728	chr11:77925099	USP35	0.48	6.86	0.39	4.75e-11	Testicular germ cell tumor;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg01918552	chr6:163521371	PACRG	0.41	6.64	0.38	1.79e-10	Fibrinogen levels;
CESC	cis	rs72627123	0.867	rs8019192	chr14:74471267	T/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.8	5.77	0.33	2.2e-8	Morning vs. evening chronotype;
CESC	cis	rs11190604	1.000	rs3750720	chr10:102248884	C/T	cg07080220	chr10:102295463	HIF1AN	0.62	5.93	0.34	9.36e-9	Palmitoleic acid (16:1n-7) levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20449327	chr14:59951241	C14orf149;JKAMP	0.56	6.05	0.35	4.95e-9	Gut microbiome composition (summer);
CESC	cis	rs10479542	0.544	rs7706275	chr5:178990305	A/G	cg00080972	chr5:178986291	RUFY1	0.47	7.26	0.41	4.23e-12	Lung cancer;
CESC	cis	rs2180341	1.000	rs6569480	chr6:127621748	A/G	cg27446573	chr6:127587934	RNF146	1.02	15.87	0.7	2.5e-40	Breast cancer;
CESC	cis	rs4835473	0.742	rs7695853	chr4:144804396	G/C	cg25736465	chr4:144833511	NA	0.41	6.3	0.36	1.26e-9	Immature fraction of reticulocytes;
CESC	cis	rs8180040	0.726	rs4682842	chr3:46982773	C/G	cg27129171	chr3:47204927	SETD2	-0.64	-9.04	-0.49	3.43e-17	Colorectal cancer;
CESC	cis	rs11098499	0.866	rs12501602	chr4:120287935	A/T	cg24375607	chr4:120327624	NA	0.41	5.13	0.3	5.7e-7	Corneal astigmatism;
CESC	cis	rs962856	0.619	rs1032158	chr2:67601028	A/C	cg09028215	chr2:67624308	ETAA1	-0.42	-5.1	-0.3	6.49e-7	Pancreatic cancer;
CESC	cis	rs6089584	0.526	rs6061965	chr20:60607858	A/C	cg24733560	chr20:60626293	TAF4	0.44	6.58	0.37	2.46e-10	Body mass index;
CESC	cis	rs11583043	0.957	rs6667932	chr1:101503755	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.49	5.26	0.31	2.91e-7	Ulcerative colitis;Inflammatory bowel disease;
CESC	cis	rs933688	0.938	rs6866923	chr5:90669352	A/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.02	14.19	0.66	2.24e-34	Smoking behavior;
CESC	cis	rs1862618	0.526	rs2591963	chr5:56237135	T/A	cg24531977	chr5:56204891	C5orf35	1.0	13.17	0.63	8.1e-31	Initial pursuit acceleration;
CESC	cis	rs7552404	0.924	rs7550974	chr1:76204185	A/G	cg22875332	chr1:76189707	ACADM	0.72	10.03	0.52	2.87e-20	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs9487051	0.676	rs9386788	chr6:109600523	C/T	cg21918786	chr6:109611834	NA	0.37	5.46	0.32	1.12e-7	Reticulocyte fraction of red cells;
CESC	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg06873352	chr17:61820015	STRADA	0.72	12.78	0.62	1.79e-29	Prudent dietary pattern;
CESC	cis	rs9916302	0.861	rs644173	chr17:37430519	T/C	cg20243544	chr17:37824526	PNMT	0.49	6.17	0.35	2.58e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs6540559	1.000	rs12070337	chr1:209992127	G/A	cg25204440	chr1:209979598	IRF6	0.7	8.66	0.47	4.75e-16	Cleft lip with or without cleft palate;
CESC	cis	rs12220238	0.554	rs10824192	chr10:76251573	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.6	5.09	0.3	6.95e-7	Soluble interleukin-2 receptor subunit alpha;
CESC	cis	rs433852	0.718	rs550455	chr19:49136515	A/G	cg06677660	chr19:49140777	SEC1;DBP	-0.45	-5.49	-0.32	9.3e-8	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;
CESC	cis	rs4727027	0.933	rs62505074	chr7:148834780	C/T	cg23583168	chr7:148888333	NA	-0.73	-10.82	-0.55	7.76e-23	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg07414643	chr4:187882934	NA	0.49	7.0	0.39	2.16e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9916302	0.898	rs8072297	chr17:37478048	A/T	cg15445000	chr17:37608096	MED1	-0.45	-7.43	-0.42	1.47e-12	Glomerular filtration rate (creatinine);
CESC	cis	rs909674	0.662	rs2899318	chr22:39837625	A/G	cg05872129	chr22:39784769	NA	-0.8	-10.41	-0.54	1.75e-21	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs9322193	0.884	rs7769115	chr6:150169932	C/T	cg09699651	chr6:150184138	LRP11	0.5	6.29	0.36	1.31e-9	Lung cancer;
CESC	cis	rs7772486	0.632	rs9386128	chr6:146049053	G/A	cg05347473	chr6:146136440	FBXO30	-0.52	-6.93	-0.39	3.22e-11	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg14538439	chr10:90750381	FAS;ACTA2	-0.47	-6.45	-0.37	5.28e-10	Fibrinogen levels;
CESC	cis	rs11031096	0.711	rs1348309	chr11:4202000	A/T	cg18678763	chr11:4115507	RRM1	-0.39	-5.06	-0.3	7.72e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	cis	rs4700695	0.719	rs27085	chr5:65435063	C/T	cg21114390	chr5:65439923	SFRS12	0.47	5.8	0.34	1.9e-8	Facial morphology (factor 19);
CESC	cis	rs6580649	0.831	rs4760620	chr12:48559642	A/G	cg05342945	chr12:48394962	COL2A1	-0.54	-6.17	-0.35	2.56e-9	Lung cancer;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg10784777	chr12:56552019	MYL6	-0.44	-6.08	-0.35	4.15e-9	Asthma;
CESC	cis	rs6977955	1.000	rs917117	chr7:28176305	G/A	cg23620719	chr7:28220237	JAZF1	0.52	5.88	0.34	1.23e-8	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs2066819	1.000	rs2371454	chr12:56647243	A/G	cg26804944	chr12:56660921	COQ10A	0.85	5.19	0.3	4.22e-7	Psoriasis vulgaris;
CESC	cis	rs75887402	0.744	rs4836002	chr5:122676161	A/G	cg27033705	chr5:122759302	CEP120	-0.74	-5.07	-0.3	7.39e-7	Breast cancer;
CESC	cis	rs4843747	0.749	rs72818535	chr16:88074039	G/A	cg17633681	chr16:88106987	BANP	0.69	9.01	0.48	4.24e-17	Menopause (age at onset);
CESC	trans	rs6572548	0.504	rs1956082	chr14:49665496	A/C	cg08327423	chr16:84150746	MBTPS1	-0.52	-5.99	-0.35	6.64e-9	Subjective well-being;
CESC	cis	rs4728302	0.869	rs958405	chr7:133597151	A/G	cg10665199	chr7:133106180	EXOC4	0.42	5.89	0.34	1.16e-8	Intelligence;Intelligence (multi-trait analysis);
CESC	cis	rs8177253	0.761	rs1830083	chr3:133508551	G/A	cg01448562	chr3:133502909	NA	-0.58	-8.45	-0.46	1.9e-15	Iron status biomarkers;
CESC	cis	rs6460942	0.732	rs73677575	chr7:12286532	A/G	cg20607287	chr7:12443886	VWDE	-0.59	-6.43	-0.37	5.83e-10	Coronary artery disease;
CESC	cis	rs2380220	0.541	rs72928277	chr6:96079745	G/T	cg15832292	chr6:96025679	MANEA	-0.77	-8.1	-0.45	2.07e-14	Behavioural disinhibition (generation interaction);
CESC	trans	rs7980799	1.000	rs7980799	chr12:33576990	A/C	cg26384229	chr12:38710491	ALG10B	-0.53	-7.24	-0.41	4.75e-12	Heart rate;Heart rate variability traits (RMSSD);
CESC	cis	rs10489525	0.599	rs7526323	chr1:115604241	G/A	cg12756093	chr1:115239321	AMPD1	-0.45	-5.44	-0.32	1.19e-7	Autism;
CESC	cis	rs4660306	0.744	rs11211114	chr1:45926243	G/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.47	5.11	0.3	6.24e-7	Homocysteine levels;
CESC	cis	rs933688	0.532	rs11740007	chr5:90545498	C/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.46	-5.49	-0.32	9.43e-8	Smoking behavior;
CESC	trans	rs9929218	0.954	rs72785165	chr16:68755635	T/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.76	-9.95	-0.52	5.04e-20	Colorectal cancer;
CESC	cis	rs3106136	0.967	rs2129595	chr4:95224454	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.45	-6.73	-0.38	1.02e-10	Capecitabine sensitivity;
CESC	cis	rs7666738	0.830	rs13124127	chr4:98990729	G/A	cg03467027	chr4:99064603	C4orf37	0.43	5.4	0.31	1.49e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17142371	chr1:155278522	FDPS	0.67	7.22	0.41	5.47e-12	Gut microbiome composition (summer);
CESC	cis	rs4665809	1.000	rs1030730	chr2:26284143	T/C	cg26314531	chr2:26401878	FAM59B	-0.77	-8.56	-0.47	9.38e-16	Gut microbiome composition (summer);
CESC	cis	rs698833	0.892	rs1067322	chr2:44630107	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	6.47	0.37	4.61e-10	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs875971	0.895	rs6460278	chr7:65662736	T/C	cg10691866	chr7:65817282	TPST1	0.32	5.36	0.31	1.8e-7	Aortic root size;
CESC	cis	rs826838	0.935	rs11169547	chr12:39185625	C/A	cg26384229	chr12:38710491	ALG10B	0.78	13.13	0.63	1.09e-30	Heart rate;
CESC	cis	rs1008375	0.835	rs9760627	chr4:17651508	C/T	cg27347728	chr4:17578864	LAP3	0.43	5.08	0.3	7e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs9549367	0.789	rs9549361	chr13:113898329	C/T	cg18105134	chr13:113819100	PROZ	0.66	7.92	0.44	6.44e-14	Platelet distribution width;
CESC	cis	rs853679	0.550	rs1233707	chr6:28172953	G/A	cg26335602	chr6:28129616	ZNF389	0.48	6.63	0.38	1.9e-10	Depression;
CESC	cis	rs7772486	0.790	rs9403750	chr6:146167762	G/A	cg23711669	chr6:146136114	FBXO30	0.9	13.27	0.63	3.71e-31	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7618501	0.573	rs2624824	chr3:50088266	T/C	cg24308560	chr3:49941425	MST1R	0.61	9.02	0.48	4.04e-17	Intelligence (multi-trait analysis);
CESC	cis	rs6912958	0.703	rs9353483	chr6:88097180	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.72	10.21	0.53	7.18e-21	Monocyte percentage of white cells;
CESC	cis	rs2243480	0.901	rs58207111	chr7:65486723	C/T	cg12463550	chr7:65579703	CRCP	0.72	5.92	0.34	9.68e-9	Diabetic kidney disease;
CESC	cis	rs9914544	1.000	rs1037036	chr17:18764077	C/T	cg26378065	chr17:18585709	ZNF286B	0.43	5.06	0.3	7.84e-7	Educational attainment (years of education);
CESC	cis	rs2228479	0.867	rs75110337	chr16:89962635	C/A	cg00800038	chr16:89945340	TCF25	-0.84	-7.29	-0.41	3.49e-12	Skin colour saturation;
CESC	cis	rs713587	0.967	rs6752378	chr2:25150116	C/A	cg01884057	chr2:25150051	NA	0.43	8.02	0.44	3.42e-14	Body mass index in non-asthmatics;
CESC	cis	rs7851660	0.870	rs55960649	chr9:100598695	C/A	cg13688889	chr9:100608707	NA	-0.69	-10.74	-0.55	1.39e-22	Strep throat;
CESC	cis	rs9911578	1.000	rs304299	chr17:56838472	C/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.16	0.3	4.76e-7	Intelligence (multi-trait analysis);
CESC	cis	rs11098499	0.865	rs4001305	chr4:120359236	G/T	cg09307838	chr4:120376055	NA	0.95	13.78	0.65	6.32e-33	Corneal astigmatism;
CESC	cis	rs11864453	0.614	rs12445586	chr16:72126276	C/T	cg01557791	chr16:72042693	DHODH	-0.46	-5.92	-0.34	9.98e-9	Fibrinogen levels;
CESC	cis	rs397969	0.596	rs17668529	chr17:19899788	G/T	cg12073167	chr17:19770448	ULK2	-0.47	-5.34	-0.31	2.04e-7	Platelet count;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg00336706	chr5:43064908	NA	-0.52	-6.21	-0.36	2.05e-9	Ulcerative colitis;
CESC	cis	rs13108904	0.935	rs1732102	chr4:1277924	T/C	cg16405210	chr4:1374714	KIAA1530	0.44	5.53	0.32	7.67e-8	Obesity-related traits;
CESC	cis	rs644799	0.648	rs1255176	chr11:95471465	A/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.47	6.74	0.38	9.72e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs7264396	0.790	rs6060542	chr20:34249061	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.64	7.77	0.43	1.78e-13	Total cholesterol levels;
CESC	cis	rs2576037	0.562	rs13381557	chr18:44513371	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.79	13.08	0.63	1.72e-30	Personality dimensions;
CESC	cis	rs873946	0.590	rs12783478	chr10:134550700	A/G	cg06453172	chr10:134556979	INPP5A	-0.4	-5.43	-0.32	1.3e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs13108904	0.650	rs3796618	chr4:1349602	T/A	cg20887711	chr4:1340912	KIAA1530	0.52	6.72	0.38	1.13e-10	Obesity-related traits;
CESC	cis	rs2066819	1.000	rs2306693	chr12:56680531	T/C	cg26714650	chr12:56694279	CS	-1.52	-10.39	-0.54	1.95e-21	Psoriasis vulgaris;
CESC	cis	rs17376456	0.569	rs11135394	chr5:93187135	C/T	cg25358565	chr5:93447407	FAM172A	-0.44	-5.05	-0.3	8.12e-7	Diabetic retinopathy;
CESC	cis	rs10479542	0.503	rs12719865	chr5:178993566	C/T	cg19723775	chr5:179050963	HNRNPH1	0.41	5.32	0.31	2.23e-7	Lung cancer;
CESC	trans	rs2235573	0.527	rs5756853	chr22:38329524	G/A	cg19894588	chr14:64061835	NA	-0.58	-7.5	-0.42	9.69e-13	Glioblastoma;Glioma;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14946105	chr17:8021876	ALOXE3	-0.59	-7.01	-0.4	2.02e-11	Gut microbiome composition (summer);
CESC	trans	rs9929218	0.551	rs2296406	chr16:68721340	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.97	17.13	0.72	8.49e-45	Colorectal cancer;
CESC	cis	rs6502050	0.835	rs8071737	chr17:80117537	T/C	cg11859384	chr17:80120422	CCDC57	-0.38	-5.18	-0.3	4.42e-7	Life satisfaction;
CESC	cis	rs896854	0.654	rs10429443	chr8:95971164	A/G	cg23172400	chr8:95962367	TP53INP1	-0.43	-8.96	-0.48	6e-17	Type 2 diabetes;
CESC	cis	rs2806561	0.828	rs944509	chr1:23542242	C/T	cg12483005	chr1:23474871	LUZP1	-0.33	-5.33	-0.31	2.07e-7	Height;
CESC	cis	rs7998202	0.720	rs914020	chr13:113352848	C/G	cg02820901	chr13:113351484	ATP11A	0.63	6.04	0.35	5.07e-9	Glycated hemoglobin levels;
CESC	cis	rs2243480	1.000	rs778679	chr7:65840911	A/G	cg18252515	chr7:66147081	NA	-1.39	-14.18	-0.66	2.5e-34	Diabetic kidney disease;
CESC	cis	rs3820068	0.603	rs16851884	chr1:15961871	A/G	cg16988262	chr1:15930761	NA	0.34	5.45	0.32	1.16e-7	Systolic blood pressure;
CESC	cis	rs3862030	0.503	rs10786673	chr10:104280537	G/A	cg22532475	chr10:104410764	TRIM8	-0.33	-5.67	-0.33	3.77e-8	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
CESC	cis	rs60154123	0.505	rs76101197	chr1:210044089	T/C	cg25204440	chr1:209979598	IRF6	0.69	6.5	0.37	3.96e-10	Coronary artery disease;
CESC	cis	rs7927771	0.965	rs11039416	chr11:47846711	G/A	cg18512352	chr11:47633146	NA	-0.6	-9.57	-0.51	8.16e-19	Subjective well-being;
CESC	cis	rs1178968	1.000	rs2353062	chr7:72740048	C/T	cg25889504	chr7:72793014	NA	0.47	5.03	0.3	8.91e-7	Triglyceride levels;
CESC	cis	rs4268898	0.662	rs714531	chr2:24399877	G/A	cg20701182	chr2:24300061	SF3B14	0.72	7.23	0.41	5.21e-12	Asthma;
CESC	cis	rs4722166	0.695	rs35779989	chr7:22800314	A/C	cg05472934	chr7:22766657	IL6	0.63	8.25	0.45	7.5e-15	Lung cancer;
CESC	cis	rs6570726	0.902	rs973855	chr6:145781850	C/T	cg23711669	chr6:146136114	FBXO30	-0.73	-10.75	-0.55	1.35e-22	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs963731	0.649	rs297149	chr2:39324469	G/C	cg04010122	chr2:39346883	SOS1	-0.74	-5.39	-0.31	1.53e-7	Corticobasal degeneration;
CESC	cis	rs4716602	0.896	rs4716427	chr7:156166490	C/T	cg04090468	chr7:156181990	NA	-0.39	-5.17	-0.3	4.54e-7	Anti-saccade response;
CESC	cis	rs7208859	0.673	rs12103588	chr17:29197460	C/T	cg19761014	chr17:28927070	LRRC37B2	0.63	5.27	0.31	2.88e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs4862750	0.872	rs9998172	chr4:187898773	T/C	cg03647317	chr4:187891568	NA	-0.39	-5.83	-0.34	1.57e-8	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs13064411	0.696	rs6799610	chr3:113248748	A/C	cg18753928	chr3:113234510	CCDC52	0.46	5.3	0.31	2.5e-7	Response to simvastatin treatment (PCSK9 protein level change);
CESC	cis	rs6439153	0.933	rs1871951	chr3:128720487	A/G	cg24203234	chr3:128598194	ACAD9	0.42	5.48	0.32	9.9e-8	Pneumococcal bacteremia;
CESC	cis	rs2109514	0.870	rs6976316	chr7:116122943	G/A	cg12739419	chr7:116140593	CAV2	-0.38	-6.75	-0.38	9.22e-11	Prevalent atrial fibrillation;
CESC	cis	rs2228479	0.717	rs1061647	chr16:89806063	G/C	cg06558623	chr16:89946397	TCF25	1.12	8.63	0.47	5.8e-16	Skin colour saturation;
CESC	cis	rs2243480	1.000	rs1167613	chr7:65487439	C/T	cg13147721	chr7:65941812	NA	-0.86	-8.36	-0.46	3.7e-15	Diabetic kidney disease;
CESC	cis	rs7666738	0.830	rs28728124	chr4:99001116	G/T	cg05340658	chr4:99064831	C4orf37	0.8	12.44	0.61	2.83e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs66887589	0.616	rs6843509	chr4:120220196	G/A	cg09307838	chr4:120376055	NA	0.67	9.16	0.49	1.51e-17	Diastolic blood pressure;
CESC	cis	rs1355223	0.583	rs2941057	chr11:34882220	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.84	13.04	0.63	2.37e-30	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs75229567	0.618	rs11177849	chr12:70182473	C/T	cg10114359	chr12:70132523	RAB3IP	-1.02	-7.08	-0.4	1.31e-11	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
CESC	cis	rs13108904	0.539	rs13135102	chr4:1330983	A/C	cg22903657	chr4:1355424	KIAA1530	-0.41	-5.77	-0.33	2.22e-8	Obesity-related traits;
CESC	cis	rs7639513	0.545	rs55977822	chr3:12704438	C/A	cg23032965	chr3:12705835	RAF1	0.7	7.82	0.43	1.29e-13	Itch intensity from mosquito bite;
CESC	cis	rs1348850	0.914	rs4893938	chr2:178250095	T/C	cg22681709	chr2:178499509	PDE11A	-0.44	-6.55	-0.37	3.02e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs780096	0.526	rs2911713	chr2:27640980	G/A	cg22903471	chr2:27725779	GCKR	-0.5	-7.15	-0.4	8.58e-12	Total body bone mineral density;
CESC	cis	rs12971120	0.685	rs34780792	chr18:72173278	G/A	cg25817165	chr18:72167213	CNDP2	-0.62	-7.22	-0.41	5.48e-12	Refractive error;
CESC	cis	rs863345	0.604	rs10908665	chr1:158499889	T/A	cg12129480	chr1:158549410	OR10X1	-0.34	-6.84	-0.39	5.41e-11	Pneumococcal bacteremia;
CESC	cis	rs6952808	0.601	rs3800882	chr7:2120758	G/A	cg21782813	chr7:2030301	MAD1L1	0.44	6.31	0.36	1.14e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs425277	0.958	rs262687	chr1:2117155	G/A	cg16545954	chr1:2118288	C1orf86	0.32	5.3	0.31	2.5e-7	Height;
CESC	cis	rs10870270	1.000	rs7078692	chr10:133775370	T/A	cg17892150	chr10:133769511	PPP2R2D	-0.86	-12.56	-0.61	1.08e-28	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs9900062	1.000	rs9900062	chr17:62739574	G/A	cg02598441	chr17:62777298	LOC146880	-0.51	-5.33	-0.31	2.11e-7	QT interval;
CESC	trans	rs2963826	0.589	rs298091	chr5:58996603	A/T	cg13445258	chr3:128369860	RPN1	0.51	6.67	0.38	1.45e-10	Obesity-related traits;
CESC	cis	rs2625529	0.617	rs2957365	chr15:72348106	C/T	cg16672083	chr15:72433130	SENP8	0.46	7.08	0.4	1.26e-11	Red blood cell count;
CESC	cis	rs362296	0.661	rs3095078	chr4:3265479	C/T	cg08886695	chr4:3369023	RGS12	0.38	5.24	0.31	3.34e-7	Parental longevity (mother's age at death);
CESC	cis	rs12136530	0.562	rs12125959	chr1:19735262	A/G	cg01832549	chr1:19774989	CAPZB	-0.45	-6.28	-0.36	1.4e-9	Lead levels in blood;
CESC	cis	rs1057239	0.510	rs3766694	chr1:175143207	T/C	cg08873628	chr1:175162347	KIAA0040	-0.45	-5.64	-0.33	4.39e-8	Diastolic blood pressure;
CESC	cis	rs13256369	0.802	rs1060107	chr8:8561399	G/T	cg00074818	chr8:8560427	CLDN23	0.36	5.22	0.31	3.65e-7	Obesity-related traits;
CESC	cis	rs514406	0.571	rs11206004	chr1:53210958	G/A	cg08736216	chr1:53307985	ZYG11A	0.3	5.05	0.3	8.32e-7	Monocyte count;
CESC	cis	rs7301826	0.651	rs10734981	chr12:131297895	C/G	cg11011512	chr12:131303247	STX2	0.47	5.84	0.34	1.52e-8	Plasma plasminogen activator levels;
CESC	trans	rs57221529	0.563	rs4957057	chr5:569230	C/G	cg25482853	chr8:67687455	SGK3	0.97	10.18	0.53	9.16e-21	Lung disease severity in cystic fibrosis;
CESC	cis	rs7084402	0.967	rs1626532	chr10:60294685	A/T	cg07615347	chr10:60278583	BICC1	0.6	9.42	0.5	2.35e-18	Refractive error;
CESC	cis	rs2066819	1.000	rs41423244	chr12:56693520	A/C	cg26734620	chr12:56694298	CS	-1.02	-6.2	-0.36	2.16e-9	Psoriasis vulgaris;
CESC	cis	rs4819052	0.851	rs2236443	chr21:46678174	T/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.47	5.99	0.35	6.63e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs6502050	0.835	rs34960918	chr17:80113925	A/G	cg23985595	chr17:80112537	CCDC57	-0.42	-6.59	-0.38	2.43e-10	Life satisfaction;
CESC	cis	rs2836974	0.644	rs9978775	chr21:40694526	A/G	cg11890956	chr21:40555474	PSMG1	-0.9	-13.98	-0.65	1.17e-33	Cognitive function;
CESC	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg24503407	chr1:205819492	PM20D1	0.78	12.28	0.6	1e-27	Menarche (age at onset);
CESC	cis	rs7208859	0.623	rs9896603	chr17:29078512	C/G	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.91e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs597539	0.615	rs629426	chr11:68671104	A/G	cg18350739	chr11:68623251	NA	-0.44	-6.8	-0.39	6.75e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs7618501	0.635	rs7635002	chr3:49989155	T/G	cg24110177	chr3:50126178	RBM5	-0.54	-7.23	-0.41	5.19e-12	Intelligence (multi-trait analysis);
CESC	cis	rs854765	0.583	rs6502627	chr17:17849671	C/T	cg04398451	chr17:18023971	MYO15A	-0.69	-9.72	-0.51	2.77e-19	Total body bone mineral density;
CESC	cis	rs7659604	0.605	rs1507994	chr4:122749541	C/T	cg19748678	chr4:122722346	EXOSC9	0.72	9.33	0.5	4.51e-18	Type 2 diabetes;
CESC	cis	rs35110281	0.548	rs7276316	chr21:45029333	A/T	cg01579765	chr21:45077557	HSF2BP	-0.55	-9.2	-0.49	1.07e-17	Mean corpuscular volume;
CESC	cis	rs9329289	0.510	rs9733402	chr10:2551532	G/A	cg15501526	chr10:2543763	NA	0.47	7.56	0.42	6.51e-13	Age-related hearing impairment;
CESC	cis	rs7949030	0.591	rs35880596	chr11:62369884	C/G	cg11742103	chr11:62369870	EML3;MTA2	0.63	9.22	0.49	9.6e-18	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs2832191	0.636	rs8131283	chr21:30516796	A/G	cg24692254	chr21:30365293	RNF160	-0.63	-7.76	-0.43	1.87e-13	Dental caries;
CESC	cis	rs1707322	1.000	rs1707338	chr1:46511981	T/G	cg03146154	chr1:46216737	IPP	-0.72	-9.73	-0.51	2.49e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22219489	chr4:122745136	CCNA2	0.55	6.34	0.36	9.69e-10	Gut microbiome composition (summer);
CESC	cis	rs2404602	0.692	rs12910382	chr15:77053442	A/C	cg26408565	chr15:76604113	ETFA	-0.38	-5.52	-0.32	8.03e-8	Blood metabolite levels;
CESC	cis	rs1799949	1.000	rs16942	chr17:41244000	T/C	cg23758822	chr17:41437982	NA	1.0	15.37	0.69	1.56e-38	Menopause (age at onset);
CESC	cis	rs4555082	0.957	rs2816627	chr14:105736109	A/G	cg06808227	chr14:105710500	BRF1	-0.61	-7.85	-0.43	1.07e-13	Mean platelet volume;Platelet distribution width;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg11380830	chr10:96123085	NOC3L	0.46	6.26	0.36	1.53e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs7618915	0.547	rs6976	chr3:52728804	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.5	0.37	3.97e-10	Bipolar disorder;
CESC	cis	rs1198430	0.636	rs2811963	chr1:23824242	A/C	cg22040403	chr1:23858016	E2F2	0.64	5.74	0.33	2.63e-8	Total cholesterol levels;
CESC	cis	rs4555082	0.718	rs75139030	chr14:105710853	A/AG	cg13114125	chr14:105738426	BRF1	-0.86	-10.3	-0.53	3.86e-21	Mean platelet volume;Platelet distribution width;
CESC	cis	rs4665809	0.590	rs35727620	chr2:26458364	G/A	cg26314531	chr2:26401878	FAM59B	0.85	9.04	0.49	3.44e-17	Gut microbiome composition (summer);
CESC	cis	rs7726839	0.540	rs4957083	chr5:659343	T/C	cg16447950	chr5:562315	NA	-0.59	-6.46	-0.37	4.92e-10	Obesity-related traits;
CESC	cis	rs7818688	0.697	rs17665714	chr8:95982542	T/C	cg16049864	chr8:95962084	TP53INP1	0.55	5.55	0.32	6.92e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs4867766	0.789	rs17781920	chr5:173955939	G/A	cg20434911	chr5:173954559	NA	-0.59	-6.34	-0.36	9.87e-10	Stroke;
CESC	cis	rs853679	0.550	rs1233699	chr6:28169158	A/T	cg19592336	chr6:28129416	ZNF389	0.52	7.19	0.4	6.45e-12	Depression;
CESC	cis	rs9916302	0.851	rs6503518	chr17:37660469	A/G	cg07936489	chr17:37558343	FBXL20	-0.82	-12.22	-0.6	1.6e-27	Glomerular filtration rate (creatinine);
CESC	cis	rs4481887	1.000	rs7517319	chr1:248466408	C/A	cg00666640	chr1:248458726	OR2T12	0.39	6.37	0.36	8.47e-10	Common traits (Other);
CESC	cis	rs896854	0.967	rs896853	chr8:95960855	G/C	cg13393036	chr8:95962371	TP53INP1	-0.55	-12.75	-0.62	2.44e-29	Type 2 diabetes;
CESC	cis	rs7914558	1.000	rs10883824	chr10:104812897	A/G	cg08650961	chr10:104748594	CNNM2	0.31	5.17	0.3	4.67e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs6500602	0.623	rs9929311	chr16:4510426	T/C	cg08645402	chr16:4508243	NA	0.43	6.25	0.36	1.64e-9	Schizophrenia;
CESC	trans	rs35110281	0.776	rs2838338	chr21:45075582	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.52	6.82	0.39	6.27e-11	Mean corpuscular volume;
CESC	cis	rs3762637	1.000	rs9968189	chr3:122175136	G/A	cg24169773	chr3:122142474	KPNA1	-0.54	-6.33	-0.36	1.04e-9	LDL cholesterol levels;
CESC	cis	rs10779751	0.960	rs1883965	chr1:11322156	A/G	cg08854313	chr1:11322531	MTOR	0.81	11.1	0.56	9.33e-24	Body mass index;
CESC	cis	rs6831352	0.819	rs1230158	chr4:99990186	T/C	cg21548116	chr4:100009993	ADH5	0.49	5.39	0.31	1.58e-7	Alcohol dependence;
CESC	cis	rs6736093	0.871	rs35471545	chr2:112756711	T/G	cg12686935	chr2:112915763	FBLN7	-0.41	-5.56	-0.32	6.64e-8	Coronary artery disease;
CESC	cis	rs4819052	0.851	rs3673	chr21:46681775	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.85	12.62	0.61	6.7200000000000006e-29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs6598955	0.724	rs3924934	chr1:26644079	A/G	cg00852783	chr1:26633632	UBXN11	0.43	6.24	0.36	1.75e-9	Obesity-related traits;
CESC	cis	rs6499129	0.867	rs8056770	chr16:67416730	A/C	cg26727032	chr16:67993705	SLC12A4	-0.52	-5.87	-0.34	1.27e-8	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs7945705	0.905	rs2568054	chr11:8876029	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.47	-7.89	-0.44	7.88e-14	Hemoglobin concentration;
CESC	cis	rs7666738	0.680	rs34267968	chr4:99002574	A/T	cg05340658	chr4:99064831	C4orf37	0.8	12.44	0.61	2.83e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7917772	0.503	rs7915589	chr10:104299264	G/A	ch.10.2196322F	chr10:104248062	ACTR1A	0.42	5.19	0.3	4.1e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs34779708	0.733	rs12240638	chr10:35542610	G/T	cg03585969	chr10:35415529	CREM	0.56	6.42	0.37	6.15e-10	Inflammatory bowel disease;Crohn's disease;
CESC	trans	rs9858542	0.953	rs9859556	chr3:49455986	G/T	cg21659725	chr3:3221576	CRBN	-0.56	-6.6	-0.38	2.17e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs7829975	0.714	rs4841042	chr8:8664622	A/G	cg06636001	chr8:8085503	FLJ10661	-0.48	-6.17	-0.35	2.51e-9	Mood instability;
CESC	cis	rs6120849	0.754	rs17319032	chr20:33643296	T/C	cg06115741	chr20:33292138	TP53INP2	0.53	5.05	0.3	8.15e-7	Protein C levels;
CESC	cis	rs7666738	0.791	rs10033211	chr4:98995624	T/A	cg05340658	chr4:99064831	C4orf37	0.8	12.44	0.61	2.83e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7618915	0.501	rs11130308	chr3:52639257	G/C	cg18099408	chr3:52552593	STAB1	-0.3	-5.11	-0.3	6.18e-7	Bipolar disorder;
CESC	cis	rs9649213	0.593	rs13307593	chr7:97986146	A/G	cg24562669	chr7:97807699	LMTK2	0.51	7.63	0.42	4.29e-13	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs3741404	0.560	rs12362602	chr11:63908660	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.6	-8.36	-0.46	3.59e-15	Platelet count;
CESC	cis	rs2736345	0.516	rs9657551	chr8:11398183	A/G	cg09528494	chr8:11338675	NA	0.32	6.03	0.35	5.34e-9	Sjögren's syndrome;Systemic lupus erythematosus;
CESC	cis	rs6860806	0.661	rs2136188	chr5:131577514	A/G	cg14196790	chr5:131705035	SLC22A5	-0.34	-5.36	-0.31	1.81e-7	Breast cancer;
CESC	cis	rs1707322	0.835	rs946525	chr1:46487277	A/T	cg05343316	chr1:45956843	TESK2	-0.45	-5.54	-0.32	7.32e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs76878669	0.561	rs1892940	chr11:66111251	A/G	cg18002602	chr11:66138449	SLC29A2	-0.41	-6.68	-0.38	1.39e-10	Educational attainment (years of education);
CESC	cis	rs4148883	0.629	rs2602899	chr4:100010128	C/T	cg12011299	chr4:100065546	ADH4	0.66	9.57	0.51	7.76e-19	Alcohol dependence;
CESC	cis	rs10883723	0.810	rs913025	chr10:104276043	C/T	cg22532475	chr10:104410764	TRIM8	-0.35	-5.9	-0.34	1.13e-8	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs17711722	0.701	rs781143	chr7:65439879	G/C	cg11764359	chr7:65958608	NA	0.68	8.69	0.47	3.76e-16	Calcium levels;
CESC	cis	rs4595586	0.545	rs4411311	chr12:39363612	C/G	cg26384229	chr12:38710491	ALG10B	0.54	7.54	0.42	7.28e-13	Morning vs. evening chronotype;
CESC	cis	rs7666738	0.830	rs4699591	chr4:98974171	A/G	cg05340658	chr4:99064831	C4orf37	0.79	12.26	0.6	1.12e-27	Colonoscopy-negative controls vs population controls;
CESC	cis	rs5753618	0.555	rs9609302	chr22:31895987	A/C	cg02404636	chr22:31891804	SFI1	0.42	5.64	0.33	4.35e-8	Colorectal cancer;
CESC	cis	rs35079168	0.961	rs66475113	chr9:137284381	C/T	cg13941235	chr9:137270186	RXRA	-0.31	-5.55	-0.32	7e-8	Intelligence;
CESC	cis	rs7618915	0.508	rs12498066	chr3:52627660	G/A	cg17372223	chr3:52568218	NT5DC2	0.43	6.43	0.37	5.84e-10	Bipolar disorder;
CESC	cis	rs7072216	0.763	rs7910247	chr10:100172252	C/T	cg26618903	chr10:100175079	PYROXD2	-0.38	-5.86	-0.34	1.38e-8	Metabolite levels;
CESC	cis	rs35146811	0.844	rs13223792	chr7:99675659	T/G	cg13334819	chr7:99746414	C7orf59	-0.42	-5.14	-0.3	5.27e-7	Coronary artery disease;
CESC	cis	rs2075371	0.933	rs1421480	chr7:133958114	A/C	cg11752832	chr7:134001865	SLC35B4	0.51	6.52	0.37	3.54e-10	Mean platelet volume;
CESC	cis	rs11166629	1.000	rs894349	chr8:135638055	T/C	cg21672855	chr8:135614777	ZFAT	0.4	5.03	0.3	9.18e-7	Smoking quantity;
CESC	cis	rs7927771	0.524	rs12362318	chr11:47682671	T/C	cg20307385	chr11:47447363	PSMC3	0.63	8.7	0.47	3.61e-16	Subjective well-being;
CESC	trans	rs916888	0.647	rs199523	chr17:44848517	C/A	cg07870213	chr5:140052090	DND1	-0.47	-6.07	-0.35	4.45e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs2279817	0.955	rs2270977	chr1:18023509	T/C	cg21791023	chr1:18019539	ARHGEF10L	0.58	8.23	0.45	8.3e-15	Neuroticism;
CESC	cis	rs9457247	0.534	rs4710149	chr6:167386346	T/C	cg25258033	chr6:167368657	RNASET2	-0.38	-5.38	-0.31	1.66e-7	Crohn's disease;
CESC	cis	rs10911232	0.507	rs10797815	chr1:182996827	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.84	13.19	0.63	6.74e-31	Hypertriglyceridemia;
CESC	cis	rs10851478	0.872	rs1818308	chr15:49815650	T/A	cg08060515	chr15:49448048	GALK2;COPS2	0.42	5.19	0.3	4.12e-7	Oral cavity cancer;
CESC	cis	rs1008375	1.000	rs6848360	chr4:17634442	G/T	cg04450456	chr4:17643702	FAM184B	0.37	5.18	0.3	4.46e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs13082711	0.863	rs35797268	chr3:27418862	T/C	cg02860705	chr3:27208620	NA	0.62	7.44	0.42	1.43e-12	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CESC	cis	rs2294693	0.945	rs13216361	chr6:41007046	C/T	cg14418226	chr6:40996092	UNC5CL	0.54	6.3	0.36	1.2e-9	Gastric cancer;Non-cardia gastric cancer;
CESC	cis	rs916888	0.821	rs415430	chr17:44859144	C/T	cg01570182	chr17:44337453	NA	-0.88	-10.64	-0.55	2.96e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs11098499	0.644	rs10009566	chr4:120558608	A/G	cg09307838	chr4:120376055	NA	0.73	9.81	0.52	1.36e-19	Corneal astigmatism;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00140813	chr16:28857836	TUFM	0.54	6.26	0.36	1.55e-9	Gut microbiome composition (summer);
CESC	cis	rs7584330	0.554	rs112402109	chr2:238429058	A/G	cg14458575	chr2:238380390	NA	0.53	5.68	0.33	3.53e-8	Prostate cancer;
CESC	cis	rs3015497	0.543	rs1565834	chr14:51011528	C/T	cg26011998	chr14:51135199	SAV1	0.49	5.59	0.32	5.55e-8	Mean platelet volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20696752	chr17:42143797	LSM12	0.57	6.27	0.36	1.47e-9	Gut microbiome composition (summer);
CESC	cis	rs1609391	0.543	rs1347209	chr3:136626697	G/T	cg15507776	chr3:136538369	TMEM22	0.82	11.97	0.59	1.08e-26	Neuroticism;
CESC	cis	rs1062177	0.756	rs2964591	chr5:151117397	A/G	cg12924095	chr5:151150029	G3BP1	-0.4	-5.11	-0.3	6.32e-7	Preschool internalizing problems;
CESC	cis	rs9649213	0.593	rs12728	chr7:97922851	C/T	cg00277769	chr7:97922759	BAIAP2L1	-0.33	-5.35	-0.31	1.87e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs13102973	0.965	rs13106621	chr4:135854975	A/T	cg14419869	chr4:135874104	NA	0.33	5.13	0.3	5.55e-7	Subjective well-being;
CESC	cis	rs9527	0.568	rs1926036	chr10:104883812	C/T	cg04362960	chr10:104952993	NT5C2	0.44	5.54	0.32	7.12e-8	Arsenic metabolism;
CESC	trans	rs79976124	0.797	rs78317899	chr6:66652896	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.76	8.75	0.47	2.61e-16	Type 2 diabetes;
CESC	cis	rs11718455	0.960	rs17076255	chr3:44002093	C/T	cg08738300	chr3:44038990	NA	0.45	6.03	0.35	5.48e-9	Coronary artery disease;
CESC	cis	rs7666738	0.830	rs10028505	chr4:98962310	C/A	cg03676636	chr4:99064102	C4orf37	0.33	5.14	0.3	5.39e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs807669	0.525	rs2282684	chr22:19184244	C/T	cg02655711	chr22:19163373	SLC25A1	0.42	6.29	0.36	1.3e-9	Metabolite levels;
CESC	trans	rs4424809	0.614	rs75435370	chr13:85572867	A/C	cg05918002	chr17:5019452	ZNF232	-0.63	-6.08	-0.35	4.29e-9	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs213032	1.000	rs213030	chr1:21653847	C/T	cg16416158	chr1:21652298	ECE1	0.31	5.04	0.3	8.78e-7	Obesity-related traits;
CESC	cis	rs67478160	0.654	rs1535097	chr14:104216649	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.49	-6.87	-0.39	4.53e-11	Schizophrenia;
CESC	cis	rs11098499	0.955	rs13113112	chr4:120156040	C/T	cg09307838	chr4:120376055	NA	0.86	11.38	0.57	1.05e-24	Corneal astigmatism;
CESC	cis	rs8114671	0.839	rs2104084	chr20:33649217	G/C	cg07148914	chr20:33460835	GGT7	-0.4	-5.11	-0.3	6.21e-7	Height;
CESC	cis	rs2242194	0.844	rs11264295	chr1:154987526	C/T	cg12436631	chr1:155007014	DCST1;DCST2	0.47	8.12	0.45	1.72e-14	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06196466	chr12:124933388	NCOR2	-0.55	-6.66	-0.38	1.53e-10	Gut microbiome composition (summer);
CESC	cis	rs9462846	0.959	rs9471958	chr6:42883669	C/T	cg02353165	chr6:42928485	GNMT	0.5	5.62	0.33	4.88e-8	Blood protein levels;
CESC	trans	rs4756846	1.000	rs4756846	chr11:16403511	C/T	cg26608174	chr17:46711035	MIR196A1	0.49	6.11	0.35	3.58e-9	Obesity and osteoporosis;
CESC	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg16132339	chr22:24313637	DDTL;DDT	0.34	5.08	0.3	7.12e-7	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs1372520	0.684	rs2572318	chr4:90718719	C/T	cg15133208	chr4:90757351	SNCA	-0.42	-5.71	-0.33	3.03e-8	Neuroticism;
CESC	cis	rs6088580	0.634	rs6088512	chr20:33095891	G/A	cg24642439	chr20:33292090	TP53INP2	0.5	6.55	0.37	3.05e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs765787	0.530	rs1706834	chr15:45517854	G/A	cg24006582	chr15:45444508	DUOX1	-0.53	-6.47	-0.37	4.75e-10	Uric acid levels;
CESC	cis	rs4737010	0.570	rs7823138	chr8:41644861	C/T	cg08923054	chr8:41654455	ANK1	-0.52	-6.53	-0.37	3.3e-10	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
CESC	cis	rs1003719	0.788	rs7277657	chr21:38469523	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.63	8.77	0.47	2.14e-16	Eye color traits;
CESC	cis	rs61008539	0.893	rs4721502	chr7:862186	A/G	cg15782153	chr7:917662	C7orf20	0.48	6.95	0.39	2.78e-11	Perceived unattractiveness to mosquitoes;
CESC	trans	rs722599	0.562	rs2287400	chr14:75182937	G/A	cg00095594	chr1:236228625	NID1	0.39	6.02	0.35	5.67e-9	IgG glycosylation;
CESC	cis	rs67311347	0.544	rs9868700	chr3:40345408	G/A	cg09455208	chr3:40491958	NA	0.37	6.51	0.37	3.77e-10	Renal cell carcinoma;
CESC	cis	rs10504229	1.000	rs17216620	chr8:58169412	A/G	cg05313129	chr8:58192883	C8orf71	-0.55	-6.37	-0.36	8.42e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs1878931	0.559	rs11643501	chr16:3392752	T/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.71	8.96	0.48	5.91e-17	Body mass index (adult);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg03747177	chr16:23568683	EARS2;UBFD1	-0.44	-6.18	-0.35	2.41e-9	Gambling;
CESC	trans	rs8073060	0.586	rs117573546	chr17:33909588	G/A	cg19694781	chr19:47549865	TMEM160	0.73	7.01	0.4	1.96e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	cis	rs2370759	1.000	rs79806114	chr10:32618022	T/C	cg01819863	chr10:32635814	EPC1	1.16	12.46	0.61	2.26e-28	Sexual dysfunction (female);
CESC	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.71	9.97	0.52	4.3e-20	Prudent dietary pattern;
CESC	cis	rs3091242	0.934	rs666686	chr1:25719511	A/G	cg12412775	chr1:25698385	RHCE	-0.3	-5.49	-0.32	9.37e-8	Erythrocyte sedimentation rate;
CESC	cis	rs7666738	0.791	rs1967978	chr4:98966152	T/C	cg03676636	chr4:99064102	C4orf37	0.33	5.14	0.3	5.39e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs4332037	1.000	rs62442899	chr7:1948454	C/T	cg11693508	chr17:37793320	STARD3	0.68	6.51	0.37	3.77e-10	Bipolar disorder;
CESC	cis	rs4604732	0.631	rs11490199	chr1:247625737	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.57	7.17	0.4	7.39e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs875971	0.862	rs12698526	chr7:65969105	T/C	cg18252515	chr7:66147081	NA	-0.47	-6.11	-0.35	3.53e-9	Aortic root size;
CESC	cis	rs7618915	0.571	rs6778844	chr3:52596398	C/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	-0.32	-5.62	-0.33	4.92e-8	Bipolar disorder;
CESC	cis	rs875971	0.522	rs4718286	chr7:65292764	A/G	cg26939375	chr7:64535504	NA	0.76	10.78	0.55	1.03e-22	Aortic root size;
CESC	trans	rs9987353	0.840	rs329994	chr8:9123233	A/G	cg16635483	chr3:96338407	NA	0.48	6.3	0.36	1.23e-9	Recombination measurement;
CESC	cis	rs3768617	0.811	rs12138049	chr1:182979546	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.66	9.0	0.48	4.41e-17	Fuchs's corneal dystrophy;
CESC	cis	rs896854	0.608	rs7004862	chr8:95876963	T/G	cg09323728	chr8:95962352	TP53INP1	-0.36	-7.64	-0.42	4.1e-13	Type 2 diabetes;
CESC	cis	rs6951245	1.000	rs11764748	chr7:1094508	T/C	cg24642844	chr7:1081250	C7orf50	-0.67	-8.14	-0.45	1.59e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7953249	0.656	rs1732391	chr12:121392341	C/T	cg02403541	chr12:121454288	C12orf43	-0.53	-6.88	-0.39	4.43e-11	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
CESC	cis	rs13385	0.769	rs35400561	chr5:139622265	G/A	cg26211634	chr5:139558579	C5orf32	0.51	5.57	0.32	6.11e-8	Atrial fibrillation;
CESC	cis	rs1593	0.734	rs4862670	chr4:187145423	A/T	cg23442198	chr4:187126114	CYP4V2	0.64	5.15	0.3	5.16e-7	Activated partial thromboplastin time;
CESC	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg18402987	chr7:1209562	NA	0.63	7.37	0.41	2.16e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs1799949	1.000	rs12936816	chr17:41301709	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.67	9.36	0.5	3.44e-18	Menopause (age at onset);
CESC	trans	rs1814175	0.817	rs10128730	chr11:50023369	G/T	cg03929089	chr4:120376271	NA	-0.94	-16.01	-0.7	7.75e-41	Height;
CESC	cis	rs1009170	0.794	rs112924085	chr14:92581713	C/T	cg10324096	chr14:92587714	CPSF2;NDUFB1	0.54	5.07	0.3	7.38e-7	Dialysis-related mortality;
CESC	cis	rs72781680	1.000	rs17762102	chr2:24085606	A/G	cg20701182	chr2:24300061	SF3B14	0.63	5.63	0.33	4.49e-8	Lymphocyte counts;
CESC	cis	rs3733585	0.624	rs7376154	chr4:9952587	C/A	cg00071950	chr4:10020882	SLC2A9	-0.69	-11.34	-0.57	1.42e-24	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs1348850	0.668	rs2365619	chr2:178497366	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.45	-5.11	-0.3	6.23e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs428668	0.523	rs10060607	chr5:150679304	A/C	cg14086364	chr5:150678334	SLC36A3	0.49	7.06	0.4	1.49e-11	Skin aging (microtopography measurement);
CESC	trans	rs3780486	0.757	rs10121987	chr9:33119818	A/G	cg04842962	chr6:43655489	MRPS18A	0.98	18.32	0.75	5.56e-49	IgG glycosylation;
CESC	cis	rs9902453	0.765	rs2874505	chr17:28037923	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.73	9.61	0.51	5.87e-19	Coffee consumption (cups per day);
CESC	cis	rs9486715	0.838	rs9486275	chr6:96901187	C/T	cg06623918	chr6:96969491	KIAA0776	0.91	14.06	0.65	6.39e-34	Headache;
CESC	cis	rs1692580	0.846	rs377599	chr1:2164699	C/T	cg21194808	chr1:2205498	SKI	0.37	5.19	0.3	4.22e-7	Coronary artery disease;
CESC	cis	rs11209002	0.522	rs2224502	chr1:67539439	A/G	cg02640540	chr1:67518911	SLC35D1	0.47	5.39	0.31	1.52e-7	Crohn's disease;
CESC	cis	rs4423214	0.559	rs10898201	chr11:71201527	C/A	cg05163923	chr11:71159392	DHCR7	-0.65	-6.55	-0.37	2.95e-10	Vitamin D levels;
CESC	cis	rs7799006	0.723	rs2270052	chr7:2291399	C/T	cg08027265	chr7:2291960	NA	-0.57	-9.9	-0.52	7.5e-20	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs300703	0.515	rs300694	chr2:182277	G/T	cg21211680	chr2:198530	NA	-0.89	-10.36	-0.54	2.36e-21	Blood protein levels;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg21382589	chr2:8785969	NA	0.49	6.32	0.36	1.08e-9	Fibrinogen levels;
CESC	cis	rs2832077	0.943	rs11701777	chr21:30155828	T/C	cg03476357	chr21:30257390	N6AMT1	-0.5	-5.51	-0.32	8.42e-8	Cognitive test performance;
CESC	trans	rs1814175	0.669	rs11040455	chr11:49669829	G/C	cg15704280	chr7:45808275	SEPT13	-0.82	-11.49	-0.58	4.55e-25	Height;
CESC	cis	rs4819052	1.000	rs2297284	chr21:46705345	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.94	12.52	0.61	1.44e-28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs2228479	0.867	rs76885005	chr16:89966668	A/G	cg06558623	chr16:89946397	TCF25	1.06	9.08	0.49	2.48e-17	Skin colour saturation;
CESC	cis	rs2404602	0.716	rs7169394	chr15:76913274	G/A	cg26408565	chr15:76604113	ETFA	-0.39	-5.49	-0.32	9.6e-8	Blood metabolite levels;
CESC	cis	rs10504229	0.683	rs10504224	chr8:58143735	A/G	cg02725872	chr8:58115012	NA	-0.42	-5.98	-0.34	7.21e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs1371867	0.846	rs1692006	chr8:101252462	C/T	cg06002616	chr8:101225028	SPAG1	0.33	5.3	0.31	2.48e-7	Atrioventricular conduction;
CESC	cis	rs769267	0.899	rs3934667	chr19:19431423	T/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.62	-7.97	-0.44	4.59e-14	Tonsillectomy;
CESC	cis	rs3540	0.597	rs1978150	chr15:91037041	A/G	cg10434728	chr15:90938212	IQGAP1	-0.42	-7.53	-0.42	8.14e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs1003719	0.680	rs2835668	chr21:38580151	C/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.61	-8.22	-0.45	9.27e-15	Eye color traits;
CESC	cis	rs7246657	0.943	rs2045908	chr19:37979768	C/G	cg23950597	chr19:37808831	NA	-0.59	-6.63	-0.38	1.86e-10	Coronary artery calcification;
CESC	cis	rs4253772	0.591	rs6008546	chr22:46686377	T/G	cg10541313	chr22:46663664	TTC38	0.63	5.6	0.33	5.27e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs3092073	0.624	rs3848719	chr20:44596545	G/A	cg00125455	chr20:44574271	PCIF1	0.39	6.15	0.35	2.81e-9	Intelligence (multi-trait analysis);
CESC	cis	rs4727963	0.846	rs1581561	chr7:122705273	C/G	cg03640110	chr7:122635026	TAS2R16	-0.37	-5.7	-0.33	3.11e-8	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
CESC	cis	rs8077889	0.957	rs17742929	chr17:41891437	C/T	cg26893861	chr17:41843967	DUSP3	0.77	8.82	0.48	1.53e-16	Triglycerides;
CESC	cis	rs34779708	0.931	rs4934724	chr10:35393669	C/T	cg03585969	chr10:35415529	CREM	0.77	10.1	0.53	1.62e-20	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs4481887	0.927	rs6666903	chr1:248465582	T/A	cg00666640	chr1:248458726	OR2T12	0.32	5.46	0.32	1.07e-7	Common traits (Other);
CESC	cis	rs7927592	0.913	rs2282563	chr11:68333200	C/T	cg20283391	chr11:68216788	NA	-0.61	-7.36	-0.41	2.26e-12	Total body bone mineral density;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg11522767	chr6:157342961	ARID1B	0.47	6.25	0.36	1.67e-9	Systemic lupus erythematosus;
CESC	cis	rs644799	0.540	rs10831419	chr11:95478037	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.65	9.05	0.49	3.06e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs9303401	0.659	rs34170300	chr17:56789905	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.03	12.82	0.62	1.31e-29	Cognitive test performance;
CESC	trans	rs4349753	0.640	rs72804498	chr5:144083143	T/C	cg22407458	chr6:35109121	TCP11	0.5	6.31	0.36	1.18e-9	Photic sneeze reflex;
CESC	cis	rs2040771	0.804	rs1091013	chr22:19248587	C/T	cg02655711	chr22:19163373	SLC25A1	0.42	6.08	0.35	4.1e-9	Metabolite levels (small molecules and protein measures);
CESC	cis	rs9611565	0.681	rs5751094	chr22:41803279	C/T	cg17376030	chr22:41985996	PMM1	-0.59	-6.24	-0.36	1.69e-9	Vitiligo;
CESC	cis	rs965469	1.000	rs3310	chr20:3237232	C/T	cg25506879	chr20:3388711	C20orf194	-0.6	-6.45	-0.37	5.14e-10	IFN-related cytopenia;
CESC	cis	rs1371867	0.817	rs1788208	chr8:101312515	T/C	cg11906718	chr8:101322791	RNF19A	0.54	6.93	0.39	3.1e-11	Atrioventricular conduction;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07874155	chr5:138089656	CTNNA1	-0.55	-6.21	-0.36	2.08e-9	Gut microbiome composition (summer);
CESC	cis	rs7089973	0.604	rs11819372	chr10:116594934	A/G	cg03647239	chr10:116582469	FAM160B1	0.44	5.76	0.33	2.28e-8	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25240468	chr2:62115958	CCT4	0.54	6.17	0.35	2.53e-9	Gut microbiome composition (summer);
CESC	cis	rs1008375	0.966	rs2872957	chr4:17651757	C/A	cg16339924	chr4:17578868	LAP3	0.65	8.27	0.45	6.38e-15	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs597539	0.652	rs602364	chr11:68662167	C/T	cg18350739	chr11:68623251	NA	-0.45	-6.96	-0.39	2.67e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs2228479	0.867	rs12919804	chr16:89945369	G/A	cg14709524	chr16:89940631	TCF25	0.74	5.75	0.33	2.43e-8	Skin colour saturation;
CESC	cis	rs2991971	0.810	rs12738318	chr1:45929589	A/G	cg24296786	chr1:45957014	TESK2	-0.61	-8.72	-0.47	3.1e-16	High light scatter reticulocyte count;
CESC	cis	rs748404	0.697	rs531910	chr15:43560607	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	7.84	0.43	1.08e-13	Lung cancer;
CESC	cis	rs4805272	0.539	rs11883172	chr19:29318536	C/T	cg12756686	chr19:29218302	NA	0.51	5.94	0.34	8.77e-9	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23374814	chr5:72292757	FCHO2	-0.65	-7.31	-0.41	3.07e-12	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01010380	chr5:32313163	MTMR12	0.56	6.48	0.37	4.56e-10	Gut microbiome composition (summer);
CESC	cis	rs1799949	0.965	rs11651623	chr17:41329847	G/A	cg23758822	chr17:41437982	NA	1.04	15.74	0.7	7.3e-40	Menopause (age at onset);
CESC	cis	rs3850699	0.666	rs7905481	chr10:104476292	T/C	cg04362960	chr10:104952993	NT5C2	0.47	5.41	0.32	1.42e-7	Prostate cancer;
CESC	cis	rs4891159	0.790	rs1056714	chr18:74149526	A/G	cg24786174	chr18:74118243	ZNF516	-0.73	-11.02	-0.56	1.72e-23	Longevity;
CESC	cis	rs2932538	0.922	rs6671645	chr1:113129128	A/G	cg22162597	chr1:113214053	CAPZA1	0.47	6.35	0.36	9.56e-10	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CESC	cis	rs736408	0.505	rs2083180	chr3:52668119	G/T	cg17372223	chr3:52568218	NT5DC2	0.42	6.41	0.37	6.55e-10	Bipolar disorder;
CESC	cis	rs7605827	0.930	rs11675805	chr2:15578274	C/T	cg19274914	chr2:15703543	NA	0.34	6.07	0.35	4.38e-9	Educational attainment (years of education);
CESC	cis	rs10876993	0.928	rs7136269	chr12:58075937	G/A	cg18357645	chr12:58087776	OS9	0.63	10.35	0.54	2.58e-21	Celiac disease or Rheumatoid arthritis;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg02405619	chr13:111906946	ARHGEF7	0.48	6.88	0.39	4.37e-11	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg07677032	chr17:61819896	STRADA	0.44	5.88	0.34	1.2e-8	Prudent dietary pattern;
CESC	cis	rs1881797	1.000	rs67977965	chr1:247687835	G/A	cg05639522	chr1:247681581	NA	0.46	6.02	0.35	5.84e-9	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg11494091	chr17:61959527	GH2	0.75	13.12	0.63	1.23e-30	Prudent dietary pattern;
CESC	cis	rs2204008	0.805	rs2874289	chr12:38258420	G/A	cg13010199	chr12:38710504	ALG10B	0.54	6.7	0.38	1.27e-10	Bladder cancer;
CESC	cis	rs2033711	0.837	rs3764535	chr19:58929052	G/A	cg11952622	chr19:58962976	ZNF324B	0.52	6.94	0.39	3.06e-11	Uric acid clearance;
CESC	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg04025307	chr7:1156635	C7orf50	0.58	9.91	0.52	6.75e-20	Longevity;Endometriosis;
CESC	cis	rs6582630	0.572	rs7315897	chr12:38449081	C/T	cg26384229	chr12:38710491	ALG10B	-0.44	-5.94	-0.34	9.08e-9	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg07157834	chr1:205819609	PM20D1	-0.57	-8.74	-0.47	2.81e-16	Monocyte percentage of white cells;
CESC	cis	rs3820068	0.553	rs7545782	chr1:15955227	G/C	cg13390004	chr1:15929781	NA	0.37	5.9	0.34	1.12e-8	Systolic blood pressure;
CESC	cis	rs796364	0.951	rs12996313	chr2:200997916	C/T	cg23649088	chr2:200775458	C2orf69	-0.52	-5.09	-0.3	6.95e-7	Schizophrenia;
CESC	cis	rs9322193	0.923	rs10782318	chr6:150075273	A/G	cg09699651	chr6:150184138	LRP11	0.41	5.14	0.3	5.44e-7	Lung cancer;
CESC	cis	rs208520	1.000	rs208523	chr6:66954195	G/C	cg07460842	chr6:66804631	NA	-0.9	-10.34	-0.54	2.79e-21	Exhaled nitric oxide output;
CESC	cis	rs60871478	0.898	rs4720929	chr7:808009	T/C	cg27478167	chr7:817139	HEATR2	-0.47	-5.61	-0.33	5.18e-8	Cerebrospinal P-tau181p levels;
CESC	cis	rs6964587	0.967	rs10246036	chr7:91558523	G/A	cg17063962	chr7:91808500	NA	-0.59	-7.88	-0.44	8.67e-14	Breast cancer;
CESC	cis	rs10887741	0.690	rs4934357	chr10:89439533	G/A	cg13926569	chr10:89418898	PAPSS2	0.4	6.08	0.35	4.2e-9	Exercise (leisure time);
CESC	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg07677032	chr17:61819896	STRADA	0.45	5.92	0.34	1.01e-8	Prudent dietary pattern;
CESC	cis	rs4704187	0.687	rs7711762	chr5:74461675	C/T	cg03227963	chr5:74354835	NA	0.29	5.32	0.31	2.25e-7	Response to amphetamines;
CESC	trans	rs4942242	0.663	rs34595450	chr13:44221245	A/G	cg19169023	chr15:41853346	TYRO3	-0.61	-7.78	-0.43	1.67e-13	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs367615	0.680	rs816542	chr5:108982624	A/G	cg17395555	chr5:108820864	NA	0.38	5.39	0.31	1.58e-7	Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs7116495	0.881	rs6592451	chr11:71674937	G/A	cg26138937	chr11:71823887	C11orf51	-0.79	-6.51	-0.37	3.77e-10	Severe influenza A (H1N1) infection;
CESC	cis	rs12681288	0.823	rs2701903	chr8:1004029	A/G	cg15309053	chr8:964076	NA	-0.35	-6.18	-0.36	2.38e-9	Schizophrenia;
CESC	cis	rs7772486	0.597	rs6912351	chr6:146264071	T/C	cg23711669	chr6:146136114	FBXO30	-0.93	-12.2	-0.6	1.79e-27	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1862618	0.671	rs173763	chr5:56225418	G/A	cg12311346	chr5:56204834	C5orf35	-0.64	-8.78	-0.47	2.01e-16	Initial pursuit acceleration;
CESC	cis	rs9611565	0.592	rs5996039	chr22:41981957	A/G	cg17376030	chr22:41985996	PMM1	0.49	5.49	0.32	9.33e-8	Vitiligo;
CESC	cis	rs2011503	0.941	rs6511027	chr19:19391851	C/T	cg11584989	chr19:19387371	SF4	0.58	6.98	0.39	2.42e-11	Bipolar disorder;
CESC	cis	rs9894429	0.646	rs8079963	chr17:79603285	C/T	cg13777783	chr17:79615861	NA	-0.37	-6.16	-0.35	2.72e-9	Eye color traits;
CESC	cis	rs12476592	0.543	rs1446569	chr2:63818314	C/G	cg17519650	chr2:63277830	OTX1	-0.45	-5.12	-0.3	5.75e-7	Childhood ear infection;
CESC	cis	rs12530845	0.561	rs73725182	chr7:135291001	C/T	cg23117316	chr7:135346802	PL-5283	-0.5	-5.59	-0.32	5.59e-8	Red blood cell traits;
CESC	cis	rs2066819	1.000	rs77447765	chr12:56690662	G/A	cg26734620	chr12:56694298	CS	1.07	6.58	0.37	2.56e-10	Psoriasis vulgaris;
CESC	cis	rs11809207	0.523	rs2783707	chr1:26504196	C/G	cg00147160	chr1:26503991	CNKSR1	0.28	5.23	0.31	3.42e-7	Height;
CESC	cis	rs2304069	1.000	rs7737689	chr5:149396159	C/A	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.75	9.38	0.5	3.04e-18	HIV-1 control;
CESC	cis	rs6674176	0.597	rs3762422	chr1:44400532	T/A	cg12908607	chr1:44402522	ARTN	-0.51	-8.0	-0.44	3.92e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs8141529	0.702	rs5762870	chr22:29261159	C/T	cg02153584	chr22:29168773	CCDC117	0.58	7.78	0.43	1.61e-13	Lymphocyte counts;
CESC	cis	rs9486719	1.000	rs4343922	chr6:96876903	C/T	cg06623918	chr6:96969491	KIAA0776	0.89	10.0	0.52	3.56e-20	Migraine;Coronary artery disease;
CESC	cis	rs17711722	0.565	rs4717276	chr7:65294741	G/T	cg07424592	chr7:64974309	NA	-0.39	-5.69	-0.33	3.43e-8	Calcium levels;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg13639345	chr22:39052718	CBY1;LOC646851	0.46	6.24	0.36	1.75e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs7561273	0.586	rs11896092	chr2:24317827	G/A	cg01493198	chr2:24299560	SF3B14	0.42	5.13	0.3	5.69e-7	Quantitative traits;
CESC	cis	rs55788414	0.932	rs12103303	chr16:81181497	A/G	cg06400318	chr16:81190750	PKD1L2	-0.6	-7.07	-0.4	1.38e-11	Left ventricular obstructive tract defect (maternal effect);
CESC	trans	rs9325144	0.560	rs10785562	chr12:38637419	A/C	cg23762105	chr12:34175262	ALG10	0.48	6.36	0.36	8.78e-10	Morning vs. evening chronotype;
CESC	trans	rs10411161	0.702	rs7251755	chr19:52388948	G/A	cg22319618	chr22:45562946	NUP50	-0.75	-7.56	-0.42	6.61e-13	Breast cancer;
CESC	cis	rs16867321	0.627	rs1009998	chr2:181579313	G/C	cg23363182	chr2:181467187	NA	0.43	6.25	0.36	1.6e-9	Obesity;
CESC	cis	rs10504229	0.775	rs56082079	chr8:58163732	T/C	cg05313129	chr8:58192883	C8orf71	-0.48	-5.18	-0.3	4.41e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs6748734	1.000	rs11898716	chr2:241828311	A/G	cg07537917	chr2:241836409	C2orf54	-0.24	-5.04	-0.3	8.46e-7	Urinary metabolites;
CESC	trans	rs875971	0.964	rs778721	chr7:65845397	C/G	cg26939375	chr7:64535504	NA	0.47	6.06	0.35	4.69e-9	Aortic root size;
CESC	cis	rs7659604	0.702	rs6815790	chr4:122695385	A/C	cg19748678	chr4:122722346	EXOSC9	0.7	9.12	0.49	1.92e-17	Type 2 diabetes;
CESC	cis	rs2777491	1.000	rs316610	chr15:41752852	C/T	cg02330683	chr15:41787940	ITPKA	0.47	7.04	0.4	1.64e-11	Ulcerative colitis;
CESC	cis	rs3892630	0.612	rs10413282	chr19:33182751	A/G	cg22980127	chr19:33182716	NUDT19	1.06	14.82	0.67	1.33e-36	Red blood cell traits;
CESC	cis	rs7789940	0.904	rs6948661	chr7:75961647	T/C	cg10167463	chr7:75959203	YWHAG	-0.56	-7.09	-0.4	1.23e-11	Multiple sclerosis;
CESC	cis	rs7618915	0.501	rs10865974	chr3:52718280	A/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	-0.31	-5.88	-0.34	1.23e-8	Bipolar disorder;
CESC	cis	rs6500395	0.962	rs13331902	chr16:48644989	A/G	cg04672837	chr16:48644449	N4BP1	0.47	5.57	0.32	6.4e-8	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs7512552	0.839	rs6662108	chr1:150420541	G/T	cg15654264	chr1:150340011	RPRD2	0.39	5.14	0.3	5.23e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg02018176	chr4:1364513	KIAA1530	0.61	7.8	0.43	1.42e-13	Longevity;
CESC	cis	rs2075371	0.966	rs2544224	chr7:133995832	A/G	cg00033643	chr7:134001901	SLC35B4	0.44	5.6	0.33	5.33e-8	Mean platelet volume;
CESC	cis	rs62064224	0.546	rs1018866	chr17:30829664	A/C	cg24550644	chr17:30846204	MYO1D	-0.39	-5.61	-0.33	5e-8	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00380150	chr22:31885763	EIF4ENIF1	0.55	6.06	0.35	4.66e-9	Gut microbiome composition (summer);
CESC	cis	rs9303542	0.559	rs62066693	chr17:46617530	G/C	cg04904318	chr17:46607828	HOXB1	-0.58	-5.67	-0.33	3.64e-8	Ovarian cancer;Epithelial ovarian cancer;
CESC	cis	rs11711311	0.824	rs35952547	chr3:113352501	G/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.63	8.13	0.45	1.68e-14	IgG glycosylation;
CESC	cis	rs4589502	0.800	rs4147433	chr15:67201152	G/A	cg12317470	chr15:67143691	NA	-0.73	-8.7	-0.47	3.56e-16	Lung cancer (smoking interaction);
CESC	cis	rs1355223	0.545	rs7123029	chr11:34874815	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.55	-6.59	-0.38	2.37e-10	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs7665939	0.929	rs13353755	chr4:190100646	T/C	cg09826759	chr4:190284978	NA	-0.72	-7.55	-0.42	6.96e-13	Amyotrophic lateral sclerosis;
CESC	cis	rs4819052	0.885	rs9980676	chr21:46665430	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.91	13.42	0.64	1.1e-31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs7178572	0.633	rs11857860	chr15:77839761	T/C	cg22256960	chr15:77711686	NA	-0.52	-6.62	-0.38	2e-10	Type 2 diabetes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17250947	chr3:42642016	NKTR	0.53	6.33	0.36	1.05e-9	Gut microbiome composition (summer);
CESC	cis	rs4588572	0.644	rs1159930	chr5:77768943	C/T	cg11547950	chr5:77652471	NA	0.45	6.33	0.36	1.03e-9	Triglycerides;
CESC	cis	rs6582630	0.519	rs8189549	chr12:38245752	A/G	cg13010199	chr12:38710504	ALG10B	0.51	6.3	0.36	1.24e-9	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs2346177	0.542	rs6757564	chr2:46702619	G/C	cg02822958	chr2:46747628	ATP6V1E2	0.45	5.75	0.33	2.45e-8	HDL cholesterol;
CESC	cis	rs9291683	0.609	rs4622999	chr4:10003395	C/G	cg11266682	chr4:10021025	SLC2A9	0.65	12.98	0.62	3.63e-30	Bone mineral density;
CESC	cis	rs9443645	0.901	rs9443638	chr6:79720867	T/A	cg05283184	chr6:79620031	NA	-0.43	-6.61	-0.38	2.06e-10	Intelligence (multi-trait analysis);
CESC	cis	rs172166	0.637	rs1071893	chr6:28167635	G/C	cg23161317	chr6:28129485	ZNF389	0.37	5.15	0.3	5.04e-7	Cardiac Troponin-T levels;
CESC	cis	rs7607369	0.536	rs4674345	chr2:219671598	A/G	cg02176678	chr2:219576539	TTLL4	-0.34	-5.95	-0.34	8.27e-9	Red blood cell count;Amyotrophic lateral sclerosis;
CESC	cis	rs9911578	1.000	rs304296	chr17:56834229	G/T	cg12560992	chr17:57184187	TRIM37	0.92	15.29	0.68	2.77e-38	Intelligence (multi-trait analysis);
CESC	cis	rs1975974	0.511	rs112710683	chr17:21741695	C/A	cg18423549	chr17:21743878	NA	-0.7	-10.07	-0.53	2.12e-20	Psoriasis;
CESC	cis	rs6860806	0.531	rs272887	chr5:131665713	A/G	cg18758796	chr5:131593413	PDLIM4	0.38	5.17	0.3	4.69e-7	Breast cancer;
CESC	cis	rs1048238	0.545	rs848199	chr1:16292742	C/T	cg22431228	chr1:16359049	CLCNKA	0.37	6.39	0.37	7.54e-10	Systolic blood pressure;
CESC	cis	rs2304069	0.837	rs10041451	chr5:149385197	A/C	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.9	11.48	0.58	4.92e-25	HIV-1 control;
CESC	cis	rs6582630	0.519	rs2387812	chr12:38381480	A/G	cg13010199	chr12:38710504	ALG10B	0.45	5.73	0.33	2.68e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs9611565	0.681	rs6002372	chr22:41801299	A/T	cg17376030	chr22:41985996	PMM1	-0.68	-7.12	-0.4	1.02e-11	Vitiligo;
CESC	cis	rs7618915	0.508	rs12498066	chr3:52627660	G/A	cg07507251	chr3:52567010	NT5DC2	0.4	6.96	0.39	2.7e-11	Bipolar disorder;
CESC	cis	rs68170813	0.559	rs17429146	chr7:106964281	A/G	cg02696742	chr7:106810147	HBP1	-0.55	-5.17	-0.3	4.51e-7	Coronary artery disease;
CESC	cis	rs3818285	0.504	rs4917547	chr10:111652285	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.55	-7.61	-0.42	4.84e-13	Superior crus of antihelix expression;
CESC	trans	rs3780486	0.846	rs10813948	chr9:33121570	G/A	cg04842962	chr6:43655489	MRPS18A	1.0	19.07	0.76	1.21e-51	IgG glycosylation;
CESC	cis	rs9303401	0.659	rs35564417	chr17:56718286	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.04	13.0	0.62	3.27e-30	Cognitive test performance;
CESC	cis	rs2408955	0.521	rs1476607	chr12:48524804	A/G	cg24011408	chr12:48396354	COL2A1	-0.51	-7.49	-0.42	1.01e-12	Glycated hemoglobin levels;
CESC	cis	rs7617480	0.544	rs6442129	chr3:48735256	T/C	cg07636037	chr3:49044803	WDR6	0.76	9.8	0.52	1.47e-19	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CESC	trans	rs650950	0.528	rs646660	chr11:35528452	C/T	cg19705215	chr14:61747501	TMEM30B	0.43	6.05	0.35	4.79e-9	Bronchopulmonary dysplasia;
CESC	cis	rs3008870	1.000	rs3008894	chr1:67377739	A/G	cg02640540	chr1:67518911	SLC35D1	0.5	5.29	0.31	2.55e-7	Lymphocyte percentage of white cells;
CESC	cis	rs4862750	0.832	rs6836426	chr4:187897837	T/G	cg03452623	chr4:187889614	NA	-0.89	-15.18	-0.68	7.11e-38	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1707322	1.000	rs11211237	chr1:46447329	G/C	cg06784218	chr1:46089804	CCDC17	0.33	5.63	0.33	4.7e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs7107217	1.000	rs1873872	chr11:129473993	A/T	cg24073613	chr1:210424721	NA	0.5	6.42	0.37	6.32e-10	Breast cancer;Type 2 diabetes;
CESC	cis	rs11764590	0.694	rs10241537	chr7:2083358	A/G	cg21782813	chr7:2030301	MAD1L1	-0.39	-5.3	-0.31	2.48e-7	Neuroticism;
CESC	cis	rs55788414	0.860	rs1806875	chr16:81184069	T/C	cg06400318	chr16:81190750	PKD1L2	-0.6	-6.82	-0.39	6.19e-11	Left ventricular obstructive tract defect (maternal effect);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05092304	chr11:107047494	NA	-0.57	-6.98	-0.39	2.36e-11	Gut microbiome composition (summer);
CESC	cis	rs7560272	0.501	rs12713793	chr2:73956114	T/C	cg20560298	chr2:73613845	ALMS1	0.43	5.89	0.34	1.14e-8	Schizophrenia;
CESC	cis	rs1005277	0.522	rs289647	chr10:37968278	A/G	cg25427524	chr10:38739819	LOC399744	-0.59	-8.61	-0.47	6.69e-16	Extrinsic epigenetic age acceleration;
CESC	cis	rs10242455	0.557	rs59672032	chr7:99058697	T/C	cg18809830	chr7:99032528	PTCD1	-0.59	-5.17	-0.3	4.59e-7	Blood metabolite levels;
CESC	cis	rs1552244	1.000	rs6442148	chr3:10078289	G/C	cg00149659	chr3:10157352	C3orf10	0.75	9.42	0.5	2.25e-18	Alzheimer's disease;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg15783703	chr7:70209588	AUTS2	-0.44	-6.15	-0.35	2.91e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7613875	0.521	rs4688754	chr3:50074641	G/T	cg24110177	chr3:50126178	RBM5	0.54	7.47	0.42	1.2e-12	Body mass index;
CESC	cis	rs4974559	0.501	rs1732115	chr4:1244416	C/T	cg02980000	chr4:1222292	CTBP1	0.76	7.84	0.43	1.12e-13	Systolic blood pressure;
CESC	cis	rs35110281	0.666	rs2236665	chr21:45108987	C/A	cg04455712	chr21:45112962	RRP1B	0.49	7.59	0.42	5.37e-13	Mean corpuscular volume;
CESC	cis	rs9488822	0.636	rs6937104	chr6:116375302	A/G	cg15226275	chr6:116381976	FRK	0.26	6.55	0.37	2.95e-10	Cholesterol, total;LDL cholesterol;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg04579211	chr15:41221939	DLL4	0.43	6.01	0.35	6.24e-9	Systemic lupus erythematosus;
CESC	cis	rs6570726	0.791	rs9373463	chr6:145894762	C/T	cg05347473	chr6:146136440	FBXO30	0.59	7.63	0.42	4.24e-13	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs11098499	0.820	rs2389885	chr4:120533931	C/T	cg25214090	chr10:38739885	LOC399744	0.66	8.57	0.47	8.55e-16	Corneal astigmatism;
CESC	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.52	6.18	0.35	2.47e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.47	-6.6	-0.38	2.2e-10	Longevity;Endometriosis;
CESC	cis	rs9896933	0.732	rs590886	chr17:80767350	A/G	cg15369054	chr17:80825471	TBCD	-0.45	-5.11	-0.3	6.18e-7	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
CESC	cis	rs453301	0.571	rs2929453	chr8:9084341	A/G	cg17143192	chr8:8559678	CLDN23	-0.47	-5.82	-0.34	1.67e-8	Joint mobility (Beighton score);
CESC	cis	rs9916302	0.904	rs34363096	chr17:37594294	G/A	cg20243544	chr17:37824526	PNMT	0.51	6.5	0.37	4.03e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs11711311	1.000	rs11711311	chr3:113430599	T/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.72	10.32	0.54	3.4e-21	IgG glycosylation;
CESC	cis	rs4664308	0.935	rs4520993	chr2:160937673	G/A	cg03641300	chr2:160917029	PLA2R1	-0.67	-9.84	-0.52	1.11e-19	Idiopathic membranous nephropathy;
CESC	cis	rs4072980	0.545	rs12120737	chr1:38422544	C/T	cg17077180	chr1:38461687	NA	0.41	5.8	0.34	1.93e-8	Coronary artery disease;
CESC	cis	rs4819052	0.851	rs2877018	chr21:46658306	G/A	cg11663144	chr21:46675770	NA	-0.63	-10.02	-0.52	3.12e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs55788414	0.932	rs28583467	chr16:81186428	G/C	cg06400318	chr16:81190750	PKD1L2	-0.58	-6.44	-0.37	5.6e-10	Left ventricular obstructive tract defect (maternal effect);
CESC	cis	rs4819052	0.851	rs914214	chr21:46697820	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.76	10.12	0.53	1.43e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07294870	chr20:44044586	PIGT	-0.6	-7.24	-0.41	4.89e-12	Gut microbiome composition (summer);
CESC	cis	rs7635838	0.819	rs7637414	chr3:11522228	C/G	cg00170343	chr3:11313890	ATG7	0.41	5.55	0.32	6.97e-8	HDL cholesterol;
CESC	cis	rs16867321	0.590	rs1528453	chr2:181581272	A/G	cg23363182	chr2:181467187	NA	0.44	6.48	0.37	4.5e-10	Obesity;
CESC	cis	rs8133932	0.555	rs374331	chr21:47338218	A/G	cg14185626	chr21:47401492	COL6A1	-0.45	-5.09	-0.3	6.84e-7	Schizophrenia;
CESC	cis	rs7829975	0.711	rs4841051	chr8:8685646	C/T	cg06636001	chr8:8085503	FLJ10661	-0.47	-6.06	-0.35	4.64e-9	Mood instability;
CESC	cis	rs7927771	0.800	rs55876153	chr11:47416636	G/A	cg05585544	chr11:47624801	NA	-0.46	-6.81	-0.39	6.58e-11	Subjective well-being;
CESC	trans	rs9929218	1.000	rs12921546	chr16:68780069	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.74	-9.67	-0.51	3.83e-19	Colorectal cancer;
CESC	cis	rs1042058	0.565	rs650110	chr10:30753132	A/G	cg18806716	chr10:30721971	MAP3K8	-0.54	-8.15	-0.45	1.46e-14	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CESC	cis	rs7618501	0.521	rs6774354	chr3:49961780	G/A	cg24110177	chr3:50126178	RBM5	-0.55	-7.72	-0.43	2.38e-13	Intelligence (multi-trait analysis);
CESC	cis	rs17376456	0.877	rs17083455	chr5:93446380	A/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.63	5.66	0.33	4.02e-8	Diabetic retinopathy;
CESC	cis	rs2603127	0.768	rs9833239	chr3:108478131	G/C	cg03329597	chr3:108125523	MYH15	0.6	5.35	0.31	1.91e-7	Hemostatic factors and hematological phenotypes;
CESC	cis	rs4665809	1.000	rs1030730	chr2:26284143	T/C	cg22920501	chr2:26401640	FAM59B	-0.79	-9.3	-0.5	5.61e-18	Gut microbiome composition (summer);
CESC	trans	rs61931739	0.613	rs61927728	chr12:33667690	T/C	cg26384229	chr12:38710491	ALG10B	-0.45	-6.34	-0.36	9.58e-10	Morning vs. evening chronotype;
CESC	cis	rs11098499	0.954	rs3890049	chr4:120326283	T/A	cg09307838	chr4:120376055	NA	0.92	12.77	0.62	2.08e-29	Corneal astigmatism;
CESC	cis	rs7605827	0.930	rs11893253	chr2:15606618	A/G	cg19274914	chr2:15703543	NA	0.33	5.96	0.34	8.22e-9	Educational attainment (years of education);
CESC	cis	rs798554	0.679	rs13230995	chr7:2887284	G/A	cg04166393	chr7:2884313	GNA12	0.59	8.08	0.44	2.29e-14	Height;
CESC	cis	rs11741688	0.557	rs6898923	chr5:178330559	C/T	cg20935368	chr5:178288625	ZNF354B	0.34	5.4	0.32	1.45e-7	Sleep duration;
CESC	cis	rs703842	0.963	rs2069506	chr12:58142854	C/A	cg00677455	chr12:58241039	CTDSP2	0.52	6.68	0.38	1.41e-10	Multiple sclerosis;
CESC	cis	rs10779751	1.000	rs12032364	chr1:11286872	G/T	cg08854313	chr1:11322531	MTOR	0.79	10.52	0.54	7.46e-22	Body mass index;
CESC	cis	rs1707322	0.826	rs10890349	chr1:46249955	T/C	cg05343316	chr1:45956843	TESK2	0.47	5.7	0.33	3.21e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs360071	0.528	rs360093	chr1:226064745	G/T	cg17950169	chr1:226067900	TMEM63A	0.35	5.35	0.31	1.9e-7	Response to radiotherapy in prostate cancer (toxicity, rectal bleeding);
CESC	cis	rs763014	0.931	rs710925	chr16:633354	G/A	cg00802000	chr16:706648	WDR90	-0.41	-6.12	-0.35	3.33e-9	Height;
CESC	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg11965913	chr1:205819406	PM20D1	0.92	17.0	0.72	2.46e-44	Menarche (age at onset);
CESC	cis	rs9733	0.596	rs7418501	chr1:150711896	A/T	cg17724175	chr1:150552817	MCL1	0.46	7.55	0.42	7.08e-13	Tonsillectomy;
CESC	cis	rs317689	0.680	rs315140	chr12:69790780	A/T	cg14784868	chr12:69753453	YEATS4	0.58	6.69	0.38	1.29e-10	Response to diuretic therapy;
CESC	cis	rs2439831	1.000	rs28666488	chr15:43741090	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.88	10.56	0.54	5.55e-22	Lung cancer in ever smokers;
CESC	cis	rs2243480	1.000	rs73142166	chr7:65375832	A/G	cg13147721	chr7:65941812	NA	-0.88	-8.09	-0.45	2.17e-14	Diabetic kidney disease;
CESC	cis	rs6429082	0.633	rs1416473	chr1:235563259	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.54	-6.77	-0.38	8.47e-11	Adiposity;
CESC	cis	rs7617480	0.616	rs9873227	chr3:48773108	G/C	cg07636037	chr3:49044803	WDR6	0.79	10.66	0.55	2.61e-22	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CESC	cis	rs7666738	0.830	rs115712871	chr4:98954535	A/T	cg05340658	chr4:99064831	C4orf37	0.8	12.4	0.61	3.76e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11098499	0.955	rs7685268	chr4:120162188	G/A	cg09307838	chr4:120376055	NA	0.86	11.44	0.58	6.63e-25	Corneal astigmatism;
CESC	cis	rs6964587	1.000	rs7805077	chr7:91644553	A/G	cg17063962	chr7:91808500	NA	0.56	7.76	0.43	1.79e-13	Breast cancer;
CESC	cis	rs10870270	0.956	rs7894	chr10:133769482	G/C	cg26149184	chr10:133730230	NA	0.37	5.1	0.3	6.63e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs7927771	0.690	rs35496532	chr11:47450338	C/T	cg20307385	chr11:47447363	PSMC3	-0.62	-7.5	-0.42	9.54e-13	Subjective well-being;
CESC	cis	rs5758659	0.622	rs6519298	chr22:42364997	C/T	cg04733989	chr22:42467013	NAGA	0.42	5.55	0.32	6.94e-8	Cognitive function;
CESC	cis	rs1018836	0.663	rs4735190	chr8:91509601	A/G	cg16814680	chr8:91681699	NA	-0.58	-7.68	-0.43	3e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs478222	0.930	rs510107	chr2:25319471	G/A	cg01884057	chr2:25150051	NA	-0.3	-5.15	-0.3	5.02e-7	Type 1 diabetes;
CESC	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg24642844	chr7:1081250	C7orf50	-0.76	-9.45	-0.5	1.94e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs4853012	0.793	rs6723185	chr2:74344884	T/A	cg01017244	chr2:74357527	NA	0.7	10.07	0.53	2.09e-20	Gestational age at birth (maternal effect);
CESC	cis	rs9443645	0.901	rs9361451	chr6:79555055	T/C	cg05283184	chr6:79620031	NA	-0.44	-6.88	-0.39	4.39e-11	Intelligence (multi-trait analysis);
CESC	cis	rs929596	0.793	rs13009407	chr2:234652347	C/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.55	-5.58	-0.32	6.03e-8	Total bilirubin levels in HIV-1 infection;
CESC	cis	rs600231	0.542	rs10896009	chr11:65246054	A/G	cg17120908	chr11:65337727	SSSCA1	0.55	5.32	0.31	2.19e-7	Bone mineral density;
CESC	cis	rs6933660	0.720	rs6913515	chr6:151753470	G/C	cg02564969	chr6:151773285	C6orf211;RMND1	0.59	8.01	0.44	3.54e-14	Menarche (age at onset);
CESC	cis	rs7945705	0.902	rs7479407	chr11:9023421	C/T	cg09997546	chr11:8931473	C11orf17;ST5	0.33	5.53	0.32	7.8e-8	Hemoglobin concentration;
CESC	cis	rs9311474	1.000	rs6445358	chr3:52308845	C/G	cg17372223	chr3:52568218	NT5DC2	0.34	5.2	0.3	3.98e-7	Electroencephalogram traits;
CESC	cis	rs6963495	0.818	rs73192141	chr7:105201129	T/G	cg02135003	chr7:105160482	PUS7	-0.48	-5.55	-0.32	7.01e-8	Bipolar disorder (body mass index interaction);
CESC	cis	rs7520050	0.966	rs61102033	chr1:46382441	G/T	cg03146154	chr1:46216737	IPP	-0.48	-6.27	-0.36	1.48e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs3857536	0.813	rs6903411	chr6:66938288	T/C	cg07460842	chr6:66804631	NA	-0.42	-5.34	-0.31	1.96e-7	Blood trace element (Cu levels);
CESC	trans	rs2502399	0.689	rs4945490	chr6:113493299	C/T	cg00285294	chr7:1089767	C7orf50	-0.33	-6.2	-0.36	2.2e-9	Plasma clusterin levels;
CESC	cis	rs9399401	0.710	rs10484733	chr6:142710988	C/G	cg04461802	chr6:142623433	GPR126	0.42	6.05	0.35	4.81e-9	Chronic obstructive pulmonary disease;
CESC	cis	rs1707322	0.963	rs1768815	chr1:46528603	G/A	cg06784218	chr1:46089804	CCDC17	-0.33	-5.57	-0.32	6.38e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs4335177	0.963	rs7858774	chr9:109359345	A/C	cg12580783	chr12:49362475	WNT10B	-0.32	-6.0	-0.35	6.3e-9	Response to paliperidone in schizophrenia (positive Marder score);
CESC	cis	rs9611565	0.605	rs202638	chr22:41855458	A/G	cg03806693	chr22:41940476	POLR3H	0.81	9.57	0.51	7.93e-19	Vitiligo;
CESC	cis	rs875971	0.545	rs73376401	chr7:65639828	G/A	cg11764359	chr7:65958608	NA	0.79	9.47	0.5	1.64e-18	Aortic root size;
CESC	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.43	-5.39	-0.31	1.59e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg08393828	chr14:102228221	PPP2R5C	-0.45	-6.38	-0.36	7.83e-10	Gambling;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg02488887	chr5:176830915	F12	-0.47	-6.97	-0.39	2.5e-11	Gambling;
CESC	cis	rs6088580	0.602	rs6059840	chr20:33030405	G/A	cg06115741	chr20:33292138	TP53INP2	0.48	6.14	0.35	3.02e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs7527798	0.592	rs11118337	chr1:207852693	G/C	cg21110645	chr1:207815933	NA	-0.33	-5.76	-0.33	2.39e-8	Erythrocyte sedimentation rate;
CESC	cis	rs13102973	0.899	rs7442212	chr4:135899800	A/G	cg14419869	chr4:135874104	NA	-0.34	-5.06	-0.3	8.02e-7	Subjective well-being;
CESC	cis	rs9894429	0.646	rs7210026	chr17:79612382	T/C	cg18240062	chr17:79603768	NPLOC4	0.54	7.05	0.4	1.55e-11	Eye color traits;
CESC	cis	rs4148883	0.603	rs1893883	chr4:100124716	C/G	cg12011299	chr4:100065546	ADH4	0.5	7.24	0.41	4.84e-12	Alcohol dependence;
CESC	trans	rs2273788	1.000	rs2273788	chr9:114348617	C/T	cg02412050	chr6:35995429	MAPK14	-0.63	-6.36	-0.36	8.96e-10	Monocyte count;
CESC	cis	rs2836974	1.000	rs28360661	chr21:40681972	G/C	cg27266027	chr21:40555129	PSMG1	0.45	5.07	0.3	7.64e-7	Cognitive function;
CESC	cis	rs1707322	1.000	rs785467	chr1:46521559	A/T	cg06784218	chr1:46089804	CCDC17	-0.35	-5.96	-0.34	7.81e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs1348850	0.914	rs3813259	chr2:178257214	G/A	cg23306229	chr2:178417860	TTC30B	0.63	7.77	0.43	1.69e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs3749237	0.557	rs7631908	chr3:49425707	T/G	cg03060546	chr3:49711283	APEH	0.75	11.31	0.57	1.91e-24	Resting heart rate;
CESC	cis	rs7336332	0.598	rs9581852	chr13:28013748	A/G	cg22138327	chr13:27999177	GTF3A	0.62	5.66	0.33	3.95e-8	Weight;
CESC	cis	rs8141529	0.748	rs5762882	chr22:29290680	C/A	cg02153584	chr22:29168773	CCDC117	0.59	7.62	0.42	4.46e-13	Lymphocyte counts;
CESC	trans	rs853679	0.546	rs200953	chr6:27837267	T/C	cg06606381	chr12:133084897	FBRSL1	-0.8	-7.56	-0.42	6.58e-13	Depression;
CESC	cis	rs7903847	0.642	rs10786339	chr10:99153076	A/G	cg20016023	chr10:99160130	RRP12	-0.3	-5.12	-0.3	5.99e-7	Granulocyte percentage of myeloid white cells;
CESC	cis	rs9322193	0.923	rs9766004	chr6:150075499	C/T	cg07701084	chr6:150067640	NUP43	0.48	6.7	0.38	1.26e-10	Lung cancer;
CESC	cis	rs853679	0.517	rs9468298	chr6:28122345	A/G	cg23161317	chr6:28129485	ZNF389	0.53	6.52	0.37	3.64e-10	Depression;
CESC	trans	rs9307551	0.817	rs11098766	chr4:80500420	G/T	cg02747103	chr19:603718	HCN2	-0.42	-6.55	-0.37	2.98e-10	Refractive error;
CESC	cis	rs9287719	0.639	rs2357649	chr2:10696788	C/T	cg00105475	chr2:10696890	NA	-0.45	-6.75	-0.38	9.11e-11	Prostate cancer;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg11114063	chr6:147524085	STXBP5	-0.51	-6.14	-0.35	2.99e-9	Ulcerative colitis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03773226	chr17:37353657	CACNB1	-0.54	-6.43	-0.37	6.02e-10	Gut microbiome composition (summer);
CESC	cis	rs7927592	0.913	rs66752716	chr11:68273626	C/T	cg20283391	chr11:68216788	NA	-0.62	-7.54	-0.42	7.45e-13	Total body bone mineral density;
CESC	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.58	6.55	0.37	3.03e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2243480	1.000	rs4718315	chr7:65648541	T/C	cg13147721	chr7:65941812	NA	0.97	9.16	0.49	1.47e-17	Diabetic kidney disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00332212	chr4:48908696	OCIAD2	0.6	6.32	0.36	1.12e-9	Gut microbiome composition (summer);
CESC	cis	rs72781680	1.000	rs56104215	chr2:24133590	T/C	cg20701182	chr2:24300061	SF3B14	0.63	5.67	0.33	3.79e-8	Lymphocyte counts;
CESC	cis	rs1003719	0.708	rs8126491	chr21:38551219	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.6	-8.13	-0.45	1.66e-14	Eye color traits;
CESC	cis	rs3126085	0.935	rs74127901	chr1:152195579	G/A	cg03465714	chr1:152285911	FLG	0.45	5.11	0.3	6.27e-7	Atopic dermatitis;
CESC	cis	rs4919694	1.000	rs11191525	chr10:104793435	G/C	cg04362960	chr10:104952993	NT5C2	0.77	6.69	0.38	1.34e-10	Arsenic metabolism;
CESC	cis	rs892961	0.932	rs35657663	chr17:75412482	T/C	cg05865280	chr17:75406074	SEPT9	0.62	12.67	0.61	4.57e-29	Airflow obstruction;
CESC	cis	rs6570726	0.791	rs9403730	chr6:145907233	C/T	cg23711669	chr6:146136114	FBXO30	0.92	13.73	0.64	9.24e-33	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9818941	0.824	rs2712320	chr3:157770116	A/G	cg08654915	chr3:157813417	NA	-0.46	-7.39	-0.41	1.96e-12	Height;
CESC	cis	rs7666738	0.830	rs4392515	chr4:98957431	A/G	cg17366294	chr4:99064904	C4orf37	0.6	8.47	0.46	1.72e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9908102	0.710	rs8071445	chr17:12914480	A/G	cg26162695	chr17:12921313	ELAC2	0.51	5.55	0.32	7.03e-8	Schizophrenia;
CESC	cis	rs6762	0.748	rs28735718	chr11:839629	A/G	cg23754390	chr11:835074	CD151	0.32	5.69	0.33	3.32e-8	Mean platelet volume;
CESC	cis	rs7605827	0.930	rs11676198	chr2:15603097	G/A	cg19274914	chr2:15703543	NA	0.35	6.28	0.36	1.39e-9	Educational attainment (years of education);
CESC	cis	rs10751667	0.666	rs4074234	chr11:977715	C/G	cg06064525	chr11:970664	AP2A2	-0.47	-9.12	-0.49	1.9e-17	Alzheimer's disease (late onset);
CESC	cis	rs2204008	0.714	rs11520135	chr12:38114863	C/T	cg26384229	chr12:38710491	ALG10B	0.74	10.72	0.55	1.6400000000000001e-22	Bladder cancer;
CESC	cis	rs7044106	0.791	rs2416797	chr9:123480600	C/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.64	8.83	0.48	1.43e-16	Hip circumference adjusted for BMI;
CESC	cis	rs6540556	0.769	rs909710	chr1:209930694	A/G	cg05527609	chr1:210001259	C1orf107	0.65	7.67	0.43	3.35e-13	Red blood cell count;
CESC	cis	rs854765	0.547	rs2955370	chr17:17966945	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.62	-8.88	-0.48	1.06e-16	Total body bone mineral density;
CESC	cis	rs6500602	0.653	rs4786488	chr16:4442527	C/T	cg08645402	chr16:4508243	NA	0.4	5.67	0.33	3.72e-8	Schizophrenia;
CESC	cis	rs7259376	0.936	rs1865073	chr19:22554980	T/G	cg02657401	chr19:22469223	NA	-0.26	-5.07	-0.3	7.61e-7	Menopause (age at onset);
CESC	cis	rs959260	0.858	rs2053156	chr17:73378440	G/T	cg20590849	chr17:73267439	MIF4GD	-0.57	-6.67	-0.38	1.53e-10	Systemic lupus erythematosus;
CESC	cis	rs8114671	0.528	rs6119542	chr20:33484545	G/T	cg06115741	chr20:33292138	TP53INP2	0.48	5.79	0.34	1.97e-8	Height;
CESC	cis	rs7809950	0.678	rs62483640	chr7:106900214	T/G	cg23024343	chr7:107201750	COG5	-0.54	-6.81	-0.39	6.51e-11	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17784606	chr1:1190558	UBE2J2	-0.57	-6.43	-0.37	6.01e-10	Gut microbiome composition (summer);
CESC	cis	rs12701220	0.522	rs12701455	chr7:1055409	A/G	cg20821713	chr7:1055600	C7orf50	-0.47	-6.13	-0.35	3.23e-9	Bronchopulmonary dysplasia;
CESC	cis	rs3617	0.625	rs2535633	chr3:52859630	C/G	cg11645453	chr3:52864694	ITIH4	-0.25	-5.05	-0.3	8.43e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
CESC	cis	rs514406	0.698	rs567880	chr1:53348564	T/G	cg16325326	chr1:53192061	ZYG11B	0.61	9.09	0.49	2.38e-17	Monocyte count;
CESC	cis	rs9916302	0.904	rs585961	chr17:37444036	G/A	cg20243544	chr17:37824526	PNMT	-0.45	-5.57	-0.32	6.16e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs17431357	0.609	rs73225229	chr12:120962627	T/A	cg25045489	chr12:120971538	RNF10	-0.93	-5.46	-0.32	1.1e-7	Insulin resistance/response;
CESC	cis	rs7927771	0.965	rs4752845	chr11:47539697	T/C	cg20135002	chr11:47629003	NA	-0.4	-5.1	-0.3	6.41e-7	Subjective well-being;
CESC	cis	rs5750830	0.621	rs5750810	chr22:39792943	A/G	cg02038168	chr22:39784481	NA	-0.61	-7.93	-0.44	6.21e-14	Intelligence (multi-trait analysis);
CESC	cis	rs17376456	0.825	rs55947981	chr5:93278104	G/T	cg21475434	chr5:93447410	FAM172A	0.77	6.39	0.37	7.61e-10	Diabetic retinopathy;
CESC	cis	rs1862618	0.754	rs252899	chr5:56188569	G/C	cg12311346	chr5:56204834	C5orf35	-0.77	-9.27	-0.49	6.75e-18	Initial pursuit acceleration;
CESC	cis	rs7772486	0.790	rs10223507	chr6:146285204	C/A	cg23711669	chr6:146136114	FBXO30	-0.83	-11.54	-0.58	3.22e-25	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7937682	0.881	rs4936678	chr11:111625085	C/T	cg09085632	chr11:111637200	PPP2R1B	1.1	12.18	0.6	2.08e-27	Primary sclerosing cholangitis;
CESC	cis	rs9611565	0.503	rs5996062	chr22:42167464	C/G	cg17376030	chr22:41985996	PMM1	-0.79	-8.37	-0.46	3.43e-15	Vitiligo;
CESC	cis	rs35110281	0.592	rs6417729	chr21:44967202	A/C	cg01579765	chr21:45077557	HSF2BP	-0.49	-7.96	-0.44	5.21e-14	Mean corpuscular volume;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg23946709	chr14:23527317	CDH24	0.52	6.87	0.39	4.44e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs637571	0.607	rs589253	chr11:65693080	G/A	cg02202077	chr11:65769826	EIF1AD;BANF1	0.45	5.78	0.33	2.07e-8	Eosinophil percentage of white cells;
CESC	cis	rs7666738	0.830	rs11097582	chr4:98772201	G/A	cg24818145	chr4:99064322	C4orf37	0.38	5.05	0.3	8.39e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6460942	0.908	rs6948654	chr7:12418546	T/A	cg06484146	chr7:12443880	VWDE	-0.74	-8.98	-0.48	5.25e-17	Coronary artery disease;
CESC	cis	rs1008375	0.933	rs6847966	chr4:17634255	G/A	cg02297831	chr4:17616191	MED28	0.62	7.91	0.44	7.23e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs2991971	0.810	rs6657237	chr1:45920108	A/T	cg05343316	chr1:45956843	TESK2	0.57	8.04	0.44	2.93e-14	High light scatter reticulocyte count;
CESC	cis	rs2249625	0.874	rs1819063	chr6:72908180	A/G	cg18830697	chr6:72922368	RIMS1	-0.37	-5.22	-0.31	3.69e-7	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05657488	chr16:23689988	PLK1	0.68	7.81	0.43	1.35e-13	Gut microbiome composition (summer);
CESC	cis	rs7590368	0.673	rs72779425	chr2:10940601	C/G	cg15705551	chr2:10952987	PDIA6	0.54	5.2	0.3	4.09e-7	Educational attainment (years of education);
CESC	cis	rs6662572	0.737	rs4423055	chr1:46259980	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.45	-5.06	-0.3	7.83e-7	Blood protein levels;
CESC	cis	rs9325144	0.600	rs34138871	chr12:38735261	A/G	cg26384229	chr12:38710491	ALG10B	0.56	8.04	0.44	3.07e-14	Morning vs. evening chronotype;
CESC	cis	rs3780486	1.000	rs3780480	chr9:33163486	G/T	cg13443165	chr9:33130375	B4GALT1	0.42	5.61	0.33	5.2100000000000003e-08	IgG glycosylation;
CESC	cis	rs1799949	0.965	rs11651623	chr17:41329847	G/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.39	5.21	0.3	3.78e-7	Menopause (age at onset);
CESC	cis	rs7542091	0.648	rs688464	chr1:209992539	C/T	cg25204440	chr1:209979598	IRF6	-0.42	-5.58	-0.32	5.82e-8	Monobrow;
CESC	cis	rs7818688	0.697	rs77402106	chr8:95970484	C/T	cg16049864	chr8:95962084	TP53INP1	0.57	5.64	0.33	4.29e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs1552244	1.000	rs56394721	chr3:10150795	A/G	cg00149659	chr3:10157352	C3orf10	0.74	8.94	0.48	6.91e-17	Alzheimer's disease;
CESC	cis	rs919433	0.926	rs12618567	chr2:198148191	A/T	cg03934865	chr2:198174659	NA	-0.42	-6.02	-0.35	5.86e-9	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs2243480	1.000	rs2243480	chr7:65599196	C/T	cg13147721	chr7:65941812	NA	-0.84	-7.86	-0.43	9.9e-14	Diabetic kidney disease;
CESC	cis	rs10256972	0.616	rs7806746	chr7:1075573	A/C	cg04025307	chr7:1156635	C7orf50	0.46	7.15	0.4	8.62e-12	Longevity;Endometriosis;
CESC	cis	rs57506017	0.585	rs3800843	chr7:12264297	G/A	cg23422036	chr7:12250390	TMEM106B	0.39	5.23	0.31	3.37e-7	Neuroticism;
CESC	cis	rs7618915	0.571	rs2289249	chr3:52597664	G/A	cg18404041	chr3:52824283	ITIH1	-0.41	-6.78	-0.38	7.92e-11	Bipolar disorder;
CESC	cis	rs7100689	0.556	rs3120976	chr10:82025682	C/A	cg00277334	chr10:82204260	NA	-0.5	-6.4	-0.37	7.14e-10	Post bronchodilator FEV1;
CESC	cis	rs9818941	0.826	rs2670286	chr3:157638213	C/G	cg08654915	chr3:157813417	NA	0.43	6.99	0.39	2.3e-11	Height;
CESC	cis	rs11958404	0.932	rs72816552	chr5:157422376	G/A	cg05962755	chr5:157440814	NA	0.63	6.86	0.39	4.87e-11	IgG glycosylation;
CESC	cis	rs910316	0.712	rs175074	chr14:75504454	G/A	cg08847533	chr14:75593920	NEK9	-0.91	-16.32	-0.71	6.26e-42	Height;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg15459342	chr1:228296991	MRPL55	0.48	6.4	0.37	7.06e-10	Systemic lupus erythematosus;
CESC	cis	rs826838	0.935	rs4583043	chr12:38645147	T/G	cg26384229	chr12:38710491	ALG10B	0.82	14.3	0.66	8.87e-35	Heart rate;
CESC	cis	rs6835098	0.924	rs2332669	chr4:174163398	G/A	cg08422745	chr4:174089978	GALNT7	-0.69	-9.85	-0.52	1.07e-19	Dementia and core Alzheimer's disease neuropathologic changes;
CESC	cis	rs17711722	0.701	rs4467826	chr7:65368708	A/G	cg06456125	chr7:65229604	NA	0.46	6.0	0.35	6.31e-9	Calcium levels;
CESC	cis	rs10504229	0.815	rs75577263	chr8:58188434	A/G	cg22535103	chr8:58192502	C8orf71	-1.05	-13.08	-0.63	1.71e-30	Developmental language disorder (linguistic errors);
CESC	trans	rs2236231	0.914	rs10138094	chr14:68037895	A/C	cg02340083	chr1:50882006	NA	0.4	6.15	0.35	2.81e-9	Plasma kynurenine levels in major depressive disorder;
CESC	trans	rs2235573	0.551	rs139891	chr22:38387914	G/T	cg19894588	chr14:64061835	NA	0.57	7.45	0.42	1.31e-12	Glioblastoma;Glioma;
CESC	cis	rs9894429	0.538	rs9747080	chr17:79606704	A/G	cg18240062	chr17:79603768	NPLOC4	0.69	9.09	0.49	2.43e-17	Eye color traits;
CESC	cis	rs2425143	1.000	rs6060572	chr20:34294015	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.8	-7.63	-0.42	4.14e-13	Blood protein levels;
CESC	cis	rs1862618	0.802	rs832560	chr5:56124423	T/A	cg22800045	chr5:56110881	MAP3K1	0.82	10.18	0.53	9.04e-21	Initial pursuit acceleration;
CESC	cis	rs4862750	0.872	rs6553030	chr4:187899234	T/C	cg03647317	chr4:187891568	NA	-0.38	-5.73	-0.33	2.75e-8	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg19349143	chr22:47189686	TBC1D22A	0.45	6.3	0.36	1.23e-9	Fibrinogen levels;
CESC	cis	rs2250402	0.510	rs7535	chr15:40328575	G/C	cg16127683	chr15:40268777	EIF2AK4	-0.63	-5.67	-0.33	3.82e-8	Corneal curvature;
CESC	cis	rs9399135	0.967	rs11756988	chr6:135347595	A/G	cg24558204	chr6:135376177	HBS1L	0.52	7.29	0.41	3.48e-12	Red blood cell count;
CESC	cis	rs3105593	1.000	rs1986074	chr15:50857452	T/C	cg08437265	chr15:50716283	USP8	0.4	5.11	0.3	6.15e-7	QT interval;
CESC	cis	rs7552404	0.731	rs10732723	chr1:76392437	C/T	cg03433033	chr1:76189801	ACADM	-0.52	-5.63	-0.33	4.58e-8	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs4665809	0.590	rs11897162	chr2:26503654	T/C	cg27170947	chr2:26402098	FAM59B	0.76	8.48	0.46	1.63e-15	Gut microbiome composition (summer);
CESC	cis	rs17376456	0.825	rs17372649	chr5:93126096	C/G	cg21475434	chr5:93447410	FAM172A	0.83	7.39	0.41	1.91e-12	Diabetic retinopathy;
CESC	cis	rs55794721	0.509	rs6699896	chr1:25762902	A/T	cg03538708	chr1:25844672	NA	-0.41	-6.16	-0.35	2.64e-9	Plateletcrit;Mean corpuscular volume;
CESC	cis	rs425277	0.606	rs2460001	chr1:2111030	T/C	cg16545954	chr1:2118288	C1orf86	0.36	7.06	0.4	1.46e-11	Height;
CESC	cis	rs2204008	0.744	rs11514071	chr12:38392076	C/T	cg13010199	chr12:38710504	ALG10B	0.47	5.89	0.34	1.15e-8	Bladder cancer;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg12498409	chr7:40174463	C7orf10;C7orf11	0.46	6.19	0.36	2.26e-9	Thyroid stimulating hormone;
CESC	cis	rs10927875	0.541	rs1739844	chr1:16343322	T/C	cg22431228	chr1:16359049	CLCNKA	-0.52	-9.9	-0.52	7.22e-20	Dilated cardiomyopathy;
CESC	cis	rs7412746	0.658	rs72704685	chr1:150897687	C/G	cg17724175	chr1:150552817	MCL1	0.38	5.9	0.34	1.11e-8	Melanoma;
CESC	cis	rs2404602	0.679	rs12908421	chr15:76881794	T/G	cg22467129	chr15:76604101	ETFA	-0.36	-5.33	-0.31	2.11e-7	Blood metabolite levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06135480	chr16:85644718	KIAA0182	0.53	6.39	0.37	7.58e-10	Gut microbiome composition (summer);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg20088969	chr10:74032886	DDIT4	-0.4	-6.31	-0.36	1.15e-9	Gambling;
CESC	cis	rs2832077	1.000	rs12329875	chr21:30137796	C/T	cg03476357	chr21:30257390	N6AMT1	-0.5	-5.46	-0.32	1.07e-7	Cognitive test performance;
CESC	cis	rs698833	0.848	rs696596	chr2:44718058	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.48	5.88	0.34	1.23e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs2243480	1.000	rs35046236	chr7:65408613	T/C	cg18252515	chr7:66147081	NA	-1.06	-9.79	-0.52	1.67e-19	Diabetic kidney disease;
CESC	cis	rs13418410	0.539	rs1545399	chr2:33843801	A/G	cg04131969	chr2:33951647	MYADML	-0.65	-8.03	-0.44	3.12e-14	Non-response to antidepressants and depression;
CESC	trans	rs2727020	0.894	rs11040333	chr11:49346332	G/A	cg03929089	chr4:120376271	NA	-0.62	-7.04	-0.4	1.66e-11	Coronary artery disease;
CESC	cis	rs875971	0.571	rs160641	chr7:65577346	G/A	cg18876405	chr7:65276391	NA	-0.55	-6.32	-0.36	1.1e-9	Aortic root size;
CESC	cis	rs9733	0.628	rs72700895	chr1:150626029	C/T	cg09365446	chr1:150670422	GOLPH3L	0.42	5.98	0.34	7.35e-9	Tonsillectomy;
CESC	cis	rs1799949	1.000	rs33920795	chr17:41329010	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	8.55	0.46	1.01e-15	Menopause (age at onset);
CESC	cis	rs1046896	0.594	rs4075209	chr17:80800027	G/T	cg02711726	chr17:80685570	FN3KRP	-0.43	-5.69	-0.33	3.41e-8	Glycated hemoglobin levels;
CESC	cis	rs2204008	0.774	rs11520273	chr12:38354075	A/T	cg26384229	chr12:38710491	ALG10B	0.69	10.42	0.54	1.6e-21	Bladder cancer;
CESC	cis	rs10504229	0.679	rs56040464	chr8:58131603	G/A	cg02725872	chr8:58115012	NA	-0.45	-7.05	-0.4	1.52e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs1790761	0.559	rs10896190	chr11:67406123	T/C	cg14500267	chr11:67383377	NA	0.33	5.36	0.31	1.83e-7	Mean corpuscular volume;
CESC	cis	rs4689592	0.546	rs10937782	chr4:7057106	G/C	cg06697600	chr4:7070879	GRPEL1	-0.48	-7.23	-0.41	5.24e-12	Monocyte percentage of white cells;
CESC	cis	rs920590	0.758	rs1826420	chr8:19664878	G/T	cg01411142	chr8:19674711	INTS10	0.51	5.89	0.34	1.17e-8	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs6089829	0.816	rs6062397	chr20:61668268	A/G	cg08564027	chr20:61660810	NA	0.9	15.44	0.69	8.75e-39	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs9858542	1.000	rs9858542	chr3:49701983	A/G	cg21659725	chr3:3221576	CRBN	0.52	6.38	0.36	7.9e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs2070997	0.607	rs2855191	chr9:133708441	C/T	cg11464064	chr9:133710261	ABL1	-0.68	-7.64	-0.42	4e-13	Response to amphetamines;
CESC	cis	rs7918232	1.000	rs7918232	chr10:27369162	A/G	cg14442939	chr10:27389572	ANKRD26	0.57	5.98	0.34	7.19e-9	Breast cancer;
CESC	cis	rs4237845	0.761	rs11172378	chr12:58298161	C/T	cg02175503	chr12:58329896	NA	0.62	7.83	0.43	1.18e-13	Intelligence (multi-trait analysis);
CESC	cis	rs9768139	0.733	rs35016950	chr7:158118710	C/A	cg25566285	chr7:158114605	PTPRN2	0.49	7.94	0.44	5.95e-14	Calcium levels;
CESC	cis	rs5750830	0.649	rs5750808	chr22:39790987	G/A	cg01416388	chr22:39784598	NA	-0.62	-7.88	-0.44	8.63e-14	Intelligence (multi-trait analysis);
CESC	cis	rs727563	0.635	rs5751149	chr22:42139501	A/G	cg17376030	chr22:41985996	PMM1	-0.78	-8.33	-0.46	4.43e-15	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs4948102	1.000	rs4948102	chr7:56097265	C/G	cg09872392	chr7:56161020	PHKG1	-0.43	-6.47	-0.37	4.79e-10	Plasma homocysteine levels (post-methionine load test);
CESC	trans	rs11764590	0.950	rs11514731	chr7:2051503	C/G	cg11693508	chr17:37793320	STARD3	0.68	6.87	0.39	4.65e-11	Neuroticism;
CESC	cis	rs2644899	0.859	rs2545755	chr19:41293162	T/G	cg24958765	chr19:41283667	RAB4B	-0.57	-6.44	-0.37	5.56e-10	Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs7259376	0.936	rs1865074	chr19:22554949	G/C	cg02657401	chr19:22469223	NA	-0.26	-5.07	-0.3	7.61e-7	Menopause (age at onset);
CESC	trans	rs17685	0.753	rs13240404	chr7:75675719	C/T	cg19862616	chr7:65841803	NCRNA00174	-0.84	-12.47	-0.61	2.15e-28	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs12410462	0.681	rs78978081	chr1:227571619	G/A	cg23173402	chr1:227635558	NA	0.68	5.73	0.33	2.78e-8	Major depressive disorder;
CESC	cis	rs7116495	1.000	rs1939245	chr11:71742532	C/T	cg26138937	chr11:71823887	C11orf51	-0.83	-6.72	-0.38	1.14e-10	Severe influenza A (H1N1) infection;
CESC	cis	rs11677370	0.603	rs10178523	chr2:3854169	G/A	cg17052675	chr2:3827356	NA	-0.45	-5.71	-0.33	2.95e-8	Type 2 diabetes;
CESC	trans	rs35110281	0.774	rs162344	chr21:44954522	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.48	6.34	0.36	9.67e-10	Mean corpuscular volume;
CESC	cis	rs208520	0.690	rs2208442	chr6:66867004	T/C	cg07460842	chr6:66804631	NA	-1.0	-13.45	-0.64	8.77e-32	Exhaled nitric oxide output;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04381898	chr2:219082190	ARPC2	0.57	6.7	0.38	1.26e-10	Gut microbiome composition (summer);
CESC	cis	rs9611565	0.765	rs28604950	chr22:41785812	A/G	cg06481639	chr22:41940642	POLR3H	-0.63	-6.6	-0.38	2.22e-10	Vitiligo;
CESC	cis	rs7927592	0.717	rs7126451	chr11:68257386	A/G	cg01657329	chr11:68192670	LRP5	0.4	5.36	0.31	1.77e-7	Total body bone mineral density;
CESC	trans	rs875971	0.862	rs12698521	chr7:65939489	T/C	cg26939375	chr7:64535504	NA	0.47	6.09	0.35	4.06e-9	Aortic root size;
CESC	cis	rs9926296	0.546	rs7187436	chr16:89845110	A/T	cg07648498	chr16:89883185	FANCA	0.44	5.42	0.32	1.32e-7	Vitiligo;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg25424237	chr12:123718121	C12orf65	-0.51	-6.64	-0.38	1.78e-10	Fibrinogen levels;
CESC	cis	rs5769765	0.862	rs9616392	chr22:50314705	G/A	cg26441486	chr22:50317300	CRELD2	0.43	5.12	0.3	5.81e-7	Schizophrenia;
CESC	cis	rs11155671	0.530	rs2342769	chr6:150216507	T/C	cg09699651	chr6:150184138	LRP11	0.54	7.5	0.42	9.91e-13	Testicular germ cell tumor;
CESC	cis	rs1801251	0.727	rs6437071	chr2:233568793	G/A	cg08000102	chr2:233561755	GIGYF2	0.65	9.43	0.5	2.23e-18	Coronary artery disease;
CESC	cis	rs10479542	0.544	rs10056863	chr5:179005100	G/A	cg22764044	chr5:178986830	RUFY1	0.44	6.25	0.36	1.62e-9	Lung cancer;
CESC	cis	rs9287719	0.967	rs7587231	chr2:10740093	C/T	cg00105475	chr2:10696890	NA	0.39	5.64	0.33	4.44e-8	Prostate cancer;
CESC	cis	rs733592	0.723	rs10875766	chr12:48593580	G/C	cg24011408	chr12:48396354	COL2A1	0.44	6.73	0.38	1.05e-10	Plateletcrit;
CESC	cis	rs1799949	0.501	rs2343819	chr17:41409653	T/G	cg06001716	chr17:41278141	BRCA1;NBR2	0.38	5.13	0.3	5.72e-7	Menopause (age at onset);
CESC	cis	rs10129255	0.536	rs10139058	chr14:107141916	C/T	cg07958169	chr14:107095056	NA	-0.46	-6.92	-0.39	3.33e-11	Kawasaki disease;
CESC	cis	rs11083475	0.557	rs2368519	chr19:39259241	C/T	cg20002381	chr19:39279703	LGALS7B	-0.24	-5.19	-0.3	4.12e-7	Heart rate;
CESC	cis	rs13102973	0.965	rs4469136	chr4:135850051	C/T	cg14419869	chr4:135874104	NA	0.33	5.19	0.3	4.29e-7	Subjective well-being;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg27612744	chr5:16465883	ZNF622	-0.44	-6.63	-0.38	1.85e-10	Gambling;
CESC	cis	rs4704187	0.687	rs10035303	chr5:74505495	A/C	cg03227963	chr5:74354835	NA	0.28	5.18	0.3	4.33e-7	Response to amphetamines;
CESC	cis	rs7607369	0.559	rs4674341	chr2:219659911	A/G	cg02176678	chr2:219576539	TTLL4	-0.4	-7.1	-0.4	1.18e-11	Red blood cell count;Amyotrophic lateral sclerosis;
CESC	cis	rs7923452	0.507	rs103441	chr10:30778184	C/T	cg25182066	chr10:30743637	MAP3K8	-0.46	-6.21	-0.36	2.04e-9	Itch intensity from mosquito bite;
CESC	trans	rs9858542	0.953	rs6779524	chr3:49450449	C/T	cg21659725	chr3:3221576	CRBN	-0.54	-6.42	-0.37	6.43e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs6546550	0.935	rs6546551	chr2:70073703	C/T	cg02498382	chr2:70120550	SNRNP27	-0.38	-6.49	-0.37	4.2e-10	Prevalent atrial fibrillation;
CESC	cis	rs10883723	0.773	rs11191303	chr10:104255158	T/C	cg22532475	chr10:104410764	TRIM8	-0.34	-5.73	-0.33	2.77e-8	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs2708240	0.967	rs2708239	chr7:147575961	G/A	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.35	-5.77	-0.33	2.23e-8	QT interval (drug interaction);
CESC	cis	rs1707322	0.686	rs2991979	chr1:46055858	A/G	cg03146154	chr1:46216737	IPP	-0.77	-10.4	-0.54	1.77e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05168378	chr7:100425517	EPHB4	0.58	6.92	0.39	3.38e-11	Gut microbiome composition (summer);
CESC	cis	rs1865721	0.958	rs72977878	chr18:73193037	T/G	cg26385618	chr18:73139727	C18orf62	-0.5	-7.4	-0.41	1.83e-12	Intelligence;
CESC	cis	rs6500602	0.634	rs2270365	chr16:4526758	G/A	cg08645402	chr16:4508243	NA	0.55	8.69	0.47	3.72e-16	Schizophrenia;
CESC	cis	rs4423214	1.000	rs11606631	chr11:71164121	C/A	cg05163923	chr11:71159392	DHCR7	0.76	10.16	0.53	1.05e-20	Vitamin D levels;
CESC	cis	rs9309473	0.607	rs11686504	chr2:73579812	T/C	cg20560298	chr2:73613845	ALMS1	-0.45	-6.09	-0.35	3.94e-9	Metabolite levels;
CESC	cis	rs9649213	0.555	rs6948346	chr7:97959956	A/G	cg08684580	chr7:98029266	BAIAP2L1	-0.33	-5.28	-0.31	2.67e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs453301	0.719	rs34004903	chr8:8892604	C/T	cg15556689	chr8:8085844	FLJ10661	-0.5	-6.27	-0.36	1.43e-9	Joint mobility (Beighton score);
CESC	cis	rs56116382	0.604	rs9858428	chr3:49877585	G/T	cg00383909	chr3:49044727	WDR6	0.82	5.31	0.31	2.3e-7	Intelligence (multi-trait analysis);High light scatter reticulocyte count;
CESC	cis	rs2273669	0.667	rs75942063	chr6:109352545	G/A	cg05315195	chr6:109294784	ARMC2	-0.67	-6.06	-0.35	4.74e-9	Prostate cancer;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg23421970	chr18:33552539	C18orf21	-0.47	-6.04	-0.35	5.09e-9	Fibrinogen levels;
CESC	trans	rs35146811	0.624	rs1727134	chr7:99813672	T/C	cg13215871	chr17:75784724	NA	-0.35	-6.39	-0.37	7.48e-10	Coronary artery disease;
CESC	cis	rs644799	1.000	rs534497	chr11:95562868	C/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	9.06	0.49	2.9e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs7044106	0.762	rs12003646	chr9:123470621	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.64	8.54	0.46	1.05e-15	Hip circumference adjusted for BMI;
CESC	cis	rs7945705	0.902	rs10769980	chr11:9014180	G/A	cg21881798	chr11:8931708	C11orf17;ST5	0.47	7.82	0.43	1.26e-13	Hemoglobin concentration;
CESC	cis	rs875971	0.929	rs12673810	chr7:65923853	T/A	cg12463550	chr7:65579703	CRCP	0.56	7.09	0.4	1.2e-11	Aortic root size;
CESC	cis	rs2066819	1.000	rs808919	chr12:56647911	C/G	cg26316697	chr12:56727976	PAN2	-0.67	-6.46	-0.37	4.99e-10	Psoriasis vulgaris;
CESC	cis	rs7208859	0.673	rs73277964	chr17:29179201	A/T	cg19761014	chr17:28927070	LRRC37B2	0.63	5.27	0.31	2.88e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs17021463	0.902	rs2865352	chr4:95253263	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.58	-9.07	-0.49	2.75e-17	Testicular germ cell tumor;
CESC	cis	rs798554	0.797	rs1182183	chr7:2873136	C/T	cg04166393	chr7:2884313	GNA12	0.58	7.58	0.42	5.85e-13	Height;
CESC	cis	rs2479724	0.846	rs1536702	chr6:41869950	T/A	cg17623882	chr6:41773611	USP49	-0.41	-5.68	-0.33	3.53e-8	Menarche (age at onset);
CESC	cis	rs7666738	0.791	rs10022061	chr4:98926821	T/C	cg05340658	chr4:99064831	C4orf37	0.82	12.2	0.6	1.81e-27	Colonoscopy-negative controls vs population controls;
CESC	cis	rs524023	1.000	rs10792441	chr11:64360629	C/T	cg07220939	chr11:64358617	SLC22A12	-0.36	-5.58	-0.32	5.95e-8	Urate levels in obese individuals;
CESC	cis	rs853679	0.517	rs17774663	chr6:28120898	G/A	cg19592336	chr6:28129416	ZNF389	0.62	8.11	0.45	1.84e-14	Depression;
CESC	cis	rs2032447	0.869	rs2230655	chr6:26033506	A/G	cg03517284	chr6:25882590	NA	0.42	5.68	0.33	3.46e-8	Intelligence (multi-trait analysis);
CESC	cis	rs7267979	1.000	rs2500432	chr20:25290512	A/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.82	15.76	0.7	6.3e-40	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs2204008	0.515	rs11495471	chr12:38027178	G/A	cg26384229	chr12:38710491	ALG10B	0.75	10.72	0.55	1.61e-22	Bladder cancer;
CESC	cis	rs6835098	0.961	rs2078475	chr4:174098226	A/C	cg08422745	chr4:174089978	GALNT7	0.73	9.33	0.5	4.31e-18	Dementia and core Alzheimer's disease neuropathologic changes;
CESC	cis	rs9916302	0.904	rs2338800	chr17:37498149	C/G	cg20243544	chr17:37824526	PNMT	-0.48	-6.13	-0.35	3.15e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs1538970	0.847	rs781230	chr1:45880751	C/T	cg05343316	chr1:45956843	TESK2	-0.79	-11.27	-0.57	2.43e-24	Platelet count;
CESC	cis	rs4819052	1.000	rs3746980	chr21:46711580	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.94	12.55	0.61	1.16e-28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs61931739	0.534	rs1844526	chr12:34102780	G/A	cg26384229	chr12:38710491	ALG10B	0.59	8.18	0.45	1.17e-14	Morning vs. evening chronotype;
CESC	cis	rs7666738	0.830	rs35433756	chr4:99070555	C/T	cg17366294	chr4:99064904	C4orf37	0.61	8.5	0.46	1.36e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs13191362	0.935	rs34268859	chr6:162934731	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.69	5.97	0.34	7.56e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs853679	0.517	rs3173443	chr6:28137027	T/G	cg12963246	chr6:28129442	ZNF389	0.54	7.12	0.4	1.02e-11	Depression;
CESC	cis	rs4713118	0.662	rs9357060	chr6:28024486	C/G	cg23161317	chr6:28129485	ZNF389	0.49	6.2	0.36	2.14e-9	Parkinson's disease;
CESC	cis	rs7552404	0.690	rs11161620	chr1:76255228	A/G	cg10523679	chr1:76189770	ACADM	-0.68	-6.82	-0.39	6.01e-11	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs919433	0.890	rs979020	chr2:198169749	T/C	cg03934865	chr2:198174659	NA	-0.46	-6.85	-0.39	5.2e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs2191566	0.881	rs1996408	chr19:44532732	G/A	cg20607764	chr19:44506953	ZNF230	-0.65	-8.55	-0.47	9.84e-16	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs2011503	1.000	rs1557723	chr19:19443033	A/G	cg11584989	chr19:19387371	SF4	-0.63	-7.42	-0.41	1.55e-12	Bipolar disorder;
CESC	cis	rs3785574	0.743	rs2727334	chr17:61969063	A/T	cg06873352	chr17:61820015	STRADA	0.48	6.88	0.39	4.26e-11	Height;
CESC	cis	rs896854	1.000	rs896854	chr8:95960511	T/C	cg23172400	chr8:95962367	TP53INP1	-0.5	-10.43	-0.54	1.43e-21	Type 2 diabetes;
CESC	cis	rs6460942	1.000	rs6460938	chr7:12406808	T/G	cg20607287	chr7:12443886	VWDE	-0.8	-9.07	-0.49	2.85e-17	Coronary artery disease;
CESC	cis	rs7208859	0.623	rs59447372	chr17:29057585	C/T	cg13385521	chr17:29058706	SUZ12P	0.81	6.53	0.37	3.28e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs6951245	0.872	rs11768895	chr7:1063691	T/C	cg18402987	chr7:1209562	NA	0.64	6.6	0.38	2.28e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7914558	0.966	rs943035	chr10:104839152	T/C	cg04362960	chr10:104952993	NT5C2	0.47	6.12	0.35	3.36e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs9660180	0.935	rs9786942	chr1:1759213	A/G	cg03396347	chr1:1875803	NA	-0.43	-6.69	-0.38	1.29e-10	Body mass index;
CESC	trans	rs6794880	0.673	rs75690303	chr3:84419526	A/G	cg03554283	chr8:76319451	NA	0.57	6.07	0.35	4.44e-9	Body mass index (joint analysis main effects and smoking interaction);BMI in non-smokers;BMI (adjusted for smoking behaviour);
CESC	cis	rs7949030	0.626	rs1061093	chr11:62334908	G/C	cg11742103	chr11:62369870	EML3;MTA2	0.65	9.89	0.52	7.57e-20	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs57506017	0.540	rs1435525	chr7:12262717	T/C	cg23422036	chr7:12250390	TMEM106B	0.39	5.23	0.31	3.51e-7	Neuroticism;
CESC	cis	rs9715521	0.775	rs62301198	chr4:59848776	C/T	cg11281224	chr4:60001000	NA	-0.5	-6.55	-0.37	2.9e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs4253772	0.637	rs9627295	chr22:46650100	C/T	cg10231785	chr22:46692440	CN5H6.4;GTSE1	0.48	5.11	0.3	6.16e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs7772486	0.743	rs2092262	chr6:146037105	C/T	cg05347473	chr6:146136440	FBXO30	-0.48	-6.45	-0.37	5.16e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4555082	0.830	rs3803319	chr14:105752458	G/A	cg13114125	chr14:105738426	BRF1	-0.86	-10.51	-0.54	8.21e-22	Mean platelet volume;Platelet distribution width;
CESC	cis	rs2213920	0.516	rs71505546	chr9:118158372	G/A	cg13918206	chr9:118159781	DEC1	-0.69	-5.52	-0.32	8.06e-8	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
CESC	cis	rs1348850	0.540	rs10172355	chr2:178443225	A/G	cg22681709	chr2:178499509	PDE11A	-0.44	-5.14	-0.3	5.3e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs597539	0.652	rs496616	chr11:68672800	G/C	cg18350739	chr11:68623251	NA	-0.45	-6.9	-0.39	3.91e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs6062302	0.522	rs2236503	chr20:62224595	G/A	cg09650180	chr20:62225654	GMEB2	-0.81	-9.23	-0.49	9e-18	Glioblastoma;
CESC	cis	rs6459788	0.692	rs10807645	chr7:157258979	T/C	cg06271696	chr7:157225062	NA	0.36	5.83	0.34	1.65e-8	Epstein-Barr virus copy number in lymphoblastoid cell lines;
CESC	cis	rs2549003	1.000	rs7701588	chr5:131819970	T/C	cg21138405	chr5:131827807	IRF1	0.54	9.24	0.49	8.12e-18	Asthma (sex interaction);
CESC	cis	rs763121	0.853	rs5757231	chr22:39071658	C/T	cg21395723	chr22:39101663	GTPBP1	-0.41	-5.07	-0.3	7.51e-7	Menopause (age at onset);
CESC	cis	rs4704187	0.687	rs4627970	chr5:74528776	G/A	cg03227963	chr5:74354835	NA	0.28	5.08	0.3	7.28e-7	Response to amphetamines;
CESC	cis	rs1005277	0.522	rs9417256	chr10:37976990	A/G	cg00409905	chr10:38381863	ZNF37A	-0.51	-7.12	-0.4	1.04e-11	Extrinsic epigenetic age acceleration;
CESC	cis	rs6089584	0.566	rs6061964	chr20:60607536	G/A	cg24733560	chr20:60626293	TAF4	0.49	7.28	0.41	3.85e-12	Body mass index;
CESC	cis	rs10540	1.000	rs117339389	chr11:505025	T/A	cg03576123	chr11:487126	PTDSS2	-1.12	-11.1	-0.56	9.13e-24	Body mass index;
CESC	cis	rs10654220	1	rs10654220	chr12:123703422	A/AGTT	cg00376283	chr12:123451042	ABCB9	0.61	6.37	0.36	8.43e-10	Platelet count;
CESC	cis	rs3126085	0.935	rs6681433	chr1:152277396	T/C	cg03465714	chr1:152285911	FLG	0.5	5.77	0.33	2.2e-8	Atopic dermatitis;
CESC	cis	rs10504229	1.000	rs17216711	chr8:58170856	T/C	cg05313129	chr8:58192883	C8orf71	-0.55	-6.37	-0.36	8.42e-10	Developmental language disorder (linguistic errors);
CESC	trans	rs7839040	0.698	rs10110295	chr8:82921482	C/T	cg14472086	chr9:107730925	NA	-0.48	-6.53	-0.37	3.31e-10	Response to methotrexate in juvenile idiopathic arthritis;
CESC	cis	rs9796	0.870	rs2927061	chr15:41302219	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.42	-6.21	-0.36	2.05e-9	Menopause (age at onset);
CESC	cis	rs12142240	0.698	rs6667861	chr1:46815749	T/C	cg00530320	chr1:46809349	NSUN4	0.58	7.89	0.44	8.17e-14	Menopause (age at onset);
CESC	cis	rs4925386	0.959	rs6121989	chr20:60916713	A/T	cg24112000	chr20:60950667	NA	0.51	7.39	0.41	1.94e-12	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs597539	0.690	rs497149	chr11:68626639	A/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.82	10.01	0.52	3.34e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs10927875	0.688	rs2009371	chr1:16348083	A/T	cg21385522	chr1:16154831	NA	0.59	6.95	0.39	2.89e-11	Dilated cardiomyopathy;
CESC	cis	rs1577917	1.000	rs10944161	chr6:86630376	A/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.44	-5.78	-0.33	2.14e-8	Response to antipsychotic treatment;
CESC	cis	rs116095464	0.558	rs7703803	chr5:292311	A/G	cg12570787	chr5:219185	SDHA;CCDC127	0.5	5.17	0.3	4.68e-7	Breast cancer;
CESC	cis	rs11958404	0.615	rs10058832	chr5:157431866	T/A	cg05962755	chr5:157440814	NA	0.4	5.74	0.33	2.54e-8	IgG glycosylation;
CESC	cis	rs9914988	0.887	rs9895625	chr17:27108516	A/G	cg20469991	chr17:27169893	C17orf63	-0.48	-5.25	-0.31	3.18e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CESC	cis	rs6741892	0.536	rs7590835	chr2:38893950	A/G	cg08308459	chr2:38893161	GALM	0.52	6.59	0.38	2.34e-10	5-HTT brain serotonin transporter levels;
CESC	cis	rs769267	0.895	rs2916073	chr19:19528324	T/G	cg03709012	chr19:19516395	GATAD2A	0.99	15.75	0.7	6.65e-40	Tonsillectomy;
CESC	cis	rs7188697	0.885	rs246194	chr16:58573901	G/A	cg02549819	chr16:58548995	SETD6	-0.42	-5.3	-0.31	2.46e-7	QT interval;
CESC	cis	rs4664293	0.967	rs10803758	chr2:160548219	T/C	cg08347373	chr2:160653686	CD302	-0.31	-5.12	-0.3	5.88e-7	Monocyte percentage of white cells;
CESC	cis	rs3750965	0.959	rs3376	chr11:68856680	G/A	cg01403660	chr11:68851641	TPCN2	0.4	5.21	0.3	3.74e-7	Hair color;
CESC	cis	rs62064224	0.765	rs62065463	chr17:30732405	G/T	cg12855166	chr17:30846586	MYO1D	0.4	5.16	0.3	4.76e-7	Schizophrenia;
CESC	cis	rs4689388	0.890	rs1801206	chr4:6302707	C/T	cg25554036	chr4:6271136	WFS1	0.54	8.64	0.47	5.27e-16	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	trans	rs61931739	0.534	rs11052983	chr12:34045787	C/A	cg26384229	chr12:38710491	ALG10B	0.53	7.22	0.41	5.44e-12	Morning vs. evening chronotype;
CESC	cis	rs926392	0.666	rs912179	chr20:37710775	G/A	cg16355469	chr20:37678765	NA	0.53	6.05	0.35	4.87e-9	Dialysis-related mortality;
CESC	cis	rs763121	0.853	rs4821816	chr22:39113134	G/A	cg21395723	chr22:39101663	GTPBP1	0.51	7.11	0.4	1.08e-11	Menopause (age at onset);
CESC	cis	rs7084402	0.967	rs1649039	chr10:60330041	C/T	cg07615347	chr10:60278583	BICC1	0.59	9.29	0.5	5.85e-18	Refractive error;
CESC	cis	rs2576037	0.583	rs9960463	chr18:44522808	T/A	cg19077165	chr18:44547161	KATNAL2	-0.63	-9.5	-0.5	1.35e-18	Personality dimensions;
CESC	cis	rs4077515	1.000	rs10870077	chr9:139263891	C/G	cg14169450	chr9:139327907	INPP5E	0.35	5.08	0.3	7.21e-7	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs9911578	0.967	rs11079368	chr17:57086473	C/T	cg12560992	chr17:57184187	TRIM37	-1.01	-17.88	-0.74	1.96e-47	Intelligence (multi-trait analysis);
CESC	cis	rs11602339	1	rs11602339	chr11:47761471	C/T	cg18512352	chr11:47633146	NA	-0.6	-9.5	-0.5	1.32e-18	Body mass index;
CESC	cis	rs1799949	0.896	rs8176086	chr17:41274778	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.67	9.34	0.5	3.98e-18	Menopause (age at onset);
CESC	cis	rs7107174	1.000	rs2511185	chr11:77982496	C/A	cg02023728	chr11:77925099	USP35	0.39	5.77	0.33	2.17e-8	Testicular germ cell tumor;
CESC	cis	rs832540	0.898	rs331498	chr5:56249842	C/G	cg14703610	chr5:56206110	C5orf35	-0.51	-6.51	-0.37	3.8e-10	Coronary artery disease;
CESC	cis	rs116095464	0.614	rs4371799	chr5:268192	C/A	cg22857025	chr5:266934	NA	-1.28	-18.52	-0.75	1.03e-49	Breast cancer;
CESC	cis	rs12541635	0.701	rs2029878	chr8:107025283	A/G	cg10147462	chr8:107024639	NA	0.4	6.25	0.36	1.61e-9	Age of smoking initiation;
CESC	cis	rs3762637	0.941	rs60222267	chr3:122179632	G/T	cg24169773	chr3:122142474	KPNA1	-0.54	-6.33	-0.36	1.04e-9	LDL cholesterol levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06264183	chr20:35202306	TGIF2	-0.58	-6.65	-0.38	1.69e-10	Gut microbiome composition (summer);
CESC	cis	rs9527	0.590	rs10509766	chr10:104926334	T/C	cg04362960	chr10:104952993	NT5C2	0.42	5.25	0.31	3.11e-7	Arsenic metabolism;
CESC	cis	rs10883723	0.810	rs2296586	chr10:104245575	C/T	ch.10.2196322F	chr10:104248062	ACTR1A	0.48	5.83	0.34	1.64e-8	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg08027265	chr7:2291960	NA	0.35	5.4	0.31	1.49e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs6840258	1.000	rs56395939	chr4:87963633	T/G	cg08197287	chr4:87952173	AFF1	-0.4	-5.52	-0.32	8.06e-8	Mean corpuscular volume;Basophil percentage of granulocytes;
CESC	cis	rs2072732	0.821	rs12034573	chr1:2948020	C/T	cg15211996	chr1:2936768	ACTRT2	0.29	5.12	0.3	5.88e-7	Plateletcrit;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg09092161	chr9:130639739	AK1	-0.45	-6.09	-0.35	3.91e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs644799	0.896	rs4430471	chr11:95646774	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.44	5.31	0.31	2.32e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs8092503	1.000	rs8092503	chr18:52479487	A/G	cg12377874	chr18:52495404	RAB27B	0.38	6.27	0.36	1.46e-9	Childhood body mass index;
CESC	cis	rs2404602	0.684	rs11072602	chr15:76873467	T/C	cg23625390	chr15:77176239	SCAPER	-0.43	-5.85	-0.34	1.44e-8	Blood metabolite levels;
CESC	cis	rs4665809	1.000	rs4665811	chr2:26260017	A/G	cg22920501	chr2:26401640	FAM59B	-0.7	-8.39	-0.46	2.85e-15	Gut microbiome composition (summer);
CESC	cis	rs2777491	0.507	rs34040639	chr15:41760807	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.01	-15.93	-0.7	1.59e-40	Ulcerative colitis;
CESC	cis	rs933688	0.532	rs13164949	chr5:90538489	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.44	-5.13	-0.3	5.63e-7	Smoking behavior;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg00930706	chr16:88752925	MGC23284;SNAI3	0.46	6.5	0.37	4.01e-10	Thyroid stimulating hormone;
CESC	cis	rs7927771	0.542	rs7122217	chr11:47777920	G/C	cg05585544	chr11:47624801	NA	-0.32	-5.11	-0.3	6.09e-7	Subjective well-being;
CESC	cis	rs6540559	0.673	rs17015361	chr1:210018901	C/G	cg21951975	chr1:209979733	IRF6	0.55	6.64	0.38	1.75e-10	Cleft lip with or without cleft palate;
CESC	cis	rs9311474	0.652	rs614288	chr3:52220203	T/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.29	5.2	0.3	3.94e-7	Electroencephalogram traits;
CESC	cis	rs55788414	0.932	rs4365300	chr16:81184460	C/T	cg06400318	chr16:81190750	PKD1L2	-0.6	-6.82	-0.39	6.19e-11	Left ventricular obstructive tract defect (maternal effect);
CESC	cis	rs6582630	0.593	rs7299329	chr12:38447943	G/C	cg13010199	chr12:38710504	ALG10B	0.46	6.0	0.35	6.56e-9	Drug-induced liver injury (flucloxacillin);
CESC	trans	rs11098499	0.863	rs3775854	chr4:120471971	C/T	cg25214090	chr10:38739885	LOC399744	0.67	9.15	0.49	1.55e-17	Corneal astigmatism;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27535044	chr8:82633568	ZFAND1	0.54	6.82	0.39	6.2e-11	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02098460	chr2:114196058	CBWD2;LOC440839	0.59	6.96	0.39	2.63e-11	Gut microbiome composition (summer);
CESC	cis	rs7937682	1.000	rs11608149	chr11:111535102	G/A	cg09085632	chr11:111637200	PPP2R1B	1.04	15.08	0.68	1.63e-37	Primary sclerosing cholangitis;
CESC	cis	rs8062405	0.721	rs151303	chr16:28492510	C/A	cg05966235	chr16:28915196	ATP2A1	0.37	5.2	0.3	4.04e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs9322193	0.923	rs12195866	chr6:150014470	A/G	cg04369109	chr6:150039330	LATS1	-0.37	-5.07	-0.3	7.56e-7	Lung cancer;
CESC	cis	rs7584330	0.554	rs10173100	chr2:238433040	A/G	cg14458575	chr2:238380390	NA	0.49	5.42	0.32	1.35e-7	Prostate cancer;
CESC	cis	rs9640161	0.673	rs11773351	chr7:150030963	T/C	cg10018233	chr7:150070692	REPIN1	0.41	5.66	0.33	3.85e-8	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs11608355	0.545	rs4766604	chr12:109892179	T/C	cg05360138	chr12:110035743	NA	0.82	8.92	0.48	7.93e-17	Neuroticism;
CESC	cis	rs9929218	1.000	rs28549017	chr16:68758828	G/C	cg02972257	chr16:68554789	NA	0.55	6.4	0.37	6.95e-10	Colorectal cancer;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg18684905	chr19:1822532	REXO1	0.42	6.18	0.35	2.42e-9	Gambling;
CESC	cis	rs765787	0.530	rs12905246	chr15:45500841	C/T	cg24006582	chr15:45444508	DUOX1	0.52	6.37	0.36	8.32e-10	Uric acid levels;
CESC	cis	rs2243480	1.000	rs73142121	chr7:65311206	C/T	cg12463550	chr7:65579703	CRCP	0.68	5.61	0.33	5.08e-8	Diabetic kidney disease;
CESC	cis	rs9910055	0.659	rs721769	chr17:42261588	T/G	cg08499158	chr17:42289980	UBTF	-0.52	-6.56	-0.37	2.85e-10	Total body bone mineral density;
CESC	cis	rs9399135	0.967	rs2327580	chr6:135364417	A/C	cg24558204	chr6:135376177	HBS1L	0.52	7.14	0.4	9.15e-12	Red blood cell count;
CESC	cis	rs35110281	0.805	rs2838318	chr21:44991825	G/A	cg21573476	chr21:45109991	RRP1B	-0.38	-5.34	-0.31	1.99e-7	Mean corpuscular volume;
CESC	cis	rs6695640	0.854	rs1555660	chr1:17731117	T/C	cg01904812	chr1:17746340	RCC2	0.35	5.19	0.3	4.15e-7	Mean platelet volume;
CESC	cis	rs59698941	0.943	rs73259116	chr5:132218461	A/G	cg02081065	chr5:132209139	LEAP2	-0.52	-5.11	-0.3	6.08e-7	Apolipoprotein A-IV levels;
CESC	cis	rs7703051	0.901	rs5744672	chr5:74877803	T/C	cg03227963	chr5:74354835	NA	0.3	5.4	0.31	1.46e-7	LDL cholesterol;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
CESC	cis	rs950776	0.752	rs62010328	chr15:78894971	C/T	cg06917634	chr15:78832804	PSMA4	0.6	6.97	0.39	2.5e-11	Sudden cardiac arrest;
CESC	cis	rs2839186	0.708	rs6518285	chr21:47644667	T/C	cg13126279	chr21:47581558	C21orf56	-0.49	-6.61	-0.38	2.13e-10	Testicular germ cell tumor;
CESC	cis	rs9287719	0.967	rs11687023	chr2:10741412	G/A	cg02196655	chr2:10830764	NOL10	-0.38	-5.83	-0.34	1.61e-8	Prostate cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11817453	chr19:8464850	RAB11B	-0.56	-6.26	-0.36	1.58e-9	Gut microbiome composition (summer);
CESC	cis	rs4665809	1.000	rs4665819	chr2:26309073	A/G	cg27170947	chr2:26402098	FAM59B	-0.6	-7.25	-0.41	4.7e-12	Gut microbiome composition (summer);
CESC	cis	rs17362650	1.000	rs66835002	chr2:9655260	T/C	cg12832956	chr2:9616023	IAH1	-0.52	-5.09	-0.3	6.69e-7	Alcohol dependence (age at onset);
CESC	cis	rs8005677	1.000	rs4982706	chr14:23381697	C/T	cg25600027	chr14:23388339	RBM23	-0.43	-5.33	-0.31	2.08e-7	Cognitive ability (multi-trait analysis);
CESC	cis	rs9611565	0.840	rs2234052	chr22:41777241	A/G	cg03806693	chr22:41940476	POLR3H	-1.07	-13.24	-0.63	4.71e-31	Vitiligo;
CESC	cis	rs9311474	0.607	rs4687625	chr3:52563718	C/T	cg18404041	chr3:52824283	ITIH1	-0.38	-6.43	-0.37	5.88e-10	Electroencephalogram traits;
CESC	cis	rs1799949	0.965	rs1842147	chr17:41435192	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.6	7.92	0.44	6.6e-14	Menopause (age at onset);
CESC	trans	rs12367822	0.956	rs9706160	chr12:57184903	G/A	cg26462586	chr2:11164677	NA	0.38	6.02	0.35	5.82e-9	Platelet aggregation;
CESC	trans	rs4471313	1.000	rs10919388	chr1:170372503	A/C	cg14876685	chr7:99177937	NA	0.43	6.47	0.37	4.67e-10	Waist-hip ratio;
CESC	cis	rs1552244	1.000	rs7610821	chr3:10136150	C/T	cg00166722	chr3:10149974	C3orf24	0.45	5.91	0.34	1.07e-8	Alzheimer's disease;
CESC	cis	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg21782813	chr7:2030301	MAD1L1	-0.48	-6.99	-0.39	2.18e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs12142240	0.667	rs12062	chr1:46830447	G/T	cg00530320	chr1:46809349	NSUN4	-0.61	-8.23	-0.45	8.56e-15	Menopause (age at onset);
CESC	cis	rs798554	0.757	rs2533882	chr7:2846894	G/T	cg19717773	chr7:2847554	GNA12	-0.57	-7.91	-0.44	7.21e-14	Height;
CESC	cis	rs75804782	0.641	rs72987304	chr2:239345532	C/T	cg18131467	chr2:239335373	ASB1	-0.66	-5.48	-0.32	9.84e-8	Morning vs. evening chronotype;Chronotype;
CESC	cis	rs1348850	0.914	rs4893823	chr2:178285811	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.86	-12.8	-0.62	1.61e-29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs2361710	0.668	rs4889830	chr17:78114528	G/A	cg06718696	chr17:78121285	EIF4A3	0.45	5.36	0.31	1.82e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
CESC	cis	rs8060686	0.641	rs2107369	chr16:68116018	A/C	cg26727032	chr16:67993705	SLC12A4	-0.55	-6.58	-0.37	2.51e-10	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs6998277	0.830	rs12543046	chr8:103603809	A/G	cg10187029	chr8:103597600	NA	-0.74	-10.06	-0.53	2.33e-20	Migraine;
CESC	cis	rs9457247	1.000	rs2149085	chr6:167371110	T/C	cg07741184	chr6:167504864	NA	-0.3	-5.28	-0.31	2.64e-7	Crohn's disease;
CESC	cis	rs10791097	0.694	rs1050071	chr11:130747231	C/G	cg12179176	chr11:130786555	SNX19	0.69	10.2	0.53	8.25e-21	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs35306767	0.715	rs17221463	chr10:1038040	T/C	cg26597838	chr10:835615	NA	0.68	6.26	0.36	1.56e-9	Eosinophil percentage of granulocytes;
CESC	cis	rs6089829	0.962	rs6122344	chr20:61661738	C/T	cg08564027	chr20:61660810	NA	0.9	15.36	0.69	1.69e-38	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs13191362	0.872	rs13213421	chr6:163203805	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.95	9.46	0.5	1.79e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs7312774	0.748	rs10492214	chr12:107294758	T/C	cg16260113	chr12:107380972	MTERFD3	0.63	5.84	0.34	1.51e-8	Severe influenza A (H1N1) infection;
CESC	cis	rs523522	0.962	rs9040	chr12:120900274	C/T	cg27279351	chr12:120934652	DYNLL1	0.68	8.55	0.47	9.73e-16	High light scatter reticulocyte count;
CESC	cis	rs6542838	0.609	rs12712043	chr2:99541494	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.41	-5.26	-0.31	3.04e-7	Fear of minor pain;
CESC	cis	rs561341	1.000	rs564714	chr17:30318404	C/T	cg23018236	chr17:30244563	NA	-0.55	-5.3	-0.31	2.42e-7	Hip circumference adjusted for BMI;
CESC	cis	rs9858542	0.537	rs34514189	chr3:49373045	A/G	cg00383909	chr3:49044727	WDR6	0.57	5.2	0.3	4.07e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg02514519	chr11:61348922	SYT7	-0.45	-6.04	-0.35	5.15e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs7584330	0.666	rs7600317	chr2:238353513	C/T	cg14458575	chr2:238380390	NA	0.71	9.55	0.51	9.12e-19	Prostate cancer;
CESC	cis	rs35146811	0.586	rs1076237	chr7:99585441	A/C	cg22906224	chr7:99728672	NA	0.42	5.06	0.3	7.83e-7	Coronary artery disease;
CESC	cis	rs17711722	0.522	rs62469933	chr7:65265639	G/A	cg02869306	chr7:64672164	INTS4L1	-0.34	-5.45	-0.32	1.16e-7	Calcium levels;
CESC	cis	rs863345	0.967	rs10908681	chr1:158522712	C/T	cg12129480	chr1:158549410	OR10X1	-0.32	-6.5	-0.37	3.89e-10	Pneumococcal bacteremia;
CESC	cis	rs12682352	0.602	rs635594	chr8:8613387	C/T	cg17143192	chr8:8559678	CLDN23	-0.43	-5.15	-0.3	5.12e-7	Neuroticism;
CESC	cis	rs875971	0.825	rs6951503	chr7:65718936	T/G	cg19163074	chr7:65112434	INTS4L2	0.41	5.1	0.3	6.46e-7	Aortic root size;
CESC	cis	rs938554	0.513	rs3775948	chr4:9995182	G/C	cg00071950	chr4:10020882	SLC2A9	0.66	8.52	0.46	1.19e-15	Blood metabolite levels;
CESC	cis	rs1046896	1.000	rs1046875	chr17:80685426	A/G	cg02711726	chr17:80685570	FN3KRP	0.6	9.04	0.49	3.37e-17	Glycated hemoglobin levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01988550	chr7:28966659	NA	0.63	6.81	0.39	6.38e-11	Gut microbiome composition (summer);
CESC	cis	rs9420	0.925	rs488769	chr11:57450720	A/C	cg23127183	chr11:57508653	C11orf31	-0.44	-5.23	-0.31	3.51e-7	Schizophrenia;
CESC	cis	rs7666738	0.747	rs2865955	chr4:99040518	A/C	cg17366294	chr4:99064904	C4orf37	0.61	8.78	0.47	2.13e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs5498	0.809	rs2075742	chr19:10401607	G/C	cg21994045	chr19:10403936	ICAM5	0.43	6.13	0.35	3.13e-9	Lymphocyte counts;Soluble ICAM-1;Blood protein levels;
CESC	cis	rs9487051	0.872	rs1320612	chr6:109611990	C/A	cg12927641	chr6:109611667	NA	-0.42	-6.59	-0.38	2.42e-10	Reticulocyte fraction of red cells;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg00442658	chr21:18885041	CXADR	-0.47	-6.05	-0.35	4.89e-9	Fibrinogen levels;
CESC	cis	rs17539620	0.624	rs62432739	chr6:154835926	A/G	cg20019720	chr6:154832845	CNKSR3	0.47	6.13	0.35	3.21e-9	Lipoprotein (a) levels;
CESC	cis	rs896854	0.654	rs13274945	chr8:95986626	C/T	cg13393036	chr8:95962371	TP53INP1	-0.49	-10.7	-0.55	1.94e-22	Type 2 diabetes;
CESC	cis	rs7666738	0.830	rs13129479	chr4:98987860	T/C	cg03467027	chr4:99064603	C4orf37	0.44	5.54	0.32	7.12e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2576037	0.561	rs513775	chr18:44396334	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.34	5.35	0.31	1.93e-7	Personality dimensions;
CESC	cis	rs2730245	0.618	rs859781	chr7:158661758	G/A	cg24397884	chr7:158709396	WDR60	0.69	10.16	0.53	1.1e-20	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05221264	chr1:15783513	CELA2A	-0.53	-6.4	-0.37	6.88e-10	Gut microbiome composition (summer);
CESC	cis	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg04267008	chr7:1944627	MAD1L1	-0.65	-7.85	-0.43	1.05e-13	Bipolar disorder and schizophrenia;
CESC	trans	rs35110281	0.744	rs162373	chr21:44927107	C/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.46	-6.2	-0.36	2.19e-9	Mean corpuscular volume;
CESC	cis	rs6089584	0.606	rs7270666	chr20:60577598	C/T	cg06108461	chr20:60628389	TAF4	-0.58	-7.59	-0.42	5.33e-13	Body mass index;
CESC	cis	rs7631605	0.905	rs61489663	chr3:37261734	T/A	cg22985146	chr3:37219077	LRRFIP2	-0.35	-5.44	-0.32	1.22e-7	Cerebrospinal P-tau181p levels;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg26631329	chr19:19496517	GATAD2A	-0.37	-6.03	-0.35	5.39e-9	Gambling;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12525736	chr1:228269915	ARF1	0.55	6.07	0.35	4.4e-9	Gut microbiome composition (summer);
CESC	cis	rs710216	0.912	rs11537640	chr1:43424519	T/G	cg07803811	chr1:43423981	SLC2A1	0.49	5.25	0.31	3.19e-7	Red cell distribution width;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16282910	chr9:112296723	NA	-0.71	-8.51	-0.46	1.3e-15	Gut microbiome composition (summer);
CESC	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg07677032	chr17:61819896	STRADA	0.46	6.21	0.36	2.06e-9	Prudent dietary pattern;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg25386820	chr18:21242428	ANKRD29	0.43	6.05	0.35	4.92e-9	Systemic lupus erythematosus;
CESC	cis	rs35306767	0.903	rs11253460	chr10:887382	C/G	cg10556349	chr10:835070	NA	0.57	5.48	0.32	9.88e-8	Eosinophil percentage of granulocytes;
CESC	cis	rs8072100	0.713	rs9807106	chr17:45457102	G/T	cg25173405	chr17:45401733	C17orf57	-0.43	-5.42	-0.32	1.36e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs56046484	0.871	rs62021203	chr15:85564077	C/T	cg08123816	chr15:85640762	PDE8A	-0.48	-5.67	-0.33	3.82e-8	Testicular germ cell tumor;
CESC	cis	rs2832191	0.903	rs11700687	chr21:30486767	A/G	cg08807101	chr21:30365312	RNF160	-0.66	-9.01	-0.48	4.11e-17	Dental caries;
CESC	cis	rs17253792	0.822	rs10150498	chr14:56064124	G/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.83	6.18	0.36	2.36e-9	Putamen volume;
CESC	trans	rs11098499	0.863	rs2291185	chr4:120434833	C/A	cg25214090	chr10:38739885	LOC399744	0.69	9.45	0.5	1.84e-18	Corneal astigmatism;
CESC	cis	rs7618915	0.571	rs34115864	chr3:52612178	A/G	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.39	6.77	0.38	8.17e-11	Bipolar disorder;
CESC	cis	rs7772486	0.686	rs9399564	chr6:146078907	C/T	cg05347473	chr6:146136440	FBXO30	-0.53	-6.97	-0.39	2.49e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs477895	0.713	rs3802933	chr11:63988102	C/T	cg04317338	chr11:64019027	PLCB3	0.88	9.18	0.49	1.29e-17	Mean platelet volume;
CESC	cis	rs6547741	0.788	rs7595739	chr2:27874563	G/T	cg27432699	chr2:27873401	GPN1	-0.55	-7.99	-0.44	4.19e-14	Oral cavity cancer;
CESC	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	22.16	0.81	2.75e-62	Prudent dietary pattern;
CESC	cis	rs8020095	0.571	rs8018750	chr14:67435567	T/G	cg19548862	chr14:67692701	FAM71D	-0.49	-6.02	-0.35	5.66e-9	Depression (quantitative trait);
CESC	cis	rs748404	0.578	rs573615	chr15:43614281	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.6	8.0	0.44	3.9e-14	Lung cancer;
CESC	cis	rs12478296	0.892	rs11897561	chr2:243014976	C/A	cg06360820	chr2:242988706	NA	-0.77	-9.5	-0.5	1.33e-18	Obesity-related traits;
CESC	cis	rs1008375	0.966	rs10939755	chr4:17693755	T/C	cg02297831	chr4:17616191	MED28	0.47	5.79	0.33	2.02e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs875971	0.505	rs1167386	chr7:65513096	G/A	cg18876405	chr7:65276391	NA	-0.68	-9.5	-0.5	1.27e-18	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10736404	chr2:62115920	CCT4	0.51	6.19	0.36	2.29e-9	Gut microbiome composition (summer);
CESC	cis	rs6762	0.719	rs7936806	chr11:839186	G/C	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.66	-8.51	-0.46	1.28e-15	Mean platelet volume;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg13686143	chr2:201828163	ORC2L	-0.51	-7.44	-0.42	1.37e-12	Gambling;
CESC	cis	rs7666738	0.830	rs35865860	chr4:98968822	C/T	cg17366294	chr4:99064904	C4orf37	0.59	8.43	0.46	2.22e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6933660	0.646	rs3736176	chr6:151773320	T/A	cg10883421	chr6:151773342	RMND1;C6orf211	0.87	15.14	0.68	9.75e-38	Menarche (age at onset);
CESC	cis	rs6831352	0.879	rs56272995	chr4:100060882	A/G	cg12011299	chr4:100065546	ADH4	-0.59	-6.59	-0.38	2.35e-10	Alcohol dependence;
CESC	cis	rs34375054	0.738	rs3751181	chr12:125626535	A/G	cg21269045	chr12:125625041	AACS	-0.34	-5.21	-0.3	3.74e-7	Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs9807841	0.538	rs892086	chr19:10837677	C/T	cg17710535	chr19:10819994	QTRT1	0.4	5.92	0.34	1.02e-8	Inflammatory skin disease;
CESC	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg18402987	chr7:1209562	NA	0.73	7.77	0.43	1.71e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7107174	0.688	rs869202	chr11:78127914	A/G	cg02023728	chr11:77925099	USP35	0.43	5.48	0.32	1.01e-7	Testicular germ cell tumor;
CESC	cis	rs4953076	0.573	rs6726680	chr2:44406686	C/G	cg04920474	chr2:44395004	PPM1B	0.56	7.12	0.4	1.02e-11	Height;
CESC	cis	rs5769765	0.954	rs5770707	chr22:50244533	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	0.47	5.47	0.32	1.07e-7	Schizophrenia;
CESC	cis	rs7843479	0.965	rs4636204	chr8:21823206	T/G	cg17168535	chr8:21777572	XPO7	0.47	6.3	0.36	1.24e-9	Mean corpuscular volume;
CESC	trans	rs3087243	0.755	rs231796	chr2:204704702	G/A	cg01841312	chr10:38069945	NA	0.38	6.35	0.36	9.06e-10	Rheumatoid arthritis;Hypothyroidism;Type 1 diabetes;
CESC	trans	rs7395662	0.591	rs4882110	chr11:48558249	G/T	cg00717180	chr2:96193071	NA	-0.44	-6.06	-0.35	4.58e-9	HDL cholesterol;
CESC	cis	rs10504229	0.595	rs36081958	chr8:58117505	C/G	cg24829409	chr8:58192753	C8orf71	-0.58	-7.21	-0.41	5.76e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs7851660	0.809	rs7032086	chr9:100656402	T/G	cg13688889	chr9:100608707	NA	-0.63	-8.84	-0.48	1.4e-16	Strep throat;
CESC	cis	rs2841277	0.741	rs9672139	chr14:105408182	T/G	cg14403583	chr14:105418241	AHNAK2	-0.65	-9.24	-0.49	8.54e-18	Rheumatoid arthritis;
CESC	cis	rs10089	1.000	rs72794396	chr5:127501386	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.76	9.53	0.51	1.09e-18	Ileal carcinoids;
CESC	cis	rs1552244	1.000	rs66838678	chr3:10150350	G/A	cg08888203	chr3:10149979	C3orf24	0.47	5.91	0.34	1.05e-8	Alzheimer's disease;
CESC	cis	rs6089584	0.586	rs4925216	chr20:60599923	G/A	cg24733560	chr20:60626293	TAF4	0.42	6.17	0.35	2.59e-9	Body mass index;
CESC	trans	rs208520	1.000	rs12199876	chr6:66989469	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.85	9.4	0.5	2.73e-18	Exhaled nitric oxide output;
CESC	cis	rs826838	0.616	rs10880754	chr12:38628154	C/T	cg26384229	chr12:38710491	ALG10B	-0.44	-5.93	-0.34	9.67e-9	Heart rate;
CESC	cis	rs838147	0.537	rs504963	chr19:49208865	G/A	cg21064579	chr19:49206444	FUT2	0.44	6.16	0.35	2.76e-9	Dietary macronutrient intake;
CESC	cis	rs9435341	0.965	rs1335053	chr1:107622823	C/T	cg02990361	chr1:107599529	PRMT6	-0.44	-5.03	-0.3	8.9e-7	Facial morphology (factor 21, depth of nasal alae);
CESC	cis	rs8072100	0.738	rs3736438	chr17:45486651	T/G	cg08085267	chr17:45401833	C17orf57	-0.52	-6.64	-0.38	1.81e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs7208859	0.510	rs216402	chr17:28917126	A/T	cg19761014	chr17:28927070	LRRC37B2	0.87	6.68	0.38	1.41e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs7560272	0.588	rs4852959	chr2:73880601	C/A	cg20560298	chr2:73613845	ALMS1	0.49	6.83	0.39	5.79e-11	Schizophrenia;
CESC	cis	rs1008375	0.932	rs9884565	chr4:17655096	A/G	cg15017067	chr4:17643749	FAM184B	0.36	5.16	0.3	4.78e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs3096299	0.933	rs3114848	chr16:89452771	G/A	cg08822215	chr16:89438651	ANKRD11	-0.43	-6.7	-0.38	1.25e-10	Multiple myeloma (IgH translocation);
CESC	cis	rs9308731	0.591	rs9808225	chr2:111943514	A/G	cg04202892	chr2:111875749	ACOXL	0.37	5.17	0.3	4.61e-7	Chronic lymphocytic leukemia;
CESC	cis	rs2249625	0.564	rs2496489	chr6:72877338	G/A	cg18830697	chr6:72922368	RIMS1	-0.47	-6.84	-0.39	5.38e-11	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CESC	cis	rs9581857	0.579	rs9581843	chr13:27980507	T/G	cg01674679	chr13:27998804	GTF3A	-0.66	-5.26	-0.31	2.91e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
CESC	cis	rs12681288	0.823	rs2701906	chr8:1003316	T/C	cg15309053	chr8:964076	NA	0.36	6.27	0.36	1.42e-9	Schizophrenia;
CESC	cis	rs9916302	0.851	rs6503518	chr17:37660469	A/G	cg19468946	chr17:37922297	IKZF3	-0.39	-5.13	-0.3	5.47e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs4563143	0.675	rs56407818	chr19:29279379	G/A	cg04546413	chr19:29218101	NA	0.55	7.35	0.41	2.45e-12	Methadone dose in opioid dependence;
CESC	cis	rs11112613	0.609	rs6539218	chr12:105934875	C/T	cg03607813	chr12:105948248	NA	0.53	5.98	0.34	7.15e-9	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CESC	cis	rs7255436	0.965	rs11666233	chr19:8452045	G/T	cg16745616	chr19:8428856	ANGPTL4	-0.37	-5.56	-0.32	6.47e-8	HDL cholesterol;
CESC	cis	rs258892	0.895	rs266424	chr5:72122660	G/A	cg21869765	chr5:72125136	TNPO1	-0.44	-5.65	-0.33	4.05e-8	Small cell lung carcinoma;
CESC	cis	rs1005277	0.541	rs2505193	chr10:38394638	G/C	cg00409905	chr10:38381863	ZNF37A	-0.47	-6.3	-0.36	1.24e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs854765	0.663	rs16960744	chr17:17755259	A/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.5	-6.66	-0.38	1.55e-10	Total body bone mineral density;
CESC	cis	rs8077889	0.871	rs11079838	chr17:41898971	G/A	cg26893861	chr17:41843967	DUSP3	0.77	10.14	0.53	1.23e-20	Triglycerides;
CESC	cis	rs9611565	0.559	rs5758397	chr22:42019251	C/T	cg17376030	chr22:41985996	PMM1	-0.81	-8.97	-0.48	5.53e-17	Vitiligo;
CESC	cis	rs459571	0.959	rs408307	chr9:136892523	A/G	cg13789015	chr9:136890014	NCRNA00094	-0.49	-7.14	-0.4	8.86e-12	Platelet distribution width;
CESC	cis	rs7662987	1.000	rs17595424	chr4:99993869	G/T	cg13256891	chr4:100009986	ADH5	-0.76	-5.58	-0.32	5.86e-8	Smoking initiation;
CESC	trans	rs61931739	0.534	rs11052991	chr12:34059018	G/T	cg26384229	chr12:38710491	ALG10B	-0.51	-6.9	-0.39	3.79e-11	Morning vs. evening chronotype;
CESC	cis	rs4423214	1.000	rs4944946	chr11:71159429	G/A	cg24826892	chr11:71159390	DHCR7	0.47	5.55	0.32	6.97e-8	Vitamin D levels;
CESC	cis	rs754466	0.510	rs55893027	chr10:79588209	C/T	cg17075019	chr10:79541650	NA	-0.75	-12.07	-0.6	4.96e-27	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs3733585	0.673	rs7378340	chr4:9955198	C/T	cg11266682	chr4:10021025	SLC2A9	-0.57	-10.74	-0.55	1.39e-22	Cleft plate (environmental tobacco smoke interaction);
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg01723929	chr2:61645604	SNORA70B;USP34	0.4	6.44	0.37	5.51e-10	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs2732480	0.538	rs2732462	chr12:48696384	A/G	cg24011408	chr12:48396354	COL2A1	0.41	5.62	0.33	4.74e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs8067545	0.611	rs2703777	chr17:20138891	C/T	cg13482628	chr17:19912719	NA	-0.42	-5.52	-0.32	8.04e-8	Schizophrenia;
CESC	cis	rs2721195	0.967	rs748195	chr8:145682514	T/C	cg11211951	chr8:145729740	GPT	0.43	6.95	0.39	2.82e-11	Age at first birth;
CESC	cis	rs6089584	0.586	rs1079755	chr20:60615262	G/A	cg24733560	chr20:60626293	TAF4	0.45	6.74	0.38	9.7e-11	Body mass index;
CESC	trans	rs79976124	0.837	rs74327235	chr6:66648353	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.76	8.71	0.47	3.31e-16	Type 2 diabetes;
CESC	cis	rs854765	0.647	rs854769	chr17:18019011	A/G	cg16928487	chr17:17741425	SREBF1	0.45	6.84	0.39	5.58e-11	Total body bone mineral density;
CESC	cis	rs2485892	0.581	rs2484032	chr1:210317225	G/A	cg12034118	chr1:209979487	IRF6	0.46	5.07	0.3	7.42e-7	Manic episodes in bipolar disorder;
CESC	cis	rs875971	0.737	rs7803424	chr7:65880605	T/C	cg18876405	chr7:65276391	NA	0.52	6.87	0.39	4.49e-11	Aortic root size;
CESC	cis	rs4604732	0.536	rs12058821	chr1:247649651	G/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.63	8.34	0.46	3.98e-15	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs6987853	0.814	rs2167338	chr8:42455079	A/G	cg09913449	chr8:42400586	C8orf40	0.41	6.97	0.39	2.57e-11	Mean corpuscular hemoglobin concentration;
CESC	cis	rs11098499	0.954	rs56270433	chr4:120406030	C/T	cg09307838	chr4:120376055	NA	0.93	13.07	0.63	1.78e-30	Corneal astigmatism;
CESC	cis	rs2303745	0.589	rs11086065	chr19:17395003	A/G	cg02221750	chr19:17393354	ANKLE1	-0.5	-6.0	-0.35	6.45e-9	Systemic lupus erythematosus;
CESC	cis	rs6089584	1.000	rs6089585	chr20:60564395	G/A	cg06108461	chr20:60628389	TAF4	-0.78	-11.36	-0.57	1.25e-24	Body mass index;
CESC	cis	rs7267979	0.903	rs2500400	chr20:25354705	A/G	cg08601574	chr20:25228251	PYGB	-0.36	-5.05	-0.3	8.13e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs17539620	0.624	rs62432735	chr6:154834055	T/C	cg17771515	chr6:154831774	CNKSR3	0.59	5.65	0.33	4.23e-8	Lipoprotein (a) levels;
CESC	cis	rs10540	1.000	rs61876339	chr11:495283	T/C	cg03576123	chr11:487126	PTDSS2	-1.1	-10.88	-0.56	5.02e-23	Body mass index;
CESC	cis	rs763121	0.853	rs5757196	chr22:39039855	G/C	cg21395723	chr22:39101663	GTPBP1	0.43	5.33	0.31	2.09e-7	Menopause (age at onset);
CESC	cis	rs7927771	0.832	rs10838699	chr11:47386073	T/C	cg05585544	chr11:47624801	NA	0.49	7.13	0.4	9.38e-12	Subjective well-being;
CESC	cis	rs2637266	0.655	rs846595	chr10:78531300	C/T	cg18941641	chr10:78392320	NA	0.41	7.81	0.43	1.34e-13	Pulmonary function;
CESC	cis	rs10504229	0.639	rs16921812	chr8:58106737	C/T	cg02725872	chr8:58115012	NA	-0.43	-6.81	-0.39	6.53e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs2243480	1.000	rs160644	chr7:65558186	C/T	cg12463550	chr7:65579703	CRCP	0.74	5.71	0.33	3.02e-8	Diabetic kidney disease;
CESC	cis	rs911555	0.755	rs10144051	chr14:103885931	A/C	cg24130564	chr14:104152367	KLC1	-0.52	-7.05	-0.4	1.56e-11	Intelligence (multi-trait analysis);
CESC	cis	rs2952156	0.959	rs2517956	chr17:37843859	G/A	cg20243544	chr17:37824526	PNMT	0.64	7.91	0.44	6.98e-14	Asthma;
CESC	cis	rs1008375	0.966	rs28441502	chr4:17598384	G/A	cg15017067	chr4:17643749	FAM184B	0.36	5.15	0.3	5.2e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs4665809	0.877	rs34536218	chr2:26287376	T/A	cg22920501	chr2:26401640	FAM59B	0.73	8.12	0.45	1.78e-14	Gut microbiome composition (summer);
CESC	cis	rs9790314	0.934	rs9290074	chr3:160997823	T/C	cg04691961	chr3:161091175	C3orf57	-0.41	-5.27	-0.31	2.87e-7	Morning vs. evening chronotype;
CESC	cis	rs9910055	0.614	rs12944572	chr17:42245241	T/C	cg08499158	chr17:42289980	UBTF	-0.52	-6.54	-0.37	3.23e-10	Total body bone mineral density;
CESC	cis	rs172166	0.637	rs1225597	chr6:28162087	C/T	cg26335602	chr6:28129616	ZNF389	0.36	5.23	0.31	3.53e-7	Cardiac Troponin-T levels;
CESC	cis	rs6964587	1.000	rs4727266	chr7:91570129	C/T	cg17063962	chr7:91808500	NA	-0.57	-7.62	-0.42	4.53e-13	Breast cancer;
CESC	cis	rs77216612	0.835	rs10845621	chr12:12887977	C/T	cg04607235	chr12:12878440	APOLD1	-1.0	-15.12	-0.68	1.12e-37	Lymphocyte counts;
CESC	cis	rs9910055	0.573	rs113184718	chr17:42206543	A/T	cg10896456	chr17:42255109	ASB16;C17orf65	-0.48	-7.22	-0.41	5.57e-12	Total body bone mineral density;
CESC	cis	rs8027181	0.839	rs11072385	chr15:73020839	A/G	cg25632853	chr15:73088954	NA	0.31	5.52	0.32	7.91e-8	Triglyceride levels;
CESC	cis	rs4481887	0.927	rs7521689	chr1:248435831	G/T	cg00666640	chr1:248458726	OR2T12	0.41	6.91	0.39	3.65e-11	Common traits (Other);
CESC	cis	rs10504229	1.000	rs56350499	chr8:58178139	C/T	cg14926445	chr8:58193284	C8orf71	-0.51	-5.47	-0.32	1.03e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs1707322	0.963	rs11211238	chr1:46449415	G/A	cg03146154	chr1:46216737	IPP	0.72	9.82	0.52	1.31e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg02951021	chr12:120934296	DYNLL1	0.51	7.29	0.41	3.51e-12	Gut microbiota (bacterial taxa);
CESC	cis	rs1882538	0.569	rs11562037	chr7:133076885	A/G	cg10665199	chr7:133106180	EXOC4	0.56	7.75	0.43	1.92e-13	Intelligence (multi-trait analysis);
CESC	cis	rs10979	0.557	rs9403517	chr6:143909400	T/C	cg25407410	chr6:143891975	LOC285740	-0.49	-6.47	-0.37	4.64e-10	Hypospadias;
CESC	cis	rs875971	0.545	rs6460276	chr7:65647277	G/A	cg18876405	chr7:65276391	NA	0.51	5.96	0.34	8.21e-9	Aortic root size;
CESC	cis	rs875971	0.767	rs61348003	chr7:66005934	C/T	cg18252515	chr7:66147081	NA	-0.47	-6.08	-0.35	4.25e-9	Aortic root size;
CESC	cis	rs17401966	0.798	rs12408435	chr1:10323342	T/A	cg15208524	chr1:10270712	KIF1B	0.49	6.23	0.36	1.86e-9	Hepatocellular carcinoma;
CESC	cis	rs9487051	0.735	rs882074	chr6:109611720	C/T	cg21918786	chr6:109611834	NA	-0.39	-5.98	-0.34	7.14e-9	Reticulocyte fraction of red cells;
CESC	cis	rs9910055	1.000	rs9895423	chr17:42285740	T/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.56	6.31	0.36	1.16e-9	Total body bone mineral density;
CESC	cis	rs736408	0.509	rs3774349	chr3:52722335	A/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.35	6.89	0.39	3.98e-11	Bipolar disorder;
CESC	cis	rs2839186	0.749	rs62226489	chr21:47710519	T/C	cg10351095	chr21:47802916	PCNT	-0.5	-6.75	-0.38	9.55e-11	Testicular germ cell tumor;
CESC	cis	rs7527798	0.592	rs1323720	chr1:207823161	T/C	cg21110645	chr1:207815933	NA	-0.33	-5.94	-0.34	9.12e-9	Erythrocyte sedimentation rate;
CESC	cis	rs4665809	0.941	rs1470096	chr2:26311482	T/C	cg04944784	chr2:26401820	FAM59B	-0.78	-8.86	-0.48	1.18e-16	Gut microbiome composition (summer);
CESC	cis	rs7107174	1.000	rs7113042	chr11:78035832	C/T	cg02023728	chr11:77925099	USP35	-0.42	-5.9	-0.34	1.11e-8	Testicular germ cell tumor;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02092590	chr10:3827595	KLF6	0.54	6.43	0.37	6.03e-10	Gut microbiome composition (summer);
CESC	cis	rs4699052	0.507	rs7662107	chr4:104258396	C/T	cg16532752	chr4:104119610	CENPE	-0.54	-7.05	-0.4	1.53e-11	Testicular germ cell tumor;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	ch.10.1676711F	chr10:79552784	DLG5	-0.53	-6.15	-0.35	2.92e-9	Gut microbiome composition (summer);
CESC	cis	rs2859741	1.000	rs1773575	chr1:37505129	T/C	cg09363841	chr1:37513479	NA	-0.67	-10.84	-0.55	6.41e-23	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
CESC	cis	rs7666738	0.830	rs10019087	chr4:99030211	C/T	cg17366294	chr4:99064904	C4orf37	0.62	8.95	0.48	6.32e-17	Colonoscopy-negative controls vs population controls;
CESC	cis	rs41271473	0.607	rs10916361	chr1:228859971	A/T	cg00850481	chr1:228891306	NA	-0.4	-5.15	-0.3	5.04e-7	Chronic lymphocytic leukemia;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg18401262	chr18:12672632	CEP76	0.4	6.1	0.35	3.78e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs7666738	0.753	rs11097594	chr4:98944486	A/G	cg18180107	chr4:99064573	C4orf37	0.4	5.07	0.3	7.33e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9322193	0.923	rs66516768	chr6:149993135	C/T	cg07701084	chr6:150067640	NUP43	0.45	6.34	0.36	9.76e-10	Lung cancer;
CESC	cis	rs9522267	1.000	rs9522265	chr13:112195182	A/G	cg10483660	chr13:112241077	NA	-0.3	-5.04	-0.3	8.69e-7	Hepatitis;
CESC	trans	rs875971	1.000	rs6945843	chr7:65734783	G/A	cg26939375	chr7:64535504	NA	-0.46	-6.04	-0.35	5.27e-9	Aortic root size;
CESC	cis	rs10206020	0.885	rs11897246	chr2:1574541	A/C	cg26248373	chr2:1572462	NA	-0.6	-6.96	-0.39	2.75e-11	IgG glycosylation;
CESC	cis	rs780096	0.526	rs780112	chr2:27665361	C/G	cg21248554	chr2:27665150	KRTCAP3	-0.36	-7.38	-0.41	2.02e-12	Total body bone mineral density;
CESC	cis	rs7116495	0.609	rs628025	chr11:71802351	A/C	cg07596299	chr11:71824057	C11orf51	-0.82	-5.15	-0.3	5.06e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs7640424	0.589	rs7612356	chr3:107811037	C/G	cg09227934	chr3:107805635	CD47	-0.44	-5.32	-0.31	2.2e-7	Body mass index;
CESC	cis	rs8062405	0.965	rs7359397	chr16:28885659	C/T	cg05966235	chr16:28915196	ATP2A1	0.34	5.03	0.3	9.05e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs10504229	1.000	rs73607871	chr8:58173007	T/C	cg24829409	chr8:58192753	C8orf71	-0.76	-10.0	-0.52	3.53e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs1552244	0.938	rs7652951	chr3:10063763	A/C	cg00166722	chr3:10149974	C3orf24	0.51	6.38	0.37	7.76e-10	Alzheimer's disease;
CESC	cis	rs736408	0.609	rs2230534	chr3:52802402	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.48	6.67	0.38	1.49e-10	Bipolar disorder;
CESC	cis	rs7246865	0.954	rs10427132	chr19:17207156	T/G	cg19418318	chr19:17219073	MYO9B	0.36	5.77	0.33	2.23e-8	Reticulocyte fraction of red cells;
CESC	cis	rs10504229	1.000	rs72652905	chr8:58188355	A/G	cg05313129	chr8:58192883	C8orf71	-0.57	-6.47	-0.37	4.59e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs12148488	0.816	rs4886655	chr15:75385568	C/T	cg09165964	chr15:75287851	SCAMP5	0.58	7.7	0.43	2.71e-13	Caffeine consumption;
CESC	cis	rs172166	0.637	rs1225597	chr6:28162087	C/T	cg23161317	chr6:28129485	ZNF389	0.37	5.15	0.3	5.08e-7	Cardiac Troponin-T levels;
CESC	cis	rs6879260	1.000	rs888922	chr5:179731635	C/G	cg23248424	chr5:179741104	GFPT2	-0.7	-9.54	-0.51	1.01e-18	Height;
CESC	cis	rs4713118	0.527	rs4713151	chr6:28136356	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.57	-6.59	-0.38	2.36e-10	Parkinson's disease;
CESC	cis	rs4253772	0.591	rs9615938	chr22:46689468	G/A	cg00784671	chr22:46762841	CELSR1	-0.58	-5.61	-0.33	4.99e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs12893668	0.514	rs3212090	chr14:104168863	C/T	cg08213375	chr14:104286397	PPP1R13B	0.31	5.1	0.3	6.45e-7	Reticulocyte count;
CESC	cis	rs4969178	0.620	rs7219625	chr17:76390080	C/T	cg05887092	chr17:76393375	PGS1	0.68	11.26	0.57	2.77e-24	HDL cholesterol levels;
CESC	cis	rs72781680	0.821	rs2176265	chr2:24158638	C/G	cg08917208	chr2:24149416	ATAD2B	0.59	5.9	0.34	1.12e-8	Lymphocyte counts;
CESC	cis	rs10504229	1.000	rs61998258	chr8:58192284	T/C	cg22535103	chr8:58192502	C8orf71	-1.05	-13.08	-0.63	1.71e-30	Developmental language disorder (linguistic errors);
CESC	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.56	-8.66	-0.47	4.79e-16	Longevity;Endometriosis;
CESC	cis	rs9611565	0.659	rs12484694	chr22:41919330	A/G	cg17376030	chr22:41985996	PMM1	0.71	7.74	0.43	2.12e-13	Vitiligo;
CESC	cis	rs12497850	0.931	rs4974087	chr3:48919232	A/G	cg06212747	chr3:49208901	KLHDC8B	0.64	8.59	0.47	7.6e-16	Parkinson's disease;
CESC	cis	rs727563	0.635	rs713988	chr22:42159072	A/G	cg03806693	chr22:41940476	POLR3H	1.19	14.07	0.65	6.09e-34	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs66887589	0.592	rs62320740	chr4:120279486	C/A	cg09307838	chr4:120376055	NA	0.66	9.16	0.49	1.47e-17	Diastolic blood pressure;
CESC	cis	rs72781680	1.000	rs56068891	chr2:24230633	A/G	cg20701182	chr2:24300061	SF3B14	0.82	6.96	0.39	2.66e-11	Lymphocyte counts;
CESC	cis	rs4851870	0.874	rs7589902	chr2:106454419	C/G	cg16077055	chr2:106428750	NCK2	-0.39	-5.06	-0.3	7.74e-7	Addiction;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg08399230	chr16:4665037	FAM100A	-0.47	-6.57	-0.37	2.61e-10	Fibrinogen levels;
CESC	cis	rs7084402	0.817	rs7099496	chr10:60265242	G/A	cg07615347	chr10:60278583	BICC1	-0.57	-8.7	-0.47	3.68e-16	Refractive error;
CESC	cis	rs4704187	0.687	rs7720620	chr5:74366023	A/G	cg03227963	chr5:74354835	NA	0.31	5.68	0.33	3.62e-8	Response to amphetamines;
CESC	cis	rs9911578	1.000	rs11869828	chr17:56609525	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	-0.41	-5.53	-0.32	7.63e-8	Intelligence (multi-trait analysis);
CESC	cis	rs36051895	0.659	rs10974935	chr9:5050307	C/T	cg02405213	chr9:5042618	JAK2	-0.44	-5.36	-0.31	1.8e-7	Pediatric autoimmune diseases;
CESC	cis	rs9911578	0.967	rs2429369	chr17:56501420	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.35	0.31	1.87e-7	Intelligence (multi-trait analysis);
CESC	cis	rs875971	0.830	rs6976714	chr7:65891461	G/A	cg10691866	chr7:65817282	TPST1	-0.31	-5.16	-0.3	4.78e-7	Aortic root size;
CESC	cis	rs514406	0.505	rs440871	chr1:53173052	C/T	cg27535305	chr1:53392650	SCP2	-0.33	-5.48	-0.32	1e-7	Monocyte count;
CESC	cis	rs698813	0.774	rs1085492	chr2:44609371	C/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.47	5.53	0.32	7.62e-8	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
CESC	cis	rs826838	1.000	rs826892	chr12:39100790	T/C	cg26384229	chr12:38710491	ALG10B	-0.62	-9.93	-0.52	5.65e-20	Heart rate;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg07355551	chr20:2489285	ZNF343	-0.44	-6.29	-0.36	1.31e-9	Gambling;
CESC	cis	rs963731	0.579	rs963730	chr2:39216773	T/C	cg04010122	chr2:39346883	SOS1	-0.57	-5.13	-0.3	5.66e-7	Corticobasal degeneration;
CESC	cis	rs644799	0.965	rs11021317	chr11:95517576	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.71	9.57	0.51	8.21e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs2882667	0.858	rs11949916	chr5:138396277	T/G	cg04439458	chr5:138467593	SIL1	-0.37	-5.84	-0.34	1.56e-8	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs72945132	0.769	rs3781645	chr11:70190374	T/C	cg14191688	chr11:70257035	CTTN	0.43	5.5	0.32	8.9e-8	Coronary artery disease;
CESC	cis	rs9788682	0.747	rs11072766	chr15:78771546	C/T	cg24631222	chr15:78858424	CHRNA5	0.62	7.26	0.41	4.19e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs116095464	0.614	rs10061564	chr5:271329	T/C	cg22496380	chr5:211416	CCDC127	-0.75	-8.59	-0.47	7.5e-16	Breast cancer;
CESC	cis	rs17711722	0.522	rs62469933	chr7:65265639	G/A	cg05332525	chr7:65337924	VKORC1L1	0.47	5.95	0.34	8.31e-9	Calcium levels;
CESC	cis	rs7666738	0.830	rs11935078	chr4:99010476	T/A	cg03467027	chr4:99064603	C4orf37	0.44	5.63	0.33	4.57e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2249694	0.959	rs4129223	chr10:135403948	A/G	cg20169779	chr10:135381914	SYCE1	-0.4	-5.77	-0.33	2.15e-8	Obesity-related traits;
CESC	cis	rs920590	0.684	rs57462676	chr8:19670848	G/C	cg03894339	chr8:19674705	INTS10	0.63	7.11	0.4	1.08e-11	Acute lymphoblastic leukemia (childhood);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg01737507	chr5:122372093	PPIC	-0.41	-6.62	-0.38	2.03e-10	Gambling;
CESC	cis	rs897984	0.542	rs6565217	chr16:31083324	C/T	cg02466173	chr16:30829666	NA	-0.4	-7.02	-0.4	1.89e-11	Dementia with Lewy bodies;
CESC	cis	rs853679	0.550	rs1150689	chr6:28165099	T/C	cg26335602	chr6:28129616	ZNF389	0.47	6.41	0.37	6.65e-10	Depression;
CESC	cis	rs921665	0.680	rs76494865	chr2:3191204	G/A	cg02624386	chr2:3182749	NA	0.53	5.24	0.31	3.23e-7	World class endurance athleticism;
CESC	cis	rs6546550	0.658	rs10186725	chr2:70015491	A/G	cg02498382	chr2:70120550	SNRNP27	-0.32	-5.5	-0.32	8.82e-8	Prevalent atrial fibrillation;
CESC	trans	rs801193	1.000	rs2659906	chr7:66165310	T/C	cg26939375	chr7:64535504	NA	0.64	8.77	0.47	2.19e-16	Aortic root size;
CESC	cis	rs12464559	0.649	rs4450595	chr2:152622603	T/C	cg01189475	chr2:152685088	ARL5A	0.66	5.77	0.33	2.26e-8	Response to cognitive-behavioural therapy in anxiety disorder;
CESC	cis	rs1707322	0.717	rs11211161	chr1:46148138	A/C	cg06784218	chr1:46089804	CCDC17	0.41	7.21	0.41	5.75e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs17818399	0.547	rs4952831	chr2:46761181	G/A	cg02822958	chr2:46747628	ATP6V1E2	0.44	5.19	0.3	4.14e-7	Height;
CESC	cis	rs6582630	0.519	rs2387812	chr12:38381480	A/G	cg26384229	chr12:38710491	ALG10B	0.69	10.38	0.54	2.09e-21	Drug-induced liver injury (flucloxacillin);
CESC	trans	rs2963826	0.589	rs298091	chr5:58996603	A/T	cg06766273	chr11:62521983	ZBTB3	0.47	6.13	0.35	3.26e-9	Obesity-related traits;
CESC	cis	rs8062405	0.964	rs11864107	chr16:28885931	T/C	cg08761264	chr16:28874980	SH2B1	-0.47	-5.85	-0.34	1.42e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs6754311	0.510	rs1374329	chr2:136421323	A/G	cg07169764	chr2:136633963	MCM6	0.81	9.94	0.52	5.26e-20	Mosquito bite size;
CESC	cis	rs9322193	0.923	rs11155670	chr6:149966128	C/G	cg04369109	chr6:150039330	LATS1	-0.38	-5.32	-0.31	2.22e-7	Lung cancer;
CESC	cis	rs897984	0.762	rs7204459	chr16:30984212	G/A	cg00531865	chr16:30841666	NA	0.51	7.03	0.4	1.76e-11	Dementia with Lewy bodies;
CESC	cis	rs8067354	0.574	rs1292033	chr17:57990597	A/T	cg13753209	chr17:57696993	CLTC	0.51	5.47	0.32	1.04e-7	Hemoglobin concentration;
CESC	cis	rs3126085	0.935	rs10888468	chr1:152181539	C/T	cg26876637	chr1:152193138	HRNR	0.48	5.44	0.32	1.21e-7	Atopic dermatitis;
CESC	cis	rs6484504	0.600	rs1323738	chr11:31344898	T/C	cg14844989	chr11:31128820	NA	0.39	5.47	0.32	1.06e-7	Red blood cell count;
CESC	cis	rs4974559	0.739	rs10029534	chr4:1322908	C/A	cg02980000	chr4:1222292	CTBP1	0.83	7.49	0.42	1.04e-12	Systolic blood pressure;
CESC	cis	rs3799379	0.530	rs10456045	chr6:26404958	A/G	cg12826209	chr6:26865740	GUSBL1	-0.44	-5.36	-0.31	1.81e-7	Intelligence (multi-trait analysis);
CESC	cis	rs155076	1.000	rs155076	chr13:21870114	A/G	cg11317459	chr13:21872234	NA	-1.15	-12.75	-0.62	2.31e-29	White matter hyperintensity burden;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26346718	chr17:79482045	NA	0.55	6.15	0.35	2.81e-9	Gut microbiome composition (summer);
CESC	cis	rs9858542	0.903	rs35999162	chr3:49597230	C/G	cg03060546	chr3:49711283	APEH	-0.49	-5.77	-0.33	2.18e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs1552244	0.872	rs7646073	chr3:10097405	G/A	cg00166722	chr3:10149974	C3orf24	0.54	6.89	0.39	4.08e-11	Alzheimer's disease;
CESC	trans	rs4671386	0.901	rs2110402	chr2:60522038	T/C	cg24386296	chr4:1723849	TMEM129;TACC3	0.51	6.39	0.37	7.28e-10	Acne (severe);
CESC	cis	rs708547	0.792	rs7667084	chr4:57727435	T/C	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.56	-6.13	-0.35	3.12e-9	Response to bleomycin (chromatid breaks);
CESC	cis	rs9633740	1.000	rs7910643	chr10:82251769	G/A	cg00277334	chr10:82204260	NA	-0.57	-5.73	-0.33	2.69e-8	Post bronchodilator FEV1;
CESC	cis	rs10256972	0.900	rs7812072	chr7:1053862	A/G	cg07930192	chr7:1003750	NA	0.41	5.53	0.32	7.54e-8	Longevity;Endometriosis;
CESC	cis	rs2880765	0.566	rs17553790	chr15:86013665	C/T	cg19183879	chr15:85880815	NA	0.32	6.05	0.35	5.04e-9	Coronary artery disease;
CESC	cis	rs1348850	0.914	rs2060929	chr2:178280031	T/C	cg23306229	chr2:178417860	TTC30B	0.65	8.41	0.46	2.59e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs1506636	0.962	rs1472808	chr7:123354536	A/G	cg03229431	chr7:123269106	ASB15	-0.52	-6.91	-0.39	3.58e-11	Plateletcrit;Platelet count;
CESC	cis	rs9443645	0.527	rs10943588	chr6:79510994	A/C	cg05283184	chr6:79620031	NA	-0.35	-5.05	-0.3	8.26e-7	Intelligence (multi-trait analysis);
CESC	cis	rs910316	1.000	rs175426	chr14:75624134	C/T	cg08847533	chr14:75593920	NEK9	-0.98	-18.95	-0.76	3.4e-51	Height;
CESC	cis	rs10129255	0.536	rs8004835	chr14:107142378	A/C	cg23076370	chr14:107095027	NA	-0.53	-7.54	-0.42	7.43e-13	Kawasaki disease;
CESC	cis	rs9916302	0.861	rs4795377	chr17:37669056	C/T	cg07936489	chr17:37558343	FBXL20	-0.81	-12.02	-0.59	7.28e-27	Glomerular filtration rate (creatinine);
CESC	cis	rs17376456	0.877	rs12716460	chr5:93416733	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.59	5.04	0.3	8.45e-7	Diabetic retinopathy;
CESC	cis	rs6831352	0.918	rs29001194	chr4:100054844	A/G	cg13256891	chr4:100009986	ADH5	-0.77	-8.45	-0.46	1.97e-15	Alcohol dependence;
CESC	cis	rs7044106	0.762	rs10760112	chr9:123467570	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.86	14.18	0.66	2.38e-34	Hip circumference adjusted for BMI;
CESC	cis	rs9902453	0.967	rs6505155	chr17:28372783	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.62	-7.84	-0.43	1.09e-13	Coffee consumption (cups per day);
CESC	cis	rs1005277	0.563	rs2800550	chr10:38482929	T/C	cg00409905	chr10:38381863	ZNF37A	-0.47	-6.33	-0.36	1.04e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs10504229	0.639	rs56825757	chr8:58106469	A/G	cg24829409	chr8:58192753	C8orf71	-0.56	-7.01	-0.4	1.97e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs7772486	0.790	rs4075694	chr6:146251108	G/C	cg05347473	chr6:146136440	FBXO30	-0.57	-7.26	-0.41	4.32e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1707322	0.686	rs3014242	chr1:46087577	G/A	cg05343316	chr1:45956843	TESK2	-0.52	-6.36	-0.36	8.77e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs35306767	0.903	rs12769431	chr10:922633	T/C	cg20503657	chr10:835505	NA	0.76	7.62	0.42	4.4e-13	Eosinophil percentage of granulocytes;
CESC	cis	rs3105593	1.000	rs56015123	chr15:50977228	G/A	cg08437265	chr15:50716283	USP8	0.46	6.06	0.35	4.64e-9	QT interval;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg15450734	chr14:103541957	NA	0.47	6.11	0.35	3.54e-9	Systemic lupus erythematosus;
CESC	cis	rs9916302	0.904	rs602282	chr17:37433021	C/T	cg20243544	chr17:37824526	PNMT	0.45	5.51	0.32	8.31e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs4555082	0.834	rs2975217	chr14:105710238	A/C	cg06808227	chr14:105710500	BRF1	-0.55	-6.4	-0.37	6.84e-10	Mean platelet volume;Platelet distribution width;
CESC	cis	rs116095464	0.558	rs112343653	chr5:257174	G/A	cg12570787	chr5:219185	SDHA;CCDC127	0.51	5.28	0.31	2.76e-7	Breast cancer;
CESC	cis	rs1669338	0.588	rs55959448	chr3:3204000	C/T	cg16797762	chr3:3221439	CRBN	-0.63	-6.72	-0.38	1.09e-10	White matter integrity;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg02306730	chr19:39109456	MAP4K1;EIF3K	0.49	6.29	0.36	1.28e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs6460942	0.915	rs62448623	chr7:12464122	A/G	cg20607287	chr7:12443886	VWDE	-0.78	-9.15	-0.49	1.61e-17	Coronary artery disease;
CESC	cis	rs7833790	1.000	rs7833384	chr8:82730915	T/C	cg17211192	chr8:82754475	SNX16	-0.68	-8.13	-0.45	1.65e-14	Diastolic blood pressure;
CESC	cis	rs7520050	0.966	rs4660321	chr1:46366760	A/G	cg03146154	chr1:46216737	IPP	-0.48	-6.34	-0.36	1e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs1843834	0.505	rs3820763	chr2:225347270	A/G	cg22455342	chr2:225449267	CUL3	-0.68	-9.35	-0.5	3.86e-18	IgE levels in asthmatics (D.p. specific);
CESC	cis	rs1707322	0.721	rs10749856	chr1:46164846	A/T	cg03146154	chr1:46216737	IPP	0.82	11.54	0.58	3.18e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs57221529	0.563	rs4957057	chr5:569230	C/G	cg09021430	chr5:549028	NA	-0.46	-6.02	-0.35	5.64e-9	Lung disease severity in cystic fibrosis;
CESC	cis	rs1801251	0.644	rs283473	chr2:233654847	A/G	cg08000102	chr2:233561755	GIGYF2	0.66	9.71	0.51	2.84e-19	Coronary artery disease;
CESC	cis	rs3733585	0.699	rs6823361	chr4:9963127	A/G	cg02734326	chr4:10020555	SLC2A9	-0.44	-6.11	-0.35	3.58e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs2797160	0.651	rs1268092	chr6:126029043	A/G	cg05901451	chr6:126070800	HEY2	-0.5	-7.19	-0.4	6.75e-12	Endometrial cancer;
CESC	cis	rs736408	0.545	rs6445529	chr3:52662722	T/A	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.31	5.59	0.32	5.53e-8	Bipolar disorder;
CESC	cis	rs7259376	0.936	rs11085524	chr19:22536422	G/C	cg02657401	chr19:22469223	NA	-0.26	-5.16	-0.3	4.84e-7	Menopause (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18140683	chr11:2950620	PHLDA2	0.58	6.35	0.36	9.08e-10	Gut microbiome composition (summer);
CESC	cis	rs7267979	1.000	rs2856	chr20:25433536	T/C	cg08601574	chr20:25228251	PYGB	0.38	5.55	0.32	6.93e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7552404	1.000	rs7552404	chr1:76135946	A/G	cg22875332	chr1:76189707	ACADM	0.67	7.93	0.44	6.22e-14	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs1348850	0.668	rs6734426	chr2:178493770	C/T	cg23306229	chr2:178417860	TTC30B	0.59	6.8	0.39	6.78e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs9911578	1.000	rs9902994	chr17:56948722	T/A	cg12560992	chr17:57184187	TRIM37	0.94	15.65	0.69	1.5e-39	Intelligence (multi-trait analysis);
CESC	cis	rs7592578	0.679	rs62181018	chr2:191323295	C/T	cg27211696	chr2:191398769	TMEM194B	-0.59	-5.91	-0.34	1.03e-8	Diastolic blood pressure;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg17014947	chr15:35529521	LOC723972	0.48	6.65	0.38	1.69e-10	Fibrinogen levels;
CESC	cis	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg04267008	chr7:1944627	MAD1L1	0.58	6.99	0.39	2.18e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs6842047	1.000	rs1877320	chr4:187131279	G/A	cg23442198	chr4:187126114	CYP4V2	0.72	5.83	0.34	1.62e-8	Blood protein levels;
CESC	cis	rs709400	0.633	rs2296484	chr14:104003094	C/T	cg12935359	chr14:103987150	CKB	-0.52	-7.4	-0.41	1.81e-12	Body mass index;
CESC	cis	rs1864400	0.690	rs2565200	chr10:43622933	A/G	cg07801480	chr10:43725741	RASGEF1A	0.39	5.24	0.31	3.31e-7	Hirschsprung disease;
CESC	trans	rs9858542	1.000	rs9812791	chr3:49682311	G/A	cg21659725	chr3:3221576	CRBN	-0.53	-6.45	-0.37	5.37e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs1799949	0.930	rs66499067	chr17:41248484	G/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.43	5.86	0.34	1.36e-8	Menopause (age at onset);
CESC	cis	rs3791556	0.898	rs3791549	chr2:240109024	A/G	cg03281426	chr2:240109471	HDAC4	-0.55	-7.09	-0.4	1.24e-11	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs2645694	0.626	rs2703115	chr4:77824442	C/T	cg10057126	chr4:77819792	ANKRD56	0.55	7.92	0.44	6.47e-14	Emphysema distribution in smoking;
CESC	cis	rs898097	0.783	rs11650335	chr17:80835111	A/G	cg08704611	chr17:80376099	HEXDC;C17orf101	-0.44	-5.08	-0.3	7.2e-7	Breast cancer;
CESC	cis	rs1799949	1.000	rs33926631	chr17:41304463	T/C	cg23758822	chr17:41437982	NA	1.03	15.83	0.7	3.6e-40	Menopause (age at onset);
CESC	cis	rs9733	0.525	rs11584184	chr1:150695689	A/T	cg22823121	chr1:150693482	HORMAD1	0.47	6.96	0.39	2.6e-11	Tonsillectomy;
CESC	cis	rs2594989	1.000	rs2606747	chr3:11374955	T/C	cg00170343	chr3:11313890	ATG7	0.56	5.04	0.3	8.81e-7	Circulating chemerin levels;
CESC	cis	rs7647973	1.000	rs4241407	chr3:49600319	C/T	cg06212747	chr3:49208901	KLHDC8B	0.58	7.74	0.43	2.1e-13	Menarche (age at onset);
CESC	cis	rs7659604	0.539	rs11731917	chr4:122783233	G/A	cg19748678	chr4:122722346	EXOSC9	0.79	10.06	0.53	2.23e-20	Type 2 diabetes;
CESC	cis	rs854765	0.623	rs9893690	chr17:17753846	A/T	cg09796270	chr17:17721594	SREBF1	-0.43	-6.23	-0.36	1.81e-9	Total body bone mineral density;
CESC	cis	rs11577318	0.853	rs1071849	chr1:26646726	A/G	cg00852783	chr1:26633632	UBXN11	0.49	6.82	0.39	6.07e-11	Granulocyte percentage of myeloid white cells;
CESC	cis	rs3733585	0.699	rs7676733	chr4:9966956	G/A	cg00071950	chr4:10020882	SLC2A9	-0.7	-11.44	-0.58	6.69e-25	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs10779751	0.770	rs6701524	chr1:11198502	A/G	cg08854313	chr1:11322531	MTOR	-0.75	-9.34	-0.5	4.11e-18	Body mass index;
CESC	cis	rs6121246	0.697	rs6060912	chr20:30325755	C/A	cg13852791	chr20:30311386	BCL2L1	0.82	8.74	0.47	2.63e-16	Mean corpuscular hemoglobin;
CESC	cis	rs71277158	0.688	rs6781454	chr3:169823096	T/C	cg04067573	chr3:169899625	PHC3	0.7	7.05	0.4	1.57e-11	Prostate cancer;
CESC	cis	rs9488822	0.636	rs10872142	chr6:116369052	C/A	cg15226275	chr6:116381976	FRK	0.25	6.35	0.36	9.34e-10	Cholesterol, total;LDL cholesterol;
CESC	cis	rs6546550	0.868	rs12713682	chr2:70154134	G/A	cg02498382	chr2:70120550	SNRNP27	-0.4	-6.95	-0.39	2.78e-11	Prevalent atrial fibrillation;
CESC	cis	rs7917772	0.503	rs1409310	chr10:104282265	T/C	ch.10.2196322F	chr10:104248062	ACTR1A	0.42	5.18	0.3	4.34e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	trans	rs11971186	0.824	rs1204513	chr7:126499977	C/T	cg10894441	chr11:111169905	C11orf92;C11orf93	-0.49	-6.22	-0.36	1.93e-9	Chemerin levels;
CESC	cis	rs1559088	0.847	rs10423531	chr19:33600140	T/C	cg27124370	chr19:33622961	WDR88	0.45	5.86	0.34	1.34e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs7130144	0.686	rs10894216	chr11:130433733	A/G	cg26307797	chr11:130446613	NA	-0.56	-5.19	-0.3	4.16e-7	Urate levels in lean individuals;
CESC	cis	rs10256972	0.616	rs6463001	chr7:1108272	A/C	cg23978390	chr7:1156363	C7orf50	0.45	6.0	0.35	6.45e-9	Longevity;Endometriosis;
CESC	cis	rs4819052	0.851	rs2838867	chr21:46713092	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.5	6.12	0.35	3.39e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs2933343	0.700	rs2249514	chr3:128643812	C/T	cg24203234	chr3:128598194	ACAD9	0.43	5.8	0.34	1.93e-8	IgG glycosylation;
CESC	cis	rs9611565	0.921	rs2235846	chr22:41741042	G/C	cg06634786	chr22:41940651	POLR3H	-0.45	-5.14	-0.3	5.43e-7	Vitiligo;
CESC	cis	rs7552404	0.924	rs1146580	chr1:76209935	T/C	cg10523679	chr1:76189770	ACADM	0.76	10.48	0.54	1e-21	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs7904368	0.806	rs3858182	chr10:16855094	C/T	cg14835575	chr10:16859367	RSU1	0.52	5.26	0.31	2.91e-7	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
CESC	cis	rs7208859	0.673	rs55658077	chr17:29156519	A/G	cg13385521	chr17:29058706	SUZ12P	0.75	6.0	0.35	6.29e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	13.63	0.64	2.03e-32	Prudent dietary pattern;
CESC	cis	rs67311347	1.000	rs73076035	chr3:40439881	G/C	cg09455208	chr3:40491958	NA	0.52	8.56	0.47	9.02e-16	Renal cell carcinoma;
CESC	cis	rs951366	0.677	rs1775140	chr1:205672107	C/A	cg14893161	chr1:205819251	PM20D1	0.86	13.57	0.64	3.44e-32	Menarche (age at onset);
CESC	cis	rs875971	0.660	rs28698552	chr7:66005018	A/G	cg10691866	chr7:65817282	TPST1	-0.31	-5.03	-0.3	9.12e-7	Aortic root size;
CESC	cis	rs11696845	0.776	rs6073538	chr20:43379264	A/C	cg25301532	chr20:43378953	KCNK15	0.41	6.7	0.38	1.24e-10	Obesity-related traits;
CESC	cis	rs9467711	0.606	rs12174623	chr6:26373086	C/T	cg12826209	chr6:26865740	GUSBL1	0.61	5.28	0.31	2.72e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs9322193	0.923	rs4869750	chr6:150177132	C/T	cg13206674	chr6:150067644	NUP43	0.41	5.31	0.31	2.29e-7	Lung cancer;
CESC	cis	rs7762018	1.000	rs6941766	chr6:170131653	A/G	cg13891659	chr6:170190454	C6orf122;C6orf208	0.58	5.99	0.35	6.64e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs11711311	0.911	rs28577577	chr3:113447276	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.72	10.27	0.53	4.81e-21	IgG glycosylation;
CESC	cis	rs9790314	0.846	rs4856738	chr3:160986637	C/G	cg03342759	chr3:160939853	NMD3	-0.45	-6.21	-0.36	2e-9	Morning vs. evening chronotype;
CESC	cis	rs7100689	0.725	rs10736340	chr10:82061071	C/T	cg00277334	chr10:82204260	NA	-0.58	-7.31	-0.41	3.1e-12	Post bronchodilator FEV1;
CESC	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg07677032	chr17:61819896	STRADA	0.46	6.06	0.35	4.71e-9	Prudent dietary pattern;
CESC	cis	rs9611565	0.559	rs132771	chr22:42025350	A/G	cg03806693	chr22:41940476	POLR3H	1.05	12.5	0.61	1.69e-28	Vitiligo;
CESC	cis	rs6964587	0.541	rs6947170	chr7:91451471	A/G	cg17063962	chr7:91808500	NA	0.42	5.77	0.33	2.23e-8	Breast cancer;
CESC	cis	rs875971	0.545	rs12673308	chr7:65631361	C/A	cg19163074	chr7:65112434	INTS4L2	-0.46	-5.05	-0.3	8.07e-7	Aortic root size;
CESC	cis	rs9322193	0.923	rs7769101	chr6:150169904	C/A	cg04369109	chr6:150039330	LATS1	-0.4	-5.23	-0.31	3.43e-7	Lung cancer;
CESC	cis	rs17253792	0.822	rs75115817	chr14:56069537	G/A	cg01858014	chr14:56050164	KTN1	-0.85	-6.99	-0.39	2.22e-11	Putamen volume;
CESC	trans	rs60843830	0.662	rs6721594	chr2:305203	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	-0.58	-7.39	-0.41	1.86e-12	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs1008375	1.000	rs60178264	chr4:17685308	G/T	cg02297831	chr4:17616191	MED28	0.42	5.44	0.32	1.2e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs9660992	0.573	rs1172161	chr1:205206495	C/T	cg21643547	chr1:205240462	TMCC2	-0.39	-5.37	-0.31	1.76e-7	Mean corpuscular volume;Mean platelet volume;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg10800280	chr6:36646508	CDKN1A	-0.44	-6.32	-0.36	1.13e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs6066835	0.702	rs6122709	chr20:47278938	C/A	cg18078177	chr20:47281410	PREX1	0.76	5.41	0.32	1.41e-7	Multiple myeloma;
CESC	cis	rs12477438	0.520	rs6717723	chr2:99756930	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.86	16.02	0.7	7.14e-41	Chronic sinus infection;
CESC	cis	rs7474896	0.583	rs10827817	chr10:37997974	A/G	cg00409905	chr10:38381863	ZNF37A	-0.44	-5.04	-0.3	8.59e-7	Obesity (extreme);
CESC	cis	rs4654899	0.802	rs1530946	chr1:21182540	A/G	cg05370193	chr1:21551575	ECE1	-0.37	-5.43	-0.32	1.26e-7	Superior frontal gyrus grey matter volume;
CESC	cis	rs4481887	1.000	rs10788781	chr1:248494262	C/T	cg00666640	chr1:248458726	OR2T12	0.41	6.71	0.38	1.17e-10	Common traits (Other);
CESC	cis	rs1256061	0.624	rs1152577	chr14:64697485	T/G	cg21174375	chr14:64681225	SYNE2	0.48	6.36	0.36	8.86e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs6088590	0.965	rs6120727	chr20:33374102	T/C	cg08999081	chr20:33150536	PIGU	0.59	8.99	0.48	4.71e-17	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02123667	chr8:127570702	FAM84B	0.59	7.03	0.4	1.8e-11	Gut microbiome composition (summer);
CESC	cis	rs2304069	0.545	rs11167492	chr5:149403101	G/A	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.46	6.26	0.36	1.5e-9	HIV-1 control;
CESC	cis	rs9303280	0.836	rs11557467	chr17:38028634	G/T	cg20243544	chr17:37824526	PNMT	0.51	6.68	0.38	1.38e-10	Self-reported allergy;
CESC	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg10819733	chr22:24237672	NA	-0.51	-7.44	-0.42	1.41e-12	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs10504229	0.595	rs36081958	chr8:58117505	C/G	cg02725872	chr8:58115012	NA	-0.45	-7.05	-0.4	1.51e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs35110281	0.811	rs9980185	chr21:45057905	A/G	cg04455712	chr21:45112962	RRP1B	0.41	5.84	0.34	1.51e-8	Mean corpuscular volume;
CESC	cis	rs4819052	0.851	rs2838839	chr21:46667858	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.76	-10.09	-0.53	1.79e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs6570726	0.935	rs434298	chr6:145846873	G/A	cg05347473	chr6:146136440	FBXO30	0.48	6.45	0.37	5.39e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs10979	1.000	rs9386038	chr6:143896358	A/G	cg25407410	chr6:143891975	LOC285740	-0.61	-9.2	-0.49	1.13e-17	Hypospadias;
CESC	cis	rs7412746	0.563	rs3768013	chr1:150815411	G/A	cg22823121	chr1:150693482	HORMAD1	0.4	5.79	0.34	1.98e-8	Melanoma;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02084811	chr12:49524778	TUBA1B	0.64	7.62	0.42	4.57e-13	Gut microbiome composition (summer);
CESC	cis	rs6964587	1.000	rs60147309	chr7:91736098	C/G	cg17063962	chr7:91808500	NA	0.55	7.54	0.42	7.58e-13	Breast cancer;
CESC	cis	rs116095464	0.558	rs6878087	chr5:223117	C/T	cg12570787	chr5:219185	SDHA;CCDC127	-0.52	-5.8	-0.34	1.93e-8	Breast cancer;
CESC	cis	rs9790314	0.521	rs13084731	chr3:161086020	G/A	cg03342759	chr3:160939853	NMD3	-0.41	-5.74	-0.33	2.52e-8	Morning vs. evening chronotype;
CESC	cis	rs7809950	0.648	rs114452520	chr7:107176780	C/T	cg23024343	chr7:107201750	COG5	-0.43	-6.01	-0.35	6.18e-9	Coronary artery disease;
CESC	cis	rs6540556	0.769	rs6679405	chr1:209926468	A/C	cg05527609	chr1:210001259	C1orf107	-0.5	-6.05	-0.35	4.84e-9	Red blood cell count;
CESC	cis	rs72949976	1.000	rs62186568	chr2:214033955	G/A	cg08319019	chr2:214017104	IKZF2	-0.43	-5.34	-0.31	2.05e-7	Lung cancer;Squamous cell lung carcinoma;
CESC	cis	rs9388451	0.839	rs3799709	chr6:126078361	A/G	cg05901451	chr6:126070800	HEY2	-0.65	-9.22	-0.49	9.86e-18	Brugada syndrome;
CESC	cis	rs1499614	1.000	rs1638731	chr7:66144679	C/T	cg18252515	chr7:66147081	NA	-1.42	-14.52	-0.67	1.58e-35	Gout;
CESC	trans	rs877282	0.797	rs7079164	chr10:756363	A/G	cg22713356	chr15:30763199	NA	0.93	8.39	0.46	3e-15	Uric acid levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17095167	chr13:21833918	NA	-0.61	-7.06	-0.4	1.45e-11	Gut microbiome composition (summer);
CESC	cis	rs709400	1.000	rs8018979	chr14:104109087	G/A	cg24130564	chr14:104152367	KLC1	-0.42	-5.39	-0.31	1.56e-7	Body mass index;
CESC	cis	rs6690583	0.697	rs2012369	chr1:85520845	T/C	cg22153463	chr1:85462885	MCOLN2	-0.66	-8.3	-0.45	5.4e-15	Serum sulfate level;
CESC	cis	rs1215050	0.791	rs1727278	chr4:98853576	A/G	cg05340658	chr4:99064831	C4orf37	-0.5	-6.59	-0.38	2.32e-10	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs8141529	0.509	rs6005927	chr22:29255884	A/G	cg02153584	chr22:29168773	CCDC117	0.59	7.91	0.44	6.92e-14	Lymphocyte counts;
CESC	cis	rs9649213	0.593	rs3823740	chr7:97957104	T/G	cg08684580	chr7:98029266	BAIAP2L1	-0.36	-5.85	-0.34	1.41e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs2898681	0.519	rs76606067	chr4:53728221	G/T	cg00791764	chr4:53727839	RASL11B	0.45	5.28	0.31	2.63e-7	Optic nerve measurement (cup area);
CESC	cis	rs739401	1.000	rs739401	chr11:3036324	C/T	cg25174290	chr11:3078921	CARS	-0.49	-6.81	-0.39	6.53e-11	Longevity;
CESC	cis	rs7659604	0.540	rs34445121	chr4:122710889	G/A	cg19748678	chr4:122722346	EXOSC9	-0.42	-5.26	-0.31	2.97e-7	Type 2 diabetes;
CESC	cis	rs113835537	0.529	rs11227500	chr11:66273233	T/C	cg24851651	chr11:66362959	CCS	0.43	5.35	0.31	1.94e-7	Airway imaging phenotypes;
CESC	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg02475777	chr4:1388615	CRIPAK	0.65	8.38	0.46	3.11e-15	Longevity;
CESC	cis	rs8141529	0.732	rs6005881	chr22:29183133	A/G	cg02153584	chr22:29168773	CCDC117	0.66	9.5	0.5	1.34e-18	Lymphocyte counts;
CESC	cis	rs1847202	0.826	rs13063441	chr3:72952400	A/G	cg25664220	chr3:72788482	NA	-0.41	-5.93	-0.34	9.21e-9	Motion sickness;
CESC	cis	rs3126085	0.935	rs12408581	chr1:152175211	A/G	cg03465714	chr1:152285911	FLG	0.46	5.22	0.31	3.65e-7	Atopic dermatitis;
CESC	cis	rs9894429	0.646	rs7405937	chr17:79597811	G/A	cg13777783	chr17:79615861	NA	-0.37	-6.15	-0.35	2.83e-9	Eye color traits;
CESC	cis	rs1847202	0.826	rs11925587	chr3:72952227	A/G	cg10804678	chr3:72788309	NA	0.39	5.1	0.3	6.45e-7	Motion sickness;
CESC	cis	rs9733	0.519	rs72704603	chr1:150707992	C/T	cg22823121	chr1:150693482	HORMAD1	0.46	6.76	0.38	8.54e-11	Tonsillectomy;
CESC	cis	rs2836974	0.800	rs73221174	chr21:40540939	T/C	cg17971929	chr21:40555470	PSMG1	1.02	15.02	0.68	2.54e-37	Cognitive function;
CESC	cis	rs79057730	0.599	rs4720893	chr7:804434	G/A	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.91	7.91	0.44	7.15e-14	Initial pursuit acceleration;
CESC	cis	rs425277	0.917	rs12410859	chr1:2038732	C/T	cg24578937	chr1:2090814	PRKCZ	0.55	9.06	0.49	2.89e-17	Height;
CESC	cis	rs67460515	0.528	rs11915989	chr3:160902259	A/G	cg03342759	chr3:160939853	NMD3	-0.54	-7.19	-0.4	6.62e-12	Parkinson's disease;
CESC	cis	rs2404602	0.692	rs3816266	chr15:76993835	T/G	cg22467129	chr15:76604101	ETFA	-0.34	-5.11	-0.3	6.27e-7	Blood metabolite levels;
CESC	cis	rs873946	0.586	rs3793684	chr10:134568645	G/A	cg27297192	chr10:134578999	INPP5A	0.4	5.13	0.3	5.54e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs514406	0.584	rs12095247	chr1:53193796	A/C	cg16325326	chr1:53192061	ZYG11B	-0.98	-16.91	-0.72	5.34e-44	Monocyte count;
CESC	cis	rs9894429	0.646	rs58398000	chr17:79576923	G/A	cg21984481	chr17:79567631	NPLOC4	0.35	5.52	0.32	8.09e-8	Eye color traits;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg15627457	chr8:141535348	NA	0.53	6.98	0.39	2.34e-11	Fibrinogen levels;
CESC	cis	rs12477438	1.000	rs1922624	chr2:99909958	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.61	-7.12	-0.4	9.89e-12	Chronic sinus infection;
CESC	trans	rs10028773	0.632	rs34481394	chr4:120248374	C/T	cg25214090	chr10:38739885	LOC399744	0.62	8.36	0.46	3.48e-15	Educational attainment;
CESC	cis	rs708547	0.599	rs1718864	chr4:57887471	G/A	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.42	-5.52	-0.32	8.06e-8	Response to bleomycin (chromatid breaks);
CESC	cis	rs34779708	0.966	rs17591857	chr10:35499043	A/G	cg03585969	chr10:35415529	CREM	-0.75	-9.86	-0.52	9.73e-20	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs1008375	1.000	rs10939738	chr4:17604295	G/C	cg27347728	chr4:17578864	LAP3	0.43	5.29	0.31	2.51e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs3008870	0.583	rs2147838	chr1:67399466	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.99	11.11	0.56	8.58e-24	Lymphocyte percentage of white cells;
CESC	cis	rs734999	0.549	rs60733400	chr1:2516781	G/A	cg18854424	chr1:2615690	NA	0.27	5.21	0.31	3.72e-7	Ulcerative colitis;
CESC	cis	rs780096	0.526	rs4582	chr2:27604279	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.32	-5.95	-0.34	8.41e-9	Total body bone mineral density;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24158363	chr17:73401717	GRB2	0.56	6.52	0.37	3.53e-10	Gut microbiome composition (summer);
CESC	cis	rs4595586	0.545	rs1562729	chr12:39406179	T/G	cg26384229	chr12:38710491	ALG10B	0.54	7.64	0.42	3.96e-13	Morning vs. evening chronotype;
CESC	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	-0.9	-13.68	-0.64	1.35e-32	Prudent dietary pattern;
CESC	cis	rs3733585	0.699	rs4408959	chr4:9948868	C/T	cg11266682	chr4:10021025	SLC2A9	-0.59	-11.14	-0.56	6.82e-24	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs4654899	0.802	rs17410008	chr1:21220701	G/C	cg05370193	chr1:21551575	ECE1	0.4	5.77	0.33	2.24e-8	Superior frontal gyrus grey matter volume;
CESC	cis	rs7216064	0.953	rs9890629	chr17:65871559	G/A	cg07042672	chr17:66097459	LOC651250	-0.57	-6.56	-0.37	2.81e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs7617480	0.648	rs9859473	chr3:48837182	A/G	cg06212747	chr3:49208901	KLHDC8B	0.45	5.19	0.3	4.27e-7	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CESC	cis	rs4819052	0.851	rs12626188	chr21:46669258	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.44	5.35	0.31	1.86e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs9399135	0.967	rs13218642	chr6:135309940	A/G	cg24558204	chr6:135376177	HBS1L	0.5	6.74	0.38	1.01e-10	Red blood cell count;
CESC	cis	rs796364	0.806	rs12619136	chr2:200910347	C/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.85	-7.93	-0.44	6.07e-14	Schizophrenia;
CESC	cis	rs1005277	0.579	rs2474599	chr10:38438939	A/G	cg25517755	chr10:38738941	LOC399744	-0.49	-6.35	-0.36	9.09e-10	Extrinsic epigenetic age acceleration;
CESC	cis	rs4862750	0.832	rs10007858	chr4:187877492	A/G	cg11301795	chr4:187892539	NA	-0.75	-12.17	-0.6	2.31e-27	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs728616	0.614	rs1538818	chr10:82122793	G/A	cg05935833	chr10:81318306	SFTPA2	-0.45	-5.74	-0.33	2.59e-8	Chronic obstructive pulmonary disease-related biomarkers;
CESC	trans	rs1728785	0.786	rs1728770	chr16:68564124	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.63	7.39	0.41	1.96e-12	Ulcerative colitis;
CESC	cis	rs7772486	0.790	rs4435956	chr6:146232403	G/C	cg23711669	chr6:146136114	FBXO30	-0.92	-13.36	-0.63	1.78e-31	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1218582	0.772	rs10796934	chr1:154849479	C/G	cg09359103	chr1:154839909	KCNN3	-0.65	-12.57	-0.61	9.63e-29	Prostate cancer;
CESC	cis	rs9733	0.566	rs112967224	chr1:150677263	G/A	cg04414720	chr1:150670196	GOLPH3L	0.63	9.0	0.48	4.53e-17	Tonsillectomy;
CESC	trans	rs561341	1.000	rs8069199	chr17:30281845	A/G	cg27661571	chr11:113659931	NA	-0.72	-7.36	-0.41	2.36e-12	Hip circumference adjusted for BMI;
CESC	cis	rs548181	0.736	rs543389	chr11:125464841	A/G	cg03464685	chr11:125439445	EI24	1.22	9.63	0.51	5.23e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs11098499	0.863	rs9884402	chr4:120489982	A/G	cg09307838	chr4:120376055	NA	0.9	12.28	0.6	9.3e-28	Corneal astigmatism;
CESC	cis	rs10504229	0.683	rs56204590	chr8:58131642	T/G	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs9790314	0.521	rs60625846	chr3:161084525	G/T	cg03342759	chr3:160939853	NMD3	-0.41	-5.74	-0.33	2.63e-8	Morning vs. evening chronotype;
CESC	cis	rs7312774	0.748	rs7295619	chr12:107316934	T/A	cg16260113	chr12:107380972	MTERFD3	0.68	6.35	0.36	9.08e-10	Severe influenza A (H1N1) infection;
CESC	cis	rs7845219	0.544	rs10956932	chr8:95948202	C/T	cg13393036	chr8:95962371	TP53INP1	0.39	7.31	0.41	3.14e-12	Type 2 diabetes;
CESC	cis	rs7208859	0.573	rs28779471	chr17:29084369	T/C	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.91e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs5769707	0.933	rs2157444	chr22:49994292	A/G	cg05373962	chr22:49881684	NA	-0.35	-5.85	-0.34	1.43e-8	Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs1568889	0.938	rs7128045	chr11:28190180	C/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.77	10.58	0.54	4.76e-22	Bipolar disorder;
CESC	cis	rs7412746	0.658	rs12068264	chr1:150727329	C/T	cg22823121	chr1:150693482	HORMAD1	0.45	6.26	0.36	1.52e-9	Melanoma;
CESC	cis	rs10885582	0.781	rs10159807	chr10:116293790	C/G	cg17056676	chr10:116301354	ABLIM1	-0.28	-5.14	-0.3	5.47e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs2859741	0.546	rs10489413	chr1:37513906	C/T	cg09363841	chr1:37513479	NA	-0.57	-8.69	-0.47	3.96e-16	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
CESC	trans	rs1553477	1.000	rs6875907	chr5:53112624	C/T	cg02960488	chr3:178863507	NA	0.36	6.24	0.36	1.72e-9	Monobrow;
CESC	cis	rs561341	0.941	rs72825746	chr17:30364610	G/A	cg00745463	chr17:30367425	LRRC37B	-0.88	-7.97	-0.44	4.86e-14	Hip circumference adjusted for BMI;
CESC	cis	rs12995491	0.933	rs12995212	chr2:88527184	C/T	cg18490616	chr2:88469792	THNSL2	-0.5	-7.27	-0.41	4.04e-12	Response to metformin (IC50);
CESC	cis	rs919433	0.927	rs1429412	chr2:198190894	A/G	cg03934865	chr2:198174659	NA	-0.49	-6.94	-0.39	3.06e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs2204008	0.744	rs8186814	chr12:38335169	C/T	cg13010199	chr12:38710504	ALG10B	0.48	6.11	0.35	3.53e-9	Bladder cancer;
CESC	cis	rs10883723	0.810	rs6584504	chr10:104253507	T/C	ch.10.2196322F	chr10:104248062	ACTR1A	0.42	5.1	0.3	6.38e-7	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs208520	1.000	rs72884017	chr6:66992513	T/G	cg07460842	chr6:66804631	NA	0.88	9.99	0.52	3.87e-20	Exhaled nitric oxide output;
CESC	cis	rs11711311	0.955	rs67550112	chr3:113401988	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.7	9.03	0.49	3.62e-17	IgG glycosylation;
CESC	cis	rs6089584	0.888	rs6089624	chr20:60619907	C/G	cg06108461	chr20:60628389	TAF4	-0.92	-14.41	-0.66	3.85e-35	Body mass index;
CESC	cis	rs863345	0.625	rs6427439	chr1:158460357	C/A	cg12129480	chr1:158549410	OR10X1	-0.36	-7.14	-0.4	8.93e-12	Pneumococcal bacteremia;
CESC	cis	rs3820928	1.000	rs1346618	chr2:227771988	C/T	cg05526886	chr2:227700861	RHBDD1	0.41	5.39	0.31	1.57e-7	Pulmonary function;
CESC	cis	rs7617773	0.784	rs9850672	chr3:48301172	C/A	cg11946769	chr3:48343235	NME6	0.8	10.73	0.55	1.57e-22	Coronary artery disease;
CESC	cis	rs12586317	0.586	rs74243590	chr14:35513246	G/A	cg16230307	chr14:35515116	FAM177A1	1.13	11.81	0.59	3.79e-26	Psoriasis;
CESC	cis	rs875971	0.862	rs1695820	chr7:65844563	G/A	cg12463550	chr7:65579703	CRCP	0.49	6.21	0.36	2.07e-9	Aortic root size;
CESC	cis	rs881375	0.933	rs7031096	chr9:123694942	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.38	5.2	0.3	4.07e-7	Rheumatoid arthritis;
CESC	cis	rs6815814	0.950	rs5743566	chr4:38805942	G/C	cg02016764	chr4:38805732	TLR1	-0.63	-7.26	-0.41	4.22e-12	Breast cancer;
CESC	cis	rs9311474	0.632	rs6445528	chr3:52572447	C/T	cg18337363	chr3:52569053	NT5DC2	-0.28	-5.39	-0.31	1.52e-7	Electroencephalogram traits;
CESC	cis	rs2629540	0.765	rs4962687	chr10:126404141	G/A	cg08799069	chr10:126477246	METTL10	-0.51	-7.37	-0.41	2.16e-12	Cocaine dependence;
CESC	cis	rs7086627	0.515	rs12245180	chr10:82211897	C/G	cg00277334	chr10:82204260	NA	-0.91	-16.25	-0.71	1.13e-41	Post bronchodilator FEV1;
CESC	cis	rs10504229	0.683	rs72649192	chr8:58110490	T/C	cg02725872	chr8:58115012	NA	-0.42	-5.87	-0.34	1.28e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs921968	0.643	rs600057	chr2:219456737	A/G	cg02176678	chr2:219576539	TTLL4	0.42	7.28	0.41	3.73e-12	Mean corpuscular hemoglobin concentration;
CESC	trans	rs17764205	0.929	rs10424718	chr19:3253630	G/T	cg19557190	chr5:56469727	GPBP1	0.62	6.27	0.36	1.48e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs4950322	0.802	rs72694705	chr1:146834025	G/A	cg22381352	chr1:146742008	CHD1L	-0.45	-5.19	-0.3	4.12e-7	Protein quantitative trait loci;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02384530	chr12:6961868	USP5;CDCA3	0.53	6.14	0.35	3.04e-9	Gut microbiome composition (summer);
CESC	cis	rs4665809	0.941	rs6735145	chr2:26270302	T/C	cg22920501	chr2:26401640	FAM59B	-0.7	-8.4	-0.46	2.75e-15	Gut microbiome composition (summer);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg23800573	chr21:45114399	RRP1B	0.45	6.39	0.37	7.38e-10	Fibrinogen levels;
CESC	trans	rs7656342	0.808	rs10003216	chr4:9766749	A/G	cg01105932	chr5:158635248	RNF145	-0.49	-6.22	-0.36	1.88e-9	Gut microbiota (bacterial taxa);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21097105	chr17:19265900	B9D1	0.64	7.24	0.41	4.86e-12	Gut microbiome composition (summer);
CESC	cis	rs4819052	1.000	rs9306123	chr21:46709922	A/G	cg11663144	chr21:46675770	NA	-0.48	-6.52	-0.37	3.49e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs8114671	0.562	rs6088640	chr20:33472509	C/T	cg24642439	chr20:33292090	TP53INP2	0.43	5.17	0.3	4.52e-7	Height;
CESC	cis	rs3862030	0.839	rs7078679	chr10:104284017	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.38	-5.26	-0.31	2.92e-7	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
CESC	cis	rs780096	0.526	rs809058	chr2:27616790	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.32	-5.94	-0.34	9.01e-9	Total body bone mineral density;
CESC	cis	rs1153858	1.000	rs56669689	chr15:45637729	A/C	cg21132104	chr15:45694354	SPATA5L1	0.82	11.02	0.56	1.72e-23	Homoarginine levels;
CESC	cis	rs763121	0.925	rs5757251	chr22:39100128	G/A	cg06022373	chr22:39101656	GTPBP1	0.71	11.21	0.57	3.95e-24	Menopause (age at onset);
CESC	cis	rs3026101	0.671	rs1806242	chr17:5304763	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.42	5.6	0.33	5.31e-8	Body mass index;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06564803	chr16:70100193	PDXDC2	0.52	6.33	0.36	1.04e-9	Gut microbiome composition (summer);
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg04936639	chr11:48922035	NA	-0.37	-6.03	-0.35	5.35e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs13191362	1.000	rs35126854	chr6:163012443	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.49	5.34	0.31	1.96e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs3845702	0.736	rs6733426	chr2:180830958	A/G	cg01881094	chr2:180872142	CWC22	-0.98	-9.07	-0.49	2.78e-17	Schizophrenia;
CESC	cis	rs9948	0.655	rs62156228	chr2:97420335	A/G	cg01990225	chr2:97406019	LMAN2L	-1.02	-7.83	-0.43	1.17e-13	Erectile dysfunction and prostate cancer treatment;
CESC	cis	rs7301826	0.967	rs4759790	chr12:131296390	T/G	cg11011512	chr12:131303247	STX2	0.4	5.09	0.3	6.77e-7	Plasma plasminogen activator levels;
CESC	cis	rs7084402	0.967	rs1658454	chr10:60306770	G/A	cg07615347	chr10:60278583	BICC1	0.59	9.34	0.5	4.23e-18	Refractive error;
CESC	cis	rs933688	1.000	rs10058025	chr5:90689052	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.18	14.27	0.66	1.16e-34	Smoking behavior;
CESC	cis	rs798554	0.757	rs1182172	chr7:2878103	G/A	cg19346786	chr7:2764209	NA	-0.48	-6.48	-0.37	4.51e-10	Height;
CESC	cis	rs2249694	0.960	rs7075572	chr10:135404358	T/C	cg19469447	chr10:135341870	CYP2E1	0.36	5.03	0.3	9.2e-7	Obesity-related traits;
CESC	cis	rs9479482	0.967	rs3860823	chr6:150356526	A/G	cg03788504	chr6:150331562	NA	-0.31	-6.23	-0.36	1.79e-9	Alopecia areata;
CESC	cis	rs9814567	1.000	rs9829092	chr3:134229866	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.43	-5.77	-0.33	2.24e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs35306767	0.715	rs11253550	chr10:1028288	C/G	cg20503657	chr10:835505	NA	0.74	6.75	0.38	9.51e-11	Eosinophil percentage of granulocytes;
CESC	cis	rs3784262	0.904	rs17820823	chr15:58239358	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.31	-5.11	-0.3	6.29e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
CESC	cis	rs769267	0.930	rs4808964	chr19:19603692	A/C	cg03709012	chr19:19516395	GATAD2A	-1.01	-15.85	-0.7	3.09e-40	Tonsillectomy;
CESC	cis	rs13256369	1.000	rs12545771	chr8:8567977	C/G	cg17143192	chr8:8559678	CLDN23	0.71	7.92	0.44	6.78e-14	Obesity-related traits;
CESC	cis	rs6952808	0.689	rs12670737	chr7:2046830	C/T	cg21782813	chr7:2030301	MAD1L1	0.49	7.05	0.4	1.58e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs34172651	0.517	rs36113933	chr16:24838862	A/G	cg02428538	chr16:24856791	SLC5A11	-0.48	-5.04	-0.3	8.45e-7	Intelligence (multi-trait analysis);
CESC	cis	rs7208859	0.623	rs7212991	chr17:29143749	T/C	cg14008862	chr17:28927542	LRRC37B2	0.65	5.14	0.3	5.34e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs1552244	1.000	rs67006488	chr3:10152993	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.82	-11.44	-0.58	6.61e-25	Alzheimer's disease;
CESC	cis	rs7267005	0.661	rs2425099	chr20:34309643	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.9	-5.69	-0.33	3.35e-8	Response to paliperidone in schizophrenia (Multivariate);
CESC	cis	rs7089973	0.604	rs7914792	chr10:116591391	T/C	cg25233709	chr10:116636983	FAM160B1	0.38	5.9	0.34	1.12e-8	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs13191362	0.810	rs34714603	chr6:163008078	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.82	8.75	0.47	2.56e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs7647973	0.600	rs35174559	chr3:49287759	T/C	cg07636037	chr3:49044803	WDR6	0.78	13.03	0.63	2.43e-30	Menarche (age at onset);
CESC	cis	rs929354	0.742	rs7784442	chr7:156934475	G/C	cg05182265	chr7:156933206	UBE3C	-0.49	-7.04	-0.4	1.69e-11	Body mass index;
CESC	cis	rs4925386	0.759	rs2427293	chr20:60925859	A/G	cg22633769	chr20:60982531	CABLES2	-0.53	-5.5	-0.32	8.96e-8	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs9291683	0.588	rs35866697	chr4:10018604	C/A	cg02734326	chr4:10020555	SLC2A9	0.52	7.42	0.41	1.61e-12	Bone mineral density;
CESC	cis	rs7937682	0.961	rs11601674	chr11:111634354	C/T	cg09085632	chr11:111637200	PPP2R1B	-1.09	-14.84	-0.67	1.15e-36	Primary sclerosing cholangitis;
CESC	cis	rs9309473	1.000	rs7607014	chr2:73730174	C/T	cg20560298	chr2:73613845	ALMS1	0.48	6.76	0.38	8.51e-11	Metabolite levels;
CESC	cis	rs28647808	1.000	rs2285481	chr9:136271744	A/G	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.9	5.73	0.33	2.75e-8	Blood protein levels;
CESC	cis	rs75804782	0.521	rs72982590	chr2:239451826	T/C	cg18131467	chr2:239335373	ASB1	-0.68	-5.47	-0.32	1.04e-7	Morning vs. evening chronotype;Chronotype;
CESC	cis	rs11155671	0.530	rs1334510	chr6:150201179	A/G	cg09699651	chr6:150184138	LRP11	0.57	7.73	0.43	2.21e-13	Testicular germ cell tumor;
CESC	cis	rs1862618	0.853	rs1833896	chr5:56097669	C/A	cg24531977	chr5:56204891	C5orf35	-0.83	-11.11	-0.56	8.79e-24	Initial pursuit acceleration;
CESC	cis	rs11792861	0.926	rs17729523	chr9:111773317	T/C	cg13535736	chr9:111863775	C9orf5	-0.49	-6.42	-0.37	6.44e-10	Menarche (age at onset);
CESC	cis	rs870825	0.616	rs4437295	chr4:185643336	C/T	cg04058563	chr4:185651563	MLF1IP	0.64	7.1	0.4	1.15e-11	Blood protein levels;
CESC	trans	rs2963826	0.589	rs298091	chr5:58996603	A/T	cg06665941	chr21:34602869	IFNAR2	0.47	6.5	0.37	3.89e-10	Obesity-related traits;
CESC	cis	rs6500395	0.775	rs13331298	chr16:48661489	G/A	cg04672837	chr16:48644449	N4BP1	0.49	6.25	0.36	1.59e-9	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs7937682	0.921	rs4534611	chr11:111440425	C/G	cg22437258	chr11:111473054	SIK2	0.6	7.22	0.41	5.47e-12	Primary sclerosing cholangitis;
CESC	cis	rs2836974	0.931	rs2836972	chr21:40652142	G/A	cg11890956	chr21:40555474	PSMG1	1.2	22.3	0.81	9.49e-63	Cognitive function;
CESC	trans	rs916888	0.821	rs415430	chr17:44859144	C/T	cg10053473	chr17:62856997	LRRC37A3	0.65	7.26	0.41	4.26e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs4727027	0.866	rs3927307	chr7:148774869	C/T	cg23158103	chr7:148848205	ZNF398	-0.4	-6.42	-0.37	6.38e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs10540	0.730	rs34690033	chr11:492677	G/C	cg03576123	chr11:487126	PTDSS2	-1.09	-10.84	-0.55	6.44e-23	Body mass index;
CESC	cis	rs7582720	0.943	rs72926799	chr2:203828192	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.36	0.41	2.34e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs7618915	0.547	rs11177	chr3:52721305	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	6.92	0.39	3.39e-11	Bipolar disorder;
CESC	trans	rs11039798	0.545	rs7118670	chr11:48532056	C/T	cg03929089	chr4:120376271	NA	0.61	6.02	0.35	5.81e-9	Axial length;
CESC	cis	rs1862618	0.671	rs906631	chr5:56245803	C/G	cg18230493	chr5:56204884	C5orf35	0.61	7.97	0.44	4.79e-14	Initial pursuit acceleration;
CESC	cis	rs561341	1.000	rs498391	chr17:30328704	G/A	cg19193384	chr17:30244184	NA	-0.62	-5.95	-0.34	8.48e-9	Hip circumference adjusted for BMI;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg05666423	chr13:60970705	TDRD3	0.45	6.04	0.35	5.26e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs9300255	0.679	rs4759420	chr12:123794871	G/C	cg19016782	chr12:123741754	C12orf65	-0.43	-6.0	-0.35	6.54e-9	Neutrophil percentage of white cells;
CESC	cis	rs3733585	0.631	rs4697924	chr4:10124239	A/G	cg11266682	chr4:10021025	SLC2A9	-0.55	-9.43	-0.5	2.21e-18	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs2576037	0.562	rs477826	chr18:44397649	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.52	-7.13	-0.4	9.42e-12	Personality dimensions;
CESC	cis	rs4654899	0.802	rs10916906	chr1:21255675	C/A	cg05370193	chr1:21551575	ECE1	0.39	5.65	0.33	4.09e-8	Superior frontal gyrus grey matter volume;
CESC	cis	rs9790314	0.521	rs13084746	chr3:161086038	G/A	cg04691961	chr3:161091175	C3orf57	-0.37	-5.09	-0.3	6.66e-7	Morning vs. evening chronotype;
CESC	cis	rs6570726	0.935	rs369458	chr6:145812809	A/G	cg05347473	chr6:146136440	FBXO30	0.49	6.49	0.37	4.31e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9815354	0.812	rs73071325	chr3:41809989	T/G	cg03022575	chr3:42003672	ULK4	0.68	6.06	0.35	4.7e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs875971	0.862	rs10256544	chr7:65675128	A/G	cg19163074	chr7:65112434	INTS4L2	-0.41	-5.11	-0.3	6.13e-7	Aortic root size;
CESC	cis	rs2463822	0.925	rs1528730	chr11:62081181	A/C	cg06239285	chr11:62104954	ASRGL1	0.94	8.82	0.48	1.61e-16	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs3820068	0.581	rs3940061	chr1:15941276	C/T	cg17385448	chr1:15911702	AGMAT	0.41	6.59	0.38	2.42e-10	Systolic blood pressure;
CESC	cis	rs75804782	0.521	rs55657931	chr2:239422072	A/G	cg18131467	chr2:239335373	ASB1	-0.68	-5.66	-0.33	3.87e-8	Morning vs. evening chronotype;Chronotype;
CESC	cis	rs35110281	0.805	rs2838330	chr21:45023876	T/A	cg01579765	chr21:45077557	HSF2BP	-0.61	-10.41	-0.54	1.7e-21	Mean corpuscular volume;
CESC	cis	rs13256369	0.951	rs13259955	chr8:8565885	C/G	cg17143192	chr8:8559678	CLDN23	0.76	8.9	0.48	9.21e-17	Obesity-related traits;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg10015802	chr19:3492440	DOHH	0.51	7.15	0.4	8.62e-12	Fibrinogen levels;
CESC	cis	rs7818345	0.935	rs6991212	chr8:19276522	C/T	cg11303988	chr8:19266685	CSGALNACT1	0.32	5.85	0.34	1.45e-8	Language performance in older adults (adjusted for episodic memory);
CESC	trans	rs9693444	0.898	rs4732697	chr8:29519861	A/G	cg14887563	chr7:86849180	C7orf23	-0.43	-6.19	-0.36	2.32e-9	Breast cancer;
CESC	cis	rs1048238	0.846	rs945420	chr1:16345208	G/A	cg21214613	chr1:16344536	HSPB7	0.33	5.4	0.31	1.48e-7	Systolic blood pressure;
CESC	cis	rs7811142	1.000	rs7794485	chr7:100068936	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.77	6.42	0.37	6.32e-10	Platelet count;
CESC	cis	rs2742234	0.656	rs1864400	chr10:43610366	G/A	cg07801480	chr10:43725741	RASGEF1A	0.43	5.61	0.33	5.14e-8	Hirschsprung disease;
CESC	cis	rs6693567	0.545	rs1260391	chr1:150373077	T/C	cg09579323	chr1:150459698	TARS2	0.48	5.98	0.34	7.23e-9	Migraine;
CESC	cis	rs2239547	0.657	rs4687554	chr3:52864135	T/C	cg11645453	chr3:52864694	ITIH4	0.35	6.37	0.36	8.36e-10	Schizophrenia;
CESC	cis	rs7586673	1.000	rs16845584	chr2:161923830	C/T	cg16506815	chr2:162101123	NA	-0.43	-5.9	-0.34	1.11e-8	Intelligence (multi-trait analysis);
CESC	cis	rs9322193	0.962	rs10214845	chr6:150104260	A/G	cg05861140	chr6:150128134	PCMT1	-0.36	-5.14	-0.3	5.22e-7	Lung cancer;
CESC	cis	rs1003719	0.680	rs767998	chr21:38525652	T/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.59	-7.95	-0.44	5.41e-14	Eye color traits;
CESC	cis	rs344364	0.511	rs1742464	chr16:1947335	A/G	cg03013636	chr16:1946785	NA	-0.47	-6.46	-0.37	5.05e-10	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs3820068	0.705	rs57440988	chr1:15879034	T/C	cg17385448	chr1:15911702	AGMAT	0.37	5.88	0.34	1.24e-8	Systolic blood pressure;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg09293122	chr7:99811980	GATS;STAG3	-0.4	-6.1	-0.35	3.68e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs863345	0.604	rs1342954	chr1:158464548	C/A	cg12129480	chr1:158549410	OR10X1	-0.35	-6.97	-0.39	2.46e-11	Pneumococcal bacteremia;
CESC	trans	rs12915820	1	rs12915820	chr15:82009111	T/G	cg07747791	chr7:27498134	NA	-0.4	-6.02	-0.35	5.91e-9	Response to paliperidone in schizophrenia (PANSS score);
CESC	cis	rs4642101	0.765	rs9871991	chr3:12827525	C/A	cg24848339	chr3:12840334	CAND2	0.35	5.37	0.31	1.73e-7	QRS complex (12-leadsum);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg02952972	chr11:972247	AP2A2	0.49	6.65	0.38	1.7e-10	Fibrinogen levels;
CESC	cis	rs798554	0.660	rs2644296	chr7:2859061	A/T	cg13628971	chr7:2884303	GNA12	0.41	5.45	0.32	1.18e-7	Height;
CESC	cis	rs477692	0.673	rs1078847	chr10:131352115	T/C	cg05714579	chr10:131428358	MGMT	0.4	5.14	0.3	5.3e-7	Response to temozolomide;
CESC	cis	rs1865721	0.958	rs11663060	chr18:73172806	T/C	cg26385618	chr18:73139727	C18orf62	-0.44	-6.59	-0.38	2.3e-10	Intelligence;
CESC	cis	rs7078219	0.505	rs11190140	chr10:101291593	T/C	cg09788492	chr10:101292477	NKX2-3	0.33	6.18	0.35	2.45e-9	Dental caries;
CESC	cis	rs2249625	0.504	rs2496508	chr6:72891398	A/G	cg18830697	chr6:72922368	RIMS1	-0.47	-7.02	-0.4	1.89e-11	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CESC	cis	rs728616	0.867	rs75447386	chr10:81739647	G/A	cg05935833	chr10:81318306	SFTPA2	-0.52	-5.06	-0.3	7.72e-7	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs8067545	0.611	rs2107565	chr17:20088492	C/T	cg13482628	chr17:19912719	NA	-0.42	-5.74	-0.33	2.6e-8	Schizophrenia;
CESC	cis	rs2243480	0.706	rs34466769	chr7:65453292	A/C	cg12463550	chr7:65579703	CRCP	0.63	5.98	0.34	7.1e-9	Diabetic kidney disease;
CESC	cis	rs9467711	0.606	rs9379856	chr6:26366836	A/C	cg14345882	chr6:26364793	BTN3A2	0.6	6.17	0.35	2.57e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs12765878	1.000	rs34300861	chr10:105643332	A/C	cg11005552	chr10:105648138	OBFC1	0.35	5.1	0.3	6.34e-7	Coronary artery disease;
CESC	cis	rs9322193	0.926	rs3805751	chr6:150112329	G/A	cg07701084	chr6:150067640	NUP43	0.44	5.99	0.35	6.96e-9	Lung cancer;
CESC	cis	rs7216064	1.000	rs2052187	chr17:65834737	T/C	cg12091567	chr17:66097778	LOC651250	-0.81	-9.18	-0.49	1.28e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg18861140	chr18:3449789	TGIF1	-0.45	-6.05	-0.35	4.97e-9	Ulcerative colitis;
CESC	cis	rs8072100	0.935	rs12150231	chr17:45717091	G/A	cg08085267	chr17:45401833	C17orf57	0.42	5.54	0.32	7.25e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs6430585	0.583	rs1435577	chr2:136624947	C/G	cg07169764	chr2:136633963	MCM6	1.29	19.73	0.77	6.43e-54	Corneal structure;
CESC	cis	rs7605827	0.866	rs11680706	chr2:15477375	T/C	cg19274914	chr2:15703543	NA	0.31	5.53	0.32	7.75e-8	Educational attainment (years of education);
CESC	cis	rs4474465	0.607	rs4945303	chr11:78283803	A/G	cg27205649	chr11:78285834	NARS2	0.53	7.32	0.41	2.95e-12	Alzheimer's disease (survival time);
CESC	cis	rs1215050	0.740	rs10025482	chr4:99053277	T/C	cg17366294	chr4:99064904	C4orf37	0.44	5.81	0.34	1.78e-8	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs2721195	0.654	rs4610795	chr8:145881333	C/T	cg15320075	chr8:145703422	NA	-0.39	-5.29	-0.31	2.51e-7	Age at first birth;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg07474076	chr16:2972993	FLYWCH1	0.46	6.14	0.35	2.97e-9	Fibrinogen levels;
CESC	cis	rs4665809	1.000	rs750451	chr2:26324241	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.66	-7.37	-0.41	2.23e-12	Gut microbiome composition (summer);
CESC	cis	rs9916302	0.645	rs1053651	chr17:37822311	A/C	cg20243544	chr17:37824526	PNMT	0.57	7.05	0.4	1.55e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs10504229	0.562	rs2014516	chr8:58128288	C/A	cg21724239	chr8:58056113	NA	0.58	5.95	0.34	8.29e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs4919087	0.683	rs7074896	chr10:99071282	T/C	cg25902810	chr10:99078978	FRAT1	-0.5	-5.62	-0.33	4.79e-8	Monocyte count;
CESC	cis	rs270601	0.739	rs3900945	chr5:131592870	T/C	cg18301423	chr5:131593218	PDLIM4	0.42	6.05	0.35	4.87e-9	Acylcarnitine levels;
CESC	trans	rs17685	0.753	rs1859791	chr7:75786043	T/C	cg19862616	chr7:65841803	NCRNA00174	0.85	12.42	0.61	3.15e-28	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs651907	0.557	rs34376498	chr3:101480156	C/T	cg12386194	chr3:101231763	SENP7	0.41	5.11	0.3	6.25e-7	Colorectal cancer;
CESC	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg18591801	chr3:52553433	STAB1	-0.29	-5.68	-0.33	3.59e-8	Electroencephalogram traits;
CESC	cis	rs4604732	0.642	rs4400652	chr1:247636479	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.46	6.57	0.37	2.61e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs11690935	0.879	rs13017585	chr2:172721808	C/A	cg13550731	chr2:172543902	DYNC1I2	-0.97	-13.65	-0.64	1.68e-32	Schizophrenia;
CESC	cis	rs4704187	0.687	rs4447960	chr5:74361857	C/A	cg03227963	chr5:74354835	NA	0.31	5.69	0.33	3.36e-8	Response to amphetamines;
CESC	cis	rs7267979	1.000	rs2500405	chr20:25360826	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.84	-15.92	-0.7	1.72e-40	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs854765	0.583	rs9904163	chr17:17830553	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.57	8.18	0.45	1.22e-14	Total body bone mineral density;
CESC	cis	rs344364	0.511	rs1657144	chr16:1963989	C/A	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.59	-6.31	-0.36	1.15e-9	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs10504229	0.683	rs7838958	chr8:58136968	T/C	cg24829409	chr8:58192753	C8orf71	-0.58	-7.2	-0.4	6.31e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs7809950	1.000	rs10258385	chr7:107243350	T/C	cg23024343	chr7:107201750	COG5	0.46	6.32	0.36	1.11e-9	Coronary artery disease;
CESC	cis	rs870825	0.616	rs6552810	chr4:185644143	G/A	cg04058563	chr4:185651563	MLF1IP	0.64	7.1	0.4	1.15e-11	Blood protein levels;
CESC	trans	rs2963826	0.589	rs298091	chr5:58996603	A/T	cg17524854	chr12:67663046	CAND1	0.48	6.2	0.36	2.13e-9	Obesity-related traits;
CESC	cis	rs2952156	0.920	rs903502	chr17:37829604	C/T	cg00129232	chr17:37814104	STARD3	-0.81	-11.81	-0.59	3.71e-26	Asthma;
CESC	cis	rs7937682	0.889	rs487985	chr11:111517908	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.99	-16.01	-0.7	8.36e-41	Primary sclerosing cholangitis;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg02145411	chr1:110528025	AHCYL1	-0.42	-6.2	-0.36	2.21e-9	Gambling;
CESC	cis	rs61776719	0.520	rs11485595	chr1:38411350	C/T	cg26398791	chr1:38455867	SF3A3	-0.41	-5.28	-0.31	2.73e-7	Coronary artery disease;
CESC	cis	rs7267979	0.932	rs6107052	chr20:25530838	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.75	13.8	0.65	5.36e-33	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs2629540	0.889	rs4962696	chr10:126445630	A/G	cg08799069	chr10:126477246	METTL10	-0.66	-9.08	-0.49	2.49e-17	Cocaine dependence;
CESC	cis	rs7615952	0.599	rs67566088	chr3:125768973	C/A	cg02807482	chr3:125708958	NA	-0.4	-5.2	-0.3	3.94e-7	Blood pressure (smoking interaction);
CESC	trans	rs11098499	0.954	rs12506546	chr4:120301618	T/C	cg25214090	chr10:38739885	LOC399744	0.68	9.16	0.49	1.46e-17	Corneal astigmatism;
CESC	cis	rs9322193	0.923	rs6913486	chr6:150026196	C/T	cg04369109	chr6:150039330	LATS1	0.44	5.95	0.34	8.47e-9	Lung cancer;
CESC	cis	rs478304	0.651	rs4930319	chr11:65555458	G/C	cg27068330	chr11:65405492	SIPA1	-0.48	-5.74	-0.33	2.57e-8	Acne (severe);
CESC	cis	rs7945705	0.902	rs10769979	chr11:9010659	C/T	cg09997546	chr11:8931473	C11orf17;ST5	0.35	5.86	0.34	1.41e-8	Hemoglobin concentration;
CESC	cis	rs7402982	0.525	rs11247361	chr15:99207392	C/G	cg03437748	chr15:99193247	IGF1R	-0.59	-7.99	-0.44	4.16e-14	Birth weight;
CESC	cis	rs1538970	0.924	rs2088100	chr1:45877575	C/T	cg06784218	chr1:46089804	CCDC17	0.33	5.49	0.32	9.28e-8	Platelet count;
CESC	cis	rs9399135	0.967	rs12526055	chr6:135325918	C/T	cg24558204	chr6:135376177	HBS1L	0.51	6.94	0.39	3.08e-11	Red blood cell count;
CESC	cis	rs9611565	0.512	rs5758465	chr22:42175314	T/C	cg17376030	chr22:41985996	PMM1	-0.79	-8.37	-0.46	3.44e-15	Vitiligo;
CESC	cis	rs12579753	0.917	rs12366599	chr12:82212112	C/T	cg24719984	chr12:82153464	PPFIA2	-0.34	-5.07	-0.3	7.37e-7	Resting heart rate;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg02718824	chr12:51442167	LETMD1	-0.47	-6.12	-0.35	3.3e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs7618501	0.572	rs4688756	chr3:50040194	T/A	cg24308560	chr3:49941425	MST1R	-0.6	-8.81	-0.48	1.7e-16	Intelligence (multi-trait analysis);
CESC	cis	rs698813	0.543	rs12468824	chr2:44482448	G/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.48	5.38	0.31	1.62e-7	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
CESC	cis	rs6693567	0.565	rs10888584	chr1:150476406	C/G	cg09579323	chr1:150459698	TARS2	0.49	5.87	0.34	1.33e-8	Migraine;
CESC	cis	rs225245	0.791	rs7406966	chr17:34013636	A/C	cg05299278	chr17:33885742	SLFN14	0.38	5.42	0.32	1.32e-7	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
CESC	cis	rs709400	0.633	rs7160208	chr14:103965528	G/A	cg12935359	chr14:103987150	CKB	-0.52	-7.55	-0.42	7.22e-13	Body mass index;
CESC	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg06873352	chr17:61820015	STRADA	0.73	13.07	0.63	1.78e-30	Prudent dietary pattern;
CESC	cis	rs8020095	0.571	rs10133107	chr14:67476864	C/G	cg19548862	chr14:67692701	FAM71D	-0.49	-6.09	-0.35	3.92e-9	Depression (quantitative trait);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg01145475	chr6:7313460	SSR1	-0.5	-6.7	-0.38	1.26e-10	Fibrinogen levels;
CESC	cis	rs1218582	0.772	rs1976559	chr1:154879788	A/T	cg03351412	chr1:154909251	PMVK	0.69	9.38	0.5	3.14e-18	Prostate cancer;
CESC	cis	rs4555082	0.874	rs2015978	chr14:105720134	G/C	cg10792982	chr14:105748885	BRF1	0.4	5.22	0.31	3.7e-7	Mean platelet volume;Platelet distribution width;
CESC	cis	rs722599	0.683	rs7145246	chr14:75242394	A/T	cg11812906	chr14:75593930	NEK9	-0.45	-5.51	-0.32	8.48e-8	IgG glycosylation;
CESC	cis	rs6963495	0.818	rs6961863	chr7:105180953	C/T	cg13798780	chr7:105162888	PUS7	0.75	8.34	0.46	4.18e-15	Bipolar disorder (body mass index interaction);
CESC	cis	rs6582630	0.519	rs12368889	chr12:38315160	G/A	cg26384229	chr12:38710491	ALG10B	0.72	10.21	0.53	7.66e-21	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs2841277	0.676	rs4264326	chr14:105411700	A/G	cg14403583	chr14:105418241	AHNAK2	-0.58	-8.11	-0.45	1.91e-14	Rheumatoid arthritis;
CESC	cis	rs7666738	0.830	rs1426670	chr4:98923572	A/G	cg17366294	chr4:99064904	C4orf37	0.6	8.23	0.45	8.37e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4819052	0.851	rs4818768	chr21:46659818	T/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.91	13.24	0.63	4.51e-31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs7666738	0.830	rs34164616	chr4:99015251	G/A	cg03467027	chr4:99064603	C4orf37	0.44	5.63	0.33	4.57e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs477895	0.838	rs11605738	chr11:64013406	G/A	cg18225595	chr11:63971243	STIP1	0.52	5.29	0.31	2.54e-7	Mean platelet volume;
CESC	cis	rs6860806	0.631	rs7736284	chr5:131588151	T/C	cg22638593	chr5:131593259	PDLIM4	0.41	5.33	0.31	2.15e-7	Breast cancer;
CESC	cis	rs780096	0.526	rs780117	chr2:27698343	C/G	cg12648201	chr2:27665141	KRTCAP3	-0.36	-6.62	-0.38	1.93e-10	Total body bone mineral density;
CESC	cis	rs1153858	1.000	rs1820518	chr15:45694579	C/T	cg14582100	chr15:45693742	SPATA5L1	0.42	5.88	0.34	1.22e-8	Homoarginine levels;
CESC	cis	rs2841277	0.802	rs2841269	chr14:105386149	C/G	cg15352829	chr14:105391018	PLD4	-0.59	-10.1	-0.53	1.69e-20	Rheumatoid arthritis;
CESC	cis	rs1483890	0.642	rs6795775	chr3:69402801	C/T	cg22125112	chr3:69402811	FRMD4B	0.39	5.26	0.31	2.98e-7	Resting heart rate;
CESC	cis	rs3785574	0.962	rs4480868	chr17:61788859	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.63	8.03	0.44	3.13e-14	Height;
CESC	cis	rs4253772	0.550	rs6007818	chr22:46703776	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.66	6.47	0.37	4.65e-10	LDL cholesterol;Cholesterol, total;
CESC	trans	rs9329221	0.678	rs560638	chr8:9882767	A/G	cg15556689	chr8:8085844	FLJ10661	-0.55	-6.94	-0.39	3.02e-11	Neuroticism;
CESC	cis	rs6860806	0.631	rs7736284	chr5:131588151	T/C	cg09877947	chr5:131593287	PDLIM4	0.47	6.26	0.36	1.56e-9	Breast cancer;
CESC	cis	rs2440129	0.611	rs1042356	chr17:6902743	G/A	cg02493798	chr17:6899577	ALOX12	0.42	7.38	0.41	2.04e-12	Tonsillectomy;
CESC	cis	rs17666538	0.792	rs1703912	chr8:600643	A/G	cg02524346	chr8:600233	NA	0.81	6.36	0.36	8.74e-10	IgG glycosylation;
CESC	cis	rs3008870	1.000	rs4620509	chr1:67449941	A/G	cg02640540	chr1:67518911	SLC35D1	-0.51	-5.52	-0.32	7.96e-8	Lymphocyte percentage of white cells;
CESC	cis	rs13064411	0.696	rs7622740	chr3:113206771	G/A	cg18753928	chr3:113234510	CCDC52	-0.48	-5.62	-0.33	4.91e-8	Response to simvastatin treatment (PCSK9 protein level change);
CESC	cis	rs8014204	0.935	rs2300596	chr14:75353855	C/T	cg26191576	chr14:75389716	RPS6KL1	-0.35	-5.07	-0.3	7.58e-7	Caffeine consumption;
CESC	cis	rs72781680	0.898	rs2879640	chr2:24043573	T/C	cg20701182	chr2:24300061	SF3B14	0.63	5.65	0.33	4.21e-8	Lymphocyte counts;
CESC	cis	rs12497850	0.931	rs9311433	chr3:48863835	T/C	cg02487422	chr3:49467188	NICN1	0.39	5.08	0.3	7.18e-7	Parkinson's disease;
CESC	cis	rs6570726	0.791	rs365869	chr6:145884751	C/T	cg05347473	chr6:146136440	FBXO30	0.56	7.11	0.4	1.06e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.38	5.28	0.31	2.65e-7	Lymphocyte counts;
CESC	cis	rs9790314	0.503	rs6441374	chr3:161064540	A/T	cg03342759	chr3:160939853	NMD3	-0.5	-7.3	-0.41	3.29e-12	Morning vs. evening chronotype;
CESC	cis	rs12318506	0.793	rs71460129	chr12:75699427	C/T	cg04728562	chr12:75699417	CAPS2	-1.19	-8.39	-0.46	2.98e-15	Coronary artery calcification;
CESC	cis	rs1953600	0.837	rs2573352	chr10:81939813	T/C	cg00277334	chr10:82204260	NA	0.45	6.28	0.36	1.39e-9	Sarcoidosis;
CESC	cis	rs1799949	1.000	rs12942277	chr17:41187974	G/C	cg25072359	chr17:41440525	NA	0.51	6.62	0.38	1.95e-10	Menopause (age at onset);
CESC	cis	rs2070433	0.534	rs2839269	chr21:47891491	A/G	cg12379764	chr21:47803548	PCNT	0.44	5.55	0.32	6.98e-8	Lymphocyte counts;
CESC	cis	rs2075671	0.855	rs11974395	chr7:100282538	G/A	cg20848291	chr7:100343083	ZAN	-0.8	-10.16	-0.53	1.09e-20	Other erythrocyte phenotypes;
CESC	cis	rs6831352	0.589	rs1133483	chr4:100023923	G/C	cg13256891	chr4:100009986	ADH5	0.7	9.86	0.52	9.41e-20	Alcohol dependence;
CESC	cis	rs853679	0.517	rs9348793	chr6:28084189	G/A	cg22143856	chr6:28129313	ZNF389	0.52	6.71	0.38	1.21e-10	Depression;
CESC	cis	rs9443645	0.869	rs7756858	chr6:79619968	A/G	cg05283184	chr6:79620031	NA	-0.41	-6.2	-0.36	2.1e-9	Intelligence (multi-trait analysis);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg04662649	chr15:41191689	VPS18	0.46	6.64	0.38	1.79e-10	Fibrinogen levels;
CESC	cis	rs66887589	1.000	rs66887589	chr4:120509279	T/C	cg09307838	chr4:120376055	NA	-0.54	-7.17	-0.4	7.62e-12	Diastolic blood pressure;
CESC	cis	rs921665	0.748	rs11677991	chr2:3185321	G/A	cg00496484	chr2:3153332	NA	-0.46	-5.03	-0.3	9.09e-7	World class endurance athleticism;
CESC	cis	rs2842992	0.789	rs9365093	chr6:160175819	C/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.76	9.49	0.5	1.41e-18	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs3096299	0.967	rs753852	chr16:89446419	G/A	cg16743903	chr16:89593216	SPG7	-0.46	-5.85	-0.34	1.43e-8	Multiple myeloma (IgH translocation);
CESC	cis	rs6005807	0.543	rs2235432	chr22:29169420	T/G	cg02153584	chr22:29168773	CCDC117	0.48	5.03	0.3	8.98e-7	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
CESC	cis	rs561341	0.714	rs547473	chr17:30297560	T/G	cg12193833	chr17:30244370	NA	-0.59	-6.02	-0.35	5.78e-9	Hip circumference adjusted for BMI;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg00252696	chr1:31769601	ZCCHC17;SNRNP40	-0.47	-6.38	-0.36	7.75e-10	Ulcerative colitis;
CESC	cis	rs4253772	0.530	rs6008616	chr22:46707954	A/G	cg09491104	chr22:46646882	C22orf40	-0.49	-5.96	-0.34	8.16e-9	LDL cholesterol;Cholesterol, total;
CESC	cis	rs72945132	0.882	rs7950916	chr11:70210001	T/C	cg14191688	chr11:70257035	CTTN	0.41	5.12	0.3	6.02e-7	Coronary artery disease;
CESC	cis	rs10752881	1.000	rs4233193	chr1:182970865	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.85	13.67	0.64	1.54e-32	Colorectal cancer;
CESC	cis	rs6582630	0.502	rs2204008	chr12:38439203	C/T	cg26384229	chr12:38710491	ALG10B	0.69	10.09	0.53	1.86e-20	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs7615952	0.641	rs4490307	chr3:125712676	T/G	cg06494592	chr3:125709126	NA	-0.46	-5.27	-0.31	2.78e-7	Blood pressure (smoking interaction);
CESC	cis	rs7727544	0.548	rs4705938	chr5:131694077	A/G	cg24060327	chr5:131705240	SLC22A5	-0.44	-5.3	-0.31	2.41e-7	Blood metabolite levels;
CESC	cis	rs3785574	0.962	rs2584623	chr17:61906679	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.57	7.05	0.4	1.57e-11	Height;
CESC	cis	rs3857536	0.813	rs2093253	chr6:66937702	A/G	cg07460842	chr6:66804631	NA	-0.42	-5.34	-0.31	1.96e-7	Blood trace element (Cu levels);
CESC	cis	rs10752881	0.967	rs10911186	chr1:182972542	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.85	13.45	0.64	8.93e-32	Colorectal cancer;
CESC	trans	rs61931739	0.517	rs11053224	chr12:34484919	G/A	cg13010199	chr12:38710504	ALG10B	0.49	6.18	0.35	2.41e-9	Morning vs. evening chronotype;
CESC	cis	rs4819052	0.851	rs1999334	chr21:46670457	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.9	13.61	0.64	2.33e-32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs478304	0.651	rs12225620	chr11:65505448	T/C	cg10518572	chr11:65560635	OVOL1	-0.32	-6.19	-0.36	2.31e-9	Acne (severe);
CESC	cis	rs761746	0.593	rs2387	chr22:31977874	T/C	cg25791279	chr22:32026902	PISD	-0.59	-5.94	-0.34	8.91e-9	Intelligence;
CESC	cis	rs6570726	0.738	rs6917199	chr6:145918320	G/A	cg23711669	chr6:146136114	FBXO30	0.97	14.47	0.66	2.25e-35	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1048238	0.506	rs698889	chr1:16267040	A/C	cg22431228	chr1:16359049	CLCNKA	0.37	6.24	0.36	1.76e-9	Systolic blood pressure;
CESC	cis	rs75477785	1.000	rs17015268	chr1:209988989	A/G	cg02304930	chr1:210405566	SERTAD4;C1orf133	-0.84	-5.68	-0.33	3.51e-8	Cleft lip with or without cleft palate;
CESC	cis	rs11098499	0.955	rs11931312	chr4:120159023	T/C	cg09307838	chr4:120376055	NA	0.86	11.43	0.57	7.37e-25	Corneal astigmatism;
CESC	cis	rs9916302	0.904	rs11655531	chr17:37697959	T/C	cg07936489	chr17:37558343	FBXL20	-0.82	-12.0	-0.59	8.91e-27	Glomerular filtration rate (creatinine);
CESC	trans	rs1973993	0.507	rs2759670	chr1:97002864	A/G	cg10631902	chr5:14652156	NA	0.46	6.89	0.39	4.05e-11	Weight;
CESC	cis	rs35110281	0.774	rs141521	chr21:44963686	G/A	cg01579765	chr21:45077557	HSF2BP	-0.57	-9.83	-0.52	1.19e-19	Mean corpuscular volume;
CESC	cis	rs13191362	1.000	rs55847707	chr6:163003414	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.83	8.39	0.46	3.02e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs367943	0.966	rs444322	chr5:112815399	C/T	cg12552261	chr5:112820674	MCC	-0.62	-7.78	-0.43	1.58e-13	Type 2 diabetes;
CESC	cis	rs875971	0.545	rs7811204	chr7:65852200	G/A	cg25405998	chr7:65216604	CCT6P1	0.51	5.52	0.32	8.13e-8	Aortic root size;
CESC	cis	rs2251381	0.750	rs8129616	chr21:30520085	C/T	cg08807101	chr21:30365312	RNF160	-0.74	-9.29	-0.5	5.68e-18	Selective IgA deficiency;
CESC	cis	rs2952156	0.959	rs2934952	chr17:37832366	G/A	cg07936489	chr17:37558343	FBXL20	-0.55	-6.66	-0.38	1.56e-10	Asthma;
CESC	cis	rs9488822	0.676	rs7774952	chr6:116380909	A/G	cg18764771	chr6:116381957	FRK	0.23	5.87	0.34	1.28e-8	Cholesterol, total;LDL cholesterol;
CESC	cis	rs75477785	0.590	rs10863800	chr1:210123774	A/G	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.94	6.76	0.38	8.97e-11	Cleft lip with or without cleft palate;
CESC	trans	rs9354352	0.818	rs9453548	chr6:66691885	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.63	-8.98	-0.48	5.18e-17	Initial pursuit acceleration in psychotic disorders;
CESC	cis	rs7267979	1.000	rs6050590	chr20:25384994	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.88	-18.14	-0.74	2.39e-48	Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs916888	0.610	rs199536	chr17:44820425	T/C	cg01341218	chr17:43662625	NA	-0.55	-7.49	-0.42	1.02e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg04908325	chr14:74353526	ZNF410	-0.48	-6.06	-0.35	4.59e-9	Ulcerative colitis;
CESC	cis	rs1005277	0.579	rs2103938	chr10:38493998	T/G	cg25517755	chr10:38738941	LOC399744	-0.45	-5.73	-0.33	2.79e-8	Extrinsic epigenetic age acceleration;
CESC	cis	rs79349575	0.756	rs937301	chr17:47046276	A/G	cg16584676	chr17:46985605	UBE2Z	-0.45	-5.51	-0.32	8.49e-8	Type 2 diabetes;
CESC	trans	rs1545843	0.593	rs11495253	chr12:84799698	A/G	cg03015433	chr16:56623111	MT3	-0.34	-6.14	-0.35	3.04e-9	Major depressive disorder;
CESC	cis	rs7568498	0.564	rs9287807	chr2:161915361	T/C	cg08807892	chr2:162101083	NA	-0.54	-5.86	-0.34	1.38e-8	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);
CESC	cis	rs2011503	1.000	rs78176666	chr19:19636702	T/C	cg11584989	chr19:19387371	SF4	0.61	7.03	0.4	1.79e-11	Bipolar disorder;
CESC	cis	rs35110281	0.633	rs4818860	chr21:45119617	C/T	cg04455712	chr21:45112962	RRP1B	0.52	8.12	0.45	1.78e-14	Mean corpuscular volume;
CESC	cis	rs57221529	0.766	rs58015612	chr5:580665	A/T	cg16447950	chr5:562315	NA	-0.62	-6.52	-0.37	3.54e-10	Lung disease severity in cystic fibrosis;
CESC	cis	rs7188697	0.922	rs4471670	chr16:58601365	G/A	cg02549819	chr16:58548995	SETD6	0.43	5.4	0.31	1.51e-7	QT interval;
CESC	trans	rs7726839	0.794	rs11739663	chr5:594083	A/G	cg25482853	chr8:67687455	SGK3	0.62	6.44	0.37	5.58e-10	Obesity-related traits;
CESC	cis	rs2066819	1.000	rs76466034	chr12:56719450	G/A	cg26804944	chr12:56660921	COQ10A	-0.85	-5.14	-0.3	5.39e-7	Psoriasis vulgaris;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06531661	chr12:57522120	LRP1	0.55	6.2	0.36	2.2e-9	Gut microbiome composition (summer);
CESC	trans	rs10905099	0.708	rs7080182	chr10:7097117	A/G	cg05230642	chr15:25439252	SNORD115-14	-0.73	-6.17	-0.35	2.6e-9	Orofacial clefts;
CESC	cis	rs1670533	1.000	rs7669622	chr4:1058659	A/G	cg04106633	chr4:1044584	NA	0.42	5.36	0.31	1.84e-7	Recombination rate (females);
CESC	cis	rs2836950	0.501	rs11702505	chr21:40700614	G/T	cg17971929	chr21:40555470	PSMG1	-0.6	-7.92	-0.44	6.45e-14	Menarche (age at onset);
CESC	cis	rs6429082	0.755	rs291384	chr1:235644300	C/T	cg26050004	chr1:235667680	B3GALNT2	0.62	7.88	0.44	8.78e-14	Adiposity;
CESC	cis	rs7116495	1.000	rs2298457	chr11:71734211	T/C	cg10381502	chr11:71823885	C11orf51	-0.64	-5.21	-0.3	3.81e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs4242434	0.854	rs3064	chr8:22451688	C/G	cg03733263	chr8:22462867	KIAA1967	-0.84	-13.4	-0.64	1.32e-31	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CESC	cis	rs798766	1.000	rs1374469	chr4:1724799	C/T	cg07041428	chr4:1763019	NA	-0.38	-5.03	-0.3	8.86e-7	Bladder cancer;Urinary bladder cancer;
CESC	cis	rs3806933	0.522	rs13179305	chr5:110444474	G/A	cg04022379	chr5:110408740	TSLP	0.46	7.41	0.41	1.71e-12	Eosinophilic esophagitis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23045373	chr8:11324048	FAM167A	0.68	8.48	0.46	1.64e-15	Gut microbiome composition (summer);
CESC	cis	rs2832191	0.791	rs2832182	chr21:30481612	G/A	cg24692254	chr21:30365293	RNF160	-0.8	-12.52	-0.61	1.4e-28	Dental caries;
CESC	cis	rs7617773	0.851	rs6775179	chr3:48313418	T/C	cg11946769	chr3:48343235	NME6	0.8	10.74	0.55	1.38e-22	Coronary artery disease;
CESC	cis	rs6540559	0.673	rs6698154	chr1:210007777	A/G	cg25204440	chr1:209979598	IRF6	0.59	5.91	0.34	1.05e-8	Cleft lip with or without cleft palate;
CESC	cis	rs9811920	0.529	rs793442	chr3:99581062	A/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.38	5.22	0.31	3.56e-7	Axial length;
CESC	cis	rs3858526	0.584	rs10769276	chr11:5868020	G/T	cg05234568	chr11:5960015	NA	-0.6	-8.54	-0.46	1.04e-15	DNA methylation (variation);
CESC	cis	rs7666738	0.830	rs7672127	chr4:98938477	A/G	cg03467027	chr4:99064603	C4orf37	0.47	5.86	0.34	1.35e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6973256	0.605	rs10227672	chr7:133326196	G/C	cg10665199	chr7:133106180	EXOC4	-0.42	-5.55	-0.32	6.85e-8	Intelligence (multi-trait analysis);
CESC	cis	rs6547741	1.000	rs6547740	chr2:27854369	C/T	cg27432699	chr2:27873401	GPN1	0.44	6.12	0.35	3.36e-9	Oral cavity cancer;
CESC	cis	rs7647973	0.807	rs4955416	chr3:49108428	T/C	cg07636037	chr3:49044803	WDR6	0.89	13.08	0.63	1.67e-30	Menarche (age at onset);
CESC	cis	rs2415984	0.622	rs7156444	chr14:46933296	C/G	cg14871534	chr14:47121158	RPL10L	-0.34	-5.12	-0.3	5.96e-7	Number of children ever born;
CESC	cis	rs34172651	0.517	rs200526	chr16:24760511	C/T	cg06028605	chr16:24865363	SLC5A11	-0.54	-8.07	-0.44	2.39e-14	Intelligence (multi-trait analysis);
CESC	cis	rs6570726	0.791	rs436498	chr6:145876347	G/A	cg05347473	chr6:146136440	FBXO30	0.57	7.21	0.4	5.99e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9911578	0.967	rs2611781	chr17:56703124	C/G	cg12560992	chr17:57184187	TRIM37	0.91	15.28	0.68	3.04e-38	Intelligence (multi-trait analysis);
CESC	cis	rs3981351	0.797	rs34394259	chr10:115441082	A/G	cg24846397	chr10:115438155	CASP7	-0.35	-5.08	-0.3	7.18e-7	Obesity-related traits;
CESC	cis	rs9309711	0.666	rs6767	chr2:3483205	C/T	cg15541040	chr2:3486749	NA	-0.43	-5.48	-0.32	1.01e-7	Neurofibrillary tangles;
CESC	cis	rs4924935	0.748	rs9915894	chr17:18752778	T/C	cg26378065	chr17:18585709	ZNF286B	0.49	5.33	0.31	2.11e-7	Pancreatic cancer;
CESC	cis	rs769267	0.930	rs1865034	chr19:19605763	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	7.33	0.41	2.75e-12	Tonsillectomy;
CESC	cis	rs56346965	0.967	rs1978273	chr2:191532039	G/A	cg27211696	chr2:191398769	TMEM194B	-0.42	-5.53	-0.32	7.69e-8	Bone mineral density (Ward's triangle area);
CESC	cis	rs595982	0.501	rs112370206	chr19:49396623	C/T	cg21252483	chr19:49399788	TULP2	-0.38	-5.57	-0.32	6.41e-8	Red cell distribution width;
CESC	cis	rs763121	0.853	rs138706	chr22:39137834	C/G	cg14440974	chr22:39074834	NA	-0.36	-5.16	-0.3	4.83e-7	Menopause (age at onset);
CESC	cis	rs7833790	0.700	rs28390260	chr8:82769175	A/T	cg02079420	chr8:82753780	SNX16	-0.53	-8.2	-0.45	1.01e-14	Diastolic blood pressure;
CESC	cis	rs1538970	0.851	rs2055145	chr1:45926495	C/G	cg24296786	chr1:45957014	TESK2	-0.46	-5.22	-0.31	3.61e-7	Platelet count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25300805	chr2:183988933	NUP35	-0.59	-6.48	-0.37	4.51e-10	Gut microbiome composition (summer);
CESC	cis	rs2228479	0.850	rs9282681	chr16:89805914	T/C	cg00800038	chr16:89945340	TCF25	-0.8	-6.47	-0.37	4.83e-10	Skin colour saturation;
CESC	cis	rs6991838	0.584	rs16932250	chr8:66511014	T/G	cg13398993	chr8:66546079	ARMC1	-0.47	-5.59	-0.32	5.56e-8	Intelligence (multi-trait analysis);
CESC	cis	rs10256972	0.786	rs3735686	chr7:1062527	G/A	cg00431813	chr7:1051703	C7orf50	-0.35	-5.39	-0.31	1.59e-7	Longevity;Endometriosis;
CESC	cis	rs68170813	0.599	rs6466162	chr7:106902625	C/T	cg02696742	chr7:106810147	HBP1	-0.53	-5.16	-0.3	4.75e-7	Coronary artery disease;
CESC	cis	rs9393692	0.620	rs9379842	chr6:26289310	C/T	cg13736514	chr6:26305472	NA	0.33	5.55	0.32	6.97e-8	Educational attainment;
CESC	cis	rs2836974	0.867	rs77959119	chr21:40542768	G/A	cg11644478	chr21:40555479	PSMG1	1.05	16.51	0.71	1.32e-42	Cognitive function;
CESC	cis	rs9611565	0.512	rs5758464	chr22:42171300	A/G	cg06634786	chr22:41940651	POLR3H	0.67	5.74	0.33	2.6e-8	Vitiligo;
CESC	cis	rs4891159	0.526	rs2848961	chr18:74129886	C/G	cg24786174	chr18:74118243	ZNF516	-0.85	-15.83	-0.7	3.64e-40	Longevity;
CESC	cis	rs2732480	0.577	rs2732481	chr12:48736985	T/G	cg04545296	chr12:48745243	ZNF641	0.44	7.22	0.41	5.44e-12	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs853679	0.517	rs9393901	chr6:28136797	A/G	cg23161317	chr6:28129485	ZNF389	0.47	5.89	0.34	1.18e-8	Depression;
CESC	cis	rs2839186	0.500	rs13049893	chr21:47707054	C/T	cg12516959	chr21:47718080	NA	-0.47	-6.38	-0.37	7.68e-10	Testicular germ cell tumor;
CESC	cis	rs4665809	0.549	rs72809635	chr2:26411674	G/A	cg27170947	chr2:26402098	FAM59B	0.75	8.39	0.46	3.03e-15	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20710888	chr6:87865238	ZNF292	0.61	6.78	0.38	8.01e-11	Gut microbiome composition (summer);
CESC	cis	rs793571	0.590	rs17190727	chr15:59073790	C/A	cg05156742	chr15:59063176	FAM63B	0.62	8.24	0.45	8.12e-15	Schizophrenia;
CESC	cis	rs8014204	0.604	rs2159906	chr14:75390912	G/T	cg11812906	chr14:75593930	NEK9	0.53	6.75	0.38	9.54e-11	Caffeine consumption;
CESC	cis	rs62408225	1.000	rs62408224	chr6:90955995	A/G	cg06866423	chr6:90926672	BACH2	0.44	5.34	0.31	2.01e-7	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs7799006	0.657	rs10447540	chr7:2301484	A/G	cg12745145	chr7:2261452	MAD1L1	-0.33	-5.22	-0.31	3.56e-7	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs1552244	1.000	rs57631744	chr3:10118962	T/C	cg00149659	chr3:10157352	C3orf10	0.73	8.89	0.48	9.97e-17	Alzheimer's disease;
CESC	cis	rs854765	0.647	rs854767	chr17:18018263	A/C	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.45	-5.65	-0.33	4.13e-8	Total body bone mineral density;
CESC	cis	rs7589342	0.929	rs6719896	chr2:106428404	C/G	cg16077055	chr2:106428750	NCK2	-0.55	-7.9	-0.44	7.3e-14	Addiction;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg07148452	chr15:90176987	KIF7	-0.49	-6.14	-0.35	3.05e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs1552244	1.000	rs1552244	chr3:10135577	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.84	-12.08	-0.6	4.61e-27	Alzheimer's disease;
CESC	cis	rs9443645	0.901	rs1572584	chr6:79690290	A/G	cg05283184	chr6:79620031	NA	0.39	6.04	0.35	5.15e-9	Intelligence (multi-trait analysis);
CESC	cis	rs754466	0.606	rs11002309	chr10:79594931	C/T	cg17075019	chr10:79541650	NA	-0.87	-13.77	-0.65	6.64e-33	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs2991971	0.934	rs2991974	chr1:46020654	A/G	cg24296786	chr1:45957014	TESK2	0.62	8.16	0.45	1.32e-14	High light scatter reticulocyte count;
CESC	trans	rs7246657	0.943	rs7255952	chr19:37988797	A/G	cg01833234	chr11:6592585	DNHD1	0.52	6.03	0.35	5.47e-9	Coronary artery calcification;
CESC	cis	rs9611565	0.546	rs132793	chr22:42063681	A/G	cg06481639	chr22:41940642	POLR3H	0.59	5.83	0.34	1.57e-8	Vitiligo;
CESC	cis	rs7818688	1.000	rs28477467	chr8:96032905	G/A	cg16049864	chr8:95962084	TP53INP1	0.59	5.77	0.33	2.17e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs1003719	0.788	rs3787782	chr21:38462909	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.63	8.77	0.47	2.14e-16	Eye color traits;
CESC	trans	rs17764205	0.777	rs112570652	chr19:3255789	G/A	cg02013146	chr16:89452259	ANKRD11	-0.77	-6.01	-0.35	6.15e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs2180341	0.960	rs9401952	chr6:127677027	A/C	cg27446573	chr6:127587934	RNF146	1.06	15.88	0.7	2.39e-40	Breast cancer;
CESC	cis	rs9614461	0.609	rs9614653	chr22:45767391	A/G	cg13318129	chr22:45737514	FAM118A	-0.51	-5.74	-0.33	2.6e-8	Tonsillectomy;
CESC	cis	rs36051895	0.658	rs10815145	chr9:5013309	G/A	cg02405213	chr9:5042618	JAK2	-0.44	-5.36	-0.31	1.81e-7	Pediatric autoimmune diseases;
CESC	cis	rs6685188	0.920	rs6593964	chr1:205662337	G/T	cg11965913	chr1:205819406	PM20D1	0.45	6.27	0.36	1.42e-9	White blood cell count (basophil);Basophil percentage of white cells;
CESC	cis	rs12999616	1.000	rs12999616	chr2:98324381	C/T	cg26665480	chr2:98280029	ACTR1B	0.61	6.01	0.35	5.98e-9	Colorectal cancer;
CESC	cis	rs10911363	0.549	rs12742245	chr1:183446922	T/A	cg09173681	chr1:183549694	NCF2	0.51	7.27	0.41	4.04e-12	Systemic lupus erythematosus;
CESC	cis	rs10208940	0.920	rs7423646	chr2:68758180	A/G	cg12452813	chr2:68675892	NA	0.51	5.1	0.3	6.39e-7	Urate levels in lean individuals;
CESC	cis	rs2108622	0.701	rs3093209	chr19:15988420	G/C	cg13772218	chr19:15982569	NA	0.31	5.86	0.34	1.34e-8	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	ch.3.2442921F	chr3:124726246	HEG1	-0.46	-6.14	-0.35	2.96e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs11920090	0.860	rs11720145	chr3:170739663	G/A	cg09710316	chr3:170744871	SLC2A2	0.42	5.04	0.3	8.74e-7	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
CESC	cis	rs796364	0.806	rs4673634	chr2:200863349	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.85	7.68	0.43	3.06e-13	Schizophrenia;
CESC	cis	rs4862750	0.872	rs1991254	chr4:187875375	T/G	cg22105103	chr4:187893119	NA	0.44	6.04	0.35	5.29e-9	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs514406	0.708	rs480299	chr1:53320274	G/T	cg08859206	chr1:53392774	SCP2	-0.71	-10.78	-0.55	1.02e-22	Monocyte count;
CESC	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg16590910	chr6:42928470	GNMT	0.38	5.4	0.32	1.46e-7	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs7666738	0.830	rs13112131	chr4:98976784	G/A	cg03467027	chr4:99064603	C4orf37	0.43	5.4	0.31	1.49e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4662945	0.737	rs4662950	chr2:130238492	A/G	cg05962382	chr2:130345044	NA	-0.4	-5.88	-0.34	1.24e-8	Response to cytidine analogues (gemcitabine);
CESC	cis	rs9549367	0.673	rs3024735	chr13:113819513	G/A	cg00898013	chr13:113819073	PROZ	-0.49	-6.59	-0.38	2.4e-10	Platelet distribution width;
CESC	cis	rs736408	0.609	rs13082208	chr3:52781539	T/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.47	6.64	0.38	1.73e-10	Bipolar disorder;
CESC	cis	rs62064224	0.714	rs11657299	chr17:30634951	G/A	cg18200150	chr17:30822561	MYO1D	0.39	5.24	0.31	3.28e-7	Schizophrenia;
CESC	trans	rs13189969	0.506	rs1608636	chr5:105320427	A/T	cg18251612	chr20:39318137	MAFB	-0.46	-6.03	-0.35	5.47e-9	Obesity-related traits;
CESC	cis	rs8018808	0.935	rs12433766	chr14:77930293	C/T	cg20045696	chr14:77926864	AHSA1	0.43	5.9	0.34	1.13e-8	Myeloid white cell count;
CESC	cis	rs1215050	0.791	rs7681599	chr4:98664109	C/T	cg05340658	chr4:99064831	C4orf37	-0.47	-6.04	-0.35	5.08e-9	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg23978390	chr7:1156363	C7orf50	0.45	5.93	0.34	9.44e-9	Longevity;Endometriosis;
CESC	cis	rs34375054	0.624	rs7132026	chr12:125678096	A/G	cg25124228	chr12:125621409	AACS	0.47	5.43	0.32	1.3e-7	Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs4704187	0.663	rs17738989	chr5:74533730	C/T	cg03227963	chr5:74354835	NA	0.27	5.04	0.3	8.67e-7	Response to amphetamines;
CESC	cis	rs9443645	0.901	rs9443632	chr6:79664440	T/C	cg05283184	chr6:79620031	NA	-0.41	-6.34	-0.36	9.66e-10	Intelligence (multi-trait analysis);
CESC	cis	rs9894429	1.000	rs7222241	chr17:79574714	C/G	cg13777783	chr17:79615861	NA	-0.36	-6.07	-0.35	4.5e-9	Eye color traits;
CESC	cis	rs6460942	0.915	rs10267801	chr7:12451931	G/A	cg20607287	chr7:12443886	VWDE	-0.65	-8.59	-0.47	7.51e-16	Coronary artery disease;
CESC	cis	rs3820928	1.000	rs4675119	chr2:227774635	A/C	cg11843606	chr2:227700838	RHBDD1	-0.39	-5.27	-0.31	2.83e-7	Pulmonary function;
CESC	cis	rs910316	0.967	rs11624893	chr14:75660124	A/G	cg11812906	chr14:75593930	NEK9	-0.84	-13.95	-0.65	1.57e-33	Height;
CESC	cis	rs941408	0.515	rs2110118	chr19:2775144	T/C	cg06609049	chr19:2785107	THOP1	0.86	13.26	0.63	3.86e-31	Total cholesterol levels;
CESC	cis	rs9435341	0.826	rs1730858	chr1:107619244	T/C	cg09367891	chr1:107599246	PRMT6	-0.71	-8.44	-0.46	2.13e-15	Facial morphology (factor 21, depth of nasal alae);
CESC	cis	rs5769765	1.000	rs5769764	chr22:50270784	G/A	cg26441486	chr22:50317300	CRELD2	-0.39	-5.5	-0.32	8.72e-8	Schizophrenia;
CESC	cis	rs8060686	0.563	rs118005841	chr16:68157562	A/T	cg26727032	chr16:67993705	SLC12A4	-0.53	-6.05	-0.35	4.9e-9	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs3820928	1.000	rs4675115	chr2:227769123	C/G	cg05526886	chr2:227700861	RHBDD1	-0.42	-5.31	-0.31	2.33e-7	Pulmonary function;
CESC	cis	rs7666738	0.753	rs7657644	chr4:99057734	T/A	cg17366294	chr4:99064904	C4orf37	0.62	8.88	0.48	1.03e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs514406	0.929	rs557715	chr1:53321593	C/G	cg08736216	chr1:53307985	ZYG11A	-0.4	-6.61	-0.38	2.09e-10	Monocyte count;
CESC	cis	rs736408	0.507	rs6445531	chr3:52717282	T/C	cg17372223	chr3:52568218	NT5DC2	0.43	6.65	0.38	1.62e-10	Bipolar disorder;
CESC	cis	rs1707322	1.000	rs7527079	chr1:46413450	C/G	cg03146154	chr1:46216737	IPP	0.72	9.82	0.52	1.31e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs636291	0.500	rs655271	chr1:10536635	G/A	cg20482658	chr1:10539492	PEX14	-0.29	-6.05	-0.35	5.04e-9	Prostate cancer;
CESC	cis	rs853679	0.599	rs13193295	chr6:28003228	C/G	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.85	5.58	0.32	6.06e-8	Depression;
CESC	cis	rs425277	1.000	rs262641	chr1:2104981	C/T	cg16545954	chr1:2118288	C1orf86	-0.34	-6.17	-0.35	2.49e-9	Height;
CESC	cis	rs796364	0.755	rs203762	chr2:200905136	C/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.85	-7.92	-0.44	6.51e-14	Schizophrenia;
CESC	cis	rs34172651	0.583	rs4787649	chr16:24700215	C/T	cg06505273	chr16:24850292	NA	-0.45	-5.6	-0.33	5.3e-8	Intelligence (multi-trait analysis);
CESC	cis	rs1218582	0.772	rs4845688	chr1:154884142	T/C	cg16680214	chr1:154839983	KCNN3	-0.44	-6.79	-0.38	7.4e-11	Prostate cancer;
CESC	cis	rs8067545	0.578	rs4925091	chr17:20066988	T/C	cg13482628	chr17:19912719	NA	0.41	5.46	0.32	1.1e-7	Schizophrenia;
CESC	cis	rs3741489	1.000	rs3741489	chr12:133417802	A/G	cg01499426	chr12:133417423	CHFR	0.87	5.43	0.32	1.28e-7	Cognitive function;
CESC	cis	rs13064411	0.696	rs9839921	chr3:113199093	G/C	cg18753928	chr3:113234510	CCDC52	-0.52	-6.32	-0.36	1.08e-9	Response to simvastatin treatment (PCSK9 protein level change);
CESC	cis	rs3785574	0.743	rs2727334	chr17:61969063	A/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.6	7.28	0.41	3.77e-12	Height;
CESC	cis	rs644148	0.967	rs613876	chr19:44968788	T/C	cg15540054	chr19:45004280	ZNF180	-0.72	-8.78	-0.47	2e-16	Personality dimensions;
CESC	cis	rs362272	0.505	rs60208975	chr4:3364530	A/G	cg08886695	chr4:3369023	RGS12	-0.45	-6.23	-0.36	1.77e-9	Serum sulfate level;
CESC	cis	rs11711311	0.955	rs12634241	chr3:113397685	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.53	6.58	0.37	2.54e-10	IgG glycosylation;
CESC	cis	rs4665809	0.590	rs7582341	chr2:26416301	A/G	cg08470875	chr2:26401718	FAM59B	-0.73	-7.98	-0.44	4.43e-14	Gut microbiome composition (summer);
CESC	cis	rs7520050	0.751	rs2230657	chr1:46073489	G/A	cg03146154	chr1:46216737	IPP	-0.56	-7.22	-0.41	5.38e-12	Red blood cell count;Reticulocyte count;
CESC	cis	rs116095464	0.558	rs7356696	chr5:284251	A/G	cg10591111	chr5:226296	SDHA	-0.53	-6.43	-0.37	6.03e-10	Breast cancer;
CESC	cis	rs10789491	1.000	rs1440487	chr1:47167075	C/T	cg15501359	chr1:47185051	KIAA0494	-0.79	-8.75	-0.47	2.58e-16	Response to hepatitis C treatment;
CESC	cis	rs9399135	0.935	rs4445070	chr6:135309212	C/T	cg22676075	chr6:135203613	NA	0.51	7.02	0.4	1.92e-11	Red blood cell count;
CESC	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg01874867	chr7:94954059	PON1	-0.34	-5.5	-0.32	8.83e-8	Paraoxonase activity;
CESC	trans	rs12356475	0.710	rs10822686	chr10:67733250	C/T	cg25649261	chr6:138725556	HEBP2	0.45	6.08	0.35	4.17e-9	Psoriatic arthritis;
CESC	cis	rs412050	0.502	rs17759796	chr22:22190163	A/C	cg17089214	chr22:22089827	YPEL1	-0.7	-5.96	-0.34	8.21e-9	Attention deficit hyperactivity disorder;
CESC	cis	rs11608355	0.618	rs4486687	chr12:109790741	T/A	cg19025524	chr12:109796872	NA	-0.53	-7.74	-0.43	2.11e-13	Neuroticism;
CESC	cis	rs7949030	0.626	rs11231144	chr11:62328038	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.67	10.06	0.53	2.22e-20	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs4819052	1.000	rs4819052	chr21:46699777	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.64	7.85	0.43	1.07e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs7618915	0.571	rs17264436	chr3:52610651	T/A	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	5.69	0.33	3.37e-8	Bipolar disorder;
CESC	cis	rs1371867	0.846	rs1660345	chr8:101322762	C/A	cg11906718	chr8:101322791	RNF19A	0.54	6.93	0.39	3.1e-11	Atrioventricular conduction;
CESC	cis	rs425277	0.583	rs4648807	chr1:2040898	A/G	cg04315214	chr1:2043799	PRKCZ	0.53	9.3	0.5	5.38e-18	Height;
CESC	cis	rs2204008	0.774	rs7305085	chr12:38263511	C/T	cg26384229	chr12:38710491	ALG10B	0.72	10.17	0.53	1.01e-20	Bladder cancer;
CESC	cis	rs7119	0.717	rs11629835	chr15:77787469	G/T	cg17802220	chr15:77601643	NA	-0.51	-7.18	-0.4	7.24e-12	Type 2 diabetes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17121955	chr11:6411382	SMPD1	0.62	7.41	0.41	1.72e-12	Gut microbiome composition (summer);
CESC	cis	rs2243480	1.000	rs1701750	chr7:65467145	T/C	cg13147721	chr7:65941812	NA	-0.86	-8.36	-0.46	3.7e-15	Diabetic kidney disease;
CESC	cis	rs1707322	1.000	rs10789479	chr1:46352500	T/C	cg03146154	chr1:46216737	IPP	0.78	10.75	0.55	1.29e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs11958404	0.932	rs72816595	chr5:157435957	A/G	cg05962755	chr5:157440814	NA	0.62	6.56	0.37	2.74e-10	IgG glycosylation;
CESC	cis	rs12142240	0.698	rs58162700	chr1:46816659	T/A	cg10495392	chr1:46806563	NSUN4	0.57	6.28	0.36	1.39e-9	Menopause (age at onset);
CESC	cis	rs736408	0.609	rs1029871	chr3:52797634	G/C	cg18404041	chr3:52824283	ITIH1	-0.45	-7.37	-0.41	2.14e-12	Bipolar disorder;
CESC	cis	rs7917772	0.636	rs4919674	chr10:104522226	T/C	cg04362960	chr10:104952993	NT5C2	0.44	5.1	0.3	6.41e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs5757676	1.000	rs5757676	chr22:39841700	T/C	cg02038168	chr22:39784481	NA	-0.63	-6.5	-0.37	3.86e-10	IgG glycosylation;
CESC	cis	rs6740322	0.895	rs6544643	chr2:43560072	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.72	-7.72	-0.43	2.45e-13	Coronary artery disease;
CESC	cis	rs9467711	0.606	rs9379900	chr6:26603811	A/C	cg12826209	chr6:26865740	GUSBL1	0.66	5.86	0.34	1.4e-8	Autism spectrum disorder or schizophrenia;
CESC	cis	rs798554	1.000	rs798545	chr7:2762386	C/T	cg18446336	chr7:2847575	GNA12	-0.4	-6.02	-0.35	5.75e-9	Height;
CESC	cis	rs2842992	0.789	rs7758895	chr6:160193465	T/C	cg26839252	chr6:160211577	TCP1;MRPL18	0.46	5.26	0.31	3.04e-7	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs7666738	0.830	rs1896154	chr4:99021161	T/C	cg18180107	chr4:99064573	C4orf37	0.41	5.3	0.31	2.43e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11822910	0.737	rs2729389	chr11:57211646	A/G	cg00522883	chr11:57194120	SLC43A3	-0.55	-7.23	-0.41	5.13e-12	Platelet distribution width;
CESC	cis	rs12050794	0.671	rs62022788	chr15:72559326	T/G	cg16672083	chr15:72433130	SENP8	0.42	6.22	0.36	1.94e-9	Metabolite levels (HVA/MHPG ratio);
CESC	cis	rs4665809	1.000	rs10170359	chr2:26272219	G/T	cg22920501	chr2:26401640	FAM59B	-0.79	-9.6	-0.51	6.47e-19	Gut microbiome composition (summer);
CESC	cis	rs1862618	0.853	rs6450409	chr5:56101399	A/G	cg22800045	chr5:56110881	MAP3K1	0.73	9.21	0.49	1e-17	Initial pursuit acceleration;
CESC	cis	rs6493487	0.512	rs11854729	chr15:51249128	T/C	cg02338191	chr15:51200825	AP4E1	0.63	5.86	0.34	1.39e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	7.63	0.42	4.23e-13	Prudent dietary pattern;
CESC	trans	rs11989744	0.957	rs57291069	chr8:23570211	G/T	cg03492747	chr16:86543808	FOXF1	0.65	7.48	0.42	1.1e-12	Waist-hip ratio;
CESC	cis	rs8103278	1.000	rs7252126	chr19:46302374	T/A	cg12641515	chr19:46296257	DMWD	-0.53	-5.83	-0.34	1.6e-8	Coronary artery disease;
CESC	cis	rs514406	0.895	rs1925673	chr1:53326984	T/G	cg24675658	chr1:53192096	ZYG11B	-0.6	-7.61	-0.42	4.78e-13	Monocyte count;
CESC	cis	rs113835537	0.529	rs11227525	chr11:66308065	T/G	cg22134325	chr11:66188745	NPAS4	0.39	5.86	0.34	1.37e-8	Airway imaging phenotypes;
CESC	trans	rs61931739	0.500	rs11053269	chr12:34545307	A/G	cg26384229	chr12:38710491	ALG10B	0.53	7.41	0.41	1.74e-12	Morning vs. evening chronotype;
CESC	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg23708337	chr7:1209742	NA	0.52	5.14	0.3	5.37e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs4862750	0.914	rs1991255	chr4:187875340	G/A	cg07414643	chr4:187882934	NA	0.55	7.6	0.42	4.98e-13	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7615952	0.576	rs66671308	chr3:125793526	T/G	cg06494592	chr3:125709126	NA	-0.51	-5.46	-0.32	1.12e-7	Blood pressure (smoking interaction);
CESC	cis	rs1691799	0.899	rs1168318	chr12:66745269	A/G	cg16791601	chr12:66731901	HELB	0.75	13.67	0.64	1.49e-32	White blood cell count (basophil);
CESC	cis	rs7917772	0.503	rs7904955	chr10:104367092	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.56	7.33	0.41	2.73e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs6933660	0.665	rs6921042	chr6:151732385	T/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.55	-7.31	-0.41	3.22e-12	Menarche (age at onset);
CESC	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg23131131	chr22:24373011	LOC391322	-0.68	-9.33	-0.5	4.27e-18	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs1218582	0.804	rs4845678	chr1:154853295	A/G	cg16680214	chr1:154839983	KCNN3	-0.43	-6.71	-0.38	1.18e-10	Prostate cancer;
CESC	cis	rs1799949	1.000	rs8070085	chr17:41341984	C/T	cg23758822	chr17:41437982	NA	-0.86	-12.07	-0.6	4.99e-27	Menopause (age at onset);
CESC	cis	rs6502050	0.605	rs35158616	chr17:80094480	A/G	cg23985595	chr17:80112537	CCDC57	-0.43	-6.63	-0.38	1.87e-10	Life satisfaction;
CESC	cis	rs10504229	0.953	rs75253516	chr8:58171547	C/A	cg05313129	chr8:58192883	C8orf71	-0.53	-6.1	-0.35	3.81e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs854765	0.505	rs4924832	chr17:17897739	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.56	7.85	0.43	1.06e-13	Total body bone mineral density;
CESC	cis	rs9303401	0.527	rs2116450	chr17:56745561	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.05	12.89	0.62	7.95e-30	Cognitive test performance;
CESC	cis	rs2675662	0.525	rs12264025	chr10:75494450	A/G	cg23231163	chr10:75533350	FUT11	-0.35	-5.28	-0.31	2.68e-7	Psoriasis vulgaris;Psoriasis;
CESC	cis	rs875971	0.862	rs778736	chr7:65813848	C/T	cg11764359	chr7:65958608	NA	0.79	11.58	0.58	2.22e-25	Aortic root size;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg15208247	chr1:244857838	PPPDE1	0.46	6.01	0.35	6.12e-9	Fibrinogen levels;
CESC	cis	rs1559088	0.625	rs10411739	chr19:33616327	T/C	cg27124370	chr19:33622961	WDR88	0.52	7.36	0.41	2.29e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs56046484	0.871	rs12904958	chr15:85558187	G/C	cg08123816	chr15:85640762	PDE8A	-0.5	-5.94	-0.34	9.11e-9	Testicular germ cell tumor;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg13895650	chr9:84228185	TLE1	-0.36	-6.09	-0.35	3.98e-9	Gambling;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg14520079	chr3:106825871	NA	0.44	6.02	0.35	5.67e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs4660306	0.961	rs7539253	chr1:45947420	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.61	-7.69	-0.43	2.86e-13	Homocysteine levels;
CESC	cis	rs514406	0.861	rs2448792	chr1:53268313	T/C	cg24675658	chr1:53192096	ZYG11B	0.56	6.99	0.39	2.2e-11	Monocyte count;
CESC	cis	rs9354308	0.901	rs2814096	chr6:66566131	G/A	cg07460842	chr6:66804631	NA	0.67	7.67	0.43	3.2e-13	Metabolite levels;
CESC	cis	rs12410462	0.681	rs74582965	chr1:227610126	C/T	cg04117972	chr1:227635322	NA	0.8	6.95	0.39	2.81e-11	Major depressive disorder;
CESC	cis	rs17711722	0.565	rs4717276	chr7:65294741	G/T	cg26939375	chr7:64535504	NA	0.69	9.76	0.51	2e-19	Calcium levels;
CESC	cis	rs2644899	0.785	rs2604895	chr19:41292263	T/A	cg24958765	chr19:41283667	RAB4B	-0.56	-6.25	-0.36	1.61e-9	Post bronchodilator FEV1/FVC ratio;
CESC	trans	rs4234798	0.546	rs4689667	chr4:7249188	A/T	cg19763168	chr4:84256184	HPSE	0.59	6.88	0.39	4.38e-11	Insulin-like growth factors;
CESC	cis	rs10097731	0.901	rs10464892	chr8:82042991	A/G	cg25230327	chr8:82042993	NA	0.57	6.4	0.37	7.03e-10	Serum total protein level;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg08054244	chr14:88789549	KCNK10	-0.44	-6.35	-0.36	9.17e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs9322193	0.847	rs9505972	chr6:150096391	A/C	cg07701084	chr6:150067640	NUP43	0.42	5.63	0.33	4.66e-8	Lung cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10405333	chr21:28516138	NA	-0.53	-6.48	-0.37	4.41e-10	Gut microbiome composition (summer);
CESC	cis	rs7927592	0.763	rs7120876	chr11:68261398	C/G	cg16797656	chr11:68205561	LRP5	0.48	7.32	0.41	2.92e-12	Total body bone mineral density;
CESC	cis	rs1879734	0.636	rs12043520	chr1:54184097	G/A	cg23596471	chr1:54105337	GLIS1	0.31	5.06	0.3	7.86e-7	Mitral valve prolapse;
CESC	cis	rs2228479	0.850	rs76075456	chr16:89834270	T/C	cg00800038	chr16:89945340	TCF25	-0.92	-7.64	-0.42	4.02e-13	Skin colour saturation;
CESC	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg03188948	chr7:1209495	NA	0.71	7.06	0.4	1.5e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs6089829	0.888	rs4809468	chr20:61673566	T/C	cg23505145	chr19:12996616	KLF1	0.51	6.42	0.37	6.17e-10	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg21548813	chr6:291882	DUSP22	-0.76	-10.58	-0.54	4.63e-22	Menopause (age at onset);
CESC	cis	rs6993244	1	rs6993244	chr8:8863059	C/G	cg06636001	chr8:8085503	FLJ10661	0.44	5.75	0.33	2.46e-8	Mean corpuscular hemoglobin;
CESC	cis	rs752010	0.746	rs10749837	chr1:42089471	T/C	cg12614395	chr1:42085415	HIVEP3	0.3	5.22	0.31	3.69e-7	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs727563	0.580	rs202626	chr22:41847190	C/A	cg03806693	chr22:41940476	POLR3H	1.12	15.09	0.68	1.44e-37	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs2204008	0.777	rs2387813	chr12:38382091	A/C	cg13010199	chr12:38710504	ALG10B	0.45	5.88	0.34	1.23e-8	Bladder cancer;
CESC	cis	rs7520050	0.931	rs6698247	chr1:46371486	C/T	cg24296786	chr1:45957014	TESK2	0.44	5.55	0.32	7.05e-8	Red blood cell count;Reticulocyte count;
CESC	cis	rs11030122	0.702	rs4910868	chr11:3980224	A/C	cg18678763	chr11:4115507	RRM1	-0.49	-6.59	-0.38	2.4e-10	Mean platelet volume;Platelet distribution width;
CESC	cis	rs9814567	1.000	rs7374158	chr3:134270156	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.45	-6.08	-0.35	4.19e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs72781680	0.848	rs715646	chr2:24010566	G/A	cg08917208	chr2:24149416	ATAD2B	0.95	8.71	0.47	3.45e-16	Lymphocyte counts;
CESC	trans	rs11039798	0.920	rs12292685	chr11:48571032	G/T	cg15704280	chr7:45808275	SEPT13	0.7	6.69	0.38	1.3100000000000001e-10	Axial length;
CESC	cis	rs9527	0.641	rs10786732	chr10:104762535	T/C	cg04362960	chr10:104952993	NT5C2	0.42	5.31	0.31	2.33e-7	Arsenic metabolism;
CESC	cis	rs6032067	0.929	rs6032055	chr20:43833336	C/T	cg11264863	chr20:43835661	SEMG1	0.48	5.29	0.31	2.57e-7	Blood protein levels;
CESC	cis	rs10751667	0.666	rs4074235	chr11:977511	C/G	cg06064525	chr11:970664	AP2A2	-0.47	-9.12	-0.49	1.9e-17	Alzheimer's disease (late onset);
CESC	cis	rs4474465	1.000	rs7950756	chr11:78157309	A/G	cg27205649	chr11:78285834	NARS2	-0.42	-5.11	-0.3	6.13e-7	Alzheimer's disease (survival time);
CESC	cis	rs4891159	0.790	rs72975930	chr18:74144645	G/A	cg24786174	chr18:74118243	ZNF516	-0.72	-10.87	-0.56	5.42e-23	Longevity;
CESC	cis	rs1008375	1.000	rs7697889	chr4:17617961	G/T	cg02297831	chr4:17616191	MED28	0.55	6.95	0.39	2.9e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	trans	rs7647973	0.626	rs4855845	chr3:49687043	T/C	cg21659725	chr3:3221576	CRBN	-0.5	-5.99	-0.35	6.66e-9	Menarche (age at onset);
CESC	cis	rs7666738	0.687	rs6839454	chr4:99073914	T/C	cg00999950	chr4:99064541	C4orf37	0.4	5.05	0.3	8.36e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs924607	0.900	rs1697950	chr5:616890	G/A	cg09021430	chr5:549028	NA	0.38	6.78	0.38	7.99e-11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs7662987	0.517	rs2034696	chr4:100024322	C/G	cg13256891	chr4:100009986	ADH5	0.75	8.03	0.44	3.21e-14	Smoking initiation;
CESC	cis	rs1707322	0.963	rs12145287	chr1:46325002	C/G	cg05343316	chr1:45956843	TESK2	0.49	5.96	0.34	7.98e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs1023500	0.505	rs134888	chr22:42674281	C/T	cg12850546	chr22:42539477	CYP2D7P1	-0.39	-5.09	-0.3	6.91e-7	Schizophrenia;
CESC	cis	rs7264396	0.635	rs6058378	chr20:34546658	G/A	cg17201900	chr20:34330562	RBM39	0.52	5.44	0.32	1.21e-7	Total cholesterol levels;
CESC	cis	rs6545883	0.862	rs778141	chr2:61682178	A/G	cg15711740	chr2:61764176	XPO1	-0.4	-5.24	-0.31	3.24e-7	Tuberculosis;
CESC	cis	rs12586317	0.586	rs2295103	chr14:35515920	C/G	cg05294307	chr14:35346193	BAZ1A	-0.53	-5.47	-0.32	1.03e-7	Psoriasis;
CESC	trans	rs4843747	0.573	rs7499959	chr16:88110422	C/G	cg26811252	chr16:29126840	RRN3P2	0.63	8.83	0.48	1.46e-16	Menopause (age at onset);
CESC	cis	rs9916302	0.904	rs11078897	chr17:37415870	C/T	cg15445000	chr17:37608096	MED1	0.41	6.59	0.38	2.43e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs763121	0.819	rs5757126	chr22:38923675	T/C	cg06544989	chr22:39130855	UNC84B	0.49	8.04	0.44	2.94e-14	Menopause (age at onset);
CESC	cis	rs4563143	0.675	rs56123392	chr19:29255631	A/C	cg12667521	chr19:29218732	NA	0.47	6.23	0.36	1.78e-9	Methadone dose in opioid dependence;
CESC	trans	rs7656342	0.808	rs10003216	chr4:9766749	A/G	cg22158956	chr4:39529514	UGDH	-0.57	-6.69	-0.38	1.33e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs7666738	0.830	rs10516426	chr4:99035827	A/G	cg03467027	chr4:99064603	C4orf37	0.47	5.94	0.34	8.93e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6594499	0.872	rs7732974	chr5:110455381	T/C	cg04022379	chr5:110408740	TSLP	0.32	5.74	0.33	2.57e-8	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs921968	0.643	rs10187066	chr2:219514759	A/G	cg02176678	chr2:219576539	TTLL4	0.41	7.3	0.41	3.26e-12	Mean corpuscular hemoglobin concentration;
CESC	cis	rs684232	0.602	rs331008	chr17:544617	C/T	cg12384639	chr17:618140	VPS53	0.41	5.31	0.31	2.36e-7	Prostate cancer;
CESC	cis	rs7811142	1.000	rs6975514	chr7:100056220	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.05	10.31	0.54	3.54e-21	Platelet count;
CESC	cis	rs7666738	0.830	rs4699598	chr4:99019158	C/T	cg03676636	chr4:99064102	C4orf37	0.33	5.15	0.3	5.05e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4948102	0.690	rs35844144	chr7:56050525	C/T	cg09872392	chr7:56161020	PHKG1	-0.44	-6.89	-0.39	3.97e-11	Plasma homocysteine levels (post-methionine load test);
CESC	cis	rs853679	0.517	rs9393898	chr6:28130376	G/T	cg19592336	chr6:28129416	ZNF389	0.63	8.37	0.46	3.45e-15	Depression;
CESC	cis	rs9818941	0.784	rs7614747	chr3:157750934	T/C	cg08654915	chr3:157813417	NA	-0.46	-7.48	-0.42	1.08e-12	Height;
CESC	trans	rs4950322	0.580	rs7515160	chr1:146592296	C/T	cg04954894	chr8:38089920	DDHD2	-0.6	-6.62	-0.38	2e-10	Protein quantitative trait loci;
CESC	cis	rs7771547	0.573	rs629297	chr6:36398146	C/T	cg04289385	chr6:36355825	ETV7	0.38	5.57	0.32	6.36e-8	Platelet distribution width;
CESC	cis	rs7666738	0.830	rs1426672	chr4:98923984	T/C	cg17366294	chr4:99064904	C4orf37	0.6	8.23	0.45	8.65e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg06873352	chr17:61820015	STRADA	0.73	12.89	0.62	7.87e-30	Prudent dietary pattern;
CESC	cis	rs12282928	1.000	rs12288484	chr11:48327476	G/T	cg26585981	chr11:48327164	OR4S1	0.39	5.34	0.31	2e-7	Migraine - clinic-based;
CESC	cis	rs4555082	0.957	rs2816629	chr14:105737261	G/A	cg27165867	chr14:105738592	BRF1	-0.53	-6.2	-0.36	2.13e-9	Mean platelet volume;Platelet distribution width;
CESC	cis	rs1008375	0.897	rs67455495	chr4:17665238	A/T	cg16339924	chr4:17578868	LAP3	-0.66	-7.59	-0.42	5.58e-13	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs36096196	0.891	rs74046969	chr1:2251348	G/A	cg00093522	chr1:2252019	NA	0.44	6.11	0.35	3.63e-9	Coronary artery disease;
CESC	cis	rs2637266	0.678	rs35278870	chr10:78471394	G/A	cg18941641	chr10:78392320	NA	0.4	7.38	0.41	2.09e-12	Pulmonary function;
CESC	cis	rs9300255	0.739	rs1980252	chr12:123745178	C/G	cg05973401	chr12:123451056	ABCB9	0.5	5.68	0.33	3.53e-8	Neutrophil percentage of white cells;
CESC	cis	rs11098499	0.874	rs6851169	chr4:120117510	T/C	cg09307838	chr4:120376055	NA	0.74	9.24	0.49	8.6e-18	Corneal astigmatism;
CESC	cis	rs2251381	0.808	rs7364112	chr21:30548968	C/A	cg24692254	chr21:30365293	RNF160	0.77	10.53	0.54	7.06e-22	Selective IgA deficiency;
CESC	cis	rs1799949	1.000	rs1973646	chr17:41310495	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.61	8.14	0.45	1.53e-14	Menopause (age at onset);
CESC	cis	rs1387259	0.839	rs7486941	chr12:48578631	C/G	cg04545296	chr12:48745243	ZNF641	-0.33	-5.87	-0.34	1.29e-8	Obstructive sleep apnea trait (apnea hypopnea index);
CESC	cis	rs7247513	0.866	rs2861405	chr19:12722332	A/C	cg01871581	chr19:12707946	ZNF490	-0.85	-13.3	-0.63	2.89e-31	Bipolar disorder;
CESC	cis	rs1018836	0.544	rs10112371	chr8:91457626	C/T	cg16814680	chr8:91681699	NA	0.46	6.21	0.36	1.98e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs1707322	0.789	rs10789473	chr1:46248131	C/T	cg06784218	chr1:46089804	CCDC17	0.36	6.14	0.35	3e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7503807	0.664	rs9902390	chr17:78574387	G/A	cg09596252	chr17:78655493	RPTOR	0.39	5.23	0.31	3.41e-7	Obesity;
CESC	cis	rs208520	0.545	rs10944874	chr6:66752080	C/T	cg07460842	chr6:66804631	NA	-1.01	-20.61	-0.78	5.53e-57	Exhaled nitric oxide output;
CESC	cis	rs1552244	0.935	rs35148833	chr3:10116937	C/A	cg00166722	chr3:10149974	C3orf24	0.53	6.6	0.38	2.26e-10	Alzheimer's disease;
CESC	cis	rs1005277	0.522	rs1208684	chr10:38093936	G/A	cg25427524	chr10:38739819	LOC399744	-0.64	-9.72	-0.51	2.69e-19	Extrinsic epigenetic age acceleration;
CESC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg23224405	chr12:12715060	DUSP16	0.44	6.08	0.35	4.1e-9	Intelligence (multi-trait analysis);
CESC	cis	rs6879260	1.000	rs10903252	chr5:179733934	T/C	cg23221052	chr5:179740743	GFPT2	-0.53	-7.15	-0.4	8.68e-12	Height;
CESC	cis	rs11792861	0.890	rs3087979	chr9:111781779	T/C	cg05043794	chr9:111880884	C9orf5	-0.41	-6.82	-0.39	6.13e-11	Menarche (age at onset);
CESC	cis	rs853679	0.882	rs4713140	chr6:28097193	C/T	cg26335602	chr6:28129616	ZNF389	0.54	5.45	0.32	1.14e-7	Depression;
CESC	cis	rs4243830	0.850	rs932112	chr1:6591937	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.98	-10.08	-0.53	1.95e-20	Body mass index;
CESC	cis	rs17122021	0.625	rs3759001	chr11:118135745	A/G	cg26487031	chr11:118134801	MPZL2	-0.26	-5.12	-0.3	5.95e-7	Pain;
CESC	cis	rs4253772	0.591	rs9615934	chr22:46682310	C/G	cg18190219	chr22:46762943	CELSR1	-0.63	-6.51	-0.37	3.65e-10	LDL cholesterol;Cholesterol, total;
CESC	cis	rs11625487	0.515	rs12434419	chr14:77855617	G/A	cg20045696	chr14:77926864	AHSA1	-0.68	-9.12	-0.49	1.94e-17	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
CESC	cis	rs2635047	0.811	rs17785419	chr18:44765469	A/G	cg24371990	chr18:44770781	NA	-0.44	-7.33	-0.41	2.73e-12	Educational attainment;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27062573	chr22:39549099	CBX7	0.61	7.05	0.4	1.51e-11	Gut microbiome composition (summer);
CESC	cis	rs1707322	0.721	rs4660883	chr1:46236098	C/T	cg05343316	chr1:45956843	TESK2	0.48	5.84	0.34	1.5e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9611565	0.765	rs132906	chr22:41799767	G/C	cg03806693	chr22:41940476	POLR3H	0.7	8.58	0.47	8.15e-16	Vitiligo;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg22833807	chr22:36925177	EIF3D	0.48	6.2	0.36	2.14e-9	Gut microbiota (bacterial taxa);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg15012766	chr1:41832369	NA	0.43	6.21	0.36	2.01e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs7927771	0.832	rs11601173	chr11:47401058	A/G	cg18512352	chr11:47633146	NA	-0.51	-7.43	-0.42	1.46e-12	Subjective well-being;
CESC	cis	rs7662987	1.000	rs13119035	chr4:99999130	A/G	cg13256891	chr4:100009986	ADH5	-0.84	-6.09	-0.35	3.92e-9	Smoking initiation;
CESC	cis	rs501120	0.929	rs2576354	chr10:44750393	G/A	cg09554077	chr10:44749378	NA	0.48	5.94	0.34	8.9e-9	Coronary artery disease;Coronary heart disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03277652	chr8:142011117	PTK2	0.56	6.33	0.36	1.06e-9	Gut microbiome composition (summer);
CESC	trans	rs9325144	0.541	rs7303395	chr12:38664124	C/T	cg23762105	chr12:34175262	ALG10	0.48	6.31	0.36	1.15e-9	Morning vs. evening chronotype;
CESC	cis	rs7666738	0.830	rs6827516	chr4:98971740	T/C	cg17366294	chr4:99064904	C4orf37	0.59	8.43	0.46	2.31e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7666738	0.791	rs7657399	chr4:98851861	T/C	cg17366294	chr4:99064904	C4orf37	0.54	7.48	0.42	1.1e-12	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6460942	0.591	rs75804221	chr7:12364319	C/T	cg20607287	chr7:12443886	VWDE	-0.62	-6.71	-0.38	1.2e-10	Coronary artery disease;
CESC	cis	rs7923609	0.902	rs7897379	chr10:65301725	T/C	cg01631684	chr10:65280961	REEP3	-0.41	-5.12	-0.3	5.95e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs10129255	1.000	rs10134517	chr14:107173745	T/C	cg07958169	chr14:107095056	NA	-0.39	-5.24	-0.31	3.21e-7	Kawasaki disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11660684	chr10:126490277	FAM175B	0.53	6.05	0.35	5.02e-9	Gut microbiome composition (summer);
CESC	trans	rs7824557	0.527	rs4634600	chr8:11239017	T/A	cg15556689	chr8:8085844	FLJ10661	-0.48	-6.09	-0.35	3.85e-9	Retinal vascular caliber;
CESC	cis	rs12586317	0.547	rs116499019	chr14:35441931	T/C	cg16230307	chr14:35515116	FAM177A1	0.96	10.66	0.55	2.55e-22	Psoriasis;
CESC	cis	rs193541	0.556	rs30024	chr5:122285160	A/G	cg19412675	chr5:122181750	SNX24	0.46	5.45	0.32	1.16e-7	Glucose homeostasis traits;
CESC	cis	rs1218582	0.710	rs4845685	chr1:154878300	C/A	cg09359103	chr1:154839909	KCNN3	-0.65	-12.33	-0.6	6.58e-28	Prostate cancer;
CESC	cis	rs7772486	0.754	rs12199362	chr6:146118225	A/G	cg05347473	chr6:146136440	FBXO30	0.56	7.19	0.4	6.72e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs763014	0.833	rs916415	chr16:632115	G/A	cg07256732	chr16:621771	PIGQ	-0.3	-5.14	-0.3	5.22e-7	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05617300	chr19:59093449	MGC2752	-0.57	-6.21	-0.36	2.06e-9	Gut microbiome composition (summer);
CESC	cis	rs4595586	0.679	rs7955725	chr12:39322903	C/T	cg26384229	chr12:38710491	ALG10B	0.43	6.31	0.36	1.2e-9	Morning vs. evening chronotype;
CESC	cis	rs8077889	1.000	rs17675122	chr17:41886190	A/G	cg26893861	chr17:41843967	DUSP3	0.84	9.77	0.51	1.89e-19	Triglycerides;
CESC	cis	rs6741892	0.536	rs13024840	chr2:38895920	T/A	cg19391498	chr2:38892846	GALM	-0.53	-6.96	-0.39	2.66e-11	5-HTT brain serotonin transporter levels;
CESC	cis	rs7631605	0.905	rs11708049	chr3:37261396	T/C	cg22985146	chr3:37219077	LRRFIP2	-0.35	-5.44	-0.32	1.18e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs8005677	0.828	rs4981450	chr14:23389304	A/G	cg01529538	chr14:23388837	RBM23	0.45	6.03	0.35	5.55e-9	Cognitive ability (multi-trait analysis);
CESC	cis	rs2635047	0.542	rs1512236	chr18:44768493	C/T	cg24371990	chr18:44770781	NA	-0.36	-5.92	-0.34	9.71e-9	Educational attainment;
CESC	cis	rs6570726	0.935	rs442254	chr6:145849118	T/C	cg05347473	chr6:146136440	FBXO30	0.49	6.62	0.38	1.96e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs13118159	0.778	rs12650998	chr4:1338832	T/C	cg05025164	chr4:1340916	KIAA1530	0.43	5.79	0.34	2e-8	Longevity;
CESC	cis	rs68092024	0.731	rs792841	chr3:99471308	G/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.42	-6.75	-0.38	9.41e-11	Cleft lip with or without cleft palate;
CESC	cis	rs10540	1.000	rs12419766	chr11:503710	C/T	cg21784768	chr11:537496	LRRC56	-0.54	-5.08	-0.3	7.13e-7	Body mass index;
CESC	cis	rs597539	0.652	rs513615	chr11:68705504	G/T	cg04772025	chr11:68637568	NA	0.55	6.29	0.36	1.3e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs8017423	0.605	rs8181930	chr14:90811289	A/G	cg14092571	chr14:90743983	NA	0.53	8.22	0.45	9.31e-15	Mortality in heart failure;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg22897130	chr10:89419623	PAPSS2	-0.43	-6.03	-0.35	5.37e-9	Fibrinogen levels;
CESC	cis	rs6570726	0.935	rs397418	chr6:145842362	C/T	cg05347473	chr6:146136440	FBXO30	0.48	6.58	0.37	2.54e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4835473	0.932	rs6827971	chr4:144743279	G/C	cg25736465	chr4:144833511	NA	-0.32	-5.09	-0.3	6.9e-7	Immature fraction of reticulocytes;
CESC	cis	rs17095355	1.000	rs2419313	chr10:111750851	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.45	-5.04	-0.3	8.75e-7	Biliary atresia;
CESC	cis	rs7520050	0.807	rs6656279	chr1:46124088	C/G	cg06784218	chr1:46089804	CCDC17	0.33	5.95	0.34	8.25e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs3008870	1.000	rs3008854	chr1:67385951	T/C	cg08660285	chr1:67390436	MIER1;WDR78	1.06	14.98	0.68	3.54e-37	Lymphocyte percentage of white cells;
CESC	cis	rs798554	0.757	rs1182187	chr7:2870454	T/G	cg19717773	chr7:2847554	GNA12	-0.56	-8.06	-0.44	2.65e-14	Height;
CESC	cis	rs10751667	0.666	rs7394427	chr11:970405	G/A	cg06064525	chr11:970664	AP2A2	-0.47	-9.13	-0.49	1.87e-17	Alzheimer's disease (late onset);
CESC	cis	rs9309473	0.500	rs11126402	chr2:73776582	G/C	cg20560298	chr2:73613845	ALMS1	-0.49	-7.07	-0.4	1.37e-11	Metabolite levels;
CESC	cis	rs11958404	0.860	rs6868839	chr5:157442196	T/G	cg05962755	chr5:157440814	NA	0.62	6.66	0.38	1.57e-10	IgG glycosylation;
CESC	cis	rs7618915	0.547	rs11720432	chr3:52672742	T/C	cg18404041	chr3:52824283	ITIH1	-0.4	-6.71	-0.38	1.2e-10	Bipolar disorder;
CESC	cis	rs6963495	0.818	rs73192149	chr7:105210910	A/G	cg13798780	chr7:105162888	PUS7	0.77	7.63	0.42	4.27e-13	Bipolar disorder (body mass index interaction);
CESC	cis	rs10791097	0.629	rs11222361	chr11:130731424	T/G	cg09137382	chr11:130731461	NA	0.39	5.84	0.34	1.51e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs7666738	0.830	rs4699601	chr4:99034429	G/A	cg18180107	chr4:99064573	C4orf37	0.42	5.4	0.31	1.48e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs12356475	0.710	rs10822686	chr10:67733250	C/T	cg15465092	chr8:128747754	MYC	-0.49	-6.09	-0.35	4.01e-9	Psoriatic arthritis;
CESC	cis	rs11122272	0.735	rs2474630	chr1:231535335	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.56	-7.66	-0.43	3.45e-13	Hemoglobin concentration;
CESC	cis	rs722599	0.961	rs2359239	chr14:75326771	C/T	cg08847533	chr14:75593920	NEK9	-0.45	-5.68	-0.33	3.53e-8	IgG glycosylation;
CESC	cis	rs9916302	0.851	rs7220650	chr17:37487168	A/G	cg19468946	chr17:37922297	IKZF3	0.39	5.08	0.3	7e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs4523957	0.620	rs8070272	chr17:2063117	A/G	cg16513277	chr17:2031491	SMG6	-0.69	-9.59	-0.51	6.97e-19	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs6785206	1.000	rs6785206	chr3:128412024	A/G	cg16766828	chr3:128327626	NA	-0.53	-5.05	-0.3	8.16e-7	Lymphocyte percentage of white cells;
CESC	cis	rs9581857	0.547	rs9319374	chr13:28047587	A/C	cg22138327	chr13:27999177	GTF3A	0.61	5.03	0.3	9.09e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg18827097	chr2:3522506	ADI1	0.5	6.72	0.38	1.11e-10	Systemic lupus erythematosus;
CESC	cis	rs1348850	0.567	rs12994392	chr2:178536640	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.54	7.16	0.4	7.91e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs875971	0.965	rs10267430	chr7:65743023	G/T	cg11764359	chr7:65958608	NA	-0.95	-15.7	-0.69	1.03e-39	Aortic root size;
CESC	cis	rs1707322	0.721	rs11211181	chr1:46236800	C/T	cg03146154	chr1:46216737	IPP	0.76	10.84	0.55	6.51e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7944584	0.502	rs10769256	chr11:47378396	C/T	cg05585544	chr11:47624801	NA	0.36	5.25	0.31	3.19e-7	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CESC	cis	rs2011503	0.943	rs2965195	chr19:19463032	A/G	cg11584989	chr19:19387371	SF4	-0.63	-7.48	-0.42	1.1e-12	Bipolar disorder;
CESC	trans	rs12542260	0.871	rs7834203	chr8:125482896	A/G	cg09438698	chr12:133365205	GOLGA3	-0.47	-6.05	-0.35	4.83e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4555082	0.874	rs2816611	chr14:105722976	G/C	cg13114125	chr14:105738426	BRF1	-0.82	-10.21	-0.53	7.24e-21	Mean platelet volume;Platelet distribution width;
CESC	cis	rs7246865	0.510	rs3816550	chr19:17173487	A/G	cg16202187	chr19:17186497	HAUS8;MYO9B	0.48	6.28	0.36	1.38e-9	Reticulocyte fraction of red cells;
CESC	cis	rs765787	0.530	rs12904265	chr15:45526713	C/T	cg24006582	chr15:45444508	DUOX1	0.58	6.97	0.39	2.5e-11	Uric acid levels;
CESC	cis	rs2046867	0.862	rs2322611	chr3:72830087	T/G	cg25664220	chr3:72788482	NA	-0.46	-6.73	-0.38	1.06e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CESC	cis	rs11602339	1	rs11602339	chr11:47761471	C/T	cg05585544	chr11:47624801	NA	-0.52	-8.05	-0.44	2.78e-14	Body mass index;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15472574	chr1:43148457	YBX1	0.55	6.03	0.35	5.52e-9	Gut microbiome composition (summer);
CESC	trans	rs864643	0.773	rs11129837	chr3:39589963	A/G	cg05906620	chr10:69523794	NA	0.52	6.66	0.38	1.59e-10	Attention deficit hyperactivity disorder;
CESC	cis	rs12681288	0.645	rs2600509	chr8:989022	C/G	cg15309053	chr8:964076	NA	-0.38	-6.47	-0.37	4.6e-10	Schizophrenia;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg25062357	chr20:2821267	VPS16;FAM113A	-0.47	-6.64	-0.38	1.73e-10	Fibrinogen levels;
CESC	cis	rs1552244	1.000	rs66797209	chr3:10078526	G/A	cg00166722	chr3:10149974	C3orf24	0.46	5.88	0.34	1.21e-8	Alzheimer's disease;
CESC	cis	rs4819052	0.851	rs2838856	chr21:46680766	T/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.47	5.95	0.34	8.43e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17738503	chr17:49244158	NME2;NME1-NME2	0.54	6.5	0.37	3.98e-10	Gut microbiome composition (summer);
CESC	cis	rs1538970	0.816	rs11211123	chr1:45957609	G/A	cg06784218	chr1:46089804	CCDC17	0.37	5.9	0.34	1.11e-8	Platelet count;
CESC	cis	rs9291683	0.609	rs34709913	chr4:10028955	T/C	cg11266682	chr4:10021025	SLC2A9	0.71	14.13	0.66	3.7e-34	Bone mineral density;
CESC	cis	rs7945705	0.870	rs4929922	chr11:8975776	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.45	-7.13	-0.4	9.76e-12	Hemoglobin concentration;
CESC	cis	rs875971	0.502	rs2946580	chr7:65531842	G/A	cg11764359	chr7:65958608	NA	-0.8	-8.96	-0.48	5.83e-17	Aortic root size;
CESC	cis	rs798554	0.797	rs1182174	chr7:2875420	G/A	cg19717773	chr7:2847554	GNA12	-0.56	-8.14	-0.45	1.52e-14	Height;
CESC	cis	rs6424115	1.000	rs12031592	chr1:24127864	A/C	cg10978503	chr1:24200527	CNR2	0.27	5.46	0.32	1.08e-7	Immature fraction of reticulocytes;
CESC	cis	rs10911232	0.507	rs10911231	chr1:183051745	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.85	13.7	0.64	1.21e-32	Hypertriglyceridemia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10236503	chr4:153456147	FBXW7	0.59	6.51	0.37	3.79e-10	Gut microbiome composition (summer);
CESC	cis	rs6952808	0.692	rs60755037	chr7:2030104	G/A	cg05863683	chr7:1912471	MAD1L1	0.43	6.35	0.36	9.24e-10	Bipolar disorder and schizophrenia;
CESC	cis	rs1153858	1.000	rs4774578	chr15:45646051	G/A	cg14582100	chr15:45693742	SPATA5L1	0.42	5.95	0.34	8.45e-9	Homoarginine levels;
CESC	cis	rs13191362	1.000	rs66534429	chr6:163003322	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.49	5.34	0.31	2.01e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs9322193	0.923	rs2151913	chr6:150130642	C/T	cg05861140	chr6:150128134	PCMT1	-0.37	-5.33	-0.31	2.07e-7	Lung cancer;
CESC	cis	rs10504073	0.584	rs56068225	chr8:49923988	A/G	cg00325661	chr8:49890786	NA	0.55	8.31	0.45	5.1e-15	Blood metabolite ratios;
CESC	cis	rs7618501	0.633	rs11925192	chr3:50038664	G/A	cg24308560	chr3:49941425	MST1R	-0.6	-8.81	-0.48	1.7e-16	Intelligence (multi-trait analysis);
CESC	cis	rs4975709	0.569	rs2353583	chr5:1858834	G/C	cg14773178	chr5:1868261	NA	0.32	5.53	0.32	7.49e-8	Cardiovascular disease risk factors;
CESC	cis	rs8078723	0.714	rs3785550	chr17:38149727	C/T	cg17467752	chr17:38218738	THRA	-0.56	-8.52	-0.46	1.25e-15	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CESC	cis	rs10791323	0.604	rs2250025	chr11:133710914	G/A	cg06766960	chr11:133703094	NA	-0.39	-5.46	-0.32	1.08e-7	Childhood ear infection;
CESC	cis	rs3762637	1.000	rs7615673	chr3:122125544	G/C	cg24169773	chr3:122142474	KPNA1	-0.49	-5.69	-0.33	3.41e-8	LDL cholesterol levels;
CESC	cis	rs9291683	0.530	rs882223	chr4:9981625	A/C	cg00071950	chr4:10020882	SLC2A9	0.78	14.43	0.66	3.07e-35	Bone mineral density;
CESC	cis	rs131777	0.526	rs86337	chr22:51020668	C/A	cg25309564	chr22:51001381	C22orf41	0.44	5.47	0.32	1.05e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	cis	rs4253772	0.550	rs6007761	chr22:46670394	C/T	cg10231785	chr22:46692440	CN5H6.4;GTSE1	-0.51	-5.61	-0.33	5.19e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs7605378	1.000	rs2577852	chr2:200687248	C/T	cg23649088	chr2:200775458	C2orf69	0.52	6.78	0.38	7.69e-11	Osteoporosis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26145502	chr1:8939074	ENO1	0.58	6.75	0.38	9.32e-11	Gut microbiome composition (summer);
CESC	cis	rs1552244	0.872	rs6803517	chr3:10065426	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-10.79	-0.55	9.74e-23	Alzheimer's disease;
CESC	cis	rs11711311	1.000	rs9851731	chr3:113502651	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	-0.56	-7.4	-0.41	1.77e-12	IgG glycosylation;
CESC	cis	rs2439831	0.850	rs12442129	chr15:44055856	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.71	8.12	0.45	1.78e-14	Lung cancer in ever smokers;
CESC	cis	rs9291683	0.517	rs11736479	chr4:10017387	G/C	cg11266682	chr4:10021025	SLC2A9	0.72	14.87	0.67	8.73e-37	Bone mineral density;
CESC	trans	rs1814175	0.781	rs1851872	chr11:50009770	A/G	cg03929089	chr4:120376271	NA	-0.93	-15.84	-0.7	3.36e-40	Height;
CESC	cis	rs6831352	0.734	rs1453872	chr4:100022482	G/A	cg12011299	chr4:100065546	ADH4	0.57	6.88	0.39	4.28e-11	Alcohol dependence;
CESC	cis	rs8067545	0.532	rs17759609	chr17:19992514	C/G	cg12073167	chr17:19770448	ULK2	-0.43	-5.22	-0.31	3.65e-7	Schizophrenia;
CESC	cis	rs72627123	0.749	rs58199545	chr14:74452495	G/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.79	5.35	0.31	1.9e-7	Morning vs. evening chronotype;
CESC	cis	rs3008870	0.920	rs3008865	chr1:67402838	T/C	cg02640540	chr1:67518911	SLC35D1	0.52	5.66	0.33	3.9e-8	Lymphocyte percentage of white cells;
CESC	cis	rs6540559	0.546	rs7551944	chr1:210029430	G/C	cg22029157	chr1:209979665	IRF6	0.73	7.21	0.41	5.76e-12	Cleft lip with or without cleft palate;
CESC	cis	rs425277	0.917	rs78609670	chr1:2045886	G/T	cg24578937	chr1:2090814	PRKCZ	0.55	9.07	0.49	2.75e-17	Height;
CESC	cis	rs7264396	0.616	rs6060744	chr20:34581555	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-7.91	-0.44	6.96e-14	Total cholesterol levels;
CESC	cis	rs4523957	0.651	rs4790315	chr17:2070529	T/C	cg16513277	chr17:2031491	SMG6	-0.72	-10.21	-0.53	7.63e-21	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs1218582	0.772	rs11264290	chr1:154912300	C/T	cg24250549	chr1:154909240	PMVK	0.72	10.46	0.54	1.18e-21	Prostate cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03700121	chr11:60610004	CCDC86	0.55	6.46	0.37	5.1e-10	Gut microbiome composition (summer);
CESC	cis	rs8078723	1.000	rs4794823	chr17:38166265	A/T	cg17467752	chr17:38218738	THRA	0.69	10.54	0.54	6.17e-22	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CESC	cis	rs11997175	0.545	rs67960786	chr8:33668770	G/A	ch.8.33884649F	chr8:33765107	NA	0.52	6.44	0.37	5.64e-10	Body mass index;
CESC	cis	rs2880765	0.835	rs4514633	chr15:86041017	T/G	cg10818794	chr15:86012489	AKAP13	-0.35	-5.39	-0.31	1.52e-7	Coronary artery disease;
CESC	cis	rs1670533	1.000	rs62294756	chr4:1097676	G/A	cg27284194	chr4:1044797	NA	-0.47	-5.98	-0.34	7.28e-9	Recombination rate (females);
CESC	cis	rs2463822	1.000	rs1406384	chr11:62083530	A/G	cg06239285	chr11:62104954	ASRGL1	-0.92	-9.18	-0.49	1.31e-17	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs3008870	0.701	rs2815367	chr1:67500762	G/A	cg02640540	chr1:67518911	SLC35D1	0.44	5.36	0.31	1.84e-7	Lymphocyte percentage of white cells;
CESC	cis	rs57602752	1.000	rs11813877	chr10:120640509	C/G	cg26403580	chr10:120936730	PRDX3	0.5	5.04	0.3	8.48e-7	Cannabis dependence;
CESC	cis	rs873946	0.648	rs12782123	chr10:134554662	G/A	cg06453172	chr10:134556979	INPP5A	-0.41	-5.31	-0.31	2.29e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs2295499	0.754	rs73207343	chr4:2628854	T/A	cg27239842	chr4:2403781	ZFYVE28	-0.32	-5.24	-0.31	3.26e-7	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
CESC	cis	rs15676	0.783	rs4837316	chr9:131577450	A/G	cg00228799	chr9:131580591	ENDOG	0.55	6.91	0.39	3.53e-11	Blood metabolite levels;
CESC	cis	rs854765	0.547	rs12150369	chr17:17911014	G/A	cg09796270	chr17:17721594	SREBF1	0.39	5.47	0.32	1.06e-7	Total body bone mineral density;
CESC	cis	rs10504229	0.645	rs6995814	chr8:58114159	C/T	cg24829409	chr8:58192753	C8orf71	-0.59	-7.32	-0.41	2.94e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs7762018	1.000	rs4716380	chr6:170090399	A/G	cg13891659	chr6:170190454	C6orf122;C6orf208	0.53	5.53	0.32	7.7e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	trans	rs61931739	0.500	rs12367292	chr12:33998075	T/C	cg26384229	chr12:38710491	ALG10B	0.58	8.14	0.45	1.51e-14	Morning vs. evening chronotype;
CESC	cis	rs12142240	0.667	rs66990604	chr1:46822073	G/A	cg00530320	chr1:46809349	NSUN4	0.6	8.04	0.44	2.96e-14	Menopause (age at onset);
CESC	cis	rs2180341	0.855	rs4308584	chr6:127714874	A/G	cg27446573	chr6:127587934	RNF146	0.81	11.43	0.57	7.46e-25	Breast cancer;
CESC	cis	rs3741404	0.757	rs2282492	chr11:63918589	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.82	11.99	0.59	9.14e-27	Platelet count;
CESC	cis	rs10256972	0.527	rs28671326	chr7:1174973	G/A	cg22907277	chr7:1156413	C7orf50	0.42	6.07	0.35	4.52e-9	Longevity;Endometriosis;
CESC	cis	rs10504229	0.683	rs59679713	chr8:58134370	G/C	cg24829409	chr8:58192753	C8orf71	-0.58	-7.21	-0.41	5.78e-12	Developmental language disorder (linguistic errors);
CESC	trans	rs10751667	1.000	rs6597972	chr11:928402	C/T	cg00159523	chr10:114713187	TCF7L2	-0.42	-6.28	-0.36	1.39e-9	Alzheimer's disease (late onset);
CESC	cis	rs12347191	0.500	rs1465965	chr9:100620326	C/T	cg13688889	chr9:100608707	NA	-0.91	-13.42	-0.64	1.07e-31	Orofacial clefts;
CESC	cis	rs7143963	0.636	rs2180393	chr14:103293845	T/C	cg24154132	chr14:103367632	TRAF3	0.34	6.31	0.36	1.16e-9	Body mass index;
CESC	cis	rs11190604	1.000	rs7070776	chr10:102264672	A/G	cg07080220	chr10:102295463	HIF1AN	0.61	5.78	0.33	2.06e-8	Palmitoleic acid (16:1n-7) levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15186648	chr13:103452789	BIVM;KDELC1	0.52	6.07	0.35	4.37e-9	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.830	rs1426669	chr4:98945534	C/T	cg05340658	chr4:99064831	C4orf37	0.82	12.66	0.61	4.8e-29	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4704187	0.687	rs9654429	chr5:74466925	C/G	cg03227963	chr5:74354835	NA	0.28	5.21	0.3	3.77e-7	Response to amphetamines;
CESC	cis	rs8067354	0.645	rs2271304	chr17:57814641	A/G	cg13753209	chr17:57696993	CLTC	0.56	6.1	0.35	3.83e-9	Hemoglobin concentration;
CESC	cis	rs4919044	1.000	rs17108043	chr10:94770697	A/G	cg16508068	chr10:94451736	HHEX	0.51	5.36	0.31	1.77e-7	Coronary artery disease;
CESC	cis	rs1218582	0.772	rs2102423	chr1:154916068	A/G	cg06221963	chr1:154839813	KCNN3	-0.67	-11.28	-0.57	2.31e-24	Prostate cancer;
CESC	cis	rs45535039	0.506	rs2511856	chr11:119144148	A/C	cg16724696	chr11:118992527	HINFP	-0.41	-5.6	-0.33	5.25e-8	Plateletcrit;
CESC	cis	rs1799949	0.896	rs8176098	chr17:41268206	A/C	cg05368731	chr17:41323189	NBR1	0.8	11.27	0.57	2.6e-24	Menopause (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10523380	chr6:7141602	RREB1	0.55	6.53	0.37	3.34e-10	Gut microbiome composition (summer);
CESC	cis	rs2952156	0.883	rs907088	chr17:37833567	G/C	cg20243544	chr17:37824526	PNMT	0.62	8.21	0.45	9.57e-15	Asthma;
CESC	cis	rs6541297	0.703	rs628035	chr1:230324145	G/T	cg20703242	chr1:230279135	GALNT2	-0.4	-5.26	-0.31	2.96e-7	Coronary artery disease;
CESC	cis	rs2033711	0.870	rs1051500	chr19:58944402	A/G	cg13877915	chr19:58951672	ZNF132	0.39	5.79	0.34	1.94e-8	Uric acid clearance;
CESC	cis	rs1552244	1.000	rs66838678	chr3:10150350	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	12.27	0.6	1.07e-27	Alzheimer's disease;
CESC	cis	rs2425143	1.000	rs1890470	chr20:34357008	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.72	6.82	0.39	6.12e-11	Blood protein levels;
CESC	cis	rs7917772	0.636	rs2250580	chr10:104505687	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.47	5.76	0.33	2.36e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs372883	0.597	rs2018956	chr21:30736622	C/A	cg24692254	chr21:30365293	RNF160	0.45	5.69	0.33	3.27e-8	Pancreatic cancer;
CESC	trans	rs10242455	0.571	rs73713595	chr7:99326659	G/A	cg09045935	chr12:6379348	NA	0.75	6.29	0.36	1.3e-9	Blood metabolite levels;
CESC	cis	rs875971	0.545	rs73152714	chr7:65999628	G/A	cg11764359	chr7:65958608	NA	0.82	10.05	0.53	2.44e-20	Aortic root size;
CESC	cis	rs17376456	0.877	rs10070390	chr5:93452345	G/A	cg21475434	chr5:93447410	FAM172A	0.82	7.56	0.42	6.81e-13	Diabetic retinopathy;
CESC	cis	rs2191566	0.576	rs381983	chr19:44494215	C/T	cg20607764	chr19:44506953	ZNF230	-0.44	-5.53	-0.32	7.62e-8	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs6089829	0.926	rs6062395	chr20:61667904	A/G	cg16240275	chr20:61666158	NCRNA00029	0.5	8.91	0.48	8.46e-17	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7949030	0.588	rs2428548	chr11:62311462	A/G	cg23462726	chr11:62437636	C11orf83;C11orf48	-0.4	-5.4	-0.31	1.52e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs1005277	0.579	rs2474575	chr10:38387901	C/T	cg00409905	chr10:38381863	ZNF37A	-0.47	-6.3	-0.36	1.23e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs2404602	0.536	rs7163946	chr15:76766049	C/G	cg26408565	chr15:76604113	ETFA	-0.43	-6.43	-0.37	5.86e-10	Blood metabolite levels;
CESC	cis	rs854765	0.522	rs63721860	chr17:17829576	T/C	cg09796270	chr17:17721594	SREBF1	0.4	5.6	0.33	5.43e-8	Total body bone mineral density;
CESC	cis	rs798554	0.759	rs2644291	chr7:2890456	T/C	cg13628971	chr7:2884303	GNA12	0.61	8.03	0.44	3.3e-14	Height;
CESC	cis	rs6088580	0.634	rs6142157	chr20:32984172	C/G	cg06115741	chr20:33292138	TP53INP2	-0.47	-6.08	-0.35	4.22e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs6459788	0.527	rs6980250	chr7:157228710	C/T	cg03453431	chr7:157225567	NA	-0.42	-7.35	-0.41	2.48e-12	Epstein-Barr virus copy number in lymphoblastoid cell lines;
CESC	cis	rs7000551	0.715	rs1879793	chr8:22313986	G/A	cg12081754	chr8:22256438	SLC39A14	0.41	5.36	0.31	1.78e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CESC	cis	rs34638657	0.702	rs35865749	chr16:82199677	T/C	cg09439754	chr16:82129088	HSD17B2	-0.38	-6.63	-0.38	1.92e-10	Lung adenocarcinoma;
CESC	cis	rs10883723	0.810	rs2296586	chr10:104245575	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.61	8.47	0.46	1.71e-15	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs7216064	0.817	rs28609796	chr17:65855104	T/A	cg07042672	chr17:66097459	LOC651250	-0.54	-5.62	-0.33	4.74e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs79387448	0.745	rs74560841	chr2:103149210	G/A	cg09003973	chr2:102972529	NA	0.7	5.44	0.32	1.2e-7	Gut microbiota (bacterial taxa);
CESC	cis	rs1048238	0.506	rs848210	chr1:16259813	A/G	cg21385522	chr1:16154831	NA	-0.43	-5.46	-0.32	1.1e-7	Systolic blood pressure;
CESC	cis	rs11722228	0.522	rs77691548	chr4:10136115	T/G	cg14348967	chr4:10160060	NA	-0.42	-5.58	-0.32	5.91e-8	Gout;Urate levels;Serum uric acid levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11354908	chr19:18255899	MAST3	-0.67	-7.45	-0.42	1.29e-12	Gut microbiome composition (summer);
CESC	cis	rs6088580	0.634	rs1205345	chr20:32914699	A/G	cg08999081	chr20:33150536	PIGU	-0.65	-11.3	-0.57	2.02e-24	Glomerular filtration rate (creatinine);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03586379	chr3:140660603	SLC25A36	0.56	6.17	0.35	2.57e-9	Gut microbiome composition (summer);
CESC	cis	rs597539	0.652	rs516425	chr11:68715675	G/A	cg01988459	chr11:68622903	NA	-0.45	-6.3	-0.36	1.22e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	trans	rs79976124	0.797	rs77895756	chr6:66626782	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.74	8.48	0.46	1.58e-15	Type 2 diabetes;
CESC	cis	rs10088262	0.527	rs3911939	chr8:124793744	T/G	cg02993010	chr8:124780839	FAM91A1	-0.68	-8.21	-0.45	1.01e-14	Pancreatic cancer;
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg20249169	chr2:64881356	SERTAD2	-0.45	-6.6	-0.38	2.27e-10	Vertical cup-disc ratio;
CESC	cis	rs9311474	0.508	rs11714565	chr3:52606292	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.57	7.93	0.44	6.13e-14	Electroencephalogram traits;
CESC	cis	rs55728055	0.661	rs9680589	chr22:31853484	G/A	cg01338084	chr22:32026380	PISD	1.13	6.83	0.39	5.9e-11	Age-related hearing impairment;
CESC	cis	rs7680126	0.633	rs4698014	chr4:10286301	C/T	cg00071950	chr4:10020882	SLC2A9	-0.46	-5.09	-0.3	6.89e-7	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	cis	rs317689	0.819	rs317660	chr12:69686203	G/A	cg14784868	chr12:69753453	YEATS4	0.5	5.37	0.31	1.69e-7	Response to diuretic therapy;
CESC	cis	rs6430585	0.527	rs59413285	chr2:136444185	G/T	cg07169764	chr2:136633963	MCM6	1.09	12.56	0.61	1.07e-28	Corneal structure;
CESC	cis	rs1046896	0.553	rs72634343	chr17:80827392	T/C	cg05255149	chr17:80675120	FN3KRP	0.45	5.04	0.3	8.76e-7	Glycated hemoglobin levels;
CESC	cis	rs76878669	0.561	rs11227465	chr11:66115879	T/A	cg18002602	chr11:66138449	SLC29A2	-0.46	-7.29	-0.41	3.64e-12	Educational attainment (years of education);
CESC	cis	rs7666738	0.830	rs13149404	chr4:99070236	A/G	cg05340658	chr4:99064831	C4orf37	0.84	12.81	0.62	1.45e-29	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3096299	0.933	rs3096297	chr16:89453155	T/G	cg02187348	chr16:89574699	SPG7	0.57	7.5	0.42	9.65e-13	Multiple myeloma (IgH translocation);
CESC	cis	rs1665050	0.534	rs8028502	chr15:59235876	C/G	cg05156742	chr15:59063176	FAM63B	0.5	6.42	0.37	6.18e-10	Atopic dermatitis;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg09254969	chr5:141303622	KIAA0141	-0.46	-6.14	-0.35	3.03e-9	Fibrinogen levels;
CESC	cis	rs933688	0.877	rs1477349	chr5:90707773	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.11	12.45	0.61	2.47e-28	Smoking behavior;
CESC	cis	rs2074585	0.583	rs28406958	chr15:91069364	C/A	cg22089800	chr15:90895588	ZNF774	-0.46	-5.42	-0.32	1.33e-7	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
CESC	cis	rs4665809	1.000	rs6546727	chr2:26275282	C/T	cg22920501	chr2:26401640	FAM59B	-0.67	-7.97	-0.44	4.81e-14	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10593459	chr1:44447478	B4GALT2	-0.53	-6.36	-0.36	8.68e-10	Gut microbiome composition (summer);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg21679509	chr7:28219613	JAZF1	-0.44	-6.19	-0.36	2.32e-9	Ulcerative colitis;
CESC	cis	rs3785574	0.962	rs62077509	chr17:61848973	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	7.29	0.41	3.54e-12	Height;
CESC	cis	rs11203032	0.831	rs7477966	chr10:90924258	A/G	cg16672925	chr10:90967113	CH25H	0.74	6.99	0.39	2.26e-11	Heart failure;
CESC	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg04234412	chr22:24373322	LOC391322	-0.52	-7.48	-0.42	1.08e-12	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs9457247	0.967	rs1794694	chr6:167404751	T/C	cg25258033	chr6:167368657	RNASET2	0.39	5.88	0.34	1.26e-8	Crohn's disease;
CESC	cis	rs3781913	0.874	rs11235559	chr11:72374037	C/T	cg04827223	chr11:72435913	ARAP1	0.31	5.05	0.3	8.32e-7	Rheumatoid arthritis;
CESC	cis	rs6893300	0.883	rs1469021	chr5:179214251	C/T	cg14593053	chr5:179126677	CANX	-0.51	-5.57	-0.32	6.16e-8	Resting heart rate;
CESC	cis	rs9303401	1.000	rs6503882	chr17:56915761	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.73	9.4	0.5	2.7e-18	Cognitive test performance;
CESC	cis	rs6460942	1.000	rs117657017	chr7:12318891	T/C	cg10578991	chr7:12443926	VWDE	-0.61	-6.41	-0.37	6.66e-10	Coronary artery disease;
CESC	cis	rs2180341	0.883	rs7760748	chr6:127690062	C/T	cg24812749	chr6:127587940	RNF146	1.05	15.12	0.68	1.2e-37	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13576294	chr9:131124572	NA	-0.62	-7.43	-0.42	1.48e-12	Gut microbiome composition (summer);
CESC	cis	rs910316	1.000	rs175449	chr14:75590846	A/T	cg11812906	chr14:75593930	NEK9	-0.87	-14.97	-0.68	3.76e-37	Height;
CESC	cis	rs1008375	0.931	rs979823	chr4:17700176	G/A	cg02297831	chr4:17616191	MED28	0.48	5.78	0.33	2.07e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs801193	1.000	rs2659912	chr7:66157999	G/C	cg11764359	chr7:65958608	NA	0.69	9.11	0.49	2.05e-17	Aortic root size;
CESC	cis	rs9733	0.818	rs6694531	chr1:150683512	C/A	cg13175981	chr1:150552382	MCL1	0.62	9.15	0.49	1.59e-17	Tonsillectomy;
CESC	cis	rs6952808	1.000	rs6953693	chr7:1886388	C/G	cg04267008	chr7:1944627	MAD1L1	-0.6	-7.44	-0.42	1.37e-12	Bipolar disorder and schizophrenia;
CESC	cis	rs10189230	0.967	rs7573758	chr2:222357326	G/T	cg14652038	chr2:222343519	EPHA4	0.33	6.85	0.39	5.06e-11	Urate levels in lean individuals;
CESC	cis	rs1580019	0.537	rs7804609	chr7:32558094	A/C	cg06627557	chr7:32535165	LSM5;AVL9	1.06	19.18	0.76	5.16e-52	Cognitive ability;
CESC	cis	rs763121	0.853	rs5757232	chr22:39071677	C/T	cg06544989	chr22:39130855	UNC84B	0.5	8.88	0.48	1.05e-16	Menopause (age at onset);
CESC	cis	rs875971	0.502	rs11769702	chr7:65720516	A/C	cg11764359	chr7:65958608	NA	0.81	9.43	0.5	2.14e-18	Aortic root size;
CESC	trans	rs10411161	0.702	rs11878583	chr19:52388546	C/T	cg22319618	chr22:45562946	NUP50	0.77	7.71	0.43	2.51e-13	Breast cancer;
CESC	cis	rs1862618	0.802	rs33327	chr5:56142693	T/G	cg24531977	chr5:56204891	C5orf35	-0.88	-11.14	-0.56	6.81e-24	Initial pursuit acceleration;
CESC	cis	rs9913156	0.793	rs8074545	chr17:4567337	C/G	cg19197139	chr17:4613644	ARRB2	-0.92	-10.59	-0.55	4.42e-22	Lymphocyte counts;
CESC	cis	rs9513593	1.000	rs2296044	chr13:100038825	T/C	cg21788972	chr13:99853209	UBAC2	0.64	7.56	0.42	6.41e-13	Psoriasis;
CESC	cis	rs7552404	0.920	rs1612097	chr1:76218875	C/T	cg03433033	chr1:76189801	ACADM	0.71	9.78	0.52	1.68e-19	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs4253772	0.575	rs74879643	chr22:46660014	T/C	cg10541313	chr22:46663664	TTC38	0.7	5.24	0.31	3.34e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs1595825	0.891	rs76450397	chr2:198786112	T/C	cg10820045	chr2:198174542	NA	0.41	5.06	0.3	7.8e-7	Ulcerative colitis;
CESC	cis	rs644799	1.000	rs509720	chr11:95562771	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	9.15	0.49	1.57e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs12681288	0.676	rs34282191	chr8:991290	G/A	cg04851639	chr8:1020857	NA	-0.32	-6.71	-0.38	1.2e-10	Schizophrenia;
CESC	cis	rs7296418	0.599	rs2277343	chr12:123794450	A/T	cg00376283	chr12:123451042	ABCB9	0.57	7.71	0.43	2.59e-13	Platelet count;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg05899741	chr4:43901084	NA	-0.38	-6.0	-0.35	6.55e-9	Asthma;
CESC	cis	rs113835537	0.559	rs57045447	chr11:66339683	A/G	cg22134325	chr11:66188745	NPAS4	0.37	5.56	0.32	6.61e-8	Airway imaging phenotypes;
CESC	cis	rs910316	1.000	rs28626045	chr14:75589195	G/C	cg08847533	chr14:75593920	NEK9	1.01	19.53	0.77	2.99e-53	Height;
CESC	cis	rs1552244	0.882	rs67762674	chr3:10014485	C/T	cg00166722	chr3:10149974	C3orf24	0.48	5.97	0.34	7.76e-9	Alzheimer's disease;
CESC	cis	rs11690935	0.788	rs10201053	chr2:172889558	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.67	-9.0	-0.48	4.41e-17	Schizophrenia;
CESC	cis	rs2576037	0.796	rs2247021	chr18:44578794	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.6	8.7	0.47	3.51e-16	Personality dimensions;
CESC	cis	rs7666738	0.830	rs6846739	chr4:99016647	G/A	cg05340658	chr4:99064831	C4orf37	0.82	13.05	0.63	2.08e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs780096	0.546	rs1104	chr2:27599875	T/G	cg12648201	chr2:27665141	KRTCAP3	-0.34	-6.26	-0.36	1.52e-9	Total body bone mineral density;
CESC	cis	rs6598163	0.712	rs10751695	chr12:132291061	A/C	cg22244940	chr12:132335942	MMP17	0.4	5.44	0.32	1.2e-7	Migraine;
CESC	cis	rs67311347	1.000	rs11715214	chr3:40403004	C/A	cg24209194	chr3:40518798	ZNF619	0.42	5.31	0.31	2.36e-7	Renal cell carcinoma;
CESC	cis	rs8002861	0.905	rs12873099	chr13:44396247	G/A	cg14210620	chr13:44453864	C13orf31;CCDC122	-0.45	-5.49	-0.32	9.56e-8	Leprosy;
CESC	trans	rs2727020	0.658	rs10839278	chr11:49450847	G/C	cg03929089	chr4:120376271	NA	-0.82	-12.73	-0.62	2.68e-29	Coronary artery disease;
CESC	cis	rs875971	0.545	rs801212	chr7:66015630	C/G	cg11764359	chr7:65958608	NA	-0.81	-9.98	-0.52	4.19e-20	Aortic root size;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg25360212	chr19:1095536	POLR2E	-0.44	-6.28	-0.36	1.36e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs514406	0.929	rs557715	chr1:53321593	C/G	cg24675658	chr1:53192096	ZYG11B	-0.59	-7.51	-0.42	9.17e-13	Monocyte count;
CESC	cis	rs12956009	0.518	rs983095	chr18:44899258	T/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.5	6.46	0.37	5.1e-10	Educational attainment (years of education);
CESC	cis	rs709400	0.643	rs11621777	chr14:104072090	A/G	cg24130564	chr14:104152367	KLC1	-0.42	-5.03	-0.3	9.09e-7	Body mass index;
CESC	cis	rs9649213	0.574	rs36099592	chr7:98002331	T/C	cg21770322	chr7:97807741	LMTK2	0.57	8.84	0.48	1.39e-16	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg04203298	chr11:59521722	STX3	-0.38	-6.12	-0.35	3.43e-9	Gambling;
CESC	cis	rs896854	0.654	rs13278601	chr8:95972974	G/C	cg09323728	chr8:95962352	TP53INP1	-0.39	-8.54	-0.46	1.04e-15	Type 2 diabetes;
CESC	cis	rs4889855	0.511	rs9908700	chr17:78466594	A/G	cg00066239	chr17:78472159	NA	-0.4	-5.46	-0.32	1.11e-7	Fractional excretion of uric acid;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg24419099	chr11:47270565	NR1H3;ACP2	-0.46	-6.22	-0.36	1.92e-9	Height;
CESC	cis	rs10918270	1.000	rs2341471	chr1:161924749	C/T	cg19735514	chr1:161762739	ATF6	-0.36	-5.47	-0.32	1.03e-7	Parkinson's disease (age of onset);
CESC	cis	rs10504229	1.000	rs59071610	chr8:58186301	A/C	cg05313129	chr8:58192883	C8orf71	-0.55	-6.29	-0.36	1.34e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs35110281	0.748	rs9981460	chr21:45030965	T/A	cg04455712	chr21:45112962	RRP1B	0.4	5.95	0.34	8.63e-9	Mean corpuscular volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24608144	chr20:62398219	ZBTB46	-0.57	-6.08	-0.35	4.1e-9	Gut microbiome composition (summer);
CESC	cis	rs7017914	0.967	rs1838393	chr8:71702591	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.42	-5.3	-0.31	2.38e-7	Bone mineral density;
CESC	cis	rs875971	1.000	rs1167612	chr7:65567976	C/A	cg12463550	chr7:65579703	CRCP	-0.6	-7.51	-0.42	9.32e-13	Aortic root size;
CESC	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg07167872	chr1:205819463	PM20D1	0.43	6.59	0.38	2.34e-10	Menarche (age at onset);
CESC	cis	rs9325144	0.647	rs12424190	chr12:39111206	A/T	cg26384229	chr12:38710491	ALG10B	-0.52	-7.35	-0.41	2.39e-12	Morning vs. evening chronotype;
CESC	cis	rs4975709	0.589	rs4975745	chr5:1861058	G/C	cg10800226	chr5:1850261	NA	0.34	5.61	0.33	4.97e-8	Cardiovascular disease risk factors;
CESC	cis	rs7071206	0.853	rs66786803	chr10:79429941	A/G	cg00983440	chr10:79422392	NA	-0.63	-7.78	-0.43	1.61e-13	Bone mineral density;
CESC	cis	rs6540556	0.769	rs7521461	chr1:209926207	C/G	cg23920097	chr1:209922102	NA	-0.36	-5.2	-0.3	4.02e-7	Red blood cell count;
CESC	cis	rs875971	0.929	rs4122249	chr7:65920936	T/C	cg18876405	chr7:65276391	NA	0.51	6.85	0.39	5.1e-11	Aortic root size;
CESC	cis	rs9611565	0.722	rs202635	chr22:41809637	C/T	cg17376030	chr22:41985996	PMM1	-0.59	-6.24	-0.36	1.69e-9	Vitiligo;
CESC	cis	rs13108904	0.901	rs4493484	chr4:1279944	G/A	cg00684032	chr4:1343700	KIAA1530	0.39	5.43	0.32	1.27e-7	Obesity-related traits;
CESC	cis	rs703842	1.000	rs11172343	chr12:58188157	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.71	8.96	0.48	5.78e-17	Multiple sclerosis;
CESC	cis	rs4665809	0.590	rs7588328	chr2:26469788	G/A	cg04944784	chr2:26401820	FAM59B	0.96	10.5	0.54	8.76e-22	Gut microbiome composition (summer);
CESC	trans	rs11098499	0.865	rs4001305	chr4:120359236	G/T	cg25214090	chr10:38739885	LOC399744	0.71	10.05	0.53	2.33e-20	Corneal astigmatism;
CESC	cis	rs11997175	0.766	rs6995220	chr8:33708919	C/A	ch.8.33884649F	chr8:33765107	NA	0.44	5.64	0.33	4.37e-8	Body mass index;
CESC	cis	rs3862435	0.572	rs2601165	chr15:90908934	C/G	cg22089800	chr15:90895588	ZNF774	-0.47	-5.04	-0.3	8.55e-7	Response to exercise (triglyceride level interaction);
CESC	cis	rs10504229	1.000	rs66840104	chr8:58190001	C/T	cg24829409	chr8:58192753	C8orf71	-0.76	-9.93	-0.52	5.87e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs9443645	0.527	rs9350792	chr6:79587173	A/G	cg05283184	chr6:79620031	NA	-0.37	-5.2	-0.3	4.08e-7	Intelligence (multi-trait analysis);
CESC	cis	rs959260	0.925	rs4788890	chr17:73389446	A/G	cg20590849	chr17:73267439	MIF4GD	-0.57	-6.41	-0.37	6.55e-10	Systemic lupus erythematosus;
CESC	cis	rs3768617	0.510	rs1886499	chr1:183095024	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.89	14.39	0.66	4.39e-35	Fuchs's corneal dystrophy;
CESC	cis	rs763512	0.532	rs1416	chr17:35894811	T/C	cg16670864	chr17:35848621	DUSP14	0.43	5.2	0.3	4.03e-7	3-hydroxypropylmercapturic acid levels in smokers;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg25804860	chr16:47178250	NETO2	0.45	6.29	0.36	1.31e-9	Systemic lupus erythematosus;
CESC	cis	rs9303401	0.659	rs35828828	chr17:56718205	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.04	12.96	0.62	4.37e-30	Cognitive test performance;
CESC	cis	rs7818688	0.585	rs2599715	chr8:96046493	G/C	cg16049864	chr8:95962084	TP53INP1	-0.46	-5.25	-0.31	3.16e-7	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs763121	0.744	rs5757140	chr22:38957013	T/C	cg06022373	chr22:39101656	GTPBP1	0.82	11.72	0.58	8.04e-26	Menopause (age at onset);
CESC	cis	rs60871478	1.000	rs6460801	chr7:810506	T/C	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.54	5.34	0.31	1.98e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs12893597	0.715	rs12896100	chr14:76825064	C/T	cg20290672	chr14:76816747	NA	-0.42	-5.88	-0.34	1.21e-8	Maximal oxygen uptake response;
CESC	cis	rs11112613	0.713	rs55646142	chr12:105949557	G/A	cg03607813	chr12:105948248	NA	0.67	8.31	0.45	5.16e-15	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CESC	cis	rs9902453	0.845	rs62068583	chr17:28001482	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.68	8.78	0.47	2.13e-16	Coffee consumption (cups per day);
CESC	cis	rs734999	0.524	rs4648448	chr1:2695687	C/T	cg18854424	chr1:2615690	NA	0.3	5.76	0.33	2.28e-8	Ulcerative colitis;
CESC	cis	rs16854884	0.632	rs4535221	chr3:143658607	A/G	cg01302019	chr3:143689584	C3orf58	-0.34	-5.08	-0.3	7.26e-7	Economic and political preferences (feminism/equality);
CESC	trans	rs2727020	0.521	rs7126835	chr11:49594658	T/C	cg15704280	chr7:45808275	SEPT13	-0.87	-10.71	-0.55	1.73e-22	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23594427	chr12:56367798	RAB5B	-0.57	-6.91	-0.39	3.68e-11	Gut microbiome composition (summer);
CESC	cis	rs11785693	0.862	rs11786186	chr8:4999059	G/C	cg26367366	chr8:4980734	NA	0.84	7.89	0.44	7.8e-14	Neuroticism (multi-trait analysis);Neuroticism;
CESC	cis	rs736408	0.509	rs3774349	chr3:52722335	A/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.34	-5.08	-0.3	7.02e-7	Bipolar disorder;
CESC	cis	rs3785574	0.962	rs2665799	chr17:61919723	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	7.28	0.41	3.85e-12	Height;
CESC	cis	rs9649213	0.593	rs7776638	chr7:97993506	C/T	cg24562669	chr7:97807699	LMTK2	0.51	7.63	0.42	4.29e-13	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs4727027	0.870	rs13237714	chr7:148884083	A/G	cg23583168	chr7:148888333	NA	-0.82	-12.56	-0.61	1.03e-28	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs7666738	0.800	rs2865987	chr4:99067852	A/C	cg05340658	chr4:99064831	C4orf37	0.86	13.1	0.63	1.39e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs66887589	0.592	rs28580295	chr4:120278873	C/T	cg09307838	chr4:120376055	NA	0.66	9.21	0.49	1.05e-17	Diastolic blood pressure;
CESC	cis	rs514406	0.858	rs574853	chr1:53310959	A/T	cg08859206	chr1:53392774	SCP2	-0.66	-8.98	-0.48	5.34e-17	Monocyte count;
CESC	cis	rs514406	0.505	rs395169	chr1:53174071	G/A	cg08859206	chr1:53392774	SCP2	-0.58	-7.68	-0.43	3.09e-13	Monocyte count;
CESC	cis	rs4665809	0.590	rs6749046	chr2:26429451	C/G	cg27170947	chr2:26402098	FAM59B	0.84	9.95	0.52	4.86e-20	Gut microbiome composition (summer);
CESC	cis	rs2455799	0.613	rs13096622	chr3:15837656	A/G	cg16303742	chr3:15540471	COLQ	-0.39	-6.08	-0.35	4.27e-9	Mean platelet volume;
CESC	cis	rs34779708	0.702	rs7087150	chr10:35542138	A/T	cg03585969	chr10:35415529	CREM	0.56	6.42	0.37	6.15e-10	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs6831352	0.693	rs2602875	chr4:100039495	C/G	cg12011299	chr4:100065546	ADH4	0.57	6.88	0.39	4.34e-11	Alcohol dependence;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15921012	chr3:15919793	NA	-0.7	-8.38	-0.46	3.06e-15	Gut microbiome composition (summer);
CESC	cis	rs8103278	1.000	rs8109951	chr19:46289503	C/T	cg12641515	chr19:46296257	DMWD	-0.51	-5.83	-0.34	1.6e-8	Coronary artery disease;
CESC	cis	rs4434138	0.664	rs62255364	chr3:52701502	C/T	cg18404041	chr3:52824283	ITIH1	-0.39	-6.58	-0.37	2.56e-10	Intelligence (multi-trait analysis);
CESC	cis	rs4819052	1.000	rs13047688	chr21:46669290	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.55	6.62	0.38	1.99e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg15229027	chr14:64805542	ESR2	0.49	6.21	0.36	2.08e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs7246865	0.510	rs1130222	chr19:17170885	C/T	cg16202187	chr19:17186497	HAUS8;MYO9B	0.48	6.26	0.36	1.56e-9	Reticulocyte fraction of red cells;
CESC	cis	rs3820068	0.608	rs7519899	chr1:16045579	A/G	cg17385448	chr1:15911702	AGMAT	0.37	5.75	0.33	2.45e-8	Systolic blood pressure;
CESC	cis	rs7216064	1.000	rs7212293	chr17:65847325	A/G	cg12091567	chr17:66097778	LOC651250	-0.78	-9.2	-0.49	1.08e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs7772486	0.790	rs9497427	chr6:146238302	T/A	cg23711669	chr6:146136114	FBXO30	-0.82	-11.64	-0.58	1.47e-25	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1707322	1.000	rs12133129	chr1:46373348	C/T	cg06784218	chr1:46089804	CCDC17	0.32	5.57	0.32	6.35e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7582720	1.000	rs72936309	chr2:204040296	G/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	6.87	0.39	4.55e-11	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs514406	0.893	rs522287	chr1:53365493	C/T	cg16325326	chr1:53192061	ZYG11B	0.82	12.71	0.62	3.3e-29	Monocyte count;
CESC	cis	rs9649213	0.574	rs12873	chr7:97922773	T/C	cg08684580	chr7:98029266	BAIAP2L1	-0.34	-5.43	-0.32	1.28e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs12928939	0.517	rs11865456	chr16:71969497	C/T	cg03805757	chr16:71968109	PKD1L3	-0.56	-6.37	-0.36	8.44e-10	Post bronchodilator FEV1;
CESC	cis	rs9811920	0.609	rs4244713	chr3:99679584	T/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.64	-10.1	-0.53	1.62e-20	Axial length;
CESC	cis	rs6088580	0.634	rs62212172	chr20:32987705	G/A	cg06115741	chr20:33292138	TP53INP2	-0.47	-6.14	-0.35	3.06e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs736408	0.609	rs13082208	chr3:52781539	T/G	cg17372223	chr3:52568218	NT5DC2	0.43	6.46	0.37	5.04e-10	Bipolar disorder;
CESC	cis	rs9916302	0.861	rs3889368	chr17:37683231	C/T	cg20243544	chr17:37824526	PNMT	0.48	6.04	0.35	5.25e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs9359856	0.510	rs17294495	chr6:90445753	T/G	cg13799429	chr6:90582589	CASP8AP2	-0.7	-7.8	-0.43	1.46e-13	Bipolar disorder;
CESC	cis	rs57506017	0.585	rs7792410	chr7:12267614	A/G	cg23422036	chr7:12250390	TMEM106B	0.4	5.43	0.32	1.26e-7	Neuroticism;
CESC	cis	rs11122272	0.735	rs2474625	chr1:231519331	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.57	-7.82	-0.43	1.29e-13	Hemoglobin concentration;
CESC	cis	rs35306767	0.903	rs11253495	chr10:937064	C/T	cg26597838	chr10:835615	NA	0.9	9.68	0.51	3.52e-19	Eosinophil percentage of granulocytes;
CESC	cis	rs796364	0.755	rs203762	chr2:200905136	C/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.84	-7.75	-0.43	1.94e-13	Schizophrenia;
CESC	cis	rs9811920	0.535	rs704572	chr3:99482314	G/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.33	-5.29	-0.31	2.59e-7	Axial length;
CESC	trans	rs3942852	0.568	rs10769313	chr11:48097466	A/G	cg03929089	chr4:120376271	NA	-0.63	-7.77	-0.43	1.78e-13	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs892961	0.932	rs3987885	chr17:75414990	A/G	cg05865280	chr17:75406074	SEPT9	0.62	12.5	0.61	1.7e-28	Airflow obstruction;
CESC	cis	rs9818941	0.824	rs1123115	chr3:157813401	C/T	cg08654915	chr3:157813417	NA	0.5	7.92	0.44	6.5e-14	Height;
CESC	cis	rs10754283	0.967	rs10801763	chr1:90120822	C/T	cg21401794	chr1:90099060	LRRC8C	0.66	8.77	0.47	2.18e-16	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs6089584	0.566	rs2181589	chr20:60622817	C/T	cg24733560	chr20:60626293	TAF4	-0.5	-7.45	-0.42	1.31e-12	Body mass index;
CESC	cis	rs7943191	0.768	rs34065644	chr11:62371938	C/T	cg13298116	chr11:62369859	EML3;MTA2	0.55	7.51	0.42	9.28e-13	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
CESC	trans	rs1814175	0.817	rs7109440	chr11:49966296	C/T	cg03929089	chr4:120376271	NA	-0.93	-15.75	-0.7	6.66e-40	Height;
CESC	cis	rs11608355	0.515	rs11609630	chr12:109918934	C/T	cg05360138	chr12:110035743	NA	0.81	8.75	0.47	2.52e-16	Neuroticism;
CESC	cis	rs7843479	1.000	rs10503715	chr8:21850687	G/A	cg17168535	chr8:21777572	XPO7	0.48	6.74	0.38	9.97e-11	Mean corpuscular volume;
CESC	cis	rs12142240	0.738	rs41293275	chr1:46806429	A/T	cg00530320	chr1:46809349	NSUN4	0.59	7.85	0.43	1.02e-13	Menopause (age at onset);
CESC	cis	rs9322193	0.962	rs4869730	chr6:150129323	A/G	cg04369109	chr6:150039330	LATS1	-0.41	-5.54	-0.32	7.16e-8	Lung cancer;
CESC	cis	rs933688	1.000	rs10474353	chr5:90732285	A/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.13	14.43	0.66	3.18e-35	Smoking behavior;
CESC	cis	rs1577917	0.771	rs4145082	chr6:86352016	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.52	-6.89	-0.39	3.97e-11	Response to antipsychotic treatment;
CESC	cis	rs7116495	1.000	rs4944258	chr11:71743393	T/A	cg10381502	chr11:71823885	C11orf51	-0.68	-5.65	-0.33	4.05e-8	Severe influenza A (H1N1) infection;
CESC	trans	rs11098499	0.863	rs28718422	chr4:120466304	C/A	cg25214090	chr10:38739885	LOC399744	0.67	9.21	0.49	1.05e-17	Corneal astigmatism;
CESC	cis	rs6951245	0.608	rs10252234	chr7:1114381	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.41	-5.43	-0.32	1.29e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7301826	0.651	rs7968675	chr12:131303377	C/T	cg11011512	chr12:131303247	STX2	0.44	5.4	0.31	1.48e-7	Plasma plasminogen activator levels;
CESC	cis	rs1371867	0.875	rs1660320	chr8:101337579	A/C	cg11906718	chr8:101322791	RNF19A	0.47	6.03	0.35	5.36e-9	Atrioventricular conduction;
CESC	cis	rs13118159	0.742	rs7679860	chr4:1333987	C/T	cg05025164	chr4:1340916	KIAA1530	0.64	8.68	0.47	4.15e-16	Longevity;
CESC	cis	rs4604732	0.631	rs60311891	chr1:247623127	C/T	cg12758973	chr1:247694275	LOC148824;OR2C3	0.5	6.29	0.36	1.31e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs1790761	0.554	rs12787511	chr11:67401635	G/C	cg14500267	chr11:67383377	NA	-0.34	-5.14	-0.3	5.33e-7	Mean corpuscular volume;
CESC	cis	rs2576037	0.583	rs1970668	chr18:44523220	A/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.32	5.09	0.3	6.92e-7	Personality dimensions;
CESC	cis	rs8072100	0.967	rs4580230	chr17:45738861	G/A	cg08085267	chr17:45401833	C17orf57	-0.43	-5.75	-0.33	2.45e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs9815354	0.953	rs6795797	chr3:41862250	A/G	cg03022575	chr3:42003672	ULK4	0.45	5.15	0.3	5.19e-7	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs7818688	0.929	rs28419772	chr8:96021436	A/T	cg16049864	chr8:95962084	TP53INP1	0.61	5.74	0.33	2.62e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs1832871	0.711	rs9459924	chr6:158703902	G/A	cg07165851	chr6:158734300	TULP4	0.61	6.52	0.37	3.57e-10	Height;
CESC	cis	rs1670533	1.000	rs1670533	chr4:1078187	G/A	cg27284194	chr4:1044797	NA	0.47	5.91	0.34	1.04e-8	Recombination rate (females);
CESC	cis	rs1008375	1.000	rs4698634	chr4:17630192	A/C	cg15017067	chr4:17643749	FAM184B	-0.37	-5.45	-0.32	1.13e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs10504229	0.906	rs7006539	chr8:58178799	A/T	cg14926445	chr8:58193284	C8orf71	-0.54	-5.78	-0.33	2.1e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs4713118	0.616	rs9348789	chr6:28025486	C/T	cg26335602	chr6:28129616	ZNF389	0.44	5.61	0.33	5.19e-8	Parkinson's disease;
CESC	cis	rs9320282	0.587	rs1546721	chr6:109625796	T/C	cg01475377	chr6:109611718	NA	-0.34	-5.23	-0.31	3.46e-7	White blood cell count (basophil);Basophil percentage of white cells;
CESC	cis	rs2629540	0.847	rs12247543	chr10:126419743	G/C	cg08799069	chr10:126477246	METTL10	0.63	8.2	0.45	1.06e-14	Cocaine dependence;
CESC	cis	rs2991971	0.716	rs7532573	chr1:45915892	A/T	cg15605315	chr1:45957053	TESK2	-0.39	-5.32	-0.31	2.25e-7	High light scatter reticulocyte count;
CESC	cis	rs8050907	0.744	rs17879291	chr16:4526104	C/T	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.9	6.28	0.36	1.39e-9	Obesity-related traits;
CESC	cis	rs8177179	0.967	rs4078166	chr3:133435979	C/A	cg16262614	chr3:133464971	TF	0.42	8.35	0.46	3.82e-15	Iron status biomarkers (transferrin levels);
CESC	cis	rs6964587	1.000	rs28410528	chr7:91647390	A/G	cg17063962	chr7:91808500	NA	0.58	8.02	0.44	3.36e-14	Breast cancer;
CESC	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg10862848	chr6:42927986	GNMT	-0.27	-6.48	-0.37	4.36e-10	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs2576037	0.583	rs541634	chr18:44420271	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.51	-7.04	-0.4	1.68e-11	Personality dimensions;
CESC	cis	rs7584330	0.780	rs2292884	chr2:238443226	A/G	cg06639874	chr2:238417703	MLPH	-0.39	-5.32	-0.31	2.24e-7	Prostate cancer;
CESC	cis	rs2073300	0.609	rs6137915	chr20:23358509	A/G	cg16736954	chr20:23401023	NAPB	-0.78	-5.96	-0.34	7.85e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs6687430	0.532	rs4846235	chr1:10632235	C/T	cg20482658	chr1:10539492	PEX14	0.39	7.96	0.44	5e-14	Hand grip strength;
CESC	cis	rs7116495	0.609	rs73531955	chr11:71687794	A/C	cg07596299	chr11:71824057	C11orf51	0.82	5.24	0.31	3.32e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs801193	0.569	rs4717315	chr7:66178325	C/T	cg12463550	chr7:65579703	CRCP	0.49	6.33	0.36	1.03e-9	Aortic root size;
CESC	cis	rs72634258	0.740	rs6665452	chr1:8172492	A/T	cg00042356	chr1:8021962	PARK7	-0.48	-5.26	-0.31	2.94e-7	Inflammatory bowel disease;
CESC	cis	rs10504229	0.683	rs56204590	chr8:58131642	T/G	cg21724239	chr8:58056113	NA	0.58	5.95	0.34	8.29e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs965469	0.779	rs6139071	chr20:3299054	A/G	cg17110299	chr20:3385021	C20orf194	0.38	5.19	0.3	4.17e-7	IFN-related cytopenia;
CESC	cis	rs1005277	0.522	rs1208681	chr10:38092975	C/T	cg25427524	chr10:38739819	LOC399744	-0.64	-9.79	-0.52	1.61e-19	Extrinsic epigenetic age acceleration;
CESC	cis	rs875971	0.862	rs11773628	chr7:65982631	G/T	cg11764359	chr7:65958608	NA	-0.81	-11.72	-0.58	8.04e-26	Aortic root size;
CESC	cis	rs12618769	0.625	rs61180742	chr2:99148078	A/G	cg10123293	chr2:99228465	UNC50	0.39	5.17	0.3	4.62e-7	Bipolar disorder;
CESC	cis	rs17021463	0.934	rs28403447	chr4:95257753	G/A	cg11021082	chr4:95130006	SMARCAD1	0.53	7.99	0.44	4.23e-14	Testicular germ cell tumor;
CESC	cis	rs1144333	0.655	rs11162053	chr1:76470267	A/C	cg10523679	chr1:76189770	ACADM	0.58	5.36	0.31	1.84e-7	Attention function in attention deficit hyperactive disorder;
CESC	cis	rs2204008	0.775	rs11514369	chr12:38305411	C/T	cg26384229	chr12:38710491	ALG10B	0.7	10.34	0.54	2.92e-21	Bladder cancer;
CESC	cis	rs9611565	0.559	rs8139993	chr22:41995335	T/C	cg06634786	chr22:41940651	POLR3H	-0.55	-6.04	-0.35	5.06e-9	Vitiligo;
CESC	cis	rs4555082	0.874	rs2735828	chr14:105710486	C/A	cg27165867	chr14:105738592	BRF1	-0.53	-6.04	-0.35	5.29e-9	Mean platelet volume;Platelet distribution width;
CESC	cis	rs1862618	0.853	rs252922	chr5:56136343	G/T	cg03609598	chr5:56110824	MAP3K1	-0.52	-5.61	-0.33	5.04e-8	Initial pursuit acceleration;
CESC	cis	rs4141404	0.651	rs5753723	chr22:32002294	T/C	cg13145458	chr22:31556086	RNF185	0.55	5.44	0.32	1.19e-7	Paclitaxel-induced neuropathy;
CESC	cis	rs8072100	0.748	rs9912592	chr17:45556945	G/A	cg25173405	chr17:45401733	C17orf57	-0.47	-6.15	-0.35	2.91e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg03188948	chr7:1209495	NA	0.7	6.71	0.38	1.2e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs4862750	0.914	rs9998558	chr4:187874691	A/G	cg07414643	chr4:187882934	NA	0.54	7.78	0.43	1.65e-13	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7772486	0.875	rs1331637	chr6:146337087	T/C	cg23711669	chr6:146136114	FBXO30	0.86	12.53	0.61	1.39e-28	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs6073597	1.000	rs6031980	chr20:43714384	C/T	cg01640215	chr16:21312637	CRYM;NCRNA00169	0.46	6.14	0.35	3.06e-9	Positive affect;
CESC	cis	rs7412746	0.658	rs11581757	chr1:150892244	A/G	cg04414720	chr1:150670196	GOLPH3L	0.5	6.57	0.37	2.71e-10	Melanoma;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10117958	chr1:161719605	DUSP12	0.55	6.05	0.35	4.98e-9	Gut microbiome composition (summer);
CESC	cis	rs7647973	0.667	rs4241405	chr3:49642027	C/T	cg13072238	chr3:49761600	GMPPB	-0.51	-5.98	-0.35	7.05e-9	Menarche (age at onset);
CESC	cis	rs3106136	0.609	rs4693000	chr4:95107657	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.46	-6.29	-0.36	1.34e-9	Capecitabine sensitivity;
CESC	cis	rs12142240	0.698	rs6659228	chr1:46811027	C/G	cg00530320	chr1:46809349	NSUN4	0.57	7.77	0.43	1.78e-13	Menopause (age at onset);
CESC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg07628558	chr20:56964831	VAPB	-0.56	-6.23	-0.36	1.85e-9	Lung cancer in ever smokers;
CESC	cis	rs1799949	0.965	rs9646418	chr17:41425901	A/G	cg23758822	chr17:41437982	NA	1.03	18.97	0.76	2.72e-51	Menopause (age at onset);
CESC	cis	rs1707322	1.000	rs6687301	chr1:46382852	T/C	cg06784218	chr1:46089804	CCDC17	0.32	5.5	0.32	8.73e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2070433	0.800	rs11700596	chr21:47874054	G/C	cg12379764	chr21:47803548	PCNT	0.66	7.47	0.42	1.13e-12	Lymphocyte counts;
CESC	cis	rs9747201	1.000	rs58119191	chr17:80155329	T/C	cg09264619	chr17:80180166	NA	-0.42	-5.05	-0.3	8.04e-7	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs7786808	0.712	rs2335170	chr7:158207101	G/A	cg09998033	chr7:158218633	PTPRN2	-0.4	-5.73	-0.33	2.77e-8	Obesity-related traits;
CESC	cis	rs2354432	0.607	rs3820130	chr1:146724003	A/G	cg25205988	chr1:146714368	CHD1L	-0.93	-8.41	-0.46	2.49e-15	Mitochondrial DNA levels;
CESC	cis	rs769267	0.965	rs7254230	chr19:19434350	C/T	cg15052019	chr19:19431593	KIAA0892;SF4	-0.42	-5.39	-0.31	1.53e-7	Tonsillectomy;
CESC	cis	rs9291683	0.509	rs10939671	chr4:10050815	T/C	cg11266682	chr4:10021025	SLC2A9	0.64	12.48	0.61	1.98e-28	Bone mineral density;
CESC	cis	rs2235642	0.826	rs8053605	chr16:1594158	G/A	cg03771183	chr16:1608904	IFT140	0.41	5.9	0.34	1.08e-8	Coronary artery disease;
CESC	trans	rs11098499	0.909	rs7681978	chr4:120383775	T/C	cg25214090	chr10:38739885	LOC399744	0.69	9.79	0.52	1.58e-19	Corneal astigmatism;
CESC	cis	rs8016982	0.674	rs3815953	chr14:81685482	G/A	cg01989461	chr14:81687754	GTF2A1	0.74	11.59	0.58	2.13e-25	Schizophrenia;
CESC	cis	rs9584850	0.794	rs9630321	chr13:99106979	C/G	cg22223119	chr13:99095684	FARP1	-0.36	-5.15	-0.3	5.06e-7	Neuroticism;
CESC	cis	rs7618915	0.547	rs11709448	chr3:52647449	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.48	6.81	0.39	6.37e-11	Bipolar disorder;
CESC	cis	rs1552244	1.000	rs12152512	chr3:10143770	C/T	cg00149659	chr3:10157352	C3orf10	0.73	9.16	0.49	1.43e-17	Alzheimer's disease;
CESC	cis	rs7103648	0.545	rs6485795	chr11:47929846	G/A	cg10504702	chr11:47789108	FNBP4	0.44	5.52	0.32	7.99e-8	Diastolic blood pressure;Systolic blood pressure;
CESC	cis	rs10845606	1.000	rs10845609	chr12:12838920	T/A	cg09462578	chr12:12878428	APOLD1	-0.66	-7.19	-0.4	6.75e-12	Systemic lupus erythematosus;
CESC	cis	rs3785574	0.962	rs57553639	chr17:61848499	C/T	cg06420487	chr17:61919686	SMARCD2	0.46	5.52	0.32	8.05e-8	Height;
CESC	cis	rs9640161	0.789	rs10282458	chr7:150045302	C/T	cg10018233	chr7:150070692	REPIN1	0.38	5.65	0.33	4.24e-8	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs72781680	0.898	rs72788302	chr2:24107246	C/T	cg08917208	chr2:24149416	ATAD2B	1.11	10.18	0.53	9.57e-21	Lymphocyte counts;
CESC	cis	rs10781543	0.839	rs7863766	chr9:139381314	T/G	cg14169450	chr9:139327907	INPP5E	0.51	7.83	0.43	1.18e-13	Monocyte percentage of white cells;
CESC	cis	rs7264396	0.676	rs6058383	chr20:34556005	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.52	6.2	0.36	2.18e-9	Total cholesterol levels;
CESC	trans	rs7618501	0.902	rs7645061	chr3:49868842	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.59	8.32	0.46	4.72e-15	Intelligence (multi-trait analysis);
CESC	trans	rs9354308	0.899	rs1938059	chr6:66539291	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.6	6.66	0.38	1.6e-10	Metabolite levels;
CESC	cis	rs2228479	0.850	rs62054224	chr16:89892071	C/T	cg06558623	chr16:89946397	TCF25	1.04	7.85	0.43	1.03e-13	Skin colour saturation;
CESC	cis	rs13255475	0.772	rs4545141	chr8:121498963	T/C	cg05978010	chr8:121408224	MRPL13	-0.36	-5.62	-0.33	4.89e-8	Cerebrospinal T-tau levels;Cerebrospinal P-tau181p levels;
CESC	cis	rs11122272	0.706	rs2749710	chr1:231535112	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.6	8.23	0.45	8.79e-15	Hemoglobin concentration;
CESC	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg23131131	chr22:24373011	LOC391322	-0.67	-8.99	-0.48	4.67e-17	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs1552244	0.872	rs6771931	chr3:10113408	C/G	cg00149659	chr3:10157352	C3orf10	0.7	8.38	0.46	3.2e-15	Alzheimer's disease;
CESC	cis	rs1707322	1.000	rs11211219	chr1:46359478	G/C	cg05343316	chr1:45956843	TESK2	0.44	5.55	0.32	7.05e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs8111998	0.826	rs60316370	chr19:22764743	T/C	cg19914732	chr19:22715077	NA	-0.37	-5.09	-0.3	6.68e-7	Corneal structure;
CESC	cis	rs12472274	0.646	rs11677736	chr2:239087198	A/T	cg17459225	chr2:239074497	NA	0.47	5.67	0.33	3.7e-8	Phospholipid levels (plasma);
CESC	cis	rs7666738	0.830	rs1124253	chr4:98949682	C/T	cg17366294	chr4:99064904	C4orf37	0.59	8.52	0.46	1.24e-15	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03658244	chr18:32621088	MAPRE2	-0.52	-6.27	-0.36	1.44e-9	Gut microbiome composition (summer);
CESC	cis	rs1005277	0.579	rs1780138	chr10:38501654	A/G	cg25517755	chr10:38738941	LOC399744	-0.44	-5.7	-0.33	3.12e-8	Extrinsic epigenetic age acceleration;
CESC	cis	rs14403	0.874	rs3006924	chr1:243650986	G/C	cg21452805	chr1:244014465	NA	0.46	5.27	0.31	2.89e-7	Schizophrenia;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg18105612	chr14:71289522	NA	-0.48	-6.23	-0.36	1.85e-9	Ulcerative colitis;
CESC	cis	rs7666738	0.830	rs17550630	chr4:99008332	G/T	cg18180107	chr4:99064573	C4orf37	0.4	5.23	0.31	3.41e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3015497	0.603	rs2934675	chr14:51082217	C/T	cg26011998	chr14:51135199	SAV1	-0.46	-5.16	-0.3	4.91e-7	Mean platelet volume;
CESC	cis	rs2479106	0.591	rs4836939	chr9:126403866	G/A	cg16191174	chr9:126692580	DENND1A	0.39	5.28	0.31	2.65e-7	Polycystic ovary syndrome;
CESC	cis	rs12477438	0.765	rs6749059	chr2:99591021	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.73	-10.99	-0.56	2.08e-23	Chronic sinus infection;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg12460765	chr7:2415105	EIF3B	0.48	7.01	0.4	1.99e-11	Fibrinogen levels;
CESC	cis	rs2645424	0.666	rs2272767	chr8:11711059	C/T	cg21281001	chr8:11725306	CTSB	0.56	6.8	0.39	6.99e-11	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);
CESC	cis	rs1799949	1.000	rs4340367	chr17:41307772	G/A	cg25072359	chr17:41440525	NA	0.44	5.88	0.34	1.23e-8	Menopause (age at onset);
CESC	cis	rs11997175	0.624	rs4526317	chr8:33682936	T/A	ch.8.33884649F	chr8:33765107	NA	0.57	7.29	0.41	3.65e-12	Body mass index;
CESC	cis	rs7582720	1.000	rs72934753	chr2:203750272	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.39	0.41	1.96e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs7618915	0.501	rs3774366	chr3:52641255	T/C	cg05564831	chr3:52568323	NT5DC2	0.47	7.48	0.42	1.12e-12	Bipolar disorder;
CESC	cis	rs4472734	0.830	rs12736454	chr1:214629641	G/A	cg00063699	chr1:214624242	PTPN14	-0.34	-5.12	-0.3	5.78e-7	Height;
CESC	cis	rs8031584	0.736	rs11635775	chr15:31160640	A/G	cg14829155	chr15:31115871	NA	-0.73	-9.94	-0.52	5.42e-20	Huntington's disease progression;
CESC	cis	rs1538970	0.962	rs2487442	chr1:45857176	C/G	cg06784218	chr1:46089804	CCDC17	-0.3	-5.11	-0.3	6.1e-7	Platelet count;
CESC	cis	rs17539620	0.624	rs871068	chr6:154837514	C/A	cg20019720	chr6:154832845	CNKSR3	0.47	6.13	0.35	3.21e-9	Lipoprotein (a) levels;
CESC	cis	rs4450131	0.522	rs3781460	chr10:126342919	A/G	cg20435097	chr10:126320824	FAM53B	-0.28	-5.12	-0.3	5.82e-7	White blood cell count (basophil);
CESC	cis	rs6540556	0.724	rs6679631	chr1:209935491	C/A	cg23920097	chr1:209922102	NA	-0.37	-5.59	-0.32	5.64e-8	Red blood cell count;
CESC	cis	rs10504229	0.679	rs4738574	chr8:58033771	T/C	cg22535103	chr8:58192502	C8orf71	-0.61	-6.86	-0.39	4.87e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs2180341	0.695	rs6569487	chr6:127726196	C/T	cg27446573	chr6:127587934	RNF146	-0.72	-10.51	-0.54	8.07e-22	Breast cancer;
CESC	cis	rs3125734	0.571	rs7100401	chr10:64024417	C/G	cg09941381	chr10:64027924	RTKN2	-0.32	-5.21	-0.3	3.89e-7	Rheumatoid arthritis;
CESC	cis	rs2204008	0.775	rs3900361	chr12:38238936	A/G	cg26384229	chr12:38710491	ALG10B	-0.66	-9.24	-0.49	8.25e-18	Bladder cancer;
CESC	cis	rs731174	0.959	rs7527344	chr1:38191560	C/A	cg06917450	chr1:38156652	C1orf109	-0.44	-5.45	-0.32	1.17e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7267979	0.816	rs390123	chr20:25480105	C/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.78	14.46	0.66	2.44e-35	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs9457247	0.534	rs12055488	chr6:167379570	A/G	cg25258033	chr6:167368657	RNASET2	-0.39	-5.7	-0.33	3.21e-8	Crohn's disease;
CESC	cis	rs35306767	0.903	rs17159950	chr10:875287	T/G	cg20503657	chr10:835505	NA	0.83	8.19	0.45	1.1e-14	Eosinophil percentage of granulocytes;
CESC	trans	rs11098499	0.954	rs11098526	chr4:120390359	C/T	cg25214090	chr10:38739885	LOC399744	0.72	10.22	0.53	7.13e-21	Corneal astigmatism;
CESC	cis	rs926938	0.527	rs7526844	chr1:115543759	T/C	cg12756093	chr1:115239321	AMPD1	0.44	6.13	0.35	3.24e-9	Autism;
CESC	cis	rs2294693	0.945	rs742494	chr6:41007835	A/T	cg14418226	chr6:40996092	UNC5CL	0.52	5.98	0.34	7.18e-9	Gastric cancer;Non-cardia gastric cancer;
CESC	cis	rs60871478	1.000	rs12531530	chr7:827366	T/C	cg15782153	chr7:917662	C7orf20	-0.47	-5.07	-0.3	7.57e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs7412746	0.611	rs10888394	chr1:150749913	C/T	cg04414720	chr1:150670196	GOLPH3L	0.58	7.55	0.42	7.07e-13	Melanoma;
CESC	cis	rs1707322	0.721	rs12091503	chr1:46107868	T/C	cg06784218	chr1:46089804	CCDC17	0.42	7.35	0.41	2.41e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2066819	1.000	rs75265219	chr12:56640341	G/A	cg26734620	chr12:56694298	CS	1.04	6.73	0.38	1.06e-10	Psoriasis vulgaris;
CESC	cis	rs1046896	0.553	rs3744160	chr17:80828303	G/A	cg19046167	chr17:80928561	B3GNTL1	0.48	5.85	0.34	1.43e-8	Glycated hemoglobin levels;
CESC	cis	rs17401966	0.838	rs6541089	chr1:10402785	A/G	cg15208524	chr1:10270712	KIF1B	0.4	5.12	0.3	5.76e-7	Hepatocellular carcinoma;
CESC	cis	rs3749237	0.595	rs7643845	chr3:49530711	A/G	cg07636037	chr3:49044803	WDR6	0.61	8.81	0.48	1.66e-16	Resting heart rate;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02602601	chr12:56618057	OBFC2B	0.57	6.67	0.38	1.45e-10	Gut microbiome composition (summer);
CESC	cis	rs854765	0.583	rs7213225	chr17:17869111	T/C	cg16928487	chr17:17741425	SREBF1	-0.57	-9.55	-0.51	9.29e-19	Total body bone mineral density;
CESC	cis	rs909674	0.818	rs5750830	chr22:39840828	C/A	cg24399712	chr22:39784796	NA	-0.82	-10.17	-0.53	1.01e-20	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs416603	0.967	rs7191538	chr16:11363389	C/G	cg00044050	chr16:11439710	C16orf75	-0.42	-5.18	-0.3	4.31e-7	Type 1 diabetes;
CESC	cis	rs1552244	0.872	rs6771931	chr3:10113408	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	12.09	0.6	4.37e-27	Alzheimer's disease;
CESC	cis	rs12497850	0.931	rs3774628	chr3:48801840	C/T	cg03060546	chr3:49711283	APEH	0.42	5.28	0.31	2.73e-7	Parkinson's disease;
CESC	cis	rs6987853	0.563	rs2974302	chr8:42443119	C/G	cg09913449	chr8:42400586	C8orf40	0.33	5.12	0.3	5.91e-7	Mean corpuscular hemoglobin concentration;
CESC	cis	rs1799949	0.965	rs4793204	chr17:41279298	A/G	cg25072359	chr17:41440525	NA	0.43	5.78	0.33	2.04e-8	Menopause (age at onset);
CESC	cis	rs909674	0.524	rs5757670	chr22:39829736	G/A	cg11247378	chr22:39784982	NA	-0.62	-9.14	-0.49	1.74e-17	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs2228479	0.718	rs11645376	chr16:89912281	G/C	cg14709524	chr16:89940631	TCF25	0.88	6.1	0.35	3.82e-9	Skin colour saturation;
CESC	cis	rs9611565	0.729	rs137831	chr22:41903813	A/C	cg03806693	chr22:41940476	POLR3H	-0.89	-11.57	-0.58	2.44e-25	Vitiligo;
CESC	cis	rs12155623	0.619	rs17641604	chr8:49842784	C/T	cg00325661	chr8:49890786	NA	0.41	5.78	0.33	2.05e-8	Sudden cardiac arrest;
CESC	cis	rs6570726	0.935	rs454614	chr6:145832633	C/T	cg05347473	chr6:146136440	FBXO30	0.49	6.69	0.38	1.3100000000000001e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2204008	0.744	rs2222344	chr12:38406832	T/G	cg13010199	chr12:38710504	ALG10B	0.45	5.86	0.34	1.39e-8	Bladder cancer;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg25631650	chr19:633157	POLRMT	0.51	6.55	0.37	2.96e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs9303280	0.936	rs12950209	chr17:38049102	T/C	cg20243544	chr17:37824526	PNMT	0.52	6.93	0.39	3.13e-11	Self-reported allergy;
CESC	cis	rs72781680	1.000	rs61739076	chr2:24149439	G/A	cg08917208	chr2:24149416	ATAD2B	1.1	9.84	0.52	1.09e-19	Lymphocyte counts;
CESC	cis	rs6088580	0.634	rs3736762	chr20:33037336	C/T	cg06115741	chr20:33292138	TP53INP2	0.47	6.1	0.35	3.84e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs2737618	0.651	rs2816974	chr1:200082686	C/G	cg21825944	chr1:200113062	NR5A2	0.45	6.82	0.39	6.19e-11	Uric acid levels;
CESC	trans	rs8007846	0.569	rs4400971	chr14:66254578	A/C	cg21543045	chr12:108154206	PRDM4	0.46	6.06	0.35	4.55e-9	Multiple sclerosis--Brain Glutamate Levels;
CESC	cis	rs67460515	0.563	rs11713441	chr3:160906855	T/C	cg03342759	chr3:160939853	NMD3	-0.53	-7.05	-0.4	1.57e-11	Parkinson's disease;
CESC	cis	rs1862618	0.853	rs1423620	chr5:56100996	G/T	cg24549020	chr5:56110836	MAP3K1	0.57	6.8	0.39	6.91e-11	Initial pursuit acceleration;
CESC	cis	rs854765	0.583	rs11869536	chr17:17826528	T/A	cg16928487	chr17:17741425	SREBF1	-0.57	-9.74	-0.51	2.41e-19	Total body bone mineral density;
CESC	cis	rs11676348	0.818	rs6436033	chr2:218983763	A/G	cg00012203	chr2:219082015	ARPC2	-0.57	-7.32	-0.41	3.02e-12	Ulcerative colitis;
CESC	cis	rs4474465	0.920	rs10899532	chr11:78208470	T/G	cg27205649	chr11:78285834	NARS2	0.43	5.54	0.32	7.3900000000000007e-08	Alzheimer's disease (survival time);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg11059266	chr4:48782139	FRYL	-0.48	-6.56	-0.37	2.85e-10	Fibrinogen levels;
CESC	cis	rs2645694	0.626	rs12502590	chr4:77823642	G/A	cg10057126	chr4:77819792	ANKRD56	0.58	8.4	0.46	2.79e-15	Emphysema distribution in smoking;
CESC	cis	rs2180341	0.782	rs6912196	chr6:127722732	C/G	cg27446573	chr6:127587934	RNF146	0.8	11.41	0.57	8.87e-25	Breast cancer;
CESC	cis	rs10504229	1.000	rs67243305	chr8:58174958	G/A	cg22535103	chr8:58192502	C8orf71	-1.05	-13.17	-0.63	8.14e-31	Developmental language disorder (linguistic errors);
CESC	cis	rs1843834	0.505	rs2140508	chr2:225355839	G/T	cg22509189	chr2:225307070	NA	-0.4	-5.41	-0.32	1.38e-7	IgE levels in asthmatics (D.p. specific);
CESC	cis	rs67311347	0.955	rs2085114	chr3:40497437	T/A	cg24209194	chr3:40518798	ZNF619	0.5	6.13	0.35	3.12e-9	Renal cell carcinoma;
CESC	trans	rs1728785	1.000	rs1170443	chr16:68573295	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.61	7.44	0.42	1.41e-12	Ulcerative colitis;
CESC	cis	rs798554	0.680	rs1713912	chr7:2895784	C/A	cg18446336	chr7:2847575	GNA12	-0.37	-5.66	-0.33	3.96e-8	Height;
CESC	cis	rs4601821	0.522	rs754672	chr11:113249136	C/T	cg14159747	chr11:113255604	NA	0.31	5.52	0.32	8.26e-8	Alcoholic chronic pancreatitis;
CESC	cis	rs17253792	0.822	rs77420254	chr14:56069646	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.76	5.39	0.31	1.56e-7	Putamen volume;
CESC	trans	rs2823962	0.759	rs2823933	chr21:18022418	G/T	cg01437917	chr17:4688569	NA	-0.44	-6.21	-0.36	2.06e-9	Amyotrophic lateral sclerosis;
CESC	cis	rs2361718	0.500	rs4889818	chr17:78085228	A/G	cg14949292	chr17:78079608	GAA	-0.37	-5.29	-0.31	2.58e-7	Yeast infection;
CESC	cis	rs10504229	0.593	rs116916898	chr8:57984958	G/A	cg22535103	chr8:58192502	C8orf71	-0.89	-7.42	-0.41	1.54e-12	Developmental language disorder (linguistic errors);
CESC	trans	rs11098499	0.863	rs7699064	chr4:120428309	A/G	cg25214090	chr10:38739885	LOC399744	-0.69	-9.58	-0.51	7.3e-19	Corneal astigmatism;
CESC	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg21422208	chr3:53164667	RFT1	0.47	6.0	0.35	6.6e-9	Morning vs. evening chronotype;
CESC	cis	rs752010	0.806	rs4457567	chr1:42091407	C/T	cg06885757	chr1:42089581	HIVEP3	0.49	8.24	0.45	8.1e-15	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs17401966	1.000	rs7520651	chr1:10329872	G/A	cg15208524	chr1:10270712	KIF1B	0.45	5.81	0.34	1.83e-8	Hepatocellular carcinoma;
CESC	cis	rs7412746	0.658	rs2275235	chr1:150730279	A/G	cg17724175	chr1:150552817	MCL1	0.42	6.43	0.37	5.8e-10	Melanoma;
CESC	cis	rs863345	0.584	rs11265018	chr1:158506409	G/A	cg12129480	chr1:158549410	OR10X1	-0.34	-6.82	-0.39	6.1e-11	Pneumococcal bacteremia;
CESC	cis	rs780096	0.506	rs2950834	chr2:27627366	G/A	cg17158414	chr2:27665306	KRTCAP3	-0.31	-5.9	-0.34	1.08e-8	Total body bone mineral density;
CESC	cis	rs13191362	1.000	rs67025553	chr6:163011552	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.87	8.98	0.48	5.33e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs826838	0.559	rs1843891	chr12:38617018	T/C	cg26384229	chr12:38710491	ALG10B	0.46	6.62	0.38	1.96e-10	Heart rate;
CESC	cis	rs9322193	0.884	rs9383865	chr6:150173179	A/G	cg07701084	chr6:150067640	NUP43	0.4	5.23	0.31	3.41e-7	Lung cancer;
CESC	cis	rs4523957	0.890	rs11655813	chr17:2119101	C/T	cg16513277	chr17:2031491	SMG6	-0.59	-7.92	-0.44	6.51e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs12188164	0.930	rs72717440	chr5:449701	A/T	cg17553881	chr5:443987	EXOC3;C5orf55	-0.38	-6.14	-0.35	2.97e-9	Cystic fibrosis severity;
CESC	trans	rs4756846	1.000	rs72871390	chr11:16462626	A/G	cg05579622	chr5:10618622	ANKRD33B	0.73	6.26	0.36	1.54e-9	Obesity and osteoporosis;
CESC	cis	rs7202877	0.706	rs247437	chr16:75431275	T/G	cg04384234	chr16:75411784	CFDP1	0.47	5.75	0.33	2.41e-8	Type 2 diabetes;Type 1 diabetes;
CESC	trans	rs495337	1.000	rs6125829	chr20:48568929	A/C	cg17603288	chr5:14405747	TRIO	-0.48	-6.07	-0.35	4.53e-9	Psoriasis;
CESC	cis	rs7216064	0.589	rs7213585	chr17:66062316	A/T	cg12091567	chr17:66097778	LOC651250	-0.92	-12.37	-0.61	4.66e-28	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs7582720	0.943	rs72936866	chr2:203787120	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.38	0.41	1.99e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs951366	1.000	rs4951261	chr1:205717823	A/C	cg07157834	chr1:205819609	PM20D1	-0.42	-5.69	-0.33	3.42e-8	Menarche (age at onset);
CESC	cis	rs67311347	0.822	rs11709089	chr3:40351484	C/T	cg09455208	chr3:40491958	NA	0.45	7.6	0.42	5.25e-13	Renal cell carcinoma;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22875749	chr7:23571782	TRA2A	0.57	6.19	0.36	2.26e-9	Gut microbiome composition (summer);
CESC	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.55	-6.17	-0.35	2.48e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs6728642	1.000	rs116171118	chr2:97695036	C/A	cg26665480	chr2:98280029	ACTR1B	-0.84	-6.63	-0.38	1.83e-10	Bipolar disorder lithium response (continuous) or schizophrenia;
CESC	cis	rs7224668	0.647	rs8070092	chr17:79246818	A/C	cg05632623	chr17:78450055	NPTX1	-0.29	-5.13	-0.3	5.59e-7	IgG glycosylation;
CESC	cis	rs611744	0.506	rs4735054	chr8:109261780	A/C	cg21045802	chr8:109455806	TTC35	-0.55	-6.78	-0.38	7.84e-11	Dupuytren's disease;
CESC	cis	rs9443645	0.901	rs2050660	chr6:79734726	C/T	cg05283184	chr6:79620031	NA	-0.43	-6.66	-0.38	1.56e-10	Intelligence (multi-trait analysis);
CESC	cis	rs1707322	0.963	rs10789484	chr1:46406978	G/C	cg05343316	chr1:45956843	TESK2	0.44	5.42	0.32	1.36e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2290720	0.930	rs7296094	chr12:101689959	A/G	cg22051763	chr12:101673672	UTP20	-0.47	-5.81	-0.34	1.8e-8	Brain structure (hippocampal volume);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg10066545	chr7:66072065	NA	0.42	6.45	0.37	5.29e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs4803468	1.000	rs11880539	chr19:41918949	A/C	cg09537434	chr19:41945824	ATP5SL	1.01	17.5	0.73	4.33e-46	Height;
CESC	cis	rs75804782	0.520	rs72987319	chr2:239351143	C/T	cg18131467	chr2:239335373	ASB1	-0.67	-5.66	-0.33	3.93e-8	Morning vs. evening chronotype;Chronotype;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg10799249	chr10:422187	DIP2C	0.45	6.19	0.36	2.33e-9	Fibrinogen levels;
CESC	cis	rs9354308	0.933	rs10455586	chr6:66571498	T/C	cg07460842	chr6:66804631	NA	0.68	7.68	0.43	3.08e-13	Metabolite levels;
CESC	cis	rs1552244	0.935	rs35148833	chr3:10116937	C/A	cg00149659	chr3:10157352	C3orf10	0.76	9.05	0.49	3.14e-17	Alzheimer's disease;
CESC	cis	rs6546537	0.571	rs4852274	chr2:69780637	G/A	cg10773587	chr2:69614142	GFPT1	-0.52	-6.8	-0.39	7.06e-11	Serum thyroid-stimulating hormone levels;
CESC	cis	rs9911578	0.900	rs8067264	chr17:57182793	G/C	cg05425664	chr17:57184151	TRIM37	-0.53	-7.31	-0.41	3.19e-12	Intelligence (multi-trait analysis);
CESC	trans	rs123509	0.913	rs123506	chr3:42775976	T/C	cg22035501	chr5:112073398	APC	0.56	6.03	0.35	5.62e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs1355223	0.583	rs2915177	chr11:34880266	A/G	cg24088639	chr11:34937564	PDHX;APIP	-0.41	-5.17	-0.3	4.63e-7	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs6964587	0.967	rs6465353	chr7:91779971	G/T	cg17063962	chr7:91808500	NA	-0.58	-8.03	-0.44	3.25e-14	Breast cancer;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg03069383	chr2:18741691	RDH14	-0.5	-7.2	-0.4	6.33e-12	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs2075371	0.933	rs1833475	chr7:133958263	C/T	cg20476274	chr7:133979776	SLC35B4	0.68	9.88	0.52	8.59e-20	Mean platelet volume;
CESC	cis	rs870825	0.616	rs6810600	chr4:185616814	T/C	cg04058563	chr4:185651563	MLF1IP	0.64	7.05	0.4	1.59e-11	Blood protein levels;
CESC	cis	rs11153306	0.529	rs11153303	chr6:111937875	G/A	cg22127309	chr6:111907043	TRAF3IP2	-0.47	-7.03	-0.4	1.8e-11	Tonsillectomy;
CESC	cis	rs7301826	0.610	rs9668291	chr12:131296908	C/G	cg11011512	chr12:131303247	STX2	0.46	5.65	0.33	4.22e-8	Plasma plasminogen activator levels;
CESC	cis	rs13191362	1.000	rs68045643	chr6:163029709	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.77	8.27	0.45	6.58e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs4233802	1.000	rs7563730	chr2:151132697	A/G	cg25300694	chr2:151184358	NA	0.93	7.83	0.43	1.14e-13	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
CESC	cis	rs28374715	0.532	rs28535540	chr15:41659277	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.04	-16.57	-0.71	8.28e-43	Ulcerative colitis;
CESC	cis	rs7917772	0.503	rs7068535	chr10:104349127	C/T	cg22532475	chr10:104410764	TRIM8	-0.36	-6.33	-0.36	1.07e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs11958404	0.789	rs78112793	chr5:157428226	A/G	cg05962755	chr5:157440814	NA	0.61	6.41	0.37	6.49e-10	IgG glycosylation;
CESC	cis	rs17376456	0.809	rs12152763	chr5:93405509	T/A	cg25358565	chr5:93447407	FAM172A	1.16	10.8	0.55	8.82e-23	Diabetic retinopathy;
CESC	cis	rs6942756	0.659	rs624118	chr7:129096653	C/T	cg02491457	chr7:128862824	NA	-0.58	-8.17	-0.45	1.27e-14	White matter hyperintensity burden;
CESC	cis	rs13082711	0.522	rs574955	chr3:27351000	T/C	cg02860705	chr3:27208620	NA	0.4	5.25	0.31	3.11e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CESC	cis	rs2991971	0.901	rs11211122	chr1:45954650	C/T	cg05343316	chr1:45956843	TESK2	-0.49	-6.41	-0.37	6.46e-10	High light scatter reticulocyte count;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg11989253	chr2:26987185	C2orf18	-0.5	-6.26	-0.36	1.55e-9	Ulcerative colitis;
CESC	cis	rs3733418	0.860	rs13110286	chr4:165956403	G/A	cg10852876	chr4:165953100	TRIM60	-0.47	-5.43	-0.32	1.28e-7	Obesity-related traits;
CESC	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg07414643	chr4:187882934	NA	0.53	7.36	0.41	2.33e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4474465	0.646	rs10793334	chr11:78278792	C/T	cg27205649	chr11:78285834	NARS2	-0.51	-6.93	-0.39	3.21e-11	Alzheimer's disease (survival time);
CESC	trans	rs9325144	0.647	rs12830095	chr12:38864199	C/T	cg10679878	chr6:156759499	NA	-0.33	-6.0	-0.35	6.61e-9	Morning vs. evening chronotype;
CESC	cis	rs881375	0.631	rs2416808	chr9:123706283	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.45	6.37	0.36	8.22e-10	Rheumatoid arthritis;
CESC	trans	rs1973993	0.967	rs10875017	chr1:96949526	C/T	cg10631902	chr5:14652156	NA	0.53	7.39	0.41	1.87e-12	Weight;
CESC	cis	rs2921073	0.605	rs2976933	chr8:8254875	A/G	cg06636001	chr8:8085503	FLJ10661	0.47	5.88	0.34	1.26e-8	Parkinson's disease;
CESC	cis	rs4835473	0.932	rs35002497	chr4:144694105	A/G	cg25736465	chr4:144833511	NA	-0.33	-5.15	-0.3	5e-7	Immature fraction of reticulocytes;
CESC	cis	rs6502050	0.835	rs4789676	chr17:80123078	C/T	cg11859384	chr17:80120422	CCDC57	-0.39	-5.34	-0.31	1.98e-7	Life satisfaction;
CESC	cis	rs7116495	1.000	rs1939245	chr11:71742532	C/T	cg10381502	chr11:71823885	C11orf51	-0.65	-5.29	-0.31	2.62e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs11166629	0.679	rs1583969	chr8:135661484	C/T	cg27224718	chr8:135614730	ZFAT	0.43	5.13	0.3	5.54e-7	Smoking quantity;
CESC	cis	rs9790314	1.000	rs4273380	chr3:160950314	A/G	cg03342759	chr3:160939853	NMD3	-0.47	-6.22	-0.36	1.91e-9	Morning vs. evening chronotype;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09327694	chr16:89751805	CDK10	-0.54	-6.61	-0.38	2.11e-10	Gut microbiome composition (summer);
CESC	cis	rs853679	0.513	rs13437444	chr6:28070998	C/T	cg19592336	chr6:28129416	ZNF389	0.55	5.97	0.34	7.62e-9	Depression;
CESC	cis	rs636291	0.517	rs673254	chr1:10550352	C/T	cg20482658	chr1:10539492	PEX14	-0.27	-5.63	-0.33	4.53e-8	Prostate cancer;
CESC	cis	rs7666738	0.830	rs7669407	chr4:98750251	G/A	cg03467027	chr4:99064603	C4orf37	0.44	5.4	0.32	1.46e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs909674	0.690	rs1972280	chr22:39831986	T/A	cg05872129	chr22:39784769	NA	-0.77	-10.46	-0.54	1.13e-21	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs60843830	1.000	rs17713396	chr2:227201	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.78	9.71	0.51	2.85e-19	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs3015497	0.537	rs2934663	chr14:51155995	T/C	cg26011998	chr14:51135199	SAV1	-0.54	-6.1	-0.35	3.84e-9	Mean platelet volume;
CESC	cis	rs9894429	0.816	rs9747093	chr17:79584280	G/A	cg13777783	chr17:79615861	NA	-0.33	-5.59	-0.33	5.5e-8	Eye color traits;
CESC	cis	rs853679	0.517	rs9380052	chr6:28064623	A/G	cg26335602	chr6:28129616	ZNF389	0.5	6.53	0.37	3.25e-10	Depression;
CESC	trans	rs208515	0.525	rs12214310	chr6:66666308	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.87	10.74	0.55	1.42e-22	Exhaled nitric oxide levels;
CESC	cis	rs9911578	1.000	rs12602346	chr17:56901713	T/C	cg05425664	chr17:57184151	TRIM37	-0.5	-6.92	-0.39	3.44e-11	Intelligence (multi-trait analysis);
CESC	cis	rs2730245	0.527	rs1188971	chr7:158664463	G/T	cg24397884	chr7:158709396	WDR60	0.83	8.53	0.46	1.15e-15	Height;
CESC	cis	rs875971	0.862	rs6962717	chr7:65883735	G/A	cg12463550	chr7:65579703	CRCP	0.49	6.21	0.36	2.07e-9	Aortic root size;
CESC	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg06873352	chr17:61820015	STRADA	0.73	12.98	0.62	3.9e-30	Prudent dietary pattern;
CESC	cis	rs9902453	0.845	rs2617865	chr17:28049804	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.66	-8.43	-0.46	2.26e-15	Coffee consumption (cups per day);
CESC	cis	rs216205	0.547	rs2641431	chr17:2030507	C/G	cg16513277	chr17:2031491	SMG6	-0.61	-6.79	-0.39	7.17e-11	Mitral valve prolapse;
CESC	cis	rs4919044	0.808	rs2486687	chr10:94778283	T/C	cg26979504	chr10:94451518	HHEX	-0.47	-5.15	-0.3	5.16e-7	Coronary artery disease;
CESC	cis	rs4654899	0.895	rs7515590	chr1:21216664	T/C	cg05370193	chr1:21551575	ECE1	-0.36	-5.15	-0.3	5.17e-7	Superior frontal gyrus grey matter volume;
CESC	cis	rs2708240	1.000	rs2247137	chr7:147581002	C/T	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.34	-5.55	-0.32	7.07e-8	QT interval (drug interaction);
CESC	cis	rs116095464	0.558	rs7356535	chr5:284117	G/T	cg22857025	chr5:266934	NA	-1.32	-14.16	-0.66	2.9e-34	Breast cancer;
CESC	cis	rs12681288	0.578	rs10503154	chr8:969343	C/G	cg04851639	chr8:1020857	NA	-0.31	-5.93	-0.34	9.26e-9	Schizophrenia;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg14094333	chr4:38666051	KLF3;FLJ13197	-0.46	-6.76	-0.38	8.69e-11	Fibrinogen levels;
CESC	cis	rs854765	0.552	rs11078407	chr17:17841083	T/C	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.52	7.01	0.4	2.02e-11	Total body bone mineral density;
CESC	cis	rs4862307	0.514	rs7696176	chr4:185014390	A/G	cg06737308	chr4:185021514	ENPP6	0.67	10.78	0.55	1.08e-22	Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	cis	rs7613875	0.641	rs2624845	chr3:50062437	C/A	cg24110177	chr3:50126178	RBM5	0.56	7.76	0.43	1.89e-13	Body mass index;
CESC	cis	rs853679	0.542	rs2295594	chr6:28053097	G/A	cg19592336	chr6:28129416	ZNF389	0.6	7.97	0.44	4.69e-14	Depression;
CESC	cis	rs736801	0.808	rs2248116	chr5:131804347	C/A	cg21138405	chr5:131827807	IRF1	0.38	5.77	0.33	2.26e-8	Breast cancer;Mosquito bite size;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg07628558	chr20:56964831	VAPB	-0.45	-6.38	-0.36	8.05e-10	Gambling;
CESC	cis	rs1707322	0.721	rs12037803	chr1:46156492	A/G	cg05343316	chr1:45956843	TESK2	0.51	6.2	0.36	2.19e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2075371	0.897	rs1646743	chr7:134003451	C/A	cg00033643	chr7:134001901	SLC35B4	0.4	5.17	0.3	4.63e-7	Mean platelet volume;
CESC	cis	rs4819052	1.000	rs2297286	chr21:46707897	C/G	cg11663144	chr21:46675770	NA	-0.48	-6.52	-0.37	3.49e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs1865721	0.771	rs6566092	chr18:73136496	C/T	cg26385618	chr18:73139727	C18orf62	-0.51	-8.36	-0.46	3.47e-15	Intelligence;
CESC	cis	rs7103648	0.545	rs6485795	chr11:47929846	G/A	cg20307385	chr11:47447363	PSMC3	0.76	10.98	0.56	2.36e-23	Diastolic blood pressure;Systolic blood pressure;
CESC	cis	rs1843834	0.539	rs3912999	chr2:225390089	C/T	cg12698349	chr2:225449008	CUL3	0.62	8.39	0.46	3.02e-15	IgE levels in asthmatics (D.p. specific);
CESC	cis	rs911555	0.755	rs2273702	chr14:103918182	C/G	cg24130564	chr14:104152367	KLC1	0.54	7.3	0.41	3.37e-12	Intelligence (multi-trait analysis);
CESC	cis	rs10887741	0.646	rs11202501	chr10:89437208	C/T	cg13926569	chr10:89418898	PAPSS2	0.47	7.15	0.4	8.25e-12	Exercise (leisure time);
CESC	cis	rs3768617	0.528	rs6686682	chr1:183080539	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.87	13.96	0.65	1.41e-33	Fuchs's corneal dystrophy;
CESC	cis	rs6089584	0.816	rs744778	chr20:60631365	A/G	cg24733560	chr20:60626293	TAF4	0.46	6.68	0.38	1.38e-10	Body mass index;
CESC	cis	rs7666738	0.830	rs10009943	chr4:99021475	G/A	cg17366294	chr4:99064904	C4orf37	0.61	8.76	0.47	2.35e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7267005	0.661	rs2425099	chr20:34309643	T/C	cg17201900	chr20:34330562	RBM39	0.93	5.07	0.3	7.47e-7	Response to paliperidone in schizophrenia (Multivariate);
CESC	cis	rs916888	0.821	rs199525	chr17:44847834	T/G	cg15921436	chr17:44337874	NA	0.74	7.89	0.44	8.12e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs6089584	0.888	rs6587283	chr20:60613727	A/C	cg06108461	chr20:60628389	TAF4	-0.92	-14.36	-0.66	5.41e-35	Body mass index;
CESC	cis	rs4665809	0.652	rs2384360	chr2:26405016	C/G	cg22920501	chr2:26401640	FAM59B	-0.86	-10.06	-0.53	2.22e-20	Gut microbiome composition (summer);
CESC	cis	rs769267	0.965	rs13964	chr19:19468710	C/G	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.43	-5.38	-0.31	1.64e-7	Tonsillectomy;
CESC	cis	rs832540	0.603	rs6870175	chr5:56093371	A/G	cg14703610	chr5:56206110	C5orf35	0.42	5.09	0.3	6.87e-7	Coronary artery disease;
CESC	cis	rs2573652	0.722	rs12898366	chr15:100543067	C/T	cg00587665	chr15:100533223	ADAMTS17	-0.43	-7.1	-0.4	1.11e-11	Height;
CESC	cis	rs3015497	0.789	rs3015496	chr14:51114051	T/C	cg09863266	chr14:51125203	SAV1	-0.34	-5.3	-0.31	2.48e-7	Mean platelet volume;
CESC	cis	rs12822507	0.868	rs34051318	chr12:12798338	T/C	cg04607235	chr12:12878440	APOLD1	-0.5	-6.42	-0.37	6.25e-10	Systemic lupus erythematosus;
CESC	cis	rs2836974	0.666	rs11910705	chr21:40685604	C/T	cg17971929	chr21:40555470	PSMG1	-0.86	-12.23	-0.6	1.45e-27	Cognitive function;
CESC	cis	rs7829975	0.659	rs4382480	chr8:8721473	C/T	cg17143192	chr8:8559678	CLDN23	0.43	5.19	0.3	4.25e-7	Mood instability;
CESC	cis	rs12541635	0.966	rs6469031	chr8:107048095	T/C	cg10147462	chr8:107024639	NA	0.42	5.97	0.34	7.51e-9	Age of smoking initiation;
CESC	cis	rs1865721	1.000	rs17283454	chr18:73186619	G/A	cg26385618	chr18:73139727	C18orf62	-0.51	-7.6	-0.42	5.14e-13	Intelligence;
CESC	cis	rs1023500	0.507	rs6002600	chr22:42488906	G/A	cg15557168	chr22:42548783	NA	0.45	6.57	0.37	2.72e-10	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26737766	chr1:24127303	GALE	-0.65	-7.75	-0.43	1.99e-13	Gut microbiome composition (summer);
CESC	cis	rs4764124	0.571	rs11830399	chr12:14956932	G/C	cg19759883	chr12:14956454	WBP11;C12orf60	0.58	8.58	0.47	8.3e-16	Pubertal anthropometrics;
CESC	cis	rs9291683	0.525	rs12506455	chr4:10031569	T/A	cg11266682	chr4:10021025	SLC2A9	0.71	14.26	0.66	1.27e-34	Bone mineral density;
CESC	cis	rs7107174	0.681	rs4340079	chr11:78007920	C/T	cg02023728	chr11:77925099	USP35	0.47	6.55	0.37	3.02e-10	Testicular germ cell tumor;
CESC	cis	rs6998277	1.000	rs4734648	chr8:103635994	G/A	cg10187029	chr8:103597600	NA	0.57	6.54	0.37	3.19e-10	Migraine;
CESC	cis	rs1580019	0.587	rs6972365	chr7:32548931	T/A	cg07520158	chr7:32535189	LSM5;AVL9	0.51	6.39	0.37	7.42e-10	Cognitive ability;
CESC	cis	rs853679	0.517	rs4713145	chr6:28106827	T/C	cg23281280	chr6:28129359	ZNF389	0.59	8.13	0.45	1.68e-14	Depression;
CESC	cis	rs7872515	1.000	rs7852067	chr9:94815594	A/G	cg01248375	chr9:94877805	SPTLC1	0.57	5.77	0.33	2.21e-8	Bipolar disorder and schizophrenia;
CESC	trans	rs17685	0.672	rs6465011	chr7:75811297	T/C	cg19862616	chr7:65841803	NCRNA00174	0.82	11.63	0.58	1.54e-25	Coffee consumption;Coffee consumption (cups per day);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15057823	chr6:42981704	MEA1;KLHDC3	0.65	7.05	0.4	1.59e-11	Gut microbiome composition (summer);
CESC	cis	rs631288	0.793	rs11239952	chr1:146715204	A/G	cg25205988	chr1:146714368	CHD1L	1.05	8.82	0.48	1.55e-16	PR interval in Tripanosoma cruzi seropositivity;
CESC	cis	rs6460942	1.000	rs77494477	chr7:12315302	A/T	cg06484146	chr7:12443880	VWDE	-0.81	-8.78	-0.47	2.13e-16	Coronary artery disease;
CESC	cis	rs35110281	0.667	rs9941787	chr21:45116042	A/G	cg21573476	chr21:45109991	RRP1B	-0.57	-8.09	-0.45	2.1e-14	Mean corpuscular volume;
CESC	cis	rs9649213	0.593	rs35535338	chr7:97962319	C/T	cg00277769	chr7:97922759	BAIAP2L1	-0.34	-5.56	-0.32	6.62e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs258892	0.895	rs34646	chr5:72113061	C/T	cg21869765	chr5:72125136	TNPO1	-0.44	-5.65	-0.33	4.05e-8	Small cell lung carcinoma;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27037990	chr4:184427250	ING2	0.56	6.21	0.36	2.04e-9	Gut microbiome composition (summer);
CESC	trans	rs2235573	0.625	rs1883471	chr22:38417510	T/C	cg19894588	chr14:64061835	NA	0.49	6.32	0.36	1.08e-9	Glioblastoma;Glioma;
CESC	cis	rs595982	0.559	rs4802516	chr19:49366170	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.7	-7.94	-0.44	5.71e-14	Red cell distribution width;
CESC	cis	rs870825	0.616	rs877276	chr4:185621249	C/T	cg04058563	chr4:185651563	MLF1IP	0.64	7.05	0.4	1.59e-11	Blood protein levels;
CESC	cis	rs3733585	0.746	rs4318650	chr4:10016868	T/C	cg00071950	chr4:10020882	SLC2A9	0.82	13.82	0.65	4.37e-33	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs1018836	0.798	rs28568272	chr8:91652958	A/G	cg16814680	chr8:91681699	NA	-0.9	-13.92	-0.65	1.97e-33	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	trans	rs7246657	0.943	rs7259968	chr19:37811854	T/C	cg24637308	chr11:6592297	DNHD1	0.52	6.07	0.35	4.35e-9	Coronary artery calcification;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06452419	chr17:55938940	NA	-0.55	-6.49	-0.37	4.27e-10	Gut microbiome composition (summer);
CESC	cis	rs9583531	0.600	rs3809344	chr13:111358705	G/A	cg15841412	chr13:111365552	ING1	0.52	6.74	0.38	1.01e-10	Coronary artery disease;
CESC	cis	rs1218582	0.772	rs10796934	chr1:154849479	C/G	cg24250549	chr1:154909240	PMVK	0.71	10.61	0.55	3.83e-22	Prostate cancer;
CESC	cis	rs3733585	0.699	rs6449158	chr4:9960459	T/C	cg02734326	chr4:10020555	SLC2A9	-0.44	-6.15	-0.35	2.85e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs9768139	0.903	rs10262701	chr7:158114591	G/A	cg06219351	chr7:158114137	PTPRN2	0.53	8.34	0.46	3.99e-15	Calcium levels;
CESC	cis	rs9303401	0.659	rs17222621	chr17:56695923	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.04	13.0	0.62	3.27e-30	Cognitive test performance;
CESC	cis	rs7659604	0.539	rs11098645	chr4:122729251	G/A	cg06713675	chr4:122721982	EXOSC9	-0.51	-6.95	-0.39	2.8e-11	Type 2 diabetes;
CESC	cis	rs7843479	0.601	rs11135764	chr8:21814004	A/G	cg17168535	chr8:21777572	XPO7	0.73	11.77	0.59	5.33e-26	Mean corpuscular volume;
CESC	cis	rs62103177	1.000	rs62103177	chr18:77624479	G/A	cg12964065	chr18:77638022	KCNG2	0.56	5.44	0.32	1.19e-7	Opioid sensitivity;
CESC	cis	rs2120019	0.938	rs35911108	chr15:75322179	G/A	cg09165964	chr15:75287851	SCAMP5	-0.8	-9.94	-0.52	5.37e-20	Blood trace element (Zn levels);
CESC	cis	rs4689388	0.926	rs1801214	chr4:6303022	C/T	cg25554036	chr4:6271136	WFS1	0.55	9.19	0.49	1.16e-17	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs9291683	0.538	rs11727199	chr4:10036190	C/T	cg02734326	chr4:10020555	SLC2A9	0.47	6.51	0.37	3.75e-10	Bone mineral density;
CESC	cis	rs2991971	1.000	rs9147	chr1:46016687	T/C	cg05343316	chr1:45956843	TESK2	-0.48	-6.08	-0.35	4.21e-9	High light scatter reticulocyte count;
CESC	cis	rs2839186	0.500	rs13049893	chr21:47707054	C/T	cg00815214	chr21:47717953	NA	-0.45	-6.17	-0.35	2.53e-9	Testicular germ cell tumor;
CESC	cis	rs10883723	0.810	rs7090276	chr10:104281239	G/T	cg22532475	chr10:104410764	TRIM8	-0.33	-5.67	-0.33	3.77e-8	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs9733	0.596	rs72702585	chr1:150696427	G/A	cg22823121	chr1:150693482	HORMAD1	0.47	6.96	0.39	2.6e-11	Tonsillectomy;
CESC	cis	rs2439831	1.000	rs2439831	chr15:43784475	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.85	12.03	0.59	7.15e-27	Lung cancer in ever smokers;
CESC	cis	rs6089829	1.000	rs6089829	chr20:61669036	C/T	cg16240275	chr20:61666158	NCRNA00029	-0.43	-7.35	-0.41	2.41e-12	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs2415984	0.579	rs1494097	chr14:46960552	T/C	cg14871534	chr14:47121158	RPL10L	0.35	5.32	0.31	2.17e-7	Number of children ever born;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23709674	chr6:36410515	PXT1;KCTD20	0.59	6.51	0.37	3.69e-10	Gut microbiome composition (summer);
CESC	cis	rs11229555	0.874	rs11229505	chr11:58274155	T/C	cg15696309	chr11:58395628	NA	-0.41	-5.03	-0.3	8.87e-7	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs7301826	1.000	rs4759793	chr12:131297238	A/G	cg11011512	chr12:131303247	STX2	0.4	5.09	0.3	6.83e-7	Plasma plasminogen activator levels;
CESC	cis	rs4925386	0.840	rs6143034	chr20:60920545	T/C	cg22633769	chr20:60982531	CABLES2	0.53	5.54	0.32	7.16e-8	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs1832871	0.672	rs62437361	chr6:158728759	C/T	cg07165851	chr6:158734300	TULP4	0.6	6.65	0.38	1.68e-10	Height;
CESC	cis	rs4727963	0.792	rs10247666	chr7:122717198	A/G	cg03640110	chr7:122635026	TAS2R16	-0.4	-6.47	-0.37	4.71e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
CESC	cis	rs6500602	0.610	rs1659499	chr16:4595269	G/A	cg08645402	chr16:4508243	NA	-0.46	-7.35	-0.41	2.53e-12	Schizophrenia;
CESC	cis	rs7772486	0.846	rs2748496	chr6:146321829	T/A	cg05347473	chr6:146136440	FBXO30	0.51	6.73	0.38	1.03e-10	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06529439	chr2:88991002	RPIA	0.59	6.85	0.39	5.19e-11	Gut microbiome composition (summer);
CESC	cis	rs9868809	0.772	rs9877501	chr3:48718390	C/G	cg03060546	chr3:49711283	APEH	-0.67	-5.77	-0.33	2.19e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs854765	0.551	rs6502626	chr17:17849450	C/T	cg16928487	chr17:17741425	SREBF1	-0.53	-8.75	-0.47	2.54e-16	Total body bone mineral density;
CESC	cis	rs477692	0.905	rs508360	chr10:131424969	A/G	cg26102564	chr10:131424627	MGMT	0.36	5.39	0.31	1.52e-7	Response to temozolomide;
CESC	cis	rs1538970	1.000	rs1417578	chr1:45850590	A/G	cg05343316	chr1:45956843	TESK2	0.77	10.92	0.56	3.56e-23	Platelet count;
CESC	cis	rs12464559	0.649	rs4664496	chr2:152522556	T/C	cg01189475	chr2:152685088	ARL5A	-0.57	-5.12	-0.3	5.91e-7	Response to cognitive-behavioural therapy in anxiety disorder;
CESC	cis	rs6088580	0.634	rs6119497	chr20:33012529	T/A	cg08999081	chr20:33150536	PIGU	0.65	11.43	0.57	7.54e-25	Glomerular filtration rate (creatinine);
CESC	cis	rs6693567	0.565	rs1694379	chr1:150292417	C/A	cg09579323	chr1:150459698	TARS2	0.49	6.22	0.36	1.96e-9	Migraine;
CESC	cis	rs1707322	0.752	rs3811435	chr1:46125790	C/A	cg05343316	chr1:45956843	TESK2	0.5	6.12	0.35	3.43e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9488822	0.676	rs873879	chr6:116391259	A/G	cg18764771	chr6:116381957	FRK	0.24	6.02	0.35	5.79e-9	Cholesterol, total;LDL cholesterol;
CESC	trans	rs9329221	0.617	rs483916	chr8:9793601	A/C	cg15556689	chr8:8085844	FLJ10661	-0.52	-6.39	-0.37	7.38e-10	Neuroticism;
CESC	cis	rs3815700	1.000	rs8101356	chr19:33093402	C/T	cg02997394	chr19:33096574	ANKRD27	0.73	7.3	0.41	3.26e-12	Eosinophilic esophagitis;
CESC	cis	rs533581	0.866	rs865102	chr16:88969969	A/G	cg16701003	chr16:89028210	CBFA2T3	0.47	6.89	0.39	4.08e-11	Social autistic-like traits;
CESC	cis	rs847577	1.000	rs847577	chr7:97694858	T/A	cg21770322	chr7:97807741	LMTK2	-0.65	-10.74	-0.55	1.45e-22	Breast cancer;
CESC	cis	rs60871478	0.838	rs7789321	chr7:800977	A/G	cg27478167	chr7:817139	HEATR2	-0.51	-5.4	-0.31	1.51e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs12464559	0.522	rs10180065	chr2:152619007	A/G	cg01189475	chr2:152685088	ARL5A	-0.77	-7.32	-0.41	2.88e-12	Response to cognitive-behavioural therapy in anxiety disorder;
CESC	cis	rs75804782	0.641	rs112066551	chr2:239362486	G/A	cg18131467	chr2:239335373	ASB1	-0.7	-5.56	-0.32	6.56e-8	Morning vs. evening chronotype;Chronotype;
CESC	cis	rs2952156	0.920	rs11078919	chr17:37835755	T/C	cg00129232	chr17:37814104	STARD3	-0.76	-11.04	-0.56	1.44e-23	Asthma;
CESC	cis	rs853679	0.517	rs9393897	chr6:28127710	G/T	cg22143856	chr6:28129313	ZNF389	0.49	6.21	0.36	2.02e-9	Depression;
CESC	cis	rs4481887	0.741	rs6421453	chr1:248533285	A/G	cg26353448	chr1:248524236	OR2T4	-0.38	-5.35	-0.31	1.9e-7	Common traits (Other);
CESC	cis	rs4253772	0.637	rs11703173	chr22:46660367	G/A	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.58	5.36	0.31	1.86e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs7116495	0.609	rs1894004	chr11:71759817	G/A	cg10381502	chr11:71823885	C11orf51	-1.16	-7.39	-0.41	1.9e-12	Severe influenza A (H1N1) infection;
CESC	cis	rs1707322	0.752	rs4586014	chr1:46150443	A/G	cg03146154	chr1:46216737	IPP	0.82	11.53	0.58	3.39e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs1552244	0.748	rs9862221	chr3:10059658	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.77	-9.47	-0.5	1.63e-18	Alzheimer's disease;
CESC	cis	rs9487051	0.676	rs9398196	chr6:109601554	A/G	cg21918786	chr6:109611834	NA	-0.39	-5.74	-0.33	2.56e-8	Reticulocyte fraction of red cells;
CESC	cis	rs2354432	0.607	rs7511989	chr1:146720160	A/G	cg25205988	chr1:146714368	CHD1L	-1.01	-8.47	-0.46	1.68e-15	Mitochondrial DNA levels;
CESC	cis	rs1609391	0.543	rs2117009	chr3:136633571	A/T	cg15507776	chr3:136538369	TMEM22	-0.83	-12.27	-0.6	1.02e-27	Neuroticism;
CESC	cis	rs6088580	0.505	rs6142219	chr20:33256345	G/A	cg24642439	chr20:33292090	TP53INP2	-0.47	-5.53	-0.32	7.81e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs1008375	0.966	rs1860599	chr4:17638900	T/C	cg16339924	chr4:17578868	LAP3	0.56	7.13	0.4	9.83e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs55883249	1.000	rs10495573	chr2:9712160	T/G	cg23886495	chr2:9695866	ADAM17	0.59	5.52	0.32	7.91e-8	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg25733915	chr17:40829168	PLEKHH3	0.48	6.28	0.36	1.34e-9	Systemic lupus erythematosus;
CESC	cis	rs12995491	0.763	rs1914735	chr2:88511953	A/T	cg14558114	chr2:88469736	THNSL2	-0.53	-7.73	-0.43	2.31e-13	Response to metformin (IC50);
CESC	cis	rs6500602	0.702	rs11076835	chr16:4549618	G/A	cg08645402	chr16:4508243	NA	0.53	8.64	0.47	5.21e-16	Schizophrenia;
CESC	cis	rs875971	1.000	rs2042133	chr7:65931922	A/G	cg11764359	chr7:65958608	NA	0.94	14.96	0.68	4.3e-37	Aortic root size;
CESC	cis	rs1799949	0.931	rs34474989	chr17:41445410	A/T	cg25072359	chr17:41440525	NA	0.45	6.7	0.38	1.28e-10	Menopause (age at onset);
CESC	trans	rs11088226	0.645	rs11702343	chr21:33937888	C/A	cg09050820	chr6:167586206	TCP10L2	0.8	7.55	0.42	7.17e-13	Gastritis;
CESC	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg11494091	chr17:61959527	GH2	0.72	12.13	0.6	3.12e-27	Prudent dietary pattern;
CESC	cis	rs2976388	0.566	rs4736373	chr8:143792357	G/C	cg10596483	chr8:143751796	JRK	-0.45	-5.51	-0.32	8.54e-8	Urinary tract infection frequency;
CESC	cis	rs2795502	1.000	rs2795503	chr10:43347224	T/A	cg20628663	chr10:43360327	NA	-0.61	-7.22	-0.41	5.62e-12	Blood protein levels;
CESC	cis	rs6933660	0.683	rs6916340	chr6:151779064	T/C	cg17179660	chr6:151773299	C6orf211;RMND1	-0.42	-5.28	-0.31	2.67e-7	Menarche (age at onset);
CESC	trans	rs7837860	0.588	rs71526930	chr8:89281625	T/A	cg04391754	chr17:18022714	MYO15A	0.52	6.12	0.35	3.41e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs818427	0.613	rs818797	chr5:112219140	G/A	cg07820702	chr5:112228657	REEP5	-0.4	-5.12	-0.3	5.75e-7	Total body bone mineral density;
CESC	cis	rs4665809	1.000	rs12475854	chr2:26267375	G/A	cg08470875	chr2:26401718	FAM59B	-0.48	-5.26	-0.31	3e-7	Gut microbiome composition (summer);
CESC	cis	rs5758659	0.652	rs133330	chr22:42409456	G/A	cg15557168	chr22:42548783	NA	-0.42	-6.27	-0.36	1.48e-9	Cognitive function;
CESC	cis	rs12200560	0.505	rs2015196	chr6:97075331	G/C	cg06623918	chr6:96969491	KIAA0776	0.5	6.49	0.37	4.13e-10	Coronary heart disease;
CESC	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	7.73	0.43	2.22e-13	Prudent dietary pattern;
CESC	cis	rs9640161	0.750	rs11769348	chr7:150026753	C/T	cg21361702	chr7:150065534	REPIN1	-0.48	-5.3	-0.31	2.42e-7	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs7618915	0.501	rs6617	chr3:52740182	C/G	cg07507251	chr3:52567010	NT5DC2	0.32	5.52	0.32	8.04e-8	Bipolar disorder;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg13699934	chr9:93956018	NA	-0.44	-6.11	-0.35	3.55e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs4474465	0.790	rs10793331	chr11:78270000	C/T	cg27205649	chr11:78285834	NARS2	0.47	6.01	0.35	6.1e-9	Alzheimer's disease (survival time);
CESC	cis	rs1448094	0.512	rs12309296	chr12:86241566	T/C	cg02569458	chr12:86230093	RASSF9	0.5	7.51	0.42	9.29e-13	Major depressive disorder;
CESC	cis	rs4713118	0.527	rs35949862	chr6:28115367	A/G	cg20151795	chr6:28129481	ZNF389	0.46	5.83	0.34	1.65e-8	Parkinson's disease;
CESC	trans	rs1437396	0.610	rs7572492	chr2:55640033	A/G	cg07921503	chr7:2445843	CHST12	0.25	6.11	0.35	3.53e-9	Alcohol dependence;
CESC	cis	rs875971	0.964	rs2161065	chr7:65932905	A/G	cg12463550	chr7:65579703	CRCP	0.57	7.2	0.4	6.12e-12	Aortic root size;
CESC	cis	rs8114671	0.551	rs4911162	chr20:33411425	G/C	cg07148914	chr20:33460835	GGT7	0.42	5.32	0.31	2.25e-7	Height;
CESC	cis	rs9311474	0.607	rs13076398	chr3:52573096	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.36	5.14	0.3	5.29e-7	Electroencephalogram traits;
CESC	cis	rs2302190	0.882	rs3803751	chr17:56650356	A/G	cg25885038	chr17:56607967	SEPT4	-0.41	-5.52	-0.32	7.89e-8	Vitamin D levels;
CESC	cis	rs453301	0.682	rs2929308	chr8:9084121	T/A	cg17143192	chr8:8559678	CLDN23	-0.45	-5.61	-0.33	5.04e-8	Joint mobility (Beighton score);
CESC	cis	rs2742234	0.955	rs2503849	chr10:43672776	G/A	cg15436174	chr10:43711423	RASGEF1A	-0.42	-5.25	-0.31	3.09e-7	Hirschsprung disease;
CESC	cis	rs4975709	0.758	rs4975756	chr5:1882443	T/C	cg15595755	chr5:1867978	NA	0.49	7.47	0.42	1.14e-12	Cardiovascular disease risk factors;
CESC	cis	rs7618915	0.547	rs3755806	chr3:52643685	C/T	cg18099408	chr3:52552593	STAB1	0.32	5.2	0.3	4.07e-7	Bipolar disorder;
CESC	cis	rs17711722	0.727	rs1880555	chr7:65432567	T/C	cg11987759	chr7:65425863	GUSB	-0.46	-6.19	-0.36	2.29e-9	Calcium levels;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg01708693	chr16:2314216	RNPS1	0.52	7.05	0.4	1.55e-11	Fibrinogen levels;
CESC	cis	rs12711979	0.740	rs6711963	chr2:3820915	A/T	cg17052675	chr2:3827356	NA	-0.41	-6.47	-0.37	4.74e-10	Itch intensity from mosquito bite adjusted by bite size;
CESC	cis	rs2933343	0.700	rs1683787	chr3:128627021	C/T	cg11901034	chr3:128598214	ACAD9	0.35	5.24	0.31	3.36e-7	IgG glycosylation;
CESC	cis	rs9322193	0.923	rs62441284	chr6:150072678	C/A	cg04369109	chr6:150039330	LATS1	-0.44	-6.06	-0.35	4.73e-9	Lung cancer;
CESC	cis	rs6964587	1.000	rs12540055	chr7:91707921	A/G	cg17063962	chr7:91808500	NA	0.53	7.07	0.4	1.41e-11	Breast cancer;
CESC	cis	rs34779708	0.966	rs35777088	chr10:35409048	T/C	cg03585969	chr10:35415529	CREM	0.77	10.1	0.53	1.71e-20	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg26338869	chr17:61819248	STRADA	0.74	9.88	0.52	8.67e-20	Prudent dietary pattern;
CESC	cis	rs9733	0.596	rs6678013	chr1:150623285	T/G	cg04414720	chr1:150670196	GOLPH3L	0.63	9.04	0.49	3.47e-17	Tonsillectomy;
CESC	cis	rs1055129	0.560	rs2666003	chr17:73942976	G/A	cg02678768	chr17:74002944	EVPL	0.38	5.25	0.31	3.07e-7	White matter hyperintensity burden;
CESC	cis	rs9486719	0.895	rs4486019	chr6:96883814	T/C	cg18709589	chr6:96969512	KIAA0776	-0.53	-5.81	-0.34	1.75e-8	Migraine;Coronary artery disease;
CESC	cis	rs4665809	0.590	rs2303892	chr2:26461733	C/G	cg22920501	chr2:26401640	FAM59B	0.91	10.38	0.54	2.08e-21	Gut microbiome composition (summer);
CESC	cis	rs597539	0.689	rs596874	chr11:68630874	C/T	cg01988459	chr11:68622903	NA	0.42	5.77	0.33	2.23e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs13108904	0.935	rs3755920	chr4:1243617	T/C	cg00684032	chr4:1343700	KIAA1530	0.35	5.43	0.32	1.3e-7	Obesity-related traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05228244	chr10:1102351	WDR37	0.53	6.24	0.36	1.68e-9	Gut microbiome composition (summer);
CESC	cis	rs7786877	0.761	rs11772705	chr7:100298904	T/C	cg16850897	chr7:100343110	ZAN	-0.68	-8.65	-0.47	4.95e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs17599629	0.502	rs2055975	chr1:150618632	G/T	cg04414720	chr1:150670196	GOLPH3L	-0.5	-6.5	-0.37	4.02e-10	Prostate cancer;
CESC	cis	rs66573146	1.000	rs55833486	chr4:6978729	C/A	cg00086871	chr4:6988644	TBC1D14	1.21	7.89	0.44	7.91e-14	Granulocyte percentage of myeloid white cells;
CESC	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg26338869	chr17:61819248	STRADA	0.72	9.53	0.51	1.05e-18	Prudent dietary pattern;
CESC	cis	rs12476592	0.543	rs10170988	chr2:63650582	T/C	cg17519650	chr2:63277830	OTX1	-0.46	-5.21	-0.3	3.83e-7	Childhood ear infection;
CESC	cis	rs12478296	1.000	rs56102931	chr2:243039936	A/G	cg06360820	chr2:242988706	NA	-0.66	-7.52	-0.42	8.51e-13	Obesity-related traits;
CESC	trans	rs7615952	0.512	rs34651730	chr3:125358640	T/C	cg00769240	chr8:12517080	NA	-0.44	-6.02	-0.35	5.7e-9	Blood pressure (smoking interaction);
CESC	cis	rs1707322	0.721	rs10890344	chr1:46166090	C/T	cg03146154	chr1:46216737	IPP	0.82	11.54	0.58	3.18e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9462846	0.919	rs12202901	chr6:42828550	A/T	cg02353165	chr6:42928485	GNMT	0.46	5.4	0.31	1.5e-7	Blood protein levels;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg06861343	chr3:52739491	GLT8D1;SPCS1	-0.46	-6.36	-0.36	8.87e-10	Asthma;
CESC	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg12419862	chr22:24373484	LOC391322	0.7	9.79	0.52	1.5700000000000001e-19	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs4819052	0.851	rs13052344	chr21:46676101	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.47	5.84	0.34	1.49e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs13191362	0.507	rs2849534	chr6:163144657	T/A	cg06582575	chr6:163149167	PACRG;PARK2	-0.5	-5.92	-0.34	1.01e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs1552244	1.000	rs6791810	chr3:10124444	A/G	cg00149659	chr3:10157352	C3orf10	-0.69	-8.76	-0.47	2.42e-16	Alzheimer's disease;
CESC	cis	rs736408	0.546	rs3733046	chr3:52621627	C/T	cg17372223	chr3:52568218	NT5DC2	0.43	6.53	0.37	3.33e-10	Bipolar disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25889035	chr2:236826311	AGAP1	-0.56	-6.48	-0.37	4.53e-10	Gut microbiome composition (summer);
CESC	cis	rs2276314	0.857	rs4799409	chr18:33592602	C/T	cg19628046	chr18:33552617	C18orf21	0.51	5.76	0.33	2.3e-8	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs1799949	1.000	rs8176220	chr17:41222462	A/G	cg05368731	chr17:41323189	NBR1	0.8	11.13	0.56	7.38e-24	Menopause (age at onset);
CESC	cis	rs9660180	0.935	rs9786942	chr1:1759213	A/G	cg20999797	chr1:1681921	NA	0.26	5.13	0.3	5.59e-7	Body mass index;
CESC	cis	rs9430161	0.579	rs9659356	chr1:11034817	A/G	cg27631724	chr1:11040367	C1orf127	0.36	5.95	0.34	8.56e-9	Ewing sarcoma;
CESC	cis	rs7714584	0.793	rs35707106	chr5:150225377	G/A	cg22134413	chr5:150180641	NA	0.52	5.64	0.33	4.31e-8	Crohn's disease;
CESC	cis	rs9291683	0.588	rs3733586	chr4:9997534	C/T	cg00071950	chr4:10020882	SLC2A9	0.85	15.67	0.69	1.27e-39	Bone mineral density;
CESC	cis	rs208520	0.690	rs12213581	chr6:66735818	T/C	cg07460842	chr6:66804631	NA	0.96	12.81	0.62	1.47e-29	Exhaled nitric oxide output;
CESC	cis	rs11098499	0.863	rs2306457	chr4:120472839	T/A	cg09307838	chr4:120376055	NA	0.9	12.43	0.61	3.08e-28	Corneal astigmatism;
CESC	cis	rs28673728	0.897	rs28391281	chr1:38408974	T/C	cg17077180	chr1:38461687	NA	0.46	6.9	0.39	3.83e-11	Red cell distribution width;
CESC	cis	rs6762	0.719	rs7936806	chr11:839186	G/C	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.66	-8.23	-0.45	8.83e-15	Mean platelet volume;
CESC	cis	rs736408	0.509	rs1108842	chr3:52720080	A/C	cg18404041	chr3:52824283	ITIH1	-0.35	-6.35	-0.36	9.25e-10	Bipolar disorder;
CESC	cis	rs1862618	0.756	rs832548	chr5:56183637	G/C	cg24531977	chr5:56204891	C5orf35	-0.87	-10.87	-0.56	5.43e-23	Initial pursuit acceleration;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg17146150	chr15:56657437	TEX9	0.47	6.05	0.35	4.9e-9	Systemic lupus erythematosus;
CESC	cis	rs9322193	0.887	rs11155662	chr6:149913867	T/G	cg04369109	chr6:150039330	LATS1	-0.4	-5.46	-0.32	1.08e-7	Lung cancer;
CESC	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg05313129	chr8:58192883	C8orf71	-0.49	-5.28	-0.31	2.72e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs4819052	0.851	rs8127834	chr21:46696109	G/A	cg11663144	chr21:46675770	NA	-0.6	-9.35	-0.5	3.74e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs72945132	0.882	rs12282678	chr11:70152457	G/A	cg00319359	chr11:70116639	PPFIA1	0.78	7.71	0.43	2.52e-13	Coronary artery disease;
CESC	cis	rs7586879	0.593	rs11689546	chr2:25130451	A/G	cg01884057	chr2:25150051	NA	0.37	7.08	0.4	1.26e-11	Body mass index;
CESC	cis	rs763121	0.853	rs138705	chr22:39133803	C/T	cg06022373	chr22:39101656	GTPBP1	0.87	13.92	0.65	2.02e-33	Menopause (age at onset);
CESC	cis	rs4595586	0.525	rs7970652	chr12:39374873	T/C	cg26384229	chr12:38710491	ALG10B	0.54	7.53	0.42	7.85e-13	Morning vs. evening chronotype;
CESC	cis	rs9309711	0.666	rs6723101	chr2:3484443	T/C	cg10845886	chr2:3471009	TTC15	-0.68	-9.33	-0.5	4.29e-18	Neurofibrillary tangles;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg23055396	chr11:62538850	TAF6L	-0.45	-6.66	-0.38	1.55e-10	Gambling;
CESC	cis	rs7208859	0.673	rs9907197	chr17:29018263	C/T	cg14008862	chr17:28927542	LRRC37B2	0.59	5.18	0.3	4.49e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs11696501	0.739	rs6073815	chr20:44234615	A/T	cg11783356	chr20:44313418	WFDC10B	-0.35	-5.31	-0.31	2.32e-7	Brain structure;
CESC	cis	rs7927771	0.524	rs7118747	chr11:47889545	C/T	cg20307385	chr11:47447363	PSMC3	-0.58	-8.1	-0.45	2.09e-14	Subjective well-being;
CESC	cis	rs897080	0.515	rs1067331	chr2:44627626	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.49	5.82	0.34	1.67e-8	Height;
CESC	cis	rs2288073	0.801	rs72797831	chr2:24366829	G/A	cg06627628	chr2:24431161	ITSN2	-0.71	-8.82	-0.48	1.53e-16	Venous thromboembolism (SNP x SNP interaction);
CESC	cis	rs258892	0.947	rs266444	chr5:72181404	C/T	cg21869765	chr5:72125136	TNPO1	0.47	5.96	0.34	8.09e-9	Small cell lung carcinoma;
CESC	cis	rs10504229	1.000	rs58608483	chr8:58195269	T/G	cg22535103	chr8:58192502	C8orf71	-0.89	-11.11	-0.56	8.23e-24	Developmental language disorder (linguistic errors);
CESC	cis	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg03188948	chr7:1209495	NA	0.6	6.83	0.39	5.73e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg09377915	chr6:56295593	NA	-0.43	-6.2	-0.36	2.2e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs4315565	0.764	rs4467309	chr2:69286921	C/T	cg12800200	chr2:69260302	ANTXR1	-0.42	-6.08	-0.35	4.23e-9	Height;
CESC	cis	rs9287719	0.967	rs10195802	chr2:10754532	C/T	cg00105475	chr2:10696890	NA	0.38	5.42	0.32	1.34e-7	Prostate cancer;
CESC	cis	rs6460942	0.597	rs17545416	chr7:12525944	A/T	cg20607287	chr7:12443886	VWDE	-0.71	-7.67	-0.43	3.19e-13	Coronary artery disease;
CESC	trans	rs9467711	0.606	rs9348726	chr6:26605206	G/A	cg06606381	chr12:133084897	FBRSL1	-0.76	-7.17	-0.4	7.32e-12	Autism spectrum disorder or schizophrenia;
CESC	cis	rs597539	0.690	rs11228383	chr11:68623228	T/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.78	9.35	0.5	3.73e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs1670533	1.000	rs7669399	chr4:1058478	T/G	cg27284194	chr4:1044797	NA	0.47	5.99	0.35	6.72e-9	Recombination rate (females);
CESC	cis	rs2228479	0.702	rs78331410	chr16:89917775	C/T	cg04013166	chr16:89971882	TCF25	0.74	5.83	0.34	1.59e-8	Skin colour saturation;
CESC	cis	rs9487051	1.000	rs7748918	chr6:109613564	A/G	cg01475377	chr6:109611718	NA	-0.42	-6.35	-0.36	9.13e-10	Reticulocyte fraction of red cells;
CESC	cis	rs17376456	0.877	rs9314101	chr5:93461593	A/T	cg21475434	chr5:93447410	FAM172A	0.82	7.56	0.42	6.81e-13	Diabetic retinopathy;
CESC	cis	rs2742234	0.541	rs1317214	chr10:43733531	C/G	cg07801480	chr10:43725741	RASGEF1A	-0.41	-5.3	-0.31	2.47e-7	Hirschsprung disease;
CESC	cis	rs7618915	0.501	rs3733045	chr3:52643307	A/G	cg18337363	chr3:52569053	NT5DC2	0.29	5.36	0.31	1.8e-7	Bipolar disorder;
CESC	cis	rs12325245	0.536	rs34129245	chr16:58588191	A/G	cg05725404	chr16:58534157	NDRG4	-0.61	-5.24	-0.31	3.21e-7	Schizophrenia;
CESC	trans	rs1814175	0.588	rs10839463	chr11:49971643	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.43	-6.26	-0.36	1.53e-9	Height;
CESC	cis	rs6582630	0.555	rs10880612	chr12:38509427	A/G	cg26384229	chr12:38710491	ALG10B	0.7	10.5	0.54	8.9e-22	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs7811142	1.000	rs67163493	chr7:100023838	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.08	10.67	0.55	2.41e-22	Platelet count;
CESC	cis	rs6502050	0.765	rs55905076	chr17:80105441	G/A	cg23985595	chr17:80112537	CCDC57	-0.42	-6.52	-0.37	3.51e-10	Life satisfaction;
CESC	cis	rs896854	0.516	rs12679044	chr8:95891356	C/A	cg23172400	chr8:95962367	TP53INP1	-0.36	-6.6	-0.38	2.21e-10	Type 2 diabetes;
CESC	cis	rs4665809	0.590	rs1122972	chr2:26418788	A/C	cg22920501	chr2:26401640	FAM59B	-0.85	-10.05	-0.53	2.42e-20	Gut microbiome composition (summer);
CESC	cis	rs965469	1.000	rs6051810	chr20:3355384	A/G	cg25506879	chr20:3388711	C20orf194	-0.57	-6.12	-0.35	3.41e-9	IFN-related cytopenia;
CESC	cis	rs9905704	0.647	rs12943705	chr17:57097047	T/C	cg12560992	chr17:57184187	TRIM37	-0.61	-7.5	-0.42	9.51e-13	Testicular germ cell tumor;
CESC	cis	rs61332075	0.518	rs72993031	chr2:239380028	A/G	cg18131467	chr2:239335373	ASB1	-0.74	-6.11	-0.35	3.58e-9	Lung function (FEV1/FVC);
CESC	cis	rs9457247	1.000	rs2013815	chr6:167373812	T/A	cg25258033	chr6:167368657	RNASET2	-0.41	-6.21	-0.36	2.09e-9	Crohn's disease;
CESC	cis	rs559928	0.606	rs78038516	chr11:63978067	C/G	cg18225595	chr11:63971243	STIP1	0.64	5.96	0.34	8.23e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CESC	cis	rs17253792	0.822	rs75560658	chr14:56079896	C/T	cg01858014	chr14:56050164	KTN1	-0.93	-7.33	-0.41	2.71e-12	Putamen volume;
CESC	cis	rs875971	0.862	rs7798630	chr7:65771479	G/C	cg12463550	chr7:65579703	CRCP	-0.46	-5.94	-0.34	8.81e-9	Aortic root size;
CESC	cis	rs11718455	0.960	rs34241796	chr3:44000394	A/T	cg08738300	chr3:44038990	NA	0.46	6.22	0.36	1.96e-9	Coronary artery disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg24589334	chr7:1097720	C7orf50;GPR146	0.44	6.07	0.35	4.52e-9	Fibrinogen levels;
CESC	cis	rs698833	1.000	rs1067352	chr2:44669724	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.43	5.28	0.31	2.75e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs9916302	0.904	rs1077715	chr17:37683548	A/T	cg19468946	chr17:37922297	IKZF3	-0.39	-5.04	-0.3	8.78e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs35110281	0.837	rs2838340	chr21:45076373	A/G	cg21573476	chr21:45109991	RRP1B	-0.42	-5.92	-0.34	1e-8	Mean corpuscular volume;
CESC	cis	rs11098499	0.954	rs10017371	chr4:120293776	A/G	cg09307838	chr4:120376055	NA	0.93	12.84	0.62	1.17e-29	Corneal astigmatism;
CESC	cis	rs4820539	0.966	rs5996470	chr22:23483255	G/A	cg14186256	chr22:23484241	RTDR1	0.87	16.05	0.7	5.72e-41	Bone mineral density;
CESC	cis	rs7116495	1.000	rs10128658	chr11:71733519	C/T	cg26138937	chr11:71823887	C11orf51	-0.77	-6.19	-0.36	2.3e-9	Severe influenza A (H1N1) infection;
CESC	cis	rs10751667	0.643	rs7395592	chr11:934094	C/G	cg20946044	chr11:1010712	AP2A2	-0.38	-5.21	-0.3	3.83e-7	Alzheimer's disease (late onset);
CESC	cis	rs801193	0.904	rs4718403	chr7:66242729	C/G	cg10691866	chr7:65817282	TPST1	-0.31	-5.08	-0.3	7e-7	Aortic root size;
CESC	trans	rs7618501	1.000	rs3749241	chr3:49744392	A/G	cg21582582	chr3:182698605	DCUN1D1	-0.44	-6.0	-0.35	6.29e-9	Intelligence (multi-trait analysis);
CESC	cis	rs12791968	0.765	rs12794751	chr11:44998769	C/G	cg11846598	chr11:44996168	LOC221122	-0.49	-5.91	-0.34	1.07e-8	Inhibitory control;
CESC	cis	rs1552244	1.000	rs7619340	chr3:10108178	C/T	cg16606324	chr3:10149918	C3orf24	0.43	5.22	0.31	3.71e-7	Alzheimer's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20074569	chr22:42372516	SEPT3	0.53	6.07	0.35	4.47e-9	Gut microbiome composition (summer);
CESC	cis	rs6754311	0.731	rs13404551	chr2:136721995	T/C	cg07169764	chr2:136633963	MCM6	0.71	9.2	0.49	1.07e-17	Mosquito bite size;
CESC	cis	rs4665809	1.000	rs4665305	chr2:26313524	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.74	-8.32	-0.46	4.64e-15	Gut microbiome composition (summer);
CESC	cis	rs6598955	0.612	rs12738188	chr1:26548029	G/C	cg00852783	chr1:26633632	UBXN11	0.43	6.34	0.36	9.77e-10	Obesity-related traits;
CESC	cis	rs7707921	0.522	rs9293290	chr5:81474225	A/T	cg15871215	chr5:81402204	ATG10	-0.47	-6.82	-0.39	6.01e-11	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00249632	chr4:1872469	WHSC1	0.54	6.3	0.36	1.24e-9	Gut microbiome composition (summer);
CESC	cis	rs3785574	0.962	rs7215915	chr17:61828385	C/T	cg06873352	chr17:61820015	STRADA	0.48	7.07	0.4	1.35e-11	Height;
CESC	cis	rs3741404	0.560	rs17699798	chr11:63898806	C/G	cg18225595	chr11:63971243	STIP1	-0.53	-7.39	-0.41	1.96e-12	Platelet count;
CESC	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.48	-5.04	-0.3	8.58e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs1878931	0.624	rs27241	chr16:3447282	C/G	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.8	-9.75	-0.51	2.17e-19	Body mass index (adult);
CESC	cis	rs7308134	0.653	rs73032440	chr12:1988912	G/A	cg19708984	chr12:1973340	CACNA2D4	0.54	5.09	0.3	6.84e-7	QRS duration in Tripanosoma cruzi seropositivity;
CESC	trans	rs5756813	0.635	rs11089856	chr22:38205784	A/C	cg19894588	chr14:64061835	NA	-0.68	-8.41	-0.46	2.62e-15	Optic cup area;Vertical cup-disc ratio;
CESC	cis	rs1808579	0.935	rs1805082	chr18:21120444	C/T	cg14672496	chr18:21087552	C18orf8	-0.37	-5.72	-0.33	2.86e-8	Hip circumference;Body mass index;BMI (adjusted for smoking behaviour);
CESC	cis	rs6540556	0.954	rs6685077	chr1:209933331	A/G	cg05527609	chr1:210001259	C1orf107	-0.45	-5.63	-0.33	4.66e-8	Red blood cell count;
CESC	cis	rs12824058	0.798	rs7968728	chr12:130804696	T/A	cg26677194	chr12:130822605	PIWIL1	0.49	6.24	0.36	1.74e-9	Menopause (age at onset);
CESC	cis	rs736408	0.716	rs2239550	chr3:52822509	G/C	cg18099408	chr3:52552593	STAB1	-0.32	-5.06	-0.3	7.8e-7	Bipolar disorder;
CESC	cis	rs193541	0.632	rs173481	chr5:122254552	G/A	cg19412675	chr5:122181750	SNX24	0.43	5.1	0.3	6.38e-7	Glucose homeostasis traits;
CESC	trans	rs637571	0.522	rs28578718	chr11:65748400	C/A	cg17712092	chr4:129076599	LARP1B	0.75	10.71	0.55	1.76e-22	Eosinophil percentage of white cells;
CESC	cis	rs34779708	0.931	rs2490663	chr10:35329735	A/G	cg03585969	chr10:35415529	CREM	-0.74	-9.91	-0.52	6.61e-20	Inflammatory bowel disease;Crohn's disease;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg00876541	chr19:10515578	MIR1181;CDC37	-0.46	-6.04	-0.35	5.09e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs4975709	0.569	rs2353583	chr5:1858834	G/C	cg17650747	chr5:1873721	NA	0.45	6.02	0.35	5.77e-9	Cardiovascular disease risk factors;
CESC	cis	rs10170846	0.861	rs4674677	chr2:223529658	G/A	cg25565276	chr2:223520875	FARSB	0.51	7.09	0.4	1.19e-11	Schizophrenia (inflammation and infection response interaction);
CESC	cis	rs7605827	0.897	rs4140714	chr2:15515723	T/A	cg19274914	chr2:15703543	NA	0.31	5.39	0.31	1.55e-7	Educational attainment (years of education);
CESC	cis	rs9894429	0.646	rs12603868	chr17:79618834	G/C	cg13777783	chr17:79615861	NA	-0.31	-5.11	-0.3	6.2e-7	Eye color traits;
CESC	cis	rs793571	0.502	rs395601	chr15:59063196	G/C	cg05156742	chr15:59063176	FAM63B	0.79	11.5	0.58	4.28e-25	Schizophrenia;
CESC	cis	rs2836974	0.563	rs6517522	chr21:40553845	T/C	cg17971929	chr21:40555470	PSMG1	0.7	9.64	0.51	4.85e-19	Cognitive function;
CESC	cis	rs1801251	1.000	rs1867778	chr2:233679644	C/T	cg08000102	chr2:233561755	GIGYF2	-0.68	-9.89	-0.52	7.66e-20	Coronary artery disease;
CESC	cis	rs11676348	0.846	rs6723449	chr2:218997580	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.44	5.93	0.34	9.61e-9	Ulcerative colitis;
CESC	cis	rs1669338	0.588	rs62228634	chr3:3184985	A/G	cg16797762	chr3:3221439	CRBN	-0.56	-6.14	-0.35	2.95e-9	White matter integrity;
CESC	cis	rs933688	1.000	rs11959525	chr5:90703840	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.08	13.37	0.63	1.66e-31	Smoking behavior;
CESC	cis	rs3820928	1.000	rs10193404	chr2:227777757	A/G	cg11843606	chr2:227700838	RHBDD1	-0.43	-5.8	-0.34	1.84e-8	Pulmonary function;
CESC	cis	rs514406	0.861	rs7513052	chr1:53241360	C/T	cg16325326	chr1:53192061	ZYG11B	-0.71	-11.84	-0.59	3e-26	Monocyte count;
CESC	cis	rs875971	0.789	rs7808013	chr7:66071196	A/G	cg11764359	chr7:65958608	NA	-0.78	-11.32	-0.57	1.76e-24	Aortic root size;
CESC	cis	rs8060686	0.641	rs79323429	chr16:68084594	A/G	cg26727032	chr16:67993705	SLC12A4	-0.54	-6.16	-0.35	2.65e-9	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs10911251	0.546	rs1062044	chr1:183112412	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.84	13.22	0.63	5.53e-31	Colorectal cancer;
CESC	cis	rs7208859	0.673	rs9909497	chr17:29173228	C/A	cg19761014	chr17:28927070	LRRC37B2	0.72	5.71	0.33	3.06e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs7605827	0.964	rs6733847	chr2:15564930	G/A	cg19274914	chr2:15703543	NA	0.35	6.29	0.36	1.3e-9	Educational attainment (years of education);
CESC	cis	rs3857067	0.740	rs6532470	chr4:95108211	C/G	cg11021082	chr4:95130006	SMARCAD1	-0.6	-9.05	-0.49	3.25e-17	QT interval;
CESC	cis	rs4835473	0.932	rs10857415	chr4:144829906	C/T	cg25736465	chr4:144833511	NA	0.41	6.32	0.36	1.09e-9	Immature fraction of reticulocytes;
CESC	cis	rs6062302	0.548	rs6089940	chr20:62252695	C/T	cg09650180	chr20:62225654	GMEB2	-0.82	-9.32	-0.5	4.63e-18	Glioblastoma;
CESC	cis	rs7980687	0.506	rs1611973	chr12:123622731	C/G	cg00376283	chr12:123451042	ABCB9	0.69	9.71	0.51	2.96e-19	Height;Educational attainment;Head circumference (infant);
CESC	cis	rs1018836	0.923	rs6998150	chr8:91645969	A/C	cg16814680	chr8:91681699	NA	-0.74	-10.39	-0.54	1.92e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs6580649	0.941	rs7312326	chr12:48480643	G/A	cg05342945	chr12:48394962	COL2A1	0.5	5.74	0.33	2.59e-8	Lung cancer;
CESC	cis	rs1552244	0.572	rs58223482	chr3:10169746	G/C	cg00149659	chr3:10157352	C3orf10	0.98	11.92	0.59	1.59e-26	Alzheimer's disease;
CESC	cis	rs13223928	0.511	rs11773338	chr7:3144508	T/C	cg19214707	chr7:3157722	NA	-0.4	-5.34	-0.31	2.02e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
CESC	cis	rs12912251	0.591	rs2643216	chr15:39003809	C/G	cg10631289	chr15:39006617	NA	-0.48	-5.13	-0.3	5.51e-7	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
CESC	cis	rs72627123	0.867	rs113257091	chr14:74461121	C/T	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.75	5.27	0.31	2.89e-7	Morning vs. evening chronotype;
CESC	cis	rs2249625	0.967	rs2496532	chr6:72919917	A/T	cg18830697	chr6:72922368	RIMS1	-0.45	-6.36	-0.36	8.97e-10	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CESC	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg05564831	chr3:52568323	NT5DC2	0.53	8.95	0.48	6.22e-17	Electroencephalogram traits;
CESC	cis	rs6860806	0.531	rs272887	chr5:131665713	A/G	cg07395648	chr5:131743802	NA	-0.43	-5.67	-0.33	3.73e-8	Breast cancer;
CESC	cis	rs9457247	1.000	rs2149085	chr6:167371110	T/C	cg25258033	chr6:167368657	RNASET2	-0.42	-6.24	-0.36	1.73e-9	Crohn's disease;
CESC	cis	rs12912251	1.000	rs2172835	chr15:38990171	C/T	cg01338139	chr15:38987640	C15orf53	-0.48	-5.71	-0.33	2.99e-8	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
CESC	cis	rs72781680	0.898	rs6712524	chr2:24083925	T/C	cg20701182	chr2:24300061	SF3B14	0.63	5.63	0.33	4.49e-8	Lymphocyte counts;
CESC	cis	rs17253792	0.915	rs17832389	chr14:56185836	A/G	cg01858014	chr14:56050164	KTN1	-0.93	-7.3	-0.41	3.33e-12	Putamen volume;
CESC	cis	rs11638352	0.661	rs2555384	chr15:44420900	T/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.56	-5.29	-0.31	2.53e-7	Lipoprotein phospholipase A2 activity in cardiovascular disease;
CESC	cis	rs5753037	0.585	rs7954	chr22:30184950	A/G	cg01021169	chr22:30184971	ASCC2	-0.57	-8.66	-0.47	4.71e-16	Type 1 diabetes;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg08230990	chr9:34377068	KIAA1161	-0.41	-6.1	-0.35	3.72e-9	Gambling;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg11088380	chr13:25497236	CENPJ	0.53	7.04	0.4	1.62e-11	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs11711311	0.826	rs13077644	chr3:113467777	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.59	7.81	0.43	1.36e-13	IgG glycosylation;
CESC	cis	rs589448	1.000	rs589448	chr12:69752200	A/G	cg22834771	chr12:69754056	YEATS4	-0.54	-7.24	-0.41	4.92e-12	Cerebrospinal fluid biomarker levels;
CESC	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg07677032	chr17:61819896	STRADA	0.45	5.97	0.34	7.74e-9	Prudent dietary pattern;
CESC	cis	rs7666738	0.830	rs17027216	chr4:99009152	G/C	cg03467027	chr4:99064603	C4orf37	0.44	5.63	0.33	4.57e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10045504	0.502	rs17456482	chr5:38737783	G/C	cg15396434	chr5:38725168	NA	-0.73	-6.84	-0.39	5.61e-11	Night sleep phenotypes;
CESC	cis	rs36051895	0.632	rs61461940	chr9:5157277	T/C	cg02405213	chr9:5042618	JAK2	-0.47	-5.84	-0.34	1.53e-8	Pediatric autoimmune diseases;
CESC	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg03188948	chr7:1209495	NA	0.46	6.01	0.35	6.1e-9	Longevity;Endometriosis;
CESC	cis	rs1707322	0.964	rs12067716	chr1:46434428	T/A	cg03146154	chr1:46216737	IPP	0.78	10.68	0.55	2.25e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9611565	0.765	rs132908	chr22:41801795	G/A	cg17376030	chr22:41985996	PMM1	-0.68	-7.12	-0.4	1.02e-11	Vitiligo;
CESC	cis	rs939658	0.776	rs35904425	chr15:79444567	G/A	cg17916960	chr15:79447300	NA	-0.36	-5.88	-0.34	1.22e-8	Refractive error;
CESC	cis	rs1005277	0.579	rs2800485	chr10:38542588	G/A	cg25427524	chr10:38739819	LOC399744	-0.73	-10.76	-0.55	1.24e-22	Extrinsic epigenetic age acceleration;
CESC	cis	rs6460942	1.000	rs7792759	chr7:12311715	A/G	cg20607287	chr7:12443886	VWDE	0.64	7.01	0.4	1.93e-11	Coronary artery disease;
CESC	cis	rs950776	0.518	rs12906951	chr15:78825562	C/T	cg06917634	chr15:78832804	PSMA4	0.8	12.12	0.6	3.34e-27	Sudden cardiac arrest;
CESC	cis	rs9790314	1.000	rs1382428	chr3:161032386	A/C	cg03342759	chr3:160939853	NMD3	-0.48	-6.25	-0.36	1.61e-9	Morning vs. evening chronotype;
CESC	trans	rs11098499	0.954	rs10006525	chr4:120408931	T/G	cg25214090	chr10:38739885	LOC399744	0.71	10.17	0.53	9.87e-21	Corneal astigmatism;
CESC	cis	rs12701220	0.503	rs13222294	chr7:1172969	G/A	cg02733842	chr7:1102375	C7orf50	-0.38	-5.21	-0.3	3.76e-7	Bronchopulmonary dysplasia;
CESC	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg11494091	chr17:61959527	GH2	0.72	12.13	0.6	3.12e-27	Prudent dietary pattern;
CESC	cis	rs875971	0.545	rs13311962	chr7:66068129	C/T	cg18876405	chr7:65276391	NA	-0.5	-5.83	-0.34	1.62e-8	Aortic root size;
CESC	cis	rs962856	0.575	rs6740919	chr2:67620055	C/G	cg09028215	chr2:67624308	ETAA1	0.41	5.25	0.31	3.06e-7	Pancreatic cancer;
CESC	trans	rs12356475	0.710	rs10822686	chr10:67733250	C/T	cg16321474	chr12:48299386	VDR	0.49	6.44	0.37	5.43e-10	Psoriatic arthritis;
CESC	cis	rs2070488	0.775	rs4371464	chr3:38548021	T/C	cg24069376	chr3:38537580	EXOG	-0.32	-5.51	-0.32	8.63e-8	Electrocardiographic conduction measures;
CESC	trans	rs11992162	0.967	rs10108320	chr8:11832263	A/T	cg15556689	chr8:8085844	FLJ10661	-0.52	-6.1	-0.35	3.72e-9	Monocyte count;
CESC	cis	rs9291683	0.546	rs13129453	chr4:10044784	T/C	cg00071950	chr4:10020882	SLC2A9	0.81	13.65	0.64	1.7e-32	Bone mineral density;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06848247	chr2:6635800	NA	-0.59	-7.23	-0.41	5.14e-12	Gut microbiome composition (summer);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg08151832	chr16:66835414	CCDC79	0.51	7.01	0.4	1.97e-11	Fibrinogen levels;
CESC	cis	rs753778	0.628	rs1045248	chr8:142204326	C/G	cg18755752	chr8:142205143	DENND3	-0.67	-10.02	-0.52	2.95e-20	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	cis	rs1371867	0.846	rs1788167	chr8:101319996	C/T	cg11906718	chr8:101322791	RNF19A	0.46	5.92	0.34	1.02e-8	Atrioventricular conduction;
CESC	cis	rs977987	0.806	rs72787160	chr16:75445162	G/C	cg03315344	chr16:75512273	CHST6	0.41	5.86	0.34	1.35e-8	Dupuytren's disease;
CESC	cis	rs9733	0.621	rs6669122	chr1:150591732	A/G	cg13175981	chr1:150552382	MCL1	0.72	10.91	0.56	3.88e-23	Tonsillectomy;
CESC	cis	rs6952808	0.500	rs3800902	chr7:2144378	C/T	cg04267008	chr7:1944627	MAD1L1	-0.61	-7.42	-0.41	1.57e-12	Bipolar disorder and schizophrenia;
CESC	cis	rs6502050	0.835	rs4641801	chr17:80154021	G/A	cg23985595	chr17:80112537	CCDC57	-0.4	-6.42	-0.37	6.32e-10	Life satisfaction;
CESC	cis	rs9898	0.589	rs6767451	chr3:186366216	A/G	cg17206748	chr3:186370508	FETUB	0.3	5.06	0.3	7.97e-7	Cerebrospinal fluid biomarker levels;Activated partial thromboplastin time;
CESC	cis	rs8031584	0.958	rs7168641	chr15:31235452	G/A	cg14829155	chr15:31115871	NA	-0.7	-9.48	-0.5	1.51e-18	Huntington's disease progression;
CESC	cis	rs34779708	0.741	rs34397613	chr10:35550313	A/G	cg04310649	chr10:35416472	CREM	-0.46	-5.23	-0.31	3.48e-7	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs116095464	0.558	rs56043030	chr5:220917	A/G	cg22496380	chr5:211416	CCDC127	-0.72	-8.57	-0.47	8.59e-16	Breast cancer;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg12145550	chr20:44600942	ZNF335	-0.38	-6.18	-0.35	2.43e-9	Gambling;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08198330	chr19:15483731	AKAP8	-0.55	-6.12	-0.35	3.4e-9	Gut microbiome composition (summer);
CESC	cis	rs8058578	1.000	rs6565197	chr16:30706477	T/C	cg02466173	chr16:30829666	NA	-0.4	-6.38	-0.36	8.06e-10	Multiple myeloma;
CESC	trans	rs56114371	0.777	rs200483	chr6:27774824	C/T	cg06606381	chr12:133084897	FBRSL1	-0.8	-8.14	-0.45	1.52e-14	Breast cancer;
CESC	cis	rs796364	0.806	rs78527234	chr2:200913453	C/T	cg23649088	chr2:200775458	C2orf69	-0.55	-5.05	-0.3	8.29e-7	Schizophrenia;
CESC	cis	rs72781680	0.898	rs113027486	chr2:24098371	G/A	cg20701182	chr2:24300061	SF3B14	0.62	5.68	0.33	3.54e-8	Lymphocyte counts;
CESC	cis	rs589448	0.967	rs2617834	chr12:69753365	T/C	cg20891283	chr12:69753455	YEATS4	1.0	17.29	0.73	2.3e-45	Cerebrospinal fluid biomarker levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26030974	chr17:45266791	CDC27	0.56	6.4	0.37	6.83e-10	Gut microbiome composition (summer);
CESC	cis	rs7216064	1.000	rs12451511	chr17:65874861	T/G	cg07042672	chr17:66097459	LOC651250	-0.52	-5.4	-0.31	1.5e-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs798554	0.797	rs798486	chr7:2803037	A/G	cg18446336	chr7:2847575	GNA12	-0.4	-5.97	-0.34	7.59e-9	Height;
CESC	cis	rs10504229	0.775	rs56155911	chr8:58163247	C/T	cg05313129	chr8:58192883	C8orf71	-0.48	-5.18	-0.3	4.41e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs8180040	0.966	rs3816779	chr3:47543389	C/T	cg27129171	chr3:47204927	SETD2	0.6	8.87	0.48	1.1e-16	Colorectal cancer;
CESC	cis	rs9303401	0.614	rs2333409	chr17:57139134	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.91	11.32	0.57	1.71e-24	Cognitive test performance;
CESC	cis	rs35110281	0.744	rs230644	chr21:44917183	C/T	cg01579765	chr21:45077557	HSF2BP	0.52	8.88	0.48	1.06e-16	Mean corpuscular volume;
CESC	cis	rs9796	0.553	rs7171437	chr15:41315168	G/A	cg02330683	chr15:41787940	ITPKA	0.39	5.33	0.31	2.12e-7	Menopause (age at onset);
CESC	cis	rs1904096	0.506	rs12511433	chr4:95162425	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.61	-9.62	-0.51	5.56e-19	Type 2 diabetes;
CESC	cis	rs9916302	0.610	rs11078902	chr17:37631883	C/G	cg00129232	chr17:37814104	STARD3	-0.53	-6.91	-0.39	3.67e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs1567558	0.554	rs2048459	chr3:140935717	G/A	cg16418163	chr3:140950828	ACPL2	-0.39	-5.03	-0.3	9.1e-7	Neutrophil count;Sum basophil neutrophil counts;
CESC	cis	rs4718428	0.705	rs10267335	chr7:66403220	G/T	cg18252515	chr7:66147081	NA	-0.47	-5.34	-0.31	2.01e-7	Corneal structure;
CESC	cis	rs6464772	0.540	rs10952668	chr7:140143520	C/T	cg17228231	chr7:140178305	MKRN1	0.51	6.88	0.39	4.37e-11	Creatinine levels in ischemic stroke;
CESC	cis	rs80282103	0.618	rs74117850	chr10:1165777	T/C	cg08668510	chr10:1095578	IDI1	0.74	5.91	0.34	1.07e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs4665809	1.000	rs1560868	chr2:26281459	A/T	cg08470875	chr2:26401718	FAM59B	0.58	6.37	0.36	8.15e-10	Gut microbiome composition (summer);
CESC	cis	rs853679	0.550	rs1233704	chr6:28166923	A/G	cg18032046	chr6:28092343	ZSCAN16	0.44	5.3	0.31	2.46e-7	Depression;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04962756	chr11:65425928	RELA	-0.47	-6.09	-0.35	4.05e-9	Gut microbiome composition (summer);
CESC	cis	rs3126085	0.935	rs114825811	chr1:152231877	G/A	cg03465714	chr1:152285911	FLG	0.49	5.42	0.32	1.36e-7	Atopic dermatitis;
CESC	cis	rs1538970	0.924	rs10890327	chr1:45891458	C/T	cg05343316	chr1:45956843	TESK2	0.89	12.41	0.61	3.59e-28	Platelet count;
CESC	cis	rs1862618	0.853	rs832568	chr5:56153776	G/A	cg24531977	chr5:56204891	C5orf35	-0.88	-10.96	-0.56	2.74e-23	Initial pursuit acceleration;
CESC	cis	rs523522	0.924	rs11065150	chr12:120958875	T/G	cg27279351	chr12:120934652	DYNLL1	0.69	9.03	0.49	3.56e-17	High light scatter reticulocyte count;
CESC	cis	rs832540	0.629	rs6888317	chr5:56093307	A/G	cg22800045	chr5:56110881	MAP3K1	-0.51	-5.98	-0.35	7.02e-9	Coronary artery disease;
CESC	cis	rs9322193	0.923	rs57012784	chr6:149948827	G/A	cg07701084	chr6:150067640	NUP43	0.45	6.23	0.36	1.86e-9	Lung cancer;
CESC	cis	rs7647973	0.580	rs11716334	chr3:49230096	G/A	cg06212747	chr3:49208901	KLHDC8B	0.72	10.97	0.56	2.5e-23	Menarche (age at onset);
CESC	cis	rs72634258	0.554	rs7556518	chr1:7847846	G/A	cg26816564	chr1:7831052	VAMP3	0.65	5.91	0.34	1.03e-8	Inflammatory bowel disease;
CESC	cis	rs9733	0.596	rs11204697	chr1:150658971	C/T	cg04414720	chr1:150670196	GOLPH3L	0.63	9.02	0.48	3.87e-17	Tonsillectomy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01192531	chr20:34287185	ROMO1;NFS1	0.63	7.07	0.4	1.37e-11	Gut microbiome composition (summer);
CESC	cis	rs6570726	0.577	rs867056	chr6:145784805	A/C	cg05347473	chr6:146136440	FBXO30	-0.72	-9.24	-0.49	8.06e-18	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs58688157	0.705	rs12800061	chr11:587425	C/A	cg02461776	chr11:598696	PHRF1	0.49	5.48	0.32	9.76e-8	Systemic lupus erythematosus;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21308919	chr4:140619560	MGST2	-0.56	-6.83	-0.39	5.8200000000000003e-11	Gut microbiome composition (summer);
CESC	cis	rs8067545	0.516	rs11869258	chr17:20206898	G/A	cg13482628	chr17:19912719	NA	-0.42	-5.61	-0.33	5.2e-8	Schizophrenia;
CESC	trans	rs10435719	0.702	rs77055881	chr8:11790581	T/C	cg15556689	chr8:8085844	FLJ10661	0.52	6.36	0.36	8.63e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
CESC	cis	rs28374715	0.532	rs1899	chr15:41689232	C/T	cg02330683	chr15:41787940	ITPKA	0.43	5.28	0.31	2.72e-7	Ulcerative colitis;
CESC	trans	rs650950	0.528	rs646660	chr11:35528452	C/T	cg02051553	chr1:10044519	NMNAT1	-0.46	-6.22	-0.36	1.89e-9	Bronchopulmonary dysplasia;
CESC	cis	rs910316	0.726	rs61979167	chr14:75663610	C/T	cg08847533	chr14:75593920	NEK9	-0.85	-14.01	-0.65	9.35e-34	Height;
CESC	cis	rs9549260	0.709	rs4581585	chr13:41203905	C/T	cg21288729	chr13:41239152	FOXO1	0.63	8.4	0.46	2.8e-15	Red blood cell count;
CESC	cis	rs7615952	0.599	rs67566088	chr3:125768973	C/A	cg06494592	chr3:125709126	NA	-0.49	-5.2	-0.3	3.92e-7	Blood pressure (smoking interaction);
CESC	cis	rs17376456	0.597	rs7733142	chr5:93322795	C/A	cg25358565	chr5:93447407	FAM172A	-0.46	-5.43	-0.32	1.28e-7	Diabetic retinopathy;
CESC	cis	rs7666738	0.830	rs13130923	chr4:99046281	T/C	cg03676636	chr4:99064102	C4orf37	0.33	5.12	0.3	5.93e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9660992	0.674	rs72745221	chr1:205262337	G/A	cg00857998	chr1:205179979	DSTYK	0.49	5.51	0.32	8.52e-8	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs425277	0.561	rs11584491	chr1:2042543	A/G	cg13918804	chr1:2043761	PRKCZ	0.27	5.12	0.3	5.84e-7	Height;
CESC	cis	rs4925386	0.840	rs6143024	chr20:60914229	A/G	cg06026331	chr20:60912101	LAMA5	0.48	5.15	0.3	5.09e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs9393777	0.513	rs9368447	chr6:26646674	A/C	cg12826209	chr6:26865740	GUSBL1	0.75	8.45	0.46	1.9e-15	Intelligence (multi-trait analysis);
CESC	cis	rs7843479	0.965	rs11135741	chr8:21801091	C/T	cg17168535	chr8:21777572	XPO7	0.51	6.96	0.39	2.6e-11	Mean corpuscular volume;
CESC	cis	rs9443189	0.570	rs661229	chr6:76293793	G/A	cg01950844	chr6:76311363	SENP6	0.87	9.54	0.51	9.61e-19	Prostate cancer;
CESC	cis	rs67478160	0.619	rs12437066	chr14:104236844	A/C	cg01849466	chr14:104193079	ZFYVE21	-0.54	-7.78	-0.43	1.62e-13	Schizophrenia;
CESC	cis	rs8060686	0.516	rs4567701	chr16:68163662	T/C	cg26727032	chr16:67993705	SLC12A4	-0.55	-7.65	-0.43	3.84e-13	HDL cholesterol;Metabolic syndrome;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg27315239	chr1:53593711	SLC1A7	0.44	6.36	0.36	8.62e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs13191362	1.000	rs34594856	chr6:163051845	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.52	5.7	0.33	3.12e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs2836950	0.565	rs2836942	chr21:40591381	A/G	cg11644478	chr21:40555479	PSMG1	-0.52	-7.01	-0.4	2.03e-11	Menarche (age at onset);
CESC	cis	rs2637266	0.703	rs6480836	chr10:78446866	C/T	cg18941641	chr10:78392320	NA	0.4	7.27	0.41	4.01e-12	Pulmonary function;
CESC	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg01024009	chr3:145968696	PLSCR4	0.53	6.96	0.39	2.74e-11	Myopia (pathological);
CESC	cis	rs2280018	0.609	rs2941253	chr16:15173746	G/A	cg27102117	chr16:15229624	NA	0.55	8.39	0.46	2.89e-15	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs7078219	0.714	rs10883369	chr10:101291367	C/T	cg09788492	chr10:101292477	NKX2-3	0.31	5.05	0.3	8.24e-7	Dental caries;
CESC	cis	rs8062405	0.754	rs62034323	chr16:28536473	C/T	cg07382826	chr16:28625726	SULT1A1	0.31	5.05	0.3	8.32e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs9549367	0.789	rs2287244	chr13:113887173	C/G	cg00898013	chr13:113819073	PROZ	0.48	7.0	0.4	2.09e-11	Platelet distribution width;
CESC	cis	rs8071756	1.000	rs8071756	chr17:1574342	C/T	ch.17.72133F	chr17:1577994	PRPF8	-0.5	-5.44	-0.32	1.22e-7	Blood protein levels;
CESC	cis	rs10129255	0.500	rs2105991	chr14:107138039	C/G	cg23076370	chr14:107095027	NA	-0.62	-9.36	-0.5	3.53e-18	Kawasaki disease;
CESC	cis	rs796364	0.806	rs11684895	chr2:201009026	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.72	-6.48	-0.37	4.47e-10	Schizophrenia;
CESC	cis	rs7618501	0.633	rs6446189	chr3:50008566	A/G	cg24110177	chr3:50126178	RBM5	-0.52	-6.97	-0.39	2.45e-11	Intelligence (multi-trait analysis);
CESC	cis	rs367943	0.637	rs6891711	chr5:113009026	G/T	cg12552261	chr5:112820674	MCC	-0.45	-5.6	-0.33	5.26e-8	Type 2 diabetes;
CESC	cis	rs10504229	1.000	rs6987435	chr8:58177334	G/A	cg22535103	chr8:58192502	C8orf71	-1.07	-13.81	-0.65	4.87e-33	Developmental language disorder (linguistic errors);
CESC	cis	rs9916302	0.904	rs8065879	chr17:37515978	G/A	cg07936489	chr17:37558343	FBXL20	0.82	11.93	0.59	1.54e-26	Glomerular filtration rate (creatinine);
CESC	cis	rs2180341	0.924	rs9285459	chr6:127631113	T/C	cg24812749	chr6:127587940	RNF146	1.07	15.48	0.69	6e-39	Breast cancer;
CESC	cis	rs7666738	0.830	rs1426667	chr4:98949772	T/C	cg05340658	chr4:99064831	C4orf37	0.8	12.48	0.61	2e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6089829	0.962	rs11086151	chr20:61664644	C/T	cg08564027	chr20:61660810	NA	0.9	15.42	0.69	9.97e-39	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs2637266	1.000	rs10219023	chr10:78364537	G/A	cg18941641	chr10:78392320	NA	0.42	7.87	0.44	8.96e-14	Pulmonary function;
CESC	cis	rs7264396	0.563	rs6060580	chr20:34310512	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.91	-10.67	-0.55	2.46e-22	Total cholesterol levels;
CESC	cis	rs7809950	0.954	rs2520243	chr7:107136973	T/C	cg23024343	chr7:107201750	COG5	-0.43	-6.08	-0.35	4.11e-9	Coronary artery disease;
CESC	cis	rs8081692	1	rs8081692	chr17:38154595	A/G	cg17467752	chr17:38218738	THRA	0.67	10.02	0.52	3.12e-20	Neutrophil count;
CESC	cis	rs6460942	0.659	rs13247370	chr7:12514632	T/C	cg06484146	chr7:12443880	VWDE	-0.64	-7.17	-0.4	7.7e-12	Coronary artery disease;
CESC	cis	rs9733	0.596	rs6692960	chr1:150695965	G/A	cg09365446	chr1:150670422	GOLPH3L	0.42	5.84	0.34	1.55e-8	Tonsillectomy;
CESC	cis	rs67311347	1.000	rs11707673	chr3:40450604	C/A	cg09455208	chr3:40491958	NA	0.52	8.48	0.46	1.61e-15	Renal cell carcinoma;
CESC	cis	rs1448094	0.817	rs10863121	chr12:86343834	A/C	cg02569458	chr12:86230093	RASSF9	-0.37	-5.44	-0.32	1.22e-7	Major depressive disorder;
CESC	trans	rs73568641	0.508	rs73572679	chr6:154101173	C/A	cg08374472	chr16:87445639	ZCCHC14	-0.46	-6.29	-0.36	1.28e-9	Methadone dose in opioid dependence;
CESC	trans	rs561341	1.000	rs2470267	chr17:30274132	G/A	cg27661571	chr11:113659931	NA	-0.68	-6.86	-0.39	4.92e-11	Hip circumference adjusted for BMI;
CESC	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg11494091	chr17:61959527	GH2	0.73	12.49	0.61	1.88e-28	Prudent dietary pattern;
CESC	trans	rs3780486	0.834	rs75443249	chr9:33149207	A/G	cg04842962	chr6:43655489	MRPS18A	0.89	13.28	0.63	3.36e-31	IgG glycosylation;
CESC	trans	rs11039798	0.588	rs59777067	chr11:49015350	C/T	cg15704280	chr7:45808275	SEPT13	0.66	6.64	0.38	1.72e-10	Axial length;
CESC	cis	rs853679	0.517	rs9468297	chr6:28118874	G/T	cg23161317	chr6:28129485	ZNF389	0.52	6.48	0.37	4.48e-10	Depression;
CESC	cis	rs801193	1.000	rs2659915	chr7:66153101	A/G	cg25985355	chr7:65971099	NA	-0.31	-5.21	-0.3	3.79e-7	Aortic root size;
CESC	cis	rs6952808	0.929	rs11761270	chr7:1923695	C/T	cg08027265	chr7:2291960	NA	-0.35	-5.22	-0.31	3.56e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs4253772	0.591	rs6008538	chr22:46685963	G/A	cg09491104	chr22:46646882	C22orf40	-0.64	-9.33	-0.5	4.39e-18	LDL cholesterol;Cholesterol, total;
CESC	cis	rs2839186	0.709	rs2156117	chr21:47669300	C/A	cg13126279	chr21:47581558	C21orf56	-0.49	-6.63	-0.38	1.83e-10	Testicular germ cell tumor;
CESC	cis	rs13118159	0.934	rs4974553	chr4:1356911	G/A	cg02018176	chr4:1364513	KIAA1530	0.46	6.7	0.38	1.23e-10	Longevity;
CESC	cis	rs9322193	0.962	rs10872653	chr6:150100043	A/C	cg13206674	chr6:150067644	NUP43	0.41	5.78	0.33	2.04e-8	Lung cancer;
CESC	cis	rs950169	1.000	rs62026530	chr15:84775840	G/T	cg17507749	chr15:85114479	UBE2QP1	0.6	6.5	0.37	3.92e-10	Schizophrenia;
CESC	cis	rs7264396	0.623	rs2425127	chr20:34332037	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.63	6.84	0.39	5.48e-11	Total cholesterol levels;
CESC	cis	rs7666738	0.830	rs10856936	chr4:99011319	T/C	cg17366294	chr4:99064904	C4orf37	0.59	8.43	0.46	2.18e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7811142	1.000	rs1000215	chr7:100004543	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.87	10.01	0.52	3.2e-20	Platelet count;
CESC	cis	rs8177179	0.967	rs6439434	chr3:133450371	T/G	cg18769074	chr3:133464867	TF	0.32	6.1	0.35	3.64e-9	Iron status biomarkers (transferrin levels);
CESC	cis	rs7208859	0.623	rs8075341	chr17:29136565	A/G	cg14008862	chr17:28927542	LRRC37B2	0.65	5.14	0.3	5.34e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs1401999	1.000	rs939336	chr3:183685534	A/G	cg01324343	chr3:183735012	ABCC5	0.62	13.06	0.63	1.92e-30	Anterior chamber depth;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27587257	chr11:1002310	AP2A2	-0.5	-6.12	-0.35	3.41e-9	Gut microbiome composition (summer);
CESC	cis	rs818427	0.896	rs818429	chr5:112220534	T/C	cg07820702	chr5:112228657	REEP5	-0.47	-6.13	-0.35	3.22e-9	Total body bone mineral density;
CESC	cis	rs889312	0.500	rs866223	chr5:56125353	A/G	cg14703610	chr5:56206110	C5orf35	0.5	6.66	0.38	1.56e-10	Breast cancer;Breast cancer (early onset);
CESC	cis	rs9640161	0.750	rs11765644	chr7:150026339	C/G	cg17279839	chr7:150038598	RARRES2	0.43	5.31	0.31	2.31e-7	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs8031584	0.706	rs2177670	chr15:31157751	G/T	cg08109568	chr15:31115862	NA	-0.71	-9.63	-0.51	5.02e-19	Huntington's disease progression;
CESC	cis	rs6484504	0.576	rs208088	chr11:31192686	T/C	cg14844989	chr11:31128820	NA	-0.42	-5.91	-0.34	1.05e-8	Red blood cell count;
CESC	cis	rs7618915	0.501	rs6804145	chr3:52694198	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	7.86	0.43	9.89e-14	Bipolar disorder;
CESC	cis	rs7666738	0.830	rs10470894	chr4:99039107	G/A	cg05340658	chr4:99064831	C4orf37	0.8	12.39	0.61	3.91e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2795502	0.873	rs3123753	chr10:43404899	C/T	cg20628663	chr10:43360327	NA	0.53	5.93	0.34	9.29e-9	Blood protein levels;
CESC	cis	rs10504229	0.683	rs73605816	chr8:58117167	T/C	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs7959452	0.590	rs7968629	chr12:69782857	G/A	cg20891283	chr12:69753455	YEATS4	0.91	15.03	0.68	2.41e-37	Blood protein levels;
CESC	cis	rs8031584	0.872	rs11634761	chr15:31243173	A/C	cg14298792	chr15:30685198	CHRFAM7A	-0.48	-5.72	-0.33	2.81e-8	Huntington's disease progression;
CESC	cis	rs9467711	0.606	rs2073531	chr6:26375256	A/G	cg14345882	chr6:26364793	BTN3A2	0.63	6.39	0.37	7.52e-10	Autism spectrum disorder or schizophrenia;
CESC	trans	rs61931739	0.500	rs11053185	chr12:34428857	A/G	cg26384229	chr12:38710491	ALG10B	0.53	7.27	0.41	3.96e-12	Morning vs. evening chronotype;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg00926502	chr13:103451549	BIVM;KDELC1	0.5	6.61	0.38	2.11e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs7178572	0.568	rs12443386	chr15:77491389	C/T	cg22256960	chr15:77711686	NA	0.53	6.38	0.36	7.89e-10	Type 2 diabetes;
CESC	cis	rs7845219	0.525	rs3019175	chr8:95949013	G/A	cg16049864	chr8:95962084	TP53INP1	-0.46	-6.61	-0.38	2.16e-10	Type 2 diabetes;
CESC	trans	rs9987353	0.840	rs329994	chr8:9123233	A/G	cg15421363	chr5:131826865	IRF1	-0.44	-6.03	-0.35	5.52e-9	Recombination measurement;
CESC	cis	rs853679	1.000	rs1778511	chr6:28229411	G/A	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	-0.71	-7.39	-0.41	1.97e-12	Depression;
CESC	cis	rs10751667	0.643	rs10902257	chr11:973577	T/C	cg06064525	chr11:970664	AP2A2	-0.46	-8.92	-0.48	7.68e-17	Alzheimer's disease (late onset);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg09622330	chr16:10205262	GRIN2A	0.5	7.26	0.41	4.19e-12	Fibrinogen levels;
CESC	cis	rs2479724	0.870	rs6902650	chr6:41764080	G/A	cg08135965	chr6:41755394	TOMM6	-0.4	-5.39	-0.31	1.58e-7	Menarche (age at onset);
CESC	cis	rs8114671	0.586	rs6087634	chr20:33413809	G/A	cg06115741	chr20:33292138	TP53INP2	0.44	5.17	0.3	4.66e-7	Height;
CESC	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg22963979	chr7:1858916	MAD1L1	0.39	5.52	0.32	8.12e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs77956314	0.515	rs10850741	chr12:117432004	A/G	cg25972092	chr12:117363249	FBXW8	0.51	5.69	0.33	3.34e-8	Subcortical brain region volumes;Hippocampal volume;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg06466203	chr10:89623360	PTEN;KILLIN	-0.43	-6.8	-0.39	6.82e-11	Gambling;
CESC	cis	rs2288073	0.562	rs112892911	chr2:24590800	G/A	cg06627628	chr2:24431161	ITSN2	-0.99	-11.28	-0.57	2.4e-24	Venous thromboembolism (SNP x SNP interaction);
CESC	cis	rs7810240	1.000	rs56333034	chr7:150093330	G/A	cg10018233	chr7:150070692	REPIN1	-0.32	-5.55	-0.32	7.08e-8	Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;
CESC	cis	rs9611565	0.694	rs106860	chr22:41840407	C/T	cg06481639	chr22:41940642	POLR3H	-0.6	-6.11	-0.35	3.47e-9	Vitiligo;
CESC	cis	rs12682352	0.652	rs1567398	chr8:8726804	A/C	cg17143192	chr8:8559678	CLDN23	-0.44	-5.59	-0.32	5.59e-8	Neuroticism;
CESC	cis	rs9486719	0.947	rs2472893	chr6:96870048	G/C	cg06623918	chr6:96969491	KIAA0776	0.81	8.29	0.45	5.61e-15	Migraine;Coronary artery disease;
CESC	cis	rs5769707	0.967	rs5769698	chr22:49997706	A/G	cg20744362	chr22:50050164	C22orf34	0.44	7.53	0.42	7.96e-13	Monocyte count;Monocyte percentage of white cells;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12882657	chr12:125448964	DHX37	-0.67	-7.44	-0.42	1.41e-12	Gut microbiome composition (summer);
CESC	cis	rs11690935	0.959	rs10204501	chr2:172588865	C/G	cg13550731	chr2:172543902	DYNC1I2	-0.97	-14.97	-0.68	4e-37	Schizophrenia;
CESC	cis	rs6740322	0.644	rs11690918	chr2:43474112	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.73	-8.0	-0.44	3.88e-14	Coronary artery disease;
CESC	cis	rs6032067	0.777	rs62208382	chr20:43785549	C/T	cg11264863	chr20:43835661	SEMG1	0.5	5.35	0.31	1.86e-7	Blood protein levels;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg19630102	chr14:68067023	PIGH	0.48	6.18	0.35	2.35e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs2072732	0.861	rs72629497	chr1:2954123	T/C	cg15211996	chr1:2936768	ACTRT2	0.34	6.04	0.35	5.27e-9	Plateletcrit;
CESC	cis	rs727505	1.000	rs10281582	chr7:124423688	A/G	cg23710748	chr7:124431027	NA	-0.39	-6.48	-0.37	4.35e-10	Lewy body disease;
CESC	cis	rs7808935	0.628	rs62451116	chr7:27938980	A/G	cg05786569	chr7:27702416	HIBADH	0.52	5.86	0.34	1.39e-8	Prostate cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22396279	chr1:154580739	ADAR	0.59	6.81	0.39	6.44e-11	Gut microbiome composition (summer);
CESC	cis	rs9322193	0.962	rs9689447	chr6:150110486	T/A	cg05861140	chr6:150128134	PCMT1	-0.37	-5.3	-0.31	2.42e-7	Lung cancer;
CESC	cis	rs78889164	0.562	rs1005731	chr19:33908717	A/C	cg02272751	chr19:33882848	PEPD	-0.39	-5.4	-0.31	1.49e-7	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9840812	0.645	rs13068119	chr3:136206369	A/G	cg15507776	chr3:136538369	TMEM22	-0.5	-5.39	-0.31	1.53e-7	Fibrinogen levels;
CESC	cis	rs4481887	0.927	rs4460676	chr1:248431781	G/A	cg00666640	chr1:248458726	OR2T12	0.41	6.81	0.39	6.53e-11	Common traits (Other);
CESC	cis	rs826838	1.000	rs34254519	chr12:39041235	G/A	cg13010199	chr12:38710504	ALG10B	0.58	8.07	0.44	2.51e-14	Heart rate;
CESC	cis	rs17826219	0.568	rs9907834	chr17:29154013	G/A	cg19761014	chr17:28927070	LRRC37B2	0.74	6.03	0.35	5.43e-9	Body mass index;
CESC	cis	rs9303401	0.646	rs9303403	chr17:57219300	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.51	-6.38	-0.36	8e-10	Cognitive test performance;
CESC	cis	rs4820539	0.966	rs2267005	chr22:23461723	A/G	cg14186256	chr22:23484241	RTDR1	0.8	14.1	0.65	4.41e-34	Bone mineral density;
CESC	cis	rs7107174	0.688	rs10899501	chr11:78131408	C/T	cg02023728	chr11:77925099	USP35	0.43	5.45	0.32	1.17e-7	Testicular germ cell tumor;
CESC	cis	rs12479064	0.724	rs28369945	chr2:100080928	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.53	-6.04	-0.35	5.28e-9	Chronic sinus infection;
CESC	cis	rs6540556	0.521	rs9430015	chr1:209911734	G/A	cg05527609	chr1:210001259	C1orf107	-0.44	-5.18	-0.3	4.42e-7	Red blood cell count;
CESC	cis	rs7086627	0.515	rs4934189	chr10:82214792	C/T	cg00277334	chr10:82204260	NA	-0.91	-15.72	-0.69	8.67e-40	Post bronchodilator FEV1;
CESC	cis	rs10463316	0.894	rs7727926	chr5:150767216	G/A	cg03212797	chr5:150827313	SLC36A1	-0.47	-6.2	-0.36	2.17e-9	Metabolite levels (Pyroglutamine);
CESC	cis	rs3740713	1.000	rs60376560	chr11:18453742	A/T	cg23797887	chr11:18477753	LDHAL6A	-0.54	-5.22	-0.31	3.61e-7	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs9790314	0.521	rs1450523	chr3:161077270	G/A	cg03342759	chr3:160939853	NMD3	-0.41	-5.95	-0.34	8.38e-9	Morning vs. evening chronotype;
CESC	trans	rs877282	0.945	rs11253390	chr10:788678	A/G	cg22713356	chr15:30763199	NA	1.32	13.44	0.64	9.25e-32	Uric acid levels;
CESC	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg00080972	chr5:178986291	RUFY1	0.47	7.68	0.43	3.18e-13	Lung cancer;
CESC	cis	rs10876993	0.893	rs4760168	chr12:58087737	T/G	cg18357645	chr12:58087776	OS9	0.63	10.42	0.54	1.53e-21	Celiac disease or Rheumatoid arthritis;
CESC	cis	rs12762955	0.687	rs4880470	chr10:1077480	G/A	cg26597838	chr10:835615	NA	-0.43	-5.4	-0.32	1.45e-7	Response to angiotensin II receptor blocker therapy;
CESC	cis	rs2652822	0.525	rs11634159	chr15:63507422	C/T	cg02713581	chr15:63449717	RPS27L	0.49	6.35	0.36	9.23e-10	Metabolic traits;
CESC	cis	rs2073300	0.609	rs3746737	chr20:23424638	C/T	cg12062639	chr20:23401060	NAPB	1.09	8.31	0.45	5.13e-15	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	trans	rs17508449	0.865	rs4838993	chr1:114135133	C/T	cg23652354	chr22:38005183	GGA1	-0.76	-6.08	-0.35	4.12e-9	Leprosy;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg18528216	chr8:66617288	MTFR1	0.4	6.1	0.35	3.72e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs736408	0.716	rs2239549	chr3:52823126	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	5.87	0.34	1.27e-8	Bipolar disorder;
CESC	cis	rs4925386	0.802	rs6142735	chr20:60918087	G/C	cg24112000	chr20:60950667	NA	-0.5	-5.87	-0.34	1.27e-8	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs35306767	0.903	rs61830933	chr10:934195	G/A	cg10556349	chr10:835070	NA	0.72	6.12	0.35	3.29e-9	Eosinophil percentage of granulocytes;
CESC	cis	rs853679	0.517	rs868987	chr6:28110148	A/G	cg23281280	chr6:28129359	ZNF389	-0.6	-8.15	-0.45	1.47e-14	Depression;
CESC	cis	rs6982240	1.000	rs6982240	chr8:142257378	A/T	cg27411547	chr8:142287226	NA	-0.43	-6.63	-0.38	1.86e-10	Tonsillectomy;
CESC	cis	rs616402	0.527	rs2274985	chr1:10573867	G/A	cg20482658	chr1:10539492	PEX14	-0.28	-5.83	-0.34	1.64e-8	Breast size;
CESC	cis	rs6456156	0.792	rs4710181	chr6:167513998	T/C	cg23791538	chr6:167370224	RNASET2	-0.4	-5.26	-0.31	2.92e-7	Primary biliary cholangitis;
CESC	cis	rs6570726	0.935	rs385185	chr6:145814992	A/G	cg05347473	chr6:146136440	FBXO30	0.5	6.71	0.38	1.15e-10	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs1814175	0.645	rs847627	chr11:49927177	G/A	cg03929089	chr4:120376271	NA	-0.92	-15.2	-0.68	6e-38	Height;
CESC	cis	rs8060686	0.641	rs12445396	chr16:68155121	G/A	cg26727032	chr16:67993705	SLC12A4	-0.53	-6.0	-0.35	6.32e-9	HDL cholesterol;Metabolic syndrome;
CESC	trans	rs61931739	0.963	rs59195137	chr12:34091838	G/A	cg26384229	chr12:38710491	ALG10B	-0.47	-6.56	-0.37	2.76e-10	Morning vs. evening chronotype;
CESC	cis	rs35955747	0.902	rs131202	chr22:31709309	A/C	cg25791279	chr22:32026902	PISD	0.47	5.57	0.32	6.26e-8	Neutrophil count;Sum basophil neutrophil counts;
CESC	cis	rs7267979	1.000	rs7343481	chr20:25300113	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.89	-18.7	-0.75	2.39e-50	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs8141529	0.748	rs5762874	chr22:29269658	C/G	cg02153584	chr22:29168773	CCDC117	0.57	7.51	0.42	9.31e-13	Lymphocyte counts;
CESC	cis	rs7666738	0.830	rs6819047	chr4:98866902	G/A	cg05340658	chr4:99064831	C4orf37	0.75	11.16	0.57	5.89e-24	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6952808	0.689	rs58227534	chr7:2046328	A/G	cg02951883	chr7:2050386	MAD1L1	-0.58	-7.81	-0.43	1.38e-13	Bipolar disorder and schizophrenia;
CESC	cis	rs8114671	0.562	rs6120746	chr20:33448496	A/G	cg24642439	chr20:33292090	TP53INP2	0.42	5.03	0.3	9.22e-7	Height;
CESC	cis	rs9354352	1.000	rs9354352	chr6:66696272	T/C	cg07460842	chr6:66804631	NA	0.66	9.67	0.51	3.82e-19	Initial pursuit acceleration in psychotic disorders;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11895240	chr10:12171245	SEC61A2	0.56	6.21	0.36	2.04e-9	Gut microbiome composition (summer);
CESC	cis	rs1790761	0.505	rs7945035	chr11:67348162	A/G	cg00290607	chr11:67383545	NA	-0.36	-5.33	-0.31	2.14e-7	Mean corpuscular volume;
CESC	cis	rs1707322	0.682	rs10890334	chr1:46100378	A/T	cg03146154	chr1:46216737	IPP	0.81	11.48	0.58	5.05e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs1814175	0.645	rs1851857	chr11:49855589	A/C	cg15704280	chr7:45808275	SEPT13	-1.01	-18.75	-0.76	1.62e-50	Height;
CESC	cis	rs4979906	1.000	rs68092325	chr10:79446719	T/A	cg07817648	chr10:79422355	NA	-0.6	-6.39	-0.37	7.58e-10	Mortality in heart failure;
CESC	cis	rs72901758	0.739	rs72901754	chr17:76244398	G/A	cg26068271	chr17:76253126	NA	0.5	7.29	0.41	3.65e-12	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
CESC	cis	rs11673344	0.528	rs563786	chr19:37412914	A/G	cg27390819	chr19:37464633	NA	-0.34	-5.12	-0.3	5.92e-7	Obesity-related traits;
CESC	cis	rs2243480	1.000	rs56016656	chr7:65383481	C/T	cg12463550	chr7:65579703	CRCP	0.71	5.5	0.32	8.79e-8	Diabetic kidney disease;
CESC	cis	rs34779708	0.931	rs4934731	chr10:35431636	T/C	cg04310649	chr10:35416472	CREM	-0.54	-6.55	-0.37	2.9e-10	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs752010	0.871	rs2038976	chr1:42094498	A/G	cg06885757	chr1:42089581	HIVEP3	0.53	8.8	0.48	1.76e-16	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs240764	0.764	rs10457800	chr6:100936628	C/T	cg21058520	chr6:100914733	NA	0.38	5.98	0.34	7.38e-9	Neuroticism;
CESC	cis	rs10788309	0.506	rs4244943	chr10:85826908	G/A	cg03623264	chr10:85672087	NA	-0.41	-5.76	-0.33	2.28e-8	Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
CESC	cis	rs1448094	0.512	rs6539927	chr12:86244486	T/C	cg02569458	chr12:86230093	RASSF9	0.49	7.27	0.41	4.07e-12	Major depressive disorder;
CESC	cis	rs7592578	0.639	rs13417431	chr2:191293055	A/G	cg10560079	chr2:191398806	TMEM194B	-0.57	-5.78	-0.33	2.14e-8	Diastolic blood pressure;
CESC	cis	rs13385	0.769	rs7705090	chr5:139618146	C/G	cg26211634	chr5:139558579	C5orf32	0.48	5.28	0.31	2.75e-7	Atrial fibrillation;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg15613982	chr20:18488017	SEC23B	-0.47	-6.08	-0.35	4.07e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs1862618	0.853	rs832568	chr5:56153776	G/A	cg22800045	chr5:56110881	MAP3K1	0.83	9.95	0.52	4.88e-20	Initial pursuit acceleration;
CESC	cis	rs853679	0.882	rs9468287	chr6:28079741	G/T	cg23372001	chr6:27791640	HIST1H4J	0.59	5.24	0.31	3.23e-7	Depression;
CESC	cis	rs360798	0.512	rs1420018	chr2:63112500	A/G	cg17519650	chr2:63277830	OTX1	0.53	6.28	0.36	1.37e-9	Coronary artery disease;
CESC	cis	rs9611565	0.532	rs202627	chr22:41847367	A/T	cg03806693	chr22:41940476	POLR3H	1.12	15.09	0.68	1.44e-37	Vitiligo;
CESC	cis	rs780094	0.564	rs4665978	chr2:27648726	T/C	cg02592271	chr2:27665507	KRTCAP3	-0.26	-5.6	-0.33	5.43e-8	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
CESC	cis	rs9346649	0.606	rs6940383	chr6:168491688	G/A	cg09211372	chr6:168490623	NA	-0.36	-5.28	-0.31	2.71e-7	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
CESC	cis	rs2439831	1.000	rs2584726	chr15:43715382	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.79	11.89	0.59	2.12e-26	Lung cancer in ever smokers;
CESC	cis	rs9322193	0.962	rs35443312	chr6:149991761	T/C	cg07701084	chr6:150067640	NUP43	0.4	5.3	0.31	2.48e-7	Lung cancer;
CESC	trans	rs4792192	1.000	rs4792192	chr17:11803461	A/G	cg08005093	chr17:63532898	AXIN2	0.53	6.25	0.36	1.6e-9	Myopia (pathological);
CESC	cis	rs4722166	0.568	rs1880241	chr7:22759469	A/G	cg05265849	chr7:22767390	IL6	0.34	5.19	0.3	4.27e-7	Lung cancer;
CESC	cis	rs2952156	1.000	rs2088126	chr17:37879030	A/G	cg07936489	chr17:37558343	FBXL20	-0.51	-6.01	-0.35	6e-9	Asthma;
CESC	cis	rs559928	0.606	rs61083753	chr11:63892665	C/T	cg05555928	chr11:63887634	MACROD1	-0.49	-5.26	-0.31	2.93e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CESC	cis	rs6691722	0.503	rs3765425	chr1:24699872	G/C	cg18323236	chr1:24743029	NIPAL3	0.4	5.95	0.34	8.62e-9	Response to interferon beta in multiple sclerosis;
CESC	cis	rs7267979	1.000	rs2257432	chr20:25271086	T/C	cg08601574	chr20:25228251	PYGB	0.39	5.65	0.33	4.13e-8	Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01941219	chr13:98795021	FARP1	0.56	6.16	0.35	2.68e-9	Gut microbiome composition (summer);
CESC	cis	rs3820928	0.874	rs10199655	chr2:227892428	T/C	cg05526886	chr2:227700861	RHBDD1	-0.45	-5.84	-0.34	1.51e-8	Pulmonary function;
CESC	cis	rs847577	0.609	rs6965016	chr7:97807882	C/A	cg24562669	chr7:97807699	LMTK2	0.83	13.66	0.64	1.57e-32	Breast cancer;
CESC	cis	rs9660180	0.967	rs6603803	chr1:1812688	A/G	cg13866156	chr1:1669148	SLC35E2	-0.52	-6.81	-0.39	6.42e-11	Body mass index;
CESC	cis	rs9291683	0.530	rs35908990	chr4:9976105	G/A	cg00071950	chr4:10020882	SLC2A9	0.78	14.51	0.67	1.66e-35	Bone mineral density;
CESC	cis	rs12618769	0.625	rs17034241	chr2:99224998	C/G	cg10123293	chr2:99228465	UNC50	0.41	5.35	0.31	1.88e-7	Bipolar disorder;
CESC	cis	rs3204270	0.639	rs11867543	chr17:79655046	C/T	cg26965718	chr17:79658957	HGS	-0.8	-5.91	-0.34	1.04e-8	Dental caries;
CESC	cis	rs2832191	0.791	rs9983651	chr21:30491227	T/A	cg24692254	chr21:30365293	RNF160	-0.79	-12.11	-0.6	3.54e-27	Dental caries;
CESC	cis	rs6502050	0.799	rs11491185	chr17:80151101	C/T	cg23985595	chr17:80112537	CCDC57	-0.42	-6.57	-0.37	2.59e-10	Life satisfaction;
CESC	cis	rs362272	0.525	rs910568	chr4:3307373	A/G	cg14583973	chr4:3374767	RGS12	0.31	5.19	0.3	4.19e-7	Serum sulfate level;
CESC	cis	rs875971	0.862	rs2024192	chr7:66041447	G/T	cg12463550	chr7:65579703	CRCP	-0.5	-6.34	-0.36	9.71e-10	Aortic root size;
CESC	cis	rs11711311	0.866	rs13313893	chr3:113400856	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.58	7.39	0.41	1.95e-12	IgG glycosylation;
CESC	cis	rs793571	0.523	rs7163162	chr15:58983588	T/A	cg05156742	chr15:59063176	FAM63B	0.58	7.87	0.44	9.28e-14	Schizophrenia;
CESC	cis	rs7089973	0.604	rs17663670	chr10:116596269	A/C	cg25233709	chr10:116636983	FAM160B1	-0.37	-5.91	-0.34	1.07e-8	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs1538970	0.962	rs2487442	chr1:45857176	C/G	cg24296786	chr1:45957014	TESK2	0.43	5.14	0.3	5.26e-7	Platelet count;
CESC	cis	rs6426558	0.537	rs2492630	chr1:227286931	A/G	cg10327440	chr1:227177885	CDC42BPA	0.47	5.76	0.33	2.3e-8	Neutrophil percentage of white cells;
CESC	cis	rs2404602	0.552	rs11630185	chr15:76959783	A/T	cg00316803	chr15:76480434	C15orf27	0.43	5.73	0.33	2.75e-8	Blood metabolite levels;
CESC	cis	rs9443645	0.901	rs9352683	chr6:79718795	T/G	cg05283184	chr6:79620031	NA	-0.43	-6.61	-0.38	2.06e-10	Intelligence (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14532426	chr21:33245908	HUNK	0.6	6.5	0.37	4e-10	Gut microbiome composition (summer);
CESC	cis	rs2777491	1.000	rs316605	chr15:41771591	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.64	-9.87	-0.52	9.37e-20	Ulcerative colitis;
CESC	cis	rs7659604	0.537	rs6823818	chr4:122731699	G/C	cg19748678	chr4:122722346	EXOSC9	0.78	9.69	0.51	3.39e-19	Type 2 diabetes;
CESC	cis	rs6121246	0.908	rs6089094	chr20:30431771	C/T	cg13852791	chr20:30311386	BCL2L1	0.7	7.24	0.41	4.82e-12	Mean corpuscular hemoglobin;
CESC	cis	rs4268898	0.931	rs2551121	chr2:24539967	T/C	cg08917208	chr2:24149416	ATAD2B	0.46	5.23	0.31	3.39e-7	Asthma;
CESC	cis	rs2050392	0.517	rs602097	chr10:30747546	C/T	cg18806716	chr10:30721971	MAP3K8	-0.5	-7.68	-0.43	3.08e-13	Inflammatory bowel disease;
CESC	cis	rs9911578	1.000	rs391370	chr17:56675050	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.22	0.31	3.55e-7	Intelligence (multi-trait analysis);
CESC	cis	rs897080	0.552	rs1085443	chr2:44635015	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	5.91	0.34	1.07e-8	Height;
CESC	cis	rs9814567	0.806	rs4074521	chr3:134325536	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.42	5.52	0.32	8.16e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs9581857	0.685	rs17808758	chr13:28036412	C/T	cg01674679	chr13:27998804	GTF3A	-0.65	-5.24	-0.31	3.34e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
CESC	cis	rs6541297	0.653	rs4846917	chr1:230299222	T/C	cg20703242	chr1:230279135	GALNT2	0.4	6.01	0.35	6.26e-9	Coronary artery disease;
CESC	cis	rs6674176	0.597	rs2352990	chr1:44393276	T/A	cg13606994	chr1:44402422	ARTN	-0.42	-6.34	-0.36	1.01e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs7520050	0.966	rs1707321	chr1:46505309	A/G	cg24296786	chr1:45957014	TESK2	0.4	5.07	0.3	7.61e-7	Red blood cell count;Reticulocyte count;
CESC	cis	rs1642645	0.831	rs2042064	chr1:42491429	C/T	cg16685388	chr1:42384056	HIVEP3	0.37	5.61	0.33	5.2e-8	Left ventricular obstructive tract defect (maternal effect);
CESC	cis	rs7100689	0.622	rs7090351	chr10:82142047	T/G	cg00277334	chr10:82204260	NA	-0.59	-7.73	-0.43	2.25e-13	Post bronchodilator FEV1;
CESC	cis	rs1003719	0.788	rs4817844	chr21:38447064	A/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.6	-8.39	-0.46	2.93e-15	Eye color traits;
CESC	cis	rs7584330	0.736	rs6431541	chr2:238376190	A/T	cg14458575	chr2:238380390	NA	0.6	8.65	0.47	5.05e-16	Prostate cancer;
CESC	cis	rs12220238	1.000	rs11000900	chr10:75918440	T/A	cg19889307	chr10:75911429	ADK;AP3M1	0.63	6.2	0.36	2.13e-9	Soluble interleukin-2 receptor subunit alpha;
CESC	cis	rs10206020	0.921	rs72776300	chr2:1571152	A/G	cg12573674	chr2:1569213	NA	-0.47	-5.35	-0.31	1.93e-7	IgG glycosylation;
CESC	cis	rs61931739	0.534	rs10844774	chr12:34166764	C/T	cg19457237	chr12:34500585	NA	-0.39	-5.33	-0.31	2.08e-7	Morning vs. evening chronotype;
CESC	cis	rs7811142	0.943	rs28578163	chr7:100044754	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.9	9.42	0.5	2.25e-18	Platelet count;
CESC	cis	rs734999	0.545	rs10910105	chr1:2538209	G/A	cg18854424	chr1:2615690	NA	0.3	5.83	0.34	1.65e-8	Ulcerative colitis;
CESC	cis	rs17666538	0.710	rs11987001	chr8:630755	T/C	cg13264159	chr8:625131	ERICH1	-0.72	-5.37	-0.31	1.7e-7	IgG glycosylation;
CESC	cis	rs11864453	0.647	rs9932062	chr16:72136055	T/C	cg01557791	chr16:72042693	DHODH	-0.43	-5.63	-0.33	4.58e-8	Fibrinogen levels;
CESC	cis	rs11997175	0.692	rs6468202	chr8:33747720	C/A	ch.8.33884649F	chr8:33765107	NA	0.56	6.96	0.39	2.73e-11	Body mass index;
CESC	cis	rs1799949	0.931	rs9912203	chr17:41445145	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	-0.53	-7.68	-0.43	3.04e-13	Menopause (age at onset);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg00069017	chr1:6051640	NPHP4	-0.53	-6.52	-0.37	3.56e-10	Ulcerative colitis;
CESC	cis	rs7927771	1.000	rs12419692	chr11:47624714	A/C	cg20307385	chr11:47447363	PSMC3	0.48	5.94	0.34	9.14e-9	Subjective well-being;
CESC	cis	rs1059312	0.932	rs4760593	chr12:129287220	A/G	cg09035930	chr12:129282057	SLC15A4	0.76	10.59	0.55	4.31e-22	Systemic lupus erythematosus;
CESC	cis	rs60871478	0.636	rs7792072	chr7:886239	C/T	cg15782153	chr7:917662	C7orf20	0.52	5.72	0.33	2.91e-8	Cerebrospinal P-tau181p levels;
CESC	cis	rs6594499	0.843	rs1993465	chr5:110433098	A/G	cg04022379	chr5:110408740	TSLP	0.33	5.95	0.34	8.31e-9	Allergic disease (asthma, hay fever or eczema);
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg12737801	chr8:54934346	TCEA1	-0.46	-6.58	-0.37	2.56e-10	Vertical cup-disc ratio;
CESC	cis	rs13256369	1.000	rs7820159	chr8:8576215	T/C	cg17143192	chr8:8559678	CLDN23	0.74	8.68	0.47	4.19e-16	Obesity-related traits;
CESC	cis	rs2758596	0.850	rs2241110	chr1:156172487	A/G	cg25208724	chr1:156163844	SLC25A44	0.66	6.6	0.38	2.24e-10	Paclitaxel disposition in epithelial ovarian cancer;
CESC	cis	rs6952808	0.594	rs3778969	chr7:2139990	A/G	cg21782813	chr7:2030301	MAD1L1	-0.51	-7.3	-0.41	3.45e-12	Bipolar disorder and schizophrenia;
CESC	cis	rs515186	1	rs515186	chr6:36397492	T/G	cg04289385	chr6:36355825	ETV7	0.38	5.57	0.32	6.41e-8	Mean platelet volume;
CESC	cis	rs763121	0.853	rs2281020	chr22:39064406	A/G	cg14440974	chr22:39074834	NA	-0.42	-5.82	-0.34	1.69e-8	Menopause (age at onset);
CESC	cis	rs2011503	1.000	rs78010159	chr19:19615905	C/T	cg11584989	chr19:19387371	SF4	0.62	7.13	0.4	9.66e-12	Bipolar disorder;
CESC	cis	rs965469	0.779	rs6133034	chr20:3337661	A/G	cg25506879	chr20:3388711	C20orf194	-0.47	-5.07	-0.3	7.62e-7	IFN-related cytopenia;
CESC	cis	rs739401	0.572	rs739400	chr11:3016520	G/A	cg25174290	chr11:3078921	CARS	0.51	7.0	0.4	2.1e-11	Longevity;
CESC	cis	rs367943	1.000	rs348941	chr5:112824166	G/C	cg12552261	chr5:112820674	MCC	-0.63	-7.8	-0.43	1.39e-13	Type 2 diabetes;
CESC	cis	rs7264396	0.563	rs2425086	chr20:34302873	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.88	-10.64	-0.55	3.06e-22	Total cholesterol levels;
CESC	cis	rs11098499	0.863	rs2291185	chr4:120434833	C/A	cg09307838	chr4:120376055	NA	0.93	12.75	0.62	2.41e-29	Corneal astigmatism;
CESC	cis	rs1551570	0.819	rs11666402	chr19:10219076	A/G	cg16327482	chr19:10226339	EIF3G	0.43	7.12	0.4	1.03e-11	Narcolepsy;
CESC	cis	rs950776	0.518	rs56007453	chr15:78826239	T/C	cg24631222	chr15:78858424	CHRNA5	-0.42	-5.33	-0.31	2.09e-7	Sudden cardiac arrest;
CESC	cis	rs9649213	0.593	rs34776142	chr7:97899873	C/T	cg08684580	chr7:98029266	BAIAP2L1	-0.33	-5.1	-0.3	6.36e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs6582630	0.500	rs35251810	chr12:38577666	T/C	cg26384229	chr12:38710491	ALG10B	-0.43	-5.67	-0.33	3.81e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs7726839	0.574	rs11739866	chr5:636299	C/T	cg16447950	chr5:562315	NA	-0.56	-5.72	-0.33	2.9e-8	Obesity-related traits;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg09292873	chr10:111683347	XPNPEP1	-0.44	-6.22	-0.36	1.93e-9	Ulcerative colitis;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg23814154	chr12:51611356	POU6F1	-0.48	-6.41	-0.37	6.59e-10	Asthma;
CESC	cis	rs2033711	0.870	rs4801583	chr19:58918405	A/G	cg11952622	chr19:58962976	ZNF324B	0.46	6.33	0.36	1.05e-9	Uric acid clearance;
CESC	cis	rs4243830	1.000	rs10158949	chr1:6583701	T/C	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.71	-5.44	-0.32	1.18e-7	Body mass index;
CESC	cis	rs7917772	0.560	rs729023	chr10:104341887	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.42	-5.83	-0.34	1.63e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs60843830	1.000	rs79716074	chr2:277003	A/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.79	10.31	0.53	3.66e-21	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs7618915	0.621	rs6788993	chr3:52605136	T/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	5.85	0.34	1.45e-8	Bipolar disorder;
CESC	cis	rs11264213	0.786	rs72659674	chr1:36243012	T/C	cg27506609	chr1:36549197	TEKT2	0.65	5.34	0.31	1.97e-7	Schizophrenia;
CESC	cis	rs1801251	1.000	rs35212961	chr2:233582762	C/T	cg25237894	chr2:233734115	C2orf82	0.5	8.34	0.46	4.03e-15	Coronary artery disease;
CESC	trans	rs4733781	1.000	rs4733781	chr8:131296767	A/C	cg15283212	chr18:21014021	C18orf45	-0.37	-6.04	-0.35	5.28e-9	Tuberculosis;
CESC	cis	rs4803468	1.000	rs8105833	chr19:41896145	G/A	cg09537434	chr19:41945824	ATP5SL	-1.02	-18.15	-0.74	2.21e-48	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04347867	chr16:56965804	HERPUD1	0.64	7.69	0.43	2.94e-13	Gut microbiome composition (summer);
CESC	cis	rs1707322	0.752	rs12027622	chr1:46130252	A/C	cg06784218	chr1:46089804	CCDC17	0.41	7.12	0.4	1.04e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs8067354	0.872	rs2645466	chr17:57853214	A/C	cg02344993	chr17:57696989	CLTC	0.49	6.51	0.37	3.7e-10	Hemoglobin concentration;
CESC	cis	rs1878931	0.668	rs2074366	chr16:3439676	G/A	cg00484396	chr16:3507460	NAT15	-0.41	-6.37	-0.36	8.54e-10	Body mass index (adult);
CESC	cis	rs67478160	0.634	rs1955660	chr14:104229985	C/T	cg08213375	chr14:104286397	PPP1R13B	0.46	9.05	0.49	3.28e-17	Schizophrenia;
CESC	cis	rs1975974	1.000	rs72842072	chr17:21730703	G/A	cg18423549	chr17:21743878	NA	-0.54	-7.65	-0.43	3.81e-13	Psoriasis;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg16029321	chr19:14544044	PKN1	-0.48	-6.31	-0.36	1.16e-9	Fibrinogen levels;
CESC	cis	rs1552244	1.000	rs57631744	chr3:10118962	T/C	cg13047869	chr3:10149882	C3orf24	0.4	5.03	0.3	8.89e-7	Alzheimer's disease;
CESC	cis	rs4689388	0.581	rs11727100	chr4:6281458	A/C	cg25554036	chr4:6271136	WFS1	0.52	6.56	0.37	2.86e-10	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs1023500	0.596	rs5751204	chr22:42433801	C/T	cg04733989	chr22:42467013	NAGA	0.77	10.68	0.55	2.3e-22	Schizophrenia;
CESC	cis	rs6460942	0.908	rs967126	chr7:12237300	G/C	cg06484146	chr7:12443880	VWDE	-0.46	-5.19	-0.3	4.21e-7	Coronary artery disease;
CESC	trans	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg13565492	chr6:43139072	SRF	-0.71	-8.22	-0.45	9.35e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs11809180	0.546	rs12059132	chr1:169401824	G/A	cg09363564	chr1:169337483	NME7;BLZF1	-1.15	-6.84	-0.39	5.62e-11	Electrocardiographic traits;
CESC	trans	rs11039798	0.588	rs7116858	chr11:48543920	C/A	cg03929089	chr4:120376271	NA	0.61	6.08	0.35	4.16e-9	Axial length;
CESC	cis	rs4713118	0.662	rs156744	chr6:27967274	G/A	cg17949981	chr6:28129498	ZNF389	0.43	5.46	0.32	1.09e-7	Parkinson's disease;
CESC	trans	rs72766638	0.848	rs11789898	chr9:136925663	A/C	cg09836344	chr4:1243392	C4orf42;CTBP1	0.59	6.09	0.35	4.04e-9	Mosquito bite size;
CESC	cis	rs7216064	0.813	rs12601919	chr17:65825374	A/G	cg12091567	chr17:66097778	LOC651250	-0.87	-8.62	-0.47	6.33e-16	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg13703070	chr9:102583386	NR4A3	0.46	6.54	0.37	3.18e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs12356475	0.710	rs10822686	chr10:67733250	C/T	cg27261378	chr19:44079792	XRCC1	0.55	6.22	0.36	1.89e-9	Psoriatic arthritis;
CESC	cis	rs7267979	0.932	rs417130	chr20:25458320	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.73	13.31	0.63	2.6e-31	Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00072720	chr17:7165831	CLDN7	-0.47	-6.2	-0.36	2.13e-9	Gut microbiome composition (summer);
CESC	cis	rs4253772	0.637	rs36125344	chr22:46655779	G/C	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.6	5.12	0.3	5.74e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs965469	0.843	rs6139122	chr20:3395871	T/G	cg25506879	chr20:3388711	C20orf194	-0.64	-6.62	-0.38	2.01e-10	IFN-related cytopenia;
CESC	cis	rs6952808	0.931	rs12537430	chr7:1868761	A/G	cg22963979	chr7:1858916	MAD1L1	0.41	5.68	0.33	3.62e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs7084402	0.935	rs10740731	chr10:60348886	G/A	cg07615347	chr10:60278583	BICC1	0.54	8.32	0.46	4.65e-15	Refractive error;
CESC	cis	rs2439831	1.000	rs689826	chr15:43749916	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.88	10.47	0.54	1.11e-21	Lung cancer in ever smokers;
CESC	cis	rs8177179	0.967	rs4443173	chr3:133439378	A/G	cg17775713	chr3:133465469	TF	0.32	5.67	0.33	3.69e-8	Iron status biomarkers (transferrin levels);
CESC	cis	rs62064224	0.533	rs11657826	chr17:30790386	T/A	cg18200150	chr17:30822561	MYO1D	0.72	11.36	0.57	1.29e-24	Schizophrenia;
CESC	cis	rs7914558	0.966	rs10748837	chr10:104880236	T/C	cg04362960	chr10:104952993	NT5C2	0.46	5.92	0.34	9.98e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs826838	0.935	rs1601579	chr12:39178606	G/C	cg13010199	chr12:38710504	ALG10B	0.58	8.08	0.44	2.36e-14	Heart rate;
CESC	cis	rs933688	0.938	rs7705465	chr5:90680949	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.99	11.87	0.59	2.36e-26	Smoking behavior;
CESC	trans	rs561341	0.709	rs11542477	chr17:30185892	A/G	cg20587970	chr11:113659929	NA	1.03	11.3	0.57	1.98e-24	Hip circumference adjusted for BMI;
CESC	cis	rs1348850	0.668	rs4893971	chr2:178495743	T/C	cg23306229	chr2:178417860	TTC30B	0.55	6.63	0.38	1.89e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs1862618	0.853	rs11739344	chr5:56111087	A/C	cg22800045	chr5:56110881	MAP3K1	0.84	10.36	0.54	2.46e-21	Initial pursuit acceleration;
CESC	cis	rs72772090	0.539	rs72773947	chr5:96125533	T/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.57	-5.26	-0.31	3.01e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs9611565	0.592	rs5758405	chr22:42076381	C/A	cg17376030	chr22:41985996	PMM1	-0.67	-7.42	-0.41	1.63e-12	Vitiligo;
CESC	cis	rs873946	0.586	rs2001426	chr10:134563871	G/A	cg18305652	chr10:134549665	INPP5A	0.46	6.35	0.36	9.4e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs9486719	1.000	rs12208124	chr6:97027942	C/T	cg06623918	chr6:96969491	KIAA0776	-0.81	-8.36	-0.46	3.69e-15	Migraine;Coronary artery disease;
CESC	cis	rs9584850	0.834	rs2031239	chr13:99111560	C/T	cg22223119	chr13:99095684	FARP1	-0.36	-5.12	-0.3	5.96e-7	Neuroticism;
CESC	cis	rs17711722	0.585	rs6942660	chr7:65302406	C/T	cg11987759	chr7:65425863	GUSB	-0.48	-6.62	-0.38	1.93e-10	Calcium levels;
CESC	cis	rs4268898	0.931	rs60716082	chr2:24526265	T/A	cg20701182	chr2:24300061	SF3B14	0.48	5.78	0.33	2.14e-8	Asthma;
CESC	cis	rs9815354	0.857	rs12108064	chr3:42016217	C/T	cg03022575	chr3:42003672	ULK4	0.62	6.55	0.37	2.97e-10	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs4835473	0.900	rs6537223	chr4:144892694	T/C	cg25736465	chr4:144833511	NA	0.39	6.0	0.35	6.45e-9	Immature fraction of reticulocytes;
CESC	cis	rs9911578	1.000	rs4793950	chr17:56593111	T/C	cg05425664	chr17:57184151	TRIM37	0.5	7.0	0.4	2.1e-11	Intelligence (multi-trait analysis);
CESC	cis	rs4819052	0.851	rs875621	chr21:46682295	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.93	14.01	0.65	9.46e-34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs62064224	0.533	rs11657826	chr17:30790386	T/A	cg09324608	chr17:30823087	MYO1D	0.53	8.17	0.45	1.27e-14	Schizophrenia;
CESC	cis	rs9611565	0.694	rs4822032	chr22:41925535	T/C	cg03806693	chr22:41940476	POLR3H	-0.8	-10.25	-0.53	5.35e-21	Vitiligo;
CESC	cis	rs7666738	0.830	rs7679299	chr4:99057620	C/A	cg03467027	chr4:99064603	C4orf37	0.48	5.98	0.35	7.02e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9287719	0.967	rs4405729	chr2:10755779	A/G	cg00105475	chr2:10696890	NA	0.38	5.42	0.32	1.34e-7	Prostate cancer;
CESC	cis	rs4713118	0.587	rs61471148	chr6:28037032	T/A	cg17949981	chr6:28129498	ZNF389	0.46	5.4	0.32	1.45e-7	Parkinson's disease;
CESC	cis	rs7811142	0.830	rs11771936	chr7:99943283	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.7	6.21	0.36	2.04e-9	Platelet count;
CESC	cis	rs11650494	0.710	rs61427980	chr17:47473580	A/G	cg08112188	chr17:47440006	ZNF652	0.83	6.31	0.36	1.17e-9	Prostate cancer;
CESC	cis	rs9291683	0.588	rs3733586	chr4:9997534	C/T	cg02734326	chr4:10020555	SLC2A9	0.48	6.91	0.39	3.56e-11	Bone mineral density;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg21337984	chr17:6544054	TXNDC17;KIAA0753	-0.43	-6.25	-0.36	1.61e-9	Gambling;
CESC	cis	rs4654899	0.758	rs6688147	chr1:21335894	A/G	cg05370193	chr1:21551575	ECE1	0.38	5.84	0.34	1.55e-8	Superior frontal gyrus grey matter volume;
CESC	cis	rs8114671	0.562	rs3746450	chr20:33508588	G/T	cg24642439	chr20:33292090	TP53INP2	0.44	5.32	0.31	2.18e-7	Height;
CESC	cis	rs6942407	0.546	rs2108271	chr7:86805372	G/A	cg02420886	chr7:86849541	C7orf23	0.52	5.04	0.3	8.76e-7	Food allergy;
CESC	cis	rs6912958	0.515	rs381782	chr6:88040649	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.51	8.78	0.47	2.08e-16	Monocyte percentage of white cells;
CESC	cis	rs7116495	1.000	rs677279	chr11:71770469	G/A	cg26138937	chr11:71823887	C11orf51	-0.83	-6.95	-0.39	2.81e-11	Severe influenza A (H1N1) infection;
CESC	trans	rs7107217	1.000	rs1873872	chr11:129473993	A/T	cg07630564	chr3:128445061	RAB7A	0.47	6.07	0.35	4.47e-9	Breast cancer;Type 2 diabetes;
CESC	cis	rs478304	0.934	rs474483	chr11:65520060	T/G	cg08755490	chr11:65554678	OVOL1	0.49	6.5	0.37	3.95e-10	Acne (severe);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg26631144	chr8:30670260	PPP2CB	-0.43	-6.37	-0.36	8.13e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs6460942	0.915	rs2216051	chr7:12304054	G/A	cg20607287	chr7:12443886	VWDE	-0.41	-5.94	-0.34	8.83e-9	Coronary artery disease;
CESC	cis	rs9611565	0.649	rs2413659	chr22:42164862	A/G	cg06634786	chr22:41940651	POLR3H	0.48	5.38	0.31	1.62e-7	Vitiligo;
CESC	cis	rs116095464	0.558	rs10057626	chr5:239720	T/G	cg12570787	chr5:219185	SDHA;CCDC127	0.5	5.31	0.31	2.3e-7	Breast cancer;
CESC	cis	rs68170813	0.559	rs61406169	chr7:106903421	A/T	cg02696742	chr7:106810147	HBP1	-0.54	-5.33	-0.31	2.15e-7	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00688900	chr17:34901364	GGNBP2	-0.61	-7.31	-0.41	3.12e-12	Gut microbiome composition (summer);
CESC	cis	rs4974559	0.641	rs28647383	chr4:1312908	G/C	cg02980000	chr4:1222292	CTBP1	0.8	7.27	0.41	3.93e-12	Systolic blood pressure;
CESC	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg23034840	chr1:205782522	SLC41A1	0.67	8.16	0.45	1.4e-14	Menarche (age at onset);
CESC	cis	rs7590368	0.774	rs3932106	chr2:10916408	C/T	cg15705551	chr2:10952987	PDIA6	0.49	5.34	0.31	2.04e-7	Educational attainment (years of education);
CESC	cis	rs7618915	0.524	rs10433615	chr3:52638482	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.59	0.38	2.35e-10	Bipolar disorder;
CESC	cis	rs2404602	0.692	rs66866130	chr15:77128574	T/C	cg22467129	chr15:76604101	ETFA	-0.34	-5.07	-0.3	7.56e-7	Blood metabolite levels;
CESC	cis	rs7772486	0.875	rs11155452	chr6:146424631	C/T	cg05347473	chr6:146136440	FBXO30	0.51	6.68	0.38	1.37e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4423214	1.000	rs11233746	chr11:71171440	A/G	cg24826892	chr11:71159390	DHCR7	0.47	5.18	0.3	4.45e-7	Vitamin D levels;
CESC	cis	rs116095464	0.558	rs7356535	chr5:284117	G/T	cg22496380	chr5:211416	CCDC127	-0.99	-10.19	-0.53	8.71e-21	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02696742	chr7:106810147	HBP1	0.58	6.41	0.37	6.63e-10	Gut microbiome composition (summer);
CESC	cis	rs7618915	0.571	rs12632381	chr3:52607685	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.47	6.59	0.38	2.33e-10	Bipolar disorder;
CESC	cis	rs2412459	1.000	rs8023482	chr15:40307095	A/C	cg16127683	chr15:40268777	EIF2AK4	-0.6	-6.01	-0.35	6.01e-9	Response to haloperidol in psychosis;
CESC	cis	rs12142240	0.730	rs56030283	chr1:46823093	C/G	cg10495392	chr1:46806563	NSUN4	0.58	6.32	0.36	1.09e-9	Menopause (age at onset);
CESC	cis	rs6570726	0.905	rs430248	chr6:145874104	A/G	cg23711669	chr6:146136114	FBXO30	0.8	11.83	0.59	3.33e-26	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1005277	0.579	rs2474588	chr10:38420870	A/G	cg25517755	chr10:38738941	LOC399744	-0.47	-6.04	-0.35	5.28e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs9393777	0.513	rs9393741	chr6:26654189	A/G	cg12826209	chr6:26865740	GUSBL1	0.73	8.13	0.45	1.7e-14	Intelligence (multi-trait analysis);
CESC	cis	rs6831352	0.918	rs17218288	chr4:100058030	A/T	cg12011299	chr4:100065546	ADH4	-0.59	-6.53	-0.37	3.26e-10	Alcohol dependence;
CESC	cis	rs2839186	0.868	rs2839199	chr21:47708269	T/C	cg10351095	chr21:47802916	PCNT	-0.5	-6.8	-0.39	7.02e-11	Testicular germ cell tumor;
CESC	cis	rs992157	0.643	rs10191283	chr2:219056755	G/A	cg00012203	chr2:219082015	ARPC2	0.86	12.5	0.61	1.74e-28	Colorectal cancer;
CESC	cis	rs2228479	1.000	rs117406136	chr16:89974605	C/T	cg00800038	chr16:89945340	TCF25	-0.93	-7.69	-0.43	2.9e-13	Skin colour saturation;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg06697439	chr19:59031463	ZBTB45	0.39	6.14	0.35	3e-9	Gambling;
CESC	cis	rs4654899	0.758	rs6697284	chr1:21295599	G/A	cg05370193	chr1:21551575	ECE1	0.37	5.62	0.33	4.79e-8	Superior frontal gyrus grey matter volume;
CESC	cis	rs2380220	0.541	rs9285413	chr6:96023439	G/A	cg23517279	chr6:96025343	MANEA	0.55	5.41	0.32	1.41e-7	Behavioural disinhibition (generation interaction);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg02884588	chr19:539155	CDC34	0.45	6.09	0.35	4e-9	Fibrinogen levels;
CESC	cis	rs6732160	0.564	rs7605716	chr2:73376250	G/A	cg01422370	chr2:73384389	NA	0.57	9.1	0.49	2.21e-17	Intelligence (multi-trait analysis);
CESC	trans	rs60843830	1.000	rs56167434	chr2:282137	G/C	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.69	8.5	0.46	1.37e-15	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs4974559	0.690	rs28641665	chr4:1288781	G/T	cg02980000	chr4:1222292	CTBP1	0.81	7.39	0.41	1.88e-12	Systolic blood pressure;
CESC	cis	rs3892630	0.824	rs34748593	chr19:33240447	T/C	cg22980127	chr19:33182716	NUDT19	1.03	11.34	0.57	1.42e-24	Red blood cell traits;
CESC	cis	rs734999	0.545	rs28568531	chr1:2555640	T/A	cg18854424	chr1:2615690	NA	0.32	6.18	0.35	2.46e-9	Ulcerative colitis;
CESC	cis	rs11122272	0.701	rs2011383	chr1:231479788	T/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-7.23	-0.41	5.18e-12	Hemoglobin concentration;
CESC	cis	rs909002	0.800	rs3753612	chr1:32082410	C/G	cg13919466	chr1:32135498	COL16A1	-0.46	-8.26	-0.45	6.82e-15	Intelligence (multi-trait analysis);
CESC	cis	rs7666738	0.791	rs2081621	chr4:98926753	C/A	cg03467027	chr4:99064603	C4orf37	0.46	5.56	0.32	6.63e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3845702	0.736	rs2367990	chr2:180843126	C/T	cg01881094	chr2:180872142	CWC22	-1.02	-9.36	-0.5	3.69e-18	Schizophrenia;
CESC	cis	rs734999	0.566	rs6424092	chr1:2532899	C/A	cg18854424	chr1:2615690	NA	-0.28	-5.41	-0.32	1.43e-7	Ulcerative colitis;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg19120073	chr13:114165365	TMCO3	0.47	6.47	0.37	4.84e-10	Fibrinogen levels;
CESC	cis	rs9300255	0.664	rs28636834	chr12:123871070	A/C	cg00376283	chr12:123451042	ABCB9	-0.58	-6.49	-0.37	4.27e-10	Neutrophil percentage of white cells;
CESC	cis	rs875971	0.964	rs1643388	chr7:65844562	T/C	cg11764359	chr7:65958608	NA	0.98	15.79	0.7	4.82e-40	Aortic root size;
CESC	cis	rs11958404	0.932	rs6894528	chr5:157434788	A/G	cg05962755	chr5:157440814	NA	0.62	6.56	0.37	2.74e-10	IgG glycosylation;
CESC	cis	rs12155623	0.932	rs34236473	chr8:49828725	A/T	cg22283653	chr8:49824208	NA	0.38	5.83	0.34	1.6e-8	Sudden cardiac arrest;
CESC	cis	rs12464483	0.591	rs67686878	chr2:30895044	C/T	cg17749961	chr2:30669863	LCLAT1	0.66	6.71	0.38	1.18e-10	Pre-treatment pain in head and neck squamous cell carcinoma;
CESC	cis	rs3820068	0.581	rs72645881	chr1:15928203	C/T	cg13390004	chr1:15929781	NA	0.35	5.58	0.32	5.83e-8	Systolic blood pressure;
CESC	cis	rs72781680	1.000	rs72796388	chr2:24171509	A/C	cg20701182	chr2:24300061	SF3B14	0.64	5.74	0.33	2.63e-8	Lymphocyte counts;
CESC	cis	rs9457247	0.508	rs9457268	chr6:167503639	A/T	cg23791538	chr6:167370224	RNASET2	-0.45	-5.89	-0.34	1.2e-8	Crohn's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16003274	chr5:139944379	APBB3;SLC35A4	0.56	6.33	0.36	1.03e-9	Gut microbiome composition (summer);
CESC	cis	rs28386778	0.799	rs12450683	chr17:61984299	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.54	7.12	0.4	9.84e-12	Prudent dietary pattern;
CESC	cis	rs5758659	0.569	rs133294	chr22:42382805	C/T	cg19513890	chr22:42538836	CYP2D7P1	-0.39	-5.39	-0.31	1.56e-7	Cognitive function;
CESC	cis	rs6570726	0.902	rs406979	chr6:145838983	G/T	cg05347473	chr6:146136440	FBXO30	0.44	5.99	0.35	6.71e-9	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2290159	0.752	rs73130368	chr3:12667374	C/T	cg23032965	chr3:12705835	RAF1	0.53	5.68	0.33	3.63e-8	Cholesterol, total;
CESC	cis	rs9837602	0.529	rs793494	chr3:99508768	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.51	-6.25	-0.36	1.65e-9	Breast cancer;
CESC	cis	rs7274811	0.711	rs291691	chr20:32002878	G/C	cg21523528	chr20:32077966	CBFA2T2	-0.47	-5.44	-0.32	1.22e-7	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06659009	chr4:95129138	SMARCAD1	0.66	7.16	0.4	8.03e-12	Gut microbiome composition (summer);
CESC	cis	rs9660180	0.837	rs915292	chr1:1792157	A/C	cg03396347	chr1:1875803	NA	-0.46	-7.22	-0.41	5.58e-12	Body mass index;
CESC	cis	rs10751667	0.643	rs7396623	chr11:934104	G/A	cg01483505	chr11:975446	AP2A2	0.37	5.03	0.3	8.9e-7	Alzheimer's disease (late onset);
CESC	trans	rs1814175	0.817	rs12287396	chr11:49819798	G/C	cg03929089	chr4:120376271	NA	-0.91	-15.23	-0.68	4.84e-38	Height;
CESC	cis	rs1799949	1.000	rs1399323	chr17:41332330	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.62	8.39	0.46	2.99e-15	Menopause (age at onset);
CESC	cis	rs875971	0.862	rs778686	chr7:65835910	C/T	cg18252515	chr7:66147081	NA	-0.43	-5.55	-0.32	6.78e-8	Aortic root size;
CESC	cis	rs16858210	0.607	rs57874587	chr3:183584749	C/T	cg25686905	chr3:183603175	PARL	-0.33	-5.72	-0.33	2.8e-8	Menopause (age at onset);
CESC	cis	rs2576037	0.562	rs9959877	chr18:44522293	T/A	cg19077165	chr18:44547161	KATNAL2	-0.63	-9.53	-0.51	1.07e-18	Personality dimensions;
CESC	cis	rs807669	0.548	rs5746685	chr22:19192596	C/G	cg02655711	chr22:19163373	SLC25A1	-0.67	-9.11	-0.49	2.07e-17	Metabolite levels;
CESC	cis	rs172166	0.637	rs1233708	chr6:28173219	C/T	cg21251018	chr6:28226885	NKAPL	0.33	5.22	0.31	3.6e-7	Cardiac Troponin-T levels;
CESC	cis	rs4253772	0.637	rs9627350	chr22:46663017	A/G	cg09491104	chr22:46646882	C22orf40	-0.57	-8.65	-0.47	5.08e-16	LDL cholesterol;Cholesterol, total;
CESC	cis	rs8017423	0.935	rs11624246	chr14:90734826	A/G	cg14092571	chr14:90743983	NA	0.56	8.58	0.47	8.26e-16	Mortality in heart failure;
CESC	cis	rs1801251	0.896	rs2197563	chr2:233687080	G/A	cg25237894	chr2:233734115	C2orf82	-0.36	-6.51	-0.37	3.81e-10	Coronary artery disease;
CESC	trans	rs79976124	0.879	rs77185357	chr6:66629070	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.71	8.09	0.45	2.16e-14	Type 2 diabetes;
CESC	cis	rs7707921	0.522	rs4703537	chr5:81480371	C/T	cg15871215	chr5:81402204	ATG10	0.48	6.9	0.39	3.84e-11	Breast cancer;
CESC	cis	rs3008870	0.727	rs4582760	chr1:67464394	G/A	cg02640540	chr1:67518911	SLC35D1	-0.45	-5.49	-0.32	9.38e-8	Lymphocyte percentage of white cells;
CESC	trans	rs1945213	0.659	rs2086558	chr11:55844453	T/G	cg15704280	chr7:45808275	SEPT13	0.76	7.31	0.41	3.15e-12	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs1018697	0.518	rs2482506	chr10:104563743	C/G	cg04362960	chr10:104952993	NT5C2	-0.55	-6.24	-0.36	1.7e-9	Colorectal adenoma (advanced);
CESC	cis	rs9487051	1.000	rs9480924	chr6:109617070	T/C	cg01475377	chr6:109611718	NA	-0.42	-6.4	-0.37	6.83e-10	Reticulocyte fraction of red cells;
CESC	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg06873352	chr17:61820015	STRADA	0.71	12.33	0.6	6.72e-28	Prudent dietary pattern;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg04367680	chr8:74005697	C8orf84	0.44	6.24	0.36	1.73e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs763121	0.853	rs2267394	chr22:39101633	T/C	cg06544989	chr22:39130855	UNC84B	0.51	9.58	0.51	7.49e-19	Menopause (age at onset);
CESC	cis	rs9467711	0.606	rs9348712	chr6:26366511	T/A	cg14345882	chr6:26364793	BTN3A2	0.6	6.17	0.35	2.57e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs9916302	0.904	rs4511574	chr17:37532916	A/G	cg07936489	chr17:37558343	FBXL20	-0.81	-11.53	-0.58	3.48e-25	Glomerular filtration rate (creatinine);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26663754	chr7:93633843	BET1	0.59	6.17	0.35	2.55e-9	Gut microbiome composition (summer);
CESC	trans	rs561341	1.000	rs117979353	chr17:30272866	A/G	cg27661571	chr11:113659931	NA	-0.87	-8.02	-0.44	3.36e-14	Hip circumference adjusted for BMI;
CESC	cis	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg02951883	chr7:2050386	MAD1L1	-0.44	-5.72	-0.33	2.93e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs992157	0.560	rs12987130	chr2:219104990	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.57	-7.4	-0.41	1.86e-12	Colorectal cancer;
CESC	cis	rs990171	0.607	rs1558642	chr2:102763960	T/G	cg22835712	chr2:102737379	NA	0.44	5.9	0.34	1.1e-8	Lymphocyte counts;
CESC	cis	rs3820068	0.581	rs58425551	chr1:15922518	A/G	cg17385448	chr1:15911702	AGMAT	0.41	6.7	0.38	1.24e-10	Systolic blood pressure;
CESC	trans	rs3102460	0.618	rs3101469	chr1:244573645	G/C	cg01977209	chr2:236293433	NA	0.47	6.23	0.36	1.87e-9	Obesity-related traits;
CESC	cis	rs9948	0.786	rs62156226	chr2:97417108	G/A	cg01990225	chr2:97406019	LMAN2L	-0.96	-7.6	-0.42	5.16e-13	Erectile dysfunction and prostate cancer treatment;
CESC	cis	rs6461049	0.800	rs3800913	chr7:2163237	A/G	cg23048001	chr7:2026167	MAD1L1	0.45	5.85	0.34	1.45e-8	Schizophrenia;
CESC	cis	rs9788682	0.747	rs2656074	chr15:78741384	T/C	cg24631222	chr15:78858424	CHRNA5	-0.6	-7.09	-0.4	1.21e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs9899728	0.539	rs56267297	chr17:73046996	T/C	cg27626185	chr17:73056755	KCTD2	-0.89	-8.06	-0.44	2.6e-14	Alzheimer's disease or small vessel stroke;
CESC	cis	rs3857067	1.000	rs7694631	chr4:95016931	G/C	cg11021082	chr4:95130006	SMARCAD1	-0.52	-8.04	-0.44	3.04e-14	QT interval;
CESC	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg16132339	chr22:24313637	DDTL;DDT	0.42	6.35	0.36	9.52e-10	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs9309473	0.632	rs7599076	chr2:73585519	G/T	cg20560298	chr2:73613845	ALMS1	-0.5	-6.92	-0.39	3.33e-11	Metabolite levels;
CESC	cis	rs17826219	0.568	rs11658027	chr17:29094882	A/G	cg13385521	chr17:29058706	SUZ12P	-0.79	-6.48	-0.37	4.5e-10	Body mass index;
CESC	cis	rs7267979	1.000	rs910997	chr20:25267301	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	18.61	0.75	5.02e-50	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs2380220	0.516	rs7748108	chr6:96008082	T/C	cg23517279	chr6:96025343	MANEA	0.54	5.74	0.33	2.57e-8	Behavioural disinhibition (generation interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01522446	chr17:41150340	RPL27	-0.65	-7.54	-0.42	7.33e-13	Gut microbiome composition (summer);
CESC	cis	rs2075371	1.000	rs2505	chr7:133979552	C/T	cg20476274	chr7:133979776	SLC35B4	0.64	9.4	0.5	2.76e-18	Mean platelet volume;
CESC	cis	rs1348850	0.651	rs1901826	chr2:178225266	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.75	10.65	0.55	2.75e-22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs11249608	0.789	rs7704963	chr5:178436854	A/G	cg01312482	chr5:178451176	ZNF879	-0.39	-5.48	-0.32	9.71e-8	Pubertal anthropometrics;
CESC	cis	rs11112613	0.775	rs10778413	chr12:105962118	G/A	cg03607813	chr12:105948248	NA	0.57	6.39	0.37	7.59e-10	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CESC	cis	rs425277	0.606	rs262669	chr1:2082489	A/G	cg16545954	chr1:2118288	C1orf86	-0.35	-6.5	-0.37	3.91e-10	Height;
CESC	cis	rs6502050	0.835	rs4789751	chr17:80092373	G/T	cg11859384	chr17:80120422	CCDC57	-0.38	-5.14	-0.3	5.31e-7	Life satisfaction;
CESC	cis	rs3780486	0.505	rs959749	chr9:33147858	T/C	cg13443165	chr9:33130375	B4GALT1	0.49	7.48	0.42	1.12e-12	IgG glycosylation;
CESC	cis	rs10129255	0.518	rs10136903	chr14:107187105	T/C	cg07958169	chr14:107095056	NA	-0.55	-8.64	-0.47	5.22e-16	Kawasaki disease;
CESC	cis	rs889398	0.835	rs12925429	chr16:69801539	G/A	cg09409435	chr16:70099608	PDXDC2	-0.42	-5.26	-0.31	2.96e-7	Body mass index;
CESC	cis	rs17641971	0.662	rs2385229	chr8:50003869	T/C	cg00325661	chr8:49890786	NA	0.37	5.25	0.31	3.11e-7	Blood metabolite levels;
CESC	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg02725872	chr8:58115012	NA	-0.42	-5.72	-0.33	2.88e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs2295499	0.673	rs55641756	chr4:2704621	C/T	cg08330972	chr4:2403930	ZFYVE28	-0.32	-5.2	-0.3	3.91e-7	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
CESC	cis	rs13242816	0.881	rs35037267	chr7:116117587	A/T	cg04696780	chr7:116139425	CAV2	-0.62	-5.46	-0.32	1.09e-7	P wave duration;
CESC	cis	rs9611565	0.921	rs6002333	chr22:41719469	C/T	cg06634786	chr22:41940651	POLR3H	-0.63	-6.6	-0.38	2.21e-10	Vitiligo;
CESC	cis	rs1878931	0.697	rs10048148	chr16:3417450	C/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.97	14.95	0.68	4.56e-37	Body mass index (adult);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16189722	chr7:73668877	RFC2	0.54	6.03	0.35	5.5e-9	Gut microbiome composition (summer);
CESC	cis	rs875971	0.666	rs13242072	chr7:65765988	A/G	cg14393609	chr7:65229607	NA	-0.42	-5.44	-0.32	1.19e-7	Aortic root size;
CESC	cis	rs9916302	0.904	rs55660616	chr17:37684990	C/A	cg15445000	chr17:37608096	MED1	0.42	6.99	0.39	2.21e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs2952156	0.920	rs1476278	chr17:37836243	C/T	cg19468946	chr17:37922297	IKZF3	-0.39	-5.03	-0.3	8.93e-7	Asthma;
CESC	cis	rs6088590	0.931	rs6088624	chr20:33436852	T/A	cg24642439	chr20:33292090	TP53INP2	0.82	11.55	0.58	2.93e-25	Coronary artery disease;
CESC	cis	rs8170	0.603	rs10259	chr19:17430915	G/A	cg04749549	chr19:17459798	NA	-0.34	-5.39	-0.31	1.54e-7	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
CESC	cis	rs6688613	0.685	rs10800276	chr1:166858941	A/G	cg07049167	chr1:166818506	POGK	-0.51	-6.15	-0.35	2.89e-9	Refractive astigmatism;
CESC	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.55	-6.1	-0.35	3.69e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs17401966	0.867	rs10492973	chr1:10398985	T/C	cg15208524	chr1:10270712	KIF1B	0.42	5.34	0.31	1.96e-7	Hepatocellular carcinoma;
CESC	cis	rs7927771	1.000	rs10838747	chr11:47716324	G/C	cg18512352	chr11:47633146	NA	-0.59	-9.38	-0.5	3.13e-18	Subjective well-being;
CESC	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg05215272	chr17:6899095	ALOX12	0.45	8.78	0.47	2e-16	Tonsillectomy;
CESC	cis	rs7552404	0.727	rs12122939	chr1:76276353	T/C	cg03433033	chr1:76189801	ACADM	0.6	6.1	0.35	3.77e-9	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs736408	0.609	rs1029871	chr3:52797634	G/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	6.33	0.36	1.01e-9	Bipolar disorder;
CESC	cis	rs853679	0.546	rs200996	chr6:27811828	G/A	cg02228804	chr6:27775720	HIST1H2AI;HIST1H2BL	0.63	5.6	0.33	5.47e-8	Depression;
CESC	cis	rs6460942	0.915	rs62448619	chr7:12457743	C/T	cg20607287	chr7:12443886	VWDE	-0.78	-9.15	-0.49	1.61e-17	Coronary artery disease;
CESC	cis	rs6088590	0.561	rs3891369	chr20:33161127	C/T	cg08999081	chr20:33150536	PIGU	0.69	12.25	0.6	1.18e-27	Coronary artery disease;
CESC	trans	rs561341	0.883	rs1034627	chr17:30219569	C/T	cg20587970	chr11:113659929	NA	-0.92	-11.47	-0.58	5.51e-25	Hip circumference adjusted for BMI;
CESC	cis	rs9354308	0.899	rs2814153	chr6:66557611	T/A	cg07460842	chr6:66804631	NA	0.61	6.86	0.39	4.83e-11	Metabolite levels;
CESC	cis	rs1256061	0.624	rs944047	chr14:64700292	C/T	cg21174375	chr14:64681225	SYNE2	0.48	6.38	0.36	7.86e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs6912958	0.559	rs376633	chr6:88042785	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.74	11.54	0.58	3.24e-25	Monocyte percentage of white cells;
CESC	cis	rs763014	0.865	rs710924	chr16:633353	T/C	cg00908189	chr16:619842	PIGQ	0.67	9.34	0.5	4.24e-18	Height;
CESC	trans	rs9987353	0.840	rs329994	chr8:9123233	A/G	cg03172717	chr10:51565268	NCOA4	-0.47	-6.48	-0.37	4.57e-10	Recombination measurement;
CESC	cis	rs3862260	0.509	rs10802124	chr1:120164252	G/A	cg11530693	chr1:120165357	ZNF697	0.69	10.58	0.55	4.58e-22	Systemic lupus erythematosus;
CESC	trans	rs1373453	0.731	rs79185255	chr12:70070288	A/G	cg19702771	chr4:82058885	PRKG2	0.75	6.12	0.35	3.4e-9	Orofacial clefts;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01256882	chr5:1271100	TERT	-0.52	-6.61	-0.38	2.12e-10	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.830	rs28728124	chr4:99001116	G/T	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.62e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs1559088	0.512	rs34266236	chr19:33564874	C/A	cg13714067	chr14:103989336	CKB	0.65	6.07	0.35	4.42e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs62103177	0.810	rs62103191	chr18:77628769	C/G	cg12964065	chr18:77638022	KCNG2	0.58	5.46	0.32	1.07e-7	Opioid sensitivity;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19734257	chr20:56064117	HMGB1L1	-0.59	-7.82	-0.43	1.26e-13	Gut microbiome composition (summer);
CESC	cis	rs8133932	0.654	rs375254	chr21:47337151	T/A	cg14185626	chr21:47401492	COL6A1	-0.45	-5.09	-0.3	6.84e-7	Schizophrenia;
CESC	cis	rs769267	0.930	rs10402451	chr19:19608537	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.47	5.84	0.34	1.51e-8	Tonsillectomy;
CESC	cis	rs1799949	0.965	rs8176310	chr17:41199913	T/C	cg05368731	chr17:41323189	NBR1	0.5	6.86	0.39	4.72e-11	Menopause (age at onset);
CESC	cis	rs6754311	0.773	rs309179	chr2:136613780	G/A	cg07169764	chr2:136633963	MCM6	-0.69	-8.56	-0.47	9.42e-16	Mosquito bite size;
CESC	cis	rs6541297	0.703	rs607553	chr1:230316444	T/A	cg20703242	chr1:230279135	GALNT2	-0.43	-5.62	-0.33	4.84e-8	Coronary artery disease;
CESC	cis	rs909674	0.690	rs5750825	chr22:39831278	A/G	cg24399712	chr22:39784796	NA	-0.8	-10.92	-0.56	3.65e-23	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs12497850	0.897	rs9681717	chr3:48872998	A/G	cg02487422	chr3:49467188	NICN1	0.41	5.08	0.3	7.03e-7	Parkinson's disease;
CESC	cis	rs3768617	0.811	rs10911200	chr1:182998377	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.65	8.83	0.48	1.43e-16	Fuchs's corneal dystrophy;
CESC	cis	rs13256369	0.851	rs11249889	chr8:8564992	G/T	cg00074818	chr8:8560427	CLDN23	0.38	5.46	0.32	1.1e-7	Obesity-related traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06340276	chr4:89204787	PPM1K	-0.58	-6.95	-0.39	2.75e-11	Gut microbiome composition (summer);
CESC	cis	rs2074585	0.560	rs1973537	chr15:91062901	T/C	cg22089800	chr15:90895588	ZNF774	-0.42	-5.13	-0.3	5.5e-7	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
CESC	cis	rs2404602	0.716	rs2404736	chr15:76875943	T/C	cg22467129	chr15:76604101	ETFA	-0.35	-5.22	-0.31	3.65e-7	Blood metabolite levels;
CESC	cis	rs1577917	1.000	rs12215903	chr6:86675028	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.45	-5.92	-0.34	9.76e-9	Response to antipsychotic treatment;
CESC	cis	rs6831352	0.918	rs29001224	chr4:100047373	G/A	cg13256891	chr4:100009986	ADH5	-0.77	-8.43	-0.46	2.27e-15	Alcohol dependence;
CESC	cis	rs1153858	1.000	rs4627277	chr15:45652768	C/A	cg14582100	chr15:45693742	SPATA5L1	0.42	5.97	0.34	7.62e-9	Homoarginine levels;
CESC	cis	rs8005677	0.828	rs712486	chr14:23425041	A/G	cg01529538	chr14:23388837	RBM23	0.44	6.01	0.35	6.28e-9	Cognitive ability (multi-trait analysis);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg10462529	chr17:78880748	RPTOR	0.44	6.43	0.37	5.77e-10	Fibrinogen levels;
CESC	cis	rs1018836	0.544	rs2339154	chr8:91459316	T/C	cg16814680	chr8:91681699	NA	-0.45	-6.0	-0.35	6.43e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	trans	rs561341	1.000	rs1557731	chr17:30321567	T/G	cg27661571	chr11:113659931	NA	-0.7	-7.12	-0.4	1.01e-11	Hip circumference adjusted for BMI;
CESC	cis	rs17711722	0.675	rs6947132	chr7:65273495	G/A	cg14393609	chr7:65229607	NA	-0.52	-7.07	-0.4	1.36e-11	Calcium levels;
CESC	cis	rs116095464	0.510	rs7723883	chr5:270798	T/C	cg12570787	chr5:219185	SDHA;CCDC127	0.5	5.28	0.31	2.72e-7	Breast cancer;
CESC	cis	rs1348850	0.651	rs4893936	chr2:178240676	C/G	cg23306229	chr2:178417860	TTC30B	0.54	7.01	0.4	1.96e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs6570726	1.000	rs455109	chr6:145872665	C/T	cg23711669	chr6:146136114	FBXO30	0.77	11.24	0.57	3.15e-24	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs35306767	0.903	rs7077278	chr10:911291	A/G	cg25019033	chr10:957182	NA	0.57	6.12	0.35	3.42e-9	Eosinophil percentage of granulocytes;
CESC	cis	rs2204008	0.806	rs7305409	chr12:38349133	G/A	cg13010199	chr12:38710504	ALG10B	0.53	6.62	0.38	2.03e-10	Bladder cancer;
CESC	cis	rs10465746	0.570	rs11163885	chr1:84472956	A/G	cg10977910	chr1:84465055	TTLL7	0.44	5.54	0.32	7.2e-8	Obesity-related traits;
CESC	cis	rs3845702	0.668	rs6759271	chr2:180844303	T/C	cg01881094	chr2:180872142	CWC22	-1.08	-9.69	-0.51	3.43e-19	Schizophrenia;
CESC	cis	rs1862618	0.853	rs832584	chr5:56179212	A/G	cg12311346	chr5:56204834	C5orf35	0.72	8.71	0.47	3.44e-16	Initial pursuit acceleration;
CESC	cis	rs9486719	0.857	rs6568392	chr6:96861476	G/T	cg18709589	chr6:96969512	KIAA0776	0.43	5.03	0.3	9.2e-7	Migraine;Coronary artery disease;
CESC	cis	rs644799	1.000	rs586238	chr11:95560371	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.56	6.94	0.39	3.08e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs1153858	1.000	rs4775906	chr15:45638294	C/T	cg21132104	chr15:45694354	SPATA5L1	0.82	11.02	0.56	1.72e-23	Homoarginine levels;
CESC	cis	rs58688157	0.705	rs11539530	chr11:609353	G/A	cg02461776	chr11:598696	PHRF1	0.46	5.11	0.3	6.24e-7	Systemic lupus erythematosus;
CESC	cis	rs68092024	0.704	rs704575	chr3:99486075	A/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.43	-6.77	-0.38	8.4e-11	Cleft lip with or without cleft palate;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg06028048	chr5:175815674	HIGD2A;NOP16	-0.46	-6.45	-0.37	5.16e-10	Gambling;
CESC	cis	rs951366	0.649	rs7522056	chr1:205735891	A/G	cg07157834	chr1:205819609	PM20D1	0.4	5.32	0.31	2.2e-7	Menarche (age at onset);
CESC	cis	rs10129255	0.500	rs8021941	chr14:107189727	C/T	cg07958169	chr14:107095056	NA	-0.58	-9.41	-0.5	2.53e-18	Kawasaki disease;
CESC	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-1.13	-20.95	-0.79	3.91e-58	Prudent dietary pattern;
CESC	cis	rs832540	0.603	rs6870175	chr5:56093371	A/G	cg24531977	chr5:56204891	C5orf35	-0.49	-5.92	-0.34	9.9e-9	Coronary artery disease;
CESC	cis	rs7829975	0.742	rs1533059	chr8:8684953	A/G	cg06636001	chr8:8085503	FLJ10661	-0.48	-5.87	-0.34	1.3e-8	Mood instability;
CESC	trans	rs864643	0.773	rs11129837	chr3:39589963	A/G	cg01487461	chr9:2017199	SMARCA2	0.54	7.14	0.4	9.11e-12	Attention deficit hyperactivity disorder;
CESC	cis	rs4132509	0.744	rs10803156	chr1:243917776	G/C	cg21452805	chr1:244014465	NA	0.64	7.03	0.4	1.71e-11	RR interval (heart rate);
CESC	cis	rs10779751	1.000	rs7525957	chr1:11318236	C/T	cg08854313	chr1:11322531	MTOR	0.84	11.92	0.59	1.57e-26	Body mass index;
CESC	cis	rs4563143	0.675	rs73025085	chr19:29247018	C/A	cg04546413	chr19:29218101	NA	0.56	7.91	0.44	6.84e-14	Methadone dose in opioid dependence;
CESC	cis	rs2066819	1.000	rs2643626	chr12:56726518	C/T	cg26714650	chr12:56694279	CS	1.24	15.03	0.68	2.31e-37	Psoriasis vulgaris;
CESC	cis	rs2559856	1.000	rs2695286	chr12:102088507	T/C	cg12213457	chr12:102090980	CHPT1	-0.36	-5.33	-0.31	2.07e-7	Blood protein levels;
CESC	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	21.26	0.79	3.33e-59	Prudent dietary pattern;
CESC	cis	rs780096	0.546	rs6547626	chr2:27646770	C/T	cg22903471	chr2:27725779	GCKR	-0.5	-7.16	-0.4	7.71e-12	Total body bone mineral density;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg20020483	chr16:32289928	NA	0.47	6.37	0.36	8.1e-10	Fibrinogen levels;
CESC	cis	rs4315565	0.764	rs11900784	chr2:69272496	A/T	cg12800200	chr2:69260302	ANTXR1	0.42	6.01	0.35	5.95e-9	Height;
CESC	cis	rs10465746	0.901	rs17534614	chr1:84383079	G/A	cg10977910	chr1:84465055	TTLL7	0.45	6.07	0.35	4.37e-9	Obesity-related traits;
CESC	cis	rs7818345	0.874	rs12674938	chr8:19300813	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.34	6.1	0.35	3.74e-9	Language performance in older adults (adjusted for episodic memory);
CESC	cis	rs709400	0.628	rs2010281	chr14:103862322	G/A	cg12935359	chr14:103987150	CKB	-0.52	-7.62	-0.42	4.4e-13	Body mass index;
CESC	cis	rs1046896	1.000	rs1046896	chr17:80685533	A/G	cg02711726	chr17:80685570	FN3KRP	0.59	8.92	0.48	7.89e-17	Glycated hemoglobin levels;
CESC	cis	rs2836974	0.644	rs9978775	chr21:40694526	A/G	cg22974920	chr21:40686053	BRWD1	-0.47	-5.72	-0.33	2.88e-8	Cognitive function;
CESC	cis	rs9486719	1.000	rs35487471	chr6:96879715	C/T	cg18709589	chr6:96969512	KIAA0776	-0.53	-5.81	-0.34	1.75e-8	Migraine;Coronary artery disease;
CESC	cis	rs2806561	0.765	rs1997866	chr1:23512524	A/G	cg12483005	chr1:23474871	LUZP1	0.39	6.11	0.35	3.63e-9	Height;
CESC	cis	rs7412746	0.611	rs111905669	chr1:150777565	T/C	cg18016565	chr1:150552671	MCL1	0.35	5.18	0.3	4.32e-7	Melanoma;
CESC	cis	rs4523957	0.855	rs1231209	chr17:2124972	G/A	cg16513277	chr17:2031491	SMG6	-0.64	-8.84	-0.48	1.36e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs9811920	0.931	rs7629487	chr3:99860401	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.47	6.11	0.35	3.56e-9	Axial length;
CESC	trans	rs11039798	1.000	rs7125559	chr11:48984207	C/G	cg15704280	chr7:45808275	SEPT13	0.7	6.52	0.37	3.51e-10	Axial length;
CESC	cis	rs9905704	0.671	rs2531736	chr17:56552204	A/G	cg12560992	chr17:57184187	TRIM37	-0.58	-5.45	-0.32	1.17e-7	Testicular germ cell tumor;
CESC	trans	rs13398848	1.000	rs10165993	chr2:84200880	A/G	cg23262351	chr6:79576851	IRAK1BP1	-0.68	-6.02	-0.35	5.73e-9	Conduct disorder (symptom count);Conduct disorder;
CESC	cis	rs7654585	1.000	rs4692025	chr4:25949759	A/C	cg10409131	chr4:25915609	C4orf52	-0.49	-6.68	-0.38	1.44e-10	Obesity-related traits;
CESC	cis	rs67311347	1.000	rs1004655	chr3:40490009	G/A	cg09455208	chr3:40491958	NA	0.52	8.27	0.45	6.69e-15	Renal cell carcinoma;
CESC	cis	rs3785574	0.962	rs2584628	chr17:61894578	T/C	cg07677032	chr17:61819896	STRADA	0.4	5.05	0.3	8.26e-7	Height;
CESC	cis	rs1218582	0.772	rs2174507	chr1:154887949	C/T	cg09359103	chr1:154839909	KCNN3	-0.65	-12.26	-0.6	1.15e-27	Prostate cancer;
CESC	cis	rs780096	0.526	rs2911713	chr2:27640980	G/A	cg24768116	chr2:27665128	KRTCAP3	-0.29	-5.47	-0.32	1.05e-7	Total body bone mineral density;
CESC	cis	rs7818688	0.578	rs73269188	chr8:95838346	C/G	cg16049864	chr8:95962084	TP53INP1	0.52	5.48	0.32	9.71e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs34779708	0.931	rs12768019	chr10:35389843	T/C	cg03585969	chr10:35415529	CREM	0.77	10.07	0.53	2.06e-20	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs6912958	1.000	rs6937823	chr6:88160386	G/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.35	-5.81	-0.34	1.82e-8	Monocyte percentage of white cells;
CESC	cis	rs9309473	1.000	rs3813227	chr2:73651967	A/G	cg20560298	chr2:73613845	ALMS1	0.46	6.27	0.36	1.48e-9	Metabolite levels;
CESC	cis	rs2204008	0.805	rs12146846	chr12:37985847	C/T	cg13010199	chr12:38710504	ALG10B	0.53	6.66	0.38	1.61e-10	Bladder cancer;
CESC	cis	rs6952808	0.825	rs11761818	chr7:1935273	C/T	cg02951883	chr7:2050386	MAD1L1	-0.49	-6.51	-0.37	3.8e-10	Bipolar disorder and schizophrenia;
CESC	cis	rs9287719	0.839	rs7600695	chr2:10739945	A/G	cg02196655	chr2:10830764	NOL10	-0.37	-5.72	-0.33	2.87e-8	Prostate cancer;
CESC	cis	rs863345	0.604	rs12120526	chr1:158498404	T/C	cg12129480	chr1:158549410	OR10X1	-0.34	-6.85	-0.39	5.15e-11	Pneumococcal bacteremia;
CESC	trans	rs12356475	0.710	rs10822686	chr10:67733250	C/T	cg10078639	chr10:116286586	ABLIM1	0.49	6.01	0.35	5.95e-9	Psoriatic arthritis;
CESC	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg24642844	chr7:1081250	C7orf50	-0.75	-9.1	-0.49	2.29e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08493879	chr7:151722810	GALNT11	0.53	6.22	0.36	1.96e-9	Gut microbiome composition (summer);
CESC	cis	rs425277	0.958	rs262688	chr1:2113565	T/G	cg24578937	chr1:2090814	PRKCZ	0.54	9.39	0.5	2.96e-18	Height;
CESC	cis	rs79057730	0.527	rs35316052	chr7:802954	C/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.9	7.88	0.44	8.53e-14	Initial pursuit acceleration;
CESC	cis	rs9914988	0.725	rs9905510	chr17:27092325	G/A	cg20469991	chr17:27169893	C17orf63	-0.48	-5.25	-0.31	3.18e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CESC	cis	rs1348850	0.632	rs13008833	chr2:178514439	G/C	cg23306229	chr2:178417860	TTC30B	0.6	7.53	0.42	7.75e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs67478160	0.643	rs876002	chr14:104239697	G/A	cg08213375	chr14:104286397	PPP1R13B	0.55	11.09	0.56	9.71e-24	Schizophrenia;
CESC	cis	rs2288073	0.965	rs13395596	chr2:24410738	T/C	cg06627628	chr2:24431161	ITSN2	-0.73	-8.64	-0.47	5.5e-16	Venous thromboembolism (SNP x SNP interaction);
CESC	cis	rs10992471	0.598	rs10761156	chr9:95171852	C/T	cg13798575	chr9:95087839	CENPP;NOL8	0.4	5.04	0.3	8.5e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CESC	cis	rs7998202	0.667	rs408220	chr13:113370267	T/C	cg02820901	chr13:113351484	ATP11A	0.65	5.41	0.32	1.4e-7	Glycated hemoglobin levels;
CESC	cis	rs7216064	1.000	rs62084213	chr17:65842016	A/G	cg12091567	chr17:66097778	LOC651250	-0.86	-8.83	-0.48	1.49e-16	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs1862618	1.000	rs1862618	chr5:56096315	C/G	cg18230493	chr5:56204884	C5orf35	-0.7	-8.62	-0.47	6.14e-16	Initial pursuit acceleration;
CESC	cis	rs4568518	0.561	rs4579426	chr7:18008259	A/T	cg03009463	chr7:17980271	SNX13	0.43	5.73	0.33	2.77e-8	Measles;
CESC	cis	rs1799949	0.965	rs6503727	chr17:41312859	C/T	cg05368731	chr17:41323189	NBR1	0.55	7.6	0.42	5.03e-13	Menopause (age at onset);
CESC	cis	rs4713118	0.586	rs6905516	chr6:28086478	A/G	cg08968635	chr6:28129556	ZNF389	0.4	5.36	0.31	1.84e-7	Parkinson's disease;
CESC	cis	rs9549367	0.713	rs9549357	chr13:113860121	C/T	cg18105134	chr13:113819100	PROZ	-0.6	-7.66	-0.43	3.56e-13	Platelet distribution width;
CESC	cis	rs2991971	0.747	rs2492841	chr1:45894891	G/T	cg03146154	chr1:46216737	IPP	0.39	5.04	0.3	8.51e-7	High light scatter reticulocyte count;
CESC	cis	rs6502050	0.799	rs4789673	chr17:80123218	T/C	cg11859384	chr17:80120422	CCDC57	-0.39	-5.34	-0.31	1.98e-7	Life satisfaction;
CESC	cis	rs9640161	0.750	rs3735173	chr7:150020526	C/T	cg10018233	chr7:150070692	REPIN1	0.49	7.87	0.44	8.84e-14	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs875971	0.862	rs7809814	chr7:65615397	G/A	cg18876405	chr7:65276391	NA	-0.53	-7.28	-0.41	3.82e-12	Aortic root size;
CESC	cis	rs1005277	0.540	rs2474598	chr10:38430296	C/T	cg25517755	chr10:38738941	LOC399744	0.45	5.77	0.33	2.19e-8	Extrinsic epigenetic age acceleration;
CESC	cis	rs2239547	0.522	rs2564947	chr3:53046216	C/T	cg11645453	chr3:52864694	ITIH4	-0.32	-5.51	-0.32	8.38e-8	Schizophrenia;
CESC	cis	rs6987853	0.563	rs2923408	chr8:42451526	A/G	cg09913449	chr8:42400586	C8orf40	0.35	5.56	0.32	6.43e-8	Mean corpuscular hemoglobin concentration;
CESC	cis	rs6088580	0.634	rs6119497	chr20:33012529	T/A	cg06115741	chr20:33292138	TP53INP2	0.48	6.13	0.35	3.2e-9	Glomerular filtration rate (creatinine);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg08249556	chr21:30365104	RNF160	-0.43	-6.18	-0.35	2.39e-9	Gambling;
CESC	cis	rs7666738	0.830	rs34135615	chr4:99001325	C/T	cg17366294	chr4:99064904	C4orf37	0.6	8.61	0.47	6.47e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs8060686	0.641	rs113162813	chr16:68038969	A/G	cg26727032	chr16:67993705	SLC12A4	-0.54	-6.15	-0.35	2.78e-9	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs798554	0.660	rs2644274	chr7:2854380	A/T	cg19717773	chr7:2847554	GNA12	-0.54	-8.49	-0.46	1.47e-15	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16294016	chr4:190862268	FRG1	0.53	6.06	0.35	4.62e-9	Gut microbiome composition (summer);
CESC	cis	rs1153858	1.000	rs60476496	chr15:45713801	C/T	cg14582100	chr15:45693742	SPATA5L1	0.41	5.79	0.33	2.03e-8	Homoarginine levels;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg21725374	chr8:145171334	KIAA1875	0.5	6.98	0.39	2.43e-11	Fibrinogen levels;
CESC	cis	rs17641971	0.684	rs7011891	chr8:49983538	A/C	cg00325661	chr8:49890786	NA	0.4	5.58	0.32	5.94e-8	Blood metabolite levels;
CESC	cis	rs2777491	1.000	rs316613	chr15:41747598	G/A	cg20272979	chr15:41787780	ITPKA	0.43	6.42	0.37	6.44e-10	Ulcerative colitis;
CESC	cis	rs4853012	1.000	rs2280643	chr2:74358286	T/C	cg19729930	chr2:74357872	NA	0.87	12.57	0.61	1e-28	Gestational age at birth (maternal effect);
CESC	cis	rs7560272	0.538	rs35767294	chr2:73922834	A/G	cg20560298	chr2:73613845	ALMS1	0.45	6.15	0.35	2.78e-9	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25846302	chr15:102501640	WASH3P	-0.51	-6.2	-0.36	2.13e-9	Gut microbiome composition (summer);
CESC	cis	rs2239547	0.618	rs4687663	chr3:52870618	T/A	cg11645453	chr3:52864694	ITIH4	0.36	6.55	0.37	2.98e-10	Schizophrenia;
CESC	cis	rs317689	0.819	rs317660	chr12:69686203	G/A	cg20891283	chr12:69753455	YEATS4	0.48	5.13	0.3	5.57e-7	Response to diuretic therapy;
CESC	trans	rs561341	0.883	rs7219239	chr17:30212016	A/G	cg27661571	chr11:113659931	NA	0.6	6.09	0.35	3.88e-9	Hip circumference adjusted for BMI;
CESC	cis	rs6076065	0.707	rs1419007	chr20:23336895	T/C	cg11657817	chr20:23433608	CST11	0.41	6.22	0.36	1.88e-9	Facial morphology (factor 15, philtrum width);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg12879381	chr18:12326166	TUBB6	0.45	6.08	0.35	4.15e-9	Fibrinogen levels;
CESC	cis	rs853679	0.628	rs9368560	chr6:28159960	T/C	cg12963246	chr6:28129442	ZNF389	0.5	6.44	0.37	5.59e-10	Depression;
CESC	cis	rs16867321	0.614	rs10204086	chr2:181449668	G/T	cg23363182	chr2:181467187	NA	-0.5	-7.42	-0.41	1.63e-12	Obesity;
CESC	cis	rs7085104	0.513	rs192569	chr10:104577915	T/C	cg04362960	chr10:104952993	NT5C2	-0.5	-6.83	-0.39	5.95e-11	Immature fraction of reticulocytes;Schizophrenia;
CESC	cis	rs9300255	0.679	rs10846507	chr12:123786492	G/T	cg19016782	chr12:123741754	C12orf65	-0.42	-5.82	-0.34	1.7e-8	Neutrophil percentage of white cells;
CESC	cis	rs637571	0.522	rs566590	chr11:65754062	C/T	cg02202077	chr11:65769826	EIF1AD;BANF1	0.45	6.02	0.35	5.67e-9	Eosinophil percentage of white cells;
CESC	cis	rs10883723	0.810	rs2281879	chr10:104268877	C/G	cg22532475	chr10:104410764	TRIM8	-0.35	-5.94	-0.34	9.07e-9	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs9584850	0.834	rs3783005	chr13:99111337	A/T	cg22223119	chr13:99095684	FARP1	0.35	5.12	0.3	5.98e-7	Neuroticism;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14065121	chr9:77643271	C9orf41	0.61	7.31	0.41	3.17e-12	Gut microbiome composition (summer);
CESC	cis	rs12579753	0.879	rs12579544	chr12:82164043	A/C	cg23701643	chr12:82153290	PPFIA2	-0.35	-5.03	-0.3	8.99e-7	Resting heart rate;
CESC	cis	rs3126085	0.877	rs12133847	chr1:152170101	T/G	cg26876637	chr1:152193138	HRNR	0.44	5.12	0.3	5.98e-7	Atopic dermatitis;
CESC	cis	rs35955747	0.838	rs5997900	chr22:31580346	C/A	cg25791279	chr22:32026902	PISD	-0.47	-5.59	-0.32	5.75e-8	Neutrophil count;Sum basophil neutrophil counts;
CESC	cis	rs5750830	0.649	rs5750815	chr22:39798449	T/C	cg05872129	chr22:39784769	NA	-0.83	-11.04	-0.56	1.48e-23	Intelligence (multi-trait analysis);
CESC	cis	rs6938	0.534	rs12907898	chr15:75207872	C/T	cg09165964	chr15:75287851	SCAMP5	0.45	6.09	0.35	3.99e-9	Breast cancer;
CESC	cis	rs7107174	1.000	rs58565853	chr11:78036707	C/T	cg03754400	chr11:77348600	CLNS1A	0.45	5.11	0.3	6.1e-7	Testicular germ cell tumor;
CESC	cis	rs10857712	1.000	rs10857712	chr10:135225666	T/C	cg01444801	chr10:135216882	MTG1	-0.44	-5.23	-0.31	3.43e-7	Systemic lupus erythematosus;
CESC	cis	rs12701220	0.520	rs7803208	chr7:1162084	C/T	cg04025307	chr7:1156635	C7orf50	0.41	5.75	0.33	2.48e-8	Bronchopulmonary dysplasia;
CESC	cis	rs7618915	0.501	rs3733039	chr3:52719088	C/T	cg17372223	chr3:52568218	NT5DC2	0.43	6.65	0.38	1.62e-10	Bipolar disorder;
CESC	cis	rs6951245	0.706	rs1133116	chr7:1195215	A/C	cg24642844	chr7:1081250	C7orf50	-0.63	-8.1	-0.45	2.06e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs72781680	0.566	rs55987381	chr2:23900938	T/C	cg08917208	chr2:24149416	ATAD2B	0.76	7.38	0.41	2.03e-12	Lymphocyte counts;
CESC	cis	rs34779708	0.931	rs55724039	chr10:35465397	A/G	cg04310649	chr10:35416472	CREM	-0.53	-6.49	-0.37	4.32e-10	Inflammatory bowel disease;Crohn's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05609414	chr7:39873832	NA	-0.53	-7.08	-0.4	1.33e-11	Gut microbiome composition (summer);
CESC	cis	rs7772486	0.686	rs9390348	chr6:146044748	C/T	cg05347473	chr6:146136440	FBXO30	-0.52	-6.93	-0.39	3.22e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2354432	0.607	rs7537279	chr1:146673642	A/G	cg25205988	chr1:146714368	CHD1L	1.19	9.08	0.49	2.58e-17	Mitochondrial DNA levels;
CESC	cis	rs7605378	0.528	rs812760	chr2:200724372	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.47	5.26	0.31	2.95e-7	Osteoporosis;
CESC	cis	rs9905704	0.918	rs36071323	chr17:56916804	C/T	cg12560992	chr17:57184187	TRIM37	0.61	7.05	0.4	1.54e-11	Testicular germ cell tumor;
CESC	trans	rs35146811	0.731	rs2257213	chr7:99810113	T/C	cg13215871	chr17:75784724	NA	-0.35	-6.45	-0.37	5.26e-10	Coronary artery disease;
CESC	cis	rs7474896	0.515	rs2738208	chr10:38306128	A/G	cg00409905	chr10:38381863	ZNF37A	0.46	5.15	0.3	5.05e-7	Obesity (extreme);
CESC	cis	rs7666738	0.830	rs28687737	chr4:99009226	G/A	cg05340658	chr4:99064831	C4orf37	0.8	12.51	0.61	1.52e-28	Colonoscopy-negative controls vs population controls;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg09315918	chr1:206137767	FAM72A	-0.45	-6.05	-0.35	4.99e-9	Fibrinogen levels;
CESC	cis	rs1862618	0.671	rs2591968	chr5:56233541	A/G	cg24531977	chr5:56204891	C5orf35	-0.66	-9.17	-0.49	1.41e-17	Initial pursuit acceleration;
CESC	cis	rs514406	0.825	rs3863643	chr1:53224577	C/T	cg24675658	chr1:53192096	ZYG11B	0.53	6.78	0.38	7.96e-11	Monocyte count;
CESC	cis	rs7762018	0.655	rs2184195	chr6:170148397	C/T	cg05834625	chr6:170176447	C6orf70	0.65	7.17	0.4	7.57e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs9902453	1.000	rs7212497	chr17:28335949	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.6	-7.52	-0.42	8.34e-13	Coffee consumption (cups per day);
CESC	trans	rs7246657	0.943	rs7255785	chr19:37971683	C/T	cg24637308	chr11:6592297	DNHD1	0.54	6.24	0.36	1.75e-9	Coronary artery calcification;
CESC	cis	rs3736485	0.966	rs12102203	chr15:51791559	A/G	cg08986416	chr15:51914746	DMXL2	-0.4	-5.24	-0.31	3.34e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs4665809	1.000	rs1470097	chr2:26312840	A/G	cg25036284	chr2:26402008	FAM59B	-0.58	-6.72	-0.38	1.09e-10	Gut microbiome composition (summer);
CESC	cis	rs4925386	0.681	rs2427295	chr20:60927431	G/A	cg22633769	chr20:60982531	CABLES2	0.56	5.95	0.34	8.51e-9	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs9443645	0.810	rs10943613	chr6:79745107	C/T	cg05283184	chr6:79620031	NA	-0.39	-5.96	-0.34	8.04e-9	Intelligence (multi-trait analysis);
CESC	cis	rs1878931	0.858	rs3760083	chr16:3450052	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.95	-14.37	-0.66	5.07e-35	Body mass index (adult);
CESC	cis	rs4594175	0.926	rs7493621	chr14:51623665	C/T	cg23942311	chr14:51606299	NA	0.34	5.07	0.3	7.54e-7	Cancer;
CESC	cis	rs6500602	0.592	rs4785966	chr16:4518754	C/T	cg08645402	chr16:4508243	NA	-0.44	-6.71	-0.38	1.2e-10	Schizophrenia;
CESC	trans	rs2693676	0.504	rs1257490	chr14:99604188	G/A	cg17465227	chr4:47427752	GABRB1	0.59	6.35	0.36	9.51e-10	Corneal curvature;
CESC	cis	rs8180040	0.620	rs9858443	chr3:47086048	G/A	cg27129171	chr3:47204927	SETD2	0.67	9.83	0.52	1.18e-19	Colorectal cancer;
CESC	cis	rs875971	0.540	rs4717275	chr7:65265180	C/T	cg18876405	chr7:65276391	NA	-0.69	-9.49	-0.5	1.4e-18	Aortic root size;
CESC	cis	rs6496667	0.510	rs16944405	chr15:90975517	A/G	cg10434728	chr15:90938212	IQGAP1	0.33	5.59	0.32	5.74e-8	Rheumatoid arthritis;
CESC	cis	rs4953076	0.573	rs6738023	chr2:44405931	T/C	cg04920474	chr2:44395004	PPM1B	0.55	7.06	0.4	1.5e-11	Height;
CESC	cis	rs7618501	1.000	rs60205400	chr3:49800272	C/T	cg24308560	chr3:49941425	MST1R	-0.52	-7.18	-0.4	7.15e-12	Intelligence (multi-trait analysis);
CESC	cis	rs6582630	0.599	rs12309369	chr12:38419683	C/G	cg26384229	chr12:38710491	ALG10B	-0.41	-5.49	-0.32	9.35e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs34779708	0.931	rs72789690	chr10:35382817	T/C	cg04310649	chr10:35416472	CREM	-0.51	-6.06	-0.35	4.62e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs1847505	0.609	rs9539004	chr13:61587049	T/C	cg25164009	chr13:61490935	NA	-0.41	-5.51	-0.32	8.54e-8	Polychlorinated biphenyl levels;
CESC	cis	rs116095464	0.558	rs10076655	chr5:239464	G/C	cg20965017	chr5:231967	SDHA	-0.46	-5.23	-0.31	3.51e-7	Breast cancer;
CESC	trans	rs877282	0.898	rs11253344	chr10:765162	C/T	cg22713356	chr15:30763199	NA	1.16	11.35	0.57	1.37e-24	Uric acid levels;
CESC	cis	rs17253792	0.822	rs74824071	chr14:56095142	T/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.79	5.91	0.34	1.06e-8	Putamen volume;
CESC	cis	rs6456156	0.774	rs9347175	chr6:167527644	A/T	cg07741184	chr6:167504864	NA	-0.31	-5.2	-0.3	4.02e-7	Primary biliary cholangitis;
CESC	cis	rs1862618	0.853	rs9283717	chr5:56078659	G/A	cg03609598	chr5:56110824	MAP3K1	-0.5	-5.4	-0.31	1.48e-7	Initial pursuit acceleration;
CESC	trans	rs61931739	0.534	rs11053073	chr12:34202412	C/T	cg26384229	chr12:38710491	ALG10B	0.64	9.15	0.49	1.59e-17	Morning vs. evening chronotype;
CESC	cis	rs514406	0.644	rs6662414	chr1:53198893	A/G	cg08859206	chr1:53392774	SCP2	0.62	8.96	0.48	6.03e-17	Monocyte count;
CESC	cis	rs7605827	0.930	rs12995845	chr2:15520539	C/T	cg19274914	chr2:15703543	NA	0.36	6.48	0.37	4.44e-10	Educational attainment (years of education);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg14272860	chr19:42580418	ZNF574	-0.47	-6.48	-0.37	4.33e-10	Fibrinogen levels;
CESC	cis	rs11166629	1.000	rs6992668	chr8:135645129	T/C	cg27224718	chr8:135614730	ZFAT	0.52	6.43	0.37	6.03e-10	Smoking quantity;
CESC	cis	rs1153858	1.000	rs7171577	chr15:45627979	G/A	cg21132104	chr15:45694354	SPATA5L1	0.84	11.38	0.57	1.09e-24	Homoarginine levels;
CESC	cis	rs1448094	0.512	rs6539933	chr12:86247611	T/C	cg00310523	chr12:86230176	RASSF9	0.35	5.4	0.32	1.45e-7	Major depressive disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00070814	chr10:70715958	DDX21	0.56	6.03	0.35	5.62e-9	Gut microbiome composition (summer);
CESC	cis	rs60154123	0.772	rs628908	chr1:210428002	C/T	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.52	5.65	0.33	4.05e-8	Coronary artery disease;
CESC	cis	rs761746	0.739	rs5753691	chr22:31952045	A/G	cg25791279	chr22:32026902	PISD	0.64	6.93	0.39	3.11e-11	Intelligence;
CESC	cis	rs3820928	0.605	rs6718767	chr2:227800776	A/G	cg05526886	chr2:227700861	RHBDD1	-0.54	-7.4	-0.41	1.8e-12	Pulmonary function;
CESC	cis	rs12541335	0.639	rs7003478	chr8:22201123	A/G	cg02463440	chr8:22132932	PIWIL2	0.39	6.0	0.35	6.34e-9	Hypertriglyceridemia;
CESC	cis	rs7772486	0.875	rs854148	chr6:146310979	G/C	cg23711669	chr6:146136114	FBXO30	0.9	13.1	0.63	1.45e-30	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9926296	0.744	rs164748	chr16:89708292	C/G	cg27121462	chr16:89883253	FANCA	-0.46	-5.53	-0.32	7.83e-8	Vitiligo;
CESC	cis	rs3820068	0.529	rs79570154	chr1:15990912	T/C	cg16988262	chr1:15930761	NA	0.35	5.61	0.33	5.18e-8	Systolic blood pressure;
CESC	cis	rs7660520	0.524	rs6839881	chr4:183729137	A/T	cg04181038	chr4:183730758	NA	0.59	6.95	0.39	2.79e-11	Pediatric autoimmune diseases;
CESC	cis	rs2479106	0.591	rs879070	chr9:126433214	T/C	cg16191174	chr9:126692580	DENND1A	0.4	5.7	0.33	3.21e-8	Polycystic ovary syndrome;
CESC	cis	rs4862750	0.872	rs7671914	chr4:187878165	A/G	cg10295955	chr4:187884368	NA	-1.07	-21.51	-0.8	4.72e-60	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7586879	0.593	rs10198275	chr2:25130542	A/C	cg01884057	chr2:25150051	NA	0.36	6.96	0.39	2.66e-11	Body mass index;
CESC	cis	rs734999	0.566	rs4648563	chr1:2536002	C/G	cg20673091	chr1:2541236	MMEL1	0.43	7.16	0.4	7.78e-12	Ulcerative colitis;
CESC	cis	rs853679	0.550	rs1150692	chr6:28173957	A/G	cg22143856	chr6:28129313	ZNF389	0.44	5.82	0.34	1.68e-8	Depression;
CESC	cis	rs208520	0.706	rs851601	chr6:66893853	G/A	cg07460842	chr6:66804631	NA	-0.93	-11.86	-0.59	2.64e-26	Exhaled nitric oxide output;
CESC	cis	rs6547741	0.967	rs4665999	chr2:27834444	T/C	cg27432699	chr2:27873401	GPN1	0.49	6.93	0.39	3.21e-11	Oral cavity cancer;
CESC	cis	rs208520	0.526	rs7771233	chr6:66819784	A/G	cg07460842	chr6:66804631	NA	-1.04	-22.74	-0.81	3.19e-64	Exhaled nitric oxide output;
CESC	cis	rs611744	0.647	rs676654	chr8:109242303	A/G	cg21045802	chr8:109455806	TTC35	0.5	6.23	0.36	1.87e-9	Dupuytren's disease;
CESC	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg11494091	chr17:61959527	GH2	0.73	12.36	0.6	5.16e-28	Prudent dietary pattern;
CESC	cis	rs1552244	1.000	rs13319597	chr3:10126312	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.91	-13.19	-0.63	7.11e-31	Alzheimer's disease;
CESC	cis	rs2115536	0.640	rs934134	chr15:80168218	T/C	cg00225070	chr15:80189496	MTHFS	0.42	5.56	0.32	6.57e-8	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CESC	cis	rs1552244	0.882	rs68080705	chr3:10025743	C/T	cg00149659	chr3:10157352	C3orf10	0.72	8.45	0.46	1.94e-15	Alzheimer's disease;
CESC	cis	rs4304924	0.500	rs9601109	chr13:79220114	A/G	cg01819759	chr13:79234251	RNF219	0.41	5.3	0.31	2.4e-7	Large artery stroke;
CESC	cis	rs896854	0.902	rs896852	chr8:95960886	G/T	cg16049864	chr8:95962084	TP53INP1	-0.72	-13.04	-0.63	2.36e-30	Type 2 diabetes;
CESC	cis	rs6461049	0.638	rs3778994	chr7:2175855	G/T	cg04267008	chr7:1944627	MAD1L1	-0.44	-5.23	-0.31	3.51e-7	Schizophrenia;
CESC	cis	rs34779708	0.736	rs34195979	chr10:35549817	T/C	cg04310649	chr10:35416472	CREM	-0.46	-5.22	-0.31	3.55e-7	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs10504229	0.773	rs1874374	chr8:58194422	A/G	cg22535103	chr8:58192502	C8orf71	-1.03	-10.96	-0.56	2.68e-23	Developmental language disorder (linguistic errors);
CESC	cis	rs2836974	0.897	rs13052882	chr21:40555351	G/C	cg11644478	chr21:40555479	PSMG1	1.06	17.9	0.74	1.63e-47	Cognitive function;
CESC	cis	rs1218582	0.596	rs11264275	chr1:154825270	G/T	cg24250549	chr1:154909240	PMVK	-0.47	-6.23	-0.36	1.82e-9	Prostate cancer;
CESC	trans	rs79349575	0.783	rs1994970	chr17:47014127	C/T	cg07977620	chr11:56380614	OR5M1;OR8U8	0.39	6.16	0.35	2.7e-9	Type 2 diabetes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13411962	chr8:28243934	ZNF395	0.59	7.2	0.4	6.07e-12	Gut microbiome composition (summer);
CESC	cis	rs9549367	0.713	rs3024761	chr13:113824090	C/G	cg18105134	chr13:113819100	PROZ	0.64	7.63	0.42	4.32e-13	Platelet distribution width;
CESC	trans	rs1814175	0.817	rs3974439	chr11:50022607	G/A	cg15704280	chr7:45808275	SEPT13	-1.05	-21.18	-0.79	6.15e-59	Height;
CESC	cis	rs17711722	0.727	rs781151	chr7:65479878	T/C	cg18876405	chr7:65276391	NA	0.73	10.35	0.54	2.61e-21	Calcium levels;
CESC	cis	rs7772486	0.658	rs6570706	chr6:145962922	T/C	cg05347473	chr6:146136440	FBXO30	0.52	6.83	0.39	5.76e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs722599	0.748	rs2537824	chr14:75367349	T/C	cg08847533	chr14:75593920	NEK9	-0.46	-5.53	-0.32	7.72e-8	IgG glycosylation;
CESC	cis	rs1568889	0.548	rs34906813	chr11:28508819	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.55	5.27	0.31	2.84e-7	Bipolar disorder;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg08944318	chr10:15139147	RPP38;C10orf111	-0.45	-6.47	-0.37	4.78e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs1218582	0.772	rs2102423	chr1:154916068	A/G	cg24250549	chr1:154909240	PMVK	0.72	10.38	0.54	2.12e-21	Prostate cancer;
CESC	cis	rs10504073	0.584	rs4873306	chr8:49950369	T/C	cg00325661	chr8:49890786	NA	0.56	8.53	0.46	1.16e-15	Blood metabolite ratios;
CESC	cis	rs78707713	0.560	rs61848436	chr10:71247714	C/T	cg08851181	chr10:71228077	TSPAN15	-0.4	-5.03	-0.3	8.9e-7	Venous thromboembolism;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg05990579	chr15:40531343	PAK6	-0.45	-6.27	-0.36	1.47e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs12042938	0.600	rs823163	chr1:231771108	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.41	5.54	0.32	7.41e-8	Neuranatomic and neurocognitive phenotypes;
CESC	trans	rs11098499	0.710	rs4145952	chr4:120155806	C/A	cg25214090	chr10:38739885	LOC399744	0.54	7.23	0.41	5.33e-12	Corneal astigmatism;
CESC	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg09177884	chr7:1199841	ZFAND2A	-0.68	-9.34	-0.5	4.23e-18	Longevity;Endometriosis;
CESC	cis	rs7084402	0.967	rs1658481	chr10:60289339	A/G	cg07615347	chr10:60278583	BICC1	0.61	9.69	0.51	3.29e-19	Refractive error;
CESC	trans	rs526821	0.595	rs504661	chr11:55312683	A/G	cg15704280	chr7:45808275	SEPT13	-0.52	-6.37	-0.36	8.32e-10	Pediatric bone mineral density (spine);
CESC	cis	rs55728055	0.661	rs62237857	chr22:32039311	G/A	cg01338084	chr22:32026380	PISD	1.29	8.72	0.47	3.17e-16	Age-related hearing impairment;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg24451981	chr15:40453319	BUB1B	-0.47	-6.52	-0.37	3.59e-10	Asthma;
CESC	cis	rs9325144	0.723	rs11169482	chr12:39164327	A/T	cg26384229	chr12:38710491	ALG10B	0.52	7.14	0.4	9.07e-12	Morning vs. evening chronotype;
CESC	cis	rs853679	0.517	rs9295758	chr6:28120663	C/G	cg18032046	chr6:28092343	ZSCAN16	-0.6	-6.82	-0.39	6.29e-11	Depression;
CESC	cis	rs3026101	0.671	rs75669379	chr17:5321355	G/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.43	5.59	0.32	5.61e-8	Body mass index;
CESC	cis	rs6570726	0.791	rs10457788	chr6:145921136	T/A	cg23711669	chr6:146136114	FBXO30	0.97	14.47	0.66	2.25e-35	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2919869	0.500	rs2970893	chr2:88415930	C/A	cg07952391	chr2:88470173	THNSL2	-0.38	-5.09	-0.3	6.92e-7	Night sleep phenotypes;
CESC	cis	rs861020	0.606	rs657844	chr1:210006873	T/G	cg05527609	chr1:210001259	C1orf107	0.73	9.55	0.51	8.98e-19	Orofacial clefts;
CESC	cis	rs861020	0.771	rs126280	chr1:210019824	A/G	cg05527609	chr1:210001259	C1orf107	1.01	13.9	0.65	2.24e-33	Orofacial clefts;
CESC	cis	rs17376456	0.877	rs10073039	chr5:93467709	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.6	5.11	0.3	6.27e-7	Diabetic retinopathy;
CESC	cis	rs9915657	0.870	rs720244	chr17:70131643	G/T	cg09344028	chr17:70110421	NA	0.35	6.25	0.36	1.59e-9	Thyroid hormone levels;
CESC	cis	rs853679	1.000	rs1679709	chr6:28228342	A/G	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	-0.78	-7.87	-0.44	9.03e-14	Depression;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg20930618	chr1:151162157	VPS72	-0.51	-6.98	-0.39	2.34e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs8072100	0.512	rs3809863	chr17:45385012	C/T	cg08085267	chr17:45401833	C17orf57	-0.54	-7.07	-0.4	1.37e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs35306767	0.714	rs12783621	chr10:1083304	C/T	cg26597838	chr10:835615	NA	0.51	5.4	0.31	1.47e-7	Eosinophil percentage of granulocytes;
CESC	cis	rs4481887	0.893	rs7528645	chr1:248427291	T/A	cg00666640	chr1:248458726	OR2T12	0.34	5.83	0.34	1.64e-8	Common traits (Other);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09194755	chr16:68298776	SLC7A6	-0.55	-6.2	-0.36	2.14e-9	Gut microbiome composition (summer);
CESC	cis	rs2303759	0.914	rs2288481	chr19:49878196	G/A	cg22307029	chr19:49891270	CCDC155	0.59	6.15	0.35	2.9e-9	Multiple sclerosis;
CESC	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.56	-6.25	-0.36	1.67e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs514406	0.861	rs4926576	chr1:53226775	C/T	cg08736216	chr1:53307985	ZYG11A	0.42	7.11	0.4	1.06e-11	Monocyte count;
CESC	cis	rs921968	0.541	rs485975	chr2:219374250	C/T	cg02176678	chr2:219576539	TTLL4	0.5	8.93	0.48	7.55e-17	Mean corpuscular hemoglobin concentration;
CESC	cis	rs1552244	1.000	rs2272125	chr3:10138069	A/C	cg16606324	chr3:10149918	C3orf24	0.42	5.17	0.3	4.58e-7	Alzheimer's disease;
CESC	cis	rs12458462	0.787	rs56006341	chr18:77439844	G/T	cg23301140	chr18:77439876	CTDP1	0.56	7.52	0.42	8.62e-13	Monocyte count;
CESC	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg26354017	chr1:205819088	PM20D1	0.5	7.23	0.41	5.3e-12	Menarche (age at onset);
CESC	cis	rs73058052	0.597	rs10406941	chr19:50091464	A/C	cg09250473	chr19:50168907	IRF3;BCL2L12	0.48	5.17	0.3	4.7e-7	Fibrinogen levels;
CESC	cis	rs4906332	0.811	rs2021965	chr14:103997248	C/A	cg04998671	chr14:104000505	TRMT61A	0.42	5.09	0.3	6.8e-7	Coronary artery disease;
CESC	cis	rs514406	0.798	rs575138	chr1:53328394	C/G	cg06600287	chr1:53387719	ECHDC2	-0.29	-5.06	-0.3	7.92e-7	Monocyte count;
CESC	cis	rs2816062	0.786	rs2745316	chr1:18896830	G/A	cg18795169	chr1:18902165	NA	-0.93	-18.37	-0.75	3.6e-49	Urate levels in lean individuals;
CESC	cis	rs2228479	0.717	rs2286392	chr16:89809549	A/G	cg14709524	chr16:89940631	TCF25	0.63	5.69	0.33	3.43e-8	Skin colour saturation;
CESC	cis	rs6089584	1.000	rs6089587	chr20:60564829	C/T	cg06108461	chr20:60628389	TAF4	-0.78	-11.36	-0.57	1.25e-24	Body mass index;
CESC	cis	rs763121	0.853	rs2294296	chr22:39053049	T/C	cg06544989	chr22:39130855	UNC84B	0.5	8.6	0.47	7.32e-16	Menopause (age at onset);
CESC	cis	rs9796	0.870	rs11854472	chr15:41357687	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.45	-6.83	-0.39	5.74e-11	Menopause (age at onset);
CESC	cis	rs6815814	0.950	rs11722788	chr4:38810738	C/G	cg02016764	chr4:38805732	TLR1	-0.62	-7.33	-0.41	2.77e-12	Breast cancer;
CESC	cis	rs4268898	0.760	rs11676939	chr2:24479057	C/T	cg06627628	chr2:24431161	ITSN2	0.57	7.28	0.41	3.85e-12	Asthma;
CESC	cis	rs2440129	0.611	rs1042356	chr17:6902743	G/A	cg21237687	chr17:6899380	ALOX12	0.5	8.49	0.46	1.51e-15	Tonsillectomy;
CESC	cis	rs9858542	0.953	rs71324979	chr3:49619651	T/C	cg03060546	chr3:49711283	APEH	-0.52	-6.04	-0.35	5.13e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	trans	rs10506458	1.000	rs12425655	chr12:63434463	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.24	-16.98	-0.72	3.02e-44	Hemostatic factors and hematological phenotypes;
CESC	trans	rs561341	0.843	rs879945	chr17:30242796	G/A	cg20587970	chr11:113659929	NA	-0.75	-9.69	-0.51	3.42e-19	Hip circumference adjusted for BMI;
CESC	cis	rs12701220	0.894	rs2141274	chr7:1034717	G/A	cg20821713	chr7:1055600	C7orf50	-0.49	-5.16	-0.3	4.9e-7	Bronchopulmonary dysplasia;
CESC	cis	rs12451471	0.620	rs11150846	chr17:78098520	C/T	cg06718696	chr17:78121285	EIF4A3	0.84	10.75	0.55	1.31e-22	Plateletcrit;Mean corpuscular hemoglobin concentration;
CESC	cis	rs8060686	0.516	rs1975802	chr16:68285847	A/G	cg26727032	chr16:67993705	SLC12A4	-0.61	-8.42	-0.46	2.36e-15	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.89	13.57	0.64	3.26e-32	Prudent dietary pattern;
CESC	trans	rs10463316	0.894	rs7708499	chr5:150765906	A/C	cg24389359	chr12:111284228	CCDC63	-0.34	-6.08	-0.35	4.19e-9	Metabolite levels (Pyroglutamine);
CESC	cis	rs853679	0.517	rs9348794	chr6:28117757	T/A	cg12963246	chr6:28129442	ZNF389	0.59	7.68	0.43	3e-13	Depression;
CESC	cis	rs7851660	0.874	rs7860144	chr9:100626884	A/G	cg13688889	chr9:100608707	NA	-0.63	-8.88	-0.48	1.05e-16	Strep throat;
CESC	cis	rs644799	1.000	rs487609	chr11:95588102	T/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.54	6.26	0.36	1.54e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs7000551	0.581	rs4872487	chr8:22256414	C/T	cg12081754	chr8:22256438	SLC39A14	0.92	13.27	0.63	3.79e-31	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg06557630	chr16:49889701	NA	-0.44	-6.25	-0.36	1.63e-9	Ulcerative colitis;
CESC	cis	rs9467711	0.606	rs28360517	chr6:26602453	A/G	cg21479132	chr6:26055353	NA	0.58	5.18	0.3	4.44e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs4561483	0.603	rs17235629	chr16:11932421	C/T	cg08843971	chr16:11963173	GSPT1	-0.45	-6.21	-0.36	2.07e-9	Testicular germ cell tumor;
CESC	cis	rs7618915	0.571	rs6805539	chr3:52609710	T/A	cg17372223	chr3:52568218	NT5DC2	0.43	6.4	0.37	7.18e-10	Bipolar disorder;
CESC	cis	rs35110281	0.715	rs2838353	chr21:45119228	C/T	cg04455712	chr21:45112962	RRP1B	0.51	7.96	0.44	5.17e-14	Mean corpuscular volume;
CESC	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.48	-5.04	-0.3	8.58e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs6570726	0.902	rs4895678	chr6:145935510	C/T	cg23711669	chr6:146136114	FBXO30	0.67	9.7	0.51	3.01e-19	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2228479	0.867	rs11645970	chr16:89958118	G/A	cg04013166	chr16:89971882	TCF25	0.78	7.19	0.4	6.56e-12	Skin colour saturation;
CESC	cis	rs7589728	0.514	rs74426843	chr2:88459388	C/T	cg18490616	chr2:88469792	THNSL2	0.55	5.25	0.31	3.06e-7	Plasma clusterin levels;
CESC	cis	rs12618769	0.597	rs72821930	chr2:99127525	C/T	cg10123293	chr2:99228465	UNC50	0.4	5.38	0.31	1.64e-7	Bipolar disorder;
CESC	cis	rs11711311	1.000	rs2305546	chr3:113503354	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.6	7.85	0.43	1e-13	IgG glycosylation;
CESC	cis	rs7589728	0.563	rs78685993	chr2:88447026	T/C	cg07952391	chr2:88470173	THNSL2	0.62	6.03	0.35	5.61e-9	Plasma clusterin levels;
CESC	cis	rs798554	0.797	rs798487	chr7:2802943	G/A	cg19717773	chr7:2847554	GNA12	-0.57	-8.09	-0.44	2.2e-14	Height;
CESC	trans	rs3942852	0.568	rs10769314	chr11:48097620	C/T	cg15704280	chr7:45808275	SEPT13	-0.72	-9.39	-0.5	2.86e-18	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs7020830	0.825	rs13297152	chr9:37075623	C/T	cg14294708	chr9:37120828	ZCCHC7	1.25	22.61	0.81	8.68e-64	Schizophrenia;
CESC	cis	rs763121	0.853	rs11704021	chr22:39074716	G/A	cg14440974	chr22:39074834	NA	-0.42	-5.83	-0.34	1.62e-8	Menopause (age at onset);
CESC	cis	rs3733585	0.699	rs4276278	chr4:9948870	T/C	cg02734326	chr4:10020555	SLC2A9	-0.41	-5.76	-0.33	2.38e-8	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs9910055	0.762	rs4239142	chr17:42205876	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.61	-7.87	-0.44	8.79e-14	Total body bone mineral density;
CESC	cis	rs3749237	0.595	rs4855861	chr3:49525962	G/T	cg02487422	chr3:49467188	NICN1	0.56	8.19	0.45	1.09e-14	Resting heart rate;
CESC	cis	rs599083	0.530	rs2472415	chr11:68185616	T/C	cg01657329	chr11:68192670	LRP5	0.44	5.21	0.3	3.85e-7	Bone mineral density (spine);
CESC	cis	rs11828289	0.660	rs79043125	chr11:23203646	T/A	cg20040320	chr11:23191996	NA	-0.71	-6.12	-0.35	3.31e-9	Cancer;
CESC	cis	rs7044106	0.791	rs4837792	chr9:123483559	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.82	13.01	0.62	3.06e-30	Hip circumference adjusted for BMI;
CESC	cis	rs4588572	0.643	rs1019803	chr5:77739154	A/G	cg11547950	chr5:77652471	NA	-0.46	-5.73	-0.33	2.78e-8	Triglycerides;
CESC	cis	rs7618501	0.602	rs2240326	chr3:50128386	G/A	cg24308560	chr3:49941425	MST1R	0.6	8.61	0.47	6.54e-16	Intelligence (multi-trait analysis);
CESC	cis	rs853679	0.517	rs3757187	chr6:28107654	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.55	-6.44	-0.37	5.7e-10	Depression;
CESC	cis	rs35110281	0.633	rs4819289	chr21:45120237	A/G	cg01579765	chr21:45077557	HSF2BP	-0.5	-8.22	-0.45	9.39e-15	Mean corpuscular volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17325912	chr2:97520089	ANKRD39	-0.55	-6.31	-0.36	1.2e-9	Gut microbiome composition (summer);
CESC	cis	rs9902453	1.000	rs62070270	chr17:28263980	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.65	8.4	0.46	2.73e-15	Coffee consumption (cups per day);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13700589	chr9:15511220	PSIP1	0.63	6.95	0.39	2.9e-11	Gut microbiome composition (summer);
CESC	cis	rs1577917	0.798	rs7772384	chr6:86639680	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-5.94	-0.34	8.86e-9	Response to antipsychotic treatment;
CESC	cis	rs2243480	1.000	rs4145008	chr7:65647511	T/G	cg18252515	chr7:66147081	NA	1.36	13.62	0.64	2.24e-32	Diabetic kidney disease;
CESC	cis	rs899997	0.862	rs57260218	chr15:78973772	C/T	cg04896959	chr15:78267971	NA	-0.41	-5.78	-0.33	2.12e-8	Coronary artery disease or large artery stroke;
CESC	trans	rs853679	0.769	rs17720293	chr6:28214698	C/T	cg06606381	chr12:133084897	FBRSL1	-0.83	-7.58	-0.42	5.68e-13	Depression;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25327839	chr11:73308997	FAM168A	0.56	6.0	0.35	6.56e-9	Gut microbiome composition (summer);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg19905630	chr1:149721664	NA	0.39	6.47	0.37	4.68e-10	Gambling;
CESC	cis	rs2749592	0.550	rs10764135	chr10:37866845	C/T	cg00409905	chr10:38381863	ZNF37A	0.43	5.71	0.33	2.99e-8	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs863345	0.967	rs11265000	chr1:158488899	A/C	cg12129480	chr1:158549410	OR10X1	-0.3	-5.7	-0.33	3.24e-8	Pneumococcal bacteremia;
CESC	cis	rs7666738	0.822	rs13110418	chr4:99046963	G/A	cg17366294	chr4:99064904	C4orf37	0.61	8.78	0.47	2.13e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6089829	0.962	rs4809455	chr20:61660781	G/C	cg03213289	chr20:61660250	NA	0.39	6.06	0.35	4.64e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs4700695	0.719	rs27046	chr5:65439964	G/C	cg21114390	chr5:65439923	SFRS12	-0.55	-6.65	-0.38	1.71e-10	Facial morphology (factor 19);
CESC	cis	rs1538970	0.924	rs4660851	chr1:45843810	A/T	cg06784218	chr1:46089804	CCDC17	0.32	5.55	0.32	7.01e-8	Platelet count;
CESC	cis	rs7771547	0.573	rs584418	chr6:36395437	G/A	cg04289385	chr6:36355825	ETV7	0.38	5.57	0.32	6.41e-8	Platelet distribution width;
CESC	cis	rs6860806	0.661	rs6871350	chr5:131580220	A/G	cg18758796	chr5:131593413	PDLIM4	0.45	6.52	0.37	3.58e-10	Breast cancer;
CESC	cis	rs561341	0.883	rs4795661	chr17:30201774	T/A	cg13647721	chr17:30228624	UTP6	-0.62	-5.84	-0.34	1.5e-8	Hip circumference adjusted for BMI;
CESC	cis	rs1670533	1.000	rs10902752	chr4:1056199	C/T	cg04106633	chr4:1044584	NA	0.41	5.19	0.3	4.11e-7	Recombination rate (females);
CESC	cis	rs36051895	0.589	rs6476946	chr9:5195275	C/G	cg02405213	chr9:5042618	JAK2	0.52	5.95	0.34	8.62e-9	Pediatric autoimmune diseases;
CESC	cis	rs7666738	0.830	rs3907020	chr4:99038583	T/C	cg17366294	chr4:99064904	C4orf37	0.6	8.51	0.46	1.33e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7666738	0.830	rs13110903	chr4:98946373	A/G	cg05340658	chr4:99064831	C4orf37	0.82	12.66	0.61	4.8e-29	Colonoscopy-negative controls vs population controls;
CESC	cis	rs735396	1.000	rs2259852	chr12:121434833	G/A	cg25281562	chr12:121454272	C12orf43	0.39	5.12	0.3	5.93e-7	N-glycan levels;
CESC	cis	rs597539	0.690	rs608810	chr11:68624118	G/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.8	9.55	0.51	9.28e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs6580649	0.941	rs3742074	chr12:48457385	C/T	cg24011408	chr12:48396354	COL2A1	-0.42	-5.28	-0.31	2.67e-7	Lung cancer;
CESC	cis	rs5753618	0.561	rs5749265	chr22:31796897	A/C	cg02404636	chr22:31891804	SFI1	0.39	5.37	0.31	1.71e-7	Colorectal cancer;
CESC	cis	rs5769765	0.862	rs9616385	chr22:50313124	C/T	cg02269571	chr22:50332266	NA	-0.56	-6.99	-0.39	2.26e-11	Schizophrenia;
CESC	cis	rs8063761	0.589	rs4238833	chr16:90050689	G/T	cg08547343	chr16:90038815	CENPBD1;AFG3L1	0.67	9.91	0.52	6.76e-20	Squamous cell carcinoma;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19110795	chr3:196159589	UBXN7	0.58	6.51	0.37	3.76e-10	Gut microbiome composition (summer);
CESC	cis	rs11809207	0.574	rs2783630	chr1:26504741	G/A	cg00147160	chr1:26503991	CNKSR1	0.29	5.44	0.32	1.21e-7	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18278596	chr14:105915860	MTA1	-0.68	-8.03	-0.44	3.16e-14	Gut microbiome composition (summer);
CESC	cis	rs7089973	0.604	rs765173	chr10:116601675	C/T	cg23260525	chr10:116636907	FAM160B1	0.41	7.9	0.44	7.32e-14	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs801193	1.000	rs2707854	chr7:66212597	G/A	cg18876405	chr7:65276391	NA	0.54	7.28	0.41	3.88e-12	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11266582	chr15:64275853	DAPK2	-0.58	-6.33	-0.36	1.02e-9	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.830	rs34212748	chr4:99068708	G/A	cg03467027	chr4:99064603	C4orf37	0.48	5.96	0.34	7.81e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2836974	0.627	rs9981301	chr21:40686078	G/C	cg22974920	chr21:40686053	BRWD1	-0.45	-5.61	-0.33	4.99e-8	Cognitive function;
CESC	trans	rs3942852	0.915	rs905477	chr11:48148606	T/C	cg03929089	chr4:120376271	NA	-0.6	-6.41	-0.37	6.75e-10	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs8180040	0.902	rs73081205	chr3:47517670	A/C	cg27129171	chr3:47204927	SETD2	-0.63	-9.49	-0.5	1.38e-18	Colorectal cancer;
CESC	cis	rs2576037	0.583	rs512699	chr18:44374681	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.76	-12.85	-0.62	1.07e-29	Personality dimensions;
CESC	cis	rs2243480	1.000	rs387676	chr7:65598220	C/T	cg12463550	chr7:65579703	CRCP	0.73	5.68	0.33	3.5e-8	Diabetic kidney disease;
CESC	cis	rs4563143	0.675	rs73029050	chr19:29276554	G/T	cg04546413	chr19:29218101	NA	0.55	7.53	0.42	8.13e-13	Methadone dose in opioid dependence;
CESC	cis	rs3733585	0.699	rs28613263	chr4:9964880	C/T	cg00071950	chr4:10020882	SLC2A9	-0.73	-11.79	-0.59	4.58e-26	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs9308433	0.553	rs9308435	chr1:214500166	C/T	cg06198575	chr1:214491504	SMYD2	0.51	6.1	0.35	3.72e-9	IgG glycosylation;
CESC	cis	rs12479064	0.724	rs62153852	chr2:99934713	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.65	-7.7	-0.43	2.65e-13	Chronic sinus infection;
CESC	cis	rs35362007	0.530	rs11621250	chr14:96011442	C/T	cg13511115	chr14:96000878	GLRX5;SNHG10;SCARNA13	0.66	5.36	0.31	1.81e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	cis	rs910316	1.000	rs8017642	chr14:75590822	G/A	cg11812906	chr14:75593930	NEK9	0.89	15.29	0.68	2.88e-38	Height;
CESC	cis	rs4253772	0.591	rs7286155	chr22:46714735	A/G	cg09491104	chr22:46646882	C22orf40	-0.49	-5.84	-0.34	1.53e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs6693567	0.507	rs828784	chr1:150335240	T/A	cg09579323	chr1:150459698	TARS2	0.48	6.09	0.35	3.89e-9	Migraine;
CESC	cis	rs67311347	0.544	rs9864601	chr3:40345318	C/T	cg09455208	chr3:40491958	NA	0.37	6.51	0.37	3.77e-10	Renal cell carcinoma;
CESC	cis	rs1862618	1.000	rs1862618	chr5:56096315	C/G	cg20203395	chr5:56204925	C5orf35	-0.44	-5.29	-0.31	2.57e-7	Initial pursuit acceleration;
CESC	cis	rs1348850	0.632	rs10167783	chr2:178519041	G/A	cg23306229	chr2:178417860	TTC30B	0.57	6.86	0.39	4.86e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs1559088	0.847	rs2287679	chr19:33600764	T/C	cg27124370	chr19:33622961	WDR88	0.45	5.86	0.34	1.34e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs13191362	0.507	rs2510207	chr6:163086592	T/C	cg21926612	chr6:163149169	PACRG;PARK2	-0.68	-8.08	-0.44	2.28e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs6963495	0.818	rs818621	chr7:105173029	T/C	cg13798780	chr7:105162888	PUS7	0.62	7.06	0.4	1.45e-11	Bipolar disorder (body mass index interaction);
CESC	cis	rs4974559	0.739	rs35571200	chr4:1268129	G/A	cg02980000	chr4:1222292	CTBP1	-0.71	-7.15	-0.4	8.42e-12	Systolic blood pressure;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg10440939	chr17:27493798	MYO18A	0.49	6.68	0.38	1.43e-10	Fibrinogen levels;
CESC	cis	rs7786877	0.680	rs28584500	chr7:100216341	G/A	cg27028030	chr7:100209634	MOSPD3	0.57	5.59	0.32	5.72e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs5769765	1.000	rs2295408	chr22:50261051	A/G	cg02269571	chr22:50332266	NA	0.46	6.2	0.36	2.13e-9	Schizophrenia;
CESC	cis	rs7923609	0.936	rs10761779	chr10:65274927	A/G	cg01631684	chr10:65280961	REEP3	-0.44	-5.45	-0.32	1.14e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs916888	0.687	rs199456	chr17:44797919	C/T	cg27589368	chr17:43923255	LOC100128977;IMP5	-0.39	-5.24	-0.31	3.31e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs910316	0.503	rs12894709	chr14:75441734	G/A	cg11812906	chr14:75593930	NEK9	0.64	9.37	0.5	3.41e-18	Height;
CESC	cis	rs9733	0.596	rs12063547	chr1:150674053	G/T	cg09365446	chr1:150670422	GOLPH3L	-0.42	-5.84	-0.34	1.55e-8	Tonsillectomy;
CESC	cis	rs6541297	0.645	rs2103827	chr1:230298285	T/A	cg20703242	chr1:230279135	GALNT2	0.57	6.49	0.37	4.14e-10	Coronary artery disease;
CESC	cis	rs7666738	0.962	rs4699596	chr4:99012924	C/T	cg03676636	chr4:99064102	C4orf37	0.35	5.3	0.31	2.45e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11086275	chr1:180991441	STX6	0.58	6.61	0.38	2.15e-10	Gut microbiome composition (summer);
CESC	cis	rs4665809	0.652	rs12611790	chr2:26404221	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-1.08	-12.62	-0.61	6.57e-29	Gut microbiome composition (summer);
CESC	cis	rs3767633	0.764	rs4233381	chr1:161910720	T/C	cg09175582	chr1:161736000	ATF6	0.85	5.41	0.32	1.38e-7	IgG glycosylation;
CESC	cis	rs7937682	0.855	rs7109592	chr11:111533105	C/A	cg22437258	chr11:111473054	SIK2	0.68	9.21	0.49	1e-17	Primary sclerosing cholangitis;
CESC	cis	rs782590	0.967	rs782586	chr2:55836165	A/C	cg18811423	chr2:55921094	PNPT1	0.8	13.14	0.63	1.09e-30	Metabolic syndrome;
CESC	cis	rs4919687	0.550	rs7904252	chr10:104456725	A/C	cg04362960	chr10:104952993	NT5C2	-0.43	-5.12	-0.3	5.94e-7	Colorectal cancer;
CESC	cis	rs875971	1.000	rs7801282	chr7:65613687	C/T	cg18876405	chr7:65276391	NA	-0.51	-6.96	-0.39	2.72e-11	Aortic root size;
CESC	cis	rs113835537	0.866	rs59320108	chr11:66365996	A/T	cg22134325	chr11:66188745	NPAS4	0.5	5.7	0.33	3.24e-8	Airway imaging phenotypes;
CESC	cis	rs4253772	0.550	rs738444	chr22:46721088	C/T	cg09491104	chr22:46646882	C22orf40	-0.59	-8.67	-0.47	4.32e-16	LDL cholesterol;Cholesterol, total;
CESC	trans	rs55704346	0.566	rs6848308	chr4:25394401	C/G	cg01822600	chr1:245751692	KIF26B	0.42	6.17	0.35	2.58e-9	Tonsillectomy;
CESC	cis	rs9399135	0.967	rs4895436	chr6:135295001	G/A	cg22676075	chr6:135203613	NA	0.52	7.21	0.4	5.94e-12	Red blood cell count;
CESC	cis	rs9308433	0.643	rs4655330	chr1:214466068	A/G	cg06198575	chr1:214491504	SMYD2	-0.43	-5.14	-0.3	5.29e-7	IgG glycosylation;
CESC	cis	rs4699052	0.662	rs1996346	chr4:104250324	C/T	cg16532752	chr4:104119610	CENPE	-0.4	-5.65	-0.33	4.24e-8	Testicular germ cell tumor;
CESC	cis	rs7829975	0.777	rs486781	chr8:8639740	A/G	cg15556689	chr8:8085844	FLJ10661	-0.42	-5.23	-0.31	3.37e-7	Mood instability;
CESC	cis	rs12477438	0.501	rs6753063	chr2:99801469	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.86	15.21	0.68	5.36e-38	Chronic sinus infection;
CESC	cis	rs3820068	0.581	rs16851841	chr1:15922713	A/G	cg16988262	chr1:15930761	NA	0.35	5.69	0.33	3.38e-8	Systolic blood pressure;
CESC	cis	rs4713118	0.513	rs149951	chr6:28033087	T/C	cg19592336	chr6:28129416	ZNF389	0.44	6.39	0.37	7.51e-10	Parkinson's disease;
CESC	cis	rs2197308	0.765	rs11182434	chr12:37923968	C/A	cg26384229	chr12:38710491	ALG10B	0.75	11.12	0.56	8.21e-24	Morning vs. evening chronotype;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22079616	chr13:21141624	IFT88	0.52	6.17	0.35	2.57e-9	Gut microbiome composition (summer);
CESC	cis	rs11997175	0.546	rs4733448	chr8:33628575	G/A	ch.8.33884649F	chr8:33765107	NA	0.56	7.26	0.41	4.36e-12	Body mass index;
CESC	cis	rs2842992	0.692	rs1128661	chr6:160211554	T/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.85	12.01	0.59	8.38e-27	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs9287719	0.935	rs728283	chr2:10750090	C/T	cg02196655	chr2:10830764	NOL10	-0.38	-5.79	-0.34	1.96e-8	Prostate cancer;
CESC	cis	rs501120	1.000	rs607363	chr10:44761623	A/G	cg09554077	chr10:44749378	NA	0.52	6.89	0.39	4.1e-11	Coronary artery disease;Coronary heart disease;
CESC	cis	rs561341	1.000	rs8077092	chr17:30281992	T/C	cg12193833	chr17:30244370	NA	-0.6	-6.06	-0.35	4.7e-9	Hip circumference adjusted for BMI;
CESC	cis	rs4665809	1.000	rs2053367	chr2:26293413	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.66	-7.43	-0.42	1.51e-12	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.830	rs3846445	chr4:99032939	T/A	cg05340658	chr4:99064831	C4orf37	0.83	13.1	0.63	1.43e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9916302	0.800	rs8081220	chr17:37473157	A/C	cg07936489	chr17:37558343	FBXL20	0.73	9.81	0.52	1.43e-19	Glomerular filtration rate (creatinine);
CESC	cis	rs6429082	0.967	rs834143	chr1:235626406	C/T	cg26050004	chr1:235667680	B3GALNT2	0.47	6.35	0.36	9.23e-10	Adiposity;
CESC	cis	rs35110281	0.837	rs2838342	chr21:45077865	G/A	cg21573476	chr21:45109991	RRP1B	-0.48	-6.8	-0.39	7.09e-11	Mean corpuscular volume;
CESC	cis	rs28374715	0.681	rs7163989	chr15:41614621	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.77	-11.04	-0.56	1.41e-23	Ulcerative colitis;
CESC	cis	rs12479064	0.671	rs4851207	chr2:100105775	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.6	-6.99	-0.39	2.28e-11	Chronic sinus infection;
CESC	cis	rs13126513	0.510	rs10516445	chr4:100524679	C/G	cg05468953	chr4:100565104	NA	0.34	5.38	0.31	1.63e-7	Metabolite levels (MHPG);
CESC	cis	rs1218582	0.772	rs4845688	chr1:154884142	T/C	cg09359103	chr1:154839909	KCNN3	-0.65	-12.25	-0.6	1.22e-27	Prostate cancer;
CESC	cis	rs4665809	1.000	rs4665305	chr2:26313524	C/T	cg04944784	chr2:26401820	FAM59B	-0.65	-7.24	-0.41	4.83e-12	Gut microbiome composition (summer);
CESC	cis	rs7917772	0.503	rs7893155	chr10:104294228	C/A	ch.10.2196322F	chr10:104248062	ACTR1A	0.42	5.17	0.3	4.66e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs727505	1.000	rs67552763	chr7:124517857	A/G	cg23710748	chr7:124431027	NA	-0.48	-7.52	-0.42	8.73e-13	Lewy body disease;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg07184411	chr3:122400006	PARP14	-0.51	-6.93	-0.39	3.25e-11	Asthma;
CESC	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg23978390	chr7:1156363	C7orf50	0.61	8.86	0.48	1.15e-16	Longevity;Endometriosis;
CESC	trans	rs1994135	0.669	rs2121831	chr12:33697674	G/A	cg26384229	chr12:38710491	ALG10B	0.48	6.6	0.38	2.22e-10	Resting heart rate;
CESC	cis	rs7772486	0.686	rs1045820	chr6:145947080	C/T	cg05347473	chr6:146136440	FBXO30	0.53	6.94	0.39	3.1e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1355223	0.506	rs7131272	chr11:34869548	A/G	cg11622362	chr11:34938112	PDHX;APIP	-0.48	-5.77	-0.33	2.22e-8	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs10791097	0.694	rs4936123	chr11:130740967	G/A	cg12179176	chr11:130786555	SNX19	0.71	11.75	0.59	6.16e-26	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	trans	rs997295	0.592	rs7162320	chr15:67766038	C/G	cg05081167	chr6:156967138	NA	0.28	6.08	0.35	4.1e-9	Motion sickness;
CESC	cis	rs10504229	0.683	rs35244711	chr8:58117762	T/G	cg02725872	chr8:58115012	NA	-0.45	-7.05	-0.4	1.52e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs8031584	0.958	rs34294266	chr15:31246840	A/G	cg08109568	chr15:31115862	NA	-0.71	-9.4	-0.5	2.77e-18	Huntington's disease progression;
CESC	cis	rs6570726	0.905	rs396492	chr6:145816180	C/G	cg23711669	chr6:146136114	FBXO30	0.77	11.31	0.57	1.91e-24	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9549367	0.789	rs12584981	chr13:113881185	T/C	cg00898013	chr13:113819073	PROZ	-0.49	-6.78	-0.38	7.6e-11	Platelet distribution width;
CESC	cis	rs977987	0.735	rs11149831	chr16:75451461	G/A	cg03315344	chr16:75512273	CHST6	0.41	5.65	0.33	4.22e-8	Dupuytren's disease;
CESC	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg03188948	chr7:1209495	NA	0.51	6.62	0.38	1.95e-10	Longevity;Endometriosis;
CESC	cis	rs9486719	0.843	rs2499792	chr6:96846264	A/C	cg18709589	chr6:96969512	KIAA0776	0.55	5.64	0.33	4.26e-8	Migraine;Coronary artery disease;
CESC	cis	rs2303745	0.589	rs7246262	chr19:17392483	C/G	cg22549504	chr19:17448937	GTPBP3	0.49	5.51	0.32	8.32e-8	Systemic lupus erythematosus;
CESC	cis	rs752092	1.000	rs7182945	chr15:101784223	C/T	cg19997662	chr15:101784653	CHSY1	-0.56	-7.69	-0.43	2.86e-13	Corneal structure;
CESC	cis	rs4665809	0.878	rs4665826	chr2:26367503	A/T	cg26119090	chr2:26468346	HADHA;HADHB	0.86	9.62	0.51	5.43e-19	Gut microbiome composition (summer);
CESC	cis	rs2859741	0.528	rs3753776	chr1:37480144	C/T	cg09363841	chr1:37513479	NA	-0.49	-7.03	-0.4	1.8e-11	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
CESC	cis	rs2933343	0.729	rs1683816	chr3:128651195	G/T	cg24203234	chr3:128598194	ACAD9	-0.44	-5.81	-0.34	1.83e-8	IgG glycosylation;
CESC	cis	rs858239	0.537	rs6955115	chr7:23227144	A/G	cg23682824	chr7:23144976	KLHL7	0.45	5.85	0.34	1.46e-8	Cerebrospinal fluid biomarker levels;
CESC	cis	rs1707322	0.721	rs28817701	chr1:46186050	C/T	cg06784218	chr1:46089804	CCDC17	0.43	7.58	0.42	5.65e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7959452	0.640	rs10878957	chr12:69699638	G/C	cg14784868	chr12:69753453	YEATS4	0.73	10.44	0.54	1.35e-21	Blood protein levels;
CESC	cis	rs9911578	0.935	rs2567912	chr17:56731270	T/C	cg05425664	chr17:57184151	TRIM37	-0.51	-7.14	-0.4	8.78e-12	Intelligence (multi-trait analysis);
CESC	cis	rs116095464	0.558	rs7708182	chr5:234788	C/G	cg10591111	chr5:226296	SDHA	-0.51	-6.29	-0.36	1.32e-9	Breast cancer;
CESC	trans	rs2749592	0.550	rs4934881	chr10:37914346	A/C	cg12057190	chr19:54976211	LENG9;CDC42EP5	-0.43	-6.15	-0.35	2.91e-9	Age-related hearing impairment (SNP x SNP interaction);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg05564938	chr15:59280649	RNF111	-0.5	-6.07	-0.35	4.41e-9	Ulcerative colitis;
CESC	cis	rs2440129	0.611	rs1126667	chr17:6902760	C/T	cg19536664	chr17:6899085	ALOX12	-0.38	-8.42	-0.46	2.32e-15	Tonsillectomy;
CESC	cis	rs7580658	0.926	rs4662725	chr2:128141320	G/A	cg10021288	chr2:128175891	PROC	-0.41	-6.47	-0.37	4.66e-10	Protein C levels;
CESC	cis	rs1348850	0.914	rs10170546	chr2:178248790	C/T	cg22681709	chr2:178499509	PDE11A	-0.43	-6.29	-0.36	1.33e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs939574	1.000	rs9989854	chr2:220086280	C/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-0.62	-6.0	-0.35	6.35e-9	Platelet distribution width;
CESC	cis	rs763014	0.966	rs4984904	chr16:680809	C/G	cg09263875	chr16:632152	PIGQ	0.68	11.78	0.59	4.9e-26	Height;
CESC	cis	rs6540559	1.000	rs2235373	chr1:209963803	G/A	cg12034118	chr1:209979487	IRF6	0.47	5.78	0.33	2.04e-8	Cleft lip with or without cleft palate;
CESC	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.48	-5.08	-0.3	7.1e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs10256972	0.616	rs6463001	chr7:1108272	A/C	cg16145915	chr7:1198662	ZFAND2A	-0.45	-6.41	-0.37	6.53e-10	Longevity;Endometriosis;
CESC	cis	rs1580019	0.520	rs13228793	chr7:32711465	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.94	11.52	0.58	3.69e-25	Cognitive ability;
CESC	cis	rs9488822	0.702	rs12196154	chr6:116327471	T/G	cg18764771	chr6:116381957	FRK	0.22	5.42	0.32	1.35e-7	Cholesterol, total;LDL cholesterol;
CESC	trans	rs875971	0.964	rs12668936	chr7:65914404	C/T	cg26939375	chr7:64535504	NA	0.46	6.0	0.35	6.4e-9	Aortic root size;
CESC	cis	rs1728785	1.000	rs698728	chr16:68625253	T/C	cg02972257	chr16:68554789	NA	-0.64	-7.22	-0.41	5.58e-12	Ulcerative colitis;
CESC	cis	rs35306767	0.903	rs12761424	chr10:967295	C/T	cg26597838	chr10:835615	NA	0.78	9.19	0.49	1.21e-17	Eosinophil percentage of granulocytes;
CESC	trans	rs9325144	0.555	rs1813392	chr12:38692203	C/T	cg23762105	chr12:34175262	ALG10	0.5	6.7	0.38	1.28e-10	Morning vs. evening chronotype;
CESC	cis	rs12477438	0.765	rs2167930	chr2:99592551	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-10.51	-0.54	7.92e-22	Chronic sinus infection;
CESC	cis	rs12893668	0.703	rs4906337	chr14:104040414	C/A	cg24130564	chr14:104152367	KLC1	-0.47	-5.73	-0.33	2.71e-8	Reticulocyte count;
CESC	cis	rs1355223	0.902	rs4465347	chr11:34727333	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.48	-6.24	-0.36	1.68e-9	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs1881797	1.000	rs66845073	chr1:247688010	C/T	cg21399703	chr1:247681439	NA	0.55	7.37	0.41	2.13e-12	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs9733	0.570	rs951281	chr1:150691122	A/C	cg17724175	chr1:150552817	MCL1	0.45	7.31	0.41	3.23e-12	Tonsillectomy;
CESC	cis	rs1448094	0.512	rs12314274	chr12:86249196	A/G	cg02569458	chr12:86230093	RASSF9	0.47	6.96	0.39	2.7e-11	Major depressive disorder;
CESC	cis	rs3820068	0.705	rs4645983	chr1:15850603	G/A	cg17385448	chr1:15911702	AGMAT	0.36	5.75	0.33	2.43e-8	Systolic blood pressure;
CESC	cis	rs28647808	0.881	rs3739894	chr9:136270871	C/T	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.9	5.73	0.33	2.75e-8	Blood protein levels;
CESC	trans	rs8073060	0.559	rs10438814	chr17:34007065	A/G	cg19694781	chr19:47549865	TMEM160	-0.71	-6.74	-0.38	9.95e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	cis	rs9325144	0.560	rs1825802	chr12:38650341	C/T	cg13010199	chr12:38710504	ALG10B	-0.45	-6.1	-0.35	3.79e-9	Morning vs. evening chronotype;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg17298884	chr22:42343226	CENPM	-0.44	-6.15	-0.35	2.87e-9	Fibrinogen levels;
CESC	cis	rs7208859	0.623	rs8068645	chr17:29104342	T/A	cg19761014	chr17:28927070	LRRC37B2	0.75	6.17	0.35	2.49e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs367943	0.712	rs1850407	chr5:112721569	C/A	cg12552261	chr5:112820674	MCC	0.39	5.22	0.31	3.62e-7	Type 2 diabetes;
CESC	cis	rs12220238	1.000	rs7904207	chr10:75884474	A/T	cg19889307	chr10:75911429	ADK;AP3M1	0.64	6.34	0.36	9.58e-10	Soluble interleukin-2 receptor subunit alpha;
CESC	cis	rs1801251	0.752	rs709938	chr2:233746457	C/T	cg08000102	chr2:233561755	GIGYF2	-0.58	-7.87	-0.44	9.23e-14	Coronary artery disease;
CESC	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg24829409	chr8:58192753	C8orf71	-0.66	-7.93	-0.44	6.14e-14	Developmental language disorder (linguistic errors);
CESC	cis	rs7618915	0.501	rs9917834	chr3:52634619	A/C	cg18099408	chr3:52552593	STAB1	-0.3	-5.11	-0.3	6.18e-7	Bipolar disorder;
CESC	cis	rs2243480	1.000	rs1167613	chr7:65487439	C/T	cg18252515	chr7:66147081	NA	-1.13	-10.9	-0.56	4.18e-23	Diabetic kidney disease;
CESC	cis	rs11650494	0.901	rs117087923	chr17:47364913	G/A	cg08112188	chr17:47440006	ZNF652	1.3	8.47	0.46	1.73e-15	Prostate cancer;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg23676784	chr1:22968681	C1QC	-0.4	-6.03	-0.35	5.39e-9	Gambling;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg24947615	chr21:44515479	U2AF1	0.57	7.5	0.42	9.85e-13	Fibrinogen levels;
CESC	cis	rs15676	0.783	rs11515530	chr9:131576367	C/T	cg00228799	chr9:131580591	ENDOG	-0.54	-6.81	-0.39	6.66e-11	Blood metabolite levels;
CESC	trans	rs61931739	0.517	rs4931771	chr12:34044557	G/A	cg26384229	chr12:38710491	ALG10B	0.6	8.36	0.46	3.68e-15	Morning vs. evening chronotype;
CESC	cis	rs1008375	1.000	rs6811887	chr4:17640858	C/T	cg02297831	chr4:17616191	MED28	0.57	7.34	0.41	2.67e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	trans	rs2997105	0.938	rs9597256	chr13:56331434	G/A	cg11410726	chr11:69625409	FGF3	0.46	6.08	0.35	4.15e-9	Response to platinum-based chemotherapy (cisplatin);
CESC	cis	rs12477438	0.798	rs4850894	chr2:99629396	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-10.57	-0.54	5.22e-22	Chronic sinus infection;
CESC	cis	rs9287719	0.967	rs4519489	chr2:10739087	A/T	cg02196655	chr2:10830764	NOL10	-0.37	-5.72	-0.33	2.87e-8	Prostate cancer;
CESC	cis	rs12477438	0.520	rs11883676	chr2:99800814	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.84	15.36	0.69	1.63e-38	Chronic sinus infection;
CESC	cis	rs35849525	0.633	rs62263602	chr3:50152491	C/T	cg24110177	chr3:50126178	RBM5	-0.45	-5.06	-0.3	7.67e-7	Intelligence (multi-trait analysis);
CESC	cis	rs2797160	1.000	rs1777194	chr6:126004883	G/A	cg05901451	chr6:126070800	HEY2	-0.45	-6.54	-0.37	3.11e-10	Endometrial cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03242101	chr16:67143792	C16orf70	0.54	6.37	0.36	8.4e-10	Gut microbiome composition (summer);
CESC	cis	rs1218582	0.772	rs6683557	chr1:154852307	C/G	cg24250549	chr1:154909240	PMVK	0.74	11.16	0.57	5.75e-24	Prostate cancer;
CESC	cis	rs2228479	0.850	rs11649510	chr16:89851004	A/G	cg14709524	chr16:89940631	TCF25	0.94	7.05	0.4	1.57e-11	Skin colour saturation;
CESC	cis	rs7829975	0.624	rs7823056	chr8:8382705	A/G	cg06636001	chr8:8085503	FLJ10661	0.54	6.44	0.37	5.46e-10	Mood instability;
CESC	cis	rs56104184	0.775	rs56146968	chr19:49398847	A/G	cg15549821	chr19:49342101	PLEKHA4	-0.6	-5.99	-0.35	6.83e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	cis	rs4332037	0.950	rs7807014	chr7:1939021	T/C	cg23422044	chr7:1970798	MAD1L1	-0.53	-5.33	-0.31	2.09e-7	Bipolar disorder;
CESC	cis	rs9616064	0.531	rs17821649	chr22:47050387	G/A	cg05621596	chr22:47072043	GRAMD4	-0.68	-9.8	-0.52	1.45e-19	Urate levels in obese individuals;
CESC	cis	rs7210086	0.821	rs3935123	chr17:70641183	C/T	cg04206342	chr17:70636940	NA	0.28	5.42	0.32	1.32e-7	Ulcerative colitis;
CESC	cis	rs763014	0.966	rs4984677	chr16:671682	A/G	cg00908189	chr16:619842	PIGQ	0.63	8.69	0.47	3.72e-16	Height;
CESC	cis	rs1395	0.778	rs17005956	chr2:27451099	C/T	cg22903471	chr2:27725779	GCKR	-0.42	-5.17	-0.3	4.56e-7	Blood metabolite levels;
CESC	cis	rs9300255	0.602	rs1727313	chr12:123640853	C/G	cg00376283	chr12:123451042	ABCB9	0.63	6.81	0.39	6.57e-11	Neutrophil percentage of white cells;
CESC	cis	rs7618915	0.533	rs35107891	chr3:52613656	G/C	cg18099408	chr3:52552593	STAB1	-0.33	-5.47	-0.32	1.02e-7	Bipolar disorder;
CESC	trans	rs408302	0.965	rs402280	chr21:31207718	A/T	cg02473327	chr2:150080315	NA	-0.39	-6.14	-0.35	3.05e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs2180341	1.000	rs6569483	chr6:127658855	G/A	cg27446573	chr6:127587934	RNF146	1.09	16.35	0.71	5.12e-42	Breast cancer;
CESC	cis	rs4665809	0.878	rs35709953	chr2:26334997	G/A	cg27170947	chr2:26402098	FAM59B	0.66	7.3	0.41	3.41e-12	Gut microbiome composition (summer);
CESC	cis	rs4843747	0.671	rs28465438	chr16:88103714	G/A	cg06915872	chr16:87998081	BANP	0.45	5.29	0.31	2.61e-7	Menopause (age at onset);
CESC	cis	rs4665809	0.652	rs10779956	chr2:26405985	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.06	-12.6	-0.61	7.79e-29	Gut microbiome composition (summer);
CESC	cis	rs1008375	1.000	rs10011865	chr4:17645710	G/A	cg15017067	chr4:17643749	FAM184B	0.35	5.07	0.3	7.59e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs2439831	0.850	rs2228368	chr15:44102010	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.72	8.11	0.45	1.87e-14	Lung cancer in ever smokers;
CESC	cis	rs10504229	0.636	rs115738451	chr8:58055133	A/T	cg22535103	chr8:58192502	C8orf71	-0.79	-8.14	-0.45	1.6e-14	Developmental language disorder (linguistic errors);
CESC	cis	rs11785400	0.701	rs9297967	chr8:143723002	A/C	cg10596483	chr8:143751796	JRK	0.4	5.14	0.3	5.32e-7	Schizophrenia;
CESC	cis	rs9910055	0.529	rs183462	chr17:42183376	G/C	cg13607699	chr17:42295918	UBTF	-0.48	-6.0	-0.35	6.55e-9	Total body bone mineral density;
CESC	cis	rs763121	0.853	rs4821816	chr22:39113134	G/A	cg06022373	chr22:39101656	GTPBP1	0.94	18.11	0.74	2.87e-48	Menopause (age at onset);
CESC	cis	rs7584330	0.554	rs76519914	chr2:238429818	G/A	cg14458575	chr2:238380390	NA	0.53	5.71	0.33	2.98e-8	Prostate cancer;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg11586605	chr11:108535779	DDX10	-0.38	-6.0	-0.35	6.46e-9	Gambling;
CESC	cis	rs2836974	0.800	rs73221174	chr21:40540939	T/C	cg27266027	chr21:40555129	PSMG1	0.46	5.45	0.32	1.16e-7	Cognitive function;
CESC	cis	rs3126085	0.935	rs11204981	chr1:152298212	C/T	cg03465714	chr1:152285911	FLG	0.47	5.46	0.32	1.11e-7	Atopic dermatitis;
CESC	cis	rs1707322	0.964	rs7546237	chr1:46285610	A/C	cg05343316	chr1:45956843	TESK2	0.44	5.42	0.32	1.35e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7605827	0.930	rs10176967	chr2:15686086	G/T	cg19274914	chr2:15703543	NA	0.37	6.7	0.38	1.22e-10	Educational attainment (years of education);
CESC	cis	rs4689388	0.853	rs6817447	chr4:6286847	G/T	cg00701064	chr4:6280414	WFS1	0.73	12.96	0.62	4.55e-30	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs10870270	1.000	rs7898755	chr10:133777122	G/A	cg26149184	chr10:133730230	NA	0.38	5.14	0.3	5.22e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02563685	chr8:117778752	UTP23	0.61	6.7	0.38	1.23e-10	Gut microbiome composition (summer);
CESC	cis	rs2230307	0.536	rs564938	chr1:100592901	T/C	cg24955406	chr1:100503596	HIAT1	-0.53	-5.31	-0.31	2.35e-7	Carotid intima media thickness;
CESC	cis	rs12971120	0.891	rs11151961	chr18:72177340	C/T	cg25817165	chr18:72167213	CNDP2	-0.61	-7.36	-0.41	2.37e-12	Refractive error;
CESC	cis	rs208520	0.661	rs6937856	chr6:66867468	A/G	cg07460842	chr6:66804631	NA	-1.0	-13.45	-0.64	8.77e-32	Exhaled nitric oxide output;
CESC	cis	rs977987	0.806	rs8057203	chr16:75404974	T/C	cg03315344	chr16:75512273	CHST6	0.4	5.71	0.33	3.09e-8	Dupuytren's disease;
CESC	cis	rs11958404	0.615	rs7717217	chr5:157447749	C/T	cg05962755	chr5:157440814	NA	0.38	5.65	0.33	4.21e-8	IgG glycosylation;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22677401	chr17:46026860	NA	0.59	7.03	0.4	1.73e-11	Gut microbiome composition (summer);
CESC	cis	rs7659604	0.539	rs2221628	chr4:122795361	G/A	cg19748678	chr4:122722346	EXOSC9	0.8	10.06	0.53	2.28e-20	Type 2 diabetes;
CESC	cis	rs34779708	0.801	rs12246600	chr10:35538121	A/C	cg04310649	chr10:35416472	CREM	-0.47	-5.36	-0.31	1.83e-7	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs7264396	0.676	rs6060730	chr20:34558503	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.52	6.18	0.36	2.37e-9	Total cholesterol levels;
CESC	cis	rs2929278	0.617	rs524908	chr15:44187991	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.4	-6.43	-0.37	6.01e-10	Schizophrenia;
CESC	cis	rs208520	0.661	rs207111	chr6:66792513	C/T	cg07460842	chr6:66804631	NA	-1.0	-13.33	-0.63	2.21e-31	Exhaled nitric oxide output;
CESC	cis	rs2576037	0.526	rs9304340	chr18:44526582	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.44	7.12	0.4	9.88e-12	Personality dimensions;
CESC	cis	rs875971	0.651	rs2420596	chr7:65915983	T/C	cg18876405	chr7:65276391	NA	0.52	7.09	0.4	1.24e-11	Aortic root size;
CESC	cis	rs3858526	0.514	rs1530973	chr11:5861449	C/T	cg02574844	chr11:5959923	NA	-0.46	-6.6	-0.38	2.2e-10	DNA methylation (variation);
CESC	cis	rs875971	0.929	rs12535036	chr7:65964063	G/T	cg11764359	chr7:65958608	NA	0.96	15.25	0.68	3.95e-38	Aortic root size;
CESC	cis	rs7178572	0.633	rs907369	chr15:77843560	A/G	cg22256960	chr15:77711686	NA	-0.53	-6.5	-0.37	3.97e-10	Type 2 diabetes;
CESC	cis	rs7769051	0.522	rs57176306	chr6:133142168	C/T	cg22852734	chr6:133119734	C6orf192	0.87	6.23	0.36	1.84e-9	Type 2 diabetes nephropathy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06719873	chr12:70133599	RAB3IP	-0.53	-6.36	-0.36	8.81e-10	Gut microbiome composition (summer);
CESC	cis	rs116095464	0.558	rs10075018	chr5:239175	G/A	cg12570787	chr5:219185	SDHA;CCDC127	0.5	5.25	0.31	3.1e-7	Breast cancer;
CESC	cis	rs9470366	0.883	rs12199346	chr6:36641546	C/A	cg08179530	chr6:36648295	CDKN1A	0.54	6.39	0.37	7.4e-10	QRS duration;
CESC	cis	rs11190604	1.000	rs2489046	chr10:102346282	A/C	cg07080220	chr10:102295463	HIF1AN	0.59	6.02	0.35	5.94e-9	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs1005277	0.579	rs1780130	chr10:38485378	T/A	cg00409905	chr10:38381863	ZNF37A	-0.46	-6.13	-0.35	3.21e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs9311474	0.659	rs7638808	chr3:52572056	C/T	cg25934064	chr3:52569026	NT5DC2	-0.25	-5.19	-0.3	4.22e-7	Electroencephalogram traits;
CESC	cis	rs10504229	1.000	rs56344560	chr8:58180626	C/G	cg02725872	chr8:58115012	NA	-0.36	-5.56	-0.32	6.54e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs10089	1.000	rs4836361	chr5:127459991	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.76	10.07	0.53	2.04e-20	Ileal carcinoids;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12354594	chr17:61850856	DDX42;CCDC47	0.55	6.32	0.36	1.12e-9	Gut microbiome composition (summer);
CESC	cis	rs672059	0.966	rs689375	chr1:183160973	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.54	7.01	0.4	1.93e-11	Hypertriglyceridemia;
CESC	cis	rs2243480	1.000	rs313832	chr7:65550891	G/T	cg12463550	chr7:65579703	CRCP	0.7	5.4	0.31	1.48e-7	Diabetic kidney disease;
CESC	cis	rs2880765	0.835	rs4360874	chr15:86040820	A/T	cg10818794	chr15:86012489	AKAP13	-0.35	-5.39	-0.31	1.52e-7	Coronary artery disease;
CESC	cis	rs2228479	0.850	rs12596934	chr16:89841605	T/G	cg00800038	chr16:89945340	TCF25	-0.92	-7.64	-0.42	4.02e-13	Skin colour saturation;
CESC	cis	rs7296418	0.961	rs11613937	chr12:123520071	C/T	cg05973401	chr12:123451056	ABCB9	0.6	7.92	0.44	6.63e-14	Platelet count;
CESC	cis	rs9902453	0.874	rs3936006	chr17:28257660	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.71	9.26	0.49	7.32e-18	Coffee consumption (cups per day);
CESC	cis	rs7086627	0.515	rs10887900	chr10:82210265	A/G	cg03267442	chr10:82210566	NA	-0.33	-5.3	-0.31	2.48e-7	Post bronchodilator FEV1;
CESC	cis	rs10504229	1.000	rs66796009	chr8:58174529	G/A	cg22535103	chr8:58192502	C8orf71	-1.05	-13.27	-0.63	3.63e-31	Developmental language disorder (linguistic errors);
CESC	cis	rs8180040	0.966	rs11705957	chr3:47443262	T/G	cg27129171	chr3:47204927	SETD2	-0.64	-9.82	-0.52	1.29e-19	Colorectal cancer;
CESC	cis	rs7824557	0.767	rs6991606	chr8:11176159	G/A	cg21775007	chr8:11205619	TDH	0.47	6.82	0.39	5.98e-11	Retinal vascular caliber;
CESC	cis	rs4253772	0.551	rs9615936	chr22:46686328	C/G	cg00784671	chr22:46762841	CELSR1	-0.51	-5.26	-0.31	3.02e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs875971	1.000	rs4718343	chr7:65874288	T/G	cg12463550	chr7:65579703	CRCP	0.58	7.41	0.41	1.67e-12	Aortic root size;
CESC	cis	rs3820068	0.581	rs1122386	chr1:15946877	C/T	cg16988262	chr1:15930761	NA	0.34	5.45	0.32	1.13e-7	Systolic blood pressure;
CESC	cis	rs875971	0.545	rs313828	chr7:65552614	T/C	cg25405998	chr7:65216604	CCT6P1	-0.5	-5.28	-0.31	2.64e-7	Aortic root size;
CESC	cis	rs2243480	1.000	rs57057549	chr7:65405738	A/G	cg12463550	chr7:65579703	CRCP	0.72	5.53	0.32	7.65e-8	Diabetic kidney disease;
CESC	cis	rs34779708	0.931	rs2384283	chr10:35326789	G/A	cg04310649	chr10:35416472	CREM	-0.49	-5.94	-0.34	9.13e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs6484504	0.576	rs208083	chr11:31196880	C/T	cg14844989	chr11:31128820	NA	-0.38	-5.52	-0.32	7.98e-8	Red blood cell count;
CESC	cis	rs637571	0.654	rs1058068	chr11:65667796	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.66	8.29	0.45	5.76e-15	Eosinophil percentage of white cells;
CESC	cis	rs6120849	0.754	rs6120790	chr20:33599090	A/T	cg24642439	chr20:33292090	TP53INP2	0.67	6.74	0.38	9.78e-11	Protein C levels;
CESC	cis	rs736408	0.522	rs6445535	chr3:52771468	T/C	cg05564831	chr3:52568323	NT5DC2	0.45	7.02	0.4	1.83e-11	Bipolar disorder;
CESC	trans	rs11039798	0.764	rs11039771	chr11:48513273	C/T	cg15704280	chr7:45808275	SEPT13	0.68	6.15	0.35	2.89e-9	Axial length;
CESC	cis	rs9513593	1.000	rs747848	chr13:100036182	C/T	cg21788972	chr13:99853209	UBAC2	0.66	7.78	0.43	1.65e-13	Psoriasis;
CESC	cis	rs8005677	1.000	rs2295685	chr14:23398153	A/G	cg25600027	chr14:23388339	RBM23	-0.44	-5.37	-0.31	1.69e-7	Cognitive ability (multi-trait analysis);
CESC	cis	rs7524258	0.868	rs916393	chr1:7272250	T/C	cg07173049	chr1:7289937	CAMTA1	0.36	5.37	0.31	1.68e-7	Tourette's syndrome or obsessive-compulsive disorder;
CESC	cis	rs6439153	0.933	rs810952	chr3:128685905	A/G	cg24203234	chr3:128598194	ACAD9	0.41	5.3	0.31	2.41e-7	Pneumococcal bacteremia;
CESC	cis	rs425277	0.583	rs925905	chr1:2044037	T/C	cg23803603	chr1:2058230	PRKCZ	-0.34	-5.99	-0.35	6.97e-9	Height;
CESC	cis	rs6748734	0.901	rs6720357	chr2:241830296	A/C	cg07537917	chr2:241836409	C2orf54	-0.25	-5.22	-0.31	3.59e-7	Urinary metabolites;
CESC	cis	rs7648466	0.592	rs2087726	chr3:46208310	G/A	cg08033130	chr3:45983597	CXCR6;FYCO1	0.37	5.16	0.3	4.77e-7	Eotaxin levels;
CESC	cis	rs6701037	0.566	rs10489326	chr1:175134677	A/G	cg00321850	chr1:175162397	KIAA0040	0.44	6.32	0.36	1.11e-9	Alcohol dependence;
CESC	cis	rs2991971	1.000	rs667626	chr1:46020551	T/C	cg03146154	chr1:46216737	IPP	-0.45	-5.58	-0.32	5.83e-8	High light scatter reticulocyte count;
CESC	cis	rs10080237	0.564	rs2490232	chr6:80814802	C/T	cg08355045	chr6:80787529	NA	-0.33	-5.22	-0.31	3.67e-7	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
CESC	cis	rs1552244	1.000	rs17032283	chr3:10081545	C/G	cg00149659	chr3:10157352	C3orf10	0.71	9.04	0.49	3.46e-17	Alzheimer's disease;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg25421043	chr12:122124840	NA	0.49	7.18	0.4	7.16e-12	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs7296418	0.518	rs28825193	chr12:123878262	T/C	cg00376283	chr12:123451042	ABCB9	0.57	7.49	0.42	1.04e-12	Platelet count;
CESC	cis	rs2070677	0.935	rs12245318	chr10:135419483	A/G	cg20169779	chr10:135381914	SYCE1	-0.73	-9.56	-0.51	8.51e-19	Gout;
CESC	cis	rs7424096	0.582	rs7600245	chr2:37220614	A/C	cg14987922	chr2:37194071	STRN	0.49	5.41	0.32	1.38e-7	High light scatter reticulocyte percentage of red cells;
CESC	cis	rs801193	0.773	rs801207	chr7:66020590	T/C	cg06456125	chr7:65229604	NA	-0.39	-5.37	-0.31	1.75e-7	Aortic root size;
CESC	cis	rs7223966	1.000	rs8075257	chr17:61728750	G/C	cg11494091	chr17:61959527	GH2	0.38	5.13	0.3	5.66e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs892961	1.000	rs2117924	chr17:75401310	C/T	cg05865280	chr17:75406074	SEPT9	0.66	13.11	0.63	1.34e-30	Airflow obstruction;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg02374996	chr9:92220771	GADD45G	-0.47	-6.18	-0.35	2.42e-9	Height;
CESC	cis	rs72781680	0.560	rs111310684	chr2:24265682	C/G	cg08917208	chr2:24149416	ATAD2B	0.63	6.09	0.35	3.87e-9	Lymphocyte counts;
CESC	cis	rs12995491	0.731	rs34991383	chr2:88500337	T/G	cg04511125	chr2:88470314	THNSL2	-0.52	-7.71	-0.43	2.5e-13	Response to metformin (IC50);
CESC	trans	rs11098499	0.604	rs2389886	chr4:120570422	C/T	cg25214090	chr10:38739885	LOC399744	0.57	7.5	0.42	9.6e-13	Corneal astigmatism;
CESC	cis	rs9640161	0.789	rs60283368	chr7:150023258	G/A	cg10018233	chr7:150070692	REPIN1	0.45	7.37	0.41	2.21e-12	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs514406	0.679	rs541852	chr1:53256834	A/G	cg27535305	chr1:53392650	SCP2	0.34	6.09	0.35	4e-9	Monocyte count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11948421	chr20:3451504	ATRN	0.61	6.72	0.38	1.11e-10	Gut microbiome composition (summer);
CESC	cis	rs709400	0.965	rs861534	chr14:104168701	C/T	cg12935359	chr14:103987150	CKB	-0.39	-5.45	-0.32	1.17e-7	Body mass index;
CESC	cis	rs4654899	0.680	rs4654881	chr1:21209769	T/C	cg05370193	chr1:21551575	ECE1	-0.35	-5.31	-0.31	2.27e-7	Superior frontal gyrus grey matter volume;
CESC	cis	rs919433	0.963	rs12469546	chr2:198178826	T/C	cg03934865	chr2:198174659	NA	-0.41	-5.5	-0.32	8.72e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs7618915	0.547	rs34537256	chr3:52657472	A/G	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.29	5.13	0.3	5.61e-7	Bipolar disorder;
CESC	cis	rs7552404	0.855	rs385897	chr1:76106962	T/C	cg10523679	chr1:76189770	ACADM	-0.7	-8.07	-0.44	2.39e-14	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs769267	0.896	rs10410664	chr19:19556651	G/A	cg03709012	chr19:19516395	GATAD2A	1.01	15.7	0.69	1.01e-39	Tonsillectomy;
CESC	cis	rs4665809	1.000	rs4233708	chr2:26291345	C/T	cg27170947	chr2:26402098	FAM59B	-0.6	-7.23	-0.41	5.28e-12	Gut microbiome composition (summer);
CESC	cis	rs2762353	0.595	rs9467591	chr6:25742699	C/T	cg03264133	chr6:25882463	NA	-0.56	-8.88	-0.48	1.05e-16	Blood metabolite levels;
CESC	cis	rs12474201	0.832	rs4953419	chr2:46989869	T/G	cg06386533	chr2:46925753	SOCS5	0.84	11.44	0.58	6.63e-25	Height;
CESC	cis	rs16854884	0.657	rs6440210	chr3:143705763	A/G	cg06585982	chr3:143692056	C3orf58	0.48	6.2	0.36	2.11e-9	Economic and political preferences (feminism/equality);
CESC	cis	rs2836974	0.653	rs8130556	chr21:40516872	C/T	cg11890956	chr21:40555474	PSMG1	1.09	18.23	0.75	1.15e-48	Cognitive function;
CESC	cis	rs12497850	0.865	rs13072911	chr3:48962128	T/G	cg06212747	chr3:49208901	KLHDC8B	0.68	9.36	0.5	3.59e-18	Parkinson's disease;
CESC	cis	rs7666738	0.830	rs17027198	chr4:98991085	G/C	cg17366294	chr4:99064904	C4orf37	0.6	8.61	0.47	6.47e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4889855	0.545	rs61171555	chr17:78465975	T/G	cg00066239	chr17:78472159	NA	-0.42	-5.74	-0.33	2.58e-8	Fractional excretion of uric acid;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26571926	chr1:8613145	RERE	-0.53	-6.02	-0.35	5.9e-9	Gut microbiome composition (summer);
CESC	cis	rs79349575	0.783	rs12601858	chr17:47017477	T/C	cg16584676	chr17:46985605	UBE2Z	0.54	6.67	0.38	1.46e-10	Type 2 diabetes;
CESC	cis	rs7618915	0.547	rs62255371	chr3:52747321	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	6.8	0.39	6.92e-11	Bipolar disorder;
CESC	trans	rs7615952	0.641	rs61048217	chr3:125807905	G/T	cg07211511	chr3:129823064	LOC729375	-0.56	-6.22	-0.36	1.92e-9	Blood pressure (smoking interaction);
CESC	cis	rs6088590	1.000	rs6088615	chr20:33400474	C/T	cg08999081	chr20:33150536	PIGU	-0.55	-8.21	-0.45	1.01e-14	Coronary artery disease;
CESC	cis	rs3106136	0.967	rs12499309	chr4:95171284	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.47	-7.2	-0.4	6.38e-12	Capecitabine sensitivity;
CESC	cis	rs4472734	0.965	rs12074811	chr1:214619102	C/A	cg00063699	chr1:214624242	PTPN14	-0.34	-5.26	-0.31	2.93e-7	Height;
CESC	cis	rs2303745	0.589	rs6512179	chr19:17399105	T/C	cg02221750	chr19:17393354	ANKLE1	-0.51	-6.24	-0.36	1.71e-9	Systemic lupus erythematosus;
CESC	cis	rs2080501	0.601	rs3803665	chr16:49672520	A/G	cg27618369	chr16:49636483	ZNF423	0.36	5.37	0.31	1.74e-7	IgG glycosylation;
CESC	cis	rs6570726	0.791	rs9403730	chr6:145907233	C/T	cg05347473	chr6:146136440	FBXO30	0.57	7.48	0.42	1.09e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4820539	1.000	rs4822357	chr22:23473231	A/G	cg14186256	chr22:23484241	RTDR1	0.73	11.91	0.59	1.75e-26	Bone mineral density;
CESC	cis	rs765787	0.530	rs4444275	chr15:45535347	T/C	cg24006582	chr15:45444508	DUOX1	-0.59	-7.23	-0.41	5.15e-12	Uric acid levels;
CESC	cis	rs425277	0.606	rs12082939	chr1:2078922	C/T	cg24578937	chr1:2090814	PRKCZ	0.34	6.14	0.35	3.05e-9	Height;
CESC	cis	rs5769765	0.773	rs138861	chr22:50202276	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.5	-5.54	-0.32	7.4e-8	Schizophrenia;
CESC	cis	rs1451375	0.583	rs11575320	chr7:50605298	A/G	cg14593290	chr7:50529359	DDC	-0.48	-5.9	-0.34	1.1e-8	Malaria;
CESC	cis	rs7666738	0.784	rs4699602	chr4:99034903	T/C	cg03467027	chr4:99064603	C4orf37	0.48	5.88	0.34	1.21e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7927771	0.524	rs2242081	chr11:47500267	T/C	cg20307385	chr11:47447363	PSMC3	0.64	8.73	0.47	2.86e-16	Subjective well-being;
CESC	cis	rs7552404	1.000	rs7534754	chr1:76185308	G/A	cg03433033	chr1:76189801	ACADM	0.68	8.05	0.44	2.87e-14	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs597539	0.689	rs596874	chr11:68630874	C/T	cg18350739	chr11:68623251	NA	0.44	6.76	0.38	8.8e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs2933343	0.729	rs1680794	chr3:128620390	A/G	cg24203234	chr3:128598194	ACAD9	0.39	5.26	0.31	2.91e-7	IgG glycosylation;
CESC	cis	rs6964587	1.000	rs10225885	chr7:91671007	A/G	cg17063962	chr7:91808500	NA	0.58	7.99	0.44	4.22e-14	Breast cancer;
CESC	cis	rs11190604	1.000	rs2495759	chr10:102320363	C/T	cg07080220	chr10:102295463	HIF1AN	0.64	5.64	0.33	4.28e-8	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs9814567	1.000	rs7611611	chr3:134307877	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.41	-5.52	-0.32	8.11e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs10883723	0.737	rs11191312	chr10:104278601	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.59	7.31	0.41	3.18e-12	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs2549003	1.000	rs10068129	chr5:131821246	A/G	cg00255919	chr5:131827918	IRF1	-0.54	-9.13	-0.49	1.77e-17	Asthma (sex interaction);
CESC	cis	rs12134245	0.776	rs61548854	chr1:92001536	C/T	cg02896835	chr1:92012615	NA	-0.53	-6.82	-0.39	6.02e-11	Breast cancer;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg14645856	chr6:18368844	NA	0.48	6.28	0.36	1.38e-9	Fibrinogen levels;
CESC	cis	rs1018836	0.564	rs7821994	chr8:91700916	C/T	cg16814680	chr8:91681699	NA	-0.96	-16.7	-0.72	2.78e-43	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs7772486	0.764	rs7762562	chr6:146158994	T/C	cg05347473	chr6:146136440	FBXO30	0.58	7.38	0.41	2.09e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs62229266	0.839	rs11702763	chr21:37470704	A/G	cg08632701	chr21:37451849	NA	-0.4	-5.33	-0.31	2.13e-7	Mitral valve prolapse;
CESC	cis	rs35306767	0.761	rs11253538	chr10:1011166	C/T	cg25019033	chr10:957182	NA	-0.6	-6.19	-0.36	2.24e-9	Eosinophil percentage of granulocytes;
CESC	cis	rs1823874	0.720	rs7162911	chr15:100355050	A/G	cg16400843	chr15:100339927	C15orf51	0.3	5.26	0.31	3e-7	IgG glycosylation;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg00874357	chr12:62997129	MIRLET7I;C12orf61	0.49	6.34	0.36	1.01e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs5758659	0.653	rs133383	chr22:42473603	C/T	cg05082376	chr22:42548792	NA	-0.36	-5.21	-0.3	3.85e-7	Cognitive function;
CESC	cis	rs7615952	0.576	rs6804482	chr3:125815762	C/T	cg04553112	chr3:125709451	NA	-0.55	-5.85	-0.34	1.44e-8	Blood pressure (smoking interaction);
CESC	cis	rs12134245	0.776	rs12137878	chr1:91973210	G/T	cg25838465	chr1:92012736	NA	-0.58	-8.52	-0.46	1.21e-15	Breast cancer;
CESC	cis	rs9790314	1.000	rs336593	chr3:161076431	T/C	cg03342759	chr3:160939853	NMD3	-0.46	-6.03	-0.35	5.48e-9	Morning vs. evening chronotype;
CESC	trans	rs3780486	0.718	rs3818593	chr9:33120706	A/G	cg04842962	chr6:43655489	MRPS18A	0.74	8.74	0.47	2.66e-16	IgG glycosylation;
CESC	cis	rs4927850	1.000	rs7614767	chr3:195753451	C/T	cg18569988	chr3:195679450	NA	0.34	5.03	0.3	8.91e-7	Pancreatic cancer;
CESC	cis	rs2439831	1.000	rs2253708	chr15:43797273	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.89	10.25	0.53	5.65e-21	Lung cancer in ever smokers;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg19575813	chr18:46476937	SMAD7	-0.48	-6.55	-0.37	2.97e-10	Fibrinogen levels;
CESC	cis	rs13256369	0.951	rs13259955	chr8:8565885	C/G	cg18904891	chr8:8559673	CLDN23	0.72	8.39	0.46	2.85e-15	Obesity-related traits;
CESC	cis	rs6963495	0.818	rs73190184	chr7:105163736	C/T	cg02135003	chr7:105160482	PUS7	-0.47	-5.59	-0.33	5.51e-8	Bipolar disorder (body mass index interaction);
CESC	cis	rs7809950	0.593	rs62482503	chr7:106987988	A/G	cg23024343	chr7:107201750	COG5	-0.53	-6.84	-0.39	5.49e-11	Coronary artery disease;
CESC	cis	rs79349575	0.783	rs61576918	chr17:46985593	A/C	cg16584676	chr17:46985605	UBE2Z	0.53	6.6	0.38	2.25e-10	Type 2 diabetes;
CESC	cis	rs7811142	0.830	rs6945952	chr7:99981775	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.01	10.03	0.52	2.83e-20	Platelet count;
CESC	cis	rs12545109	0.723	rs2610045	chr8:57413439	A/G	cg09654669	chr8:57350985	NA	0.45	5.73	0.33	2.69e-8	Obesity-related traits;
CESC	cis	rs12541335	0.639	rs4871994	chr8:22206038	G/A	cg02463440	chr8:22132932	PIWIL2	0.37	5.61	0.33	5.04e-8	Hypertriglyceridemia;
CESC	trans	rs11098499	0.954	rs13151285	chr4:120314741	C/A	cg25214090	chr10:38739885	LOC399744	0.68	9.2	0.49	1.14e-17	Corneal astigmatism;
CESC	cis	rs7666738	0.791	rs7678564	chr4:99057341	A/G	cg18180107	chr4:99064573	C4orf37	0.41	5.25	0.31	3.18e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4901869	0.966	rs60800733	chr14:59337778	A/G	cg02291164	chr14:59296302	NA	0.45	7.73	0.43	2.21e-13	Panic disorder;
CESC	cis	rs7927592	0.913	rs3740631	chr11:68341722	T/G	cg20283391	chr11:68216788	NA	-0.61	-7.29	-0.41	3.48e-12	Total body bone mineral density;
CESC	cis	rs17253792	0.545	rs12894613	chr14:56016221	T/C	cg01858014	chr14:56050164	KTN1	-0.87	-6.37	-0.36	8.34e-10	Putamen volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18159533	chr12:133357242	GOLGA3	-0.54	-6.36	-0.36	8.77e-10	Gut microbiome composition (summer);
CESC	cis	rs9658691	0.607	rs9658791	chr10:90777338	G/A	cg03111039	chr10:90751583	FAS;ACTA2	-0.59	-5.06	-0.3	7.75e-7	Mosquito bite size;
CESC	cis	rs752010	0.841	rs6661784	chr1:42080312	A/T	cg06885757	chr1:42089581	HIVEP3	0.47	7.55	0.42	7.19e-13	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs12545109	0.800	rs1440763	chr8:57410481	C/A	cg09654669	chr8:57350985	NA	-0.56	-6.65	-0.38	1.67e-10	Obesity-related traits;
CESC	cis	rs9640161	0.750	rs3735169	chr7:150034378	A/G	cg21361702	chr7:150065534	REPIN1	0.53	5.74	0.33	2.53e-8	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs40363	0.951	rs250632	chr16:3523047	C/T	cg00484396	chr16:3507460	NAT15	0.62	7.98	0.44	4.51e-14	Tuberculosis;
CESC	cis	rs17376456	0.877	rs10061080	chr5:93420559	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.62	5.32	0.31	2.19e-7	Diabetic retinopathy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13179880	chr1:46016123	AKR1A1	-0.48	-6.09	-0.35	3.98e-9	Gut microbiome composition (summer);
CESC	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg03188948	chr7:1209495	NA	0.7	6.78	0.38	7.86e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs9322193	0.923	rs11155671	chr6:149972132	G/A	cg04369109	chr6:150039330	LATS1	-0.36	-5.03	-0.3	9.02e-7	Lung cancer;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg09447457	chr6:24721528	NA	-0.52	-6.31	-0.36	1.17e-9	Ulcerative colitis;
CESC	cis	rs1018836	0.892	rs2187981	chr8:91549629	T/C	cg16814680	chr8:91681699	NA	-0.64	-9.06	-0.49	2.94e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs2230307	0.536	rs687513	chr1:100598867	C/T	cg24955406	chr1:100503596	HIAT1	-0.53	-5.43	-0.32	1.25e-7	Carotid intima media thickness;
CESC	cis	rs10504229	1.000	rs73607875	chr8:58173522	T/C	cg22535103	chr8:58192502	C8orf71	-1.05	-13.27	-0.63	3.63e-31	Developmental language disorder (linguistic errors);
CESC	cis	rs4819052	0.851	rs2838833	chr21:46665160	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.89	12.86	0.62	9.89e-30	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs10788264	0.504	rs7069328	chr10:124030741	G/C	cg09507567	chr10:124027408	NA	0.43	6.04	0.35	5.22e-9	Total body bone mineral density;
CESC	cis	rs1552244	0.882	rs56332224	chr3:10037321	G/A	cg00149659	chr3:10157352	C3orf10	0.69	8.2	0.45	1.02e-14	Alzheimer's disease;
CESC	cis	rs8072100	0.934	rs9905583	chr17:45741016	C/T	cg08085267	chr17:45401833	C17orf57	-0.43	-5.73	-0.33	2.73e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs2050392	0.590	rs685319	chr10:30719331	G/A	cg25182066	chr10:30743637	MAP3K8	-0.46	-6.02	-0.35	5.85e-9	Inflammatory bowel disease;
CESC	cis	rs3008870	0.958	rs34367328	chr1:67445321	T/C	cg02640540	chr1:67518911	SLC35D1	-0.51	-5.58	-0.32	5.89e-8	Lymphocyte percentage of white cells;
CESC	cis	rs7727544	0.735	rs272842	chr5:131656517	A/G	cg24060327	chr5:131705240	SLC22A5	-0.64	-8.58	-0.47	8.34e-16	Blood metabolite levels;
CESC	cis	rs807669	0.807	rs698422	chr22:19205826	A/T	cg02655711	chr22:19163373	SLC25A1	0.54	7.95	0.44	5.46e-14	Metabolite levels;
CESC	cis	rs710216	0.917	rs3754223	chr1:43419091	A/T	cg22176566	chr1:43424700	SLC2A1	0.54	6.16	0.35	2.63e-9	Red cell distribution width;
CESC	cis	rs10740039	0.729	rs6479728	chr10:62490801	A/G	cg02922035	chr10:62493342	NA	-0.45	-5.7	-0.33	3.16e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CESC	cis	rs9322193	0.923	rs57012784	chr6:149948827	G/A	cg13206674	chr6:150067644	NUP43	0.42	6.02	0.35	5.81e-9	Lung cancer;
CESC	cis	rs763014	0.932	rs2384974	chr16:651279	C/G	cg00802000	chr16:706648	WDR90	-0.41	-6.26	-0.36	1.51e-9	Height;
CESC	cis	rs6502050	0.835	rs8077926	chr17:80117315	C/A	cg11859384	chr17:80120422	CCDC57	-0.38	-5.18	-0.3	4.43e-7	Life satisfaction;
CESC	cis	rs12545109	0.800	rs2576599	chr8:57388410	G/A	cg09654669	chr8:57350985	NA	-0.55	-6.56	-0.37	2.84e-10	Obesity-related traits;
CESC	cis	rs12188164	0.930	rs72717436	chr5:448291	C/A	cg26850624	chr5:429559	AHRR	-0.5	-6.67	-0.38	1.52e-10	Cystic fibrosis severity;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08620789	chr7:157129638	DNAJB6	0.54	6.44	0.37	5.63e-10	Gut microbiome composition (summer);
CESC	cis	rs6088580	0.634	rs6059868	chr20:33079460	A/G	cg08999081	chr20:33150536	PIGU	0.66	11.75	0.59	6.14e-26	Glomerular filtration rate (creatinine);
CESC	cis	rs7762018	1.000	rs17860606	chr6:170099561	G/A	cg13891659	chr6:170190454	C6orf122;C6orf208	0.52	5.42	0.32	1.37e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs898097	0.841	rs4986136	chr17:80865119	A/G	cg15664640	chr17:80829946	TBCD	0.61	8.98	0.48	5.23e-17	Breast cancer;
CESC	cis	rs4862307	0.754	rs6846007	chr4:184991604	A/G	cg06737308	chr4:185021514	ENPP6	-0.42	-5.76	-0.33	2.35e-8	Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	cis	rs9457247	1.000	rs376574	chr6:167389956	A/T	cg25258033	chr6:167368657	RNASET2	0.39	5.87	0.34	1.31e-8	Crohn's disease;
CESC	cis	rs595982	0.559	rs73061643	chr19:49368151	A/G	cg15549821	chr19:49342101	PLEKHA4	-0.71	-7.96	-0.44	5.22e-14	Red cell distribution width;
CESC	cis	rs763121	0.853	rs5757211	chr22:39051705	C/T	cg14440974	chr22:39074834	NA	-0.4	-5.48	-0.32	9.77e-8	Menopause (age at onset);
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg00714078	chr2:135809744	RAB3GAP1	-0.44	-6.38	-0.36	7.98e-10	Asthma;
CESC	cis	rs9322193	0.683	rs113281309	chr6:150108425	T/G	cg13206674	chr6:150067644	NUP43	0.42	5.9	0.34	1.13e-8	Lung cancer;
CESC	cis	rs920590	0.758	rs17091534	chr8:19670651	C/T	cg17834443	chr8:19674713	INTS10	0.55	6.17	0.35	2.57e-9	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs6952808	0.531	rs3779003	chr7:2184902	C/T	cg02951883	chr7:2050386	MAD1L1	-0.48	-6.24	-0.36	1.73e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs9039	0.959	rs12925781	chr16:9216914	A/G	cg08831531	chr16:9218945	NA	0.54	7.01	0.4	1.95e-11	Menopause (age at onset);
CESC	cis	rs4132509	1.000	rs1458024	chr1:243937445	G/C	cg21452805	chr1:244014465	NA	0.44	5.54	0.32	7.13e-8	RR interval (heart rate);
CESC	cis	rs72781680	0.752	rs72796119	chr2:23917179	C/T	cg20701182	chr2:24300061	SF3B14	0.79	6.88	0.39	4.25e-11	Lymphocyte counts;
CESC	cis	rs11250464	0.833	rs2387653	chr10:1407826	A/G	cg26394196	chr10:1453818	ADARB2	0.4	5.23	0.31	3.46e-7	Radiation response;
CESC	cis	rs7666738	0.830	rs13130923	chr4:99046281	T/C	cg05340658	chr4:99064831	C4orf37	0.82	12.88	0.62	8.44e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9435341	0.965	rs1335055	chr1:107624563	A/G	cg09367891	chr1:107599246	PRMT6	0.55	6.95	0.39	2.84e-11	Facial morphology (factor 21, depth of nasal alae);
CESC	cis	rs9311474	0.508	rs11720243	chr3:52618018	T/C	cg18404041	chr3:52824283	ITIH1	-0.39	-6.75	-0.38	9.41e-11	Electroencephalogram traits;
CESC	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg18765753	chr7:1198926	ZFAND2A	-0.5	-7.41	-0.41	1.66e-12	Longevity;Endometriosis;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg27135125	chr7:23510082	IGF2BP3	-0.45	-6.19	-0.36	2.3e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs2204008	0.692	rs11613378	chr12:38213138	T/A	cg26384229	chr12:38710491	ALG10B	0.74	10.7	0.55	1.96e-22	Bladder cancer;
CESC	cis	rs7124681	0.528	rs74608150	chr11:47696214	A/T	cg20307385	chr11:47447363	PSMC3	0.62	8.65	0.47	5.02e-16	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
CESC	cis	rs6963495	0.818	rs6956249	chr7:105149743	A/T	cg19920283	chr7:105172520	RINT1	0.66	6.28	0.36	1.36e-9	Bipolar disorder (body mass index interaction);
CESC	cis	rs11997175	0.595	rs7386404	chr8:33762842	T/C	ch.8.33884649F	chr8:33765107	NA	0.5	5.73	0.33	2.73e-8	Body mass index;
CESC	cis	rs9322193	0.923	rs10782314	chr6:150056663	C/T	cg00933542	chr6:150070202	PCMT1	0.3	5.11	0.3	6.15e-7	Lung cancer;
CESC	trans	rs1545843	0.564	rs2468284	chr12:84892620	A/C	cg03015433	chr16:56623111	MT3	0.33	6.1	0.35	3.76e-9	Major depressive disorder;
CESC	cis	rs864537	0.622	rs2949661	chr1:167424924	C/T	cg09179987	chr1:167433047	CD247	0.54	7.88	0.44	8.5e-14	Celiac disease or Rheumatoid arthritis;Celiac disease;
CESC	cis	rs4253772	0.550	rs9615949	chr22:46722531	C/T	cg10541313	chr22:46663664	TTC38	0.64	5.09	0.3	6.86e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs4722585	0.533	rs2237335	chr7:26200213	A/G	cg07876897	chr7:26191696	NFE2L3	0.42	5.31	0.31	2.32e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
CESC	cis	rs2243480	1.000	rs427044	chr7:65508545	G/A	cg12463550	chr7:65579703	CRCP	0.7	5.46	0.32	1.1e-7	Diabetic kidney disease;
CESC	cis	rs6690583	0.573	rs75119114	chr1:85451385	A/C	cg22153463	chr1:85462885	MCOLN2	0.71	7.12	0.4	1.01e-11	Serum sulfate level;
CESC	cis	rs17253792	0.822	rs112238223	chr14:56056144	C/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.84	5.62	0.33	4.81e-8	Putamen volume;
CESC	cis	rs1728785	1.000	rs1615609	chr16:68596401	C/A	cg02972257	chr16:68554789	NA	-0.59	-6.72	-0.38	1.09e-10	Ulcerative colitis;
CESC	cis	rs9399401	0.667	rs7757571	chr6:142702589	A/C	cg03128060	chr6:142623767	GPR126	0.37	6.5	0.37	4e-10	Chronic obstructive pulmonary disease;
CESC	cis	rs7131987	0.903	rs11050152	chr12:29404424	G/T	cg09582351	chr12:29534625	ERGIC2	-0.36	-5.67	-0.33	3.66e-8	QT interval;
CESC	cis	rs9611565	0.681	rs132918	chr22:41808350	C/T	cg03806693	chr22:41940476	POLR3H	1.04	12.98	0.62	3.76e-30	Vitiligo;
CESC	trans	rs453301	0.624	rs330058	chr8:9089809	G/A	cg06636001	chr8:8085503	FLJ10661	-0.52	-6.7	-0.38	1.24e-10	Joint mobility (Beighton score);
CESC	cis	rs10242455	0.571	rs55830753	chr7:99292222	A/G	cg07338983	chr7:99679036	ZNF3	0.68	5.13	0.3	5.49e-7	Blood metabolite levels;
CESC	cis	rs7084402	0.967	rs1649033	chr10:60279634	T/C	cg07615347	chr10:60278583	BICC1	-0.58	-9.28	-0.5	6.18e-18	Refractive error;
CESC	cis	rs4900538	0.963	rs1190553	chr14:102915331	G/T	cg18135206	chr14:102964638	TECPR2	-0.78	-10.28	-0.53	4.49e-21	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	trans	rs17685	0.753	rs3757593	chr7:75678735	G/A	cg19862616	chr7:65841803	NCRNA00174	-0.84	-12.47	-0.61	2.15e-28	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs11190604	1.000	rs7073586	chr10:102307671	A/G	cg07080220	chr10:102295463	HIF1AN	0.58	5.89	0.34	1.2e-8	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs2549003	1.000	rs9282761	chr5:131822224	T/C	cg00255919	chr5:131827918	IRF1	0.51	8.68	0.47	4.19e-16	Asthma (sex interaction);
CESC	cis	rs7078219	0.543	rs7095491	chr10:101274058	A/G	cg09788492	chr10:101292477	NKX2-3	0.32	6.04	0.35	5.1e-9	Dental caries;
CESC	cis	rs7666738	0.830	rs10049627	chr4:99025272	A/C	cg24818145	chr4:99064322	C4orf37	0.39	5.09	0.3	6.95e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4835473	0.932	rs35277115	chr4:144656154	T/C	cg25736465	chr4:144833511	NA	-0.34	-5.45	-0.32	1.15e-7	Immature fraction of reticulocytes;
CESC	cis	rs7762018	0.607	rs75999653	chr6:170066927	A/G	cg15199489	chr6:170068458	WDR27	0.68	5.2	0.3	4.03e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs12541635	0.677	rs4734892	chr8:106990088	G/C	cg10147462	chr8:107024639	NA	0.43	6.38	0.37	7.67e-10	Age of smoking initiation;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg09312446	chr16:2051647	ZNF598	0.5	6.74	0.38	9.81e-11	Fibrinogen levels;
CESC	cis	rs4665809	0.525	rs10865402	chr2:26535383	A/G	cg27170947	chr2:26402098	FAM59B	-0.53	-6.74	-0.38	1.01e-10	Gut microbiome composition (summer);
CESC	cis	rs4665809	1.000	rs1560868	chr2:26281459	A/T	cg25036284	chr2:26402008	FAM59B	0.72	8.26	0.45	7.04e-15	Gut microbiome composition (summer);
CESC	cis	rs6500395	0.962	rs9941336	chr16:48652769	G/A	cg04672837	chr16:48644449	N4BP1	0.47	5.57	0.32	6.4e-8	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs2180341	0.618	rs11961994	chr6:127649350	A/G	cg27446573	chr6:127587934	RNF146	-0.61	-8.27	-0.45	6.54e-15	Breast cancer;
CESC	cis	rs2625529	0.652	rs2957745	chr15:72288077	T/C	cg16672083	chr15:72433130	SENP8	0.41	6.31	0.36	1.18e-9	Red blood cell count;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg18050295	chr3:12949921	IQSEC1	0.49	6.46	0.37	4.86e-10	Fibrinogen levels;
CESC	cis	rs270601	0.770	rs61352298	chr5:131600589	G/C	cg18301423	chr5:131593218	PDLIM4	0.38	5.5	0.32	8.83e-8	Acylcarnitine levels;
CESC	cis	rs870825	0.616	rs28579226	chr4:185650458	A/C	cg04058563	chr4:185651563	MLF1IP	0.63	6.96	0.39	2.74e-11	Blood protein levels;
CESC	cis	rs514406	0.758	rs532242	chr1:53308665	C/G	cg24675658	chr1:53192096	ZYG11B	-0.55	-6.86	-0.39	4.79e-11	Monocyte count;
CESC	cis	rs736408	0.608	rs6445534	chr3:52743384	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.62	8.86	0.48	1.22e-16	Bipolar disorder;
CESC	cis	rs10979	0.964	rs9321922	chr6:143895231	A/G	cg25407410	chr6:143891975	LOC285740	-0.61	-9.2	-0.49	1.13e-17	Hypospadias;
CESC	cis	rs9403521	1.000	rs6907410	chr6:143995142	A/G	cg21026257	chr6:143998961	PHACTR2	0.47	5.2	0.3	4e-7	Obesity-related traits;
CESC	cis	rs853679	0.517	rs9348797	chr6:28137533	G/C	cg12963246	chr6:28129442	ZNF389	0.54	7.12	0.4	1.02e-11	Depression;
CESC	cis	rs10870270	1.000	rs9971066	chr10:133788233	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.86	-12.51	-0.61	1.56e-28	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs712039	0.652	rs829163	chr17:35766026	G/C	cg16670864	chr17:35848621	DUSP14	0.44	5.48	0.32	9.81e-8	Tuberculosis;
CESC	cis	rs698813	0.604	rs12712916	chr2:44482099	A/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.47	5.33	0.31	2.12e-7	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
CESC	cis	rs4835473	0.900	rs34772566	chr4:144655508	G/A	cg25736465	chr4:144833511	NA	-0.33	-5.15	-0.3	5.08e-7	Immature fraction of reticulocytes;
CESC	cis	rs1843834	0.539	rs6749402	chr2:225443901	T/G	cg22509189	chr2:225307070	NA	-0.42	-5.63	-0.33	4.6e-8	IgE levels in asthmatics (D.p. specific);
CESC	cis	rs10504229	0.683	rs11787247	chr8:58131528	G/T	cg02725872	chr8:58115012	NA	-0.45	-7.05	-0.4	1.52e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs9303542	0.559	rs2326012	chr17:46618581	C/T	cg04904318	chr17:46607828	HOXB1	-0.54	-5.39	-0.31	1.54e-7	Ovarian cancer;Epithelial ovarian cancer;
CESC	cis	rs9902453	0.689	rs7216948	chr17:28203173	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.71	9.14	0.49	1.74e-17	Coffee consumption (cups per day);
CESC	cis	rs7116495	0.609	rs7126394	chr11:71685429	A/G	cg10381502	chr11:71823885	C11orf51	-1.18	-7.75	-0.43	1.95e-13	Severe influenza A (H1N1) infection;
CESC	cis	rs826838	1.000	rs4768328	chr12:39129315	C/T	cg13010199	chr12:38710504	ALG10B	-0.45	-6.26	-0.36	1.51e-9	Heart rate;
CESC	cis	rs2290159	0.800	rs57884385	chr3:12673551	G/C	cg23032965	chr3:12705835	RAF1	0.53	5.68	0.33	3.63e-8	Cholesterol, total;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg05599930	chr11:119252487	USP2	-0.48	-6.55	-0.37	3.04e-10	Fibrinogen levels;
CESC	cis	rs7833986	0.501	rs2719258	chr8:56941389	C/T	cg26371346	chr8:56986568	SNORD54;RPS20	0.57	5.27	0.31	2.81e-7	Height;
CESC	cis	rs6952808	0.723	rs4721295	chr7:2036669	G/T	cg22963979	chr7:1858916	MAD1L1	0.38	5.31	0.31	2.36e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs2243480	1.000	rs4718316	chr7:65648731	A/G	cg13147721	chr7:65941812	NA	0.97	9.16	0.49	1.47e-17	Diabetic kidney disease;
CESC	cis	rs6502050	0.835	rs4789751	chr17:80092373	G/T	cg23985595	chr17:80112537	CCDC57	-0.42	-6.6	-0.38	2.18e-10	Life satisfaction;
CESC	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.63	7.27	0.41	4.09e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7666738	0.924	rs62318940	chr4:99064768	C/T	cg18180107	chr4:99064573	C4orf37	0.48	5.84	0.34	1.5e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs734999	0.588	rs6689711	chr1:2531467	T/C	cg20673091	chr1:2541236	MMEL1	-0.43	-7.12	-0.4	1.03e-11	Ulcerative colitis;
CESC	cis	rs875971	0.964	rs697969	chr7:65558478	C/A	cg10691866	chr7:65817282	TPST1	0.33	5.23	0.31	3.45e-7	Aortic root size;
CESC	trans	rs4349753	0.663	rs28626847	chr5:144089514	C/T	cg22407458	chr6:35109121	TCP11	0.5	6.22	0.36	1.94e-9	Photic sneeze reflex;
CESC	cis	rs9457247	1.000	rs415890	chr6:167406633	C/G	cg23791538	chr6:167370224	RNASET2	0.6	8.45	0.46	1.92e-15	Crohn's disease;
CESC	cis	rs34779708	0.733	rs12240638	chr10:35542610	G/T	cg04310649	chr10:35416472	CREM	-0.47	-5.39	-0.31	1.59e-7	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs9858542	1.000	rs4283605	chr3:49678651	A/G	cg07274523	chr3:49395745	GPX1	0.67	8.46	0.46	1.87e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs7412746	0.634	rs72704658	chr1:150833010	T/C	cg22823121	chr1:150693482	HORMAD1	0.44	6.07	0.35	4.39e-9	Melanoma;
CESC	cis	rs780096	0.546	rs2911712	chr2:27626945	A/T	cg22903471	chr2:27725779	GCKR	-0.5	-7.22	-0.41	5.42e-12	Total body bone mineral density;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg07241146	chr10:134145514	LRRC27	-0.45	-6.05	-0.35	4.9e-9	Asthma;
CESC	cis	rs881375	0.678	rs10118357	chr9:123680068	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.49	7.16	0.4	7.88e-12	Rheumatoid arthritis;
CESC	cis	rs4474465	0.688	rs7945812	chr11:78280509	T/C	cg01578073	chr11:78285783	NARS2	-0.44	-5.1	-0.3	6.33e-7	Alzheimer's disease (survival time);
CESC	cis	rs7618501	0.633	rs11130228	chr3:50003246	C/T	cg24308560	chr3:49941425	MST1R	-0.63	-9.23	-0.49	8.99e-18	Intelligence (multi-trait analysis);
CESC	cis	rs8005677	0.798	rs4982713	chr14:23404102	C/T	cg01529538	chr14:23388837	RBM23	0.43	5.69	0.33	3.3e-8	Cognitive ability (multi-trait analysis);
CESC	cis	rs1949733	0.656	rs2688243	chr4:8436286	A/G	cg11789530	chr4:8429930	ACOX3	0.76	10.53	0.54	7.02e-22	Response to antineoplastic agents;
CESC	cis	rs11690935	0.550	rs62183769	chr2:172838074	A/C	cg13550731	chr2:172543902	DYNC1I2	0.5	6.86	0.39	4.72e-11	Schizophrenia;
CESC	cis	rs4594175	0.926	rs10145287	chr14:51626808	G/T	cg23942311	chr14:51606299	NA	0.35	5.26	0.31	2.93e-7	Cancer;
CESC	cis	rs7918232	0.782	rs7910168	chr10:27465296	G/A	cg14442939	chr10:27389572	ANKRD26	0.69	6.91	0.39	3.51e-11	Breast cancer;
CESC	cis	rs9308731	0.568	rs28723045	chr2:111935698	T/G	cg04202892	chr2:111875749	ACOXL	0.38	5.27	0.31	2.76e-7	Chronic lymphocytic leukemia;
CESC	cis	rs7208859	0.623	rs55638872	chr17:29149552	G/C	cg19761014	chr17:28927070	LRRC37B2	0.79	6.47	0.37	4.6e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs9309711	0.643	rs4264589	chr2:3481098	G/T	cg10845886	chr2:3471009	TTC15	-0.68	-9.43	-0.5	2.13e-18	Neurofibrillary tangles;
CESC	cis	rs1915146	0.546	rs2681919	chr10:126859029	A/G	cg00406319	chr10:126851303	NA	0.37	5.78	0.33	2.05e-8	Menarche (age at onset);
CESC	cis	rs763121	0.752	rs5757222	chr22:39060473	C/T	cg06022373	chr22:39101656	GTPBP1	0.88	13.88	0.65	2.66e-33	Menopause (age at onset);
CESC	cis	rs11098499	0.954	rs6847248	chr4:120225955	A/G	cg09307838	chr4:120376055	NA	0.9	11.64	0.58	1.49e-25	Corneal astigmatism;
CESC	cis	rs7089973	0.525	rs11196945	chr10:116600424	G/A	cg23260525	chr10:116636907	FAM160B1	0.4	7.2	0.4	6.31e-12	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs3858526	0.959	rs61876224	chr11:5952859	G/A	cg02574844	chr11:5959923	NA	-0.44	-5.57	-0.32	6.18e-8	DNA methylation (variation);
CESC	cis	rs17711722	0.701	rs781143	chr7:65439879	G/C	cg14393609	chr7:65229607	NA	0.53	7.07	0.4	1.34e-11	Calcium levels;
CESC	cis	rs10504229	0.683	rs61306359	chr8:58134646	G/A	cg21724239	chr8:58056113	NA	0.58	5.95	0.34	8.29e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs7927771	0.864	rs2053979	chr11:47439444	A/G	cg20307385	chr11:47447363	PSMC3	-0.64	-7.7	-0.43	2.65e-13	Subjective well-being;
CESC	cis	rs7116495	0.609	rs7113436	chr11:71689599	A/T	cg10381502	chr11:71823885	C11orf51	1.18	7.06	0.4	1.45e-11	Severe influenza A (H1N1) infection;
CESC	cis	rs60843830	0.661	rs6755432	chr2:106692	T/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.52	6.19	0.36	2.26e-9	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs901683	1.000	rs17157884	chr10:46015942	C/T	cg16031567	chr10:46195673	NA	-0.77	-5.04	-0.3	8.57e-7	Red blood cell traits;Mean corpuscular volume;
CESC	cis	rs2576037	0.526	rs2010834	chr18:44560875	C/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.42	-6.95	-0.39	2.78e-11	Personality dimensions;
CESC	cis	rs1707322	0.752	rs28890893	chr1:46186576	T/G	cg06784218	chr1:46089804	CCDC17	0.41	7.21	0.41	5.75e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs589249	0.637	rs906227	chr1:37189396	C/T	cg19869746	chr6:7107108	RREB1	0.44	6.0	0.35	6.61e-9	Neuroticism (multi-trait analysis);Schizophrenia;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg02894226	chr20:3190561	ITPA	0.45	6.2	0.36	2.14e-9	Systemic lupus erythematosus;
CESC	cis	rs2836974	0.863	rs1065242	chr21:40567716	C/G	cg27266027	chr21:40555129	PSMG1	0.46	5.51	0.32	8.65e-8	Cognitive function;
CESC	cis	rs736408	0.812	rs1076425	chr3:52825462	A/G	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	5.39	0.31	1.56e-7	Bipolar disorder;
CESC	cis	rs8067545	0.611	rs2703803	chr17:20107069	G/T	cg13482628	chr17:19912719	NA	-0.42	-5.7	-0.33	3.18e-8	Schizophrenia;
CESC	cis	rs2274273	0.662	rs66476033	chr14:55660863	C/A	cg04306507	chr14:55594613	LGALS3	0.31	5.27	0.31	2.78e-7	Protein biomarker;
CESC	cis	rs9837602	0.938	rs1021341	chr3:99786289	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.44	6.65	0.38	1.69e-10	Breast cancer;
CESC	cis	rs1881797	1.000	rs12061460	chr1:247686787	G/A	cg05639522	chr1:247681581	NA	0.46	6.02	0.35	5.84e-9	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs9611519	0.754	rs4820435	chr22:41652846	G/T	cg17376030	chr22:41985996	PMM1	0.5	5.55	0.32	7.02e-8	Neuroticism;
CESC	cis	rs11190604	1.000	rs10883511	chr10:102299407	A/G	cg07080220	chr10:102295463	HIF1AN	0.68	6.34	0.36	9.76e-10	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs10089	1.000	rs6595800	chr5:127411647	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.78	10.34	0.54	2.74e-21	Ileal carcinoids;
CESC	cis	rs12995491	0.933	rs13008732	chr2:88528771	G/A	cg07952391	chr2:88470173	THNSL2	-0.55	-8.32	-0.46	4.66e-15	Response to metformin (IC50);
CESC	cis	rs13191362	0.935	rs67673890	chr6:163107647	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.66	6.51	0.37	3.77e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs2204008	0.837	rs55962152	chr12:38234281	G/A	cg13010199	chr12:38710504	ALG10B	0.49	6.15	0.35	2.82e-9	Bladder cancer;
CESC	cis	rs4711336	1.000	rs2296742	chr6:33659793	G/A	cg14003231	chr6:33640908	ITPR3	0.32	5.42	0.32	1.34e-7	Height;
CESC	cis	rs12618769	0.597	rs56197140	chr2:99113740	T/C	cg10123293	chr2:99228465	UNC50	0.41	5.44	0.32	1.24e-7	Bipolar disorder;
CESC	cis	rs478304	0.651	rs11604462	chr11:65551648	G/A	cg27068330	chr11:65405492	SIPA1	-0.46	-5.55	-0.32	6.83e-8	Acne (severe);
CESC	cis	rs77216612	1.000	rs77216612	chr12:12877983	A/G	cg04607235	chr12:12878440	APOLD1	-1.05	-16.25	-0.71	1.17e-41	Lymphocyte counts;
CESC	cis	rs4867766	0.871	rs11747479	chr5:173955389	C/T	cg20434911	chr5:173954559	NA	-0.6	-6.57	-0.37	2.66e-10	Stroke;
CESC	cis	rs9322193	0.962	rs4552	chr6:150132319	A/T	cg07701084	chr6:150067640	NUP43	0.43	5.8	0.34	1.87e-8	Lung cancer;
CESC	cis	rs2952156	0.959	rs2941503	chr17:37828745	A/G	cg07936489	chr17:37558343	FBXL20	-0.52	-6.24	-0.36	1.72e-9	Asthma;
CESC	trans	rs208520	0.608	rs3846803	chr6:66805743	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.99	-12.78	-0.62	1.78e-29	Exhaled nitric oxide output;
CESC	cis	rs5753037	0.702	rs81800	chr22:30200362	C/G	cg01021169	chr22:30184971	ASCC2	0.47	6.6	0.38	2.28e-10	Type 1 diabetes;
CESC	cis	rs7520050	0.966	rs12411269	chr1:46271052	C/T	cg03146154	chr1:46216737	IPP	-0.47	-6.19	-0.36	2.34e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs2842992	0.830	rs2758320	chr6:160070676	T/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.65	7.47	0.42	1.15e-12	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs8067354	0.872	rs2645488	chr17:57889405	T/G	cg13753209	chr17:57696993	CLTC	0.5	6.83	0.39	5.83e-11	Hemoglobin concentration;
CESC	cis	rs4253772	0.530	rs79354880	chr22:46746419	C/A	cg18190219	chr22:46762943	CELSR1	-0.68	-6.23	-0.36	1.85e-9	LDL cholesterol;Cholesterol, total;
CESC	cis	rs1005277	0.540	rs2145487	chr10:38010077	A/G	cg25427524	chr10:38739819	LOC399744	-0.64	-9.44	-0.5	1.98e-18	Extrinsic epigenetic age acceleration;
CESC	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg04025307	chr7:1156635	C7orf50	0.57	9.81	0.52	1.4e-19	Longevity;Endometriosis;
CESC	cis	rs78889164	0.592	rs1423066	chr19:33850667	T/C	cg02272751	chr19:33882848	PEPD	-0.37	-5.48	-0.32	9.97e-8	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4808199	0.947	rs2163804	chr19:19575965	G/A	cg03709012	chr19:19516395	GATAD2A	1.17	13.38	0.63	1.53e-31	Nonalcoholic fatty liver disease;
CESC	cis	rs7937682	0.855	rs7934922	chr11:111500026	T/C	cg22437258	chr11:111473054	SIK2	0.7	9.18	0.49	1.31e-17	Primary sclerosing cholangitis;
CESC	cis	rs10479542	0.630	rs6879664	chr5:178974576	T/G	cg26516362	chr5:178986906	RUFY1	0.41	6.02	0.35	5.78e-9	Lung cancer;
CESC	cis	rs60871478	0.787	rs4720928	chr7:808002	T/C	cg27478167	chr7:817139	HEATR2	-0.46	-5.41	-0.32	1.39e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs4835473	0.932	rs4597770	chr4:144656392	C/A	cg25736465	chr4:144833511	NA	-0.33	-5.3	-0.31	2.48e-7	Immature fraction of reticulocytes;
CESC	cis	rs4727027	0.804	rs13231262	chr7:148886058	C/T	cg23583168	chr7:148888333	NA	-0.87	-13.55	-0.64	3.91e-32	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs514406	0.861	rs7417821	chr1:53295117	A/G	cg08859206	chr1:53392774	SCP2	-0.61	-8.9	-0.48	9.3e-17	Monocyte count;
CESC	trans	rs12599106	0.707	rs2163977	chr16:34916134	A/G	cg21548813	chr6:291882	DUSP22	-0.71	-9.4	-0.5	2.71e-18	Menopause (age at onset);
CESC	trans	rs11088226	0.681	rs2833901	chr21:33939318	T/C	cg09050820	chr6:167586206	TCP10L2	0.84	7.8	0.43	1.41e-13	Gastritis;
CESC	cis	rs8028182	0.636	rs11636199	chr15:75825337	A/G	cg20655648	chr15:75932815	IMP3	0.5	6.25	0.36	1.66e-9	Sudden cardiac arrest;
CESC	cis	rs2415984	0.622	rs1761025	chr14:46930439	T/C	cg14871534	chr14:47121158	RPL10L	0.36	5.52	0.32	7.98e-8	Number of children ever born;
CESC	cis	rs4975709	0.569	rs931509	chr5:1858821	A/T	cg10800226	chr5:1850261	NA	0.36	5.72	0.33	2.93e-8	Cardiovascular disease risk factors;
CESC	cis	rs7772486	0.754	rs702306	chr6:145991029	T/C	cg23711669	chr6:146136114	FBXO30	-0.96	-14.73	-0.67	2.74e-36	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs1728785	1.000	rs11647432	chr16:68565426	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.61	7.42	0.41	1.57e-12	Ulcerative colitis;
CESC	cis	rs8177253	1.000	rs1525892	chr3:133484712	C/T	cg01448562	chr3:133502909	NA	-0.41	-5.78	-0.33	2.04e-8	Iron status biomarkers;
CESC	cis	rs2637266	0.703	rs11001859	chr10:78464869	G/C	cg18941641	chr10:78392320	NA	0.38	6.86	0.39	4.82e-11	Pulmonary function;
CESC	trans	rs7246657	0.891	rs7253114	chr19:37988725	G/A	cg01833234	chr11:6592585	DNHD1	0.52	6.16	0.35	2.73e-9	Coronary artery calcification;
CESC	cis	rs7178572	0.633	rs12900004	chr15:77844904	A/G	cg22256960	chr15:77711686	NA	-0.48	-6.12	-0.35	3.32e-9	Type 2 diabetes;
CESC	cis	rs12956009	0.518	rs3889651	chr18:44865012	T/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.51	6.73	0.38	1.02e-10	Educational attainment (years of education);
CESC	cis	rs4727027	0.899	rs11768971	chr7:148825826	C/G	cg23583168	chr7:148888333	NA	-0.79	-12.21	-0.6	1.63e-27	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs6701037	1.000	rs7512413	chr1:175124789	C/T	cg00321850	chr1:175162397	KIAA0040	-0.42	-5.88	-0.34	1.22e-8	Alcohol dependence;
CESC	cis	rs3785574	0.962	rs7215915	chr17:61828385	C/T	cg06420487	chr17:61919686	SMARCD2	0.45	5.39	0.31	1.56e-7	Height;
CESC	cis	rs2836950	0.565	rs2836945	chr21:40596757	C/T	cg11644478	chr21:40555479	PSMG1	-0.52	-7.02	-0.4	1.82e-11	Menarche (age at onset);
CESC	cis	rs12620999	0.774	rs13402764	chr2:237951984	C/T	cg23555395	chr2:238036564	NA	-0.47	-6.25	-0.36	1.66e-9	Systemic lupus erythematosus;
CESC	cis	rs1030877	0.515	rs2679895	chr2:105906480	C/G	cg02079111	chr2:105885981	TGFBRAP1	0.47	6.18	0.36	2.35e-9	Obesity-related traits;
CESC	cis	rs1499972	0.938	rs817509	chr3:117750861	A/G	cg07612923	chr3:117604196	NA	-0.79	-5.81	-0.34	1.75e-8	Schizophrenia;
CESC	cis	rs2191566	0.576	rs396148	chr19:44494548	A/T	cg20607764	chr19:44506953	ZNF230	0.45	5.71	0.33	2.96e-8	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs1468333	0.592	rs217272	chr5:137486426	A/G	cg27119451	chr5:137514611	BRD8;KIF20A	0.49	5.2	0.3	3.96e-7	Resting heart rate;
CESC	cis	rs7666738	0.830	rs17027225	chr4:99028564	C/T	cg17366294	chr4:99064904	C4orf37	0.62	8.95	0.48	6.32e-17	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2243480	1.000	rs7778911	chr7:65694506	T/C	cg13147721	chr7:65941812	NA	0.98	9.24	0.49	8.25e-18	Diabetic kidney disease;
CESC	cis	rs10484885	0.690	rs292236	chr6:90528422	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.85	-9.71	-0.51	2.91e-19	QRS interval (sulfonylurea treatment interaction);
CESC	cis	rs3785574	0.927	rs2008018	chr17:61954471	C/T	cg06873352	chr17:61820015	STRADA	0.45	6.73	0.38	1.03e-10	Height;
CESC	cis	rs2404602	0.647	rs2404600	chr15:77173557	C/T	cg06336613	chr15:77223807	RCN2	0.4	5.07	0.3	7.56e-7	Blood metabolite levels;
CESC	cis	rs832540	0.629	rs10055224	chr5:56081201	C/T	cg22800045	chr5:56110881	MAP3K1	-0.44	-5.4	-0.31	1.48e-7	Coronary artery disease;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg16280946	chr22:20716554	NA	-0.47	-6.34	-0.36	1.01e-9	Gut microbiota (bacterial taxa);
CESC	trans	rs1814175	0.708	rs10839464	chr11:49981386	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.43	-6.26	-0.36	1.53e-9	Height;
CESC	cis	rs9322193	0.926	rs9766562	chr6:150109845	C/G	cg05861140	chr6:150128134	PCMT1	-0.35	-5.07	-0.3	7.48e-7	Lung cancer;
CESC	cis	rs875971	0.545	rs1796222	chr7:66057154	T/C	cg18527119	chr7:66119851	NA	0.46	5.09	0.3	6.71e-7	Aortic root size;
CESC	cis	rs1552244	1.000	rs17032299	chr3:10087638	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.89	11.77	0.59	5.23e-26	Alzheimer's disease;
CESC	cis	rs17253792	0.732	rs8017891	chr14:56172967	A/G	cg01858014	chr14:56050164	KTN1	0.61	5.55	0.32	7e-8	Putamen volume;
CESC	cis	rs6084875	0.733	rs6037959	chr20:4741723	A/G	cg05143360	chr20:4741328	NA	0.54	7.39	0.41	1.89e-12	Systemic lupus erythematosus;
CESC	cis	rs10504229	0.679	rs1596142	chr8:58032406	G/A	cg24829409	chr8:58192753	C8orf71	-0.46	-5.93	-0.34	9.43e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs2404602	0.684	rs8029283	chr15:76837140	A/G	cg23625390	chr15:77176239	SCAPER	-0.44	-6.09	-0.35	3.98e-9	Blood metabolite levels;
CESC	cis	rs9811920	0.515	rs792836	chr3:99476384	G/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.33	-5.42	-0.32	1.37e-7	Axial length;
CESC	cis	rs7618501	0.602	rs2071206	chr3:50160109	G/A	cg24110177	chr3:50126178	RBM5	0.54	7.58	0.42	5.85e-13	Intelligence (multi-trait analysis);
CESC	cis	rs12477438	0.953	rs3851334	chr2:99794704	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.67	-7.85	-0.43	1.06e-13	Chronic sinus infection;
CESC	cis	rs8017423	0.904	rs12433417	chr14:90804028	A/G	cg14092571	chr14:90743983	NA	0.57	8.86	0.48	1.18e-16	Mortality in heart failure;
CESC	cis	rs7927771	1.000	rs7947730	chr11:47786184	C/T	cg18512352	chr11:47633146	NA	-0.61	-9.64	-0.51	4.87e-19	Subjective well-being;
CESC	cis	rs10504229	0.683	rs72649192	chr8:58110490	T/C	cg22535103	chr8:58192502	C8orf71	-0.94	-9.92	-0.52	6.44e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs17376456	0.877	rs7728736	chr5:93404277	C/T	cg21475434	chr5:93447410	FAM172A	0.8	7.26	0.41	4.26e-12	Diabetic retinopathy;
CESC	cis	rs8062405	0.964	rs11860513	chr16:28825420	C/T	cg08761264	chr16:28874980	SH2B1	-0.47	-5.86	-0.34	1.34e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs909674	0.541	rs5757655	chr22:39797178	C/G	cg11247378	chr22:39784982	NA	0.6	9.06	0.49	2.94e-17	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs1215050	0.755	rs6843393	chr4:98822619	C/G	cg05340658	chr4:99064831	C4orf37	0.51	6.58	0.37	2.5e-10	Waist-to-hip ratio adjusted for body mass index;
CESC	trans	rs2727020	0.587	rs1164658	chr11:49298551	C/A	cg03929089	chr4:120376271	NA	0.78	11.91	0.59	1.83e-26	Coronary artery disease;
CESC	cis	rs2361718	0.603	rs12951255	chr17:78085597	A/G	cg21238619	chr17:78079768	GAA	-0.37	-5.92	-0.34	1.01e-8	Yeast infection;
CESC	cis	rs854765	0.647	rs854769	chr17:18019011	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.61	-8.36	-0.46	3.54e-15	Total body bone mineral density;
CESC	cis	rs4148883	0.651	rs2851301	chr4:100010127	C/T	cg12011299	chr4:100065546	ADH4	0.66	9.57	0.51	7.76e-19	Alcohol dependence;
CESC	cis	rs1832871	0.672	rs13437296	chr6:158762819	A/C	cg07165851	chr6:158734300	TULP4	0.58	6.19	0.36	2.31e-9	Height;
CESC	cis	rs7811142	1.000	rs4463351	chr7:100078226	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.87	9.07	0.49	2.8e-17	Platelet count;
CESC	cis	rs7666738	0.830	rs62321597	chr4:99014221	C/A	cg18180107	chr4:99064573	C4orf37	0.4	5.3	0.31	2.48e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9399137	0.507	rs4896128	chr6:135349756	A/G	cg24558204	chr6:135376177	HBS1L	-0.67	-9.51	-0.5	1.18e-18	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	cis	rs9916302	0.904	rs55689507	chr17:37404436	G/C	cg00129232	chr17:37814104	STARD3	-0.55	-6.96	-0.39	2.68e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs875971	0.965	rs10267430	chr7:65743023	G/T	cg10691866	chr7:65817282	TPST1	0.33	5.62	0.33	4.91e-8	Aortic root size;
CESC	cis	rs6089584	0.545	rs6089578	chr20:60554636	G/T	cg24733560	chr20:60626293	TAF4	0.42	6.12	0.35	3.33e-9	Body mass index;
CESC	cis	rs12950390	0.853	rs17773010	chr17:45858297	C/T	cg00777063	chr17:45855553	NA	-0.39	-5.77	-0.33	2.26e-8	IgG glycosylation;
CESC	cis	rs950169	1.000	rs1911155	chr15:84787635	A/G	cg17507749	chr15:85114479	UBE2QP1	0.61	6.67	0.38	1.53e-10	Schizophrenia;
CESC	cis	rs6460942	0.915	rs62448600	chr7:12454944	T/G	cg20607287	chr7:12443886	VWDE	-0.78	-9.15	-0.49	1.61e-17	Coronary artery disease;
CESC	cis	rs1355223	0.867	rs1377495	chr11:34682962	A/C	cg11058730	chr11:34937778	PDHX;APIP	0.46	5.96	0.34	7.99e-9	Systemic lupus erythematosus and Systemic sclerosis;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg26081025	chr14:92570361	ATXN3	0.42	6.17	0.35	2.58e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs910316	0.789	rs175457	chr14:75584507	C/T	cg08847533	chr14:75593920	NEK9	-0.9	-15.66	-0.69	1.36e-39	Height;
CESC	cis	rs7520050	0.931	rs6697557	chr1:46307809	G/A	cg24296786	chr1:45957014	TESK2	0.42	5.39	0.31	1.6e-7	Red blood cell count;Reticulocyte count;
CESC	cis	rs9290065	0.519	rs956447	chr3:160668917	G/C	cg03342759	chr3:160939853	NMD3	-0.42	-5.45	-0.32	1.15e-7	Kawasaki disease;
CESC	cis	rs807669	0.500	rs5746668	chr22:19149151	T/G	cg02655711	chr22:19163373	SLC25A1	0.57	6.72	0.38	1.08e-10	Metabolite levels;
CESC	cis	rs17376456	0.877	rs17083455	chr5:93446380	A/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.57	5.08	0.3	7.18e-7	Diabetic retinopathy;
CESC	cis	rs7208859	0.573	rs11654035	chr17:29136426	T/C	cg19761014	chr17:28927070	LRRC37B2	0.78	6.27	0.36	1.45e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs2228479	0.702	rs62056100	chr16:89939753	C/T	cg00800038	chr16:89945340	TCF25	-0.95	-7.79	-0.43	1.48e-13	Skin colour saturation;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02161084	chr15:73989526	CD276	-0.53	-6.42	-0.37	6.18e-10	Gut microbiome composition (summer);
CESC	cis	rs2882667	0.858	rs11957633	chr5:138364394	T/C	cg04439458	chr5:138467593	SIL1	-0.4	-6.21	-0.36	2.06e-9	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs7940866	0.838	rs10750455	chr11:130800330	C/T	cg14779329	chr11:130786720	SNX19	0.34	5.2	0.3	4.02e-7	Schizophrenia;
CESC	cis	rs16854884	0.584	rs2164554	chr3:143755528	A/G	cg06585982	chr3:143692056	C3orf58	0.47	5.86	0.34	1.34e-8	Economic and political preferences (feminism/equality);
CESC	cis	rs514406	0.621	rs1930306	chr1:53195686	C/G	cg08859206	chr1:53392774	SCP2	0.6	7.73	0.43	2.28e-13	Monocyte count;
CESC	cis	rs1448094	0.512	rs6539931	chr12:86247473	C/T	cg02569458	chr12:86230093	RASSF9	0.49	7.27	0.41	3.98e-12	Major depressive disorder;
CESC	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg24642844	chr7:1081250	C7orf50	-0.78	-9.53	-0.51	1.05e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs10883723	0.641	rs80146619	chr10:104405850	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.57	5.93	0.34	9.56e-9	Allergic disease (asthma, hay fever or eczema);
CESC	trans	rs12599106	0.625	rs12923277	chr16:34896261	G/A	cg05064044	chr6:292385	DUSP22	-0.65	-8.13	-0.45	1.64e-14	Menopause (age at onset);
CESC	cis	rs921968	0.565	rs6757772	chr2:219618497	T/G	cg02176678	chr2:219576539	TTLL4	-0.43	-7.65	-0.43	3.63e-13	Mean corpuscular hemoglobin concentration;
CESC	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg26338869	chr17:61819248	STRADA	0.67	8.78	0.47	2.04e-16	Prudent dietary pattern;
CESC	cis	rs1215050	0.791	rs2865943	chr4:98778449	C/T	cg05340658	chr4:99064831	C4orf37	0.52	6.69	0.38	1.3e-10	Waist-to-hip ratio adjusted for body mass index;
CESC	trans	rs17772222	0.740	rs28493481	chr14:88977835	G/T	cg16524936	chr4:1340807	KIAA1530	-0.5	-6.01	-0.35	5.96e-9	Coronary artery calcification;
CESC	cis	rs6088590	0.735	rs2273684	chr20:33529766	G/T	cg08999081	chr20:33150536	PIGU	-0.52	-8.12	-0.45	1.74e-14	Coronary artery disease;
CESC	cis	rs5753618	0.583	rs8141150	chr22:31800336	C/T	cg02404636	chr22:31891804	SFI1	0.41	5.6	0.33	5.36e-8	Colorectal cancer;
CESC	cis	rs12898370	0.651	rs11634056	chr15:77539914	G/A	cg17802220	chr15:77601643	NA	-0.55	-6.03	-0.35	5.51e-9	Risky sexual behaviors (alcohol dependence interaction);
CESC	cis	rs8177253	0.829	rs9813689	chr3:133514822	C/T	cg12373951	chr3:133503437	NA	0.5	7.22	0.41	5.64e-12	Iron status biomarkers;
CESC	cis	rs2197308	0.692	rs1904964	chr12:37933241	T/A	cg26384229	chr12:38710491	ALG10B	0.71	10.58	0.54	4.86e-22	Morning vs. evening chronotype;
CESC	cis	rs6582630	0.502	rs10880092	chr12:38262965	A/T	cg26384229	chr12:38710491	ALG10B	0.72	10.17	0.53	1.01e-20	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs514406	0.621	rs2003250	chr1:53196666	T/C	cg16325326	chr1:53192061	ZYG11B	-1.0	-17.81	-0.74	3.35e-47	Monocyte count;
CESC	cis	rs9393777	0.513	rs9368447	chr6:26646674	A/C	cg14345882	chr6:26364793	BTN3A2	0.41	5.12	0.3	5.89e-7	Intelligence (multi-trait analysis);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg13643966	chr4:124036498	SPATA5	0.55	7.39	0.41	1.88e-12	Fibrinogen levels;
CESC	trans	rs9693444	0.898	rs4732697	chr8:29519861	A/G	cg21871583	chr3:15374148	SH3BP5	-0.4	-6.43	-0.37	5.8e-10	Breast cancer;
CESC	cis	rs4665809	0.941	rs11126336	chr2:26245931	C/T	cg08470875	chr2:26401718	FAM59B	-0.47	-5.05	-0.3	8.27e-7	Gut microbiome composition (summer);
CESC	cis	rs1728785	1.000	rs1749791	chr16:68572347	C/T	cg02972257	chr16:68554789	NA	-0.55	-6.34	-0.36	9.7e-10	Ulcerative colitis;
CESC	cis	rs4423214	1.000	rs12790010	chr11:71170653	T/C	cg05163923	chr11:71159392	DHCR7	0.78	10.34	0.54	2.91e-21	Vitamin D levels;
CESC	cis	rs2120019	1.000	rs12898259	chr15:75369780	G/A	cg17294928	chr15:75287854	SCAMP5	-0.59	-6.65	-0.38	1.64e-10	Blood trace element (Zn levels);
CESC	cis	rs10911232	0.507	rs4652764	chr1:182994115	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.84	13.2	0.63	6.49e-31	Hypertriglyceridemia;
CESC	cis	rs67311347	1.000	rs9854493	chr3:40423622	T/C	cg24209194	chr3:40518798	ZNF619	0.49	6.05	0.35	5e-9	Renal cell carcinoma;
CESC	cis	rs2011503	1.000	rs4808951	chr19:19550306	C/G	cg11584989	chr19:19387371	SF4	0.62	7.22	0.41	5.54e-12	Bipolar disorder;
CESC	cis	rs875971	0.862	rs778705	chr7:65861115	G/A	cg18252515	chr7:66147081	NA	-0.46	-6.05	-0.35	5e-9	Aortic root size;
CESC	cis	rs12497850	0.829	rs12636030	chr3:49182237	A/G	cg03060546	chr3:49711283	APEH	0.55	6.66	0.38	1.6e-10	Parkinson's disease;
CESC	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	7.63	0.42	4.35e-13	Prudent dietary pattern;
CESC	cis	rs3824867	0.920	rs7105122	chr11:47449544	A/G	cg20307385	chr11:47447363	PSMC3	0.48	5.68	0.33	3.5e-8	Mean corpuscular hemoglobin;
CESC	cis	rs9926296	0.533	rs10852623	chr16:89865242	T/C	cg07648498	chr16:89883185	FANCA	0.49	6.19	0.36	2.28e-9	Vitiligo;
CESC	cis	rs3806843	1.000	rs3756342	chr5:140165624	G/A	cg26395211	chr5:140044315	WDR55	-0.42	-5.43	-0.32	1.26e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs3768617	0.510	rs1413390	chr1:183096634	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.89	14.39	0.66	4.39e-35	Fuchs's corneal dystrophy;
CESC	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg10295955	chr4:187884368	NA	-1.04	-20.81	-0.79	1.12e-57	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2404602	0.655	rs8028294	chr15:77084877	T/C	cg26408565	chr15:76604113	ETFA	-0.38	-5.52	-0.32	8.03e-8	Blood metabolite levels;
CESC	cis	rs7551222	0.752	rs35270244	chr1:204548416	A/C	cg20240347	chr1:204465584	NA	-0.27	-5.51	-0.32	8.41e-8	Schizophrenia;
CESC	trans	rs123509	0.913	rs121993	chr3:42776601	T/C	cg22035501	chr5:112073398	APC	0.57	6.07	0.35	4.49e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs2456568	0.802	rs1108910	chr11:93629677	C/T	cg26875233	chr11:93583750	C11orf90	0.3	5.31	0.31	2.27e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
CESC	cis	rs400736	0.729	rs9434949	chr1:8006083	C/G	cg25007680	chr1:8021821	PARK7	-0.57	-7.77	-0.43	1.68e-13	Response to antidepressants and depression;
CESC	cis	rs7927771	0.832	rs7105851	chr11:47383275	T/C	cg20307385	chr11:47447363	PSMC3	0.61	7.28	0.41	3.78e-12	Subjective well-being;
CESC	cis	rs10242455	0.702	rs73713531	chr7:99222379	C/T	cg25640893	chr7:99214727	ZNF498	0.73	5.11	0.3	6.08e-7	Blood metabolite levels;
CESC	cis	rs4253772	0.530	rs11090865	chr22:46731689	G/T	cg10541313	chr22:46663664	TTC38	0.65	5.13	0.3	5.65e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs12541335	0.590	rs11136002	chr8:22217082	C/T	cg26039829	chr8:22132926	PIWIL2	0.38	5.84	0.34	1.52e-8	Hypertriglyceridemia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04951051	chr10:79601860	DLG5	-0.48	-5.99	-0.35	6.68e-9	Gut microbiome composition (summer);
CESC	cis	rs7824557	0.628	rs7841394	chr8:11185671	G/T	cg21775007	chr8:11205619	TDH	0.52	8.04	0.44	3.07e-14	Retinal vascular caliber;
CESC	cis	rs7589728	0.563	rs80324973	chr2:88447264	T/G	cg14558114	chr2:88469736	THNSL2	0.57	5.4	0.31	1.5e-7	Plasma clusterin levels;
CESC	cis	rs10504229	0.953	rs72652908	chr8:58191324	G/A	cg24829409	chr8:58192753	C8orf71	-0.76	-9.93	-0.52	5.87e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs2066819	0.892	rs77415512	chr12:56627300	A/G	cg26714650	chr12:56694279	CS	-1.53	-10.32	-0.54	3.19e-21	Psoriasis vulgaris;
CESC	cis	rs9322193	0.923	rs9688517	chr6:150061791	T/C	cg09699651	chr6:150184138	LRP11	0.39	5.04	0.3	8.69e-7	Lung cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26796727	chr8:145634724	CPSF1	0.6	7.1	0.4	1.12e-11	Gut microbiome composition (summer);
CESC	cis	rs1552244	0.554	rs6762397	chr3:10007840	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.55	-7.05	-0.4	1.58e-11	Alzheimer's disease;
CESC	cis	rs17253792	0.822	rs58569951	chr14:56152245	T/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.7	5.41	0.32	1.39e-7	Putamen volume;
CESC	cis	rs11166629	1.000	rs966659	chr8:135639045	C/T	cg21672855	chr8:135614777	ZFAT	-0.4	-5.13	-0.3	5.49e-7	Smoking quantity;
CESC	cis	rs5769765	1.000	rs4824112	chr22:50284345	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.51	-5.61	-0.33	5.08e-8	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26193882	chr7:74489851	WBSCR16	0.51	6.03	0.35	5.62e-9	Gut microbiome composition (summer);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg27397625	chr6:42952298	PPP2R5D	-0.47	-6.98	-0.39	2.31e-11	Gambling;
CESC	cis	rs13118159	0.641	rs4974598	chr4:1313220	C/T	cg20887711	chr4:1340912	KIAA1530	0.56	7.79	0.43	1.56e-13	Longevity;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg26207357	chr2:190539199	NA	0.49	6.4	0.37	6.97e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs1862618	0.620	rs189695	chr5:56225769	T/C	cg22800045	chr5:56110881	MAP3K1	0.59	7.76	0.43	1.86e-13	Initial pursuit acceleration;
CESC	cis	rs7618915	0.501	rs11714030	chr3:52765882	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	8.39	0.46	2.91e-15	Bipolar disorder;
CESC	trans	rs1814175	0.645	rs28436748	chr11:50046422	G/A	cg15704280	chr7:45808275	SEPT13	-1.0	-18.7	-0.75	2.39e-50	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07466433	chr2:7005728	CMPK2	0.56	6.63	0.38	1.93e-10	Gut microbiome composition (summer);
CESC	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg22907277	chr7:1156413	C7orf50	0.42	5.95	0.34	8.56e-9	Longevity;Endometriosis;
CESC	cis	rs854765	0.547	rs6502633	chr17:17941037	G/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.63	8.89	0.48	9.49e-17	Total body bone mineral density;
CESC	cis	rs9457247	1.000	rs1819333	chr6:167373547	G/T	cg25258033	chr6:167368657	RNASET2	0.43	6.47	0.37	4.84e-10	Crohn's disease;
CESC	cis	rs875971	0.545	rs2460427	chr7:65619205	T/C	cg25405998	chr7:65216604	CCT6P1	-0.45	-5.06	-0.3	7.71e-7	Aortic root size;
CESC	cis	rs1005277	0.602	rs1740743	chr10:38519222	C/T	cg25427524	chr10:38739819	LOC399744	-0.73	-10.95	-0.56	2.97e-23	Extrinsic epigenetic age acceleration;
CESC	cis	rs1775715	0.737	rs2778661	chr10:32159191	C/T	cg18675610	chr10:32216311	ARHGAP12	0.35	5.4	0.32	1.45e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21026086	chr20:42939820	FITM2	0.61	7.05	0.4	1.51e-11	Gut microbiome composition (summer);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg03951180	chr7:72742151	TRIM50;FKBP6	0.47	7.06	0.4	1.48e-11	Fibrinogen levels;
CESC	cis	rs3749237	0.595	rs4855873	chr3:49459114	A/C	cg07636037	chr3:49044803	WDR6	0.62	9.09	0.49	2.43e-17	Resting heart rate;
CESC	cis	rs76419734	0.558	rs3796920	chr4:106544526	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.53	5.15	0.3	5.01e-7	Post bronchodilator FEV1;
CESC	cis	rs992157	0.710	rs10167446	chr2:219056866	A/G	cg20019365	chr2:219134978	PNKD;AAMP	0.64	8.73	0.47	2.94e-16	Colorectal cancer;
CESC	cis	rs11122272	0.735	rs2486741	chr1:231516450	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.57	-7.82	-0.43	1.29e-13	Hemoglobin concentration;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13704629	chr14:73396469	DCAF4	-0.56	-6.28	-0.36	1.42e-9	Gut microbiome composition (summer);
CESC	cis	rs4819052	0.885	rs28576202	chr21:46674684	G/A	cg11663144	chr21:46675770	NA	-0.63	-9.84	-0.52	1.12e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs9611565	0.592	rs9611612	chr22:41961189	T/C	cg06634786	chr22:41940651	POLR3H	-0.62	-6.84	-0.39	5.38e-11	Vitiligo;
CESC	cis	rs782590	0.738	rs4312532	chr2:55812061	A/G	cg18811423	chr2:55921094	PNPT1	-0.67	-10.16	-0.53	1.06e-20	Metabolic syndrome;
CESC	cis	rs6693567	0.565	rs698913	chr1:150299145	G/A	cg09579323	chr1:150459698	TARS2	0.49	6.28	0.36	1.35e-9	Migraine;
CESC	cis	rs4835473	0.838	rs34521499	chr4:144698781	T/C	cg25736465	chr4:144833511	NA	-0.42	-6.42	-0.37	6.21e-10	Immature fraction of reticulocytes;
CESC	cis	rs9733	0.650	rs4970923	chr1:150608300	A/G	cg18016565	chr1:150552671	MCL1	-0.42	-6.96	-0.39	2.64e-11	Tonsillectomy;
CESC	trans	rs4073582	0.595	rs555360	chr11:65960061	T/C	cg12039611	chr1:156786653	NTRK1;SH2D2A	0.34	6.07	0.35	4.37e-9	Gout;
CESC	cis	rs3947	0.789	rs9009	chr8:11702006	A/T	cg00262122	chr8:11665843	FDFT1	0.52	6.13	0.35	3.11e-9	Blood protein levels;
CESC	trans	rs6054906	0.710	rs6117744	chr20:7265038	A/C	cg21220336	chr9:79008793	RFK	0.46	6.28	0.36	1.36e-9	Response to amphetamines;
CESC	cis	rs9911578	1.000	rs2531729	chr17:56539890	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.41	5.52	0.32	7.9e-8	Intelligence (multi-trait analysis);
CESC	cis	rs10752881	1.000	rs10797812	chr1:182984597	A/G	ch.1.3577855R	chr1:183094577	LAMC1	-0.85	-13.34	-0.63	2.02e-31	Colorectal cancer;
CESC	cis	rs13118159	0.778	rs12640984	chr4:1338834	G/A	cg02018176	chr4:1364513	KIAA1530	0.44	6.28	0.36	1.41e-9	Longevity;
CESC	cis	rs9902453	0.967	rs12449783	chr17:28527653	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	7.7	0.43	2.63e-13	Coffee consumption (cups per day);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00242597	chr9:19380425	RPS6	-0.66	-8.0	-0.44	3.88e-14	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00990212	chr12:6641042	NCAPD2	-0.65	-8.24	-0.45	8.17e-15	Gut microbiome composition (summer);
CESC	cis	rs703842	0.964	rs10431552	chr12:58178148	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.73	9.5	0.5	1.32e-18	Multiple sclerosis;
CESC	cis	rs3924048	0.574	rs11121928	chr1:12615888	C/G	cg00291366	chr1:12616550	NA	0.4	7.21	0.4	5.88e-12	Optic cup area;
CESC	cis	rs17428076	0.831	rs55957712	chr2:172587956	C/T	cg13550731	chr2:172543902	DYNC1I2	0.47	5.3	0.31	2.48e-7	Myopia;
CESC	cis	rs7301826	1.000	rs1609985	chr12:131320170	A/G	cg11011512	chr12:131303247	STX2	0.42	5.23	0.31	3.48e-7	Plasma plasminogen activator levels;
CESC	cis	rs7193541	0.564	rs4888274	chr16:74706298	A/T	cg01733217	chr16:74700730	RFWD3	1.04	20.73	0.79	2.17e-57	Multiple myeloma;
CESC	cis	rs4713118	0.587	rs61471148	chr6:28037032	T/A	cg26335602	chr6:28129616	ZNF389	0.5	6.14	0.35	2.97e-9	Parkinson's disease;
CESC	cis	rs597539	0.652	rs613128	chr11:68638058	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.77	9.59	0.51	6.99e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs6541297	0.703	rs586712	chr1:230315242	A/G	cg20703242	chr1:230279135	GALNT2	-0.43	-5.62	-0.33	4.84e-8	Coronary artery disease;
CESC	cis	rs7927592	0.956	rs948315	chr11:68309140	T/C	cg16797656	chr11:68205561	LRP5	0.4	5.59	0.32	5.55e-8	Total body bone mineral density;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg13491959	chr9:139292811	SNAPC4	0.53	7.86	0.43	9.69e-14	Fibrinogen levels;
CESC	cis	rs2249625	0.967	rs4510633	chr6:72924275	A/G	cg18830697	chr6:72922368	RIMS1	-0.43	-6.16	-0.35	2.68e-9	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CESC	cis	rs2404618	0.624	rs28439223	chr8:1476901	C/G	cg13402656	chr8:1511478	DLGAP2	-0.51	-7.04	-0.4	1.65e-11	Lung cancer;
CESC	cis	rs7216064	1.000	rs4271626	chr17:65930133	G/A	cg12091567	chr17:66097778	LOC651250	-0.75	-7.69	-0.43	2.84e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs4803468	1.000	rs2241708	chr19:41912270	C/T	cg14132834	chr19:41945861	ATP5SL	-0.57	-7.03	-0.4	1.7e-11	Height;
CESC	cis	rs7615952	0.576	rs6804482	chr3:125815762	C/T	cg02807482	chr3:125708958	NA	-0.4	-5.17	-0.3	4.73e-7	Blood pressure (smoking interaction);
CESC	cis	rs9911578	1.000	rs2531732	chr17:56548420	T/A	cg12560992	chr17:57184187	TRIM37	-0.92	-15.31	-0.69	2.4e-38	Intelligence (multi-trait analysis);
CESC	cis	rs62432291	0.681	rs420137	chr6:159652931	G/C	cg14500486	chr6:159655392	FNDC1	-0.61	-6.04	-0.35	5.2e-9	Joint mobility (Beighton score);
CESC	trans	rs4665809	1.000	rs6546767	chr2:26328746	A/G	cg09258813	chr8:37823409	ADRB3	-0.37	-6.1	-0.35	3.65e-9	Gut microbiome composition (summer);
CESC	trans	rs916888	0.821	rs199525	chr17:44847834	T/G	cg22433210	chr17:43662623	NA	0.96	10.7	0.55	1.87e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs13191362	0.507	rs13211655	chr6:163177542	C/G	cg06582575	chr6:163149167	PACRG;PARK2	0.49	5.52	0.32	8.21e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs9457247	0.765	rs9459836	chr6:167419105	G/A	cg23791538	chr6:167370224	RNASET2	-0.54	-7.48	-0.42	1.1e-12	Crohn's disease;
CESC	cis	rs116095464	0.558	rs28635197	chr5:279071	T/C	cg22496380	chr5:211416	CCDC127	-0.74	-8.46	-0.46	1.77e-15	Breast cancer;
CESC	cis	rs11209002	0.567	rs2224501	chr1:67532526	G/T	cg02640540	chr1:67518911	SLC35D1	0.48	5.47	0.32	1.04e-7	Crohn's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21249729	chr9:138392748	C9orf116;MRPS2	0.56	6.58	0.37	2.52e-10	Gut microbiome composition (summer);
CESC	cis	rs10191773	0.589	rs11676628	chr2:112953355	A/G	cg24977338	chr2:113188963	RGPD8;RGPD5	0.68	6.78	0.38	7.87e-11	Yeast infection;
CESC	cis	rs597539	0.690	rs497149	chr11:68626639	A/T	cg06028808	chr11:68637592	NA	0.48	5.73	0.33	2.68e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs3106136	0.546	rs2664880	chr4:95144177	T/A	cg11021082	chr4:95130006	SMARCAD1	-0.7	-11.56	-0.58	2.74e-25	Capecitabine sensitivity;
CESC	trans	rs916888	0.738	rs199515	chr17:44856641	C/G	cg10053473	chr17:62856997	LRRC37A3	0.65	7.43	0.42	1.5e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg16373769	chr10:30024815	SVIL	-0.47	-6.43	-0.37	5.95e-10	Fibrinogen levels;
CESC	cis	rs7216064	0.953	rs75231441	chr17:65885485	A/G	cg07042672	chr17:66097459	LOC651250	-0.52	-5.4	-0.31	1.5e-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs7223966	1.000	rs16947042	chr17:61766457	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	7.63	0.42	4.2e-13	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs67311347	1.000	rs2371186	chr3:40488713	G/C	cg09455208	chr3:40491958	NA	0.49	8.04	0.44	2.91e-14	Renal cell carcinoma;
CESC	cis	rs9611565	0.512	rs139562	chr22:42196684	G/C	cg06481639	chr22:41940642	POLR3H	-0.58	-5.78	-0.33	2.11e-8	Vitiligo;
CESC	trans	rs916888	0.773	rs199457	chr17:44795469	C/T	cg22433210	chr17:43662623	NA	0.99	11.09	0.56	9.69e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs9649213	0.593	rs736754	chr7:97931559	C/T	cg24562669	chr7:97807699	LMTK2	0.48	6.92	0.39	3.3e-11	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs801193	0.935	rs2286683	chr7:66129843	G/A	cg14393609	chr7:65229607	NA	-0.45	-6.02	-0.35	5.91e-9	Aortic root size;
CESC	cis	rs6537837	0.793	rs17575742	chr1:110083603	C/A	cg05049280	chr1:110155535	GNAT2	0.38	5.3	0.31	2.45e-7	Major depressive disorder;
CESC	cis	rs35110281	0.693	rs2838345	chr21:45092715	C/T	cg21573476	chr21:45109991	RRP1B	-0.53	-8.0	-0.44	3.92e-14	Mean corpuscular volume;
CESC	cis	rs10752881	1.000	rs10737237	chr1:182989269	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.84	13.31	0.63	2.66e-31	Colorectal cancer;
CESC	cis	rs35110281	0.667	rs4819285	chr21:45118970	C/T	cg04455712	chr21:45112962	RRP1B	-0.49	-7.81	-0.43	1.33e-13	Mean corpuscular volume;
CESC	cis	rs959260	1.000	rs4789186	chr17:73386086	C/T	cg12999837	chr17:73267436	MIF4GD	-0.51	-5.74	-0.33	2.57e-8	Systemic lupus erythematosus;
CESC	cis	rs1372520	0.684	rs2619368	chr4:90729747	T/G	cg15133208	chr4:90757351	SNCA	-0.43	-5.79	-0.33	2.02e-8	Neuroticism;
CESC	cis	rs6835098	0.924	rs13125240	chr4:174151619	T/C	cg08422745	chr4:174089978	GALNT7	0.71	9.0	0.48	4.41e-17	Dementia and core Alzheimer's disease neuropathologic changes;
CESC	cis	rs7640424	0.649	rs6795280	chr3:107876232	T/C	cg09227934	chr3:107805635	CD47	-0.44	-5.67	-0.33	3.75e-8	Body mass index;
CESC	cis	rs782590	0.935	rs10460508	chr2:55882565	A/C	cg18811423	chr2:55921094	PNPT1	0.79	12.9	0.62	6.94e-30	Metabolic syndrome;
CESC	cis	rs8077577	0.671	rs4925178	chr17:18252911	T/C	cg16794390	chr17:18148240	FLII	0.38	6.25	0.36	1.59e-9	Obesity-related traits;
CESC	cis	rs881375	0.967	rs1014529	chr9:123684943	C/G	cg00246817	chr9:123691163	NA	-0.41	-5.05	-0.3	8.25e-7	Rheumatoid arthritis;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg15420520	chr20:55043481	C20orf43	-0.47	-6.01	-0.35	6.19e-9	Ulcerative colitis;
CESC	cis	rs8180040	0.764	rs12630534	chr3:47001043	T/C	cg27129171	chr3:47204927	SETD2	0.66	9.69	0.51	3.31e-19	Colorectal cancer;
CESC	cis	rs7666738	0.791	rs10005118	chr4:99038196	A/C	cg03676636	chr4:99064102	C4orf37	0.33	5.12	0.3	5.85e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2836974	0.666	rs11910705	chr21:40685604	C/T	cg22974920	chr21:40686053	BRWD1	-0.46	-5.59	-0.32	5.73e-8	Cognitive function;
CESC	cis	rs2404602	0.684	rs965818	chr15:76866785	T/C	cg23625390	chr15:77176239	SCAPER	-0.42	-5.74	-0.33	2.53e-8	Blood metabolite levels;
CESC	cis	rs2637266	0.703	rs35654095	chr10:78472016	C/T	cg18941641	chr10:78392320	NA	0.4	7.3	0.41	3.46e-12	Pulmonary function;
CESC	trans	rs916888	0.773	rs199445	chr17:44817408	C/T	cg22433210	chr17:43662623	NA	0.98	11.39	0.57	9.63e-25	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs2120019	1.000	rs67544533	chr15:75361539	A/G	cg17294928	chr15:75287854	SCAMP5	-0.67	-7.47	-0.42	1.19e-12	Blood trace element (Zn levels);
CESC	cis	rs6964587	0.967	rs17164315	chr7:91659150	C/G	cg17063962	chr7:91808500	NA	0.57	7.86	0.43	9.58e-14	Breast cancer;
CESC	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg03188948	chr7:1209495	NA	0.7	6.71	0.38	1.2e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7666738	0.830	rs60411337	chr4:99046617	T/C	cg03676636	chr4:99064102	C4orf37	0.33	5.12	0.3	5.93e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1048257	0.553	rs2819421	chr14:105408811	A/G	cg17340268	chr14:105411764	AHNAK2	-0.51	-6.7	-0.38	1.22e-10	Systemic lupus erythematosus;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26877631	chr10:21823297	MLLT10	-0.56	-6.47	-0.37	4.65e-10	Gut microbiome composition (summer);
CESC	cis	rs9811920	0.609	rs793467	chr3:99539664	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.59	9.5	0.5	1.33e-18	Axial length;
CESC	cis	rs6728642	1.000	rs17037402	chr2:98014883	C/T	cg26665480	chr2:98280029	ACTR1B	-0.88	-6.29	-0.36	1.29e-9	Bipolar disorder lithium response (continuous) or schizophrenia;
CESC	cis	rs5769765	0.913	rs4824111	chr22:50284305	A/G	cg26441486	chr22:50317300	CRELD2	-0.4	-5.16	-0.3	4.95e-7	Schizophrenia;
CESC	cis	rs514406	0.505	rs269286	chr1:53169018	C/T	cg16325326	chr1:53192061	ZYG11B	-0.79	-13.18	-0.63	7.46e-31	Monocyte count;
CESC	cis	rs6964587	0.839	rs6949881	chr7:91433827	C/T	cg17063962	chr7:91808500	NA	0.51	6.55	0.37	2.99e-10	Breast cancer;
CESC	cis	rs9611565	0.512	rs768414	chr22:42135751	T/C	cg17376030	chr22:41985996	PMM1	-0.78	-8.33	-0.46	4.43e-15	Vitiligo;
CESC	cis	rs514406	0.505	rs146750	chr1:53183447	C/G	cg24675658	chr1:53192096	ZYG11B	-0.48	-6.0	-0.35	6.49e-9	Monocyte count;
CESC	trans	rs116095464	0.558	rs9312978	chr5:221930	C/G	cg00938859	chr5:1591904	SDHAP3	0.66	6.24	0.36	1.72e-9	Breast cancer;
CESC	cis	rs910316	0.967	rs2024653	chr14:75595154	G/A	cg08847533	chr14:75593920	NEK9	0.99	18.93	0.76	3.76e-51	Height;
CESC	cis	rs1124376	1.000	rs11712709	chr3:20139777	G/C	cg05072819	chr3:20081367	KAT2B	0.54	5.93	0.34	9.47e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs8031584	0.781	rs4779498	chr15:31177476	C/T	cg08704250	chr15:31115839	NA	-0.56	-7.37	-0.41	2.12e-12	Huntington's disease progression;
CESC	cis	rs4074961	0.565	rs10908362	chr1:38061706	G/C	cg13401533	chr1:37979913	MEAF6	0.43	5.45	0.32	1.13e-7	Axial length;
CESC	cis	rs11997175	0.574	rs12541661	chr8:33649856	T/G	ch.8.33884649F	chr8:33765107	NA	0.65	8.33	0.46	4.44e-15	Body mass index;
CESC	cis	rs1005277	0.579	rs2021649	chr10:38392122	C/T	cg25517755	chr10:38738941	LOC399744	-0.47	-6.04	-0.35	5.12e-9	Extrinsic epigenetic age acceleration;
CESC	trans	rs773506	0.565	rs4354431	chr9:94109406	T/A	cg02954284	chr22:21367447	MGC16703	0.35	6.27	0.36	1.44e-9	Type 2 diabetes nephropathy;
CESC	cis	rs4604732	0.603	rs4546958	chr1:247639478	G/C	cg12758973	chr1:247694275	LOC148824;OR2C3	0.38	5.38	0.31	1.63e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs7937682	0.924	rs489783	chr11:111520522	A/G	cg22437258	chr11:111473054	SIK2	0.7	9.35	0.5	3.83e-18	Primary sclerosing cholangitis;
CESC	cis	rs2228479	0.850	rs79244293	chr16:89896220	T/C	cg00800038	chr16:89945340	TCF25	-0.85	-6.5	-0.37	3.94e-10	Skin colour saturation;
CESC	cis	rs10089	1.000	rs3805612	chr5:127505316	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.75	10.09	0.53	1.74e-20	Ileal carcinoids;
CESC	cis	rs1799949	1.000	rs9646417	chr17:41424253	G/A	cg23758822	chr17:41437982	NA	1.05	15.6	0.69	2.24e-39	Menopause (age at onset);
CESC	cis	rs2228479	0.681	rs7196840	chr16:89959647	A/G	cg04013166	chr16:89971882	TCF25	0.72	8.84	0.48	1.39e-16	Skin colour saturation;
CESC	cis	rs8114671	0.562	rs6088653	chr20:33520321	T/C	cg06115741	chr20:33292138	TP53INP2	0.46	5.58	0.32	6.06e-8	Height;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg17546822	chr22:41865178	ACO2;PHF5A	0.51	7.61	0.42	4.86e-13	Gut microbiota (bacterial taxa);
CESC	cis	rs7659604	0.702	rs61217486	chr4:122693973	T/C	cg20573242	chr4:122745356	CCNA2	0.52	6.45	0.37	5.41e-10	Type 2 diabetes;
CESC	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg07677032	chr17:61819896	STRADA	0.45	5.92	0.34	1.01e-8	Prudent dietary pattern;
CESC	cis	rs9815354	0.812	rs73073364	chr3:41843058	T/C	cg03022575	chr3:42003672	ULK4	0.7	6.04	0.35	5.26e-9	Pulse pressure;Diastolic blood pressure;
CESC	trans	rs6089829	0.962	rs2872543	chr20:61665017	G/A	cg23505145	chr19:12996616	KLF1	0.52	6.71	0.38	1.15e-10	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7587476	0.784	rs62202001	chr2:215690359	C/G	cg04004882	chr2:215674386	BARD1	0.53	5.91	0.34	1.05e-8	Neuroblastoma;
CESC	cis	rs7829975	0.667	rs1877119	chr8:8707197	C/G	cg15556689	chr8:8085844	FLJ10661	0.41	5.04	0.3	8.76e-7	Mood instability;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg08156809	chr7:74071310	GTF2I	-0.5	-6.56	-0.37	2.81e-10	Ulcerative colitis;
CESC	cis	rs654950	0.875	rs2810550	chr1:41995339	T/C	cg06885757	chr1:42089581	HIVEP3	-0.44	-6.82	-0.39	6.21e-11	Airway imaging phenotypes;
CESC	cis	rs853679	0.517	rs9368556	chr6:28131153	T/C	cg26335602	chr6:28129616	ZNF389	0.52	6.81	0.39	6.59e-11	Depression;
CESC	cis	rs7666738	0.830	rs2114425	chr4:99023967	T/C	cg18180107	chr4:99064573	C4orf37	0.42	5.47	0.32	1.06e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9311474	0.539	rs12489828	chr3:52567014	G/T	cg17372223	chr3:52568218	NT5DC2	0.56	9.68	0.51	3.68e-19	Electroencephalogram traits;
CESC	cis	rs2656056	1	rs2656056	chr15:78722519	T/C	cg24631222	chr15:78858424	CHRNA5	-0.6	-6.99	-0.39	2.2e-11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
CESC	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg22907277	chr7:1156413	C7orf50	0.42	5.86	0.34	1.38e-8	Longevity;Endometriosis;
CESC	cis	rs721399	0.719	rs4646257	chr8:18262546	A/G	cg18736775	chr8:18248649	NAT2	0.47	5.07	0.3	7.41e-7	Blood metabolite levels;
CESC	cis	rs67478160	0.595	rs2295146	chr14:104199356	C/T	cg08213375	chr14:104286397	PPP1R13B	0.47	8.87	0.48	1.12e-16	Schizophrenia;
CESC	cis	rs116095464	0.558	rs62347678	chr5:227496	A/G	cg12570787	chr5:219185	SDHA;CCDC127	0.51	5.44	0.32	1.19e-7	Breast cancer;
CESC	cis	rs79387448	0.810	rs76229479	chr2:103123912	A/C	cg09003973	chr2:102972529	NA	0.79	6.08	0.35	4.17e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs4594175	0.926	rs11624975	chr14:51628347	T/C	cg23942311	chr14:51606299	NA	0.36	5.43	0.32	1.28e-7	Cancer;
CESC	cis	rs7833790	1.000	rs7460277	chr8:82709777	T/C	cg07697082	chr8:82753677	SNX16	0.37	5.07	0.3	7.36e-7	Diastolic blood pressure;
CESC	cis	rs7772486	0.641	rs2748489	chr6:146331287	T/G	cg05347473	chr6:146136440	FBXO30	0.65	8.13	0.45	1.63e-14	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs1814175	0.645	rs7928714	chr11:49887622	G/A	cg15704280	chr7:45808275	SEPT13	-0.98	-18.32	-0.75	5.46e-49	Height;
CESC	cis	rs1799949	0.965	rs34633610	chr17:41419385	A/G	cg05368731	chr17:41323189	NBR1	0.79	10.65	0.55	2.72e-22	Menopause (age at onset);
CESC	cis	rs72781680	1.000	rs56068891	chr2:24230633	A/G	cg08917208	chr2:24149416	ATAD2B	1.13	9.83	0.52	1.17e-19	Lymphocyte counts;
CESC	cis	rs10504229	1.000	rs67237174	chr8:58175776	T/C	cg14926445	chr8:58193284	C8orf71	-0.53	-5.69	-0.33	3.33e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs7267979	1.000	rs2257808	chr20:25266450	G/C	cg08601574	chr20:25228251	PYGB	0.39	5.65	0.33	4.08e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs9291683	0.530	rs4235346	chr4:9945296	C/T	cg11266682	chr4:10021025	SLC2A9	-0.63	-12.73	-0.62	2.68e-29	Bone mineral density;
CESC	cis	rs1983891	0.779	rs4714475	chr6:41509901	G/T	cg20194872	chr6:41519635	FOXP4	0.58	8.23	0.45	8.38e-15	Prostate cancer;
CESC	cis	rs2282802	0.685	rs13359519	chr5:139654664	G/A	cg26211634	chr5:139558579	C5orf32	0.51	7.37	0.41	2.24e-12	Intelligence (multi-trait analysis);
CESC	cis	rs6502050	0.805	rs4789740	chr17:80119202	T/C	cg23985595	chr17:80112537	CCDC57	-0.42	-6.56	-0.37	2.88e-10	Life satisfaction;
CESC	trans	rs11098499	0.954	rs10006706	chr4:120409152	A/G	cg25214090	chr10:38739885	LOC399744	0.69	9.49	0.5	1.38e-18	Corneal astigmatism;
CESC	cis	rs72627123	0.867	rs8020310	chr14:74494437	A/G	cg08255017	chr14:74727001	VSX2	0.58	5.23	0.31	3.37e-7	Morning vs. evening chronotype;
CESC	cis	rs7223966	1.000	rs2854218	chr17:61942940	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.5	5.77	0.33	2.16e-8	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs926938	0.765	rs1884296	chr1:115235716	A/C	cg12756093	chr1:115239321	AMPD1	-0.64	-9.93	-0.52	5.96e-20	Autism;
CESC	cis	rs9487051	0.837	rs6568561	chr6:109592909	A/G	cg12927641	chr6:109611667	NA	-0.41	-6.43	-0.37	5.98e-10	Reticulocyte fraction of red cells;
CESC	cis	rs2228479	0.850	rs17227057	chr16:89816333	C/T	cg14709524	chr16:89940631	TCF25	0.93	6.94	0.39	3.03e-11	Skin colour saturation;
CESC	cis	rs10465746	0.746	rs12749350	chr1:84456948	T/A	cg10977910	chr1:84465055	TTLL7	0.52	7.13	0.4	9.47e-12	Obesity-related traits;
CESC	cis	rs514406	0.708	rs536621	chr1:53309097	A/G	cg08859206	chr1:53392774	SCP2	-0.66	-9.71	-0.51	2.99e-19	Monocyte count;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04578738	chr17:34136331	TAF15	0.48	6.31	0.36	1.16e-9	Gut microbiota (bacterial taxa);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg07389500	chr5:137681244	FAM53C	0.47	6.18	0.35	2.46e-9	Fibrinogen levels;
CESC	cis	rs2414059	0.518	rs3098171	chr15:50771511	C/G	cg05456662	chr15:50716270	USP8	-0.41	-5.44	-0.32	1.2e-7	QT interval;
CESC	cis	rs4713118	0.621	rs9295755	chr6:28033174	C/T	cg12963246	chr6:28129442	ZNF389	-0.55	-7.32	-0.41	3.05e-12	Parkinson's disease;
CESC	cis	rs1799949	1.000	rs4793197	chr17:41231902	C/T	cg23758822	chr17:41437982	NA	1.02	14.96	0.68	4.21e-37	Menopause (age at onset);
CESC	cis	rs3820068	0.603	rs7536654	chr1:15989141	C/G	cg17385448	chr1:15911702	AGMAT	0.44	7.64	0.42	3.91e-13	Systolic blood pressure;
CESC	cis	rs62432291	0.681	rs417719	chr6:159658042	C/T	cg14500486	chr6:159655392	FNDC1	-0.61	-6.2	-0.36	2.19e-9	Joint mobility (Beighton score);
CESC	cis	rs7927771	0.725	rs11039265	chr11:47523214	C/A	cg18512352	chr11:47633146	NA	-0.6	-9.05	-0.49	3.14e-17	Subjective well-being;
CESC	cis	rs1003719	0.680	rs2835664	chr21:38573429	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.61	-8.29	-0.45	5.58e-15	Eye color traits;
CESC	cis	rs9916302	0.904	rs9904334	chr17:37468336	G/A	cg00129232	chr17:37814104	STARD3	0.56	7.28	0.41	3.73e-12	Glomerular filtration rate (creatinine);
CESC	cis	rs7267979	0.903	rs6115101	chr20:25229564	C/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.82	15.1	0.68	1.39e-37	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs3857067	1.000	rs1397025	chr4:95018987	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.52	-8.04	-0.44	3.04e-14	QT interval;
CESC	cis	rs7927771	1.000	rs7120333	chr11:47817441	C/T	cg20307385	chr11:47447363	PSMC3	-0.49	-6.04	-0.35	5.24e-9	Subjective well-being;
CESC	cis	rs4843747	0.749	rs72818535	chr16:88074039	G/A	cg06374794	chr16:88002281	BANP	0.41	5.39	0.31	1.57e-7	Menopause (age at onset);
CESC	cis	rs11255400	0.590	rs12412852	chr10:7999085	A/G	cg12123470	chr10:7215341	SFMBT2	-0.55	-5.36	-0.31	1.84e-7	IgG glycosylation;
CESC	cis	rs1348850	0.632	rs4470372	chr2:178505857	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.59	7.59	0.42	5.54e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs7659604	0.539	rs2063165	chr4:122750005	A/G	cg20573242	chr4:122745356	CCNA2	0.66	8.08	0.44	2.34e-14	Type 2 diabetes;
CESC	cis	rs7618915	0.547	rs4130905	chr3:52709831	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	6.76	0.38	8.8e-11	Bipolar disorder;
CESC	cis	rs2070677	0.935	rs7907312	chr10:135417364	A/G	cg20169779	chr10:135381914	SYCE1	-0.74	-9.71	-0.51	2.99e-19	Gout;
CESC	cis	rs9915657	0.870	rs720244	chr17:70131643	G/T	cg06234051	chr17:70120541	SOX9	-0.47	-6.85	-0.39	5.21e-11	Thyroid hormone levels;
CESC	cis	rs1862618	0.853	rs11739344	chr5:56111087	A/C	cg03609598	chr5:56110824	MAP3K1	-0.49	-5.23	-0.31	3.48e-7	Initial pursuit acceleration;
CESC	cis	rs1152591	0.967	rs1152589	chr14:64683926	A/T	cg23250157	chr14:64679961	SYNE2	-0.56	-8.2	-0.45	1.06e-14	Atrial fibrillation;
CESC	cis	rs7216064	0.953	rs11871285	chr17:65840809	G/T	cg07042672	chr17:66097459	LOC651250	-0.54	-5.67	-0.33	3.73e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs1215050	0.740	rs1084784	chr4:98961711	T/G	cg05340658	chr4:99064831	C4orf37	-0.56	-7.54	-0.42	7.65e-13	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs4595586	0.546	rs10876163	chr12:39244915	G/A	cg13010199	chr12:38710504	ALG10B	0.56	7.54	0.42	7.63e-13	Morning vs. evening chronotype;
CESC	cis	rs36051895	0.632	rs62541958	chr9:5175621	T/C	cg02405213	chr9:5042618	JAK2	-0.48	-5.5	-0.32	8.93e-8	Pediatric autoimmune diseases;
CESC	cis	rs9457247	1.000	rs2769347	chr6:167371737	T/A	cg25258033	chr6:167368657	RNASET2	-0.41	-6.22	-0.36	1.98e-9	Crohn's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12133393	chr1:3816695	C1orf174;LOC100133612	0.58	6.78	0.38	7.65e-11	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.830	rs1426668	chr4:98945585	T/A	cg17366294	chr4:99064904	C4orf37	0.6	8.53	0.46	1.15e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2832191	0.740	rs2832177	chr21:30478353	G/A	cg24692254	chr21:30365293	RNF160	-0.99	-17.21	-0.73	4.35e-45	Dental caries;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg26156301	chr20:30193024	ID1	-0.48	-6.24	-0.36	1.68e-9	Fibrinogen levels;
CESC	cis	rs7826238	0.539	rs2945891	chr8:8155475	C/T	cg15556689	chr8:8085844	FLJ10661	0.49	5.83	0.34	1.6e-8	Systolic blood pressure;
CESC	cis	rs858239	0.539	rs10270695	chr7:23188988	C/T	cg23682824	chr7:23144976	KLHL7	-0.52	-6.87	-0.39	4.48e-11	Cerebrospinal fluid biomarker levels;
CESC	trans	rs1493916	0.967	rs1389532	chr18:31392323	C/T	cg27147174	chr7:100797783	AP1S1	-0.52	-7.04	-0.4	1.62e-11	Life satisfaction;
CESC	cis	rs796364	1.000	rs281763	chr2:200794870	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.83	8.38	0.46	3.17e-15	Schizophrenia;
CESC	cis	rs6942756	1.000	rs7806089	chr7:128972215	C/G	cg02491457	chr7:128862824	NA	-0.67	-9.07	-0.49	2.72e-17	White matter hyperintensity burden;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg12141744	chr12:34319939	NA	-0.44	-6.03	-0.35	5.48e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs1552244	0.938	rs66915020	chr3:10110174	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-11.04	-0.56	1.41e-23	Alzheimer's disease;
CESC	cis	rs8050907	0.744	rs11862204	chr16:4519586	G/A	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.9	6.28	0.36	1.39e-9	Obesity-related traits;
CESC	cis	rs17539620	0.624	rs4566892	chr6:154837346	C/T	cg17771515	chr6:154831774	CNKSR3	0.59	5.85	0.34	1.43e-8	Lipoprotein (a) levels;
CESC	cis	rs66573146	1.000	rs6812771	chr4:6964048	G/A	cg00086871	chr4:6988644	TBC1D14	1.16	6.56	0.37	2.82e-10	Granulocyte percentage of myeloid white cells;
CESC	cis	rs9322193	0.962	rs12175575	chr6:150084487	G/A	cg05861140	chr6:150128134	PCMT1	-0.38	-5.43	-0.32	1.29e-7	Lung cancer;
CESC	cis	rs539096	0.566	rs3011220	chr1:44308867	A/G	cg12908607	chr1:44402522	ARTN	-0.48	-7.19	-0.4	6.6e-12	Intelligence (multi-trait analysis);
CESC	cis	rs7249921	0.833	rs62111373	chr19:35660844	G/C	cg15419183	chr19:35660584	FXYD5	0.56	8.42	0.46	2.36e-15	Platelet count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19188060	chr3:184017239	PSMD2	0.55	6.1	0.35	3.7e-9	Gut microbiome composition (summer);
CESC	cis	rs920590	0.758	rs7011322	chr8:19661937	C/T	cg17834443	chr8:19674713	INTS10	0.58	6.53	0.37	3.27e-10	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg26338869	chr17:61819248	STRADA	0.69	9.1	0.49	2.2e-17	Prudent dietary pattern;
CESC	cis	rs35306767	0.903	rs11253495	chr10:937064	C/T	cg10556349	chr10:835070	NA	0.56	5.44	0.32	1.19e-7	Eosinophil percentage of granulocytes;
CESC	cis	rs8038465	0.615	rs11072430	chr15:73981701	A/G	cg15420318	chr15:73925796	NPTN	-0.47	-6.96	-0.39	2.72e-11	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs3008870	0.755	rs12562761	chr1:67396739	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.64	8.31	0.45	5e-15	Lymphocyte percentage of white cells;
CESC	cis	rs4819052	0.851	rs8134392	chr21:46663790	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.91	-13.32	-0.63	2.41e-31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs2777491	0.957	rs1757454	chr15:41777934	A/G	cg02330683	chr15:41787940	ITPKA	0.49	7.24	0.41	4.75e-12	Ulcerative colitis;
CESC	cis	rs10504229	0.679	rs111843870	chr8:58126798	A/G	cg21724239	chr8:58056113	NA	0.57	5.76	0.33	2.29e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs6594713	0.602	rs33992630	chr5:112903169	G/A	cg12552261	chr5:112820674	MCC	0.55	5.45	0.32	1.15e-7	Brain cytoarchitecture;
CESC	cis	rs6951245	0.608	rs10252234	chr7:1114381	C/T	cg18402987	chr7:1209562	NA	0.47	5.35	0.31	1.93e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs4253772	0.513	rs12171124	chr22:46710693	A/C	cg09491104	chr22:46646882	C22orf40	-0.49	-5.92	-0.34	9.8e-9	LDL cholesterol;Cholesterol, total;
CESC	cis	rs1799949	0.965	rs8176130	chr17:41258043	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.67	9.43	0.5	2.2e-18	Menopause (age at onset);
CESC	cis	rs8050907	0.744	rs8047271	chr16:4536634	A/G	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.75	5.31	0.31	2.32e-7	Obesity-related traits;
CESC	cis	rs9291683	0.609	rs34709913	chr4:10028955	T/C	cg00071950	chr4:10020882	SLC2A9	0.9	16.44	0.71	2.41e-42	Bone mineral density;
CESC	cis	rs6762	0.550	rs8672	chr11:838634	C/G	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.67	-8.9	-0.48	8.91e-17	Mean platelet volume;
CESC	cis	rs7949030	0.653	rs2516634	chr11:62367186	G/A	cg13298116	chr11:62369859	EML3;MTA2	-0.61	-9.03	-0.48	3.75e-17	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs8038465	1.000	rs8032531	chr15:73977271	A/G	cg15420318	chr15:73925796	NPTN	0.44	6.23	0.36	1.85e-9	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs17854409	0.764	rs73613593	chr20:61471582	T/C	cg05147244	chr20:61493195	TCFL5	1.11	5.94	0.34	9.08e-9	Obesity-related traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09266924	chr15:29034669	NA	-0.54	-6.44	-0.37	5.66e-10	Gut microbiome composition (summer);
CESC	cis	rs10464366	0.544	rs1525799	chr7:39153131	C/G	cg18850127	chr7:39170497	POU6F2	-0.37	-5.2	-0.3	4.03e-7	IgG glycosylation;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	ch.2.195648145F	chr2:195939902	NA	0.58	7.8	0.43	1.38e-13	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs3857067	0.806	rs6857967	chr4:95112303	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.6	-9.12	-0.49	1.89e-17	QT interval;
CESC	cis	rs7224314	1.000	rs8070689	chr17:65387405	G/T	cg01507342	chr17:65387096	PITPNC1	-0.48	-5.67	-0.33	3.82e-8	Diisocyanate-induced asthma;
CESC	cis	rs3782089	1.000	rs11605810	chr11:65300619	A/G	cg00206168	chr11:65308501	LTBP3	0.95	6.33	0.36	1.07e-9	Height;
CESC	cis	rs899997	0.862	rs8043123	chr15:78973393	C/T	cg04896959	chr15:78267971	NA	-0.41	-5.73	-0.33	2.7e-8	Coronary artery disease or large artery stroke;
CESC	cis	rs11608355	0.545	rs4766603	chr12:109892106	T/C	cg05360138	chr12:110035743	NA	0.82	8.92	0.48	7.93e-17	Neuroticism;
CESC	cis	rs6963495	0.818	rs56177071	chr7:105165648	C/T	cg02135003	chr7:105160482	PUS7	-0.47	-5.59	-0.33	5.51e-8	Bipolar disorder (body mass index interaction);
CESC	cis	rs736408	0.509	rs1108842	chr3:52720080	A/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.35	6.85	0.39	5.3e-11	Bipolar disorder;
CESC	cis	rs34172651	0.517	rs200528	chr16:24759131	A/G	cg04756594	chr16:24857601	SLC5A11	-0.45	-5.52	-0.32	8.21e-8	Intelligence (multi-trait analysis);
CESC	cis	rs116095464	0.558	rs2288457	chr5:231270	C/T	cg22496380	chr5:211416	CCDC127	-0.74	-8.5	-0.46	1.44e-15	Breast cancer;
CESC	trans	rs7656342	0.808	rs10003216	chr4:9766749	A/G	cg22548015	chr20:30539544	PDRG1	-0.47	-6.07	-0.35	4.31e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs1799949	1.000	rs4793212	chr17:41302750	T/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.42	5.76	0.33	2.3e-8	Menopause (age at onset);
CESC	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg07677032	chr17:61819896	STRADA	0.44	5.89	0.34	1.15e-8	Prudent dietary pattern;
CESC	cis	rs1862618	0.671	rs2591958	chr5:56239369	C/G	cg18230493	chr5:56204884	C5orf35	0.61	8.11	0.45	1.9e-14	Initial pursuit acceleration;
CESC	cis	rs4665809	1.000	rs6739061	chr2:26256147	C/T	cg08470875	chr2:26401718	FAM59B	-0.49	-5.38	-0.31	1.65e-7	Gut microbiome composition (summer);
CESC	cis	rs12135062	1.000	rs12135062	chr1:3103312	A/C	cg21609526	chr1:3105151	PRDM16	0.39	5.49	0.32	9.46e-8	Migraine;
CESC	cis	rs4819052	0.565	rs35776291	chr21:46706142	T/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.51	6.71	0.38	1.18e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs72634258	0.554	rs34020118	chr1:7895015	C/T	cg26816564	chr1:7831052	VAMP3	0.61	5.31	0.31	2.35e-7	Inflammatory bowel disease;
CESC	cis	rs739401	0.588	rs10219272	chr11:3020789	G/A	cg08508325	chr11:3079039	CARS	-0.56	-10.58	-0.55	4.58e-22	Longevity;
CESC	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg07677032	chr17:61819896	STRADA	0.44	5.76	0.33	2.34e-8	Prudent dietary pattern;
CESC	cis	rs2820315	0.505	rs10800792	chr1:201811144	G/A	cg11586189	chr1:201857591	SHISA4	0.33	5.54	0.32	7.12e-8	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
CESC	cis	rs1707322	0.717	rs3014246	chr1:46086077	C/T	cg03146154	chr1:46216737	IPP	-0.78	-10.75	-0.55	1.33e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg01860753	chr1:206730586	RASSF5	-0.5	-6.44	-0.37	5.59e-10	Fibrinogen levels;
CESC	cis	rs7914558	0.966	rs11191471	chr10:104702050	T/A	cg04362960	chr10:104952993	NT5C2	0.42	5.38	0.31	1.63e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs34779708	0.733	rs16935945	chr10:35540320	A/C	cg03585969	chr10:35415529	CREM	0.56	6.42	0.37	6.15e-10	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs4654899	0.931	rs6661116	chr1:21337155	C/G	cg05370193	chr1:21551575	ECE1	0.41	6.25	0.36	1.63e-9	Superior frontal gyrus grey matter volume;
CESC	cis	rs875971	0.862	rs937494	chr7:65764678	T/A	cg18876405	chr7:65276391	NA	-0.49	-6.83	-0.39	5.72e-11	Aortic root size;
CESC	cis	rs950776	0.616	rs3743077	chr15:78894896	C/T	cg06917634	chr15:78832804	PSMA4	0.62	8.14	0.45	1.52e-14	Sudden cardiac arrest;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01834151	chr15:52971181	KIAA1370	-0.56	-6.03	-0.35	5.43e-9	Gut microbiome composition (summer);
CESC	cis	rs1670533	0.932	rs13106586	chr4:1054182	G/A	cg27284194	chr4:1044797	NA	0.46	5.8	0.34	1.84e-8	Recombination rate (females);
CESC	cis	rs9322193	0.923	rs9383812	chr6:150033491	C/T	cg04369109	chr6:150039330	LATS1	-0.43	-6.19	-0.36	2.31e-9	Lung cancer;
CESC	cis	rs2932538	0.922	rs6658555	chr1:113098534	C/T	cg22162597	chr1:113214053	CAPZA1	0.61	7.36	0.41	2.27e-12	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CESC	cis	rs12765878	1.000	rs61277100	chr10:105643352	A/G	cg11005552	chr10:105648138	OBFC1	0.35	5.1	0.3	6.34e-7	Coronary artery disease;
CESC	cis	rs3733585	0.762	rs6449217	chr4:10009151	T/A	cg00071950	chr4:10020882	SLC2A9	0.8	13.04	0.63	2.25e-30	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs909674	0.818	rs5750833	chr22:39843091	C/A	cg01416388	chr22:39784598	NA	-0.61	-7.47	-0.42	1.14e-12	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs1341267	0.529	rs6492720	chr13:95256305	T/C	cg18412871	chr13:95254051	GPR180	-0.52	-6.87	-0.39	4.55e-11	Triglyceride levels;
CESC	cis	rs832540	0.593	rs96844	chr5:56196604	G/A	cg14703610	chr5:56206110	C5orf35	0.46	5.81	0.34	1.81e-8	Coronary artery disease;
CESC	cis	rs9787249	0.957	rs41267029	chr1:40214367	A/G	cg24920358	chr1:40204285	PPIE	0.43	6.4	0.37	7.07e-10	Blood protein levels;
CESC	cis	rs9611565	0.659	rs9607815	chr22:41950671	A/T	cg17376030	chr22:41985996	PMM1	0.66	7.24	0.41	5.01e-12	Vitiligo;
CESC	cis	rs2204008	0.774	rs2387811	chr12:38369794	C/A	cg13010199	chr12:38710504	ALG10B	0.53	6.61	0.38	2.14e-10	Bladder cancer;
CESC	cis	rs712039	0.652	rs8069062	chr17:35829306	C/T	cg16670864	chr17:35848621	DUSP14	0.44	5.34	0.31	1.97e-7	Tuberculosis;
CESC	cis	rs3768617	0.782	rs10911211	chr1:183022299	A/T	ch.1.3577855R	chr1:183094577	LAMC1	0.65	8.84	0.48	1.33e-16	Fuchs's corneal dystrophy;
CESC	cis	rs1552244	1.000	rs7622966	chr3:10139833	C/T	cg00166722	chr3:10149974	C3orf24	0.44	5.65	0.33	4.11e-8	Alzheimer's disease;
CESC	cis	rs1461503	0.966	rs4936764	chr11:122844492	G/A	cg27398637	chr11:122830231	C11orf63	-0.55	-8.32	-0.45	4.77e-15	Menarche (age at onset);
CESC	cis	rs6546537	0.955	rs1396798	chr2:69887837	G/T	cg10773587	chr2:69614142	GFPT1	-0.45	-5.38	-0.31	1.66e-7	Serum thyroid-stimulating hormone levels;
CESC	cis	rs6952808	0.501	rs3778999	chr7:2180885	G/A	cg05863683	chr7:1912471	MAD1L1	0.39	5.7	0.33	3.27e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs7582720	1.000	rs72934767	chr2:203766563	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.39	0.41	1.96e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs6866344	0.697	rs72812613	chr5:178135257	G/A	cg03877680	chr5:178157825	ZNF354A	0.78	8.94	0.48	6.74e-17	Neutrophil percentage of white cells;
CESC	trans	rs78049276	0.736	rs6841473	chr4:148407652	C/T	cg13149281	chr14:23389818	RBM23;PRMT5	-0.63	-6.74	-0.38	1.01e-10	Pulse pressure;
CESC	cis	rs4722166	0.597	rs2069845	chr7:22770149	G/A	cg13104385	chr7:22767384	IL6	0.35	5.32	0.31	2.16e-7	Lung cancer;
CESC	cis	rs7103648	0.966	rs874896	chr11:47418953	C/G	cg20307385	chr11:47447363	PSMC3	0.94	16.43	0.71	2.71e-42	Diastolic blood pressure;Systolic blood pressure;
CESC	cis	rs2295499	0.754	rs3864117	chr4:2626569	G/A	cg08330972	chr4:2403930	ZFYVE28	-0.34	-5.54	-0.32	7.38e-8	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
CESC	trans	rs7144011	0.654	rs4903847	chr14:79854832	A/G	cg12233833	chr10:830825	NA	-0.48	-6.1	-0.35	3.78e-9	Waist circumference;Hip circumference;
CESC	cis	rs6502050	0.799	rs9675196	chr17:80096655	C/T	cg01763666	chr17:80159506	CCDC57	-0.37	-5.26	-0.31	2.93e-7	Life satisfaction;
CESC	cis	rs62344088	0.590	rs6882234	chr5:177389	C/G	cg22857025	chr5:266934	NA	-1.1	-8.56	-0.47	9.31e-16	Asthma (childhood onset);
CESC	cis	rs17376456	0.825	rs10061377	chr5:93174513	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.6	5.08	0.3	7.11e-7	Diabetic retinopathy;
CESC	cis	rs7666738	0.747	rs2865955	chr4:99040518	A/C	cg18180107	chr4:99064573	C4orf37	0.41	5.29	0.31	2.51e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11098499	0.604	rs2389887	chr4:120570644	T/C	cg25214090	chr10:38739885	LOC399744	0.6	7.88	0.44	8.29e-14	Corneal astigmatism;
CESC	cis	rs8141529	0.748	rs7287918	chr22:29281710	G/A	cg15103426	chr22:29168792	CCDC117	0.61	7.81	0.43	1.31e-13	Lymphocyte counts;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg22648015	chr20:57485794	GNAS	-0.44	-6.12	-0.35	3.32e-9	Systemic lupus erythematosus;
CESC	cis	rs9733	0.596	rs2275236	chr1:150669952	A/G	cg18016565	chr1:150552671	MCL1	-0.33	-5.07	-0.3	7.47e-7	Tonsillectomy;
CESC	trans	rs1814175	0.817	rs7946556	chr11:49944874	G/A	cg03929089	chr4:120376271	NA	-0.93	-15.62	-0.69	1.95e-39	Height;
CESC	cis	rs3749237	0.595	rs1568661	chr3:49520958	A/G	cg03060546	chr3:49711283	APEH	0.76	11.23	0.57	3.32e-24	Resting heart rate;
CESC	cis	rs10492096	0.945	rs2041386	chr12:6562538	C/T	cg13857086	chr12:6580257	VAMP1	0.63	5.98	0.34	7.09e-9	Hip geometry;
CESC	cis	rs11828289	0.660	rs17306384	chr11:23189320	T/C	cg20040320	chr11:23191996	NA	-0.68	-5.87	-0.34	1.31e-8	Cancer;
CESC	cis	rs7845219	0.525	rs6471501	chr8:95922491	A/G	cg13393036	chr8:95962371	TP53INP1	-0.44	-8.18	-0.45	1.17e-14	Type 2 diabetes;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg23575115	chr20:49348591	PARD6B	-0.43	-6.51	-0.37	3.81e-10	Gambling;
CESC	cis	rs7219021	1.000	rs4553671	chr17:46848272	T/C	cg16584676	chr17:46985605	UBE2Z	-0.7	-7.72	-0.43	2.37e-13	Schizophrenia or bipolar disorder;
CESC	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg26338869	chr17:61819248	STRADA	0.7	9.32	0.5	4.6e-18	Prudent dietary pattern;
CESC	cis	rs17376456	0.825	rs12188163	chr5:93250608	A/G	cg25358565	chr5:93447407	FAM172A	-1.1	-10.4	-0.54	1.75e-21	Diabetic retinopathy;
CESC	cis	rs2415984	0.562	rs1389604	chr14:46972218	C/A	cg14871534	chr14:47121158	RPL10L	0.4	5.59	0.32	5.71e-8	Number of children ever born;
CESC	cis	rs9473147	0.571	rs9463335	chr6:47479136	G/A	cg20196966	chr6:47445060	CD2AP	0.43	5.48	0.32	9.88e-8	Platelet distribution width;Mean platelet volume;
CESC	cis	rs17401966	0.838	rs912963	chr1:10348042	C/T	cg15208524	chr1:10270712	KIF1B	0.4	5.16	0.3	4.94e-7	Hepatocellular carcinoma;
CESC	cis	rs9311474	0.508	rs4687629	chr3:52615227	G/C	cg18404041	chr3:52824283	ITIH1	-0.39	-6.69	-0.38	1.29e-10	Electroencephalogram traits;
CESC	cis	rs6952808	0.689	rs12670737	chr7:2046830	C/T	cg02951883	chr7:2050386	MAD1L1	-0.54	-7.24	-0.41	4.9e-12	Bipolar disorder and schizophrenia;
CESC	cis	rs3126085	0.935	rs4845733	chr1:152162568	T/C	cg26876637	chr1:152193138	HRNR	0.45	5.12	0.3	5.84e-7	Atopic dermatitis;
CESC	cis	rs6893300	0.961	rs11739042	chr5:179182495	G/A	cg14593053	chr5:179126677	CANX	-0.52	-5.74	-0.33	2.58e-8	Resting heart rate;
CESC	cis	rs4975616	0.804	rs462608	chr5:1336626	T/A	cg06550200	chr5:1325588	CLPTM1L	-0.65	-9.84	-0.52	1.16e-19	Lung cancer;
CESC	cis	rs6540559	0.543	rs672819	chr1:210436404	T/A	cg22029157	chr1:209979665	IRF6	0.52	5.89	0.34	1.17e-8	Cleft lip with or without cleft palate;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg11397493	chr1:3307215	PRDM16	0.38	6.06	0.35	4.71e-9	Fibrinogen levels;
CESC	cis	rs66486766	1	rs66486766	chr15:84806060	G/A	cg17507749	chr15:85114479	UBE2QP1	0.61	6.8	0.39	6.94e-11	Bipolar disorder lithium response (categorical) or schizophrenia;
CESC	cis	rs9443645	0.901	rs9352686	chr6:79758223	T/G	cg05283184	chr6:79620031	NA	-0.44	-6.86	-0.39	4.89e-11	Intelligence (multi-trait analysis);
CESC	cis	rs16854884	0.657	rs6769910	chr3:143737830	C/G	cg06585982	chr3:143692056	C3orf58	0.5	6.7	0.38	1.26e-10	Economic and political preferences (feminism/equality);
CESC	cis	rs9660992	1.000	rs1779410	chr1:205248759	A/G	cg21643547	chr1:205240462	TMCC2	-0.44	-7.07	-0.4	1.38e-11	Mean corpuscular volume;Mean platelet volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06551418	chr8:145111391	OPLAH	-0.53	-6.38	-0.36	7.72e-10	Gut microbiome composition (summer);
CESC	cis	rs8005677	0.798	rs4982711	chr14:23398990	T/G	cg01529538	chr14:23388837	RBM23	0.43	5.76	0.33	2.3e-8	Cognitive ability (multi-trait analysis);
CESC	cis	rs847577	0.588	rs12666406	chr7:97790991	G/A	cg24562669	chr7:97807699	LMTK2	0.83	13.66	0.64	1.64e-32	Breast cancer;
CESC	cis	rs11030122	0.632	rs10835556	chr11:4083013	A/G	cg18678763	chr11:4115507	RRM1	-0.52	-6.97	-0.39	2.59e-11	Mean platelet volume;Platelet distribution width;
CESC	cis	rs2180341	0.960	rs6900074	chr6:127685893	A/G	cg27446573	chr6:127587934	RNF146	1.05	15.58	0.69	2.65e-39	Breast cancer;
CESC	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg14926445	chr8:58193284	C8orf71	-0.54	-5.16	-0.3	4.76e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs8103278	1.000	rs9676288	chr19:46292060	G/T	cg20908204	chr19:46285434	DMPK	-0.35	-5.1	-0.3	6.47e-7	Coronary artery disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg09039436	chr11:46369515	DGKZ	-0.45	-6.02	-0.35	5.86e-9	Fibrinogen levels;
CESC	cis	rs6088580	0.609	rs6058029	chr20:32969643	T/C	cg24642439	chr20:33292090	TP53INP2	-0.52	-6.9	-0.39	3.82e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs12541635	0.639	rs6415444	chr8:107043797	G/A	cg10147462	chr8:107024639	NA	0.43	6.31	0.36	1.16e-9	Age of smoking initiation;
CESC	cis	rs34779708	0.733	rs4391768	chr10:35547595	A/G	cg04310649	chr10:35416472	CREM	-0.45	-5.14	-0.3	5.34e-7	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs9303401	0.659	rs9303399	chr17:56672309	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.06	13.0	0.62	3.28e-30	Cognitive test performance;
CESC	cis	rs4704187	0.687	rs6866661	chr5:74534372	A/G	cg03227963	chr5:74354835	NA	0.27	5.04	0.3	8.67e-7	Response to amphetamines;
CESC	cis	rs9522267	0.737	rs12429582	chr13:112226657	A/G	cg10483660	chr13:112241077	NA	-0.31	-5.19	-0.3	4.26e-7	Hepatitis;
CESC	cis	rs919433	0.926	rs787997	chr2:198216271	A/G	cg10820045	chr2:198174542	NA	0.39	5.88	0.34	1.21e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs4665809	1.000	rs4665309	chr2:26335502	T/C	cg26314531	chr2:26401878	FAM59B	-0.62	-6.99	-0.39	2.29e-11	Gut microbiome composition (summer);
CESC	trans	rs66573146	0.656	rs56094305	chr4:6956086	C/T	cg07817883	chr1:32538562	TMEM39B	1.25	8.67	0.47	4.33e-16	Granulocyte percentage of myeloid white cells;
CESC	cis	rs13064411	0.735	rs13098166	chr3:113210038	A/G	cg18753928	chr3:113234510	CCDC52	-0.52	-6.31	-0.36	1.17e-9	Response to simvastatin treatment (PCSK9 protein level change);
CESC	cis	rs2033711	0.840	rs10423138	chr19:58928302	T/C	cg11952622	chr19:58962976	ZNF324B	0.46	6.13	0.35	3.11e-9	Uric acid clearance;
CESC	cis	rs2228479	0.702	rs78331410	chr16:89917775	C/T	cg06558623	chr16:89946397	TCF25	1.15	8.39	0.46	2.95e-15	Skin colour saturation;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg10519680	chr8:37707506	BRF2	0.47	6.14	0.35	3.04e-9	Systemic lupus erythematosus;
CESC	cis	rs9649213	0.593	rs2158553	chr7:97951131	G/A	cg21770322	chr7:97807741	LMTK2	0.54	8.15	0.45	1.45e-14	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs801193	1.000	rs4279493	chr7:66226620	C/T	cg18876405	chr7:65276391	NA	0.54	7.06	0.4	1.5e-11	Aortic root size;
CESC	trans	rs11088226	1.000	rs2833889	chr21:33927768	G/T	cg09050820	chr6:167586206	TCP10L2	-0.58	-6.06	-0.35	4.63e-9	Gastritis;
CESC	trans	rs3749237	1.000	rs11717256	chr3:49868520	C/T	cg21659725	chr3:3221576	CRBN	0.53	6.38	0.36	8.01e-10	Resting heart rate;
CESC	cis	rs9399137	0.507	rs4895437	chr6:135317354	G/A	cg24558204	chr6:135376177	HBS1L	0.72	10.08	0.53	1.92e-20	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	cis	rs2072732	0.861	rs72856440	chr1:2956582	A/G	cg03976712	chr1:2946727	NA	0.33	5.52	0.32	8.2e-8	Plateletcrit;
CESC	cis	rs9814567	1.000	rs7371896	chr3:134249769	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.44	-5.92	-0.34	9.73e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs12926788	0.689	rs34365165	chr16:24856208	G/A	cg06505273	chr16:24850292	NA	0.48	5.46	0.32	1.11e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs1023500	0.505	rs134886	chr22:42673856	C/T	cg15557168	chr22:42548783	NA	0.46	7.26	0.41	4.39e-12	Schizophrenia;
CESC	cis	rs10208940	0.920	rs13422657	chr2:68706989	T/C	cg12452813	chr2:68675892	NA	0.52	5.24	0.31	3.26e-7	Urate levels in lean individuals;
CESC	cis	rs1065852	0.526	rs4822079	chr22:42394612	G/C	cg22189786	chr22:42395067	WBP2NL	0.44	5.46	0.32	1.08e-7	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06033368	chr22:38597807	MAFF	0.57	6.06	0.35	4.73e-9	Gut microbiome composition (summer);
CESC	cis	rs7927771	0.524	rs10838774	chr11:47856114	A/G	cg18512352	chr11:47633146	NA	0.35	5.43	0.32	1.24e-7	Subjective well-being;
CESC	cis	rs8031584	0.672	rs17815726	chr15:31313252	C/G	cg08704250	chr15:31115839	NA	0.65	7.21	0.41	5.81e-12	Huntington's disease progression;
CESC	cis	rs898097	0.841	rs55810435	chr17:80836722	G/C	cg15664640	chr17:80829946	TBCD	-0.6	-8.58	-0.47	8e-16	Breast cancer;
CESC	cis	rs2108622	0.727	rs12609900	chr19:15982414	G/A	cg13772218	chr19:15982569	NA	0.29	5.8	0.34	1.85e-8	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CESC	cis	rs75477785	0.590	rs4844502	chr1:210104743	A/T	cg02304930	chr1:210405566	SERTAD4;C1orf133	-0.87	-6.68	-0.38	1.42e-10	Cleft lip with or without cleft palate;
CESC	cis	rs8114671	0.836	rs2425012	chr20:33581955	G/A	cg06115741	chr20:33292138	TP53INP2	-0.44	-5.22	-0.31	3.55e-7	Height;
CESC	trans	rs453301	0.571	rs330057	chr8:9089793	C/T	cg15556689	chr8:8085844	FLJ10661	-0.52	-6.52	-0.37	3.52e-10	Joint mobility (Beighton score);
CESC	cis	rs9303401	0.704	rs7359501	chr17:56641200	C/T	cg12560992	chr17:57184187	TRIM37	0.56	7.18	0.4	6.88e-12	Cognitive test performance;
CESC	cis	rs55986470	0.763	rs10188853	chr2:239430558	G/C	cg18131467	chr2:239335373	ASB1	-0.52	-5.75	-0.33	2.39e-8	Chronotype;
CESC	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg21951975	chr1:209979733	IRF6	0.75	16.51	0.71	1.35e-42	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
CESC	cis	rs10479542	0.929	rs10078796	chr5:178978883	T/A	cg26516362	chr5:178986906	RUFY1	0.45	7.08	0.4	1.28e-11	Lung cancer;
CESC	cis	rs9649213	0.593	rs6465677	chr7:98003552	C/T	cg00277769	chr7:97922759	BAIAP2L1	-0.33	-5.48	-0.32	9.89e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs9322193	0.923	rs9767105	chr6:149980727	A/G	cg07701084	chr6:150067640	NUP43	0.52	7.22	0.41	5.55e-12	Lung cancer;
CESC	cis	rs9322193	0.962	rs9478848	chr6:150146216	G/T	cg04369109	chr6:150039330	LATS1	-0.4	-5.61	-0.33	4.98e-8	Lung cancer;
CESC	cis	rs7811142	1.000	rs7803454	chr7:99991548	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.11	10.85	0.55	6.37e-23	Platelet count;
CESC	cis	rs10089	1.000	rs10478798	chr5:127442394	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.77	10.58	0.55	4.65e-22	Ileal carcinoids;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04835431	chr14:105684005	BRF1	-0.53	-6.03	-0.35	5.59e-9	Gut microbiome composition (summer);
CESC	cis	rs9926296	0.585	rs8045232	chr16:89857548	A/G	cg07648498	chr16:89883185	FANCA	0.43	5.37	0.31	1.71e-7	Vitiligo;
CESC	cis	rs10851478	0.872	rs12908624	chr15:49797933	G/A	cg08060515	chr15:49448048	GALK2;COPS2	0.42	5.19	0.3	4.12e-7	Oral cavity cancer;
CESC	cis	rs4481887	0.927	rs10788779	chr1:248481661	C/G	cg00666640	chr1:248458726	OR2T12	0.34	5.76	0.33	2.35e-8	Common traits (Other);
CESC	cis	rs801193	1.000	rs7783924	chr7:66209057	A/C	cg14393609	chr7:65229607	NA	0.47	6.31	0.36	1.17e-9	Aortic root size;
CESC	cis	rs9487051	0.714	rs7755970	chr6:109602359	A/G	cg12927641	chr6:109611667	NA	-0.37	-5.57	-0.32	6.2e-8	Reticulocyte fraction of red cells;
CESC	cis	rs7301826	0.651	rs10848210	chr12:131312020	G/A	cg11011512	chr12:131303247	STX2	0.46	5.75	0.33	2.48e-8	Plasma plasminogen activator levels;
CESC	cis	rs7937682	0.681	rs2156580	chr11:111394328	C/G	cg09085632	chr11:111637200	PPP2R1B	0.49	5.7	0.33	3.25e-8	Primary sclerosing cholangitis;
CESC	cis	rs1862618	0.853	rs866222	chr5:56184444	T/C	cg24531977	chr5:56204891	C5orf35	-0.87	-10.87	-0.56	5.43e-23	Initial pursuit acceleration;
CESC	cis	rs6461049	0.800	rs1860831	chr7:2160931	T/C	cg04267008	chr7:1944627	MAD1L1	-0.47	-5.58	-0.32	5.95e-8	Schizophrenia;
CESC	cis	rs6681460	0.800	rs539014	chr1:67211887	C/T	cg02459107	chr1:67143332	SGIP1	-0.34	-5.07	-0.3	7.5e-7	Presence of antiphospholipid antibodies;
CESC	cis	rs67311347	1.000	rs6762251	chr3:40531136	A/G	cg09455208	chr3:40491958	NA	-0.44	-7.31	-0.41	3.12e-12	Renal cell carcinoma;
CESC	cis	rs2836974	0.932	rs8128734	chr21:40569511	G/A	cg11890956	chr21:40555474	PSMG1	1.17	21.82	0.8	4.14e-61	Cognitive function;
CESC	trans	rs7615952	0.512	rs11929125	chr3:125359443	G/A	cg21747405	chr11:67723411	NA	-0.44	-6.69	-0.38	1.3100000000000001e-10	Blood pressure (smoking interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15993083	chr12:4381788	CCND2	-0.48	-6.34	-0.36	1e-9	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03813443	chr1:232765924	NA	0.58	6.26	0.36	1.55e-9	Gut microbiome composition (summer);
CESC	cis	rs2991971	0.934	rs7903	chr1:45976472	G/C	cg05343316	chr1:45956843	TESK2	-0.51	-6.75	-0.38	9.49e-11	High light scatter reticulocyte count;
CESC	cis	rs67460515	0.859	rs7610800	chr3:161002582	C/T	cg03342759	chr3:160939853	NMD3	-0.52	-7.44	-0.42	1.45e-12	Parkinson's disease;
CESC	cis	rs12200560	0.505	rs211173	chr6:97070804	C/T	cg06623918	chr6:96969491	KIAA0776	0.46	5.75	0.33	2.48e-8	Coronary heart disease;
CESC	cis	rs910316	1.000	rs10143132	chr14:75525850	G/A	cg11812906	chr14:75593930	NEK9	0.89	14.86	0.67	9.77e-37	Height;
CESC	cis	rs4664308	0.870	rs55959207	chr2:161016981	A/C	cg03641300	chr2:160917029	PLA2R1	-0.62	-9.13	-0.49	1.82e-17	Idiopathic membranous nephropathy;
CESC	cis	rs10883723	0.810	rs2296589	chr10:104248106	T/A	ch.10.2196322F	chr10:104248062	ACTR1A	0.42	5.16	0.3	4.93e-7	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs909341	0.710	rs6011016	chr20:62302650	C/G	cg03999872	chr20:62272968	STMN3	0.56	5.47	0.32	1.06e-7	Atopic dermatitis;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg00760200	chr1:115053833	TRIM33	-0.42	-6.01	-0.35	6.1e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs10504229	0.683	rs55807014	chr8:58131801	T/C	cg21724239	chr8:58056113	NA	0.58	5.95	0.34	8.29e-9	Developmental language disorder (linguistic errors);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg11317343	chr5:177580912	NHP2	0.45	6.08	0.35	4.14e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs10504229	0.683	rs11775506	chr8:58133639	G/T	cg02725872	chr8:58115012	NA	-0.44	-6.89	-0.39	3.94e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs4665809	0.759	rs62128394	chr2:26364026	T/G	cg25036284	chr2:26402008	FAM59B	0.76	8.46	0.46	1.79e-15	Gut microbiome composition (summer);
CESC	cis	rs6032067	0.777	rs62208385	chr20:43789823	A/T	cg10761708	chr20:43804764	PI3	0.56	6.55	0.37	3.01e-10	Blood protein levels;
CESC	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg18402987	chr7:1209562	NA	0.75	8.6	0.47	7.26e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg02442412	chr4:83720054	SCD5	0.46	6.68	0.38	1.38e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs3857536	0.740	rs9354392	chr6:66894555	G/T	cg07460842	chr6:66804631	NA	-0.43	-5.54	-0.32	7.31e-8	Blood trace element (Cu levels);
CESC	cis	rs4819052	0.851	rs914218	chr21:46698445	G/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.45	5.6	0.33	5.44e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs798554	1.000	rs798554	chr7:2759795	C/T	cg18446336	chr7:2847575	GNA12	-0.36	-5.54	-0.32	7.32e-8	Height;
CESC	cis	rs863345	0.967	rs7526514	chr1:158532405	T/G	cg12129480	chr1:158549410	OR10X1	-0.33	-6.66	-0.38	1.58e-10	Pneumococcal bacteremia;
CESC	cis	rs2836974	0.568	rs442972	chr21:40534757	C/T	cg17971929	chr21:40555470	PSMG1	-0.87	-12.84	-0.62	1.11e-29	Cognitive function;
CESC	cis	rs897080	0.552	rs1067378	chr2:44648047	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.48	5.56	0.32	6.51e-8	Height;
CESC	trans	rs208520	0.955	rs208538	chr6:66964492	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.78	-8.63	-0.47	5.64e-16	Exhaled nitric oxide output;
CESC	cis	rs7552404	1.000	rs9662166	chr1:76235906	C/A	cg03433033	chr1:76189801	ACADM	0.54	6.25	0.36	1.65e-9	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs5750830	0.649	rs7949	chr22:39827553	G/A	cg11247378	chr22:39784982	NA	-0.63	-9.52	-0.5	1.14e-18	Intelligence (multi-trait analysis);
CESC	cis	rs7474896	0.515	rs2738203	chr10:38277596	G/A	cg25427524	chr10:38739819	LOC399744	0.52	5.58	0.32	5.94e-8	Obesity (extreme);
CESC	trans	rs9987353	0.840	rs329994	chr8:9123233	A/G	cg07970400	chr15:40650285	DISP2	-0.45	-6.04	-0.35	5.2e-9	Recombination measurement;
CESC	cis	rs9916302	0.851	rs6503518	chr17:37660469	A/G	cg00129232	chr17:37814104	STARD3	-0.57	-7.57	-0.42	6.31e-13	Glomerular filtration rate (creatinine);
CESC	cis	rs875971	0.638	rs3898855	chr7:66036398	G/C	cg14393609	chr7:65229607	NA	-0.47	-6.31	-0.36	1.14e-9	Aortic root size;
CESC	cis	rs4891159	1.000	rs4891159	chr18:74101941	A/G	cg24786174	chr18:74118243	ZNF516	0.58	8.53	0.46	1.14e-15	Longevity;
CESC	cis	rs35110281	0.811	rs7275705	chr21:45056453	G/C	cg04455712	chr21:45112962	RRP1B	0.38	5.58	0.32	6.09e-8	Mean corpuscular volume;
CESC	cis	rs7703051	0.901	rs4704223	chr5:74773420	T/C	cg03227963	chr5:74354835	NA	0.29	5.35	0.31	1.92e-7	LDL cholesterol;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
CESC	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.55	-6.17	-0.35	2.48e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs9926296	0.744	rs164747	chr16:89708680	T/G	cg03605463	chr16:89740564	NA	0.64	7.48	0.42	1.08e-12	Vitiligo;
CESC	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.65	7.41	0.41	1.72e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg08822737	chr17:71088851	SLC39A11	-0.49	-6.52	-0.37	3.49e-10	Fibrinogen levels;
CESC	cis	rs7605827	0.930	rs7605730	chr2:15598696	A/G	cg19274914	chr2:15703543	NA	0.32	5.67	0.33	3.71e-8	Educational attainment (years of education);
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg17286491	chr1:179923514	CEP350	0.47	6.17	0.35	2.57e-9	Systemic lupus erythematosus;
CESC	cis	rs780096	0.526	rs704791	chr2:27657167	T/C	cg21248554	chr2:27665150	KRTCAP3	-0.36	-7.38	-0.41	2.02e-12	Total body bone mineral density;
CESC	cis	rs35520189	0.591	rs12618418	chr2:113707645	G/T	cg06156847	chr2:113672199	IL1F7	0.37	5.31	0.31	2.3e-7	Obstructive sleep apnea trait (apnea hypopnea index);
CESC	cis	rs1348850	0.526	rs10930797	chr2:178437553	C/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.57	5.05	0.3	8.17e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs13242816	1.000	rs35595472	chr7:116122306	G/A	cg04696780	chr7:116139425	CAV2	-0.59	-5.23	-0.31	3.42e-7	P wave duration;
CESC	cis	rs35110281	0.743	rs2329443	chr21:45059431	C/T	cg01579765	chr21:45077557	HSF2BP	-0.57	-9.28	-0.5	6.43e-18	Mean corpuscular volume;
CESC	cis	rs9487051	0.714	rs9487053	chr6:109619697	T/C	cg21918786	chr6:109611834	NA	-0.36	-5.28	-0.31	2.64e-7	Reticulocyte fraction of red cells;
CESC	cis	rs921968	0.678	rs500422	chr2:219432995	C/A	cg02176678	chr2:219576539	TTLL4	0.39	6.68	0.38	1.44e-10	Mean corpuscular hemoglobin concentration;
CESC	cis	rs12478296	1.000	rs73007138	chr2:243007041	C/T	cg06360820	chr2:242988706	NA	-1.01	-10.1	-0.53	1.72e-20	Obesity-related traits;
CESC	cis	rs9393777	0.513	rs9368450	chr6:26652489	A/C	cg12292205	chr6:26970375	C6orf41	-0.55	-5.81	-0.34	1.74e-8	Intelligence (multi-trait analysis);
CESC	cis	rs7662987	0.517	rs1453874	chr4:100022724	G/A	cg12011299	chr4:100065546	ADH4	0.6	6.6	0.38	2.23e-10	Smoking initiation;
CESC	trans	rs3780486	0.505	rs10758188	chr9:33123386	C/T	cg04842962	chr6:43655489	MRPS18A	-0.73	-11.43	-0.57	7.37e-25	IgG glycosylation;
CESC	cis	rs7666738	0.830	rs6823718	chr4:99063202	C/T	cg03676636	chr4:99064102	C4orf37	0.33	5.04	0.3	8.47e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7084402	0.967	rs1649035	chr10:60332701	A/T	cg07615347	chr10:60278583	BICC1	0.57	8.91	0.48	8.63e-17	Refractive error;
CESC	cis	rs3747547	1.000	rs72724190	chr9:37942005	A/G	cg13774184	chr9:37916125	SHB	-0.75	-6.32	-0.36	1.12e-9	Metabolite levels (Dihydroxy docosatrienoic acid);
CESC	cis	rs763014	0.966	rs4144003	chr16:645968	C/T	cg00802000	chr16:706648	WDR90	-0.4	-6.07	-0.35	4.32e-9	Height;
CESC	cis	rs8114671	0.562	rs6087641	chr20:33467717	T/C	cg24642439	chr20:33292090	TP53INP2	0.41	5.05	0.3	8.09e-7	Height;
CESC	cis	rs2749592	1.000	rs2749592	chr10:38258842	A/C	cg25427524	chr10:38739819	LOC399744	-0.46	-5.83	-0.34	1.61e-8	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs17826219	0.500	rs2449749	chr17:29078298	C/T	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.91e-10	Body mass index;
CESC	cis	rs6546550	0.901	rs6546556	chr2:70139001	A/G	cg02498382	chr2:70120550	SNRNP27	-0.41	-7.26	-0.41	4.34e-12	Prevalent atrial fibrillation;
CESC	cis	rs12497850	0.797	rs61583136	chr3:49189195	C/T	cg06212747	chr3:49208901	KLHDC8B	0.76	10.35	0.54	2.7e-21	Parkinson's disease;
CESC	cis	rs3785574	0.962	rs2584623	chr17:61906679	G/A	cg06420487	chr17:61919686	SMARCD2	0.44	5.3	0.31	2.43e-7	Height;
CESC	cis	rs8067545	0.750	rs4005937	chr17:19959828	A/C	cg13482628	chr17:19912719	NA	0.37	5.06	0.3	7.79e-7	Schizophrenia;
CESC	cis	rs6547741	0.935	rs2384626	chr2:27773648	A/G	cg21248554	chr2:27665150	KRTCAP3	0.26	5.41	0.32	1.4e-7	Oral cavity cancer;
CESC	cis	rs6732160	0.613	rs57208378	chr2:73389999	G/A	cg01422370	chr2:73384389	NA	0.55	8.67	0.47	4.33e-16	Intelligence (multi-trait analysis);
CESC	cis	rs7618501	0.602	rs9311446	chr3:50092226	G/A	cg24110177	chr3:50126178	RBM5	0.52	7.18	0.4	6.85e-12	Intelligence (multi-trait analysis);
CESC	cis	rs7296418	0.885	rs1051434	chr12:123641200	C/T	cg05973401	chr12:123451056	ABCB9	0.53	6.78	0.38	8.01e-11	Platelet count;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg25109393	chr5:73936428	ENC1	-0.52	-7.17	-0.4	7.47e-12	Fibrinogen levels;
CESC	cis	rs780096	0.565	rs10169261	chr2:27727314	C/T	cg22903471	chr2:27725779	GCKR	-0.54	-7.39	-0.41	1.93e-12	Total body bone mineral density;
CESC	cis	rs425277	1.000	rs196128	chr1:2078444	T/G	cg24578937	chr1:2090814	PRKCZ	0.55	9.54	0.51	9.57e-19	Height;
CESC	cis	rs6842047	1.000	rs1877320	chr4:187131279	G/A	cg02012338	chr4:187126139	CYP4V2	0.74	5.96	0.34	7.84e-9	Blood protein levels;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg12064626	chr21:40817896	SH3BGR	-0.46	-6.39	-0.37	7.38e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs9916302	0.861	rs2338801	chr17:37490780	G/T	cg00129232	chr17:37814104	STARD3	0.57	7.58	0.42	5.64e-13	Glomerular filtration rate (creatinine);
CESC	cis	rs11264213	0.786	rs72659673	chr1:36242004	G/A	cg27506609	chr1:36549197	TEKT2	0.65	5.34	0.31	1.97e-7	Schizophrenia;
CESC	cis	rs7586879	1.000	rs6736711	chr2:25116456	C/T	cg01884057	chr2:25150051	NA	0.28	5.12	0.3	5.86e-7	Body mass index;
CESC	cis	rs947211	1.000	rs947211	chr1:205752665	A/G	cg26354017	chr1:205819088	PM20D1	0.41	5.18	0.3	4.42e-7	Parkinson's disease;
CESC	cis	rs9300255	0.722	rs28458312	chr12:123863265	G/T	cg19016782	chr12:123741754	C12orf65	0.46	6.33	0.36	1.04e-9	Neutrophil percentage of white cells;
CESC	cis	rs6815814	0.731	rs28532329	chr4:38771368	C/T	cg02016764	chr4:38805732	TLR1	-0.44	-6.08	-0.35	4.24e-9	Breast cancer;
CESC	cis	rs12048904	0.964	rs3188491	chr1:101338482	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.54	7.04	0.4	1.62e-11	Multiple sclerosis;
CESC	cis	rs2290159	0.948	rs11711270	chr3:12639596	C/T	cg23032965	chr3:12705835	RAF1	0.49	5.45	0.32	1.14e-7	Cholesterol, total;
CESC	cis	rs7618915	0.571	rs1961959	chr3:52585760	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.47	6.53	0.37	3.24e-10	Bipolar disorder;
CESC	trans	rs1814175	0.646	rs1722010	chr11:49897958	A/G	cg15704280	chr7:45808275	SEPT13	-1.0	-18.78	-0.76	1.35e-50	Height;
CESC	trans	rs6414928	0.516	rs34286815	chr5:25935440	C/T	cg17053223	chr7:94535617	PPP1R9A	-0.56	-6.17	-0.35	2.49e-9	Facial morphology (factor 5, width of mouth relative to central midface);
CESC	cis	rs863345	0.604	rs1873511	chr1:158461366	C/T	cg12129480	chr1:158549410	OR10X1	-0.35	-7.17	-0.4	7.58e-12	Pneumococcal bacteremia;
CESC	cis	rs3741404	0.825	rs11604782	chr11:63946650	G/A	cg18225595	chr11:63971243	STIP1	0.72	9.62	0.51	5.43e-19	Platelet count;
CESC	cis	rs711245	0.574	rs1179494	chr2:36809496	C/G	cg09467607	chr2:36825704	FEZ2	-0.55	-10.16	-0.53	1.04e-20	Height;
CESC	cis	rs3764400	0.506	rs72827851	chr17:46452495	C/A	cg10706073	chr17:46328419	SKAP1	-0.66	-5.15	-0.3	5.03e-7	Body mass index;
CESC	cis	rs514406	0.505	rs374849	chr1:53185631	G/A	cg08859206	chr1:53392774	SCP2	-0.59	-7.77	-0.43	1.69e-13	Monocyte count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01204535	chr5:162888518	NUDCD2;HMMR	-0.56	-6.57	-0.37	2.6e-10	Gut microbiome composition (summer);
CESC	cis	rs644799	0.965	rs1944080	chr11:95503636	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.55	6.94	0.39	3.05e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs7824557	0.778	rs6601572	chr8:11093337	C/G	cg21775007	chr8:11205619	TDH	-0.35	-5.27	-0.31	2.89e-7	Retinal vascular caliber;
CESC	cis	rs7949030	0.626	rs11231144	chr11:62328038	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.67	10.4	0.54	1.88e-21	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs922182	0.547	rs12907026	chr15:64271604	A/C	cg24729988	chr15:64271149	DAPK2	-0.61	-9.06	-0.49	2.93e-17	Blood protein levels;
CESC	cis	rs66573146	0.572	rs67252699	chr4:6946411	A/G	cg26116260	chr4:7069785	GRPEL1	-0.8	-5.23	-0.31	3.39e-7	Granulocyte percentage of myeloid white cells;
CESC	cis	rs7666738	0.830	rs34244876	chr4:99031336	G/A	cg24818145	chr4:99064322	C4orf37	0.39	5.09	0.3	6.95e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9322193	0.923	rs9767105	chr6:149980727	A/G	cg13206674	chr6:150067644	NUP43	0.49	7.03	0.4	1.79e-11	Lung cancer;
CESC	cis	rs769267	0.930	rs2288852	chr19:19605348	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.46	5.89	0.34	1.15e-8	Tonsillectomy;
CESC	cis	rs11997175	0.550	rs7464954	chr8:33832202	A/G	ch.8.33884649F	chr8:33765107	NA	0.6	7.45	0.42	1.35e-12	Body mass index;
CESC	cis	rs4665809	0.549	rs3828255	chr2:26413252	G/A	cg04944784	chr2:26401820	FAM59B	0.85	9.15	0.49	1.61e-17	Gut microbiome composition (summer);
CESC	trans	rs7937682	0.889	rs541198	chr11:111475340	A/G	cg18187862	chr3:45730750	SACM1L	0.48	6.11	0.35	3.49e-9	Primary sclerosing cholangitis;
CESC	cis	rs7945705	0.902	rs10743093	chr11:8869129	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.47	7.44	0.42	1.36e-12	Hemoglobin concentration;
CESC	cis	rs4689388	0.926	rs4689391	chr4:6280449	G/A	cg00701064	chr4:6280414	WFS1	0.77	14.05	0.65	7.04e-34	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs7095944	0.614	rs4962697	chr10:126447545	G/C	cg08799069	chr10:126477246	METTL10	-0.37	-5.28	-0.31	2.7e-7	Asthma;
CESC	cis	rs17384381	0.859	rs28529751	chr1:85910951	G/A	cg16011679	chr1:85725395	C1orf52	0.68	6.92	0.39	3.45e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs12995491	0.763	rs1914735	chr2:88511953	A/T	cg07952391	chr2:88470173	THNSL2	-0.55	-8.35	-0.46	3.72e-15	Response to metformin (IC50);
CESC	cis	rs2273669	0.588	rs6568555	chr6:109331777	A/G	cg05315195	chr6:109294784	ARMC2	-0.67	-6.32	-0.36	1.13e-9	Prostate cancer;
CESC	cis	rs7927771	0.507	rs12366244	chr11:47882130	C/A	cg18512352	chr11:47633146	NA	0.35	5.43	0.32	1.29e-7	Subjective well-being;
CESC	cis	rs6429082	0.818	rs291341	chr1:235663174	G/T	cg26050004	chr1:235667680	B3GALNT2	0.67	8.42	0.46	2.43e-15	Adiposity;
CESC	cis	rs17666538	0.585	rs6559064	chr8:623061	G/A	cg02524346	chr8:600233	NA	0.84	5.97	0.34	7.53e-9	IgG glycosylation;
CESC	cis	rs7666738	0.830	rs2019163	chr4:99022747	C/T	cg03676636	chr4:99064102	C4orf37	0.33	5.15	0.3	5.05e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6570726	0.837	rs636894	chr6:145864122	T/C	cg05347473	chr6:146136440	FBXO30	0.46	6.16	0.35	2.72e-9	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs644799	1.000	rs7749	chr11:95565789	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.54	6.55	0.37	2.97e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg08948823	chr16:67881367	CENPT;NUTF2	-0.5	-6.07	-0.35	4.31e-9	Lung cancer in ever smokers;
CESC	cis	rs6714710	0.603	rs4311104	chr2:98424802	A/G	cg26665480	chr2:98280029	ACTR1B	0.56	7.96	0.44	5.02e-14	Posterior cortical atrophy and Alzheimer's disease;
CESC	cis	rs3733585	0.699	rs57574512	chr4:9960182	T/C	cg11266682	chr4:10021025	SLC2A9	-0.6	-11.2	-0.57	4.42e-24	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs2842992	0.789	rs6908680	chr6:160218209	G/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.78	9.64	0.51	4.81e-19	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs7246865	0.510	rs2305756	chr19:17169936	C/T	cg16202187	chr19:17186497	HAUS8;MYO9B	0.49	6.44	0.37	5.52e-10	Reticulocyte fraction of red cells;
CESC	cis	rs9612	1.000	rs1059	chr19:44268348	C/T	cg08581076	chr19:44259116	C19orf61	0.49	5.76	0.33	2.35e-8	Exhaled nitric oxide output;
CESC	cis	rs4862750	0.872	rs6821507	chr4:187876829	G/T	cg07414643	chr4:187882934	NA	-0.52	-7.38	-0.41	2.04e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs72781680	1.000	rs17763442	chr2:24255991	C/T	cg20701182	chr2:24300061	SF3B14	0.99	8.48	0.46	1.64e-15	Lymphocyte counts;
CESC	cis	rs4700695	0.719	rs27586	chr5:65445873	G/A	cg21114390	chr5:65439923	SFRS12	-0.49	-6.04	-0.35	5.09e-9	Facial morphology (factor 19);
CESC	cis	rs854765	0.583	rs66531105	chr17:17809001	C/T	cg04398451	chr17:18023971	MYO15A	-0.67	-9.59	-0.51	6.66e-19	Total body bone mineral density;
CESC	cis	rs2839186	0.619	rs55689527	chr21:47622727	A/G	cg12379764	chr21:47803548	PCNT	-0.46	-5.85	-0.34	1.46e-8	Testicular germ cell tumor;
CESC	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg03188948	chr7:1209495	NA	0.67	6.45	0.37	5.33e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	22.28	0.81	1.08e-62	Prudent dietary pattern;
CESC	cis	rs7520050	1.000	rs7540699	chr1:46338585	A/G	cg03146154	chr1:46216737	IPP	-0.48	-6.22	-0.36	1.98e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs9818941	0.826	rs2712321	chr3:157644344	C/T	cg08654915	chr3:157813417	NA	0.49	7.86	0.43	9.52e-14	Height;
CESC	cis	rs4665809	1.000	rs6729080	chr2:26301282	G/A	cg22920501	chr2:26401640	FAM59B	-0.67	-8.12	-0.45	1.72e-14	Gut microbiome composition (summer);
CESC	cis	rs1003719	0.680	rs7275984	chr21:38505696	C/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-8.47	-0.46	1.69e-15	Eye color traits;
CESC	cis	rs79349575	0.783	rs4793995	chr17:47019399	A/C	cg16584676	chr17:46985605	UBE2Z	0.54	6.67	0.38	1.46e-10	Type 2 diabetes;
CESC	cis	rs3806843	1.000	rs1030165	chr5:140185448	G/A	cg16179182	chr5:140090404	VTRNA1-1	-0.41	-5.33	-0.31	2.08e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs8077889	0.672	rs2106764	chr17:41852717	T/A	cg26893861	chr17:41843967	DUSP3	1.0	18.44	0.75	2.03e-49	Triglycerides;
CESC	cis	rs6575793	1.000	rs8006176	chr14:101033288	A/G	cg18516195	chr14:101012996	BEGAIN	0.47	6.42	0.37	6.4e-10	Menarche (age at onset);
CESC	cis	rs6570726	0.818	rs412350	chr6:145852409	T/C	cg23711669	chr6:146136114	FBXO30	1.01	15.66	0.69	1.45e-39	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6502050	0.764	rs35416122	chr17:80119006	A/G	cg23985595	chr17:80112537	CCDC57	-0.41	-6.46	-0.37	4.95e-10	Life satisfaction;
CESC	cis	rs2243480	1.000	rs34637256	chr7:65360131	G/A	cg25894440	chr7:65020034	NA	-0.59	-5.03	-0.3	9.19e-7	Diabetic kidney disease;
CESC	cis	rs7647973	0.577	rs6446247	chr3:49102001	A/T	cg06212747	chr3:49208901	KLHDC8B	0.49	5.51	0.32	8.6e-8	Menarche (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22980722	chr21:45719818	PFKL	0.6	7.41	0.41	1.69e-12	Gut microbiome composition (summer);
CESC	trans	rs8073060	0.586	rs4796100	chr17:33997657	G/T	cg19694781	chr19:47549865	TMEM160	0.75	7.38	0.41	2.07e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	cis	rs6582630	0.555	rs7978749	chr12:38527141	G/T	cg13010199	chr12:38710504	ALG10B	0.46	5.95	0.34	8.41e-9	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs17854409	0.881	rs12625401	chr20:61472939	A/T	cg05147244	chr20:61493195	TCFL5	0.98	6.61	0.38	2.1e-10	Obesity-related traits;
CESC	cis	rs9322193	0.962	rs11155685	chr6:150102785	A/C	cg05861140	chr6:150128134	PCMT1	-0.37	-5.3	-0.31	2.42e-7	Lung cancer;
CESC	trans	rs116095464	0.558	rs2288457	chr5:231270	C/T	cg00938859	chr5:1591904	SDHAP3	0.63	6.87	0.39	4.48e-11	Breast cancer;
CESC	cis	rs7659604	0.540	rs10020581	chr4:122676559	A/C	cg19671926	chr4:122722719	EXOSC9	0.53	6.7	0.38	1.21e-10	Type 2 diabetes;
CESC	cis	rs4713118	0.621	rs10484403	chr6:28033523	A/G	cg23161317	chr6:28129485	ZNF389	0.49	6.29	0.36	1.31e-9	Parkinson's disease;
CESC	cis	rs9430161	0.644	rs6685766	chr1:11037051	T/C	cg27631724	chr1:11040367	C1orf127	0.46	7.81	0.43	1.36e-13	Ewing sarcoma;
CESC	cis	rs17401966	0.931	rs11585794	chr1:10443867	G/A	cg15208524	chr1:10270712	KIF1B	0.41	5.23	0.31	3.51e-7	Hepatocellular carcinoma;
CESC	cis	rs10189230	0.967	rs13026378	chr2:222352712	G/A	cg14652038	chr2:222343519	EPHA4	0.37	7.76	0.43	1.85e-13	Urate levels in lean individuals;
CESC	cis	rs7937682	0.855	rs10891285	chr11:111527775	T/C	cg09085632	chr11:111637200	PPP2R1B	-1.0	-16.54	-0.71	1.09e-42	Primary sclerosing cholangitis;
CESC	cis	rs6582630	0.555	rs11182217	chr12:38480030	G/A	cg26384229	chr12:38710491	ALG10B	0.67	10.0	0.52	3.5e-20	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs4853012	0.941	rs4852329	chr2:74354544	A/G	cg19729930	chr2:74357872	NA	0.94	12.23	0.6	1.48e-27	Gestational age at birth (maternal effect);
CESC	cis	rs2952156	0.920	rs8078228	chr17:37834998	C/T	cg07936489	chr17:37558343	FBXL20	-0.6	-7.98	-0.44	4.35e-14	Asthma;
CESC	cis	rs4835473	0.932	rs6537231	chr4:144907642	T/C	cg25736465	chr4:144833511	NA	0.41	6.29	0.36	1.28e-9	Immature fraction of reticulocytes;
CESC	cis	rs712039	0.652	rs11656503	chr17:35772021	G/T	cg16670864	chr17:35848621	DUSP14	0.44	5.5	0.32	8.74e-8	Tuberculosis;
CESC	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg06873352	chr17:61820015	STRADA	0.72	12.77	0.62	2.07e-29	Prudent dietary pattern;
CESC	cis	rs7044106	0.762	rs1158554	chr9:123400898	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.36	5.86	0.34	1.38e-8	Hip circumference adjusted for BMI;
CESC	cis	rs6582630	0.537	rs12823925	chr12:38409323	C/T	cg26384229	chr12:38710491	ALG10B	0.69	10.57	0.54	4.96e-22	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs2236918	0.643	rs1776139	chr1:242027363	T/G	cg17736920	chr1:242011382	EXO1	0.5	6.39	0.37	7.43e-10	Menopause (age at onset);
CESC	trans	rs17685	0.753	rs869804	chr7:75688954	A/G	cg19862616	chr7:65841803	NCRNA00174	0.83	12.47	0.61	2.23e-28	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs9359856	0.517	rs11962350	chr6:90592406	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.8	-7.56	-0.42	6.5e-13	Bipolar disorder;
CESC	cis	rs11599315	1.000	rs11599315	chr10:1343017	C/T	cg09624528	chr10:1369823	ADARB2	0.44	5.96	0.34	7.9e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs12545109	0.800	rs1996105	chr8:57413123	A/G	cg09654669	chr8:57350985	NA	-0.54	-6.35	-0.36	9.45e-10	Obesity-related traits;
CESC	cis	rs858239	1.000	rs156407	chr7:23315639	G/A	cg23682824	chr7:23144976	KLHL7	0.45	5.96	0.34	8.22e-9	Cerebrospinal fluid biomarker levels;
CESC	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg05313129	chr8:58192883	C8orf71	-0.47	-5.13	-0.3	5.63e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs17376456	0.825	rs10214278	chr5:93237679	C/T	cg21475434	chr5:93447410	FAM172A	-0.79	-6.62	-0.38	1.95e-10	Diabetic retinopathy;
CESC	cis	rs757110	0.866	rs5213	chr11:17408404	C/T	cg11839944	chr11:17409644	KCNJ11	0.41	5.57	0.32	6.12e-8	Type 2 diabetes;
CESC	cis	rs1046896	0.514	rs67735447	chr17:80823042	G/T	cg05255149	chr17:80675120	FN3KRP	0.45	5.1	0.3	6.33e-7	Glycated hemoglobin levels;
CESC	cis	rs6502050	0.835	rs12600852	chr17:80104593	G/A	cg11859384	chr17:80120422	CCDC57	-0.38	-5.11	-0.3	6.21e-7	Life satisfaction;
CESC	cis	rs7666738	0.830	rs13139078	chr4:99020774	C/T	cg17366294	chr4:99064904	C4orf37	0.61	8.76	0.47	2.35e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2652822	0.584	rs1017546	chr15:63566702	G/T	cg02713581	chr15:63449717	RPS27L	-0.46	-6.04	-0.35	5.29e-9	Metabolic traits;
CESC	cis	rs34779708	0.966	rs2045915	chr10:35418616	G/C	cg04310649	chr10:35416472	CREM	-0.53	-6.32	-0.36	1.1e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs116095464	0.558	rs28558836	chr5:285748	C/G	cg22496380	chr5:211416	CCDC127	-0.72	-8.29	-0.45	5.54e-15	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13411897	chr3:12526166	TSEN2	0.56	6.53	0.37	3.27e-10	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.924	rs62318940	chr4:99064768	C/T	cg03676636	chr4:99064102	C4orf37	0.37	5.36	0.31	1.84e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6860806	0.507	rs270601	chr5:131656997	T/C	cg18758796	chr5:131593413	PDLIM4	0.4	5.5	0.32	9.08e-8	Breast cancer;
CESC	cis	rs9837602	0.592	rs694429	chr3:99459669	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.46	-5.94	-0.34	8.93e-9	Breast cancer;
CESC	trans	rs757081	0.667	rs7108067	chr11:17200220	G/A	cg00391031	chr10:72237473	KIAA1274	0.31	6.05	0.35	4.99e-9	Systolic blood pressure;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg14741666	chr17:34842576	ZNHIT3	0.56	7.15	0.4	8.23e-12	Gut microbiota (bacterial taxa);
CESC	cis	rs1371867	0.846	rs1660323	chr8:101278724	T/A	cg11906718	chr8:101322791	RNF19A	0.5	6.39	0.37	7.26e-10	Atrioventricular conduction;
CESC	cis	rs909002	0.962	rs10798883	chr1:32140305	C/T	cg13919466	chr1:32135498	COL16A1	-0.51	-9.54	-0.51	9.73e-19	Intelligence (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10972431	chr13:100258753	CLYBL	0.56	6.17	0.35	2.59e-9	Gut microbiome composition (summer);
CESC	cis	rs6688613	0.694	rs11576455	chr1:166811970	G/A	cg07049167	chr1:166818506	POGK	0.46	5.47	0.32	1.03e-7	Refractive astigmatism;
CESC	trans	rs61931739	0.517	rs7958856	chr12:34294737	T/C	cg26384229	chr12:38710491	ALG10B	0.62	8.67	0.47	4.48e-16	Morning vs. evening chronotype;
CESC	cis	rs6500602	0.647	rs4785967	chr16:4523208	G/A	cg08645402	chr16:4508243	NA	0.57	9.04	0.49	3.3e-17	Schizophrenia;
CESC	cis	rs228437	1.000	rs228436	chr6:134896913	A/T	cg24504307	chr6:134963096	NA	0.5	5.42	0.32	1.37e-7	Melanoma;
CESC	cis	rs1784581	0.775	rs7755404	chr6:162427731	T/C	cg17173639	chr6:162384350	PARK2	0.61	9.43	0.5	2.11e-18	Itch intensity from mosquito bite;
CESC	cis	rs2370759	1.000	rs16933225	chr10:32599464	C/T	cg18270830	chr10:32634957	EPC1	0.73	7.64	0.43	3.89e-13	Sexual dysfunction (female);
CESC	cis	rs847577	0.630	rs3801294	chr7:97822210	G/A	cg24562669	chr7:97807699	LMTK2	0.84	13.88	0.65	2.69e-33	Breast cancer;
CESC	cis	rs10032549	0.535	rs4859445	chr4:77382068	T/C	cg20311846	chr4:77356250	SHROOM3	-0.28	-5.32	-0.31	2.21e-7	Glomerular filtration rate;
CESC	cis	rs61542988	0.570	rs62448268	chr7:22829464	G/A	cg13679077	chr7:22862647	TOMM7	0.64	7.36	0.41	2.3e-12	Fibrinogen levels;
CESC	cis	rs7071206	0.853	rs57420220	chr10:79428886	C/T	cg07817648	chr10:79422355	NA	-0.88	-11.32	-0.57	1.77e-24	Bone mineral density;
CESC	cis	rs4253772	0.530	rs55653327	chr22:46682976	C/T	cg10541313	chr22:46663664	TTC38	0.75	5.44	0.32	1.19e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs9549367	0.773	rs9549717	chr13:113908826	A/G	cg18105134	chr13:113819100	PROZ	-0.69	-8.82	-0.48	1.53e-16	Platelet distribution width;
CESC	cis	rs7666738	0.791	rs6532725	chr4:99061479	T/C	cg03467027	chr4:99064603	C4orf37	0.48	5.98	0.35	7.05e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs5498	0.809	rs2075742	chr19:10401607	G/C	cg08845333	chr19:10403403	ICAM5	0.41	5.62	0.33	4.76e-8	Lymphocyte counts;Soluble ICAM-1;Blood protein levels;
CESC	cis	rs10540	1.000	rs61876341	chr11:495892	C/G	cg03934478	chr11:495069	RNH1	0.55	5.35	0.31	1.87e-7	Body mass index;
CESC	cis	rs7615952	0.866	rs11922276	chr3:125631326	G/T	cg05084668	chr3:125655381	ALG1L	-0.47	-5.54	-0.32	7.34e-8	Blood pressure (smoking interaction);
CESC	cis	rs9987353	0.566	rs13260067	chr8:9071033	A/G	cg15556689	chr8:8085844	FLJ10661	-0.51	-5.91	-0.34	1.07e-8	Recombination measurement;
CESC	cis	rs17601876	0.814	rs8039089	chr15:51561328	T/G	cg19946085	chr15:51559439	CYP19A1	-0.33	-5.37	-0.31	1.76e-7	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg01657511	chr8:142318170	NA	-0.47	-6.21	-0.36	2.07e-9	Fibrinogen levels;
CESC	cis	rs9815354	0.761	rs73083329	chr3:41927151	C/T	cg03022575	chr3:42003672	ULK4	0.71	6.44	0.37	5.46e-10	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs9300255	0.602	rs1051431	chr12:123645803	G/A	cg00376283	chr12:123451042	ABCB9	0.7	8.86	0.48	1.16e-16	Neutrophil percentage of white cells;
CESC	cis	rs3820928	1.000	rs10167422	chr2:227777554	G/A	cg05526886	chr2:227700861	RHBDD1	-0.44	-5.75	-0.33	2.45e-8	Pulmonary function;
CESC	cis	rs4803468	0.967	rs2304243	chr19:41942708	C/G	cg14132834	chr19:41945861	ATP5SL	0.6	7.54	0.42	7.5e-13	Height;
CESC	cis	rs4450798	0.739	rs9840302	chr3:13741999	C/T	cg05589046	chr3:13742034	LOC285375	0.37	5.57	0.32	6.39e-8	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs11122272	0.735	rs2437149	chr1:231490105	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.48	-6.48	-0.37	4.51e-10	Hemoglobin concentration;
CESC	cis	rs35110281	0.641	rs4818858	chr21:45083097	C/T	cg04455712	chr21:45112962	RRP1B	-0.46	-7.01	-0.4	1.93e-11	Mean corpuscular volume;
CESC	cis	rs6460942	0.915	rs17444044	chr7:12458736	A/G	cg20607287	chr7:12443886	VWDE	-0.78	-9.15	-0.49	1.61e-17	Coronary artery disease;
CESC	cis	rs2832191	0.729	rs2832201	chr21:30499841	A/G	cg24692254	chr21:30365293	RNF160	-0.95	-15.57	-0.69	2.9e-39	Dental caries;
CESC	cis	rs6460942	0.591	rs62448728	chr7:12332915	A/T	cg02935154	chr7:12443704	VWDE	-0.53	-5.5	-0.32	9.01e-8	Coronary artery disease;
CESC	cis	rs1707322	1.000	rs6693336	chr1:46354595	C/T	cg06784218	chr1:46089804	CCDC17	0.32	5.57	0.32	6.35e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08633134	chr19:50935017	MYBPC2	0.55	6.06	0.35	4.63e-9	Gut microbiome composition (summer);
CESC	cis	rs1707322	0.752	rs11211152	chr1:46114157	C/T	cg06784218	chr1:46089804	CCDC17	0.41	7.12	0.4	1.04e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7923609	0.967	rs10761762	chr10:65184717	T/C	cg01631684	chr10:65280961	REEP3	-0.44	-5.48	-0.32	9.84e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07247970	chr1:150293881	PRPF3	0.62	6.77	0.38	8.35e-11	Gut microbiome composition (summer);
CESC	cis	rs9914578	0.943	rs9904872	chr17:2005241	T/A	cg16513277	chr17:2031491	SMG6	-0.57	-6.62	-0.38	1.99e-10	Body mass index;
CESC	cis	rs881375	0.934	rs2159778	chr9:123678129	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.38	5.07	0.3	7.52e-7	Rheumatoid arthritis;
CESC	trans	rs10435719	0.610	rs76311455	chr8:11790526	C/G	cg15556689	chr8:8085844	FLJ10661	0.53	6.51	0.37	3.7e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
CESC	cis	rs2415984	0.622	rs61993294	chr14:46932466	C/G	cg14871534	chr14:47121158	RPL10L	-0.35	-5.26	-0.31	2.95e-7	Number of children ever born;
CESC	cis	rs4704187	0.617	rs6898134	chr5:74456731	T/C	cg03227963	chr5:74354835	NA	0.3	5.46	0.32	1.07e-7	Response to amphetamines;
CESC	cis	rs798766	1.000	rs11732213	chr4:1704244	T/C	cg10756475	chr4:1757242	NA	-0.47	-5.77	-0.33	2.16e-8	Bladder cancer;Urinary bladder cancer;
CESC	cis	rs4665809	0.941	rs7602922	chr2:26265782	C/T	cg04944784	chr2:26401820	FAM59B	-0.8	-8.98	-0.48	5.03e-17	Gut microbiome composition (summer);
CESC	cis	rs2952156	0.920	rs2517954	chr17:37843550	T/C	cg20243544	chr17:37824526	PNMT	0.6	7.42	0.41	1.62e-12	Asthma;
CESC	cis	rs1344694	0.566	rs4672790	chr2:216892446	C/T	cg25588852	chr2:216877276	MREG	-0.36	-5.91	-0.34	1.07e-8	Alcohol dependence;
CESC	cis	rs9309473	1.000	rs6705489	chr2:73648811	G/T	cg20560298	chr2:73613845	ALMS1	-0.54	-7.2	-0.4	6.21e-12	Metabolite levels;
CESC	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.54	6.63	0.38	1.87e-10	Prudent dietary pattern;
CESC	cis	rs7044106	0.762	rs10760110	chr9:123412563	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.77	-11.25	-0.57	2.95e-24	Hip circumference adjusted for BMI;
CESC	cis	rs601339	1.000	rs11059384	chr12:123170301	C/A	cg11919336	chr12:123188078	GPR109A	0.45	5.86	0.34	1.36e-8	Adiponectin levels;
CESC	cis	rs12121840	0.573	rs927844	chr1:165510312	G/T	cg16553119	chr1:165599451	MGST3	0.44	5.6	0.33	5.35e-8	Interleukin-1-receptor antagonist levels;
CESC	cis	rs710216	0.843	rs3768043	chr1:43419354	C/A	cg07803811	chr1:43423981	SLC2A1	-0.46	-5.25	-0.31	3.13e-7	Red cell distribution width;
CESC	cis	rs6831352	0.734	rs1154400	chr4:100010010	C/T	cg13256891	chr4:100009986	ADH5	0.7	8.33	0.46	4.31e-15	Alcohol dependence;
CESC	cis	rs6952808	0.582	rs871925	chr7:2047875	G/A	cg21782813	chr7:2030301	MAD1L1	-0.4	-5.57	-0.32	6.23e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs7552404	1.000	rs11161515	chr1:76212559	C/T	cg10523679	chr1:76189770	ACADM	0.67	7.61	0.42	4.79e-13	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs1268083	0.546	rs9398785	chr6:126057748	A/G	cg05901451	chr6:126070800	HEY2	-0.53	-7.62	-0.42	4.61e-13	Migraine;
CESC	cis	rs769267	0.965	rs2965188	chr19:19522557	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.49	6.18	0.36	2.37e-9	Tonsillectomy;
CESC	cis	rs599083	0.530	rs640569	chr11:68184820	A/G	cg16797656	chr11:68205561	LRP5	-0.39	-5.18	-0.3	4.48e-7	Bone mineral density (spine);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg17899198	chr3:127323650	MCM2	0.43	6.0	0.35	6.37e-9	Fibrinogen levels;
CESC	cis	rs5769765	0.955	rs2295406	chr22:50260169	G/A	cg26441486	chr22:50317300	CRELD2	-0.39	-5.51	-0.32	8.4e-8	Schizophrenia;
CESC	cis	rs875971	0.522	rs1617484	chr7:65463095	G/A	cg11987759	chr7:65425863	GUSB	-0.49	-6.55	-0.37	3.03e-10	Aortic root size;
CESC	cis	rs910316	0.789	rs4899552	chr14:75667921	C/A	cg16144293	chr14:75469539	EIF2B2	0.42	5.38	0.31	1.62e-7	Height;
CESC	cis	rs7635838	0.819	rs4684782	chr3:11518755	C/T	cg00170343	chr3:11313890	ATG7	-0.42	-5.67	-0.33	3.76e-8	HDL cholesterol;
CESC	trans	rs1814175	0.519	rs3913237	chr11:49551828	G/A	cg03929089	chr4:120376271	NA	0.7	7.9	0.44	7.44e-14	Height;
CESC	cis	rs17711722	0.522	rs6957759	chr7:65271785	A/G	cg11764359	chr7:65958608	NA	0.47	5.96	0.34	7.99e-9	Calcium levels;
CESC	cis	rs3096299	0.685	rs12935112	chr16:89542858	C/T	cg02034447	chr16:89574710	SPG7	-0.46	-5.95	-0.34	8.63e-9	Multiple myeloma (IgH translocation);
CESC	cis	rs4665809	0.590	rs1368902	chr2:26440576	T/C	cg08470875	chr2:26401718	FAM59B	-0.75	-7.79	-0.43	1.49e-13	Gut microbiome composition (summer);
CESC	cis	rs763121	0.853	rs5757166	chr22:38995385	G/T	cg21395723	chr22:39101663	GTPBP1	0.5	6.72	0.38	1.12e-10	Menopause (age at onset);
CESC	cis	rs7520050	0.771	rs4660882	chr1:46116292	C/T	cg24296786	chr1:45957014	TESK2	-0.48	-6.17	-0.35	2.58e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs3740713	1.000	rs73440636	chr11:18473556	C/T	cg23797887	chr11:18477753	LDHAL6A	-0.57	-5.91	-0.34	1.06e-8	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs2243480	1.000	rs316318	chr7:65612904	A/G	cg18252515	chr7:66147081	NA	-1.41	-14.48	-0.66	2.11e-35	Diabetic kidney disease;
CESC	cis	rs523522	0.962	rs11065145	chr12:120947419	A/G	cg12219531	chr12:120966889	COQ5	0.75	9.99	0.52	3.7e-20	High light scatter reticulocyte count;
CESC	cis	rs853679	0.550	rs1233701	chr6:28168726	C/G	cg22143856	chr6:28129313	ZNF389	-0.46	-6.14	-0.35	3.05e-9	Depression;
CESC	cis	rs7811142	1.000	rs66632384	chr7:100018904	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.01	9.85	0.52	1.05e-19	Platelet count;
CESC	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg24846343	chr22:24311635	DDTL	0.61	10.31	0.53	3.66e-21	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs12188164	0.686	rs72711365	chr5:416672	G/A	cg26850624	chr5:429559	AHRR	-0.49	-6.72	-0.38	1.08e-10	Cystic fibrosis severity;
CESC	trans	rs11098499	0.554	rs2175381	chr4:120265967	T/C	cg25214090	chr10:38739885	LOC399744	0.59	7.99	0.44	4.13e-14	Corneal astigmatism;
CESC	cis	rs2735413	0.914	rs12448754	chr16:78066747	T/C	cg04733911	chr16:78082701	NA	-0.49	-7.7	-0.43	2.64e-13	Systolic blood pressure (alcohol consumption interaction);
CESC	cis	rs9322193	0.923	rs12660304	chr6:150060783	A/G	cg04369109	chr6:150039330	LATS1	-0.44	-6.25	-0.36	1.68e-9	Lung cancer;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg25983288	chr5:137681122	FAM53C	0.47	6.54	0.37	3.15e-10	Fibrinogen levels;
CESC	cis	rs2712184	0.756	rs2541388	chr2:217664284	A/G	cg05032264	chr2:217675019	NA	0.35	5.43	0.32	1.3e-7	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
CESC	cis	rs9611565	0.694	rs5758347	chr22:41821019	G/T	cg03806693	chr22:41940476	POLR3H	1.2	14.5	0.67	1.86e-35	Vitiligo;
CESC	cis	rs7186831	1	rs7186831	chr16:75473155	G/A	cg03315344	chr16:75512273	CHST6	0.42	6.12	0.35	3.38e-9	Chronic obstructive pulmonary disease;
CESC	cis	rs2760061	0.819	rs708115	chr1:228198046	C/T	cg18477163	chr1:228402036	OBSCN	0.32	5.62	0.33	4.75e-8	Diastolic blood pressure;
CESC	cis	rs4555082	0.915	rs79048296	chr14:105754944	G/A	cg13114125	chr14:105738426	BRF1	-0.89	-10.92	-0.56	3.7e-23	Mean platelet volume;Platelet distribution width;
CESC	cis	rs977987	0.872	rs1559339	chr16:75318646	A/G	cg03315344	chr16:75512273	CHST6	0.4	5.71	0.33	2.97e-8	Dupuytren's disease;
CESC	cis	rs769267	1.000	rs2074089	chr19:19449603	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.43	-5.43	-0.32	1.24e-7	Tonsillectomy;
CESC	cis	rs10256972	0.524	rs6945202	chr7:1116558	T/C	cg04025307	chr7:1156635	C7orf50	0.47	7.78	0.43	1.61e-13	Longevity;Endometriosis;
CESC	cis	rs2712184	0.756	rs2712161	chr2:217662384	G/A	cg05032264	chr2:217675019	NA	-0.39	-5.93	-0.34	9.65e-9	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
CESC	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.75	10.62	0.55	3.37e-22	Prudent dietary pattern;
CESC	cis	rs7539624	0.588	rs10916602	chr1:223897425	G/A	cg10100437	chr1:223903862	CAPN2	0.43	5.44	0.32	1.22e-7	Schizophrenia;
CESC	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.47	-6.56	-0.37	2.75e-10	Longevity;Endometriosis;
CESC	cis	rs7520050	0.966	rs10789481	chr1:46383583	C/G	cg24296786	chr1:45957014	TESK2	0.45	5.66	0.33	3.96e-8	Red blood cell count;Reticulocyte count;
CESC	cis	rs8114671	0.562	rs4911163	chr20:33470694	C/T	cg24642439	chr20:33292090	TP53INP2	0.43	5.17	0.3	4.52e-7	Height;
CESC	cis	rs17253792	0.642	rs10483648	chr14:56104278	T/C	cg01858014	chr14:56050164	KTN1	-0.96	-7.52	-0.42	8.3e-13	Putamen volume;
CESC	cis	rs290268	0.838	rs290989	chr9:93561836	T/C	cg02608019	chr9:93564028	SYK	0.63	9.64	0.51	4.92e-19	Platelet count;
CESC	cis	rs875971	0.520	rs2420597	chr7:65915986	A/G	cg12463550	chr7:65579703	CRCP	0.49	6.17	0.35	2.57e-9	Aortic root size;
CESC	cis	rs597539	0.652	rs514296	chr11:68654182	G/T	cg18350739	chr11:68623251	NA	-0.43	-6.91	-0.39	3.52e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs514406	0.929	rs557920	chr1:53338757	C/A	cg08859206	chr1:53392774	SCP2	-0.58	-7.51	-0.42	9.12e-13	Monocyte count;
CESC	cis	rs367615	0.840	rs113540823	chr5:108879084	C/T	cg17395555	chr5:108820864	NA	0.56	8.33	0.46	4.38e-15	Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs9649213	0.593	rs3779194	chr7:98010277	A/G	cg08684580	chr7:98029266	BAIAP2L1	-0.35	-5.67	-0.33	3.8e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs11098499	0.562	rs2389879	chr4:120557684	G/A	cg09307838	chr4:120376055	NA	-0.64	-8.31	-0.45	5.07e-15	Corneal astigmatism;
CESC	cis	rs1552244	0.938	rs34750074	chr3:10091740	G/A	cg00149659	chr3:10157352	C3orf10	0.71	8.36	0.46	3.63e-15	Alzheimer's disease;
CESC	cis	rs2066819	1.000	rs41392645	chr12:56696742	A/G	cg26734620	chr12:56694298	CS	1.04	6.73	0.38	1.06e-10	Psoriasis vulgaris;
CESC	cis	rs1023500	0.573	rs133370	chr22:42465260	T/C	cg15557168	chr22:42548783	NA	-0.45	-6.5	-0.37	3.87e-10	Schizophrenia;
CESC	cis	rs6952808	0.564	rs73038441	chr7:2139286	T/C	cg05863683	chr7:1912471	MAD1L1	0.37	5.36	0.31	1.77e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs6120849	0.707	rs3746448	chr20:33572979	C/T	cg24642439	chr20:33292090	TP53INP2	0.71	6.66	0.38	1.6e-10	Protein C levels;
CESC	cis	rs853679	0.517	rs9393894	chr6:28112562	A/G	cg17949981	chr6:28129498	ZNF389	0.44	5.39	0.31	1.55e-7	Depression;
CESC	cis	rs5750830	0.649	rs5757664	chr22:39821536	A/G	cg24399712	chr22:39784796	NA	-0.83	-11.2	-0.57	4.21e-24	Intelligence (multi-trait analysis);
CESC	cis	rs1881797	1.000	rs10925062	chr1:247658978	G/C	cg21399703	chr1:247681439	NA	0.61	7.87	0.44	9.01e-14	Acute lymphoblastic leukemia (childhood);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg27305525	chr1:154955752	FLAD1	0.5	6.49	0.37	4.12e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs2276314	0.802	rs58906216	chr18:33630297	T/C	cg05985134	chr18:33552581	C18orf21	0.62	7.16	0.4	8.06e-12	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs798554	0.759	rs1636255	chr7:2892804	A/C	cg13628971	chr7:2884303	GNA12	-0.64	-8.62	-0.47	5.99e-16	Height;
CESC	cis	rs798554	0.757	rs1182198	chr7:2862906	C/T	cg19717773	chr7:2847554	GNA12	-0.56	-7.7	-0.43	2.64e-13	Height;
CESC	cis	rs10899021	1.000	rs7935426	chr11:74363890	C/T	cg25880958	chr11:74394337	NA	-0.73	-7.19	-0.4	6.53e-12	Response to metformin (IC50);
CESC	cis	rs7917772	0.502	rs2296583	chr10:104244322	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.55	7.65	0.43	3.63e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs3733585	0.783	rs13148371	chr4:10032561	C/T	cg00071950	chr4:10020882	SLC2A9	0.88	15.98	0.7	1.01e-40	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg07677032	chr17:61819896	STRADA	0.45	6.05	0.35	4.97e-9	Prudent dietary pattern;
CESC	cis	rs208515	0.525	rs10944863	chr6:66676238	C/T	cg07460842	chr6:66804631	NA	0.85	10.63	0.55	3.24e-22	Exhaled nitric oxide levels;
CESC	trans	rs683257	0.929	rs72990194	chr6:141223008	A/G	cg06418282	chr8:90913525	OSGIN2	-0.68	-6.1	-0.35	3.8e-9	Facial emotion recognition (angry faces);
CESC	cis	rs2404602	0.647	rs12898810	chr15:76904738	T/C	cg06336613	chr15:77223807	RCN2	0.41	5.18	0.3	4.49e-7	Blood metabolite levels;
CESC	cis	rs2708240	0.791	rs2710122	chr7:147572391	A/G	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.33	-5.51	-0.32	8.58e-8	QT interval (drug interaction);
CESC	cis	rs12477438	0.501	rs2632260	chr2:99771590	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.86	16.02	0.7	7.14e-41	Chronic sinus infection;
CESC	cis	rs3859192	0.557	rs12602514	chr17:38159745	A/G	cg17467752	chr17:38218738	THRA	-0.43	-5.65	-0.33	4.24e-8	White blood cell count;
CESC	cis	rs34286592	1.000	rs4787480	chr16:29857316	G/A	cg27338089	chr16:29820515	MAZ	0.48	5.04	0.3	8.68e-7	Multiple sclerosis;
CESC	cis	rs6546550	0.867	rs4401231	chr2:70063563	G/C	cg02498382	chr2:70120550	SNRNP27	-0.39	-6.68	-0.38	1.37e-10	Prevalent atrial fibrillation;
CESC	trans	rs9866054	0.681	rs10212419	chr3:139004920	A/G	cg03750606	chr1:217262978	ESRRG	-0.46	-6.03	-0.35	5.34e-9	Lobe attachment (rater scored);
CESC	cis	rs736408	0.521	rs13074853	chr3:52779801	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.62	8.73	0.47	2.84e-16	Bipolar disorder;
CESC	cis	rs9840812	0.655	rs4452981	chr3:136307767	A/G	cg15507776	chr3:136538369	TMEM22	0.42	5.14	0.3	5.27e-7	Fibrinogen levels;
CESC	cis	rs10791323	0.604	rs2851116	chr11:133705759	G/A	cg15485101	chr11:133734466	NA	0.41	6.63	0.38	1.88e-10	Childhood ear infection;
CESC	cis	rs28551159	1	rs28551159	chr6:26376368	A/G	cg12826209	chr6:26865740	GUSBL1	0.64	5.26	0.31	3.04e-7	Urinary tract infection frequency;
CESC	cis	rs875971	0.964	rs6978721	chr7:65883204	A/G	cg12463550	chr7:65579703	CRCP	0.58	7.41	0.41	1.67e-12	Aortic root size;
CESC	cis	rs6912958	0.781	rs2284908	chr6:88194500	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.46	-5.99	-0.35	6.73e-9	Monocyte percentage of white cells;
CESC	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.55	0.37	2.98e-10	Prudent dietary pattern;
CESC	cis	rs780096	0.506	rs1728922	chr2:27644464	A/C	cg21248554	chr2:27665150	KRTCAP3	-0.34	-7.08	-0.4	1.27e-11	Total body bone mineral density;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23677363	chr1:111682944	DRAM2;CEPT1	-0.61	-7.56	-0.42	6.43e-13	Gut microbiome composition (summer);
CESC	cis	rs1008375	0.932	rs7697329	chr4:17657853	C/A	cg02297831	chr4:17616191	MED28	0.65	8.03	0.44	3.15e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs7592578	0.640	rs56127319	chr2:191296429	G/A	cg10560079	chr2:191398806	TMEM194B	-0.62	-6.13	-0.35	3.22e-9	Diastolic blood pressure;
CESC	cis	rs3820928	0.904	rs2396431	chr2:227765488	G/A	cg05526886	chr2:227700861	RHBDD1	-0.44	-5.55	-0.32	6.93e-8	Pulmonary function;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09104050	chr16:68563912	NA	0.53	6.66	0.38	1.55e-10	Gut microbiome composition (summer);
CESC	cis	rs11122272	0.735	rs2572252	chr1:231513653	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.57	-7.82	-0.43	1.29e-13	Hemoglobin concentration;
CESC	cis	rs710865	0.966	rs709683	chr1:19565344	C/G	cg13387374	chr1:19411106	UBR4	0.55	7.27	0.41	3.96e-12	Brain structure;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg13883939	chr12:118541731	VSIG10	-0.44	-6.26	-0.36	1.52e-9	Gut microbiota (bacterial taxa);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21654404	chr12:118814431	SUDS3	0.63	7.25	0.41	4.67e-12	Gut microbiome composition (summer);
CESC	cis	rs4132509	1.000	rs10803158	chr1:243923229	A/G	cg21452805	chr1:244014465	NA	0.41	5.17	0.3	4.64e-7	RR interval (heart rate);
CESC	cis	rs4648739	0.613	rs13303201	chr1:1903712	G/T	cg04624458	chr1:1913527	KIAA1751	0.38	5.52	0.32	8.01e-8	Severe influenza A (H1N1) infection;
CESC	cis	rs1847202	0.793	rs13088835	chr3:72949861	A/T	cg10804678	chr3:72788309	NA	-0.4	-5.34	-0.31	2.04e-7	Motion sickness;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18588052	chr6:111408752	SLC16A10	0.52	6.15	0.35	2.8e-9	Gut microbiome composition (summer);
CESC	cis	rs116095464	0.558	rs10067021	chr5:221490	C/T	cg10591111	chr5:226296	SDHA	-0.51	-6.35	-0.36	9.22e-10	Breast cancer;
CESC	cis	rs228769	0.673	rs228787	chr17:42099488	C/T	cg13607699	chr17:42295918	UBTF	-0.48	-5.49	-0.32	9.53e-8	Bone mineral density (hip);Bone mineral density (spine);
CESC	cis	rs7100689	0.577	rs756208	chr10:82041751	A/G	cg09936400	chr10:82049201	MAT1A	0.41	6.2	0.36	2.13e-9	Post bronchodilator FEV1;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24846594	chr1:236687271	LGALS8	0.58	6.17	0.35	2.55e-9	Gut microbiome composition (summer);
CESC	cis	rs2625529	0.730	rs6494975	chr15:72177825	T/A	cg16672083	chr15:72433130	SENP8	0.44	6.35	0.36	9.26e-10	Red blood cell count;
CESC	cis	rs2014572	0.967	rs8111977	chr19:57759158	T/A	cg24459738	chr19:57751996	ZNF805	-0.53	-7.48	-0.42	1.08e-12	Hyperactive-impulsive symptoms;
CESC	cis	rs2204008	0.840	rs3892363	chr12:38479487	G/A	cg26384229	chr12:38710491	ALG10B	0.71	10.82	0.55	7.82e-23	Bladder cancer;
CESC	cis	rs9916302	0.706	rs11657153	chr17:37699729	A/G	cg00129232	chr17:37814104	STARD3	-0.55	-5.69	-0.33	3.39e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs36051895	0.559	rs72701682	chr9:5208025	A/G	cg02405213	chr9:5042618	JAK2	-0.46	-5.22	-0.31	3.67e-7	Pediatric autoimmune diseases;
CESC	cis	rs1008375	1.000	rs1558378	chr4:17650351	T/C	cg04450456	chr4:17643702	FAM184B	0.36	5.06	0.3	7.87e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs7945705	0.902	rs7479407	chr11:9023421	C/T	cg12365402	chr11:9010492	NRIP3	0.42	7.13	0.4	9.41e-12	Hemoglobin concentration;
CESC	cis	rs4853012	0.838	rs12619982	chr2:74356022	G/A	cg01017244	chr2:74357527	NA	0.82	11.94	0.59	1.42e-26	Gestational age at birth (maternal effect);
CESC	trans	rs6089829	0.816	rs6062397	chr20:61668268	A/G	cg23505145	chr19:12996616	KLF1	0.51	6.68	0.38	1.37e-10	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg23978390	chr7:1156363	C7orf50	0.6	8.41	0.46	2.63e-15	Longevity;Endometriosis;
CESC	cis	rs897080	0.515	rs1067368	chr2:44654889	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	5.92	0.34	9.71e-9	Height;
CESC	cis	rs10751667	0.666	rs10902255	chr11:967268	T/C	cg20946044	chr11:1010712	AP2A2	-0.4	-5.46	-0.32	1.12e-7	Alzheimer's disease (late onset);
CESC	cis	rs3126085	0.935	rs4845740	chr1:152183310	G/A	cg26876637	chr1:152193138	HRNR	0.48	5.5	0.32	8.93e-8	Atopic dermatitis;
CESC	cis	rs875971	0.522	rs56028712	chr7:65466565	C/T	cg05332525	chr7:65337924	VKORC1L1	0.49	5.98	0.34	7.28e-9	Aortic root size;
CESC	cis	rs3741151	0.773	rs17244616	chr11:73293112	C/T	cg17517138	chr11:73019481	ARHGEF17	1.02	7.43	0.42	1.51e-12	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs6952808	0.792	rs12531315	chr7:1953650	C/G	cg05863683	chr7:1912471	MAD1L1	0.44	6.8	0.39	6.93e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg24829409	chr8:58192753	C8orf71	-0.69	-7.68	-0.43	3.13e-13	Developmental language disorder (linguistic errors);
CESC	cis	rs7605827	0.930	rs7605727	chr2:15598693	A/G	cg19274914	chr2:15703543	NA	0.34	6.1	0.35	3.79e-9	Educational attainment (years of education);
CESC	cis	rs8014204	0.804	rs35769520	chr14:75255115	G/A	cg08847533	chr14:75593920	NEK9	0.47	5.97	0.34	7.75e-9	Caffeine consumption;
CESC	cis	rs2721195	0.614	rs12719778	chr8:145879883	T/C	cg15857475	chr8:145742913	RECQL4;LRRC14	0.76	10.99	0.56	2.15e-23	Age at first birth;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg09400194	chr10:81107848	PPIF	-0.47	-6.87	-0.39	4.65e-11	Gambling;
CESC	cis	rs853679	0.550	rs1150689	chr6:28165099	T/C	cg12963246	chr6:28129442	ZNF389	0.49	6.8	0.39	6.72e-11	Depression;
CESC	cis	rs6032067	0.929	rs11699850	chr20:43809049	T/C	cg11264863	chr20:43835661	SEMG1	0.49	5.36	0.31	1.81e-7	Blood protein levels;
CESC	cis	rs8114671	0.570	rs3761144	chr20:33544075	C/G	cg07148914	chr20:33460835	GGT7	0.41	5.28	0.31	2.75e-7	Height;
CESC	cis	rs7666738	0.830	rs13147195	chr4:98893334	G/T	cg05340658	chr4:99064831	C4orf37	0.74	10.68	0.55	2.26e-22	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4474465	0.790	rs4945290	chr11:78252249	C/T	cg27205649	chr11:78285834	NARS2	0.43	5.41	0.32	1.4e-7	Alzheimer's disease (survival time);
CESC	cis	rs67311347	0.911	rs6776044	chr3:40377503	T/G	cg24209194	chr3:40518798	ZNF619	0.43	5.47	0.32	1.03e-7	Renal cell carcinoma;
CESC	cis	rs4665809	0.590	rs7586047	chr2:26447335	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.1	-12.68	-0.61	4e-29	Gut microbiome composition (summer);
CESC	cis	rs61931739	0.500	rs10844829	chr12:34304916	G/T	cg19457237	chr12:34500585	NA	-0.39	-5.44	-0.32	1.23e-7	Morning vs. evening chronotype;
CESC	cis	rs501120	0.810	rs684666	chr10:44745847	T/C	cg09554077	chr10:44749378	NA	0.5	6.64	0.38	1.74e-10	Coronary artery disease;Coronary heart disease;
CESC	cis	rs12926788	0.640	rs73551577	chr16:24845143	G/A	cg04756594	chr16:24857601	SLC5A11	0.46	5.68	0.33	3.49e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs6912958	0.500	rs9342104	chr6:87798512	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.63	-7.74	-0.43	2.04e-13	Monocyte percentage of white cells;
CESC	cis	rs730566	1.000	rs4858819	chr3:48478088	C/T	cg07636037	chr3:49044803	WDR6	-0.42	-5.13	-0.3	5.68e-7	Prion diseases;
CESC	cis	rs597539	0.652	rs667989	chr11:68685776	T/A	cg21963583	chr11:68658836	MRPL21	0.4	5.63	0.33	4.63e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs6952808	0.595	rs3778984	chr7:2166514	T/C	cg21782813	chr7:2030301	MAD1L1	0.51	7.27	0.41	4.04e-12	Bipolar disorder and schizophrenia;
CESC	cis	rs4803468	1.000	rs13344563	chr19:41945904	G/C	cg09537434	chr19:41945824	ATP5SL	1.06	19.91	0.77	1.51e-54	Height;
CESC	cis	rs4665809	0.878	rs4665826	chr2:26367503	A/T	cg04944784	chr2:26401820	FAM59B	0.86	9.84	0.52	1.13e-19	Gut microbiome composition (summer);
CESC	cis	rs9303280	0.806	rs11078928	chr17:38064469	T/C	cg19468946	chr17:37922297	IKZF3	-0.39	-5.07	-0.3	7.51e-7	Self-reported allergy;
CESC	trans	rs561341	0.883	rs72821942	chr17:30234460	C/T	cg27661571	chr11:113659931	NA	-0.65	-6.49	-0.37	4.23e-10	Hip circumference adjusted for BMI;
CESC	cis	rs10870270	0.830	rs11146269	chr10:133761820	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.84	-12.23	-0.6	1.45e-27	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs10779751	0.960	rs4845988	chr1:11319587	A/G	cg08854313	chr1:11322531	MTOR	0.91	14.3	0.66	9.13e-35	Body mass index;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21843114	chr4:26334859	RBPJ	-0.61	-7.14	-0.4	9.08e-12	Gut microbiome composition (summer);
CESC	cis	rs2839186	0.508	rs6518278	chr21:47640571	A/G	cg10351095	chr21:47802916	PCNT	0.49	5.82	0.34	1.73e-8	Testicular germ cell tumor;
CESC	cis	rs6493487	0.512	rs77629026	chr15:51122225	C/T	cg02338191	chr15:51200825	AP4E1	0.5	5.11	0.3	6.05e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs1707322	1.000	rs4660328	chr1:46444831	G/T	cg03146154	chr1:46216737	IPP	0.72	9.82	0.52	1.31e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs324780	0.544	rs3110203	chr12:83884862	G/A	cg22140261	chr22:42466895	NAGA	0.47	6.03	0.35	5.38e-9	Vertical cup-disc ratio;
CESC	cis	rs4253772	0.938	rs9626814	chr22:46637254	C/T	cg18190219	chr22:46762943	CELSR1	-0.49	-6.53	-0.37	3.36e-10	LDL cholesterol;Cholesterol, total;
CESC	cis	rs1862618	0.853	rs11739344	chr5:56111087	A/C	cg24549020	chr5:56110836	MAP3K1	0.67	7.67	0.43	3.3e-13	Initial pursuit acceleration;
CESC	cis	rs5758511	0.680	rs1033459	chr22:42619067	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.59	8.76	0.47	2.44e-16	Birth weight;
CESC	cis	rs4664308	1.000	rs17831251	chr2:160914156	C/T	cg03641300	chr2:160917029	PLA2R1	-0.68	-10.17	-0.53	9.67e-21	Idiopathic membranous nephropathy;
CESC	cis	rs12479064	0.724	rs11885942	chr2:100004165	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.63	-7.56	-0.42	6.67e-13	Chronic sinus infection;
CESC	trans	rs3780486	0.846	rs10116966	chr9:33122370	T/A	cg20290983	chr6:43655470	MRPS18A	0.98	18.32	0.75	5.36e-49	IgG glycosylation;
CESC	cis	rs2075371	1.000	rs2244694	chr7:133987093	C/T	cg20476274	chr7:133979776	SLC35B4	0.65	9.41	0.5	2.53e-18	Mean platelet volume;
CESC	cis	rs854765	0.583	rs11078405	chr17:17824978	G/T	cg16928487	chr17:17741425	SREBF1	-0.58	-9.9	-0.52	7.25e-20	Total body bone mineral density;
CESC	cis	rs863345	0.527	rs7514555	chr1:158445138	G/T	cg12129480	chr1:158549410	OR10X1	-0.36	-7.16	-0.4	8.01e-12	Pneumococcal bacteremia;
CESC	cis	rs12048904	0.964	rs8888	chr1:101338324	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.57	7.38	0.41	2.03e-12	Multiple sclerosis;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg21386795	chr1:3559630	WDR8	0.46	6.46	0.37	5.07e-10	Fibrinogen levels;
CESC	cis	rs17539620	0.624	rs117591255	chr6:154839118	G/A	cg20019720	chr6:154832845	CNKSR3	0.46	6.04	0.35	5.07e-9	Lipoprotein (a) levels;
CESC	cis	rs1448094	0.511	rs61930590	chr12:86159959	T/A	cg00310523	chr12:86230176	RASSF9	0.33	5.29	0.31	2.53e-7	Major depressive disorder;
CESC	cis	rs9487051	0.768	rs458185	chr6:109524074	A/G	cg01475377	chr6:109611718	NA	-0.44	-6.7	-0.38	1.26e-10	Reticulocyte fraction of red cells;
CESC	cis	rs7103648	0.695	rs12223593	chr11:47789082	T/G	cg10504702	chr11:47789108	FNBP4	0.43	5.47	0.32	1.03e-7	Diastolic blood pressure;Systolic blood pressure;
CESC	cis	rs875971	0.545	rs73152714	chr7:65999628	G/A	cg25405998	chr7:65216604	CCT6P1	0.46	5.21	0.3	3.87e-7	Aortic root size;
CESC	cis	rs17376456	0.877	rs10059630	chr5:93459807	C/A	cg21475434	chr5:93447410	FAM172A	0.82	7.56	0.42	6.81e-13	Diabetic retinopathy;
CESC	cis	rs1881797	0.872	rs2141544	chr1:247690800	A/G	cg05639522	chr1:247681581	NA	0.44	6.67	0.38	1.45e-10	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs2425143	1.000	rs733609	chr20:34393074	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.79	-7.16	-0.4	7.72e-12	Blood protein levels;
CESC	cis	rs2455799	0.613	rs11128762	chr3:15883439	C/T	cg16303742	chr3:15540471	COLQ	-0.38	-5.97	-0.34	7.75e-9	Mean platelet volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10601548	chr6:167116288	RPS6KA2	-0.55	-6.49	-0.37	4.31e-10	Gut microbiome composition (summer);
CESC	cis	rs4253772	0.530	rs6008662	chr22:46713917	G/A	cg18190219	chr22:46762943	CELSR1	-0.47	-6.0	-0.35	6.29e-9	LDL cholesterol;Cholesterol, total;
CESC	cis	rs7666738	0.830	rs62318504	chr4:98935558	T/G	cg17366294	chr4:99064904	C4orf37	0.61	8.56	0.47	9.36e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1008375	1.000	rs12507142	chr4:17656103	A/G	cg04450456	chr4:17643702	FAM184B	0.37	5.23	0.31	3.4e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	trans	rs877282	0.786	rs10904558	chr10:797509	C/T	cg22713356	chr15:30763199	NA	1.25	13.11	0.63	1.33e-30	Uric acid levels;
CESC	cis	rs1008375	0.966	rs6813375	chr4:17649499	T/G	cg15017067	chr4:17643749	FAM184B	0.38	5.35	0.31	1.86e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs116095464	0.558	rs10060089	chr5:205565	G/A	cg22857025	chr5:266934	NA	-1.28	-14.21	-0.66	1.88e-34	Breast cancer;
CESC	cis	rs1552244	0.572	rs3894322	chr3:10168965	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.68	-7.65	-0.43	3.85e-13	Alzheimer's disease;
CESC	cis	rs921665	0.831	rs11682390	chr2:3187698	G/A	cg02624386	chr2:3182749	NA	0.52	5.07	0.3	7.58e-7	World class endurance athleticism;
CESC	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg07414643	chr4:187882934	NA	0.56	8.14	0.45	1.53e-14	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2243480	1.000	rs2533288	chr7:66056711	C/G	cg18252515	chr7:66147081	NA	-1.4	-14.23	-0.66	1.55e-34	Diabetic kidney disease;
CESC	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg07677032	chr17:61819896	STRADA	-0.48	-6.54	-0.37	3.19e-10	Prudent dietary pattern;
CESC	cis	rs472402	0.507	rs8192139	chr5:6636973	C/G	cg10789808	chr5:6633262	NSUN2;SRD5A1	-0.45	-5.92	-0.34	1.01e-8	Response to amphetamines;
CESC	cis	rs6540559	0.673	rs4556361	chr1:210019654	C/G	cg22029157	chr1:209979665	IRF6	-0.66	-7.68	-0.43	3.11e-13	Cleft lip with or without cleft palate;
CESC	cis	rs11676348	0.811	rs4674255	chr2:218987325	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.46	-6.16	-0.35	2.74e-9	Ulcerative colitis;
CESC	cis	rs13118159	0.836	rs2276903	chr4:1343405	A/G	cg00684032	chr4:1343700	KIAA1530	0.35	5.17	0.3	4.6e-7	Longevity;
CESC	cis	rs10463316	0.894	rs13361298	chr5:150765549	T/C	cg03212797	chr5:150827313	SLC36A1	-0.46	-6.04	-0.35	5.23e-9	Metabolite levels (Pyroglutamine);
CESC	trans	rs7937682	0.883	rs12366001	chr11:111433916	A/G	cg18187862	chr3:45730750	SACM1L	-0.57	-6.74	-0.38	9.63e-11	Primary sclerosing cholangitis;
CESC	cis	rs9467711	0.606	rs9358932	chr6:26362705	A/G	cg14345882	chr6:26364793	BTN3A2	-0.62	-6.66	-0.38	1.54e-10	Autism spectrum disorder or schizophrenia;
CESC	cis	rs10256972	0.786	rs3735686	chr7:1062527	G/A	cg18765753	chr7:1198926	ZFAND2A	-0.38	-5.32	-0.31	2.2e-7	Longevity;Endometriosis;
CESC	cis	rs1577917	1.000	rs955197	chr6:86729675	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.47	-6.07	-0.35	4.48e-9	Response to antipsychotic treatment;
CESC	cis	rs412050	0.512	rs117865454	chr22:22240214	T/C	cg17089214	chr22:22089827	YPEL1	0.75	5.13	0.3	5.7e-7	Attention deficit hyperactivity disorder;
CESC	cis	rs2933343	0.649	rs2638845	chr3:128587369	A/G	cg24203234	chr3:128598194	ACAD9	0.41	5.69	0.33	3.33e-8	IgG glycosylation;
CESC	cis	rs3785574	1.000	rs7223257	chr17:61787684	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	1.09	19.39	0.77	9.9e-53	Height;
CESC	cis	rs2228479	0.681	rs2270461	chr16:89972345	C/T	cg00800038	chr16:89945340	TCF25	0.59	6.61	0.38	2.08e-10	Skin colour saturation;
CESC	cis	rs17021463	0.555	rs7693950	chr4:95324901	A/T	cg11021082	chr4:95130006	SMARCAD1	0.42	5.76	0.33	2.34e-8	Testicular germ cell tumor;
CESC	trans	rs11098499	0.754	rs17595608	chr4:120250506	C/T	cg25214090	chr10:38739885	LOC399744	0.62	8.81	0.48	1.69e-16	Corneal astigmatism;
CESC	cis	rs2439831	0.867	rs2278860	chr15:43659046	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.93	-11.57	-0.58	2.55e-25	Lung cancer in ever smokers;
CESC	cis	rs4930561	0.739	rs12225316	chr11:67976003	T/C	cg16338278	chr11:67432957	ALDH3B2	0.43	5.28	0.31	2.63e-7	Breast cancer in childhood cancer survivors;IgG glycosylation;
CESC	trans	rs393155	0.517	rs330050	chr8:9087679	G/C	cg06636001	chr8:8085503	FLJ10661	-0.53	-6.82	-0.39	6.1e-11	Neuroticism;
CESC	cis	rs7666738	0.819	rs13120307	chr4:99036100	A/C	cg05340658	chr4:99064831	C4orf37	0.82	12.42	0.61	3.27e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2073300	0.609	rs12625164	chr20:23354269	T/C	cg16736954	chr20:23401023	NAPB	0.79	5.84	0.34	1.5e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs4132509	0.603	rs12408951	chr1:243679364	A/G	cg21452805	chr1:244014465	NA	0.54	6.02	0.35	5.7e-9	RR interval (heart rate);
CESC	cis	rs7560272	0.538	rs12619258	chr2:73935915	G/T	cg20560298	chr2:73613845	ALMS1	0.43	5.84	0.34	1.51e-8	Schizophrenia;
CESC	cis	rs35110281	0.627	rs1836855	chr21:44965414	C/G	cg21573476	chr21:45109991	RRP1B	-0.37	-5.12	-0.3	5.99e-7	Mean corpuscular volume;
CESC	cis	rs875971	0.830	rs778711	chr7:65851657	G/A	cg12463550	chr7:65579703	CRCP	0.51	6.41	0.37	6.58e-10	Aortic root size;
CESC	cis	rs2204008	0.747	rs11514040	chr12:38201040	G/A	cg26384229	chr12:38710491	ALG10B	0.74	10.7	0.55	1.96e-22	Bladder cancer;
CESC	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.59	-7.61	-0.42	4.9e-13	Prudent dietary pattern;
CESC	cis	rs61542988	0.606	rs4722185	chr7:22832711	G/A	cg13679077	chr7:22862647	TOMM7	0.64	7.27	0.41	4e-12	Fibrinogen levels;
CESC	trans	rs561341	1.000	rs530209	chr17:30315287	A/G	cg20587970	chr11:113659929	NA	-1.41	-18.23	-0.75	1.08e-48	Hip circumference adjusted for BMI;
CESC	cis	rs8017423	0.935	rs11628952	chr14:90734953	T/C	cg14092571	chr14:90743983	NA	0.56	8.58	0.47	8.26e-16	Mortality in heart failure;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg20032723	chr11:126174041	DCPS	-0.44	-6.42	-0.37	6.14e-10	Gambling;
CESC	cis	rs2832191	0.791	rs2832197	chr21:30497790	T/C	cg24692254	chr21:30365293	RNF160	-0.79	-12.11	-0.6	3.71e-27	Dental caries;
CESC	cis	rs7811142	0.830	rs7792959	chr7:99972403	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.83	8.82	0.48	1.58e-16	Platelet count;
CESC	cis	rs72781680	0.898	rs12623079	chr2:24103749	G/A	cg20701182	chr2:24300061	SF3B14	0.64	5.82	0.34	1.73e-8	Lymphocyte counts;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg11234017	chr17:42767172	CCDC43	0.47	6.69	0.38	1.35e-10	Systemic lupus erythematosus;
CESC	cis	rs9788333	0.707	rs12584557	chr13:21886171	C/A	cg23743428	chr13:21893420	NA	-0.34	-5.92	-0.34	1.01e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs2710642	0.611	rs10172216	chr2:62869546	C/G	cg17519650	chr2:63277830	OTX1	0.45	5.32	0.31	2.24e-7	LDL cholesterol levels;LDL cholesterol;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg12271800	chr19:59028764	ZBTB45	0.48	6.69	0.38	1.3100000000000001e-10	Fibrinogen levels;
CESC	trans	rs61931739	0.500	rs12809868	chr12:34464905	C/T	cg26384229	chr12:38710491	ALG10B	0.7	10.49	0.54	9.45e-22	Morning vs. evening chronotype;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg27507545	chr10:103880405	LDB1	-0.46	-6.05	-0.35	4.79e-9	Height;
CESC	cis	rs2070997	0.667	rs13287613	chr9:133715291	T/C	cg11464064	chr9:133710261	ABL1	0.68	7.65	0.43	3.64e-13	Response to amphetamines;
CESC	cis	rs2243480	1.000	rs35283677	chr7:65359233	C/T	cg12463550	chr7:65579703	CRCP	0.69	5.53	0.32	7.85e-8	Diabetic kidney disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17783671	chr19:59070436	UBE2M;LOC100131691	0.6	7.05	0.4	1.53e-11	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03811478	chr3:137483696	SOX14	-0.47	-6.06	-0.35	4.75e-9	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00752806	chr2:220462673	STK11IP	-0.55	-6.28	-0.36	1.39e-9	Gut microbiome composition (summer);
CESC	cis	rs826838	1.000	rs11183196	chr12:38685915	G/T	cg26384229	chr12:38710491	ALG10B	0.84	14.75	0.67	2.36e-36	Heart rate;
CESC	cis	rs9831754	0.756	rs1512476	chr3:78434219	G/A	cg06138941	chr3:78371609	NA	-0.48	-6.0	-0.35	6.33e-9	Calcium levels;
CESC	cis	rs4780401	0.609	rs9923954	chr16:11816855	G/T	cg01061890	chr16:11836724	TXNDC11	-0.56	-7.52	-0.42	8.36e-13	Rheumatoid arthritis;
CESC	cis	rs9899728	0.665	rs2307008	chr17:73042682	G/A	cg27626185	chr17:73056755	KCTD2	-0.61	-5.93	-0.34	9.6e-9	Alzheimer's disease or small vessel stroke;
CESC	cis	rs6842047	1.000	rs72647308	chr4:187135129	G/A	cg23442198	chr4:187126114	CYP4V2	-0.72	-6.02	-0.35	5.93e-9	Blood protein levels;
CESC	cis	rs7666738	0.830	rs7673385	chr4:99024922	T/G	cg18180107	chr4:99064573	C4orf37	0.41	5.32	0.31	2.16e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4862307	0.720	rs12650935	chr4:184989565	G/A	cg06737308	chr4:185021514	ENPP6	0.46	6.21	0.36	2.02e-9	Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	cis	rs270601	0.770	rs932019	chr5:131599370	T/C	cg11843238	chr5:131593191	PDLIM4	0.35	5.17	0.3	4.72e-7	Acylcarnitine levels;
CESC	cis	rs425277	0.561	rs925906	chr1:2044054	A/C	cg13918804	chr1:2043761	PRKCZ	0.29	5.31	0.31	2.37e-7	Height;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg22157255	chr2:190788356	NA	-0.4	-6.13	-0.35	3.24e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs6502050	0.835	rs8065981	chr17:80091393	G/T	cg11859384	chr17:80120422	CCDC57	-0.38	-5.14	-0.3	5.31e-7	Life satisfaction;
CESC	cis	rs2243480	1.000	rs781157	chr7:65478311	G/A	cg12463550	chr7:65579703	CRCP	0.73	5.94	0.34	8.85e-9	Diabetic kidney disease;
CESC	trans	rs1814175	0.791	rs10839468	chr11:49986288	A/G	cg03929089	chr4:120376271	NA	-0.94	-16.03	-0.7	7.02e-41	Height;
CESC	cis	rs17125944	0.505	rs74642116	chr14:53213507	A/G	cg13660082	chr14:53194042	PSMC6	-0.67	-5.98	-0.34	7.29e-9	Alzheimer's disease (late onset);
CESC	cis	rs6842047	1.000	rs72647308	chr4:187135129	G/A	cg02012338	chr4:187126139	CYP4V2	-0.74	-6.18	-0.35	2.4e-9	Blood protein levels;
CESC	trans	rs916888	0.821	rs70600	chr17:44860021	C/T	cg07870213	chr5:140052090	DND1	0.6	6.33	0.36	1.05e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs6582630	0.533	rs11504406	chr12:38334580	C/T	cg26384229	chr12:38710491	ALG10B	-0.45	-5.88	-0.34	1.23e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs4819052	0.807	rs7283915	chr21:46671288	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.92	13.67	0.64	1.52e-32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs116095464	0.558	rs6875291	chr5:264192	T/C	cg20965017	chr5:231967	SDHA	-0.48	-5.43	-0.32	1.25e-7	Breast cancer;
CESC	cis	rs7914558	0.933	rs10786729	chr10:104719378	A/G	cg15744005	chr10:104629667	AS3MT	-0.35	-5.46	-0.32	1.12e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs853679	0.882	rs3757188	chr6:28107357	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.7	-6.28	-0.36	1.35e-9	Depression;
CESC	cis	rs2733201	1.000	rs1160066	chr15:44410937	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.61	-5.62	-0.33	4.75e-8	Lipoprotein phospholipase A2 activity in cardiovascular disease;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg11050527	chr8:54755511	ATP6V1H	0.47	6.44	0.37	5.62e-10	Systemic lupus erythematosus;
CESC	cis	rs501120	0.810	rs498810	chr10:44740776	A/C	cg09554077	chr10:44749378	NA	0.48	6.18	0.35	2.46e-9	Coronary artery disease;Coronary heart disease;
CESC	cis	rs6964587	1.000	rs13230588	chr7:91615427	C/A	cg17063962	chr7:91808500	NA	0.57	7.74	0.43	2.11e-13	Breast cancer;
CESC	cis	rs1003719	0.591	rs2040125	chr21:38549236	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.48	6.23	0.36	1.84e-9	Eye color traits;
CESC	cis	rs67460515	0.596	rs35589595	chr3:160930984	G/A	cg03342759	chr3:160939853	NMD3	-0.55	-7.46	-0.42	1.22e-12	Parkinson's disease;
CESC	trans	rs1814175	0.669	rs10839315	chr11:49654406	G/A	cg15704280	chr7:45808275	SEPT13	-0.83	-11.45	-0.58	6.23e-25	Height;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg05485520	chr3:45883628	LZTFL1	-0.46	-6.79	-0.38	7.38e-11	Gambling;
CESC	cis	rs6570726	0.693	rs450921	chr6:145864260	C/T	cg05347473	chr6:146136440	FBXO30	0.58	7.33	0.41	2.84e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9660180	0.934	rs12729990	chr1:1812035	T/A	cg20999797	chr1:1681921	NA	0.28	5.42	0.32	1.36e-7	Body mass index;
CESC	cis	rs6089829	0.962	rs2872543	chr20:61665017	G/A	cg08564027	chr20:61660810	NA	0.9	15.35	0.69	1.71e-38	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs2120019	1.000	rs2415255	chr15:75332412	A/G	cg09165964	chr15:75287851	SCAMP5	-0.76	-9.18	-0.49	1.25e-17	Blood trace element (Zn levels);
CESC	cis	rs7264396	0.563	rs17092980	chr20:34289005	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.64	6.87	0.39	4.47e-11	Total cholesterol levels;
CESC	cis	rs67311347	1.000	rs7612015	chr3:40399974	A/C	cg24209194	chr3:40518798	ZNF619	0.46	5.98	0.34	7.32e-9	Renal cell carcinoma;
CESC	cis	rs654950	0.653	rs2810568	chr1:42054247	A/G	cg06885757	chr1:42089581	HIVEP3	-0.64	-10.41	-0.54	1.63e-21	Airway imaging phenotypes;
CESC	cis	rs1904096	0.506	rs3113863	chr4:95147827	G/C	cg11021082	chr4:95130006	SMARCAD1	-0.7	-11.56	-0.58	2.74e-25	Type 2 diabetes;
CESC	cis	rs3947	0.688	rs1293326	chr8:11694765	G/C	cg00262122	chr8:11665843	FDFT1	-0.49	-5.22	-0.31	3.67e-7	Blood protein levels;
CESC	cis	rs9322193	0.962	rs3763163	chr6:150140906	G/T	cg13206674	chr6:150067644	NUP43	0.4	5.61	0.33	4.96e-8	Lung cancer;
CESC	cis	rs2479106	0.963	rs10986093	chr9:126494022	T/C	cg16191174	chr9:126692580	DENND1A	0.49	6.68	0.38	1.38e-10	Polycystic ovary syndrome;
CESC	cis	rs9309473	0.904	rs78450880	chr2:73821381	T/G	cg20560298	chr2:73613845	ALMS1	-0.55	-7.07	-0.4	1.34e-11	Metabolite levels;
CESC	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg18765753	chr7:1198926	ZFAND2A	-0.44	-6.37	-0.36	8.14e-10	Longevity;Endometriosis;
CESC	cis	rs16895831	0.519	rs12200153	chr6:42577712	C/T	cg10605015	chr6:42532144	UBR2	0.5	5.71	0.33	2.98e-8	Granulocyte percentage of myeloid white cells;Neutrophil percentage of white cells;Eosinophil percentage of white cells;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Neutrophil count;Sum basophil neutrophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
CESC	cis	rs40363	0.723	rs2379831	chr16:3538927	T/C	cg05754148	chr16:3507555	NAT15	-0.62	-6.1	-0.35	3.68e-9	Tuberculosis;
CESC	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg21724239	chr8:58056113	NA	0.6	5.56	0.32	6.59e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs2842992	0.789	rs9364536	chr6:160225559	G/C	cg11366901	chr6:160182831	ACAT2	0.76	9.18	0.49	1.3e-17	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs7178572	0.633	rs11854328	chr15:77840129	A/G	cg22256960	chr15:77711686	NA	-0.52	-6.62	-0.38	2e-10	Type 2 diabetes;
CESC	cis	rs1862618	0.802	rs2591949	chr5:56132627	T/C	cg24549020	chr5:56110836	MAP3K1	0.68	7.76	0.43	1.85e-13	Initial pursuit acceleration;
CESC	cis	rs644799	0.932	rs572015	chr11:95637416	T/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.85	12.78	0.62	1.88e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs12476592	0.602	rs10176522	chr2:63722433	T/C	cg17519650	chr2:63277830	OTX1	-0.49	-5.43	-0.32	1.3e-7	Childhood ear infection;
CESC	cis	rs7937682	0.924	rs12791699	chr11:111505880	T/C	cg22437258	chr11:111473054	SIK2	0.7	9.35	0.5	3.83e-18	Primary sclerosing cholangitis;
CESC	cis	rs854765	0.583	rs11871899	chr17:17826748	C/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.48	6.23	0.36	1.86e-9	Total body bone mineral density;
CESC	cis	rs765787	0.530	rs2413780	chr15:45538866	A/G	cg24006582	chr15:45444508	DUOX1	-0.59	-7.32	-0.41	3.04e-12	Uric acid levels;
CESC	cis	rs17253792	0.731	rs74829671	chr14:56112759	G/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.81	5.98	0.34	7.23e-9	Putamen volume;
CESC	cis	rs2688608	0.592	rs3849967	chr10:75483366	C/T	cg23231163	chr10:75533350	FUT11	-0.34	-5.28	-0.31	2.75e-7	Inflammatory bowel disease;
CESC	cis	rs7937682	0.855	rs539553	chr11:111477333	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.95	-14.78	-0.67	1.84e-36	Primary sclerosing cholangitis;
CESC	cis	rs2073300	0.609	rs6137910	chr20:23346515	C/G	cg12062639	chr20:23401060	NAPB	0.98	7.59	0.42	5.37e-13	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs501120	1.000	rs622956	chr10:44755183	A/G	cg09554077	chr10:44749378	NA	0.52	6.89	0.39	3.96e-11	Coronary artery disease;Coronary heart disease;
CESC	cis	rs710216	0.917	rs900834	chr1:43412343	A/G	cg07803811	chr1:43423981	SLC2A1	-0.52	-5.65	-0.33	4.1e-8	Red cell distribution width;
CESC	cis	rs15676	1.000	rs15676	chr9:131572027	A/G	cg00228799	chr9:131580591	ENDOG	-0.44	-5.32	-0.31	2.26e-7	Blood metabolite levels;
CESC	cis	rs10504229	1.000	rs59275611	chr8:58195191	G/A	cg24829409	chr8:58192753	C8orf71	-0.79	-10.07	-0.53	2.04e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs2439831	0.702	rs28699233	chr15:44122866	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.64	5.15	0.3	5.16e-7	Lung cancer in ever smokers;
CESC	cis	rs2841277	0.616	rs1048257	chr14:105404384	T/C	cg19901468	chr14:105411992	AHNAK2	-0.61	-8.66	-0.47	4.85e-16	Rheumatoid arthritis;
CESC	cis	rs6466055	0.720	rs62484712	chr7:105005741	G/A	cg04380332	chr7:105027541	SRPK2	-0.42	-5.51	-0.32	8.53e-8	Schizophrenia;
CESC	cis	rs6496667	1.000	rs8023776	chr15:90897952	A/G	cg22089800	chr15:90895588	ZNF774	-0.56	-5.71	-0.33	2.96e-8	Rheumatoid arthritis;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg24830314	chr6:83775579	UBE2CBP	-0.48	-6.5	-0.37	3.86e-10	Ulcerative colitis;
CESC	cis	rs2066819	1.000	rs2291361	chr12:56717805	G/A	cg26734620	chr12:56694298	CS	1.03	6.25	0.36	1.65e-9	Psoriasis vulgaris;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25808926	chr13:21714709	SAP18	0.57	6.63	0.38	1.84e-10	Gut microbiome composition (summer);
CESC	cis	rs1865760	0.566	rs2794720	chr6:26087202	G/C	cg17691542	chr6:26056736	HIST1H1C	0.42	5.57	0.32	6.13e-8	Height;
CESC	cis	rs853679	0.517	rs9348797	chr6:28137533	G/C	cg20151795	chr6:28129481	ZNF389	0.41	5.3	0.31	2.46e-7	Depression;
CESC	cis	rs11214589	0.620	rs34601878	chr11:113260898	G/A	cg14159747	chr11:113255604	NA	0.35	6.17	0.35	2.59e-9	Neuroticism;
CESC	cis	rs9430161	0.579	rs6694011	chr1:11036935	G/A	cg02454025	chr1:11042201	C1orf127	0.93	14.49	0.66	1.93e-35	Ewing sarcoma;
CESC	cis	rs9457247	0.967	rs388406	chr6:167409562	A/G	cg25258033	chr6:167368657	RNASET2	0.4	6.14	0.35	3.04e-9	Crohn's disease;
CESC	cis	rs2228479	0.850	rs1108063	chr16:89893983	A/G	cg06558623	chr16:89946397	TCF25	1.05	7.89	0.44	8e-14	Skin colour saturation;
CESC	cis	rs7129220	0.512	rs58652557	chr11:10121925	C/G	cg01453529	chr11:10209919	SBF2	-0.48	-5.38	-0.31	1.67e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CESC	cis	rs9660180	0.967	rs61422524	chr1:1767565	C/A	cg05132306	chr1:1846340	CALML6	-0.33	-6.95	-0.39	2.81e-11	Body mass index;
CESC	cis	rs6089584	0.962	rs6142913	chr20:60566950	A/G	cg06108461	chr20:60628389	TAF4	-0.84	-12.68	-0.61	4.06e-29	Body mass index;
CESC	cis	rs4853012	0.793	rs6723185	chr2:74344884	T/A	cg05890377	chr2:74357713	NA	0.79	10.61	0.55	3.7e-22	Gestational age at birth (maternal effect);
CESC	cis	rs4722166	0.603	rs7801406	chr7:22788274	A/G	cg26061582	chr7:22766209	IL6	0.5	5.44	0.32	1.21e-7	Lung cancer;
CESC	cis	rs12681366	0.663	rs2921389	chr8:95466366	G/A	cg13257157	chr8:95487014	RAD54B	0.39	5.34	0.31	2.04e-7	Nonsyndromic cleft lip with cleft palate;
CESC	cis	rs853679	0.517	rs9393884	chr6:28046789	A/G	cg23161317	chr6:28129485	ZNF389	0.53	6.77	0.38	8.08e-11	Depression;
CESC	cis	rs34375054	0.738	rs10846834	chr12:125625570	A/G	cg06287003	chr12:125626642	AACS	-0.34	-5.44	-0.32	1.19e-7	Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs761746	0.705	rs2092905	chr22:31966274	T/C	cg25791279	chr22:32026902	PISD	-0.67	-7.52	-0.42	8.53e-13	Intelligence;
CESC	cis	rs3747547	0.818	rs72724194	chr9:37945506	A/G	cg13774184	chr9:37916125	SHB	-0.58	-5.96	-0.34	7.95e-9	Metabolite levels (Dihydroxy docosatrienoic acid);
CESC	cis	rs11711311	0.747	rs7638449	chr3:113343646	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.41	5.42	0.32	1.35e-7	IgG glycosylation;
CESC	cis	rs4523957	0.855	rs9897160	chr17:2121566	A/G	cg16513277	chr17:2031491	SMG6	-0.63	-8.77	-0.47	2.29e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs8031584	0.678	rs798086	chr15:31129211	C/G	cg14298792	chr15:30685198	CHRFAM7A	0.49	6.01	0.35	6.11e-9	Huntington's disease progression;
CESC	trans	rs17307778	0.710	rs4415715	chr11:25357536	C/T	cg22888484	chr20:37075185	SNHG11	-0.63	-6.06	-0.35	4.53e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs7582720	1.000	rs72934732	chr2:203739856	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.32	0.41	3.04e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	trans	rs9364687	1.000	rs6921172	chr6:163808114	C/T	cg08378220	chr11:102678779	NA	-0.4	-6.28	-0.36	1.39e-9	Body mass index;
CESC	cis	rs9322193	0.923	rs10747276	chr6:150079875	G/A	cg00933542	chr6:150070202	PCMT1	0.29	5.05	0.3	8.43e-7	Lung cancer;
CESC	cis	rs7552404	1.000	rs7513559	chr1:76173744	A/G	cg10523679	chr1:76189770	ACADM	0.68	7.81	0.43	1.32e-13	Blood metabolite levels;Acylcarnitine levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22469355	chr7:73082054	VPS37D	0.62	7.21	0.4	5.8e-12	Gut microbiome composition (summer);
CESC	trans	rs2764766	0.721	rs245193	chr5:127187830	C/G	cg15764593	chr10:829463	NA	-0.4	-6.19	-0.36	2.3e-9	Schizophrenia;
CESC	cis	rs7618915	0.501	rs12486554	chr3:52742537	A/T	cg07507251	chr3:52567010	NT5DC2	0.36	6.07	0.35	4.36e-9	Bipolar disorder;
CESC	trans	rs877282	0.945	rs11253388	chr10:787852	A/G	cg22713356	chr15:30763199	NA	1.32	13.44	0.64	9.25e-32	Uric acid levels;
CESC	cis	rs703842	1.000	rs2072052	chr12:58146719	A/C	cg00677455	chr12:58241039	CTDSP2	0.52	6.71	0.38	1.2e-10	Multiple sclerosis;
CESC	cis	rs4919694	1.000	rs4919694	chr10:104698978	T/C	cg04362960	chr10:104952993	NT5C2	0.71	6.21	0.36	1.99e-9	Arsenic metabolism;
CESC	trans	rs12599106	0.584	rs12929704	chr16:34898258	C/A	cg18110333	chr6:292329	DUSP22	-0.73	-9.64	-0.51	4.77e-19	Menopause (age at onset);
CESC	cis	rs7914558	1.000	rs12780843	chr10:104769335	G/C	cg15744005	chr10:104629667	AS3MT	-0.34	-5.56	-0.32	6.54e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs7860634	1.000	rs7860634	chr9:139089679	C/T	cg04455058	chr9:139085579	NA	0.3	5.14	0.3	5.22e-7	Thyroid hormone levels;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg25674709	chr12:105724273	C12orf75	0.49	6.52	0.37	3.49e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs170557	0.573	rs6657016	chr1:210114848	T/A	cg22029157	chr1:209979665	IRF6	-0.41	-5.18	-0.3	4.48e-7	Alopecia areata;
CESC	cis	rs801193	0.569	rs6951302	chr7:66132512	T/C	cg18876405	chr7:65276391	NA	-0.45	-6.21	-0.36	2e-9	Aortic root size;
CESC	cis	rs919433	0.963	rs1896857	chr2:198164530	A/G	cg03934865	chr2:198174659	NA	-0.44	-6.28	-0.36	1.41e-9	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs838147	0.507	rs692854	chr19:49209464	C/A	cg21064579	chr19:49206444	FUT2	0.46	6.27	0.36	1.42e-9	Dietary macronutrient intake;
CESC	cis	rs57502260	0.704	rs2306862	chr11:68177510	C/T	cg20283391	chr11:68216788	NA	-0.57	-5.17	-0.3	4.71e-7	Total body bone mineral density (age 45-60);
CESC	cis	rs8070624	0.543	rs57728924	chr17:17875342	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.6	8.13	0.45	1.68e-14	Total body bone mineral density;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23286353	chr2:97523832	ANKRD39	0.52	6.07	0.35	4.42e-9	Gut microbiome composition (summer);
CESC	cis	rs4253772	0.550	rs6008600	chr22:46704676	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.66	6.5	0.37	4.07e-10	LDL cholesterol;Cholesterol, total;
CESC	cis	rs6537837	0.793	rs17575798	chr1:110086451	G/A	cg05049280	chr1:110155535	GNAT2	0.41	5.75	0.33	2.51e-8	Major depressive disorder;
CESC	cis	rs896854	0.967	rs896853	chr8:95960855	G/C	cg26343298	chr8:95960752	TP53INP1	0.35	5.87	0.34	1.29e-8	Type 2 diabetes;
CESC	trans	rs875971	0.638	rs801216	chr7:66011667	T/C	cg26939375	chr7:64535504	NA	-0.63	-8.63	-0.47	5.82e-16	Aortic root size;
CESC	cis	rs7546094	1.000	rs7524494	chr1:113197800	A/G	cg22162597	chr1:113214053	CAPZA1	-0.39	-6.01	-0.35	6.17e-9	Platelet distribution width;
CESC	cis	rs9435341	0.965	rs1762485	chr1:107625056	C/T	cg09367891	chr1:107599246	PRMT6	-0.73	-8.75	-0.47	2.52e-16	Facial morphology (factor 21, depth of nasal alae);
CESC	trans	rs979961	0.500	rs80068177	chr4:117983735	T/C	cg09069900	chr13:113776964	F10	-0.82	-6.06	-0.35	4.68e-9	Ulcerative colitis;
CESC	cis	rs12142240	0.698	rs3991877	chr1:46853749	C/A	cg10495392	chr1:46806563	NSUN4	0.56	6.15	0.35	2.86e-9	Menopause (age at onset);
CESC	cis	rs798554	0.549	rs1623138	chr7:2899410	A/G	cg19717773	chr7:2847554	GNA12	-0.49	-7.36	-0.41	2.38e-12	Height;
CESC	cis	rs7520050	0.751	rs592214	chr1:46024505	G/A	cg03146154	chr1:46216737	IPP	-0.52	-6.66	-0.38	1.56e-10	Red blood cell count;Reticulocyte count;
CESC	cis	rs6502050	0.787	rs8080682	chr17:80058901	G/A	cg23985595	chr17:80112537	CCDC57	0.4	6.12	0.35	3.28e-9	Life satisfaction;
CESC	cis	rs12681288	0.550	rs4272405	chr8:959014	C/G	cg15309053	chr8:964076	NA	0.48	8.23	0.45	8.5e-15	Schizophrenia;
CESC	cis	rs7618915	0.547	rs11130311	chr3:52675005	T/C	cg18404041	chr3:52824283	ITIH1	-0.39	-6.55	-0.37	2.9e-10	Bipolar disorder;
CESC	cis	rs7395581	0.918	rs4752825	chr11:47352409	G/A	cg25783544	chr11:47291846	MADD	0.6	7.79	0.43	1.49e-13	HDL cholesterol;
CESC	cis	rs2425143	1.000	rs6060639	chr20:34438183	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.79	-7.16	-0.4	7.86e-12	Blood protein levels;
CESC	cis	rs1348850	0.526	rs7582179	chr2:178370631	A/G	cg23306229	chr2:178417860	TTC30B	0.82	7.63	0.42	4.2e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs698833	0.962	rs698832	chr2:44734823	C/G	cg18685995	chr2:44588913	PREPL;C2orf34	-0.5	-6.25	-0.36	1.66e-9	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs728616	0.558	rs35547640	chr10:82139150	C/T	cg05935833	chr10:81318306	SFTPA2	-0.45	-5.64	-0.33	4.25e-8	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs4688759	0.609	rs113176147	chr3:49534439	G/T	cg00383909	chr3:49044727	WDR6	0.95	5.91	0.34	1.06e-8	Blood protein levels;
CESC	cis	rs13118159	0.934	rs4974608	chr4:1356780	C/T	cg20887711	chr4:1340912	KIAA1530	0.42	5.73	0.33	2.78e-8	Longevity;
CESC	cis	rs7923609	0.846	rs10740115	chr10:65094990	G/A	cg01631684	chr10:65280961	REEP3	-0.42	-5.26	-0.31	3.04e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23642587	chr17:54911515	DGKE	0.6	6.48	0.37	4.36e-10	Gut microbiome composition (summer);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg07080049	chr9:96214194	FAM120A;FAM120AOS	-0.48	-6.85	-0.39	5.19e-11	Gambling;
CESC	cis	rs7618915	0.508	rs11717043	chr3:52656092	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	6.88	0.39	4.18e-11	Bipolar disorder;
CESC	cis	rs832540	0.552	rs252924	chr5:56205643	A/G	cg12311346	chr5:56204834	C5orf35	-0.5	-6.2	-0.36	2.21e-9	Coronary artery disease;
CESC	cis	rs6060717	0.536	rs6060666	chr20:34478954	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.66	5.7	0.33	3.16e-8	Hip circumference adjusted for BMI;
CESC	cis	rs3892630	0.824	rs34425841	chr19:33231619	C/T	cg22980127	chr19:33182716	NUDT19	0.99	9.44	0.5	1.98e-18	Red blood cell traits;
CESC	cis	rs17376456	0.569	rs1349711	chr5:93179032	C/T	cg25358565	chr5:93447407	FAM172A	-0.71	-7.64	-0.42	3.99e-13	Diabetic retinopathy;
CESC	cis	rs6860806	0.507	rs274572	chr5:131710917	T/G	cg18758796	chr5:131593413	PDLIM4	-0.43	-5.96	-0.34	8.15e-9	Breast cancer;
CESC	cis	rs9733	0.628	rs7540874	chr1:150702663	A/C	cg22823121	chr1:150693482	HORMAD1	0.47	6.96	0.39	2.6e-11	Tonsillectomy;
CESC	cis	rs2878628	0.650	rs56098033	chr3:52758571	T/A	cg17372223	chr3:52568218	NT5DC2	0.44	6.67	0.38	1.47e-10	Intelligence (multi-trait analysis);
CESC	cis	rs11958404	0.932	rs61478293	chr5:157426299	G/A	cg05962755	chr5:157440814	NA	0.59	6.54	0.37	3.09e-10	IgG glycosylation;
CESC	cis	rs10129255	0.500	rs6576230	chr14:107186778	C/A	cg07958169	chr14:107095056	NA	-0.55	-8.65	-0.47	4.94e-16	Kawasaki disease;
CESC	trans	rs34421088	0.560	rs2248325	chr8:11396874	A/G	cg15556689	chr8:8085844	FLJ10661	-0.51	-6.0	-0.35	6.33e-9	Neuroticism;
CESC	cis	rs9916302	0.904	rs2061338	chr17:37421767	T/C	cg15445000	chr17:37608096	MED1	0.4	6.45	0.37	5.35e-10	Glomerular filtration rate (creatinine);
CESC	trans	rs2727020	0.704	rs4144700	chr11:49370834	C/A	cg15704280	chr7:45808275	SEPT13	-0.87	-14.54	-0.67	1.28e-35	Coronary artery disease;
CESC	cis	rs67311347	1.000	rs73078162	chr3:40477109	G/A	cg09455208	chr3:40491958	NA	0.51	8.35	0.46	3.82e-15	Renal cell carcinoma;
CESC	cis	rs477692	0.647	rs11016853	chr10:131443990	A/G	cg24747557	chr10:131355152	MGMT	0.38	5.36	0.31	1.8e-7	Response to temozolomide;
CESC	cis	rs60871478	1.000	rs4397290	chr7:828493	T/C	cg05535760	chr7:792225	HEATR2	-0.91	-10.53	-0.54	6.78e-22	Cerebrospinal P-tau181p levels;
CESC	cis	rs7084402	0.967	rs1649074	chr10:60295342	T/G	cg07615347	chr10:60278583	BICC1	0.62	9.85	0.52	1.05e-19	Refractive error;
CESC	cis	rs733592	0.894	rs886589	chr12:48477197	C/T	cg24011408	chr12:48396354	COL2A1	-0.5	-7.62	-0.42	4.5e-13	Plateletcrit;
CESC	cis	rs9549260	0.755	rs2721045	chr13:41162632	T/A	cg21288729	chr13:41239152	FOXO1	0.63	7.87	0.44	9.15e-14	Red blood cell count;
CESC	cis	rs2204008	0.522	rs12370263	chr12:38113311	A/G	cg26384229	chr12:38710491	ALG10B	0.65	8.93	0.48	7.3e-17	Bladder cancer;
CESC	trans	rs4332037	0.950	rs62442895	chr7:1936938	G/A	cg11693508	chr17:37793320	STARD3	0.64	6.08	0.35	4.19e-9	Bipolar disorder;
CESC	cis	rs2625529	0.652	rs8023788	chr15:72459847	A/G	cg16672083	chr15:72433130	SENP8	0.49	7.35	0.41	2.47e-12	Red blood cell count;
CESC	cis	rs875971	0.522	rs56028712	chr7:65466565	C/T	cg10691866	chr7:65817282	TPST1	-0.32	-5.08	-0.3	7.15e-7	Aortic root size;
CESC	cis	rs12497850	0.897	rs9681717	chr3:48872998	A/G	cg07636037	chr3:49044803	WDR6	1.04	18.36	0.75	3.83e-49	Parkinson's disease;
CESC	cis	rs11997175	0.583	rs66622174	chr8:33812542	T/G	ch.8.33884649F	chr8:33765107	NA	0.46	5.94	0.34	9.11e-9	Body mass index;
CESC	cis	rs854765	0.583	rs7207395	chr17:17819335	C/T	cg16928487	chr17:17741425	SREBF1	-0.6	-10.42	-0.54	1.58e-21	Total body bone mineral density;
CESC	cis	rs6952808	0.723	rs11766575	chr7:2005747	T/C	cg04267008	chr7:1944627	MAD1L1	-0.63	-7.55	-0.42	7.17e-13	Bipolar disorder and schizophrenia;
CESC	cis	rs4889855	0.578	rs7216808	chr17:78484187	A/G	cg00066239	chr17:78472159	NA	-0.38	-5.22	-0.31	3.55e-7	Fractional excretion of uric acid;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05708167	chr16:74782424	FA2H	-0.51	-6.47	-0.37	4.85e-10	Gut microbiome composition (summer);
CESC	cis	rs9640161	0.711	rs55881542	chr7:150025734	G/A	cg10018233	chr7:150070692	REPIN1	0.43	6.41	0.37	6.56e-10	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs7666738	0.830	rs2015828	chr4:98984594	A/G	cg17366294	chr4:99064904	C4orf37	0.59	8.46	0.46	1.84e-15	Colonoscopy-negative controls vs population controls;
CESC	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg05564625	chr6:116892562	RWDD1	0.56	7.41	0.41	1.68e-12	Myopia (pathological);
CESC	cis	rs769267	0.965	rs2315024	chr19:19423817	T/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.44	5.38	0.31	1.61e-7	Tonsillectomy;
CESC	cis	rs3733585	0.699	rs4588456	chr4:9963895	A/T	cg00071950	chr4:10020882	SLC2A9	-0.73	-11.79	-0.59	4.58e-26	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs16866061	1.000	rs10933068	chr2:225418360	G/A	cg12698349	chr2:225449008	CUL3	0.75	11.58	0.58	2.29e-25	Acute graft versus host disease in bone marrow transplantation (recipient effect);
CESC	cis	rs17345786	0.906	rs72946021	chr3:101250008	T/G	cg12386194	chr3:101231763	SENP7	0.59	6.53	0.37	3.42e-10	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4713118	0.621	rs9368548	chr6:28034737	A/G	cg12963246	chr6:28129442	ZNF389	0.54	6.89	0.39	4.02e-11	Parkinson's disease;
CESC	cis	rs9916302	0.800	rs9892675	chr17:37549200	C/T	cg00129232	chr17:37814104	STARD3	0.51	5.65	0.33	4.18e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs7020830	0.867	rs56098516	chr9:37362220	A/G	cg14294708	chr9:37120828	ZCCHC7	1.11	19.1	0.76	9.61e-52	Schizophrenia;
CESC	cis	rs9488822	0.636	rs1544155	chr6:116346394	C/A	cg05304507	chr6:116381966	FRK	0.26	6.59	0.38	2.37e-10	Cholesterol, total;LDL cholesterol;
CESC	cis	rs6952808	0.601	rs3778978	chr7:2159817	A/G	cg08027265	chr7:2291960	NA	-0.46	-7.08	-0.4	1.27e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs9916302	0.904	rs11869109	chr17:37518205	G/T	cg00129232	chr17:37814104	STARD3	0.59	7.82	0.43	1.22e-13	Glomerular filtration rate (creatinine);
CESC	cis	rs7618915	0.524	rs12488461	chr3:52698417	T/C	cg17372223	chr3:52568218	NT5DC2	0.44	6.59	0.38	2.34e-10	Bipolar disorder;
CESC	cis	rs12497850	0.931	rs28642807	chr3:48926816	A/G	cg03060546	chr3:49711283	APEH	0.43	5.27	0.31	2.84e-7	Parkinson's disease;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg03984859	chr1:165668066	ALDH9A1	-0.45	-6.03	-0.35	5.51e-9	Thyroid stimulating hormone;
CESC	cis	rs34172651	0.917	rs11642302	chr16:24770856	G/A	cg06028605	chr16:24865363	SLC5A11	0.35	5.44	0.32	1.2e-7	Intelligence (multi-trait analysis);
CESC	cis	rs17376456	0.877	rs10476599	chr5:93383423	A/G	cg25358565	chr5:93447407	FAM172A	1.11	10.64	0.55	2.98e-22	Diabetic retinopathy;
CESC	cis	rs12541335	0.639	rs7003478	chr8:22201123	A/G	cg27266060	chr8:22091797	NA	0.38	7.85	0.43	1.04e-13	Hypertriglyceridemia;
CESC	cis	rs7044106	0.791	rs2416797	chr9:123480600	C/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.77	11.39	0.57	1.01e-24	Hip circumference adjusted for BMI;
CESC	cis	rs1003719	0.679	rs1133001	chr21:38512956	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.6	-8.06	-0.44	2.56e-14	Eye color traits;
CESC	cis	rs12701220	0.689	rs12533004	chr7:1095410	C/T	cg26769984	chr7:1090371	C7orf50	0.58	5.99	0.35	6.9e-9	Bronchopulmonary dysplasia;
CESC	cis	rs748404	0.631	rs6493086	chr15:43655394	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.54	8.3	0.45	5.5e-15	Lung cancer;
CESC	trans	rs7726839	0.718	rs6887972	chr5:597274	C/G	cg25482853	chr8:67687455	SGK3	0.62	6.36	0.36	8.59e-10	Obesity-related traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00307266	chr5:31532303	RNASEN;C5orf22	0.55	6.23	0.36	1.79e-9	Gut microbiome composition (summer);
CESC	cis	rs9399135	1.000	rs11754265	chr6:135356216	C/G	cg22676075	chr6:135203613	NA	0.49	6.89	0.39	4.05e-11	Red blood cell count;
CESC	trans	rs1814175	0.615	rs10839378	chr11:49806943	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.42	-6.08	-0.35	4.23e-9	Height;
CESC	cis	rs1707322	0.752	rs10430105	chr1:46138876	G/A	cg06784218	chr1:46089804	CCDC17	0.41	7.21	0.41	5.75e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs6912958	0.754	rs7762864	chr6:88236213	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.37	-6.01	-0.35	6.1e-9	Monocyte percentage of white cells;
CESC	cis	rs8180040	0.593	rs10433549	chr3:47031433	C/T	cg27129171	chr3:47204927	SETD2	-0.66	-9.62	-0.51	5.48e-19	Colorectal cancer;
CESC	cis	rs3771570	1.000	rs4346380	chr2:242263223	G/A	cg21155796	chr2:242212141	HDLBP	0.6	5.12	0.3	5.96e-7	Prostate cancer;
CESC	cis	rs7618915	0.501	rs3733041	chr3:52731598	T/C	cg18099408	chr3:52552593	STAB1	-0.3	-5.05	-0.3	8.07e-7	Bipolar disorder;
CESC	cis	rs1799949	0.930	rs35292991	chr17:41334016	C/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.59	7.71	0.43	2.62e-13	Menopause (age at onset);
CESC	cis	rs798554	0.959	rs798557	chr7:2758982	G/A	cg04166393	chr7:2884313	GNA12	0.53	6.66	0.38	1.61e-10	Height;
CESC	cis	rs9649213	0.593	rs6949214	chr7:97960233	G/A	cg21770322	chr7:97807741	LMTK2	0.56	8.61	0.47	6.55e-16	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs12142240	0.698	rs6696777	chr1:46810970	A/G	cg10495392	chr1:46806563	NSUN4	0.57	6.29	0.36	1.33e-9	Menopause (age at onset);
CESC	cis	rs514406	0.893	rs1242330	chr1:53396842	T/G	cg08736216	chr1:53307985	ZYG11A	-0.41	-6.69	-0.38	1.34e-10	Monocyte count;
CESC	cis	rs832540	0.656	rs6862118	chr5:56106474	G/A	cg12311346	chr5:56204834	C5orf35	-0.45	-5.53	-0.32	7.82e-8	Coronary artery disease;
CESC	cis	rs4604732	0.631	rs76761880	chr1:247626377	T/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.57	7.17	0.4	7.39e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg07677032	chr17:61819896	STRADA	0.46	6.21	0.36	2.06e-9	Prudent dietary pattern;
CESC	cis	rs10504229	0.636	rs72649133	chr8:58054681	G/A	cg21724239	chr8:58056113	NA	0.6	5.33	0.31	2.12e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs826838	0.684	rs12367400	chr12:38618673	G/T	cg13010199	chr12:38710504	ALG10B	0.53	6.89	0.39	4.13e-11	Heart rate;
CESC	cis	rs1707322	0.717	rs2253862	chr1:46081960	C/T	cg05343316	chr1:45956843	TESK2	-0.53	-6.5	-0.37	3.98e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs736408	0.774	rs4687551	chr3:52823448	C/T	cg05564831	chr3:52568323	NT5DC2	-0.41	-6.02	-0.35	5.65e-9	Bipolar disorder;
CESC	cis	rs7927771	1.000	rs11039255	chr11:47495746	G/T	cg18512352	chr11:47633146	NA	-0.58	-8.64	-0.47	5.56e-16	Subjective well-being;
CESC	cis	rs1879734	0.731	rs7555711	chr1:54158220	A/G	cg23596471	chr1:54105337	GLIS1	0.35	5.67	0.33	3.77e-8	Mitral valve prolapse;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19980912	chr5:133304180	C5orf15	0.6	6.87	0.39	4.63e-11	Gut microbiome composition (summer);
CESC	trans	rs7615952	0.932	rs7629977	chr3:125649573	T/G	cg07211511	chr3:129823064	LOC729375	-1.1	-14.44	-0.66	2.92e-35	Blood pressure (smoking interaction);
CESC	cis	rs9549367	0.789	rs2287253	chr13:113891075	G/A	cg18105134	chr13:113819100	PROZ	0.57	6.97	0.39	2.58e-11	Platelet distribution width;
CESC	cis	rs2249625	0.564	rs2496496	chr6:72884053	A/G	cg18830697	chr6:72922368	RIMS1	-0.46	-6.81	-0.39	6.53e-11	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CESC	cis	rs875971	1.000	rs7801282	chr7:65613687	C/T	cg12463550	chr7:65579703	CRCP	-0.57	-7.4	-0.41	1.79e-12	Aortic root size;
CESC	cis	rs4253772	0.515	rs7287164	chr22:46781008	T/C	cg18190219	chr22:46762943	CELSR1	-0.68	-6.09	-0.35	3.89e-9	LDL cholesterol;Cholesterol, total;
CESC	cis	rs172166	0.637	rs1225595	chr6:28151340	A/T	cg26335602	chr6:28129616	ZNF389	0.37	5.52	0.32	7.92e-8	Cardiac Troponin-T levels;
CESC	cis	rs11098499	0.863	rs2306456	chr4:120472422	C/G	cg09307838	chr4:120376055	NA	0.91	12.68	0.61	4e-29	Corneal astigmatism;
CESC	cis	rs9487051	0.837	rs932223	chr6:109586656	A/G	cg12927641	chr6:109611667	NA	-0.4	-6.31	-0.36	1.18e-9	Reticulocyte fraction of red cells;
CESC	cis	rs6582630	0.576	rs2222345	chr12:38356020	G/A	cg26384229	chr12:38710491	ALG10B	-0.47	-6.07	-0.35	4.34e-9	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs2806561	0.734	rs10799788	chr1:23356864	G/A	cg12483005	chr1:23474871	LUZP1	0.34	5.23	0.31	3.44e-7	Height;
CESC	cis	rs2303745	0.589	rs1864115	chr19:17393327	G/C	cg02221750	chr19:17393354	ANKLE1	-0.5	-6.0	-0.35	6.45e-9	Systemic lupus erythematosus;
CESC	cis	rs1865721	0.771	rs72975988	chr18:73128289	T/G	cg26385618	chr18:73139727	C18orf62	-0.52	-8.29	-0.45	5.91e-15	Intelligence;
CESC	trans	rs6715284	0.892	rs56828879	chr2:202241323	T/C	cg00425217	chr19:13205470	NFIX	-0.6	-6.0	-0.35	6.38e-9	Rheumatoid arthritis;
CESC	cis	rs7520050	0.966	rs12021587	chr1:46472759	G/T	cg24296786	chr1:45957014	TESK2	0.44	5.5	0.32	9.17e-8	Red blood cell count;Reticulocyte count;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg17375167	chr15:99192228	IGF1R	0.46	6.15	0.35	2.79e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg10224311	chr22:35817371	MCM5	-0.41	-6.02	-0.35	5.64e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs10838687	0.800	rs4752983	chr11:47352138	C/T	cg25783544	chr11:47291846	MADD	0.55	6.23	0.36	1.8e-9	Proinsulin levels;
CESC	cis	rs6500602	0.627	rs4786494	chr16:4506232	G/A	cg08645402	chr16:4508243	NA	0.45	6.43	0.37	5.96e-10	Schizophrenia;
CESC	cis	rs7811142	0.775	rs1636980	chr7:99938864	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	-1.03	-10.77	-0.55	1.13e-22	Platelet count;
CESC	cis	rs801193	0.904	rs4718405	chr7:66254646	A/G	cg18876405	chr7:65276391	NA	0.62	8.1	0.45	2e-14	Aortic root size;
CESC	cis	rs1949733	0.598	rs16842480	chr4:8535621	G/T	cg11789530	chr4:8429930	ACOX3	-0.61	-7.96	-0.44	5.13e-14	Response to antineoplastic agents;
CESC	cis	rs4253772	0.550	rs739164	chr22:46684558	C/T	cg18190219	chr22:46762943	CELSR1	0.48	6.21	0.36	2.09e-9	LDL cholesterol;Cholesterol, total;
CESC	cis	rs12142240	0.698	rs56358525	chr1:46849520	C/T	cg10495392	chr1:46806563	NSUN4	0.56	6.15	0.35	2.86e-9	Menopause (age at onset);
CESC	cis	rs4720575	0.931	rs10242850	chr7:47099868	A/C	cg00036614	chr7:47093842	NA	-0.42	-6.48	-0.37	4.39e-10	Angiotensin-converting enzyme inhibitor intolerance;
CESC	cis	rs10088262	0.629	rs7828192	chr8:124804669	C/T	cg20713898	chr8:124780851	FAM91A1	-0.64	-8.51	-0.46	1.27e-15	Pancreatic cancer;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg26728986	chr19:45540955	SFRS16;RELB	0.52	7.08	0.4	1.31e-11	Fibrinogen levels;
CESC	cis	rs3820068	0.580	rs12082523	chr1:16005792	A/G	cg17385448	chr1:15911702	AGMAT	-0.38	-6.17	-0.35	2.61e-9	Systolic blood pressure;
CESC	cis	rs9389248	0.690	rs728030	chr6:135246294	G/T	cg24558204	chr6:135376177	HBS1L	-0.63	-8.88	-0.48	1e-16	High light scatter reticulocyte percentage of red cells;
CESC	cis	rs11098499	0.863	rs3775843	chr4:120427844	T/C	cg24375607	chr4:120327624	NA	0.44	5.23	0.31	3.48e-7	Corneal astigmatism;
CESC	cis	rs6964587	1.000	rs11982213	chr7:91722966	A/G	cg17063962	chr7:91808500	NA	0.56	7.73	0.43	2.31e-13	Breast cancer;
CESC	cis	rs7552404	1.000	rs4949875	chr1:76173080	G/A	cg22875332	chr1:76189707	ACADM	0.63	7.33	0.41	2.78e-12	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs10256972	0.524	rs6945202	chr7:1116558	T/C	cg07308232	chr7:1071921	C7orf50	-0.44	-6.0	-0.35	6.58e-9	Longevity;Endometriosis;
CESC	cis	rs12765878	1.000	rs3814220	chr10:105647300	A/G	cg24587175	chr10:105670608	OBFC1	0.32	5.16	0.3	4.78e-7	Coronary artery disease;
CESC	cis	rs12477438	0.765	rs6735801	chr2:99657995	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.64	-8.73	-0.47	2.94e-16	Chronic sinus infection;
CESC	cis	rs7959452	0.535	rs10784771	chr12:69621264	A/G	cg14784868	chr12:69753453	YEATS4	0.72	10.24	0.53	5.76e-21	Blood protein levels;
CESC	cis	rs1552244	1.000	rs58275763	chr3:10143274	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.88	12.02	0.59	7.31e-27	Alzheimer's disease;
CESC	cis	rs17023223	0.537	rs11487668	chr1:119726796	T/C	cg05756136	chr1:119680316	WARS2	-0.47	-5.69	-0.33	3.34e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CESC	cis	rs4720575	0.868	rs7779776	chr7:47092914	C/G	cg00036614	chr7:47093842	NA	-0.43	-6.65	-0.38	1.69e-10	Angiotensin-converting enzyme inhibitor intolerance;
CESC	cis	rs7666738	0.830	rs17027102	chr4:98919221	A/G	cg05340658	chr4:99064831	C4orf37	-0.76	-11.4	-0.57	9.42e-25	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4423214	1.000	rs7935125	chr11:71184190	C/A	cg05163923	chr11:71159392	DHCR7	0.8	10.72	0.55	1.69e-22	Vitamin D levels;
CESC	cis	rs9549260	0.664	rs9532575	chr13:41225361	G/C	cg21288729	chr13:41239152	FOXO1	0.65	8.5	0.46	1.4e-15	Red blood cell count;
CESC	cis	rs40363	0.645	rs250629	chr16:3525431	C/A	cg00484396	chr16:3507460	NAT15	0.44	7.35	0.41	2.39e-12	Tuberculosis;
CESC	cis	rs131777	0.577	rs5770928	chr22:51029091	G/C	cg25309564	chr22:51001381	C22orf41	0.64	8.1	0.45	2.03e-14	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	cis	rs11098499	0.913	rs11098496	chr4:120167466	C/G	cg24375607	chr4:120327624	NA	0.44	5.28	0.31	2.66e-7	Corneal astigmatism;
CESC	cis	rs477692	0.905	rs693402	chr10:131422882	G/A	cg05714579	chr10:131428358	MGMT	0.57	8.16	0.45	1.36e-14	Response to temozolomide;
CESC	cis	rs2749592	0.550	rs4934881	chr10:37914346	A/C	cg25427524	chr10:38739819	LOC399744	0.58	7.96	0.44	5.09e-14	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs6570726	0.935	rs425731	chr6:145834151	A/G	cg23711669	chr6:146136114	FBXO30	0.8	12.02	0.59	7.3e-27	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs10791323	0.593	rs2282604	chr11:133714672	A/G	cg15485101	chr11:133734466	NA	0.39	6.57	0.37	2.63e-10	Childhood ear infection;
CESC	cis	rs3925075	0.966	rs12935192	chr16:31359330	G/A	cg02846316	chr16:31340340	ITGAM	0.42	6.65	0.38	1.66e-10	IgA nephropathy;
CESC	cis	rs4727963	0.846	rs4731083	chr7:122725490	G/C	cg03640110	chr7:122635026	TAS2R16	-0.37	-5.62	-0.33	4.72e-8	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
CESC	cis	rs10779751	0.770	rs12097293	chr1:11197467	A/G	cg08854313	chr1:11322531	MTOR	-0.7	-8.35	-0.46	3.85e-15	Body mass index;
CESC	cis	rs1595825	0.786	rs75619425	chr2:198537281	A/G	cg10820045	chr2:198174542	NA	0.42	5.23	0.31	3.4e-7	Ulcerative colitis;
CESC	cis	rs708547	0.836	rs1718882	chr4:57859533	C/G	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.6	-7.36	-0.41	2.25e-12	Response to bleomycin (chromatid breaks);
CESC	cis	rs2228479	0.850	rs11640188	chr16:89807732	C/T	cg04013166	chr16:89971882	TCF25	0.77	6.63	0.38	1.9e-10	Skin colour saturation;
CESC	cis	rs11048434	0.736	rs12423746	chr12:9113002	G/T	cg23795048	chr12:9217529	LOC144571	0.34	5.32	0.31	2.2e-7	Sjögren's syndrome;
CESC	cis	rs2749592	0.505	rs7915670	chr10:37870212	T/C	cg25427524	chr10:38739819	LOC399744	0.55	7.6	0.42	5.27e-13	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs709400	1.000	rs61995780	chr14:104120612	A/G	cg12935359	chr14:103987150	CKB	-0.45	-6.09	-0.35	3.94e-9	Body mass index;
CESC	cis	rs2242194	0.816	rs2242193	chr1:154995503	A/G	cg06221963	chr1:154839813	KCNN3	0.38	5.55	0.32	6.92e-8	Schizophrenia;
CESC	trans	rs57221529	0.766	rs12519763	chr5:559145	C/T	cg25482853	chr8:67687455	SGK3	1.11	11.94	0.59	1.39e-26	Lung disease severity in cystic fibrosis;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg01737828	chr15:75230659	COX5A	-0.4	-6.03	-0.35	5.41e-9	Gambling;
CESC	cis	rs798554	0.757	rs1182181	chr7:2873247	C/G	cg19346786	chr7:2764209	NA	-0.45	-6.51	-0.37	3.68e-10	Height;
CESC	cis	rs6952808	0.630	rs4719443	chr7:2161099	A/G	cg08027265	chr7:2291960	NA	-0.46	-7.01	-0.4	2.02e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs13191362	1.000	rs34591938	chr6:163087003	C/G	cg14584255	chr6:163149320	PACRG;PARK2	0.63	6.47	0.37	4.82e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05998816	chr21:47859926	PCNT	-0.61	-7.67	-0.43	3.31e-13	Gut microbiome composition (summer);
CESC	cis	rs9910055	0.659	rs112114764	chr17:42201041	G/T	cg09913183	chr17:42254507	C17orf65;ASB16	-0.66	-8.84	-0.48	1.36e-16	Total body bone mineral density;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg27265637	chr10:75504303	SEC24C	0.49	6.91	0.39	3.6e-11	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs1008375	0.932	rs6841784	chr4:17626418	G/A	cg16339924	chr4:17578868	LAP3	0.7	8.84	0.48	1.33e-16	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs2115630	0.645	rs3825878	chr15:85174755	C/T	cg11189052	chr15:85197271	WDR73	-0.5	-6.84	-0.39	5.31e-11	P wave terminal force;
CESC	cis	rs10883723	0.810	rs7090034	chr10:104281155	C/G	cg22532475	chr10:104410764	TRIM8	-0.33	-5.67	-0.33	3.77e-8	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs2952156	0.834	rs903503	chr17:37829571	C/A	cg00129232	chr17:37814104	STARD3	-0.81	-11.81	-0.59	3.71e-26	Asthma;
CESC	cis	rs10751667	0.577	rs7946461	chr11:974035	A/G	cg06064525	chr11:970664	AP2A2	-0.46	-8.92	-0.48	7.68e-17	Alzheimer's disease (late onset);
CESC	cis	rs9649213	0.593	rs736753	chr7:97931489	G/T	cg24562669	chr7:97807699	LMTK2	0.48	6.92	0.39	3.3e-11	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs9457247	1.000	rs415842	chr6:167406681	G/A	cg25258033	chr6:167368657	RNASET2	0.39	5.89	0.34	1.15e-8	Crohn's disease;
CESC	cis	rs5769765	0.825	rs9616780	chr22:50292763	T/C	cg02269571	chr22:50332266	NA	-0.45	-6.05	-0.35	4.98e-9	Schizophrenia;
CESC	cis	rs9486719	1.000	rs12214469	chr6:97019471	G/T	cg18709589	chr6:96969512	KIAA0776	-0.52	-5.7	-0.33	3.16e-8	Migraine;Coronary artery disease;
CESC	cis	rs8053891	0.756	rs9925462	chr16:72000195	C/G	cg04254540	chr16:71951199	KIAA0174	-0.42	-5.41	-0.32	1.39e-7	Coronary artery disease;
CESC	cis	rs17253792	0.642	rs10483648	chr14:56104278	T/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.8	5.65	0.33	4.2e-8	Putamen volume;
CESC	trans	rs9693444	0.898	rs4732697	chr8:29519861	A/G	cg22185043	chr18:12947723	SEH1L	-0.41	-6.17	-0.35	2.48e-9	Breast cancer;
CESC	trans	rs853679	0.546	rs200989	chr6:27816442	A/G	cg06606381	chr12:133084897	FBRSL1	-0.82	-7.7	-0.43	2.68e-13	Depression;
CESC	cis	rs2073300	0.609	rs77908916	chr20:23405626	C/G	cg12062639	chr20:23401060	NAPB	1.06	8.07	0.44	2.51e-14	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs977987	0.898	rs12918974	chr16:75493943	T/A	cg03315344	chr16:75512273	CHST6	0.54	7.77	0.43	1.75e-13	Dupuytren's disease;
CESC	cis	rs2073300	0.609	rs6132605	chr20:23354839	A/C	cg16736954	chr20:23401023	NAPB	0.79	5.84	0.34	1.5e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs9814567	1.000	rs6800862	chr3:134228628	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.4	-5.44	-0.32	1.24e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs644799	0.601	rs7902	chr11:95565288	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.53	7.48	0.42	1.09e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs3809863	0.602	rs6504833	chr17:45396087	A/G	cg25173405	chr17:45401733	C17orf57	-0.55	-7.18	-0.4	7.16e-12	Glaucoma (primary open-angle);
CESC	cis	rs11030122	0.661	rs4910877	chr11:4062153	A/G	cg18678763	chr11:4115507	RRM1	-0.41	-5.48	-0.32	9.72e-8	Mean platelet volume;Platelet distribution width;
CESC	cis	rs2880765	0.835	rs4842887	chr15:86035810	T/C	cg10818794	chr15:86012489	AKAP13	-0.34	-5.27	-0.31	2.8e-7	Coronary artery disease;
CESC	cis	rs801193	1.000	rs6975195	chr7:66124774	T/A	cg18876405	chr7:65276391	NA	-0.54	-7.06	-0.4	1.46e-11	Aortic root size;
CESC	cis	rs2243480	0.666	rs1880311	chr7:65276752	G/C	cg12463550	chr7:65579703	CRCP	-0.72	-5.61	-0.33	5.07e-8	Diabetic kidney disease;
CESC	cis	rs6785206	0.772	rs2811493	chr3:128357299	C/G	cg16766828	chr3:128327626	NA	-0.6	-5.96	-0.34	8.15e-9	Lymphocyte percentage of white cells;
CESC	cis	rs9322193	0.962	rs9688750	chr6:149978769	T/C	cg07701084	chr6:150067640	NUP43	0.43	5.94	0.34	8.9e-9	Lung cancer;
CESC	cis	rs10504229	1.000	rs34616626	chr8:58184650	C/T	cg05313129	chr8:58192883	C8orf71	-0.55	-6.29	-0.36	1.34e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs1953600	0.870	rs2236557	chr10:81923961	A/G	cg00277334	chr10:82204260	NA	0.44	6.06	0.35	4.76e-9	Sarcoidosis;
CESC	cis	rs4969178	1.000	rs7212201	chr17:76393896	C/A	cg20026190	chr17:76395443	PGS1	0.48	7.7	0.43	2.68e-13	HDL cholesterol levels;
CESC	cis	rs5758659	1.000	rs134882	chr22:42670965	A/G	cg00645731	chr22:42541494	CYP2D7P1	-0.3	-5.15	-0.3	5.17e-7	Cognitive function;
CESC	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.55	-6.09	-0.35	3.98e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs11098499	0.954	rs13145352	chr4:120409963	C/T	cg25214090	chr10:38739885	LOC399744	-0.69	-9.21	-0.49	1.06e-17	Corneal astigmatism;
CESC	cis	rs12142240	0.698	rs56284503	chr1:46847127	C/G	cg10495392	chr1:46806563	NSUN4	0.56	6.15	0.35	2.86e-9	Menopause (age at onset);
CESC	cis	rs7666738	0.830	rs7662199	chr4:99019766	G/A	cg05340658	chr4:99064831	C4orf37	0.8	12.42	0.61	3.08e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9311474	0.508	rs11718420	chr3:52611413	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.49	7.15	0.4	8.38e-12	Electroencephalogram traits;
CESC	cis	rs10751667	1.000	rs11246359	chr11:967943	T/C	cg06064525	chr11:970664	AP2A2	-0.38	-6.77	-0.38	8.29e-11	Alzheimer's disease (late onset);
CESC	cis	rs6840258	1.000	rs72667754	chr4:87942061	T/C	cg08197287	chr4:87952173	AFF1	-0.41	-5.57	-0.32	6.14e-8	Mean corpuscular volume;Basophil percentage of granulocytes;
CESC	cis	rs1018836	0.923	rs2157607	chr8:91600268	A/G	cg16814680	chr8:91681699	NA	-0.69	-9.45	-0.5	1.83e-18	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs11711311	0.747	rs9882193	chr3:113349451	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	-0.38	-5.05	-0.3	8.1e-7	IgG glycosylation;
CESC	cis	rs9549260	0.755	rs2701863	chr13:41170140	C/T	cg21288729	chr13:41239152	FOXO1	0.59	7.35	0.41	2.53e-12	Red blood cell count;
CESC	cis	rs6933660	0.760	rs1825368	chr6:151775259	C/A	cg14416726	chr6:151773293	C6orf211;RMND1	-0.53	-7.02	-0.4	1.88e-11	Menarche (age at onset);
CESC	cis	rs10845606	1.000	rs11055013	chr12:12829037	T/C	cg09462578	chr12:12878428	APOLD1	-0.63	-6.94	-0.39	3.05e-11	Systemic lupus erythematosus;
CESC	cis	rs2180341	1.000	rs6569486	chr6:127708424	A/C	cg24812749	chr6:127587940	RNF146	1.03	14.56	0.67	1.13e-35	Breast cancer;
CESC	cis	rs6088590	0.735	rs6060003	chr20:33294945	T/C	cg24642439	chr20:33292090	TP53INP2	0.64	8.27	0.45	6.39e-15	Coronary artery disease;
CESC	cis	rs35955747	0.869	rs9621216	chr22:31590208	A/C	cg25791279	chr22:32026902	PISD	-0.45	-5.3	-0.31	2.5e-7	Neutrophil count;Sum basophil neutrophil counts;
CESC	cis	rs1256061	0.533	rs2357479	chr14:64792764	G/T	cg23250157	chr14:64679961	SYNE2	0.52	7.26	0.41	4.25e-12	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs3125734	0.633	rs6479791	chr10:63980341	T/C	cg09941381	chr10:64027924	RTKN2	-0.32	-5.34	-0.31	2e-7	Rheumatoid arthritis;
CESC	trans	rs208520	0.690	rs1233103	chr6:66855943	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.0	-12.93	-0.62	5.39e-30	Exhaled nitric oxide output;
CESC	cis	rs4919087	0.892	rs10882880	chr10:99008068	G/A	cg25902810	chr10:99078978	FRAT1	0.65	9.33	0.5	4.51e-18	Monocyte count;
CESC	cis	rs5750830	0.649	rs4821895	chr22:39823015	A/G	cg24399712	chr22:39784796	NA	-0.81	-11.11	-0.56	8.72e-24	Intelligence (multi-trait analysis);
CESC	cis	rs7945705	0.870	rs10840142	chr11:8906078	A/G	cg12365402	chr11:9010492	NRIP3	0.38	5.82	0.34	1.66e-8	Hemoglobin concentration;
CESC	cis	rs12950390	0.893	rs4794110	chr17:45847230	A/G	cg00777063	chr17:45855553	NA	-0.41	-6.24	-0.36	1.72e-9	IgG glycosylation;
CESC	cis	rs597539	0.652	rs667989	chr11:68685776	T/A	cg01988459	chr11:68622903	NA	-0.44	-6.14	-0.35	3.07e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	trans	rs61931739	0.517	rs1843735	chr12:34047389	C/G	cg26384229	chr12:38710491	ALG10B	0.51	6.94	0.39	2.97e-11	Morning vs. evening chronotype;
CESC	cis	rs2985684	0.894	rs6572585	chr14:50021075	A/G	cg02151108	chr14:50098012	C14orf104	-0.39	-5.19	-0.3	4.16e-7	Carotid intima media thickness;
CESC	cis	rs13191362	1.000	rs13201023	chr6:162981381	C/G	cg21926612	chr6:163149169	PACRG;PARK2	0.86	9.19	0.49	1.15e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs7659604	0.689	rs59131059	chr4:122666357	C/T	cg19671926	chr4:122722719	EXOSC9	-0.49	-5.94	-0.34	9.04e-9	Type 2 diabetes;
CESC	cis	rs7116495	0.609	rs1892920	chr11:71702431	A/G	cg10381502	chr11:71823885	C11orf51	-1.13	-7.5	-0.42	9.35e-13	Severe influenza A (H1N1) infection;
CESC	cis	rs9611565	0.694	rs202631	chr22:41863423	A/G	cg06634786	chr22:41940651	POLR3H	0.62	6.81	0.39	6.4e-11	Vitiligo;
CESC	cis	rs977987	0.806	rs11865004	chr16:75395777	C/T	cg03315344	chr16:75512273	CHST6	0.39	5.64	0.33	4.3e-8	Dupuytren's disease;
CESC	cis	rs9322193	0.923	rs3924871	chr6:149983216	G/A	cg13206674	chr6:150067644	NUP43	0.44	6.29	0.36	1.27e-9	Lung cancer;
CESC	cis	rs7811142	1.000	rs7783550	chr7:99987805	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	-0.73	-6.87	-0.39	4.48e-11	Platelet count;
CESC	cis	rs3015497	0.646	rs2934687	chr14:51111889	G/A	cg26011998	chr14:51135199	SAV1	-0.6	-6.73	-0.38	1.02e-10	Mean platelet volume;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg24480577	chr20:62169334	PTK6	-0.48	-7.22	-0.41	5.6e-12	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs854765	0.551	rs8070748	chr17:17859421	A/G	cg04398451	chr17:18023971	MYO15A	-0.69	-9.72	-0.51	2.77e-19	Total body bone mineral density;
CESC	cis	rs6674176	0.542	rs803679	chr1:44349405	G/A	cg12908607	chr1:44402522	ARTN	-0.41	-5.5	-0.32	9.08e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs7666738	0.830	rs9992391	chr4:98916052	G/A	cg03467027	chr4:99064603	C4orf37	0.44	5.4	0.31	1.48e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11039798	0.588	rs3924476	chr11:48581733	T/C	cg15704280	chr7:45808275	SEPT13	0.63	6.57	0.37	2.69e-10	Axial length;
CESC	cis	rs11758351	0.929	rs6906367	chr6:26187125	C/T	cg23601095	chr6:26197514	HIST1H3D	0.58	6.5	0.37	3.95e-10	Gout;Renal underexcretion gout;
CESC	cis	rs1552244	0.554	rs3732963	chr3:10048885	G/T	cg00149659	chr3:10157352	C3orf10	0.53	6.51	0.37	3.81e-10	Alzheimer's disease;
CESC	cis	rs1448094	0.511	rs2405621	chr12:86149336	A/T	cg02569458	chr12:86230093	RASSF9	-0.42	-6.46	-0.37	4.89e-10	Major depressive disorder;
CESC	cis	rs7904368	0.806	rs12242261	chr10:16872929	T/C	cg23933602	chr10:16859644	RSU1	0.62	5.71	0.33	3.05e-8	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
CESC	cis	rs7143963	0.697	rs2273393	chr14:103357603	G/T	cg24154132	chr14:103367632	TRAF3	0.38	6.71	0.38	1.18e-10	Body mass index;
CESC	cis	rs6066835	0.702	rs6095229	chr20:47283774	C/T	cg18078177	chr20:47281410	PREX1	0.72	5.08	0.3	7.06e-7	Multiple myeloma;
CESC	cis	rs6502050	0.799	rs7406257	chr17:80089340	G/A	cg23985595	chr17:80112537	CCDC57	-0.42	-6.6	-0.38	2.18e-10	Life satisfaction;
CESC	cis	rs7520050	0.931	rs11211213	chr1:46342517	G/A	cg24296786	chr1:45957014	TESK2	0.43	5.41	0.32	1.4e-7	Red blood cell count;Reticulocyte count;
CESC	cis	rs2576037	0.763	rs2060418	chr18:44576535	A/C	cg19077165	chr18:44547161	KATNAL2	0.52	7.39	0.41	1.91e-12	Personality dimensions;
CESC	cis	rs736408	0.562	rs12497998	chr3:52793602	C/T	cg18337363	chr3:52569053	NT5DC2	0.29	5.07	0.3	7.56e-7	Bipolar disorder;
CESC	cis	rs8180040	0.764	rs4082155	chr3:47125385	G/A	cg27129171	chr3:47204927	SETD2	0.7	10.51	0.54	7.71e-22	Colorectal cancer;
CESC	cis	rs992157	0.764	rs13020391	chr2:219184436	C/T	cg00012203	chr2:219082015	ARPC2	-0.59	-7.19	-0.4	6.77e-12	Colorectal cancer;
CESC	cis	rs9457247	1.000	rs400837	chr6:167411008	T/C	cg23791538	chr6:167370224	RNASET2	-0.61	-8.81	-0.48	1.71e-16	Crohn's disease;
CESC	cis	rs40363	0.680	rs72778116	chr16:3530752	A/G	cg22508957	chr16:3507546	NAT15	0.72	7.69	0.43	2.82e-13	Tuberculosis;
CESC	cis	rs80282103	0.618	rs10794720	chr10:1156165	A/G	cg24064224	chr10:1156594	WDR37	0.45	5.44	0.32	1.24e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs733592	0.524	rs10875726	chr12:48425992	A/G	cg24011408	chr12:48396354	COL2A1	-0.51	-8.59	-0.47	7.74e-16	Plateletcrit;
CESC	cis	rs4665809	0.590	rs4665315	chr2:26416036	T/G	cg04944784	chr2:26401820	FAM59B	-0.93	-10.75	-0.55	1.28e-22	Gut microbiome composition (summer);
CESC	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg24829409	chr8:58192753	C8orf71	-0.67	-7.99	-0.44	4.08e-14	Developmental language disorder (linguistic errors);
CESC	cis	rs798554	0.797	rs798488	chr7:2802522	T/C	cg19717773	chr7:2847554	GNA12	-0.57	-8.13	-0.45	1.66e-14	Height;
CESC	cis	rs807669	0.934	rs1780643	chr22:19191725	T/C	cg02655711	chr22:19163373	SLC25A1	0.96	14.07	0.65	5.72e-34	Metabolite levels;
CESC	cis	rs9322193	0.632	rs3828700	chr6:150112169	C/G	cg04369109	chr6:150039330	LATS1	-0.39	-5.28	-0.31	2.65e-7	Lung cancer;
CESC	cis	rs2735413	0.918	rs2344494	chr16:78078111	C/T	cg04733911	chr16:78082701	NA	-0.53	-9.01	-0.48	4.08e-17	Systolic blood pressure (alcohol consumption interaction);
CESC	cis	rs477895	0.653	rs34113693	chr11:63900123	G/T	cg04317338	chr11:64019027	PLCB3	0.87	9.06	0.49	3.04e-17	Mean platelet volume;
CESC	cis	rs763121	0.651	rs738249	chr22:39037979	T/C	cg21395723	chr22:39101663	GTPBP1	0.42	5.21	0.3	3.82e-7	Menopause (age at onset);
CESC	cis	rs6570726	0.764	rs9403733	chr6:145912311	A/C	cg05347473	chr6:146136440	FBXO30	0.57	7.24	0.41	4.72e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1401999	0.899	rs2313211	chr3:183738626	T/A	cg01324343	chr3:183735012	ABCC5	0.67	14.52	0.67	1.5e-35	Anterior chamber depth;
CESC	cis	rs2235544	0.541	rs928442	chr1:54473488	C/G	cg25741118	chr1:54482237	LDLRAD1	-0.25	-6.28	-0.36	1.41e-9	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
CESC	trans	rs61931739	0.500	rs10844848	chr12:34409705	A/C	cg26384229	chr12:38710491	ALG10B	0.7	10.43	0.54	1.43e-21	Morning vs. evening chronotype;
CESC	cis	rs9399401	1.000	rs1040525	chr6:142703669	C/T	cg03128060	chr6:142623767	GPR126	0.26	5.24	0.31	3.31e-7	Chronic obstructive pulmonary disease;
CESC	cis	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg04025307	chr7:1156635	C7orf50	0.48	7.73	0.43	2.31e-13	Longevity;Endometriosis;
CESC	cis	rs17655565	0.533	rs12301094	chr12:52707610	A/G	cg08257133	chr12:52711352	KRT83	0.5	8.85	0.48	1.25e-16	Plasma amyloid beta peptide concentrations (ABx-42);
CESC	cis	rs801193	0.569	rs10950050	chr7:66239588	A/C	cg18252515	chr7:66147081	NA	-0.43	-5.94	-0.34	8.95e-9	Aortic root size;
CESC	cis	rs1728785	0.892	rs1103955	chr16:68588488	T/G	cg02972257	chr16:68554789	NA	-0.58	-6.68	-0.38	1.42e-10	Ulcerative colitis;
CESC	cis	rs780096	0.565	rs10169261	chr2:27727314	C/T	cg21248554	chr2:27665150	KRTCAP3	-0.43	-8.78	-0.47	2e-16	Total body bone mineral density;
CESC	cis	rs7618915	0.501	rs13060048	chr3:52598608	G/A	cg07507251	chr3:52567010	NT5DC2	0.33	5.69	0.33	3.36e-8	Bipolar disorder;
CESC	cis	rs875971	1.000	rs875971	chr7:65617595	A/G	cg11764359	chr7:65958608	NA	-0.91	-14.38	-0.66	4.81e-35	Aortic root size;
CESC	cis	rs4727963	0.846	rs1554703	chr7:122702062	T/C	cg03640110	chr7:122635026	TAS2R16	-0.37	-5.78	-0.33	2.04e-8	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
CESC	cis	rs8017423	0.967	rs11845329	chr14:90727749	C/T	cg14092571	chr14:90743983	NA	-0.55	-8.33	-0.46	4.46e-15	Mortality in heart failure;
CESC	cis	rs919433	0.963	rs4850430	chr2:198182796	A/T	cg03934865	chr2:198174659	NA	-0.4	-5.45	-0.32	1.15e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs6912958	0.967	rs6905947	chr6:88161949	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.38	-6.31	-0.36	1.2e-9	Monocyte percentage of white cells;
CESC	cis	rs8141529	0.778	rs7287806	chr22:29213011	G/A	cg02153584	chr22:29168773	CCDC117	0.64	9.3	0.5	5.56e-18	Lymphocyte counts;
CESC	cis	rs9733	0.596	rs11807058	chr1:150640475	G/A	cg09365446	chr1:150670422	GOLPH3L	0.42	5.93	0.34	9.63e-9	Tonsillectomy;
CESC	cis	rs6860806	0.507	rs635619	chr5:131720265	G/A	cg07395648	chr5:131743802	NA	0.42	5.52	0.32	7.92e-8	Breast cancer;
CESC	cis	rs1050631	0.563	rs685042	chr18:33743998	A/G	cg25426722	chr18:33708991	SLC39A6;ELP2	0.53	7.25	0.41	4.63e-12	Esophageal squamous cell cancer (length of survival);
CESC	cis	rs7592578	0.882	rs61117285	chr2:191468986	G/C	cg27211696	chr2:191398769	TMEM194B	-0.62	-5.67	-0.33	3.64e-8	Diastolic blood pressure;
CESC	cis	rs6912958	0.781	rs9444504	chr6:88181046	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.3	-5.1	-0.3	6.48e-7	Monocyte percentage of white cells;
CESC	trans	rs11039798	0.588	rs10437592	chr11:48598859	G/T	cg15704280	chr7:45808275	SEPT13	0.61	6.16	0.35	2.65e-9	Axial length;
CESC	cis	rs7084402	0.967	rs1658493	chr10:60281090	C/T	cg07615347	chr10:60278583	BICC1	-0.59	-9.44	-0.5	2.03e-18	Refractive error;
CESC	cis	rs2857078	0.732	rs9893756	chr17:42321109	T/C	cg13607699	chr17:42295918	UBTF	-0.83	-11.82	-0.59	3.56e-26	Red cell distribution width;Reticulocyte count;
CESC	trans	rs1973993	0.934	rs588660	chr1:96886604	G/A	cg10631902	chr5:14652156	NA	0.54	7.47	0.42	1.16e-12	Weight;
CESC	cis	rs4319547	0.956	rs10847179	chr12:123040985	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.59	-6.66	-0.38	1.57e-10	Body mass index;
CESC	cis	rs11608355	0.545	rs11613021	chr12:109897998	T/G	cg05360138	chr12:110035743	NA	0.82	8.92	0.48	7.93e-17	Neuroticism;
CESC	cis	rs6088580	0.609	rs6059845	chr20:33036500	G/A	cg24642439	chr20:33292090	TP53INP2	0.51	6.75	0.38	9.47e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs7949030	0.653	rs17773169	chr11:62318530	G/T	cg02375832	chr11:62437615	C11orf48	-0.35	-5.21	-0.3	3.89e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs7617773	1.000	rs7617773	chr3:48193515	C/T	cg11946769	chr3:48343235	NME6	-0.68	-9.11	-0.49	2.01e-17	Coronary artery disease;
CESC	cis	rs514406	0.505	rs269287	chr1:53168842	T/C	cg16325326	chr1:53192061	ZYG11B	0.9	15.51	0.69	4.6e-39	Monocyte count;
CESC	cis	rs34779708	0.931	rs4934724	chr10:35393669	C/T	cg04310649	chr10:35416472	CREM	-0.51	-6.06	-0.35	4.72e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs4566357	0.615	rs10174591	chr2:227913140	G/A	cg11843606	chr2:227700838	RHBDD1	-0.5	-6.82	-0.39	6.08e-11	Coronary artery disease;
CESC	cis	rs4237845	0.537	rs9645819	chr12:58270063	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.5	5.61	0.33	5.17e-8	Intelligence (multi-trait analysis);
CESC	cis	rs2952156	0.876	rs903501	chr17:37839493	T/C	cg20243544	chr17:37824526	PNMT	0.61	7.55	0.42	7.25e-13	Asthma;
CESC	cis	rs853679	0.517	rs9393897	chr6:28127710	G/T	cg23161317	chr6:28129485	ZNF389	0.52	6.46	0.37	5.08e-10	Depression;
CESC	cis	rs2109514	1.000	rs6466579	chr7:116151155	T/C	cg12739419	chr7:116140593	CAV2	-0.36	-6.54	-0.37	3.22e-10	Prevalent atrial fibrillation;
CESC	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg22535103	chr8:58192502	C8orf71	-0.94	-9.92	-0.52	6.46e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs1003719	0.788	rs9977314	chr21:38471963	G/T	cg10648535	chr21:38446584	PIGP;TTC3	0.63	8.62	0.47	6.19e-16	Eye color traits;
CESC	cis	rs7552404	1.000	rs1498312	chr1:76177849	C/T	cg10523679	chr1:76189770	ACADM	0.72	8.4	0.46	2.75e-15	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs1865721	0.682	rs3745082	chr18:73142734	G/T	cg26385618	chr18:73139727	C18orf62	-0.48	-7.63	-0.42	4.28e-13	Intelligence;
CESC	cis	rs7937682	0.883	rs517982	chr11:111462687	T/C	cg09085632	chr11:111637200	PPP2R1B	-0.9	-12.87	-0.62	9.33e-30	Primary sclerosing cholangitis;
CESC	cis	rs7045138	1	rs7045138	chr9:100591463	C/T	cg13688889	chr9:100608707	NA	-0.58	-9.03	-0.49	3.69e-17	Thyroid hormone levels;
CESC	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg24642844	chr7:1081250	C7orf50	-0.75	-9.03	-0.49	3.61e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7086627	0.515	rs10887903	chr10:82210641	C/T	cg03267442	chr10:82210566	NA	-0.34	-5.81	-0.34	1.82e-8	Post bronchodilator FEV1;
CESC	cis	rs10504229	1.000	rs56168206	chr8:58184485	G/A	cg14926445	chr8:58193284	C8orf71	-0.51	-5.52	-0.32	8.28e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs1448094	0.556	rs61930632	chr12:86168937	A/C	cg00310523	chr12:86230176	RASSF9	0.42	6.27	0.36	1.47e-9	Major depressive disorder;
CESC	cis	rs7937682	0.814	rs1784788	chr11:111486136	T/G	cg22437258	chr11:111473054	SIK2	0.71	9.4	0.5	2.72e-18	Primary sclerosing cholangitis;
CESC	cis	rs7959452	0.640	rs4761154	chr12:69705362	A/G	cg20891283	chr12:69753455	YEATS4	-0.76	-11.32	-0.57	1.71e-24	Blood protein levels;
CESC	cis	rs17001868	0.568	rs909669	chr22:40742417	C/T	cg07138101	chr22:40742427	ADSL	0.58	5.46	0.32	1.08e-7	Mammographic density (dense area);
CESC	cis	rs735396	0.731	rs1182933	chr12:121454622	C/T	cg02403541	chr12:121454288	C12orf43	0.74	10.2	0.53	7.97e-21	N-glycan levels;
CESC	cis	rs1881797	1.000	rs1881796	chr1:247688931	G/A	cg11166453	chr1:247681781	NA	0.44	5.8	0.34	1.87e-8	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs8177253	0.896	rs34252038	chr3:133490621	G/T	cg01448562	chr3:133502909	NA	-0.43	-5.91	-0.34	1.02e-8	Iron status biomarkers;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg17546822	chr22:41865178	ACO2;PHF5A	-0.4	-6.45	-0.37	5.29e-10	Gambling;
CESC	cis	rs7044106	0.762	rs1158554	chr9:123400898	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.68	9.82	0.52	1.27e-19	Hip circumference adjusted for BMI;
CESC	trans	rs10007810	0.760	rs7674730	chr4:41594636	G/T	cg05088549	chr3:183978344	ECE2;CAMK2N2	-0.49	-6.05	-0.35	4.87e-9	Longevity (90 years and older);
CESC	cis	rs10493773	0.928	rs12741600	chr1:86191172	A/C	cg17807903	chr1:86174739	ZNHIT6	-0.43	-5.91	-0.34	1.07e-8	Urate levels in overweight individuals;
CESC	cis	rs10791097	0.694	rs4264159	chr11:130755784	G/T	cg12179176	chr11:130786555	SNX19	0.65	10.14	0.53	1.21e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs2522056	0.808	rs1016988	chr5:131744574	T/C	cg24060327	chr5:131705240	SLC22A5	0.67	7.44	0.42	1.37e-12	Lymphocyte counts;Fibrinogen;
CESC	cis	rs9733	0.543	rs72702558	chr1:150683251	G/A	cg18016565	chr1:150552671	MCL1	0.35	5.36	0.31	1.86e-7	Tonsillectomy;
CESC	trans	rs2115172	0.836	rs4835799	chr5:122762229	A/G	cg08504905	chr19:54663436	LENG1	0.48	6.42	0.37	6.23e-10	Weight;
CESC	cis	rs9733	0.596	rs72702557	chr1:150680130	A/G	cg18016565	chr1:150552671	MCL1	0.35	5.36	0.31	1.86e-7	Tonsillectomy;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg26979279	chr8:99057120	RPL30	0.46	6.05	0.35	4.87e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs4604732	0.631	rs76761880	chr1:247626377	T/A	cg12754571	chr1:247694271	LOC148824;OR2C3	0.44	5.44	0.32	1.21e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04020816	chr5:109025456	MAN2A1	0.57	6.4	0.37	6.84e-10	Gut microbiome composition (summer);
CESC	cis	rs742614	0.533	rs736953	chr20:32415089	G/T	cg06304546	chr20:32448765	NA	-0.42	-5.38	-0.31	1.62e-7	Stearic acid (18:0) levels;
CESC	trans	rs7943203	1.000	rs4754322	chr11:108311655	T/C	cg24643211	chr18:11851603	GNAL;CHMP1B	-0.47	-6.13	-0.35	3.12e-9	Red blood cell count;Mean corpuscular volume;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg02501984	chr12:133263946	POLE;PXMP2	-0.4	-6.22	-0.36	1.96e-9	Gambling;
CESC	cis	rs6545883	0.965	rs2305156	chr2:61729268	T/C	cg15711740	chr2:61764176	XPO1	-0.42	-5.28	-0.31	2.66e-7	Tuberculosis;
CESC	cis	rs9611565	0.659	rs9611603	chr22:41912750	A/G	cg17376030	chr22:41985996	PMM1	0.71	7.76	0.43	1.81e-13	Vitiligo;
CESC	cis	rs2576037	0.526	rs1789152	chr18:44433092	G/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.41	6.86	0.39	4.85e-11	Personality dimensions;
CESC	cis	rs7605827	0.836	rs13009246	chr2:15640237	A/G	cg19274914	chr2:15703543	NA	0.36	6.4	0.37	6.84e-10	Educational attainment (years of education);
CESC	cis	rs7666738	0.830	rs6831219	chr4:98993576	C/A	cg05340658	chr4:99064831	C4orf37	0.8	12.44	0.61	2.83e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs694739	0.536	rs11231740	chr11:64046641	C/T	cg05555928	chr11:63887634	MACROD1	0.55	8.19	0.45	1.15e-14	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CESC	cis	rs1451375	0.617	rs9942686	chr7:50596381	G/A	cg14593290	chr7:50529359	DDC	0.5	6.04	0.35	5.34e-9	Malaria;
CESC	cis	rs9457247	1.000	rs376574	chr6:167389956	A/T	cg23791538	chr6:167370224	RNASET2	-0.6	-8.65	-0.47	4.96e-16	Crohn's disease;
CESC	trans	rs11098499	0.738	rs10026493	chr4:120384194	C/G	cg25214090	chr10:38739885	LOC399744	0.69	9.79	0.52	1.58e-19	Corneal astigmatism;
CESC	cis	rs6964587	1.000	rs411	chr7:91557758	C/G	cg17063962	chr7:91808500	NA	-0.58	-7.83	-0.43	1.15e-13	Breast cancer;
CESC	cis	rs2859741	0.528	rs6686296	chr1:37489380	G/T	cg09363841	chr1:37513479	NA	0.49	7.12	0.4	1.03e-11	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
CESC	cis	rs1008375	0.686	rs34338142	chr4:17626174	T/A	cg04450456	chr4:17643702	FAM184B	0.36	5.21	0.3	3.81e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs71277158	0.688	rs6762609	chr3:169916919	A/G	cg04067573	chr3:169899625	PHC3	-0.64	-6.39	-0.37	7.22e-10	Prostate cancer;
CESC	cis	rs1448094	0.549	rs7297996	chr12:86235899	C/T	cg02569458	chr12:86230093	RASSF9	0.52	7.52	0.42	8.77e-13	Major depressive disorder;
CESC	cis	rs7178572	0.568	rs28584877	chr15:77599003	C/A	cg22256960	chr15:77711686	NA	0.53	6.37	0.36	8.52e-10	Type 2 diabetes;
CESC	cis	rs9815354	0.597	rs59432762	chr3:41812294	G/C	cg03022575	chr3:42003672	ULK4	0.7	6.17	0.35	2.5e-9	Pulse pressure;Diastolic blood pressure;
CESC	trans	rs629535	0.814	rs571682	chr8:70062793	A/G	cg21567404	chr3:27674614	NA	0.82	9.72	0.51	2.63e-19	Dupuytren's disease;
CESC	cis	rs80130819	0.636	rs2634690	chr12:48712638	C/T	cg05342945	chr12:48394962	COL2A1	-0.47	-5.26	-0.31	2.92e-7	Prostate cancer;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg16452840	chr11:59383203	OSBP	-0.52	-6.77	-0.38	8.45e-11	Asthma;
CESC	cis	rs9828933	0.766	rs3774725	chr3:63974258	T/G	cg16258503	chr3:63850278	ATXN7;THOC7	-0.82	-8.1	-0.45	2e-14	Type 2 diabetes;
CESC	cis	rs9354308	1.000	rs9354308	chr6:66565353	A/G	cg07460842	chr6:66804631	NA	0.49	6.05	0.35	4.83e-9	Metabolite levels;
CESC	cis	rs8028182	0.636	rs62027181	chr15:75839952	A/G	cg20655648	chr15:75932815	IMP3	0.48	6.0	0.35	6.42e-9	Sudden cardiac arrest;
CESC	cis	rs9787249	0.957	rs7518431	chr1:40214944	C/T	cg24920358	chr1:40204285	PPIE	-0.4	-6.01	-0.35	6.09e-9	Blood protein levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14871650	chr4:170541668	CLCN3	0.74	8.25	0.45	7.34e-15	Gut microbiome composition (summer);
CESC	cis	rs9649213	0.593	rs1859482	chr7:97983774	C/T	cg24562669	chr7:97807699	LMTK2	0.51	7.63	0.42	4.29e-13	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs965513	1.000	rs7030280	chr9:100535267	C/T	cg13688889	chr9:100608707	NA	-0.59	-8.31	-0.45	5.05e-15	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
CESC	cis	rs13191362	0.938	rs13208970	chr6:163006368	G/T	cg14584255	chr6:163149320	PACRG;PARK2	0.49	5.36	0.31	1.82e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs1707322	1.000	rs1768817	chr1:46514534	C/G	cg05343316	chr1:45956843	TESK2	-0.44	-5.44	-0.32	1.2e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7927592	0.956	rs10896348	chr11:68357368	T/C	cg01657329	chr11:68192670	LRP5	-0.4	-5.11	-0.3	6.03e-7	Total body bone mineral density;
CESC	trans	rs10463316	0.894	rs954339	chr5:150752161	C/A	cg24389359	chr12:111284228	CCDC63	-0.35	-6.17	-0.35	2.52e-9	Metabolite levels (Pyroglutamine);
CESC	cis	rs7666738	0.716	rs7656233	chr4:99079237	G/A	cg17366294	chr4:99064904	C4orf37	0.55	7.46	0.42	1.21e-12	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6540559	0.543	rs664097	chr1:210422179	C/T	cg22029157	chr1:209979665	IRF6	0.48	5.85	0.34	1.46e-8	Cleft lip with or without cleft palate;
CESC	trans	rs17033621	0.549	rs6706779	chr2:107569609	G/T	cg17982866	chr13:113637695	MCF2L	-0.4	-6.0	-0.35	6.47e-9	Intelligence (multi-trait analysis);
CESC	cis	rs2933343	0.700	rs789240	chr3:128630635	T/C	cg24203234	chr3:128598194	ACAD9	0.39	5.25	0.31	3.19e-7	IgG glycosylation;
CESC	cis	rs12477438	0.520	rs11123762	chr2:99727789	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.86	15.87	0.7	2.48e-40	Chronic sinus infection;
CESC	cis	rs12200560	0.505	rs927271	chr6:97075910	T/G	cg06623918	chr6:96969491	KIAA0776	0.41	5.29	0.31	2.6e-7	Coronary heart disease;
CESC	cis	rs853679	0.517	rs1904841	chr6:28108085	C/T	cg17949981	chr6:28129498	ZNF389	0.48	6.07	0.35	4.37e-9	Depression;
CESC	cis	rs896854	0.738	rs1713669	chr8:95958637	C/G	cg23172400	chr8:95962367	TP53INP1	-0.42	-8.03	-0.44	3.14e-14	Type 2 diabetes;
CESC	cis	rs763014	0.932	rs35067229	chr16:649638	T/C	cg00802000	chr16:706648	WDR90	-0.4	-6.16	-0.35	2.71e-9	Height;
CESC	cis	rs875971	0.638	rs6960778	chr7:66071597	C/T	cg18876405	chr7:65276391	NA	-0.58	-7.66	-0.43	3.57e-13	Aortic root size;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg22395299	chr21:47706029	MCM3AP;C21orf57	-0.55	-6.96	-0.39	2.69e-11	Ulcerative colitis;
CESC	cis	rs910316	1.000	rs12589376	chr14:75561152	C/T	cg08847533	chr14:75593920	NEK9	0.99	18.74	0.75	1.84e-50	Height;
CESC	cis	rs3782089	1.000	rs11602375	chr11:65296540	C/T	cg00206168	chr11:65308501	LTBP3	1.0	6.54	0.37	3.15e-10	Height;
CESC	cis	rs561341	0.882	rs72825748	chr17:30367396	G/A	cg19193384	chr17:30244184	NA	-0.68	-6.26	-0.36	1.53e-9	Hip circumference adjusted for BMI;
CESC	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	10.31	0.54	3.43e-21	Prudent dietary pattern;
CESC	cis	rs7659604	0.539	rs3217773	chr4:122739121	A/G	cg20573242	chr4:122745356	CCNA2	0.62	7.64	0.42	3.94e-13	Type 2 diabetes;
CESC	cis	rs798554	0.679	rs2266922	chr7:2824707	G/A	cg13628971	chr7:2884303	GNA12	0.4	5.33	0.31	2.08e-7	Height;
CESC	cis	rs9902453	0.791	rs6505141	chr17:27998187	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.79	10.74	0.55	1.47e-22	Coffee consumption (cups per day);
CESC	cis	rs9359856	0.564	rs56224741	chr6:90475231	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.61	-5.66	-0.33	3.93e-8	Bipolar disorder;
CESC	cis	rs1707322	1.000	rs10890360	chr1:46338444	C/T	cg06784218	chr1:46089804	CCDC17	0.32	5.57	0.32	6.35e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7917772	0.582	rs10786696	chr10:104378134	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.39	5.41	0.32	1.43e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs2479724	0.846	rs2254474	chr6:41843044	T/G	cg08135965	chr6:41755394	TOMM6	0.41	5.5	0.32	9.15e-8	Menarche (age at onset);
CESC	cis	rs818427	0.795	rs454968	chr5:112188456	T/C	cg07820702	chr5:112228657	REEP5	0.43	5.42	0.32	1.33e-7	Total body bone mineral density;
CESC	cis	rs10504229	0.593	rs76118562	chr8:57988110	G/C	cg24829409	chr8:58192753	C8orf71	-0.69	-7.52	-0.42	8.6e-13	Developmental language disorder (linguistic errors);
CESC	cis	rs61935443	0.720	rs892493	chr12:95283943	T/C	cg21533806	chr12:95267307	NA	0.6	7.4	0.41	1.82e-12	Schizophrenia;
CESC	cis	rs3741151	1.000	rs79778136	chr11:73041339	T/C	cg17517138	chr11:73019481	ARHGEF17	1.06	7.44	0.42	1.38e-12	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs6963495	0.585	rs1706923	chr7:105221097	A/G	cg19920283	chr7:105172520	RINT1	0.5	5.81	0.34	1.76e-8	Bipolar disorder (body mass index interaction);
CESC	cis	rs9790314	0.905	rs6441370	chr3:160993754	C/T	cg03342759	chr3:160939853	NMD3	-0.47	-6.2	-0.36	2.18e-9	Morning vs. evening chronotype;
CESC	cis	rs9322193	0.923	rs10872651	chr6:150089409	A/T	cg13206674	chr6:150067644	NUP43	0.43	5.9	0.34	1.1e-8	Lung cancer;
CESC	cis	rs2985684	0.779	rs12160	chr14:50091932	T/A	cg10008539	chr14:50087325	RPL36AL;MGAT2	-0.48	-5.66	-0.33	3.83e-8	Carotid intima media thickness;
CESC	cis	rs4253772	0.744	rs1134224	chr22:46633371	A/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.58	6.78	0.38	7.94e-11	LDL cholesterol;Cholesterol, total;
CESC	cis	rs1355223	0.872	rs7112608	chr11:34699269	G/T	cg11058730	chr11:34937778	PDHX;APIP	-0.45	-6.01	-0.35	5.99e-9	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.55	7.31	0.41	3.08e-12	Lymphocyte counts;
CESC	cis	rs6545883	0.894	rs10496092	chr2:61524679	C/T	cg15711740	chr2:61764176	XPO1	0.39	5.08	0.3	7.29e-7	Tuberculosis;
CESC	cis	rs780096	0.506	rs1262430	chr2:27673798	T/C	cg22903471	chr2:27725779	GCKR	-0.52	-7.37	-0.41	2.16e-12	Total body bone mineral density;
CESC	cis	rs17376456	0.569	rs10076965	chr5:93094972	G/A	cg25358565	chr5:93447407	FAM172A	0.67	7.16	0.4	7.97e-12	Diabetic retinopathy;
CESC	cis	rs28489187	0.558	rs6576763	chr1:85859376	T/C	cg16011679	chr1:85725395	C1orf52	-0.43	-5.21	-0.3	3.89e-7	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	cis	rs2901656	0.629	rs10752946	chr1:172376632	C/T	cg03748243	chr1:172413542	C1orf105;PIGC	0.51	8.18	0.45	1.16e-14	Red cell distribution width;Platelet distribution width;
CESC	cis	rs9611565	0.506	rs2024566	chr22:41697338	A/G	cg17376030	chr22:41985996	PMM1	0.48	5.38	0.31	1.6e-7	Vitiligo;
CESC	cis	rs3105593	1.000	rs3105590	chr15:50864145	A/G	cg08437265	chr15:50716283	USP8	0.42	5.51	0.32	8.52e-8	QT interval;
CESC	cis	rs9467711	0.517	rs16901784	chr6:26555433	C/A	cg12826209	chr6:26865740	GUSBL1	0.6	5.7	0.33	3.27e-8	Autism spectrum disorder or schizophrenia;
CESC	cis	rs921968	0.643	rs613539	chr2:219455967	G/T	cg02176678	chr2:219576539	TTLL4	0.42	7.12	0.4	1.01e-11	Mean corpuscular hemoglobin concentration;
CESC	cis	rs9303401	0.659	rs12150536	chr17:56640834	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.02	12.93	0.62	5.59e-30	Cognitive test performance;
CESC	cis	rs11785400	1.000	rs4297023	chr8:143733307	C/A	cg24634471	chr8:143751801	JRK	0.46	6.06	0.35	4.68e-9	Schizophrenia;
CESC	cis	rs9303401	0.612	rs2526370	chr17:56487636	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.51	6.9	0.39	3.85e-11	Cognitive test performance;
CESC	cis	rs7618915	0.501	rs34754793	chr3:52629177	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	7.55	0.42	7.15e-13	Bipolar disorder;
CESC	cis	rs7618915	0.501	rs9917834	chr3:52634619	A/C	cg17372223	chr3:52568218	NT5DC2	0.42	6.42	0.37	6.33e-10	Bipolar disorder;
CESC	cis	rs6800768	0.604	rs76298099	chr3:24155775	G/T	cg10674438	chr3:24145617	LOC152024	-0.46	-6.04	-0.35	5.08e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs898097	0.690	rs12452304	chr17:80811659	G/A	cg10494973	chr17:80897199	TBCD	0.49	5.71	0.33	3.04e-8	Breast cancer;
CESC	trans	rs9929218	0.501	rs12448999	chr16:68815549	T/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.87	14.08	0.65	5.62e-34	Colorectal cancer;
CESC	cis	rs780096	0.526	rs4803	chr2:27667297	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.29	-5.79	-0.34	2e-8	Total body bone mineral density;
CESC	cis	rs10465746	0.905	rs34274953	chr1:84415011	G/A	cg10977910	chr1:84465055	TTLL7	0.47	6.36	0.36	8.77e-10	Obesity-related traits;
CESC	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	10.45	0.54	1.29e-21	Prudent dietary pattern;
CESC	cis	rs4665809	1.000	rs1030730	chr2:26284143	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.83	-9.25	-0.49	7.55e-18	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05843257	chr22:24951377	SNRPD3;C22orf13	-0.61	-7.03	-0.4	1.73e-11	Gut microbiome composition (summer);
CESC	cis	rs5753618	0.583	rs5753615	chr22:31828027	T/C	cg13145458	chr22:31556086	RNF185	-0.49	-5.86	-0.34	1.35e-8	Colorectal cancer;
CESC	cis	rs1862626	0.506	rs7716644	chr5:56043426	C/T	cg14703610	chr5:56206110	C5orf35	0.42	5.61	0.33	5.03e-8	Cancer (pleiotropy);
CESC	cis	rs1670533	0.685	rs56019586	chr4:1059842	C/G	cg27284194	chr4:1044797	NA	0.48	6.14	0.35	3.08e-9	Recombination rate (females);
CESC	cis	rs933688	0.532	rs868557	chr5:90550379	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.44	-5.08	-0.3	7.22e-7	Smoking behavior;
CESC	trans	rs61931739	0.517	rs9668303	chr12:34366701	C/T	cg26384229	chr12:38710491	ALG10B	0.66	9.81	0.52	1.38e-19	Morning vs. evening chronotype;
CESC	cis	rs4727963	0.740	rs12706479	chr7:122736336	G/A	cg03640110	chr7:122635026	TAS2R16	0.4	6.2	0.36	2.14e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
CESC	cis	rs10200850	0.656	rs13429815	chr2:240216070	T/C	cg26975040	chr2:240205772	HDAC4	-0.58	-5.04	-0.3	8.44e-7	Perioperative myocardial infarction in coronary artery bypass surgery;
CESC	cis	rs10463316	0.894	rs4099169	chr5:150766526	C/T	cg03212797	chr5:150827313	SLC36A1	-0.45	-5.81	-0.34	1.74e-8	Metabolite levels (Pyroglutamine);
CESC	cis	rs7599312	0.553	rs6710653	chr2:213404893	A/G	cg16329650	chr2:213403929	ERBB4	0.59	8.57	0.47	8.74e-16	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg09294055	chr16:3314419	NA	-0.46	-6.09	-0.35	4.03e-9	Fibrinogen levels;
CESC	cis	rs506597	0.764	rs221783	chr7:100292914	T/C	cg10426581	chr7:100472382	SRRT	-0.69	-5.39	-0.31	1.57e-7	Pursuit maintenance gain in psychotic disorders;
CESC	cis	rs1799949	1.000	rs35956818	chr17:41422985	T/C	cg23758822	chr17:41437982	NA	1.05	16.03	0.7	6.73e-41	Menopause (age at onset);
CESC	cis	rs7666738	0.830	rs10012167	chr4:99048579	T/C	cg05340658	chr4:99064831	C4orf37	0.82	12.88	0.62	8.44e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs870825	0.616	rs6844146	chr4:185636396	G/A	cg04058563	chr4:185651563	MLF1IP	0.62	6.86	0.39	4.91e-11	Blood protein levels;
CESC	cis	rs853679	0.517	rs9393897	chr6:28127710	G/T	cg17949981	chr6:28129498	ZNF389	0.45	5.56	0.32	6.54e-8	Depression;
CESC	cis	rs9457247	0.967	rs433191	chr6:167409662	T/A	cg25258033	chr6:167368657	RNASET2	0.4	6.04	0.35	5.18e-9	Crohn's disease;
CESC	cis	rs7917772	0.560	rs35095897	chr10:104377759	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.39	-5.23	-0.31	3.36e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs9611565	0.512	rs5751148	chr22:42139078	A/G	cg17376030	chr22:41985996	PMM1	-0.78	-8.33	-0.46	4.43e-15	Vitiligo;
CESC	cis	rs17711722	0.740	rs7809991	chr7:65406218	A/G	cg06456125	chr7:65229604	NA	0.45	5.91	0.34	1.07e-8	Calcium levels;
CESC	cis	rs36051895	0.530	rs2093447	chr9:5230374	G/T	cg02405213	chr9:5042618	JAK2	-0.58	-6.61	-0.38	2.05e-10	Pediatric autoimmune diseases;
CESC	cis	rs4692589	1.000	rs7666219	chr4:170932739	T/C	cg19918862	chr4:170955249	NA	0.36	5.61	0.33	5.02e-8	Anxiety disorder;
CESC	cis	rs6963495	0.818	rs55825845	chr7:105166713	A/G	cg02135003	chr7:105160482	PUS7	-0.46	-5.51	-0.32	8.38e-8	Bipolar disorder (body mass index interaction);
CESC	cis	rs9549260	0.564	rs8000965	chr13:41279488	C/T	cg21288729	chr13:41239152	FOXO1	0.57	7.42	0.41	1.63e-12	Red blood cell count;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg10829727	chr17:73084309	SLC16A5	-0.39	-6.03	-0.35	5.45e-9	Gambling;
CESC	cis	rs10089	0.953	rs1432615	chr5:127395371	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.78	10.15	0.53	1.14e-20	Ileal carcinoids;
CESC	cis	rs7714584	1.000	rs11748158	chr5:150226345	C/T	cg22134413	chr5:150180641	NA	0.52	5.64	0.33	4.31e-8	Crohn's disease;
CESC	cis	rs7116495	1.000	rs679926	chr11:71769936	A/G	cg26138937	chr11:71823887	C11orf51	0.85	7.24	0.41	4.87e-12	Severe influenza A (H1N1) infection;
CESC	cis	rs12368653	0.591	rs1038914	chr12:58011066	G/A	cg18357645	chr12:58087776	OS9	-0.37	-5.3	-0.31	2.39e-7	Multiple sclerosis;
CESC	cis	rs10504229	0.679	rs60869047	chr8:58053221	G/A	cg02725872	chr8:58115012	NA	-0.33	-5.04	-0.3	8.84e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs1190552	0.846	rs4906212	chr14:102981595	A/G	cg18135206	chr14:102964638	TECPR2	-0.44	-5.24	-0.31	3.22e-7	Blood protein levels;
CESC	cis	rs9486719	0.947	rs11757102	chr6:96885073	G/A	cg18709589	chr6:96969512	KIAA0776	-0.53	-5.81	-0.34	1.75e-8	Migraine;Coronary artery disease;
CESC	cis	rs2439831	0.867	rs16957630	chr15:43642780	A/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.85	12.05	0.59	6.08e-27	Lung cancer in ever smokers;
CESC	trans	rs7246760	0.867	rs56307296	chr19:9744099	G/T	cg02900749	chr2:68251473	NA	-0.85	-7.53	-0.42	8.04e-13	Pursuit maintenance gain;
CESC	cis	rs7568498	0.564	rs10490563	chr2:161914168	G/A	cg22496339	chr2:162101262	NA	-0.53	-5.63	-0.33	4.49e-8	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);
CESC	cis	rs4555772	0.573	rs7714420	chr5:74340327	A/C	cg03227963	chr5:74354835	NA	0.33	5.74	0.33	2.54e-8	Stearic acid (18:0) levels;
CESC	trans	rs12356475	0.710	rs10822686	chr10:67733250	C/T	cg12639324	chr10:92617735	HTR7	0.48	6.29	0.36	1.28e-9	Psoriatic arthritis;
CESC	cis	rs8067545	0.586	rs57837691	chr17:20203073	T/C	cg13482628	chr17:19912719	NA	-0.42	-5.62	-0.33	4.73e-8	Schizophrenia;
CESC	trans	rs7615952	0.512	rs2979334	chr3:125358824	G/A	cg00769240	chr8:12517080	NA	-0.44	-6.02	-0.35	5.7e-9	Blood pressure (smoking interaction);
CESC	cis	rs1008375	1.000	rs1008374	chr4:17683219	G/A	cg16339924	chr4:17578868	LAP3	0.49	6.23	0.36	1.85e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs12477438	0.798	rs6704766	chr2:99642818	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.75	-10.87	-0.56	5.17e-23	Chronic sinus infection;
CESC	trans	rs163030	0.902	rs2560076	chr5:76736907	G/C	cg26150533	chr8:82396069	FABP4	-0.39	-6.0	-0.35	6.5e-9	Caudate nucleus volume;
CESC	cis	rs12893668	0.514	rs3212090	chr14:104168863	C/T	cg24130564	chr14:104152367	KLC1	-0.49	-6.47	-0.37	4.74e-10	Reticulocyte count;
CESC	cis	rs425277	1.000	rs262665	chr1:2083173	A/G	cg16545954	chr1:2118288	C1orf86	0.33	5.6	0.33	5.35e-8	Height;
CESC	cis	rs6740322	0.895	rs9309097	chr2:43554397	T/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.69	-7.44	-0.42	1.45e-12	Coronary artery disease;
CESC	cis	rs2439831	0.681	rs528517	chr15:43612925	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.91	11.19	0.57	4.78e-24	Lung cancer in ever smokers;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05060602	chr4:183838922	DCTD	-0.57	-6.26	-0.36	1.53e-9	Gut microbiome composition (summer);
CESC	cis	rs1775715	0.737	rs2808078	chr10:32172552	C/T	cg18675610	chr10:32216311	ARHGAP12	0.35	5.38	0.31	1.65e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs1348850	0.914	rs4893944	chr2:178289357	G/T	cg22681709	chr2:178499509	PDE11A	-0.4	-5.9	-0.34	1.08e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs752010	0.714	rs6658500	chr1:42088344	A/G	cg06885757	chr1:42089581	HIVEP3	-0.51	-8.82	-0.48	1.56e-16	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs6952808	0.630	rs1860832	chr7:2161849	G/A	cg02951883	chr7:2050386	MAD1L1	-0.45	-5.81	-0.34	1.78e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg18337363	chr3:52569053	NT5DC2	0.35	6.85	0.39	5.04e-11	Electroencephalogram traits;
CESC	cis	rs7647973	1.000	rs1982861	chr3:49577665	A/G	cg06212747	chr3:49208901	KLHDC8B	0.61	8.05	0.44	2.84e-14	Menarche (age at onset);
CESC	cis	rs40363	0.857	rs55989968	chr16:3530658	C/G	cg22508957	chr16:3507546	NAT15	0.73	8.99	0.48	4.92e-17	Tuberculosis;
CESC	cis	rs736408	0.688	rs2239551	chr3:52818579	A/G	cg17372223	chr3:52568218	NT5DC2	-0.39	-5.63	-0.33	4.51e-8	Bipolar disorder;
CESC	cis	rs6679073	1.000	rs10494874	chr1:205754688	C/G	cg14159672	chr1:205819179	PM20D1	0.38	5.1	0.3	6.59e-7	Prostate-specific antigen levels;
CESC	cis	rs10463316	0.928	rs10060441	chr5:150750006	A/G	cg03212797	chr5:150827313	SLC36A1	-0.51	-6.63	-0.38	1.83e-10	Metabolite levels (Pyroglutamine);
CESC	cis	rs9811920	0.599	rs1688758	chr3:99539890	A/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.58	-9.25	-0.49	7.99e-18	Axial length;
CESC	cis	rs7647973	1.000	rs7613491	chr3:49508976	T/C	cg07636037	chr3:49044803	WDR6	-0.7	-9.53	-0.51	1.06e-18	Menarche (age at onset);
CESC	cis	rs9611565	0.559	rs5758397	chr22:42019251	C/T	cg06481639	chr22:41940642	POLR3H	0.61	6.22	0.36	1.93e-9	Vitiligo;
CESC	cis	rs11650494	0.908	rs73324323	chr17:47420054	G/T	cg08112188	chr17:47440006	ZNF652	1.11	7.72	0.43	2.31e-13	Prostate cancer;
CESC	cis	rs4566357	1.000	rs12612535	chr2:227926998	T/C	cg11843606	chr2:227700838	RHBDD1	-0.43	-5.46	-0.32	1.1e-7	Coronary artery disease;
CESC	cis	rs17376456	0.569	rs7702348	chr5:93065683	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.46	-5.21	-0.31	3.73e-7	Diabetic retinopathy;
CESC	cis	rs12497850	0.864	rs6779394	chr3:49157771	G/A	cg06212747	chr3:49208901	KLHDC8B	0.73	9.46	0.5	1.72e-18	Parkinson's disease;
CESC	cis	rs6933660	0.720	rs6936936	chr6:151753395	A/G	cg14262678	chr6:151773367	RMND1;C6orf211	0.67	9.57	0.51	8.08e-19	Menarche (age at onset);
CESC	cis	rs561341	0.883	rs1034626	chr17:30219500	C/G	cg12193833	chr17:30244370	NA	0.56	5.88	0.34	1.2e-8	Hip circumference adjusted for BMI;
CESC	cis	rs1799949	0.930	rs4584865	chr17:41424919	C/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	8.49	0.46	1.54e-15	Menopause (age at onset);
CESC	cis	rs6460942	0.915	rs62448620	chr7:12458170	C/T	cg10578991	chr7:12443926	VWDE	-0.5	-5.52	-0.32	7.93e-8	Coronary artery disease;
CESC	cis	rs7116495	0.609	rs2735787	chr11:71717873	T/C	cg26138937	chr11:71823887	C11orf51	-1.27	-8.3	-0.45	5.44e-15	Severe influenza A (H1N1) infection;
CESC	cis	rs12500824	0.534	rs2136854	chr4:77384592	A/G	cg20311846	chr4:77356250	SHROOM3	-0.31	-5.73	-0.33	2.69e-8	Coronary artery disease;
CESC	trans	rs10489896	0.541	rs6693478	chr1:234593403	T/C	cg10395685	chr11:86085715	CCDC81	-0.43	-6.15	-0.35	2.9e-9	Cognitive test performance;
CESC	cis	rs863345	0.604	rs950260	chr1:158491520	G/A	cg12129480	chr1:158549410	OR10X1	-0.34	-6.85	-0.39	5.17e-11	Pneumococcal bacteremia;
CESC	cis	rs9443645	0.901	rs6937465	chr6:79570345	G/T	cg05283184	chr6:79620031	NA	-0.43	-6.76	-0.38	8.52e-11	Intelligence (multi-trait analysis);
CESC	cis	rs763014	0.931	rs59476302	chr16:629006	C/T	cg09263875	chr16:632152	PIGQ	0.65	10.88	0.56	4.93e-23	Height;
CESC	cis	rs7811142	1.000	rs28490152	chr7:100020982	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.1	13.02	0.62	2.73e-30	Platelet count;
CESC	cis	rs2797160	0.904	rs1612274	chr6:126014907	C/A	cg05901451	chr6:126070800	HEY2	0.48	6.89	0.39	4.13e-11	Endometrial cancer;
CESC	trans	rs526821	0.595	rs485555	chr11:55323570	A/G	cg15704280	chr7:45808275	SEPT13	0.52	6.33	0.36	1.04e-9	Pediatric bone mineral density (spine);
CESC	cis	rs6460942	0.915	rs62447639	chr7:12486803	T/C	cg10578991	chr7:12443926	VWDE	-0.49	-5.22	-0.31	3.59e-7	Coronary artery disease;
CESC	cis	rs10504073	0.584	rs4873092	chr8:49974053	T/C	cg00325661	chr8:49890786	NA	0.58	8.84	0.48	1.34e-16	Blood metabolite ratios;
CESC	cis	rs617791	0.569	rs11227370	chr11:65747693	C/T	cg04055107	chr11:65626734	MUS81;CFL1	-0.45	-5.1	-0.3	6.46e-7	Breast cancer;
CESC	cis	rs1509123	0.609	rs11078650	chr17:6704816	T/C	cg12642237	chr17:6703447	TEKT1	-0.62	-5.08	-0.3	7.26e-7	Blood metabolite levels;
CESC	cis	rs10463316	0.894	rs4246024	chr5:150740987	C/T	cg03212797	chr5:150827313	SLC36A1	-0.48	-6.07	-0.35	4.52e-9	Metabolite levels (Pyroglutamine);
CESC	cis	rs7927771	0.826	rs2293578	chr11:47437403	C/T	cg18512352	chr11:47633146	NA	-0.52	-7.37	-0.41	2.22e-12	Subjective well-being;
CESC	trans	rs801193	0.935	rs2286683	chr7:66129843	G/A	cg26939375	chr7:64535504	NA	-0.64	-8.57	-0.47	8.53e-16	Aortic root size;
CESC	cis	rs10242455	0.702	rs58348977	chr7:99188014	G/A	cg25640893	chr7:99214727	ZNF498	0.69	5.21	0.3	3.84e-7	Blood metabolite levels;
CESC	cis	rs2243480	0.764	rs2460423	chr7:65601216	A/T	cg13147721	chr7:65941812	NA	-0.98	-9.28	-0.5	6.25e-18	Diabetic kidney disease;
CESC	cis	rs2573652	0.657	rs2573668	chr15:100541776	C/T	cg09918751	chr15:100517450	ADAMTS17	0.33	5.94	0.34	8.97e-9	Height;
CESC	cis	rs11792861	0.926	rs11787878	chr9:111866749	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.41	5.12	0.3	5.97e-7	Menarche (age at onset);
CESC	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.56	0.37	2.89e-10	Prudent dietary pattern;
CESC	cis	rs79349575	0.783	rs62075852	chr17:47017176	T/C	cg16584676	chr17:46985605	UBE2Z	0.54	6.67	0.38	1.46e-10	Type 2 diabetes;
CESC	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg19318889	chr4:1322082	MAEA	-0.59	-7.21	-0.41	5.78e-12	Longevity;
CESC	cis	rs447735	0.587	rs11647958	chr16:89720909	A/T	cg04240660	chr16:89714849	CHMP1A	-0.37	-5.41	-0.32	1.44e-7	Hemoglobin concentration;
CESC	cis	rs875971	0.964	rs697969	chr7:65558478	C/A	cg11764359	chr7:65958608	NA	-0.94	-14.21	-0.66	1.83e-34	Aortic root size;
CESC	trans	rs3780486	0.846	rs3780490	chr9:33129839	A/G	cg04842962	chr6:43655489	MRPS18A	1.01	19.68	0.77	9.13e-54	IgG glycosylation;
CESC	cis	rs9308731	0.591	rs60982612	chr2:111940939	C/T	cg04202892	chr2:111875749	ACOXL	0.41	5.8	0.34	1.88e-8	Chronic lymphocytic leukemia;
CESC	cis	rs4819052	0.851	rs2838839	chr21:46667858	C/G	cg11663144	chr21:46675770	NA	0.61	9.61	0.51	5.9e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs6540559	1.000	rs6696825	chr1:209982372	A/G	cg22442454	chr1:209979470	IRF6	0.47	5.82	0.34	1.7e-8	Cleft lip with or without cleft palate;
CESC	cis	rs7412746	0.553	rs59337856	chr1:150746406	G/T	cg09365446	chr1:150670422	GOLPH3L	0.4	5.26	0.31	3.03e-7	Melanoma;
CESC	cis	rs172166	0.637	rs1225597	chr6:28162087	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.42	-5.33	-0.31	2.11e-7	Cardiac Troponin-T levels;
CESC	cis	rs1808579	0.904	rs12457261	chr18:21146085	C/T	cg14672496	chr18:21087552	C18orf8	0.38	5.72	0.33	2.87e-8	Hip circumference;Body mass index;BMI (adjusted for smoking behaviour);
CESC	cis	rs6500395	0.962	rs1477135	chr16:48726823	C/T	cg04672837	chr16:48644449	N4BP1	0.47	5.58	0.32	6.02e-8	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs7772486	0.790	rs2249386	chr6:146186611	G/A	cg05347473	chr6:146136440	FBXO30	0.6	7.64	0.42	4.02e-13	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs854765	0.693	rs8080061	chr17:17776389	C/T	cg16928487	chr17:17741425	SREBF1	0.59	10.63	0.55	3.2800000000000002e-22	Total body bone mineral density;
CESC	cis	rs9303401	0.659	rs35103007	chr17:56900738	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.01	12.51	0.61	1.62e-28	Cognitive test performance;
CESC	cis	rs4803455	0.565	rs11083616	chr19:41865643	A/G	cg09537434	chr19:41945824	ATP5SL	0.67	9.22	0.49	9.38e-18	Migraine;Coronary artery disease;
CESC	cis	rs4843747	0.671	rs28671027	chr16:88116323	G/A	cg06915872	chr16:87998081	BANP	0.43	5.06	0.3	7.77e-7	Menopause (age at onset);
CESC	cis	rs55794721	0.509	rs12027110	chr1:25775682	A/T	cg03538708	chr1:25844672	NA	-0.41	-6.18	-0.35	2.45e-9	Plateletcrit;Mean corpuscular volume;
CESC	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg26338869	chr17:61819248	STRADA	0.69	8.98	0.48	5.08e-17	Prudent dietary pattern;
CESC	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg23034840	chr1:205782522	SLC41A1	0.5	5.75	0.33	2.49e-8	Menarche (age at onset);
CESC	cis	rs5750830	0.649	rs5757657	chr22:39798429	G/T	cg11247378	chr22:39784982	NA	-0.64	-9.76	-0.51	1.96e-19	Intelligence (multi-trait analysis);
CESC	cis	rs9287719	0.967	rs6721514	chr2:10751062	T/C	cg00105475	chr2:10696890	NA	0.38	5.57	0.32	6.34e-8	Prostate cancer;
CESC	cis	rs919433	0.889	rs788004	chr2:198219032	C/T	cg20885578	chr2:198174922	NA	0.4	5.42	0.32	1.31e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs4713118	0.662	rs149901	chr6:27965503	C/T	cg12963246	chr6:28129442	ZNF389	0.42	5.78	0.33	2.1e-8	Parkinson's disease;
CESC	cis	rs2180341	0.960	rs7745944	chr6:127709574	A/G	cg24812749	chr6:127587940	RNF146	1.03	14.49	0.66	2.01e-35	Breast cancer;
CESC	cis	rs4588572	0.643	rs1035950	chr5:77785858	G/A	cg11547950	chr5:77652471	NA	-0.48	-6.11	-0.35	3.6e-9	Triglycerides;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12903924	chr2:242448061	STK25	0.57	6.82	0.39	6.05e-11	Gut microbiome composition (summer);
CESC	cis	rs735396	0.770	rs2257764	chr12:121446446	T/A	cg02403541	chr12:121454288	C12orf43	-0.73	-10.13	-0.53	1.34e-20	N-glycan levels;
CESC	cis	rs780096	0.546	rs2293572	chr2:27728777	C/G	cg22903471	chr2:27725779	GCKR	0.5	6.9	0.39	3.75e-11	Total body bone mineral density;
CESC	cis	rs11122272	0.701	rs2491402	chr1:231494338	T/C	cg06096015	chr1:231504339	EGLN1	0.41	5.89	0.34	1.19e-8	Hemoglobin concentration;
CESC	cis	rs4595586	1.000	rs4768388	chr12:39223924	G/A	cg26384229	chr12:38710491	ALG10B	-0.37	-5.14	-0.3	5.35e-7	Morning vs. evening chronotype;
CESC	cis	rs1348850	0.632	rs11678875	chr2:178509068	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.58	7.46	0.42	1.24e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs763121	0.853	rs6519120	chr22:38991393	A/C	cg14440974	chr22:39074834	NA	0.41	5.44	0.32	1.19e-7	Menopause (age at onset);
CESC	cis	rs1552244	1.000	rs33917318	chr3:10067797	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.88	11.96	0.59	1.2e-26	Alzheimer's disease;
CESC	cis	rs1799949	1.000	rs8176103	chr17:41267050	G/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.47	6.55	0.37	2.92e-10	Menopause (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21408716	chr3:52279700	PPM1M	0.58	6.79	0.38	7.22e-11	Gut microbiome composition (summer);
CESC	cis	rs3020736	0.500	rs6002605	chr22:42494335	A/G	cg12850546	chr22:42539477	CYP2D7P1	0.43	5.16	0.3	4.96e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs6500395	1.000	rs2111243	chr16:48724897	C/T	cg04672837	chr16:48644449	N4BP1	-0.51	-6.37	-0.36	8.39e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs6060717	0.536	rs6060666	chr20:34478954	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-6.93	-0.39	3.22e-11	Hip circumference adjusted for BMI;
CESC	cis	rs1218582	0.774	rs4845681	chr1:154868055	G/T	cg16680214	chr1:154839983	KCNN3	-0.47	-7.52	-0.42	8.68e-13	Prostate cancer;
CESC	cis	rs501120	1.000	rs554568	chr10:44755446	C/T	cg09554077	chr10:44749378	NA	0.54	7.1	0.4	1.14e-11	Coronary artery disease;Coronary heart disease;
CESC	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg06074448	chr4:187884817	NA	-0.37	-5.43	-0.32	1.27e-7	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7072216	0.763	rs2147900	chr10:100174721	T/C	cg26618903	chr10:100175079	PYROXD2	-0.38	-5.82	-0.34	1.66e-8	Metabolite levels;
CESC	cis	rs9443189	0.950	rs6453845	chr6:76576527	G/T	cg01950844	chr6:76311363	SENP6	-0.58	-6.13	-0.35	3.19e-9	Prostate cancer;
CESC	cis	rs60871478	1.000	rs4720930	chr7:808073	G/A	cg00475322	chr7:917719	C7orf20	-0.45	-5.05	-0.3	8.27e-7	Cerebrospinal P-tau181p levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05222119	chr17:80211999	CSNK1D	-0.57	-6.1	-0.35	3.72e-9	Gut microbiome composition (summer);
CESC	cis	rs881375	0.967	rs10739579	chr9:123694788	C/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.38	5.14	0.3	5.24e-7	Rheumatoid arthritis;
CESC	cis	rs116988415	0.584	rs4902311	chr14:65241933	G/A	cg25083366	chr14:65239357	SPTB	0.69	5.03	0.3	8.89e-7	Daytime sleep phenotypes;
CESC	cis	rs12142240	0.698	rs1984490	chr1:46858734	C/T	cg00530320	chr1:46809349	NSUN4	-0.59	-8.27	-0.45	6.45e-15	Menopause (age at onset);
CESC	cis	rs1046896	0.519	rs9900369	chr17:80829807	G/A	cg02711726	chr17:80685570	FN3KRP	-0.4	-5.29	-0.31	2.54e-7	Glycated hemoglobin levels;
CESC	cis	rs7662987	1.000	rs7658118	chr4:99994608	C/T	cg13256891	chr4:100009986	ADH5	-0.81	-6.09	-0.35	4.04e-9	Smoking initiation;
CESC	trans	rs1814175	0.645	rs28627251	chr11:50048125	G/T	cg15704280	chr7:45808275	SEPT13	-1.01	-18.82	-0.76	9.27e-51	Height;
CESC	cis	rs7481584	0.624	rs449466	chr11:3047603	C/T	cg08508325	chr11:3079039	CARS	0.29	5.08	0.3	7.06e-7	Calcium levels;
CESC	cis	rs28489187	0.683	rs67611930	chr1:85846592	A/G	cg16011679	chr1:85725395	C1orf52	0.47	5.62	0.33	4.9e-8	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	cis	rs4727027	0.901	rs6944781	chr7:148829566	A/G	cg23158103	chr7:148848205	ZNF398	-0.4	-6.34	-0.36	9.68e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11872076	chr14:75744010	FOS	0.57	6.43	0.37	5.98e-10	Gut microbiome composition (summer);
CESC	cis	rs12142240	0.698	rs13374893	chr1:46843800	A/G	cg10495392	chr1:46806563	NSUN4	0.55	5.99	0.35	6.69e-9	Menopause (age at onset);
CESC	cis	rs4835473	0.900	rs13123407	chr4:144879866	A/G	cg25736465	chr4:144833511	NA	0.41	6.11	0.35	3.59e-9	Immature fraction of reticulocytes;
CESC	cis	rs10461617	0.617	rs1423623	chr5:56065575	A/G	cg24549020	chr5:56110836	MAP3K1	-0.44	-5.28	-0.31	2.69e-7	Type 2 diabetes;
CESC	cis	rs7584330	0.737	rs7595979	chr2:238364492	G/T	cg14458575	chr2:238380390	NA	0.61	8.29	0.45	5.8e-15	Prostate cancer;
CESC	cis	rs6938	0.618	rs12912839	chr15:75221245	C/T	cg14664628	chr15:75095509	CSK	-0.53	-6.91	-0.39	3.64e-11	Breast cancer;
CESC	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg22535103	chr8:58192502	C8orf71	-0.96	-9.81	-0.52	1.45e-19	Developmental language disorder (linguistic errors);
CESC	trans	rs9393777	0.920	rs35869525	chr6:26946687	C/T	cg06606381	chr12:133084897	FBRSL1	-1.01	-8.05	-0.44	2.76e-14	Intelligence (multi-trait analysis);
CESC	trans	rs4843747	0.636	rs11117358	chr16:88105053	T/A	cg26811252	chr16:29126840	RRN3P2	0.67	9.45	0.5	1.91e-18	Menopause (age at onset);
CESC	cis	rs13242816	1.000	rs12669740	chr7:116138576	T/C	cg04696780	chr7:116139425	CAV2	-0.61	-5.51	-0.32	8.44e-8	P wave duration;
CESC	trans	rs561341	1.000	rs1681718	chr17:30296445	G/A	cg27661571	chr11:113659931	NA	-0.83	-7.69	-0.43	2.82e-13	Hip circumference adjusted for BMI;
CESC	cis	rs748404	0.697	rs505249	chr15:43559960	T/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.51	7.92	0.44	6.6e-14	Lung cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07780669	chr5:140018814	TMCO6	-0.68	-8.12	-0.45	1.72e-14	Gut microbiome composition (summer);
CESC	cis	rs796364	1.000	rs281788	chr2:200783705	A/T	cg23649088	chr2:200775458	C2orf69	0.56	5.26	0.31	3e-7	Schizophrenia;
CESC	cis	rs3096299	0.719	rs2965945	chr16:89514017	T/C	cg00750074	chr16:89608354	SPG7	-0.42	-6.1	-0.35	3.68e-9	Multiple myeloma (IgH translocation);
CESC	cis	rs10189230	0.967	rs12479119	chr2:222354213	C/T	cg14652038	chr2:222343519	EPHA4	0.35	7.15	0.4	8.61e-12	Urate levels in lean individuals;
CESC	cis	rs2204008	0.837	rs11181857	chr12:38413255	C/G	cg26384229	chr12:38710491	ALG10B	0.64	9.71	0.51	2.81e-19	Bladder cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25894045	chr1:226374346	ACBD3	0.55	6.05	0.35	4.8e-9	Gut microbiome composition (summer);
CESC	cis	rs6964587	0.967	rs12535601	chr7:91718346	A/G	cg17063962	chr7:91808500	NA	0.56	7.8	0.43	1.39e-13	Breast cancer;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg19198791	chr17:73975107	ACOX1;C17orf106	-0.52	-6.41	-0.37	6.67e-10	Ulcerative colitis;
CESC	cis	rs2228479	0.850	rs62056061	chr16:89901767	G/A	cg14709524	chr16:89940631	TCF25	0.88	6.1	0.35	3.82e-9	Skin colour saturation;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10799249	chr10:422187	DIP2C	-0.64	-7.42	-0.41	1.64e-12	Gut microbiome composition (summer);
CESC	cis	rs72945132	0.825	rs2298411	chr11:70206046	G/A	cg00319359	chr11:70116639	PPFIA1	0.71	6.85	0.39	5.11e-11	Coronary artery disease;
CESC	cis	rs667920	0.512	rs13069695	chr3:136291562	T/C	cg15507776	chr3:136538369	TMEM22	-0.69	-5.37	-0.31	1.71e-7	Coronary artery disease;
CESC	cis	rs736408	0.609	rs13082960	chr3:52785168	A/C	cg05564831	chr3:52568323	NT5DC2	0.44	6.69	0.38	1.3e-10	Bipolar disorder;
CESC	trans	rs3780486	0.801	rs56687083	chr9:33132134	A/G	cg04842962	chr6:43655489	MRPS18A	1.01	19.64	0.77	1.24e-53	IgG glycosylation;
CESC	cis	rs10540	1.000	rs61876335	chr11:488878	T/C	cg03352830	chr11:487213	PTDSS2	0.67	6.55	0.37	3.02e-10	Body mass index;
CESC	cis	rs6964587	0.773	rs2097810	chr7:91977226	G/A	cg17063962	chr7:91808500	NA	0.55	7.07	0.4	1.36e-11	Breast cancer;
CESC	cis	rs8014204	0.905	rs8014289	chr14:75377352	A/G	cg11812906	chr14:75593930	NEK9	-0.45	-5.6	-0.33	5.49e-8	Caffeine consumption;
CESC	cis	rs56235845	0.964	rs4075958	chr5:176784512	A/G	cg16006841	chr5:176797999	RGS14	-0.59	-6.32	-0.36	1.11e-9	Hemoglobin concentration;Hematocrit;
CESC	cis	rs6860806	0.695	rs6867282	chr5:131583120	G/C	cg11843238	chr5:131593191	PDLIM4	0.36	5.21	0.3	3.82e-7	Breast cancer;
CESC	cis	rs11679564	0.714	rs4389320	chr2:37172531	T/C	cg14987922	chr2:37194071	STRN	0.4	5.07	0.3	7.53e-7	Immature fraction of reticulocytes;
CESC	cis	rs172166	0.694	rs203884	chr6:28077374	G/T	cg19592336	chr6:28129416	ZNF389	0.47	6.51	0.37	3.74e-10	Cardiac Troponin-T levels;
CESC	cis	rs12497850	0.931	rs11924597	chr3:48937790	T/C	cg06212747	chr3:49208901	KLHDC8B	0.67	9.2	0.49	1.1e-17	Parkinson's disease;
CESC	cis	rs6977660	0.507	rs72591448	chr7:19775298	C/T	cg05791153	chr7:19748676	TWISTNB	0.76	6.96	0.39	2.66e-11	Thyroid stimulating hormone;
CESC	cis	rs7772486	0.790	rs2247429	chr6:146217769	T/C	cg05347473	chr6:146136440	FBXO30	0.57	7.31	0.41	3.07e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.76	10.62	0.55	3.45e-22	Prudent dietary pattern;
CESC	cis	rs3768617	0.528	rs2027082	chr1:183084608	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.89	14.36	0.66	5.49e-35	Fuchs's corneal dystrophy;
CESC	cis	rs796364	0.760	rs11690371	chr2:200989616	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.76	-6.52	-0.37	3.46e-10	Schizophrenia;
CESC	cis	rs6866344	0.661	rs72812606	chr5:178129094	A/T	cg03877680	chr5:178157825	ZNF354A	0.76	8.61	0.47	6.55e-16	Neutrophil percentage of white cells;
CESC	cis	rs7044106	0.762	rs1158554	chr9:123400898	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.8	12.45	0.61	2.61e-28	Hip circumference adjusted for BMI;
CESC	cis	rs13191362	1.000	rs68045643	chr6:163029709	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.46	5.11	0.3	6.16e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs67311347	1.000	rs2887995	chr3:40409029	C/G	cg24209194	chr3:40518798	ZNF619	0.45	5.92	0.34	9.94e-9	Renal cell carcinoma;
CESC	cis	rs7666738	0.830	rs13139024	chr4:99020700	C/T	cg17366294	chr4:99064904	C4orf37	0.61	8.76	0.47	2.35e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2075371	0.796	rs1646645	chr7:134012232	G/T	cg20476274	chr7:133979776	SLC35B4	-0.53	-7.18	-0.4	7.18e-12	Mean platelet volume;
CESC	cis	rs55788414	0.872	rs12102958	chr16:81186207	T/A	cg06400318	chr16:81190750	PKD1L2	-0.58	-6.71	-0.38	1.2e-10	Left ventricular obstructive tract defect (maternal effect);
CESC	cis	rs853679	0.517	rs9393896	chr6:28127703	C/T	cg20151795	chr6:28129481	ZNF389	0.44	5.57	0.32	6.17e-8	Depression;
CESC	cis	rs9815354	0.627	rs73073268	chr3:42021403	C/A	cg03022575	chr3:42003672	ULK4	0.75	6.64	0.38	1.72e-10	Pulse pressure;Diastolic blood pressure;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg11759246	chr18:9615209	PPP4R1	0.46	6.25	0.36	1.65e-9	Systemic lupus erythematosus;
CESC	cis	rs2228479	0.850	rs11645916	chr16:89835234	G/A	cg04013166	chr16:89971882	TCF25	0.78	6.69	0.38	1.3e-10	Skin colour saturation;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg03112782	chr1:37979729	MEAF6	0.48	6.21	0.36	2e-9	Systemic lupus erythematosus;
CESC	cis	rs739401	0.566	rs7931504	chr11:3026712	C/T	cg25174290	chr11:3078921	CARS	0.55	7.37	0.41	2.19e-12	Longevity;
CESC	cis	rs7044106	0.537	rs10818474	chr9:123489964	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.76	10.04	0.52	2.65e-20	Hip circumference adjusted for BMI;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg13323912	chr4:48343649	SLAIN2	0.48	6.05	0.35	4.8e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs7914558	0.966	rs10883805	chr10:104708251	T/C	cg04362960	chr10:104952993	NT5C2	0.44	5.7	0.33	3.14e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	trans	rs12599106	0.715	rs34006830	chr16:34878550	C/A	cg26668828	chr6:292823	DUSP22	-0.72	-9.18	-0.49	1.32e-17	Menopause (age at onset);
CESC	cis	rs909002	0.811	rs11575883	chr1:32085485	G/A	cg13919466	chr1:32135498	COL16A1	-0.46	-8.15	-0.45	1.5e-14	Intelligence (multi-trait analysis);
CESC	cis	rs3091242	1.000	rs9689	chr1:25688276	A/G	cg03538708	chr1:25844672	NA	-0.4	-6.01	-0.35	5.97e-9	Erythrocyte sedimentation rate;
CESC	cis	rs3858526	0.727	rs10769353	chr11:5954809	C/T	cg13902645	chr11:5959945	NA	0.76	12.07	0.6	5.11e-27	DNA methylation (variation);
CESC	cis	rs9815354	0.812	rs113528686	chr3:41951547	T/C	cg03022575	chr3:42003672	ULK4	0.68	5.92	0.34	9.9e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs10788972	0.620	rs34764952	chr1:54483694	C/T	cg25741118	chr1:54482237	LDLRAD1	-0.24	-5.7	-0.33	3.12e-8	Parkinson disease and lewy body pathology;
CESC	cis	rs1707322	0.721	rs12069121	chr1:46231984	G/A	cg05343316	chr1:45956843	TESK2	0.5	6.16	0.35	2.72e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs1218582	0.711	rs4845677	chr1:154838050	C/T	cg24250549	chr1:154909240	PMVK	0.64	8.98	0.48	5.24e-17	Prostate cancer;
CESC	cis	rs684232	0.712	rs2955626	chr17:618100	C/G	cg15660573	chr17:549704	VPS53	0.69	9.51	0.5	1.21e-18	Prostate cancer;
CESC	cis	rs826838	1.000	rs11514441	chr12:38775190	C/T	cg26384229	chr12:38710491	ALG10B	0.83	14.61	0.67	7.36e-36	Heart rate;
CESC	cis	rs6466055	0.720	rs1204058	chr7:104958129	T/G	cg04380332	chr7:105027541	SRPK2	0.42	5.4	0.31	1.49e-7	Schizophrenia;
CESC	cis	rs9522267	0.535	rs9522290	chr13:112233130	A/G	cg10483660	chr13:112241077	NA	-0.33	-5.79	-0.33	2.04e-8	Hepatitis;
CESC	cis	rs4132509	0.793	rs10803152	chr1:243846167	C/A	cg21452805	chr1:244014465	NA	0.57	6.57	0.37	2.69e-10	RR interval (heart rate);
CESC	cis	rs2985684	1.000	rs8014170	chr14:50071694	C/G	cg02151108	chr14:50098012	C14orf104	-0.4	-5.23	-0.31	3.48e-7	Carotid intima media thickness;
CESC	cis	rs10791097	0.678	rs10894272	chr11:130731081	A/G	cg09137382	chr11:130731461	NA	0.39	5.99	0.35	6.95e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg12623088	chr15:66585521	DIS3L	-0.46	-6.7	-0.38	1.26e-10	Vertical cup-disc ratio;
CESC	cis	rs55728055	0.661	rs62237814	chr22:31992574	G/C	cg01338084	chr22:32026380	PISD	1.26	8.55	0.47	9.7e-16	Age-related hearing impairment;
CESC	cis	rs6674176	0.628	rs12145999	chr1:44428632	C/T	cg12908607	chr1:44402522	ARTN	-0.47	-6.74	-0.38	9.71e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs7647973	1.000	rs3905330	chr3:49550774	A/G	cg03060546	chr3:49711283	APEH	0.4	5.07	0.3	7.65e-7	Menarche (age at onset);
CESC	cis	rs875971	0.545	rs73376401	chr7:65639828	G/A	cg25405998	chr7:65216604	CCT6P1	0.45	5.11	0.3	6.14e-7	Aortic root size;
CESC	cis	rs736408	0.509	rs3774349	chr3:52722335	A/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.39	7.64	0.43	3.86e-13	Bipolar disorder;
CESC	cis	rs8177253	1.000	rs8177247	chr3:133479499	T/G	cg01448562	chr3:133502909	NA	-0.46	-6.44	-0.37	5.67e-10	Iron status biomarkers;
CESC	cis	rs2281558	0.876	rs12625157	chr20:25345549	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.61	8.25	0.45	7.67e-15	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;
CESC	cis	rs287982	0.932	rs9973577	chr2:9960703	C/G	cg10881225	chr2:9984929	TAF1B	0.43	5.37	0.31	1.72e-7	Nonsyndromic cleft lip with cleft palate;
CESC	cis	rs7582720	1.000	rs72926791	chr2:203822891	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.36	0.41	2.34e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs7666738	0.830	rs62321565	chr4:98976571	G/A	cg05340658	chr4:99064831	C4orf37	0.77	11.71	0.58	8.52e-26	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2075671	0.810	rs12531792	chr7:100280624	G/A	cg20848291	chr7:100343083	ZAN	-0.78	-9.91	-0.52	6.51e-20	Other erythrocyte phenotypes;
CESC	cis	rs4689388	0.926	rs3821940	chr4:6286711	C/A	cg00701064	chr4:6280414	WFS1	0.74	13.11	0.63	1.3e-30	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs2380220	0.574	rs7766765	chr6:95997362	G/A	cg15832292	chr6:96025679	MANEA	0.63	7.18	0.4	7.12e-12	Behavioural disinhibition (generation interaction);
CESC	cis	rs6681460	0.966	rs4655650	chr1:67142286	A/G	cg02459107	chr1:67143332	SGIP1	0.37	5.31	0.31	2.29e-7	Presence of antiphospholipid antibodies;
CESC	cis	rs728616	0.764	rs117833443	chr10:81738136	A/C	cg05935833	chr10:81318306	SFTPA2	-0.52	-5.06	-0.3	7.72e-7	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs9303401	0.659	rs35082010	chr17:56936867	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	1.01	12.45	0.61	2.57e-28	Cognitive test performance;
CESC	cis	rs1448094	0.512	rs12297441	chr12:86233980	C/T	cg19622623	chr12:86230825	RASSF9	-0.48	-6.14	-0.35	3.05e-9	Major depressive disorder;
CESC	cis	rs1552244	1.000	rs76041173	chr3:10078695	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.78	-10.61	-0.55	3.8e-22	Alzheimer's disease;
CESC	cis	rs7917772	0.582	rs10883744	chr10:104347247	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.41	5.64	0.33	4.41e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08732456	chr1:2020870	PRKCZ	-0.52	-6.11	-0.35	3.62e-9	Gut microbiome composition (summer);
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg03685910	chr17:39844834	EIF1	-0.51	-7.34	-0.41	2.58e-12	Height;
CESC	cis	rs1801251	1.000	rs13013142	chr2:233600606	A/G	cg25237894	chr2:233734115	C2orf82	0.45	7.82	0.43	1.27e-13	Coronary artery disease;
CESC	cis	rs35306767	0.903	rs7067865	chr10:908387	C/T	cg20503657	chr10:835505	NA	0.77	7.65	0.43	3.68e-13	Eosinophil percentage of granulocytes;
CESC	cis	rs2980439	0.556	rs2921059	chr8:8317887	G/T	cg06636001	chr8:8085503	FLJ10661	0.54	7.25	0.41	4.6e-12	Neuroticism;
CESC	cis	rs2235642	0.750	rs763152	chr16:1658056	T/C	cg03771183	chr16:1608904	IFT140	0.4	5.91	0.34	1.04e-8	Coronary artery disease;
CESC	cis	rs7666738	0.830	rs6532720	chr4:99043781	C/T	cg24818145	chr4:99064322	C4orf37	0.38	5.04	0.3	8.49e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs916888	0.610	rs199436	chr17:44789285	C/T	cg10053473	chr17:62856997	LRRC37A3	0.67	9.07	0.49	2.69e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs1552244	0.872	rs6803517	chr3:10065426	C/T	cg00166722	chr3:10149974	C3orf24	0.51	6.38	0.37	7.76e-10	Alzheimer's disease;
CESC	cis	rs8180040	0.966	rs6787422	chr3:47418509	G/T	cg27129171	chr3:47204927	SETD2	0.64	9.85	0.52	1.05e-19	Colorectal cancer;
CESC	trans	rs13098911	0.598	rs71327003	chr3:46036521	C/T	cg10236987	chr1:228114221	WNT9A	0.66	6.54	0.37	3.11e-10	Celiac disease;
CESC	cis	rs853679	0.517	rs9380059	chr6:28132358	A/C	cg12963246	chr6:28129442	ZNF389	0.56	7.38	0.41	1.99e-12	Depression;
CESC	cis	rs9322193	0.923	rs35961297	chr6:149989065	T/C	cg13206674	chr6:150067644	NUP43	0.43	6.15	0.35	2.86e-9	Lung cancer;
CESC	cis	rs1670533	1.000	rs6836350	chr4:1069973	C/T	cg27284194	chr4:1044797	NA	0.46	5.99	0.35	6.7e-9	Recombination rate (females);
CESC	cis	rs2228479	0.850	rs2238532	chr16:89863672	T/C	cg06558623	chr16:89946397	TCF25	1.14	9.04	0.49	3.36e-17	Skin colour saturation;
CESC	cis	rs7618501	0.633	rs9866695	chr3:50069452	G/T	cg24110177	chr3:50126178	RBM5	0.5	6.75	0.38	9.48e-11	Intelligence (multi-trait analysis);
CESC	cis	rs79407237	0.635	rs12631431	chr3:14755263	C/G	cg09623510	chr3:14105751	TPRXL	0.54	5.09	0.3	6.79e-7	Sjögren's syndrome;
CESC	cis	rs7927592	0.731	rs643609	chr11:68241833	A/G	cg01657329	chr11:68192670	LRP5	-0.47	-6.23	-0.36	1.8e-9	Total body bone mineral density;
CESC	cis	rs929596	0.563	rs1105879	chr2:234602202	A/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.43	-5.34	-0.31	1.98e-7	Total bilirubin levels in HIV-1 infection;
CESC	cis	rs17376456	0.757	rs10066431	chr5:93198204	A/G	cg21475434	chr5:93447410	FAM172A	0.84	7.45	0.42	1.35e-12	Diabetic retinopathy;
CESC	cis	rs4555082	0.834	rs2735817	chr14:105717796	A/G	cg27165867	chr14:105738592	BRF1	0.48	5.24	0.31	3.29e-7	Mean platelet volume;Platelet distribution width;
CESC	cis	rs7107174	1.000	rs10899468	chr11:78016650	C/T	cg02023728	chr11:77925099	USP35	0.48	6.32	0.36	1.09e-9	Testicular germ cell tumor;
CESC	cis	rs7635838	0.827	rs9848170	chr3:11495983	G/C	cg00170343	chr3:11313890	ATG7	0.44	5.98	0.34	7.35e-9	HDL cholesterol;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg21515243	chr18:21033072	RIOK3	0.49	6.67	0.38	1.52e-10	Systemic lupus erythematosus;
CESC	cis	rs1355223	0.583	rs2116085	chr11:34884001	C/A	cg24088639	chr11:34937564	PDHX;APIP	-0.41	-5.17	-0.3	4.72e-7	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs1448094	0.511	rs11610371	chr12:86163487	A/G	cg02569458	chr12:86230093	RASSF9	0.49	7.61	0.42	4.69e-13	Major depressive disorder;
CESC	cis	rs1864400	0.696	rs2742239	chr10:43621712	A/G	cg15436174	chr10:43711423	RASGEF1A	-0.46	-5.4	-0.31	1.51e-7	Hirschsprung disease;
CESC	cis	rs7714584	1.000	rs75774363	chr5:150223722	C/T	cg22134413	chr5:150180641	NA	0.53	5.52	0.32	8.03e-8	Crohn's disease;
CESC	cis	rs6540559	1.000	rs6696825	chr1:209982372	A/G	cg22029157	chr1:209979665	IRF6	0.66	9.48	0.5	1.54e-18	Cleft lip with or without cleft palate;
CESC	cis	rs11608355	0.573	rs7970666	chr12:109793495	T/G	cg19025524	chr12:109796872	NA	-0.54	-7.96	-0.44	5.01e-14	Neuroticism;
CESC	cis	rs8060686	0.545	rs10500543	chr16:68281311	T/C	cg26727032	chr16:67993705	SLC12A4	-0.52	-5.6	-0.33	5.23e-8	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs7086627	0.515	rs11202963	chr10:82210392	A/G	cg00277334	chr10:82204260	NA	-0.91	-15.99	-0.7	9.86e-41	Post bronchodilator FEV1;
CESC	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg24642844	chr7:1081250	C7orf50	-0.64	-8.35	-0.46	3.86e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs9325144	0.600	rs11183505	chr12:38759110	G/T	cg26384229	chr12:38710491	ALG10B	-0.57	-7.91	-0.44	6.79e-14	Morning vs. evening chronotype;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11887960	chr12:57824829	NA	0.59	6.44	0.37	5.51e-10	Gut microbiome composition (summer);
CESC	cis	rs2295359	1.000	rs4655682	chr1:67610967	C/T	cg03340356	chr1:67600835	NA	0.32	5.47	0.32	1.06e-7	Psoriasis;
CESC	cis	rs1545257	0.514	rs2584940	chr2:24641639	A/C	cg06627628	chr2:24431161	ITSN2	-0.47	-5.91	-0.34	1.05e-8	Sjögren's syndrome;
CESC	cis	rs7618915	0.547	rs2268027	chr3:52766606	G/A	cg18404041	chr3:52824283	ITIH1	-0.41	-6.88	-0.39	4.39e-11	Bipolar disorder;
CESC	cis	rs6674176	0.660	rs3791112	chr1:44379248	T/G	cg12908607	chr1:44402522	ARTN	-0.5	-7.52	-0.42	8.43e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs7811142	0.830	rs11771936	chr7:99943283	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.1	11.29	0.57	2.15e-24	Platelet count;
CESC	cis	rs501120	0.925	rs1746050	chr10:44777188	C/A	cg09554077	chr10:44749378	NA	0.53	5.91	0.34	1.05e-8	Coronary artery disease;Coronary heart disease;
CESC	cis	rs4604732	0.536	rs4925674	chr1:247636906	C/T	cg12754571	chr1:247694271	LOC148824;OR2C3	0.4	5.45	0.32	1.15e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs2404602	0.569	rs283793	chr15:76774752	G/A	cg23625390	chr15:77176239	SCAPER	0.38	5.54	0.32	7.24e-8	Blood metabolite levels;
CESC	cis	rs12586317	0.534	rs2273157	chr14:35438836	A/G	cg16230307	chr14:35515116	FAM177A1	0.84	10.41	0.54	1.74e-21	Psoriasis;
CESC	cis	rs704795	0.775	rs4665975	chr2:27626017	A/T	cg12648201	chr2:27665141	KRTCAP3	-0.29	-5.17	-0.3	4.72e-7	Menopause (age at onset);
CESC	cis	rs11190604	0.943	rs3750632	chr10:102279295	G/C	cg07080220	chr10:102295463	HIF1AN	0.68	6.29	0.36	1.31e-9	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs1862618	0.525	rs2662016	chr5:56269047	A/G	cg24531977	chr5:56204891	C5orf35	0.9	11.51	0.58	3.86e-25	Initial pursuit acceleration;
CESC	cis	rs8031584	0.958	rs35256769	chr15:31237776	G/A	cg08109568	chr15:31115862	NA	-0.7	-9.33	-0.5	4.49e-18	Huntington's disease progression;
CESC	cis	rs4141404	0.851	rs8135417	chr22:31559255	G/A	cg13145458	chr22:31556086	RNF185	0.54	6.52	0.37	3.56e-10	Paclitaxel-induced neuropathy;
CESC	cis	rs7107174	1.000	rs11601161	chr11:78073280	A/G	cg02023728	chr11:77925099	USP35	0.47	6.18	0.35	2.45e-9	Testicular germ cell tumor;
CESC	cis	rs35160687	0.644	rs1863056	chr2:86491245	C/T	cg01119172	chr2:86362222	SNORD94;PTCD3	-0.39	-5.18	-0.3	4.46e-7	Night sleep phenotypes;
CESC	cis	rs727563	0.593	rs5758461	chr22:42162189	G/C	cg03806693	chr22:41940476	POLR3H	1.19	14.1	0.65	4.45e-34	Crohn's disease;Inflammatory bowel disease;
CESC	trans	rs79976124	0.876	rs17511913	chr6:66644361	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.71	8.16	0.45	1.39e-14	Type 2 diabetes;
CESC	cis	rs921968	0.612	rs2384950	chr2:219499719	T/C	cg02176678	chr2:219576539	TTLL4	0.4	7.01	0.4	1.92e-11	Mean corpuscular hemoglobin concentration;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20682991	chr2:74981952	NA	-0.66	-7.63	-0.42	4.32e-13	Gut microbiome composition (summer);
CESC	cis	rs4689388	0.890	rs6446481	chr4:6295583	C/A	cg25554036	chr4:6271136	WFS1	0.51	8.21	0.45	9.51e-15	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg15164871	chr12:123380523	VPS37B	-0.45	-6.28	-0.36	1.38e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs2731664	0.756	rs335433	chr5:176867207	T/C	cg23176889	chr5:176863531	GRK6	-0.64	-10.94	-0.56	3.01e-23	Intelligence (multi-trait analysis);
CESC	cis	rs8112211	1.000	rs56849284	chr19:38826947	T/C	cg14299480	chr19:38876666	GGN	-0.44	-5.95	-0.34	8.35e-9	Blood protein levels;
CESC	cis	rs459571	0.959	rs2520099	chr9:136918139	T/C	cg13789015	chr9:136890014	NCRNA00094	0.54	7.89	0.44	7.77e-14	Platelet distribution width;
CESC	cis	rs1552244	0.882	rs6443276	chr3:10008905	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.75	-9.51	-0.5	1.22e-18	Alzheimer's disease;
CESC	cis	rs597539	0.652	rs592697	chr11:68650064	G/A	cg04772025	chr11:68637568	NA	0.5	6.13	0.35	3.13e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs1538970	0.884	rs781232	chr1:45890399	C/T	cg05343316	chr1:45956843	TESK2	-0.8	-11.33	-0.57	1.58e-24	Platelet count;
CESC	cis	rs1059312	0.808	rs12816551	chr12:129295616	T/C	cg09035930	chr12:129282057	SLC15A4	0.69	9.2	0.49	1.1e-17	Systemic lupus erythematosus;
CESC	cis	rs7666738	0.830	rs28416660	chr4:98899525	C/G	cg03467027	chr4:99064603	C4orf37	0.43	5.28	0.31	2.66e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs67460515	0.563	rs1599375	chr3:160897771	C/T	cg03342759	chr3:160939853	NMD3	0.55	7.2	0.4	6.08e-12	Parkinson's disease;
CESC	trans	rs7672847	0.547	rs57526222	chr4:170483960	T/C	cg19308436	chr1:237949471	RYR2	0.65	7.03	0.4	1.79e-11	Subjective well-being;
CESC	cis	rs1707322	1.000	rs10890380	chr1:46449469	A/G	cg06784218	chr1:46089804	CCDC17	0.33	5.67	0.33	3.8e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs911555	0.723	rs7149767	chr14:103863545	G/A	cg12935359	chr14:103987150	CKB	0.63	9.21	0.49	1.05e-17	Intelligence (multi-trait analysis);
CESC	cis	rs4853012	0.838	rs72915068	chr2:74356185	G/A	cg05776053	chr2:74358815	NA	0.42	5.08	0.3	6.99e-7	Gestational age at birth (maternal effect);
CESC	cis	rs1577917	0.666	rs6454471	chr6:86214456	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.57	7.77	0.43	1.76e-13	Response to antipsychotic treatment;
CESC	trans	rs6137287	0.924	rs6047279	chr20:21142353	C/T	cg18162120	chr1:224621880	WDR26	0.44	6.08	0.35	4.23e-9	Height;
CESC	cis	rs6687430	0.526	rs12127400	chr1:10613660	C/T	cg07384165	chr1:10488281	NA	-0.48	-6.73	-0.38	1.04e-10	Hand grip strength;
CESC	cis	rs13256369	0.950	rs13270006	chr8:8574197	C/A	cg17143192	chr8:8559678	CLDN23	0.73	8.76	0.47	2.39e-16	Obesity-related traits;
CESC	cis	rs6540559	1.000	rs2235372	chr1:209960436	A/G	cg09509183	chr1:209979624	IRF6	-0.46	-5.63	-0.33	4.53e-8	Cleft lip with or without cleft palate;
CESC	cis	rs4728302	0.838	rs10264922	chr7:133598975	A/G	cg10665199	chr7:133106180	EXOC4	0.42	5.83	0.34	1.57e-8	Intelligence;Intelligence (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16699022	chr16:89371566	ANKRD11	-0.57	-6.46	-0.37	4.95e-10	Gut microbiome composition (summer);
CESC	cis	rs9549328	0.731	rs55804996	chr13:113625367	A/G	cg22951483	chr13:113628068	MCF2L	-0.34	-5.07	-0.3	7.41e-7	Systolic blood pressure;
CESC	cis	rs1499614	1.000	rs1638731	chr7:66144679	C/T	cg12463550	chr7:65579703	CRCP	0.77	6.04	0.35	5.23e-9	Gout;
CESC	cis	rs796364	0.806	rs203769	chr2:200900866	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.81	-7.58	-0.42	5.82e-13	Schizophrenia;
CESC	trans	rs10435719	0.764	rs10103485	chr8:11787563	C/T	cg15556689	chr8:8085844	FLJ10661	0.52	6.47	0.37	4.6e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
CESC	cis	rs524023	1.000	rs9734313	chr11:64358311	C/T	cg07220939	chr11:64358617	SLC22A12	-0.35	-5.46	-0.32	1.09e-7	Urate levels in obese individuals;
CESC	cis	rs9354308	0.866	rs2814095	chr6:66535706	C/G	cg07460842	chr6:66804631	NA	0.58	6.6	0.38	2.28e-10	Metabolite levels;
CESC	cis	rs3771570	0.901	rs73008106	chr2:242422446	C/T	cg21155796	chr2:242212141	HDLBP	0.55	5.19	0.3	4.13e-7	Prostate cancer;
CESC	cis	rs4819052	0.635	rs2838808	chr21:46621106	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.57	6.9	0.39	3.92e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs12995491	0.731	rs34991383	chr2:88500337	T/G	cg18490616	chr2:88469792	THNSL2	-0.52	-7.71	-0.43	2.48e-13	Response to metformin (IC50);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg10078639	chr10:116286586	ABLIM1	-0.4	-6.24	-0.36	1.72e-9	Gambling;
CESC	cis	rs2249694	0.810	rs2987785	chr10:135365003	C/T	cg20169779	chr10:135381914	SYCE1	0.38	5.36	0.31	1.85e-7	Obesity-related traits;
CESC	cis	rs2841277	0.616	rs1048257	chr14:105404384	T/C	cg14403583	chr14:105418241	AHNAK2	-0.57	-7.84	-0.43	1.14e-13	Rheumatoid arthritis;
CESC	cis	rs7814319	0.966	rs6993518	chr8:97256341	T/A	cg20787634	chr8:97240163	UQCRB	-0.59	-7.82	-0.43	1.26e-13	Lung function (FVC);
CESC	cis	rs66887589	0.775	rs6843229	chr4:120424087	T/C	cg09307838	chr4:120376055	NA	0.53	7.12	0.4	9.9e-12	Diastolic blood pressure;
CESC	cis	rs6500602	0.627	rs9938228	chr16:4530597	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.41	5.81	0.34	1.83e-8	Schizophrenia;
CESC	cis	rs2243480	0.803	rs160649	chr7:65543199	C/T	cg13147721	chr7:65941812	NA	-0.93	-8.86	-0.48	1.16e-16	Diabetic kidney disease;
CESC	cis	rs7560272	0.501	rs12624267	chr2:73986931	C/T	cg20560298	chr2:73613845	ALMS1	0.39	5.45	0.32	1.13e-7	Schizophrenia;
CESC	cis	rs4665809	0.590	rs36064164	chr2:26502768	C/T	cg27170947	chr2:26402098	FAM59B	0.84	9.12	0.49	1.92e-17	Gut microbiome composition (summer);
CESC	cis	rs6502050	0.835	rs12938965	chr17:80128646	G/A	cg23985595	chr17:80112537	CCDC57	-0.41	-6.57	-0.37	2.61e-10	Life satisfaction;
CESC	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg18402987	chr7:1209562	NA	0.76	7.61	0.42	4.74e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs425277	0.561	rs11584491	chr1:2042543	A/G	cg16545954	chr1:2118288	C1orf86	-0.33	-6.25	-0.36	1.65e-9	Height;
CESC	cis	rs709400	0.832	rs10145755	chr14:104121984	C/T	cg12935359	chr14:103987150	CKB	-0.45	-6.08	-0.35	4.23e-9	Body mass index;
CESC	trans	rs9929218	0.551	rs4783663	chr16:68720271	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.97	16.72	0.72	2.52e-43	Colorectal cancer;
CESC	cis	rs3820928	0.935	rs12151597	chr2:227859224	A/G	cg11843606	chr2:227700838	RHBDD1	-0.42	-5.45	-0.32	1.12e-7	Pulmonary function;
CESC	cis	rs17854409	1.000	rs17854409	chr20:61491494	T/C	cg05147244	chr20:61493195	TCFL5	0.92	6.02	0.35	5.91e-9	Obesity-related traits;
CESC	cis	rs8070740	0.786	rs34856659	chr17:5327572	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.51	6.29	0.36	1.34e-9	Menopause (age at onset);
CESC	cis	rs3741151	1.000	rs76610873	chr11:73084387	C/T	cg17517138	chr11:73019481	ARHGEF17	0.93	6.32	0.36	1.1e-9	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg23131131	chr22:24373011	LOC391322	-0.7	-9.7	-0.51	3.09e-19	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs3768617	0.510	rs12095664	chr1:183101686	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.89	14.39	0.66	4.39e-35	Fuchs's corneal dystrophy;
CESC	cis	rs3741151	0.892	rs2027761	chr11:73036179	C/T	cg17517138	chr11:73019481	ARHGEF17	0.61	5.21	0.3	3.89e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs6500395	1.000	rs8044519	chr16:48669081	G/T	cg04672837	chr16:48644449	N4BP1	0.53	6.74	0.38	9.91e-11	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs7666738	0.761	rs28758886	chr4:99059704	C/T	cg03676636	chr4:99064102	C4orf37	0.34	5.09	0.3	6.74e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3785574	0.962	rs2665835	chr17:61903258	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.09	19.2	0.76	4.43e-52	Height;
CESC	cis	rs2066819	1.000	rs117683816	chr12:56638267	T/C	cg26714650	chr12:56694279	CS	-1.42	-10.05	-0.53	2.39e-20	Psoriasis vulgaris;
CESC	cis	rs2228479	0.717	rs1007932	chr16:89838541	C/T	cg06558623	chr16:89946397	TCF25	0.88	7.89	0.44	7.98e-14	Skin colour saturation;
CESC	cis	rs763014	0.932	rs2384975	chr16:651115	G/T	cg00908189	chr16:619842	PIGQ	0.64	9.15	0.49	1.62e-17	Height;
CESC	cis	rs2243480	1.000	rs35058610	chr7:65390925	G/A	cg12463550	chr7:65579703	CRCP	0.7	5.58	0.32	5.87e-8	Diabetic kidney disease;
CESC	cis	rs2857078	0.654	rs9896789	chr17:42314567	C/T	cg19774624	chr17:42201019	HDAC5	-0.47	-6.1	-0.35	3.65e-9	Red cell distribution width;Reticulocyte count;
CESC	cis	rs9322193	0.847	rs56103941	chr6:150137231	A/G	cg07701084	chr6:150067640	NUP43	0.42	5.69	0.33	3.36e-8	Lung cancer;
CESC	cis	rs4718428	0.705	rs13220977	chr7:66337648	A/T	cg12165864	chr7:66369176	NA	0.55	6.22	0.36	1.92e-9	Corneal structure;
CESC	cis	rs7917772	0.503	rs7068535	chr10:104349127	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.53	7.47	0.42	1.15e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs727505	0.607	rs67313231	chr7:124804532	T/A	cg23710748	chr7:124431027	NA	-0.37	-5.72	-0.33	2.94e-8	Lewy body disease;
CESC	cis	rs589448	0.902	rs315134	chr12:69762713	G/A	cg22834771	chr12:69754056	YEATS4	-0.57	-7.68	-0.43	3.15e-13	Cerebrospinal fluid biomarker levels;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg26628795	chr2:111435723	BUB1	-0.43	-6.07	-0.35	4.42e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs61863818	0.709	rs10786343	chr10:99159465	C/A	cg20016023	chr10:99160130	RRP12	-0.31	-5.33	-0.31	2.1e-7	Monocyte percentage of white cells;
CESC	cis	rs10911232	0.507	rs4642853	chr1:182996242	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.84	13.19	0.63	6.74e-31	Hypertriglyceridemia;
CESC	cis	rs11098499	0.863	rs2170276	chr4:120485824	A/C	cg24375607	chr4:120327624	NA	0.45	5.51	0.32	8.55e-8	Corneal astigmatism;
CESC	cis	rs11249608	0.636	rs6888567	chr5:178449074	C/T	cg21905437	chr5:178450457	ZNF879	-0.61	-8.81	-0.48	1.63e-16	Pubertal anthropometrics;
CESC	cis	rs7666738	0.830	rs62321587	chr4:98997958	T/C	cg03676636	chr4:99064102	C4orf37	0.34	5.19	0.3	4.24e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1046896	0.520	rs8074086	chr17:80818460	A/C	cg05255149	chr17:80675120	FN3KRP	0.47	5.15	0.3	5.1e-7	Glycated hemoglobin levels;
CESC	cis	rs7107174	1.000	rs7128666	chr11:78102363	A/T	cg02023728	chr11:77925099	USP35	0.47	6.3	0.36	1.24e-9	Testicular germ cell tumor;
CESC	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg18402987	chr7:1209562	NA	0.77	7.88	0.44	8.56e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs10089	1.000	rs13357268	chr5:127423051	G/A	cg19767477	chr5:127420684	SLC12A2	-0.42	-5.75	-0.33	2.51e-8	Ileal carcinoids;
CESC	cis	rs1707322	0.752	rs28438704	chr1:46170544	G/A	cg03146154	chr1:46216737	IPP	0.82	11.54	0.58	3.18e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs34779708	0.966	rs4934538	chr10:35472150	T/C	cg03585969	chr10:35415529	CREM	0.77	10.32	0.54	3.35e-21	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs780096	0.526	rs1260341	chr2:27663215	T/A	cg22903471	chr2:27725779	GCKR	-0.52	-7.39	-0.41	1.88e-12	Total body bone mineral density;
CESC	cis	rs7666738	0.830	rs11941844	chr4:99042722	A/T	cg17366294	chr4:99064904	C4orf37	0.61	8.78	0.47	2.13e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4654899	0.802	rs4654724	chr1:21177210	C/T	cg05370193	chr1:21551575	ECE1	0.4	5.64	0.33	4.34e-8	Superior frontal gyrus grey matter volume;
CESC	cis	rs453301	0.571	rs2929453	chr8:9084341	A/G	cg06636001	chr8:8085503	FLJ10661	-0.53	-6.95	-0.39	2.85e-11	Joint mobility (Beighton score);
CESC	cis	rs11785400	0.793	rs35985277	chr8:143736137	C/T	cg10596483	chr8:143751796	JRK	0.43	5.37	0.31	1.7e-7	Schizophrenia;
CESC	cis	rs6502050	0.835	rs8071425	chr17:80117335	C/T	cg23985595	chr17:80112537	CCDC57	0.41	6.52	0.37	3.55e-10	Life satisfaction;
CESC	cis	rs36051895	0.554	rs7856773	chr9:5204705	T/C	cg02405213	chr9:5042618	JAK2	-0.49	-5.69	-0.33	3.41e-8	Pediatric autoimmune diseases;
CESC	cis	rs12701220	0.894	rs10257744	chr7:1045612	C/T	cg26769984	chr7:1090371	C7orf50	0.65	7.42	0.41	1.64e-12	Bronchopulmonary dysplasia;
CESC	cis	rs57221529	0.766	rs1399381	chr5:589853	G/T	cg16447950	chr5:562315	NA	-0.58	-6.06	-0.35	4.59e-9	Lung disease severity in cystic fibrosis;
CESC	cis	rs12497850	0.931	rs6791542	chr3:48787219	A/G	cg07636037	chr3:49044803	WDR6	0.99	18.41	0.75	2.66e-49	Parkinson's disease;
CESC	cis	rs6963495	0.818	rs6977748	chr7:105167462	T/G	cg19920283	chr7:105172520	RINT1	0.7	6.35	0.36	9.44e-10	Bipolar disorder (body mass index interaction);
CESC	cis	rs17711722	0.701	rs781145	chr7:65440370	A/C	cg11764359	chr7:65958608	NA	0.67	8.65	0.47	5.08e-16	Calcium levels;
CESC	cis	rs1801251	1.000	rs9653383	chr2:233670380	A/C	cg08000102	chr2:233561755	GIGYF2	-0.68	-9.69	-0.51	3.29e-19	Coronary artery disease;
CESC	cis	rs2637266	1.000	rs35991266	chr10:78378733	A/G	cg18941641	chr10:78392320	NA	0.43	8.26	0.45	6.94e-15	Pulmonary function;
CESC	cis	rs7727544	0.661	rs273900	chr5:131694606	G/A	cg24060327	chr5:131705240	SLC22A5	-0.64	-8.53	-0.46	1.17e-15	Blood metabolite levels;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg13370280	chr6:137539688	IFNGR1	0.46	6.19	0.36	2.24e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs9300255	0.699	rs11057204	chr12:123725827	T/C	cg00376283	chr12:123451042	ABCB9	0.72	8.84	0.48	1.38e-16	Neutrophil percentage of white cells;
CESC	cis	rs4819052	1.000	rs2297286	chr21:46707897	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.93	12.47	0.61	2.14e-28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs2075371	1.000	rs2241335	chr7:133979368	C/T	cg11752832	chr7:134001865	SLC35B4	0.52	6.76	0.38	8.81e-11	Mean platelet volume;
CESC	cis	rs8114671	0.836	rs6141526	chr20:33615255	G/T	cg24642439	chr20:33292090	TP53INP2	-0.46	-5.59	-0.32	5.53e-8	Height;
CESC	cis	rs13336428	0.730	rs3946124	chr16:1525779	A/G	cg26690334	chr16:1524521	CLCN7	0.35	5.15	0.3	5.19e-7	Bone mineral density;
CESC	cis	rs2073300	0.609	rs74809795	chr20:23372383	A/C	cg12062639	chr20:23401060	NAPB	1.07	8.85	0.48	1.29e-16	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs7520050	0.807	rs3013594	chr1:46138000	T/C	cg06784218	chr1:46089804	CCDC17	0.31	5.37	0.31	1.74e-7	Red blood cell count;Reticulocyte count;
CESC	cis	rs8141529	0.843	rs1065497	chr22:29279991	C/T	cg15103426	chr22:29168792	CCDC117	0.61	7.74	0.43	2.08e-13	Lymphocyte counts;
CESC	cis	rs3857536	0.704	rs4710570	chr6:66890244	A/G	cg07460842	chr6:66804631	NA	-0.41	-5.36	-0.31	1.82e-7	Blood trace element (Cu levels);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16973203	chr2:230876010	FBXO36	-0.51	-6.31	-0.36	1.14e-9	Gut microbiome composition (summer);
CESC	cis	rs12477438	0.765	rs2167930	chr2:99592551	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.7	-10.22	-0.53	6.79e-21	Chronic sinus infection;
CESC	cis	rs5758659	0.652	rs133313	chr22:42401749	G/T	cg04733989	chr22:42467013	NAGA	0.43	5.72	0.33	2.8e-8	Cognitive function;
CESC	cis	rs2274273	0.905	rs2075601	chr14:55609234	C/T	cg04306507	chr14:55594613	LGALS3	0.29	5.79	0.34	2e-8	Protein biomarker;
CESC	cis	rs2302190	0.769	rs7218778	chr17:56664248	T/G	cg25885038	chr17:56607967	SEPT4	-0.4	-5.43	-0.32	1.27e-7	Vitamin D levels;
CESC	cis	rs826838	1.000	rs55828987	chr12:39056421	A/C	cg26384229	chr12:38710491	ALG10B	0.81	13.7	0.64	1.14e-32	Heart rate;
CESC	cis	rs2439831	0.867	rs3101443	chr15:43912372	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.82	8.62	0.47	6.32e-16	Lung cancer in ever smokers;
CESC	cis	rs6952808	0.760	rs11764960	chr7:1950532	G/A	cg21782813	chr7:2030301	MAD1L1	0.42	5.93	0.34	9.37e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs425277	1.000	rs262667	chr1:2082722	T/C	cg24578937	chr1:2090814	PRKCZ	0.55	9.56	0.51	8.69e-19	Height;
CESC	cis	rs6952808	0.782	rs4236271	chr7:1881369	C/T	cg13880726	chr7:1868755	MAD1L1	0.54	7.39	0.41	1.95e-12	Bipolar disorder and schizophrenia;
CESC	cis	rs597539	0.616	rs10896386	chr11:68722694	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.78	9.49	0.5	1.42e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs7412746	0.658	rs897815	chr1:150879101	C/T	cg22823121	chr1:150693482	HORMAD1	-0.4	-5.55	-0.32	6.9e-8	Melanoma;
CESC	cis	rs3762637	0.941	rs112768052	chr3:122169384	G/A	cg24169773	chr3:122142474	KPNA1	-0.53	-6.17	-0.35	2.56e-9	LDL cholesterol levels;
CESC	cis	rs7605827	0.930	rs7579714	chr2:15686869	A/C	cg19274914	chr2:15703543	NA	0.37	6.7	0.38	1.22e-10	Educational attainment (years of education);
CESC	cis	rs7100689	0.577	rs9285726	chr10:82035150	A/T	cg00277334	chr10:82204260	NA	-0.53	-6.64	-0.38	1.82e-10	Post bronchodilator FEV1;
CESC	cis	rs258892	0.895	rs34302030	chr5:72059832	T/A	cg21869765	chr5:72125136	TNPO1	-0.43	-5.35	-0.31	1.93e-7	Small cell lung carcinoma;
CESC	cis	rs8072100	0.701	rs8078309	chr17:45774072	T/C	cg08085267	chr17:45401833	C17orf57	-0.43	-5.41	-0.32	1.4e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs6076065	0.548	rs1112818	chr20:23323936	G/A	cg11657817	chr20:23433608	CST11	0.35	5.13	0.3	5.55e-7	Facial morphology (factor 15, philtrum width);
CESC	cis	rs4664308	0.618	rs4665139	chr2:160890692	G/T	cg03641300	chr2:160917029	PLA2R1	-0.59	-8.52	-0.46	1.24e-15	Idiopathic membranous nephropathy;
CESC	cis	rs11690935	0.632	rs6737308	chr2:172872042	G/A	cg13550731	chr2:172543902	DYNC1I2	0.45	6.27	0.36	1.44e-9	Schizophrenia;
CESC	cis	rs11792861	0.926	rs77567374	chr9:111835034	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.41	5.1	0.3	6.34e-7	Menarche (age at onset);
CESC	cis	rs10504229	0.609	rs56289889	chr8:58116276	G/C	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs4144743	0.759	rs4289057	chr17:45321030	G/A	cg18085866	chr17:45331354	ITGB3	-0.65	-6.24	-0.36	1.77e-9	Body mass index;
CESC	cis	rs11190604	1.000	rs2489034	chr10:102319192	C/T	cg07080220	chr10:102295463	HIF1AN	0.62	5.9	0.34	1.1e-8	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs1062177	1.000	rs2964585	chr5:151141895	C/T	cg00977110	chr5:151150581	G3BP1	0.68	7.31	0.41	3.09e-12	Preschool internalizing problems;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08647641	chr7:91763896	CYP51A1	0.57	6.99	0.39	2.26e-11	Gut microbiome composition (summer);
CESC	cis	rs763121	0.853	rs138702	chr22:39132601	A/T	cg14440974	chr22:39074834	NA	0.37	5.29	0.31	2.61e-7	Menopause (age at onset);
CESC	cis	rs6893300	0.961	rs4700838	chr5:179185121	A/G	cg14593053	chr5:179126677	CANX	-0.52	-5.65	-0.33	4.07e-8	Resting heart rate;
CESC	cis	rs933688	1.000	rs6866191	chr5:90746852	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.15	13.75	0.65	8.01e-33	Smoking behavior;
CESC	trans	rs2415984	0.846	rs10137074	chr14:46850751	A/G	cg14945696	chr3:52713679	PBRM1	-0.4	-6.19	-0.36	2.32e-9	Number of children ever born;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg25003565	chr1:150207434	ANP32E	-0.46	-6.12	-0.35	3.36e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs17412740	0.619	rs7820947	chr8:20461056	G/C	cg04640250	chr12:72667526	LOC283392;TRHDE	-0.7	-6.0	-0.35	6.52e-9	Preeclampsia;
CESC	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg07167872	chr1:205819463	PM20D1	-0.75	-12.59	-0.61	8.21e-29	Menarche (age at onset);
CESC	cis	rs7216064	1.000	rs6504549	chr17:65888784	A/G	cg07042672	chr17:66097459	LOC651250	-0.62	-7.45	-0.42	1.35e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs6582630	0.555	rs56228141	chr12:38518652	T/G	cg26384229	chr12:38710491	ALG10B	0.73	11.35	0.57	1.32e-24	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs4803468	1.000	rs11670757	chr19:41913431	G/T	cg09537434	chr19:41945824	ATP5SL	-1.03	-18.28	-0.75	7.53e-49	Height;
CESC	cis	rs9300255	0.569	rs1727320	chr12:123700476	T/A	cg00376283	chr12:123451042	ABCB9	0.7	8.83	0.48	1.45e-16	Neutrophil percentage of white cells;
CESC	cis	rs317689	0.702	rs544696	chr12:69749939	T/C	cg20891283	chr12:69753455	YEATS4	0.77	10.19	0.53	8.91e-21	Response to diuretic therapy;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg06191203	chr2:152266755	RIF1	-0.52	-6.7	-0.38	1.25e-10	Ulcerative colitis;
CESC	cis	rs1580019	0.587	rs7806113	chr7:32553084	A/G	cg06627557	chr7:32535165	LSM5;AVL9	1.06	18.98	0.76	2.51e-51	Cognitive ability;
CESC	cis	rs897984	0.542	rs7197717	chr16:31083075	A/C	cg02466173	chr16:30829666	NA	-0.39	-6.77	-0.38	8.03e-11	Dementia with Lewy bodies;
CESC	cis	rs12477438	1.000	rs1922624	chr2:99909958	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.7	-8.12	-0.45	1.72e-14	Chronic sinus infection;
CESC	trans	rs10506458	0.915	rs12426308	chr12:63405778	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.38	-18.17	-0.74	1.81e-48	Hemostatic factors and hematological phenotypes;
CESC	cis	rs35306767	0.855	rs2050944	chr10:918910	T/C	cg26597838	chr10:835615	NA	0.86	8.89	0.48	9.97e-17	Eosinophil percentage of granulocytes;
CESC	cis	rs4722166	0.541	rs1800795	chr7:22766645	C/G	cg26061582	chr7:22766209	IL6	0.49	5.66	0.33	3.9e-8	Lung cancer;
CESC	cis	rs1878931	0.520	rs12447807	chr16:3413896	A/G	cg22508957	chr16:3507546	NAT15	-0.4	-5.81	-0.34	1.79e-8	Body mass index (adult);
CESC	cis	rs7107174	1.000	rs2511169	chr11:77965321	T/C	cg02023728	chr11:77925099	USP35	0.4	5.96	0.34	8.18e-9	Testicular germ cell tumor;
CESC	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg23708337	chr7:1209742	NA	0.55	5.47	0.32	1.04e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2011503	0.943	rs8102502	chr19:19652746	T/C	cg03709012	chr19:19516395	GATAD2A	0.52	5.35	0.31	1.9e-7	Bipolar disorder;
CESC	cis	rs9322193	0.923	rs2184369	chr6:150097817	G/A	cg13206674	chr6:150067644	NUP43	0.41	5.74	0.33	2.64e-8	Lung cancer;
CESC	cis	rs6439153	0.933	rs7648877	chr3:128709980	T/C	cg25356066	chr3:128598488	ACAD9	0.55	7.17	0.4	7.55e-12	Pneumococcal bacteremia;
CESC	cis	rs8028182	0.636	rs28610581	chr15:75812474	A/G	cg20655648	chr15:75932815	IMP3	0.48	5.89	0.34	1.14e-8	Sudden cardiac arrest;
CESC	cis	rs75887402	0.744	rs17150337	chr5:122677252	G/A	cg27033705	chr5:122759302	CEP120	0.92	6.11	0.35	3.51e-9	Breast cancer;
CESC	cis	rs17209837	1.000	rs4148815	chr7:87087834	A/T	cg00919237	chr7:87102261	ABCB4	-0.5	-5.83	-0.34	1.6e-8	Gallbladder cancer;
CESC	trans	rs11098499	0.909	rs10026736	chr4:120384322	G/C	cg25214090	chr10:38739885	LOC399744	0.7	9.73	0.51	2.45e-19	Corneal astigmatism;
CESC	trans	rs9354308	0.933	rs2814134	chr6:66566658	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.71	7.96	0.44	5.21e-14	Metabolite levels;
CESC	cis	rs875971	0.862	rs6978028	chr7:65886300	G/C	cg12463550	chr7:65579703	CRCP	0.51	6.41	0.37	6.58e-10	Aortic root size;
CESC	cis	rs9543976	1.000	rs73223968	chr13:76141721	C/A	cg01531495	chr13:76123901	UCHL3	-0.55	-5.45	-0.32	1.14e-7	Diabetic retinopathy;
CESC	cis	rs1799949	1.000	rs12944597	chr17:41187684	A/C	cg25072359	chr17:41440525	NA	0.51	6.62	0.38	1.95e-10	Menopause (age at onset);
CESC	cis	rs72781680	1.000	rs72781667	chr2:24225667	A/G	cg20701182	chr2:24300061	SF3B14	0.74	6.38	0.36	7.9e-10	Lymphocyte counts;
CESC	cis	rs1707322	0.721	rs10789468	chr1:46124558	A/G	cg03146154	chr1:46216737	IPP	0.77	10.98	0.56	2.37e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20364594	chr6:158981615	TMEM181	0.58	6.44	0.37	5.67e-10	Gut microbiome composition (summer);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg07194495	chr7:148958859	ZNF783	0.51	6.94	0.39	3.07e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs597539	0.652	rs654071	chr11:68653432	A/C	cg04772025	chr11:68637568	NA	0.5	6.13	0.35	3.13e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs11792861	1.000	rs11792861	chr9:111809295	A/C	cg13535736	chr9:111863775	C9orf5	-0.5	-6.61	-0.38	2.09e-10	Menarche (age at onset);
CESC	cis	rs782590	0.902	rs4672052	chr2:55732018	A/C	cg18811423	chr2:55921094	PNPT1	0.78	11.81	0.59	3.76e-26	Metabolic syndrome;
CESC	cis	rs7130144	0.541	rs58761476	chr11:130463195	T/G	cg26307797	chr11:130446613	NA	-0.74	-6.5	-0.37	3.95e-10	Urate levels in lean individuals;
CESC	cis	rs8067354	0.645	rs2645487	chr17:57886125	T/G	cg13753209	chr17:57696993	CLTC	0.66	8.26	0.45	7.21e-15	Hemoglobin concentration;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg19467356	chr22:41601070	L3MBTL2	0.45	6.31	0.36	1.18e-9	Systemic lupus erythematosus;
CESC	cis	rs9858542	0.953	rs1873625	chr3:49666964	C/A	cg07274523	chr3:49395745	GPX1	0.67	8.45	0.46	1.91e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs12545109	0.642	rs2055984	chr8:57418332	A/G	cg09654669	chr8:57350985	NA	-0.55	-6.51	-0.37	3.81e-10	Obesity-related traits;
CESC	cis	rs7412746	0.658	rs7521719	chr1:150913134	G/A	cg17724175	chr1:150552817	MCL1	0.38	5.9	0.34	1.13e-8	Melanoma;
CESC	cis	rs9300255	0.602	rs1716165	chr12:123648881	C/T	cg05973401	chr12:123451056	ABCB9	0.5	5.81	0.34	1.79e-8	Neutrophil percentage of white cells;
CESC	cis	rs1594829	0.553	rs1564577	chr8:26164723	G/A	cg11498726	chr8:26250323	BNIP3L	-0.4	-6.06	-0.35	4.68e-9	Height;
CESC	cis	rs9902453	0.780	rs57037139	chr17:28173283	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.65	8.22	0.45	9.05e-15	Coffee consumption (cups per day);
CESC	cis	rs72848980	0.512	rs56033495	chr10:105383611	G/A	cg00126946	chr10:105363258	SH3PXD2A	0.6	8.48	0.46	1.62e-15	White matter hyperintensity burden;
CESC	cis	rs10208940	0.920	rs13417100	chr2:68821725	C/T	cg12452813	chr2:68675892	NA	-0.52	-5.2	-0.3	4.01e-7	Urate levels in lean individuals;
CESC	trans	rs74054849	0.850	rs56338141	chr1:16037825	T/C	cg06826283	chr7:600452	PRKAR1B	0.7	6.17	0.35	2.56e-9	Alcoholic chronic pancreatitis;
CESC	cis	rs6141600	0.540	rs761312	chr20:34687809	A/G	cg07747181	chr20:34652970	NA	-0.37	-5.17	-0.3	4.53e-7	Height;Hip circumference;
CESC	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.52	6.79	0.39	7.26e-11	Prudent dietary pattern;
CESC	cis	rs9660992	0.710	rs1172111	chr1:205232980	C/T	cg00857998	chr1:205179979	DSTYK	0.43	5.04	0.3	8.82e-7	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs1847505	0.609	rs1514541	chr13:61586096	C/G	cg25164009	chr13:61490935	NA	-0.43	-6.18	-0.35	2.43e-9	Polychlorinated biphenyl levels;
CESC	cis	rs826838	1.000	rs860400	chr12:39081279	A/G	cg13010199	chr12:38710504	ALG10B	-0.4	-5.36	-0.31	1.79e-7	Heart rate;
CESC	cis	rs1707322	0.963	rs6666763	chr1:46436451	C/A	cg05343316	chr1:45956843	TESK2	0.44	5.42	0.32	1.36e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs6582630	0.502	rs11181210	chr12:38298069	G/A	cg26384229	chr12:38710491	ALG10B	0.71	10.63	0.55	3.23e-22	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs116095464	0.558	rs28635197	chr5:279071	T/C	cg20965017	chr5:231967	SDHA	-0.46	-5.2	-0.3	4.02e-7	Breast cancer;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04792727	chr1:231664260	TSNAX-DISC1;TSNAX	-0.46	-6.48	-0.37	4.5e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs9787249	0.957	rs11206754	chr1:40216234	A/G	cg02773041	chr1:40204384	PPIE	0.55	7.81	0.43	1.32e-13	Blood protein levels;
CESC	cis	rs12618769	0.652	rs1139829	chr2:99225168	C/T	cg10123293	chr2:99228465	UNC50	0.39	5.05	0.3	8.21e-7	Bipolar disorder;
CESC	cis	rs4689592	0.513	rs2358718	chr4:7068743	A/C	cg26116260	chr4:7069785	GRPEL1	-0.87	-12.39	-0.61	4.18e-28	Monocyte percentage of white cells;
CESC	cis	rs4604732	0.631	rs7546720	chr1:247627229	G/A	cg12758973	chr1:247694275	LOC148824;OR2C3	0.51	6.36	0.36	8.65e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs1355223	0.902	rs1361645	chr11:34746385	G/C	cg11058730	chr11:34937778	PDHX;APIP	-0.48	-6.36	-0.36	8.66e-10	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs7666738	0.657	rs13102002	chr4:98617794	T/C	cg05340658	chr4:99064831	C4orf37	0.51	5.09	0.3	6.65e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs5769765	1.000	rs738711	chr22:50282603	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.46	5.32	0.31	2.21e-7	Schizophrenia;
CESC	cis	rs769267	0.895	rs2315279	chr19:19479936	C/A	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.44	-5.76	-0.33	2.36e-8	Tonsillectomy;
CESC	cis	rs9929218	0.954	rs17715762	chr16:68828250	T/G	cg02972257	chr16:68554789	NA	0.44	5.25	0.31	3.09e-7	Colorectal cancer;
CESC	cis	rs2273669	0.667	rs12195836	chr6:109357701	T/G	cg05315195	chr6:109294784	ARMC2	-0.67	-6.32	-0.36	1.13e-9	Prostate cancer;
CESC	cis	rs911555	0.755	rs8016676	chr14:103904842	C/A	cg12935359	chr14:103987150	CKB	0.65	9.61	0.51	5.83e-19	Intelligence (multi-trait analysis);
CESC	cis	rs2075371	0.933	rs431306	chr7:133955974	A/T	cg11752832	chr7:134001865	SLC35B4	0.51	6.42	0.37	6.21e-10	Mean platelet volume;
CESC	cis	rs9911578	1.000	rs9897326	chr17:56902297	A/G	cg05425664	chr17:57184151	TRIM37	-0.5	-6.92	-0.39	3.44e-11	Intelligence (multi-trait analysis);
CESC	cis	rs8018808	1.000	rs176767	chr14:77865614	A/G	cg20045696	chr14:77926864	AHSA1	0.38	5.17	0.3	4.56e-7	Myeloid white cell count;
CESC	cis	rs2072732	0.861	rs16823392	chr1:2953833	C/G	cg03976712	chr1:2946727	NA	0.33	5.53	0.32	7.83e-8	Plateletcrit;
CESC	cis	rs10463316	0.832	rs246484	chr5:150730938	T/C	cg03212797	chr5:150827313	SLC36A1	-0.54	-6.95	-0.39	2.83e-11	Metabolite levels (Pyroglutamine);
CESC	cis	rs11723261	0.582	rs6814287	chr4:122323	C/T	cg12746427	chr4:53362	ZNF718;ZNF595	0.5	6.54	0.37	3.14e-10	Immune response to smallpox vaccine (IL-6);
CESC	cis	rs7618501	0.602	rs2071206	chr3:50160109	G/A	cg24308560	chr3:49941425	MST1R	0.61	9.04	0.49	3.43e-17	Intelligence (multi-trait analysis);
CESC	cis	rs7666738	0.570	rs10032272	chr4:99095601	T/C	cg17366294	chr4:99064904	C4orf37	0.47	6.1	0.35	3.84e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs79349575	0.783	rs318090	chr17:46991752	G/A	cg16584676	chr17:46985605	UBE2Z	0.53	6.6	0.38	2.25e-10	Type 2 diabetes;
CESC	cis	rs617791	0.678	rs551659	chr11:65749645	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.43	6.26	0.36	1.55e-9	Breast cancer;
CESC	cis	rs1552244	1.000	rs6442148	chr3:10078289	G/C	cg00166722	chr3:10149974	C3orf24	0.48	6.13	0.35	3.09e-9	Alzheimer's disease;
CESC	cis	rs10206020	0.885	rs11887527	chr2:1578080	A/G	cg26248373	chr2:1572462	NA	-0.61	-7.12	-0.4	9.87e-12	IgG glycosylation;
CESC	cis	rs734999	0.505	rs60687045	chr1:2539603	G/A	cg20673091	chr1:2541236	MMEL1	0.46	7.62	0.42	4.66e-13	Ulcerative colitis;
CESC	cis	rs4727963	0.765	rs1525470	chr7:122733854	T/C	cg03640110	chr7:122635026	TAS2R16	0.4	6.2	0.36	2.14e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
CESC	trans	rs629535	0.911	rs688612	chr8:70011887	C/T	cg21567404	chr3:27674614	NA	-0.91	-10.9	-0.56	4.13e-23	Dupuytren's disease;
CESC	cis	rs6502050	0.835	rs35555954	chr17:80122438	T/C	cg23985595	chr17:80112537	CCDC57	-0.4	-6.44	-0.37	5.74e-10	Life satisfaction;
CESC	cis	rs12137294	0.866	rs1172153	chr1:205220661	T/C	cg21643547	chr1:205240462	TMCC2	-0.34	-5.46	-0.32	1.1e-7	Red cell distribution width;
CESC	cis	rs4604732	0.631	rs12091081	chr1:247623064	C/T	cg12758973	chr1:247694275	LOC148824;OR2C3	0.48	6.04	0.35	5.29e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs6460942	0.915	rs6968695	chr7:12443878	G/C	cg02935154	chr7:12443704	VWDE	-0.6	-6.82	-0.39	6.02e-11	Coronary artery disease;
CESC	cis	rs2072732	0.808	rs55784203	chr1:2936754	G/T	cg03976712	chr1:2946727	NA	0.33	5.15	0.3	5.01e-7	Plateletcrit;
CESC	cis	rs8068544	0.606	rs77681389	chr17:40154419	T/C	cg18442075	chr17:40169520	DNAJC7;NKIRAS2	-0.94	-8.43	-0.46	2.27e-15	Reticulocyte fraction of red cells;Reticulocyte count;
CESC	cis	rs9649213	1.000	rs9649213	chr7:98021211	A/G	cg24562669	chr7:97807699	LMTK2	-0.38	-5.24	-0.31	3.28e-7	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs12356475	0.710	rs10822686	chr10:67733250	C/T	cg08526825	chr16:2802229	SRRM2;LOC100128788	0.52	6.16	0.35	2.68e-9	Psoriatic arthritis;
CESC	cis	rs1059312	0.771	rs11059922	chr12:129290418	C/T	cg09035930	chr12:129282057	SLC15A4	0.69	9.2	0.49	1.1e-17	Systemic lupus erythematosus;
CESC	cis	rs1775715	0.835	rs113450267	chr10:32223728	G/A	cg04359828	chr10:32216031	ARHGAP12	0.37	5.11	0.3	6.12e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs748404	0.560	rs1869258	chr15:43803621	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.49	7.29	0.41	3.47e-12	Lung cancer;
CESC	cis	rs7605827	0.930	rs2052438	chr2:15701951	G/A	cg19274914	chr2:15703543	NA	0.3	5.34	0.31	2.03e-7	Educational attainment (years of education);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	ch.19.702771R	chr19:16673058	SLC35E1	-0.63	-7.52	-0.42	8.53e-13	Gut microbiome composition (summer);
CESC	cis	rs10883723	0.810	rs2296585	chr10:104245549	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.54	7.39	0.41	1.93e-12	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs6580649	0.943	rs1859444	chr12:48399403	T/C	cg24011408	chr12:48396354	COL2A1	0.4	5.21	0.3	3.75e-7	Lung cancer;
CESC	cis	rs1862618	0.853	rs832553	chr5:56114786	A/G	cg24549020	chr5:56110836	MAP3K1	0.65	7.56	0.42	6.42e-13	Initial pursuit acceleration;
CESC	cis	rs10489202	1.000	rs718885	chr1:167954659	A/G	cg24449463	chr1:168025552	DCAF6	-0.46	-5.34	-0.31	2.02e-7	Schizophrenia;
CESC	cis	rs11203032	1.000	rs11203030	chr10:90964286	A/G	cg16672925	chr10:90967113	CH25H	0.74	7.21	0.4	5.94e-12	Heart failure;
CESC	cis	rs9911578	1.000	rs9907499	chr17:56949044	A/G	cg12560992	chr17:57184187	TRIM37	0.94	15.65	0.69	1.5e-39	Intelligence (multi-trait analysis);
CESC	cis	rs34779708	0.931	rs34304999	chr10:35365705	C/T	cg03585969	chr10:35415529	CREM	0.75	9.73	0.51	2.43e-19	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs6942756	1.000	rs66864889	chr7:128952560	G/A	cg02491457	chr7:128862824	NA	-0.66	-8.86	-0.48	1.21e-16	White matter hyperintensity burden;
CESC	cis	rs7826238	0.566	rs2945886	chr8:8148270	C/G	cg15556689	chr8:8085844	FLJ10661	0.55	6.8	0.39	7.03e-11	Systolic blood pressure;
CESC	cis	rs8068544	0.818	rs8079958	chr17:40155467	C/T	cg26502583	chr17:39992600	KLHL10;NT5C3L	-0.77	-6.21	-0.36	2.06e-9	Reticulocyte fraction of red cells;Reticulocyte count;
CESC	cis	rs9486719	1.000	rs12191653	chr6:96903898	T/C	cg06623918	chr6:96969491	KIAA0776	-0.81	-8.3	-0.45	5.45e-15	Migraine;Coronary artery disease;
CESC	cis	rs2952156	0.920	rs2517951	chr17:37853097	C/T	cg20243544	chr17:37824526	PNMT	0.61	7.75	0.43	1.95e-13	Asthma;
CESC	cis	rs1707322	0.721	rs4660314	chr1:46229885	T/C	cg03146154	chr1:46216737	IPP	0.81	11.42	0.57	8.15e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs477895	0.653	rs7102327	chr11:63908720	C/T	cg04317338	chr11:64019027	PLCB3	0.87	9.06	0.49	3.04e-17	Mean platelet volume;
CESC	cis	rs597539	0.731	rs664229	chr11:68624483	C/G	cg04772025	chr11:68637568	NA	0.57	6.6	0.38	2.2e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs477692	0.789	rs506915	chr10:131398005	A/G	cg05714579	chr10:131428358	MGMT	0.46	6.07	0.35	4.35e-9	Response to temozolomide;
CESC	cis	rs2119480	0.731	rs453757	chr13:111303200	A/G	cg16216153	chr13:111290848	CARKD	-0.36	-5.51	-0.32	8.51e-8	Diastolic blood pressure;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg11050116	chr8:17780536	PCM1	0.46	6.12	0.35	3.35e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs9322193	0.566	rs4869767	chr6:150245110	A/G	cg01145232	chr6:150245071	RAET1G	-0.57	-7.19	-0.4	6.69e-12	Lung cancer;
CESC	cis	rs2204008	0.550	rs11495600	chr12:38126654	C/T	cg26384229	chr12:38710491	ALG10B	0.74	10.7	0.55	1.96e-22	Bladder cancer;
CESC	cis	rs1552244	1.000	rs2160869	chr3:10079255	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-10.99	-0.56	2.21e-23	Alzheimer's disease;
CESC	cis	rs2841277	0.708	rs10083374	chr14:105402994	T/C	cg15352829	chr14:105391018	PLD4	-0.6	-10.55	-0.54	5.89e-22	Rheumatoid arthritis;
CESC	cis	rs7811142	1.000	rs11761725	chr7:100039815	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.09	10.26	0.53	5.11e-21	Platelet count;
CESC	cis	rs561341	1.000	rs501957	chr17:30314504	C/T	cg00745463	chr17:30367425	LRRC37B	-0.78	-7.16	-0.4	8.17e-12	Hip circumference adjusted for BMI;
CESC	cis	rs6570726	0.935	rs449377	chr6:145852437	C/G	cg23711669	chr6:146136114	FBXO30	0.8	12.27	0.6	1.05e-27	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs911555	0.755	rs8014800	chr14:103946302	T/C	cg24130564	chr14:104152367	KLC1	0.48	6.21	0.36	2.09e-9	Intelligence (multi-trait analysis);
CESC	cis	rs2730245	0.563	rs2709857	chr7:158685257	T/C	cg01943577	chr7:158741284	NA	-0.45	-6.02	-0.35	5.64e-9	Height;
CESC	cis	rs79349575	0.783	rs2112617	chr17:46977125	G/A	cg16584676	chr17:46985605	UBE2Z	0.48	5.75	0.33	2.45e-8	Type 2 diabetes;
CESC	cis	rs4561483	0.583	rs1029285	chr16:11987118	G/A	cg08843971	chr16:11963173	GSPT1	0.46	6.47	0.37	4.65e-10	Testicular germ cell tumor;
CESC	cis	rs9611565	0.694	rs202613	chr22:41821993	C/A	cg06481639	chr22:41940642	POLR3H	0.64	6.41	0.37	6.73e-10	Vitiligo;
CESC	cis	rs597539	0.617	rs669659	chr11:68635623	G/C	cg04772025	chr11:68637568	NA	0.53	6.32	0.36	1.08e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs6459788	0.720	rs11768765	chr7:157253133	C/T	cg06271696	chr7:157225062	NA	-0.37	-5.21	-0.3	3.85e-7	Epstein-Barr virus copy number in lymphoblastoid cell lines;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23194712	chr12:132401025	ULK1	-0.59	-6.35	-0.36	9.45e-10	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10330885	chr16:88729968	MGC23284;MVD	-0.64	-7.71	-0.43	2.47e-13	Gut microbiome composition (summer);
CESC	cis	rs10504229	0.861	rs59873610	chr8:58172290	T/A	cg22535103	chr8:58192502	C8orf71	-1.03	-12.86	-0.62	9.66e-30	Developmental language disorder (linguistic errors);
CESC	cis	rs2760061	0.598	rs605410	chr1:228116281	A/G	cg01973587	chr1:228161476	NA	0.34	5.24	0.31	3.32e-7	Diastolic blood pressure;
CESC	cis	rs1413885	0.526	rs9728544	chr1:65847105	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.47	6.15	0.35	2.8e-9	Anticoagulant levels;
CESC	cis	rs35306767	0.715	rs11253539	chr10:1011347	G/A	cg26597838	chr10:835615	NA	0.76	7.38	0.41	2.08e-12	Eosinophil percentage of granulocytes;
CESC	trans	rs7395662	0.591	rs4882093	chr11:48530820	G/A	cg00717180	chr2:96193071	NA	-0.44	-6.06	-0.35	4.54e-9	HDL cholesterol;
CESC	cis	rs9479482	1.000	rs5006620	chr6:150336665	C/T	cg03788504	chr6:150331562	NA	-0.4	-7.68	-0.43	3.09e-13	Alopecia areata;
CESC	cis	rs2439831	0.717	rs10518820	chr15:43888976	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.73	7.78	0.43	1.58e-13	Lung cancer in ever smokers;
CESC	cis	rs7909074	1.000	rs4948926	chr10:45392604	G/C	cg05187965	chr10:45406764	TMEM72	-0.34	-5.29	-0.31	2.52e-7	Mean corpuscular volume;
CESC	cis	rs7552404	0.727	rs12093623	chr1:76256232	T/G	cg22875332	chr1:76189707	ACADM	0.61	6.21	0.36	2.03e-9	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs6570726	0.791	rs383841	chr6:145888329	G/T	cg23711669	chr6:146136114	FBXO30	-1.0	-15.56	-0.69	3.24e-39	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs13191362	1.000	rs66789102	chr6:163104432	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.53	5.19	0.3	4.15e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs8180040	0.764	rs13084117	chr3:47183239	C/A	cg27129171	chr3:47204927	SETD2	0.69	10.44	0.54	1.33e-21	Colorectal cancer;
CESC	cis	rs761746	0.577	rs131245	chr22:32126763	T/C	cg25791279	chr22:32026902	PISD	0.47	5.03	0.3	9.05e-7	Intelligence;
CESC	cis	rs1008375	0.898	rs10008445	chr4:17593978	G/T	cg16339924	chr4:17578868	LAP3	0.73	9.5	0.5	1.31e-18	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg23131131	chr22:24373011	LOC391322	-0.71	-10.14	-0.53	1.21e-20	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs7584330	0.518	rs74003106	chr2:238447004	A/G	cg14458575	chr2:238380390	NA	0.67	6.29	0.36	1.3e-9	Prostate cancer;
CESC	cis	rs9309473	0.950	rs13391258	chr2:73848933	C/T	cg20560298	chr2:73613845	ALMS1	-0.45	-5.89	-0.34	1.17e-8	Metabolite levels;
CESC	cis	rs7666738	0.830	rs7678250	chr4:98922109	G/A	cg17366294	chr4:99064904	C4orf37	0.6	8.23	0.45	8.65e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3008870	1.000	rs4620509	chr1:67449941	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-1.06	-15.18	-0.68	7.11e-38	Lymphocyte percentage of white cells;
CESC	cis	rs9318086	0.935	rs9553083	chr13:24441525	C/G	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.38	-5.21	-0.3	3.84e-7	Myopia (pathological);
CESC	cis	rs698813	0.555	rs7605771	chr2:44479778	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.47	5.33	0.31	2.11e-7	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
CESC	cis	rs4253772	0.575	rs9615364	chr22:46797503	G/A	cg00784671	chr22:46762841	CELSR1	-0.49	-5.18	-0.3	4.42e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs10876993	0.928	rs1678540	chr12:58065002	A/G	cg18357645	chr12:58087776	OS9	0.62	10.34	0.54	2.74e-21	Celiac disease or Rheumatoid arthritis;
CESC	cis	rs9611565	0.643	rs202634	chr22:41809623	A/G	cg03806693	chr22:41940476	POLR3H	1.08	12.4	0.61	3.72e-28	Vitiligo;
CESC	cis	rs2408955	0.501	rs8716	chr12:48539482	T/G	cg04545296	chr12:48745243	ZNF641	0.35	6.1	0.35	3.65e-9	Glycated hemoglobin levels;
CESC	cis	rs798554	0.660	rs1182196	chr7:2866478	T/G	cg09658497	chr7:2847517	GNA12	-0.38	-5.73	-0.33	2.75e-8	Height;
CESC	cis	rs698813	0.674	rs6759891	chr2:44496005	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.51	5.63	0.33	4.6e-8	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
CESC	trans	rs7562732	0.546	rs17048092	chr2:119195525	C/T	cg22678073	chr1:8087421	ERRFI1	-0.72	-6.1	-0.35	3.71e-9	Depression in response to interferon-based therapy in chronic hepatitis C;
CESC	cis	rs6121246	0.520	rs6060425	chr20:30224355	C/T	cg13852791	chr20:30311386	BCL2L1	0.69	6.84	0.39	5.36e-11	Mean corpuscular hemoglobin;
CESC	cis	rs514406	0.929	rs2607095	chr1:53325639	T/C	cg24675658	chr1:53192096	ZYG11B	-0.6	-7.61	-0.42	4.78e-13	Monocyte count;
CESC	cis	rs62458065	0.513	rs10268803	chr7:32547835	A/G	cg20159608	chr7:32802032	NA	-0.56	-6.23	-0.36	1.81e-9	Metabolite levels (HVA/MHPG ratio);
CESC	cis	rs7927771	1.000	rs35624992	chr11:47615798	G/C	cg05585544	chr11:47624801	NA	-0.53	-8.11	-0.45	1.89e-14	Subjective well-being;
CESC	cis	rs2486288	0.656	rs9921025	chr15:45546602	G/A	cg21132104	chr15:45694354	SPATA5L1	-0.54	-6.65	-0.38	1.71e-10	Glomerular filtration rate;
CESC	cis	rs2251381	0.750	rs2255055	chr21:30537045	C/T	cg24692254	chr21:30365293	RNF160	0.76	10.49	0.54	9.28e-22	Selective IgA deficiency;
CESC	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg24503407	chr1:205819492	PM20D1	-0.71	-12.03	-0.59	6.95e-27	Monocyte percentage of white cells;
CESC	cis	rs2842992	0.830	rs1475123	chr6:160178007	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.7	8.4	0.46	2.76e-15	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs1799949	1.000	rs16942	chr17:41244000	T/C	cg05368731	chr17:41323189	NBR1	0.78	11.02	0.56	1.73e-23	Menopause (age at onset);
CESC	cis	rs10504229	0.683	rs35840293	chr8:58117634	C/T	cg21724239	chr8:58056113	NA	0.58	5.95	0.34	8.29e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs2439831	0.717	rs7165471	chr15:43644788	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.9	10.46	0.54	1.12e-21	Lung cancer in ever smokers;
CESC	cis	rs801193	0.660	rs10950049	chr7:66230860	T/C	cg11764359	chr7:65958608	NA	0.85	12.95	0.62	4.93e-30	Aortic root size;
CESC	cis	rs329122	0.528	rs4559047	chr5:133848660	C/T	cg26284174	chr5:133860141	NA	0.45	5.13	0.3	5.62e-7	Body mass index;Type 2 diabetes;
CESC	cis	rs780096	0.527	rs12471703	chr2:27738854	C/T	cg24768116	chr2:27665128	KRTCAP3	-0.33	-5.88	-0.34	1.26e-8	Total body bone mineral density;
CESC	cis	rs853679	0.569	rs9348798	chr6:28143011	G/A	cg20151795	chr6:28129481	ZNF389	0.41	5.28	0.31	2.69e-7	Depression;
CESC	cis	rs2559856	1.000	rs2695291	chr12:102087543	G/A	cg15068132	chr12:102092402	CHPT1	-0.4	-5.32	-0.31	2.16e-7	Blood protein levels;
CESC	cis	rs2408955	0.522	rs6580650	chr12:48418556	G/T	cg04545296	chr12:48745243	ZNF641	-0.36	-6.07	-0.35	4.33e-9	Glycated hemoglobin levels;
CESC	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg15112475	chr7:1198522	ZFAND2A	-0.41	-6.45	-0.37	5.15e-10	Longevity;Endometriosis;
CESC	cis	rs6502050	0.835	rs8074267	chr17:80158325	A/G	cg23985595	chr17:80112537	CCDC57	-0.39	-6.24	-0.36	1.76e-9	Life satisfaction;
CESC	cis	rs9584850	0.834	rs745638	chr13:99119307	C/G	cg20750642	chr13:99100586	FARP1	0.4	6.08	0.35	4.28e-9	Neuroticism;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg10540759	chr22:19159404	NA	-0.48	-6.14	-0.35	3.05e-9	Ulcerative colitis;
CESC	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg10351095	chr21:47802916	PCNT	0.46	6.35	0.36	9.48e-10	Testicular germ cell tumor;
CESC	cis	rs751728	0.687	rs9357164	chr6:33761021	T/C	cg25922239	chr6:33757077	LEMD2	0.44	6.07	0.35	4.33e-9	Crohn's disease;
CESC	cis	rs7666738	0.791	rs1830231	chr4:99026185	A/C	cg24818145	chr4:99064322	C4orf37	0.39	5.09	0.3	6.95e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs8141529	0.719	rs132561	chr22:29351179	C/T	cg15103426	chr22:29168792	CCDC117	-0.59	-7.48	-0.42	1.07e-12	Lymphocyte counts;
CESC	cis	rs35110281	0.715	rs969060	chr21:45080852	T/G	cg01579765	chr21:45077557	HSF2BP	-0.57	-9.45	-0.5	1.85e-18	Mean corpuscular volume;
CESC	cis	rs7208859	0.573	rs4055105	chr17:29102550	A/G	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.17e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg17357984	chr19:532039	CDC34	-0.49	-6.11	-0.35	3.58e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs9486719	1.000	rs12529248	chr6:96895377	T/G	cg06623918	chr6:96969491	KIAA0776	-0.81	-8.29	-0.45	5.61e-15	Migraine;Coronary artery disease;
CESC	cis	rs9488822	0.676	rs13210143	chr6:116389636	G/A	cg15226275	chr6:116381976	FRK	0.26	6.64	0.38	1.81e-10	Cholesterol, total;LDL cholesterol;
CESC	cis	rs1218582	0.772	rs11264282	chr1:154867370	G/A	cg16680214	chr1:154839983	KCNN3	-0.45	-6.89	-0.39	3.95e-11	Prostate cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13417256	chr12:32112244	C12orf35	0.57	6.02	0.35	5.85e-9	Gut microbiome composition (summer);
CESC	cis	rs2228479	0.702	rs12600047	chr16:89831630	G/A	cg00800038	chr16:89945340	TCF25	-0.93	-7.62	-0.42	4.61e-13	Skin colour saturation;
CESC	cis	rs9916302	0.653	rs11657058	chr17:37699378	T/G	cg00129232	chr17:37814104	STARD3	-0.55	-5.69	-0.33	3.39e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs10832963	1.000	rs11024739	chr11:18645843	A/C	cg20219074	chr11:18656078	SPTY2D1	-0.81	-12.1	-0.6	3.87e-27	Breast cancer;
CESC	cis	rs11098499	0.954	rs13145352	chr4:120409963	C/T	cg09307838	chr4:120376055	NA	-0.94	-12.7	-0.62	3.39e-29	Corneal astigmatism;
CESC	cis	rs9513593	1.000	rs9300540	chr13:100018225	T/A	cg21788972	chr13:99853209	UBAC2	0.6	6.82	0.39	6.27e-11	Psoriasis;
CESC	cis	rs4243830	0.677	rs6693922	chr1:6584804	A/T	cg22792644	chr1:6614718	TAS1R1;NOL9	0.78	7.85	0.43	1.01e-13	Body mass index;
CESC	cis	rs1005277	0.579	rs1740745	chr10:38520056	T/C	cg00409905	chr10:38381863	ZNF37A	-0.52	-7.03	-0.4	1.8e-11	Extrinsic epigenetic age acceleration;
CESC	cis	rs875971	0.545	rs75840613	chr7:65841386	G/A	cg18876405	chr7:65276391	NA	0.5	5.77	0.33	2.16e-8	Aortic root size;
CESC	cis	rs4253772	0.530	rs9615933	chr22:46677298	G/A	cg00784671	chr22:46762841	CELSR1	-0.57	-5.66	-0.33	4.01e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs7520050	0.966	rs61783220	chr1:46335312	G/A	cg24296786	chr1:45957014	TESK2	0.42	5.37	0.31	1.69e-7	Red blood cell count;Reticulocyte count;
CESC	cis	rs13108904	0.901	rs7668661	chr4:1300172	A/G	cg16405210	chr4:1374714	KIAA1530	-0.48	-6.09	-0.35	3.96e-9	Obesity-related traits;
CESC	cis	rs1552244	0.572	rs2054478	chr3:10172211	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.77	8.58	0.47	8.32e-16	Alzheimer's disease;
CESC	cis	rs13191362	1.000	rs35449999	chr6:163023465	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.82	8.24	0.45	7.98e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs11190604	1.000	rs74210981	chr10:102287520	C/T	cg07080220	chr10:102295463	HIF1AN	0.66	6.02	0.35	5.76e-9	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs7301826	0.651	rs10744484	chr12:131298506	T/G	cg11011512	chr12:131303247	STX2	0.47	5.84	0.34	1.52e-8	Plasma plasminogen activator levels;
CESC	cis	rs6580649	1.000	rs7305954	chr12:48403530	C/T	cg05342945	chr12:48394962	COL2A1	-0.54	-6.81	-0.39	6.46e-11	Lung cancer;
CESC	cis	rs9902453	0.904	rs4994353	chr17:28386280	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.65	-8.17	-0.45	1.27e-14	Coffee consumption (cups per day);
CESC	cis	rs6456156	0.846	rs7774396	chr6:167519786	G/A	cg23791538	chr6:167370224	RNASET2	-0.39	-5.06	-0.3	7.68e-7	Primary biliary cholangitis;
CESC	cis	rs6545883	0.895	rs2177961	chr2:61560264	T/C	cg15711740	chr2:61764176	XPO1	0.42	5.21	0.31	3.71e-7	Tuberculosis;
CESC	cis	rs8027181	1.000	rs12900863	chr15:73094671	C/T	cg25632853	chr15:73088954	NA	0.36	6.48	0.37	4.48e-10	Triglyceride levels;
CESC	cis	rs1552244	1.000	rs7651058	chr3:10066964	C/T	cg00166722	chr3:10149974	C3orf24	0.5	6.37	0.36	8.41e-10	Alzheimer's disease;
CESC	cis	rs113835537	0.529	rs78999944	chr11:66251228	C/G	cg24851651	chr11:66362959	CCS	0.45	5.62	0.33	4.87e-8	Airway imaging phenotypes;
CESC	cis	rs4728302	0.838	rs755664	chr7:133596671	C/G	cg10665199	chr7:133106180	EXOC4	0.4	5.54	0.32	7.3e-8	Intelligence;Intelligence (multi-trait analysis);
CESC	cis	rs7071206	0.947	rs4979902	chr10:79399946	C/T	cg07817648	chr10:79422355	NA	0.91	11.91	0.59	1.72e-26	Bone mineral density;
CESC	cis	rs9660992	0.547	rs748012	chr1:205216573	C/T	cg21643547	chr1:205240462	TMCC2	-0.39	-5.37	-0.31	1.69e-7	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs524023	0.957	rs552307	chr11:64357539	G/A	cg07220939	chr11:64358617	SLC22A12	0.35	5.47	0.32	1.02e-7	Urate levels in obese individuals;
CESC	cis	rs9910055	0.530	rs11656758	chr17:42301541	A/G	cg08499158	chr17:42289980	UBTF	-0.41	-5.25	-0.31	3.19e-7	Total body bone mineral density;
CESC	cis	rs72781680	0.948	rs72781652	chr2:24213754	G/A	cg08917208	chr2:24149416	ATAD2B	0.92	8.28	0.45	6.31e-15	Lymphocyte counts;
CESC	cis	rs9916302	0.706	rs7208487	chr17:37543449	T/G	cg07936489	chr17:37558343	FBXL20	0.9	9.82	0.52	1.27e-19	Glomerular filtration rate (creatinine);
CESC	cis	rs1153858	0.945	rs1974981	chr15:45729123	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.75	-9.29	-0.5	5.93e-18	Homoarginine levels;
CESC	cis	rs13253111	0.766	rs56232071	chr8:28063230	A/T	cg26534493	chr8:28060551	NA	0.62	10.82	0.55	7.87e-23	Childhood body mass index;
CESC	cis	rs7666738	0.830	rs732299	chr4:98995389	C/T	cg17366294	chr4:99064904	C4orf37	0.59	8.43	0.46	2.2e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9818758	0.607	rs13068038	chr3:49294250	C/A	cg00383909	chr3:49044727	WDR6	0.8	6.15	0.35	2.8e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CESC	cis	rs3857536	0.776	rs1002764	chr6:66945760	C/A	cg07460842	chr6:66804631	NA	-0.42	-5.29	-0.31	2.55e-7	Blood trace element (Cu levels);
CESC	cis	rs1953600	0.668	rs7091565	chr10:81913561	A/G	cg00277334	chr10:82204260	NA	-0.4	-5.56	-0.32	6.69e-8	Sarcoidosis;
CESC	cis	rs9611565	0.918	rs9538	chr22:41755857	G/T	cg17376030	chr22:41985996	PMM1	0.63	6.68	0.38	1.36e-10	Vitiligo;
CESC	cis	rs13242816	1.000	rs34295495	chr7:116068266	C/A	cg04696780	chr7:116139425	CAV2	-0.63	-5.54	-0.32	7.28e-8	P wave duration;
CESC	cis	rs514406	0.698	rs576891	chr1:53364976	A/G	cg08859206	chr1:53392774	SCP2	-0.68	-10.01	-0.52	3.33e-20	Monocyte count;
CESC	cis	rs7044106	0.762	rs966396	chr9:123453281	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.65	8.79	0.47	1.99e-16	Hip circumference adjusted for BMI;
CESC	cis	rs6714710	0.627	rs6748124	chr2:98519014	T/C	cg26665480	chr2:98280029	ACTR1B	0.56	7.88	0.44	8.37e-14	Posterior cortical atrophy and Alzheimer's disease;
CESC	cis	rs1862618	0.853	rs252902	chr5:56116085	A/G	cg22800045	chr5:56110881	MAP3K1	0.8	9.9	0.52	7.3e-20	Initial pursuit acceleration;
CESC	trans	rs7587026	0.806	rs62179390	chr2:166916817	C/T	cg24507762	chr20:48099890	KCNB1	-0.37	-6.22	-0.36	1.88e-9	Mesial temporal lobe epilepsy with hippocampal sclerosis;
CESC	cis	rs1215050	0.755	rs783958	chr4:98893836	A/T	cg05340658	chr4:99064831	C4orf37	-0.52	-6.82	-0.39	6.23e-11	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs2235544	0.565	rs12758219	chr1:54466145	G/A	cg25741118	chr1:54482237	LDLRAD1	0.24	5.8	0.34	1.91e-8	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
CESC	cis	rs10751667	0.580	rs11246363	chr11:971667	T/C	cg20946044	chr11:1010712	AP2A2	-0.37	-5.11	-0.3	6.25e-7	Alzheimer's disease (late onset);
CESC	cis	rs734999	0.588	rs4648652	chr1:2535758	A/G	cg20673091	chr1:2541236	MMEL1	0.45	7.84	0.43	1.09e-13	Ulcerative colitis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15090714	chr17:60142985	MED13	0.57	6.27	0.36	1.47e-9	Gut microbiome composition (summer);
CESC	cis	rs1153858	1.000	rs1145085	chr15:45657804	A/G	cg21132104	chr15:45694354	SPATA5L1	0.77	10.24	0.53	5.86e-21	Homoarginine levels;
CESC	cis	rs7223966	1.000	rs8081612	chr17:61724695	A/G	cg11494091	chr17:61959527	GH2	-0.38	-5.31	-0.31	2.36e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs11195062	0.521	rs4562740	chr10:111951930	C/A	cg00817464	chr10:111662876	XPNPEP1	-0.52	-7.15	-0.4	8.49e-12	Multiple myeloma;
CESC	cis	rs8072100	0.576	rs7216112	chr17:45406345	C/T	cg25173405	chr17:45401733	C17orf57	0.5	6.17	0.35	2.57e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs7216064	0.953	rs10445361	chr17:65962238	G/T	cg07042672	chr17:66097459	LOC651250	0.56	6.5	0.37	4e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs3741151	0.881	rs73542929	chr11:73094539	G/T	cg17517138	chr11:73019481	ARHGEF17	0.98	6.98	0.39	2.4e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs8044868	0.586	rs7188962	chr16:72098962	A/G	cg01557791	chr16:72042693	DHODH	-0.43	-5.89	-0.34	1.17e-8	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CESC	cis	rs8072100	0.967	rs12452315	chr17:45479446	G/T	cg08085267	chr17:45401833	C17orf57	0.51	6.84	0.39	5.43e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	trans	rs877282	0.583	rs11253425	chr10:815173	G/A	cg22713356	chr15:30763199	NA	1.01	9.05	0.49	3.08e-17	Uric acid levels;
CESC	cis	rs9291683	0.530	rs4697698	chr4:9942577	C/T	cg00071950	chr4:10020882	SLC2A9	0.77	14.18	0.66	2.49e-34	Bone mineral density;
CESC	cis	rs6460942	0.915	rs6965564	chr7:12306013	C/T	cg20607287	chr7:12443886	VWDE	-0.43	-6.05	-0.35	5.03e-9	Coronary artery disease;
CESC	cis	rs9916302	0.904	rs8081338	chr17:37406139	C/T	cg20243544	chr17:37824526	PNMT	0.48	5.96	0.34	8.16e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs7959452	0.605	rs12819406	chr12:69696400	G/T	cg20891283	chr12:69753455	YEATS4	0.77	11.3	0.57	2.02e-24	Blood protein levels;
CESC	cis	rs116095464	0.558	rs10462754	chr5:246669	T/C	cg20965017	chr5:231967	SDHA	-0.48	-5.4	-0.31	1.47e-7	Breast cancer;
CESC	cis	rs959260	1.000	rs2033608	chr17:73367208	T/C	cg20590849	chr17:73267439	MIF4GD	-0.57	-6.51	-0.37	3.78e-10	Systemic lupus erythematosus;
CESC	cis	rs3749237	0.595	rs10865955	chr3:49499829	G/A	cg03060546	chr3:49711283	APEH	0.77	11.67	0.58	1.13e-25	Resting heart rate;
CESC	cis	rs780096	0.525	rs13388159	chr2:27648284	A/T	cg12648201	chr2:27665141	KRTCAP3	-0.35	-6.47	-0.37	4.71e-10	Total body bone mineral density;
CESC	cis	rs11718455	0.960	rs4682712	chr3:43997971	T/C	cg08738300	chr3:44038990	NA	0.46	6.01	0.35	6.02e-9	Coronary artery disease;
CESC	cis	rs1729951	0.575	rs10935214	chr3:136693485	G/A	cg04103450	chr3:136751342	NA	0.4	5.31	0.31	2.32e-7	Neuroticism;
CESC	cis	rs2075371	0.830	rs1421478	chr7:133922793	T/A	cg00033643	chr7:134001901	SLC35B4	0.41	5.28	0.31	2.74e-7	Mean platelet volume;
CESC	cis	rs8067354	0.574	rs9789060	chr17:58018570	A/G	cg13753209	chr17:57696993	CLTC	0.54	5.86	0.34	1.38e-8	Hemoglobin concentration;
CESC	cis	rs8077889	0.956	rs4792910	chr17:41840229	T/C	cg26893861	chr17:41843967	DUSP3	0.86	9.73	0.51	2.48e-19	Triglycerides;
CESC	cis	rs853679	0.517	rs9468292	chr6:28095355	G/A	cg19592336	chr6:28129416	ZNF389	0.6	8.08	0.44	2.36e-14	Depression;
CESC	cis	rs4253772	0.551	rs9615936	chr22:46686328	C/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.63	5.32	0.31	2.26e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs2625529	0.556	rs35603965	chr15:72523043	C/T	cg16672083	chr15:72433130	SENP8	0.46	6.92	0.39	3.4e-11	Red blood cell count;
CESC	cis	rs12497850	0.931	rs4974082	chr3:48999323	G/A	cg07636037	chr3:49044803	WDR6	1.02	18.27	0.75	7.8199999999999992e-49	Parkinson's disease;
CESC	cis	rs73019876	0.869	rs10410985	chr19:22147337	C/T	cg11619707	chr19:22235551	ZNF257	-0.28	-5.19	-0.3	4.11e-7	Testicular germ cell tumor;
CESC	cis	rs4819052	0.851	rs7276828	chr21:46695039	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.75	10.07	0.53	2.09e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs875971	0.505	rs2462573	chr7:65507392	C/T	cg11764359	chr7:65958608	NA	-0.7	-9.27	-0.49	6.71e-18	Aortic root size;
CESC	cis	rs854765	0.964	rs12943202	chr17:17994332	T/A	cg04398451	chr17:18023971	MYO15A	0.66	9.37	0.5	3.21e-18	Total body bone mineral density;
CESC	cis	rs651907	0.535	rs1460097	chr3:101497569	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.45	6.03	0.35	5.44e-9	Colorectal cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16794665	chr9:111882389	C9orf5	-0.58	-6.47	-0.37	4.76e-10	Gut microbiome composition (summer);
CESC	cis	rs514406	0.893	rs476108	chr1:53317351	C/T	cg16325326	chr1:53192061	ZYG11B	0.81	12.77	0.62	2.07e-29	Monocyte count;
CESC	cis	rs2115630	0.875	rs8039472	chr15:85361644	A/G	cg12501888	chr15:85177176	SCAND2	-0.45	-5.69	-0.33	3.33e-8	P wave terminal force;
CESC	trans	rs61931739	0.534	rs4086956	chr12:34105047	A/T	cg26384229	chr12:38710491	ALG10B	0.52	7.06	0.4	1.45e-11	Morning vs. evening chronotype;
CESC	cis	rs9858542	0.953	rs11706370	chr3:49441091	G/A	cg03060546	chr3:49711283	APEH	-0.52	-5.96	-0.34	7.89e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs4665809	0.938	rs35844686	chr2:26304949	A/G	cg25036284	chr2:26402008	FAM59B	0.68	7.36	0.41	2.38e-12	Gut microbiome composition (summer);
CESC	trans	rs11250098	0.503	rs7821826	chr8:10769439	C/T	cg15556689	chr8:8085844	FLJ10661	-0.55	-6.72	-0.38	1.11e-10	Morning vs. evening chronotype;
CESC	cis	rs875971	0.862	rs1860469	chr7:66106875	A/G	cg18252515	chr7:66147081	NA	0.52	6.96	0.39	2.64e-11	Aortic root size;
CESC	cis	rs637571	0.780	rs677029	chr11:65683531	A/G	cg02202077	chr11:65769826	EIF1AD;BANF1	0.42	5.21	0.3	3.82e-7	Eosinophil percentage of white cells;
CESC	cis	rs1552244	0.882	rs13066757	chr3:10045030	C/A	cg00149659	chr3:10157352	C3orf10	0.69	8.2	0.45	1.02e-14	Alzheimer's disease;
CESC	cis	rs4073582	0.595	rs555360	chr11:65960061	T/C	cg14036092	chr11:66035641	RAB1B	-0.53	-7.48	-0.42	1.06e-12	Gout;
CESC	cis	rs3806843	0.897	rs2531338	chr5:140136957	A/T	cg26395211	chr5:140044315	WDR55	0.39	5.17	0.3	4.51e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs4665809	0.590	rs34728554	chr2:26481959	C/G	cg08470875	chr2:26401718	FAM59B	0.75	7.78	0.43	1.63e-13	Gut microbiome composition (summer);
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg24809958	chr1:6662478	KLHL21	0.5	6.66	0.38	1.57e-10	Systemic lupus erythematosus;
CESC	cis	rs7208859	0.623	rs7208088	chr17:29143667	C/T	cg14008862	chr17:28927542	LRRC37B2	0.65	5.14	0.3	5.34e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs7208859	0.673	rs56846352	chr17:29119188	C/T	cg14008862	chr17:28927542	LRRC37B2	0.57	5.43	0.32	1.3e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs34779708	0.733	rs4391768	chr10:35547595	A/G	cg03585969	chr10:35415529	CREM	0.55	6.37	0.36	8.28e-10	Inflammatory bowel disease;Crohn's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09597195	chr6:116575322	TSPYL4	-0.58	-6.68	-0.38	1.39e-10	Gut microbiome composition (summer);
CESC	cis	rs2274273	0.638	rs3759667	chr14:55658421	A/G	cg04306507	chr14:55594613	LGALS3	0.31	5.33	0.31	2.14e-7	Protein biomarker;
CESC	cis	rs853679	0.628	rs9368560	chr6:28159960	T/C	cg23281280	chr6:28129359	ZNF389	0.51	6.65	0.38	1.63e-10	Depression;
CESC	cis	rs2708240	1.000	rs2710096	chr7:147579836	T/G	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.36	-6.05	-0.35	4.82e-9	QT interval (drug interaction);
CESC	cis	rs2439831	0.850	rs16965120	chr15:44100342	T/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.65	6.14	0.35	2.98e-9	Lung cancer in ever smokers;
CESC	cis	rs1050631	1.000	rs1789514	chr18:33692654	T/C	cg25426722	chr18:33708991	SLC39A6;ELP2	0.44	5.73	0.33	2.74e-8	Esophageal squamous cell cancer (length of survival);
CESC	cis	rs67460515	0.563	rs16831981	chr3:160897780	T/C	cg03342759	chr3:160939853	NMD3	-0.53	-6.9	-0.39	3.76e-11	Parkinson's disease;
CESC	cis	rs9649213	0.574	rs62478236	chr7:98030377	G/A	cg24562669	chr7:97807699	LMTK2	0.54	7.93	0.44	6.35e-14	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs832540	0.669	rs832538	chr5:56200016	C/T	cg22800045	chr5:56110881	MAP3K1	0.53	6.88	0.39	4.39e-11	Coronary artery disease;
CESC	cis	rs7618915	0.501	rs3733039	chr3:52719088	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.61	8.82	0.48	1.53e-16	Bipolar disorder;
CESC	cis	rs3859192	0.537	rs12309	chr17:38175462	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.62	9.17	0.49	1.33e-17	White blood cell count;
CESC	cis	rs875971	0.830	rs587360	chr7:65522698	C/A	cg10691866	chr7:65817282	TPST1	-0.34	-5.47	-0.32	1.03e-7	Aortic root size;
CESC	cis	rs11696501	0.688	rs4810465	chr20:44311354	A/G	cg11783356	chr20:44313418	WFDC10B	0.31	5.03	0.3	9.22e-7	Brain structure;
CESC	cis	rs10751667	0.666	rs7395182	chr11:927553	A/C	cg06064525	chr11:970664	AP2A2	-0.52	-10.25	-0.53	5.74e-21	Alzheimer's disease (late onset);
CESC	cis	rs459571	1.000	rs467387	chr9:136907005	G/A	cg13789015	chr9:136890014	NCRNA00094	0.55	7.65	0.43	3.82e-13	Platelet distribution width;
CESC	trans	rs12505749	1.000	rs12505749	chr4:57334112	C/G	cg11734164	chr3:87101920	NA	0.95	6.21	0.36	2.01e-9	Airflow obstruction;
CESC	cis	rs12142240	0.698	rs72677593	chr1:46824363	T/C	cg00530320	chr1:46809349	NSUN4	0.6	8.04	0.44	2.96e-14	Menopause (age at onset);
CESC	cis	rs763014	0.833	rs3743903	chr16:632736	T/C	cg00802000	chr16:706648	WDR90	-0.41	-6.12	-0.35	3.33e-9	Height;
CESC	cis	rs6598163	0.712	rs10751695	chr12:132291061	A/C	cg10319629	chr12:132285459	NA	0.47	6.84	0.39	5.43e-11	Migraine;
CESC	cis	rs2072499	0.838	rs2758619	chr1:156162559	A/G	cg24450063	chr1:156163899	SLC25A44	1.11	24.14	0.83	7.44e-69	Testicular germ cell tumor;
CESC	cis	rs10875943	0.751	rs11168962	chr12:49672739	A/T	cg14846292	chr12:49726500	C1QL4	-0.36	-5.05	-0.3	8.1e-7	Prostate cancer;
CESC	cis	rs6543140	0.964	rs6543143	chr2:103085420	A/C	cg04239558	chr2:103089729	SLC9A4	0.47	6.23	0.36	1.83e-9	Blood protein levels;
CESC	trans	rs17685	0.712	rs28506984	chr7:75763484	A/G	cg19862616	chr7:65841803	NCRNA00174	0.87	12.63	0.61	5.97e-29	Coffee consumption;Coffee consumption (cups per day);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07719547	chr12:9102628	M6PR	0.55	6.2	0.36	2.11e-9	Gut microbiome composition (summer);
CESC	cis	rs9858542	0.953	rs9853683	chr3:49512588	A/G	cg07274523	chr3:49395745	GPX1	0.66	8.05	0.44	2.78e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs1595825	0.891	rs3851979	chr2:198707638	A/T	cg00982548	chr2:198649783	BOLL	0.48	5.08	0.3	7.26e-7	Ulcerative colitis;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg19207856	chr21:38444952	PIGP;TTC3	-0.48	-6.16	-0.35	2.74e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs875971	0.522	rs2008188	chr7:65429013	G/C	cg11764359	chr7:65958608	NA	0.68	8.79	0.48	1.9e-16	Aortic root size;
CESC	cis	rs12900413	0.959	rs11632886	chr15:90322945	A/G	cg24249390	chr15:90295951	MESP1	-0.4	-5.23	-0.31	3.38e-7	Coronary artery aneurysm in Kawasaki disease;
CESC	cis	rs8067545	0.611	rs11653630	chr17:20189046	C/T	cg13482628	chr17:19912719	NA	-0.42	-5.61	-0.33	5.2e-8	Schizophrenia;
CESC	cis	rs9581857	0.615	rs9581849	chr13:28005782	G/T	cg22138327	chr13:27999177	GTF3A	0.66	5.35	0.31	1.9e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
CESC	cis	rs7829975	0.540	rs2976909	chr8:8346690	C/T	cg06636001	chr8:8085503	FLJ10661	-0.43	-5.33	-0.31	2.13e-7	Mood instability;
CESC	cis	rs2730245	0.527	rs2527202	chr7:158738849	T/C	cg24397884	chr7:158709396	WDR60	-0.92	-8.72	-0.47	3.05e-16	Height;
CESC	cis	rs801193	0.569	rs3846973	chr7:66120035	T/C	cg12463550	chr7:65579703	CRCP	-0.5	-6.43	-0.37	5.9e-10	Aortic root size;
CESC	cis	rs2180341	0.920	rs9398836	chr6:127576497	T/G	cg27446573	chr6:127587934	RNF146	1.09	15.97	0.7	1.16e-40	Breast cancer;
CESC	cis	rs7678296	0.649	rs77896458	chr4:37237843	A/G	cg06805348	chr4:37245195	KIAA1239	0.53	5.79	0.33	2.04e-8	3-hydroxypropylmercapturic acid levels in smokers;
CESC	cis	rs4434138	0.664	rs62255364	chr3:52701502	C/T	cg07507251	chr3:52567010	NT5DC2	0.4	7.1	0.4	1.15e-11	Intelligence (multi-trait analysis);
CESC	cis	rs9926296	0.527	rs1800335	chr16:89846195	A/G	cg04287289	chr16:89883240	FANCA	0.9	15.28	0.68	3.23e-38	Vitiligo;
CESC	cis	rs4665809	0.590	rs4665840	chr2:26444962	C/T	cg25036284	chr2:26402008	FAM59B	-0.86	-9.4	-0.5	2.74e-18	Gut microbiome composition (summer);
CESC	cis	rs6120849	0.754	rs6120804	chr20:33623701	C/A	cg24642439	chr20:33292090	TP53INP2	0.68	6.77	0.38	8.46e-11	Protein C levels;
CESC	cis	rs1348850	0.513	rs6730406	chr2:178492722	C/T	cg23306229	chr2:178417860	TTC30B	0.58	6.72	0.38	1.13e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs4975709	0.569	rs2077269	chr5:1863506	C/T	cg12288994	chr5:1860383	NA	0.41	6.85	0.39	5e-11	Cardiovascular disease risk factors;
CESC	cis	rs11031096	0.711	rs10767881	chr11:4205122	C/G	cg18678763	chr11:4115507	RRM1	-0.42	-5.57	-0.32	6.39e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	cis	rs7508	0.694	rs2410446	chr8:17923142	G/A	cg18067069	chr8:17937731	ASAH1	-0.41	-5.43	-0.32	1.28e-7	Atrial fibrillation;
CESC	cis	rs1712517	0.525	rs11191642	chr10:105055912	A/G	cg04362960	chr10:104952993	NT5C2	-0.48	-5.67	-0.33	3.78e-8	Migraine;
CESC	cis	rs514406	0.929	rs557715	chr1:53321593	C/G	cg08859206	chr1:53392774	SCP2	-0.62	-8.41	-0.46	2.57e-15	Monocyte count;
CESC	cis	rs6952808	0.636	rs6964522	chr7:1953523	C/T	cg04267008	chr7:1944627	MAD1L1	-0.63	-8.2	-0.45	1.05e-14	Bipolar disorder and schizophrenia;
CESC	cis	rs9768139	0.627	rs57920447	chr7:158121243	A/G	cg27057461	chr7:158136379	PTPRN2	-0.33	-5.05	-0.3	8.15e-7	Calcium levels;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg07516076	chr7:64197245	NA	0.45	6.22	0.36	1.97e-9	Fibrinogen levels;
CESC	cis	rs7264396	0.779	rs2425162	chr20:34429974	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.8	-10.31	-0.54	3.46e-21	Total cholesterol levels;
CESC	cis	rs7659604	0.539	rs11098648	chr4:122759872	C/T	cg19748678	chr4:122722346	EXOSC9	0.79	10.06	0.53	2.23e-20	Type 2 diabetes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21422024	chr8:64080841	YTHDF3	0.68	8.44	0.46	2.11e-15	Gut microbiome composition (summer);
CESC	cis	rs6570726	0.935	rs413916	chr6:145831400	T/C	cg23711669	chr6:146136114	FBXO30	0.81	12.0	0.59	8.59e-27	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2637266	0.600	rs11001844	chr10:78405461	A/G	cg18941641	chr10:78392320	NA	0.33	5.29	0.31	2.59e-7	Pulmonary function;
CESC	cis	rs4654899	0.865	rs72973154	chr1:21459125	G/T	cg05370193	chr1:21551575	ECE1	0.46	7.03	0.4	1.79e-11	Superior frontal gyrus grey matter volume;
CESC	cis	rs7772486	0.817	rs2144477	chr6:146406248	C/T	cg05347473	chr6:146136440	FBXO30	0.5	6.55	0.37	2.93e-10	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs9467711	0.606	rs2073530	chr6:26375243	T/C	cg06606381	chr12:133084897	FBRSL1	-0.77	-6.78	-0.38	7.69e-11	Autism spectrum disorder or schizophrenia;
CESC	cis	rs372883	0.648	rs4817279	chr21:30638285	T/C	cg08807101	chr21:30365312	RNF160	-0.46	-5.5	-0.32	9.14e-8	Pancreatic cancer;
CESC	cis	rs4803468	1.000	rs3810174	chr19:41904165	C/T	cg14132834	chr19:41945861	ATP5SL	-0.61	-7.74	-0.43	2.09e-13	Height;
CESC	cis	rs5758659	0.714	rs5758589	chr22:42518382	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.31	5.39	0.31	1.55e-7	Cognitive function;
CESC	cis	rs6088580	0.634	rs6088483	chr20:32984714	T/A	cg06115741	chr20:33292138	TP53INP2	-0.47	-6.03	-0.35	5.36e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs9443645	0.808	rs2050661	chr6:79661125	T/C	cg05283184	chr6:79620031	NA	-0.41	-6.38	-0.36	7.91e-10	Intelligence (multi-trait analysis);
CESC	cis	rs13191362	1.000	rs34714518	chr6:163080778	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.0	10.3	0.53	3.82e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs172166	0.694	rs203884	chr6:28077374	G/T	cg18032046	chr6:28092343	ZSCAN16	-0.5	-6.3	-0.36	1.2e-9	Cardiac Troponin-T levels;
CESC	cis	rs5769765	0.955	rs1321	chr22:50297435	A/G	cg26441486	chr22:50317300	CRELD2	0.4	5.56	0.32	6.6e-8	Schizophrenia;
CESC	cis	rs28374715	0.635	rs28557159	chr15:41657353	T/C	cg20272979	chr15:41787780	ITPKA	0.39	5.29	0.31	2.54e-7	Ulcerative colitis;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg01546243	chr14:61748019	TMEM30B	0.44	6.23	0.36	1.8e-9	Systemic lupus erythematosus;
CESC	cis	rs1707322	0.717	rs2991988	chr1:46082431	C/A	cg03146154	chr1:46216737	IPP	-0.8	-11.01	-0.56	1.87e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs116095464	0.558	rs9312979	chr5:222057	A/C	cg22857025	chr5:266934	NA	-1.28	-14.18	-0.66	2.32e-34	Breast cancer;
CESC	cis	rs1448094	0.512	rs61930864	chr12:86246740	G/A	cg00310523	chr12:86230176	RASSF9	0.35	5.4	0.32	1.45e-7	Major depressive disorder;
CESC	cis	rs1862618	0.671	rs2591957	chr5:56243146	A/T	cg24549020	chr5:56110836	MAP3K1	-0.5	-6.23	-0.36	1.87e-9	Initial pursuit acceleration;
CESC	cis	rs1799949	1.000	rs12944458	chr17:41180772	C/T	cg25072359	chr17:41440525	NA	0.49	6.42	0.37	6.13e-10	Menopause (age at onset);
CESC	cis	rs7301826	0.610	rs7957899	chr12:131279076	T/C	cg11011512	chr12:131303247	STX2	0.47	5.73	0.33	2.69e-8	Plasma plasminogen activator levels;
CESC	cis	rs72781680	1.000	rs72788280	chr2:24095907	A/G	cg08917208	chr2:24149416	ATAD2B	0.91	8.38	0.46	3.17e-15	Lymphocyte counts;
CESC	cis	rs1799949	1.000	rs8176318	chr17:41197274	G/T	cg25072359	chr17:41440525	NA	0.48	6.57	0.37	2.63e-10	Menopause (age at onset);
CESC	cis	rs11229030	0.893	rs2584859	chr11:57207447	A/G	cg00522883	chr11:57194120	SLC43A3	0.45	5.96	0.34	7.85e-9	Crohn's disease;
CESC	cis	rs2777491	0.915	rs7180418	chr15:41629502	A/C	cg02330683	chr15:41787940	ITPKA	0.43	6.27	0.36	1.43e-9	Ulcerative colitis;
CESC	cis	rs10927875	0.894	rs10927878	chr1:16319957	C/T	cg22431228	chr1:16359049	CLCNKA	0.35	5.76	0.33	2.38e-8	Dilated cardiomyopathy;
CESC	trans	rs1814175	0.646	rs61904497	chr11:49883449	A/T	cg15704280	chr7:45808275	SEPT13	-1.0	-18.65	-0.75	3.79e-50	Height;
CESC	cis	rs1322639	0.614	rs6940913	chr6:169563666	G/A	cg03254818	chr6:169586852	NA	0.5	5.45	0.32	1.14e-7	Pulse pressure;
CESC	cis	rs4927850	0.881	rs7630489	chr3:195753401	T/C	cg00031303	chr3:195681400	NA	0.45	5.65	0.33	4.21e-8	Pancreatic cancer;
CESC	cis	rs7267979	0.966	rs2227892	chr20:25264814	T/C	cg08601574	chr20:25228251	PYGB	0.39	5.65	0.33	4.08e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs1008375	0.897	rs3733577	chr4:17649233	T/G	cg16339924	chr4:17578868	LAP3	0.63	8.03	0.44	3.2e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs60871478	1.000	rs12531530	chr7:827366	T/C	cg00934597	chr7:893267	UNC84A	0.51	5.16	0.3	4.79e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs863345	0.967	rs10797027	chr1:158523232	T/C	cg12129480	chr1:158549410	OR10X1	-0.33	-6.63	-0.38	1.83e-10	Pneumococcal bacteremia;
CESC	trans	rs2207136	0.835	rs569384	chr6:50913724	C/G	cg06522515	chr3:184090630	THPO	-0.36	-6.12	-0.35	3.3e-9	Myopia;
CESC	cis	rs801193	1.000	rs2286684	chr7:66129830	G/T	cg14393609	chr7:65229607	NA	-0.45	-6.02	-0.35	5.91e-9	Aortic root size;
CESC	cis	rs6430585	0.941	rs6708957	chr2:136520043	C/T	cg07169764	chr2:136633963	MCM6	0.97	12.15	0.6	2.59e-27	Corneal structure;
CESC	cis	rs56399783	0.901	rs17132744	chr7:2874982	T/C	cg19731401	chr7:2775893	GNA12	0.58	5.25	0.31	3.12e-7	Childhood ear infection;
CESC	cis	rs1218582	0.688	rs2135219	chr1:154857217	G/A	cg24250549	chr1:154909240	PMVK	0.59	7.83	0.43	1.19e-13	Prostate cancer;
CESC	cis	rs2439831	0.850	rs7179388	chr15:44123945	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.66	5.66	0.33	3.88e-8	Lung cancer in ever smokers;
CESC	cis	rs2370759	1.000	rs16933225	chr10:32599464	C/T	cg01819863	chr10:32635814	EPC1	1.14	13.72	0.64	9.55e-33	Sexual dysfunction (female);
CESC	cis	rs735396	1.000	rs1169309	chr12:121439192	G/T	cg25281562	chr12:121454272	C12orf43	0.39	5.09	0.3	6.93e-7	N-glycan levels;
CESC	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg11965913	chr1:205819406	PM20D1	0.95	17.45	0.73	6.39e-46	Menarche (age at onset);
CESC	cis	rs7542091	0.739	rs10863793	chr1:210037420	G/A	cg21951975	chr1:209979733	IRF6	0.43	7.06	0.4	1.49e-11	Monobrow;
CESC	cis	rs4728302	0.869	rs10954434	chr7:133597864	A/G	cg10665199	chr7:133106180	EXOC4	0.42	5.83	0.34	1.57e-8	Intelligence;Intelligence (multi-trait analysis);
CESC	cis	rs35306767	0.715	rs1871622	chr10:1049309	T/G	cg20503657	chr10:835505	NA	0.69	6.31	0.36	1.19e-9	Eosinophil percentage of granulocytes;
CESC	cis	rs10504229	0.683	rs16921823	chr8:58108612	G/C	cg24829409	chr8:58192753	C8orf71	-0.56	-7.01	-0.4	1.97e-11	Developmental language disorder (linguistic errors);
CESC	trans	rs916888	0.773	rs199448	chr17:44809001	A/G	cg23590916	chr17:43697445	MGC57346	0.63	6.6	0.38	2.28e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs12893668	0.603	rs12896171	chr14:104135966	A/G	cg24130564	chr14:104152367	KLC1	-0.49	-6.46	-0.37	4.98e-10	Reticulocyte count;
CESC	cis	rs2637266	1.000	rs2637266	chr10:78331318	C/T	cg18941641	chr10:78392320	NA	-0.3	-5.64	-0.33	4.36e-8	Pulmonary function;
CESC	cis	rs11690935	1.000	rs2138348	chr2:172558172	A/C	cg13550731	chr2:172543902	DYNC1I2	0.94	14.12	0.66	4.02e-34	Schizophrenia;
CESC	cis	rs6952808	0.531	rs3778998	chr7:2180753	C/A	cg23048001	chr7:2026167	MAD1L1	0.39	5.16	0.3	4.87e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs2425143	0.908	rs6060605	chr20:34378132	T/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.67	5.67	0.33	3.81e-8	Blood protein levels;
CESC	cis	rs854765	0.547	rs12150369	chr17:17911014	G/A	cg16928487	chr17:17741425	SREBF1	-0.58	-10.22	-0.53	6.92e-21	Total body bone mineral density;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg09325174	chr14:50154983	POLE2	-0.47	-6.44	-0.37	5.66e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs151234	0.676	rs151320	chr16:28568678	A/G	cg01378222	chr16:28622494	SULT1A1	0.56	7.13	0.4	9.54e-12	Platelet distribution width;
CESC	cis	rs317689	0.690	rs547827	chr12:69669703	G/A	cg20891283	chr12:69753455	YEATS4	0.47	5.13	0.3	5.51e-7	Response to diuretic therapy;
CESC	cis	rs9287719	0.967	rs6432113	chr2:10744889	C/T	cg00105475	chr2:10696890	NA	-0.38	-5.52	-0.32	7.88e-8	Prostate cancer;
CESC	cis	rs2281558	0.517	rs16987966	chr20:25643414	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.51	5.76	0.33	2.34e-8	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;
CESC	cis	rs9325144	0.560	rs13377717	chr12:38639474	T/A	cg13010199	chr12:38710504	ALG10B	-0.44	-6.06	-0.35	4.73e-9	Morning vs. evening chronotype;
CESC	cis	rs2075371	0.966	rs722657	chr7:133994956	T/C	cg20476274	chr7:133979776	SLC35B4	0.65	9.4	0.5	2.68e-18	Mean platelet volume;
CESC	cis	rs7264396	0.709	rs2425073	chr20:34293699	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.85	-11.54	-0.58	3.15e-25	Total cholesterol levels;
CESC	cis	rs7726839	0.540	rs56325086	chr5:640728	G/A	cg16447950	chr5:562315	NA	-0.57	-6.02	-0.35	5.68e-9	Obesity-related traits;
CESC	cis	rs10463316	0.817	rs1810083	chr5:150776807	A/G	cg03212797	chr5:150827313	SLC36A1	0.41	5.13	0.3	5.66e-7	Metabolite levels (Pyroglutamine);
CESC	cis	rs6964587	1.000	rs11982047	chr7:91705274	G/A	cg17063962	chr7:91808500	NA	0.54	7.24	0.41	4.99e-12	Breast cancer;
CESC	cis	rs6540559	0.611	rs11810817	chr1:210011747	C/G	cg22029157	chr1:209979665	IRF6	0.66	7.39	0.41	1.89e-12	Cleft lip with or without cleft palate;
CESC	cis	rs561341	0.505	rs28708703	chr17:30386845	C/G	cg00745463	chr17:30367425	LRRC37B	-0.63	-6.16	-0.35	2.69e-9	Hip circumference adjusted for BMI;
CESC	cis	rs514406	0.929	rs515857	chr1:53336859	A/G	cg08736216	chr1:53307985	ZYG11A	-0.41	-6.89	-0.39	4.15e-11	Monocyte count;
CESC	cis	rs4253772	0.591	rs10854854	chr22:46684706	C/G	cg00784671	chr22:46762841	CELSR1	-0.46	-5.16	-0.3	4.96e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs858239	0.601	rs4140959	chr7:23170776	C/T	cg23682824	chr7:23144976	KLHL7	0.56	7.86	0.43	9.69e-14	Cerebrospinal fluid biomarker levels;
CESC	cis	rs61935443	0.832	rs11107768	chr12:95274182	A/T	cg21533806	chr12:95267307	NA	-0.58	-7.08	-0.4	1.26e-11	Schizophrenia;
CESC	cis	rs853679	0.517	rs35227624	chr6:28132726	A/G	cg26335602	chr6:28129616	ZNF389	0.52	6.81	0.39	6.59e-11	Depression;
CESC	cis	rs8077577	0.943	rs62073603	chr17:18064316	C/T	cg16794390	chr17:18148240	FLII	0.43	5.87	0.34	1.32e-8	Obesity-related traits;
CESC	cis	rs854765	0.547	rs2955370	chr17:17966945	C/T	cg04398451	chr17:18023971	MYO15A	0.73	10.49	0.54	9.47e-22	Total body bone mineral density;
CESC	cis	rs7219021	0.634	rs9905428	chr17:46948709	C/G	cg16584676	chr17:46985605	UBE2Z	-0.6	-7.25	-0.41	4.46e-12	Schizophrenia or bipolar disorder;
CESC	cis	rs3793683	0.597	rs2182620	chr10:134590715	C/T	cg27297192	chr10:134578999	INPP5A	0.39	5.16	0.3	4.75e-7	Migraine;
CESC	cis	rs1050631	0.592	rs9958282	chr18:33710440	T/A	cg25426722	chr18:33708991	SLC39A6;ELP2	-0.57	-7.98	-0.44	4.53e-14	Esophageal squamous cell cancer (length of survival);
CESC	cis	rs8114671	0.570	rs3761144	chr20:33544075	C/G	cg24642439	chr20:33292090	TP53INP2	0.43	5.04	0.3	8.53e-7	Height;
CESC	cis	rs60871478	0.636	rs12534606	chr7:895928	A/G	cg00475322	chr7:917719	C7orf20	0.46	5.1	0.3	6.53e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg14893161	chr1:205819251	PM20D1	-0.86	-15.16	-0.68	8.52e-38	Menarche (age at onset);
CESC	cis	rs9894429	1.000	rs4074915	chr17:79579230	G/A	cg21984481	chr17:79567631	NPLOC4	0.48	7.91	0.44	6.83e-14	Eye color traits;
CESC	cis	rs4409675	0.576	rs2749110	chr1:28235010	T/C	cg23691781	chr1:28212827	C1orf38	0.29	5.8	0.34	1.84e-8	Corneal astigmatism;
CESC	cis	rs2486288	0.656	rs11632920	chr15:45551264	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.55	-6.75	-0.38	9.23e-11	Glomerular filtration rate;
CESC	trans	rs4662834	0.872	rs6431023	chr2:129476347	A/G	cg12497543	chr10:97515377	ENTPD1	-0.36	-6.16	-0.35	2.64e-9	Response to bleomycin (chromatid breaks);
CESC	cis	rs1799949	1.000	rs67060599	chr17:41255102	A/G	cg23758822	chr17:41437982	NA	1.01	15.3	0.68	2.61e-38	Menopause (age at onset);
CESC	cis	rs2070433	0.660	rs11701034	chr21:47793235	A/G	cg12379764	chr21:47803548	PCNT	0.69	7.71	0.43	2.5e-13	Lymphocyte counts;
CESC	cis	rs9323205	0.773	rs4334206	chr14:51702414	G/C	cg23942311	chr14:51606299	NA	-0.45	-5.4	-0.32	1.45e-7	Cancer;
CESC	cis	rs28647808	0.881	rs28602295	chr9:136267471	G/A	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.84	5.73	0.33	2.7e-8	Blood protein levels;
CESC	cis	rs8058578	1.000	rs7198250	chr16:30746822	C/A	cg00531865	chr16:30841666	NA	-0.46	-6.26	-0.36	1.51e-9	Multiple myeloma;
CESC	cis	rs9611565	0.546	rs5758431	chr22:42109917	A/G	cg17376030	chr22:41985996	PMM1	-0.72	-7.68	-0.43	3.15e-13	Vitiligo;
CESC	cis	rs3733585	0.699	rs7694997	chr4:9947811	A/G	cg02734326	chr4:10020555	SLC2A9	-0.41	-5.73	-0.33	2.72e-8	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs875971	0.825	rs66981195	chr7:66079035	C/A	cg10691866	chr7:65817282	TPST1	0.33	5.53	0.32	7.81e-8	Aortic root size;
CESC	cis	rs863345	0.604	rs12118446	chr1:158496235	T/C	cg12129480	chr1:158549410	OR10X1	-0.35	-6.86	-0.39	4.78e-11	Pneumococcal bacteremia;
CESC	trans	rs9929218	0.551	rs2274239	chr16:68725783	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.93	15.86	0.7	2.78e-40	Colorectal cancer;
CESC	cis	rs3820068	0.529	rs79570154	chr1:15990912	T/C	cg13390004	chr1:15929781	NA	0.35	5.47	0.32	1.03e-7	Systolic blood pressure;
CESC	cis	rs17253792	0.822	rs17683614	chr14:56041058	G/A	cg01858014	chr14:56050164	KTN1	-0.99	-7.46	-0.42	1.21e-12	Putamen volume;
CESC	trans	rs4950322	0.542	rs3766520	chr1:146686228	C/T	cg04954894	chr8:38089920	DDHD2	-0.62	-6.34	-0.36	9.73e-10	Protein quantitative trait loci;
CESC	cis	rs6951245	0.872	rs57068908	chr7:1060084	A/C	cg24642844	chr7:1081250	C7orf50	-0.64	-8.13	-0.45	1.67e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2635047	0.638	rs13381713	chr18:44669499	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.4	5.38	0.31	1.61e-7	Educational attainment;
CESC	cis	rs1387259	0.929	rs2634666	chr12:48663670	G/T	cg04545296	chr12:48745243	ZNF641	0.42	7.06	0.4	1.47e-11	Obstructive sleep apnea trait (apnea hypopnea index);
CESC	cis	rs5758659	1.000	rs5758659	chr22:42622003	C/T	cg05082376	chr22:42548792	NA	-0.37	-5.5	-0.32	8.95e-8	Cognitive function;
CESC	trans	rs6934970	0.860	rs6902327	chr6:112983118	G/C	cg05146922	chr2:10634174	NA	-0.37	-6.17	-0.35	2.53e-9	Bipolar disorder (body mass index interaction);
CESC	cis	rs67311347	0.955	rs6599100	chr3:40447362	C/T	cg24209194	chr3:40518798	ZNF619	0.46	5.94	0.34	8.93e-9	Renal cell carcinoma;
CESC	cis	rs35306767	0.761	rs12770910	chr10:1050318	A/G	cg25019033	chr10:957182	NA	-0.56	-5.57	-0.32	6.34e-8	Eosinophil percentage of granulocytes;
CESC	cis	rs2108225	0.837	rs7810937	chr7:107447500	A/G	cg18560240	chr7:107437656	SLC26A3	-0.44	-5.96	-0.34	7.93e-9	Ulcerative colitis;
CESC	cis	rs796364	0.806	rs74266490	chr2:201005995	A/C	cg23649088	chr2:200775458	C2orf69	-0.55	-5.04	-0.3	8.69e-7	Schizophrenia;
CESC	cis	rs7937682	0.889	rs3017767	chr11:111508098	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.99	-16.01	-0.7	8.36e-41	Primary sclerosing cholangitis;
CESC	cis	rs6541297	1.000	rs2144298	chr1:230280198	T/C	cg20703242	chr1:230279135	GALNT2	0.73	11.12	0.56	8.07e-24	Coronary artery disease;
CESC	cis	rs34779708	0.931	rs7099593	chr10:35366878	A/C	cg04310649	chr10:35416472	CREM	-0.52	-6.4	-0.37	7.03e-10	Inflammatory bowel disease;Crohn's disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg01935492	chr4:84256334	HPSE	-0.5	-6.44	-0.37	5.46e-10	Fibrinogen levels;
CESC	cis	rs344364	0.511	rs1742473	chr16:1953095	T/C	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.51	-5.68	-0.33	3.62e-8	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs4566357	0.615	rs10198406	chr2:227913539	A/G	cg11843606	chr2:227700838	RHBDD1	-0.48	-6.58	-0.37	2.45e-10	Coronary artery disease;
CESC	cis	rs5769765	0.954	rs5770709	chr22:50245196	G/T	cg26441486	chr22:50317300	CRELD2	-0.4	-5.49	-0.32	9.39e-8	Schizophrenia;
CESC	cis	rs7017914	0.967	rs13256250	chr8:71596193	G/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.09	-0.3	6.93e-7	Bone mineral density;
CESC	cis	rs7714584	1.000	rs7736554	chr5:150258308	T/C	cg22134413	chr5:150180641	NA	0.48	5.35	0.31	1.86e-7	Crohn's disease;
CESC	cis	rs6570726	0.791	rs12205752	chr6:145896118	A/G	cg23711669	chr6:146136114	FBXO30	0.97	14.77	0.67	2.05e-36	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs3785574	0.962	rs2584623	chr17:61906679	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.57	6.96	0.39	2.69e-11	Height;
CESC	cis	rs6500395	0.962	rs2101372	chr16:48627306	G/A	cg04672837	chr16:48644449	N4BP1	0.47	5.82	0.34	1.72e-8	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs10504229	0.683	rs56196593	chr8:58141898	G/A	cg02725872	chr8:58115012	NA	-0.46	-7.18	-0.4	6.99e-12	Developmental language disorder (linguistic errors);
CESC	trans	rs11098499	0.657	rs10434028	chr4:120294464	T/G	cg25214090	chr10:38739885	LOC399744	0.66	9.12	0.49	1.88e-17	Corneal astigmatism;
CESC	cis	rs4423214	1.000	rs7928249	chr11:71161063	A/G	cg05163923	chr11:71159392	DHCR7	0.85	12.42	0.61	3.08e-28	Vitamin D levels;
CESC	cis	rs10504229	0.775	rs55734109	chr8:58162322	G/A	cg24829409	chr8:58192753	C8orf71	-0.65	-7.68	-0.43	3.03e-13	Developmental language disorder (linguistic errors);
CESC	cis	rs3741151	0.686	rs7944346	chr11:73244230	C/T	cg17517138	chr11:73019481	ARHGEF17	0.57	5.17	0.3	4.64e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs559928	0.606	rs1011219	chr11:63973396	A/G	cg18225595	chr11:63971243	STIP1	-0.56	-5.59	-0.32	5.68e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CESC	cis	rs6831352	0.879	rs36034266	chr4:100061388	T/C	cg12011299	chr4:100065546	ADH4	-0.59	-6.59	-0.38	2.35e-10	Alcohol dependence;
CESC	cis	rs5769765	0.913	rs8135071	chr22:50299587	T/C	cg02269571	chr22:50332266	NA	-0.49	-6.49	-0.37	4.14e-10	Schizophrenia;
CESC	cis	rs11677370	0.603	rs10174064	chr2:3849806	C/T	cg17052675	chr2:3827356	NA	-0.44	-5.67	-0.33	3.78e-8	Type 2 diabetes;
CESC	cis	rs7772486	0.875	rs1331639	chr6:146431869	A/G	cg23711669	chr6:146136114	FBXO30	-0.77	-11.06	-0.56	1.21e-23	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2991971	0.967	rs2356551	chr1:46009318	C/T	cg15605315	chr1:45957053	TESK2	0.48	6.23	0.36	1.8e-9	High light scatter reticulocyte count;
CESC	cis	rs2806561	0.765	rs1757046	chr1:23511821	T/C	cg12483005	chr1:23474871	LUZP1	0.38	6.03	0.35	5.51e-9	Height;
CESC	cis	rs17376456	1.000	rs61132622	chr5:93539684	G/A	cg25358565	chr5:93447407	FAM172A	1.16	11.45	0.58	6.45e-25	Diabetic retinopathy;
CESC	cis	rs709400	0.930	rs10149249	chr14:104047757	C/T	cg12935359	chr14:103987150	CKB	-0.47	-6.2	-0.36	2.1e-9	Body mass index;
CESC	cis	rs7618915	0.501	rs2079929	chr3:52765646	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.61	8.64	0.47	5.45e-16	Bipolar disorder;
CESC	cis	rs9611565	0.525	rs9611549	chr22:41705909	C/G	cg03806693	chr22:41940476	POLR3H	-0.76	-8.65	-0.47	5.19e-16	Vitiligo;
CESC	cis	rs9443645	0.527	rs12527806	chr6:79507667	A/T	cg05283184	chr6:79620031	NA	-0.36	-5.29	-0.31	2.62e-7	Intelligence (multi-trait analysis);
CESC	cis	rs73110464	0.609	rs727266	chr12:53356411	C/T	cg16329197	chr12:53359506	NA	-0.68	-9.95	-0.52	4.95e-20	Cancer (pleiotropy);
CESC	cis	rs11792861	0.926	rs1051474	chr9:111881856	T/C	cg13535736	chr9:111863775	C9orf5	-0.51	-6.71	-0.38	1.16e-10	Menarche (age at onset);
CESC	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-6.21	-0.36	2.01e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs367615	0.879	rs2201015	chr5:108947450	C/T	cg17395555	chr5:108820864	NA	0.49	6.94	0.39	2.98e-11	Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs910316	1.000	rs10140851	chr14:75512612	G/A	cg08847533	chr14:75593920	NEK9	0.99	17.94	0.74	1.18e-47	Height;
CESC	cis	rs7937682	0.961	rs4935790	chr11:111633014	T/C	cg09085632	chr11:111637200	PPP2R1B	1.11	15.23	0.68	4.83e-38	Primary sclerosing cholangitis;
CESC	cis	rs12188164	0.930	rs72717440	chr5:449701	A/T	cg21144161	chr5:423903	AHRR	0.37	5.98	0.34	7.12e-9	Cystic fibrosis severity;
CESC	cis	rs7666738	0.546	rs13149516	chr4:98913030	T/A	cg17366294	chr4:99064904	C4orf37	0.52	6.57	0.37	2.65e-10	Colonoscopy-negative controls vs population controls;
CESC	cis	rs78456975	0.941	rs11886649	chr2:1567757	A/G	cg26248373	chr2:1572462	NA	-0.55	-5.27	-0.31	2.84e-7	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs4713118	0.515	rs9368549	chr6:28050047	T/A	cg17949981	chr6:28129498	ZNF389	0.45	5.62	0.33	4.9e-8	Parkinson's disease;
CESC	cis	rs4076764	0.958	rs6688997	chr1:163411562	G/A	cg24596788	chr1:163392923	NA	-0.51	-7.3	-0.41	3.38e-12	Motion sickness;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10277268	chr16:30825733	NA	0.6	6.97	0.39	2.54e-11	Gut microbiome composition (summer);
CESC	trans	rs7980799	0.649	rs10772088	chr12:33663849	A/T	cg26384229	chr12:38710491	ALG10B	-0.58	-8.17	-0.45	1.26e-14	Heart rate;Heart rate variability traits (RMSSD);
CESC	cis	rs780096	0.526	rs1647266	chr2:27693485	T/C	cg24768116	chr2:27665128	KRTCAP3	-0.3	-5.57	-0.32	6.2e-8	Total body bone mineral density;
CESC	cis	rs5753618	0.583	rs7285619	chr22:31842554	C/T	cg00478049	chr22:31556069	RNF185	-0.43	-5.08	-0.3	7e-7	Colorectal cancer;
CESC	cis	rs3091242	0.933	rs7541095	chr1:25761291	T/C	cg03538708	chr1:25844672	NA	-0.4	-6.08	-0.35	4.21e-9	Erythrocyte sedimentation rate;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg21547979	chr19:49141364	SEC1;DBP;CA11	0.49	6.19	0.36	2.3e-9	Ulcerative colitis;
CESC	trans	rs1814175	0.817	rs10769618	chr11:49822336	A/G	cg03929089	chr4:120376271	NA	-0.91	-15.19	-0.68	6.5e-38	Height;
CESC	cis	rs111706465	1	rs111706465	chr2:239452382	A/C	cg18131467	chr2:239335373	ASB1	-0.66	-5.25	-0.31	3.12e-7	Morning vs. evening chronotype;
CESC	cis	rs68170813	0.605	rs10464620	chr7:107135653	A/G	cg02696742	chr7:106810147	HBP1	0.55	5.08	0.3	7.25e-7	Coronary artery disease;
CESC	cis	rs921968	0.643	rs471846	chr2:219432237	C/T	cg02176678	chr2:219576539	TTLL4	0.39	6.8	0.39	6.94e-11	Mean corpuscular hemoglobin concentration;
CESC	cis	rs2243480	1.000	rs34970380	chr7:65431493	C/T	cg13147721	chr7:65941812	NA	-0.9	-8.7	-0.47	3.69e-16	Diabetic kidney disease;
CESC	cis	rs854765	0.655	rs4470201	chr17:17844870	G/A	cg09796270	chr17:17721594	SREBF1	0.43	6.05	0.35	4.89e-9	Total body bone mineral density;
CESC	cis	rs9611519	0.639	rs7290458	chr22:41476337	C/T	cg03806693	chr22:41940476	POLR3H	0.42	5.11	0.3	6.24e-7	Neuroticism;
CESC	cis	rs753778	0.629	rs2278447	chr8:142206905	G/C	cg23750338	chr8:142222470	SLC45A4	0.36	5.2	0.3	4.03e-7	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	cis	rs9902453	0.817	rs59420007	chr17:28196114	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.64	8.01	0.44	3.58e-14	Coffee consumption (cups per day);
CESC	cis	rs477895	0.653	rs12797120	chr11:63906819	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.93	10.18	0.53	9.01e-21	Mean platelet volume;
CESC	trans	rs6934970	0.860	rs4509158	chr6:112981509	T/C	cg05146922	chr2:10634174	NA	-0.38	-6.18	-0.35	2.35e-9	Bipolar disorder (body mass index interaction);
CESC	cis	rs875971	0.505	rs1723275	chr7:65504633	G/C	cg05332525	chr7:65337924	VKORC1L1	-0.5	-6.16	-0.35	2.63e-9	Aortic root size;
CESC	cis	rs4665809	0.887	rs4665825	chr2:26333100	A/G	cg25036284	chr2:26402008	FAM59B	-0.59	-6.88	-0.39	4.37e-11	Gut microbiome composition (summer);
CESC	cis	rs9916302	0.904	rs7503705	chr17:37669704	A/G	cg00129232	chr17:37814104	STARD3	-0.53	-6.9	-0.39	3.76e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs2635047	0.638	rs9961383	chr18:44604001	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.44	6.11	0.35	3.59e-9	Educational attainment;
CESC	cis	rs875971	0.522	rs4718286	chr7:65292764	A/G	cg06456125	chr7:65229604	NA	0.43	5.61	0.33	5.03e-8	Aortic root size;
CESC	cis	rs1348850	0.793	rs12990917	chr2:178487259	T/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.56	7.36	0.41	2.29e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs714031	0.967	rs4821910	chr22:40067470	T/C	cg21377881	chr22:40064566	CACNA1I	-0.33	-5.25	-0.31	3.05e-7	Schizophrenia;
CESC	cis	rs74377301	1	rs74377301	chr7:123232495	C/T	cg03229431	chr7:123269106	ASB15	-0.39	-5.19	-0.3	4.09e-7	Left ventricular obstructive tract defect (inherited effect);
CESC	cis	rs815815	0.608	rs815808	chr2:47381097	C/T	cg27223769	chr2:47403360	CALM2	0.55	6.44	0.37	5.48e-10	Dialysis-related mortality;
CESC	cis	rs644148	0.781	rs630469	chr19:44970167	T/C	cg15540054	chr19:45004280	ZNF180	-0.72	-8.77	-0.47	2.23e-16	Personality dimensions;
CESC	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	13.65	0.64	1.8e-32	Prudent dietary pattern;
CESC	cis	rs4911259	0.552	rs11700082	chr20:31460244	A/G	cg13636640	chr20:31349939	DNMT3B	-0.56	-7.81	-0.43	1.34e-13	Inflammatory bowel disease;
CESC	cis	rs8072100	0.840	rs11079774	chr17:45479706	C/G	cg25173405	chr17:45401733	C17orf57	-0.41	-5.47	-0.32	1.02e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	trans	rs9693444	0.898	rs4732697	chr8:29519861	A/G	cg21496518	chr3:15374154	SH3BP5	-0.36	-6.12	-0.35	3.26e-9	Breast cancer;
CESC	cis	rs1975974	1.000	rs1985717	chr17:21731807	T/A	cg18423549	chr17:21743878	NA	-0.52	-7.08	-0.4	1.3e-11	Psoriasis;
CESC	cis	rs780096	0.506	rs1647286	chr2:27714517	A/T	cg12648201	chr2:27665141	KRTCAP3	-0.35	-6.56	-0.37	2.85e-10	Total body bone mineral density;
CESC	cis	rs11098499	1.000	rs6849889	chr4:120186348	A/C	cg09307838	chr4:120376055	NA	0.89	11.8	0.59	4.03e-26	Corneal astigmatism;
CESC	cis	rs6543140	0.964	rs13383602	chr2:103085962	C/T	cg04239558	chr2:103089729	SLC9A4	0.47	6.23	0.36	1.83e-9	Blood protein levels;
CESC	cis	rs7666738	0.830	rs1426666	chr4:99030887	A/G	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.58e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02322203	chr16:67464610	HSD11B2	0.61	6.72	0.38	1.14e-10	Gut microbiome composition (summer);
CESC	cis	rs10883723	0.810	rs1056857	chr10:104240003	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.54	7.44	0.42	1.43e-12	Allergic disease (asthma, hay fever or eczema);
CESC	trans	rs9693444	0.898	rs4732697	chr8:29519861	A/G	cg24167567	chr20:21283808	XRN2	-0.43	-6.48	-0.37	4.52e-10	Breast cancer;
CESC	cis	rs4423214	0.959	rs12794668	chr11:71168715	C/T	cg05163923	chr11:71159392	DHCR7	0.77	10.41	0.54	1.69e-21	Vitamin D levels;
CESC	trans	rs9325144	0.555	rs4882284	chr12:38710459	C/T	cg23762105	chr12:34175262	ALG10	0.49	6.62	0.38	2.02e-10	Morning vs. evening chronotype;
CESC	cis	rs1799949	1.000	rs11659028	chr17:41195025	T/A	cg05368731	chr17:41323189	NBR1	0.78	10.34	0.54	2.84e-21	Menopause (age at onset);
CESC	cis	rs4665809	0.878	rs6748745	chr2:26364190	C/T	cg22920501	chr2:26401640	FAM59B	-0.66	-8.06	-0.44	2.66e-14	Gut microbiome composition (summer);
CESC	cis	rs6893300	0.785	rs7705530	chr5:179190994	C/T	cg14593053	chr5:179126677	CANX	-0.49	-5.85	-0.34	1.43e-8	Resting heart rate;
CESC	cis	rs704	0.523	rs11080054	chr17:26645991	G/A	cg10494684	chr17:26645200	TMEM97	-0.39	-5.39	-0.31	1.56e-7	Osteoprotegerin levels;
CESC	cis	rs9314323	0.767	rs6557915	chr8:26209062	C/A	cg11498726	chr8:26250323	BNIP3L	-0.46	-6.72	-0.38	1.08e-10	Red cell distribution width;
CESC	cis	rs7937682	0.921	rs34584980	chr11:111441537	G/A	cg22437258	chr11:111473054	SIK2	-0.61	-6.1	-0.35	3.77e-9	Primary sclerosing cholangitis;
CESC	cis	rs228769	0.635	rs228754	chr17:42116056	C/A	cg19774624	chr17:42201019	HDAC5	0.53	6.04	0.35	5.08e-9	Bone mineral density (hip);Bone mineral density (spine);
CESC	cis	rs7208859	0.623	rs9890855	chr17:29111707	G/C	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.91e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs2242116	0.796	rs9852082	chr3:46972377	T/C	cg02527881	chr3:46936655	PTH1R	-0.5	-6.91	-0.39	3.53e-11	Birth weight;
CESC	cis	rs962856	0.619	rs1842958	chr2:67576559	G/T	cg09028215	chr2:67624308	ETAA1	-0.43	-5.14	-0.3	5.38e-7	Pancreatic cancer;
CESC	cis	rs34172651	0.517	rs3803716	chr16:24802325	C/T	cg04756594	chr16:24857601	SLC5A11	0.45	5.53	0.32	7.79e-8	Intelligence (multi-trait analysis);
CESC	cis	rs9814567	0.752	rs4318591	chr3:134328333	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.41	-5.16	-0.3	4.8e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs7666738	0.830	rs880470	chr4:98922522	A/T	cg03467027	chr4:99064603	C4orf37	0.46	5.59	0.32	5.78e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9611565	0.546	rs34077262	chr22:42061639	A/G	cg03806693	chr22:41940476	POLR3H	0.97	11.68	0.58	1.1e-25	Vitiligo;
CESC	cis	rs9916302	0.904	rs12600751	chr17:37553651	G/C	cg20243544	chr17:37824526	PNMT	-0.5	-5.96	-0.34	8.2e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs2573652	1.000	rs2727196	chr15:100513529	C/T	cg00587665	chr15:100533223	ADAMTS17	-0.34	-5.45	-0.32	1.13e-7	Height;
CESC	cis	rs7809950	1.000	rs2712189	chr7:107195747	G/A	cg23024343	chr7:107201750	COG5	-0.42	-5.87	-0.34	1.33e-8	Coronary artery disease;
CESC	cis	rs9300255	0.506	rs11057251	chr12:123791227	A/G	cg00376283	chr12:123451042	ABCB9	-0.59	-8.05	-0.44	2.72e-14	Neutrophil percentage of white cells;
CESC	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg18402987	chr7:1209562	NA	0.75	7.49	0.42	1.04e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs4727027	0.801	rs12666337	chr7:148796253	C/T	cg23583168	chr7:148888333	NA	-0.79	-12.08	-0.6	4.71e-27	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs7412746	0.658	rs3768016	chr1:150809919	T/C	cg22823121	chr1:150693482	HORMAD1	0.44	6.19	0.36	2.26e-9	Melanoma;
CESC	cis	rs4975709	0.610	rs4975705	chr5:1860359	T/C	cg11168104	chr5:1857477	NA	-0.38	-5.67	-0.33	3.63e-8	Cardiovascular disease risk factors;
CESC	cis	rs13102973	0.863	rs13129178	chr4:135858219	A/C	cg14419869	chr4:135874104	NA	0.34	5.28	0.31	2.75e-7	Subjective well-being;
CESC	cis	rs2836974	0.899	rs68004583	chr21:40659587	T/C	cg27266027	chr21:40555129	PSMG1	0.48	5.69	0.33	3.29e-8	Cognitive function;
CESC	cis	rs6687430	0.526	rs12117392	chr1:10608583	T/C	cg07384165	chr1:10488281	NA	-0.48	-6.58	-0.37	2.5e-10	Hand grip strength;
CESC	cis	rs10504229	0.595	rs77615399	chr8:58117394	C/G	cg21724239	chr8:58056113	NA	0.58	5.95	0.34	8.29e-9	Developmental language disorder (linguistic errors);
CESC	trans	rs11098499	0.954	rs28572238	chr4:120316686	T/G	cg25214090	chr10:38739885	LOC399744	0.69	9.38	0.5	3.13e-18	Corneal astigmatism;
CESC	cis	rs9815354	0.812	rs116393551	chr3:41865476	G/A	cg03022575	chr3:42003672	ULK4	0.66	5.38	0.31	1.66e-7	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs58688157	0.705	rs11539530	chr11:609353	G/A	cg17005319	chr11:655579	DEAF1	0.51	5.11	0.3	6.27e-7	Systemic lupus erythematosus;
CESC	cis	rs1729951	0.575	rs16844326	chr3:136678385	G/C	cg25687071	chr3:136751404	NA	0.39	5.17	0.3	4.65e-7	Neuroticism;
CESC	trans	rs864643	0.773	rs11129837	chr3:39589963	A/G	cg01204655	chr5:156692969	CYFIP2	-0.44	-6.02	-0.35	5.65e-9	Attention deficit hyperactivity disorder;
CESC	cis	rs17376456	0.825	rs34592268	chr5:93232751	G/C	cg21475434	chr5:93447410	FAM172A	0.75	6.64	0.38	1.73e-10	Diabetic retinopathy;
CESC	cis	rs10949834	0.878	rs36010170	chr7:73499498	C/A	cg07137043	chr7:73588983	EIF4H	-0.64	-5.51	-0.32	8.31e-8	Verbal memory performance (residualized delayed recall change);
CESC	cis	rs10754283	0.535	rs1215507	chr1:90088895	A/G	cg21401794	chr1:90099060	LRRC8C	0.4	5.1	0.3	6.56e-7	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs2073300	1.000	rs6132623	chr20:23442324	T/A	cg12062639	chr20:23401060	NAPB	0.91	6.41	0.37	6.71e-10	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs9649213	0.559	rs56997921	chr7:98009224	G/A	cg09267113	chr7:98030324	BAIAP2L1	-0.43	-5.81	-0.34	1.82e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs1580019	0.587	rs9638880	chr7:32552401	A/G	cg06627557	chr7:32535165	LSM5;AVL9	1.06	18.9	0.76	5.11e-51	Cognitive ability;
CESC	cis	rs801193	0.844	rs2244022	chr7:66202430	A/G	cg11764359	chr7:65958608	NA	0.52	6.83	0.39	5.78e-11	Aortic root size;
CESC	cis	rs67478160	0.643	rs6575997	chr14:104228546	C/T	cg01849466	chr14:104193079	ZFYVE21	0.5	7.2	0.4	6.23e-12	Schizophrenia;
CESC	cis	rs425277	0.565	rs3128293	chr1:2065339	A/G	cg04315214	chr1:2043799	PRKCZ	0.51	8.2	0.45	1.03e-14	Height;
CESC	cis	rs12464559	0.522	rs7583148	chr2:152620986	C/T	cg01189475	chr2:152685088	ARL5A	0.7	6.72	0.38	1.13e-10	Response to cognitive-behavioural therapy in anxiety disorder;
CESC	cis	rs478304	0.651	rs4014192	chr11:65498915	C/T	cg10518572	chr11:65560635	OVOL1	-0.33	-6.61	-0.38	2.09e-10	Acne (severe);
CESC	cis	rs763121	0.853	rs1569492	chr22:38975511	A/G	cg06544989	chr22:39130855	UNC84B	-0.44	-8.23	-0.45	8.58e-15	Menopause (age at onset);
CESC	cis	rs7927771	1.000	rs7105282	chr11:47805614	C/A	cg20307385	chr11:47447363	PSMC3	-0.5	-6.15	-0.35	2.89e-9	Subjective well-being;
CESC	trans	rs1814175	0.653	rs10839480	chr11:50034556	C/T	cg15704280	chr7:45808275	SEPT13	-1.05	-20.97	-0.79	3.22e-58	Height;
CESC	cis	rs7666738	0.830	rs10049627	chr4:99025272	A/C	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.58e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7937682	0.883	rs472465	chr11:111468962	C/T	cg22437258	chr11:111473054	SIK2	0.71	9.19	0.49	1.16e-17	Primary sclerosing cholangitis;
CESC	cis	rs67311347	0.544	rs4974047	chr3:40339653	G/T	cg09455208	chr3:40491958	NA	0.36	6.35	0.36	9.37e-10	Renal cell carcinoma;
CESC	cis	rs7772486	0.790	rs9403749	chr6:146162239	A/G	cg23711669	chr6:146136114	FBXO30	0.95	14.46	0.66	2.54e-35	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2354432	0.607	rs6703847	chr1:146669444	G/A	cg25205988	chr1:146714368	CHD1L	1.19	9.08	0.49	2.58e-17	Mitochondrial DNA levels;
CESC	cis	rs6547741	0.743	rs7564625	chr2:27862397	C/T	cg27432699	chr2:27873401	GPN1	-0.61	-9.12	-0.49	1.9e-17	Oral cavity cancer;
CESC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg27552081	chr17:25621774	WSB1	0.46	6.22	0.36	1.96e-9	Tetralogy of Fallot;
CESC	cis	rs72634258	0.554	rs10462018	chr1:7879627	C/T	cg26816564	chr1:7831052	VAMP3	0.64	6.1	0.35	3.72e-9	Inflammatory bowel disease;
CESC	cis	rs12681288	0.862	rs7814070	chr8:1020991	A/G	cg04851639	chr8:1020857	NA	-0.38	-8.67	-0.47	4.47e-16	Schizophrenia;
CESC	cis	rs3815700	0.688	rs259252	chr19:33149991	G/C	cg25945090	chr19:33463020	C19orf40;CCDC123	0.75	5.2	0.3	3.95e-7	Eosinophilic esophagitis;
CESC	cis	rs1348850	0.914	rs7565022	chr2:178320222	A/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.74	10.48	0.54	1.04e-21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs10242455	0.702	rs6974831	chr7:99131605	A/G	cg25640893	chr7:99214727	ZNF498	0.71	5.19	0.3	4.21e-7	Blood metabolite levels;
CESC	cis	rs1799949	1.000	rs8176212	chr17:41226601	G/C	cg25072359	chr17:41440525	NA	0.46	6.13	0.35	3.09e-9	Menopause (age at onset);
CESC	cis	rs11792861	0.962	rs72607162	chr9:111793719	T/C	cg05043794	chr9:111880884	C9orf5	-0.42	-6.93	-0.39	3.25e-11	Menarche (age at onset);
CESC	cis	rs78456975	1.000	rs13416881	chr2:1554808	G/A	cg01028140	chr2:1542097	TPO	-0.58	-5.9	-0.34	1.1e-8	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs2425143	0.908	rs12480111	chr20:34423186	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.64	5.27	0.31	2.82e-7	Blood protein levels;
CESC	cis	rs9649213	0.593	rs7807455	chr7:97957622	C/A	cg24562669	chr7:97807699	LMTK2	0.51	7.57	0.42	6.13e-13	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs61931739	0.817	rs7963318	chr12:34244929	C/G	cg26384229	chr12:38710491	ALG10B	-0.48	-6.76	-0.38	8.92e-11	Morning vs. evening chronotype;
CESC	cis	rs3820928	0.904	rs1835159	chr2:227764057	A/G	cg11843606	chr2:227700838	RHBDD1	-0.44	-5.85	-0.34	1.46e-8	Pulmonary function;
CESC	cis	rs9291683	0.530	rs10939620	chr4:9946132	C/T	cg00071950	chr4:10020882	SLC2A9	-0.77	-13.95	-0.65	1.55e-33	Bone mineral density;
CESC	cis	rs9303542	0.625	rs6504340	chr17:46617019	A/G	cg04904318	chr17:46607828	HOXB1	0.48	5.44	0.32	1.22e-7	Ovarian cancer;Epithelial ovarian cancer;
CESC	cis	rs1005277	0.579	rs2474567	chr10:38382492	C/T	cg25427524	chr10:38739819	LOC399744	-0.65	-9.48	-0.5	1.51e-18	Extrinsic epigenetic age acceleration;
CESC	cis	rs660899	0.595	rs37459	chr1:44289397	A/G	cg11704212	chr1:44303111	ST3GAL3	-0.4	-5.36	-0.31	1.78e-7	Hypertension risk in short sleep duration;
CESC	cis	rs1707322	0.752	rs8179402	chr1:46142466	C/A	cg05343316	chr1:45956843	TESK2	0.51	6.2	0.36	2.19e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7084402	1.000	rs4113952	chr10:60268599	A/G	cg07615347	chr10:60278583	BICC1	0.58	8.71	0.47	3.33e-16	Refractive error;
CESC	cis	rs6499255	0.951	rs11641233	chr16:69734563	C/T	cg15192750	chr16:69999425	NA	0.48	5.69	0.33	3.36e-8	IgE levels;
CESC	cis	rs7914558	1.000	rs6584540	chr10:104927634	A/G	cg04362960	chr10:104952993	NT5C2	0.47	6.21	0.36	2e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs561341	0.714	rs75861674	chr17:30304317	A/G	cg19193384	chr17:30244184	NA	-0.58	-6.14	-0.35	2.98e-9	Hip circumference adjusted for BMI;
CESC	cis	rs7666738	0.830	rs7672720	chr4:98938760	A/T	cg03467027	chr4:99064603	C4orf37	0.48	5.96	0.34	7.94e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9828933	0.678	rs704366	chr3:63871648	A/G	cg16258503	chr3:63850278	ATXN7;THOC7	0.65	6.48	0.37	4.53e-10	Type 2 diabetes;
CESC	cis	rs2658782	1.000	rs2605582	chr11:93163799	C/T	cg15737290	chr11:93063684	CCDC67	0.53	6.62	0.38	2e-10	Pulmonary function decline;
CESC	cis	rs73019876	0.869	rs10418985	chr19:22147952	T/C	cg11619707	chr19:22235551	ZNF257	-0.28	-5.21	-0.3	3.76e-7	Testicular germ cell tumor;
CESC	cis	rs9913156	0.793	rs72835643	chr17:4573612	G/A	cg19197139	chr17:4613644	ARRB2	0.95	10.62	0.55	3.4e-22	Lymphocyte counts;
CESC	cis	rs4466137	0.830	rs6886442	chr5:82973210	A/C	cg16102102	chr5:83017553	HAPLN1	0.34	5.25	0.31	3.15e-7	Prostate cancer;
CESC	trans	rs7326068	0.576	rs9552273	chr13:21333750	A/C	cg00192819	chr18:76486611	NA	0.43	6.18	0.35	2.37e-9	Schizophrenia, bipolar disorder and depression (combined);
CESC	cis	rs651907	0.557	rs35850993	chr3:101437433	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.51	6.77	0.38	8.14e-11	Colorectal cancer;
CESC	cis	rs1552244	0.882	rs17050672	chr3:10025463	G/A	cg00166722	chr3:10149974	C3orf24	0.53	6.16	0.35	2.74e-9	Alzheimer's disease;
CESC	cis	rs10752881	1.000	rs10797811	chr1:182984432	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.84	13.34	0.63	2.03e-31	Colorectal cancer;
CESC	cis	rs7500321	1.000	rs7500321	chr16:28977020	G/A	cg08761264	chr16:28874980	SH2B1	0.47	5.62	0.33	4.85e-8	Intelligence (multi-trait analysis);
CESC	cis	rs4523957	0.651	rs898748	chr17:2085475	G/T	cg16513277	chr17:2031491	SMG6	-0.71	-10.17	-0.53	1.04e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs1775715	0.677	rs2808074	chr10:32179184	A/C	cg18675610	chr10:32216311	ARHGAP12	0.35	5.33	0.31	2.08e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs72627123	0.656	rs17096314	chr14:74567952	C/T	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.74	5.09	0.3	6.91e-7	Morning vs. evening chronotype;
CESC	cis	rs35110281	0.667	rs4819291	chr21:45123139	G/A	cg01579765	chr21:45077557	HSF2BP	-0.53	-8.77	-0.47	2.19e-16	Mean corpuscular volume;
CESC	cis	rs875971	0.862	rs57866200	chr7:65565392	A/G	cg18876405	chr7:65276391	NA	-0.57	-7.55	-0.42	6.85e-13	Aortic root size;
CESC	cis	rs8067545	0.611	rs2703807	chr17:20109189	C/T	cg13482628	chr17:19912719	NA	-0.44	-5.92	-0.34	9.91e-9	Schizophrenia;
CESC	cis	rs10504229	0.906	rs2270607	chr8:58194699	A/G	cg24829409	chr8:58192753	C8orf71	-0.6	-8.03	-0.44	3.19e-14	Developmental language disorder (linguistic errors);
CESC	cis	rs10838687	0.736	rs326224	chr11:47255598	T/C	cg25783544	chr11:47291846	MADD	-0.55	-6.14	-0.35	2.94e-9	Proinsulin levels;
CESC	cis	rs2576037	0.526	rs2051292	chr18:44484372	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.6	8.6	0.47	7.14e-16	Personality dimensions;
CESC	cis	rs7666738	0.791	rs13149968	chr4:99070262	G/T	cg05340658	chr4:99064831	C4orf37	0.84	12.81	0.62	1.45e-29	Colonoscopy-negative controls vs population controls;
CESC	cis	rs12971120	0.891	rs2278158	chr18:72178300	G/T	cg25817165	chr18:72167213	CNDP2	-0.61	-7.36	-0.41	2.37e-12	Refractive error;
CESC	cis	rs7945705	0.967	rs10769973	chr11:8928615	C/G	cg21881798	chr11:8931708	C11orf17;ST5	0.53	8.36	0.46	3.52e-15	Hemoglobin concentration;
CESC	cis	rs9611565	0.694	rs19573	chr22:41865809	C/A	cg17376030	chr22:41985996	PMM1	-0.55	-6.16	-0.35	2.68e-9	Vitiligo;
CESC	cis	rs9322193	0.884	rs62439837	chr6:149991516	G/T	cg04369109	chr6:150039330	LATS1	-0.43	-5.84	-0.34	1.51e-8	Lung cancer;
CESC	cis	rs34779708	0.931	rs7897457	chr10:35386040	A/G	cg04310649	chr10:35416472	CREM	-0.52	-6.4	-0.37	7.03e-10	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs2904967	0.636	rs239256	chr11:64987391	C/T	cg23743554	chr11:65321226	LTBP3	-0.4	-5.21	-0.3	3.82e-7	Mean corpuscular volume;
CESC	cis	rs734999	0.588	rs11585048	chr1:2534087	C/T	cg20673091	chr1:2541236	MMEL1	0.43	7.23	0.41	5.16e-12	Ulcerative colitis;
CESC	cis	rs9910055	0.530	rs2269905	chr17:42294462	A/G	cg19774624	chr17:42201019	HDAC5	-0.6	-8.5	-0.46	1.39e-15	Total body bone mineral density;
CESC	cis	rs7552404	0.883	rs2185436	chr1:76203783	A/G	cg03433033	chr1:76189801	ACADM	0.76	10.66	0.55	2.64e-22	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs921968	0.541	rs514356	chr2:219375018	C/T	cg02176678	chr2:219576539	TTLL4	0.5	9.05	0.49	3.15e-17	Mean corpuscular hemoglobin concentration;
CESC	cis	rs9322193	0.884	rs7450246	chr6:150023653	C/T	cg09699651	chr6:150184138	LRP11	0.4	5.26	0.31	2.96e-7	Lung cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03753597	chr21:47706070	MCM3AP;C21orf57	0.65	7.95	0.44	5.4e-14	Gut microbiome composition (summer);
CESC	cis	rs34779708	0.931	rs12261654	chr10:35322024	G/A	cg03585969	chr10:35415529	CREM	0.76	10.17	0.53	9.87e-21	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs4835473	0.800	rs1988210	chr4:144912663	G/C	cg25736465	chr4:144833511	NA	0.43	6.54	0.37	3.17e-10	Immature fraction of reticulocytes;
CESC	cis	rs2839186	0.500	rs13049893	chr21:47707054	C/T	cg12379764	chr21:47803548	PCNT	-0.52	-6.26	-0.36	1.52e-9	Testicular germ cell tumor;
CESC	cis	rs9611565	0.729	rs9611570	chr22:41782721	G/T	cg17376030	chr22:41985996	PMM1	0.6	6.6	0.38	2.27e-10	Vitiligo;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26788107	chr19:34895122	PDCD2L	-0.55	-6.31	-0.36	1.17e-9	Gut microbiome composition (summer);
CESC	trans	rs4596713	0.508	rs4745650	chr9:71777892	G/A	cg16512924	chr15:28394682	HERC2	0.48	6.14	0.35	2.95e-9	Headache;
CESC	cis	rs7618915	0.547	rs11130315	chr3:52697163	A/G	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.71	0.38	1.17e-10	Bipolar disorder;
CESC	cis	rs9399135	0.967	rs6909975	chr6:135315570	C/T	cg24558204	chr6:135376177	HBS1L	0.5	6.77	0.38	8.49e-11	Red blood cell count;
CESC	cis	rs12497850	1.000	rs4858798	chr3:48727112	C/T	cg06641503	chr3:48959341	ARIH2	-0.32	-5.03	-0.3	9.07e-7	Parkinson's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18891615	chr8:101962925	YWHAZ	0.57	6.17	0.35	2.5e-9	Gut microbiome composition (summer);
CESC	cis	rs853679	0.546	rs200996	chr6:27811828	G/A	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.88	7.86	0.43	9.49e-14	Depression;
CESC	cis	rs2280018	0.538	rs7404526	chr16:15129162	A/G	cg27102117	chr16:15229624	NA	0.52	8.08	0.44	2.34e-14	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs9291683	0.588	rs2240722	chr4:10020757	A/G	cg02734326	chr4:10020555	SLC2A9	0.52	7.36	0.41	2.28e-12	Bone mineral density;
CESC	cis	rs8078723	0.738	rs8066582	chr17:38146929	A/G	cg17467752	chr17:38218738	THRA	-0.58	-8.86	-0.48	1.22e-16	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CESC	cis	rs763121	0.962	rs6001159	chr22:38966487	A/G	cg06022373	chr22:39101656	GTPBP1	0.78	12.45	0.61	2.62e-28	Menopause (age at onset);
CESC	cis	rs1808579	1.000	rs1808579	chr18:21104888	C/T	cg14672496	chr18:21087552	C18orf8	0.44	6.57	0.37	2.6e-10	Hip circumference;Body mass index;BMI (adjusted for smoking behaviour);
CESC	cis	rs7618501	0.699	rs6446187	chr3:49907111	C/A	cg24110177	chr3:50126178	RBM5	-0.45	-6.04	-0.35	5.07e-9	Intelligence (multi-trait analysis);
CESC	cis	rs7772486	0.817	rs12198065	chr6:146385286	G/C	cg05347473	chr6:146136440	FBXO30	0.5	6.55	0.37	2.9e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9467711	0.606	rs1977	chr6:26377546	A/G	cg14345882	chr6:26364793	BTN3A2	0.58	6.57	0.37	2.59e-10	Autism spectrum disorder or schizophrenia;
CESC	cis	rs2204008	0.603	rs4397954	chr12:38089157	T/C	cg26384229	chr12:38710491	ALG10B	0.72	10.07	0.53	2.16e-20	Bladder cancer;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg13309628	chr20:3801056	C20orf29	-0.46	-6.58	-0.37	2.48e-10	Gambling;
CESC	trans	rs10411161	0.702	rs11878586	chr19:52388576	A/G	cg22319618	chr22:45562946	NUP50	-0.75	-7.58	-0.42	5.85e-13	Breast cancer;
CESC	cis	rs1707322	0.717	rs1972410	chr1:46080947	G/T	cg03146154	chr1:46216737	IPP	0.79	10.9	0.56	4.22e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9303401	1.000	rs9904677	chr17:56873025	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.73	9.6	0.51	6.34e-19	Cognitive test performance;
CESC	cis	rs9311474	0.507	rs4687644	chr3:52746541	T/G	cg18404041	chr3:52824283	ITIH1	-0.4	-6.73	-0.38	1.04e-10	Electroencephalogram traits;
CESC	cis	rs7923609	0.967	rs10740126	chr10:65210935	A/G	cg01631684	chr10:65280961	REEP3	-0.43	-5.39	-0.31	1.55e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs2997447	0.846	rs61775430	chr1:26411109	G/A	cg24596570	chr1:26146463	FAM54B;LOC646471	0.62	5.33	0.31	2.14e-7	QRS complex (12-leadsum);
CESC	cis	rs9486719	0.947	rs2472893	chr6:96870048	G/C	cg18709589	chr6:96969512	KIAA0776	0.53	5.81	0.34	1.75e-8	Migraine;Coronary artery disease;
CESC	cis	rs514406	0.861	rs35581164	chr1:53271373	C/G	cg08736216	chr1:53307985	ZYG11A	-0.42	-7.09	-0.4	1.19e-11	Monocyte count;
CESC	cis	rs2066819	1.000	rs118130855	chr12:56677979	T/A	cg26804944	chr12:56660921	COQ10A	-0.85	-5.19	-0.3	4.22e-7	Psoriasis vulgaris;
CESC	cis	rs959260	1.000	rs4789183	chr17:73380221	G/A	cg20590849	chr17:73267439	MIF4GD	-0.57	-6.73	-0.38	1.07e-10	Systemic lupus erythematosus;
CESC	cis	rs4900538	0.855	rs12587464	chr14:102886561	G/C	cg18135206	chr14:102964638	TECPR2	-0.72	-8.98	-0.48	5.19e-17	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	cis	rs4665809	0.590	rs3792007	chr2:26497541	C/T	cg25036284	chr2:26402008	FAM59B	0.82	8.69	0.47	3.88e-16	Gut microbiome composition (summer);
CESC	cis	rs4957048	0.891	rs11960196	chr5:568857	C/A	cg16447950	chr5:562315	NA	-0.66	-7.73	-0.43	2.18e-13	Ulcerative colitis;
CESC	cis	rs2576037	0.763	rs2060418	chr18:44576535	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.6	-8.64	-0.47	5.52e-16	Personality dimensions;
CESC	cis	rs2573652	1.000	rs2573652	chr15:100514614	A/G	cg09918751	chr15:100517450	ADAMTS17	-0.39	-7.56	-0.42	6.72e-13	Height;
CESC	cis	rs6952808	0.825	rs34922657	chr7:1938655	C/T	cg05863683	chr7:1912471	MAD1L1	0.45	6.85	0.39	5.1e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs1552244	1.000	rs6782602	chr3:10116541	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	12.09	0.6	4.37e-27	Alzheimer's disease;
CESC	cis	rs7923609	0.870	rs10822156	chr10:65080727	T/C	cg01631684	chr10:65280961	REEP3	-0.45	-5.61	-0.33	5.09e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs10088262	0.629	rs7015861	chr8:124795613	C/T	cg20713898	chr8:124780851	FAM91A1	-0.67	-9.08	-0.49	2.61e-17	Pancreatic cancer;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg12145550	chr20:44600942	ZNF335	-0.47	-6.58	-0.37	2.51e-10	Ulcerative colitis;
CESC	cis	rs1800469	1.000	rs1982072	chr19:41864509	T/A	cg09537434	chr19:41945824	ATP5SL	-0.71	-8.63	-0.47	5.86e-16	Colorectal cancer;
CESC	cis	rs7116495	0.609	rs7942626	chr11:71703849	G/A	cg18441811	chr11:71824068	C11orf51	-0.78	-5.3	-0.31	2.43e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs6502050	0.769	rs4789741	chr17:80119184	A/C	cg11859384	chr17:80120422	CCDC57	-0.39	-5.34	-0.31	1.98e-7	Life satisfaction;
CESC	cis	rs1387259	0.690	rs1601985	chr12:48761914	A/G	cg04545296	chr12:48745243	ZNF641	0.37	6.26	0.36	1.52e-9	Obstructive sleep apnea trait (apnea hypopnea index);
CESC	cis	rs7789940	0.904	rs56919252	chr7:75937520	T/C	cg10167463	chr7:75959203	YWHAG	-0.53	-6.31	-0.36	1.16e-9	Multiple sclerosis;
CESC	cis	rs637571	0.584	rs7107912	chr11:65603252	G/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.68	-8.68	-0.47	4.24e-16	Eosinophil percentage of white cells;
CESC	cis	rs9733	0.527	rs11204694	chr1:150653391	G/A	cg09365446	chr1:150670422	GOLPH3L	0.38	5.32	0.31	2.22e-7	Tonsillectomy;
CESC	cis	rs1355223	0.506	rs7131272	chr11:34869548	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.53	6.43	0.37	6.05e-10	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs10089	0.953	rs7713860	chr5:127428789	G/T	cg19767477	chr5:127420684	SLC12A2	-0.43	-5.88	-0.34	1.23e-8	Ileal carcinoids;
CESC	cis	rs2228479	0.618	rs34689166	chr16:89860697	C/T	cg00800038	chr16:89945340	TCF25	-0.9	-7.49	-0.42	1.01e-12	Skin colour saturation;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg21852503	chr1:40348977	TRIT1	-0.5	-6.0	-0.35	6.61e-9	Ulcerative colitis;
CESC	cis	rs1691799	0.867	rs1027399	chr12:66760942	G/A	cg16791601	chr12:66731901	HELB	-0.77	-13.44	-0.64	9.26e-32	White blood cell count (basophil);
CESC	cis	rs6570726	0.935	rs376991	chr6:145828073	G/C	cg05347473	chr6:146136440	FBXO30	0.49	6.69	0.38	1.3100000000000001e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs10504229	1.000	rs79561699	chr8:58170601	A/G	cg22535103	chr8:58192502	C8orf71	-1.01	-12.36	-0.6	5.35e-28	Developmental language disorder (linguistic errors);
CESC	cis	rs9905704	0.647	rs12940492	chr17:56954655	C/G	cg12560992	chr17:57184187	TRIM37	0.62	7.85	0.43	1.03e-13	Testicular germ cell tumor;
CESC	cis	rs4819052	0.679	rs4819053	chr21:46711357	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.68	-9.08	-0.49	2.58e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs4268898	0.931	rs7603997	chr2:24524958	C/T	cg20701182	chr2:24300061	SF3B14	0.48	5.78	0.33	2.14e-8	Asthma;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg23921860	chr17:4608406	PELP1	-0.45	-6.2	-0.36	2.15e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs1707322	1.000	rs12077546	chr1:46431806	C/T	cg06784218	chr1:46089804	CCDC17	0.33	5.63	0.33	4.7e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs1707322	0.717	rs3014249	chr1:46079493	A/G	cg03146154	chr1:46216737	IPP	-0.8	-11.11	-0.56	8.69e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7481584	0.626	rs2071103	chr11:3040087	C/T	cg25174290	chr11:3078921	CARS	-0.44	-6.04	-0.35	5.21e-9	Calcium levels;
CESC	cis	rs362272	0.525	rs910568	chr4:3307373	A/G	cg08886695	chr4:3369023	RGS12	-0.42	-5.6	-0.33	5.32e-8	Serum sulfate level;
CESC	cis	rs11779988	0.538	rs12541567	chr8:17920077	T/A	cg18067069	chr8:17937731	ASAH1	-0.47	-6.35	-0.36	9.38e-10	Breast cancer;
CESC	cis	rs7267979	0.668	rs4815398	chr20:25237338	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.6	-8.89	-0.48	9.62e-17	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs4819052	0.724	rs1304487	chr21:46657283	C/G	cg11663144	chr21:46675770	NA	0.5	7.56	0.42	6.5e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs7666738	0.830	rs13149779	chr4:99010145	G/T	cg03467027	chr4:99064603	C4orf37	0.44	5.62	0.33	4.83e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7219021	0.926	rs56144347	chr17:46856640	C/T	cg16584676	chr17:46985605	UBE2Z	-0.56	-6.32	-0.36	1.08e-9	Schizophrenia or bipolar disorder;
CESC	cis	rs2415984	0.622	rs1761027	chr14:46929611	G/A	cg14871534	chr14:47121158	RPL10L	0.35	5.38	0.31	1.67e-7	Number of children ever born;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg11342277	chr1:116915598	ATP1A1	-0.45	-6.16	-0.35	2.74e-9	Fibrinogen levels;
CESC	cis	rs2204008	0.774	rs7304438	chr12:38361146	T/G	cg13010199	chr12:38710504	ALG10B	0.48	6.06	0.35	4.62e-9	Bladder cancer;
CESC	cis	rs7927771	0.524	rs7124396	chr11:47787434	T/G	cg20307385	chr11:47447363	PSMC3	-0.58	-8.01	-0.44	3.54e-14	Subjective well-being;
CESC	cis	rs8177253	0.574	rs6775042	chr3:133442245	G/T	cg16262614	chr3:133464971	TF	0.28	5.07	0.3	7.52e-7	Iron status biomarkers;
CESC	cis	rs933688	1.000	rs6452951	chr5:90653868	T/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.17	16.78	0.72	1.55e-43	Smoking behavior;
CESC	cis	rs7267979	1.000	rs2482919	chr20:25299756	T/C	cg08601574	chr20:25228251	PYGB	-0.36	-5.13	-0.3	5.74e-7	Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg09378111	chr2:211036309	C2orf67	-0.45	-6.42	-0.37	6.36e-10	Gambling;
CESC	cis	rs854765	0.583	rs12452219	chr17:17829423	C/T	cg09796270	chr17:17721594	SREBF1	0.46	6.39	0.37	7.34e-10	Total body bone mineral density;
CESC	cis	rs1023500	0.573	rs133374	chr22:42465941	G/A	cg04733989	chr22:42467013	NAGA	0.79	12.05	0.59	5.98e-27	Schizophrenia;
CESC	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg11494091	chr17:61959527	GH2	0.73	12.66	0.61	4.86e-29	Prudent dietary pattern;
CESC	cis	rs3820928	0.874	rs1917127	chr2:227895125	A/G	cg05526886	chr2:227700861	RHBDD1	-0.45	-5.73	-0.33	2.72e-8	Pulmonary function;
CESC	cis	rs76878669	0.561	rs12794121	chr11:66126169	G/T	cg18002602	chr11:66138449	SLC29A2	0.4	6.65	0.38	1.71e-10	Educational attainment (years of education);
CESC	cis	rs208520	0.874	rs208473	chr6:66917265	G/C	cg07460842	chr6:66804631	NA	-0.89	-10.85	-0.55	6.35e-23	Exhaled nitric oxide output;
CESC	cis	rs2933343	0.679	rs789254	chr3:128574593	A/G	cg24203234	chr3:128598194	ACAD9	0.43	5.86	0.34	1.38e-8	IgG glycosylation;
CESC	cis	rs7666738	0.800	rs2865988	chr4:99067807	T/C	cg03467027	chr4:99064603	C4orf37	0.48	5.96	0.34	7.81e-9	Colonoscopy-negative controls vs population controls;
CESC	trans	rs9467711	0.606	rs9379864	chr6:26372584	G/A	cg06606381	chr12:133084897	FBRSL1	-0.76	-6.89	-0.39	4.1e-11	Autism spectrum disorder or schizophrenia;
CESC	cis	rs854765	0.583	rs4925129	chr17:17807186	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.57	7.81	0.43	1.33e-13	Total body bone mineral density;
CESC	cis	rs736801	0.569	rs12517950	chr5:131731326	A/G	cg14196790	chr5:131705035	SLC22A5	0.35	5.34	0.31	2.03e-7	Breast cancer;Mosquito bite size;
CESC	cis	rs1552244	1.000	rs112847840	chr3:10101652	C/T	cg00149659	chr3:10157352	C3orf10	0.72	8.61	0.47	6.41e-16	Alzheimer's disease;
CESC	cis	rs736408	0.812	rs9324	chr3:52825585	T/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.3	5.07	0.3	7.31e-7	Bipolar disorder;
CESC	cis	rs10887741	0.546	rs4316430	chr10:89443649	G/A	cg13926569	chr10:89418898	PAPSS2	0.45	6.91	0.39	3.67e-11	Exercise (leisure time);
CESC	cis	rs2836974	0.897	rs13052882	chr21:40555351	G/C	cg17971929	chr21:40555470	PSMG1	1.07	16.74	0.72	2.15e-43	Cognitive function;
CESC	cis	rs10256972	0.869	rs1007766	chr7:1034903	G/A	cg07930192	chr7:1003750	NA	0.41	5.47	0.32	1.03e-7	Longevity;Endometriosis;
CESC	cis	rs6542838	0.641	rs4851176	chr2:99534859	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.47	-5.95	-0.34	8.33e-9	Fear of minor pain;
CESC	cis	rs7772486	0.754	rs864148	chr6:145976675	T/C	cg05347473	chr6:146136440	FBXO30	-0.55	-7.0	-0.39	2.13e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1005277	0.579	rs1740747	chr10:38520465	G/A	cg25427524	chr10:38739819	LOC399744	-0.73	-10.95	-0.56	2.97e-23	Extrinsic epigenetic age acceleration;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12226046	chr10:91403655	PANK1	-0.62	-7.29	-0.41	3.65e-12	Gut microbiome composition (summer);
CESC	cis	rs2733201	1.000	rs4419034	chr15:44348400	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	-0.51	-5.55	-0.32	6.84e-8	Lipoprotein phospholipase A2 activity in cardiovascular disease;
CESC	cis	rs62064224	0.658	rs62065460	chr17:30715007	A/G	cg25809561	chr17:30822961	MYO1D	0.59	8.31	0.45	5.15e-15	Schizophrenia;
CESC	cis	rs6540559	1.000	rs2235373	chr1:209963803	G/A	cg22442454	chr1:209979470	IRF6	0.48	5.67	0.33	3.66e-8	Cleft lip with or without cleft palate;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg09428653	chr13:99740388	NA	0.48	6.51	0.37	3.73e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs881375	0.715	rs10985073	chr9:123643855	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.47	6.78	0.38	7.82e-11	Rheumatoid arthritis;
CESC	cis	rs11031096	0.678	rs17284356	chr11:4189232	G/C	cg18678763	chr11:4115507	RRM1	-0.4	-5.18	-0.3	4.46e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11787367	chr19:38865418	PSMD8	0.6	7.25	0.41	4.55e-12	Gut microbiome composition (summer);
CESC	cis	rs9487051	0.735	rs1260595	chr6:109519873	T/G	cg01475377	chr6:109611718	NA	-0.37	-5.55	-0.32	6.99e-8	Reticulocyte fraction of red cells;
CESC	cis	rs6714016	0.744	rs2551347	chr2:23912401	C/T	cg20701182	chr2:24300061	SF3B14	-0.55	-6.29	-0.36	1.3e-9	Plateletcrit;
CESC	cis	rs9894429	0.646	rs12603868	chr17:79618834	G/C	cg18240062	chr17:79603768	NPLOC4	0.48	6.22	0.36	1.89e-9	Eye color traits;
CESC	cis	rs7267979	0.966	rs3002698	chr20:25303379	C/G	cg08601574	chr20:25228251	PYGB	-0.37	-5.24	-0.31	3.3e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs9486719	1.000	rs11152968	chr6:96908653	A/G	cg18709589	chr6:96969512	KIAA0776	0.54	5.9	0.34	1.11e-8	Migraine;Coronary artery disease;
CESC	cis	rs3092073	0.624	rs7275164	chr20:44604822	G/A	cg00125455	chr20:44574271	PCIF1	0.38	5.97	0.34	7.46e-9	Intelligence (multi-trait analysis);
CESC	cis	rs7818688	0.697	rs74861094	chr8:95981385	A/G	cg16049864	chr8:95962084	TP53INP1	0.55	5.55	0.32	6.92e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs11785400	1.000	rs13265663	chr8:143732255	A/C	cg24634471	chr8:143751801	JRK	0.45	5.87	0.34	1.28e-8	Schizophrenia;
CESC	cis	rs7089973	0.604	rs765173	chr10:116601675	C/T	cg03647239	chr10:116582469	FAM160B1	0.46	6.02	0.35	5.91e-9	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs3820928	0.845	rs13419076	chr2:227873028	A/G	cg05526886	chr2:227700861	RHBDD1	-0.44	-5.49	-0.32	9.38e-8	Pulmonary function;
CESC	trans	rs7819412	0.775	rs2001329	chr8:10986859	C/T	cg15556689	chr8:8085844	FLJ10661	-0.52	-6.44	-0.37	5.66e-10	Triglycerides;
CESC	cis	rs28489187	0.706	rs233074	chr1:85809065	T/C	cg16011679	chr1:85725395	C1orf52	0.55	6.29	0.36	1.31e-9	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	cis	rs4665809	0.590	rs13019536	chr2:26526978	C/A	cg22920501	chr2:26401640	FAM59B	-0.52	-5.96	-0.34	8.06e-9	Gut microbiome composition (summer);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg08252533	chr2:238875575	UBE2F	-0.41	-6.16	-0.35	2.65e-9	Gambling;
CESC	cis	rs7520050	0.898	rs785502	chr1:46581444	T/C	cg03146154	chr1:46216737	IPP	-0.43	-5.57	-0.32	6.33e-8	Red blood cell count;Reticulocyte count;
CESC	trans	rs916888	0.773	rs199448	chr17:44809001	A/G	cg22433210	chr17:43662623	NA	0.97	11.31	0.57	1.89e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12320322	chr11:63439260	ATL3	0.55	6.35	0.36	9.24e-10	Gut microbiome composition (summer);
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg09909877	chr22:38203717	GCAT	-0.46	-6.36	-0.36	8.84e-10	Asthma;
CESC	cis	rs6032067	0.641	rs34622539	chr20:43756548	A/T	cg10761708	chr20:43804764	PI3	0.49	5.27	0.31	2.77e-7	Blood protein levels;
CESC	cis	rs853679	0.517	rs9393894	chr6:28112562	A/G	cg19592336	chr6:28129416	ZNF389	0.62	8.14	0.45	1.55e-14	Depression;
CESC	cis	rs6815814	0.731	rs4504265	chr4:38773865	G/T	cg02016764	chr4:38805732	TLR1	-0.44	-6.08	-0.35	4.24e-9	Breast cancer;
CESC	trans	rs4132699	0.566	rs13292725	chr9:92061948	C/G	cg23619769	chr11:71952356	PHOX2A	0.42	5.99	0.35	6.71e-9	Orofacial clefts;Nonsyndromic cleft lip with or without cleft palate;
CESC	cis	rs4654899	0.802	rs9651021	chr1:21222770	A/C	cg05370193	chr1:21551575	ECE1	0.38	5.64	0.33	4.32e-8	Superior frontal gyrus grey matter volume;
CESC	cis	rs6714710	0.580	rs13032265	chr2:98409565	T/C	cg26665480	chr2:98280029	ACTR1B	0.56	7.92	0.44	6.75e-14	Posterior cortical atrophy and Alzheimer's disease;
CESC	trans	rs9987353	0.840	rs329994	chr8:9123233	A/G	cg02536620	chr8:413240	FBXO25	-0.43	-6.16	-0.35	2.64e-9	Recombination measurement;
CESC	cis	rs4253772	0.513	rs6008612	chr22:46707907	G/A	cg24881330	chr22:46731750	TRMU	0.94	10.37	0.54	2.3e-21	LDL cholesterol;Cholesterol, total;
CESC	cis	rs7811142	0.779	rs77370288	chr7:99947897	A/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.15	12.02	0.59	7.59e-27	Platelet count;
CESC	cis	rs1322639	0.614	rs6937001	chr6:169565086	C/T	cg03254818	chr6:169586852	NA	-0.47	-5.42	-0.32	1.34e-7	Pulse pressure;
CESC	cis	rs1927790	0.727	rs7996549	chr13:96975175	T/G	cg02571835	chr13:96230311	CLDN10	-0.37	-5.3	-0.31	2.4e-7	Body mass index;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13510114	chr14:64971263	ZBTB25;ZBTB1	0.56	6.41	0.37	6.62e-10	Gut microbiome composition (summer);
CESC	cis	rs6728642	0.519	rs62152905	chr2:97572222	C/T	cg26665480	chr2:98280029	ACTR1B	-0.58	-5.28	-0.31	2.75e-7	Bipolar disorder lithium response (continuous) or schizophrenia;
CESC	cis	rs4713675	0.584	rs3227	chr6:33662295	G/C	cg14003231	chr6:33640908	ITPR3	0.33	5.69	0.33	3.35e-8	Plateletcrit;
CESC	cis	rs853679	0.517	rs9380060	chr6:28132603	G/A	cg08968635	chr6:28129556	ZNF389	0.4	5.22	0.31	3.69e-7	Depression;
CESC	cis	rs7267979	1.000	rs2257988	chr20:25270003	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	18.61	0.75	5.02e-50	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs4853012	0.793	rs6707619	chr2:74344656	G/A	cg01017244	chr2:74357527	NA	0.68	9.78	0.51	1.75e-19	Gestational age at birth (maternal effect);
CESC	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg26338869	chr17:61819248	STRADA	0.68	8.93	0.48	7.3e-17	Prudent dietary pattern;
CESC	cis	rs9926296	0.632	rs9935559	chr16:89800529	C/T	cg03388025	chr16:89894329	SPIRE2	-0.3	-5.09	-0.3	6.64e-7	Vitiligo;
CESC	trans	rs6600671	1.000	rs1832558	chr1:121177380	A/G	cg17023122	chr1:144479586	NA	0.45	6.25	0.36	1.63e-9	Hip geometry;
CESC	cis	rs17666538	0.585	rs10090260	chr8:608034	T/C	cg02524346	chr8:600233	NA	0.89	6.81	0.39	6.35e-11	IgG glycosylation;
CESC	cis	rs12410462	0.681	rs76191945	chr1:227673919	A/G	cg04117972	chr1:227635322	NA	0.79	6.75	0.38	9.16e-11	Major depressive disorder;
CESC	cis	rs7613875	0.620	rs7624030	chr3:50071279	A/C	cg24110177	chr3:50126178	RBM5	0.55	7.59	0.42	5.6e-13	Body mass index;
CESC	cis	rs7264396	0.563	rs2425081	chr20:34299733	C/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.63	6.7	0.38	1.23e-10	Total cholesterol levels;
CESC	cis	rs6540556	0.769	rs6540552	chr1:209927710	C/T	cg23920097	chr1:209922102	NA	0.36	5.05	0.3	8.21e-7	Red blood cell count;
CESC	cis	rs896854	0.967	rs10956933	chr8:95967688	C/G	cg26343298	chr8:95960752	TP53INP1	0.36	5.91	0.34	1.06e-8	Type 2 diabetes;
CESC	cis	rs1865721	0.771	rs72975985	chr18:73127648	C/T	cg26385618	chr18:73139727	C18orf62	-0.52	-8.29	-0.45	5.91e-15	Intelligence;
CESC	cis	rs4665809	1.000	rs4665817	chr2:26305167	G/A	cg04944784	chr2:26401820	FAM59B	-0.8	-8.93	-0.48	7.17e-17	Gut microbiome composition (summer);
CESC	cis	rs826838	1.000	rs1684395	chr12:39083161	T/G	cg26384229	chr12:38710491	ALG10B	-0.62	-9.95	-0.52	5e-20	Heart rate;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14838070	chr5:150030486	SYNPO	-0.47	-6.35	-0.36	9.5e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs344364	0.529	rs186941	chr16:1930088	T/C	cg26897989	chr16:1907736	C16orf73	0.5	6.04	0.35	5.22e-9	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs7223966	0.921	rs6504186	chr17:61863932	G/A	cg11494091	chr17:61959527	GH2	0.38	5.17	0.3	4.56e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs7100689	0.646	rs4468295	chr10:82119276	C/G	cg00277334	chr10:82204260	NA	-0.59	-7.86	-0.43	9.6e-14	Post bronchodilator FEV1;
CESC	cis	rs5758659	0.594	rs739292	chr22:42368857	G/A	cg15557168	chr22:42548783	NA	-0.42	-6.12	-0.35	3.37e-9	Cognitive function;
CESC	cis	rs9325144	0.505	rs10785560	chr12:38636622	C/T	cg13010199	chr12:38710504	ALG10B	0.48	6.58	0.37	2.56e-10	Morning vs. evening chronotype;
CESC	cis	rs3796619	0.503	rs13147452	chr4:1078124	G/A	cg27284194	chr4:1044797	NA	0.59	9.64	0.51	4.71e-19	Recombination rate (males);
CESC	cis	rs4700695	0.668	rs20768	chr5:65484805	C/T	cg21114390	chr5:65439923	SFRS12	-0.47	-5.71	-0.33	3.1e-8	Facial morphology (factor 19);
CESC	cis	rs7666738	0.830	rs34070283	chr4:98893027	A/T	cg05340658	chr4:99064831	C4orf37	0.75	11.14	0.56	6.81e-24	Colonoscopy-negative controls vs population controls;
CESC	cis	rs662064	0.962	rs2506901	chr1:10563492	A/G	cg20482658	chr1:10539492	PEX14	0.36	7.29	0.41	3.52e-12	Asthma;
CESC	cis	rs7927592	0.956	rs11228251	chr11:68244558	G/T	cg16797656	chr11:68205561	LRP5	0.42	6.29	0.36	1.32e-9	Total body bone mineral density;
CESC	trans	rs1814175	0.645	rs28538913	chr11:50040718	C/T	cg15704280	chr7:45808275	SEPT13	-1.01	-18.71	-0.75	2.23e-50	Height;
CESC	cis	rs763014	0.966	rs35642938	chr16:642249	T/C	cg07343612	chr16:622815	PIGQ	-0.53	-7.87	-0.44	8.81e-14	Height;
CESC	cis	rs10751667	0.961	rs10902263	chr11:992691	A/C	cg06064525	chr11:970664	AP2A2	0.4	6.32	0.36	1.1e-9	Alzheimer's disease (late onset);
CESC	cis	rs1707322	1.000	rs1768818	chr1:46514286	G/C	cg06784218	chr1:46089804	CCDC17	-0.33	-5.65	-0.33	4.08e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7666738	0.791	rs11097601	chr4:98960103	C/T	cg18180107	chr4:99064573	C4orf37	0.4	5.14	0.3	5.26e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2243480	1.000	rs35396113	chr7:65495461	C/T	cg12463550	chr7:65579703	CRCP	0.68	5.46	0.32	1.09e-7	Diabetic kidney disease;
CESC	cis	rs3820928	0.874	rs4234066	chr2:227882180	G/A	cg05526886	chr2:227700861	RHBDD1	-0.43	-5.48	-0.32	9.75e-8	Pulmonary function;
CESC	cis	rs1348850	0.918	rs12622298	chr2:178450651	C/T	cg23306229	chr2:178417860	TTC30B	0.53	6.88	0.39	4.2e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs8060686	0.516	rs7206792	chr16:68168200	C/G	cg26727032	chr16:67993705	SLC12A4	-0.55	-7.65	-0.43	3.84e-13	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg23708337	chr7:1209742	NA	0.52	5.19	0.3	4.12e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs10463316	0.894	rs7712569	chr5:150766089	A/C	cg03212797	chr5:150827313	SLC36A1	-0.47	-6.22	-0.36	1.93e-9	Metabolite levels (Pyroglutamine);
CESC	cis	rs17881320	0.510	rs6503699	chr17:40554261	C/G	cg05878104	chr17:40932452	WNK4	0.48	5.2	0.3	4.01e-7	Atopic dermatitis;
CESC	cis	rs1552244	0.554	rs2272121	chr3:10047680	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.56	-7.26	-0.41	4.31e-12	Alzheimer's disease;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg14685339	chr14:77787351	POMT2;GSTZ1	-0.47	-6.71	-0.38	1.15e-10	Gambling;
CESC	cis	rs7659604	0.502	rs10013916	chr4:122702179	T/G	cg19748678	chr4:122722346	EXOSC9	-0.43	-5.42	-0.32	1.35e-7	Type 2 diabetes;
CESC	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg24503407	chr1:205819492	PM20D1	-0.69	-11.76	-0.59	5.76e-26	Monocyte percentage of white cells;
CESC	cis	rs10899021	1.000	rs11236186	chr11:74362865	G/A	cg25880958	chr11:74394337	NA	-0.73	-7.19	-0.4	6.53e-12	Response to metformin (IC50);
CESC	cis	rs73206853	0.686	rs60439011	chr12:110909179	T/C	cg12870014	chr12:110450643	ANKRD13A	0.65	5.59	0.32	5.78e-8	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs7772486	0.743	rs111332144	chr6:146056681	C/T	cg05347473	chr6:146136440	FBXO30	-0.41	-5.57	-0.32	6.26e-8	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7927771	0.864	rs755553	chr11:47432303	G/A	cg18512352	chr11:47633146	NA	0.44	6.35	0.36	9.06e-10	Subjective well-being;
CESC	cis	rs1609391	0.543	rs9881139	chr3:136634040	A/G	cg15507776	chr3:136538369	TMEM22	0.83	12.09	0.6	4.41e-27	Neuroticism;
CESC	cis	rs17608059	0.566	rs5005684	chr17:13910633	T/C	cg11395062	chr17:14139857	CDRT15	0.45	5.57	0.32	6.12e-8	Temperament;
CESC	cis	rs7520050	0.966	rs4376778	chr1:46288846	C/G	cg24296786	chr1:45957014	TESK2	0.42	5.39	0.31	1.6e-7	Red blood cell count;Reticulocyte count;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg05162533	chr17:74137399	FOXJ1	0.46	6.41	0.37	6.65e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs1707322	1.000	rs785484	chr1:46574015	T/C	cg03146154	chr1:46216737	IPP	-0.74	-9.64	-0.51	4.75e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs7246657	0.943	rs4803229	chr19:37864682	T/G	cg24637308	chr11:6592297	DNHD1	0.53	6.17	0.35	2.55e-9	Coronary artery calcification;
CESC	cis	rs2228479	0.850	rs11642010	chr16:89845111	T/C	cg06558623	chr16:89946397	TCF25	1.04	7.44	0.42	1.39e-12	Skin colour saturation;
CESC	cis	rs965469	1.000	rs2236098	chr20:3267133	A/G	cg25506879	chr20:3388711	C20orf194	-0.55	-5.96	-0.34	7.97e-9	IFN-related cytopenia;
CESC	cis	rs67478160	0.643	rs34813623	chr14:104263294	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.51	-7.08	-0.4	1.26e-11	Schizophrenia;
CESC	cis	rs9902453	0.967	rs11080121	chr17:28528842	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	7.61	0.42	4.87e-13	Coffee consumption (cups per day);
CESC	cis	rs13102973	0.931	rs13128765	chr4:135888141	A/G	cg14419869	chr4:135874104	NA	0.34	5.39	0.31	1.54e-7	Subjective well-being;
CESC	cis	rs1448094	0.512	rs1900701	chr12:86236231	T/C	cg19622623	chr12:86230825	RASSF9	-0.47	-5.95	-0.34	8.28e-9	Major depressive disorder;
CESC	cis	rs10493773	0.532	rs12064199	chr1:86187073	A/T	cg17807903	chr1:86174739	ZNHIT6	-0.41	-6.14	-0.35	2.97e-9	Urate levels in overweight individuals;
CESC	cis	rs12497850	0.931	rs9846123	chr3:49088112	C/T	cg07636037	chr3:49044803	WDR6	-1.03	-19.47	-0.77	4.91e-53	Parkinson's disease;
CESC	cis	rs7940866	0.774	rs12420126	chr11:130834811	C/T	cg12179176	chr11:130786555	SNX19	0.68	10.29	0.53	4.19e-21	Schizophrenia;
CESC	cis	rs9399137	0.507	rs13064	chr6:135287533	A/G	cg22676075	chr6:135203613	NA	0.53	7.0	0.39	2.14e-11	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	trans	rs4129059	0.831	rs72759615	chr1:214677827	G/A	cg08821431	chr12:34491090	NA	0.59	6.5	0.37	4.05e-10	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs514406	0.727	rs61768342	chr1:53217028	G/A	cg08859206	chr1:53392774	SCP2	0.61	9.01	0.48	4.28e-17	Monocyte count;
CESC	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.71	-11.38	-0.57	1.11e-24	Longevity;Endometriosis;
CESC	cis	rs6570726	0.791	rs441290	chr6:145883183	A/G	cg05347473	chr6:146136440	FBXO30	0.49	6.45	0.37	5.43e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2204008	0.678	rs61929520	chr12:38446800	T/C	cg26384229	chr12:38710491	ALG10B	-0.44	-5.95	-0.34	8.4e-9	Bladder cancer;
CESC	cis	rs62005083	1.000	rs62005113	chr14:74521914	C/T	cg05179529	chr14:74551516	LIN52;ALDH6A1	0.7	5.22	0.31	3.68e-7	Mean corpuscular volume;
CESC	cis	rs6088580	0.634	rs2424992	chr20:33012060	C/T	cg06115741	chr20:33292138	TP53INP2	0.48	6.13	0.35	3.2e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs2235642	0.826	rs8053605	chr16:1594158	G/A	cg09080909	chr16:1797204	MAPK8IP3	-0.37	-5.12	-0.3	5.84e-7	Coronary artery disease;
CESC	cis	rs938554	0.571	rs4144	chr4:10016322	T/C	cg00071950	chr4:10020882	SLC2A9	0.7	8.3	0.45	5.48e-15	Blood metabolite levels;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg05001908	chr7:128045859	IMPDH1	-0.46	-6.09	-0.35	3.96e-9	Ulcerative colitis;
CESC	cis	rs4319547	0.737	rs11058226	chr12:122938958	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.51	-6.21	-0.36	2.07e-9	Body mass index;
CESC	cis	rs710216	0.763	rs9438964	chr1:43443742	C/T	cg03128534	chr1:43423976	SLC2A1	0.46	5.03	0.3	9.19e-7	Red cell distribution width;
CESC	cis	rs7177699	0.550	rs4468572	chr15:79124475	C/T	cg04896959	chr15:78267971	NA	0.32	5.28	0.31	2.76e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
CESC	cis	rs8017423	0.967	rs7146640	chr14:90720114	C/T	cg14092571	chr14:90743983	NA	0.53	7.87	0.44	9.2e-14	Mortality in heart failure;
CESC	cis	rs938554	0.513	rs3733588	chr4:9997303	A/G	cg11266682	chr4:10021025	SLC2A9	-0.43	-6.31	-0.36	1.17e-9	Blood metabolite levels;
CESC	cis	rs7618915	0.547	rs1561337	chr3:52659963	C/T	cg17372223	chr3:52568218	NT5DC2	0.45	6.7	0.38	1.25e-10	Bipolar disorder;
CESC	cis	rs7539624	0.947	rs2040103	chr1:223901742	G/A	cg10100437	chr1:223903862	CAPN2	-0.4	-5.97	-0.34	7.49e-9	Schizophrenia;
CESC	cis	rs9457247	0.967	rs1211447	chr6:167381979	C/T	cg07741184	chr6:167504864	NA	0.31	5.53	0.32	7.76e-8	Crohn's disease;
CESC	cis	rs7635838	1.000	rs7635838	chr3:11412604	A/G	cg00170343	chr3:11313890	ATG7	0.38	5.07	0.3	7.41e-7	HDL cholesterol;
CESC	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg06873352	chr17:61820015	STRADA	0.71	12.15	0.6	2.69e-27	Prudent dietary pattern;
CESC	cis	rs4713118	0.621	rs9295755	chr6:28033174	C/T	cg26335602	chr6:28129616	ZNF389	-0.5	-6.55	-0.37	2.98e-10	Parkinson's disease;
CESC	cis	rs6088580	0.634	rs6087588	chr20:33066369	T/C	cg08999081	chr20:33150536	PIGU	0.66	11.67	0.58	1.11e-25	Glomerular filtration rate (creatinine);
CESC	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg03188948	chr7:1209495	NA	0.59	6.77	0.38	8.31e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs11976180	0.517	rs6949375	chr7:143773851	T/G	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.66	-7.04	-0.4	1.64e-11	Obesity-related traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19683457	chr6:105307726	HACE1	0.55	6.32	0.36	1.11e-9	Gut microbiome composition (summer);
CESC	cis	rs1799949	0.501	rs2343819	chr17:41409653	T/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.41	5.64	0.33	4.45e-8	Menopause (age at onset);
CESC	cis	rs7208859	0.623	rs11658022	chr17:29085359	A/T	cg13385521	chr17:29058706	SUZ12P	0.85	6.63	0.38	1.86e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs76917914	0.820	rs58427887	chr9:100820671	C/T	cg03040243	chr9:100819229	NANS	0.5	5.6	0.33	5.33e-8	Immature fraction of reticulocytes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05881034	chr3:42623675	SEC22C	0.59	6.48	0.37	4.41e-10	Gut microbiome composition (summer);
CESC	cis	rs6120849	0.707	rs752075	chr20:33591591	C/A	cg24642439	chr20:33292090	TP53INP2	0.67	6.62	0.38	1.94e-10	Protein C levels;
CESC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg09060823	chr12:56862504	SPRYD4	-0.57	-6.49	-0.37	4.29e-10	Lung cancer in ever smokers;
CESC	cis	rs10461617	0.541	rs7715822	chr5:56043600	G/T	cg18230493	chr5:56204884	C5orf35	-0.57	-5.15	-0.3	5.13e-7	Type 2 diabetes;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg13415434	chr3:49044522	P4HTM;WDR6	-0.5	-7.35	-0.41	2.52e-12	Gambling;
CESC	cis	rs9875589	0.957	rs35485647	chr3:13937937	G/C	cg19554555	chr3:13937349	NA	0.54	6.89	0.39	4.01e-11	Ovarian reserve;
CESC	cis	rs1218582	0.600	rs72702224	chr1:154911689	G/A	cg16680214	chr1:154839983	KCNN3	-0.46	-6.89	-0.39	3.94e-11	Prostate cancer;
CESC	cis	rs6502050	0.835	rs3924781	chr17:80113130	T/C	cg11859384	chr17:80120422	CCDC57	-0.39	-5.33	-0.31	2.08e-7	Life satisfaction;
CESC	cis	rs9322193	0.810	rs62439811	chr6:149961552	C/T	cg02462569	chr6:150064036	NUP43	-0.35	-5.19	-0.3	4.2e-7	Lung cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15414828	chr11:71791511	LRTOMT;NUMA1	0.6	7.23	0.41	5.13e-12	Gut microbiome composition (summer);
CESC	cis	rs7179456	0.547	rs653765	chr15:59042012	T/C	cg05156742	chr15:59063176	FAM63B	0.58	7.33	0.41	2.71e-12	Asperger disorder;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg19859335	chr2:70142152	MXD1	0.48	6.16	0.35	2.71e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg13171016	chr1:40219054	PPIE	-0.46	-6.33	-0.36	1.02e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs3733585	0.683	rs13112015	chr4:9933796	C/T	cg11266682	chr4:10021025	SLC2A9	-0.55	-10.65	-0.55	2.8e-22	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs2204008	0.502	rs2387275	chr12:38142836	G/A	cg13010199	chr12:38710504	ALG10B	0.53	6.51	0.37	3.72e-10	Bladder cancer;
CESC	cis	rs8114671	0.804	rs6088666	chr20:33564570	A/G	cg07148914	chr20:33460835	GGT7	0.42	5.44	0.32	1.18e-7	Height;
CESC	cis	rs2710642	0.525	rs1601673	chr2:62842559	G/C	cg17519650	chr2:63277830	OTX1	0.5	6.66	0.38	1.57e-10	LDL cholesterol levels;LDL cholesterol;
CESC	cis	rs9911578	0.934	rs58092632	chr17:57111101	T/C	cg12560992	chr17:57184187	TRIM37	-1.01	-17.65	-0.74	1.26e-46	Intelligence (multi-trait analysis);
CESC	cis	rs4268898	0.552	rs6754391	chr2:24369019	C/T	cg06627628	chr2:24431161	ITSN2	-0.59	-8.21	-0.45	9.9e-15	Asthma;
CESC	cis	rs4727027	0.704	rs1123992	chr7:148907201	C/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.42	5.03	0.3	9.1e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs2249625	1.000	rs2463717	chr6:72921806	C/A	cg18830697	chr6:72922368	RIMS1	-0.43	-6.15	-0.35	2.8e-9	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CESC	cis	rs780096	0.526	rs780106	chr2:27681598	A/C	cg17158414	chr2:27665306	KRTCAP3	-0.32	-5.97	-0.34	7.45e-9	Total body bone mineral density;
CESC	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg22535103	chr8:58192502	C8orf71	-0.92	-10.19	-0.53	8.81e-21	Developmental language disorder (linguistic errors);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06938235	chr12:56498303	PA2G4	0.58	6.35	0.36	9.12e-10	Gut microbiome composition (summer);
CESC	cis	rs72627123	0.867	rs73303116	chr14:74483615	C/T	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.78	5.82	0.34	1.74e-8	Morning vs. evening chronotype;
CESC	cis	rs6991838	0.584	rs7835313	chr8:66546126	C/G	cg13398993	chr8:66546079	ARMC1	0.46	5.65	0.33	4.19e-8	Intelligence (multi-trait analysis);
CESC	cis	rs72945132	0.882	rs4567496	chr11:70193208	A/T	cg14191688	chr11:70257035	CTTN	0.47	5.57	0.32	6.1e-8	Coronary artery disease;
CESC	cis	rs4975709	0.610	rs4975704	chr5:1859807	C/A	cg10800226	chr5:1850261	NA	0.36	5.9	0.34	1.11e-8	Cardiovascular disease risk factors;
CESC	cis	rs6032067	0.632	rs35632684	chr20:43802889	C/T	cg11264863	chr20:43835661	SEMG1	0.5	5.38	0.31	1.62e-7	Blood protein levels;
CESC	cis	rs6912958	0.559	rs373646	chr6:88056896	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.49	8.55	0.47	9.9e-16	Monocyte percentage of white cells;
CESC	cis	rs4950322	0.570	rs72691090	chr1:146769569	T/C	cg16700924	chr1:146552102	NA	-0.41	-5.06	-0.3	7.82e-7	Protein quantitative trait loci;
CESC	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg22535103	chr8:58192502	C8orf71	-0.92	-10.16	-0.53	1.04e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs11098499	0.754	rs66900435	chr4:120249425	C/A	cg09307838	chr4:120376055	NA	0.77	10.45	0.54	1.22e-21	Corneal astigmatism;
CESC	cis	rs1799949	0.965	rs9646413	chr17:41426157	A/G	cg05368731	chr17:41323189	NBR1	0.61	8.34	0.46	4.03e-15	Menopause (age at onset);
CESC	cis	rs11166927	0.870	rs11166930	chr8:140824621	A/G	cg16909799	chr8:140841666	TRAPPC9	-0.5	-7.24	-0.41	4.9e-12	Pediatric non-alcoholic fatty liver disease activity score;
CESC	cis	rs9916302	0.861	rs33933929	chr17:37426441	A/C	cg20243544	chr17:37824526	PNMT	0.46	5.75	0.33	2.52e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs1348850	0.561	rs1838890	chr2:178410938	C/A	cg22681709	chr2:178499509	PDE11A	-0.5	-5.3	-0.31	2.44e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs13242816	1.000	rs17138747	chr7:116132670	G/A	cg04696780	chr7:116139425	CAV2	-0.61	-5.51	-0.32	8.44e-8	P wave duration;
CESC	cis	rs35110281	0.627	rs11701746	chr21:44975137	C/T	cg01579765	chr21:45077557	HSF2BP	-0.51	-8.55	-0.46	1e-15	Mean corpuscular volume;
CESC	trans	rs1728785	0.688	rs7203363	chr16:68587692	T/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.65	7.83	0.43	1.2e-13	Ulcerative colitis;
CESC	cis	rs75477785	0.590	rs4844937	chr1:210176904	A/G	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.92	6.23	0.36	1.82e-9	Cleft lip with or without cleft palate;
CESC	cis	rs6741892	0.536	rs11688977	chr2:38896631	C/T	cg05604112	chr2:38893237	GALM	-0.51	-6.68	-0.38	1.38e-10	5-HTT brain serotonin transporter levels;
CESC	cis	rs10540	1.000	rs10540	chr11:494662	G/A	cg03576123	chr11:487126	PTDSS2	-1.12	-11.17	-0.57	5.31e-24	Body mass index;
CESC	cis	rs2425143	0.730	rs6060624	chr20:34413663	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.68	5.91	0.34	1.03e-8	Blood protein levels;
CESC	cis	rs6696846	0.765	rs2836	chr1:205111761	G/T	cg00857998	chr1:205179979	DSTYK	-0.51	-6.63	-0.38	1.92e-10	Red blood cell count;
CESC	cis	rs7412746	0.658	rs7528773	chr1:150915875	G/A	cg17724175	chr1:150552817	MCL1	0.38	5.9	0.34	1.13e-8	Melanoma;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg18755698	chr11:134046415	NCAPD3	-0.43	-6.08	-0.35	4.17e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs6460942	0.591	rs62448733	chr7:12350526	C/T	cg06484146	chr7:12443880	VWDE	-0.65	-7.09	-0.4	1.2e-11	Coronary artery disease;
CESC	trans	rs10411161	0.702	rs7251929	chr19:52389258	C/T	cg22319618	chr22:45562946	NUP50	-0.75	-7.55	-0.42	7.24e-13	Breast cancer;
CESC	cis	rs4555082	0.957	rs2816629	chr14:105737261	G/A	cg13114125	chr14:105738426	BRF1	-0.75	-9.72	-0.51	2.62e-19	Mean platelet volume;Platelet distribution width;
CESC	cis	rs703842	1.000	rs1599932	chr12:58177943	G/A	cg18357645	chr12:58087776	OS9	-0.43	-5.94	-0.34	9.06e-9	Multiple sclerosis;
CESC	cis	rs1707322	0.717	rs1547925	chr1:46085356	C/T	cg05343316	chr1:45956843	TESK2	-0.49	-6.14	-0.35	2.99e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9443189	0.865	rs2748940	chr6:76434027	C/T	cg01950844	chr6:76311363	SENP6	-0.58	-6.49	-0.37	4.31e-10	Prostate cancer;
CESC	cis	rs4727027	0.833	rs2107846	chr7:148832774	G/A	cg23583168	chr7:148888333	NA	-0.78	-11.97	-0.59	1.08e-26	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs6502050	0.761	rs62078754	chr17:80058666	C/T	cg23985595	chr17:80112537	CCDC57	0.42	6.38	0.36	7.88e-10	Life satisfaction;
CESC	cis	rs6456156	0.586	rs911632	chr6:167471461	T/C	cg23791538	chr6:167370224	RNASET2	-0.5	-6.47	-0.37	4.66e-10	Primary biliary cholangitis;
CESC	cis	rs1950626	0.716	rs34158896	chr14:101447373	T/C	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.82	11.17	0.57	5.57e-24	Pelvic organ prolapse (moderate/severe);
CESC	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg24642844	chr7:1081250	C7orf50	-0.76	-9.26	-0.49	7.23e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2880765	0.677	rs7181410	chr15:86006335	A/G	cg10818794	chr15:86012489	AKAP13	0.34	5.27	0.31	2.83e-7	Coronary artery disease;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg06943149	chr12:77157476	ZDHHC17	-0.42	-6.28	-0.36	1.4e-9	Gambling;
CESC	cis	rs17376456	0.825	rs12716453	chr5:93271697	T/C	cg25358565	chr5:93447407	FAM172A	1.12	10.4	0.54	1.88e-21	Diabetic retinopathy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04510639	chr17:74722764	JMJD6;C17orf95	0.57	6.6	0.38	2.26e-10	Gut microbiome composition (summer);
CESC	trans	rs7866350	0.604	rs1935389	chr9:100994470	A/G	cg26100137	chr18:77203667	NFATC1	-0.4	-6.04	-0.35	5.16e-9	Post-traumatic stress disorder;
CESC	cis	rs7953508	0.506	rs2200160	chr12:93963873	C/T	cg18151635	chr12:93972918	NA	-0.44	-5.89	-0.34	1.19e-8	Pubertal anthropometrics;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg12241299	chr14:20929705	TMEM55B	-0.45	-6.12	-0.35	3.34e-9	Asthma;
CESC	cis	rs17039065	0.920	rs11737760	chr4:109441230	A/G	cg16022748	chr4:109541635	LOC285456;RPL34	0.67	6.4	0.37	7.14e-10	Gut microbiome composition (summer);
CESC	cis	rs7927592	0.956	rs12271290	chr11:68326236	A/G	cg20283391	chr11:68216788	NA	0.49	6.01	0.35	6.22e-9	Total body bone mineral density;
CESC	cis	rs7829975	0.714	rs12544992	chr8:8661681	C/G	cg06636001	chr8:8085503	FLJ10661	0.44	5.71	0.33	3e-8	Mood instability;
CESC	cis	rs7953249	0.594	rs11065384	chr12:121423285	T/C	cg02403541	chr12:121454288	C12orf43	-0.65	-8.68	-0.47	4.12e-16	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
CESC	cis	rs4889855	0.556	rs4278795	chr17:78533189	A/T	cg16591659	chr17:78472290	NA	0.39	6.6	0.38	2.28e-10	Fractional excretion of uric acid;
CESC	cis	rs6867032	0.527	rs13162781	chr5:2012235	C/T	cg26168224	chr5:2018326	NA	0.73	12.54	0.61	1.28e-28	Gut microbiome composition (winter);
CESC	trans	rs561341	1.000	rs521919	chr17:30298039	G/T	cg20587970	chr11:113659929	NA	-1.14	-14.35	-0.66	6.11e-35	Hip circumference adjusted for BMI;
CESC	cis	rs1005277	0.528	rs2057228	chr10:38515766	T/C	cg25427524	chr10:38739819	LOC399744	-0.73	-10.93	-0.56	3.43e-23	Extrinsic epigenetic age acceleration;
CESC	cis	rs3741151	1.000	rs112840535	chr11:73066771	G/A	cg17517138	chr11:73019481	ARHGEF17	0.96	6.55	0.37	3e-10	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs10197940	0.662	rs10173699	chr2:152281561	C/G	cg19508488	chr2:152266495	RIF1	-0.49	-5.35	-0.31	1.92e-7	Lung cancer;
CESC	cis	rs3008870	1.000	rs2009319	chr1:67481070	G/T	cg08660285	chr1:67390436	MIER1;WDR78	1.03	14.0	0.65	1e-33	Lymphocyte percentage of white cells;
CESC	cis	rs9640161	0.789	rs3735172	chr7:150028958	C/T	cg17279839	chr7:150038598	RARRES2	-0.42	-5.5	-0.32	9.1e-8	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs1552244	1.000	rs17032276	chr3:10076975	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.79	-10.53	-0.54	7e-22	Alzheimer's disease;
CESC	cis	rs873946	0.648	rs3750578	chr10:134563366	A/G	cg18305652	chr10:134549665	INPP5A	0.49	6.91	0.39	3.58e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs875971	0.862	rs2420611	chr7:65999320	A/G	cg12463550	chr7:65579703	CRCP	0.51	6.36	0.36	8.66e-10	Aortic root size;
CESC	cis	rs1046896	0.731	rs8067667	chr17:80785875	A/G	cg02711726	chr17:80685570	FN3KRP	-0.39	-5.05	-0.3	8.21e-7	Glycated hemoglobin levels;
CESC	cis	rs1707322	0.721	rs11211149	chr1:46112218	T/C	cg03146154	chr1:46216737	IPP	0.82	11.48	0.58	5.01e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs4665809	1.000	rs750452	chr2:26324995	G/A	cg25036284	chr2:26402008	FAM59B	-0.59	-6.77	-0.38	8.41e-11	Gut microbiome composition (summer);
CESC	cis	rs12701220	0.696	rs12112029	chr7:1137889	G/A	cg23978390	chr7:1156363	C7orf50	0.67	6.54	0.37	3.07e-10	Bronchopulmonary dysplasia;
CESC	cis	rs4665809	0.590	rs13019536	chr2:26526978	C/A	cg25036284	chr2:26402008	FAM59B	-0.57	-6.51	-0.37	3.81e-10	Gut microbiome composition (summer);
CESC	cis	rs7264396	0.515	rs2425134	chr20:34339439	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.6	6.68	0.38	1.41e-10	Total cholesterol levels;
CESC	cis	rs4665809	1.000	rs6546767	chr2:26328746	A/G	cg04944784	chr2:26401820	FAM59B	-0.66	-7.58	-0.42	5.83e-13	Gut microbiome composition (summer);
CESC	cis	rs7086627	0.515	rs7088877	chr10:82208860	C/G	cg00277334	chr10:82204260	NA	-0.91	-15.92	-0.7	1.67e-40	Post bronchodilator FEV1;
CESC	cis	rs9733	0.596	rs6681990	chr1:150695929	A/G	cg04414720	chr1:150670196	GOLPH3L	0.62	8.8	0.48	1.76e-16	Tonsillectomy;
CESC	cis	rs4713118	0.516	rs7739216	chr6:28079946	G/T	cg22143856	chr6:28129313	ZNF389	0.52	6.71	0.38	1.21e-10	Parkinson's disease;
CESC	cis	rs6952808	0.798	rs28970524	chr7:1927484	C/T	cg21782813	chr7:2030301	MAD1L1	0.44	6.24	0.36	1.74e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs9611565	0.512	rs5758450	chr22:42141640	G/A	cg03806693	chr22:41940476	POLR3H	1.18	13.87	0.65	2.9e-33	Vitiligo;
CESC	cis	rs6582630	0.502	rs11181230	chr12:38300085	A/G	cg26384229	chr12:38710491	ALG10B	0.7	10.34	0.54	2.92e-21	Drug-induced liver injury (flucloxacillin);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg02031769	chr6:161695303	AGPAT4	0.49	6.55	0.37	3.02e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs1552244	0.935	rs7618815	chr3:10151045	A/G	cg16606324	chr3:10149918	C3orf24	0.41	5.03	0.3	8.88e-7	Alzheimer's disease;
CESC	cis	rs244293	0.760	rs12952166	chr17:53005586	C/T	cg19360675	chr17:53046073	COX11;STXBP4	-0.44	-5.6	-0.33	5.37e-8	Menarche (age at onset);
CESC	cis	rs758324	0.812	rs4280859	chr5:131246941	A/T	cg06307176	chr5:131281290	NA	-0.39	-5.25	-0.31	3.12e-7	Alzheimer's disease in APOE e4- carriers;
CESC	cis	rs7223966	1.000	rs6504182	chr17:61823672	T/C	cg11494091	chr17:61959527	GH2	0.41	5.73	0.33	2.71e-8	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs7542091	0.635	rs7550733	chr1:210044968	G/A	cg09509183	chr1:209979624	IRF6	0.4	5.78	0.33	2.12e-8	Monobrow;
CESC	cis	rs796364	0.951	rs59695400	chr2:201021325	C/T	cg23649088	chr2:200775458	C2orf69	-0.53	-5.47	-0.32	1.04e-7	Schizophrenia;
CESC	cis	rs1905108	0.510	rs12544004	chr8:49543160	T/C	cg22836229	chr8:49647717	EFCAB1	0.31	5.14	0.3	5.43e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11122272	0.735	rs2749705	chr1:231526696	C/T	cg06096015	chr1:231504339	EGLN1	0.43	6.12	0.35	3.28e-9	Hemoglobin concentration;
CESC	cis	rs736408	0.527	rs2577831	chr3:52628056	C/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.44	6.69	0.38	1.33e-10	Bipolar disorder;
CESC	cis	rs66887589	0.777	rs4643791	chr4:120265619	A/G	cg09307838	chr4:120376055	NA	-0.56	-7.69	-0.43	2.98e-13	Diastolic blood pressure;
CESC	cis	rs71403859	0.685	rs12444890	chr16:71636026	G/A	cg08717414	chr16:71523259	ZNF19	-0.79	-6.93	-0.39	3.26e-11	Post bronchodilator FEV1;
CESC	cis	rs6741892	0.536	rs7590835	chr2:38893950	A/G	cg00359181	chr2:38893519	GALM	0.6	8.71	0.47	3.25e-16	5-HTT brain serotonin transporter levels;
CESC	cis	rs7267979	0.966	rs6107031	chr20:25350677	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.88	-18.14	-0.74	2.23e-48	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs1878931	0.543	rs1129568	chr16:3483475	G/A	cg21433313	chr16:3507492	NAT15	-0.34	-5.03	-0.3	8.85e-7	Body mass index (adult);
CESC	cis	rs6456156	0.526	rs3093025	chr6:167532731	A/G	cg23791538	chr6:167370224	RNASET2	0.42	5.37	0.31	1.74e-7	Primary biliary cholangitis;
CESC	cis	rs61776719	0.747	rs28428561	chr1:38434306	G/A	cg12658694	chr1:38397304	INPP5B	-0.8	-12.18	-0.6	2.15e-27	Coronary artery disease;
CESC	cis	rs6904897	0.563	rs6569976	chr6:135224753	A/C	cg24558204	chr6:135376177	HBS1L	0.56	7.6	0.42	5.16e-13	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	cis	rs2832191	0.716	rs2297252	chr21:30377104	G/A	cg24692254	chr21:30365293	RNF160	1.02	18.44	0.75	2.04e-49	Dental caries;
CESC	cis	rs35306767	0.903	rs11253493	chr10:936931	T/C	cg10556349	chr10:835070	NA	0.57	5.56	0.32	6.44e-8	Eosinophil percentage of granulocytes;
CESC	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg07092213	chr7:1199455	ZFAND2A	-0.5	-5.93	-0.34	9.31e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2997447	0.761	rs17257107	chr1:26448447	A/G	cg24596570	chr1:26146463	FAM54B;LOC646471	0.59	5.17	0.3	4.68e-7	QRS complex (12-leadsum);
CESC	cis	rs6840360	0.554	rs4643789	chr4:152726691	C/T	cg22705602	chr4:152727874	NA	-0.39	-5.66	-0.33	3.97e-8	Intelligence (multi-trait analysis);
CESC	cis	rs9910055	0.529	rs408282	chr17:42182267	A/G	cg13607699	chr17:42295918	UBTF	-0.49	-6.0	-0.35	6.38e-9	Total body bone mineral density;
CESC	cis	rs11203032	0.831	rs10887920	chr10:90924415	C/T	cg16672925	chr10:90967113	CH25H	0.7	6.65	0.38	1.62e-10	Heart failure;
CESC	cis	rs7264396	0.676	rs6060723	chr20:34549947	G/C	cg17201900	chr20:34330562	RBM39	0.49	5.11	0.3	6.08e-7	Total cholesterol levels;
CESC	cis	rs9611565	0.918	rs9611562	chr22:41760172	T/G	cg06634786	chr22:41940651	POLR3H	-0.65	-6.67	-0.38	1.46e-10	Vitiligo;
CESC	cis	rs1008375	1.000	rs1558377	chr4:17650758	A/G	cg04450456	chr4:17643702	FAM184B	0.36	5.06	0.3	7.87e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs72829446	0.530	rs72827503	chr17:7371268	G/T	cg02795151	chr17:7402630	POLR2A	0.53	5.07	0.3	7.53e-7	Androgen levels;
CESC	cis	rs4689388	0.890	rs13130845	chr4:6297646	A/C	cg14416269	chr4:6271139	WFS1	0.46	7.62	0.42	4.6e-13	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs9916302	0.706	rs9906612	chr17:37547631	A/C	cg07936489	chr17:37558343	FBXL20	0.9	9.82	0.52	1.27e-19	Glomerular filtration rate (creatinine);
CESC	cis	rs9287719	0.967	rs12464817	chr2:10707212	A/G	cg02196655	chr2:10830764	NOL10	-0.36	-5.42	-0.32	1.31e-7	Prostate cancer;
CESC	cis	rs6540559	1.000	rs1044516	chr1:209959614	G/T	cg12034118	chr1:209979487	IRF6	0.42	5.12	0.3	5.96e-7	Cleft lip with or without cleft palate;
CESC	cis	rs7267979	1.000	rs761025	chr20:25426968	G/A	cg08601574	chr20:25228251	PYGB	0.38	5.57	0.32	6.24e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs2070433	0.500	rs2070435	chr21:47961711	C/T	cg12379764	chr21:47803548	PCNT	0.53	6.97	0.39	2.52e-11	Lymphocyte counts;
CESC	cis	rs6964587	0.934	rs6465344	chr7:91640273	G/A	cg17063962	chr7:91808500	NA	0.55	7.63	0.42	4.25e-13	Breast cancer;
CESC	cis	rs6724607	0.905	rs7603849	chr2:191438741	A/C	cg21644426	chr2:191273491	MFSD6	0.48	6.31	0.36	1.17e-9	Pulse pressure;
CESC	cis	rs4689388	0.890	rs9993624	chr4:6286528	C/T	cg14416269	chr4:6271139	WFS1	0.46	7.66	0.43	3.53e-13	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs614226	0.872	rs787827	chr12:120937794	A/G	cg01236616	chr12:121019343	POP5	1.55	19.98	0.78	8.29e-55	Type 1 diabetes nephropathy;
CESC	cis	rs10465746	0.780	rs11163867	chr1:84384847	C/T	cg10977910	chr1:84465055	TTLL7	0.51	6.87	0.39	4.59e-11	Obesity-related traits;
CESC	cis	rs7605827	0.866	rs6717492	chr2:15538171	A/G	cg19274914	chr2:15703543	NA	0.36	6.55	0.37	2.91e-10	Educational attainment (years of education);
CESC	cis	rs854765	0.663	rs1052299	chr17:17750419	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.51	-7.12	-0.4	9.92e-12	Total body bone mineral density;
CESC	cis	rs7520050	0.902	rs9429088	chr1:46497500	T/A	cg03146154	chr1:46216737	IPP	-0.47	-6.19	-0.36	2.27e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs11577318	0.853	rs2276712	chr1:26627478	T/C	cg00852783	chr1:26633632	UBXN11	0.51	6.99	0.39	2.2e-11	Granulocyte percentage of myeloid white cells;
CESC	cis	rs873946	0.586	rs61862838	chr10:134572282	C/T	cg27297192	chr10:134578999	INPP5A	0.39	5.03	0.3	9.01e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg14521523	chr1:115212675	DENND2C	-0.44	-6.54	-0.37	3.19e-10	Fibrinogen levels;
CESC	cis	rs1577917	1.000	rs11758849	chr6:86708262	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.44	-5.8	-0.34	1.87e-8	Response to antipsychotic treatment;
CESC	cis	rs1008375	1.000	rs4698198	chr4:17656536	G/A	cg02297831	chr4:17616191	MED28	0.53	6.7	0.38	1.24e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.65	0.38	1.71e-10	Prudent dietary pattern;
CESC	cis	rs2243480	1.000	rs1796220	chr7:66062100	C/T	cg13147721	chr7:65941812	NA	-0.93	-8.74	-0.47	2.72e-16	Diabetic kidney disease;
CESC	cis	rs1707322	1.000	rs1707303	chr1:46598273	A/C	cg03146154	chr1:46216737	IPP	-0.7	-8.81	-0.48	1.64e-16	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7683537	0.673	rs1401363	chr4:185643862	A/G	cg04058563	chr4:185651563	MLF1IP	0.65	7.16	0.4	8e-12	Systemic lupus erythematosus;
CESC	cis	rs12893668	0.543	rs1799796	chr14:104165927	T/C	cg24130564	chr14:104152367	KLC1	-0.49	-6.47	-0.37	4.74e-10	Reticulocyte count;
CESC	cis	rs11098499	0.779	rs80242894	chr4:120375752	G/A	cg09307838	chr4:120376055	NA	0.95	13.78	0.65	6.32e-33	Corneal astigmatism;
CESC	cis	rs6502050	0.835	rs56232956	chr17:80078929	C/T	cg23985595	chr17:80112537	CCDC57	0.42	6.57	0.37	2.6200000000000003e-10	Life satisfaction;
CESC	cis	rs5750830	0.546	rs4821891	chr22:39785381	C/T	cg01416388	chr22:39784598	NA	-0.59	-7.58	-0.42	5.96e-13	Intelligence (multi-trait analysis);
CESC	cis	rs172166	0.611	rs203882	chr6:28078502	G/A	cg22143856	chr6:28129313	ZNF389	0.38	5.38	0.31	1.6e-7	Cardiac Troponin-T levels;
CESC	cis	rs780096	0.505	rs12475426	chr2:27599132	G/A	cg02592271	chr2:27665507	KRTCAP3	-0.28	-5.62	-0.33	4.89e-8	Total body bone mineral density;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg20134190	chr8:99129593	POP1;HRSP12	-0.54	-7.91	-0.44	6.9e-14	Gambling;
CESC	cis	rs796364	0.806	rs11684895	chr2:201009026	C/T	cg23649088	chr2:200775458	C2orf69	-0.55	-5.04	-0.3	8.69e-7	Schizophrenia;
CESC	cis	rs7872515	0.536	rs7864340	chr9:94777390	T/C	cg01248375	chr9:94877805	SPTLC1	0.61	5.4	0.31	1.48e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs1797885	0.816	rs2596829	chr3:12563639	T/C	cg26432171	chr3:12704882	RAF1	-0.48	-6.12	-0.35	3.35e-9	Immature fraction of reticulocytes;
CESC	cis	rs7552404	1.000	rs11163924	chr1:76132070	A/C	cg22875332	chr1:76189707	ACADM	-0.64	-7.42	-0.41	1.63e-12	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs72781680	1.000	rs72796358	chr2:24160132	T/A	cg08917208	chr2:24149416	ATAD2B	0.94	8.52	0.46	1.26e-15	Lymphocyte counts;
CESC	cis	rs7561273	0.586	rs12477718	chr2:24330539	A/G	cg20701182	chr2:24300061	SF3B14	0.51	6.52	0.37	3.55e-10	Quantitative traits;
CESC	cis	rs6940638	0.688	rs9393790	chr6:27114052	A/C	cg12292205	chr6:26970375	C6orf41	0.39	5.1	0.3	6.49e-7	Intelligence (multi-trait analysis);
CESC	trans	rs61931739	0.500	rs10844829	chr12:34304916	G/T	cg26384229	chr12:38710491	ALG10B	0.62	8.77	0.47	2.23e-16	Morning vs. evening chronotype;
CESC	cis	rs763121	0.819	rs4560233	chr22:38982442	A/T	cg21395723	chr22:39101663	GTPBP1	0.41	5.14	0.3	5.47e-7	Menopause (age at onset);
CESC	cis	rs853679	0.882	rs4713139	chr6:28092685	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.72	-6.44	-0.37	5.75e-10	Depression;
CESC	cis	rs6540559	0.546	rs7551944	chr1:210029430	G/C	cg21951975	chr1:209979733	IRF6	0.58	6.15	0.35	2.77e-9	Cleft lip with or without cleft palate;
CESC	cis	rs2354432	0.714	rs7531962	chr1:146746023	G/A	cg25205988	chr1:146714368	CHD1L	-1.03	-11.99	-0.59	9.69e-27	Mitochondrial DNA levels;
CESC	cis	rs1559088	0.847	rs3760891	chr19:33599708	C/T	cg17764715	chr19:33622953	WDR88	0.48	6.2	0.36	2.2e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs8072100	0.935	rs78737171	chr17:45668760	A/T	cg08085267	chr17:45401833	C17orf57	0.4	5.15	0.3	5.18e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs67072384	0.748	rs6592484	chr11:72464470	C/T	cg04827223	chr11:72435913	ARAP1	-0.7	-7.1	-0.4	1.16e-11	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
CESC	cis	rs708547	1.000	rs708547	chr4:57821309	T/C	cg16868167	chr4:57843880	C4orf14;POLR2B	0.7	7.59	0.42	5.56e-13	Response to bleomycin (chromatid breaks);
CESC	cis	rs9902453	1.000	rs8065261	chr17:28418041	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.63	-7.93	-0.44	6.25e-14	Coffee consumption (cups per day);
CESC	trans	rs853679	0.546	rs35016036	chr6:28314880	C/T	cg01620082	chr3:125678407	NA	-0.76	-6.21	-0.36	2.08e-9	Depression;
CESC	cis	rs2760061	0.819	rs708111	chr1:228191365	G/A	cg18477163	chr1:228402036	OBSCN	0.31	5.5	0.32	9.1e-8	Diastolic blood pressure;
CESC	cis	rs9910055	0.659	rs3826412	chr17:42255097	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.47	6.83	0.39	5.85e-11	Total body bone mineral density;
CESC	cis	rs4803468	1.000	rs284654	chr19:41928724	G/A	cg09537434	chr19:41945824	ATP5SL	-1.09	-20.16	-0.78	2.05e-55	Height;
CESC	cis	rs801193	0.569	rs881285	chr7:66119420	A/G	cg11764359	chr7:65958608	NA	-0.73	-10.44	-0.54	1.38e-21	Aortic root size;
CESC	cis	rs4253772	0.637	rs11703173	chr22:46660367	G/A	cg24881330	chr22:46731750	TRMU	0.75	6.45	0.37	5.18e-10	LDL cholesterol;Cholesterol, total;
CESC	cis	rs6060717	0.654	rs6058347	chr20:34483781	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.66	6.73	0.38	1.06e-10	Hip circumference adjusted for BMI;
CESC	cis	rs17376456	0.825	rs10072232	chr5:93398890	G/A	cg25358565	chr5:93447407	FAM172A	1.11	10.75	0.55	1.35e-22	Diabetic retinopathy;
CESC	cis	rs9660992	0.674	rs17345816	chr1:205262868	A/T	cg00857998	chr1:205179979	DSTYK	-0.47	-5.3	-0.31	2.42e-7	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs7726839	0.540	rs11739847	chr5:609661	G/A	cg16447950	chr5:562315	NA	-0.58	-5.93	-0.34	9.42e-9	Obesity-related traits;
CESC	cis	rs2066819	1.000	rs76151170	chr12:56659320	C/T	cg26734620	chr12:56694298	CS	1.03	6.76	0.38	8.6e-11	Psoriasis vulgaris;
CESC	cis	rs11168351	1.000	rs11168351	chr12:48403765	C/T	cg24011408	chr12:48396354	COL2A1	0.51	8.0	0.44	4e-14	Bipolar disorder and schizophrenia;
CESC	cis	rs2075371	0.966	rs2544214	chr7:133985736	G/A	cg11752832	chr7:134001865	SLC35B4	0.55	7.23	0.41	5.27e-12	Mean platelet volume;
CESC	cis	rs3008870	1.000	rs2985825	chr1:67412822	T/G	cg02640540	chr1:67518911	SLC35D1	0.52	5.59	0.33	5.5e-8	Lymphocyte percentage of white cells;
CESC	cis	rs13191362	1.000	rs13193282	chr6:163015442	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.87	9.04	0.49	3.35e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs763121	0.925	rs4821797	chr22:39016182	T/C	cg06022373	chr22:39101656	GTPBP1	0.89	15.01	0.68	2.93e-37	Menopause (age at onset);
CESC	cis	rs769267	0.566	rs7249692	chr19:19670688	T/C	cg03709012	chr19:19516395	GATAD2A	-0.68	-8.39	-0.46	2.84e-15	Tonsillectomy;
CESC	trans	rs3780486	0.846	rs10971420	chr9:33125000	T/C	cg20290983	chr6:43655470	MRPS18A	0.99	18.4	0.75	2.85e-49	IgG glycosylation;
CESC	cis	rs225245	0.791	rs6505492	chr17:34026597	C/T	cg05299278	chr17:33885742	SLFN14	0.39	5.66	0.33	3.97e-8	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
CESC	cis	rs6500395	1.000	rs11649236	chr16:48632478	C/T	cg04672837	chr16:48644449	N4BP1	0.52	6.51	0.37	3.7e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs6089829	0.962	rs6122352	chr20:61668284	T/C	cg16240275	chr20:61666158	NCRNA00029	0.5	8.91	0.48	8.46e-17	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs2243480	1.000	rs1553174	chr7:65731194	T/C	cg13147721	chr7:65941812	NA	0.98	9.24	0.49	8.25e-18	Diabetic kidney disease;
CESC	cis	rs12477438	0.501	rs34272114	chr2:99737443	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.8	12.74	0.62	2.5e-29	Chronic sinus infection;
CESC	cis	rs728616	0.614	rs61859196	chr10:82109048	A/G	cg05935833	chr10:81318306	SFTPA2	-0.47	-5.91	-0.34	1.06e-8	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs2050392	0.965	rs2480279	chr10:30700032	C/T	cg18806716	chr10:30721971	MAP3K8	-0.43	-6.22	-0.36	1.89e-9	Inflammatory bowel disease;
CESC	cis	rs861020	1.000	rs642961	chr1:209989270	A/G	cg05527609	chr1:210001259	C1orf107	1.0	12.54	0.61	1.2e-28	Orofacial clefts;
CESC	cis	rs9611565	0.659	rs9607813	chr22:41941479	G/A	cg03806693	chr22:41940476	POLR3H	-1.24	-16.78	-0.72	1.44e-43	Vitiligo;
CESC	cis	rs28374715	0.578	rs13313520	chr15:41629127	T/G	cg20272979	chr15:41787780	ITPKA	0.47	5.6	0.33	5.38e-8	Ulcerative colitis;
CESC	cis	rs4665809	0.590	rs4665837	chr2:26434022	C/A	cg22920501	chr2:26401640	FAM59B	-0.9	-10.21	-0.53	7.46e-21	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01600100	chr12:96794307	CDK17	0.58	6.2	0.36	2.21e-9	Gut microbiome composition (summer);
CESC	cis	rs7312774	0.618	rs35435903	chr12:107346572	G/C	cg16260113	chr12:107380972	MTERFD3	0.82	7.48	0.42	1.11e-12	Severe influenza A (H1N1) infection;
CESC	trans	rs7980799	0.649	rs11052736	chr12:33669583	T/C	cg26384229	chr12:38710491	ALG10B	0.58	8.14	0.45	1.5e-14	Heart rate;Heart rate variability traits (RMSSD);
CESC	cis	rs2573652	0.722	rs968412	chr15:100544512	C/G	cg09918751	chr15:100517450	ADAMTS17	-0.31	-5.74	-0.33	2.6e-8	Height;
CESC	cis	rs4253772	0.637	rs3087501	chr22:46647909	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.66	7.77	0.43	1.74e-13	LDL cholesterol;Cholesterol, total;
CESC	cis	rs17601876	0.814	rs749292	chr15:51558731	A/G	cg19946085	chr15:51559439	CYP19A1	0.34	5.41	0.32	1.41e-7	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
CESC	cis	rs8177179	0.967	rs4994581	chr3:133437563	T/C	cg24879335	chr3:133465180	TF	0.41	7.51	0.42	8.82e-13	Iron status biomarkers (transferrin levels);
CESC	cis	rs910316	0.763	rs175047	chr14:75479039	C/G	cg16144293	chr14:75469539	EIF2B2	0.4	5.36	0.31	1.77e-7	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04953292	chr16:66835552	CCDC79	-0.61	-6.75	-0.38	9.41e-11	Gut microbiome composition (summer);
CESC	cis	rs2688608	0.592	rs2306328	chr10:75579510	C/T	cg23231163	chr10:75533350	FUT11	-0.33	-5.04	-0.3	8.53e-7	Inflammatory bowel disease;
CESC	cis	rs13091206	1	rs13091206	chr3:49238718	A/G	cg06212747	chr3:49208901	KLHDC8B	0.49	5.08	0.3	7.17e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs3858526	0.839	rs10466484	chr11:5943696	A/G	cg05234568	chr11:5960015	NA	-0.62	-7.34	-0.41	2.56e-12	DNA methylation (variation);
CESC	cis	rs9300255	0.568	rs1621194	chr12:123651018	T/C	cg05973401	chr12:123451056	ABCB9	0.5	5.81	0.34	1.79e-8	Neutrophil percentage of white cells;
CESC	cis	rs523522	0.962	rs12371550	chr12:120987643	C/T	cg12219531	chr12:120966889	COQ5	0.75	9.9	0.52	7e-20	High light scatter reticulocyte count;
CESC	cis	rs1552244	1.000	rs6804473	chr3:10060425	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-10.79	-0.55	9.74e-23	Alzheimer's disease;
CESC	cis	rs66530629	0.874	rs9332415	chr1:25098245	T/C	cg22509179	chr1:25234806	RUNX3	-0.44	-5.64	-0.33	4.27e-8	Plateletcrit;
CESC	cis	rs9487051	0.676	rs6928622	chr6:109595112	C/T	cg12927641	chr6:109611667	NA	-0.37	-5.56	-0.32	6.46e-8	Reticulocyte fraction of red cells;
CESC	cis	rs1927790	0.727	rs7320065	chr13:96937738	C/G	cg02571835	chr13:96230311	CLDN10	-0.39	-5.58	-0.32	5.79e-8	Body mass index;
CESC	cis	rs1707322	1.000	rs1622208	chr1:46498375	A/G	cg05343316	chr1:45956843	TESK2	-0.5	-6.05	-0.35	4.86e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs6952808	0.929	rs34145223	chr7:1926237	G/A	cg02951883	chr7:2050386	MAD1L1	-0.51	-6.79	-0.39	7.2e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs1559088	0.649	rs4528686	chr19:33556074	A/G	cg27124370	chr19:33622961	WDR88	0.43	5.5	0.32	8.75e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs1018836	0.608	rs1033347	chr8:91464137	G/A	cg16814680	chr8:91681699	NA	-0.51	-6.98	-0.39	2.42e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs17376456	1.000	rs58734583	chr5:93532155	C/T	cg25358565	chr5:93447407	FAM172A	1.18	11.77	0.59	5.27e-26	Diabetic retinopathy;
CESC	cis	rs514406	0.607	rs6696940	chr1:53203427	C/T	cg24675658	chr1:53192096	ZYG11B	0.6	7.55	0.42	7.13e-13	Monocyte count;
CESC	cis	rs34779708	0.931	rs4934693	chr10:35271844	G/A	cg03585969	chr10:35415529	CREM	0.77	10.13	0.53	1.39e-20	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs769267	0.930	rs4808208	chr19:19650096	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.48	6.13	0.35	3.14e-9	Tonsillectomy;
CESC	cis	rs9513627	1.000	rs9517755	chr13:100168408	C/A	cg25919922	chr13:100150906	NA	0.64	5.07	0.3	7.61e-7	Obesity-related traits;
CESC	cis	rs9811920	0.609	rs793447	chr3:99598278	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.59	7.22	0.41	5.61e-12	Axial length;
CESC	cis	rs9467711	0.516	rs1324088	chr6:25841122	C/T	cg21479132	chr6:26055353	NA	0.59	6.41	0.37	6.79e-10	Autism spectrum disorder or schizophrenia;
CESC	trans	rs1814175	0.817	rs28594987	chr11:50045181	C/T	cg03929089	chr4:120376271	NA	-0.94	-15.73	-0.69	7.69e-40	Height;
CESC	cis	rs12926788	0.640	rs12924246	chr16:24844629	A/G	cg00339695	chr16:24857497	SLC5A11	0.51	6.68	0.38	1.36e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	trans	rs637571	0.726	rs669371	chr11:65674153	G/T	cg17712092	chr4:129076599	LARP1B	-0.8	-10.62	-0.55	3.62e-22	Eosinophil percentage of white cells;
CESC	cis	rs12497850	0.863	rs4974084	chr3:48939080	G/A	cg06212747	chr3:49208901	KLHDC8B	0.7	9.47	0.5	1.64e-18	Parkinson's disease;
CESC	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg24846343	chr22:24311635	DDTL	-0.52	-8.36	-0.46	3.5e-15	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs17039065	0.920	rs11932814	chr4:109461558	G/A	cg16022748	chr4:109541635	LOC285456;RPL34	0.65	5.96	0.34	8.08e-9	Gut microbiome composition (summer);
CESC	cis	rs10504229	0.683	rs7820302	chr8:58142502	C/T	cg02725872	chr8:58115012	NA	-0.42	-6.73	-0.38	1.05e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs514406	0.929	rs1672909	chr1:53340824	A/G	cg25767906	chr1:53392781	SCP2	-0.46	-5.82	-0.34	1.66e-8	Monocyte count;
CESC	cis	rs9911578	1.000	rs8076121	chr17:57041699	G/A	cg12560992	chr17:57184187	TRIM37	0.92	15.24	0.68	4.34e-38	Intelligence (multi-trait analysis);
CESC	cis	rs4889855	0.505	rs6565467	chr17:78610113	A/G	cg16591659	chr17:78472290	NA	-0.32	-5.17	-0.3	4.53e-7	Fractional excretion of uric acid;
CESC	cis	rs12410462	0.792	rs994666	chr1:227651454	C/T	cg04117972	chr1:227635322	NA	-0.6	-5.94	-0.34	9.13e-9	Major depressive disorder;
CESC	cis	rs896854	0.818	rs13262110	chr8:95926890	C/T	cg13393036	chr8:95962371	TP53INP1	-0.5	-10.81	-0.55	8.28e-23	Type 2 diabetes;
CESC	cis	rs921968	0.565	rs1554622	chr2:219606218	T/G	cg02176678	chr2:219576539	TTLL4	-0.46	-8.13	-0.45	1.7e-14	Mean corpuscular hemoglobin concentration;
CESC	cis	rs2425143	1.000	rs11699793	chr20:34271574	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.82	-7.36	-0.41	2.28e-12	Blood protein levels;
CESC	cis	rs213032	1.000	rs213032	chr1:21654735	T/C	cg16416158	chr1:21652298	ECE1	0.33	5.37	0.31	1.71e-7	Obesity-related traits;
CESC	cis	rs225245	0.755	rs6505491	chr17:34026335	A/G	cg05299278	chr17:33885742	SLFN14	0.39	5.51	0.32	8.5e-8	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
CESC	cis	rs7553864	0.636	rs7543740	chr1:87609026	C/T	cg17420885	chr1:87600446	LOC339524	-0.46	-6.28	-0.36	1.36e-9	Smoking behavior;
CESC	cis	rs3125734	0.633	rs4979772	chr10:63967600	C/T	cg09941381	chr10:64027924	RTKN2	0.31	5.09	0.3	6.86e-7	Rheumatoid arthritis;
CESC	cis	rs1862618	0.671	rs2034244	chr5:56242774	T/C	cg12311346	chr5:56204834	C5orf35	0.64	8.57	0.47	8.86e-16	Initial pursuit acceleration;
CESC	cis	rs6952808	0.723	rs11766575	chr7:2005747	T/C	cg05863683	chr7:1912471	MAD1L1	0.41	5.95	0.34	8.26e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs6088590	0.707	rs67159833	chr20:33488079	T/C	cg06115741	chr20:33292138	TP53INP2	0.62	7.21	0.4	5.94e-12	Coronary artery disease;
CESC	cis	rs11112613	0.762	rs66754070	chr12:105949779	G/A	cg03607813	chr12:105948248	NA	0.68	8.35	0.46	3.94e-15	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CESC	cis	rs722599	0.847	rs2058919	chr14:75310812	C/G	cg11812906	chr14:75593930	NEK9	-0.4	-5.26	-0.31	2.97e-7	IgG glycosylation;
CESC	cis	rs13191362	1.000	rs13200329	chr6:163004418	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.49	5.36	0.31	1.78e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs17253792	0.822	rs112238223	chr14:56056144	C/A	cg01858014	chr14:56050164	KTN1	-0.96	-7.13	-0.4	9.72e-12	Putamen volume;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg11502736	chr1:179923845	CEP350	0.47	6.47	0.37	4.73e-10	Systemic lupus erythematosus;
CESC	cis	rs1862618	0.853	rs33322	chr5:56175226	A/G	cg18230493	chr5:56204884	C5orf35	-0.74	-8.65	-0.47	4.87e-16	Initial pursuit acceleration;
CESC	cis	rs9287719	0.556	rs10168351	chr2:10736810	T/C	cg00105475	chr2:10696890	NA	0.38	5.17	0.3	4.51e-7	Prostate cancer;
CESC	cis	rs151234	0.741	rs56236750	chr16:28594711	C/T	cg01378222	chr16:28622494	SULT1A1	-0.55	-6.74	-0.38	9.63e-11	Platelet distribution width;
CESC	cis	rs7927771	0.864	rs10838724	chr11:47527052	G/T	cg18512352	chr11:47633146	NA	-0.57	-8.73	-0.47	2.92e-16	Subjective well-being;
CESC	trans	rs6818288	0.778	rs7663721	chr4:30076944	T/A	cg12528397	chr3:62933670	NA	0.42	6.13	0.35	3.2e-9	Obesity-related traits;
CESC	cis	rs853679	0.550	rs1233704	chr6:28166923	A/G	cg12963246	chr6:28129442	ZNF389	-0.5	-6.93	-0.39	3.17e-11	Depression;
CESC	cis	rs10887741	0.646	rs12413510	chr10:89436979	T/C	cg13926569	chr10:89418898	PAPSS2	0.47	7.15	0.4	8.25e-12	Exercise (leisure time);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg12010544	chr10:135102440	TUBGCP2	-0.47	-6.08	-0.35	4.13e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs7044106	0.791	rs10760116	chr9:123494681	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.34	5.52	0.32	8.07e-8	Hip circumference adjusted for BMI;
CESC	cis	rs5997397	0.934	rs6005863	chr22:29156448	A/G	cg15103426	chr22:29168792	CCDC117	0.49	6.33	0.36	1.05e-9	Red cell distribution width;
CESC	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg07092213	chr7:1199455	ZFAND2A	-0.43	-5.68	-0.33	3.45e-8	Longevity;Endometriosis;
CESC	cis	rs67478160	0.643	rs7156697	chr14:104211136	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.49	-6.87	-0.39	4.47e-11	Schizophrenia;
CESC	cis	rs7927592	0.913	rs7116994	chr11:68254627	C/T	cg20283391	chr11:68216788	NA	-0.52	-6.36	-0.36	8.87e-10	Total body bone mineral density;
CESC	cis	rs3767633	0.858	rs6698065	chr1:161891528	G/A	cg09175582	chr1:161736000	ATF6	0.78	6.6	0.38	2.25e-10	IgG glycosylation;
CESC	cis	rs7818345	0.904	rs6997164	chr8:19287856	G/T	cg11303988	chr8:19266685	CSGALNACT1	0.38	6.73	0.38	1.04e-10	Language performance in older adults (adjusted for episodic memory);
CESC	cis	rs7949030	0.588	rs2509982	chr11:62312318	C/T	cg13298116	chr11:62369859	EML3;MTA2	0.58	8.58	0.47	8.21e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs9393777	0.623	rs7756567	chr6:26481642	T/G	cg14345882	chr6:26364793	BTN3A2	0.43	5.34	0.31	2.01e-7	Intelligence (multi-trait analysis);
CESC	cis	rs870825	0.616	rs7682557	chr4:185640773	A/G	cg04058563	chr4:185651563	MLF1IP	0.64	7.1	0.4	1.15e-11	Blood protein levels;
CESC	cis	rs7520050	0.966	rs6662641	chr1:46571509	T/A	cg03146154	chr1:46216737	IPP	-0.43	-5.52	-0.32	8.27e-8	Red blood cell count;Reticulocyte count;
CESC	trans	rs7726839	0.540	rs28364691	chr5:664084	G/A	cg25482853	chr8:67687455	SGK3	0.97	9.73	0.51	2.43e-19	Obesity-related traits;
CESC	cis	rs7666738	0.830	rs11944855	chr4:99068258	G/A	cg17366294	chr4:99064904	C4orf37	0.61	8.5	0.46	1.41e-15	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18560442	chr1:39174410	NA	-0.63	-7.26	-0.41	4.27e-12	Gut microbiome composition (summer);
CESC	cis	rs2806561	0.704	rs674386	chr1:23521835	G/A	cg12483005	chr1:23474871	LUZP1	0.43	6.55	0.37	2.93e-10	Height;
CESC	cis	rs7680126	0.609	rs11723742	chr4:10111572	A/G	cg00071950	chr4:10020882	SLC2A9	-0.61	-7.39	-0.41	1.98e-12	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	cis	rs654950	0.807	rs61773660	chr1:41993298	C/T	cg06885757	chr1:42089581	HIVEP3	-0.46	-7.18	-0.4	6.91e-12	Airway imaging phenotypes;
CESC	cis	rs3820068	0.603	rs7537618	chr1:15977682	G/A	cg18133145	chr1:16060689	PLEKHM2	-0.4	-5.09	-0.3	6.65e-7	Systolic blood pressure;
CESC	cis	rs1707322	0.691	rs11211175	chr1:46220884	C/G	cg05343316	chr1:45956843	TESK2	0.48	6.1	0.35	3.82e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7937682	0.889	rs12360825	chr11:111528786	A/T	cg22437258	chr11:111473054	SIK2	0.69	9.26	0.49	7.48e-18	Primary sclerosing cholangitis;
CESC	cis	rs34779708	0.966	rs12774834	chr10:35400070	A/T	cg03585969	chr10:35415529	CREM	0.77	10.1	0.53	1.71e-20	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs4862750	0.832	rs6836426	chr4:187897837	T/G	cg10295955	chr4:187884368	NA	-1.07	-19.89	-0.77	1.66e-54	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs3096299	0.754	rs2965816	chr16:89514183	G/T	cg00750074	chr16:89608354	SPG7	0.44	6.43	0.37	5.77e-10	Multiple myeloma (IgH translocation);
CESC	cis	rs9905704	0.918	rs35934668	chr17:56894638	A/G	cg12560992	chr17:57184187	TRIM37	0.61	7.14	0.4	9.17e-12	Testicular germ cell tumor;
CESC	cis	rs1799949	1.000	rs11653231	chr17:41331460	G/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.41	5.57	0.32	6.16e-8	Menopause (age at onset);
CESC	cis	rs7208859	0.623	rs11650982	chr17:29129955	A/G	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.79e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs1790761	0.587	rs4930431	chr11:67294308	C/T	cg00290607	chr11:67383545	NA	-0.42	-6.3	-0.36	1.24e-9	Mean corpuscular volume;
CESC	cis	rs853679	0.517	rs9380060	chr6:28132603	G/A	cg23281280	chr6:28129359	ZNF389	0.59	7.9	0.44	7.47e-14	Depression;
CESC	cis	rs7927771	0.524	rs7101597	chr11:47797917	A/T	cg18512352	chr11:47633146	NA	0.34	5.24	0.31	3.35e-7	Subjective well-being;
CESC	cis	rs4930103	0.935	rs11042170	chr11:2021625	C/T	cg23202291	chr11:1979235	NA	0.36	5.11	0.3	6.11e-7	DNA methylation (parent-of-origin);DNA methylation (variation);
CESC	cis	rs3733585	0.699	rs10017674	chr4:9967053	T/C	cg11266682	chr4:10021025	SLC2A9	-0.58	-10.94	-0.56	3.03e-23	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs992157	0.710	rs12694432	chr2:219082330	A/G	cg20019365	chr2:219134978	PNKD;AAMP	0.68	9.61	0.51	5.92e-19	Colorectal cancer;
CESC	cis	rs1862618	0.853	rs6885541	chr5:56110857	G/C	cg18230493	chr5:56204884	C5orf35	-0.7	-8.28	-0.45	6.03e-15	Initial pursuit acceleration;
CESC	cis	rs12042938	0.507	rs2570408	chr1:231732934	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.58	-8.5	-0.46	1.43e-15	Neuranatomic and neurocognitive phenotypes;
CESC	cis	rs875971	0.862	rs7809814	chr7:65615397	G/A	cg12463550	chr7:65579703	CRCP	-0.5	-6.42	-0.37	6.3e-10	Aortic root size;
CESC	cis	rs9443189	1.000	rs9443189	chr6:76495882	A/G	cg01950844	chr6:76311363	SENP6	0.63	6.38	0.37	7.69e-10	Prostate cancer;
CESC	cis	rs561341	0.941	rs17780080	chr17:30343146	G/A	cg23018236	chr17:30244563	NA	-0.54	-5.08	-0.3	7.28e-7	Hip circumference adjusted for BMI;
CESC	cis	rs6963495	0.818	rs73190133	chr7:105147821	G/C	cg19920283	chr7:105172520	RINT1	0.66	6.28	0.36	1.36e-9	Bipolar disorder (body mass index interaction);
CESC	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg14926445	chr8:58193284	C8orf71	-0.53	-5.2	-0.3	3.9e-7	Developmental language disorder (linguistic errors);
CESC	trans	rs916888	0.610	rs199454	chr17:44800110	G/A	cg10053473	chr17:62856997	LRRC37A3	0.65	8.79	0.48	1.9e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs2522056	1.000	rs6874639	chr5:131778716	C/T	cg24060327	chr5:131705240	SLC22A5	-0.65	-7.93	-0.44	6.05e-14	Lymphocyte counts;Fibrinogen;
CESC	cis	rs950776	0.518	rs12591557	chr15:78811732	A/G	cg06917634	chr15:78832804	PSMA4	0.78	11.39	0.57	9.64e-25	Sudden cardiac arrest;
CESC	cis	rs10493773	0.775	rs6667672	chr1:86171072	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.43	-5.78	-0.33	2.06e-8	Urate levels in overweight individuals;
CESC	cis	rs7666738	0.830	rs35491210	chr4:99003364	T/C	cg18180107	chr4:99064573	C4orf37	0.4	5.18	0.3	4.42e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs7726839	0.574	rs72705017	chr5:623733	G/A	cg25482853	chr8:67687455	SGK3	1.02	10.05	0.53	2.35e-20	Obesity-related traits;
CESC	cis	rs7223966	1.000	rs9747164	chr17:61864787	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.45	-5.09	-0.3	6.66e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs9649213	0.593	rs10953257	chr7:97960664	A/G	cg21770322	chr7:97807741	LMTK2	-0.54	-8.22	-0.45	8.89e-15	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg14159672	chr1:205819179	PM20D1	0.77	11.58	0.58	2.27e-25	Menarche (age at onset);
CESC	cis	rs7927592	0.956	rs10896337	chr11:68284236	T/C	cg16797656	chr11:68205561	LRP5	0.38	5.3	0.31	2.48e-7	Total body bone mineral density;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13513270	chr19:48867481	TMEM143;SYNGR4	0.51	6.05	0.35	4.85e-9	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09419297	chr15:77712428	HMG20A	-0.62	-7.15	-0.4	8.39e-12	Gut microbiome composition (summer);
CESC	cis	rs7000551	0.751	rs2461481	chr8:22382780	A/G	cg12081754	chr8:22256438	SLC39A14	-0.43	-5.85	-0.34	1.48e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CESC	cis	rs477895	0.629	rs7130030	chr11:63933733	T/G	cg18225595	chr11:63971243	STIP1	0.53	5.23	0.31	3.51e-7	Mean platelet volume;
CESC	cis	rs1862618	0.641	rs252893	chr5:56224714	T/C	cg20203395	chr5:56204925	C5orf35	-0.39	-5.25	-0.31	3.07e-7	Initial pursuit acceleration;
CESC	cis	rs910316	0.591	rs7157158	chr14:75457238	A/G	cg11812906	chr14:75593930	NEK9	0.78	12.23	0.6	1.38e-27	Height;
CESC	cis	rs9512730	0.553	rs6491212	chr13:28049631	T/C	cg08193333	chr13:27998609	GTF3A	0.47	5.83	0.34	1.58e-8	Schizophrenia;
CESC	cis	rs6570726	0.818	rs437147	chr6:145875423	A/T	cg23711669	chr6:146136114	FBXO30	1.03	15.86	0.7	2.71e-40	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9915657	0.840	rs10512582	chr17:70139393	A/C	cg09344028	chr17:70110421	NA	0.34	6.15	0.35	2.81e-9	Thyroid hormone levels;
CESC	cis	rs769267	0.965	rs1469712	chr19:19528821	C/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.49	6.19	0.36	2.33e-9	Tonsillectomy;
CESC	cis	rs10504229	0.953	rs67677367	chr8:58175264	T/G	cg05313129	chr8:58192883	C8orf71	-0.55	-6.37	-0.36	8.42e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs9611565	0.649	rs9623450	chr22:42175231	G/A	cg03806693	chr22:41940476	POLR3H	0.79	9.47	0.5	1.59e-18	Vitiligo;
CESC	cis	rs1008375	1.000	rs10805358	chr4:17652450	A/C	cg02297831	chr4:17616191	MED28	0.53	6.7	0.38	1.26e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs7264396	0.635	rs6060685	chr20:34512023	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.58	7.06	0.4	1.44e-11	Total cholesterol levels;
CESC	cis	rs7937682	0.824	rs11213962	chr11:111506027	G/A	cg22437258	chr11:111473054	SIK2	0.7	9.35	0.5	3.83e-18	Primary sclerosing cholangitis;
CESC	trans	rs801193	1.000	rs11773829	chr7:66141074	G/A	cg26939375	chr7:64535504	NA	-0.65	-8.74	-0.47	2.7e-16	Aortic root size;
CESC	cis	rs919433	0.783	rs2565155	chr2:198236425	A/G	cg03934865	chr2:198174659	NA	0.43	6.21	0.36	2.01e-9	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs11098499	0.954	rs17046116	chr4:120387259	G/A	cg09307838	chr4:120376055	NA	0.95	13.96	0.65	1.42e-33	Corneal astigmatism;
CESC	cis	rs2985684	0.846	rs4476096	chr14:50019391	A/C	cg02151108	chr14:50098012	C14orf104	-0.38	-5.04	-0.3	8.48e-7	Carotid intima media thickness;
CESC	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg11905131	chr22:24372483	LOC391322	-0.72	-10.75	-0.55	1.34e-22	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs10504229	0.683	rs16921823	chr8:58108612	G/C	cg22535103	chr8:58192502	C8orf71	-0.77	-8.76	-0.47	2.37e-16	Developmental language disorder (linguistic errors);
CESC	cis	rs6788895	1.000	rs16862842	chr3:150484844	A/G	cg07663535	chr3:150480033	SIAH2	0.72	5.03	0.3	9.16e-7	Breast cancer;
CESC	cis	rs863345	0.935	rs10797026	chr1:158519710	T/C	cg12129480	chr1:158549410	OR10X1	-0.33	-6.56	-0.37	2.84e-10	Pneumococcal bacteremia;
CESC	cis	rs9611565	0.659	rs73178632	chr22:41934573	C/T	cg06481639	chr22:41940642	POLR3H	-0.62	-6.41	-0.37	6.55e-10	Vitiligo;
CESC	cis	rs7666738	0.830	rs3907020	chr4:99038583	T/C	cg18180107	chr4:99064573	C4orf37	0.4	5.2	0.3	4.08e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7811142	0.830	rs11761426	chr7:99956893	A/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.87	8.33	0.46	4.25e-15	Platelet count;
CESC	cis	rs4862750	0.872	rs6830426	chr4:187897270	T/A	cg10295955	chr4:187884368	NA	-1.08	-22.82	-0.81	1.67e-64	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7580658	0.963	rs62157555	chr2:128107176	C/T	cg10021288	chr2:128175891	PROC	-0.41	-6.47	-0.37	4.67e-10	Protein C levels;
CESC	cis	rs3091242	0.900	rs4649086	chr1:25778967	T/A	cg12412775	chr1:25698385	RHCE	-0.28	-5.08	-0.3	7.05e-7	Erythrocyte sedimentation rate;
CESC	cis	rs9309473	0.583	rs6546822	chr2:73575098	G/A	cg20560298	chr2:73613845	ALMS1	-0.46	-6.43	-0.37	5.79e-10	Metabolite levels;
CESC	cis	rs60515486	0.527	rs2254240	chr11:47357170	G/A	cg25783544	chr11:47291846	MADD	0.56	6.43	0.37	6.02e-10	Lymphocyte counts;
CESC	cis	rs7216064	0.911	rs6504551	chr17:65903326	T/G	cg12091567	chr17:66097778	LOC651250	-0.66	-8.4	-0.46	2.81e-15	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs11864453	0.786	rs1050362	chr16:72130815	C/A	cg01557791	chr16:72042693	DHODH	-0.51	-6.59	-0.38	2.39e-10	Fibrinogen levels;
CESC	cis	rs6120849	0.754	rs6088691	chr20:33633758	C/T	cg24642439	chr20:33292090	TP53INP2	0.68	6.77	0.38	8.46e-11	Protein C levels;
CESC	cis	rs3916	0.641	rs2393749	chr12:121131891	C/T	cg20569203	chr12:120799911	MSI1	0.31	5.17	0.3	4.54e-7	Urinary metabolites (H-NMR features);
CESC	cis	rs6456156	0.755	rs4710182	chr6:167514061	G/A	cg23791538	chr6:167370224	RNASET2	-0.4	-5.26	-0.31	2.92e-7	Primary biliary cholangitis;
CESC	cis	rs10885582	0.781	rs10885578	chr10:116303554	G/C	cg17056676	chr10:116301354	ABLIM1	-0.29	-5.31	-0.31	2.37e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs11264213	0.786	rs72659702	chr1:36317471	G/C	cg27506609	chr1:36549197	TEKT2	0.57	5.08	0.3	6.98e-7	Schizophrenia;
CESC	cis	rs7811142	1.000	rs74460138	chr7:100027339	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.11	10.96	0.56	2.75e-23	Platelet count;
CESC	cis	rs7818688	0.591	rs10098025	chr8:95989583	T/A	cg16049864	chr8:95962084	TP53INP1	0.52	5.29	0.31	2.54e-7	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs3096299	0.967	rs2965932	chr16:89477051	C/T	cg08822215	chr16:89438651	ANKRD11	0.39	6.01	0.35	6.1e-9	Multiple myeloma (IgH translocation);
CESC	cis	rs2456568	0.548	rs10765647	chr11:93662459	T/C	cg26875233	chr11:93583750	C11orf90	-0.33	-5.86	-0.34	1.37e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
CESC	cis	rs3806843	0.933	rs2879087	chr5:140188575	G/C	cg26395211	chr5:140044315	WDR55	-0.41	-5.19	-0.3	4.17e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs7927771	0.864	rs2293580	chr11:47440283	T/A	cg20307385	chr11:47447363	PSMC3	0.69	8.91	0.48	8.43e-17	Subjective well-being;
CESC	cis	rs7582720	1.000	rs76461893	chr2:203865515	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.36	0.41	2.34e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs6089584	0.706	rs6089625	chr20:60620622	T/C	cg13770153	chr20:60521292	NA	-0.43	-5.57	-0.32	6.26e-8	Body mass index;
CESC	cis	rs2842992	0.513	rs7759086	chr6:160193853	A/G	cg11366901	chr6:160182831	ACAT2	0.65	8.23	0.45	8.74e-15	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs7666738	0.830	rs10470894	chr4:99039107	G/A	cg17366294	chr4:99064904	C4orf37	0.6	8.51	0.46	1.33e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9894429	0.690	rs11869779	chr17:79570067	C/T	cg18240062	chr17:79603768	NPLOC4	-0.87	-13.0	-0.62	3.32e-30	Eye color traits;
CESC	cis	rs6460942	1.000	rs7796485	chr7:12405676	G/A	cg02935154	chr7:12443704	VWDE	-0.57	-5.8	-0.34	1.89e-8	Coronary artery disease;
CESC	cis	rs11122272	0.735	rs2739516	chr1:231505527	G/A	cg06096015	chr1:231504339	EGLN1	0.43	6.18	0.35	2.46e-9	Hemoglobin concentration;
CESC	cis	rs875971	0.522	rs1917563	chr7:65415647	C/T	cg10691866	chr7:65817282	TPST1	0.33	5.31	0.31	2.35e-7	Aortic root size;
CESC	cis	rs763121	0.853	rs1065201	chr22:39069510	T/C	cg21395723	chr22:39101663	GTPBP1	0.42	5.32	0.31	2.17e-7	Menopause (age at onset);
CESC	cis	rs6952808	0.792	rs4721184	chr7:1950784	T/C	cg05863683	chr7:1912471	MAD1L1	0.44	6.65	0.38	1.65e-10	Bipolar disorder and schizophrenia;
CESC	cis	rs10876993	0.890	rs1585781	chr12:58056701	T/G	cg18357645	chr12:58087776	OS9	0.63	10.22	0.53	7.1e-21	Celiac disease or Rheumatoid arthritis;
CESC	cis	rs344364	0.511	rs911391	chr16:1947016	C/A	cg26617929	chr16:1858877	NA	-0.49	-5.15	-0.3	5.09e-7	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs9487051	0.872	rs7773331	chr6:109609208	C/T	cg12927641	chr6:109611667	NA	-0.43	-6.7	-0.38	1.22e-10	Reticulocyte fraction of red cells;
CESC	cis	rs6964587	0.692	rs4729021	chr7:91758422	C/A	cg17063962	chr7:91808500	NA	0.42	5.9	0.34	1.13e-8	Breast cancer;
CESC	cis	rs11098499	0.863	rs12502389	chr4:120454191	A/G	cg09307838	chr4:120376055	NA	0.91	12.54	0.61	1.24e-28	Corneal astigmatism;
CESC	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg06873352	chr17:61820015	STRADA	0.73	12.96	0.62	4.25e-30	Prudent dietary pattern;
CESC	cis	rs4713118	0.662	rs149961	chr6:28015569	A/C	cg23281280	chr6:28129359	ZNF389	0.48	6.33	0.36	1.07e-9	Parkinson's disease;
CESC	cis	rs3741798	1.000	rs78028836	chr12:12485448	G/A	cg08615371	chr12:12503544	MANSC1	0.87	6.35	0.36	9.19e-10	Cerebrospinal fluid biomarker levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18550509	chr15:100273145	LYSMD4	0.62	7.38	0.41	2.09e-12	Gut microbiome composition (summer);
CESC	cis	rs1538970	0.781	rs10890330	chr1:45920406	G/A	cg24296786	chr1:45957014	TESK2	-0.46	-5.15	-0.3	5.16e-7	Platelet count;
CESC	cis	rs7918232	0.882	rs6415983	chr10:27357211	A/G	cg14442939	chr10:27389572	ANKRD26	0.59	5.47	0.32	1.03e-7	Breast cancer;
CESC	cis	rs4665809	0.627	rs1465720	chr2:26412638	G/T	cg26314531	chr2:26401878	FAM59B	-0.82	-9.0	-0.48	4.62e-17	Gut microbiome composition (summer);
CESC	cis	rs1801251	0.963	rs35362030	chr2:233612845	A/G	cg08000102	chr2:233561755	GIGYF2	0.65	9.33	0.5	4.51e-18	Coronary artery disease;
CESC	cis	rs8067354	0.507	rs72840511	chr17:57806011	G/T	cg13753209	chr17:57696993	CLTC	0.58	6.29	0.36	1.28e-9	Hemoglobin concentration;
CESC	cis	rs847851	0.617	rs73403805	chr6:34964724	C/T	cg13137465	chr6:34857473	ANKS1A	0.7	7.19	0.4	6.42e-12	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2228479	0.850	rs11641147	chr16:89813589	C/T	cg06558623	chr16:89946397	TCF25	1.19	9.55	0.51	8.99e-19	Skin colour saturation;
CESC	cis	rs798554	0.524	rs2283784	chr7:2855337	T/C	cg04166393	chr7:2884313	GNA12	0.39	5.1	0.3	6.42e-7	Height;
CESC	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.52	7.09	0.4	1.2e-11	Lymphocyte counts;
CESC	cis	rs3096299	0.967	rs28689480	chr16:89460093	T/C	cg08392591	chr16:89556376	ANKRD11	0.42	5.29	0.31	2.53e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs6690583	0.623	rs893620	chr1:85425821	T/C	cg22153463	chr1:85462885	MCOLN2	0.79	7.7	0.43	2.71e-13	Serum sulfate level;
CESC	trans	rs2727020	0.615	rs35423199	chr11:49514914	T/C	cg03929089	chr4:120376271	NA	-0.85	-13.58	-0.64	2.94e-32	Coronary artery disease;
CESC	cis	rs77216612	0.835	rs56692845	chr12:12887811	C/T	cg04607235	chr12:12878440	APOLD1	-0.99	-14.75	-0.67	2.4e-36	Lymphocyte counts;
CESC	cis	rs9899728	0.539	rs12940199	chr17:73054759	C/T	cg27626185	chr17:73056755	KCTD2	-0.95	-8.43	-0.46	2.23e-15	Alzheimer's disease or small vessel stroke;
CESC	cis	rs798554	0.679	rs2533868	chr7:2886559	G/A	cg13628971	chr7:2884303	GNA12	0.64	8.84	0.48	1.33e-16	Height;
CESC	cis	rs7399018	0.739	rs6580811	chr12:51612501	T/C	cg25754956	chr12:51612065	POU6F1	0.75	8.32	0.46	4.65e-15	Cisplatin-induced ototoxicity;
CESC	cis	rs4853012	0.941	rs60291089	chr2:74344890	T/G	cg20891558	chr2:74357851	NA	0.8	11.63	0.58	1.59e-25	Gestational age at birth (maternal effect);
CESC	trans	rs61931739	0.534	rs7965503	chr12:34199349	A/G	cg26384229	chr12:38710491	ALG10B	0.65	9.14	0.49	1.71e-17	Morning vs. evening chronotype;
CESC	cis	rs11645898	0.748	rs72787056	chr16:72099694	C/T	cg14768367	chr16:72042858	DHODH	-0.8	-6.39	-0.37	7.41e-10	Blood protein levels;
CESC	cis	rs10504229	0.545	rs56394419	chr8:58128982	T/C	cg21724239	chr8:58056113	NA	0.58	5.95	0.34	8.29e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs4253772	0.938	rs11704979	chr22:46632994	G/A	cg00784671	chr22:46762841	CELSR1	-0.57	-5.63	-0.33	4.54e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs2249625	0.844	rs2496497	chr6:72884121	T/C	cg18830697	chr6:72922368	RIMS1	-0.39	-5.5	-0.32	8.88e-8	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CESC	cis	rs9325144	0.560	rs2387923	chr12:38662677	G/A	cg26384229	chr12:38710491	ALG10B	-0.62	-9.6	-0.51	6.43e-19	Morning vs. evening chronotype;
CESC	trans	rs2764766	0.721	rs151882	chr5:127188318	G/C	cg15764593	chr10:829463	NA	-0.4	-6.19	-0.36	2.33e-9	Schizophrenia;
CESC	cis	rs698813	0.763	rs786614	chr2:44590567	C/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.49	5.83	0.34	1.58e-8	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
CESC	cis	rs2625529	0.652	rs2957361	chr15:72345218	G/A	cg16672083	chr15:72433130	SENP8	0.42	6.57	0.37	2.59e-10	Red blood cell count;
CESC	cis	rs7927771	1.000	rs7947730	chr11:47786184	C/T	cg20307385	chr11:47447363	PSMC3	-0.51	-6.23	-0.36	1.79e-9	Subjective well-being;
CESC	cis	rs13064411	0.696	rs6438159	chr3:113217341	T/C	cg18753928	chr3:113234510	CCDC52	-0.51	-6.22	-0.36	1.9e-9	Response to simvastatin treatment (PCSK9 protein level change);
CESC	cis	rs2274273	0.840	rs10467798	chr14:55724927	C/T	cg04306507	chr14:55594613	LGALS3	0.3	5.86	0.34	1.37e-8	Protein biomarker;
CESC	cis	rs9611565	0.545	rs5758432	chr22:42111693	T/C	cg03806693	chr22:41940476	POLR3H	1.16	13.32	0.63	2.5e-31	Vitiligo;
CESC	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg03188948	chr7:1209495	NA	0.72	6.94	0.39	2.94e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7845219	0.506	rs12548999	chr8:95929843	C/T	cg09323728	chr8:95962352	TP53INP1	-0.31	-5.91	-0.34	1.05e-8	Type 2 diabetes;
CESC	cis	rs7089973	0.604	rs2420067	chr10:116590348	A/G	cg03647239	chr10:116582469	FAM160B1	0.43	5.29	0.31	2.6e-7	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs13191362	0.935	rs66923841	chr6:163177317	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.98	9.31	0.5	5.22e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs8141529	0.778	rs9625566	chr22:29162506	G/A	cg15103426	chr22:29168792	CCDC117	0.7	9.96	0.52	4.8e-20	Lymphocyte counts;
CESC	cis	rs11030122	0.604	rs10835557	chr11:4083121	A/G	cg18678763	chr11:4115507	RRM1	-0.49	-6.5	-0.37	4.05e-10	Mean platelet volume;Platelet distribution width;
CESC	cis	rs1218582	0.510	rs2878411	chr1:154823545	C/T	cg24250549	chr1:154909240	PMVK	0.49	6.26	0.36	1.55e-9	Prostate cancer;
CESC	cis	rs1018836	0.923	rs62526886	chr8:91627676	G/A	cg16814680	chr8:91681699	NA	-0.72	-10.07	-0.53	2.16e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs9733	0.596	rs17658705	chr1:150678071	A/C	cg22823121	chr1:150693482	HORMAD1	-0.49	-7.25	-0.41	4.56e-12	Tonsillectomy;
CESC	cis	rs7264396	0.563	rs73902913	chr20:34432784	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.61	6.21	0.36	2.05e-9	Total cholesterol levels;
CESC	cis	rs853679	0.517	rs9348796	chr6:28126202	A/G	cg20151795	chr6:28129481	ZNF389	0.44	5.55	0.32	6.85e-8	Depression;
CESC	cis	rs7523050	0.643	rs35907086	chr1:109406625	A/G	cg08274380	chr1:109419600	GPSM2	0.91	5.92	0.34	9.78e-9	Fat distribution (HIV);
CESC	cis	rs1552244	0.882	rs2030564	chr3:10039044	A/G	cg08888203	chr3:10149979	C3orf24	0.48	6.09	0.35	4.02e-9	Alzheimer's disease;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg02739853	chr6:159398502	RSPH3	0.43	6.35	0.36	9.44e-10	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs7944584	0.502	rs10769256	chr11:47378396	C/T	cg20307385	chr11:47447363	PSMC3	0.84	11.68	0.58	1.04e-25	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CESC	cis	rs887829	0.569	rs3755319	chr2:234667582	A/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.45	-5.98	-0.34	7.1e-9	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CESC	cis	rs9303401	1.000	rs6503877	chr17:56841948	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.73	9.6	0.51	6.34e-19	Cognitive test performance;
CESC	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg26338869	chr17:61819248	STRADA	0.67	8.75	0.47	2.6e-16	Prudent dietary pattern;
CESC	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	10.16	0.53	1.09e-20	Prudent dietary pattern;
CESC	cis	rs11676348	0.755	rs13410318	chr2:219022910	T/G	cg20019365	chr2:219134978	PNKD;AAMP	0.45	5.83	0.34	1.6e-8	Ulcerative colitis;
CESC	cis	rs727505	0.789	rs4731233	chr7:124736291	C/T	cg23710748	chr7:124431027	NA	-0.4	-6.53	-0.37	3.37e-10	Lewy body disease;
CESC	cis	rs769267	0.930	rs1865034	chr19:19605763	C/T	cg03709012	chr19:19516395	GATAD2A	1.0	15.33	0.69	1.99e-38	Tonsillectomy;
CESC	cis	rs6429082	0.818	rs291344	chr1:235663860	C/G	cg26050004	chr1:235667680	B3GALNT2	-0.64	-7.89	-0.44	7.97e-14	Adiposity;
CESC	cis	rs7811142	1.000	rs67471932	chr7:100009985	C/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.08	10.6	0.55	3.94e-22	Platelet count;
CESC	cis	rs9914988	0.887	rs4795463	chr17:27146389	G/C	cg20469991	chr17:27169893	C17orf63	-0.48	-5.25	-0.31	3.18e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CESC	cis	rs9487051	1.000	rs1546723	chr6:109625879	G/A	cg01475377	chr6:109611718	NA	-0.4	-6.04	-0.35	5.31e-9	Reticulocyte fraction of red cells;
CESC	cis	rs2625529	0.824	rs2415121	chr15:72134018	C/T	cg16672083	chr15:72433130	SENP8	-0.51	-7.37	-0.41	2.15e-12	Red blood cell count;
CESC	cis	rs72945132	0.882	rs6592522	chr11:70128271	G/A	cg14191688	chr11:70257035	CTTN	0.42	5.15	0.3	5.16e-7	Coronary artery disease;
CESC	cis	rs826838	0.967	rs826858	chr12:39116731	A/G	cg13010199	chr12:38710504	ALG10B	-0.46	-6.44	-0.37	5.5e-10	Heart rate;
CESC	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.56	-6.24	-0.36	1.77e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs3105593	1.000	rs11636964	chr15:50899616	A/G	cg08437265	chr15:50716283	USP8	0.41	5.37	0.31	1.76e-7	QT interval;
CESC	cis	rs9911578	0.933	rs2531725	chr17:56517962	G/A	cg12560992	chr17:57184187	TRIM37	0.91	15.37	0.69	1.45e-38	Intelligence (multi-trait analysis);
CESC	cis	rs870825	0.655	rs7683556	chr4:185632019	T/A	cg04058563	chr4:185651563	MLF1IP	0.63	6.91	0.39	3.7e-11	Blood protein levels;
CESC	cis	rs1005277	0.579	rs1614236	chr10:38502996	C/T	cg25427524	chr10:38739819	LOC399744	-0.71	-10.4	-0.54	1.84e-21	Extrinsic epigenetic age acceleration;
CESC	cis	rs9926296	0.585	rs8058009	chr16:89856439	G/C	cg27130406	chr16:89901659	SPIRE2	-0.55	-6.52	-0.37	3.49e-10	Vitiligo;
CESC	cis	rs950169	0.840	rs12905223	chr15:85114268	T/C	cg17507749	chr15:85114479	UBE2QP1	0.54	6.15	0.35	2.86e-9	Schizophrenia;
CESC	cis	rs4481887	0.927	rs10788765	chr1:248445642	A/G	cg00666640	chr1:248458726	OR2T12	-0.4	-6.81	-0.39	6.58e-11	Common traits (Other);
CESC	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg07677032	chr17:61819896	STRADA	0.44	5.84	0.34	1.5e-8	Prudent dietary pattern;
CESC	cis	rs2243480	1.000	rs316315	chr7:65591205	C/T	cg18252515	chr7:66147081	NA	1.18	13.81	0.65	4.73e-33	Diabetic kidney disease;
CESC	cis	rs3733585	0.673	rs4627861	chr4:9954238	T/G	cg11266682	chr4:10021025	SLC2A9	-0.58	-11.0	-0.56	2.04e-23	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs7618915	0.501	rs6804145	chr3:52694198	C/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	5.85	0.34	1.46e-8	Bipolar disorder;
CESC	cis	rs55823223	0.680	rs57287238	chr17:73850940	T/C	cg23806715	chr17:73775811	H3F3B	0.61	6.69	0.38	1.34e-10	Psoriasis;
CESC	cis	rs3785574	0.925	rs2727340	chr17:61970224	T/A	cg06873352	chr17:61820015	STRADA	0.48	6.94	0.39	3.07e-11	Height;
CESC	cis	rs7208859	0.623	rs8082537	chr17:29015932	T/C	cg19761014	chr17:28927070	LRRC37B2	0.65	5.77	0.33	2.21e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs10791323	0.569	rs546381	chr11:133760651	T/G	cg15485101	chr11:133734466	NA	0.3	5.06	0.3	7.85e-7	Childhood ear infection;
CESC	cis	rs2075671	0.903	rs11520986	chr7:100276994	A/G	cg16850897	chr7:100343110	ZAN	-0.7	-9.06	-0.49	2.89e-17	Other erythrocyte phenotypes;
CESC	cis	rs11677416	1.000	rs3783514	chr2:113547425	A/G	cg27083787	chr2:113543245	IL1A	0.61	7.53	0.42	7.75e-13	Response to antipsychotic treatment in schizophrenia (working memory);
CESC	cis	rs873946	0.648	rs3793673	chr10:134547732	A/C	cg27286337	chr10:134555280	INPP5A	0.63	7.32	0.41	3.04e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs4523957	0.855	rs1231206	chr17:2125605	G/A	cg16513277	chr17:2031491	SMG6	-0.62	-8.67	-0.47	4.51e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs2228479	0.850	rs17233497	chr16:89815152	G/A	cg06558623	chr16:89946397	TCF25	1.04	6.59	0.37	2.43e-10	Skin colour saturation;
CESC	cis	rs9911578	0.967	rs302843	chr17:56727986	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.27	0.31	2.87e-7	Intelligence (multi-trait analysis);
CESC	cis	rs3126085	0.935	rs11204941	chr1:152203343	A/G	cg03465714	chr1:152285911	FLG	-0.44	-5.37	-0.31	1.73e-7	Atopic dermatitis;
CESC	cis	rs7216064	0.954	rs8079291	chr17:65887622	A/G	cg12091567	chr17:66097778	LOC651250	-0.86	-8.82	-0.48	1.55e-16	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs10540	1.000	rs12794284	chr11:477623	C/T	cg03576123	chr11:487126	PTDSS2	-1.07	-11.04	-0.56	1.45e-23	Body mass index;
CESC	cis	rs798554	0.836	rs13243214	chr7:2817455	G/T	cg19717773	chr7:2847554	GNA12	-0.57	-7.79	-0.43	1.55e-13	Height;
CESC	cis	rs9929218	0.861	rs3114409	chr16:68732049	A/C	cg02972257	chr16:68554789	NA	0.58	6.96	0.39	2.72e-11	Colorectal cancer;
CESC	trans	rs11088226	0.846	rs2154501	chr21:33926451	G/A	cg09050820	chr6:167586206	TCP10L2	0.63	6.88	0.39	4.22e-11	Gastritis;
CESC	cis	rs453301	0.571	rs330057	chr8:9089793	C/T	cg17143192	chr8:8559678	CLDN23	-0.44	-5.3	-0.31	2.38e-7	Joint mobility (Beighton score);
CESC	cis	rs3806843	0.771	rs2563336	chr5:140107199	A/G	cg26395211	chr5:140044315	WDR55	0.47	6.05	0.35	4.82e-9	Depressive symptoms (multi-trait analysis);
CESC	cis	rs7264396	0.563	rs6058296	chr20:34269225	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.9	-9.78	-0.51	1.8e-19	Total cholesterol levels;
CESC	cis	rs9359856	0.623	rs1179907	chr6:90324849	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.55	-6.32	-0.36	1.1e-9	Bipolar disorder;
CESC	trans	rs10832139	0.553	rs7929534	chr11:13945218	G/T	cg11511669	chr12:131556214	GPR133	0.5	6.06	0.35	4.74e-9	P wave terminal force;
CESC	cis	rs6598955	0.543	rs3795687	chr1:26560745	G/A	cg04990556	chr1:26633338	UBXN11	0.83	9.48	0.5	1.56e-18	Obesity-related traits;
CESC	cis	rs9322193	0.886	rs4870055	chr6:150169569	C/T	cg09699651	chr6:150184138	LRP11	0.5	6.09	0.35	4.03e-9	Lung cancer;
CESC	cis	rs1552244	0.938	rs9873794	chr3:10074153	T/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.87	11.9	0.59	1.94e-26	Alzheimer's disease;
CESC	cis	rs826838	1.000	rs12366971	chr12:38737687	T/G	cg26384229	chr12:38710491	ALG10B	0.82	14.66	0.67	4.97e-36	Heart rate;
CESC	cis	rs8040855	0.756	rs2342118	chr15:85693016	C/T	cg08123816	chr15:85640762	PDE8A	0.34	5.31	0.31	2.27e-7	Bulimia nervosa;
CESC	cis	rs9910055	0.659	rs721769	chr17:42261588	T/G	cg13607699	chr17:42295918	UBTF	0.59	7.54	0.42	7.35e-13	Total body bone mineral density;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10491242	chr19:50366052	PNKP	-0.56	-6.49	-0.37	4.23e-10	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21893394	chr19:10342123	S1PR2	0.62	7.14	0.4	9.02e-12	Gut microbiome composition (summer);
CESC	cis	rs9322193	0.884	rs7744105	chr6:150170444	A/G	cg07701084	chr6:150067640	NUP43	0.38	5.09	0.3	6.88e-7	Lung cancer;
CESC	cis	rs6752107	0.967	rs3792111	chr2:234179690	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.47	6.37	0.36	8.49e-10	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs3741151	1.000	rs76887714	chr11:73045500	C/T	cg17517138	chr11:73019481	ARHGEF17	0.62	5.15	0.3	5.08e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs2286503	0.752	rs59538378	chr7:22877097	G/A	cg11367502	chr7:22862612	TOMM7	0.43	5.62	0.33	4.76e-8	Fibrinogen;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg27164762	chr5:175815688	HIGD2A;NOP16	0.48	6.3	0.36	1.21e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs7208859	0.623	rs12103440	chr17:29086657	A/G	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.17e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs1799949	1.000	rs67060599	chr17:41255102	A/G	cg25072359	chr17:41440525	NA	0.47	6.4	0.37	6.83e-10	Menopause (age at onset);
CESC	trans	rs2391518	0.553	rs2969006	chr4:130781463	G/T	cg04981619	chr2:43328122	NA	0.38	6.0	0.35	6.59e-9	Body mass index;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05903298	chr11:107992155	ACAT1	0.55	6.76	0.38	8.95e-11	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14692768	chr2:219925688	IHH	-0.58	-6.95	-0.39	2.79e-11	Gut microbiome composition (summer);
CESC	cis	rs4665809	0.590	rs72809668	chr2:26467653	C/T	cg08470875	chr2:26401718	FAM59B	0.75	7.79	0.43	1.49e-13	Gut microbiome composition (summer);
CESC	cis	rs873946	0.564	rs12772704	chr10:134557318	G/A	cg06453172	chr10:134556979	INPP5A	-0.42	-5.32	-0.31	2.19e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs1153858	1.000	rs16952714	chr15:45650358	G/A	cg21132104	chr15:45694354	SPATA5L1	0.84	11.41	0.57	8.8e-25	Homoarginine levels;
CESC	cis	rs9303280	0.806	rs12709365	chr17:38027400	A/G	cg20243544	chr17:37824526	PNMT	0.5	6.43	0.37	5.86e-10	Self-reported allergy;
CESC	cis	rs2576037	0.901	rs2571021	chr18:44583498	A/G	cg19077165	chr18:44547161	KATNAL2	0.53	7.59	0.42	5.33e-13	Personality dimensions;
CESC	cis	rs9309473	0.948	rs2421577	chr2:73840998	G/T	cg20560298	chr2:73613845	ALMS1	-0.43	-5.78	-0.33	2.12e-8	Metabolite levels;
CESC	cis	rs1577917	0.771	rs2842602	chr6:86331887	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.54	-7.42	-0.41	1.63e-12	Response to antipsychotic treatment;
CESC	cis	rs7267979	0.816	rs443009	chr20:25499817	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.77	-14.59	-0.67	8.94e-36	Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10975873	chr1:149783778	HIST2H2BF	-0.6	-6.65	-0.38	1.64e-10	Gut microbiome composition (summer);
CESC	cis	rs116095464	0.510	rs10057501	chr5:239545	T/C	cg20965017	chr5:231967	SDHA	-0.47	-5.29	-0.31	2.6e-7	Breast cancer;
CESC	cis	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06343987	chr4:99849709	EIF4E	-0.59	-6.94	-0.39	2.92e-11	Gut microbiome composition (summer);
CESC	trans	rs7772486	0.686	rs9376961	chr6:146048737	C/T	cg09789590	chr19:46800479	HIF3A	-0.44	-6.26	-0.36	1.59e-9	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs428668	0.523	rs3926389	chr5:150677806	C/T	cg14086364	chr5:150678334	SLC36A3	0.49	7.09	0.4	1.2e-11	Skin aging (microtopography measurement);
CESC	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg18402987	chr7:1209562	NA	0.71	7.26	0.41	4.25e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs9649213	0.593	rs55825602	chr7:98013039	T/C	cg21770322	chr7:97807741	LMTK2	0.57	8.61	0.47	6.62e-16	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs4665809	1.000	rs2384322	chr2:26291146	C/G	cg08470875	chr2:26401718	FAM59B	-0.62	-6.71	-0.38	1.2e-10	Gut microbiome composition (summer);
CESC	cis	rs4268898	0.636	rs72787371	chr2:24570073	T/A	cg06627628	chr2:24431161	ITSN2	-1.0	-11.45	-0.58	6.19e-25	Asthma;
CESC	cis	rs7223966	1.000	rs6504171	chr17:61710010	G/A	cg11494091	chr17:61959527	GH2	0.38	5.44	0.32	1.24e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs780096	0.526	rs780106	chr2:27681598	A/C	cg02592271	chr2:27665507	KRTCAP3	-0.29	-5.79	-0.34	2e-8	Total body bone mineral density;
CESC	cis	rs4604732	0.536	rs12049066	chr1:247642655	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.59	7.97	0.44	4.65e-14	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg15112475	chr7:1198522	ZFAND2A	-0.42	-6.66	-0.38	1.61e-10	Longevity;Endometriosis;
CESC	cis	rs6541297	0.653	rs4846841	chr1:230302661	A/G	cg20703242	chr1:230279135	GALNT2	0.38	5.84	0.34	1.54e-8	Coronary artery disease;
CESC	cis	rs757110	0.705	rs10832778	chr11:17394073	C/G	cg15432903	chr11:17409602	KCNJ11	0.6	8.47	0.46	1.74e-15	Type 2 diabetes;
CESC	cis	rs1862618	0.853	rs252909	chr5:56121131	T/C	cg24531977	chr5:56204891	C5orf35	-0.88	-11.15	-0.57	6.07e-24	Initial pursuit acceleration;
CESC	cis	rs11098499	0.722	rs7673476	chr4:120248683	C/T	cg09307838	chr4:120376055	NA	0.76	10.25	0.53	5.52e-21	Corneal astigmatism;
CESC	cis	rs28830936	0.967	rs9672671	chr15:41917075	C/T	cg11010575	chr15:42129464	JMJD7-PLA2G4B;JMJD7	-0.36	-5.16	-0.3	4.94e-7	Diastolic blood pressure;
CESC	cis	rs10911232	0.507	rs10911198	chr1:182997318	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.84	13.19	0.63	6.74e-31	Hypertriglyceridemia;
CESC	cis	rs4819052	0.679	rs28623526	chr21:46712324	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	9.26	0.49	7.13e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs1799949	1.000	rs33920795	chr17:41329010	A/G	cg23758822	chr17:41437982	NA	1.05	16.2	0.71	1.69e-41	Menopause (age at onset);
CESC	cis	rs7107174	1.000	rs10899486	chr11:78072398	A/G	cg02023728	chr11:77925099	USP35	0.47	6.23	0.36	1.82e-9	Testicular germ cell tumor;
CESC	cis	rs7107174	0.901	rs2450136	chr11:77925273	T/G	cg02023728	chr11:77925099	USP35	0.49	6.89	0.39	4.06e-11	Testicular germ cell tumor;
CESC	cis	rs6540559	0.673	rs2357230	chr1:210019498	G/A	cg21951975	chr1:209979733	IRF6	0.59	7.16	0.4	8.01e-12	Cleft lip with or without cleft palate;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg10224311	chr22:35817371	MCM5	0.4	6.0	0.35	6.36e-9	Fibrinogen levels;
CESC	cis	rs7580658	0.680	rs12468304	chr2:128193812	A/G	cg10021288	chr2:128175891	PROC	0.41	6.02	0.35	5.72e-9	Protein C levels;
CESC	cis	rs2404602	0.536	rs7165025	chr15:76766434	G/A	cg22467129	chr15:76604101	ETFA	-0.38	-5.84	-0.34	1.53e-8	Blood metabolite levels;
CESC	cis	rs2115536	0.692	rs8036559	chr15:80170563	C/T	cg11839771	chr15:80205821	ST20	-0.39	-5.7	-0.33	3.16e-8	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CESC	cis	rs11264213	0.551	rs172081	chr1:36497498	T/G	cg27506609	chr1:36549197	TEKT2	0.76	6.98	0.39	2.31e-11	Schizophrenia;
CESC	cis	rs4919694	1.000	rs11191445	chr10:104651055	C/T	cg04362960	chr10:104952993	NT5C2	0.78	6.53	0.37	3.35e-10	Arsenic metabolism;
CESC	cis	rs3916	0.794	rs10431384	chr12:121127347	C/T	cg26008908	chr12:120799332	MSI1	-0.32	-5.13	-0.3	5.61e-7	Urinary metabolites (H-NMR features);
CESC	cis	rs4727027	0.754	rs11764892	chr7:148858916	G/A	cg23583168	chr7:148888333	NA	-0.75	-9.95	-0.52	4.91e-20	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19138250	chr10:69524126	NA	-0.57	-6.47	-0.37	4.6e-10	Gut microbiome composition (summer);
CESC	cis	rs6815814	0.731	rs11096956	chr4:38776180	G/T	cg02016764	chr4:38805732	TLR1	-0.45	-6.16	-0.35	2.65e-9	Breast cancer;
CESC	cis	rs2072732	0.861	rs12040299	chr1:2951041	C/T	cg15211996	chr1:2936768	ACTRT2	0.33	5.88	0.34	1.22e-8	Plateletcrit;
CESC	cis	rs6088590	1.000	rs6087623	chr20:33317662	C/G	cg24642439	chr20:33292090	TP53INP2	0.84	11.76	0.59	5.72e-26	Coronary artery disease;
CESC	cis	rs2243480	1.000	rs1167613	chr7:65487439	C/T	cg12463550	chr7:65579703	CRCP	0.72	5.92	0.34	9.68e-9	Diabetic kidney disease;
CESC	cis	rs8177253	1.000	rs8177252	chr3:133480174	C/A	cg12373951	chr3:133503437	NA	0.44	6.46	0.37	5.01e-10	Iron status biomarkers;
CESC	trans	rs916888	0.773	rs199534	chr17:44824213	T/G	cg22433210	chr17:43662623	NA	0.96	10.69	0.55	2.12e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26667821	chr1:155099774	EFNA1	-0.58	-6.36	-0.36	8.77e-10	Gut microbiome composition (summer);
CESC	cis	rs2742417	0.603	rs2673032	chr3:45756927	C/T	cg04837898	chr3:45731254	SACM1L	-0.48	-6.55	-0.37	2.96e-10	Response to anti-depressant treatment in major depressive disorder;
CESC	cis	rs2108622	0.958	rs79400241	chr19:15984402	C/G	cg13772218	chr19:15982569	NA	0.38	7.05	0.4	1.52e-11	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CESC	cis	rs2878628	0.596	rs57039206	chr3:52758570	T/A	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.68	0.38	1.41e-10	Intelligence (multi-trait analysis);
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg21584983	chr19:11640070	ECSIT	-0.46	-6.43	-0.37	5.77e-10	Height;
CESC	cis	rs2235642	0.533	rs2667679	chr16:1654946	G/A	cg09080909	chr16:1797204	MAPK8IP3	-0.45	-6.22	-0.36	1.96e-9	Coronary artery disease;
CESC	cis	rs5769707	0.616	rs6009786	chr22:50015145	A/G	cg20744362	chr22:50050164	C22orf34	0.36	5.14	0.3	5.33e-7	Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs9346455	1.000	rs9342829	chr6:72020763	G/C	cg27238071	chr6:71998145	OGFRL1	0.62	5.55	0.32	6.98e-8	Antipsychotic drug-induced weight gain (time interaction);Antipsychotic drug-induced weight gain;
CESC	cis	rs57506017	0.585	rs12668625	chr7:12269817	G/A	cg23422036	chr7:12250390	TMEM106B	0.38	5.13	0.3	5.58e-7	Neuroticism;
CESC	cis	rs6582630	0.519	rs11514078	chr12:38408817	G/C	cg26384229	chr12:38710491	ALG10B	0.68	9.85	0.52	1.03e-19	Drug-induced liver injury (flucloxacillin);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg11081703	chr12:108909056	FICD	-0.41	-6.1	-0.35	3.68e-9	Gambling;
CESC	cis	rs9649213	0.593	rs6944262	chr7:97985415	T/G	cg24562669	chr7:97807699	LMTK2	0.52	7.74	0.43	2.16e-13	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs11098499	0.913	rs10010696	chr4:120164303	T/C	cg09307838	chr4:120376055	NA	0.87	11.44	0.57	6.97e-25	Corneal astigmatism;
CESC	cis	rs1878931	0.555	rs27228	chr16:3431933	C/T	cg22508957	chr16:3507546	NAT15	0.45	5.88	0.34	1.24e-8	Body mass index (adult);
CESC	cis	rs1570884	0.516	rs7330830	chr13:50167929	T/A	cg08779649	chr13:50194554	NA	0.4	6.93	0.39	3.17e-11	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
CESC	cis	rs921968	0.565	rs1078803	chr2:219606538	A/C	cg02176678	chr2:219576539	TTLL4	0.45	7.93	0.44	6.07e-14	Mean corpuscular hemoglobin concentration;
CESC	cis	rs262150	0.579	rs4481540	chr7:158785846	A/G	cg23096020	chr7:158799433	NA	0.45	5.15	0.3	5.21e-7	Facial morphology (factor 20);
CESC	cis	rs7523050	0.643	rs17563938	chr1:109401654	C/T	cg08274380	chr1:109419600	GPSM2	0.86	5.69	0.33	3.36e-8	Fat distribution (HIV);
CESC	cis	rs727505	0.954	rs66691367	chr7:124654217	G/T	cg23710748	chr7:124431027	NA	-0.45	-6.98	-0.39	2.31e-11	Lewy body disease;
CESC	cis	rs9486719	1.000	rs1303852	chr6:96864523	C/T	cg18709589	chr6:96969512	KIAA0776	0.53	5.81	0.34	1.75e-8	Migraine;Coronary artery disease;
CESC	cis	rs4727027	0.704	rs1123992	chr7:148907201	C/G	cg23583168	chr7:148888333	NA	-0.84	-11.97	-0.59	1.13e-26	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs7116495	1.000	rs4338555	chr11:71755696	T/C	cg26138937	chr11:71823887	C11orf51	-0.85	-7.16	-0.4	8.12e-12	Severe influenza A (H1N1) infection;
CESC	trans	rs9929218	0.954	rs34530130	chr16:68827620	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.62	-8.06	-0.44	2.65e-14	Colorectal cancer;
CESC	cis	rs9858542	0.903	rs35999162	chr3:49597230	C/G	cg07274523	chr3:49395745	GPX1	0.65	8.34	0.46	4.1e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs9815354	0.516	rs75047809	chr3:42033437	T/C	cg03022575	chr3:42003672	ULK4	0.75	6.64	0.38	1.72e-10	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs2576037	0.623	rs2576040	chr18:44582027	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.46	6.16	0.35	2.63e-9	Personality dimensions;
CESC	cis	rs660498	0.516	rs638324	chr10:27730261	A/C	cg25705717	chr10:27608719	NA	0.43	5.41	0.32	1.43e-7	Asthma (childhood onset);
CESC	cis	rs12900413	0.687	rs28465116	chr15:90310152	T/C	cg24249390	chr15:90295951	MESP1	-0.4	-5.5	-0.32	9.05e-8	Coronary artery aneurysm in Kawasaki disease;
CESC	cis	rs61935443	0.832	rs11107773	chr12:95282000	C/T	cg21533806	chr12:95267307	NA	0.58	7.11	0.4	1.07e-11	Schizophrenia;
CESC	cis	rs896854	1.000	rs7003387	chr8:95961979	C/G	cg13393036	chr8:95962371	TP53INP1	-0.55	-12.25	-0.6	1.25e-27	Type 2 diabetes;
CESC	cis	rs10751667	1.000	rs10794349	chr11:945678	T/C	cg20946044	chr11:1010712	AP2A2	-0.44	-5.86	-0.34	1.4e-8	Alzheimer's disease (late onset);
CESC	cis	rs514406	0.727	rs61768342	chr1:53217028	G/A	cg27535305	chr1:53392650	SCP2	0.32	5.68	0.33	3.6e-8	Monocyte count;
CESC	cis	rs801193	1.000	rs17566701	chr7:66193183	T/C	cg11764359	chr7:65958608	NA	0.66	8.46	0.46	1.82e-15	Aortic root size;
CESC	cis	rs7216064	0.906	rs1976052	chr17:65830578	C/T	cg12091567	chr17:66097778	LOC651250	-0.86	-8.58	-0.47	8.22e-16	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs11718455	0.960	rs11921942	chr3:44007957	T/C	cg08738300	chr3:44038990	NA	0.46	6.15	0.35	2.87e-9	Coronary artery disease;
CESC	cis	rs1568889	1.000	rs66857704	chr11:28212346	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.74	9.23	0.49	8.63e-18	Bipolar disorder;
CESC	cis	rs1348850	0.668	rs6734683	chr2:178494012	C/G	cg22681709	chr2:178499509	PDE11A	-0.41	-5.9	-0.34	1.09e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs2455799	0.634	rs6771390	chr3:15906637	C/G	cg16303742	chr3:15540471	COLQ	-0.39	-5.91	-0.34	1.06e-8	Mean platelet volume;
CESC	cis	rs9790314	1.000	rs7653361	chr3:160992291	C/T	cg04691961	chr3:161091175	C3orf57	-0.41	-5.27	-0.31	2.87e-7	Morning vs. evening chronotype;
CESC	cis	rs10779751	0.762	rs6540965	chr1:11325521	C/G	cg08854313	chr1:11322531	MTOR	-0.67	-9.07	-0.49	2.74e-17	Body mass index;
CESC	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg11814155	chr7:99998594	ZCWPW1	0.5	5.11	0.3	6.07e-7	Platelet count;
CESC	cis	rs7927771	0.832	rs11039212	chr11:47393303	A/T	cg20307385	chr11:47447363	PSMC3	0.57	6.87	0.39	4.69e-11	Subjective well-being;
CESC	cis	rs7811142	1.000	rs4463351	chr7:100078226	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.98	10.48	0.54	9.63e-22	Platelet count;
CESC	cis	rs801193	1.000	rs7788576	chr7:66148302	G/A	cg11764359	chr7:65958608	NA	-0.67	-8.78	-0.47	2.12e-16	Aortic root size;
CESC	trans	rs61931739	0.517	rs7975714	chr12:34055611	T/C	cg26384229	chr12:38710491	ALG10B	0.6	8.36	0.46	3.68e-15	Morning vs. evening chronotype;
CESC	cis	rs2108622	0.727	rs62106155	chr19:15980360	G/C	cg13772218	chr19:15982569	NA	0.3	5.89	0.34	1.18e-8	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CESC	trans	rs1116547	0.571	rs12519323	chr5:112894805	A/G	cg10115368	chr14:100435663	NA	0.51	6.02	0.35	5.91e-9	Cerebral amyloid angiopathy;
CESC	cis	rs2573652	1.000	rs12440866	chr15:100517010	G/A	cg00587665	chr15:100533223	ADAMTS17	-0.41	-6.53	-0.37	3.34e-10	Height;
CESC	cis	rs11122272	0.705	rs2486731	chr1:231532511	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.48	6.54	0.37	3.2e-10	Hemoglobin concentration;
CESC	cis	rs12042052	0.793	rs7534632	chr1:232910796	G/A	cg00951395	chr1:232941775	KIAA1383	0.69	6.24	0.36	1.76e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CESC	cis	rs1030877	0.515	rs2576741	chr2:105897964	T/C	cg02079111	chr2:105885981	TGFBRAP1	0.49	6.51	0.37	3.66e-10	Obesity-related traits;
CESC	cis	rs514406	0.760	rs475969	chr1:53292607	T/A	cg08736216	chr1:53307985	ZYG11A	-0.36	-6.21	-0.36	2.06e-9	Monocyte count;
CESC	trans	rs89107	0.575	rs72958930	chr6:118983681	G/C	cg15017278	chr16:127449	MPG	-0.32	-6.0	-0.35	6.53e-9	Cardiac structure and function;
CESC	cis	rs12422267	0.536	rs12303540	chr12:132609679	A/G	cg09764611	chr12:132620959	NA	0.51	6.55	0.37	3.02e-10	Plasma amyloid beta peptide concentrations (ABx-40);
CESC	cis	rs6545883	0.894	rs2694639	chr2:61595291	G/A	cg15711740	chr2:61764176	XPO1	0.4	5.07	0.3	7.63e-7	Tuberculosis;
CESC	cis	rs12188164	0.965	rs72717438	chr5:448663	C/T	cg15813090	chr5:442598	EXOC3;C5orf55	0.42	6.26	0.36	1.51e-9	Cystic fibrosis severity;
CESC	cis	rs11214589	0.774	rs877137	chr11:113256330	C/T	cg14159747	chr11:113255604	NA	0.36	6.73	0.38	1.03e-10	Neuroticism;
CESC	cis	rs9467773	0.595	rs7767847	chr6:26597893	A/T	cg11502198	chr6:26597334	ABT1	0.49	7.03	0.4	1.79e-11	Intelligence (multi-trait analysis);
CESC	cis	rs7589342	0.628	rs35482041	chr2:106409436	A/G	cg16077055	chr2:106428750	NCK2	0.55	6.85	0.39	5.18e-11	Addiction;
CESC	cis	rs1451375	0.652	rs10265930	chr7:50627449	C/T	cg14593290	chr7:50529359	DDC	0.49	5.88	0.34	1.24e-8	Malaria;
CESC	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg15112475	chr7:1198522	ZFAND2A	-0.33	-5.12	-0.3	5.75e-7	Longevity;Endometriosis;
CESC	trans	rs7849270	1.000	rs713219	chr9:131900920	T/C	cg05583848	chr6:35265411	DEF6	-0.46	-6.36	-0.36	8.9e-10	Blood metabolite ratios;
CESC	cis	rs2594989	1.000	rs346081	chr3:11329085	A/G	cg01796438	chr3:11312864	ATG7	-0.46	-5.19	-0.3	4.09e-7	Circulating chemerin levels;
CESC	cis	rs1799949	0.930	rs34210004	chr17:41370337	A/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.47	6.48	0.37	4.38e-10	Menopause (age at onset);
CESC	cis	rs17023223	0.537	rs10923766	chr1:119726932	G/A	cg05756136	chr1:119680316	WARS2	-0.47	-5.69	-0.33	3.34e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CESC	cis	rs6089829	0.925	rs3746748	chr20:61667526	C/T	cg16240275	chr20:61666158	NCRNA00029	0.5	8.91	0.48	8.46e-17	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg23290719	chr2:241511151	RNPEPL1	-0.47	-6.25	-0.36	1.65e-9	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs7615952	0.512	rs4234285	chr3:125404477	G/A	cg00769240	chr8:12517080	NA	-0.44	-6.05	-0.35	4.91e-9	Blood pressure (smoking interaction);
CESC	cis	rs12477438	0.520	rs6741773	chr2:99738962	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.85	15.4	0.69	1.17e-38	Chronic sinus infection;
CESC	cis	rs7772486	0.875	rs6934467	chr6:146410529	G/T	cg05347473	chr6:146136440	FBXO30	0.5	6.57	0.37	2.61e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs875971	0.545	rs73376394	chr7:65637681	C/T	cg11764359	chr7:65958608	NA	0.73	8.93	0.48	7.48e-17	Aortic root size;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg27272293	chr12:76531007	NA	0.51	6.65	0.38	1.7e-10	Fibrinogen levels;
CESC	cis	rs9911578	0.967	rs302843	chr17:56727986	C/T	cg05425664	chr17:57184151	TRIM37	-0.51	-7.21	-0.4	6.03e-12	Intelligence (multi-trait analysis);
CESC	cis	rs4975616	0.804	rs31489	chr5:1342714	C/A	cg06550200	chr5:1325588	CLPTM1L	-0.66	-9.83	-0.52	1.24e-19	Lung cancer;
CESC	cis	rs9910055	0.659	rs7212573	chr17:42254281	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.74	9.98	0.52	3.9e-20	Total body bone mineral density;
CESC	cis	rs757110	0.933	rs4148646	chr11:17415190	C/G	cg15432903	chr11:17409602	KCNJ11	0.65	9.19	0.49	1.17e-17	Type 2 diabetes;
CESC	cis	rs4253772	0.550	rs6008613	chr22:46707924	G/T	cg00784671	chr22:46762841	CELSR1	-0.48	-5.59	-0.32	5.77e-8	LDL cholesterol;Cholesterol, total;
CESC	trans	rs4140564	0.557	rs12145449	chr1:186665945	A/C	cg22110973	chr15:91499626	RCCD1	0.77	6.23	0.36	1.8e-9	Knee osteoarthritis;
CESC	cis	rs9399135	0.967	rs2183709	chr6:135377091	C/T	cg24558204	chr6:135376177	HBS1L	0.52	7.19	0.4	6.52e-12	Red blood cell count;
CESC	cis	rs7178572	0.568	rs11858641	chr15:77585820	C/T	cg22256960	chr15:77711686	NA	-0.53	-6.6	-0.38	2.26e-10	Type 2 diabetes;
CESC	cis	rs1559088	1.000	rs12985438	chr19:33559368	G/A	cg27124370	chr19:33622961	WDR88	0.43	5.42	0.32	1.37e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs2836950	0.772	rs62222988	chr21:40569508	T/C	cg17971929	chr21:40555470	PSMG1	-0.61	-7.31	-0.41	3.09e-12	Menarche (age at onset);
CESC	cis	rs875971	0.508	rs10950045	chr7:66066373	T/C	cg18876405	chr7:65276391	NA	-0.54	-7.7	-0.43	2.74e-13	Aortic root size;
CESC	cis	rs9549367	0.724	rs7985335	chr13:113869244	G/T	cg18105134	chr13:113819100	PROZ	0.62	8.22	0.45	9.21e-15	Platelet distribution width;
CESC	cis	rs10504229	0.595	rs116490935	chr8:58117531	A/G	cg02725872	chr8:58115012	NA	-0.45	-7.05	-0.4	1.51e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs27434	0.583	rs151911	chr5:96157084	A/G	cg16492584	chr5:96139282	ERAP1	-0.36	-5.09	-0.3	6.81e-7	Ankylosing spondylitis;
CESC	cis	rs12464559	0.649	rs3922997	chr2:152609704	C/T	cg01189475	chr2:152685088	ARL5A	0.65	5.56	0.32	6.46e-8	Response to cognitive-behavioural therapy in anxiety disorder;
CESC	cis	rs4073221	0.520	rs66569729	chr3:18189623	A/C	cg07694806	chr3:18168406	NA	-0.71	-5.59	-0.32	5.74e-8	Parkinson's disease;
CESC	cis	rs1707322	1.000	rs10890376	chr1:46406582	C/T	cg03146154	chr1:46216737	IPP	0.78	10.77	0.55	1.17e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs35110281	0.687	rs4819284	chr21:45084548	C/T	cg04455712	chr21:45112962	RRP1B	0.44	6.81	0.39	6.41e-11	Mean corpuscular volume;
CESC	cis	rs1801251	1.000	rs7587309	chr2:233705702	G/T	cg08000102	chr2:233561755	GIGYF2	-0.69	-10.02	-0.52	2.98e-20	Coronary artery disease;
CESC	trans	rs10905099	0.615	rs77158703	chr10:7093576	C/T	cg05230642	chr15:25439252	SNORD115-14	-0.73	-6.17	-0.35	2.6e-9	Orofacial clefts;
CESC	cis	rs1008375	1.000	rs4698199	chr4:17656738	G/C	cg16339924	chr4:17578868	LAP3	0.56	7.02	0.4	1.9e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs34779708	0.931	rs4934704	chr10:35332164	C/T	cg04310649	chr10:35416472	CREM	-0.52	-6.27	-0.36	1.45e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs561341	1.000	rs555629	chr17:30294136	T/C	cg12193833	chr17:30244370	NA	-0.71	-6.53	-0.37	3.38e-10	Hip circumference adjusted for BMI;
CESC	cis	rs2243480	1.000	rs7795242	chr7:65390094	T/C	cg12463550	chr7:65579703	CRCP	0.7	5.7	0.33	3.21e-8	Diabetic kidney disease;
CESC	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	10.54	0.54	6.46e-22	Prudent dietary pattern;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg15737319	chr2:74425763	MTHFD2	-0.42	-6.05	-0.35	4.84e-9	Gambling;
CESC	cis	rs1552244	0.882	rs13084194	chr3:10031492	T/A	cg08888203	chr3:10149979	C3orf24	0.5	6.02	0.35	5.84e-9	Alzheimer's disease;
CESC	cis	rs12893668	0.542	rs12884809	chr14:104095320	G/A	cg08213375	chr14:104286397	PPP1R13B	0.32	5.28	0.31	2.68e-7	Reticulocyte count;
CESC	cis	rs6912958	0.684	rs6931069	chr6:88367082	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.44	-5.77	-0.33	2.19e-8	Monocyte percentage of white cells;
CESC	cis	rs3008870	1.000	rs2985817	chr1:67398607	G/C	cg08660285	chr1:67390436	MIER1;WDR78	1.06	15.19	0.68	6.65e-38	Lymphocyte percentage of white cells;
CESC	cis	rs6088580	0.634	rs6059866	chr20:33075810	A/C	cg08999081	chr20:33150536	PIGU	0.55	9.46	0.5	1.71e-18	Glomerular filtration rate (creatinine);
CESC	cis	rs3733418	0.860	rs13129396	chr4:165936346	G/A	cg10852876	chr4:165953100	TRIM60	-0.49	-5.77	-0.33	2.22e-8	Obesity-related traits;
CESC	cis	rs2075371	1.000	rs2598297	chr7:133993001	T/G	cg00033643	chr7:134001901	SLC35B4	0.43	5.42	0.32	1.34e-7	Mean platelet volume;
CESC	cis	rs1153858	1.000	rs10444821	chr15:45647236	C/T	cg21132104	chr15:45694354	SPATA5L1	0.84	11.4	0.57	9.5e-25	Homoarginine levels;
CESC	cis	rs9811920	0.599	rs61148087	chr3:99539891	C/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.39	5.34	0.31	2.05e-7	Axial length;
CESC	cis	rs9291683	0.507	rs3796837	chr4:10011321	C/G	cg00071950	chr4:10020882	SLC2A9	0.82	13.78	0.65	5.92e-33	Bone mineral density;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12090654	chr8:6424636	MCPH1	-0.59	-6.42	-0.37	6.1e-10	Gut microbiome composition (summer);
CESC	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	10.54	0.54	6.46e-22	Prudent dietary pattern;
CESC	cis	rs258892	0.895	rs13158966	chr5:72059510	C/T	cg21869765	chr5:72125136	TNPO1	-0.43	-5.35	-0.31	1.93e-7	Small cell lung carcinoma;
CESC	cis	rs11166629	0.883	rs11778878	chr8:135599220	C/T	cg27224718	chr8:135614730	ZFAT	-0.47	-5.87	-0.34	1.27e-8	Smoking quantity;
CESC	cis	rs6430585	0.527	rs2254780	chr2:136435526	C/T	cg07169764	chr2:136633963	MCM6	0.99	11.95	0.59	1.26e-26	Corneal structure;
CESC	cis	rs9611565	0.802	rs4822028	chr22:41789408	A/G	cg03806693	chr22:41940476	POLR3H	-1.02	-12.85	-0.62	1.08e-29	Vitiligo;
CESC	trans	rs11098499	0.909	rs17046118	chr4:120387496	T/G	cg25214090	chr10:38739885	LOC399744	0.7	9.93	0.52	5.63e-20	Corneal astigmatism;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05704155	chr1:10459140	PGD	0.58	6.74	0.38	9.66e-11	Gut microbiome composition (summer);
CESC	cis	rs73019876	0.869	rs10408274	chr19:22144930	C/T	cg11619707	chr19:22235551	ZNF257	-0.28	-5.21	-0.3	3.89e-7	Testicular germ cell tumor;
CESC	cis	rs12973672	0.812	rs2280744	chr19:35755386	G/A	cg12095397	chr19:35769544	USF2	0.5	5.97	0.34	7.49e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	trans	rs7980799	0.840	rs7315695	chr12:33551841	G/C	cg26384229	chr12:38710491	ALG10B	-0.52	-7.04	-0.4	1.64e-11	Heart rate;Heart rate variability traits (RMSSD);
CESC	trans	rs561341	1.000	rs72821971	chr17:30269343	T/G	cg20587970	chr11:113659929	NA	-1.43	-18.77	-0.76	1.45e-50	Hip circumference adjusted for BMI;
CESC	cis	rs6087990	0.806	rs992472	chr20:31385269	G/T	cg13636640	chr20:31349939	DNMT3B	0.84	13.88	0.65	2.71e-33	Ulcerative colitis;
CESC	cis	rs1552244	0.572	rs6442154	chr3:10168785	A/G	cg00149659	chr3:10157352	C3orf10	0.99	11.82	0.59	3.47e-26	Alzheimer's disease;
CESC	cis	rs35306767	0.903	rs11816064	chr10:931176	A/C	cg10556349	chr10:835070	NA	0.54	5.27	0.31	2.78e-7	Eosinophil percentage of granulocytes;
CESC	cis	rs60843830	1.000	rs62114548	chr2:274672	C/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.89	11.87	0.59	2.49e-26	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs117623576	0.941	rs16932939	chr10:32407862	T/C	cg03047570	chr10:32398778	NA	-0.84	-8.6	-0.47	7.18e-16	Anti-saccade response;
CESC	cis	rs6540559	0.611	rs76766079	chr1:209997731	C/T	cg25204440	chr1:209979598	IRF6	0.68	6.57	0.37	2.59e-10	Cleft lip with or without cleft palate;
CESC	cis	rs823128	1.000	rs823128	chr1:205713378	G/A	cg13473505	chr1:205738393	RAB7L1	0.69	5.76	0.33	2.35e-8	Parkinson's disease;
CESC	cis	rs4664308	0.935	rs6739867	chr2:160942818	G/A	cg03641300	chr2:160917029	PLA2R1	-0.67	-9.84	-0.52	1.11e-19	Idiopathic membranous nephropathy;
CESC	cis	rs1799949	1.000	rs11653253	chr17:41182662	G/A	cg05368731	chr17:41323189	NBR1	0.8	10.6	0.55	3.93e-22	Menopause (age at onset);
CESC	cis	rs4566357	0.615	rs3769642	chr2:227917323	T/C	cg05526886	chr2:227700861	RHBDD1	-0.52	-6.83	-0.39	5.73e-11	Coronary artery disease;
CESC	cis	rs2463822	0.844	rs7104149	chr11:62171627	A/G	cg06239285	chr11:62104954	ASRGL1	-0.89	-7.75	-0.43	1.92e-13	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs3785574	0.621	rs1051684	chr17:62006497	A/G	cg06873352	chr17:61820015	STRADA	-0.36	-5.21	-0.3	3.83e-7	Height;
CESC	cis	rs2075371	1.000	rs1862050	chr7:133980999	T/C	cg00033643	chr7:134001901	SLC35B4	0.44	5.78	0.33	2.04e-8	Mean platelet volume;
CESC	cis	rs72829446	0.530	rs4796420	chr17:7379617	A/T	cg02795151	chr17:7402630	POLR2A	0.53	5.74	0.33	2.52e-8	Androgen levels;
CESC	cis	rs8072100	0.713	rs4968257	chr17:45430534	A/G	cg25173405	chr17:45401733	C17orf57	-0.44	-5.48	-0.32	9.98e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs1707322	0.662	rs11211160	chr1:46146229	T/A	cg05343316	chr1:45956843	TESK2	0.52	6.43	0.37	5.88e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs6582630	0.519	rs7305545	chr12:38349223	G/A	cg26384229	chr12:38710491	ALG10B	0.73	10.95	0.56	2.81e-23	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs2832191	0.636	rs8131295	chr21:30516819	A/T	cg08807101	chr21:30365312	RNF160	-0.56	-6.46	-0.37	4.91e-10	Dental caries;
CESC	cis	rs6964587	0.782	rs13221571	chr7:91500236	C/T	cg17063962	chr7:91808500	NA	-0.53	-7.23	-0.41	5.15e-12	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20044168	chr6:87865051	ZNF292	0.57	6.3	0.36	1.26e-9	Gut microbiome composition (summer);
CESC	cis	rs3820928	0.605	rs10186145	chr2:227781150	A/G	cg11843606	chr2:227700838	RHBDD1	-0.59	-8.4	-0.46	2.68e-15	Pulmonary function;
CESC	trans	rs9319321	0.592	rs1927510	chr13:27416616	G/C	cg14332112	chr6:47277683	TNFRSF21	-0.49	-6.22	-0.36	1.97e-9	Asthma (toluene diisocyanate-induced);
CESC	cis	rs546131	0.963	rs539044	chr11:34841542	G/T	cg11058730	chr11:34937778	PDHX;APIP	0.49	6.38	0.36	7.87e-10	Lung disease severity in cystic fibrosis;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg27100149	chr18:77196899	NFATC1	-0.43	-6.67	-0.38	1.5e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs72781680	0.716	rs2551343	chr2:24027002	C/G	cg08917208	chr2:24149416	ATAD2B	0.61	5.99	0.35	6.74e-9	Lymphocyte counts;
CESC	cis	rs6831352	0.734	rs3018046	chr4:100030388	C/T	cg12011299	chr4:100065546	ADH4	0.57	6.88	0.39	4.34e-11	Alcohol dependence;
CESC	cis	rs514406	0.584	rs7524702	chr1:53197830	G/A	cg24675658	chr1:53192096	ZYG11B	0.62	7.68	0.43	3.04e-13	Monocyte count;
CESC	cis	rs763121	0.853	rs7289577	chr22:39042214	C/G	cg06022373	chr22:39101656	GTPBP1	0.88	13.79	0.65	5.43e-33	Menopause (age at onset);
CESC	cis	rs11792861	0.890	rs3087979	chr9:111781779	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.47	5.98	0.34	7.2e-9	Menarche (age at onset);
CESC	cis	rs2354432	0.607	rs58941651	chr1:146784919	T/C	cg25205988	chr1:146714368	CHD1L	-1.0	-8.9	-0.48	9.01e-17	Mitochondrial DNA levels;
CESC	cis	rs561341	0.882	rs111484028	chr17:30287701	G/A	cg19193384	chr17:30244184	NA	-0.61	-6.41	-0.37	6.51e-10	Hip circumference adjusted for BMI;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg05611199	chr16:88637223	ZC3H18	-0.47	-6.12	-0.35	3.33e-9	Ulcerative colitis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21318521	chr6:107349259	C6orf203	0.58	7.02	0.4	1.83e-11	Gut microbiome composition (summer);
CESC	cis	rs3925075	0.764	rs8044482	chr16:31345752	T/C	cg02846316	chr16:31340340	ITGAM	0.41	6.49	0.37	4.24e-10	IgA nephropathy;
CESC	cis	rs9910055	0.676	rs11079983	chr17:42198170	C/T	cg19774624	chr17:42201019	HDAC5	-0.66	-9.67	-0.51	3.77e-19	Total body bone mineral density;
CESC	trans	rs4471313	1.000	rs861121	chr1:170354106	G/A	cg14876685	chr7:99177937	NA	-0.41	-6.21	-0.36	2.03e-9	Waist-hip ratio;
CESC	cis	rs2635047	0.935	rs2576031	chr18:44658146	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.5	6.77	0.38	8.5e-11	Educational attainment;
CESC	cis	rs4665809	0.590	rs3806515	chr2:26466975	C/T	cg08470875	chr2:26401718	FAM59B	0.75	7.79	0.43	1.49e-13	Gut microbiome composition (summer);
CESC	trans	rs1814175	0.616	rs1722020	chr11:49904189	G/A	cg15704280	chr7:45808275	SEPT13	-1.01	-18.94	-0.76	3.64e-51	Height;
CESC	cis	rs7412746	0.586	rs2864882	chr1:150883037	C/T	cg04414720	chr1:150670196	GOLPH3L	0.45	5.95	0.34	8.27e-9	Melanoma;
CESC	cis	rs941408	0.515	rs1736188	chr19:2782368	A/G	cg00079169	chr19:2811669	THOP1	0.37	5.16	0.3	4.77e-7	Total cholesterol levels;
CESC	cis	rs854765	0.547	rs9896837	chr17:17924868	A/G	cg16928487	chr17:17741425	SREBF1	-0.53	-8.87	-0.48	1.11e-16	Total body bone mineral density;
CESC	cis	rs11098499	0.644	rs10050092	chr4:120532085	T/C	cg09307838	chr4:120376055	NA	0.74	10.02	0.52	2.95e-20	Corneal astigmatism;
CESC	cis	rs914615	0.507	rs4971085	chr1:155138222	T/C	cg02153340	chr1:155202674	NA	-0.38	-5.59	-0.32	5.57e-8	Urinary albumin-to-creatinine ratio;
CESC	cis	rs660498	0.507	rs12413784	chr10:27729599	C/G	cg08398567	chr10:27609333	NA	0.39	5.39	0.31	1.6e-7	Asthma (childhood onset);
CESC	cis	rs4808199	1.000	rs60321073	chr19:19499598	A/G	cg03709012	chr19:19516395	GATAD2A	1.13	13.27	0.63	3.7e-31	Nonalcoholic fatty liver disease;
CESC	cis	rs6076065	0.802	rs2424527	chr20:23357329	A/C	cg11657817	chr20:23433608	CST11	0.42	6.36	0.36	8.95e-10	Facial morphology (factor 15, philtrum width);
CESC	cis	rs6500395	1.000	rs2129243	chr16:48646852	A/T	cg04672837	chr16:48644449	N4BP1	0.49	5.79	0.34	1.97e-8	Response to tocilizumab in rheumatoid arthritis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08365438	chr10:21683093	NA	-0.75	-9.21	-0.49	1.04e-17	Gut microbiome composition (summer);
CESC	cis	rs425277	0.585	rs3128294	chr1:2065343	G/C	cg04315214	chr1:2043799	PRKCZ	0.51	8.2	0.45	1.03e-14	Height;
CESC	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg23978390	chr7:1156363	C7orf50	0.53	7.14	0.4	8.89e-12	Longevity;Endometriosis;
CESC	trans	rs634534	0.562	rs642293	chr11:65730217	G/A	cg17712092	chr4:129076599	LARP1B	0.7	9.65	0.51	4.44e-19	Sum eosinophil basophil counts;Eosinophil counts;
CESC	trans	rs722599	0.748	rs1059326	chr14:75369385	C/T	cg00095594	chr1:236228625	NID1	-0.4	-6.19	-0.36	2.31e-9	IgG glycosylation;
CESC	cis	rs17711722	0.701	rs781143	chr7:65439879	G/C	cg06456125	chr7:65229604	NA	0.45	5.83	0.34	1.57e-8	Calcium levels;
CESC	cis	rs1808579	0.904	rs1788783	chr18:21161134	C/T	cg14672496	chr18:21087552	C18orf8	0.37	5.25	0.31	3.07e-7	Hip circumference;Body mass index;BMI (adjusted for smoking behaviour);
CESC	cis	rs734999	0.572	rs4310388	chr1:2507415	G/T	cg20673091	chr1:2541236	MMEL1	0.41	6.75	0.38	9.34e-11	Ulcerative colitis;
CESC	cis	rs9467711	0.538	rs35934643	chr6:26355094	G/A	cg14345882	chr6:26364793	BTN3A2	0.6	6.29	0.36	1.33e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs4450798	0.793	rs9831150	chr3:13740916	C/T	cg05589046	chr3:13742034	LOC285375	0.37	5.49	0.32	9.59e-8	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs2439831	0.850	rs28684672	chr15:44107662	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.69	7.69	0.43	2.87e-13	Lung cancer in ever smokers;
CESC	cis	rs3806843	0.735	rs778595	chr5:140036681	G/A	cg16179182	chr5:140090404	VTRNA1-1	0.41	5.39	0.31	1.55e-7	Depressive symptoms (multi-trait analysis);
CESC	trans	rs1994135	0.549	rs2218650	chr12:33734783	A/G	cg26384229	chr12:38710491	ALG10B	0.44	6.29	0.36	1.28e-9	Resting heart rate;
CESC	cis	rs11792861	0.781	rs11789252	chr9:111762010	A/T	cg05043794	chr9:111880884	C9orf5	-0.38	-6.14	-0.35	2.93e-9	Menarche (age at onset);
CESC	cis	rs7084402	0.935	rs1658492	chr10:60281267	C/T	cg07615347	chr10:60278583	BICC1	-0.59	-9.48	-0.5	1.48e-18	Refractive error;
CESC	cis	rs11864453	0.647	rs10492813	chr16:72122463	A/G	cg16558253	chr16:72132732	DHX38	0.53	8.27	0.45	6.34e-15	Fibrinogen levels;
CESC	cis	rs7811142	0.666	rs28401739	chr7:99905684	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.75	7.09	0.4	1.25e-11	Platelet count;
CESC	cis	rs11638352	1.000	rs8038096	chr15:44367290	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	-0.47	-5.25	-0.31	3.12e-7	Lipoprotein phospholipase A2 activity in cardiovascular disease;
CESC	cis	rs8062405	0.690	rs62034351	chr16:28565489	G/A	cg07382826	chr16:28625726	SULT1A1	0.39	6.35	0.36	9.44e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs736408	0.609	rs2230535	chr3:52800284	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.49	6.74	0.38	1e-10	Bipolar disorder;
CESC	cis	rs514406	0.505	rs440871	chr1:53173052	C/T	cg08736216	chr1:53307985	ZYG11A	-0.41	-6.84	-0.39	5.46e-11	Monocyte count;
CESC	cis	rs736408	0.716	rs2239550	chr3:52822509	G/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	6.64	0.38	1.8e-10	Bipolar disorder;
CESC	cis	rs4665809	0.590	rs7260	chr2:26413917	C/T	cg08470875	chr2:26401718	FAM59B	-0.67	-7.46	-0.42	1.25e-12	Gut microbiome composition (summer);
CESC	cis	rs27434	0.583	rs40091	chr5:96154919	A/G	cg16492584	chr5:96139282	ERAP1	-0.37	-5.46	-0.32	1.09e-7	Ankylosing spondylitis;
CESC	cis	rs1799949	1.000	rs8176242	chr17:41217874	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	8.32	0.46	4.71e-15	Menopause (age at onset);
CESC	cis	rs757110	0.868	rs5219	chr11:17409572	T/C	cg11839944	chr11:17409644	KCNJ11	0.39	5.18	0.3	4.49e-7	Type 2 diabetes;
CESC	cis	rs704	0.585	rs2227735	chr17:26693258	C/T	cg10494684	chr17:26645200	TMEM97	-0.38	-5.32	-0.31	2.25e-7	Osteoprotegerin levels;
CESC	trans	rs12492269	0.702	rs41381644	chr3:178161614	A/G	cg24455024	chr3:179370471	USP13	-0.71	-6.06	-0.35	4.54e-9	Plasma clusterin levels;
CESC	cis	rs2243480	1.000	rs6964245	chr7:65718717	G/A	cg18252515	chr7:66147081	NA	1.41	14.3	0.66	9.43e-35	Diabetic kidney disease;
CESC	cis	rs524281	0.861	rs7124165	chr11:65901218	C/T	cg14036092	chr11:66035641	RAB1B	-0.58	-5.84	-0.34	1.5e-8	Electroencephalogram traits;
CESC	cis	rs6952808	0.929	rs12667688	chr7:1931030	C/T	cg04267008	chr7:1944627	MAD1L1	-0.73	-9.35	-0.5	3.82e-18	Bipolar disorder and schizophrenia;
CESC	cis	rs3015497	0.570	rs2934679	chr14:51093745	C/T	cg26011998	chr14:51135199	SAV1	0.47	5.16	0.3	4.8e-7	Mean platelet volume;
CESC	trans	rs6572548	0.504	rs1956082	chr14:49665496	A/C	cg10632811	chr17:45918739	SCRN2	-0.54	-6.28	-0.36	1.37e-9	Subjective well-being;
CESC	cis	rs6952808	0.595	rs2398705	chr7:2164995	G/A	cg05863683	chr7:1912471	MAD1L1	0.38	5.54	0.32	7.31e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs4665809	0.590	rs36064164	chr2:26502768	C/T	cg26314531	chr2:26401878	FAM59B	0.83	8.36	0.46	3.57e-15	Gut microbiome composition (summer);
CESC	cis	rs826838	0.620	rs11614695	chr12:39331847	C/T	cg13010199	chr12:38710504	ALG10B	0.51	6.51	0.37	3.66e-10	Heart rate;
CESC	cis	rs2235642	0.928	rs2076435	chr16:1607574	C/T	cg08296037	chr16:1584118	IFT140;TMEM204	-0.31	-5.21	-0.3	3.88e-7	Coronary artery disease;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg10823546	chr9:88555702	NAA35	-0.46	-6.05	-0.35	4.79e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs4481887	1.000	rs4489592	chr1:248470697	A/T	cg00666640	chr1:248458726	OR2T12	0.4	6.57	0.37	2.7e-10	Common traits (Other);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06096994	chr13:41635664	WBP4	0.6	7.3	0.41	3.42e-12	Gut microbiome composition (summer);
CESC	trans	rs801193	1.000	rs2659909	chr7:66160279	G/A	cg26939375	chr7:64535504	NA	0.66	8.84	0.48	1.4e-16	Aortic root size;
CESC	cis	rs6499255	1.000	rs4078387	chr16:69814047	G/A	cg15192750	chr16:69999425	NA	0.46	5.64	0.33	4.46e-8	IgE levels;
CESC	cis	rs67311347	0.955	rs60554147	chr3:40472503	T/C	cg09455208	chr3:40491958	NA	0.44	7.56	0.42	6.51e-13	Renal cell carcinoma;
CESC	cis	rs1475911	1.000	rs2839465	chr21:43511232	C/T	cg19766460	chr21:43528205	UMODL1;C21orf128	0.55	6.26	0.36	1.52e-9	IgG glycosylation;
CESC	cis	rs12711979	0.509	rs10181286	chr2:3824567	G/A	cg17052675	chr2:3827356	NA	-0.66	-11.02	-0.56	1.71e-23	Itch intensity from mosquito bite adjusted by bite size;
CESC	cis	rs4234798	0.500	rs10937793	chr4:7219614	C/T	cg18431297	chr4:7219810	SORCS2	0.56	9.37	0.5	3.28e-18	Insulin-like growth factors;
CESC	cis	rs7605827	0.930	rs7596435	chr2:15605091	T/C	cg19274914	chr2:15703543	NA	0.36	6.42	0.37	6.17e-10	Educational attainment (years of education);
CESC	trans	rs9944275	0.860	rs34769936	chr15:97191343	T/C	cg26794346	chr6:16472305	ATXN1	0.73	6.06	0.35	4.65e-9	Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
CESC	cis	rs6964587	0.692	rs2299233	chr7:91626953	C/T	cg17063962	chr7:91808500	NA	-0.46	-6.67	-0.38	1.5e-10	Breast cancer;
CESC	cis	rs2549003	0.870	rs10053046	chr5:131821558	A/G	cg21138405	chr5:131827807	IRF1	0.54	9.32	0.5	4.74e-18	Asthma (sex interaction);
CESC	cis	rs2932538	0.922	rs12758377	chr1:113137221	C/A	cg22162597	chr1:113214053	CAPZA1	0.55	7.11	0.4	1.1e-11	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CESC	cis	rs514406	0.505	rs6703127	chr1:53180565	C/T	cg16325326	chr1:53192061	ZYG11B	0.9	16.12	0.7	3.36e-41	Monocyte count;
CESC	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg26338869	chr17:61819248	STRADA	0.69	8.92	0.48	7.86e-17	Prudent dietary pattern;
CESC	cis	rs9325144	0.624	rs7312879	chr12:39150752	G/A	cg26384229	chr12:38710491	ALG10B	-0.51	-7.05	-0.4	1.59e-11	Morning vs. evening chronotype;
CESC	trans	rs916888	0.610	rs142167	chr17:44795234	C/T	cg01341218	chr17:43662625	NA	-0.55	-7.38	-0.41	1.99e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs1008375	0.966	rs6832414	chr4:17696866	C/G	cg16339924	chr4:17578868	LAP3	0.59	7.4	0.41	1.83e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs6580649	0.825	rs4760611	chr12:48421449	A/G	cg05342945	chr12:48394962	COL2A1	-0.53	-6.21	-0.36	2.09e-9	Lung cancer;
CESC	cis	rs870825	0.655	rs28726376	chr4:185638954	A/G	cg04058563	chr4:185651563	MLF1IP	0.64	7.07	0.4	1.39e-11	Blood protein levels;
CESC	cis	rs7811142	0.830	rs76798830	chr7:99952828	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.89	7.95	0.44	5.36e-14	Platelet count;
CESC	cis	rs9788682	1.000	rs34138960	chr15:78831668	A/G	cg24631222	chr15:78858424	CHRNA5	0.81	10.53	0.54	6.79e-22	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	trans	rs916888	0.821	rs199525	chr17:44847834	T/G	cg07870213	chr5:140052090	DND1	0.64	6.81	0.39	6.47e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs3749237	1.000	rs2291542	chr3:49751585	C/T	cg03060546	chr3:49711283	APEH	0.56	6.72	0.38	1.11e-10	Resting heart rate;
CESC	cis	rs7267979	0.844	rs2257649	chr20:25263457	T/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.79	14.52	0.67	1.49e-35	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7274811	0.744	rs6119395	chr20:32244711	G/T	cg21523528	chr20:32077966	CBFA2T2	0.57	6.58	0.37	2.47e-10	Height;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg22515636	chr2:109150313	NA	0.5	6.56	0.37	2.85e-10	Systemic lupus erythematosus;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg19831303	chr11:64126461	RPS6KA4	-0.43	-6.29	-0.36	1.28e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs854765	0.552	rs11078407	chr17:17841083	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.59	8.71	0.47	3.29e-16	Total body bone mineral density;
CESC	cis	rs6685188	0.920	rs6676110	chr1:205662977	G/A	cg24503407	chr1:205819492	PM20D1	-0.45	-6.16	-0.35	2.76e-9	White blood cell count (basophil);Basophil percentage of white cells;
CESC	cis	rs1691799	0.867	rs1168347	chr12:66757303	T/C	cg16791601	chr12:66731901	HELB	-0.62	-10.09	-0.53	1.79e-20	White blood cell count (basophil);
CESC	cis	rs12824058	0.831	rs1390849	chr12:130811547	A/G	cg24838063	chr12:130822603	PIWIL1	0.62	8.55	0.47	9.78e-16	Menopause (age at onset);
CESC	cis	rs1062177	0.950	rs892005	chr5:151180621	A/G	cg12924095	chr5:151150029	G3BP1	0.49	6.44	0.37	5.67e-10	Preschool internalizing problems;
CESC	cis	rs751837	0.591	rs9806052	chr14:103417519	T/G	cg10087771	chr14:103399429	CDC42BPB	0.6	5.55	0.32	6.86e-8	Large B-cell lymphoma;
CESC	cis	rs2235642	0.821	rs8051895	chr16:1602811	A/G	cg07639376	chr16:1584516	IFT140;TMEM204	-0.31	-5.07	-0.3	7.41e-7	Coronary artery disease;
CESC	cis	rs4812048	0.649	rs3761255	chr20:57618802	T/C	cg14073986	chr20:57617431	SLMO2	0.79	6.96	0.39	2.61e-11	Mean platelet volume;
CESC	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg24642844	chr7:1081250	C7orf50	-0.76	-9.35	-0.5	3.75e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs1215050	0.791	rs1530904	chr4:98805436	A/G	cg05340658	chr4:99064831	C4orf37	0.52	6.88	0.39	4.36e-11	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg24642844	chr7:1081250	C7orf50	-0.77	-9.3	-0.5	5.54e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs9303401	0.614	rs34900851	chr17:56566399	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.01	12.08	0.6	4.54e-27	Cognitive test performance;
CESC	cis	rs1707322	1.000	rs4660336	chr1:46487976	T/C	cg05343316	chr1:45956843	TESK2	-0.44	-5.38	-0.31	1.66e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2836974	0.897	rs2836944	chr21:40593539	G/A	cg27266027	chr21:40555129	PSMG1	0.46	5.43	0.32	1.27e-7	Cognitive function;
CESC	cis	rs11792861	0.926	rs7046725	chr9:111882729	T/G	cg13535736	chr9:111863775	C9orf5	-0.5	-6.68	-0.38	1.43e-10	Menarche (age at onset);
CESC	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	10.23	0.53	6.6e-21	Prudent dietary pattern;
CESC	cis	rs6662572	1.000	rs28433203	chr1:46196813	G/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.52	5.45	0.32	1.17e-7	Blood protein levels;
CESC	cis	rs2735413	0.837	rs4888734	chr16:78083685	C/G	cg04733911	chr16:78082701	NA	-0.53	-8.89	-0.48	9.44e-17	Systolic blood pressure (alcohol consumption interaction);
CESC	cis	rs7927592	0.731	rs488381	chr11:68291693	G/A	cg16797656	chr11:68205561	LRP5	-0.49	-7.54	-0.42	7.54e-13	Total body bone mineral density;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07785726	chr13:50159788	RCBTB1	0.54	6.33	0.36	1.04e-9	Gut microbiome composition (summer);
CESC	cis	rs2180341	0.618	rs11961994	chr6:127649350	A/G	cg24812749	chr6:127587940	RNF146	-0.59	-7.92	-0.44	6.62e-14	Breast cancer;
CESC	cis	rs4595586	0.545	rs4254106	chr12:39389342	G/A	cg26384229	chr12:38710491	ALG10B	0.53	7.55	0.42	6.93e-13	Morning vs. evening chronotype;
CESC	cis	rs910316	0.737	rs424120	chr14:75482828	G/T	cg11812906	chr14:75593930	NEK9	-0.81	-13.05	-0.63	2.11e-30	Height;
CESC	cis	rs35110281	0.755	rs4819270	chr21:45020919	G/A	cg04455712	chr21:45112962	RRP1B	0.39	5.76	0.33	2.35e-8	Mean corpuscular volume;
CESC	cis	rs2735413	0.918	rs4888725	chr16:78076761	C/T	cg04733911	chr16:78082701	NA	-0.53	-9.01	-0.48	4.08e-17	Systolic blood pressure (alcohol consumption interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18958584	chr17:18266764	SHMT1	0.64	7.31	0.41	3.14e-12	Gut microbiome composition (summer);
CESC	cis	rs10927875	0.632	rs7535248	chr1:16129598	C/T	cg21385522	chr1:16154831	NA	-1.03	-16.9	-0.72	5.51e-44	Dilated cardiomyopathy;
CESC	cis	rs8002861	0.692	rs9533646	chr13:44410669	T/C	cg19180546	chr13:44453867	C13orf31;CCDC122	-0.39	-5.11	-0.3	6.03e-7	Leprosy;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg25011051	chr17:40718249	MLX;COASY	0.46	6.66	0.38	1.54e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs1881797	1.000	rs7527856	chr1:247688139	C/T	cg11166453	chr1:247681781	NA	0.47	6.33	0.36	1.05e-9	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs769267	0.965	rs12977937	chr19:19429975	C/G	cg03709012	chr19:19516395	GATAD2A	0.96	13.77	0.65	6.58e-33	Tonsillectomy;
CESC	cis	rs2637266	1.000	rs12262400	chr10:78386862	T/C	cg18941641	chr10:78392320	NA	0.43	8.21	0.45	9.73e-15	Pulmonary function;
CESC	cis	rs477692	1.000	rs508303	chr10:131424996	A/T	cg05714579	chr10:131428358	MGMT	-0.53	-7.11	-0.4	1.09e-11	Response to temozolomide;
CESC	cis	rs9910055	0.659	rs227584	chr17:42225547	A/C	cg08499158	chr17:42289980	UBTF	-0.52	-6.57	-0.37	2.68e-10	Total body bone mineral density;
CESC	cis	rs4835473	0.864	rs4835343	chr4:144787191	A/C	cg25736465	chr4:144833511	NA	0.44	6.58	0.37	2.48e-10	Immature fraction of reticulocytes;
CESC	cis	rs889312	0.500	rs33323	chr5:56175566	C/G	cg14703610	chr5:56206110	C5orf35	0.48	6.22	0.36	1.96e-9	Breast cancer;Breast cancer (early onset);
CESC	cis	rs910316	0.967	rs4899551	chr14:75660246	C/G	cg11812906	chr14:75593930	NEK9	-0.85	-14.19	-0.66	2.25e-34	Height;
CESC	cis	rs6547741	0.563	rs10196039	chr2:27971195	C/T	cg27432699	chr2:27873401	GPN1	-0.55	-7.6	-0.42	5.08e-13	Oral cavity cancer;
CESC	cis	rs7208859	0.673	rs2470251	chr17:29095061	T/C	cg14008862	chr17:28927542	LRRC37B2	0.56	5.24	0.31	3.36e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs796364	0.951	rs281793	chr2:200847990	G/A	cg23649088	chr2:200775458	C2orf69	0.55	5.16	0.3	4.74e-7	Schizophrenia;
CESC	cis	rs769267	0.965	rs2965188	chr19:19522557	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.45	5.92	0.34	1.01e-8	Tonsillectomy;
CESC	cis	rs67478160	0.619	rs11160761	chr14:104254856	A/T	cg08213375	chr14:104286397	PPP1R13B	0.55	10.84	0.55	6.53e-23	Schizophrenia;
CESC	cis	rs7615952	0.641	rs66520539	chr3:125780374	G/A	cg02807482	chr3:125708958	NA	-0.4	-5.2	-0.3	3.94e-7	Blood pressure (smoking interaction);
CESC	cis	rs3733585	0.699	rs4276278	chr4:9948870	T/C	cg00071950	chr4:10020882	SLC2A9	-0.72	-11.95	-0.59	1.27e-26	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs763121	1.000	rs86796	chr22:38881454	A/C	cg06022373	chr22:39101656	GTPBP1	-0.7	-10.45	-0.54	1.22e-21	Menopause (age at onset);
CESC	cis	rs2191566	0.960	rs6509133	chr19:44522913	A/G	cg20607764	chr19:44506953	ZNF230	0.56	7.11	0.4	1.07e-11	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs7927771	0.864	rs2293577	chr11:47437202	C/T	cg05585544	chr11:47624801	NA	0.42	6.19	0.36	2.33e-9	Subjective well-being;
CESC	cis	rs10504229	0.593	rs12155520	chr8:58014318	C/T	cg24829409	chr8:58192753	C8orf71	-0.67	-7.32	-0.41	3e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs9894429	0.634	rs11655346	chr17:79572399	A/G	cg18240062	chr17:79603768	NPLOC4	-0.54	-7.2	-0.4	6.24e-12	Eye color traits;
CESC	cis	rs3741798	1.000	rs61922052	chr12:12497620	A/G	cg08615371	chr12:12503544	MANSC1	0.79	5.65	0.33	4.22e-8	Cerebrospinal fluid biomarker levels;
CESC	cis	rs10788264	0.621	rs9633734	chr10:124057667	T/C	cg09507567	chr10:124027408	NA	0.36	5.23	0.31	3.5e-7	Total body bone mineral density;
CESC	cis	rs6912958	0.559	rs242281	chr6:88048916	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.44	7.8	0.43	1.47e-13	Monocyte percentage of white cells;
CESC	cis	rs10504229	1.000	rs59071610	chr8:58186301	A/C	cg24829409	chr8:58192753	C8orf71	-0.76	-9.93	-0.52	5.87e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs6831352	0.918	rs7670241	chr4:100059619	G/T	cg12011299	chr4:100065546	ADH4	-0.6	-6.62	-0.38	2.04e-10	Alcohol dependence;
CESC	cis	rs617791	0.508	rs10896074	chr11:65776304	C/T	cg04055107	chr11:65626734	MUS81;CFL1	-0.48	-5.39	-0.31	1.58e-7	Breast cancer;
CESC	cis	rs4986811	0.852	rs72893517	chr11:32451921	G/C	cg27409910	chr11:32454216	WT1	0.48	6.2	0.36	2.18e-9	Rubella-specific interleukin-6 secretion;
CESC	cis	rs4665809	1.000	rs2289022	chr2:26350136	G/T	cg08470875	chr2:26401718	FAM59B	-0.47	-5.24	-0.31	3.31e-7	Gut microbiome composition (summer);
CESC	cis	rs10256972	0.967	rs1881122	chr7:1040946	A/T	cg04025307	chr7:1156635	C7orf50	0.4	6.39	0.37	7.38e-10	Longevity;Endometriosis;
CESC	cis	rs9894429	0.752	rs6565610	chr17:79592652	A/G	cg18240062	chr17:79603768	NPLOC4	0.9	13.2	0.63	6.66e-31	Eye color traits;
CESC	cis	rs4642101	0.765	rs4321514	chr3:12825901	C/T	cg05775895	chr3:12838266	CAND2	0.39	5.99	0.35	6.95e-9	QRS complex (12-leadsum);
CESC	cis	rs6741892	0.536	rs13024840	chr2:38895920	T/A	cg08308459	chr2:38893161	GALM	-0.54	-6.72	-0.38	1.12e-10	5-HTT brain serotonin transporter levels;
CESC	cis	rs8017423	0.967	rs55667096	chr14:90714798	C/T	cg14092571	chr14:90743983	NA	-0.58	-8.66	-0.47	4.57e-16	Mortality in heart failure;
CESC	cis	rs4481887	1.000	rs9660769	chr1:248484558	C/G	cg00666640	chr1:248458726	OR2T12	-0.43	-7.07	-0.4	1.37e-11	Common traits (Other);
CESC	cis	rs7044106	0.762	rs10818471	chr9:123394045	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.76	10.99	0.56	2.18e-23	Hip circumference adjusted for BMI;
CESC	cis	rs7267979	0.873	rs7453	chr20:25207074	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.81	16.14	0.7	2.75e-41	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs763121	0.853	rs1043441	chr22:39130964	C/T	cg14440974	chr22:39074834	NA	-0.4	-5.55	-0.32	6.82e-8	Menopause (age at onset);
CESC	cis	rs7818345	0.967	rs7006702	chr8:19272533	G/C	cg11303988	chr8:19266685	CSGALNACT1	0.34	6.03	0.35	5.51e-9	Language performance in older adults (adjusted for episodic memory);
CESC	cis	rs7044106	0.762	rs966397	chr9:123453312	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.36	5.83	0.34	1.58e-8	Hip circumference adjusted for BMI;
CESC	cis	rs1401999	0.565	rs4912515	chr3:183653718	A/G	cg01324343	chr3:183735012	ABCC5	0.34	6.14	0.35	2.93e-9	Anterior chamber depth;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25793566	chr3:196467045	PAK2	0.52	6.24	0.36	1.75e-9	Gut microbiome composition (summer);
CESC	cis	rs9908102	0.710	rs4792314	chr17:12918451	G/A	cg26162695	chr17:12921313	ELAC2	0.56	6.04	0.35	5.13e-9	Schizophrenia;
CESC	cis	rs938554	0.735	rs11942223	chr4:9962765	T/C	cg00071950	chr4:10020882	SLC2A9	-0.52	-6.04	-0.35	5.3300000000000004e-09	Blood metabolite levels;
CESC	trans	rs17685	0.712	rs11770149	chr7:75791644	G/A	cg19862616	chr7:65841803	NCRNA00174	0.79	11.08	0.56	1.09e-23	Coffee consumption;Coffee consumption (cups per day);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg12933314	chr7:4815160	KIAA0415	-0.5	-7.48	-0.42	1.09e-12	Gambling;
CESC	cis	rs2573652	0.722	rs12914189	chr15:100544429	A/T	cg09918751	chr15:100517450	ADAMTS17	0.27	5.13	0.3	5.64e-7	Height;
CESC	cis	rs6456156	0.586	rs12203510	chr6:167473006	C/T	cg23791538	chr6:167370224	RNASET2	-0.48	-6.0	-0.35	6.29e-9	Primary biliary cholangitis;
CESC	cis	rs10465746	0.905	rs12127266	chr1:84360767	T/G	cg10977910	chr1:84465055	TTLL7	0.47	6.36	0.36	8.7e-10	Obesity-related traits;
CESC	cis	rs6598955	0.670	rs7531518	chr1:26539749	T/C	cg00852783	chr1:26633632	UBXN11	0.41	5.97	0.34	7.44e-9	Obesity-related traits;
CESC	cis	rs9910055	0.659	rs3826412	chr17:42255097	A/G	cg13607699	chr17:42295918	UBTF	0.57	7.14	0.4	8.93e-12	Total body bone mineral density;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg11814422	chr18:47018265	SNORD58A;RPL17;SNORD58B	0.47	6.18	0.35	2.46e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs3762637	1.000	rs72960431	chr3:122228661	T/C	cg24169773	chr3:122142474	KPNA1	-0.57	-6.98	-0.39	2.36e-11	LDL cholesterol levels;
CESC	cis	rs1322639	0.592	rs7743597	chr6:169591678	T/C	cg04662567	chr6:169592167	NA	-0.43	-6.12	-0.35	3.42e-9	Pulse pressure;
CESC	cis	rs2364543	0.624	rs61774752	chr1:41847024	T/C	cg08462924	chr1:41848221	NA	0.43	6.0	0.35	6.55e-9	Intelligence (multi-trait analysis);
CESC	cis	rs11758351	0.660	rs55848726	chr6:26224434	T/C	cg01420254	chr6:26195488	NA	0.77	8.49	0.46	1.48e-15	Gout;Renal underexcretion gout;
CESC	cis	rs7666738	0.791	rs1896156	chr4:99020882	C/G	cg03676636	chr4:99064102	C4orf37	0.33	5.15	0.3	5.05e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs9693444	0.898	rs4732697	chr8:29519861	A/G	cg01830674	chr2:219433148	RQCD1;USP37	-0.41	-6.21	-0.36	2.01e-9	Breast cancer;
CESC	cis	rs116979167	0.575	rs818470	chr7:105165350	A/C	cg13798780	chr7:105162888	PUS7	0.53	6.41	0.37	6.67e-10	Bipolar disorder (body mass index interaction);
CESC	cis	rs977987	0.806	rs8056236	chr16:75448273	C/T	cg03315344	chr16:75512273	CHST6	0.41	5.81	0.34	1.79e-8	Dupuytren's disease;
CESC	cis	rs4595586	0.545	rs7294600	chr12:39373416	A/G	cg26384229	chr12:38710491	ALG10B	0.54	7.53	0.42	7.85e-13	Morning vs. evening chronotype;
CESC	trans	rs8073060	0.586	rs225256	chr17:33955756	C/T	cg19694781	chr19:47549865	TMEM160	-0.73	-7.03	-0.4	1.79e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	cis	rs763121	0.626	rs5750643	chr22:39009017	A/G	cg21395723	chr22:39101663	GTPBP1	0.51	6.76	0.38	8.67e-11	Menopause (age at onset);
CESC	cis	rs769267	0.930	rs1054284	chr19:19616953	T/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.51	6.38	0.36	8.06e-10	Tonsillectomy;
CESC	cis	rs10504229	0.679	rs72649109	chr8:58031274	A/T	cg14926445	chr8:58193284	C8orf71	-0.54	-5.19	-0.3	4.29e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs898097	0.841	rs4986122	chr17:80825500	C/T	cg15369054	chr17:80825471	TBCD	0.55	7.76	0.43	1.89e-13	Breast cancer;
CESC	cis	rs6540556	0.859	rs1007693	chr1:209931799	C/T	cg05527609	chr1:210001259	C1orf107	-0.45	-5.72	-0.33	2.86e-8	Red blood cell count;
CESC	cis	rs1538970	0.924	rs7528573	chr1:45913860	T/C	cg24296786	chr1:45957014	TESK2	-0.46	-5.25	-0.31	3.14e-7	Platelet count;
CESC	cis	rs651907	0.557	rs7645391	chr3:101361506	C/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.45	5.85	0.34	1.45e-8	Colorectal cancer;
CESC	cis	rs2463822	0.925	rs6863	chr11:62160725	G/T	cg06239285	chr11:62104954	ASRGL1	-1.0	-8.65	-0.47	5.18e-16	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs74781061	0.722	rs77102700	chr15:74896941	G/A	cg17294928	chr15:75287854	SCAMP5	-0.54	-5.35	-0.31	1.94e-7	Endometriosis;
CESC	cis	rs1008375	1.000	rs11724495	chr4:17621310	G/A	cg02297831	chr4:17616191	MED28	0.53	6.71	0.38	1.16e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs17739794	0.557	rs7816977	chr8:814612	A/G	cg07178994	chr8:816998	NA	0.29	5.08	0.3	7.12e-7	Clozapine-induced cytotoxicity;
CESC	cis	rs2249694	0.960	rs11101890	chr10:135421321	G/A	cg19469447	chr10:135341870	CYP2E1	0.37	5.2	0.3	3.99e-7	Obesity-related traits;
CESC	cis	rs1552244	0.882	rs13088350	chr3:10044626	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	10.82	0.55	7.67e-23	Alzheimer's disease;
CESC	cis	rs5758659	0.652	rs133347	chr22:42423645	A/T	cg15557168	chr22:42548783	NA	-0.48	-7.56	-0.42	6.56e-13	Cognitive function;
CESC	cis	rs7520050	0.931	rs35743647	chr1:46407252	T/C	cg24296786	chr1:45957014	TESK2	0.44	5.49	0.32	9.64e-8	Red blood cell count;Reticulocyte count;
CESC	cis	rs4253772	0.591	rs9615348	chr22:46729338	C/G	cg24881330	chr22:46731750	TRMU	0.8	5.7	0.33	3.13e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs8028182	1.000	rs8028182	chr15:75718669	G/T	cg20655648	chr15:75932815	IMP3	0.46	5.3	0.31	2.44e-7	Sudden cardiac arrest;
CESC	cis	rs2295499	0.700	rs12503424	chr4:2702807	A/G	cg27239842	chr4:2403781	ZFYVE28	-0.32	-5.32	-0.31	2.2e-7	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
CESC	cis	rs9486719	0.947	rs72932805	chr6:96902933	T/G	cg06623918	chr6:96969491	KIAA0776	-0.81	-8.3	-0.45	5.45e-15	Migraine;Coronary artery disease;
CESC	cis	rs7666738	0.830	rs4292341	chr4:98959724	C/T	cg05340658	chr4:99064831	C4orf37	0.63	9.73	0.51	2.42e-19	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9900062	0.519	rs2676293	chr17:62710461	T/C	cg02598441	chr17:62777298	LOC146880	-0.49	-5.19	-0.3	4.21e-7	QT interval;
CESC	cis	rs601339	1.000	rs35683065	chr12:123164062	G/C	cg11919336	chr12:123188078	GPR109A	0.45	5.85	0.34	1.47e-8	Adiponectin levels;
CESC	cis	rs7772486	0.623	rs735535	chr6:146036829	C/T	cg23711669	chr6:146136114	FBXO30	-0.89	-13.19	-0.63	6.74e-31	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs910316	0.967	rs11159121	chr14:75666029	A/T	cg11812906	chr14:75593930	NEK9	-0.82	-13.42	-0.64	1.14e-31	Height;
CESC	cis	rs2836950	0.501	rs11702505	chr21:40700614	G/T	cg11644478	chr21:40555479	PSMG1	-0.56	-7.65	-0.43	3.72e-13	Menarche (age at onset);
CESC	cis	rs6942756	0.747	rs691124	chr7:129098439	A/G	cg02491457	chr7:128862824	NA	-0.59	-8.05	-0.44	2.79e-14	White matter hyperintensity burden;
CESC	cis	rs8114671	0.836	rs2104083	chr20:33649133	G/A	cg06115741	chr20:33292138	TP53INP2	-0.43	-5.15	-0.3	5.03e-7	Height;
CESC	cis	rs7666738	0.791	rs10010438	chr4:99022177	C/T	cg17366294	chr4:99064904	C4orf37	0.61	8.76	0.47	2.35e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg10819733	chr22:24237672	NA	-0.44	-6.34	-0.36	1e-9	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs12368653	0.557	rs903067	chr12:58011857	G/A	cg00700412	chr12:58011837	NA	-0.43	-6.61	-0.38	2.11e-10	Multiple sclerosis;
CESC	cis	rs9549367	0.789	rs12584008	chr13:113881228	C/T	cg00898013	chr13:113819073	PROZ	-0.5	-6.9	-0.39	3.77e-11	Platelet distribution width;
CESC	cis	rs6690583	0.573	rs61768854	chr1:85460021	T/C	cg22153463	chr1:85462885	MCOLN2	0.76	7.2	0.4	6.15e-12	Serum sulfate level;
CESC	cis	rs4713118	0.516	rs4713142	chr6:28106347	T/G	cg18032046	chr6:28092343	ZSCAN16	-0.55	-6.39	-0.37	7.41e-10	Parkinson's disease;
CESC	cis	rs7116495	0.609	rs10793014	chr11:71698838	A/G	cg10381502	chr11:71823885	C11orf51	-1.19	-7.81	-0.43	1.32e-13	Severe influenza A (H1N1) infection;
CESC	cis	rs9311474	0.508	rs11714565	chr3:52606292	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.49	7.18	0.4	6.94e-12	Electroencephalogram traits;
CESC	cis	rs916888	0.779	rs199498	chr17:44865603	A/G	cg01570182	chr17:44337453	NA	0.61	7.34	0.41	2.57e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs4595586	0.545	rs17546137	chr12:39401124	G/A	cg26384229	chr12:38710491	ALG10B	0.62	8.72	0.47	3.18e-16	Morning vs. evening chronotype;
CESC	cis	rs9486719	0.741	rs2049927	chr6:96848958	C/G	cg18709589	chr6:96969512	KIAA0776	-0.5	-5.36	-0.31	1.83e-7	Migraine;Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15252948	chr8:42698594	THAP1	0.54	6.09	0.35	4.02e-9	Gut microbiome composition (summer);
CESC	cis	rs17253792	0.822	rs78386830	chr14:56069224	G/A	cg01858014	chr14:56050164	KTN1	-0.85	-6.99	-0.39	2.22e-11	Putamen volume;
CESC	cis	rs875971	1.000	rs1565531	chr7:65663113	T/A	cg11764359	chr7:65958608	NA	-0.92	-14.72	-0.67	2.89e-36	Aortic root size;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg09249682	chr7:17338253	AHR	0.47	6.0	0.35	6.4e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs1005224	0.853	rs2360035	chr14:76297093	A/T	cg25116370	chr14:76127843	TTLL5;C14orf1	0.44	5.88	0.34	1.2e-8	Large artery stroke;
CESC	cis	rs12477438	0.501	rs13033012	chr2:99795149	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.78	12.45	0.61	2.6e-28	Chronic sinus infection;
CESC	cis	rs793571	0.590	rs442495	chr15:59022615	T/C	cg05156742	chr15:59063176	FAM63B	0.58	7.69	0.43	2.96e-13	Schizophrenia;
CESC	cis	rs35306767	0.903	rs12769431	chr10:922633	T/C	cg10556349	chr10:835070	NA	0.55	5.25	0.31	3.05e-7	Eosinophil percentage of granulocytes;
CESC	cis	rs1801251	0.778	rs778338	chr2:233740227	A/G	cg25237894	chr2:233734115	C2orf82	-0.5	-8.81	-0.48	1.65e-16	Coronary artery disease;
CESC	cis	rs769267	0.931	rs2965193	chr19:19454828	G/A	cg15052019	chr19:19431593	KIAA0892;SF4	-0.4	-5.09	-0.3	6.73e-7	Tonsillectomy;
CESC	cis	rs10791097	0.694	rs1893017	chr11:130756253	C/T	cg12179176	chr11:130786555	SNX19	0.66	10.36	0.54	2.45e-21	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs11630290	0.592	rs12232261	chr15:64153302	A/G	cg12036633	chr15:63758958	NA	0.46	5.67	0.33	3.82e-8	Iris characteristics;
CESC	cis	rs4595586	0.525	rs4511319	chr12:39340457	T/C	cg26384229	chr12:38710491	ALG10B	0.45	6.38	0.36	7.93e-10	Morning vs. evening chronotype;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg13369981	chr7:100027501	MEPCE;ZCWPW1	-0.45	-7.17	-0.4	7.56e-12	Gambling;
CESC	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg14893161	chr1:205819251	PM20D1	0.89	14.24	0.66	1.42e-34	Menarche (age at onset);
CESC	cis	rs1008375	1.000	rs28693609	chr4:17645233	C/T	cg15017067	chr4:17643749	FAM184B	0.37	5.23	0.31	3.39e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs977987	0.843	rs12928036	chr16:75483132	G/A	cg03315344	chr16:75512273	CHST6	0.43	6.26	0.36	1.5e-9	Dupuytren's disease;
CESC	cis	rs806215	0.950	rs2073561	chr7:127227769	G/C	cg25922125	chr7:127225783	GCC1	-0.44	-5.05	-0.3	8.14e-7	Type 2 diabetes;
CESC	cis	rs2730245	1.000	rs2657345	chr7:158744169	T/C	cg24397884	chr7:158709396	WDR60	-0.88	-13.41	-0.64	1.25e-31	Height;
CESC	cis	rs2243480	1.000	rs1499613	chr7:65730860	G/A	cg12463550	chr7:65579703	CRCP	-0.74	-5.73	-0.33	2.74e-8	Diabetic kidney disease;
CESC	cis	rs2108622	0.727	rs7251296	chr19:15983736	A/G	cg13772218	chr19:15982569	NA	0.28	5.68	0.33	3.62e-8	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CESC	trans	rs1728785	0.901	rs11075687	chr16:68655894	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.71	8.19	0.45	1.15e-14	Ulcerative colitis;
CESC	cis	rs7940866	0.874	rs10791113	chr11:130873165	A/G	cg12179176	chr11:130786555	SNX19	0.69	9.96	0.52	4.82e-20	Schizophrenia;
CESC	cis	rs2439831	0.867	rs2927072	chr15:43922398	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.81	8.35	0.46	3.84e-15	Lung cancer in ever smokers;
CESC	cis	rs8031584	0.678	rs8035703	chr15:31168472	T/C	cg14829155	chr15:31115871	NA	-0.75	-10.54	-0.54	6.55e-22	Huntington's disease progression;
CESC	trans	rs2963826	0.589	rs298091	chr5:58996603	A/T	cg22146484	chr8:57123862	CHCHD7;PLAG1	0.48	6.07	0.35	4.39e-9	Obesity-related traits;
CESC	cis	rs6582630	0.519	rs4436613	chr12:38293653	T/C	cg26384229	chr12:38710491	ALG10B	0.71	10.63	0.55	3.23e-22	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs7274811	0.723	rs6120329	chr20:32210238	T/G	cg21523528	chr20:32077966	CBFA2T2	0.64	7.35	0.41	2.42e-12	Height;
CESC	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg03188948	chr7:1209495	NA	0.71	7.06	0.4	1.5e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs950169	1.000	rs12903820	chr15:84723820	A/G	cg17507749	chr15:85114479	UBE2QP1	0.63	6.93	0.39	3.26e-11	Schizophrenia;
CESC	cis	rs651907	0.557	rs11925001	chr3:101373966	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.48	6.2	0.36	2.21e-9	Colorectal cancer;
CESC	cis	rs13385	0.769	rs28573694	chr5:139609951	T/G	cg26211634	chr5:139558579	C5orf32	0.47	5.19	0.3	4.23e-7	Atrial fibrillation;
CESC	cis	rs875971	0.502	rs6460311	chr7:66111873	C/T	cg11764359	chr7:65958608	NA	-0.82	-9.26	-0.49	7.38e-18	Aortic root size;
CESC	cis	rs2228479	0.557	rs62056064	chr16:89903843	G/A	cg06558623	chr16:89946397	TCF25	1.12	8.22	0.45	9.28e-15	Skin colour saturation;
CESC	cis	rs711830	0.587	rs10188827	chr2:177007664	C/T	cg13092806	chr2:177043255	NA	0.57	6.43	0.37	5.76e-10	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
CESC	cis	rs4925386	1.000	rs6089351	chr20:60916153	G/A	cg22633769	chr20:60982531	CABLES2	-0.43	-5.09	-0.3	6.95e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs4819052	0.851	rs13052344	chr21:46676101	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.95	14.1	0.65	4.6e-34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs611744	0.573	rs629996	chr8:109255206	C/T	cg21045802	chr8:109455806	TTC35	0.56	7.02	0.4	1.89e-11	Dupuytren's disease;
CESC	cis	rs7084402	0.967	rs1649038	chr10:60330439	G/A	cg07615347	chr10:60278583	BICC1	0.59	9.15	0.49	1.57e-17	Refractive error;
CESC	cis	rs6860806	0.507	rs272878	chr5:131671769	C/T	cg24060327	chr5:131705240	SLC22A5	0.76	10.74	0.55	1.43e-22	Breast cancer;
CESC	trans	rs7618501	1.000	rs6785549	chr3:49736565	G/A	cg21659725	chr3:3221576	CRBN	-0.82	-13.41	-0.64	1.16e-31	Intelligence (multi-trait analysis);
CESC	cis	rs7666738	0.830	rs28619044	chr4:98789814	G/C	cg24818145	chr4:99064322	C4orf37	0.38	5.05	0.3	8.39e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11638815	0.954	rs783544	chr15:83240293	A/C	cg25333056	chr10:135107159	TUBGCP2	0.48	6.05	0.35	4.97e-9	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;
CESC	cis	rs3733585	0.624	rs7376154	chr4:9952587	C/A	cg11266682	chr4:10021025	SLC2A9	-0.58	-11.0	-0.56	2.04e-23	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs6060717	0.536	rs6060699	chr20:34523833	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.73	-7.76	-0.43	1.86e-13	Hip circumference adjusted for BMI;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg08977639	chr16:1047820	NA	-0.42	-6.31	-0.36	1.19e-9	Gambling;
CESC	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg12419862	chr22:24373484	LOC391322	-0.91	-14.19	-0.66	2.24e-34	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs7647973	1.000	rs10865956	chr3:49581559	C/A	cg07636037	chr3:49044803	WDR6	0.7	10.18	0.53	9.15e-21	Menarche (age at onset);
CESC	cis	rs7412746	0.658	rs72704685	chr1:150897687	C/G	cg22823121	chr1:150693482	HORMAD1	0.4	5.64	0.33	4.46e-8	Melanoma;
CESC	cis	rs1707322	0.721	rs7520123	chr1:46235219	C/G	cg05343316	chr1:45956843	TESK2	0.49	6.27	0.36	1.47e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs6831352	0.959	rs1139490	chr4:100045141	C/T	cg13256891	chr4:100009986	ADH5	0.61	7.26	0.41	4.35e-12	Alcohol dependence;
CESC	cis	rs1538970	0.924	rs4660858	chr1:45936351	G/A	cg05343316	chr1:45956843	TESK2	0.9	12.33	0.6	6.6e-28	Platelet count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15645344	chr4:165109574	MARCH1	-0.54	-6.21	-0.36	2.05e-9	Gut microbiome composition (summer);
CESC	trans	rs66573146	1.000	rs6812771	chr4:6964048	G/A	cg07817883	chr1:32538562	TMEM39B	1.51	9.21	0.49	1.06e-17	Granulocyte percentage of myeloid white cells;
CESC	cis	rs1707322	1.000	rs4454479	chr1:46423555	G/A	cg06784218	chr1:46089804	CCDC17	0.33	5.63	0.33	4.7e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	7.83	0.43	1.17e-13	Prudent dietary pattern;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22511293	chr12:109915400	KCTD10;UBE3B	0.58	6.42	0.37	6.34e-10	Gut microbiome composition (summer);
CESC	cis	rs79976124	0.719	rs34488909	chr6:66637850	T/C	cg07460842	chr6:66804631	NA	0.69	8.03	0.44	3.13e-14	Type 2 diabetes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00677986	chr12:80084523	PAWR	0.65	7.91	0.44	7.12e-14	Gut microbiome composition (summer);
CESC	cis	rs7727544	0.735	rs274566	chr5:131715011	A/G	cg24060327	chr5:131705240	SLC22A5	0.69	9.24	0.49	8.12e-18	Blood metabolite levels;
CESC	cis	rs7772486	0.902	rs1331643	chr6:146398873	T/A	cg23711669	chr6:146136114	FBXO30	0.74	10.93	0.56	3.43e-23	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2282802	0.685	rs2116790	chr5:139654115	G/A	cg26211634	chr5:139558579	C5orf32	0.52	7.49	0.42	1.01e-12	Intelligence (multi-trait analysis);
CESC	cis	rs7666738	0.830	rs9307218	chr4:99024885	T/C	cg05340658	chr4:99064831	C4orf37	0.81	12.59	0.61	8.13e-29	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4642101	0.855	rs9836128	chr3:12845426	G/C	cg05775895	chr3:12838266	CAND2	0.39	5.78	0.33	2.1e-8	QRS complex (12-leadsum);
CESC	cis	rs7927771	0.864	rs60075622	chr11:47449101	T/G	cg20307385	chr11:47447363	PSMC3	-0.62	-7.41	-0.41	1.72e-12	Subjective well-being;
CESC	cis	rs7917772	0.604	rs10883756	chr10:104400112	T/C	cg04362960	chr10:104952993	NT5C2	0.39	5.04	0.3	8.43e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs10504229	0.679	rs17193048	chr8:58055392	G/A	cg22535103	chr8:58192502	C8orf71	-0.83	-8.17	-0.45	1.31e-14	Developmental language disorder (linguistic errors);
CESC	cis	rs10905065	0.965	rs2797488	chr10:5784509	C/T	cg11519256	chr10:5708881	ASB13	0.42	5.58	0.32	6.03e-8	Menopause (age at onset);
CESC	cis	rs9393777	0.920	rs35869525	chr6:26946687	C/T	cg21479132	chr6:26055353	NA	0.81	5.92	0.34	9.95e-9	Intelligence (multi-trait analysis);
CESC	trans	rs8073060	0.586	rs72829923	chr17:34045089	T/A	cg19694781	chr19:47549865	TMEM160	0.72	6.47	0.37	4.78e-10	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	cis	rs7927592	0.956	rs11228278	chr11:68308530	G/A	cg20283391	chr11:68216788	NA	-0.49	-6.25	-0.36	1.61e-9	Total body bone mineral density;
CESC	cis	rs1348850	0.632	rs1358328	chr2:178517532	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.59	7.37	0.41	2.12e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs10504229	0.953	rs57131327	chr8:58171895	T/C	cg24829409	chr8:58192753	C8orf71	-0.76	-10.0	-0.52	3.53e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs7116495	0.609	rs3750907	chr11:71822560	T/C	cg07596299	chr11:71824057	C11orf51	0.82	5.06	0.3	8e-7	Severe influenza A (H1N1) infection;
CESC	trans	rs61931739	0.500	rs7295779	chr12:34460652	T/C	cg26384229	chr12:38710491	ALG10B	0.56	7.89	0.44	7.84e-14	Morning vs. evening chronotype;
CESC	cis	rs889398	0.651	rs1566455	chr16:69900164	G/T	cg09409435	chr16:70099608	PDXDC2	0.4	5.11	0.3	6.15e-7	Body mass index;
CESC	cis	rs1559088	0.739	rs9304845	chr19:33592794	A/G	cg17764715	chr19:33622953	WDR88	0.48	6.27	0.36	1.49e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs9818758	0.607	rs9880088	chr3:49178990	G/A	cg00383909	chr3:49044727	WDR6	0.85	6.44	0.37	5.54e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CESC	cis	rs2404602	0.591	rs11635162	chr15:76951105	C/T	cg00316803	chr15:76480434	C15orf27	0.43	5.84	0.34	1.56e-8	Blood metabolite levels;
CESC	trans	rs7307889	0.793	rs55712234	chr12:6006618	G/T	cg18407955	chr7:158110685	PTPRN2	-0.74	-6.29	-0.36	1.29e-9	Obesity-related traits;
CESC	cis	rs1707322	0.721	rs11211181	chr1:46236800	C/T	cg06784218	chr1:46089804	CCDC17	0.39	7.05	0.4	1.55e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2425143	1.000	rs8115150	chr20:34397189	G/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.68	5.88	0.34	1.24e-8	Blood protein levels;
CESC	cis	rs11098499	0.954	rs10034623	chr4:120397829	G/A	cg24375607	chr4:120327624	NA	0.45	5.68	0.33	3.51e-8	Corneal astigmatism;
CESC	trans	rs2733310	0.948	rs2703594	chr15:57488790	C/G	cg08773106	chr17:30055218	NA	0.39	6.01	0.35	6.15e-9	Mean platelet volume;
CESC	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg06873352	chr17:61820015	STRADA	0.73	12.96	0.62	4.25e-30	Prudent dietary pattern;
CESC	cis	rs172166	0.694	rs1770131	chr6:28086413	C/T	cg19592336	chr6:28129416	ZNF389	0.47	6.96	0.39	2.68e-11	Cardiac Troponin-T levels;
CESC	cis	rs1348850	0.598	rs12616259	chr2:178503803	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.59	7.56	0.42	6.75e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs7216064	0.589	rs8072723	chr17:66056970	T/A	cg07042672	chr17:66097459	LOC651250	0.67	8.94	0.48	7.02e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg18402987	chr7:1209562	NA	0.75	7.49	0.42	1.04e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs853679	0.517	rs1904841	chr6:28108085	C/T	cg19592336	chr6:28129416	ZNF389	0.64	8.79	0.47	1.97e-16	Depression;
CESC	cis	rs6493487	0.512	rs2899459	chr15:51130369	A/T	cg02338191	chr15:51200825	AP4E1	0.5	5.12	0.3	5.93e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs875971	0.522	rs2008188	chr7:65429013	G/C	cg11987759	chr7:65425863	GUSB	-0.46	-6.24	-0.36	1.69e-9	Aortic root size;
CESC	cis	rs7551222	0.752	rs4245736	chr1:204486205	G/C	cg20240347	chr1:204465584	NA	-0.28	-5.61	-0.33	5.15e-8	Schizophrenia;
CESC	cis	rs6912958	0.703	rs9362427	chr6:88097634	G/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.72	10.33	0.54	2.98e-21	Monocyte percentage of white cells;
CESC	cis	rs1799949	0.965	rs8067269	chr17:41235799	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.48	6.9	0.39	3.72e-11	Menopause (age at onset);
CESC	cis	rs10979	0.557	rs9376768	chr6:143909492	C/T	cg25407410	chr6:143891975	LOC285740	-0.49	-6.55	-0.37	2.98e-10	Hypospadias;
CESC	cis	rs17711722	0.727	rs2658585	chr7:65461941	A/T	cg11764359	chr7:65958608	NA	0.7	8.96	0.48	5.88e-17	Calcium levels;
CESC	cis	rs7666738	0.753	rs7698541	chr4:98986351	T/A	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.67e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11088226	0.681	rs2833895	chr21:33929802	G/A	cg09050820	chr6:167586206	TCP10L2	0.87	8.52	0.46	1.23e-15	Gastritis;
CESC	cis	rs4072980	0.527	rs11210825	chr1:38446986	G/A	cg04673462	chr1:38461896	NA	0.4	6.12	0.35	3.3e-9	Coronary artery disease;
CESC	cis	rs6120849	1.000	rs6120849	chr20:33730387	C/T	cg06115741	chr20:33292138	TP53INP2	0.5	5.16	0.3	4.95e-7	Protein C levels;
CESC	cis	rs9398803	0.723	rs853972	chr6:127068293	C/G	cg19875578	chr6:126661172	C6orf173	-0.42	-5.85	-0.34	1.41e-8	Male-pattern baldness;
CESC	cis	rs721399	0.513	rs35354956	chr8:18241319	T/C	cg18736775	chr8:18248649	NAT2	-0.57	-5.93	-0.34	9.51e-9	Blood metabolite levels;
CESC	cis	rs4243830	0.850	rs6679649	chr1:6606608	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	1.03	10.76	0.55	1.18e-22	Body mass index;
CESC	cis	rs736408	0.527	rs2577831	chr3:52628056	C/A	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.39	7.52	0.42	8.72e-13	Bipolar disorder;
CESC	cis	rs4588572	0.643	rs10942857	chr5:77760241	A/G	cg11547950	chr5:77652471	NA	-0.44	-5.48	-0.32	9.67e-8	Triglycerides;
CESC	cis	rs798554	0.616	rs1636251	chr7:2884720	T/C	cg04166393	chr7:2884313	GNA12	0.42	5.58	0.32	6.06e-8	Height;
CESC	cis	rs17826219	0.706	rs28469200	chr17:29133572	T/A	cg19761014	chr17:28927070	LRRC37B2	0.73	6.11	0.35	3.45e-9	Body mass index;
CESC	cis	rs3767633	0.925	rs2499855	chr1:161929761	C/T	cg09175582	chr1:161736000	ATF6	0.96	7.8	0.43	1.44e-13	IgG glycosylation;
CESC	cis	rs9581857	0.685	rs9319368	chr13:28042275	T/G	cg01674679	chr13:27998804	GTF3A	-0.69	-5.52	-0.32	8.1e-8	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
CESC	cis	rs13118159	0.872	rs4974605	chr4:1346389	C/G	cg05025164	chr4:1340916	KIAA1530	0.44	5.75	0.33	2.4e-8	Longevity;
CESC	cis	rs9457247	0.646	rs239934	chr6:167412048	G/A	cg23791538	chr6:167370224	RNASET2	-0.6	-8.71	-0.47	3.24e-16	Crohn's disease;
CESC	cis	rs7224314	1.000	rs8066725	chr17:65387326	G/A	cg01507342	chr17:65387096	PITPNC1	-0.48	-5.67	-0.33	3.82e-8	Diisocyanate-induced asthma;
CESC	cis	rs9549367	0.713	rs1323315	chr13:113859658	T/C	cg00898013	chr13:113819073	PROZ	0.45	6.84	0.39	5.47e-11	Platelet distribution width;
CESC	cis	rs3096299	0.685	rs12935112	chr16:89542858	C/T	cg16743903	chr16:89593216	SPG7	0.4	5.23	0.31	3.44e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs765787	0.530	rs2899381	chr15:45529630	C/T	cg24006582	chr15:45444508	DUOX1	-0.59	-7.23	-0.41	5.15e-12	Uric acid levels;
CESC	cis	rs12118280	0.612	rs591141	chr1:108694894	A/G	cg11967332	chr1:108735228	SLC25A24	0.59	6.73	0.38	1.04e-10	Myeloid white cell count;
CESC	trans	rs931812	0.825	rs13271753	chr8:101895491	T/C	cg20993868	chr7:22813445	NA	0.55	7.69	0.43	2.83e-13	Attention deficit hyperactivity disorder and conduct disorder;
CESC	cis	rs853679	0.517	rs9380060	chr6:28132603	G/A	cg20151795	chr6:28129481	ZNF389	0.44	5.55	0.32	6.85e-8	Depression;
CESC	cis	rs2288073	0.562	rs112892911	chr2:24590800	G/A	cg20701182	chr2:24300061	SF3B14	0.62	6.65	0.38	1.62e-10	Venous thromboembolism (SNP x SNP interaction);
CESC	cis	rs34779708	0.931	rs4934704	chr10:35332164	C/T	cg03585969	chr10:35415529	CREM	0.77	10.25	0.53	5.44e-21	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs854765	0.547	rs7224047	chr17:17932931	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.6	8.66	0.47	4.83e-16	Total body bone mineral density;
CESC	cis	rs1691799	0.899	rs903587	chr12:66746061	C/A	cg16791601	chr12:66731901	HELB	-0.79	-14.55	-0.67	1.18e-35	White blood cell count (basophil);
CESC	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	10.43	0.54	1.5e-21	Prudent dietary pattern;
CESC	cis	rs1862618	0.853	rs1423621	chr5:56101035	G/T	cg12311346	chr5:56204834	C5orf35	-0.66	-8.11	-0.45	1.85e-14	Initial pursuit acceleration;
CESC	cis	rs68170813	0.559	rs12537733	chr7:106965447	A/T	cg02696742	chr7:106810147	HBP1	-0.56	-5.36	-0.31	1.79e-7	Coronary artery disease;
CESC	cis	rs6987853	0.787	rs2923437	chr8:42425399	A/C	cg09913449	chr8:42400586	C8orf40	0.46	7.81	0.43	1.34e-13	Mean corpuscular hemoglobin concentration;
CESC	cis	rs4635969	0.718	rs27068	chr5:1347239	C/T	cg06550200	chr5:1325588	CLPTM1L	-0.71	-8.13	-0.45	1.62e-14	Testicular germ cell tumor;Testicular germ cell cancer;
CESC	cis	rs8002861	0.905	rs12428350	chr13:44446161	G/A	cg14210620	chr13:44453864	C13orf31;CCDC122	-0.45	-5.63	-0.33	4.47e-8	Leprosy;
CESC	cis	rs524281	0.861	rs1862005	chr11:65863402	T/C	cg14036092	chr11:66035641	RAB1B	-0.62	-6.29	-0.36	1.27e-9	Electroencephalogram traits;
CESC	cis	rs7666738	0.830	rs6829567	chr4:99047340	T/C	cg03676636	chr4:99064102	C4orf37	0.33	5.12	0.3	5.93e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs796364	0.760	rs56225698	chr2:200910653	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.84	-7.75	-0.43	1.94e-13	Schizophrenia;
CESC	cis	rs12079745	0.793	rs10919079	chr1:169133805	A/G	cg09363564	chr1:169337483	NME7;BLZF1	-0.98	-5.99	-0.35	6.97e-9	QT interval;
CESC	cis	rs826838	0.834	rs826874	chr12:39122599	C/A	cg13010199	chr12:38710504	ALG10B	-0.42	-5.83	-0.34	1.61e-8	Heart rate;
CESC	cis	rs1595825	0.838	rs57437055	chr2:198782617	A/C	cg10820045	chr2:198174542	NA	0.41	5.06	0.3	7.8e-7	Ulcerative colitis;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg11285937	chr4:39979757	PDS5A	-0.44	-6.19	-0.36	2.34e-9	Gambling;
CESC	cis	rs1941023	0.584	rs10897057	chr11:60172273	A/T	cg08716584	chr11:60157161	MS4A7	-0.55	-9.03	-0.48	3.7e-17	Congenital heart disease (maternal effect);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg01034784	chr2:95831832	ZNF2	0.44	6.23	0.36	1.83e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs7811142	0.830	rs1063945	chr7:99930447	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.05	10.62	0.55	3.47e-22	Platelet count;
CESC	cis	rs2108622	0.727	rs3093216	chr19:15987737	A/G	cg13772218	chr19:15982569	NA	0.31	5.86	0.34	1.34e-8	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg27301331	chr6:20401917	E2F3	-0.49	-6.29	-0.36	1.33e-9	Height;
CESC	cis	rs11971779	0.638	rs77668044	chr7:139111085	T/A	cg07862535	chr7:139043722	LUC7L2	0.53	5.03	0.3	9.18e-7	Diisocyanate-induced asthma;
CESC	cis	rs2439831	0.850	rs28513374	chr15:44125495	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.68	7.43	0.42	1.45e-12	Lung cancer in ever smokers;
CESC	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg17178900	chr1:205818956	PM20D1	0.89	15.71	0.69	9.72e-40	Menarche (age at onset);
CESC	cis	rs8020095	0.571	rs10148117	chr14:67426228	G/A	cg19548862	chr14:67692701	FAM71D	-0.48	-5.86	-0.34	1.4e-8	Depression (quantitative trait);
CESC	cis	rs3087591	0.960	rs4795593	chr17:29613600	G/C	cg24425628	chr17:29625626	OMG;NF1	-0.44	-5.46	-0.32	1.09e-7	Hip circumference;
CESC	cis	rs61931739	0.500	rs11053207	chr12:34459827	A/G	cg23762105	chr12:34175262	ALG10	-0.4	-5.22	-0.31	3.7e-7	Morning vs. evening chronotype;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	ch.2.1420302F	chr2:62093097	NA	-0.53	-6.34	-0.36	9.82e-10	Gut microbiome composition (summer);
CESC	cis	rs727563	0.565	rs132774	chr22:42031953	C/G	cg03806693	chr22:41940476	POLR3H	-0.73	-8.59	-0.47	7.79e-16	Crohn's disease;Inflammatory bowel disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12446722	chr1:226374380	ACBD3	0.58	6.4	0.37	7.03e-10	Gut microbiome composition (summer);
CESC	cis	rs4654899	1.000	rs6426659	chr1:21361302	G/A	cg05370193	chr1:21551575	ECE1	0.39	5.85	0.34	1.47e-8	Superior frontal gyrus grey matter volume;
CESC	cis	rs6028335	0.674	rs67379757	chr20:37671051	C/G	cg16355469	chr20:37678765	NA	0.52	5.15	0.3	5.19e-7	Alcohol and nicotine co-dependence;
CESC	cis	rs909002	0.819	rs2292989	chr1:32135773	A/G	cg13919466	chr1:32135498	COL16A1	0.39	6.56	0.37	2.88e-10	Intelligence (multi-trait analysis);
CESC	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg07092213	chr7:1199455	ZFAND2A	-0.45	-5.21	-0.3	3.88e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs875971	1.000	rs2420820	chr7:66091907	T/C	cg13147721	chr7:65941812	NA	0.37	5.04	0.3	8.52e-7	Aortic root size;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg25365034	chr2:23785230	KLHL29	0.47	6.14	0.35	2.96e-9	Fibrinogen levels;
CESC	cis	rs11166927	0.548	rs2100803	chr8:140839371	A/C	cg16909799	chr8:140841666	TRAPPC9	-0.65	-10.2	-0.53	8.15e-21	Pediatric non-alcoholic fatty liver disease activity score;
CESC	cis	rs3015497	0.586	rs12587821	chr14:51092554	A/G	cg09863266	chr14:51125203	SAV1	-0.32	-5.07	-0.3	7.62e-7	Mean platelet volume;
CESC	cis	rs2732480	0.577	rs2732457	chr12:48758379	A/G	cg04545296	chr12:48745243	ZNF641	-0.4	-6.66	-0.38	1.55e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs7937682	0.961	rs552387	chr11:111490047	T/G	cg09085632	chr11:111637200	PPP2R1B	-0.92	-14.14	-0.66	3.34e-34	Primary sclerosing cholangitis;
CESC	cis	rs8108034	0.666	rs40353	chr19:39879663	A/G	cg02980416	chr19:40502895	ZNF546	0.57	5.31	0.31	2.34e-7	Lung adenocarcinoma;
CESC	cis	rs2115630	1.000	rs6496441	chr15:85363348	A/G	cg12501888	chr15:85177176	SCAND2	-0.39	-5.1	-0.3	6.42e-7	P wave terminal force;
CESC	cis	rs9611565	0.729	rs73176686	chr22:41782119	C/T	cg17376030	chr22:41985996	PMM1	0.7	7.6	0.42	5.18e-13	Vitiligo;
CESC	cis	rs7927771	0.832	rs10838697	chr11:47384484	T/A	cg05585544	chr11:47624801	NA	-0.51	-7.36	-0.41	2.28e-12	Subjective well-being;
CESC	cis	rs472109	0.967	rs173396	chr11:9759918	G/A	cg03108697	chr11:9732066	SWAP70	-0.37	-5.54	-0.32	7.15e-8	Coronary artery disease;
CESC	cis	rs3740713	1.000	rs73440615	chr11:18467283	T/C	cg23797887	chr11:18477753	LDHAL6A	-0.53	-5.26	-0.31	2.98e-7	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs7116495	0.786	rs610004	chr11:71797939	C/T	cg10381502	chr11:71823885	C11orf51	-0.66	-5.4	-0.31	1.51e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs10504229	1.000	rs66870803	chr8:58180022	G/C	cg14926445	chr8:58193284	C8orf71	-0.51	-5.47	-0.32	1.03e-7	Developmental language disorder (linguistic errors);
CESC	trans	rs7656342	0.808	rs10003216	chr4:9766749	A/G	cg18891404	chr1:37940488	ZC3H12A	-0.57	-6.69	-0.38	1.33e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs8014204	0.804	rs2287403	chr14:75259140	C/T	cg08847533	chr14:75593920	NEK9	0.47	5.9	0.34	1.08e-8	Caffeine consumption;
CESC	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg23708337	chr7:1209742	NA	0.55	5.42	0.32	1.33e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs3780486	0.846	rs10971419	chr9:33124161	T/C	cg04842962	chr6:43655489	MRPS18A	1.01	19.48	0.77	4.55e-53	IgG glycosylation;
CESC	cis	rs6933660	0.745	rs9397405	chr6:151736084	G/T	cg02564969	chr6:151773285	C6orf211;RMND1	0.64	8.72	0.47	3.02e-16	Menarche (age at onset);
CESC	cis	rs7532866	0.885	rs7520137	chr1:26731035	T/G	cg17456097	chr1:26900765	RPS6KA1	-0.47	-6.04	-0.35	5.23e-9	Height;
CESC	cis	rs761746	0.739	rs5753714	chr22:31990930	G/T	cg25791279	chr22:32026902	PISD	-0.66	-7.58	-0.42	5.96e-13	Intelligence;
CESC	cis	rs875971	0.929	rs34406470	chr7:65929956	A/G	cg18876405	chr7:65276391	NA	0.52	6.87	0.39	4.58e-11	Aortic root size;
CESC	cis	rs7959452	0.535	rs7308481	chr12:69659299	A/G	cg20891283	chr12:69753455	YEATS4	0.76	11.37	0.57	1.16e-24	Blood protein levels;
CESC	cis	rs1862618	0.525	rs832403	chr5:56265992	G/T	cg20203395	chr5:56204925	C5orf35	0.48	5.64	0.33	4.44e-8	Initial pursuit acceleration;
CESC	cis	rs9611519	0.894	rs9623320	chr22:41478482	G/A	cg03806693	chr22:41940476	POLR3H	-0.58	-6.03	-0.35	5.61e-9	Neuroticism;
CESC	cis	rs561341	0.941	rs8066558	chr17:30272879	G/T	cg12193833	chr17:30244370	NA	-0.61	-6.2	-0.36	2.19e-9	Hip circumference adjusted for BMI;
CESC	cis	rs8063761	1.000	rs8063761	chr16:90027626	A/T	cg08547343	chr16:90038815	CENPBD1;AFG3L1	0.57	7.23	0.41	5.26e-12	Squamous cell carcinoma;
CESC	cis	rs6570726	0.902	rs396681	chr6:145853603	T/C	cg05347473	chr6:146136440	FBXO30	0.47	6.19	0.36	2.25e-9	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2404602	0.692	rs35498563	chr15:76958868	C/T	cg22467129	chr15:76604101	ETFA	-0.35	-5.14	-0.3	5.22e-7	Blood metabolite levels;
CESC	cis	rs60843830	1.000	rs60484953	chr2:221560	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.78	9.77	0.51	1.94e-19	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs1499972	0.938	rs843852	chr3:117721428	A/G	cg07612923	chr3:117604196	NA	-0.78	-5.78	-0.33	2.13e-8	Schizophrenia;
CESC	trans	rs9951602	0.512	rs9946123	chr18:76654557	A/G	cg02800362	chr5:177631904	HNRNPAB	0.66	8.63	0.47	5.9e-16	Obesity-related traits;
CESC	cis	rs6775745	0.654	rs12695570	chr3:131782365	C/T	cg12213930	chr3:131751605	CPNE4	0.48	5.46	0.32	1.08e-7	Neutrophil count;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg00465686	chr8:66701377	PDE7A	0.38	6.36	0.36	8.89e-10	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs7666738	0.830	rs10049627	chr4:99025272	A/C	cg03467027	chr4:99064603	C4orf37	0.49	6.18	0.35	2.44e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3733585	0.699	rs6852441	chr4:9973744	C/T	cg00071950	chr4:10020882	SLC2A9	-0.69	-11.21	-0.57	3.85e-24	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs6570726	0.935	rs377130	chr6:145836632	C/T	cg05347473	chr6:146136440	FBXO30	0.49	6.69	0.38	1.3100000000000001e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6089584	0.888	rs2892060	chr20:60617955	G/T	cg24733560	chr20:60626293	TAF4	0.45	6.44	0.37	5.45e-10	Body mass index;
CESC	cis	rs7772486	0.686	rs857882	chr6:145969716	T/G	cg23711669	chr6:146136114	FBXO30	-0.98	-15.19	-0.68	6.34e-38	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2658782	0.547	rs3020064	chr11:93060851	A/G	cg15737290	chr11:93063684	CCDC67	0.53	7.2	0.4	6.34e-12	Pulmonary function decline;
CESC	cis	rs7599312	0.534	rs2128321	chr2:213405276	G/T	cg20637307	chr2:213403960	ERBB4	0.56	9.03	0.49	3.55e-17	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs6570726	0.791	rs9390336	chr6:145896823	A/T	cg23711669	chr6:146136114	FBXO30	0.97	15.02	0.68	2.59e-37	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7255436	0.965	rs7254882	chr19:8453822	A/G	cg10174797	chr19:8464628	RAB11B	0.38	5.39	0.31	1.55e-7	HDL cholesterol;
CESC	cis	rs826838	1.000	rs7315028	chr12:38710523	G/A	cg13010199	chr12:38710504	ALG10B	0.61	8.88	0.48	1.03e-16	Heart rate;
CESC	cis	rs761746	0.960	rs14034	chr22:32015406	T/C	cg25791279	chr22:32026902	PISD	0.56	6.55	0.37	2.93e-10	Intelligence;
CESC	cis	rs4595586	0.545	rs58154430	chr12:39386649	C/T	cg26384229	chr12:38710491	ALG10B	0.62	8.69	0.47	3.89e-16	Morning vs. evening chronotype;
CESC	cis	rs4253772	0.591	rs73886791	chr22:46687212	A/G	cg18190219	chr22:46762943	CELSR1	-0.43	-5.4	-0.31	1.46e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs7613875	0.600	rs1138536	chr3:50153356	C/T	cg24308560	chr3:49941425	MST1R	-0.53	-7.51	-0.42	9.01e-13	Body mass index;
CESC	cis	rs1881797	0.872	rs12404733	chr1:247690417	A/C	cg21399703	chr1:247681439	NA	0.53	7.49	0.42	1.05e-12	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs11098499	0.863	rs28718422	chr4:120466304	C/A	cg09307838	chr4:120376055	NA	0.91	12.73	0.62	2.82e-29	Corneal astigmatism;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg21159473	chr9:15510228	PSIP1	-0.48	-6.57	-0.37	2.71e-10	Ulcerative colitis;
CESC	cis	rs10089	1.000	rs72794392	chr5:127490061	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.76	9.58	0.51	7.24e-19	Ileal carcinoids;
CESC	cis	rs9916302	0.904	rs11655531	chr17:37697959	T/C	cg15445000	chr17:37608096	MED1	0.42	6.9	0.39	3.93e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs17376456	0.825	rs6865441	chr5:93284746	G/A	cg21475434	chr5:93447410	FAM172A	0.79	6.2	0.36	2.11e-9	Diabetic retinopathy;
CESC	cis	rs9910055	0.659	rs186603	chr17:42207884	C/T	cg13607699	chr17:42295918	UBTF	-0.57	-7.41	-0.41	1.71e-12	Total body bone mineral density;
CESC	cis	rs853679	0.517	rs9393891	chr6:28079160	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.58	-6.75	-0.38	9.45e-11	Depression;
CESC	cis	rs9303280	0.901	rs9303277	chr17:37976469	C/T	cg20243544	chr17:37824526	PNMT	0.47	6.45	0.37	5.3e-10	Self-reported allergy;
CESC	cis	rs7666738	0.830	rs7663438	chr4:99014582	C/T	cg05340658	chr4:99064831	C4orf37	0.79	12.42	0.61	3.26e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs8070624	0.574	rs9914127	chr17:17875836	A/T	cg16928487	chr17:17741425	SREBF1	-0.54	-8.64	-0.47	5.35e-16	Total body bone mineral density;
CESC	trans	rs7656342	0.808	rs10003216	chr4:9766749	A/G	cg10069470	chr5:102594905	C5orf30	-0.47	-6.11	-0.35	3.56e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs1538970	0.924	rs2088100	chr1:45877575	C/T	cg05343316	chr1:45956843	TESK2	0.85	11.89	0.59	1.99e-26	Platelet count;
CESC	cis	rs7726839	0.561	rs4957048	chr5:583442	G/A	cg16447950	chr5:562315	NA	-0.55	-6.19	-0.36	2.29e-9	Obesity-related traits;
CESC	cis	rs7084402	1.000	rs1863664	chr10:60266839	A/G	cg07615347	chr10:60278583	BICC1	-0.58	-8.92	-0.48	8.11e-17	Refractive error;
CESC	cis	rs36051895	0.626	rs10815149	chr9:5063701	T/C	cg02405213	chr9:5042618	JAK2	-0.45	-5.69	-0.33	3.38e-8	Pediatric autoimmune diseases;
CESC	cis	rs9584850	0.834	rs9584854	chr13:99118590	C/T	cg22223119	chr13:99095684	FARP1	-0.35	-5.05	-0.3	8.13e-7	Neuroticism;
CESC	cis	rs4555082	0.756	rs76863138	chr14:105736379	C/T	cg10792982	chr14:105748885	BRF1	0.42	5.24	0.31	3.21e-7	Mean platelet volume;Platelet distribution width;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	ch.1.1697717F	chr1:59122002	NA	0.46	6.12	0.35	3.32e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs950027	0.620	rs1719246	chr15:45625479	T/A	cg21132104	chr15:45694354	SPATA5L1	0.68	8.74	0.47	2.67e-16	Response to fenofibrate (adiponectin levels);
CESC	cis	rs892961	0.867	rs312909	chr17:75413954	T/C	cg05865280	chr17:75406074	SEPT9	0.63	12.81	0.62	1.5e-29	Airflow obstruction;
CESC	cis	rs863345	0.526	rs10908669	chr1:158501938	C/T	cg12129480	chr1:158549410	OR10X1	-0.34	-6.76	-0.38	8.6e-11	Pneumococcal bacteremia;
CESC	cis	rs28647808	0.881	rs4246171	chr9:136264731	G/A	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.84	5.73	0.33	2.7e-8	Blood protein levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17860962	chr6:44214684	HSP90AB1	-0.56	-6.52	-0.37	3.64e-10	Gut microbiome composition (summer);
CESC	cis	rs9926296	0.605	rs12448860	chr16:89849629	T/A	cg27121462	chr16:89883253	FANCA	0.78	11.15	0.57	6.29e-24	Vitiligo;
CESC	cis	rs2439831	0.681	rs540031	chr15:43608855	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.9	11.15	0.56	6.51e-24	Lung cancer in ever smokers;
CESC	cis	rs10463316	0.780	rs6894899	chr5:150775913	C/T	cg03212797	chr5:150827313	SLC36A1	-0.44	-5.7	-0.33	3.19e-8	Metabolite levels (Pyroglutamine);
CESC	cis	rs12893668	0.572	rs34000399	chr14:104101417	T/C	cg08213375	chr14:104286397	PPP1R13B	0.32	5.32	0.31	2.21e-7	Reticulocyte count;
CESC	cis	rs62103177	0.525	rs62101233	chr18:77724288	C/T	cg12964065	chr18:77638022	KCNG2	0.43	5.04	0.3	8.46e-7	Opioid sensitivity;
CESC	cis	rs8077577	0.708	rs4450455	chr17:18140447	A/G	cg16794390	chr17:18148240	FLII	-0.43	-6.28	-0.36	1.36e-9	Obesity-related traits;
CESC	cis	rs17711722	0.522	rs6957759	chr7:65271785	A/G	cg05332525	chr7:65337924	VKORC1L1	0.47	6.01	0.35	6.14e-9	Calcium levels;
CESC	cis	rs4819052	0.851	rs2838840	chr21:46668494	A/G	cg11663144	chr21:46675770	NA	-0.62	-9.71	-0.51	2.89e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs9399135	0.967	rs17638970	chr6:135320063	A/G	cg24558204	chr6:135376177	HBS1L	0.53	7.28	0.41	3.85e-12	Red blood cell count;
CESC	trans	rs2018683	0.711	rs2158788	chr7:28971958	G/A	cg19402173	chr7:128379420	CALU	-0.54	-7.01	-0.4	1.93e-11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CESC	cis	rs4862750	0.872	rs6830426	chr4:187897270	T/A	cg11301795	chr4:187892539	NA	-0.75	-12.37	-0.61	4.63e-28	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg06873352	chr17:61820015	STRADA	0.73	12.98	0.62	3.9e-30	Prudent dietary pattern;
CESC	cis	rs6736093	0.966	rs71414616	chr2:112696684	T/C	cg12686935	chr2:112915763	FBLN7	-0.43	-5.56	-0.32	6.75e-8	Coronary artery disease;
CESC	cis	rs2742417	0.603	rs2742449	chr3:45764544	T/C	cg04837898	chr3:45731254	SACM1L	-0.47	-6.17	-0.35	2.54e-9	Response to anti-depressant treatment in major depressive disorder;
CESC	cis	rs7615952	0.641	rs4422257	chr3:125774363	A/G	cg15145296	chr3:125709740	NA	-0.53	-5.52	-0.32	8.24e-8	Blood pressure (smoking interaction);
CESC	cis	rs7618915	0.547	rs2336542	chr3:52710636	A/G	cg18404041	chr3:52824283	ITIH1	-0.39	-6.53	-0.37	3.33e-10	Bipolar disorder;
CESC	cis	rs4722166	0.630	rs1829927	chr7:22779918	G/A	cg05265849	chr7:22767390	IL6	0.57	7.11	0.4	1.06e-11	Lung cancer;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg17327406	chr4:6303265	WFS1	0.51	6.78	0.38	7.64e-11	Fibrinogen levels;
CESC	cis	rs2836633	0.895	rs62217513	chr21:40024416	A/T	cg12884169	chr21:40033163	ERG	0.38	5.87	0.34	1.33e-8	Coronary artery disease;
CESC	cis	rs7618501	0.966	rs2246832	chr3:49881134	A/T	cg24308560	chr3:49941425	MST1R	-0.55	-7.5	-0.42	9.72e-13	Intelligence (multi-trait analysis);
CESC	cis	rs853679	0.517	rs1340004	chr6:28103691	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.57	-6.25	-0.36	1.65e-9	Depression;
CESC	cis	rs10129255	0.957	rs8022165	chr14:107189919	C/G	cg23076370	chr14:107095027	NA	-0.46	-5.95	-0.34	8.57e-9	Kawasaki disease;
CESC	cis	rs1790761	0.505	rs7106423	chr11:67314144	A/G	cg24690094	chr11:67383802	NA	-0.32	-5.39	-0.31	1.52e-7	Mean corpuscular volume;
CESC	cis	rs6693567	0.565	rs8006	chr1:150280801	G/C	cg09579323	chr1:150459698	TARS2	-0.46	-5.97	-0.34	7.61e-9	Migraine;
CESC	cis	rs9300255	0.596	rs10734900	chr12:123743445	G/A	cg19016782	chr12:123741754	C12orf65	-0.38	-5.73	-0.33	2.74e-8	Neutrophil percentage of white cells;
CESC	cis	rs9322193	0.923	rs9800614	chr6:149965740	G/A	cg07701084	chr6:150067640	NUP43	0.46	6.42	0.37	6.39e-10	Lung cancer;
CESC	cis	rs9916302	0.706	rs9899069	chr17:37540772	A/G	cg07936489	chr17:37558343	FBXL20	0.9	9.82	0.52	1.27e-19	Glomerular filtration rate (creatinine);
CESC	cis	rs643506	0.817	rs1940392	chr11:111776846	G/A	cg09085632	chr11:111637200	PPP2R1B	0.41	5.36	0.31	1.79e-7	Breast cancer;
CESC	cis	rs1862618	0.754	rs252899	chr5:56188569	G/C	cg24531977	chr5:56204891	C5orf35	-0.88	-11.18	-0.57	4.92e-24	Initial pursuit acceleration;
CESC	cis	rs9926296	0.585	rs6500441	chr16:89828669	C/G	cg03388025	chr16:89894329	SPIRE2	0.38	7.25	0.41	4.6e-12	Vitiligo;
CESC	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg26338869	chr17:61819248	STRADA	-0.7	-9.34	-0.5	4.19e-18	Prudent dietary pattern;
CESC	cis	rs9902453	0.868	rs9902340	chr17:28476458	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.66	-8.44	-0.46	2.07e-15	Coffee consumption (cups per day);
CESC	cis	rs12586317	0.586	rs74243591	chr14:35520917	C/T	cg05294307	chr14:35346193	BAZ1A	-0.57	-5.82	-0.34	1.71e-8	Psoriasis;
CESC	cis	rs1005224	0.963	rs11626062	chr14:76136329	T/C	cg25116370	chr14:76127843	TTLL5;C14orf1	-0.41	-5.5	-0.32	8.98e-8	Large artery stroke;
CESC	cis	rs875971	0.964	rs778721	chr7:65845397	C/G	cg10691866	chr7:65817282	TPST1	-0.34	-5.46	-0.32	1.12e-7	Aortic root size;
CESC	cis	rs7666738	0.830	rs7659593	chr4:98934823	T/C	cg03467027	chr4:99064603	C4orf37	0.48	5.91	0.34	1.03e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7811142	1.000	rs11559117	chr7:100076614	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.98	10.48	0.54	9.63e-22	Platelet count;
CESC	cis	rs1008375	0.931	rs6449328	chr4:17700474	C/T	cg16339924	chr4:17578868	LAP3	0.62	7.64	0.42	4.03e-13	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs2243480	1.000	rs35058610	chr7:65390925	G/A	cg25894440	chr7:65020034	NA	-0.59	-5.07	-0.3	7.57e-7	Diabetic kidney disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17340796	chr11:85339599	TMEM126B;DLG2	0.61	7.04	0.4	1.6e-11	Gut microbiome composition (summer);
CESC	cis	rs1483890	0.642	rs9825849	chr3:69404575	C/T	cg22125112	chr3:69402811	FRMD4B	0.39	5.32	0.31	2.22e-7	Resting heart rate;
CESC	cis	rs4665809	0.627	rs35461456	chr2:26482361	C/G	cg04944784	chr2:26401820	FAM59B	0.96	10.5	0.54	8.76e-22	Gut microbiome composition (summer);
CESC	cis	rs2637266	0.654	rs846576	chr10:78500388	T/A	cg18941641	chr10:78392320	NA	0.39	7.43	0.42	1.54e-12	Pulmonary function;
CESC	cis	rs1348850	0.831	rs1345139	chr2:178449791	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.54	7.27	0.41	4.13e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs853679	0.517	rs9295761	chr6:28147987	A/G	cg26335602	chr6:28129616	ZNF389	0.52	6.86	0.39	4.89e-11	Depression;
CESC	cis	rs9443645	0.901	rs55755815	chr6:79607121	G/T	cg05283184	chr6:79620031	NA	-0.43	-6.5	-0.37	3.91e-10	Intelligence (multi-trait analysis);
CESC	cis	rs2932538	0.922	rs12137107	chr1:113127437	A/G	cg22162597	chr1:113214053	CAPZA1	0.54	6.9	0.39	3.82e-11	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CESC	cis	rs5758511	0.680	rs5758698	chr22:42684818	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.59	8.95	0.48	6.42e-17	Birth weight;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg20831041	chr11:464554	PTDSS2	0.45	6.01	0.35	6.27e-9	Fibrinogen levels;
CESC	cis	rs1008375	1.000	rs4698649	chr4:17692782	A/G	cg16339924	chr4:17578868	LAP3	0.6	7.44	0.42	1.45e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs1448094	0.511	rs7976647	chr12:86158766	A/G	cg02569458	chr12:86230093	RASSF9	0.48	7.44	0.42	1.4e-12	Major depressive disorder;
CESC	cis	rs780096	0.526	rs1260341	chr2:27663215	T/A	cg21248554	chr2:27665150	KRTCAP3	-0.36	-7.38	-0.41	2.02e-12	Total body bone mineral density;
CESC	cis	rs4481887	0.927	rs4453080	chr1:248474671	T/C	cg00666640	chr1:248458726	OR2T12	0.35	5.93	0.34	9.43e-9	Common traits (Other);
CESC	cis	rs875971	0.755	rs76288834	chr7:66069802	G/A	cg12463550	chr7:65579703	CRCP	-0.52	-6.65	-0.38	1.65e-10	Aortic root size;
CESC	cis	rs9287719	0.967	rs7582775	chr2:10738449	C/T	cg00105475	chr2:10696890	NA	0.39	5.61	0.33	4.96e-8	Prostate cancer;
CESC	cis	rs10918270	1.000	rs10800151	chr1:161914283	A/G	cg19735514	chr1:161762739	ATF6	-0.37	-5.41	-0.32	1.41e-7	Parkinson's disease (age of onset);
CESC	cis	rs684232	0.666	rs461521	chr17:622497	G/T	cg15660573	chr17:549704	VPS53	-0.66	-9.12	-0.49	1.92e-17	Prostate cancer;
CESC	cis	rs4862750	0.872	rs13143414	chr4:187878213	G/A	cg07414643	chr4:187882934	NA	0.49	7.04	0.4	1.65e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs709400	0.663	rs11628969	chr14:103940911	G/A	cg12935359	chr14:103987150	CKB	-0.51	-7.44	-0.42	1.39e-12	Body mass index;
CESC	cis	rs3857067	0.806	rs34396894	chr4:95097600	T/G	cg11021082	chr4:95130006	SMARCAD1	-0.61	-9.07	-0.49	2.67e-17	QT interval;
CESC	cis	rs1552244	1.000	rs35993975	chr3:10067794	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.75	-9.09	-0.49	2.35e-17	Alzheimer's disease;
CESC	cis	rs2050392	0.928	rs6481677	chr10:30701816	A/G	cg25182066	chr10:30743637	MAP3K8	-0.38	-5.16	-0.3	4.81e-7	Inflammatory bowel disease;
CESC	trans	rs2235573	0.625	rs713991	chr22:38426043	A/G	cg19894588	chr14:64061835	NA	0.47	6.15	0.35	2.81e-9	Glioblastoma;Glioma;
CESC	cis	rs760805	1.000	rs7517302	chr1:25254317	C/T	cg22509179	chr1:25234806	RUNX3	-0.6	-8.45	-0.46	1.98e-15	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs7940866	0.740	rs2162060	chr11:130830763	A/G	cg12179176	chr11:130786555	SNX19	0.62	9.14	0.49	1.64e-17	Schizophrenia;
CESC	cis	rs736408	0.562	rs12497998	chr3:52793602	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.38	-5.13	-0.3	5.56e-7	Bipolar disorder;
CESC	cis	rs2576037	0.899	rs7233515	chr18:44585955	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.61	8.63	0.47	5.71e-16	Personality dimensions;
CESC	cis	rs3733585	0.673	rs10018204	chr4:9964570	C/T	cg11266682	chr4:10021025	SLC2A9	-0.59	-10.94	-0.56	3.01e-23	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs10791323	0.572	rs4353292	chr11:133742656	A/G	cg15485101	chr11:133734466	NA	0.33	5.59	0.32	5.57e-8	Childhood ear infection;
CESC	cis	rs9926296	0.605	rs7205053	chr16:89856763	G/C	cg21285383	chr16:89894308	SPIRE2	0.32	5.7	0.33	3.24e-8	Vitiligo;
CESC	cis	rs1862618	0.853	rs832578	chr5:56164223	C/T	cg03609598	chr5:56110824	MAP3K1	-0.5	-5.39	-0.31	1.52e-7	Initial pursuit acceleration;
CESC	cis	rs769267	0.965	rs10419245	chr19:19383755	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.42	5.35	0.31	1.94e-7	Tonsillectomy;
CESC	cis	rs651907	0.557	rs59596156	chr3:101394217	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.51	6.74	0.38	9.97e-11	Colorectal cancer;
CESC	cis	rs501120	0.925	rs559469	chr10:44752118	C/T	cg09554077	chr10:44749378	NA	-0.56	-7.56	-0.42	6.45e-13	Coronary artery disease;Coronary heart disease;
CESC	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg19626725	chr5:178986131	RUFY1	-0.41	-6.69	-0.38	1.35e-10	Lung cancer;
CESC	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	10.28	0.53	4.4e-21	Prudent dietary pattern;
CESC	cis	rs12477438	0.501	rs11685756	chr2:99766215	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.87	15.48	0.69	6.26e-39	Chronic sinus infection;
CESC	cis	rs11122272	0.735	rs973253	chr1:231520874	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.57	-7.82	-0.43	1.29e-13	Hemoglobin concentration;
CESC	cis	rs11792861	0.890	rs57387569	chr9:111920392	T/C	cg13535736	chr9:111863775	C9orf5	-0.53	-6.82	-0.39	6.2e-11	Menarche (age at onset);
CESC	cis	rs2576037	0.583	rs504668	chr18:44410749	T/C	cg19077165	chr18:44547161	KATNAL2	-0.61	-9.19	-0.49	1.2e-17	Personality dimensions;
CESC	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg14159672	chr1:205819179	PM20D1	0.81	12.95	0.62	4.67e-30	Menarche (age at onset);
CESC	cis	rs1865721	1.000	rs62089503	chr18:73177766	C/T	cg26385618	chr18:73139727	C18orf62	-0.52	-7.51	-0.42	8.78e-13	Intelligence;
CESC	cis	rs12711979	0.509	rs10205540	chr2:3827839	A/G	cg17052675	chr2:3827356	NA	-0.67	-11.25	-0.57	2.84e-24	Itch intensity from mosquito bite adjusted by bite size;
CESC	cis	rs11696501	0.688	rs6073851	chr20:44306978	C/T	cg11783356	chr20:44313418	WFDC10B	-0.31	-5.05	-0.3	8.38e-7	Brain structure;
CESC	cis	rs854765	0.583	rs7207395	chr17:17819335	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.52	7.13	0.4	9.44e-12	Total body bone mineral density;
CESC	cis	rs7621025	0.500	rs12629000	chr3:136643571	T/A	cg15507776	chr3:136538369	TMEM22	0.77	9.21	0.49	1e-17	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
CESC	cis	rs1018836	0.608	rs11997663	chr8:91474484	A/C	cg16814680	chr8:91681699	NA	-0.55	-7.5	-0.42	9.77e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs9467711	0.606	rs9358936	chr6:26370657	A/G	cg14345882	chr6:26364793	BTN3A2	0.6	6.21	0.36	2.06e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs17818399	0.926	rs13032670	chr2:46830794	C/T	cg06386533	chr2:46925753	SOCS5	0.47	5.19	0.3	4.11e-7	Height;
CESC	trans	rs13247936	0.574	rs12702800	chr7:8965291	A/G	cg13381646	chr12:105379979	C12orf45	-0.48	-6.32	-0.36	1.09e-9	Schizophrenia;
CESC	cis	rs6815814	0.950	rs5743580	chr4:38804405	C/T	cg02016764	chr4:38805732	TLR1	-0.62	-7.23	-0.41	5.15e-12	Breast cancer;
CESC	cis	rs4665809	0.941	rs41285975	chr2:26351144	T/C	cg04944784	chr2:26401820	FAM59B	-0.66	-7.62	-0.42	4.62e-13	Gut microbiome composition (summer);
CESC	cis	rs881375	0.967	rs2416806	chr9:123690292	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.38	5.08	0.3	7.23e-7	Rheumatoid arthritis;
CESC	cis	rs875971	0.545	rs7787063	chr7:65628999	G/A	cg18876405	chr7:65276391	NA	0.51	5.96	0.34	8.21e-9	Aortic root size;
CESC	cis	rs11245387	0.633	rs2086945	chr10:126543993	C/T	cg08799069	chr10:126477246	METTL10	0.43	5.63	0.33	4.71e-8	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
CESC	cis	rs9796	0.663	rs11853192	chr15:41368515	G/A	cg20272979	chr15:41787780	ITPKA	0.37	5.62	0.33	4.95e-8	Menopause (age at onset);
CESC	cis	rs1707322	0.721	rs12037803	chr1:46156492	A/G	cg06784218	chr1:46089804	CCDC17	0.43	7.58	0.42	5.65e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7647973	0.600	rs11920267	chr3:49275964	G/A	cg02487422	chr3:49467188	NICN1	0.39	5.43	0.32	1.25e-7	Menarche (age at onset);
CESC	cis	rs780096	0.526	rs1647267	chr2:27651054	A/T	cg02592271	chr2:27665507	KRTCAP3	-0.29	-5.79	-0.34	2e-8	Total body bone mineral density;
CESC	cis	rs7202877	0.706	rs8054586	chr16:75410705	G/C	cg04384234	chr16:75411784	CFDP1	-0.47	-5.73	-0.33	2.72e-8	Type 2 diabetes;Type 1 diabetes;
CESC	cis	rs2243480	1.000	rs34529418	chr7:65403209	A/G	cg18252515	chr7:66147081	NA	-1.0	-9.22	-0.49	9.27e-18	Diabetic kidney disease;
CESC	cis	rs6474412	1.000	rs13280604	chr8:42559586	G/A	cg25026480	chr8:42547641	NA	0.32	5.16	0.3	4.93e-7	Smoking behavior;
CESC	cis	rs6570726	0.764	rs9322028	chr6:145895797	G/T	cg05347473	chr6:146136440	FBXO30	0.59	7.63	0.42	4.24e-13	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg07168392	chr1:86861658	ODF2L	0.45	6.19	0.36	2.22e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs9393777	0.513	rs9295702	chr6:26634040	T/C	cg14345882	chr6:26364793	BTN3A2	0.41	5.35	0.31	1.94e-7	Intelligence (multi-trait analysis);
CESC	cis	rs2228479	0.850	rs11645916	chr16:89835234	G/A	cg06558623	chr16:89946397	TCF25	1.17	9.29	0.5	5.84e-18	Skin colour saturation;
CESC	cis	rs4434138	0.568	rs6414569	chr3:52708075	A/T	cg18337363	chr3:52569053	NT5DC2	0.28	5.05	0.3	8.27e-7	Intelligence (multi-trait analysis);
CESC	cis	rs2075371	0.897	rs1646733	chr7:134002228	C/A	cg11752832	chr7:134001865	SLC35B4	0.58	7.48	0.42	1.08e-12	Mean platelet volume;
CESC	cis	rs736408	0.522	rs11716747	chr3:52748857	C/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	5.69	0.33	3.32e-8	Bipolar disorder;
CESC	cis	rs1215050	0.791	rs6838628	chr4:98809574	A/G	cg17366294	chr4:99064904	C4orf37	0.39	5.06	0.3	7.75e-7	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs763121	0.776	rs4820346	chr22:39125074	C/G	cg14440974	chr22:39074834	NA	0.39	5.36	0.31	1.79e-7	Menopause (age at onset);
CESC	cis	rs9660992	0.573	rs7531256	chr1:205191202	T/G	cg21643547	chr1:205240462	TMCC2	-0.39	-5.48	-0.32	9.91e-8	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs6973256	0.604	rs6975134	chr7:133531432	T/C	cg10665199	chr7:133106180	EXOC4	0.43	6.06	0.35	4.73e-9	Intelligence (multi-trait analysis);
CESC	cis	rs7666738	0.715	rs3857216	chr4:99032129	G/T	cg17366294	chr4:99064904	C4orf37	0.62	8.95	0.48	6.32e-17	Colonoscopy-negative controls vs population controls;
CESC	cis	rs5769765	0.817	rs8142561	chr22:50291750	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.45	-5.2	-0.3	4.01e-7	Schizophrenia;
CESC	cis	rs6736093	0.966	rs34527376	chr2:112755699	C/T	cg12686935	chr2:112915763	FBLN7	-0.43	-5.66	-0.33	3.94e-8	Coronary artery disease;
CESC	cis	rs10170846	0.861	rs7571732	chr2:223538316	A/C	cg25565276	chr2:223520875	FARSB	-0.51	-7.21	-0.4	5.9e-12	Schizophrenia (inflammation and infection response interaction);
CESC	cis	rs4727027	0.870	rs62507512	chr7:148799338	C/T	cg23158103	chr7:148848205	ZNF398	-0.42	-6.84	-0.39	5.49e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs763121	0.962	rs5757130	chr22:38937794	G/A	cg06022373	chr22:39101656	GTPBP1	0.73	11.13	0.56	7.51e-24	Menopause (age at onset);
CESC	cis	rs875971	0.964	rs778708	chr7:65856319	T/C	cg10691866	chr7:65817282	TPST1	-0.34	-5.51	-0.32	8.3e-8	Aortic root size;
CESC	cis	rs780096	0.546	rs4665976	chr2:27640325	A/G	cg22903471	chr2:27725779	GCKR	-0.5	-7.15	-0.4	8.58e-12	Total body bone mineral density;
CESC	cis	rs9436747	0.566	rs112314233	chr1:65973295	C/G	cg14976592	chr1:65886160	LEPROT;LEPR	-0.43	-5.23	-0.31	3.38e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
CESC	trans	rs2823962	0.687	rs2154727	chr21:18017766	T/C	cg06419850	chr17:4688683	VMO1	-0.42	-6.13	-0.35	3.23e-9	Amyotrophic lateral sclerosis;
CESC	cis	rs1881797	0.872	rs12408686	chr1:247691141	C/T	cg11166453	chr1:247681781	NA	0.48	6.13	0.35	3.19e-9	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs13102973	0.965	rs11099302	chr4:135880751	G/T	cg14419869	chr4:135874104	NA	0.33	5.23	0.31	3.44e-7	Subjective well-being;
CESC	cis	rs10416265	0.527	rs6510337	chr19:33545701	C/T	cg17764715	chr19:33622953	WDR88	0.6	8.3	0.45	5.51e-15	Bone properties (heel);
CESC	cis	rs7160336	0.604	rs10149539	chr14:74682227	C/T	cg08255017	chr14:74727001	VSX2	-0.38	-5.53	-0.32	7.71e-8	Blood protein levels;
CESC	cis	rs41005	0.805	rs10469618	chr2:8117622	C/T	cg03155496	chr2:8117019	LOC339788	-0.37	-5.22	-0.31	3.65e-7	Response to anti-TNF therapy in rheumatoid arthritis;
CESC	cis	rs910316	0.967	rs2268619	chr14:75640354	C/G	cg11812906	chr14:75593930	NEK9	-0.84	-12.97	-0.62	3.96e-30	Height;
CESC	cis	rs9640161	0.750	rs59211922	chr7:150023790	T/G	cg13722127	chr7:150037890	RARRES2	0.34	5.17	0.3	4.68e-7	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs7274811	0.711	rs291700	chr20:31981849	C/T	cg21523528	chr20:32077966	CBFA2T2	0.47	5.57	0.32	6.15e-8	Height;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg26420824	chr1:28562883	ATPIF1	-0.45	-6.25	-0.36	1.67e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs798554	0.679	rs1636253	chr7:2885123	A/G	cg09658497	chr7:2847517	GNA12	-0.35	-5.09	-0.3	6.67e-7	Height;
CESC	cis	rs8077889	0.871	rs8081101	chr17:41904332	C/T	cg26893861	chr17:41843967	DUSP3	0.74	9.39	0.5	2.82e-18	Triglycerides;
CESC	cis	rs4889855	0.614	rs9898443	chr17:78469357	C/T	cg00066239	chr17:78472159	NA	0.4	5.64	0.33	4.29e-8	Fractional excretion of uric acid;
CESC	cis	rs7666738	0.830	rs6854994	chr4:98977624	C/G	cg03676636	chr4:99064102	C4orf37	0.34	5.2	0.3	3.93e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs763121	0.752	rs6001190	chr22:39073811	T/C	cg14440974	chr22:39074834	NA	-0.42	-5.84	-0.34	1.52e-8	Menopause (age at onset);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg04899896	chr4:79860379	PAQR3	-0.44	-6.12	-0.35	3.37e-9	Gambling;
CESC	cis	rs763014	0.966	rs15564	chr16:677854	G/T	cg00908189	chr16:619842	PIGQ	0.65	9.39	0.5	2.8e-18	Height;
CESC	cis	rs2239547	0.657	rs12496077	chr3:52886241	G/A	cg11645453	chr3:52864694	ITIH4	0.33	6.25	0.36	1.61e-9	Schizophrenia;
CESC	trans	rs2727020	0.566	rs10839234	chr11:49185524	C/T	cg03929089	chr4:120376271	NA	-0.78	-11.85	-0.59	2.83e-26	Coronary artery disease;
CESC	cis	rs965469	1.000	rs6037535	chr20:3270621	C/T	cg25506879	chr20:3388711	C20orf194	-0.6	-6.35	-0.36	9.17e-10	IFN-related cytopenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24568548	chr11:43544500	NA	-0.62	-7.55	-0.42	7.09e-13	Gut microbiome composition (summer);
CESC	cis	rs13256369	0.851	rs13258283	chr8:8563630	T/C	cg18904891	chr8:8559673	CLDN23	0.73	8.11	0.45	1.94e-14	Obesity-related traits;
CESC	cis	rs763014	0.931	rs710925	chr16:633354	G/A	cg09263875	chr16:632152	PIGQ	0.67	11.24	0.57	3.15e-24	Height;
CESC	cis	rs27434	0.821	rs28337	chr5:96125314	A/T	cg16492584	chr5:96139282	ERAP1	-0.47	-6.54	-0.37	3.08e-10	Ankylosing spondylitis;
CESC	cis	rs11608355	0.545	rs2302703	chr12:109898832	G/A	cg05360138	chr12:110035743	NA	0.82	8.92	0.48	7.93e-17	Neuroticism;
CESC	cis	rs9640161	0.789	rs2098053	chr7:150043205	G/A	cg10018233	chr7:150070692	REPIN1	0.38	5.3	0.31	2.39e-7	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs4727027	0.866	rs1358062	chr7:148783743	T/C	cg23583168	chr7:148888333	NA	-0.82	-12.47	-0.61	2.17e-28	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs2576037	0.526	rs607780	chr18:44417456	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.41	6.84	0.39	5.54e-11	Personality dimensions;
CESC	cis	rs60843830	1.000	rs6709534	chr2:217334	G/C	cg00108164	chr2:264199	ACP1;SH3YL1	0.75	9.46	0.5	1.69e-18	Spherical equivalent (joint analysis main effects and education interaction);
CESC	trans	rs11098499	0.866	rs9995136	chr4:120286845	A/G	cg25214090	chr10:38739885	LOC399744	0.65	9.11	0.49	2.04e-17	Corneal astigmatism;
CESC	cis	rs9322193	0.962	rs7818	chr6:150132092	A/G	cg13206674	chr6:150067644	NUP43	0.41	5.93	0.34	9.4e-9	Lung cancer;
CESC	cis	rs17345786	0.953	rs78645744	chr3:101327789	T/A	cg12386194	chr3:101231763	SENP7	0.57	6.55	0.37	3e-10	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2832077	0.527	rs1048546	chr21:30244877	G/T	cg24692254	chr21:30365293	RNF160	-0.52	-6.64	-0.38	1.74e-10	Cognitive test performance;
CESC	cis	rs155076	0.938	rs9509633	chr13:21844482	G/C	cg11317459	chr13:21872234	NA	-1.01	-11.12	-0.56	7.88e-24	White matter hyperintensity burden;
CESC	cis	rs644799	0.930	rs3802764	chr11:95514599	T/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	14.73	0.67	2.69e-36	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs12142240	0.660	rs112560929	chr1:46822297	A/G	cg10495392	chr1:46806563	NSUN4	0.58	6.32	0.36	1.09e-9	Menopause (age at onset);
CESC	trans	rs9354308	0.899	rs2814094	chr6:66536275	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.56	-6.31	-0.36	1.19e-9	Metabolite levels;
CESC	cis	rs10242455	0.702	rs28668326	chr7:98998153	G/A	cg25640893	chr7:99214727	ZNF498	1.07	6.65	0.38	1.68e-10	Blood metabolite levels;
CESC	cis	rs72627509	1.000	rs57265257	chr4:57839280	A/T	cg26694713	chr4:57773883	REST	0.54	5.13	0.3	5.49e-7	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CESC	cis	rs1538970	0.962	rs4660301	chr1:45820149	T/A	cg03146154	chr1:46216737	IPP	0.45	5.39	0.31	1.54e-7	Platelet count;
CESC	cis	rs2522056	1.000	rs2522047	chr5:131795882	G/T	cg24060327	chr5:131705240	SLC22A5	0.59	6.63	0.38	1.85e-10	Lymphocyte counts;Fibrinogen;
CESC	cis	rs11676348	0.818	rs6436031	chr2:218979259	T/C	cg00012203	chr2:219082015	ARPC2	-0.57	-7.39	-0.41	1.96e-12	Ulcerative colitis;
CESC	cis	rs9790314	0.695	rs7630763	chr3:160864865	T/C	cg03342759	chr3:160939853	NMD3	-0.4	-5.49	-0.32	9.28e-8	Morning vs. evening chronotype;
CESC	cis	rs854765	0.547	rs6502632	chr17:17913057	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.56	7.91	0.44	6.89e-14	Total body bone mineral density;
CESC	cis	rs854765	0.547	rs2955378	chr17:17930253	G/A	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.51	6.68	0.38	1.41e-10	Total body bone mineral density;
CESC	cis	rs858239	0.601	rs764534	chr7:23153935	C/T	cg23682824	chr7:23144976	KLHL7	0.49	6.49	0.37	4.19e-10	Cerebrospinal fluid biomarker levels;
CESC	cis	rs7618915	0.547	rs11130315	chr3:52697163	A/G	cg18404041	chr3:52824283	ITIH1	-0.39	-6.58	-0.37	2.56e-10	Bipolar disorder;
CESC	cis	rs7208859	0.673	rs11653955	chr17:29033292	C/A	cg19761014	chr17:28927070	LRRC37B2	0.79	6.36	0.36	8.58e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs6901004	0.803	rs354539	chr6:111517829	T/C	cg15721981	chr6:111408429	SLC16A10	-0.36	-5.19	-0.3	4.23e-7	Blood metabolite levels;
CESC	cis	rs6500395	1.000	rs8059905	chr16:48629934	C/T	cg04672837	chr16:48644449	N4BP1	0.53	6.85	0.39	5e-11	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs4665809	1.000	rs6729757	chr2:26285102	A/G	cg08470875	chr2:26401718	FAM59B	-0.46	-5.14	-0.3	5.45e-7	Gut microbiome composition (summer);
CESC	cis	rs9815354	0.812	rs77047799	chr3:41958895	T/C	cg03022575	chr3:42003672	ULK4	0.67	6.09	0.35	3.97e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs34779708	0.966	rs10827493	chr10:35454976	C/T	cg04310649	chr10:35416472	CREM	-0.54	-6.78	-0.38	7.74e-11	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs6499255	1.000	rs73579497	chr16:69824150	C/G	cg15192750	chr16:69999425	NA	0.43	5.35	0.31	1.91e-7	IgE levels;
CESC	cis	rs72781680	0.821	rs17046004	chr2:24144873	A/G	cg08917208	chr2:24149416	ATAD2B	0.57	5.62	0.33	4.79e-8	Lymphocyte counts;
CESC	cis	rs367943	0.698	rs9326900	chr5:112972859	A/G	cg12552261	chr5:112820674	MCC	0.43	5.49	0.32	9.31e-8	Type 2 diabetes;
CESC	cis	rs9768139	0.708	rs11771764	chr7:158119871	A/G	cg24154853	chr7:158122151	PTPRN2	0.43	6.62	0.38	1.98e-10	Calcium levels;
CESC	cis	rs920590	0.642	rs6993525	chr8:19671104	A/G	cg17834443	chr8:19674713	INTS10	-0.47	-5.27	-0.31	2.87e-7	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs4843185	0.576	rs381624	chr16:85728679	G/A	cg05245094	chr16:85669572	KIAA0182	0.42	5.23	0.31	3.48e-7	Platelet distribution width;
CESC	cis	rs2243480	1.000	rs160643	chr7:65558222	C/T	cg18252515	chr7:66147081	NA	-1.2	-11.72	-0.58	7.75e-26	Diabetic kidney disease;
CESC	cis	rs7824557	0.767	rs2164272	chr8:11162496	A/C	cg21775007	chr8:11205619	TDH	0.5	7.29	0.41	3.6e-12	Retinal vascular caliber;
CESC	cis	rs1801251	0.778	rs2250665	chr2:233752639	A/T	cg25237894	chr2:233734115	C2orf82	-0.5	-8.87	-0.48	1.14e-16	Coronary artery disease;
CESC	cis	rs875971	1.000	rs778685	chr7:65836176	G/T	cg10691866	chr7:65817282	TPST1	-0.34	-5.46	-0.32	1.08e-7	Aortic root size;
CESC	cis	rs2011503	1.000	rs1560687	chr19:19562902	G/A	cg11584989	chr19:19387371	SF4	0.62	7.22	0.41	5.54e-12	Bipolar disorder;
CESC	cis	rs523522	0.962	rs687873	chr12:121019634	G/A	cg12219531	chr12:120966889	COQ5	0.76	10.07	0.53	2.15e-20	High light scatter reticulocyte count;
CESC	cis	rs11249608	0.789	rs7704963	chr5:178436854	A/G	cg21905437	chr5:178450457	ZNF879	0.49	6.99	0.39	2.22e-11	Pubertal anthropometrics;
CESC	cis	rs7923609	0.869	rs9971352	chr10:65265108	A/T	cg01631684	chr10:65280961	REEP3	-0.44	-5.5	-0.32	8.8e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs17253792	0.822	rs77741349	chr14:56097462	C/T	cg01858014	chr14:56050164	KTN1	-0.93	-7.33	-0.41	2.71e-12	Putamen volume;
CESC	cis	rs6499255	0.951	rs16958970	chr16:69627793	G/A	cg15192750	chr16:69999425	NA	0.55	6.39	0.37	7.58e-10	IgE levels;
CESC	cis	rs2204008	0.748	rs11180579	chr12:38237830	A/G	cg26384229	chr12:38710491	ALG10B	0.73	10.35	0.54	2.55e-21	Bladder cancer;
CESC	cis	rs7618915	0.501	rs62253740	chr3:52684128	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.61	8.97	0.48	5.62e-17	Bipolar disorder;
CESC	cis	rs1862618	0.671	rs72644088	chr5:56241019	G/A	cg12311346	chr5:56204834	C5orf35	0.66	8.74	0.47	2.72e-16	Initial pursuit acceleration;
CESC	cis	rs2243480	1.000	rs781156	chr7:65479141	C/A	cg18252515	chr7:66147081	NA	-1.19	-11.57	-0.58	2.56e-25	Diabetic kidney disease;
CESC	cis	rs9900062	0.535	rs753917	chr17:62673136	C/T	cg02598441	chr17:62777298	LOC146880	-0.56	-5.85	-0.34	1.47e-8	QT interval;
CESC	cis	rs6466055	0.720	rs7357199	chr7:105019355	G/C	cg04380332	chr7:105027541	SRPK2	-0.42	-5.36	-0.31	1.81e-7	Schizophrenia;
CESC	cis	rs1799949	0.965	rs4793233	chr17:41435437	G/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.4	5.39	0.31	1.52e-7	Menopause (age at onset);
CESC	cis	rs7809950	0.953	rs28687365	chr7:107106712	A/C	cg23024343	chr7:107201750	COG5	-0.43	-6.11	-0.35	3.58e-9	Coronary artery disease;
CESC	cis	rs4555082	0.834	rs2816631	chr14:105739477	G/A	cg13114125	chr14:105738426	BRF1	-0.89	-11.0	-0.56	2.0500000000000001e-23	Mean platelet volume;Platelet distribution width;
CESC	cis	rs1023500	0.573	rs2413666	chr22:42459622	C/T	cg15557168	chr22:42548783	NA	-0.46	-6.53	-0.37	3.27e-10	Schizophrenia;
CESC	cis	rs2304069	0.614	rs216140	chr5:149443298	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.5	6.84	0.39	5.42e-11	HIV-1 control;
CESC	cis	rs6089829	0.926	rs6062395	chr20:61667904	A/G	cg08564027	chr20:61660810	NA	0.9	15.44	0.69	8.75e-39	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs74181299	0.684	rs12713532	chr2:65356552	G/C	cg05010058	chr2:65284262	CEP68	-0.32	-5.13	-0.3	5.56e-7	Pulse pressure;
CESC	cis	rs875971	0.895	rs3857684	chr7:65938158	G/C	cg11764359	chr7:65958608	NA	0.94	14.96	0.68	4.34e-37	Aortic root size;
CESC	cis	rs7605378	0.528	rs7592587	chr2:200786516	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.47	5.21	0.3	3.84e-7	Osteoporosis;
CESC	cis	rs769267	0.792	rs4808961	chr19:19577215	C/G	cg03709012	chr19:19516395	GATAD2A	1.0	15.1	0.68	1.35e-37	Tonsillectomy;
CESC	cis	rs7429990	0.965	rs2166770	chr3:48005673	A/C	cg11946769	chr3:48343235	NME6	0.45	5.34	0.31	1.96e-7	Educational attainment (years of education);
CESC	cis	rs875971	1.000	rs1182882	chr7:65562063	C/T	cg18876405	chr7:65276391	NA	-0.55	-7.28	-0.41	3.91e-12	Aortic root size;
CESC	cis	rs113835537	0.935	rs76228630	chr11:66458676	T/C	cg22134325	chr11:66188745	NPAS4	0.52	5.94	0.34	8.91e-9	Airway imaging phenotypes;
CESC	cis	rs2066819	1.000	rs2695788	chr12:56697110	G/A	cg26734620	chr12:56694298	CS	-0.93	-9.55	-0.51	9.4e-19	Psoriasis vulgaris;
CESC	cis	rs4665809	1.000	rs6749855	chr2:26255263	A/G	cg04944784	chr2:26401820	FAM59B	-0.68	-7.49	-0.42	1.03e-12	Gut microbiome composition (summer);
CESC	cis	rs7937682	0.855	rs521947	chr11:111492616	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.95	-14.6	-0.67	8.26e-36	Primary sclerosing cholangitis;
CESC	cis	rs568617	0.767	rs2231884	chr11:65656564	C/T	cg04055107	chr11:65626734	MUS81;CFL1	0.92	9.41	0.5	2.54e-18	Crohn's disease;
CESC	cis	rs6951245	0.580	rs10257426	chr7:1213694	G/A	cg18402987	chr7:1209562	NA	0.7	8.04	0.44	3.07e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7177699	0.557	rs10083696	chr15:79124016	G/A	cg04896959	chr15:78267971	NA	0.32	5.04	0.3	8.74e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
CESC	cis	rs7191439	0.789	rs4598894	chr16:88776141	G/A	cg27087555	chr16:88793112	FAM38A	-1.34	-10.77	-0.55	1.16e-22	Plateletcrit;
CESC	cis	rs6674970	0.518	rs6587552	chr1:151018861	C/T	cg04469105	chr1:151031679	CDC42SE1;MLLT11	0.46	5.56	0.32	6.6e-8	Childhood ear infection;
CESC	cis	rs7618915	0.501	rs55678971	chr3:52717229	T/A	cg07507251	chr3:52567010	NT5DC2	0.4	6.94	0.39	2.98e-11	Bipolar disorder;
CESC	cis	rs8027181	0.839	rs62017600	chr15:73072236	T/A	cg25632853	chr15:73088954	NA	0.34	6.06	0.35	4.61e-9	Triglyceride levels;
CESC	cis	rs6088590	0.603	rs6579186	chr20:33282198	G/C	cg06115741	chr20:33292138	TP53INP2	0.53	6.62	0.38	1.99e-10	Coronary artery disease;
CESC	cis	rs4689388	0.926	rs4234730	chr4:6296343	A/G	cg14416269	chr4:6271139	WFS1	0.45	7.5	0.42	9.45e-13	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	trans	rs1728785	1.000	rs1728785	chr16:68591230	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.73	-8.84	-0.48	1.36e-16	Ulcerative colitis;
CESC	cis	rs67311347	1.000	rs73078169	chr3:40483798	G/A	cg09455208	chr3:40491958	NA	0.49	8.07	0.44	2.53e-14	Renal cell carcinoma;
CESC	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg26338869	chr17:61819248	STRADA	0.69	9.11	0.49	2.04e-17	Prudent dietary pattern;
CESC	cis	rs9733	0.519	rs2184833	chr1:150675483	C/T	cg18016565	chr1:150552671	MCL1	0.33	5.08	0.3	7.3e-7	Tonsillectomy;
CESC	cis	rs13191362	0.507	rs1079020	chr6:163066596	C/T	cg06582575	chr6:163149167	PACRG;PARK2	-0.53	-6.22	-0.36	1.98e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	trans	rs650950	0.528	rs646660	chr11:35528452	C/T	cg00385906	chr1:117910225	MAN1A2	0.42	6.09	0.35	4.04e-9	Bronchopulmonary dysplasia;
CESC	cis	rs7618501	0.633	rs6446193	chr3:50059758	T/C	cg24110177	chr3:50126178	RBM5	0.54	7.69	0.43	2.83e-13	Intelligence (multi-trait analysis);
CESC	cis	rs896854	0.967	rs13257021	chr8:95965695	A/G	cg09323728	chr8:95962352	TP53INP1	-0.42	-9.16	-0.49	1.5e-17	Type 2 diabetes;
CESC	cis	rs10504229	1.000	rs67630725	chr8:58185580	G/A	cg22535103	chr8:58192502	C8orf71	-1.05	-13.08	-0.63	1.71e-30	Developmental language disorder (linguistic errors);
CESC	cis	rs13118159	1.000	rs13118159	chr4:1365127	A/G	cg16405210	chr4:1374714	KIAA1530	-0.42	-5.46	-0.32	1.12e-7	Longevity;
CESC	cis	rs6540559	0.673	rs17015224	chr1:209968918	G/A	cg10074409	chr1:209979377	IRF6	0.4	5.32	0.31	2.16e-7	Cleft lip with or without cleft palate;
CESC	cis	rs6800768	0.633	rs58523227	chr3:24116856	C/A	cg10674438	chr3:24145617	LOC152024	-0.43	-5.83	-0.34	1.62e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs7264396	0.676	rs1341603	chr20:34556216	A/G	cg17201900	chr20:34330562	RBM39	0.5	5.2	0.3	3.93e-7	Total cholesterol levels;
CESC	cis	rs473651	0.935	rs472357	chr2:239355454	A/G	cg21699342	chr2:239360505	ASB1	-0.53	-9.47	-0.5	1.67e-18	Multiple system atrophy;
CESC	cis	rs67478160	0.643	rs11160762	chr14:104255083	A/G	cg08213375	chr14:104286397	PPP1R13B	-0.54	-10.79	-0.55	9.95e-23	Schizophrenia;
CESC	cis	rs13256369	0.756	rs13282580	chr8:8562903	C/T	cg18904891	chr8:8559673	CLDN23	0.73	8.12	0.45	1.74e-14	Obesity-related traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12448860	chr6:106959601	AIM1	0.58	6.22	0.36	1.95e-9	Gut microbiome composition (summer);
CESC	cis	rs34172651	0.917	rs8049667	chr16:24773524	G/A	cg06028605	chr16:24865363	SLC5A11	0.41	6.2	0.36	2.13e-9	Intelligence (multi-trait analysis);
CESC	cis	rs12422267	0.536	rs12303484	chr12:132609558	G/A	cg09764611	chr12:132620959	NA	-0.5	-6.48	-0.37	4.39e-10	Plasma amyloid beta peptide concentrations (ABx-40);
CESC	cis	rs208520	1.000	rs208536	chr6:66963440	T/C	cg07460842	chr6:66804631	NA	-0.9	-10.34	-0.54	2.79e-21	Exhaled nitric oxide output;
CESC	trans	rs9826463	0.590	rs1871349	chr3:142535409	C/G	cg10107929	chr13:49550206	FNDC3A	0.51	6.33	0.36	1.02e-9	QRS duration in Tripanosoma cruzi seropositivity;
CESC	cis	rs704	0.605	rs2227736	chr17:26693231	G/C	cg10342447	chr17:26645325	TMEM97	-0.43	-5.93	-0.34	9.49e-9	Osteoprotegerin levels;
CESC	cis	rs7577696	0.597	rs34197800	chr2:32389646	C/A	cg02381751	chr2:32503542	YIPF4	-0.46	-5.46	-0.32	1.11e-7	Inflammatory biomarkers;
CESC	cis	rs801193	0.660	rs1016265	chr7:66214567	C/T	cg18876405	chr7:65276391	NA	0.47	6.27	0.36	1.47e-9	Aortic root size;
CESC	cis	rs951366	0.677	rs1775140	chr1:205672107	C/A	cg26354017	chr1:205819088	PM20D1	0.81	11.83	0.59	3.4e-26	Menarche (age at onset);
CESC	cis	rs9925964	0.933	rs8050894	chr16:31104509	C/G	cg02466173	chr16:30829666	NA	0.33	5.2	0.3	3.91e-7	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs9549367	0.789	rs9549699	chr13:113878263	T/A	cg00898013	chr13:113819073	PROZ	-0.49	-6.87	-0.39	4.59e-11	Platelet distribution width;
CESC	cis	rs9910055	0.659	rs3826412	chr17:42255097	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.67	8.72	0.47	3.11e-16	Total body bone mineral density;
CESC	cis	rs1799949	0.965	rs799912	chr17:41257134	T/C	cg05368731	chr17:41323189	NBR1	0.53	7.43	0.42	1.48e-12	Menopause (age at onset);
CESC	cis	rs9311474	0.508	rs6786919	chr3:52599789	A/G	cg17372223	chr3:52568218	NT5DC2	0.39	5.91	0.34	1.03e-8	Electroencephalogram traits;
CESC	cis	rs36051895	0.589	rs10283734	chr9:5217139	A/T	cg02405213	chr9:5042618	JAK2	-0.58	-6.99	-0.39	2.23e-11	Pediatric autoimmune diseases;
CESC	cis	rs651907	0.557	rs2288272	chr3:101378476	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.48	6.21	0.36	2.07e-9	Colorectal cancer;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg02113521	chr15:22892956	CYFIP1	0.5	6.92	0.39	3.49e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs6860806	0.661	rs2136187	chr5:131577894	T/C	cg22638593	chr5:131593259	PDLIM4	0.4	5.24	0.31	3.26e-7	Breast cancer;
CESC	cis	rs9443645	0.901	rs4421161	chr6:79564219	A/G	cg05283184	chr6:79620031	NA	0.46	6.95	0.39	2.83e-11	Intelligence (multi-trait analysis);
CESC	cis	rs4604732	0.631	rs11490201	chr1:247626262	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.57	7.17	0.4	7.39e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs250677	0.687	rs2963485	chr5:148452043	A/G	cg18129178	chr5:148520854	ABLIM3	0.47	5.37	0.31	1.73e-7	Breast cancer;
CESC	cis	rs6502050	0.835	rs7502676	chr17:80093433	C/G	cg23985595	chr17:80112537	CCDC57	-0.42	-6.67	-0.38	1.49e-10	Life satisfaction;
CESC	cis	rs9309473	0.528	rs2091022	chr2:73564570	G/A	cg20560298	chr2:73613845	ALMS1	-0.48	-6.34	-0.36	9.87e-10	Metabolite levels;
CESC	cis	rs4835473	0.897	rs2323325	chr4:144758714	C/T	cg25736465	chr4:144833511	NA	0.45	6.65	0.38	1.67e-10	Immature fraction of reticulocytes;
CESC	trans	rs7943203	1.000	rs61913875	chr11:108298852	A/G	cg01416241	chr5:148737479	PCYOX1L	-0.48	-6.1	-0.35	3.72e-9	Red blood cell count;Mean corpuscular volume;
CESC	cis	rs6570726	0.935	rs372378	chr6:145816227	A/G	cg05347473	chr6:146136440	FBXO30	0.5	6.71	0.38	1.15e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1775715	0.870	rs3847415	chr10:32219456	G/T	cg18675610	chr10:32216311	ARHGAP12	0.36	5.51	0.32	8.56e-8	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs2243480	1.000	rs1723269	chr7:65472786	C/G	cg25894440	chr7:65020034	NA	-0.67	-5.78	-0.33	2.11e-8	Diabetic kidney disease;
CESC	cis	rs10870270	1.000	rs10870292	chr10:133770782	G/C	cg26149184	chr10:133730230	NA	0.37	5.03	0.3	9.2e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs4563143	0.675	rs73029042	chr19:29267979	A/T	cg12756686	chr19:29218302	NA	0.58	7.52	0.42	8.38e-13	Methadone dose in opioid dependence;
CESC	cis	rs8141529	0.732	rs5752798	chr22:29181868	A/G	cg02153584	chr22:29168773	CCDC117	0.69	9.9	0.52	7.13e-20	Lymphocyte counts;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg15238519	chr22:50683529	TUBGCP6	-0.48	-6.49	-0.37	4.2e-10	Ulcerative colitis;
CESC	cis	rs4704187	0.687	rs4703657	chr5:74461850	T/G	cg03227963	chr5:74354835	NA	0.3	5.35	0.31	1.89e-7	Response to amphetamines;
CESC	cis	rs763014	0.931	rs3752568	chr16:628302	A/G	cg00802000	chr16:706648	WDR90	-0.42	-6.36	-0.36	8.74e-10	Height;
CESC	cis	rs6580649	0.941	rs17122612	chr12:48459488	C/G	cg05342945	chr12:48394962	COL2A1	0.49	5.78	0.33	2.13e-8	Lung cancer;
CESC	trans	rs11098499	0.774	rs73842616	chr4:120290683	G/A	cg25214090	chr10:38739885	LOC399744	0.65	9.11	0.49	2.04e-17	Corneal astigmatism;
CESC	cis	rs6466055	0.720	rs1204056	chr7:104957761	G/A	cg04380332	chr7:105027541	SRPK2	0.42	5.43	0.32	1.25e-7	Schizophrenia;
CESC	cis	rs965513	1.000	rs1443438	chr9:100550028	T/C	cg13688889	chr9:100608707	NA	-0.6	-8.62	-0.47	6.31e-16	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
CESC	cis	rs7072216	0.763	rs3750601	chr10:100174561	C/A	cg26618903	chr10:100175079	PYROXD2	-0.38	-5.82	-0.34	1.69e-8	Metabolite levels;
CESC	cis	rs10129255	0.518	rs28378320	chr14:107216845	T/C	cg23076370	chr14:107095027	NA	-0.72	-11.14	-0.56	6.76e-24	Kawasaki disease;
CESC	cis	rs1448094	0.511	rs58742237	chr12:86166444	C/T	cg02569458	chr12:86230093	RASSF9	0.56	8.07	0.44	2.43e-14	Major depressive disorder;
CESC	trans	rs561341	1.000	rs55959993	chr17:30254771	C/G	cg27661571	chr11:113659931	NA	-0.87	-7.9	-0.44	7.5e-14	Hip circumference adjusted for BMI;
CESC	cis	rs11098499	0.604	rs2389882	chr4:120566733	A/C	cg09307838	chr4:120376055	NA	0.73	9.3	0.5	5.33e-18	Corneal astigmatism;
CESC	cis	rs6088580	0.713	rs1884669	chr20:33171287	G/A	cg24642439	chr20:33292090	TP53INP2	0.62	8.31	0.45	5.09e-15	Glomerular filtration rate (creatinine);
CESC	cis	rs597539	0.652	rs553875	chr11:68695144	T/G	cg06028808	chr11:68637592	NA	0.45	5.34	0.31	1.96e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs10504229	0.683	rs58883273	chr8:58138275	A/G	cg24829409	chr8:58192753	C8orf71	-0.58	-7.2	-0.4	6.31e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs854765	0.693	rs4924823	chr17:17764502	A/G	cg04398451	chr17:18023971	MYO15A	0.68	10.07	0.53	2.1e-20	Total body bone mineral density;
CESC	cis	rs9399135	0.967	rs6923765	chr6:135335176	C/G	cg24558204	chr6:135376177	HBS1L	-0.56	-7.79	-0.43	1.48e-13	Red blood cell count;
CESC	cis	rs7520050	0.553	rs2993263	chr1:46021630	A/G	cg06784218	chr1:46089804	CCDC17	0.29	5.1	0.3	6.36e-7	Red blood cell count;Reticulocyte count;
CESC	cis	rs2243480	1.000	rs7792391	chr7:65773429	A/G	cg18252515	chr7:66147081	NA	1.41	14.3	0.66	9.43e-35	Diabetic kidney disease;
CESC	cis	rs1788820	0.957	rs1652375	chr18:21109269	T/C	cg14672496	chr18:21087552	C18orf8	0.53	7.11	0.4	1.07e-11	Body mass index;
CESC	cis	rs9916302	0.706	rs8075737	chr17:37727316	C/T	cg00129232	chr17:37814104	STARD3	0.53	5.68	0.33	3.53e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs6500602	0.627	rs11639998	chr16:4527109	T/C	cg08645402	chr16:4508243	NA	0.42	5.94	0.34	8.95e-9	Schizophrenia;
CESC	cis	rs1153858	1.000	rs7402650	chr15:45701895	C/T	cg14582100	chr15:45693742	SPATA5L1	0.41	5.79	0.33	2.03e-8	Homoarginine levels;
CESC	cis	rs9287719	0.967	rs6712406	chr2:10754420	A/G	cg02196655	chr2:10830764	NOL10	-0.37	-5.69	-0.33	3.39e-8	Prostate cancer;
CESC	cis	rs853679	0.517	rs9368553	chr6:28082265	T/C	cg20151795	chr6:28129481	ZNF389	0.45	5.87	0.34	1.29e-8	Depression;
CESC	cis	rs7618501	0.521	rs2352984	chr3:49948728	T/C	cg24308560	chr3:49941425	MST1R	-0.6	-8.79	-0.47	1.98e-16	Intelligence (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18822446	chr2:157198283	NA	0.57	6.11	0.35	3.53e-9	Gut microbiome composition (summer);
CESC	cis	rs514406	0.505	rs437954	chr1:53173321	C/G	cg08859206	chr1:53392774	SCP2	-0.59	-7.83	-0.43	1.19e-13	Monocyte count;
CESC	cis	rs6964587	0.967	rs2040499	chr7:91809657	C/G	cg17063962	chr7:91808500	NA	-0.55	-7.66	-0.43	3.51e-13	Breast cancer;
CESC	cis	rs9902453	0.904	rs8078638	chr17:28290358	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.76	10.01	0.52	3.23e-20	Coffee consumption (cups per day);
CESC	cis	rs10089	1.000	rs4836366	chr5:127482494	A/T	cg19767477	chr5:127420684	SLC12A2	-0.39	-5.18	-0.3	4.42e-7	Ileal carcinoids;
CESC	cis	rs780096	0.526	rs13391837	chr2:27649375	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.3	-5.59	-0.32	5.66e-8	Total body bone mineral density;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg21220614	chr22:43266108	NA	0.43	6.04	0.35	5.25e-9	Fibrinogen levels;
CESC	cis	rs9486715	0.964	rs6921480	chr6:97066329	C/G	cg18709589	chr6:96969512	KIAA0776	-0.46	-6.48	-0.37	4.56e-10	Headache;
CESC	cis	rs7727544	0.735	rs272879	chr5:131670546	C/G	cg24060327	chr5:131705240	SLC22A5	-0.67	-8.93	-0.48	7.2e-17	Blood metabolite levels;
CESC	cis	rs12142240	0.659	rs72677591	chr1:46818219	T/G	cg10495392	chr1:46806563	NSUN4	0.57	6.27	0.36	1.47e-9	Menopause (age at onset);
CESC	cis	rs9354308	0.840	rs1827157	chr6:66615761	A/G	cg07460842	chr6:66804631	NA	0.64	7.08	0.4	1.31e-11	Metabolite levels;
CESC	cis	rs1552244	0.882	rs6796419	chr3:10040812	G/A	cg08888203	chr3:10149979	C3orf24	0.49	6.24	0.36	1.68e-9	Alzheimer's disease;
CESC	cis	rs9467773	0.595	rs12525810	chr6:26623511	T/TA	cg11502198	chr6:26597334	ABT1	0.56	5.31	0.31	2.38e-7	Intelligence (multi-trait analysis);
CESC	cis	rs897984	0.762	rs897986	chr16:30980902	T/C	cg00531865	chr16:30841666	NA	0.5	6.84	0.39	5.3e-11	Dementia with Lewy bodies;
CESC	trans	rs9858542	1.000	rs11130213	chr3:49712297	C/T	cg21659725	chr3:3221576	CRBN	-0.55	-6.72	-0.38	1.11e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.89	13.19	0.63	6.84e-31	Prudent dietary pattern;
CESC	cis	rs2742540	0.524	rs2653562	chr11:8918160	A/T	cg14711859	chr11:8959438	ASCL3	0.36	5.43	0.32	1.25e-7	Hematocrit;
CESC	cis	rs3762637	1.000	rs9858558	chr3:122139742	G/A	cg24169773	chr3:122142474	KPNA1	-0.51	-6.03	-0.35	5.56e-9	LDL cholesterol levels;
CESC	cis	rs7208859	0.573	rs7223803	chr17:29077193	A/G	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.79e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg20530339	chr18:21594203	TTC39C	-0.54	-6.48	-0.37	4.46e-10	Response to antipsychotic treatment;
CESC	cis	rs2645694	0.626	rs2703140	chr4:77830057	C/G	cg10057126	chr4:77819792	ANKRD56	0.6	8.45	0.46	1.91e-15	Emphysema distribution in smoking;
CESC	cis	rs11583043	0.918	rs11582211	chr1:101416871	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.54	5.92	0.34	9.72e-9	Ulcerative colitis;Inflammatory bowel disease;
CESC	cis	rs1707322	0.648	rs4439382	chr1:46150805	C/T	cg06784218	chr1:46089804	CCDC17	0.41	7.21	0.41	5.75e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg01596986	chr13:48611463	NUDT15	-0.46	-6.21	-0.36	2.03e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs10089	0.953	rs6875982	chr5:127529197	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.7	9.39	0.5	2.81e-18	Ileal carcinoids;
CESC	cis	rs1728785	1.000	rs12918865	chr16:68566546	G/A	cg02972257	chr16:68554789	NA	-0.55	-6.37	-0.36	8.21e-10	Ulcerative colitis;
CESC	cis	rs6860806	0.507	rs272868	chr5:131680751	C/G	cg18758796	chr5:131593413	PDLIM4	0.39	5.38	0.31	1.67e-7	Breast cancer;
CESC	cis	rs2243480	1.000	rs2420171	chr7:65637760	T/C	cg12463550	chr7:65579703	CRCP	-0.73	-5.71	-0.33	3.1e-8	Diabetic kidney disease;
CESC	cis	rs847577	0.609	rs6965016	chr7:97807882	C/A	cg21770322	chr7:97807741	LMTK2	0.85	14.36	0.66	5.78e-35	Breast cancer;
CESC	cis	rs1832871	0.711	rs56043101	chr6:158682277	A/G	cg07165851	chr6:158734300	TULP4	0.59	6.27	0.36	1.46e-9	Height;
CESC	cis	rs1552244	0.572	rs7645667	chr3:10157337	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.8	8.59	0.47	7.6e-16	Alzheimer's disease;
CESC	cis	rs6460942	0.915	rs80345607	chr7:12442249	T/C	cg17427002	chr7:12443146	VWDE	-0.53	-5.18	-0.3	4.34e-7	Coronary artery disease;
CESC	cis	rs9611519	0.780	rs5751072	chr22:41656509	C/T	cg03806693	chr22:41940476	POLR3H	-0.55	-6.25	-0.36	1.66e-9	Neuroticism;
CESC	cis	rs9309473	0.948	rs7566385	chr2:73756817	G/T	cg20560298	chr2:73613845	ALMS1	-0.45	-6.11	-0.35	3.57e-9	Metabolite levels;
CESC	cis	rs7592578	0.713	rs60915953	chr2:191331304	G/C	cg27211696	chr2:191398769	TMEM194B	-0.63	-5.65	-0.33	4.19e-8	Diastolic blood pressure;
CESC	cis	rs4665809	0.941	rs1434079	chr2:26284670	C/G	cg25036284	chr2:26402008	FAM59B	-0.59	-6.9	-0.39	3.85e-11	Gut microbiome composition (summer);
CESC	cis	rs7216064	1.000	rs12451511	chr17:65874861	T/G	cg12091567	chr17:66097778	LOC651250	-0.86	-8.82	-0.48	1.55e-16	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs9329289	0.926	rs10903784	chr10:2541943	G/T	cg15501526	chr10:2543763	NA	-0.64	-11.58	-0.58	2.23e-25	Age-related hearing impairment;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg14107975	chr11:96076498	MAML2	-0.42	-6.06	-0.35	4.57e-9	Fibrinogen levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09371693	chr12:57855541	GLI1	0.57	6.3	0.36	1.22e-9	Gut microbiome composition (summer);
CESC	cis	rs9359856	0.564	rs17228548	chr6:90439164	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.62	-5.88	-0.34	1.23e-8	Bipolar disorder;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg02125554	chr16:90238222	NA	-0.41	-6.13	-0.35	3.13e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	trans	rs61931739	0.517	rs11052977	chr12:34035030	A/C	cg26384229	chr12:38710491	ALG10B	0.59	8.08	0.44	2.33e-14	Morning vs. evening chronotype;
CESC	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	21.97	0.8	1.29e-61	Prudent dietary pattern;
CESC	cis	rs7927771	0.524	rs7122182	chr11:47843133	A/C	cg20307385	chr11:47447363	PSMC3	-0.58	-8.03	-0.44	3.12e-14	Subjective well-being;
CESC	cis	rs854765	0.724	rs62072049	chr17:17906520	T/C	cg04398451	chr17:18023971	MYO15A	-0.68	-10.1	-0.53	1.73e-20	Total body bone mineral density;
CESC	cis	rs3126085	0.935	rs6670717	chr1:152249956	T/C	cg03465714	chr1:152285911	FLG	0.5	5.75	0.33	2.47e-8	Atopic dermatitis;
CESC	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg11965913	chr1:205819406	PM20D1	-0.69	-11.8	-0.59	4.11e-26	Monocyte percentage of white cells;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg21219744	chr4:44680344	GUF1	-0.47	-6.92	-0.39	3.44e-11	Gambling;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00959725	chr1:33282965	S100PBP;YARS	0.6	6.9	0.39	3.75e-11	Gut microbiome composition (summer);
CESC	cis	rs4665809	1.000	rs7588802	chr2:26277789	A/G	cg27170947	chr2:26402098	FAM59B	-0.68	-7.96	-0.44	5.12e-14	Gut microbiome composition (summer);
CESC	cis	rs7131987	0.903	rs7974221	chr12:29399448	A/G	cg09582351	chr12:29534625	ERGIC2	-0.34	-5.39	-0.31	1.57e-7	QT interval;
CESC	cis	rs116095464	0.558	rs9312957	chr5:202194	C/T	cg22496380	chr5:211416	CCDC127	-0.93	-10.2	-0.53	8.09e-21	Breast cancer;
CESC	cis	rs6502050	0.871	rs9916649	chr17:80075739	G/A	cg23985595	chr17:80112537	CCDC57	0.41	6.42	0.37	6.41e-10	Life satisfaction;
CESC	cis	rs1005277	0.579	rs1614236	chr10:38502996	C/T	cg25517755	chr10:38738941	LOC399744	-0.49	-6.36	-0.36	8.84e-10	Extrinsic epigenetic age acceleration;
CESC	cis	rs7555523	0.830	rs1547725	chr1:165670958	T/C	cg24409356	chr1:165738333	TMCO1	0.81	6.78	0.38	7.67e-11	Intraocular pressure;Glaucoma (high intraocular pressure);
CESC	cis	rs1552244	1.000	rs722509	chr3:10102377	T/A	cg08888203	chr3:10149979	C3orf24	0.53	6.72	0.38	1.11e-10	Alzheimer's disease;
CESC	cis	rs7618915	0.570	rs11130312	chr3:52675055	A/C	cg18099408	chr3:52552593	STAB1	-0.31	-5.09	-0.3	6.65e-7	Bipolar disorder;
CESC	cis	rs2576037	0.526	rs11082562	chr18:44522671	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.55	-7.54	-0.42	7.32e-13	Personality dimensions;
CESC	trans	rs2727020	0.595	rs10466496	chr11:49501514	C/T	cg03929089	chr4:120376271	NA	-0.85	-13.5	-0.64	5.83e-32	Coronary artery disease;
CESC	cis	rs34779708	0.931	rs3740083	chr10:35320383	C/T	cg03585969	chr10:35415529	CREM	0.76	10.17	0.53	9.87e-21	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs909002	0.849	rs6425777	chr1:32105447	G/C	cg13919466	chr1:32135498	COL16A1	-0.47	-8.05	-0.44	2.79e-14	Intelligence (multi-trait analysis);
CESC	cis	rs959260	1.000	rs4789185	chr17:73383368	C/T	cg20590849	chr17:73267439	MIF4GD	-0.57	-6.73	-0.38	1.07e-10	Systemic lupus erythematosus;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22162010	chr1:113249994	RHOC	0.55	6.22	0.36	1.92e-9	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.830	rs17550610	chr4:99008273	T/C	cg17366294	chr4:99064904	C4orf37	0.6	8.61	0.47	6.47e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs911555	0.755	rs35233301	chr14:103885291	A/G	cg12935359	chr14:103987150	CKB	0.63	9.16	0.49	1.51e-17	Intelligence (multi-trait analysis);
CESC	cis	rs13031619	0.950	rs7589966	chr2:3696636	A/G	cg19052272	chr2:3704530	ALLC	0.51	6.59	0.38	2.3e-10	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CESC	cis	rs1707322	0.752	rs6662164	chr1:46146230	T/A	cg03146154	chr1:46216737	IPP	0.77	10.78	0.55	1.04e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg19123408	chr17:7232769	NEURL4	-0.42	-6.15	-0.35	2.82e-9	Gambling;
CESC	cis	rs9682041	0.688	rs7621787	chr3:170146862	T/A	cg11886554	chr3:170076028	SKIL	0.92	7.07	0.4	1.35e-11	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CESC	cis	rs7116495	0.609	rs628025	chr11:71802351	A/C	cg26138937	chr11:71823887	C11orf51	-1.36	-8.51	-0.46	1.28e-15	Severe influenza A (H1N1) infection;
CESC	cis	rs898097	0.625	rs898095	chr17:80890638	T/C	cg19046167	chr17:80928561	B3GNTL1	0.41	5.47	0.32	1.04e-7	Breast cancer;
CESC	cis	rs8017423	0.967	rs2151748	chr14:90694897	G/C	cg14092571	chr14:90743983	NA	-0.55	-7.91	-0.44	7.09e-14	Mortality in heart failure;
CESC	cis	rs769267	0.930	rs7254927	chr19:19404786	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	7.46	0.42	1.24e-12	Tonsillectomy;
CESC	cis	rs736408	0.509	rs1108842	chr3:52720080	A/C	cg15147215	chr3:52552868	STAB1	-0.31	-5.55	-0.32	6.79e-8	Bipolar disorder;
CESC	cis	rs4975709	0.589	rs4975744	chr5:1860049	A/G	cg14773178	chr5:1868261	NA	0.31	5.57	0.32	6.41e-8	Cardiovascular disease risk factors;
CESC	cis	rs9303401	0.659	rs34818467	chr17:56643109	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.83	-10.44	-0.54	1.36e-21	Cognitive test performance;
CESC	cis	rs7845219	0.539	rs713113	chr8:95877787	C/T	cg13393036	chr8:95962371	TP53INP1	0.37	6.9	0.39	3.71e-11	Type 2 diabetes;
CESC	cis	rs6460942	1.000	rs7791634	chr7:12401482	A/T	cg02935154	chr7:12443704	VWDE	-0.57	-6.18	-0.35	2.42e-9	Coronary artery disease;
CESC	cis	rs748404	0.560	rs1869258	chr15:43803621	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.58	7.37	0.41	2.18e-12	Lung cancer;
CESC	cis	rs77106637	0.860	rs1552224	chr11:72433098	A/C	cg03713592	chr11:72463424	ARAP1	1.22	11.1	0.56	9.43e-24	Type 2 diabetes;
CESC	cis	rs7945705	0.902	rs11042152	chr11:9020987	C/T	cg12365402	chr11:9010492	NRIP3	0.43	7.02	0.4	1.9e-11	Hemoglobin concentration;
CESC	cis	rs6500602	1.000	rs7204827	chr16:4467533	C/T	cg08645402	chr16:4508243	NA	0.45	6.87	0.39	4.69e-11	Schizophrenia;
CESC	cis	rs6121246	0.522	rs6088736	chr20:30195166	C/G	cg13852791	chr20:30311386	BCL2L1	0.58	5.56	0.32	6.65e-8	Mean corpuscular hemoglobin;
CESC	cis	rs7618915	0.531	rs77146033	chr3:52701501	G/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	7.04	0.4	1.62e-11	Bipolar disorder;
CESC	cis	rs651907	0.535	rs17347156	chr3:101504674	G/A	cg12386194	chr3:101231763	SENP7	0.42	5.34	0.31	2.04e-7	Colorectal cancer;
CESC	cis	rs40363	0.523	rs757270	chr16:3534451	C/T	cg21433313	chr16:3507492	NAT15	-0.47	-7.67	-0.43	3.32e-13	Tuberculosis;
CESC	cis	rs7824557	0.602	rs7820895	chr8:11206262	T/C	cg21775007	chr8:11205619	TDH	0.58	8.93	0.48	7.48e-17	Retinal vascular caliber;
CESC	cis	rs6088580	0.609	rs6059845	chr20:33036500	G/A	cg08999081	chr20:33150536	PIGU	0.66	11.66	0.58	1.25e-25	Glomerular filtration rate (creatinine);
CESC	cis	rs1707322	1.000	rs3922887	chr1:46473802	A/G	cg03146154	chr1:46216737	IPP	0.73	9.95	0.52	5.12e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9287719	0.967	rs6750891	chr2:10738563	T/C	cg02196655	chr2:10830764	NOL10	-0.37	-5.72	-0.33	2.87e-8	Prostate cancer;
CESC	cis	rs17711722	0.510	rs73142128	chr7:65331109	A/C	cg25405998	chr7:65216604	CCT6P1	0.51	6.49	0.37	4.11e-10	Calcium levels;
CESC	cis	rs2637266	0.783	rs2583070	chr10:78518555	C/T	cg18941641	chr10:78392320	NA	0.43	8.42	0.46	2.39e-15	Pulmonary function;
CESC	cis	rs769267	0.930	rs747050	chr19:19584987	C/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.47	5.87	0.34	1.28e-8	Tonsillectomy;
CESC	cis	rs28374715	0.617	rs28626792	chr15:41562218	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.53	-7.59	-0.42	5.57e-13	Ulcerative colitis;
CESC	cis	rs3733585	0.699	rs6852441	chr4:9973744	C/T	cg02734326	chr4:10020555	SLC2A9	-0.4	-5.69	-0.33	3.43e-8	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs9300255	0.739	rs1969354	chr12:123741776	T/C	cg19016782	chr12:123741754	C12orf65	-0.48	-6.9	-0.39	3.71e-11	Neutrophil percentage of white cells;
CESC	cis	rs4253772	0.637	rs9627295	chr22:46650100	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.69	8.18	0.45	1.16e-14	LDL cholesterol;Cholesterol, total;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg20299236	chr22:32870557	FBXO7	-0.42	-6.18	-0.35	2.34e-9	Gambling;
CESC	cis	rs7523050	0.730	rs12726126	chr1:109436128	A/G	cg08274380	chr1:109419600	GPSM2	0.91	6.41	0.37	6.51e-10	Fat distribution (HIV);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg22767166	chr8:49833685	SNAI2	-0.38	-6.67	-0.38	1.44e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs300703	0.515	rs440617	chr2:189818	A/G	cg21211680	chr2:198530	NA	-0.91	-10.78	-0.55	1.02e-22	Blood protein levels;
CESC	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.95	-16.01	-0.7	8.35e-41	Prudent dietary pattern;
CESC	cis	rs546131	0.928	rs550313	chr11:34830919	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.47	5.84	0.34	1.52e-8	Lung disease severity in cystic fibrosis;
CESC	cis	rs11785400	0.731	rs9720504	chr8:143725502	T/C	cg24634471	chr8:143751801	JRK	0.46	5.82	0.34	1.73e-8	Schizophrenia;
CESC	cis	rs4843747	0.671	rs4075599	chr16:88107423	C/G	cg17633681	chr16:88106987	BANP	0.67	9.01	0.48	4.34e-17	Menopause (age at onset);
CESC	cis	rs7412746	0.658	rs6660845	chr1:150841066	G/A	cg04414720	chr1:150670196	GOLPH3L	0.56	7.44	0.42	1.41e-12	Melanoma;
CESC	cis	rs10504229	0.906	rs61638902	chr8:58193511	A/C	cg22535103	chr8:58192502	C8orf71	-0.99	-12.69	-0.61	3.79e-29	Developmental language disorder (linguistic errors);
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg13850925	chr2:191666976	NA	0.39	6.34	0.36	9.64e-10	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs9443645	0.527	rs9352691	chr6:79785607	C/T	cg05283184	chr6:79620031	NA	-0.38	-5.46	-0.32	1.09e-7	Intelligence (multi-trait analysis);
CESC	cis	rs7267979	1.000	rs2257420	chr20:25275890	C/A	cg08601574	chr20:25228251	PYGB	0.39	5.57	0.32	6.14e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs36051895	0.587	rs7019418	chr9:5259847	G/C	cg02405213	chr9:5042618	JAK2	-0.52	-6.41	-0.37	6.8e-10	Pediatric autoimmune diseases;
CESC	cis	rs6456156	0.805	rs6909252	chr6:167527097	C/T	cg07741184	chr6:167504864	NA	-0.31	-5.2	-0.3	3.98e-7	Primary biliary cholangitis;
CESC	trans	rs9329221	0.537	rs6601414	chr8:9976748	G/A	cg15556689	chr8:8085844	FLJ10661	0.49	6.24	0.36	1.72e-9	Neuroticism;
CESC	cis	rs7192750	0.652	rs150617	chr16:72139396	T/C	cg14768367	chr16:72042858	DHODH	0.73	5.73	0.33	2.7e-8	LDL cholesterol levels;Total cholesterol levels;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg02370978	chr2:86333167	PTCD3;POLR1A	-0.48	-6.17	-0.35	2.49e-9	Ulcerative colitis;
CESC	cis	rs4689388	0.926	rs3821940	chr4:6286711	C/A	cg14416269	chr4:6271139	WFS1	0.45	7.45	0.42	1.36e-12	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	trans	rs4332037	0.950	rs11767515	chr7:1941051	C/T	cg11693508	chr17:37793320	STARD3	0.67	6.4	0.37	6.96e-10	Bipolar disorder;
CESC	cis	rs9399135	0.967	rs59329760	chr6:135342437	G/A	cg24558204	chr6:135376177	HBS1L	0.52	7.28	0.41	3.9e-12	Red blood cell count;
CESC	cis	rs72781680	1.000	rs7594510	chr2:24173377	A/G	cg08917208	chr2:24149416	ATAD2B	0.94	8.58	0.47	7.87e-16	Lymphocyte counts;
CESC	cis	rs4604732	0.536	rs10925056	chr1:247650472	T/C	cg12754571	chr1:247694271	LOC148824;OR2C3	0.4	5.12	0.3	5.94e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs4730250	0.707	rs6960148	chr7:106786142	A/G	cg02696742	chr7:106810147	HBP1	0.56	5.29	0.31	2.59e-7	Osteoarthritis;
CESC	cis	rs62229266	0.839	rs11088335	chr21:37470335	C/T	cg08632701	chr21:37451849	NA	-0.39	-5.37	-0.31	1.71e-7	Mitral valve prolapse;
CESC	cis	rs1799949	0.965	rs8176130	chr17:41258043	C/T	cg06001716	chr17:41278141	BRCA1;NBR2	0.38	5.3	0.31	2.39e-7	Menopause (age at onset);
CESC	cis	rs2204008	0.744	rs11514071	chr12:38392076	C/T	cg26384229	chr12:38710491	ALG10B	0.72	10.46	0.54	1.17e-21	Bladder cancer;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg24224884	chr10:99447166	AVPI1	-0.45	-6.2	-0.36	2.21e-9	Fibrinogen levels;
CESC	cis	rs4713118	0.512	rs2622319	chr6:28120401	G/C	cg26335602	chr6:28129616	ZNF389	0.37	5.3	0.31	2.4e-7	Parkinson's disease;
CESC	cis	rs853679	0.550	rs6901017	chr6:28152583	T/C	cg20151795	chr6:28129481	ZNF389	0.39	5.24	0.31	3.32e-7	Depression;
CESC	cis	rs9457247	0.565	rs12178491	chr6:167512474	C/T	cg07741184	chr6:167504864	NA	0.43	7.7	0.43	2.68e-13	Crohn's disease;
CESC	cis	rs4835473	0.800	rs2089839	chr4:144902108	G/A	cg25736465	chr4:144833511	NA	0.4	6.2	0.36	2.13e-9	Immature fraction of reticulocytes;
CESC	cis	rs6502050	0.835	rs8081949	chr17:80117490	G/A	cg23985595	chr17:80112537	CCDC57	-0.41	-6.47	-0.37	4.79e-10	Life satisfaction;
CESC	cis	rs7940866	0.804	rs6590540	chr11:130805444	T/C	cg12179176	chr11:130786555	SNX19	0.67	10.39	0.54	2.02e-21	Schizophrenia;
CESC	trans	rs1814175	0.935	rs7482690	chr11:49648814	C/T	cg15704280	chr7:45808275	SEPT13	-0.97	-16.94	-0.72	3.96e-44	Height;
CESC	cis	rs2281845	0.507	rs11589642	chr1:201100748	A/G	cg06714761	chr1:201096289	NA	-0.47	-7.31	-0.41	3.16e-12	Permanent tooth development;
CESC	cis	rs425277	1.000	rs262641	chr1:2104981	C/T	cg23803603	chr1:2058230	PRKCZ	-0.31	-5.12	-0.3	5.82e-7	Height;
CESC	cis	rs875971	0.540	rs1723268	chr7:65473080	A/C	cg14393609	chr7:65229607	NA	0.51	7.01	0.4	2.03e-11	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02306730	chr19:39109456	MAP4K1;EIF3K	0.73	8.13	0.45	1.63e-14	Gut microbiome composition (summer);
CESC	cis	rs4919044	0.808	rs2486687	chr10:94778283	T/C	cg16508068	chr10:94451736	HHEX	-0.5	-5.49	-0.32	9.61e-8	Coronary artery disease;
CESC	cis	rs4474465	0.850	rs11237546	chr11:78266924	T/C	cg27205649	chr11:78285834	NARS2	0.44	5.7	0.33	3.24e-8	Alzheimer's disease (survival time);
CESC	cis	rs9291683	0.588	rs12647117	chr4:10022059	T/C	cg02734326	chr4:10020555	SLC2A9	0.49	7.03	0.4	1.74e-11	Bone mineral density;
CESC	cis	rs854765	0.547	rs4365348	chr17:17912548	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.54	7.7	0.43	2.77e-13	Total body bone mineral density;
CESC	trans	rs1814175	0.817	rs10769641	chr11:49960141	A/G	cg03929089	chr4:120376271	NA	-0.93	-15.75	-0.7	6.66e-40	Height;
CESC	cis	rs593982	1.000	rs665191	chr11:65493658	G/A	cg08755490	chr11:65554678	OVOL1	1.23	13.78	0.65	6.27e-33	Atopic dermatitis;
CESC	cis	rs9987353	0.589	rs1053036	chr8:9060077	A/G	cg15556689	chr8:8085844	FLJ10661	-0.5	-5.85	-0.34	1.44e-8	Recombination measurement;
CESC	cis	rs7520050	0.966	rs7556436	chr1:46363880	C/T	cg24296786	chr1:45957014	TESK2	-0.44	-5.62	-0.33	4.76e-8	Red blood cell count;Reticulocyte count;
CESC	cis	rs875971	0.545	rs7783889	chr7:65748353	T/A	cg18876405	chr7:65276391	NA	0.47	5.68	0.33	3.46e-8	Aortic root size;
CESC	cis	rs4906332	0.966	rs59858038	chr14:103867102	C/T	cg09975044	chr14:104007538	NA	0.46	6.34	0.36	9.93e-10	Coronary artery disease;
CESC	cis	rs941873	0.868	rs7332	chr10:81114060	G/A	cg09469691	chr10:81107165	PPIF	0.56	7.56	0.42	6.79e-13	Height;
CESC	cis	rs57502260	0.704	rs17149179	chr11:68351722	C/T	cg20283391	chr11:68216788	NA	-0.65	-5.37	-0.31	1.74e-7	Total body bone mineral density (age 45-60);
CESC	cis	rs3806843	0.966	rs2240693	chr5:140183325	G/C	cg16179182	chr5:140090404	VTRNA1-1	-0.41	-5.26	-0.31	2.95e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs2119480	0.731	rs378399	chr13:111308040	G/C	cg16216153	chr13:111290848	CARKD	-0.36	-5.43	-0.32	1.26e-7	Diastolic blood pressure;
CESC	cis	rs854765	0.647	rs7211714	chr17:17986955	A/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.49	6.16	0.35	2.7e-9	Total body bone mineral density;
CESC	cis	rs4588572	0.643	rs1159929	chr5:77768820	A/G	cg11547950	chr5:77652471	NA	0.45	5.66	0.33	3.83e-8	Triglycerides;
CESC	cis	rs1050631	1.000	rs1789550	chr18:33699553	C/T	cg25426722	chr18:33708991	SLC39A6;ELP2	-0.41	-5.31	-0.31	2.31e-7	Esophageal squamous cell cancer (length of survival);
CESC	trans	rs8014252	0.667	rs10150707	chr14:70843703	C/G	cg03123320	chr1:229394665	NA	-0.49	-6.44	-0.37	5.61e-10	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
CESC	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.37	5.46	0.32	1.1e-7	Electroencephalogram traits;
CESC	cis	rs1003719	0.715	rs2835642	chr21:38539066	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.59	-7.98	-0.44	4.49e-14	Eye color traits;
CESC	cis	rs9913156	0.793	rs55884013	chr17:4579301	G/A	cg00122941	chr17:4613640	ARRB2	0.81	9.13	0.49	1.87e-17	Lymphocyte counts;
CESC	cis	rs7660520	0.524	rs12643521	chr4:183728242	C/G	cg09197432	chr4:183729176	NA	0.56	5.6	0.33	5.29e-8	Pediatric autoimmune diseases;
CESC	cis	rs7605827	0.930	rs722328	chr2:15657164	T/C	cg19274914	chr2:15703543	NA	0.37	6.65	0.38	1.7e-10	Educational attainment (years of education);
CESC	cis	rs1448094	0.512	rs57278040	chr12:86237886	A/G	cg19622623	chr12:86230825	RASSF9	-0.47	-6.08	-0.35	4.25e-9	Major depressive disorder;
CESC	cis	rs992157	0.764	rs2015863	chr2:219185161	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.56	-7.18	-0.4	7.02e-12	Colorectal cancer;
CESC	cis	rs881375	0.967	rs2109896	chr9:123683106	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.38	5.05	0.3	8.31e-7	Rheumatoid arthritis;
CESC	cis	rs950169	0.610	rs34529571	chr15:84691807	A/G	cg17507749	chr15:85114479	UBE2QP1	0.6	5.92	0.34	9.68e-9	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22215737	chr17:4643257	CXCL16;ZMYND15	0.51	6.29	0.36	1.34e-9	Gut microbiome composition (summer);
CESC	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg26338869	chr17:61819248	STRADA	0.67	8.77	0.47	2.24e-16	Prudent dietary pattern;
CESC	cis	rs9300255	0.620	rs7313483	chr12:123726834	C/T	cg05973401	chr12:123451056	ABCB9	0.5	5.54	0.32	7.18e-8	Neutrophil percentage of white cells;
CESC	cis	rs2289328	0.943	rs12905240	chr15:40672145	C/T	cg13931752	chr15:40660718	DISP2	0.46	5.47	0.32	1.07e-7	Intelligence (multi-trait analysis);Cognitive ability;Cognitive ability (multi-trait analysis);
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg24280607	chr15:41709584	RTF1	0.44	6.16	0.35	2.67e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs3785574	0.927	rs2008018	chr17:61954471	C/T	cg06420487	chr17:61919686	SMARCD2	0.44	5.35	0.31	1.88e-7	Height;
CESC	cis	rs1018836	0.923	rs7837230	chr8:91574281	C/T	cg16814680	chr8:91681699	NA	-0.69	-9.74	-0.51	2.4e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs8040855	0.576	rs62022528	chr15:85535261	C/T	cg08123816	chr15:85640762	PDE8A	-0.42	-5.88	-0.34	1.2e-8	Bulimia nervosa;
CESC	cis	rs7615952	0.515	rs7637246	chr3:125678706	A/G	cg05084668	chr3:125655381	ALG1L	-0.53	-5.77	-0.33	2.22e-8	Blood pressure (smoking interaction);
CESC	cis	rs10851478	0.872	rs12591659	chr15:49933823	G/A	cg08060515	chr15:49448048	GALK2;COPS2	0.43	5.26	0.31	3e-7	Oral cavity cancer;
CESC	cis	rs12142240	0.667	rs41293287	chr1:46808852	C/T	cg10495392	chr1:46806563	NSUN4	0.59	6.34	0.36	9.65e-10	Menopause (age at onset);
CESC	cis	rs7618915	0.571	rs12632381	chr3:52607685	G/A	cg17372223	chr3:52568218	NT5DC2	0.43	6.36	0.36	9.03e-10	Bipolar disorder;
CESC	cis	rs769267	0.965	rs1469712	chr19:19528821	C/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	7.57	0.42	6.29e-13	Tonsillectomy;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg21123913	chr4:89513664	HERC3	-0.52	-6.67	-0.38	1.49e-10	Fibrinogen levels;
CESC	cis	rs11711311	1.000	rs2712348	chr3:113460614	C/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.64	8.85	0.48	1.26e-16	IgG glycosylation;
CESC	cis	rs6580649	0.941	rs72644841	chr12:48411987	A/G	cg24011408	chr12:48396354	COL2A1	-0.41	-5.18	-0.3	4.47e-7	Lung cancer;
CESC	cis	rs56104184	0.668	rs73063523	chr19:49408943	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.57	-5.76	-0.33	2.33e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	cis	rs2777491	0.957	rs7181911	chr15:41674060	T/C	cg02330683	chr15:41787940	ITPKA	0.43	6.2	0.36	2.2e-9	Ulcerative colitis;
CESC	cis	rs9399137	0.507	rs4451150	chr6:135279063	T/G	cg24558204	chr6:135376177	HBS1L	0.66	8.68	0.47	4.24e-16	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg16782613	chr7:44058922	POLR2J4	-0.48	-6.27	-0.36	1.45e-9	Ulcerative colitis;
CESC	cis	rs7640424	0.649	rs1369555	chr3:107901184	A/G	cg09227934	chr3:107805635	CD47	0.45	5.77	0.33	2.16e-8	Body mass index;
CESC	cis	rs1862618	0.853	rs43184	chr5:56141777	G/C	cg24531977	chr5:56204891	C5orf35	-0.88	-11.14	-0.56	6.81e-24	Initial pursuit acceleration;
CESC	cis	rs8177253	0.665	rs9831392	chr3:133451473	A/T	cg24879335	chr3:133465180	TF	0.37	6.47	0.37	4.62e-10	Iron status biomarkers;
CESC	cis	rs12612435	0.518	rs35309679	chr2:137064759	C/T	cg23554286	chr2:137951070	THSD7B	0.64	5.31	0.31	2.34e-7	Takotsubo syndrome;
CESC	cis	rs9916302	0.904	rs801426	chr17:37441109	C/T	cg00129232	chr17:37814104	STARD3	0.51	6.67	0.38	1.46e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs1348850	0.597	rs13014417	chr2:178417835	T/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.66	6.79	0.38	7.41e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs7617773	0.780	rs4479622	chr3:48338173	C/T	cg11946769	chr3:48343235	NME6	0.89	12.11	0.6	3.63e-27	Coronary artery disease;
CESC	cis	rs71391092	1	rs71391092	chr16:74567075	C/G	cg01733217	chr16:74700730	RFWD3	-0.66	-6.01	-0.35	5.96e-9	Schizophrenia;
CESC	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg18402987	chr7:1209562	NA	0.76	7.57	0.42	6.37e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs4595586	0.505	rs12823590	chr12:39399750	A/T	cg26384229	chr12:38710491	ALG10B	0.58	7.81	0.43	1.35e-13	Morning vs. evening chronotype;
CESC	cis	rs77741769	0.529	rs10849791	chr12:121235280	T/C	cg02419362	chr12:121203948	SPPL3	0.35	5.72	0.33	2.83e-8	Mean corpuscular volume;
CESC	cis	rs2304069	0.545	rs13168011	chr5:149392377	C/T	cg12661370	chr5:149340060	SLC26A2	0.47	6.27	0.36	1.49e-9	HIV-1 control;
CESC	cis	rs1005277	0.505	rs719569	chr10:38154415	T/G	cg25427524	chr10:38739819	LOC399744	0.68	10.16	0.53	1.05e-20	Extrinsic epigenetic age acceleration;
CESC	cis	rs1799949	0.965	rs6503727	chr17:41312859	C/T	cg25072359	chr17:41440525	NA	0.5	7.55	0.42	6.88e-13	Menopause (age at onset);
CESC	cis	rs3733585	0.699	rs6449177	chr4:9968050	T/C	cg11266682	chr4:10021025	SLC2A9	-0.57	-10.49	-0.54	9.13e-22	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg21280719	chr6:42927975	GNMT	-0.3	-6.94	-0.39	3.09e-11	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs9314323	0.767	rs6557915	chr8:26209062	C/A	cg13160058	chr8:26243215	BNIP3L	-0.32	-5.03	-0.3	8.87e-7	Red cell distribution width;
CESC	cis	rs6831352	0.877	rs2602890	chr4:100043179	C/T	cg12011299	chr4:100065546	ADH4	0.59	6.58	0.37	2.55e-10	Alcohol dependence;
CESC	cis	rs56104184	0.775	rs73061689	chr19:49397214	C/T	cg21252483	chr19:49399788	TULP2	-0.53	-5.72	-0.33	2.94e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	cis	rs13191362	0.938	rs59067610	chr6:163030440	C/A	cg21926612	chr6:163149169	PACRG;PARK2	0.77	8.27	0.45	6.58e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs660498	0.507	rs34354872	chr10:27735673	T/G	cg25705717	chr10:27608719	NA	0.48	5.77	0.33	2.17e-8	Asthma (childhood onset);
CESC	cis	rs2880765	0.743	rs16940052	chr15:86006674	G/A	cg10818794	chr15:86012489	AKAP13	-0.33	-5.1	-0.3	6.63e-7	Coronary artery disease;
CESC	cis	rs8114671	0.562	rs6058120	chr20:33402829	A/G	cg06115741	chr20:33292138	TP53INP2	0.47	5.65	0.33	4.04e-8	Height;
CESC	cis	rs2243480	1.000	rs73142122	chr7:65311298	C/A	cg13147721	chr7:65941812	NA	-0.9	-8.76	-0.47	2.35e-16	Diabetic kidney disease;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg03028685	chr10:99078963	FRAT1	-0.47	-7.33	-0.41	2.83e-12	Gambling;
CESC	cis	rs736408	0.677	rs1042779	chr3:52821011	A/G	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	5.45	0.32	1.15e-7	Bipolar disorder;
CESC	cis	rs875971	0.862	rs6978028	chr7:65886300	G/C	cg18876405	chr7:65276391	NA	0.53	7.32	0.41	3.01e-12	Aortic root size;
CESC	cis	rs2836950	0.545	rs11700449	chr21:40522419	A/T	cg11644478	chr21:40555479	PSMG1	-0.56	-7.66	-0.43	3.43e-13	Menarche (age at onset);
CESC	cis	rs9314323	0.964	rs3808576	chr8:26266834	G/A	cg11498726	chr8:26250323	BNIP3L	-0.44	-6.47	-0.37	4.73e-10	Red cell distribution width;
CESC	cis	rs12200560	0.505	rs984519	chr6:97076223	A/G	cg06623918	chr6:96969491	KIAA0776	-0.49	-6.4	-0.37	7.08e-10	Coronary heart disease;
CESC	cis	rs4409675	0.576	rs10751725	chr1:28216191	A/C	cg23691781	chr1:28212827	C1orf38	-0.28	-5.6	-0.33	5.36e-8	Corneal astigmatism;
CESC	cis	rs1005224	0.889	rs2059382	chr14:76158916	T/C	cg25116370	chr14:76127843	TTLL5;C14orf1	-0.43	-5.98	-0.34	7.22e-9	Large artery stroke;
CESC	cis	rs7927771	0.864	rs755554	chr11:47432034	G/C	cg18512352	chr11:47633146	NA	0.43	6.2	0.36	2.13e-9	Subjective well-being;
CESC	cis	rs1799949	0.965	rs12950779	chr17:41306523	C/T	cg05368731	chr17:41323189	NBR1	0.79	11.2	0.57	4.27e-24	Menopause (age at onset);
CESC	cis	rs853679	0.599	rs149990	chr6:27998258	G/A	cg20933634	chr6:27740509	NA	0.58	5.16	0.3	4.82e-7	Depression;
CESC	cis	rs1003719	0.715	rs4261789	chr21:38503762	T/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-8.54	-0.46	1.04e-15	Eye color traits;
CESC	cis	rs1034435	0.755	rs5767171	chr22:48891881	A/G	cg05992904	chr22:48892994	FAM19A5	-0.57	-10.22	-0.53	6.78e-21	Late-onset Alzheimer's disease;
CESC	cis	rs2204008	0.837	rs11495722	chr12:38337245	G/A	cg13010199	chr12:38710504	ALG10B	0.54	6.73	0.38	1.05e-10	Bladder cancer;
CESC	cis	rs57221529	0.713	rs72703072	chr5:590626	A/G	cg16447950	chr5:562315	NA	-0.58	-6.05	-0.35	4.93e-9	Lung disease severity in cystic fibrosis;
CESC	trans	rs7980799	0.682	rs1580396	chr12:33615841	C/A	cg26384229	chr12:38710491	ALG10B	-0.55	-7.81	-0.43	1.32e-13	Heart rate;Heart rate variability traits (RMSSD);
CESC	cis	rs9303280	0.806	rs34189114	chr17:38032460	C/T	cg20243544	chr17:37824526	PNMT	0.53	6.93	0.39	3.14e-11	Self-reported allergy;
CESC	cis	rs10129255	0.917	rs8022493	chr14:107190057	C/T	cg07958169	chr14:107095056	NA	-0.4	-5.54	-0.32	7.3e-8	Kawasaki disease;
CESC	cis	rs7208859	0.673	rs216440	chr17:28928309	A/T	cg04154034	chr17:28927549	LRRC37B2	0.61	5.93	0.34	9.61e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs28489187	0.577	rs3920521	chr1:85848866	A/C	cg16011679	chr1:85725395	C1orf52	0.45	5.32	0.31	2.21e-7	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	cis	rs6582630	0.502	rs3902522	chr12:38271203	T/C	cg13010199	chr12:38710504	ALG10B	0.46	5.61	0.33	5.13e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs60871478	0.588	rs6952577	chr7:872100	C/T	cg05535760	chr7:792225	HEATR2	0.75	7.85	0.43	1e-13	Cerebrospinal P-tau181p levels;
CESC	cis	rs12295403	1.000	rs12789252	chr11:18690389	C/T	cg09887367	chr11:18690185	NA	-0.38	-5.62	-0.33	4.95e-8	Ovarian reserve;
CESC	cis	rs2276314	0.857	rs28431958	chr18:33578401	T/G	cg19628046	chr18:33552617	C18orf21	0.5	5.49	0.32	9.29e-8	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs116988415	0.584	rs1875054	chr14:65255066	G/A	cg25083366	chr14:65239357	SPTB	0.7	5.29	0.31	2.6e-7	Daytime sleep phenotypes;
CESC	cis	rs4819052	0.851	rs2255766	chr21:46683777	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.93	13.94	0.65	1.64e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs853679	0.517	rs4713141	chr6:28101678	G/C	cg19592336	chr6:28129416	ZNF389	0.61	8.29	0.45	5.77e-15	Depression;
CESC	cis	rs9905704	0.647	rs33922512	chr17:57114148	C/G	cg12560992	chr17:57184187	TRIM37	-0.61	-7.52	-0.42	8.64e-13	Testicular germ cell tumor;
CESC	cis	rs60843830	0.550	rs300751	chr2:209063	A/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.54	7.0	0.4	2.08e-11	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs2011503	1.000	rs34067609	chr19:19653524	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.52	5.09	0.3	6.68e-7	Bipolar disorder;
CESC	cis	rs875971	1.000	rs6945843	chr7:65734783	G/A	cg12463550	chr7:65579703	CRCP	-0.55	-7.03	-0.4	1.79e-11	Aortic root size;
CESC	cis	rs873946	0.648	rs12766050	chr10:134549108	G/A	cg18305652	chr10:134549665	INPP5A	0.47	6.68	0.38	1.43e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	trans	rs1549733	0.577	rs16857851	chr2:218418350	A/G	cg23408253	chr19:17438755	ANO8	-0.46	-6.01	-0.35	6.22e-9	Optic disc area;
CESC	cis	rs637571	0.565	rs570387	chr11:65637076	T/C	cg26695010	chr11:65641043	EFEMP2	0.5	6.11	0.35	3.58e-9	Eosinophil percentage of white cells;
CESC	cis	rs1008375	1.000	rs10939747	chr4:17691166	C/A	cg16339924	chr4:17578868	LAP3	0.64	7.7	0.43	2.69e-13	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs10823500	0.777	rs10999196	chr10:71982305	T/C	cg02100629	chr10:71892760	AIFM2	-0.32	-5.13	-0.3	5.6e-7	Blood protein levels;
CESC	trans	rs10085978	0.604	rs10099944	chr8:143234817	A/G	cg27186271	chr11:842611	TSPAN4;POLR2L	0.53	6.09	0.35	4e-9	Mosquito bite size;
CESC	cis	rs6430585	0.941	rs60963894	chr2:136539670	T/G	cg07169764	chr2:136633963	MCM6	0.97	12.27	0.6	1.02e-27	Corneal structure;
CESC	cis	rs10392	0.543	rs16987679	chr20:37557185	G/C	cg27552599	chr20:37590471	DHX35	0.39	5.92	0.34	9.73e-9	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
CESC	cis	rs1620921	0.505	rs12214254	chr6:161195932	C/A	cg01280913	chr6:161186852	NA	-0.4	-6.12	-0.35	3.42e-9	Lipoprotein (a) - cholesterol levels;
CESC	cis	rs10540	0.730	rs61876338	chr11:493730	A/G	cg03576123	chr11:487126	PTDSS2	-1.09	-10.78	-0.55	1.02e-22	Body mass index;
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg02239891	chr2:214016774	IKZF2	0.42	6.2	0.36	2.15e-9	Vertical cup-disc ratio;
CESC	cis	rs7089973	0.872	rs60820172	chr10:116625891	C/T	cg23260525	chr10:116636907	FAM160B1	0.38	6.42	0.37	6.35e-10	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs950776	0.616	rs3743077	chr15:78894896	C/T	cg24631222	chr15:78858424	CHRNA5	-0.44	-5.42	-0.32	1.32e-7	Sudden cardiac arrest;
CESC	cis	rs35110281	0.633	rs762400	chr21:45113629	C/G	cg01579765	chr21:45077557	HSF2BP	0.47	8.13	0.45	1.69e-14	Mean corpuscular volume;
CESC	cis	rs7712401	0.560	rs13168225	chr5:122347264	C/T	cg19412675	chr5:122181750	SNX24	-0.43	-5.07	-0.3	7.41e-7	Mean platelet volume;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg05992347	chr16:33964783	MIR1826	0.5	6.63	0.38	1.93e-10	Fibrinogen levels;
CESC	cis	rs3768617	0.528	rs10911240	chr1:183062948	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.88	14.24	0.66	1.45e-34	Fuchs's corneal dystrophy;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg21232937	chr17:56408691	MIR142	-0.42	-6.8	-0.39	6.72e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs1163251	0.837	rs2764886	chr1:120241771	C/T	cg19096424	chr1:120255104	PHGDH	0.52	6.67	0.38	1.52e-10	Blood metabolite levels;
CESC	cis	rs539096	0.566	rs3011220	chr1:44308867	A/G	cg23954153	chr1:44402353	ARTN	-0.34	-5.28	-0.31	2.65e-7	Intelligence (multi-trait analysis);
CESC	cis	rs12134245	0.755	rs11164928	chr1:92012678	G/A	cg02896835	chr1:92012615	NA	-0.56	-7.68	-0.43	3.1400000000000003e-13	Breast cancer;
CESC	trans	rs9693444	0.898	rs4732697	chr8:29519861	A/G	cg18992706	chr13:44453352	CCDC122;C13orf31	-0.42	-6.22	-0.36	1.98e-9	Breast cancer;
CESC	cis	rs2463822	0.687	rs118012228	chr11:62155914	G/A	cg06239285	chr11:62104954	ASRGL1	-1.05	-8.98	-0.48	5.35e-17	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs7617480	0.648	rs9848268	chr3:48762271	C/T	cg07636037	chr3:49044803	WDR6	0.79	10.38	0.54	2.14e-21	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CESC	cis	rs11686934	0.780	rs6731423	chr2:70173327	A/C	cg02498382	chr2:70120550	SNRNP27	-0.3	-5.18	-0.3	4.32e-7	High light scatter reticulocyte count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08929390	chr7:10979341	NDUFA4	-0.58	-6.99	-0.39	2.24e-11	Gut microbiome composition (summer);
CESC	cis	rs72781680	0.898	rs55657921	chr2:24008091	C/G	cg20701182	chr2:24300061	SF3B14	0.63	5.65	0.33	4.21e-8	Lymphocyte counts;
CESC	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.71	-9.85	-0.52	1.04e-19	Prudent dietary pattern;
CESC	cis	rs9311474	0.713	rs352168	chr3:52237970	C/T	cg18099408	chr3:52552593	STAB1	-0.34	-5.83	-0.34	1.61e-8	Electroencephalogram traits;
CESC	cis	rs3796352	1.000	rs3806692	chr3:53080987	C/G	cg07884673	chr3:53033167	SFMBT1	0.59	5.29	0.31	2.58e-7	Immune reponse to smallpox (secreted IL-2);
CESC	cis	rs2075371	0.863	rs12672691	chr7:133954431	C/T	cg00033643	chr7:134001901	SLC35B4	0.4	5.12	0.3	5.93e-7	Mean platelet volume;
CESC	cis	rs2576037	0.901	rs6507719	chr18:44581310	A/T	cg19077165	chr18:44547161	KATNAL2	0.54	7.78	0.43	1.59e-13	Personality dimensions;
CESC	cis	rs7927771	0.524	rs7942074	chr11:47720509	T/C	cg20307385	chr11:47447363	PSMC3	0.61	8.56	0.47	9.2e-16	Subjective well-being;
CESC	cis	rs10504229	1.000	rs68112919	chr8:58188247	G/A	cg24829409	chr8:58192753	C8orf71	-0.75	-9.78	-0.52	1.72e-19	Developmental language disorder (linguistic errors);
CESC	cis	rs2404602	0.716	rs12437627	chr15:76845050	T/C	cg26408565	chr15:76604113	ETFA	-0.43	-6.25	-0.36	1.67e-9	Blood metabolite levels;
CESC	cis	rs1799949	0.965	rs11658499	chr17:41334749	C/T	cg05368731	chr17:41323189	NBR1	0.76	10.35	0.54	2.73e-21	Menopause (age at onset);
CESC	cis	rs7208859	0.673	rs11656462	chr17:29160700	G/A	cg19761014	chr17:28927070	LRRC37B2	0.63	5.28	0.31	2.72e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs1552244	1.000	rs67134728	chr3:10151431	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-10.9	-0.56	4.33e-23	Alzheimer's disease;
CESC	trans	rs61931739	0.500	rs11053193	chr12:34438838	G/T	cg13010199	chr12:38710504	ALG10B	0.49	6.34	0.36	9.81e-10	Morning vs. evening chronotype;
CESC	cis	rs13385	0.769	rs7737342	chr5:139611011	A/T	cg26211634	chr5:139558579	C5orf32	0.47	5.19	0.3	4.23e-7	Atrial fibrillation;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg22349489	chr6:27114943	HIST1H2BK;HIST1H2AH	0.45	6.34	0.36	9.97e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg00997411	chr1:205290916	NUAK2	-0.45	-6.23	-0.36	1.86e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg11672159	chr11:77531853	C11orf67;RSF1	-0.49	-6.42	-0.37	6.2e-10	Asthma;
CESC	cis	rs2276314	0.857	rs9304155	chr18:33585710	A/C	cg05985134	chr18:33552581	C18orf21	0.62	7.46	0.42	1.21e-12	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs250677	0.916	rs17109279	chr5:148416581	A/G	cg18129178	chr5:148520854	ABLIM3	-0.52	-5.78	-0.33	2.05e-8	Breast cancer;
CESC	cis	rs7914558	0.966	rs11191518	chr10:104782853	C/G	cg04362960	chr10:104952993	NT5C2	0.43	5.74	0.33	2.59e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs1949733	0.917	rs10461079	chr4:8392724	G/A	cg11789530	chr4:8429930	ACOX3	-0.78	-10.65	-0.55	2.74e-22	Response to antineoplastic agents;
CESC	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg02018176	chr4:1364513	KIAA1530	0.62	7.97	0.44	4.61e-14	Longevity;
CESC	cis	rs1559088	0.576	rs4805852	chr19:33609441	C/T	cg27124370	chr19:33622961	WDR88	0.53	7.53	0.42	7.97e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs9487051	0.768	rs437779	chr6:109527691	T/G	cg01475377	chr6:109611718	NA	-0.44	-6.65	-0.38	1.71e-10	Reticulocyte fraction of red cells;
CESC	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.46	7.23	0.41	5.1e-12	Bipolar disorder;
CESC	cis	rs2204008	0.775	rs11514369	chr12:38305411	C/T	cg13010199	chr12:38710504	ALG10B	0.45	5.65	0.33	4.06e-8	Bladder cancer;
CESC	cis	rs7666738	0.830	rs3852123	chr4:98697586	A/G	cg24818145	chr4:99064322	C4orf37	0.4	5.15	0.3	5.03e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2404602	0.598	rs11855999	chr15:76627333	A/C	cg00316803	chr15:76480434	C15orf27	0.45	6.14	0.35	2.94e-9	Blood metabolite levels;
CESC	cis	rs71007656	1	rs71007656	chr10:37970845	CGGCTG/C	cg25427524	chr10:38739819	LOC399744	-0.62	-9.04	-0.49	3.33e-17	Extrinsic epigenetic age acceleration;
CESC	cis	rs3820068	0.581	rs72645893	chr1:15930943	C/G	cg16988262	chr1:15930761	NA	0.35	5.65	0.33	4.18e-8	Systolic blood pressure;
CESC	cis	rs5769765	0.817	rs9616212	chr22:50317687	G/A	cg26441486	chr22:50317300	CRELD2	0.48	5.75	0.33	2.44e-8	Schizophrenia;
CESC	cis	rs763121	0.853	rs5750669	chr22:39080638	T/A	cg21395723	chr22:39101663	GTPBP1	0.43	5.31	0.31	2.32e-7	Menopause (age at onset);
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg24485284	chr11:30358536	C11orf46	0.37	6.3	0.36	1.26e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs2034088	0.833	rs7219151	chr17:440497	G/A	cg06217071	chr17:408420	NA	0.49	9.43	0.5	2.12e-18	Hip circumference adjusted for BMI;
CESC	cis	rs730775	0.505	rs324137	chr6:44273546	G/T	cg21130236	chr6:44246755	TMEM151B	0.26	5.27	0.31	2.83e-7	Monocyte percentage of white cells;Monocyte count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02928052	chr19:34988812	WTIP	-0.56	-6.63	-0.38	1.86e-10	Gut microbiome composition (summer);
CESC	cis	rs754466	0.512	rs67607593	chr10:79649050	A/G	cg17075019	chr10:79541650	NA	-0.83	-12.1	-0.6	4.06e-27	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs727563	0.594	rs5758408	chr22:42077737	A/C	cg17376030	chr22:41985996	PMM1	-0.79	-8.55	-0.47	9.65e-16	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs9300255	0.596	rs10773002	chr12:123746961	A/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	0.33	5.04	0.3	8.72e-7	Neutrophil percentage of white cells;
CESC	cis	rs2839186	0.934	rs17176520	chr21:47682081	T/C	cg12516959	chr21:47718080	NA	-0.35	-5.16	-0.3	4.83e-7	Testicular germ cell tumor;
CESC	cis	rs9790314	0.967	rs463928	chr3:161087734	A/T	cg04691961	chr3:161091175	C3orf57	-0.4	-5.15	-0.3	5.06e-7	Morning vs. evening chronotype;
CESC	cis	rs7799006	0.593	rs12531150	chr7:2289888	C/T	cg08027265	chr7:2291960	NA	-0.56	-9.7	-0.51	2.99e-19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	trans	rs35146811	0.700	rs2950520	chr7:99827148	T/C	cg13215871	chr17:75784724	NA	-0.34	-6.33	-0.36	1.07e-9	Coronary artery disease;
CESC	cis	rs9905704	0.647	rs2036730	chr17:57038282	A/G	cg12560992	chr17:57184187	TRIM37	0.62	7.82	0.43	1.22e-13	Testicular germ cell tumor;
CESC	cis	rs9322193	0.962	rs62439843	chr6:149997657	T/C	cg07701084	chr6:150067640	NUP43	0.41	5.56	0.32	6.68e-8	Lung cancer;
CESC	cis	rs7091068	0.616	rs1890657	chr10:95506087	G/A	cg20715218	chr10:95462985	C10orf4	0.57	5.37	0.31	1.71e-7	Urinary tract infection frequency;
CESC	cis	rs941873	0.805	rs8837	chr10:81114813	C/G	cg11057378	chr10:81107060	PPIF	0.36	5.7	0.33	3.22e-8	Height;
CESC	cis	rs9399137	0.507	rs13197750	chr6:135312380	G/A	cg22676075	chr6:135203613	NA	0.53	7.09	0.4	1.22e-11	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	cis	rs16854884	0.802	rs6783329	chr3:143798454	T/G	cg06585982	chr3:143692056	C3orf58	0.44	5.58	0.32	6.09e-8	Economic and political preferences (feminism/equality);
CESC	cis	rs1008375	1.000	rs1121089	chr4:17676476	C/A	cg02297831	chr4:17616191	MED28	0.45	5.64	0.33	4.42e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs9915657	0.870	rs12600458	chr17:70130545	C/T	cg09344028	chr17:70110421	NA	0.34	6.08	0.35	4.26e-9	Thyroid hormone levels;
CESC	cis	rs13191362	0.935	rs73023493	chr6:162952769	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.76	7.05	0.4	1.57e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs4835473	0.932	rs17695782	chr4:144751464	A/G	cg25736465	chr4:144833511	NA	-0.45	-6.75	-0.38	9.22e-11	Immature fraction of reticulocytes;
CESC	cis	rs3820928	0.874	rs6707265	chr2:227849255	T/A	cg05526886	chr2:227700861	RHBDD1	-0.42	-5.12	-0.3	5.89e-7	Pulmonary function;
CESC	cis	rs4455778	0.536	rs38771	chr7:48940564	C/A	cg26309511	chr7:48887640	NA	0.35	5.11	0.3	6.1e-7	Lung cancer in never smokers;
CESC	cis	rs17345786	0.906	rs56171035	chr3:101111108	G/C	cg12386194	chr3:101231763	SENP7	0.57	6.08	0.35	4.12e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs514406	0.505	rs269287	chr1:53168842	T/C	cg08859206	chr1:53392774	SCP2	-0.6	-8.11	-0.45	1.95e-14	Monocyte count;
CESC	trans	rs687914	0.710	rs938662	chr2:45864578	A/G	cg19752117	chr17:4850710	PFN1	0.6	6.37	0.36	8.28e-10	Diastolic blood pressure;
CESC	cis	rs941873	0.868	rs2145998	chr10:81121696	T/A	cg09469691	chr10:81107165	PPIF	0.55	7.62	0.42	4.4e-13	Height;
CESC	cis	rs12188164	0.965	rs1056465	chr5:442438	T/A	cg17553881	chr5:443987	EXOC3;C5orf55	-0.38	-6.1	-0.35	3.77e-9	Cystic fibrosis severity;
CESC	cis	rs4925386	0.625	rs3810550	chr20:60912117	C/T	cg22307297	chr20:60903441	LAMA5	0.39	5.27	0.31	2.88e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs1552244	0.572	rs2054478	chr3:10172211	C/T	cg00149659	chr3:10157352	C3orf10	0.97	11.51	0.58	3.85e-25	Alzheimer's disease;
CESC	cis	rs929354	0.772	rs2366214	chr7:156992461	A/G	cg05182265	chr7:156933206	UBE3C	-0.51	-7.51	-0.42	9.08e-13	Body mass index;
CESC	cis	rs3785574	0.582	rs62072238	chr17:61948841	A/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.43	5.18	0.3	4.38e-7	Height;
CESC	trans	rs9467711	0.606	rs2235251	chr6:26431982	C/T	cg06606381	chr12:133084897	FBRSL1	-0.82	-6.98	-0.39	2.4e-11	Autism spectrum disorder or schizophrenia;
CESC	cis	rs9486719	0.901	rs13206547	chr6:97006942	T/C	cg18709589	chr6:96969512	KIAA0776	-0.52	-5.69	-0.33	3.43e-8	Migraine;Coronary artery disease;
CESC	cis	rs2836950	0.502	rs2150411	chr21:40574552	G/T	cg11890956	chr21:40555474	PSMG1	-0.67	-9.54	-0.51	1e-18	Menarche (age at onset);
CESC	cis	rs4253772	0.513	rs9306512	chr22:46716603	T/C	cg24881330	chr22:46731750	TRMU	0.94	10.78	0.55	1.06e-22	LDL cholesterol;Cholesterol, total;
CESC	cis	rs3858526	0.833	rs4758184	chr11:5926719	A/G	cg05234568	chr11:5960015	NA	-0.55	-6.41	-0.37	6.48e-10	DNA methylation (variation);
CESC	cis	rs7680126	0.633	rs11727390	chr4:10296760	C/T	cg00071950	chr4:10020882	SLC2A9	-0.52	-6.0	-0.35	6.44e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	cis	rs6582630	0.555	rs1969362	chr12:38514843	C/T	cg26384229	chr12:38710491	ALG10B	0.7	10.65	0.55	2.78e-22	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs6087990	0.735	rs4911260	chr20:31376490	T/C	cg13636640	chr20:31349939	DNMT3B	0.81	13.12	0.63	1.18e-30	Ulcerative colitis;
CESC	cis	rs501120	1.000	rs620356	chr10:44761073	A/C	cg09554077	chr10:44749378	NA	0.52	6.89	0.39	4.1e-11	Coronary artery disease;Coronary heart disease;
CESC	cis	rs7819412	0.775	rs2898257	chr8:10935368	A/C	cg21775007	chr8:11205619	TDH	-0.37	-5.06	-0.3	7.87e-7	Triglycerides;
CESC	cis	rs75477785	0.590	rs72649955	chr1:210304209	A/C	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.77	5.34	0.31	2.03e-7	Cleft lip with or without cleft palate;
CESC	cis	rs780096	0.545	rs6716894	chr2:27583273	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.3	-6.0	-0.35	6.61e-9	Total body bone mineral density;
CESC	cis	rs7100689	0.577	rs10749550	chr10:82031197	A/G	cg09936400	chr10:82049201	MAT1A	0.39	5.66	0.33	3.94e-8	Post bronchodilator FEV1;
CESC	cis	rs12497850	0.931	rs7430198	chr3:48988760	T/C	cg07636037	chr3:49044803	WDR6	1.08	19.57	0.77	2.17e-53	Parkinson's disease;
CESC	cis	rs3741404	1.000	rs3741404	chr11:63999240	G/C	cg04317338	chr11:64019027	PLCB3	0.6	7.34	0.41	2.58e-12	Platelet count;
CESC	cis	rs798554	0.723	rs798518	chr7:2777825	A/G	cg04166393	chr7:2884313	GNA12	0.62	7.92	0.44	6.73e-14	Height;
CESC	cis	rs4689592	0.503	rs11937667	chr4:7057037	C/G	cg26116260	chr4:7069785	GRPEL1	-0.87	-9.0	-0.48	4.52e-17	Monocyte percentage of white cells;
CESC	cis	rs10751667	0.961	rs7395928	chr11:952605	T/G	cg01483505	chr11:975446	AP2A2	0.39	5.25	0.31	3.18e-7	Alzheimer's disease (late onset);
CESC	cis	rs4969178	1.000	rs7212201	chr17:76393896	C/A	cg05887092	chr17:76393375	PGS1	0.59	9.26	0.49	7.46e-18	HDL cholesterol levels;
CESC	cis	rs7666738	0.830	rs62321564	chr4:98976496	C/G	cg17366294	chr4:99064904	C4orf37	0.59	8.43	0.46	2.31e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2842992	0.830	rs2758313	chr6:160154099	C/G	cg11366901	chr6:160182831	ACAT2	0.8	10.23	0.53	6.37e-21	Age-related macular degeneration (geographic atrophy);
CESC	trans	rs35110281	0.777	rs7276215	chr21:44990697	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.56	7.51	0.42	8.97e-13	Mean corpuscular volume;
CESC	cis	rs4319547	0.619	rs7973869	chr12:122874284	G/C	cg05707623	chr12:122985044	ZCCHC8	-0.51	-5.82	-0.34	1.68e-8	Body mass index;
CESC	cis	rs1008375	0.966	rs10939758	chr4:17698255	C/T	cg16339924	chr4:17578868	LAP3	0.59	7.28	0.41	3.74e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs9926296	0.546	rs7187436	chr16:89845110	A/T	cg03388025	chr16:89894329	SPIRE2	0.39	7.41	0.41	1.74e-12	Vitiligo;
CESC	cis	rs854765	0.533	rs2955354	chr17:17948716	G/C	cg09796270	chr17:17721594	SREBF1	-0.38	-5.07	-0.3	7.66e-7	Total body bone mineral density;
CESC	trans	rs8017423	1.000	rs8015379	chr14:90679432	C/T	cg01911440	chr17:78818045	RPTOR	-0.4	-6.03	-0.35	5.43e-9	Mortality in heart failure;
CESC	cis	rs67311347	1.000	rs2305521	chr3:40429183	A/G	cg24209194	chr3:40518798	ZNF619	0.47	6.0	0.35	6.55e-9	Renal cell carcinoma;
CESC	cis	rs1801251	1.000	rs7558609	chr2:233700379	C/T	cg08000102	chr2:233561755	GIGYF2	0.67	9.54	0.51	9.96e-19	Coronary artery disease;
CESC	cis	rs9611565	0.840	rs3788584	chr22:41779073	T/A	cg03806693	chr22:41940476	POLR3H	-1.12	-13.98	-0.65	1.23e-33	Vitiligo;
CESC	trans	rs2727020	0.523	rs4115783	chr11:49556026	G/A	cg15704280	chr7:45808275	SEPT13	0.86	10.72	0.55	1.6e-22	Coronary artery disease;
CESC	cis	rs7103648	0.695	rs7933019	chr11:47509137	G/C	cg20307385	chr11:47447363	PSMC3	0.83	12.3	0.6	8.59e-28	Diastolic blood pressure;Systolic blood pressure;
CESC	cis	rs7264396	0.790	rs2425125	chr20:34330954	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.84	11.47	0.58	5.47e-25	Total cholesterol levels;
CESC	cis	rs6963495	0.818	rs73190166	chr7:105159955	G/A	cg13798780	chr7:105162888	PUS7	0.76	7.69	0.43	2.93e-13	Bipolar disorder (body mass index interaction);
CESC	cis	rs4720575	1.000	rs6463383	chr7:47091686	A/G	cg00036614	chr7:47093842	NA	0.42	6.65	0.38	1.63e-10	Angiotensin-converting enzyme inhibitor intolerance;
CESC	cis	rs12477438	0.520	rs13023744	chr2:99738224	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	15.18	0.68	6.85e-38	Chronic sinus infection;
CESC	cis	rs72781680	0.846	rs72780198	chr2:24014883	T/A	cg20701182	chr2:24300061	SF3B14	0.63	5.65	0.33	4.21e-8	Lymphocyte counts;
CESC	cis	rs12477438	0.605	rs4585080	chr2:99557327	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.63	-8.47	-0.46	1.69e-15	Chronic sinus infection;
CESC	cis	rs2576037	0.501	rs7245049	chr18:44528213	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.44	7.24	0.41	4.8e-12	Personality dimensions;
CESC	cis	rs3749237	0.595	rs35701831	chr3:49515000	A/C	cg03060546	chr3:49711283	APEH	0.78	11.83	0.59	3.2e-26	Resting heart rate;
CESC	cis	rs7552404	0.961	rs448710	chr1:76116554	T/C	cg22875332	chr1:76189707	ACADM	-0.65	-7.69	-0.43	2.95e-13	Blood metabolite levels;Acylcarnitine levels;
CESC	trans	rs9987353	0.840	rs329994	chr8:9123233	A/G	cg11072298	chr12:113772666	SLC24A6	-0.47	-6.09	-0.35	3.97e-9	Recombination measurement;
CESC	cis	rs4604732	0.685	rs4925673	chr1:247636800	T/C	cg12758973	chr1:247694275	LOC148824;OR2C3	0.38	5.4	0.32	1.45e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs977987	0.872	rs4243111	chr16:75320827	C/T	cg03315344	chr16:75512273	CHST6	0.39	5.63	0.33	4.57e-8	Dupuytren's disease;
CESC	cis	rs6681460	0.932	rs2044400	chr1:67054081	T/A	cg02459107	chr1:67143332	SGIP1	0.36	5.08	0.3	7.08e-7	Presence of antiphospholipid antibodies;
CESC	cis	rs3739821	1.000	rs3739821	chr9:130702477	A/G	cg09665592	chr9:130699885	DPM2	-0.51	-5.33	-0.31	2.13e-7	Glaucoma (primary angle closure);
CESC	cis	rs11650776	1	rs11650776	chr17:37641402	G/A	cg20243544	chr17:37824526	PNMT	0.51	6.5	0.37	3.97e-10	Lung function (FEV1);
CESC	cis	rs7927771	0.800	rs35996350	chr11:47389223	A/G	cg20307385	chr11:47447363	PSMC3	-0.57	-6.82	-0.39	6.24e-11	Subjective well-being;
CESC	cis	rs9311474	0.508	rs7652191	chr3:52610415	T/C	cg07507251	chr3:52567010	NT5DC2	0.33	5.7	0.33	3.2e-8	Electroencephalogram traits;
CESC	cis	rs9322193	0.923	rs56397000	chr6:150060483	C/T	cg04369109	chr6:150039330	LATS1	-0.44	-6.38	-0.36	7.99e-10	Lung cancer;
CESC	cis	rs2710642	0.611	rs2204656	chr2:62883868	C/T	cg17519650	chr2:63277830	OTX1	-0.44	-5.28	-0.31	2.63e-7	LDL cholesterol levels;LDL cholesterol;
CESC	cis	rs9611565	0.729	rs2413646	chr22:41906325	C/T	cg17376030	chr22:41985996	PMM1	0.76	8.18	0.45	1.22e-14	Vitiligo;
CESC	cis	rs10876993	0.715	rs2169987	chr12:58012111	G/A	cg18357645	chr12:58087776	OS9	-0.55	-8.32	-0.45	4.8e-15	Celiac disease or Rheumatoid arthritis;
CESC	trans	rs17181170	0.553	rs4858949	chr3:87175728	C/G	ch.2.199792288R	chr2:200084043	NA	-0.44	-6.04	-0.35	5.3300000000000004e-09	Prostate cancer;
CESC	cis	rs9303401	0.614	rs3887355	chr17:56538639	T/C	cg12560992	chr17:57184187	TRIM37	0.51	5.08	0.3	7.08e-7	Cognitive test performance;
CESC	cis	rs6502050	0.761	rs7225637	chr17:80059758	A/G	cg23985595	chr17:80112537	CCDC57	-0.38	-5.52	-0.32	8.11e-8	Life satisfaction;
CESC	cis	rs17711722	0.523	rs365896	chr7:65510697	A/G	cg18876405	chr7:65276391	NA	-0.48	-6.49	-0.37	4.22e-10	Calcium levels;
CESC	cis	rs7193541	0.662	rs8052367	chr16:74658867	G/A	cg05580060	chr16:74700937	RFWD3	-0.43	-5.53	-0.32	7.64e-8	Multiple myeloma;
CESC	cis	rs7216064	1.000	rs62085993	chr17:65923152	T/C	cg12091567	chr17:66097778	LOC651250	-0.71	-7.28	-0.41	3.82e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs1023500	0.552	rs133368	chr22:42463689	T/C	cg05082376	chr22:42548792	NA	-0.37	-5.06	-0.3	7.78e-7	Schizophrenia;
CESC	cis	rs7537052	0.564	rs6669395	chr1:36653717	A/G	cg24686825	chr1:36642396	MAP7D1	-0.59	-8.79	-0.47	1.99e-16	Schizophrenia;
CESC	cis	rs7312933	0.618	rs7315968	chr12:42637086	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.46	6.11	0.35	3.53e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs7927592	0.913	rs6591346	chr11:68384618	T/A	cg16797656	chr11:68205561	LRP5	0.41	6.02	0.35	5.69e-9	Total body bone mineral density;
CESC	cis	rs1670533	0.932	rs13140341	chr4:1054235	T/C	cg04106633	chr4:1044584	NA	0.41	5.25	0.31	3.17e-7	Recombination rate (females);
CESC	cis	rs6598955	0.724	rs7547520	chr1:26592310	C/T	cg04990556	chr1:26633338	UBXN11	-0.78	-11.08	-0.56	1.05e-23	Obesity-related traits;
CESC	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg18003189	chr10:30723096	MAP3K8	-0.4	-6.21	-0.36	2e-9	Metabolic traits;
CESC	cis	rs72901758	0.739	rs72901754	chr17:76244398	G/A	cg23302638	chr17:76210176	BIRC5	0.5	5.45	0.32	1.13e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
CESC	cis	rs36051895	0.623	rs1575283	chr9:5238588	C/T	cg02405213	chr9:5042618	JAK2	-0.56	-6.77	-0.38	8.35e-11	Pediatric autoimmune diseases;
CESC	cis	rs561341	0.831	rs11658469	chr17:30206426	T/C	cg13647721	chr17:30228624	UTP6	-0.62	-5.84	-0.34	1.5e-8	Hip circumference adjusted for BMI;
CESC	cis	rs6570726	0.791	rs11155433	chr6:145907831	A/G	cg05347473	chr6:146136440	FBXO30	-0.53	-6.89	-0.39	4.05e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7666738	0.753	rs11097607	chr4:99011640	C/T	cg17366294	chr4:99064904	C4orf37	0.6	8.58	0.47	8.16e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9790314	1.000	rs4597724	chr3:160963110	A/G	cg03342759	chr3:160939853	NMD3	-0.44	-5.77	-0.33	2.17e-8	Morning vs. evening chronotype;
CESC	cis	rs3820928	0.874	rs4234063	chr2:227828335	A/T	cg05526886	chr2:227700861	RHBDD1	0.4	5.09	0.3	6.84e-7	Pulmonary function;
CESC	cis	rs896854	0.625	rs13281709	chr8:95972819	T/A	cg23172400	chr8:95962367	TP53INP1	-0.44	-9.04	-0.49	3.45e-17	Type 2 diabetes;
CESC	cis	rs769267	0.930	rs4808957	chr19:19567248	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.46	5.93	0.34	9.3e-9	Tonsillectomy;
CESC	cis	rs2414059	0.518	rs2289108	chr15:50782335	G/A	cg08437265	chr15:50716283	USP8	-0.46	-5.89	-0.34	1.18e-8	QT interval;
CESC	cis	rs853679	0.517	rs9380062	chr6:28137569	G/A	cg23161317	chr6:28129485	ZNF389	0.47	5.89	0.34	1.18e-8	Depression;
CESC	cis	rs11871801	0.750	rs7216927	chr17:40651497	T/A	cg21433558	chr17:40837037	CNTNAP1	0.45	5.34	0.31	2.03e-7	Crohn's disease;
CESC	cis	rs1559088	0.948	rs12610266	chr19:33581237	C/G	cg17764715	chr19:33622953	WDR88	-0.52	-6.9	-0.39	3.8e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs7618915	0.798	rs353547	chr3:52268866	A/G	cg07507251	chr3:52567010	NT5DC2	-0.34	-5.59	-0.32	5.78e-8	Bipolar disorder;
CESC	cis	rs6032067	0.538	rs13042667	chr20:43739664	C/T	cg10761708	chr20:43804764	PI3	0.45	5.11	0.3	6.08e-7	Blood protein levels;
CESC	cis	rs12936587	0.538	rs1869771	chr17:17561094	C/A	cg04398451	chr17:18023971	MYO15A	0.42	5.35	0.31	1.95e-7	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14546197	chr17:38137043	PSMD3	0.59	6.94	0.39	2.99e-11	Gut microbiome composition (summer);
CESC	trans	rs877282	0.898	rs12358966	chr10:758703	A/G	cg22713356	chr15:30763199	NA	1.08	10.52	0.54	7.14e-22	Uric acid levels;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg21676273	chr3:45635931	LIMD1	0.47	6.11	0.35	3.56e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs5758659	0.714	rs6002626	chr22:42517989	C/G	cg00645731	chr22:42541494	CYP2D7P1	0.33	5.62	0.33	4.75e-8	Cognitive function;
CESC	cis	rs7618915	0.547	rs6762813	chr3:52726695	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.5	7.17	0.4	7.53e-12	Bipolar disorder;
CESC	cis	rs1862618	0.853	rs861283	chr5:56184610	C/T	cg12311346	chr5:56204834	C5orf35	-0.74	-8.81	-0.48	1.71e-16	Initial pursuit acceleration;
CESC	cis	rs1348850	0.645	rs4893963	chr2:178430747	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.56	-5.99	-0.35	6.95e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs6138458	1.000	rs227651	chr20:24929834	A/G	cg06937882	chr20:24974362	C20orf3	-0.35	-5.11	-0.3	6.15e-7	Blood protein levels;
CESC	cis	rs4790333	0.653	rs2447103	chr17:2262997	A/C	cg02569219	chr17:2266849	SGSM2	0.45	6.22	0.36	1.93e-9	Proinsulin levels;
CESC	cis	rs12701220	0.655	rs9638973	chr7:1133678	A/G	cg04025307	chr7:1156635	C7orf50	0.45	5.12	0.3	5.99e-7	Bronchopulmonary dysplasia;
CESC	cis	rs3091242	0.934	rs666686	chr1:25719511	A/G	cg27572855	chr1:25598939	RHD	0.46	7.86	0.43	9.53e-14	Erythrocyte sedimentation rate;
CESC	cis	rs9913156	0.793	rs11568061	chr17:4546445	G/A	cg19197139	chr17:4613644	ARRB2	0.92	10.05	0.53	2.34e-20	Lymphocyte counts;
CESC	cis	rs10089	0.951	rs1864923	chr5:127420843	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.78	10.48	0.54	9.74e-22	Ileal carcinoids;
CESC	cis	rs10540	1.000	rs10540	chr11:494662	G/A	cg03934478	chr11:495069	RNH1	0.56	5.36	0.31	1.77e-7	Body mass index;
CESC	cis	rs6723226	0.803	rs387780	chr2:32502495	T/C	cg02381751	chr2:32503542	YIPF4	0.9	12.67	0.61	4.51e-29	Intelligence (multi-trait analysis);
CESC	cis	rs5769765	1.000	rs2092982	chr22:50282204	C/A	cg02269571	chr22:50332266	NA	0.46	6.28	0.36	1.39e-9	Schizophrenia;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg08386897	chr10:134073820	STK32C	0.44	6.36	0.36	8.99e-10	Fibrinogen levels;
CESC	cis	rs2204008	0.805	rs11169513	chr12:37988640	G/A	cg13010199	chr12:38710504	ALG10B	0.53	6.69	0.38	1.33e-10	Bladder cancer;
CESC	cis	rs4689388	0.926	rs9998519	chr4:6292909	C/T	cg00701064	chr4:6280414	WFS1	0.71	12.57	0.61	9.71e-29	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs4253772	0.591	rs6008538	chr22:46685963	G/A	cg24881330	chr22:46731750	TRMU	0.95	10.25	0.53	5.51e-21	LDL cholesterol;Cholesterol, total;
CESC	cis	rs4460629	0.742	rs11264312	chr1:155075888	T/C	cg01019262	chr1:155095195	NA	-0.3	-5.05	-0.3	8.42e-7	Serum magnesium levels;
CESC	cis	rs2243480	0.711	rs1626926	chr7:65435792	C/T	cg18252515	chr7:66147081	NA	-1.08	-10.48	-0.54	9.71e-22	Diabetic kidney disease;
CESC	cis	rs2832077	0.506	rs10222093	chr21:30163518	T/C	cg08807101	chr21:30365312	RNF160	-0.46	-5.15	-0.3	5.11e-7	Cognitive test performance;
CESC	trans	rs5756813	0.754	rs4820308	chr22:38176216	G/A	cg19894588	chr14:64061835	NA	-0.68	-8.83	-0.48	1.45e-16	Optic cup area;Vertical cup-disc ratio;
CESC	cis	rs7772486	0.790	rs9376968	chr6:146180364	T/C	cg05347473	chr6:146136440	FBXO30	0.56	7.28	0.41	3.8e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9921222	0.565	rs10903014	chr16:377623	A/G	cg26944245	chr16:421049	TMEM8A;MRPL28	0.43	6.79	0.39	7.2e-11	Bone mineral density (spine);Bone mineral density;
CESC	cis	rs807669	0.770	rs807458	chr22:19220648	G/T	cg02655711	chr22:19163373	SLC25A1	0.37	5.34	0.31	1.99e-7	Metabolite levels;
CESC	cis	rs11630290	0.592	rs1039817	chr15:64155367	T/A	cg12036633	chr15:63758958	NA	0.45	5.44	0.32	1.21e-7	Iris characteristics;
CESC	trans	rs2270927	1.000	rs13174383	chr5:75580416	T/G	cg13563193	chr19:33072644	PDCD5	0.76	6.21	0.36	2.04e-9	Mean corpuscular volume;
CESC	cis	rs2074585	0.517	rs11638010	chr15:91079920	A/G	cg10434728	chr15:90938212	IQGAP1	-0.32	-5.23	-0.31	3.42e-7	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
CESC	cis	rs5750830	0.569	rs5750809	chr22:39791491	T/G	cg24399712	chr22:39784796	NA	-0.86	-11.91	-0.59	1.8e-26	Intelligence (multi-trait analysis);
CESC	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg14893161	chr1:205819251	PM20D1	0.51	7.71	0.43	2.61e-13	Menarche (age at onset);
CESC	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg04025307	chr7:1156635	C7orf50	0.45	7.28	0.41	3.73e-12	Longevity;Endometriosis;
CESC	cis	rs116095464	0.850	rs6896163	chr5:303686	A/G	cg10591111	chr5:226296	SDHA	-0.63	-5.9	-0.34	1.13e-8	Breast cancer;
CESC	cis	rs55728055	0.661	rs62237843	chr22:32026946	C/G	cg01338084	chr22:32026380	PISD	1.26	8.23	0.45	8.62e-15	Age-related hearing impairment;
CESC	cis	rs7592578	0.766	rs62181052	chr2:191387858	A/G	cg27211696	chr2:191398769	TMEM194B	-0.62	-5.32	-0.31	2.26e-7	Diastolic blood pressure;
CESC	cis	rs10911232	0.507	rs7515822	chr1:183037803	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.85	13.23	0.63	5.11e-31	Hypertriglyceridemia;
CESC	cis	rs6545883	0.894	rs4672431	chr2:61519922	C/A	cg15711740	chr2:61764176	XPO1	0.39	5.11	0.3	6.04e-7	Tuberculosis;
CESC	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg18402987	chr7:1209562	NA	0.76	7.79	0.43	1.5e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs10949834	1.000	rs34346732	chr7:73485813	G/A	cg07137043	chr7:73588983	EIF4H	-0.62	-5.08	-0.3	7.24e-7	Verbal memory performance (residualized delayed recall change);
CESC	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	10.25	0.53	5.71e-21	Prudent dietary pattern;
CESC	cis	rs8060686	0.621	rs35432211	chr16:68095449	T/C	cg26727032	chr16:67993705	SLC12A4	-0.55	-6.15	-0.35	2.9e-9	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs1215050	0.791	rs13107606	chr4:98823187	C/A	cg05340658	chr4:99064831	C4orf37	0.51	6.63	0.38	1.87e-10	Waist-to-hip ratio adjusted for body mass index;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg10578696	chr1:65532742	NA	-0.49	-6.54	-0.37	3.13e-10	Thyroid stimulating hormone;
CESC	cis	rs6912958	0.712	rs2307379	chr6:88366771	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.33	-5.34	-0.31	1.96e-7	Monocyte percentage of white cells;
CESC	cis	rs17818399	0.547	rs13020299	chr2:46758717	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.44	5.34	0.31	1.97e-7	Height;
CESC	cis	rs2991971	0.776	rs12139364	chr1:45890155	T/C	cg05343316	chr1:45956843	TESK2	-0.59	-8.39	-0.46	3.01e-15	High light scatter reticulocyte count;
CESC	cis	rs736408	0.812	rs6778329	chr3:52824610	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	6.43	0.37	6.06e-10	Bipolar disorder;
CESC	cis	rs2836974	0.897	rs13052882	chr21:40555351	G/C	cg27266027	chr21:40555129	PSMG1	0.47	5.62	0.33	4.79e-8	Cognitive function;
CESC	cis	rs4481887	0.893	rs28579823	chr1:248506881	C/T	cg00666640	chr1:248458726	OR2T12	0.35	6.04	0.35	5.14e-9	Common traits (Other);
CESC	cis	rs77106637	0.556	rs7123876	chr11:72444583	T/C	cg04827223	chr11:72435913	ARAP1	-0.72	-11.63	-0.58	1.57e-25	Type 2 diabetes;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg07927839	chr12:53491483	IGFBP6	0.53	6.97	0.39	2.45e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs757110	0.868	rs5219	chr11:17409572	T/C	cg15432903	chr11:17409602	KCNJ11	0.67	9.58	0.51	7.26e-19	Type 2 diabetes;
CESC	cis	rs7618915	0.501	rs7611731	chr3:52692721	T/C	cg18404041	chr3:52824283	ITIH1	-0.38	-6.51	-0.37	3.7e-10	Bipolar disorder;
CESC	cis	rs7824557	0.707	rs3808518	chr8:11143272	A/C	cg21775007	chr8:11205619	TDH	-0.49	-7.12	-0.4	1.02e-11	Retinal vascular caliber;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg14794786	chr7:150815320	AGAP3	0.44	6.0	0.35	6.41e-9	Fibrinogen levels;
CESC	cis	rs4692589	1.000	rs4692784	chr4:170938581	A/G	cg19918862	chr4:170955249	NA	0.35	5.49	0.32	9.23e-8	Anxiety disorder;
CESC	cis	rs6540559	0.673	rs17015183	chr1:209948711	A/C	cg09509183	chr1:209979624	IRF6	0.52	5.68	0.33	3.51e-8	Cleft lip with or without cleft palate;
CESC	trans	rs17508449	0.865	rs4838993	chr1:114135133	C/T	cg23028848	chr11:57092561	TNKS1BP1	-0.76	-6.0	-0.35	6.46e-9	Leprosy;
CESC	cis	rs62005083	1.000	rs12147975	chr14:74642792	A/G	cg05179529	chr14:74551516	LIN52;ALDH6A1	0.71	5.52	0.32	7.97e-8	Mean corpuscular volume;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg01897796	chr15:59225903	SLTM	-0.44	-6.2	-0.36	2.2e-9	Asthma;
CESC	cis	rs938554	0.736	rs13125646	chr4:9982330	A/G	cg00071950	chr4:10020882	SLC2A9	0.48	5.69	0.33	3.33e-8	Blood metabolite levels;
CESC	cis	rs864537	0.622	rs2949661	chr1:167424924	C/T	cg22356347	chr1:167427500	CD247	-0.4	-8.13	-0.45	1.64e-14	Celiac disease or Rheumatoid arthritis;Celiac disease;
CESC	cis	rs9549260	0.755	rs2151785	chr13:41243660	G/A	cg21288729	chr13:41239152	FOXO1	0.68	8.53	0.46	1.15e-15	Red blood cell count;
CESC	cis	rs5769765	0.865	rs9616369	chr22:50304591	A/C	cg02269571	chr22:50332266	NA	-0.5	-6.52	-0.37	3.52e-10	Schizophrenia;
CESC	cis	rs514406	0.929	rs11206035	chr1:53323571	T/C	cg25767906	chr1:53392781	SCP2	-0.44	-5.61	-0.33	4.98e-8	Monocyte count;
CESC	cis	rs875971	0.862	rs801204	chr7:66022921	T/C	cg18252515	chr7:66147081	NA	0.46	5.96	0.34	8.08e-9	Aortic root size;
CESC	cis	rs10189230	0.967	rs11692482	chr2:222352405	C/T	cg14652038	chr2:222343519	EPHA4	0.37	7.73	0.43	2.26e-13	Urate levels in lean individuals;
CESC	cis	rs1215050	0.740	rs13134479	chr4:99067723	G/A	cg05340658	chr4:99064831	C4orf37	0.57	7.49	0.42	1.04e-12	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs853679	0.546	rs200952	chr6:27836976	C/T	cg02228804	chr6:27775720	HIST1H2AI;HIST1H2BL	0.64	5.44	0.32	1.21e-7	Depression;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg09381484	chr1:161147450	B4GALT3	0.46	6.04	0.35	5.15e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs6674176	0.660	rs11210936	chr1:44391438	A/T	cg13606994	chr1:44402422	ARTN	-0.41	-6.27	-0.36	1.44e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs6460942	1.000	rs17191008	chr7:12417690	T/G	cg20607287	chr7:12443886	VWDE	-0.8	-9.11	-0.49	2.07e-17	Coronary artery disease;
CESC	cis	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg23422044	chr7:1970798	MAD1L1	0.41	5.56	0.32	6.71e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs7712401	0.601	rs246285	chr5:122244968	C/G	cg19412675	chr5:122181750	SNX24	-0.4	-5.04	-0.3	8.63e-7	Mean platelet volume;
CESC	cis	rs9611565	0.659	rs9611603	chr22:41912750	A/G	cg06634786	chr22:41940651	POLR3H	-0.65	-6.68	-0.38	1.44e-10	Vitiligo;
CESC	cis	rs6540559	0.673	rs17317411	chr1:209961314	C/T	cg23283495	chr1:209979779	IRF6	-0.46	-5.04	-0.3	8.69e-7	Cleft lip with or without cleft palate;
CESC	cis	rs34779708	0.966	rs2045917	chr10:35418526	G/A	cg04310649	chr10:35416472	CREM	-0.54	-6.56	-0.37	2.73e-10	Inflammatory bowel disease;Crohn's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17091266	chr1:1850736	TMEM52	-0.53	-6.13	-0.35	3.17e-9	Gut microbiome composition (summer);
CESC	cis	rs6695640	0.854	rs2800699	chr1:17733136	C/T	cg01904812	chr1:17746340	RCC2	0.35	5.17	0.3	4.64e-7	Mean platelet volume;
CESC	cis	rs1728785	1.000	rs11647432	chr16:68565426	C/T	cg02972257	chr16:68554789	NA	-0.55	-6.37	-0.36	8.21e-10	Ulcerative colitis;
CESC	trans	rs60843830	1.000	rs4497901	chr2:239969	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.64	8.04	0.44	2.96e-14	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	13.76	0.65	7.11e-33	Prudent dietary pattern;
CESC	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg06877462	chr1:205807181	PM20D1	0.43	6.48	0.37	4.5e-10	Menarche (age at onset);
CESC	cis	rs7618915	0.571	rs7623199	chr3:52605974	C/T	cg18404041	chr3:52824283	ITIH1	-0.41	-6.78	-0.38	7.61e-11	Bipolar disorder;
CESC	cis	rs909674	0.690	rs5750823	chr22:39829973	C/T	cg11247378	chr22:39784982	NA	-0.55	-8.24	-0.45	8.23e-15	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs6952808	0.689	rs12670737	chr7:2046830	C/T	cg23048001	chr7:2026167	MAD1L1	0.47	6.13	0.35	3.22e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs1448094	0.791	rs7303256	chr12:86333217	C/T	cg02569458	chr12:86230093	RASSF9	-0.41	-5.83	-0.34	1.65e-8	Major depressive disorder;
CESC	cis	rs7267979	0.933	rs2424708	chr20:25281398	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.84	16.13	0.7	3.07e-41	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7772486	0.754	rs6922507	chr6:146250155	A/T	cg05347473	chr6:146136440	FBXO30	-0.57	-7.26	-0.41	4.32e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1790761	0.667	rs4147581	chr11:67351585	C/G	cg24690094	chr11:67383802	NA	0.38	6.26	0.36	1.51e-9	Mean corpuscular volume;
CESC	cis	rs7264396	0.623	rs2425123	chr20:34329547	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.88	-10.7	-0.55	1.88e-22	Total cholesterol levels;
CESC	cis	rs7914558	1.000	rs11191577	chr10:104902165	A/G	cg04362960	chr10:104952993	NT5C2	0.46	5.9	0.34	1.08e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08281556	chr6:105628013	POPDC3	0.6	6.72	0.38	1.14e-10	Gut microbiome composition (summer);
CESC	cis	rs11581903	0.568	rs11590859	chr1:53073838	G/T	cg19751897	chr1:52520827	TXNDC12;BTF3L4	0.73	5.47	0.32	1.06e-7	Joint mobility (Beighton score);
CESC	cis	rs4664308	0.692	rs10497213	chr2:160963603	G/A	cg03641300	chr2:160917029	PLA2R1	-0.44	-6.23	-0.36	1.86e-9	Idiopathic membranous nephropathy;
CESC	cis	rs4253772	0.550	rs738444	chr22:46721088	C/T	cg10231785	chr22:46692440	CN5H6.4;GTSE1	0.57	5.91	0.34	1.07e-8	LDL cholesterol;Cholesterol, total;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10585161	chr5:115420544	COMMD10	-0.68	-8.11	-0.45	1.88e-14	Gut microbiome composition (summer);
CESC	cis	rs2282802	0.685	rs67813630	chr5:139623592	C/A	cg26211634	chr5:139558579	C5orf32	0.48	6.95	0.39	2.78e-11	Intelligence (multi-trait analysis);
CESC	cis	rs5769707	0.681	rs135879	chr22:50018651	C/T	cg05373962	chr22:49881684	NA	-0.33	-5.15	-0.3	5.18e-7	Monocyte count;Monocyte percentage of white cells;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg24695950	chr2:162364264	NA	-0.51	-6.43	-0.37	5.8e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs1008375	0.933	rs6847966	chr4:17634255	G/A	cg16339924	chr4:17578868	LAP3	0.66	8.45	0.46	1.95e-15	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs36051895	0.623	rs1830610	chr9:5260079	C/T	cg02405213	chr9:5042618	JAK2	-0.53	-6.55	-0.37	2.97e-10	Pediatric autoimmune diseases;
CESC	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg15147215	chr3:52552868	STAB1	-0.31	-5.7	-0.33	3.25e-8	Bipolar disorder;
CESC	cis	rs870825	0.616	rs7660064	chr4:185617529	T/C	cg04058563	chr4:185651563	MLF1IP	0.64	7.05	0.4	1.59e-11	Blood protein levels;
CESC	cis	rs13631	0.894	rs7856589	chr9:140003921	A/G	cg14289826	chr9:140003911	NA	-0.37	-7.12	-0.4	1e-11	Cerebrospinal fluid biomarker levels;
CESC	cis	rs10504229	0.679	rs72649114	chr8:58037491	G/T	cg22535103	chr8:58192502	C8orf71	-0.63	-7.02	-0.4	1.86e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs3780486	0.846	rs12554995	chr9:33132044	A/G	cg13443165	chr9:33130375	B4GALT1	0.45	6.46	0.37	5e-10	IgG glycosylation;
CESC	cis	rs6942756	1.000	rs66538149	chr7:128974061	G/A	cg02491457	chr7:128862824	NA	-0.68	-9.08	-0.49	2.52e-17	White matter hyperintensity burden;
CESC	cis	rs8031584	0.918	rs11639169	chr15:31255438	C/T	cg08704250	chr15:31115839	NA	-0.57	-7.15	-0.4	8.22e-12	Huntington's disease progression;
CESC	cis	rs11583043	0.918	rs58029001	chr1:101393409	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.56	6.35	0.36	9.26e-10	Ulcerative colitis;Inflammatory bowel disease;
CESC	cis	rs9916302	0.904	rs2338798	chr17:37547269	T/C	cg20243544	chr17:37824526	PNMT	-0.48	-6.12	-0.35	3.41e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs7246865	0.510	rs7254154	chr19:17178119	A/C	cg16202187	chr19:17186497	HAUS8;MYO9B	0.51	6.56	0.37	2.84e-10	Reticulocyte fraction of red cells;
CESC	cis	rs4631830	0.540	rs2843562	chr10:51496796	A/G	cg16070123	chr10:51489643	NA	0.33	5.13	0.3	5.71e-7	Prostate-specific antigen levels;
CESC	cis	rs875971	0.862	rs6460282	chr7:65691246	T/C	cg19163074	chr7:65112434	INTS4L2	0.45	5.57	0.32	6.16e-8	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12457035	chr5:180688144	TRIM52	0.52	6.02	0.35	5.91e-9	Gut microbiome composition (summer);
CESC	cis	rs703842	1.000	rs10877012	chr12:58162085	G/T	cg00677455	chr12:58241039	CTDSP2	0.51	6.57	0.37	2.6200000000000003e-10	Multiple sclerosis;
CESC	cis	rs1499972	0.590	rs62264777	chr3:117653515	G/C	cg07612923	chr3:117604196	NA	0.69	6.3	0.36	1.22e-9	Schizophrenia;
CESC	trans	rs7726839	0.561	rs4957049	chr5:579080	C/A	cg25482853	chr8:67687455	SGK3	0.88	9.47	0.5	1.62e-18	Obesity-related traits;
CESC	cis	rs17376456	0.877	rs13169675	chr5:93331284	A/G	cg25358565	chr5:93447407	FAM172A	1.12	10.33	0.54	3.07e-21	Diabetic retinopathy;
CESC	cis	rs10463316	0.779	rs6871318	chr5:150801545	G/A	cg03212797	chr5:150827313	SLC36A1	-0.5	-6.57	-0.37	2.71e-10	Metabolite levels (Pyroglutamine);
CESC	cis	rs7107174	1.000	rs7941617	chr11:78021146	C/T	cg02023728	chr11:77925099	USP35	0.39	5.6	0.33	5.42e-8	Testicular germ cell tumor;
CESC	cis	rs78456975	1.000	rs13429866	chr2:1555211	C/A	cg26248373	chr2:1572462	NA	-0.58	-5.22	-0.31	3.68e-7	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs8017423	0.967	rs7147952	chr14:90720831	G/A	cg14092571	chr14:90743983	NA	-0.55	-8.26	-0.45	6.87e-15	Mortality in heart failure;
CESC	cis	rs2839186	0.708	rs17183123	chr21:47671961	G/C	cg13126279	chr21:47581558	C21orf56	-0.5	-6.88	-0.39	4.33e-11	Testicular germ cell tumor;
CESC	cis	rs17818399	0.926	rs35350086	chr2:46834036	C/G	cg06386533	chr2:46925753	SOCS5	0.48	5.32	0.31	2.18e-7	Height;
CESC	cis	rs2658782	0.547	rs10765602	chr11:93048165	G/T	cg15737290	chr11:93063684	CCDC67	0.52	7.24	0.41	4.88e-12	Pulmonary function decline;
CESC	cis	rs9309473	1.000	rs2140195	chr2:73702344	A/G	cg20560298	chr2:73613845	ALMS1	-0.5	-6.75	-0.38	9.15e-11	Metabolite levels;
CESC	cis	rs4835473	0.863	rs7696828	chr4:144621999	G/C	cg25736465	chr4:144833511	NA	0.36	5.38	0.31	1.63e-7	Immature fraction of reticulocytes;
CESC	cis	rs7772486	0.875	rs2748497	chr6:146319417	C/T	cg23711669	chr6:146136114	FBXO30	0.74	10.31	0.53	3.65e-21	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6860806	0.507	rs272892	chr5:131664349	C/T	cg18758796	chr5:131593413	PDLIM4	0.38	5.12	0.3	5.79e-7	Breast cancer;
CESC	cis	rs17407555	0.779	rs6851524	chr4:10155041	C/A	cg11266682	chr4:10021025	SLC2A9	-0.49	-5.66	-0.33	3.92e-8	Schizophrenia (age at onset);
CESC	cis	rs2204008	0.777	rs8189597	chr12:38307739	G/C	cg13010199	chr12:38710504	ALG10B	-0.54	-6.79	-0.38	7.4e-11	Bladder cancer;
CESC	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg04025307	chr7:1156635	C7orf50	0.41	5.62	0.33	4.93e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs67311347	1.000	rs6801185	chr3:40505060	C/T	cg09455208	chr3:40491958	NA	-0.47	-8.04	-0.44	2.9e-14	Renal cell carcinoma;
CESC	cis	rs9611565	0.729	rs137831	chr22:41903813	A/C	cg06481639	chr22:41940642	POLR3H	-0.47	-5.43	-0.32	1.25e-7	Vitiligo;
CESC	cis	rs801193	0.839	rs6968619	chr7:66068867	T/C	cg18252515	chr7:66147081	NA	0.4	5.21	0.3	3.78e-7	Aortic root size;
CESC	cis	rs11785400	0.793	rs9297970	chr8:143723386	C/T	cg24634471	chr8:143751801	JRK	0.46	5.82	0.34	1.73e-8	Schizophrenia;
CESC	cis	rs546131	0.928	rs483976	chr11:34840167	C/G	cg11058730	chr11:34937778	PDHX;APIP	0.48	6.02	0.35	5.66e-9	Lung disease severity in cystic fibrosis;
CESC	cis	rs4975709	1.000	rs4975709	chr5:1877280	A/C	cg15595755	chr5:1867978	NA	0.47	7.61	0.42	4.78e-13	Cardiovascular disease risk factors;
CESC	trans	rs10489896	0.541	rs16843133	chr1:234564255	A/G	cg10395685	chr11:86085715	CCDC81	0.41	6.02	0.35	5.86e-9	Cognitive test performance;
CESC	cis	rs7914558	0.966	rs10883805	chr10:104708251	T/C	cg08650961	chr10:104748594	CNNM2	0.32	5.22	0.31	3.62e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs9649213	0.593	rs1468340	chr7:97987676	T/G	cg00277769	chr7:97922759	BAIAP2L1	-0.33	-5.41	-0.32	1.41e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs11871801	0.517	rs645692	chr17:40701073	C/T	cg21433558	chr17:40837037	CNTNAP1	0.52	6.41	0.37	6.56e-10	Crohn's disease;
CESC	cis	rs6502050	0.835	rs3924781	chr17:80113130	T/C	cg23985595	chr17:80112537	CCDC57	-0.4	-6.25	-0.36	1.64e-9	Life satisfaction;
CESC	cis	rs7542091	0.704	rs2142907	chr1:210039505	T/C	cg22029157	chr1:209979665	IRF6	0.5	7.7	0.43	2.78e-13	Monobrow;
CESC	cis	rs1267303	0.675	rs1267312	chr1:46986748	C/G	cg25110126	chr1:46999211	NA	-0.72	-8.9	-0.48	8.74e-17	Monobrow;
CESC	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg07677032	chr17:61819896	STRADA	0.45	5.97	0.34	7.74e-9	Prudent dietary pattern;
CESC	trans	rs1814175	0.617	rs6486020	chr11:49769149	T/G	cg15704280	chr7:45808275	SEPT13	-0.99	-17.45	-0.73	6.41e-46	Height;
CESC	cis	rs9399135	0.967	rs7766189	chr6:135353851	A/C	cg24558204	chr6:135376177	HBS1L	0.51	7.1	0.4	1.13e-11	Red blood cell count;
CESC	cis	rs7818345	0.967	rs4481612	chr8:19285336	T/G	cg11303988	chr8:19266685	CSGALNACT1	0.37	6.42	0.37	6.36e-10	Language performance in older adults (adjusted for episodic memory);
CESC	cis	rs7100689	0.577	rs9420359	chr10:82054873	C/T	cg09936400	chr10:82049201	MAT1A	0.4	6.04	0.35	5.06e-9	Post bronchodilator FEV1;
CESC	cis	rs763121	0.813	rs4821807	chr22:39065582	A/G	cg06022373	chr22:39101656	GTPBP1	0.89	13.91	0.65	2.08e-33	Menopause (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18968306	chr11:134093878	NCAPD3;VPS26B	0.62	7.3	0.41	3.41e-12	Gut microbiome composition (summer);
CESC	trans	rs1814175	0.645	rs28445479	chr11:50047999	A/G	cg03929089	chr4:120376271	NA	-0.9	-14.49	-0.66	1.88e-35	Height;
CESC	trans	rs7618501	1.000	rs34614773	chr3:49753003	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.58	-8.44	-0.46	2.06e-15	Intelligence (multi-trait analysis);
CESC	cis	rs11098499	0.908	rs71614449	chr4:120387055	C/T	cg09307838	chr4:120376055	NA	0.95	13.96	0.65	1.42e-33	Corneal astigmatism;
CESC	cis	rs780096	0.506	rs1647265	chr2:27692261	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.35	-6.56	-0.37	2.79e-10	Total body bone mineral density;
CESC	cis	rs9790314	0.871	rs339114	chr3:161109220	C/T	cg03342759	chr3:160939853	NMD3	0.48	6.68	0.38	1.44e-10	Morning vs. evening chronotype;
CESC	cis	rs9291683	0.507	rs6849273	chr4:10021595	C/T	cg00071950	chr4:10020882	SLC2A9	0.81	14.09	0.65	4.84e-34	Bone mineral density;
CESC	cis	rs61776719	0.520	rs72661887	chr1:38416310	C/T	cg26398791	chr1:38455867	SF3A3	-0.41	-5.28	-0.31	2.69e-7	Coronary artery disease;
CESC	cis	rs2952156	0.920	rs732084	chr17:37834357	A/C	cg07936489	chr17:37558343	FBXL20	-0.6	-7.98	-0.44	4.35e-14	Asthma;
CESC	cis	rs4720118	0.875	rs3779239	chr7:33430271	G/A	cg22798885	chr7:33102694	NT5C3	-0.37	-5.1	-0.3	6.42e-7	Leprosy;
CESC	cis	rs4665809	0.590	rs10495756	chr2:26485586	A/G	cg25036284	chr2:26402008	FAM59B	0.86	9.34	0.5	4.17e-18	Gut microbiome composition (summer);
CESC	cis	rs2836974	0.897	rs14194	chr21:40549466	T/C	cg27266027	chr21:40555129	PSMG1	0.43	5.25	0.31	3.13e-7	Cognitive function;
CESC	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg16132339	chr22:24313637	DDTL;DDT	0.46	7.05	0.4	1.58e-11	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs7618915	0.547	rs3755806	chr3:52643685	C/T	cg18404041	chr3:52824283	ITIH1	0.39	6.5	0.37	3.94e-10	Bipolar disorder;
CESC	cis	rs7520050	0.966	rs10789475	chr1:46304177	C/G	cg24296786	chr1:45957014	TESK2	0.42	5.42	0.32	1.33e-7	Red blood cell count;Reticulocyte count;
CESC	cis	rs11098499	0.675	rs11098534	chr4:120556772	T/G	cg09307838	chr4:120376055	NA	0.77	10.26	0.53	4.96e-21	Corneal astigmatism;
CESC	cis	rs4282054	0.631	rs13081155	chr3:52732429	A/G	cg15147215	chr3:52552868	STAB1	-0.32	-5.73	-0.33	2.73e-8	Cognitive function;
CESC	cis	rs2979489	0.624	rs62505275	chr8:30437639	C/T	cg26383811	chr8:30366931	RBPMS	-0.7	-7.99	-0.44	4.03e-14	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CESC	cis	rs11083475	0.607	rs6508816	chr19:39267783	G/A	cg07905965	chr19:39260460	NA	0.38	5.63	0.33	4.56e-8	Heart rate;
CESC	cis	rs965469	1.000	rs6051703	chr20:3252347	A/T	cg25506879	chr20:3388711	C20orf194	-0.58	-6.24	-0.36	1.7e-9	IFN-related cytopenia;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg09138524	chr22:19776431	GNB1L	0.46	6.18	0.35	2.45e-9	Fibrinogen levels;
CESC	cis	rs5750830	0.649	rs5750818	chr22:39820885	A/G	cg05872129	chr22:39784769	NA	-0.84	-11.4	-0.57	9.27e-25	Intelligence (multi-trait analysis);
CESC	cis	rs11252926	0.604	rs12359454	chr10:568081	T/C	cg16386425	chr10:429943	DIP2C	0.47	5.64	0.33	4.42e-8	Psychosis in Alzheimer's disease;
CESC	cis	rs7666738	0.830	rs62321565	chr4:98976571	G/A	cg17366294	chr4:99064904	C4orf37	0.58	8.25	0.45	7.41e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4970988	0.501	rs11204713	chr1:150694623	T/A	cg22823121	chr1:150693482	HORMAD1	0.47	7.05	0.4	1.51e-11	Urate levels;
CESC	cis	rs4665809	1.000	rs6729757	chr2:26285102	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.67	-7.6	-0.42	4.99e-13	Gut microbiome composition (summer);
CESC	cis	rs921968	0.541	rs7604319	chr2:219538799	A/C	cg02176678	chr2:219576539	TTLL4	-0.57	-9.75	-0.51	2.11e-19	Mean corpuscular hemoglobin concentration;
CESC	cis	rs7116495	0.609	rs7113436	chr11:71689599	A/T	cg26138937	chr11:71823887	C11orf51	1.31	7.73	0.43	2.18e-13	Severe influenza A (H1N1) infection;
CESC	cis	rs7927771	0.832	rs11039212	chr11:47393303	A/T	cg05585544	chr11:47624801	NA	0.49	7.37	0.41	2.2e-12	Subjective well-being;
CESC	cis	rs79349575	0.749	rs1057902	chr17:47005588	C/T	cg16584676	chr17:46985605	UBE2Z	0.54	6.62	0.38	1.98e-10	Type 2 diabetes;
CESC	cis	rs1552244	0.882	rs7633769	chr3:10020622	C/T	cg00166722	chr3:10149974	C3orf24	0.51	6.26	0.36	1.58e-9	Alzheimer's disease;
CESC	cis	rs7666738	0.830	rs1426672	chr4:98923984	T/C	cg05340658	chr4:99064831	C4orf37	0.82	12.2	0.6	1.81e-27	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9926296	0.568	rs7203907	chr16:89833774	C/G	cg27121462	chr16:89883253	FANCA	0.75	10.53	0.54	6.74e-22	Vitiligo;
CESC	cis	rs4803468	0.967	rs7259900	chr19:41889429	A/T	cg09537434	chr19:41945824	ATP5SL	-1.05	-18.71	-0.75	2.35e-50	Height;
CESC	cis	rs1552244	0.935	rs35515831	chr3:10071362	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.88	11.96	0.59	1.2e-26	Alzheimer's disease;
CESC	cis	rs7666738	0.712	rs11731393	chr4:98859070	G/C	cg05340658	chr4:99064831	C4orf37	0.56	5.54	0.32	7.28e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs12681366	0.734	rs28641679	chr8:95406693	G/A	cg13257157	chr8:95487014	RAD54B	0.39	5.24	0.31	3.24e-7	Nonsyndromic cleft lip with cleft palate;
CESC	cis	rs698833	0.509	rs10198291	chr2:44539009	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.52	5.25	0.31	3.1e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs7107174	1.000	rs2510045	chr11:77920563	G/T	cg02023728	chr11:77925099	USP35	0.46	6.16	0.35	2.68e-9	Testicular germ cell tumor;
CESC	cis	rs7084402	0.967	rs2577393	chr10:60286159	C/T	cg07615347	chr10:60278583	BICC1	0.59	9.44	0.5	2.04e-18	Refractive error;
CESC	cis	rs8005677	0.798	rs61977741	chr14:23400979	G/C	cg01529538	chr14:23388837	RBM23	0.43	5.71	0.33	3.05e-8	Cognitive ability (multi-trait analysis);
CESC	cis	rs12995491	0.569	rs6724281	chr2:88529531	T/G	cg18490616	chr2:88469792	THNSL2	-0.72	-10.68	-0.55	2.25e-22	Response to metformin (IC50);
CESC	cis	rs6748734	1.000	rs4293565	chr2:241834770	A/G	cg04034577	chr2:241836375	C2orf54	-0.5	-8.74	-0.47	2.65e-16	Urinary metabolites;
CESC	cis	rs2749592	0.611	rs176888	chr10:38406161	C/A	cg25427524	chr10:38739819	LOC399744	-0.63	-8.36	-0.46	3.58e-15	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs3126085	0.935	rs12738889	chr1:152257688	G/A	cg03465714	chr1:152285911	FLG	0.45	5.54	0.32	7.12e-8	Atopic dermatitis;
CESC	cis	rs6460942	0.731	rs75994414	chr7:12307992	C/A	cg10578991	chr7:12443926	VWDE	-0.59	-6.16	-0.35	2.63e-9	Coronary artery disease;
CESC	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg18402987	chr7:1209562	NA	0.5	6.89	0.39	4.15e-11	Longevity;Endometriosis;
CESC	cis	rs1950626	0.623	rs2295657	chr14:101430620	A/C	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.69	9.41	0.5	2.44e-18	Pelvic organ prolapse (moderate/severe);
CESC	cis	rs7649275	0.832	rs2577326	chr3:53780082	A/G	cg21503701	chr3:53781065	CACNA1D	-0.38	-5.08	-0.3	7.14e-7	Trans fatty acid levels;
CESC	cis	rs7666738	0.830	rs62318472	chr4:98926030	G/A	cg03467027	chr4:99064603	C4orf37	0.44	5.31	0.31	2.29e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs12476592	0.571	rs7577952	chr2:63787212	C/T	cg17519650	chr2:63277830	OTX1	-0.48	-5.42	-0.32	1.34e-7	Childhood ear infection;
CESC	cis	rs4481887	0.861	rs4295906	chr1:248429861	C/T	cg00666640	chr1:248458726	OR2T12	0.39	6.7	0.38	1.23e-10	Common traits (Other);
CESC	cis	rs7084402	0.934	rs1658453	chr10:60309602	T/C	cg07615347	chr10:60278583	BICC1	0.59	9.34	0.5	4.21e-18	Refractive error;
CESC	cis	rs11264213	0.901	rs72661607	chr1:36331411	G/C	cg27506609	chr1:36549197	TEKT2	0.66	5.63	0.33	4.53e-8	Schizophrenia;
CESC	cis	rs344364	0.511	rs1742395	chr16:1955965	G/A	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.53	-6.1	-0.35	3.81e-9	Glomerular filtration rate in chronic kidney disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13640924	chr14:105695311	BRF1	-0.53	-6.34	-0.36	9.87e-10	Gut microbiome composition (summer);
CESC	cis	rs3008870	1.000	rs1925411	chr1:67370292	C/T	cg02640540	chr1:67518911	SLC35D1	0.5	5.33	0.31	2.11e-7	Lymphocyte percentage of white cells;
CESC	cis	rs9611565	0.546	rs5758430	chr22:42109844	G/T	cg17376030	chr22:41985996	PMM1	-0.72	-7.68	-0.43	3.15e-13	Vitiligo;
CESC	cis	rs1552244	1.000	rs9824585	chr3:10114802	T/C	cg00149659	chr3:10157352	C3orf10	0.7	8.38	0.46	3.2e-15	Alzheimer's disease;
CESC	trans	rs10411161	0.702	rs17835311	chr19:52386781	A/C	cg22319618	chr22:45562946	NUP50	-0.73	-7.12	-0.4	1.02e-11	Breast cancer;
CESC	cis	rs11229555	1.000	rs12808544	chr11:58373221	C/A	cg15696309	chr11:58395628	NA	-0.43	-5.64	-0.33	4.3e-8	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs9393777	0.513	rs7740197	chr6:26663478	C/T	cg12292205	chr6:26970375	C6orf41	0.53	5.91	0.34	1.04e-8	Intelligence (multi-trait analysis);
CESC	cis	rs7044106	0.791	rs7036766	chr9:123479621	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.38	6.13	0.35	3.25e-9	Hip circumference adjusted for BMI;
CESC	cis	rs910316	0.967	rs12890371	chr14:75593839	T/C	cg08847533	chr14:75593920	NEK9	1.01	19.64	0.77	1.3e-53	Height;
CESC	cis	rs863345	0.604	rs10908653	chr1:158455353	A/G	cg12129480	chr1:158549410	OR10X1	-0.36	-7.14	-0.4	8.83e-12	Pneumococcal bacteremia;
CESC	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg06873352	chr17:61820015	STRADA	0.71	12.11	0.6	3.78e-27	Prudent dietary pattern;
CESC	cis	rs67072384	0.901	rs67288233	chr11:72458361	G/A	cg04827223	chr11:72435913	ARAP1	-0.71	-6.96	-0.39	2.61e-11	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
CESC	cis	rs2742234	0.590	rs2503863	chr10:43667398	G/A	cg15436174	chr10:43711423	RASGEF1A	-0.5	-5.84	-0.34	1.5e-8	Hirschsprung disease;
CESC	cis	rs4237845	0.537	rs4237844	chr12:58267987	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	-0.46	-5.04	-0.3	8.8e-7	Intelligence (multi-trait analysis);
CESC	cis	rs7131987	0.934	rs2216854	chr12:29423460	G/A	cg09582351	chr12:29534625	ERGIC2	-0.31	-5.12	-0.3	5.78e-7	QT interval;
CESC	cis	rs72634258	0.519	rs744001	chr1:7934557	G/A	cg00042356	chr1:8021962	PARK7	0.61	6.02	0.35	5.71e-9	Inflammatory bowel disease;
CESC	cis	rs8031584	0.541	rs2955777	chr15:31219788	A/C	cg08704250	chr15:31115839	NA	0.63	8.61	0.47	6.65e-16	Huntington's disease progression;
CESC	cis	rs2243480	1.000	rs10807702	chr7:65767843	C/T	cg13147721	chr7:65941812	NA	-0.91	-8.33	-0.46	4.48e-15	Diabetic kidney disease;
CESC	cis	rs4664330	1	rs4664330	chr2:161333128	G/C	cg03641300	chr2:160917029	PLA2R1	-0.44	-5.64	-0.33	4.43e-8	Monocyte percentage of white cells;
CESC	cis	rs9987353	0.566	rs6998368	chr8:9070288	G/C	cg06636001	chr8:8085503	FLJ10661	-0.6	-7.14	-0.4	9.11e-12	Recombination measurement;
CESC	cis	rs2404602	0.716	rs12441247	chr15:76812316	T/C	cg26408565	chr15:76604113	ETFA	-0.42	-6.21	-0.36	2.01e-9	Blood metabolite levels;
CESC	cis	rs9911578	1.000	rs1971659	chr17:57004787	A/G	cg12560992	chr17:57184187	TRIM37	0.92	15.19	0.68	6.64e-38	Intelligence (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00270594	chr10:70716161	DDX21	0.54	6.69	0.38	1.3100000000000001e-10	Gut microbiome composition (summer);
CESC	cis	rs6088590	0.561	rs2295444	chr20:33173883	C/T	cg24642439	chr20:33292090	TP53INP2	0.63	8.39	0.46	2.84e-15	Coronary artery disease;
CESC	trans	rs2075371	0.932	rs1862048	chr7:133978167	C/G	cg06584028	chr2:69614451	GFPT1	0.56	6.37	0.36	8.46e-10	Mean platelet volume;
CESC	cis	rs8111998	0.625	rs7255845	chr19:22766051	C/T	cg19914732	chr19:22715077	NA	-0.37	-5.18	-0.3	4.45e-7	Corneal structure;
CESC	cis	rs2011503	0.943	rs1529745	chr19:19517325	C/G	cg11584989	chr19:19387371	SF4	0.62	7.32	0.41	3.06e-12	Bipolar disorder;
CESC	cis	rs921968	0.678	rs689116	chr2:219433888	C/A	cg02176678	chr2:219576539	TTLL4	0.41	7.08	0.4	1.29e-11	Mean corpuscular hemoglobin concentration;
CESC	cis	rs75477785	0.590	rs72649925	chr1:210136902	C/T	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.86	5.83	0.34	1.65e-8	Cleft lip with or without cleft palate;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23814154	chr12:51611356	POU6F1	-0.65	-7.55	-0.42	7.12e-13	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.791	rs1559860	chr4:99024422	C/T	cg24818145	chr4:99064322	C4orf37	0.39	5.09	0.3	6.95e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1348850	0.915	rs10930798	chr2:178446141	G/A	cg23306229	chr2:178417860	TTC30B	0.54	7.1	0.4	1.16e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs7605827	0.893	rs7589238	chr2:15606409	C/A	cg19274914	chr2:15703543	NA	0.35	6.13	0.35	3.19e-9	Educational attainment (years of education);
CESC	cis	rs1552244	0.882	rs13063929	chr3:10010308	T/C	cg00149659	chr3:10157352	C3orf10	0.68	7.98	0.44	4.5e-14	Alzheimer's disease;
CESC	cis	rs9457247	0.905	rs377232	chr6:167409638	C/A	cg25258033	chr6:167368657	RNASET2	0.41	6.23	0.36	1.81e-9	Crohn's disease;
CESC	cis	rs9399135	0.660	rs4440481	chr6:135276696	A/G	cg22676075	chr6:135203613	NA	0.49	6.83	0.39	5.73e-11	Red blood cell count;
CESC	cis	rs826838	0.967	rs1719853	chr12:39128515	A/G	cg13010199	chr12:38710504	ALG10B	-0.44	-5.97	-0.34	7.74e-9	Heart rate;
CESC	cis	rs10504229	0.817	rs78138632	chr8:58191341	G/T	cg22535103	chr8:58192502	C8orf71	-1.05	-11.32	-0.57	1.73e-24	Developmental language disorder (linguistic errors);
CESC	cis	rs61935443	0.720	rs10859785	chr12:95295081	A/T	cg21533806	chr12:95267307	NA	0.53	6.48	0.37	4.54e-10	Schizophrenia;
CESC	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.38	-5.46	-0.32	1.09e-7	Electroencephalogram traits;
CESC	cis	rs17711722	0.653	rs2460421	chr7:65491123	A/T	cg18876405	chr7:65276391	NA	-0.65	-9.28	-0.5	6.26e-18	Calcium levels;
CESC	cis	rs2635047	0.783	rs9948677	chr18:44790343	G/A	cg24371990	chr18:44770781	NA	0.42	6.57	0.37	2.66e-10	Educational attainment;
CESC	cis	rs2075371	0.932	rs1862052	chr7:133981227	G/A	cg00033643	chr7:134001901	SLC35B4	0.4	5.12	0.3	5.81e-7	Mean platelet volume;
CESC	cis	rs1371867	0.817	rs7846076	chr8:101327629	A/G	cg11906718	chr8:101322791	RNF19A	0.5	6.51	0.37	3.78e-10	Atrioventricular conduction;
CESC	cis	rs3617	0.573	rs9880978	chr3:52923251	C/G	cg11645453	chr3:52864694	ITIH4	0.28	5.5	0.32	8.89e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
CESC	cis	rs6076065	1.000	rs6083105	chr20:23368475	C/A	cg12062639	chr20:23401060	NAPB	0.41	5.16	0.3	4.95e-7	Facial morphology (factor 15, philtrum width);
CESC	cis	rs11792861	0.641	rs10979586	chr9:111647764	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.49	6.22	0.36	1.9e-9	Menarche (age at onset);
CESC	cis	rs36051895	0.623	rs10975024	chr9:5246403	A/T	cg02405213	chr9:5042618	JAK2	-0.52	-6.49	-0.37	4.27e-10	Pediatric autoimmune diseases;
CESC	cis	rs6083	0.512	rs17269397	chr15:58857378	A/G	cg05156742	chr15:59063176	FAM63B	-0.72	-10.21	-0.53	7.23e-21	Schizophrenia;
CESC	cis	rs1580019	0.563	rs764483	chr7:32578150	A/T	cg07520158	chr7:32535189	LSM5;AVL9	0.51	6.4	0.37	7e-10	Cognitive ability;
CESC	cis	rs853679	0.517	rs56364346	chr6:28050762	T/G	cg08968635	chr6:28129556	ZNF389	0.39	5.22	0.31	3.64e-7	Depression;
CESC	cis	rs2370759	1.000	rs79578760	chr10:32611264	C/A	cg18270830	chr10:32634957	EPC1	0.71	6.8	0.39	6.75e-11	Sexual dysfunction (female);
CESC	cis	rs7666738	0.830	rs2865949	chr4:99039967	A/G	cg24818145	chr4:99064322	C4orf37	0.38	5.04	0.3	8.49e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg26338869	chr17:61819248	STRADA	0.7	9.28	0.5	6.1e-18	Prudent dietary pattern;
CESC	cis	rs2901656	0.934	rs2285176	chr1:172421744	G/A	cg03748243	chr1:172413542	C1orf105;PIGC	0.41	5.93	0.34	9.27e-9	Red cell distribution width;Platelet distribution width;
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg01953119	chr2:20425340	SDC1	-0.41	-6.1	-0.35	3.7e-9	Vertical cup-disc ratio;
CESC	cis	rs4268898	0.679	rs2543666	chr2:24446042	C/T	cg20701182	chr2:24300061	SF3B14	-0.5	-5.7	-0.33	3.17e-8	Asthma;
CESC	cis	rs3806843	0.735	rs2530235	chr5:140072647	G/T	cg16179182	chr5:140090404	VTRNA1-1	0.41	5.29	0.31	2.56e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs1707322	1.000	rs10890380	chr1:46449469	A/G	cg05343316	chr1:45956843	TESK2	0.45	5.54	0.32	7.24e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs3736485	0.934	rs8036609	chr15:51861426	C/G	cg08986416	chr15:51914746	DMXL2	-0.4	-5.12	-0.3	5.86e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs9487051	0.676	rs7753697	chr6:109593292	A/G	cg01475377	chr6:109611718	NA	-0.44	-6.99	-0.39	2.19e-11	Reticulocyte fraction of red cells;
CESC	cis	rs4835473	0.932	rs4835118	chr4:144903147	A/T	cg25736465	chr4:144833511	NA	0.41	6.36	0.36	8.7e-10	Immature fraction of reticulocytes;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg20332471	chr1:2447853	PANK4	0.53	7.37	0.41	2.22e-12	Fibrinogen levels;
CESC	cis	rs7666738	0.830	rs9999200	chr4:99030690	A/C	cg05340658	chr4:99064831	C4orf37	0.83	13.1	0.63	1.43e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs780096	0.506	rs72819512	chr2:27614449	G/A	cg02592271	chr2:27665507	KRTCAP3	-0.29	-5.71	-0.33	3.04e-8	Total body bone mineral density;
CESC	cis	rs6582630	0.502	rs11520234	chr12:38255005	G/A	cg13010199	chr12:38710504	ALG10B	0.52	6.38	0.36	8.04e-10	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs644799	0.710	rs56384142	chr11:95502075	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.77	11.59	0.58	2.13e-25	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs6662572	0.585	rs12042481	chr1:45964766	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.58	5.61	0.33	5.13e-8	Blood protein levels;
CESC	cis	rs116095464	0.558	rs7356696	chr5:284251	A/G	cg22496380	chr5:211416	CCDC127	-0.74	-8.46	-0.46	1.77e-15	Breast cancer;
CESC	cis	rs11764590	0.671	rs3800872	chr7:2110272	C/G	cg27530443	chr7:1977877	MAD1L1	0.44	5.12	0.3	6.02e-7	Neuroticism;
CESC	cis	rs9733	0.526	rs11204698	chr1:150659545	G/A	cg09365446	chr1:150670422	GOLPH3L	0.41	5.76	0.33	2.36e-8	Tonsillectomy;
CESC	cis	rs72945132	0.882	rs947812	chr11:70209169	C/T	cg00319359	chr11:70116639	PPFIA1	0.78	7.36	0.41	2.3e-12	Coronary artery disease;
CESC	cis	rs4481887	0.927	rs4350233	chr1:248489994	G/A	cg00666640	chr1:248458726	OR2T12	0.36	6.17	0.35	2.56e-9	Common traits (Other);
CESC	cis	rs8141529	0.748	rs2064261	chr22:29287730	C/T	cg02153584	chr22:29168773	CCDC117	0.58	7.55	0.42	6.89e-13	Lymphocyte counts;
CESC	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg11494091	chr17:61959527	GH2	0.74	12.24	0.6	1.3e-27	Prudent dietary pattern;
CESC	trans	rs61931739	0.517	rs10772139	chr12:34186178	A/T	cg26384229	chr12:38710491	ALG10B	0.65	9.11	0.49	2.1e-17	Morning vs. evening chronotype;
CESC	cis	rs9926296	0.533	rs7190823	chr16:89866043	A/G	cg07648498	chr16:89883185	FANCA	0.5	6.41	0.37	6.59e-10	Vitiligo;
CESC	cis	rs10979	1.000	rs9376763	chr6:143887386	C/T	cg25407410	chr6:143891975	LOC285740	-0.61	-9.13	-0.49	1.86e-17	Hypospadias;
CESC	cis	rs7666738	0.830	rs6839277	chr4:99015563	C/T	cg03676636	chr4:99064102	C4orf37	0.33	5.16	0.3	4.86e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg25324976	chr17:61989376	CSHL1	-0.33	-5.04	-0.3	8.68e-7	Prudent dietary pattern;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18018640	chr7:2599151	IQCE	0.65	7.44	0.42	1.44e-12	Gut microbiome composition (summer);
CESC	cis	rs2836974	1.000	rs2836974	chr21:40663181	A/G	cg17971929	chr21:40555470	PSMG1	-1.05	-15.98	-0.7	1.02e-40	Cognitive function;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05511689	chr6:71123154	FAM135A	0.61	6.68	0.38	1.42e-10	Gut microbiome composition (summer);
CESC	cis	rs3741404	0.560	rs2875748	chr11:63915537	G/A	cg05555928	chr11:63887634	MACROD1	0.34	5.12	0.3	5.86e-7	Platelet count;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg11087358	chr12:57940980	DCTN2	0.48	6.18	0.35	2.39e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs1008375	1.000	rs1974624	chr4:17650281	A/G	cg04450456	chr4:17643702	FAM184B	0.37	5.23	0.31	3.4e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs12476592	0.602	rs4671065	chr2:63791131	G/A	cg17519650	chr2:63277830	OTX1	-0.48	-5.42	-0.32	1.34e-7	Childhood ear infection;
CESC	cis	rs754466	0.580	rs1058198	chr10:79566632	G/A	cg17075019	chr10:79541650	NA	-0.83	-12.74	-0.62	2.47e-29	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs1499972	0.941	rs55864156	chr3:117664968	C/G	cg07612923	chr3:117604196	NA	0.89	7.41	0.41	1.71e-12	Schizophrenia;
CESC	cis	rs9303280	0.517	rs12939566	chr17:38038390	A/T	cg19468946	chr17:37922297	IKZF3	-0.41	-5.42	-0.32	1.31e-7	Self-reported allergy;
CESC	cis	rs28374715	0.681	rs28687846	chr15:41599902	C/T	cg20272979	chr15:41787780	ITPKA	0.43	5.14	0.3	5.29e-7	Ulcerative colitis;
CESC	cis	rs7707921	0.752	rs6882565	chr5:81356421	G/A	cg15871215	chr5:81402204	ATG10	-0.44	-5.82	-0.34	1.68e-8	Breast cancer;
CESC	cis	rs17711722	0.640	rs13237956	chr7:65318029	G/A	cg26939375	chr7:64535504	NA	0.76	10.85	0.55	6.19e-23	Calcium levels;
CESC	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.89	13.67	0.64	1.49e-32	Prudent dietary pattern;
CESC	cis	rs3747547	0.581	rs1928236	chr9:38132477	T/C	cg13774184	chr9:37916125	SHB	-0.65	-5.3	-0.31	2.4e-7	Metabolite levels (Dihydroxy docosatrienoic acid);
CESC	cis	rs13102973	0.931	rs12499856	chr4:135868573	C/T	cg14419869	chr4:135874104	NA	0.36	5.75	0.33	2.45e-8	Subjective well-being;
CESC	cis	rs2075371	0.965	rs2544216	chr7:133987902	G/A	cg20476274	chr7:133979776	SLC35B4	0.67	9.79	0.52	1.65e-19	Mean platelet volume;
CESC	cis	rs631288	0.793	rs7555913	chr1:146764442	G/T	cg25205988	chr1:146714368	CHD1L	1.13	6.67	0.38	1.51e-10	PR interval in Tripanosoma cruzi seropositivity;
CESC	cis	rs1538970	1.000	rs17395553	chr1:45864761	C/T	cg03146154	chr1:46216737	IPP	0.45	5.46	0.32	1.08e-7	Platelet count;
CESC	cis	rs10883723	0.810	rs7094751	chr10:104274818	G/A	cg22532475	chr10:104410764	TRIM8	-0.33	-5.68	-0.33	3.5e-8	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs1707322	0.721	rs6429575	chr1:46134216	G/C	cg03146154	chr1:46216737	IPP	0.82	11.52	0.58	3.64e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs10504229	0.683	rs34804288	chr8:58117570	C/A	cg21724239	chr8:58056113	NA	0.58	5.95	0.34	8.29e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs853679	0.517	rs4713150	chr6:28136212	G/A	cg23281280	chr6:28129359	ZNF389	0.56	7.62	0.42	4.55e-13	Depression;
CESC	cis	rs41271473	0.687	rs35637401	chr1:228883578	T/C	cg00850481	chr1:228891306	NA	-0.38	-5.15	-0.3	5e-7	Chronic lymphocytic leukemia;
CESC	cis	rs67478160	0.595	rs67768834	chr14:104221085	C/G	cg01849466	chr14:104193079	ZFYVE21	-0.49	-6.79	-0.38	7.51e-11	Schizophrenia;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg03584783	chr1:173836803	GAS5;SNORD76;SNORD75;SNORD77;ZBTB37	-0.5	-6.29	-0.36	1.28e-9	Ulcerative colitis;
CESC	cis	rs7666738	0.791	rs6851549	chr4:99029827	G/A	cg24818145	chr4:99064322	C4orf37	0.4	5.19	0.3	4.13e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04632724	chr15:102192393	TM2D3	0.56	6.34	0.36	9.99e-10	Gut microbiome composition (summer);
CESC	trans	rs3198697	0.663	rs12928099	chr16:15150505	C/A	cg04146151	chr16:2155961	PKD1	-0.61	-6.88	-0.39	4.4e-11	Triglycerides;
CESC	cis	rs8031584	0.958	rs7168641	chr15:31235452	G/A	cg08704250	chr15:31115839	NA	-0.62	-8.07	-0.44	2.4e-14	Huntington's disease progression;
CESC	cis	rs7412746	0.658	rs2275235	chr1:150730279	A/G	cg22823121	chr1:150693482	HORMAD1	0.47	6.49	0.37	4.09e-10	Melanoma;
CESC	cis	rs1580019	0.520	rs6945238	chr7:32646096	C/T	cg06627557	chr7:32535165	LSM5;AVL9	-0.89	-10.75	-0.55	1.27e-22	Cognitive ability;
CESC	cis	rs10463316	0.817	rs906679	chr5:150779302	T/A	cg03212797	chr5:150827313	SLC36A1	-0.47	-5.9	-0.34	1.1e-8	Metabolite levels (Pyroglutamine);
CESC	cis	rs6120849	0.754	rs11167253	chr20:33614449	T/C	cg06115741	chr20:33292138	TP53INP2	0.53	5.05	0.3	8.15e-7	Protein C levels;
CESC	cis	rs60871478	0.679	rs6962050	chr7:817201	A/G	cg27478167	chr7:817139	HEATR2	-0.5	-5.22	-0.31	3.56e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs4665809	1.000	rs4665298	chr2:26256378	G/A	cg25036284	chr2:26402008	FAM59B	-0.58	-6.72	-0.38	1.13e-10	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15100112	chr5:64331517	NA	0.56	6.71	0.38	1.2e-10	Gut microbiome composition (summer);
CESC	cis	rs6942407	0.546	rs2108272	chr7:86805399	C/T	cg02420886	chr7:86849541	C7orf23	0.52	5.03	0.3	9.11e-7	Food allergy;
CESC	cis	rs1538970	0.816	rs11211124	chr1:45962409	T/C	cg03146154	chr1:46216737	IPP	0.49	5.57	0.32	6.31e-8	Platelet count;
CESC	cis	rs780096	0.546	rs7563162	chr2:27631191	C/T	cg12648201	chr2:27665141	KRTCAP3	-0.34	-6.27	-0.36	1.49e-9	Total body bone mineral density;
CESC	cis	rs476633	0.691	rs28409265	chr15:41539404	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.48	-6.94	-0.39	2.95e-11	Glomerular filtration rate (creatinine);
CESC	trans	rs10028773	0.515	rs9994651	chr4:120587803	C/T	cg25214090	chr10:38739885	LOC399744	0.56	7.79	0.43	1.56e-13	Educational attainment;
CESC	cis	rs113835537	0.935	rs75863187	chr11:66443461	G/A	cg24851651	chr11:66362959	CCS	0.63	5.68	0.33	3.48e-8	Airway imaging phenotypes;
CESC	cis	rs959260	1.000	rs12604003	chr17:73399598	G/A	cg20590849	chr17:73267439	MIF4GD	-0.59	-6.55	-0.37	3.01e-10	Systemic lupus erythematosus;
CESC	cis	rs7949030	0.626	rs71490390	chr11:62329185	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.65	9.87	0.52	9.19e-20	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	trans	rs7615952	0.576	rs6804482	chr3:125815762	C/T	cg07211511	chr3:129823064	LOC729375	-0.57	-6.31	-0.36	1.15e-9	Blood pressure (smoking interaction);
CESC	cis	rs4423214	1.000	rs3750997	chr11:71158841	A/C	cg05163923	chr11:71159392	DHCR7	0.84	11.94	0.59	1.4e-26	Vitamin D levels;
CESC	cis	rs34779708	0.931	rs68039650	chr10:35385499	C/A	cg03585969	chr10:35415529	CREM	0.77	10.07	0.53	2.06e-20	Inflammatory bowel disease;Crohn's disease;
CESC	trans	rs875971	0.964	rs1643388	chr7:65844562	T/C	cg26939375	chr7:64535504	NA	0.47	6.06	0.35	4.69e-9	Aortic root size;
CESC	cis	rs79387448	0.592	rs76362690	chr2:102951477	A/G	cg09003973	chr2:102972529	NA	1.08	8.1	0.45	2.05e-14	Gut microbiota (bacterial taxa);
CESC	cis	rs4253772	0.515	rs9615969	chr22:46773592	C/G	cg09491104	chr22:46646882	C22orf40	-0.58	-5.15	-0.3	5.03e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs3857067	0.806	rs10212784	chr4:95101638	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.6	-9.01	-0.48	4.22e-17	QT interval;
CESC	cis	rs9788682	0.947	rs7169584	chr15:78822660	A/T	cg24631222	chr15:78858424	CHRNA5	0.76	9.77	0.51	1.88e-19	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs875971	0.862	rs778734	chr7:65814849	C/G	cg11764359	chr7:65958608	NA	0.79	11.86	0.59	2.52e-26	Aortic root size;
CESC	cis	rs854765	0.647	rs854808	chr17:18006634	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.6	8.35	0.46	3.95e-15	Total body bone mineral density;
CESC	cis	rs9611565	0.559	rs132761	chr22:42004371	C/T	cg06481639	chr22:41940642	POLR3H	0.61	6.26	0.36	1.56e-9	Vitiligo;
CESC	cis	rs4820539	1.000	rs2267002	chr22:23456702	T/C	cg14186256	chr22:23484241	RTDR1	0.83	15.26	0.68	3.56e-38	Bone mineral density;
CESC	cis	rs875971	0.862	rs6958294	chr7:65794796	C/A	cg10691866	chr7:65817282	TPST1	0.32	5.47	0.32	1.06e-7	Aortic root size;
CESC	cis	rs9549367	0.789	rs7999579	chr13:113879357	T/C	cg00898013	chr13:113819073	PROZ	-0.49	-6.87	-0.39	4.59e-11	Platelet distribution width;
CESC	trans	rs1814175	0.645	rs1851853	chr11:49953434	C/T	cg15704280	chr7:45808275	SEPT13	-1.01	-19.02	-0.76	1.83e-51	Height;
CESC	trans	rs2727020	0.658	rs4980440	chr11:49386017	C/T	cg03929089	chr4:120376271	NA	-0.81	-12.68	-0.61	4.09e-29	Coronary artery disease;
CESC	trans	rs7178375	1.000	rs9806159	chr15:31209654	G/T	cg04373760	chr16:53404718	NA	0.53	7.3	0.41	3.38e-12	Hypertriglyceridemia;
CESC	cis	rs7613875	0.543	rs34034116	chr3:49959156	C/A	cg24110177	chr3:50126178	RBM5	-0.52	-7.12	-0.4	1.04e-11	Body mass index;
CESC	cis	rs6696846	0.515	rs10900450	chr1:205106238	C/G	cg00857998	chr1:205179979	DSTYK	0.39	5.32	0.31	2.26e-7	Red blood cell count;
CESC	cis	rs1348850	0.561	rs1838890	chr2:178410938	C/A	cg23306229	chr2:178417860	TTC30B	0.85	7.9	0.44	7.47e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs6736093	0.796	rs34128716	chr2:112812856	C/G	cg12686935	chr2:112915763	FBLN7	-0.43	-5.65	-0.33	4.2e-8	Coronary artery disease;
CESC	cis	rs4481887	0.893	rs1934544	chr1:248505582	G/A	cg00666640	chr1:248458726	OR2T12	0.35	6.04	0.35	5.14e-9	Common traits (Other);
CESC	trans	rs17211056	0.744	rs2584281	chr18:73347313	C/T	cg15724534	chr2:211018363	C2orf67	-0.64	-6.15	-0.35	2.81e-9	Serum uric acid levels in response to allopurinol in gout;
CESC	cis	rs3806843	0.735	rs801168	chr5:140080298	A/G	cg16179182	chr5:140090404	VTRNA1-1	0.42	5.43	0.32	1.26e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs1256061	0.624	rs944046	chr14:64700299	G/A	cg21174375	chr14:64681225	SYNE2	0.48	6.38	0.36	7.86e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs736408	0.609	rs13087772	chr3:52782274	T/G	cg18404041	chr3:52824283	ITIH1	-0.41	-6.88	-0.39	4.42e-11	Bipolar disorder;
CESC	cis	rs73001065	0.901	rs73004959	chr19:19711139	C/T	cg03709012	chr19:19516395	GATAD2A	0.95	5.72	0.33	2.87e-8	LDL cholesterol;
CESC	cis	rs950169	0.810	rs2879976	chr15:85109578	G/A	cg17507749	chr15:85114479	UBE2QP1	0.56	6.35	0.36	9.37e-10	Schizophrenia;
CESC	cis	rs832540	0.966	rs252923	chr5:56205662	T/G	cg12311346	chr5:56204834	C5orf35	-0.46	-5.83	-0.34	1.59e-8	Coronary artery disease;
CESC	cis	rs1109430	0.661	rs12405601	chr1:210143254	T/C	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.91	6.32	0.36	1.09e-9	Orofacial clefts;
CESC	cis	rs1862618	0.671	rs2034244	chr5:56242774	T/C	cg24531977	chr5:56204891	C5orf35	0.7	9.51	0.5	1.21e-18	Initial pursuit acceleration;
CESC	cis	rs6582630	0.555	rs10880607	chr12:38508184	A/G	cg13010199	chr12:38710504	ALG10B	0.53	6.69	0.38	1.35e-10	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs3105593	1.000	rs3109895	chr15:50880560	A/T	cg08437265	chr15:50716283	USP8	0.42	5.49	0.32	9.52e-8	QT interval;
CESC	cis	rs6088590	1.000	rs6058111	chr20:33310999	T/C	cg24642439	chr20:33292090	TP53INP2	0.83	11.65	0.58	1.29e-25	Coronary artery disease;
CESC	cis	rs7666738	0.830	rs7662114	chr4:99019985	A/G	cg03676636	chr4:99064102	C4orf37	0.33	5.15	0.3	5.05e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs144345632	1	rs144345632	chr6:96886894	T/TA	cg18709589	chr6:96969512	KIAA0776	-0.53	-5.81	-0.34	1.75e-8	Facial morphology (factor 17, height of vermillion upper lip);
CESC	cis	rs6912958	0.559	rs451465	chr6:88043372	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.74	-11.47	-0.58	5.19e-25	Monocyte percentage of white cells;
CESC	cis	rs6951245	0.832	rs79808627	chr7:1092519	C/G	cg24642844	chr7:1081250	C7orf50	-0.67	-8.34	-0.46	3.98e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs698833	0.852	rs2241869	chr2:44549229	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	-0.56	-7.19	-0.4	6.51e-12	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs875971	0.830	rs28714531	chr7:65968237	G/A	cg18876405	chr7:65276391	NA	0.52	6.98	0.39	2.44e-11	Aortic root size;
CESC	cis	rs12136530	0.593	rs12125806	chr1:19734781	A/G	cg01832549	chr1:19774989	CAPZB	-0.44	-6.25	-0.36	1.64e-9	Lead levels in blood;
CESC	cis	rs6502050	0.835	rs6502065	chr17:80095642	T/C	cg11859384	chr17:80120422	CCDC57	-0.38	-5.14	-0.3	5.29e-7	Life satisfaction;
CESC	cis	rs73591976	0.539	rs12446198	chr16:68125972	G/A	cg26727032	chr16:67993705	SLC12A4	-0.53	-5.87	-0.34	1.31e-8	HDL cholesterol;
CESC	cis	rs8020095	0.571	rs7157418	chr14:67562815	G/T	cg19548862	chr14:67692701	FAM71D	-0.47	-5.63	-0.33	4.6e-8	Depression (quantitative trait);
CESC	cis	rs116095464	0.558	rs13356367	chr5:242395	C/T	cg22857025	chr5:266934	NA	-1.27	-18.37	-0.75	3.49e-49	Breast cancer;
CESC	cis	rs921968	0.565	rs1529382	chr2:219626489	C/T	cg02176678	chr2:219576539	TTLL4	-0.44	-7.74	-0.43	2.04e-13	Mean corpuscular hemoglobin concentration;
CESC	cis	rs7851660	0.844	rs12343182	chr9:100624259	G/C	cg13688889	chr9:100608707	NA	-0.63	-8.95	-0.48	6.32e-17	Strep throat;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg26815021	chr17:74733172	MIR636;MFSD11;SFRS2	0.48	6.28	0.36	1.36e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg07507251	chr3:52567010	NT5DC2	0.47	9.25	0.49	7.84e-18	Electroencephalogram traits;
CESC	cis	rs12586317	0.620	rs17103042	chr14:35575428	T/C	cg16230307	chr14:35515116	FAM177A1	0.92	9.94	0.52	5.62e-20	Psoriasis;
CESC	cis	rs6460942	0.591	rs7800823	chr7:12378697	G/T	cg20607287	chr7:12443886	VWDE	-0.42	-6.52	-0.37	3.48e-10	Coronary artery disease;
CESC	trans	rs1505368	0.817	rs6435701	chr2:213283512	A/G	cg00572323	chr16:29706151	QPRT	-0.38	-6.09	-0.35	3.89e-9	Symmetrical dimethylarginine levels;
CESC	cis	rs2832191	0.740	rs2832168	chr21:30463695	G/A	cg24692254	chr21:30365293	RNF160	1.0	17.21	0.73	4.53e-45	Dental caries;
CESC	cis	rs3782089	0.744	rs11545200	chr11:65319751	G/A	cg21890820	chr11:65308645	LTBP3	1.08	8.18	0.45	1.2e-14	Height;
CESC	cis	rs9916302	0.904	rs801419	chr17:37466327	A/G	cg15445000	chr17:37608096	MED1	-0.4	-6.38	-0.36	7.99e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs7586673	1.000	rs7586673	chr2:161923520	C/A	cg22496339	chr2:162101262	NA	0.51	6.83	0.39	5.73e-11	Intelligence (multi-trait analysis);
CESC	trans	rs656319	0.625	rs34427895	chr8:9875221	G/C	cg06636001	chr8:8085503	FLJ10661	-0.5	-6.07	-0.35	4.36e-9	Myopia (pathological);
CESC	cis	rs8114671	0.562	rs3746450	chr20:33508588	G/T	cg07148914	chr20:33460835	GGT7	0.45	5.9	0.34	1.09e-8	Height;
CESC	cis	rs875971	0.895	rs4145009	chr7:65726615	T/C	cg10691866	chr7:65817282	TPST1	0.33	5.52	0.32	8.15e-8	Aortic root size;
CESC	cis	rs9581857	0.547	rs74518675	chr13:27972180	A/G	cg01674679	chr13:27998804	GTF3A	-0.65	-5.12	-0.3	5.86e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
CESC	trans	rs7107217	1.000	rs1873872	chr11:129473993	A/T	cg24641125	chr21:40721130	HMGN1	-0.5	-6.71	-0.38	1.18e-10	Breast cancer;Type 2 diabetes;
CESC	cis	rs11112613	0.713	rs11112588	chr12:105943801	A/C	cg03607813	chr12:105948248	NA	0.64	7.77	0.43	1.69e-13	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CESC	cis	rs514406	0.698	rs522259	chr1:53365481	A/G	cg06600287	chr1:53387719	ECHDC2	-0.28	-5.04	-0.3	8.52e-7	Monocyte count;
CESC	cis	rs2228479	0.702	rs62056087	chr16:89920383	C/A	cg06558623	chr16:89946397	TCF25	1.15	8.39	0.46	2.95e-15	Skin colour saturation;
CESC	cis	rs1559088	0.948	rs2019603	chr19:33577367	C/T	cg17764715	chr19:33622953	WDR88	-0.52	-6.9	-0.39	3.8e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs12586317	0.620	rs28870452	chr14:35536878	C/A	cg16230307	chr14:35515116	FAM177A1	0.93	9.91	0.52	6.88e-20	Psoriasis;
CESC	cis	rs6988985	0.530	rs57268571	chr8:143942602	A/G	cg10324643	chr8:143916377	GML	0.34	5.08	0.3	7.11e-7	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
CESC	cis	rs9311474	1.000	rs1060330	chr3:52288945	T/C	cg25934064	chr3:52569026	NT5DC2	0.3	6.09	0.35	3.99e-9	Electroencephalogram traits;
CESC	cis	rs2204008	0.683	rs7305703	chr12:38138381	T/C	cg26384229	chr12:38710491	ALG10B	0.68	9.62	0.51	5.64e-19	Bladder cancer;
CESC	cis	rs6500395	1.000	rs9930199	chr16:48571263	A/G	cg04672837	chr16:48644449	N4BP1	0.49	6.08	0.35	4.07e-9	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs6752107	1.000	rs2289472	chr2:234182240	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.49	6.7	0.38	1.25e-10	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs1218582	0.772	rs12095061	chr1:154912968	A/T	cg03351412	chr1:154909251	PMVK	0.68	9.09	0.49	2.32e-17	Prostate cancer;
CESC	trans	rs17764205	0.929	rs8101372	chr19:3253830	T/C	cg27384338	chr17:2031545	SMG6	-0.64	-6.02	-0.35	5.87e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs6598955	0.724	rs7547520	chr1:26592310	C/T	cg00852783	chr1:26633632	UBXN11	0.43	6.27	0.36	1.45e-9	Obesity-related traits;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg05236530	chr12:7362357	PEX5	0.52	7.15	0.4	8.32e-12	Fibrinogen levels;
CESC	cis	rs9902453	1.000	rs9896062	chr17:28357047	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.62	-7.84	-0.43	1.1e-13	Coffee consumption (cups per day);
CESC	cis	rs6938	0.618	rs11072514	chr15:75221865	T/A	cg17294928	chr15:75287854	SCAMP5	0.5	6.48	0.37	4.49e-10	Breast cancer;
CESC	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg06877462	chr1:205807181	PM20D1	0.37	5.35	0.31	1.91e-7	Menarche (age at onset);
CESC	cis	rs4819052	1.000	rs13047688	chr21:46669290	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.82	10.41	0.54	1.63e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs9929218	1.000	rs13339591	chr16:68809273	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.61	-8.03	-0.44	3.1e-14	Colorectal cancer;
CESC	cis	rs9910055	0.762	rs11080007	chr17:42265442	A/G	cg19774624	chr17:42201019	HDAC5	0.65	9.27	0.49	6.87e-18	Total body bone mineral density;
CESC	cis	rs9287719	0.967	rs6432117	chr2:10749359	G/C	cg02196655	chr2:10830764	NOL10	-0.38	-5.79	-0.34	1.96e-8	Prostate cancer;
CESC	cis	rs9287719	0.967	rs6432121	chr2:10753804	G/C	cg02196655	chr2:10830764	NOL10	-0.37	-5.69	-0.33	3.39e-8	Prostate cancer;
CESC	cis	rs9649213	0.593	rs3801254	chr7:98010811	G/A	cg00277769	chr7:97922759	BAIAP2L1	-0.32	-5.32	-0.31	2.25e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs6701037	0.681	rs2285220	chr1:175130773	T/A	cg00321850	chr1:175162397	KIAA0040	-0.43	-6.19	-0.36	2.33e-9	Alcohol dependence;
CESC	cis	rs7927771	0.524	rs3758655	chr11:47703943	T/C	cg20307385	chr11:47447363	PSMC3	0.61	8.46	0.46	1.87e-15	Subjective well-being;
CESC	cis	rs514406	0.505	rs387436	chr1:53179376	C/T	cg27535305	chr1:53392650	SCP2	0.32	5.2	0.3	3.99e-7	Monocyte count;
CESC	cis	rs2404602	0.716	rs66754747	chr15:76828568	G/A	cg22467129	chr15:76604101	ETFA	-0.35	-5.31	-0.31	2.33e-7	Blood metabolite levels;
CESC	cis	rs8044868	0.586	rs12917999	chr16:72089451	T/C	cg01557791	chr16:72042693	DHODH	-0.42	-5.69	-0.33	3.29e-8	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24694326	chr1:151162561	VPS72	0.68	7.44	0.42	1.38e-12	Gut microbiome composition (summer);
CESC	cis	rs3785574	0.962	rs2665835	chr17:61903258	C/T	cg06420487	chr17:61919686	SMARCD2	0.44	5.3	0.31	2.43e-7	Height;
CESC	cis	rs763121	0.925	rs1043312	chr22:39131727	T/G	cg14440974	chr22:39074834	NA	-0.36	-5.24	-0.31	3.27e-7	Menopause (age at onset);
CESC	cis	rs11792861	0.781	rs2151426	chr9:111743797	A/C	cg13535736	chr9:111863775	C9orf5	-0.44	-5.76	-0.33	2.36e-8	Menarche (age at onset);
CESC	cis	rs6460942	0.915	rs10488158	chr7:12508894	C/T	cg06484146	chr7:12443880	VWDE	-0.76	-8.45	-0.46	1.97e-15	Coronary artery disease;
CESC	cis	rs17293817	0.589	rs2805511	chr10:1427710	G/T	cg04271617	chr10:1416546	ADARB2	0.3	5.05	0.3	8.36e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs10504229	0.906	rs73607869	chr8:58172665	G/T	cg05313129	chr8:58192883	C8orf71	-0.55	-6.37	-0.36	8.42e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs9549260	0.651	rs57735994	chr13:41226561	C/G	cg21288729	chr13:41239152	FOXO1	0.65	8.5	0.46	1.4e-15	Red blood cell count;
CESC	cis	rs7224314	1.000	rs62084082	chr17:65388046	A/G	cg01507342	chr17:65387096	PITPNC1	-0.48	-5.67	-0.33	3.82e-8	Diisocyanate-induced asthma;
CESC	cis	rs116095464	0.558	rs7713524	chr5:276200	C/T	cg22496380	chr5:211416	CCDC127	0.74	8.66	0.47	4.58e-16	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15392351	chr1:40563091	PPT1	0.59	6.39	0.37	7.25e-10	Gut microbiome composition (summer);
CESC	cis	rs6546550	0.901	rs897120	chr2:70160982	C/T	cg02498382	chr2:70120550	SNRNP27	0.4	6.82	0.39	6.25e-11	Prevalent atrial fibrillation;
CESC	cis	rs9916302	0.904	rs34363096	chr17:37594294	G/A	cg00129232	chr17:37814104	STARD3	-0.56	-7.35	-0.41	2.4e-12	Glomerular filtration rate (creatinine);
CESC	cis	rs9487051	0.703	rs351755	chr6:109538073	G/A	cg01475377	chr6:109611718	NA	0.39	5.8	0.34	1.87e-8	Reticulocyte fraction of red cells;
CESC	cis	rs1018836	0.828	rs10091275	chr8:91559751	A/G	cg16814680	chr8:91681699	NA	-0.64	-9.15	-0.49	1.58e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs863345	0.967	rs11265002	chr1:158489063	T/C	cg12129480	chr1:158549410	OR10X1	-0.3	-5.97	-0.34	7.49e-9	Pneumococcal bacteremia;
CESC	cis	rs6088590	0.561	rs6088528	chr20:33156742	G/A	cg08999081	chr20:33150536	PIGU	0.7	12.32	0.6	6.97e-28	Coronary artery disease;
CESC	cis	rs4450131	0.522	rs3781455	chr10:126347688	T/C	cg20435097	chr10:126320824	FAM53B	0.28	5.09	0.3	6.88e-7	White blood cell count (basophil);
CESC	cis	rs3026101	0.671	rs57085931	chr17:5305370	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.42	5.6	0.33	5.31e-8	Body mass index;
CESC	trans	rs7819412	0.654	rs34741518	chr8:10776860	A/C	cg15556689	chr8:8085844	FLJ10661	-0.61	-7.74	-0.43	2.1e-13	Triglycerides;
CESC	cis	rs6032067	0.852	rs6032053	chr20:43829935	G/T	cg10761708	chr20:43804764	PI3	0.52	6.32	0.36	1.07e-9	Blood protein levels;
CESC	cis	rs963731	0.649	rs78510010	chr2:39348662	T/C	cg04010122	chr2:39346883	SOS1	0.73	5.17	0.3	4.6e-7	Corticobasal degeneration;
CESC	cis	rs1218582	0.772	rs6699043	chr1:154913021	T/C	cg16680214	chr1:154839983	KCNN3	-0.45	-6.95	-0.39	2.84e-11	Prostate cancer;
CESC	cis	rs79349575	0.749	rs318093	chr17:46989354	A/G	cg16584676	chr17:46985605	UBE2Z	0.53	6.6	0.38	2.25e-10	Type 2 diabetes;
CESC	cis	rs904092	0.678	rs1230026	chr4:100185619	T/G	cg12011299	chr4:100065546	ADH4	0.52	6.09	0.35	3.95e-9	Alcohol dependence;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg25061772	chr1:87794525	LMO4	-0.49	-6.03	-0.35	5.59e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs826838	0.967	rs11183022	chr12:38652519	G/A	cg26384229	chr12:38710491	ALG10B	0.82	14.26	0.66	1.22e-34	Heart rate;
CESC	cis	rs7412746	0.658	rs3768015	chr1:150812954	C/T	cg17724175	chr1:150552817	MCL1	0.41	6.36	0.36	8.58e-10	Melanoma;
CESC	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg18402987	chr7:1209562	NA	0.74	8.54	0.46	1.07e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs12410462	0.502	rs77615958	chr1:227806083	T/C	cg04117972	chr1:227635322	NA	0.77	5.42	0.32	1.37e-7	Major depressive disorder;
CESC	cis	rs12142240	0.698	rs932816	chr1:46859749	G/A	cg00530320	chr1:46809349	NSUN4	0.6	8.27	0.45	6.54e-15	Menopause (age at onset);
CESC	cis	rs6662572	0.703	rs9429090	chr1:46502393	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.46	5.13	0.3	5.54e-7	Blood protein levels;
CESC	cis	rs12048904	0.505	rs6577209	chr1:101255080	A/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.53	6.53	0.37	3.4e-10	Multiple sclerosis;
CESC	cis	rs11122272	0.705	rs1416914	chr1:231533196	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.58	-8.05	-0.44	2.72e-14	Hemoglobin concentration;
CESC	cis	rs7618915	0.571	rs2251219	chr3:52584787	C/T	cg18404041	chr3:52824283	ITIH1	0.43	6.77	0.38	8.21e-11	Bipolar disorder;
CESC	cis	rs12956009	0.518	rs1434518	chr18:44833498	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.51	6.88	0.39	4.39e-11	Educational attainment (years of education);
CESC	cis	rs7618915	0.547	rs34537256	chr3:52657472	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.48	6.77	0.38	8.42e-11	Bipolar disorder;
CESC	cis	rs7605827	0.897	rs11684844	chr2:15640552	T/A	cg19274914	chr2:15703543	NA	0.36	6.32	0.36	1.13e-9	Educational attainment (years of education);
CESC	cis	rs6967414	1.000	rs6967414	chr7:6749758	G/A	cg09896999	chr7:6746977	ZNF12	-0.51	-6.93	-0.39	3.16e-11	Hematocrit;Hemoglobin concentration;
CESC	cis	rs2979489	0.891	rs4733495	chr8:30366883	A/G	cg26383811	chr8:30366931	RBPMS	0.79	10.64	0.55	3.1e-22	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CESC	cis	rs36229146	1	rs36229146	chr7:22784486	TTATATATAAATATATATATATATATA/T	cg05472934	chr7:22766657	IL6	0.91	11.59	0.58	2.11e-25	Eosinophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;
CESC	cis	rs79387448	0.655	rs17639215	chr2:102953444	G/A	cg09003973	chr2:102972529	NA	1.1	8.42	0.46	2.42e-15	Gut microbiota (bacterial taxa);
CESC	cis	rs9581857	0.615	rs9581849	chr13:28005782	G/T	cg01674679	chr13:27998804	GTF3A	-0.71	-5.67	-0.33	3.72e-8	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
CESC	cis	rs72945132	0.882	rs947781	chr11:70212755	G/A	cg00319359	chr11:70116639	PPFIA1	0.73	7.04	0.4	1.67e-11	Coronary artery disease;
CESC	cis	rs7216064	0.655	rs8078543	chr17:66037251	G/T	cg12091567	chr17:66097778	LOC651250	0.87	11.51	0.58	3.91e-25	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs34779708	0.733	rs7914468	chr10:35548071	G/A	cg03585969	chr10:35415529	CREM	0.55	6.37	0.36	8.28e-10	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs9926296	0.605	rs6500449	chr16:89856393	T/C	cg03388025	chr16:89894329	SPIRE2	0.41	7.9	0.44	7.6e-14	Vitiligo;
CESC	cis	rs10392	0.543	rs3752292	chr20:37570475	G/A	cg27552599	chr20:37590471	DHX35	0.38	5.74	0.33	2.62e-8	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
CESC	cis	rs7223966	0.729	rs2003549	chr17:62008437	C/T	cg11494091	chr17:61959527	GH2	0.4	5.19	0.3	4.29e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs9325144	0.560	rs2387924	chr12:38662883	A/G	cg26384229	chr12:38710491	ALG10B	-0.62	-9.6	-0.51	6.43e-19	Morning vs. evening chronotype;
CESC	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg07157834	chr1:205819609	PM20D1	0.81	13.02	0.62	2.83e-30	Menarche (age at onset);
CESC	trans	rs9391997	0.568	rs7454545	chr6:434348	A/G	cg18341491	chr13:38174258	POSTN	0.32	6.18	0.35	2.37e-9	Chronic lymphocytic leukemia;
CESC	cis	rs9649213	0.593	rs6969234	chr7:97987986	T/C	cg08684580	chr7:98029266	BAIAP2L1	-0.35	-5.8	-0.34	1.85e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs6540559	0.673	rs4556361	chr1:210019654	C/G	cg25204440	chr1:209979598	IRF6	-0.56	-5.81	-0.34	1.81e-8	Cleft lip with or without cleft palate;
CESC	cis	rs898097	0.812	rs56274787	chr17:80862682	C/T	cg10494973	chr17:80897199	TBCD	0.51	5.91	0.34	1.07e-8	Breast cancer;
CESC	cis	rs3749237	0.964	rs34522271	chr3:49808517	A/G	cg03060546	chr3:49711283	APEH	0.64	7.52	0.42	8.74e-13	Resting heart rate;
CESC	cis	rs1962636	1	rs1962636	chr16:22064395	A/C	cg07571928	chr16:22020630	C16orf52	0.32	5.49	0.32	9.5e-8	Schizophrenia;
CESC	cis	rs13191362	1.000	rs13204013	chr6:163002480	T/A	cg14584255	chr6:163149320	PACRG;PARK2	0.5	5.17	0.3	4.64e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs1018836	0.923	rs9693182	chr8:91621876	T/C	cg16814680	chr8:91681699	NA	-0.72	-10.07	-0.53	2.11e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg01163298	chr12:49393408	DDN	-0.47	-6.46	-0.37	4.89e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs2243480	0.764	rs2460423	chr7:65601216	A/T	cg12463550	chr7:65579703	CRCP	0.74	5.75	0.33	2.42e-8	Diabetic kidney disease;
CESC	cis	rs9443645	0.527	rs36128361	chr6:79684340	C/G	cg05283184	chr6:79620031	NA	-0.35	-5.11	-0.3	6.1e-7	Intelligence (multi-trait analysis);
CESC	cis	rs763014	0.898	rs916416	chr16:632198	T/A	cg09263875	chr16:632152	PIGQ	0.67	11.24	0.57	3.15e-24	Height;
CESC	trans	rs2727020	0.701	rs7949044	chr11:49597334	C/T	cg03929089	chr4:120376271	NA	-0.73	-9.16	-0.49	1.46e-17	Coronary artery disease;
CESC	cis	rs1707322	0.963	rs12145287	chr1:46325002	C/G	cg03146154	chr1:46216737	IPP	0.78	10.75	0.55	1.29e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs1862618	0.802	rs4389648	chr5:56103602	A/G	cg24549020	chr5:56110836	MAP3K1	0.66	7.5	0.42	9.87e-13	Initial pursuit acceleration;
CESC	cis	rs35306767	0.903	rs1341741	chr10:888073	A/G	cg26597838	chr10:835615	NA	0.85	8.99	0.48	4.92e-17	Eosinophil percentage of granulocytes;
CESC	cis	rs35306767	0.903	rs12763396	chr10:927357	C/A	cg20503657	chr10:835505	NA	0.78	8.23	0.45	8.52e-15	Eosinophil percentage of granulocytes;
CESC	cis	rs1927790	0.667	rs7981845	chr13:96942533	C/T	cg02571835	chr13:96230311	CLDN10	-0.4	-5.73	-0.33	2.74e-8	Body mass index;
CESC	cis	rs4805272	0.626	rs12610050	chr19:29331324	A/T	cg14983838	chr19:29218262	NA	0.45	6.11	0.35	3.51e-9	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
CESC	cis	rs1008375	1.000	rs3815413	chr4:17654648	T/C	cg15017067	chr4:17643749	FAM184B	0.38	5.35	0.31	1.86e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs2832191	1.000	rs8131214	chr21:30483386	T/G	cg24692254	chr21:30365293	RNF160	-0.74	-10.95	-0.56	2.98e-23	Dental caries;
CESC	cis	rs13118159	0.651	rs4974599	chr4:1314430	A/C	cg02018176	chr4:1364513	KIAA1530	0.45	6.22	0.36	1.88e-9	Longevity;
CESC	trans	rs163030	0.902	rs388924	chr5:76738247	A/G	cg26150533	chr8:82396069	FABP4	-0.39	-6.0	-0.35	6.49e-9	Caudate nucleus volume;
CESC	cis	rs9457247	1.000	rs398278	chr6:167388169	A/G	cg25258033	chr6:167368657	RNASET2	0.36	5.32	0.31	2.16e-7	Crohn's disease;
CESC	cis	rs35110281	0.807	rs4818850	chr21:45028071	T/G	cg21573476	chr21:45109991	RRP1B	-0.46	-6.37	-0.36	8.55e-10	Mean corpuscular volume;
CESC	cis	rs3020736	0.500	rs4147641	chr22:42482502	C/G	cg15557168	chr22:42548783	NA	0.45	6.57	0.37	2.72e-10	Autism spectrum disorder or schizophrenia;
CESC	cis	rs4423214	0.798	rs12224205	chr11:71180992	A/G	cg05163923	chr11:71159392	DHCR7	-0.72	-8.81	-0.48	1.65e-16	Vitamin D levels;
CESC	cis	rs4925386	0.681	rs2427294	chr20:60927257	G/A	cg24112000	chr20:60950667	NA	-0.46	-5.77	-0.33	2.18e-8	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs6540559	1.000	rs2235373	chr1:209963803	G/A	cg25204440	chr1:209979598	IRF6	0.66	8.3	0.45	5.31e-15	Cleft lip with or without cleft palate;
CESC	trans	rs877282	0.898	rs11253338	chr10:759559	C/T	cg22713356	chr15:30763199	NA	0.84	7.7	0.43	2.79e-13	Uric acid levels;
CESC	cis	rs6570726	0.935	rs408768	chr6:145871735	A/G	cg23711669	chr6:146136114	FBXO30	0.8	11.92	0.59	1.67e-26	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02105261	chr17:1945138	DPH1;OVCA2	0.55	6.12	0.35	3.33e-9	Gut microbiome composition (summer);
CESC	cis	rs2637266	1.000	rs2579747	chr10:78327759	C/T	cg18941641	chr10:78392320	NA	0.41	7.48	0.42	1.13e-12	Pulmonary function;
CESC	cis	rs1059312	1.000	rs9738216	chr12:129281788	C/T	cg09035930	chr12:129282057	SLC15A4	0.76	10.75	0.55	1.32e-22	Systemic lupus erythematosus;
CESC	cis	rs9640161	0.830	rs13307276	chr7:150061525	T/C	cg10018233	chr7:150070692	REPIN1	0.38	5.87	0.34	1.32e-8	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs896854	0.654	rs4735337	chr8:95973465	T/C	cg13393036	chr8:95962371	TP53INP1	-0.5	-10.56	-0.54	5.46e-22	Type 2 diabetes;
CESC	cis	rs12971120	1.000	rs2278162	chr18:72175814	A/G	cg26446133	chr18:72167187	CNDP2	-0.77	-10.02	-0.52	2.97e-20	Refractive error;
CESC	cis	rs1215050	0.740	rs1648568	chr4:98957619	A/G	cg05340658	chr4:99064831	C4orf37	-0.54	-7.3	-0.41	3.3e-12	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs9311474	0.508	rs17052256	chr3:52593119	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.49	7.16	0.4	8.18e-12	Electroencephalogram traits;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg12815271	chr11:65625153	CFL1	-0.53	-6.76	-0.38	8.55e-11	Asthma;
CESC	cis	rs6426558	0.537	rs2813969	chr1:227404082	T/C	cg10327440	chr1:227177885	CDC42BPA	0.5	6.36	0.36	9.03e-10	Neutrophil percentage of white cells;
CESC	cis	rs2832191	0.703	rs2853827	chr21:30443596	T/C	cg24692254	chr21:30365293	RNF160	1.0	17.4	0.73	9.35e-46	Dental caries;
CESC	cis	rs4862750	0.832	rs10007858	chr4:187877492	A/G	cg03452623	chr4:187889614	NA	-0.88	-15.6	-0.69	2.23e-39	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24941513	chr1:220267397	IARS2	0.57	6.15	0.35	2.87e-9	Gut microbiome composition (summer);
CESC	trans	rs2727020	0.718	rs1404366	chr11:49415899	T/A	cg03929089	chr4:120376271	NA	-0.69	-8.16	-0.45	1.32e-14	Coronary artery disease;
CESC	cis	rs736408	0.688	rs2239551	chr3:52818579	A/G	cg13284614	chr3:52569169	NT5DC2;LOC440957	-0.36	-6.13	-0.35	3.17e-9	Bipolar disorder;
CESC	trans	rs17685	0.735	rs11763339	chr7:75761541	T/C	cg19862616	chr7:65841803	NCRNA00174	0.85	12.41	0.61	3.51e-28	Coffee consumption;Coffee consumption (cups per day);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08115172	chr1:1990868	PRKCZ	-0.55	-6.26	-0.36	1.54e-9	Gut microbiome composition (summer);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg04822973	chr14:68086311	ARG2	-0.41	-6.06	-0.35	4.67e-9	Gambling;
CESC	cis	rs4889855	0.505	rs8082303	chr17:78605012	A/G	cg16591659	chr17:78472290	NA	-0.34	-5.49	-0.32	9.53e-8	Fractional excretion of uric acid;
CESC	cis	rs7927771	0.965	rs3817335	chr11:47643891	T/A	cg20307385	chr11:47447363	PSMC3	-0.5	-6.16	-0.35	2.7e-9	Subjective well-being;
CESC	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	-0.5	-5.86	-0.34	1.38e-8	Prudent dietary pattern;
CESC	cis	rs926938	0.583	rs12401670	chr1:115244337	C/T	cg12756093	chr1:115239321	AMPD1	-0.49	-5.79	-0.34	1.94e-8	Autism;
CESC	cis	rs12477438	0.798	rs1993230	chr2:99686079	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-10.57	-0.54	5.22e-22	Chronic sinus infection;
CESC	cis	rs10129255	0.957	rs7493713	chr14:107191922	T/C	cg23076370	chr14:107095027	NA	-0.47	-5.93	-0.34	9.55e-9	Kawasaki disease;
CESC	cis	rs1348850	0.574	rs4893835	chr2:178442592	T/C	cg23306229	chr2:178417860	TTC30B	0.59	5.8	0.34	1.86e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs9291683	0.566	rs13115776	chr4:10040189	C/G	cg00071950	chr4:10020882	SLC2A9	0.82	14.01	0.65	9.72e-34	Bone mineral density;
CESC	cis	rs1348850	0.519	rs13034781	chr2:178523550	C/A	cg22681709	chr2:178499509	PDE11A	-0.49	-7.08	-0.4	1.29e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs6912958	0.525	rs242262	chr6:88018057	A/C	cg04972856	chr6:88032051	C6orf162;GJB7	0.38	6.09	0.35	3.87e-9	Monocyte percentage of white cells;
CESC	trans	rs208520	0.802	rs4710314	chr6:66883656	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.92	-11.49	-0.58	4.62e-25	Exhaled nitric oxide output;
CESC	cis	rs9457247	0.663	rs9295384	chr6:167448113	T/A	cg23791538	chr6:167370224	RNASET2	-0.56	-7.61	-0.42	4.78e-13	Crohn's disease;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg00365569	chr17:17876108	TOM1L2;LRRC48	0.52	6.71	0.38	1.15e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs9916302	0.904	rs1077715	chr17:37683548	A/T	cg20243544	chr17:37824526	PNMT	0.49	6.17	0.35	2.55e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs2836974	0.666	rs4818015	chr21:40675493	A/C	cg11644478	chr21:40555479	PSMG1	0.81	12.04	0.59	6.61e-27	Cognitive function;
CESC	cis	rs3733585	0.699	rs12498956	chr4:9950705	G/T	cg00071950	chr4:10020882	SLC2A9	-0.71	-12.0	-0.59	8.62e-27	Cleft plate (environmental tobacco smoke interaction);
CESC	trans	rs2727020	0.521	rs7114564	chr11:49571231	C/T	cg03929089	chr4:120376271	NA	0.7	7.99	0.44	4.25e-14	Coronary artery disease;
CESC	cis	rs2243480	1.000	rs6949812	chr7:65387101	G/A	cg13147721	chr7:65941812	NA	-0.86	-8.15	-0.45	1.48e-14	Diabetic kidney disease;
CESC	cis	rs62158211	0.955	rs7556815	chr2:114085785	G/A	cg17784749	chr2:114082611	LOC440839	0.74	8.46	0.46	1.88e-15	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;
CESC	cis	rs61931739	0.500	rs34167298	chr12:34534338	G/A	cg19457237	chr12:34500585	NA	-0.37	-5.08	-0.3	6.97e-7	Morning vs. evening chronotype;
CESC	cis	rs9359856	0.510	rs4053618	chr6:90459454	G/A	cg13799429	chr6:90582589	CASP8AP2	0.69	7.7	0.43	2.73e-13	Bipolar disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00244634	chr12:100661419	SCYL2;DEPDC4	0.61	7.33	0.41	2.83e-12	Gut microbiome composition (summer);
CESC	cis	rs3096299	0.967	rs2911255	chr16:89487137	C/T	cg08392591	chr16:89556376	ANKRD11	0.44	5.7	0.33	3.23e-8	Multiple myeloma (IgH translocation);
CESC	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg13880726	chr7:1868755	MAD1L1	0.51	6.75	0.38	9.19e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs2576037	0.796	rs2571030	chr18:44573854	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.44	5.64	0.33	4.28e-8	Personality dimensions;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03118206	chr6:138482933	KIAA1244	0.58	6.55	0.37	2.9e-10	Gut microbiome composition (summer);
CESC	cis	rs2274273	1.000	rs1009977	chr14:55603002	T/G	cg04306507	chr14:55594613	LGALS3	0.31	6.2	0.36	2.15e-9	Protein biomarker;
CESC	cis	rs801193	0.901	rs4273746	chr7:66301111	C/T	cg11764359	chr7:65958608	NA	-0.63	-7.6	-0.42	5.19e-13	Aortic root size;
CESC	cis	rs11763147	1	rs11763147	chr7:65326821	C/T	cg06456125	chr7:65229604	NA	-0.45	-5.83	-0.34	1.61e-8	Corneal structure;
CESC	cis	rs514406	0.929	rs557920	chr1:53338757	C/A	cg24675658	chr1:53192096	ZYG11B	-0.57	-7.01	-0.4	1.98e-11	Monocyte count;
CESC	cis	rs4689592	0.619	rs2359011	chr4:7066052	T/G	cg06697600	chr4:7070879	GRPEL1	-0.48	-7.22	-0.41	5.58e-12	Monocyte percentage of white cells;
CESC	cis	rs12541335	0.639	rs4871994	chr8:22206038	G/A	cg27266060	chr8:22091797	NA	0.37	7.37	0.41	2.15e-12	Hypertriglyceridemia;
CESC	cis	rs1005277	0.505	rs7069702	chr10:38247359	G/T	cg25517755	chr10:38738941	LOC399744	0.39	5.04	0.3	8.59e-7	Extrinsic epigenetic age acceleration;
CESC	cis	rs9948	0.867	rs17119598	chr2:97486315	A/G	cg01990225	chr2:97406019	LMAN2L	0.74	5.42	0.32	1.34e-7	Erectile dysfunction and prostate cancer treatment;
CESC	cis	rs5769765	0.908	rs9616216	chr22:50318927	T/C	cg26441486	chr22:50317300	CRELD2	0.48	5.78	0.33	2.08e-8	Schizophrenia;
CESC	cis	rs7909074	1.000	rs10900128	chr10:45393201	G/T	cg05187965	chr10:45406764	TMEM72	-0.33	-5.13	-0.3	5.61e-7	Mean corpuscular volume;
CESC	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.55	0.37	2.91e-10	Prudent dietary pattern;
CESC	cis	rs6831352	0.918	rs7670638	chr4:100059807	G/C	cg12011299	chr4:100065546	ADH4	-0.59	-6.59	-0.38	2.35e-10	Alcohol dependence;
CESC	cis	rs2075371	0.764	rs1643034	chr7:134006176	A/G	cg20476274	chr7:133979776	SLC35B4	0.59	8.31	0.45	5e-15	Mean platelet volume;
CESC	cis	rs546131	0.890	rs485845	chr11:34830389	G/T	cg11058730	chr11:34937778	PDHX;APIP	-0.43	-5.16	-0.3	4.9e-7	Lung disease severity in cystic fibrosis;
CESC	cis	rs796364	0.951	rs1105964	chr2:201000776	T/A	cg23649088	chr2:200775458	C2orf69	-0.54	-5.39	-0.31	1.53e-7	Schizophrenia;
CESC	cis	rs3741404	0.825	rs2845597	chr11:63954370	G/A	cg04317338	chr11:64019027	PLCB3	0.48	5.77	0.33	2.16e-8	Platelet count;
CESC	cis	rs4919087	0.748	rs701815	chr10:98975893	A/C	cg25902810	chr10:99078978	FRAT1	-0.5	-5.74	-0.33	2.54e-8	Monocyte count;
CESC	cis	rs4835473	0.932	rs4585249	chr4:144902326	A/G	cg25736465	chr4:144833511	NA	-0.39	-6.11	-0.35	3.59e-9	Immature fraction of reticulocytes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27314324	chr1:112476724	KCND3	-0.45	-6.06	-0.35	4.69e-9	Gut microbiome composition (summer);
CESC	cis	rs2425143	1.000	rs55761608	chr20:34344226	A/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.67	5.92	0.34	1.01e-8	Blood protein levels;
CESC	cis	rs864537	0.646	rs1773542	chr1:167432949	T/C	cg22356347	chr1:167427500	CD247	-0.37	-7.65	-0.43	3.84e-13	Celiac disease or Rheumatoid arthritis;Celiac disease;
CESC	cis	rs28489187	0.643	rs233054	chr1:85840191	T/G	cg16011679	chr1:85725395	C1orf52	0.53	6.21	0.36	2.08e-9	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	cis	rs4144743	1.000	rs4541130	chr17:45321037	G/A	cg18085866	chr17:45331354	ITGB3	-0.65	-7.07	-0.4	1.39e-11	Body mass index;
CESC	trans	rs2727020	0.704	rs4144700	chr11:49370834	C/A	cg03929089	chr4:120376271	NA	-0.79	-11.97	-0.59	1.09e-26	Coronary artery disease;
CESC	cis	rs1005277	0.522	rs1208767	chr10:38042295	G/T	cg25427524	chr10:38739819	LOC399744	-0.64	-9.43	-0.5	2.24e-18	Extrinsic epigenetic age acceleration;
CESC	cis	rs780096	0.526	rs11126999	chr2:27670307	G/A	cg22903471	chr2:27725779	GCKR	-0.55	-7.77	-0.43	1.69e-13	Total body bone mineral density;
CESC	cis	rs1124376	1.000	rs73038113	chr3:20139025	T/A	cg05072819	chr3:20081367	KAT2B	0.54	5.93	0.34	9.47e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs1059312	0.808	rs2306683	chr12:129299675	C/G	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.86	-13.01	-0.62	2.89e-30	Systemic lupus erythematosus;
CESC	trans	rs9467711	0.606	rs9358935	chr6:26369587	A/G	cg06606381	chr12:133084897	FBRSL1	-0.76	-6.86	-0.39	4.71e-11	Autism spectrum disorder or schizophrenia;
CESC	cis	rs4665809	1.000	rs2053367	chr2:26293413	T/C	cg25036284	chr2:26402008	FAM59B	-0.58	-6.79	-0.38	7.5e-11	Gut microbiome composition (summer);
CESC	cis	rs4330281	0.715	rs4908940	chr3:17797271	A/C	cg20981856	chr3:17787350	NA	0.35	5.05	0.3	8.36e-7	Schizophrenia;
CESC	cis	rs2295499	0.610	rs12502642	chr4:2714023	T/C	cg27239842	chr4:2403781	ZFYVE28	-0.34	-5.67	-0.33	3.67e-8	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
CESC	cis	rs7551222	0.749	rs7532236	chr1:204561617	A/G	cg20240347	chr1:204465584	NA	0.27	5.57	0.32	6.33e-8	Schizophrenia;
CESC	trans	rs2115172	0.836	rs4835799	chr5:122762229	A/G	cg09031165	chr17:17586474	RAI1	0.46	6.08	0.35	4.14e-9	Weight;
CESC	cis	rs7503807	0.967	rs8064502	chr17:78562434	C/A	cg09596252	chr17:78655493	RPTOR	0.46	6.29	0.36	1.27e-9	Obesity;
CESC	cis	rs1008375	0.932	rs12500947	chr4:17603424	C/T	cg16339924	chr4:17578868	LAP3	0.68	8.73	0.47	2.9e-16	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09188840	chr17:4699533	PSMB6	0.58	6.2	0.36	2.16e-9	Gut microbiome composition (summer);
CESC	cis	rs8177179	0.967	rs4287912	chr3:133437778	A/G	cg16262614	chr3:133464971	TF	0.38	7.48	0.42	1.11e-12	Iron status biomarkers (transferrin levels);
CESC	cis	rs1218582	0.741	rs7544528	chr1:154844585	C/T	cg03351412	chr1:154909251	PMVK	0.59	7.57	0.42	6.1e-13	Prostate cancer;
CESC	trans	rs1814175	0.588	rs10466497	chr11:49864381	A/T	cg11707556	chr5:10655725	ANKRD33B	-0.42	-6.2	-0.36	2.17e-9	Height;
CESC	trans	rs17685	0.712	rs869805	chr7:75688596	C/T	cg19862616	chr7:65841803	NCRNA00174	0.83	12.38	0.61	4.45e-28	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs9487051	0.676	rs13210693	chr6:109598964	A/G	cg21918786	chr6:109611834	NA	0.38	5.58	0.32	5.93e-8	Reticulocyte fraction of red cells;
CESC	cis	rs72781680	0.679	rs718138	chr2:23976324	G/A	cg08917208	chr2:24149416	ATAD2B	0.57	5.63	0.33	4.62e-8	Lymphocyte counts;
CESC	cis	rs2463822	1.000	rs2463822	chr11:62103420	T/C	cg06239285	chr11:62104954	ASRGL1	0.99	8.95	0.48	6.5e-17	Chronic obstructive pulmonary disease-related biomarkers;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg15687780	chr3:184294839	EPHB3	-0.49	-6.61	-0.38	2.1e-10	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs9733	0.519	rs11204717	chr1:150709129	T/A	cg04414720	chr1:150670196	GOLPH3L	0.61	8.59	0.47	7.48e-16	Tonsillectomy;
CESC	cis	rs11871801	0.846	rs4792923	chr17:40690118	G/C	cg21433558	chr17:40837037	CNTNAP1	-0.45	-5.1	-0.3	6.33e-7	Crohn's disease;
CESC	cis	rs4481887	0.927	rs4523548	chr1:248472399	G/T	cg00666640	chr1:248458726	OR2T12	0.35	5.93	0.34	9.43e-9	Common traits (Other);
CESC	cis	rs9479482	0.967	rs1543547	chr6:150346532	T/C	cg03788504	chr6:150331562	NA	-0.3	-5.81	-0.34	1.79e-8	Alopecia areata;
CESC	cis	rs11098499	0.955	rs7685268	chr4:120162188	G/A	cg24375607	chr4:120327624	NA	0.43	5.24	0.31	3.34e-7	Corneal astigmatism;
CESC	cis	rs3780486	0.801	rs10971424	chr9:33138775	T/C	cg13443165	chr9:33130375	B4GALT1	0.44	6.37	0.36	8.54e-10	IgG glycosylation;
CESC	cis	rs7084402	0.967	rs1649045	chr10:60327047	T/C	cg07615347	chr10:60278583	BICC1	0.6	9.38	0.5	3.01e-18	Refractive error;
CESC	cis	rs11077998	0.903	rs8064554	chr17:80501093	A/G	cg10255544	chr17:80519551	FOXK2	0.54	8.77	0.47	2.16e-16	Reticulocyte fraction of red cells;
CESC	cis	rs2228479	0.717	rs11649210	chr16:89807233	C/G	cg00800038	chr16:89945340	TCF25	-0.65	-6.51	-0.37	3.8e-10	Skin colour saturation;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16105075	chr15:62682529	NA	0.56	6.04	0.35	5.25e-9	Gut microbiome composition (summer);
CESC	trans	rs61931739	0.500	rs11053282	chr12:34561151	T/C	cg26384229	chr12:38710491	ALG10B	0.72	10.84	0.55	6.43e-23	Morning vs. evening chronotype;
CESC	trans	rs61931739	0.500	rs7965421	chr12:34523624	G/T	cg13010199	chr12:38710504	ALG10B	0.5	6.42	0.37	6.3e-10	Morning vs. evening chronotype;
CESC	cis	rs4803468	0.967	rs892044	chr19:41903671	A/G	cg09537434	chr19:41945824	ATP5SL	-1.02	-18.28	-0.75	7.49e-49	Height;
CESC	cis	rs1005277	0.522	rs289650	chr10:37975505	G/T	cg25427524	chr10:38739819	LOC399744	-0.61	-8.92	-0.48	7.65e-17	Extrinsic epigenetic age acceleration;
CESC	cis	rs3105593	0.933	rs3105592	chr15:50870271	C/T	cg08437265	chr15:50716283	USP8	-0.41	-5.41	-0.32	1.4e-7	QT interval;
CESC	cis	rs9649213	0.593	rs6465664	chr7:97921834	A/G	cg08684580	chr7:98029266	BAIAP2L1	-0.34	-5.41	-0.32	1.44e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs9926296	0.585	rs6500450	chr16:89858024	A/G	cg21285383	chr16:89894308	SPIRE2	0.3	5.39	0.31	1.6e-7	Vitiligo;
CESC	cis	rs4746818	1.000	rs906217	chr10:70954661	T/C	cg11621586	chr10:70884670	VPS26A	0.85	8.42	0.46	2.46e-15	Left atrial antero-posterior diameter;
CESC	cis	rs17253792	0.822	rs78429067	chr14:56092551	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.76	5.39	0.31	1.56e-7	Putamen volume;
CESC	cis	rs4665809	0.618	rs7579199	chr2:26266496	G/A	cg26314531	chr2:26401878	FAM59B	-0.62	-6.92	-0.39	3.46e-11	Gut microbiome composition (summer);
CESC	cis	rs9733	0.596	rs3087960	chr1:150620569	C/G	cg22823121	chr1:150693482	HORMAD1	0.48	7.0	0.4	2.04e-11	Tonsillectomy;
CESC	cis	rs60871478	0.679	rs6962050	chr7:817201	A/G	cg05535760	chr7:792225	HEATR2	1.01	11.54	0.58	3.23e-25	Cerebrospinal P-tau181p levels;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg15864317	chr7:57485543	NA	0.38	6.24	0.36	1.77e-9	Fibrinogen levels;
CESC	cis	rs7772486	0.743	rs62433835	chr6:146032688	C/G	cg23711669	chr6:146136114	FBXO30	-0.82	-12.04	-0.59	6.45e-27	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7666738	0.753	rs17483788	chr4:98985623	G/A	cg05340658	chr4:99064831	C4orf37	0.8	12.42	0.61	3.31e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7264396	0.563	rs2425090	chr20:34304783	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.88	-10.64	-0.55	3.06e-22	Total cholesterol levels;
CESC	cis	rs4665809	0.878	rs35709953	chr2:26334997	G/A	cg26314531	chr2:26401878	FAM59B	0.7	7.48	0.42	1.12e-12	Gut microbiome composition (summer);
CESC	cis	rs1048238	0.506	rs698889	chr1:16267040	A/C	cg21385522	chr1:16154831	NA	-0.43	-5.33	-0.31	2.1e-7	Systolic blood pressure;
CESC	cis	rs1008375	0.966	rs6832387	chr4:17697546	G/T	cg04450456	chr4:17643702	FAM184B	0.36	5.15	0.3	5.16e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs763121	0.889	rs2267390	chr22:38889657	C/T	cg06022373	chr22:39101656	GTPBP1	0.81	11.83	0.59	3.18e-26	Menopause (age at onset);
CESC	cis	rs7666738	0.830	rs7673880	chr4:99057262	A/G	cg18180107	chr4:99064573	C4orf37	0.4	5.18	0.3	4.41e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs9929218	0.817	rs3114404	chr16:68722096	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.82	-10.05	-0.53	2.5e-20	Colorectal cancer;
CESC	cis	rs782590	0.574	rs12991445	chr2:55675939	C/T	cg18811423	chr2:55921094	PNPT1	0.43	5.95	0.34	8.68e-9	Metabolic syndrome;
CESC	cis	rs2645424	0.530	rs1293303	chr8:11720227	C/G	cg21281001	chr8:11725306	CTSB	-0.52	-6.48	-0.37	4.57e-10	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);
CESC	cis	rs7429990	0.965	rs13075795	chr3:48024629	A/T	cg11946769	chr3:48343235	NME6	-0.44	-5.37	-0.31	1.75e-7	Educational attainment (years of education);
CESC	cis	rs7481584	1.000	rs12798150	chr11:3019260	C/T	cg25174290	chr11:3078921	CARS	-0.43	-5.32	-0.31	2.16e-7	Calcium levels;
CESC	cis	rs7618915	0.547	rs13064064	chr3:52657002	T/C	cg17372223	chr3:52568218	NT5DC2	0.42	6.35	0.36	9.4e-10	Bipolar disorder;
CESC	cis	rs870825	0.616	rs28607131	chr4:185651617	A/G	cg04058563	chr4:185651563	MLF1IP	0.63	6.96	0.39	2.74e-11	Blood protein levels;
CESC	cis	rs637571	0.607	rs589253	chr11:65693080	G/A	cg04055107	chr11:65626734	MUS81;CFL1	0.48	5.84	0.34	1.53e-8	Eosinophil percentage of white cells;
CESC	cis	rs2066819	1.000	rs11575231	chr12:56744445	T/C	cg26714650	chr12:56694279	CS	-1.39	-9.17	-0.49	1.37e-17	Psoriasis vulgaris;
CESC	cis	rs6426558	0.537	rs648877	chr1:227283614	A/G	cg10327440	chr1:227177885	CDC42BPA	0.48	5.86	0.34	1.34e-8	Neutrophil percentage of white cells;
CESC	cis	rs801193	1.000	rs2055682	chr7:66260289	A/G	cg11764359	chr7:65958608	NA	0.64	8.12	0.45	1.79e-14	Aortic root size;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg04846540	chr14:35183905	CFL2	-0.48	-6.35	-0.36	9.28e-10	Fibrinogen levels;
CESC	cis	rs7586879	1.000	rs1865687	chr2:25112885	G/A	cg01884057	chr2:25150051	NA	0.28	5.12	0.3	5.86e-7	Body mass index;
CESC	cis	rs2274273	0.615	rs17672058	chr14:55673394	C/T	cg04306507	chr14:55594613	LGALS3	0.31	5.24	0.31	3.34e-7	Protein biomarker;
CESC	cis	rs6688613	0.545	rs10800270	chr1:166827602	A/T	cg07049167	chr1:166818506	POGK	0.42	5.1	0.3	6.34e-7	Refractive astigmatism;
CESC	cis	rs1448094	0.511	rs7959372	chr12:86160680	T/C	cg02569458	chr12:86230093	RASSF9	0.48	7.58	0.42	5.99e-13	Major depressive disorder;
CESC	cis	rs2017305	0.834	rs12242235	chr10:70782556	A/T	cg01024728	chr10:70782572	NA	0.56	5.38	0.31	1.67e-7	Depression (quantitative trait);
CESC	cis	rs919433	0.783	rs787980	chr2:198239225	C/T	cg03934865	chr2:198174659	NA	0.44	6.27	0.36	1.49e-9	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs10781543	0.763	rs10781539	chr9:139320965	G/A	cg14169450	chr9:139327907	INPP5E	0.5	7.7	0.43	2.79e-13	Monocyte percentage of white cells;
CESC	cis	rs6120849	0.754	rs6119560	chr20:33606977	G/C	cg24642439	chr20:33292090	TP53INP2	0.68	6.77	0.38	8.46e-11	Protein C levels;
CESC	cis	rs79057730	0.599	rs79272827	chr7:807015	C/G	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.88	7.39	0.41	1.91e-12	Initial pursuit acceleration;
CESC	cis	rs6831352	0.879	rs56272995	chr4:100060882	A/G	cg13256891	chr4:100009986	ADH5	-0.75	-8.21	-0.45	9.89e-15	Alcohol dependence;
CESC	cis	rs2836974	0.931	rs13047663	chr21:40708818	C/T	cg17971929	chr21:40555470	PSMG1	0.93	12.53	0.61	1.32e-28	Cognitive function;
CESC	cis	rs6723226	0.572	rs176404	chr2:32638846	T/C	cg02381751	chr2:32503542	YIPF4	-0.53	-6.94	-0.39	2.95e-11	Intelligence (multi-trait analysis);
CESC	cis	rs3762637	1.000	rs16845530	chr3:122142447	T/C	cg24169773	chr3:122142474	KPNA1	-0.53	-6.36	-0.36	8.82e-10	LDL cholesterol levels;
CESC	cis	rs11785693	0.862	rs11786595	chr8:5001621	T/G	cg26367366	chr8:4980734	NA	0.81	7.76	0.43	1.88e-13	Neuroticism (multi-trait analysis);Neuroticism;
CESC	cis	rs698833	0.852	rs698823	chr2:44720947	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.48	6.02	0.35	5.68e-9	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs317689	0.690	rs604168	chr12:69671158	C/T	cg20891283	chr12:69753455	YEATS4	0.47	5.12	0.3	5.88e-7	Response to diuretic therapy;
CESC	cis	rs854765	0.647	rs854808	chr17:18006634	C/T	cg04398451	chr17:18023971	MYO15A	-0.8	-11.86	-0.59	2.52e-26	Total body bone mineral density;
CESC	cis	rs13118159	0.742	rs34947293	chr4:1335034	T/C	cg16405210	chr4:1374714	KIAA1530	-0.6	-8.29	-0.45	5.79e-15	Longevity;
CESC	cis	rs514406	0.893	rs2897561	chr1:53388747	C/A	cg08859206	chr1:53392774	SCP2	-0.57	-7.41	-0.41	1.68e-12	Monocyte count;
CESC	cis	rs72781680	0.716	rs2712061	chr2:24026411	G/A	cg08917208	chr2:24149416	ATAD2B	0.61	5.99	0.35	6.76e-9	Lymphocyte counts;
CESC	cis	rs1552244	1.000	rs33917318	chr3:10067797	T/C	cg00166722	chr3:10149974	C3orf24	0.5	6.31	0.36	1.19e-9	Alzheimer's disease;
CESC	cis	rs4466137	0.553	rs16898	chr5:82986149	T/C	cg16102102	chr5:83017553	HAPLN1	-0.33	-5.21	-0.3	3.78e-7	Prostate cancer;
CESC	cis	rs2288073	0.801	rs10175668	chr2:24367275	G/A	cg06627628	chr2:24431161	ITSN2	-0.71	-9.18	-0.49	1.31e-17	Venous thromboembolism (SNP x SNP interaction);
CESC	cis	rs13118159	0.771	rs13117476	chr4:1334721	A/G	cg20887711	chr4:1340912	KIAA1530	0.55	7.82	0.43	1.24e-13	Longevity;
CESC	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg04234412	chr22:24373322	LOC391322	-0.73	-11.4	-0.57	9.02e-25	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs12586317	0.511	rs11540758	chr14:35498485	C/T	cg05294307	chr14:35346193	BAZ1A	-0.51	-5.4	-0.31	1.49e-7	Psoriasis;
CESC	cis	rs4481887	0.745	rs4540687	chr1:248476099	C/G	cg00666640	chr1:248458726	OR2T12	0.36	6.12	0.35	3.33e-9	Common traits (Other);
CESC	cis	rs9486719	0.843	rs3849198	chr6:97036539	C/A	cg06623918	chr6:96969491	KIAA0776	-0.8	-8.21	-0.45	9.56e-15	Migraine;Coronary artery disease;
CESC	cis	rs6860806	0.661	rs2136188	chr5:131577514	A/G	cg09877947	chr5:131593287	PDLIM4	-0.47	-6.08	-0.35	4.23e-9	Breast cancer;
CESC	cis	rs12765878	1.000	rs9325507	chr10:105645622	C/T	cg24587175	chr10:105670608	OBFC1	0.32	5.17	0.3	4.58e-7	Coronary artery disease;
CESC	cis	rs7829975	0.840	rs572366	chr8:8578794	A/T	cg15556689	chr8:8085844	FLJ10661	0.43	5.49	0.32	9.41e-8	Mood instability;
CESC	cis	rs6460942	0.591	rs7804805	chr7:12332066	C/G	cg02935154	chr7:12443704	VWDE	-0.53	-5.5	-0.32	9.01e-8	Coronary artery disease;
CESC	cis	rs4268898	0.552	rs11125444	chr2:24367205	G/T	cg20701182	chr2:24300061	SF3B14	-0.39	-5.47	-0.32	1.03e-7	Asthma;
CESC	cis	rs9910055	0.659	rs7214540	chr17:42256604	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.5	7.5	0.42	9.57e-13	Total body bone mineral density;
CESC	trans	rs60843830	1.000	rs2126129	chr2:212548	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.65	7.98	0.44	4.51e-14	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs9581857	0.556	rs9581864	chr13:28041567	T/C	cg22138327	chr13:27999177	GTF3A	0.65	7.23	0.41	5.33e-12	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
CESC	cis	rs9612	1.000	rs346524	chr19:44260572	T/C	cg08581076	chr19:44259116	C19orf61	0.52	6.19	0.36	2.33e-9	Exhaled nitric oxide output;
CESC	cis	rs2075371	1.000	rs1421485	chr7:133985181	C/T	cg00033643	chr7:134001901	SLC35B4	0.44	5.6	0.33	5.4e-8	Mean platelet volume;
CESC	cis	rs7937682	0.824	rs577044	chr11:111490420	G/T	cg09085632	chr11:111637200	PPP2R1B	-0.92	-14.14	-0.66	3.34e-34	Primary sclerosing cholangitis;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg21515243	chr18:21033072	RIOK3	-0.47	-6.49	-0.37	4.16e-10	Height;
CESC	cis	rs896854	1.000	rs896854	chr8:95960511	T/C	cg16049864	chr8:95962084	TP53INP1	-0.72	-13.04	-0.63	2.36e-30	Type 2 diabetes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22736280	chr8:95565249	KIAA1429	0.59	6.55	0.37	2.94e-10	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06463913	chr11:207296	BET1L;RIC8A	0.51	6.03	0.35	5.35e-9	Gut microbiome composition (summer);
CESC	cis	rs1364505	0.575	rs2341821	chr7:132014934	C/G	cg03295361	chr7:131864608	PLXNA4	-0.38	-5.05	-0.3	8.22e-7	Venous thromboembolism (SNP x SNP interaction);
CESC	cis	rs7267979	1.000	rs6050630	chr20:25430745	A/G	cg08601574	chr20:25228251	PYGB	0.38	5.64	0.33	4.4e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7116495	1.000	rs949325	chr11:71729656	A/G	cg10381502	chr11:71823885	C11orf51	-0.66	-5.61	-0.33	5.06e-8	Severe influenza A (H1N1) infection;
CESC	cis	rs1448094	0.512	rs7309500	chr12:86249647	C/T	cg00310523	chr12:86230176	RASSF9	0.35	5.39	0.31	1.59e-7	Major depressive disorder;
CESC	cis	rs35306767	0.903	rs35637113	chr10:874149	G/C	cg26597838	chr10:835615	NA	0.9	9.35	0.5	3.76e-18	Eosinophil percentage of granulocytes;
CESC	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.51	0.37	3.65e-10	Prudent dietary pattern;
CESC	cis	rs425277	0.606	rs451061	chr1:2075068	C/G	cg12718519	chr1:2058417	PRKCZ	0.24	5.14	0.3	5.23e-7	Height;
CESC	cis	rs79349575	0.721	rs1008834	chr17:46968008	G/C	cg16584676	chr17:46985605	UBE2Z	0.54	6.6	0.38	2.2e-10	Type 2 diabetes;
CESC	cis	rs698833	0.819	rs12053381	chr2:44570804	C/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.55	6.86	0.39	4.84e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs7666738	0.830	rs6825211	chr4:98807698	A/T	cg05340658	chr4:99064831	C4orf37	0.77	11.6	0.58	2.01e-25	Colonoscopy-negative controls vs population controls;
CESC	cis	rs561341	1.000	rs483301	chr17:30293398	G/T	cg19193384	chr17:30244184	NA	-0.71	-6.6	-0.38	2.17e-10	Hip circumference adjusted for BMI;
CESC	cis	rs3857067	0.806	rs7654919	chr4:95136164	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.6	-9.15	-0.49	1.55e-17	QT interval;
CESC	cis	rs4689388	0.890	rs6838400	chr4:6295427	C/G	cg00701064	chr4:6280414	WFS1	0.68	11.71	0.58	8.68e-26	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg08865097	chr6:119256162	MCM9	-0.49	-6.02	-0.35	5.91e-9	Ulcerative colitis;
CESC	cis	rs6762477	0.505	rs17304079	chr3:50085153	A/G	cg24110177	chr3:50126178	RBM5	-0.43	-5.06	-0.3	7.7300000000000005e-07	Menarche (age at onset);
CESC	cis	rs9549260	0.709	rs12585870	chr13:41199487	A/C	cg21288729	chr13:41239152	FOXO1	0.64	8.27	0.45	6.6e-15	Red blood cell count;
CESC	cis	rs12477438	0.520	rs2964969	chr2:99782811	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.85	15.73	0.69	8.16e-40	Chronic sinus infection;
CESC	cis	rs9303401	0.703	rs9909925	chr17:57210069	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.59	-7.82	-0.43	1.28e-13	Cognitive test performance;
CESC	cis	rs7659604	0.676	rs6855269	chr4:122697418	T/G	cg06713675	chr4:122721982	EXOSC9	-0.43	-5.99	-0.35	6.69e-9	Type 2 diabetes;
CESC	cis	rs9322193	0.923	rs10782311	chr6:149943728	A/G	cg07701084	chr6:150067640	NUP43	0.43	6.0	0.35	6.52e-9	Lung cancer;
CESC	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg21548813	chr6:291882	DUSP22	0.74	10.14	0.53	1.21e-20	Menopause (age at onset);
CESC	cis	rs6460942	0.597	rs4721107	chr7:12535105	T/G	cg20607287	chr7:12443886	VWDE	-0.72	-7.71	-0.43	2.51e-13	Coronary artery disease;
CESC	trans	rs2727020	0.658	rs7120136	chr11:49384358	A/C	cg03929089	chr4:120376271	NA	-0.81	-12.68	-0.61	4.19e-29	Coronary artery disease;
CESC	cis	rs6714710	0.580	rs55886305	chr2:98495661	T/G	cg26665480	chr2:98280029	ACTR1B	0.56	7.86	0.43	9.67e-14	Posterior cortical atrophy and Alzheimer's disease;
CESC	cis	rs2576037	0.583	rs9947131	chr18:44534769	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.77	12.35	0.6	5.48e-28	Personality dimensions;
CESC	cis	rs1044826	0.642	rs295482	chr3:139229264	A/T	cg00490450	chr3:139108681	COPB2	-0.44	-5.43	-0.32	1.31e-7	Obesity-related traits;
CESC	trans	rs2832077	0.527	rs2738953	chr21:30238363	G/C	cg14791747	chr16:20752902	THUMPD1	-0.47	-6.56	-0.37	2.78e-10	Cognitive test performance;
CESC	cis	rs654950	1.000	rs600401	chr1:41984658	C/T	cg06885757	chr1:42089581	HIVEP3	0.47	7.42	0.41	1.6e-12	Airway imaging phenotypes;
CESC	trans	rs79976124	0.837	rs75346757	chr6:66648386	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.76	8.71	0.47	3.31e-16	Type 2 diabetes;
CESC	trans	rs9325144	0.555	rs2387843	chr12:38711203	T/C	cg23762105	chr12:34175262	ALG10	-0.49	-6.51	-0.37	3.8e-10	Morning vs. evening chronotype;
CESC	cis	rs9486719	0.690	rs2092094	chr6:96844123	G/C	cg06623918	chr6:96969491	KIAA0776	0.78	7.39	0.41	1.89e-12	Migraine;Coronary artery disease;
CESC	cis	rs12042938	0.507	rs1765777	chr1:231731742	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.59	-8.53	-0.46	1.16e-15	Neuranatomic and neurocognitive phenotypes;
CESC	cis	rs4253772	0.626	rs9615960	chr22:46752307	G/A	cg18190219	chr22:46762943	CELSR1	-0.73	-6.33	-0.36	1.01e-9	LDL cholesterol;Cholesterol, total;
CESC	cis	rs62005083	1.000	rs62006777	chr14:74635749	T/G	cg05179529	chr14:74551516	LIN52;ALDH6A1	0.64	5.38	0.31	1.63e-7	Mean corpuscular volume;
CESC	cis	rs1006703	0.544	rs55673593	chr17:3834179	T/C	cg06463185	chr17:3833770	ATP2A3	-0.56	-6.01	-0.35	6.17e-9	Glucose homeostasis traits;
CESC	cis	rs11785400	0.793	rs13255558	chr8:143748080	C/T	cg24634471	chr8:143751801	JRK	0.46	5.71	0.33	3.03e-8	Schizophrenia;
CESC	cis	rs2075371	1.000	rs2241334	chr7:133979225	C/G	cg11752832	chr7:134001865	SLC35B4	0.54	6.98	0.39	2.33e-11	Mean platelet volume;
CESC	cis	rs793571	0.590	rs673813	chr15:59077171	A/T	cg05156742	chr15:59063176	FAM63B	0.63	8.19	0.45	1.08e-14	Schizophrenia;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg07257649	chr6:4776641	CDYL	-0.48	-6.13	-0.35	3.21e-9	Ulcerative colitis;
CESC	trans	rs7827545	0.545	rs6988000	chr8:135559534	C/T	cg24633756	chr6:26577808	NA	-0.53	-6.17	-0.35	2.52e-9	Hypertension (SNP x SNP interaction);
CESC	cis	rs453301	0.686	rs11785634	chr8:8892597	G/T	cg15556689	chr8:8085844	FLJ10661	-0.49	-6.0	-0.35	6.54e-9	Joint mobility (Beighton score);
CESC	cis	rs35306767	0.903	rs11813210	chr10:919796	G/A	cg10556349	chr10:835070	NA	0.59	5.59	0.32	5.54e-8	Eosinophil percentage of granulocytes;
CESC	cis	rs9916302	0.851	rs12947620	chr17:37605364	T/C	cg00129232	chr17:37814104	STARD3	-0.54	-7.14	-0.4	9.08e-12	Glomerular filtration rate (creatinine);
CESC	cis	rs7474896	0.609	rs1830612	chr10:37999883	A/G	cg00409905	chr10:38381863	ZNF37A	-0.44	-5.08	-0.3	6.97e-7	Obesity (extreme);
CESC	cis	rs73206853	0.764	rs7953794	chr12:111081197	A/G	cg12870014	chr12:110450643	ANKRD13A	0.66	5.94	0.34	8.88e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs7927771	0.965	rs35184771	chr11:47475189	G/T	cg20307385	chr11:47447363	PSMC3	-0.52	-6.1	-0.35	3.66e-9	Subjective well-being;
CESC	cis	rs270601	0.770	rs932019	chr5:131599370	T/C	cg04518342	chr5:131593106	PDLIM4	0.42	6.42	0.37	6.39e-10	Acylcarnitine levels;
CESC	cis	rs2486288	0.656	rs11629807	chr15:45547037	T/C	cg21132104	chr15:45694354	SPATA5L1	-0.54	-6.55	-0.37	2.96e-10	Glomerular filtration rate;
CESC	cis	rs10927875	0.722	rs1763606	chr1:16338282	A/G	cg22431228	chr1:16359049	CLCNKA	-0.47	-7.82	-0.43	1.22e-13	Dilated cardiomyopathy;
CESC	cis	rs597539	0.652	rs514833	chr11:68657734	C/T	cg21963583	chr11:68658836	MRPL21	0.38	5.47	0.32	1.03e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs27434	0.605	rs39840	chr5:96120054	G/C	cg16492584	chr5:96139282	ERAP1	-0.5	-5.97	-0.34	7.61e-9	Ankylosing spondylitis;
CESC	cis	rs708547	0.647	rs4864609	chr4:57878141	T/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.47	6.61	0.38	2.11e-10	Response to bleomycin (chromatid breaks);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg03988161	chr6:122720663	HSF2	-0.49	-6.4	-0.37	7.01e-10	Ulcerative colitis;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg12032620	chr15:43802735	TP53BP1	-0.43	-6.06	-0.35	4.68e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs9660180	0.868	rs12567685	chr1:1806647	T/C	cg05132306	chr1:1846340	CALML6	-0.3	-6.3	-0.36	1.26e-9	Body mass index;
CESC	cis	rs10751667	1.000	rs7396798	chr11:970510	G/T	cg06064525	chr11:970664	AP2A2	-0.37	-6.55	-0.37	2.92e-10	Alzheimer's disease (late onset);
CESC	cis	rs7551222	0.752	rs6594016	chr1:204539462	G/A	cg20240347	chr1:204465584	NA	-0.28	-5.64	-0.33	4.38e-8	Schizophrenia;
CESC	cis	rs7539624	0.898	rs7554857	chr1:223891552	T/C	cg10100437	chr1:223903862	CAPN2	-0.41	-6.02	-0.35	5.77e-9	Schizophrenia;
CESC	cis	rs4664304	0.903	rs72957576	chr2:160754132	A/C	cg03641300	chr2:160917029	PLA2R1	-0.48	-6.85	-0.39	5.03e-11	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs17253792	0.822	rs74412558	chr14:56054311	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.84	5.66	0.33	3.95e-8	Putamen volume;
CESC	cis	rs6088580	0.602	rs6058064	chr20:33086622	A/G	cg24642439	chr20:33292090	TP53INP2	0.5	6.59	0.38	2.42e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs1372520	0.684	rs356188	chr4:90691537	T/C	cg15133208	chr4:90757351	SNCA	0.4	5.17	0.3	4.51e-7	Neuroticism;
CESC	cis	rs10927875	0.632	rs6677321	chr1:16149301	A/C	cg05821634	chr1:16164109	FLJ37453	0.35	5.04	0.3	8.7e-7	Dilated cardiomyopathy;
CESC	cis	rs477895	0.713	rs1059440	chr11:63991801	C/T	cg18225595	chr11:63971243	STIP1	-0.5	-5.11	-0.3	6.24e-7	Mean platelet volume;
CESC	cis	rs9837602	1.000	rs62285462	chr3:99769834	T/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.51	7.29	0.41	3.59e-12	Breast cancer;
CESC	cis	rs2463822	0.858	rs2513077	chr11:62105925	A/G	cg06239285	chr11:62104954	ASRGL1	-0.86	-8.85	-0.48	1.27e-16	Chronic obstructive pulmonary disease-related biomarkers;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17543123	chr19:30155994	PLEKHF1	-0.6	-7.2	-0.4	6.13e-12	Gut microbiome composition (summer);
CESC	cis	rs425277	0.538	rs169037	chr1:2095582	G/T	cg16545954	chr1:2118288	C1orf86	0.36	7.02	0.4	1.81e-11	Height;
CESC	cis	rs6942756	0.713	rs692597	chr7:129132554	T/G	cg02491457	chr7:128862824	NA	-0.55	-7.69	-0.43	2.86e-13	White matter hyperintensity burden;
CESC	cis	rs12500824	0.564	rs116609504	chr4:77315062	C/A	cg20311846	chr4:77356250	SHROOM3	0.38	7.35	0.41	2.4e-12	Coronary artery disease;
CESC	cis	rs9287719	0.967	rs6721739	chr2:10751246	G/T	cg02196655	chr2:10830764	NOL10	0.35	5.27	0.31	2.79e-7	Prostate cancer;
CESC	cis	rs1023500	0.551	rs133371	chr22:42465574	G/A	cg04733989	chr22:42467013	NAGA	0.79	12.05	0.59	5.98e-27	Schizophrenia;
CESC	cis	rs8077577	0.895	rs16960990	chr17:18108601	A/G	cg16794390	chr17:18148240	FLII	0.41	5.77	0.33	2.23e-8	Obesity-related traits;
CESC	cis	rs6815814	0.950	rs73236615	chr4:38786869	G/T	cg02016764	chr4:38805732	TLR1	-0.64	-7.93	-0.44	6.35e-14	Breast cancer;
CESC	trans	rs4596713	0.507	rs9314865	chr9:71801495	A/G	cg16512924	chr15:28394682	HERC2	0.48	6.11	0.35	3.47e-9	Headache;
CESC	cis	rs694739	0.595	rs11606015	chr11:64136877	C/G	cg23796481	chr11:64053134	BAD;GPR137	0.58	7.09	0.4	1.23e-11	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CESC	cis	rs9733	0.744	rs2089081	chr1:150800117	T/C	cg13175981	chr1:150552382	MCL1	0.5	6.98	0.39	2.34e-11	Tonsillectomy;
CESC	cis	rs7959452	0.590	rs11177619	chr12:69758871	G/A	cg22834771	chr12:69754056	YEATS4	-0.48	-6.38	-0.37	7.7e-10	Blood protein levels;
CESC	cis	rs11577318	0.853	rs7416513	chr1:26647949	G/C	cg00813993	chr1:26644493	UBXN11;CD52	-0.39	-6.26	-0.36	1.51e-9	Granulocyte percentage of myeloid white cells;
CESC	cis	rs9612	0.718	rs346531	chr19:44239927	T/C	cg08581076	chr19:44259116	C19orf61	0.42	5.08	0.3	7.05e-7	Exhaled nitric oxide output;
CESC	cis	rs10504229	1.000	rs59549824	chr8:58186205	A/C	cg05313129	chr8:58192883	C8orf71	-0.54	-6.27	-0.36	1.48e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs7123876	0.553	rs10898868	chr11:72431679	A/G	cg03713592	chr11:72463424	ARAP1	0.53	6.22	0.36	1.93e-9	Body mass index;
CESC	cis	rs559928	0.597	rs11600667	chr11:63976183	C/T	cg18225595	chr11:63971243	STIP1	0.65	5.71	0.33	2.95e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CESC	cis	rs763121	0.853	rs5757234	chr22:39072686	C/T	cg06544989	chr22:39130855	UNC84B	0.52	9.99	0.52	3.63e-20	Menopause (age at onset);
CESC	cis	rs739401	0.611	rs391188	chr11:3047634	G/A	cg08508325	chr11:3079039	CARS	-0.51	-9.99	-0.52	3.69e-20	Longevity;
CESC	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.58	7.5	0.42	9.36e-13	Prudent dietary pattern;
CESC	cis	rs6088590	0.687	rs6088582	chr20:33286798	G/A	cg08999081	chr20:33150536	PIGU	0.65	10.69	0.55	1.99e-22	Coronary artery disease;
CESC	cis	rs61935443	0.673	rs11107770	chr12:95275147	C/T	cg21533806	chr12:95267307	NA	-0.57	-7.04	-0.4	1.62e-11	Schizophrenia;
CESC	cis	rs6032067	0.929	rs2868238	chr20:43826993	C/G	cg11264863	chr20:43835661	SEMG1	0.49	5.29	0.31	2.5e-7	Blood protein levels;
CESC	cis	rs677665	0.537	rs6688233	chr1:9335745	A/G	cg25755851	chr1:9335794	NA	-0.97	-14.38	-0.66	4.88e-35	Eosinophil percentage of white cells;
CESC	cis	rs10489202	0.632	rs202273	chr1:167919963	A/G	cg24449463	chr1:168025552	DCAF6	-0.46	-6.2	-0.36	2.1e-9	Schizophrenia;
CESC	cis	rs367615	0.918	rs10051855	chr5:108859958	G/A	cg17395555	chr5:108820864	NA	0.55	8.19	0.45	1.13e-14	Colorectal cancer (SNP x SNP interaction);
CESC	trans	rs5756813	0.782	rs3171656	chr22:38172213	G/A	cg19894588	chr14:64061835	NA	-0.7	-8.74	-0.47	2.75e-16	Optic cup area;Vertical cup-disc ratio;
CESC	cis	rs4808199	0.895	rs4808196	chr19:19476520	G/A	cg03709012	chr19:19516395	GATAD2A	1.14	13.02	0.62	2.66e-30	Nonalcoholic fatty liver disease;
CESC	cis	rs829880	0.858	rs733180	chr12:98842588	C/T	cg25150519	chr12:98850993	NA	0.8	11.83	0.59	3.36e-26	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7772486	0.790	rs2247666	chr6:146220409	C/A	cg23711669	chr6:146136114	FBXO30	0.94	13.73	0.64	9.31e-33	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1568889	1.000	rs11826837	chr11:28322566	C/G	cg06544937	chr11:28130018	METT5D1;KIF18A	-0.75	-10.69	-0.55	2.02e-22	Bipolar disorder;
CESC	cis	rs2996428	0.561	rs2275833	chr1:3745721	C/T	cg13057898	chr1:3703894	LRRC47	0.38	5.64	0.33	4.37e-8	Red cell distribution width;
CESC	trans	rs10776614	0.799	rs1445148	chr10:49763709	T/A	cg19218067	chr2:181235115	NA	0.5	6.1	0.35	3.7e-9	Self-employment;
CESC	cis	rs11711311	1.000	rs7622403	chr3:113472434	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	-0.7	-9.94	-0.52	5.6e-20	IgG glycosylation;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg10345337	chr14:65569751	MAX	-0.46	-6.48	-0.37	4.47e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg09033563	chr22:24373618	LOC391322	0.52	7.05	0.4	1.52e-11	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs896854	0.967	rs10956933	chr8:95967688	C/G	cg23172400	chr8:95962367	TP53INP1	-0.47	-9.92	-0.52	6.36e-20	Type 2 diabetes;
CESC	cis	rs12940923	0.655	rs2526372	chr17:56440526	G/A	cg12560992	chr17:57184187	TRIM37	0.64	5.64	0.33	4.42e-8	Circulating myeloperoxidase levels (plasma);
CESC	cis	rs13191362	0.872	rs13213421	chr6:163203805	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.93	9.06	0.49	2.99e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs7903847	0.642	rs2297668	chr10:99160046	C/T	cg20016023	chr10:99160130	RRP12	-0.3	-5.2	-0.3	4.02e-7	Granulocyte percentage of myeloid white cells;
CESC	cis	rs4972806	0.849	rs1542180	chr2:177028767	C/T	cg14324370	chr2:177042789	NA	0.43	6.14	0.35	3.05e-9	IgG glycosylation;
CESC	cis	rs9487051	0.652	rs13210424	chr6:109598737	G/A	cg21918786	chr6:109611834	NA	-0.37	-5.53	-0.32	7.81e-8	Reticulocyte fraction of red cells;
CESC	cis	rs7100689	0.646	rs9420370	chr10:82073248	C/T	cg00277334	chr10:82204260	NA	-0.61	-8.08	-0.44	2.26e-14	Post bronchodilator FEV1;
CESC	cis	rs478304	0.651	rs11600918	chr11:65511965	A/G	cg27068330	chr11:65405492	SIPA1	-0.45	-5.45	-0.32	1.15e-7	Acne (severe);
CESC	cis	rs875971	0.862	rs2901152	chr7:65765004	G/A	cg19163074	chr7:65112434	INTS4L2	0.4	5.16	0.3	4.86e-7	Aortic root size;
CESC	cis	rs3126085	0.935	rs6587647	chr1:152192631	C/T	cg26876637	chr1:152193138	HRNR	0.48	5.5	0.32	8.93e-8	Atopic dermatitis;
CESC	cis	rs2842992	0.789	rs9355748	chr6:160194882	G/A	cg26839252	chr6:160211577	TCP1;MRPL18	0.47	5.38	0.31	1.61e-7	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs6430585	0.583	rs730005	chr2:136582694	T/C	cg07169764	chr2:136633963	MCM6	1.35	20.15	0.78	2.09e-55	Corneal structure;
CESC	cis	rs3096299	0.617	rs2353030	chr16:89405827	C/T	cg16743903	chr16:89593216	SPG7	0.41	5.09	0.3	6.9e-7	Multiple myeloma (IgH translocation);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14104172	chr9:79074807	GCNT1	-0.58	-6.67	-0.38	1.48e-10	Gut microbiome composition (summer);
CESC	cis	rs2228479	0.850	rs2283565	chr16:89827556	G/T	cg14709524	chr16:89940631	TCF25	0.91	6.75	0.38	9.26e-11	Skin colour saturation;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg25367318	chr6:138725211	HEBP2	-0.42	-6.19	-0.36	2.27e-9	Gambling;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19969113	chr12:118810441	TAOK3	0.58	6.77	0.38	8.29e-11	Gut microbiome composition (summer);
CESC	cis	rs4718428	0.705	rs28648401	chr7:66367132	T/C	cg12165864	chr7:66369176	NA	-0.67	-7.74	-0.43	2.09e-13	Corneal structure;
CESC	cis	rs4148883	0.504	rs4147544	chr4:100134514	G/T	cg13256891	chr4:100009986	ADH5	-0.49	-6.3	-0.36	1.22e-9	Alcohol dependence;
CESC	cis	rs61931739	0.500	rs7484658	chr12:34515879	A/G	cg06521331	chr12:34319734	NA	-0.37	-5.09	-0.3	6.85e-7	Morning vs. evening chronotype;
CESC	cis	rs9291683	0.575	rs3756223	chr4:10105797	C/T	cg00071950	chr4:10020882	SLC2A9	0.58	8.69	0.47	3.84e-16	Bone mineral density;
CESC	cis	rs1832871	0.711	rs7770047	chr6:158685696	A/G	cg07165851	chr6:158734300	TULP4	0.59	6.23	0.36	1.87e-9	Height;
CESC	cis	rs9322193	0.923	rs9322209	chr6:150012362	A/G	cg07701084	chr6:150067640	NUP43	0.47	6.54	0.37	3.07e-10	Lung cancer;
CESC	cis	rs2228479	0.618	rs17233623	chr16:89811209	C/T	cg06558623	chr16:89946397	TCF25	0.93	8.15	0.45	1.47e-14	Skin colour saturation;
CESC	cis	rs4523957	0.583	rs7225168	chr17:2023089	T/G	cg16513277	chr17:2031491	SMG6	-0.71	-10.1	-0.53	1.62e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs896854	0.846	rs2340584	chr8:95916811	A/G	cg09323728	chr8:95962352	TP53INP1	-0.41	-8.95	-0.48	6.25e-17	Type 2 diabetes;
CESC	cis	rs9911578	1.000	rs302840	chr17:56673079	C/G	cg12560992	chr17:57184187	TRIM37	0.93	15.48	0.69	6.05e-39	Intelligence (multi-trait analysis);
CESC	cis	rs1005277	0.522	rs289647	chr10:37968278	A/G	cg00409905	chr10:38381863	ZNF37A	-0.47	-6.6	-0.38	2.27e-10	Extrinsic epigenetic age acceleration;
CESC	cis	rs7084402	0.935	rs12264028	chr10:60278140	C/T	cg07615347	chr10:60278583	BICC1	-0.58	-9.25	-0.49	7.59e-18	Refractive error;
CESC	cis	rs854765	0.547	rs9913277	chr17:17919749	G/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.53	7.4	0.41	1.77e-12	Total body bone mineral density;
CESC	cis	rs763014	0.931	rs3752567	chr16:628130	A/G	cg00908189	chr16:619842	PIGQ	0.66	9.17	0.49	1.34e-17	Height;
CESC	cis	rs9916302	0.821	rs4795386	chr17:37746847	A/G	cg07936489	chr17:37558343	FBXL20	-0.76	-10.13	-0.53	1.32e-20	Glomerular filtration rate (creatinine);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22752895	chr6:3118674	BPHL	0.68	7.67	0.43	3.26e-13	Gut microbiome composition (summer);
CESC	cis	rs736408	0.677	rs2286798	chr3:52821177	G/T	cg07507251	chr3:52567010	NT5DC2	-0.32	-5.3	-0.31	2.5e-7	Bipolar disorder;
CESC	cis	rs3096299	0.667	rs2965947	chr16:89518670	T/C	cg02034447	chr16:89574710	SPG7	0.5	6.48	0.37	4.52e-10	Multiple myeloma (IgH translocation);
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg12317515	chr5:74063363	GFM2;NSA2	-0.47	-6.45	-0.37	5.33e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs3096299	0.642	rs12934829	chr16:89523349	T/A	cg16743903	chr16:89593216	SPG7	-0.43	-5.49	-0.32	9.57e-8	Multiple myeloma (IgH translocation);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08537418	chr17:5342414	C1QBP	0.58	6.51	0.37	3.68e-10	Gut microbiome composition (summer);
CESC	cis	rs7590368	0.651	rs56093996	chr2:10931302	T/C	cg15705551	chr2:10952987	PDIA6	0.55	5.29	0.31	2.52e-7	Educational attainment (years of education);
CESC	cis	rs1008375	0.966	rs3733581	chr4:17695206	C/G	cg27347728	chr4:17578864	LAP3	-0.46	-5.35	-0.31	1.93e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs6051080	1	rs6051080	chr20:25975674	A/G	cg21995068	chr20:25989032	LOC100134868	-0.35	-5.91	-0.34	1.05e-8	Colorectal or endometrial cancer;
CESC	cis	rs9926296	0.581	rs12598477	chr16:89902482	T/C	cg04287289	chr16:89883240	FANCA	0.67	8.73	0.47	2.95e-16	Vitiligo;
CESC	cis	rs1348850	0.645	rs7571386	chr2:178442687	A/C	cg23306229	chr2:178417860	TTC30B	0.67	7.13	0.4	9.75e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs208520	0.754	rs7753158	chr6:66875633	A/C	cg07460842	chr6:66804631	NA	-0.92	-11.54	-0.58	3.16e-25	Exhaled nitric oxide output;
CESC	cis	rs6952808	0.531	rs73039217	chr7:2178731	G/A	cg21782813	chr7:2030301	MAD1L1	0.49	6.96	0.39	2.66e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs4803468	0.967	rs4803461	chr19:41908871	G/A	cg09537434	chr19:41945824	ATP5SL	-1.01	-17.89	-0.74	1.82e-47	Height;
CESC	cis	rs738322	0.775	rs13056506	chr22:38580917	G/T	cg25457927	chr22:38595422	NA	0.33	6.17	0.35	2.49e-9	Cutaneous nevi;
CESC	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg06873352	chr17:61820015	STRADA	0.72	12.67	0.61	4.43e-29	Prudent dietary pattern;
CESC	cis	rs6540559	1.000	rs12070337	chr1:209992127	G/A	cg22029157	chr1:209979665	IRF6	0.75	10.6	0.55	4.22e-22	Cleft lip with or without cleft palate;
CESC	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg16405210	chr4:1374714	KIAA1530	0.97	13.85	0.65	3.45e-33	Longevity;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg22352186	chr4:1722180	TMEM129;TACC3	-0.44	-6.31	-0.36	1.16e-9	Gambling;
CESC	cis	rs17039065	0.920	rs11097990	chr4:109432223	T/C	cg16022748	chr4:109541635	LOC285456;RPL34	0.61	5.16	0.3	4.75e-7	Gut microbiome composition (summer);
CESC	cis	rs5753618	0.583	rs738657	chr22:31841749	T/A	cg00478049	chr22:31556069	RNF185	-0.43	-5.26	-0.31	2.94e-7	Colorectal cancer;
CESC	cis	rs2836974	0.526	rs1888488	chr21:40686521	C/T	cg11644478	chr21:40555479	PSMG1	-0.79	-11.71	-0.58	8.23e-26	Cognitive function;
CESC	cis	rs3857536	0.740	rs7769722	chr6:66891363	C/T	cg07460842	chr6:66804631	NA	-0.4	-5.23	-0.31	3.47e-7	Blood trace element (Cu levels);
CESC	trans	rs17132261	0.661	rs12521859	chr5:109671958	C/G	cg14311597	chr17:2652531	MIR1253	-0.51	-6.06	-0.35	4.64e-9	Cardiac structure and function;Left ventricle wall thickness;
CESC	trans	rs7656342	0.808	rs10003216	chr4:9766749	A/G	cg06549955	chr12:110434341	GIT2	-0.54	-6.67	-0.38	1.49e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs763014	0.931	rs11648728	chr16:635525	C/T	cg00908189	chr16:619842	PIGQ	0.65	9.02	0.48	4.04e-17	Height;
CESC	cis	rs2797501	0.615	rs2797493	chr10:5794025	C/T	cg11519256	chr10:5708881	ASB13	0.5	5.05	0.3	8.14e-7	Osteosarcoma;
CESC	cis	rs6952808	0.792	rs2056478	chr7:1953897	C/T	cg22963979	chr7:1858916	MAD1L1	-0.4	-5.5	-0.32	8.82e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs6690583	0.562	rs12024977	chr1:85531051	A/C	cg22488158	chr1:85528044	WDR63	0.53	5.24	0.31	3.28e-7	Serum sulfate level;
CESC	cis	rs7772486	0.686	rs2092263	chr6:146029687	G/A	cg05347473	chr6:146136440	FBXO30	-0.52	-6.93	-0.39	3.22e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1707322	0.685	rs6690926	chr1:46134978	T/C	cg05343316	chr1:45956843	TESK2	0.5	6.12	0.35	3.43e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9487051	0.735	rs459956	chr6:109524760	A/G	cg01475377	chr6:109611718	NA	-0.46	-6.92	-0.39	3.45e-11	Reticulocyte fraction of red cells;
CESC	trans	rs2823962	0.759	rs2823929	chr21:18014226	C/G	cg06419850	chr17:4688683	VMO1	0.44	6.47	0.37	4.59e-10	Amyotrophic lateral sclerosis;
CESC	cis	rs4132509	1.000	rs10927051	chr1:243805936	G/C	cg21452805	chr1:244014465	NA	0.44	5.31	0.31	2.29e-7	RR interval (heart rate);
CESC	cis	rs11098499	0.863	rs1383533	chr4:120434576	G/A	cg09307838	chr4:120376055	NA	0.93	12.75	0.62	2.41e-29	Corneal astigmatism;
CESC	cis	rs7662987	0.517	rs1453873	chr4:100022571	T/C	cg13256891	chr4:100009986	ADH5	0.75	8.03	0.44	3.21e-14	Smoking initiation;
CESC	cis	rs1881797	1.000	rs7527856	chr1:247688139	C/T	cg18198730	chr1:247681584	NA	0.59	7.81	0.43	1.32e-13	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs17023223	0.537	rs12097967	chr1:119702913	A/G	cg05756136	chr1:119680316	WARS2	-0.47	-5.69	-0.33	3.34e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CESC	cis	rs12681288	0.862	rs2004701	chr8:1022287	A/G	cg15309053	chr8:964076	NA	0.34	5.73	0.33	2.78e-8	Schizophrenia;
CESC	cis	rs1862618	0.853	rs2113079	chr5:56157951	A/G	cg18230493	chr5:56204884	C5orf35	-0.75	-8.97	-0.48	5.46e-17	Initial pursuit acceleration;
CESC	cis	rs6032067	0.777	rs17332620	chr20:43777506	C/T	cg10761708	chr20:43804764	PI3	0.54	6.45	0.37	5.33e-10	Blood protein levels;
CESC	cis	rs72781680	0.611	rs4149373	chr2:24300023	C/T	cg06627628	chr2:24431161	ITSN2	-0.67	-6.5	-0.37	4.03e-10	Lymphocyte counts;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17589437	chr7:87563717	ADAM22	0.58	6.98	0.39	2.37e-11	Gut microbiome composition (summer);
CESC	cis	rs6835098	0.961	rs17322893	chr4:174122556	A/G	cg08422745	chr4:174089978	GALNT7	0.72	9.27	0.49	6.92e-18	Dementia and core Alzheimer's disease neuropathologic changes;
CESC	cis	rs524023	0.874	rs506338	chr11:64440920	T/C	cg19131476	chr11:64387923	NRXN2	-0.32	-5.05	-0.3	8.11e-7	Urate levels in obese individuals;
CESC	cis	rs1355223	1.000	rs11604069	chr11:34764251	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.49	-6.36	-0.36	9e-10	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs7666738	0.830	rs4699331	chr4:99059816	T/C	cg18180107	chr4:99064573	C4orf37	0.41	5.26	0.31	2.99e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs12310956	0.515	rs1872745	chr12:33985987	G/A	cg26384229	chr12:38710491	ALG10B	0.48	6.64	0.38	1.82e-10	Morning vs. evening chronotype;
CESC	cis	rs35110281	0.776	rs2838316	chr21:44990036	C/T	cg04455712	chr21:45112962	RRP1B	0.36	5.21	0.3	3.79e-7	Mean corpuscular volume;
CESC	cis	rs1218582	0.741	rs10908444	chr1:154840287	G/A	cg03351412	chr1:154909251	PMVK	0.68	9.09	0.49	2.43e-17	Prostate cancer;
CESC	trans	rs17685	0.753	rs10251863	chr7:75790192	T/C	cg19862616	chr7:65841803	NCRNA00174	0.84	12.03	0.59	6.77e-27	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs2836974	0.897	rs2836925	chr21:40532353	T/C	cg11890956	chr21:40555474	PSMG1	1.17	22.42	0.81	3.65e-63	Cognitive function;
CESC	cis	rs6547741	1.000	rs1528402	chr2:27857517	G/A	cg21248554	chr2:27665150	KRTCAP3	0.25	5.3	0.31	2.42e-7	Oral cavity cancer;
CESC	trans	rs7615952	0.599	rs12486459	chr3:125741465	T/G	cg07211511	chr3:129823064	LOC729375	-0.59	-6.62	-0.38	2e-10	Blood pressure (smoking interaction);
CESC	cis	rs208520	1.000	rs12216109	chr6:66987488	C/G	cg07460842	chr6:66804631	NA	0.88	10.12	0.53	1.49e-20	Exhaled nitric oxide output;
CESC	cis	rs7312774	0.618	rs9651926	chr12:107356820	G/A	cg16260113	chr12:107380972	MTERFD3	0.85	7.24	0.41	4.9e-12	Severe influenza A (H1N1) infection;
CESC	cis	rs514406	0.861	rs503296	chr1:53283088	A/G	cg08736216	chr1:53307985	ZYG11A	0.43	7.16	0.4	7.71e-12	Monocyte count;
CESC	cis	rs1799949	1.000	rs11653253	chr17:41182662	G/A	cg23758822	chr17:41437982	NA	1.03	14.75	0.67	2.37e-36	Menopause (age at onset);
CESC	cis	rs2953145	0.545	rs2975755	chr2:241524919	G/A	cg07929629	chr2:241523174	NA	0.65	8.96	0.48	6.08e-17	Bipolar disorder;
CESC	cis	rs7833790	1.000	rs1463259	chr8:82737745	A/G	cg07697082	chr8:82753677	SNX16	0.37	5.15	0.3	5.13e-7	Diastolic blood pressure;
CESC	cis	rs616402	0.527	rs604369	chr1:10567208	C/A	cg07384165	chr1:10488281	NA	-0.58	-8.63	-0.47	5.96e-16	Breast size;
CESC	cis	rs863345	0.604	rs7525362	chr1:158493890	G/C	cg12129480	chr1:158549410	OR10X1	-0.35	-6.86	-0.39	4.75e-11	Pneumococcal bacteremia;
CESC	cis	rs72945132	0.882	rs6592552	chr11:70223831	A/T	cg14191688	chr11:70257035	CTTN	0.4	5.13	0.3	5.7e-7	Coronary artery disease;
CESC	cis	rs8028182	0.636	rs12708520	chr15:75830539	C/T	cg20655648	chr15:75932815	IMP3	0.48	6.02	0.35	5.64e-9	Sudden cardiac arrest;
CESC	cis	rs4604732	0.536	rs7528219	chr1:247628307	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.53	6.57	0.37	2.7e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs826838	1.000	rs10880914	chr12:38720543	C/T	cg26384229	chr12:38710491	ALG10B	0.83	14.87	0.67	9.19e-37	Heart rate;
CESC	cis	rs4268898	0.662	rs72795824	chr2:24435837	T/C	cg20701182	chr2:24300061	SF3B14	0.68	7.16	0.4	7.75e-12	Asthma;
CESC	cis	rs8103278	1.000	rs36091860	chr19:46312880	G/A	cg14061069	chr19:46274453	DMPK	-0.4	-5.48	-0.32	9.81e-8	Coronary artery disease;
CESC	trans	rs10411161	0.752	rs4584941	chr19:52392141	C/T	cg22319618	chr22:45562946	NUP50	-0.8	-8.04	-0.44	2.96e-14	Breast cancer;
CESC	cis	rs801193	0.935	rs11772264	chr7:66176387	T/C	cg18876405	chr7:65276391	NA	0.54	7.27	0.41	4.04e-12	Aortic root size;
CESC	cis	rs7772486	0.776	rs2265467	chr6:146218339	T/A	cg05347473	chr6:146136440	FBXO30	0.49	6.45	0.37	5.3e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs853679	0.517	rs7755442	chr6:28039015	T/C	cg20151795	chr6:28129481	ZNF389	0.44	5.59	0.33	5.5e-8	Depression;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23506944	chr17:28257236	EFCAB5;SSH2	0.52	6.09	0.35	3.89e-9	Gut microbiome composition (summer);
CESC	cis	rs16854884	0.632	rs1910691	chr3:143656905	G/A	cg01302019	chr3:143689584	C3orf58	-0.34	-5.18	-0.3	4.45e-7	Economic and political preferences (feminism/equality);
CESC	cis	rs1862618	0.853	rs252909	chr5:56121131	T/C	cg24549020	chr5:56110836	MAP3K1	0.68	7.71	0.43	2.61e-13	Initial pursuit acceleration;
CESC	cis	rs9457247	0.602	rs6456152	chr6:167472062	A/G	cg07741184	chr6:167504864	NA	0.38	6.7	0.38	1.22e-10	Crohn's disease;
CESC	cis	rs7208859	0.623	rs9912283	chr17:29110373	A/G	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.17e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs11252926	0.574	rs4881313	chr10:487973	C/T	cg18196295	chr10:418757	DIP2C	-0.42	-5.54	-0.32	7.3e-8	Psychosis in Alzheimer's disease;
CESC	cis	rs9616064	0.557	rs5767318	chr22:47048792	A/G	cg25730555	chr22:47059586	GRAMD4	0.46	5.73	0.33	2.71e-8	Urate levels in obese individuals;
CESC	cis	rs4555082	0.874	rs2735828	chr14:105710486	C/A	cg13114125	chr14:105738426	BRF1	-0.75	-9.32	-0.5	4.64e-18	Mean platelet volume;Platelet distribution width;
CESC	trans	rs7246657	0.943	rs7255407	chr19:37933936	G/A	cg24637308	chr11:6592297	DNHD1	0.54	6.34	0.36	1.01e-9	Coronary artery calcification;
CESC	cis	rs3925075	1.000	rs3925075	chr16:31347748	C/T	cg02846316	chr16:31340340	ITGAM	-0.4	-6.35	-0.36	9.23e-10	IgA nephropathy;
CESC	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg06873352	chr17:61820015	STRADA	0.72	12.7	0.62	3.41e-29	Prudent dietary pattern;
CESC	cis	rs9302690	0.557	rs223869	chr16:57494992	C/A	cg27017172	chr16:57497170	POLR2C	0.64	5.52	0.32	8.22e-8	Blood protein levels;
CESC	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.59	6.87	0.39	4.55e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs4746818	1.000	rs7091695	chr10:70964997	A/G	cg04149295	chr10:70884716	VPS26A	-0.6	-5.29	-0.31	2.55e-7	Left atrial antero-posterior diameter;
CESC	cis	rs1707322	0.716	rs10890342	chr1:46157087	C/T	cg05343316	chr1:45956843	TESK2	0.51	6.32	0.36	1.09e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9926296	0.744	rs164747	chr16:89708680	T/G	cg27121462	chr16:89883253	FANCA	-0.45	-5.21	-0.3	3.8e-7	Vitiligo;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg04062965	chr2:219188029	PNKD	-0.55	-7.03	-0.4	1.73e-11	Asthma;
CESC	cis	rs4727027	0.704	rs12704071	chr7:148904795	C/T	cg23583168	chr7:148888333	NA	-0.86	-14.32	-0.66	8.03e-35	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs853679	0.882	rs9380069	chr6:28203300	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.71	-6.59	-0.38	2.37e-10	Depression;
CESC	cis	rs10504229	0.683	rs67077711	chr8:58139769	G/T	cg22535103	chr8:58192502	C8orf71	-0.8	-9.09	-0.49	2.46e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs6694270	0.529	rs4076925	chr1:19113026	C/T	cg26220594	chr1:19110978	NA	0.4	5.39	0.31	1.52e-7	Drug-induced liver injury (nitrofurantoin);
CESC	cis	rs11785400	0.793	rs2976400	chr8:143743611	G/A	cg24634471	chr8:143751801	JRK	0.43	5.48	0.32	9.95e-8	Schizophrenia;
CESC	cis	rs1865760	0.588	rs9467658	chr6:26010881	T/G	cg16482183	chr6:26056742	HIST1H1C	0.4	5.64	0.33	4.42e-8	Height;
CESC	cis	rs60871478	1.000	rs62432253	chr7:802928	A/G	cg13798912	chr7:905769	UNC84A	0.52	5.11	0.3	6.23e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs1707322	0.721	rs11211149	chr1:46112218	T/C	cg06784218	chr1:46089804	CCDC17	0.4	7.04	0.4	1.69e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs4523957	0.533	rs216216	chr17:2145046	A/G	cg16513277	chr17:2031491	SMG6	0.5	5.35	0.31	1.94e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	trans	rs6479874	1.000	rs7080757	chr10:52759553	T/G	cg14115756	chr9:125795935	GPR21;RABGAP1	0.68	6.0	0.35	6.41e-9	Migraine;
CESC	cis	rs9894429	1.000	rs9674872	chr17:79581931	T/A	cg21984481	chr17:79567631	NPLOC4	-0.49	-8.04	-0.44	2.97e-14	Eye color traits;
CESC	cis	rs7267979	1.000	rs2258066	chr20:25271326	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	18.62	0.75	4.72e-50	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs2120019	1.000	rs7168680	chr15:75369212	G/A	cg09165964	chr15:75287851	SCAMP5	-0.66	-7.96	-0.44	5.22e-14	Blood trace element (Zn levels);
CESC	cis	rs6460942	0.524	rs6948366	chr7:12369905	A/G	cg02935154	chr7:12443704	VWDE	-0.45	-5.95	-0.34	8.54e-9	Coronary artery disease;
CESC	cis	rs3617	0.625	rs2239548	chr3:52854186	A/C	cg07507251	chr3:52567010	NT5DC2	0.34	5.88	0.34	1.2e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
CESC	cis	rs3092073	0.603	rs4810477	chr20:44544654	C/T	cg27529037	chr20:44575021	PCIF1	0.64	9.5	0.5	1.32e-18	Intelligence (multi-trait analysis);
CESC	cis	rs6089584	0.627	rs55875402	chr20:60559925	G/A	cg24733560	chr20:60626293	TAF4	0.42	6.29	0.36	1.33e-9	Body mass index;
CESC	cis	rs7772486	0.875	rs9403765	chr6:146368041	C/T	cg23711669	chr6:146136114	FBXO30	-0.81	-11.32	-0.57	1.76e-24	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1862618	0.853	rs832569	chr5:56154584	T/A	cg03609598	chr5:56110824	MAP3K1	-0.53	-5.57	-0.32	6.1e-8	Initial pursuit acceleration;
CESC	cis	rs1799949	1.000	rs8176234	chr17:41219780	T/C	cg05368731	chr17:41323189	NBR1	0.79	11.1	0.56	8.99e-24	Menopause (age at onset);
CESC	cis	rs6460942	0.749	rs62448592	chr7:12435985	A/T	cg10578991	chr7:12443926	VWDE	-0.51	-5.67	-0.33	3.75e-8	Coronary artery disease;
CESC	cis	rs7772486	0.754	rs2064185	chr6:146066814	G/A	cg23711669	chr6:146136114	FBXO30	-1.01	-15.7	-0.69	1.03e-39	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs1838239	0.908	rs7898983	chr10:4692213	T/C	cg24270710	chr12:132930766	NA	0.57	6.13	0.35	3.24e-9	Major depressive disorder;
CESC	cis	rs9916302	0.904	rs588193	chr17:37440439	A/C	cg00129232	chr17:37814104	STARD3	0.54	6.9	0.39	3.73e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs698833	0.828	rs2850298	chr2:44731590	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	5.77	0.33	2.24e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs3008870	1.000	rs1925412	chr1:67405057	G/A	cg08660285	chr1:67390436	MIER1;WDR78	1.04	14.53	0.67	1.38e-35	Lymphocyte percentage of white cells;
CESC	cis	rs1799949	0.965	rs11650132	chr17:41326087	T/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.39	5.18	0.3	4.5e-7	Menopause (age at onset);
CESC	cis	rs1153858	1.000	rs2467864	chr15:45641098	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.77	-10.2	-0.53	8.3e-21	Homoarginine levels;
CESC	cis	rs7246657	0.943	rs7257672	chr19:37823859	G/C	cg23950597	chr19:37808831	NA	-0.55	-6.04	-0.35	5.24e-9	Coronary artery calcification;
CESC	cis	rs875971	0.619	rs10278371	chr7:66051540	C/A	cg06456125	chr7:65229604	NA	-0.43	-5.43	-0.32	1.25e-7	Aortic root size;
CESC	cis	rs3857067	1.000	rs7682116	chr4:95002704	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.52	-8.04	-0.44	3e-14	QT interval;
CESC	cis	rs2439831	0.867	rs2255042	chr15:43834318	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.82	-9.18	-0.49	1.26e-17	Lung cancer in ever smokers;
CESC	cis	rs1976403	0.633	rs1697422	chr1:21821897	T/C	cg21906605	chr1:21766650	NBPF3	0.4	5.19	0.3	4.18e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs4594175	0.707	rs12432912	chr14:51739395	T/C	cg23942311	chr14:51606299	NA	0.37	5.61	0.33	5.05e-8	Cancer;
CESC	trans	rs7980799	0.682	rs1601005	chr12:33634658	A/G	cg26384229	chr12:38710491	ALG10B	-0.57	-8.23	-0.45	8.55e-15	Heart rate;Heart rate variability traits (RMSSD);
CESC	trans	rs11098499	0.874	rs6826823	chr4:120112098	G/C	cg25214090	chr10:38739885	LOC399744	0.58	7.71	0.43	2.54e-13	Corneal astigmatism;
CESC	cis	rs7208859	0.573	rs7223803	chr17:29077193	A/G	cg14008862	chr17:28927542	LRRC37B2	0.65	5.14	0.3	5.34e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs12497850	0.805	rs11130176	chr3:48844077	A/G	cg02487422	chr3:49467188	NICN1	0.39	5.05	0.3	8.06e-7	Parkinson's disease;
CESC	cis	rs7927592	0.913	rs11228287	chr11:68349754	A/G	cg20283391	chr11:68216788	NA	-0.61	-7.29	-0.41	3.48e-12	Total body bone mineral density;
CESC	cis	rs425277	0.583	rs3107151	chr1:2051513	T/G	cg16545954	chr1:2118288	C1orf86	-0.33	-6.15	-0.35	2.83e-9	Height;
CESC	cis	rs10504229	0.728	rs56180705	chr8:58149734	T/C	cg05313129	chr8:58192883	C8orf71	-0.49	-5.35	-0.31	1.88e-7	Developmental language disorder (linguistic errors);
CESC	trans	rs61931739	0.517	rs860950	chr12:34104376	C/G	cg26384229	chr12:38710491	ALG10B	0.52	7.06	0.4	1.45e-11	Morning vs. evening chronotype;
CESC	cis	rs875971	0.545	rs10950036	chr7:65818228	G/T	cg18876405	chr7:65276391	NA	0.49	5.83	0.34	1.62e-8	Aortic root size;
CESC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg04815758	chr6:43423089	DLK2	0.41	6.07	0.35	4.32e-9	Intelligence (multi-trait analysis);
CESC	cis	rs4642101	0.686	rs13085726	chr3:12832672	A/C	cg24848339	chr3:12840334	CAND2	0.39	6.1	0.35	3.71e-9	QRS complex (12-leadsum);
CESC	cis	rs7208859	0.623	rs1061343	chr17:29114276	G/A	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.1e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs1218582	0.804	rs869506	chr1:154859581	A/C	cg06221963	chr1:154839813	KCNN3	-0.66	-11.44	-0.58	6.67e-25	Prostate cancer;
CESC	cis	rs1801251	1.000	rs2592102	chr2:233726772	G/T	cg08000102	chr2:233561755	GIGYF2	-0.69	-9.79	-0.52	1.6e-19	Coronary artery disease;
CESC	cis	rs7520050	0.751	rs592214	chr1:46024505	G/A	cg06784218	chr1:46089804	CCDC17	-0.33	-5.76	-0.33	2.29e-8	Red blood cell count;Reticulocyte count;
CESC	cis	rs2408955	0.522	rs3997	chr12:48481587	T/C	cg04545296	chr12:48745243	ZNF641	-0.39	-6.71	-0.38	1.2e-10	Glycated hemoglobin levels;
CESC	cis	rs7520050	0.966	rs10789475	chr1:46304177	C/G	cg03146154	chr1:46216737	IPP	-0.48	-6.36	-0.36	8.91e-10	Red blood cell count;Reticulocyte count;
CESC	cis	rs2652834	0.851	rs4468558	chr15:63346681	T/C	cg05507819	chr15:63340323	TPM1	0.59	5.8	0.34	1.85e-8	HDL cholesterol;
CESC	cis	rs7078219	0.543	rs7096296	chr10:101277816	A/G	cg09788492	chr10:101292477	NKX2-3	-0.3	-5.61	-0.33	5.03e-8	Dental caries;
CESC	cis	rs9303401	0.538	rs2240258	chr17:56458183	C/A	cg25039879	chr17:56429692	SUPT4H1	0.7	6.8	0.39	6.75e-11	Cognitive test performance;
CESC	cis	rs7312933	0.510	rs10880223	chr12:42413443	G/A	cg01256987	chr12:42539512	GXYLT1	-0.45	-6.95	-0.39	2.81e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs11078597	0.731	rs12946666	chr17:1651304	C/G	cg18436246	chr17:1640651	WDR81	0.61	7.43	0.42	1.46e-12	Serum albumin level;
CESC	cis	rs4665809	1.000	rs10170359	chr2:26272219	G/T	cg27170947	chr2:26402098	FAM59B	-0.68	-8.02	-0.44	3.52e-14	Gut microbiome composition (summer);
CESC	cis	rs2280018	1.000	rs2280017	chr16:15151361	A/G	cg07549590	chr16:15018862	NA	0.48	7.91	0.44	7.1e-14	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs7666738	0.791	rs11730069	chr4:98945772	A/G	cg03467027	chr4:99064603	C4orf37	0.46	5.82	0.34	1.74e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6963495	0.745	rs73192151	chr7:105211876	A/G	cg19920283	chr7:105172520	RINT1	0.7	6.36	0.36	8.94e-10	Bipolar disorder (body mass index interaction);
CESC	cis	rs2204008	0.654	rs1733410	chr12:38132172	G/A	cg26384229	chr12:38710491	ALG10B	-0.43	-5.92	-0.34	9.92e-9	Bladder cancer;
CESC	cis	rs1580019	0.665	rs34147895	chr7:32531796	G/C	cg07520158	chr7:32535189	LSM5;AVL9	0.51	6.28	0.36	1.37e-9	Cognitive ability;
CESC	cis	rs344364	0.511	rs62040569	chr16:1948137	C/T	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.55	-6.2	-0.36	2.15e-9	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs6754311	0.551	rs10928545	chr2:136501840	A/G	cg15123519	chr2:136567270	LCT	0.3	5.05	0.3	8.29e-7	Mosquito bite size;
CESC	cis	rs7829975	0.714	rs60315134	chr8:8670599	A/G	cg15556689	chr8:8085844	FLJ10661	0.43	5.44	0.32	1.18e-7	Mood instability;
CESC	cis	rs9467711	0.659	rs66941101	chr6:26530376	C/T	cg21479132	chr6:26055353	NA	0.72	5.15	0.3	5.19e-7	Autism spectrum disorder or schizophrenia;
CESC	trans	rs459571	1.000	rs467387	chr9:136907005	G/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.66	-8.4	-0.46	2.81e-15	Platelet distribution width;
CESC	cis	rs3749237	0.595	rs4855864	chr3:49521974	C/T	cg03060546	chr3:49711283	APEH	0.78	11.82	0.59	3.47e-26	Resting heart rate;
CESC	cis	rs34891900	0.507	rs2535679	chr22:18202850	A/G	cg19898043	chr22:18121309	BCL2L13	0.57	6.78	0.38	7.99e-11	Sum neutrophil eosinophil counts;
CESC	cis	rs6545883	0.931	rs9807965	chr2:61732159	T/C	cg15711740	chr2:61764176	XPO1	-0.42	-5.3	-0.31	2.48e-7	Tuberculosis;
CESC	cis	rs6032067	0.777	rs34073275	chr20:43788917	C/T	cg10761708	chr20:43804764	PI3	0.56	6.55	0.37	3.01e-10	Blood protein levels;
CESC	cis	rs853679	0.517	rs1904841	chr6:28108085	C/T	cg23281280	chr6:28129359	ZNF389	0.62	8.72	0.47	3.21e-16	Depression;
CESC	cis	rs524023	0.914	rs4930556	chr11:64377726	G/C	cg07220939	chr11:64358617	SLC22A12	-0.35	-5.32	-0.31	2.24e-7	Urate levels in obese individuals;
CESC	cis	rs4927850	0.752	rs7624460	chr3:195748530	C/T	cg00031303	chr3:195681400	NA	0.43	5.34	0.31	1.96e-7	Pancreatic cancer;
CESC	cis	rs7949030	0.653	rs17773169	chr11:62318530	G/T	cg11742103	chr11:62369870	EML3;MTA2	0.62	9.63	0.51	5.18e-19	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg21899992	chr5:179306587	TBC1D9B	0.51	7.42	0.41	1.63e-12	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs11048434	0.761	rs1805765	chr12:9094548	A/G	cg04155231	chr12:9217510	LOC144571	0.34	5.41	0.32	1.41e-7	Sjögren's syndrome;
CESC	cis	rs6089829	0.962	rs2872543	chr20:61665017	G/A	cg03213289	chr20:61660250	NA	0.38	5.95	0.34	8.37e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs208520	1.000	rs12191598	chr6:66983962	T/C	cg07460842	chr6:66804631	NA	0.88	10.14	0.53	1.22e-20	Exhaled nitric oxide output;
CESC	cis	rs3733585	0.673	rs116046986	chr4:9957794	A/G	cg02734326	chr4:10020555	SLC2A9	-0.42	-5.92	-0.34	9.7e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs72781680	0.706	rs72796108	chr2:23904990	C/A	cg08917208	chr2:24149416	ATAD2B	1.16	10.42	0.54	1.59e-21	Lymphocyte counts;
CESC	cis	rs9308433	0.505	rs867446	chr1:214502322	G/T	cg06198575	chr1:214491504	SMYD2	0.46	5.23	0.31	3.48e-7	IgG glycosylation;
CESC	cis	rs1949733	1.000	rs1916326	chr4:8500023	G/A	cg11789530	chr4:8429930	ACOX3	-0.76	-10.74	-0.55	1.45e-22	Response to antineoplastic agents;
CESC	cis	rs2635047	0.713	rs9952628	chr18:44754651	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.43	5.64	0.33	4.41e-8	Educational attainment;
CESC	cis	rs9905704	0.560	rs2632507	chr17:56530597	C/A	cg12560992	chr17:57184187	TRIM37	0.57	5.46	0.32	1.12e-7	Testicular germ cell tumor;
CESC	cis	rs4253772	0.530	rs9615961	chr22:46754993	T/C	cg18190219	chr22:46762943	CELSR1	-0.67	-6.19	-0.36	2.32e-9	LDL cholesterol;Cholesterol, total;
CESC	cis	rs6539267	0.847	rs17217845	chr12:106697802	C/T	cg02476566	chr12:106696527	TCP11L2	-0.63	-6.63	-0.38	1.83e-10	Tourette syndrome;
CESC	trans	rs116095464	0.558	rs28558836	chr5:285748	C/G	cg00938859	chr5:1591904	SDHAP3	0.64	7.04	0.4	1.65e-11	Breast cancer;
CESC	cis	rs9549367	0.774	rs9549364	chr13:113903745	T/C	cg00898013	chr13:113819073	PROZ	-0.53	-7.21	-0.41	5.74e-12	Platelet distribution width;
CESC	cis	rs6502050	0.799	rs4789674	chr17:80123200	G/A	cg11859384	chr17:80120422	CCDC57	-0.39	-5.34	-0.31	1.98e-7	Life satisfaction;
CESC	cis	rs1707322	0.928	rs61785614	chr1:46446047	A/G	cg03146154	chr1:46216737	IPP	0.72	9.82	0.52	1.31e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7301826	0.610	rs4759791	chr12:131296495	A/G	cg11011512	chr12:131303247	STX2	0.47	5.84	0.34	1.52e-8	Plasma plasminogen activator levels;
CESC	cis	rs6582630	0.519	rs11182021	chr12:38443709	A/T	cg13010199	chr12:38710504	ALG10B	-0.43	-5.55	-0.32	6.99e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs34779708	0.702	rs4244995	chr10:35547175	A/G	cg04310649	chr10:35416472	CREM	-0.45	-5.14	-0.3	5.34e-7	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs9768139	0.733	rs13309363	chr7:158122179	C/A	cg06219351	chr7:158114137	PTPRN2	-0.49	-7.54	-0.42	7.44e-13	Calcium levels;
CESC	cis	rs9323205	0.731	rs56024569	chr14:51697655	A/G	cg23942311	chr14:51606299	NA	-0.46	-5.17	-0.3	4.65e-7	Cancer;
CESC	cis	rs617791	0.678	rs551659	chr11:65749645	C/T	cg02202077	chr11:65769826	EIF1AD;BANF1	0.44	5.81	0.34	1.83e-8	Breast cancer;
CESC	cis	rs7811142	0.830	rs11768967	chr7:99967644	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.83	9.27	0.49	6.85e-18	Platelet count;
CESC	cis	rs1843834	0.539	rs2047135	chr2:225427302	G/C	cg22509189	chr2:225307070	NA	-0.4	-5.36	-0.31	1.77e-7	IgE levels in asthmatics (D.p. specific);
CESC	cis	rs6432018	1.000	rs6432018	chr2:9721896	C/A	cg23886495	chr2:9695866	ADAM17	0.44	5.14	0.3	5.32e-7	Heart rate variability traits;
CESC	cis	rs2228479	0.717	rs9282682	chr16:89805794	A/G	cg04287289	chr16:89883240	FANCA	0.63	5.81	0.34	1.82e-8	Skin colour saturation;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg07475247	chr7:102938279	PMPCB	0.48	6.21	0.36	2.08e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs7666738	0.830	rs3846445	chr4:99032939	T/A	cg17366294	chr4:99064904	C4orf37	0.62	8.95	0.48	6.32e-17	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1577917	0.958	rs12215232	chr6:86785430	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.45	-5.82	-0.34	1.66e-8	Response to antipsychotic treatment;
CESC	cis	rs1707322	1.000	rs1768801	chr1:46549137	C/G	cg03146154	chr1:46216737	IPP	-0.69	-9.04	-0.49	3.51e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs17376456	1.000	rs10514382	chr5:93566534	G/A	cg21475434	chr5:93447410	FAM172A	0.85	6.52	0.37	3.53e-10	Diabetic retinopathy;
CESC	trans	rs208520	0.690	rs4386800	chr6:66755242	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.94	11.91	0.59	1.73e-26	Exhaled nitric oxide output;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19968619	chr21:42676391	NA	-0.54	-6.11	-0.35	3.54e-9	Gut microbiome composition (summer);
CESC	cis	rs79387448	0.655	rs75579337	chr2:102917302	C/A	cg09003973	chr2:102972529	NA	1.07	7.99	0.44	4.25e-14	Gut microbiota (bacterial taxa);
CESC	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg22764044	chr5:178986830	RUFY1	-0.48	-7.21	-0.4	5.91e-12	Lung cancer;
CESC	cis	rs9393777	0.513	rs9393739	chr6:26646966	T/G	cg14345882	chr6:26364793	BTN3A2	0.41	5.12	0.3	5.89e-7	Intelligence (multi-trait analysis);
CESC	cis	rs11252926	0.673	rs10795161	chr10:497748	G/T	cg16386425	chr10:429943	DIP2C	-0.45	-5.89	-0.34	1.16e-8	Psychosis in Alzheimer's disease;
CESC	cis	rs748404	0.723	rs565658	chr15:43556307	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	7.96	0.44	4.96e-14	Lung cancer;
CESC	cis	rs2370759	1.000	rs79442609	chr10:32608749	C/T	cg18270830	chr10:32634957	EPC1	0.71	6.83	0.39	5.84e-11	Sexual dysfunction (female);
CESC	cis	rs4253772	0.591	rs6520010	chr22:46721223	G/A	cg18190219	chr22:46762943	CELSR1	-0.44	-5.6	-0.33	5.38e-8	LDL cholesterol;Cholesterol, total;
CESC	trans	rs208520	1.000	rs72880045	chr6:66965232	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.85	9.42	0.5	2.36e-18	Exhaled nitric oxide output;
CESC	cis	rs12477438	0.520	rs2516830	chr2:99773702	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.79	12.62	0.61	6.6e-29	Chronic sinus infection;
CESC	cis	rs3733585	0.673	rs4627861	chr4:9954238	T/G	cg00071950	chr4:10020882	SLC2A9	-0.69	-11.34	-0.57	1.42e-24	Cleft plate (environmental tobacco smoke interaction);
CESC	trans	rs650950	0.528	rs646660	chr11:35528452	C/T	cg27535044	chr8:82633568	ZFAND1	0.43	6.23	0.36	1.84e-9	Bronchopulmonary dysplasia;
CESC	cis	rs6933660	0.646	rs9397051	chr6:151778325	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.88	15.11	0.68	1.29e-37	Menarche (age at onset);
CESC	cis	rs2425143	0.598	rs2425118	chr20:34324098	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.88	-10.7	-0.55	1.88e-22	Blood protein levels;
CESC	cis	rs8049634	0.528	rs76669578	chr16:84096577	A/G	cg06572904	chr16:84086012	NA	-0.51	-5.49	-0.32	9.28e-8	Small cell lung carcinoma;
CESC	cis	rs929596	0.639	rs2070959	chr2:234602191	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.45	-5.73	-0.33	2.66e-8	Total bilirubin levels in HIV-1 infection;
CESC	cis	rs17407555	0.821	rs55851451	chr4:10139189	G/A	cg11266682	chr4:10021025	SLC2A9	-0.51	-5.32	-0.31	2.22e-7	Schizophrenia (age at onset);
CESC	cis	rs7943191	0.810	rs7942154	chr11:62337163	G/A	cg11742103	chr11:62369870	EML3;MTA2	0.56	8.08	0.44	2.31e-14	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
CESC	cis	rs8114671	0.552	rs2024635	chr20:33422614	G/A	cg06115741	chr20:33292138	TP53INP2	0.45	5.32	0.31	2.21e-7	Height;
CESC	cis	rs780096	0.526	rs7594812	chr2:27611469	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.34	-7.0	-0.4	2.04e-11	Total body bone mineral density;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12476490	chr10:64576179	EGR2	-0.61	-7.08	-0.4	1.26e-11	Gut microbiome composition (summer);
CESC	cis	rs736408	0.609	rs2336545	chr3:52787603	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.45	-6.4	-0.37	6.88e-10	Bipolar disorder;
CESC	cis	rs2836950	0.545	rs2836956	chr21:40623018	C/G	cg17971929	chr21:40555470	PSMG1	0.59	7.72	0.43	2.41e-13	Menarche (age at onset);
CESC	cis	rs11583043	0.667	rs873760	chr1:101540561	C/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.5	5.41	0.32	1.42e-7	Ulcerative colitis;Inflammatory bowel disease;
CESC	cis	rs17253792	0.822	rs80085988	chr14:56096173	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.79	5.91	0.34	1.06e-8	Putamen volume;
CESC	cis	rs7811142	1.000	rs28490152	chr7:100020982	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.92	9.83	0.52	1.17e-19	Platelet count;
CESC	cis	rs7666738	0.546	rs11097591	chr4:98910173	G/A	cg17366294	chr4:99064904	C4orf37	0.47	5.66	0.33	3.94e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2046867	0.818	rs6808341	chr3:72914847	A/G	cg25664220	chr3:72788482	NA	-0.39	-5.87	-0.34	1.3e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CESC	cis	rs9311474	0.508	rs11718420	chr3:52611413	T/C	cg05564831	chr3:52568323	NT5DC2	0.48	7.5	0.42	9.67e-13	Electroencephalogram traits;
CESC	cis	rs7089973	0.624	rs10885613	chr10:116589400	G/A	cg23260525	chr10:116636907	FAM160B1	0.4	7.19	0.4	6.76e-12	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs721399	0.553	rs10109286	chr8:18243603	A/G	cg18736775	chr8:18248649	NAT2	-0.53	-5.86	-0.34	1.35e-8	Blood metabolite levels;
CESC	cis	rs881375	0.900	rs1930786	chr9:123691469	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.38	5.14	0.3	5.24e-7	Rheumatoid arthritis;
CESC	trans	rs7819412	0.521	rs9329238	chr8:11033737	C/T	cg06636001	chr8:8085503	FLJ10661	-0.54	-6.29	-0.36	1.33e-9	Triglycerides;
CESC	cis	rs8064299	0.597	rs2166703	chr17:72781812	G/A	cg25054828	chr17:72772726	NAT9;TMEM104	0.85	14.24	0.66	1.5e-34	Monocyte count;
CESC	cis	rs11864453	0.647	rs7194397	chr16:72128299	C/T	cg16558253	chr16:72132732	DHX38	-0.54	-8.48	-0.46	1.59e-15	Fibrinogen levels;
CESC	cis	rs7412746	0.611	rs4509581	chr1:150774465	A/G	cg18016565	chr1:150552671	MCL1	0.34	5.04	0.3	8.8e-7	Melanoma;
CESC	cis	rs1799949	0.896	rs33933393	chr17:41317432	C/T	cg06001716	chr17:41278141	BRCA1;NBR2	0.37	5.04	0.3	8.59e-7	Menopause (age at onset);
CESC	cis	rs2337406	0.714	rs7152055	chr14:107227228	C/T	cg07958169	chr14:107095056	NA	-0.48	-5.12	-0.3	5.89e-7	Alzheimer's disease (late onset);
CESC	cis	rs4727027	0.933	rs4727028	chr7:148874666	A/G	cg23583168	chr7:148888333	NA	0.79	12.11	0.6	3.54e-27	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs1153858	1.000	rs8042786	chr15:45703539	T/C	cg14582100	chr15:45693742	SPATA5L1	0.41	5.79	0.33	2.03e-8	Homoarginine levels;
CESC	cis	rs7777484	0.534	rs2258709	chr7:2832365	C/T	cg09658497	chr7:2847517	GNA12	0.43	6.8	0.39	6.83e-11	Height;
CESC	cis	rs472109	0.785	rs415895	chr11:9769562	C/G	cg03108697	chr11:9732066	SWAP70	-0.41	-6.14	-0.35	2.96e-9	Coronary artery disease;
CESC	cis	rs4665809	0.941	rs7602922	chr2:26265782	C/T	cg22920501	chr2:26401640	FAM59B	-0.79	-9.31	-0.5	5.24e-18	Gut microbiome composition (summer);
CESC	cis	rs10089	1.000	rs13355233	chr5:127425350	A/G	cg19767477	chr5:127420684	SLC12A2	0.43	5.9	0.34	1.08e-8	Ileal carcinoids;
CESC	cis	rs1552244	0.832	rs3732968	chr3:10013273	A/G	cg00149659	chr3:10157352	C3orf10	0.71	8.29	0.45	5.55e-15	Alzheimer's disease;
CESC	cis	rs7666738	0.830	rs28802909	chr4:99039410	G/A	cg17366294	chr4:99064904	C4orf37	0.61	8.78	0.47	2.13e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs896854	0.684	rs2340534	chr8:95992330	G/A	cg13393036	chr8:95962371	TP53INP1	-0.47	-10.14	-0.53	1.27e-20	Type 2 diabetes;
CESC	cis	rs807669	0.903	rs1780642	chr22:19170604	T/C	cg02655711	chr22:19163373	SLC25A1	0.95	14.43	0.66	3.1e-35	Metabolite levels;
CESC	cis	rs7647973	0.600	rs13064780	chr3:49274826	T/G	cg03060546	chr3:49711283	APEH	0.51	6.82	0.39	6.1e-11	Menarche (age at onset);
CESC	cis	rs5750830	0.569	rs5750809	chr22:39791491	T/G	cg05872129	chr22:39784769	NA	-0.86	-11.83	-0.59	3.41e-26	Intelligence (multi-trait analysis);
CESC	cis	rs10479542	0.544	rs7706275	chr5:178990305	A/G	cg22764044	chr5:178986830	RUFY1	0.45	6.5	0.37	3.88e-10	Lung cancer;
CESC	cis	rs1620921	0.505	rs9458030	chr6:161209985	G/A	cg01280913	chr6:161186852	NA	-0.39	-5.83	-0.34	1.6e-8	Lipoprotein (a) - cholesterol levels;
CESC	cis	rs8027181	0.617	rs28827493	chr15:73083121	G/A	cg25632853	chr15:73088954	NA	-0.39	-5.95	-0.34	8.45e-9	Triglyceride levels;
CESC	cis	rs963731	0.649	rs1947432	chr2:39227063	C/T	cg04010122	chr2:39346883	SOS1	0.68	5.21	0.3	3.74e-7	Corticobasal degeneration;
CESC	cis	rs826838	1.000	rs55828987	chr12:39056421	A/C	cg13010199	chr12:38710504	ALG10B	0.58	8.03	0.44	3.13e-14	Heart rate;
CESC	cis	rs910316	1.000	rs10138183	chr14:75615227	T/C	cg08847533	chr14:75593920	NEK9	1.02	19.83	0.77	2.88e-54	Height;
CESC	cis	rs1065852	0.510	rs5758666	chr22:42632833	G/A	cg00645731	chr22:42541494	CYP2D7P1	0.37	6.07	0.35	4.31e-9	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
CESC	cis	rs13191362	1.000	rs66594243	chr6:163169024	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.0	9.67	0.51	3.78e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs9486719	1.000	rs2273622	chr6:97058567	A/G	cg18709589	chr6:96969512	KIAA0776	-0.53	-5.89	-0.34	1.19e-8	Migraine;Coronary artery disease;
CESC	cis	rs34638657	0.702	rs12599988	chr16:82200063	T/C	cg09439754	chr16:82129088	HSD17B2	-0.37	-6.42	-0.37	6.31e-10	Lung adenocarcinoma;
CESC	cis	rs11122272	0.735	rs2474633	chr1:231486989	A/C	cg06096015	chr1:231504339	EGLN1	0.42	6.08	0.35	4.12e-9	Hemoglobin concentration;
CESC	cis	rs7772486	0.686	rs702305	chr6:145973840	A/G	cg05347473	chr6:146136440	FBXO30	-0.55	-7.18	-0.4	6.9e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7020830	0.898	rs495863	chr9:37346955	T/C	cg14294708	chr9:37120828	ZCCHC7	1.09	18.86	0.76	6.59e-51	Schizophrenia;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg16265552	chr3:113667068	ZDHHC23	0.49	6.58	0.37	2.57e-10	Systemic lupus erythematosus;
CESC	cis	rs1799949	0.965	rs8176087	chr17:41270666	C/A	cg05368731	chr17:41323189	NBR1	0.8	10.98	0.56	2.35e-23	Menopause (age at onset);
CESC	cis	rs938554	0.578	rs7663032	chr4:9993838	C/T	cg00071950	chr4:10020882	SLC2A9	0.69	9.03	0.48	3.75e-17	Blood metabolite levels;
CESC	cis	rs2066819	1.000	rs76745316	chr12:56627652	A/C	cg26714650	chr12:56694279	CS	-1.53	-10.32	-0.54	3.19e-21	Psoriasis vulgaris;
CESC	cis	rs4242434	0.927	rs11781149	chr8:22473158	C/T	cg03733263	chr8:22462867	KIAA1967	0.94	13.12	0.63	1.2e-30	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CESC	trans	rs11971186	1.000	rs2299521	chr7:126431625	T/A	cg10894441	chr11:111169905	C11orf92;C11orf93	0.49	6.05	0.35	5.04e-9	Chemerin levels;
CESC	cis	rs9322193	0.923	rs2342765	chr6:150180009	C/G	cg09699651	chr6:150184138	LRP11	0.43	5.41	0.32	1.42e-7	Lung cancer;
CESC	cis	rs10504229	0.683	rs11785258	chr8:58132893	A/G	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs6062302	0.522	rs13038448	chr20:62218453	C/T	cg09650180	chr20:62225654	GMEB2	-0.8	-8.97	-0.48	5.35e-17	Glioblastoma;
CESC	cis	rs10504229	0.679	rs12679941	chr8:58051812	G/T	cg24829409	chr8:58192753	C8orf71	-0.5	-6.18	-0.36	2.37e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs10504229	0.775	rs17804888	chr8:58158315	G/T	cg24829409	chr8:58192753	C8orf71	0.69	8.02	0.44	3.34e-14	Developmental language disorder (linguistic errors);
CESC	cis	rs854765	0.583	rs11650649	chr17:17790319	C/A	cg16928487	chr17:17741425	SREBF1	0.61	10.63	0.55	3.17e-22	Total body bone mineral density;
CESC	cis	rs854765	0.583	rs66531105	chr17:17809001	C/T	cg16928487	chr17:17741425	SREBF1	-0.56	-9.71	-0.51	2.83e-19	Total body bone mineral density;
CESC	cis	rs8028182	0.636	rs7184046	chr15:75866150	G/C	cg20655648	chr15:75932815	IMP3	0.48	5.89	0.34	1.19e-8	Sudden cardiac arrest;
CESC	cis	rs9929218	1.000	rs13334326	chr16:68809207	C/T	cg02972257	chr16:68554789	NA	0.43	5.08	0.3	7.13e-7	Colorectal cancer;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg24219929	chr15:60884748	RORA	-0.52	-6.26	-0.36	1.52e-9	Ulcerative colitis;
CESC	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg07167872	chr1:205819463	PM20D1	0.8	13.95	0.65	1.5e-33	Menarche (age at onset);
CESC	cis	rs736801	0.780	rs2188962	chr5:131770805	C/T	cg07395648	chr5:131743802	NA	-0.43	-5.41	-0.32	1.42e-7	Breast cancer;Mosquito bite size;
CESC	cis	rs8060686	0.641	rs12600199	chr16:68069742	C/T	cg26727032	chr16:67993705	SLC12A4	-0.54	-6.21	-0.36	2.01e-9	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs6545883	0.929	rs3732170	chr2:61749716	C/T	cg15711740	chr2:61764176	XPO1	-0.44	-5.47	-0.32	1.05e-7	Tuberculosis;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg04686114	chr12:57081832	PTGES3	-0.47	-6.99	-0.39	2.22e-11	Fibrinogen levels;
CESC	cis	rs1862618	0.573	rs2591962	chr5:56237155	G/A	cg12311346	chr5:56204834	C5orf35	0.87	10.78	0.55	1.05e-22	Initial pursuit acceleration;
CESC	trans	rs6759922	1.000	rs10865093	chr2:22459372	T/C	cg21162304	chr4:80247171	NAA11	0.38	6.09	0.35	3.88e-9	Subjective well-being (multi-trait analysis);
CESC	cis	rs854765	0.647	rs854763	chr17:18010095	C/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.63	8.77	0.47	2.21e-16	Total body bone mineral density;
CESC	cis	rs7116495	0.609	rs6592447	chr11:71641093	A/T	cg10381502	chr11:71823885	C11orf51	-1.09	-7.67	-0.43	3.3e-13	Severe influenza A (H1N1) infection;
CESC	cis	rs9640161	0.658	rs74348353	chr7:150053655	C/A	cg10018233	chr7:150070692	REPIN1	0.41	5.85	0.34	1.41e-8	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs2470135	1	rs2470135	chr15:43995789	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.49	6.16	0.35	2.7e-9	Diastolic blood pressure;
CESC	cis	rs853679	0.517	rs9380047	chr6:28037893	G/T	cg22143856	chr6:28129313	ZNF389	0.49	6.25	0.36	1.64e-9	Depression;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg02388999	chr6:131384671	EPB41L2	-0.43	-6.08	-0.35	4.07e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs7666738	0.611	rs34982650	chr4:98819530	T/A	cg17366294	chr4:99064904	C4orf37	0.55	7.5	0.42	9.71e-13	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25130390	chr15:65810150	DPP8	0.56	6.41	0.37	6.76e-10	Gut microbiome composition (summer);
CESC	cis	rs4986811	1.000	rs5030157	chr11:32450825	C/T	cg27409910	chr11:32454216	WT1	0.44	5.52	0.32	7.9e-8	Rubella-specific interleukin-6 secretion;
CESC	cis	rs425277	0.538	rs169037	chr1:2095582	G/T	cg12718519	chr1:2058417	PRKCZ	0.25	5.34	0.31	2.03e-7	Height;
CESC	cis	rs765787	0.530	rs1648285	chr15:45517505	C/G	cg24006582	chr15:45444508	DUOX1	-0.56	-6.74	-0.38	9.92e-11	Uric acid levels;
CESC	cis	rs11997175	0.740	rs4467902	chr8:33693415	G/T	ch.8.33884649F	chr8:33765107	NA	0.44	5.62	0.33	4.75e-8	Body mass index;
CESC	cis	rs9911578	0.967	rs12603238	chr17:57130785	C/T	cg12560992	chr17:57184187	TRIM37	-1.02	-17.96	-0.74	9.86e-48	Intelligence (multi-trait analysis);
CESC	cis	rs7605827	0.897	rs9973344	chr2:15632583	G/T	cg19274914	chr2:15703543	NA	0.37	6.52	0.37	3.45e-10	Educational attainment (years of education);
CESC	trans	rs9329221	0.537	rs6601415	chr8:9976805	C/A	cg15556689	chr8:8085844	FLJ10661	0.51	6.53	0.37	3.33e-10	Neuroticism;
CESC	cis	rs2213920	0.516	rs34302658	chr9:118168158	T/A	cg13918206	chr9:118159781	DEC1	-0.67	-5.5	-0.32	9.03e-8	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
CESC	cis	rs28595532	0.702	rs72670250	chr4:119337134	T/C	cg21605333	chr4:119757512	SEC24D	0.99	5.78	0.33	2.05e-8	Cannabis dependence symptom count;
CESC	cis	rs1983891	0.955	rs7753653	chr6:41548430	C/T	cg20194872	chr6:41519635	FOXP4	-0.55	-7.77	-0.43	1.68e-13	Prostate cancer;
CESC	cis	rs34779708	0.931	rs35886556	chr10:35334985	C/T	cg03585969	chr10:35415529	CREM	0.75	9.89	0.52	7.72e-20	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs2072732	0.861	rs12040299	chr1:2951041	C/T	cg03976712	chr1:2946727	NA	0.33	5.58	0.32	6.04e-8	Plateletcrit;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg13171016	chr1:40219054	PPIE	0.45	6.39	0.37	7.33e-10	Fibrinogen levels;
CESC	cis	rs1552244	1.000	rs6764168	chr3:10123805	A/G	cg16606324	chr3:10149918	C3orf24	0.42	5.16	0.3	4.9e-7	Alzheimer's disease;
CESC	trans	rs8057939	0.593	rs12598511	chr16:49434930	A/G	cg15532236	chr6:170188124	NA	0.49	6.1	0.35	3.68e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs1153858	1.000	rs67831559	chr15:45649307	G/T	cg21132104	chr15:45694354	SPATA5L1	0.84	11.42	0.57	7.96e-25	Homoarginine levels;
CESC	cis	rs12701220	0.542	rs6957866	chr7:1111674	G/A	cg26769984	chr7:1090371	C7orf50	0.56	5.68	0.33	3.52e-8	Bronchopulmonary dysplasia;
CESC	cis	rs7107174	1.000	rs10899457	chr11:78001163	T/A	cg02023728	chr11:77925099	USP35	0.5	6.63	0.38	1.85e-10	Testicular germ cell tumor;
CESC	cis	rs57083693	0.518	rs10778113	chr12:101741961	G/A	cg22051763	chr12:101673672	UTP20	-0.42	-5.3	-0.31	2.47e-7	Alcohol dependence (age at onset);
CESC	cis	rs6570726	0.791	rs379040	chr6:145889035	T/C	cg05347473	chr6:146136440	FBXO30	0.54	7.08	0.4	1.28e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9910055	0.639	rs7217858	chr17:42254527	T/G	cg08499158	chr17:42289980	UBTF	-0.47	-5.74	-0.33	2.53e-8	Total body bone mineral density;
CESC	trans	rs5769765	0.908	rs9616376	chr22:50310829	A/G	cg09872104	chr7:134855509	C7orf49	-0.55	-6.27	-0.36	1.47e-9	Schizophrenia;
CESC	cis	rs270601	0.770	rs10463891	chr5:131597392	C/T	cg24060327	chr5:131705240	SLC22A5	0.51	6.57	0.37	2.69e-10	Acylcarnitine levels;
CESC	cis	rs9910055	0.571	rs28897216	chr17:42240824	A/G	cg19774624	chr17:42201019	HDAC5	-0.9	-14.84	-0.67	1.09e-36	Total body bone mineral density;
CESC	cis	rs78456975	1.000	rs10208449	chr2:1563257	G/A	cg01028140	chr2:1542097	TPO	-0.63	-5.87	-0.34	1.29e-8	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs4722585	0.533	rs3753097	chr7:26198207	A/G	cg07876897	chr7:26191696	NFE2L3	0.44	5.62	0.33	4.89e-8	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
CESC	cis	rs3809566	0.963	rs3809565	chr15:63333619	A/G	cg05507819	chr15:63340323	TPM1	0.5	6.0	0.35	6.42e-9	Platelet count;
CESC	cis	rs193541	0.632	rs430069	chr5:122263351	G/A	cg19412675	chr5:122181750	SNX24	0.42	5.1	0.3	6.39e-7	Glucose homeostasis traits;
CESC	cis	rs72781680	0.611	rs2111884	chr2:24289472	A/T	cg06627628	chr2:24431161	ITSN2	-0.67	-6.33	-0.36	1.06e-9	Lymphocyte counts;
CESC	cis	rs2688608	0.592	rs10824032	chr10:75528130	G/A	cg23231163	chr10:75533350	FUT11	-0.35	-5.31	-0.31	2.33e-7	Inflammatory bowel disease;
CESC	cis	rs6840258	1.000	rs56406125	chr4:87940205	G/T	cg08197287	chr4:87952173	AFF1	-0.41	-5.24	-0.31	3.23e-7	Mean corpuscular volume;Basophil percentage of granulocytes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26612947	chr15:75495112	C15orf39	-0.56	-6.22	-0.36	1.9e-9	Gut microbiome composition (summer);
CESC	cis	rs10779751	1.000	rs4845986	chr1:11288633	G/C	cg08854313	chr1:11322531	MTOR	0.83	11.83	0.59	3.29e-26	Body mass index;
CESC	trans	rs35110281	0.805	rs162402	chr21:44963418	G/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.49	6.44	0.37	5.53e-10	Mean corpuscular volume;
CESC	cis	rs11658309	1	rs11658309	chr17:17762247	T/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.49	-6.58	-0.37	2.43e-10	Strep throat;
CESC	cis	rs4665809	0.590	rs2303894	chr2:26508187	A/G	cg04944784	chr2:26401820	FAM59B	0.89	9.24	0.49	8.39e-18	Gut microbiome composition (summer);
CESC	cis	rs929354	1.000	rs1182391	chr7:157038368	T/C	cg05182265	chr7:156933206	UBE3C	0.4	5.5	0.32	9.06e-8	Body mass index;
CESC	cis	rs752010	0.841	rs17363834	chr1:42076607	C/T	cg06885757	chr1:42089581	HIVEP3	0.47	7.59	0.42	5.33e-13	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs10744422	1.000	rs7139055	chr12:123364198	A/G	cg25930673	chr12:123319894	HIP1R	0.79	5.92	0.34	9.84e-9	Schizophrenia;
CESC	cis	rs10504229	0.953	rs115634610	chr8:58190533	G/A	cg24829409	chr8:58192753	C8orf71	-0.75	-10.01	-0.52	3.22e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs2404602	0.692	rs35138393	chr15:76977617	G/A	cg26408565	chr15:76604113	ETFA	-0.39	-5.72	-0.33	2.94e-8	Blood metabolite levels;
CESC	trans	rs650950	0.528	rs646660	chr11:35528452	C/T	cg22792938	chr2:228337242	AGFG1	0.47	6.74	0.38	9.98e-11	Bronchopulmonary dysplasia;
CESC	cis	rs7666738	0.830	rs62321565	chr4:98976571	G/A	cg03467027	chr4:99064603	C4orf37	0.42	5.29	0.31	2.5e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11098499	0.774	rs11098505	chr4:120284627	C/T	cg24375607	chr4:120327624	NA	0.42	5.19	0.3	4.19e-7	Corneal astigmatism;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02470565	chr22:29702866	GAS2L1	0.58	6.51	0.37	3.77e-10	Gut microbiome composition (summer);
CESC	cis	rs10876993	0.826	rs1678534	chr12:58057435	A/C	cg18357645	chr12:58087776	OS9	0.62	9.82	0.52	1.26e-19	Celiac disease or Rheumatoid arthritis;
CESC	cis	rs734999	0.545	rs41300092	chr1:2537838	C/T	cg18854424	chr1:2615690	NA	0.3	5.83	0.34	1.65e-8	Ulcerative colitis;
CESC	cis	rs2191566	0.747	rs4803667	chr19:44533604	T/C	cg20607764	chr19:44506953	ZNF230	-0.59	-7.45	-0.42	1.28e-12	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs3858526	0.584	rs10769266	chr11:5858460	C/T	cg13902645	chr11:5959945	NA	-0.67	-9.05	-0.49	3.08e-17	DNA methylation (variation);
CESC	trans	rs875971	1.000	rs778706	chr7:65860424	A/G	cg26939375	chr7:64535504	NA	0.47	6.06	0.35	4.77e-9	Aortic root size;
CESC	cis	rs7917772	0.619	rs2251772	chr10:104470918	T/C	cg22532475	chr10:104410764	TRIM8	-0.37	-5.31	-0.31	2.32e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs8114671	0.562	rs6060064	chr20:33406339	C/G	cg08999081	chr20:33150536	PIGU	-0.37	-5.32	-0.31	2.22e-7	Height;
CESC	cis	rs9322193	0.962	rs10872656	chr6:150120580	A/C	cg04369109	chr6:150039330	LATS1	-0.4	-5.5	-0.32	9.07e-8	Lung cancer;
CESC	cis	rs6540559	0.673	rs6694552	chr1:209976459	A/C	cg22029157	chr1:209979665	IRF6	0.76	8.93	0.48	7.36e-17	Cleft lip with or without cleft palate;
CESC	cis	rs3733585	0.673	rs9994266	chr4:9954450	C/T	cg02734326	chr4:10020555	SLC2A9	-0.39	-5.61	-0.33	5.13e-8	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs1552244	0.935	rs7649243	chr3:10089470	T/A	cg00166722	chr3:10149974	C3orf24	0.52	6.38	0.36	7.91e-10	Alzheimer's disease;
CESC	cis	rs2549003	0.966	rs839	chr5:131819126	C/T	cg02551604	chr5:131831745	NA	-0.37	-5.22	-0.31	3.53e-7	Asthma (sex interaction);
CESC	cis	rs5753618	0.561	rs13054220	chr22:31704492	A/G	cg00478049	chr22:31556069	RNF185	-0.45	-5.04	-0.3	8.52e-7	Colorectal cancer;
CESC	cis	rs7520050	0.966	rs6668284	chr1:46354510	G/A	cg24296786	chr1:45957014	TESK2	0.43	5.41	0.32	1.42e-7	Red blood cell count;Reticulocyte count;
CESC	cis	rs4076764	1.000	rs4076764	chr1:163441286	A/G	cg24596788	chr1:163392923	NA	-0.46	-6.73	-0.38	1.05e-10	Motion sickness;
CESC	trans	rs386965	0.545	rs2348180	chr16:79650056	T/A	cg27092986	chr12:7858592	NA	-0.43	-6.23	-0.36	1.78e-9	Multiple sclerosis;
CESC	cis	rs561341	1.000	rs72823789	chr17:30284084	G/A	cg19193384	chr17:30244184	NA	-0.71	-6.6	-0.38	2.17e-10	Hip circumference adjusted for BMI;
CESC	cis	rs1707322	1.000	rs946524	chr1:46487560	A/G	cg03146154	chr1:46216737	IPP	-0.72	-9.88	-0.52	8.55e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs13256369	1.000	rs10110591	chr8:8576608	G/T	cg18904891	chr8:8559673	CLDN23	-0.67	-8.11	-0.45	1.84e-14	Obesity-related traits;
CESC	cis	rs2228479	0.557	rs12933317	chr16:89828220	A/G	cg14709524	chr16:89940631	TCF25	0.89	6.55	0.37	2.99e-10	Skin colour saturation;
CESC	cis	rs2463822	0.925	rs12292586	chr11:62156312	C/T	cg06239285	chr11:62104954	ASRGL1	-0.98	-8.69	-0.47	3.91e-16	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs344364	0.511	rs911392	chr16:1947259	A/G	cg26617929	chr16:1858877	NA	-0.49	-5.24	-0.31	3.24e-7	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs7943191	0.810	rs7942154	chr11:62337163	G/A	cg13298116	chr11:62369859	EML3;MTA2	0.53	7.43	0.42	1.47e-12	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
CESC	cis	rs875971	0.862	rs1860469	chr7:66106875	A/G	cg13147721	chr7:65941812	NA	0.38	5.36	0.31	1.77e-7	Aortic root size;
CESC	cis	rs733592	0.507	rs10875739	chr12:48480919	C/T	cg24011408	chr12:48396354	COL2A1	0.49	7.94	0.44	5.87e-14	Plateletcrit;
CESC	cis	rs9300255	0.512	rs2851436	chr12:123667354	G/T	cg05973401	chr12:123451056	ABCB9	0.49	5.49	0.32	9.51e-8	Neutrophil percentage of white cells;
CESC	cis	rs1707322	1.000	rs11211239	chr1:46451947	A/G	cg05343316	chr1:45956843	TESK2	0.44	5.42	0.32	1.36e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs6964587	1.000	rs415	chr7:91580490	A/G	cg17063962	chr7:91808500	NA	-0.57	-7.68	-0.43	3.06e-13	Breast cancer;
CESC	cis	rs3204270	0.759	rs8066217	chr17:79672615	C/G	cg18367735	chr17:79674897	NA	0.66	5.46	0.32	1.12e-7	Dental caries;
CESC	cis	rs6484504	0.576	rs9971609	chr11:31434104	C/T	cg14844989	chr11:31128820	NA	0.42	5.84	0.34	1.49e-8	Red blood cell count;
CESC	cis	rs7412746	0.658	rs10888397	chr1:150886752	A/G	cg22823121	chr1:150693482	HORMAD1	-0.37	-5.18	-0.3	4.47e-7	Melanoma;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg11869233	chr2:48009809	MSH6	0.48	6.8	0.39	7.11e-11	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs17818399	1.000	rs17818399	chr2:46826026	A/C	cg02822958	chr2:46747628	ATP6V1E2	0.48	5.97	0.34	7.53e-9	Height;
CESC	cis	rs780096	0.546	rs1647284	chr2:27608115	C/T	cg02592271	chr2:27665507	KRTCAP3	-0.28	-5.67	-0.33	3.77e-8	Total body bone mineral density;
CESC	cis	rs67311347	0.713	rs4974018	chr3:40307419	G/A	cg09455208	chr3:40491958	NA	0.43	7.28	0.41	3.69e-12	Renal cell carcinoma;
CESC	cis	rs4523957	0.651	rs4790316	chr17:2074977	T/C	cg16513277	chr17:2031491	SMG6	-0.69	-9.45	-0.5	1.87e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs780096	0.565	rs13022659	chr2:27743630	C/T	cg21248554	chr2:27665150	KRTCAP3	-0.35	-7.15	-0.4	8.38e-12	Total body bone mineral density;
CESC	cis	rs9322193	0.923	rs11155677	chr6:150078089	C/G	cg13206674	chr6:150067644	NUP43	0.46	6.63	0.38	1.84e-10	Lung cancer;
CESC	trans	rs116095464	0.558	rs10075018	chr5:239175	G/A	cg00938859	chr5:1591904	SDHAP3	0.65	7.19	0.4	6.47e-12	Breast cancer;
CESC	cis	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg21782813	chr7:2030301	MAD1L1	0.43	6.09	0.35	3.99e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs523522	0.962	rs10849758	chr12:120971149	C/T	cg12219531	chr12:120966889	COQ5	0.75	9.99	0.52	3.7e-20	High light scatter reticulocyte count;
CESC	cis	rs9611565	0.649	rs2413659	chr22:42164862	A/G	cg03806693	chr22:41940476	POLR3H	0.8	9.72	0.51	2.66e-19	Vitiligo;
CESC	cis	rs698833	0.886	rs698766	chr2:44574277	C/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.47	5.81	0.34	1.77e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18548362	chr4:1857197	LETM1	0.66	8.08	0.44	2.28e-14	Gut microbiome composition (summer);
CESC	cis	rs941408	0.515	rs2110118	chr19:2775144	T/C	cg02580895	chr19:2754563	NA	-0.46	-6.3	-0.36	1.21e-9	Total cholesterol levels;
CESC	cis	rs2933343	1.000	rs6785869	chr3:128643144	G/A	cg25356066	chr3:128598488	ACAD9	0.61	7.52	0.42	8.33e-13	IgG glycosylation;
CESC	cis	rs6500395	0.962	rs7499213	chr16:48680597	T/C	cg04672837	chr16:48644449	N4BP1	0.46	5.46	0.32	1.08e-7	Response to tocilizumab in rheumatoid arthritis;
CESC	trans	rs11250098	0.600	rs4240671	chr8:10767748	A/G	cg15556689	chr8:8085844	FLJ10661	0.52	6.55	0.37	3.04e-10	Morning vs. evening chronotype;
CESC	cis	rs9287719	0.967	rs9679581	chr2:10751736	G/A	cg00105475	chr2:10696890	NA	0.38	5.57	0.32	6.34e-8	Prostate cancer;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg06666157	chr19:4791552	FEM1A	-0.53	-7.76	-0.43	1.85e-13	Gambling;
CESC	cis	rs7618501	0.699	rs9821675	chr3:49902544	A/G	cg24308560	chr3:49941425	MST1R	-0.7	-10.4	-0.54	1.82e-21	Intelligence (multi-trait analysis);
CESC	cis	rs1799949	1.000	rs9646412	chr17:41425893	A/T	cg05368731	chr17:41323189	NBR1	0.77	10.49	0.54	9.27e-22	Menopause (age at onset);
CESC	cis	rs2228479	0.541	rs9806913	chr16:89953773	A/G	cg00800038	chr16:89945340	TCF25	-0.64	-7.05	-0.4	1.57e-11	Skin colour saturation;
CESC	cis	rs4728302	0.869	rs10224683	chr7:133590937	A/G	cg10665199	chr7:133106180	EXOC4	-0.39	-5.38	-0.31	1.64e-7	Intelligence;Intelligence (multi-trait analysis);
CESC	cis	rs7618915	0.524	rs35249778	chr3:52661640	G/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	7.07	0.4	1.36e-11	Bipolar disorder;
CESC	cis	rs10276381	0.786	rs73089302	chr7:28187134	G/A	cg23620719	chr7:28220237	JAZF1	0.74	7.96	0.44	5.01e-14	Crohn's disease;
CESC	cis	rs34779708	0.931	rs66887762	chr10:35330577	C/T	cg03585969	chr10:35415529	CREM	0.78	10.23	0.53	6.43e-21	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs1165640	0.522	rs2687735	chr3:193558082	A/G	cg21197336	chr3:193587490	NA	0.47	5.38	0.31	1.64e-7	Smoking cessation in chronic obstructive pulmonary disease;
CESC	cis	rs9388451	0.903	rs7758115	chr6:126061502	C/T	cg05901451	chr6:126070800	HEY2	-0.64	-9.58	-0.51	7.15e-19	Brugada syndrome;
CESC	cis	rs3008870	0.959	rs2985826	chr1:67412918	G/C	cg08660285	chr1:67390436	MIER1;WDR78	1.06	15.19	0.68	6.65e-38	Lymphocyte percentage of white cells;
CESC	cis	rs2295499	0.744	rs2282768	chr4:2716147	A/C	cg08330972	chr4:2403930	ZFYVE28	-0.32	-5.22	-0.31	3.62e-7	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
CESC	cis	rs9911578	0.933	rs2531725	chr17:56517962	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.39	5.23	0.31	3.52e-7	Intelligence (multi-trait analysis);
CESC	cis	rs1552244	1.000	rs6781811	chr3:10121922	A/G	cg00166722	chr3:10149974	C3orf24	-0.52	-6.89	-0.39	4.13e-11	Alzheimer's disease;
CESC	cis	rs9660992	0.674	rs12122105	chr1:205256818	C/T	cg21643547	chr1:205240462	TMCC2	-0.44	-5.92	-0.34	1.01e-8	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs7914558	1.000	rs7914558	chr10:104775908	G/A	cg15744005	chr10:104629667	AS3MT	-0.33	-5.38	-0.31	1.63e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs875971	0.862	rs1983372	chr7:65611351	C/T	cg11764359	chr7:65958608	NA	-0.78	-11.42	-0.57	8.05e-25	Aortic root size;
CESC	cis	rs7246657	0.943	rs10426666	chr19:37828514	C/G	cg23950597	chr19:37808831	NA	-0.62	-6.3	-0.36	1.26e-9	Coronary artery calcification;
CESC	cis	rs5758511	0.633	rs5751258	chr22:42663871	C/G	cg00645731	chr22:42541494	CYP2D7P1	0.58	8.76	0.47	2.43e-16	Birth weight;
CESC	cis	rs875971	0.545	rs1065265	chr7:65841203	C/T	cg11764359	chr7:65958608	NA	0.82	9.37	0.5	3.25e-18	Aortic root size;
CESC	cis	rs6547741	0.844	rs7382	chr2:27873415	G/A	cg27432699	chr2:27873401	GPN1	-0.6	-8.78	-0.47	2.1e-16	Oral cavity cancer;
CESC	cis	rs36051895	0.632	rs10121316	chr9:5147539	C/T	cg02405213	chr9:5042618	JAK2	0.47	6.11	0.35	3.53e-9	Pediatric autoimmune diseases;
CESC	cis	rs4665809	0.627	rs35461456	chr2:26482361	C/G	cg08470875	chr2:26401718	FAM59B	0.75	7.78	0.43	1.63e-13	Gut microbiome composition (summer);
CESC	cis	rs4975709	0.569	rs2353583	chr5:1858834	G/C	cg12288994	chr5:1860383	NA	0.42	6.85	0.39	5.21e-11	Cardiovascular disease risk factors;
CESC	cis	rs763014	0.932	rs2384972	chr16:674424	G/A	cg07343612	chr16:622815	PIGQ	-0.57	-8.34	-0.46	4.2e-15	Height;
CESC	cis	rs11750568	0.967	rs4701034	chr5:178513921	T/C	cg10208897	chr5:178548229	ADAMTS2	0.38	5.37	0.31	1.72e-7	Height;
CESC	cis	rs1670533	0.932	rs2045067	chr4:1052355	C/T	cg27284194	chr4:1044797	NA	0.45	5.78	0.33	2.07e-8	Recombination rate (females);
CESC	cis	rs9948	1.000	rs10203346	chr2:97517237	A/G	cg01990225	chr2:97406019	LMAN2L	-0.68	-5.19	-0.3	4.13e-7	Erectile dysfunction and prostate cancer treatment;
CESC	cis	rs847577	0.569	rs7804318	chr7:97796635	A/G	cg21770322	chr7:97807741	LMTK2	-0.81	-13.47	-0.64	7.67e-32	Breast cancer;
CESC	cis	rs7959452	0.640	rs4274230	chr12:69700772	T/G	cg20891283	chr12:69753455	YEATS4	0.77	11.22	0.57	3.71e-24	Blood protein levels;
CESC	cis	rs6762	0.748	rs1130663	chr11:837582	G/A	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.68	-9.16	-0.49	1.45e-17	Mean platelet volume;
CESC	cis	rs597539	0.617	rs672853	chr11:68636362	G/A	cg04772025	chr11:68637568	NA	0.53	5.97	0.34	7.49e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg01516881	chr6:292596	DUSP22	-0.83	-11.34	-0.57	1.42e-24	Menopause (age at onset);
CESC	cis	rs6912958	0.874	rs2103764	chr6:88157392	T/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.32	-5.31	-0.31	2.31e-7	Monocyte percentage of white cells;
CESC	cis	rs9486719	0.947	rs12208556	chr6:96903486	C/T	cg06623918	chr6:96969491	KIAA0776	-0.85	-9.54	-0.51	9.97e-19	Migraine;Coronary artery disease;
CESC	cis	rs3820928	1.000	rs3731593	chr2:227773924	A/G	cg11843606	chr2:227700838	RHBDD1	-0.45	-5.97	-0.34	7.51e-9	Pulmonary function;
CESC	cis	rs11098499	0.645	rs78422072	chr4:120281042	C/T	cg09307838	chr4:120376055	NA	0.85	11.06	0.56	1.25e-23	Corneal astigmatism;
CESC	cis	rs61931739	0.500	rs11053280	chr12:34559297	G/T	cg19457237	chr12:34500585	NA	-0.37	-5.08	-0.3	6.97e-7	Morning vs. evening chronotype;
CESC	cis	rs1728785	1.000	rs1170436	chr16:68607486	T/A	cg02972257	chr16:68554789	NA	-0.6	-6.82	-0.39	6.06e-11	Ulcerative colitis;
CESC	cis	rs4342066	0.593	rs34692982	chr3:28276558	A/T	cg15038811	chr3:28283857	CMC1	0.39	5.04	0.3	8.55e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9457247	0.534	rs2757053	chr6:167380338	A/C	cg23791538	chr6:167370224	RNASET2	0.7	10.02	0.52	2.95e-20	Crohn's disease;
CESC	cis	rs4523957	0.553	rs2172593	chr17:2025544	G/C	cg16513277	chr17:2031491	SMG6	-0.77	-11.34	-0.57	1.43e-24	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg01353464	chr3:38180116	ACAA1;MYD88	0.44	6.01	0.35	6e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs832540	0.931	rs33319	chr5:56206675	C/A	cg12311346	chr5:56204834	C5orf35	-0.45	-5.69	-0.33	3.39e-8	Coronary artery disease;
CESC	cis	rs17764205	0.929	rs10415057	chr19:3255643	C/T	cg04171554	chr19:2761892	SGTA	-0.55	-5.15	-0.3	4.97e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs1728785	0.818	rs11648503	chr16:68598938	G/A	cg02972257	chr16:68554789	NA	-0.68	-7.63	-0.42	4.2e-13	Ulcerative colitis;
CESC	cis	rs56235845	0.694	rs11748912	chr5:176765395	G/A	cg17509989	chr5:176798049	RGS14	0.49	6.21	0.36	2.02e-9	Hemoglobin concentration;Hematocrit;
CESC	cis	rs10088262	0.629	rs1367829	chr8:124797135	A/G	cg15047889	chr8:124780837	FAM91A1	-0.52	-6.58	-0.37	2.57e-10	Pancreatic cancer;
CESC	cis	rs11098499	0.954	rs6822679	chr4:120402702	A/C	cg24375607	chr4:120327624	NA	0.44	5.44	0.32	1.19e-7	Corneal astigmatism;
CESC	cis	rs514406	0.825	rs6695819	chr1:53223366	T/C	cg16325326	chr1:53192061	ZYG11B	-0.89	-15.32	-0.69	2.26e-38	Monocyte count;
CESC	cis	rs2243480	0.803	rs423187	chr7:65509499	G/C	cg18252515	chr7:66147081	NA	-1.33	-13.11	-0.63	1.29e-30	Diabetic kidney disease;
CESC	cis	rs4819052	0.918	rs34886433	chr21:46680538	G/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.61	7.06	0.4	1.43e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs10504229	0.683	rs6995355	chr8:58113870	C/T	cg24829409	chr8:58192753	C8orf71	-0.59	-7.32	-0.41	2.94e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs3105593	0.933	rs3131588	chr15:50842052	G/T	cg08437265	chr15:50716283	USP8	0.42	5.52	0.32	8.18e-8	QT interval;
CESC	cis	rs854765	0.547	rs7209003	chr17:17907393	T/A	cg09796270	chr17:17721594	SREBF1	0.39	5.47	0.32	1.06e-7	Total body bone mineral density;
CESC	cis	rs9311474	0.508	rs1570	chr3:52586682	T/A	cg18404041	chr3:52824283	ITIH1	-0.38	-6.46	-0.37	4.94e-10	Electroencephalogram traits;
CESC	cis	rs6087990	0.806	rs6088008	chr20:31382860	A/G	cg13636640	chr20:31349939	DNMT3B	0.79	12.15	0.6	2.7e-27	Ulcerative colitis;
CESC	cis	rs12950390	1.000	rs12950390	chr17:45830948	A/G	cg00777063	chr17:45855553	NA	-0.38	-5.07	-0.3	7.5e-7	IgG glycosylation;
CESC	cis	rs644799	1.000	rs11021319	chr11:95523123	C/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.53	6.61	0.38	2.16e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	13.67	0.64	1.44e-32	Prudent dietary pattern;
CESC	cis	rs896854	0.684	rs10099059	chr8:95986972	G/C	cg23172400	chr8:95962367	TP53INP1	-0.44	-9.22	-0.49	9.93e-18	Type 2 diabetes;
CESC	cis	rs7179456	0.545	rs585192	chr15:59052210	T/C	cg05156742	chr15:59063176	FAM63B	0.6	7.59	0.42	5.54e-13	Asperger disorder;
CESC	cis	rs5758511	0.634	rs1001587	chr22:42670111	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.58	8.66	0.47	4.81e-16	Birth weight;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg05207227	chr22:29703180	GAS2L1	0.4	6.15	0.35	2.86e-9	Systemic lupus erythematosus;
CESC	cis	rs875971	0.789	rs28815324	chr7:65565776	A/T	cg19163074	chr7:65112434	INTS4L2	0.52	5.35	0.31	1.87e-7	Aortic root size;
CESC	cis	rs863345	0.504	rs857714	chr1:158566972	C/T	cg12129480	chr1:158549410	OR10X1	0.27	5.04	0.3	8.45e-7	Pneumococcal bacteremia;
CESC	cis	rs7312774	0.881	rs12320167	chr12:107310167	G/A	cg16260113	chr12:107380972	MTERFD3	0.64	6.08	0.35	4.15e-9	Severe influenza A (H1N1) infection;
CESC	cis	rs2718058	0.519	rs2598071	chr7:37875347	G/A	cg15028436	chr7:37888078	TXNDC3	0.51	7.22	0.41	5.62e-12	Alzheimer's disease (late onset);
CESC	cis	rs7666738	1.000	rs13106934	chr4:99028685	C/T	cg03676636	chr4:99064102	C4orf37	0.37	5.41	0.32	1.39e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10129255	0.500	rs7157975	chr14:107212287	G/A	cg23076370	chr14:107095027	NA	-0.64	-9.43	-0.5	2.13e-18	Kawasaki disease;
CESC	cis	rs3820068	0.581	rs74054797	chr1:15926217	G/A	cg16988262	chr1:15930761	NA	0.35	5.65	0.33	4.18e-8	Systolic blood pressure;
CESC	cis	rs9929218	0.953	rs17772411	chr16:68810923	T/C	cg02972257	chr16:68554789	NA	0.43	5.14	0.3	5.28e-7	Colorectal cancer;
CESC	cis	rs7666738	0.830	rs1593570	chr4:99017058	T/C	cg17366294	chr4:99064904	C4orf37	0.61	8.77	0.47	2.15e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs722599	0.683	rs8014695	chr14:75301617	C/G	cg11812906	chr14:75593930	NEK9	0.45	5.53	0.32	7.6e-8	IgG glycosylation;
CESC	cis	rs2204008	0.774	rs9669565	chr12:38294428	C/A	cg13010199	chr12:38710504	ALG10B	0.45	5.65	0.33	4.06e-8	Bladder cancer;
CESC	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg23708337	chr7:1209742	NA	0.52	5.16	0.3	4.88e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs9300255	0.602	rs2682431	chr12:123703226	T/A	cg05973401	chr12:123451056	ABCB9	0.5	5.68	0.33	3.48e-8	Neutrophil percentage of white cells;
CESC	cis	rs875971	0.862	rs778686	chr7:65835910	C/T	cg11764359	chr7:65958608	NA	0.81	11.99	0.59	9.35e-27	Aortic root size;
CESC	trans	rs12599106	0.584	rs12929704	chr16:34898258	C/A	cg16103275	chr6:290800	DUSP22	0.43	6.0	0.35	6.6e-9	Menopause (age at onset);
CESC	cis	rs2836974	0.644	rs719230	chr21:40676307	C/T	cg17971929	chr21:40555470	PSMG1	-0.87	-12.61	-0.61	6.96e-29	Cognitive function;
CESC	trans	rs629535	0.814	rs651985	chr8:70054966	G/A	cg21567404	chr3:27674614	NA	0.92	10.87	0.56	5.21e-23	Dupuytren's disease;
CESC	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg27094323	chr7:1216898	NA	-0.42	-5.81	-0.34	1.83e-8	Longevity;Endometriosis;
CESC	cis	rs1215050	0.740	rs6855827	chr4:99065706	G/A	cg17366294	chr4:99064904	C4orf37	0.43	5.6	0.33	5.33e-8	Waist-to-hip ratio adjusted for body mass index;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg09829838	chr6:42952307	PPP2R5D	-0.44	-6.17	-0.35	2.5e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20647962	chr15:41136443	SPINT1	0.66	7.64	0.42	3.9e-13	Gut microbiome composition (summer);
CESC	trans	rs12356475	0.710	rs10822686	chr10:67733250	C/T	cg08984023	chr10:64133896	ZNF365	0.44	6.17	0.35	2.54e-9	Psoriatic arthritis;
CESC	cis	rs5769765	0.773	rs9616378	chr22:50311973	A/G	cg02269571	chr22:50332266	NA	-0.55	-6.79	-0.38	7.53e-11	Schizophrenia;
CESC	cis	rs6942756	0.806	rs1880854	chr7:128949748	G/T	cg02491457	chr7:128862824	NA	0.6	8.66	0.47	4.6e-16	White matter hyperintensity burden;
CESC	cis	rs35160687	0.623	rs718292	chr2:86473740	A/G	cg01119172	chr2:86362222	SNORD94;PTCD3	0.38	5.18	0.3	4.35e-7	Night sleep phenotypes;
CESC	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.4	5.25	0.31	3.12e-7	Lymphocyte counts;
CESC	cis	rs733592	0.524	rs10875727	chr12:48426143	T/C	cg24011408	chr12:48396354	COL2A1	-0.51	-8.59	-0.47	7.74e-16	Plateletcrit;
CESC	cis	rs2204008	0.715	rs3899385	chr12:38169880	C/G	cg13010199	chr12:38710504	ALG10B	0.52	6.6	0.38	2.18e-10	Bladder cancer;
CESC	cis	rs7312933	0.528	rs10880238	chr12:42489613	A/G	cg01256987	chr12:42539512	GXYLT1	-0.45	-6.97	-0.39	2.51e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs875971	1.000	rs2042133	chr7:65931922	A/G	cg10691866	chr7:65817282	TPST1	-0.34	-5.67	-0.33	3.76e-8	Aortic root size;
CESC	cis	rs34779708	0.643	rs4275563	chr10:35545286	G/A	cg03585969	chr10:35415529	CREM	0.55	6.41	0.37	6.66e-10	Inflammatory bowel disease;Crohn's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18021690	chr1:150039108	VPS45	0.58	6.3	0.36	1.24e-9	Gut microbiome composition (summer);
CESC	cis	rs736408	0.522	rs11716747	chr3:52748857	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.6	8.38	0.46	3.24e-15	Bipolar disorder;
CESC	cis	rs736408	0.688	rs2239551	chr3:52818579	A/G	cg08365687	chr3:52569147	NT5DC2;LOC440957	-0.3	-5.12	-0.3	5.82e-7	Bipolar disorder;
CESC	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.47	-5.48	-0.32	9.95e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg17178900	chr1:205818956	PM20D1	0.89	15.71	0.69	9.72e-40	Menarche (age at onset);
CESC	cis	rs6461049	0.638	rs1859993	chr7:2183702	A/G	cg04267008	chr7:1944627	MAD1L1	-0.42	-5.12	-0.3	5.77e-7	Schizophrenia;
CESC	cis	rs1552244	0.882	rs17050699	chr3:10037167	G/A	cg00149659	chr3:10157352	C3orf10	0.7	8.24	0.45	7.79e-15	Alzheimer's disease;
CESC	cis	rs9443645	0.901	rs9352669	chr6:79584141	T/G	cg05283184	chr6:79620031	NA	-0.43	-6.56	-0.37	2.85e-10	Intelligence (multi-trait analysis);
CESC	cis	rs10504229	1.000	rs73609747	chr8:58189104	G/C	cg24829409	chr8:58192753	C8orf71	-0.76	-9.93	-0.52	5.87e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs4689592	0.622	rs2276968	chr4:7070118	T/G	cg26116260	chr4:7069785	GRPEL1	0.94	11.44	0.58	6.64e-25	Monocyte percentage of white cells;
CESC	cis	rs853679	0.517	rs9393885	chr6:28050009	A/T	cg12963246	chr6:28129442	ZNF389	0.55	7.35	0.41	2.46e-12	Depression;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg27022615	chr11:70049105	FADD	-0.53	-6.8	-0.39	6.81e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	trans	rs864643	0.773	rs11129837	chr3:39589963	A/G	cg20646317	chr12:50794494	LARP4	0.51	6.55	0.37	3.02e-10	Attention deficit hyperactivity disorder;
CESC	cis	rs7551222	0.749	rs4951409	chr1:204560990	A/T	cg20240347	chr1:204465584	NA	-0.26	-5.41	-0.32	1.43e-7	Schizophrenia;
CESC	cis	rs17711722	0.510	rs11767457	chr7:65290615	C/T	cg18876405	chr7:65276391	NA	0.49	6.33	0.36	1.02e-9	Calcium levels;
CESC	cis	rs2034088	0.897	rs11652657	chr17:439124	A/G	cg13332499	chr17:408570	NA	0.48	8.35	0.46	3.79e-15	Hip circumference adjusted for BMI;
CESC	cis	rs1018836	0.632	rs6988302	chr8:91477660	C/T	cg16814680	chr8:91681699	NA	-0.62	-8.7	-0.47	3.59e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs1008375	1.000	rs7661631	chr4:17679751	T/C	cg02297831	chr4:17616191	MED28	-0.48	-5.81	-0.34	1.78e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs116095464	0.558	rs12173244	chr5:269524	G/A	cg10591111	chr5:226296	SDHA	-0.52	-6.36	-0.36	8.59e-10	Breast cancer;
CESC	cis	rs61931739	0.534	rs10844767	chr12:34152368	C/G	cg19457237	chr12:34500585	NA	-0.39	-5.35	-0.31	1.93e-7	Morning vs. evening chronotype;
CESC	cis	rs7621025	0.630	rs1681816	chr3:136474762	C/G	cg15507776	chr3:136538369	TMEM22	-0.53	-6.23	-0.36	1.81e-9	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
CESC	cis	rs4073221	0.520	rs13072195	chr3:18199498	C/T	cg07694806	chr3:18168406	NA	-0.66	-5.61	-0.33	5.2e-8	Parkinson's disease;
CESC	cis	rs6500395	0.962	rs3743780	chr16:48647480	A/G	cg04672837	chr16:48644449	N4BP1	0.51	6.21	0.36	2.08e-9	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs7811142	1.000	rs7811142	chr7:100065443	A/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.78	6.73	0.38	1.02e-10	Platelet count;
CESC	cis	rs12136530	0.774	rs11590840	chr1:19779673	A/G	cg01832549	chr1:19774989	CAPZB	-0.45	-6.61	-0.38	2.1e-10	Lead levels in blood;
CESC	cis	rs2836974	0.932	rs2150415	chr21:40615367	A/G	cg17971929	chr21:40555470	PSMG1	0.93	13.11	0.63	1.28e-30	Cognitive function;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18845578	chr2:240003174	HDAC4	-0.68	-7.55	-0.42	6.86e-13	Gut microbiome composition (summer);
CESC	cis	rs7618915	0.501	rs2159644	chr3:52774530	C/T	cg18404041	chr3:52824283	ITIH1	-0.39	-6.59	-0.38	2.4e-10	Bipolar disorder;
CESC	cis	rs9467711	0.606	rs9379864	chr6:26372584	G/A	cg12826209	chr6:26865740	GUSBL1	0.62	5.24	0.31	3.25e-7	Autism spectrum disorder or schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09863028	chr2:242076577	PASK	-0.62	-6.88	-0.39	4.26e-11	Gut microbiome composition (summer);
CESC	cis	rs4474465	0.646	rs4945301	chr11:78283362	A/G	cg27205649	chr11:78285834	NARS2	0.48	6.31	0.36	1.14e-9	Alzheimer's disease (survival time);
CESC	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg27588902	chr6:42928151	GNMT	-0.27	-5.15	-0.3	5.2e-7	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs4699052	0.787	rs2169508	chr4:104066890	T/A	cg16532752	chr4:104119610	CENPE	-0.39	-5.21	-0.3	3.79e-7	Testicular germ cell tumor;
CESC	cis	rs2200578	1.000	rs72954221	chr2:99899445	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.5	5.6	0.33	5.23e-8	IgG glycosylation;
CESC	cis	rs2243480	1.000	rs160633	chr7:65528228	T/C	cg18252515	chr7:66147081	NA	-1.23	-12.45	-0.61	2.44e-28	Diabetic kidney disease;
CESC	cis	rs1218582	0.688	rs2135219	chr1:154857217	G/A	cg03351412	chr1:154909251	PMVK	0.52	6.35	0.36	9.27e-10	Prostate cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21528620	chr1:110753221	KCNC4	0.67	8.45	0.46	1.94e-15	Gut microbiome composition (summer);
CESC	trans	rs7618501	1.000	rs9872864	chr3:49792023	A/G	cg21659725	chr3:3221576	CRBN	-0.83	-13.35	-0.63	1.98e-31	Intelligence (multi-trait analysis);
CESC	cis	rs9487051	1.000	rs9487051	chr6:109617079	A/G	cg21918786	chr6:109611834	NA	-0.36	-5.22	-0.31	3.63e-7	Reticulocyte fraction of red cells;
CESC	cis	rs2836974	0.899	rs34176878	chr21:40548855	C/A	cg27266027	chr21:40555129	PSMG1	0.43	5.24	0.31	3.28e-7	Cognitive function;
CESC	cis	rs6665290	0.545	rs6426584	chr1:227374949	A/T	cg10327440	chr1:227177885	CDC42BPA	-0.9	-13.38	-0.64	1.5e-31	Myeloid white cell count;
CESC	cis	rs3011225	0.710	rs3011222	chr1:44317545	C/T	cg13606994	chr1:44402422	ARTN	-0.35	-5.14	-0.3	5.31e-7	Amyotrophic lateral sclerosis (age of onset);
CESC	cis	rs10779751	0.727	rs4845852	chr1:11233559	C/T	cg08854313	chr1:11322531	MTOR	0.86	12.62	0.61	6.52e-29	Body mass index;
CESC	cis	rs8062405	0.965	rs8049439	chr16:28837515	A/G	cg08761264	chr16:28874980	SH2B1	-0.47	-6.16	-0.35	2.74e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs9309473	0.950	rs7566364	chr2:73842889	T/C	cg20560298	chr2:73613845	ALMS1	-0.43	-5.74	-0.33	2.61e-8	Metabolite levels;
CESC	cis	rs2075371	0.965	rs2544216	chr7:133987902	G/A	cg11752832	chr7:134001865	SLC35B4	0.55	7.23	0.41	5.27e-12	Mean platelet volume;
CESC	cis	rs826838	0.967	rs1684414	chr12:39129553	A/G	cg13010199	chr12:38710504	ALG10B	-0.45	-6.26	-0.36	1.51e-9	Heart rate;
CESC	cis	rs1801251	0.778	rs2592116	chr2:233735709	G/A	cg25237894	chr2:233734115	C2orf82	-0.5	-8.76	-0.47	2.34e-16	Coronary artery disease;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg18366782	chr14:77423080	NA	-0.48	-6.8	-0.39	7.05e-11	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs2066819	1.000	rs2643623	chr12:56689725	G/C	cg26714650	chr12:56694279	CS	1.29	16.3	0.71	7.7e-42	Psoriasis vulgaris;
CESC	trans	rs7178375	1.000	rs4779797	chr15:31208425	C/T	cg04373760	chr16:53404718	NA	-0.52	-6.85	-0.39	5.05e-11	Hypertriglyceridemia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23946709	chr14:23527317	CDH24	0.57	6.25	0.36	1.68e-9	Gut microbiome composition (summer);
CESC	cis	rs2180341	1.000	rs2057223	chr6:127637374	T/C	cg27446573	chr6:127587934	RNF146	1.09	16.38	0.71	3.79e-42	Breast cancer;
CESC	cis	rs6866344	0.697	rs17184302	chr5:178127676	C/T	cg03877680	chr5:178157825	ZNF354A	0.75	8.5	0.46	1.36e-15	Neutrophil percentage of white cells;
CESC	cis	rs597539	0.652	rs613128	chr11:68638058	G/T	cg18350739	chr11:68623251	NA	-0.46	-7.02	-0.4	1.88e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs12478296	0.792	rs6738361	chr2:243014257	C/T	cg06360820	chr2:242988706	NA	-0.85	-9.36	-0.5	3.54e-18	Obesity-related traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22655561	chr5:176883211	PRR7	-0.72	-8.25	-0.45	7.42e-15	Gut microbiome composition (summer);
CESC	cis	rs9291683	0.935	rs1860911	chr4:10275057	C/T	cg00071950	chr4:10020882	SLC2A9	0.55	8.32	0.46	4.7e-15	Bone mineral density;
CESC	cis	rs611744	0.870	rs633794	chr8:109174702	A/G	cg21045802	chr8:109455806	TTC35	0.47	5.67	0.33	3.81e-8	Dupuytren's disease;
CESC	cis	rs4803468	1.000	rs284652	chr19:41928652	C/T	cg09537434	chr19:41945824	ATP5SL	-1.11	-20.58	-0.78	6.86e-57	Height;
CESC	cis	rs9348721	0.673	rs9358934	chr6:26363755	G/C	cg12826209	chr6:26865740	GUSBL1	0.62	5.31	0.31	2.27e-7	Intelligence (multi-trait analysis);
CESC	cis	rs7089973	0.604	rs11819372	chr10:116594934	A/G	cg25233709	chr10:116636983	FAM160B1	0.37	6.21	0.36	2.05e-9	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs67311347	0.577	rs2371129	chr3:40248393	C/T	cg24209194	chr3:40518798	ZNF619	-0.41	-5.08	-0.3	7.26e-7	Renal cell carcinoma;
CESC	cis	rs7772486	0.558	rs62435775	chr6:146136415	G/C	cg05347473	chr6:146136440	FBXO30	0.73	9.41	0.5	2.43e-18	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg18501264	chr19:33555827	RHPN2	-0.53	-7.28	-0.41	3.7e-12	Fibrinogen levels;
CESC	trans	rs916888	0.647	rs199449	chr17:44808902	G/A	cg22968622	chr17:43663579	NA	0.78	10.71	0.55	1.83e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs4853012	0.838	rs2177707	chr2:74356850	A/G	cg01017244	chr2:74357527	NA	0.73	10.07	0.53	2.09e-20	Gestational age at birth (maternal effect);
CESC	cis	rs992157	0.835	rs2292551	chr2:219143229	G/A	cg00012203	chr2:219082015	ARPC2	-0.76	-9.55	-0.51	9.45e-19	Colorectal cancer;
CESC	cis	rs4253772	0.575	rs9615983	chr22:46793314	G/A	cg00784671	chr22:46762841	CELSR1	-0.52	-5.28	-0.31	2.63e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs11203032	0.831	rs11203009	chr10:90927163	G/A	cg16672925	chr10:90967113	CH25H	0.74	6.99	0.39	2.26e-11	Heart failure;
CESC	cis	rs6088580	0.634	rs6058070	chr20:33103521	G/C	cg24642439	chr20:33292090	TP53INP2	0.5	6.55	0.37	3.05e-10	Glomerular filtration rate (creatinine);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24957950	chr19:39616336	PAK4	0.52	6.25	0.36	1.62e-9	Gut microbiome composition (summer);
CESC	trans	rs347313	1.000	rs347282	chr1:162312753	G/T	cg16315582	chr11:104839349	CASP4	0.43	6.13	0.35	3.24e-9	Body mass index (change over time);
CESC	cis	rs853679	0.569	rs9348798	chr6:28143011	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.56	-6.42	-0.37	6.22e-10	Depression;
CESC	cis	rs736801	0.891	rs10900809	chr5:131826322	G/A	cg00255919	chr5:131827918	IRF1	-0.44	-5.74	-0.33	2.57e-8	Breast cancer;Mosquito bite size;
CESC	cis	rs12973672	1.000	rs10405246	chr19:35768949	A/G	cg12095397	chr19:35769544	USF2	0.54	7.35	0.41	2.49e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs4727027	0.870	rs62507512	chr7:148799338	C/T	cg23583168	chr7:148888333	NA	-0.79	-12.1	-0.6	4.02e-27	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs854765	0.583	rs8078105	chr17:17853782	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.59	8.26	0.45	7.24e-15	Total body bone mineral density;
CESC	cis	rs7259376	0.905	rs2082480	chr19:22538650	G/A	cg02657401	chr19:22469223	NA	-0.25	-5.05	-0.3	8.16e-7	Menopause (age at onset);
CESC	cis	rs11252926	0.545	rs11252693	chr10:532139	A/G	cg03684893	chr10:554711	DIP2C	-0.43	-6.88	-0.39	4.35e-11	Psychosis in Alzheimer's disease;
CESC	cis	rs7824557	0.628	rs6988922	chr8:11194911	A/G	cg21775007	chr8:11205619	TDH	0.55	8.74	0.47	2.75e-16	Retinal vascular caliber;
CESC	cis	rs2299587	0.965	rs7843298	chr8:17806156	T/C	cg08627089	chr8:17753878	FGL1	-0.38	-5.11	-0.3	6.14e-7	Economic and political preferences;
CESC	cis	rs35306767	0.953	rs7908138	chr10:962978	C/T	cg10556349	chr10:835070	NA	0.57	5.98	0.34	7.08e-9	Eosinophil percentage of granulocytes;
CESC	cis	rs9287719	0.967	rs6735074	chr2:10734766	G/T	cg02196655	chr2:10830764	NOL10	0.35	5.39	0.31	1.53e-7	Prostate cancer;
CESC	cis	rs9303401	0.646	rs7213269	chr17:57237796	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.56	7.2	0.4	6.32e-12	Cognitive test performance;
CESC	cis	rs6570726	0.516	rs10484700	chr6:145728933	C/T	cg23711669	chr6:146136114	FBXO30	0.5	6.27	0.36	1.46e-9	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7539624	0.588	rs7555491	chr1:223894889	C/T	cg10100437	chr1:223903862	CAPN2	-0.4	-5.07	-0.3	7.32e-7	Schizophrenia;
CESC	cis	rs3733585	0.699	rs6834893	chr4:9959123	C/T	cg00071950	chr4:10020882	SLC2A9	-0.73	-11.79	-0.59	4.58e-26	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs4713118	0.515	rs9368549	chr6:28050047	T/A	cg23161317	chr6:28129485	ZNF389	0.5	6.31	0.36	1.19e-9	Parkinson's disease;
CESC	cis	rs6693567	0.565	rs12739706	chr1:150261653	C/G	cg09579323	chr1:150459698	TARS2	-0.46	-5.74	-0.33	2.58e-8	Migraine;
CESC	cis	rs3741404	0.594	rs11231704	chr11:63898182	C/T	cg24431193	chr11:63883947	FLRT1;MACROD1	-0.42	-5.73	-0.33	2.68e-8	Platelet count;
CESC	cis	rs8067354	0.645	rs2665400	chr17:57880201	G/A	cg02344993	chr17:57696989	CLTC	0.67	8.28	0.45	6.3e-15	Hemoglobin concentration;
CESC	cis	rs3858526	0.642	rs10838783	chr11:5900282	T/G	cg05234568	chr11:5960015	NA	-0.53	-6.67	-0.38	1.48e-10	DNA methylation (variation);
CESC	cis	rs763121	0.815	rs4821799	chr22:39021326	T/G	cg06022373	chr22:39101656	GTPBP1	0.8	12.74	0.62	2.55e-29	Menopause (age at onset);
CESC	cis	rs9309473	1.000	rs10189574	chr2:73698518	C/A	cg20560298	chr2:73613845	ALMS1	-0.46	-6.24	-0.36	1.7e-9	Metabolite levels;
CESC	cis	rs2576037	0.583	rs11660085	chr18:44529603	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.77	-12.31	-0.6	7.9e-28	Personality dimensions;
CESC	cis	rs9300255	0.722	rs67624109	chr12:123824635	C/T	cg19016782	chr12:123741754	C12orf65	0.43	5.41	0.32	1.41e-7	Neutrophil percentage of white cells;
CESC	cis	rs4253772	0.530	rs6008616	chr22:46707954	A/G	cg18190219	chr22:46762943	CELSR1	-0.58	-6.66	-0.38	1.6e-10	LDL cholesterol;Cholesterol, total;
CESC	cis	rs910316	0.967	rs175502	chr14:75533679	A/G	cg08847533	chr14:75593920	NEK9	-0.98	-18.49	-0.75	1.32e-49	Height;
CESC	trans	rs6429703	0.543	rs4661562	chr1:15341251	A/G	cg21586453	chr5:36239673	C5orf33	-0.6	-6.56	-0.37	2.75e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
CESC	cis	rs10504229	1.000	rs9650139	chr8:58190508	G/T	cg24829409	chr8:58192753	C8orf71	-0.75	-10.01	-0.52	3.22e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs4689388	0.856	rs1046314	chr4:6303955	A/G	cg14416269	chr4:6271139	WFS1	-0.46	-7.73	-0.43	2.2e-13	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs9393777	0.513	rs9295702	chr6:26634040	T/C	cg12292205	chr6:26970375	C6orf41	-0.5	-5.67	-0.33	3.8e-8	Intelligence (multi-trait analysis);
CESC	trans	rs1728785	1.000	rs7196104	chr16:68579746	C/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.61	7.49	0.42	1.04e-12	Ulcerative colitis;
CESC	cis	rs6724607	1.000	rs28452331	chr2:191471847	C/T	cg10560079	chr2:191398806	TMEM194B	-0.5	-7.26	-0.41	4.24e-12	Pulse pressure;
CESC	cis	rs539096	0.500	rs803678	chr1:44350898	G/T	cg23954153	chr1:44402353	ARTN	-0.35	-5.54	-0.32	7.21e-8	Intelligence (multi-trait analysis);
CESC	cis	rs796364	1.000	rs281771	chr2:200812202	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.79	-8.33	-0.46	4.48e-15	Schizophrenia;
CESC	cis	rs9322193	0.566	rs4870118	chr6:150245013	G/A	cg01145232	chr6:150245071	RAET1G	-0.57	-7.19	-0.4	6.69e-12	Lung cancer;
CESC	cis	rs7772486	0.875	rs2328712	chr6:146344563	T/C	cg05347473	chr6:146136440	FBXO30	0.5	6.7	0.38	1.23e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2180341	0.843	rs4895821	chr6:127572761	T/A	cg27446573	chr6:127587934	RNF146	1.09	15.97	0.7	1.16e-40	Breast cancer;
CESC	cis	rs644799	0.965	rs3016295	chr11:95554311	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	8.96	0.48	5.74e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs244293	0.965	rs8068337	chr17:53177899	T/C	cg19360675	chr17:53046073	COX11;STXBP4	0.39	5.06	0.3	7.95e-7	Menarche (age at onset);
CESC	cis	rs1862618	0.671	rs2591961	chr5:56238597	A/G	cg22800045	chr5:56110881	MAP3K1	-0.58	-7.38	-0.41	2.1e-12	Initial pursuit acceleration;
CESC	cis	rs7726839	0.540	rs12520279	chr5:657291	T/C	cg16447950	chr5:562315	NA	-0.59	-6.46	-0.37	4.92e-10	Obesity-related traits;
CESC	cis	rs7429990	0.901	rs6442091	chr3:48043058	T/C	cg11946769	chr3:48343235	NME6	-0.5	-6.09	-0.35	4.02e-9	Educational attainment (years of education);
CESC	trans	rs877282	0.945	rs71491311	chr10:791747	G/A	cg22713356	chr15:30763199	NA	1.32	13.44	0.64	9.25e-32	Uric acid levels;
CESC	cis	rs2228479	0.850	rs17227263	chr16:89810598	G/A	cg19635926	chr16:89946313	TCF25	0.66	5.04	0.3	8.52e-7	Skin colour saturation;
CESC	cis	rs238295	0.805	rs6116855	chr20:5555317	A/G	cg24001556	chr20:5591874	RP5-1022P6.2	-0.46	-5.17	-0.3	4.58e-7	Occipital cortical area (total cortical area interaction);
CESC	cis	rs12249377	0.519	rs7087400	chr10:92587180	A/G	cg14313238	chr10:92632228	RPP30	0.43	5.26	0.31	2.92e-7	White matter microstructure (global fractional anisotropy);
CESC	cis	rs1218582	0.804	rs4845398	chr1:154859038	G/C	cg03351412	chr1:154909251	PMVK	0.66	8.89	0.48	9.97e-17	Prostate cancer;
CESC	trans	rs561341	1.000	rs535151	chr17:30317405	C/T	cg20587970	chr11:113659929	NA	-0.85	-10.93	-0.56	3.31e-23	Hip circumference adjusted for BMI;
CESC	cis	rs9926296	0.533	rs12102290	chr16:89812617	C/T	cg21285383	chr16:89894308	SPIRE2	0.3	5.39	0.31	1.55e-7	Vitiligo;
CESC	cis	rs9311474	0.508	rs11720243	chr3:52618018	T/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.82	0.39	6.2e-11	Electroencephalogram traits;
CESC	cis	rs6580649	0.941	rs12580764	chr12:48453882	G/A	cg05342945	chr12:48394962	COL2A1	0.5	5.85	0.34	1.47e-8	Lung cancer;
CESC	cis	rs2635047	0.638	rs16954921	chr18:44610526	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.41	5.66	0.33	3.87e-8	Educational attainment;
CESC	cis	rs7524258	0.868	rs4908610	chr1:7311260	C/A	cg07173049	chr1:7289937	CAMTA1	0.38	5.8	0.34	1.87e-8	Tourette's syndrome or obsessive-compulsive disorder;
CESC	cis	rs4716602	0.898	rs4717047	chr7:156160671	T/C	cg04090468	chr7:156181990	NA	0.41	5.26	0.31	2.93e-7	Anti-saccade response;
CESC	cis	rs798554	0.757	rs960273	chr7:2857876	T/C	cg09658497	chr7:2847517	GNA12	-0.43	-5.87	-0.34	1.27e-8	Height;
CESC	cis	rs35146811	0.844	rs10281368	chr7:99655897	A/G	cg22906224	chr7:99728672	NA	0.49	5.76	0.33	2.28e-8	Coronary artery disease;
CESC	cis	rs769267	0.930	rs1054284	chr19:19616953	T/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.46	5.8	0.34	1.85e-8	Tonsillectomy;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg11593656	chr13:76112039	COMMD6	0.54	7.16	0.4	8.18e-12	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs921968	0.509	rs832813	chr2:219354569	T/C	cg02176678	chr2:219576539	TTLL4	0.49	8.82	0.48	1.53e-16	Mean corpuscular hemoglobin concentration;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg06194536	chr1:220701829	MARK1	-0.51	-6.63	-0.38	1.88e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs9811920	0.514	rs1287283	chr3:99515750	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.5	-5.95	-0.34	8.66e-9	Axial length;
CESC	cis	rs6952808	0.531	rs73039217	chr7:2178731	G/A	cg23048001	chr7:2026167	MAD1L1	0.42	5.3	0.31	2.46e-7	Bipolar disorder and schizophrenia;
CESC	trans	rs6479874	1.000	rs7895755	chr10:52774048	C/T	cg14115756	chr9:125795935	GPR21;RABGAP1	0.66	6.07	0.35	4.31e-9	Migraine;
CESC	cis	rs3008870	0.755	rs2755243	chr1:67482783	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.62	8.04	0.44	3.01e-14	Lymphocyte percentage of white cells;
CESC	trans	rs16843372	0.576	rs10184397	chr2:159695242	A/T	cg17808901	chr3:39093368	WDR48	0.51	6.04	0.35	5.26e-9	Obesity-related traits;
CESC	cis	rs2228479	0.702	rs2074963	chr16:89877269	T/C	cg04013166	chr16:89971882	TCF25	0.71	5.69	0.33	3.32e-8	Skin colour saturation;
CESC	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg17178900	chr1:205818956	PM20D1	0.79	12.65	0.61	5.03e-29	Menarche (age at onset);
CESC	cis	rs9611565	0.765	rs9607800	chr22:41784562	A/G	cg03806693	chr22:41940476	POLR3H	-1.05	-12.33	-0.6	6.57e-28	Vitiligo;
CESC	cis	rs506597	0.920	rs221798	chr7:100287495	C/G	cg10426581	chr7:100472382	SRRT	-0.66	-5.1	-0.3	6.56e-7	Pursuit maintenance gain in psychotic disorders;
CESC	cis	rs7408868	0.908	rs62113793	chr19:15277336	G/A	cg14696996	chr19:15285081	NOTCH3	1.11	11.3	0.57	2.05e-24	Pulse pressure;
CESC	cis	rs7129220	0.588	rs7129047	chr11:10143942	C/A	cg01453529	chr11:10209919	SBF2	-0.48	-5.63	-0.33	4.67e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg26074535	chr5:134094528	DDX46	-0.47	-6.1	-0.35	3.67e-9	Asthma;
CESC	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg26338869	chr17:61819248	STRADA	0.69	9.18	0.49	1.31e-17	Prudent dietary pattern;
CESC	cis	rs4481887	0.741	rs6587458	chr1:248532290	T/A	cg26353448	chr1:248524236	OR2T4	-0.38	-5.35	-0.31	1.9e-7	Common traits (Other);
CESC	cis	rs7692995	1.000	rs16896271	chr4:18012454	T/C	cg08925142	chr4:18023851	LCORL	-0.44	-5.12	-0.3	6e-7	Height;
CESC	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg24642844	chr7:1081250	C7orf50	-0.78	-9.49	-0.5	1.38e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs9527	0.545	rs7894588	chr10:104756030	A/T	cg04362960	chr10:104952993	NT5C2	0.42	5.18	0.3	4.37e-7	Arsenic metabolism;
CESC	cis	rs1008375	0.931	rs6449310	chr4:17575530	T/C	cg27347728	chr4:17578864	LAP3	0.43	5.14	0.3	5.44e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs7659604	0.540	rs4361412	chr4:122669403	C/T	cg19671926	chr4:122722719	EXOSC9	0.53	6.55	0.37	3e-10	Type 2 diabetes;
CESC	cis	rs1983170	0.778	rs906241	chr1:92012154	G/T	cg25838465	chr1:92012736	NA	-0.43	-5.28	-0.31	2.72e-7	Eosinophil percentage of white cells;
CESC	cis	rs385076	0.503	rs212702	chr2:32444250	A/G	cg02381751	chr2:32503542	YIPF4	0.6	6.64	0.38	1.79e-10	Interleukin-18 levels;
CESC	cis	rs875971	0.660	rs10263935	chr7:66096028	A/G	cg11764359	chr7:65958608	NA	0.43	5.36	0.31	1.79e-7	Aortic root size;
CESC	cis	rs763121	0.853	rs2179142	chr22:39037954	G/A	cg06544989	chr22:39130855	UNC84B	0.52	9.28	0.5	6.07e-18	Menopause (age at onset);
CESC	cis	rs898097	0.812	rs72859941	chr17:80837459	G/A	cg10494973	chr17:80897199	TBCD	0.51	5.88	0.34	1.25e-8	Breast cancer;
CESC	cis	rs6964587	1.000	rs2282975	chr7:91761638	A/G	cg17063962	chr7:91808500	NA	0.58	7.97	0.44	4.71e-14	Breast cancer;
CESC	cis	rs66573146	0.831	rs6832482	chr4:7023433	A/T	cg00086871	chr4:6988644	TBC1D14	0.96	6.09	0.35	3.9e-9	Granulocyte percentage of myeloid white cells;
CESC	cis	rs12190007	0.512	rs2984464	chr6:169837242	T/C	cg15038512	chr6:170123185	PHF10	-0.51	-7.26	-0.41	4.39e-12	Obesity-related traits;
CESC	cis	rs870825	0.616	rs1401362	chr4:185643775	G/A	cg04058563	chr4:185651563	MLF1IP	0.64	7.1	0.4	1.15e-11	Blood protein levels;
CESC	trans	rs12599106	0.715	rs34006830	chr16:34878550	C/A	cg15383120	chr6:291909	DUSP22	-0.67	-8.22	-0.45	9e-15	Menopause (age at onset);
CESC	cis	rs13385	0.769	rs13186305	chr5:139608926	C/T	cg26211634	chr5:139558579	C5orf32	0.47	5.08	0.3	6.98e-7	Atrial fibrillation;
CESC	cis	rs9596863	1.000	rs4471558	chr13:54413349	A/T	ch.13.53330881F	chr13:54432880	NA	0.6	5.27	0.31	2.83e-7	Epilepsy and lamotrigine-induced maculopapular eruptions;
CESC	cis	rs9649465	1.000	rs13230338	chr7:123373622	T/C	cg04330084	chr7:123175371	IQUB	-0.38	-5.18	-0.3	4.46e-7	Migraine;
CESC	cis	rs34172651	0.517	rs2287783	chr16:24831727	C/T	cg00339695	chr16:24857497	SLC5A11	0.5	6.43	0.37	5.94e-10	Intelligence (multi-trait analysis);
CESC	cis	rs7267979	1.000	rs6083809	chr20:25329309	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.87	-18.09	-0.74	3.41e-48	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs9788333	0.695	rs12871086	chr13:21890224	A/T	cg23743428	chr13:21893420	NA	-0.34	-5.84	-0.34	1.5e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs9733	0.596	rs72702573	chr1:150689050	C/T	cg18016565	chr1:150552671	MCL1	0.35	5.36	0.31	1.86e-7	Tonsillectomy;
CESC	cis	rs4666360	1.000	rs4666360	chr2:20335709	G/A	cg23291376	chr2:20336282	NA	-0.38	-6.28	-0.36	1.41e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel);
CESC	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.47	6.28	0.36	1.39e-9	Lymphocyte counts;
CESC	cis	rs965469	0.779	rs6139071	chr20:3299054	A/G	cg25506879	chr20:3388711	C20orf194	-0.47	-5.27	-0.31	2.89e-7	IFN-related cytopenia;
CESC	cis	rs9894429	0.646	rs7405870	chr17:79617284	G/A	cg21984481	chr17:79567631	NPLOC4	-0.34	-5.24	-0.31	3.35e-7	Eye color traits;
CESC	cis	rs2050392	0.928	rs2250077	chr10:30702929	A/G	cg18806716	chr10:30721971	MAP3K8	-0.41	-5.95	-0.34	8.61e-9	Inflammatory bowel disease;
CESC	trans	rs10074525	0.923	rs34879738	chr5:90272197	A/G	cg22855255	chr17:50237267	CA10	-0.35	-6.06	-0.35	4.65e-9	Obesity-related traits;
CESC	cis	rs593982	0.719	rs11606668	chr11:65472758	A/G	cg08755490	chr11:65554678	OVOL1	-0.83	-7.49	-0.42	1e-12	Atopic dermatitis;
CESC	trans	rs3780486	0.801	rs10971424	chr9:33138775	T/C	cg04842962	chr6:43655489	MRPS18A	1.01	19.75	0.77	5.15e-54	IgG glycosylation;
CESC	cis	rs6032067	0.538	rs17422688	chr20:43739119	G/A	cg10761708	chr20:43804764	PI3	0.45	5.07	0.3	7.44e-7	Blood protein levels;
CESC	cis	rs3008870	1.000	rs4655663	chr1:67430103	C/T	cg02640540	chr1:67518911	SLC35D1	0.52	5.69	0.33	3.28e-8	Lymphocyte percentage of white cells;
CESC	cis	rs1008375	0.866	rs2109518	chr4:17572162	G/A	cg02297831	chr4:17616191	MED28	0.5	6.1	0.35	3.84e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs4423214	0.840	rs3794057	chr11:71186744	G/A	cg05163923	chr11:71159392	DHCR7	-0.68	-7.76	-0.43	1.82e-13	Vitamin D levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18387343	chr1:27248345	NUDC	0.58	6.42	0.37	6.09e-10	Gut microbiome composition (summer);
CESC	cis	rs6489785	0.687	rs3213567	chr12:121222556	T/C	cg02419362	chr12:121203948	SPPL3	0.36	5.87	0.34	1.27e-8	Longevity;Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs12681288	0.754	rs4735975	chr8:1000470	T/C	cg04851639	chr8:1020857	NA	-0.32	-7.17	-0.4	7.66e-12	Schizophrenia;
CESC	cis	rs5753618	0.607	rs5753621	chr22:31847647	T/C	cg00478049	chr22:31556069	RNF185	-0.43	-5.08	-0.3	6.98e-7	Colorectal cancer;
CESC	cis	rs2735413	0.918	rs34094825	chr16:78081392	G/C	cg04733911	chr16:78082701	NA	-0.53	-9.01	-0.48	4.08e-17	Systolic blood pressure (alcohol consumption interaction);
CESC	cis	rs3105593	0.555	rs3131568	chr15:50757721	C/T	cg05456662	chr15:50716270	USP8	0.39	5.28	0.31	2.73e-7	QT interval;
CESC	cis	rs9811920	0.638	rs1688782	chr3:99630527	C/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.52	-6.58	-0.37	2.49e-10	Axial length;
CESC	cis	rs7615952	0.599	rs12486459	chr3:125741465	T/G	cg15145296	chr3:125709740	NA	-0.5	-5.26	-0.31	3.01e-7	Blood pressure (smoking interaction);
CESC	cis	rs8018808	0.905	rs11622359	chr14:77939449	C/T	cg20045696	chr14:77926864	AHSA1	-0.43	-5.93	-0.34	9.43e-9	Myeloid white cell count;
CESC	cis	rs2836950	0.545	rs2836959	chr21:40623668	T/G	cg11644478	chr21:40555479	PSMG1	-0.55	-7.52	-0.42	8.26e-13	Menarche (age at onset);
CESC	cis	rs9291683	0.546	rs6820188	chr4:10051655	C/T	cg02734326	chr4:10020555	SLC2A9	0.46	6.55	0.37	3e-10	Bone mineral density;
CESC	cis	rs801193	0.660	rs974239	chr7:66213491	G/A	cg11764359	chr7:65958608	NA	0.89	13.78	0.65	6.18e-33	Aortic root size;
CESC	trans	rs9987353	0.840	rs329994	chr8:9123233	A/G	cg04159488	chr11:64578146	MEN1	-0.46	-6.11	-0.35	3.49e-9	Recombination measurement;
CESC	cis	rs6762	0.719	rs28620453	chr11:836971	G/C	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.7	-9.31	-0.5	5.15e-18	Mean platelet volume;
CESC	cis	rs2228479	0.717	rs34027607	chr16:89808939	T/C	cg04013166	chr16:89971882	TCF25	0.72	7.87	0.44	9.3e-14	Skin colour saturation;
CESC	cis	rs7615952	0.576	rs2276727	chr3:125826243	C/T	cg15145296	chr3:125709740	NA	-0.53	-5.67	-0.33	3.82e-8	Blood pressure (smoking interaction);
CESC	cis	rs12497850	0.931	rs9755490	chr3:48871664	A/C	cg02487422	chr3:49467188	NICN1	0.4	5.15	0.3	5.11e-7	Parkinson's disease;
CESC	cis	rs10504229	0.593	rs1442127	chr8:57992136	T/C	cg24829409	chr8:58192753	C8orf71	-0.49	-5.88	-0.34	1.21e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs4704187	0.687	rs6453111	chr5:74379926	C/T	cg03227963	chr5:74354835	NA	0.32	5.95	0.34	8.68e-9	Response to amphetamines;
CESC	trans	rs9929218	1.000	rs13330350	chr16:68800849	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.63	-8.44	-0.46	2.13e-15	Colorectal cancer;
CESC	cis	rs3845702	0.736	rs6433816	chr2:180809317	G/C	cg01881094	chr2:180872142	CWC22	-1.05	-8.97	-0.48	5.56e-17	Schizophrenia;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg14819942	chr15:35414228	NA	-0.47	-6.65	-0.38	1.67e-10	Gut microbiota (bacterial taxa);
CESC	trans	rs7618501	1.000	rs7634902	chr3:49762662	G/T	cg21582582	chr3:182698605	DCUN1D1	-0.44	-6.01	-0.35	6.18e-9	Intelligence (multi-trait analysis);
CESC	trans	rs877282	0.583	rs11253441	chr10:828288	C/T	cg22713356	chr15:30763199	NA	-1.04	-9.6	-0.51	6.21e-19	Uric acid levels;
CESC	cis	rs1799949	1.000	rs16941	chr17:41244435	T/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.42	5.71	0.33	3.07e-8	Menopause (age at onset);
CESC	cis	rs7666738	0.830	rs11726604	chr4:99000969	T/C	cg05340658	chr4:99064831	C4orf37	0.8	12.44	0.61	2.83e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2635047	0.904	rs2635046	chr18:44728429	G/A	cg19077165	chr18:44547161	KATNAL2	-0.41	-5.67	-0.33	3.73e-8	Educational attainment;
CESC	cis	rs870825	0.616	rs7682505	chr4:185640648	C/T	cg04058563	chr4:185651563	MLF1IP	0.64	7.1	0.4	1.15e-11	Blood protein levels;
CESC	cis	rs933688	1.000	rs889213	chr5:90682151	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.99	11.87	0.59	2.36e-26	Smoking behavior;
CESC	cis	rs67072384	1.000	rs2365441	chr11:72450226	T/C	cg04827223	chr11:72435913	ARAP1	-0.71	-6.85	-0.39	5e-11	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
CESC	cis	rs9911578	0.835	rs9904993	chr17:56468569	G/T	cg05425664	chr17:57184151	TRIM37	0.45	6.29	0.36	1.27e-9	Intelligence (multi-trait analysis);
CESC	cis	rs55794721	0.509	rs12027135	chr1:25775733	A/T	cg02931644	chr1:25747376	RHCE	0.43	7.2	0.4	6.14e-12	Plateletcrit;Mean corpuscular volume;
CESC	cis	rs9611565	0.649	rs9623450	chr22:42175231	G/A	cg06634786	chr22:41940651	POLR3H	0.46	5.06	0.3	7.69e-7	Vitiligo;
CESC	cis	rs9486719	0.948	rs2472906	chr6:96875318	G/T	cg18709589	chr6:96969512	KIAA0776	0.53	5.81	0.34	1.75e-8	Migraine;Coronary artery disease;
CESC	cis	rs9583531	0.527	rs6492302	chr13:111352354	C/T	cg15841412	chr13:111365552	ING1	-0.49	-6.44	-0.37	5.67e-10	Coronary artery disease;
CESC	cis	rs7623687	1.000	rs7623687	chr3:49448566	A/C	cg07274523	chr3:49395745	GPX1	0.64	5.58	0.32	5.83e-8	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;
CESC	cis	rs2249625	0.584	rs2496506	chr6:72891324	A/C	cg18830697	chr6:72922368	RIMS1	-0.47	-7.02	-0.4	1.89e-11	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CESC	cis	rs7666738	0.924	rs13124368	chr4:99039615	T/C	cg24818145	chr4:99064322	C4orf37	0.38	5.04	0.3	8.49e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7481584	0.624	rs375579	chr11:3065300	G/C	cg25174290	chr11:3078921	CARS	-0.53	-7.36	-0.41	2.32e-12	Calcium levels;
CESC	cis	rs5750830	0.595	rs4821892	chr22:39795683	G/C	cg05872129	chr22:39784769	NA	-0.84	-11.54	-0.58	3.09e-25	Intelligence (multi-trait analysis);
CESC	cis	rs3026445	0.832	rs7975364	chr12:110602275	A/T	cg12870014	chr12:110450643	ANKRD13A	0.46	6.0	0.35	6.59e-9	QT interval;
CESC	cis	rs7959452	0.590	rs56054057	chr12:69775972	C/T	cg14784868	chr12:69753453	YEATS4	0.83	12.99	0.62	3.47e-30	Blood protein levels;
CESC	cis	rs66530629	0.874	rs6604978	chr1:25090446	C/G	cg22509179	chr1:25234806	RUNX3	-0.43	-5.48	-0.32	9.73e-8	Plateletcrit;
CESC	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg11965913	chr1:205819406	PM20D1	0.81	13.33	0.63	2.2e-31	Menarche (age at onset);
CESC	cis	rs2276314	0.857	rs8097597	chr18:33619448	A/G	cg05985134	chr18:33552581	C18orf21	0.58	7.18	0.4	7.18e-12	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs1801251	0.929	rs10933409	chr2:233629386	A/G	cg08000102	chr2:233561755	GIGYF2	0.67	9.48	0.5	1.53e-18	Coronary artery disease;
CESC	cis	rs9911578	1.000	rs304292	chr17:56824123	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.21	0.3	3.88e-7	Intelligence (multi-trait analysis);
CESC	cis	rs11250464	0.833	rs2387653	chr10:1407826	A/G	cg08668359	chr10:1443807	ADARB2	-0.56	-6.6	-0.38	2.18e-10	Radiation response;
CESC	cis	rs5758511	0.514	rs2899354	chr22:42554409	G/T	cg00645731	chr22:42541494	CYP2D7P1	0.6	8.89	0.48	9.89e-17	Birth weight;
CESC	cis	rs6952808	0.692	rs56727870	chr7:2029940	T/C	cg04267008	chr7:1944627	MAD1L1	-0.63	-7.72	-0.43	2.43e-13	Bipolar disorder and schizophrenia;
CESC	trans	rs1447537	0.683	rs28819387	chr2:84213355	G/C	cg03726739	chr5:168254759	SLIT3	0.43	6.08	0.35	4.12e-9	RR interval (heart rate);
CESC	cis	rs3785574	0.927	rs2854183	chr17:61968002	C/T	cg06873352	chr17:61820015	STRADA	0.48	6.95	0.39	2.8e-11	Height;
CESC	cis	rs6430585	0.527	rs2304366	chr2:136467119	C/T	cg07169764	chr2:136633963	MCM6	1.09	12.44	0.61	2.64e-28	Corneal structure;
CESC	cis	rs62408225	1.000	rs62408233	chr6:90976609	G/A	cg06866423	chr6:90926672	BACH2	0.43	5.18	0.3	4.38e-7	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs637571	0.522	rs1151512	chr11:65757533	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.74	10.73	0.55	1.58e-22	Eosinophil percentage of white cells;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16487280	chr20:42295503	MYBL2	0.56	6.6	0.38	2.28e-10	Gut microbiome composition (summer);
CESC	cis	rs1862618	0.671	rs2255726	chr5:56243128	T/C	cg18230493	chr5:56204884	C5orf35	0.61	7.98	0.44	4.33e-14	Initial pursuit acceleration;
CESC	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg11905131	chr22:24372483	LOC391322	-0.78	-11.7	-0.58	9.3e-26	Liver enzyme levels (gamma-glutamyl transferase);
CESC	trans	rs66573146	0.831	rs67602077	chr4:7024244	A/G	cg07817883	chr1:32538562	TMEM39B	1.15	6.88	0.39	4.22e-11	Granulocyte percentage of myeloid white cells;
CESC	cis	rs524281	0.682	rs6591202	chr11:65806093	T/A	cg14036092	chr11:66035641	RAB1B	0.5	5.08	0.3	7.08e-7	Electroencephalogram traits;
CESC	cis	rs6724607	1.000	rs28452331	chr2:191471847	C/T	cg27211696	chr2:191398769	TMEM194B	-0.53	-8.0	-0.44	3.94e-14	Pulse pressure;
CESC	cis	rs1707322	1.000	rs785468	chr1:46521517	G/A	cg03146154	chr1:46216737	IPP	-0.72	-9.73	-0.51	2.49e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2303745	0.589	rs6512179	chr19:17399105	T/C	cg04248312	chr19:17393744	ANKLE1	-0.92	-14.85	-0.67	1.01e-36	Systemic lupus erythematosus;
CESC	cis	rs10504229	0.774	rs72650880	chr8:58164727	C/T	cg22535103	chr8:58192502	C8orf71	-1.02	-11.22	-0.57	3.61e-24	Developmental language disorder (linguistic errors);
CESC	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg26338869	chr17:61819248	STRADA	-0.61	-7.99	-0.44	4.05e-14	Prudent dietary pattern;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18489012	chr6:36561954	SFRS3	0.53	6.02	0.35	5.9e-9	Gut microbiome composition (summer);
CESC	cis	rs11166927	1.000	rs12549587	chr8:140804310	G/A	cg16909799	chr8:140841666	TRAPPC9	0.61	8.85	0.48	1.31e-16	Pediatric non-alcoholic fatty liver disease activity score;
CESC	cis	rs6570726	0.967	rs403584	chr6:145807010	G/A	cg05347473	chr6:146136440	FBXO30	0.43	5.82	0.34	1.74e-8	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg08305803	chr16:28565427	CCDC101	-0.51	-6.02	-0.35	5.74e-9	Ulcerative colitis;
CESC	cis	rs7772486	0.875	rs7766595	chr6:146364507	A/T	cg05347473	chr6:146136440	FBXO30	0.47	6.16	0.35	2.66e-9	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs739401	0.611	rs10833048	chr11:3020040	A/G	cg25174290	chr11:3078921	CARS	0.56	7.39	0.41	1.95e-12	Longevity;
CESC	trans	rs1493916	1.000	rs7238717	chr18:31395186	C/T	cg27147174	chr7:100797783	AP1S1	-0.52	-7.06	-0.4	1.45e-11	Life satisfaction;
CESC	cis	rs6964587	1.000	rs10236397	chr7:91691601	C/T	cg17063962	chr7:91808500	NA	0.6	8.37	0.46	3.45e-15	Breast cancer;
CESC	cis	rs11098499	0.731	rs9995026	chr4:120490499	T/A	cg09307838	chr4:120376055	NA	0.9	12.28	0.6	9.3e-28	Corneal astigmatism;
CESC	cis	rs7914558	0.966	rs11191438	chr10:104637864	C/G	cg04362960	chr10:104952993	NT5C2	0.49	6.66	0.38	1.55e-10	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs7191439	0.858	rs2340973	chr16:88773396	G/A	cg02389323	chr16:88786976	FAM38A	0.97	7.74	0.43	2.13e-13	Plateletcrit;
CESC	cis	rs1552244	1.000	rs12152512	chr3:10143770	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	12.82	0.62	1.39e-29	Alzheimer's disease;
CESC	cis	rs2228479	0.850	rs17232630	chr16:89851179	C/T	cg14709524	chr16:89940631	TCF25	0.94	7.05	0.4	1.57e-11	Skin colour saturation;
CESC	cis	rs7191439	0.722	rs6500491	chr16:88783521	T/C	cg27087555	chr16:88793112	FAM38A	-1.22	-9.32	-0.5	4.71e-18	Plateletcrit;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg09431544	chr19:14629187	DNAJB1	-0.5	-6.73	-0.38	1.06e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs1552244	0.882	rs13066757	chr3:10045030	C/A	cg08888203	chr3:10149979	C3orf24	0.48	6.09	0.35	3.99e-9	Alzheimer's disease;
CESC	cis	rs2795502	0.882	rs3123754	chr10:43339011	G/A	cg20628663	chr10:43360327	NA	-0.63	-7.47	-0.42	1.16e-12	Blood protein levels;
CESC	trans	rs1814175	0.645	rs10839456	chr11:49964093	C/T	cg15704280	chr7:45808275	SEPT13	-0.98	-18.56	-0.75	7.41e-50	Height;
CESC	cis	rs17401966	0.931	rs4846213	chr1:10399178	A/G	cg15208524	chr1:10270712	KIF1B	0.43	5.48	0.32	1e-7	Hepatocellular carcinoma;
CESC	cis	rs17490626	0.568	rs2033371	chr10:71212310	G/A	cg12610070	chr10:71211762	TSPAN15	-0.31	-6.62	-0.38	1.98e-10	Thrombosis;
CESC	cis	rs2576037	0.526	rs9304340	chr18:44526582	G/A	cg19077165	chr18:44547161	KATNAL2	-0.51	-7.31	-0.41	3.17e-12	Personality dimensions;
CESC	cis	rs367943	0.608	rs4705463	chr5:112980273	C/G	cg12552261	chr5:112820674	MCC	0.39	5.03	0.3	8.99e-7	Type 2 diabetes;
CESC	cis	rs2243480	1.000	rs67728539	chr7:65378124	G/A	cg12463550	chr7:65579703	CRCP	0.7	5.7	0.33	3.21e-8	Diabetic kidney disease;
CESC	cis	rs11577318	0.853	rs12743998	chr1:26629882	G/A	cg19743891	chr1:26644573	UBXN11;CD52	-0.28	-5.11	-0.3	6.05e-7	Granulocyte percentage of myeloid white cells;
CESC	cis	rs10789491	1.000	rs601060	chr1:47139580	C/G	cg15501359	chr1:47185051	KIAA0494	-0.81	-8.79	-0.48	1.86e-16	Response to hepatitis C treatment;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03602124	chr1:113258101	PPM1J	0.52	6.19	0.36	2.28e-9	Gut microbiome composition (summer);
CESC	cis	rs7833986	0.501	rs2953922	chr8:56977485	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.61	7.55	0.42	6.89e-13	Height;
CESC	cis	rs6815814	0.731	rs4513579	chr4:38773816	T/C	cg02016764	chr4:38805732	TLR1	-0.44	-6.08	-0.35	4.24e-9	Breast cancer;
CESC	cis	rs798554	0.567	rs1182192	chr7:2869274	G/A	cg19717773	chr7:2847554	GNA12	-0.5	-7.61	-0.42	4.85e-13	Height;
CESC	cis	rs6570726	0.599	rs9403725	chr6:145897622	A/T	cg23711669	chr6:146136114	FBXO30	-0.82	-9.94	-0.52	5.52e-20	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs722599	0.748	rs17093914	chr14:75363641	A/G	cg00095594	chr1:236228625	NID1	0.41	6.32	0.36	1.13e-9	IgG glycosylation;
CESC	cis	rs11214589	0.875	rs10891540	chr11:113239082	A/G	cg14159747	chr11:113255604	NA	-0.28	-5.1	-0.3	6.56e-7	Neuroticism;
CESC	cis	rs763014	0.865	rs4006748	chr16:632225	T/C	cg00802000	chr16:706648	WDR90	-0.41	-6.12	-0.35	3.33e-9	Height;
CESC	cis	rs4604732	0.536	rs7528219	chr1:247628307	C/T	cg12758973	chr1:247694275	LOC148824;OR2C3	0.48	6.01	0.35	6.07e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs10751667	1.000	rs6597965	chr11:964476	A/G	cg20946044	chr11:1010712	AP2A2	-0.42	-5.66	-0.33	3.95e-8	Alzheimer's disease (late onset);
CESC	cis	rs4472734	0.965	rs4535974	chr1:214628958	A/G	cg00063699	chr1:214624242	PTPN14	-0.33	-5.04	-0.3	8.73e-7	Height;
CESC	cis	rs10870270	1.000	rs11146324	chr10:133767445	A/C	cg26149184	chr10:133730230	NA	0.37	5.1	0.3	6.42e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs9902453	0.967	rs4994355	chr17:28386284	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.6	-7.56	-0.42	6.56e-13	Coffee consumption (cups per day);
CESC	cis	rs826838	0.616	rs2387921	chr12:38624767	T/C	cg26384229	chr12:38710491	ALG10B	-0.43	-5.65	-0.33	4.09e-8	Heart rate;
CESC	cis	rs13102973	0.965	rs28874134	chr4:135867088	C/A	cg14419869	chr4:135874104	NA	-0.4	-6.29	-0.36	1.32e-9	Subjective well-being;
CESC	cis	rs7923609	0.841	rs7920036	chr10:65293860	T/C	cg01631684	chr10:65280961	REEP3	-0.44	-5.52	-0.32	8.13e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs6952808	0.743	rs4719308	chr7:1877502	T/G	cg24247370	chr13:99142703	STK24	-0.42	-6.27	-0.36	1.45e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs4595586	0.505	rs11611321	chr12:39390803	C/T	cg26384229	chr12:38710491	ALG10B	0.54	7.64	0.42	3.96e-13	Morning vs. evening chronotype;
CESC	cis	rs1256061	0.624	rs1760988	chr14:64696813	A/G	cg21174375	chr14:64681225	SYNE2	0.48	6.36	0.36	8.86e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs7580658	0.963	rs867304	chr2:128078488	G/A	cg10021288	chr2:128175891	PROC	-0.41	-6.49	-0.37	4.24e-10	Protein C levels;
CESC	cis	rs13191362	0.810	rs35509380	chr6:163053028	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.87	8.31	0.45	4.9e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs9549367	0.756	rs3861723	chr13:113910926	A/G	cg18105134	chr13:113819100	PROZ	-0.62	-7.9	-0.44	7.32e-14	Platelet distribution width;
CESC	cis	rs10504229	0.679	rs72649107	chr8:58030453	C/A	cg24829409	chr8:58192753	C8orf71	-0.44	-5.73	-0.33	2.75e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs9902453	0.845	rs3102559	chr17:28029723	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	8.53	0.46	1.15e-15	Coffee consumption (cups per day);
CESC	cis	rs155076	0.711	rs9550724	chr13:21885030	G/T	cg25811766	chr13:21894605	NA	0.56	5.65	0.33	4.1e-8	White matter hyperintensity burden;
CESC	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.73	-11.94	-0.59	1.35e-26	Longevity;Endometriosis;
CESC	cis	rs10242455	0.764	rs2740561	chr7:99321441	G/A	cg07715041	chr7:99302981	CYP3A7	-0.43	-5.42	-0.32	1.36e-7	Blood metabolite levels;
CESC	trans	rs78472555	0.661	rs2570934	chr15:100143999	A/T	cg17514665	chr17:1657533	SERPINF2	-0.46	-6.17	-0.35	2.52e-9	Post bronchodilator FEV1/FVC ratio in COPD;
CESC	cis	rs4268898	0.662	rs59996104	chr2:24404064	C/T	cg06627628	chr2:24431161	ITSN2	-0.97	-9.78	-0.51	1.78e-19	Asthma;
CESC	cis	rs832540	0.656	rs702689	chr5:56177443	G/A	cg22800045	chr5:56110881	MAP3K1	0.44	5.29	0.31	2.58e-7	Coronary artery disease;
CESC	cis	rs5751150	1	rs5751150	chr22:42153292	T/G	cg17376030	chr22:41985996	PMM1	-0.77	-8.07	-0.44	2.39e-14	Cannabis dependence symptom count;
CESC	cis	rs2439831	0.681	rs1095386	chr15:43609509	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.9	10.8	0.55	8.69e-23	Lung cancer in ever smokers;
CESC	cis	rs7131987	0.868	rs737160	chr12:29429012	T/C	cg09582351	chr12:29534625	ERGIC2	-0.31	-5.19	-0.3	4.26e-7	QT interval;
CESC	cis	rs67311347	0.822	rs11709089	chr3:40351484	C/T	cg24209194	chr3:40518798	ZNF619	0.4	5.06	0.3	7.99e-7	Renal cell carcinoma;
CESC	cis	rs514406	0.861	rs12038438	chr1:53230581	A/T	cg16325326	chr1:53192061	ZYG11B	-0.89	-15.49	-0.69	5.54e-39	Monocyte count;
CESC	cis	rs2075371	0.932	rs2241333	chr7:133970750	C/T	cg20476274	chr7:133979776	SLC35B4	0.69	10.2	0.53	8.1899999999999992e-21	Mean platelet volume;
CESC	cis	rs2455799	0.613	rs12485852	chr3:15914511	G/C	cg09340198	chr3:15902540	ANKRD28	-0.32	-5.1	-0.3	6.52e-7	Mean platelet volume;
CESC	cis	rs12579753	0.917	rs10862375	chr12:82254809	C/G	cg24719984	chr12:82153464	PPFIA2	0.36	5.46	0.32	1.11e-7	Resting heart rate;
CESC	cis	rs10979	0.597	rs9321927	chr6:143913295	A/G	cg25407410	chr6:143891975	LOC285740	0.47	6.3	0.36	1.2e-9	Hypospadias;
CESC	cis	rs6912958	0.559	rs499373	chr6:88042062	A/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.5	8.64	0.47	5.32e-16	Monocyte percentage of white cells;
CESC	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.54	6.66	0.38	1.57e-10	Prudent dietary pattern;
CESC	cis	rs4843747	0.519	rs12599755	chr16:88107006	A/G	cg17633681	chr16:88106987	BANP	0.71	9.39	0.5	2.89e-18	Menopause (age at onset);
CESC	cis	rs72781680	1.000	rs72781667	chr2:24225667	A/G	cg08917208	chr2:24149416	ATAD2B	1.02	8.9	0.48	9.29e-17	Lymphocyte counts;
CESC	cis	rs9291683	0.507	rs3796837	chr4:10011321	C/G	cg11266682	chr4:10021025	SLC2A9	0.67	13.0	0.62	3.08e-30	Bone mineral density;
CESC	cis	rs6088590	1.000	rs6120708	chr20:33335526	G/A	cg08999081	chr20:33150536	PIGU	0.58	8.84	0.48	1.37e-16	Coronary artery disease;
CESC	cis	rs2204008	0.693	rs12372025	chr12:38202028	G/A	cg26384229	chr12:38710491	ALG10B	0.73	10.48	0.54	9.85e-22	Bladder cancer;
CESC	cis	rs7818688	0.745	rs73271178	chr8:95907230	C/T	cg16049864	chr8:95962084	TP53INP1	0.55	5.38	0.31	1.63e-7	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs67311347	1.000	rs6793596	chr3:40457795	C/T	cg09455208	chr3:40491958	NA	0.53	8.84	0.48	1.37e-16	Renal cell carcinoma;
CESC	cis	rs6938	0.534	rs12904897	chr15:75217686	A/G	cg10253484	chr15:75165896	SCAMP2	-0.55	-7.3	-0.41	3.32e-12	Breast cancer;
CESC	trans	rs9467711	0.659	rs36033628	chr6:26456074	T/G	cg01620082	chr3:125678407	NA	-0.86	-6.47	-0.37	4.66e-10	Autism spectrum disorder or schizophrenia;
CESC	cis	rs3026101	0.671	rs28619210	chr17:5319053	C/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.4	5.22	0.31	3.64e-7	Body mass index;
CESC	cis	rs7937682	0.883	rs510388	chr11:111451869	G/T	cg22437258	chr11:111473054	SIK2	-0.63	-8.39	-0.46	2.94e-15	Primary sclerosing cholangitis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23845507	chr1:91966731	CDC7	0.74	8.12	0.45	1.74e-14	Gut microbiome composition (summer);
CESC	cis	rs12681366	0.762	rs1598713	chr8:95381289	G/T	cg13257157	chr8:95487014	RAD54B	0.38	5.15	0.3	5.09e-7	Nonsyndromic cleft lip with cleft palate;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg08473553	chr1:236304799	GPR137B	-0.49	-6.12	-0.35	3.34e-9	Ulcerative colitis;
CESC	cis	rs614226	0.935	rs7137953	chr12:120894685	C/T	cg01236616	chr12:121019343	POP5	-1.39	-15.84	-0.7	3.24e-40	Type 1 diabetes nephropathy;
CESC	cis	rs6570726	0.791	rs12205752	chr6:145896118	A/G	cg05347473	chr6:146136440	FBXO30	0.59	7.63	0.42	4.24e-13	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7091068	0.522	rs10882322	chr10:95483273	C/G	cg20715218	chr10:95462985	C10orf4	0.5	5.89	0.34	1.14e-8	Urinary tract infection frequency;
CESC	cis	rs10267417	0.514	rs2072184	chr7:19748883	A/G	cg05791153	chr7:19748676	TWISTNB	0.86	9.13	0.49	1.75e-17	Night sleep phenotypes;
CESC	cis	rs17253792	0.822	rs77033617	chr14:56129746	T/A	cg01858014	chr14:56050164	KTN1	-0.97	-7.54	-0.42	7.36e-13	Putamen volume;
CESC	cis	rs9322193	0.847	rs62439808	chr6:149950826	C/T	cg13206674	chr6:150067644	NUP43	0.41	5.77	0.33	2.24e-8	Lung cancer;
CESC	cis	rs6831352	0.918	rs2851246	chr4:100046104	A/G	cg12011299	chr4:100065546	ADH4	0.58	6.61	0.38	2.12e-10	Alcohol dependence;
CESC	cis	rs854765	0.663	rs12941550	chr17:17753828	C/A	cg16928487	chr17:17741425	SREBF1	0.63	11.68	0.58	1.05e-25	Total body bone mineral density;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg00352397	chr1:45477801	UROD;HECTD3	0.47	6.15	0.35	2.87e-9	Systemic lupus erythematosus;
CESC	cis	rs727505	0.954	rs59283092	chr7:124678282	T/C	cg23710748	chr7:124431027	NA	-0.41	-6.39	-0.37	7.48e-10	Lewy body disease;
CESC	cis	rs9549260	0.753	rs2297628	chr13:41233905	T/C	cg21288729	chr13:41239152	FOXO1	0.54	5.33	0.31	2.11e-7	Red blood cell count;
CESC	cis	rs9894429	0.700	rs113915083	chr17:79552696	G/C	cg13777783	chr17:79615861	NA	0.32	5.07	0.3	7.39e-7	Eye color traits;
CESC	cis	rs2712184	0.756	rs2712181	chr2:217654869	C/T	cg05032264	chr2:217675019	NA	0.36	5.54	0.32	7.32e-8	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
CESC	cis	rs7267979	1.000	rs6083862	chr20:25411086	A/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.8	-16.6	-0.71	6.7e-43	Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs7839040	0.698	rs10102209	chr8:82926791	A/G	cg14472086	chr9:107730925	NA	-0.47	-6.33	-0.36	1.02e-9	Response to methotrexate in juvenile idiopathic arthritis;
CESC	cis	rs5753037	0.653	rs140121	chr22:30138689	C/T	cg01021169	chr22:30184971	ASCC2	-0.44	-6.12	-0.35	3.3e-9	Type 1 diabetes;
CESC	cis	rs9912789	0.744	rs9893755	chr17:79187432	C/T	cg25342872	chr17:79175132	AZI1	0.51	6.29	0.36	1.3e-9	Frontotemporal dementia;
CESC	cis	rs853679	0.517	rs1904840	chr6:28108232	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.55	-6.36	-0.36	8.66e-10	Depression;
CESC	cis	rs1862618	0.713	rs832549	chr5:56183542	C/T	cg24531977	chr5:56204891	C5orf35	-0.87	-10.91	-0.56	3.87e-23	Initial pursuit acceleration;
CESC	cis	rs11785400	1.000	rs7002932	chr8:143738816	C/A	cg10596483	chr8:143751796	JRK	0.43	5.65	0.33	4.1e-8	Schizophrenia;
CESC	cis	rs10791323	0.604	rs2723598	chr11:133711652	G/A	cg15485101	chr11:133734466	NA	0.41	6.55	0.37	3.06e-10	Childhood ear infection;
CESC	cis	rs3020736	0.500	rs4147638	chr22:42487900	G/A	cg15557168	chr22:42548783	NA	0.44	6.25	0.36	1.6e-9	Autism spectrum disorder or schizophrenia;
CESC	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg21548813	chr6:291882	DUSP22	-0.74	-10.17	-0.53	1.01e-20	Menopause (age at onset);
CESC	cis	rs16854884	1.000	rs7649614	chr3:143789028	G/A	cg06585982	chr3:143692056	C3orf58	0.48	5.45	0.32	1.13e-7	Economic and political preferences (feminism/equality);
CESC	cis	rs9303401	0.659	rs12952325	chr17:56899371	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.01	12.5	0.61	1.71e-28	Cognitive test performance;
CESC	cis	rs60871478	0.636	rs4276575	chr7:900035	C/T	cg13798912	chr7:905769	UNC84A	-0.52	-5.27	-0.31	2.8e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs5769765	0.658	rs2157536	chr22:50190180	G/A	cg02269571	chr22:50332266	NA	-0.46	-5.97	-0.34	7.67e-9	Schizophrenia;
CESC	cis	rs10883723	0.810	rs6584504	chr10:104253507	T/C	cg22532475	chr10:104410764	TRIM8	-0.34	-5.71	-0.33	2.98e-8	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs898097	0.812	rs72859941	chr17:80837459	G/A	cg08704611	chr17:80376099	HEXDC;C17orf101	-0.44	-5.13	-0.3	5.54e-7	Breast cancer;
CESC	cis	rs7091068	1.000	rs7091068	chr10:95420385	G/T	cg20715218	chr10:95462985	C10orf4	0.57	5.22	0.31	3.56e-7	Urinary tract infection frequency;
CESC	cis	rs5753618	0.555	rs5749291	chr22:31907523	C/G	cg00478049	chr22:31556069	RNF185	-0.46	-5.52	-0.32	7.99e-8	Colorectal cancer;
CESC	cis	rs2991971	0.967	rs7526665	chr1:46005832	G/T	cg05343316	chr1:45956843	TESK2	-0.51	-6.57	-0.37	2.7e-10	High light scatter reticulocyte count;
CESC	cis	rs2932538	0.614	rs6537741	chr1:113085175	A/C	cg22162597	chr1:113214053	CAPZA1	-0.56	-6.78	-0.38	7.79e-11	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CESC	cis	rs9875589	0.509	rs2733548	chr3:14094478	C/T	cg19554555	chr3:13937349	NA	-0.46	-5.98	-0.35	7.03e-9	Ovarian reserve;
CESC	cis	rs11971779	0.793	rs11543827	chr7:139032693	G/A	cg07862535	chr7:139043722	LUC7L2	0.51	5.65	0.33	4.17e-8	Diisocyanate-induced asthma;
CESC	cis	rs12586317	0.513	rs74564132	chr14:35472882	C/T	cg05294307	chr14:35346193	BAZ1A	-0.51	-5.45	-0.32	1.16e-7	Psoriasis;
CESC	trans	rs8073060	0.586	rs226089	chr17:34016935	C/T	cg19694781	chr19:47549865	TMEM160	-0.74	-6.91	-0.39	3.64e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	cis	rs1448094	0.512	rs12314318	chr12:86249238	T/C	cg19622623	chr12:86230825	RASSF9	-0.46	-5.89	-0.34	1.14e-8	Major depressive disorder;
CESC	cis	rs56235845	0.694	rs36102285	chr5:176774018	C/T	cg16006841	chr5:176797999	RGS14	0.43	5.17	0.3	4.68e-7	Hemoglobin concentration;Hematocrit;
CESC	cis	rs4722166	0.508	rs1474347	chr7:22768124	A/C	cg05265849	chr7:22767390	IL6	-0.43	-5.75	-0.33	2.51e-8	Lung cancer;
CESC	cis	rs17021463	0.902	rs36099342	chr4:95239783	T/C	cg11021082	chr4:95130006	SMARCAD1	0.53	7.96	0.44	4.97e-14	Testicular germ cell tumor;
CESC	cis	rs6912958	0.781	rs9450752	chr6:88300013	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-6.58	-0.37	2.55e-10	Monocyte percentage of white cells;
CESC	cis	rs2075371	1.000	rs2075373	chr7:133984683	A/C	cg20476274	chr7:133979776	SLC35B4	0.65	9.41	0.5	2.53e-18	Mean platelet volume;
CESC	cis	rs2439831	0.867	rs2927072	chr15:43922398	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.71	8.69	0.47	3.81e-16	Lung cancer in ever smokers;
CESC	cis	rs4730250	0.707	rs1981696	chr7:106794100	C/T	cg02696742	chr7:106810147	HBP1	0.55	5.35	0.31	1.87e-7	Osteoarthritis;
CESC	cis	rs4665809	1.000	rs7599132	chr2:26279810	A/T	cg27170947	chr2:26402098	FAM59B	0.66	7.91	0.44	6.83e-14	Gut microbiome composition (summer);
CESC	cis	rs4919087	0.705	rs701812	chr10:98975413	A/G	cg25902810	chr10:99078978	FRAT1	-0.45	-5.2	-0.3	3.96e-7	Monocyte count;
CESC	cis	rs12822507	0.868	rs12580006	chr12:12789646	C/T	cg11838227	chr12:12764436	CREBL2	-0.41	-5.43	-0.32	1.25e-7	Systemic lupus erythematosus;
CESC	cis	rs72781680	1.000	rs7578969	chr2:24168620	T/C	cg20701182	chr2:24300061	SF3B14	0.64	5.74	0.33	2.63e-8	Lymphocyte counts;
CESC	cis	rs213032	0.958	rs213036	chr1:21655345	T/C	cg16416158	chr1:21652298	ECE1	0.33	5.39	0.31	1.57e-7	Obesity-related traits;
CESC	cis	rs7208859	0.524	rs8069400	chr17:29075967	G/T	cg13385521	chr17:29058706	SUZ12P	0.82	6.58	0.37	2.48e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs6460942	1.000	rs62448568	chr7:12407445	A/G	cg06484146	chr7:12443880	VWDE	-0.8	-9.01	-0.48	4.07e-17	Coronary artery disease;
CESC	cis	rs16922576	0.656	rs2093448	chr9:5230444	T/G	cg02405213	chr9:5042618	JAK2	-0.51	-6.18	-0.35	2.46e-9	Allergic disease (asthma, hay fever or eczema);
CESC	trans	rs10488023	0.649	rs73119923	chr7:36925535	T/C	cg21282997	chr2:103035835	IL18RAP	0.39	6.13	0.35	3.26e-9	Breast size;
CESC	cis	rs5750830	0.649	rs5757657	chr22:39798429	G/T	cg01416388	chr22:39784598	NA	-0.58	-7.27	-0.41	4.15e-12	Intelligence (multi-trait analysis);
CESC	cis	rs1448094	0.512	rs7970842	chr12:86243258	C/T	cg19622623	chr12:86230825	RASSF9	-0.47	-5.95	-0.34	8.32e-9	Major depressive disorder;
CESC	cis	rs2576037	0.796	rs2247221	chr18:44580082	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.6	-8.73	-0.47	2.88e-16	Personality dimensions;
CESC	cis	rs7589728	0.563	rs4972044	chr2:88466196	T/C	cg14558114	chr2:88469736	THNSL2	0.59	5.56	0.32	6.52e-8	Plasma clusterin levels;
CESC	cis	rs34779708	0.702	rs4007272	chr10:35546859	T/G	cg03585969	chr10:35415529	CREM	0.55	6.37	0.36	8.28e-10	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs561341	1.000	rs550264	chr17:30317540	G/T	cg19193384	chr17:30244184	NA	-0.69	-6.51	-0.37	3.73e-10	Hip circumference adjusted for BMI;
CESC	cis	rs873946	0.586	rs12782567	chr10:134576709	C/G	cg27286337	chr10:134555280	INPP5A	-0.69	-7.98	-0.44	4.35e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs9287719	0.967	rs7587231	chr2:10740093	C/T	cg02196655	chr2:10830764	NOL10	-0.38	-5.83	-0.34	1.61e-8	Prostate cancer;
CESC	cis	rs2204008	0.837	rs7974888	chr12:37945215	A/G	cg26384229	chr12:38710491	ALG10B	0.67	9.77	0.51	1.9e-19	Bladder cancer;
CESC	cis	rs11122272	0.705	rs2491411	chr1:231533448	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.56	-7.66	-0.43	3.45e-13	Hemoglobin concentration;
CESC	cis	rs1401999	1.000	rs6800217	chr3:183685893	T/C	cg01324343	chr3:183735012	ABCC5	0.62	13.06	0.63	1.92e-30	Anterior chamber depth;
CESC	cis	rs2603127	0.768	rs13321325	chr3:108456798	A/G	cg03329597	chr3:108125523	MYH15	-0.54	-5.08	-0.3	7.07e-7	Hemostatic factors and hematological phenotypes;
CESC	cis	rs10911251	0.508	rs944970	chr1:183112566	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.84	13.22	0.63	5.53e-31	Colorectal cancer;
CESC	cis	rs875971	0.929	rs778682	chr7:65837934	A/G	cg18876405	chr7:65276391	NA	0.5	6.64	0.38	1.75e-10	Aortic root size;
CESC	cis	rs9311474	0.508	rs1570	chr3:52586682	T/A	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.5	0.37	3.88e-10	Electroencephalogram traits;
CESC	cis	rs654950	0.840	rs647146	chr1:41986286	G/A	cg06885757	chr1:42089581	HIVEP3	0.42	6.65	0.38	1.66e-10	Airway imaging phenotypes;
CESC	cis	rs965469	0.779	rs6051746	chr20:3307290	C/G	cg25506879	chr20:3388711	C20orf194	-0.53	-5.7	-0.33	3.12e-8	IFN-related cytopenia;
CESC	cis	rs7312774	0.881	rs1822737	chr12:107309175	A/G	cg16260113	chr12:107380972	MTERFD3	0.63	5.94	0.34	8.71e-9	Severe influenza A (H1N1) infection;
CESC	cis	rs1799949	0.860	rs8176279	chr17:41210396	A/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.48	6.69	0.38	1.36e-10	Menopause (age at onset);
CESC	cis	rs7412746	0.658	rs2272214	chr1:150931462	C/T	cg18016565	chr1:150552671	MCL1	0.34	5.07	0.3	7.35e-7	Melanoma;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg03178185	chr16:71758038	NA	-0.49	-7.09	-0.4	1.25e-11	Gambling;
CESC	cis	rs5758659	0.714	rs2413668	chr22:42505841	G/A	cg19513890	chr22:42538836	CYP2D7P1	0.36	5.37	0.31	1.74e-7	Cognitive function;
CESC	cis	rs2836974	0.623	rs34240248	chr21:40685239	A/G	cg17971929	chr21:40555470	PSMG1	-0.87	-12.35	-0.6	5.7e-28	Cognitive function;
CESC	cis	rs11785400	0.793	rs4736366	chr8:143742413	C/T	cg10596483	chr8:143751796	JRK	0.46	5.75	0.33	2.43e-8	Schizophrenia;
CESC	cis	rs2952156	0.920	rs2517958	chr17:37838751	G/A	cg00129232	chr17:37814104	STARD3	-0.82	-12.14	-0.6	2.94e-27	Asthma;
CESC	cis	rs9309711	0.560	rs6548164	chr2:3472665	C/T	cg10845886	chr2:3471009	TTC15	0.58	7.94	0.44	5.58e-14	Neurofibrillary tangles;
CESC	cis	rs1008375	1.000	rs2315556	chr4:17670861	T/C	cg02297831	chr4:17616191	MED28	0.45	5.68	0.33	3.53e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs4561483	0.801	rs33660	chr16:11961858	A/G	cg08843971	chr16:11963173	GSPT1	-0.56	-8.18	-0.45	1.18e-14	Testicular germ cell tumor;
CESC	cis	rs116095464	0.558	rs10055354	chr5:243794	G/A	cg20965017	chr5:231967	SDHA	-0.47	-5.38	-0.31	1.65e-7	Breast cancer;
CESC	cis	rs362272	0.545	rs2236052	chr4:3318413	C/T	cg08886695	chr4:3369023	RGS12	0.4	5.52	0.32	8.03e-8	Serum sulfate level;
CESC	cis	rs7179456	0.513	rs640704	chr15:59049021	A/G	cg05156742	chr15:59063176	FAM63B	0.63	8.22	0.45	9.04e-15	Asperger disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22271113	chr17:8370397	NDEL1	-0.55	-6.17	-0.35	2.51e-9	Gut microbiome composition (summer);
CESC	cis	rs7107174	1.000	rs2510040	chr11:77944548	T/A	cg03754400	chr11:77348600	CLNS1A	0.49	5.19	0.3	4.16e-7	Testicular germ cell tumor;
CESC	cis	rs7539542	0.556	rs10753925	chr1:202854488	C/T	cg19681188	chr1:202830198	LOC148709	0.41	5.29	0.31	2.56e-7	Mean platelet volume;
CESC	cis	rs4969178	0.896	rs1976704	chr17:76401318	C/T	cg05887092	chr17:76393375	PGS1	0.58	9.26	0.49	7e-18	HDL cholesterol levels;
CESC	cis	rs3540	0.513	rs2601154	chr15:90894284	T/C	cg22089800	chr15:90895588	ZNF774	0.73	10.0	0.52	3.46e-20	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs9611565	0.605	rs202638	chr22:41855458	A/G	cg06481639	chr22:41940642	POLR3H	0.51	5.77	0.33	2.22e-8	Vitiligo;
CESC	cis	rs8020095	0.571	rs728647	chr14:67378055	G/T	cg19548862	chr14:67692701	FAM71D	-0.49	-6.03	-0.35	5.38e-9	Depression (quantitative trait);
CESC	cis	rs4819052	0.851	rs2877020	chr21:46658742	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.91	13.24	0.63	4.51e-31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs514406	0.861	rs562182	chr1:53270010	C/T	cg08859206	chr1:53392774	SCP2	-0.55	-7.24	-0.41	4.76e-12	Monocyte count;
CESC	cis	rs8072100	0.688	rs8075843	chr17:45442363	C/T	cg08085267	chr17:45401833	C17orf57	-0.53	-6.65	-0.38	1.65e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs6088580	0.634	rs6088483	chr20:32984714	T/A	cg08999081	chr20:33150536	PIGU	-0.65	-11.34	-0.57	1.5e-24	Glomerular filtration rate (creatinine);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg09754991	chr13:107220236	ARGLU1	-0.48	-6.67	-0.38	1.45e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs9300255	0.739	rs4759371	chr12:123742563	T/C	cg05973401	chr12:123451056	ABCB9	0.49	5.52	0.32	8.03e-8	Neutrophil percentage of white cells;
CESC	trans	rs55872338	0.588	rs7923238	chr10:44539457	T/C	cg04664161	chr19:1876758	NA	0.63	6.13	0.35	3.16e-9	Facial morphology (factor 20);
CESC	cis	rs1552244	0.752	rs9867091	chr3:10043429	T/C	cg08888203	chr3:10149979	C3orf24	0.49	6.14	0.35	2.98e-9	Alzheimer's disease;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg11278799	chr20:13765577	ESF1;C20orf7	-0.5	-6.14	-0.35	2.97e-9	Ulcerative colitis;
CESC	cis	rs2479724	0.846	rs2488338	chr6:41808351	A/G	cg08135965	chr6:41755394	TOMM6	0.41	5.49	0.32	9.26e-8	Menarche (age at onset);
CESC	cis	rs7208859	0.673	rs73265612	chr17:29225983	A/G	cg19761014	chr17:28927070	LRRC37B2	0.73	5.77	0.33	2.22e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs7618915	0.501	rs3774366	chr3:52641255	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	7.54	0.42	7.51e-13	Bipolar disorder;
CESC	cis	rs870825	0.616	rs35818632	chr4:185649661	G/T	cg04058563	chr4:185651563	MLF1IP	0.64	6.51	0.37	3.78e-10	Blood protein levels;
CESC	cis	rs4253772	0.530	rs6008623	chr22:46710024	G/A	cg18190219	chr22:46762943	CELSR1	-0.59	-6.57	-0.37	2.66e-10	LDL cholesterol;Cholesterol, total;
CESC	cis	rs858239	0.539	rs6965833	chr7:23192366	T/C	cg23682824	chr7:23144976	KLHL7	0.5	6.78	0.38	7.91e-11	Cerebrospinal fluid biomarker levels;
CESC	cis	rs721399	0.553	rs10095072	chr8:18244662	G/T	cg18736775	chr8:18248649	NAT2	-0.47	-5.36	-0.31	1.83e-7	Blood metabolite levels;
CESC	cis	rs1790761	0.559	rs10896190	chr11:67406123	T/C	cg00290607	chr11:67383545	NA	0.46	6.71	0.38	1.2e-10	Mean corpuscular volume;
CESC	cis	rs1862618	0.573	rs185220	chr5:56205357	A/G	cg18230493	chr5:56204884	C5orf35	-0.79	-9.6	-0.51	6.61e-19	Initial pursuit acceleration;
CESC	cis	rs6032067	0.777	rs13037087	chr20:43834313	T/C	cg11264863	chr20:43835661	SEMG1	0.48	5.29	0.31	2.56e-7	Blood protein levels;
CESC	cis	rs9611565	0.625	rs12483991	chr22:41935285	A/G	cg06634786	chr22:41940651	POLR3H	-0.48	-5.25	-0.31	3.1e-7	Vitiligo;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg13576061	chr5:55291172	IL6ST	-0.49	-6.8	-0.39	7.12e-11	Gut microbiota (bacterial taxa);
CESC	trans	rs17685	0.753	rs6951808	chr7:75772413	A/G	cg19862616	chr7:65841803	NCRNA00174	0.85	12.42	0.61	3.15e-28	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs4819052	1.000	rs733738	chr21:46666396	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.82	-10.58	-0.54	4.86e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs1707322	0.721	rs10430123	chr1:46221440	T/C	cg05343316	chr1:45956843	TESK2	0.51	6.2	0.36	2.19e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs77216612	0.877	rs7956514	chr12:12879254	T/G	cg24098013	chr12:12878779	APOLD1	0.56	6.87	0.39	4.46e-11	Lymphocyte counts;
CESC	cis	rs722599	0.715	rs61978928	chr14:75321714	T/C	cg08847533	chr14:75593920	NEK9	-0.48	-5.94	-0.34	8.71e-9	IgG glycosylation;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg11851257	chr17:47903406	MYST2	0.4	6.09	0.35	3.97e-9	Gambling;
CESC	cis	rs727563	0.635	rs5758444	chr22:42133921	T/A	cg17376030	chr22:41985996	PMM1	-0.71	-7.49	-0.42	1.06e-12	Crohn's disease;Inflammatory bowel disease;
CESC	trans	rs1728785	0.901	rs8050289	chr16:68566976	T/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.61	7.42	0.41	1.57e-12	Ulcerative colitis;
CESC	cis	rs3820068	0.581	rs72645874	chr1:15926238	C/G	cg13390004	chr1:15929781	NA	0.35	5.58	0.32	5.83e-8	Systolic blood pressure;
CESC	trans	rs916888	0.773	rs199451	chr17:44801784	G/A	cg27125505	chr17:43679177	LOC644172	0.51	6.6	0.38	2.29e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs9291683	0.620	rs717615	chr4:10104670	C/T	cg00071950	chr4:10020882	SLC2A9	0.59	9.39	0.5	2.9e-18	Bone mineral density;
CESC	cis	rs6582630	0.531	rs3850000	chr12:38483752	T/C	cg13010199	chr12:38710504	ALG10B	0.47	6.11	0.35	3.63e-9	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs3008870	0.536	rs2208576	chr1:67513401	C/G	cg02640540	chr1:67518911	SLC35D1	-0.64	-8.57	-0.47	8.4e-16	Lymphocyte percentage of white cells;
CESC	trans	rs1814175	0.645	rs1874969	chr11:49826700	G/A	cg03929089	chr4:120376271	NA	-0.86	-13.73	-0.64	8.88e-33	Height;
CESC	cis	rs1348850	0.918	rs4893966	chr2:178470138	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.6	7.67	0.43	3.36e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs13108904	0.875	rs10024013	chr4:1280792	C/T	cg16405210	chr4:1374714	KIAA1530	0.45	5.58	0.32	5.89e-8	Obesity-related traits;
CESC	cis	rs478304	0.593	rs7120713	chr11:65483374	G/C	cg10518572	chr11:65560635	OVOL1	-0.26	-5.05	-0.3	8.26e-7	Acne (severe);
CESC	cis	rs12681366	0.734	rs10102233	chr8:95401657	A/T	cg13257157	chr8:95487014	RAD54B	0.38	5.14	0.3	5.22e-7	Nonsyndromic cleft lip with cleft palate;
CESC	cis	rs9549367	0.773	rs9549717	chr13:113908826	A/G	cg00898013	chr13:113819073	PROZ	-0.52	-7.46	-0.42	1.2e-12	Platelet distribution width;
CESC	cis	rs4720575	1.000	rs1074575	chr7:47090545	A/C	cg00036614	chr7:47093842	NA	-0.43	-6.63	-0.38	1.82e-10	Angiotensin-converting enzyme inhibitor intolerance;
CESC	cis	rs10504229	1.000	rs61998258	chr8:58192284	T/C	cg05313129	chr8:58192883	C8orf71	-0.55	-6.29	-0.36	1.34e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs2439831	0.850	rs7174208	chr15:44052682	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.71	6.75	0.38	9.27e-11	Lung cancer in ever smokers;
CESC	cis	rs524281	0.647	rs2302883	chr11:65824994	T/C	cg14036092	chr11:66035641	RAB1B	-0.58	-6.33	-0.36	1.02e-9	Electroencephalogram traits;
CESC	cis	rs7481584	0.624	rs428726	chr11:3046201	G/A	cg25174290	chr11:3078921	CARS	-0.48	-6.65	-0.38	1.68e-10	Calcium levels;
CESC	cis	rs870825	0.616	rs28649620	chr4:185648997	G/A	cg04058563	chr4:185651563	MLF1IP	0.63	6.96	0.39	2.59e-11	Blood protein levels;
CESC	cis	rs6061231	1.000	rs11696991	chr20:60959694	G/T	cg06197360	chr20:60970103	CABLES2	-0.41	-5.31	-0.31	2.27e-7	Colorectal cancer;
CESC	cis	rs9905704	0.914	rs2643117	chr17:56829516	G/A	cg12560992	chr17:57184187	TRIM37	0.62	7.1	0.4	1.11e-11	Testicular germ cell tumor;
CESC	cis	rs7666738	0.687	rs6839454	chr4:99073914	T/C	cg24818145	chr4:99064322	C4orf37	0.44	5.55	0.32	6.81e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs12497850	0.897	rs6781790	chr3:49044767	C/T	cg03060546	chr3:49711283	APEH	0.49	6.03	0.35	5.41e-9	Parkinson's disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg19143282	chr18:77507733	CTDP1	0.48	6.72	0.38	1.13e-10	Fibrinogen levels;
CESC	cis	rs8177253	0.606	rs6787177	chr3:133450720	C/T	cg16262614	chr3:133464971	TF	0.31	5.47	0.32	1.02e-7	Iron status biomarkers;
CESC	cis	rs2361718	0.564	rs2304844	chr17:78084507	G/C	cg14949292	chr17:78079608	GAA	-0.35	-5.14	-0.3	5.29e-7	Yeast infection;
CESC	cis	rs7511006	0.893	rs2038049	chr22:50654888	G/C	cg16473166	chr22:50639996	SELO	0.59	8.12	0.45	1.72e-14	Obesity-related traits;
CESC	cis	rs2933343	1.000	rs1680790	chr3:128625853	G/T	cg25356066	chr3:128598488	ACAD9	0.61	7.44	0.42	1.37e-12	IgG glycosylation;
CESC	cis	rs2404602	0.679	rs12899871	chr15:76757347	T/C	cg22467129	chr15:76604101	ETFA	-0.38	-5.81	-0.34	1.81e-8	Blood metabolite levels;
CESC	cis	rs7959452	0.640	rs11177599	chr12:69721970	G/A	cg22834771	chr12:69754056	YEATS4	-0.39	-5.1	-0.3	6.57e-7	Blood protein levels;
CESC	cis	rs7560272	0.502	rs4513320	chr2:73920741	T/C	cg20560298	chr2:73613845	ALMS1	0.45	6.13	0.35	3.12e-9	Schizophrenia;
CESC	cis	rs780096	0.526	rs13391837	chr2:27649375	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.29	-5.35	-0.31	1.89e-7	Total body bone mineral density;
CESC	cis	rs2354432	0.556	rs885305	chr1:146786080	G/A	cg25205988	chr1:146714368	CHD1L	-1.04	-8.87	-0.48	1.13e-16	Mitochondrial DNA levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19558860	chr14:93582779	ITPK1	0.59	7.15	0.4	8.59e-12	Gut microbiome composition (summer);
CESC	cis	rs4821897	0.514	rs739141	chr22:39824450	A/G	cg02038168	chr22:39784481	NA	0.54	7.0	0.4	2.07e-11	IgG glycosylation;
CESC	cis	rs13108904	0.967	rs11730939	chr4:1285560	G/A	cg00684032	chr4:1343700	KIAA1530	0.4	5.46	0.32	1.1e-7	Obesity-related traits;
CESC	cis	rs4253772	0.550	rs9615953	chr22:46731024	C/G	cg00784671	chr22:46762841	CELSR1	-0.62	-6.0	-0.35	6.33e-9	LDL cholesterol;Cholesterol, total;
CESC	cis	rs6952809	0.532	rs6956223	chr7:2431331	T/C	cg23289794	chr7:2394357	EIF3B	-0.85	-7.73	-0.43	2.24e-13	Multiple sclerosis;
CESC	cis	rs7727544	0.684	rs274561	chr5:131719228	A/C	cg07395648	chr5:131743802	NA	-0.4	-5.22	-0.31	3.62e-7	Blood metabolite levels;
CESC	cis	rs11098499	0.954	rs59394118	chr4:120295551	A/G	cg09307838	chr4:120376055	NA	0.94	12.84	0.62	1.16e-29	Corneal astigmatism;
CESC	cis	rs708547	0.647	rs1713982	chr4:57881715	G/A	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.42	-5.58	-0.32	6.06e-8	Response to bleomycin (chromatid breaks);
CESC	cis	rs9527	0.590	rs943039	chr10:104825132	C/T	cg04362960	chr10:104952993	NT5C2	0.45	5.76	0.33	2.34e-8	Arsenic metabolism;
CESC	cis	rs1801251	1.000	rs1044480	chr2:233633736	A/G	cg25237894	chr2:233734115	C2orf82	0.44	7.63	0.42	4.32e-13	Coronary artery disease;
CESC	cis	rs9457247	0.663	rs2282860	chr6:167440244	T/C	cg23791538	chr6:167370224	RNASET2	-0.57	-7.7	-0.43	2.7e-13	Crohn's disease;
CESC	cis	rs523522	0.962	rs603574	chr12:120998443	A/G	cg27279351	chr12:120934652	DYNLL1	0.68	8.84	0.48	1.4e-16	High light scatter reticulocyte count;
CESC	cis	rs698833	0.886	rs2241871	chr2:44548613	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.59	7.25	0.41	4.68e-12	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs6460942	1.000	rs6460935	chr7:12401317	A/T	cg06484146	chr7:12443880	VWDE	-0.7	-8.06	-0.44	2.57e-14	Coronary artery disease;
CESC	cis	rs2576037	0.526	rs998819	chr18:44564181	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.69	-10.85	-0.55	6.13e-23	Personality dimensions;
CESC	cis	rs2836974	0.590	rs9974757	chr21:40617244	T/C	cg11644478	chr21:40555479	PSMG1	-0.8	-12.02	-0.59	7.35e-27	Cognitive function;
CESC	cis	rs2370759	1.000	rs11597888	chr10:32635834	G/A	cg18270830	chr10:32634957	EPC1	0.71	6.87	0.39	4.58e-11	Sexual dysfunction (female);
CESC	cis	rs4925325	1.000	rs4925325	chr20:60514224	G/A	cg06108461	chr20:60628389	TAF4	0.52	6.16	0.35	2.63e-9	Obesity-related traits;
CESC	cis	rs12188164	0.965	rs11745789	chr5:450777	T/C	cg17553881	chr5:443987	EXOC3;C5orf55	-0.38	-6.14	-0.35	2.97e-9	Cystic fibrosis severity;
CESC	cis	rs6499255	0.951	rs16959025	chr16:69695589	G/T	cg15192750	chr16:69999425	NA	-0.47	-5.09	-0.3	6.69e-7	IgE levels;
CESC	cis	rs72949976	0.864	rs62186566	chr2:214024421	G/A	cg08319019	chr2:214017104	IKZF2	-0.46	-5.71	-0.33	3.08e-8	Lung cancer;Squamous cell lung carcinoma;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00437443	chr6:11094621	LOC221710	-0.58	-6.35	-0.36	9.33e-10	Gut microbiome composition (summer);
CESC	cis	rs12497850	1.000	rs4858831	chr3:48735558	C/T	cg06212747	chr3:49208901	KLHDC8B	0.6	8.1	0.45	2.05e-14	Parkinson's disease;
CESC	cis	rs4654899	1.000	rs10799685	chr1:21465930	A/C	cg05370193	chr1:21551575	ECE1	-0.38	-5.75	-0.33	2.4e-8	Superior frontal gyrus grey matter volume;
CESC	cis	rs7666738	0.830	rs2167892	chr4:99048503	G/C	cg17366294	chr4:99064904	C4orf37	0.61	8.78	0.47	2.13e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs5758659	0.652	rs4822084	chr22:42435868	A/G	cg19513890	chr22:42538836	CYP2D7P1	0.37	5.26	0.31	2.92e-7	Cognitive function;
CESC	cis	rs561341	1.000	rs560132	chr17:30320019	C/T	cg23018236	chr17:30244563	NA	-0.55	-5.29	-0.31	2.57e-7	Hip circumference adjusted for BMI;
CESC	cis	rs7654585	0.645	rs6828416	chr4:25933273	C/T	cg10409131	chr4:25915609	C4orf52	0.7	9.52	0.5	1.1e-18	Obesity-related traits;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg06745235	chr1:180471494	ACBD6	-0.42	-6.17	-0.35	2.49e-9	Gambling;
CESC	cis	rs9796	0.621	rs2918462	chr15:41481254	A/G	cg18705301	chr15:41695430	NDUFAF1	0.44	6.51	0.37	3.8e-10	Menopause (age at onset);
CESC	cis	rs651907	0.535	rs11707250	chr3:101509371	A/T	cg12386194	chr3:101231763	SENP7	-0.43	-5.57	-0.32	6.16e-8	Colorectal cancer;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg08330572	chr5:620259	CEP72	0.47	6.16	0.35	2.65e-9	Fibrinogen levels;
CESC	cis	rs2262909	0.962	rs56369285	chr19:22267185	T/C	cg11619707	chr19:22235551	ZNF257	0.34	5.44	0.32	1.24e-7	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
CESC	cis	rs9300255	0.596	rs10734901	chr12:123743447	G/A	cg05973401	chr12:123451056	ABCB9	0.44	5.46	0.32	1.12e-7	Neutrophil percentage of white cells;
CESC	cis	rs116095464	0.558	rs59284383	chr5:284525	C/G	cg10591111	chr5:226296	SDHA	-0.53	-6.43	-0.37	6.03e-10	Breast cancer;
CESC	cis	rs589448	0.867	rs623853	chr12:69753830	G/A	cg14784868	chr12:69753453	YEATS4	0.92	14.57	0.67	1.05e-35	Cerebrospinal fluid biomarker levels;
CESC	trans	rs61931739	0.534	rs11052960	chr12:33997754	A/T	cg26384229	chr12:38710491	ALG10B	0.58	8.14	0.45	1.51e-14	Morning vs. evening chronotype;
CESC	cis	rs9287719	0.901	rs10210859	chr2:10733929	C/T	cg02196655	chr2:10830764	NOL10	-0.36	-5.57	-0.32	6.1e-8	Prostate cancer;
CESC	cis	rs34638657	0.732	rs62045962	chr16:82200604	T/C	cg09439754	chr16:82129088	HSD17B2	-0.36	-6.24	-0.36	1.71e-9	Lung adenocarcinoma;
CESC	cis	rs7851660	0.775	rs7034336	chr9:100661100	C/T	cg13688889	chr9:100608707	NA	-0.62	-8.87	-0.48	1.11e-16	Strep throat;
CESC	cis	rs12220238	1.000	rs10824076	chr10:75886956	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.66	6.68	0.38	1.42e-10	Soluble interleukin-2 receptor subunit alpha;
CESC	cis	rs2242194	0.816	rs6671688	chr1:154994265	T/C	cg12436631	chr1:155007014	DCST1;DCST2	0.47	8.26	0.45	6.78e-15	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13762257	chr11:45864900	NA	-0.56	-6.79	-0.38	7.38e-11	Gut microbiome composition (summer);
CESC	cis	rs1055129	0.560	rs56248937	chr17:73915153	T/A	cg08125733	chr17:73851984	WBP2	0.52	7.12	0.4	1.02e-11	White matter hyperintensity burden;
CESC	cis	rs910316	0.663	rs175034	chr14:75463687	T/G	cg16144293	chr14:75469539	EIF2B2	0.41	5.45	0.32	1.18e-7	Height;
CESC	cis	rs6582630	0.533	rs11181379	chr12:38332381	C/T	cg26384229	chr12:38710491	ALG10B	0.43	5.97	0.34	7.51e-9	Drug-induced liver injury (flucloxacillin);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg09026224	chr5:172484103	C5orf41	-0.43	-6.06	-0.35	4.59e-9	Gambling;
CESC	cis	rs870825	0.616	rs28450662	chr4:185638900	G/A	cg04058563	chr4:185651563	MLF1IP	0.64	7.09	0.4	1.21e-11	Blood protein levels;
CESC	cis	rs9788682	1.000	rs2036534	chr15:78826948	T/C	cg24631222	chr15:78858424	CHRNA5	0.77	9.97	0.52	4.29e-20	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs2288073	0.965	rs36101491	chr2:24387532	C/T	cg06627628	chr2:24431161	ITSN2	-0.86	-9.78	-0.52	1.73e-19	Venous thromboembolism (SNP x SNP interaction);
CESC	cis	rs4319547	1.000	rs6489156	chr12:123100397	C/T	cg23029597	chr12:123009494	RSRC2	-0.45	-5.12	-0.3	6.02e-7	Body mass index;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00222982	chr11:125439225	EI24	0.57	6.8	0.39	6.78e-11	Gut microbiome composition (summer);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg14551182	chr11:16626476	NA	-0.42	-6.58	-0.37	2.44e-10	Gambling;
CESC	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg24829409	chr8:58192753	C8orf71	-0.66	-7.57	-0.42	6.15e-13	Developmental language disorder (linguistic errors);
CESC	cis	rs9430161	0.611	rs35033941	chr1:11034382	C/T	cg02454025	chr1:11042201	C1orf127	0.99	16.1	0.7	3.84e-41	Ewing sarcoma;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04246357	chr6:158589294	SERAC1;GTF2H5	0.56	6.35	0.36	9.07e-10	Gut microbiome composition (summer);
CESC	cis	rs2303745	0.589	rs1864116	chr19:17393015	C/T	cg02221750	chr19:17393354	ANKLE1	-0.5	-6.0	-0.35	6.62e-9	Systemic lupus erythematosus;
CESC	cis	rs4835473	0.868	rs5025156	chr4:144659178	T/A	cg25736465	chr4:144833511	NA	-0.43	-6.57	-0.37	2.72e-10	Immature fraction of reticulocytes;
CESC	cis	rs7940866	0.774	rs10466547	chr11:130823576	T/C	cg12179176	chr11:130786555	SNX19	0.68	10.05	0.53	2.44e-20	Schizophrenia;
CESC	cis	rs7927592	0.763	rs624003	chr11:68231240	C/T	cg20283391	chr11:68216788	NA	-0.46	-5.63	-0.33	4.67e-8	Total body bone mineral density;
CESC	cis	rs1348850	0.632	rs1358328	chr2:178517532	G/A	cg22681709	chr2:178499509	PDE11A	-0.58	-8.82	-0.48	1.58e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs7078219	0.505	rs6584282	chr10:101286495	A/G	cg09788492	chr10:101292477	NKX2-3	0.33	6.25	0.36	1.62e-9	Dental caries;
CESC	cis	rs2880765	0.835	rs6496027	chr15:86049988	C/T	cg19183879	chr15:85880815	NA	-0.25	-5.12	-0.3	5.89e-7	Coronary artery disease;
CESC	cis	rs6963495	0.818	rs56251768	chr7:105165591	A/G	cg19920283	chr7:105172520	RINT1	0.7	6.66	0.38	1.58e-10	Bipolar disorder (body mass index interaction);
CESC	trans	rs801193	1.000	rs10252765	chr7:66228732	C/G	cg26939375	chr7:64535504	NA	0.62	7.87	0.44	9.34e-14	Aortic root size;
CESC	cis	rs763121	0.853	rs9610986	chr22:39025277	T/C	cg21395723	chr22:39101663	GTPBP1	0.43	5.29	0.31	2.58e-7	Menopause (age at onset);
CESC	cis	rs3008870	0.755	rs2815364	chr1:67498384	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.6	7.97	0.44	4.75e-14	Lymphocyte percentage of white cells;
CESC	cis	rs4986811	1.000	rs11031780	chr11:32452945	C/G	cg27409910	chr11:32454216	WT1	0.49	6.29	0.36	1.3e-9	Rubella-specific interleukin-6 secretion;
CESC	cis	rs11264213	0.901	rs79303353	chr1:36402056	G/A	cg27506609	chr1:36549197	TEKT2	0.66	5.55	0.32	6.79e-8	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02759888	chr15:63449753	RPS27L	0.64	7.66	0.43	3.49e-13	Gut microbiome composition (summer);
CESC	cis	rs7635838	0.964	rs7624086	chr3:11412620	C/G	cg00170343	chr3:11313890	ATG7	0.39	5.12	0.3	5.85e-7	HDL cholesterol;
CESC	cis	rs2742234	0.541	rs10899778	chr10:43718509	G/C	cg15436174	chr10:43711423	RASGEF1A	0.47	5.58	0.32	5.81e-8	Hirschsprung disease;
CESC	cis	rs6860806	0.631	rs4705931	chr5:131588345	T/C	cg04518342	chr5:131593106	PDLIM4	0.41	6.16	0.35	2.72e-9	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06538771	chr22:50636937	TRABD	-0.51	-6.04	-0.35	5.08e-9	Gut microbiome composition (summer);
CESC	cis	rs1005277	0.505	rs200936	chr10:38134935	T/C	cg00409905	chr10:38381863	ZNF37A	-0.55	-7.6	-0.42	5.03e-13	Extrinsic epigenetic age acceleration;
CESC	cis	rs12824058	0.831	rs7310433	chr12:130809289	C/T	cg24838063	chr12:130822603	PIWIL1	0.62	8.55	0.47	9.78e-16	Menopause (age at onset);
CESC	cis	rs7772486	0.738	rs9485039	chr6:146319387	C/T	cg05347473	chr6:146136440	FBXO30	0.5	6.53	0.37	3.39e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4889855	0.530	rs7220588	chr17:78598231	G/A	cg16591659	chr17:78472290	NA	-0.33	-5.25	-0.31	3.08e-7	Fractional excretion of uric acid;
CESC	cis	rs854765	0.693	rs4924823	chr17:17764502	A/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.45	-5.86	-0.34	1.4e-8	Total body bone mineral density;
CESC	cis	rs2710642	0.586	rs12713462	chr2:62804482	C/T	cg17519650	chr2:63277830	OTX1	0.45	6.02	0.35	5.82e-9	LDL cholesterol levels;LDL cholesterol;
CESC	cis	rs9733	0.596	rs72702504	chr1:150635374	G/C	cg22823121	chr1:150693482	HORMAD1	0.48	7.12	0.4	1.02e-11	Tonsillectomy;
CESC	cis	rs8177179	0.967	rs9820225	chr3:133449189	A/G	cg24879335	chr3:133465180	TF	0.47	9.17	0.49	1.4e-17	Iron status biomarkers (transferrin levels);
CESC	cis	rs6540559	0.673	rs11803382	chr1:209986426	G/A	cg10074409	chr1:209979377	IRF6	0.4	5.22	0.31	3.59e-7	Cleft lip with or without cleft palate;
CESC	cis	rs6500395	0.926	rs8057777	chr16:48565643	T/C	cg04672837	chr16:48644449	N4BP1	0.44	5.26	0.31	2.96e-7	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg02353165	chr6:42928485	GNMT	0.85	14.82	0.67	1.36e-36	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs4481887	1.000	rs6659039	chr1:248465689	C/T	cg00666640	chr1:248458726	OR2T12	0.39	6.31	0.36	1.19e-9	Common traits (Other);
CESC	cis	rs853679	0.517	rs9380057	chr6:28104634	G/T	cg26335602	chr6:28129616	ZNF389	0.54	7.3	0.41	3.37e-12	Depression;
CESC	cis	rs9788682	0.747	rs11637630	chr15:78899719	G/A	cg24631222	chr15:78858424	CHRNA5	-0.82	-10.19	-0.53	8.81e-21	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs4713118	0.629	rs203889	chr6:28021775	T/G	cg18032046	chr6:28092343	ZSCAN16	-0.52	-5.99	-0.35	6.73e-9	Parkinson's disease;
CESC	cis	rs4523957	0.820	rs216193	chr17:2203453	A/G	cg16513277	chr17:2031491	SMG6	0.54	7.08	0.4	1.28e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs6933660	0.760	rs6904364	chr6:151754273	T/C	cg02564969	chr6:151773285	C6orf211;RMND1	0.6	8.04	0.44	3.09e-14	Menarche (age at onset);
CESC	cis	rs12701220	0.604	rs12702122	chr7:1149494	C/G	cg04025307	chr7:1156635	C7orf50	0.44	5.33	0.31	2.16e-7	Bronchopulmonary dysplasia;
CESC	cis	rs35110281	0.837	rs2838341	chr21:45076443	A/G	cg04455712	chr21:45112962	RRP1B	0.4	5.99	0.35	6.65e-9	Mean corpuscular volume;
CESC	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	10.23	0.53	6.6e-21	Prudent dietary pattern;
CESC	cis	rs1538970	0.816	rs11211124	chr1:45962409	T/C	cg06784218	chr1:46089804	CCDC17	0.37	5.9	0.34	1.11e-8	Platelet count;
CESC	cis	rs939658	0.805	rs11634679	chr15:79432475	T/C	cg17916960	chr15:79447300	NA	-0.39	-6.34	-0.36	1.01e-9	Refractive error;
CESC	cis	rs4891159	0.790	rs683306	chr18:74112473	C/G	cg24786174	chr18:74118243	ZNF516	-0.76	-12.12	-0.6	3.38e-27	Longevity;
CESC	cis	rs4604732	0.588	rs7549495	chr1:247627806	G/A	cg12758973	chr1:247694275	LOC148824;OR2C3	0.48	6.01	0.35	6.07e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs897984	0.683	rs72799316	chr16:30827205	A/G	cg00531865	chr16:30841666	NA	-0.57	-8.63	-0.47	5.61e-16	Dementia with Lewy bodies;
CESC	cis	rs9457247	0.967	rs385460	chr6:167403888	A/T	cg07741184	chr6:167504864	NA	0.28	5.1	0.3	6.54e-7	Crohn's disease;
CESC	cis	rs523522	0.924	rs11065150	chr12:120958875	T/G	cg12219531	chr12:120966889	COQ5	0.74	9.95	0.52	5.04e-20	High light scatter reticulocyte count;
CESC	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-5.95	-0.34	8.57e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7659604	0.539	rs56159666	chr4:122782879	G/A	cg19748678	chr4:122722346	EXOSC9	0.79	10.06	0.53	2.23e-20	Type 2 diabetes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18911472	chr17:56736863	TEX14	0.54	6.12	0.35	3.36e-9	Gut microbiome composition (summer);
CESC	cis	rs2046867	0.818	rs67355490	chr3:72830935	T/C	cg25664220	chr3:72788482	NA	-0.46	-6.73	-0.38	1.06e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CESC	cis	rs826838	0.868	rs864324	chr12:39122853	A/G	cg26384229	chr12:38710491	ALG10B	0.61	9.8	0.52	1.48e-19	Heart rate;
CESC	cis	rs769267	0.929	rs34538000	chr19:19481379	G/T	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.44	-5.76	-0.33	2.36e-8	Tonsillectomy;
CESC	cis	rs7264396	0.747	rs2425151	chr20:34394541	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.83	-11.37	-0.57	1.2e-24	Total cholesterol levels;
CESC	cis	rs728616	0.614	rs59806247	chr10:82097974	T/C	cg05935833	chr10:81318306	SFTPA2	-0.37	-5.37	-0.31	1.76e-7	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs11997175	0.603	rs4739382	chr8:33807012	C/T	ch.8.33884649F	chr8:33765107	NA	0.5	5.99	0.35	6.87e-9	Body mass index;
CESC	cis	rs3815700	1.000	rs8104328	chr19:33094371	G/A	cg24916020	chr19:33096688	ANKRD27	0.59	5.8	0.34	1.92e-8	Eosinophilic esophagitis;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg04792727	chr1:231664260	TSNAX-DISC1;TSNAX	-0.45	-6.21	-0.36	2.05e-9	Asthma;
CESC	cis	rs1538970	1.000	rs11211101	chr1:45849311	C/G	cg05343316	chr1:45956843	TESK2	0.8	11.45	0.58	6.43e-25	Platelet count;
CESC	cis	rs6570726	0.791	rs9376953	chr6:145912226	G/T	cg23711669	chr6:146136114	FBXO30	0.97	14.47	0.66	2.25e-35	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7264396	0.528	rs6058370	chr20:34518592	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.79	-9.27	-0.49	6.63e-18	Total cholesterol levels;
CESC	cis	rs10911251	0.508	rs10797854	chr1:183106739	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.83	12.94	0.62	5.33e-30	Colorectal cancer;
CESC	cis	rs9811920	0.809	rs793464	chr3:99626028	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.47	7.83	0.43	1.2e-13	Axial length;
CESC	cis	rs34779708	0.766	rs35308730	chr10:35549796	C/T	cg04310649	chr10:35416472	CREM	-0.46	-5.22	-0.31	3.55e-7	Inflammatory bowel disease;Crohn's disease;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg22174355	chr9:114413582	DNAJC25;DNAJC25-GNG10	0.46	7.52	0.42	8.68e-13	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs9787249	0.957	rs10888958	chr1:40211737	T/C	cg02773041	chr1:40204384	PPIE	0.54	7.68	0.43	3.02e-13	Blood protein levels;
CESC	cis	rs875971	0.862	rs28491091	chr7:65669064	G/T	cg18876405	chr7:65276391	NA	-0.56	-7.74	-0.43	2.15e-13	Aortic root size;
CESC	cis	rs4803468	1.000	rs284657	chr19:41929915	G/C	cg09537434	chr19:41945824	ATP5SL	-1.04	-18.8	-0.76	1.09e-50	Height;
CESC	cis	rs864537	0.676	rs2988279	chr1:167419839	G/A	cg22356347	chr1:167427500	CD247	-0.37	-7.68	-0.43	3.06e-13	Celiac disease or Rheumatoid arthritis;Celiac disease;
CESC	cis	rs6089829	0.925	rs4809270	chr20:61676709	C/A	cg03213289	chr20:61660250	NA	0.35	5.23	0.31	3.49e-7	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs7980799	0.716	rs10161311	chr12:33623204	G/A	cg26384229	chr12:38710491	ALG10B	-0.58	-8.26	-0.45	7.19e-15	Heart rate;Heart rate variability traits (RMSSD);
CESC	cis	rs853679	0.517	rs4713137	chr6:28083521	C/G	cg23161317	chr6:28129485	ZNF389	0.51	6.53	0.37	3.44e-10	Depression;
CESC	cis	rs9549367	0.789	rs7338235	chr13:113888687	T/C	cg00898013	chr13:113819073	PROZ	-0.51	-6.85	-0.39	5.17e-11	Platelet distribution width;
CESC	cis	rs9583531	0.600	rs754599	chr13:111354788	C/A	cg24331049	chr13:111365604	ING1	0.71	10.37	0.54	2.35e-21	Coronary artery disease;
CESC	cis	rs7665939	0.932	rs10022377	chr4:190108803	C/T	cg14840187	chr4:190284988	NA	-0.54	-5.68	-0.33	3.54e-8	Amyotrophic lateral sclerosis;
CESC	cis	rs6690583	0.562	rs6665436	chr1:85532894	T/C	cg22153463	chr1:85462885	MCOLN2	0.74	7.15	0.4	8.67e-12	Serum sulfate level;
CESC	cis	rs40363	0.951	rs250632	chr16:3523047	C/T	cg22508957	chr16:3507546	NAT15	0.72	9.08	0.49	2.51e-17	Tuberculosis;
CESC	cis	rs4561483	0.801	rs33620	chr16:12008546	C/G	cg08843971	chr16:11963173	GSPT1	-0.55	-8.19	-0.45	1.12e-14	Testicular germ cell tumor;
CESC	cis	rs10504229	1.000	rs67243305	chr8:58174958	G/A	cg14926445	chr8:58193284	C8orf71	-0.51	-5.49	-0.32	9.21e-8	Developmental language disorder (linguistic errors);
CESC	trans	rs459571	0.916	rs467303	chr9:136904835	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.6	-7.69	-0.43	2.96e-13	Platelet distribution width;
CESC	cis	rs10129255	0.518	rs11847766	chr14:107187425	T/C	cg23076370	chr14:107095027	NA	-0.66	-10.03	-0.52	2.9e-20	Kawasaki disease;
CESC	cis	rs11190604	0.945	rs2495746	chr10:102328270	T/C	cg07080220	chr10:102295463	HIF1AN	0.55	5.37	0.31	1.76e-7	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs710216	0.536	rs710222	chr1:43413653	A/G	cg07803811	chr1:43423981	SLC2A1	0.62	8.42	0.46	2.43e-15	Red cell distribution width;
CESC	cis	rs10504229	1.000	rs57261109	chr8:58172152	C/T	cg14926445	chr8:58193284	C8orf71	-0.51	-5.47	-0.32	1.03e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs2522056	1.000	rs2405528	chr5:131794298	G/A	cg24060327	chr5:131705240	SLC22A5	0.62	7.18	0.4	6.85e-12	Lymphocyte counts;Fibrinogen;
CESC	cis	rs4237845	0.537	rs1599931	chr12:58258850	A/G	cg00677455	chr12:58241039	CTDSP2	0.78	10.5	0.54	8.36e-22	Intelligence (multi-trait analysis);
CESC	cis	rs7927771	0.524	rs7936948	chr11:47704200	T/G	cg18512352	chr11:47633146	NA	0.35	5.39	0.31	1.53e-7	Subjective well-being;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12163800	chr17:74475355	RHBDF2	-0.53	-6.64	-0.38	1.74e-10	Gut microbiome composition (summer);
CESC	cis	rs631288	0.793	rs10793659	chr1:146763438	A/G	cg25205988	chr1:146714368	CHD1L	1.14	7.58	0.42	5.91e-13	PR interval in Tripanosoma cruzi seropositivity;
CESC	cis	rs7927592	0.913	rs12272917	chr11:68263370	T/C	cg20283391	chr11:68216788	NA	-0.62	-7.54	-0.42	7.45e-13	Total body bone mineral density;
CESC	cis	rs875971	1.000	rs11971949	chr7:65626014	A/G	cg12463550	chr7:65579703	CRCP	-0.55	-7.09	-0.4	1.19e-11	Aortic root size;
CESC	cis	rs4555082	0.834	rs2816651	chr14:105708470	A/G	cg13114125	chr14:105738426	BRF1	-0.79	-9.77	-0.51	1.91e-19	Mean platelet volume;Platelet distribution width;
CESC	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg03188948	chr7:1209495	NA	0.57	6.61	0.38	2.07e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs6690583	0.623	rs893618	chr1:85513770	C/T	cg22488158	chr1:85528044	WDR63	0.56	5.74	0.33	2.6e-8	Serum sulfate level;
CESC	cis	rs11168351	0.833	rs6580652	chr12:48447105	C/A	cg24011408	chr12:48396354	COL2A1	-0.49	-7.41	-0.41	1.74e-12	Bipolar disorder and schizophrenia;
CESC	cis	rs4666360	1.000	rs4666359	chr2:20335614	G/A	cg23291376	chr2:20336282	NA	-0.37	-6.11	-0.35	3.48e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel);
CESC	cis	rs9611565	0.614	rs4822053	chr22:42212936	C/A	cg03806693	chr22:41940476	POLR3H	-0.69	-8.23	-0.45	8.34e-15	Vitiligo;
CESC	cis	rs9549367	0.789	rs35569628	chr13:113872712	T/C	cg18105134	chr13:113819100	PROZ	-0.69	-9.08	-0.49	2.62e-17	Platelet distribution width;
CESC	cis	rs926938	0.584	rs360606	chr1:115391769	C/T	cg12756093	chr1:115239321	AMPD1	0.46	6.28	0.36	1.38e-9	Autism;
CESC	cis	rs2243480	1.000	rs160637	chr7:65584318	C/T	cg13147721	chr7:65941812	NA	-0.99	-9.36	-0.5	3.5e-18	Diabetic kidney disease;
CESC	cis	rs2012796	1.000	rs12436146	chr14:81821282	A/G	cg02996355	chr14:81879375	NA	0.51	5.94	0.34	9.08e-9	Night sleep phenotypes;
CESC	cis	rs34172651	0.517	rs34172679	chr16:24840381	C/T	cg04756594	chr16:24857601	SLC5A11	0.51	6.04	0.35	5.3300000000000004e-09	Intelligence (multi-trait analysis);
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg03260790	chr12:56211718	ORMDL2;SARNP	-0.5	-6.48	-0.37	4.5e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs798554	0.797	rs798494	chr7:2798294	C/A	cg09658497	chr7:2847517	GNA12	-0.43	-6.15	-0.35	2.86e-9	Height;
CESC	cis	rs6570726	0.791	rs400329	chr6:145879442	A/T	cg23711669	chr6:146136114	FBXO30	0.98	15.12	0.68	1.11e-37	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7666738	0.830	rs9992391	chr4:98916052	G/A	cg17366294	chr4:99064904	C4orf37	0.57	7.93	0.44	6.29e-14	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6693567	0.545	rs2133129	chr1:150355537	T/C	cg09579323	chr1:150459698	TARS2	0.47	5.91	0.34	1.04e-8	Migraine;
CESC	cis	rs36051895	0.622	rs12335546	chr9:5072182	C/T	cg02405213	chr9:5042618	JAK2	-0.48	-5.91	-0.34	1.06e-8	Pediatric autoimmune diseases;
CESC	cis	rs763014	0.932	rs2384975	chr16:651115	G/T	cg00802000	chr16:706648	WDR90	-0.4	-6.17	-0.35	2.52e-9	Height;
CESC	cis	rs9389248	0.690	rs6939543	chr6:135255143	A/G	cg22676075	chr6:135203613	NA	-0.6	-8.55	-0.46	1.03e-15	High light scatter reticulocyte percentage of red cells;
CESC	cis	rs10504229	0.683	rs10504223	chr8:58140944	G/A	cg02725872	chr8:58115012	NA	-0.45	-7.12	-0.4	1.02e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs72901758	0.768	rs11657271	chr17:76249682	A/T	cg25512537	chr17:76250053	NA	0.38	5.28	0.31	2.74e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
CESC	cis	rs2952156	1.000	rs2643194	chr17:37853048	C/T	cg07936489	chr17:37558343	FBXL20	-0.5	-5.91	-0.34	1.04e-8	Asthma;
CESC	cis	rs2997447	0.655	rs11247852	chr1:26383125	C/G	cg19633962	chr1:26362018	EXTL1	0.58	6.14	0.35	2.95e-9	QRS complex (12-leadsum);
CESC	cis	rs798554	0.757	rs1182176	chr7:2874601	A/G	cg18446336	chr7:2847575	GNA12	-0.34	-5.39	-0.31	1.52e-7	Height;
CESC	cis	rs7833986	0.501	rs2719258	chr8:56941389	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.59	7.4	0.41	1.78e-12	Height;
CESC	cis	rs1005277	0.602	rs1831315	chr10:38473353	T/C	cg00409905	chr10:38381863	ZNF37A	-0.46	-6.13	-0.35	3.17e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs11098499	0.697	rs35280960	chr4:120257059	G/A	cg09307838	chr4:120376055	NA	0.79	10.45	0.54	1.29e-21	Corneal astigmatism;
CESC	cis	rs9487051	0.807	rs1915835	chr6:109597483	C/T	cg21918786	chr6:109611834	NA	-0.39	-6.04	-0.35	5.08e-9	Reticulocyte fraction of red cells;
CESC	cis	rs3733585	0.637	rs6850684	chr4:9964380	G/T	cg11266682	chr4:10021025	SLC2A9	-0.6	-11.15	-0.57	6.33e-24	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs2439831	0.867	rs2255440	chr15:43830467	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.76	8.28	0.45	6.19e-15	Lung cancer in ever smokers;
CESC	cis	rs6752107	0.967	rs6431661	chr2:234167421	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.46	6.33	0.36	1.03e-9	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs9467711	0.606	rs9379859	chr6:26369549	C/T	cg14345882	chr6:26364793	BTN3A2	0.6	6.21	0.36	2.06e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs2180341	0.961	rs9375501	chr6:127652539	C/T	cg24812749	chr6:127587940	RNF146	1.07	15.4	0.69	1.16e-38	Breast cancer;
CESC	cis	rs372883	0.648	rs11088117	chr21:30737816	G/C	cg08807101	chr21:30365312	RNF160	0.43	5.04	0.3	8.76e-7	Pancreatic cancer;
CESC	cis	rs2243480	1.000	rs73142121	chr7:65311206	C/T	cg25894440	chr7:65020034	NA	-0.6	-5.32	-0.31	2.19e-7	Diabetic kidney disease;
CESC	cis	rs1005277	0.579	rs2474580	chr10:38398713	G/A	cg25517755	chr10:38738941	LOC399744	-0.47	-6.04	-0.35	5.12e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs8092503	0.953	rs11152005	chr18:52480578	G/A	cg12377874	chr18:52495404	RAB27B	0.38	6.2	0.36	2.13e-9	Childhood body mass index;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg25722142	chr6:139695762	CITED2	-0.44	-6.39	-0.37	7.33e-10	Gambling;
CESC	cis	rs12451471	0.500	rs8077056	chr17:78076006	C/T	cg24585782	chr17:78113791	EIF4A3	-0.56	-7.07	-0.4	1.42e-11	Plateletcrit;Mean corpuscular hemoglobin concentration;
CESC	cis	rs2836950	0.501	rs2070865	chr21:40715519	C/T	cg11644478	chr21:40555479	PSMG1	-0.49	-6.29	-0.36	1.29e-9	Menarche (age at onset);
CESC	cis	rs3008870	0.755	rs2755242	chr1:67479598	T/C	cg02640540	chr1:67518911	SLC35D1	0.45	5.43	0.32	1.25e-7	Lymphocyte percentage of white cells;
CESC	cis	rs7429990	0.965	rs4599334	chr3:48066400	A/C	cg11946769	chr3:48343235	NME6	-0.5	-6.0	-0.35	6.52e-9	Educational attainment (years of education);
CESC	cis	rs5753037	0.543	rs131287	chr22:30158463	C/T	cg01021169	chr22:30184971	ASCC2	-0.55	-7.84	-0.43	1.13e-13	Type 1 diabetes;
CESC	cis	rs863345	0.625	rs10908663	chr1:158492121	C/T	cg12129480	chr1:158549410	OR10X1	-0.34	-6.85	-0.39	5.17e-11	Pneumococcal bacteremia;
CESC	cis	rs1799949	1.000	rs4340367	chr17:41307772	G/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.45	6.24	0.36	1.69e-9	Menopause (age at onset);
CESC	cis	rs9522267	0.535	rs11069897	chr13:112231319	A/G	cg10483660	chr13:112241077	NA	-0.33	-5.83	-0.34	1.65e-8	Hepatitis;
CESC	cis	rs71277158	0.565	rs16854778	chr3:169748111	G/A	cg04067573	chr3:169899625	PHC3	0.55	5.42	0.32	1.33e-7	Prostate cancer;
CESC	cis	rs9309473	0.950	rs6711001	chr2:73850820	C/G	cg20560298	chr2:73613845	ALMS1	-0.47	-6.19	-0.36	2.31e-9	Metabolite levels;
CESC	cis	rs921968	0.643	rs2303561	chr2:219527005	C/T	cg02176678	chr2:219576539	TTLL4	-0.42	-7.45	-0.42	1.33e-12	Mean corpuscular hemoglobin concentration;
CESC	cis	rs3087591	0.960	rs2953000	chr17:29509791	C/T	cg24425628	chr17:29625626	OMG;NF1	0.44	5.57	0.32	6.21e-8	Hip circumference;
CESC	cis	rs3733585	0.673	rs9993410	chr4:9951264	C/T	cg02734326	chr4:10020555	SLC2A9	-0.4	-5.66	-0.33	3.93e-8	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs7474896	0.559	rs1024202	chr10:38278977	A/C	cg25427524	chr10:38739819	LOC399744	0.49	5.42	0.32	1.35e-7	Obesity (extreme);
CESC	cis	rs514406	0.548	rs6670871	chr1:53212082	A/C	cg16325326	chr1:53192061	ZYG11B	-0.98	-17.59	-0.73	1.95e-46	Monocyte count;
CESC	cis	rs2404602	0.716	rs117129193	chr15:76656803	A/G	cg22467129	chr15:76604101	ETFA	-0.38	-5.73	-0.33	2.69e-8	Blood metabolite levels;
CESC	cis	rs7524258	0.900	rs12035586	chr1:7273020	C/T	cg07173049	chr1:7289937	CAMTA1	-0.36	-5.6	-0.33	5.35e-8	Tourette's syndrome or obsessive-compulsive disorder;
CESC	cis	rs17253792	0.822	rs10149408	chr14:56046075	G/A	cg01858014	chr14:56050164	KTN1	-0.94	-7.66	-0.43	3.47e-13	Putamen volume;
CESC	cis	rs875971	0.545	rs67775320	chr7:65658779	T/C	cg25405998	chr7:65216604	CCT6P1	0.45	5.06	0.3	7.71e-7	Aortic root size;
CESC	cis	rs7726839	0.574	rs72705014	chr5:619815	C/G	cg16447950	chr5:562315	NA	-0.58	-5.93	-0.34	9.42e-9	Obesity-related traits;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg14503796	chr3:15248442	DVWA;CAPN7	0.49	7.02	0.4	1.89e-11	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs10504229	0.635	rs72649130	chr8:58053810	G/T	cg21724239	chr8:58056113	NA	0.6	5.33	0.31	2.12e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs2836950	0.509	rs11088466	chr21:40580017	T/A	cg11890956	chr21:40555474	PSMG1	-0.61	-8.58	-0.47	8.08e-16	Menarche (age at onset);
CESC	cis	rs2522056	1.000	rs2522054	chr5:131799526	G/T	cg07395648	chr5:131743802	NA	0.44	5.03	0.3	9.06e-7	Lymphocyte counts;Fibrinogen;
CESC	cis	rs7274811	0.554	rs6120299	chr20:32133491	T/G	cg21523528	chr20:32077966	CBFA2T2	0.63	7.25	0.41	4.68e-12	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10490227	chr1:40348903	TRIT1	0.52	6.14	0.35	2.98e-9	Gut microbiome composition (summer);
CESC	cis	rs9039	1.000	rs9932208	chr16:9218267	T/C	cg08831531	chr16:9218945	NA	-0.44	-6.21	-0.36	2.05e-9	Menopause (age at onset);
CESC	cis	rs4843185	0.576	rs380996	chr16:85728813	A/G	cg05245094	chr16:85669572	KIAA0182	-0.39	-5.07	-0.3	7.34e-7	Platelet distribution width;
CESC	cis	rs7552404	0.690	rs2029681	chr1:76333846	G/A	cg22875332	chr1:76189707	ACADM	-0.64	-6.77	-0.38	8.23e-11	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs1348850	0.519	rs10201883	chr2:178471407	T/C	cg23306229	chr2:178417860	TTC30B	0.77	6.91	0.39	3.5e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg11766577	chr21:47581405	C21orf56	-0.47	-6.47	-0.37	4.84e-10	Testicular germ cell tumor;
CESC	cis	rs3733585	0.673	rs4467564	chr4:9953472	G/T	cg00071950	chr4:10020882	SLC2A9	-0.69	-11.34	-0.57	1.42e-24	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs11718455	1.000	rs28731098	chr3:44019816	A/C	cg08738300	chr3:44038990	NA	0.45	5.81	0.34	1.78e-8	Coronary artery disease;
CESC	cis	rs3858526	0.874	rs10838879	chr11:5950169	C/T	cg02574844	chr11:5959923	NA	-0.44	-5.53	-0.32	7.81e-8	DNA methylation (variation);
CESC	cis	rs4460629	0.742	rs6427158	chr1:155074903	G/T	cg01019262	chr1:155095195	NA	-0.3	-5.05	-0.3	8.42e-7	Serum magnesium levels;
CESC	cis	rs807669	0.548	rs723414	chr22:19185736	G/A	cg17887427	chr22:19166691	SLC25A1	-0.44	-5.29	-0.31	2.54e-7	Metabolite levels;
CESC	cis	rs72781680	0.898	rs6545127	chr2:24060670	C/T	cg08917208	chr2:24149416	ATAD2B	0.93	8.48	0.46	1.57e-15	Lymphocyte counts;
CESC	cis	rs2439831	0.850	rs28858500	chr15:44156942	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.68	7.46	0.42	1.22e-12	Lung cancer in ever smokers;
CESC	cis	rs1051424	0.651	rs1292063	chr17:57907768	T/A	cg02344993	chr17:57696989	CLTC	-0.68	-8.37	-0.46	3.31e-15	Obesity-related traits;
CESC	cis	rs1348850	0.914	rs10170667	chr2:178336878	A/G	cg23306229	chr2:178417860	TTC30B	0.65	7.98	0.44	4.46e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs1790761	0.520	rs7124513	chr11:67395714	C/T	cg24690094	chr11:67383802	NA	-0.37	-6.2	-0.36	2.13e-9	Mean corpuscular volume;
CESC	cis	rs929596	0.728	rs6744284	chr2:234625297	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.63	-8.15	-0.45	1.45e-14	Total bilirubin levels in HIV-1 infection;
CESC	cis	rs941873	0.900	rs4979862	chr10:81131599	G/A	cg08514558	chr10:81106712	PPIF	0.39	6.91	0.39	3.69e-11	Height;
CESC	cis	rs4862750	0.872	rs13101408	chr4:187894777	G/A	cg07414643	chr4:187882934	NA	0.58	8.29	0.45	5.75e-15	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9300255	0.698	rs4759416	chr12:123746357	C/G	cg05973401	chr12:123451056	ABCB9	0.51	5.75	0.33	2.4e-8	Neutrophil percentage of white cells;
CESC	cis	rs10504229	0.861	rs114700910	chr8:58170642	C/T	cg22535103	chr8:58192502	C8orf71	-1.05	-12.93	-0.62	5.44e-30	Developmental language disorder (linguistic errors);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00252332	chr13:73633178	KLF5	0.55	6.38	0.36	7.75e-10	Gut microbiome composition (summer);
CESC	cis	rs2576037	0.583	rs11659693	chr18:44458733	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.79	13.26	0.63	3.89e-31	Personality dimensions;
CESC	cis	rs9926296	0.527	rs1800335	chr16:89846195	A/G	cg07648498	chr16:89883185	FANCA	0.44	5.42	0.32	1.32e-7	Vitiligo;
CESC	cis	rs539096	0.500	rs803678	chr1:44350898	G/T	cg12908607	chr1:44402522	ARTN	-0.49	-7.49	-0.42	1.04e-12	Intelligence (multi-trait analysis);
CESC	cis	rs6502050	0.835	rs8067875	chr17:80092778	C/T	cg23985595	chr17:80112537	CCDC57	-0.42	-6.42	-0.37	6.22e-10	Life satisfaction;
CESC	cis	rs1801251	1.000	rs13035829	chr2:233604487	A/T	cg08000102	chr2:233561755	GIGYF2	0.64	9.1	0.49	2.29e-17	Coronary artery disease;
CESC	cis	rs1707322	1.000	rs4660331	chr1:46458783	A/C	cg05343316	chr1:45956843	TESK2	0.45	5.59	0.32	5.74e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs6866344	0.570	rs1071882	chr5:178136040	C/T	cg03877680	chr5:178157825	ZNF354A	0.8	10.15	0.53	1.12e-20	Neutrophil percentage of white cells;
CESC	cis	rs1707322	0.716	rs28370457	chr1:46172062	C/T	cg05343316	chr1:45956843	TESK2	0.51	6.32	0.36	1.09e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs61931739	0.500	rs7309931	chr12:34483471	A/C	cg06521331	chr12:34319734	NA	-0.37	-5.05	-0.3	8.21e-7	Morning vs. evening chronotype;
CESC	cis	rs7615952	0.576	rs2276727	chr3:125826243	C/T	cg02772935	chr3:125709198	NA	-0.46	-5.03	-0.3	8.9e-7	Blood pressure (smoking interaction);
CESC	cis	rs798554	0.679	rs7784066	chr7:2819727	T/A	cg09658497	chr7:2847517	GNA12	-0.44	-6.17	-0.35	2.59e-9	Height;
CESC	cis	rs6665290	0.904	rs1045285	chr1:227179054	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.21	-32.2	-0.89	1.35e-93	Myeloid white cell count;
CESC	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg14926445	chr8:58193284	C8orf71	-0.54	-5.16	-0.3	4.76e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs2273669	0.667	rs1407241	chr6:109328432	G/A	cg05315195	chr6:109294784	ARMC2	-0.67	-6.32	-0.36	1.13e-9	Prostate cancer;
CESC	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg17178900	chr1:205818956	PM20D1	0.92	16.1	0.7	3.72e-41	Menarche (age at onset);
CESC	cis	rs7772486	0.754	rs12199362	chr6:146118225	A/G	cg23711669	chr6:146136114	FBXO30	1.01	15.9	0.7	2.05e-40	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2072732	0.808	rs67908307	chr1:2954297	T/C	cg03976712	chr1:2946727	NA	0.33	5.53	0.32	7.83e-8	Plateletcrit;
CESC	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-6.15	-0.35	2.85e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7520050	0.902	rs4638056	chr1:46458153	T/G	cg24296786	chr1:45957014	TESK2	0.45	5.65	0.33	4.17e-8	Red blood cell count;Reticulocyte count;
CESC	cis	rs3806933	0.522	rs17553936	chr5:110454681	A/G	cg04022379	chr5:110408740	TSLP	0.45	7.3	0.41	3.37e-12	Eosinophilic esophagitis;
CESC	cis	rs3540	0.514	rs2601192	chr15:90936704	G/A	cg10434728	chr15:90938212	IQGAP1	0.44	8.12	0.45	1.81e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs2836974	0.666	rs35182074	chr21:40685284	A/C	cg17971929	chr21:40555470	PSMG1	-0.86	-12.42	-0.61	3.16e-28	Cognitive function;
CESC	cis	rs77106637	1.000	rs11605166	chr11:72669777	T/C	cg03713592	chr11:72463424	ARAP1	1.14	10.42	0.54	1.59e-21	Type 2 diabetes;
CESC	cis	rs7527798	0.592	rs12022909	chr1:207859743	T/C	cg21110645	chr1:207815933	NA	-0.33	-5.88	-0.34	1.26e-8	Erythrocyte sedimentation rate;
CESC	cis	rs853679	0.517	rs34716816	chr6:28046169	C/A	cg22143856	chr6:28129313	ZNF389	0.49	6.3	0.36	1.2e-9	Depression;
CESC	cis	rs2072499	0.750	rs2241109	chr1:156173082	C/T	cg25208724	chr1:156163844	SLC25A44	0.96	12.46	0.61	2.25e-28	Testicular germ cell tumor;
CESC	cis	rs4727027	0.866	rs3927307	chr7:148774869	C/T	cg23583168	chr7:148888333	NA	-0.78	-11.69	-0.58	9.58e-26	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs9303401	0.614	rs34683543	chr17:56520036	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.95	11.87	0.59	2.32e-26	Cognitive test performance;
CESC	cis	rs9733	0.596	rs6692960	chr1:150695965	G/A	cg22823121	chr1:150693482	HORMAD1	0.47	6.96	0.39	2.6e-11	Tonsillectomy;
CESC	cis	rs853679	0.513	rs9468296	chr6:28113730	A/G	cg19592336	chr6:28129416	ZNF389	0.62	8.14	0.45	1.59e-14	Depression;
CESC	cis	rs10838687	0.932	rs2596397	chr11:47247621	G/A	cg25783544	chr11:47291846	MADD	-0.57	-7.25	-0.41	4.71e-12	Proinsulin levels;
CESC	cis	rs34375054	0.558	rs67041765	chr12:125672913	T/G	cg05341575	chr12:125625032	AACS	-0.38	-5.42	-0.32	1.33e-7	Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs72781680	1.000	rs72781648	chr2:24210333	T/C	cg08917208	chr2:24149416	ATAD2B	0.92	8.28	0.45	6.31e-15	Lymphocyte counts;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg18336435	chr15:60884637	RORA	-0.46	-6.04	-0.35	5.31e-9	Ulcerative colitis;
CESC	cis	rs523522	0.962	rs603574	chr12:120998443	A/G	cg12219531	chr12:120966889	COQ5	0.75	9.89	0.52	7.64e-20	High light scatter reticulocyte count;
CESC	trans	rs9693444	0.898	rs4732697	chr8:29519861	A/G	cg18185028	chr3:154042079	DHX36	-0.42	-6.37	-0.36	8.43e-10	Breast cancer;
CESC	trans	rs61931739	0.500	rs11053207	chr12:34459827	A/G	cg26384229	chr12:38710491	ALG10B	0.54	7.5	0.42	9.79e-13	Morning vs. evening chronotype;
CESC	cis	rs3857536	0.785	rs1935895	chr6:66936606	T/G	cg07460842	chr6:66804631	NA	-0.42	-5.34	-0.31	1.96e-7	Blood trace element (Cu levels);
CESC	cis	rs3733585	0.605	rs7656624	chr4:10121097	T/C	cg00071950	chr4:10020882	SLC2A9	-0.65	-10.42	-0.54	1.6e-21	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs909002	0.800	rs1056526	chr1:32084904	C/T	cg13919466	chr1:32135498	COL16A1	-0.45	-8.08	-0.44	2.28e-14	Intelligence (multi-trait analysis);
CESC	cis	rs3087591	0.920	rs7225014	chr17:29572973	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.42	-5.23	-0.31	3.48e-7	Hip circumference;
CESC	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg16132339	chr22:24313637	DDTL;DDT	-0.44	-6.85	-0.39	5.06e-11	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs6860806	0.507	rs183898	chr5:131716902	C/G	cg18758796	chr5:131593413	PDLIM4	-0.41	-5.66	-0.33	3.99e-8	Breast cancer;
CESC	cis	rs6089829	0.925	rs13041507	chr20:61666180	T/C	cg16240275	chr20:61666158	NCRNA00029	0.5	8.96	0.48	6.1e-17	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs10504229	0.512	rs77289815	chr8:57995242	A/G	cg22535103	chr8:58192502	C8orf71	-0.89	-7.36	-0.41	2.3e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs10200850	1.000	rs4502439	chr2:240214762	G/A	cg26975040	chr2:240205772	HDAC4	-0.58	-5.04	-0.3	8.44e-7	Perioperative myocardial infarction in coronary artery bypass surgery;
CESC	cis	rs7809799	1.000	rs2395022	chr7:98750379	A/C	cg05967295	chr7:98741636	SMURF1	-0.79	-5.65	-0.33	4.24e-8	Ulcerative colitis;
CESC	cis	rs9457247	1.000	rs408080	chr6:167392522	T/C	cg07741184	chr6:167504864	NA	0.3	5.51	0.32	8.58e-8	Crohn's disease;
CESC	cis	rs769267	0.930	rs9917108	chr19:19572785	A/G	cg03709012	chr19:19516395	GATAD2A	1.01	15.7	0.69	1.01e-39	Tonsillectomy;
CESC	cis	rs7084402	0.967	rs7098606	chr10:60277089	C/T	cg07615347	chr10:60278583	BICC1	-0.6	-9.67	-0.51	3.99e-19	Refractive error;
CESC	cis	rs559928	0.606	rs17773078	chr11:63906224	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.68	6.06	0.35	4.55e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CESC	trans	rs7307889	0.793	rs7314675	chr12:6018045	C/T	cg18407955	chr7:158110685	PTPRN2	-0.78	-6.69	-0.38	1.34e-10	Obesity-related traits;
CESC	cis	rs1728785	1.000	rs1170442	chr16:68574064	G/T	cg02972257	chr16:68554789	NA	-0.55	-6.31	-0.36	1.17e-9	Ulcerative colitis;
CESC	cis	rs9916302	0.851	rs6503518	chr17:37660469	A/G	cg15445000	chr17:37608096	MED1	0.41	6.83	0.39	5.8200000000000003e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs12900413	0.603	rs4448912	chr15:90299690	G/A	cg24249390	chr15:90295951	MESP1	-0.37	-5.08	-0.3	7.2e-7	Coronary artery aneurysm in Kawasaki disease;
CESC	cis	rs2637266	1.000	rs12783273	chr10:78353221	T/C	cg18941641	chr10:78392320	NA	0.42	7.79	0.43	1.49e-13	Pulmonary function;
CESC	cis	rs875971	0.545	rs73136346	chr7:65566082	A/G	cg19163074	chr7:65112434	INTS4L2	0.52	5.33	0.31	2.13e-7	Aortic root size;
CESC	cis	rs950776	0.518	rs56007453	chr15:78826239	T/C	cg06917634	chr15:78832804	PSMA4	0.8	12.12	0.6	3.34e-27	Sudden cardiac arrest;
CESC	cis	rs12042052	1.000	rs72752168	chr1:232922800	G/A	cg06935979	chr1:232941706	KIAA1383	0.62	5.48	0.32	9.65e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CESC	cis	rs668210	0.793	rs1151514	chr11:65758854	G/A	cg02202077	chr11:65769826	EIF1AD;BANF1	0.69	7.56	0.42	6.56e-13	Cerebrospinal fluid biomarker levels;
CESC	trans	rs11992162	1.000	rs12334769	chr8:11833161	A/T	cg15556689	chr8:8085844	FLJ10661	0.54	6.25	0.36	1.64e-9	Monocyte count;
CESC	cis	rs2576037	0.583	rs9960463	chr18:44522808	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.77	12.56	0.61	1.06e-28	Personality dimensions;
CESC	cis	rs7727544	0.735	rs272842	chr5:131656517	A/G	cg07395648	chr5:131743802	NA	-0.45	-6.04	-0.35	5.29e-9	Blood metabolite levels;
CESC	cis	rs3857536	0.741	rs9363556	chr6:66934399	T/C	cg07460842	chr6:66804631	NA	-0.42	-5.34	-0.31	1.96e-7	Blood trace element (Cu levels);
CESC	cis	rs3733585	0.781	rs13103879	chr4:9972879	T/C	cg00071950	chr4:10020882	SLC2A9	-0.77	-13.74	-0.64	8.54e-33	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs1008375	1.000	rs1860596	chr4:17660082	C/T	cg02297831	chr4:17616191	MED28	0.56	6.82	0.39	6.21e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs748404	0.723	rs565658	chr15:43556307	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.61	7.92	0.44	6.42e-14	Lung cancer;
CESC	cis	rs523522	0.962	rs509445	chr12:121017243	A/C	cg12219531	chr12:120966889	COQ5	0.77	10.16	0.53	1.1e-20	High light scatter reticulocyte count;
CESC	cis	rs2072499	1.000	rs2253809	chr1:156172125	T/C	cg24450063	chr1:156163899	SLC25A44	1.08	22.47	0.81	2.52e-63	Testicular germ cell tumor;
CESC	cis	rs9858542	0.537	rs56038006	chr3:49362369	C/T	cg00383909	chr3:49044727	WDR6	0.57	5.12	0.3	5.94e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs2292884	0.505	rs78063959	chr2:238428961	G/A	cg14458575	chr2:238380390	NA	0.53	5.68	0.33	3.53e-8	Prostate cancer;
CESC	cis	rs4713118	0.586	rs9468290	chr6:28087674	C/T	cg17949981	chr6:28129498	ZNF389	0.45	5.63	0.33	4.71e-8	Parkinson's disease;
CESC	cis	rs4474465	0.688	rs10793336	chr11:78281867	A/G	cg27205649	chr11:78285834	NARS2	0.48	6.24	0.36	1.72e-9	Alzheimer's disease (survival time);
CESC	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg23708337	chr7:1209742	NA	0.55	5.33	0.31	2.08e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2836974	0.568	rs8130795	chr21:40549983	T/A	cg11890956	chr21:40555474	PSMG1	0.96	15.87	0.7	2.49e-40	Cognitive function;
CESC	cis	rs7918232	0.941	rs1753415	chr10:27395102	T/C	cg14240646	chr10:27532245	ACBD5	-0.68	-6.35	-0.36	9.2e-10	Breast cancer;
CESC	cis	rs875971	0.651	rs2420596	chr7:65915983	T/C	cg12463550	chr7:65579703	CRCP	0.49	6.17	0.35	2.57e-9	Aortic root size;
CESC	cis	rs12145833	0.665	rs78871868	chr1:243422322	C/T	cg02356786	chr1:243265016	LOC731275	0.77	5.8	0.34	1.93e-8	Obesity (early onset extreme);
CESC	cis	rs6495122	0.699	rs1378940	chr15:75083494	C/A	cg14664628	chr15:75095509	CSK	-0.67	-9.26	-0.49	7.44e-18	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
CESC	cis	rs2996428	0.667	rs72640928	chr1:3768568	T/C	cg13057898	chr1:3703894	LRRC47	0.45	6.15	0.35	2.83e-9	Red cell distribution width;
CESC	cis	rs4862750	0.872	rs7679956	chr4:187900229	C/T	cg07414643	chr4:187882934	NA	0.47	6.85	0.39	5.26e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs875971	1.000	rs6958271	chr7:65979331	A/C	cg12463550	chr7:65579703	CRCP	0.56	6.94	0.39	3.07e-11	Aortic root size;
CESC	cis	rs7904368	0.806	rs7900527	chr10:16857992	C/G	cg23933602	chr10:16859644	RSU1	0.66	6.13	0.35	3.15e-9	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
CESC	cis	rs67311347	0.544	rs9821440	chr3:40342347	T/C	cg09455208	chr3:40491958	NA	0.37	6.49	0.37	4.2e-10	Renal cell carcinoma;
CESC	cis	rs10791323	0.575	rs4489760	chr11:133732265	A/T	cg15485101	chr11:133734466	NA	0.39	6.59	0.38	2.4e-10	Childhood ear infection;
CESC	cis	rs523522	0.962	rs7471	chr12:120941215	T/C	cg12219531	chr12:120966889	COQ5	0.75	9.97	0.52	4.31e-20	High light scatter reticulocyte count;
CESC	cis	rs4319547	0.956	rs10773302	chr12:123043145	G/T	cg23029597	chr12:123009494	RSRC2	-0.45	-5.13	-0.3	5.58e-7	Body mass index;
CESC	cis	rs8092503	1.000	rs3764512	chr18:52495324	G/T	cg12377874	chr18:52495404	RAB27B	0.36	5.67	0.33	3.64e-8	Childhood body mass index;
CESC	cis	rs3749237	0.595	rs1464567	chr3:49459252	C/G	cg06212747	chr3:49208901	KLHDC8B	-0.52	-7.03	-0.4	1.72e-11	Resting heart rate;
CESC	cis	rs2842992	0.768	rs2273824	chr6:160211445	C/T	cg26839252	chr6:160211577	TCP1;MRPL18	0.49	6.15	0.35	2.83e-9	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs2075371	1.000	rs2544218	chr7:133992315	C/A	cg00033643	chr7:134001901	SLC35B4	0.44	5.71	0.33	3.05e-8	Mean platelet volume;
CESC	cis	rs67311347	0.956	rs11714871	chr3:40428938	T/G	cg09455208	chr3:40491958	NA	0.45	7.5	0.42	9.87e-13	Renal cell carcinoma;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20235901	chr18:34409524	KIAA1328;C18orf10	-0.53	-6.16	-0.35	2.62e-9	Gut microbiome composition (summer);
CESC	cis	rs6964587	0.904	rs2023785	chr7:91547369	C/A	cg17063962	chr7:91808500	NA	-0.52	-6.87	-0.39	4.7e-11	Breast cancer;
CESC	cis	rs17376456	1.000	rs17376207	chr5:93545524	C/T	cg21475434	chr5:93447410	FAM172A	-0.83	-7.48	-0.42	1.1e-12	Diabetic retinopathy;
CESC	cis	rs2228479	0.557	rs2293584	chr16:89888686	C/G	cg04013166	chr16:89971882	TCF25	0.73	5.77	0.33	2.2e-8	Skin colour saturation;
CESC	cis	rs17376456	0.809	rs10476602	chr5:93445255	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.63	5.66	0.33	4.02e-8	Diabetic retinopathy;
CESC	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg11494091	chr17:61959527	GH2	0.73	12.49	0.61	1.88e-28	Prudent dietary pattern;
CESC	cis	rs3125734	0.633	rs12217669	chr10:63988456	A/G	cg09941381	chr10:64027924	RTKN2	0.31	5.1	0.3	6.62e-7	Rheumatoid arthritis;
CESC	cis	rs35110281	0.627	rs7282704	chr21:44966253	A/G	cg04455712	chr21:45112962	RRP1B	0.35	5.08	0.3	7.29e-7	Mean corpuscular volume;
CESC	cis	rs9300255	0.544	rs2049114	chr12:123657338	T/C	cg00376283	chr12:123451042	ABCB9	0.71	8.65	0.47	4.88e-16	Neutrophil percentage of white cells;
CESC	cis	rs4665809	0.590	rs2303894	chr2:26508187	A/G	cg26119090	chr2:26468346	HADHA;HADHB	1.08	11.71	0.58	8.22e-26	Gut microbiome composition (summer);
CESC	cis	rs2204008	0.774	rs8186954	chr12:38318566	C/A	cg13010199	chr12:38710504	ALG10B	0.42	5.3	0.31	2.42e-7	Bladder cancer;
CESC	cis	rs727505	0.866	rs67724276	chr7:124719719	G/A	cg23710748	chr7:124431027	NA	-0.4	-6.51	-0.37	3.76e-10	Lewy body disease;
CESC	cis	rs6493487	0.512	rs7179865	chr15:51108951	A/G	cg02338191	chr15:51200825	AP4E1	-0.52	-5.04	-0.3	8.51e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs10504229	0.511	rs16921553	chr8:57979314	T/C	cg22535103	chr8:58192502	C8orf71	-0.71	-7.13	-0.4	9.56e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs9302635	0.816	rs7202323	chr16:72217113	T/G	cg01557791	chr16:72042693	DHODH	-0.58	-6.25	-0.36	1.66e-9	Blood protein levels;
CESC	cis	rs17818399	0.645	rs35870739	chr2:46784231	A/C	cg06386533	chr2:46925753	SOCS5	0.48	5.28	0.31	2.7e-7	Height;
CESC	cis	rs853679	0.517	rs9295758	chr6:28120663	C/G	cg23161317	chr6:28129485	ZNF389	0.53	6.51	0.37	3.8e-10	Depression;
CESC	cis	rs60871478	0.679	rs6962050	chr7:817201	A/G	cg15782153	chr7:917662	C7orf20	-0.49	-5.24	-0.31	3.25e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs7937682	0.883	rs659529	chr11:111436896	T/A	cg09085632	chr11:111637200	PPP2R1B	-0.97	-14.3	-0.66	8.89e-35	Primary sclerosing cholangitis;
CESC	trans	rs66573146	0.831	rs56031152	chr4:6973832	C/A	cg07817883	chr1:32538562	TMEM39B	1.25	8.46	0.46	1.88e-15	Granulocyte percentage of myeloid white cells;
CESC	cis	rs10129255	0.500	rs9324092	chr14:107139823	A/G	cg07958169	chr14:107095056	NA	0.58	9.22	0.49	9.67e-18	Kawasaki disease;
CESC	cis	rs10504229	0.683	rs11786845	chr8:58133642	T/C	cg24829409	chr8:58192753	C8orf71	-0.58	-7.12	-0.4	1.02e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs868036	0.881	rs12708496	chr15:68054098	T/C	cg08079166	chr15:68083412	MAP2K5	-0.42	-6.51	-0.37	3.67e-10	Restless legs syndrome;
CESC	cis	rs7520050	0.933	rs6661163	chr1:46255004	A/G	cg06784218	chr1:46089804	CCDC17	-0.3	-5.4	-0.31	1.46e-7	Red blood cell count;Reticulocyte count;
CESC	cis	rs2011503	1.000	rs6511029	chr19:19471419	G/T	cg11584989	chr19:19387371	SF4	-0.62	-7.24	-0.41	4.75e-12	Bipolar disorder;
CESC	cis	rs7684253	0.565	rs13130605	chr4:57810071	G/A	cg21154227	chr4:57904332	IGFBP7	0.37	5.36	0.31	1.84e-7	Migraine;
CESC	cis	rs1707322	0.827	rs6694302	chr1:46245645	A/T	cg06784218	chr1:46089804	CCDC17	0.37	6.27	0.36	1.45e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7312933	0.703	rs10492388	chr12:42608001	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.5	6.48	0.37	4.46e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs1371867	0.875	rs1788169	chr8:101326314	C/T	cg11906718	chr8:101322791	RNF19A	0.54	6.89	0.39	4.05e-11	Atrioventricular conduction;
CESC	cis	rs8067545	1.000	rs7211535	chr17:19922364	A/G	cg13482628	chr17:19912719	NA	0.42	5.63	0.33	4.63e-8	Schizophrenia;
CESC	cis	rs6964587	1.000	rs2282972	chr7:91666369	C/T	cg17063962	chr7:91808500	NA	0.6	8.31	0.45	4.96e-15	Breast cancer;
CESC	cis	rs875971	0.505	rs6955582	chr7:65431686	A/G	cg26939375	chr7:64535504	NA	0.74	10.62	0.55	3.48e-22	Aortic root size;
CESC	cis	rs3026101	0.647	rs4790263	chr17:5307084	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.48	6.36	0.36	8.61e-10	Body mass index;
CESC	cis	rs10206020	0.759	rs11903889	chr2:1576601	C/T	cg26248373	chr2:1572462	NA	-0.59	-6.93	-0.39	3.22e-11	IgG glycosylation;
CESC	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.89	13.55	0.64	3.99e-32	Prudent dietary pattern;
CESC	cis	rs2985684	1.000	rs56098064	chr14:50105849	T/C	cg15316458	chr14:50087796	RPL36AL;MGAT2	0.46	5.31	0.31	2.28e-7	Carotid intima media thickness;
CESC	cis	rs10504229	0.681	rs11779172	chr8:58045538	A/G	cg24829409	chr8:58192753	C8orf71	-0.51	-6.11	-0.35	3.63e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs854765	0.583	rs4925130	chr17:17807858	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.53	7.32	0.41	2.99e-12	Total body bone mineral density;
CESC	cis	rs12893668	0.637	rs12892038	chr14:104068629	G/A	cg08213375	chr14:104286397	PPP1R13B	0.33	5.16	0.3	4.79e-7	Reticulocyte count;
CESC	cis	rs1008375	0.900	rs13144986	chr4:17675019	C/A	cg16339924	chr4:17578868	LAP3	-0.67	-7.74	-0.43	2.14e-13	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs514406	0.505	rs856721	chr1:53162156	C/A	cg08736216	chr1:53307985	ZYG11A	-0.39	-6.35	-0.36	9.46e-10	Monocyte count;
CESC	cis	rs17376456	0.825	rs35426871	chr5:93291613	C/T	cg25358565	chr5:93447407	FAM172A	1.1	10.12	0.53	1.4e-20	Diabetic retinopathy;
CESC	cis	rs2836974	0.831	rs6517521	chr21:40551588	A/G	cg17971929	chr21:40555470	PSMG1	1.03	15.89	0.7	2.13e-40	Cognitive function;
CESC	cis	rs12545109	0.800	rs2576591	chr8:57423606	A/G	cg09654669	chr8:57350985	NA	-0.54	-6.63	-0.38	1.89e-10	Obesity-related traits;
CESC	cis	rs11122272	0.735	rs2790897	chr1:231491712	C/A	cg06096015	chr1:231504339	EGLN1	0.45	6.59	0.38	2.39e-10	Hemoglobin concentration;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20540608	chr5:60241003	NDUFAF2;ERCC8	0.59	6.21	0.36	1.99e-9	Gut microbiome composition (summer);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg16371082	chr3:134083158	AMOTL2	-0.48	-6.52	-0.37	3.46e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs7666738	0.830	rs13121558	chr4:99002848	G/A	cg03467027	chr4:99064603	C4orf37	0.44	5.51	0.32	8.65e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1552244	1.000	rs57631744	chr3:10118962	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.85	-11.68	-0.58	1.06e-25	Alzheimer's disease;
CESC	cis	rs3785574	0.962	rs2727329	chr17:61924566	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	7.26	0.41	4.32e-12	Height;
CESC	cis	rs270601	0.837	rs367805	chr5:131701279	T/C	cg07395648	chr5:131743802	NA	-0.41	-5.24	-0.31	3.31e-7	Acylcarnitine levels;
CESC	cis	rs798554	0.757	rs2644312	chr7:2841164	G/A	cg19346786	chr7:2764209	NA	-0.5	-7.19	-0.4	6.47e-12	Height;
CESC	cis	rs7246657	0.714	rs12972195	chr19:37752505	T/C	cg23950597	chr19:37808831	NA	-0.58	-6.47	-0.37	4.61e-10	Coronary artery calcification;
CESC	cis	rs798554	0.610	rs2251491	chr7:2852835	T/C	cg04166393	chr7:2884313	GNA12	0.39	5.14	0.3	5.3e-7	Height;
CESC	cis	rs2576037	0.583	rs578451	chr18:44404525	T/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.35	5.6	0.33	5.37e-8	Personality dimensions;
CESC	cis	rs13242816	1.000	rs34228114	chr7:116106986	C/T	cg04696780	chr7:116139425	CAV2	-0.62	-5.69	-0.33	3.31e-8	P wave duration;
CESC	cis	rs67311347	0.544	rs9877105	chr3:40333366	T/C	cg24209194	chr3:40518798	ZNF619	0.38	5.2	0.3	3.91e-7	Renal cell carcinoma;
CESC	trans	rs116095464	0.558	rs10068203	chr5:206618	C/T	cg00938859	chr5:1591904	SDHAP3	0.66	6.26	0.36	1.55e-9	Breast cancer;
CESC	cis	rs769267	0.965	rs1010207	chr19:19416045	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.44	5.46	0.32	1.11e-7	Tonsillectomy;
CESC	cis	rs62283056	0.512	rs752854	chr4:6281961	C/T	cg25554036	chr4:6271136	WFS1	0.5	6.96	0.39	2.59e-11	Cisplatin-induced ototoxicity;
CESC	trans	rs1814175	0.645	rs28839231	chr11:50044292	G/T	cg03929089	chr4:120376271	NA	-0.91	-14.92	-0.68	5.78e-37	Height;
CESC	cis	rs6752107	0.901	rs2289477	chr2:234160345	T/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.49	6.91	0.39	3.59e-11	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs1355223	0.902	rs1539250	chr11:34742775	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.48	-6.43	-0.37	5.9e-10	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs875971	0.825	rs1129531	chr7:65619104	C/T	cg12463550	chr7:65579703	CRCP	-0.49	-6.2	-0.36	2.16e-9	Aortic root size;
CESC	cis	rs1862618	0.853	rs6450408	chr5:56098146	T/C	cg24531977	chr5:56204891	C5orf35	-0.88	-11.27	-0.57	2.42e-24	Initial pursuit acceleration;
CESC	cis	rs7605827	0.930	rs4668919	chr2:15662171	C/T	cg19274914	chr2:15703543	NA	0.32	5.66	0.33	3.88e-8	Educational attainment (years of education);
CESC	cis	rs2050392	0.929	rs10826798	chr10:30700904	G/A	cg18806716	chr10:30721971	MAP3K8	0.43	6.17	0.35	2.55e-9	Inflammatory bowel disease;
CESC	cis	rs2204008	0.837	rs11180482	chr12:38235950	G/A	cg26384229	chr12:38710491	ALG10B	0.69	9.8	0.52	1.51e-19	Bladder cancer;
CESC	trans	rs9987353	0.840	rs329994	chr8:9123233	A/G	cg26071963	chr14:88945568	PTPN21	0.47	6.05	0.35	4.95e-9	Recombination measurement;
CESC	cis	rs7945705	0.774	rs6486060	chr11:9024630	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.4	6.87	0.39	4.45e-11	Hemoglobin concentration;
CESC	cis	rs2439831	1.000	rs537115	chr15:43729948	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.82	11.89	0.59	2.04e-26	Lung cancer in ever smokers;
CESC	cis	rs875971	0.830	rs6967708	chr7:65657313	A/T	cg10691866	chr7:65817282	TPST1	0.31	5.24	0.31	3.34e-7	Aortic root size;
CESC	cis	rs61931739	0.534	rs12372721	chr12:34175301	C/T	cg19457237	chr12:34500585	NA	-0.4	-5.33	-0.31	2.11e-7	Morning vs. evening chronotype;
CESC	cis	rs1256061	0.624	rs1152577	chr14:64697485	T/G	cg23250157	chr14:64679961	SYNE2	0.52	7.37	0.41	2.22e-12	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs875971	1.000	rs12698523	chr7:65968113	C/G	cg11764359	chr7:65958608	NA	0.96	15.25	0.68	3.95e-38	Aortic root size;
CESC	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.53	6.29	0.36	1.32e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs853679	0.542	rs9393892	chr6:28081394	A/G	cg19592336	chr6:28129416	ZNF389	0.62	8.34	0.46	4.05e-15	Depression;
CESC	cis	rs12188164	0.965	rs11744539	chr5:451425	C/T	cg15813090	chr5:442598	EXOC3;C5orf55	0.43	6.48	0.37	4.56e-10	Cystic fibrosis severity;
CESC	cis	rs17711722	0.522	rs6957759	chr7:65271785	A/G	cg25405998	chr7:65216604	CCT6P1	0.45	5.89	0.34	1.17e-8	Calcium levels;
CESC	cis	rs9682041	0.932	rs7631221	chr3:170069893	A/G	cg11886554	chr3:170076028	SKIL	0.7	6.5	0.37	3.86e-10	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CESC	cis	rs72781680	1.000	rs7581107	chr2:24173565	C/T	cg20701182	chr2:24300061	SF3B14	0.64	5.74	0.33	2.63e-8	Lymphocyte counts;
CESC	cis	rs4332037	0.522	rs4721098	chr7:1881527	G/C	cg13880726	chr7:1868755	MAD1L1	0.5	5.12	0.3	5.91e-7	Bipolar disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16218964	chr11:62473680	BSCL2;GNG3	0.63	7.36	0.41	2.28e-12	Gut microbiome composition (summer);
CESC	cis	rs9325144	0.555	rs4882279	chr12:38688918	C/A	cg26384229	chr12:38710491	ALG10B	0.58	8.59	0.47	7.74e-16	Morning vs. evening chronotype;
CESC	cis	rs2050392	0.624	rs303447	chr10:30728464	T/C	cg18806716	chr10:30721971	MAP3K8	-0.63	-9.55	-0.51	9.45e-19	Inflammatory bowel disease;
CESC	trans	rs853679	0.546	rs17695758	chr6:27837183	T/C	cg21479132	chr6:26055353	NA	0.81	6.09	0.35	4.04e-9	Depression;
CESC	cis	rs6088580	0.634	rs6088484	chr20:32985961	T/C	cg24642439	chr20:33292090	TP53INP2	-0.53	-6.98	-0.39	2.39e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs12579753	0.917	rs10778834	chr12:82199742	A/C	cg24719984	chr12:82153464	PPFIA2	-0.33	-5.09	-0.3	6.86e-7	Resting heart rate;
CESC	cis	rs317689	0.581	rs160829	chr12:69769538	G/C	cg20891283	chr12:69753455	YEATS4	0.75	10.04	0.53	2.54e-20	Response to diuretic therapy;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg25837738	chr7:148725785	PDIA4	-0.46	-6.57	-0.37	2.69e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs66561647	0.597	rs34390452	chr8:128940141	G/A	cg05480350	chr8:128972681	MIR1205;PVT1	0.42	5.66	0.33	3.96e-8	Hemoglobin concentration;
CESC	cis	rs36051895	0.554	rs59053556	chr9:5200524	G/A	cg02405213	chr9:5042618	JAK2	-0.47	-5.5	-0.32	8.72e-8	Pediatric autoimmune diseases;
CESC	cis	rs1878931	0.696	rs35175748	chr16:3445427	C/G	cg26668626	chr16:3451006	ZNF174;ZNF434	1.1	19.25	0.76	2.97e-52	Body mass index (adult);
CESC	cis	rs6460942	1.000	rs6460936	chr7:12404913	T/C	cg20607287	chr7:12443886	VWDE	-0.79	-8.72	-0.47	3.1e-16	Coronary artery disease;
CESC	cis	rs875971	0.522	rs9530	chr7:65425894	A/G	cg05332525	chr7:65337924	VKORC1L1	0.5	6.02	0.35	5.74e-9	Aortic root size;
CESC	cis	rs72627509	0.904	rs56281640	chr4:57765816	G/A	cg26694713	chr4:57773883	REST	0.58	5.67	0.33	3.63e-8	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CESC	cis	rs6912958	0.559	rs2985039	chr6:88041757	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.5	8.65	0.47	5.2e-16	Monocyte percentage of white cells;
CESC	cis	rs9831754	0.906	rs1588650	chr3:78410750	T/G	cg06138941	chr3:78371609	NA	-0.61	-7.62	-0.42	4.54e-13	Calcium levels;
CESC	cis	rs34779708	0.966	rs34605125	chr10:35411246	A/G	cg03585969	chr10:35415529	CREM	0.77	10.12	0.53	1.47e-20	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs7264396	0.580	rs2425181	chr20:34447709	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.65	6.64	0.38	1.77e-10	Total cholesterol levels;
CESC	cis	rs6669072	0.647	rs814544	chr1:91241693	G/A	cg08895590	chr1:91227319	NA	-0.33	-5.71	-0.33	2.98e-8	Cognitive function;
CESC	cis	rs67311347	1.000	rs11716675	chr3:40485280	G/T	cg01475735	chr3:40494733	NA	-0.4	-5.05	-0.3	8.35e-7	Renal cell carcinoma;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg25581932	chr17:7892150	NA	0.43	6.35	0.36	9.37e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs763121	0.853	rs8138996	chr22:39047435	G/T	cg06544989	chr22:39130855	UNC84B	0.5	8.66	0.47	4.63e-16	Menopause (age at onset);
CESC	cis	rs250677	0.687	rs250671	chr5:148446523	T/C	cg18129178	chr5:148520854	ABLIM3	-0.51	-5.83	-0.34	1.58e-8	Breast cancer;
CESC	cis	rs12530845	0.623	rs76485854	chr7:135352668	T/C	cg23117316	chr7:135346802	PL-5283	-0.59	-6.35	-0.36	9.26e-10	Red blood cell traits;
CESC	cis	rs1707322	0.721	rs7519900	chr1:46234947	C/T	cg05343316	chr1:45956843	TESK2	0.52	6.36	0.36	8.66e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs11098499	0.909	rs1546502	chr4:120235898	A/G	cg09307838	chr4:120376055	NA	0.92	12.74	0.62	2.59e-29	Corneal astigmatism;
CESC	cis	rs9916302	0.752	rs676882	chr17:37433424	A/T	cg07936489	chr17:37558343	FBXL20	0.89	8.83	0.48	1.44e-16	Glomerular filtration rate (creatinine);
CESC	cis	rs2243480	0.901	rs73148097	chr7:65431787	A/C	cg18252515	chr7:66147081	NA	-1.24	-12.17	-0.6	2.31e-27	Diabetic kidney disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07375367	chr13:28194831	POLR1D;LNX2	0.51	6.1	0.35	3.75e-9	Gut microbiome composition (summer);
CESC	cis	rs1552244	0.872	rs6771931	chr3:10113408	C/G	cg00166722	chr3:10149974	C3orf24	0.54	6.89	0.39	4.08e-11	Alzheimer's disease;
CESC	cis	rs9467711	0.659	rs3734542	chr6:26468326	G/A	cg21479132	chr6:26055353	NA	0.74	5.4	0.31	1.48e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs9649213	0.574	rs7791321	chr7:97944125	G/C	cg08684580	chr7:98029266	BAIAP2L1	-0.35	-5.7	-0.33	3.23e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs9660180	0.967	rs2272908	chr1:1721479	A/G	cg03396347	chr1:1875803	NA	0.42	6.63	0.38	1.87e-10	Body mass index;
CESC	cis	rs2842992	0.715	rs2277073	chr6:160182749	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.7	8.92	0.48	7.8e-17	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs3733585	0.638	rs6449155	chr4:9956547	T/G	cg02734326	chr4:10020555	SLC2A9	-0.41	-5.87	-0.34	1.32e-8	Cleft plate (environmental tobacco smoke interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07228441	chr8:681215	ERICH1	0.57	6.38	0.36	7.81e-10	Gut microbiome composition (summer);
CESC	cis	rs6968419	0.788	rs60671526	chr7:115823069	T/C	cg02561103	chr7:115862891	TES	-0.39	-5.24	-0.31	3.34e-7	Intraocular pressure;
CESC	cis	rs763014	0.865	rs8909	chr16:633851	T/C	cg07256732	chr16:621771	PIGQ	-0.3	-5.07	-0.3	7.47e-7	Height;
CESC	cis	rs7795096	0.806	rs10277544	chr7:151540633	T/C	cg17008978	chr7:151542804	PRKAG2	0.39	7.25	0.41	4.53e-12	Bipolar disorder (age of onset and psychotic symptoms);
CESC	trans	rs7945705	0.935	rs1883098	chr11:8890594	G/A	cg10637292	chr12:52960529	KRT74	0.35	6.23	0.36	1.86e-9	Hemoglobin concentration;
CESC	cis	rs2006771	0.818	rs8142376	chr22:32001037	C/T	cg13145458	chr22:31556086	RNF185	0.44	5.43	0.32	1.31e-7	Nonsyndromic cleft lip with cleft palate;
CESC	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.58	7.49	0.42	1.01e-12	Prudent dietary pattern;
CESC	cis	rs4665809	0.590	rs13006973	chr2:26454707	C/T	cg08470875	chr2:26401718	FAM59B	0.75	7.79	0.43	1.49e-13	Gut microbiome composition (summer);
CESC	cis	rs870825	0.616	rs6818447	chr4:185650154	G/A	cg04058563	chr4:185651563	MLF1IP	0.63	6.96	0.39	2.74e-11	Blood protein levels;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg02843535	chr17:18759628	NA	0.45	6.02	0.35	5.8e-9	Systemic lupus erythematosus;
CESC	cis	rs7296418	0.922	rs1727293	chr12:123648032	C/T	cg00376283	chr12:123451042	ABCB9	0.67	9.46	0.5	1.75e-18	Platelet count;
CESC	cis	rs896854	0.631	rs10097617	chr8:95961626	T/C	cg16049864	chr8:95962084	TP53INP1	-0.71	-13.05	-0.63	2.08e-30	Type 2 diabetes;
CESC	cis	rs1788820	0.833	rs1429934	chr18:21162288	C/T	cg14672496	chr18:21087552	C18orf8	0.45	6.07	0.35	4.44e-9	Body mass index;
CESC	cis	rs7089973	0.604	rs10490909	chr10:116593532	C/T	cg03647239	chr10:116582469	FAM160B1	0.41	5.07	0.3	7.53e-7	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21815536	chr7:35840623	SEPT7	0.62	7.54	0.42	7.57e-13	Gut microbiome composition (summer);
CESC	cis	rs2898681	0.519	rs3811781	chr4:53729166	T/G	cg00791764	chr4:53727839	RASL11B	0.43	5.06	0.3	7.75e-7	Optic nerve measurement (cup area);
CESC	cis	rs2243480	1.000	rs7804223	chr7:65664559	T/G	cg13147721	chr7:65941812	NA	0.97	9.19	0.49	1.2e-17	Diabetic kidney disease;
CESC	cis	rs155076	0.711	rs4770131	chr13:21897468	A/G	cg25811766	chr13:21894605	NA	0.6	5.45	0.32	1.17e-7	White matter hyperintensity burden;
CESC	cis	rs2832191	0.716	rs2249028	chr21:30365322	G/A	cg24692254	chr21:30365293	RNF160	1.02	18.35	0.75	4.23e-49	Dental caries;
CESC	cis	rs7618915	0.547	rs13065019	chr3:52685244	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	7.13	0.4	9.62e-12	Bipolar disorder;
CESC	cis	rs7617773	0.539	rs35460860	chr3:48392085	A/T	cg11946769	chr3:48343235	NME6	0.64	8.04	0.44	2.93e-14	Coronary artery disease;
CESC	cis	rs4253772	0.513	rs12171124	chr22:46710693	A/C	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.68	6.58	0.37	2.47e-10	LDL cholesterol;Cholesterol, total;
CESC	trans	rs1814175	0.509	rs60698301	chr11:49877672	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.42	-6.16	-0.35	2.66e-9	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16988976	chr2:99953032	EIF5B;TXNDC9	-0.59	-6.28	-0.36	1.36e-9	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.791	rs1896155	chr4:99020948	C/A	cg18180107	chr4:99064573	C4orf37	0.41	5.39	0.31	1.57e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9522267	0.535	rs9522291	chr13:112233761	T/C	cg10483660	chr13:112241077	NA	-0.33	-5.79	-0.33	2.04e-8	Hepatitis;
CESC	cis	rs3540	0.557	rs11634314	chr15:91042066	A/C	cg22089800	chr15:90895588	ZNF774	-0.62	-8.14	-0.45	1.56e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs2130392	1.000	rs11132254	chr4:185611592	G/T	cg21366198	chr4:185655624	MLF1IP	-0.51	-6.88	-0.39	4.2e-11	Kawasaki disease;
CESC	cis	rs6430585	0.591	rs3098103	chr2:136656094	T/C	cg07169764	chr2:136633963	MCM6	1.17	15.49	0.69	5.74e-39	Corneal structure;
CESC	cis	rs514406	0.893	rs1242330	chr1:53396842	T/G	cg16325326	chr1:53192061	ZYG11B	0.9	14.85	0.67	1.06e-36	Monocyte count;
CESC	cis	rs7666738	0.830	rs13116691	chr4:98929771	A/C	cg17366294	chr4:99064904	C4orf37	0.6	8.22	0.45	9.04e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9322193	0.926	rs9383546	chr6:150143879	T/A	cg04369109	chr6:150039330	LATS1	-0.43	-5.92	-0.34	1.02e-8	Lung cancer;
CESC	cis	rs4563143	0.502	rs73029061	chr19:29283980	T/A	cg12667521	chr19:29218732	NA	0.48	5.92	0.34	1.02e-8	Methadone dose in opioid dependence;
CESC	cis	rs820218	0.770	rs9907115	chr17:73676391	G/A	cg01592526	chr17:73663357	RECQL5;SAP30BP	-0.42	-5.72	-0.33	2.94e-8	Rotator cuff tears;
CESC	cis	rs9733	0.687	rs12410050	chr1:150857141	A/G	cg22823121	chr1:150693482	HORMAD1	-0.37	-5.32	-0.31	2.17e-7	Tonsillectomy;
CESC	cis	rs9467711	0.606	rs9393707	chr6:26362486	T/C	cg14345882	chr6:26364793	BTN3A2	0.61	6.49	0.37	4.31e-10	Autism spectrum disorder or schizophrenia;
CESC	cis	rs7296418	0.961	rs10773921	chr12:123541606	C/T	cg00376283	chr12:123451042	ABCB9	0.75	11.0	0.56	2.04e-23	Platelet count;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg11413751	chr19:45458585	CLPTM1	-0.41	-6.16	-0.35	2.69e-9	Gambling;
CESC	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg26338869	chr17:61819248	STRADA	0.67	8.77	0.47	2.24e-16	Prudent dietary pattern;
CESC	cis	rs12497850	0.765	rs12487580	chr3:49182932	G/A	cg07636037	chr3:49044803	WDR6	1.05	18.71	0.75	2.31e-50	Parkinson's disease;
CESC	cis	rs6460942	1.000	rs2053382	chr7:12400587	A/G	cg13733410	chr7:12443478	VWDE	-0.55	-5.43	-0.32	1.26e-7	Coronary artery disease;
CESC	cis	rs2204008	0.774	rs11495721	chr12:38337224	A/C	cg26384229	chr12:38710491	ALG10B	0.69	10.42	0.54	1.61e-21	Bladder cancer;
CESC	cis	rs4969178	0.965	rs12451791	chr17:76397343	G/A	cg05887092	chr17:76393375	PGS1	0.58	9.22	0.49	9.9e-18	HDL cholesterol levels;
CESC	cis	rs748404	0.660	rs2467738	chr15:43739936	T/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.58	7.67	0.43	3.24e-13	Lung cancer;
CESC	cis	rs7085104	0.684	rs7092690	chr10:104609365	T/C	cg04362960	chr10:104952993	NT5C2	0.52	6.74	0.38	1.01e-10	Immature fraction of reticulocytes;Schizophrenia;
CESC	cis	rs798554	0.797	rs1182183	chr7:2873136	C/T	cg19717773	chr7:2847554	GNA12	-0.57	-8.36	-0.46	3.61e-15	Height;
CESC	cis	rs1461503	0.932	rs7944492	chr11:122838745	G/T	cg27398637	chr11:122830231	C11orf63	-0.57	-8.68	-0.47	4.17e-16	Menarche (age at onset);
CESC	cis	rs17711722	0.701	rs781145	chr7:65440370	A/C	cg06456125	chr7:65229604	NA	0.44	5.7	0.33	3.19e-8	Calcium levels;
CESC	cis	rs6582630	0.519	rs11495724	chr12:38337507	T/C	cg26384229	chr12:38710491	ALG10B	0.71	10.65	0.55	2.77e-22	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs6570726	0.791	rs9399558	chr6:145911730	T/C	cg05347473	chr6:146136440	FBXO30	0.57	7.24	0.41	4.72e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs61776719	0.738	rs7555461	chr1:38444749	T/C	cg26528311	chr1:38462546	FHL3	-0.41	-6.67	-0.38	1.49e-10	Coronary artery disease;
CESC	cis	rs4566357	0.615	rs12618793	chr2:227909552	T/C	cg05526886	chr2:227700861	RHBDD1	-0.45	-5.86	-0.34	1.34e-8	Coronary artery disease;
CESC	cis	rs854765	0.565	rs854768	chr17:18018806	T/C	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.5	6.29	0.36	1.34e-9	Total body bone mineral density;
CESC	trans	rs916888	0.773	rs199448	chr17:44809001	A/G	cg01341218	chr17:43662625	NA	0.9	10.86	0.55	5.9e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs9894429	0.966	rs6565604	chr17:79589242	G/A	cg18240062	chr17:79603768	NPLOC4	0.73	10.23	0.53	6.51e-21	Eye color traits;
CESC	cis	rs1552244	1.000	rs7631678	chr3:10078816	T/G	cg00149659	chr3:10157352	C3orf10	0.77	9.66	0.51	4.22e-19	Alzheimer's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13902409	chr5:179922147	CNOT6	-0.57	-6.07	-0.35	4.5e-9	Gut microbiome composition (summer);
CESC	cis	rs2439831	0.717	rs7165471	chr15:43644788	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.84	12.1	0.6	4.05e-27	Lung cancer in ever smokers;
CESC	cis	rs3820068	0.655	rs59605679	chr1:15863796	T/G	cg18192808	chr1:15853278	DNAJC16	0.46	5.63	0.33	4.49e-8	Systolic blood pressure;
CESC	cis	rs72781680	0.898	rs7563564	chr2:23993404	T/C	cg08917208	chr2:24149416	ATAD2B	0.95	8.71	0.47	3.45e-16	Lymphocyte counts;
CESC	cis	rs3820068	0.608	rs2057304	chr1:16017710	A/G	cg17385448	chr1:15911702	AGMAT	0.38	6.08	0.35	4.28e-9	Systolic blood pressure;
CESC	cis	rs77106637	0.860	rs75896506	chr11:72429579	G/A	cg04827223	chr11:72435913	ARAP1	-0.62	-6.26	-0.36	1.58e-9	Type 2 diabetes;
CESC	cis	rs881375	0.715	rs7858209	chr9:123645760	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	6.09	0.35	4.05e-9	Rheumatoid arthritis;
CESC	cis	rs3785574	0.927	rs2727313	chr17:61961914	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.77	9.93	0.52	5.72e-20	Height;
CESC	cis	rs7089973	0.836	rs12765350	chr10:116635305	G/A	cg23260525	chr10:116636907	FAM160B1	0.37	6.15	0.35	2.84e-9	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs4843747	0.671	rs28679286	chr16:88106307	C/T	cg06374794	chr16:88002281	BANP	0.39	5.16	0.3	4.78e-7	Menopause (age at onset);
CESC	cis	rs2952156	1.000	rs2643194	chr17:37853048	C/T	cg20243544	chr17:37824526	PNMT	0.62	7.48	0.42	1.09e-12	Asthma;
CESC	cis	rs3741151	0.764	rs7101561	chr11:73264219	G/C	cg17517138	chr11:73019481	ARHGEF17	1.05	7.73	0.43	2.25e-13	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs2882667	0.537	rs7704790	chr5:138410096	A/C	cg22797968	chr5:138629998	MATR3	0.38	5.04	0.3	8.69e-7	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs7208859	0.623	rs73269974	chr17:29112384	C/T	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.91e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs3785574	0.962	rs2584621	chr17:61912436	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.09	19.2	0.76	4.43e-52	Height;
CESC	cis	rs6754311	0.731	rs3754686	chr2:136603276	T/C	cg15123519	chr2:136567270	LCT	0.31	5.17	0.3	4.51e-7	Mosquito bite size;
CESC	cis	rs3785574	0.962	rs62077512	chr17:61851435	C/T	cg06420487	chr17:61919686	SMARCD2	0.47	5.59	0.32	5.68e-8	Height;
CESC	cis	rs668210	0.894	rs1786171	chr11:65769809	G/C	cg02427764	chr11:65769310	BANF1;EIF1AD	0.49	5.42	0.32	1.31e-7	Cerebrospinal fluid biomarker levels;
CESC	cis	rs4665809	0.590	rs7586047	chr2:26447335	A/G	cg04944784	chr2:26401820	FAM59B	-0.95	-10.35	-0.54	2.65e-21	Gut microbiome composition (summer);
CESC	cis	rs703842	0.964	rs2014886	chr12:58177437	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.71	9.04	0.49	3.3e-17	Multiple sclerosis;
CESC	cis	rs9308731	0.591	rs879623	chr2:111946824	G/A	cg04202892	chr2:111875749	ACOXL	0.4	5.53	0.32	7.58e-8	Chronic lymphocytic leukemia;
CESC	cis	rs9611565	0.592	rs5996037	chr22:41965292	A/G	cg17376030	chr22:41985996	PMM1	0.54	5.98	0.35	7.02e-9	Vitiligo;
CESC	cis	rs3106136	0.546	rs2276910	chr4:95129238	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.61	-9.26	-0.49	7.25e-18	Capecitabine sensitivity;
CESC	cis	rs739401	0.611	rs2239900	chr11:3030992	C/T	cg08508325	chr11:3079039	CARS	-0.51	-9.67	-0.51	3.75e-19	Longevity;
CESC	cis	rs12155623	0.619	rs870397	chr8:49861225	C/T	cg00325661	chr8:49890786	NA	0.41	5.64	0.33	4.3e-8	Sudden cardiac arrest;
CESC	cis	rs7666738	0.830	rs10000573	chr4:99048785	G/C	cg05340658	chr4:99064831	C4orf37	0.82	12.88	0.62	8.44e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1775715	0.737	rs1419171	chr10:32214831	C/A	cg18675610	chr10:32216311	ARHGAP12	0.36	5.47	0.32	1.04e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs6120849	0.754	rs6088678	chr20:33607551	A/G	cg24642439	chr20:33292090	TP53INP2	-0.65	-6.47	-0.37	4.79e-10	Protein C levels;
CESC	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg24642844	chr7:1081250	C7orf50	-0.7	-8.64	-0.47	5.26e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs9457247	0.934	rs2345571	chr6:167403400	T/G	cg23791538	chr6:167370224	RNASET2	-0.58	-8.19	-0.45	1.1e-14	Crohn's disease;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg19000349	chr2:75061841	HK2	-0.44	-6.27	-0.36	1.45e-9	Gambling;
CESC	cis	rs2576037	0.583	rs2576050	chr18:44558912	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.35	-5.52	-0.32	7.99e-8	Personality dimensions;
CESC	cis	rs10504229	0.683	rs11781690	chr8:58132931	C/G	cg02725872	chr8:58115012	NA	-0.45	-7.05	-0.4	1.52e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs11676348	0.714	rs4674254	chr2:218986077	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.46	-6.03	-0.35	5.51e-9	Ulcerative colitis;
CESC	cis	rs754466	0.561	rs67332822	chr10:79706118	G/A	cg17075019	chr10:79541650	NA	-0.68	-6.31	-0.36	1.16e-9	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs8177253	0.761	rs1830084	chr3:133508464	A/T	cg18769074	chr3:133464867	TF	-0.31	-5.42	-0.32	1.36e-7	Iron status biomarkers;
CESC	cis	rs4803468	0.935	rs284660	chr19:41932084	G/T	cg09537434	chr19:41945824	ATP5SL	-1.06	-19.39	-0.77	9.44e-53	Height;
CESC	cis	rs7659604	0.517	rs56311153	chr4:122729685	T/C	cg19748678	chr4:122722346	EXOSC9	0.78	9.68	0.51	3.7e-19	Type 2 diabetes;
CESC	cis	rs4665809	0.590	rs4665319	chr2:26424583	A/C	cg08470875	chr2:26401718	FAM59B	-0.65	-7.34	-0.41	2.65e-12	Gut microbiome composition (summer);
CESC	cis	rs11864453	0.680	rs8047377	chr16:72148339	T/C	cg16558253	chr16:72132732	DHX38	-0.54	-8.58	-0.47	8.07e-16	Fibrinogen levels;
CESC	cis	rs10779751	0.770	rs11121691	chr1:11181327	C/T	cg08854313	chr1:11322531	MTOR	-0.73	-8.67	-0.47	4.47e-16	Body mass index;
CESC	cis	rs4654899	0.865	rs61779065	chr1:21356474	A/T	cg05370193	chr1:21551575	ECE1	0.43	6.21	0.36	2.09e-9	Superior frontal gyrus grey matter volume;
CESC	cis	rs7589342	0.628	rs35866817	chr2:106402569	T/C	cg16077055	chr2:106428750	NCK2	0.54	6.73	0.38	1.07e-10	Addiction;
CESC	cis	rs7945705	0.934	rs1988709	chr11:8882890	A/T	cg21881798	chr11:8931708	C11orf17;ST5	0.48	7.56	0.42	6.46e-13	Hemoglobin concentration;
CESC	cis	rs2303745	0.589	rs1864115	chr19:17393327	G/C	cg04248312	chr19:17393744	ANKLE1	-0.93	-15.26	-0.68	3.79e-38	Systemic lupus erythematosus;
CESC	cis	rs4073582	0.595	rs801741	chr11:65917084	A/G	cg14036092	chr11:66035641	RAB1B	0.56	7.93	0.44	6e-14	Gout;
CESC	cis	rs11621710	0.898	rs10147080	chr14:35596092	C/A	cg16230307	chr14:35515116	FAM177A1	0.53	6.83	0.39	5.95e-11	Granulocyte percentage of myeloid white cells;
CESC	cis	rs6061231	1.000	rs13043313	chr20:60958269	A/G	cg24112000	chr20:60950667	NA	-0.6	-8.37	-0.46	3.41e-15	Colorectal cancer;
CESC	cis	rs116095464	0.558	rs73031482	chr5:227594	G/A	cg10591111	chr5:226296	SDHA	-0.53	-6.65	-0.38	1.64e-10	Breast cancer;
CESC	cis	rs514406	0.861	rs2065477	chr1:53250213	C/T	cg24675658	chr1:53192096	ZYG11B	-0.58	-7.39	-0.41	1.97e-12	Monocyte count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19545258	chr7:73703601	CLIP2	0.6	7.01	0.4	2.01e-11	Gut microbiome composition (summer);
CESC	cis	rs6762	0.692	rs7928925	chr11:839155	G/A	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.67	-8.65	-0.47	5.11e-16	Mean platelet volume;
CESC	cis	rs1008375	0.931	rs2098151	chr4:17577490	T/C	cg02297831	chr4:17616191	MED28	0.5	6.07	0.35	4.52e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs34734847	0.750	rs3829290	chr12:121126438	T/C	cg26008908	chr12:120799332	MSI1	0.35	5.43	0.32	1.3e-7	Mean corpuscular volume;
CESC	cis	rs35110281	0.659	rs73367822	chr21:45024252	C/T	cg04455712	chr21:45112962	RRP1B	0.41	6.11	0.35	3.58e-9	Mean corpuscular volume;
CESC	trans	rs2727020	0.757	rs7924526	chr11:49267043	G/A	cg15704280	chr7:45808275	SEPT13	0.81	11.1	0.56	9.45e-24	Coronary artery disease;
CESC	cis	rs7264396	0.790	rs6060542	chr20:34249061	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.86	-11.84	-0.59	3.14e-26	Total cholesterol levels;
CESC	cis	rs11785400	0.731	rs4294163	chr8:143730830	G/T	cg10596483	chr8:143751796	JRK	0.42	5.33	0.31	2.06e-7	Schizophrenia;
CESC	cis	rs7914558	1.000	rs7896547	chr10:104866958	A/G	cg04362960	chr10:104952993	NT5C2	0.46	5.92	0.34	9.98e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs6461049	0.638	rs3778994	chr7:2175855	G/T	cg21782813	chr7:2030301	MAD1L1	0.4	5.76	0.33	2.28e-8	Schizophrenia;
CESC	cis	rs10751667	0.961	rs7479171	chr11:926809	G/A	cg20946044	chr11:1010712	AP2A2	-0.43	-5.65	-0.33	4.21e-8	Alzheimer's disease (late onset);
CESC	cis	rs853679	0.542	rs6934769	chr6:28090931	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.56	-6.49	-0.37	4.23e-10	Depression;
CESC	cis	rs7116495	1.000	rs656640	chr11:71781710	T/C	cg26138937	chr11:71823887	C11orf51	-0.84	-6.79	-0.38	7.37e-11	Severe influenza A (H1N1) infection;
CESC	cis	rs9902453	0.845	rs3102558	chr17:28023142	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	8.53	0.46	1.15e-15	Coffee consumption (cups per day);
CESC	cis	rs9309711	0.544	rs9309712	chr2:3491327	G/T	cg15541040	chr2:3486749	NA	-0.42	-5.46	-0.32	1.11e-7	Neurofibrillary tangles;
CESC	cis	rs11098499	1.000	rs6837898	chr4:120179154	C/T	cg09307838	chr4:120376055	NA	0.87	11.47	0.58	5.45e-25	Corneal astigmatism;
CESC	cis	rs1506636	1.000	rs767637	chr7:123321978	C/A	cg03229431	chr7:123269106	ASB15	-0.51	-6.78	-0.38	7.66e-11	Plateletcrit;Platelet count;
CESC	cis	rs644799	0.540	rs10831419	chr11:95478037	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.46	5.85	0.34	1.45e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs7582720	1.000	rs72932557	chr2:203846817	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.36	0.41	2.34e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	trans	rs1814175	0.645	rs1851850	chr11:50012168	G/A	cg03929089	chr4:120376271	NA	-0.9	-14.56	-0.67	1.12e-35	Height;
CESC	cis	rs7666738	0.606	rs6839946	chr4:99076132	A/C	cg05340658	chr4:99064831	C4orf37	0.67	9.37	0.5	3.33e-18	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7084402	0.967	rs1365741	chr10:60277489	C/T	cg07615347	chr10:60278583	BICC1	-0.59	-9.45	-0.5	1.94e-18	Refractive error;
CESC	cis	rs2228479	0.850	rs62054638	chr16:89821131	G/C	cg04013166	chr16:89971882	TCF25	0.77	6.66	0.38	1.58e-10	Skin colour saturation;
CESC	cis	rs7666738	0.753	rs9991512	chr4:99007205	T/C	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.62e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6912958	0.514	rs1980792	chr6:87889917	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.35	-5.55	-0.32	6.83e-8	Monocyte percentage of white cells;
CESC	cis	rs4819052	0.851	rs7281263	chr21:46695606	T/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.45	5.67	0.33	3.77e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs12478296	1.000	rs6743297	chr2:243013814	A/G	cg06360820	chr2:242988706	NA	-0.78	-9.78	-0.51	1.78e-19	Obesity-related traits;
CESC	cis	rs7772486	0.875	rs7739371	chr6:146424353	C/G	cg05347473	chr6:146136440	FBXO30	0.51	6.75	0.38	9.04e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs8078723	0.668	rs56030650	chr17:38131187	C/A	cg17467752	chr17:38218738	THRA	0.58	8.49	0.46	1.49e-15	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CESC	cis	rs2404602	0.692	rs12904198	chr15:77146978	G/A	cg22467129	chr15:76604101	ETFA	-0.35	-5.23	-0.31	3.42e-7	Blood metabolite levels;
CESC	cis	rs11122272	0.735	rs2808595	chr1:231526238	G/A	cg06096015	chr1:231504339	EGLN1	0.42	5.96	0.34	8.07e-9	Hemoglobin concentration;
CESC	cis	rs2836974	0.568	rs11910906	chr21:40685662	T/C	cg22974920	chr21:40686053	BRWD1	-0.47	-5.66	-0.33	3.83e-8	Cognitive function;
CESC	cis	rs12458462	0.892	rs58675823	chr18:77463672	G/A	cg23301140	chr18:77439876	CTDP1	0.58	7.78	0.43	1.6e-13	Monocyte count;
CESC	cis	rs6460942	0.597	rs7798779	chr7:12543490	A/G	cg20607287	chr7:12443886	VWDE	-0.7	-7.29	-0.41	3.65e-12	Coronary artery disease;
CESC	cis	rs425277	0.606	rs262653	chr1:2090095	T/G	cg23803603	chr1:2058230	PRKCZ	0.3	5.14	0.3	5.36e-7	Height;
CESC	cis	rs2836974	0.897	rs8132568	chr21:40527916	C/T	cg27266027	chr21:40555129	PSMG1	0.47	5.84	0.34	1.53e-8	Cognitive function;
CESC	cis	rs10489525	0.560	rs10858062	chr1:115602563	A/G	cg01522456	chr1:115632236	TSPAN2	0.5	6.03	0.35	5.63e-9	Autism;
CESC	cis	rs892961	0.777	rs747483	chr17:75412091	C/T	cg05865280	chr17:75406074	SEPT9	0.62	12.7	0.62	3.53e-29	Airflow obstruction;
CESC	cis	rs2191566	0.576	rs397683	chr19:44494054	A/G	cg20607764	chr19:44506953	ZNF230	0.4	5.12	0.3	5.92e-7	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs17376456	0.877	rs12716457	chr5:93397627	T/C	cg21475434	chr5:93447410	FAM172A	0.79	6.99	0.39	2.2e-11	Diabetic retinopathy;
CESC	cis	rs651907	0.535	rs34263427	chr3:101507805	A/G	cg12386194	chr3:101231763	SENP7	0.41	5.13	0.3	5.65e-7	Colorectal cancer;
CESC	cis	rs1670533	1.000	rs10084890	chr4:1053934	C/G	cg27284194	chr4:1044797	NA	-0.47	-5.93	-0.34	9.34e-9	Recombination rate (females);
CESC	cis	rs7264396	0.635	rs6121102	chr20:34544274	A/G	cg17201900	chr20:34330562	RBM39	0.5	5.21	0.3	3.88e-7	Total cholesterol levels;
CESC	cis	rs7584330	0.910	rs880930	chr2:238396872	G/C	cg11271282	chr2:238384023	NA	0.48	5.6	0.33	5.34e-8	Prostate cancer;
CESC	trans	rs11252926	0.528	rs11252090	chr10:436547	C/T	cg00953403	chr17:74099816	EXOC7	-0.58	-7.4	-0.41	1.77e-12	Psychosis in Alzheimer's disease;
CESC	cis	rs11098499	0.908	rs2017057	chr4:120257711	A/G	cg24375607	chr4:120327624	NA	0.46	5.76	0.33	2.36e-8	Corneal astigmatism;
CESC	cis	rs17376456	0.935	rs13156002	chr5:93508931	G/A	cg25358565	chr5:93447407	FAM172A	1.18	11.54	0.58	3.22e-25	Diabetic retinopathy;
CESC	cis	rs753778	0.667	rs10103731	chr8:142206068	C/T	cg18755752	chr8:142205143	DENND3	-0.63	-9.03	-0.48	3.72e-17	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	cis	rs7917772	0.619	rs2251772	chr10:104470918	T/C	cg04362960	chr10:104952993	NT5C2	-0.47	-5.14	-0.3	5.46e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs55823223	0.648	rs936393	chr17:73847613	A/G	cg06969265	chr17:73775802	H3F3B	0.6	6.56	0.37	2.74e-10	Psoriasis;
CESC	cis	rs7560272	0.538	rs4852977	chr2:73938295	C/T	cg20560298	chr2:73613845	ALMS1	0.41	5.63	0.33	4.5e-8	Schizophrenia;
CESC	cis	rs2479724	0.776	rs2250428	chr6:41832772	T/A	cg08135965	chr6:41755394	TOMM6	0.41	5.5	0.32	9.15e-8	Menarche (age at onset);
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg01375172	chr16:23464338	COG7	-0.49	-6.62	-0.38	1.98e-10	Height;
CESC	cis	rs1707322	1.000	rs10890359	chr1:46336635	A/G	cg05343316	chr1:45956843	TESK2	0.43	5.23	0.31	3.41e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9457247	1.000	rs364451	chr6:167384756	G/A	cg25258033	chr6:167368657	RNASET2	0.38	5.73	0.33	2.73e-8	Crohn's disease;
CESC	trans	rs1814175	0.645	rs10128731	chr11:50023554	G/T	cg15704280	chr7:45808275	SEPT13	-1.0	-18.53	-0.75	9.55e-50	Height;
CESC	cis	rs875971	1.000	rs6460292	chr7:65810075	G/A	cg11764359	chr7:65958608	NA	-0.94	-15.05	-0.68	1.96e-37	Aortic root size;
CESC	cis	rs7193541	0.826	rs56143602	chr16:74694692	T/C	cg01733217	chr16:74700730	RFWD3	0.92	13.43	0.64	1.06e-31	Multiple myeloma;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25275331	chr1:40723935	ZMPSTE24	0.67	7.94	0.44	5.72e-14	Gut microbiome composition (summer);
CESC	cis	rs4481887	0.741	rs4360554	chr1:248553206	C/T	cg26353448	chr1:248524236	OR2T4	-0.37	-5.23	-0.31	3.46e-7	Common traits (Other);
CESC	trans	rs1814175	0.645	rs28441045	chr11:50048971	C/T	cg15704280	chr7:45808275	SEPT13	-1.0	-18.7	-0.75	2.39e-50	Height;
CESC	cis	rs2549003	1.000	rs2549002	chr5:131829578	C/A	cg00255919	chr5:131827918	IRF1	-0.61	-10.9	-0.56	4.22e-23	Asthma (sex interaction);
CESC	cis	rs597539	0.652	rs501799	chr11:68631240	G/T	cg18350739	chr11:68623251	NA	-0.47	-7.42	-0.41	1.61e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs9309711	0.506	rs9284794	chr2:3492052	G/A	cg10845886	chr2:3471009	TTC15	-0.61	-8.25	-0.45	7.51e-15	Neurofibrillary tangles;
CESC	cis	rs941408	0.515	rs12610096	chr19:2778129	C/T	cg02580895	chr19:2754563	NA	-0.41	-5.25	-0.31	3.07e-7	Total cholesterol levels;
CESC	cis	rs9811920	0.609	rs704583	chr3:99643693	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.59	7.22	0.41	5.61e-12	Axial length;
CESC	cis	rs12824058	0.737	rs11060829	chr12:130814996	G/T	cg23887609	chr12:130822674	PIWIL1	0.45	5.82	0.34	1.69e-8	Menopause (age at onset);
CESC	cis	rs7666738	0.791	rs1896155	chr4:99020948	C/A	cg05340658	chr4:99064831	C4orf37	0.82	12.99	0.62	3.34e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6938	0.618	rs11857695	chr15:75165751	G/T	cg10253484	chr15:75165896	SCAMP2	-0.51	-6.97	-0.39	2.5e-11	Breast cancer;
CESC	cis	rs6430585	1.000	rs73958618	chr2:136500475	A/G	cg07169764	chr2:136633963	MCM6	1.03	13.14	0.63	1.02e-30	Corneal structure;
CESC	cis	rs9486715	0.867	rs9384602	chr6:96919561	G/A	cg06623918	chr6:96969491	KIAA0776	0.95	14.79	0.67	1.64e-36	Headache;
CESC	cis	rs941408	0.515	rs7253128	chr19:2776982	C/T	cg02580895	chr19:2754563	NA	-0.48	-6.49	-0.37	4.25e-10	Total cholesterol levels;
CESC	cis	rs897080	0.515	rs786405	chr2:44710367	G/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.49	5.52	0.32	8.26e-8	Height;
CESC	cis	rs367943	0.698	rs728915	chr5:112995748	C/T	cg12552261	chr5:112820674	MCC	0.45	5.35	0.31	1.87e-7	Type 2 diabetes;
CESC	cis	rs7927592	0.763	rs7120876	chr11:68261398	C/G	cg01657329	chr11:68192670	LRP5	-0.46	-6.06	-0.35	4.62e-9	Total body bone mineral density;
CESC	trans	rs11098499	0.754	rs1980025	chr4:120252806	A/G	cg25214090	chr10:38739885	LOC399744	-0.59	-8.33	-0.46	4.28e-15	Corneal astigmatism;
CESC	cis	rs1153858	1.000	rs7169818	chr15:45640191	G/A	cg21132104	chr15:45694354	SPATA5L1	0.76	10.18	0.53	9.28e-21	Homoarginine levels;
CESC	cis	rs13040088	1.000	rs13040088	chr20:61549202	A/G	cg23096297	chr20:61557774	DIDO1	0.95	10.83	0.55	7.11e-23	Menopause (age at onset);
CESC	cis	rs9916302	0.861	rs8081033	chr17:37506650	A/G	cg19468946	chr17:37922297	IKZF3	0.39	5.03	0.3	8.9e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs13336428	0.730	rs28653458	chr16:1525850	T/C	cg07835181	chr16:1525278	CLCN7	0.72	9.86	0.52	9.78e-20	Bone mineral density;
CESC	cis	rs854765	0.583	rs6502627	chr17:17849671	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.59	8.26	0.45	7.24e-15	Total body bone mineral density;
CESC	cis	rs2991971	0.810	rs2356413	chr1:45914048	A/T	cg24296786	chr1:45957014	TESK2	-0.62	-8.77	-0.47	2.21e-16	High light scatter reticulocyte count;
CESC	cis	rs79976124	0.837	rs12201218	chr6:66653619	C/T	cg07460842	chr6:66804631	NA	-0.7	-8.49	-0.46	1.5e-15	Type 2 diabetes;
CESC	cis	rs858239	1.000	rs156421	chr7:23312487	A/G	cg23682824	chr7:23144976	KLHL7	0.43	5.69	0.33	3.41e-8	Cerebrospinal fluid biomarker levels;
CESC	cis	rs2412488	0.853	rs35089837	chr4:54354341	C/T	cg22241045	chr4:54363911	LNX1	-0.37	-5.22	-0.31	3.58e-7	DNA methylation (variation);
CESC	cis	rs3858526	0.523	rs10838750	chr11:5886246	C/T	cg25319279	chr11:5960081	NA	0.33	5.14	0.3	5.25e-7	DNA methylation (variation);
CESC	cis	rs6963495	0.745	rs73192152	chr7:105212258	A/C	cg02135003	chr7:105160482	PUS7	-0.48	-5.51	-0.32	8.52e-8	Bipolar disorder (body mass index interaction);
CESC	cis	rs7555523	0.830	rs4656460	chr1:165672367	A/C	cg24409356	chr1:165738333	TMCO1	0.8	6.7	0.38	1.25e-10	Intraocular pressure;Glaucoma (high intraocular pressure);
CESC	cis	rs13102973	0.965	rs11099306	chr4:135895674	A/G	cg14419869	chr4:135874104	NA	0.34	5.33	0.31	2.13e-7	Subjective well-being;
CESC	cis	rs1215050	0.740	rs700740	chr4:98976003	A/C	cg17366294	chr4:99064904	C4orf37	-0.38	-5.04	-0.3	8.72e-7	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs72901758	0.768	rs1567237	chr17:76246294	A/G	cg26068271	chr17:76253126	NA	-0.49	-7.46	-0.42	1.22e-12	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
CESC	cis	rs9612	1.000	rs346528	chr19:44259232	G/T	cg08581076	chr19:44259116	C19orf61	0.52	6.14	0.35	2.96e-9	Exhaled nitric oxide output;
CESC	cis	rs12540874	0.698	rs10899736	chr7:50546925	C/T	cg18232548	chr7:50535776	DDC	-0.4	-5.84	-0.34	1.51e-8	Systemic sclerosis;
CESC	cis	rs9311474	0.507	rs4687644	chr3:52746541	T/G	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.72	0.38	1.12e-10	Electroencephalogram traits;
CESC	cis	rs6088590	1.000	rs28542147	chr20:33376323	G/A	cg08999081	chr20:33150536	PIGU	0.59	8.99	0.48	4.71e-17	Coronary artery disease;
CESC	cis	rs9902453	0.765	rs2250320	chr17:28128657	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-10.34	-0.54	2.82e-21	Coffee consumption (cups per day);
CESC	cis	rs514406	0.798	rs504816	chr1:53307957	T/G	cg24675658	chr1:53192096	ZYG11B	-0.7	-9.41	-0.5	2.53e-18	Monocyte count;
CESC	cis	rs854765	0.647	rs854769	chr17:18019011	A/G	cg04398451	chr17:18023971	MYO15A	0.73	10.31	0.54	3.55e-21	Total body bone mineral density;
CESC	cis	rs2243480	1.000	rs160642	chr7:65558373	C/T	cg13147721	chr7:65941812	NA	-0.98	-9.11	-0.49	2.06e-17	Diabetic kidney disease;
CESC	cis	rs7917772	0.636	rs7894154	chr10:104524647	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.44	-5.18	-0.3	4.3e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs4713118	0.621	rs9295755	chr6:28033174	C/T	cg17949981	chr6:28129498	ZNF389	-0.43	-5.34	-0.31	2e-7	Parkinson's disease;
CESC	cis	rs911555	0.713	rs10162425	chr14:103931621	C/T	cg12935359	chr14:103987150	CKB	-0.58	-8.34	-0.46	4.23e-15	Intelligence (multi-trait analysis);
CESC	cis	rs9640161	0.742	rs11767726	chr7:150018096	A/C	cg10018233	chr7:150070692	REPIN1	-0.49	-8.01	-0.44	3.72e-14	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs12142240	0.698	rs7548675	chr1:46809321	C/G	cg10495392	chr1:46806563	NSUN4	0.59	6.34	0.36	9.65e-10	Menopause (age at onset);
CESC	cis	rs2559856	1.000	rs10745921	chr12:102087193	A/G	cg15068132	chr12:102092402	CHPT1	-0.39	-5.18	-0.3	4.38e-7	Blood protein levels;
CESC	cis	rs2046867	0.774	rs62249873	chr3:72907115	G/A	cg25664220	chr3:72788482	NA	-0.49	-7.04	-0.4	1.63e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CESC	cis	rs2425143	1.000	rs111597121	chr20:34371913	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.79	-7.16	-0.4	8.09e-12	Blood protein levels;
CESC	cis	rs3126085	1.000	rs72696952	chr1:152172694	A/T	cg03465714	chr1:152285911	FLG	0.45	5.06	0.3	8.03e-7	Atopic dermatitis;
CESC	trans	rs7107217	1.000	rs1873872	chr11:129473993	A/T	cg16143763	chr17:41116517	AARSD1	0.5	6.44	0.37	5.62e-10	Breast cancer;Type 2 diabetes;
CESC	cis	rs9486719	0.895	rs12527021	chr6:97025496	C/T	cg18709589	chr6:96969512	KIAA0776	-0.52	-5.7	-0.33	3.16e-8	Migraine;Coronary artery disease;
CESC	cis	rs4664304	0.802	rs3749114	chr2:160832996	A/T	cg03641300	chr2:160917029	PLA2R1	-0.51	-7.32	-0.41	3.04e-12	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs10979	0.928	rs9496676	chr6:143895610	A/G	cg25407410	chr6:143891975	LOC285740	-0.6	-9.11	-0.49	2.12e-17	Hypospadias;
CESC	cis	rs7615952	0.641	rs12495947	chr3:125771698	C/T	cg04553112	chr3:125709451	NA	-0.52	-5.47	-0.32	1.05e-7	Blood pressure (smoking interaction);
CESC	cis	rs6445797	0.632	rs2291501	chr3:56654141	C/T	cg13792233	chr3:56591045	CCDC66	0.38	5.14	0.3	5.29e-7	Gastritis;
CESC	cis	rs6831352	0.734	rs2602856	chr4:100029145	C/A	cg12011299	chr4:100065546	ADH4	0.64	8.19	0.45	1.15e-14	Alcohol dependence;
CESC	cis	rs4450798	0.793	rs9882340	chr3:13755427	G/C	cg05589046	chr3:13742034	LOC285375	0.38	5.72	0.33	2.94e-8	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs4689388	0.853	rs11729672	chr4:6293838	A/G	cg14416269	chr4:6271139	WFS1	0.46	7.76	0.43	1.79e-13	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs12477438	0.501	rs17759607	chr2:99737005	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.79	13.0	0.62	3.21e-30	Chronic sinus infection;
CESC	cis	rs2652822	0.509	rs8468	chr15:63434110	C/T	cg02713581	chr15:63449717	RPS27L	0.45	5.27	0.31	2.79e-7	Metabolic traits;
CESC	cis	rs2688608	0.592	rs11000758	chr10:75493610	A/T	cg23231163	chr10:75533350	FUT11	-0.34	-5.28	-0.31	2.75e-7	Inflammatory bowel disease;
CESC	cis	rs514406	0.644	rs7552663	chr1:53204352	C/T	cg08736216	chr1:53307985	ZYG11A	0.3	5.05	0.3	8.16e-7	Monocyte count;
CESC	cis	rs344364	0.511	rs1742467	chr16:1950187	G/T	cg03013636	chr16:1946785	NA	0.48	6.62	0.38	2.02e-10	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs1595825	0.838	rs80172713	chr2:198508044	T/C	cg10820045	chr2:198174542	NA	0.42	5.15	0.3	5.02e-7	Ulcerative colitis;
CESC	trans	rs8099014	1.000	rs9946396	chr18:56107163	G/A	cg06677321	chr17:67603831	NA	0.43	6.15	0.35	2.89e-9	Platelet count;
CESC	cis	rs7949030	0.626	rs11231154	chr11:62362293	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.65	9.53	0.51	1.02e-18	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs9400467	0.506	rs11153281	chr6:111594594	C/T	cg15721981	chr6:111408429	SLC16A10	0.53	5.11	0.3	6.28e-7	Blood metabolite levels;Amino acid levels;
CESC	cis	rs62458065	0.513	rs787216	chr7:32578891	G/A	cg20159608	chr7:32802032	NA	-0.55	-6.15	-0.35	2.89e-9	Metabolite levels (HVA/MHPG ratio);
CESC	trans	rs2797160	0.904	rs1739370	chr6:126011231	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.48	6.45	0.37	5.41e-10	Endometrial cancer;
CESC	cis	rs10504229	0.636	rs77691549	chr8:58055126	G/T	cg22535103	chr8:58192502	C8orf71	-0.77	-8.01	-0.44	3.74e-14	Developmental language disorder (linguistic errors);
CESC	trans	rs11098499	0.908	rs12504149	chr4:120318577	G/A	cg25214090	chr10:38739885	LOC399744	0.7	9.7	0.51	3.1400000000000002e-19	Corneal astigmatism;
CESC	cis	rs7208859	0.725	rs9891656	chr17:29243355	A/T	cg19761014	chr17:28927070	LRRC37B2	0.59	5.88	0.34	1.21e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs941873	0.772	rs1892498	chr10:81103862	A/G	cg09469691	chr10:81107165	PPIF	0.5	6.6	0.38	2.28e-10	Height;
CESC	cis	rs533581	0.789	rs7404039	chr16:88975954	A/G	cg16701003	chr16:89028210	CBFA2T3	0.55	8.38	0.46	3.21e-15	Social autistic-like traits;
CESC	cis	rs748404	0.586	rs2584700	chr15:43685332	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.54	8.07	0.44	2.44e-14	Lung cancer;
CESC	trans	rs916888	0.773	rs199533	chr17:44828931	G/A	cg10053473	chr17:62856997	LRRC37A3	-0.73	-7.89	-0.44	7.89e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs2074038	1.000	rs2074038	chr11:44087989	G/T	cg15894661	chr11:44088124	ACCS	-0.69	-5.47	-0.32	1.03e-7	IgA nephropathy;
CESC	cis	rs60871478	1.000	rs4720930	chr7:808073	G/A	cg27478167	chr7:817139	HEATR2	-0.48	-5.25	-0.31	3.11e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs7618915	0.547	rs11130313	chr3:52676190	A/C	cg05564831	chr3:52568323	NT5DC2	0.45	6.91	0.39	3.55e-11	Bipolar disorder;
CESC	cis	rs651907	0.535	rs11714444	chr3:101513682	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.46	6.05	0.35	4.95e-9	Colorectal cancer;
CESC	cis	rs9916302	0.904	rs7503069	chr17:37697128	C/G	cg20243544	chr17:37824526	PNMT	0.51	6.5	0.37	3.89e-10	Glomerular filtration rate (creatinine);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03562744	chr8:27168757	TRIM35;PTK2B	0.57	6.4	0.37	6.85e-10	Gut microbiome composition (summer);
CESC	cis	rs7267979	0.565	rs4815437	chr20:25584788	C/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.69	-11.07	-0.56	1.14e-23	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs12220238	1.000	rs11000924	chr10:75972311	T/A	cg19889307	chr10:75911429	ADK;AP3M1	0.6	5.45	0.32	1.13e-7	Soluble interleukin-2 receptor subunit alpha;
CESC	cis	rs2841277	0.616	rs1048257	chr14:105404384	T/C	cg17340268	chr14:105411764	AHNAK2	-0.52	-6.8	-0.39	6.73e-11	Rheumatoid arthritis;
CESC	cis	rs11098499	0.874	rs6822498	chr4:120120183	T/C	cg09307838	chr4:120376055	NA	0.74	9.31	0.5	5.18e-18	Corneal astigmatism;
CESC	cis	rs6502050	0.835	rs7213172	chr17:80085703	G/T	cg11859384	chr17:80120422	CCDC57	0.38	5.12	0.3	6.01e-7	Life satisfaction;
CESC	cis	rs959260	0.557	rs12936583	chr17:73304710	A/C	cg20590849	chr17:73267439	MIF4GD	0.45	5.64	0.33	4.32e-8	Systemic lupus erythematosus;
CESC	cis	rs59918340	0.936	rs6982449	chr8:142234642	T/C	cg23750338	chr8:142222470	SLC45A4	-0.41	-6.38	-0.37	7.65e-10	Immature fraction of reticulocytes;
CESC	cis	rs11997175	0.716	rs7460818	chr8:33816362	A/G	ch.8.33884649F	chr8:33765107	NA	0.66	9.06	0.49	3.02e-17	Body mass index;
CESC	cis	rs12545109	0.571	rs4237014	chr8:57284479	C/A	cg09654669	chr8:57350985	NA	-0.48	-5.86	-0.34	1.41e-8	Obesity-related traits;
CESC	cis	rs2933343	0.679	rs1091938	chr3:128637025	T/C	cg11901034	chr3:128598214	ACAD9	-0.37	-5.37	-0.31	1.71e-7	IgG glycosylation;
CESC	cis	rs67311347	0.544	rs2887965	chr3:40334154	A/G	cg24209194	chr3:40518798	ZNF619	-0.39	-5.38	-0.31	1.62e-7	Renal cell carcinoma;
CESC	cis	rs7607369	0.536	rs13032993	chr2:219666377	T/C	cg02176678	chr2:219576539	TTLL4	-0.35	-6.05	-0.35	5.04e-9	Red blood cell count;Amyotrophic lateral sclerosis;
CESC	cis	rs7772486	0.875	rs864390	chr6:146315035	G/T	cg23711669	chr6:146136114	FBXO30	0.77	10.98	0.56	2.36e-23	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4909189	1.000	rs12698214	chr7:158136204	T/G	cg24154853	chr7:158122151	PTPRN2	0.51	6.44	0.37	5.73e-10	Response to amphetamines;
CESC	cis	rs7100689	0.646	rs7092237	chr10:82165640	A/G	cg00277334	chr10:82204260	NA	-0.43	-6.05	-0.35	4.98e-9	Post bronchodilator FEV1;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg17436946	chr4:39699568	UBE2K	0.47	6.16	0.35	2.74e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs12477438	0.501	rs6727749	chr2:99793590	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.79	12.62	0.61	6.6e-29	Chronic sinus infection;
CESC	cis	rs73019876	0.869	rs8101183	chr19:22170551	C/A	cg11619707	chr19:22235551	ZNF257	-0.28	-5.13	-0.3	5.6e-7	Testicular germ cell tumor;
CESC	cis	rs708547	0.671	rs1718863	chr4:57887586	G/T	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.42	-5.52	-0.32	8.06e-8	Response to bleomycin (chromatid breaks);
CESC	cis	rs1879734	0.689	rs6695509	chr1:54161112	A/G	cg23596471	chr1:54105337	GLIS1	0.35	5.56	0.32	6.52e-8	Mitral valve prolapse;
CESC	cis	rs12701220	0.553	rs7782024	chr7:1157502	G/T	cg00990874	chr7:1149470	C7orf50	-0.48	-5.12	-0.3	5.9e-7	Bronchopulmonary dysplasia;
CESC	cis	rs7116495	0.609	rs4245463	chr11:71743213	C/A	cg07596299	chr11:71824057	C11orf51	-0.86	-5.2	-0.3	3.99e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs9399135	0.967	rs7741515	chr6:135374368	C/G	cg22676075	chr6:135203613	NA	-0.5	-6.96	-0.39	2.61e-11	Red blood cell count;
CESC	cis	rs2243480	1.000	rs313820	chr7:65574466	A/C	cg12463550	chr7:65579703	CRCP	0.74	5.77	0.33	2.23e-8	Diabetic kidney disease;
CESC	cis	rs2836974	0.966	rs2836977	chr21:40666066	T/C	cg17971929	chr21:40555470	PSMG1	1.04	15.63	0.69	1.78e-39	Cognitive function;
CESC	cis	rs12478296	1.000	rs56323081	chr2:243040807	A/G	cg06360820	chr2:242988706	NA	-0.86	-8.97	-0.48	5.46e-17	Obesity-related traits;
CESC	cis	rs17023223	0.581	rs11811859	chr1:119707680	A/G	cg05756136	chr1:119680316	WARS2	-0.47	-5.69	-0.33	3.35e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CESC	cis	rs4948102	0.727	rs4948097	chr7:56056571	A/G	cg09872392	chr7:56161020	PHKG1	-0.46	-7.17	-0.4	7.37e-12	Plasma homocysteine levels (post-methionine load test);
CESC	cis	rs6662572	0.737	rs77017199	chr1:46532407	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.48	5.25	0.31	3.18e-7	Blood protein levels;
CESC	cis	rs2243480	1.000	rs437889	chr7:65509234	G/A	cg25894440	chr7:65020034	NA	-0.61	-5.09	-0.3	6.78e-7	Diabetic kidney disease;
CESC	cis	rs8060686	0.641	rs12598256	chr16:68084021	G/A	cg26727032	chr16:67993705	SLC12A4	-0.54	-6.16	-0.35	2.65e-9	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs17711722	0.565	rs73372653	chr7:65442795	A/T	cg02869306	chr7:64672164	INTS4L1	-0.37	-5.77	-0.33	2.16e-8	Calcium levels;
CESC	cis	rs12912251	0.947	rs7171233	chr15:38988760	T/A	cg01338139	chr15:38987640	C15orf53	-0.47	-5.43	-0.32	1.26e-7	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg03051979	chr16:58283909	CCDC113	-0.43	-6.03	-0.35	5.55e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs4835473	0.900	rs13105571	chr4:144655394	C/T	cg25736465	chr4:144833511	NA	-0.32	-5.04	-0.3	8.48e-7	Immature fraction of reticulocytes;
CESC	cis	rs40363	0.680	rs72778116	chr16:3530752	A/G	cg00484396	chr16:3507460	NAT15	0.6	6.53	0.37	3.32e-10	Tuberculosis;
CESC	cis	rs3096299	0.692	rs4785565	chr16:89515759	T/C	cg00750074	chr16:89608354	SPG7	-0.42	-6.16	-0.35	2.66e-9	Multiple myeloma (IgH translocation);
CESC	cis	rs7412746	0.611	rs2271076	chr1:150916657	C/T	cg04414720	chr1:150670196	GOLPH3L	0.45	5.96	0.34	8.13e-9	Melanoma;
CESC	cis	rs1707322	0.686	rs2275085	chr1:46085852	C/T	cg03146154	chr1:46216737	IPP	-0.79	-10.85	-0.55	6.39e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16922275	chr15:59063609	FAM63B	0.56	6.37	0.36	8.26e-10	Gut microbiome composition (summer);
CESC	cis	rs116095464	0.558	rs1812843	chr5:267658	A/G	cg12570787	chr5:219185	SDHA;CCDC127	0.53	5.49	0.32	9.44e-8	Breast cancer;
CESC	cis	rs5769707	0.967	rs5769698	chr22:49997706	A/G	cg05373962	chr22:49881684	NA	-0.36	-6.29	-0.36	1.29e-9	Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs365132	1.000	rs353478	chr5:176370988	T/C	cg16309518	chr5:176445507	NA	-0.37	-5.36	-0.31	1.77e-7	Menarche and menopause (age at onset);Menopause (age at onset);
CESC	cis	rs62064224	0.791	rs2344977	chr17:30720573	C/G	cg25809561	chr17:30822961	MYO1D	0.56	7.73	0.43	2.19e-13	Schizophrenia;
CESC	cis	rs798554	0.757	rs1182187	chr7:2870454	T/G	cg04166393	chr7:2884313	GNA12	0.59	7.57	0.42	6.3e-13	Height;
CESC	cis	rs17253792	0.731	rs3736876	chr14:56120178	T/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.8	5.65	0.33	4.2e-8	Putamen volume;
CESC	cis	rs6088580	0.634	rs1205338	chr20:32925625	C/G	cg08999081	chr20:33150536	PIGU	-0.64	-11.05	-0.56	1.39e-23	Glomerular filtration rate (creatinine);
CESC	cis	rs769267	0.930	rs10414830	chr19:19562332	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	7.45	0.42	1.34e-12	Tonsillectomy;
CESC	cis	rs708547	0.874	rs1614251	chr4:57891386	C/T	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.52	-5.43	-0.32	1.27e-7	Response to bleomycin (chromatid breaks);
CESC	cis	rs7267979	0.744	rs6050463	chr20:25208990	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.72	12.67	0.61	4.3e-29	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7020830	0.898	rs7038219	chr9:37182892	C/A	cg14294708	chr9:37120828	ZCCHC7	1.1	20.4	0.78	2.91e-56	Schizophrenia;
CESC	cis	rs2295499	0.553	rs17164088	chr4:2675893	A/G	cg27239842	chr4:2403781	ZFYVE28	-0.31	-5.2	-0.3	3.96e-7	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
CESC	cis	rs67311347	1.000	rs6762997	chr3:40478151	C/T	cg09455208	chr3:40491958	NA	0.46	8.05	0.44	2.79e-14	Renal cell carcinoma;
CESC	cis	rs1062177	1.000	rs41494545	chr5:151235094	A/G	cg12924095	chr5:151150029	G3BP1	-0.48	-6.42	-0.37	6.21e-10	Preschool internalizing problems;
CESC	cis	rs9399135	0.967	rs4896121	chr6:135293645	T/C	cg24558204	chr6:135376177	HBS1L	0.51	6.77	0.38	8.2e-11	Red blood cell count;
CESC	cis	rs12477438	0.508	rs2516832	chr2:99771268	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	15.46	0.69	7.45e-39	Chronic sinus infection;
CESC	cis	rs36051895	0.554	rs11789744	chr9:5134213	G/A	cg02405213	chr9:5042618	JAK2	-0.5	-5.92	-0.34	1.01e-8	Pediatric autoimmune diseases;
CESC	cis	rs7833790	0.929	rs10958048	chr8:82792914	C/T	cg02079420	chr8:82753780	SNX16	-0.56	-7.56	-0.42	6.68e-13	Diastolic blood pressure;
CESC	cis	rs1008375	0.931	rs10939734	chr4:17570709	C/T	cg16339924	chr4:17578868	LAP3	0.74	9.62	0.51	5.34e-19	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs7809950	0.953	rs2237670	chr7:107131485	A/G	cg23024343	chr7:107201750	COG5	-0.42	-5.86	-0.34	1.37e-8	Coronary artery disease;
CESC	cis	rs7555523	0.887	rs4657475	chr1:165687175	T/C	cg24409356	chr1:165738333	TMCO1	0.76	6.98	0.39	2.44e-11	Intraocular pressure;Glaucoma (high intraocular pressure);
CESC	cis	rs2017305	0.834	rs12266901	chr10:70783522	T/C	cg01024728	chr10:70782572	NA	0.56	5.38	0.31	1.67e-7	Depression (quantitative trait);
CESC	cis	rs62158211	0.565	rs2121243	chr2:114099346	C/T	cg17784749	chr2:114082611	LOC440839	0.55	7.12	0.4	1.04e-11	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;
CESC	cis	rs12188164	0.543	rs2672722	chr5:453567	G/A	cg16584290	chr5:462447	EXOC3	0.48	7.3	0.41	3.28e-12	Cystic fibrosis severity;
CESC	cis	rs1008375	0.966	rs2302393	chr4:17654341	G/A	cg16339924	chr4:17578868	LAP3	0.58	7.23	0.41	5.33e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs10791323	0.582	rs2723613	chr11:133706696	G/A	cg06766960	chr11:133703094	NA	-0.38	-5.33	-0.31	2.15e-7	Childhood ear infection;
CESC	cis	rs6545883	0.929	rs1186700	chr2:61663372	A/C	cg15711740	chr2:61764176	XPO1	-0.4	-5.18	-0.3	4.35e-7	Tuberculosis;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg23183521	chr12:57146030	PRIM1	-0.47	-6.32	-0.36	1.08e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25228755	chr3:142315566	PLS1	-0.53	-6.15	-0.35	2.85e-9	Gut microbiome composition (summer);
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg11050527	chr8:54755511	ATP6V1H	-0.45	-6.21	-0.36	1.98e-9	Height;
CESC	cis	rs9911578	1.000	rs437732	chr17:56675861	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.27	0.31	2.87e-7	Intelligence (multi-trait analysis);
CESC	cis	rs7582720	1.000	rs1541853	chr2:203835177	A/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.36	0.41	2.34e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs9929218	0.581	rs4783676	chr16:68801077	A/C	cg02972257	chr16:68554789	NA	-0.42	-5.3	-0.31	2.41e-7	Colorectal cancer;
CESC	cis	rs2243480	1.000	rs34974928	chr7:65364006	T/C	cg13147721	chr7:65941812	NA	-0.83	-7.97	-0.44	4.85e-14	Diabetic kidney disease;
CESC	cis	rs7618915	0.508	rs12498066	chr3:52627660	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	6.77	0.38	8.38e-11	Bipolar disorder;
CESC	cis	rs9858542	0.953	rs11719996	chr3:49525958	T/C	cg03060546	chr3:49711283	APEH	-0.54	-6.12	-0.35	3.44e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs12142240	0.698	rs41293273	chr1:46806393	T/C	cg10495392	chr1:46806563	NSUN4	0.59	6.36	0.36	8.9e-10	Menopause (age at onset);
CESC	cis	rs1552244	0.572	rs57268864	chr3:10164233	C/A	cg00149659	chr3:10157352	C3orf10	1.0	11.96	0.59	1.22e-26	Alzheimer's disease;
CESC	cis	rs853679	0.517	rs9393895	chr6:28127621	T/C	cg23281280	chr6:28129359	ZNF389	0.59	7.9	0.44	7.47e-14	Depression;
CESC	cis	rs11608355	0.515	rs11611012	chr12:109945203	G/A	cg05360138	chr12:110035743	NA	0.8	7.82	0.43	1.29e-13	Neuroticism;
CESC	cis	rs35955747	0.633	rs2006771	chr22:31998612	G/A	cg25791279	chr22:32026902	PISD	-0.46	-5.52	-0.32	7.95e-8	Neutrophil count;Sum basophil neutrophil counts;
CESC	cis	rs763121	1.000	rs1946990	chr22:38912771	C/T	cg06022373	chr22:39101656	GTPBP1	-0.76	-11.87	-0.59	2.48e-26	Menopause (age at onset);
CESC	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	13.77	0.65	6.55e-33	Prudent dietary pattern;
CESC	cis	rs698813	0.604	rs12712917	chr2:44482190	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.49	5.61	0.33	5.15e-8	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
CESC	cis	rs2440129	0.611	rs434473	chr17:6904934	A/G	cg12262378	chr17:6899522	ALOX12	-0.35	-5.64	-0.33	4.29e-8	Tonsillectomy;
CESC	cis	rs7914558	0.901	rs1926034	chr10:104829102	G/A	cg15744005	chr10:104629667	AS3MT	-0.33	-5.27	-0.31	2.88e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs3741404	0.791	rs7112960	chr11:63907079	A/G	cg18225595	chr11:63971243	STIP1	0.74	10.31	0.53	3.67e-21	Platelet count;
CESC	cis	rs11785400	0.762	rs4401833	chr8:143739731	A/T	cg10596483	chr8:143751796	JRK	0.42	5.31	0.31	2.32e-7	Schizophrenia;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg01830674	chr2:219433148	RQCD1;USP37	-0.48	-6.01	-0.35	6.2e-9	Ulcerative colitis;
CESC	cis	rs597539	0.652	rs667989	chr11:68685776	T/A	cg04772025	chr11:68637568	NA	0.52	6.14	0.35	3.05e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs7666738	0.800	rs12163918	chr4:98835794	T/C	cg17366294	chr4:99064904	C4orf37	0.52	7.04	0.4	1.6e-11	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3096299	0.754	rs3102382	chr16:89409742	C/G	cg02187348	chr16:89574699	SPG7	0.46	5.95	0.34	8.64e-9	Multiple myeloma (IgH translocation);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg27005181	chr13:20208413	MPHOSPH8	0.51	6.84	0.39	5.56e-11	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs13191362	0.507	rs2803083	chr6:163111199	A/C	cg21926612	chr6:163149169	PACRG;PARK2	0.65	7.91	0.44	7.16e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg27295716	chr12:118542069	VSIG10	0.51	6.53	0.37	3.39e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs6121246	0.567	rs7361893	chr20:30200751	C/T	cg13852791	chr20:30311386	BCL2L1	0.66	6.54	0.37	3.19e-10	Mean corpuscular hemoglobin;
CESC	trans	rs17685	0.753	rs4573217	chr7:75733946	G/A	cg19862616	chr7:65841803	NCRNA00174	0.87	12.7	0.62	3.58e-29	Coffee consumption;Coffee consumption (cups per day);
CESC	trans	rs2119507	0.556	rs7567271	chr2:104671174	A/T	cg06678084	chr11:65600739	SNX32	-0.52	-6.37	-0.36	8.41e-10	Attention deficit hyperactivity disorder (hyperactivity-impulsivity symptoms);
CESC	cis	rs1799949	0.965	rs33988650	chr17:41287880	A/G	cg06001716	chr17:41278141	BRCA1;NBR2	0.39	5.26	0.31	3e-7	Menopause (age at onset);
CESC	cis	rs12477438	0.520	rs4851188	chr2:99745898	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.79	12.89	0.62	7.96e-30	Chronic sinus infection;
CESC	cis	rs13191362	1.000	rs13193282	chr6:163015442	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.82	8.29	0.45	5.87e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs72781680	0.821	rs72781644	chr2:24209348	T/C	cg08917208	chr2:24149416	ATAD2B	0.64	6.22	0.36	1.95e-9	Lymphocyte counts;
CESC	cis	rs12541635	0.966	rs6987512	chr8:106998770	C/T	cg10147462	chr8:107024639	NA	0.38	5.4	0.31	1.51e-7	Age of smoking initiation;
CESC	cis	rs7520050	0.778	rs12404197	chr1:46232420	G/A	cg03146154	chr1:46216737	IPP	-0.5	-6.6	-0.38	2.2e-10	Red blood cell count;Reticulocyte count;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg20683799	chr1:63989117	ITGB3BP;EFCAB7	-0.45	-6.02	-0.35	5.74e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs4970988	0.640	rs7524734	chr1:150655686	C/T	cg09365446	chr1:150670422	GOLPH3L	0.42	5.9	0.34	1.09e-8	Urate levels;
CESC	cis	rs1062177	1.000	rs62377945	chr5:151208004	C/G	cg00977110	chr5:151150581	G3BP1	0.63	6.72	0.38	1.12e-10	Preschool internalizing problems;
CESC	cis	rs9322193	0.923	rs66516768	chr6:149993135	C/T	cg04369109	chr6:150039330	LATS1	-0.43	-6.03	-0.35	5.6e-9	Lung cancer;
CESC	cis	rs35306767	0.903	rs7077278	chr10:911291	A/G	cg20503657	chr10:835505	NA	-0.77	-7.72	-0.43	2.42e-13	Eosinophil percentage of granulocytes;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg13497155	chr3:50374949	RASSF1	-0.49	-6.25	-0.36	1.68e-9	Asthma;
CESC	cis	rs6565180	0.926	rs8046445	chr16:30386262	A/G	cg17640201	chr16:30407289	ZNF48	-0.92	-14.91	-0.68	6.18e-37	Tonsillectomy;
CESC	cis	rs4718428	0.672	rs12530806	chr7:66390724	A/G	cg18252515	chr7:66147081	NA	-0.46	-5.2	-0.3	3.95e-7	Corneal structure;
CESC	cis	rs9309711	0.643	rs10188449	chr2:3480366	T/C	cg10845886	chr2:3471009	TTC15	-0.67	-9.11	-0.49	2.05e-17	Neurofibrillary tangles;
CESC	cis	rs6142102	0.602	rs10485503	chr20:32557842	A/G	cg08999081	chr20:33150536	PIGU	0.33	5.08	0.3	6.99e-7	Skin pigmentation;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg09378105	chr7:100895380	NA	-0.44	-6.1	-0.35	3.74e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg00867453	chr9:88555863	NAA35	-0.47	-6.08	-0.35	4.25e-9	Height;
CESC	cis	rs10883723	0.810	rs7079810	chr10:104243883	C/T	ch.10.2196322F	chr10:104248062	ACTR1A	0.42	5.14	0.3	5.47e-7	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs67311347	1.000	rs12638199	chr3:40475285	A/G	cg24209194	chr3:40518798	ZNF619	0.46	5.99	0.35	6.9e-9	Renal cell carcinoma;
CESC	cis	rs7666738	0.791	rs4440223	chr4:99044796	G/A	cg24818145	chr4:99064322	C4orf37	0.38	5.04	0.3	8.49e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs40363	0.620	rs1137454	chr16:3533577	C/G	cg00484396	chr16:3507460	NAT15	-0.45	-7.24	-0.41	4.88e-12	Tuberculosis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14522427	chr10:73533468	CDH23;C10orf54	0.58	6.41	0.37	6.49e-10	Gut microbiome composition (summer);
CESC	cis	rs9303401	0.538	rs35454383	chr17:56475599	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.87	9.58	0.51	7.16e-19	Cognitive test performance;
CESC	cis	rs7399018	0.739	rs6580811	chr12:51612501	T/C	cg12163867	chr12:51592794	POU6F1	-0.52	-6.9	-0.39	3.92e-11	Cisplatin-induced ototoxicity;
CESC	cis	rs7552404	1.000	rs211723	chr1:76103030	C/T	cg03433033	chr1:76189801	ACADM	-0.62	-7.16	-0.4	8.01e-12	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs3741489	1.000	rs2306545	chr12:133419296	G/A	cg01499426	chr12:133417423	CHFR	0.9	5.59	0.32	5.77e-8	Cognitive function;
CESC	cis	rs853679	1.000	rs13200462	chr6:28218199	A/C	cg12740337	chr6:28058973	ZSCAN12L1	0.32	5.03	0.3	9.18e-7	Depression;
CESC	trans	rs1814175	0.817	rs4881658	chr11:49941123	G/A	cg15704280	chr7:45808275	SEPT13	-1.03	-20.29	-0.78	6.84e-56	Height;
CESC	cis	rs6542838	0.611	rs6742047	chr2:99531460	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.47	-5.95	-0.34	8.33e-9	Fear of minor pain;
CESC	cis	rs68170813	0.559	rs10487271	chr7:106898458	T/C	cg02696742	chr7:106810147	HBP1	-0.52	-5.09	-0.3	6.84e-7	Coronary artery disease;
CESC	cis	rs662064	0.963	rs10864459	chr1:10563609	C/T	cg20482658	chr1:10539492	PEX14	0.3	5.99	0.35	6.9e-9	Asthma;
CESC	cis	rs7666738	0.791	rs1896156	chr4:99020882	C/G	cg03467027	chr4:99064603	C4orf37	0.46	5.81	0.34	1.8e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2075371	0.863	rs12707139	chr7:133954153	A/G	cg00033643	chr7:134001901	SLC35B4	0.4	5.14	0.3	5.22e-7	Mean platelet volume;
CESC	cis	rs6662572	1.000	rs6662572	chr1:46146812	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.53	5.83	0.34	1.65e-8	Blood protein levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05340489	chr16:50775671	CYLD	-0.57	-6.64	-0.38	1.72e-10	Gut microbiome composition (summer);
CESC	cis	rs17125944	0.556	rs7152229	chr14:53313405	T/C	cg00686598	chr14:53173677	PSMC6	-0.73	-6.43	-0.37	5.93e-10	Alzheimer's disease (late onset);
CESC	cis	rs6089584	0.888	rs6587283	chr20:60613727	A/C	cg24733560	chr20:60626293	TAF4	0.45	6.47	0.37	4.62e-10	Body mass index;
CESC	cis	rs7267979	0.932	rs431579	chr20:25470056	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.78	14.77	0.67	2.04e-36	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs9486719	1.000	rs10457159	chr6:96993139	G/A	cg18709589	chr6:96969512	KIAA0776	-0.53	-5.83	-0.34	1.64e-8	Migraine;Coronary artery disease;
CESC	cis	rs3820928	0.869	rs2396436	chr2:227795464	G/A	cg11843606	chr2:227700838	RHBDD1	-0.43	-5.75	-0.33	2.46e-8	Pulmonary function;
CESC	cis	rs9611565	0.694	rs5758411	chr22:42079734	G/A	cg06481639	chr22:41940642	POLR3H	0.46	5.33	0.31	2.06e-7	Vitiligo;
CESC	cis	rs4409675	0.597	rs1467464	chr1:28211650	T/C	cg23691781	chr1:28212827	C1orf38	0.29	5.74	0.33	2.62e-8	Corneal astigmatism;
CESC	cis	rs9323205	0.861	rs56137183	chr14:51693463	C/A	cg23942311	chr14:51606299	NA	-0.46	-5.82	-0.34	1.73e-8	Cancer;
CESC	cis	rs1707322	0.963	rs12022335	chr1:46402732	C/A	cg03146154	chr1:46216737	IPP	0.72	9.82	0.52	1.31e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs5769765	1.000	rs768618	chr22:50286827	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.45	-5.2	-0.3	4.05e-7	Schizophrenia;
CESC	cis	rs9660992	0.710	rs1668869	chr1:205239779	G/C	cg21643547	chr1:205240462	TMCC2	-0.47	-6.34	-0.36	1.01e-9	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs4862750	0.872	rs9998173	chr4:187898778	T/A	cg03452623	chr4:187889614	NA	-0.88	-16.31	-0.71	7.08e-42	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6570726	0.818	rs398812	chr6:145817271	T/C	cg05347473	chr6:146136440	FBXO30	0.49	6.71	0.38	1.2e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2050392	0.590	rs685319	chr10:30719331	G/A	cg18806716	chr10:30721971	MAP3K8	-0.63	-9.25	-0.49	7.67e-18	Inflammatory bowel disease;
CESC	cis	rs7772486	0.790	rs7753833	chr6:146161432	C/A	cg05347473	chr6:146136440	FBXO30	0.56	7.3	0.41	3.39e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs853679	0.550	rs1225599	chr6:28165190	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.48	-5.69	-0.33	3.41e-8	Depression;
CESC	cis	rs35306767	0.715	rs12772979	chr10:1034412	C/T	cg26597838	chr10:835615	NA	0.72	6.49	0.37	4.21e-10	Eosinophil percentage of granulocytes;
CESC	cis	rs2549003	1.000	rs2549005	chr5:131827191	C/T	cg21138405	chr5:131827807	IRF1	0.45	5.72	0.33	2.84e-8	Asthma (sex interaction);
CESC	cis	rs7923609	0.967	rs3999089	chr10:65203808	C/T	cg01631684	chr10:65280961	REEP3	0.43	5.36	0.31	1.84e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs727505	1.000	rs28844358	chr7:124562695	A/C	cg23710748	chr7:124431027	NA	-0.47	-7.43	-0.42	1.47e-12	Lewy body disease;
CESC	cis	rs763014	0.833	rs3743902	chr16:632728	T/C	cg07256732	chr16:621771	PIGQ	-0.3	-5.14	-0.3	5.22e-7	Height;
CESC	trans	rs9693444	0.898	rs4732697	chr8:29519861	A/G	cg15793563	chr11:910950	CHID1	-0.41	-6.26	-0.36	1.5e-9	Breast cancer;
CESC	cis	rs1109430	0.661	rs72649921	chr1:210112077	C/A	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.96	6.89	0.39	4.16e-11	Orofacial clefts;
CESC	cis	rs6460942	0.908	rs73677559	chr7:12270819	A/C	cg20607287	chr7:12443886	VWDE	-0.56	-5.91	-0.34	1.07e-8	Coronary artery disease;
CESC	cis	rs1552244	0.938	rs7625049	chr3:10115619	C/T	cg08888203	chr3:10149979	C3orf24	0.53	6.83	0.39	5.8200000000000003e-11	Alzheimer's disease;
CESC	cis	rs873946	0.586	rs3829130	chr10:134563122	C/T	cg18305652	chr10:134549665	INPP5A	0.46	6.35	0.36	9.4e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs11630290	0.736	rs4777239	chr15:64148098	T/A	cg12036633	chr15:63758958	NA	0.56	5.89	0.34	1.17e-8	Iris characteristics;
CESC	cis	rs7666738	0.791	rs1115615	chr4:99006614	G/A	cg05340658	chr4:99064831	C4orf37	0.8	12.44	0.61	2.83e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs74781061	0.929	rs8028430	chr15:74845745	A/G	cg17294928	chr15:75287854	SCAMP5	-0.48	-5.15	-0.3	5.08e-7	Endometriosis;
CESC	cis	rs9916302	0.861	rs752314	chr17:37410700	C/T	cg15445000	chr17:37608096	MED1	0.41	6.59	0.38	2.34e-10	Glomerular filtration rate (creatinine);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16985259	chr1:44412491	IPO13	0.63	7.04	0.4	1.63e-11	Gut microbiome composition (summer);
CESC	cis	rs6032067	0.602	rs2741523	chr20:43920446	C/T	cg10761708	chr20:43804764	PI3	0.39	5.04	0.3	8.82e-7	Blood protein levels;
CESC	cis	rs2486288	0.656	rs7171312	chr15:45570225	C/G	cg21132104	chr15:45694354	SPATA5L1	-0.57	-6.66	-0.38	1.55e-10	Glomerular filtration rate;
CESC	cis	rs8072100	0.713	rs8075058	chr17:45482857	A/G	cg25173405	chr17:45401733	C17orf57	-0.44	-5.48	-0.32	9.7e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs8067354	0.645	rs2665403	chr17:57889985	G/A	cg13753209	chr17:57696993	CLTC	0.56	6.3	0.36	1.21e-9	Hemoglobin concentration;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26330088	chr7:77427924	PHTF2;TMEM60	0.6	6.37	0.36	8.55e-10	Gut microbiome composition (summer);
CESC	cis	rs11677370	0.603	rs10164826	chr2:3849951	G/C	cg17052675	chr2:3827356	NA	-0.43	-5.5	-0.32	8.9e-8	Type 2 diabetes;
CESC	cis	rs3820068	0.581	rs56128111	chr1:15928948	T/G	cg16988262	chr1:15930761	NA	0.35	5.65	0.33	4.18e-8	Systolic blood pressure;
CESC	cis	rs11098499	0.708	rs1546506	chr4:120241240	T/C	cg09307838	chr4:120376055	NA	0.79	10.57	0.54	5.11e-22	Corneal astigmatism;
CESC	cis	rs11203032	1.000	rs11203031	chr10:90964395	G/T	cg16672925	chr10:90967113	CH25H	0.73	7.36	0.41	2.33e-12	Heart failure;
CESC	cis	rs9457247	0.967	rs447042	chr6:167405435	C/T	cg25258033	chr6:167368657	RNASET2	0.39	5.89	0.34	1.15e-8	Crohn's disease;
CESC	cis	rs3008870	1.000	rs12041926	chr1:67434602	A/G	cg02640540	chr1:67518911	SLC35D1	0.5	5.4	0.31	1.47e-7	Lymphocyte percentage of white cells;
CESC	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.55	-6.13	-0.35	3.19e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7208859	0.623	rs9915546	chr17:29132144	G/T	cg14008862	chr17:28927542	LRRC37B2	0.65	5.14	0.3	5.34e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs796364	0.806	rs74266489	chr2:201005732	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.72	-6.48	-0.37	4.47e-10	Schizophrenia;
CESC	cis	rs7267979	1.000	rs6050544	chr20:25320228	T/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.86	-16.77	-0.72	1.62e-43	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs9888739	1.000	rs73534420	chr16:31311374	G/T	cg15817542	chr16:31343056	ITGAM	-0.41	-5.32	-0.31	2.25e-7	Systemic lupus erythematosus;
CESC	cis	rs1048238	0.506	rs10737911	chr1:16167855	C/T	cg22431228	chr1:16359049	CLCNKA	0.36	6.46	0.37	5e-10	Systolic blood pressure;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14777817	chr13:80055594	NDFIP2	0.59	7.22	0.41	5.61e-12	Gut microbiome composition (summer);
CESC	cis	rs4722166	0.630	rs6461667	chr7:22796743	A/G	cg05265849	chr7:22767390	IL6	0.53	6.33	0.36	1.06e-9	Lung cancer;
CESC	cis	rs3733585	0.577	rs5014939	chr4:9953253	T/A	cg02734326	chr4:10020555	SLC2A9	-0.39	-5.64	-0.33	4.45e-8	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs6088580	0.524	rs6087616	chr20:33263033	T/C	cg08999081	chr20:33150536	PIGU	-0.43	-6.02	-0.35	5.65e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs514406	0.571	rs11206004	chr1:53210958	G/A	cg25767906	chr1:53392781	SCP2	0.42	5.74	0.33	2.58e-8	Monocyte count;
CESC	cis	rs4835473	0.897	rs1817027	chr4:144634489	C/T	cg25736465	chr4:144833511	NA	-0.45	-6.81	-0.39	6.71e-11	Immature fraction of reticulocytes;
CESC	cis	rs7959452	0.719	rs57954211	chr12:69748397	C/A	cg14784868	chr12:69753453	YEATS4	0.82	12.52	0.61	1.43e-28	Blood protein levels;
CESC	trans	rs9329221	0.868	rs7831557	chr8:10280228	C/T	cg17143192	chr8:8559678	CLDN23	-0.6	-6.95	-0.39	2.9100000000000002e-11	Neuroticism;
CESC	cis	rs4132509	0.744	rs12021907	chr1:243995640	A/G	cg21452805	chr1:244014465	NA	-0.65	-7.26	-0.41	4.2e-12	RR interval (heart rate);
CESC	cis	rs6840258	0.760	rs10032244	chr4:87917931	C/T	cg08197287	chr4:87952173	AFF1	-0.35	-5.17	-0.3	4.56e-7	Mean corpuscular volume;Basophil percentage of granulocytes;
CESC	cis	rs769267	0.930	rs1063966	chr19:19616742	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.47	6.05	0.35	5.05e-9	Tonsillectomy;
CESC	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg09033563	chr22:24373618	LOC391322	-0.41	-5.34	-0.31	1.97e-7	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs2762353	0.526	rs6912391	chr6:25710763	C/G	cg25753631	chr6:25732923	NA	0.26	5.13	0.3	5.49e-7	Blood metabolite levels;
CESC	cis	rs7851660	0.809	rs9299258	chr9:100666543	T/G	cg13688889	chr9:100608707	NA	-0.63	-8.95	-0.48	6.33e-17	Strep throat;
CESC	cis	rs9291683	0.595	rs11722930	chr4:10035454	G/A	cg00071950	chr4:10020882	SLC2A9	0.87	15.52	0.69	4.3e-39	Bone mineral density;
CESC	cis	rs1050631	0.564	rs589213	chr18:33743610	G/A	cg25426722	chr18:33708991	SLC39A6;ELP2	0.6	8.4	0.46	2.72e-15	Esophageal squamous cell cancer (length of survival);
CESC	trans	rs9467711	0.606	rs9379857	chr6:26367654	G/C	cg06606381	chr12:133084897	FBRSL1	-0.76	-6.86	-0.39	4.71e-11	Autism spectrum disorder or schizophrenia;
CESC	cis	rs2718058	0.639	rs2718036	chr7:37775288	T/A	cg15028436	chr7:37888078	TXNDC3	0.44	6.01	0.35	6.04e-9	Alzheimer's disease (late onset);
CESC	cis	rs9457247	1.000	rs2013815	chr6:167373812	T/A	cg07741184	chr6:167504864	NA	-0.3	-5.39	-0.31	1.55e-7	Crohn's disease;
CESC	cis	rs7666738	0.830	rs6817645	chr4:99016054	T/C	cg03676636	chr4:99064102	C4orf37	0.33	5.16	0.3	4.86e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7412746	0.566	rs2864871	chr1:150766964	T/C	cg17724175	chr1:150552817	MCL1	0.42	6.35	0.36	9.49e-10	Melanoma;
CESC	cis	rs7605378	1.000	rs769954	chr2:200692159	C/G	cg23649088	chr2:200775458	C2orf69	-0.53	-7.08	-0.4	1.29e-11	Osteoporosis;
CESC	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg23708337	chr7:1209742	NA	0.56	5.63	0.33	4.56e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs11871801	0.517	rs10454087	chr17:40735641	C/T	cg16308533	chr17:40838983	CNTNAP1	0.4	5.19	0.3	4.19e-7	Crohn's disease;
CESC	cis	rs9911578	1.000	rs2611782	chr17:56717956	T/C	cg05425664	chr17:57184151	TRIM37	-0.51	-7.21	-0.4	6.03e-12	Intelligence (multi-trait analysis);
CESC	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg03188948	chr7:1209495	NA	0.7	6.71	0.38	1.17e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs6952808	0.792	rs4721184	chr7:1950784	T/C	cg02951883	chr7:2050386	MAD1L1	-0.49	-6.61	-0.38	2.11e-10	Bipolar disorder and schizophrenia;
CESC	cis	rs2777491	0.915	rs7178634	chr15:41634587	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.6	-9.0	-0.48	4.34e-17	Ulcerative colitis;
CESC	cis	rs10504229	0.953	rs114853497	chr8:58176176	A/T	cg14926445	chr8:58193284	C8orf71	-0.51	-5.47	-0.32	1.03e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs1538970	0.816	rs868351	chr1:46009818	G/T	cg06784218	chr1:46089804	CCDC17	0.33	5.46	0.32	1.08e-7	Platelet count;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg07762761	chr8:104033118	ATP6V1C1	0.43	6.74	0.38	9.84e-11	Gambling;
CESC	cis	rs751837	0.591	rs34407983	chr14:103429786	T/C	cg10087771	chr14:103399429	CDC42BPB	0.68	5.95	0.34	8.68e-9	Large B-cell lymphoma;
CESC	cis	rs7552404	0.961	rs211710	chr1:76109038	G/A	cg22875332	chr1:76189707	ACADM	-0.58	-6.56	-0.37	2.79e-10	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs1879734	0.648	rs7549345	chr1:54145288	T/C	cg23596471	chr1:54105337	GLIS1	0.34	5.33	0.31	2.07e-7	Mitral valve prolapse;
CESC	cis	rs6460942	0.591	rs62448726	chr7:12330881	A/G	cg20607287	chr7:12443886	VWDE	-0.63	-6.83	-0.39	5.83e-11	Coronary artery disease;
CESC	cis	rs4144743	1.000	rs7223003	chr17:45324293	G/A	cg18085866	chr17:45331354	ITGB3	-0.66	-7.59	-0.42	5.59e-13	Body mass index;
CESC	trans	rs163030	0.902	rs335604	chr5:76750386	T/C	cg26150533	chr8:82396069	FABP4	-0.39	-6.0	-0.35	6.37e-9	Caudate nucleus volume;
CESC	cis	rs10089	0.953	rs4835940	chr5:127406596	A/G	cg19767477	chr5:127420684	SLC12A2	-0.39	-5.07	-0.3	7.34e-7	Ileal carcinoids;
CESC	cis	rs2361710	0.669	rs12940486	chr17:78118569	T/C	cg06718696	chr17:78121285	EIF4A3	0.46	5.44	0.32	1.24e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
CESC	cis	rs2274273	0.837	rs10131913	chr14:55787420	A/G	cg04306507	chr14:55594613	LGALS3	0.32	6.38	0.36	8.01e-10	Protein biomarker;
CESC	cis	rs7520050	0.966	rs6675946	chr1:46371774	G/T	cg24296786	chr1:45957014	TESK2	0.44	5.58	0.32	5.79e-8	Red blood cell count;Reticulocyte count;
CESC	cis	rs12822507	0.732	rs4763855	chr12:12767758	C/A	cg11838227	chr12:12764436	CREBL2	0.42	5.64	0.33	4.27e-8	Systemic lupus erythematosus;
CESC	cis	rs7248779	0.532	rs10153475	chr19:2413961	G/C	cg22729335	chr19:2427816	TIMM13	1.13	20.19	0.78	1.62e-55	Cortisol levels (saliva);
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg01330391	chr1:26324448	PAFAH2	-0.48	-6.32	-0.36	1.08e-9	Height;
CESC	cis	rs8177253	0.896	rs34252038	chr3:133490621	G/T	cg11941060	chr3:133502564	NA	-0.45	-6.01	-0.35	6.04e-9	Iron status biomarkers;
CESC	cis	rs514406	0.679	rs499239	chr1:53310594	A/G	cg08859206	chr1:53392774	SCP2	-0.64	-9.57	-0.51	7.94e-19	Monocyte count;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg19988671	chr7:155589783	NA	-0.39	-6.19	-0.36	2.33e-9	Gambling;
CESC	cis	rs300703	0.719	rs389621	chr2:206636	C/T	cg21211680	chr2:198530	NA	-0.96	-9.72	-0.51	2.75e-19	Blood protein levels;
CESC	cis	rs7481584	0.581	rs515481	chr11:3047184	A/G	cg25174290	chr11:3078921	CARS	-0.45	-6.3	-0.36	1.21e-9	Calcium levels;
CESC	cis	rs6582630	0.519	rs8189599	chr12:38280748	A/G	cg13010199	chr12:38710504	ALG10B	0.5	6.26	0.36	1.53e-9	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs1552244	1.000	rs61077902	chr3:10126153	T/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-10.99	-0.56	2.11e-23	Alzheimer's disease;
CESC	cis	rs36051895	0.589	rs6476945	chr9:5191793	C/T	cg02405213	chr9:5042618	JAK2	-0.54	-6.76	-0.38	8.98e-11	Pediatric autoimmune diseases;
CESC	cis	rs10504229	0.954	rs114134184	chr8:58181969	G/A	cg22535103	chr8:58192502	C8orf71	-1.05	-13.08	-0.63	1.71e-30	Developmental language disorder (linguistic errors);
CESC	trans	rs16875333	0.588	rs7715383	chr5:5350637	C/G	cg25408055	chr13:113977663	LAMP1	0.7	6.08	0.35	4.23e-9	Breast cancer;
CESC	cis	rs11190604	1.000	rs6584383	chr10:102303065	C/G	cg07080220	chr10:102295463	HIF1AN	0.58	5.52	0.32	8.22e-8	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs4409675	0.576	rs11247705	chr1:28212272	G/A	cg11176159	chr1:28213800	NA	0.22	5.09	0.3	6.84e-7	Corneal astigmatism;
CESC	cis	rs12497850	0.931	rs6442130	chr3:48778027	A/G	cg06641503	chr3:48959341	ARIH2	-0.37	-5.46	-0.32	1.1e-7	Parkinson's disease;
CESC	cis	rs6456156	0.875	rs55802221	chr6:167517320	G/A	cg07741184	chr6:167504864	NA	-0.37	-6.61	-0.38	2.11e-10	Primary biliary cholangitis;
CESC	cis	rs1005277	0.579	rs1780122	chr10:38529509	C/A	cg25427524	chr10:38739819	LOC399744	-0.7	-10.26	-0.53	5.29e-21	Extrinsic epigenetic age acceleration;
CESC	cis	rs13108904	0.905	rs1680074	chr4:1279621	G/A	cg16405210	chr4:1374714	KIAA1530	0.47	5.97	0.34	7.64e-9	Obesity-related traits;
CESC	cis	rs1801251	1.000	rs12990821	chr2:233617585	C/G	cg25237894	chr2:233734115	C2orf82	0.45	7.9	0.44	7.6e-14	Coronary artery disease;
CESC	cis	rs13108904	0.901	rs4516656	chr4:1279860	A/G	cg00684032	chr4:1343700	KIAA1530	0.39	5.43	0.32	1.27e-7	Obesity-related traits;
CESC	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg24503407	chr1:205819492	PM20D1	-0.8	-13.51	-0.64	5.47e-32	Menarche (age at onset);
CESC	cis	rs1062177	1.000	rs2964585	chr5:151141895	C/T	cg12924095	chr5:151150029	G3BP1	0.48	6.15	0.35	2.82e-9	Preschool internalizing problems;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg26030974	chr17:45266791	CDC27	-0.47	-6.51	-0.37	3.78e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs76419734	0.510	rs28450989	chr4:106630007	G/C	cg24545054	chr4:106630052	GSTCD;INTS12	0.68	8.21	0.45	9.87e-15	Post bronchodilator FEV1;
CESC	cis	rs67478160	0.584	rs12433009	chr14:104196405	C/G	cg08213375	chr14:104286397	PPP1R13B	0.37	6.74	0.38	9.63e-11	Schizophrenia;
CESC	cis	rs72627123	0.867	rs17093884	chr14:74482039	A/G	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.73	5.65	0.33	4.21e-8	Morning vs. evening chronotype;
CESC	cis	rs6963495	0.818	rs73192122	chr7:105171471	G/A	cg19920283	chr7:105172520	RINT1	0.69	6.54	0.37	3.15e-10	Bipolar disorder (body mass index interaction);
CESC	cis	rs7959452	0.590	rs28778648	chr12:69771911	C/A	cg22834771	chr12:69754056	YEATS4	-0.48	-6.46	-0.37	4.9e-10	Blood protein levels;
CESC	cis	rs2487048	0.773	rs2472493	chr9:107695848	G/A	cg14470647	chr9:107690075	ABCA1	-0.47	-5.37	-0.31	1.7e-7	Intraocular pressure;
CESC	cis	rs4722166	0.695	rs6946509	chr7:22809490	T/C	cg05265849	chr7:22767390	IL6	0.44	6.17	0.35	2.53e-9	Lung cancer;
CESC	cis	rs7633770	0.841	rs11130100	chr3:46679198	A/T	cg11219411	chr3:46661640	NA	-0.42	-6.49	-0.37	4.14e-10	Coronary artery disease;
CESC	cis	rs8077577	0.708	rs2290502	chr17:18133495	G/A	cg16794390	chr17:18148240	FLII	-0.45	-6.69	-0.38	1.35e-10	Obesity-related traits;
CESC	cis	rs6089829	0.925	rs6062396	chr20:61667949	T/C	cg16240275	chr20:61666158	NCRNA00029	0.5	8.91	0.48	8.46e-17	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs11696501	0.739	rs2235600	chr20:44238299	T/G	cg11783356	chr20:44313418	WFDC10B	-0.34	-5.26	-0.31	3.02e-7	Brain structure;
CESC	cis	rs10504229	1.000	rs61733801	chr8:58192513	A/G	cg05313129	chr8:58192883	C8orf71	-0.55	-6.29	-0.36	1.34e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs1003719	0.737	rs9974374	chr21:38479885	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.63	8.62	0.47	6.19e-16	Eye color traits;
CESC	cis	rs1707322	0.686	rs1541131	chr1:46084934	G/A	cg03146154	chr1:46216737	IPP	-0.77	-10.61	-0.55	3.67e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9596863	1.000	rs9596858	chr13:54421858	A/G	ch.13.53330881F	chr13:54432880	NA	0.66	5.25	0.31	3.08e-7	Epilepsy and lamotrigine-induced maculopapular eruptions;
CESC	cis	rs1348850	0.645	rs13431091	chr2:178434615	A/G	cg22681709	chr2:178499509	PDE11A	-0.52	-6.49	-0.37	4.18e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs12348691	0.503	rs7849497	chr9:100615660	G/C	cg13688889	chr9:100608707	NA	-0.9	-13.65	-0.64	1.78e-32	Alopecia areata;
CESC	cis	rs3916	0.910	rs7306541	chr12:121130046	A/G	cg21892295	chr12:121157589	UNC119B	-0.36	-5.32	-0.31	2.2e-7	Urinary metabolites (H-NMR features);
CESC	cis	rs7264396	0.580	rs2064511	chr20:34448810	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.83	9.33	0.5	4.43e-18	Total cholesterol levels;
CESC	cis	rs3096299	0.869	rs748941	chr16:89440754	T/A	cg08822215	chr16:89438651	ANKRD11	-0.41	-6.29	-0.36	1.3e-9	Multiple myeloma (IgH translocation);
CESC	cis	rs12618769	0.597	rs11902825	chr2:99129137	T/C	cg10123293	chr2:99228465	UNC50	0.39	5.13	0.3	5.6e-7	Bipolar disorder;
CESC	cis	rs6693567	0.565	rs1260404	chr1:150304150	T/A	cg09579323	chr1:150459698	TARS2	0.49	6.28	0.36	1.35e-9	Migraine;
CESC	cis	rs11871801	0.517	rs6963	chr17:40731597	A/T	cg14558262	chr17:40713999	COASY	-0.49	-5.67	-0.33	3.74e-8	Crohn's disease;
CESC	cis	rs13064411	0.696	rs3732803	chr3:113211957	T/C	cg18753928	chr3:113234510	CCDC52	-0.5	-5.9	-0.34	1.11e-8	Response to simvastatin treatment (PCSK9 protein level change);
CESC	cis	rs875971	0.862	rs7809814	chr7:65615397	G/A	cg11764359	chr7:65958608	NA	-0.78	-11.42	-0.57	8.03e-25	Aortic root size;
CESC	cis	rs9479482	1.000	rs9478362	chr6:150340526	T/C	cg03788504	chr6:150331562	NA	-0.36	-7.03	-0.4	1.72e-11	Alopecia areata;
CESC	cis	rs8114671	0.967	rs6088753	chr20:33768252	C/T	cg24642439	chr20:33292090	TP53INP2	0.44	5.37	0.31	1.73e-7	Height;
CESC	cis	rs3820928	0.935	rs10203363	chr2:227896976	C/T	cg11843606	chr2:227700838	RHBDD1	-0.49	-6.49	-0.37	4.29e-10	Pulmonary function;
CESC	trans	rs650950	0.528	rs646660	chr11:35528452	C/T	cg11993436	chr7:155437098	RBM33	0.46	6.3	0.36	1.25e-9	Bronchopulmonary dysplasia;
CESC	cis	rs4665809	0.590	rs1865324	chr2:26417533	C/A	cg26314531	chr2:26401878	FAM59B	-0.83	-9.23	-0.49	8.99e-18	Gut microbiome composition (summer);
CESC	cis	rs875971	0.862	rs1167408	chr7:65556108	G/A	cg11764359	chr7:65958608	NA	-0.78	-10.74	-0.55	1.44e-22	Aortic root size;
CESC	cis	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg21782813	chr7:2030301	MAD1L1	0.44	6.13	0.35	3.23e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs780096	0.546	rs715325	chr2:27725572	C/A	cg12648201	chr2:27665141	KRTCAP3	-0.39	-7.07	-0.4	1.39e-11	Total body bone mineral density;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg22373519	chr2:236761021	AGAP1	-0.46	-6.15	-0.35	2.83e-9	Systemic lupus erythematosus;
CESC	cis	rs7247513	0.759	rs8110545	chr19:12754898	C/T	cg01871581	chr19:12707946	ZNF490	-0.85	-13.51	-0.64	5.46e-32	Bipolar disorder;
CESC	cis	rs4853012	0.838	rs60705299	chr2:74345370	C/G	cg05890377	chr2:74357713	NA	0.77	10.44	0.54	1.39e-21	Gestational age at birth (maternal effect);
CESC	cis	rs9393777	0.513	rs13215020	chr6:26656073	G/A	cg14345882	chr6:26364793	BTN3A2	0.41	5.12	0.3	5.79e-7	Intelligence (multi-trait analysis);
CESC	cis	rs9837602	1.000	rs704582	chr3:99571926	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.51	7.09	0.4	1.21e-11	Breast cancer;
CESC	cis	rs7772486	0.790	rs80050589	chr6:146230454	T/C	cg23711669	chr6:146136114	FBXO30	-0.94	-13.73	-0.64	9.31e-33	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7103648	0.897	rs11606287	chr11:47407439	C/A	cg20307385	chr11:47447363	PSMC3	0.94	14.8	0.67	1.56e-36	Diastolic blood pressure;Systolic blood pressure;
CESC	cis	rs6785206	1.000	rs2712370	chr3:128425204	C/G	cg16766828	chr3:128327626	NA	-0.53	-5.28	-0.31	2.66e-7	Lymphocyte percentage of white cells;
CESC	cis	rs4975616	0.836	rs460073	chr5:1336459	T/C	cg26373071	chr5:1325741	CLPTM1L	0.43	6.88	0.39	4.26e-11	Lung cancer;
CESC	cis	rs9322193	0.962	rs9322219	chr6:150103399	C/T	cg09699651	chr6:150184138	LRP11	0.4	5.1	0.3	6.34e-7	Lung cancer;
CESC	cis	rs3925075	0.903	rs36100148	chr16:31345023	C/T	cg02846316	chr16:31340340	ITGAM	0.42	6.74	0.38	9.88e-11	IgA nephropathy;
CESC	cis	rs72781680	0.898	rs12623079	chr2:24103749	G/A	cg08917208	chr2:24149416	ATAD2B	0.93	8.63	0.47	5.68e-16	Lymphocyte counts;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20053329	chr13:42535228	KIAA0564	0.59	6.44	0.37	5.63e-10	Gut microbiome composition (summer);
CESC	cis	rs7833790	0.963	rs7836040	chr8:82698328	G/A	cg02079420	chr8:82753780	SNX16	0.54	7.36	0.41	2.35e-12	Diastolic blood pressure;
CESC	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg03188948	chr7:1209495	NA	0.71	7.71	0.43	2.51e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7772486	0.790	rs2265472	chr6:146220758	G/C	cg05347473	chr6:146136440	FBXO30	0.55	7.05	0.4	1.57e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs35306767	0.903	rs11253460	chr10:887382	C/G	cg20503657	chr10:835505	NA	0.79	7.99	0.44	4.07e-14	Eosinophil percentage of granulocytes;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg24330485	chr2:207023983	EEF1B2;NDUFS1	0.47	6.22	0.36	1.91e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs1018836	0.828	rs12548806	chr8:91564256	C/T	cg16814680	chr8:91681699	NA	-0.63	-9.08	-0.49	2.55e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs36051895	0.632	rs10815167	chr9:5150058	A/G	cg02405213	chr9:5042618	JAK2	-0.51	-6.4	-0.37	6.99e-10	Pediatric autoimmune diseases;
CESC	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg05025164	chr4:1340916	KIAA1530	0.91	12.29	0.6	8.61e-28	Longevity;
CESC	cis	rs2249625	0.545	rs2496488	chr6:72875985	A/T	cg18830697	chr6:72922368	RIMS1	-0.48	-7.18	-0.4	6.94e-12	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CESC	cis	rs367615	0.704	rs60538082	chr5:108829101	A/G	cg17395555	chr5:108820864	NA	0.64	11.16	0.57	5.88e-24	Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs926938	0.505	rs360593	chr1:115472265	T/G	cg12756093	chr1:115239321	AMPD1	0.45	6.18	0.35	2.44e-9	Autism;
CESC	cis	rs6701037	0.555	rs10912898	chr1:175120469	A/G	cg00321850	chr1:175162397	KIAA0040	-0.42	-6.28	-0.36	1.4e-9	Alcohol dependence;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25135143	chr10:115934548	MIR2110;C10orf118	-0.64	-7.14	-0.4	8.89e-12	Gut microbiome composition (summer);
CESC	cis	rs7267979	0.966	rs8123949	chr20:25388133	C/T	cg08601574	chr20:25228251	PYGB	-0.37	-5.37	-0.31	1.76e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs9311474	0.508	rs17052259	chr3:52593138	A/G	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.36	6.47	0.37	4.74e-10	Electroencephalogram traits;
CESC	cis	rs483180	0.531	rs541503	chr1:120208297	A/G	cg19096424	chr1:120255104	PHGDH	-0.42	-5.15	-0.3	5.08e-7	Macular telangiectasia type 2;
CESC	cis	rs1348850	0.567	rs1527401	chr2:178522104	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.54	7.29	0.41	3.53e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	trans	rs1814175	0.702	rs4881644	chr11:49786367	C/T	cg15704280	chr7:45808275	SEPT13	-1.02	-19.84	-0.77	2.5e-54	Height;
CESC	cis	rs854765	0.583	rs10048206	chr17:17866897	A/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.54	7.08	0.4	1.28e-11	Total body bone mineral density;
CESC	cis	rs1003719	0.788	rs2835588	chr21:38462716	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.63	8.77	0.47	2.14e-16	Eye color traits;
CESC	cis	rs7089973	0.604	rs10490909	chr10:116593532	C/T	cg25233709	chr10:116636983	FAM160B1	0.38	5.99	0.35	6.97e-9	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs6032067	0.929	rs17424356	chr20:43804190	A/G	cg10761708	chr20:43804764	PI3	0.51	6.06	0.35	4.58e-9	Blood protein levels;
CESC	cis	rs477692	0.637	rs10829598	chr10:131319774	C/G	cg05714579	chr10:131428358	MGMT	0.41	5.36	0.31	1.83e-7	Response to temozolomide;
CESC	trans	rs1814175	0.647	rs4881649	chr11:49845560	A/G	cg03929089	chr4:120376271	NA	-0.71	-9.2	-0.49	1.09e-17	Height;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg00261325	chr5:178199408	AACSL	-0.45	-6.79	-0.38	7.51e-11	Systemic lupus erythematosus;
CESC	cis	rs40363	0.620	rs1137454	chr16:3533577	C/G	cg21433313	chr16:3507492	NAT15	-0.51	-8.11	-0.45	1.85e-14	Tuberculosis;
CESC	cis	rs763121	0.853	rs9610993	chr22:39042818	C/A	cg06544989	chr22:39130855	UNC84B	0.5	8.66	0.47	4.63e-16	Menopause (age at onset);
CESC	cis	rs7666738	0.830	rs35865860	chr4:98968822	C/T	cg03467027	chr4:99064603	C4orf37	0.43	5.42	0.32	1.34e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs4665809	1.000	rs750451	chr2:26324241	G/A	cg09258813	chr8:37823409	ADRB3	-0.37	-6.14	-0.35	2.99e-9	Gut microbiome composition (summer);
CESC	cis	rs1055129	0.537	rs10852766	chr17:73951864	T/C	cg02678768	chr17:74002944	EVPL	-0.43	-5.84	-0.34	1.55e-8	White matter hyperintensity burden;
CESC	cis	rs992157	0.764	rs4672886	chr2:219185545	C/T	cg00012203	chr2:219082015	ARPC2	-0.61	-7.66	-0.43	3.59e-13	Colorectal cancer;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg16600119	chr3:129033604	NA	0.43	6.15	0.35	2.77e-9	Systemic lupus erythematosus;
CESC	cis	rs4722166	0.508	rs1474347	chr7:22768124	A/C	cg13104385	chr7:22767384	IL6	-0.39	-5.55	-0.32	6.83e-8	Lung cancer;
CESC	cis	rs2842992	0.672	rs4708845	chr6:160219601	T/G	cg11366901	chr6:160182831	ACAT2	0.76	9.31	0.5	4.95e-18	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs17711722	0.727	rs2658585	chr7:65461941	A/T	cg26939375	chr7:64535504	NA	0.77	10.93	0.56	3.25e-23	Calcium levels;
CESC	cis	rs2204008	0.837	rs12146734	chr12:38237079	A/G	cg13010199	chr12:38710504	ALG10B	0.49	6.1	0.35	3.78e-9	Bladder cancer;
CESC	cis	rs9302635	0.513	rs12444701	chr16:72155240	C/T	cg01557791	chr16:72042693	DHODH	-0.57	-6.65	-0.38	1.66e-10	Blood protein levels;
CESC	cis	rs258892	0.842	rs34956	chr5:72203696	T/C	cg21869765	chr5:72125136	TNPO1	0.44	5.57	0.32	6.25e-8	Small cell lung carcinoma;
CESC	cis	rs3761847	0.500	rs7037673	chr9:123740484	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.4	5.35	0.31	1.9e-7	Rheumatoid arthritis;
CESC	cis	rs68170813	0.605	rs4730227	chr7:106904031	G/C	cg02696742	chr7:106810147	HBP1	-0.54	-5.33	-0.31	2.15e-7	Coronary artery disease;
CESC	cis	rs1005277	0.579	rs11011461	chr10:38431427	G/A	cg25517755	chr10:38738941	LOC399744	-0.48	-6.27	-0.36	1.42e-9	Extrinsic epigenetic age acceleration;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00053292	chr17:61678300	TACO1	-0.58	-6.42	-0.37	6.35e-10	Gut microbiome composition (summer);
CESC	cis	rs11809207	0.523	rs2802343	chr1:26498570	T/C	cg00147160	chr1:26503991	CNKSR1	0.28	5.28	0.31	2.67e-7	Height;
CESC	cis	rs7937682	0.883	rs1784775	chr11:111472460	T/C	cg22437258	chr11:111473054	SIK2	0.74	9.86	0.52	9.59e-20	Primary sclerosing cholangitis;
CESC	cis	rs3204270	0.639	rs11867543	chr17:79655046	C/T	cg18367735	chr17:79674897	NA	0.7	5.79	0.34	1.95e-8	Dental caries;
CESC	cis	rs875971	1.000	rs4718344	chr7:65874381	C/A	cg12463550	chr7:65579703	CRCP	0.59	7.52	0.42	8.29e-13	Aortic root size;
CESC	trans	rs11098499	0.954	rs10014845	chr4:120301077	T/G	cg25214090	chr10:38739885	LOC399744	0.68	9.2	0.49	1.14e-17	Corneal astigmatism;
CESC	cis	rs116095464	0.558	rs28729548	chr5:229025	C/T	cg20965017	chr5:231967	SDHA	-0.45	-5.08	-0.3	7.29e-7	Breast cancer;
CESC	cis	rs10463316	0.894	rs7727770	chr5:150767116	G/T	cg03212797	chr5:150827313	SLC36A1	-0.47	-6.2	-0.36	2.17e-9	Metabolite levels (Pyroglutamine);
CESC	cis	rs7312933	0.558	rs1796394	chr12:42826359	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.5	-6.72	-0.38	1.08e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs4689388	0.890	rs4688989	chr4:6290594	T/C	cg00701064	chr4:6280414	WFS1	0.7	11.96	0.59	1.17e-26	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs7631605	0.875	rs4678921	chr3:37022803	T/C	cg22985146	chr3:37219077	LRRFIP2	-0.33	-5.15	-0.3	5.21e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs8031584	0.958	rs11629793	chr15:31238423	G/A	cg14298792	chr15:30685198	CHRFAM7A	-0.45	-5.39	-0.31	1.55e-7	Huntington's disease progression;
CESC	cis	rs2440129	0.611	rs434473	chr17:6904934	A/G	cg25987502	chr17:6899865	ALOX12	-0.47	-7.47	-0.42	1.14e-12	Tonsillectomy;
CESC	cis	rs801193	0.660	rs10950049	chr7:66230860	T/C	cg12463550	chr7:65579703	CRCP	0.55	7.11	0.4	1.07e-11	Aortic root size;
CESC	cis	rs9487051	0.702	rs368467	chr6:109519451	T/C	cg01475377	chr6:109611718	NA	-0.37	-5.55	-0.32	6.99e-8	Reticulocyte fraction of red cells;
CESC	cis	rs62005083	1.000	rs55878372	chr14:74509023	G/A	cg05179529	chr14:74551516	LIN52;ALDH6A1	0.7	5.22	0.31	3.68e-7	Mean corpuscular volume;
CESC	cis	rs250677	0.687	rs41181	chr5:148444257	C/G	cg18129178	chr5:148520854	ABLIM3	0.51	5.78	0.33	2.09e-8	Breast cancer;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg03576636	chr19:1918189	SCAMP4	0.49	6.9	0.39	3.91e-11	Fibrinogen levels;
CESC	cis	rs11677416	1.000	rs1878319	chr2:113544826	G/A	cg27083787	chr2:113543245	IL1A	0.42	5.28	0.31	2.72e-7	Response to antipsychotic treatment in schizophrenia (working memory);
CESC	cis	rs116095464	0.510	rs55750776	chr5:230467	T/C	cg20965017	chr5:231967	SDHA	-0.45	-5.08	-0.3	7.29e-7	Breast cancer;
CESC	cis	rs13064411	0.735	rs6778800	chr3:113149236	A/G	cg18753928	chr3:113234510	CCDC52	-0.47	-5.56	-0.32	6.63e-8	Response to simvastatin treatment (PCSK9 protein level change);
CESC	cis	rs853679	0.517	rs9393884	chr6:28046789	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.5	-5.8	-0.34	1.86e-8	Depression;
CESC	cis	rs9916302	0.706	rs1054488	chr17:37687968	A/G	cg20243544	chr17:37824526	PNMT	0.53	5.26	0.31	3.03e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs7937682	0.883	rs12804962	chr11:111442683	A/T	cg22437258	chr11:111473054	SIK2	-0.64	-7.89	-0.44	7.79e-14	Primary sclerosing cholangitis;
CESC	cis	rs9649213	0.593	rs35941058	chr7:97918159	T/C	cg08684580	chr7:98029266	BAIAP2L1	-0.33	-5.26	-0.31	2.92e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs921968	0.613	rs1344642	chr2:219555262	G/A	cg02176678	chr2:219576539	TTLL4	-0.47	-8.34	-0.46	4.03e-15	Mean corpuscular hemoglobin concentration;
CESC	cis	rs9911578	0.933	rs2632508	chr17:56533235	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.4	5.43	0.32	1.25e-7	Intelligence (multi-trait analysis);
CESC	cis	rs7223966	1.000	rs7209758	chr17:61913621	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.53	6.28	0.36	1.35e-9	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs990171	0.607	rs871659	chr2:102771855	C/T	cg22835712	chr2:102737379	NA	0.43	6.06	0.35	4.71e-9	Lymphocyte counts;
CESC	cis	rs1568889	1.000	rs11602768	chr11:28351786	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.69	8.16	0.45	1.33e-14	Bipolar disorder;
CESC	cis	rs4568518	0.587	rs4576329	chr7:18007152	A/G	cg03009463	chr7:17980271	SNX13	0.44	5.88	0.34	1.2e-8	Measles;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22922770	chr7:98923339	ARPC1A	0.55	6.47	0.37	4.74e-10	Gut microbiome composition (summer);
CESC	cis	rs911555	0.755	rs1138400	chr14:103956833	A/G	cg09975044	chr14:104007538	NA	0.43	5.28	0.31	2.68e-7	Intelligence (multi-trait analysis);
CESC	cis	rs2288073	0.619	rs6713263	chr2:24375463	A/G	cg01493198	chr2:24299560	SF3B14	0.38	5.15	0.3	5.13e-7	Venous thromboembolism (SNP x SNP interaction);
CESC	cis	rs16854884	0.586	rs4616638	chr3:143735423	A/T	cg06585982	chr3:143692056	C3orf58	-0.5	-7.09	-0.4	1.21e-11	Economic and political preferences (feminism/equality);
CESC	cis	rs6750047	0.566	rs1157185	chr2:38285735	C/T	cg07380506	chr2:38303506	CYP1B1	0.43	5.6	0.33	5.46e-8	Cutaneous malignant melanoma;Melanoma;
CESC	cis	rs28498503	0.867	rs58491155	chr18:76647526	T/G	cg00806245	chr18:76673096	NA	-0.63	-5.27	-0.31	2.77e-7	Attention function in attention deficit hyperactive disorder;
CESC	cis	rs17764205	0.568	rs72987040	chr19:3251116	C/A	cg02612712	chr19:3985498	EEF2	0.66	5.11	0.3	6.17e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs798554	0.671	rs1182195	chr7:2868730	A/G	cg19717773	chr7:2847554	GNA12	-0.55	-8.17	-0.45	1.27e-14	Height;
CESC	cis	rs4665809	0.941	rs1470096	chr2:26311482	T/C	cg22920501	chr2:26401640	FAM59B	-0.78	-9.21	-0.49	1.03e-17	Gut microbiome composition (summer);
CESC	cis	rs6088580	0.634	rs6088502	chr20:33037644	A/T	cg08999081	chr20:33150536	PIGU	0.66	11.61	0.58	1.85e-25	Glomerular filtration rate (creatinine);
CESC	cis	rs539096	0.500	rs2906457	chr1:44338575	A/C	cg12908607	chr1:44402522	ARTN	-0.49	-7.59	-0.42	5.52e-13	Intelligence (multi-trait analysis);
CESC	cis	rs11122272	0.735	rs2486743	chr1:231506928	C/G	cg06096015	chr1:231504339	EGLN1	0.39	5.68	0.33	3.49e-8	Hemoglobin concentration;
CESC	cis	rs11958404	0.789	rs7736318	chr5:157477593	A/G	cg05962755	chr5:157440814	NA	0.62	7.23	0.41	5.17e-12	IgG glycosylation;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg11488864	chr4:8379238	ACOX3	0.46	6.36	0.36	8.99e-10	Fibrinogen levels;
CESC	cis	rs710865	1.000	rs710865	chr1:19568972	A/G	cg13387374	chr1:19411106	UBR4	0.54	7.06	0.4	1.43e-11	Brain structure;
CESC	cis	rs9815354	0.812	rs17214945	chr3:41808660	A/C	cg03022575	chr3:42003672	ULK4	0.7	6.34	0.36	9.96e-10	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs1847202	0.793	rs11918132	chr3:72952144	C/T	cg25664220	chr3:72788482	NA	-0.39	-5.67	-0.33	3.68e-8	Motion sickness;
CESC	cis	rs6693567	0.565	rs698921	chr1:150379517	G/A	cg09579323	chr1:150459698	TARS2	0.47	5.93	0.34	9.3e-9	Migraine;
CESC	cis	rs7914558	0.966	rs56946876	chr10:104653545	T/C	cg08650961	chr10:104748594	CNNM2	0.33	5.37	0.31	1.75e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs2012796	0.957	rs8009083	chr14:81818289	A/G	cg02996355	chr14:81879375	NA	0.44	5.45	0.32	1.17e-7	Night sleep phenotypes;
CESC	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg03647317	chr4:187891568	NA	-0.44	-6.78	-0.38	7.98e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs10751667	0.621	rs11246345	chr11:934924	T/C	cg06064525	chr11:970664	AP2A2	-0.52	-10.37	-0.54	2.34e-21	Alzheimer's disease (late onset);
CESC	cis	rs7613875	0.620	rs17657664	chr3:50032008	T/G	cg24110177	chr3:50126178	RBM5	-0.56	-7.76	-0.43	1.85e-13	Body mass index;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	ch.3.1042801R	chr3:49084142	QRICH1	-0.53	-6.03	-0.35	5.55e-9	Gut microbiome composition (summer);
CESC	cis	rs35079168	0.735	rs1887309	chr9:137308242	A/G	cg13941235	chr9:137270186	RXRA	0.33	6.08	0.35	4.23e-9	Intelligence;
CESC	cis	rs7107174	1.000	rs10899492	chr11:78109810	G/A	cg02023728	chr11:77925099	USP35	0.37	5.28	0.31	2.63e-7	Testicular germ cell tumor;
CESC	cis	rs9611565	0.546	rs739129	chr22:42118249	G/A	cg06634786	chr22:41940651	POLR3H	0.66	6.64	0.38	1.73e-10	Vitiligo;
CESC	cis	rs1008375	0.966	rs2159582	chr4:17695655	T/C	cg15017067	chr4:17643749	FAM184B	0.38	5.4	0.31	1.49e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs11168618	0.567	rs56354789	chr12:48803943	C/A	cg24011408	chr12:48396354	COL2A1	0.36	5.61	0.33	5.17e-8	Adiponectin levels;
CESC	cis	rs826838	0.967	rs1352123	chr12:39130992	T/C	cg26384229	chr12:38710491	ALG10B	-0.67	-11.03	-0.56	1.63e-23	Heart rate;
CESC	cis	rs6951245	0.507	rs11763865	chr7:1194274	G/A	cg24642844	chr7:1081250	C7orf50	-0.5	-7.05	-0.4	1.53e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs4713118	0.516	rs7739216	chr6:28079946	G/T	cg23281280	chr6:28129359	ZNF389	0.58	7.93	0.44	6.31e-14	Parkinson's disease;
CESC	cis	rs7520050	0.778	rs3014218	chr1:46026328	A/C	cg06784218	chr1:46089804	CCDC17	-0.34	-6.19	-0.36	2.25e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs13191362	1.000	rs35575481	chr6:163007746	T/A	cg14584255	chr6:163149320	PACRG;PARK2	0.5	5.19	0.3	4.29e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs4771122	0.740	rs1006353	chr13:28047269	A/G	cg22138327	chr13:27999177	GTF3A	-0.53	-6.47	-0.37	4.83e-10	Body mass index;
CESC	cis	rs754466	0.580	rs2289308	chr10:79579251	G/A	cg17075019	chr10:79541650	NA	-0.88	-13.73	-0.64	9.13e-33	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs748404	0.516	rs523156	chr15:43811843	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.54	-6.56	-0.37	2.76e-10	Lung cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11122148	chr13:45150705	TSC22D1	0.63	7.38	0.41	2.1e-12	Gut microbiome composition (summer);
CESC	cis	rs1862618	0.853	rs33322	chr5:56175226	A/G	cg03609598	chr5:56110824	MAP3K1	-0.52	-5.44	-0.32	1.2e-7	Initial pursuit acceleration;
CESC	cis	rs6500395	1.000	rs1486411	chr16:48587083	T/C	cg04672837	chr16:48644449	N4BP1	0.49	6.23	0.36	1.83e-9	Response to tocilizumab in rheumatoid arthritis;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg13232424	chr2:128849480	UGGT1	0.46	6.0	0.35	6.54e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs7546094	0.935	rs3013439	chr1:113200671	T/G	cg22162597	chr1:113214053	CAPZA1	-0.39	-6.01	-0.35	6.14e-9	Platelet distribution width;
CESC	cis	rs8072100	0.713	rs2136750	chr17:45456100	A/G	cg25173405	chr17:45401733	C17orf57	-0.43	-5.46	-0.32	1.12e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	trans	rs9987353	0.840	rs329994	chr8:9123233	A/G	cg10083149	chr2:3321068	TSSC1	0.48	6.17	0.35	2.52e-9	Recombination measurement;
CESC	cis	rs3857067	0.806	rs722486	chr4:95092315	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.61	-9.04	-0.49	3.47e-17	QT interval;
CESC	cis	rs11871801	1.000	rs12948909	chr17:40570602	A/C	cg21433558	chr17:40837037	CNTNAP1	0.46	5.27	0.31	2.89e-7	Crohn's disease;
CESC	cis	rs34330	0.562	rs10845615	chr12:12863470	C/T	cg04607235	chr12:12878440	APOLD1	-0.81	-9.32	-0.5	4.71e-18	Systemic lupus erythematosus;
CESC	cis	rs79349575	0.756	rs2291726	chr17:47039254	T/C	cg16584676	chr17:46985605	UBE2Z	-0.48	-5.94	-0.34	9.15e-9	Type 2 diabetes;
CESC	cis	rs10411936	0.924	rs8110761	chr19:16501005	A/G	cg10248733	chr19:16607483	C19orf44;CALR3	0.54	6.48	0.37	4.5e-10	White blood cell count;Multiple sclerosis;
CESC	cis	rs35110281	0.720	rs162392	chr21:44941406	A/G	cg21573476	chr21:45109991	RRP1B	-0.42	-5.78	-0.33	2.05e-8	Mean corpuscular volume;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg26726589	chr20:306364	SOX12	-0.43	-6.04	-0.35	5.3300000000000004e-09	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs425277	0.917	rs12410859	chr1:2038732	C/T	cg04315214	chr1:2043799	PRKCZ	-0.46	-6.39	-0.37	7.56e-10	Height;
CESC	cis	rs10504229	0.906	rs2270608	chr8:58194688	T/C	cg24829409	chr8:58192753	C8orf71	-0.75	-9.61	-0.51	6.02e-19	Developmental language disorder (linguistic errors);
CESC	trans	rs6073597	1.000	rs6031980	chr20:43714384	C/T	cg24528447	chr5:92918517	NR2F1	0.46	6.67	0.38	1.51e-10	Positive affect;
CESC	cis	rs6088590	0.965	rs13040449	chr20:33358901	T/A	cg08999081	chr20:33150536	PIGU	0.61	9.23	0.49	9.02e-18	Coronary artery disease;
CESC	cis	rs3026101	0.671	rs8077471	chr17:5299356	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.42	5.59	0.32	5.77e-8	Body mass index;
CESC	cis	rs514406	0.679	rs499239	chr1:53310594	A/G	cg24675658	chr1:53192096	ZYG11B	-0.67	-9.55	-0.51	9.18e-19	Monocyte count;
CESC	cis	rs11690935	0.655	rs12997093	chr2:172564438	A/G	cg13550731	chr2:172543902	DYNC1I2	0.56	7.81	0.43	1.32e-13	Schizophrenia;
CESC	cis	rs2777491	0.574	rs316611	chr15:41751678	A/G	cg20272979	chr15:41787780	ITPKA	-0.4	-5.03	-0.3	9.12e-7	Ulcerative colitis;
CESC	cis	rs796364	0.806	rs12619136	chr2:200910347	C/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.84	-7.75	-0.43	1.94e-13	Schizophrenia;
CESC	cis	rs2721195	0.626	rs59464125	chr8:145857786	G/A	cg11211951	chr8:145729740	GPT	-0.32	-5.41	-0.32	1.41e-7	Age at first birth;
CESC	cis	rs4253772	0.530	rs9615933	chr22:46677298	G/A	cg10541313	chr22:46663664	TTC38	0.71	5.26	0.31	2.99e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs6089584	0.854	rs2380146	chr20:60632233	C/T	cg24733560	chr20:60626293	TAF4	0.46	6.91	0.39	3.52e-11	Body mass index;
CESC	cis	rs6547741	1.000	rs4666007	chr2:27856495	T/C	cg27432699	chr2:27873401	GPN1	0.46	6.43	0.37	5.87e-10	Oral cavity cancer;
CESC	cis	rs9354308	0.966	rs1909533	chr6:66565658	G/A	cg07460842	chr6:66804631	NA	0.67	7.67	0.43	3.2e-13	Metabolite levels;
CESC	trans	rs9388451	0.626	rs3734637	chr6:126081319	G/T	cg05039488	chr6:79577232	IRAK1BP1	-0.62	-8.64	-0.47	5.41e-16	Brugada syndrome;
CESC	cis	rs7666738	0.830	rs10010698	chr4:98981594	C/T	cg03467027	chr4:99064603	C4orf37	0.43	5.44	0.32	1.24e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs8040855	0.627	rs35668291	chr15:85652813	A/G	cg08123816	chr15:85640762	PDE8A	-0.39	-5.67	-0.33	3.75e-8	Bulimia nervosa;
CESC	trans	rs2018683	0.624	rs2286219	chr7:28998663	G/A	cg19402173	chr7:128379420	CALU	-0.57	-6.97	-0.39	2.58e-11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CESC	cis	rs1797885	0.844	rs2655260	chr3:12563640	T/C	cg26432171	chr3:12704882	RAF1	-0.48	-6.12	-0.35	3.35e-9	Immature fraction of reticulocytes;
CESC	cis	rs1153858	0.621	rs2687512	chr15:45581495	T/C	cg09092052	chr15:45571596	NA	0.45	5.11	0.3	6.31e-7	Homoarginine levels;
CESC	cis	rs7615952	0.599	rs12485717	chr3:125707075	C/T	cg04553112	chr3:125709451	NA	0.53	5.82	0.34	1.66e-8	Blood pressure (smoking interaction);
CESC	cis	rs7267979	0.740	rs2259961	chr20:25282626	T/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.79	14.56	0.67	1.07e-35	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7210086	0.948	rs60947290	chr17:70636944	C/A	cg04206342	chr17:70636940	NA	-0.31	-5.48	-0.32	9.7e-8	Ulcerative colitis;
CESC	cis	rs1167827	0.680	rs1167796	chr7:75173180	C/T	cg04978709	chr7:75101039	POM121C	-0.45	-5.79	-0.34	1.96e-8	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs9790314	0.586	rs11710086	chr3:161125858	A/T	cg03342759	chr3:160939853	NMD3	-0.44	-5.71	-0.33	2.99e-8	Morning vs. evening chronotype;
CESC	cis	rs7937682	1.000	rs11608149	chr11:111535102	G/A	cg22437258	chr11:111473054	SIK2	-0.69	-8.24	-0.45	7.81e-15	Primary sclerosing cholangitis;
CESC	cis	rs6424115	0.830	rs2501426	chr1:24199364	G/A	cg10978503	chr1:24200527	CNR2	0.33	6.63	0.38	1.85e-10	Immature fraction of reticulocytes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25675393	chr21:46494274	ADARB1;C21orf122	0.58	6.7	0.38	1.23e-10	Gut microbiome composition (summer);
CESC	cis	rs10504229	0.516	rs7821160	chr8:57986281	C/T	cg22535103	chr8:58192502	C8orf71	0.48	5.94	0.34	8.74e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs7772486	0.790	rs4435956	chr6:146232403	G/C	cg05347473	chr6:146136440	FBXO30	-0.55	-7.05	-0.4	1.57e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9902453	0.808	rs1986555	chr17:28014448	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.68	8.76	0.47	2.29e-16	Coffee consumption (cups per day);
CESC	cis	rs2370759	0.945	rs74625866	chr10:32597618	A/T	cg05361325	chr10:32636312	EPC1	-0.57	-5.47	-0.32	1.06e-7	Sexual dysfunction (female);
CESC	cis	rs853679	0.517	rs9380058	chr6:28127444	T/C	cg08968635	chr6:28129556	ZNF389	0.41	5.37	0.31	1.76e-7	Depression;
CESC	cis	rs2841277	0.738	rs1036713	chr14:105396693	C/G	cg21017887	chr14:105400489	NA	-0.38	-6.22	-0.36	1.93e-9	Rheumatoid arthritis;
CESC	cis	rs2197308	0.655	rs1971964	chr12:37870474	C/T	cg26384229	chr12:38710491	ALG10B	0.74	10.98	0.56	2.29e-23	Morning vs. evening chronotype;
CESC	cis	rs10838687	0.673	rs4752965	chr11:47159053	G/A	cg25783544	chr11:47291846	MADD	0.54	5.43	0.32	1.29e-7	Proinsulin levels;
CESC	cis	rs7659604	0.605	rs67772833	chr4:122723106	G/A	cg19748678	chr4:122722346	EXOSC9	0.61	7.77	0.43	1.75e-13	Type 2 diabetes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07074586	chr12:56555325	MYL6	-0.5	-6.04	-0.35	5.13e-9	Gut microbiome composition (summer);
CESC	cis	rs12134245	0.747	rs35654098	chr1:92001452	T/A	cg02896835	chr1:92012615	NA	-0.53	-6.82	-0.39	6.02e-11	Breast cancer;
CESC	cis	rs4629180	1.000	rs974374	chr2:102105846	C/T	cg04415270	chr2:102091202	RFX8	0.46	7.52	0.42	8.52e-13	Chronic rhinosinusitis with nasal polyps;
CESC	cis	rs10191773	0.589	rs72831636	chr2:112948248	G/A	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.71	-6.9	-0.39	3.9e-11	Yeast infection;
CESC	cis	rs875971	1.000	rs6961155	chr7:65933295	T/C	cg11764359	chr7:65958608	NA	0.97	15.5	0.69	5.25e-39	Aortic root size;
CESC	cis	rs7605827	0.930	rs6431704	chr2:15592061	G/T	cg19274914	chr2:15703543	NA	0.36	6.45	0.37	5.41e-10	Educational attainment (years of education);
CESC	cis	rs9300255	0.602	rs1716160	chr12:123700225	C/T	cg05973401	chr12:123451056	ABCB9	0.49	5.63	0.33	4.65e-8	Neutrophil percentage of white cells;
CESC	cis	rs3820928	0.845	rs7570869	chr2:227878818	A/C	cg05526886	chr2:227700861	RHBDD1	-0.46	-5.74	-0.33	2.61e-8	Pulmonary function;
CESC	cis	rs4689388	0.890	rs13130845	chr4:6297646	A/C	cg00701064	chr4:6280414	WFS1	0.68	11.52	0.58	3.75e-25	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg24391471	chr3:44974926	ZDHHC3	0.5	6.61	0.38	2.17e-10	Fibrinogen levels;
CESC	cis	rs36096196	0.891	rs74046969	chr1:2251348	G/A	cg17974515	chr1:2252516	NA	0.45	7.53	0.42	8.2e-13	Coronary artery disease;
CESC	cis	rs698833	0.926	rs1067370	chr2:44652343	T/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.46	5.87	0.34	1.3e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	trans	rs11098499	0.863	rs13134665	chr4:120426430	T/C	cg25214090	chr10:38739885	LOC399744	0.72	9.81	0.52	1.36e-19	Corneal astigmatism;
CESC	trans	rs9569823	0.813	rs7324740	chr13:58696106	A/G	cg09262171	chr16:4140361	ADCY9	0.36	6.07	0.35	4.31e-9	Intelligence (multi-trait analysis);
CESC	cis	rs9322193	0.923	rs35967444	chr6:149996724	G/A	cg07701084	chr6:150067640	NUP43	0.45	6.27	0.36	1.42e-9	Lung cancer;
CESC	cis	rs7927771	0.965	rs35985502	chr11:47847428	G/A	cg20307385	chr11:47447363	PSMC3	-0.49	-6.04	-0.35	5.24e-9	Subjective well-being;
CESC	cis	rs2637266	0.505	rs17467566	chr10:78293458	C/T	cg18941641	chr10:78392320	NA	0.3	5.12	0.3	5.91e-7	Pulmonary function;
CESC	cis	rs12042938	0.600	rs823161	chr1:231775017	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.41	5.49	0.32	9.29e-8	Neuranatomic and neurocognitive phenotypes;
CESC	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg16132339	chr22:24313637	DDTL;DDT	0.37	5.53	0.32	7.74e-8	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs897984	0.683	rs13337900	chr16:30822409	G/A	cg02466173	chr16:30829666	NA	-0.59	-11.46	-0.58	5.99e-25	Dementia with Lewy bodies;
CESC	cis	rs9486719	0.843	rs2499793	chr6:96846402	A/C	cg18709589	chr6:96969512	KIAA0776	0.55	5.64	0.33	4.26e-8	Migraine;Coronary artery disease;
CESC	cis	rs17253792	0.732	rs10146604	chr14:56045770	C/G	cg01858014	chr14:56050164	KTN1	-0.94	-7.66	-0.43	3.47e-13	Putamen volume;
CESC	cis	rs1865760	0.588	rs9467658	chr6:26010881	T/G	cg17691542	chr6:26056736	HIST1H1C	0.38	5.16	0.3	4.86e-7	Height;
CESC	cis	rs9916302	0.861	rs7503514	chr17:37669884	G/C	cg15445000	chr17:37608096	MED1	0.4	6.56	0.37	2.85e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs8060686	0.641	rs113704872	chr16:68032598	G/A	cg26727032	chr16:67993705	SLC12A4	-0.52	-5.78	-0.33	2.09e-8	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs7225537	0.509	rs11870035	chr17:17033397	C/T	cg20098446	chr17:17120238	FLCN	0.34	5.28	0.31	2.69e-7	Mean platelet volume;
CESC	cis	rs6974235	0.806	rs42079	chr7:95711301	A/G	cg21022364	chr7:95948586	SLC25A13	0.37	5.2	0.3	3.91e-7	Total body bone mineral density;
CESC	cis	rs11030122	0.635	rs10835540	chr11:4071429	T/A	cg18678763	chr11:4115507	RRM1	-0.47	-6.26	-0.36	1.58e-9	Mean platelet volume;Platelet distribution width;
CESC	cis	rs72781680	0.611	rs7596060	chr2:24334361	A/G	cg06627628	chr2:24431161	ITSN2	0.67	6.61	0.38	2.15e-10	Lymphocyte counts;
CESC	cis	rs10779751	0.762	rs6671083	chr1:11325910	A/G	cg08854313	chr1:11322531	MTOR	-0.69	-9.52	-0.5	1.14e-18	Body mass index;
CESC	cis	rs7618915	0.570	rs11130312	chr3:52675055	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	7.08	0.4	1.27e-11	Bipolar disorder;
CESC	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.56	-6.24	-0.36	1.77e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs2573652	0.722	rs968412	chr15:100544512	C/G	cg01831454	chr5:148417172	SH3TC2	0.31	6.05	0.35	4.87e-9	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03024183	chr8:37963317	ASH2L	0.64	7.84	0.43	1.12e-13	Gut microbiome composition (summer);
CESC	trans	rs61931739	0.534	rs12371021	chr12:34062252	T/C	cg26384229	chr12:38710491	ALG10B	0.61	8.47	0.46	1.67e-15	Morning vs. evening chronotype;
CESC	cis	rs208520	0.526	rs4710310	chr6:66802808	T/C	cg07460842	chr6:66804631	NA	-1.12	-27.01	-0.86	4.56e-78	Exhaled nitric oxide output;
CESC	cis	rs4566357	1.000	rs3769637	chr2:227922623	T/C	cg11843606	chr2:227700838	RHBDD1	-0.42	-5.37	-0.31	1.68e-7	Coronary artery disease;
CESC	cis	rs10504229	1.000	rs17217082	chr8:58180918	G/A	cg14926445	chr8:58193284	C8orf71	-0.51	-5.47	-0.32	1.03e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs9486719	1.000	rs35487471	chr6:96879715	C/T	cg06623918	chr6:96969491	KIAA0776	-0.81	-8.29	-0.45	5.61e-15	Migraine;Coronary artery disease;
CESC	cis	rs7085104	0.660	rs3781286	chr10:104595719	C/T	cg04362960	chr10:104952993	NT5C2	0.51	6.58	0.37	2.53e-10	Immature fraction of reticulocytes;Schizophrenia;
CESC	cis	rs11719291	0.833	rs34037363	chr3:48821036	C/T	cg00383909	chr3:49044727	WDR6	0.92	6.66	0.38	1.62e-10	Cognitive function;
CESC	cis	rs7178572	0.568	rs7166927	chr15:77673459	A/G	cg22256960	chr15:77711686	NA	0.53	6.89	0.39	4.01e-11	Type 2 diabetes;
CESC	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg24101359	chr6:42928495	GNMT	0.56	7.91	0.44	7.1e-14	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs2204008	0.548	rs8189475	chr12:38037115	C/T	cg26384229	chr12:38710491	ALG10B	0.57	8.23	0.45	8.76e-15	Bladder cancer;
CESC	cis	rs853679	0.517	rs3757187	chr6:28107654	T/C	cg23281280	chr6:28129359	ZNF389	0.59	8.21	0.45	9.45e-15	Depression;
CESC	cis	rs17253792	0.822	rs28549152	chr14:56091239	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.79	5.91	0.34	1.06e-8	Putamen volume;
CESC	cis	rs9300255	0.544	rs1790130	chr12:123701270	A/C	cg00376283	chr12:123451042	ABCB9	0.7	8.83	0.48	1.45e-16	Neutrophil percentage of white cells;
CESC	cis	rs8114671	0.562	rs6119536	chr20:33450041	A/G	cg07148914	chr20:33460835	GGT7	-0.45	-6.65	-0.38	1.72e-10	Height;
CESC	cis	rs734999	0.545	rs6684865	chr1:2546229	A/G	cg20673091	chr1:2541236	MMEL1	-0.43	-7.22	-0.41	5.54e-12	Ulcerative colitis;
CESC	cis	rs854765	0.520	rs7219324	chr17:17909775	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.52	-7.23	-0.41	5.19e-12	Total body bone mineral density;
CESC	trans	rs875971	0.660	rs2013222	chr7:66035936	C/G	cg26939375	chr7:64535504	NA	-0.64	-8.61	-0.47	6.57e-16	Aortic root size;
CESC	cis	rs12134245	0.776	rs625525	chr1:91997593	C/T	cg21854759	chr1:92012499	NA	-0.42	-5.25	-0.31	3.08e-7	Breast cancer;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg04050850	chr2:219536800	STK36;RNF25	-0.49	-6.42	-0.37	6.19e-10	Ulcerative colitis;
CESC	cis	rs36051895	0.593	rs12340379	chr9:5176352	C/T	cg02405213	chr9:5042618	JAK2	-0.5	-6.46	-0.37	5.09e-10	Pediatric autoimmune diseases;
CESC	cis	rs10751667	0.600	rs6597948	chr11:1005308	C/T	cg01483505	chr11:975446	AP2A2	0.39	5.04	0.3	8.53e-7	Alzheimer's disease (late onset);
CESC	cis	rs6500395	1.000	rs9933237	chr16:48676562	T/C	cg04672837	chr16:48644449	N4BP1	0.51	6.31	0.36	1.16e-9	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs3015497	0.789	rs7147956	chr14:51142605	G/A	cg09863266	chr14:51125203	SAV1	-0.34	-5.17	-0.3	4.73e-7	Mean platelet volume;
CESC	cis	rs3762637	0.882	rs72958418	chr3:122160373	G/C	cg24169773	chr3:122142474	KPNA1	-0.55	-6.59	-0.38	2.38e-10	LDL cholesterol levels;
CESC	trans	rs66573146	0.831	rs67315413	chr4:6987910	T/C	cg07817883	chr1:32538562	TMEM39B	1.14	7.98	0.44	4.51e-14	Granulocyte percentage of myeloid white cells;
CESC	cis	rs1799949	0.501	rs35399157	chr17:41411602	G/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.41	5.64	0.33	4.45e-8	Menopause (age at onset);
CESC	cis	rs6502050	0.777	rs7406162	chr17:80086386	C/T	cg23985595	chr17:80112537	CCDC57	0.42	6.55	0.37	2.99e-10	Life satisfaction;
CESC	cis	rs7927771	0.524	rs7943213	chr11:47715524	T/C	cg18512352	chr11:47633146	NA	0.36	5.46	0.32	1.09e-7	Subjective well-being;
CESC	cis	rs1178968	0.688	rs6951676	chr7:72753243	C/T	cg25889504	chr7:72793014	NA	0.47	5.03	0.3	8.91e-7	Triglyceride levels;
CESC	cis	rs2033711	0.870	rs4801583	chr19:58918405	A/G	cg13877915	chr19:58951672	ZNF132	0.39	5.79	0.34	1.98e-8	Uric acid clearance;
CESC	cis	rs9467711	0.606	rs9379857	chr6:26367654	G/C	cg14345882	chr6:26364793	BTN3A2	0.6	6.21	0.36	2.06e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs12973672	0.812	rs35497966	chr19:35764965	A/C	cg12095397	chr19:35769544	USF2	0.52	6.58	0.37	2.53e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs1538970	0.961	rs884962	chr1:45847981	G/A	cg03146154	chr1:46216737	IPP	0.46	5.53	0.32	7.61e-8	Platelet count;
CESC	cis	rs6089584	0.507	rs6061999	chr20:60637429	G/A	cg06108461	chr20:60628389	TAF4	-0.57	-7.56	-0.42	6.49e-13	Body mass index;
CESC	cis	rs2243480	1.000	rs937108	chr7:65428452	G/A	cg18252515	chr7:66147081	NA	-1.08	-10.42	-0.54	1.55e-21	Diabetic kidney disease;
CESC	cis	rs4819052	0.918	rs34886433	chr21:46680538	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.84	10.25	0.53	5.72e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs2839186	0.632	rs2839184	chr21:47689013	G/A	cg00815214	chr21:47717953	NA	-0.46	-6.42	-0.37	6.39e-10	Testicular germ cell tumor;
CESC	cis	rs7833790	0.632	rs6415653	chr8:82702536	A/G	cg07697082	chr8:82753677	SNX16	0.36	5.54	0.32	7.16e-8	Diastolic blood pressure;
CESC	cis	rs597539	0.652	rs686877	chr11:68637169	G/A	cg21963583	chr11:68658836	MRPL21	0.4	5.52	0.32	8.06e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs9815354	0.812	rs114034165	chr3:41823297	G/A	cg03022575	chr3:42003672	ULK4	0.7	6.2	0.36	2.11e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs6121246	0.567	rs6058187	chr20:30190923	T/C	cg13852791	chr20:30311386	BCL2L1	0.58	5.56	0.32	6.65e-8	Mean corpuscular hemoglobin;
CESC	cis	rs9818941	0.955	rs4362677	chr3:157667357	A/G	cg08654915	chr3:157813417	NA	0.46	7.95	0.44	5.45e-14	Height;
CESC	trans	rs1814175	0.645	rs10128563	chr11:50023681	T/C	cg15704280	chr7:45808275	SEPT13	-1.0	-18.54	-0.75	9.01e-50	Height;
CESC	cis	rs9811920	0.638	rs7629426	chr3:99652577	C/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.57	-7.02	-0.4	1.84e-11	Axial length;
CESC	cis	rs2050392	0.630	rs303428	chr10:30739058	C/T	cg18806716	chr10:30721971	MAP3K8	0.42	6.05	0.35	5.03e-9	Inflammatory bowel disease;
CESC	cis	rs4803468	0.967	rs11083619	chr19:41913267	A/C	cg14132834	chr19:41945861	ATP5SL	-0.67	-8.31	-0.45	5.08e-15	Height;
CESC	trans	rs9987353	0.840	rs329994	chr8:9123233	A/G	cg17804498	chr8:23167318	LOXL2	0.45	6.4	0.37	6.91e-10	Recombination measurement;
CESC	cis	rs727505	0.819	rs4142718	chr7:124731688	T/A	cg23710748	chr7:124431027	NA	-0.4	-6.52	-0.37	3.56e-10	Lewy body disease;
CESC	cis	rs3741404	0.594	rs11231704	chr11:63898182	C/T	cg26318627	chr11:63887540	MACROD1	0.36	5.44	0.32	1.24e-7	Platelet count;
CESC	cis	rs4253772	0.530	rs6008662	chr22:46713917	G/A	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.79	9.3	0.5	5.26e-18	LDL cholesterol;Cholesterol, total;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16361266	chr1:1313144	NA	0.5	6.02	0.35	5.92e-9	Gut microbiome composition (summer);
CESC	cis	rs932287	0.536	rs10840160	chr11:9053536	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.44	-7.01	-0.4	1.92e-11	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7666738	0.830	rs1593570	chr4:99017058	T/C	cg03676636	chr4:99064102	C4orf37	0.33	5.14	0.3	5.3e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs727505	0.564	rs4731236	chr7:124827236	G/T	cg23710748	chr7:124431027	NA	-0.33	-5.04	-0.3	8.75e-7	Lewy body disease;
CESC	trans	rs1814175	0.817	rs12295885	chr11:50036762	T/G	cg03929089	chr4:120376271	NA	-0.94	-15.92	-0.7	1.64e-40	Height;
CESC	cis	rs3791556	0.853	rs35245395	chr2:240107661	C/T	cg03281426	chr2:240109471	HDAC4	0.54	6.95	0.39	2.81e-11	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs10504229	0.861	rs67042991	chr8:58191749	G/C	cg14926445	chr8:58193284	C8orf71	-0.51	-5.52	-0.32	8.28e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs6912958	1.000	rs9450701	chr6:88173167	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.34	-5.79	-0.34	2e-8	Monocyte percentage of white cells;
CESC	cis	rs8040855	0.657	rs6496733	chr15:85673176	G/T	cg08123816	chr15:85640762	PDE8A	0.36	5.28	0.31	2.68e-7	Bulimia nervosa;
CESC	cis	rs2200578	1.000	rs116648076	chr2:99882347	T/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.49	5.32	0.31	2.21e-7	IgG glycosylation;
CESC	cis	rs77741769	0.591	rs73413868	chr12:121301732	T/C	cg02419362	chr12:121203948	SPPL3	0.34	5.59	0.32	5.6e-8	Mean corpuscular volume;
CESC	cis	rs4919694	0.572	rs12240508	chr10:104939232	G/A	cg04362960	chr10:104952993	NT5C2	0.64	6.44	0.37	5.66e-10	Arsenic metabolism;
CESC	cis	rs3820928	0.839	rs13404750	chr2:227876129	G/A	cg05526886	chr2:227700861	RHBDD1	-0.42	-5.16	-0.3	4.96e-7	Pulmonary function;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg14821842	chr8:118532860	MED30	-0.48	-6.16	-0.35	2.66e-9	Thyroid stimulating hormone;
CESC	cis	rs12541635	0.966	rs10955409	chr8:107022586	A/C	cg10147462	chr8:107024639	NA	0.43	6.42	0.37	6.16e-10	Age of smoking initiation;
CESC	cis	rs7914558	0.966	rs943035	chr10:104839152	T/C	cg15744005	chr10:104629667	AS3MT	-0.32	-5.04	-0.3	8.72e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs847577	0.609	rs6977321	chr7:97774859	A/G	cg24562669	chr7:97807699	LMTK2	0.83	13.76	0.65	7.37e-33	Breast cancer;
CESC	cis	rs6788895	1.000	rs74950732	chr3:150482621	C/T	cg07663535	chr3:150480033	SIAH2	0.72	5.09	0.3	6.94e-7	Breast cancer;
CESC	trans	rs875971	1.000	rs1540651	chr7:65650121	C/T	cg26939375	chr7:64535504	NA	-0.48	-6.37	-0.36	8.2e-10	Aortic root size;
CESC	cis	rs208520	0.690	rs12213928	chr6:66762978	G/A	cg07460842	chr6:66804631	NA	0.96	13.05	0.63	2.22e-30	Exhaled nitric oxide output;
CESC	cis	rs950169	0.922	rs11639244	chr15:84832650	G/A	cg17507749	chr15:85114479	UBE2QP1	0.55	6.25	0.36	1.66e-9	Schizophrenia;
CESC	cis	rs7044106	0.734	rs1981020	chr9:123388464	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.8	12.55	0.61	1.17e-28	Hip circumference adjusted for BMI;
CESC	cis	rs9911578	1.000	rs7223955	chr17:56917053	C/A	cg05425664	chr17:57184151	TRIM37	-0.5	-6.92	-0.39	3.44e-11	Intelligence (multi-trait analysis);
CESC	cis	rs4561483	0.583	rs9925010	chr16:11956668	A/G	cg08843971	chr16:11963173	GSPT1	0.46	6.42	0.37	6.1e-10	Testicular germ cell tumor;
CESC	cis	rs35110281	0.626	rs162368	chr21:44934767	G/A	cg21573476	chr21:45109991	RRP1B	-0.36	-5.16	-0.3	4.88e-7	Mean corpuscular volume;
CESC	cis	rs10504229	0.636	rs77691549	chr8:58055126	G/T	cg02725872	chr8:58115012	NA	-0.41	-5.94	-0.34	8.93e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs763014	0.898	rs916414	chr16:632073	C/T	cg07256732	chr16:621771	PIGQ	-0.3	-5.14	-0.3	5.22e-7	Height;
CESC	cis	rs7666738	0.791	rs17549003	chr4:98969132	A/C	cg03467027	chr4:99064603	C4orf37	0.43	5.42	0.32	1.34e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11098499	0.775	rs10021601	chr4:120282563	G/A	cg09307838	chr4:120376055	NA	0.87	12.16	0.6	2.41e-27	Corneal astigmatism;
CESC	cis	rs1784581	0.588	rs9295178	chr6:162419226	T/A	cg17173639	chr6:162384350	PARK2	0.56	8.62	0.47	6.34e-16	Itch intensity from mosquito bite;
CESC	cis	rs8092503	1.000	rs12457761	chr18:52476870	T/A	cg12377874	chr18:52495404	RAB27B	0.39	6.16	0.35	2.63e-9	Childhood body mass index;
CESC	cis	rs863345	0.967	rs10399681	chr1:158525551	C/T	cg12129480	chr1:158549410	OR10X1	-0.31	-6.42	-0.37	6.27e-10	Pneumococcal bacteremia;
CESC	cis	rs9863	0.828	rs4765541	chr12:124465995	T/C	cg17562584	chr12:124393655	DNAH10	0.32	5.51	0.32	8.62e-8	White blood cell count;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg17498856	chr1:1457042	ATAD3A	0.44	6.12	0.35	3.36e-9	Fibrinogen levels;
CESC	cis	rs11122272	0.706	rs2749710	chr1:231535112	A/C	cg06096015	chr1:231504339	EGLN1	-0.42	-6.02	-0.35	5.79e-9	Hemoglobin concentration;
CESC	cis	rs1218582	0.682	rs12046459	chr1:154912017	A/C	cg03351412	chr1:154909251	PMVK	0.69	9.08	0.49	2.5e-17	Prostate cancer;
CESC	cis	rs6912958	0.559	rs373646	chr6:88056896	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	0.35	5.74	0.33	2.57e-8	Monocyte percentage of white cells;
CESC	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg22535103	chr8:58192502	C8orf71	-0.92	-10.22	-0.53	6.79e-21	Developmental language disorder (linguistic errors);
CESC	cis	rs6831352	0.918	rs17218162	chr4:100056060	G/A	cg13256891	chr4:100009986	ADH5	-0.77	-8.45	-0.46	1.97e-15	Alcohol dependence;
CESC	cis	rs11098499	0.775	rs2002049	chr4:120257417	A/G	cg09307838	chr4:120376055	NA	0.8	10.89	0.56	4.43e-23	Corneal astigmatism;
CESC	cis	rs9457247	1.000	rs405553	chr6:167395058	A/G	cg23791538	chr6:167370224	RNASET2	-0.6	-8.65	-0.47	4.96e-16	Crohn's disease;
CESC	cis	rs10089	0.953	rs1012851	chr5:127360241	T/C	cg19767477	chr5:127420684	SLC12A2	-0.39	-5.11	-0.3	6.08e-7	Ileal carcinoids;
CESC	cis	rs2439831	1.000	rs690002	chr15:43729349	C/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.89	10.6	0.55	4.2e-22	Lung cancer in ever smokers;
CESC	cis	rs875971	0.862	rs6952182	chr7:65683317	T/G	cg11764359	chr7:65958608	NA	-0.77	-10.96	-0.56	2.75e-23	Aortic root size;
CESC	cis	rs965469	1.000	rs6037547	chr20:3299228	C/A	cg25506879	chr20:3388711	C20orf194	-0.56	-6.08	-0.35	4.16e-9	IFN-related cytopenia;
CESC	cis	rs910316	0.737	rs91144	chr14:75449517	G/A	cg08847533	chr14:75593920	NEK9	-0.89	-15.08	-0.68	1.65e-37	Height;
CESC	cis	rs9916302	0.904	rs4239222	chr17:37696235	A/C	cg00129232	chr17:37814104	STARD3	0.57	7.28	0.41	3.91e-12	Glomerular filtration rate (creatinine);
CESC	trans	rs4349753	0.663	rs7718290	chr5:144075908	A/C	cg22407458	chr6:35109121	TCP11	0.5	6.29	0.36	1.31e-9	Photic sneeze reflex;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg02930078	chr6:17706856	NUP153	-0.45	-6.08	-0.35	4.07e-9	Fibrinogen levels;
CESC	cis	rs3540	0.533	rs11633692	chr15:91056043	G/A	cg10434728	chr15:90938212	IQGAP1	-0.4	-6.97	-0.39	2.51e-11	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs11671005	0.695	rs8106061	chr19:58917990	G/C	cg26874164	chr19:58962979	ZNF324B	0.8	11.95	0.59	1.29e-26	Mean platelet volume;
CESC	cis	rs7917772	0.582	rs10883736	chr10:104320029	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.42	5.76	0.33	2.35e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs35146811	0.622	rs6946204	chr7:99589125	T/C	cg22906224	chr7:99728672	NA	0.43	5.18	0.3	4.42e-7	Coronary artery disease;
CESC	cis	rs7582720	1.000	rs72934510	chr2:203925360	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.84	7.25	0.41	4.63e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs28498503	1.000	rs9964465	chr18:76662714	A/G	cg00806245	chr18:76673096	NA	0.63	5.61	0.33	5.2e-8	Attention function in attention deficit hyperactive disorder;
CESC	cis	rs11608355	0.521	rs7978210	chr12:109835990	A/G	cg19025524	chr12:109796872	NA	-0.52	-7.25	-0.41	4.67e-12	Neuroticism;
CESC	cis	rs523522	0.923	rs10774553	chr12:120954984	T/C	cg27279351	chr12:120934652	DYNLL1	0.69	9.11	0.49	2.02e-17	High light scatter reticulocyte count;
CESC	trans	rs3213758	0.588	rs12931642	chr16:53599637	G/A	cg22729726	chr1:3123854	PRDM16	-0.5	-6.1	-0.35	3.68e-9	Vitiligo (non-segmental);
CESC	cis	rs6942756	0.876	rs6953598	chr7:129033741	A/G	cg02491457	chr7:128862824	NA	0.58	8.1	0.45	2.08e-14	White matter hyperintensity burden;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24117104	chr4:149366997	NA	-0.6	-7.34	-0.41	2.55e-12	Gut microbiome composition (summer);
CESC	cis	rs11750568	0.904	rs1826864	chr5:178509565	C/T	cg10208897	chr5:178548229	ADAMTS2	0.37	5.23	0.31	3.5e-7	Height;
CESC	trans	rs2727020	0.658	rs7111215	chr11:49430552	T/C	cg03929089	chr4:120376271	NA	-0.8	-12.5	-0.61	1.64e-28	Coronary artery disease;
CESC	cis	rs4595586	0.525	rs10506132	chr12:39404599	C/T	cg13010199	chr12:38710504	ALG10B	0.44	5.51	0.32	8.48e-8	Morning vs. evening chronotype;
CESC	cis	rs6088590	0.523	rs6058084	chr20:33183804	C/T	cg24642439	chr20:33292090	TP53INP2	0.63	8.4	0.46	2.65e-15	Coronary artery disease;
CESC	cis	rs35306767	0.951	rs55742421	chr10:961037	A/C	cg10556349	chr10:835070	NA	0.66	6.32	0.36	1.08e-9	Eosinophil percentage of granulocytes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16119628	chr10:88282035	WAPAL	0.57	7.02	0.4	1.85e-11	Gut microbiome composition (summer);
CESC	cis	rs873946	0.586	rs12767391	chr10:134573844	A/G	cg26818010	chr10:134567672	INPP5A	0.85	10.48	0.54	9.91e-22	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs2549003	1.000	rs10214312	chr5:131821866	T/G	cg00255919	chr5:131827918	IRF1	0.51	8.68	0.47	4.19e-16	Asthma (sex interaction);
CESC	cis	rs8067545	0.586	rs3850779	chr17:20171872	C/T	cg13482628	chr17:19912719	NA	-0.42	-5.62	-0.33	4.93e-8	Schizophrenia;
CESC	cis	rs72781680	0.652	rs72794281	chr2:23893265	G/A	cg20701182	chr2:24300061	SF3B14	0.81	7.11	0.4	1.11e-11	Lymphocyte counts;
CESC	cis	rs76878669	0.561	rs7105015	chr11:66159390	A/G	cg18002602	chr11:66138449	SLC29A2	0.43	6.95	0.39	2.79e-11	Educational attainment (years of education);
CESC	cis	rs2279817	1.000	rs35148872	chr1:18020184	G/A	cg21791023	chr1:18019539	ARHGEF10L	-0.63	-8.69	-0.47	3.73e-16	Neuroticism;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg03751324	chr16:4029315	ADCY9	0.47	6.38	0.36	7.79e-10	Fibrinogen levels;
CESC	cis	rs698833	0.886	rs17580226	chr2:44570776	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.56	6.99	0.39	2.27e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs1559088	1.000	rs1559087	chr19:33551041	A/G	cg17764715	chr19:33622953	WDR88	0.45	5.62	0.33	4.72e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs2777491	1.000	rs7177641	chr15:41743426	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.58	-8.41	-0.46	2.5e-15	Ulcerative colitis;
CESC	cis	rs854765	0.964	rs854764	chr17:18011750	A/G	cg04398451	chr17:18023971	MYO15A	0.6	7.65	0.43	3.8e-13	Total body bone mineral density;
CESC	cis	rs9488822	0.636	rs1544155	chr6:116346394	C/A	cg26893134	chr6:116381904	FRK	0.25	6.1	0.35	3.71e-9	Cholesterol, total;LDL cholesterol;
CESC	cis	rs7904368	0.806	rs7900527	chr10:16857992	C/G	cg14835575	chr10:16859367	RSU1	0.5	5.19	0.3	4.17e-7	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
CESC	cis	rs1799949	0.930	rs34210004	chr17:41370337	A/T	cg23758822	chr17:41437982	NA	1.01	17.08	0.72	1.29e-44	Menopause (age at onset);
CESC	cis	rs854765	0.618	rs9908017	chr17:17774422	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.54	-7.79	-0.43	1.51e-13	Total body bone mineral density;
CESC	cis	rs1862618	0.620	rs2591967	chr5:56233551	C/G	cg12311346	chr5:56204834	C5orf35	0.63	8.71	0.47	3.31e-16	Initial pursuit acceleration;
CESC	cis	rs3820068	0.705	rs4646109	chr1:15817319	T/C	cg18192808	chr1:15853278	DNAJC16	0.44	5.37	0.31	1.71e-7	Systolic blood pressure;
CESC	trans	rs61931739	0.500	rs11053235	chr12:34507899	G/A	cg13010199	chr12:38710504	ALG10B	0.5	6.42	0.37	6.3e-10	Morning vs. evening chronotype;
CESC	cis	rs8177253	0.965	rs1525889	chr3:133490033	A/C	cg01448562	chr3:133502909	NA	-0.42	-5.74	-0.33	2.63e-8	Iron status biomarkers;
CESC	cis	rs72781680	0.593	rs72797817	chr2:24350569	A/G	cg20701182	chr2:24300061	SF3B14	0.9	10.37	0.54	2.26e-21	Lymphocyte counts;
CESC	cis	rs12497850	0.931	rs9846123	chr3:49088112	C/T	cg02487422	chr3:49467188	NICN1	-0.39	-5.11	-0.3	6.16e-7	Parkinson's disease;
CESC	cis	rs17039065	0.920	rs7695026	chr4:109436476	G/A	cg16022748	chr4:109541635	LOC285456;RPL34	0.67	6.4	0.37	7.14e-10	Gut microbiome composition (summer);
CESC	cis	rs1005277	0.579	rs176886	chr10:38403974	C/T	cg25427524	chr10:38739819	LOC399744	-0.67	-9.69	-0.51	3.27e-19	Extrinsic epigenetic age acceleration;
CESC	cis	rs9905704	0.846	rs2567894	chr17:56794115	G/A	cg12560992	chr17:57184187	TRIM37	0.62	7.78	0.43	1.6e-13	Testicular germ cell tumor;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26987855	chr6:10426637	NA	-0.6	-6.37	-0.36	8.29e-10	Gut microbiome composition (summer);
CESC	cis	rs3785574	0.962	rs13030	chr17:61908556	C/T	cg06873352	chr17:61820015	STRADA	0.47	6.85	0.39	5.19e-11	Height;
CESC	cis	rs796364	0.760	rs2881594	chr2:201026183	T/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.78	-6.71	-0.38	1.2e-10	Schizophrenia;
CESC	cis	rs801193	0.569	rs6978178	chr7:66123084	G/A	cg11764359	chr7:65958608	NA	-0.73	-10.48	-0.54	1.01e-21	Aortic root size;
CESC	cis	rs9660992	0.674	rs17345837	chr1:205263122	C/T	cg21643547	chr1:205240462	TMCC2	-0.44	-5.81	-0.34	1.83e-8	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs13108904	0.934	rs13125842	chr4:1280947	G/A	cg00684032	chr4:1343700	KIAA1530	0.39	5.43	0.32	1.27e-7	Obesity-related traits;
CESC	cis	rs7552404	0.545	rs12748741	chr1:76351193	A/G	cg03433033	chr1:76189801	ACADM	-0.55	-5.68	-0.33	3.49e-8	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs77972916	0.505	rs11899984	chr2:43578246	C/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.64	-6.62	-0.38	1.98e-10	Granulocyte percentage of myeloid white cells;
CESC	cis	rs1862618	1.000	rs1862618	chr5:56096315	C/G	cg22800045	chr5:56110881	MAP3K1	0.77	9.43	0.5	2.14e-18	Initial pursuit acceleration;
CESC	cis	rs6062302	0.522	rs11696202	chr20:62246292	G/C	cg09650180	chr20:62225654	GMEB2	-0.82	-9.38	-0.5	3.04e-18	Glioblastoma;
CESC	cis	rs763014	0.838	rs4984670	chr16:641044	A/G	cg00908189	chr16:619842	PIGQ	0.64	8.51	0.46	1.28e-15	Height;
CESC	cis	rs2404602	0.692	rs58889902	chr15:77173070	A/C	cg22467129	chr15:76604101	ETFA	-0.35	-5.27	-0.31	2.8e-7	Blood metabolite levels;
CESC	cis	rs7845219	0.544	rs34208552	chr8:95908067	C/G	cg23172400	chr8:95962367	TP53INP1	-0.39	-7.21	-0.41	5.68e-12	Type 2 diabetes;
CESC	cis	rs10463316	0.817	rs58892766	chr5:150776115	T/C	cg03212797	chr5:150827313	SLC36A1	-0.42	-5.3	-0.31	2.49e-7	Metabolite levels (Pyroglutamine);
CESC	cis	rs514406	0.679	rs12563825	chr1:53238324	G/T	cg27535305	chr1:53392650	SCP2	0.31	5.56	0.32	6.61e-8	Monocyte count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27381194	chr2:96932018	CIAO1;TMEM127	0.57	6.79	0.38	7.45e-11	Gut microbiome composition (summer);
CESC	cis	rs250677	0.687	rs168750	chr5:148446756	A/G	cg18129178	chr5:148520854	ABLIM3	-0.51	-5.83	-0.34	1.58e-8	Breast cancer;
CESC	cis	rs34638657	0.732	rs11866711	chr16:82201038	A/C	cg09439754	chr16:82129088	HSD17B2	-0.36	-6.24	-0.36	1.71e-9	Lung adenocarcinoma;
CESC	trans	rs3942852	0.806	rs1875696	chr11:48133526	G/A	cg03929089	chr4:120376271	NA	-0.56	-6.28	-0.36	1.38e-9	Acute lymphoblastic leukemia (childhood);
CESC	trans	rs877282	0.853	rs11253332	chr10:755262	G/C	cg22713356	chr15:30763199	NA	0.93	8.39	0.46	3e-15	Uric acid levels;
CESC	cis	rs1552244	1.000	rs3826	chr3:10141065	T/G	cg08888203	chr3:10149979	C3orf24	0.46	6.01	0.35	6.24e-9	Alzheimer's disease;
CESC	cis	rs17445774	0.503	rs17531061	chr2:201113452	G/T	cg23649088	chr2:200775458	C2orf69	-0.57	-5.37	-0.31	1.68e-7	LDL cholesterol to HDL cholesterol ratio;
CESC	trans	rs12599106	0.680	rs34728702	chr16:34896584	A/G	cg03395511	chr6:291903	DUSP22	-0.71	-8.91	-0.48	8.28e-17	Menopause (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17243582	chr15:59969081	BNIP2	-0.63	-6.71	-0.38	1.18e-10	Gut microbiome composition (summer);
CESC	cis	rs10129255	1.000	rs4612959	chr14:107175298	A/G	cg07958169	chr14:107095056	NA	-0.39	-5.31	-0.31	2.31e-7	Kawasaki disease;
CESC	trans	rs4733781	1.000	rs4733781	chr8:131296767	A/C	cg19926776	chr19:18682709	UBA52	-0.47	-6.45	-0.37	5.38e-10	Tuberculosis;
CESC	cis	rs4975709	0.589	rs1684967	chr5:1863055	G/C	cg10800226	chr5:1850261	NA	0.34	5.69	0.33	3.33e-8	Cardiovascular disease risk factors;
CESC	cis	rs4919044	0.866	rs2478233	chr10:94778903	G/A	cg16508068	chr10:94451736	HHEX	-0.47	-5.13	-0.3	5.65e-7	Coronary artery disease;
CESC	cis	rs2979489	0.891	rs2915624	chr8:30381245	T/C	cg26383811	chr8:30366931	RBPMS	-0.79	-9.7	-0.51	3.17e-19	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CESC	cis	rs1775715	0.513	rs2808089	chr10:32145112	A/T	cg18675610	chr10:32216311	ARHGAP12	0.34	5.4	0.31	1.47e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	trans	rs3741578	0.702	rs1813812	chr12:57333395	A/G	cg14720773	chr17:17603531	RAI1	0.48	6.46	0.37	4.9e-10	Asthma;
CESC	cis	rs2842992	0.662	rs2273826	chr6:160211421	A/G	cg26839252	chr6:160211577	TCP1;MRPL18	0.49	6.15	0.35	2.83e-9	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs116095464	0.558	rs10068203	chr5:206618	C/T	cg16372103	chr5:203701	NA	0.49	5.29	0.31	2.6e-7	Breast cancer;
CESC	cis	rs3741151	0.686	rs12277924	chr11:73219678	T/C	cg17517138	chr11:73019481	ARHGEF17	0.57	5.07	0.3	7.46e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs2953174	1.000	rs1133353	chr2:241522267	A/T	cg07929629	chr2:241523174	NA	-0.54	-5.46	-0.32	1.09e-7	Bipolar disorder;
CESC	cis	rs8180040	0.966	rs9683177	chr3:47490493	G/A	cg27129171	chr3:47204927	SETD2	0.62	9.25	0.49	7.87e-18	Colorectal cancer;
CESC	cis	rs561341	0.941	rs550213	chr17:30317518	C/G	cg19193384	chr17:30244184	NA	-0.61	-6.45	-0.37	5.21e-10	Hip circumference adjusted for BMI;
CESC	cis	rs11785400	0.793	rs2976400	chr8:143743611	G/A	cg10596483	chr8:143751796	JRK	0.4	5.06	0.3	7.75e-7	Schizophrenia;
CESC	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg07308232	chr7:1071921	C7orf50	-0.42	-5.69	-0.33	3.39e-8	Longevity;Endometriosis;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg08943809	chr16:58059531	MMP15	0.44	6.15	0.35	2.92e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs1799949	0.896	rs8176086	chr17:41274778	G/A	cg05368731	chr17:41323189	NBR1	0.8	11.32	0.57	1.66e-24	Menopause (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26392439	chr4:87927884	AFF1	-0.59	-6.18	-0.35	2.46e-9	Gut microbiome composition (summer);
CESC	trans	rs12310956	0.532	rs11494810	chr12:33952881	C/A	cg26384229	chr12:38710491	ALG10B	0.49	6.79	0.38	7.36e-11	Morning vs. evening chronotype;
CESC	cis	rs1552244	0.882	rs61429272	chr3:10037320	G/C	cg00149659	chr3:10157352	C3orf10	0.7	8.31	0.45	5.08e-15	Alzheimer's disease;
CESC	cis	rs796364	0.806	rs79897806	chr2:201073968	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.77	-6.53	-0.37	3.37e-10	Schizophrenia;
CESC	cis	rs7089973	0.604	rs10885618	chr10:116617718	A/G	cg23260525	chr10:116636907	FAM160B1	0.42	8.12	0.45	1.8e-14	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	trans	rs11098499	0.820	rs28535956	chr4:120536858	C/T	cg25214090	chr10:38739885	LOC399744	-0.65	-8.93	-0.48	7.19e-17	Corneal astigmatism;
CESC	cis	rs5751150	1	rs5751150	chr22:42153292	T/G	cg06634786	chr22:41940651	POLR3H	0.7	7.03	0.4	1.8e-11	Cannabis dependence symptom count;
CESC	cis	rs875971	0.660	rs801193	chr7:66030612	A/C	cg18876405	chr7:65276391	NA	-0.58	-7.81	-0.43	1.32e-13	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25266327	chr19:16435660	KLF2	0.57	6.67	0.38	1.49e-10	Gut microbiome composition (summer);
CESC	cis	rs13256369	1.000	rs4840352	chr8:8573508	A/G	cg18904891	chr8:8559673	CLDN23	0.72	8.37	0.46	3.27e-15	Obesity-related traits;
CESC	trans	rs9467711	0.606	rs9393711	chr6:26370659	C/T	cg06606381	chr12:133084897	FBRSL1	-0.76	-6.86	-0.39	4.71e-11	Autism spectrum disorder or schizophrenia;
CESC	cis	rs10504229	0.683	rs56235637	chr8:58106008	T/C	cg22535103	chr8:58192502	C8orf71	-0.8	-8.99	-0.48	4.84e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs7618915	0.547	rs4687638	chr3:52651966	A/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.29	5.13	0.3	5.61e-7	Bipolar disorder;
CESC	cis	rs10791323	0.604	rs2723607	chr11:133711018	C/G	cg06766960	chr11:133703094	NA	-0.39	-5.46	-0.32	1.08e-7	Childhood ear infection;
CESC	cis	rs4589502	0.502	rs2169460	chr15:67197240	A/G	cg18595228	chr15:67193261	NA	-0.49	-6.36	-0.36	8.93e-10	Lung cancer (smoking interaction);
CESC	cis	rs6912958	0.967	rs9450688	chr6:88159276	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.32	-5.16	-0.3	4.87e-7	Monocyte percentage of white cells;
CESC	cis	rs6686643	0.762	rs61800372	chr1:165611981	T/C	cg19407955	chr1:165599744	MGST3	-0.54	-5.68	-0.33	3.55e-8	Total ventricular volume;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg26203055	chr18:19284713	ABHD3	-0.38	-6.14	-0.35	2.94e-9	Gambling;
CESC	cis	rs10461617	0.541	rs832575	chr5:56161787	C/T	cg18230493	chr5:56204884	C5orf35	-0.59	-5.77	-0.33	2.26e-8	Type 2 diabetes;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg12609600	chr11:1595974	HCCA2;LOC338651	0.42	6.14	0.35	3.04e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs7605827	0.897	rs10929371	chr2:15662299	A/G	cg19274914	chr2:15703543	NA	0.37	6.67	0.38	1.47e-10	Educational attainment (years of education);
CESC	cis	rs801193	1.000	rs2659909	chr7:66160279	G/A	cg18876405	chr7:65276391	NA	0.59	7.78	0.43	1.64e-13	Aortic root size;
CESC	cis	rs2243480	1.000	rs55895244	chr7:65387678	C/G	cg13147721	chr7:65941812	NA	-0.83	-7.92	-0.44	6.77e-14	Diabetic kidney disease;
CESC	cis	rs4555082	0.834	rs2816653	chr14:105713973	A/G	cg13114125	chr14:105738426	BRF1	-0.76	-9.36	-0.5	3.57e-18	Mean platelet volume;Platelet distribution width;
CESC	cis	rs736408	0.511	rs12637632	chr3:52708073	A/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	5.77	0.33	2.16e-8	Bipolar disorder;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg22423294	chr13:114286133	TFDP1	0.47	6.72	0.38	1.1e-10	Fibrinogen levels;
CESC	cis	rs4906332	1.000	rs3783398	chr14:103949378	C/T	cg09975044	chr14:104007538	NA	-0.47	-6.44	-0.37	5.55e-10	Coronary artery disease;
CESC	cis	rs965469	1.000	rs6051718	chr20:3270370	C/T	cg25506879	chr20:3388711	C20orf194	-0.59	-6.24	-0.36	1.7e-9	IFN-related cytopenia;
CESC	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg05657792	chr17:6899758	ALOX12	0.4	7.06	0.4	1.45e-11	Tonsillectomy;
CESC	cis	rs5753618	0.555	rs9609304	chr22:31897795	T/C	cg02404636	chr22:31891804	SFI1	0.42	5.7	0.33	3.25e-8	Colorectal cancer;
CESC	cis	rs6120849	0.707	rs6088703	chr20:33676049	T/A	cg24642439	chr20:33292090	TP53INP2	0.67	6.58	0.37	2.48e-10	Protein C levels;
CESC	cis	rs9287719	0.967	rs7563816	chr2:10763400	C/T	cg00105475	chr2:10696890	NA	0.38	5.37	0.31	1.7e-7	Prostate cancer;
CESC	cis	rs3091242	0.933	rs35148262	chr1:25766623	A/G	cg02931644	chr1:25747376	RHCE	0.47	8.06	0.44	2.6e-14	Erythrocyte sedimentation rate;
CESC	cis	rs8031584	0.678	rs3122	chr15:31170290	A/T	cg08109568	chr15:31115862	NA	0.75	10.2	0.53	7.73e-21	Huntington's disease progression;
CESC	cis	rs7044106	0.648	rs2031369	chr9:123360294	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.74	10.84	0.55	6.79e-23	Hip circumference adjusted for BMI;
CESC	cis	rs17253792	0.822	rs117050012	chr14:56038729	G/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.84	5.73	0.33	2.76e-8	Putamen volume;
CESC	cis	rs2439831	0.702	rs28699233	chr15:44122866	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.68	6.65	0.38	1.64e-10	Lung cancer in ever smokers;
CESC	cis	rs9640161	0.750	rs3735167	chr7:150039555	C/T	cg10018233	chr7:150070692	REPIN1	0.4	5.61	0.33	4.99e-8	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs9488822	0.636	rs7745074	chr6:116347432	G/A	cg18764771	chr6:116381957	FRK	0.22	5.44	0.32	1.23e-7	Cholesterol, total;LDL cholesterol;
CESC	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg07677032	chr17:61819896	STRADA	-0.52	-7.25	-0.41	4.71e-12	Prudent dietary pattern;
CESC	cis	rs10823500	0.777	rs10762348	chr10:71952322	C/A	cg02100629	chr10:71892760	AIFM2	-0.32	-5.12	-0.3	5.77e-7	Blood protein levels;
CESC	cis	rs13385	0.813	rs12187444	chr5:139664820	T/C	cg26211634	chr5:139558579	C5orf32	0.48	5.09	0.3	6.88e-7	Atrial fibrillation;
CESC	cis	rs858239	0.539	rs6976957	chr7:23187333	T/A	cg23682824	chr7:23144976	KLHL7	0.49	6.43	0.37	6.08e-10	Cerebrospinal fluid biomarker levels;
CESC	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg07677032	chr17:61819896	STRADA	0.45	5.99	0.35	6.8e-9	Prudent dietary pattern;
CESC	cis	rs7845219	0.544	rs7017487	chr8:95922752	A/G	cg09323728	chr8:95962352	TP53INP1	0.34	6.82	0.39	6.3e-11	Type 2 diabetes;
CESC	trans	rs7824557	0.564	rs2572386	chr8:11236975	A/G	cg06636001	chr8:8085503	FLJ10661	-0.5	-6.16	-0.35	2.7e-9	Retinal vascular caliber;
CESC	cis	rs274567	0.501	rs2631368	chr5:131705297	T/G	cg18758796	chr5:131593413	PDLIM4	-0.42	-5.65	-0.33	4.19e-8	Blood metabolite levels;
CESC	cis	rs7618501	0.602	rs2624853	chr3:50128893	A/G	cg24308560	chr3:49941425	MST1R	0.61	8.83	0.48	1.47e-16	Intelligence (multi-trait analysis);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg27656398	chr12:123451108	ABCB9	-0.48	-6.49	-0.37	4.22e-10	Fibrinogen levels;
CESC	cis	rs2637266	0.967	rs4608018	chr10:78376110	T/C	cg18941641	chr10:78392320	NA	0.43	8.24	0.45	8.17e-15	Pulmonary function;
CESC	cis	rs3020736	0.500	rs8143153	chr22:42515637	G/C	cg12850546	chr22:42539477	CYP2D7P1	0.43	5.14	0.3	5.37e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs5758511	0.689	rs5758691	chr22:42668504	G/C	cg00645731	chr22:42541494	CYP2D7P1	0.58	8.66	0.47	4.81e-16	Birth weight;
CESC	cis	rs4975616	0.869	rs421284	chr5:1325590	T/C	cg06550200	chr5:1325588	CLPTM1L	-0.71	-11.3	-0.57	2.07e-24	Lung cancer;
CESC	cis	rs1879734	0.681	rs12076192	chr1:54157742	A/G	cg23596471	chr1:54105337	GLIS1	0.34	5.41	0.32	1.42e-7	Mitral valve prolapse;
CESC	trans	rs916888	0.773	rs199534	chr17:44824213	T/G	cg07870213	chr5:140052090	DND1	0.63	6.68	0.38	1.39e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs11577318	0.853	rs4450008	chr1:26643860	C/A	cg00852783	chr1:26633632	UBXN11	0.51	7.21	0.4	5.9e-12	Granulocyte percentage of myeloid white cells;
CESC	cis	rs514406	0.798	rs575138	chr1:53328394	C/G	cg24675658	chr1:53192096	ZYG11B	-0.66	-8.7	-0.47	3.67e-16	Monocyte count;
CESC	cis	rs17807624	1.000	rs17807624	chr8:11463015	A/G	cg00262122	chr8:11665843	FDFT1	-0.39	-5.11	-0.3	6.09e-7	Systemic lupus erythematosus;
CESC	cis	rs9640161	0.789	rs28432021	chr7:150046235	G/C	cg10018233	chr7:150070692	REPIN1	0.36	5.21	0.3	3.76e-7	Blood protein levels;Circulating chemerin levels;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg17535283	chr2:26541115	GPR113	-0.4	-6.38	-0.36	8.07e-10	Gambling;
CESC	cis	rs9905704	0.647	rs11079367	chr17:57009024	A/G	cg12560992	chr17:57184187	TRIM37	0.62	7.8	0.43	1.47e-13	Testicular germ cell tumor;
CESC	cis	rs1478897	0.898	rs2249040	chr8:11390779	A/T	cg09528494	chr8:11338675	NA	-0.3	-5.44	-0.32	1.22e-7	Systemic lupus erythematosus;
CESC	cis	rs4727027	0.901	rs4727017	chr7:148822062	A/G	cg23583168	chr7:148888333	NA	-0.79	-12.21	-0.6	1.63e-27	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	trans	rs1814175	0.534	rs1983448	chr11:49933856	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.43	-6.18	-0.35	2.4e-9	Height;
CESC	trans	rs853679	0.546	rs35016036	chr6:28314880	C/T	cg06606381	chr12:133084897	FBRSL1	-1.11	-8.84	-0.48	1.35e-16	Depression;
CESC	cis	rs2032447	0.507	rs199748	chr6:25909045	C/G	cg03264133	chr6:25882463	NA	-0.65	-9.56	-0.51	8.82e-19	Intelligence (multi-trait analysis);
CESC	trans	rs12518099	0.874	rs56052030	chr5:89564170	A/G	cg26280695	chr10:106072440	ITPRIP	-0.47	-6.02	-0.35	5.65e-9	Type 2 diabetes and other traits;
CESC	cis	rs10504229	0.516	rs11781671	chr8:57992733	T/C	cg24829409	chr8:58192753	C8orf71	-0.36	-5.11	-0.3	6.21e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs2629540	0.765	rs12221075	chr10:126534855	G/A	cg08799069	chr10:126477246	METTL10	-0.53	-7.42	-0.41	1.63e-12	Cocaine dependence;
CESC	cis	rs1005277	0.579	rs9299760	chr10:38377920	C/T	cg25517755	chr10:38738941	LOC399744	-0.48	-6.22	-0.36	1.94e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs7552404	0.727	rs1146653	chr1:76280438	A/G	cg03433033	chr1:76189801	ACADM	0.62	6.78	0.38	7.6e-11	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs10088262	0.629	rs7833650	chr8:124822969	C/T	cg15047889	chr8:124780837	FAM91A1	-0.5	-6.14	-0.35	2.92e-9	Pancreatic cancer;
CESC	cis	rs7666738	0.830	rs28867388	chr4:98962794	A/T	cg05340658	chr4:99064831	C4orf37	0.8	12.39	0.61	3.96e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs12477438	0.748	rs4851185	chr2:99666497	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.64	-8.73	-0.47	2.94e-16	Chronic sinus infection;
CESC	cis	rs7932354	0.528	rs12796744	chr11:47132724	A/T	cg25783544	chr11:47291846	MADD	0.43	5.71	0.33	3.02e-8	Bone mineral density (hip);Bone mineral density;
CESC	cis	rs9322193	0.962	rs2151912	chr6:150152908	A/G	cg05861140	chr6:150128134	PCMT1	-0.37	-5.25	-0.31	3.12e-7	Lung cancer;
CESC	cis	rs1707322	1.000	rs1707337	chr1:46508769	A/G	cg05343316	chr1:45956843	TESK2	-0.44	-5.44	-0.32	1.2e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs4648845	0.777	rs2477689	chr1:2395538	G/C	cg02275930	chr1:2372054	NA	-0.46	-7.53	-0.42	8.23e-13	Schizophrenia;
CESC	cis	rs7635838	0.827	rs4273358	chr3:11415160	T/G	cg00170343	chr3:11313890	ATG7	0.43	5.72	0.33	2.89e-8	HDL cholesterol;
CESC	cis	rs10504229	0.679	rs72649115	chr8:58037631	T/G	cg24829409	chr8:58192753	C8orf71	-0.66	-7.3	-0.41	3.3e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs6088580	0.634	rs6120644	chr20:33023810	G/A	cg24642439	chr20:33292090	TP53INP2	0.52	6.79	0.39	7.18e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs8135665	0.625	rs8142185	chr22:38451080	A/C	cg13116946	chr22:38479732	SLC16A8	0.42	5.2	0.3	4.03e-7	Advanced age-related macular degeneration;Age-related macular degeneration;
CESC	cis	rs9640161	0.742	rs2108852	chr7:150019628	T/C	cg10018233	chr7:150070692	REPIN1	0.46	7.29	0.41	3.59e-12	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs6121246	0.559	rs6119728	chr20:30413121	G/A	cg13852791	chr20:30311386	BCL2L1	0.83	10.64	0.55	2.92e-22	Mean corpuscular hemoglobin;
CESC	cis	rs6762	0.748	rs7928935	chr11:839127	G/A	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.67	-8.76	-0.47	2.4e-16	Mean platelet volume;
CESC	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg03188948	chr7:1209495	NA	0.71	6.99	0.39	2.17e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs3749237	0.964	rs1799845	chr3:49847623	A/G	cg21659725	chr3:3221576	CRBN	0.51	6.13	0.35	3.21e-9	Resting heart rate;
CESC	cis	rs829883	0.664	rs1096148	chr12:98851005	A/G	cg25150519	chr12:98850993	NA	0.87	14.77	0.67	2.01e-36	Colorectal adenoma (advanced);
CESC	cis	rs4665809	1.000	rs4665306	chr2:26319124	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.68	-7.72	-0.43	2.4e-13	Gut microbiome composition (summer);
CESC	cis	rs6460942	0.597	rs6961238	chr7:12535428	C/T	cg06484146	chr7:12443880	VWDE	-0.73	-7.77	-0.43	1.68e-13	Coronary artery disease;
CESC	cis	rs9611565	0.503	rs5751156	chr22:42170025	A/G	cg17376030	chr22:41985996	PMM1	-0.79	-8.32	-0.46	4.67e-15	Vitiligo;
CESC	cis	rs9914544	0.966	rs9915346	chr17:18787931	G/A	cg26378065	chr17:18585709	ZNF286B	0.46	5.62	0.33	4.89e-8	Educational attainment (years of education);
CESC	cis	rs7647973	1.000	rs11710434	chr3:49346130	T/C	cg07636037	chr3:49044803	WDR6	0.67	9.54	0.51	9.63e-19	Menarche (age at onset);
CESC	cis	rs9682041	0.660	rs13089256	chr3:170113601	G/A	cg11886554	chr3:170076028	SKIL	0.7	6.46	0.37	4.94e-10	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CESC	cis	rs933688	1.000	rs985434	chr5:90744509	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.15	13.7	0.64	1.17e-32	Smoking behavior;
CESC	cis	rs11031096	0.683	rs55898672	chr11:4189284	G/C	cg18678763	chr11:4115507	RRM1	-0.4	-5.18	-0.3	4.46e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	cis	rs12579753	0.917	rs12372724	chr12:82193628	C/T	cg24719984	chr12:82153464	PPFIA2	-0.33	-5.04	-0.3	8.55e-7	Resting heart rate;
CESC	cis	rs514406	0.825	rs9661082	chr1:53245472	A/T	cg08859206	chr1:53392774	SCP2	0.54	7.15	0.4	8.22e-12	Monocyte count;
CESC	cis	rs2046867	0.818	rs17010188	chr3:72870351	T/C	cg25664220	chr3:72788482	NA	-0.45	-6.54	-0.37	3.08e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CESC	cis	rs2625529	0.652	rs28650442	chr15:72155445	A/T	cg16672083	chr15:72433130	SENP8	-0.47	-7.03	-0.4	1.75e-11	Red blood cell count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07151637	chr22:32149913	DEPDC5	0.6	6.86	0.39	4.93e-11	Gut microbiome composition (summer);
CESC	trans	rs11098499	0.954	rs2389803	chr4:120393511	A/G	cg25214090	chr10:38739885	LOC399744	-0.68	-9.67	-0.51	3.85e-19	Corneal astigmatism;
CESC	cis	rs2710247	1	rs2710247	chr2:219467508	A/G	cg02176678	chr2:219576539	TTLL4	0.4	6.72	0.38	1.1e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9486715	1.000	rs11153082	chr6:97059666	A/G	cg18709589	chr6:96969512	KIAA0776	-0.46	-6.4	-0.37	6.94e-10	Headache;
CESC	cis	rs11750568	0.967	rs931619	chr5:178514729	C/T	cg10208897	chr5:178548229	ADAMTS2	-0.38	-5.36	-0.31	1.8e-7	Height;
CESC	cis	rs9733	0.569	rs11204691	chr1:150644339	A/T	cg17724175	chr1:150552817	MCL1	0.44	7.23	0.41	5.25e-12	Tonsillectomy;
CESC	cis	rs6540556	0.723	rs12138452	chr1:209886578	T/A	cg05527609	chr1:210001259	C1orf107	-0.7	-7.5	-0.42	9.83e-13	Red blood cell count;
CESC	cis	rs78456975	0.527	rs10203194	chr2:1558021	A/G	cg12573674	chr2:1569213	NA	-0.45	-5.29	-0.31	2.57e-7	Placebo response in major depressive disorder (% change in symptom score);
CESC	trans	rs61931739	0.517	rs7960878	chr12:34055645	C/A	cg26384229	chr12:38710491	ALG10B	0.6	8.36	0.46	3.68e-15	Morning vs. evening chronotype;
CESC	cis	rs72945132	0.882	rs55905028	chr11:70127750	G/A	cg00319359	chr11:70116639	PPFIA1	0.78	7.78	0.43	1.6e-13	Coronary artery disease;
CESC	cis	rs208515	0.518	rs12209790	chr6:66662965	T/C	cg07460842	chr6:66804631	NA	0.83	10.33	0.54	3.09e-21	Exhaled nitric oxide levels;
CESC	cis	rs7267979	1.000	rs6083856	chr20:25407585	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.84	-16.42	-0.71	2.87e-42	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs941207	0.507	rs7297289	chr12:57076487	T/C	cg05584118	chr12:57595605	LRP1	-0.37	-5.04	-0.3	8.53e-7	Platelet count;
CESC	cis	rs9815354	0.812	rs73071341	chr3:41826211	C/T	cg03022575	chr3:42003672	ULK4	0.71	6.2	0.36	2.11e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs7208859	0.524	rs73263982	chr17:28920624	T/C	cg04154034	chr17:28927549	LRRC37B2	0.67	6.02	0.35	5.73e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs5167	0.504	rs7248162	chr19:45454686	T/C	cg20090143	chr19:45452003	APOC2	0.37	6.39	0.37	7.51e-10	Blood protein levels;
CESC	cis	rs2549003	1.000	rs9282763	chr5:131822133	T/C	cg02551604	chr5:131831745	NA	-0.37	-5.27	-0.31	2.81e-7	Asthma (sex interaction);
CESC	cis	rs7666738	0.830	rs1527517	chr4:98931907	C/T	cg05340658	chr4:99064831	C4orf37	0.82	12.17	0.6	2.24e-27	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4664304	0.816	rs67045814	chr2:160821119	A/C	cg03641300	chr2:160917029	PLA2R1	-0.41	-5.59	-0.33	5.5e-8	Crohn's disease;Inflammatory bowel disease;
CESC	trans	rs13360092	1.000	rs78895441	chr5:50563723	C/G	cg03200537	chr16:87022121	NA	0.69	6.01	0.35	6.15e-9	Verbal declarative memory;
CESC	cis	rs4727027	0.901	rs1534198	chr7:148772323	T/C	cg23583168	chr7:148888333	NA	-0.78	-11.78	-0.59	4.8e-26	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs2742417	0.603	rs2064062	chr3:45761115	G/C	cg04837898	chr3:45731254	SACM1L	-0.47	-6.21	-0.36	2.08e-9	Response to anti-depressant treatment in major depressive disorder;
CESC	cis	rs9910055	0.529	rs425038	chr17:42182028	T/C	cg08499158	chr17:42289980	UBTF	0.42	5.07	0.3	7.61e-7	Total body bone mineral density;
CESC	cis	rs17253792	0.822	rs78826571	chr14:56048906	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.85	5.74	0.33	2.53e-8	Putamen volume;
CESC	cis	rs7296418	0.663	rs4553407	chr12:123750748	G/C	cg00376283	chr12:123451042	ABCB9	0.61	8.4	0.46	2.77e-15	Platelet count;
CESC	cis	rs7927771	0.524	rs2869024	chr11:47674101	G/A	cg20307385	chr11:47447363	PSMC3	-0.62	-8.64	-0.47	5.55e-16	Subjective well-being;
CESC	trans	rs11039571	0.588	rs61917001	chr11:48233667	G/C	cg15704280	chr7:45808275	SEPT13	0.72	7.16	0.4	7.74e-12	D-dimer levels;
CESC	cis	rs2066819	1.000	rs17118409	chr12:56630764	G/A	cg26714650	chr12:56694279	CS	-1.42	-10.04	-0.53	2.52e-20	Psoriasis vulgaris;
CESC	cis	rs6690583	0.623	rs6679539	chr1:85479457	G/T	cg22153463	chr1:85462885	MCOLN2	-0.77	-7.73	-0.43	2.29e-13	Serum sulfate level;
CESC	cis	rs10779751	0.959	rs2092642	chr1:11317320	C/T	cg08854313	chr1:11322531	MTOR	0.91	14.45	0.66	2.77e-35	Body mass index;
CESC	cis	rs9929218	0.906	rs34565494	chr16:68741769	C/T	cg02972257	chr16:68554789	NA	0.57	6.36	0.36	8.78e-10	Colorectal cancer;
CESC	cis	rs2576037	0.526	rs4890703	chr18:44522037	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.6	-8.16	-0.45	1.38e-14	Personality dimensions;
CESC	cis	rs6785206	0.892	rs6439143	chr3:128425132	C/T	cg16766828	chr3:128327626	NA	-0.53	-5.28	-0.31	2.66e-7	Lymphocyte percentage of white cells;
CESC	cis	rs10504229	0.683	rs72649192	chr8:58110490	T/C	cg24829409	chr8:58192753	C8orf71	-0.65	-7.42	-0.41	1.6e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs875971	0.830	rs1167406	chr7:65556936	G/C	cg11764359	chr7:65958608	NA	-0.78	-10.74	-0.55	1.44e-22	Aortic root size;
CESC	cis	rs1878931	0.696	rs35984213	chr16:3451030	G/A	cg22508957	chr16:3507546	NAT15	-0.44	-6.47	-0.37	4.72e-10	Body mass index (adult);
CESC	cis	rs1559088	0.545	rs7257431	chr19:33566924	A/G	cg17764715	chr19:33622953	WDR88	0.6	8.48	0.46	1.6e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs9362426	0.708	rs7744793	chr6:88102040	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.52	6.09	0.35	3.86e-9	Depressive episodes in bipolar disorder;
CESC	cis	rs11690935	0.959	rs10194102	chr2:172626143	G/C	cg13550731	chr2:172543902	DYNC1I2	-0.97	-14.95	-0.68	4.66e-37	Schizophrenia;
CESC	cis	rs6693567	0.565	rs1260374	chr1:150331593	G/A	cg09579323	chr1:150459698	TARS2	0.49	6.22	0.36	1.92e-9	Migraine;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg09847284	chr11:45907071	MAPK8IP1	0.49	6.26	0.36	1.55e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs72781680	0.560	rs111310684	chr2:24265682	C/G	cg20701182	chr2:24300061	SF3B14	0.94	10.66	0.55	2.67e-22	Lymphocyte counts;
CESC	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	22.13	0.81	3.58e-62	Prudent dietary pattern;
CESC	cis	rs11676348	0.791	rs6726126	chr2:218952233	G/A	cg00012203	chr2:219082015	ARPC2	-0.53	-6.96	-0.39	2.64e-11	Ulcerative colitis;
CESC	cis	rs10791097	0.547	rs12365680	chr11:130749059	C/T	cg12179176	chr11:130786555	SNX19	0.69	10.8	0.55	8.78e-23	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs7592578	0.599	rs62180992	chr2:191285732	A/G	cg27211696	chr2:191398769	TMEM194B	-0.61	-5.93	-0.34	9.44e-9	Diastolic blood pressure;
CESC	cis	rs11718455	0.920	rs4682927	chr3:44033299	C/A	cg08738300	chr3:44038990	NA	0.45	6.1	0.35	3.68e-9	Coronary artery disease;
CESC	trans	rs1728785	1.000	rs1170439	chr16:68608511	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	7.89	0.44	7.95e-14	Ulcerative colitis;
CESC	cis	rs6938	0.618	rs12912839	chr15:75221245	C/T	cg17294928	chr15:75287854	SCAMP5	0.5	6.48	0.37	4.49e-10	Breast cancer;
CESC	cis	rs11785400	1.000	rs4557682	chr8:143738182	T/C	cg10596483	chr8:143751796	JRK	0.43	5.65	0.33	4.1e-8	Schizophrenia;
CESC	cis	rs79149102	0.649	rs1531163	chr15:75113083	A/G	cg09165964	chr15:75287851	SCAMP5	-0.78	-6.1	-0.35	3.79e-9	Lung cancer;
CESC	cis	rs7267979	0.586	rs1473695	chr20:25186965	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.66	10.94	0.56	3.16e-23	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs2425143	1.000	rs57963833	chr20:34344225	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.84	-7.89	-0.44	8.21e-14	Blood protein levels;
CESC	cis	rs710216	0.917	rs4660691	chr1:43417150	T/G	cg22176566	chr1:43424700	SLC2A1	-0.51	-5.68	-0.33	3.46e-8	Red cell distribution width;
CESC	cis	rs7017914	0.967	rs6993115	chr8:71699183	G/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.42	-5.3	-0.31	2.38e-7	Bone mineral density;
CESC	cis	rs1707322	0.721	rs11211178	chr1:46227566	G/T	cg06784218	chr1:46089804	CCDC17	0.41	7.22	0.41	5.64e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs642858	0.822	rs2050717	chr6:140369781	C/T	cg27524944	chr6:140295369	NA	-0.34	-5.07	-0.3	7.32e-7	Type 2 diabetes;
CESC	cis	rs1552244	0.572	rs58223482	chr3:10169746	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.77	8.79	0.48	1.96e-16	Alzheimer's disease;
CESC	cis	rs1670533	0.872	rs13108222	chr4:1054256	C/A	cg04106633	chr4:1044584	NA	0.41	5.2	0.3	4.01e-7	Recombination rate (females);
CESC	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg18402987	chr7:1209562	NA	0.78	7.99	0.44	4.1e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs3768617	0.811	rs10911205	chr1:183009277	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.65	8.89	0.48	9.94e-17	Fuchs's corneal dystrophy;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg06484986	chr15:42841099	LRRC57;HAUS2	0.43	6.01	0.35	6.05e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs4919087	0.748	rs701814	chr10:98975719	C/T	cg25902810	chr10:99078978	FRAT1	-0.45	-5.22	-0.31	3.57e-7	Monocyte count;
CESC	cis	rs12188164	0.686	rs72711367	chr5:418494	A/G	cg15813090	chr5:442598	EXOC3;C5orf55	0.39	5.79	0.34	1.95e-8	Cystic fibrosis severity;
CESC	cis	rs35306767	0.761	rs12773961	chr10:1013215	C/G	cg25019033	chr10:957182	NA	-0.61	-6.33	-0.36	1.02e-9	Eosinophil percentage of granulocytes;
CESC	cis	rs6967385	0.704	rs17149929	chr7:12406080	A/T	cg20607287	chr7:12443886	VWDE	0.34	5.57	0.32	6.15e-8	Response to taxane treatment (placlitaxel);
CESC	cis	rs963731	0.649	rs2924710	chr2:39302757	G/C	cg04010122	chr2:39346883	SOS1	-0.76	-5.75	-0.33	2.4e-8	Corticobasal degeneration;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02838608	chr17:47438799	ZNF652	-0.54	-6.61	-0.38	2.16e-10	Gut microbiome composition (summer);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg17095167	chr13:21833918	NA	0.5	7.03	0.4	1.72e-11	Fibrinogen levels;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg08638312	chr10:12171805	SEC61A2	-0.54	-6.92	-0.39	3.38e-11	Asthma;
CESC	trans	rs6952808	0.823	rs58222895	chr7:1885064	G/A	cg24247370	chr13:99142703	STK24	-0.41	-6.15	-0.35	2.78e-9	Bipolar disorder and schizophrenia;
CESC	trans	rs208520	1.000	rs72882102	chr6:66983408	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.84	9.33	0.5	4.5e-18	Exhaled nitric oxide output;
CESC	cis	rs6089829	0.855	rs6090205	chr20:61665269	A/G	cg03213289	chr20:61660250	NA	0.39	6.16	0.35	2.7e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs6951245	0.706	rs28522260	chr7:1183964	C/A	cg23708337	chr7:1209742	NA	0.49	5.3	0.31	2.46e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs12477438	0.798	rs13414153	chr2:99624748	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.64	-9.2	-0.49	1.14e-17	Chronic sinus infection;
CESC	cis	rs9611565	0.592	rs57102627	chr22:41987627	T/C	cg17376030	chr22:41985996	PMM1	0.49	5.49	0.32	9.33e-8	Vitiligo;
CESC	cis	rs13108904	0.870	rs4974578	chr4:1266072	A/G	cg00684032	chr4:1343700	KIAA1530	0.42	5.96	0.34	7.99e-9	Obesity-related traits;
CESC	cis	rs79349575	0.783	rs12453394	chr17:46994970	G/A	cg16584676	chr17:46985605	UBE2Z	0.53	6.6	0.38	2.25e-10	Type 2 diabetes;
CESC	cis	rs2070433	0.706	rs55696586	chr21:47733918	T/C	cg12379764	chr21:47803548	PCNT	0.6	6.32	0.36	1.1e-9	Lymphocyte counts;
CESC	cis	rs7829975	0.714	rs6994038	chr8:8660538	C/A	cg06636001	chr8:8085503	FLJ10661	0.48	6.19	0.36	2.27e-9	Mood instability;
CESC	cis	rs4713118	0.662	rs9468275	chr6:28026136	G/T	cg18032046	chr6:28092343	ZSCAN16	-0.54	-6.2	-0.36	2.21e-9	Parkinson's disease;
CESC	cis	rs2439831	0.850	rs28524541	chr15:44124831	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.68	7.46	0.42	1.22e-12	Lung cancer in ever smokers;
CESC	cis	rs2836950	0.565	rs8131132	chr21:40538256	T/C	cg11890956	chr21:40555474	PSMG1	-0.63	-8.81	-0.48	1.69e-16	Menarche (age at onset);
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg01825986	chr20:47804552	STAU1	-0.44	-6.16	-0.35	2.62e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7953508	0.506	rs3869308	chr12:93959918	A/G	cg18151635	chr12:93972918	NA	-0.47	-6.44	-0.37	5.54e-10	Pubertal anthropometrics;
CESC	cis	rs853679	0.517	rs9380057	chr6:28104634	G/T	cg08968635	chr6:28129556	ZNF389	0.42	5.72	0.33	2.82e-8	Depression;
CESC	cis	rs8067545	0.611	rs2703805	chr17:20107773	T/C	cg13482628	chr17:19912719	NA	-0.44	-5.95	-0.34	8.25e-9	Schizophrenia;
CESC	cis	rs7122539	0.646	rs682842	chr11:66568943	A/G	cg24851651	chr11:66362959	CCS	-0.49	-7.17	-0.4	7.45e-12	HIV-1 susceptibility;
CESC	cis	rs2073300	1.000	rs6137959	chr20:23442640	T/C	cg12062639	chr20:23401060	NAPB	0.91	6.41	0.37	6.71e-10	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs4563143	0.675	rs17498203	chr19:29279734	G/T	cg12667521	chr19:29218732	NA	0.48	6.19	0.36	2.22e-9	Methadone dose in opioid dependence;
CESC	cis	rs1568889	0.877	rs7933326	chr11:28288416	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.79	10.83	0.55	7.18e-23	Bipolar disorder;
CESC	cis	rs2932538	0.922	rs6690169	chr1:113114974	A/G	cg22162597	chr1:113214053	CAPZA1	0.55	6.96	0.39	2.59e-11	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CESC	cis	rs941873	0.805	rs876678	chr10:81111036	G/T	cg09469691	chr10:81107165	PPIF	0.51	6.91	0.39	3.52e-11	Height;
CESC	cis	rs873946	0.586	rs3793685	chr10:134569316	G/A	cg18305652	chr10:134549665	INPP5A	0.46	6.32	0.36	1.13e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs780096	0.526	rs3845687	chr2:27689899	T/C	cg02592271	chr2:27665507	KRTCAP3	-0.3	-5.97	-0.34	7.49e-9	Total body bone mineral density;
CESC	cis	rs6964587	0.839	rs9656002	chr7:91475007	A/G	cg17063962	chr7:91808500	NA	-0.48	-6.21	-0.36	2.07e-9	Breast cancer;
CESC	cis	rs3806843	0.966	rs1030166	chr5:140185473	G/A	cg16179182	chr5:140090404	VTRNA1-1	-0.41	-5.33	-0.31	2.08e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs1046896	0.594	rs4075209	chr17:80800027	G/T	cg19500275	chr17:80737654	TBCD	0.49	5.59	0.32	5.75e-8	Glycated hemoglobin levels;
CESC	cis	rs7811142	0.943	rs67483801	chr7:100031758	G/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.12	12.99	0.62	3.48e-30	Platelet count;
CESC	cis	rs7959452	0.535	rs10878953	chr12:69674187	A/G	cg20891283	chr12:69753455	YEATS4	0.72	10.26	0.53	5.19e-21	Blood protein levels;
CESC	cis	rs17666538	0.585	rs1669733	chr8:606696	C/T	cg07685180	chr8:600429	NA	-0.66	-5.08	-0.3	6.97e-7	IgG glycosylation;
CESC	cis	rs9488822	0.676	rs868943	chr6:116337503	G/A	cg18764771	chr6:116381957	FRK	0.22	5.44	0.32	1.23e-7	Cholesterol, total;LDL cholesterol;
CESC	cis	rs9457247	0.602	rs13204839	chr6:167471119	G/A	cg07741184	chr6:167504864	NA	0.38	6.7	0.38	1.22e-10	Crohn's disease;
CESC	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg03188948	chr7:1209495	NA	0.69	6.56	0.37	2.74e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7605827	0.866	rs34815739	chr2:15533375	A/G	cg19274914	chr2:15703543	NA	0.36	6.59	0.38	2.3e-10	Educational attainment (years of education);
CESC	cis	rs7095944	0.614	rs7898003	chr10:126451385	G/A	cg08799069	chr10:126477246	METTL10	-0.35	-5.15	-0.3	5.19e-7	Asthma;
CESC	cis	rs9828933	0.752	rs28675788	chr3:63942188	C/G	cg16258503	chr3:63850278	ATXN7;THOC7	-0.95	-8.42	-0.46	2.43e-15	Type 2 diabetes;
CESC	cis	rs17376456	0.877	rs12109629	chr5:93359702	A/G	cg25358565	chr5:93447407	FAM172A	1.1	10.93	0.56	3.31e-23	Diabetic retinopathy;
CESC	cis	rs2072499	0.966	rs1137703	chr1:156184458	T/C	cg25208724	chr1:156163844	SLC25A44	0.99	17.9	0.74	1.68e-47	Testicular germ cell tumor;
CESC	cis	rs3106136	0.967	rs2171381	chr4:95224768	T/A	cg11021082	chr4:95130006	SMARCAD1	-0.45	-6.53	-0.37	3.34e-10	Capecitabine sensitivity;
CESC	cis	rs6547741	0.904	rs2384628	chr2:27774702	T/G	cg27432699	chr2:27873401	GPN1	0.47	6.62	0.38	1.95e-10	Oral cavity cancer;
CESC	cis	rs8031584	0.652	rs2691683	chr15:31135060	A/G	cg08109568	chr15:31115862	NA	0.73	9.9	0.52	7.4e-20	Huntington's disease progression;
CESC	cis	rs10744422	0.925	rs3825143	chr12:123352179	C/T	cg25930673	chr12:123319894	HIP1R	-0.67	-5.29	-0.31	2.54e-7	Schizophrenia;
CESC	cis	rs6456156	0.586	rs12527827	chr6:167469271	C/T	cg07741184	chr6:167504864	NA	0.36	6.17	0.35	2.48e-9	Primary biliary cholangitis;
CESC	cis	rs10504229	1.000	rs66936919	chr8:58172868	C/G	cg22535103	chr8:58192502	C8orf71	-1.03	-12.78	-0.62	1.84e-29	Developmental language disorder (linguistic errors);
CESC	cis	rs9914988	0.673	rs9890212	chr17:27169890	G/C	cg20469991	chr17:27169893	C17orf63	-0.51	-5.76	-0.33	2.32e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CESC	cis	rs7618915	0.547	rs2289250	chr3:52682946	A/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	-0.33	-5.95	-0.34	8.25e-9	Bipolar disorder;
CESC	cis	rs796364	0.806	rs76112266	chr2:201087157	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.77	-6.66	-0.38	1.59e-10	Schizophrenia;
CESC	cis	rs2033711	0.755	rs4801587	chr19:58936679	C/A	cg00825309	chr19:58991885	ZNF446	-0.54	-7.55	-0.42	7.07e-13	Uric acid clearance;
CESC	cis	rs6964587	1.000	rs35317449	chr7:91637010	G/A	cg17063962	chr7:91808500	NA	0.57	7.93	0.44	6.22e-14	Breast cancer;
CESC	cis	rs28489187	0.617	rs233061	chr1:85799282	G/A	cg16011679	chr1:85725395	C1orf52	0.46	5.52	0.32	7.91e-8	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	cis	rs9660180	0.967	rs10907191	chr1:1774820	A/T	cg03396347	chr1:1875803	NA	-0.43	-6.69	-0.38	1.33e-10	Body mass index;
CESC	cis	rs4631830	0.869	rs11006207	chr10:51538176	T/C	cg16070123	chr10:51489643	NA	-0.34	-5.07	-0.3	7.4e-7	Prostate-specific antigen levels;
CESC	cis	rs9309473	0.950	rs7596773	chr2:73846000	C/T	cg20560298	chr2:73613845	ALMS1	-0.51	-6.54	-0.37	3.17e-10	Metabolite levels;
CESC	cis	rs1552244	1.000	rs2272123	chr3:10140115	G/A	cg00149659	chr3:10157352	C3orf10	0.73	8.97	0.48	5.62e-17	Alzheimer's disease;
CESC	cis	rs17376456	1.000	rs34756085	chr5:93556294	A/G	cg21475434	chr5:93447410	FAM172A	0.89	7.34	0.41	2.62e-12	Diabetic retinopathy;
CESC	cis	rs12682352	0.579	rs7006589	chr8:8668486	A/G	cg17143192	chr8:8559678	CLDN23	0.43	5.07	0.3	7.61e-7	Neuroticism;
CESC	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg07308232	chr7:1071921	C7orf50	-0.41	-5.5	-0.32	9.14e-8	Longevity;Endometriosis;
CESC	trans	rs10776614	0.799	rs7350424	chr10:49765730	C/A	cg19218067	chr2:181235115	NA	0.49	6.0	0.35	6.35e-9	Self-employment;
CESC	cis	rs9611565	0.512	rs5996063	chr22:42168767	G/A	cg06634786	chr22:41940651	POLR3H	0.68	6.78	0.38	7.6e-11	Vitiligo;
CESC	cis	rs11098499	1.000	rs13116504	chr4:120209412	A/C	cg09307838	chr4:120376055	NA	0.88	11.9	0.59	1.87e-26	Corneal astigmatism;
CESC	cis	rs9393777	0.588	rs6941920	chr6:26492149	C/T	cg12826209	chr6:26865740	GUSBL1	0.59	6.91	0.39	3.52e-11	Intelligence (multi-trait analysis);
CESC	cis	rs4713118	0.662	rs149970	chr6:27980220	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.48	-5.81	-0.34	1.76e-8	Parkinson's disease;
CESC	cis	rs7084402	0.935	rs4141671	chr10:60338753	T/C	cg07615347	chr10:60278583	BICC1	-0.56	-8.48	-0.46	1.63e-15	Refractive error;
CESC	cis	rs2191566	0.576	rs395803	chr19:44494694	A/G	cg20607764	chr19:44506953	ZNF230	0.45	5.7	0.33	3.16e-8	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs12476592	0.602	rs1867849	chr2:63726932	C/T	cg17519650	chr2:63277830	OTX1	-0.47	-5.4	-0.31	1.46e-7	Childhood ear infection;
CESC	cis	rs2737618	0.651	rs2816975	chr1:200081159	A/G	cg21825944	chr1:200113062	NR5A2	-0.43	-6.85	-0.39	5.28e-11	Uric acid levels;
CESC	cis	rs17711722	0.523	rs365896	chr7:65510697	A/G	cg05332525	chr7:65337924	VKORC1L1	-0.45	-5.74	-0.33	2.61e-8	Calcium levels;
CESC	cis	rs2522056	1.000	rs2106854	chr5:131769174	C/T	cg24060327	chr5:131705240	SLC22A5	0.65	7.5	0.42	9.49e-13	Lymphocyte counts;Fibrinogen;
CESC	cis	rs1552244	0.935	rs11926481	chr3:10142102	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	12.84	0.62	1.12e-29	Alzheimer's disease;
CESC	cis	rs8103278	1.000	rs36091860	chr19:46312880	G/A	cg11657440	chr19:46296263	DMWD	-0.59	-7.24	-0.41	4.98e-12	Coronary artery disease;
CESC	cis	rs1707322	0.963	rs11211202	chr1:46292382	C/T	cg06784218	chr1:46089804	CCDC17	0.32	5.5	0.32	8.73e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs35110281	0.782	rs9981291	chr21:45031458	A/G	cg01579765	chr21:45077557	HSF2BP	-0.56	-9.24	-0.49	8.15e-18	Mean corpuscular volume;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg13725913	chr9:140675929	EHMT1	0.45	6.46	0.37	4.87e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs2361718	0.568	rs1042397	chr17:78092063	G/A	cg21238619	chr17:78079768	GAA	-0.38	-6.16	-0.35	2.73e-9	Yeast infection;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	ch.7.2254086F	chr7:105135578	PUS7	0.46	6.43	0.37	6.07e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs13108904	0.967	rs4974582	chr4:1279687	C/T	cg00684032	chr4:1343700	KIAA1530	0.39	5.43	0.32	1.27e-7	Obesity-related traits;
CESC	cis	rs56046484	0.956	rs17540501	chr15:85638101	C/G	cg08123816	chr15:85640762	PDE8A	-0.5	-6.02	-0.35	5.77e-9	Testicular germ cell tumor;
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg10315922	chr12:66563928	TMBIM4	-0.4	-6.37	-0.36	8.18e-10	Vertical cup-disc ratio;
CESC	cis	rs3747547	0.642	rs35690683	chr9:38076664	C/T	cg13774184	chr9:37916125	SHB	-0.66	-5.62	-0.33	4.82e-8	Metabolite levels (Dihydroxy docosatrienoic acid);
CESC	cis	rs9322193	0.884	rs11155679	chr6:150080017	T/C	cg02462569	chr6:150064036	NUP43	-0.38	-5.42	-0.32	1.32e-7	Lung cancer;
CESC	cis	rs26868	0.766	rs27556	chr16:2249325	T/C	cg07587117	chr16:2239488	CASKIN1	0.33	5.34	0.31	2.02e-7	Height;
CESC	cis	rs7786877	0.521	rs2293767	chr7:100361675	A/G	cg20848291	chr7:100343083	ZAN	0.5	6.18	0.36	2.35e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs854765	0.663	rs4925120	chr17:17754633	C/T	cg16928487	chr17:17741425	SREBF1	0.61	11.39	0.57	9.98e-25	Total body bone mineral density;
CESC	cis	rs7945705	0.870	rs10840142	chr11:8906078	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.51	8.08	0.44	2.3e-14	Hemoglobin concentration;
CESC	cis	rs8067354	0.574	rs1292043	chr17:57934169	A/G	cg13753209	chr17:57696993	CLTC	0.57	6.09	0.35	3.89e-9	Hemoglobin concentration;
CESC	cis	rs12477438	0.520	rs6542866	chr2:99764592	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.79	12.89	0.62	7.96e-30	Chronic sinus infection;
CESC	cis	rs875971	0.660	rs1860470	chr7:66103694	G/C	cg18876405	chr7:65276391	NA	-0.5	-6.54	-0.37	3.16e-10	Aortic root size;
CESC	cis	rs4237845	0.537	rs2002275	chr12:58283385	A/G	cg00677455	chr12:58241039	CTDSP2	0.7	9.54	0.51	9.85e-19	Intelligence (multi-trait analysis);
CESC	cis	rs9322193	0.923	rs4870509	chr6:150023348	C/G	cg09699651	chr6:150184138	LRP11	0.4	5.08	0.3	7.24e-7	Lung cancer;
CESC	cis	rs9910055	0.762	rs2526020	chr17:42216588	G/T	cg10896456	chr17:42255109	ASB16;C17orf65	0.46	6.83	0.39	5.87e-11	Total body bone mineral density;
CESC	trans	rs7947523	0.813	rs4999940	chr11:80942337	C/T	cg26035463	chr12:117627651	FBXO21	0.48	6.2	0.36	2.15e-9	Emphysema imaging phenotypes;
CESC	cis	rs6831352	0.918	rs17217949	chr4:100054312	A/G	cg13256891	chr4:100009986	ADH5	-0.77	-8.45	-0.46	1.97e-15	Alcohol dependence;
CESC	cis	rs11264213	0.591	rs399393	chr1:36553673	A/G	cg27506609	chr1:36549197	TEKT2	-0.75	-7.15	-0.4	8.51e-12	Schizophrenia;
CESC	cis	rs7772486	0.754	rs9399561	chr6:145955687	C/G	cg05347473	chr6:146136440	FBXO30	0.56	7.07	0.4	1.37e-11	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09938328	chr1:39325620	RRAGC	0.5	6.43	0.37	5.9e-10	Gut microbiome composition (summer);
CESC	cis	rs6831352	0.918	rs2602895	chr4:100045840	C/T	cg13256891	chr4:100009986	ADH5	0.74	8.13	0.45	1.63e-14	Alcohol dependence;
CESC	cis	rs7772486	0.840	rs2814867	chr6:146334030	C/A	cg23711669	chr6:146136114	FBXO30	0.82	11.9	0.59	1.96e-26	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs11711311	1.000	rs34475696	chr3:113458293	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.72	10.27	0.53	4.81e-21	IgG glycosylation;
CESC	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.71	0.8	9.48e-61	Prudent dietary pattern;
CESC	cis	rs875971	0.830	rs427575	chr7:65519219	A/G	cg18876405	chr7:65276391	NA	0.54	7.18	0.4	7.22e-12	Aortic root size;
CESC	cis	rs72781680	0.752	rs55859418	chr2:23904231	C/A	cg20701182	chr2:24300061	SF3B14	0.81	6.94	0.39	3.05e-11	Lymphocyte counts;
CESC	cis	rs3858526	0.959	rs61876223	chr11:5943393	G/A	cg05234568	chr11:5960015	NA	-0.61	-7.29	-0.41	3.68e-12	DNA methylation (variation);
CESC	cis	rs875971	0.862	rs2024192	chr7:66041447	G/T	cg11764359	chr7:65958608	NA	-0.78	-11.17	-0.57	5.37e-24	Aortic root size;
CESC	cis	rs10927875	0.793	rs1763619	chr1:16326935	A/G	cg21214613	chr1:16344536	HSPB7	0.37	5.28	0.31	2.69e-7	Dilated cardiomyopathy;
CESC	cis	rs9768139	0.733	rs71545585	chr7:158118672	G/A	cg06219351	chr7:158114137	PTPRN2	-0.48	-7.29	-0.41	3.58e-12	Calcium levels;
CESC	cis	rs9300255	0.510	rs1790109	chr12:123637752	C/G	cg00376283	chr12:123451042	ABCB9	0.7	8.88	0.48	1.03e-16	Neutrophil percentage of white cells;
CESC	cis	rs7584330	0.744	rs10929234	chr2:238380034	C/G	cg14458575	chr2:238380390	NA	-0.88	-12.58	-0.61	9.33e-29	Prostate cancer;
CESC	cis	rs72781680	0.821	rs111571980	chr2:24201695	C/G	cg08917208	chr2:24149416	ATAD2B	0.64	6.22	0.36	1.92e-9	Lymphocyte counts;
CESC	cis	rs1670533	1.000	rs12645644	chr4:1054159	C/T	cg27284194	chr4:1044797	NA	0.41	5.23	0.31	3.37e-7	Recombination rate (females);
CESC	cis	rs7017914	0.967	rs13257800	chr8:71714133	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.44	-5.71	-0.33	2.97e-8	Bone mineral density;
CESC	cis	rs1059312	0.966	rs35907548	chr12:129282180	T/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.71	-10.09	-0.53	1.81e-20	Systemic lupus erythematosus;
CESC	cis	rs6089584	0.888	rs6089623	chr20:60615759	A/G	cg24733560	chr20:60626293	TAF4	0.44	6.28	0.36	1.37e-9	Body mass index;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg17446216	chr1:32480239	KHDRBS1	-0.45	-6.46	-0.37	4.94e-10	Asthma;
CESC	cis	rs2637266	0.626	rs846619	chr10:78545449	A/G	cg18941641	chr10:78392320	NA	0.41	7.71	0.43	2.48e-13	Pulmonary function;
CESC	cis	rs514406	0.858	rs574853	chr1:53310959	A/T	cg24675658	chr1:53192096	ZYG11B	-0.6	-7.73	-0.43	2.23e-13	Monocyte count;
CESC	cis	rs4665809	0.590	rs6716858	chr2:26423414	G/A	cg27170947	chr2:26402098	FAM59B	-0.76	-9.71	-0.51	2.95e-19	Gut microbiome composition (summer);
CESC	cis	rs9640161	0.789	rs34728606	chr7:150054694	G/A	cg10018233	chr7:150070692	REPIN1	0.4	5.72	0.33	2.86e-8	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs6504340	0.793	rs56128659	chr17:46621828	T/A	cg04904318	chr17:46607828	HOXB1	-0.56	-5.21	-0.3	3.76e-7	Primary tooth development (number of teeth);
CESC	cis	rs919433	0.889	rs12693816	chr2:198208420	T/A	cg10820045	chr2:198174542	NA	-0.41	-5.98	-0.34	7.31e-9	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs9303401	0.614	rs34920953	chr17:56589406	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.99	12.53	0.61	1.36e-28	Cognitive test performance;
CESC	cis	rs6977955	1.000	rs6977955	chr7:28156887	A/G	cg23620719	chr7:28220237	JAZF1	-0.47	-5.43	-0.32	1.28e-7	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs853679	0.517	rs4713146	chr6:28111536	A/T	cg23161317	chr6:28129485	ZNF389	0.5	6.22	0.36	1.89e-9	Depression;
CESC	cis	rs40363	0.672	rs1617722	chr16:3520806	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	0.46	5.67	0.33	3.73e-8	Tuberculosis;
CESC	cis	rs875971	0.862	rs10950033	chr7:65739673	A/G	cg18876405	chr7:65276391	NA	-0.49	-6.75	-0.38	9.38e-11	Aortic root size;
CESC	cis	rs1552244	0.935	rs11926481	chr3:10142102	G/T	cg08888203	chr3:10149979	C3orf24	0.47	6.07	0.35	4.31e-9	Alzheimer's disease;
CESC	cis	rs4523957	0.855	rs216212	chr17:2134214	T/C	cg16513277	chr17:2031491	SMG6	0.63	8.84	0.48	1.36e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs13392177	0.660	rs10932762	chr2:219076213	G/C	cg00012203	chr2:219082015	ARPC2	-0.66	-8.25	-0.45	7.36e-15	Pyoderma gangrenosum in inflammatory bowel disease;
CESC	cis	rs7927771	0.524	rs7107792	chr11:47669249	A/C	cg18512352	chr11:47633146	NA	0.34	5.34	0.31	2.01e-7	Subjective well-being;
CESC	cis	rs4819052	0.679	rs2255761	chr21:46683622	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.69	9.48	0.5	1.49e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs514406	0.644	rs928451	chr1:53195800	A/G	cg24675658	chr1:53192096	ZYG11B	0.64	7.96	0.44	5.13e-14	Monocyte count;
CESC	cis	rs807669	0.772	rs809901	chr22:19228736	C/T	cg02655711	chr22:19163373	SLC25A1	0.54	7.96	0.44	5.14e-14	Metabolite levels;
CESC	cis	rs1862618	0.671	rs252897	chr5:56223000	G/A	cg18230493	chr5:56204884	C5orf35	-0.62	-8.17	-0.45	1.27e-14	Initial pursuit acceleration;
CESC	trans	rs1814175	0.645	rs28436748	chr11:50046422	G/A	cg03929089	chr4:120376271	NA	-0.91	-14.82	-0.67	1.29e-36	Height;
CESC	cis	rs2644899	0.793	rs2644916	chr19:41309211	A/G	cg24958765	chr19:41283667	RAB4B	-0.55	-5.93	-0.34	9.25e-9	Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs7828089	0.582	rs7825938	chr8:22266866	G/A	cg13512537	chr8:22265999	SLC39A14	-0.36	-5.13	-0.3	5.71e-7	Verbal declarative memory;
CESC	cis	rs73206853	0.686	rs7139314	chr12:110923871	G/A	cg12870014	chr12:110450643	ANKRD13A	0.65	5.59	0.32	5.78e-8	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs2380220	0.938	rs6923253	chr6:95970141	C/G	cg15832292	chr6:96025679	MANEA	0.66	6.13	0.35	3.09e-9	Behavioural disinhibition (generation interaction);
CESC	cis	rs9399135	0.967	rs4451151	chr6:135310546	C/T	cg24558204	chr6:135376177	HBS1L	0.51	6.92	0.39	3.31e-11	Red blood cell count;
CESC	cis	rs6565180	0.888	rs12447833	chr16:30390314	T/C	cg17640201	chr16:30407289	ZNF48	0.94	13.64	0.64	1.91e-32	Tonsillectomy;
CESC	cis	rs131805	1.000	rs3091397	chr22:50957520	C/T	cg25309564	chr22:51001381	C22orf41	0.59	6.72	0.38	1.13e-10	Granulocyte percentage of myeloid white cells;
CESC	cis	rs11190604	1.000	rs4919465	chr10:102221703	C/T	cg07080220	chr10:102295463	HIF1AN	0.55	5.51	0.32	8.5e-8	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs6460942	0.841	rs17444203	chr7:12461864	C/G	cg20607287	chr7:12443886	VWDE	0.76	10.98	0.56	2.3e-23	Coronary artery disease;
CESC	cis	rs2985684	0.948	rs6572592	chr14:50080871	G/A	cg02151108	chr14:50098012	C14orf104	-0.41	-5.43	-0.32	1.26e-7	Carotid intima media thickness;
CESC	cis	rs117623576	0.680	rs11008756	chr10:32363137	A/G	cg03047570	chr10:32398778	NA	-0.61	-6.61	-0.38	2.17e-10	Anti-saccade response;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27572068	chr3:25728371	NA	-0.58	-6.88	-0.39	4.43e-11	Gut microbiome composition (summer);
CESC	cis	rs10733682	0.659	rs13287548	chr9:129466456	C/T	cg00232160	chr9:129468157	NA	0.38	6.07	0.35	4.51e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs1023500	0.573	rs2413666	chr22:42459622	C/T	cg04733989	chr22:42467013	NAGA	0.78	11.69	0.58	9.73e-26	Schizophrenia;
CESC	cis	rs10504229	0.683	rs7816733	chr8:58129855	G/A	cg02725872	chr8:58115012	NA	-0.45	-7.05	-0.4	1.52e-11	Developmental language disorder (linguistic errors);
CESC	trans	rs427691	0.625	rs845738	chr5:109018115	G/A	cg00054525	chr16:88717587	CYBA	-0.61	-6.64	-0.38	1.73e-10	Autism spectrum disorder or schizophrenia;
CESC	cis	rs4253772	0.591	rs6008365	chr22:46652929	G/A	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.68	8.12	0.45	1.8e-14	LDL cholesterol;Cholesterol, total;
CESC	cis	rs12477438	0.520	rs6741772	chr2:99738961	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	15.15	0.68	9.04e-38	Chronic sinus infection;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg17343483	chr2:97527523	SEMA4C	-0.52	-7.04	-0.4	1.66e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs3020736	0.500	rs6002597	chr22:42488160	C/A	cg12850546	chr22:42539477	CYP2D7P1	0.44	5.23	0.31	3.44e-7	Autism spectrum disorder or schizophrenia;
CESC	trans	rs9391997	0.567	rs4256472	chr6:434915	A/G	cg18341491	chr13:38174258	POSTN	0.31	6.1	0.35	3.66e-9	Chronic lymphocytic leukemia;
CESC	cis	rs7917772	0.503	rs7899576	chr10:104307504	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.55	7.65	0.43	3.63e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs9549367	0.789	rs9549701	chr13:113881752	G/C	cg00898013	chr13:113819073	PROZ	-0.5	-6.85	-0.39	5.21e-11	Platelet distribution width;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05102554	chr3:38388371	XYLB	0.65	7.4	0.41	1.76e-12	Gut microbiome composition (summer);
CESC	cis	rs7618915	0.501	rs3733039	chr3:52719088	C/T	cg18404041	chr3:52824283	ITIH1	-0.38	-6.53	-0.37	3.29e-10	Bipolar disorder;
CESC	cis	rs9733	0.519	rs1336899	chr1:150678910	T/C	cg17724175	chr1:150552817	MCL1	0.45	7.39	0.41	1.88e-12	Tonsillectomy;
CESC	cis	rs3733585	0.699	rs7657340	chr4:9966772	A/T	cg11266682	chr4:10021025	SLC2A9	-0.58	-10.94	-0.56	3.08e-23	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs4561483	0.583	rs11075027	chr16:11948895	T/C	cg08843971	chr16:11963173	GSPT1	0.48	6.64	0.38	1.78e-10	Testicular germ cell tumor;
CESC	cis	rs4713118	0.527	rs4713151	chr6:28136356	G/A	cg12963246	chr6:28129442	ZNF389	0.54	7.12	0.4	1.02e-11	Parkinson's disease;
CESC	cis	rs2295499	0.754	rs2285082	chr4:2627698	G/A	cg27239842	chr4:2403781	ZFYVE28	-0.33	-5.45	-0.32	1.15e-7	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06697439	chr19:59031463	ZBTB45	-0.6	-7.26	-0.41	4.25e-12	Gut microbiome composition (summer);
CESC	cis	rs854765	0.693	rs4924823	chr17:17764502	A/G	cg16928487	chr17:17741425	SREBF1	0.55	9.67	0.51	3.93e-19	Total body bone mineral density;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09744376	chr3:53080176	SFMBT1	0.59	6.85	0.39	5.22e-11	Gut microbiome composition (summer);
CESC	cis	rs11025559	0.812	rs10833336	chr11:20514288	C/G	cg19653624	chr11:20408972	PRMT3	-0.44	-5.05	-0.3	8.25e-7	Pursuit maintenance gain;
CESC	cis	rs9790314	0.740	rs4856767	chr3:161004379	C/T	cg03342759	chr3:160939853	NMD3	-0.52	-7.47	-0.42	1.18e-12	Morning vs. evening chronotype;
CESC	cis	rs870825	0.616	rs7654208	chr4:185648877	C/T	cg04058563	chr4:185651563	MLF1IP	0.63	6.96	0.39	2.59e-11	Blood protein levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05714672	chr3:15469004	METTL6;EAF1	0.58	6.67	0.38	1.47e-10	Gut microbiome composition (summer);
CESC	cis	rs2486288	0.656	rs6493145	chr15:45573862	G/T	cg09092052	chr15:45571596	NA	0.44	5.27	0.31	2.8e-7	Glomerular filtration rate;
CESC	cis	rs11030122	0.702	rs10835407	chr11:3993231	C/T	cg18678763	chr11:4115507	RRM1	0.47	6.22	0.36	1.88e-9	Mean platelet volume;Platelet distribution width;
CESC	cis	rs782590	0.967	rs782588	chr2:55841640	T/C	cg18811423	chr2:55921094	PNPT1	0.82	13.33	0.63	2.34e-31	Metabolic syndrome;
CESC	cis	rs12477438	0.798	rs12477754	chr2:99628073	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.75	-10.87	-0.56	5.17e-23	Chronic sinus infection;
CESC	cis	rs2576037	0.583	rs9304336	chr18:44461687	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.34	5.37	0.31	1.76e-7	Personality dimensions;
CESC	cis	rs765787	0.530	rs4775837	chr15:45537684	G/T	cg24006582	chr15:45444508	DUOX1	-0.59	-7.32	-0.41	3.04e-12	Uric acid levels;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg02908720	chr7:127292155	SND1	-0.41	-6.15	-0.35	2.88e-9	Gambling;
CESC	cis	rs2267137	0.903	rs2283850	chr22:29772391	G/C	cg07256473	chr22:29710276	RASL10A	0.42	6.5	0.37	4.08e-10	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	cis	rs854765	0.647	rs854763	chr17:18010095	C/G	cg16928487	chr17:17741425	SREBF1	-0.53	-8.5	-0.46	1.38e-15	Total body bone mineral density;
CESC	cis	rs6089829	0.962	rs3746749	chr20:61667333	T/C	cg16240275	chr20:61666158	NCRNA00029	0.5	8.91	0.48	8.46e-17	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs10883723	0.810	rs2296589	chr10:104248106	T/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.54	7.48	0.42	1.09e-12	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs4523957	0.928	rs6502155	chr17:2176964	A/G	cg16513277	chr17:2031491	SMG6	-0.59	-8.07	-0.44	2.41e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs9815354	0.680	rs73073301	chr3:42028777	T/C	cg03022575	chr3:42003672	ULK4	0.75	6.64	0.38	1.72e-10	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs9916302	0.904	rs755500	chr17:37409865	C/T	cg15445000	chr17:37608096	MED1	0.39	6.21	0.36	2.02e-9	Glomerular filtration rate (creatinine);
CESC	trans	rs3749237	1.000	rs11920900	chr3:49823024	G/C	cg21659725	chr3:3221576	CRBN	0.53	6.33	0.36	1.04e-9	Resting heart rate;
CESC	cis	rs780096	0.527	rs11127044	chr2:27740404	C/G	cg24768116	chr2:27665128	KRTCAP3	-0.3	-5.47	-0.32	1.06e-7	Total body bone mineral density;
CESC	cis	rs12477438	0.520	rs6717729	chr2:99756941	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.88	15.37	0.69	1.49e-38	Chronic sinus infection;
CESC	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg05313129	chr8:58192883	C8orf71	-0.49	-5.34	-0.31	1.98e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs9443189	0.570	rs72884926	chr6:76266208	T/C	cg01950844	chr6:76311363	SENP6	0.86	9.09	0.49	2.37e-17	Prostate cancer;
CESC	cis	rs7394190	0.748	rs78790589	chr10:75539598	G/A	cg07699608	chr10:75541558	CHCHD1	0.64	5.28	0.31	2.63e-7	Incident atrial fibrillation;
CESC	cis	rs10411936	0.785	rs2363120	chr19:16519871	C/A	cg10248733	chr19:16607483	C19orf44;CALR3	-0.45	-5.56	-0.32	6.62e-8	White blood cell count;Multiple sclerosis;
CESC	cis	rs875971	0.522	rs4502988	chr7:65297746	A/G	cg11987759	chr7:65425863	GUSB	-0.48	-6.56	-0.37	2.82e-10	Aortic root size;
CESC	cis	rs9486719	0.947	rs11755945	chr6:96908038	G/C	cg06623918	chr6:96969491	KIAA0776	-0.8	-8.21	-0.45	9.55e-15	Migraine;Coronary artery disease;
CESC	cis	rs11785400	1.000	rs4518642	chr8:143737396	T/C	cg10596483	chr8:143751796	JRK	0.43	5.67	0.33	3.65e-8	Schizophrenia;
CESC	cis	rs4595586	0.545	rs6580895	chr12:39372011	C/T	cg26384229	chr12:38710491	ALG10B	-0.51	-7.15	-0.4	8.31e-12	Morning vs. evening chronotype;
CESC	cis	rs9916302	0.904	rs4795357	chr17:37569551	T/C	cg07936489	chr17:37558343	FBXL20	-0.78	-10.65	-0.55	2.75e-22	Glomerular filtration rate (creatinine);
CESC	cis	rs853679	0.517	rs9380059	chr6:28132358	A/C	cg22143856	chr6:28129313	ZNF389	0.49	6.24	0.36	1.73e-9	Depression;
CESC	cis	rs2842992	0.830	rs2758313	chr6:160154099	C/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.69	8.35	0.46	3.94e-15	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs1552244	1.000	rs6789156	chr3:10124120	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	11.62	0.58	1.72e-25	Alzheimer's disease;
CESC	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg10295955	chr4:187884368	NA	-1.05	-18.46	-0.75	1.69e-49	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs763121	0.853	rs2179142	chr22:39037954	G/A	cg06022373	chr22:39101656	GTPBP1	0.92	15.05	0.68	2.09e-37	Menopause (age at onset);
CESC	cis	rs7089973	0.604	rs2420067	chr10:116590348	A/G	cg25233709	chr10:116636983	FAM160B1	0.38	5.9	0.34	1.12e-8	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs1008375	0.806	rs13139898	chr4:17706928	T/G	cg16339924	chr4:17578868	LAP3	-0.66	-7.93	-0.44	6.23e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs17125944	0.615	rs7151643	chr14:53313661	G/C	cg00686598	chr14:53173677	PSMC6	-0.56	-5.09	-0.3	6.79e-7	Alzheimer's disease (late onset);
CESC	cis	rs36051895	0.664	rs11788834	chr9:5092466	G/A	cg02405213	chr9:5042618	JAK2	-0.52	-6.38	-0.36	7.97e-10	Pediatric autoimmune diseases;
CESC	cis	rs7020830	0.867	rs7852593	chr9:37332380	A/T	cg14294708	chr9:37120828	ZCCHC7	1.23	23.26	0.82	5.6e-66	Schizophrenia;
CESC	cis	rs1062177	1.000	rs2915869	chr5:151171509	C/T	cg00977110	chr5:151150581	G3BP1	0.66	7.11	0.4	1.06e-11	Preschool internalizing problems;
CESC	cis	rs7618915	0.501	rs35526119	chr3:52749334	C/T	cg17372223	chr3:52568218	NT5DC2	0.44	6.62	0.38	1.95e-10	Bipolar disorder;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg11167532	chr17:46570090	NA	0.51	6.79	0.38	7.55e-11	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs877282	0.891	rs11253406	chr10:796297	G/A	cg22713356	chr15:30763199	NA	1.32	13.47	0.64	7.47e-32	Uric acid levels;
CESC	cis	rs7914558	1.000	rs2275271	chr10:104814162	T/C	cg04362960	chr10:104952993	NT5C2	0.47	6.32	0.36	1.11e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg01171360	chr6:293285	DUSP22	-0.68	-9.18	-0.49	1.29e-17	Menopause (age at onset);
CESC	cis	rs7264396	0.635	rs6058375	chr20:34531997	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.79	-10.89	-0.56	4.64e-23	Total cholesterol levels;
CESC	cis	rs11048434	0.698	rs1805745	chr12:9065226	A/T	cg04155231	chr12:9217510	LOC144571	0.33	5.32	0.31	2.16e-7	Sjögren's syndrome;
CESC	cis	rs60154123	0.505	rs76426571	chr1:210041634	C/T	cg22029157	chr1:209979665	IRF6	0.72	7.16	0.4	8.04e-12	Coronary artery disease;
CESC	cis	rs854765	0.583	rs4414547	chr17:17859052	G/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.59	8.26	0.45	7.24e-15	Total body bone mineral density;
CESC	cis	rs6460942	0.915	rs62448593	chr7:12436845	G/C	cg02935154	chr7:12443704	VWDE	-0.59	-6.31	-0.36	1.14e-9	Coronary artery disease;
CESC	cis	rs8067545	1.000	rs2108979	chr17:19928566	G/A	cg13482628	chr17:19912719	NA	0.42	5.63	0.33	4.61e-8	Schizophrenia;
CESC	cis	rs6752107	1.000	rs3828309	chr2:234180410	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	-0.44	-5.73	-0.33	2.66e-8	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs11098499	0.863	rs7657849	chr4:120455494	T/C	cg24375607	chr4:120327624	NA	0.43	5.21	0.3	3.82e-7	Corneal astigmatism;
CESC	cis	rs6089584	0.566	rs2181589	chr20:60622817	C/T	cg06108461	chr20:60628389	TAF4	0.63	8.38	0.46	3.16e-15	Body mass index;
CESC	cis	rs4237845	0.837	rs7954957	chr12:58299250	C/T	cg00677455	chr12:58241039	CTDSP2	0.43	5.62	0.33	4.88e-8	Intelligence (multi-trait analysis);
CESC	cis	rs7618915	0.501	rs12635140	chr3:52738165	C/T	cg18404041	chr3:52824283	ITIH1	0.39	6.72	0.38	1.12e-10	Bipolar disorder;
CESC	cis	rs2242194	0.816	rs11264296	chr1:154994750	T/C	cg09359103	chr1:154839909	KCNN3	-0.41	-6.61	-0.38	2.14e-10	Schizophrenia;
CESC	cis	rs9788682	1.000	rs7163730	chr15:78814681	A/G	cg06917634	chr15:78832804	PSMA4	-0.54	-6.36	-0.36	8.71e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs7809950	0.598	rs2283038	chr7:106835410	C/T	cg23024343	chr7:107201750	COG5	-0.56	-6.79	-0.38	7.33e-11	Coronary artery disease;
CESC	cis	rs3931020	0.548	rs969435	chr1:75273866	A/G	cg21906852	chr1:75198582	TYW3;CRYZ	-0.4	-5.15	-0.3	4.97e-7	Resistin levels;
CESC	cis	rs10791097	0.694	rs1054869	chr11:130742630	G/A	cg12179176	chr11:130786555	SNX19	0.65	10.07	0.53	2.16e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs16854884	0.537	rs16855026	chr3:143868350	A/C	cg01302019	chr3:143689584	C3orf58	-0.35	-5.34	-0.31	2.01e-7	Economic and political preferences (feminism/equality);
CESC	cis	rs9362426	1.000	rs6930076	chr6:88088654	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.49	6.13	0.35	3.09e-9	Depressive episodes in bipolar disorder;
CESC	cis	rs11630290	0.592	rs4777332	chr15:64158112	A/G	cg12036633	chr15:63758958	NA	0.45	5.34	0.31	2e-7	Iris characteristics;
CESC	trans	rs57221529	0.766	rs12522140	chr5:587261	C/A	cg25482853	chr8:67687455	SGK3	1.01	9.99	0.52	3.67e-20	Lung disease severity in cystic fibrosis;
CESC	cis	rs2404602	0.583	rs11072580	chr15:76540231	G/A	cg26408565	chr15:76604113	ETFA	-0.42	-6.37	-0.36	8.13e-10	Blood metabolite levels;
CESC	cis	rs704795	0.836	rs1083865	chr2:27620827	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.34	-6.29	-0.36	1.31e-9	Menopause (age at onset);
CESC	cis	rs4700695	0.719	rs40176	chr5:65464965	C/T	cg21114390	chr5:65439923	SFRS12	-0.48	-5.85	-0.34	1.46e-8	Facial morphology (factor 19);
CESC	cis	rs4474465	0.920	rs7947824	chr11:78223731	C/G	cg02023728	chr11:77925099	USP35	-0.41	-5.21	-0.3	3.78e-7	Alzheimer's disease (survival time);
CESC	cis	rs8031584	0.918	rs34693097	chr15:31253984	A/G	cg14829155	chr15:31115871	NA	-0.72	-9.75	-0.51	2.15e-19	Huntington's disease progression;
CESC	cis	rs1499614	1.000	rs2707838	chr7:66159201	C/T	cg12463550	chr7:65579703	CRCP	0.73	5.73	0.33	2.78e-8	Gout;
CESC	cis	rs7811142	1.000	rs67239991	chr7:100046504	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.83	8.3	0.45	5.39e-15	Platelet count;
CESC	cis	rs1215050	0.740	rs1084777	chr4:99017542	C/T	cg17366294	chr4:99064904	C4orf37	-0.4	-5.31	-0.31	2.3e-7	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs4665809	1.000	rs11126364	chr2:26314515	A/G	cg22920501	chr2:26401640	FAM59B	-0.67	-8.12	-0.45	1.72e-14	Gut microbiome composition (summer);
CESC	cis	rs274567	0.501	rs581968	chr5:131710202	G/A	cg24060327	chr5:131705240	SLC22A5	0.76	10.65	0.55	2.72e-22	Blood metabolite levels;
CESC	cis	rs35110281	0.782	rs2329442	chr21:45041790	T/C	cg04455712	chr21:45112962	RRP1B	0.4	5.93	0.34	9.32e-9	Mean corpuscular volume;
CESC	cis	rs524281	0.773	rs10791863	chr11:66027358	C/T	cg14036092	chr11:66035641	RAB1B	-0.55	-5.38	-0.31	1.62e-7	Electroencephalogram traits;
CESC	cis	rs7772486	0.875	rs11755334	chr6:146399297	T/C	cg05347473	chr6:146136440	FBXO30	0.48	6.57	0.37	2.58e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs11690935	0.959	rs7608403	chr2:172646765	A/C	cg13550731	chr2:172543902	DYNC1I2	-1.01	-16.71	-0.72	2.64e-43	Schizophrenia;
CESC	cis	rs9322193	0.847	rs868375	chr6:150166041	T/A	cg04369109	chr6:150039330	LATS1	-0.42	-5.6	-0.33	5.35e-8	Lung cancer;
CESC	cis	rs9815354	0.812	rs73071356	chr3:41829486	C/T	cg03022575	chr3:42003672	ULK4	0.7	6.04	0.35	5.26e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs644799	0.965	rs10831425	chr11:95500628	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.94	15.21	0.68	5.57e-38	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs60843830	1.000	rs59937473	chr2:271797	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.88	12.15	0.6	2.66e-27	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs6540559	0.546	rs7551944	chr1:210029430	G/C	cg25204440	chr1:209979598	IRF6	0.66	5.89	0.34	1.19e-8	Cleft lip with or without cleft palate;
CESC	cis	rs17655565	0.553	rs7956996	chr12:52724938	C/T	cg00777198	chr12:52828273	KRT75	0.36	5.25	0.31	3.07e-7	Plasma amyloid beta peptide concentrations (ABx-42);
CESC	cis	rs1448094	0.527	rs59445394	chr12:86237843	C/T	cg19622623	chr12:86230825	RASSF9	-0.43	-5.27	-0.31	2.78e-7	Major depressive disorder;
CESC	cis	rs7552404	0.924	rs1146574	chr1:76202671	A/G	cg03433033	chr1:76189801	ACADM	0.72	10.17	0.53	1.02e-20	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs2625529	0.689	rs2957742	chr15:72302894	C/G	cg16672083	chr15:72433130	SENP8	0.4	6.17	0.35	2.51e-9	Red blood cell count;
CESC	cis	rs4835473	0.897	rs4835454	chr4:144651234	C/T	cg25736465	chr4:144833511	NA	0.36	5.42	0.32	1.31e-7	Immature fraction of reticulocytes;
CESC	cis	rs763121	0.853	rs5757187	chr22:39021522	A/G	cg21395723	chr22:39101663	GTPBP1	-0.42	-5.15	-0.3	5e-7	Menopause (age at onset);
CESC	cis	rs477692	0.663	rs491929	chr10:131368111	G/A	cg05714579	chr10:131428358	MGMT	0.41	5.37	0.31	1.7e-7	Response to temozolomide;
CESC	cis	rs4728302	0.869	rs6954712	chr7:133618853	G/A	cg10665199	chr7:133106180	EXOC4	0.4	5.34	0.31	1.98e-7	Intelligence;Intelligence (multi-trait analysis);
CESC	cis	rs896854	0.625	rs4735335	chr8:95973327	G/C	cg23172400	chr8:95962367	TP53INP1	-0.44	-9.04	-0.49	3.45e-17	Type 2 diabetes;
CESC	cis	rs9908102	0.710	rs7215456	chr17:12900675	A/C	cg26162695	chr17:12921313	ELAC2	0.5	5.49	0.32	9.61e-8	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02729269	chr16:127772	MPG	0.49	6.23	0.36	1.83e-9	Gut microbiome composition (summer);
CESC	trans	rs55863869	0.748	rs2291309	chr2:179623577	G/T	cg24136754	chr22:37403978	C22orf33	0.44	6.07	0.35	4.34e-9	QT interval;
CESC	cis	rs4141404	0.561	rs5994376	chr22:31563555	A/C	cg13145458	chr22:31556086	RNF185	0.42	5.1	0.3	6.61e-7	Paclitaxel-induced neuropathy;
CESC	cis	rs2072732	0.808	rs55784203	chr1:2936754	G/T	cg15211996	chr1:2936768	ACTRT2	0.34	5.51	0.32	8.71e-8	Plateletcrit;
CESC	cis	rs2072499	0.966	rs2853641	chr1:156181770	A/G	cg25208724	chr1:156163844	SLC25A44	0.88	16.16	0.7	2.43e-41	Testicular germ cell tumor;
CESC	cis	rs853679	0.517	rs9380061	chr6:28132803	T/C	cg26335602	chr6:28129616	ZNF389	0.52	6.81	0.39	6.59e-11	Depression;
CESC	cis	rs9649213	0.593	rs6973775	chr7:98004685	G/A	cg24562669	chr7:97807699	LMTK2	0.51	7.43	0.42	1.51e-12	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg21515243	chr18:21033072	RIOK3	-0.46	-6.92	-0.39	3.3e-11	Gambling;
CESC	cis	rs9815354	1.000	rs9820192	chr3:41889281	G/A	cg03022575	chr3:42003672	ULK4	0.45	5.23	0.31	3.48e-7	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs858239	0.600	rs7789237	chr7:23124713	T/G	cg23682824	chr7:23144976	KLHL7	0.54	7.54	0.42	7.42e-13	Cerebrospinal fluid biomarker levels;
CESC	cis	rs9611565	0.568	rs2413656	chr22:42129357	G/T	cg03806693	chr22:41940476	POLR3H	0.77	9.39	0.5	2.95e-18	Vitiligo;
CESC	cis	rs754466	0.580	rs1054608	chr10:79543308	T/G	cg17075019	chr10:79541650	NA	-0.87	-13.99	-0.65	1.09e-33	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs7703051	0.829	rs7733436	chr5:74666492	C/T	cg03227963	chr5:74354835	NA	0.29	5.34	0.31	1.99e-7	LDL cholesterol;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
CESC	cis	rs2180341	0.924	rs877661	chr6:127587915	T/G	cg24812749	chr6:127587940	RNF146	1.07	15.61	0.69	2.13e-39	Breast cancer;
CESC	cis	rs854765	0.547	rs2955385	chr17:17939247	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.61	8.76	0.47	2.3e-16	Total body bone mineral density;
CESC	cis	rs67311347	1.000	rs4973993	chr3:40452960	T/C	cg24209194	chr3:40518798	ZNF619	0.49	6.23	0.36	1.78e-9	Renal cell carcinoma;
CESC	cis	rs3741404	0.620	rs11231722	chr11:63967770	C/G	cg18225595	chr11:63971243	STIP1	0.62	8.77	0.47	2.15e-16	Platelet count;
CESC	cis	rs4835473	0.838	rs34819068	chr4:144708483	C/G	cg25736465	chr4:144833511	NA	-0.35	-5.61	-0.33	5e-8	Immature fraction of reticulocytes;
CESC	cis	rs6570726	0.599	rs9376951	chr6:145898911	C/T	cg23711669	chr6:146136114	FBXO30	0.92	11.95	0.59	1.27e-26	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs34779708	0.897	rs7900480	chr10:35338699	A/G	cg04310649	chr10:35416472	CREM	0.55	6.49	0.37	4.13e-10	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs3740713	1.000	rs76708296	chr11:18456133	A/T	cg23797887	chr11:18477753	LDHAL6A	-0.53	-5.11	-0.3	6.1e-7	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs7692995	1.000	rs13151431	chr4:17959581	C/A	cg08925142	chr4:18023851	LCORL	-0.45	-5.13	-0.3	5.66e-7	Height;
CESC	cis	rs35110281	0.667	rs2155722	chr21:45096206	A/G	cg01579765	chr21:45077557	HSF2BP	0.5	8.92	0.48	7.75e-17	Mean corpuscular volume;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg25789201	chr7:72395803	POM121	0.49	6.52	0.37	3.61e-10	Systemic lupus erythematosus;
CESC	cis	rs2749592	0.531	rs994804	chr10:37900140	A/C	cg00409905	chr10:38381863	ZNF37A	0.43	5.69	0.33	3.28e-8	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs644148	0.748	rs542150	chr19:44967453	T/C	cg15540054	chr19:45004280	ZNF180	0.59	6.46	0.37	4.92e-10	Personality dimensions;
CESC	cis	rs10504229	1.000	rs58947041	chr8:58188934	G/A	cg05313129	chr8:58192883	C8orf71	-0.55	-6.29	-0.36	1.34e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs6088580	0.634	rs2378134	chr20:32938085	C/T	cg06115741	chr20:33292138	TP53INP2	-0.43	-5.4	-0.32	1.45e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs8016982	1.000	rs8016982	chr14:81707057	C/T	cg01989461	chr14:81687754	GTF2A1	0.53	6.9	0.39	3.81e-11	Schizophrenia;
CESC	cis	rs9486719	1.000	rs2971608	chr6:97039757	T/C	cg06623918	chr6:96969491	KIAA0776	-0.86	-10.44	-0.54	1.35e-21	Migraine;Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02878701	chr21:47706221	MCM3AP;C21orf57	0.59	6.55	0.37	3.01e-10	Gut microbiome composition (summer);
CESC	trans	rs9929218	0.953	rs28608872	chr16:68802038	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.63	-8.44	-0.46	2.13e-15	Colorectal cancer;
CESC	cis	rs4819052	0.851	rs1056100	chr21:46678711	A/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.96	14.51	0.67	1.65e-35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs1847202	0.717	rs13063437	chr3:72952388	A/G	cg25664220	chr3:72788482	NA	-0.4	-5.74	-0.33	2.55e-8	Motion sickness;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg25080152	chr8:128748155	MYC	-0.46	-6.1	-0.35	3.75e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs35110281	0.840	rs7276633	chr21:45078800	C/T	cg21573476	chr21:45109991	RRP1B	-0.49	-6.92	-0.39	3.41e-11	Mean corpuscular volume;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg07352798	chr5:141488591	NDFIP1	-0.44	-6.06	-0.35	4.67e-9	Ulcerative colitis;
CESC	cis	rs1020064	0.636	rs1529975	chr2:105929901	T/C	cg02079111	chr2:105885981	TGFBRAP1	0.38	5.19	0.3	4.15e-7	AIDS;
CESC	trans	rs7666738	0.830	rs4292341	chr4:98959724	C/T	cg19256675	chr7:74988891	PMS2L2;STAG3L1	0.44	6.02	0.35	5.68e-9	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14929266	chr13:113864086	CUL4A;PCID2	0.53	6.0	0.35	6.43e-9	Gut microbiome composition (summer);
CESC	cis	rs523522	0.962	rs12814055	chr12:120987391	G/A	cg12219531	chr12:120966889	COQ5	0.75	9.9	0.52	7e-20	High light scatter reticulocyte count;
CESC	cis	rs514406	0.505	rs269290	chr1:53167027	A/T	cg24675658	chr1:53192096	ZYG11B	-0.52	-6.6	-0.38	2.19e-10	Monocyte count;
CESC	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.47	-5.53	-0.32	7.83e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs9549367	0.774	rs9549364	chr13:113903745	T/C	cg18105134	chr13:113819100	PROZ	-0.68	-8.25	-0.45	7.53e-15	Platelet distribution width;
CESC	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	21.97	0.8	1.29e-61	Prudent dietary pattern;
CESC	cis	rs7116495	0.609	rs4945392	chr11:71694645	C/T	cg18441811	chr11:71824068	C11orf51	-0.82	-5.33	-0.31	2.05e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.64	0.38	1.81e-10	Prudent dietary pattern;
CESC	cis	rs7618915	0.547	rs34173654	chr3:52634605	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	6.67	0.38	1.48e-10	Bipolar disorder;
CESC	trans	rs916888	0.610	rs199438	chr17:44791643	G/A	cg22433210	chr17:43662623	NA	0.58	7.25	0.41	4.48e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs1552244	0.935	rs7652190	chr3:10105150	G/A	cg00149659	chr3:10157352	C3orf10	0.74	8.69	0.47	3.76e-16	Alzheimer's disease;
CESC	cis	rs4423214	0.840	rs1790328	chr11:71148038	G/A	cg05163923	chr11:71159392	DHCR7	-0.61	-7.24	-0.41	4.76e-12	Vitamin D levels;
CESC	cis	rs7833986	0.501	rs2953910	chr8:56968761	C/G	cg26371346	chr8:56986568	SNORD54;RPS20	0.57	5.16	0.3	4.9e-7	Height;
CESC	cis	rs55986470	0.670	rs56313033	chr2:239346202	C/T	cg18131467	chr2:239335373	ASB1	-0.67	-5.56	-0.32	6.65e-8	Chronotype;
CESC	cis	rs7193541	0.929	rs12933037	chr16:74660174	G/A	cg01733217	chr16:74700730	RFWD3	0.9	13.16	0.63	9.03e-31	Multiple myeloma;
CESC	cis	rs4819052	1.000	rs733739	chr21:46666210	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.82	10.47	0.54	1.04e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs875971	0.522	rs2949690	chr7:65483242	C/T	cg08632164	chr7:65971372	NA	0.32	5.2	0.3	3.94e-7	Aortic root size;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg14501914	chr9:131219228	ODF2	-0.44	-6.01	-0.35	6.14e-9	Fibrinogen levels;
CESC	cis	rs3820928	0.874	rs13423714	chr2:227896652	C/G	cg05526886	chr2:227700861	RHBDD1	0.43	5.34	0.31	2.02e-7	Pulmonary function;
CESC	cis	rs2479106	0.549	rs10986070	chr9:126366529	C/T	cg16191174	chr9:126692580	DENND1A	-0.38	-5.26	-0.31	2.96e-7	Polycystic ovary syndrome;
CESC	cis	rs3857067	1.000	rs1397026	chr4:95013729	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.52	-8.04	-0.44	3.04e-14	QT interval;
CESC	cis	rs2304069	0.507	rs7728264	chr5:149394954	C/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.47	6.36	0.36	8.69e-10	HIV-1 control;
CESC	cis	rs10129255	0.957	rs12590667	chr14:107187462	A/G	cg07958169	chr14:107095056	NA	0.44	6.2	0.36	2.11e-9	Kawasaki disease;
CESC	cis	rs10927875	0.526	rs35340817	chr1:16178917	T/C	cg21385522	chr1:16154831	NA	-0.92	-10.54	-0.54	6.39e-22	Dilated cardiomyopathy;
CESC	cis	rs7727544	0.684	rs611084	chr5:131709739	A/C	cg24060327	chr5:131705240	SLC22A5	0.63	8.31	0.45	5.15e-15	Blood metabolite levels;
CESC	trans	rs2727020	0.619	rs11040300	chr11:49269984	C/A	cg03929089	chr4:120376271	NA	0.71	8.65	0.47	5.16e-16	Coronary artery disease;
CESC	cis	rs9302635	0.513	rs12928732	chr16:72188683	C/T	cg01557791	chr16:72042693	DHODH	-0.63	-7.08	-0.4	1.33e-11	Blood protein levels;
CESC	cis	rs1153858	1.000	rs12101539	chr15:45650666	C/G	cg14582100	chr15:45693742	SPATA5L1	0.43	6.15	0.35	2.82e-9	Homoarginine levels;
CESC	cis	rs4566357	0.557	rs6707158	chr2:227911269	A/G	cg11843606	chr2:227700838	RHBDD1	-0.47	-6.49	-0.37	4.32e-10	Coronary artery disease;
CESC	cis	rs2737618	0.722	rs2737680	chr1:200088559	C/A	cg21825944	chr1:200113062	NR5A2	-0.45	-6.73	-0.38	1.02e-10	Uric acid levels;
CESC	cis	rs9815354	0.812	rs17282671	chr3:41887455	T/C	cg03022575	chr3:42003672	ULK4	0.71	6.23	0.36	1.84e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs2066819	1.000	rs80317430	chr12:56727705	G/A	cg26714650	chr12:56694279	CS	-1.39	-9.17	-0.49	1.33e-17	Psoriasis vulgaris;
CESC	cis	rs9549367	0.713	rs4907593	chr13:113830459	C/T	cg18105134	chr13:113819100	PROZ	0.55	7.14	0.4	8.88e-12	Platelet distribution width;
CESC	cis	rs7843479	0.601	rs4872209	chr8:21848832	A/T	cg17168535	chr8:21777572	XPO7	0.73	11.62	0.58	1.7e-25	Mean corpuscular volume;
CESC	cis	rs4819052	0.851	rs4819038	chr21:46659393	C/T	cg11663144	chr21:46675770	NA	-0.63	-10.02	-0.52	3.12e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs7833986	0.501	rs2667981	chr8:56894303	T/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.58	7.16	0.4	8.04e-12	Height;
CESC	cis	rs7833790	1.000	rs1463259	chr8:82737745	A/G	cg27398817	chr8:82754497	SNX16	-0.55	-6.41	-0.37	6.75e-10	Diastolic blood pressure;
CESC	cis	rs1801251	0.964	rs6748027	chr2:233629552	T/C	cg08000102	chr2:233561755	GIGYF2	0.67	9.48	0.5	1.53e-18	Coronary artery disease;
CESC	cis	rs12545109	0.800	rs2576592	chr8:57419357	A/C	cg09654669	chr8:57350985	NA	-0.45	-6.27	-0.36	1.47e-9	Obesity-related traits;
CESC	cis	rs12079745	0.793	rs78483993	chr1:169410428	G/A	cg09363564	chr1:169337483	NME7;BLZF1	-1.26	-7.33	-0.41	2.72e-12	QT interval;
CESC	cis	rs2522056	1.000	rs2522056	chr5:131801726	C/T	cg07395648	chr5:131743802	NA	0.43	5.13	0.3	5.66e-7	Lymphocyte counts;Fibrinogen;
CESC	cis	rs2412488	0.893	rs6822201	chr4:54359743	T/C	cg22241045	chr4:54363911	LNX1	-0.39	-5.32	-0.31	2.2e-7	DNA methylation (variation);
CESC	cis	rs477895	0.653	rs66648159	chr11:63899429	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.93	10.18	0.53	9.01e-21	Mean platelet volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04882175	chr6:131122610	NA	-0.61	-6.67	-0.38	1.44e-10	Gut microbiome composition (summer);
CESC	cis	rs896854	0.654	rs13248607	chr8:95986637	T/G	cg26343298	chr8:95960752	TP53INP1	0.37	6.14	0.35	3.07e-9	Type 2 diabetes;
CESC	cis	rs72781680	0.898	rs7589440	chr2:24038595	G/A	cg08917208	chr2:24149416	ATAD2B	0.95	8.71	0.47	3.45e-16	Lymphocyte counts;
CESC	cis	rs3806843	1.000	rs1476768	chr5:140173597	G/A	cg26395211	chr5:140044315	WDR55	-0.42	-5.35	-0.31	1.9e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs2932538	0.922	rs12750023	chr1:113118329	G/A	cg22162597	chr1:113214053	CAPZA1	0.54	6.95	0.39	2.77e-11	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CESC	cis	rs12477438	0.798	rs10196680	chr2:99628617	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-10.57	-0.54	5.22e-22	Chronic sinus infection;
CESC	cis	rs7561273	0.586	rs6545264	chr2:24310105	A/G	cg20701182	chr2:24300061	SF3B14	0.52	6.69	0.38	1.3e-10	Quantitative traits;
CESC	cis	rs67311347	1.000	rs2305522	chr3:40429358	A/G	cg09455208	chr3:40491958	NA	0.45	7.7	0.43	2.71e-13	Renal cell carcinoma;
CESC	cis	rs9399137	0.507	rs4520025	chr6:135278619	G/T	cg24558204	chr6:135376177	HBS1L	0.71	9.64	0.51	4.75e-19	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	cis	rs801193	1.000	rs2003301	chr7:66147656	G/C	cg11764359	chr7:65958608	NA	-0.69	-9.06	-0.49	2.98e-17	Aortic root size;
CESC	cis	rs7527798	0.592	rs4097398	chr1:207857760	C/T	cg21110645	chr1:207815933	NA	-0.33	-5.86	-0.34	1.33e-8	Erythrocyte sedimentation rate;
CESC	cis	rs10504229	0.683	rs6980850	chr8:58127204	A/G	cg24829409	chr8:58192753	C8orf71	-0.59	-7.24	-0.41	4.79e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs208520	0.690	rs1580430	chr6:66715162	T/A	cg07460842	chr6:66804631	NA	0.96	13.01	0.62	2.95e-30	Exhaled nitric oxide output;
CESC	cis	rs9486719	0.947	rs6916232	chr6:96985959	A/T	cg06623918	chr6:96969491	KIAA0776	0.77	8.17	0.45	1.26e-14	Migraine;Coronary artery disease;
CESC	cis	rs9916302	0.808	rs12943928	chr17:37611330	G/A	cg20243544	chr17:37824526	PNMT	0.51	6.5	0.37	3.97e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs8018808	1.000	rs8018808	chr14:77858336	A/G	cg20045696	chr14:77926864	AHSA1	-0.37	-5.06	-0.3	7.85e-7	Myeloid white cell count;
CESC	cis	rs1862618	0.853	rs832551	chr5:56180112	T/G	cg03609598	chr5:56110824	MAP3K1	-0.51	-5.32	-0.31	2.22e-7	Initial pursuit acceleration;
CESC	cis	rs7621025	0.505	rs34281413	chr3:136461860	C/T	cg15507776	chr3:136538369	TMEM22	-0.81	-7.29	-0.41	3.66e-12	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
CESC	cis	rs3806843	0.933	rs2240696	chr5:140168070	A/G	cg26395211	chr5:140044315	WDR55	-0.42	-5.43	-0.32	1.26e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs7116495	1.000	rs10736786	chr11:71763274	C/T	cg10381502	chr11:71823885	C11orf51	-0.66	-5.36	-0.31	1.81e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs40363	0.620	rs1137454	chr16:3533577	C/G	cg05754148	chr16:3507555	NAT15	-0.58	-8.48	-0.46	1.62e-15	Tuberculosis;
CESC	cis	rs2204008	0.837	rs7308714	chr12:38274307	T/C	cg13010199	chr12:38710504	ALG10B	0.48	6.04	0.35	5.23e-9	Bladder cancer;
CESC	cis	rs8031584	0.541	rs1983459	chr15:31208749	C/T	cg08109568	chr15:31115862	NA	-0.65	-9.24	-0.49	8.28e-18	Huntington's disease progression;
CESC	cis	rs9902453	0.868	rs8066731	chr17:28523121	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	8.09	0.45	2.15e-14	Coffee consumption (cups per day);
CESC	cis	rs4665809	0.590	rs4665313	chr2:26415897	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.07	-13.11	-0.63	1.33e-30	Gut microbiome composition (summer);
CESC	cis	rs6570726	0.846	rs411468	chr6:145832792	A/G	cg23711669	chr6:146136114	FBXO30	0.8	12.02	0.59	7.3e-27	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs10504229	0.511	rs75967910	chr8:58024231	C/G	cg22535103	chr8:58192502	C8orf71	-0.9	-8.95	-0.48	6.29e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg06873352	chr17:61820015	STRADA	0.72	12.8	0.62	1.61e-29	Prudent dietary pattern;
CESC	cis	rs7927592	0.763	rs11822059	chr11:68300822	T/G	cg01657329	chr11:68192670	LRP5	-0.48	-6.38	-0.37	7.71e-10	Total body bone mineral density;
CESC	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg05552183	chr6:42928497	GNMT	0.77	11.93	0.59	1.55e-26	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs72781680	0.898	rs17763224	chr2:24213776	T/C	cg20701182	chr2:24300061	SF3B14	0.63	5.58	0.32	6.04e-8	Lymphocyte counts;
CESC	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.55	-7.18	-0.4	6.94e-12	Prudent dietary pattern;
CESC	cis	rs1461503	0.934	rs930982	chr11:122834378	C/T	cg27398637	chr11:122830231	C11orf63	-0.57	-8.43	-0.46	2.31e-15	Menarche (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08408874	chr17:62493199	POLG2	0.58	6.37	0.36	8.14e-10	Gut microbiome composition (summer);
CESC	cis	rs4689388	0.856	rs10016157	chr4:6294414	T/C	cg00701064	chr4:6280414	WFS1	0.68	11.71	0.58	8.68e-26	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs1568889	0.838	rs7125749	chr11:28154692	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.81	13.78	0.65	6.22e-33	Bipolar disorder;
CESC	cis	rs4319547	0.910	rs6416298	chr12:123002143	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.56	-6.07	-0.35	4.33e-9	Body mass index;
CESC	cis	rs2573652	0.722	rs12903458	chr15:100542673	T/G	cg09918751	chr15:100517450	ADAMTS17	-0.31	-5.76	-0.33	2.28e-8	Height;
CESC	cis	rs17601876	0.814	rs2414101	chr15:51562434	A/G	cg19946085	chr15:51559439	CYP19A1	-0.34	-5.5	-0.32	8.88e-8	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
CESC	cis	rs9837602	0.938	rs28503408	chr3:99794842	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.45	6.29	0.36	1.3e-9	Breast cancer;
CESC	cis	rs2760061	0.603	rs697761	chr1:228192397	G/A	cg02753203	chr1:228287806	NA	0.79	11.5	0.58	4.28e-25	Diastolic blood pressure;
CESC	cis	rs1552244	0.882	rs55808392	chr3:10054681	C/T	cg00166722	chr3:10149974	C3orf24	0.48	5.95	0.34	8.64e-9	Alzheimer's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21184926	chr2:198318139	COQ10B	0.57	6.82	0.39	6.13e-11	Gut microbiome composition (summer);
CESC	cis	rs7618915	0.547	rs4687636	chr3:52633929	G/A	cg07507251	chr3:52567010	NT5DC2	0.41	7.21	0.4	5.94e-12	Bipolar disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03135535	chr4:141564017	TBC1D9	-0.57	-6.74	-0.38	9.62e-11	Gut microbiome composition (summer);
CESC	cis	rs6688613	0.694	rs12562794	chr1:166828957	A/G	ch.1.3259774R	chr1:166827647	TADA1	0.58	5.87	0.34	1.33e-8	Refractive astigmatism;
CESC	trans	rs9858542	0.953	rs9878943	chr3:49434654	G/A	cg21659725	chr3:3221576	CRBN	-0.54	-6.47	-0.37	4.62e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs73206853	0.843	rs12320025	chr12:110742991	A/G	cg12870014	chr12:110450643	ANKRD13A	0.62	5.88	0.34	1.23e-8	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs9611565	0.592	rs57102627	chr22:41987627	T/C	cg06481639	chr22:41940642	POLR3H	-0.56	-6.32	-0.36	1.13e-9	Vitiligo;
CESC	trans	rs2749592	0.550	rs9733309	chr10:37882405	G/A	cg12057190	chr19:54976211	LENG9;CDC42EP5	-0.43	-6.16	-0.35	2.63e-9	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs7264396	0.580	rs6060648	chr20:34456704	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.84	-9.22	-0.49	9.7e-18	Total cholesterol levels;
CESC	cis	rs2835872	0.758	rs1709818	chr21:39036211	T/C	cg06728970	chr21:39037746	KCNJ6	0.3	5.59	0.32	5.77e-8	Electroencephalographic traits in alcoholism;
CESC	cis	rs7605827	0.930	rs1019359	chr2:15524615	T/C	cg19274914	chr2:15703543	NA	0.35	6.27	0.36	1.43e-9	Educational attainment (years of education);
CESC	cis	rs10781543	0.845	rs10781540	chr9:139321836	G/A	cg14019695	chr9:139328340	INPP5E	0.34	5.09	0.3	6.76e-7	Monocyte percentage of white cells;
CESC	cis	rs941873	0.835	rs4246944	chr10:81105684	C/T	cg09469691	chr10:81107165	PPIF	0.57	7.93	0.44	6.11e-14	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02656441	chr13:111367915	ING1	-0.53	-6.31	-0.36	1.18e-9	Gut microbiome composition (summer);
CESC	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg02071572	chr4:1403502	NA	0.38	5.88	0.34	1.26e-8	Longevity;
CESC	cis	rs4423214	0.570	rs7118246	chr11:71231124	G/C	cg24826892	chr11:71159390	DHCR7	0.5	5.65	0.33	4.19e-8	Vitamin D levels;
CESC	cis	rs7301826	0.585	rs6486600	chr12:131292977	C/T	cg11011512	chr12:131303247	STX2	0.49	5.98	0.35	7.05e-9	Plasma plasminogen activator levels;
CESC	cis	rs4969178	0.965	rs12944051	chr17:76395856	C/T	cg05887092	chr17:76393375	PGS1	-0.54	-8.3	-0.45	5.19e-15	HDL cholesterol levels;
CESC	cis	rs79839061	0.732	rs56852661	chr4:826257	G/A	cg07828340	chr4:882639	GAK	0.81	5.89	0.34	1.16e-8	Intelligence (multi-trait analysis);
CESC	cis	rs660899	0.595	rs37456	chr1:44292989	C/T	cg11704212	chr1:44303111	ST3GAL3	-0.41	-5.38	-0.31	1.65e-7	Hypertension risk in short sleep duration;
CESC	cis	rs769267	1.000	rs769267	chr19:19446936	A/G	cg03709012	chr19:19516395	GATAD2A	0.98	14.6	0.67	8.23e-36	Tonsillectomy;
CESC	cis	rs875971	1.000	rs1968225	chr7:65874773	T/C	cg18876405	chr7:65276391	NA	0.5	6.68	0.38	1.43e-10	Aortic root size;
CESC	cis	rs7772486	0.790	rs2254288	chr6:146204470	G/A	cg23711669	chr6:146136114	FBXO30	0.82	11.79	0.59	4.46e-26	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20898347	chr17:21117939	TMEM11	-0.57	-6.19	-0.36	2.25e-9	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18265938	chr17:55162298	AKAP1	0.6	7.03	0.4	1.8e-11	Gut microbiome composition (summer);
CESC	cis	rs7592578	0.882	rs61117285	chr2:191468986	G/C	cg10560079	chr2:191398806	TMEM194B	-0.68	-6.16	-0.35	2.74e-9	Diastolic blood pressure;
CESC	cis	rs4665809	1.000	rs1470097	chr2:26312840	A/G	cg04944784	chr2:26401820	FAM59B	-0.63	-7.27	-0.41	3.93e-12	Gut microbiome composition (summer);
CESC	cis	rs760805	1.000	rs61774728	chr1:25258867	G/C	cg22509179	chr1:25234806	RUNX3	-0.6	-8.56	-0.47	9.51e-16	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs2425143	0.818	rs35448195	chr20:34542365	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.79	-7.1	-0.4	1.13e-11	Blood protein levels;
CESC	cis	rs11792861	0.926	rs12683988	chr9:111867290	T/C	cg13535736	chr9:111863775	C9orf5	-0.5	-6.66	-0.38	1.6e-10	Menarche (age at onset);
CESC	trans	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg22433210	chr17:43662623	NA	0.96	11.5	0.58	4.39e-25	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs7707921	0.752	rs2406909	chr5:81276087	T/C	cg15871215	chr5:81402204	ATG10	0.49	6.85	0.39	5.1e-11	Breast cancer;
CESC	cis	rs7116495	1.000	rs10751193	chr11:71785356	A/C	cg10381502	chr11:71823885	C11orf51	-0.68	-5.48	-0.32	9.68e-8	Severe influenza A (H1N1) infection;
CESC	cis	rs875971	0.706	rs1643374	chr7:65872682	T/A	cg14393609	chr7:65229607	NA	0.41	5.23	0.31	3.51e-7	Aortic root size;
CESC	cis	rs6084875	1.000	rs6084876	chr20:4742937	A/G	cg05143360	chr20:4741328	NA	-0.41	-5.48	-0.32	9.86e-8	Systemic lupus erythematosus;
CESC	cis	rs644799	0.965	rs2950522	chr11:95524719	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	13.95	0.65	1.57e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs60871478	0.636	rs4721834	chr7:896142	C/T	cg00475322	chr7:917719	C7orf20	0.46	5.1	0.3	6.53e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs7666738	0.830	rs11722272	chr4:99000839	C/T	cg05340658	chr4:99064831	C4orf37	0.74	10.46	0.54	1.18e-21	Colonoscopy-negative controls vs population controls;
CESC	cis	rs854765	0.583	rs4257260	chr17:17857003	A/G	cg09796270	chr17:17721594	SREBF1	0.45	6.15	0.35	2.87e-9	Total body bone mineral density;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg06753985	chr16:1825890	EME2	0.48	6.77	0.38	8.03e-11	Fibrinogen levels;
CESC	cis	rs12618769	0.681	rs72823792	chr2:99215142	G/A	cg10123293	chr2:99228465	UNC50	0.4	5.19	0.3	4.2e-7	Bipolar disorder;
CESC	cis	rs6942407	0.649	rs4727146	chr7:86856555	A/G	cg02420886	chr7:86849541	C7orf23	0.56	5.27	0.31	2.77e-7	Food allergy;
CESC	cis	rs3096299	0.900	rs3114867	chr16:89428967	A/C	cg08822215	chr16:89438651	ANKRD11	-0.4	-6.24	-0.36	1.73e-9	Multiple myeloma (IgH translocation);
CESC	cis	rs2549003	1.000	rs2070724	chr5:131822072	A/G	cg21138405	chr5:131827807	IRF1	0.54	9.32	0.5	4.74e-18	Asthma (sex interaction);
CESC	cis	rs9733	0.565	rs11804276	chr1:150685761	T/A	cg17724175	chr1:150552817	MCL1	0.45	7.31	0.41	3.23e-12	Tonsillectomy;
CESC	cis	rs4853012	0.941	rs60291089	chr2:74344890	T/G	cg05890377	chr2:74357713	NA	0.77	10.42	0.54	1.51e-21	Gestational age at birth (maternal effect);
CESC	cis	rs2276314	1.000	rs56050783	chr18:33553791	A/G	cg05985134	chr18:33552581	C18orf21	0.65	7.57	0.42	6.14e-13	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs12995491	0.731	rs13019346	chr2:88509321	A/G	cg04511125	chr2:88470314	THNSL2	-0.43	-6.25	-0.36	1.66e-9	Response to metformin (IC50);
CESC	cis	rs7264396	0.513	rs3787169	chr20:34419884	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.64	6.53	0.37	3.37e-10	Total cholesterol levels;
CESC	trans	rs916888	0.821	rs199514	chr17:44856881	G/A	cg10053473	chr17:62856997	LRRC37A3	0.63	6.77	0.38	8.25e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg20699036	chr5:38556796	LIFR	0.51	6.58	0.37	2.46e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs9682041	0.627	rs4955722	chr3:170102959	G/T	cg11886554	chr3:170076028	SKIL	0.7	6.46	0.37	4.94e-10	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CESC	cis	rs9467711	0.606	rs72841536	chr6:26378288	T/A	cg12826209	chr6:26865740	GUSBL1	0.63	5.11	0.3	6.25e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs3785574	0.886	rs62077504	chr17:61837734	A/G	cg06873352	chr17:61820015	STRADA	0.49	7.1	0.4	1.17e-11	Height;
CESC	cis	rs1348850	0.914	rs7587604	chr2:178309848	T/A	cg22681709	chr2:178499509	PDE11A	-0.39	-5.82	-0.34	1.71e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs4141404	0.740	rs9609301	chr22:31895940	C/T	cg02404636	chr22:31891804	SFI1	0.42	5.64	0.33	4.35e-8	Paclitaxel-induced neuropathy;
CESC	cis	rs10504229	0.817	rs78138632	chr8:58191341	G/T	cg14926445	chr8:58193284	C8orf71	-0.54	-5.26	-0.31	2.95e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs4843747	0.518	rs4072777	chr16:88107030	G/A	cg17633681	chr16:88106987	BANP	0.76	10.51	0.54	8.01e-22	Menopause (age at onset);
CESC	cis	rs933688	1.000	rs11959525	chr5:90703840	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.04	12.08	0.6	4.54e-27	Smoking behavior;
CESC	cis	rs17376456	1.000	rs66978370	chr5:93553633	G/A	cg25358565	chr5:93447407	FAM172A	1.2	11.25	0.57	2.85e-24	Diabetic retinopathy;
CESC	cis	rs6032067	0.641	rs17423617	chr20:43768050	G/C	cg10761708	chr20:43804764	PI3	0.55	6.12	0.35	3.4e-9	Blood protein levels;
CESC	cis	rs933688	1.000	rs12188467	chr5:90765632	A/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.0	12.25	0.6	1.24e-27	Smoking behavior;
CESC	cis	rs9611565	0.694	rs202665	chr22:41814401	A/G	cg06634786	chr22:41940651	POLR3H	0.72	7.58	0.42	5.66e-13	Vitiligo;
CESC	trans	rs7656342	0.808	rs10003216	chr4:9766749	A/G	cg15109221	chr6:15245772	JARID2	-0.52	-6.02	-0.35	5.85e-9	Gut microbiota (bacterial taxa);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg00777555	chr3:57583074	ARF4	-0.44	-6.59	-0.38	2.36e-10	Gambling;
CESC	cis	rs763121	0.853	rs4821816	chr22:39113134	G/A	cg06544989	chr22:39130855	UNC84B	0.49	9.47	0.5	1.67e-18	Menopause (age at onset);
CESC	cis	rs7267979	0.966	rs2257712	chr20:25264910	T/C	cg08601574	chr20:25228251	PYGB	0.39	5.65	0.33	4.08e-8	Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs12599106	0.707	rs2163977	chr16:34916134	A/G	cg11235426	chr6:292522	DUSP22	-0.67	-8.61	-0.47	6.51e-16	Menopause (age at onset);
CESC	cis	rs6582630	0.576	rs4403871	chr12:38292193	G/A	cg26384229	chr12:38710491	ALG10B	-0.44	-5.59	-0.32	5.74e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs9788682	0.894	rs4461039	chr15:78817447	A/T	cg06917634	chr15:78832804	PSMA4	0.57	6.98	0.39	2.39e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs1797081	1.000	rs780634	chr10:16864327	T/G	cg23933602	chr10:16859644	RSU1	1.13	24.93	0.84	1.94e-71	Platelet distribution width;
CESC	cis	rs10489525	0.502	rs12026930	chr1:115597836	G/A	cg01522456	chr1:115632236	TSPAN2	0.46	5.8	0.34	1.91e-8	Autism;
CESC	cis	rs6460942	0.915	rs6945067	chr7:12444731	A/C	cg20607287	chr7:12443886	VWDE	-0.7	-8.49	-0.46	1.46e-15	Coronary artery disease;
CESC	cis	rs1707322	0.752	rs12024590	chr1:46127496	A/C	cg05343316	chr1:45956843	TESK2	0.51	6.24	0.36	1.7e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs644799	0.562	rs515546	chr11:95588756	G/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.55	7.18	0.4	7.13e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg21280719	chr6:42927975	GNMT	-0.29	-6.57	-0.37	2.72e-10	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs1728785	1.000	rs889561	chr16:68605741	G/A	cg02972257	chr16:68554789	NA	-0.68	-7.6	-0.42	5.05e-13	Ulcerative colitis;
CESC	cis	rs66782572	1	rs66782572	chr3:52567617	A/G	cg18404041	chr3:52824283	ITIH1	-0.35	-6.27	-0.36	1.45e-9	Hemoglobin concentration;
CESC	cis	rs60871478	0.704	rs62432895	chr7:822050	C/G	cg05535760	chr7:792225	HEATR2	0.86	10.72	0.55	1.67e-22	Cerebrospinal P-tau181p levels;
CESC	cis	rs7914558	0.966	rs10786721	chr10:104654383	C/A	cg08650961	chr10:104748594	CNNM2	0.33	5.37	0.31	1.75e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs2273669	0.667	rs11153155	chr6:109359963	G/A	cg05315195	chr6:109294784	ARMC2	-0.67	-6.09	-0.35	3.97e-9	Prostate cancer;
CESC	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.43	-5.72	-0.33	2.86e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs2727020	0.530	rs7113153	chr11:49457957	G/A	cg15704280	chr7:45808275	SEPT13	-0.81	-9.71	-0.51	2.94e-19	Coronary artery disease;
CESC	trans	rs3942852	0.955	rs4752897	chr11:48136990	C/T	cg15704280	chr7:45808275	SEPT13	-0.56	-6.31	-0.36	1.17e-9	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs2637266	0.935	rs2579775	chr10:78401677	G/A	cg18941641	chr10:78392320	NA	0.45	8.65	0.47	4.9e-16	Pulmonary function;
CESC	cis	rs2070488	0.699	rs6599205	chr3:38529440	C/G	cg24069376	chr3:38537580	EXOG	0.31	5.1	0.3	6.47e-7	Electrocardiographic conduction measures;
CESC	cis	rs4835473	0.524	rs4404495	chr4:144900944	A/G	cg25736465	chr4:144833511	NA	0.4	5.91	0.34	1.03e-8	Immature fraction of reticulocytes;
CESC	cis	rs8017423	0.874	rs2149656	chr14:90707508	A/C	cg14092571	chr14:90743983	NA	-0.55	-8.08	-0.44	2.37e-14	Mortality in heart failure;
CESC	cis	rs597539	0.617	rs672853	chr11:68636362	G/A	cg01988459	chr11:68622903	NA	-0.4	-5.23	-0.31	3.38e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs875971	0.545	rs1547529	chr7:65723846	T/C	cg18876405	chr7:65276391	NA	0.46	5.61	0.33	4.98e-8	Aortic root size;
CESC	cis	rs7127900	0.614	rs11564708	chr11:2206326	C/G	cg25635251	chr11:2234043	NA	0.48	5.32	0.31	2.26e-7	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
CESC	cis	rs727505	0.564	rs56068095	chr7:124831906	A/T	cg23710748	chr7:124431027	NA	-0.33	-5.1	-0.3	6.44e-7	Lewy body disease;
CESC	cis	rs10779751	1.000	rs1205592	chr1:11305663	C/T	cg08854313	chr1:11322531	MTOR	0.78	10.2	0.53	7.99e-21	Body mass index;
CESC	cis	rs1799949	1.000	rs11656097	chr17:41290613	G/T	cg06001716	chr17:41278141	BRCA1;NBR2	0.39	5.26	0.31	3e-7	Menopause (age at onset);
CESC	cis	rs780096	0.546	rs1260320	chr2:27722416	A/G	cg21248554	chr2:27665150	KRTCAP3	0.39	8.38	0.46	3.21e-15	Total body bone mineral density;
CESC	cis	rs460214	0.539	rs28718905	chr21:40032244	C/A	cg05519781	chr21:40033154	ERG	-0.45	-5.41	-0.32	1.43e-7	Response to cognitive-behavioural therapy in anxiety disorder;
CESC	trans	rs12356475	0.710	rs10822686	chr10:67733250	C/T	cg23486179	chr3:49466665	NICN1	0.53	6.01	0.35	6.06e-9	Psoriatic arthritis;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg06988368	chr1:147142773	ACP6	-0.52	-6.79	-0.38	7.3e-11	Fibrinogen levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02204578	chr7:132766399	CHCHD3	-0.55	-6.5	-0.37	3.91e-10	Gut microbiome composition (summer);
CESC	cis	rs514406	0.505	rs405208	chr1:53176674	C/T	cg27535305	chr1:53392650	SCP2	-0.34	-5.56	-0.32	6.75e-8	Monocyte count;
CESC	cis	rs561341	1.000	rs546748	chr17:30324293	A/C	cg00745463	chr17:30367425	LRRC37B	-0.49	-5.42	-0.32	1.37e-7	Hip circumference adjusted for BMI;
CESC	cis	rs4924935	1.000	rs11658555	chr17:18817486	C/T	cg26378065	chr17:18585709	ZNF286B	-0.52	-6.33	-0.36	1.06e-9	Pancreatic cancer;
CESC	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg23708337	chr7:1209742	NA	0.55	5.41	0.32	1.44e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs4665809	0.627	rs1465720	chr2:26412638	G/T	cg26119090	chr2:26468346	HADHA;HADHB	-1.05	-12.42	-0.61	3.18e-28	Gut microbiome composition (summer);
CESC	cis	rs875971	0.767	rs1695815	chr7:65831344	A/G	cg18876405	chr7:65276391	NA	0.5	6.64	0.38	1.75e-10	Aortic root size;
CESC	cis	rs8072100	0.640	rs3851808	chr17:45425144	C/T	cg25173405	chr17:45401733	C17orf57	-0.44	-5.48	-0.32	9.98e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg26313349	chr1:145589328	NUDT17	-0.43	-6.04	-0.35	5.16e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs9303280	0.901	rs12950743	chr17:38049233	T/C	cg20243544	chr17:37824526	PNMT	0.51	6.7	0.38	1.27e-10	Self-reported allergy;
CESC	cis	rs4803468	0.967	rs284661	chr19:41932120	C/T	cg14132834	chr19:41945861	ATP5SL	-0.6	-7.51	-0.42	8.94e-13	Height;
CESC	cis	rs1862618	0.573	rs832532	chr5:56221938	T/C	cg22800045	chr5:56110881	MAP3K1	0.76	8.79	0.48	1.93e-16	Initial pursuit acceleration;
CESC	cis	rs34779708	1.000	rs34779708	chr10:35466185	T/G	cg04310649	chr10:35416472	CREM	-0.51	-6.12	-0.35	3.38e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs6537837	1.000	rs6537837	chr1:110119732	C/T	cg05049280	chr1:110155535	GNAT2	0.41	5.83	0.34	1.58e-8	Major depressive disorder;
CESC	cis	rs6540559	0.932	rs764093	chr1:209983331	A/G	cg12034118	chr1:209979487	IRF6	0.43	5.36	0.31	1.8e-7	Cleft lip with or without cleft palate;
CESC	cis	rs2573652	1.000	rs11634977	chr15:100516472	G/A	cg00587665	chr15:100533223	ADAMTS17	-0.41	-6.71	-0.38	1.2e-10	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19099736	chr22:29702810	GAS2L1	0.53	6.2	0.36	2.18e-9	Gut microbiome composition (summer);
CESC	cis	rs9788333	0.962	rs61951450	chr13:21886354	G/A	cg21970626	chr13:21893289	NA	-0.42	-6.09	-0.35	3.85e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs34779708	0.931	rs4934524	chr10:35270921	G/C	cg03585969	chr10:35415529	CREM	0.77	10.13	0.53	1.39e-20	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs7917772	0.565	rs61869210	chr10:104437175	A/C	cg04362960	chr10:104952993	NT5C2	-0.46	-5.04	-0.3	8.45e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs10489525	0.599	rs7526323	chr1:115604241	G/A	cg01522456	chr1:115632236	TSPAN2	0.5	6.03	0.35	5.63e-9	Autism;
CESC	cis	rs7219021	1.000	rs2032844	chr17:46847364	C/A	cg16584676	chr17:46985605	UBE2Z	-0.64	-7.23	-0.41	5.13e-12	Schizophrenia or bipolar disorder;
CESC	cis	rs1559088	0.895	rs7259582	chr19:33593979	A/G	cg17764715	chr19:33622953	WDR88	0.49	6.32	0.36	1.11e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs6474412	1.000	rs13277254	chr8:42549982	G/A	cg25026480	chr8:42547641	NA	0.33	5.1	0.3	6.57e-7	Smoking behavior;
CESC	cis	rs11190604	1.000	rs4919468	chr10:102288343	G/C	cg07080220	chr10:102295463	HIF1AN	0.66	6.02	0.35	5.76e-9	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs193541	0.632	rs7729834	chr5:122122159	A/G	cg19412675	chr5:122181750	SNX24	0.45	5.27	0.31	2.86e-7	Glucose homeostasis traits;
CESC	cis	rs7084402	0.935	rs1593675	chr10:60291694	G/A	cg07615347	chr10:60278583	BICC1	0.59	9.28	0.5	6.23e-18	Refractive error;
CESC	cis	rs72781680	0.898	rs2339851	chr2:23938883	G/A	cg08917208	chr2:24149416	ATAD2B	1.1	10.15	0.53	1.18e-20	Lymphocyte counts;
CESC	cis	rs7811142	0.887	rs111972532	chr7:100069088	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.13	10.92	0.56	3.67e-23	Platelet count;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg19552494	chr11:60674271	PRPF19	0.53	7.04	0.4	1.61e-11	Systemic lupus erythematosus;
CESC	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg08219700	chr8:58056026	NA	0.46	5.97	0.34	7.75e-9	Developmental language disorder (linguistic errors);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg04665351	chr12:3000000	TULP3	-0.48	-6.97	-0.39	2.47e-11	Fibrinogen levels;
CESC	cis	rs2032447	0.714	rs199725	chr6:25953684	A/G	cg03517284	chr6:25882590	NA	-0.42	-5.72	-0.33	2.89e-8	Intelligence (multi-trait analysis);
CESC	cis	rs1005277	0.522	rs7072977	chr10:37940440	C/A	cg25427524	chr10:38739819	LOC399744	-0.63	-9.11	-0.49	2.03e-17	Extrinsic epigenetic age acceleration;
CESC	cis	rs858239	0.539	rs1358442	chr7:23189739	C/T	cg23682824	chr7:23144976	KLHL7	0.51	6.83	0.39	5.81e-11	Cerebrospinal fluid biomarker levels;
CESC	cis	rs2197308	0.765	rs11182964	chr12:37935052	C/T	cg26384229	chr12:38710491	ALG10B	0.75	11.19	0.57	4.49e-24	Morning vs. evening chronotype;
CESC	cis	rs7940866	0.774	rs7480903	chr11:130832276	A/G	cg12179176	chr11:130786555	SNX19	0.67	10.26	0.53	5.15e-21	Schizophrenia;
CESC	trans	rs916888	0.773	rs199443	chr17:44819565	C/T	cg22968622	chr17:43663579	NA	1.29	17.88	0.74	1.92e-47	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs1215050	0.791	rs548892	chr4:98724701	C/T	cg05340658	chr4:99064831	C4orf37	0.5	6.33	0.36	1.02e-9	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs10992471	0.756	rs2761681	chr9:95186937	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.45	-5.73	-0.33	2.77e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CESC	cis	rs7424096	0.613	rs111805423	chr2:37248924	G/T	cg14987922	chr2:37194071	STRN	0.48	5.26	0.31	2.93e-7	High light scatter reticulocyte percentage of red cells;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06819360	chr2:231921616	PSMD1	0.51	6.16	0.35	2.66e-9	Gut microbiome composition (summer);
CESC	cis	rs4891159	0.824	rs17059362	chr18:74144307	G/A	cg24786174	chr18:74118243	ZNF516	-0.72	-10.87	-0.56	5.42e-23	Longevity;
CESC	cis	rs17095355	0.901	rs11194947	chr10:111763731	A/T	cg00817464	chr10:111662876	XPNPEP1	-0.54	-6.18	-0.35	2.46e-9	Biliary atresia;
CESC	cis	rs6912958	0.525	rs59322	chr6:88020521	C/A	cg04972856	chr6:88032051	C6orf162;GJB7	0.36	5.61	0.33	5.17e-8	Monocyte percentage of white cells;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18068487	chr7:150778340	FASTK;TMUB1	0.53	6.45	0.37	5.28e-10	Gut microbiome composition (summer);
CESC	cis	rs11083475	0.599	rs7250443	chr19:39267345	T/C	cg07905965	chr19:39260460	NA	0.36	5.35	0.31	1.94e-7	Heart rate;
CESC	cis	rs9457247	0.765	rs4710171	chr6:167430186	A/G	cg07741184	chr6:167504864	NA	0.36	6.6	0.38	2.26e-10	Crohn's disease;
CESC	cis	rs4790333	0.813	rs2926992	chr17:2256026	C/A	cg02569219	chr17:2266849	SGSM2	0.41	5.27	0.31	2.78e-7	Proinsulin levels;
CESC	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg16145915	chr7:1198662	ZFAND2A	-0.61	-9.15	-0.49	1.55e-17	Longevity;Endometriosis;
CESC	cis	rs7635838	0.684	rs2606750	chr3:11372151	T/C	cg00170343	chr3:11313890	ATG7	0.54	7.77	0.43	1.73e-13	HDL cholesterol;
CESC	cis	rs73206853	0.841	rs56209636	chr12:110841998	T/C	cg12870014	chr12:110450643	ANKRD13A	0.63	5.23	0.31	3.48e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	trans	rs916888	0.821	rs199507	chr17:44858855	A/G	cg22433210	chr17:43662623	NA	-0.91	-10.81	-0.55	8.16e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs7267979	1.000	rs2257985	chr20:25269743	G/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	18.61	0.75	5.02e-50	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs6691722	0.503	rs12135404	chr1:24704263	C/T	cg02336364	chr1:24764700	NIPAL3	-0.34	-6.99	-0.39	2.19e-11	Response to interferon beta in multiple sclerosis;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg06722285	chr1:61925875	NFIA	0.42	6.52	0.37	3.61e-10	Gut microbiota (bacterial taxa);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg17774305	chr12:50505649	C12orf62	0.49	6.48	0.37	4.33e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs3771570	1.000	rs56052835	chr2:242243251	T/G	cg21155796	chr2:242212141	HDLBP	0.61	5.16	0.3	4.88e-7	Prostate cancer;
CESC	cis	rs826838	0.616	rs4418873	chr12:38625473	C/A	cg26384229	chr12:38710491	ALG10B	0.46	6.62	0.38	1.96e-10	Heart rate;
CESC	cis	rs9473147	0.571	rs9369717	chr6:47554468	T/G	cg20196966	chr6:47445060	CD2AP	0.41	5.29	0.31	2.59e-7	Platelet distribution width;Mean platelet volume;
CESC	cis	rs9296736	0.890	rs9637973	chr6:53903152	C/T	cg04374786	chr6:53939321	C6orf142	0.37	5.7	0.33	3.16e-8	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs7811142	0.830	rs61735533	chr7:99955866	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.04	10.52	0.54	7.52e-22	Platelet count;
CESC	cis	rs1784581	0.721	rs9365356	chr6:162414789	A/G	cg17173639	chr6:162384350	PARK2	0.61	9.42	0.5	2.25e-18	Itch intensity from mosquito bite;
CESC	cis	rs709400	1.000	rs3783404	chr14:104118498	A/G	cg12935359	chr14:103987150	CKB	-0.45	-6.08	-0.35	4.23e-9	Body mass index;
CESC	cis	rs7666738	0.962	rs11932892	chr4:99072967	C/T	cg18180107	chr4:99064573	C4orf37	0.53	6.31	0.36	1.19e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg07677032	chr17:61819896	STRADA	0.45	6.05	0.35	5.02e-9	Prudent dietary pattern;
CESC	cis	rs4862750	0.872	rs6553029	chr4:187876470	G/T	cg03647317	chr4:187891568	NA	0.42	5.85	0.34	1.42e-8	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2000999	0.524	rs36125653	chr16:72190805	G/A	cg04254540	chr16:71951199	KIAA0174	-0.69	-5.63	-0.33	4.49e-8	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
CESC	cis	rs727505	1.000	rs7795943	chr7:124483796	C/A	cg23710748	chr7:124431027	NA	-0.48	-7.6	-0.42	4.99e-13	Lewy body disease;
CESC	cis	rs6060717	0.702	rs6060756	chr20:34608479	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.53	6.52	0.37	3.55e-10	Hip circumference adjusted for BMI;
CESC	cis	rs1957429	0.520	rs230718	chr14:65318943	A/G	cg23373153	chr14:65346875	NA	-0.73	-5.65	-0.33	4.21e-8	Pediatric areal bone mineral density (radius);
CESC	cis	rs6502050	0.764	rs28676462	chr17:80105100	G/C	cg11859384	chr17:80120422	CCDC57	-0.38	-5.11	-0.3	6.21e-7	Life satisfaction;
CESC	cis	rs3793917	0.948	rs3750847	chr10:124215421	C/T	cg24884230	chr10:124216658	ARMS2	0.3	5.13	0.3	5.48e-7	Age-related macular degeneration;
CESC	cis	rs875971	0.862	rs6962717	chr7:65883735	G/A	cg18876405	chr7:65276391	NA	0.5	6.87	0.39	4.63e-11	Aortic root size;
CESC	cis	rs1799949	0.965	rs7223952	chr17:41194885	T/C	cg05368731	chr17:41323189	NBR1	0.58	7.93	0.44	6.04e-14	Menopause (age at onset);
CESC	cis	rs698833	0.926	rs1067353	chr2:44666626	G/A	cg04920474	chr2:44395004	PPM1B	0.36	5.04	0.3	8.57e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs7769051	0.522	rs6934155	chr6:133124021	C/T	cg07930552	chr6:133119739	C6orf192	1.14	7.79	0.43	1.5e-13	Type 2 diabetes nephropathy;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg23892547	chr17:29886066	MIR193A	-0.47	-6.19	-0.36	2.31e-9	Ulcerative colitis;
CESC	cis	rs1387259	0.570	rs12368659	chr12:48562299	C/A	cg24011408	chr12:48396354	COL2A1	0.49	7.42	0.41	1.59e-12	Obstructive sleep apnea trait (apnea hypopnea index);
CESC	cis	rs11741688	0.557	rs6600994	chr5:178336005	T/A	cg20935368	chr5:178288625	ZNF354B	0.34	5.37	0.31	1.71e-7	Sleep duration;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01068452	chr8:53626947	RB1CC1	0.56	6.37	0.36	8.55e-10	Gut microbiome composition (summer);
CESC	cis	rs113835537	0.529	rs60358007	chr11:66222353	G/A	cg22134325	chr11:66188745	NPAS4	0.44	6.67	0.38	1.49e-10	Airway imaging phenotypes;
CESC	cis	rs514406	0.505	rs269286	chr1:53169018	C/T	cg08859206	chr1:53392774	SCP2	0.59	8.27	0.45	6.72e-15	Monocyte count;
CESC	cis	rs72945132	0.882	rs66627443	chr11:70199036	C/G	cg00319359	chr11:70116639	PPFIA1	0.73	6.97	0.39	2.49e-11	Coronary artery disease;
CESC	cis	rs1799949	1.000	rs2292595	chr17:41290674	G/C	cg23758822	chr17:41437982	NA	1.02	15.64	0.69	1.65e-39	Menopause (age at onset);
CESC	cis	rs9790314	1.000	rs975323	chr3:161021322	A/G	cg03342759	chr3:160939853	NMD3	-0.44	-5.77	-0.33	2.15e-8	Morning vs. evening chronotype;
CESC	cis	rs6685188	0.920	rs10751444	chr1:205662144	A/G	cg07167872	chr1:205819463	PM20D1	-0.43	-6.24	-0.36	1.76e-9	White blood cell count (basophil);Basophil percentage of white cells;
CESC	cis	rs875971	0.929	rs4122249	chr7:65920936	T/C	cg10691866	chr7:65817282	TPST1	-0.32	-5.28	-0.31	2.73e-7	Aortic root size;
CESC	cis	rs58235267	0.553	rs11890276	chr2:63366191	C/T	cg17519650	chr2:63277830	OTX1	0.59	7.98	0.44	4.32e-14	Prostate-specific antigen levels (conditioned on lead SNPs);
CESC	cis	rs7100689	0.622	rs1340373	chr10:82129250	G/A	cg00277334	chr10:82204260	NA	-0.58	-7.76	-0.43	1.84e-13	Post bronchodilator FEV1;
CESC	cis	rs7809950	1.000	rs3801944	chr7:107255548	T/C	cg23024343	chr7:107201750	COG5	0.42	5.85	0.34	1.42e-8	Coronary artery disease;
CESC	cis	rs4665809	0.549	rs34075014	chr2:26520842	T/C	cg08470875	chr2:26401718	FAM59B	0.61	5.77	0.33	2.25e-8	Gut microbiome composition (summer);
CESC	cis	rs3540	0.533	rs7495080	chr15:91056681	G/A	cg22089800	chr15:90895588	ZNF774	-0.62	-8.63	-0.47	5.79e-16	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs2337406	0.500	rs57619050	chr14:107228305	G/A	cg23076370	chr14:107095027	NA	-0.52	-5.26	-0.31	3.04e-7	Alzheimer's disease (late onset);
CESC	cis	rs9457247	0.765	rs9459838	chr6:167426599	C/G	cg07741184	chr6:167504864	NA	0.36	6.65	0.38	1.62e-10	Crohn's disease;
CESC	cis	rs4665809	0.680	rs3955310	chr2:26290828	T/G	cg04944784	chr2:26401820	FAM59B	-0.66	-7.66	-0.43	3.61e-13	Gut microbiome composition (summer);
CESC	cis	rs13191362	1.000	rs68045643	chr6:163029709	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.73	7.77	0.43	1.74e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs80130819	0.688	rs2634672	chr12:48649640	G/A	cg05342945	chr12:48394962	COL2A1	-0.49	-5.33	-0.31	2.14e-7	Prostate cancer;
CESC	cis	rs2072499	0.932	rs3001790	chr1:156165290	T/G	cg25208724	chr1:156163844	SLC25A44	1.01	19.0	0.76	2.19e-51	Testicular germ cell tumor;
CESC	cis	rs10779751	0.770	rs6674994	chr1:11239515	T/C	cg08854313	chr1:11322531	MTOR	0.86	12.52	0.61	1.42e-28	Body mass index;
CESC	cis	rs4523957	0.583	rs9907384	chr17:2045375	A/C	cg16513277	chr17:2031491	SMG6	-0.75	-11.01	-0.56	1.89e-23	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs910316	0.967	rs119076	chr14:75572419	G/T	cg11812906	chr14:75593930	NEK9	-0.86	-14.71	-0.67	3.14e-36	Height;
CESC	cis	rs597539	0.652	rs668576	chr11:68668208	A/G	cg04772025	chr11:68637568	NA	0.5	5.99	0.35	6.85e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs7116495	1.000	rs2511116	chr11:71802160	G/A	cg10381502	chr11:71823885	C11orf51	-0.66	-5.4	-0.31	1.51e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs67311347	0.955	rs6599100	chr3:40447362	C/T	cg09455208	chr3:40491958	NA	0.46	7.82	0.43	1.24e-13	Renal cell carcinoma;
CESC	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg22336633	chr11:17099688	RPS13	0.48	6.28	0.36	1.41e-9	Schizophrenia;
CESC	cis	rs1862618	0.853	rs3099459	chr5:56137170	G/C	cg03609598	chr5:56110824	MAP3K1	-0.54	-5.69	-0.33	3.42e-8	Initial pursuit acceleration;
CESC	cis	rs662064	0.962	rs585870	chr1:10549628	G/T	cg20482658	chr1:10539492	PEX14	-0.42	-8.87	-0.48	1.08e-16	Asthma;
CESC	cis	rs12476592	0.602	rs964880	chr2:63826932	C/A	cg17519650	chr2:63277830	OTX1	-0.45	-5.12	-0.3	5.75e-7	Childhood ear infection;
CESC	cis	rs4481887	1.000	rs4244179	chr1:248470984	T/A	cg00666640	chr1:248458726	OR2T12	0.41	6.65	0.38	1.71e-10	Common traits (Other);
CESC	cis	rs6963495	0.818	rs73192145	chr7:105203628	A/C	cg02135003	chr7:105160482	PUS7	-0.48	-5.62	-0.33	4.83e-8	Bipolar disorder (body mass index interaction);
CESC	cis	rs514406	0.683	rs10157120	chr1:53210888	A/G	cg16325326	chr1:53192061	ZYG11B	0.97	16.8	0.72	1.27e-43	Monocyte count;
CESC	cis	rs34602589	0.535	rs7346579	chr20:43844722	A/G	cg11264863	chr20:43835661	SEMG1	0.5	5.44	0.32	1.23e-7	Parental longevity (mother's age at death);
CESC	cis	rs977987	0.778	rs12930452	chr16:75462055	A/G	cg03315344	chr16:75512273	CHST6	0.41	5.93	0.34	9.41e-9	Dupuytren's disease;
CESC	cis	rs898097	0.625	rs898095	chr17:80890638	T/C	cg10494973	chr17:80897199	TBCD	-0.43	-5.29	-0.31	2.6e-7	Breast cancer;
CESC	cis	rs875971	0.862	rs1083554	chr7:65852341	T/C	cg11764359	chr7:65958608	NA	0.78	11.31	0.57	1.86e-24	Aortic root size;
CESC	cis	rs9902453	0.765	rs2729447	chr17:28099002	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-10.34	-0.54	2.82e-21	Coffee consumption (cups per day);
CESC	cis	rs8114671	0.562	rs7266550	chr20:33495510	C/T	cg24642439	chr20:33292090	TP53INP2	0.43	5.19	0.3	4.19e-7	Height;
CESC	cis	rs2243480	0.901	rs2949697	chr7:65464236	A/G	cg13147721	chr7:65941812	NA	-0.86	-8.36	-0.46	3.7e-15	Diabetic kidney disease;
CESC	cis	rs10883723	0.810	rs1884929	chr10:104275418	C/T	ch.10.2196322F	chr10:104248062	ACTR1A	0.42	5.16	0.3	4.76e-7	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg06877462	chr1:205807181	PM20D1	0.46	6.95	0.39	2.84e-11	Menarche (age at onset);
CESC	cis	rs6831352	0.819	rs1154401	chr4:100009738	G/C	cg12011299	chr4:100065546	ADH4	0.65	8.38	0.46	3.18e-15	Alcohol dependence;
CESC	cis	rs10097731	0.901	rs4398860	chr8:82041753	C/T	cg25230327	chr8:82042993	NA	-0.59	-6.6	-0.38	2.28e-10	Serum total protein level;
CESC	cis	rs644799	1.000	rs514170	chr11:95556696	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.55	6.76	0.38	8.51e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs9916302	0.904	rs35335692	chr17:37710006	A/G	cg00129232	chr17:37814104	STARD3	-0.57	-7.5	-0.42	9.44e-13	Glomerular filtration rate (creatinine);
CESC	cis	rs9815354	0.680	rs73073291	chr3:42028004	G/C	cg03022575	chr3:42003672	ULK4	0.75	6.64	0.38	1.72e-10	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs11048434	0.636	rs7306161	chr12:9059075	T/A	cg23795048	chr12:9217529	LOC144571	0.32	5.06	0.3	7.93e-7	Sjögren's syndrome;
CESC	cis	rs7795096	0.512	rs7776488	chr7:151546696	G/A	cg17008978	chr7:151542804	PRKAG2	0.35	5.52	0.32	7.96e-8	Bipolar disorder (age of onset and psychotic symptoms);
CESC	cis	rs9300255	0.602	rs1716168	chr12:123651966	C/G	cg05973401	chr12:123451056	ABCB9	-0.51	-5.84	-0.34	1.52e-8	Neutrophil percentage of white cells;
CESC	cis	rs727505	0.721	rs67607629	chr7:124765867	C/T	cg23710748	chr7:124431027	NA	-0.34	-5.75	-0.33	2.41e-8	Lewy body disease;
CESC	cis	rs11122272	0.638	rs2739514	chr1:231514806	G/A	cg06096015	chr1:231504339	EGLN1	0.42	5.96	0.34	7.9e-9	Hemoglobin concentration;
CESC	cis	rs10504229	1.000	rs72652906	chr8:58188360	C/A	cg14926445	chr8:58193284	C8orf71	-0.51	-5.42	-0.32	1.37e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs6121246	0.865	rs6058421	chr20:30295013	G/C	cg13852791	chr20:30311386	BCL2L1	0.8	8.48	0.46	1.57e-15	Mean corpuscular hemoglobin;
CESC	cis	rs853679	0.517	rs9393898	chr6:28130376	G/T	cg20151795	chr6:28129481	ZNF389	0.46	5.9	0.34	1.1e-8	Depression;
CESC	cis	rs6543140	0.964	rs4851589	chr2:103077145	A/G	cg04239558	chr2:103089729	SLC9A4	0.43	5.77	0.33	2.25e-8	Blood protein levels;
CESC	cis	rs172166	0.694	rs203877	chr6:28048624	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.46	-5.96	-0.34	8.05e-9	Cardiac Troponin-T levels;
CESC	cis	rs2836950	0.509	rs11088466	chr21:40580017	T/A	cg17971929	chr21:40555470	PSMG1	-0.56	-7.41	-0.41	1.73e-12	Menarche (age at onset);
CESC	cis	rs7833986	0.501	rs72653941	chr8:56942247	T/C	cg26371346	chr8:56986568	SNORD54;RPS20	0.59	5.49	0.32	9.26e-8	Height;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg05815920	chr10:103880348	LDB1	-0.44	-6.06	-0.35	4.58e-9	Fibrinogen levels;
CESC	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg26338869	chr17:61819248	STRADA	0.68	8.97	0.48	5.62e-17	Prudent dietary pattern;
CESC	cis	rs8018808	0.935	rs4899654	chr14:77867314	A/C	cg20045696	chr14:77926864	AHSA1	0.4	5.55	0.32	7.09e-8	Myeloid white cell count;
CESC	cis	rs769267	0.598	rs8108705	chr19:19675367	G/T	cg03709012	chr19:19516395	GATAD2A	-0.68	-8.39	-0.46	2.84e-15	Tonsillectomy;
CESC	cis	rs7727544	0.735	rs2631370	chr5:131703776	T/C	cg07395648	chr5:131743802	NA	0.41	5.3	0.31	2.4e-7	Blood metabolite levels;
CESC	cis	rs10484885	0.887	rs2273246	chr6:90453263	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.68	-7.68	-0.43	3.1400000000000003e-13	QRS interval (sulfonylurea treatment interaction);
CESC	cis	rs7107174	1.000	rs2244508	chr11:77948515	T/A	cg02023728	chr11:77925099	USP35	0.47	6.3	0.36	1.24e-9	Testicular germ cell tumor;
CESC	cis	rs4906332	0.782	rs7161305	chr14:104002234	G/A	cg04998671	chr14:104000505	TRMT61A	-0.46	-5.37	-0.31	1.73e-7	Coronary artery disease;
CESC	cis	rs5769765	0.773	rs11090920	chr22:50320105	A/G	cg02269571	chr22:50332266	NA	-0.62	-6.79	-0.39	7.14e-11	Schizophrenia;
CESC	cis	rs72781680	0.611	rs72783636	chr2:24328706	C/T	cg20701182	chr2:24300061	SF3B14	0.92	10.55	0.54	6.09e-22	Lymphocyte counts;
CESC	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.51	-6.94	-0.39	2.95e-11	Lymphocyte counts;
CESC	cis	rs7264396	0.747	rs2425112	chr20:34319775	A/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.63	7.61	0.42	4.76e-13	Total cholesterol levels;
CESC	cis	rs9814567	1.000	rs7645295	chr3:134307734	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.41	-5.47	-0.32	1.02e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs17376456	0.825	rs67328989	chr5:93243133	T/A	cg21475434	chr5:93447410	FAM172A	0.73	6.04	0.35	5.29e-9	Diabetic retinopathy;
CESC	cis	rs7208859	0.623	rs170051	chr17:28914153	G/A	cg14008862	chr17:28927542	LRRC37B2	0.76	5.68	0.33	3.49e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs6540559	0.673	rs6694552	chr1:209976459	A/C	cg25204440	chr1:209979598	IRF6	0.65	6.71	0.38	1.21e-10	Cleft lip with or without cleft palate;
CESC	cis	rs3617	0.625	rs6445541	chr3:52880128	G/T	cg07507251	chr3:52567010	NT5DC2	0.32	5.62	0.33	4.78e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
CESC	cis	rs4144743	1.000	rs4144745	chr17:45323349	T/C	cg18085866	chr17:45331354	ITGB3	-0.66	-7.64	-0.43	3.87e-13	Body mass index;
CESC	cis	rs7949030	0.591	rs11231156	chr11:62366454	G/A	cg11742103	chr11:62369870	EML3;MTA2	0.65	9.83	0.52	1.21e-19	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs1707322	1.000	rs11211200	chr1:46288352	A/G	cg05343316	chr1:45956843	TESK2	0.42	5.27	0.31	2.83e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2735413	0.874	rs12917942	chr16:78064220	T/G	cg04733911	chr16:78082701	NA	-0.48	-7.62	-0.42	4.38e-13	Systolic blood pressure (alcohol consumption interaction);
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg23260255	chr3:187871479	LPP	-0.49	-6.54	-0.37	3.13e-10	Height;
CESC	cis	rs4665809	0.652	rs12611790	chr2:26404221	C/T	cg22920501	chr2:26401640	FAM59B	-0.86	-9.93	-0.52	5.84e-20	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11817910	chr12:31944836	H3F3C	-0.71	-8.73	-0.47	2.81e-16	Gut microbiome composition (summer);
CESC	cis	rs8099014	0.861	rs17669	chr18:56118493	C/T	cg19312305	chr18:56117016	MIR122	-0.26	-5.21	-0.3	3.85e-7	Platelet count;
CESC	cis	rs3858526	0.883	rs7481923	chr11:5933342	T/C	cg13902645	chr11:5959945	NA	-0.64	-7.7	-0.43	2.65e-13	DNA methylation (variation);
CESC	cis	rs34172651	0.617	rs9922436	chr16:24704490	C/G	cg06505273	chr16:24850292	NA	0.43	5.27	0.31	2.87e-7	Intelligence (multi-trait analysis);
CESC	cis	rs1348850	0.958	rs12471741	chr2:178448196	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.6	8.24	0.45	7.83e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs1003719	0.553	rs1063948	chr21:38574674	C/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.61	-8.29	-0.45	5.58e-15	Eye color traits;
CESC	cis	rs25645	0.760	rs11870683	chr17:38129841	T/A	cg17344932	chr17:38183730	MED24;SNORD124	0.53	7.46	0.42	1.27e-12	Myeloid white cell count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03622875	chr16:50187540	PAPD5	0.56	6.39	0.37	7.32e-10	Gut microbiome composition (summer);
CESC	cis	rs1538970	0.924	rs4660858	chr1:45936351	G/A	cg24296786	chr1:45957014	TESK2	-0.45	-5.1	-0.3	6.6e-7	Platelet count;
CESC	cis	rs4862750	0.872	rs13143414	chr4:187878213	G/A	cg27532560	chr4:187881888	NA	-0.4	-6.14	-0.35	3e-9	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1355223	0.867	rs7943755	chr11:34691451	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.51	-6.61	-0.38	2.15e-10	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs2228479	0.850	rs62056066	chr16:89906563	G/A	cg00800038	chr16:89945340	TCF25	-0.89	-6.89	-0.39	4.13e-11	Skin colour saturation;
CESC	cis	rs7586673	0.893	rs889925	chr2:161971597	T/C	cg08807892	chr2:162101083	NA	0.46	6.27	0.36	1.48e-9	Intelligence (multi-trait analysis);
CESC	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.74	-10.62	-0.55	3.56e-22	Prudent dietary pattern;
CESC	cis	rs7552404	0.924	rs7544117	chr1:76158246	A/G	cg03433033	chr1:76189801	ACADM	0.7	9.38	0.5	2.99e-18	Blood metabolite levels;Acylcarnitine levels;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg15045943	chr5:171614719	STK10	-0.47	-6.26	-0.36	1.55e-9	Height;
CESC	cis	rs875971	0.502	rs1796227	chr7:66087019	G/C	cg25405998	chr7:65216604	CCT6P1	-0.49	-5.39	-0.31	1.57e-7	Aortic root size;
CESC	cis	rs853679	0.517	rs9393896	chr6:28127703	C/T	cg23161317	chr6:28129485	ZNF389	0.52	6.46	0.37	5.08e-10	Depression;
CESC	cis	rs9815354	0.812	rs73071307	chr3:41798699	T/C	cg03022575	chr3:42003672	ULK4	0.72	6.35	0.36	9.12e-10	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs208520	0.690	rs207119	chr6:66786408	C/T	cg07460842	chr6:66804631	NA	-1.0	-13.33	-0.63	2.21e-31	Exhaled nitric oxide output;
CESC	cis	rs7937682	0.632	rs2070894	chr11:111780837	G/A	cg09085632	chr11:111637200	PPP2R1B	0.88	11.23	0.57	3.51e-24	Primary sclerosing cholangitis;
CESC	cis	rs2730245	0.550	rs2657364	chr7:158683825	T/C	cg01943577	chr7:158741284	NA	-0.47	-6.2	-0.36	2.1e-9	Height;
CESC	cis	rs2354432	0.607	rs9661159	chr1:146757923	G/A	cg25205988	chr1:146714368	CHD1L	-0.92	-7.89	-0.44	7.91e-14	Mitochondrial DNA levels;
CESC	cis	rs2455799	0.613	rs12637353	chr3:15831525	T/C	cg16303742	chr3:15540471	COLQ	-0.37	-5.55	-0.32	7.01e-8	Mean platelet volume;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg00371891	chr19:4723959	DPP9	-0.45	-6.13	-0.35	3.11e-9	Height;
CESC	cis	rs2295499	0.754	rs35679952	chr4:2619709	G/A	cg27239842	chr4:2403781	ZFYVE28	0.33	5.53	0.32	7.8e-8	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
CESC	cis	rs7552404	1.000	rs4949875	chr1:76173080	G/A	cg03433033	chr1:76189801	ACADM	0.65	7.67	0.43	3.3e-13	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs143626010	1	rs143626010	chr16:28539398	GTGTA/G	cg07382826	chr16:28625726	SULT1A1	0.39	6.49	0.37	4.29e-10	Mosquito bite size;
CESC	cis	rs9322193	0.962	rs2342861	chr6:150098697	C/T	cg07701084	chr6:150067640	NUP43	0.42	5.74	0.33	2.61e-8	Lung cancer;
CESC	cis	rs6088590	0.931	rs6088624	chr20:33436852	T/A	cg08999081	chr20:33150536	PIGU	0.57	8.8	0.48	1.8e-16	Coronary artery disease;
CESC	cis	rs4665809	0.941	rs7602922	chr2:26265782	C/T	cg27170947	chr2:26402098	FAM59B	-0.72	-8.36	-0.46	3.48e-15	Gut microbiome composition (summer);
CESC	cis	rs4665809	0.878	rs4665826	chr2:26367503	A/T	cg22920501	chr2:26401640	FAM59B	0.83	9.89	0.52	8.05e-20	Gut microbiome composition (summer);
CESC	cis	rs10242455	0.702	rs28753399	chr7:98997259	C/T	cg25640893	chr7:99214727	ZNF498	1.07	6.65	0.38	1.68e-10	Blood metabolite levels;
CESC	cis	rs8177253	0.829	rs9882812	chr3:133506127	A/G	cg18769074	chr3:133464867	TF	0.33	5.67	0.33	3.73e-8	Iron status biomarkers;
CESC	cis	rs2742234	0.541	rs11238490	chr10:43747598	G/A	cg07801480	chr10:43725741	RASGEF1A	-0.4	-5.09	-0.3	6.78e-7	Hirschsprung disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07352798	chr5:141488591	NDFIP1	0.6	7.6	0.42	5.12e-13	Gut microbiome composition (summer);
CESC	cis	rs193541	0.632	rs400207	chr5:122318497	C/T	cg19412675	chr5:122181750	SNX24	-0.46	-5.39	-0.31	1.58e-7	Glucose homeostasis traits;
CESC	cis	rs7666738	0.677	rs13120306	chr4:99036099	A/T	cg03467027	chr4:99064603	C4orf37	0.48	5.92	0.34	9.73e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11625487	0.957	rs7156032	chr14:77951364	G/A	cg20045696	chr14:77926864	AHSA1	-0.7	-7.57	-0.42	6.39e-13	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
CESC	cis	rs1062177	0.724	rs2915828	chr5:151118121	G/A	cg00977110	chr5:151150581	G3BP1	-0.6	-6.17	-0.35	2.52e-9	Preschool internalizing problems;
CESC	cis	rs3096299	0.685	rs4785571	chr16:89565169	A/G	cg02034447	chr16:89574710	SPG7	0.56	7.46	0.42	1.24e-12	Multiple myeloma (IgH translocation);
CESC	cis	rs10883723	0.810	rs2296590	chr10:104262628	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.54	7.43	0.42	1.49e-12	Allergic disease (asthma, hay fever or eczema);
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg21511036	chr2:227663538	IRS1	0.44	6.1	0.35	3.78e-9	Systemic lupus erythematosus;
CESC	cis	rs7296418	0.961	rs4275659	chr12:123447928	C/T	cg05973401	chr12:123451056	ABCB9	-0.58	-7.56	-0.42	6.64e-13	Platelet count;
CESC	cis	rs17345786	0.861	rs79181492	chr3:101216021	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.51	-5.67	-0.33	3.71e-8	Colonoscopy-negative controls vs population controls;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05826458	chr2:111875031	ACOXL	0.39	6.07	0.35	4.49e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs9309473	0.898	rs11126403	chr2:73796923	A/G	cg20560298	chr2:73613845	ALMS1	-0.48	-6.51	-0.37	3.74e-10	Metabolite levels;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg25312474	chr6:142468512	VTA1	-0.53	-7.0	-0.4	2.1e-11	Ulcerative colitis;
CESC	cis	rs7208859	0.623	rs7219712	chr17:29080570	G/T	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.91e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs2836633	0.929	rs4143428	chr21:40030582	G/T	cg05519781	chr21:40033154	ERG	0.79	13.49	0.64	6.12e-32	Coronary artery disease;
CESC	cis	rs853679	0.517	rs17711801	chr6:28092307	C/G	cg26335602	chr6:28129616	ZNF389	0.53	7.09	0.4	1.19e-11	Depression;
CESC	cis	rs703842	1.000	rs703842	chr12:58162739	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	-0.68	-8.89	-0.48	9.91e-17	Multiple sclerosis;
CESC	cis	rs853679	0.517	rs34716816	chr6:28046169	C/A	cg23281280	chr6:28129359	ZNF389	0.57	7.78	0.43	1.61e-13	Depression;
CESC	cis	rs62432291	0.681	rs404435	chr6:159654487	G/T	cg14500486	chr6:159655392	FNDC1	-0.61	-6.12	-0.35	3.29e-9	Joint mobility (Beighton score);
CESC	cis	rs17384381	1.000	rs12138852	chr1:85878208	C/T	cg16011679	chr1:85725395	C1orf52	0.76	7.79	0.43	1.51e-13	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs963731	0.649	rs1454221	chr2:39215672	C/T	cg04010122	chr2:39346883	SOS1	-0.7	-5.22	-0.31	3.64e-7	Corticobasal degeneration;
CESC	cis	rs7017914	0.967	rs13254801	chr8:71688984	T/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.2	-0.3	3.94e-7	Bone mineral density;
CESC	cis	rs9926296	0.581	rs12598477	chr16:89902482	T/C	cg27121462	chr16:89883253	FANCA	0.62	7.48	0.42	1.11e-12	Vitiligo;
CESC	cis	rs6060717	0.536	rs6060704	chr20:34530270	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.65	5.58	0.32	5.82e-8	Hip circumference adjusted for BMI;
CESC	cis	rs116095464	0.614	rs28736753	chr5:274081	G/A	cg22496380	chr5:211416	CCDC127	-0.7	-7.73	-0.43	2.21e-13	Breast cancer;
CESC	cis	rs2933343	0.729	rs789224	chr3:128598231	A/C	cg24203234	chr3:128598194	ACAD9	0.44	5.9	0.34	1.09e-8	IgG glycosylation;
CESC	cis	rs2721195	0.967	rs748193	chr8:145682115	C/T	cg15320075	chr8:145703422	NA	0.63	8.75	0.47	2.46e-16	Age at first birth;
CESC	cis	rs6991838	0.584	rs4388482	chr8:66496203	T/G	cg13398993	chr8:66546079	ARMC1	-0.48	-5.74	-0.33	2.62e-8	Intelligence (multi-trait analysis);
CESC	cis	rs7927771	0.894	rs12798346	chr11:47583121	C/T	cg20135002	chr11:47629003	NA	-0.39	-5.03	-0.3	9.04e-7	Subjective well-being;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00320862	chr3:170588302	RPL22L1	0.58	6.71	0.38	1.14e-10	Gut microbiome composition (summer);
CESC	cis	rs561341	1.000	rs4795668	chr17:30244554	G/A	cg23018236	chr17:30244563	NA	-0.52	-5.59	-0.32	5.57e-8	Hip circumference adjusted for BMI;
CESC	cis	rs951366	1.000	rs951366	chr1:205685352	C/T	cg14893161	chr1:205819251	PM20D1	0.45	6.38	0.37	7.65e-10	Menarche (age at onset);
CESC	cis	rs1395	0.778	rs11126918	chr2:27438710	G/A	cg22903471	chr2:27725779	GCKR	-0.41	-5.07	-0.3	7.39e-7	Blood metabolite levels;
CESC	cis	rs6088813	1.000	rs6088823	chr20:33994265	G/T	cg14752227	chr20:34000481	UQCC	-0.4	-5.08	-0.3	7.17e-7	Height;
CESC	cis	rs17384381	0.953	rs11161597	chr1:85784936	G/A	cg16011679	chr1:85725395	C1orf52	0.78	7.93	0.44	6.03e-14	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7586673	0.857	rs16845580	chr2:161920884	T/C	cg16506815	chr2:162101123	NA	0.43	5.89	0.34	1.16e-8	Intelligence (multi-trait analysis);
CESC	cis	rs8114671	0.562	rs6120763	chr20:33506400	C/G	cg07148914	chr20:33460835	GGT7	0.45	5.9	0.34	1.09e-8	Height;
CESC	cis	rs9457247	0.582	rs9459855	chr6:167466150	G/T	cg23791538	chr6:167370224	RNASET2	-0.52	-6.87	-0.39	4.45e-11	Crohn's disease;
CESC	trans	rs10776614	0.799	rs7094216	chr10:49766949	A/G	cg19218067	chr2:181235115	NA	0.49	6.0	0.35	6.35e-9	Self-employment;
CESC	cis	rs7932354	0.710	rs2306032	chr11:46897253	G/C	cg25783544	chr11:47291846	MADD	-0.39	-5.03	-0.3	8.94e-7	Bone mineral density (hip);Bone mineral density;
CESC	cis	rs57506017	0.585	rs1468803	chr7:12275675	A/C	cg23422036	chr7:12250390	TMEM106B	0.39	5.24	0.31	3.34e-7	Neuroticism;
CESC	cis	rs7918232	0.941	rs1753413	chr10:27397112	T/C	cg14442939	chr10:27389572	ANKRD26	0.68	6.36	0.36	8.89e-10	Breast cancer;
CESC	cis	rs9584850	0.874	rs9168	chr13:99101583	C/A	cg20750642	chr13:99100586	FARP1	-0.4	-5.92	-0.34	9.74e-9	Neuroticism;
CESC	cis	rs2075371	0.933	rs1421482	chr7:133964383	A/G	cg11752832	chr7:134001865	SLC35B4	0.52	6.69	0.38	1.33e-10	Mean platelet volume;
CESC	cis	rs2836974	0.831	rs11911149	chr21:40528375	C/T	cg11644478	chr21:40555479	PSMG1	1.04	17.66	0.74	1.16e-46	Cognitive function;
CESC	cis	rs1552244	1.000	rs17032276	chr3:10076975	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.88	12.05	0.59	5.97e-27	Alzheimer's disease;
CESC	cis	rs514406	0.825	rs7523761	chr1:53250915	T/C	cg24675658	chr1:53192096	ZYG11B	0.54	7.49	0.42	1.05e-12	Monocyte count;
CESC	cis	rs7917772	0.582	rs3936017	chr10:104354424	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.41	5.63	0.33	4.48e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs8070740	0.617	rs1058117	chr17:5323206	T/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.54	7.29	0.41	3.59e-12	Menopause (age at onset);
CESC	cis	rs6088580	0.634	rs6087588	chr20:33066369	T/C	cg24642439	chr20:33292090	TP53INP2	0.51	6.72	0.38	1.12e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs854765	0.964	rs854762	chr17:18009102	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.48	-6.29	-0.36	1.27e-9	Total body bone mineral density;
CESC	cis	rs1707322	1.000	rs10890365	chr1:46359348	C/T	cg06784218	chr1:46089804	CCDC17	0.33	5.73	0.33	2.78e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs4253772	0.637	rs9627402	chr22:46702586	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.65	5.89	0.34	1.16e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs9733	0.596	rs2065900	chr1:150652202	A/G	cg09365446	chr1:150670422	GOLPH3L	0.42	5.9	0.34	1.09e-8	Tonsillectomy;
CESC	cis	rs2213920	0.516	rs71505548	chr9:118169753	G/A	cg13918206	chr9:118159781	DEC1	-0.67	-5.5	-0.32	8.77e-8	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
CESC	cis	rs9815354	0.812	rs73073371	chr3:41843443	A/G	cg03022575	chr3:42003672	ULK4	0.7	6.04	0.35	5.26e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs5758659	0.714	rs7245	chr22:42481849	G/A	cg19513890	chr22:42538836	CYP2D7P1	0.38	5.55	0.32	6.79e-8	Cognitive function;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg24833071	chr7:75115655	POM121C	0.46	6.1	0.35	3.74e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs9291683	0.595	rs11731110	chr4:10037346	T/C	cg02734326	chr4:10020555	SLC2A9	0.49	6.83	0.39	5.64e-11	Bone mineral density;
CESC	cis	rs5769765	0.954	rs5770739	chr22:50268014	C/G	cg26441486	chr22:50317300	CRELD2	-0.39	-5.5	-0.32	8.72e-8	Schizophrenia;
CESC	cis	rs9733	0.519	rs7511673	chr1:150707636	A/T	cg22823121	chr1:150693482	HORMAD1	0.47	6.89	0.39	4.04e-11	Tonsillectomy;
CESC	cis	rs72627123	0.867	rs112965033	chr14:74461117	T/A	cg08255017	chr14:74727001	VSX2	0.61	5.06	0.3	7.74e-7	Morning vs. evening chronotype;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05644321	chr20:20693493	RALGAPA2	-0.65	-8.13	-0.45	1.67e-14	Gut microbiome composition (summer);
CESC	cis	rs4819052	0.808	rs2246697	chr21:46689999	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.75	10.02	0.52	2.97e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs11235843	0.516	rs666839	chr11:73346041	A/G	cg19180555	chr12:5982295	ANO2	-0.44	-6.18	-0.35	2.34e-9	Hand grip strength;
CESC	cis	rs12136530	0.774	rs12137160	chr1:19763379	C/T	cg01832549	chr1:19774989	CAPZB	-0.43	-6.15	-0.35	2.88e-9	Lead levels in blood;
CESC	trans	rs11098499	0.754	rs1849457	chr4:120254355	A/G	cg25214090	chr10:38739885	LOC399744	0.63	8.75	0.47	2.48e-16	Corneal astigmatism;
CESC	cis	rs4563143	0.647	rs34218744	chr19:29256821	A/T	cg12667521	chr19:29218732	NA	0.48	6.28	0.36	1.37e-9	Methadone dose in opioid dependence;
CESC	cis	rs875971	1.000	rs4718357	chr7:65960878	A/G	cg12463550	chr7:65579703	CRCP	0.56	7.07	0.4	1.39e-11	Aortic root size;
CESC	cis	rs4481887	1.000	rs10888356	chr1:248465044	C/T	cg00666640	chr1:248458726	OR2T12	-0.36	-5.82	-0.34	1.72e-8	Common traits (Other);
CESC	trans	rs10820912	0.673	rs75401888	chr9:92883308	C/G	cg23943268	chr13:33589621	KL	-0.48	-6.0	-0.35	6.55e-9	Left atrial antero-posterior diameter;
CESC	cis	rs9916302	0.904	rs7223331	chr17:37482930	A/G	cg00129232	chr17:37814104	STARD3	0.57	7.67	0.43	3.29e-13	Glomerular filtration rate (creatinine);
CESC	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg26338869	chr17:61819248	STRADA	0.68	8.79	0.48	1.94e-16	Prudent dietary pattern;
CESC	cis	rs2294693	0.947	rs9369254	chr6:40989408	T/C	cg14418226	chr6:40996092	UNC5CL	0.52	6.47	0.37	4.68e-10	Gastric cancer;Non-cardia gastric cancer;
CESC	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg03188948	chr7:1209495	NA	0.6	6.76	0.38	8.54e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs13395018	0.892	rs6730556	chr2:170947722	C/G	cg09813610	chr5:3601357	IRX1	-0.56	-6.0	-0.35	6.55e-9	Pulse pressure;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg27284088	chr4:84031130	PLAC8	-0.51	-6.88	-0.39	4.39e-11	Height;
CESC	cis	rs2404602	0.608	rs12911035	chr15:76606591	T/C	cg05617483	chr15:76483344	C15orf27	0.39	5.17	0.3	4.51e-7	Blood metabolite levels;
CESC	cis	rs7618501	0.633	rs2526751	chr3:50064867	T/C	cg24110177	chr3:50126178	RBM5	0.53	7.3	0.41	3.38e-12	Intelligence (multi-trait analysis);
CESC	cis	rs826838	1.000	rs11610522	chr12:38687575	C/T	cg13010199	chr12:38710504	ALG10B	0.63	8.85	0.48	1.29e-16	Heart rate;
CESC	cis	rs7666738	0.830	rs28587201	chr4:98991733	C/T	cg05340658	chr4:99064831	C4orf37	0.8	12.44	0.61	2.83e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9300255	0.537	rs2682429	chr12:123642955	C/G	cg05973401	chr12:123451056	ABCB9	0.5	5.81	0.34	1.79e-8	Neutrophil percentage of white cells;
CESC	trans	rs7246760	0.867	rs8107594	chr19:9835957	G/C	cg02900749	chr2:68251473	NA	-0.85	-7.44	-0.42	1.38e-12	Pursuit maintenance gain;
CESC	cis	rs2485892	0.553	rs2494191	chr1:210346053	G/C	cg23283495	chr1:209979779	IRF6	0.46	5.61	0.33	5.16e-8	Manic episodes in bipolar disorder;
CESC	cis	rs1018836	0.892	rs7819519	chr8:91565504	C/T	cg16814680	chr8:91681699	NA	-0.6	-8.37	-0.46	3.34e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08974966	chr11:3078805	CARS	0.61	7.2	0.4	6.22e-12	Gut microbiome composition (summer);
CESC	cis	rs16867321	0.950	rs1919155	chr2:181457053	T/C	cg23363182	chr2:181467187	NA	-0.44	-5.46	-0.32	1.1e-7	Obesity;
CESC	cis	rs60843830	1.000	rs62114505	chr2:242426	A/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.79	10.12	0.53	1.47e-20	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs921968	0.541	rs55996799	chr2:219558193	C/G	cg02176678	chr2:219576539	TTLL4	-0.59	-10.36	-0.54	2.52e-21	Mean corpuscular hemoglobin concentration;
CESC	cis	rs881375	0.678	rs10760128	chr9:123696325	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.44	6.35	0.36	9.27e-10	Rheumatoid arthritis;
CESC	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg03188948	chr7:1209495	NA	0.73	7.17	0.4	7.66e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg14230542	chr1:110577941	FAM40A	-0.42	-6.01	-0.35	6.08e-9	Gambling;
CESC	cis	rs1355223	1.000	rs1396879	chr11:34766653	A/C	cg11058730	chr11:34937778	PDHX;APIP	-0.45	-5.9	-0.34	1.11e-8	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs1784581	0.588	rs9355971	chr6:162421242	A/G	cg17173639	chr6:162384350	PARK2	0.58	8.89	0.48	9.87e-17	Itch intensity from mosquito bite;
CESC	cis	rs2991971	0.967	rs12743512	chr1:45954033	A/G	cg24296786	chr1:45957014	TESK2	-0.67	-9.33	-0.5	4.34e-18	High light scatter reticulocyte count;
CESC	cis	rs72792276	0.908	rs10478797	chr5:127442066	G/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.64	5.77	0.33	2.25e-8	Red cell distribution width;
CESC	cis	rs10504229	0.679	rs72649115	chr8:58037631	T/G	cg02725872	chr8:58115012	NA	-0.38	-5.03	-0.3	8.86e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs7618915	0.547	rs8906	chr3:52739520	T/C	cg18404041	chr3:52824283	ITIH1	-0.41	-6.93	-0.39	3.13e-11	Bipolar disorder;
CESC	cis	rs7084402	0.534	rs7911971	chr10:60305160	G/A	cg07615347	chr10:60278583	BICC1	-0.57	-8.14	-0.45	1.58e-14	Refractive error;
CESC	cis	rs1580019	0.885	rs1610141	chr7:32498435	C/T	cg07520158	chr7:32535189	LSM5;AVL9	0.42	5.07	0.3	7.45e-7	Cognitive ability;
CESC	cis	rs11252926	0.550	rs10904148	chr10:454551	G/T	cg18196295	chr10:418757	DIP2C	0.52	7.06	0.4	1.49e-11	Psychosis in Alzheimer's disease;
CESC	cis	rs6598955	0.724	rs12754536	chr1:26639605	T/C	cg19743891	chr1:26644573	UBXN11;CD52	-0.26	-5.03	-0.3	9.2e-7	Obesity-related traits;
CESC	cis	rs9486715	0.867	rs9486181	chr6:96868132	G/A	cg18709589	chr6:96969512	KIAA0776	0.45	6.46	0.37	5.05e-10	Headache;
CESC	cis	rs1878931	0.580	rs4578649	chr16:3407258	C/T	cg22508957	chr16:3507546	NAT15	0.34	5.05	0.3	8.11e-7	Body mass index (adult);
CESC	cis	rs6570726	0.935	rs428659	chr6:145827039	T/C	cg05347473	chr6:146136440	FBXO30	0.49	6.69	0.38	1.3100000000000001e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7674212	0.510	rs6856593	chr4:104177699	T/C	cg16532752	chr4:104119610	CENPE	-0.43	-5.89	-0.34	1.16e-8	Type 2 diabetes;
CESC	cis	rs2880765	0.835	rs4360874	chr15:86040820	A/T	cg19183879	chr15:85880815	NA	-0.26	-5.34	-0.31	2.01e-7	Coronary artery disease;
CESC	cis	rs4144743	1.000	rs67080286	chr17:45322248	T/G	cg18085866	chr17:45331354	ITGB3	-0.64	-7.03	-0.4	1.78e-11	Body mass index;
CESC	cis	rs6088590	0.735	rs6060003	chr20:33294945	T/C	cg08999081	chr20:33150536	PIGU	0.53	7.95	0.44	5.51e-14	Coronary artery disease;
CESC	cis	rs287982	0.611	rs115657324	chr2:9983856	A/G	cg10881225	chr2:9984929	TAF1B	0.68	5.39	0.31	1.53e-7	Nonsyndromic cleft lip with cleft palate;
CESC	cis	rs7845219	0.544	rs7016078	chr8:95922615	G/A	cg09323728	chr8:95962352	TP53INP1	-0.34	-6.76	-0.38	8.55e-11	Type 2 diabetes;
CESC	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg10150615	chr22:24372951	LOC391322	0.56	7.7	0.43	2.76e-13	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs4665809	1.000	rs2289022	chr2:26350136	G/T	cg26314531	chr2:26401878	FAM59B	-0.62	-6.99	-0.39	2.29e-11	Gut microbiome composition (summer);
CESC	cis	rs6088580	0.609	rs6058029	chr20:32969643	T/C	cg08999081	chr20:33150536	PIGU	-0.66	-11.72	-0.58	8.03e-26	Glomerular filtration rate (creatinine);
CESC	cis	rs4727027	0.901	rs4727019	chr7:148822266	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.41	5.08	0.3	7.22e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs17376456	0.877	rs10044066	chr5:93437580	T/C	cg25358565	chr5:93447407	FAM172A	1.13	11.5	0.58	4.18e-25	Diabetic retinopathy;
CESC	cis	rs7666738	0.830	rs10049985	chr4:99023517	C/T	cg03467027	chr4:99064603	C4orf37	0.46	5.81	0.34	1.8e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4319547	0.695	rs4758648	chr12:122900460	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.5	-6.15	-0.35	2.82e-9	Body mass index;
CESC	cis	rs7923609	0.967	rs7920058	chr10:65293924	T/G	cg01631684	chr10:65280961	REEP3	-0.43	-5.44	-0.32	1.2e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg16937126	chr8:38088972	DDHD2	0.48	6.25	0.36	1.61e-9	Systemic lupus erythematosus;
CESC	cis	rs9815354	0.680	rs78402272	chr3:42028425	G/C	cg03022575	chr3:42003672	ULK4	0.75	6.64	0.38	1.72e-10	Pulse pressure;Diastolic blood pressure;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16383001	chr1:100435543	SLC35A3	0.49	6.02	0.35	5.69e-9	Gut microbiome composition (summer);
CESC	cis	rs3820068	0.608	rs6668919	chr1:16049893	A/G	cg13390004	chr1:15929781	NA	-0.34	-5.29	-0.31	2.53e-7	Systolic blood pressure;
CESC	cis	rs1062177	1.000	rs1062177	chr5:151184701	C/T	cg12924095	chr5:151150029	G3BP1	0.49	6.5	0.37	3.86e-10	Preschool internalizing problems;
CESC	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg07414643	chr4:187882934	NA	0.57	8.18	0.45	1.2e-14	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7916697	0.891	rs7897809	chr10:70000293	A/G	cg06988349	chr10:69991859	ATOH7	0.38	6.46	0.37	5.12e-10	Optic disc area;
CESC	cis	rs55794721	0.509	rs909834	chr1:25757996	A/G	cg27572855	chr1:25598939	RHD	0.47	7.74	0.43	2.16e-13	Plateletcrit;Mean corpuscular volume;
CESC	cis	rs290268	1.000	rs290268	chr9:93552450	A/G	cg02608019	chr9:93564028	SYK	0.64	9.42	0.5	2.31e-18	Platelet count;
CESC	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg06873352	chr17:61820015	STRADA	0.73	12.98	0.62	3.9e-30	Prudent dietary pattern;
CESC	cis	rs807669	0.505	rs2236759	chr22:19187427	C/G	cg02655711	chr22:19163373	SLC25A1	0.43	6.45	0.37	5.25e-10	Metabolite levels;
CESC	cis	rs1215050	0.791	rs6532702	chr4:98766641	C/T	cg05340658	chr4:99064831	C4orf37	0.51	6.58	0.37	2.52e-10	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs853679	0.517	rs12332979	chr6:28141548	T/G	cg18032046	chr6:28092343	ZSCAN16	-0.56	-6.42	-0.37	6.22e-10	Depression;
CESC	cis	rs7945705	0.712	rs61876274	chr11:9019190	A/T	cg21881798	chr11:8931708	C11orf17;ST5	0.39	6.12	0.35	3.36e-9	Hemoglobin concentration;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg21933743	chr11:65367160	MAP3K11	0.42	6.17	0.35	2.48e-9	Fibrinogen levels;
CESC	cis	rs6690583	0.623	rs7522239	chr1:85484366	C/T	cg22153463	chr1:85462885	MCOLN2	0.75	7.59	0.42	5.63e-13	Serum sulfate level;
CESC	cis	rs853679	0.542	rs2295594	chr6:28053097	G/A	cg23281280	chr6:28129359	ZNF389	0.57	7.78	0.43	1.61e-13	Depression;
CESC	cis	rs7772486	0.754	rs6570708	chr6:145989428	C/T	cg05347473	chr6:146136440	FBXO30	-0.49	-6.29	-0.36	1.34e-9	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1862618	0.853	rs6885541	chr5:56110857	G/C	cg24531977	chr5:56204891	C5orf35	-0.87	-10.94	-0.56	3.15e-23	Initial pursuit acceleration;
CESC	trans	rs941207	0.542	rs2888096	chr12:57187635	A/T	cg26462586	chr2:11164677	NA	0.38	6.02	0.35	5.82e-9	Platelet count;
CESC	cis	rs11098499	0.863	rs13140409	chr4:120503460	A/G	cg09307838	chr4:120376055	NA	0.95	12.98	0.62	3.72e-30	Corneal astigmatism;
CESC	cis	rs7552404	0.920	rs1612097	chr1:76218875	C/T	cg10523679	chr1:76189770	ACADM	0.75	10.09	0.53	1.8e-20	Blood metabolite levels;Acylcarnitine levels;
CESC	trans	rs7824557	0.524	rs7835318	chr8:10953874	G/A	cg15556689	chr8:8085844	FLJ10661	-0.5	-6.17	-0.35	2.58e-9	Retinal vascular caliber;
CESC	trans	rs804280	0.542	rs34117651	chr8:11791617	G/C	cg15556689	chr8:8085844	FLJ10661	0.52	6.36	0.36	8.65e-10	Myopia (pathological);
CESC	cis	rs1799949	1.000	rs8176265	chr17:41213996	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.6	7.79	0.43	1.49e-13	Menopause (age at onset);
CESC	cis	rs6860806	0.661	rs6871350	chr5:131580220	A/G	cg11843238	chr5:131593191	PDLIM4	0.37	5.43	0.32	1.27e-7	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14374347	chr1:38158195	CDCA8	-0.65	-7.87	-0.44	8.94e-14	Gut microbiome composition (summer);
CESC	cis	rs1153858	0.887	rs7171163	chr15:45636395	A/C	cg14582100	chr15:45693742	SPATA5L1	0.42	6.08	0.35	4.2e-9	Homoarginine levels;
CESC	cis	rs9311474	0.607	rs4234633	chr3:52557038	C/T	cg18099408	chr3:52552593	STAB1	-0.38	-6.49	-0.37	4.17e-10	Electroencephalogram traits;
CESC	cis	rs9611565	0.512	rs45500192	chr22:42177899	A/G	cg06481639	chr22:41940642	POLR3H	-0.59	-5.81	-0.34	1.81e-8	Vitiligo;
CESC	cis	rs780096	0.506	rs1647286	chr2:27714517	A/T	cg24768116	chr2:27665128	KRTCAP3	-0.3	-5.64	-0.33	4.33e-8	Total body bone mineral density;
CESC	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg15112475	chr7:1198522	ZFAND2A	-0.34	-5.5	-0.32	9.04e-8	Longevity;Endometriosis;
CESC	cis	rs559928	0.597	rs2186572	chr11:63895887	A/G	cg18225595	chr11:63971243	STIP1	0.66	5.64	0.33	4.29e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CESC	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.5	-7.34	-0.41	2.64e-12	Longevity;Endometriosis;
CESC	cis	rs17601876	0.814	rs28637352	chr15:51559666	C/A	cg19946085	chr15:51559439	CYP19A1	-0.33	-5.37	-0.31	1.76e-7	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
CESC	cis	rs2952156	0.883	rs2941505	chr17:37832704	A/G	cg07936489	chr17:37558343	FBXL20	-0.58	-7.33	-0.41	2.84e-12	Asthma;
CESC	trans	rs7615952	0.558	rs7641353	chr3:125339879	T/C	cg00769240	chr8:12517080	NA	-0.43	-6.04	-0.35	5.34e-9	Blood pressure (smoking interaction);
CESC	cis	rs17253792	0.822	rs76819679	chr14:56134672	C/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.81	5.68	0.33	3.46e-8	Putamen volume;
CESC	cis	rs9911578	1.000	rs3744108	chr17:56585872	G/C	cg05425664	chr17:57184151	TRIM37	0.51	7.26	0.41	4.42e-12	Intelligence (multi-trait analysis);
CESC	cis	rs2282802	0.635	rs269767	chr5:139536922	A/G	cg26211634	chr5:139558579	C5orf32	0.4	5.31	0.31	2.3e-7	Intelligence (multi-trait analysis);
CESC	cis	rs6460942	0.555	rs7803268	chr7:12306793	G/A	cg06484146	chr7:12443880	VWDE	-0.78	-8.3	-0.45	5.42e-15	Coronary artery disease;
CESC	trans	rs875971	1.000	rs4718344	chr7:65874381	C/A	cg26939375	chr7:64535504	NA	0.47	6.14	0.35	3.07e-9	Aortic root size;
CESC	cis	rs6952808	0.609	rs6950151	chr7:1953521	T/C	cg05863683	chr7:1912471	MAD1L1	0.38	5.85	0.34	1.42e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs2836974	0.831	rs2836964	chr21:40631006	T/C	cg11890956	chr21:40555474	PSMG1	1.19	22.08	0.8	5.3e-62	Cognitive function;
CESC	cis	rs12579753	0.692	rs11115064	chr12:82278683	G/A	cg21193143	chr12:82153300	PPFIA2	-0.36	-5.44	-0.32	1.18e-7	Resting heart rate;
CESC	cis	rs6121246	0.821	rs115585940	chr20:30317902	T/C	cg13852791	chr20:30311386	BCL2L1	0.79	7.36	0.41	2.36e-12	Mean corpuscular hemoglobin;
CESC	cis	rs1707322	0.721	rs4330955	chr1:46217485	G/C	cg03146154	chr1:46216737	IPP	0.82	11.54	0.58	3.18e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7666738	1.000	rs13116475	chr4:99054843	C/T	cg05340658	chr4:99064831	C4orf37	-0.64	-8.17	-0.45	1.24e-14	Colonoscopy-negative controls vs population controls;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg09071690	chr1:59012457	OMA1	-0.45	-6.19	-0.36	2.34e-9	Fibrinogen levels;
CESC	trans	rs7824557	0.527	rs57629785	chr8:11235150	C/A	cg06636001	chr8:8085503	FLJ10661	-0.48	-6.05	-0.35	4.93e-9	Retinal vascular caliber;
CESC	cis	rs6142102	0.649	rs4911382	chr20:32553095	C/T	cg08999081	chr20:33150536	PIGU	0.34	5.1	0.3	6.63e-7	Skin pigmentation;
CESC	cis	rs8072100	0.782	rs28507314	chr17:45551402	C/T	cg25173405	chr17:45401733	C17orf57	-0.47	-6.16	-0.35	2.75e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs11098499	0.863	rs7678400	chr4:120461957	G/A	cg09307838	chr4:120376055	NA	0.9	12.32	0.6	6.96e-28	Corneal astigmatism;
CESC	cis	rs258892	0.843	rs155431	chr5:72120916	A/T	cg21869765	chr5:72125136	TNPO1	-0.45	-5.72	-0.33	2.94e-8	Small cell lung carcinoma;
CESC	cis	rs9303280	0.837	rs907092	chr17:37922259	A/G	cg20243544	chr17:37824526	PNMT	-0.52	-6.97	-0.39	2.53e-11	Self-reported allergy;
CESC	cis	rs10788264	0.513	rs10749455	chr10:124035030	A/G	cg09507567	chr10:124027408	NA	0.41	5.91	0.34	1.04e-8	Total body bone mineral density;
CESC	cis	rs79518236	1	rs79518236	chr7:98026554	ACT/A	cg09267113	chr7:98030324	BAIAP2L1	-0.43	-5.8	-0.34	1.89e-8	Breast cancer;
CESC	cis	rs3096299	0.606	rs8052103	chr16:89541243	A/T	cg08392591	chr16:89556376	ANKRD11	-0.42	-5.13	-0.3	5.65e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs2836950	0.501	rs4818018	chr21:40694072	C/T	cg17971929	chr21:40555470	PSMG1	-0.59	-7.65	-0.43	3.67e-13	Menarche (age at onset);
CESC	cis	rs140364877	1	rs140364877	chr7:1885178	C/T	cg13880726	chr7:1868755	MAD1L1	0.53	7.16	0.4	8.13e-12	Autism spectrum disorder or schizophrenia;
CESC	cis	rs79057730	0.527	rs34519158	chr7:811114	G/A	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.91	7.83	0.43	1.19e-13	Initial pursuit acceleration;
CESC	cis	rs875971	0.545	rs316306	chr7:65618674	G/A	cg11764359	chr7:65958608	NA	-0.79	-9.51	-0.5	1.18e-18	Aortic root size;
CESC	trans	rs9325144	0.532	rs12812406	chr12:38719802	G/A	cg23762105	chr12:34175262	ALG10	0.49	6.24	0.36	1.76e-9	Morning vs. evening chronotype;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg03951724	chr22:30723125	TBC1D10A	-0.47	-6.8	-0.39	6.81e-11	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs3820928	0.904	rs2217359	chr2:227759892	C/T	cg11843606	chr2:227700838	RHBDD1	-0.46	-5.96	-0.34	8.02e-9	Pulmonary function;
CESC	cis	rs6582630	0.519	rs11609739	chr12:38547969	G/A	cg13010199	chr12:38710504	ALG10B	0.51	6.56	0.37	2.88e-10	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs6088590	0.965	rs6087619	chr20:33288511	C/G	cg06115741	chr20:33292138	TP53INP2	0.6	7.53	0.42	8.12e-13	Coronary artery disease;
CESC	cis	rs13256369	0.802	rs11249884	chr8:8561552	C/T	cg18904891	chr8:8559673	CLDN23	-0.64	-7.17	-0.4	7.3e-12	Obesity-related traits;
CESC	cis	rs2836974	0.863	rs6517519	chr21:40540245	A/G	cg17971929	chr21:40555470	PSMG1	1.06	16.34	0.71	5.24e-42	Cognitive function;
CESC	cis	rs1808579	0.904	rs6507708	chr18:21101456	C/A	cg14672496	chr18:21087552	C18orf8	0.44	6.73	0.38	1.02e-10	Hip circumference;Body mass index;BMI (adjusted for smoking behaviour);
CESC	cis	rs11785400	1.000	rs7459630	chr8:143738585	A/C	cg10596483	chr8:143751796	JRK	0.43	5.69	0.33	3.4e-8	Schizophrenia;
CESC	cis	rs1707322	1.000	rs7519181	chr1:46387829	G/C	cg03146154	chr1:46216737	IPP	0.72	9.82	0.52	1.31e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7264396	0.635	rs6058378	chr20:34546658	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.57	6.83	0.39	5.63e-11	Total cholesterol levels;
CESC	cis	rs7582720	1.000	rs72936869	chr2:203788950	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.38	0.41	1.99e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs863345	0.604	rs11265009	chr1:158498772	C/T	cg12129480	chr1:158549410	OR10X1	-0.34	-6.97	-0.39	2.51e-11	Pneumococcal bacteremia;
CESC	cis	rs644799	1.000	rs1944074	chr11:95511445	C/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	14.69	0.67	3.96e-36	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs4665809	1.000	rs4665298	chr2:26256378	G/A	cg26314531	chr2:26401878	FAM59B	-0.61	-6.88	-0.39	4.31e-11	Gut microbiome composition (summer);
CESC	cis	rs4555082	0.874	rs2816620	chr14:105732704	G/T	cg27165867	chr14:105738592	BRF1	-0.52	-5.59	-0.32	5.65e-8	Mean platelet volume;Platelet distribution width;
CESC	cis	rs2842992	0.830	rs2842974	chr6:160159034	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.75	9.57	0.51	8.01e-19	Age-related macular degeneration (geographic atrophy);
CESC	trans	rs1814175	0.754	rs10219245	chr11:49645052	C/T	cg03929089	chr4:120376271	NA	-0.94	-15.57	-0.69	2.82e-39	Height;
CESC	cis	rs3747547	0.892	rs72726022	chr9:38019703	C/T	cg13774184	chr9:37916125	SHB	-0.73	-6.25	-0.36	1.61e-9	Metabolite levels (Dihydroxy docosatrienoic acid);
CESC	cis	rs5769765	0.862	rs138870	chr22:50209737	C/T	cg26441486	chr22:50317300	CRELD2	0.39	5.11	0.3	6.2e-7	Schizophrenia;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03625951	chr6:149867442	PPIL4	0.5	6.46	0.37	4.86e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs13191362	0.507	rs2849518	chr6:163134248	T/C	cg21926612	chr6:163149169	PACRG;PARK2	-0.59	-6.94	-0.39	2.97e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs62064224	0.593	rs916663	chr17:30835833	A/C	cg25809561	chr17:30822961	MYO1D	-0.52	-7.3	-0.41	3.37e-12	Schizophrenia;
CESC	cis	rs7937682	0.575	rs11604704	chr11:111764396	G/A	cg09085632	chr11:111637200	PPP2R1B	0.91	11.73	0.58	7.11e-26	Primary sclerosing cholangitis;
CESC	trans	rs875971	0.660	rs7807930	chr7:66087165	C/T	cg26939375	chr7:64535504	NA	-0.63	-8.44	-0.46	2.1e-15	Aortic root size;
CESC	cis	rs208520	0.526	rs7776413	chr6:66783241	A/G	cg07460842	chr6:66804631	NA	-1.11	-26.19	-0.85	1.74e-75	Exhaled nitric oxide output;
CESC	cis	rs1371867	0.846	rs1660316	chr8:101333049	T/C	cg11906718	chr8:101322791	RNF19A	0.53	6.86	0.39	4.86e-11	Atrioventricular conduction;
CESC	cis	rs4523957	0.553	rs2131703	chr17:2025360	G/T	cg16513277	chr17:2031491	SMG6	-0.77	-11.28	-0.57	2.37e-24	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs116095464	0.558	rs7710005	chr5:233572	A/G	cg22496380	chr5:211416	CCDC127	-0.72	-8.27	-0.45	6.43e-15	Breast cancer;
CESC	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	13.65	0.64	1.8e-32	Prudent dietary pattern;
CESC	cis	rs2737618	0.651	rs2249172	chr1:200082955	A/G	cg21825944	chr1:200113062	NR5A2	0.41	6.4	0.37	7.08e-10	Uric acid levels;
CESC	cis	rs780096	0.505	rs12475426	chr2:27599132	G/A	cg24768116	chr2:27665128	KRTCAP3	-0.28	-5.14	-0.3	5.27e-7	Total body bone mineral density;
CESC	cis	rs7959452	0.640	rs4761233	chr12:69722880	T/C	cg14784868	chr12:69753453	YEATS4	0.73	10.42	0.54	1.53e-21	Blood protein levels;
CESC	cis	rs9322193	0.923	rs9767652	chr6:150055638	A/T	cg09699651	chr6:150184138	LRP11	0.44	5.63	0.33	4.66e-8	Lung cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06371280	chr2:172017419	TLK1	-0.59	-6.52	-0.37	3.55e-10	Gut microbiome composition (summer);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg17098857	chr11:82556674	PRCP	0.43	6.04	0.35	5.1e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs477692	0.563	rs12266634	chr10:131412659	G/C	cg24747557	chr10:131355152	MGMT	0.45	6.17	0.35	2.61e-9	Response to temozolomide;
CESC	cis	rs7412746	0.571	rs12402939	chr1:150615094	A/C	cg09365446	chr1:150670422	GOLPH3L	0.4	5.38	0.31	1.61e-7	Melanoma;
CESC	cis	rs5771069	0.931	rs5771222	chr22:50445704	C/T	cg03721641	chr22:50451245	IL17REL	-0.33	-5.64	-0.33	4.27e-8	Ulcerative colitis;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg15764058	chr3:66024691	MAGI1	-0.44	-6.23	-0.36	1.79e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs9287719	0.967	rs6432126	chr2:10757101	A/G	cg02196655	chr2:10830764	NOL10	-0.37	-5.67	-0.33	3.73e-8	Prostate cancer;
CESC	cis	rs35146811	0.961	rs11771139	chr7:99736059	C/T	cg22906224	chr7:99728672	NA	0.45	5.21	0.3	3.76e-7	Coronary artery disease;
CESC	cis	rs7312933	1.000	rs11181308	chr12:42445259	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.41	5.44	0.32	1.24e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs9815354	0.812	rs10510733	chr3:42009192	T/C	cg03022575	chr3:42003672	ULK4	0.69	6.24	0.36	1.72e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs7618915	0.547	rs11714419	chr3:52628816	A/G	cg18337363	chr3:52569053	NT5DC2	0.3	5.44	0.32	1.22e-7	Bipolar disorder;
CESC	cis	rs17739794	0.557	rs7816977	chr8:814612	A/G	cg01971667	chr8:817044	NA	0.28	5.16	0.3	4.77e-7	Clozapine-induced cytotoxicity;
CESC	cis	rs7586879	0.593	rs10200566	chr2:25130462	G/T	cg01884057	chr2:25150051	NA	-0.4	-7.57	-0.42	6.2800000000000005e-13	Body mass index;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18346784	chr1:10754162	CASZ1	0.59	6.67	0.38	1.47e-10	Gut microbiome composition (summer);
CESC	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg03188948	chr7:1209495	NA	0.4	5.09	0.3	6.84e-7	Longevity;Endometriosis;
CESC	cis	rs2637266	0.935	rs7909808	chr10:78392318	A/G	cg18941641	chr10:78392320	NA	0.44	7.94	0.44	5.63e-14	Pulmonary function;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg18030007	chr8:33370902	C8orf41	0.48	6.07	0.35	4.44e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs6952808	1.000	rs4721122	chr7:1893311	C/G	cg04267008	chr7:1944627	MAD1L1	-0.55	-6.6	-0.38	2.19e-10	Bipolar disorder and schizophrenia;
CESC	cis	rs3806843	0.676	rs778593	chr5:140027216	T/C	cg26395211	chr5:140044315	WDR55	0.51	6.48	0.37	4.45e-10	Depressive symptoms (multi-trait analysis);
CESC	trans	rs1814175	0.765	rs1722003	chr11:49895896	G/A	cg03929089	chr4:120376271	NA	-0.91	-15.64	-0.69	1.68e-39	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11227645	chr1:224544764	CNIH4	0.55	6.44	0.37	5.48e-10	Gut microbiome composition (summer);
CESC	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.39	-5.12	-0.3	5.81e-7	Lymphocyte counts;
CESC	cis	rs8114671	0.805	rs4616	chr20:33590358	C/T	cg24642439	chr20:33292090	TP53INP2	-0.47	-5.59	-0.32	5.7e-8	Height;
CESC	cis	rs9858542	0.953	rs3811699	chr3:49396360	T/C	cg03060546	chr3:49711283	APEH	-0.53	-6.05	-0.35	4.8e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs2439831	0.867	rs496584	chr15:43831923	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.79	7.86	0.43	9.77e-14	Lung cancer in ever smokers;
CESC	cis	rs9733	0.596	rs11807058	chr1:150640475	G/A	cg18016565	chr1:150552671	MCL1	0.33	5.15	0.3	5.13e-7	Tonsillectomy;
CESC	cis	rs59918340	0.764	rs4961258	chr8:142232878	A/G	cg16341495	chr8:142228727	SLC45A4	0.45	5.56	0.32	6.62e-8	Immature fraction of reticulocytes;
CESC	cis	rs6540559	1.000	rs1044516	chr1:209959614	G/T	cg25204440	chr1:209979598	IRF6	0.61	7.67	0.43	3.33e-13	Cleft lip with or without cleft palate;
CESC	cis	rs10463316	0.817	rs730526	chr5:150789232	A/G	cg03212797	chr5:150827313	SLC36A1	-0.42	-5.05	-0.3	8.21e-7	Metabolite levels (Pyroglutamine);
CESC	cis	rs501120	1.000	rs915083	chr10:44755406	T/G	cg09554077	chr10:44749378	NA	0.52	6.89	0.39	3.96e-11	Coronary artery disease;Coronary heart disease;
CESC	cis	rs17376456	1.000	rs6867042	chr5:93555761	C/T	cg25358565	chr5:93447407	FAM172A	1.19	10.67	0.55	2.43e-22	Diabetic retinopathy;
CESC	cis	rs7249142	0.549	rs62135499	chr19:19294237	T/C	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.38	5.11	0.3	6.18e-7	IgG glycosylation;
CESC	cis	rs2280018	0.526	rs2941257	chr16:15166445	T/C	cg07549590	chr16:15018862	NA	-0.61	-9.76	-0.51	2.07e-19	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs5758659	1.000	rs134873	chr22:42657566	T/G	cg05082376	chr22:42548792	NA	-0.38	-5.59	-0.32	5.55e-8	Cognitive function;
CESC	cis	rs1143633	0.553	rs2723197	chr2:113689747	G/A	cg12858261	chr2:113808755	IL1F8	-0.42	-5.18	-0.3	4.36e-7	Allergic disease (asthma, hay fever or eczema);
CESC	trans	rs877282	0.898	rs10904547	chr10:766283	C/T	cg22713356	chr15:30763199	NA	1.15	11.31	0.57	1.89e-24	Uric acid levels;
CESC	cis	rs9905704	0.628	rs2531735	chr17:56551139	A/G	cg12560992	chr17:57184187	TRIM37	-0.63	-5.75	-0.33	2.48e-8	Testicular germ cell tumor;
CESC	cis	rs9796	0.870	rs8042088	chr15:41337487	C/T	cg18705301	chr15:41695430	NDUFAF1	0.45	6.73	0.38	1.05e-10	Menopause (age at onset);
CESC	cis	rs7247513	0.639	rs12984441	chr19:12760287	A/C	cg23899408	chr19:12877188	HOOK2	0.43	5.31	0.31	2.34e-7	Bipolar disorder;
CESC	cis	rs7666738	0.830	rs6832209	chr4:98994120	A/G	cg05340658	chr4:99064831	C4orf37	0.78	11.87	0.59	2.5e-26	Colonoscopy-negative controls vs population controls;
CESC	cis	rs172166	0.694	rs1225716	chr6:28113746	A/C	cg23281280	chr6:28129359	ZNF389	0.44	6.46	0.37	4.96e-10	Cardiac Troponin-T levels;
CESC	cis	rs9926296	0.682	rs467357	chr16:89717397	A/G	cg27121462	chr16:89883253	FANCA	-0.49	-5.74	-0.33	2.61e-8	Vitiligo;
CESC	cis	rs7264396	0.790	rs6058293	chr20:34248891	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.86	-11.84	-0.59	3.14e-26	Total cholesterol levels;
CESC	cis	rs11758351	0.929	rs6906367	chr6:26187125	C/T	cg01420254	chr6:26195488	NA	0.55	6.43	0.37	5.88e-10	Gout;Renal underexcretion gout;
CESC	cis	rs9818758	0.556	rs13086240	chr3:49001409	G/A	cg00383909	chr3:49044727	WDR6	0.95	6.66	0.38	1.59e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CESC	cis	rs7833986	0.501	rs72653948	chr8:56955689	A/G	cg26371346	chr8:56986568	SNORD54;RPS20	0.58	5.3	0.31	2.38e-7	Height;
CESC	cis	rs6963495	0.745	rs73192150	chr7:105211610	A/C	cg13798780	chr7:105162888	PUS7	0.77	7.56	0.42	6.63e-13	Bipolar disorder (body mass index interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07142678	chr1:112162349	RAP1A	0.59	6.42	0.37	6.15e-10	Gut microbiome composition (summer);
CESC	cis	rs2032447	0.507	rs478349	chr6:25894057	T/C	cg03264133	chr6:25882463	NA	-0.66	-9.71	-0.51	2.79e-19	Intelligence (multi-trait analysis);
CESC	cis	rs3806843	0.966	rs10053945	chr5:140160127	C/T	cg26395211	chr5:140044315	WDR55	-0.42	-5.31	-0.31	2.31e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs7833790	0.632	rs6415653	chr8:82702536	A/G	cg17211192	chr8:82754475	SNX16	-0.58	-7.62	-0.42	4.64e-13	Diastolic blood pressure;
CESC	cis	rs9894429	0.690	rs11869779	chr17:79570067	C/T	cg21984481	chr17:79567631	NPLOC4	0.57	9.4	0.5	2.72e-18	Eye color traits;
CESC	cis	rs2288073	0.965	rs6545338	chr2:24422156	C/T	cg06627628	chr2:24431161	ITSN2	-0.78	-9.27	-0.49	6.66e-18	Venous thromboembolism (SNP x SNP interaction);
CESC	cis	rs4434138	0.683	rs13063160	chr3:52602274	T/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.33	5.99	0.35	6.83e-9	Intelligence (multi-trait analysis);
CESC	cis	rs300703	0.816	rs434818	chr2:200477	G/A	cg21211680	chr2:198530	NA	0.82	7.2	0.4	6.14e-12	Blood protein levels;
CESC	cis	rs4253772	0.550	rs9615949	chr22:46722531	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.59	5.17	0.3	4.66e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs4819052	0.851	rs2838850	chr21:46671445	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.75	9.88	0.52	8.11e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs6580649	0.941	rs1635529	chr12:48395102	T/G	cg05342945	chr12:48394962	COL2A1	-0.56	-6.62	-0.38	2.02e-10	Lung cancer;
CESC	cis	rs910316	1.000	rs7147118	chr14:75610170	G/C	cg16144293	chr14:75469539	EIF2B2	-0.39	-5.03	-0.3	9.07e-7	Height;
CESC	cis	rs4664308	0.618	rs66667042	chr2:160886703	A/C	cg03641300	chr2:160917029	PLA2R1	-0.59	-8.54	-0.46	1.06e-15	Idiopathic membranous nephropathy;
CESC	cis	rs7918232	0.882	rs10829190	chr10:27409555	C/T	cg14240646	chr10:27532245	ACBD5	-0.63	-6.25	-0.36	1.59e-9	Breast cancer;
CESC	trans	rs7089973	0.523	rs7071789	chr10:116735341	T/C	cg17463145	chr7:79084011	MAGI2	0.31	6.1	0.35	3.75e-9	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs7762018	0.655	rs2184194	chr6:170148394	C/T	cg05834625	chr6:170176447	C6orf70	0.65	7.17	0.4	7.57e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs28829049	0.597	rs34219832	chr1:19502432	C/T	cg13387374	chr1:19411106	UBR4	0.43	5.45	0.32	1.13e-7	QRS duration in Tripanosoma cruzi seropositivity;
CESC	trans	rs637571	0.558	rs10896064	chr11:65641033	G/C	cg17712092	chr4:129076599	LARP1B	-0.7	-8.8	-0.48	1.78e-16	Eosinophil percentage of white cells;
CESC	cis	rs7666738	0.830	rs13102652	chr4:99006737	T/G	cg18180107	chr4:99064573	C4orf37	0.4	5.23	0.31	3.41e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3741151	0.773	rs73544720	chr11:73173496	A/G	cg17517138	chr11:73019481	ARHGEF17	1.0	7.41	0.41	1.74e-12	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs12618769	0.625	rs3820945	chr2:99105156	G/A	cg10123293	chr2:99228465	UNC50	0.39	5.13	0.3	5.6e-7	Bipolar disorder;
CESC	cis	rs1878931	0.582	rs40633	chr16:3425325	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.68	-8.4	-0.46	2.77e-15	Body mass index (adult);
CESC	cis	rs4242434	0.757	rs4872531	chr8:22529695	A/G	cg03733263	chr8:22462867	KIAA1967	-0.78	-11.01	-0.56	1.83e-23	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CESC	cis	rs4803468	1.000	rs10422783	chr19:41906436	T/C	cg14132834	chr19:41945861	ATP5SL	-0.65	-8.13	-0.45	1.69e-14	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04460041	chr16:2293178	DCI	-0.61	-6.69	-0.38	1.3e-10	Gut microbiome composition (summer);
CESC	cis	rs6032067	0.929	rs17333381	chr20:43804919	C/T	cg10761708	chr20:43804764	PI3	0.53	6.33	0.36	1.04e-9	Blood protein levels;
CESC	cis	rs561341	0.714	rs547473	chr17:30297560	T/G	cg19193384	chr17:30244184	NA	-0.61	-6.41	-0.37	6.51e-10	Hip circumference adjusted for BMI;
CESC	cis	rs561341	1.000	rs117979353	chr17:30272866	A/G	cg12193833	chr17:30244370	NA	-0.79	-7.25	-0.41	4.49e-12	Hip circumference adjusted for BMI;
CESC	cis	rs6120849	0.708	rs6087659	chr20:33606383	C/A	cg06115741	chr20:33292138	TP53INP2	0.54	5.13	0.3	5.65e-7	Protein C levels;
CESC	cis	rs875971	1.000	rs778726	chr7:65828731	C/T	cg12463550	chr7:65579703	CRCP	0.59	7.45	0.42	1.29e-12	Aortic root size;
CESC	cis	rs2950393	0.929	rs10876916	chr12:57086512	G/A	cg05584118	chr12:57595605	LRP1	-0.38	-5.41	-0.32	1.4e-7	Platelet distribution width;
CESC	cis	rs7264396	0.563	rs2425117	chr20:34323776	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.63	6.81	0.39	6.52e-11	Total cholesterol levels;
CESC	cis	rs752010	0.838	rs11210505	chr1:42104731	G/C	cg06885757	chr1:42089581	HIVEP3	0.49	7.78	0.43	1.61e-13	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs922692	0.744	rs1825087	chr15:79077114	A/G	cg04896959	chr15:78267971	NA	0.35	5.1	0.3	6.61e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
CESC	cis	rs11638352	1.000	rs1365456	chr15:44378843	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.69	-5.06	-0.3	7.71e-7	Lipoprotein phospholipase A2 activity in cardiovascular disease;
CESC	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg11494091	chr17:61959527	GH2	0.73	12.66	0.61	4.86e-29	Prudent dietary pattern;
CESC	cis	rs2742234	0.666	rs715106	chr10:43616751	C/A	cg07801480	chr10:43725741	RASGEF1A	0.43	5.54	0.32	7.14e-8	Hirschsprung disease;
CESC	trans	rs4077515	0.874	rs10781505	chr9:139271355	C/T	cg11586158	chr1:175013920	NA	0.39	6.04	0.35	5.14e-9	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs10883723	0.810	rs10748823	chr10:104274465	C/G	cg22532475	chr10:104410764	TRIM8	-0.33	-5.68	-0.33	3.5e-8	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs9908102	0.710	rs56988654	chr17:12912635	T/G	cg26162695	chr17:12921313	ELAC2	0.52	5.71	0.33	3.04e-8	Schizophrenia;
CESC	trans	rs997295	0.529	rs12592315	chr15:68040266	A/G	cg22838674	chr8:37619818	PROSC	0.47	6.02	0.35	5.88e-9	Motion sickness;
CESC	cis	rs75804782	0.521	rs72993033	chr2:239382882	A/G	cg18131467	chr2:239335373	ASB1	-0.73	-5.88	-0.34	1.23e-8	Morning vs. evening chronotype;Chronotype;
CESC	cis	rs344364	0.511	rs1742460	chr16:1945441	G/C	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.6	-6.37	-0.36	8.54e-10	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs10504229	0.562	rs2014516	chr8:58128288	C/A	cg24829409	chr8:58192753	C8orf71	-0.58	-7.2	-0.4	6.31e-12	Developmental language disorder (linguistic errors);
CESC	trans	rs9858542	0.953	rs35169793	chr3:49423274	A/G	cg21659725	chr3:3221576	CRBN	-0.54	-6.47	-0.37	4.62e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs6060717	0.536	rs11699815	chr20:34543125	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.65	5.58	0.32	6e-8	Hip circumference adjusted for BMI;
CESC	cis	rs3026101	0.671	rs3026115	chr17:5285222	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.46	6.21	0.36	2e-9	Body mass index;
CESC	cis	rs4713118	0.516	rs4713142	chr6:28106347	T/G	cg17949981	chr6:28129498	ZNF389	0.45	5.71	0.33	3.07e-8	Parkinson's disease;
CESC	cis	rs9616064	0.740	rs6520049	chr22:46996309	C/T	cg05621596	chr22:47072043	GRAMD4	-0.44	-6.67	-0.38	1.5e-10	Urate levels in obese individuals;
CESC	cis	rs17641971	0.684	rs7005693	chr8:49987965	A/C	cg00325661	chr8:49890786	NA	0.39	5.5	0.32	8.94e-8	Blood metabolite levels;
CESC	cis	rs7605827	0.930	rs11902128	chr2:15515269	T/G	cg19274914	chr2:15703543	NA	0.31	5.39	0.31	1.55e-7	Educational attainment (years of education);
CESC	cis	rs11122272	0.735	rs2486733	chr1:231531465	C/T	cg06096015	chr1:231504339	EGLN1	0.43	6.15	0.35	2.9e-9	Hemoglobin concentration;
CESC	cis	rs9814567	0.806	rs2888670	chr3:134326684	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.4	-5.12	-0.3	5.96e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	trans	rs1814175	0.616	rs1851848	chr11:49992254	G/C	cg15704280	chr7:45808275	SEPT13	-1.0	-19.0	-0.76	2.19e-51	Height;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg12402495	chr1:154192844	C1orf43;UBAP2L	0.48	6.38	0.36	7.9e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs10905065	1.000	rs10737013	chr10:5746772	C/G	cg11519256	chr10:5708881	ASB13	0.49	6.64	0.38	1.81e-10	Menopause (age at onset);
CESC	cis	rs7917772	0.503	rs7893155	chr10:104294228	C/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.54	7.41	0.41	1.67e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs9322193	0.884	rs9397036	chr6:150172923	C/T	cg09699651	chr6:150184138	LRP11	0.51	6.43	0.37	5.91e-10	Lung cancer;
CESC	cis	rs9486719	0.948	rs12203657	chr6:96883285	G/A	cg06623918	chr6:96969491	KIAA0776	-0.81	-8.29	-0.45	5.61e-15	Migraine;Coronary artery disease;
CESC	cis	rs9322193	0.923	rs9689599	chr6:149953109	A/C	cg07701084	chr6:150067640	NUP43	0.46	6.45	0.37	5.26e-10	Lung cancer;
CESC	cis	rs9388451	0.505	rs6920965	chr6:126179111	G/A	cg05901451	chr6:126070800	HEY2	-0.42	-5.58	-0.32	5.99e-8	Brugada syndrome;
CESC	cis	rs3106136	0.843	rs4282187	chr4:95273145	T/C	cg11021082	chr4:95130006	SMARCAD1	0.39	5.46	0.32	1.08e-7	Capecitabine sensitivity;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22425913	chr8:144099991	LY6E;LOC100133669	0.61	6.84	0.39	5.44e-11	Gut microbiome composition (summer);
CESC	cis	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg02951883	chr7:2050386	MAD1L1	-0.41	-5.22	-0.31	3.7e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs4332037	0.950	rs11771828	chr7:1941003	T/C	cg23422044	chr7:1970798	MAD1L1	-0.53	-5.33	-0.31	2.09e-7	Bipolar disorder;
CESC	cis	rs637571	0.522	rs493899	chr11:65747952	A/C	cg02202077	chr11:65769826	EIF1AD;BANF1	0.45	6.05	0.35	5.01e-9	Eosinophil percentage of white cells;
CESC	cis	rs61931739	0.517	rs10844830	chr12:34308133	C/T	cg06521331	chr12:34319734	NA	-0.4	-5.55	-0.32	6.78e-8	Morning vs. evening chronotype;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg17994379	chr17:43025264	KIF18B	0.48	6.15	0.35	2.79e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs7072216	0.763	rs12259939	chr10:100169021	T/C	cg26618903	chr10:100175079	PYROXD2	-0.37	-5.76	-0.33	2.33e-8	Metabolite levels;
CESC	cis	rs7772486	0.902	rs2777480	chr6:146309983	T/A	cg23711669	chr6:146136114	FBXO30	0.75	10.71	0.55	1.72e-22	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs11583043	0.575	rs56403901	chr1:101586047	A/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.48	5.33	0.31	2.11e-7	Ulcerative colitis;Inflammatory bowel disease;
CESC	cis	rs6951245	0.580	rs10257426	chr7:1213694	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.49	-6.2	-0.36	2.19e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7824557	0.569	rs35418978	chr8:11186453	T/C	cg21775007	chr8:11205619	TDH	0.5	7.23	0.41	5.21e-12	Retinal vascular caliber;
CESC	cis	rs6460942	1.000	rs2033871	chr7:12405098	C/A	cg13733410	chr7:12443478	VWDE	-0.53	-5.33	-0.31	2.12e-7	Coronary artery disease;
CESC	cis	rs4423214	1.000	rs12422045	chr11:71154820	C/T	cg05163923	chr11:71159392	DHCR7	0.83	11.73	0.58	7.01e-26	Vitamin D levels;
CESC	cis	rs798554	0.757	rs1182176	chr7:2874601	A/G	cg09658497	chr7:2847517	GNA12	-0.38	-5.52	-0.32	8.01e-8	Height;
CESC	cis	rs13256369	1.000	rs885000	chr8:8568875	G/T	cg17143192	chr8:8559678	CLDN23	0.71	7.78	0.43	1.61e-13	Obesity-related traits;
CESC	cis	rs7552404	0.924	rs1146574	chr1:76202671	A/G	cg10523679	chr1:76189770	ACADM	0.76	10.46	0.54	1.18e-21	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs34311866	0.748	rs10029038	chr4:899352	T/C	cg07828340	chr4:882639	GAK	1.06	7.74	0.43	2.06e-13	Parkinson's disease;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg26240532	chr19:52643172	ZNF616	-0.42	-6.16	-0.35	2.69e-9	Gambling;
CESC	cis	rs798554	0.679	rs2266922	chr7:2824707	G/A	cg19717773	chr7:2847554	GNA12	-0.57	-9.19	-0.49	1.2e-17	Height;
CESC	cis	rs6502050	0.805	rs9898507	chr17:80119628	C/T	cg11859384	chr17:80120422	CCDC57	-0.39	-5.34	-0.31	1.96e-7	Life satisfaction;
CESC	cis	rs477692	0.699	rs528549	chr10:131381574	A/G	cg24747557	chr10:131355152	MGMT	-0.37	-5.04	-0.3	8.51e-7	Response to temozolomide;
CESC	cis	rs796364	0.951	rs10931888	chr2:201022952	T/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.71	-6.95	-0.39	2.83e-11	Schizophrenia;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg05065690	chr12:49246007	DDX23	-0.47	-6.75	-0.38	9.09e-11	Gambling;
CESC	cis	rs2404602	0.655	rs8028294	chr15:77084877	T/C	cg22467129	chr15:76604101	ETFA	-0.34	-5.16	-0.3	4.84e-7	Blood metabolite levels;
CESC	cis	rs5758659	1.000	rs5758677	chr22:42643039	A/C	cg05082376	chr22:42548792	NA	-0.37	-5.49	-0.32	9.45e-8	Cognitive function;
CESC	cis	rs8177179	0.967	rs4994582	chr3:133437566	G/C	cg24879335	chr3:133465180	TF	0.41	7.51	0.42	8.82e-13	Iron status biomarkers (transferrin levels);
CESC	cis	rs2859741	0.587	rs516139	chr1:37471617	C/G	cg09363841	chr1:37513479	NA	-0.46	-6.38	-0.36	7.94e-10	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
CESC	cis	rs12477438	0.765	rs4374423	chr2:99662348	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.64	-8.73	-0.47	2.94e-16	Chronic sinus infection;
CESC	cis	rs4727027	0.933	rs10238826	chr7:148830888	A/G	cg23158103	chr7:148848205	ZNF398	-0.4	-6.51	-0.37	3.67e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	trans	rs17181170	0.500	rs12493464	chr3:87209157	A/C	ch.2.199792288R	chr2:200084043	NA	-0.46	-6.0	-0.35	6.33e-9	Prostate cancer;
CESC	cis	rs9560113	0.573	rs7988040	chr13:112226534	C/G	cg10483660	chr13:112241077	NA	0.42	7.1	0.4	1.13e-11	Menarche (age at onset);
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg18551892	chr11:86667149	FZD4	0.45	6.11	0.35	3.49e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs4969178	0.965	rs8071884	chr17:76398058	C/G	cg20026190	chr17:76395443	PGS1	0.49	7.78	0.43	1.65e-13	HDL cholesterol levels;
CESC	cis	rs875971	0.964	rs2277911	chr7:65958625	T/G	cg12463550	chr7:65579703	CRCP	0.55	6.86	0.39	4.77e-11	Aortic root size;
CESC	cis	rs11123610	0.520	rs66557864	chr2:3720812	C/A	cg10645314	chr2:3704589	ALLC	-0.46	-5.09	-0.3	6.83e-7	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CESC	cis	rs17818399	0.890	rs34544165	chr2:46836906	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.45	5.61	0.33	5.14e-8	Height;
CESC	cis	rs7618915	0.547	rs11130323	chr3:52770277	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	7.2	0.4	6.31e-12	Bipolar disorder;
CESC	cis	rs13191362	0.935	rs34587258	chr6:162945580	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.73	6.42	0.37	6.43e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs4130590	0.934	rs7041940	chr9:130109746	T/C	cg13736810	chr9:130213283	LRSAM1;RPL12	0.51	6.13	0.35	3.17e-9	Bipolar disorder;
CESC	cis	rs9611565	0.559	rs5758412	chr22:42080803	T/A	cg06634786	chr22:41940651	POLR3H	0.62	6.25	0.36	1.67e-9	Vitiligo;
CESC	cis	rs7429990	0.965	rs1013431	chr3:48029118	A/C	cg11946769	chr3:48343235	NME6	-0.43	-5.2	-0.3	4e-7	Educational attainment (years of education);
CESC	cis	rs4953318	1.000	rs4953318	chr2:46355051	A/C	cg12428440	chr2:46370979	PRKCE	0.37	5.29	0.31	2.61e-7	Red blood cell count;Hematocrit;Red blood cell traits;
CESC	cis	rs7481584	0.581	rs105686	chr11:3062467	G/A	cg25174290	chr11:3078921	CARS	-0.51	-7.12	-0.4	1e-11	Calcium levels;
CESC	cis	rs6088580	0.660	rs6059893	chr20:33105897	T/G	cg06115741	chr20:33292138	TP53INP2	0.44	5.69	0.33	3.34e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs1215050	0.791	rs684210	chr4:98678740	G/C	cg05340658	chr4:99064831	C4orf37	0.47	6.04	0.35	5.08e-9	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.51	0.37	3.75e-10	Prudent dietary pattern;
CESC	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg19318889	chr4:1322082	MAEA	0.43	5.48	0.32	9.86e-8	Longevity;
CESC	cis	rs2933343	0.700	rs1680778	chr3:128614185	A/C	cg25356066	chr3:128598488	ACAD9	0.59	7.9	0.44	7.52e-14	IgG glycosylation;
CESC	cis	rs28829049	0.597	rs34215816	chr1:19433953	G/A	cg13387374	chr1:19411106	UBR4	0.41	5.07	0.3	7.4e-7	QRS duration in Tripanosoma cruzi seropositivity;
CESC	cis	rs10129255	0.500	rs8004923	chr14:107194164	A/G	cg07958169	chr14:107095056	NA	-0.53	-8.18	-0.45	1.23e-14	Kawasaki disease;
CESC	cis	rs1707322	1.000	rs4539075	chr1:46358010	C/T	cg05343316	chr1:45956843	TESK2	0.44	5.55	0.32	7.05e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9309473	0.607	rs7574291	chr2:73594941	A/G	cg20560298	chr2:73613845	ALMS1	-0.51	-7.2	-0.4	6.35e-12	Metabolite levels;
CESC	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg07677032	chr17:61819896	STRADA	0.41	5.35	0.31	1.95e-7	Prudent dietary pattern;
CESC	cis	rs5769765	0.773	rs9616395	chr22:50317803	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.55	-5.06	-0.3	7.81e-7	Schizophrenia;
CESC	cis	rs1799949	0.683	rs55737636	chr17:41264739	C/T	cg07153921	chr17:41440717	NA	-0.38	-5.06	-0.3	7.75e-7	Menopause (age at onset);
CESC	cis	rs2742234	0.554	rs1254963	chr10:43696086	C/T	cg15436174	chr10:43711423	RASGEF1A	0.5	5.85	0.34	1.45e-8	Hirschsprung disease;
CESC	cis	rs2836950	0.565	rs7276046	chr21:40581293	T/C	cg17971929	chr21:40555470	PSMG1	-0.6	-8.04	-0.44	2.96e-14	Menarche (age at onset);
CESC	cis	rs1580019	0.713	rs2167274	chr7:32524844	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.51	6.36	0.36	8.68e-10	Cognitive ability;
CESC	cis	rs9435341	0.930	rs12408634	chr1:107579540	G/A	cg09367891	chr1:107599246	PRMT6	0.7	8.3	0.45	5.32e-15	Facial morphology (factor 21, depth of nasal alae);
CESC	cis	rs7173419	0.607	rs1448488	chr15:28216857	C/T	cg20906524	chr15:28200668	OCA2	-0.37	-5.12	-0.3	5.98e-7	Eye color;
CESC	cis	rs3091242	0.728	rs706845	chr1:25730713	G/A	cg03538708	chr1:25844672	NA	-0.4	-5.92	-0.34	1e-8	Erythrocyte sedimentation rate;
CESC	cis	rs4319547	0.956	rs10847179	chr12:123040985	T/C	cg23029597	chr12:123009494	RSRC2	-0.49	-5.32	-0.31	2.21e-7	Body mass index;
CESC	cis	rs79349575	0.783	rs28409394	chr17:46998118	T/C	cg16584676	chr17:46985605	UBE2Z	0.56	7.02	0.4	1.86e-11	Type 2 diabetes;
CESC	cis	rs6662572	0.737	rs4660887	chr1:46275959	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.45	-5.11	-0.3	6.16e-7	Blood protein levels;
CESC	cis	rs9640161	0.659	rs11975886	chr7:150010362	G/A	cg21361702	chr7:150065534	REPIN1	0.54	6.29	0.36	1.3e-9	Blood protein levels;Circulating chemerin levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17014947	chr15:35529521	LOC723972	-0.66	-7.67	-0.43	3.23e-13	Gut microbiome composition (summer);
CESC	cis	rs6120849	0.754	rs6087666	chr20:33640242	G/A	cg06115741	chr20:33292138	TP53INP2	0.53	5.05	0.3	8.15e-7	Protein C levels;
CESC	cis	rs2249694	0.878	rs2987792	chr10:135371466	T/C	cg20169779	chr10:135381914	SYCE1	0.4	5.72	0.33	2.88e-8	Obesity-related traits;
CESC	cis	rs35306767	0.953	rs7908138	chr10:962978	C/T	cg20503657	chr10:835505	NA	0.74	8.11	0.45	1.89e-14	Eosinophil percentage of granulocytes;
CESC	cis	rs7412746	0.658	rs11204723	chr1:150731618	T/C	cg22823121	chr1:150693482	HORMAD1	0.47	6.49	0.37	4.09e-10	Melanoma;
CESC	cis	rs116095464	0.558	rs10075018	chr5:239175	G/A	cg20965017	chr5:231967	SDHA	-0.46	-5.25	-0.31	3.06e-7	Breast cancer;
CESC	cis	rs3931020	0.508	rs11485298	chr1:75217752	C/T	cg26855724	chr1:75198818	TYW3;CRYZ	0.44	5.17	0.3	4.69e-7	Resistin levels;
CESC	cis	rs1799949	0.965	rs4239149	chr17:41328095	A/G	cg25072359	chr17:41440525	NA	-0.51	-7.57	-0.42	6.05e-13	Menopause (age at onset);
CESC	cis	rs4819052	0.851	rs13049337	chr21:46663460	T/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.46	5.81	0.34	1.81e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs9902453	1.000	rs11080114	chr17:28407287	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.64	-8.06	-0.44	2.71e-14	Coffee consumption (cups per day);
CESC	cis	rs736408	0.609	rs13087772	chr3:52782274	T/G	cg07507251	chr3:52567010	NT5DC2	0.43	7.44	0.42	1.36e-12	Bipolar disorder;
CESC	cis	rs7666738	0.830	rs11944035	chr4:98931618	C/T	cg05340658	chr4:99064831	C4orf37	0.82	12.17	0.6	2.24e-27	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7851660	0.967	rs7851552	chr9:100610652	C/A	cg13688889	chr9:100608707	NA	-0.68	-10.64	-0.55	3.08e-22	Strep throat;
CESC	cis	rs6502050	0.835	rs9911379	chr17:80114529	A/G	cg11859384	chr17:80120422	CCDC57	-0.39	-5.43	-0.32	1.26e-7	Life satisfaction;
CESC	cis	rs8177179	0.967	rs6782434	chr3:133438834	C/G	cg16262614	chr3:133464971	TF	0.42	8.23	0.45	8.64e-15	Iron status biomarkers (transferrin levels);
CESC	cis	rs10504073	0.669	rs57085792	chr8:50018355	T/C	cg00325661	chr8:49890786	NA	0.52	7.95	0.44	5.53e-14	Blood metabolite ratios;
CESC	cis	rs10479542	0.702	rs13183521	chr5:178975606	A/G	cg05457628	chr5:178986728	RUFY1	-0.41	-5.7	-0.33	3.11e-8	Lung cancer;
CESC	cis	rs2072732	0.861	rs16823392	chr1:2953833	C/G	cg15211996	chr1:2936768	ACTRT2	0.34	6.04	0.35	5.27e-9	Plateletcrit;
CESC	cis	rs6964587	0.869	rs6975243	chr7:91514672	G/A	cg17063962	chr7:91808500	NA	-0.51	-6.84	-0.39	5.36e-11	Breast cancer;
CESC	cis	rs6582630	0.504	rs4882367	chr12:38330878	A/T	cg26384229	chr12:38710491	ALG10B	-0.46	-6.0	-0.35	6.62e-9	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs6546537	1.000	rs4286306	chr2:69885647	G/C	cg10773587	chr2:69614142	GFPT1	-0.43	-5.23	-0.31	3.4e-7	Serum thyroid-stimulating hormone levels;
CESC	cis	rs763121	0.853	rs6001191	chr22:39074452	T/C	cg06022373	chr22:39101656	GTPBP1	0.89	14.42	0.66	3.47e-35	Menopause (age at onset);
CESC	cis	rs524023	1.000	rs12786214	chr11:64364203	G/A	cg07220939	chr11:64358617	SLC22A12	-0.36	-5.55	-0.32	6.77e-8	Urate levels in obese individuals;
CESC	cis	rs4835473	0.897	rs11723113	chr4:144628436	C/T	cg25736465	chr4:144833511	NA	0.38	5.77	0.33	2.19e-8	Immature fraction of reticulocytes;
CESC	cis	rs1799949	1.000	rs72829113	chr17:41181835	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	8.22	0.45	9.28e-15	Menopause (age at onset);
CESC	cis	rs6748734	0.625	rs7598309	chr2:241824876	A/T	cg04034577	chr2:241836375	C2orf54	-0.29	-5.25	-0.31	3.1e-7	Urinary metabolites;
CESC	cis	rs6582630	0.555	rs11182193	chr12:38474090	C/G	cg26384229	chr12:38710491	ALG10B	0.71	10.82	0.55	7.82e-23	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs9929218	0.954	rs9925923	chr16:68819614	C/T	cg02972257	chr16:68554789	NA	0.48	5.67	0.33	3.72e-8	Colorectal cancer;
CESC	cis	rs2836974	0.644	rs7281853	chr21:40693490	A/G	cg11890956	chr21:40555474	PSMG1	-0.87	-13.02	-0.62	2.65e-30	Cognitive function;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24975666	chr17:80416629	NARF	0.59	6.79	0.38	7.15e-11	Gut microbiome composition (summer);
CESC	cis	rs11741688	0.631	rs4444956	chr5:178325515	A/G	cg20935368	chr5:178288625	ZNF354B	0.35	5.35	0.31	1.91e-7	Sleep duration;
CESC	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg26338869	chr17:61819248	STRADA	0.68	8.87	0.48	1.08e-16	Prudent dietary pattern;
CESC	cis	rs2932538	0.922	rs3790612	chr1:113084146	G/A	cg22162597	chr1:113214053	CAPZA1	0.54	6.68	0.38	1.39e-10	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CESC	cis	rs4665809	1.000	rs4233710	chr2:26291565	G/A	cg22920501	chr2:26401640	FAM59B	-0.78	-9.21	-0.49	1.03e-17	Gut microbiome composition (summer);
CESC	cis	rs561341	1.000	rs111454793	chr17:30319267	T/C	cg12193833	chr17:30244370	NA	-0.72	-6.64	-0.38	1.78e-10	Hip circumference adjusted for BMI;
CESC	trans	rs9354308	0.933	rs2802064	chr6:66564352	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.7	7.85	0.43	1.02e-13	Metabolite levels;
CESC	cis	rs7829975	0.623	rs7010753	chr8:8373956	A/G	cg06636001	chr8:8085503	FLJ10661	0.53	6.75	0.38	9.31e-11	Mood instability;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17371350	chr17:655677	ELP2P;GEMIN4	0.55	6.62	0.38	2.01e-10	Gut microbiome composition (summer);
CESC	cis	rs9925964	0.748	rs4889603	chr16:30982225	C/T	cg02466173	chr16:30829666	NA	-0.35	-5.38	-0.31	1.63e-7	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs6424115	0.830	rs3003336	chr1:24201448	C/T	cg10978503	chr1:24200527	CNR2	0.33	6.64	0.38	1.73e-10	Immature fraction of reticulocytes;
CESC	cis	rs4713118	0.621	rs10484403	chr6:28033523	A/G	cg17949981	chr6:28129498	ZNF389	0.42	5.26	0.31	2.96e-7	Parkinson's disease;
CESC	cis	rs35306767	0.903	rs7074642	chr10:878359	A/G	cg10556349	chr10:835070	NA	0.56	5.38	0.31	1.63e-7	Eosinophil percentage of granulocytes;
CESC	cis	rs5758659	0.714	rs5751220	chr22:42516205	A/C	cg15557168	chr22:42548783	NA	0.48	7.42	0.41	1.62e-12	Cognitive function;
CESC	cis	rs3820068	0.705	rs16851727	chr1:15857918	C/T	cg18192808	chr1:15853278	DNAJC16	0.46	5.53	0.32	7.73e-8	Systolic blood pressure;
CESC	cis	rs858239	0.730	rs858289	chr7:23248158	C/T	cg23682824	chr7:23144976	KLHL7	0.42	5.54	0.32	7.17e-8	Cerebrospinal fluid biomarker levels;
CESC	cis	rs4148883	0.651	rs10020052	chr4:100086331	C/G	cg12011299	chr4:100065546	ADH4	0.67	9.84	0.52	1.16e-19	Alcohol dependence;
CESC	cis	rs7618915	0.571	rs6778844	chr3:52596398	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.46	-6.38	-0.36	7.84e-10	Bipolar disorder;
CESC	cis	rs2243480	1.000	rs34970380	chr7:65431493	C/T	cg12463550	chr7:65579703	CRCP	0.68	5.46	0.32	1.08e-7	Diabetic kidney disease;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg12440566	chr8:37553131	ZNF703	-0.45	-6.42	-0.37	6.37e-10	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs4843747	0.573	rs7499959	chr16:88110422	C/G	cg06915872	chr16:87998081	BANP	0.44	5.38	0.31	1.67e-7	Menopause (age at onset);
CESC	cis	rs9649213	0.593	rs7807455	chr7:97957622	C/A	cg08684580	chr7:98029266	BAIAP2L1	-0.34	-5.63	-0.33	4.6e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs12134245	0.742	rs17501381	chr1:92003919	A/G	cg07090678	chr1:91966139	CDC7	0.42	5.71	0.33	2.97e-8	Breast cancer;
CESC	cis	rs2180341	1.000	rs9398838	chr6:127635285	C/T	cg24812749	chr6:127587940	RNF146	1.07	15.48	0.69	6.31e-39	Breast cancer;
CESC	cis	rs9837602	1.000	rs7620228	chr3:99790332	A/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.5	6.95	0.39	2.75e-11	Breast cancer;
CESC	cis	rs9926296	0.605	rs8047486	chr16:89854025	A/T	cg27121462	chr16:89883253	FANCA	0.73	10.09	0.53	1.79e-20	Vitiligo;
CESC	cis	rs2732480	0.577	rs2732448	chr12:48730600	T/C	cg04545296	chr12:48745243	ZNF641	0.43	7.3	0.41	3.34e-12	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs12681366	0.762	rs6997115	chr8:95365885	C/T	cg13257157	chr8:95487014	RAD54B	0.4	5.48	0.32	9.97e-8	Nonsyndromic cleft lip with cleft palate;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg00332575	chr22:36925175	EIF3D	-0.47	-6.25	-0.36	1.65e-9	Height;
CESC	cis	rs644799	1.000	rs693597	chr11:95589629	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.53	6.18	0.35	2.42e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs922182	0.633	rs12904468	chr15:64268890	A/T	cg24729988	chr15:64271149	DAPK2	-0.46	-6.43	-0.37	6.01e-10	Blood protein levels;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg26878675	chr16:88783039	FAM38A	0.43	6.03	0.35	5.42e-9	Fibrinogen levels;
CESC	cis	rs66573146	0.572	rs68169399	chr4:6952491	T/A	cg26116260	chr4:7069785	GRPEL1	-0.79	-5.25	-0.31	3.14e-7	Granulocyte percentage of myeloid white cells;
CESC	cis	rs853679	0.550	rs9295762	chr6:28155418	C/T	cg21251018	chr6:28226885	NKAPL	-0.33	-5.07	-0.3	7.53e-7	Depression;
CESC	cis	rs17376456	0.877	rs2290937	chr5:93356515	A/T	cg21475434	chr5:93447410	FAM172A	0.7	6.59	0.38	2.39e-10	Diabetic retinopathy;
CESC	cis	rs72781680	1.000	rs72781632	chr2:24198342	A/C	cg20701182	chr2:24300061	SF3B14	0.79	6.83	0.39	5.75e-11	Lymphocyte counts;
CESC	cis	rs9910055	0.636	rs7089	chr17:42269017	T/C	cg08499158	chr17:42289980	UBTF	-0.51	-6.38	-0.36	7.82e-10	Total body bone mineral density;
CESC	cis	rs4330281	0.631	rs6789467	chr3:17802134	G/C	cg20981856	chr3:17787350	NA	0.36	5.06	0.3	7.84e-7	Schizophrenia;
CESC	cis	rs7772486	0.905	rs9373486	chr6:146446024	C/G	cg23711669	chr6:146136114	FBXO30	-0.82	-11.9	-0.59	1.84e-26	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2635047	0.811	rs28471970	chr18:44788439	G/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.42	5.51	0.32	8.36e-8	Educational attainment;
CESC	cis	rs13191362	0.935	rs13219926	chr6:163004213	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.83	8.39	0.46	3.02e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs1322639	0.614	rs7768154	chr6:169565470	A/G	cg03254818	chr6:169586852	NA	0.53	5.71	0.33	3.03e-8	Pulse pressure;
CESC	cis	rs2070997	0.607	rs4740204	chr9:133676052	T/G	cg11464064	chr9:133710261	ABL1	0.64	7.6	0.42	5.21e-13	Response to amphetamines;
CESC	cis	rs6460942	0.915	rs1595800	chr7:12439816	G/A	cg19099843	chr7:12443191	VWDE	-0.51	-5.39	-0.31	1.59e-7	Coronary artery disease;
CESC	trans	rs11764590	0.950	rs62444919	chr7:2109499	C/T	cg11693508	chr17:37793320	STARD3	0.68	6.86	0.39	4.97e-11	Neuroticism;
CESC	cis	rs10851478	0.657	rs12916839	chr15:49735665	C/T	cg08060515	chr15:49448048	GALK2;COPS2	0.54	6.68	0.38	1.43e-10	Oral cavity cancer;
CESC	cis	rs7590368	0.926	rs12621237	chr2:10957538	T/C	cg15705551	chr2:10952987	PDIA6	0.5	5.65	0.33	4.04e-8	Educational attainment (years of education);
CESC	cis	rs8067354	0.507	rs2645478	chr17:58014712	G/A	cg13753209	chr17:57696993	CLTC	0.51	5.63	0.33	4.57e-8	Hemoglobin concentration;
CESC	cis	rs2549003	1.000	rs2706384	chr5:131826880	G/T	cg21138405	chr5:131827807	IRF1	-0.6	-10.77	-0.55	1.14e-22	Asthma (sex interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07252851	chr5:74063056	GFM2;NSA2	0.61	7.14	0.4	8.96e-12	Gut microbiome composition (summer);
CESC	cis	rs4906332	0.811	rs2021965	chr14:103997248	C/A	cg19000871	chr14:103996768	TRMT61A	0.36	5.34	0.31	2e-7	Coronary artery disease;
CESC	trans	rs12681287	0.547	rs56752411	chr8:87515156	C/T	cg27317242	chr8:23145699	R3HCC1	-0.51	-6.05	-0.35	4.96e-9	Caudate activity during reward;
CESC	cis	rs2455799	0.613	rs13078485	chr3:15883236	T/C	cg16303742	chr3:15540471	COLQ	-0.36	-5.42	-0.32	1.32e-7	Mean platelet volume;
CESC	cis	rs7618915	0.501	rs3852066	chr3:52621839	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.6	8.56	0.47	9.4e-16	Bipolar disorder;
CESC	cis	rs35110281	0.659	rs73367822	chr21:45024252	C/T	cg01579765	chr21:45077557	HSF2BP	-0.57	-9.74	-0.51	2.4e-19	Mean corpuscular volume;
CESC	cis	rs751837	0.591	rs10135200	chr14:103411004	A/G	cg10087771	chr14:103399429	CDC42BPB	0.64	5.74	0.33	2.57e-8	Large B-cell lymphoma;
CESC	cis	rs9910055	0.529	rs850851	chr17:42177674	C/T	cg19774624	chr17:42201019	HDAC5	0.56	7.43	0.42	1.49e-12	Total body bone mineral density;
CESC	cis	rs60871478	0.636	rs73045423	chr7:893952	G/A	cg00475322	chr7:917719	C7orf20	0.46	5.1	0.3	6.53e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs4835473	0.932	rs1828502	chr4:144906950	C/G	cg25736465	chr4:144833511	NA	0.41	6.29	0.36	1.28e-9	Immature fraction of reticulocytes;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg08850400	chr17:18231786	SHMT1	-0.44	-6.07	-0.35	4.3e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs425277	0.527	rs3107144	chr1:2045380	C/A	cg04315214	chr1:2043799	PRKCZ	0.62	11.23	0.57	3.43e-24	Height;
CESC	cis	rs7927771	1.000	rs12421210	chr11:47779586	C/T	cg05585544	chr11:47624801	NA	-0.51	-7.89	-0.44	8.01e-14	Subjective well-being;
CESC	cis	rs11785400	0.753	rs9773415	chr8:143731170	G/A	cg10596483	chr8:143751796	JRK	0.42	5.24	0.31	3.25e-7	Schizophrenia;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg15605888	chr2:109403293	CCDC138	0.46	6.26	0.36	1.51e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs425277	0.606	rs2503705	chr1:2076741	A/G	cg04315214	chr1:2043799	PRKCZ	-0.45	-7.3	-0.41	3.26e-12	Height;
CESC	cis	rs8114671	0.562	rs2378294	chr20:33500378	G/A	cg24642439	chr20:33292090	TP53INP2	0.44	5.26	0.31	2.98e-7	Height;
CESC	cis	rs72901758	0.662	rs56326958	chr17:76250439	C/G	cg26068271	chr17:76253126	NA	0.46	6.6	0.38	2.25e-10	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
CESC	cis	rs9388451	0.531	rs9375414	chr6:126154475	G/A	cg05901451	chr6:126070800	HEY2	-0.44	-5.89	-0.34	1.16e-8	Brugada syndrome;
CESC	cis	rs9486719	1.000	rs9400016	chr6:96940883	G/T	cg06623918	chr6:96969491	KIAA0776	-0.81	-8.48	-0.46	1.62e-15	Migraine;Coronary artery disease;
CESC	cis	rs9311474	0.607	rs13076398	chr3:52573096	G/A	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.29	5.22	0.31	3.56e-7	Electroencephalogram traits;
CESC	cis	rs1348850	0.872	rs12991272	chr2:178457339	T/C	cg23306229	chr2:178417860	TTC30B	0.45	5.46	0.32	1.1e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16136840	chr5:95997740	CAST	0.69	8.17	0.45	1.25e-14	Gut microbiome composition (summer);
CESC	cis	rs73001065	0.591	rs57009615	chr19:19613622	A/G	cg03709012	chr19:19516395	GATAD2A	1.05	10.28	0.53	4.39e-21	LDL cholesterol;
CESC	cis	rs9614461	0.702	rs3788648	chr22:45727180	G/A	cg15911859	chr22:45810043	RIBC2;SMC1B	0.72	7.8	0.43	1.4e-13	Tonsillectomy;
CESC	cis	rs524281	0.861	rs2177053	chr11:65966145	A/C	cg14036092	chr11:66035641	RAB1B	-0.59	-6.08	-0.35	4.11e-9	Electroencephalogram traits;
CESC	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg07677032	chr17:61819896	STRADA	0.46	6.17	0.35	2.57e-9	Prudent dietary pattern;
CESC	cis	rs2742234	0.541	rs11238481	chr10:43719286	A/G	cg15436174	chr10:43711423	RASGEF1A	0.47	5.58	0.32	5.81e-8	Hirschsprung disease;
CESC	cis	rs736408	0.677	rs2286798	chr3:52821177	G/T	cg05564831	chr3:52568323	NT5DC2	-0.41	-6.07	-0.35	4.31e-9	Bipolar disorder;
CESC	cis	rs34172651	0.917	rs12923476	chr16:24798079	G/A	cg06028605	chr16:24865363	SLC5A11	0.48	7.19	0.4	6.43e-12	Intelligence (multi-trait analysis);
CESC	cis	rs6432018	1.000	rs7596929	chr2:9717645	A/T	cg23886495	chr2:9695866	ADAM17	0.43	5.04	0.3	8.54e-7	Heart rate variability traits;
CESC	cis	rs7124681	0.565	rs2203712	chr11:47534964	T/C	cg20307385	chr11:47447363	PSMC3	0.64	8.77	0.47	2.17e-16	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06988368	chr1:147142773	ACP6	0.68	7.47	0.42	1.18e-12	Gut microbiome composition (summer);
CESC	cis	rs2880765	0.835	rs6497206	chr15:86029225	A/G	cg10818794	chr15:86012489	AKAP13	-0.34	-5.33	-0.31	2.07e-7	Coronary artery disease;
CESC	cis	rs2072732	0.861	rs34408665	chr1:2950067	A/G	cg03976712	chr1:2946727	NA	0.35	5.84	0.34	1.49e-8	Plateletcrit;
CESC	cis	rs597539	0.652	rs488363	chr11:68658298	C/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.79	10.29	0.53	4.1e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs1580019	0.563	rs764483	chr7:32578150	A/T	cg06627557	chr7:32535165	LSM5;AVL9	1.06	18.96	0.76	2.97e-51	Cognitive ability;
CESC	cis	rs2933343	1.000	rs876755	chr3:128627933	C/T	cg25356066	chr3:128598488	ACAD9	0.6	7.39	0.41	1.92e-12	IgG glycosylation;
CESC	cis	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg04267008	chr7:1944627	MAD1L1	-0.6	-7.33	-0.41	2.81e-12	Bipolar disorder and schizophrenia;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg27505538	chr15:81616786	STARD5	-0.42	-6.12	-0.35	3.35e-9	Gambling;
CESC	cis	rs1862618	0.853	rs832583	chr5:56178217	A/C	cg03609598	chr5:56110824	MAP3K1	-0.51	-5.37	-0.31	1.68e-7	Initial pursuit acceleration;
CESC	cis	rs763121	0.962	rs5757135	chr22:38952573	C/T	cg06544989	chr22:39130855	UNC84B	0.46	8.43	0.46	2.19e-15	Menopause (age at onset);
CESC	trans	rs10242455	0.702	rs73403286	chr7:99154865	A/C	cg09045935	chr12:6379348	NA	0.91	6.98	0.39	2.36e-11	Blood metabolite levels;
CESC	cis	rs1728785	0.901	rs3087783	chr16:68599668	C/T	cg02972257	chr16:68554789	NA	-0.68	-7.63	-0.42	4.2e-13	Ulcerative colitis;
CESC	cis	rs10493773	0.775	rs12564080	chr1:86196586	A/C	cg17807903	chr1:86174739	ZNHIT6	-0.39	-5.38	-0.31	1.64e-7	Urate levels in overweight individuals;
CESC	trans	rs10832139	0.553	rs61884784	chr11:13947617	A/G	cg11511669	chr12:131556214	GPR133	0.52	6.42	0.37	6.19e-10	P wave terminal force;
CESC	cis	rs7605827	0.930	rs4668444	chr2:15515642	C/T	cg19274914	chr2:15703543	NA	0.31	5.39	0.31	1.55e-7	Educational attainment (years of education);
CESC	cis	rs9914988	0.832	rs35033748	chr17:27179590	T/C	cg20469991	chr17:27169893	C17orf63	-0.43	-5.14	-0.3	5.43e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CESC	cis	rs7945705	0.783	rs11042125	chr11:8938049	A/T	cg12365402	chr11:9010492	NRIP3	-0.39	-6.15	-0.35	2.82e-9	Hemoglobin concentration;
CESC	cis	rs7551222	0.716	rs6679717	chr1:204560677	A/G	cg20240347	chr1:204465584	NA	-0.26	-5.47	-0.32	1.03e-7	Schizophrenia;
CESC	cis	rs12887734	0.524	rs12888002	chr14:104238647	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.42	-5.31	-0.31	2.36e-7	Schizophrenia;Autism spectrum disorder or schizophrenia;
CESC	cis	rs116095464	0.558	rs9312957	chr5:202194	C/T	cg22857025	chr5:266934	NA	-1.25	-14.44	-0.66	2.84e-35	Breast cancer;
CESC	cis	rs3768617	0.565	rs4652775	chr1:183061825	A/T	ch.1.3577855R	chr1:183094577	LAMC1	0.84	13.13	0.63	1.12e-30	Fuchs's corneal dystrophy;
CESC	cis	rs10504073	0.647	rs9643395	chr8:50014500	A/C	cg00325661	chr8:49890786	NA	0.52	7.97	0.44	4.85e-14	Blood metabolite ratios;
CESC	cis	rs539096	0.540	rs3011219	chr1:44306120	A/G	cg12908607	chr1:44402522	ARTN	-0.47	-6.96	-0.39	2.59e-11	Intelligence (multi-trait analysis);
CESC	cis	rs2072732	0.821	rs12038530	chr1:2946726	T/A	cg15211996	chr1:2936768	ACTRT2	0.33	5.76	0.33	2.36e-8	Plateletcrit;
CESC	cis	rs7116495	0.609	rs6592447	chr11:71641093	A/T	cg07596299	chr11:71824057	C11orf51	-0.8	-5.59	-0.32	5.72e-8	Severe influenza A (H1N1) infection;
CESC	cis	rs2933343	0.729	rs789228	chr3:128601050	A/G	cg25356066	chr3:128598488	ACAD9	0.66	9.22	0.49	9.52e-18	IgG glycosylation;
CESC	cis	rs4665809	0.887	rs28699126	chr2:26357294	C/T	cg25036284	chr2:26402008	FAM59B	-0.56	-6.51	-0.37	3.79e-10	Gut microbiome composition (summer);
CESC	cis	rs7072216	0.763	rs7909822	chr10:100172035	A/C	cg26618903	chr10:100175079	PYROXD2	-0.36	-5.68	-0.33	3.54e-8	Metabolite levels;
CESC	cis	rs12956009	0.583	rs1115360	chr18:44894550	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.5	6.5	0.37	3.94e-10	Educational attainment (years of education);
CESC	cis	rs709400	0.663	rs62007718	chr14:103940436	G/A	cg12935359	chr14:103987150	CKB	-0.57	-8.39	-0.46	2.88e-15	Body mass index;
CESC	cis	rs7103648	1.000	rs7947450	chr11:47429904	G/A	cg03711944	chr11:47377212	SPI1	-0.31	-5.05	-0.3	8.22e-7	Diastolic blood pressure;Systolic blood pressure;
CESC	cis	rs17818399	0.926	rs1378764	chr2:46839681	C/T	cg02822958	chr2:46747628	ATP6V1E2	0.47	5.73	0.33	2.73e-8	Height;
CESC	cis	rs1552244	0.816	rs56387520	chr3:10042782	C/T	cg00149659	chr3:10157352	C3orf10	0.7	8.26	0.45	6.82e-15	Alzheimer's disease;
CESC	cis	rs3892630	0.529	rs35300319	chr19:33409948	G/A	cg22980127	chr19:33182716	NUDT19	0.72	7.92	0.44	6.43e-14	Red blood cell traits;
CESC	cis	rs9815354	1.000	rs2128834	chr3:41862645	A/G	cg03022575	chr3:42003672	ULK4	0.5	5.63	0.33	4.67e-8	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs60871478	0.947	rs62432866	chr7:809281	T/G	cg05535760	chr7:792225	HEATR2	0.89	10.79	0.55	9.93e-23	Cerebrospinal P-tau181p levels;
CESC	cis	rs698833	0.926	rs1067367	chr2:44654905	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.52	6.78	0.38	7.76e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs9875589	0.957	rs60060718	chr3:13950333	G/A	cg19554555	chr3:13937349	NA	0.52	6.52	0.37	3.48e-10	Ovarian reserve;
CESC	cis	rs8180040	1.000	rs1024037	chr3:47318449	C/A	cg27129171	chr3:47204927	SETD2	-0.67	-10.3	-0.53	3.84e-21	Colorectal cancer;
CESC	cis	rs7666738	0.753	rs35194639	chr4:99053819	G/C	cg05340658	chr4:99064831	C4orf37	0.82	12.88	0.62	8.44e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1552244	0.882	rs17050699	chr3:10037167	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.74	-9.39	-0.5	2.94e-18	Alzheimer's disease;
CESC	cis	rs4713118	0.629	rs172165	chr6:28020814	T/G	cg22143856	chr6:28129313	ZNF389	0.42	5.27	0.31	2.83e-7	Parkinson's disease;
CESC	cis	rs826838	0.967	rs11169169	chr12:39093153	A/C	cg26384229	chr12:38710491	ALG10B	0.8	13.52	0.64	4.93e-32	Heart rate;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13165422	chr6:52926772	ICK	0.59	6.76	0.38	8.91e-11	Gut microbiome composition (summer);
CESC	cis	rs7714584	1.000	rs12656538	chr5:150251380	A/G	cg22134413	chr5:150180641	NA	0.61	5.92	0.34	9.83e-9	Crohn's disease;
CESC	cis	rs2303759	0.709	rs10422677	chr19:49824290	C/T	cg22307029	chr19:49891270	CCDC155	0.55	6.0	0.35	6.6e-9	Multiple sclerosis;
CESC	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg11965913	chr1:205819406	PM20D1	0.82	13.95	0.65	1.49e-33	Menarche (age at onset);
CESC	cis	rs7666738	0.753	rs17483788	chr4:98985623	G/A	cg17366294	chr4:99064904	C4orf37	0.59	8.57	0.47	8.46e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs13118159	0.725	rs71614967	chr4:1341291	A/G	cg13395646	chr4:1353034	KIAA1530	-0.41	-5.34	-0.31	1.98e-7	Longevity;
CESC	cis	rs6089584	1.000	rs6089583	chr20:60563624	G/A	cg13770153	chr20:60521292	NA	-0.45	-5.91	-0.34	1.02e-8	Body mass index;
CESC	cis	rs7044106	0.762	rs13291660	chr9:123392748	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.36	5.73	0.33	2.7e-8	Hip circumference adjusted for BMI;
CESC	cis	rs12079745	0.793	rs76254504	chr1:169182779	T/A	cg09363564	chr1:169337483	NME7;BLZF1	-1.0	-6.14	-0.35	3e-9	QT interval;
CESC	cis	rs6456156	0.792	rs10946213	chr6:167516095	A/G	cg23791538	chr6:167370224	RNASET2	0.41	5.38	0.31	1.61e-7	Primary biliary cholangitis;
CESC	cis	rs3796352	0.892	rs3821872	chr3:53080555	C/G	cg12962167	chr3:53033115	SFMBT1	-0.53	-5.09	-0.3	6.86e-7	Immune reponse to smallpox (secreted IL-2);
CESC	cis	rs9733	0.519	rs6700022	chr1:150670484	G/T	cg17724175	chr1:150552817	MCL1	-0.46	-7.65	-0.43	3.71e-13	Tonsillectomy;
CESC	cis	rs561341	0.654	rs6505265	chr17:30172580	C/T	cg00745463	chr17:30367425	LRRC37B	0.58	5.36	0.31	1.79e-7	Hip circumference adjusted for BMI;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg22328890	chr16:68298258	SLC7A6	-0.44	-6.47	-0.37	4.67e-10	Gambling;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg03789152	chr12:72233372	TBC1D15	-0.5	-6.36	-0.36	8.91e-10	Ulcerative colitis;
CESC	cis	rs12900413	0.687	rs12913572	chr15:90319313	T/C	cg24249390	chr15:90295951	MESP1	-0.42	-5.81	-0.34	1.78e-8	Coronary artery aneurysm in Kawasaki disease;
CESC	cis	rs2408955	0.522	rs4760612	chr12:48421856	C/T	cg24011408	chr12:48396354	COL2A1	-0.52	-8.06	-0.44	2.55e-14	Glycated hemoglobin levels;
CESC	cis	rs921968	0.643	rs4674321	chr2:219511368	G/A	cg02176678	chr2:219576539	TTLL4	0.41	7.03	0.4	1.76e-11	Mean corpuscular hemoglobin concentration;
CESC	cis	rs16867321	0.627	rs1025125	chr2:181580502	A/G	cg23363182	chr2:181467187	NA	0.44	6.49	0.37	4.12e-10	Obesity;
CESC	cis	rs10861342	0.786	rs11112393	chr12:105548053	C/T	cg23923672	chr12:105501055	KIAA1033	0.66	5.5	0.32	8.92e-8	IgG glycosylation;
CESC	cis	rs35306767	0.807	rs72778228	chr10:938435	A/G	cg26597838	chr10:835615	NA	1.17	11.57	0.58	2.57e-25	Eosinophil percentage of granulocytes;
CESC	cis	rs12200560	0.505	rs211162	chr6:97067344	G/A	cg06623918	chr6:96969491	KIAA0776	0.48	6.06	0.35	4.55e-9	Coronary heart disease;
CESC	cis	rs597539	0.652	rs584108	chr11:68630282	A/T	cg18350739	chr11:68623251	NA	0.47	7.29	0.41	3.6e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs7296418	0.961	rs949143	chr12:123595163	G/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.32	-5.16	-0.3	4.74e-7	Platelet count;
CESC	cis	rs10461617	0.617	rs6874733	chr5:56069600	A/G	cg24531977	chr5:56204891	C5orf35	-0.68	-8.63	-0.47	5.97e-16	Type 2 diabetes;
CESC	cis	rs9325144	0.600	rs10785621	chr12:38744912	C/T	cg26384229	chr12:38710491	ALG10B	0.56	8.07	0.44	2.52e-14	Morning vs. evening chronotype;
CESC	cis	rs13392177	0.684	rs62185965	chr2:219073779	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.52	-6.44	-0.37	5.71e-10	Pyoderma gangrenosum in inflammatory bowel disease;
CESC	cis	rs875971	0.964	rs6945019	chr7:65922458	C/G	cg11764359	chr7:65958608	NA	0.97	15.32	0.69	2.28e-38	Aortic root size;
CESC	cis	rs7246657	0.943	rs34603719	chr19:37794528	T/G	cg23950597	chr19:37808831	NA	-0.63	-6.43	-0.37	5.83e-10	Coronary artery calcification;
CESC	cis	rs13242816	1.000	rs13235720	chr7:116113663	T/C	cg04696780	chr7:116139425	CAV2	-0.58	-5.2	-0.3	4.08e-7	P wave duration;
CESC	cis	rs7618915	0.547	rs2878726	chr3:52748271	C/G	cg05564831	chr3:52568323	NT5DC2	0.44	6.64	0.38	1.77e-10	Bipolar disorder;
CESC	cis	rs4819052	0.851	rs2838828	chr21:46663423	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.75	9.94	0.52	5.31e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04671591	chr1:147400503	GPR89B	-0.61	-7.16	-0.4	7.82e-12	Gut microbiome composition (summer);
CESC	cis	rs7618915	0.501	rs9917834	chr3:52634619	A/C	cg18337363	chr3:52569053	NT5DC2	0.29	5.27	0.31	2.85e-7	Bipolar disorder;
CESC	cis	rs1881797	1.000	rs67977965	chr1:247687835	G/A	cg11166453	chr1:247681781	NA	0.44	5.77	0.33	2.24e-8	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs12995491	0.933	rs34029976	chr2:88537797	T/C	cg04511125	chr2:88470314	THNSL2	-0.51	-7.44	-0.42	1.38e-12	Response to metformin (IC50);
CESC	cis	rs2576037	0.526	rs6507714	chr18:44519574	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.51	-6.85	-0.39	5.17e-11	Personality dimensions;
CESC	cis	rs12995491	0.933	rs13023008	chr2:88530933	G/A	cg07952391	chr2:88470173	THNSL2	-0.55	-8.33	-0.46	4.44e-15	Response to metformin (IC50);
CESC	cis	rs3785574	0.962	rs2584621	chr17:61912436	G/A	cg06420487	chr17:61919686	SMARCD2	0.44	5.3	0.31	2.43e-7	Height;
CESC	cis	rs5758659	0.653	rs133383	chr22:42473603	C/T	cg00645731	chr22:42541494	CYP2D7P1	-0.34	-5.73	-0.33	2.71e-8	Cognitive function;
CESC	cis	rs3782089	0.546	rs76146604	chr11:65277512	G/T	cg00206168	chr11:65308501	LTBP3	0.97	6.49	0.37	4.11e-10	Height;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg16490896	chr11:72853324	FCHSD2	0.43	6.04	0.35	5.24e-9	Thyroid stimulating hormone;
CESC	cis	rs12478296	1.000	rs113129906	chr2:243004253	C/T	cg06360820	chr2:242988706	NA	-0.96	-10.24	-0.53	5.76e-21	Obesity-related traits;
CESC	cis	rs12220238	1.000	rs111704178	chr10:75957251	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.6	5.45	0.32	1.13e-7	Soluble interleukin-2 receptor subunit alpha;
CESC	cis	rs644148	0.836	rs2686774	chr19:44999827	T/C	cg15540054	chr19:45004280	ZNF180	-0.71	-8.42	-0.46	2.38e-15	Personality dimensions;
CESC	cis	rs13118159	0.771	rs13117476	chr4:1334721	A/G	cg00684032	chr4:1343700	KIAA1530	0.36	5.56	0.32	6.59e-8	Longevity;
CESC	trans	rs11264799	0.765	rs12125713	chr1:157636657	A/G	cg22691776	chr3:15032403	NR2C2	0.33	6.15	0.35	2.92e-9	IgA nephropathy;
CESC	cis	rs4727027	0.870	rs62507485	chr7:148764182	C/T	cg23583168	chr7:148888333	NA	-0.78	-11.73	-0.58	7.4e-26	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs3008870	1.000	rs1925408	chr1:67365034	C/T	cg08660285	chr1:67390436	MIER1;WDR78	1.02	14.11	0.65	4.32e-34	Lymphocyte percentage of white cells;
CESC	cis	rs657075	0.697	rs3792880	chr5:131644965	A/C	cg00255919	chr5:131827918	IRF1	-0.57	-5.09	-0.3	6.68e-7	Rheumatoid arthritis;
CESC	cis	rs8103278	0.507	rs62111759	chr19:46296230	A/T	cg12641515	chr19:46296257	DMWD	0.76	9.9	0.52	7.12e-20	Coronary artery disease;
CESC	cis	rs2191566	0.664	rs7250774	chr19:44551867	A/T	cg20607764	chr19:44506953	ZNF230	-0.44	-5.64	-0.33	4.34e-8	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg06074448	chr4:187884817	NA	-0.49	-7.54	-0.42	7.67e-13	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7727544	0.735	rs274558	chr5:131721174	A/G	cg07395648	chr5:131743802	NA	0.47	6.35	0.36	9.28e-10	Blood metabolite levels;
CESC	cis	rs6089584	0.528	rs4925335	chr20:60627034	G/A	cg24733560	chr20:60626293	TAF4	0.48	7.12	0.4	1e-11	Body mass index;
CESC	cis	rs2115536	0.692	rs6495450	chr15:80162499	C/A	cg00225070	chr15:80189496	MTHFS	0.41	5.42	0.32	1.32e-7	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CESC	cis	rs4835473	0.868	rs4629390	chr4:144656455	A/G	cg25736465	chr4:144833511	NA	-0.32	-5.07	-0.3	7.58e-7	Immature fraction of reticulocytes;
CESC	cis	rs67478160	0.643	rs11628332	chr14:104241141	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.51	-7.04	-0.4	1.65e-11	Schizophrenia;
CESC	cis	rs7592578	0.882	rs16832765	chr2:191468762	T/C	cg10560079	chr2:191398806	TMEM194B	-0.64	-5.47	-0.32	1.07e-7	Diastolic blood pressure;
CESC	cis	rs2050392	0.762	rs306587	chr10:30722908	G/C	cg18806716	chr10:30721971	MAP3K8	-0.41	-5.88	-0.34	1.2e-8	Inflammatory bowel disease;
CESC	cis	rs62064224	0.589	rs4132610	chr17:30801441	C/T	cg18200150	chr17:30822561	MYO1D	0.39	5.07	0.3	7.34e-7	Schizophrenia;
CESC	cis	rs9611565	0.592	rs5996037	chr22:41965292	A/G	cg03806693	chr22:41940476	POLR3H	-0.97	-11.84	-0.59	2.96e-26	Vitiligo;
CESC	cis	rs1552244	1.000	rs7615646	chr3:10089773	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	11.78	0.59	4.93e-26	Alzheimer's disease;
CESC	trans	rs9858542	0.953	rs6446264	chr3:49417243	C/A	cg21659725	chr3:3221576	CRBN	-0.55	-6.53	-0.37	3.34e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs1799949	1.000	rs3950989	chr17:41237953	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.66	9.36	0.5	3.64e-18	Menopause (age at onset);
CESC	cis	rs1832871	0.672	rs6899322	chr6:158753669	G/T	cg07165851	chr6:158734300	TULP4	0.61	6.43	0.37	5.94e-10	Height;
CESC	cis	rs7959452	0.868	rs12812860	chr12:69746671	T/C	cg14784868	chr12:69753453	YEATS4	0.6	8.41	0.46	2.62e-15	Blood protein levels;
CESC	cis	rs7666738	0.830	rs4699603	chr4:99056172	T/C	cg03467027	chr4:99064603	C4orf37	0.48	6.04	0.35	5.29e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9733	0.596	rs56058687	chr1:150635066	C/T	cg22823121	chr1:150693482	HORMAD1	0.48	7.14	0.4	9.05e-12	Tonsillectomy;
CESC	cis	rs7666738	0.830	rs7657982	chr4:99044015	G/A	cg03676636	chr4:99064102	C4orf37	0.34	5.26	0.31	3.04e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05899741	chr4:43901084	NA	-0.46	-6.09	-0.35	3.99e-9	Gut microbiome composition (summer);
CESC	cis	rs208520	0.690	rs851467	chr6:66802721	A/G	cg07460842	chr6:66804631	NA	-1.0	-13.43	-0.64	1.05e-31	Exhaled nitric oxide output;
CESC	cis	rs7927771	0.524	rs11039345	chr11:47720228	A/G	cg18512352	chr11:47633146	NA	0.35	5.42	0.32	1.34e-7	Subjective well-being;
CESC	cis	rs2444217	0.872	rs2531977	chr16:4043701	C/G	cg09300795	chr16:4042428	ADCY9	0.6	9.3	0.5	5.28e-18	Body mass index;
CESC	cis	rs9487051	0.676	rs9400268	chr6:109600550	C/T	cg01475377	chr6:109611718	NA	-0.44	-7.07	-0.4	1.34e-11	Reticulocyte fraction of red cells;
CESC	cis	rs2228479	0.850	rs11648689	chr16:89806732	G/A	cg06558623	chr16:89946397	TCF25	1.16	9.11	0.49	2.01e-17	Skin colour saturation;
CESC	cis	rs72781680	0.948	rs72790326	chr2:24126153	C/T	cg20701182	chr2:24300061	SF3B14	0.63	5.67	0.33	3.79e-8	Lymphocyte counts;
CESC	cis	rs9322193	0.962	rs9397022	chr6:150133188	C/T	cg04369109	chr6:150039330	LATS1	-0.43	-6.11	-0.35	3.56e-9	Lung cancer;
CESC	cis	rs10129255	0.500	rs2027903	chr14:107215283	A/C	cg07958169	chr14:107095056	NA	-0.6	-9.64	-0.51	4.8e-19	Kawasaki disease;
CESC	cis	rs2645694	0.626	rs2703120	chr4:77822470	G/A	cg10057126	chr4:77819792	ANKRD56	0.57	8.46	0.46	1.78e-15	Emphysema distribution in smoking;
CESC	cis	rs2404602	0.716	rs12902174	chr15:76863540	T/C	cg26408565	chr15:76604113	ETFA	-0.4	-5.72	-0.33	2.92e-8	Blood metabolite levels;
CESC	cis	rs7011049	0.673	rs17256515	chr8:53827232	C/T	cg26025543	chr8:53854495	NA	0.4	5.07	0.3	7.4e-7	Systolic blood pressure;
CESC	cis	rs67311347	1.000	rs17078511	chr3:40396254	A/G	cg24209194	chr3:40518798	ZNF619	0.42	5.28	0.31	2.76e-7	Renal cell carcinoma;
CESC	cis	rs4689388	0.890	rs4689398	chr4:6302199	C/T	cg25554036	chr4:6271136	WFS1	0.55	9.07	0.49	2.77e-17	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs7146395	1	rs7146395	chr14:75228647	A/C	cg11812906	chr14:75593930	NEK9	0.45	5.49	0.32	9.6e-8	Platelet count;
CESC	cis	rs7666738	0.830	rs10031751	chr4:98939134	G/A	cg05340658	chr4:99064831	C4orf37	0.82	12.54	0.61	1.29e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7618915	0.547	rs11130317	chr3:52731483	C/T	cg07507251	chr3:52567010	NT5DC2	0.4	7.02	0.4	1.89e-11	Bipolar disorder;
CESC	cis	rs2839186	0.559	rs2277826	chr21:47639492	C/G	cg10351095	chr21:47802916	PCNT	0.44	5.93	0.34	9.33e-9	Testicular germ cell tumor;
CESC	cis	rs6665290	0.935	rs1929864	chr1:227195500	T/G	cg10327440	chr1:227177885	CDC42BPA	-1.22	-32.73	-0.9	4.4e-95	Myeloid white cell count;
CESC	cis	rs9457247	0.967	rs425039	chr6:167410527	C/T	cg25258033	chr6:167368657	RNASET2	0.4	6.14	0.35	2.93e-9	Crohn's disease;
CESC	cis	rs10484885	0.824	rs11967579	chr6:90540008	G/T	cg13799429	chr6:90582589	CASP8AP2	-0.77	-7.03	-0.4	1.71e-11	QRS interval (sulfonylurea treatment interaction);
CESC	cis	rs798554	1.000	rs798548	chr7:2760935	A/G	cg09658497	chr7:2847517	GNA12	-0.38	-5.64	-0.33	4.29e-8	Height;
CESC	cis	rs933688	0.938	rs7708782	chr5:90718517	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.16	14.28	0.66	1.09e-34	Smoking behavior;
CESC	cis	rs78456975	1.000	rs72776251	chr2:1525097	G/A	cg01028140	chr2:1542097	TPO	-0.62	-5.88	-0.34	1.2e-8	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs9611565	0.694	rs202639	chr22:41856137	T/A	cg03806693	chr22:41940476	POLR3H	1.2	14.94	0.68	5.18e-37	Vitiligo;
CESC	cis	rs9457247	0.663	rs9457258	chr6:167444254	T/C	cg25258033	chr6:167368657	RNASET2	0.37	5.4	0.31	1.51e-7	Crohn's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14628942	chr2:128186071	PROC	-0.55	-6.02	-0.35	5.71e-9	Gut microbiome composition (summer);
CESC	cis	rs7605827	0.930	rs10207209	chr2:15512701	A/G	cg19274914	chr2:15703543	NA	0.32	5.73	0.33	2.75e-8	Educational attainment (years of education);
CESC	cis	rs6866344	0.697	rs11739893	chr5:178127837	G/A	cg03877680	chr5:178157825	ZNF354A	0.76	8.63	0.47	5.64e-16	Neutrophil percentage of white cells;
CESC	cis	rs6987853	0.686	rs7818789	chr8:42354257	A/G	cg09913449	chr8:42400586	C8orf40	0.36	5.89	0.34	1.16e-8	Mean corpuscular hemoglobin concentration;
CESC	trans	rs11098499	0.738	rs28408407	chr4:120376030	C/G	cg25214090	chr10:38739885	LOC399744	0.7	9.96	0.52	4.71e-20	Corneal astigmatism;
CESC	cis	rs11676348	0.714	rs4674254	chr2:218986077	T/C	cg00012203	chr2:219082015	ARPC2	-0.56	-7.31	-0.41	3.18e-12	Ulcerative colitis;
CESC	cis	rs3771570	1.000	rs62193202	chr2:242303717	G/A	cg21155796	chr2:242212141	HDLBP	0.6	5.27	0.31	2.89e-7	Prostate cancer;
CESC	trans	rs916888	0.687	rs199456	chr17:44797919	C/T	cg01341218	chr17:43662625	NA	0.92	10.64	0.55	3.07e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs1018836	0.663	rs2205151	chr8:91483468	A/C	cg16814680	chr8:91681699	NA	-0.62	-8.27	-0.45	6.46e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs780096	0.526	rs4803	chr2:27667297	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.32	-5.97	-0.34	7.45e-9	Total body bone mineral density;
CESC	cis	rs7216064	1.000	rs59950564	chr17:65860859	A/G	cg12091567	chr17:66097778	LOC651250	-0.86	-8.81	-0.48	1.63e-16	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs9811920	0.638	rs796978	chr3:99564321	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.4	5.5	0.32	9.11e-8	Axial length;
CESC	cis	rs7147624	0.608	rs4902413	chr14:66187091	T/C	cg03016385	chr14:66212404	NA	-0.49	-5.15	-0.3	5.2e-7	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs1215050	0.791	rs260893	chr4:98744785	A/C	cg05340658	chr4:99064831	C4orf37	0.51	6.65	0.38	1.63e-10	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs7618915	0.547	rs2590846	chr3:52692359	C/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.49	7.14	0.4	9.11e-12	Bipolar disorder;
CESC	cis	rs853679	0.517	rs1947862	chr6:28105196	C/T	cg19592336	chr6:28129416	ZNF389	0.61	8.14	0.45	1.54e-14	Depression;
CESC	cis	rs6540559	0.546	rs634601	chr1:210421594	C/T	cg25204440	chr1:209979598	IRF6	0.48	5.35	0.31	1.94e-7	Cleft lip with or without cleft palate;
CESC	cis	rs2276314	0.857	rs72883058	chr18:33612917	G/A	cg05985134	chr18:33552581	C18orf21	0.62	7.36	0.41	2.29e-12	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs66573146	0.634	rs56097119	chr4:7018692	C/G	cg00086871	chr4:6988644	TBC1D14	0.88	5.58	0.32	5.84e-8	Granulocyte percentage of myeloid white cells;
CESC	trans	rs2823962	0.759	rs9984105	chr21:18016495	C/T	cg06419850	chr17:4688683	VMO1	-0.43	-6.17	-0.35	2.48e-9	Amyotrophic lateral sclerosis;
CESC	cis	rs7666738	0.791	rs4699329	chr4:99056212	G/A	cg03467027	chr4:99064603	C4orf37	0.48	6.04	0.35	5.29e-9	Colonoscopy-negative controls vs population controls;
CESC	trans	rs8073060	0.586	rs4795086	chr17:34042190	G/A	cg19694781	chr19:47549865	TMEM160	0.69	6.3	0.36	1.25e-9	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	cis	rs4853012	0.838	rs12619982	chr2:74356022	G/A	cg19729930	chr2:74357872	NA	0.96	14.17	0.66	2.67e-34	Gestational age at birth (maternal effect);
CESC	cis	rs6912958	0.684	rs4707382	chr6:88320641	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.32	-5.25	-0.31	3.18e-7	Monocyte percentage of white cells;
CESC	cis	rs897984	0.806	rs12928852	chr16:30943988	C/T	cg00531865	chr16:30841666	NA	0.51	7.12	0.4	1.01e-11	Dementia with Lewy bodies;
CESC	trans	rs2727020	0.729	rs1164666	chr11:49295867	C/T	cg15704280	chr7:45808275	SEPT13	-0.87	-14.59	-0.67	8.81e-36	Coronary artery disease;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg12468647	chr15:75975061	CSPG4	-0.49	-6.4	-0.37	6.91e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs1552244	0.935	rs35148833	chr3:10116937	C/A	cg16606324	chr3:10149918	C3orf24	0.44	5.3	0.31	2.38e-7	Alzheimer's disease;
CESC	cis	rs10851478	0.558	rs17478785	chr15:49740304	A/C	cg08060515	chr15:49448048	GALK2;COPS2	0.51	6.36	0.36	8.62e-10	Oral cavity cancer;
CESC	cis	rs7089973	0.966	rs12775180	chr10:116639754	T/C	cg23260525	chr10:116636907	FAM160B1	0.36	5.57	0.32	6.33e-8	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs8062405	0.755	rs12447461	chr16:28582941	C/A	cg07382826	chr16:28625726	SULT1A1	0.4	6.59	0.38	2.4e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs3858704	0.517	rs7297186	chr12:111778178	C/T	cg10833066	chr12:111807467	FAM109A	-0.33	-5.29	-0.31	2.6e-7	Idiopathic osteonecrosis of the femoral head;
CESC	cis	rs965469	1.000	rs6037579	chr20:3347980	G/A	cg25506879	chr20:3388711	C20orf194	-0.58	-6.12	-0.35	3.43e-9	IFN-related cytopenia;
CESC	cis	rs2637266	0.935	rs2583052	chr10:78403288	C/G	cg18941641	chr10:78392320	NA	0.44	8.58	0.47	7.88e-16	Pulmonary function;
CESC	cis	rs4713118	0.662	rs9393881	chr6:28023751	C/G	cg23281280	chr6:28129359	ZNF389	0.47	6.2	0.36	2.2e-9	Parkinson's disease;
CESC	cis	rs8040855	0.627	rs62019482	chr15:85615027	A/C	cg08123816	chr15:85640762	PDE8A	-0.39	-5.79	-0.34	1.94e-8	Bulimia nervosa;
CESC	cis	rs1046896	0.553	rs3744160	chr17:80828303	G/A	cg02711726	chr17:80685570	FN3KRP	-0.39	-5.14	-0.3	5.32e-7	Glycated hemoglobin levels;
CESC	cis	rs1008375	0.900	rs4698622	chr4:17589557	C/T	cg16339924	chr4:17578868	LAP3	0.82	10.37	0.54	2.27e-21	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs2985684	1.000	rs3007031	chr14:50102269	G/C	cg15316458	chr14:50087796	RPL36AL;MGAT2	0.45	5.15	0.3	4.99e-7	Carotid intima media thickness;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg04489846	chr17:79980949	LRRC45;STRA13	-0.44	-6.22	-0.36	1.97e-9	Gambling;
CESC	cis	rs9309473	0.948	rs10183818	chr2:73714556	A/G	cg20560298	chr2:73613845	ALMS1	-0.55	-6.9	-0.39	3.86e-11	Metabolite levels;
CESC	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg27588902	chr6:42928151	GNMT	-0.29	-5.67	-0.33	3.64e-8	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs61542988	0.570	rs10950919	chr7:22833821	A/G	cg13679077	chr7:22862647	TOMM7	0.62	7.04	0.4	1.61e-11	Fibrinogen levels;
CESC	cis	rs4819052	0.851	rs13052312	chr21:46662359	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.9	13.15	0.63	1e-30	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs921968	0.541	rs642520	chr2:219423605	A/G	cg02176678	chr2:219576539	TTLL4	-0.49	-8.94	-0.48	6.89e-17	Mean corpuscular hemoglobin concentration;
CESC	cis	rs1568889	0.838	rs11030220	chr11:28145769	C/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.81	13.51	0.64	5.16e-32	Bipolar disorder;
CESC	cis	rs12926788	0.689	rs1862450	chr16:24856775	A/G	cg02428538	chr16:24856791	SLC5A11	0.66	6.92	0.39	3.37e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	7.7	0.43	2.77e-13	Prudent dietary pattern;
CESC	cis	rs3824867	0.959	rs4237544	chr11:47454271	G/T	cg20307385	chr11:47447363	PSMC3	-0.49	-6.08	-0.35	4.07e-9	Mean corpuscular hemoglobin;
CESC	cis	rs2011503	0.941	rs113145184	chr19:19419984	T/C	cg11584989	chr19:19387371	SF4	0.67	7.93	0.44	6e-14	Bipolar disorder;
CESC	cis	rs7927771	0.832	rs10838699	chr11:47386073	T/C	cg18512352	chr11:47633146	NA	0.52	7.49	0.42	1.06e-12	Subjective well-being;
CESC	cis	rs10876993	0.928	rs774890	chr12:58068388	C/T	cg18357645	chr12:58087776	OS9	0.61	10.25	0.53	5.6e-21	Celiac disease or Rheumatoid arthritis;
CESC	cis	rs8017423	0.522	rs12887028	chr14:90819605	A/G	cg14092571	chr14:90743983	NA	0.44	6.62	0.38	1.93e-10	Mortality in heart failure;
CESC	cis	rs67311347	0.955	rs6782746	chr3:40510592	A/G	cg09455208	chr3:40491958	NA	-0.49	-8.32	-0.46	4.59e-15	Renal cell carcinoma;
CESC	cis	rs7208859	0.623	rs609063	chr17:28951513	A/G	cg19761014	chr17:28927070	LRRC37B2	0.87	6.6	0.38	2.2e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	trans	rs7943203	0.962	rs11212636	chr11:108311965	G/A	cg24643211	chr18:11851603	GNAL;CHMP1B	-0.48	-6.05	-0.35	4.95e-9	Red blood cell count;Mean corpuscular volume;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg22123309	chr1:31191561	MATN1	-0.5	-6.14	-0.35	2.96e-9	Ulcerative colitis;
CESC	cis	rs801193	0.935	rs2659916	chr7:66151352	C/G	cg14393609	chr7:65229607	NA	0.47	6.31	0.36	1.15e-9	Aortic root size;
CESC	cis	rs4835473	0.897	rs11735341	chr4:144637183	G/C	cg25736465	chr4:144833511	NA	-0.45	-6.81	-0.39	6.71e-11	Immature fraction of reticulocytes;
CESC	cis	rs6580649	1.000	rs6580647	chr12:48403229	G/T	cg05342945	chr12:48394962	COL2A1	0.53	6.73	0.38	1.05e-10	Lung cancer;
CESC	cis	rs1538970	0.962	rs4660849	chr1:45819872	A/G	cg06784218	chr1:46089804	CCDC17	-0.31	-5.15	-0.3	5.19e-7	Platelet count;
CESC	cis	rs34375054	0.738	rs10773145	chr12:125625603	C/T	cg05341575	chr12:125625032	AACS	0.32	5.09	0.3	6.68e-7	Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs703842	1.000	rs3782130	chr12:58161898	G/C	cg00677455	chr12:58241039	CTDSP2	0.52	6.65	0.38	1.69e-10	Multiple sclerosis;
CESC	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg07677032	chr17:61819896	STRADA	0.45	6.05	0.35	5.02e-9	Prudent dietary pattern;
CESC	cis	rs7103648	0.966	rs896817	chr11:47394305	A/G	cg03711944	chr11:47377212	SPI1	0.33	5.21	0.3	3.79e-7	Diastolic blood pressure;Systolic blood pressure;
CESC	cis	rs6598955	0.670	rs7522905	chr1:26609259	C/T	cg00852783	chr1:26633632	UBXN11	0.42	6.28	0.36	1.39e-9	Obesity-related traits;
CESC	cis	rs35955747	0.934	rs926928	chr22:31821719	G/A	cg25791279	chr22:32026902	PISD	-0.44	-5.19	-0.3	4.18e-7	Neutrophil count;Sum basophil neutrophil counts;
CESC	cis	rs7824557	0.564	rs12550129	chr8:11233917	C/T	cg21775007	chr8:11205619	TDH	-0.52	-7.67	-0.43	3.23e-13	Retinal vascular caliber;
CESC	cis	rs7666738	0.830	rs1426670	chr4:98923572	A/G	cg03467027	chr4:99064603	C4orf37	0.46	5.57	0.32	6.21e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs116095464	0.558	rs10068203	chr5:206618	C/T	cg22857025	chr5:266934	NA	-1.28	-14.21	-0.66	1.88e-34	Breast cancer;
CESC	trans	rs35146811	0.625	rs2906645	chr7:99817859	A/G	cg13215871	chr17:75784724	NA	-0.34	-6.39	-0.37	7.46e-10	Coronary artery disease;
CESC	cis	rs1707322	0.647	rs6686944	chr1:46156308	G/T	cg03146154	chr1:46216737	IPP	0.82	11.47	0.58	5.26e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2836974	0.899	rs34433511	chr21:40618883	A/C	cg27266027	chr21:40555129	PSMG1	0.44	5.23	0.31	3.47e-7	Cognitive function;
CESC	cis	rs9549260	0.755	rs7333037	chr13:41215256	A/T	cg21288729	chr13:41239152	FOXO1	0.65	8.62	0.47	6.27e-16	Red blood cell count;
CESC	cis	rs2380220	0.808	rs2380224	chr6:95895553	C/T	cg15832292	chr6:96025679	MANEA	-0.65	-5.95	-0.34	8.46e-9	Behavioural disinhibition (generation interaction);
CESC	cis	rs853679	0.713	rs200991	chr6:27815494	A/C	cg18032046	chr6:28092343	ZSCAN16	0.56	5.65	0.33	4.14e-8	Depression;
CESC	cis	rs10927875	0.965	rs3961710	chr1:16313172	C/T	cg22431228	chr1:16359049	CLCNKA	0.37	5.73	0.33	2.68e-8	Dilated cardiomyopathy;
CESC	cis	rs9487051	0.735	rs351754	chr6:109537553	A/G	cg01475377	chr6:109611718	NA	0.4	5.98	0.35	7.01e-9	Reticulocyte fraction of red cells;
CESC	cis	rs9486719	0.843	rs2472876	chr6:96845723	A/G	cg06623918	chr6:96969491	KIAA0776	0.78	7.39	0.41	1.89e-12	Migraine;Coronary artery disease;
CESC	cis	rs9649213	0.574	rs34717219	chr7:97962271	A/C	cg08684580	chr7:98029266	BAIAP2L1	-0.35	-5.76	-0.33	2.34e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs3780486	0.505	rs7868663	chr9:33141229	A/G	cg13443165	chr9:33130375	B4GALT1	0.46	7.07	0.4	1.37e-11	IgG glycosylation;
CESC	cis	rs3738443	0.520	rs6699577	chr1:247387454	G/A	cg07706540	chr1:247373924	NA	-0.45	-5.51	-0.32	8.4e-8	Alcohol dependence;
CESC	cis	rs1620921	0.505	rs13203571	chr6:161208765	A/G	cg01280913	chr6:161186852	NA	-0.38	-5.66	-0.33	3.96e-8	Lipoprotein (a) - cholesterol levels;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg21271961	chr1:95285780	SLC44A3	0.47	6.38	0.36	7.73e-10	Systemic lupus erythematosus;
CESC	cis	rs7666738	0.830	rs62321587	chr4:98997958	T/C	cg17366294	chr4:99064904	C4orf37	0.59	8.49	0.46	1.49e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9430161	0.611	rs12081197	chr1:11034239	T/C	cg02454025	chr1:11042201	C1orf127	0.99	16.1	0.7	3.84e-41	Ewing sarcoma;
CESC	cis	rs853679	0.517	rs9348794	chr6:28117757	T/A	cg26335602	chr6:28129616	ZNF389	0.53	6.75	0.38	9.35e-11	Depression;
CESC	trans	rs6572548	0.504	rs1956082	chr14:49665496	A/C	cg00605358	chr12:89747739	DUSP6	-0.54	-6.09	-0.35	3.96e-9	Subjective well-being;
CESC	cis	rs8060686	0.641	rs7188085	chr16:68113873	A/G	cg26727032	chr16:67993705	SLC12A4	-0.56	-6.61	-0.38	2.06e-10	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs752092	1.000	rs752092	chr15:101781934	C/T	cg19997662	chr15:101784653	CHSY1	0.56	7.72	0.43	2.37e-13	Corneal structure;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26185531	chr11:75479825	DGAT2	0.56	6.38	0.36	7.72e-10	Gut microbiome composition (summer);
CESC	cis	rs6867032	0.917	rs10474734	chr5:2004208	A/G	cg26168224	chr5:2018326	NA	0.77	12.75	0.62	2.4e-29	Gut microbiome composition (winter);
CESC	cis	rs2742234	0.590	rs2565201	chr10:43618484	T/C	cg15436174	chr10:43711423	RASGEF1A	-0.46	-5.41	-0.32	1.39e-7	Hirschsprung disease;
CESC	cis	rs8002861	0.846	rs12869521	chr13:44478346	A/G	cg19180546	chr13:44453867	C13orf31;CCDC122	-0.45	-5.86	-0.34	1.39e-8	Leprosy;
CESC	cis	rs28386778	0.734	rs12946669	chr17:62006007	A/G	cg07677032	chr17:61819896	STRADA	0.47	6.13	0.35	3.23e-9	Prudent dietary pattern;
CESC	cis	rs28595532	0.748	rs113336496	chr4:119336957	C/T	cg21605333	chr4:119757512	SEC24D	0.93	5.92	0.34	1.02e-8	Cannabis dependence symptom count;
CESC	cis	rs1552244	1.000	rs2272123	chr3:10140115	G/A	cg08888203	chr3:10149979	C3orf24	0.46	5.9	0.34	1.09e-8	Alzheimer's disease;
CESC	cis	rs1707322	0.686	rs3014235	chr1:46091512	A/G	cg03146154	chr1:46216737	IPP	-0.79	-11.05	-0.56	1.36e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg02475777	chr4:1388615	CRIPAK	-0.68	-8.61	-0.47	6.5e-16	Longevity;
CESC	cis	rs79976124	0.800	rs12194767	chr6:66639599	A/G	cg07460842	chr6:66804631	NA	0.71	8.51	0.46	1.3e-15	Type 2 diabetes;
CESC	cis	rs2439831	0.850	rs8042868	chr15:43939642	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.74	6.52	0.37	3.5e-10	Lung cancer in ever smokers;
CESC	cis	rs1775715	0.737	rs2808090	chr10:32143208	A/C	cg18675610	chr10:32216311	ARHGAP12	0.35	5.44	0.32	1.18e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs9308731	0.568	rs6754736	chr2:111948541	T/C	cg04202892	chr2:111875749	ACOXL	0.39	5.33	0.31	2.12e-7	Chronic lymphocytic leukemia;
CESC	cis	rs1552244	0.608	rs3732962	chr3:10048951	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.62	7.95	0.44	5.32e-14	Alzheimer's disease;
CESC	cis	rs9911578	0.902	rs12948746	chr17:57071892	A/G	cg12560992	chr17:57184187	TRIM37	1.0	17.01	0.72	2.3e-44	Intelligence (multi-trait analysis);
CESC	trans	rs57221529	0.709	rs72706611	chr5:561146	C/A	cg25482853	chr8:67687455	SGK3	1.12	11.92	0.59	1.58e-26	Lung disease severity in cystic fibrosis;
CESC	cis	rs4523957	0.620	rs9906467	chr17:2069003	C/T	cg16513277	chr17:2031491	SMG6	-0.79	-11.85	-0.59	2.89e-26	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs238295	0.805	rs1983694	chr20:5574134	T/C	cg24001556	chr20:5591874	RP5-1022P6.2	-0.46	-5.19	-0.3	4.27e-7	Occipital cortical area (total cortical area interaction);
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg05357137	chr10:28527770	MPP7	0.4	6.23	0.36	1.78e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs798554	0.704	rs798503	chr7:2789704	G/A	cg13628971	chr7:2884303	GNA12	0.41	5.45	0.32	1.17e-7	Height;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg08591886	chr16:81111003	C16orf46	-0.46	-6.09	-0.35	3.92e-9	Ulcerative colitis;
CESC	cis	rs2985684	0.894	rs8005990	chr14:50022248	G/A	cg02151108	chr14:50098012	C14orf104	-0.38	-5.18	-0.3	4.4e-7	Carotid intima media thickness;
CESC	cis	rs10504229	0.815	rs55855654	chr8:58164299	T/G	cg24829409	chr8:58192753	C8orf71	-0.67	-7.97	-0.44	4.6e-14	Developmental language disorder (linguistic errors);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04005938	chr7:148334417	NA	-0.53	-6.88	-0.39	4.25e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs1218582	0.772	rs1109815	chr1:154909268	A/G	cg16680214	chr1:154839983	KCNN3	-0.45	-6.87	-0.39	4.46e-11	Prostate cancer;
CESC	cis	rs1153858	1.000	rs12440038	chr15:45706739	A/G	cg21132104	chr15:45694354	SPATA5L1	0.86	11.69	0.58	9.6e-26	Homoarginine levels;
CESC	cis	rs13191362	0.872	rs13194619	chr6:163203657	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.66	6.37	0.36	8.45e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	trans	rs561341	1.000	rs550264	chr17:30317540	G/T	cg20587970	chr11:113659929	NA	-1.42	-18.3	-0.75	6.25e-49	Hip circumference adjusted for BMI;
CESC	trans	rs1555543	0.517	rs2391766	chr1:96909240	T/C	cg01125333	chr16:2835331	PRSS33	-0.52	-6.15	-0.35	2.86e-9	Body mass index;
CESC	cis	rs6460942	0.597	rs17448193	chr7:12525641	G/A	cg20607287	chr7:12443886	VWDE	-0.71	-7.67	-0.43	3.19e-13	Coronary artery disease;
CESC	cis	rs897984	0.568	rs4889651	chr16:30895545	C/T	cg02466173	chr16:30829666	NA	-0.44	-6.39	-0.37	7.24e-10	Dementia with Lewy bodies;
CESC	cis	rs8099014	0.861	rs4245270	chr18:56112854	A/G	cg19312305	chr18:56117016	MIR122	-0.27	-5.26	-0.31	3e-7	Platelet count;
CESC	cis	rs4665809	0.590	rs7582341	chr2:26416301	A/G	cg04944784	chr2:26401820	FAM59B	-0.93	-10.75	-0.55	1.28e-22	Gut microbiome composition (summer);
CESC	cis	rs67311347	0.911	rs9849224	chr3:40392562	T/C	cg24209194	chr3:40518798	ZNF619	0.45	5.94	0.34	8.86e-9	Renal cell carcinoma;
CESC	cis	rs10129255	0.957	rs10141052	chr14:107184767	G/A	cg07958169	chr14:107095056	NA	-0.42	-5.87	-0.34	1.28e-8	Kawasaki disease;
CESC	trans	rs1814175	0.587	rs847628	chr11:49927064	A/T	cg11707556	chr5:10655725	ANKRD33B	-0.43	-6.36	-0.36	8.98e-10	Height;
CESC	cis	rs4450798	0.649	rs7631252	chr3:13803506	C/T	cg05589046	chr3:13742034	LOC285375	0.33	5.11	0.3	6.31e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs684232	0.602	rs401592	chr17:551316	T/C	cg12384639	chr17:618140	VPS53	0.41	5.31	0.31	2.36e-7	Prostate cancer;
CESC	cis	rs11792861	0.926	rs7856626	chr9:111775502	C/G	cg05043794	chr9:111880884	C9orf5	-0.42	-6.89	-0.39	4.05e-11	Menarche (age at onset);
CESC	cis	rs3768617	0.811	rs12563494	chr1:183039698	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.66	9.15	0.49	1.56e-17	Fuchs's corneal dystrophy;
CESC	cis	rs6088590	1.000	rs2180276	chr20:33360785	T/A	cg24642439	chr20:33292090	TP53INP2	0.84	11.86	0.59	2.69e-26	Coronary artery disease;
CESC	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg06500355	chr6:111804104	REV3L	0.46	6.15	0.35	2.79e-9	Myopia (pathological);
CESC	cis	rs3091242	0.933	rs28530483	chr1:25740847	A/C	cg02931644	chr1:25747376	RHCE	0.39	6.42	0.37	6.29e-10	Erythrocyte sedimentation rate;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14214323	chr14:35873275	NFKBIA	0.54	6.16	0.35	2.66e-9	Gut microbiome composition (summer);
CESC	cis	rs875971	0.789	rs28815324	chr7:65565776	A/T	cg11764359	chr7:65958608	NA	-0.8	-8.87	-0.48	1.14e-16	Aortic root size;
CESC	cis	rs1008375	1.000	rs6848360	chr4:17634442	G/T	cg16339924	chr4:17578868	LAP3	0.66	8.45	0.46	1.95e-15	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs6991838	0.584	rs4449837	chr8:66488152	C/T	cg13398993	chr8:66546079	ARMC1	-0.46	-5.54	-0.32	7.22e-8	Intelligence (multi-trait analysis);
CESC	cis	rs7512552	0.839	rs11577600	chr1:150407443	G/A	cg15654264	chr1:150340011	RPRD2	0.4	5.29	0.31	2.63e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs714031	0.967	rs5757763	chr22:40065005	A/G	cg21377881	chr22:40064566	CACNA1I	-0.39	-6.41	-0.37	6.78e-10	Schizophrenia;
CESC	cis	rs2243480	1.000	rs7804223	chr7:65664559	T/G	cg12463550	chr7:65579703	CRCP	-0.73	-5.71	-0.33	3.1e-8	Diabetic kidney disease;
CESC	cis	rs4665809	0.652	rs2241739	chr2:26411894	C/T	cg08470875	chr2:26401718	FAM59B	-0.67	-7.5	-0.42	9.76e-13	Gut microbiome composition (summer);
CESC	cis	rs12477438	0.501	rs2516833	chr2:99777405	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.79	12.62	0.61	6.6e-29	Chronic sinus infection;
CESC	trans	rs2727020	0.576	rs1917321	chr11:49377760	A/C	cg15704280	chr7:45808275	SEPT13	-0.67	-8.84	-0.48	1.33e-16	Coronary artery disease;
CESC	cis	rs875971	1.000	rs3981131	chr7:65951677	A/G	cg11764359	chr7:65958608	NA	0.95	14.36	0.66	5.81e-35	Aortic root size;
CESC	cis	rs4481887	0.893	rs10888347	chr1:248448566	T/C	cg00666640	chr1:248458726	OR2T12	0.38	6.42	0.37	6.37e-10	Common traits (Other);
CESC	cis	rs1790761	0.554	rs12787511	chr11:67401635	G/C	cg24690094	chr11:67383802	NA	-0.35	-5.48	-0.32	9.74e-8	Mean corpuscular volume;
CESC	trans	rs11088226	0.681	rs2833903	chr21:33940819	C/T	cg09050820	chr6:167586206	TCP10L2	0.83	7.75	0.43	2.01e-13	Gastritis;
CESC	cis	rs5753618	0.509	rs5997902	chr22:31583007	A/G	cg13145458	chr22:31556086	RNF185	0.49	5.5	0.32	8.74e-8	Colorectal cancer;
CESC	cis	rs9291683	0.530	rs11723970	chr4:9980462	T/C	cg00071950	chr4:10020882	SLC2A9	0.79	14.49	0.66	1.98e-35	Bone mineral density;
CESC	cis	rs1448094	0.621	rs10863090	chr12:86282211	C/T	cg02569458	chr12:86230093	RASSF9	0.42	6.15	0.35	2.81e-9	Major depressive disorder;
CESC	cis	rs7927592	0.913	rs7106339	chr11:68240241	C/T	cg20283391	chr11:68216788	NA	-0.64	-7.78	-0.43	1.65e-13	Total body bone mineral density;
CESC	cis	rs10883723	0.737	rs11191312	chr10:104278601	T/C	ch.10.2196322F	chr10:104248062	ACTR1A	0.49	5.38	0.31	1.62e-7	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs9611565	0.659	rs169361	chr22:41877989	A/G	cg06634786	chr22:41940651	POLR3H	0.71	7.19	0.4	6.68e-12	Vitiligo;
CESC	cis	rs4822044	0.617	rs13054514	chr22:42130383	A/G	cg06634786	chr22:41940651	POLR3H	0.49	5.5	0.32	8.83e-8	Cannabis dependence symptom count;
CESC	cis	rs1707322	1.000	rs4454479	chr1:46423555	G/A	cg05343316	chr1:45956843	TESK2	0.44	5.42	0.32	1.36e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs6011002	1.000	rs56010802	chr20:62304114	G/C	cg15212369	chr20:62274085	STMN3	-0.57	-5.16	-0.3	4.82e-7	Dental caries;
CESC	cis	rs4950322	0.570	rs66580541	chr1:146780541	T/G	cg16700924	chr1:146552102	NA	-0.41	-5.1	-0.3	6.37e-7	Protein quantitative trait loci;
CESC	cis	rs7980687	0.596	rs1727319	chr12:123701353	T/C	cg00376283	chr12:123451042	ABCB9	0.67	9.21	0.49	1.03e-17	Height;Educational attainment;Head circumference (infant);
CESC	cis	rs561341	0.843	rs879945	chr17:30242796	G/A	cg13647721	chr17:30228624	UTP6	0.77	8.85	0.48	1.32e-16	Hip circumference adjusted for BMI;
CESC	cis	rs9987353	0.566	rs34491841	chr8:9065510	C/A	cg15556689	chr8:8085844	FLJ10661	-0.57	-6.53	-0.37	3.4e-10	Recombination measurement;
CESC	cis	rs7560272	0.723	rs13386124	chr2:73771695	C/G	cg20560298	chr2:73613845	ALMS1	-0.44	-6.25	-0.36	1.6e-9	Schizophrenia;
CESC	cis	rs7116495	1.000	rs4945434	chr11:71759087	A/G	cg10381502	chr11:71823885	C11orf51	0.72	5.78	0.33	2.04e-8	Severe influenza A (H1N1) infection;
CESC	cis	rs15676	0.947	rs2293968	chr9:131587240	G/A	cg00228799	chr9:131580591	ENDOG	0.44	5.61	0.33	5.1e-8	Blood metabolite levels;
CESC	cis	rs3749237	0.595	rs1464567	chr3:49459252	C/G	cg02487422	chr3:49467188	NICN1	-0.53	-7.61	-0.42	4.73e-13	Resting heart rate;
CESC	cis	rs2066819	1.000	rs79436528	chr12:56686997	C/T	cg26714650	chr12:56694279	CS	-1.52	-10.39	-0.54	1.95e-21	Psoriasis vulgaris;
CESC	cis	rs4819052	0.851	rs2838848	chr21:46671017	A/G	cg11663144	chr21:46675770	NA	-0.64	-10.02	-0.52	2.95e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs4908768	0.501	rs910581	chr1:8529524	T/C	cg00120948	chr1:8484417	RERE	-0.34	-5.22	-0.31	3.65e-7	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
CESC	cis	rs9916302	0.904	rs8077104	chr17:37530510	A/G	cg20243544	chr17:37824526	PNMT	-0.49	-6.14	-0.35	3.08e-9	Glomerular filtration rate (creatinine);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20936892	chr17:57297306	GDPD1	-0.47	-6.12	-0.35	3.29e-9	Gut microbiome composition (summer);
CESC	trans	rs2235573	0.625	rs139905	chr22:38409596	C/T	cg19894588	chr14:64061835	NA	-0.46	-6.05	-0.35	5e-9	Glioblastoma;Glioma;
CESC	cis	rs9297145	0.761	rs62473005	chr7:98742510	G/C	cg05967295	chr7:98741636	SMURF1	0.9	9.17	0.49	1.34e-17	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
CESC	cis	rs13385	0.769	rs13175916	chr5:139611508	T/C	cg26211634	chr5:139558579	C5orf32	0.49	5.41	0.32	1.41e-7	Atrial fibrillation;
CESC	cis	rs12135062	0.538	rs2651929	chr1:3101353	C/T	cg25382214	chr1:3105252	PRDM16	0.36	5.24	0.31	3.36e-7	Migraine;
CESC	cis	rs7666738	0.830	rs11097608	chr4:99011693	T/C	cg03676636	chr4:99064102	C4orf37	0.34	5.25	0.31	3.18e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs847577	0.722	rs6951277	chr7:97711783	A/G	cg24562669	chr7:97807699	LMTK2	0.63	10.27	0.53	4.67e-21	Breast cancer;
CESC	cis	rs2486288	0.656	rs2271438	chr15:45557468	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.55	-6.71	-0.38	1.16e-10	Glomerular filtration rate;
CESC	cis	rs2243480	1.000	rs13310597	chr7:65598540	A/G	cg12463550	chr7:65579703	CRCP	0.73	5.68	0.33	3.5e-8	Diabetic kidney disease;
CESC	cis	rs1670533	1.000	rs13119276	chr4:1051574	T/C	cg04106633	chr4:1044584	NA	0.4	5.09	0.3	6.77e-7	Recombination rate (females);
CESC	cis	rs9309473	0.950	rs6735946	chr2:73790058	A/G	cg20560298	chr2:73613845	ALMS1	-0.53	-6.96	-0.39	2.6e-11	Metabolite levels;
CESC	cis	rs244293	0.965	rs244361	chr17:53191356	A/G	cg19360675	chr17:53046073	COX11;STXBP4	-0.39	-5.05	-0.3	8.18e-7	Menarche (age at onset);
CESC	cis	rs35306767	0.903	rs61830933	chr10:934195	G/A	cg26597838	chr10:835615	NA	1.16	11.43	0.57	7.45e-25	Eosinophil percentage of granulocytes;
CESC	cis	rs7917772	0.582	rs12784963	chr10:104336986	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.4	-5.4	-0.31	1.49e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs2070488	0.804	rs13092473	chr3:38458958	A/G	cg24069376	chr3:38537580	EXOG	0.35	6.01	0.35	6.11e-9	Electrocardiographic conduction measures;
CESC	cis	rs10504073	0.626	rs6472220	chr8:50008477	C/A	cg00325661	chr8:49890786	NA	0.5	7.58	0.42	5.91e-13	Blood metabolite ratios;
CESC	cis	rs11098499	0.954	rs12506546	chr4:120301618	T/C	cg09307838	chr4:120376055	NA	0.92	12.54	0.61	1.23e-28	Corneal astigmatism;
CESC	cis	rs453301	0.598	rs10104303	chr8:8834528	A/T	cg15556689	chr8:8085844	FLJ10661	0.44	5.68	0.33	3.6e-8	Joint mobility (Beighton score);
CESC	cis	rs7116495	0.609	rs567026	chr11:71769952	C/T	cg26138937	chr11:71823887	C11orf51	1.29	8.23	0.45	8.75e-15	Severe influenza A (H1N1) infection;
CESC	cis	rs7777484	0.500	rs2533885	chr7:2835655	C/T	cg09658497	chr7:2847517	GNA12	-0.43	-6.86	-0.39	4.74e-11	Height;
CESC	cis	rs854765	0.547	rs7223696	chr17:17915791	G/T	cg09796270	chr17:17721594	SREBF1	0.38	5.38	0.31	1.65e-7	Total body bone mineral density;
CESC	cis	rs6500395	0.926	rs11076572	chr16:48623621	T/G	cg04672837	chr16:48644449	N4BP1	0.47	5.82	0.34	1.72e-8	Response to tocilizumab in rheumatoid arthritis;
CESC	trans	rs561341	0.609	rs739800	chr17:30190083	T/A	cg20587970	chr11:113659929	NA	0.57	6.96	0.39	2.65e-11	Hip circumference adjusted for BMI;
CESC	cis	rs4242434	0.819	rs6999893	chr8:22465427	T/C	cg03733263	chr8:22462867	KIAA1967	0.88	15.23	0.68	4.59e-38	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CESC	cis	rs672059	1.000	rs672059	chr1:183162539	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.55	7.16	0.4	7.77e-12	Hypertriglyceridemia;
CESC	cis	rs933688	0.509	rs2973472	chr5:90519496	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.43	-5.23	-0.31	3.46e-7	Smoking behavior;
CESC	cis	rs7772486	0.790	rs4280983	chr6:146280790	G/C	cg05347473	chr6:146136440	FBXO30	-0.56	-7.17	-0.4	7.61e-12	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09430954	chr19:46236890	NA	-0.56	-6.39	-0.37	7.64e-10	Gut microbiome composition (summer);
CESC	cis	rs6429082	0.806	rs2382570	chr1:235570523	G/A	cg26050004	chr1:235667680	B3GALNT2	-0.41	-5.32	-0.31	2.19e-7	Adiposity;
CESC	cis	rs9611565	0.694	rs5758365	chr22:41858657	A/G	cg06634786	chr22:41940651	POLR3H	0.74	7.63	0.42	4.36e-13	Vitiligo;
CESC	cis	rs7923452	0.507	rs103441	chr10:30778184	C/T	cg18806716	chr10:30721971	MAP3K8	-0.54	-8.17	-0.45	1.24e-14	Itch intensity from mosquito bite;
CESC	cis	rs17407555	0.779	rs57757169	chr4:10115703	G/A	cg00071950	chr4:10020882	SLC2A9	-0.53	-5.53	-0.32	7.69e-8	Schizophrenia (age at onset);
CESC	cis	rs1801251	0.963	rs7591176	chr2:233581803	C/A	cg25237894	chr2:233734115	C2orf82	0.5	8.36	0.46	3.53e-15	Coronary artery disease;
CESC	cis	rs7520050	0.778	rs3014238	chr1:46090214	A/G	cg03146154	chr1:46216737	IPP	-0.5	-6.67	-0.38	1.5e-10	Red blood cell count;Reticulocyte count;
CESC	cis	rs7666738	0.753	rs1830230	chr4:99026186	G/C	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.58e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10028773	0.568	rs6838457	chr4:120267367	A/G	cg09307838	chr4:120376055	NA	0.76	10.03	0.52	2.87e-20	Educational attainment;
CESC	cis	rs798766	1.000	rs2166580	chr4:1743169	G/A	cg10756475	chr4:1757242	NA	0.47	6.08	0.35	4.14e-9	Bladder cancer;Urinary bladder cancer;
CESC	cis	rs10838687	0.932	rs4752973	chr11:47269159	T/C	cg25783544	chr11:47291846	MADD	0.6	7.47	0.42	1.2e-12	Proinsulin levels;
CESC	cis	rs2130392	0.886	rs2077205	chr4:185637418	C/T	cg21366198	chr4:185655624	MLF1IP	-0.42	-6.12	-0.35	3.29e-9	Kawasaki disease;
CESC	cis	rs1163251	0.902	rs487081	chr1:120217389	G/A	cg19096424	chr1:120255104	PHGDH	0.43	5.22	0.31	3.62e-7	Blood metabolite levels;
CESC	cis	rs826838	0.967	rs11183577	chr12:38781887	A/G	cg26384229	chr12:38710491	ALG10B	0.83	14.6	0.67	8.06e-36	Heart rate;
CESC	cis	rs9914988	0.943	rs9898892	chr17:27150750	T/C	cg20469991	chr17:27169893	C17orf63	-0.48	-5.25	-0.31	3.18e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CESC	cis	rs36051895	0.623	rs10975023	chr9:5239549	A/G	cg02405213	chr9:5042618	JAK2	0.56	6.55	0.37	2.98e-10	Pediatric autoimmune diseases;
CESC	cis	rs1062746	0.738	rs2303764	chr16:87377455	C/G	cg02258303	chr16:87377426	FBXO31	0.47	6.12	0.35	3.34e-9	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
CESC	cis	rs1799949	1.000	rs12944458	chr17:41180772	C/T	cg23758822	chr17:41437982	NA	1.03	14.6	0.67	7.88e-36	Menopause (age at onset);
CESC	cis	rs9905704	0.914	rs2611777	chr17:56826958	A/G	cg12560992	chr17:57184187	TRIM37	0.61	7.09	0.4	1.25e-11	Testicular germ cell tumor;
CESC	cis	rs4604732	0.631	rs12038793	chr1:247624262	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	-0.6	-7.66	-0.43	3.46e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs9287719	0.967	rs10929686	chr2:10743705	A/C	cg00105475	chr2:10696890	NA	0.39	5.69	0.33	3.32e-8	Prostate cancer;
CESC	cis	rs763121	0.813	rs2179143	chr22:39037984	A/G	cg06544989	chr22:39130855	UNC84B	0.47	8.58	0.47	8.2e-16	Menopause (age at onset);
CESC	cis	rs1552244	1.000	rs6786638	chr3:10118075	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.8	-10.48	-0.54	9.87e-22	Alzheimer's disease;
CESC	cis	rs9649465	1.000	rs56396297	chr7:123350535	T/C	cg04330084	chr7:123175371	IQUB	-0.38	-5.18	-0.3	4.34e-7	Migraine;
CESC	cis	rs514406	0.525	rs269291	chr1:53189297	C/T	cg08859206	chr1:53392774	SCP2	-0.58	-7.3	-0.41	3.34e-12	Monocyte count;
CESC	cis	rs910316	1.000	rs876402	chr14:75601862	C/T	cg08847533	chr14:75593920	NEK9	-1.02	-20.0	-0.78	7.09e-55	Height;
CESC	cis	rs6964587	1.000	rs61244255	chr7:91751662	C/T	cg01689657	chr7:91764605	CYP51A1	0.28	5.06	0.3	7.82e-7	Breast cancer;
CESC	cis	rs2243480	1.000	rs1701758	chr7:65470201	T/A	cg18252515	chr7:66147081	NA	-1.13	-10.9	-0.56	4.18e-23	Diabetic kidney disease;
CESC	cis	rs634534	0.622	rs1192168	chr11:65730945	T/G	cg04055107	chr11:65626734	MUS81;CFL1	0.43	5.46	0.32	1.07e-7	Sum eosinophil basophil counts;Eosinophil counts;
CESC	cis	rs116095464	0.558	rs7725227	chr5:233517	G/A	cg10591111	chr5:226296	SDHA	-0.51	-6.32	-0.36	1.13e-9	Breast cancer;
CESC	cis	rs7618501	0.633	rs13060128	chr3:50025028	A/G	cg24308560	chr3:49941425	MST1R	-0.63	-9.14	-0.49	1.64e-17	Intelligence (multi-trait analysis);
CESC	cis	rs9911578	1.000	rs1971659	chr17:57004787	A/G	cg05425664	chr17:57184151	TRIM37	-0.49	-6.81	-0.39	6.39e-11	Intelligence (multi-trait analysis);
CESC	cis	rs7223966	1.000	rs56383601	chr17:61929968	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.51	5.85	0.34	1.45e-8	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs12410462	0.581	rs7543931	chr1:227550976	A/T	cg04117972	chr1:227635322	NA	0.66	5.6	0.33	5.36e-8	Major depressive disorder;
CESC	cis	rs7927592	1.000	rs7927592	chr11:68369960	G/A	cg20283391	chr11:68216788	NA	-0.5	-5.97	-0.34	7.5e-9	Total body bone mineral density;
CESC	cis	rs644799	0.965	rs499076	chr11:95546341	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	9.15	0.49	1.61e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	trans	rs1606974	0.649	rs9973354	chr2:51929410	G/C	cg21066735	chr11:15671806	NA	-0.72	-6.0	-0.35	6.57e-9	Educational attainment (years of education);Educational attainment;
CESC	cis	rs17431357	0.737	rs117725109	chr12:120981551	C/T	cg25045489	chr12:120971538	RNF10	-0.93	-5.46	-0.32	1.1e-7	Insulin resistance/response;
CESC	cis	rs10465746	0.905	rs11163875	chr1:84429605	T/G	cg10977910	chr1:84465055	TTLL7	0.46	6.18	0.35	2.45e-9	Obesity-related traits;
CESC	cis	rs2070488	0.861	rs1858740	chr3:38438372	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.93	16.23	0.71	1.38e-41	Electrocardiographic conduction measures;
CESC	cis	rs6570726	0.967	rs9403707	chr6:145800010	A/G	cg05347473	chr6:146136440	FBXO30	0.42	5.54	0.32	7.36e-8	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs3858526	0.676	rs10838772	chr11:5895754	T/C	cg05234568	chr11:5960015	NA	-0.51	-6.08	-0.35	4.15e-9	DNA methylation (variation);
CESC	cis	rs12946454	0.668	rs4792867	chr17:43249444	C/T	cg10701640	chr17:43249399	NA	0.45	8.4	0.46	2.7e-15	Systolic blood pressure;
CESC	cis	rs7216064	1.000	rs62084240	chr17:65859233	C/A	cg07042672	chr17:66097459	LOC651250	-0.51	-5.22	-0.31	3.55e-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs769267	0.896	rs2315610	chr19:19597240	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	7.47	0.42	1.15e-12	Tonsillectomy;
CESC	cis	rs72781680	0.611	rs72797819	chr2:24351141	T/G	cg06627628	chr2:24431161	ITSN2	-0.67	-6.45	-0.37	5.4e-10	Lymphocyte counts;
CESC	cis	rs2929278	0.561	rs3099045	chr15:43923955	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.52	6.63	0.38	1.82e-10	Schizophrenia;
CESC	cis	rs4234798	0.500	rs7661077	chr4:7219889	C/T	cg18431297	chr4:7219810	SORCS2	0.55	9.27	0.49	6.97e-18	Insulin-like growth factors;
CESC	trans	rs677673	1.000	rs617775	chr20:10478606	T/C	cg16021678	chr13:55475951	NA	0.52	6.47	0.37	4.66e-10	Body mass index (change over time) in chronic obstructive pulmonary disease;
CESC	cis	rs34779708	0.966	rs34776628	chr10:35426324	G/A	cg03585969	chr10:35415529	CREM	0.76	10.3	0.53	3.72e-21	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs936229	0.668	rs67411922	chr15:75187612	A/G	cg10253484	chr15:75165896	SCAMP2	-0.44	-5.03	-0.3	9.07e-7	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CESC	cis	rs875971	1.000	rs2077593	chr7:65892530	A/G	cg10691866	chr7:65817282	TPST1	-0.34	-5.55	-0.32	6.87e-8	Aortic root size;
CESC	cis	rs8141529	0.673	rs132548	chr22:29317559	C/G	cg15103426	chr22:29168792	CCDC117	-0.62	-8.21	-0.45	9.64e-15	Lymphocyte counts;
CESC	cis	rs2075371	1.000	rs2544213	chr7:133982867	G/C	cg11752832	chr7:134001865	SLC35B4	0.54	7.01	0.4	1.96e-11	Mean platelet volume;
CESC	cis	rs4237845	0.514	rs4760339	chr12:58268149	G/T	cg02175503	chr12:58329896	NA	0.51	6.08	0.35	4.27e-9	Intelligence (multi-trait analysis);
CESC	cis	rs10504229	0.683	rs73603877	chr8:58108428	C/T	cg22535103	chr8:58192502	C8orf71	-0.77	-8.76	-0.47	2.37e-16	Developmental language disorder (linguistic errors);
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg21800906	chr11:32914818	QSER1	0.48	6.45	0.37	5.2400000000000005e-10	Systemic lupus erythematosus;
CESC	cis	rs1552244	0.572	rs41464050	chr3:10158393	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.75	8.51	0.46	1.26e-15	Alzheimer's disease;
CESC	cis	rs10791323	0.628	rs2853117	chr11:133705266	T/G	cg06766960	chr11:133703094	NA	-0.39	-5.6	-0.33	5.25e-8	Childhood ear infection;
CESC	cis	rs7044106	0.791	rs3904196	chr9:123480369	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.73	10.79	0.55	9.56e-23	Hip circumference adjusted for BMI;
CESC	cis	rs11792861	0.962	rs72607162	chr9:111793719	T/C	cg14384093	chr9:111878565	C9orf5	-0.41	-5.09	-0.3	6.73e-7	Menarche (age at onset);
CESC	cis	rs1185460	0.967	rs1168568	chr11:118949799	G/A	cg23280166	chr11:118938394	VPS11	0.55	7.46	0.42	1.25e-12	Coronary artery disease;
CESC	cis	rs6690583	0.623	rs61769366	chr1:85534062	G/A	cg22153463	chr1:85462885	MCOLN2	0.71	6.54	0.37	3.23e-10	Serum sulfate level;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03849754	chr1:220220103	EPRS	-0.53	-6.13	-0.35	3.14e-9	Gut microbiome composition (summer);
CESC	cis	rs12497850	0.627	rs4974078	chr3:49009386	C/T	cg03060546	chr3:49711283	APEH	0.62	8.58	0.47	8.13e-16	Parkinson's disease;
CESC	cis	rs7666738	0.546	rs1813970	chr4:98887167	A/G	cg17366294	chr4:99064904	C4orf37	-0.48	-6.05	-0.35	4.89e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2933343	0.649	rs789219	chr3:128592520	G/A	cg25356066	chr3:128598488	ACAD9	0.61	8.67	0.47	4.37e-16	IgG glycosylation;
CESC	cis	rs7590720	0.819	rs1344694	chr2:216893637	T/G	cg12620499	chr2:216877984	MREG	0.94	14.24	0.66	1.49e-34	Alcohol dependence;
CESC	cis	rs6540556	0.643	rs2236903	chr1:209883480	A/T	cg05527609	chr1:210001259	C1orf107	-0.45	-5.32	-0.31	2.19e-7	Red blood cell count;
CESC	cis	rs1799949	1.000	rs1060915	chr17:41234470	A/G	cg25072359	chr17:41440525	NA	0.48	6.46	0.37	4.9e-10	Menopause (age at onset);
CESC	cis	rs12618769	0.652	rs11896729	chr2:99225645	T/C	cg10123293	chr2:99228465	UNC50	0.41	5.38	0.31	1.68e-7	Bipolar disorder;
CESC	cis	rs1552244	1.000	rs66797209	chr3:10078526	G/A	cg08888203	chr3:10149979	C3orf24	0.46	5.9	0.34	1.11e-8	Alzheimer's disease;
CESC	cis	rs12410462	0.581	rs7543931	chr1:227550976	A/T	cg10327440	chr1:227177885	CDC42BPA	-0.66	-5.46	-0.32	1.11e-7	Major depressive disorder;
CESC	cis	rs4713118	0.516	rs6931858	chr6:28078411	A/T	cg23161317	chr6:28129485	ZNF389	0.49	6.02	0.35	5.87e-9	Parkinson's disease;
CESC	cis	rs9611565	0.802	rs9611577	chr22:41793090	T/G	cg06481639	chr22:41940642	POLR3H	-0.59	-6.29	-0.36	1.32e-9	Vitiligo;
CESC	cis	rs7772486	0.597	rs2485631	chr6:146190077	G/C	cg13319975	chr6:146136371	FBXO30	-0.42	-5.03	-0.3	9.05e-7	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7584330	0.518	rs7585969	chr2:238439073	G/A	cg14458575	chr2:238380390	NA	0.6	5.91	0.34	1.07e-8	Prostate cancer;
CESC	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg06873352	chr17:61820015	STRADA	0.71	12.33	0.6	6.72e-28	Prudent dietary pattern;
CESC	cis	rs4233802	1.000	rs4577299	chr2:151138798	A/C	cg25300694	chr2:151184358	NA	-0.81	-7.28	-0.41	3.71e-12	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04083751	chr10:73533414	CDH23;C10orf54	0.55	6.32	0.36	1.13e-9	Gut microbiome composition (summer);
CESC	cis	rs10751667	0.961	rs7482484	chr11:927020	C/T	cg20946044	chr11:1010712	AP2A2	-0.43	-5.63	-0.33	4.57e-8	Alzheimer's disease (late onset);
CESC	cis	rs6724607	1.000	rs4321393	chr2:191452899	G/T	cg27211696	chr2:191398769	TMEM194B	0.52	7.75	0.43	2e-13	Pulse pressure;
CESC	cis	rs1008375	0.966	rs11733730	chr4:17625209	G/C	cg04450456	chr4:17643702	FAM184B	0.38	5.42	0.32	1.35e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs7666738	0.830	rs6848404	chr4:98946750	A/G	cg17366294	chr4:99064904	C4orf37	0.6	8.53	0.46	1.15e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6121246	0.529	rs2889528	chr20:30210021	C/T	cg13852791	chr20:30311386	BCL2L1	0.59	5.49	0.32	9.22e-8	Mean corpuscular hemoglobin;
CESC	trans	rs13035304	0.773	rs6727916	chr2:130510147	A/G	cg18827756	chr15:42130735	JMJD7-PLA2G4B;PLA2G4B	0.45	6.21	0.36	1.98e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
CESC	cis	rs34779708	0.931	rs58159560	chr10:35351249	C/T	cg03585969	chr10:35415529	CREM	0.77	10.01	0.52	3.32e-20	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs4727027	0.866	rs7778766	chr7:148806729	A/G	cg23583168	chr7:148888333	NA	-0.74	-10.71	-0.55	1.73e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs6502050	0.835	rs9911379	chr17:80114529	A/G	cg23985595	chr17:80112537	CCDC57	-0.41	-6.53	-0.37	3.38e-10	Life satisfaction;
CESC	cis	rs9322193	0.923	rs9322214	chr6:150025122	C/T	cg13206674	chr6:150067644	NUP43	0.43	6.02	0.35	5.84e-9	Lung cancer;
CESC	cis	rs9916302	0.861	rs9903363	chr17:37499604	C/G	cg07936489	chr17:37558343	FBXL20	0.81	11.8	0.59	4.01e-26	Glomerular filtration rate (creatinine);
CESC	cis	rs2845885	0.793	rs3751120	chr11:63884453	C/T	cg26318627	chr11:63887540	MACROD1	-0.43	-5.12	-0.3	5.89e-7	Body mass index;
CESC	cis	rs3771570	1.000	rs62193207	chr2:242318501	G/C	cg21155796	chr2:242212141	HDLBP	0.6	5.27	0.31	2.89e-7	Prostate cancer;
CESC	cis	rs7927592	0.956	rs10896348	chr11:68357368	T/C	cg16797656	chr11:68205561	LRP5	0.41	6.02	0.35	5.92e-9	Total body bone mineral density;
CESC	cis	rs1552244	1.000	rs6804473	chr3:10060425	C/T	cg00166722	chr3:10149974	C3orf24	0.51	6.38	0.37	7.76e-10	Alzheimer's disease;
CESC	cis	rs9658691	0.607	rs12411452	chr10:90780607	G/A	cg03111039	chr10:90751583	FAS;ACTA2	-0.57	-5.19	-0.3	4.25e-7	Mosquito bite size;
CESC	cis	rs11048434	0.736	rs1805732	chr12:9090892	A/G	cg23795048	chr12:9217529	LOC144571	-0.38	-5.81	-0.34	1.77e-8	Sjögren's syndrome;
CESC	cis	rs344364	0.511	rs2982449	chr16:1947878	C/G	cg03013636	chr16:1946785	NA	0.48	6.62	0.38	2.02e-10	Glomerular filtration rate in chronic kidney disease;
CESC	trans	rs629535	0.748	rs689410	chr8:70037558	G/A	cg21567404	chr3:27674614	NA	0.93	11.25	0.57	2.83e-24	Dupuytren's disease;
CESC	cis	rs9611565	0.649	rs202657	chr22:41844786	G/T	cg06634786	chr22:41940651	POLR3H	0.69	6.93	0.39	3.16e-11	Vitiligo;
CESC	cis	rs7666738	0.861	rs10018654	chr4:99002226	A/G	cg03676636	chr4:99064102	C4orf37	0.34	5.23	0.31	3.46e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4665809	0.525	rs10865402	chr2:26535383	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.58	-6.88	-0.39	4.37e-11	Gut microbiome composition (summer);
CESC	cis	rs694739	1.000	rs646153	chr11:64089588	C/T	cg23796481	chr11:64053134	BAD;GPR137	0.73	9.32	0.5	4.75e-18	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CESC	cis	rs2304069	0.954	rs6861548	chr5:149384680	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.91	11.57	0.58	2.48e-25	HIV-1 control;
CESC	cis	rs4665809	1.000	rs4233710	chr2:26291565	G/A	cg26314531	chr2:26401878	FAM59B	-0.76	-8.49	-0.46	1.47e-15	Gut microbiome composition (summer);
CESC	cis	rs1336900	0.641	rs6587756	chr1:150546865	A/T	cg18016565	chr1:150552671	MCL1	-0.36	-5.36	-0.31	1.83e-7	Blood protein levels;
CESC	cis	rs11048434	0.761	rs2110190	chr12:9128289	A/C	cg23795048	chr12:9217529	LOC144571	0.34	5.05	0.3	8.31e-7	Sjögren's syndrome;
CESC	cis	rs7219021	0.705	rs12939844	chr17:47025559	T/A	cg16584676	chr17:46985605	UBE2Z	-0.62	-7.12	-0.4	1.04e-11	Schizophrenia or bipolar disorder;
CESC	cis	rs7528419	0.895	rs583104	chr1:109821307	G/T	cg00908766	chr1:109817496	CELSR2	0.34	5.05	0.3	8.35e-7	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06725760	chr10:1102461	WDR37	0.57	6.31	0.36	1.18e-9	Gut microbiome composition (summer);
CESC	cis	rs34172651	0.545	rs7185291	chr16:24714679	C/T	cg06028605	chr16:24865363	SLC5A11	-0.39	-6.2	-0.36	2.12e-9	Intelligence (multi-trait analysis);
CESC	cis	rs2251381	0.778	rs722013	chr21:30549245	G/T	cg24692254	chr21:30365293	RNF160	0.78	10.72	0.55	1.6400000000000001e-22	Selective IgA deficiency;
CESC	cis	rs977987	0.806	rs11640674	chr16:75394944	A/G	cg03315344	chr16:75512273	CHST6	0.39	5.64	0.33	4.3e-8	Dupuytren's disease;
CESC	cis	rs854765	0.583	rs9908832	chr17:17871068	C/T	cg09796270	chr17:17721594	SREBF1	0.41	5.65	0.33	4.08e-8	Total body bone mineral density;
CESC	cis	rs9322193	0.923	rs11155674	chr6:150032247	T/C	cg13206674	chr6:150067644	NUP43	0.46	6.59	0.38	2.43e-10	Lung cancer;
CESC	cis	rs8077889	0.917	rs9901676	chr17:41911818	T/C	cg26893861	chr17:41843967	DUSP3	0.76	10.25	0.53	5.58e-21	Triglycerides;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg10620530	chr9:139922595	C9orf139;ABCA2	0.45	6.14	0.35	3.06e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs7937682	0.883	rs529529	chr11:111461128	C/T	cg22437258	chr11:111473054	SIK2	0.71	9.09	0.49	2.34e-17	Primary sclerosing cholangitis;
CESC	cis	rs561341	0.941	rs8066156	chr17:30361629	A/G	cg00745463	chr17:30367425	LRRC37B	-0.6	-6.13	-0.35	3.18e-9	Hip circumference adjusted for BMI;
CESC	cis	rs7932354	0.528	rs7946709	chr11:47100796	G/T	cg25783544	chr11:47291846	MADD	-0.41	-5.46	-0.32	1.08e-7	Bone mineral density (hip);Bone mineral density;
CESC	cis	rs2576037	0.507	rs2571019	chr18:44585287	A/T	cg19077165	chr18:44547161	KATNAL2	0.55	8.06	0.44	2.61e-14	Personality dimensions;
CESC	cis	rs2845885	0.793	rs3751120	chr11:63884453	C/T	cg05555928	chr11:63887634	MACROD1	-0.54	-6.18	-0.35	2.43e-9	Body mass index;
CESC	cis	rs11958404	0.932	rs6895484	chr5:157429159	T/C	cg05962755	chr5:157440814	NA	0.62	6.53	0.37	3.41e-10	IgG glycosylation;
CESC	cis	rs9467711	0.606	rs1978	chr6:26377573	A/T	cg12826209	chr6:26865740	GUSBL1	0.66	5.65	0.33	4.13e-8	Autism spectrum disorder or schizophrenia;
CESC	cis	rs6976053	0.518	rs314357	chr7:100410069	A/G	cg03098644	chr7:100410630	EPHB4	-0.46	-5.88	-0.34	1.2e-8	Plasminogen activator inhibitor type 1 levels (PAI-1);
CESC	cis	rs826838	0.804	rs6580755	chr12:39159190	C/T	cg13010199	chr12:38710504	ALG10B	0.58	8.12	0.45	1.73e-14	Heart rate;
CESC	cis	rs1788820	0.957	rs1652340	chr18:21099831	A/C	cg14672496	chr18:21087552	C18orf8	0.53	7.19	0.4	6.58e-12	Body mass index;
CESC	cis	rs4132509	0.948	rs12048930	chr1:243940076	C/T	cg21452805	chr1:244014465	NA	0.52	6.3	0.36	1.22e-9	RR interval (heart rate);
CESC	cis	rs2836974	0.863	rs8128026	chr21:40533702	T/C	cg11890956	chr21:40555474	PSMG1	1.19	23.04	0.82	3.05e-65	Cognitive function;
CESC	cis	rs8044868	0.586	rs6499564	chr16:72189655	G/A	cg16558253	chr16:72132732	DHX38	-0.39	-5.94	-0.34	8.84e-9	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CESC	cis	rs10504229	0.683	rs56058640	chr8:58128862	C/T	cg24829409	chr8:58192753	C8orf71	-0.58	-7.2	-0.4	6.31e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs7635838	0.892	rs4684775	chr3:11436413	A/G	cg00170343	chr3:11313890	ATG7	0.41	5.51	0.32	8.61e-8	HDL cholesterol;
CESC	cis	rs3809863	0.602	rs11650072	chr17:45393665	A/G	cg25173405	chr17:45401733	C17orf57	-0.53	-6.89	-0.39	4.16e-11	Glaucoma (primary open-angle);
CESC	cis	rs769267	0.930	rs10422819	chr19:19643028	C/A	cg03709012	chr19:19516395	GATAD2A	1.01	15.26	0.68	3.79e-38	Tonsillectomy;
CESC	cis	rs9894429	0.538	rs9747080	chr17:79606704	A/G	cg13777783	chr17:79615861	NA	-0.36	-5.81	-0.34	1.77e-8	Eye color traits;
CESC	cis	rs763014	0.931	rs2071980	chr16:626346	A/C	cg09263875	chr16:632152	PIGQ	0.67	10.97	0.56	2.57e-23	Height;
CESC	cis	rs7208859	0.673	rs216409	chr17:28906269	C/T	cg14008862	chr17:28927542	LRRC37B2	-0.64	-5.8	-0.34	1.91e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs6502050	0.698	rs36043222	chr17:80117822	G/T	cg11859384	chr17:80120422	CCDC57	-0.38	-5.18	-0.3	4.43e-7	Life satisfaction;
CESC	cis	rs12155623	0.592	rs12682003	chr8:49865454	G/T	cg22283653	chr8:49824208	NA	0.37	5.4	0.32	1.45e-7	Sudden cardiac arrest;
CESC	trans	rs10242455	0.702	rs74347626	chr7:99206021	G/T	cg09045935	chr12:6379348	NA	0.9	6.63	0.38	1.85e-10	Blood metabolite levels;
CESC	cis	rs11252926	0.583	rs4881333	chr10:519164	G/C	cg16386425	chr10:429943	DIP2C	-0.47	-5.95	-0.34	8.27e-9	Psychosis in Alzheimer's disease;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg22403471	chr8:68256159	ARFGEF1	0.48	6.36	0.36	8.96e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs8060686	0.698	rs8044558	chr16:68210165	T/C	cg26727032	chr16:67993705	SLC12A4	-0.51	-6.18	-0.36	2.35e-9	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg25517151	chr20:30467953	TTLL9	-0.43	-5.2	-0.3	3.91e-7	Ulcerative colitis;
CESC	cis	rs644799	1.000	rs617999	chr11:95589935	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.52	6.2	0.36	2.17e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs3096299	0.967	rs2911256	chr16:89485096	G/C	cg16743903	chr16:89593216	SPG7	-0.43	-5.53	-0.32	7.51e-8	Multiple myeloma (IgH translocation);
CESC	cis	rs9325144	0.581	rs2730929	chr12:38942739	T/C	cg26384229	chr12:38710491	ALG10B	-0.67	-10.82	-0.55	7.9399999999999994e-23	Morning vs. evening chronotype;
CESC	cis	rs4665809	1.000	rs4665308	chr2:26330514	C/A	cg04944784	chr2:26401820	FAM59B	-0.66	-7.62	-0.42	4.62e-13	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27176796	chr16:84495427	ATP2C2	-0.53	-6.44	-0.37	5.58e-10	Gut microbiome composition (summer);
CESC	cis	rs287982	1.000	rs1119633	chr2:9967532	G/A	cg10881225	chr2:9984929	TAF1B	0.42	5.31	0.31	2.27e-7	Nonsyndromic cleft lip with cleft palate;
CESC	cis	rs7539542	0.556	rs2000331	chr1:202857578	G/T	cg19681188	chr1:202830198	LOC148709	0.44	5.62	0.33	4.71e-8	Mean platelet volume;
CESC	cis	rs34172651	0.517	rs35560136	chr16:24788915	T/A	cg04756594	chr16:24857601	SLC5A11	0.5	5.8	0.34	1.92e-8	Intelligence (multi-trait analysis);
CESC	cis	rs7666738	0.761	rs13136913	chr4:98998031	C/T	cg17366294	chr4:99064904	C4orf37	0.6	8.61	0.47	6.47e-16	Colonoscopy-negative controls vs population controls;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg23422060	chr21:43916508	RSPH1	-0.49	-6.71	-0.38	1.18e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs9611565	0.592	rs5996038	chr22:41965300	T/C	cg03806693	chr22:41940476	POLR3H	-0.97	-11.84	-0.59	2.96e-26	Vitiligo;
CESC	trans	rs1814175	0.654	rs1164676	chr11:49324868	T/C	cg03929089	chr4:120376271	NA	0.72	9.88	0.52	8.34e-20	Height;
CESC	trans	rs916888	0.610	rs199453	chr17:44800946	C/T	cg22433210	chr17:43662623	NA	0.6	7.75	0.43	2.02e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs55788414	1.000	rs9921827	chr16:81181869	T/C	cg06400318	chr16:81190750	PKD1L2	-0.59	-7.04	-0.4	1.62e-11	Left ventricular obstructive tract defect (maternal effect);
CESC	cis	rs4689388	0.926	rs10937719	chr4:6295322	C/G	cg00701064	chr4:6280414	WFS1	0.68	11.33	0.57	1.53e-24	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs13385	0.769	rs7715649	chr5:139605517	G/A	cg26211634	chr5:139558579	C5orf32	0.47	5.16	0.3	4.78e-7	Atrial fibrillation;
CESC	cis	rs6952808	0.656	rs12699646	chr7:2093162	T/G	cg21782813	chr7:2030301	MAD1L1	-0.48	-6.86	-0.39	4.73e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs7264396	0.513	rs2425092	chr20:34306815	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.89	-10.65	-0.55	2.79e-22	Total cholesterol levels;
CESC	cis	rs7264396	0.563	rs6060580	chr20:34310512	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.66	6.86	0.39	4.97e-11	Total cholesterol levels;
CESC	cis	rs72781680	0.611	rs55788848	chr2:24268721	C/T	cg08917208	chr2:24149416	ATAD2B	0.63	6.09	0.35	3.87e-9	Lymphocyte counts;
CESC	cis	rs1729951	0.546	rs835632	chr3:136676525	A/T	cg25687071	chr3:136751404	NA	0.38	5.1	0.3	6.56e-7	Neuroticism;
CESC	cis	rs8031584	0.678	rs4779496	chr15:31151054	A/G	cg14829155	chr15:31115871	NA	-0.76	-10.62	-0.55	3.5e-22	Huntington's disease progression;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04800816	chr11:93210603	NA	-0.59	-6.5	-0.37	3.95e-10	Gut microbiome composition (summer);
CESC	cis	rs2997447	0.761	rs56299762	chr1:26441638	G/A	cg24596570	chr1:26146463	FAM54B;LOC646471	0.62	5.41	0.32	1.41e-7	QRS complex (12-leadsum);
CESC	cis	rs3785574	0.962	rs16947051	chr17:61790917	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	1.1	19.8	0.77	3.59e-54	Height;
CESC	cis	rs9902453	1.000	rs8065059	chr17:28417376	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.62	-7.79	-0.43	1.51e-13	Coffee consumption (cups per day);
CESC	cis	rs7772486	0.727	rs6941429	chr6:145952283	G/A	cg05347473	chr6:146136440	FBXO30	0.58	7.37	0.41	2.23e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7131987	0.644	rs6487817	chr12:29548210	G/A	cg09582351	chr12:29534625	ERGIC2	0.35	5.52	0.32	8.2e-8	QT interval;
CESC	cis	rs4660306	0.672	rs532639	chr1:46024481	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.61	-7.6	-0.42	5.15e-13	Homocysteine levels;
CESC	cis	rs8070128	0.568	rs3935505	chr17:17882020	T/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.55	6.84	0.39	5.57e-11	Total body bone mineral density;
CESC	cis	rs9462846	0.959	rs9471960	chr6:42884750	A/C	cg02353165	chr6:42928485	GNMT	0.45	5.23	0.31	3.51e-7	Blood protein levels;
CESC	cis	rs888194	0.677	rs10850139	chr12:109875934	A/C	cg19025524	chr12:109796872	NA	-0.41	-6.24	-0.36	1.75e-9	Neuroticism;
CESC	cis	rs2425143	0.908	rs11697087	chr20:34427583	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.63	5.22	0.31	3.67e-7	Blood protein levels;
CESC	trans	rs1814175	0.586	rs10769603	chr11:49688837	T/C	cg15704280	chr7:45808275	SEPT13	-0.97	-15.42	-0.69	1.02e-38	Height;
CESC	cis	rs6502050	0.731	rs76421195	chr17:80109326	T/C	cg11859384	chr17:80120422	CCDC57	-0.4	-5.33	-0.31	2.14e-7	Life satisfaction;
CESC	cis	rs11785400	0.793	rs4736362	chr8:143741381	G/A	cg24634471	chr8:143751801	JRK	0.44	5.61	0.33	5.15e-8	Schizophrenia;
CESC	cis	rs7116495	0.609	rs1892920	chr11:71702431	A/G	cg18441811	chr11:71824068	C11orf51	-0.78	-5.16	-0.3	4.95e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs9486719	1.000	rs9400016	chr6:96940883	G/T	cg18709589	chr6:96969512	KIAA0776	-0.54	-5.95	-0.34	8.34e-9	Migraine;Coronary artery disease;
CESC	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg26338869	chr17:61819248	STRADA	0.67	8.78	0.47	2.04e-16	Prudent dietary pattern;
CESC	trans	rs9325144	0.510	rs7952795	chr12:38720686	C/T	cg23762105	chr12:34175262	ALG10	-0.48	-6.38	-0.36	7.96e-10	Morning vs. evening chronotype;
CESC	cis	rs11650494	0.710	rs11653775	chr17:47472365	A/G	cg08112188	chr17:47440006	ZNF652	0.84	6.33	0.36	1.02e-9	Prostate cancer;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg14958951	chr2:178128766	NFE2L2	-0.58	-7.16	-0.4	7.88e-12	Ulcerative colitis;
CESC	cis	rs7520050	0.966	rs12139630	chr1:46350935	A/G	cg03146154	chr1:46216737	IPP	-0.48	-6.22	-0.36	1.94e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs17384381	0.861	rs35240561	chr1:85775217	C/G	cg16011679	chr1:85725395	C1orf52	0.88	8.98	0.48	5.04e-17	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6754311	0.834	rs12465802	chr2:136381348	A/G	cg07169764	chr2:136633963	MCM6	-0.59	-6.5	-0.37	3.89e-10	Mosquito bite size;
CESC	cis	rs2066819	0.892	rs75274818	chr12:56627619	A/G	cg26714650	chr12:56694279	CS	-1.54	-10.81	-0.55	8.19e-23	Psoriasis vulgaris;
CESC	cis	rs9733	0.519	rs3768005	chr1:150680988	A/T	cg22823121	chr1:150693482	HORMAD1	0.47	6.97	0.39	2.5e-11	Tonsillectomy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17748167	chr1:31769917	ZCCHC17;SNRNP40	0.62	7.68	0.43	3e-13	Gut microbiome composition (summer);
CESC	cis	rs1538970	1.000	rs1538970	chr1:45847562	G/A	cg05343316	chr1:45956843	TESK2	0.82	11.49	0.58	4.44e-25	Platelet count;
CESC	cis	rs16895831	0.519	rs16895856	chr6:42564921	A/C	cg10605015	chr6:42532144	UBR2	-0.52	-5.76	-0.33	2.32e-8	Granulocyte percentage of myeloid white cells;Neutrophil percentage of white cells;Eosinophil percentage of white cells;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Neutrophil count;Sum basophil neutrophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
CESC	cis	rs9322193	0.884	rs2095375	chr6:150128173	C/A	cg05861140	chr6:150128134	PCMT1	-0.37	-5.34	-0.31	2.02e-7	Lung cancer;
CESC	trans	rs11098499	0.955	rs13129661	chr4:120152909	C/G	cg25214090	chr10:38739885	LOC399744	0.65	8.59	0.47	7.54e-16	Corneal astigmatism;
CESC	cis	rs11247915	0.600	rs3795686	chr1:26582091	G/A	cg00852783	chr1:26633632	UBXN11	0.41	5.06	0.3	7.91e-7	Obesity-related traits;
CESC	cis	rs7666738	0.830	rs6854902	chr4:99033416	T/G	cg24818145	chr4:99064322	C4orf37	0.39	5.09	0.3	6.95e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2573652	0.722	rs12898366	chr15:100543067	C/T	cg09918751	chr15:100517450	ADAMTS17	-0.31	-5.73	-0.33	2.65e-8	Height;
CESC	cis	rs965469	0.779	rs6051771	chr20:3328271	A/G	cg17110299	chr20:3385021	C20orf194	0.4	5.25	0.31	3.1e-7	IFN-related cytopenia;
CESC	cis	rs4727963	0.755	rs1525471	chr7:122733962	C/T	cg03640110	chr7:122635026	TAS2R16	0.41	6.39	0.37	7.58e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
CESC	cis	rs2933343	0.761	rs789225	chr3:128600229	G/A	cg25356066	chr3:128598488	ACAD9	0.63	8.94	0.48	6.95e-17	IgG glycosylation;
CESC	cis	rs4500972	1	rs4500972	chr2:73767897	G/A	cg20560298	chr2:73613845	ALMS1	-0.46	-6.23	-0.36	1.8e-9	Glomerular filtration rate (creatinine);
CESC	trans	rs7726839	0.540	rs4957083	chr5:659343	T/C	cg25482853	chr8:67687455	SGK3	0.93	9.54	0.51	9.85e-19	Obesity-related traits;
CESC	cis	rs7020830	0.898	rs308495	chr9:37277603	G/T	cg14294708	chr9:37120828	ZCCHC7	1.12	20.6	0.78	5.91e-57	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09248284	chr2:27851818	CCDC121;GPN1	0.6	7.05	0.4	1.6e-11	Gut microbiome composition (summer);
CESC	cis	rs17253792	0.822	rs74940664	chr14:56135065	A/G	cg01858014	chr14:56050164	KTN1	-0.97	-7.54	-0.42	7.36e-13	Putamen volume;
CESC	cis	rs929596	0.556	rs35984508	chr2:234587852	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.43	-5.28	-0.31	2.75e-7	Total bilirubin levels in HIV-1 infection;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14697246	chr3:48487981	ATRIP	0.58	6.37	0.36	8.13e-10	Gut microbiome composition (summer);
CESC	cis	rs2836974	0.867	rs77959119	chr21:40542768	G/A	cg17971929	chr21:40555470	PSMG1	1.05	15.27	0.68	3.41e-38	Cognitive function;
CESC	cis	rs6500602	0.674	rs7191664	chr16:4541924	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.4	5.78	0.33	2.05e-8	Schizophrenia;
CESC	cis	rs11146838	1	rs11146838	chr10:39149977	A/T	cg18963800	chr10:38644991	HSD17B7P2	-0.44	-5.48	-0.32	9.9e-8	Breast cancer;
CESC	cis	rs597539	0.617	rs686348	chr11:68636996	A/G	cg04772025	chr11:68637568	NA	0.55	6.49	0.37	4.17e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	trans	rs7615952	0.512	rs34651730	chr3:125358640	T/C	cg21747405	chr11:67723411	NA	-0.44	-6.69	-0.38	1.3100000000000001e-10	Blood pressure (smoking interaction);
CESC	cis	rs2204008	0.582	rs11179135	chr12:38204689	A/C	cg13010199	chr12:38710504	ALG10B	0.53	6.43	0.37	5.94e-10	Bladder cancer;
CESC	cis	rs2274273	0.967	rs8009670	chr14:55583477	G/A	cg04306507	chr14:55594613	LGALS3	0.31	6.29	0.36	1.32e-9	Protein biomarker;
CESC	cis	rs9831754	0.526	rs11927217	chr3:78341723	A/G	cg06138941	chr3:78371609	NA	-0.45	-5.96	-0.34	8.03e-9	Calcium levels;
CESC	cis	rs9640161	0.711	rs3800781	chr7:150027324	T/A	cg21361702	chr7:150065534	REPIN1	0.47	5.03	0.3	8.98e-7	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs6831352	0.725	rs2602846	chr4:100025151	T/A	cg13256891	chr4:100009986	ADH5	0.75	8.03	0.44	3.21e-14	Alcohol dependence;
CESC	cis	rs763121	0.853	rs2076028	chr22:39150450	G/A	cg06544989	chr22:39130855	UNC84B	0.51	9.01	0.48	4.1e-17	Menopause (age at onset);
CESC	cis	rs1538970	0.816	rs12029322	chr1:45970446	C/T	cg06784218	chr1:46089804	CCDC17	0.37	5.9	0.34	1.11e-8	Platelet count;
CESC	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg17178900	chr1:205818956	PM20D1	0.8	13.19	0.63	7.15e-31	Menarche (age at onset);
CESC	cis	rs6674176	0.569	rs11210935	chr1:44369444	G/A	cg12908607	chr1:44402522	ARTN	-0.43	-5.96	-0.34	7.83e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs6893300	0.506	rs35320050	chr5:179131013	C/T	cg14593053	chr5:179126677	CANX	0.59	8.53	0.46	1.16e-15	Resting heart rate;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg11656663	chr1:202976539	TMEM183A;TMEM183B	-0.51	-6.18	-0.35	2.38e-9	Ulcerative colitis;
CESC	cis	rs12824058	0.844	rs7956408	chr12:130807547	A/T	cg24838063	chr12:130822603	PIWIL1	-0.48	-6.92	-0.39	3.41e-11	Menopause (age at onset);
CESC	cis	rs5758659	0.714	rs5751216	chr22:42508937	G/T	cg04733989	chr22:42467013	NAGA	-0.45	-6.23	-0.36	1.83e-9	Cognitive function;
CESC	cis	rs1594829	0.553	rs2046225	chr8:26151802	A/C	cg11498726	chr8:26250323	BNIP3L	0.42	6.3	0.36	1.21e-9	Height;
CESC	cis	rs17021463	0.676	rs62320932	chr4:95307037	C/T	cg11021082	chr4:95130006	SMARCAD1	0.52	7.18	0.4	6.91e-12	Testicular germ cell tumor;
CESC	cis	rs6963495	0.818	rs55983796	chr7:105170941	C/T	cg13798780	chr7:105162888	PUS7	0.77	7.87	0.44	9.18e-14	Bipolar disorder (body mass index interaction);
CESC	cis	rs2625529	0.652	rs2957724	chr15:72248474	A/C	cg16672083	chr15:72433130	SENP8	0.41	6.25	0.36	1.61e-9	Red blood cell count;
CESC	cis	rs7259376	0.936	rs2195964	chr19:22538338	C/T	cg02657401	chr19:22469223	NA	-0.25	-5.08	-0.3	7.02e-7	Menopause (age at onset);
CESC	cis	rs4234798	1.000	rs4689088	chr4:7222253	G/A	cg18431297	chr4:7219810	SORCS2	0.47	7.59	0.42	5.63e-13	Insulin-like growth factors;
CESC	cis	rs611744	0.647	rs2597658	chr8:109256014	C/T	cg21045802	chr8:109455806	TTC35	0.51	6.2	0.36	2.15e-9	Dupuytren's disease;
CESC	cis	rs1448094	0.511	rs10506918	chr12:86227913	A/G	cg00310523	chr12:86230176	RASSF9	-0.35	-5.52	-0.32	8.27e-8	Major depressive disorder;
CESC	trans	rs6084875	0.641	rs4815737	chr20:4722770	C/G	cg10192164	chr16:30419175	ZNF771	-0.5	-6.16	-0.35	2.7e-9	Systemic lupus erythematosus;
CESC	cis	rs6701037	0.512	rs4650716	chr1:175128711	C/A	cg00321850	chr1:175162397	KIAA0040	0.46	6.61	0.38	2.15e-10	Alcohol dependence;
CESC	cis	rs10504073	0.584	rs10957356	chr8:49980634	G/A	cg00325661	chr8:49890786	NA	0.58	8.69	0.47	3.86e-16	Blood metabolite ratios;
CESC	cis	rs7666738	0.753	rs13111199	chr4:98953705	A/G	cg17366294	chr4:99064904	C4orf37	0.6	8.47	0.46	1.72e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2288073	0.965	rs36101491	chr2:24387532	C/T	cg20701182	chr2:24300061	SF3B14	0.49	5.4	0.31	1.49e-7	Venous thromboembolism (SNP x SNP interaction);
CESC	cis	rs1355223	0.867	rs7925421	chr11:34681677	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.49	-6.41	-0.37	6.59e-10	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs17067123	1.000	rs17067123	chr4:180048362	C/T	cg26610307	chr4:180072759	NA	-0.56	-6.06	-0.35	4.63e-9	Response to hepatitis C treatment;
CESC	cis	rs66573146	0.656	rs111560662	chr4:6952766	C/T	cg00086871	chr4:6988644	TBC1D14	0.97	5.99	0.35	6.8e-9	Granulocyte percentage of myeloid white cells;
CESC	cis	rs1065852	0.526	rs9607869	chr22:42418110	T/A	cg22189786	chr22:42395067	WBP2NL	0.45	5.65	0.33	4.07e-8	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
CESC	cis	rs9311474	0.508	rs7614498	chr3:52618941	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.6	8.5	0.46	1.36e-15	Electroencephalogram traits;
CESC	trans	rs1973993	0.745	rs986427	chr1:96932736	A/G	cg10631902	chr5:14652156	NA	-0.5	-6.65	-0.38	1.7e-10	Weight;
CESC	cis	rs6952808	0.689	rs4719391	chr7:2048136	T/C	cg21782813	chr7:2030301	MAD1L1	0.5	7.18	0.4	6.92e-12	Bipolar disorder and schizophrenia;
CESC	cis	rs7560272	0.538	rs12233115	chr2:73931891	G/A	cg20560298	chr2:73613845	ALMS1	0.47	6.47	0.37	4.84e-10	Schizophrenia;
CESC	cis	rs7618501	0.540	rs11130241	chr3:50131459	A/T	cg24308560	chr3:49941425	MST1R	0.6	8.57	0.47	8.95e-16	Intelligence (multi-trait analysis);
CESC	cis	rs4803468	0.967	rs3826713	chr19:41892269	C/T	cg14132834	chr19:41945861	ATP5SL	-0.56	-6.91	-0.39	3.57e-11	Height;
CESC	cis	rs72781680	1.000	rs72781679	chr2:24237712	G/A	cg08917208	chr2:24149416	ATAD2B	1.13	9.83	0.52	1.17e-19	Lymphocyte counts;
CESC	cis	rs1215050	0.740	rs804051	chr4:98935935	A/T	cg17366294	chr4:99064904	C4orf37	-0.38	-5.04	-0.3	8.58e-7	Waist-to-hip ratio adjusted for body mass index;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg19572947	chr1:182808556	DHX9	0.48	6.07	0.35	4.36e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs4853012	0.838	rs4429500	chr2:74345336	A/G	cg20891558	chr2:74357851	NA	0.76	10.75	0.55	1.31e-22	Gestational age at birth (maternal effect);
CESC	cis	rs73206853	0.686	rs56339227	chr12:111164963	T/C	cg12870014	chr12:110450643	ANKRD13A	0.64	5.66	0.33	3.91e-8	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs6840258	0.941	rs6854749	chr4:87968798	A/T	cg08197287	chr4:87952173	AFF1	-0.37	-5.06	-0.3	7.8e-7	Mean corpuscular volume;Basophil percentage of granulocytes;
CESC	cis	rs875971	1.000	rs12532998	chr7:65967459	A/C	cg18876405	chr7:65276391	NA	0.48	6.32	0.36	1.09e-9	Aortic root size;
CESC	cis	rs919433	0.817	rs10931780	chr2:198175297	G/C	cg03934865	chr2:198174659	NA	-0.49	-7.67	-0.43	3.24e-13	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs7542091	0.704	rs7537294	chr1:210043777	A/G	cg21951975	chr1:209979733	IRF6	0.47	8.25	0.45	7.51e-15	Monobrow;
CESC	cis	rs7666738	0.609	rs35214820	chr4:98864692	G/A	cg05340658	chr4:99064831	C4orf37	0.53	6.33	0.36	1.04e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9303401	0.614	rs34678056	chr17:57177549	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.92	11.49	0.58	4.47e-25	Cognitive test performance;
CESC	cis	rs611744	0.810	rs672161	chr8:109164182	G/A	cg21045802	chr8:109455806	TTC35	0.45	5.49	0.32	9.39e-8	Dupuytren's disease;
CESC	cis	rs8031584	0.958	rs34909055	chr15:31284170	C/T	cg08704250	chr15:31115839	NA	-0.52	-6.59	-0.38	2.37e-10	Huntington's disease progression;
CESC	cis	rs422421	1.000	rs442856	chr5:176517292	A/G	cg00618323	chr5:176515533	FGFR4	0.4	5.19	0.3	4.18e-7	Height;
CESC	cis	rs2204008	0.806	rs3922574	chr12:38329069	C/T	cg26384229	chr12:38710491	ALG10B	0.72	10.82	0.55	7.48e-23	Bladder cancer;
CESC	cis	rs826838	0.874	rs10880943	chr12:38734317	C/T	cg26384229	chr12:38710491	ALG10B	0.84	15.0	0.68	3e-37	Heart rate;
CESC	cis	rs684232	0.602	rs445268	chr17:563338	G/A	cg15660573	chr17:549704	VPS53	-0.81	-11.96	-0.59	1.18e-26	Prostate cancer;
CESC	cis	rs11583043	0.708	rs874905	chr1:101539702	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.5	5.41	0.32	1.42e-7	Ulcerative colitis;Inflammatory bowel disease;
CESC	cis	rs1050631	0.924	rs1785918	chr18:33693198	C/T	cg25426722	chr18:33708991	SLC39A6;ELP2	0.44	5.62	0.33	4.79e-8	Esophageal squamous cell cancer (length of survival);
CESC	cis	rs4820539	1.000	rs916585	chr22:23469438	G/A	cg14186256	chr22:23484241	RTDR1	0.83	15.0	0.68	3.12e-37	Bone mineral density;
CESC	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg03188948	chr7:1209495	NA	0.71	7.06	0.4	1.5e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs12545109	0.800	rs1561224	chr8:57419922	T/C	cg09654669	chr8:57350985	NA	-0.45	-6.27	-0.36	1.47e-9	Obesity-related traits;
CESC	cis	rs295140	0.605	rs159321	chr2:201184713	C/T	cg23649088	chr2:200775458	C2orf69	-0.46	-6.28	-0.36	1.41e-9	QT interval;
CESC	cis	rs55986470	0.703	rs11887099	chr2:239447550	T/C	cg18131467	chr2:239335373	ASB1	-0.54	-6.09	-0.35	3.99e-9	Chronotype;
CESC	cis	rs1559088	1.000	rs2161225	chr19:33551899	C/T	cg17764715	chr19:33622953	WDR88	0.46	5.85	0.34	1.42e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs9287719	0.967	rs12467642	chr2:10761484	G/A	cg02196655	chr2:10830764	NOL10	-0.37	-5.56	-0.32	6.58e-8	Prostate cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18810133	chr1:6557779	PLEKHG5	0.56	6.18	0.35	2.35e-9	Gut microbiome composition (summer);
CESC	cis	rs1008375	1.000	rs28480159	chr4:17685707	A/C	cg02297831	chr4:17616191	MED28	0.42	5.44	0.32	1.2e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs8050907	0.744	rs13330134	chr16:4526923	T/G	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.9	6.28	0.36	1.39e-9	Obesity-related traits;
CESC	cis	rs10832963	0.924	rs10832950	chr11:18635815	A/G	cg20219074	chr11:18656078	SPTY2D1	0.8	11.77	0.59	5.17e-26	Breast cancer;
CESC	cis	rs2404602	0.583	rs2139190	chr15:76555539	G/C	cg05617483	chr15:76483344	C15orf27	0.42	5.62	0.33	4.95e-8	Blood metabolite levels;
CESC	cis	rs35740288	0.539	rs11629991	chr15:86336664	A/G	cg20737812	chr15:86336631	KLHL25	-0.42	-5.28	-0.31	2.71e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
CESC	trans	rs3780486	0.846	rs7864705	chr9:33140352	A/C	cg04842962	chr6:43655489	MRPS18A	1.01	20.1	0.78	3.2e-55	IgG glycosylation;
CESC	cis	rs7044106	0.615	rs10818470	chr9:123359204	A/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.32	5.12	0.3	5.97e-7	Hip circumference adjusted for BMI;
CESC	cis	rs4074961	0.604	rs4411102	chr1:38063424	C/G	cg13401533	chr1:37979913	MEAF6	0.54	7.12	0.4	1.04e-11	Axial length;
CESC	cis	rs763121	0.853	rs3827357	chr22:39079413	A/G	cg06544989	chr22:39130855	UNC84B	0.52	9.06	0.49	2.96e-17	Menopause (age at onset);
CESC	cis	rs4713118	0.662	rs464312	chr6:27967591	T/A	cg23281280	chr6:28129359	ZNF389	0.47	6.51	0.37	3.76e-10	Parkinson's disease;
CESC	cis	rs13242816	1.000	rs34234085	chr7:116114066	G/A	cg04696780	chr7:116139425	CAV2	-0.58	-5.2	-0.3	4.08e-7	P wave duration;
CESC	cis	rs55986470	0.646	rs112559043	chr2:239446187	A/G	cg18131467	chr2:239335373	ASB1	-0.79	-5.94	-0.34	9.01e-9	Chronotype;
CESC	cis	rs9488822	0.702	rs10872141	chr6:116323246	C/A	cg05304507	chr6:116381966	FRK	0.26	6.56	0.37	2.82e-10	Cholesterol, total;LDL cholesterol;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10073349	chr19:1568082	MEX3D	0.62	7.39	0.41	1.95e-12	Gut microbiome composition (summer);
CESC	cis	rs72781680	0.898	rs72782138	chr2:24048162	T/C	cg20701182	chr2:24300061	SF3B14	0.63	5.65	0.33	4.21e-8	Lymphocyte counts;
CESC	cis	rs9611565	0.765	rs28604950	chr22:41785812	A/G	cg06634786	chr22:41940651	POLR3H	-0.72	-7.51	-0.42	9.19e-13	Vitiligo;
CESC	cis	rs9611565	0.592	rs4481089	chr22:41980892	T/C	cg17376030	chr22:41985996	PMM1	0.49	5.49	0.32	9.33e-8	Vitiligo;
CESC	cis	rs4665809	1.000	rs6546768	chr2:26328800	A/G	cg08470875	chr2:26401718	FAM59B	-0.48	-5.27	-0.31	2.79e-7	Gut microbiome composition (summer);
CESC	cis	rs2249694	0.922	rs4306261	chr10:135410989	A/G	cg20169779	chr10:135381914	SYCE1	-0.4	-5.65	-0.33	4.05e-8	Obesity-related traits;
CESC	cis	rs6460942	1.000	rs6948314	chr7:12418363	T/A	cg06484146	chr7:12443880	VWDE	-0.66	-7.86	-0.43	9.73e-14	Coronary artery disease;
CESC	cis	rs798554	0.796	rs2533884	chr7:2836848	T/G	cg18446336	chr7:2847575	GNA12	-0.37	-5.38	-0.31	1.65e-7	Height;
CESC	cis	rs57221529	0.709	rs72706611	chr5:561146	C/A	cg09021430	chr5:549028	NA	-0.43	-5.41	-0.32	1.43e-7	Lung disease severity in cystic fibrosis;
CESC	cis	rs1691799	0.867	rs1168342	chr12:66758734	A/T	cg16791601	chr12:66731901	HELB	-0.79	-14.11	-0.65	4.25e-34	White blood cell count (basophil);
CESC	cis	rs4819052	0.851	rs7276103	chr21:46666078	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.83	12.0	0.59	8.55e-27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs9814567	1.000	rs11919350	chr3:134235970	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.45	6.08	0.35	4.15e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs10129255	0.500	rs4774008	chr14:107137290	A/T	cg23076370	chr14:107095027	NA	-0.67	-10.15	-0.53	1.14e-20	Kawasaki disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg08621418	chr6:79944414	HMGN3	-0.47	-6.46	-0.37	4.89e-10	Fibrinogen levels;
CESC	cis	rs17401966	1.000	rs12130220	chr1:10359944	T/G	cg15208524	chr1:10270712	KIF1B	0.48	6.11	0.35	3.52e-9	Hepatocellular carcinoma;
CESC	cis	rs8114671	0.562	rs34837802	chr20:33424908	C/G	cg24642439	chr20:33292090	TP53INP2	0.45	5.44	0.32	1.2e-7	Height;
CESC	cis	rs7618915	1.000	rs3852063	chr3:52349204	A/G	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.35	5.42	0.32	1.35e-7	Bipolar disorder;
CESC	cis	rs4072980	0.527	rs11210825	chr1:38446986	G/A	cg26398791	chr1:38455867	SF3A3	-0.43	-5.49	-0.32	9.36e-8	Coronary artery disease;
CESC	cis	rs72634258	0.945	rs2050198	chr1:8111839	T/G	cg00042356	chr1:8021962	PARK7	0.76	6.78	0.38	7.86e-11	Inflammatory bowel disease;
CESC	cis	rs7666738	0.830	rs11097608	chr4:99011693	T/C	cg05340658	chr4:99064831	C4orf37	0.81	12.42	0.61	3.22e-28	Colonoscopy-negative controls vs population controls;
CESC	trans	rs116095464	0.558	rs10056628	chr5:279512	G/A	cg00938859	chr5:1591904	SDHAP3	0.72	6.62	0.38	2.03e-10	Breast cancer;
CESC	cis	rs1950626	0.743	rs12887333	chr14:101462612	C/A	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.84	10.54	0.54	6.26e-22	Pelvic organ prolapse (moderate/severe);
CESC	cis	rs6088580	0.634	rs6058070	chr20:33103521	G/C	cg08999081	chr20:33150536	PIGU	0.65	11.45	0.58	6.19e-25	Glomerular filtration rate (creatinine);
CESC	cis	rs12824058	0.831	rs12310049	chr12:130811260	C/G	cg23887609	chr12:130822674	PIWIL1	0.45	5.82	0.34	1.69e-8	Menopause (age at onset);
CESC	cis	rs694739	0.628	rs538147	chr11:64129722	G/A	cg02228329	chr11:64053129	BAD;GPR137	0.61	7.61	0.42	4.85e-13	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CESC	cis	rs10870270	0.956	rs4131689	chr10:133744328	A/C	cg08754478	chr10:133766260	PPP2R2D	0.59	7.77	0.43	1.78e-13	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs870825	0.616	rs4263438	chr4:185624238	C/T	cg04058563	chr4:185651563	MLF1IP	0.64	7.05	0.4	1.59e-11	Blood protein levels;
CESC	cis	rs1799949	0.965	rs11080034	chr17:41443014	T/C	cg23758822	chr17:41437982	NA	0.99	17.26	0.73	2.91e-45	Menopause (age at onset);
CESC	cis	rs4595586	0.505	rs12827467	chr12:39374014	A/G	cg26384229	chr12:38710491	ALG10B	0.54	7.53	0.42	7.85e-13	Morning vs. evening chronotype;
CESC	cis	rs2191566	0.576	rs381091	chr19:44495315	G/A	cg20607764	chr19:44506953	ZNF230	0.45	5.69	0.33	3.38e-8	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs35306767	0.903	rs12249828	chr10:894838	C/T	cg25019033	chr10:957182	NA	-0.55	-6.1	-0.35	3.79e-9	Eosinophil percentage of granulocytes;
CESC	cis	rs6860806	0.661	rs1588263	chr5:131577158	T/C	cg24060327	chr5:131705240	SLC22A5	-0.41	-5.21	-0.3	3.79e-7	Breast cancer;
CESC	cis	rs12711979	0.509	rs10187740	chr2:3823965	A/G	cg17052675	chr2:3827356	NA	0.64	10.71	0.55	1.75e-22	Itch intensity from mosquito bite adjusted by bite size;
CESC	cis	rs11190604	1.000	rs4919470	chr10:102298920	C/T	cg07080220	chr10:102295463	HIF1AN	0.64	5.81	0.34	1.78e-8	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs7412746	0.658	rs3768016	chr1:150809919	T/C	cg17724175	chr1:150552817	MCL1	0.41	6.23	0.36	1.83e-9	Melanoma;
CESC	cis	rs778371	1.000	rs709937	chr2:233744021	A/G	cg08000102	chr2:233561755	GIGYF2	0.82	13.01	0.62	3.07e-30	Schizophrenia;
CESC	cis	rs6963495	0.818	rs117028299	chr7:105162310	T/C	cg19920283	chr7:105172520	RINT1	0.69	6.56	0.37	2.85e-10	Bipolar disorder (body mass index interaction);
CESC	cis	rs1552244	0.554	rs34883592	chr3:10046165	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.62	7.99	0.44	4.24e-14	Alzheimer's disease;
CESC	cis	rs3768617	0.782	rs12143211	chr1:182990172	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.66	9.04	0.49	3.3e-17	Fuchs's corneal dystrophy;
CESC	cis	rs16854884	0.837	rs13083224	chr3:143801696	C/T	cg06585982	chr3:143692056	C3orf58	0.43	5.34	0.31	2.03e-7	Economic and political preferences (feminism/equality);
CESC	cis	rs9584850	0.794	rs17574433	chr13:99138057	A/G	cg20750642	chr13:99100586	FARP1	0.37	5.55	0.32	6.98e-8	Neuroticism;
CESC	cis	rs9611565	0.921	rs5758297	chr22:41720697	A/G	cg03806693	chr22:41940476	POLR3H	-0.67	-8.06	-0.44	2.57e-14	Vitiligo;
CESC	trans	rs916888	0.610	rs199438	chr17:44791643	G/A	cg01341218	chr17:43662625	NA	0.51	6.64	0.38	1.8e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs2933343	0.700	rs1683777	chr3:128624880	T/G	cg11901034	chr3:128598214	ACAD9	-0.39	-5.71	-0.33	3.1e-8	IgG glycosylation;
CESC	cis	rs9649213	0.574	rs62479853	chr7:97917158	G/T	cg00277769	chr7:97922759	BAIAP2L1	-0.34	-5.54	-0.32	7.11e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs875971	0.862	rs35378740	chr7:65987712	C/A	cg18252515	chr7:66147081	NA	-0.47	-6.08	-0.35	4.25e-9	Aortic root size;
CESC	cis	rs56046484	0.826	rs35816571	chr15:85554122	C/G	cg08123816	chr15:85640762	PDE8A	-0.5	-5.89	-0.34	1.14e-8	Testicular germ cell tumor;
CESC	cis	rs4665809	0.590	rs2033317	chr2:26477650	G/A	cg22920501	chr2:26401640	FAM59B	0.93	10.89	0.56	4.54e-23	Gut microbiome composition (summer);
CESC	cis	rs11864453	0.826	rs6499559	chr16:72132064	G/C	cg01557791	chr16:72042693	DHODH	-0.51	-6.59	-0.38	2.43e-10	Fibrinogen levels;
CESC	cis	rs9916302	0.861	rs11078896	chr17:37415544	C/T	cg00129232	chr17:37814104	STARD3	-0.56	-7.24	-0.41	4.76e-12	Glomerular filtration rate (creatinine);
CESC	cis	rs4665809	0.590	rs1865324	chr2:26417533	C/A	cg25036284	chr2:26402008	FAM59B	-0.84	-9.59	-0.51	7.11e-19	Gut microbiome composition (summer);
CESC	cis	rs9300255	0.602	rs2510885	chr12:123614813	G/C	cg05973401	chr12:123451056	ABCB9	0.51	5.91	0.34	1.08e-8	Neutrophil percentage of white cells;
CESC	cis	rs9486719	1.000	rs12193732	chr6:96942609	G/A	cg18709589	chr6:96969512	KIAA0776	-0.55	-6.02	-0.35	5.81e-9	Migraine;Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20690483	chr2:96874741	STARD7	0.55	6.29	0.36	1.27e-9	Gut microbiome composition (summer);
CESC	cis	rs11098499	0.542	rs10440343	chr4:120309787	G/C	cg24375607	chr4:120327624	NA	0.46	5.55	0.32	6.98e-8	Corneal astigmatism;
CESC	trans	rs629535	0.590	rs62513426	chr8:70136843	T/G	cg21567404	chr3:27674614	NA	-0.84	-9.23	-0.49	9.08e-18	Dupuytren's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04346410	chr2:132238154	TUBA3D	-0.52	-6.02	-0.35	5.72e-9	Gut microbiome composition (summer);
CESC	trans	rs875971	0.895	rs12698520	chr7:65918707	C/A	cg26939375	chr7:64535504	NA	0.47	6.01	0.35	5.95e-9	Aortic root size;
CESC	cis	rs4253772	0.591	rs6007726	chr22:46650858	A/C	cg09491104	chr22:46646882	C22orf40	-0.59	-9.15	-0.49	1.58e-17	LDL cholesterol;Cholesterol, total;
CESC	cis	rs3782089	1.000	rs11600543	chr11:65298939	G/A	cg00206168	chr11:65308501	LTBP3	1.0	6.54	0.37	3.15e-10	Height;
CESC	cis	rs1355223	0.902	rs11819839	chr11:34715778	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.48	-6.43	-0.37	6.04e-10	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs8177253	0.965	rs4854760	chr3:133498741	C/T	cg11941060	chr3:133502564	NA	0.37	5.12	0.3	5.77e-7	Iron status biomarkers;
CESC	cis	rs13191362	1.000	rs35911566	chr6:162994154	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.86	8.98	0.48	5.03e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs6541297	0.703	rs621328	chr1:230310414	G/A	cg20703242	chr1:230279135	GALNT2	-0.44	-5.52	-0.32	7.95e-8	Coronary artery disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg07278332	chr7:94294290	PEG10	0.49	6.64	0.38	1.79e-10	Fibrinogen levels;
CESC	cis	rs2204008	0.811	rs12368410	chr12:38305705	C/T	cg13010199	chr12:38710504	ALG10B	0.51	6.28	0.36	1.35e-9	Bladder cancer;
CESC	cis	rs870825	0.616	rs4616798	chr4:185634144	C/T	cg04058563	chr4:185651563	MLF1IP	-0.64	-6.91	-0.39	3.59e-11	Blood protein levels;
CESC	cis	rs67478160	0.619	rs55824307	chr14:104271207	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.51	-7.09	-0.4	1.2e-11	Schizophrenia;
CESC	cis	rs1878931	0.531	rs9635548	chr16:3417156	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.77	10.42	0.54	1.58e-21	Body mass index (adult);
CESC	cis	rs9649213	0.555	rs67132564	chr7:98014900	T/A	cg24562669	chr7:97807699	LMTK2	0.52	7.6	0.42	5.03e-13	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7666738	0.830	rs10011009	chr4:98981749	G/A	cg05340658	chr4:99064831	C4orf37	0.77	11.85	0.59	2.88e-26	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2880765	0.743	rs8039631	chr15:86007931	A/G	cg10818794	chr15:86012489	AKAP13	-0.33	-5.12	-0.3	6.02e-7	Coronary artery disease;
CESC	cis	rs2439831	0.681	rs3742971	chr15:43622916	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.89	-10.82	-0.55	8.03e-23	Lung cancer in ever smokers;
CESC	cis	rs9649213	0.555	rs34695842	chr7:97931062	G/T	cg08684580	chr7:98029266	BAIAP2L1	-0.34	-5.55	-0.32	6.96e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs6762	0.719	rs7936806	chr11:839186	G/C	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.74	-9.73	-0.51	2.49e-19	Mean platelet volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09174855	chr19:1592510	MBD3	-0.64	-7.0	-0.4	2.15e-11	Gut microbiome composition (summer);
CESC	cis	rs929354	0.772	rs6459741	chr7:157014553	G/T	cg05182265	chr7:156933206	UBE3C	-0.5	-7.39	-0.41	1.88e-12	Body mass index;
CESC	trans	rs116095464	0.558	rs6555056	chr5:226222	T/C	cg00938859	chr5:1591904	SDHAP3	0.61	6.84	0.39	5.52e-11	Breast cancer;
CESC	cis	rs34779708	0.733	rs7081597	chr10:35546331	G/C	cg03585969	chr10:35415529	CREM	0.56	6.54	0.37	3.17e-10	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs6088590	0.610	rs6120663	chr20:33081906	A/C	cg06115741	chr20:33292138	TP53INP2	-0.51	-6.63	-0.38	1.89e-10	Coronary artery disease;
CESC	cis	rs910316	0.737	rs28687415	chr14:75495482	T/C	cg11812906	chr14:75593930	NEK9	0.83	13.51	0.64	5.28e-32	Height;
CESC	cis	rs1707322	0.663	rs3935296	chr1:46180470	T/C	cg03146154	chr1:46216737	IPP	-0.82	-11.54	-0.58	3.18e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs9858542	0.953	rs9821311	chr3:49543656	C/T	cg21659725	chr3:3221576	CRBN	-0.54	-6.37	-0.36	8.2e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs8114671	0.562	rs6087641	chr20:33467717	T/C	cg06115741	chr20:33292138	TP53INP2	0.44	5.41	0.32	1.38e-7	Height;
CESC	cis	rs7666738	0.830	rs6833312	chr4:98951356	A/T	cg03676636	chr4:99064102	C4orf37	0.33	5.09	0.3	6.71e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1799949	1.000	rs12952790	chr17:41299607	A/G	cg06001716	chr17:41278141	BRCA1;NBR2	0.39	5.26	0.31	3e-7	Menopause (age at onset);
CESC	cis	rs754466	0.580	rs11002294	chr10:79540588	T/C	cg17075019	chr10:79541650	NA	-0.88	-14.04	-0.65	7.39e-34	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs637571	0.524	rs674363	chr11:65699134	G/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.56	-6.95	-0.39	2.86e-11	Eosinophil percentage of white cells;
CESC	cis	rs3785574	0.962	rs2727332	chr17:61878584	T/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.57	7.03	0.4	1.78e-11	Height;
CESC	trans	rs11165623	0.740	rs12126692	chr1:96889258	C/G	cg10631902	chr5:14652156	NA	0.55	8.15	0.45	1.45e-14	Hip circumference;Waist circumference;
CESC	trans	rs9329221	0.683	rs4598253	chr8:9890304	A/T	cg06636001	chr8:8085503	FLJ10661	-0.54	-7.27	-0.41	4.16e-12	Neuroticism;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg09959495	chr2:237029385	AGAP1	-0.46	-6.03	-0.35	5.34e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs4974559	0.739	rs4333131	chr4:1323789	A/G	cg02980000	chr4:1222292	CTBP1	0.69	7.76	0.43	1.86e-13	Systolic blood pressure;
CESC	cis	rs10504229	0.683	rs2101864	chr8:58113226	C/T	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs3820068	0.705	rs57971278	chr1:15838604	G/A	cg17385448	chr1:15911702	AGMAT	0.38	5.97	0.34	7.47e-9	Systolic blood pressure;
CESC	cis	rs9300255	0.543	rs1617156	chr12:123590165	T/C	cg19016782	chr12:123741754	C12orf65	-0.39	-5.08	-0.3	7.18e-7	Neutrophil percentage of white cells;
CESC	cis	rs9910055	0.530	rs2269907	chr17:42294215	G/A	cg19774624	chr17:42201019	HDAC5	-0.59	-8.54	-0.46	1.04e-15	Total body bone mineral density;
CESC	cis	rs6546550	0.867	rs726920	chr2:70152027	G/C	cg02498382	chr2:70120550	SNRNP27	-0.41	-7.25	-0.41	4.69e-12	Prevalent atrial fibrillation;
CESC	cis	rs7605827	0.823	rs6431692	chr2:15478364	A/G	cg19274914	chr2:15703543	NA	0.3	5.32	0.31	2.16e-7	Educational attainment (years of education);
CESC	cis	rs9291683	0.632	rs7679916	chr4:10042160	C/T	cg00071950	chr4:10020882	SLC2A9	0.83	14.41	0.66	3.63e-35	Bone mineral density;
CESC	cis	rs6089584	0.888	rs6061981	chr20:60618973	T/C	cg24733560	chr20:60626293	TAF4	0.45	6.44	0.37	5.45e-10	Body mass index;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03925809	chr19:6393419	GTF2F1	-0.55	-6.32	-0.36	1.09e-9	Gut microbiome composition (summer);
CESC	cis	rs9309711	0.961	rs11675119	chr2:3476422	C/A	cg10845886	chr2:3471009	TTC15	-0.87	-12.48	-0.61	2.01e-28	Neurofibrillary tangles;
CESC	cis	rs3820928	0.839	rs4675123	chr2:227800205	T/C	cg11843606	chr2:227700838	RHBDD1	-0.42	-5.62	-0.33	4.72e-8	Pulmonary function;
CESC	cis	rs734999	0.545	rs6698817	chr1:2564183	T/C	cg18854424	chr1:2615690	NA	-0.31	-5.91	-0.34	1.08e-8	Ulcerative colitis;
CESC	cis	rs72627123	0.867	rs78742875	chr14:74457214	T/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.8	5.37	0.31	1.71e-7	Morning vs. evening chronotype;
CESC	cis	rs763014	0.932	rs2269559	chr16:682297	T/C	cg07256732	chr16:621771	PIGQ	-0.3	-5.27	-0.31	2.8e-7	Height;
CESC	cis	rs2859741	0.507	rs564198	chr1:37467325	C/G	cg09363841	chr1:37513479	NA	-0.48	-6.21	-0.36	2.03e-9	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
CESC	cis	rs734999	0.566	rs12748729	chr1:2558740	C/T	cg18854424	chr1:2615690	NA	-0.3	-5.83	-0.34	1.62e-8	Ulcerative colitis;
CESC	cis	rs2841277	0.802	rs2841269	chr14:105386149	C/G	cg21017887	chr14:105400489	NA	0.41	6.57	0.37	2.6e-10	Rheumatoid arthritis;
CESC	cis	rs3126085	0.935	rs2291770	chr1:152179792	G/C	cg26876637	chr1:152193138	HRNR	0.48	5.44	0.32	1.21e-7	Atopic dermatitis;
CESC	trans	rs7947523	0.813	rs4999940	chr11:80942337	C/T	cg24701985	chr7:149535383	ZNF862	0.46	6.04	0.35	5.08e-9	Emphysema imaging phenotypes;
CESC	cis	rs853679	0.517	rs9393898	chr6:28130376	G/T	cg23161317	chr6:28129485	ZNF389	0.53	6.72	0.38	1.1e-10	Depression;
CESC	cis	rs6964587	0.967	rs6973896	chr7:91778465	A/G	cg17063962	chr7:91808500	NA	0.59	8.22	0.45	8.94e-15	Breast cancer;
CESC	cis	rs2154427	0.938	rs114440021	chr21:34202672	C/T	cg03746930	chr21:34165763	C21orf62;C21orf49	-0.53	-5.32	-0.31	2.17e-7	Bilirubin levels;
CESC	cis	rs17376456	0.825	rs6898842	chr5:93213221	T/C	cg25358565	chr5:93447407	FAM172A	1.11	10.53	0.54	6.8e-22	Diabetic retinopathy;
CESC	cis	rs597539	0.552	rs6591361	chr11:68719284	T/C	cg18350739	chr11:68623251	NA	-0.38	-5.61	-0.33	5.08e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs6456156	0.586	rs6909180	chr6:167460537	A/G	cg23791538	chr6:167370224	RNASET2	-0.49	-6.37	-0.36	8.2e-10	Primary biliary cholangitis;
CESC	cis	rs13256369	0.851	rs13255061	chr8:8563834	G/A	cg17143192	chr8:8559678	CLDN23	0.78	8.81	0.48	1.63e-16	Obesity-related traits;
CESC	cis	rs3092073	0.624	rs11696196	chr20:44574533	C/T	cg27529037	chr20:44575021	PCIF1	0.64	9.71	0.51	2.97e-19	Intelligence (multi-trait analysis);
CESC	cis	rs12900413	0.687	rs7176948	chr15:90315707	A/C	cg24249390	chr15:90295951	MESP1	-0.41	-5.73	-0.33	2.78e-8	Coronary artery aneurysm in Kawasaki disease;
CESC	cis	rs9488822	0.676	rs11757115	chr6:116362619	C/T	cg26893134	chr6:116381904	FRK	0.25	6.04	0.35	5.3300000000000004e-09	Cholesterol, total;LDL cholesterol;
CESC	cis	rs7512552	0.839	rs1260459	chr1:150348253	T/G	cg15654264	chr1:150340011	RPRD2	0.39	5.25	0.31	3.16e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs780096	0.527	rs11127044	chr2:27740404	C/G	cg02592271	chr2:27665507	KRTCAP3	-0.3	-5.87	-0.34	1.32e-8	Total body bone mineral density;
CESC	cis	rs11098499	0.954	rs2892848	chr4:120381341	C/T	cg09307838	chr4:120376055	NA	0.95	13.8	0.65	5e-33	Corneal astigmatism;
CESC	cis	rs875971	0.929	rs778712	chr7:65849978	C/T	cg18876405	chr7:65276391	NA	0.51	6.85	0.39	5.05e-11	Aortic root size;
CESC	cis	rs11048434	0.736	rs11048190	chr12:9104939	C/T	cg04155231	chr12:9217510	LOC144571	0.33	5.23	0.31	3.47e-7	Sjögren's syndrome;
CESC	cis	rs3785574	0.962	rs9944483	chr17:61783553	G/T	cg06873352	chr17:61820015	STRADA	-0.43	-6.29	-0.36	1.33e-9	Height;
CESC	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.51	0.37	3.65e-10	Prudent dietary pattern;
CESC	cis	rs8070463	0.515	rs11655943	chr17:45385640	A/G	cg25173405	chr17:45401733	C17orf57	-0.4	-5.09	-0.3	6.64e-7	Multiple sclerosis;Ankylosing spondylitis;
CESC	cis	rs13223928	0.565	rs10240820	chr7:3154415	T/C	cg19214707	chr7:3157722	NA	-0.45	-6.05	-0.35	5.01e-9	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
CESC	cis	rs9322193	0.962	rs7818	chr6:150132092	A/G	cg07701084	chr6:150067640	NUP43	0.42	5.83	0.34	1.63e-8	Lung cancer;
CESC	cis	rs977987	0.806	rs4888425	chr16:75476363	T/C	cg03315344	chr16:75512273	CHST6	0.43	6.13	0.35	3.23e-9	Dupuytren's disease;
CESC	cis	rs2180341	0.618	rs12210968	chr6:127596985	A/G	cg27446573	chr6:127587934	RNF146	0.62	8.48	0.46	1.62e-15	Breast cancer;
CESC	cis	rs597539	0.690	rs635529	chr11:68626294	C/T	cg18350739	chr11:68623251	NA	-0.45	-6.37	-0.36	8.34e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs13118159	0.641	rs4974598	chr4:1313220	C/T	cg05025164	chr4:1340916	KIAA1530	0.54	7.4	0.41	1.85e-12	Longevity;
CESC	cis	rs9649465	1.000	rs2299982	chr7:123356511	A/C	cg04330084	chr7:123175371	IQUB	-0.39	-5.23	-0.31	3.47e-7	Migraine;
CESC	cis	rs116095464	0.558	rs61492827	chr5:225774	A/G	cg22496380	chr5:211416	CCDC127	-0.74	-8.72	-0.47	3.15e-16	Breast cancer;
CESC	cis	rs11252926	0.603	rs17293419	chr10:537014	G/A	cg18196295	chr10:418757	DIP2C	-0.5	-6.78	-0.38	7.57e-11	Psychosis in Alzheimer's disease;
CESC	cis	rs9420	0.961	rs1647405	chr11:57477889	C/T	cg23127183	chr11:57508653	C11orf31	-0.43	-5.14	-0.3	5.44e-7	Schizophrenia;
CESC	cis	rs116095464	0.558	rs9687621	chr5:229194	C/T	cg22857025	chr5:266934	NA	-1.33	-14.37	-0.66	5.08e-35	Breast cancer;
CESC	cis	rs7811142	1.000	rs7803454	chr7:99991548	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.77	6.63	0.38	1.87e-10	Platelet count;
CESC	cis	rs79349575	0.783	rs9912829	chr17:46982749	G/C	cg16584676	chr17:46985605	UBE2Z	0.53	6.6	0.38	2.25e-10	Type 2 diabetes;
CESC	cis	rs5750830	0.594	rs9611166	chr22:39775268	T/C	cg02038168	chr22:39784481	NA	-0.56	-7.35	-0.41	2.5e-12	Intelligence (multi-trait analysis);
CESC	cis	rs11122272	0.735	rs2749706	chr1:231527170	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.56	-7.69	-0.43	2.92e-13	Hemoglobin concentration;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg07105891	chr1:21031312	KIF17	0.47	6.44	0.37	5.57e-10	Fibrinogen levels;
CESC	cis	rs4900538	0.821	rs7012	chr14:102814945	C/T	cg18135206	chr14:102964638	TECPR2	-0.68	-8.57	-0.47	8.46e-16	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	cis	rs9611565	0.512	rs9611672	chr22:42209922	A/G	cg17376030	chr22:41985996	PMM1	0.77	7.96	0.44	5.16e-14	Vitiligo;
CESC	cis	rs10242455	1.000	rs6948775	chr7:98945480	A/G	cg05403484	chr7:98973169	ARPC1B	-0.57	-5.14	-0.3	5.34e-7	Blood metabolite levels;
CESC	trans	rs6429422	0.687	rs115012184	chr1:243304666	A/T	cg10713773	chr13:51796714	FAM124A	0.46	6.17	0.35	2.56e-9	Cognitive ability (multi-trait analysis);
CESC	cis	rs9308731	0.644	rs3789061	chr2:111918230	T/C	cg04202892	chr2:111875749	ACOXL	0.44	6.34	0.36	9.87e-10	Chronic lymphocytic leukemia;
CESC	cis	rs300703	0.719	rs385909	chr2:199678	A/G	cg21211680	chr2:198530	NA	1.02	10.89	0.56	4.57e-23	Blood protein levels;
CESC	cis	rs1538970	0.962	rs9429158	chr1:45821393	A/G	cg06784218	chr1:46089804	CCDC17	0.3	5.05	0.3	8.3e-7	Platelet count;
CESC	cis	rs854765	0.565	rs854768	chr17:18018806	T/C	cg16928487	chr17:17741425	SREBF1	-0.47	-7.39	-0.41	1.92e-12	Total body bone mineral density;
CESC	cis	rs2072499	0.966	rs1137703	chr1:156184458	T/C	cg24450063	chr1:156163899	SLC25A44	1.07	20.83	0.79	9.98e-58	Testicular germ cell tumor;
CESC	cis	rs1348850	0.554	rs7595576	chr2:178371921	C/T	cg23306229	chr2:178417860	TTC30B	0.78	6.92	0.39	3.32e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs1707322	0.963	rs1768815	chr1:46528603	G/A	cg03146154	chr1:46216737	IPP	-0.7	-9.19	-0.49	1.23e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg18402987	chr7:1209562	NA	0.56	6.65	0.38	1.63e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs1552244	0.554	rs13079240	chr3:10047246	C/T	cg00149659	chr3:10157352	C3orf10	0.54	6.55	0.37	2.98e-10	Alzheimer's disease;
CESC	cis	rs13191362	1.000	rs36107456	chr6:162997399	T/G	cg06582575	chr6:163149167	PACRG;PARK2	0.79	8.31	0.45	5.17e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs61542988	1.000	rs61542988	chr7:22882291	C/T	cg13679077	chr7:22862647	TOMM7	0.51	6.29	0.36	1.34e-9	Fibrinogen levels;
CESC	cis	rs5769765	1.000	rs2295409	chr22:50261060	G/C	cg22709217	chr22:50311962	ALG12;CRELD2	0.46	5.28	0.31	2.69e-7	Schizophrenia;
CESC	cis	rs2997447	0.761	rs72886625	chr1:26455319	A/G	cg24596570	chr1:26146463	FAM54B;LOC646471	0.59	5.16	0.3	4.76e-7	QRS complex (12-leadsum);
CESC	cis	rs7772486	0.764	rs2265471	chr6:146220250	G/A	cg23711669	chr6:146136114	FBXO30	0.88	12.96	0.62	4.27e-30	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2243480	1.000	rs431318	chr7:65511597	G/A	cg18252515	chr7:66147081	NA	-1.28	-12.48	-0.61	2.04e-28	Diabetic kidney disease;
CESC	cis	rs6952808	0.531	rs3779002	chr7:2183219	C/T	cg04267008	chr7:1944627	MAD1L1	-0.58	-6.81	-0.39	6.69e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs780096	0.526	rs12476704	chr2:27613031	C/A	cg22903471	chr2:27725779	GCKR	-0.55	-7.81	-0.43	1.31e-13	Total body bone mineral density;
CESC	cis	rs694739	0.628	rs645078	chr11:64135298	A/C	cg02228329	chr11:64053129	BAD;GPR137	0.59	6.95	0.39	2.81e-11	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CESC	cis	rs11640533	0.901	rs2908790	chr16:53412161	T/C	cg04653913	chr16:53407753	NA	0.42	5.66	0.33	3.87e-8	Intelligence (multi-trait analysis);
CESC	cis	rs75804782	0.641	rs72983861	chr2:239326126	G/A	cg18131467	chr2:239335373	ASB1	-0.68	-5.62	-0.33	4.84e-8	Morning vs. evening chronotype;Chronotype;
CESC	cis	rs7208859	0.623	rs9911490	chr17:29073013	C/T	cg14008862	chr17:28927542	LRRC37B2	0.65	5.14	0.3	5.34e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs1552244	1.000	rs7622963	chr3:10139825	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.85	-12.15	-0.6	2.74e-27	Alzheimer's disease;
CESC	cis	rs698813	0.674	rs4953080	chr2:44500849	C/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.46	5.15	0.3	5.08e-7	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
CESC	cis	rs11792861	0.962	rs3750452	chr9:111801353	T/C	cg14384093	chr9:111878565	C9orf5	-0.41	-5.16	-0.3	4.83e-7	Menarche (age at onset);
CESC	cis	rs1448094	0.512	rs57278040	chr12:86237886	A/G	cg02569458	chr12:86230093	RASSF9	0.48	7.22	0.41	5.66e-12	Major depressive disorder;
CESC	cis	rs11098499	0.954	rs13107475	chr4:120393011	A/T	cg24375607	chr4:120327624	NA	0.45	5.7	0.33	3.16e-8	Corneal astigmatism;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg10568689	chr11:73591256	PAAF1	0.49	6.27	0.36	1.42e-9	Thyroid stimulating hormone;
CESC	cis	rs7726839	0.561	rs4957049	chr5:579080	C/A	cg09021430	chr5:549028	NA	-0.44	-5.96	-0.34	8.23e-9	Obesity-related traits;
CESC	cis	rs7044106	0.791	rs7036766	chr9:123479621	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.73	10.79	0.55	9.56e-23	Hip circumference adjusted for BMI;
CESC	cis	rs736408	0.660	rs2019065	chr3:52809525	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.47	-6.79	-0.39	7.13e-11	Bipolar disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01544351	chr19:46142757	MIR330;EML2	0.55	6.08	0.35	4.18e-9	Gut microbiome composition (summer);
CESC	cis	rs977987	0.778	rs2113232	chr16:75391185	T/C	cg03315344	chr16:75512273	CHST6	0.39	5.64	0.33	4.3e-8	Dupuytren's disease;
CESC	cis	rs9790314	0.765	rs4856768	chr3:161004392	G/A	cg04691961	chr3:161091175	C3orf57	-0.38	-5.06	-0.3	7.9e-7	Morning vs. evening chronotype;
CESC	cis	rs11098499	0.863	rs13140391	chr4:120503437	A/G	cg24375607	chr4:120327624	NA	0.46	5.47	0.32	1.05e-7	Corneal astigmatism;
CESC	trans	rs208520	0.690	rs864314	chr6:66814830	G/T	cg08225398	chr13:45563328	KIAA1704;NUFIP1	0.7	6.64	0.38	1.74e-10	Exhaled nitric oxide output;
CESC	cis	rs1953600	0.870	rs12770550	chr10:81953451	G/T	cg00277334	chr10:82204260	NA	0.46	6.41	0.37	6.68e-10	Sarcoidosis;
CESC	cis	rs754466	0.651	rs11813532	chr10:79637991	T/C	cg17075019	chr10:79541650	NA	-0.86	-12.88	-0.62	8.37e-30	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs59918340	0.738	rs3739235	chr8:142229145	A/G	cg16341495	chr8:142228727	SLC45A4	-0.44	-5.34	-0.31	1.98e-7	Immature fraction of reticulocytes;
CESC	cis	rs2011503	0.941	rs55762233	chr19:19367319	C/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.48	5.09	0.3	6.95e-7	Bipolar disorder;
CESC	cis	rs875971	0.862	rs35034167	chr7:65580166	C/G	cg12463550	chr7:65579703	CRCP	-0.52	-6.49	-0.37	4.08e-10	Aortic root size;
CESC	cis	rs12912251	1.000	rs35102843	chr15:38988107	C/A	cg01338139	chr15:38987640	C15orf53	-0.47	-5.43	-0.32	1.26e-7	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
CESC	cis	rs807669	0.903	rs1780637	chr22:19178250	A/G	cg02655711	chr22:19163373	SLC25A1	0.96	14.54	0.67	1.32e-35	Metabolite levels;
CESC	cis	rs6993244	1	rs6993244	chr8:8863059	C/G	cg15556689	chr8:8085844	FLJ10661	0.45	5.89	0.34	1.19e-8	Mean corpuscular hemoglobin;
CESC	cis	rs736408	0.608	rs6445534	chr3:52743384	G/A	cg05564831	chr3:52568323	NT5DC2	0.45	7.15	0.4	8.3e-12	Bipolar disorder;
CESC	cis	rs7089973	0.604	rs2420065	chr10:116583753	A/G	cg03647239	chr10:116582469	FAM160B1	0.42	5.13	0.3	5.48e-7	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs8180040	0.620	rs17784127	chr3:47061700	T/C	cg27129171	chr3:47204927	SETD2	-0.66	-9.85	-0.52	1.04e-19	Colorectal cancer;
CESC	cis	rs4819052	0.851	rs2877019	chr21:46658647	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.75	9.92	0.52	6.43e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs965469	0.895	rs6139123	chr20:3396634	C/T	cg25506879	chr20:3388711	C20orf194	-0.63	-6.6	-0.38	2.24e-10	IFN-related cytopenia;
CESC	cis	rs2204008	0.744	rs11168870	chr12:37973333	A/G	cg13010199	chr12:38710504	ALG10B	0.53	6.61	0.38	2.1e-10	Bladder cancer;
CESC	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg24503407	chr1:205819492	PM20D1	0.87	15.57	0.69	2.98e-39	Menarche (age at onset);
CESC	cis	rs4555082	0.750	rs2816650	chr14:105708343	C/T	cg27165867	chr14:105738592	BRF1	-0.49	-5.29	-0.31	2.59e-7	Mean platelet volume;Platelet distribution width;
CESC	cis	rs3747547	0.818	rs16934639	chr9:37943092	T/C	cg13774184	chr9:37916125	SHB	-0.54	-5.58	-0.32	5.79e-8	Metabolite levels (Dihydroxy docosatrienoic acid);
CESC	cis	rs798554	0.797	rs798487	chr7:2802943	G/A	cg18446336	chr7:2847575	GNA12	-0.4	-5.97	-0.34	7.59e-9	Height;
CESC	cis	rs1443512	0.812	rs2078098	chr12:54337527	C/A	cg12374095	chr12:54320830	NA	-0.44	-6.1	-0.35	3.65e-9	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
CESC	cis	rs4523957	0.928	rs4790325	chr17:2192085	C/T	cg16513277	chr17:2031491	SMG6	-0.59	-8.08	-0.44	2.29e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs7953249	0.514	rs1169312	chr12:121441461	G/T	cg25281562	chr12:121454272	C12orf43	0.39	5.09	0.3	6.73e-7	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
CESC	cis	rs9649213	0.555	rs34695842	chr7:97931062	G/T	cg21770322	chr7:97807741	LMTK2	0.57	8.68	0.47	4.01e-16	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs4727027	0.899	rs4727025	chr7:148862863	A/G	cg23583168	chr7:148888333	NA	-0.81	-12.68	-0.61	4.05e-29	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs1865721	0.804	rs7243462	chr18:73147998	A/T	cg26385618	chr18:73139727	C18orf62	-0.52	-8.04	-0.44	2.92e-14	Intelligence;
CESC	cis	rs6988985	0.560	rs4418320	chr8:143944138	G/A	cg10324643	chr8:143916377	GML	0.34	5.08	0.3	7.1e-7	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
CESC	cis	rs67311347	1.000	rs6599094	chr3:40399593	A/G	cg09455208	chr3:40491958	NA	0.5	8.94	0.48	6.79e-17	Renal cell carcinoma;
CESC	cis	rs853679	0.517	rs9380061	chr6:28132803	T/C	cg23281280	chr6:28129359	ZNF389	0.59	7.9	0.44	7.47e-14	Depression;
CESC	cis	rs599083	0.530	rs576118	chr11:68177708	C/T	cg16797656	chr11:68205561	LRP5	-0.38	-5.17	-0.3	4.61e-7	Bone mineral density (spine);
CESC	cis	rs863345	0.625	rs11265006	chr1:158498485	C/G	cg12129480	chr1:158549410	OR10X1	-0.34	-6.84	-0.39	5.54e-11	Pneumococcal bacteremia;
CESC	cis	rs2573652	0.722	rs12595247	chr15:100541689	C/T	cg09918751	chr15:100517450	ADAMTS17	-0.33	-6.17	-0.35	2.55e-9	Height;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg08886844	chr19:8373286	CD320	-0.48	-6.21	-0.36	2.05e-9	Fibrinogen levels;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg06766450	chr1:16766999	NECAP2	-0.45	-6.09	-0.35	4.06e-9	Height;
CESC	cis	rs9733	0.650	rs2048558	chr1:150571730	A/G	cg22823121	chr1:150693482	HORMAD1	-0.36	-5.28	-0.31	2.65e-7	Tonsillectomy;
CESC	trans	rs208520	0.526	rs9354366	chr6:66788559	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.1	-24.71	-0.84	9.81e-71	Exhaled nitric oxide output;
CESC	cis	rs10927875	0.526	rs2179615	chr1:16282426	G/A	cg21385522	chr1:16154831	NA	-0.88	-9.73	-0.51	2.53e-19	Dilated cardiomyopathy;
CESC	cis	rs763014	0.966	rs12935215	chr16:670605	T/C	cg00802000	chr16:706648	WDR90	-0.43	-6.57	-0.37	2.64e-10	Height;
CESC	cis	rs4790312	0.935	rs3744274	chr17:1990959	G/T	cg20777128	chr17:1945076	DPH1;OVCA2	-0.42	-5.04	-0.3	8.83e-7	Left atrial antero-posterior diameter;
CESC	cis	rs611744	0.647	rs628206	chr8:109247873	A/G	cg21045802	chr8:109455806	TTC35	0.46	5.67	0.33	3.65e-8	Dupuytren's disease;
CESC	cis	rs6502050	0.842	rs7218075	chr17:80076808	C/G	cg11859384	chr17:80120422	CCDC57	0.4	5.5	0.32	8.88e-8	Life satisfaction;
CESC	cis	rs6866344	0.697	rs17184281	chr5:178127563	G/A	cg03877680	chr5:178157825	ZNF354A	0.77	8.67	0.47	4.29e-16	Neutrophil percentage of white cells;
CESC	cis	rs4975709	0.569	rs4975743	chr5:1859941	G/T	cg14773178	chr5:1868261	NA	0.32	5.68	0.33	3.53e-8	Cardiovascular disease risk factors;
CESC	cis	rs561341	1.000	rs72823787	chr17:30283809	A/T	cg23018236	chr17:30244563	NA	-0.54	-5.27	-0.31	2.78e-7	Hip circumference adjusted for BMI;
CESC	cis	rs1559088	0.600	rs58173463	chr19:33596749	C/T	cg03563238	chr19:33554763	RHPN2	-0.32	-5.87	-0.34	1.28e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs9790314	0.663	rs796609	chr3:160705600	C/G	cg04691961	chr3:161091175	C3orf57	-0.38	-5.03	-0.3	9.05e-7	Morning vs. evening chronotype;
CESC	cis	rs2243480	0.901	rs35256305	chr7:65306405	T/C	cg13147721	chr7:65941812	NA	-0.85	-8.51	-0.46	1.26e-15	Diabetic kidney disease;
CESC	trans	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg23590916	chr17:43697445	MGC57346	0.65	6.48	0.37	4.51e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs11077998	0.967	rs7502945	chr17:80495039	T/C	cg10255544	chr17:80519551	FOXK2	0.54	8.75	0.47	2.59e-16	Reticulocyte fraction of red cells;
CESC	cis	rs5758659	1.000	rs134882	chr22:42670965	A/G	cg04733989	chr22:42467013	NAGA	0.4	5.54	0.32	7.36e-8	Cognitive function;
CESC	cis	rs6570726	0.905	rs442435	chr6:145815559	C/T	cg23711669	chr6:146136114	FBXO30	0.77	11.31	0.57	1.91e-24	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9322193	0.847	rs9383844	chr6:150037404	T/C	cg13206674	chr6:150067644	NUP43	0.46	6.73	0.38	1.03e-10	Lung cancer;
CESC	cis	rs875971	1.000	rs778710	chr7:65854834	T/C	cg12463550	chr7:65579703	CRCP	0.59	7.52	0.42	8.29e-13	Aortic root size;
CESC	cis	rs6076065	0.748	rs6048784	chr20:23382652	A/T	cg11657817	chr20:23433608	CST11	0.4	6.1	0.35	3.7e-9	Facial morphology (factor 15, philtrum width);
CESC	cis	rs7847628	0.587	rs4837796	chr9:123610288	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.95	-19.25	-0.76	2.89e-52	Birth weight;
CESC	cis	rs9916302	0.904	rs11078915	chr17:37715426	T/C	cg00129232	chr17:37814104	STARD3	-0.57	-7.46	-0.42	1.22e-12	Glomerular filtration rate (creatinine);
CESC	cis	rs1008375	0.966	rs3775923	chr4:17585625	T/C	cg02297831	chr4:17616191	MED28	0.52	5.98	0.34	7.1e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07136949	chr6:7986672	MGC26597	-0.64	-7.95	-0.44	5.31e-14	Gut microbiome composition (summer);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg22242926	chr17:73627717	RECQL5	0.45	6.3	0.36	1.23e-9	Fibrinogen levels;
CESC	trans	rs916888	0.821	rs70600	chr17:44860021	C/T	cg22433210	chr17:43662623	NA	0.94	10.47	0.54	1.07e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs6540559	0.673	rs17015330	chr1:210012795	T/G	cg21951975	chr1:209979733	IRF6	0.54	6.54	0.37	3.19e-10	Cleft lip with or without cleft palate;
CESC	cis	rs7264396	0.563	rs2425109	chr20:34316218	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.64	6.79	0.39	7.19e-11	Total cholesterol levels;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg14839808	chr12:28343774	NA	-0.5	-6.93	-0.39	3.25e-11	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs7833790	0.632	rs6415653	chr8:82702536	A/G	cg02079420	chr8:82753780	SNX16	0.5	7.56	0.42	6.82e-13	Diastolic blood pressure;
CESC	cis	rs13385	0.769	rs28450136	chr5:139598090	A/G	cg26211634	chr5:139558579	C5orf32	0.46	5.12	0.3	5.97e-7	Atrial fibrillation;
CESC	cis	rs3820068	0.705	rs72645803	chr1:15868232	G/A	cg17385448	chr1:15911702	AGMAT	0.38	5.9	0.34	1.1e-8	Systolic blood pressure;
CESC	cis	rs873946	0.586	rs12251911	chr10:134570595	A/G	cg26818010	chr10:134567672	INPP5A	-0.9	-11.15	-0.56	6.51e-24	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs9611565	0.546	rs5758431	chr22:42109917	A/G	cg06634786	chr22:41940651	POLR3H	0.66	6.76	0.38	8.7e-11	Vitiligo;
CESC	cis	rs2228479	0.618	rs72477006	chr16:89950299	G/C	cg06558623	chr16:89946397	TCF25	1.03	8.33	0.46	4.25e-15	Skin colour saturation;
CESC	cis	rs11690935	0.632	rs12998411	chr2:172530707	G/C	cg13550731	chr2:172543902	DYNC1I2	0.57	7.98	0.44	4.34e-14	Schizophrenia;
CESC	cis	rs2412459	0.536	rs7173301	chr15:40269843	C/T	cg25407064	chr15:40226267	EIF2AK4	0.55	5.54	0.32	7.3e-8	Response to haloperidol in psychosis;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg01663295	chr11:65837194	PACS1	0.5	6.85	0.39	5.11e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs910316	1.000	rs4903281	chr14:75554361	G/C	cg08847533	chr14:75593920	NEK9	1.0	19.06	0.76	1.38e-51	Height;
CESC	cis	rs2108225	0.900	rs2395930	chr7:107451677	T/C	cg18560240	chr7:107437656	SLC26A3	-0.4	-5.4	-0.31	1.51e-7	Ulcerative colitis;
CESC	cis	rs853679	0.517	rs9393894	chr6:28112562	A/G	cg23281280	chr6:28129359	ZNF389	0.59	7.91	0.44	7.14e-14	Depression;
CESC	cis	rs4835473	0.592	rs11100825	chr4:144886056	G/A	cg25736465	chr4:144833511	NA	0.41	6.25	0.36	1.64e-9	Immature fraction of reticulocytes;
CESC	cis	rs929354	0.713	rs6946660	chr7:156948648	T/C	cg05182265	chr7:156933206	UBE3C	-0.5	-7.29	-0.41	3.49e-12	Body mass index;
CESC	cis	rs1799949	0.501	rs2343819	chr17:41409653	T/G	cg25072359	chr17:41440525	NA	0.47	6.36	0.36	8.86e-10	Menopause (age at onset);
CESC	cis	rs6076065	0.748	rs6048750	chr20:23334192	T/G	cg11657817	chr20:23433608	CST11	0.41	6.23	0.36	1.83e-9	Facial morphology (factor 15, philtrum width);
CESC	cis	rs7223966	1.000	rs78172786	chr17:61847114	A/C	cg11494091	chr17:61959527	GH2	0.4	5.32	0.31	2.25e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24054683	chr1:2085751	PRKCZ	-0.56	-6.07	-0.35	4.49e-9	Gut microbiome composition (summer);
CESC	cis	rs7107174	0.901	rs901105	chr11:77924607	A/C	cg02023728	chr11:77925099	USP35	0.47	5.97	0.34	7.71e-9	Testicular germ cell tumor;
CESC	cis	rs7246865	0.906	rs11666569	chr19:17214073	A/G	cg16202187	chr19:17186497	HAUS8;MYO9B	-0.41	-5.03	-0.3	8.99e-7	Reticulocyte fraction of red cells;
CESC	cis	rs763121	0.776	rs4820346	chr22:39125074	C/G	cg06022373	chr22:39101656	GTPBP1	-0.89	-14.0	-0.65	1.05e-33	Menopause (age at onset);
CESC	cis	rs9486719	0.790	rs2499790	chr6:96845078	G/A	cg06623918	chr6:96969491	KIAA0776	0.78	7.39	0.41	1.89e-12	Migraine;Coronary artery disease;
CESC	cis	rs1862618	0.853	rs863840	chr5:56128999	C/G	cg20203395	chr5:56204925	C5orf35	-0.42	-5.05	-0.3	8.07e-7	Initial pursuit acceleration;
CESC	cis	rs2806561	0.929	rs6660880	chr1:23540302	T/C	cg12483005	chr1:23474871	LUZP1	-0.33	-5.33	-0.31	2.07e-7	Height;
CESC	cis	rs3785574	0.962	rs35448669	chr17:61938923	G/A	cg06420487	chr17:61919686	SMARCD2	0.42	5.12	0.3	5.95e-7	Height;
CESC	cis	rs9733	0.596	rs7529998	chr1:150662531	C/T	cg09365446	chr1:150670422	GOLPH3L	0.42	5.91	0.34	1.03e-8	Tonsillectomy;
CESC	trans	rs3780486	0.505	rs10117038	chr9:33122626	T/C	cg20290983	chr6:43655470	MRPS18A	0.76	12.11	0.6	3.58e-27	IgG glycosylation;
CESC	cis	rs13108904	0.557	rs1250098	chr4:1238256	A/T	cg19318889	chr4:1322082	MAEA	-0.46	-6.0	-0.35	6.58e-9	Obesity-related traits;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg02604939	chr3:50330083	IFRD2	0.45	6.03	0.35	5.56e-9	Thyroid stimulating hormone;
CESC	cis	rs3785574	0.962	rs58131426	chr17:61854375	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	1.11	19.57	0.77	2.18e-53	Height;
CESC	cis	rs9300255	0.568	rs1627724	chr12:123638580	T/A	cg00376283	chr12:123451042	ABCB9	0.7	8.89	0.48	9.5e-17	Neutrophil percentage of white cells;
CESC	cis	rs4665809	1.000	rs1470097	chr2:26312840	A/G	cg22920501	chr2:26401640	FAM59B	-0.64	-7.67	-0.43	3.37e-13	Gut microbiome composition (summer);
CESC	cis	rs67311347	1.000	rs11714032	chr3:40431605	G/A	cg24209194	chr3:40518798	ZNF619	0.5	6.12	0.35	3.3e-9	Renal cell carcinoma;
CESC	trans	rs561341	1.000	rs111454793	chr17:30319267	T/C	cg20587970	chr11:113659929	NA	-1.42	-18.3	-0.75	6.25e-49	Hip circumference adjusted for BMI;
CESC	cis	rs10752881	0.905	rs10797830	chr1:183036274	A/T	ch.1.3577855R	chr1:183094577	LAMC1	0.87	13.77	0.65	6.86e-33	Colorectal cancer;
CESC	cis	rs6459788	0.502	rs9692347	chr7:157232659	C/T	cg06271696	chr7:157225062	NA	-0.46	-7.71	-0.43	2.6e-13	Epstein-Barr virus copy number in lymphoblastoid cell lines;
CESC	cis	rs9300255	0.602	rs2695476	chr12:123694206	T/C	cg00376283	chr12:123451042	ABCB9	0.61	6.37	0.36	8.43e-10	Neutrophil percentage of white cells;
CESC	trans	rs1667255	0.830	rs2034404	chr18:29156302	A/G	cg21547979	chr19:49141364	SEC1;DBP;CA11	0.46	6.23	0.36	1.84e-9	Retinol levels;
CESC	cis	rs6088580	0.634	rs6059824	chr20:33014543	T/C	cg08999081	chr20:33150536	PIGU	0.66	11.54	0.58	3.17e-25	Glomerular filtration rate (creatinine);
CESC	cis	rs3126085	0.935	rs4845736	chr1:152175551	G/A	cg26876637	chr1:152193138	HRNR	0.45	5.2	0.3	3.98e-7	Atopic dermatitis;
CESC	cis	rs7264396	0.563	rs2425090	chr20:34304783	C/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.63	6.7	0.38	1.23e-10	Total cholesterol levels;
CESC	cis	rs2320614	0.806	rs17471740	chr4:164100276	C/T	cg15586945	chr4:164088095	NAF1	-0.47	-5.91	-0.34	1.05e-8	Lung adenocarcinoma;
CESC	cis	rs6991838	0.612	rs7832407	chr8:66533306	C/T	cg13398993	chr8:66546079	ARMC1	0.46	5.65	0.33	4.19e-8	Intelligence (multi-trait analysis);
CESC	cis	rs4803468	1.000	rs10422783	chr19:41906436	T/C	cg09537434	chr19:41945824	ATP5SL	-1.06	-19.22	-0.76	3.86e-52	Height;
CESC	cis	rs6063312	0.667	rs9679994	chr20:47281853	T/C	cg18078177	chr20:47281410	PREX1	0.67	8.56	0.47	9.44e-16	Tonometry;
CESC	trans	rs7307889	0.793	rs12301367	chr12:6009024	C/T	cg18407955	chr7:158110685	PTPRN2	-0.72	-6.66	-0.38	1.53e-10	Obesity-related traits;
CESC	cis	rs13256369	0.901	rs12681327	chr8:8566414	G/T	cg00074818	chr8:8560427	CLDN23	0.36	5.29	0.31	2.51e-7	Obesity-related traits;
CESC	cis	rs7412746	0.611	rs4970931	chr1:150910727	G/A	cg04414720	chr1:150670196	GOLPH3L	0.45	5.96	0.34	8.13e-9	Melanoma;
CESC	cis	rs2439831	1.000	rs527921	chr15:43770416	G/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.89	-10.44	-0.54	1.31e-21	Lung cancer in ever smokers;
CESC	cis	rs244293	0.730	rs9898020	chr17:53057715	G/A	cg19360675	chr17:53046073	COX11;STXBP4	-0.46	-6.1	-0.35	3.71e-9	Menarche (age at onset);
CESC	cis	rs3785574	0.962	rs9944483	chr17:61783553	G/T	cg06601766	chr17:61851465	DDX42;CCDC47	-0.77	-10.12	-0.53	1.47e-20	Height;
CESC	cis	rs597539	0.652	rs660614	chr11:68659488	G/A	cg18350739	chr11:68623251	NA	-0.45	-6.88	-0.39	4.4e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs11122272	0.735	rs2486734	chr1:231531392	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.56	-7.66	-0.43	3.45e-13	Hemoglobin concentration;
CESC	cis	rs10905065	0.804	rs2380202	chr10:5823397	C/T	cg11519256	chr10:5708881	ASB13	-0.39	-5.12	-0.3	5.79e-7	Menopause (age at onset);
CESC	cis	rs8072100	0.713	rs9895776	chr17:45486003	A/G	cg08085267	chr17:45401833	C17orf57	-0.52	-6.64	-0.38	1.81e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	trans	rs7107217	1.000	rs1873872	chr11:129473993	A/T	cg13834670	chr9:129677390	RALGPS1	0.46	6.32	0.36	1.08e-9	Breast cancer;Type 2 diabetes;
CESC	cis	rs875971	1.000	rs6946143	chr7:65579722	A/C	cg11764359	chr7:65958608	NA	0.91	13.19	0.63	7.05e-31	Aortic root size;
CESC	cis	rs3733585	0.534	rs7375642	chr4:9955236	A/G	cg11266682	chr4:10021025	SLC2A9	-0.57	-10.92	-0.56	3.75e-23	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs4253772	0.591	rs8143066	chr22:46656607	C/T	cg09491104	chr22:46646882	C22orf40	-0.6	-9.36	-0.5	3.69e-18	LDL cholesterol;Cholesterol, total;
CESC	cis	rs10504229	1.000	rs77823122	chr8:58170161	A/G	cg24829409	chr8:58192753	C8orf71	-0.76	-9.92	-0.52	6.14e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs7605378	1.000	rs796363	chr2:200693668	T/C	cg23649088	chr2:200775458	C2orf69	0.5	6.65	0.38	1.66e-10	Osteoporosis;
CESC	cis	rs642803	0.613	rs565427	chr11:65532825	G/A	cg02870584	chr11:65547924	DKFZp761E198	0.53	6.65	0.38	1.65e-10	Urate levels;
CESC	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg10295955	chr4:187884368	NA	-1.08	-23.01	-0.82	4.07e-65	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1801251	0.893	rs6733151	chr2:233592341	A/C	cg25237894	chr2:233734115	C2orf82	0.46	7.86	0.43	9.9e-14	Coronary artery disease;
CESC	cis	rs79349575	0.783	rs62078370	chr17:47026836	G/C	cg16584676	chr17:46985605	UBE2Z	0.54	6.67	0.38	1.46e-10	Type 2 diabetes;
CESC	cis	rs798554	0.757	rs2533879	chr7:2859847	G/A	cg09658497	chr7:2847517	GNA12	-0.42	-5.86	-0.34	1.37e-8	Height;
CESC	cis	rs2070677	0.935	rs12245492	chr10:135419727	A/G	cg20169779	chr10:135381914	SYCE1	-0.73	-9.56	-0.51	8.51e-19	Gout;
CESC	cis	rs2273669	0.667	rs12374658	chr6:109345930	T/C	cg05315195	chr6:109294784	ARMC2	-0.67	-6.32	-0.36	1.13e-9	Prostate cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11038604	chr10:14996337	DCLRE1C	-0.58	-6.6	-0.38	2.29e-10	Gut microbiome composition (summer);
CESC	cis	rs12893668	0.667	rs11844466	chr14:104066422	G/A	cg08213375	chr14:104286397	PPP1R13B	0.32	5.1	0.3	6.33e-7	Reticulocyte count;
CESC	cis	rs896854	0.654	rs2011566	chr8:95971921	G/A	cg09323728	chr8:95962352	TP53INP1	-0.38	-8.37	-0.46	3.31e-15	Type 2 diabetes;
CESC	cis	rs733175	0.951	rs6846692	chr4:10031133	C/G	cg00071950	chr4:10020882	SLC2A9	0.45	5.15	0.3	5.06e-7	Psychosis and Alzheimer's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04765098	chr4:184644154	NA	0.57	6.58	0.37	2.49e-10	Gut microbiome composition (summer);
CESC	cis	rs4665809	0.938	rs4665822	chr2:26312555	C/G	cg08470875	chr2:26401718	FAM59B	-0.48	-5.27	-0.31	2.84e-7	Gut microbiome composition (summer);
CESC	trans	rs1557351	0.602	rs948650	chr18:54721870	G/A	cg11433624	chr6:7146702	RREB1	0.38	6.14	0.35	2.94e-9	Multiple sclerosis (age of onset);
CESC	trans	rs916888	0.779	rs199528	chr17:44843136	C/T	cg07870213	chr5:140052090	DND1	0.64	6.81	0.39	6.47e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs7809950	0.678	rs7777950	chr7:107004672	T/C	cg23024343	chr7:107201750	COG5	-0.52	-6.72	-0.38	1.08e-10	Coronary artery disease;
CESC	cis	rs4642101	0.597	rs9865624	chr3:12822786	T/A	cg24848339	chr3:12840334	CAND2	0.39	5.96	0.34	8.16e-9	QRS complex (12-leadsum);
CESC	cis	rs7917772	0.503	rs11191347	chr10:104351617	C/T	cg22532475	chr10:104410764	TRIM8	-0.36	-6.35	-0.36	9.36e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs16858210	0.874	rs55666767	chr3:183573235	C/T	cg25686905	chr3:183603175	PARL	-0.33	-5.98	-0.34	7.2e-9	Menopause (age at onset);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg14659771	chr2:231917362	NA	-0.44	-6.11	-0.35	3.64e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs12599106	0.818	rs17723574	chr16:34602945	C/G	cg01516881	chr6:292596	DUSP22	-0.52	-6.92	-0.39	3.43e-11	Menopause (age at onset);
CESC	cis	rs738322	1.000	rs4379	chr22:38569171	T/C	cg17652424	chr22:38574118	PLA2G6	-0.34	-6.03	-0.35	5.53e-9	Cutaneous nevi;
CESC	cis	rs7828089	0.561	rs13266541	chr8:22266135	G/A	cg12081754	chr8:22256438	SLC39A14	0.62	8.72	0.47	3.21e-16	Verbal declarative memory;
CESC	cis	rs7980687	0.596	rs1727319	chr12:123701353	T/C	cg19016782	chr12:123741754	C12orf65	-0.34	-5.1	-0.3	6.57e-7	Height;Educational attainment;Head circumference (infant);
CESC	cis	rs933688	1.000	rs61612071	chr5:90741470	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.95	11.04	0.56	1.47e-23	Smoking behavior;
CESC	cis	rs17253792	0.908	rs9972177	chr14:56073206	G/A	cg01858014	chr14:56050164	KTN1	-0.83	-7.03	-0.4	1.7e-11	Putamen volume;
CESC	cis	rs763121	0.853	rs3788545	chr22:39065172	A/G	cg06544989	chr22:39130855	UNC84B	0.5	8.61	0.47	6.7e-16	Menopause (age at onset);
CESC	trans	rs6763848	0.545	rs2648451	chr3:1525557	C/T	cg08653403	chr1:16212402	SPEN	-0.39	-6.08	-0.35	4.09e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs1949733	0.701	rs871768	chr4:8454938	G/A	cg11789530	chr4:8429930	ACOX3	0.76	11.12	0.56	8.15e-24	Response to antineoplastic agents;
CESC	cis	rs7188873	1	rs7188873	chr16:24727064	A/G	cg06028605	chr16:24865363	SLC5A11	-0.34	-5.26	-0.31	2.97e-7	Intelligence (multi-trait analysis);
CESC	cis	rs10504229	0.645	rs6995814	chr8:58114159	C/T	cg02725872	chr8:58115012	NA	-0.45	-7.04	-0.4	1.66e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs7666738	0.861	rs28829607	chr4:98964325	G/C	cg03676636	chr4:99064102	C4orf37	0.33	5.14	0.3	5.39e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6570726	0.935	rs408768	chr6:145871735	A/G	cg05347473	chr6:146136440	FBXO30	0.48	6.49	0.37	4.11e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs3540	0.554	rs34650360	chr15:91059017	T/C	cg10434728	chr15:90938212	IQGAP1	-0.4	-6.97	-0.39	2.48e-11	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs55728055	0.661	rs62239172	chr22:32047941	G/A	cg01338084	chr22:32026380	PISD	1.29	8.72	0.47	3.17e-16	Age-related hearing impairment;
CESC	cis	rs8020095	0.528	rs73279056	chr14:67701536	T/G	cg19548862	chr14:67692701	FAM71D	-0.47	-5.66	-0.33	4.01e-8	Depression (quantitative trait);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21186779	chr16:46462885	NA	-0.61	-6.81	-0.39	6.46e-11	Gut microbiome composition (summer);
CESC	cis	rs752092	0.894	rs8042989	chr15:101770761	T/A	cg19997662	chr15:101784653	CHSY1	-0.42	-5.48	-0.32	1e-7	Corneal structure;
CESC	cis	rs514406	0.861	rs1571979	chr1:53237526	G/A	cg08736216	chr1:53307985	ZYG11A	0.43	7.24	0.41	4.72e-12	Monocyte count;
CESC	cis	rs4819052	0.851	rs2838866	chr21:46713014	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.85	11.93	0.59	1.56e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs2288073	0.896	rs13404513	chr2:24410780	G/A	cg06627628	chr2:24431161	ITSN2	-0.74	-8.68	-0.47	4.02e-16	Venous thromboembolism (SNP x SNP interaction);
CESC	cis	rs11122272	0.735	rs2491404	chr1:231512127	C/T	cg06096015	chr1:231504339	EGLN1	0.43	6.18	0.35	2.46e-9	Hemoglobin concentration;
CESC	cis	rs7098414	0.511	rs7907575	chr10:82152675	T/G	cg00277334	chr10:82204260	NA	-0.5	-7.37	-0.41	2.23e-12	Post bronchodilator FEV1;
CESC	cis	rs7508679	1.000	rs10401485	chr19:7222234	T/C	cg00428638	chr19:7224713	INSR	0.47	7.42	0.41	1.56e-12	Hypothyroidism;
CESC	cis	rs9420	0.816	rs674094	chr11:57665336	A/C	cg23127183	chr11:57508653	C11orf31	0.48	5.11	0.3	6.08e-7	Schizophrenia;
CESC	cis	rs714031	0.934	rs738315	chr22:40069245	T/C	cg21377881	chr22:40064566	CACNA1I	-0.32	-5.1	-0.3	6.38e-7	Schizophrenia;
CESC	cis	rs854765	0.647	rs9303144	chr17:17977355	T/C	cg16928487	chr17:17741425	SREBF1	-0.52	-8.4	-0.46	2.72e-15	Total body bone mineral density;
CESC	trans	rs1493916	0.870	rs8097667	chr18:31387003	C/T	cg27147174	chr7:100797783	AP1S1	-0.49	-6.81	-0.39	6.62e-11	Life satisfaction;
CESC	cis	rs72781680	1.000	rs6731001	chr2:24192952	A/G	cg20701182	chr2:24300061	SF3B14	0.64	5.74	0.33	2.56e-8	Lymphocyte counts;
CESC	cis	rs4819052	0.851	rs2838829	chr21:46664040	A/C	cg11663144	chr21:46675770	NA	-0.63	-9.99	-0.52	3.64e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs172166	0.694	rs203884	chr6:28077374	G/T	cg23161317	chr6:28129485	ZNF389	0.38	5.05	0.3	8.16e-7	Cardiac Troponin-T levels;
CESC	trans	rs1829883	0.514	rs62375908	chr5:98753389	G/A	cg23861655	chr4:57411219	NA	0.39	6.32	0.36	1.1e-9	Hemostatic factors and hematological phenotypes;
CESC	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg18402987	chr7:1209562	NA	0.44	5.8	0.34	1.86e-8	Longevity;Endometriosis;
CESC	cis	rs9768139	0.733	rs34173461	chr7:158122175	C/G	cg06219351	chr7:158114137	PTPRN2	-0.51	-7.88	-0.44	8.68e-14	Calcium levels;
CESC	cis	rs1847202	1.000	rs6807627	chr3:72939767	C/T	cg25664220	chr3:72788482	NA	-0.36	-5.4	-0.31	1.46e-7	Motion sickness;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17890828	chr19:36103534	HAUS5	0.61	7.21	0.4	5.75e-12	Gut microbiome composition (summer);
CESC	cis	rs59918340	0.764	rs753779	chr8:142228809	T/C	cg23750338	chr8:142222470	SLC45A4	0.62	9.26	0.49	7.46e-18	Immature fraction of reticulocytes;
CESC	cis	rs4689592	0.546	rs10937784	chr4:7060935	G/C	cg19539972	chr4:7069911	GRPEL1	0.78	10.38	0.54	2.04e-21	Monocyte percentage of white cells;
CESC	cis	rs5743618	0.537	rs11734337	chr4:38773067	A/G	cg02016764	chr4:38805732	TLR1	-0.33	-5.15	-0.3	4.97e-7	Asthma;Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs2243480	1.000	rs35825738	chr7:65318027	A/G	cg13147721	chr7:65941812	NA	-0.85	-8.51	-0.46	1.26e-15	Diabetic kidney disease;
CESC	cis	rs36051895	0.659	rs59668095	chr9:5043688	C/G	cg02405213	chr9:5042618	JAK2	-0.49	-5.84	-0.34	1.55e-8	Pediatric autoimmune diseases;
CESC	cis	rs5750830	0.594	rs9611166	chr22:39775268	T/C	cg05872129	chr22:39784769	NA	-0.75	-10.71	-0.55	1.76e-22	Intelligence (multi-trait analysis);
CESC	trans	rs3780486	0.846	rs7850878	chr9:33126570	A/G	cg04842962	chr6:43655489	MRPS18A	1.0	19.21	0.76	4.11e-52	IgG glycosylation;
CESC	cis	rs2576037	0.526	rs998819	chr18:44564181	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.42	-6.98	-0.39	2.33e-11	Personality dimensions;
CESC	cis	rs7772486	0.754	rs4896841	chr6:146041522	T/C	cg05347473	chr6:146136440	FBXO30	-0.57	-7.25	-0.41	4.46e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs17384381	0.861	rs12736004	chr1:85901367	G/A	cg16011679	chr1:85725395	C1orf52	0.74	7.49	0.42	1.04e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9916302	0.904	rs9898773	chr17:37532507	C/G	cg00129232	chr17:37814104	STARD3	0.59	7.81	0.43	1.3e-13	Glomerular filtration rate (creatinine);
CESC	cis	rs12497850	0.931	rs9840684	chr3:48893780	T/C	cg03060546	chr3:49711283	APEH	0.45	5.5	0.32	9e-8	Parkinson's disease;
CESC	cis	rs72781680	0.752	rs56343114	chr2:23900629	C/G	cg20701182	chr2:24300061	SF3B14	0.72	6.32	0.36	1.09e-9	Lymphocyte counts;
CESC	cis	rs6964587	1.000	rs2106171	chr7:91750450	A/G	cg17063962	chr7:91808500	NA	0.58	8.02	0.44	3.33e-14	Breast cancer;
CESC	cis	rs712039	0.652	rs1102920	chr17:35760940	A/G	cg16670864	chr17:35848621	DUSP14	0.48	6.12	0.35	3.34e-9	Tuberculosis;
CESC	cis	rs9916302	0.904	rs9944411	chr17:37483599	T/C	cg15445000	chr17:37608096	MED1	-0.42	-6.67	-0.38	1.49e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs875971	0.522	rs4718286	chr7:65292764	A/G	cg18876405	chr7:65276391	NA	0.69	9.72	0.51	2.78e-19	Aortic root size;
CESC	cis	rs4654899	0.758	rs6698462	chr1:21341293	G/C	cg05370193	chr1:21551575	ECE1	0.37	5.65	0.33	4.12e-8	Superior frontal gyrus grey matter volume;
CESC	cis	rs12410462	0.581	rs6675521	chr1:227544702	C/T	cg10327440	chr1:227177885	CDC42BPA	-0.67	-5.69	-0.33	3.43e-8	Major depressive disorder;
CESC	cis	rs2191566	0.576	rs436790	chr19:44491927	A/G	cg20607764	chr19:44506953	ZNF230	-0.43	-5.31	-0.31	2.29e-7	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs9768139	0.935	rs7809076	chr7:158118438	C/T	cg25566285	chr7:158114605	PTPRN2	-0.49	-8.31	-0.45	4.93e-15	Calcium levels;
CESC	cis	rs7927771	0.697	rs11039307	chr11:47611152	C/T	cg18512352	chr11:47633146	NA	-0.46	-7.06	-0.4	1.44e-11	Subjective well-being;
CESC	trans	rs561341	0.941	rs4525554	chr17:30312819	T/C	cg27661571	chr11:113659931	NA	-0.83	-7.76	-0.43	1.9e-13	Hip circumference adjusted for BMI;
CESC	cis	rs3204270	0.714	rs8074828	chr17:79657136	G/C	cg26965718	chr17:79658957	HGS	-0.76	-5.67	-0.33	3.81e-8	Dental caries;
CESC	cis	rs8077577	0.708	rs3862147	chr17:18133713	G/T	cg16794390	chr17:18148240	FLII	-0.45	-6.69	-0.38	1.35e-10	Obesity-related traits;
CESC	cis	rs863345	0.901	rs1342956	chr1:158467755	A/G	cg12129480	chr1:158549410	OR10X1	-0.32	-6.27	-0.36	1.42e-9	Pneumococcal bacteremia;
CESC	cis	rs2439831	1.000	rs2444029	chr15:43737484	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.89	10.63	0.55	3.35e-22	Lung cancer in ever smokers;
CESC	cis	rs7116495	0.619	rs7116188	chr11:71841753	A/G	cg26138937	chr11:71823887	C11orf51	0.77	6.17	0.35	2.58e-9	Severe influenza A (H1N1) infection;
CESC	cis	rs2295499	0.643	rs59609182	chr4:2721530	C/T	cg27239842	chr4:2403781	ZFYVE28	-0.31	-5.32	-0.31	2.21e-7	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
CESC	cis	rs4665809	0.549	rs17527979	chr2:26428132	A/G	cg25036284	chr2:26402008	FAM59B	-0.75	-7.88	-0.44	8.74e-14	Gut microbiome composition (summer);
CESC	cis	rs2243480	1.000	rs160655	chr7:65533214	T/C	cg18252515	chr7:66147081	NA	-1.33	-13.56	-0.64	3.72e-32	Diabetic kidney disease;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg15901550	chr1:17997619	ARHGEF10L	-0.45	-6.27	-0.36	1.44e-9	Asthma;
CESC	cis	rs13118159	0.725	rs71614967	chr4:1341291	A/G	cg16405210	chr4:1374714	KIAA1530	-0.57	-7.51	-0.42	8.89e-13	Longevity;
CESC	cis	rs1878931	0.567	rs7196196	chr16:3411855	C/A	cg22508957	chr16:3507546	NAT15	-0.36	-5.17	-0.3	4.68e-7	Body mass index (adult);
CESC	cis	rs2011503	0.891	rs2965190	chr19:19451591	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.51	-5.13	-0.3	5.64e-7	Bipolar disorder;
CESC	cis	rs5758511	0.680	rs5758692	chr22:42669029	T/A	cg00645731	chr22:42541494	CYP2D7P1	0.59	8.55	0.47	9.64e-16	Birth weight;
CESC	cis	rs4588572	0.601	rs1529500	chr5:77721643	C/T	cg11547950	chr5:77652471	NA	-0.45	-5.65	-0.33	4.15e-8	Triglycerides;
CESC	trans	rs9467711	0.606	rs9358930	chr6:26357011	C/T	cg06606381	chr12:133084897	FBRSL1	-0.76	-6.87	-0.39	4.66e-11	Autism spectrum disorder or schizophrenia;
CESC	cis	rs478304	0.651	rs11600918	chr11:65511965	A/G	cg10518572	chr11:65560635	OVOL1	-0.32	-6.12	-0.35	3.44e-9	Acne (severe);
CESC	cis	rs780096	0.526	rs704791	chr2:27657167	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.32	-5.97	-0.34	7.45e-9	Total body bone mineral density;
CESC	cis	rs763014	0.932	rs2269560	chr16:682442	A/C	cg07256732	chr16:621771	PIGQ	-0.3	-5.25	-0.31	3.09e-7	Height;
CESC	cis	rs3749237	0.595	rs3924462	chr3:49524236	T/G	cg07636037	chr3:49044803	WDR6	0.61	8.81	0.48	1.66e-16	Resting heart rate;
CESC	cis	rs11098499	0.754	rs2964	chr4:120240131	T/C	cg09307838	chr4:120376055	NA	0.79	10.77	0.55	1.17e-22	Corneal astigmatism;
CESC	cis	rs35110281	0.712	rs167930	chr21:44946625	G/A	cg01579765	chr21:45077557	HSF2BP	-0.55	-9.61	-0.51	6.1e-19	Mean corpuscular volume;
CESC	cis	rs7666738	0.830	rs1876192	chr4:98727555	T/C	cg05340658	chr4:99064831	C4orf37	0.74	10.76	0.55	1.18e-22	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9611565	0.840	rs3788584	chr22:41779073	T/A	cg06634786	chr22:41940651	POLR3H	-0.7	-7.42	-0.41	1.63e-12	Vitiligo;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20879272	chr20:3996372	RNF24	0.56	6.06	0.35	4.69e-9	Gut microbiome composition (summer);
CESC	cis	rs6460942	0.915	rs62448599	chr7:12453764	C/T	cg02935154	chr7:12443704	VWDE	-0.56	-5.88	-0.34	1.24e-8	Coronary artery disease;
CESC	cis	rs10504073	0.605	rs62507176	chr8:49930321	G/A	cg00325661	chr8:49890786	NA	0.55	8.31	0.45	5.1e-15	Blood metabolite ratios;
CESC	cis	rs10504229	0.724	rs58715581	chr8:58134568	A/G	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs412050	0.547	rs17821500	chr22:22152480	T/C	cg17089214	chr22:22089827	YPEL1	0.67	5.8	0.34	1.92e-8	Attention deficit hyperactivity disorder;
CESC	cis	rs7666738	0.822	rs17484018	chr4:98988960	G/A	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.6e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9837602	1.000	rs9841186	chr3:99795651	C/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.46	-6.43	-0.37	6.02e-10	Breast cancer;
CESC	cis	rs7100689	0.754	rs10736339	chr10:82059970	G/C	cg09936400	chr10:82049201	MAT1A	0.37	5.31	0.31	2.34e-7	Post bronchodilator FEV1;
CESC	cis	rs9309473	1.000	rs7572722	chr2:73724675	T/C	cg20560298	chr2:73613845	ALMS1	-0.55	-7.15	-0.4	8.23e-12	Metabolite levels;
CESC	cis	rs1594829	0.535	rs11784209	chr8:26170246	T/C	cg11498726	chr8:26250323	BNIP3L	-0.41	-6.2	-0.36	2.2e-9	Height;
CESC	cis	rs72781680	0.566	rs55987381	chr2:23900938	T/C	cg20701182	chr2:24300061	SF3B14	0.71	7.18	0.4	7.24e-12	Lymphocyte counts;
CESC	cis	rs947211	0.948	rs863725	chr1:205751196	C/T	cg17178900	chr1:205818956	PM20D1	0.39	5.08	0.3	7.01e-7	Parkinson's disease;
CESC	trans	rs7746199	0.673	rs35501037	chr6:27739566	T/A	cg01620082	chr3:125678407	NA	-0.75	-6.08	-0.35	4.29e-9	Gait speed in old age;Autism spectrum disorder or schizophrenia;
CESC	cis	rs2425143	0.908	rs6060625	chr20:34414318	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.64	5.49	0.32	9.59e-8	Blood protein levels;
CESC	cis	rs9457247	1.000	rs400837	chr6:167411008	T/C	cg25258033	chr6:167368657	RNASET2	0.4	6.14	0.35	2.93e-9	Crohn's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14212983	chr1:21985742	RAP1GAP	0.57	6.85	0.39	5.24e-11	Gut microbiome composition (summer);
CESC	cis	rs11645898	0.745	rs72787062	chr16:72105844	G/A	cg14768367	chr16:72042858	DHODH	-0.74	-6.32	-0.36	1.09e-9	Blood protein levels;
CESC	cis	rs8180040	0.966	rs4858868	chr3:47455086	G/A	cg27129171	chr3:47204927	SETD2	0.63	9.61	0.51	6.12e-19	Colorectal cancer;
CESC	cis	rs17376456	0.877	rs28637444	chr5:93495548	C/T	cg25358565	chr5:93447407	FAM172A	1.17	10.96	0.56	2.63e-23	Diabetic retinopathy;
CESC	cis	rs9309473	0.519	rs6746971	chr2:73669462	A/G	cg20560298	chr2:73613845	ALMS1	-0.5	-7.21	-0.41	5.7e-12	Metabolite levels;
CESC	cis	rs4727027	0.933	rs917122	chr7:148848257	T/C	cg23158103	chr7:148848205	ZNF398	-0.43	-7.08	-0.4	1.27e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs11098499	0.863	rs59732491	chr4:120489588	G/C	cg24375607	chr4:120327624	NA	0.48	5.95	0.34	8.26e-9	Corneal astigmatism;
CESC	cis	rs4665809	0.877	rs35224700	chr2:26298037	T/C	cg08470875	chr2:26401718	FAM59B	0.59	6.16	0.35	2.71e-9	Gut microbiome composition (summer);
CESC	cis	rs1552244	0.572	rs6797536	chr3:10168802	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	0.66	7.12	0.4	1.04e-11	Alzheimer's disease;
CESC	cis	rs561341	1.000	rs535151	chr17:30317405	C/T	cg19193384	chr17:30244184	NA	-0.52	-6.16	-0.35	2.67e-9	Hip circumference adjusted for BMI;
CESC	cis	rs4665809	1.000	rs6749855	chr2:26255263	A/G	cg26314531	chr2:26401878	FAM59B	-0.66	-7.14	-0.4	8.76e-12	Gut microbiome composition (summer);
CESC	cis	rs4803468	0.763	rs17318596	chr19:41937095	A/G	cg09537434	chr19:41945824	ATP5SL	-1.1	-20.07	-0.78	4.09e-55	Height;
CESC	cis	rs929354	0.772	rs1182362	chr7:157019535	A/G	cg05182265	chr7:156933206	UBE3C	0.52	7.57	0.42	6.18e-13	Body mass index;
CESC	cis	rs1577917	1.000	rs12209127	chr6:86724427	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-6.17	-0.35	2.58e-9	Response to antipsychotic treatment;
CESC	cis	rs7412746	0.611	rs16827671	chr1:150738759	T/C	cg17724175	chr1:150552817	MCL1	0.4	6.09	0.35	3.97e-9	Melanoma;
CESC	cis	rs10465746	0.746	rs6663949	chr1:84452853	T/C	cg10977910	chr1:84465055	TTLL7	0.51	6.99	0.39	2.27e-11	Obesity-related traits;
CESC	cis	rs9858542	0.953	rs9837341	chr3:49664767	A/G	cg03060546	chr3:49711283	APEH	-0.57	-6.71	-0.38	1.21e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs7474896	0.559	rs10740949	chr10:37978435	A/G	cg25427524	chr10:38739819	LOC399744	-0.46	-5.37	-0.31	1.76e-7	Obesity (extreme);
CESC	cis	rs9837602	1.000	rs13064704	chr3:99767541	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.53	7.51	0.42	8.91e-13	Breast cancer;
CESC	cis	rs7617773	0.780	rs6442111	chr3:48312060	G/C	cg11946769	chr3:48343235	NME6	0.8	10.74	0.55	1.38e-22	Coronary artery disease;
CESC	cis	rs1707322	0.752	rs28438704	chr1:46170544	G/A	cg05343316	chr1:45956843	TESK2	0.51	6.2	0.36	2.19e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs6088580	0.524	rs6088560	chr20:33228549	T/C	cg07148914	chr20:33460835	GGT7	-0.4	-5.06	-0.3	7.78e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs854765	0.547	rs2955384	chr17:17939573	C/T	cg04398451	chr17:18023971	MYO15A	-0.7	-10.46	-0.54	1.16e-21	Total body bone mineral density;
CESC	cis	rs11229555	1.000	rs3168135	chr11:58386177	G/A	cg15696309	chr11:58395628	NA	-0.43	-5.64	-0.33	4.3e-8	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs7666738	0.830	rs4699603	chr4:99056172	T/C	cg03676636	chr4:99064102	C4orf37	0.34	5.15	0.3	5.06e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4975709	0.758	rs4975756	chr5:1882443	T/C	cg12288994	chr5:1860383	NA	0.37	5.76	0.33	2.29e-8	Cardiovascular disease risk factors;
CESC	cis	rs9815354	0.812	rs73069390	chr3:41785513	C/T	cg03022575	chr3:42003672	ULK4	0.73	6.35	0.36	9.44e-10	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs962856	0.964	rs1552359	chr2:67615429	A/G	cg09028215	chr2:67624308	ETAA1	-0.4	-5.34	-0.31	2.01e-7	Pancreatic cancer;
CESC	cis	rs2952156	1.000	rs2952156	chr17:37876835	A/G	cg07936489	chr17:37558343	FBXL20	-0.52	-6.05	-0.35	4.96e-9	Asthma;
CESC	cis	rs2070488	0.931	rs6599212	chr3:38558906	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.91	-16.62	-0.71	5.46e-43	Electrocardiographic conduction measures;
CESC	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg07677032	chr17:61819896	STRADA	0.45	5.94	0.34	8.83e-9	Prudent dietary pattern;
CESC	cis	rs2276314	0.512	rs7227264	chr18:33454631	A/C	cg05985134	chr18:33552581	C18orf21	0.42	5.04	0.3	8.71e-7	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs13082711	0.554	rs34066402	chr3:27387987	G/A	cg02860705	chr3:27208620	NA	0.74	8.35	0.46	3.74e-15	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CESC	cis	rs6964587	1.000	rs6969981	chr7:91689461	G/C	cg17063962	chr7:91808500	NA	0.6	8.37	0.46	3.45e-15	Breast cancer;
CESC	cis	rs875971	1.000	rs2042133	chr7:65931922	A/G	cg18876405	chr7:65276391	NA	0.52	7.03	0.4	1.8e-11	Aortic root size;
CESC	cis	rs6461049	0.646	rs3778970	chr7:2143208	C/A	cg05863683	chr7:1912471	MAD1L1	0.39	5.58	0.32	5.85e-8	Schizophrenia;
CESC	trans	rs7618501	0.699	rs9821675	chr3:49902544	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.49	6.7	0.38	1.25e-10	Intelligence (multi-trait analysis);
CESC	cis	rs546131	0.928	rs553789	chr11:34827579	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.49	6.31	0.36	1.14e-9	Lung disease severity in cystic fibrosis;
CESC	cis	rs17826219	0.568	rs9898097	chr17:29072672	T/G	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.1e-10	Body mass index;
CESC	cis	rs1577917	0.958	rs12208227	chr6:86670944	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-6.19	-0.36	2.31e-9	Response to antipsychotic treatment;
CESC	cis	rs10791097	0.720	rs6590516	chr11:130733393	G/T	cg12179176	chr11:130786555	SNX19	0.62	9.25	0.49	7.75e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs13256369	0.851	rs13254997	chr8:8563753	G/C	cg00074818	chr8:8560427	CLDN23	0.37	5.45	0.32	1.16e-7	Obesity-related traits;
CESC	cis	rs11676348	0.846	rs13009946	chr2:219007752	A/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.39	-5.13	-0.3	5.64e-7	Ulcerative colitis;
CESC	cis	rs6964587	1.000	rs6465347	chr7:91693837	A/G	cg17063962	chr7:91808500	NA	0.6	8.37	0.46	3.45e-15	Breast cancer;
CESC	cis	rs1499972	0.590	rs62264780	chr3:117654869	T/C	cg07612923	chr3:117604196	NA	0.69	6.3	0.36	1.22e-9	Schizophrenia;
CESC	cis	rs708547	0.624	rs1718886	chr4:57849251	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.57	8.45	0.46	1.95e-15	Response to bleomycin (chromatid breaks);
CESC	cis	rs6466055	0.501	rs7776707	chr7:104605530	C/A	cg04380332	chr7:105027541	SRPK2	-0.38	-5.48	-0.32	9.76e-8	Schizophrenia;
CESC	cis	rs7772486	0.790	rs3924499	chr6:146232978	A/T	cg05347473	chr6:146136440	FBXO30	-0.57	-7.16	-0.4	8.07e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs12971120	0.891	rs3764510	chr18:72166846	A/G	cg25817165	chr18:72167213	CNDP2	-0.61	-7.15	-0.4	8.4e-12	Refractive error;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16349006	chr20:48807369	CEBPB	0.6	6.99	0.39	2.26e-11	Gut microbiome composition (summer);
CESC	cis	rs11997175	0.546	rs13282996	chr8:33596397	C/T	ch.8.33884649F	chr8:33765107	NA	0.56	7.23	0.41	5.07e-12	Body mass index;
CESC	cis	rs9322193	0.607	rs6557165	chr6:150228019	C/G	cg01145232	chr6:150245071	RAET1G	-0.47	-6.14	-0.35	3.01e-9	Lung cancer;
CESC	cis	rs863345	0.604	rs11264981	chr1:158455890	C/T	cg12129480	chr1:158549410	OR10X1	-0.36	-7.14	-0.4	8.77e-12	Pneumococcal bacteremia;
CESC	cis	rs6963495	0.818	rs6961233	chr7:105150469	C/T	cg13798780	chr7:105162888	PUS7	0.76	7.8	0.43	1.47e-13	Bipolar disorder (body mass index interaction);
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg07596148	chr16:88772396	CTU2;RNF166	0.44	6.0	0.35	6.38e-9	Thyroid stimulating hormone;
CESC	trans	rs4699982	0.531	rs4700434	chr5:61035802	A/G	cg17766468	chr2:74709216	TTC31;CCDC142	-0.52	-6.1	-0.35	3.81e-9	IgG glycosylation;
CESC	cis	rs3768617	0.811	rs12738377	chr1:183031256	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.66	9.02	0.48	3.97e-17	Fuchs's corneal dystrophy;
CESC	cis	rs1552244	0.882	rs13064570	chr3:9997545	G/C	cg08888203	chr3:10149979	C3orf24	0.46	6.0	0.35	6.31e-9	Alzheimer's disease;
CESC	trans	rs2727020	0.573	rs7925419	chr11:49231859	C/T	cg03929089	chr4:120376271	NA	-0.61	-7.67	-0.43	3.36e-13	Coronary artery disease;
CESC	cis	rs7605827	0.930	rs12692266	chr2:15572380	T/C	cg19274914	chr2:15703543	NA	0.31	5.44	0.32	1.24e-7	Educational attainment (years of education);
CESC	cis	rs13392177	0.684	rs11682371	chr2:219079513	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.52	-6.45	-0.37	5.27e-10	Pyoderma gangrenosum in inflammatory bowel disease;
CESC	cis	rs2996428	0.709	rs6424052	chr1:3713746	A/G	cg22529645	chr1:3704559	LRRC47	0.42	5.37	0.31	1.74e-7	Red cell distribution width;
CESC	cis	rs3106136	0.967	rs3113862	chr4:95143122	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.48	-7.41	-0.41	1.65e-12	Capecitabine sensitivity;
CESC	cis	rs2836974	0.831	rs2836921	chr21:40516070	C/T	cg11644478	chr21:40555479	PSMG1	0.96	13.77	0.65	6.85e-33	Cognitive function;
CESC	cis	rs7713065	0.765	rs2158101	chr5:131769273	G/A	cg10809880	chr5:131517096	NA	-0.47	-5.24	-0.31	3.36e-7	Lung function (FEV1/FVC);
CESC	cis	rs78456975	0.943	rs13421238	chr2:1576879	G/A	cg26248373	chr2:1572462	NA	-0.54	-5.25	-0.31	3.14e-7	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs7605827	0.866	rs13417550	chr2:15533895	A/G	cg19274914	chr2:15703543	NA	0.35	6.35	0.36	9.17e-10	Educational attainment (years of education);
CESC	cis	rs10754283	0.967	rs10922685	chr1:90118320	A/G	cg21401794	chr1:90099060	LRRC8C	0.69	9.16	0.49	1.49e-17	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs10197940	0.624	rs10497081	chr2:152353395	T/G	cg06191203	chr2:152266755	RIF1	-0.45	-5.2	-0.3	4e-7	Lung cancer;
CESC	cis	rs4689388	0.889	rs13128674	chr4:6294517	C/T	cg00701064	chr4:6280414	WFS1	0.68	11.71	0.58	8.68e-26	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	trans	rs12356475	0.710	rs10822686	chr10:67733250	C/T	cg26475306	chr20:33999876	UQCC	0.51	6.36	0.36	8.56e-10	Psoriatic arthritis;
CESC	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg18402987	chr7:1209562	NA	0.76	7.79	0.43	1.5e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs1552244	0.810	rs4019706	chr3:10112862	G/A	cg08888203	chr3:10149979	C3orf24	0.53	6.83	0.39	5.8200000000000003e-11	Alzheimer's disease;
CESC	cis	rs662064	0.928	rs685746	chr1:10537437	C/G	cg07384165	chr1:10488281	NA	-0.44	-5.67	-0.33	3.75e-8	Asthma;
CESC	cis	rs7267979	1.000	rs6076336	chr20:25319212	C/T	cg08601574	chr20:25228251	PYGB	-0.39	-5.61	-0.33	4.99e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs1322639	0.614	rs9364361	chr6:169580499	C/T	cg03254818	chr6:169586852	NA	0.55	5.95	0.34	8.36e-9	Pulse pressure;
CESC	cis	rs9787249	0.957	rs1046988	chr1:40219065	A/G	cg24920358	chr1:40204285	PPIE	-0.41	-6.15	-0.35	2.84e-9	Blood protein levels;
CESC	cis	rs4906332	1.000	rs13987	chr14:103969909	A/G	cg09975044	chr14:104007538	NA	0.47	6.16	0.35	2.65e-9	Coronary artery disease;
CESC	cis	rs539096	0.500	rs803678	chr1:44350898	G/T	cg13606994	chr1:44402422	ARTN	-0.39	-6.09	-0.35	3.94e-9	Intelligence (multi-trait analysis);
CESC	cis	rs13191362	1.000	rs4489133	chr6:163137793	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.66	6.56	0.37	2.8e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs1008375	0.966	rs3733581	chr4:17695206	C/G	cg16339924	chr4:17578868	LAP3	-0.62	-7.38	-0.41	2.03e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs9309473	0.950	rs10189885	chr2:73877055	A/G	cg20560298	chr2:73613845	ALMS1	-0.54	-6.87	-0.39	4.68e-11	Metabolite levels;
CESC	cis	rs2228479	0.702	rs12599561	chr16:89894358	C/G	cg06558623	chr16:89946397	TCF25	1.12	8.24	0.45	7.86e-15	Skin colour saturation;
CESC	cis	rs1371867	0.513	rs1542812	chr8:101207064	G/A	cg11906718	chr8:101322791	RNF19A	-0.44	-5.68	-0.33	3.58e-8	Atrioventricular conduction;
CESC	cis	rs9443189	0.865	rs2133190	chr6:76443493	A/G	cg01950844	chr6:76311363	SENP6	-0.56	-6.15	-0.35	2.84e-9	Prostate cancer;
CESC	cis	rs4665809	0.838	rs6546780	chr2:26352857	T/C	cg08470875	chr2:26401718	FAM59B	-0.47	-5.22	-0.31	3.63e-7	Gut microbiome composition (summer);
CESC	cis	rs9916302	0.861	rs9903363	chr17:37499604	C/G	cg19468946	chr17:37922297	IKZF3	0.39	5.09	0.3	6.85e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs875971	0.862	rs2901152	chr7:65765004	G/A	cg12463550	chr7:65579703	CRCP	-0.46	-5.81	-0.34	1.76e-8	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21306218	chr16:89787478	ZNF276;C16orf7	0.56	7.03	0.4	1.75e-11	Gut microbiome composition (summer);
CESC	cis	rs4665809	0.680	rs3955310	chr2:26290828	T/G	cg25036284	chr2:26402008	FAM59B	-0.59	-6.9	-0.39	3.85e-11	Gut microbiome composition (summer);
CESC	cis	rs9457247	0.765	rs9457249	chr6:167426438	A/G	cg23791538	chr6:167370224	RNASET2	-0.53	-7.29	-0.41	3.51e-12	Crohn's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13187433	chr1:9416179	SPSB1	-0.61	-7.0	-0.4	2.11e-11	Gut microbiome composition (summer);
CESC	cis	rs6815814	0.678	rs9715841	chr4:38774503	T/C	cg02016764	chr4:38805732	TLR1	-0.44	-6.08	-0.35	4.24e-9	Breast cancer;
CESC	cis	rs12912251	1.000	rs12912251	chr15:38986368	G/T	cg01338139	chr15:38987640	C15orf53	-0.48	-5.51	-0.32	8.36e-8	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
CESC	cis	rs61008539	0.586	rs6959154	chr7:856320	C/T	cg15782153	chr7:917662	C7orf20	0.5	7.17	0.4	7.53e-12	Perceived unattractiveness to mosquitoes;
CESC	cis	rs798554	0.679	rs1639066	chr7:2892972	A/G	cg19717773	chr7:2847554	GNA12	-0.45	-6.39	-0.37	7.45e-10	Height;
CESC	cis	rs796364	0.760	rs2202922	chr2:200882610	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.85	7.76	0.43	1.81e-13	Schizophrenia;
CESC	cis	rs4919087	0.962	rs10748694	chr10:99056190	A/T	cg25902810	chr10:99078978	FRAT1	0.71	10.43	0.54	1.5e-21	Monocyte count;
CESC	cis	rs875971	1.000	rs2420820	chr7:66091907	T/C	cg10691866	chr7:65817282	TPST1	0.34	5.59	0.32	5.54e-8	Aortic root size;
CESC	cis	rs8058578	0.832	rs7500719	chr16:30840877	C/T	cg00531865	chr16:30841666	NA	-0.43	-5.53	-0.32	7.71e-8	Multiple myeloma;
CESC	cis	rs798766	0.909	rs28521716	chr4:1745751	A/G	cg05874882	chr4:1763078	NA	-0.56	-7.25	-0.41	4.65e-12	Bladder cancer;Urinary bladder cancer;
CESC	cis	rs3820928	0.934	rs66959645	chr2:227761582	C/A	cg11843606	chr2:227700838	RHBDD1	-0.44	-5.84	-0.34	1.54e-8	Pulmonary function;
CESC	cis	rs6968419	0.755	rs3823977	chr7:115893407	A/T	cg02561103	chr7:115862891	TES	-0.4	-5.13	-0.3	5.62e-7	Intraocular pressure;
CESC	cis	rs2228479	0.850	rs11640336	chr16:89941153	T/C	cg04013166	chr16:89971882	TCF25	0.77	7.03	0.4	1.73e-11	Skin colour saturation;
CESC	cis	rs861020	0.883	rs680331	chr1:209959872	G/A	cg05527609	chr1:210001259	C1orf107	1.02	13.35	0.63	1.89e-31	Orofacial clefts;
CESC	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg24829409	chr8:58192753	C8orf71	-0.64	-7.17	-0.4	7.42e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs1348850	0.872	rs4893824	chr2:178298104	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.8	10.45	0.54	1.24e-21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs7503807	1.000	rs8079537	chr17:78600818	A/G	cg09596252	chr17:78655493	RPTOR	0.5	7.24	0.41	4.84e-12	Obesity;
CESC	cis	rs1448094	0.617	rs2221319	chr12:86468064	C/A	cg02569458	chr12:86230093	RASSF9	-0.38	-5.52	-0.32	8.26e-8	Major depressive disorder;
CESC	cis	rs11741688	0.597	rs6880072	chr5:178334480	G/C	cg20935368	chr5:178288625	ZNF354B	0.34	5.37	0.31	1.71e-7	Sleep duration;
CESC	cis	rs6540559	1.000	rs6540559	chr1:209982025	G/A	cg12034118	chr1:209979487	IRF6	0.42	5.29	0.31	2.55e-7	Cleft lip with or without cleft palate;
CESC	cis	rs6426558	0.537	rs4351610	chr1:227325245	A/G	cg10327440	chr1:227177885	CDC42BPA	-0.47	-5.9	-0.34	1.13e-8	Neutrophil percentage of white cells;
CESC	cis	rs11711311	1.000	rs12695295	chr3:113474866	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.58	7.86	0.43	9.5e-14	IgG glycosylation;
CESC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg22394521	chr20:61569754	DIDO1;C20orf11	0.45	6.22	0.36	1.9e-9	Intelligence (multi-trait analysis);
CESC	cis	rs9300255	0.770	rs7980687	chr12:123822711	G/A	cg00376283	chr12:123451042	ABCB9	-0.61	-6.6	-0.38	2.23e-10	Neutrophil percentage of white cells;
CESC	cis	rs4563143	0.675	rs55849754	chr19:29279665	G/A	cg14983838	chr19:29218262	NA	0.48	5.62	0.33	4.73e-8	Methadone dose in opioid dependence;
CESC	cis	rs875971	0.756	rs4718328	chr7:65693337	A/G	cg11764359	chr7:65958608	NA	-0.78	-11.6	-0.58	1.91e-25	Aortic root size;
CESC	cis	rs2625529	0.689	rs4526973	chr15:72138719	A/G	cg16672083	chr15:72433130	SENP8	-0.42	-6.23	-0.36	1.82e-9	Red blood cell count;
CESC	cis	rs7772486	0.754	rs9386134	chr6:146145508	G/A	cg05347473	chr6:146136440	FBXO30	0.55	6.8	0.39	6.94e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7809950	1.000	rs2520271	chr7:107194949	C/T	cg23024343	chr7:107201750	COG5	-0.42	-5.89	-0.34	1.14e-8	Coronary artery disease;
CESC	cis	rs7666738	0.830	rs28852677	chr4:99039509	T/G	cg03676636	chr4:99064102	C4orf37	0.33	5.12	0.3	5.93e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9549260	0.755	rs2721044	chr13:41162225	C/T	cg21288729	chr13:41239152	FOXO1	0.63	7.87	0.44	9.15e-14	Red blood cell count;
CESC	cis	rs2180341	0.924	rs6930849	chr6:127630963	A/T	cg24812749	chr6:127587940	RNF146	1.07	15.48	0.69	6e-39	Breast cancer;
CESC	cis	rs875971	0.545	rs11770063	chr7:65783016	G/A	cg25405998	chr7:65216604	CCT6P1	0.52	5.79	0.34	1.99e-8	Aortic root size;
CESC	cis	rs13382862	0.823	rs12710743	chr2:20880714	T/C	cg07755735	chr2:20870362	GDF7	-0.46	-6.87	-0.39	4.7e-11	Abdominal aortic aneurysm;
CESC	cis	rs7927771	1.000	rs35902101	chr11:47795169	C/T	cg05585544	chr11:47624801	NA	-0.5	-7.86	-0.43	9.61e-14	Subjective well-being;
CESC	cis	rs2243480	0.706	rs34466769	chr7:65453292	A/C	cg25985355	chr7:65971099	NA	-0.44	-5.7	-0.33	3.14e-8	Diabetic kidney disease;
CESC	cis	rs72781680	0.611	rs55868657	chr2:24295385	G/A	cg20701182	chr2:24300061	SF3B14	0.93	10.58	0.54	4.83e-22	Lymphocyte counts;
CESC	cis	rs11098499	0.820	rs12503082	chr4:120284317	A/G	cg09307838	chr4:120376055	NA	0.87	12.16	0.6	2.41e-27	Corneal astigmatism;
CESC	cis	rs6688613	0.694	rs3820387	chr1:166820284	A/T	ch.1.3259774R	chr1:166827647	TADA1	0.55	5.49	0.32	9.6e-8	Refractive astigmatism;
CESC	cis	rs4713118	0.621	rs4713132	chr6:28034035	A/G	cg23161317	chr6:28129485	ZNF389	0.51	6.38	0.36	7.9e-10	Parkinson's disease;
CESC	cis	rs11030122	0.702	rs66503725	chr11:3980998	G/A	cg18678763	chr11:4115507	RRM1	-0.49	-6.59	-0.38	2.4e-10	Mean platelet volume;Platelet distribution width;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13077517	chr20:2082435	STK35	0.58	7.22	0.41	5.56e-12	Gut microbiome composition (summer);
CESC	cis	rs28374715	0.681	rs8037574	chr15:41630770	T/C	cg02330683	chr15:41787940	ITPKA	0.47	6.28	0.36	1.35e-9	Ulcerative colitis;
CESC	cis	rs7618915	0.508	rs11717043	chr3:52656092	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.48	6.9	0.39	3.85e-11	Bipolar disorder;
CESC	cis	rs6460942	0.591	rs62448726	chr7:12330881	A/G	cg02935154	chr7:12443704	VWDE	-0.53	-5.5	-0.32	9.01e-8	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03729288	chr17:7232752	NEURL4	0.63	7.25	0.41	4.65e-12	Gut microbiome composition (summer);
CESC	cis	rs4481887	0.927	rs4453081	chr1:248475691	C/G	cg00666640	chr1:248458726	OR2T12	0.33	5.3	0.31	2.45e-7	Common traits (Other);
CESC	cis	rs4319547	0.695	rs6488939	chr12:122858250	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.45	-5.29	-0.31	2.62e-7	Body mass index;
CESC	cis	rs875971	1.000	rs811880	chr7:65818646	T/C	cg11764359	chr7:65958608	NA	0.95	15.41	0.69	1.05e-38	Aortic root size;
CESC	cis	rs60871478	1.000	rs62432251	chr7:801855	T/G	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.53	5.26	0.31	2.97e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs10242455	0.702	rs57832867	chr7:98966396	C/T	cg25640893	chr7:99214727	ZNF498	0.85	5.47	0.32	1.02e-7	Blood metabolite levels;
CESC	cis	rs7666738	0.791	rs60028147	chr4:99046618	G/A	cg18180107	chr4:99064573	C4orf37	0.4	5.2	0.3	4.08e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11098499	0.754	rs10518300	chr4:120249499	G/T	cg09307838	chr4:120376055	NA	-0.65	-8.17	-0.45	1.26e-14	Corneal astigmatism;
CESC	cis	rs10207060	1.000	rs10207060	chr2:240687289	A/C	cg07506560	chr2:240697449	NA	0.36	5.2	0.3	3.89e-7	Obesity-related traits;
CESC	cis	rs10504073	0.647	rs12156111	chr8:50017328	G/C	cg00325661	chr8:49890786	NA	0.53	8.1	0.45	1.98e-14	Blood metabolite ratios;
CESC	cis	rs6089584	0.528	rs4925334	chr20:60626769	C/T	cg24733560	chr20:60626293	TAF4	0.48	7.12	0.4	1e-11	Body mass index;
CESC	cis	rs708547	0.581	rs10020462	chr4:57825593	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.53	-6.87	-0.39	4.55e-11	Response to bleomycin (chromatid breaks);
CESC	cis	rs9660992	0.649	rs12128229	chr1:205268014	C/A	cg00857998	chr1:205179979	DSTYK	0.48	5.33	0.31	2.15e-7	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs35110281	0.693	rs2838345	chr21:45092715	C/T	cg04455712	chr21:45112962	RRP1B	0.46	7.4	0.41	1.77e-12	Mean corpuscular volume;
CESC	cis	rs17345786	0.906	rs72940399	chr3:101122575	A/T	cg11279151	chr3:101281821	RG9MTD1	-0.46	-5.17	-0.3	4.72e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs1973993	0.662	rs2057427	chr1:96888897	C/G	cg10631902	chr5:14652156	NA	-0.5	-6.49	-0.37	4.21e-10	Weight;
CESC	cis	rs873946	0.586	rs12770021	chr10:134562021	G/A	cg18305652	chr10:134549665	INPP5A	0.49	6.96	0.39	2.7e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs4409675	0.576	rs2295367	chr1:28224312	C/T	cg23691781	chr1:28212827	C1orf38	0.28	5.68	0.33	3.53e-8	Corneal astigmatism;
CESC	cis	rs597539	0.652	rs592697	chr11:68650064	G/A	cg21963583	chr11:68658836	MRPL21	0.38	5.59	0.32	5.63e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs11997175	0.646	rs7464237	chr8:33716596	C/T	ch.8.33884649F	chr8:33765107	NA	0.55	7.36	0.41	2.26e-12	Body mass index;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03665832	chr7:98923565	ARPC1A	0.54	6.5	0.37	4.08e-10	Gut microbiome composition (summer);
CESC	cis	rs4819052	0.851	rs10470247	chr21:46659018	T/C	cg11663144	chr21:46675770	NA	-0.62	-9.74	-0.51	2.36e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs35079168	0.923	rs10858276	chr9:137287913	C/T	cg00753924	chr9:137298813	RXRA	-0.35	-5.52	-0.32	7.88e-8	Intelligence;
CESC	cis	rs6676180	0.555	rs12060730	chr1:119770702	A/G	cg05756136	chr1:119680316	WARS2	-0.4	-5.26	-0.31	3.03e-7	Monobrow;
CESC	cis	rs7772486	0.654	rs6906402	chr6:146089307	C/G	cg05347473	chr6:146136440	FBXO30	-0.55	-6.97	-0.39	2.54e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6089584	0.927	rs3787427	chr20:60579789	T/C	cg13770153	chr20:60521292	NA	-0.44	-5.71	-0.33	3.02e-8	Body mass index;
CESC	cis	rs2046867	0.818	rs62249875	chr3:72911858	G/A	cg25664220	chr3:72788482	NA	-0.45	-6.65	-0.38	1.64e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CESC	cis	rs793571	0.503	rs1427281	chr15:58959273	T/C	cg05156742	chr15:59063176	FAM63B	0.51	6.3	0.36	1.21e-9	Schizophrenia;
CESC	cis	rs28830936	1.000	rs2412622	chr15:41960311	A/G	cg11010575	chr15:42129464	JMJD7-PLA2G4B;JMJD7	-0.37	-5.29	-0.31	2.63e-7	Diastolic blood pressure;
CESC	cis	rs7555523	0.887	rs12691499	chr1:165687665	A/C	cg24409356	chr1:165738333	TMCO1	0.73	6.67	0.38	1.5e-10	Intraocular pressure;Glaucoma (high intraocular pressure);
CESC	cis	rs2204008	0.806	rs11525001	chr12:38234397	A/G	cg13010199	chr12:38710504	ALG10B	0.45	5.57	0.32	6.11e-8	Bladder cancer;
CESC	cis	rs7202877	0.706	rs247434	chr16:75445304	G/A	cg04384234	chr16:75411784	CFDP1	0.48	5.57	0.32	6.29e-8	Type 2 diabetes;Type 1 diabetes;
CESC	cis	rs7666738	0.830	rs10019087	chr4:99030211	C/T	cg18180107	chr4:99064573	C4orf37	0.42	5.43	0.32	1.29e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs35110281	0.715	rs8129601	chr21:45119104	A/G	cg21573476	chr21:45109991	RRP1B	-0.51	-7.31	-0.41	3.19e-12	Mean corpuscular volume;
CESC	cis	rs1005277	0.579	rs1985707	chr10:38434098	C/T	cg25427524	chr10:38739819	LOC399744	-0.67	-9.8	-0.52	1.46e-19	Extrinsic epigenetic age acceleration;
CESC	cis	rs3785574	0.925	rs2727340	chr17:61970224	T/A	cg07677032	chr17:61819896	STRADA	0.44	5.58	0.32	6.08e-8	Height;
CESC	cis	rs977987	0.778	rs4888409	chr16:75436231	A/T	cg03315344	chr16:75512273	CHST6	0.41	5.85	0.34	1.43e-8	Dupuytren's disease;
CESC	cis	rs17539620	0.534	rs6557363	chr6:154827813	A/G	cg20019720	chr6:154832845	CNKSR3	0.41	5.85	0.34	1.43e-8	Lipoprotein (a) levels;
CESC	cis	rs780096	0.526	rs10182937	chr2:27651693	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.32	-5.97	-0.34	7.45e-9	Total body bone mineral density;
CESC	cis	rs28489187	0.706	rs173026	chr1:85804249	G/A	cg16011679	chr1:85725395	C1orf52	0.48	5.6	0.33	5.29e-8	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	trans	rs629535	0.734	rs659430	chr8:70009988	A/G	cg21567404	chr3:27674614	NA	0.58	7.32	0.41	2.95e-12	Dupuytren's disease;
CESC	cis	rs72781680	0.651	rs13019016	chr2:23894773	C/G	cg20701182	chr2:24300061	SF3B14	0.56	5.07	0.3	7.45e-7	Lymphocyte counts;
CESC	cis	rs875971	0.502	rs2465121	chr7:65621004	A/G	cg11764359	chr7:65958608	NA	-0.8	-9.04	-0.49	3.45e-17	Aortic root size;
CESC	cis	rs853679	0.542	rs6934769	chr6:28090931	A/G	cg17949981	chr6:28129498	ZNF389	0.44	5.58	0.32	5.97e-8	Depression;
CESC	cis	rs9929218	0.954	rs35794312	chr16:68827785	G/A	cg02972257	chr16:68554789	NA	0.46	5.45	0.32	1.12e-7	Colorectal cancer;
CESC	cis	rs1552244	1.000	rs6764068	chr3:10153842	A/G	cg00149659	chr3:10157352	C3orf10	0.7	8.47	0.46	1.68e-15	Alzheimer's disease;
CESC	cis	rs2777491	0.574	rs1757468	chr15:41743574	T/A	cg02330683	chr15:41787940	ITPKA	0.42	5.09	0.3	6.8e-7	Ulcerative colitis;
CESC	cis	rs793571	0.500	rs2555356	chr15:59016431	T/G	cg05156742	chr15:59063176	FAM63B	0.58	7.72	0.43	2.43e-13	Schizophrenia;
CESC	cis	rs12497850	1.000	rs1352420	chr3:48757291	A/G	cg07636037	chr3:49044803	WDR6	0.97	16.72	0.72	2.42e-43	Parkinson's disease;
CESC	cis	rs4481887	0.927	rs10158431	chr1:248481253	A/G	cg00666640	chr1:248458726	OR2T12	0.41	6.56	0.37	2.84e-10	Common traits (Other);
CESC	cis	rs2109514	0.840	rs6953982	chr7:116129290	C/T	cg12739419	chr7:116140593	CAV2	-0.38	-6.76	-0.38	8.91e-11	Prevalent atrial fibrillation;
CESC	cis	rs929354	0.772	rs6954050	chr7:156978554	A/G	cg05182265	chr7:156933206	UBE3C	-0.51	-7.5	-0.42	9.58e-13	Body mass index;
CESC	cis	rs9322193	0.962	rs952165	chr6:150120036	T/C	cg07701084	chr6:150067640	NUP43	0.42	5.78	0.33	2.07e-8	Lung cancer;
CESC	cis	rs9815354	1.000	rs9830064	chr3:41881801	T/C	cg03022575	chr3:42003672	ULK4	0.45	5.26	0.31	2.97e-7	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs61996546	0.635	rs61998671	chr15:26853000	T/C	cg15066197	chr15:26874202	GABRB3	-0.35	-5.19	-0.3	4.1e-7	Response to methotrexate in juvenile idiopathic arthritis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03161587	chr2:220405163	CHPF	-0.61	-6.93	-0.39	3.18e-11	Gut microbiome composition (summer);
CESC	cis	rs9522267	0.535	rs9515454	chr13:112236885	A/G	cg10483660	chr13:112241077	NA	-0.33	-5.78	-0.33	2.14e-8	Hepatitis;
CESC	cis	rs651907	0.557	rs3094297	chr3:101399260	A/G	cg12386194	chr3:101231763	SENP7	0.43	5.54	0.32	7.32e-8	Colorectal cancer;
CESC	cis	rs2286503	1.000	rs1029740	chr7:22873586	C/A	cg13679077	chr7:22862647	TOMM7	0.43	5.46	0.32	1.12e-7	Fibrinogen;
CESC	cis	rs734999	0.545	rs12752515	chr1:2564465	T/C	cg20673091	chr1:2541236	MMEL1	-0.47	-7.84	-0.43	1.11e-13	Ulcerative colitis;
CESC	cis	rs10392	0.543	rs4810245	chr20:37549309	G/A	cg27552599	chr20:37590471	DHX35	0.38	5.47	0.32	1.05e-7	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
CESC	cis	rs796364	0.806	rs55985986	chr2:201120987	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.72	-6.5	-0.37	3.91e-10	Schizophrenia;
CESC	cis	rs9303401	0.659	rs17222523	chr17:56620501	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	1.03	12.7	0.62	3.54e-29	Cognitive test performance;
CESC	cis	rs9322193	0.923	rs4455682	chr6:150021297	C/T	cg13206674	chr6:150067644	NUP43	0.45	6.48	0.37	4.53e-10	Lung cancer;
CESC	cis	rs4594175	0.926	rs10149006	chr14:51615265	A/C	cg23942311	chr14:51606299	NA	0.36	5.37	0.31	1.76e-7	Cancer;
CESC	cis	rs7116495	0.609	rs628025	chr11:71802351	A/C	cg18441811	chr11:71824068	C11orf51	-0.84	-5.32	-0.31	2.22e-7	Severe influenza A (H1N1) infection;
CESC	trans	rs4803480	0.766	rs115449590	chr19:42088883	T/C	cg14584244	chr5:176003139	PCDH24	-0.47	-6.17	-0.35	2.49e-9	Schizophrenia;
CESC	cis	rs2836974	0.831	rs4375956	chr21:40521788	G/A	cg11644478	chr21:40555479	PSMG1	1.01	15.65	0.69	1.48e-39	Cognitive function;
CESC	cis	rs473651	0.904	rs472247	chr2:239362573	G/A	cg18131467	chr2:239335373	ASB1	0.99	18.97	0.76	2.74e-51	Multiple system atrophy;
CESC	cis	rs8072100	1.000	rs4375701	chr17:45712218	C/T	cg08085267	chr17:45401833	C17orf57	-0.43	-5.66	-0.33	3.85e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs13191362	1.000	rs13207671	chr6:162979056	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.86	9.01	0.48	4.24e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs7662987	1.000	rs11547772	chr4:99992793	A/C	cg13256891	chr4:100009986	ADH5	-0.82	-6.15	-0.35	2.89e-9	Smoking initiation;
CESC	cis	rs35306767	0.903	rs12762228	chr10:880854	G/A	cg20503657	chr10:835505	NA	1.09	9.95	0.52	4.95e-20	Eosinophil percentage of granulocytes;
CESC	cis	rs7666738	0.830	rs1426664	chr4:98988264	A/C	cg03467027	chr4:99064603	C4orf37	0.44	5.56	0.32	6.57e-8	Colonoscopy-negative controls vs population controls;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg15072735	chr9:72375102	PTAR1	-0.42	-6.01	-0.35	5.99e-9	Gambling;
CESC	cis	rs2304069	0.565	rs13183261	chr5:149421847	T/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.48	6.5	0.37	3.98e-10	HIV-1 control;
CESC	cis	rs9583531	0.600	rs9555724	chr13:111354110	C/T	cg24331049	chr13:111365604	ING1	-0.67	-10.23	-0.53	6.24e-21	Coronary artery disease;
CESC	cis	rs1976403	0.659	rs10799699	chr1:21820961	C/T	cg04349561	chr1:21808255	NBPF3	-0.4	-5.81	-0.34	1.77e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs9527	0.590	rs10883843	chr10:104947493	C/G	cg04362960	chr10:104952993	NT5C2	0.43	5.43	0.32	1.3e-7	Arsenic metabolism;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21609034	chr20:3869759	PANK2	0.58	6.75	0.38	9.17e-11	Gut microbiome composition (summer);
CESC	cis	rs7212590	0.748	rs58681483	chr17:57934654	A/G	cg20303301	chr17:57937339	TUBD1	-0.58	-5.71	-0.33	3.05e-8	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg18402987	chr7:1209562	NA	0.76	7.79	0.43	1.5e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs597539	0.652	rs613128	chr11:68638058	G/T	cg01988459	chr11:68622903	NA	-0.39	-5.21	-0.3	3.76e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs2302729	0.578	rs11062298	chr12:2771709	A/C	cg19945202	chr12:2788847	CACNA1C	-0.47	-7.01	-0.4	2e-11	Sleep quality;
CESC	cis	rs7259376	0.936	rs7256749	chr19:22592289	A/G	cg02657401	chr19:22469223	NA	0.26	5.14	0.3	5.46e-7	Menopause (age at onset);
CESC	cis	rs7940866	0.838	rs10736592	chr11:130800572	C/T	cg12179176	chr11:130786555	SNX19	0.66	10.05	0.53	2.38e-20	Schizophrenia;
CESC	cis	rs10744422	0.920	rs897393	chr12:123312051	A/G	cg25930673	chr12:123319894	HIP1R	0.65	5.3	0.31	2.42e-7	Schizophrenia;
CESC	cis	rs9322193	0.923	rs62441303	chr6:150088683	A/G	cg13206674	chr6:150067644	NUP43	0.43	5.98	0.34	7.33e-9	Lung cancer;
CESC	cis	rs7089973	0.628	rs11196953	chr10:116607707	A/G	cg23260525	chr10:116636907	FAM160B1	0.4	7.2	0.4	6.31e-12	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	trans	rs6073597	1.000	rs6031980	chr20:43714384	C/T	cg19857114	chr3:176741225	TBL1XR1	0.46	6.41	0.37	6.68e-10	Positive affect;
CESC	cis	rs243505	0.559	rs10215159	chr7:148479071	G/C	cg09806900	chr7:148480153	CUL1	0.44	5.31	0.31	2.35e-7	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs916888	0.779	rs199528	chr17:44843136	C/T	cg15921436	chr17:44337874	NA	0.74	7.89	0.44	8.12e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs2842992	0.789	rs10945635	chr6:160214487	C/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.75	9.82	0.52	1.34e-19	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs6502050	0.871	rs6502054	chr17:80066715	G/A	cg23985595	chr17:80112537	CCDC57	0.41	6.34	0.36	9.73e-10	Life satisfaction;
CESC	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.55	-6.13	-0.35	3.19e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs6460942	0.730	rs73053536	chr7:12323131	C/G	cg10578991	chr7:12443926	VWDE	-0.62	-6.19	-0.36	2.29e-9	Coronary artery disease;
CESC	cis	rs3026101	0.671	rs17636147	chr17:5315299	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.44	5.83	0.34	1.6e-8	Body mass index;
CESC	cis	rs1552244	0.572	rs3774208	chr3:10164722	T/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.68	-7.55	-0.42	6.87e-13	Alzheimer's disease;
CESC	cis	rs10504229	0.683	rs7822631	chr8:58130916	C/G	cg02725872	chr8:58115012	NA	-0.45	-7.05	-0.4	1.52e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	-0.89	-13.73	-0.64	8.78e-33	Prudent dietary pattern;
CESC	cis	rs7918232	0.782	rs7910168	chr10:27465296	G/A	cg14240646	chr10:27532245	ACBD5	-0.67	-6.55	-0.37	3.03e-10	Breast cancer;
CESC	cis	rs1799949	0.536	rs4793227	chr17:41412250	A/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	7.74	0.43	2.09e-13	Menopause (age at onset);
CESC	cis	rs1552244	1.000	rs7637888	chr3:10080722	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.87	11.84	0.59	2.99e-26	Alzheimer's disease;
CESC	cis	rs6540559	1.000	rs2235372	chr1:209960436	A/G	cg23283495	chr1:209979779	IRF6	-0.5	-7.05	-0.4	1.52e-11	Cleft lip with or without cleft palate;
CESC	cis	rs5769765	0.955	rs1321	chr22:50297435	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.47	-5.55	-0.32	7.08e-8	Schizophrenia;
CESC	trans	rs650950	0.528	rs646660	chr11:35528452	C/T	cg01936430	chr1:204380496	PPP1R15B	0.47	6.44	0.37	5.45e-10	Bronchopulmonary dysplasia;
CESC	cis	rs875971	0.862	rs11984115	chr7:65773859	C/T	cg10691866	chr7:65817282	TPST1	0.32	5.46	0.32	1.08e-7	Aortic root size;
CESC	cis	rs933688	1.000	rs1035476	chr5:90745976	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.15	13.92	0.65	1.96e-33	Smoking behavior;
CESC	cis	rs7927771	0.864	rs2868459	chr11:47454972	C/G	cg18512352	chr11:47633146	NA	-0.52	-7.39	-0.41	1.92e-12	Subjective well-being;
CESC	cis	rs425277	1.000	rs421992	chr1:2077260	C/T	cg24578937	chr1:2090814	PRKCZ	0.55	9.56	0.51	8.64e-19	Height;
CESC	cis	rs16854884	0.657	rs35193361	chr3:143716420	A/G	cg06585982	chr3:143692056	C3orf58	0.45	5.32	0.31	2.23e-7	Economic and political preferences (feminism/equality);
CESC	cis	rs17253792	0.822	rs77420254	chr14:56069646	C/T	cg01858014	chr14:56050164	KTN1	-0.93	-7.33	-0.41	2.71e-12	Putamen volume;
CESC	cis	rs4973397	0.774	rs12998237	chr2:232276651	T/C	cg09339159	chr2:232260559	B3GNT7	0.58	5.86	0.34	1.4e-8	Anti-saccade response;
CESC	cis	rs6547741	0.935	rs6749426	chr2:27847606	T/C	cg27432699	chr2:27873401	GPN1	0.49	6.89	0.39	3.95e-11	Oral cavity cancer;
CESC	cis	rs10861342	1.000	rs7136344	chr12:105528268	A/G	cg23923672	chr12:105501055	KIAA1033	0.66	5.71	0.33	3.09e-8	IgG glycosylation;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg08514185	chr20:61847713	YTHDF1	-0.42	-5.99	-0.35	6.69e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs9583531	0.600	rs2119479	chr13:111371181	A/C	cg24331049	chr13:111365604	ING1	0.74	10.91	0.56	4.04e-23	Coronary artery disease;
CESC	cis	rs7666738	0.830	rs13130923	chr4:99046281	T/C	cg03467027	chr4:99064603	C4orf37	0.47	5.98	0.34	7.19e-9	Colonoscopy-negative controls vs population controls;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg01252513	chr12:111758092	CUX2	0.46	6.26	0.36	1.53e-9	Fibrinogen levels;
CESC	cis	rs7520050	0.898	rs4660885	chr1:46243756	C/T	cg24296786	chr1:45957014	TESK2	0.47	5.88	0.34	1.21e-8	Red blood cell count;Reticulocyte count;
CESC	cis	rs17376456	0.825	rs10038828	chr5:93124056	C/T	cg21475434	chr5:93447410	FAM172A	0.83	7.39	0.41	1.91e-12	Diabetic retinopathy;
CESC	trans	rs2727020	0.575	rs10769587	chr11:49549849	C/G	cg03929089	chr4:120376271	NA	-0.81	-12.24	-0.6	1.37e-27	Coronary artery disease;
CESC	cis	rs703842	1.000	rs11172335	chr12:58175201	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.71	9.02	0.48	4e-17	Multiple sclerosis;
CESC	cis	rs6089829	0.962	rs6062776	chr20:61663736	A/G	cg08564027	chr20:61660810	NA	0.9	15.42	0.69	9.97e-39	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs2087017	0.744	rs60796731	chr3:113818727	T/A	cg11311190	chr3:113822454	NA	-0.35	-6.07	-0.35	4.41e-9	Personality dimensions;
CESC	cis	rs10870270	0.913	rs115236491	chr10:133766855	T/G	cg26149184	chr10:133730230	NA	0.38	5.17	0.3	4.57e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs870825	0.616	rs57271221	chr4:185627198	C/T	cg04058563	chr4:185651563	MLF1IP	0.64	6.48	0.37	4.51e-10	Blood protein levels;
CESC	cis	rs4919087	0.715	rs946981	chr10:98995076	A/G	cg25902810	chr10:99078978	FRAT1	-0.48	-5.37	-0.31	1.72e-7	Monocyte count;
CESC	cis	rs9308433	0.529	rs3767842	chr1:214498306	C/T	cg06198575	chr1:214491504	SMYD2	0.49	5.98	0.34	7.22e-9	IgG glycosylation;
CESC	cis	rs3749237	0.595	rs4855864	chr3:49521974	C/T	cg02487422	chr3:49467188	NICN1	0.59	8.52	0.46	1.2e-15	Resting heart rate;
CESC	cis	rs9858542	1.000	rs6770670	chr3:49686682	T/C	cg07274523	chr3:49395745	GPX1	0.67	8.54	0.46	1.03e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs4654899	0.865	rs6673455	chr1:21361048	T/C	cg05370193	chr1:21551575	ECE1	0.41	6.17	0.35	2.58e-9	Superior frontal gyrus grey matter volume;
CESC	cis	rs7089973	0.604	rs765173	chr10:116601675	C/T	cg25233709	chr10:116636983	FAM160B1	0.39	6.49	0.37	4.27e-10	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs62244186	0.516	rs11922470	chr3:44777795	C/T	cg15225532	chr3:44803084	KIF15;KIAA1143	0.71	10.48	0.54	9.68e-22	Depressive symptoms;
CESC	cis	rs2836974	0.897	rs68090597	chr21:40535633	A/G	cg11644478	chr21:40555479	PSMG1	1.03	17.63	0.73	1.42e-46	Cognitive function;
CESC	cis	rs75477785	1.000	rs2235371	chr1:209964080	C/T	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.81	5.47	0.32	1.04e-7	Cleft lip with or without cleft palate;
CESC	cis	rs7173419	0.607	rs11633338	chr15:28217011	G/A	cg20906524	chr15:28200668	OCA2	-0.38	-5.25	-0.31	3.07e-7	Eye color;
CESC	cis	rs116095464	0.558	rs7703803	chr5:292311	A/G	cg22857025	chr5:266934	NA	-1.28	-17.85	-0.74	2.52e-47	Breast cancer;
CESC	cis	rs11122272	0.735	rs2486737	chr1:231520523	T/C	cg06096015	chr1:231504339	EGLN1	0.43	6.18	0.35	2.46e-9	Hemoglobin concentration;
CESC	cis	rs2032447	0.670	rs198834	chr6:26114372	G/A	cg12310025	chr6:25882481	NA	0.44	6.56	0.37	2.78e-10	Intelligence (multi-trait analysis);
CESC	cis	rs9840812	0.725	rs696517	chr3:136067655	T/C	cg15507776	chr3:136538369	TMEM22	0.51	5.24	0.31	3.29e-7	Fibrinogen levels;
CESC	cis	rs7666738	0.962	rs17027204	chr4:98997049	G/A	cg17366294	chr4:99064904	C4orf37	0.53	7.06	0.4	1.42e-11	Colonoscopy-negative controls vs population controls;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg16218964	chr11:62473680	BSCL2;GNG3	-0.49	-6.22	-0.36	1.96e-9	Ulcerative colitis;
CESC	cis	rs6952808	1.000	rs10233560	chr7:1885415	T/C	cg13880726	chr7:1868755	MAD1L1	0.51	6.9	0.39	3.91e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs11048434	0.736	rs56130437	chr12:9093001	G/A	cg04155231	chr12:9217510	LOC144571	0.31	5.04	0.3	8.46e-7	Sjögren's syndrome;
CESC	cis	rs9640161	0.742	rs2108853	chr7:150017589	A/C	cg10018233	chr7:150070692	REPIN1	0.45	7.18	0.4	6.86e-12	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs8114671	0.967	rs2093058	chr20:33791281	C/T	cg24642439	chr20:33292090	TP53INP2	-0.42	-5.03	-0.3	9.18e-7	Height;
CESC	cis	rs9486715	0.867	rs9384628	chr6:96960232	T/C	cg06623918	chr6:96969491	KIAA0776	0.93	14.38	0.66	4.75e-35	Headache;
CESC	cis	rs10129255	0.912	rs8009135	chr14:107185767	A/G	cg07958169	chr14:107095056	NA	-0.44	-6.07	-0.35	4.32e-9	Kawasaki disease;
CESC	cis	rs3820068	0.603	rs6695903	chr1:15985940	C/T	cg17385448	chr1:15911702	AGMAT	0.42	7.18	0.4	7.09e-12	Systolic blood pressure;
CESC	cis	rs35306767	0.903	rs11253458	chr10:882843	T/C	cg10556349	chr10:835070	NA	0.58	5.55	0.32	6.87e-8	Eosinophil percentage of granulocytes;
CESC	cis	rs2479724	0.935	rs2254936	chr6:41846569	A/G	cg17623882	chr6:41773611	USP49	-0.42	-6.08	-0.35	4.16e-9	Menarche (age at onset);
CESC	cis	rs1568889	0.838	rs10835273	chr11:28156598	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.81	13.78	0.65	6.22e-33	Bipolar disorder;
CESC	cis	rs2688608	0.618	rs28553894	chr10:75489843	C/A	cg23231163	chr10:75533350	FUT11	-0.37	-5.57	-0.32	6.23e-8	Inflammatory bowel disease;
CESC	cis	rs636291	0.517	rs11121579	chr1:10541824	G/C	cg20482658	chr1:10539492	PEX14	-0.28	-5.91	-0.34	1.04e-8	Prostate cancer;
CESC	cis	rs7091068	0.518	rs4919436	chr10:95461475	C/T	cg20715218	chr10:95462985	C10orf4	0.53	6.61	0.38	2.05e-10	Urinary tract infection frequency;
CESC	cis	rs12325245	0.536	rs35432891	chr16:58561966	G/A	cg01152986	chr16:58549298	SETD6	0.89	5.4	0.32	1.45e-7	Schizophrenia;
CESC	cis	rs9487051	0.872	rs4601178	chr6:109611246	C/T	cg01475377	chr6:109611718	NA	-0.49	-8.2	-0.45	1.08e-14	Reticulocyte fraction of red cells;
CESC	cis	rs1707322	1.000	rs10890381	chr1:46451771	T/G	cg06784218	chr1:46089804	CCDC17	0.36	6.01	0.35	5.95e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs1046896	0.552	rs12602280	chr17:80805421	G/C	cg19500275	chr17:80737654	TBCD	0.48	5.5	0.32	9.14e-8	Glycated hemoglobin levels;
CESC	cis	rs10242455	0.702	rs73713580	chr7:99241610	C/T	cg25640893	chr7:99214727	ZNF498	0.78	5.24	0.31	3.31e-7	Blood metabolite levels;
CESC	cis	rs597539	0.690	rs578791	chr11:68625809	C/T	cg01988459	chr11:68622903	NA	-0.41	-5.3	-0.31	2.42e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs7542091	0.648	rs688464	chr1:209992539	C/T	cg05527609	chr1:210001259	C1orf107	0.47	5.84	0.34	1.53e-8	Monobrow;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg10188299	chr14:67982149	TMEM229B	-0.5	-6.28	-0.36	1.41e-9	Asthma;
CESC	cis	rs561341	0.941	rs736678	chr17:30347423	G/T	cg00745463	chr17:30367425	LRRC37B	-0.88	-7.75	-0.43	2.01e-13	Hip circumference adjusted for BMI;
CESC	cis	rs79349575	0.783	rs11079844	chr17:47028334	G/A	cg16584676	chr17:46985605	UBE2Z	0.54	6.67	0.38	1.46e-10	Type 2 diabetes;
CESC	cis	rs9788682	0.747	rs6495308	chr15:78907656	A/G	cg24631222	chr15:78858424	CHRNA5	0.75	9.41	0.5	2.5e-18	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs4474465	0.850	rs7122676	chr11:78268525	A/G	cg27205649	chr11:78285834	NARS2	0.42	5.1	0.3	6.45e-7	Alzheimer's disease (survival time);
CESC	cis	rs13191362	0.810	rs13200053	chr6:163011443	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.87	8.98	0.48	5.33e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs2730245	0.527	rs62476464	chr7:158698063	C/T	cg24397884	chr7:158709396	WDR60	0.85	8.85	0.48	1.3e-16	Height;
CESC	cis	rs4906332	1.000	rs17617935	chr14:103952886	A/T	cg09975044	chr14:104007538	NA	0.47	6.39	0.37	7.49e-10	Coronary artery disease;
CESC	cis	rs7772486	0.837	rs2474354	chr6:146323795	T/A	cg23711669	chr6:146136114	FBXO30	0.73	10.36	0.54	2.37e-21	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7660520	0.524	rs6839881	chr4:183729137	A/T	cg04526738	chr4:183727387	NA	0.64	6.38	0.36	7.87e-10	Pediatric autoimmune diseases;
CESC	cis	rs9399135	0.967	rs11755229	chr6:135369913	A/G	cg22676075	chr6:135203613	NA	0.5	7.06	0.4	1.43e-11	Red blood cell count;
CESC	cis	rs7618501	1.000	rs1491986	chr3:49739086	C/T	cg24308560	chr3:49941425	MST1R	0.5	6.86	0.39	4.8e-11	Intelligence (multi-trait analysis);
CESC	cis	rs7666738	0.830	rs4699584	chr4:98952019	A/G	cg03676636	chr4:99064102	C4orf37	0.33	5.12	0.3	5.82e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs709400	1.000	rs58133129	chr14:104104759	A/G	cg12935359	chr14:103987150	CKB	-0.45	-6.17	-0.35	2.58e-9	Body mass index;
CESC	cis	rs1215050	0.765	rs471500	chr4:98714820	T/C	cg05340658	chr4:99064831	C4orf37	0.51	6.55	0.37	3.04e-10	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs7635838	0.892	rs9838141	chr3:11488639	C/T	cg00170343	chr3:11313890	ATG7	0.42	5.68	0.33	3.57e-8	HDL cholesterol;
CESC	cis	rs67311347	0.910	rs7651204	chr3:40512835	C/T	cg01475735	chr3:40494733	NA	0.41	5.17	0.3	4.71e-7	Renal cell carcinoma;
CESC	cis	rs9322193	0.923	rs9322208	chr6:149979683	A/T	cg13206674	chr6:150067644	NUP43	0.44	6.42	0.37	6.24e-10	Lung cancer;
CESC	cis	rs875971	1.000	rs778696	chr7:65870813	C/G	cg12463550	chr7:65579703	CRCP	0.59	7.52	0.42	8.29e-13	Aortic root size;
CESC	cis	rs798554	0.679	rs13230995	chr7:2887284	G/A	cg13628971	chr7:2884303	GNA12	0.63	8.76	0.47	2.41e-16	Height;
CESC	cis	rs4665809	1.000	rs11126375	chr2:26344787	G/A	cg27170947	chr2:26402098	FAM59B	-0.59	-7.07	-0.4	1.36e-11	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24908708	chr8:95835570	INTS8	0.57	6.69	0.38	1.3e-10	Gut microbiome composition (summer);
CESC	cis	rs9581857	0.579	rs79904593	chr13:27996893	G/A	cg22138327	chr13:27999177	GTF3A	0.69	5.56	0.32	6.74e-8	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
CESC	cis	rs73206853	0.764	rs59527539	chr12:110968119	A/G	cg12870014	chr12:110450643	ANKRD13A	0.65	5.65	0.33	4.14e-8	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg06254406	chr13:103450982	BIVM;KDELC1	-0.47	-7.17	-0.4	7.54e-12	Vertical cup-disc ratio;
CESC	cis	rs9911578	1.000	rs9892795	chr17:57023054	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.12	0.3	5.94e-7	Intelligence (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15622040	chr3:49823987	IP6K1	0.55	6.07	0.35	4.46e-9	Gut microbiome composition (summer);
CESC	cis	rs17253792	0.822	rs79262019	chr14:56092704	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.77	5.98	0.34	7.23e-9	Putamen volume;
CESC	trans	rs163030	0.875	rs335610	chr5:76747820	A/T	cg26150533	chr8:82396069	FABP4	-0.39	-6.0	-0.35	6.54e-9	Caudate nucleus volume;
CESC	trans	rs875971	0.660	rs1860468	chr7:66107252	T/C	cg26939375	chr7:64535504	NA	-0.56	-7.61	-0.42	4.92e-13	Aortic root size;
CESC	cis	rs7831492	0.564	rs57596574	chr8:41609843	G/A	cg17182837	chr8:41585554	ANK1	-0.41	-6.27	-0.36	1.5e-9	Colorectal cancer;
CESC	cis	rs2979489	0.891	rs2915592	chr8:30396417	C/T	cg26383811	chr8:30366931	RBPMS	-0.79	-9.95	-0.52	5.05e-20	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CESC	cis	rs2279817	0.735	rs11203432	chr1:17991196	A/G	cg21791023	chr1:18019539	ARHGEF10L	-0.54	-7.11	-0.4	1.1e-11	Neuroticism;
CESC	cis	rs2898290	0.540	rs35005793	chr8:11450472	G/A	cg21775007	chr8:11205619	TDH	0.45	6.42	0.37	6.19e-10	Systolic blood pressure;
CESC	cis	rs7937682	0.883	rs1611989	chr11:111456299	A/G	cg22437258	chr11:111473054	SIK2	0.71	9.1	0.49	2.27e-17	Primary sclerosing cholangitis;
CESC	cis	rs9322193	0.683	rs113281309	chr6:150108425	T/G	cg07701084	chr6:150067640	NUP43	0.44	5.94	0.34	8.89e-9	Lung cancer;
CESC	cis	rs250677	0.522	rs6580590	chr5:148360374	C/T	cg18129178	chr5:148520854	ABLIM3	0.47	5.16	0.3	4.93e-7	Breast cancer;
CESC	cis	rs17608059	0.518	rs4792436	chr17:13972307	T/A	cg11395062	chr17:14139857	CDRT15	-0.54	-6.99	-0.39	2.17e-11	Temperament;
CESC	cis	rs7666738	0.830	rs11941844	chr4:99042722	A/T	cg24818145	chr4:99064322	C4orf37	0.38	5.04	0.3	8.49e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs367943	1.000	rs348963	chr5:112819027	A/G	cg12552261	chr5:112820674	MCC	-0.6	-7.62	-0.42	4.44e-13	Type 2 diabetes;
CESC	cis	rs854765	0.583	rs8078583	chr17:17811465	C/T	cg09796270	chr17:17721594	SREBF1	0.46	6.42	0.37	6.23e-10	Total body bone mineral density;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01804284	chr1:41157659	NFYC;LOC100130557	0.6	6.49	0.37	4.22e-10	Gut microbiome composition (summer);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg11645754	chr17:21188174	MAP2K3	-0.39	-6.02	-0.35	5.66e-9	Gambling;
CESC	cis	rs12801636	0.739	rs12790427	chr11:65384727	C/T	cg26668713	chr11:65405903	SIPA1	0.67	7.75	0.43	1.98e-13	Coronary artery disease;HDL cholesterol;HDL cholesterol levels;
CESC	cis	rs3096299	0.632	rs8051537	chr16:89544384	T/A	cg02034447	chr16:89574710	SPG7	0.46	5.91	0.34	1.02e-8	Multiple myeloma (IgH translocation);
CESC	cis	rs4332037	0.707	rs4721096	chr7:1877311	T/C	cg23422044	chr7:1970798	MAD1L1	0.57	5.83	0.34	1.6e-8	Bipolar disorder;
CESC	cis	rs748404	0.604	rs2278857	chr15:43632549	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.59	7.54	0.42	7.73e-13	Lung cancer;
CESC	cis	rs10504229	0.595	rs36081958	chr8:58117505	C/G	cg21724239	chr8:58056113	NA	0.58	5.97	0.34	7.54e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.58	7.51	0.42	8.95e-13	Prudent dietary pattern;
CESC	cis	rs4595586	0.545	rs2388177	chr12:39364403	T/C	cg26384229	chr12:38710491	ALG10B	0.54	7.54	0.42	7.28e-13	Morning vs. evening chronotype;
CESC	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg18402987	chr7:1209562	NA	0.76	7.57	0.42	6.04e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7615952	0.576	rs2276726	chr3:125826287	C/G	cg18479299	chr3:125709523	NA	-0.5	-5.75	-0.33	2.5e-8	Blood pressure (smoking interaction);
CESC	trans	rs17685	0.672	rs1639618	chr7:75701987	T/C	cg19862616	chr7:65841803	NCRNA00174	0.85	12.47	0.61	2.13e-28	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs644799	0.965	rs3789960	chr11:95509037	C/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	14.64	0.67	5.65e-36	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs763014	0.932	rs34498660	chr16:666149	A/G	cg07256732	chr16:621771	PIGQ	-0.32	-5.64	-0.33	4.27e-8	Height;
CESC	cis	rs514406	0.505	rs405208	chr1:53176674	C/T	cg24675658	chr1:53192096	ZYG11B	-0.53	-6.59	-0.38	2.36e-10	Monocyte count;
CESC	trans	rs11098499	0.954	rs10034623	chr4:120397829	G/A	cg25214090	chr10:38739885	LOC399744	0.71	10.41	0.54	1.73e-21	Corneal astigmatism;
CESC	cis	rs1577917	1.000	rs13194429	chr6:86646705	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.47	-6.03	-0.35	5.49e-9	Response to antipsychotic treatment;
CESC	cis	rs9926296	0.605	rs7205053	chr16:89856763	G/C	cg01097406	chr16:89675127	NA	-0.34	-5.21	-0.31	3.71e-7	Vitiligo;
CESC	cis	rs7429990	0.965	rs5012971	chr3:48074547	C/T	cg11946769	chr3:48343235	NME6	-0.44	-5.36	-0.31	1.8e-7	Educational attainment (years of education);
CESC	cis	rs965469	0.779	rs6139048	chr20:3239753	T/G	cg25506879	chr20:3388711	C20orf194	-0.51	-5.57	-0.32	6.1e-8	IFN-related cytopenia;
CESC	cis	rs826838	1.000	rs2129627	chr12:38653036	C/T	cg26384229	chr12:38710491	ALG10B	0.82	14.26	0.66	1.22e-34	Heart rate;
CESC	cis	rs7824557	0.806	rs10503418	chr8:11118983	C/T	cg21775007	chr8:11205619	TDH	-0.39	-5.9	-0.34	1.09e-8	Retinal vascular caliber;
CESC	cis	rs2290159	0.948	rs9852128	chr3:12635623	A/G	cg23032965	chr3:12705835	RAF1	0.5	5.54	0.32	7.34e-8	Cholesterol, total;
CESC	trans	rs1814175	0.588	rs1794144	chr11:49918233	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.43	-6.36	-0.36	8.98e-10	Height;
CESC	cis	rs1670533	1.000	rs2290411	chr4:1051077	T/C	cg04106633	chr4:1044584	NA	0.4	5.09	0.3	6.77e-7	Recombination rate (females);
CESC	cis	rs6547741	0.967	rs4665986	chr2:27755168	G/A	cg27432699	chr2:27873401	GPN1	0.49	6.83	0.39	5.72e-11	Oral cavity cancer;
CESC	cis	rs7666738	0.753	rs7657644	chr4:99057734	T/A	cg18180107	chr4:99064573	C4orf37	0.41	5.24	0.31	3.24e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs801193	0.935	rs11772264	chr7:66176387	T/C	cg11764359	chr7:65958608	NA	0.69	9.18	0.49	1.32e-17	Aortic root size;
CESC	cis	rs514406	0.929	rs12145105	chr1:53340564	T/C	cg24675658	chr1:53192096	ZYG11B	-0.57	-6.92	-0.39	3.47e-11	Monocyte count;
CESC	cis	rs10870270	0.956	rs4131689	chr10:133744328	A/C	cg26149184	chr10:133730230	NA	-0.4	-5.48	-0.32	9.68e-8	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs10411936	1.000	rs873636	chr19:16514771	C/T	cg10248733	chr19:16607483	C19orf44;CALR3	0.45	5.46	0.32	1.12e-7	White blood cell count;Multiple sclerosis;
CESC	cis	rs28673728	0.868	rs28380108	chr1:38409103	G/C	cg26398791	chr1:38455867	SF3A3	-0.41	-5.23	-0.31	3.4e-7	Red cell distribution width;
CESC	cis	rs3740713	1.000	rs75381502	chr11:18451886	T/G	cg23797887	chr11:18477753	LDHAL6A	-0.52	-5.19	-0.3	4.27e-7	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs11577318	0.853	rs12728971	chr1:26626612	C/T	cg00852783	chr1:26633632	UBXN11	0.5	6.99	0.39	2.17e-11	Granulocyte percentage of myeloid white cells;
CESC	cis	rs35306767	0.903	rs12249634	chr10:872744	G/A	cg26597838	chr10:835615	NA	0.94	9.61	0.51	5.87e-19	Eosinophil percentage of granulocytes;
CESC	cis	rs9291683	0.509	rs998676	chr4:9948564	T/C	cg11266682	chr4:10021025	SLC2A9	-0.61	-12.6	-0.61	7.45e-29	Bone mineral density;
CESC	cis	rs10911232	0.507	rs10911212	chr1:183024469	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.89	13.65	0.64	1.79e-32	Hypertriglyceridemia;
CESC	cis	rs2262909	0.962	rs73019889	chr19:22277826	C/G	cg11619707	chr19:22235551	ZNF257	0.35	5.76	0.33	2.38e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
CESC	cis	rs7602441	0.521	rs1434985	chr2:14767916	C/T	cg06545361	chr2:14773388	FAM84A	0.69	6.86	0.39	4.91e-11	Visceral adipose tissue adjusted for BMI;
CESC	cis	rs9910055	0.659	rs227584	chr17:42225547	A/C	cg13607699	chr17:42295918	UBTF	0.59	7.59	0.42	5.44e-13	Total body bone mineral density;
CESC	cis	rs2228479	0.702	rs2074903	chr16:89811663	T/C	cg19635926	chr16:89946313	TCF25	0.68	5.17	0.3	4.67e-7	Skin colour saturation;
CESC	cis	rs2011503	1.000	rs11670882	chr19:19649748	C/G	cg11584989	chr19:19387371	SF4	0.48	5.81	0.34	1.76e-8	Bipolar disorder;
CESC	cis	rs1348850	0.914	rs12469386	chr2:178358281	A/G	cg22681709	chr2:178499509	PDE11A	0.39	5.77	0.33	2.15e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs7666738	0.830	rs7657179	chr4:98948569	G/A	cg17366294	chr4:99064904	C4orf37	0.6	8.52	0.46	1.21e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4889855	0.530	rs9914854	chr17:78598662	A/G	cg16591659	chr17:78472290	NA	-0.33	-5.25	-0.31	3.08e-7	Fractional excretion of uric acid;
CESC	cis	rs2243480	0.901	rs57126451	chr7:65416306	T/C	cg18252515	chr7:66147081	NA	-1.07	-10.28	-0.53	4.35e-21	Diabetic kidney disease;
CESC	cis	rs4727027	0.745	rs10952801	chr7:148864757	T/C	cg23158103	chr7:148848205	ZNF398	-0.42	-6.88	-0.39	4.26e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs12477438	0.501	rs2632284	chr2:99775865	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.87	16.26	0.71	1.06e-41	Chronic sinus infection;
CESC	cis	rs853679	0.517	rs9283884	chr6:28135660	C/G	cg22143856	chr6:28129313	ZNF389	-0.47	-5.91	-0.34	1.05e-8	Depression;
CESC	cis	rs425277	1.000	rs74877653	chr1:2065949	C/T	cg23803603	chr1:2058230	PRKCZ	0.33	5.07	0.3	7.49e-7	Height;
CESC	cis	rs7216064	1.000	rs73352808	chr17:65875157	G/A	cg12091567	chr17:66097778	LOC651250	-0.79	-8.59	-0.47	7.61e-16	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs17253792	0.915	rs77252471	chr14:56178075	C/T	cg01858014	chr14:56050164	KTN1	-0.91	-7.03	-0.4	1.8e-11	Putamen volume;
CESC	cis	rs9400271	0.632	rs9384706	chr6:109601504	C/T	cg01475377	chr6:109611718	NA	-0.45	-6.99	-0.39	2.28e-11	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg10827434	chr1:84944976	RPF1	-0.46	-6.15	-0.35	2.78e-9	Fibrinogen levels;
CESC	cis	rs208520	0.661	rs1100950	chr6:66827285	A/C	cg07460842	chr6:66804631	NA	-1.0	-13.37	-0.63	1.62e-31	Exhaled nitric oxide output;
CESC	cis	rs34779708	0.900	rs73262807	chr10:35496386	C/T	cg04310649	chr10:35416472	CREM	-0.52	-6.31	-0.36	1.18e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs2576037	0.501	rs7227700	chr18:44537102	T/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.55	-7.51	-0.42	9.03e-13	Personality dimensions;
CESC	cis	rs6547741	0.967	rs4665995	chr2:27813827	T/G	cg27432699	chr2:27873401	GPN1	0.49	6.85	0.39	5.03e-11	Oral cavity cancer;
CESC	cis	rs10504229	0.871	rs10504226	chr8:58159283	A/G	cg02725872	chr8:58115012	NA	-0.37	-5.72	-0.33	2.84e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs4862750	0.758	rs2375915	chr4:187896255	A/C	cg06074448	chr4:187884817	NA	-0.38	-5.35	-0.31	1.91e-7	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9814567	1.000	rs9814567	chr3:134218557	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.44	6.2	0.36	2.13e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs727563	0.552	rs4822045	chr22:41985958	C/A	cg06481639	chr22:41940642	POLR3H	-0.65	-6.38	-0.37	7.65e-10	Crohn's disease;Inflammatory bowel disease;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg13108601	chr6:41748242	FRS3;PRICKLE4	-0.43	-6.24	-0.36	1.73e-9	Gambling;
CESC	cis	rs4974559	0.947	rs28437782	chr4:1355062	A/G	cg02980000	chr4:1222292	CTBP1	0.71	6.6	0.38	2.28e-10	Systolic blood pressure;
CESC	cis	rs1008375	0.933	rs7689101	chr4:17694034	G/A	cg02297831	chr4:17616191	MED28	0.47	5.72	0.33	2.91e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs6750795	0.569	rs1667313	chr2:232408018	A/C	cg19187155	chr2:232395269	NMUR1	0.62	10.99	0.56	2.13e-23	Height;
CESC	cis	rs601339	1.000	rs509548	chr12:123181855	T/A	cg11919336	chr12:123188078	GPR109A	0.47	6.27	0.36	1.49e-9	Adiponectin levels;
CESC	cis	rs801193	0.548	rs2659891	chr7:66201114	A/G	cg12463550	chr7:65579703	CRCP	0.49	6.33	0.36	1.03e-9	Aortic root size;
CESC	cis	rs1008375	0.897	rs6820164	chr4:17630115	G/A	cg02297831	chr4:17616191	MED28	0.64	8.07	0.44	2.45e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs3820928	0.874	rs7562776	chr2:227806550	G/A	cg11843606	chr2:227700838	RHBDD1	-0.43	-5.66	-0.33	3.83e-8	Pulmonary function;
CESC	cis	rs7267979	1.000	rs2259837	chr20:25280205	T/C	cg08601574	chr20:25228251	PYGB	0.39	5.57	0.32	6.14e-8	Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs3942852	0.774	rs11039519	chr11:48130094	G/C	cg15704280	chr7:45808275	SEPT13	-0.63	-7.33	-0.41	2.76e-12	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs651907	0.514	rs10936744	chr3:101433440	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.45	5.88	0.34	1.22e-8	Colorectal cancer;
CESC	cis	rs7647973	1.000	rs7613491	chr3:49508976	T/C	cg06212747	chr3:49208901	KLHDC8B	-0.56	-6.93	-0.39	3.22e-11	Menarche (age at onset);
CESC	trans	rs5758511	0.773	rs8140869	chr22:42344297	A/G	cg15080870	chr19:47770746	CCDC9	-0.49	-6.11	-0.35	3.48e-9	Birth weight;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04559647	chr10:126150293	LHPP	0.69	7.5	0.42	9.89e-13	Gut microbiome composition (summer);
CESC	trans	rs637571	0.522	rs606978	chr11:65711517	A/C	cg17712092	chr4:129076599	LARP1B	0.73	9.96	0.52	4.69e-20	Eosinophil percentage of white cells;
CESC	cis	rs754466	1.000	rs754466	chr10:79680434	A/T	cg17075019	chr10:79541650	NA	-0.68	-8.91	-0.48	8.59e-17	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs561341	0.883	rs72821942	chr17:30234460	C/T	cg12193833	chr17:30244370	NA	-0.61	-6.18	-0.36	2.36e-9	Hip circumference adjusted for BMI;
CESC	cis	rs9311474	0.508	rs11720243	chr3:52618018	T/C	cg18099408	chr3:52552593	STAB1	-0.32	-5.34	-0.31	2e-7	Electroencephalogram traits;
CESC	cis	rs11792861	0.566	rs6477687	chr9:111837791	A/T	cg05043794	chr9:111880884	C9orf5	0.3	5.43	0.32	1.26e-7	Menarche (age at onset);
CESC	cis	rs2011503	1.000	rs7256028	chr19:19628240	C/T	cg11584989	chr19:19387371	SF4	0.56	6.6	0.38	2.18e-10	Bipolar disorder;
CESC	cis	rs9430161	0.598	rs34350247	chr1:11034460	A/G	cg02454025	chr1:11042201	C1orf127	0.99	16.16	0.7	2.35e-41	Ewing sarcoma;
CESC	cis	rs3785574	0.745	rs2854162	chr17:61975610	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.42	-5.03	-0.3	8.85e-7	Height;
CESC	cis	rs11792861	0.816	rs17792434	chr9:111667319	C/T	cg05043794	chr9:111880884	C9orf5	-0.38	-6.38	-0.36	7.81e-10	Menarche (age at onset);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg00577569	chr7:66093764	KCTD7	-0.42	-6.54	-0.37	3.09e-10	Gambling;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16351957	chr6:71874784	NA	-0.6	-6.97	-0.39	2.53e-11	Gut microbiome composition (summer);
CESC	cis	rs853679	0.542	rs9393892	chr6:28081394	A/G	cg22143856	chr6:28129313	ZNF389	0.52	6.72	0.38	1.09e-10	Depression;
CESC	cis	rs8077889	0.672	rs2074143	chr17:41856622	A/G	cg26893861	chr17:41843967	DUSP3	1.01	18.74	0.76	1.74e-50	Triglycerides;
CESC	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg10862848	chr6:42927986	GNMT	-0.27	-6.83	-0.39	5.91e-11	Alzheimer's disease in APOE e4+ carriers;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg01538984	chr7:140396422	LOC100134713;NDUFB2	-0.42	-6.04	-0.35	5.22e-9	Gambling;
CESC	cis	rs6933660	0.745	rs6912830	chr6:151743629	A/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.66	9.39	0.5	2.91e-18	Menarche (age at onset);
CESC	cis	rs763014	0.865	rs2018789	chr16:632051	T/C	cg07256732	chr16:621771	PIGQ	-0.3	-5.14	-0.3	5.22e-7	Height;
CESC	cis	rs9457247	1.000	rs400063	chr6:167386592	C/T	cg07741184	chr6:167504864	NA	0.32	5.88	0.34	1.21e-8	Crohn's disease;
CESC	cis	rs6459788	0.720	rs6965466	chr7:157250749	G/T	cg06271696	chr7:157225062	NA	-0.36	-5.13	-0.3	5.49e-7	Epstein-Barr virus copy number in lymphoblastoid cell lines;
CESC	cis	rs3540	0.533	rs12916560	chr15:91056259	A/C	cg10434728	chr15:90938212	IQGAP1	-0.4	-6.97	-0.39	2.51e-11	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs2249625	0.874	rs2463747	chr6:72878113	T/A	cg18830697	chr6:72922368	RIMS1	-0.39	-5.53	-0.32	7.83e-8	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CESC	cis	rs9581857	0.556	rs9581863	chr13:28040171	A/G	cg01674679	chr13:27998804	GTF3A	-0.55	-5.89	-0.34	1.17e-8	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
CESC	cis	rs10504229	0.679	rs16921683	chr8:58053270	T/C	cg22535103	chr8:58192502	C8orf71	-0.65	-7.25	-0.41	4.69e-12	Developmental language disorder (linguistic errors);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02963556	chr12:132588637	EP400NL	-0.59	-6.6	-0.38	2.2e-10	Gut microbiome composition (summer);
CESC	cis	rs71277158	0.688	rs3772186	chr3:169889331	A/T	cg04067573	chr3:169899625	PHC3	-0.63	-6.51	-0.37	3.82e-10	Prostate cancer;
CESC	cis	rs561341	1.000	rs498391	chr17:30328704	G/A	cg12193833	chr17:30244370	NA	-0.64	-5.98	-0.34	7.35e-9	Hip circumference adjusted for BMI;
CESC	cis	rs7843479	0.601	rs1031882	chr8:21788934	T/G	cg17168535	chr8:21777572	XPO7	0.8	13.33	0.63	2.3e-31	Mean corpuscular volume;
CESC	cis	rs6831352	0.918	rs7670060	chr4:100059568	G/T	cg12011299	chr4:100065546	ADH4	-0.59	-6.49	-0.37	4.3e-10	Alcohol dependence;
CESC	cis	rs7116495	0.609	rs7126394	chr11:71685429	A/G	cg18441811	chr11:71824068	C11orf51	-0.81	-5.3	-0.31	2.44e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs7833790	0.660	rs10091077	chr8:82705464	A/G	cg06027949	chr8:82754900	SNX16	-0.44	-5.29	-0.31	2.58e-7	Diastolic blood pressure;
CESC	cis	rs3733585	0.673	rs4314284	chr4:9956096	C/T	cg02734326	chr4:10020555	SLC2A9	-0.38	-5.43	-0.32	1.3e-7	Cleft plate (environmental tobacco smoke interaction);
CESC	trans	rs2727020	0.857	rs1917324	chr11:49371759	G/C	cg03929089	chr4:120376271	NA	-0.65	-7.61	-0.42	4.95e-13	Coronary artery disease;
CESC	cis	rs7647973	0.580	rs12629759	chr3:49237394	T/C	cg06212747	chr3:49208901	KLHDC8B	0.73	11.06	0.56	1.29e-23	Menarche (age at onset);
CESC	cis	rs7208859	0.673	rs11657270	chr17:29214387	A/G	cg13385521	chr17:29058706	SUZ12P	0.66	5.03	0.3	9.15e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	trans	rs1814175	0.645	rs11040699	chr11:50023798	C/G	cg11707556	chr5:10655725	ANKRD33B	-0.42	-6.13	-0.35	3.1e-9	Height;
CESC	cis	rs9916302	0.904	rs612194	chr17:37442707	T/A	cg15445000	chr17:37608096	MED1	-0.4	-6.55	-0.37	3.05e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs7107174	1.000	rs10899478	chr11:78052238	C/T	cg02023728	chr11:77925099	USP35	0.38	5.4	0.31	1.47e-7	Testicular germ cell tumor;
CESC	trans	rs11098499	0.874	rs17839089	chr4:120111069	A/G	cg25214090	chr10:38739885	LOC399744	0.58	7.71	0.43	2.54e-13	Corneal astigmatism;
CESC	cis	rs27434	0.660	rs27043	chr5:96117300	A/G	cg16492584	chr5:96139282	ERAP1	0.49	5.92	0.34	9.97e-9	Ankylosing spondylitis;
CESC	cis	rs9649213	0.593	rs6967457	chr7:97912221	T/G	cg00277769	chr7:97922759	BAIAP2L1	-0.34	-5.53	-0.32	7.61e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs9916302	0.904	rs12952384	chr17:37669536	T/C	cg20243544	chr17:37824526	PNMT	0.51	6.5	0.37	3.88e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs933688	1.000	rs6866191	chr5:90746852	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.94	11.09	0.56	1.03e-23	Smoking behavior;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg19824897	chr13:79979916	RBM26	-0.44	-6.31	-0.36	1.14e-9	Gambling;
CESC	cis	rs7020830	0.898	rs12000309	chr9:37230844	G/A	cg14294708	chr9:37120828	ZCCHC7	1.24	24.36	0.83	1.35e-69	Schizophrenia;
CESC	cis	rs1215050	0.791	rs260889	chr4:98742340	A/G	cg05340658	chr4:99064831	C4orf37	0.51	6.65	0.38	1.63e-10	Waist-to-hip ratio adjusted for body mass index;
CESC	trans	rs7726839	0.574	rs11134149	chr5:637277	A/G	cg25482853	chr8:67687455	SGK3	0.93	9.77	0.51	1.86e-19	Obesity-related traits;
CESC	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg02353165	chr6:42928485	GNMT	0.84	13.25	0.63	4.46e-31	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs9457247	1.000	rs364451	chr6:167384756	G/A	cg23791538	chr6:167370224	RNASET2	-0.58	-8.33	-0.46	4.4e-15	Crohn's disease;
CESC	cis	rs977987	0.843	rs62062564	chr16:75442622	G/A	cg03315344	chr16:75512273	CHST6	0.4	5.83	0.34	1.57e-8	Dupuytren's disease;
CESC	cis	rs72772090	0.539	rs11747896	chr5:96113397	A/G	cg17330273	chr5:96107758	CAST;ERAP1	0.57	5.11	0.3	6.1e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg06844209	chr11:66629644	PC	-0.44	-6.07	-0.35	4.48e-9	Systemic lupus erythematosus;
CESC	cis	rs7809950	1.000	rs12668402	chr7:107173020	G/A	cg23024343	chr7:107201750	COG5	-0.41	-5.71	-0.33	3.03e-8	Coronary artery disease;
CESC	cis	rs78132593	0.723	rs115291189	chr1:150675007	C/A	cg04414720	chr1:150670196	GOLPH3L	-0.51	-6.01	-0.35	6.17e-9	High light scatter reticulocyte count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23659696	chr6:39083005	C6orf64	0.58	7.24	0.41	4.77e-12	Gut microbiome composition (summer);
CESC	cis	rs9467711	0.606	rs9393712	chr6:26371000	G/C	cg14345882	chr6:26364793	BTN3A2	0.6	6.21	0.36	2.06e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs2455799	0.573	rs2455831	chr3:15751583	T/A	cg09340198	chr3:15902540	ANKRD28	-0.33	-5.22	-0.31	3.57e-7	Mean platelet volume;
CESC	cis	rs4713118	0.629	rs172165	chr6:28020814	T/G	cg18032046	chr6:28092343	ZSCAN16	-0.51	-5.82	-0.34	1.73e-8	Parkinson's disease;
CESC	cis	rs2573652	0.722	rs8034841	chr15:100541593	G/T	cg09918751	chr15:100517450	ADAMTS17	-0.32	-5.95	-0.34	8.48e-9	Height;
CESC	cis	rs853679	0.517	rs9380058	chr6:28127444	T/C	cg17221315	chr6:27791827	HIST1H4J	0.45	5.07	0.3	7.46e-7	Depression;
CESC	cis	rs7188697	0.922	rs37040	chr16:58578262	T/C	cg21335942	chr16:58549945	SETD6	0.46	5.48	0.32	1.01e-7	QT interval;
CESC	cis	rs6691722	0.503	rs3765432	chr1:24706461	A/G	cg18323236	chr1:24743029	NIPAL3	0.37	5.55	0.32	7.02e-8	Response to interferon beta in multiple sclerosis;
CESC	cis	rs9487051	0.872	rs6924815	chr6:109612344	A/G	cg01475377	chr6:109611718	NA	-0.5	-8.41	-0.46	2.52e-15	Reticulocyte fraction of red cells;
CESC	trans	rs9987353	0.840	rs329994	chr8:9123233	A/G	cg23495556	chr7:44836196	PPIA	-0.5	-6.78	-0.38	7.95e-11	Recombination measurement;
CESC	trans	rs7746199	0.736	rs58616630	chr6:27474715	A/G	cg01620082	chr3:125678407	NA	-0.79	-6.42	-0.37	6.38e-10	Gait speed in old age;Autism spectrum disorder or schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13995389	chr5:132202281	UQCRQ	0.55	6.34	0.36	9.65e-10	Gut microbiome composition (summer);
CESC	cis	rs4975709	0.589	rs931508	chr5:1861224	C/G	cg10800226	chr5:1850261	NA	0.34	5.67	0.33	3.65e-8	Cardiovascular disease risk factors;
CESC	cis	rs362272	0.524	rs3129334	chr4:3368526	T/C	cg14583973	chr4:3374767	RGS12	0.31	5.43	0.32	1.29e-7	Serum sulfate level;
CESC	cis	rs7937682	0.710	rs674230	chr11:111437887	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.97	-14.3	-0.66	8.89e-35	Primary sclerosing cholangitis;
CESC	cis	rs12887734	0.569	rs66953418	chr14:104271470	G/A	cg08213375	chr14:104286397	PPP1R13B	0.41	6.8	0.39	7.09e-11	Schizophrenia;Autism spectrum disorder or schizophrenia;
CESC	cis	rs7666738	0.830	rs921522	chr4:98841608	C/T	cg24818145	chr4:99064322	C4orf37	0.39	5.13	0.3	5.69e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3020736	0.500	rs5996110	chr22:42493767	A/G	cg15557168	chr22:42548783	NA	0.45	6.57	0.37	2.72e-10	Autism spectrum disorder or schizophrenia;
CESC	cis	rs1348850	0.789	rs2197611	chr2:178369036	G/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.87	12.61	0.61	7.17e-29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs12410462	0.792	rs994666	chr1:227651454	C/T	cg23173402	chr1:227635558	NA	-0.55	-5.52	-0.32	7.94e-8	Major depressive disorder;
CESC	trans	rs801193	0.967	rs34356500	chr7:66236607	G/T	cg26939375	chr7:64535504	NA	0.67	9.01	0.48	4.12e-17	Aortic root size;
CESC	cis	rs16867321	0.627	rs6730229	chr2:181579985	A/C	cg23363182	chr2:181467187	NA	0.44	6.5	0.37	3.86e-10	Obesity;
CESC	cis	rs1008375	0.932	rs4698650	chr4:17692878	G/C	cg02297831	chr4:17616191	MED28	0.46	5.62	0.33	4.91e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs1552244	0.810	rs35711405	chr3:10116939	C/T	cg16606324	chr3:10149918	C3orf24	0.45	5.37	0.31	1.69e-7	Alzheimer's disease;
CESC	cis	rs2282802	0.660	rs2436390	chr5:139586501	G/A	cg26211634	chr5:139558579	C5orf32	-0.49	-7.19	-0.4	6.76e-12	Intelligence (multi-trait analysis);
CESC	cis	rs9487051	0.802	rs6568558	chr6:109592701	A/T	cg12927641	chr6:109611667	NA	-0.41	-6.43	-0.37	5.98e-10	Reticulocyte fraction of red cells;
CESC	cis	rs7666738	0.830	rs7696686	chr4:98938445	T/C	cg17366294	chr4:99064904	C4orf37	0.61	8.56	0.47	9.36e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs55794721	0.543	rs1293260	chr1:25709104	C/G	cg02931644	chr1:25747376	RHCE	0.47	7.96	0.44	5.1e-14	Plateletcrit;Mean corpuscular volume;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg00147976	chr12:53846229	PCBP2	0.47	6.43	0.37	5.75e-10	Thyroid stimulating hormone;
CESC	cis	rs13118159	0.725	rs71614967	chr4:1341291	A/G	cg20887711	chr4:1340912	KIAA1530	0.47	6.28	0.36	1.41e-9	Longevity;
CESC	trans	rs61931739	0.500	rs7489270	chr12:34432062	C/T	cg13010199	chr12:38710504	ALG10B	0.49	6.3	0.36	1.24e-9	Morning vs. evening chronotype;
CESC	cis	rs16910800	0.731	rs1065631	chr11:23186810	T/C	cg20040320	chr11:23191996	NA	-0.67	-6.66	-0.38	1.53e-10	Cancer;
CESC	cis	rs2929278	0.617	rs693919	chr15:44102328	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.56	-7.29	-0.41	3.59e-12	Schizophrenia;
CESC	cis	rs1707322	0.964	rs785516	chr1:46564758	T/G	cg06784218	chr1:46089804	CCDC17	-0.36	-5.93	-0.34	9.35e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs6696846	0.777	rs2369526	chr1:205054406	C/T	cg00857998	chr1:205179979	DSTYK	0.47	6.33	0.36	1.01e-9	Red blood cell count;
CESC	cis	rs965513	0.901	rs7045465	chr9:100534823	A/T	cg13688889	chr9:100608707	NA	-0.45	-6.43	-0.37	5.86e-10	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg13190986	chr12:133263482	PXMP2;POLE	0.5	6.32	0.36	1.07e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs36207871	1	rs36207871	chr12:56684496	TAGGAA/T	cg26316697	chr12:56727976	PAN2	-0.69	-6.64	-0.38	1.74e-10	Inflammatory skin disease;
CESC	cis	rs67311347	1.000	rs73078123	chr3:40458963	G/A	cg09455208	chr3:40491958	NA	0.53	8.86	0.48	1.15e-16	Renal cell carcinoma;
CESC	cis	rs6942756	1.000	rs66970518	chr7:128871006	G/A	cg02491457	chr7:128862824	NA	-0.72	-10.44	-0.54	1.31e-21	White matter hyperintensity burden;
CESC	cis	rs17666538	0.636	rs10107345	chr8:603700	G/T	cg23958373	chr8:599963	NA	0.74	6.33	0.36	1.05e-9	IgG glycosylation;
CESC	cis	rs798766	1.000	rs1665366	chr4:1728381	A/G	cg10756475	chr4:1757242	NA	-0.46	-5.76	-0.33	2.28e-8	Bladder cancer;Urinary bladder cancer;
CESC	cis	rs9462846	0.959	rs10456518	chr6:42830484	G/A	cg02353165	chr6:42928485	GNMT	0.45	5.18	0.3	4.45e-7	Blood protein levels;
CESC	cis	rs853679	0.546	rs200952	chr6:27836976	C/T	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.85	7.2	0.4	6.18e-12	Depression;
CESC	cis	rs3857536	0.813	rs7769683	chr6:66946256	G/A	cg07460842	chr6:66804631	NA	-0.42	-5.29	-0.31	2.55e-7	Blood trace element (Cu levels);
CESC	cis	rs919433	1.000	rs6741380	chr2:198165121	A/G	cg10820045	chr2:198174542	NA	0.38	5.75	0.33	2.4e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs7044106	0.708	rs10760113	chr9:123474050	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.72	10.59	0.55	4.52e-22	Hip circumference adjusted for BMI;
CESC	cis	rs8114671	0.562	rs6088622	chr20:33419977	C/A	cg24642439	chr20:33292090	TP53INP2	0.46	5.45	0.32	1.14e-7	Height;
CESC	cis	rs17711722	0.585	rs6942660	chr7:65302406	C/T	cg26939375	chr7:64535504	NA	0.76	10.78	0.55	1.03e-22	Calcium levels;
CESC	cis	rs1448094	0.512	rs7137596	chr12:86239884	C/G	cg19622623	chr12:86230825	RASSF9	-0.47	-6.14	-0.35	3.04e-9	Major depressive disorder;
CESC	cis	rs9393777	0.841	rs13191474	chr6:27413345	C/T	cg26587870	chr6:27730563	NA	-0.7	-5.13	-0.3	5.48e-7	Intelligence (multi-trait analysis);
CESC	cis	rs60843830	1.000	rs57542652	chr2:228088	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.78	9.67	0.51	3.87e-19	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs1707322	0.686	rs1541131	chr1:46084934	G/A	cg05343316	chr1:45956843	TESK2	-0.49	-5.96	-0.34	8.16e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs308403	0.568	rs309344	chr4:123644812	G/A	cg18677716	chr21:47865349	PCNT	-0.47	-6.06	-0.35	4.69e-9	Blood protein levels;
CESC	cis	rs10818894	1.000	rs10818894	chr9:126695770	A/G	cg16191174	chr9:126692580	DENND1A	-0.62	-8.15	-0.45	1.45e-14	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
CESC	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg18402987	chr7:1209562	NA	0.75	7.49	0.42	1.04e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs8062405	0.755	rs17640009	chr16:28595700	A/G	cg01378222	chr16:28622494	SULT1A1	0.31	5.24	0.31	3.33e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs4665809	1.000	rs6750681	chr2:26329677	C/T	cg08470875	chr2:26401718	FAM59B	-0.47	-5.23	-0.31	3.38e-7	Gut microbiome composition (summer);
CESC	cis	rs2455826	0.500	rs2455852	chr3:15688688	C/T	cg16303742	chr3:15540471	COLQ	-0.5	-8.1	-0.45	2.05e-14	Inflammatory skin disease;
CESC	cis	rs13108904	0.557	rs1250086	chr4:1248051	G/A	cg20887711	chr4:1340912	KIAA1530	-0.66	-8.89	-0.48	9.87e-17	Obesity-related traits;
CESC	cis	rs4665809	0.567	rs12999875	chr2:26414847	A/C	cg26119090	chr2:26468346	HADHA;HADHB	1.08	12.83	0.62	1.2e-29	Gut microbiome composition (summer);
CESC	cis	rs644799	0.710	rs11021311	chr11:95505227	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.77	11.31	0.57	1.91e-24	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs10465746	0.967	rs1475263	chr1:84339497	A/T	cg10977910	chr1:84465055	TTLL7	0.48	6.52	0.37	3.64e-10	Obesity-related traits;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg15239874	chr12:121148841	UNC119B	-0.47	-6.82	-0.39	6.09e-11	Gambling;
CESC	cis	rs9287719	0.810	rs1990612	chr2:10781944	A/G	cg00105475	chr2:10696890	NA	0.36	5.17	0.3	4.67e-7	Prostate cancer;
CESC	cis	rs2299587	0.521	rs3739406	chr8:17739538	T/C	cg08627089	chr8:17753878	FGL1	-0.39	-5.56	-0.32	6.63e-8	Economic and political preferences;
CESC	cis	rs9486715	0.830	rs4425602	chr6:96893906	G/A	cg18709589	chr6:96969512	KIAA0776	0.45	6.3	0.36	1.22e-9	Headache;
CESC	cis	rs7772486	0.743	rs62433835	chr6:146032688	C/G	cg05347473	chr6:146136440	FBXO30	-0.48	-6.45	-0.37	5.16e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs796364	0.806	rs6435041	chr2:200867144	A/G	cg23649088	chr2:200775458	C2orf69	0.6	5.3	0.31	2.44e-7	Schizophrenia;
CESC	cis	rs8050907	0.744	rs7192051	chr16:4542117	A/C	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.76	5.74	0.33	2.6e-8	Obesity-related traits;
CESC	cis	rs9811920	0.715	rs1017967	chr3:99905803	C/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.38	5.84	0.34	1.51e-8	Axial length;
CESC	cis	rs7829975	0.522	rs6601689	chr8:8172283	C/T	cg06636001	chr8:8085503	FLJ10661	0.53	6.43	0.37	5.75e-10	Mood instability;
CESC	cis	rs1008375	0.933	rs7689101	chr4:17694034	G/A	cg16339924	chr4:17578868	LAP3	0.58	7.08	0.4	1.33e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs798554	0.721	rs2527680	chr7:2892361	C/T	cg13628971	chr7:2884303	GNA12	0.63	8.31	0.45	4.89e-15	Height;
CESC	cis	rs1062177	1.000	rs12653926	chr5:151250248	C/A	cg12924095	chr5:151150029	G3BP1	0.47	6.01	0.35	6.01e-9	Preschool internalizing problems;
CESC	cis	rs9322193	0.962	rs3763162	chr6:150140810	A/G	cg13206674	chr6:150067644	NUP43	-0.42	-5.85	-0.34	1.43e-8	Lung cancer;
CESC	cis	rs7927771	0.524	rs11039392	chr11:47798753	A/G	cg20307385	chr11:47447363	PSMC3	0.62	8.69	0.47	3.96e-16	Subjective well-being;
CESC	trans	rs7107217	1.000	rs1873872	chr11:129473993	A/T	cg07151637	chr22:32149913	DEPDC5	0.46	6.19	0.36	2.29e-9	Breast cancer;Type 2 diabetes;
CESC	cis	rs17384381	0.906	rs2300639	chr1:85823676	T/A	cg16011679	chr1:85725395	C1orf52	0.83	8.44	0.46	2.15e-15	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7586673	0.893	rs889925	chr2:161971597	T/C	cg16506815	chr2:162101123	NA	0.42	5.83	0.34	1.63e-8	Intelligence (multi-trait analysis);
CESC	cis	rs7000551	0.725	rs2461483	chr8:22386479	C/T	cg12081754	chr8:22256438	SLC39A14	0.41	5.41	0.32	1.43e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CESC	cis	rs17253792	0.822	rs79483507	chr14:56164718	G/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.81	5.68	0.33	3.46e-8	Putamen volume;
CESC	cis	rs6089584	0.888	rs6061405	chr20:60617033	A/G	cg13770153	chr20:60521292	NA	-0.46	-5.88	-0.34	1.23e-8	Body mass index;
CESC	cis	rs12478296	0.786	rs6721704	chr2:242994923	A/G	cg06360820	chr2:242988706	NA	-0.74	-9.37	-0.5	3.4e-18	Obesity-related traits;
CESC	cis	rs6582630	0.502	rs11181210	chr12:38298069	G/A	cg13010199	chr12:38710504	ALG10B	0.46	5.88	0.34	1.26e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs8058578	1.000	rs6565197	chr16:30706477	T/C	cg00531865	chr16:30841666	NA	-0.44	-5.84	-0.34	1.51e-8	Multiple myeloma;
CESC	cis	rs2075371	0.796	rs1643040	chr7:134011703	G/C	cg11752832	chr7:134001865	SLC35B4	0.48	6.0	0.35	6.58e-9	Mean platelet volume;
CESC	cis	rs1799949	1.000	rs8176233	chr17:41219804	T/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.45	6.21	0.36	2.01e-9	Menopause (age at onset);
CESC	cis	rs2932538	0.922	rs12136781	chr1:113090655	C/T	cg22162597	chr1:113214053	CAPZA1	0.56	7.01	0.4	1.96e-11	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CESC	cis	rs597539	0.652	rs622082	chr11:68703959	A/G	cg01988459	chr11:68622903	NA	-0.45	-6.36	-0.36	8.85e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs11674184	0.632	rs17529680	chr2:11727087	A/C	cg07314298	chr2:11723111	GREB1	0.59	8.64	0.47	5.5e-16	Endometriosis;
CESC	cis	rs875971	0.545	rs1796222	chr7:66057154	T/C	cg18876405	chr7:65276391	NA	-0.49	-5.44	-0.32	1.24e-7	Aortic root size;
CESC	cis	rs9796	0.662	rs8033435	chr15:41436479	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.46	-6.74	-0.38	1e-10	Menopause (age at onset);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg24546153	chr1:203830887	SNRPE	-0.51	-6.25	-0.36	1.6e-9	Ulcerative colitis;
CESC	cis	rs13102973	0.899	rs10213137	chr4:135900543	T/C	cg14419869	chr4:135874104	NA	-0.34	-5.17	-0.3	4.69e-7	Subjective well-being;
CESC	cis	rs6952808	0.792	rs2056481	chr7:1955435	A/G	cg22963979	chr7:1858916	MAD1L1	-0.39	-5.43	-0.32	1.28e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs3768617	0.706	rs6678517	chr1:183002639	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.7	9.99	0.52	3.8e-20	Fuchs's corneal dystrophy;
CESC	cis	rs9488822	0.676	rs12524249	chr6:116368813	G/A	cg05304507	chr6:116381966	FRK	0.26	6.75	0.38	9.45e-11	Cholesterol, total;LDL cholesterol;
CESC	cis	rs7917772	0.502	rs2296583	chr10:104244322	T/G	cg22532475	chr10:104410764	TRIM8	-0.33	-5.65	-0.33	4.1e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs798554	0.797	rs1182174	chr7:2875420	G/A	cg19346786	chr7:2764209	NA	-0.46	-6.71	-0.38	1.16e-10	Height;
CESC	cis	rs60733400	0.644	rs28774982	chr1:2621352	C/G	cg18854424	chr1:2615690	NA	-0.3	-5.64	-0.33	4.25e-8	Multiple sclerosis;
CESC	cis	rs3796352	1.000	rs34244302	chr3:53102236	C/G	cg07884673	chr3:53033167	SFMBT1	0.67	5.67	0.33	3.66e-8	Immune reponse to smallpox (secreted IL-2);
CESC	cis	rs9443645	0.901	rs9352670	chr6:79584433	A/G	cg05283184	chr6:79620031	NA	-0.43	-6.55	-0.37	2.95e-10	Intelligence (multi-trait analysis);
CESC	cis	rs17376456	0.877	rs10062711	chr5:93348659	G/A	cg21475434	chr5:93447410	FAM172A	0.79	7.01	0.4	1.95e-11	Diabetic retinopathy;
CESC	cis	rs6685188	0.920	rs6676110	chr1:205662977	G/A	cg07167872	chr1:205819463	PM20D1	-0.43	-6.03	-0.35	5.35e-9	White blood cell count (basophil);Basophil percentage of white cells;
CESC	cis	rs11098499	0.863	rs11731756	chr4:120478696	T/G	cg09307838	chr4:120376055	NA	0.9	12.45	0.61	2.6e-28	Corneal astigmatism;
CESC	cis	rs1559088	0.600	rs7259117	chr19:33550113	G/T	cg03563238	chr19:33554763	RHPN2	-0.32	-5.81	-0.34	1.8e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs4268898	0.610	rs72791170	chr2:24449776	C/T	cg06627628	chr2:24431161	ITSN2	-0.99	-11.27	-0.57	2.58e-24	Asthma;
CESC	trans	rs208520	0.955	rs12216176	chr6:67005130	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.76	8.46	0.46	1.85e-15	Exhaled nitric oxide output;
CESC	cis	rs11696501	0.588	rs6073831	chr20:44279550	A/T	cg11783356	chr20:44313418	WFDC10B	-0.33	-5.16	-0.3	4.82e-7	Brain structure;
CESC	cis	rs34779708	0.931	rs7923172	chr10:35309367	G/A	cg03585969	chr10:35415529	CREM	0.75	10.02	0.52	2.93e-20	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs6061231	0.631	rs2427317	chr20:60975725	C/T	cg22633769	chr20:60982531	CABLES2	0.56	7.21	0.4	5.96e-12	Colorectal cancer;
CESC	cis	rs10887741	0.690	rs10509410	chr10:89440001	C/T	cg13926569	chr10:89418898	PAPSS2	0.37	5.57	0.32	6.15e-8	Exercise (leisure time);
CESC	cis	rs1144333	1.000	rs1586936	chr1:76366877	T/C	cg10523679	chr1:76189770	ACADM	0.56	5.2	0.3	3.94e-7	Attention function in attention deficit hyperactive disorder;
CESC	cis	rs208520	1.000	rs12209225	chr6:66996443	G/T	cg07460842	chr6:66804631	NA	0.87	9.84	0.52	1.09e-19	Exhaled nitric oxide output;
CESC	cis	rs208520	0.770	rs2153941	chr6:66885521	A/T	cg07460842	chr6:66804631	NA	-0.94	-12.15	-0.6	2.75e-27	Exhaled nitric oxide output;
CESC	cis	rs9322193	0.884	rs9322210	chr6:150016576	G/A	cg13206674	chr6:150067644	NUP43	0.45	6.47	0.37	4.75e-10	Lung cancer;
CESC	cis	rs11677416	0.961	rs1894399	chr2:113540177	C/T	cg27083787	chr2:113543245	IL1A	0.41	5.17	0.3	4.65e-7	Response to antipsychotic treatment in schizophrenia (working memory);
CESC	cis	rs6546537	0.550	rs12617329	chr2:69781530	C/A	cg10773587	chr2:69614142	GFPT1	-0.43	-5.48	-0.32	1.01e-7	Serum thyroid-stimulating hormone levels;
CESC	cis	rs4253772	0.591	rs73886791	chr22:46687212	A/G	cg09491104	chr22:46646882	C22orf40	-0.63	-9.37	-0.5	3.4e-18	LDL cholesterol;Cholesterol, total;
CESC	cis	rs6952808	0.792	rs2056481	chr7:1955435	A/G	cg21782813	chr7:2030301	MAD1L1	0.41	5.87	0.34	1.31e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs7828089	0.582	rs13259873	chr8:22266292	C/T	cg12081754	chr8:22256438	SLC39A14	0.64	9.0	0.48	4.4e-17	Verbal declarative memory;
CESC	cis	rs9311474	0.508	rs4687546	chr3:52605943	T/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.57	7.93	0.44	6.13e-14	Electroencephalogram traits;
CESC	cis	rs3820068	0.705	rs11577225	chr1:15864242	T/C	cg18192808	chr1:15853278	DNAJC16	0.43	5.28	0.31	2.66e-7	Systolic blood pressure;
CESC	cis	rs826838	0.904	rs10876086	chr12:39188208	C/A	cg13010199	chr12:38710504	ALG10B	0.58	8.05	0.44	2.77e-14	Heart rate;
CESC	cis	rs7044106	0.791	rs4617229	chr9:123480696	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.36	5.87	0.34	1.3e-8	Hip circumference adjusted for BMI;
CESC	cis	rs72634258	0.842	rs4908727	chr1:8163122	C/T	cg00042356	chr1:8021962	PARK7	0.48	5.16	0.3	4.95e-7	Inflammatory bowel disease;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg17103929	chr8:101225361	SPAG1	0.48	6.15	0.35	2.9e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs4665809	1.000	rs10048683	chr2:26320519	C/T	cg04944784	chr2:26401820	FAM59B	-0.66	-7.63	-0.42	4.16e-13	Gut microbiome composition (summer);
CESC	cis	rs2108622	0.727	rs62106156	chr19:15980424	C/T	cg13772218	chr19:15982569	NA	0.29	5.71	0.33	3.02e-8	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CESC	cis	rs7216064	1.000	rs35243555	chr17:65876477	G/C	cg07042672	chr17:66097459	LOC651250	-0.52	-5.4	-0.31	1.5e-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs9322193	0.683	rs113281309	chr6:150108425	T/G	cg05861140	chr6:150128134	PCMT1	-0.35	-5.03	-0.3	8.87e-7	Lung cancer;
CESC	cis	rs875971	0.898	rs6977501	chr7:65693342	T/C	cg12463550	chr7:65579703	CRCP	-0.55	-7.18	-0.4	7.17e-12	Aortic root size;
CESC	cis	rs116095464	0.558	rs62346508	chr5:203668	T/C	cg22857025	chr5:266934	NA	-1.28	-14.06	-0.65	6.33e-34	Breast cancer;
CESC	cis	rs76419734	0.510	rs12504088	chr4:106662004	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.72	8.76	0.47	2.42e-16	Post bronchodilator FEV1;
CESC	cis	rs7851660	0.809	rs7048255	chr9:100665698	A/G	cg13688889	chr9:100608707	NA	-0.63	-8.95	-0.48	6.33e-17	Strep throat;
CESC	cis	rs9863	0.862	rs6488912	chr12:124442752	T/C	cg17562584	chr12:124393655	DNAH10	0.33	5.66	0.33	3.98e-8	White blood cell count;
CESC	cis	rs7193541	0.691	rs3851728	chr16:74480660	C/T	cg01733217	chr16:74700730	RFWD3	0.68	9.52	0.5	1.12e-18	Multiple myeloma;
CESC	cis	rs9929218	0.954	rs4485355	chr16:68754730	C/T	cg02972257	chr16:68554789	NA	0.54	6.26	0.36	1.52e-9	Colorectal cancer;
CESC	cis	rs1018836	0.923	rs4735230	chr8:91574184	G/C	cg16814680	chr8:91681699	NA	-0.72	-10.32	-0.54	3.27e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs1707322	1.000	rs11211239	chr1:46451947	A/G	cg03146154	chr1:46216737	IPP	0.72	9.82	0.52	1.31e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs8013055	0.706	rs8003957	chr14:105971702	A/G	cg23356831	chr14:105996513	TMEM121	0.38	5.12	0.3	5.98e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
CESC	cis	rs965469	1.000	rs2236104	chr20:3277602	C/A	cg25506879	chr20:3388711	C20orf194	-0.54	-5.88	-0.34	1.24e-8	IFN-related cytopenia;
CESC	cis	rs12971120	0.947	rs8084410	chr18:72168486	T/C	cg26446133	chr18:72167187	CNDP2	-0.75	-11.21	-0.57	4.12e-24	Refractive error;
CESC	cis	rs1005277	0.602	rs1740743	chr10:38519222	C/T	cg00409905	chr10:38381863	ZNF37A	-0.52	-7.03	-0.4	1.8e-11	Extrinsic epigenetic age acceleration;
CESC	trans	rs561341	1.000	rs548957	chr17:30302411	G/A	cg27661571	chr11:113659931	NA	-0.83	-7.76	-0.43	1.9e-13	Hip circumference adjusted for BMI;
CESC	cis	rs11711311	0.955	rs9860642	chr3:113419211	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.66	8.94	0.48	7e-17	IgG glycosylation;
CESC	trans	rs11098499	0.865	rs28845498	chr4:120405186	G/A	cg25214090	chr10:38739885	LOC399744	0.72	10.18	0.53	9.16e-21	Corneal astigmatism;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16699849	chr7:98923489	ARPC1A	0.54	6.36	0.36	8.57e-10	Gut microbiome composition (summer);
CESC	trans	rs561341	0.941	rs72825746	chr17:30364610	G/A	cg27661571	chr11:113659931	NA	-0.87	-7.99	-0.44	4.25e-14	Hip circumference adjusted for BMI;
CESC	cis	rs7667	1.000	rs10799805	chr1:19707951	C/T	cg15026089	chr1:19640712	PQLC2	-0.31	-5.12	-0.3	5.84e-7	Crohn's disease and psoriasis;
CESC	cis	rs7666738	0.830	rs6831925	chr4:98947401	T/C	cg05340658	chr4:99064831	C4orf37	0.82	12.66	0.61	4.8e-29	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1355223	0.902	rs1901831	chr11:34725175	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.48	-6.2	-0.36	2.18e-9	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg22907277	chr7:1156413	C7orf50	0.46	5.4	0.32	1.45e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs853679	0.517	rs6941992	chr6:28106141	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.55	-6.39	-0.37	7.41e-10	Depression;
CESC	cis	rs733175	0.855	rs10022499	chr4:10006537	C/A	cg00071950	chr4:10020882	SLC2A9	0.57	6.69	0.38	1.32e-10	Psychosis and Alzheimer's disease;
CESC	cis	rs10504229	0.953	rs67677367	chr8:58175264	T/G	cg22535103	chr8:58192502	C8orf71	-1.05	-13.27	-0.63	3.63e-31	Developmental language disorder (linguistic errors);
CESC	cis	rs7552404	0.961	rs1061337	chr1:76227022	A/G	cg03433033	chr1:76189801	ACADM	0.63	7.35	0.41	2.5e-12	Blood metabolite levels;Acylcarnitine levels;
CESC	trans	rs877282	0.853	rs7092652	chr10:756109	G/A	cg22713356	chr15:30763199	NA	0.93	8.39	0.46	3e-15	Uric acid levels;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg14115740	chr9:98054883	FANCC	0.52	6.97	0.39	2.57e-11	Fibrinogen levels;
CESC	cis	rs6537837	1.000	rs7371	chr1:110135308	G/A	cg05049280	chr1:110155535	GNAT2	0.38	5.34	0.31	1.96e-7	Major depressive disorder;
CESC	cis	rs853679	0.517	rs4713146	chr6:28111536	A/T	cg08968635	chr6:28129556	ZNF389	0.4	5.26	0.31	3e-7	Depression;
CESC	trans	rs801193	1.000	rs2659889	chr7:66217112	A/G	cg26939375	chr7:64535504	NA	0.64	8.67	0.47	4.31e-16	Aortic root size;
CESC	cis	rs34779708	1.000	rs12769189	chr10:35399668	A/G	cg04310649	chr10:35416472	CREM	-0.53	-6.38	-0.37	7.66e-10	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs13108904	0.967	rs11247987	chr4:1294532	G/A	cg00684032	chr4:1343700	KIAA1530	0.39	5.46	0.32	1.11e-7	Obesity-related traits;
CESC	cis	rs3741151	0.686	rs60860405	chr11:73248673	A/C	cg17517138	chr11:73019481	ARHGEF17	0.57	5.06	0.3	7.75e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	trans	rs1814175	0.645	rs866427	chr11:49923853	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.43	-6.36	-0.36	8.98e-10	Height;
CESC	cis	rs6032067	0.929	rs13039108	chr20:43829584	T/C	cg11264863	chr20:43835661	SEMG1	0.48	5.29	0.31	2.57e-7	Blood protein levels;
CESC	cis	rs3740540	0.530	rs10794163	chr10:126291398	A/G	cg04949429	chr10:126290192	LHPP	0.4	5.61	0.33	5.04e-8	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
CESC	cis	rs4665809	0.590	rs36064164	chr2:26502768	C/T	cg25036284	chr2:26402008	FAM59B	0.85	8.95	0.48	6.29e-17	Gut microbiome composition (summer);
CESC	trans	rs875971	1.000	rs6979382	chr7:65886375	C/T	cg26939375	chr7:64535504	NA	0.47	6.04	0.35	5.14e-9	Aortic root size;
CESC	cis	rs13191362	1.000	rs60719662	chr6:163006643	A/C	cg14584255	chr6:163149320	PACRG;PARK2	0.49	5.36	0.31	1.82e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs7116495	1.000	rs560777	chr11:71770602	C/T	cg26138937	chr11:71823887	C11orf51	0.84	7.18	0.4	7.24e-12	Severe influenza A (H1N1) infection;
CESC	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.4	5.27	0.31	2.86e-7	Lymphocyte counts;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01588546	chr19:1104635	GPX4	0.54	6.07	0.35	4.42e-9	Gut microbiome composition (summer);
CESC	cis	rs7123876	0.504	rs1157343	chr11:72429141	A/G	cg03713592	chr11:72463424	ARAP1	-0.44	-5.31	-0.31	2.34e-7	Body mass index;
CESC	cis	rs11098499	0.820	rs11737395	chr4:120520704	C/G	cg09307838	chr4:120376055	NA	0.92	12.45	0.61	2.6e-28	Corneal astigmatism;
CESC	cis	rs1401999	1.000	rs939337	chr3:183701147	G/C	cg01324343	chr3:183735012	ABCC5	0.64	13.63	0.64	2.08e-32	Anterior chamber depth;
CESC	cis	rs9733	0.519	rs3768005	chr1:150680988	A/T	cg17724175	chr1:150552817	MCL1	0.43	6.92	0.39	3.42e-11	Tonsillectomy;
CESC	cis	rs4481887	0.854	rs4534423	chr1:248474993	G/C	cg00666640	chr1:248458726	OR2T12	0.34	5.62	0.33	4.8e-8	Common traits (Other);
CESC	cis	rs875971	0.861	rs801215	chr7:66011938	A/T	cg18876405	chr7:65276391	NA	-0.53	-7.28	-0.41	3.9e-12	Aortic root size;
CESC	cis	rs2050392	0.965	rs2265371	chr10:30690840	C/T	cg18806716	chr10:30721971	MAP3K8	-0.4	-5.66	-0.33	3.91e-8	Inflammatory bowel disease;
CESC	cis	rs3106136	0.967	rs2087170	chr4:95162960	A/C	cg11021082	chr4:95130006	SMARCAD1	-0.47	-7.15	-0.4	8.38e-12	Capecitabine sensitivity;
CESC	cis	rs7909791	0.632	rs3752948	chr10:105670762	G/A	cg24587175	chr10:105670608	OBFC1	0.42	5.86	0.34	1.4e-8	White matter hyperintensity burden;
CESC	cis	rs8050907	0.744	rs8055559	chr16:4540227	A/G	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.89	6.22	0.36	1.94e-9	Obesity-related traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05373286	chr10:76969678	VDAC2	0.61	7.08	0.4	1.32e-11	Gut microbiome composition (summer);
CESC	cis	rs9811920	0.638	rs10936008	chr3:99686665	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.4	-5.49	-0.32	9.31e-8	Axial length;
CESC	cis	rs7662987	0.517	rs2602876	chr4:100039535	A/T	cg12011299	chr4:100065546	ADH4	0.54	6.02	0.35	5.91e-9	Smoking initiation;
CESC	cis	rs6088590	0.561	rs6087600	chr20:33157217	T/C	cg06115741	chr20:33292138	TP53INP2	0.5	6.49	0.37	4.16e-10	Coronary artery disease;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg15525503	chr1:3773166	DFFB;KIAA0562	0.44	6.01	0.35	6.06e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs8114671	0.836	rs6142280	chr20:33622242	A/C	cg24642439	chr20:33292090	TP53INP2	-0.47	-5.64	-0.33	4.27e-8	Height;
CESC	trans	rs324780	0.544	rs2201718	chr12:83925736	T/C	cg22140261	chr22:42466895	NAGA	-0.48	-6.12	-0.35	3.34e-9	Vertical cup-disc ratio;
CESC	cis	rs1375194	0.582	rs4670735	chr2:33801456	C/T	cg04131969	chr2:33951647	MYADML	-0.51	-6.5	-0.37	4.02e-10	Response to antidepressants in depression;
CESC	cis	rs4970988	0.556	rs2280078	chr1:150600181	C/T	cg22823121	chr1:150693482	HORMAD1	-0.45	-6.42	-0.37	6.25e-10	Urate levels;
CESC	cis	rs274567	0.599	rs11242110	chr5:131743777	A/C	cg07395648	chr5:131743802	NA	0.63	9.25	0.49	7.67e-18	Blood metabolite levels;
CESC	trans	rs3749237	1.000	rs1317140	chr3:49878652	G/A	cg21659725	chr3:3221576	CRBN	0.55	6.45	0.37	5.38e-10	Resting heart rate;
CESC	cis	rs113835537	0.529	rs2305533	chr11:66298623	A/C	cg22134325	chr11:66188745	NPAS4	0.39	5.94	0.34	8.94e-9	Airway imaging phenotypes;
CESC	cis	rs208520	0.955	rs208532	chr6:66961280	T/A	cg07460842	chr6:66804631	NA	-0.9	-10.34	-0.54	2.79e-21	Exhaled nitric oxide output;
CESC	cis	rs3781458	0.803	rs10901793	chr10:126324209	G/A	cg20435097	chr10:126320824	FAM53B	0.3	5.22	0.31	3.69e-7	Male-pattern baldness;
CESC	cis	rs9916302	0.904	rs7210488	chr17:37539819	T/G	cg20243544	chr17:37824526	PNMT	-0.51	-6.44	-0.37	5.46e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs7267979	0.966	rs6037097	chr20:25347221	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.88	18.2	0.75	1.43e-48	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs875971	0.522	rs34973832	chr7:65396204	A/G	cg26939375	chr7:64535504	NA	0.77	11.14	0.56	6.68e-24	Aortic root size;
CESC	cis	rs2191566	0.664	rs4482396	chr19:44562000	C/T	cg20607764	chr19:44506953	ZNF230	-0.44	-5.64	-0.33	4.34e-8	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.58	7.33	0.41	2.84e-12	Prudent dietary pattern;
CESC	cis	rs2455799	0.613	rs2470548	chr3:15737689	G/A	cg16303742	chr3:15540471	COLQ	-0.33	-5.13	-0.3	5.62e-7	Mean platelet volume;
CESC	cis	rs1008375	1.000	rs6449319	chr4:17640283	T/A	cg02297831	chr4:17616191	MED28	0.62	7.96	0.44	4.97e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs7208859	0.673	rs55658077	chr17:29156519	A/G	cg19761014	chr17:28927070	LRRC37B2	0.74	6.03	0.35	5.43e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.65	7.41	0.41	1.72e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs10883723	0.810	rs7094366	chr10:104274730	C/G	cg22532475	chr10:104410764	TRIM8	-0.33	-5.34	-0.31	2e-7	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg05863683	chr7:1912471	MAD1L1	0.44	6.62	0.38	1.98e-10	Bipolar disorder and schizophrenia;
CESC	cis	rs7945705	0.869	rs4909952	chr11:8963946	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.5	8.13	0.45	1.63e-14	Hemoglobin concentration;
CESC	cis	rs769267	0.965	rs6511026	chr19:19391402	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.42	5.38	0.31	1.66e-7	Tonsillectomy;
CESC	cis	rs10979	1.000	rs12738	chr6:143890049	A/G	cg25407410	chr6:143891975	LOC285740	-0.61	-9.14	-0.49	1.72e-17	Hypospadias;
CESC	cis	rs4722166	0.630	rs13311199	chr7:22789793	A/C	cg13104385	chr7:22767384	IL6	0.49	6.56	0.37	2.81e-10	Lung cancer;
CESC	cis	rs910316	0.763	rs175435	chr14:75612025	A/G	cg11812906	chr14:75593930	NEK9	0.8	12.82	0.62	1.38e-29	Height;
CESC	cis	rs1387259	0.931	rs1107654	chr12:48681097	T/G	cg24011408	chr12:48396354	COL2A1	0.43	6.07	0.35	4.46e-9	Obstructive sleep apnea trait (apnea hypopnea index);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23231910	chr2:202899550	FZD7	-0.53	-6.18	-0.35	2.45e-9	Gut microbiome composition (summer);
CESC	cis	rs2066819	1.000	rs76745316	chr12:56627652	A/C	cg26804944	chr12:56660921	COQ10A	-0.86	-5.22	-0.31	3.69e-7	Psoriasis vulgaris;
CESC	cis	rs7666738	0.830	rs28818180	chr4:98953625	A/G	cg17366294	chr4:99064904	C4orf37	0.6	8.47	0.46	1.72e-15	Colonoscopy-negative controls vs population controls;
CESC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg06710522	chr17:45908972	MRPL10;LRRC46	-0.49	-6.01	-0.35	6.25e-9	Lung cancer in ever smokers;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg19719329	chr22:46727417	NA	0.46	6.01	0.35	5.97e-9	Fibrinogen levels;
CESC	cis	rs7552404	0.924	rs1858536	chr1:76161595	G/T	cg22875332	chr1:76189707	ACADM	0.69	9.24	0.49	8.13e-18	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs7264396	0.747	rs2425158	chr20:34419664	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.62	7.51	0.42	9.34e-13	Total cholesterol levels;
CESC	cis	rs1008375	0.966	rs7675735	chr4:17587137	T/A	cg27347728	chr4:17578864	LAP3	0.46	5.49	0.32	9.24e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg19683457	chr6:105307726	HACE1	-0.46	-6.35	-0.36	9.29e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs514406	0.505	rs431427	chr1:53179094	C/A	cg16325326	chr1:53192061	ZYG11B	0.92	16.14	0.7	2.8e-41	Monocyte count;
CESC	cis	rs17376456	0.877	rs2085960	chr5:93399934	A/G	cg21475434	chr5:93447410	FAM172A	0.79	6.96	0.39	2.71e-11	Diabetic retinopathy;
CESC	cis	rs1881797	0.872	rs2141544	chr1:247690800	A/G	cg11166453	chr1:247681781	NA	0.46	6.88	0.39	4.35e-11	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs4481887	0.927	rs6678798	chr1:248476617	C/T	cg00666640	chr1:248458726	OR2T12	0.35	5.93	0.34	9.43e-9	Common traits (Other);
CESC	cis	rs11098499	0.691	rs12502524	chr4:120271414	G/A	cg09307838	chr4:120376055	NA	0.77	10.19	0.53	8.72e-21	Corneal astigmatism;
CESC	cis	rs9768139	0.708	rs921616	chr7:158117960	A/G	cg27057461	chr7:158136379	PTPRN2	-0.33	-5.17	-0.3	4.6e-7	Calcium levels;
CESC	cis	rs4481887	0.927	rs4586010	chr1:248437568	G/A	cg00666640	chr1:248458726	OR2T12	0.4	6.7	0.38	1.26e-10	Common traits (Other);
CESC	cis	rs910316	1.000	rs876403	chr14:75602834	A/T	cg08847533	chr14:75593920	NEK9	1.01	19.64	0.77	1.26e-53	Height;
CESC	cis	rs763121	0.853	rs2064088	chr22:39053382	A/G	cg06544989	chr22:39130855	UNC84B	0.49	8.52	0.46	1.22e-15	Menopause (age at onset);
CESC	cis	rs9487051	0.714	rs9386797	chr6:109632520	C/A	cg21918786	chr6:109611834	NA	-0.39	-5.71	-0.33	3.06e-8	Reticulocyte fraction of red cells;
CESC	cis	rs7811142	1.000	rs11773661	chr7:100073069	G/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.14	11.43	0.57	7.11e-25	Platelet count;
CESC	cis	rs13191362	0.507	rs6907151	chr6:163200701	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.47	5.53	0.32	7.67e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs3125734	0.633	rs4979774	chr10:63967795	A/T	cg09941381	chr10:64027924	RTKN2	-0.33	-5.49	-0.32	9.39e-8	Rheumatoid arthritis;
CESC	cis	rs7551222	0.752	rs4252687	chr1:204497335	G/C	cg20240347	chr1:204465584	NA	-0.28	-5.64	-0.33	4.33e-8	Schizophrenia;
CESC	cis	rs7267979	0.966	rs2257461	chr20:25265554	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	18.61	0.75	5.02e-50	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7772486	0.875	rs2777476	chr6:146345024	A/G	cg23711669	chr6:146136114	FBXO30	0.86	12.53	0.61	1.39e-28	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs780096	0.526	rs10182937	chr2:27651693	T/C	cg02592271	chr2:27665507	KRTCAP3	-0.29	-5.79	-0.34	2e-8	Total body bone mineral density;
CESC	cis	rs6088580	0.609	rs6059844	chr20:33036482	A/G	cg24642439	chr20:33292090	TP53INP2	0.51	6.8	0.39	6.97e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs3093024	0.595	rs4412174	chr6:167476066	A/G	cg23791538	chr6:167370224	RNASET2	-0.52	-6.9	-0.39	3.81e-11	Rheumatoid arthritis;
CESC	cis	rs17539620	0.624	rs7770107	chr6:154836862	A/G	cg20019720	chr6:154832845	CNKSR3	0.47	6.13	0.35	3.21e-9	Lipoprotein (a) levels;
CESC	cis	rs2952156	0.920	rs1018246	chr17:37835240	C/T	cg07936489	chr17:37558343	FBXL20	-0.61	-8.1	-0.45	2.04e-14	Asthma;
CESC	cis	rs9611565	0.918	rs12484074	chr22:41752747	G/A	cg03806693	chr22:41940476	POLR3H	-1.04	-11.81	-0.59	3.87e-26	Vitiligo;
CESC	cis	rs25645	0.823	rs12453334	chr17:38153473	C/T	cg17467752	chr17:38218738	THRA	-0.46	-6.05	-0.35	4.9e-9	Myeloid white cell count;
CESC	cis	rs12410462	0.581	rs111356515	chr1:227537236	C/G	cg10327440	chr1:227177885	CDC42BPA	-0.68	-5.62	-0.33	4.84e-8	Major depressive disorder;
CESC	cis	rs13082711	0.554	rs73055724	chr3:27380397	T/G	cg02860705	chr3:27208620	NA	0.73	8.18	0.45	1.19e-14	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CESC	cis	rs477692	0.905	rs514963	chr10:131419707	C/T	cg05714579	chr10:131428358	MGMT	0.51	7.26	0.41	4.17e-12	Response to temozolomide;
CESC	cis	rs7116495	0.609	rs4245463	chr11:71743213	C/A	cg26138937	chr11:71823887	C11orf51	-1.37	-8.21	-0.45	9.44e-15	Severe influenza A (H1N1) infection;
CESC	cis	rs2228479	1.000	rs62052180	chr16:89963289	C/G	cg06558623	chr16:89946397	TCF25	1.05	8.66	0.47	4.66e-16	Skin colour saturation;
CESC	cis	rs3733585	0.699	rs7677710	chr4:9969517	T/G	cg02734326	chr4:10020555	SLC2A9	-0.39	-5.57	-0.32	6.13e-8	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs7542091	1.000	rs7542091	chr1:210031948	G/C	cg09509183	chr1:209979624	IRF6	0.36	5.09	0.3	6.64e-7	Monobrow;
CESC	cis	rs1008375	0.932	rs12500912	chr4:17603318	C/T	cg02297831	chr4:17616191	MED28	0.54	6.73	0.38	1.06e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs17711722	0.565	rs73372653	chr7:65442795	A/T	cg11764359	chr7:65958608	NA	0.47	5.74	0.33	2.56e-8	Calcium levels;
CESC	cis	rs10216189	0.967	rs4724700	chr7:5526789	A/G	cg05318486	chr7:5553423	FBXL18	-0.44	-5.69	-0.33	3.3e-8	Relative hand skill in reading disability;
CESC	cis	rs11625487	0.609	rs45493395	chr14:77976468	T/C	cg20045696	chr14:77926864	AHSA1	-0.65	-5.29	-0.31	2.53e-7	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
CESC	cis	rs6028335	0.674	rs66486072	chr20:37647882	G/A	cg16355469	chr20:37678765	NA	0.51	5.08	0.3	7.07e-7	Alcohol and nicotine co-dependence;
CESC	cis	rs7771547	0.573	rs566742	chr6:36395668	C/T	cg04289385	chr6:36355825	ETV7	0.38	5.5	0.32	8.74e-8	Platelet distribution width;
CESC	cis	rs4642101	0.618	rs9877079	chr3:12821287	A/G	cg24848339	chr3:12840334	CAND2	0.39	6.13	0.35	3.24e-9	QRS complex (12-leadsum);
CESC	cis	rs6089584	0.526	rs6089316	chr20:60627552	C/T	cg06108461	chr20:60628389	TAF4	-0.61	-8.18	-0.45	1.16e-14	Body mass index;
CESC	cis	rs9911578	1.000	rs8079774	chr17:56908188	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.26	0.31	3.04e-7	Intelligence (multi-trait analysis);
CESC	cis	rs9611565	0.802	rs9611577	chr22:41793090	T/G	cg17376030	chr22:41985996	PMM1	0.58	6.3	0.36	1.21e-9	Vitiligo;
CESC	cis	rs9322193	0.923	rs1112729	chr6:150087627	C/A	cg04369109	chr6:150039330	LATS1	-0.39	-5.27	-0.31	2.82e-7	Lung cancer;
CESC	cis	rs9649213	0.555	rs7785612	chr7:97933867	T/A	cg24562669	chr7:97807699	LMTK2	0.54	7.85	0.43	1.02e-13	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs10489202	0.583	rs203782	chr1:167882386	A/G	cg24449463	chr1:168025552	DCAF6	0.43	5.62	0.33	4.83e-8	Schizophrenia;
CESC	cis	rs10504229	0.639	rs17331850	chr8:58113538	G/T	cg02725872	chr8:58115012	NA	-0.45	-7.04	-0.4	1.66e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs17253792	1.000	rs28616134	chr14:56178802	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.73	5.13	0.3	5.7e-7	Putamen volume;
CESC	cis	rs8018808	0.935	rs7146784	chr14:77932111	A/G	cg20045696	chr14:77926864	AHSA1	0.43	5.9	0.34	1.13e-8	Myeloid white cell count;
CESC	cis	rs8114671	0.804	rs3803936	chr20:33632775	T/C	cg06115741	chr20:33292138	TP53INP2	-0.44	-5.29	-0.31	2.53e-7	Height;
CESC	cis	rs7618501	1.000	rs35261599	chr3:49773236	G/A	cg24308560	chr3:49941425	MST1R	0.51	7.06	0.4	1.47e-11	Intelligence (multi-trait analysis);
CESC	cis	rs9910055	0.762	rs1135215	chr17:42253519	T/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.64	8.51	0.46	1.28e-15	Total body bone mineral density;
CESC	cis	rs2637266	1.000	rs2395385	chr10:78341125	G/A	cg18941641	chr10:78392320	NA	0.41	7.87	0.44	8.88e-14	Pulmonary function;
CESC	trans	rs9650657	0.645	rs4841407	chr8:10516185	G/A	cg15556689	chr8:8085844	FLJ10661	-0.5	-6.45	-0.37	5.33e-10	Neuroticism;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14549777	chr3:12599374	MKRN2	-0.47	-6.4	-0.37	7.16e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs863345	0.933	rs12041380	chr1:158482138	A/G	cg12129480	chr1:158549410	OR10X1	-0.3	-5.87	-0.34	1.28e-8	Pneumococcal bacteremia;
CESC	cis	rs829883	0.659	rs11109517	chr12:98921574	A/C	cg25150519	chr12:98850993	NA	0.6	7.58	0.42	5.9e-13	Colorectal adenoma (advanced);
CESC	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg24642844	chr7:1081250	C7orf50	-0.81	-9.86	-0.52	9.58e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs116095464	0.614	rs28736753	chr5:274081	G/A	cg00938859	chr5:1591904	SDHAP3	0.64	6.78	0.38	7.61e-11	Breast cancer;
CESC	cis	rs2479724	0.905	rs2274578	chr6:41888827	C/G	cg08135965	chr6:41755394	TOMM6	0.43	5.92	0.34	9.98e-9	Menarche (age at onset);
CESC	cis	rs9300255	0.550	rs10772997	chr12:123719880	C/A	cg05973401	chr12:123451056	ABCB9	0.45	5.51	0.32	8.49e-8	Neutrophil percentage of white cells;
CESC	cis	rs3741151	0.773	rs73542967	chr11:73123512	C/T	cg17517138	chr11:73019481	ARHGEF17	0.94	6.86	0.39	4.87e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs875971	0.545	rs2420456	chr7:65745606	T/G	cg25405998	chr7:65216604	CCT6P1	0.46	5.28	0.31	2.68e-7	Aortic root size;
CESC	cis	rs477895	0.713	rs67546972	chr11:63962162	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.95	10.43	0.54	1.45e-21	Mean platelet volume;
CESC	cis	rs2354432	0.556	rs2353984	chr1:146813358	C/T	cg25205988	chr1:146714368	CHD1L	0.95	8.23	0.45	8.56e-15	Mitochondrial DNA levels;
CESC	cis	rs763121	0.962	rs6001193	chr22:39074737	A/G	cg21395723	chr22:39101663	GTPBP1	0.38	5.15	0.3	5.05e-7	Menopause (age at onset);
CESC	cis	rs12136530	0.714	rs34553579	chr1:19779378	A/C	cg01832549	chr1:19774989	CAPZB	-0.48	-6.95	-0.39	2.8e-11	Lead levels in blood;
CESC	cis	rs12325245	0.536	rs12931124	chr16:58620063	G/A	cg01152986	chr16:58549298	SETD6	0.86	5.08	0.3	7.1e-7	Schizophrenia;
CESC	cis	rs7666738	0.791	rs1896155	chr4:99020948	C/A	cg17366294	chr4:99064904	C4orf37	0.61	8.76	0.47	2.35e-16	Colonoscopy-negative controls vs population controls;
CESC	trans	rs17685	0.753	rs6976532	chr7:75681094	A/G	cg19862616	chr7:65841803	NCRNA00174	0.88	12.91	0.62	6.43e-30	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs2425143	1.000	rs6060578	chr20:34305445	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.6	5.15	0.3	5.07e-7	Blood protein levels;
CESC	cis	rs9494145	0.680	rs9402686	chr6:135427817	G/A	cg22676075	chr6:135203613	NA	0.46	5.57	0.32	6.41e-8	Mean platelet volume;Platelet count;Fetal hemoglobin levels in sickle cell anemia;Red blood cell traits;
CESC	cis	rs7678296	1.000	rs28385504	chr4:37200490	G/A	cg06805348	chr4:37245195	KIAA1239	0.45	5.07	0.3	7.52e-7	3-hydroxypropylmercapturic acid levels in smokers;
CESC	trans	rs9329221	0.905	rs17709397	chr8:10249861	G/A	cg15556689	chr8:8085844	FLJ10661	-0.53	-6.13	-0.35	3.26e-9	Neuroticism;
CESC	cis	rs12701220	0.894	rs10263252	chr7:1049949	G/A	cg26769984	chr7:1090371	C7orf50	0.54	6.52	0.37	3.5e-10	Bronchopulmonary dysplasia;
CESC	cis	rs10504229	0.683	rs16921814	chr8:58107421	A/T	cg22535103	chr8:58192502	C8orf71	-0.77	-8.68	-0.47	4.09e-16	Developmental language disorder (linguistic errors);
CESC	cis	rs5757673	1	rs5757673	chr22:39837920	T/C	cg02038168	chr22:39784481	NA	-0.68	-7.86	-0.43	9.97e-14	Post bronchodilator FEV1;
CESC	cis	rs617791	0.530	rs735942	chr11:65749337	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.44	-5.2	-0.3	4e-7	Breast cancer;
CESC	cis	rs2243480	1.000	rs34933526	chr7:65383199	A/G	cg18252515	chr7:66147081	NA	-1.06	-9.79	-0.52	1.67e-19	Diabetic kidney disease;
CESC	cis	rs7927771	0.864	rs4752999	chr11:47428565	C/T	cg18512352	chr11:47633146	NA	-0.51	-7.3	-0.41	3.35e-12	Subjective well-being;
CESC	cis	rs35146811	0.807	rs6465761	chr7:99620277	G/C	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.43	5.32	0.31	2.23e-7	Coronary artery disease;
CESC	cis	rs4718428	0.924	rs6971897	chr7:66412774	T/A	cg12165864	chr7:66369176	NA	-0.44	-5.17	-0.3	4.73e-7	Corneal structure;
CESC	cis	rs728616	0.558	rs61859215	chr10:82151148	G/A	cg05935833	chr10:81318306	SFTPA2	-0.46	-5.71	-0.33	3.08e-8	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs617791	0.669	rs4994056	chr11:65750997	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.44	6.57	0.37	2.71e-10	Breast cancer;
CESC	cis	rs4665809	0.590	rs72809668	chr2:26467653	C/T	cg27170947	chr2:26402098	FAM59B	0.87	9.89	0.52	7.6e-20	Gut microbiome composition (summer);
CESC	cis	rs12541635	0.934	rs2029882	chr8:107022894	G/A	cg10147462	chr8:107024639	NA	0.41	5.74	0.33	2.63e-8	Age of smoking initiation;
CESC	cis	rs7872515	0.793	rs10820936	chr9:94830974	C/T	cg01248375	chr9:94877805	SPTLC1	-0.53	-5.66	-0.33	3.95e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs2732480	0.557	rs2732484	chr12:48737245	A/C	cg24011408	chr12:48396354	COL2A1	0.44	5.95	0.34	8.54e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs1348850	0.526	rs7582179	chr2:178370631	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.69	6.38	0.36	7.87e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs10504073	0.584	rs62507178	chr8:49938572	A/C	cg00325661	chr8:49890786	NA	0.6	8.94	0.48	6.75e-17	Blood metabolite ratios;
CESC	cis	rs12474201	0.928	rs12998753	chr2:46938385	A/G	cg06386533	chr2:46925753	SOCS5	0.91	12.52	0.61	1.51e-28	Height;
CESC	cis	rs7524258	0.900	rs1476047	chr1:7312172	C/T	cg07173049	chr1:7289937	CAMTA1	0.38	5.94	0.34	9.14e-9	Tourette's syndrome or obsessive-compulsive disorder;
CESC	cis	rs6088590	1.000	rs6087632	chr20:33407704	A/C	cg08999081	chr20:33150536	PIGU	0.59	8.94	0.48	6.65e-17	Coronary artery disease;
CESC	cis	rs3820928	0.935	rs10203363	chr2:227896976	C/T	cg05526886	chr2:227700861	RHBDD1	-0.45	-5.73	-0.33	2.7e-8	Pulmonary function;
CESC	cis	rs902774	0.554	rs4919749	chr12:53358034	C/T	cg16329197	chr12:53359506	NA	-0.62	-8.88	-0.48	1.06e-16	Prostate cancer;
CESC	cis	rs7927771	0.864	rs3781625	chr11:47443080	T/C	cg20307385	chr11:47447363	PSMC3	-0.63	-7.61	-0.42	4.69e-13	Subjective well-being;
CESC	cis	rs344364	0.511	rs12599337	chr16:1946751	A/G	cg09830162	chr16:1889614	FAHD1;C16orf73	0.52	5.92	0.34	1.01e-8	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs3809566	1.000	rs10851721	chr15:63332383	T/C	cg05507819	chr15:63340323	TPM1	0.51	6.16	0.35	2.66e-9	Platelet count;
CESC	cis	rs965469	0.857	rs1922990	chr20:3252348	G/A	cg25506879	chr20:3388711	C20orf194	-0.49	-5.36	-0.31	1.8e-7	IFN-related cytopenia;
CESC	cis	rs2228479	0.764	rs7184960	chr16:89961661	C/T	cg04013166	chr16:89971882	TCF25	0.7	7.24	0.41	5.01e-12	Skin colour saturation;
CESC	cis	rs9457247	1.000	rs397713	chr6:167386714	G/A	cg25258033	chr6:167368657	RNASET2	0.39	5.87	0.34	1.31e-8	Crohn's disease;
CESC	cis	rs7089973	0.668	rs7898347	chr10:116644324	G/A	cg25233709	chr10:116636983	FAM160B1	0.41	6.6	0.38	2.28e-10	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg18402987	chr7:1209562	NA	0.76	7.57	0.42	6.04e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg25846339	chr11:85359022	TMEM126A	0.49	6.4	0.37	7.03e-10	Systemic lupus erythematosus;
CESC	cis	rs59918340	0.764	rs2304282	chr8:142229543	A/G	cg16341495	chr8:142228727	SLC45A4	-0.42	-5.07	-0.3	7.6e-7	Immature fraction of reticulocytes;
CESC	trans	rs765547	0.871	rs1372344	chr8:19852939	A/T	cg12649343	chr22:47023005	GRAMD4	-0.3	-6.12	-0.35	3.27e-9	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
CESC	cis	rs4862750	0.914	rs11943333	chr4:187872455	A/G	cg06074448	chr4:187884817	NA	-0.34	-5.18	-0.3	4.31e-7	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7772486	0.840	rs854144	chr6:146360880	G/T	cg23711669	chr6:146136114	FBXO30	-0.56	-7.37	-0.41	2.15e-12	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19652678	chr17:73975160	ACOX1;C17orf106	0.59	6.79	0.38	7.15e-11	Gut microbiome composition (summer);
CESC	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg11494091	chr17:61959527	GH2	0.72	12.38	0.61	4.46e-28	Prudent dietary pattern;
CESC	cis	rs6460942	0.908	rs7781919	chr7:12235351	T/C	cg06484146	chr7:12443880	VWDE	-0.46	-5.19	-0.3	4.09e-7	Coronary artery disease;
CESC	cis	rs4665809	1.000	rs10048683	chr2:26320519	C/T	cg26314531	chr2:26401878	FAM59B	-0.6	-6.94	-0.39	3.01e-11	Gut microbiome composition (summer);
CESC	cis	rs73206853	0.764	rs28362526	chr12:110561779	C/A	cg12870014	chr12:110450643	ANKRD13A	0.64	5.42	0.32	1.36e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs963731	0.649	rs2060989	chr2:39293530	G/A	cg04010122	chr2:39346883	SOS1	-0.74	-5.88	-0.34	1.23e-8	Corticobasal degeneration;
CESC	cis	rs933688	0.938	rs7705465	chr5:90680949	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.11	12.36	0.6	5.17e-28	Smoking behavior;
CESC	cis	rs9611565	0.765	rs132921	chr22:41812044	G/A	cg17376030	chr22:41985996	PMM1	-0.52	-5.71	-0.33	3e-8	Vitiligo;
CESC	cis	rs10131894	0.611	rs175002	chr14:75436466	C/G	cg08847533	chr14:75593920	NEK9	0.74	12.01	0.59	8.12e-27	Coronary artery disease;
CESC	cis	rs16854884	0.657	rs1867608	chr3:143752938	G/A	cg01302019	chr3:143689584	C3orf58	-0.35	-5.42	-0.32	1.33e-7	Economic and political preferences (feminism/equality);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17237962	chr11:57479805	MED19;TMX2	-0.65	-7.19	-0.4	6.46e-12	Gut microbiome composition (summer);
CESC	cis	rs4862750	0.837	rs1863404	chr4:187874654	T/C	cg06074448	chr4:187884817	NA	-0.36	-5.17	-0.3	4.63e-7	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg03188948	chr7:1209495	NA	0.51	6.63	0.38	1.83e-10	Longevity;Endometriosis;
CESC	cis	rs7336332	0.598	rs9581852	chr13:28013748	A/G	cg01674679	chr13:27998804	GTF3A	-0.59	-5.25	-0.31	3.08e-7	Weight;
CESC	cis	rs258892	0.895	rs465388	chr5:72135899	C/T	cg21869765	chr5:72125136	TNPO1	0.45	5.72	0.33	2.82e-8	Small cell lung carcinoma;
CESC	cis	rs9916302	0.904	rs4239222	chr17:37696235	A/C	cg15445000	chr17:37608096	MED1	-0.4	-6.31	-0.36	1.2e-9	Glomerular filtration rate (creatinine);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16260355	chr10:72575844	SGPL1	0.55	6.35	0.36	9.09e-10	Gut microbiome composition (summer);
CESC	cis	rs1348850	0.574	rs2365617	chr2:178421934	C/A	cg22681709	chr2:178499509	PDE11A	-0.51	-5.23	-0.31	3.52e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs727505	1.000	rs2286175	chr7:124431032	G/A	cg23710748	chr7:124431027	NA	-0.49	-7.89	-0.44	7.75e-14	Lewy body disease;
CESC	cis	rs561341	0.882	rs28649357	chr17:30367190	A/G	cg19193384	chr17:30244184	NA	-0.51	-5.42	-0.32	1.33e-7	Hip circumference adjusted for BMI;
CESC	cis	rs798554	0.757	rs1182185	chr7:2872233	A/G	cg04166393	chr7:2884313	GNA12	0.58	7.78	0.43	1.6e-13	Height;
CESC	cis	rs1670533	1.000	rs11731320	chr4:1057916	T/A	cg04106633	chr4:1044584	NA	0.41	5.19	0.3	4.11e-7	Recombination rate (females);
CESC	cis	rs11722228	0.522	rs2241468	chr4:10113905	G/A	cg14348967	chr4:10160060	NA	-0.43	-5.33	-0.31	2.11e-7	Gout;Urate levels;Serum uric acid levels;
CESC	cis	rs2839186	0.500	rs13052701	chr21:47660045	A/T	cg12379764	chr21:47803548	PCNT	-0.47	-5.51	-0.32	8.65e-8	Testicular germ cell tumor;
CESC	cis	rs1707322	0.964	rs6697830	chr1:46290477	C/A	cg03146154	chr1:46216737	IPP	0.72	9.83	0.52	1.2e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs4253772	0.872	rs11704508	chr22:46638540	A/G	cg18190219	chr22:46762943	CELSR1	-0.61	-5.82	-0.34	1.66e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs963731	0.737	rs6544197	chr2:39315388	T/C	cg04010122	chr2:39346883	SOS1	-0.74	-5.39	-0.31	1.54e-7	Corticobasal degeneration;
CESC	cis	rs9457247	1.000	rs394522	chr6:167398071	A/C	cg25258033	chr6:167368657	RNASET2	0.41	6.17	0.35	2.55e-9	Crohn's disease;
CESC	cis	rs3105593	1.000	rs3131596	chr15:50877575	T/C	cg08437265	chr15:50716283	USP8	0.42	5.33	0.31	2.12e-7	QT interval;
CESC	cis	rs2440129	0.611	rs1126667	chr17:6902760	C/T	cg03404566	chr17:6899310	ALOX12	-0.39	-6.53	-0.37	3.34e-10	Tonsillectomy;
CESC	cis	rs73129298	0.551	rs6020166	chr20:48594678	A/G	cg25655593	chr20:48599521	SNAI1	0.46	5.15	0.3	5.05e-7	Inflammatory skin disease;
CESC	cis	rs651907	0.535	rs13059470	chr3:101424800	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.47	-6.08	-0.35	4.23e-9	Colorectal cancer;
CESC	cis	rs7937682	0.855	rs7934922	chr11:111500026	T/C	cg09085632	chr11:111637200	PPP2R1B	-0.99	-15.77	-0.7	5.94e-40	Primary sclerosing cholangitis;
CESC	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg23708337	chr7:1209742	NA	0.54	5.4	0.31	1.48e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs4665809	1.000	rs12475854	chr2:26267375	G/A	cg25036284	chr2:26402008	FAM59B	-0.58	-6.62	-0.38	1.98e-10	Gut microbiome composition (summer);
CESC	cis	rs9379850	0.527	rs9393704	chr6:26358775	T/C	cg14345882	chr6:26364793	BTN3A2	0.59	6.06	0.35	4.66e-9	Intelligence (multi-trait analysis);
CESC	cis	rs3892630	0.619	rs61062732	chr19:33304717	T/C	cg13157960	chr19:33183277	NUDT19	0.55	5.59	0.32	5.67e-8	Red blood cell traits;
CESC	cis	rs1692580	0.870	rs590367	chr1:2162944	C/T	cg21194808	chr1:2205498	SKI	0.39	5.45	0.32	1.17e-7	Coronary artery disease;
CESC	cis	rs5769765	0.955	rs5769767	chr22:50276909	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	0.46	5.32	0.31	2.21e-7	Schizophrenia;
CESC	cis	rs34779708	0.733	rs4244997	chr10:35547254	T/C	cg04310649	chr10:35416472	CREM	-0.45	-5.14	-0.3	5.34e-7	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs7264396	0.512	rs2425072	chr20:34293686	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.88	-10.51	-0.54	8.09e-22	Total cholesterol levels;
CESC	cis	rs2262909	0.962	rs439574	chr19:22232024	A/C	cg11619707	chr19:22235551	ZNF257	-0.3	-5.17	-0.3	4.72e-7	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
CESC	cis	rs9479482	0.967	rs34006533	chr6:150350574	C/A	cg03788504	chr6:150331562	NA	-0.38	-7.09	-0.4	1.21e-11	Alopecia areata;
CESC	cis	rs7618501	1.000	rs57648519	chr3:49813169	C/A	cg24308560	chr3:49941425	MST1R	-0.52	-7.04	-0.4	1.63e-11	Intelligence (multi-trait analysis);
CESC	cis	rs1552244	1.000	rs9824585	chr3:10114802	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-11.04	-0.56	1.41e-23	Alzheimer's disease;
CESC	cis	rs12893668	0.697	rs67899457	chr14:104060066	A/T	cg08213375	chr14:104286397	PPP1R13B	0.35	5.68	0.33	3.57e-8	Reticulocyte count;
CESC	cis	rs8049040	0.586	rs8060176	chr16:71456757	T/C	cg08717414	chr16:71523259	ZNF19	-0.44	-5.05	-0.3	8.15e-7	Blood protein levels;
CESC	cis	rs6741892	0.536	rs7590835	chr2:38893950	A/G	cg01546378	chr2:38892901	GALM	0.51	7.14	0.4	8.85e-12	5-HTT brain serotonin transporter levels;
CESC	cis	rs9894429	0.546	rs55917554	chr17:79608776	T/C	cg21984481	chr17:79567631	NPLOC4	-0.4	-6.02	-0.35	5.7e-9	Eye color traits;
CESC	cis	rs11676348	0.776	rs11690316	chr2:219017462	A/G	cg00012203	chr2:219082015	ARPC2	-0.6	-7.65	-0.43	3.64e-13	Ulcerative colitis;
CESC	cis	rs769267	0.965	rs7254230	chr19:19434350	C/T	cg03709012	chr19:19516395	GATAD2A	-0.96	-14.2	-0.66	2.12e-34	Tonsillectomy;
CESC	cis	rs1008375	1.000	rs7694020	chr4:17682597	C/T	cg16339924	chr4:17578868	LAP3	0.49	6.22	0.36	1.88e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs1832871	0.711	rs9459769	chr6:158666493	T/C	cg07165851	chr6:158734300	TULP4	0.6	6.41	0.37	6.66e-10	Height;
CESC	cis	rs9311474	1.000	rs7614727	chr3:52295895	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.35	6.72	0.38	1.11e-10	Electroencephalogram traits;
CESC	trans	rs11098499	0.754	rs12513083	chr4:120249612	A/T	cg25214090	chr10:38739885	LOC399744	0.62	8.7	0.47	3.58e-16	Corneal astigmatism;
CESC	cis	rs1023500	0.596	rs133369	chr22:42463814	C/T	cg04733989	chr22:42467013	NAGA	0.83	12.3	0.6	8.24e-28	Schizophrenia;
CESC	cis	rs1552244	0.554	rs13079240	chr3:10047246	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.56	-7.26	-0.41	4.31e-12	Alzheimer's disease;
CESC	cis	rs3820068	0.603	rs7531396	chr1:15969870	G/C	cg16988262	chr1:15930761	NA	0.33	5.36	0.31	1.85e-7	Systolic blood pressure;
CESC	cis	rs2836974	0.583	rs2410124	chr21:40704760	C/G	cg11644478	chr21:40555479	PSMG1	-0.81	-11.99	-0.59	9.12e-27	Cognitive function;
CESC	cis	rs2985684	0.894	rs4581611	chr14:50043520	A/T	cg04989706	chr14:50066350	PPIL5	-0.45	-5.05	-0.3	8.09e-7	Carotid intima media thickness;
CESC	cis	rs10821556	1	rs10821556	chr9:136942136	C/A	cg13495838	chr9:136934004	BRD3	0.45	5.26	0.31	3.04e-7	Mean platelet volume;
CESC	cis	rs939574	1.000	rs2293078	chr2:220100683	C/G	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.83	7.3	0.41	3.45e-12	Platelet distribution width;
CESC	cis	rs17376456	0.825	rs10053405	chr5:93275403	A/G	cg21475434	chr5:93447410	FAM172A	-0.67	-5.3	-0.31	2.4e-7	Diabetic retinopathy;
CESC	cis	rs662064	0.748	rs2506896	chr1:10603716	T/C	cg20482658	chr1:10539492	PEX14	0.43	8.91	0.48	8.55e-17	Asthma;
CESC	cis	rs10779751	1.000	rs4845982	chr1:11271576	T/C	cg08854313	chr1:11322531	MTOR	0.78	10.56	0.54	5.31e-22	Body mass index;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg04018571	chr2:96874059	STARD7	-0.41	-6.46	-0.37	4.85e-10	Gambling;
CESC	trans	rs61931739	0.511	rs2035659	chr12:33826241	T/C	cg26384229	chr12:38710491	ALG10B	0.45	6.25	0.36	1.61e-9	Morning vs. evening chronotype;
CESC	cis	rs6460942	0.915	rs6968695	chr7:12443878	G/C	cg10578991	chr7:12443926	VWDE	-0.45	-5.09	-0.3	6.83e-7	Coronary artery disease;
CESC	cis	rs1799949	0.894	rs71367985	chr17:41374463	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.53	7.3	0.41	3.37e-12	Menopause (age at onset);
CESC	cis	rs61996546	0.622	rs1426219	chr15:26855799	C/T	cg14859324	chr15:26874363	GABRB3	-0.37	-5.06	-0.3	7.97e-7	Response to methotrexate in juvenile idiopathic arthritis;
CESC	cis	rs2404602	0.647	rs3812909	chr15:77176200	A/T	cg23625390	chr15:77176239	SCAPER	-0.45	-6.35	-0.36	9.29e-10	Blood metabolite levels;
CESC	cis	rs861020	0.677	rs12723578	chr1:210032392	G/A	cg05527609	chr1:210001259	C1orf107	-1.04	-12.0	-0.59	8.74e-27	Orofacial clefts;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg06006530	chr2:242608094	ATG4B	0.44	6.07	0.35	4.38e-9	Fibrinogen levels;
CESC	cis	rs863345	0.604	rs11265024	chr1:158513255	A/G	cg12129480	chr1:158549410	OR10X1	-0.35	-6.95	-0.39	2.92e-11	Pneumococcal bacteremia;
CESC	cis	rs6815814	0.851	rs73235002	chr4:38769018	A/G	cg02016764	chr4:38805732	TLR1	-0.67	-7.46	-0.42	1.21e-12	Breast cancer;
CESC	cis	rs8031584	0.918	rs11639169	chr15:31255438	C/T	cg14829155	chr15:31115871	NA	-0.66	-8.51	-0.46	1.27e-15	Huntington's disease progression;
CESC	trans	rs4824093	0.535	rs73443931	chr22:50291603	G/A	cg09872104	chr7:134855509	C7orf49	-0.94	-6.17	-0.35	2.52e-9	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs13385	0.769	rs17208094	chr5:139597580	T/G	cg26211634	chr5:139558579	C5orf32	0.47	5.04	0.3	8.72e-7	Atrial fibrillation;
CESC	cis	rs763121	0.853	rs138709	chr22:39139216	C/G	cg21395723	chr22:39101663	GTPBP1	0.47	6.51	0.37	3.84e-10	Menopause (age at onset);
CESC	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.58	0.37	2.49e-10	Prudent dietary pattern;
CESC	cis	rs11190604	1.000	rs10883500	chr10:102238324	T/G	cg07080220	chr10:102295463	HIF1AN	0.56	5.59	0.32	5.61e-8	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs875971	0.522	rs1880556	chr7:65432544	T/C	cg14393609	chr7:65229607	NA	0.51	6.75	0.38	9.12e-11	Aortic root size;
CESC	cis	rs763014	0.966	rs4984675	chr16:670117	T/C	cg09263875	chr16:632152	PIGQ	0.67	11.39	0.57	1e-24	Height;
CESC	cis	rs12464559	0.579	rs1523181	chr2:152679462	T/C	cg01189475	chr2:152685088	ARL5A	0.66	5.81	0.34	1.74e-8	Response to cognitive-behavioural therapy in anxiety disorder;
CESC	cis	rs7666738	0.753	rs35194639	chr4:99053819	G/C	cg03467027	chr4:99064603	C4orf37	0.47	5.98	0.34	7.19e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs870825	0.655	rs7675046	chr4:185652201	G/A	cg04058563	chr4:185651563	MLF1IP	-0.6	-6.93	-0.39	3.28e-11	Blood protein levels;
CESC	cis	rs27434	0.605	rs152468	chr5:96167536	T/C	cg16492584	chr5:96139282	ERAP1	-0.53	-6.42	-0.37	6.14e-10	Ankylosing spondylitis;
CESC	cis	rs8016982	0.657	rs11625861	chr14:81735001	C/T	cg01989461	chr14:81687754	GTF2A1	-0.65	-9.73	-0.51	2.58e-19	Schizophrenia;
CESC	cis	rs769267	0.965	rs2315024	chr19:19423817	T/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.61	7.68	0.43	3.13e-13	Tonsillectomy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24631870	chr3:142297635	ATR	0.57	6.07	0.35	4.48e-9	Gut microbiome composition (summer);
CESC	cis	rs116095464	0.558	rs12173015	chr5:269967	A/C	cg22496380	chr5:211416	CCDC127	0.54	5.95	0.34	8.26e-9	Breast cancer;
CESC	trans	rs2727020	0.664	rs4929893	chr11:49196332	C/T	cg03929089	chr4:120376271	NA	-0.78	-11.69	-0.58	1e-25	Coronary artery disease;
CESC	cis	rs769267	0.896	rs2074298	chr19:19377716	C/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.44	5.35	0.31	1.91e-7	Tonsillectomy;
CESC	cis	rs7116495	0.609	rs4477459	chr11:71720616	T/C	cg26138937	chr11:71823887	C11orf51	-1.31	-8.57	-0.47	8.98e-16	Severe influenza A (H1N1) infection;
CESC	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg16132339	chr22:24313637	DDTL;DDT	0.38	5.78	0.33	2.08e-8	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs6087771	0.642	rs6060411	chr20:30222139	T/C	cg13852791	chr20:30311386	BCL2L1	0.67	7.77	0.43	1.7e-13	Subcortical brain region volumes;Putamen volume;
CESC	cis	rs1799949	1.000	rs2271574	chr17:41327648	T/C	cg25072359	chr17:41440525	NA	0.48	6.47	0.37	4.76e-10	Menopause (age at onset);
CESC	cis	rs11235843	0.613	rs71464090	chr11:73596791	T/G	cg18195628	chr11:73498948	MRPL48	0.56	6.07	0.35	4.34e-9	Hand grip strength;
CESC	cis	rs9322193	0.886	rs9718079	chr6:149967083	T/C	cg07701084	chr6:150067640	NUP43	0.45	6.38	0.36	8e-10	Lung cancer;
CESC	cis	rs1008375	0.966	rs10939736	chr4:17581617	T/A	cg02297831	chr4:17616191	MED28	0.5	6.07	0.35	4.52e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs9815354	0.680	rs61646756	chr3:42029352	A/C	cg03022575	chr3:42003672	ULK4	0.75	6.64	0.38	1.72e-10	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs4642101	0.793	rs3889513	chr3:12844070	G/A	cg05775895	chr3:12838266	CAND2	0.39	5.78	0.33	2.1e-8	QRS complex (12-leadsum);
CESC	cis	rs7811142	1.000	rs11763414	chr7:100016844	C/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.09	10.81	0.55	8.61e-23	Platelet count;
CESC	cis	rs1862618	0.754	rs252899	chr5:56188569	G/C	cg18230493	chr5:56204884	C5orf35	-0.75	-8.98	-0.48	5.21e-17	Initial pursuit acceleration;
CESC	cis	rs57502260	0.680	rs7104806	chr11:68222188	C/T	cg20283391	chr11:68216788	NA	-0.66	-5.76	-0.33	2.35e-8	Total body bone mineral density (age 45-60);
CESC	cis	rs6540559	0.673	rs58637469	chr1:209971480	T/A	cg10074409	chr1:209979377	IRF6	0.4	5.32	0.31	2.16e-7	Cleft lip with or without cleft palate;
CESC	cis	rs6598955	0.724	rs12068388	chr1:26621596	G/A	cg00852783	chr1:26633632	UBXN11	0.44	6.41	0.37	6.69e-10	Obesity-related traits;
CESC	cis	rs875971	0.502	rs2946580	chr7:65531842	G/A	cg18876405	chr7:65276391	NA	-0.55	-6.11	-0.35	3.49e-9	Aortic root size;
CESC	cis	rs13256369	0.802	rs4840350	chr8:8561442	A/G	cg18904891	chr8:8559673	CLDN23	0.7	7.82	0.43	1.26e-13	Obesity-related traits;
CESC	cis	rs3105593	1.000	rs2115671	chr15:50956432	G/C	cg08437265	chr15:50716283	USP8	0.46	6.04	0.35	5.08e-9	QT interval;
CESC	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg10150615	chr22:24372951	LOC391322	-0.59	-8.05	-0.44	2.87e-14	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg22185043	chr18:12947723	SEH1L	0.43	5.84	0.34	1.53e-8	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs7666738	0.830	rs28887893	chr4:98963006	G/A	cg18180107	chr4:99064573	C4orf37	0.4	5.14	0.3	5.26e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2549003	1.000	rs2070728	chr5:131819977	C/T	cg21138405	chr5:131827807	IRF1	0.54	9.24	0.49	8.12e-18	Asthma (sex interaction);
CESC	cis	rs4975709	0.610	rs4975704	chr5:1859807	C/A	cg14773178	chr5:1868261	NA	0.32	5.71	0.33	2.98e-8	Cardiovascular disease risk factors;
CESC	cis	rs7116495	0.737	rs670802	chr11:71799668	A/C	cg10381502	chr11:71823885	C11orf51	-0.65	-5.24	-0.31	3.2e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs2204008	0.546	rs11519978	chr12:37998170	C/T	cg13010199	chr12:38710504	ALG10B	0.53	6.63	0.38	1.87e-10	Bladder cancer;
CESC	cis	rs1552244	0.810	rs7612908	chr3:10089148	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	11.78	0.59	4.93e-26	Alzheimer's disease;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg22052955	chr12:53625898	RARG	-0.44	-6.26	-0.36	1.53e-9	Gambling;
CESC	cis	rs6460942	1.000	rs62448565	chr7:12400458	G/A	cg06484146	chr7:12443880	VWDE	-0.69	-7.94	-0.44	5.59e-14	Coronary artery disease;
CESC	cis	rs6504950	0.566	rs7226272	chr17:53046447	G/A	cg19360675	chr17:53046073	COX11;STXBP4	0.43	5.49	0.32	9.53e-8	Breast cancer;
CESC	cis	rs7666738	0.830	rs13133355	chr4:98919415	A/G	cg05340658	chr4:99064831	C4orf37	0.76	11.36	0.57	1.29e-24	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2625529	0.652	rs7497104	chr15:72154000	C/T	cg16672083	chr15:72433130	SENP8	-0.47	-7.09	-0.4	1.25e-11	Red blood cell count;
CESC	cis	rs67311347	1.000	rs7633809	chr3:40517737	A/G	cg24209194	chr3:40518798	ZNF619	-0.54	-7.02	-0.4	1.81e-11	Renal cell carcinoma;
CESC	trans	rs10411161	0.702	rs8100716	chr19:52384061	T/C	cg22319618	chr22:45562946	NUP50	-0.71	-6.88	-0.39	4.2e-11	Breast cancer;
CESC	cis	rs524281	0.861	rs11227403	chr11:65858428	T/C	cg14036092	chr11:66035641	RAB1B	-0.62	-6.29	-0.36	1.27e-9	Electroencephalogram traits;
CESC	trans	rs916888	0.821	rs199513	chr17:44856932	A/G	cg01341218	chr17:43662625	NA	-0.8	-9.59	-0.51	6.96e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs2880765	0.835	rs7163958	chr15:86045215	G/A	cg10818794	chr15:86012489	AKAP13	-0.34	-5.24	-0.31	3.28e-7	Coronary artery disease;
CESC	cis	rs853679	0.517	rs868987	chr6:28110148	A/G	cg18032046	chr6:28092343	ZSCAN16	0.57	6.58	0.37	2.47e-10	Depression;
CESC	cis	rs9814567	0.896	rs11915964	chr3:134348930	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.43	5.87	0.34	1.3e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs1005277	0.579	rs2472178	chr10:38384750	T/C	cg25427524	chr10:38739819	LOC399744	-0.69	-10.26	-0.53	5.12e-21	Extrinsic epigenetic age acceleration;
CESC	cis	rs7537660	1.000	rs10888257	chr1:248004877	C/T	cg12080717	chr1:248004886	OR11L1	-0.46	-5.62	-0.33	4.74e-8	Platelet distribution width;
CESC	cis	rs7666738	0.830	rs17484890	chr4:99013778	T/C	cg03467027	chr4:99064603	C4orf37	0.44	5.52	0.32	7.98e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4780401	0.546	rs3743588	chr16:11836508	G/A	cg01061890	chr16:11836724	TXNDC11	0.66	8.31	0.45	4.99e-15	Rheumatoid arthritis;
CESC	cis	rs734999	0.588	rs3748817	chr1:2525665	T/C	cg20673091	chr1:2541236	MMEL1	0.44	7.49	0.42	1.01e-12	Ulcerative colitis;
CESC	cis	rs875971	0.862	rs778684	chr7:65836403	A/T	cg18876405	chr7:65276391	NA	0.5	6.84	0.39	5.47e-11	Aortic root size;
CESC	cis	rs1003719	0.788	rs4411798	chr21:38453183	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.56	7.43	0.42	1.51e-12	Eye color traits;
CESC	cis	rs7116495	1.000	rs17161966	chr11:71815308	T/C	cg10381502	chr11:71823885	C11orf51	0.66	5.35	0.31	1.93e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs1153858	1.000	rs12593370	chr15:45617417	C/T	cg21132104	chr15:45694354	SPATA5L1	0.82	10.84	0.55	6.43e-23	Homoarginine levels;
CESC	cis	rs9309473	0.607	rs6546826	chr2:73599808	A/G	cg20560298	chr2:73613845	ALMS1	0.52	7.22	0.41	5.45e-12	Metabolite levels;
CESC	cis	rs67311347	1.000	rs11714912	chr3:40494065	A/G	cg01475735	chr3:40494733	NA	0.4	5.16	0.3	4.81e-7	Renal cell carcinoma;
CESC	cis	rs1552244	0.554	rs3732965	chr3:10048760	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.61	7.88	0.44	8.63e-14	Alzheimer's disease;
CESC	cis	rs1559088	0.948	rs10410778	chr19:33592301	C/A	cg27124370	chr19:33622961	WDR88	0.45	6.0	0.35	6.49e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs7072216	0.763	rs2274246	chr10:100175060	C/T	cg26618903	chr10:100175079	PYROXD2	-0.38	-5.85	-0.34	1.41e-8	Metabolite levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25949093	chr19:5142198	KDM4B	-0.55	-6.67	-0.38	1.48e-10	Gut microbiome composition (summer);
CESC	cis	rs734999	0.505	rs10797437	chr1:2539006	T/C	cg20673091	chr1:2541236	MMEL1	0.45	7.79	0.43	1.5e-13	Ulcerative colitis;
CESC	cis	rs6460942	0.841	rs17443848	chr7:12443688	A/G	cg02935154	chr7:12443704	VWDE	-0.58	-7.77	-0.43	1.76e-13	Coronary artery disease;
CESC	cis	rs8072100	0.840	rs12453233	chr17:45454570	C/T	cg08085267	chr17:45401833	C17orf57	-0.54	-7.22	-0.41	5.38e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs736408	0.522	rs6445535	chr3:52771468	T/C	cg07507251	chr3:52567010	NT5DC2	0.33	5.62	0.33	4.71e-8	Bipolar disorder;
CESC	trans	rs748404	0.578	rs2278856	chr15:43631356	G/A	cg24053811	chr14:70265306	SLC10A1	0.42	6.08	0.35	4.18e-9	Lung cancer;
CESC	cis	rs2549003	0.934	rs2549006	chr5:131827065	A/G	cg21138405	chr5:131827807	IRF1	-0.63	-10.68	-0.55	2.24e-22	Asthma (sex interaction);
CESC	cis	rs938554	0.694	rs4697700	chr4:9945792	C/G	cg11266682	chr4:10021025	SLC2A9	0.39	5.29	0.31	2.59e-7	Blood metabolite levels;
CESC	cis	rs853679	0.517	rs4713141	chr6:28101678	G/C	cg20151795	chr6:28129481	ZNF389	0.46	5.96	0.34	8.01e-9	Depression;
CESC	cis	rs7824557	0.527	rs2572447	chr8:11239510	G/A	cg21775007	chr8:11205619	TDH	-0.52	-7.78	-0.43	1.65e-13	Retinal vascular caliber;
CESC	cis	rs3105593	1.000	rs3101852	chr15:50848370	C/T	cg08437265	chr15:50716283	USP8	-0.42	-5.53	-0.32	7.82e-8	QT interval;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17533455	chr5:130599827	CDC42SE2	0.67	8.13	0.45	1.69e-14	Gut microbiome composition (summer);
CESC	cis	rs3781458	0.842	rs897300	chr10:126320902	A/G	cg20435097	chr10:126320824	FAM53B	0.28	5.41	0.32	1.43e-7	Male-pattern baldness;
CESC	cis	rs7772486	0.658	rs4895683	chr6:146113654	T/A	cg05347473	chr6:146136440	FBXO30	-0.53	-7.0	-0.39	2.13e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs34172651	0.517	rs7204288	chr16:24784531	A/G	cg06028605	chr16:24865363	SLC5A11	0.55	8.13	0.45	1.62e-14	Intelligence (multi-trait analysis);
CESC	trans	rs11239930	0.517	rs590286	chr1:146545604	A/C	cg23400715	chr22:48900624	FAM19A5	-0.35	-6.07	-0.35	4.4e-9	AIDS progression;
CESC	cis	rs172166	0.694	rs203876	chr6:28046673	T/C	cg17221315	chr6:27791827	HIST1H4J	0.46	6.09	0.35	3.98e-9	Cardiac Troponin-T levels;
CESC	cis	rs4665809	1.000	rs6546736	chr2:26293878	C/T	cg22920501	chr2:26401640	FAM59B	0.64	7.97	0.44	4.77e-14	Gut microbiome composition (summer);
CESC	cis	rs4268898	0.662	rs2891382	chr2:24511491	C/G	cg08917208	chr2:24149416	ATAD2B	0.51	5.23	0.31	3.43e-7	Asthma;
CESC	cis	rs9322193	0.923	rs9322207	chr6:149978321	G/A	cg04369109	chr6:150039330	LATS1	-0.4	-5.54	-0.32	7.28e-8	Lung cancer;
CESC	cis	rs4319547	0.695	rs113841747	chr12:122886088	G/T	cg05707623	chr12:122985044	ZCCHC8	0.54	6.14	0.35	3.02e-9	Body mass index;
CESC	cis	rs2073300	0.609	rs8183135	chr20:23384284	C/T	cg12062639	chr20:23401060	NAPB	1.07	8.85	0.48	1.29e-16	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs910316	0.789	rs175457	chr14:75584507	C/T	cg16144293	chr14:75469539	EIF2B2	0.41	5.38	0.31	1.61e-7	Height;
CESC	cis	rs9929218	1.000	rs8045022	chr16:68807087	T/C	cg02972257	chr16:68554789	NA	0.43	5.12	0.3	5.89e-7	Colorectal cancer;
CESC	cis	rs1005277	0.579	rs2474563	chr10:38375938	T/C	cg25517755	chr10:38738941	LOC399744	-0.48	-6.22	-0.36	1.94e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs2836633	0.929	rs2836610	chr21:40044502	C/T	cg05519781	chr21:40033154	ERG	0.73	11.68	0.58	1.02e-25	Coronary artery disease;
CESC	cis	rs6088580	0.634	rs6059875	chr20:33086090	T/G	cg08999081	chr20:33150536	PIGU	0.65	11.45	0.58	6.19e-25	Glomerular filtration rate (creatinine);
CESC	cis	rs7246657	0.943	rs4417644	chr19:37852472	A/G	cg23950597	chr19:37808831	NA	-0.62	-6.3	-0.36	1.26e-9	Coronary artery calcification;
CESC	cis	rs7833790	0.724	rs6473309	chr8:82707880	A/G	cg17211192	chr8:82754475	SNX16	-0.56	-7.13	-0.4	9.36e-12	Diastolic blood pressure;
CESC	cis	rs9814567	1.000	rs7637227	chr3:134244155	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.45	-6.08	-0.35	4.19e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs9916302	0.847	rs7218670	chr17:37500424	G/A	cg00129232	chr17:37814104	STARD3	0.57	7.67	0.43	3.29e-13	Glomerular filtration rate (creatinine);
CESC	cis	rs9311474	0.569	rs7614981	chr3:52566914	G/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.34	6.51	0.37	3.79e-10	Electroencephalogram traits;
CESC	cis	rs853679	0.517	rs9393895	chr6:28127621	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.57	-6.49	-0.37	4.32e-10	Depression;
CESC	trans	rs208515	0.525	rs12215007	chr6:66671008	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.91	-11.47	-0.58	5.22e-25	Exhaled nitric oxide levels;
CESC	cis	rs7618915	0.547	rs3774365	chr3:52642487	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	6.73	0.38	1.04e-10	Bipolar disorder;
CESC	cis	rs853679	0.882	rs9461432	chr6:28086883	T/C	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.81	7.45	0.42	1.31e-12	Depression;
CESC	cis	rs7927592	0.956	rs12277225	chr11:68340967	T/C	cg16797656	chr11:68205561	LRP5	0.39	5.37	0.31	1.72e-7	Total body bone mineral density;
CESC	cis	rs798554	0.721	rs2527680	chr7:2892361	C/T	cg04166393	chr7:2884313	GNA12	0.61	7.85	0.43	1.03e-13	Height;
CESC	trans	rs4335177	0.963	rs969650	chr9:109378080	T/C	cg12580783	chr12:49362475	WNT10B	-0.34	-6.55	-0.37	2.96e-10	Response to paliperidone in schizophrenia (positive Marder score);
CESC	cis	rs10088262	0.629	rs7833650	chr8:124822969	C/T	cg02993010	chr8:124780839	FAM91A1	-0.66	-8.05	-0.44	2.76e-14	Pancreatic cancer;
CESC	cis	rs7829975	0.564	rs2921060	chr8:8317817	G/T	cg15556689	chr8:8085844	FLJ10661	-0.59	-7.82	-0.43	1.28e-13	Mood instability;
CESC	cis	rs921968	0.565	rs13412324	chr2:219620521	T/C	cg02176678	chr2:219576539	TTLL4	-0.44	-7.67	-0.43	3.29e-13	Mean corpuscular hemoglobin concentration;
CESC	cis	rs6430585	0.646	rs12468768	chr2:136494985	C/T	cg07169764	chr2:136633963	MCM6	1.35	15.39	0.69	1.31e-38	Corneal structure;
CESC	cis	rs6500395	1.000	rs3826174	chr16:48591012	T/C	cg04672837	chr16:48644449	N4BP1	0.5	6.23	0.36	1.78e-9	Response to tocilizumab in rheumatoid arthritis;
CESC	trans	rs10435719	0.899	rs9329251	chr8:11793606	G/A	cg15556689	chr8:8085844	FLJ10661	0.52	6.39	0.37	7.33e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
CESC	cis	rs8070740	0.898	rs9896735	chr17:5325808	G/T	cg25236894	chr17:5323110	RPAIN;NUP88	-0.51	-6.56	-0.37	2.75e-10	Menopause (age at onset);
CESC	cis	rs9905704	0.633	rs4793588	chr17:56471051	G/T	cg12560992	chr17:57184187	TRIM37	-0.62	-5.72	-0.33	2.94e-8	Testicular germ cell tumor;
CESC	cis	rs10504229	0.871	rs60342323	chr8:58154899	T/C	cg22535103	chr8:58192502	C8orf71	-0.92	-11.29	-0.57	2.15e-24	Developmental language disorder (linguistic errors);
CESC	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg24829409	chr8:58192753	C8orf71	-0.67	-7.99	-0.44	4.08e-14	Developmental language disorder (linguistic errors);
CESC	cis	rs7666738	0.830	rs13137808	chr4:99047095	T/C	cg03467027	chr4:99064603	C4orf37	0.47	5.98	0.34	7.19e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9910055	0.529	rs228746	chr17:42173752	T/C	cg08499158	chr17:42289980	UBTF	0.43	5.21	0.3	3.86e-7	Total body bone mineral density;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg15537487	chr10:1043368	GTPBP4	-0.47	-6.48	-0.37	4.41e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17105206	chr16:67211972	KIAA0895L	0.61	7.24	0.41	4.97e-12	Gut microbiome composition (summer);
CESC	trans	rs875971	1.000	rs6460296	chr7:65895139	C/T	cg26939375	chr7:64535504	NA	0.47	6.09	0.35	4.06e-9	Aortic root size;
CESC	cis	rs2710642	0.925	rs72807578	chr2:63008044	G/A	cg17519650	chr2:63277830	OTX1	-0.53	-6.45	-0.37	5.27e-10	LDL cholesterol levels;LDL cholesterol;
CESC	cis	rs7918232	0.825	rs4749233	chr10:27467967	G/A	cg14240646	chr10:27532245	ACBD5	-0.67	-6.57	-0.37	2.65e-10	Breast cancer;
CESC	cis	rs12464483	0.591	rs4952170	chr2:30885429	G/A	cg17749961	chr2:30669863	LCLAT1	0.7	7.16	0.4	8.11e-12	Pre-treatment pain in head and neck squamous cell carcinoma;
CESC	cis	rs6448317	0.954	rs13139649	chr4:24922007	C/A	cg21108841	chr4:24914750	CCDC149	-0.56	-6.68	-0.38	1.36e-10	Heschl's gyrus morphology;
CESC	cis	rs875971	0.862	rs801204	chr7:66022921	T/C	cg19163074	chr7:65112434	INTS4L2	0.42	5.25	0.31	3.18e-7	Aortic root size;
CESC	cis	rs61931739	0.500	rs11053242	chr12:34511625	A/G	cg06521331	chr12:34319734	NA	-0.37	-5.09	-0.3	6.85e-7	Morning vs. evening chronotype;
CESC	cis	rs11098499	0.604	rs12642411	chr4:120580525	T/C	cg24375607	chr4:120327624	NA	0.42	5.08	0.3	7.07e-7	Corneal astigmatism;
CESC	trans	rs8073060	0.586	rs7212488	chr17:33993476	A/T	cg19694781	chr19:47549865	TMEM160	-0.75	-7.46	-0.42	1.21e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	cis	rs7940866	0.903	rs10791112	chr11:130870215	A/C	cg12179176	chr11:130786555	SNX19	-0.56	-7.93	-0.44	6.2e-14	Schizophrenia;
CESC	cis	rs9457247	1.000	rs422562	chr6:167406318	A/G	cg25258033	chr6:167368657	RNASET2	0.41	6.14	0.35	3.06e-9	Crohn's disease;
CESC	cis	rs8077577	1.000	rs7207276	chr17:18065737	G/C	cg16794390	chr17:18148240	FLII	0.41	5.65	0.33	4.04e-8	Obesity-related traits;
CESC	trans	rs6499129	0.702	rs6499119	chr16:67277666	T/A	cg17013778	chr10:135130084	NA	-0.72	-6.28	-0.36	1.37e-9	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs9649213	0.555	rs12667634	chr7:97965442	A/G	cg24562669	chr7:97807699	LMTK2	0.49	7.17	0.4	7.48e-12	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs2050392	0.517	rs603072	chr10:30755778	C/T	cg25182066	chr10:30743637	MAP3K8	0.5	7.13	0.4	9.74e-12	Inflammatory bowel disease;
CESC	trans	rs1945213	0.694	rs10895985	chr11:55831595	T/C	cg03929089	chr4:120376271	NA	0.76	7.23	0.41	5.06e-12	Acute lymphoblastic leukemia (childhood);
CESC	trans	rs7937682	0.924	rs10891283	chr11:111527672	A/G	cg18187862	chr3:45730750	SACM1L	0.48	6.08	0.35	4.15e-9	Primary sclerosing cholangitis;
CESC	cis	rs7845219	0.544	rs4735331	chr8:95917958	C/T	cg16049864	chr8:95962084	TP53INP1	-0.5	-7.48	-0.42	1.06e-12	Type 2 diabetes;
CESC	cis	rs7017914	0.934	rs78923624	chr8:71677839	G/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.22	-0.31	3.65e-7	Bone mineral density;
CESC	cis	rs854765	0.547	rs7224047	chr17:17932931	G/A	cg16928487	chr17:17741425	SREBF1	-0.53	-8.99	-0.48	4.71e-17	Total body bone mineral density;
CESC	cis	rs7618915	0.547	rs12496634	chr3:52709259	A/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.69	0.38	1.29e-10	Bipolar disorder;
CESC	cis	rs909674	0.514	rs7423	chr22:39781429	C/T	cg24399712	chr22:39784796	NA	-0.73	-10.58	-0.55	4.55e-22	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs372883	0.563	rs1153293	chr21:30691325	C/T	cg24692254	chr21:30365293	RNF160	0.59	7.28	0.41	3.75e-12	Pancreatic cancer;
CESC	cis	rs2836974	0.863	rs1065242	chr21:40567716	C/G	cg17971929	chr21:40555470	PSMG1	1.06	15.93	0.7	1.54e-40	Cognitive function;
CESC	cis	rs4253772	0.515	rs6008591	chr22:46703664	T/C	cg18190219	chr22:46762943	CELSR1	-0.56	-6.44	-0.37	5.69e-10	LDL cholesterol;Cholesterol, total;
CESC	cis	rs12824058	0.831	rs11609362	chr12:130810526	T/C	cg26677194	chr12:130822605	PIWIL1	0.52	6.81	0.39	6.58e-11	Menopause (age at onset);
CESC	cis	rs7666738	0.830	rs11735193	chr4:98761900	C/T	cg03467027	chr4:99064603	C4orf37	0.44	5.4	0.32	1.46e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg26338869	chr17:61819248	STRADA	0.67	8.66	0.47	4.55e-16	Prudent dietary pattern;
CESC	cis	rs9911578	1.000	rs9907499	chr17:56949044	A/G	cg05425664	chr17:57184151	TRIM37	-0.5	-6.96	-0.39	2.6e-11	Intelligence (multi-trait analysis);
CESC	cis	rs798554	0.600	rs2679259	chr7:2885322	C/G	cg04166393	chr7:2884313	GNA12	0.42	5.58	0.32	6.06e-8	Height;
CESC	cis	rs8017423	0.967	rs8009493	chr14:90690083	G/C	cg14092571	chr14:90743983	NA	-0.56	-8.24	-0.45	7.77e-15	Mortality in heart failure;
CESC	cis	rs1707322	1.000	rs34446427	chr1:46417655	A/C	cg05343316	chr1:45956843	TESK2	0.44	5.42	0.32	1.36e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg23978390	chr7:1156363	C7orf50	0.63	8.77	0.47	2.17e-16	Longevity;Endometriosis;
CESC	cis	rs9322193	0.962	rs9322219	chr6:150103399	C/T	cg04369109	chr6:150039330	LATS1	-0.42	-5.95	-0.34	8.52e-9	Lung cancer;
CESC	cis	rs367943	0.608	rs6859352	chr5:113007384	A/C	cg12552261	chr5:112820674	MCC	0.44	5.36	0.31	1.85e-7	Type 2 diabetes;
CESC	trans	rs35110281	0.715	rs969060	chr21:45080852	T/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.52	6.65	0.38	1.71e-10	Mean corpuscular volume;
CESC	cis	rs2180341	0.597	rs3798859	chr6:127663116	C/T	cg27446573	chr6:127587934	RNF146	0.63	8.53	0.46	1.18e-15	Breast cancer;
CESC	cis	rs5769707	0.706	rs2071903	chr22:50034517	G/A	cg20744362	chr22:50050164	C22orf34	0.37	5.12	0.3	6.01e-7	Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs17666538	0.585	rs4735812	chr8:607766	C/G	cg02524346	chr8:600233	NA	0.85	6.05	0.35	5.02e-9	IgG glycosylation;
CESC	cis	rs295140	0.506	rs4673854	chr2:201134736	G/A	cg23649088	chr2:200775458	C2orf69	-0.39	-5.12	-0.3	5.86e-7	QT interval;
CESC	cis	rs916888	0.773	rs199457	chr17:44795469	C/T	cg15921436	chr17:44337874	NA	0.75	7.9	0.44	7.36e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg12165864	chr7:66369176	NA	0.5	6.61	0.38	2.1e-10	Fibrinogen levels;
CESC	cis	rs1538970	0.816	rs61788356	chr1:46006675	C/T	cg05343316	chr1:45956843	TESK2	0.87	11.58	0.58	2.38e-25	Platelet count;
CESC	cis	rs9875589	0.509	rs9836573	chr3:14065239	G/A	cg19554555	chr3:13937349	NA	-0.44	-5.6	-0.33	5.43e-8	Ovarian reserve;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04454272	chr22:31795531	DRG1	0.6	6.65	0.38	1.63e-10	Gut microbiome composition (summer);
CESC	cis	rs35306767	0.951	rs11253530	chr10:993729	T/C	cg26597838	chr10:835615	NA	0.82	8.72	0.47	3.1e-16	Eosinophil percentage of granulocytes;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg08862778	chr1:11322643	MTOR	-0.47	-7.16	-0.4	7.72e-12	Gambling;
CESC	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg26338869	chr17:61819248	STRADA	0.67	8.72	0.47	3.12e-16	Prudent dietary pattern;
CESC	cis	rs9894429	0.621	rs9747119	chr17:79607017	A/G	cg21984481	chr17:79567631	NPLOC4	-0.35	-5.34	-0.31	1.97e-7	Eye color traits;
CESC	cis	rs8111998	0.826	rs10418805	chr19:22765991	A/G	cg19914732	chr19:22715077	NA	-0.4	-5.27	-0.31	2.88e-7	Corneal structure;
CESC	cis	rs1497406	0.773	rs7538833	chr1:16504381	T/C	cg20430773	chr1:16534157	ARHGEF19	0.33	5.33	0.31	2.11e-7	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
CESC	trans	rs8029989	0.869	rs8039162	chr15:38740829	A/G	cg24306142	chr1:17231793	NA	-0.44	-6.1	-0.35	3.77e-9	Psychosis (atypical);
CESC	cis	rs6456156	0.586	rs9459862	chr6:167487011	A/G	cg07741184	chr6:167504864	NA	-0.34	-5.99	-0.35	6.88e-9	Primary biliary cholangitis;
CESC	cis	rs7149337	0.869	rs10137445	chr14:51694416	G/A	cg23942311	chr14:51606299	NA	0.45	7.36	0.41	2.33e-12	Cancer;
CESC	cis	rs7224668	0.647	rs2292184	chr17:79244802	T/C	cg05632623	chr17:78450055	NPTX1	-0.29	-5.06	-0.3	7.79e-7	IgG glycosylation;
CESC	cis	rs9322193	0.923	rs4870529	chr6:150037572	A/G	cg13206674	chr6:150067644	NUP43	0.45	6.53	0.37	3.37e-10	Lung cancer;
CESC	cis	rs6893300	0.785	rs7704520	chr5:179191054	G/A	cg14593053	chr5:179126677	CANX	-0.49	-5.85	-0.34	1.43e-8	Resting heart rate;
CESC	cis	rs56309584	0.673	rs11078735	chr17:8116861	C/A	cg06726167	chr17:8076949	TMEM107	-0.5	-5.16	-0.3	4.88e-7	Initial pursuit acceleration;
CESC	cis	rs4662945	0.525	rs28819474	chr2:130264623	T/C	cg05903289	chr2:130345205	NA	-0.41	-6.36	-0.36	8.81e-10	Response to cytidine analogues (gemcitabine);
CESC	cis	rs1707322	0.721	rs6699418	chr1:46100181	G/A	cg05343316	chr1:45956843	TESK2	0.5	6.34	0.36	9.93e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg23214207	chr17:18476059	NA	-0.46	-6.22	-0.36	1.9e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs1707322	1.000	rs785510	chr1:46528618	T/C	cg03146154	chr1:46216737	IPP	-0.74	-9.67	-0.51	3.81e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9790314	1.000	rs336583	chr3:161081981	A/T	cg04691961	chr3:161091175	C3orf57	0.43	5.44	0.32	1.22e-7	Morning vs. evening chronotype;
CESC	cis	rs7786877	0.626	rs11770389	chr7:100221218	T/G	cg16850897	chr7:100343110	ZAN	-0.62	-6.54	-0.37	3.07e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs6964587	0.610	rs6465338	chr7:91450624	T/C	cg17063962	chr7:91808500	NA	0.42	5.77	0.33	2.23e-8	Breast cancer;
CESC	cis	rs2455799	0.613	rs4684261	chr3:15796505	G/A	cg09340198	chr3:15902540	ANKRD28	-0.33	-5.16	-0.3	4.94e-7	Mean platelet volume;
CESC	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg04871131	chr7:94954202	PON1	-0.41	-5.72	-0.33	2.92e-8	Paraoxonase activity;
CESC	cis	rs2839186	0.619	rs55689527	chr21:47622727	A/G	cg00612595	chr21:47717864	NA	-0.41	-5.62	-0.33	4.93e-8	Testicular germ cell tumor;
CESC	cis	rs11203032	0.710	rs10887923	chr10:90930404	C/T	cg16672925	chr10:90967113	CH25H	0.7	6.65	0.38	1.62e-10	Heart failure;
CESC	cis	rs2952156	0.959	rs2941503	chr17:37828745	A/G	cg20243544	chr17:37824526	PNMT	0.64	7.93	0.44	6.26e-14	Asthma;
CESC	cis	rs7618915	0.547	rs6762813	chr3:52726695	C/T	cg05564831	chr3:52568323	NT5DC2	0.44	6.68	0.38	1.43e-10	Bipolar disorder;
CESC	trans	rs1606974	0.737	rs4971757	chr2:51934748	G/A	cg00084019	chr7:176739	NA	0.47	6.05	0.35	4.98e-9	Educational attainment (years of education);Educational attainment;
CESC	cis	rs2425143	1.000	rs6058304	chr20:34299851	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.81	-7.35	-0.41	2.49e-12	Blood protein levels;
CESC	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg23708337	chr7:1209742	NA	0.55	5.42	0.32	1.33e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs9287719	0.967	rs9287720	chr2:10752664	C/T	cg00105475	chr2:10696890	NA	0.38	5.42	0.32	1.34e-7	Prostate cancer;
CESC	cis	rs7666738	0.830	rs10021709	chr4:99030587	G/A	cg05340658	chr4:99064831	C4orf37	0.83	13.1	0.63	1.43e-30	Colonoscopy-negative controls vs population controls;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg01026192	chr7:2763915	NA	0.47	6.36	0.36	8.72e-10	Fibrinogen levels;
CESC	cis	rs4253772	0.550	rs55926596	chr22:46682955	C/T	cg18190219	chr22:46762943	CELSR1	-0.59	-5.53	-0.32	7.79e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs6952808	0.531	rs4721441	chr7:2184060	A/G	cg04267008	chr7:1944627	MAD1L1	-0.47	-5.64	-0.33	4.27e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs3785574	0.927	rs2854160	chr17:61977248	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.75	9.89	0.52	7.54e-20	Height;
CESC	cis	rs2522056	1.000	rs2057655	chr5:131807624	A/G	cg24060327	chr5:131705240	SLC22A5	-0.65	-7.27	-0.41	4.05e-12	Lymphocyte counts;Fibrinogen;
CESC	cis	rs1005277	0.577	rs4934906	chr10:38015028	C/T	cg00409905	chr10:38381863	ZNF37A	-0.49	-6.57	-0.37	2.69e-10	Extrinsic epigenetic age acceleration;
CESC	cis	rs3820928	0.874	rs4234064	chr2:227857497	G/T	cg11843606	chr2:227700838	RHBDD1	-0.44	-5.65	-0.33	4.14e-8	Pulmonary function;
CESC	cis	rs6460942	0.915	rs62447640	chr7:12488282	A/T	cg06484146	chr7:12443880	VWDE	-0.77	-8.63	-0.47	5.59e-16	Coronary artery disease;
CESC	trans	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg13565492	chr6:43139072	SRF	-0.74	-8.99	-0.48	4.93e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs1862618	0.802	rs4389648	chr5:56103602	A/G	cg24531977	chr5:56204891	C5orf35	-0.88	-11.21	-0.57	3.87e-24	Initial pursuit acceleration;
CESC	cis	rs703842	1.000	rs10783847	chr12:58196447	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.69	8.91	0.48	8.44e-17	Multiple sclerosis;
CESC	cis	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg23422044	chr7:1970798	MAD1L1	-0.39	-5.38	-0.31	1.65e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs9300255	0.596	rs11057207	chr12:123730891	T/G	cg00376283	chr12:123451042	ABCB9	0.67	8.91	0.48	8.16e-17	Neutrophil percentage of white cells;
CESC	cis	rs9311474	0.607	rs4234633	chr3:52557038	C/T	cg18404041	chr3:52824283	ITIH1	-0.38	-6.44	-0.37	5.61e-10	Electroencephalogram traits;
CESC	cis	rs9908102	0.756	rs7210890	chr17:12917134	A/G	cg26162695	chr17:12921313	ELAC2	0.55	5.96	0.34	7.96e-9	Schizophrenia;
CESC	cis	rs4930103	0.904	rs4929984	chr11:2024683	A/C	cg23202291	chr11:1979235	NA	-0.36	-5.52	-0.32	7.95e-8	DNA methylation (parent-of-origin);DNA methylation (variation);
CESC	cis	rs10242455	0.702	rs10251282	chr7:98990236	T/C	cg18809830	chr7:99032528	PTCD1	-0.89	-6.1	-0.35	3.84e-9	Blood metabolite levels;
CESC	cis	rs7772486	0.790	rs1062067	chr6:146207563	A/G	cg05347473	chr6:146136440	FBXO30	0.55	7.05	0.4	1.52e-11	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg11235871	chr3:49142143	QARS	0.5	6.22	0.36	1.91e-9	Thyroid stimulating hormone;
CESC	cis	rs244293	0.730	rs2332314	chr17:53033007	T/G	cg19360675	chr17:53046073	COX11;STXBP4	-0.43	-5.74	-0.33	2.52e-8	Menarche (age at onset);
CESC	trans	rs2273788	1.000	rs2273788	chr9:114348617	C/T	cg04898443	chr2:242254495	SEPT2;HDLBP	-0.6	-6.23	-0.36	1.87e-9	Monocyte count;
CESC	trans	rs11098499	0.863	rs13136462	chr4:120543173	C/T	cg25214090	chr10:38739885	LOC399744	0.69	9.52	0.5	1.14e-18	Corneal astigmatism;
CESC	cis	rs875971	0.862	rs7798630	chr7:65771479	G/C	cg18252515	chr7:66147081	NA	0.43	5.73	0.33	2.76e-8	Aortic root size;
CESC	trans	rs11039571	0.588	rs61917001	chr11:48233667	G/C	cg03929089	chr4:120376271	NA	0.64	6.2	0.36	2.2e-9	D-dimer levels;
CESC	cis	rs9457247	0.663	rs2282861	chr6:167440128	C/T	cg07741184	chr6:167504864	NA	0.34	6.09	0.35	3.9e-9	Crohn's disease;
CESC	cis	rs634534	0.622	rs1308733	chr11:65720841	T/C	cg04055107	chr11:65626734	MUS81;CFL1	-0.46	-5.63	-0.33	4.47e-8	Sum eosinophil basophil counts;Eosinophil counts;
CESC	cis	rs9910055	0.659	rs7216294	chr17:42251095	T/C	cg10896456	chr17:42255109	ASB16;C17orf65	0.5	7.43	0.42	1.47e-12	Total body bone mineral density;
CESC	cis	rs6963495	0.818	rs73190200	chr7:105165856	T/C	cg02135003	chr7:105160482	PUS7	-0.47	-5.59	-0.33	5.51e-8	Bipolar disorder (body mass index interaction);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg03883228	chr11:68778570	MRGPRF	-0.41	-6.29	-0.36	1.29e-9	Gambling;
CESC	cis	rs9354308	0.753	rs10455590	chr6:66598194	A/G	cg07460842	chr6:66804631	NA	-0.42	-5.07	-0.3	7.54e-7	Metabolite levels;
CESC	cis	rs34779708	0.833	rs12777517	chr10:35473927	T/G	cg04310649	chr10:35416472	CREM	-0.51	-6.24	-0.36	1.69e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg16132339	chr22:24313637	DDTL;DDT	0.39	6.17	0.35	2.52e-9	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs3020736	0.500	rs6002597	chr22:42488160	C/A	cg04733989	chr22:42467013	NAGA	-0.82	-12.02	-0.59	7.23e-27	Autism spectrum disorder or schizophrenia;
CESC	cis	rs4566357	0.615	rs10198214	chr2:227913314	A/C	cg11843606	chr2:227700838	RHBDD1	-0.48	-6.58	-0.37	2.45e-10	Coronary artery disease;
CESC	cis	rs6831352	0.877	rs29001183	chr4:100056539	C/T	cg13256891	chr4:100009986	ADH5	-0.77	-8.45	-0.46	1.97e-15	Alcohol dependence;
CESC	cis	rs3793683	0.597	rs12783367	chr10:134587334	T/C	cg27297192	chr10:134578999	INPP5A	0.39	5.16	0.3	4.75e-7	Migraine;
CESC	cis	rs1799949	0.965	rs11080034	chr17:41443014	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	7.05	0.4	1.58e-11	Menopause (age at onset);
CESC	cis	rs1707322	0.721	rs10157795	chr1:46228192	G/A	cg03146154	chr1:46216737	IPP	0.74	10.62	0.55	3.46e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs3785574	0.745	rs2854162	chr17:61975610	T/C	cg06873352	chr17:61820015	STRADA	-0.48	-7.02	-0.4	1.87e-11	Height;
CESC	cis	rs6089584	0.888	rs6089623	chr20:60615759	A/G	cg13770153	chr20:60521292	NA	-0.45	-5.81	-0.34	1.75e-8	Body mass index;
CESC	cis	rs854765	0.583	rs8078138	chr17:17811251	C/T	cg04398451	chr17:18023971	MYO15A	-0.65	-9.11	-0.49	2.07e-17	Total body bone mineral density;
CESC	cis	rs12497850	0.931	rs10780033	chr3:48891275	T/C	cg07636037	chr3:49044803	WDR6	1.02	18.99	0.76	2.3e-51	Parkinson's disease;
CESC	cis	rs2901656	0.677	rs10752957	chr1:172408271	A/G	cg03748243	chr1:172413542	C1orf105;PIGC	0.57	8.85	0.48	1.3e-16	Red cell distribution width;Platelet distribution width;
CESC	cis	rs11098499	0.955	rs1511018	chr4:120161580	G/T	cg09307838	chr4:120376055	NA	0.87	11.47	0.58	5.45e-25	Corneal astigmatism;
CESC	cis	rs6964587	1.000	rs34043009	chr7:91578447	T/C	cg17063962	chr7:91808500	NA	-0.57	-7.62	-0.42	4.53e-13	Breast cancer;
CESC	cis	rs77372450	0.636	rs28712355	chr5:157023508	A/G	cg25077558	chr5:156991510	ADAM19	0.46	5.1	0.3	6.47e-7	Bipolar disorder (body mass index interaction);
CESC	cis	rs2425143	0.818	rs11167280	chr20:34560526	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.65	5.58	0.32	6e-8	Blood protein levels;
CESC	cis	rs9457247	0.534	rs9355610	chr6:167383075	G/A	cg25258033	chr6:167368657	RNASET2	-0.38	-5.45	-0.32	1.15e-7	Crohn's disease;
CESC	cis	rs7555523	0.887	rs4656461	chr1:165687205	G/A	cg24409356	chr1:165738333	TMCO1	0.76	6.98	0.39	2.44e-11	Intraocular pressure;Glaucoma (high intraocular pressure);
CESC	cis	rs6725517	0.737	rs7576788	chr2:25083310	A/G	cg01884057	chr2:25150051	NA	0.32	6.24	0.36	1.72e-9	Breast cancer;
CESC	trans	rs7922314	0.557	rs61865713	chr10:64737184	C/T	cg06935979	chr1:232941706	KIAA1383	-0.69	-6.38	-0.36	7.94e-10	Cutaneous psoriasis;
CESC	cis	rs9916302	0.904	rs57399933	chr17:37551189	A/G	cg20243544	chr17:37824526	PNMT	-0.51	-6.5	-0.37	4.03e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs1862618	0.853	rs1833896	chr5:56097669	C/A	cg22800045	chr5:56110881	MAP3K1	0.73	9.21	0.49	1e-17	Initial pursuit acceleration;
CESC	cis	rs875971	0.545	rs1796217	chr7:66085918	A/G	cg25405998	chr7:65216604	CCT6P1	-0.46	-5.07	-0.3	7.52e-7	Aortic root size;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg14329673	chr8:95732141	DPY19L4	-0.48	-6.6	-0.38	2.19e-10	Fibrinogen levels;
CESC	cis	rs7660520	0.557	rs76004373	chr4:183731011	C/G	cg12483801	chr4:183727862	NA	0.75	6.88	0.39	4.24e-11	Pediatric autoimmune diseases;
CESC	cis	rs7714584	1.000	rs7715981	chr5:150258107	A/G	cg22134413	chr5:150180641	NA	0.48	5.35	0.31	1.86e-7	Crohn's disease;
CESC	cis	rs9914988	0.943	rs12951232	chr17:27132638	G/C	cg20469991	chr17:27169893	C17orf63	-0.48	-5.25	-0.31	3.18e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CESC	trans	rs3087243	0.755	rs6715389	chr2:204694621	T/C	cg01841312	chr10:38069945	NA	-0.38	-6.35	-0.36	9.46e-10	Rheumatoid arthritis;Hypothyroidism;Type 1 diabetes;
CESC	cis	rs7586879	0.639	rs4077678	chr2:25122840	C/G	cg01884057	chr2:25150051	NA	0.38	7.35	0.41	2.43e-12	Body mass index;
CESC	cis	rs704795	0.836	rs1647281	chr2:27612938	G/C	cg24768116	chr2:27665128	KRTCAP3	-0.29	-5.36	-0.31	1.85e-7	Menopause (age at onset);
CESC	cis	rs2742234	0.910	rs2505511	chr10:43641029	T/A	cg07801480	chr10:43725741	RASGEF1A	0.37	5.26	0.31	2.98e-7	Hirschsprung disease;
CESC	cis	rs2573652	0.722	rs11636047	chr15:100543341	A/G	cg00587665	chr15:100533223	ADAMTS17	-0.42	-6.91	-0.39	3.58e-11	Height;
CESC	trans	rs2018683	0.707	rs917219	chr7:28975343	A/G	cg19402173	chr7:128379420	CALU	-0.51	-6.63	-0.38	1.85e-10	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06932616	chr19:48908335	GRIN2D	-0.5	-6.4	-0.37	7.18e-10	Gut microbiome composition (summer);
CESC	cis	rs9905704	0.874	rs28483505	chr17:56844109	G/C	cg12560992	chr17:57184187	TRIM37	0.61	7.12	0.4	9.95e-12	Testicular germ cell tumor;
CESC	cis	rs514406	0.792	rs1242201	chr1:53344748	G/A	cg24675658	chr1:53192096	ZYG11B	-0.6	-7.6	-0.42	5.08e-13	Monocyte count;
CESC	cis	rs4889855	0.530	rs9901467	chr17:78574008	G/A	cg16591659	chr17:78472290	NA	-0.34	-5.57	-0.32	6.41e-8	Fractional excretion of uric acid;
CESC	cis	rs3741404	0.609	rs669913	chr11:63869879	A/G	cg18225595	chr11:63971243	STIP1	0.51	6.7	0.38	1.24e-10	Platelet count;
CESC	cis	rs910316	0.763	rs1548807	chr14:75479582	T/G	cg08847533	chr14:75593920	NEK9	0.91	16.36	0.71	4.8e-42	Height;
CESC	cis	rs9287719	0.967	rs11674433	chr2:10730839	T/C	cg02196655	chr2:10830764	NOL10	-0.36	-5.57	-0.32	6.1e-8	Prostate cancer;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg06212498	chr3:49045151	WDR6	0.47	6.04	0.35	5.15e-9	Asthma;
CESC	cis	rs9457247	0.602	rs2157388	chr6:167481912	G/A	cg23791538	chr6:167370224	RNASET2	-0.53	-6.97	-0.39	2.57e-11	Crohn's disease;
CESC	cis	rs1862618	0.853	rs43184	chr5:56141777	G/C	cg22800045	chr5:56110881	MAP3K1	0.83	9.99	0.52	3.69e-20	Initial pursuit acceleration;
CESC	cis	rs7312933	0.567	rs11181399	chr12:42666412	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.46	5.97	0.34	7.71e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs314370	0.951	rs12705092	chr7:100473550	G/A	cg10426581	chr7:100472382	SRRT	0.86	8.37	0.46	3.32e-15	Resting heart rate;
CESC	cis	rs9287719	0.967	rs6759714	chr2:10747207	A/G	cg00105475	chr2:10696890	NA	0.38	5.57	0.32	6.34e-8	Prostate cancer;
CESC	cis	rs644799	1.000	rs632388	chr11:95563775	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	14.27	0.66	1.19e-34	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs6867032	0.695	rs3902820	chr5:2000330	T/A	cg26168224	chr5:2018326	NA	-0.86	-14.09	-0.65	4.81e-34	Gut microbiome composition (winter);
CESC	cis	rs2404602	0.716	rs1125932	chr15:76820540	C/T	cg26408565	chr15:76604113	ETFA	-0.39	-5.72	-0.33	2.83e-8	Blood metabolite levels;
CESC	cis	rs5769707	0.740	rs79946167	chr22:50017556	G/A	cg20744362	chr22:50050164	C22orf34	0.37	6.37	0.36	8.45e-10	Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs7937682	0.663	rs35581942	chr11:111756286	C/T	cg09085632	chr11:111637200	PPP2R1B	0.87	10.93	0.56	3.49e-23	Primary sclerosing cholangitis;
CESC	cis	rs9768139	0.708	rs921615	chr7:158117935	A/G	cg24154853	chr7:158122151	PTPRN2	0.44	6.89	0.39	4.02e-11	Calcium levels;
CESC	cis	rs1018836	0.595	rs2223010	chr8:91480068	A/G	cg16814680	chr8:91681699	NA	-0.63	-8.67	-0.47	4.27e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs9911578	1.000	rs12449365	chr17:56600660	C/G	cg12560992	chr17:57184187	TRIM37	-0.93	-15.59	-0.69	2.43e-39	Intelligence (multi-trait analysis);
CESC	cis	rs7659604	1.000	rs35901586	chr4:122664757	T/A	cg19671926	chr4:122722719	EXOSC9	-0.44	-5.3	-0.31	2.49e-7	Type 2 diabetes;
CESC	cis	rs1799949	1.000	rs12516	chr17:41196408	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	8.6	0.47	7.02e-16	Menopause (age at onset);
CESC	cis	rs10504229	0.683	rs949856	chr8:58144496	G/A	cg02725872	chr8:58115012	NA	-0.42	-6.61	-0.38	2.1e-10	Developmental language disorder (linguistic errors);
CESC	trans	rs3780486	1.000	rs3780480	chr9:33163486	G/T	cg20290983	chr6:43655470	MRPS18A	0.84	12.08	0.6	4.54e-27	IgG glycosylation;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14795305	chr7:150974453	SMARCD3	-0.59	-7.53	-0.42	8.22e-13	Gut microbiome composition (summer);
CESC	cis	rs2797160	0.547	rs9401836	chr6:125956736	T/C	cg05901451	chr6:126070800	HEY2	-0.39	-5.4	-0.32	1.45e-7	Endometrial cancer;
CESC	cis	rs2070488	0.861	rs2067082	chr3:38438182	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.92	15.9	0.7	2.01e-40	Electrocardiographic conduction measures;
CESC	cis	rs4713118	0.662	rs9468275	chr6:28026136	G/T	cg22143856	chr6:28129313	ZNF389	0.42	5.26	0.31	2.91e-7	Parkinson's disease;
CESC	cis	rs7666738	0.791	rs13125277	chr4:99009922	T/G	cg03467027	chr4:99064603	C4orf37	0.44	5.63	0.33	4.57e-8	Colonoscopy-negative controls vs population controls;
CESC	trans	rs1814175	0.588	rs1721994	chr11:49914050	G/A	cg15704280	chr7:45808275	SEPT13	-1.01	-18.94	-0.76	3.64e-51	Height;
CESC	cis	rs9814567	0.762	rs13079012	chr3:134247706	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.46	5.81	0.34	1.74e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs501120	0.850	rs642222	chr10:44770473	A/G	cg09554077	chr10:44749378	NA	0.52	6.89	0.39	4.1e-11	Coronary artery disease;Coronary heart disease;
CESC	cis	rs6752107	1.000	rs2241880	chr2:234183368	A/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.49	6.7	0.38	1.25e-10	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs6032067	0.777	rs56063128	chr20:43783210	G/A	cg11264863	chr20:43835661	SEMG1	0.5	5.41	0.32	1.4e-7	Blood protein levels;
CESC	cis	rs2228479	0.718	rs62054253	chr16:89896932	T/C	cg14709524	chr16:89940631	TCF25	0.85	5.79	0.34	1.98e-8	Skin colour saturation;
CESC	cis	rs9858542	0.953	rs11926781	chr3:49603289	C/T	cg07274523	chr3:49395745	GPX1	0.64	8.17	0.45	1.24e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs8062405	1.000	rs7498555	chr16:28893571	T/C	cg08761264	chr16:28874980	SH2B1	-0.44	-5.47	-0.32	1.04e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs7937682	0.883	rs1789358	chr11:111474116	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.94	-13.87	-0.65	2.84e-33	Primary sclerosing cholangitis;
CESC	cis	rs6496667	0.683	rs2589973	chr15:90892293	C/T	cg22089800	chr15:90895588	ZNF774	0.62	7.74	0.43	2.16e-13	Rheumatoid arthritis;
CESC	cis	rs6696846	0.791	rs11240352	chr1:205051711	C/G	cg00857998	chr1:205179979	DSTYK	-0.54	-7.14	-0.4	8.88e-12	Red blood cell count;
CESC	cis	rs9322193	0.923	rs2297932	chr6:150039361	C/G	cg07701084	chr6:150067640	NUP43	0.48	6.85	0.39	5.03e-11	Lung cancer;
CESC	trans	rs10100465	0.596	rs218009	chr8:118716275	A/G	cg19935481	chr15:70390365	TLE3	0.66	6.6	0.38	2.2e-10	Leprosy;
CESC	cis	rs4654899	0.865	rs1472831	chr1:21435940	C/T	cg05370193	chr1:21551575	ECE1	0.45	6.86	0.39	4.86e-11	Superior frontal gyrus grey matter volume;
CESC	cis	rs9300255	0.507	rs1615350	chr12:123650335	C/T	cg05973401	chr12:123451056	ABCB9	0.46	5.8	0.34	1.88e-8	Neutrophil percentage of white cells;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg11487532	chr11:44586968	CD82	-0.5	-6.71	-0.38	1.19e-10	Ulcerative colitis;
CESC	trans	rs3749237	1.000	rs6804655	chr3:49738945	C/T	cg21659725	chr3:3221576	CRBN	0.54	6.33	0.36	1.01e-9	Resting heart rate;
CESC	cis	rs853679	1.000	rs1419183	chr6:28242794	A/C	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.71	7.37	0.41	2.16e-12	Depression;
CESC	cis	rs798554	0.704	rs2527684	chr7:2825922	G/T	cg19717773	chr7:2847554	GNA12	-0.56	-8.77	-0.47	2.27e-16	Height;
CESC	cis	rs7615952	0.641	rs66520539	chr3:125780374	G/A	cg06494592	chr3:125709126	NA	-0.49	-5.2	-0.3	3.92e-7	Blood pressure (smoking interaction);
CESC	cis	rs12971120	0.891	rs11151960	chr18:72177232	G/A	cg26446133	chr18:72167187	CNDP2	-0.76	-9.43	-0.5	2.15e-18	Refractive error;
CESC	cis	rs873946	0.648	rs12766166	chr10:134556403	G/C	cg18305652	chr10:134549665	INPP5A	0.5	7.25	0.41	4.67e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11744524	chr6:4078970	C6orf146;C6orf201	-0.55	-6.39	-0.37	7.47e-10	Gut microbiome composition (summer);
CESC	cis	rs3925075	1.000	rs9673404	chr16:31347592	A/T	cg02846316	chr16:31340340	ITGAM	0.41	6.52	0.37	3.54e-10	IgA nephropathy;
CESC	cis	rs17376456	0.877	rs10035340	chr5:93490465	C/T	cg25358565	chr5:93447407	FAM172A	1.17	10.96	0.56	2.63e-23	Diabetic retinopathy;
CESC	cis	rs739401	0.611	rs2301140	chr11:3022629	C/T	cg25174290	chr11:3078921	CARS	0.55	7.02	0.4	1.87e-11	Longevity;
CESC	cis	rs992157	0.710	rs7569907	chr2:219070551	C/T	cg00012203	chr2:219082015	ARPC2	0.86	12.41	0.61	3.6e-28	Colorectal cancer;
CESC	cis	rs12822507	0.732	rs10845586	chr12:12751662	A/G	cg11838227	chr12:12764436	CREBL2	-0.4	-5.5	-0.32	9.06e-8	Systemic lupus erythematosus;
CESC	trans	rs10905099	0.708	rs71481705	chr10:7091857	G/A	cg05230642	chr15:25439252	SNORD115-14	-0.73	-6.13	-0.35	3.15e-9	Orofacial clefts;
CESC	cis	rs113835537	0.529	rs7928882	chr11:66234765	C/T	cg24851651	chr11:66362959	CCS	0.46	5.68	0.33	3.57e-8	Airway imaging phenotypes;
CESC	cis	rs1865721	0.755	rs3213875	chr18:73184048	C/T	cg26385618	chr18:73139727	C18orf62	-0.41	-6.74	-0.38	9.86e-11	Intelligence;
CESC	cis	rs9896933	0.830	rs113051447	chr17:80791806	A/G	cg19500275	chr17:80737654	TBCD	0.49	5.14	0.3	5.39e-7	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
CESC	cis	rs317689	0.513	rs529268	chr12:69687051	G/A	cg14784868	chr12:69753453	YEATS4	0.53	6.57	0.37	2.72e-10	Response to diuretic therapy;
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg21553154	chr22:36784489	MYH9	-0.47	-7.07	-0.4	1.39e-11	Vertical cup-disc ratio;
CESC	cis	rs736408	0.812	rs1076425	chr3:52825462	A/G	cg07507251	chr3:52567010	NT5DC2	0.34	5.46	0.32	1.1e-7	Bipolar disorder;
CESC	cis	rs34311866	0.808	rs62294491	chr4:969111	C/T	cg07828340	chr4:882639	GAK	0.86	6.68	0.38	1.37e-10	Parkinson's disease;
CESC	cis	rs10752881	1.000	rs12753817	chr1:182970337	A/T	ch.1.3577855R	chr1:183094577	LAMC1	0.85	13.6	0.64	2.54e-32	Colorectal cancer;
CESC	cis	rs941207	0.526	rs2255074	chr12:57030026	T/C	cg05584118	chr12:57595605	LRP1	0.38	5.34	0.31	2.02e-7	Platelet count;
CESC	cis	rs61776719	0.500	rs11210866	chr1:38449565	T/C	cg12658694	chr1:38397304	INPP5B	0.65	9.42	0.5	2.36e-18	Coronary artery disease;
CESC	cis	rs1799949	1.000	rs8176133	chr17:41257458	A/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.64	8.72	0.47	3.18e-16	Menopause (age at onset);
CESC	cis	rs6940638	0.688	rs7744759	chr6:27119826	G/A	cg12292205	chr6:26970375	C6orf41	-0.41	-5.51	-0.32	8.42e-8	Intelligence (multi-trait analysis);
CESC	cis	rs6460942	0.597	rs6977059	chr7:12535157	T/G	cg06484146	chr7:12443880	VWDE	-0.73	-7.77	-0.43	1.68e-13	Coronary artery disease;
CESC	cis	rs933688	0.536	rs332537	chr5:90794973	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	-0.81	-7.48	-0.42	1.09e-12	Smoking behavior;
CESC	cis	rs875971	0.790	rs10257911	chr7:65743770	A/G	cg12463550	chr7:65579703	CRCP	-0.47	-5.96	-0.34	7.88e-9	Aortic root size;
CESC	cis	rs9660992	0.662	rs12092492	chr1:205251880	T/C	cg21643547	chr1:205240462	TMCC2	-0.48	-6.94	-0.39	2.92e-11	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs34779708	0.702	rs4007272	chr10:35546859	T/G	cg04310649	chr10:35416472	CREM	-0.45	-5.14	-0.3	5.34e-7	Inflammatory bowel disease;Crohn's disease;
CESC	trans	rs7726839	0.540	rs55929359	chr5:595956	C/G	cg25482853	chr8:67687455	SGK3	1.02	9.86	0.52	1e-19	Obesity-related traits;
CESC	cis	rs10504229	0.683	rs6982990	chr8:58115275	C/T	cg21724239	chr8:58056113	NA	-0.58	-5.95	-0.34	8.37e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs7264396	0.563	rs3827029	chr20:34332784	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.84	10.63	0.55	3.3e-22	Total cholesterol levels;
CESC	cis	rs11718455	1.000	rs1524885	chr3:44031847	G/A	cg08738300	chr3:44038990	NA	0.48	6.41	0.37	6.74e-10	Coronary artery disease;
CESC	cis	rs7165102	1.000	rs11637431	chr15:65882251	T/C	cg11441148	chr15:65824328	PTPLAD1	0.32	5.39	0.31	1.53e-7	Mean corpuscular hemoglobin;
CESC	cis	rs644799	0.511	rs10831420	chr11:95478209	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.65	9.15	0.49	1.62e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs1799949	1.000	rs1960605	chr17:41305397	C/T	cg05368731	chr17:41323189	NBR1	0.79	11.23	0.57	3.39e-24	Menopause (age at onset);
CESC	cis	rs9527	0.545	rs10218853	chr10:104796787	A/C	cg04362960	chr10:104952993	NT5C2	0.45	5.78	0.33	2.07e-8	Arsenic metabolism;
CESC	cis	rs798554	0.797	rs1182174	chr7:2875420	G/A	cg09658497	chr7:2847517	GNA12	-0.43	-6.2	-0.36	2.17e-9	Height;
CESC	cis	rs2836974	0.897	rs12481860	chr21:40537836	T/A	cg11644478	chr21:40555479	PSMG1	1.03	16.81	0.72	1.13e-43	Cognitive function;
CESC	trans	rs17764205	0.777	rs28729385	chr19:3258882	T/C	cg27384338	chr17:2031545	SMG6	-0.75	-6.09	-0.35	3.9e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs4253772	0.591	rs6520010	chr22:46721223	G/A	cg09491104	chr22:46646882	C22orf40	-0.59	-8.67	-0.47	4.32e-16	LDL cholesterol;Cholesterol, total;
CESC	cis	rs7617773	0.779	rs11718329	chr3:48309828	C/G	cg11946769	chr3:48343235	NME6	0.77	10.14	0.53	1.25e-20	Coronary artery disease;
CESC	cis	rs873946	0.564	rs2803991	chr10:134557068	A/G	cg27286337	chr10:134555280	INPP5A	0.68	8.6	0.47	7.11e-16	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs950776	0.684	rs61012457	chr15:78865694	C/G	cg06917634	chr15:78832804	PSMA4	0.61	7.5	0.42	9.8e-13	Sudden cardiac arrest;
CESC	cis	rs7666738	0.830	rs11932887	chr4:99072965	C/G	cg03676636	chr4:99064102	C4orf37	0.34	5.07	0.3	7.47e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9916302	0.706	rs11657153	chr17:37699729	A/G	cg07936489	chr17:37558343	FBXL20	-0.98	-11.47	-0.58	5.54e-25	Glomerular filtration rate (creatinine);
CESC	cis	rs854765	0.583	rs8078138	chr17:17811251	C/T	cg09796270	chr17:17721594	SREBF1	0.46	6.39	0.37	7.34e-10	Total body bone mineral density;
CESC	cis	rs6540559	0.808	rs11119358	chr1:210042456	T/C	cg22029157	chr1:209979665	IRF6	0.69	9.02	0.48	3.96e-17	Cleft lip with or without cleft palate;
CESC	cis	rs7659604	1.000	rs6816071	chr4:122665185	G/A	cg19671926	chr4:122722719	EXOSC9	-0.49	-5.89	-0.34	1.14e-8	Type 2 diabetes;
CESC	trans	rs11098499	0.909	rs11723839	chr4:120299673	G/A	cg25214090	chr10:38739885	LOC399744	0.68	9.16	0.49	1.46e-17	Corneal astigmatism;
CESC	cis	rs3793683	0.520	rs4880426	chr10:134590610	G/A	cg27297192	chr10:134578999	INPP5A	0.4	5.42	0.32	1.36e-7	Migraine;
CESC	cis	rs9733	0.569	rs11204691	chr1:150644339	A/T	cg18016565	chr1:150552671	MCL1	0.33	5.16	0.3	4.96e-7	Tonsillectomy;
CESC	cis	rs8044868	0.512	rs10048144	chr16:72052891	C/G	cg01557791	chr16:72042693	DHODH	-0.42	-5.65	-0.33	4.14e-8	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CESC	cis	rs6424115	1.000	rs1018396	chr1:24133612	G/A	cg15997130	chr1:24165203	NA	0.44	6.2	0.36	2.18e-9	Immature fraction of reticulocytes;
CESC	cis	rs2354432	0.607	rs2353999	chr1:146830686	T/C	cg25205988	chr1:146714368	CHD1L	-0.99	-8.69	-0.47	3.77e-16	Mitochondrial DNA levels;
CESC	cis	rs17253792	0.822	rs77555779	chr14:56078430	A/G	cg01858014	chr14:56050164	KTN1	-0.93	-7.33	-0.41	2.71e-12	Putamen volume;
CESC	cis	rs7618915	0.570	rs2336145	chr3:52629750	A/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	5.57	0.32	6.26e-8	Bipolar disorder;
CESC	cis	rs2952156	0.920	rs1476278	chr17:37836243	C/T	cg20243544	chr17:37824526	PNMT	0.64	8.63	0.47	5.62e-16	Asthma;
CESC	trans	rs7618501	1.000	rs7374277	chr3:49784777	T/C	cg21659725	chr3:3221576	CRBN	-0.83	-13.35	-0.63	1.98e-31	Intelligence (multi-trait analysis);
CESC	cis	rs9908102	0.770	rs8071726	chr17:12914584	C/T	cg26162695	chr17:12921313	ELAC2	0.53	6.12	0.35	3.26e-9	Schizophrenia;
CESC	cis	rs873946	0.586	rs12782567	chr10:134576709	C/G	cg27297192	chr10:134578999	INPP5A	-0.39	-5.19	-0.3	4.12e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs861020	0.606	rs629224	chr1:210005071	C/T	cg05527609	chr1:210001259	C1orf107	0.73	9.55	0.51	9.08e-19	Orofacial clefts;
CESC	trans	rs877282	0.853	rs7069720	chr10:754487	A/G	cg22713356	chr15:30763199	NA	0.93	8.39	0.46	3e-15	Uric acid levels;
CESC	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg16132339	chr22:24313637	DDTL;DDT	0.38	5.84	0.34	1.52e-8	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs6032067	0.929	rs2868238	chr20:43826993	C/G	cg10761708	chr20:43804764	PI3	0.53	6.39	0.37	7.37e-10	Blood protein levels;
CESC	cis	rs1126510	0.897	rs9304662	chr19:47121745	A/G	cg07844738	chr19:47129343	PTGIR	0.32	5.11	0.3	6.08e-7	Ulcerative colitis;
CESC	cis	rs1707322	1.000	rs10890376	chr1:46406582	C/T	cg05343316	chr1:45956843	TESK2	0.5	6.13	0.35	3.11e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs10979	0.931	rs9403509	chr6:143888691	G/A	cg25407410	chr6:143891975	LOC285740	-0.61	-9.14	-0.49	1.72e-17	Hypospadias;
CESC	cis	rs921968	0.565	rs12611632	chr2:219621258	C/T	cg02176678	chr2:219576539	TTLL4	-0.44	-7.67	-0.43	3.29e-13	Mean corpuscular hemoglobin concentration;
CESC	cis	rs7523050	0.643	rs7551313	chr1:109399881	G/A	cg08274380	chr1:109419600	GPSM2	0.83	5.58	0.32	5.89e-8	Fat distribution (HIV);
CESC	cis	rs6741892	0.536	rs6761563	chr2:38891406	A/T	cg08308459	chr2:38893161	GALM	-0.55	-6.75	-0.38	9.44e-11	5-HTT brain serotonin transporter levels;
CESC	cis	rs2857078	0.654	rs9896789	chr17:42314567	C/T	cg08499158	chr17:42289980	UBTF	-0.49	-6.02	-0.35	5.77e-9	Red cell distribution width;Reticulocyte count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26398656	chr18:21852327	OSBPL1A	-0.52	-6.27	-0.36	1.43e-9	Gut microbiome composition (summer);
CESC	cis	rs4268898	0.552	rs11125455	chr2:24374557	C/G	cg20701182	chr2:24300061	SF3B14	-0.38	-5.28	-0.31	2.72e-7	Asthma;
CESC	cis	rs7617773	0.780	rs34589064	chr3:48339549	G/A	cg11946769	chr3:48343235	NME6	0.89	12.11	0.6	3.63e-27	Coronary artery disease;
CESC	cis	rs1784581	0.851	rs1784591	chr6:162388893	C/G	cg17173639	chr6:162384350	PARK2	-0.82	-13.59	-0.64	2.74e-32	Itch intensity from mosquito bite;
CESC	trans	rs3741489	1.000	rs2062161	chr12:133428032	G/A	cg24132527	chr5:140019269	TMCO6	1.1	7.42	0.41	1.61e-12	Cognitive function;
CESC	cis	rs2249694	0.960	rs7084384	chr10:135412322	A/G	cg20169779	chr10:135381914	SYCE1	-0.4	-5.65	-0.33	4.05e-8	Obesity-related traits;
CESC	trans	rs12356475	0.710	rs10822686	chr10:67733250	C/T	cg09472203	chr15:83378614	AP3B2	0.49	6.12	0.35	3.4e-9	Psoriatic arthritis;
CESC	cis	rs7814319	0.901	rs13253635	chr8:97240847	A/G	cg20787634	chr8:97240163	UQCRB	-0.63	-8.2	-0.45	1.03e-14	Lung function (FVC);
CESC	cis	rs6964587	0.967	rs12671991	chr7:91559481	T/C	cg17063962	chr7:91808500	NA	-0.59	-7.88	-0.44	8.67e-14	Breast cancer;
CESC	cis	rs75229567	0.717	rs77874289	chr12:70234203	A/G	cg10114359	chr12:70132523	RAB3IP	0.89	6.44	0.37	5.52e-10	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
CESC	cis	rs4076764	0.846	rs12036398	chr1:163422204	C/T	cg24596788	chr1:163392923	NA	0.4	5.63	0.33	4.55e-8	Motion sickness;
CESC	trans	rs1728785	1.000	rs1170429	chr16:68604126	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.65	7.93	0.44	6e-14	Ulcerative colitis;
CESC	trans	rs9325144	0.556	rs34565156	chr12:39028239	G/A	cg23762105	chr12:34175262	ALG10	0.47	6.1	0.35	3.73e-9	Morning vs. evening chronotype;
CESC	cis	rs2836974	0.544	rs8128919	chr21:40711862	C/T	cg11890956	chr21:40555474	PSMG1	0.69	9.49	0.5	1.38e-18	Cognitive function;
CESC	cis	rs854765	0.583	rs11650890	chr17:17790882	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.52	-7.21	-0.4	5.86e-12	Total body bone mineral density;
CESC	cis	rs2404602	0.692	rs35999717	chr15:77193367	G/C	cg26408565	chr15:76604113	ETFA	-0.39	-5.68	-0.33	3.56e-8	Blood metabolite levels;
CESC	trans	rs11098499	0.954	rs13107475	chr4:120393011	A/T	cg25214090	chr10:38739885	LOC399744	0.71	10.33	0.54	3.07e-21	Corneal astigmatism;
CESC	cis	rs17253792	0.822	rs77415412	chr14:56154146	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.81	5.68	0.33	3.46e-8	Putamen volume;
CESC	cis	rs2066819	1.000	rs77120931	chr12:56646213	A/C	cg26714650	chr12:56694279	CS	-1.43	-10.51	-0.54	7.79e-22	Psoriasis vulgaris;
CESC	cis	rs11098499	0.954	rs12502423	chr4:120424172	A/C	cg09307838	chr4:120376055	NA	0.93	13.0	0.62	3.31e-30	Corneal astigmatism;
CESC	cis	rs548181	0.536	rs503288	chr11:125461787	C/T	cg03464685	chr11:125439445	EI24	-0.94	-8.74	-0.47	2.7e-16	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs1005277	0.528	rs2057228	chr10:38515766	T/C	cg25517755	chr10:38738941	LOC399744	-0.44	-5.7	-0.33	3.12e-8	Extrinsic epigenetic age acceleration;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg20574949	chr11:9336117	TMEM41B	0.47	6.21	0.36	2.06e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs35306767	0.715	rs12777801	chr10:1036285	T/A	cg25019033	chr10:957182	NA	-0.6	-5.84	-0.34	1.54e-8	Eosinophil percentage of granulocytes;
CESC	cis	rs896854	0.653	rs13266313	chr8:95975302	C/T	cg13393036	chr8:95962371	TP53INP1	-0.49	-10.52	-0.54	7.38e-22	Type 2 diabetes;
CESC	cis	rs863345	0.604	rs10908660	chr1:158466189	G/A	cg12129480	chr1:158549410	OR10X1	-0.36	-7.13	-0.4	9.54e-12	Pneumococcal bacteremia;
CESC	trans	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg13565492	chr6:43139072	SRF	-0.75	-9.04	-0.49	3.45e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs9611565	0.659	rs9611604	chr22:41916001	C/G	cg06634786	chr22:41940651	POLR3H	-0.7	-7.15	-0.4	8.38e-12	Vitiligo;
CESC	cis	rs7432375	0.641	rs835649	chr3:136671890	G/A	cg15507776	chr3:136538369	TMEM22	0.59	7.58	0.42	5.7e-13	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
CESC	cis	rs3785574	0.962	rs35448669	chr17:61938923	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.58	7.44	0.42	1.41e-12	Height;
CESC	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg18402987	chr7:1209562	NA	0.59	7.0	0.4	2.06e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7561273	0.586	rs4149372	chr2:24305512	T/G	cg20701182	chr2:24300061	SF3B14	0.52	6.67	0.38	1.45e-10	Quantitative traits;
CESC	trans	rs12356475	0.710	rs10822686	chr10:67733250	C/T	cg01925094	chr20:36322369	CTNNBL1	0.52	6.0	0.35	6.47e-9	Psoriatic arthritis;
CESC	cis	rs317689	0.581	rs160829	chr12:69769538	G/C	cg14784868	chr12:69753453	YEATS4	0.73	9.61	0.51	6.01e-19	Response to diuretic therapy;
CESC	cis	rs7220401	0.512	rs2289629	chr17:27959903	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.55	5.84	0.34	1.53e-8	Coronary artery disease;
CESC	cis	rs17384381	0.953	rs3768223	chr1:85809183	T/C	cg16011679	chr1:85725395	C1orf52	0.8	8.2	0.45	1.03e-14	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9649213	0.593	rs11760930	chr7:97915789	G/A	cg21770322	chr7:97807741	LMTK2	0.55	8.0	0.44	3.92e-14	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs9322193	0.847	rs880246	chr6:150167108	G/A	cg09699651	chr6:150184138	LRP11	0.45	5.46	0.32	1.11e-7	Lung cancer;
CESC	cis	rs10752881	1.000	rs4402094	chr1:182986441	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.84	13.3	0.63	2.79e-31	Colorectal cancer;
CESC	cis	rs6061231	0.505	rs13037253	chr20:60928724	G/A	cg24112000	chr20:60950667	NA	-0.51	-6.31	-0.36	1.16e-9	Colorectal cancer;
CESC	cis	rs950776	0.518	rs4887063	chr15:78839715	C/T	cg06917634	chr15:78832804	PSMA4	-0.73	-10.45	-0.54	1.24e-21	Sudden cardiac arrest;
CESC	trans	rs60380162	0.963	rs72725861	chr1:87726780	C/T	cg20163645	chr8:1900353	ARHGEF10	-0.43	-6.03	-0.35	5.48e-9	Loneliness (linear analysis);
CESC	cis	rs8072100	0.576	rs12948299	chr17:45403057	T/C	cg25173405	chr17:45401733	C17orf57	-0.5	-5.85	-0.34	1.47e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs17433780	0.504	rs6428494	chr1:89472196	C/T	cg09516651	chr1:89888402	LOC400759	0.48	6.71	0.38	1.17e-10	Carotid intima media thickness;
CESC	cis	rs12477438	0.798	rs6705821	chr2:99602832	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.75	-10.87	-0.56	5.17e-23	Chronic sinus infection;
CESC	cis	rs10832963	1.000	rs10832962	chr11:18656271	C/T	cg09201001	chr11:18656081	SPTY2D1	0.82	12.42	0.61	3.32e-28	Breast cancer;
CESC	cis	rs73206853	0.563	rs73194032	chr12:111162182	G/A	cg12870014	chr12:110450643	ANKRD13A	0.64	5.66	0.33	3.91e-8	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs7771547	0.573	rs544267	chr6:36398302	A/G	cg04289385	chr6:36355825	ETV7	0.38	5.57	0.32	6.41e-8	Platelet distribution width;
CESC	cis	rs3858526	0.839	rs10466484	chr11:5943696	A/G	cg13902645	chr11:5959945	NA	-0.66	-7.93	-0.44	6.29e-14	DNA methylation (variation);
CESC	cis	rs9943465	0.688	rs318929	chr10:132071772	T/C	cg12765123	chr10:132100019	NA	0.42	5.13	0.3	5.64e-7	Epstein-Barr virus copy number in lymphoblastoid cell lines;
CESC	cis	rs919433	0.963	rs6738836	chr2:198182432	A/G	cg03934865	chr2:198174659	NA	-0.4	-5.46	-0.32	1.09e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs7833986	0.534	rs17814089	chr8:56965563	A/G	cg26371346	chr8:56986568	SNORD54;RPS20	-0.57	-5.21	-0.3	3.82e-7	Height;
CESC	cis	rs1729951	0.575	rs361244	chr3:136697506	C/T	cg04103450	chr3:136751342	NA	0.4	5.35	0.31	1.92e-7	Neuroticism;
CESC	cis	rs4588572	0.688	rs2115436	chr5:77692617	A/T	cg11547950	chr5:77652471	NA	-0.42	-5.94	-0.34	8.76e-9	Triglycerides;
CESC	cis	rs265548	0.608	rs36690	chr19:17910483	C/T	cg21960279	chr19:17905606	B3GNT3	0.48	7.09	0.4	1.22e-11	Tumor biomarkers;
CESC	cis	rs2380220	0.606	rs4559095	chr6:95994154	A/C	cg23517279	chr6:96025343	MANEA	0.51	5.54	0.32	7.25e-8	Behavioural disinhibition (generation interaction);
CESC	cis	rs4660306	0.961	rs2991966	chr1:45999503	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.6	-7.58	-0.42	5.74e-13	Homocysteine levels;
CESC	trans	rs7178375	1.000	rs7169064	chr15:31210862	C/T	cg04373760	chr16:53404718	NA	0.53	7.19	0.4	6.74e-12	Hypertriglyceridemia;
CESC	cis	rs9287719	0.967	rs12622765	chr2:10728331	T/C	cg02196655	chr2:10830764	NOL10	-0.36	-5.57	-0.32	6.1e-8	Prostate cancer;
CESC	cis	rs7786808	0.525	rs10253961	chr7:158194858	G/A	cg09998033	chr7:158218633	PTPRN2	0.35	5.37	0.31	1.73e-7	Obesity-related traits;
CESC	cis	rs6088590	1.000	rs6087625	chr20:33342477	A/G	cg24642439	chr20:33292090	TP53INP2	-0.85	-11.88	-0.59	2.28e-26	Coronary artery disease;
CESC	cis	rs7084402	0.565	rs10826200	chr10:60333847	T/C	cg07615347	chr10:60278583	BICC1	0.38	5.45	0.32	1.17e-7	Refractive error;
CESC	cis	rs7296418	0.961	rs7957096	chr12:123544878	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.35	-5.47	-0.32	1.03e-7	Platelet count;
CESC	cis	rs9733	0.596	rs72702570	chr1:150688196	C/T	cg18016565	chr1:150552671	MCL1	0.35	5.36	0.31	1.86e-7	Tonsillectomy;
CESC	cis	rs2066819	1.000	rs75754909	chr12:56726349	A/G	cg26714650	chr12:56694279	CS	-1.39	-9.17	-0.49	1.33e-17	Psoriasis vulgaris;
CESC	cis	rs644799	0.542	rs10831416	chr11:95467220	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.42	5.3	0.31	2.48e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05162533	chr17:74137399	FOXJ1	-0.58	-6.61	-0.38	2.05e-10	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00033668	chr12:15942561	EPS8	0.53	6.03	0.35	5.56e-9	Gut microbiome composition (summer);
CESC	cis	rs6594713	0.717	rs10056194	chr5:112857862	T/G	cg12552261	chr5:112820674	MCC	0.55	5.55	0.32	6.78e-8	Brain cytoarchitecture;
CESC	cis	rs514406	0.861	rs12141260	chr1:53300127	C/T	cg08736216	chr1:53307985	ZYG11A	-0.43	-7.17	-0.4	7.3e-12	Monocyte count;
CESC	cis	rs2637266	1.000	rs2395386	chr10:78341623	C/T	cg18941641	chr10:78392320	NA	0.38	7.16	0.4	7.8e-12	Pulmonary function;
CESC	cis	rs6987853	0.787	rs12677427	chr8:42414226	T/A	cg09913449	chr8:42400586	C8orf40	0.45	7.44	0.42	1.39e-12	Mean corpuscular hemoglobin concentration;
CESC	cis	rs3796352	1.000	rs11712653	chr3:53070875	A/C	cg12962167	chr3:53033115	SFMBT1	-0.6	-5.45	-0.32	1.16e-7	Immune reponse to smallpox (secreted IL-2);
CESC	cis	rs736408	0.509	rs1108842	chr3:52720080	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.48	7.6	0.42	5.06e-13	Bipolar disorder;
CESC	cis	rs5753618	0.504	rs5753671	chr22:31910734	T/C	cg00478049	chr22:31556069	RNF185	-0.46	-5.59	-0.32	5.63e-8	Colorectal cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13627451	chr15:52043674	TMOD2;LYSMD2	0.6	7.21	0.4	5.73e-12	Gut microbiome composition (summer);
CESC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg23284323	chr21:40685679	BRWD1	0.42	6.08	0.35	4.08e-9	Tetralogy of Fallot;
CESC	cis	rs6963495	0.818	rs73192125	chr7:105175068	A/C	cg02135003	chr7:105160482	PUS7	-0.44	-5.62	-0.33	4.79e-8	Bipolar disorder (body mass index interaction);
CESC	cis	rs10751667	0.643	rs10902244	chr11:949981	A/G	cg06064525	chr11:970664	AP2A2	-0.49	-9.81	-0.52	1.42e-19	Alzheimer's disease (late onset);
CESC	cis	rs736408	0.522	rs11716747	chr3:52748857	C/T	cg05564831	chr3:52568323	NT5DC2	0.45	7.01	0.4	2.03e-11	Bipolar disorder;
CESC	cis	rs2249694	1.000	rs4240522	chr10:135355557	C/T	cg20169779	chr10:135381914	SYCE1	0.42	5.74	0.33	2.58e-8	Obesity-related traits;
CESC	cis	rs10504229	0.871	rs56372514	chr8:58157166	A/G	cg24829409	chr8:58192753	C8orf71	-0.63	-8.33	-0.46	4.44e-15	Developmental language disorder (linguistic errors);
CESC	cis	rs10791097	0.720	rs4936121	chr11:130733878	A/G	cg12179176	chr11:130786555	SNX19	0.65	9.92	0.52	6.44e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs9322193	0.632	rs3828700	chr6:150112169	C/G	cg05861140	chr6:150128134	PCMT1	-0.37	-5.29	-0.31	2.52e-7	Lung cancer;
CESC	cis	rs1062177	0.951	rs2915876	chr5:151150745	C/A	cg12924095	chr5:151150029	G3BP1	0.48	6.14	0.35	2.94e-9	Preschool internalizing problems;
CESC	cis	rs5760092	0.618	rs4461358	chr22:24260106	T/C	cg11905131	chr22:24372483	LOC391322	0.64	8.02	0.44	3.34e-14	Urinary 1,3-butadiene metabolite levels in smokers;
CESC	cis	rs6681460	0.901	rs1570815	chr1:67139667	C/T	cg02459107	chr1:67143332	SGIP1	0.38	5.25	0.31	3.16e-7	Presence of antiphospholipid antibodies;
CESC	cis	rs6736093	0.933	rs4848229	chr2:112692650	C/A	cg12686935	chr2:112915763	FBLN7	-0.44	-5.72	-0.33	2.86e-8	Coronary artery disease;
CESC	cis	rs853679	0.517	rs9393897	chr6:28127710	G/T	cg12963246	chr6:28129442	ZNF389	0.56	7.4	0.41	1.8e-12	Depression;
CESC	cis	rs644799	0.526	rs530914	chr11:95632156	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.46	6.03	0.35	5.51e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs6952808	0.531	rs3778991	chr7:2172455	G/A	cg02951883	chr7:2050386	MAD1L1	-0.51	-6.62	-0.38	2.04e-10	Bipolar disorder and schizophrenia;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg01669482	chr16:25043131	NA	0.55	7.17	0.4	7.37e-12	Gut microbiota (bacterial taxa);
CESC	cis	rs4689388	0.926	rs10937720	chr4:6295451	A/G	cg00701064	chr4:6280414	WFS1	0.68	11.71	0.58	8.68e-26	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs873946	0.564	rs12263364	chr10:134555548	G/T	cg27297192	chr10:134578999	INPP5A	0.37	5.05	0.3	8.04e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs9916302	0.904	rs2168785	chr17:37407135	C/T	cg00129232	chr17:37814104	STARD3	-0.57	-7.49	-0.42	1.01e-12	Glomerular filtration rate (creatinine);
CESC	cis	rs2985684	1.000	rs17121651	chr14:50097172	T/C	cg10008539	chr14:50087325	RPL36AL;MGAT2	-0.43	-5.14	-0.3	5.39e-7	Carotid intima media thickness;
CESC	cis	rs172166	0.611	rs203883	chr6:28078356	A/G	cg23161317	chr6:28129485	ZNF389	0.4	5.69	0.33	3.29e-8	Cardiac Troponin-T levels;
CESC	cis	rs796364	0.865	rs769948	chr2:200728475	C/A	cg23649088	chr2:200775458	C2orf69	0.54	5.1	0.3	6.38e-7	Schizophrenia;
CESC	cis	rs9905704	0.627	rs1267544	chr17:56643398	T/G	cg12560992	chr17:57184187	TRIM37	-0.61	-6.3	-0.36	1.24e-9	Testicular germ cell tumor;
CESC	cis	rs9487051	0.799	rs351724	chr6:109546577	T/C	cg01475377	chr6:109611718	NA	-0.38	-5.74	-0.33	2.63e-8	Reticulocyte fraction of red cells;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02580404	chr16:19729857	C16orf88;IQCK	0.57	6.61	0.38	2.11e-10	Gut microbiome composition (summer);
CESC	cis	rs1801251	0.778	rs2675967	chr2:233736133	C/G	cg25237894	chr2:233734115	C2orf82	-0.58	-9.36	-0.5	3.54e-18	Coronary artery disease;
CESC	cis	rs34638657	0.702	rs12599946	chr16:82199831	T/C	cg09439754	chr16:82129088	HSD17B2	-0.37	-6.42	-0.37	6.31e-10	Lung adenocarcinoma;
CESC	cis	rs2820292	0.619	rs41299585	chr1:201853165	G/T	cg11586189	chr1:201857591	SHISA4	-0.37	-5.91	-0.34	1.06e-8	Waist circumference;Body mass index (joint analysis main effects and smoking interaction);Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg21595526	chr15:50647267	GABPB1;LOC100129387;FLJ10038	-0.49	-6.26	-0.36	1.58e-9	Asthma;
CESC	cis	rs55728055	0.661	rs75785548	chr22:31991363	C/T	cg01338084	chr22:32026380	PISD	1.22	8.02	0.44	3.48e-14	Age-related hearing impairment;
CESC	cis	rs4713118	0.662	rs149901	chr6:27965503	C/T	cg23281280	chr6:28129359	ZNF389	0.47	6.51	0.37	3.76e-10	Parkinson's disease;
CESC	cis	rs9467711	0.606	rs9358937	chr6:26374274	C/G	cg14345882	chr6:26364793	BTN3A2	0.59	5.92	0.34	1.01e-8	Autism spectrum disorder or schizophrenia;
CESC	cis	rs963731	0.649	rs297140	chr2:39319121	A/G	cg04010122	chr2:39346883	SOS1	-0.74	-5.39	-0.31	1.54e-7	Corticobasal degeneration;
CESC	cis	rs9322193	0.923	rs7753812	chr6:150011286	C/T	cg04369109	chr6:150039330	LATS1	-0.37	-5.07	-0.3	7.4e-7	Lung cancer;
CESC	cis	rs17376456	0.877	rs34595581	chr5:93369422	G/A	cg21475434	chr5:93447410	FAM172A	0.8	6.98	0.39	2.35e-11	Diabetic retinopathy;
CESC	cis	rs780096	0.506	rs2950834	chr2:27627366	G/A	cg02592271	chr2:27665507	KRTCAP3	-0.28	-5.61	-0.33	5.22e-8	Total body bone mineral density;
CESC	cis	rs2486288	0.656	rs1719232	chr15:45572072	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.62	-7.26	-0.41	4.19e-12	Glomerular filtration rate;
CESC	cis	rs1008375	0.902	rs7654332	chr4:17691778	A/T	cg16339924	chr4:17578868	LAP3	0.63	7.67	0.43	3.27e-13	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs2932538	0.922	rs12402469	chr1:113076625	G/A	cg22162597	chr1:113214053	CAPZA1	0.53	6.59	0.38	2.32e-10	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CESC	cis	rs3785574	0.962	rs2247435	chr17:61892862	G/A	cg06420487	chr17:61919686	SMARCD2	0.44	5.28	0.31	2.68e-7	Height;
CESC	cis	rs7020830	0.861	rs2291589	chr9:37079661	T/G	cg14294708	chr9:37120828	ZCCHC7	1.26	25.15	0.84	3.81e-72	Schizophrenia;
CESC	cis	rs35110281	0.627	rs6518268	chr21:44967448	A/G	cg21573476	chr21:45109991	RRP1B	-0.38	-5.23	-0.31	3.44e-7	Mean corpuscular volume;
CESC	cis	rs1790761	0.772	rs36089024	chr11:67244644	C/T	cg14500267	chr11:67383377	NA	-0.31	-5.13	-0.3	5.61e-7	Mean corpuscular volume;
CESC	cis	rs1153858	1.000	rs12909158	chr15:45621174	A/G	cg14582100	chr15:45693742	SPATA5L1	0.41	5.71	0.33	3.08e-8	Homoarginine levels;
CESC	cis	rs7666738	0.830	rs28522896	chr4:99008243	C/T	cg03467027	chr4:99064603	C4orf37	0.44	5.51	0.32	8.65e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg24846343	chr22:24311635	DDTL	0.59	9.51	0.5	1.21e-18	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs1580019	0.587	rs34488151	chr7:32548146	A/G	cg06627557	chr7:32535165	LSM5;AVL9	1.06	18.8	0.76	1.12e-50	Cognitive ability;
CESC	cis	rs787274	1.000	rs787301	chr9:115542737	G/T	cg13803584	chr9:115635662	SNX30	0.55	5.27	0.31	2.9e-7	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs7666738	0.830	rs17550735	chr4:99014076	T/G	cg17366294	chr4:99064904	C4orf37	0.6	8.62	0.47	6.37e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs28386778	0.700	rs12449555	chr17:62003982	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.57	-7.04	-0.4	1.63e-11	Prudent dietary pattern;
CESC	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg12419862	chr22:24373484	LOC391322	-0.82	-12.14	-0.6	2.98e-27	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs3793683	0.545	rs12784446	chr10:134589094	T/G	cg27286337	chr10:134555280	INPP5A	0.63	7.29	0.41	3.62e-12	Migraine;
CESC	cis	rs1008375	1.000	rs11724495	chr4:17621310	G/A	cg04450456	chr4:17643702	FAM184B	0.37	5.29	0.31	2.51e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs763121	0.814	rs5757212	chr22:39053757	G/C	cg21395723	chr22:39101663	GTPBP1	0.5	6.72	0.38	1.1e-10	Menopause (age at onset);
CESC	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.63	0.38	1.89e-10	Prudent dietary pattern;
CESC	cis	rs13191362	0.507	rs2849534	chr6:163144657	T/A	cg21926612	chr6:163149169	PACRG;PARK2	-0.51	-6.1	-0.35	3.7e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg01159515	chr5:127420616	SLC12A2	-0.48	-6.2	-0.36	2.1e-9	Thyroid stimulating hormone;
CESC	cis	rs1062177	1.000	rs2964578	chr5:151147198	T/A	cg12924095	chr5:151150029	G3BP1	0.48	6.15	0.35	2.82e-9	Preschool internalizing problems;
CESC	cis	rs2014572	0.967	rs10412975	chr19:57770554	C/A	cg24459738	chr19:57751996	ZNF805	-0.53	-7.46	-0.42	1.23e-12	Hyperactive-impulsive symptoms;
CESC	cis	rs6499255	0.951	rs7200935	chr16:69564497	T/C	cg15192750	chr16:69999425	NA	0.55	6.43	0.37	6.07e-10	IgE levels;
CESC	cis	rs9486719	0.552	rs9399923	chr6:96850379	G/A	cg18709589	chr6:96969512	KIAA0776	0.44	5.15	0.3	5.19e-7	Migraine;Coronary artery disease;
CESC	cis	rs2816062	0.775	rs2816046	chr1:18893708	A/G	cg18795169	chr1:18902165	NA	-0.9	-17.73	-0.74	6.5e-47	Urate levels in lean individuals;
CESC	cis	rs13095912	0.512	rs115865582	chr3:185308598	A/C	cg11274856	chr3:185301563	NA	0.36	5.34	0.31	1.95e-7	Systolic blood pressure;
CESC	trans	rs13360092	0.764	rs9283700	chr5:50561921	T/C	cg03200537	chr16:87022121	NA	0.68	6.0	0.35	6.57e-9	Verbal declarative memory;
CESC	cis	rs17253792	0.732	rs28380739	chr14:56088402	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.79	5.91	0.34	1.06e-8	Putamen volume;
CESC	trans	rs801193	1.000	rs62466793	chr7:66191517	G/A	cg26939375	chr7:64535504	NA	0.64	8.77	0.47	2.19e-16	Aortic root size;
CESC	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg18538332	chr22:24372958	LOC391322	-0.71	-10.34	-0.54	2.74e-21	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs4955124	0.558	rs62244405	chr3:32037605	G/A	cg05935571	chr3:32023257	ZNF860;OSBPL10	0.96	7.02	0.4	1.91e-11	Schizophrenia;
CESC	cis	rs4665809	0.838	rs6546780	chr2:26352857	T/C	cg27170947	chr2:26402098	FAM59B	-0.58	-6.85	-0.39	5.06e-11	Gut microbiome composition (summer);
CESC	cis	rs4481887	1.000	rs6666690	chr1:248465323	T/C	cg00666640	chr1:248458726	OR2T12	0.37	6.04	0.35	5.32e-9	Common traits (Other);
CESC	cis	rs7851660	0.527	rs7859751	chr9:100575888	C/T	cg13688889	chr9:100608707	NA	-0.88	-14.33	-0.66	7.23e-35	Strep throat;
CESC	cis	rs7618915	0.547	rs7642198	chr3:52677960	T/C	cg05564831	chr3:52568323	NT5DC2	0.45	6.91	0.39	3.55e-11	Bipolar disorder;
CESC	cis	rs7605827	0.930	rs13019216	chr2:15659539	A/G	cg19274914	chr2:15703543	NA	0.37	6.65	0.38	1.65e-10	Educational attainment (years of education);
CESC	cis	rs2637266	0.600	rs11001823	chr10:78326767	G/A	cg18941641	chr10:78392320	NA	-0.34	-5.22	-0.31	3.68e-7	Pulmonary function;
CESC	cis	rs72781680	0.898	rs72782113	chr2:24024952	G/C	cg08917208	chr2:24149416	ATAD2B	0.95	8.71	0.47	3.45e-16	Lymphocyte counts;
CESC	cis	rs2011503	1.000	rs6511029	chr19:19471419	G/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.53	-5.34	-0.31	1.98e-7	Bipolar disorder;
CESC	cis	rs172166	0.694	rs1225716	chr6:28113746	A/C	cg26335602	chr6:28129616	ZNF389	0.38	5.39	0.31	1.57e-7	Cardiac Troponin-T levels;
CESC	cis	rs7100689	0.646	rs1953971	chr10:82145647	G/C	cg00277334	chr10:82204260	NA	-0.58	-7.62	-0.42	4.52e-13	Post bronchodilator FEV1;
CESC	cis	rs13191362	0.935	rs13193473	chr6:162966852	C/A	cg06582575	chr6:163149167	PACRG;PARK2	0.76	6.81	0.39	6.69e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs4975709	0.589	rs4975746	chr5:1861069	G/A	cg17650747	chr5:1873721	NA	0.43	5.87	0.34	1.28e-8	Cardiovascular disease risk factors;
CESC	cis	rs2072732	0.821	rs10909864	chr1:2948178	T/C	cg15211996	chr1:2936768	ACTRT2	0.32	5.82	0.34	1.7e-8	Plateletcrit;
CESC	cis	rs3213545	0.700	rs2260445	chr12:121468863	C/A	cg25281562	chr12:121454272	C12orf43	0.4	5.06	0.3	8.03e-7	Subjective well-being;Cardiovascular disease risk factors;
CESC	cis	rs28374715	0.627	rs28516832	chr15:41367036	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.83	-10.44	-0.54	1.39e-21	Ulcerative colitis;
CESC	cis	rs6500395	1.000	rs34844432	chr16:48682418	C/T	cg04672837	chr16:48644449	N4BP1	0.51	6.36	0.36	8.64e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs7617773	0.963	rs6766754	chr3:48182589	T/C	cg11946769	chr3:48343235	NME6	-0.61	-8.18	-0.45	1.18e-14	Coronary artery disease;
CESC	cis	rs4665809	0.627	rs1465720	chr2:26412638	G/T	cg08470875	chr2:26401718	FAM59B	-0.7	-7.52	-0.42	8.6e-13	Gut microbiome composition (summer);
CESC	cis	rs1799949	0.965	rs9646413	chr17:41426157	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	7.8	0.43	1.41e-13	Menopause (age at onset);
CESC	cis	rs568617	0.859	rs1204650	chr11:65645580	A/C	cg04055107	chr11:65626734	MUS81;CFL1	-0.69	-7.4	-0.41	1.81e-12	Crohn's disease;
CESC	cis	rs17253792	0.822	rs28409547	chr14:56047826	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.82	5.88	0.34	1.25e-8	Putamen volume;
CESC	cis	rs778371	0.723	rs10210953	chr2:233698830	G/A	cg08000102	chr2:233561755	GIGYF2	-0.84	-14.5	-0.67	1.84e-35	Schizophrenia;
CESC	cis	rs12973672	1.000	rs1051995	chr19:35770292	C/T	cg12095397	chr19:35769544	USF2	0.54	7.35	0.41	2.49e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	trans	rs9325144	0.647	rs35138700	chr12:38804474	C/T	cg10679878	chr6:156759499	NA	-0.33	-6.02	-0.35	5.73e-9	Morning vs. evening chronotype;
CESC	cis	rs17376456	0.825	rs13156202	chr5:93157721	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.61	-5.23	-0.31	3.48e-7	Diabetic retinopathy;
CESC	cis	rs7107174	1.000	rs2512537	chr11:77971947	T/C	cg02023728	chr11:77925099	USP35	0.48	6.34	0.36	9.87e-10	Testicular germ cell tumor;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09251995	chr19:18392994	JUND	-0.59	-6.58	-0.37	2.55e-10	Gut microbiome composition (summer);
CESC	cis	rs7772486	0.686	rs857883	chr6:145969214	G/T	cg23711669	chr6:146136114	FBXO30	-0.98	-15.19	-0.68	6.34e-38	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs6084875	0.620	rs4813711	chr20:4722646	T/G	cg10192164	chr16:30419175	ZNF771	-0.5	-6.16	-0.35	2.7e-9	Systemic lupus erythematosus;
CESC	cis	rs60733400	0.500	rs72644697	chr1:2533605	G/A	cg20673091	chr1:2541236	MMEL1	0.43	7.22	0.41	5.36e-12	Multiple sclerosis;
CESC	cis	rs1799949	0.965	rs11656945	chr17:41330265	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.38	5.06	0.3	7.89e-7	Menopause (age at onset);
CESC	cis	rs7223966	1.000	rs9901507	chr17:61765524	G/A	cg11494091	chr17:61959527	GH2	0.38	5.42	0.32	1.33e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs11969893	0.850	rs9390697	chr6:101294431	G/A	cg12253828	chr6:101329408	ASCC3	1.12	9.48	0.5	1.56e-18	Economic and political preferences (immigration/crime);
CESC	cis	rs8014204	0.935	rs1799900	chr14:75367740	G/A	cg26191576	chr14:75389716	RPS6KL1	0.36	5.25	0.31	3.06e-7	Caffeine consumption;
CESC	cis	rs8133932	0.654	rs10854475	chr21:47332749	A/G	cg14185626	chr21:47401492	COL6A1	0.46	5.12	0.3	5.88e-7	Schizophrenia;
CESC	cis	rs6570726	0.791	rs370654	chr6:145879005	C/G	cg05347473	chr6:146136440	FBXO30	0.55	7.06	0.4	1.45e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs12145833	0.538	rs12026408	chr1:243366805	G/A	cg02356786	chr1:243265016	LOC731275	0.81	6.54	0.37	3.07e-10	Obesity (early onset extreme);
CESC	cis	rs8077577	0.747	rs2294913	chr17:18202996	C/T	cg16794390	chr17:18148240	FLII	0.41	6.45	0.37	5.26e-10	Obesity-related traits;
CESC	cis	rs7524258	0.900	rs7514988	chr1:7271651	C/T	cg07173049	chr1:7289937	CAMTA1	0.34	5.21	0.3	3.74e-7	Tourette's syndrome or obsessive-compulsive disorder;
CESC	cis	rs1707322	1.000	rs2458400	chr1:46530798	C/T	cg03146154	chr1:46216737	IPP	-0.7	-9.2	-0.49	1.08e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs6459788	0.720	rs11974772	chr7:157250645	G/A	cg06271696	chr7:157225062	NA	-0.36	-5.08	-0.3	7.23e-7	Epstein-Barr virus copy number in lymphoblastoid cell lines;
CESC	cis	rs4713118	0.629	rs203887	chr6:28021269	C/T	cg17221315	chr6:27791827	HIST1H4J	0.47	5.06	0.3	7.72e-7	Parkinson's disease;
CESC	cis	rs116095464	0.558	rs60251075	chr5:245292	T/C	cg20965017	chr5:231967	SDHA	-0.47	-5.38	-0.31	1.65e-7	Breast cancer;
CESC	cis	rs10905065	0.965	rs2890365	chr10:5773876	C/A	cg11519256	chr10:5708881	ASB13	-0.42	-5.64	-0.33	4.39e-8	Menopause (age at onset);
CESC	cis	rs7618501	0.573	rs7634917	chr3:50049299	T/G	cg24110177	chr3:50126178	RBM5	0.53	7.28	0.41	3.85e-12	Intelligence (multi-trait analysis);
CESC	cis	rs6088590	0.930	rs6087618	chr20:33288407	C/T	cg08999081	chr20:33150536	PIGU	0.59	9.21	0.49	1.04e-17	Coronary artery disease;
CESC	cis	rs2204008	0.775	rs12099736	chr12:38344111	C/G	cg26384229	chr12:38710491	ALG10B	0.73	10.93	0.56	3.37e-23	Bladder cancer;
CESC	cis	rs2836974	0.867	rs77959119	chr21:40542768	G/A	cg27266027	chr21:40555129	PSMG1	0.49	5.8	0.34	1.89e-8	Cognitive function;
CESC	cis	rs1799949	1.000	rs8176126	chr17:41259049	A/G	cg25072359	chr17:41440525	NA	-0.44	-5.89	-0.34	1.14e-8	Menopause (age at onset);
CESC	cis	rs6831352	0.918	rs34936974	chr4:100052384	A/G	cg12011299	chr4:100065546	ADH4	0.45	5.3	0.31	2.41e-7	Alcohol dependence;
CESC	cis	rs1847202	0.762	rs62249896	chr3:72949857	C/G	cg10804678	chr3:72788309	NA	-0.4	-5.32	-0.31	2.26e-7	Motion sickness;
CESC	cis	rs6502050	0.835	rs35131307	chr17:80128439	G/A	cg11859384	chr17:80120422	CCDC57	-0.39	-5.34	-0.31	1.97e-7	Life satisfaction;
CESC	cis	rs72781680	0.678	rs56145919	chr2:24088489	A/G	cg08917208	chr2:24149416	ATAD2B	0.58	5.78	0.33	2.07e-8	Lymphocyte counts;
CESC	cis	rs2760061	0.626	rs635563	chr1:228136834	C/T	cg01973587	chr1:228161476	NA	0.37	5.75	0.33	2.47e-8	Diastolic blood pressure;
CESC	cis	rs9311474	0.569	rs7614981	chr3:52566914	G/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.42	8.22	0.45	9.35e-15	Electroencephalogram traits;
CESC	cis	rs2576037	0.583	rs2156049	chr18:44455717	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.35	5.68	0.33	3.49e-8	Personality dimensions;
CESC	cis	rs1998418	0.736	rs10901804	chr10:126366238	T/C	cg03585084	chr10:126284563	LHPP	0.53	5.12	0.3	5.74e-7	Mean platelet volume;
CESC	cis	rs425277	0.585	rs2222217	chr1:2063164	G/A	cg16545954	chr1:2118288	C1orf86	-0.33	-6.05	-0.35	5e-9	Height;
CESC	cis	rs2046867	0.818	rs11928620	chr3:72863209	A/C	cg25664220	chr3:72788482	NA	-0.47	-6.98	-0.39	2.32e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CESC	cis	rs7927771	0.524	rs11039329	chr11:47684908	A/G	cg18512352	chr11:47633146	NA	0.34	5.08	0.3	7.18e-7	Subjective well-being;
CESC	cis	rs2361718	0.603	rs12951255	chr17:78085597	A/G	cg27427491	chr17:78079615	GAA	-0.39	-6.04	-0.35	5.13e-9	Yeast infection;
CESC	cis	rs7927771	0.524	rs10742814	chr11:47554337	G/A	cg20307385	chr11:47447363	PSMC3	0.63	8.74	0.47	2.71e-16	Subjective well-being;
CESC	cis	rs858239	0.601	rs15775	chr7:23164701	C/T	cg23682824	chr7:23144976	KLHL7	0.55	7.73	0.43	2.27e-13	Cerebrospinal fluid biomarker levels;
CESC	cis	rs8082590	1	rs8082590	chr17:17958402	G/A	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.54	-7.02	-0.4	1.86e-11	Schizophrenia;
CESC	cis	rs896854	0.624	rs9297949	chr8:95969445	A/C	cg13393036	chr8:95962371	TP53INP1	-0.47	-9.81	-0.52	1.38e-19	Type 2 diabetes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06273763	chr15:59664907	MYO1E	0.61	7.33	0.41	2.77e-12	Gut microbiome composition (summer);
CESC	cis	rs4604732	0.631	rs1106721	chr1:247624676	A/C	cg12758973	chr1:247694275	LOC148824;OR2C3	0.51	6.36	0.36	8.65e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs9768139	0.733	rs13225172	chr7:158120334	G/A	cg06219351	chr7:158114137	PTPRN2	-0.48	-7.14	-0.4	8.87e-12	Calcium levels;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg27274463	chr12:110338238	TCHP	-0.47	-6.56	-0.37	2.82e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs10896135	0.526	rs484262	chr11:66399681	C/T	cg24851651	chr11:66362959	CCS	-0.51	-6.9	-0.39	3.79e-11	Bipolar disorder;
CESC	cis	rs10504229	0.773	rs1874373	chr8:58194423	T/C	cg05313129	chr8:58192883	C8orf71	-0.52	-6.03	-0.35	5.41e-9	Developmental language disorder (linguistic errors);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11662851	chr11:18343665	GTF2H1;HPS5	0.59	6.53	0.37	3.33e-10	Gut microbiome composition (summer);
CESC	cis	rs6430585	0.591	rs309170	chr2:136672775	C/T	cg07169764	chr2:136633963	MCM6	1.03	14.65	0.67	5.12e-36	Corneal structure;
CESC	cis	rs12130219	1.000	rs34428306	chr1:152184316	G/C	cg25272121	chr1:152190972	HRNR	0.4	5.03	0.3	8.92e-7	Inflammatory skin disease;
CESC	cis	rs7116495	0.609	rs674319	chr11:71775391	T/C	cg18441811	chr11:71824068	C11orf51	-0.82	-5.14	-0.3	5.31e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs9815354	1.000	rs9828398	chr3:41895893	C/T	cg03022575	chr3:42003672	ULK4	0.45	5.23	0.31	3.48e-7	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs3008870	1.000	rs11208979	chr1:67442275	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-1.06	-15.19	-0.68	6.65e-38	Lymphocyte percentage of white cells;
CESC	cis	rs7680126	0.633	rs4697745	chr4:10305081	G/A	cg11266682	chr4:10021025	SLC2A9	-0.42	-5.36	-0.31	1.81e-7	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	cis	rs12142240	0.698	rs41534051	chr1:46828734	A/G	cg00530320	chr1:46809349	NSUN4	0.6	7.88	0.44	8.35e-14	Menopause (age at onset);
CESC	cis	rs2072732	0.861	rs12408197	chr1:2951511	C/T	cg15211996	chr1:2936768	ACTRT2	0.34	5.95	0.34	8.31e-9	Plateletcrit;
CESC	cis	rs9926296	0.744	rs6860	chr16:89711120	C/T	cg03605463	chr16:89740564	NA	0.66	7.77	0.43	1.72e-13	Vitiligo;
CESC	cis	rs1413885	0.549	rs9436725	chr1:65852870	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.48	6.32	0.36	1.13e-9	Anticoagulant levels;
CESC	cis	rs12142240	0.698	rs67487250	chr1:46811333	T/C	cg10495392	chr1:46806563	NSUN4	0.57	6.29	0.36	1.33e-9	Menopause (age at onset);
CESC	cis	rs7523050	0.730	rs77425121	chr1:109417677	C/A	cg08274380	chr1:109419600	GPSM2	0.92	6.41	0.37	6.62e-10	Fat distribution (HIV);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08744727	chr4:206112	ZNF876P	-0.61	-6.4	-0.37	7.07e-10	Gut microbiome composition (summer);
CESC	cis	rs9457247	0.602	rs6456152	chr6:167472062	A/G	cg23791538	chr6:167370224	RNASET2	-0.52	-6.9	-0.39	3.81e-11	Crohn's disease;
CESC	cis	rs9322193	0.962	rs2275046	chr6:150157001	A/G	cg05861140	chr6:150128134	PCMT1	-0.38	-5.34	-0.31	1.96e-7	Lung cancer;
CESC	cis	rs9325144	0.534	rs6582538	chr12:38629997	A/C	cg13010199	chr12:38710504	ALG10B	-0.42	-5.65	-0.33	4.16e-8	Morning vs. evening chronotype;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18421429	chr6:89673507	RNGTT	0.66	7.41	0.41	1.68e-12	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26167861	chr12:16035689	STRAP	0.52	6.73	0.38	1.02e-10	Gut microbiome composition (summer);
CESC	cis	rs113835537	0.877	rs2229455	chr11:66328055	A/G	cg24851651	chr11:66362959	CCS	0.54	5.14	0.3	5.23e-7	Airway imaging phenotypes;
CESC	cis	rs1153858	0.621	rs2413769	chr15:45561868	A/C	cg21132104	chr15:45694354	SPATA5L1	0.72	8.58	0.47	8.19e-16	Homoarginine levels;
CESC	trans	rs11755845	0.847	rs10948111	chr6:43908624	A/G	cg26163234	chr15:99789622	TTC23	-0.43	-6.05	-0.35	4.89e-9	Thyroid hormone levels;
CESC	cis	rs7208859	0.623	rs11651857	chr17:28926362	G/T	cg13385521	chr17:29058706	SUZ12P	0.77	5.67	0.33	3.8e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs916888	0.821	rs199505	chr17:44859410	A/G	cg17911788	chr17:44343683	NA	0.53	7.06	0.4	1.46e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg06873352	chr17:61820015	STRADA	0.72	12.74	0.62	2.56e-29	Prudent dietary pattern;
CESC	cis	rs798554	1.000	rs798540	chr7:2764130	G/A	cg04166393	chr7:2884313	GNA12	0.55	7.0	0.4	2.05e-11	Height;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg11141013	chr16:30583056	ZNF688	-0.48	-6.35	-0.36	9.15e-10	Fibrinogen levels;
CESC	cis	rs644799	0.526	rs542509	chr11:95641602	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.53	7.13	0.4	9.7e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg22164177	chr12:117013718	MAP1LC3B2	0.44	6.16	0.35	2.64e-9	Fibrinogen levels;
CESC	cis	rs6460942	0.597	rs7811374	chr7:12517437	T/C	cg06484146	chr7:12443880	VWDE	-0.71	-7.6	-0.42	5.22e-13	Coronary artery disease;
CESC	cis	rs2073300	0.609	rs1076776	chr20:23427399	C/T	cg16736954	chr20:23401023	NAPB	-0.67	-5.12	-0.3	5.97e-7	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs7762018	0.514	rs60671539	chr6:170165981	A/G	cg17545662	chr6:170176663	C6orf70	0.56	7.92	0.44	6.65e-14	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs3096299	0.754	rs3102382	chr16:89409742	C/G	cg00750074	chr16:89608354	SPG7	-0.43	-6.3	-0.36	1.22e-9	Multiple myeloma (IgH translocation);
CESC	cis	rs7044106	0.791	rs735109	chr9:123488879	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.72	10.65	0.55	2.85e-22	Hip circumference adjusted for BMI;
CESC	cis	rs9733	0.566	rs11204675	chr1:150570985	A/C	cg13175981	chr1:150552382	MCL1	0.68	10.35	0.54	2.67e-21	Tonsillectomy;
CESC	cis	rs1949733	0.666	rs3103070	chr4:8508825	A/G	cg11789530	chr4:8429930	ACOX3	-0.7	-9.84	-0.52	1.1e-19	Response to antineoplastic agents;
CESC	cis	rs9910055	0.762	rs7213436	chr17:42252163	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.6	-7.98	-0.44	4.54e-14	Total body bone mineral density;
CESC	cis	rs4555082	0.718	rs75139030	chr14:105710853	A/AG	cg06808227	chr14:105710500	BRF1	-0.51	-5.65	-0.33	4.08e-8	Mean platelet volume;Platelet distribution width;
CESC	trans	rs7246760	0.737	rs60584926	chr19:9797014	C/T	cg02900749	chr2:68251473	NA	-0.85	-7.53	-0.42	8.04e-13	Pursuit maintenance gain;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg26475306	chr20:33999876	UQCC	0.45	6.66	0.38	1.54e-10	Systemic lupus erythematosus;
CESC	cis	rs2576037	0.561	rs513775	chr18:44396334	T/C	cg19077165	chr18:44547161	KATNAL2	-0.61	-9.16	-0.49	1.44e-17	Personality dimensions;
CESC	cis	rs1348850	0.914	rs7604673	chr2:178392346	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.87	12.56	0.61	1.04e-28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs6570726	0.935	rs374000	chr6:145855290	C/T	cg05347473	chr6:146136440	FBXO30	0.48	6.47	0.37	4.82e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs10078	0.559	rs2671891	chr5:456386	A/G	cg08916839	chr5:415575	AHRR	0.59	6.81	0.39	6.34e-11	Fat distribution (HIV);
CESC	cis	rs9303401	0.659	rs35082010	chr17:56936867	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	1.01	12.69	0.61	3.78e-29	Cognitive test performance;
CESC	cis	rs11098499	0.863	rs13136462	chr4:120543173	C/T	cg24375607	chr4:120327624	NA	0.44	5.46	0.32	1.11e-7	Corneal astigmatism;
CESC	cis	rs10197940	0.624	rs6724796	chr2:152412813	C/T	cg19508488	chr2:152266495	RIF1	0.51	5.99	0.35	6.85e-9	Lung cancer;
CESC	cis	rs7772486	0.875	rs12194437	chr6:146411440	A/G	cg23711669	chr6:146136114	FBXO30	0.86	12.72	0.62	2.98e-29	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs7836436	0.686	rs7010457	chr8:120955012	A/G	cg22699279	chr15:79383890	RASGRF1	-0.7	-6.72	-0.38	1.13e-10	HIV-1 viral setpoint;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13665184	chr16:68057062	DUS2L;DDX28	0.55	6.17	0.35	2.55e-9	Gut microbiome composition (summer);
CESC	trans	rs7726839	0.561	rs4957050	chr5:579066	A/C	cg25482853	chr8:67687455	SGK3	0.88	9.47	0.5	1.62e-18	Obesity-related traits;
CESC	cis	rs10489202	1.000	rs7535138	chr1:167931462	T/G	cg24449463	chr1:168025552	DCAF6	-0.46	-5.38	-0.31	1.63e-7	Schizophrenia;
CESC	cis	rs875971	0.862	rs908915	chr7:65614651	G/T	cg19163074	chr7:65112434	INTS4L2	0.4	5.04	0.3	8.54e-7	Aortic root size;
CESC	cis	rs6088580	0.634	rs6058051	chr20:33044862	G/A	cg08999081	chr20:33150536	PIGU	0.66	11.55	0.58	2.83e-25	Glomerular filtration rate (creatinine);
CESC	cis	rs7726839	0.561	rs6555357	chr5:560923	A/G	cg09021430	chr5:549028	NA	-0.47	-6.36	-0.36	8.68e-10	Obesity-related traits;
CESC	cis	rs16854884	0.609	rs9872126	chr3:143683851	G/A	cg06585982	chr3:143692056	C3orf58	0.56	7.58	0.42	5.77e-13	Economic and political preferences (feminism/equality);
CESC	cis	rs9486719	1.000	rs11152959	chr6:96900272	C/T	cg06623918	chr6:96969491	KIAA0776	-0.81	-8.3	-0.45	5.21e-15	Migraine;Coronary artery disease;
CESC	cis	rs7615952	0.576	rs4646748	chr3:125826329	G/A	cg15145296	chr3:125709740	NA	-0.55	-5.85	-0.34	1.48e-8	Blood pressure (smoking interaction);
CESC	cis	rs5997397	1.000	rs5997397	chr22:29154455	A/G	cg02153584	chr22:29168773	CCDC117	0.52	7.17	0.4	7.58e-12	Red cell distribution width;
CESC	cis	rs2228479	0.850	rs11076624	chr16:89855749	T/C	cg00800038	chr16:89945340	TCF25	-0.9	-7.5	-0.42	9.55e-13	Skin colour saturation;
CESC	cis	rs10465746	0.935	rs6692233	chr1:84327214	A/G	cg10977910	chr1:84465055	TTLL7	-0.46	-6.01	-0.35	6.12e-9	Obesity-related traits;
CESC	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg07677032	chr17:61819896	STRADA	0.49	6.67	0.38	1.46e-10	Prudent dietary pattern;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg23611233	chr1:249133059	ZNF672	-0.52	-7.06	-0.4	1.42e-11	Fibrinogen levels;
CESC	cis	rs7618915	0.547	rs11714419	chr3:52628816	A/G	cg18099408	chr3:52552593	STAB1	-0.31	-5.2	-0.3	3.94e-7	Bipolar disorder;
CESC	cis	rs3733585	0.699	rs6449172	chr4:9966036	A/T	cg11266682	chr4:10021025	SLC2A9	-0.59	-11.12	-0.56	7.83e-24	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs4253772	0.637	rs3087501	chr22:46647909	A/G	cg10231785	chr22:46692440	CN5H6.4;GTSE1	0.49	5.18	0.3	4.45e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs2014572	0.967	rs8112572	chr19:57759612	T/C	cg12963866	chr19:57752005	ZNF805	-0.48	-6.37	-0.36	8.12e-10	Hyperactive-impulsive symptoms;
CESC	cis	rs12956009	0.583	rs4452038	chr18:44856529	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.46	6.17	0.35	2.6e-9	Educational attainment (years of education);
CESC	cis	rs6141600	0.540	rs964786	chr20:34688491	T/C	cg07747181	chr20:34652970	NA	-0.38	-5.44	-0.32	1.21e-7	Height;Hip circumference;
CESC	cis	rs67478160	0.634	rs2368559	chr14:104230535	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.53	-7.73	-0.43	2.26e-13	Schizophrenia;
CESC	cis	rs2415984	0.579	rs28636061	chr14:46959848	T/C	cg14871534	chr14:47121158	RPL10L	-0.35	-5.38	-0.31	1.6e-7	Number of children ever born;
CESC	cis	rs947211	0.898	rs10900524	chr1:205748309	G/A	cg26354017	chr1:205819088	PM20D1	0.44	5.46	0.32	1.1e-7	Parkinson's disease;
CESC	cis	rs1568889	1.000	rs12802830	chr11:28321196	G/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.73	8.7	0.47	3.58e-16	Bipolar disorder;
CESC	cis	rs1153858	1.000	rs2114501	chr15:45670316	G/A	cg21132104	chr15:45694354	SPATA5L1	0.86	11.62	0.58	1.67e-25	Homoarginine levels;
CESC	cis	rs116095464	0.558	rs55776650	chr5:273826	G/A	cg20965017	chr5:231967	SDHA	-0.47	-5.3	-0.31	2.46e-7	Breast cancer;
CESC	cis	rs736801	0.521	rs2070729	chr5:131819921	G/T	cg21138405	chr5:131827807	IRF1	0.37	6.5	0.37	4e-10	Breast cancer;Mosquito bite size;
CESC	cis	rs4664304	1.000	rs57771571	chr2:160767804	G/C	cg03641300	chr2:160917029	PLA2R1	-0.49	-6.94	-0.39	3.06e-11	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs3785574	1.000	rs3785574	chr17:61763185	T/C	cg06873352	chr17:61820015	STRADA	0.49	6.84	0.39	5.46e-11	Height;
CESC	trans	rs7702057	0.619	rs7716923	chr5:115700307	A/G	cg17756860	chr4:110510374	CCDC109B	0.56	6.2	0.36	2.17e-9	Amyotrophic lateral sclerosis;
CESC	cis	rs4867766	0.789	rs17725606	chr5:173956965	A/C	cg20434911	chr5:173954559	NA	-0.59	-6.34	-0.36	9.87e-10	Stroke;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg25531986	chr19:53144247	ZNF83	-0.43	-6.28	-0.36	1.41e-9	Asthma;
CESC	cis	rs2075371	1.000	rs378358	chr7:133970628	A/G	cg20476274	chr7:133979776	SLC35B4	0.69	10.23	0.53	6.57e-21	Mean platelet volume;
CESC	cis	rs1799949	0.965	rs11651623	chr17:41329847	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.6	7.87	0.44	9.29e-14	Menopause (age at onset);
CESC	cis	rs7666738	0.830	rs6818045	chr4:99049374	G/A	cg03467027	chr4:99064603	C4orf37	0.47	5.91	0.34	1.06e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9486715	0.867	rs9486444	chr6:96963619	A/G	cg18709589	chr6:96969512	KIAA0776	0.45	6.24	0.36	1.76e-9	Headache;
CESC	cis	rs703842	0.964	rs10431552	chr12:58178148	G/A	cg18357645	chr12:58087776	OS9	-0.4	-5.62	-0.33	4.76e-8	Multiple sclerosis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22966060	chr19:5686806	HSD11B1L	-0.56	-6.3	-0.36	1.24e-9	Gut microbiome composition (summer);
CESC	cis	rs4129585	1.000	rs4129585	chr8:143312933	A/C	cg16886403	chr8:143471632	TSNARE1	0.45	5.68	0.33	3.49e-8	Schizophrenia;Autism spectrum disorder or schizophrenia;
CESC	trans	rs7618501	0.633	rs6772095	chr3:49978069	C/T	cg21659725	chr3:3221576	CRBN	0.55	7.6	0.42	5.29e-13	Intelligence (multi-trait analysis);
CESC	cis	rs10771431	0.597	rs10771412	chr12:9354353	A/C	cg08997352	chr12:9597637	DDX12	-0.71	-8.82	-0.48	1.57e-16	Breast size;
CESC	trans	rs864643	0.773	rs11129837	chr3:39589963	A/G	cg19219231	chr2:61108086	REL	0.48	6.22	0.36	1.93e-9	Attention deficit hyperactivity disorder;
CESC	cis	rs9291683	0.530	rs4235346	chr4:9945296	C/T	cg00071950	chr4:10020882	SLC2A9	-0.8	-14.84	-0.67	1.1e-36	Bone mineral density;
CESC	cis	rs3733585	0.699	rs28610447	chr4:9971517	T/C	cg11266682	chr4:10021025	SLC2A9	-0.58	-10.87	-0.56	5.3e-23	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs10887741	0.646	rs7903568	chr10:89433931	T/A	cg13926569	chr10:89418898	PAPSS2	0.46	6.89	0.39	4.15e-11	Exercise (leisure time);
CESC	cis	rs6987853	0.761	rs2923391	chr8:42415942	G/A	cg09913449	chr8:42400586	C8orf40	0.45	7.44	0.42	1.39e-12	Mean corpuscular hemoglobin concentration;
CESC	trans	rs747782	0.528	rs11039674	chr11:48336116	C/T	cg15704280	chr7:45808275	SEPT13	0.68	6.31	0.36	1.19e-9	Intraocular pressure;
CESC	cis	rs3820068	0.705	rs11589076	chr1:15827027	C/T	cg17385448	chr1:15911702	AGMAT	0.4	6.14	0.35	3.04e-9	Systolic blood pressure;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg23100370	chr2:109336342	RANBP2	-0.49	-6.5	-0.37	3.97e-10	Ulcerative colitis;
CESC	cis	rs7216064	1.000	rs62084246	chr17:65867911	G/C	cg12091567	chr17:66097778	LOC651250	-0.85	-8.7	-0.47	3.61e-16	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg07859478	chr19:808116	PTBP1	-0.48	-6.2	-0.36	2.21e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs3892630	0.818	rs80137870	chr19:33182750	C/T	cg22980127	chr19:33182716	NUDT19	1.02	11.74	0.58	6.86e-26	Red blood cell traits;
CESC	cis	rs2777491	1.000	rs316613	chr15:41747598	G/A	cg02330683	chr15:41787940	ITPKA	0.47	6.95	0.39	2.9e-11	Ulcerative colitis;
CESC	cis	rs6815814	0.808	rs11721824	chr4:38767749	G/A	cg02016764	chr4:38805732	TLR1	-0.69	-7.48	-0.42	1.06e-12	Breast cancer;
CESC	cis	rs6831352	0.879	rs29001215	chr4:100051722	T/C	cg13256891	chr4:100009986	ADH5	-0.77	-8.43	-0.46	2.27e-15	Alcohol dependence;
CESC	cis	rs7267979	1.000	rs2258879	chr20:25279213	T/C	cg08601574	chr20:25228251	PYGB	0.39	5.57	0.32	6.14e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs889312	0.521	rs12651942	chr5:56088484	C/T	cg14703610	chr5:56206110	C5orf35	0.46	6.07	0.35	4.3e-9	Breast cancer;Breast cancer (early onset);
CESC	cis	rs561341	0.739	rs7213369	chr17:30211878	G/A	cg13647721	chr17:30228624	UTP6	-0.76	-9.3	-0.5	5.52e-18	Hip circumference adjusted for BMI;
CESC	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	7.89	0.44	7.83e-14	Prudent dietary pattern;
CESC	cis	rs2072732	0.904	rs9660819	chr1:2952823	C/T	cg03976712	chr1:2946727	NA	0.33	5.45	0.32	1.17e-7	Plateletcrit;
CESC	cis	rs9902453	1.000	rs56280226	chr17:28429575	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	7.99	0.44	4.06e-14	Coffee consumption (cups per day);
CESC	cis	rs611744	0.608	rs667742	chr8:109254003	T/C	cg21045802	chr8:109455806	TTC35	0.46	5.67	0.33	3.65e-8	Dupuytren's disease;
CESC	cis	rs763121	0.853	rs1065201	chr22:39069510	T/C	cg14440974	chr22:39074834	NA	-0.42	-5.89	-0.34	1.14e-8	Menopause (age at onset);
CESC	cis	rs12530845	0.887	rs6948382	chr7:135323576	G/A	cg23117316	chr7:135346802	PL-5283	-0.47	-5.76	-0.33	2.33e-8	Red blood cell traits;
CESC	cis	rs7940866	0.845	rs1433976	chr11:130875123	C/T	cg12179176	chr11:130786555	SNX19	-0.61	-8.37	-0.46	3.35e-15	Schizophrenia;
CESC	cis	rs7819412	0.745	rs7017567	chr8:10933699	T/A	cg21775007	chr8:11205619	TDH	-0.43	-5.94	-0.34	9e-9	Triglycerides;
CESC	cis	rs4665809	0.680	rs3955310	chr2:26290828	T/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.67	-7.6	-0.42	4.99e-13	Gut microbiome composition (summer);
CESC	cis	rs4927850	1.000	rs7627706	chr3:195753353	A/C	cg12923728	chr3:195709715	SDHAP1	-0.67	-8.99	-0.48	4.91e-17	Pancreatic cancer;
CESC	cis	rs7586673	0.893	rs889925	chr2:161971597	T/C	cg22496339	chr2:162101262	NA	0.49	6.51	0.37	3.64e-10	Intelligence (multi-trait analysis);
CESC	cis	rs9611565	0.694	rs202628	chr22:41849513	A/G	cg06634786	chr22:41940651	POLR3H	-0.6	-6.61	-0.38	2.07e-10	Vitiligo;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09535750	chr10:122702484	NA	-0.55	-6.27	-0.36	1.44e-9	Gut microbiome composition (summer);
CESC	cis	rs796364	0.906	rs281784	chr2:200749749	T/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.86	8.18	0.45	1.19e-14	Schizophrenia;
CESC	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg23978390	chr7:1156363	C7orf50	0.65	9.17	0.49	1.37e-17	Longevity;Endometriosis;
CESC	cis	rs8070740	1.000	rs8070740	chr17:5331896	A/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.56	6.77	0.38	8.23e-11	Menopause (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19257979	chr20:37101387	RALGAPB	0.59	6.67	0.38	1.49e-10	Gut microbiome composition (summer);
CESC	cis	rs1878931	0.624	rs27235	chr16:3439138	G/C	cg02880119	chr16:3481970	NA	0.4	5.08	0.3	7.26e-7	Body mass index (adult);
CESC	cis	rs6460942	1.000	rs2033871	chr7:12405098	C/A	cg20607287	chr7:12443886	VWDE	-0.68	-7.91	-0.44	6.85e-14	Coronary artery disease;
CESC	cis	rs8062405	0.755	rs4788080	chr16:28558081	C/T	cg07382826	chr16:28625726	SULT1A1	0.4	6.69	0.38	1.3e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg07677032	chr17:61819896	STRADA	-0.45	-5.99	-0.35	6.94e-9	Prudent dietary pattern;
CESC	cis	rs873946	0.689	rs2803993	chr10:134550606	T/C	cg06453172	chr10:134556979	INPP5A	-0.38	-5.13	-0.3	5.55e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs9902453	0.765	rs6505143	chr17:28150585	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.76	10.24	0.53	5.98e-21	Coffee consumption (cups per day);
CESC	cis	rs875971	0.545	rs6979636	chr7:65741625	A/G	cg18527119	chr7:66119851	NA	-0.45	-5.14	-0.3	5.4e-7	Aortic root size;
CESC	cis	rs9393777	0.513	rs13195210	chr6:26646521	C/T	cg12292205	chr6:26970375	C6orf41	-0.55	-5.96	-0.34	7.88e-9	Intelligence (multi-trait analysis);
CESC	cis	rs4253772	0.550	rs9615951	chr22:46728056	C/A	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.66	5.88	0.34	1.21e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs6580649	0.941	rs57380031	chr12:48452237	C/T	cg24011408	chr12:48396354	COL2A1	-0.42	-5.28	-0.31	2.67e-7	Lung cancer;
CESC	cis	rs1005277	0.540	rs2474598	chr10:38430296	C/T	cg25427524	chr10:38739819	LOC399744	0.65	9.3	0.5	5.35e-18	Extrinsic epigenetic age acceleration;
CESC	cis	rs9487051	0.872	rs1111866	chr6:109610846	A/C	cg01475377	chr6:109611718	NA	0.52	8.64	0.47	5.22e-16	Reticulocyte fraction of red cells;
CESC	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg22907277	chr7:1156413	C7orf50	0.45	6.52	0.37	3.54e-10	Longevity;Endometriosis;
CESC	cis	rs78889164	0.955	rs78042672	chr19:33848695	C/A	cg02272751	chr19:33882848	PEPD	-0.51	-6.6	-0.38	2.26e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs950169	0.960	rs12905475	chr15:84800495	G/A	cg17507749	chr15:85114479	UBE2QP1	0.6	6.56	0.37	2.82e-10	Schizophrenia;
CESC	cis	rs9581857	0.579	rs2780341	chr13:27996401	C/T	cg01674679	chr13:27998804	GTF3A	0.67	5.59	0.32	5.75e-8	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
CESC	cis	rs13106227	0.550	rs1849215	chr4:77377449	T/C	cg20311846	chr4:77356250	SHROOM3	-0.31	-5.67	-0.33	3.65e-8	Eosinophilic esophagitis (pediatric);
CESC	cis	rs1552244	0.810	rs35711405	chr3:10116939	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-10.26	-0.53	5.05e-21	Alzheimer's disease;
CESC	cis	rs2439831	0.867	rs3213991	chr15:43670280	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.86	13.09	0.63	1.57e-30	Lung cancer in ever smokers;
CESC	cis	rs9611565	0.918	rs6002351	chr22:41757223	C/T	cg03806693	chr22:41940476	POLR3H	-0.74	-8.96	-0.48	5.97e-17	Vitiligo;
CESC	cis	rs8180040	0.627	rs58956475	chr3:47224615	G/C	cg27129171	chr3:47204927	SETD2	-0.67	-9.83	-0.52	1.2e-19	Colorectal cancer;
CESC	cis	rs6964587	0.967	rs7788092	chr7:91646198	C/T	cg17063962	chr7:91808500	NA	0.55	7.63	0.42	4.25e-13	Breast cancer;
CESC	cis	rs911555	0.655	rs10141157	chr14:104018105	T/C	cg12935359	chr14:103987150	CKB	-0.4	-5.52	-0.32	8.15e-8	Intelligence (multi-trait analysis);
CESC	cis	rs875971	1.000	rs6961990	chr7:65888570	C/A	cg10691866	chr7:65817282	TPST1	-0.35	-5.77	-0.33	2.18e-8	Aortic root size;
CESC	cis	rs7666738	0.830	rs3846445	chr4:99032939	T/A	cg18180107	chr4:99064573	C4orf37	0.42	5.43	0.32	1.29e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3820928	0.904	rs6735069	chr2:227893660	A/G	cg11843606	chr2:227700838	RHBDD1	-0.48	-6.2	-0.36	2.12e-9	Pulmonary function;
CESC	cis	rs4566357	1.000	rs6705783	chr2:227923268	C/T	cg11843606	chr2:227700838	RHBDD1	-0.41	-5.25	-0.31	3.09e-7	Coronary artery disease;
CESC	cis	rs9322193	0.923	rs10872650	chr6:150082095	A/G	cg07701084	chr6:150067640	NUP43	0.49	6.73	0.38	1.07e-10	Lung cancer;
CESC	cis	rs798554	0.567	rs1182194	chr7:2868824	C/G	cg19717773	chr7:2847554	GNA12	-0.49	-7.34	-0.41	2.58e-12	Height;
CESC	cis	rs736408	0.609	rs2230534	chr3:52802402	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	6.61	0.38	2.15e-10	Bipolar disorder;
CESC	trans	rs208520	1.000	rs12216109	chr6:66987488	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.84	9.34	0.5	4.23e-18	Exhaled nitric oxide output;
CESC	cis	rs6460942	1.000	rs79964328	chr7:12319392	A/C	cg02935154	chr7:12443704	VWDE	-0.59	-5.84	-0.34	1.5e-8	Coronary artery disease;
CESC	cis	rs34375054	0.558	rs12578774	chr12:125681761	A/G	cg25124228	chr12:125621409	AACS	0.47	5.61	0.33	5.11e-8	Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs3540	0.574	rs2657946	chr15:90967513	G/C	cg10434728	chr15:90938212	IQGAP1	0.42	7.35	0.41	2.41e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs8005677	0.962	rs8003934	chr14:23401142	A/G	cg25600027	chr14:23388339	RBM23	-0.43	-5.24	-0.31	3.22e-7	Cognitive ability (multi-trait analysis);
CESC	cis	rs863345	0.967	rs10797014	chr1:158468202	C/T	cg12129480	chr1:158549410	OR10X1	-0.31	-6.23	-0.36	1.78e-9	Pneumococcal bacteremia;
CESC	cis	rs589448	0.967	rs2617835	chr12:69753420	C/A	cg22834771	chr12:69754056	YEATS4	-0.55	-7.29	-0.41	3.61e-12	Cerebrospinal fluid biomarker levels;
CESC	cis	rs644799	0.763	rs2950521	chr11:95536870	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	13.69	0.64	1.25e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs12545109	0.959	rs12546307	chr8:57314790	T/A	cg09654669	chr8:57350985	NA	-0.58	-6.97	-0.39	2.44e-11	Obesity-related traits;
CESC	cis	rs17253792	0.822	rs76557162	chr14:56064701	A/G	cg01858014	chr14:56050164	KTN1	-0.87	-6.75	-0.38	9.11e-11	Putamen volume;
CESC	cis	rs9443645	0.869	rs11754419	chr6:79729648	A/G	cg05283184	chr6:79620031	NA	-0.44	-6.79	-0.39	7.19e-11	Intelligence (multi-trait analysis);
CESC	cis	rs7568458	0.709	rs2592551	chr2:85780131	G/A	cg02493740	chr2:85810744	VAMP5	-0.57	-8.42	-0.46	2.41e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CESC	cis	rs72781680	1.000	rs72781689	chr2:24256349	C/T	cg08917208	chr2:24149416	ATAD2B	1.07	8.78	0.47	2.02e-16	Lymphocyte counts;
CESC	cis	rs9815354	0.812	rs59138513	chr3:41908611	T/G	cg03022575	chr3:42003672	ULK4	0.7	6.18	0.36	2.38e-9	Pulse pressure;Diastolic blood pressure;
CESC	trans	rs561341	0.882	rs28649357	chr17:30367190	A/G	cg27661571	chr11:113659931	NA	-0.6	-6.12	-0.35	3.28e-9	Hip circumference adjusted for BMI;
CESC	cis	rs7666738	0.800	rs13107147	chr4:99028753	C/T	cg17366294	chr4:99064904	C4orf37	0.61	8.67	0.47	4.35e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4713118	0.587	rs9393899	chr6:28133528	G/C	cg22143856	chr6:28129313	ZNF389	0.49	6.24	0.36	1.73e-9	Parkinson's disease;
CESC	cis	rs3859192	0.561	rs12453343	chr17:38181176	C/A	cg17467752	chr17:38218738	THRA	-0.47	-6.34	-0.36	9.92e-10	White blood cell count;
CESC	cis	rs10088262	0.629	rs9918907	chr8:124816862	A/G	cg02993010	chr8:124780839	FAM91A1	-0.65	-8.15	-0.45	1.47e-14	Pancreatic cancer;
CESC	cis	rs9911578	0.900	rs7214335	chr17:57158840	G/A	cg12560992	chr17:57184187	TRIM37	0.94	15.69	0.69	1.11e-39	Intelligence (multi-trait analysis);
CESC	cis	rs36051895	0.623	rs6476955	chr9:5256533	C/G	cg02405213	chr9:5042618	JAK2	-0.49	-5.94	-0.34	9.08e-9	Pediatric autoimmune diseases;
CESC	cis	rs13191362	1.000	rs34697913	chr6:163000187	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.88	9.16	0.49	1.46e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs597539	0.652	rs602805	chr11:68662076	A/T	cg18350739	chr11:68623251	NA	-0.45	-6.96	-0.39	2.67e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs2066819	1.000	rs59626664	chr12:56636975	C/G	cg26714650	chr12:56694279	CS	-1.42	-10.05	-0.53	2.39e-20	Psoriasis vulgaris;
CESC	cis	rs67478160	0.619	rs28698555	chr14:104316486	C/A	cg08213375	chr14:104286397	PPP1R13B	-0.54	-10.59	-0.55	4.43e-22	Schizophrenia;
CESC	cis	rs1799949	1.000	rs8077486	chr17:41212805	C/T	cg23758822	chr17:41437982	NA	0.97	16.05	0.7	5.97e-41	Menopause (age at onset);
CESC	trans	rs637571	0.544	rs12361552	chr11:65701204	G/A	cg17712092	chr4:129076599	LARP1B	-0.68	-8.74	-0.47	2.67e-16	Eosinophil percentage of white cells;
CESC	cis	rs5753618	0.583	rs9606839	chr22:31802710	A/C	cg00478049	chr22:31556069	RNF185	-0.42	-5.03	-0.3	8.97e-7	Colorectal cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27193691	chr11:568206	MIR210	0.53	6.26	0.36	1.57e-9	Gut microbiome composition (summer);
CESC	cis	rs35740288	0.520	rs56183577	chr15:86319706	A/G	cg20737812	chr15:86336631	KLHL25	-0.46	-5.41	-0.32	1.42e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
CESC	cis	rs7000551	0.751	rs2469775	chr8:22373238	T/C	cg12081754	chr8:22256438	SLC39A14	0.4	5.4	0.32	1.45e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CESC	trans	rs7751419	0.527	rs4714216	chr6:39106207	G/A	cg14065446	chr9:133818825	NA	0.36	6.92	0.39	3.45e-11	Cardiovascular disease in hypertension (calcium channel blocker interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13196216	chr6:34231128	NA	-0.61	-6.75	-0.38	9.23e-11	Gut microbiome composition (summer);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg24023618	chr6:114292459	HDAC2	0.54	7.13	0.4	9.63e-12	Gut microbiota (bacterial taxa);
CESC	cis	rs6540559	0.673	rs11803382	chr1:209986426	G/A	cg09509183	chr1:209979624	IRF6	0.56	5.68	0.33	3.47e-8	Cleft lip with or without cleft palate;
CESC	cis	rs10504229	0.679	rs17801003	chr8:58050930	A/G	cg24829409	chr8:58192753	C8orf71	-0.68	-7.47	-0.42	1.2e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs72901758	0.768	rs11655421	chr17:76251518	T/A	cg26068271	chr17:76253126	NA	0.47	6.64	0.38	1.76e-10	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
CESC	cis	rs10788309	0.506	rs12359165	chr10:85821884	C/T	cg03623264	chr10:85672087	NA	-0.41	-5.83	-0.34	1.64e-8	Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
CESC	cis	rs561341	0.739	rs4795663	chr17:30214542	T/C	cg13647721	chr17:30228624	UTP6	-0.79	-10.09	-0.53	1.87e-20	Hip circumference adjusted for BMI;
CESC	cis	rs8180040	0.647	rs57756484	chr3:47239333	A/G	cg27129171	chr3:47204927	SETD2	-0.66	-9.64	-0.51	4.74e-19	Colorectal cancer;
CESC	cis	rs6062302	0.522	rs3810492	chr20:62219740	G/A	cg06363034	chr20:62225388	GMEB2	-0.5	-6.35	-0.36	9.21e-10	Glioblastoma;
CESC	cis	rs1983170	1.000	rs1983170	chr1:91986482	G/A	cg02896835	chr1:92012615	NA	0.56	6.43	0.37	6.04e-10	Eosinophil percentage of white cells;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg22708233	chr11:47198576	ARFGAP2	-0.44	-6.21	-0.36	2.08e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs10883723	0.738	rs3781290	chr10:104244948	G/C	cg22532475	chr10:104410764	TRIM8	-0.33	-5.64	-0.33	4.32e-8	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs11864453	0.826	rs8062041	chr16:72088964	C/T	cg23815491	chr16:72088622	HP	0.37	5.07	0.3	7.58e-7	Fibrinogen levels;
CESC	cis	rs514406	0.825	rs28817407	chr1:53226116	G/A	cg08859206	chr1:53392774	SCP2	0.53	7.09	0.4	1.19e-11	Monocyte count;
CESC	cis	rs1799949	1.000	rs1799966	chr17:41223094	T/C	cg23758822	chr17:41437982	NA	1.03	15.62	0.69	2.01e-39	Menopause (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15278734	chr4:147443742	SLC10A7	0.63	7.01	0.4	2e-11	Gut microbiome composition (summer);
CESC	cis	rs7264396	0.790	rs6121015	chr20:34243017	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.86	-11.74	-0.58	6.79e-26	Total cholesterol levels;
CESC	cis	rs10504229	0.683	rs2873638	chr8:58114593	G/A	cg02725872	chr8:58115012	NA	-0.45	-7.02	-0.4	1.83e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs2242116	0.796	rs7623898	chr3:46974172	C/T	cg02527881	chr3:46936655	PTH1R	0.51	7.18	0.4	7.14e-12	Birth weight;
CESC	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.89	13.57	0.64	3.36e-32	Prudent dietary pattern;
CESC	cis	rs10479542	0.549	rs4376229	chr5:179042971	A/G	cg05457628	chr5:178986728	RUFY1	0.46	6.5	0.37	3.88e-10	Lung cancer;
CESC	cis	rs13191362	1.000	rs2156257	chr6:163100710	G/T	cg18825119	chr6:163149453	PACRG;PARK2	0.54	5.2	0.3	4.01e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs9815354	0.812	rs11129932	chr3:41838767	C/A	cg03022575	chr3:42003672	ULK4	0.7	6.04	0.35	5.26e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs62229266	0.626	rs7280896	chr21:37460906	G/A	cg12218747	chr21:37451666	NA	-0.51	-7.7	-0.43	2.67e-13	Mitral valve prolapse;
CESC	cis	rs7666738	0.830	rs2114425	chr4:99023967	T/C	cg17366294	chr4:99064904	C4orf37	0.61	8.77	0.47	2.28e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6025261	0.874	rs454279	chr20:55513949	C/T	cg04763273	chr20:55502381	NA	0.31	5.27	0.31	2.88e-7	Verbal memory performance (delayed recall level);
CESC	cis	rs864537	0.618	rs1214595	chr1:167427557	G/A	cg22356347	chr1:167427500	CD247	-0.41	-8.43	-0.46	2.18e-15	Celiac disease or Rheumatoid arthritis;Celiac disease;
CESC	cis	rs2836974	0.897	rs8133146	chr21:40614298	T/C	cg27266027	chr21:40555129	PSMG1	0.43	5.09	0.3	6.68e-7	Cognitive function;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05792856	chr11:34379731	ABTB2	0.61	6.9	0.39	3.74e-11	Gut microbiome composition (summer);
CESC	cis	rs514406	0.767	rs551591	chr1:53301876	A/G	cg25767906	chr1:53392781	SCP2	-0.48	-6.4	-0.37	7.01e-10	Monocyte count;
CESC	cis	rs17345786	0.861	rs79181492	chr3:101216021	G/A	cg12386194	chr3:101231763	SENP7	0.61	6.4	0.37	7.01e-10	Colonoscopy-negative controls vs population controls;
CESC	cis	rs8072100	0.539	rs36043200	chr17:45629406	G/A	cg08085267	chr17:45401833	C17orf57	0.45	5.9	0.34	1.11e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs17293817	0.618	rs56117517	chr10:1430552	A/C	cg04271617	chr10:1416546	ADARB2	0.33	5.03	0.3	9.18e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs4713118	0.513	rs9368547	chr6:28028067	A/G	cg19592336	chr6:28129416	ZNF389	0.44	6.34	0.36	9.85e-10	Parkinson's disease;
CESC	cis	rs1008375	0.900	rs4698622	chr4:17589557	C/T	cg02297831	chr4:17616191	MED28	0.53	6.06	0.35	4.58e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	trans	rs4332037	0.539	rs11763750	chr7:2080114	G/A	cg11693508	chr17:37793320	STARD3	0.61	6.11	0.35	3.54e-9	Bipolar disorder;
CESC	cis	rs736408	0.812	rs1075653	chr3:52825528	T/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.3	5.04	0.3	8.79e-7	Bipolar disorder;
CESC	cis	rs854765	0.583	rs8070722	chr17:17813562	C/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.55	7.25	0.41	4.49e-12	Total body bone mineral density;
CESC	trans	rs2235573	0.527	rs139883	chr22:38369027	C/T	cg19894588	chr14:64061835	NA	0.57	7.43	0.42	1.5e-12	Glioblastoma;Glioma;
CESC	cis	rs6964587	0.732	rs12539523	chr7:91710836	G/A	cg17063962	chr7:91808500	NA	0.55	7.46	0.42	1.26e-12	Breast cancer;
CESC	cis	rs1832871	0.711	rs76962726	chr6:158674041	C/T	cg07165851	chr6:158734300	TULP4	0.59	6.26	0.36	1.5e-9	Height;
CESC	cis	rs875971	0.545	rs6460281	chr7:65681115	A/C	cg11764359	chr7:65958608	NA	0.79	9.37	0.5	3.25e-18	Aortic root size;
CESC	cis	rs2795502	1.000	rs2796575	chr10:43374911	A/G	cg27426351	chr10:43362370	NA	0.5	6.18	0.36	2.35e-9	Blood protein levels;
CESC	cis	rs6580649	0.943	rs3803183	chr12:48398080	T/A	cg24011408	chr12:48396354	COL2A1	0.4	5.24	0.31	3.22e-7	Lung cancer;
CESC	cis	rs853679	0.517	rs9368550	chr6:28051803	T/A	cg19592336	chr6:28129416	ZNF389	0.6	7.97	0.44	4.69e-14	Depression;
CESC	cis	rs4423214	0.840	rs1790339	chr11:71182761	C/A	cg05163923	chr11:71159392	DHCR7	-0.68	-7.76	-0.43	1.82e-13	Vitamin D levels;
CESC	cis	rs734999	0.545	rs12749591	chr1:2563250	G/T	cg18854424	chr1:2615690	NA	-0.29	-5.92	-0.34	1e-8	Ulcerative colitis;
CESC	cis	rs2836974	0.965	rs7354783	chr21:40652992	G/A	cg11890956	chr21:40555474	PSMG1	1.2	22.3	0.81	9.49e-63	Cognitive function;
CESC	cis	rs10771431	0.713	rs17794353	chr12:9361783	C/T	cg00504896	chr12:9437009	LOC642846	0.38	5.13	0.3	5.65e-7	Breast size;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg01353569	chr7:106810328	HBP1	0.48	6.47	0.37	4.81e-10	Systemic lupus erythematosus;
CESC	cis	rs9399137	0.507	rs7754722	chr6:135260303	T/C	cg24558204	chr6:135376177	HBS1L	-0.7	-9.45	-0.5	1.91e-18	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	cis	rs4665809	0.590	rs6749046	chr2:26429451	C/G	cg04944784	chr2:26401820	FAM59B	0.93	10.63	0.55	3.17e-22	Gut microbiome composition (summer);
CESC	cis	rs79349575	0.783	rs4793992	chr17:47008207	A/G	cg26022315	chr17:47021804	SNF8	0.39	5.15	0.3	5.04e-7	Type 2 diabetes;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg23539498	chr22:35654203	HMGXB4	-0.46	-6.55	-0.37	2.89e-10	Asthma;
CESC	cis	rs5758511	0.680	rs739146	chr22:42660414	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.57	8.69	0.47	3.84e-16	Birth weight;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18772858	chr7:2296703	SNX8	-0.59	-6.53	-0.37	3.25e-10	Gut microbiome composition (summer);
CESC	cis	rs763014	0.833	rs3743902	chr16:632728	T/C	cg00802000	chr16:706648	WDR90	-0.41	-6.12	-0.35	3.33e-9	Height;
CESC	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.64	7.2	0.4	6.35e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs637571	0.522	rs12797319	chr11:65735672	G/A	cg17712092	chr4:129076599	LARP1B	0.75	10.36	0.54	2.39e-21	Eosinophil percentage of white cells;
CESC	cis	rs4642101	0.793	rs6763619	chr3:12822147	T/G	cg24848339	chr3:12840334	CAND2	0.39	5.96	0.34	8.16e-9	QRS complex (12-leadsum);
CESC	cis	rs753778	0.667	rs10092439	chr8:142210881	C/T	cg18755752	chr8:142205143	DENND3	-0.68	-10.04	-0.53	2.54e-20	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	trans	rs983392	0.679	rs7128450	chr11:60031270	G/C	cg13921652	chr1:144931966	PDE4DIP	0.48	6.15	0.35	2.91e-9	Alzheimer's disease (late onset);
CESC	cis	rs9916302	0.904	rs34363096	chr17:37594294	G/A	cg07936489	chr17:37558343	FBXL20	-0.8	-11.5	-0.58	4.2e-25	Glomerular filtration rate (creatinine);
CESC	trans	rs875971	0.660	rs62465434	chr7:66005152	A/C	cg26939375	chr7:64535504	NA	0.63	8.63	0.47	5.93e-16	Aortic root size;
CESC	cis	rs6714710	0.603	rs13008968	chr2:98435982	C/T	cg26665480	chr2:98280029	ACTR1B	0.6	8.4	0.46	2.67e-15	Posterior cortical atrophy and Alzheimer's disease;
CESC	cis	rs11153306	1.000	rs17703931	chr6:111950995	C/T	cg22127309	chr6:111907043	TRAF3IP2	0.36	5.44	0.32	1.18e-7	Tonsillectomy;
CESC	cis	rs7647973	0.626	rs9824435	chr3:49674343	A/G	cg13072238	chr3:49761600	GMPPB	0.51	5.78	0.33	2.14e-8	Menarche (age at onset);
CESC	cis	rs200367988	1	rs200367988	chr10:122674849	G/A	cg14149699	chr10:122610679	WDR11	-0.48	-7.1	-0.4	1.14e-11	Prostate-specific antigen levels (conditioned on lead SNPs);Prostate-specific antigen levels;
CESC	cis	rs34779708	0.966	rs35079558	chr10:35479886	A/G	cg04310649	chr10:35416472	CREM	-0.5	-5.94	-0.34	8.97e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs9399401	0.961	rs9403381	chr6:142661156	A/C	cg03128060	chr6:142623767	GPR126	-0.26	-5.17	-0.3	4.53e-7	Chronic obstructive pulmonary disease;
CESC	cis	rs9858542	1.000	rs9823546	chr3:49705512	T/A	cg07274523	chr3:49395745	GPX1	0.65	8.36	0.46	3.58e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs7618501	0.966	rs2352974	chr3:49890613	C/T	cg24308560	chr3:49941425	MST1R	-0.47	-6.13	-0.35	3.14e-9	Intelligence (multi-trait analysis);
CESC	cis	rs9650657	0.530	rs6982381	chr8:10952500	A/T	cg21775007	chr8:11205619	TDH	-0.36	-5.04	-0.3	8.76e-7	Neuroticism;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg04179819	chr10:7860513	TAF3	-0.47	-6.35	-0.36	9.29e-10	Ulcerative colitis;
CESC	cis	rs2832077	0.527	rs2738953	chr21:30238363	G/C	cg24692254	chr21:30365293	RNF160	0.53	6.9	0.39	3.79e-11	Cognitive test performance;
CESC	cis	rs34172651	0.917	rs17771137	chr16:24792242	G/A	cg06028605	chr16:24865363	SLC5A11	0.41	6.22	0.36	1.94e-9	Intelligence (multi-trait analysis);
CESC	cis	rs4474465	0.850	rs4245460	chr11:78258147	G/C	cg02023728	chr11:77925099	USP35	-0.39	-5.14	-0.3	5.25e-7	Alzheimer's disease (survival time);
CESC	cis	rs4974559	0.739	rs3817604	chr4:1291337	C/T	cg02980000	chr4:1222292	CTBP1	0.8	7.12	0.4	1.02e-11	Systolic blood pressure;
CESC	cis	rs6582630	0.555	rs7965311	chr12:38513307	G/A	cg26384229	chr12:38710491	ALG10B	-0.65	-9.76	-0.51	1.94e-19	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs853679	0.542	rs9380063	chr6:28137853	A/G	cg23281280	chr6:28129359	ZNF389	0.56	7.61	0.42	4.93e-13	Depression;
CESC	cis	rs4835473	0.832	rs62337616	chr4:144658460	A/C	cg25736465	chr4:144833511	NA	-0.33	-5.25	-0.31	3.1e-7	Immature fraction of reticulocytes;
CESC	cis	rs3806843	0.966	rs2240693	chr5:140183325	G/C	cg26395211	chr5:140044315	WDR55	-0.42	-5.33	-0.31	2.07e-7	Depressive symptoms (multi-trait analysis);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg23112213	chr5:137549144	CDC23	0.43	6.11	0.35	3.5e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs3749237	0.615	rs55957735	chr3:49438158	G/A	cg02487422	chr3:49467188	NICN1	0.55	7.99	0.44	4.23e-14	Resting heart rate;
CESC	cis	rs7692995	1.000	rs7671110	chr4:17874089	C/T	cg08925142	chr4:18023851	LCORL	-0.46	-5.26	-0.31	3e-7	Height;
CESC	cis	rs760805	1.000	rs10903115	chr1:25261696	A/G	cg22509179	chr1:25234806	RUNX3	-0.63	-9.41	-0.5	2.44e-18	Allergic disease (asthma, hay fever or eczema);
CESC	trans	rs61931739	0.500	rs7306334	chr12:34482900	A/G	cg26384229	chr12:38710491	ALG10B	-0.71	-10.7	-0.55	1.85e-22	Morning vs. evening chronotype;
CESC	cis	rs17666538	0.585	rs4333567	chr8:636611	C/T	cg07234876	chr8:600039	NA	0.86	5.3	0.31	2.49e-7	IgG glycosylation;
CESC	cis	rs2072732	0.861	rs12041583	chr1:2950886	A/G	cg03976712	chr1:2946727	NA	0.33	5.45	0.32	1.17e-7	Plateletcrit;
CESC	cis	rs11098499	0.954	rs71614438	chr4:120371252	G/A	cg09307838	chr4:120376055	NA	0.94	13.7	0.64	1.18e-32	Corneal astigmatism;
CESC	cis	rs3947	1.000	rs3947	chr8:11702375	G/A	cg00262122	chr8:11665843	FDFT1	-0.5	-5.12	-0.3	5.8e-7	Blood protein levels;
CESC	cis	rs793571	0.536	rs7183336	chr15:58966236	C/T	cg05156742	chr15:59063176	FAM63B	0.58	7.19	0.4	6.73e-12	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08854560	chr22:38453474	PICK1	0.57	6.14	0.35	2.99e-9	Gut microbiome composition (summer);
CESC	cis	rs801193	0.805	rs12532355	chr7:66070584	C/G	cg18876405	chr7:65276391	NA	-0.54	-7.57	-0.42	6.03e-13	Aortic root size;
CESC	trans	rs6089829	0.926	rs6062395	chr20:61667904	A/G	cg23505145	chr19:12996616	KLF1	0.51	6.68	0.38	1.37e-10	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs763121	0.853	rs5750672	chr22:39104168	C/T	cg21395723	chr22:39101663	GTPBP1	-0.41	-5.09	-0.3	6.79e-7	Menopause (age at onset);
CESC	trans	rs2109514	0.505	rs1633714	chr7:116022538	C/T	cg22605924	chr3:168526498	C3orf50	0.39	6.18	0.35	2.47e-9	Prevalent atrial fibrillation;
CESC	cis	rs938554	0.577	rs4591605	chr4:10002719	T/C	cg11266682	chr4:10021025	SLC2A9	0.45	6.21	0.36	2.07e-9	Blood metabolite levels;
CESC	cis	rs4629710	0.592	rs9492865	chr6:131534403	T/A	cg12606694	chr6:131520996	AKAP7	0.47	5.77	0.33	2.2e-8	Multiple myeloma (IgH translocation);
CESC	cis	rs2274273	0.840	rs6573020	chr14:55871452	C/T	cg04306507	chr14:55594613	LGALS3	0.27	5.4	0.31	1.51e-7	Protein biomarker;
CESC	cis	rs748404	0.578	rs478028	chr15:43610772	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.6	8.0	0.44	3.9e-14	Lung cancer;
CESC	cis	rs1348850	0.914	rs3902850	chr2:178315899	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.88	12.77	0.62	2e-29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs798554	0.797	rs798488	chr7:2802522	T/C	cg09658497	chr7:2847517	GNA12	-0.43	-6.09	-0.35	4.05e-9	Height;
CESC	cis	rs36051895	0.632	rs12352285	chr9:5141476	C/G	cg02405213	chr9:5042618	JAK2	-0.49	-6.21	-0.36	2.09e-9	Pediatric autoimmune diseases;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg24833071	chr7:75115655	POM121C	-0.46	-6.21	-0.36	2.06e-9	Fibrinogen levels;
CESC	cis	rs34172651	0.571	rs9922156	chr16:24704329	C/A	cg06505273	chr16:24850292	NA	-0.45	-5.56	-0.32	6.46e-8	Intelligence (multi-trait analysis);
CESC	cis	rs9287719	0.839	rs7600695	chr2:10739945	A/G	cg00105475	chr2:10696890	NA	0.39	5.61	0.33	4.96e-8	Prostate cancer;
CESC	trans	rs1814175	0.754	rs7103235	chr11:49699191	A/G	cg03929089	chr4:120376271	NA	-0.76	-10.19	-0.53	8.33e-21	Height;
CESC	cis	rs4919694	1.000	rs111622998	chr10:104953021	C/A	cg04362960	chr10:104952993	NT5C2	0.85	7.39	0.41	1.91e-12	Arsenic metabolism;
CESC	cis	rs2415984	0.562	rs1494092	chr14:46970304	T/C	cg14871534	chr14:47121158	RPL10L	0.4	5.62	0.33	4.94e-8	Number of children ever born;
CESC	cis	rs12497850	0.765	rs12487580	chr3:49182932	G/A	cg02487422	chr3:49467188	NICN1	0.48	6.16	0.35	2.75e-9	Parkinson's disease;
CESC	cis	rs11608355	0.515	rs12826754	chr12:109923244	A/G	cg05360138	chr12:110035743	NA	0.81	8.75	0.47	2.52e-16	Neuroticism;
CESC	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.48	-5.2	-0.3	4.05e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs9902453	0.780	rs3115093	chr17:28039755	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.76	10.12	0.53	1.41e-20	Coffee consumption (cups per day);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06747916	chr17:57784835	TMEM49;PTRH2	0.63	7.05	0.4	1.59e-11	Gut microbiome composition (summer);
CESC	cis	rs72781680	0.898	rs72786298	chr2:24083011	C/T	cg20701182	chr2:24300061	SF3B14	0.79	6.89	0.39	4.15e-11	Lymphocyte counts;
CESC	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg06873352	chr17:61820015	STRADA	0.72	12.56	0.61	1.02e-28	Prudent dietary pattern;
CESC	cis	rs6502050	0.799	rs4789674	chr17:80123200	G/A	cg23985595	chr17:80112537	CCDC57	-0.41	-6.57	-0.37	2.6200000000000003e-10	Life satisfaction;
CESC	cis	rs2204008	0.713	rs2320522	chr12:38251438	C/T	cg13010199	chr12:38710504	ALG10B	0.52	6.38	0.36	8.04e-10	Bladder cancer;
CESC	trans	rs916888	0.821	rs415430	chr17:44859144	C/T	cg07870213	chr5:140052090	DND1	-0.61	-6.89	-0.39	4.01e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs300703	0.542	rs300696	chr2:183330	G/A	cg21211680	chr2:198530	NA	-0.85	-9.2	-0.49	1.08e-17	Blood protein levels;
CESC	cis	rs9300255	0.602	rs1790116	chr12:123618544	G/T	cg00376283	chr12:123451042	ABCB9	0.69	8.67	0.47	4.33e-16	Neutrophil percentage of white cells;
CESC	cis	rs1801251	0.685	rs1515961	chr2:233623763	C/A	cg08000102	chr2:233561755	GIGYF2	0.66	9.78	0.51	1.79e-19	Coronary artery disease;
CESC	cis	rs10851478	0.872	rs1948975	chr15:49984805	C/A	cg08060515	chr15:49448048	GALK2;COPS2	0.44	5.24	0.31	3.22e-7	Oral cavity cancer;
CESC	cis	rs1218582	0.744	rs6674853	chr1:154892753	G/C	cg09359103	chr1:154839909	KCNN3	-0.63	-11.19	-0.57	4.58e-24	Prostate cancer;
CESC	cis	rs9905704	0.846	rs28363318	chr17:56798207	T/C	cg12560992	chr17:57184187	TRIM37	0.62	7.78	0.43	1.6e-13	Testicular germ cell tumor;
CESC	cis	rs9311474	0.659	rs1133415	chr3:52575831	G/A	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.31	5.64	0.33	4.27e-8	Electroencephalogram traits;
CESC	cis	rs2836974	0.965	rs8131126	chr21:40655754	A/G	cg27266027	chr21:40555129	PSMG1	0.47	5.36	0.31	1.84e-7	Cognitive function;
CESC	cis	rs7618501	1.000	rs1049256	chr3:49763338	T/C	cg24308560	chr3:49941425	MST1R	0.5	6.81	0.39	6.39e-11	Intelligence (multi-trait analysis);
CESC	cis	rs116095464	0.558	rs62346526	chr5:220614	T/C	cg22857025	chr5:266934	NA	-1.27	-18.89	-0.76	5.51e-51	Breast cancer;
CESC	cis	rs4253772	0.513	rs6008700	chr22:46722560	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.78	9.29	0.5	5.98e-18	LDL cholesterol;Cholesterol, total;
CESC	cis	rs9300255	0.537	rs1727334	chr12:123714236	A/G	cg19016782	chr12:123741754	C12orf65	-0.5	-7.08	-0.4	1.33e-11	Neutrophil percentage of white cells;
CESC	cis	rs4713118	0.540	rs469227	chr6:27970705	A/C	cg23281280	chr6:28129359	ZNF389	0.45	6.18	0.35	2.39e-9	Parkinson's disease;
CESC	cis	rs5769765	1.000	rs5770728	chr22:50259984	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	0.45	5.26	0.31	2.9e-7	Schizophrenia;
CESC	cis	rs7605827	0.930	rs1015835	chr2:15625768	T/C	cg19274914	chr2:15703543	NA	0.36	6.41	0.37	6.6e-10	Educational attainment (years of education);
CESC	cis	rs3785574	0.962	rs8079161	chr17:61808561	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.81	10.8	0.55	8.72e-23	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22804502	chr6:7389831	CAGE1;RIOK1	0.56	6.46	0.37	4.91e-10	Gut microbiome composition (summer);
CESC	cis	rs2985684	0.894	rs4581611	chr14:50043520	A/T	cg10008539	chr14:50087325	RPL36AL;MGAT2	-0.43	-5.21	-0.3	3.82e-7	Carotid intima media thickness;
CESC	trans	rs12339966	0.689	rs2586344	chr9:11677296	A/G	cg03904639	chr13:37677730	CSNK1A1L	0.39	6.06	0.35	4.67e-9	Systolic blood pressure;
CESC	cis	rs2243480	0.901	rs35823062	chr7:65965821	A/G	cg12463550	chr7:65579703	CRCP	0.71	5.51	0.32	8.58e-8	Diabetic kidney disease;
CESC	trans	rs9693444	0.898	rs4732697	chr8:29519861	A/G	cg11199428	chr13:52027379	INTS6	-0.43	-6.21	-0.36	2.02e-9	Breast cancer;
CESC	cis	rs459482	1.000	rs464783	chr21:42796480	A/G	cg14166395	chr21:42792516	MX1	-0.57	-7.41	-0.41	1.68e-12	IgG glycosylation;
CESC	cis	rs6963495	0.585	rs1728653	chr7:105191335	A/G	cg19920283	chr7:105172520	RINT1	0.61	7.08	0.4	1.29e-11	Bipolar disorder (body mass index interaction);
CESC	cis	rs7666738	0.830	rs11727653	chr4:99001774	T/C	cg17366294	chr4:99064904	C4orf37	0.6	8.61	0.47	6.47e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6570726	0.599	rs455001	chr6:145854450	A/T	cg23711669	chr6:146136114	FBXO30	0.93	12.22	0.6	1.57e-27	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs7824557	0.510	rs1435274	chr8:11235910	G/A	cg06636001	chr8:8085503	FLJ10661	-0.51	-6.31	-0.36	1.19e-9	Retinal vascular caliber;
CESC	cis	rs801193	0.569	rs2659893	chr7:66199993	G/A	cg18876405	chr7:65276391	NA	0.45	6.09	0.35	3.92e-9	Aortic root size;
CESC	cis	rs4803455	0.565	rs11083616	chr19:41865643	A/G	cg08477640	chr19:41863820	B9D2	-0.48	-6.78	-0.38	7.67e-11	Migraine;Coronary artery disease;
CESC	cis	rs7551222	0.752	rs4951407	chr1:204558070	G/T	cg20240347	chr1:204465584	NA	0.31	6.47	0.37	4.68e-10	Schizophrenia;
CESC	trans	rs7937682	0.889	rs479667	chr11:111484034	C/T	cg18187862	chr3:45730750	SACM1L	0.47	6.02	0.35	5.75e-9	Primary sclerosing cholangitis;
CESC	cis	rs1862618	0.525	rs2662021	chr5:56261691	C/T	cg24549020	chr5:56110836	MAP3K1	-0.54	-6.11	-0.35	3.54e-9	Initial pursuit acceleration;
CESC	cis	rs8062405	0.755	rs2077031	chr16:28603168	T/A	cg07382826	chr16:28625726	SULT1A1	0.4	6.6	0.38	2.18e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs2274273	0.837	rs11625968	chr14:55801004	G/C	cg04306507	chr14:55594613	LGALS3	0.3	5.75	0.33	2.48e-8	Protein biomarker;
CESC	cis	rs875971	0.522	rs4718286	chr7:65292764	A/G	cg05332525	chr7:65337924	VKORC1L1	0.52	6.43	0.37	6.04e-10	Aortic root size;
CESC	cis	rs4803468	1.000	rs3810175	chr19:41904396	C/T	cg14132834	chr19:41945861	ATP5SL	0.67	8.38	0.46	3.22e-15	Height;
CESC	cis	rs7247513	0.658	rs4804728	chr19:12752928	G/A	cg01871581	chr19:12707946	ZNF490	-0.74	-10.68	-0.55	2.17e-22	Bipolar disorder;
CESC	cis	rs12711979	0.729	rs6714956	chr2:3820454	T/C	cg17052675	chr2:3827356	NA	-0.42	-6.47	-0.37	4.59e-10	Itch intensity from mosquito bite adjusted by bite size;
CESC	cis	rs2991971	1.000	rs2934859	chr1:46017836	C/T	cg06784218	chr1:46089804	CCDC17	-0.3	-5.16	-0.3	4.9e-7	High light scatter reticulocyte count;
CESC	cis	rs155076	1.000	rs658244	chr13:21850976	T/C	cg11317459	chr13:21872234	NA	-1.03	-11.01	-0.56	1.8e-23	White matter hyperintensity burden;
CESC	cis	rs597539	0.552	rs10896384	chr11:68720011	A/G	cg04772025	chr11:68637568	NA	-0.49	-5.74	-0.33	2.59e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs3857067	1.000	rs28840089	chr4:95000403	A/T	cg11021082	chr4:95130006	SMARCAD1	-0.52	-8.0	-0.44	3.93e-14	QT interval;
CESC	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.89	13.55	0.64	3.99e-32	Prudent dietary pattern;
CESC	cis	rs7613875	0.620	rs7430334	chr3:50078221	T/C	cg24308560	chr3:49941425	MST1R	0.6	8.72	0.47	3.17e-16	Body mass index;
CESC	cis	rs8062405	0.573	rs7187575	chr16:28990101	C/T	cg05966235	chr16:28915196	ATP2A1	-0.4	-5.61	-0.33	5.1e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs116161686	0.500	rs55871867	chr1:210051029	A/G	cg22029157	chr1:209979665	IRF6	0.68	7.09	0.4	1.19e-11	Coronary artery disease;
CESC	cis	rs597539	0.617	rs669659	chr11:68635623	G/C	cg21963583	chr11:68658836	MRPL21	0.42	5.89	0.34	1.15e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs7666738	0.791	rs4440223	chr4:99044796	G/A	cg03467027	chr4:99064603	C4orf37	0.47	5.98	0.34	7.19e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs854765	0.583	rs4244602	chr17:17841456	A/G	cg16928487	chr17:17741425	SREBF1	-0.59	-10.04	-0.53	2.52e-20	Total body bone mineral density;
CESC	trans	rs11098499	0.954	rs10017371	chr4:120293776	A/G	cg25214090	chr10:38739885	LOC399744	0.69	9.32	0.5	4.71e-18	Corneal astigmatism;
CESC	cis	rs9815354	0.812	rs73081370	chr3:41916258	G/C	cg03022575	chr3:42003672	ULK4	0.68	5.92	0.34	9.93e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs561341	1.000	rs55959993	chr17:30254771	C/G	cg00745463	chr17:30367425	LRRC37B	-0.85	-7.62	-0.42	4.38e-13	Hip circumference adjusted for BMI;
CESC	cis	rs7772486	0.686	rs1292334	chr6:145968288	A/G	cg05347473	chr6:146136440	FBXO30	0.55	7.06	0.4	1.5e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9488822	0.676	rs12202181	chr6:116327102	A/G	cg15226275	chr6:116381976	FRK	0.25	6.18	0.35	2.39e-9	Cholesterol, total;LDL cholesterol;
CESC	cis	rs11098499	0.863	rs12502389	chr4:120454191	A/G	cg24375607	chr4:120327624	NA	0.43	5.21	0.3	3.82e-7	Corneal astigmatism;
CESC	cis	rs8014204	0.870	rs3742790	chr14:75308758	C/T	cg11812906	chr14:75593930	NEK9	-0.43	-5.46	-0.32	1.07e-7	Caffeine consumption;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22100228	chr8:94929017	PDP1	0.63	6.95	0.39	2.89e-11	Gut microbiome composition (summer);
CESC	trans	rs17685	0.625	rs1639630	chr7:75730499	T/C	cg19862616	chr7:65841803	NCRNA00174	0.85	12.5	0.61	1.68e-28	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.52	-6.44	-0.37	5.55e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg27005181	chr13:20208413	MPHOSPH8	-0.43	-6.19	-0.36	2.24e-9	Vertical cup-disc ratio;
CESC	cis	rs853679	0.517	rs4713137	chr6:28083521	C/G	cg26335602	chr6:28129616	ZNF389	0.53	7.06	0.4	1.48e-11	Depression;
CESC	cis	rs8031584	1.000	rs35811129	chr15:31241346	G/A	cg08109568	chr15:31115862	NA	-0.75	-9.45	-0.5	1.91e-18	Huntington's disease progression;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17597374	chr11:61106595	DAK	-0.68	-7.88	-0.44	8.29e-14	Gut microbiome composition (summer);
CESC	cis	rs9403521	1.000	rs9403521	chr6:143994199	C/T	cg21026257	chr6:143998961	PHACTR2	-0.47	-5.16	-0.3	4.84e-7	Obesity-related traits;
CESC	cis	rs1538970	0.924	rs11211118	chr1:45930270	A/C	cg24296786	chr1:45957014	TESK2	-0.46	-5.17	-0.3	4.58e-7	Platelet count;
CESC	cis	rs4713118	0.629	rs203890	chr6:28022248	T/C	cg22143856	chr6:28129313	ZNF389	0.42	5.24	0.31	3.35e-7	Parkinson's disease;
CESC	cis	rs17376456	0.741	rs12374432	chr5:93481348	C/A	cg25358565	chr5:93447407	FAM172A	1.17	11.51	0.58	3.92e-25	Diabetic retinopathy;
CESC	cis	rs3785574	0.582	rs62072238	chr17:61948841	A/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.06	17.85	0.74	2.52e-47	Height;
CESC	cis	rs1801251	1.000	rs10933412	chr2:233707226	G/C	cg25237894	chr2:233734115	C2orf82	-0.46	-8.1	-0.45	2.01e-14	Coronary artery disease;
CESC	cis	rs2742417	0.603	rs1019129	chr3:45780780	T/C	cg04837898	chr3:45731254	SACM1L	-0.49	-6.31	-0.36	1.19e-9	Response to anti-depressant treatment in major depressive disorder;
CESC	trans	rs61931739	0.534	rs11052959	chr12:33997095	T/C	cg26384229	chr12:38710491	ALG10B	0.58	8.13	0.45	1.64e-14	Morning vs. evening chronotype;
CESC	cis	rs523522	0.962	rs2235218	chr12:120888619	A/C	cg12219531	chr12:120966889	COQ5	0.73	9.13	0.49	1.83e-17	High light scatter reticulocyte count;
CESC	cis	rs300703	0.654	rs393277	chr2:121539	G/T	cg21211680	chr2:198530	NA	-0.97	-9.92	-0.52	6.44e-20	Blood protein levels;
CESC	cis	rs67311347	1.000	rs6793596	chr3:40457795	C/T	cg24209194	chr3:40518798	ZNF619	0.5	6.16	0.35	2.66e-9	Renal cell carcinoma;
CESC	cis	rs6674176	0.597	rs6671164	chr1:44403489	G/T	cg23954153	chr1:44402353	ARTN	-0.34	-5.24	-0.31	3.22e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs7666738	0.830	rs35951881	chr4:98999474	A/C	cg05340658	chr4:99064831	C4orf37	0.8	12.44	0.61	2.83e-28	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09352908	chr3:37017749	NA	-0.7	-8.3	-0.45	5.37e-15	Gut microbiome composition (summer);
CESC	trans	rs1814175	0.645	rs10839382	chr11:49823172	C/T	cg03929089	chr4:120376271	NA	-0.89	-13.85	-0.65	3.4e-33	Height;
CESC	cis	rs7917772	0.503	rs10883732	chr10:104293461	G/A	cg22532475	chr10:104410764	TRIM8	-0.34	-5.81	-0.34	1.82e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs4423214	0.879	rs1790353	chr11:71136730	C/T	cg05163923	chr11:71159392	DHCR7	-0.63	-7.28	-0.41	3.75e-12	Vitamin D levels;
CESC	cis	rs4713118	0.621	rs9295756	chr6:28033396	G/T	cg18032046	chr6:28092343	ZSCAN16	-0.53	-5.98	-0.35	7.05e-9	Parkinson's disease;
CESC	cis	rs73411413	0.661	rs11599981	chr11:1520063	C/T	cg03836507	chr11:1520812	HCCA2	-0.48	-5.27	-0.31	2.87e-7	Myringotomy;
CESC	cis	rs7666738	0.830	rs1534319	chr4:98964804	T/C	cg03676636	chr4:99064102	C4orf37	0.33	5.14	0.3	5.39e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9649465	0.967	rs768680	chr7:123364127	T/C	cg04330084	chr7:123175371	IQUB	-0.38	-5.18	-0.3	4.33e-7	Migraine;
CESC	cis	rs7202877	0.706	rs247447	chr16:75486648	A/G	cg04384234	chr16:75411784	CFDP1	0.48	5.6	0.33	5.22e-8	Type 2 diabetes;Type 1 diabetes;
CESC	trans	rs6600671	0.934	rs11249431	chr1:121286203	A/G	cg17023122	chr1:144479586	NA	-0.5	-6.61	-0.38	2.11e-10	Hip geometry;
CESC	cis	rs2109514	0.593	rs9649394	chr7:116171510	A/G	cg04696780	chr7:116139425	CAV2	-0.3	-5.45	-0.32	1.12e-7	Prevalent atrial fibrillation;
CESC	cis	rs4819052	0.959	rs8130866	chr21:46672112	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.55	6.66	0.38	1.55e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs6502050	0.835	rs10163483	chr17:80110396	C/A	cg23985595	chr17:80112537	CCDC57	-0.41	-6.41	-0.37	6.76e-10	Life satisfaction;
CESC	cis	rs40363	0.645	rs250631	chr16:3523215	G/C	cg22508957	chr16:3507546	NAT15	0.57	9.03	0.48	3.76e-17	Tuberculosis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07464025	chr10:13482639	BEND7	0.6	6.63	0.38	1.9e-10	Gut microbiome composition (summer);
CESC	trans	rs1549733	0.552	rs16857862	chr2:218420477	T/C	cg23408253	chr19:17438755	ANO8	-0.46	-6.01	-0.35	6.2e-9	Optic disc area;
CESC	cis	rs7301826	1.000	rs4759787	chr12:131290180	A/C	cg11011512	chr12:131303247	STX2	0.4	5.08	0.3	7.16e-7	Plasma plasminogen activator levels;
CESC	cis	rs7336332	0.598	rs9581850	chr13:28012265	A/G	cg22138327	chr13:27999177	GTF3A	0.62	5.82	0.34	1.71e-8	Weight;
CESC	cis	rs1816752	0.935	rs4770676	chr13:25003883	A/G	cg02811702	chr13:24901961	NA	0.38	5.49	0.32	9.38e-8	Obesity-related traits;
CESC	cis	rs752010	0.905	rs10890150	chr1:42095603	A/C	cg06885757	chr1:42089581	HIVEP3	0.54	8.91	0.48	8.52e-17	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs2841277	0.708	rs10083496	chr14:105402786	G/A	cg19901468	chr14:105411992	AHNAK2	-0.59	-8.46	-0.46	1.81e-15	Rheumatoid arthritis;
CESC	cis	rs34638657	0.732	rs12597534	chr16:82200276	G/T	cg09439754	chr16:82129088	HSD17B2	-0.35	-6.22	-0.36	1.93e-9	Lung adenocarcinoma;
CESC	cis	rs7680126	0.633	rs4698023	chr4:10304726	A/G	cg00071950	chr4:10020882	SLC2A9	-0.43	-5.03	-0.3	8.86e-7	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	cis	rs208520	1.000	rs72882079	chr6:66973878	T/C	cg07460842	chr6:66804631	NA	0.9	10.27	0.53	4.61e-21	Exhaled nitric oxide output;
CESC	trans	rs9929218	0.954	rs12924033	chr16:68822599	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.62	-7.97	-0.44	4.84e-14	Colorectal cancer;
CESC	cis	rs7937682	0.961	rs17113227	chr11:111620491	A/G	cg22437258	chr11:111473054	SIK2	0.55	6.52	0.37	3.44e-10	Primary sclerosing cholangitis;
CESC	cis	rs2742234	0.656	rs1864400	chr10:43610366	G/A	cg15436174	chr10:43711423	RASGEF1A	-0.45	-5.18	-0.3	4.4e-7	Hirschsprung disease;
CESC	cis	rs727505	0.721	rs55890146	chr7:124755461	A/T	cg23710748	chr7:124431027	NA	-0.38	-6.17	-0.35	2.6e-9	Lewy body disease;
CESC	cis	rs4332037	0.851	rs34040190	chr7:1920356	G/A	cg23422044	chr7:1970798	MAD1L1	-0.59	-6.1	-0.35	3.68e-9	Bipolar disorder;
CESC	cis	rs4901847	0.643	rs1998101	chr14:58598706	T/C	cg15908186	chr14:58618357	C14orf37	0.35	5.15	0.3	4.98e-7	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs13108904	0.935	rs2293633	chr4:1291640	T/C	cg16405210	chr4:1374714	KIAA1530	-0.49	-6.19	-0.36	2.34e-9	Obesity-related traits;
CESC	cis	rs6456156	0.565	rs12529959	chr6:167469292	T/C	cg23791538	chr6:167370224	RNASET2	-0.5	-6.47	-0.37	4.66e-10	Primary biliary cholangitis;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg23181591	chr8:123793873	ZHX2	-0.46	-6.12	-0.35	3.44e-9	Height;
CESC	trans	rs9324380	0.735	rs4634961	chr1:98487763	A/G	cg27522060	chr15:65360366	RASL12	-0.6	-6.11	-0.35	3.55e-9	Intelligence (multi-trait analysis);
CESC	cis	rs6815814	0.950	rs5743593	chr4:38802913	A/G	cg02016764	chr4:38805732	TLR1	-0.63	-7.4	-0.41	1.8e-12	Breast cancer;
CESC	cis	rs514406	0.755	rs10888754	chr1:53228751	C/G	cg27535305	chr1:53392650	SCP2	0.31	5.48	0.32	9.77e-8	Monocyte count;
CESC	cis	rs754466	1.000	rs12220328	chr10:79681482	G/C	cg17075019	chr10:79541650	NA	-0.7	-8.93	-0.48	7.17e-17	Liver enzyme levels (gamma-glutamyl transferase);
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	ch.10.2372731R	chr10:112966440	NA	-0.47	-6.3	-0.36	1.25e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs270601	0.739	rs1979981	chr5:131601720	G/A	cg24060327	chr5:131705240	SLC22A5	-0.47	-6.09	-0.35	4.03e-9	Acylcarnitine levels;
CESC	cis	rs7809950	0.678	rs62482507	chr7:107024488	T/G	cg23024343	chr7:107201750	COG5	-0.6	-7.6	-0.42	5.09e-13	Coronary artery disease;
CESC	cis	rs1003719	0.707	rs9976360	chr21:38587860	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.6	-8.12	-0.45	1.81e-14	Eye color traits;
CESC	cis	rs2070488	0.965	rs6805386	chr3:38557921	T/C	cg24069376	chr3:38537580	EXOG	-0.46	-8.5	-0.46	1.37e-15	Electrocardiographic conduction measures;
CESC	cis	rs55794721	0.509	rs2375313	chr1:25748235	G/A	cg03538708	chr1:25844672	NA	-0.42	-6.26	-0.36	1.58e-9	Plateletcrit;Mean corpuscular volume;
CESC	cis	rs7086627	0.515	rs10887905	chr10:82210855	A/T	cg03267442	chr10:82210566	NA	-0.34	-5.66	-0.33	3.98e-8	Post bronchodilator FEV1;
CESC	cis	rs11098499	0.863	rs10019674	chr4:120443489	C/T	cg24375607	chr4:120327624	NA	-0.49	-6.15	-0.35	2.77e-9	Corneal astigmatism;
CESC	cis	rs3011225	0.710	rs3011222	chr1:44317545	C/T	cg12908607	chr1:44402522	ARTN	-0.46	-6.6	-0.38	2.26e-10	Amyotrophic lateral sclerosis (age of onset);
CESC	cis	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg25809561	chr17:30822961	MYO1D	-0.44	-6.23	-0.36	1.79e-9	Schizophrenia;
CESC	cis	rs1348850	0.609	rs1348851	chr2:178418677	C/T	cg23306229	chr2:178417860	TTC30B	-0.86	-7.47	-0.42	1.14e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg24642844	chr7:1081250	C7orf50	-0.78	-9.71	-0.51	2.98e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg02184338	chr7:101331866	NA	-0.45	-6.14	-0.35	2.99e-9	Fibrinogen levels;
CESC	cis	rs1153858	1.000	rs1890565	chr15:45663299	T/C	cg21132104	chr15:45694354	SPATA5L1	0.86	11.62	0.58	1.67e-25	Homoarginine levels;
CESC	cis	rs11098499	0.954	rs7681544	chr4:120411255	T/C	cg24375607	chr4:120327624	NA	0.46	5.63	0.33	4.52e-8	Corneal astigmatism;
CESC	cis	rs131805	1.000	rs131805	chr22:50964153	T/C	cg25309564	chr22:51001381	C22orf41	0.64	6.39	0.37	7.6e-10	Granulocyte percentage of myeloid white cells;
CESC	cis	rs4523957	0.583	rs8077597	chr17:2043818	C/T	cg16513277	chr17:2031491	SMG6	-0.79	-11.73	-0.58	6.95e-26	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs5769765	0.955	rs9616394	chr22:50314927	G/C	cg02269571	chr22:50332266	NA	-0.55	-6.33	-0.36	1.05e-9	Schizophrenia;
CESC	cis	rs2816062	0.813	rs2745318	chr1:18895844	C/T	cg18795169	chr1:18902165	NA	0.92	18.72	0.75	2.15e-50	Urate levels in lean individuals;
CESC	cis	rs7216064	1.000	rs11079707	chr17:65835617	A/G	cg07042672	chr17:66097459	LOC651250	0.51	5.72	0.33	2.86e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs4654899	0.627	rs637990	chr1:21047616	A/G	cg05370193	chr1:21551575	ECE1	-0.37	-5.33	-0.31	2.15e-7	Superior frontal gyrus grey matter volume;
CESC	cis	rs7552404	0.924	rs1611823	chr1:76221706	T/G	cg10523679	chr1:76189770	ACADM	0.75	10.09	0.53	1.8e-20	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs13191362	1.000	rs35583420	chr6:163214327	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.57	5.35	0.31	1.91e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs35306767	0.855	rs12781100	chr10:838636	C/T	cg26597838	chr10:835615	NA	1.18	12.02	0.59	7.45e-27	Eosinophil percentage of granulocytes;
CESC	cis	rs425277	0.606	rs262663	chr1:2084598	T/C	cg04315214	chr1:2043799	PRKCZ	-0.45	-7.35	-0.41	2.54e-12	Height;
CESC	cis	rs2997447	0.706	rs17184877	chr1:26443908	A/T	cg24596570	chr1:26146463	FAM54B;LOC646471	0.62	5.41	0.32	1.41e-7	QRS complex (12-leadsum);
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg27319730	chr6:36237037	PNPLA1	-0.44	-6.47	-0.37	4.69e-10	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs5769765	0.862	rs9616774	chr22:50290599	G/A	cg26441486	chr22:50317300	CRELD2	0.38	5.32	0.31	2.17e-7	Schizophrenia;
CESC	cis	rs1580019	0.885	rs4460270	chr7:32496450	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.72	9.97	0.52	4.3e-20	Cognitive ability;
CESC	cis	rs2228479	0.867	rs11646448	chr16:89966357	A/T	cg06558623	chr16:89946397	TCF25	1.03	9.47	0.5	1.58e-18	Skin colour saturation;
CESC	cis	rs4948102	0.731	rs4543497	chr7:56047215	T/C	cg09872392	chr7:56161020	PHKG1	-0.46	-7.25	-0.41	4.59e-12	Plasma homocysteine levels (post-methionine load test);
CESC	cis	rs2425143	1.000	rs56052651	chr20:34344084	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.64	5.59	0.32	5.53e-8	Blood protein levels;
CESC	cis	rs6460942	0.915	rs75158182	chr7:12456059	C/T	cg06484146	chr7:12443880	VWDE	-0.78	-9.14	-0.49	1.68e-17	Coronary artery disease;
CESC	cis	rs4665809	1.000	rs4665811	chr2:26260017	A/G	cg27170947	chr2:26402098	FAM59B	-0.6	-7.11	-0.4	1.1e-11	Gut microbiome composition (summer);
CESC	cis	rs875971	0.522	rs1917563	chr7:65415647	C/T	cg06456125	chr7:65229604	NA	-0.43	-5.65	-0.33	4.24e-8	Aortic root size;
CESC	cis	rs7580658	0.864	rs4150441	chr2:128040915	T/C	cg10021288	chr2:128175891	PROC	-0.38	-6.03	-0.35	5.43e-9	Protein C levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05559558	chr6:138483092	KIAA1244	0.6	7.07	0.4	1.38e-11	Gut microbiome composition (summer);
CESC	cis	rs3820068	0.581	rs59991988	chr1:15950552	T/A	cg17385448	chr1:15911702	AGMAT	0.42	6.88	0.39	4.26e-11	Systolic blood pressure;
CESC	cis	rs79839061	0.610	rs11726280	chr4:864077	C/T	cg07828340	chr4:882639	GAK	1.08	7.9	0.44	7.59e-14	Intelligence (multi-trait analysis);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg11737246	chr15:40401244	BMF	-0.45	-6.2	-0.36	2.14e-9	Fibrinogen levels;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg26815021	chr17:74733172	MIR636;MFSD11;SFRS2	-0.47	-6.88	-0.39	4.19e-11	Gambling;
CESC	cis	rs6952808	0.609	rs6950151	chr7:1953521	T/C	cg20295408	chr7:1910781	MAD1L1	-0.4	-5.22	-0.31	3.55e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs1552244	0.816	rs13076197	chr3:10019773	T/C	cg08888203	chr3:10149979	C3orf24	0.49	6.17	0.35	2.49e-9	Alzheimer's disease;
CESC	cis	rs854765	0.547	rs7212167	chr17:17913504	G/A	cg04398451	chr17:18023971	MYO15A	-0.7	-10.3	-0.53	3.77e-21	Total body bone mineral density;
CESC	cis	rs9660180	0.868	rs12567685	chr1:1806647	T/C	cg23982607	chr1:1823379	GNB1	-0.8	-12.99	-0.62	3.33e-30	Body mass index;
CESC	cis	rs561341	1.000	rs521919	chr17:30298039	G/T	cg12193833	chr17:30244370	NA	-0.59	-5.89	-0.34	1.19e-8	Hip circumference adjusted for BMI;
CESC	cis	rs9291683	0.588	rs2240721	chr4:10020564	G/A	cg02734326	chr4:10020555	SLC2A9	0.52	7.49	0.42	9.99e-13	Bone mineral density;
CESC	cis	rs6952808	0.543	rs4719436	chr7:2141239	G/A	cg04267008	chr7:1944627	MAD1L1	-0.61	-7.41	-0.41	1.65e-12	Bipolar disorder and schizophrenia;
CESC	cis	rs11711311	1.000	rs9830975	chr3:113486019	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.73	10.31	0.54	3.51e-21	IgG glycosylation;
CESC	cis	rs9650657	0.645	rs4841407	chr8:10516185	G/A	cg27411982	chr8:10470053	RP1L1	-0.39	-5.16	-0.3	4.9e-7	Neuroticism;
CESC	cis	rs7737355	0.773	rs32112	chr5:131048122	G/A	cg06307176	chr5:131281290	NA	0.36	5.04	0.3	8.7e-7	Life satisfaction;
CESC	cis	rs8180040	0.620	rs1811652	chr3:47208698	C/G	cg27129171	chr3:47204927	SETD2	-0.67	-9.83	-0.52	1.2e-19	Colorectal cancer;
CESC	cis	rs13191362	0.935	rs35378894	chr6:163123933	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.05	10.33	0.54	2.97e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs763014	0.865	rs4006748	chr16:632225	T/C	cg07343612	chr16:622815	PIGQ	-0.57	-8.23	-0.45	8.47e-15	Height;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg08493338	chr16:354269	AXIN1	0.55	7.51	0.42	8.85e-13	Fibrinogen levels;
CESC	trans	rs208520	0.690	rs851465	chr6:66840293	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.99	-13.08	-0.63	1.69e-30	Exhaled nitric oxide output;
CESC	cis	rs2243480	1.000	rs2961102	chr7:65424658	A/G	cg25894440	chr7:65020034	NA	-0.68	-5.88	-0.34	1.22e-8	Diabetic kidney disease;
CESC	cis	rs13191362	1.000	rs73035023	chr6:163000927	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.5	5.17	0.3	4.64e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs7582720	0.945	rs72936860	chr2:203783484	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.38	0.41	1.99e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs17384381	1.000	rs12743049	chr1:85897386	G/A	cg16011679	chr1:85725395	C1orf52	0.74	7.58	0.42	5.98e-13	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7666738	0.791	rs13149968	chr4:99070262	G/T	cg03467027	chr4:99064603	C4orf37	0.48	5.9	0.34	1.11e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7264396	0.635	rs6058355	chr20:34491343	A/G	cg17201900	chr20:34330562	RBM39	0.49	5.1	0.3	6.63e-7	Total cholesterol levels;
CESC	cis	rs7523050	0.643	rs35520362	chr1:109419841	C/T	cg08274380	chr1:109419600	GPSM2	0.92	6.41	0.37	6.62e-10	Fat distribution (HIV);
CESC	cis	rs17253792	0.822	rs79807559	chr14:56108117	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.8	5.65	0.33	4.2e-8	Putamen volume;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg11857025	chr1:109633344	TMEM167B	0.46	6.39	0.37	7.34e-10	Asthma;
CESC	cis	rs10899021	0.920	rs11236174	chr11:74334201	G/A	cg25880958	chr11:74394337	NA	-0.74	-7.86	-0.43	9.71e-14	Response to metformin (IC50);
CESC	cis	rs637571	0.522	rs679581	chr11:65746653	A/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.44	6.46	0.37	4.88e-10	Eosinophil percentage of white cells;
CESC	cis	rs7216064	1.000	rs2128792	chr17:65857177	C/T	cg07042672	chr17:66097459	LOC651250	-0.54	-5.56	-0.32	6.49e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs1506636	1.000	rs614645	chr7:123442349	T/C	cg03229431	chr7:123269106	ASB15	0.48	5.99	0.35	6.71e-9	Plateletcrit;Platelet count;
CESC	cis	rs10751667	0.643	rs10902234	chr11:935578	A/G	cg20946044	chr11:1010712	AP2A2	-0.38	-5.23	-0.31	3.48e-7	Alzheimer's disease (late onset);
CESC	cis	rs2243480	0.711	rs2420172	chr7:65635341	T/C	cg12463550	chr7:65579703	CRCP	-0.73	-5.71	-0.33	3.1e-8	Diabetic kidney disease;
CESC	cis	rs6089584	0.606	rs7270666	chr20:60577598	C/T	cg24733560	chr20:60626293	TAF4	0.48	7.18	0.4	6.91e-12	Body mass index;
CESC	cis	rs709400	1.000	rs10135248	chr14:104122310	T/C	cg24130564	chr14:104152367	KLC1	-0.44	-5.74	-0.33	2.57e-8	Body mass index;
CESC	cis	rs80130819	0.515	rs6580656	chr12:48570604	C/T	cg05342945	chr12:48394962	COL2A1	-0.48	-5.68	-0.33	3.53e-8	Prostate cancer;
CESC	trans	rs7246760	1.000	rs57736549	chr19:9937558	A/G	cg02900749	chr2:68251473	NA	-0.82	-6.85	-0.39	5.23e-11	Pursuit maintenance gain;
CESC	cis	rs7116495	0.609	rs7942626	chr11:71703849	G/A	cg07596299	chr11:71824057	C11orf51	-0.8	-5.35	-0.31	1.92e-7	Severe influenza A (H1N1) infection;
CESC	trans	rs561341	0.714	rs7218466	chr17:30263314	A/G	cg20587970	chr11:113659929	NA	-0.8	-9.94	-0.52	5.27e-20	Hip circumference adjusted for BMI;
CESC	cis	rs9863	0.861	rs34878139	chr12:124446253	T/C	cg17562584	chr12:124393655	DNAH10	0.32	5.48	0.32	9.77e-8	White blood cell count;
CESC	cis	rs11750568	0.967	rs931618	chr5:178514747	T/C	cg10208897	chr5:178548229	ADAMTS2	0.39	5.43	0.32	1.29e-7	Height;
CESC	cis	rs950027	0.595	rs2486288	chr15:45712339	T/C	cg21132104	chr15:45694354	SPATA5L1	0.65	8.47	0.46	1.66e-15	Response to fenofibrate (adiponectin levels);
CESC	cis	rs295140	0.546	rs295137	chr2:201150040	C/T	cg23649088	chr2:200775458	C2orf69	0.46	6.0	0.35	6.31e-9	QT interval;
CESC	cis	rs11792861	0.890	rs2900481	chr9:111831825	G/A	cg13535736	chr9:111863775	C9orf5	-0.51	-6.84	-0.39	5.58e-11	Menarche (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13404532	chr3:128483276	RAB7A	-0.59	-6.76	-0.38	8.59e-11	Gut microbiome composition (summer);
CESC	cis	rs7336332	0.598	rs7669	chr13:28009851	C/T	cg22138327	chr13:27999177	GTF3A	0.61	5.9	0.34	1.12e-8	Weight;
CESC	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	13.72	0.64	1.03e-32	Prudent dietary pattern;
CESC	cis	rs7666738	0.830	rs10001701	chr4:98918871	G/C	cg05340658	chr4:99064831	C4orf37	0.75	10.73	0.55	1.56e-22	Colonoscopy-negative controls vs population controls;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg04515913	chr15:89182103	ISG20	-0.46	-6.53	-0.37	3.25e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs7448080	0.510	rs1501762	chr5:123242975	G/A	cg10971134	chr1:56877429	NA	0.94	6.3	0.36	1.21e-9	Alcohol dependence (age at onset);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg18864739	chr5:31214888	CDH6	-0.42	-6.49	-0.37	4.09e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs2011503	1.000	rs11669730	chr19:19648713	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.52	5.09	0.3	6.68e-7	Bipolar disorder;
CESC	cis	rs7552404	0.921	rs10873685	chr1:76218818	A/C	cg10523679	chr1:76189770	ACADM	0.73	8.56	0.47	9.29e-16	Blood metabolite levels;Acylcarnitine levels;
CESC	trans	rs11098499	0.954	rs9993199	chr4:120392873	A/G	cg25214090	chr10:38739885	LOC399744	-0.7	-10.11	-0.53	1.56e-20	Corneal astigmatism;
CESC	cis	rs10504229	0.683	rs72650849	chr8:58140323	A/G	cg22535103	chr8:58192502	C8orf71	-0.8	-9.09	-0.49	2.46e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs7666738	0.830	rs7698771	chr4:98986479	T/G	cg03467027	chr4:99064603	C4orf37	0.44	5.54	0.32	7.12e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2070997	0.618	rs3780282	chr9:133743654	G/A	cg01000188	chr9:133769184	QRFP	0.34	5.29	0.31	2.61e-7	Response to amphetamines;
CESC	cis	rs244293	0.831	rs11654268	chr17:53151290	A/G	cg19360675	chr17:53046073	COX11;STXBP4	0.42	5.38	0.31	1.66e-7	Menarche (age at onset);
CESC	cis	rs7647973	1.000	rs11928090	chr3:49604904	G/A	cg06212747	chr3:49208901	KLHDC8B	0.6	7.83	0.43	1.18e-13	Menarche (age at onset);
CESC	cis	rs72781680	0.611	rs72797824	chr2:24356456	T/G	cg06627628	chr2:24431161	ITSN2	-0.69	-6.8	-0.39	6.87e-11	Lymphocyte counts;
CESC	cis	rs28830936	1.000	rs12441300	chr15:42102845	A/G	cg11010575	chr15:42129464	JMJD7-PLA2G4B;JMJD7	-0.44	-5.92	-0.34	9.69e-9	Diastolic blood pressure;
CESC	cis	rs754466	0.724	rs11002318	chr10:79633807	G/A	cg17075019	chr10:79541650	NA	-0.86	-12.94	-0.62	5.28e-30	Liver enzyme levels (gamma-glutamyl transferase);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08306365	chr15:62543301	NA	-0.51	-6.72	-0.38	1.11e-10	Gut microbiome composition (summer);
CESC	cis	rs4594175	0.926	rs7160948	chr14:51612537	T/A	cg23942311	chr14:51606299	NA	0.36	5.43	0.32	1.29e-7	Cancer;
CESC	cis	rs1003719	0.788	rs3787783	chr21:38462959	T/A	cg10648535	chr21:38446584	PIGP;TTC3	0.63	8.77	0.47	2.14e-16	Eye color traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26728986	chr19:45540955	SFRS16;RELB	-0.6	-6.69	-0.38	1.29e-10	Gut microbiome composition (summer);
CESC	cis	rs9581857	0.579	rs79904593	chr13:27996893	G/A	cg01674679	chr13:27998804	GTF3A	-0.69	-5.45	-0.32	1.13e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
CESC	cis	rs2273669	0.667	rs12215344	chr6:109329641	A/C	cg05315195	chr6:109294784	ARMC2	-0.67	-6.06	-0.35	4.74e-9	Prostate cancer;
CESC	cis	rs2806561	0.894	rs598438	chr1:23531563	C/T	cg12483005	chr1:23474871	LUZP1	0.33	5.17	0.3	4.56e-7	Height;
CESC	cis	rs524281	0.861	rs10896080	chr11:65876796	G/A	cg14036092	chr11:66035641	RAB1B	-0.63	-6.45	-0.37	5.41e-10	Electroencephalogram traits;
CESC	cis	rs9308731	0.605	rs6754738	chr2:111948543	T/C	cg04202892	chr2:111875749	ACOXL	0.4	5.41	0.32	1.42e-7	Chronic lymphocytic leukemia;
CESC	cis	rs7552404	0.696	rs67487205	chr1:76373756	T/C	cg03433033	chr1:76189801	ACADM	0.57	5.57	0.32	6.26e-8	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs11638352	1.000	rs2615292	chr15:44414376	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.61	-5.62	-0.33	4.75e-8	Lipoprotein phospholipase A2 activity in cardiovascular disease;
CESC	cis	rs73206853	0.563	rs1973505	chr12:111160003	A/G	cg12870014	chr12:110450643	ANKRD13A	-0.79	-7.94	-0.44	5.58e-14	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs7267979	0.780	rs2500413	chr20:25241155	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.71	11.37	0.57	1.18e-24	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs4268898	0.735	rs12469585	chr2:24489054	A/T	cg06627628	chr2:24431161	ITSN2	0.58	7.41	0.41	1.65e-12	Asthma;
CESC	cis	rs10743315	0.557	rs17343287	chr12:19420064	T/C	cg02471346	chr12:19282374	PLEKHA5	0.71	5.19	0.3	4.15e-7	Gut microbiota (bacterial taxa);
CESC	cis	rs7666738	0.830	rs6532724	chr4:99060993	C/T	cg17366294	chr4:99064904	C4orf37	0.62	8.89	0.48	9.9e-17	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9325144	0.647	rs11169222	chr12:39105210	C/T	cg26384229	chr12:38710491	ALG10B	-0.5	-7.06	-0.4	1.47e-11	Morning vs. evening chronotype;
CESC	cis	rs10752881	0.967	rs4652757	chr1:182974750	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.83	13.29	0.63	3.24e-31	Colorectal cancer;
CESC	cis	rs868036	1.000	rs4776975	chr15:68102220	G/C	cg08079166	chr15:68083412	MAP2K5	0.44	6.95	0.39	2.89e-11	Restless legs syndrome;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08874598	chr8:102217901	ZNF706	0.57	6.37	0.36	8.38e-10	Gut microbiome composition (summer);
CESC	cis	rs7786877	0.508	rs11765509	chr7:100310990	T/G	cg16850897	chr7:100343110	ZAN	-0.66	-8.14	-0.45	1.54e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs10504229	0.775	rs56082079	chr8:58163732	T/C	cg24829409	chr8:58192753	C8orf71	-0.67	-7.97	-0.44	4.6e-14	Developmental language disorder (linguistic errors);
CESC	cis	rs2795502	0.938	rs3121324	chr10:43379515	C/T	cg20628663	chr10:43360327	NA	0.56	6.64	0.38	1.78e-10	Blood protein levels;
CESC	cis	rs2066819	1.000	rs11171806	chr12:56733531	A/G	cg26734620	chr12:56694298	CS	-0.97	-6.13	-0.35	3.18e-9	Psoriasis vulgaris;
CESC	cis	rs9910055	0.571	rs28897216	chr17:42240824	A/G	cg08499158	chr17:42289980	UBTF	-0.52	-6.54	-0.37	3.23e-10	Total body bone mineral density;
CESC	cis	rs2836974	0.899	rs114399588	chr21:40653958	G/A	cg27266027	chr21:40555129	PSMG1	0.47	5.5	0.32	8.74e-8	Cognitive function;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg00759295	chr19:42388476	ARHGEF1	-0.49	-6.57	-0.37	2.7e-10	Fibrinogen levels;
CESC	cis	rs1483890	0.642	rs1843050	chr3:69403918	C/T	cg22125112	chr3:69402811	FRMD4B	-0.38	-5.19	-0.3	4.26e-7	Resting heart rate;
CESC	cis	rs2228479	0.702	rs11646374	chr16:89857935	G/A	cg19635926	chr16:89946313	TCF25	0.68	5.16	0.3	4.81e-7	Skin colour saturation;
CESC	cis	rs13108904	0.604	rs11946375	chr4:1313488	T/C	cg13395646	chr4:1353034	KIAA1530	-0.41	-5.12	-0.3	5.76e-7	Obesity-related traits;
CESC	cis	rs2658782	0.951	rs72972357	chr11:93118840	T/C	cg15737290	chr11:93063684	CCDC67	-0.51	-6.21	-0.36	2.07e-9	Pulmonary function decline;
CESC	cis	rs1799949	1.000	rs8074136	chr17:41342313	A/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.41	5.56	0.32	6.43e-8	Menopause (age at onset);
CESC	cis	rs1569175	0.850	rs3106088	chr2:200907393	A/C	cg19045956	chr2:200819837	C2orf60;C2orf47	0.64	5.41	0.32	1.44e-7	Response to treatment for acute lymphoblastic leukemia;
CESC	cis	rs936229	0.690	rs2472300	chr15:75033909	A/G	cg14664628	chr15:75095509	CSK	-0.75	-10.21	-0.53	7.44e-21	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15554505	chr19:22123728	NA	-0.57	-7.78	-0.43	1.67e-13	Gut microbiome composition (summer);
CESC	cis	rs6089584	0.566	rs6061972	chr20:60610245	C/T	cg06108461	chr20:60628389	TAF4	-0.58	-7.7	-0.43	2.67e-13	Body mass index;
CESC	cis	rs916888	0.610	rs142167	chr17:44795234	C/T	cg15921436	chr17:44337874	NA	-0.47	-5.99	-0.35	6.67e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs9581857	0.615	rs79553479	chr13:28007862	G/A	cg01674679	chr13:27998804	GTF3A	-0.71	-5.67	-0.33	3.75e-8	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
CESC	cis	rs7188861	0.768	rs62023605	chr16:11380861	A/C	cg01510278	chr16:11456238	NA	0.33	5.12	0.3	5.81e-7	HDL cholesterol;
CESC	cis	rs7851660	0.809	rs3824495	chr9:100663700	A/C	cg13688889	chr9:100608707	NA	0.62	8.98	0.48	5.2e-17	Strep throat;
CESC	cis	rs7914558	0.966	rs4532960	chr10:104667406	C/T	cg15744005	chr10:104629667	AS3MT	-0.35	-5.5	-0.32	8.98e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg17806437	chr15:42211581	EHD4	0.53	7.39	0.41	1.98e-12	Fibrinogen levels;
CESC	cis	rs12410462	0.581	rs111356515	chr1:227537236	C/G	cg04117972	chr1:227635322	NA	0.64	5.35	0.31	1.9e-7	Major depressive disorder;
CESC	cis	rs12325245	0.536	rs34161389	chr16:58622604	G/A	cg05725404	chr16:58534157	NDRG4	-0.63	-5.34	-0.31	2.01e-7	Schizophrenia;
CESC	cis	rs78456975	0.506	rs6756310	chr2:1549809	A/G	cg26248373	chr2:1572462	NA	-0.58	-6.59	-0.38	2.38e-10	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs3806843	0.735	rs778597	chr5:140040665	A/G	cg16179182	chr5:140090404	VTRNA1-1	-0.41	-5.43	-0.32	1.28e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs2228479	0.850	rs62056063	chr16:89903680	C/T	cg04013166	chr16:89971882	TCF25	0.72	5.75	0.33	2.41e-8	Skin colour saturation;
CESC	cis	rs1862618	0.802	rs194058	chr5:56188977	G/A	cg18230493	chr5:56204884	C5orf35	-0.75	-9.01	-0.48	4.28e-17	Initial pursuit acceleration;
CESC	cis	rs3126085	0.935	rs12407553	chr1:152297517	A/G	cg03465714	chr1:152285911	FLG	0.5	5.71	0.33	2.96e-8	Atopic dermatitis;
CESC	cis	rs4662945	0.603	rs10168574	chr2:130267823	C/T	cg05962382	chr2:130345044	NA	-0.48	-6.8	-0.39	7.04e-11	Response to cytidine analogues (gemcitabine);
CESC	cis	rs561341	1.000	rs506766	chr17:30289659	T/C	cg00745463	chr17:30367425	LRRC37B	-0.81	-6.94	-0.39	3.02e-11	Hip circumference adjusted for BMI;
CESC	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.64	-9.7	-0.51	3.1400000000000002e-19	Longevity;Endometriosis;
CESC	cis	rs1003719	0.713	rs7277150	chr21:38490006	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.63	8.7	0.47	3.66e-16	Eye color traits;
CESC	cis	rs734999	0.545	rs12749591	chr1:2563250	G/T	cg20673091	chr1:2541236	MMEL1	-0.47	-8.15	-0.45	1.49e-14	Ulcerative colitis;
CESC	cis	rs10504229	1.000	rs73609747	chr8:58189104	G/C	cg22535103	chr8:58192502	C8orf71	-1.05	-13.08	-0.63	1.71e-30	Developmental language disorder (linguistic errors);
CESC	cis	rs2251381	0.750	rs2251186	chr21:30528880	G/A	cg08807101	chr21:30365312	RNF160	0.68	8.22	0.45	9.12e-15	Selective IgA deficiency;
CESC	cis	rs818427	0.548	rs395858	chr5:112187356	G/A	cg07820702	chr5:112228657	REEP5	0.39	5.18	0.3	4.41e-7	Total body bone mineral density;
CESC	cis	rs7020830	0.894	rs12337316	chr9:37148105	G/A	cg14294708	chr9:37120828	ZCCHC7	1.15	22.08	0.8	5.18e-62	Schizophrenia;
CESC	cis	rs250677	0.522	rs12520924	chr5:148349149	C/T	cg18129178	chr5:148520854	ABLIM3	0.47	5.04	0.3	8.44e-7	Breast cancer;
CESC	cis	rs4689388	0.889	rs13101355	chr4:6293446	T/C	cg00701064	chr4:6280414	WFS1	0.68	11.71	0.58	8.68e-26	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs1670533	1.000	rs62879260	chr4:1050850	T/C	cg04106633	chr4:1044584	NA	0.41	5.12	0.3	5.87e-7	Recombination rate (females);
CESC	cis	rs2836950	0.772	rs62222988	chr21:40569508	T/C	cg11890956	chr21:40555474	PSMG1	-0.61	-7.59	-0.42	5.47e-13	Menarche (age at onset);
CESC	cis	rs798554	0.644	rs1639040	chr7:2884116	G/T	cg19717773	chr7:2847554	GNA12	-0.47	-6.75	-0.38	9.38e-11	Height;
CESC	cis	rs875971	1.000	rs4718357	chr7:65960878	A/G	cg18876405	chr7:65276391	NA	0.48	6.31	0.36	1.16e-9	Aortic root size;
CESC	trans	rs7726839	0.561	rs72703046	chr5:580129	T/C	cg25482853	chr8:67687455	SGK3	0.88	9.29	0.5	5.67e-18	Obesity-related traits;
CESC	trans	rs12356475	0.710	rs10822686	chr10:67733250	C/T	cg09360458	chr1:14075560	PRDM2	-0.5	-6.03	-0.35	5.48e-9	Psoriatic arthritis;
CESC	cis	rs875971	0.862	rs6944374	chr7:65686929	C/G	cg19163074	chr7:65112434	INTS4L2	0.43	5.32	0.31	2.22e-7	Aortic root size;
CESC	cis	rs2228479	0.618	rs17233623	chr16:89811209	C/T	cg14709524	chr16:89940631	TCF25	0.73	6.04	0.35	5.32e-9	Skin colour saturation;
CESC	cis	rs2991971	0.903	rs2991973	chr1:46020632	G/A	cg05343316	chr1:45956843	TESK2	-0.48	-6.12	-0.35	3.41e-9	High light scatter reticulocyte count;
CESC	cis	rs1008375	0.966	rs1860599	chr4:17638900	T/C	cg15017067	chr4:17643749	FAM184B	0.36	5.19	0.3	4.25e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs9649213	0.593	rs3801255	chr7:98000929	C/T	cg24562669	chr7:97807699	LMTK2	0.51	7.63	0.42	4.29e-13	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs6460942	0.659	rs6969309	chr7:12515847	T/C	cg06484146	chr7:12443880	VWDE	-0.71	-7.6	-0.42	5.22e-13	Coronary artery disease;
CESC	cis	rs71403859	0.502	rs71403847	chr16:71468226	T/C	cg08717414	chr16:71523259	ZNF19	-1.0	-9.12	-0.49	1.88e-17	Post bronchodilator FEV1;
CESC	cis	rs752010	0.806	rs4641303	chr1:42091310	A/G	cg06885757	chr1:42089581	HIVEP3	0.49	8.24	0.45	8.1e-15	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs853679	0.517	rs9380057	chr6:28104634	G/T	cg19592336	chr6:28129416	ZNF389	0.61	8.24	0.45	8.13e-15	Depression;
CESC	cis	rs6724607	1.000	rs7598979	chr2:191453375	A/G	cg27211696	chr2:191398769	TMEM194B	0.49	7.32	0.41	2.94e-12	Pulse pressure;
CESC	cis	rs10788972	0.510	rs665817	chr1:54469948	T/G	cg25741118	chr1:54482237	LDLRAD1	0.24	5.76	0.33	2.29e-8	Parkinson disease and lewy body pathology;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg17976829	chr10:131934431	GLRX3	-0.47	-6.72	-0.38	1.13e-10	Gambling;
CESC	cis	rs11229555	0.645	rs17474373	chr11:58191243	G/A	cg15696309	chr11:58395628	NA	-0.42	-5.05	-0.3	8.13e-7	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs875971	0.862	rs6945775	chr7:65968974	G/A	cg11764359	chr7:65958608	NA	0.81	11.74	0.58	6.73e-26	Aortic root size;
CESC	trans	rs1728785	1.000	rs1728784	chr16:68591156	T/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.7	8.28	0.45	6.13e-15	Ulcerative colitis;
CESC	cis	rs7412746	0.611	rs12410869	chr1:150856153	G/T	cg17724175	chr1:150552817	MCL1	0.33	5.13	0.3	5.51e-7	Melanoma;
CESC	cis	rs77741769	0.529	rs1467283	chr12:121210220	G/C	cg02419362	chr12:121203948	SPPL3	0.35	5.62	0.33	4.88e-8	Mean corpuscular volume;
CESC	cis	rs9611565	0.659	rs73178626	chr22:41928371	T/G	cg06634786	chr22:41940651	POLR3H	-0.68	-7.15	-0.4	8.28e-12	Vitiligo;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg12366118	chr12:62860687	MON2	0.47	6.01	0.35	6.06e-9	Gut microbiota (bacterial taxa);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg01172114	chr10:5979283	FBXO18	0.52	6.87	0.39	4.67e-11	Fibrinogen levels;
CESC	cis	rs11792861	0.926	rs7856626	chr9:111775502	C/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.46	5.75	0.33	2.48e-8	Menarche (age at onset);
CESC	cis	rs1862618	0.671	rs2591955	chr5:56244948	C/T	cg12311346	chr5:56204834	C5orf35	0.64	8.49	0.46	1.47e-15	Initial pursuit acceleration;
CESC	cis	rs9790314	0.663	rs1599379	chr3:160860665	A/G	cg03342759	chr3:160939853	NMD3	-0.38	-5.16	-0.3	4.85e-7	Morning vs. evening chronotype;
CESC	cis	rs7772486	0.558	rs9376965	chr6:146130055	G/A	cg05347473	chr6:146136440	FBXO30	0.71	9.2	0.49	1.09e-17	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7845219	0.544	rs10956930	chr8:95919786	C/G	cg16049864	chr8:95962084	TP53INP1	-0.49	-7.22	-0.41	5.48e-12	Type 2 diabetes;
CESC	cis	rs62244186	0.593	rs9814298	chr3:44871899	T/A	cg15225532	chr3:44803084	KIF15;KIAA1143	0.46	6.05	0.35	4.85e-9	Depressive symptoms;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15656181	chr5:71654404	PTCD2	-0.53	-6.57	-0.37	2.6200000000000003e-10	Gut microbiome composition (summer);
CESC	trans	rs7582180	0.700	rs1437971	chr2:100986964	A/C	cg26079571	chr12:3186499	TSPAN9	0.62	6.31	0.36	1.2e-9	Intelligence (multi-trait analysis);
CESC	cis	rs12464559	0.649	rs11894672	chr2:152657055	C/T	cg01189475	chr2:152685088	ARL5A	0.66	5.81	0.34	1.74e-8	Response to cognitive-behavioural therapy in anxiety disorder;
CESC	cis	rs6987853	0.966	rs2084709	chr8:42423190	A/G	cg09913449	chr8:42400586	C8orf40	0.4	6.49	0.37	4.15e-10	Mean corpuscular hemoglobin concentration;
CESC	cis	rs6089584	0.830	rs4925331	chr20:60580174	T/C	cg24733560	chr20:60626293	TAF4	0.41	5.91	0.34	1.04e-8	Body mass index;
CESC	cis	rs3096299	0.933	rs747485	chr16:89474094	T/C	cg08822215	chr16:89438651	ANKRD11	-0.43	-6.64	-0.38	1.74e-10	Multiple myeloma (IgH translocation);
CESC	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg11905131	chr22:24372483	LOC391322	-0.74	-10.76	-0.55	1.23e-22	Liver enzyme levels (gamma-glutamyl transferase);
CESC	trans	rs35110281	0.627	rs1595167	chr21:44965874	T/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.57	7.61	0.42	4.68e-13	Mean corpuscular volume;
CESC	cis	rs7116495	0.609	rs10736780	chr11:71650241	T/C	cg26138937	chr11:71823887	C11orf51	-1.23	-8.41	-0.46	2.56e-15	Severe influenza A (H1N1) infection;
CESC	cis	rs950169	0.922	rs2033284	chr15:84946273	C/T	cg17507749	chr15:85114479	UBE2QP1	0.57	6.27	0.36	1.43e-9	Schizophrenia;
CESC	cis	rs3820068	0.608	rs9660255	chr1:16031891	T/G	cg13390004	chr1:15929781	NA	0.33	5.13	0.3	5.64e-7	Systolic blood pressure;
CESC	cis	rs6500602	0.647	rs4786501	chr16:4536165	G/T	cg08645402	chr16:4508243	NA	-0.47	-7.22	-0.41	5.59e-12	Schizophrenia;
CESC	cis	rs11098499	0.863	rs3775848	chr4:120447724	C/T	cg09307838	chr4:120376055	NA	0.92	12.61	0.61	7.4e-29	Corneal astigmatism;
CESC	cis	rs875971	0.862	rs4718377	chr7:66049678	C/T	cg18252515	chr7:66147081	NA	0.46	5.96	0.34	8.03e-9	Aortic root size;
CESC	cis	rs898097	0.578	rs9906163	chr17:80908174	T/C	cg15369054	chr17:80825471	TBCD	-0.39	-5.59	-0.32	5.76e-8	Breast cancer;
CESC	cis	rs6032067	0.929	rs13038355	chr20:43805555	C/T	cg10761708	chr20:43804764	PI3	0.53	6.33	0.36	1.04e-9	Blood protein levels;
CESC	cis	rs1707322	0.627	rs3014213	chr1:46045522	T/C	cg05343316	chr1:45956843	TESK2	-0.53	-6.5	-0.37	3.87e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs477692	1.000	rs530466	chr10:131427717	A/G	cg05714579	chr10:131428358	MGMT	0.56	7.7	0.43	2.72e-13	Response to temozolomide;
CESC	cis	rs3857536	0.740	rs4710574	chr6:66890631	T/G	cg07460842	chr6:66804631	NA	-0.4	-5.23	-0.31	3.47e-7	Blood trace element (Cu levels);
CESC	trans	rs9929218	1.000	rs4783681	chr16:68806508	C/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.61	-8.03	-0.44	3.1e-14	Colorectal cancer;
CESC	cis	rs10885582	0.781	rs7893570	chr10:116294295	G/A	cg17056676	chr10:116301354	ABLIM1	-0.28	-5.13	-0.3	5.66e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs2075371	1.000	rs2241335	chr7:133979368	C/T	cg00033643	chr7:134001901	SLC35B4	0.41	5.24	0.31	3.25e-7	Mean platelet volume;
CESC	cis	rs13108904	0.539	rs13145722	chr4:1338422	T/A	cg00684032	chr4:1343700	KIAA1530	0.56	8.59	0.47	7.56e-16	Obesity-related traits;
CESC	cis	rs6964587	0.692	rs17672805	chr7:91573466	A/G	cg17063962	chr7:91808500	NA	-0.45	-6.25	-0.36	1.65e-9	Breast cancer;
CESC	cis	rs9467711	0.606	rs9358937	chr6:26374274	C/G	cg12826209	chr6:26865740	GUSBL1	0.62	5.11	0.3	6.24e-7	Autism spectrum disorder or schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05295236	chr10:135192197	PAOX	0.56	6.41	0.37	6.64e-10	Gut microbiome composition (summer);
CESC	cis	rs752010	0.574	rs2148636	chr1:42119844	C/T	cg06885757	chr1:42089581	HIVEP3	-0.44	-7.28	-0.41	3.84e-12	Lupus nephritis in systemic lupus erythematosus;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg15331097	chr6:90539609	CASP8AP2	-0.49	-6.07	-0.35	4.51e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs826838	0.934	rs10875647	chr12:38856995	G/A	cg13010199	chr12:38710504	ALG10B	0.6	8.53	0.46	1.18e-15	Heart rate;
CESC	cis	rs1003719	0.688	rs2835662	chr21:38568967	T/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.61	-8.29	-0.45	5.58e-15	Eye color traits;
CESC	cis	rs1797885	0.966	rs1619599	chr3:12504290	G/A	cg26432171	chr3:12704882	RAF1	-0.5	-6.43	-0.37	5.83e-10	Immature fraction of reticulocytes;
CESC	cis	rs6860806	0.507	rs273901	chr5:131694360	G/T	cg18758796	chr5:131593413	PDLIM4	0.39	5.25	0.31	3.11e-7	Breast cancer;
CESC	cis	rs425277	0.606	rs2460001	chr1:2111030	T/C	cg23803603	chr1:2058230	PRKCZ	0.33	5.77	0.33	2.22e-8	Height;
CESC	cis	rs6987853	0.933	rs2974340	chr8:42397731	T/C	cg09913449	chr8:42400586	C8orf40	0.39	6.13	0.35	3.15e-9	Mean corpuscular hemoglobin concentration;
CESC	trans	rs9325144	0.554	rs1906264	chr12:38739490	A/G	cg23762105	chr12:34175262	ALG10	-0.45	-6.03	-0.35	5.52e-9	Morning vs. evening chronotype;
CESC	cis	rs7085104	0.572	rs284858	chr10:104573936	T/C	cg23093090	chr10:104574429	C10orf26	0.34	5.37	0.31	1.71e-7	Immature fraction of reticulocytes;Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19250579	chr3:75487529	NA	-0.54	-7.21	-0.4	5.74e-12	Gut microbiome composition (summer);
CESC	cis	rs4665809	1.000	rs4665304	chr2:26313406	C/T	cg22920501	chr2:26401640	FAM59B	-0.64	-7.67	-0.43	3.37e-13	Gut microbiome composition (summer);
CESC	cis	rs11690935	0.595	rs788166	chr2:172915489	G/C	cg13550731	chr2:172543902	DYNC1I2	0.51	6.9	0.39	3.81e-11	Schizophrenia;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg09504196	chr7:148823235	ZNF425;ZNF398	0.47	6.06	0.35	4.57e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs9311474	0.713	rs352169	chr3:52236762	C/T	cg15147215	chr3:52552868	STAB1	-0.3	-5.21	-0.31	3.71e-7	Electroencephalogram traits;
CESC	cis	rs7193541	0.564	rs4888274	chr16:74706298	A/T	cg05580060	chr16:74700937	RFWD3	-0.44	-5.79	-0.34	1.99e-8	Multiple myeloma;
CESC	cis	rs35146811	0.586	rs1076237	chr7:99585441	A/C	cg22531904	chr7:99595276	NA	-0.38	-5.12	-0.3	5.84e-7	Coronary artery disease;
CESC	cis	rs1707322	0.963	rs4553121	chr1:46375253	G/A	cg03146154	chr1:46216737	IPP	0.71	9.86	0.52	9.69e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2439831	0.681	rs524527	chr15:43599116	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.96	-11.25	-0.57	2.93e-24	Lung cancer in ever smokers;
CESC	cis	rs733592	0.524	rs10875744	chr12:48498440	G/C	cg24011408	chr12:48396354	COL2A1	0.51	8.52	0.46	1.22e-15	Plateletcrit;
CESC	cis	rs5758659	0.967	rs5758670	chr22:42636687	T/C	cg05082376	chr22:42548792	NA	-0.37	-5.45	-0.32	1.13e-7	Cognitive function;
CESC	cis	rs2576037	0.796	rs2576034	chr18:44588548	G/A	cg19077165	chr18:44547161	KATNAL2	0.54	7.47	0.42	1.14e-12	Personality dimensions;
CESC	cis	rs2933343	0.729	rs1680786	chr3:128644840	T/C	cg25356066	chr3:128598488	ACAD9	0.6	8.44	0.46	2.09e-15	IgG glycosylation;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06792366	chr2:113012520	ZC3H8	-0.57	-6.62	-0.38	1.97e-10	Gut microbiome composition (summer);
CESC	cis	rs1847505	0.559	rs1475496	chr13:61566031	G/C	cg25164009	chr13:61490935	NA	-0.41	-5.48	-0.32	9.91e-8	Polychlorinated biphenyl levels;
CESC	cis	rs6714710	0.603	rs6757357	chr2:98491750	T/C	cg26665480	chr2:98280029	ACTR1B	0.57	7.97	0.44	4.74e-14	Posterior cortical atrophy and Alzheimer's disease;
CESC	cis	rs6540559	0.673	rs6540560	chr1:209982073	A/G	cg21951975	chr1:209979733	IRF6	-0.58	-7.53	-0.42	7.97e-13	Cleft lip with or without cleft palate;
CESC	cis	rs7927771	0.894	rs12798346	chr11:47583121	C/T	cg20307385	chr11:47447363	PSMC3	-0.5	-6.09	-0.35	4.06e-9	Subjective well-being;
CESC	cis	rs10242455	0.614	rs2687072	chr7:99316926	A/G	cg07715041	chr7:99302981	CYP3A7	-0.43	-5.42	-0.32	1.36e-7	Blood metabolite levels;
CESC	cis	rs2637266	1.000	rs11001835	chr10:78364770	A/G	cg18941641	chr10:78392320	NA	0.43	8.26	0.45	6.94e-15	Pulmonary function;
CESC	cis	rs754466	0.651	rs11818687	chr10:79637709	C/T	cg17075019	chr10:79541650	NA	-0.86	-12.94	-0.62	5.28e-30	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs2228479	0.702	rs12600151	chr16:89831558	C/T	cg14709524	chr16:89940631	TCF25	0.91	6.74	0.38	1e-10	Skin colour saturation;
CESC	cis	rs9906944	0.624	rs2411759	chr17:47071074	C/T	cg16584676	chr17:46985605	UBE2Z	-0.46	-5.56	-0.32	6.74e-8	Intelligence (multi-trait analysis);Body fat percentage;
CESC	cis	rs34172651	0.876	rs964782	chr16:24811740	T/C	cg06028605	chr16:24865363	SLC5A11	0.41	6.17	0.35	2.5e-9	Intelligence (multi-trait analysis);
CESC	cis	rs1153858	1.000	rs12101539	chr15:45650666	C/G	cg21132104	chr15:45694354	SPATA5L1	0.84	11.41	0.57	8.8e-25	Homoarginine levels;
CESC	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg00369194	chr7:157950511	PTPRN2	0.31	5.06	0.3	7.87e-7	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CESC	cis	rs2710642	0.564	rs6545962	chr2:62821318	G/A	cg17519650	chr2:63277830	OTX1	0.49	6.45	0.37	5.18e-10	LDL cholesterol levels;LDL cholesterol;
CESC	cis	rs7851660	0.809	rs1561957	chr9:100670272	T/C	cg13688889	chr9:100608707	NA	-0.62	-8.66	-0.47	4.74e-16	Strep throat;
CESC	cis	rs1775715	0.707	rs2808088	chr10:32146150	A/G	cg18675610	chr10:32216311	ARHGAP12	0.34	5.4	0.31	1.47e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs921968	0.541	rs7601872	chr2:219319885	C/G	cg02176678	chr2:219576539	TTLL4	-0.56	-9.86	-0.52	9.65e-20	Mean corpuscular hemoglobin concentration;
CESC	cis	rs9910055	0.762	rs227579	chr17:42223134	A/T	cg13607699	chr17:42295918	UBTF	-0.69	-9.5	-0.5	1.35e-18	Total body bone mineral density;
CESC	cis	rs2839186	0.564	rs4819215	chr21:47623573	G/A	cg10351095	chr21:47802916	PCNT	-0.43	-5.51	-0.32	8.53e-8	Testicular germ cell tumor;
CESC	cis	rs9322193	0.923	rs9479494	chr6:150060244	A/G	cg07701084	chr6:150067640	NUP43	0.48	6.67	0.38	1.5e-10	Lung cancer;
CESC	cis	rs3820928	0.874	rs7421491	chr2:227839278	C/A	cg11843606	chr2:227700838	RHBDD1	-0.5	-6.53	-0.37	3.36e-10	Pulmonary function;
CESC	cis	rs796364	0.906	rs6740981	chr2:201060216	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	0.58	5.9	0.34	1.11e-8	Schizophrenia;
CESC	cis	rs9291683	0.546	rs6820188	chr4:10051655	C/T	cg00071950	chr4:10020882	SLC2A9	0.8	13.89	0.65	2.47e-33	Bone mineral density;
CESC	cis	rs796364	0.951	rs3098341	chr2:200792498	G/T	cg23649088	chr2:200775458	C2orf69	0.55	5.24	0.31	3.29e-7	Schizophrenia;
CESC	cis	rs951366	0.966	rs11240565	chr1:205722958	C/T	cg14159672	chr1:205819179	PM20D1	-0.5	-6.73	-0.38	1.03e-10	Menarche (age at onset);
CESC	cis	rs78132593	0.723	rs115291189	chr1:150675007	C/A	cg22823121	chr1:150693482	HORMAD1	-0.43	-5.33	-0.31	2.13e-7	High light scatter reticulocyte count;
CESC	cis	rs2839186	0.708	rs17183123	chr21:47671961	G/C	cg10351095	chr21:47802916	PCNT	-0.48	-6.58	-0.37	2.46e-10	Testicular germ cell tumor;
CESC	trans	rs7618501	1.000	rs7372725	chr3:49790544	C/A	cg21659725	chr3:3221576	CRBN	-0.83	-13.42	-0.64	1.08e-31	Intelligence (multi-trait analysis);
CESC	cis	rs36051895	0.623	rs10975031	chr9:5253153	G/T	cg02405213	chr9:5042618	JAK2	-0.54	-6.61	-0.38	2.16e-10	Pediatric autoimmune diseases;
CESC	cis	rs9303401	0.527	rs7224468	chr17:56749943	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.05	12.89	0.62	7.95e-30	Cognitive test performance;
CESC	cis	rs1355223	1.000	rs35365094	chr11:34767790	A/C	cg11058730	chr11:34937778	PDHX;APIP	-0.45	-5.85	-0.34	1.47e-8	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs7116495	0.609	rs10751191	chr11:71680920	C/T	cg10381502	chr11:71823885	C11orf51	-1.18	-7.71	-0.43	2.53e-13	Severe influenza A (H1N1) infection;
CESC	cis	rs13191362	1.000	rs34192365	chr6:163012382	T/G	cg14584255	chr6:163149320	PACRG;PARK2	0.5	5.17	0.3	4.63e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs9908102	0.740	rs7211778	chr17:12901227	A/C	cg26162695	chr17:12921313	ELAC2	0.53	5.93	0.34	9.61e-9	Schizophrenia;
CESC	cis	rs7666738	0.830	rs9992639	chr4:98940400	G/T	cg05340658	chr4:99064831	C4orf37	0.82	12.52	0.61	1.44e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs798554	0.797	rs1182174	chr7:2875420	G/A	cg13628971	chr7:2884303	GNA12	0.61	7.97	0.44	4.84e-14	Height;
CESC	cis	rs1568889	1.000	rs12804198	chr11:28143114	C/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.75	9.44	0.5	2.08e-18	Bipolar disorder;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg00579481	chr22:21271797	CRKL	-0.43	-6.0	-0.35	6.41e-9	Gambling;
CESC	cis	rs17023223	0.537	rs10923767	chr1:119732347	C/T	cg05756136	chr1:119680316	WARS2	-0.49	-5.99	-0.35	6.86e-9	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CESC	cis	rs7772486	0.875	rs865913	chr6:146308874	C/T	cg05347473	chr6:146136440	FBXO30	0.56	7.37	0.41	2.14e-12	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14712964	chr3:9773672	BRPF1	0.58	6.51	0.37	3.84e-10	Gut microbiome composition (summer);
CESC	cis	rs863345	0.564	rs34701257	chr1:158480955	A/G	cg12129480	chr1:158549410	OR10X1	-0.34	-6.74	-0.38	9.86e-11	Pneumococcal bacteremia;
CESC	cis	rs7666738	0.830	rs921523	chr4:98841659	C/T	cg17366294	chr4:99064904	C4orf37	0.5	6.83	0.39	5.9e-11	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7508	0.596	rs7824644	chr8:17920807	A/G	cg18067069	chr8:17937731	ASAH1	-0.41	-5.36	-0.31	1.81e-7	Atrial fibrillation;
CESC	cis	rs4862750	0.872	rs9998173	chr4:187898778	T/A	cg10295955	chr4:187884368	NA	-1.08	-23.24	-0.82	6.56e-66	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs61931739	0.500	rs7955933	chr12:34473608	A/G	cg23762105	chr12:34175262	ALG10	-0.39	-5.05	-0.3	8.28e-7	Morning vs. evening chronotype;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg15695852	chr2:43864466	PLEKHH2	-0.45	-6.48	-0.37	4.56e-10	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs9733	0.744	rs3754211	chr1:150951857	G/A	cg22823121	chr1:150693482	HORMAD1	0.36	5.17	0.3	4.58e-7	Tonsillectomy;
CESC	cis	rs2228479	0.850	rs11646766	chr16:89838578	A/T	cg04013166	chr16:89971882	TCF25	0.78	6.69	0.38	1.3e-10	Skin colour saturation;
CESC	cis	rs10256972	0.521	rs7457418	chr7:1110255	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.43	-6.1	-0.35	3.68e-9	Longevity;Endometriosis;
CESC	cis	rs12450688	1	rs12450688	chr17:38144229	G/A	cg17344932	chr17:38183730	MED24;SNORD124	0.36	5.21	0.3	3.74e-7	Sum eosinophil basophil counts;
CESC	cis	rs2988277	0.737	rs2949668	chr1:167434721	T/C	cg09179987	chr1:167433047	CD247	0.47	7.03	0.4	1.75e-11	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs7223966	0.921	rs7225092	chr17:61864005	G/T	cg11494091	chr17:61959527	GH2	0.38	5.2	0.3	3.99e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs6460942	1.000	rs2053381	chr7:12400710	C/A	cg06484146	chr7:12443880	VWDE	-0.69	-7.97	-0.44	4.66e-14	Coronary artery disease;
CESC	cis	rs9513593	1.000	rs7323390	chr13:99997968	A/G	cg21788972	chr13:99853209	UBAC2	0.6	6.95	0.39	2.9100000000000002e-11	Psoriasis;
CESC	cis	rs362272	0.524	rs10937924	chr4:3374898	T/C	cg14583973	chr4:3374767	RGS12	0.34	6.14	0.35	2.96e-9	Serum sulfate level;
CESC	cis	rs7833790	0.963	rs10958046	chr8:82729210	A/G	cg27398817	chr8:82754497	SNX16	-0.57	-6.5	-0.37	3.86e-10	Diastolic blood pressure;
CESC	cis	rs7659604	1.000	rs7659943	chr4:122665560	C/T	cg19671926	chr4:122722719	EXOSC9	-0.51	-6.37	-0.36	8.5e-10	Type 2 diabetes;
CESC	cis	rs875971	0.545	rs313830	chr7:65551931	T/C	cg11764359	chr7:65958608	NA	-0.8	-8.87	-0.48	1.14e-16	Aortic root size;
CESC	cis	rs4665809	0.590	rs10179959	chr2:26426403	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-1.12	-13.53	-0.64	4.67e-32	Gut microbiome composition (summer);
CESC	cis	rs752010	0.714	rs6664708	chr1:42083070	G/A	cg06885757	chr1:42089581	HIVEP3	0.52	9.06	0.49	2.9e-17	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs9768139	0.733	rs56205111	chr7:158121055	T/C	cg25566285	chr7:158114605	PTPRN2	0.49	8.13	0.45	1.64e-14	Calcium levels;
CESC	cis	rs6582630	0.555	rs2004152	chr12:38478951	C/T	cg26384229	chr12:38710491	ALG10B	0.72	10.64	0.55	3.12e-22	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs1552244	0.515	rs111560858	chr3:10166845	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.68	-7.7	-0.43	2.64e-13	Alzheimer's disease;
CESC	cis	rs1023500	0.573	rs4822088	chr22:42470589	G/C	cg12850546	chr22:42539477	CYP2D7P1	-0.43	-5.12	-0.3	5.88e-7	Schizophrenia;
CESC	cis	rs875971	1.000	rs811880	chr7:65818646	T/C	cg12463550	chr7:65579703	CRCP	0.57	7.33	0.41	2.73e-12	Aortic root size;
CESC	cis	rs12822507	0.868	rs34051318	chr12:12798338	T/C	cg11838227	chr12:12764436	CREBL2	-0.41	-5.39	-0.31	1.57e-7	Systemic lupus erythematosus;
CESC	cis	rs7666738	0.830	rs28729647	chr4:99059552	T/C	cg17366294	chr4:99064904	C4orf37	0.62	8.75	0.47	2.55e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs12545109	0.800	rs1440746	chr8:57415912	G/A	cg09654669	chr8:57350985	NA	-0.45	-6.21	-0.36	2.01e-9	Obesity-related traits;
CESC	cis	rs7100689	0.784	rs3802637	chr10:82179699	G/C	cg00277334	chr10:82204260	NA	-0.61	-7.42	-0.41	1.57e-12	Post bronchodilator FEV1;
CESC	cis	rs4925114	0.568	rs4925109	chr17:17661802	A/G	cg04398451	chr17:18023971	MYO15A	0.44	5.35	0.31	1.89e-7	Body mass index;
CESC	cis	rs250677	1.000	rs250676	chr5:148425518	A/T	cg18129178	chr5:148520854	ABLIM3	-0.47	-5.57	-0.32	6.38e-8	Breast cancer;
CESC	cis	rs2243480	1.000	rs73150014	chr7:65450919	A/C	cg25894440	chr7:65020034	NA	-0.66	-5.69	-0.33	3.42e-8	Diabetic kidney disease;
CESC	cis	rs801193	0.569	rs10950050	chr7:66239588	A/C	cg18876405	chr7:65276391	NA	0.44	6.12	0.35	3.34e-9	Aortic root size;
CESC	cis	rs2180341	0.782	rs6912552	chr6:127722946	C/G	cg27446573	chr6:127587934	RNF146	-0.77	-11.16	-0.57	5.7e-24	Breast cancer;
CESC	cis	rs9913156	0.793	rs55782417	chr17:4562845	G/A	cg00122941	chr17:4613640	ARRB2	0.85	9.99	0.52	3.79e-20	Lymphocyte counts;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg05602567	chr22:32871203	FBXO7	-0.45	-6.0	-0.35	6.35e-9	Asthma;
CESC	cis	rs17253792	0.822	rs28481586	chr14:56053863	C/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.83	6.03	0.35	5.45e-9	Putamen volume;
CESC	cis	rs644799	0.965	rs11021305	chr11:95498269	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.52	6.52	0.37	3.44e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs6952808	0.689	rs1107591	chr7:2041638	G/A	cg08027265	chr7:2291960	NA	-0.36	-5.47	-0.32	1.05e-7	Bipolar disorder and schizophrenia;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg09273779	chr9:35605990	TESK1	0.51	6.68	0.38	1.42e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs12681288	0.862	rs7015529	chr8:1020249	A/G	cg04851639	chr8:1020857	NA	-0.39	-8.41	-0.46	2.62e-15	Schizophrenia;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg01905589	chr1:26856408	RPS6KA1	-0.47	-6.15	-0.35	2.86e-9	Ulcerative colitis;
CESC	cis	rs9467773	1.000	rs9467791	chr6:26562486	A/G	cg24633756	chr6:26577808	NA	-0.35	-5.39	-0.31	1.55e-7	Intelligence (multi-trait analysis);
CESC	cis	rs9640161	0.750	rs3735169	chr7:150034378	A/G	cg10018233	chr7:150070692	REPIN1	0.46	6.86	0.39	4.92e-11	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs698833	0.886	rs698824	chr2:44723123	G/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.51	6.47	0.37	4.77e-10	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs2549003	1.000	rs2706384	chr5:131826880	G/T	cg00255919	chr5:131827918	IRF1	-0.58	-10.12	-0.53	1.41e-20	Asthma (sex interaction);
CESC	cis	rs367943	1.000	rs348958	chr5:112821137	G/A	cg12552261	chr5:112820674	MCC	-0.64	-8.05	-0.44	2.83e-14	Type 2 diabetes;
CESC	cis	rs7474896	0.522	rs117157955	chr10:37984164	G/T	cg00409905	chr10:38381863	ZNF37A	-0.45	-5.15	-0.3	4.98e-7	Obesity (extreme);
CESC	cis	rs262150	0.574	rs2730272	chr7:158798622	G/C	cg19418458	chr7:158789849	NA	-0.41	-6.45	-0.37	5.28e-10	Facial morphology (factor 20);
CESC	cis	rs11711311	1.000	rs921741	chr3:113444051	A/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.57	7.56	0.42	6.49e-13	IgG glycosylation;
CESC	cis	rs4268898	0.965	rs4665673	chr2:24459737	A/T	cg06627628	chr2:24431161	ITSN2	0.66	8.01	0.44	3.69e-14	Asthma;
CESC	cis	rs11958404	0.932	rs6865373	chr5:157436728	A/G	cg05962755	chr5:157440814	NA	0.62	6.56	0.37	2.74e-10	IgG glycosylation;
CESC	cis	rs2073300	1.000	rs6048811	chr20:23446719	G/C	cg12062639	chr20:23401060	NAPB	0.74	5.43	0.32	1.3e-7	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs56104184	0.723	rs73063515	chr19:49407715	C/T	cg15549821	chr19:49342101	PLEKHA4	-0.57	-5.76	-0.33	2.33e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	cis	rs35365539	1	rs35365539	chr3:49794347	A/AC	cg24308560	chr3:49941425	MST1R	0.51	6.99	0.39	2.28e-11	Blood protein levels;
CESC	cis	rs4808199	0.947	rs4808960	chr19:19574277	G/C	cg03709012	chr19:19516395	GATAD2A	1.17	13.38	0.63	1.53e-31	Nonalcoholic fatty liver disease;
CESC	cis	rs35110281	0.667	rs4819285	chr21:45118970	C/T	cg01579765	chr21:45077557	HSF2BP	0.52	8.97	0.48	5.48e-17	Mean corpuscular volume;
CESC	cis	rs3738443	0.569	rs6704060	chr1:247381524	C/T	cg07706540	chr1:247373924	NA	-0.47	-5.67	-0.33	3.63e-8	Alcohol dependence;
CESC	cis	rs1023500	0.596	rs5751209	chr22:42451603	A/G	cg04733989	chr22:42467013	NAGA	0.8	11.04	0.56	1.44e-23	Schizophrenia;
CESC	cis	rs9309473	0.500	rs10189578	chr2:73728609	C/A	cg20560298	chr2:73613845	ALMS1	-0.48	-6.86	-0.39	4.92e-11	Metabolite levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10592546	chr5:180649562	TRIM41	0.53	6.02	0.35	5.73e-9	Gut microbiome composition (summer);
CESC	cis	rs926392	0.666	rs56877916	chr20:37696192	A/T	cg16355469	chr20:37678765	NA	0.53	5.86	0.34	1.36e-8	Dialysis-related mortality;
CESC	cis	rs10782582	0.569	rs74090722	chr1:76197262	A/G	cg10523679	chr1:76189770	ACADM	-0.49	-5.79	-0.33	2.02e-8	Daytime sleep phenotypes;
CESC	cis	rs4810479	0.513	rs3746506	chr20:44586036	G/A	cg27529037	chr20:44575021	PCIF1	0.43	6.33	0.36	1.06e-9	Metabolite levels;
CESC	cis	rs6831352	0.879	rs2602879	chr4:100040652	G/A	cg12011299	chr4:100065546	ADH4	0.6	6.56	0.37	2.83e-10	Alcohol dependence;
CESC	cis	rs4454254	0.966	rs4631439	chr8:141059650	C/T	cg06693505	chr8:141057453	TRAPPC9	-0.35	-5.74	-0.33	2.57e-8	Pulse pressure;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23682824	chr7:23144976	KLHL7	-0.62	-7.04	-0.4	1.66e-11	Gut microbiome composition (summer);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg06614436	chr3:179065438	MFN1	-0.52	-6.18	-0.35	2.38e-9	Ulcerative colitis;
CESC	cis	rs7508679	1.000	rs7248104	chr19:7224431	A/G	cg09779027	chr19:7224513	INSR	0.59	9.45	0.5	1.81e-18	Hypothyroidism;
CESC	cis	rs7666738	0.830	rs6851253	chr4:99029980	A/G	cg05340658	chr4:99064831	C4orf37	0.83	13.1	0.63	1.43e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7618915	0.547	rs2268027	chr3:52766606	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	6.64	0.38	1.81e-10	Bipolar disorder;
CESC	cis	rs17253792	0.749	rs74979160	chr14:56097568	G/A	cg01858014	chr14:56050164	KTN1	-0.93	-7.33	-0.41	2.71e-12	Putamen volume;
CESC	cis	rs6964587	0.967	rs10231496	chr7:91741132	T/C	cg17063962	chr7:91808500	NA	0.54	7.58	0.42	5.65e-13	Breast cancer;
CESC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg03406422	chr11:77850844	ALG8	0.46	6.03	0.35	5.56e-9	Intelligence (multi-trait analysis);
CESC	trans	rs1814175	0.615	rs12417290	chr11:49876951	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.43	-6.27	-0.36	1.42e-9	Height;
CESC	cis	rs11048434	0.636	rs7306165	chr12:9059081	T/C	cg23795048	chr12:9217529	LOC144571	0.32	5.03	0.3	8.89e-7	Sjögren's syndrome;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg07640473	chr3:50193232	SEMA3F	-0.47	-7.16	-0.4	7.98e-12	Gut microbiota (bacterial taxa);
CESC	cis	rs7615952	0.641	rs4490307	chr3:125712676	T/G	cg02807482	chr3:125708958	NA	-0.37	-5.18	-0.3	4.5e-7	Blood pressure (smoking interaction);
CESC	cis	rs344364	0.511	rs1742467	chr16:1950187	G/T	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.55	-6.2	-0.36	2.15e-9	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs67478160	0.643	rs8005225	chr14:104300151	C/T	cg01849466	chr14:104193079	ZFYVE21	0.51	7.2	0.4	6.29e-12	Schizophrenia;
CESC	cis	rs7527798	0.544	rs11118354	chr1:207856868	A/G	cg21110645	chr1:207815933	NA	-0.33	-5.86	-0.34	1.33e-8	Erythrocyte sedimentation rate;
CESC	trans	rs61931739	0.500	rs11053194	chr12:34440841	A/G	cg26384229	chr12:38710491	ALG10B	0.54	7.5	0.42	9.79e-13	Morning vs. evening chronotype;
CESC	cis	rs60843830	1.000	rs60149603	chr2:285421	A/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.78	9.99	0.52	3.67e-20	Spherical equivalent (joint analysis main effects and education interaction);
CESC	trans	rs1814175	0.647	rs2903409	chr11:49953612	C/G	cg15704280	chr7:45808275	SEPT13	-0.82	-11.47	-0.58	5.18e-25	Height;
CESC	cis	rs853679	0.569	rs9348798	chr6:28143011	G/A	cg23161317	chr6:28129485	ZNF389	0.47	5.88	0.34	1.21e-8	Depression;
CESC	cis	rs9916302	0.851	rs11657899	chr17:37626963	G/A	cg15445000	chr17:37608096	MED1	0.41	6.76	0.38	8.83e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs300703	0.719	rs385272	chr2:206704	A/G	cg21211680	chr2:198530	NA	-0.94	-10.26	-0.53	4.97e-21	Blood protein levels;
CESC	cis	rs7618501	0.602	rs2240326	chr3:50128386	G/A	cg24110177	chr3:50126178	RBM5	0.51	6.95	0.39	2.77e-11	Intelligence (multi-trait analysis);
CESC	cis	rs2730245	0.851	rs2657333	chr7:158728743	G/A	cg24397884	chr7:158709396	WDR60	-0.88	-13.46	-0.64	7.72e-32	Height;
CESC	cis	rs6458375	1.000	rs6916554	chr6:44204736	T/A	cg02172915	chr6:44211962	NA	0.47	5.34	0.31	2.04e-7	Interleukin-10 levels;
CESC	cis	rs72781680	0.898	rs72781639	chr2:24204148	C/G	cg08917208	chr2:24149416	ATAD2B	0.92	8.28	0.45	6.31e-15	Lymphocyte counts;
CESC	cis	rs9611565	0.546	rs5758426	chr22:42098763	T/G	cg06481639	chr22:41940642	POLR3H	0.45	5.15	0.3	5.13e-7	Vitiligo;
CESC	trans	rs7142881	0.508	rs1954441	chr14:32118713	A/G	cg08127348	chr19:17448311	GTPBP3	-0.44	-6.06	-0.35	4.64e-9	Response to iloperidone treatment (QT prolongation);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02396040	chr6:88117726	C6orf165	0.56	6.24	0.36	1.69e-9	Gut microbiome composition (summer);
CESC	trans	rs7672847	0.547	rs58602886	chr4:170427848	G/A	cg19308436	chr1:237949471	RYR2	0.61	6.44	0.37	5.7e-10	Subjective well-being;
CESC	cis	rs72627123	0.867	rs8015927	chr14:74465756	A/T	cg12022184	chr14:74485813	ENTPD5;C14orf45	-0.75	-5.68	-0.33	3.61e-8	Morning vs. evening chronotype;
CESC	cis	rs295137	0.799	rs4145969	chr2:201139961	C/T	cg23649088	chr2:200775458	C2orf69	-0.44	-5.9	-0.34	1.11e-8	Asthma (bronchodilator response);
CESC	cis	rs875971	0.862	rs1983372	chr7:65611351	C/T	cg18876405	chr7:65276391	NA	-0.53	-7.39	-0.41	1.96e-12	Aortic root size;
CESC	cis	rs7659604	0.502	rs13128434	chr4:122672461	A/C	cg19671926	chr4:122722719	EXOSC9	0.58	7.34	0.41	2.66e-12	Type 2 diabetes;
CESC	cis	rs8005677	0.828	rs35085068	chr14:23409909	C/A	cg01529538	chr14:23388837	RBM23	0.44	5.83	0.34	1.63e-8	Cognitive ability (multi-trait analysis);
CESC	cis	rs2295359	0.892	rs10889657	chr1:67615487	A/G	cg17031739	chr1:67600172	NA	0.39	5.2	0.3	3.91e-7	Psoriasis;
CESC	cis	rs9733	0.650	rs4970923	chr1:150608300	A/G	cg13175981	chr1:150552382	MCL1	0.75	11.23	0.57	3.32e-24	Tonsillectomy;
CESC	cis	rs4423214	1.000	rs28364617	chr11:71159764	T/G	cg05163923	chr11:71159392	DHCR7	0.85	12.11	0.6	3.72e-27	Vitamin D levels;
CESC	cis	rs2204008	0.806	rs7305409	chr12:38349133	G/A	cg26384229	chr12:38710491	ALG10B	0.73	10.65	0.55	2.87e-22	Bladder cancer;
CESC	cis	rs17039065	0.920	rs1595197	chr4:109472301	A/G	cg16022748	chr4:109541635	LOC285456;RPL34	0.71	6.16	0.35	2.74e-9	Gut microbiome composition (summer);
CESC	cis	rs13102973	0.931	rs13134190	chr4:135854932	T/C	cg14419869	chr4:135874104	NA	0.33	5.16	0.3	4.75e-7	Subjective well-being;
CESC	trans	rs17125944	0.506	rs7151491	chr14:53313711	C/G	cg01134794	chr4:78529898	CXCL13	0.54	6.09	0.35	3.9e-9	Alzheimer's disease (late onset);
CESC	cis	rs2952156	0.920	rs11078919	chr17:37835755	T/C	cg07936489	chr17:37558343	FBXL20	-0.59	-7.77	-0.43	1.68e-13	Asthma;
CESC	cis	rs61542988	0.570	rs62448268	chr7:22829464	G/A	cg11367502	chr7:22862612	TOMM7	0.54	6.42	0.37	6.32e-10	Fibrinogen levels;
CESC	cis	rs11864453	0.645	rs7194668	chr16:72128207	G/C	cg01557791	chr16:72042693	DHODH	-0.45	-5.46	-0.32	1.08e-7	Fibrinogen levels;
CESC	cis	rs644799	1.000	rs12291986	chr11:95523030	T/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.52	6.41	0.37	6.47e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs6504663	0.525	rs557	chr17:48563234	C/T	cg03168497	chr17:48586147	MYCBPAP	0.46	5.44	0.32	1.21e-7	Visceral fat;
CESC	cis	rs7666738	0.830	rs4699594	chr4:98980775	T/C	cg03467027	chr4:99064603	C4orf37	0.43	5.44	0.32	1.18e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1568889	1.000	rs16917689	chr11:28064466	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.77	10.83	0.55	7.35e-23	Bipolar disorder;
CESC	trans	rs1285495	0.627	rs10912059	chr1:187354887	C/T	cg08429943	chr16:29606618	NA	-0.51	-6.22	-0.36	1.91e-9	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
CESC	cis	rs7772486	0.754	rs9386132	chr6:146140751	T/C	cg05347473	chr6:146136440	FBXO30	0.57	7.29	0.41	3.56e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs8077889	1.000	rs17674998	chr17:41879544	A/G	cg26893861	chr17:41843967	DUSP3	0.7	8.21	0.45	1.01e-14	Triglycerides;
CESC	cis	rs7659604	0.539	rs3217753	chr4:122746325	A/G	cg20573242	chr4:122745356	CCNA2	0.63	8.17	0.45	1.24e-14	Type 2 diabetes;
CESC	cis	rs7267979	1.000	rs4815411	chr20:25350223	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.88	-18.41	-0.75	2.65e-49	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs10256972	0.967	rs1881122	chr7:1040946	A/T	cg07930192	chr7:1003750	NA	0.42	5.71	0.33	3.02e-8	Longevity;Endometriosis;
CESC	trans	rs2361710	0.611	rs12451471	chr17:78102517	C/T	cg00575896	chr3:50357171	HYAL2	-0.39	-6.03	-0.35	5.49e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
CESC	cis	rs1218582	0.772	rs4240875	chr1:154885782	G/A	cg16680214	chr1:154839983	KCNN3	-0.45	-6.79	-0.39	7.19e-11	Prostate cancer;
CESC	cis	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg22963979	chr7:1858916	MAD1L1	-0.39	-5.29	-0.31	2.59e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs4253772	0.591	rs6008595	chr22:46703860	A/T	cg00784671	chr22:46762841	CELSR1	-0.48	-5.59	-0.32	5.72e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs3747547	0.710	rs7863948	chr9:37949409	A/C	cg13774184	chr9:37916125	SHB	-0.57	-5.83	-0.34	1.57e-8	Metabolite levels (Dihydroxy docosatrienoic acid);
CESC	cis	rs12477438	0.798	rs2123686	chr2:99690135	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.64	-8.73	-0.47	2.94e-16	Chronic sinus infection;
CESC	cis	rs7666738	0.830	rs1834645	chr4:98979593	T/A	cg03467027	chr4:99064603	C4orf37	0.43	5.39	0.31	1.58e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs853679	0.517	rs9380065	chr6:28144751	A/G	cg19592336	chr6:28129416	ZNF389	0.59	7.78	0.43	1.63e-13	Depression;
CESC	trans	rs10435719	0.773	rs7842810	chr8:11794163	A/G	cg15556689	chr8:8085844	FLJ10661	0.51	6.32	0.36	1.1e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
CESC	trans	rs9325144	0.650	rs6582631	chr12:38744135	T/C	cg23762105	chr12:34175262	ALG10	-0.48	-6.46	-0.37	4.99e-10	Morning vs. evening chronotype;
CESC	cis	rs6460942	0.915	rs62448596	chr7:12446869	C/T	cg02935154	chr7:12443704	VWDE	-0.6	-6.82	-0.39	6.02e-11	Coronary artery disease;
CESC	cis	rs9911578	1.000	rs7342903	chr17:56914588	C/G	cg12560992	chr17:57184187	TRIM37	0.94	15.75	0.7	6.57e-40	Intelligence (multi-trait analysis);
CESC	cis	rs8060686	0.623	rs2418736	chr16:68154862	A/G	cg26727032	chr16:67993705	SLC12A4	0.58	8.72	0.47	3.02e-16	HDL cholesterol;Metabolic syndrome;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06539400	chr16:4365605	NA	0.58	6.55	0.37	3.03e-10	Gut microbiome composition (summer);
CESC	cis	rs2303759	0.918	rs8107548	chr19:49870643	T/C	cg22307029	chr19:49891270	CCDC155	0.69	8.11	0.45	1.92e-14	Multiple sclerosis;
CESC	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.65	0.38	1.71e-10	Prudent dietary pattern;
CESC	cis	rs12701220	0.655	rs34344742	chr7:1149288	C/G	cg00990874	chr7:1149470	C7orf50	-0.46	-5.08	-0.3	7.21e-7	Bronchopulmonary dysplasia;
CESC	cis	rs7855088	1.000	rs1572025	chr9:100741115	A/C	cg13688889	chr9:100608707	NA	-0.38	-5.72	-0.33	2.94e-8	Serum thyroid-stimulating hormone levels;
CESC	cis	rs798554	0.757	rs1182177	chr7:2874540	C/T	cg18446336	chr7:2847575	GNA12	-0.38	-5.76	-0.33	2.28e-8	Height;
CESC	cis	rs4704187	0.687	rs4621537	chr5:74362222	A/G	cg03227963	chr5:74354835	NA	0.31	5.71	0.33	2.97e-8	Response to amphetamines;
CESC	cis	rs3782123	0.539	rs10902111	chr11:241489	C/T	cg00562011	chr11:252351	PSMD13	0.67	5.59	0.32	5.72e-8	Glycated hemoglobin levels;Red cell distribution width;
CESC	cis	rs11098499	0.954	rs12507964	chr4:120413061	T/A	cg24375607	chr4:120327624	NA	0.46	5.63	0.33	4.52e-8	Corneal astigmatism;
CESC	cis	rs1448094	0.511	rs61930037	chr12:86154503	G/A	cg02569458	chr12:86230093	RASSF9	0.51	7.7	0.43	2.65e-13	Major depressive disorder;
CESC	cis	rs12497850	0.864	rs3212	chr3:49145741	T/C	cg07636037	chr3:49044803	WDR6	1.05	18.53	0.75	9.5e-50	Parkinson's disease;
CESC	cis	rs875971	0.862	rs11765791	chr7:65936574	A/G	cg10691866	chr7:65817282	TPST1	-0.32	-5.33	-0.31	2.07e-7	Aortic root size;
CESC	cis	rs3091242	1.000	rs646867	chr1:25709258	A/C	cg02931644	chr1:25747376	RHCE	0.41	6.66	0.38	1.54e-10	Erythrocyte sedimentation rate;
CESC	cis	rs7084402	0.967	rs12259990	chr10:60297574	A/G	cg07615347	chr10:60278583	BICC1	-0.57	-8.56	-0.47	9.58e-16	Refractive error;
CESC	cis	rs6860806	0.507	rs200837	chr5:131699958	G/A	cg24060327	chr5:131705240	SLC22A5	-0.75	-10.06	-0.53	2.31e-20	Breast cancer;
CESC	cis	rs7762018	1.000	rs73242910	chr6:170114670	A/G	cg05834625	chr6:170176447	C6orf70	0.64	7.53	0.42	7.96e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs9894429	0.809	rs9889642	chr17:79591762	T/C	cg18240062	chr17:79603768	NPLOC4	0.73	10.23	0.53	6.51e-21	Eye color traits;
CESC	cis	rs477692	0.571	rs10764890	chr10:131347163	G/A	cg05714579	chr10:131428358	MGMT	0.43	5.78	0.33	2.1e-8	Response to temozolomide;
CESC	cis	rs11098499	0.604	rs17051352	chr4:120581427	G/A	cg24375607	chr4:120327624	NA	0.45	5.46	0.32	1.08e-7	Corneal astigmatism;
CESC	cis	rs4423214	0.802	rs4402322	chr11:71184015	C/G	cg05163923	chr11:71159392	DHCR7	-0.68	-7.76	-0.43	1.82e-13	Vitamin D levels;
CESC	cis	rs11098499	0.866	rs6857892	chr4:120282696	G/T	cg24375607	chr4:120327624	NA	0.42	5.19	0.3	4.19e-7	Corneal astigmatism;
CESC	cis	rs7412746	0.611	rs1889740	chr1:150799755	C/T	cg22823121	chr1:150693482	HORMAD1	0.38	5.58	0.32	5.92e-8	Melanoma;
CESC	cis	rs1799949	1.000	rs8176202	chr17:41230228	G/A	cg05368731	chr17:41323189	NBR1	0.76	10.4	0.54	1.76e-21	Menopause (age at onset);
CESC	cis	rs7666738	0.830	rs17558193	chr4:99049593	A/G	cg24818145	chr4:99064322	C4orf37	0.38	5.04	0.3	8.49e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9788682	0.947	rs7169584	chr15:78822660	A/T	cg06917634	chr15:78832804	PSMA4	-0.56	-6.68	-0.38	1.38e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24590075	chr17:40224031	NA	-0.54	-6.16	-0.35	2.74e-9	Gut microbiome composition (summer);
CESC	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg10150615	chr22:24372951	LOC391322	-0.59	-7.93	-0.44	6.07e-14	Liver enzyme levels (gamma-glutamyl transferase);
CESC	trans	rs7618501	1.000	rs9859153	chr3:49807085	G/T	cg21659725	chr3:3221576	CRBN	0.83	13.56	0.64	3.67e-32	Intelligence (multi-trait analysis);
CESC	cis	rs3916	0.794	rs3021337	chr12:121163261	C/T	cg21892295	chr12:121157589	UNC119B	-0.4	-6.31	-0.36	1.14e-9	Urinary metabolites (H-NMR features);
CESC	cis	rs6831352	0.918	rs2602891	chr4:100043284	C/T	cg12011299	chr4:100065546	ADH4	0.59	6.58	0.37	2.55e-10	Alcohol dependence;
CESC	cis	rs10751667	0.643	rs7394436	chr11:970373	G/C	cg06064525	chr11:970664	AP2A2	-0.47	-9.13	-0.49	1.87e-17	Alzheimer's disease (late onset);
CESC	cis	rs72781680	0.846	rs72780198	chr2:24014883	T/A	cg08917208	chr2:24149416	ATAD2B	0.95	8.71	0.47	3.45e-16	Lymphocyte counts;
CESC	cis	rs9815354	0.680	rs79239400	chr3:42030249	C/A	cg03022575	chr3:42003672	ULK4	0.75	6.64	0.38	1.72e-10	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs11864453	0.826	rs6499560	chr16:72147666	G/T	cg16558253	chr16:72132732	DHX38	0.61	9.75	0.51	2.2e-19	Fibrinogen levels;
CESC	cis	rs938554	0.612	rs13113918	chr4:9998493	A/G	cg11266682	chr4:10021025	SLC2A9	0.47	6.54	0.37	3.22e-10	Blood metabolite levels;
CESC	cis	rs8031584	0.918	rs35784593	chr15:31254588	G/A	cg08109568	chr15:31115862	NA	-0.71	-9.5	-0.5	1.29e-18	Huntington's disease progression;
CESC	cis	rs8141529	0.509	rs6005927	chr22:29255884	A/G	cg15103426	chr22:29168792	CCDC117	0.63	8.32	0.45	4.8e-15	Lymphocyte counts;
CESC	cis	rs2832077	0.527	rs9980449	chr21:30224889	G/C	cg24692254	chr21:30365293	RNF160	-0.66	-9.15	-0.49	1.56e-17	Cognitive test performance;
CESC	cis	rs853679	0.517	rs9357066	chr6:28129831	T/C	cg20151795	chr6:28129481	ZNF389	0.44	5.55	0.32	6.85e-8	Depression;
CESC	cis	rs853679	0.517	rs9380056	chr6:28104476	C/T	cg20151795	chr6:28129481	ZNF389	0.45	5.92	0.34	9.77e-9	Depression;
CESC	cis	rs6598955	0.670	rs7520517	chr1:26556385	A/C	cg00852783	chr1:26633632	UBXN11	0.43	6.4	0.37	6.97e-10	Obesity-related traits;
CESC	trans	rs1814175	0.676	rs11040647	chr11:49935947	A/C	cg03929089	chr4:120376271	NA	-0.92	-15.2	-0.68	6e-38	Height;
CESC	cis	rs11098499	0.866	rs72676074	chr4:120359841	A/C	cg24375607	chr4:120327624	NA	0.45	5.6	0.33	5.42e-8	Corneal astigmatism;
CESC	cis	rs1348850	0.801	rs11890163	chr2:178327134	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.64	5.38	0.31	1.66e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs910316	1.000	rs4899544	chr14:75546556	C/T	cg11812906	chr14:75593930	NEK9	0.89	15.23	0.68	4.57e-38	Height;
CESC	cis	rs9611565	0.512	rs8141103	chr22:42136930	T/C	cg03806693	chr22:41940476	POLR3H	1.16	13.59	0.64	2.85e-32	Vitiligo;
CESC	cis	rs12249377	0.519	rs12259060	chr10:92579949	A/G	cg14313238	chr10:92632228	RPP30	0.42	5.05	0.3	8.05e-7	White matter microstructure (global fractional anisotropy);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg09755102	chr1:33283495	S100PBP;YARS	0.52	6.85	0.39	5.14e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs35995292	0.500	rs6945239	chr7:38932208	C/T	cg19327137	chr7:38886074	VPS41	0.67	11.01	0.56	1.76e-23	Subjective well-being (multi-trait analysis);
CESC	cis	rs4713118	0.662	rs149970	chr6:27980220	C/T	cg19592336	chr6:28129416	ZNF389	0.49	6.85	0.39	5.12e-11	Parkinson's disease;
CESC	cis	rs2836974	0.931	rs7283569	chr21:40644062	T/G	cg11890956	chr21:40555474	PSMG1	1.2	22.3	0.81	9.49e-63	Cognitive function;
CESC	cis	rs67311347	0.955	rs11711994	chr3:40391086	T/C	cg24209194	chr3:40518798	ZNF619	0.49	5.98	0.34	7.39e-9	Renal cell carcinoma;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg21080633	chr12:132263633	SFRS8	0.52	6.73	0.38	1.04e-10	Fibrinogen levels;
CESC	cis	rs10129255	0.518	rs11847766	chr14:107187425	T/C	cg07958169	chr14:107095056	NA	-0.55	-8.65	-0.47	4.94e-16	Kawasaki disease;
CESC	cis	rs9291683	0.679	rs13137795	chr4:10051506	G/A	cg11266682	chr4:10021025	SLC2A9	0.66	13.03	0.62	2.6e-30	Bone mineral density;
CESC	cis	rs9790314	1.000	rs336593	chr3:161076431	T/C	cg04691961	chr3:161091175	C3orf57	-0.41	-5.3	-0.31	2.44e-7	Morning vs. evening chronotype;
CESC	cis	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg22963979	chr7:1858916	MAD1L1	-0.43	-5.87	-0.34	1.31e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs7917772	0.582	rs729024	chr10:104341975	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.42	5.71	0.33	3.01e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs7786877	0.583	rs41303510	chr7:100226129	C/T	cg16850897	chr7:100343110	ZAN	-0.62	-6.63	-0.38	1.9e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs28374715	0.532	rs7168431	chr15:41672384	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.08	-17.7	-0.74	8.28e-47	Ulcerative colitis;
CESC	cis	rs12136530	0.774	rs904966	chr1:19772177	G/C	cg01832549	chr1:19774989	CAPZB	-0.48	-6.91	-0.39	3.65e-11	Lead levels in blood;
CESC	cis	rs13256369	0.802	rs13280101	chr8:8562773	G/A	cg18904891	chr8:8559673	CLDN23	0.7	7.74	0.43	2.1e-13	Obesity-related traits;
CESC	cis	rs3754214	0.823	rs10888579	chr1:150261925	C/T	cg09579323	chr1:150459698	TARS2	-0.46	-5.74	-0.33	2.58e-8	Cerebrospinal fluid biomarker levels;
CESC	cis	rs2154427	0.938	rs2833967	chr21:34191308	G/A	cg21871883	chr21:34145043	C21orf49;C21orf66	0.62	5.12	0.3	5.81e-7	Bilirubin levels;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg15544184	chr11:49872191	NA	-0.33	-6.3	-0.36	1.26e-9	Asthma;
CESC	cis	rs2562152	0.515	rs2562176	chr16:146487	G/C	cg02949481	chr16:131562	MPG	0.74	7.38	0.41	2.08e-12	Glioblastoma;
CESC	cis	rs6942756	1.000	rs11769045	chr7:128895335	A/G	cg02491457	chr7:128862824	NA	-0.7	-9.97	-0.52	4.48e-20	White matter hyperintensity burden;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19900852	chr14:35451793	SRP54	0.56	6.53	0.37	3.25e-10	Gut microbiome composition (summer);
CESC	cis	rs36051895	0.632	rs10758674	chr9:5163645	G/A	cg02405213	chr9:5042618	JAK2	-0.5	-6.29	-0.36	1.27e-9	Pediatric autoimmune diseases;
CESC	cis	rs10170846	0.893	rs10932967	chr2:223544111	C/T	cg25565276	chr2:223520875	FARSB	0.57	7.86	0.43	9.85e-14	Schizophrenia (inflammation and infection response interaction);
CESC	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg24829409	chr8:58192753	C8orf71	-0.67	-8.14	-0.45	1.54e-14	Developmental language disorder (linguistic errors);
CESC	cis	rs17376456	0.877	rs12153788	chr5:93405437	A/G	cg21475434	chr5:93447410	FAM172A	0.82	7.28	0.41	3.91e-12	Diabetic retinopathy;
CESC	trans	rs7985867	0.645	rs471864	chr13:26032843	G/C	cg26929337	chr19:52511726	ZNF615	0.44	6.07	0.35	4.32e-9	Common carotid intima-media thickness;
CESC	cis	rs67311347	1.000	rs4973994	chr3:40453024	T/C	cg09455208	chr3:40491958	NA	0.51	8.55	0.47	9.79e-16	Renal cell carcinoma;
CESC	cis	rs7520050	0.966	rs1085244	chr1:46563680	C/A	cg24296786	chr1:45957014	TESK2	0.41	5.17	0.3	4.63e-7	Red blood cell count;Reticulocyte count;
CESC	cis	rs727563	0.638	rs5996058	chr22:42141452	A/G	cg06481639	chr22:41940642	POLR3H	0.59	5.85	0.34	1.45e-8	Crohn's disease;Inflammatory bowel disease;
CESC	trans	rs61931739	0.500	rs6416261	chr12:34540377	T/C	cg26384229	chr12:38710491	ALG10B	0.53	7.41	0.41	1.74e-12	Morning vs. evening chronotype;
CESC	cis	rs6089584	1.000	rs3787425	chr20:60559256	C/T	cg24733560	chr20:60626293	TAF4	0.4	5.77	0.33	2.15e-8	Body mass index;
CESC	cis	rs4595586	0.525	rs73096109	chr12:39355720	C/A	cg26384229	chr12:38710491	ALG10B	0.63	8.79	0.48	1.9e-16	Morning vs. evening chronotype;
CESC	cis	rs7607369	0.526	rs4674322	chr2:219513782	C/T	cg02176678	chr2:219576539	TTLL4	0.44	5.46	0.32	1.1e-7	Red blood cell count;Amyotrophic lateral sclerosis;
CESC	cis	rs7937682	1.000	rs11608122	chr11:111535105	C/T	cg09085632	chr11:111637200	PPP2R1B	1.02	14.04	0.65	7.45e-34	Primary sclerosing cholangitis;
CESC	cis	rs208520	0.690	rs12192851	chr6:66705862	G/C	cg07460842	chr6:66804631	NA	0.97	13.24	0.63	4.76e-31	Exhaled nitric oxide output;
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg18986332	chr3:33759647	CLASP2	0.41	6.06	0.35	4.75e-9	Vertical cup-disc ratio;
CESC	trans	rs7726839	0.540	rs3792720	chr5:643028	T/G	cg25482853	chr8:67687455	SGK3	0.93	9.65	0.51	4.47e-19	Obesity-related traits;
CESC	cis	rs7937682	0.889	rs7926485	chr11:111536670	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.99	-16.33	-0.71	5.97e-42	Primary sclerosing cholangitis;
CESC	trans	rs748404	0.631	rs3809482	chr15:43661802	T/C	cg24053811	chr14:70265306	SLC10A1	0.42	6.0	0.35	6.55e-9	Lung cancer;
CESC	cis	rs11122272	0.735	rs2491410	chr1:231532287	C/T	cg06096015	chr1:231504339	EGLN1	0.41	5.81	0.34	1.74e-8	Hemoglobin concentration;
CESC	cis	rs9611565	0.512	rs768414	chr22:42135751	T/C	cg03806693	chr22:41940476	POLR3H	1.16	13.59	0.64	2.85e-32	Vitiligo;
CESC	cis	rs6545883	0.859	rs62149714	chr2:61603869	T/G	cg15711740	chr2:61764176	XPO1	0.4	5.1	0.3	6.53e-7	Tuberculosis;
CESC	cis	rs9905704	0.846	rs304267	chr17:56799380	A/G	cg12560992	chr17:57184187	TRIM37	0.62	7.78	0.43	1.6e-13	Testicular germ cell tumor;
CESC	cis	rs12477438	0.520	rs11695379	chr2:99742161	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.87	16.11	0.7	3.54e-41	Chronic sinus infection;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg16636692	chr6:27115249	HIST1H2BK;HIST1H2AH	-0.52	-6.78	-0.38	7.75e-11	Fibrinogen levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13272430	chr14:67708475	MPP5	0.57	6.09	0.35	3.89e-9	Gut microbiome composition (summer);
CESC	cis	rs2841277	0.708	rs28600075	chr14:105408315	T/C	cg17340268	chr14:105411764	AHNAK2	-0.51	-6.84	-0.39	5.32e-11	Rheumatoid arthritis;
CESC	cis	rs10463316	0.817	rs6877498	chr5:150802876	C/T	cg03212797	chr5:150827313	SLC36A1	-0.48	-6.2	-0.36	2.21e-9	Metabolite levels (Pyroglutamine);
CESC	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg18402987	chr7:1209562	NA	0.76	7.56	0.42	6.59e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs17293817	0.617	rs12775843	chr10:1412326	T/C	cg04271617	chr10:1416546	ADARB2	0.33	5.03	0.3	8.84e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	trans	rs1728785	0.818	rs12926059	chr16:68569459	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.61	7.43	0.42	1.5e-12	Ulcerative colitis;
CESC	cis	rs698833	0.852	rs2582918	chr2:44582275	G/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.55	6.9	0.39	3.72e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg11905131	chr22:24372483	LOC391322	-0.8	-12.13	-0.6	3.08e-27	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs992157	0.798	rs1017698	chr2:219170525	A/G	cg00012203	chr2:219082015	ARPC2	-0.75	-10.2	-0.53	8.03e-21	Colorectal cancer;
CESC	cis	rs8067354	0.574	rs1292035	chr17:57989557	G/A	cg13753209	chr17:57696993	CLTC	0.54	5.69	0.33	3.36e-8	Hemoglobin concentration;
CESC	cis	rs2072732	0.861	rs10909867	chr1:2961402	G/T	cg15211996	chr1:2936768	ACTRT2	0.35	5.87	0.34	1.31e-8	Plateletcrit;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg27284088	chr4:84031130	PLAC8	-0.43	-6.18	-0.35	2.36e-9	Gambling;
CESC	cis	rs12413816	0.517	rs4750400	chr10:13765923	A/G	cg16485048	chr10:13749193	FRMD4A	0.43	5.94	0.34	8.88e-9	Red cell distribution width;
CESC	cis	rs7312933	1.000	rs12372597	chr12:42412850	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.42	5.46	0.32	1.09e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs12497850	0.931	rs7430501	chr3:48890119	C/T	cg06212747	chr3:49208901	KLHDC8B	0.67	8.99	0.48	4.66e-17	Parkinson's disease;
CESC	cis	rs9815354	0.680	rs17218936	chr3:42019392	C/T	cg03022575	chr3:42003672	ULK4	0.74	6.64	0.38	1.79e-10	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs4065321	0.522	rs11078930	chr17:38141955	C/T	cg17467752	chr17:38218738	THRA	-0.44	-5.81	-0.34	1.76e-8	White blood cell count (basophil);White blood cell count;
CESC	cis	rs9649213	0.613	rs2286074	chr7:97952011	G/A	cg08684580	chr7:98029266	BAIAP2L1	-0.35	-5.69	-0.33	3.38e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs2120019	1.000	rs60425110	chr15:75333000	T/A	cg09165964	chr15:75287851	SCAMP5	-0.78	-9.31	-0.5	5.05e-18	Blood trace element (Zn levels);
CESC	cis	rs7949030	0.588	rs2509961	chr11:62310909	T/C	cg02375832	chr11:62437615	C11orf48	-0.36	-5.34	-0.31	1.98e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs8078723	0.966	rs57968500	chr17:38145828	A/G	cg17467752	chr17:38218738	THRA	0.68	10.22	0.53	6.77e-21	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CESC	cis	rs7727544	0.735	rs2569266	chr5:131706791	T/C	cg07395648	chr5:131743802	NA	0.43	5.71	0.33	2.96e-8	Blood metabolite levels;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg06766273	chr11:62521983	ZBTB3	0.47	6.24	0.36	1.69e-9	Systemic lupus erythematosus;
CESC	cis	rs8038465	0.622	rs2509	chr15:73859488	A/T	cg15420318	chr15:73925796	NPTN	-0.45	-6.23	-0.36	1.8e-9	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs2280018	0.538	rs7404526	chr16:15129162	A/G	cg07549590	chr16:15018862	NA	-0.54	-8.81	-0.48	1.71e-16	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs3820928	0.934	rs4675117	chr2:227769794	A/G	cg05526886	chr2:227700861	RHBDD1	0.47	5.72	0.33	2.84e-8	Pulmonary function;
CESC	cis	rs864745	0.600	rs849327	chr7:28232457	A/G	cg23620719	chr7:28220237	JAZF1	-0.43	-5.1	-0.3	6.62e-7	Crohn's disease;Type 2 diabetes;
CESC	cis	rs10927875	0.691	rs1048261	chr1:16340951	A/T	cg21385522	chr1:16154831	NA	0.62	7.44	0.42	1.39e-12	Dilated cardiomyopathy;
CESC	cis	rs6831352	0.959	rs6848050	chr4:100053733	T/C	cg21548116	chr4:100009993	ADH5	0.48	5.09	0.3	6.72e-7	Alcohol dependence;
CESC	trans	rs7132746	0.620	rs61928911	chr12:86195973	A/G	cg06215984	chr1:203258903	NA	-0.56	-6.16	-0.35	2.64e-9	Lewy body disease;
CESC	cis	rs9640161	0.658	rs74348353	chr7:150053655	C/A	cg17279839	chr7:150038598	RARRES2	0.45	5.43	0.32	1.3e-7	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs514406	0.565	rs897732	chr1:53382816	A/C	cg24675658	chr1:53192096	ZYG11B	-0.65	-8.83	-0.48	1.43e-16	Monocyte count;
CESC	cis	rs7267979	1.000	rs4815420	chr20:25383979	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.87	-17.74	-0.74	6.08e-47	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs6754311	0.861	rs12475139	chr2:136786651	A/T	cg07169764	chr2:136633963	MCM6	0.62	7.91	0.44	7.19e-14	Mosquito bite size;
CESC	cis	rs748404	0.660	rs2467742	chr15:43750237	C/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.57	7.56	0.42	6.43e-13	Lung cancer;
CESC	cis	rs2455799	0.552	rs2470519	chr3:15762847	G/A	cg16303742	chr3:15540471	COLQ	-0.39	-6.24	-0.36	1.76e-9	Mean platelet volume;
CESC	cis	rs4654899	0.865	rs7532667	chr1:21438239	A/G	cg05370193	chr1:21551575	ECE1	0.43	6.87	0.39	4.69e-11	Superior frontal gyrus grey matter volume;
CESC	cis	rs1008375	1.000	rs1860597	chr4:17657650	C/T	cg16339924	chr4:17578868	LAP3	0.55	6.93	0.39	3.22e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs6121246	0.559	rs12479491	chr20:30265450	T/C	cg13852791	chr20:30311386	BCL2L1	0.8	10.41	0.54	1.72e-21	Mean corpuscular hemoglobin;
CESC	cis	rs2404602	0.716	rs67204011	chr15:76846555	C/T	cg26408565	chr15:76604113	ETFA	-0.4	-5.82	-0.34	1.71e-8	Blood metabolite levels;
CESC	cis	rs1475911	1.000	rs12482477	chr21:43517233	T/A	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.39	-5.82	-0.34	1.67e-8	IgG glycosylation;
CESC	cis	rs898097	0.812	rs7406011	chr17:80829980	C/T	cg20271620	chr17:80763330	TBCD	0.44	5.16	0.3	4.79e-7	Breast cancer;
CESC	cis	rs72945132	0.714	rs117232799	chr11:70157182	G/A	cg00319359	chr11:70116639	PPFIA1	0.75	6.21	0.36	2.06e-9	Coronary artery disease;
CESC	cis	rs4332037	0.851	rs73050128	chr7:1961882	C/A	cg23422044	chr7:1970798	MAD1L1	-0.57	-5.99	-0.35	6.71e-9	Bipolar disorder;
CESC	cis	rs1372520	0.684	rs356162	chr4:90697157	T/C	cg15133208	chr4:90757351	SNCA	0.42	5.4	0.31	1.5e-7	Neuroticism;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg03005121	chr22:46933669	CELSR1	0.45	6.0	0.35	6.56e-9	Fibrinogen levels;
CESC	cis	rs67257959	0.586	rs111818766	chr19:17158092	G/A	cg16202187	chr19:17186497	HAUS8;MYO9B	0.52	6.84	0.39	5.33e-11	Selective IgA deficiency;
CESC	cis	rs2072499	0.966	rs1060604	chr1:156184268	T/C	cg25208724	chr1:156163844	SLC25A44	0.95	15.46	0.69	7.1e-39	Testicular germ cell tumor;
CESC	cis	rs11645898	1.000	rs72791115	chr16:72207315	T/C	cg14768367	chr16:72042858	DHODH	-0.64	-5.16	-0.3	4.75e-7	Blood protein levels;
CESC	cis	rs10208940	0.777	rs6726966	chr2:68855856	A/G	cg12452813	chr2:68675892	NA	0.49	5.04	0.3	8.69e-7	Urate levels in lean individuals;
CESC	cis	rs7274811	0.711	rs373618	chr20:31992639	C/A	cg21523528	chr20:32077966	CBFA2T2	-0.49	-5.66	-0.33	4.01e-8	Height;
CESC	cis	rs7017914	0.934	rs13255886	chr8:71565954	G/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.4	-5.05	-0.3	8.32e-7	Bone mineral density;
CESC	cis	rs7937682	0.883	rs12366001	chr11:111433916	A/G	cg22437258	chr11:111473054	SIK2	-0.72	-8.72	-0.47	3.05e-16	Primary sclerosing cholangitis;
CESC	cis	rs8017423	0.967	rs8021881	chr14:90722276	T/C	cg14092571	chr14:90743983	NA	-0.55	-8.31	-0.45	5.06e-15	Mortality in heart failure;
CESC	cis	rs11167764	1.000	rs6887599	chr5:141484349	G/A	cg08523384	chr5:141488047	NDFIP1	-0.37	-5.44	-0.32	1.2e-7	Crohn's disease;
CESC	cis	rs2180341	0.814	rs9401959	chr6:127736464	T/C	cg27446573	chr6:127587934	RNF146	0.83	12.03	0.59	6.99e-27	Breast cancer;
CESC	cis	rs1552244	1.000	rs3846177	chr3:10068572	G/T	cg08888203	chr3:10149979	C3orf24	0.49	6.29	0.36	1.3e-9	Alzheimer's disease;
CESC	cis	rs7107174	0.901	rs10899497	chr11:78124534	T/C	cg02023728	chr11:77925099	USP35	0.43	5.61	0.33	5.1e-8	Testicular germ cell tumor;
CESC	trans	rs6952407	1	rs6952407	chr7:66045512	A/G	cg26939375	chr7:64535504	NA	-0.68	-9.1	-0.49	2.18e-17	Cotinine glucuronidation;
CESC	cis	rs2235642	0.821	rs8051895	chr16:1602811	A/G	cg03771183	chr16:1608904	IFT140	0.4	5.9	0.34	1.12e-8	Coronary artery disease;
CESC	cis	rs728616	0.558	rs72817596	chr10:82151594	T/C	cg05935833	chr10:81318306	SFTPA2	-0.46	-5.79	-0.34	1.94e-8	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs709400	0.633	rs10141433	chr14:103962559	A/G	cg12935359	chr14:103987150	CKB	-0.51	-7.44	-0.42	1.39e-12	Body mass index;
CESC	cis	rs5753037	0.543	rs131268	chr22:30147938	C/G	cg01021169	chr22:30184971	ASCC2	-0.55	-7.8	-0.43	1.39e-13	Type 1 diabetes;
CESC	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg10862848	chr6:42927986	GNMT	-0.22	-5.53	-0.32	7.61e-8	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs60843830	0.928	rs55742348	chr2:217563	T/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.87	11.47	0.58	5.47e-25	Spherical equivalent (joint analysis main effects and education interaction);
CESC	trans	rs7144011	0.654	rs11159407	chr14:79868133	T/C	cg24213196	chr17:40834836	CNTNAP1;CCR10	-0.46	-6.03	-0.35	5.47e-9	Waist circumference;Hip circumference;
CESC	cis	rs1865721	0.804	rs72977816	chr18:73146779	A/T	cg26385618	chr18:73139727	C18orf62	-0.52	-8.21	-0.45	1e-14	Intelligence;
CESC	cis	rs7116495	0.867	rs4378421	chr11:71761996	T/C	cg10381502	chr11:71823885	C11orf51	-1.16	-6.81	-0.39	6.4e-11	Severe influenza A (H1N1) infection;
CESC	cis	rs2228479	0.850	rs45567439	chr16:89814604	G/A	cg06558623	chr16:89946397	TCF25	1.16	9.28	0.5	6.08e-18	Skin colour saturation;
CESC	cis	rs7116495	0.609	rs7115513	chr11:71664495	T/A	cg26138937	chr11:71823887	C11orf51	-1.21	-8.23	-0.45	8.31e-15	Severe influenza A (H1N1) infection;
CESC	cis	rs4555082	0.957	rs2816622	chr14:105733114	T/C	cg27165867	chr14:105738592	BRF1	-0.48	-5.42	-0.32	1.32e-7	Mean platelet volume;Platelet distribution width;
CESC	cis	rs6920965	0.602	rs10872302	chr6:126180631	G/T	cg05901451	chr6:126070800	HEY2	-0.38	-5.23	-0.31	3.37e-7	High light scatter reticulocyte count;
CESC	cis	rs13256369	0.802	rs12153	chr8:8560909	G/C	cg18904891	chr8:8559673	CLDN23	0.71	7.96	0.44	4.92e-14	Obesity-related traits;
CESC	cis	rs13191362	0.872	rs67712738	chr6:163245768	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.64	6.3	0.36	1.22e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs896854	0.625	rs7823886	chr8:95986459	A/T	cg09323728	chr8:95962352	TP53INP1	-0.38	-8.23	-0.45	8.74e-15	Type 2 diabetes;
CESC	trans	rs7107174	1.000	rs731600	chr11:77963133	A/G	cg17250296	chr17:37331628	CACNB1	0.4	6.17	0.35	2.48e-9	Testicular germ cell tumor;
CESC	cis	rs7618501	0.933	rs1128535	chr3:49866392	C/T	cg24308560	chr3:49941425	MST1R	-0.52	-6.97	-0.39	2.55e-11	Intelligence (multi-trait analysis);
CESC	cis	rs6121246	0.697	rs45557936	chr20:30226690	G/A	cg13852791	chr20:30311386	BCL2L1	0.77	7.87	0.44	9.26e-14	Mean corpuscular hemoglobin;
CESC	cis	rs763121	0.853	rs9306329	chr22:39072454	C/T	cg21395723	chr22:39101663	GTPBP1	0.42	5.32	0.31	2.17e-7	Menopause (age at onset);
CESC	cis	rs8067545	0.586	rs11657161	chr17:20180715	A/G	cg13482628	chr17:19912719	NA	-0.42	-5.62	-0.33	4.92e-8	Schizophrenia;
CESC	cis	rs10504229	1.000	rs55944282	chr8:58180821	A/G	cg05313129	chr8:58192883	C8orf71	-0.55	-6.37	-0.36	8.42e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs875971	0.862	rs2088653	chr7:65808608	G/A	cg11764359	chr7:65958608	NA	-0.79	-11.58	-0.58	2.22e-25	Aortic root size;
CESC	cis	rs7552404	0.924	rs1146580	chr1:76209935	T/C	cg22875332	chr1:76189707	ACADM	0.71	9.93	0.52	5.79e-20	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs295140	0.605	rs3739119	chr2:201194279	C/A	cg23649088	chr2:200775458	C2orf69	-0.43	-5.64	-0.33	4.41e-8	QT interval;
CESC	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg10150615	chr22:24372951	LOC391322	-0.56	-7.39	-0.41	1.88e-12	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs1577917	0.917	rs12202170	chr6:86590386	A/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-6.23	-0.36	1.83e-9	Response to antipsychotic treatment;
CESC	cis	rs2463822	0.844	rs2513737	chr11:62119495	G/C	cg06239285	chr11:62104954	ASRGL1	0.86	8.63	0.47	5.79e-16	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs709400	0.633	rs1951391	chr14:103898313	T/C	cg12935359	chr14:103987150	CKB	-0.48	-6.9	-0.39	3.71e-11	Body mass index;
CESC	cis	rs7308134	0.766	rs73038195	chr12:2024092	T/C	cg19708984	chr12:1973340	CACNA2D4	0.58	5.14	0.3	5.36e-7	QRS duration in Tripanosoma cruzi seropositivity;
CESC	cis	rs4665809	0.838	rs6546749	chr2:26306288	T/C	cg22920501	chr2:26401640	FAM59B	-0.79	-9.3	-0.5	5.61e-18	Gut microbiome composition (summer);
CESC	cis	rs9443645	0.901	rs1567167	chr6:79553827	C/T	cg05283184	chr6:79620031	NA	-0.43	-6.8	-0.39	6.92e-11	Intelligence (multi-trait analysis);
CESC	cis	rs9291683	0.618	rs13137343	chr4:10043028	C/A	cg11266682	chr4:10021025	SLC2A9	0.67	13.02	0.62	2.72e-30	Bone mineral density;
CESC	cis	rs7811142	1.000	rs6962151	chr7:100028484	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.85	8.83	0.48	1.5e-16	Platelet count;
CESC	cis	rs9611565	0.512	rs9611672	chr22:42209922	A/G	cg06634786	chr22:41940651	POLR3H	-0.65	-6.3	-0.36	1.21e-9	Vitiligo;
CESC	cis	rs780096	0.526	rs704795	chr2:27716494	G/A	cg02592271	chr2:27665507	KRTCAP3	-0.3	-6.11	-0.35	3.62e-9	Total body bone mineral density;
CESC	cis	rs8020095	0.571	rs10131614	chr14:67363542	A/C	cg19548862	chr14:67692701	FAM71D	-0.49	-6.03	-0.35	5.41e-9	Depression (quantitative trait);
CESC	cis	rs8180040	1.000	rs1638676	chr3:47327651	A/G	cg27129171	chr3:47204927	SETD2	0.66	10.09	0.53	1.82e-20	Colorectal cancer;
CESC	cis	rs3091242	0.904	rs6661533	chr1:25771715	A/G	cg27572855	chr1:25598939	RHD	0.49	8.4	0.46	2.82e-15	Erythrocyte sedimentation rate;
CESC	trans	rs62103177	0.713	rs62103186	chr18:77627574	G/C	cg05926928	chr17:57297772	GDPD1	1.18	10.14	0.53	1.27e-20	Opioid sensitivity;
CESC	cis	rs9486719	0.948	rs11153059	chr6:97014537	T/A	cg18709589	chr6:96969512	KIAA0776	-0.52	-5.69	-0.33	3.43e-8	Migraine;Coronary artery disease;
CESC	cis	rs7264396	0.790	rs6060518	chr20:34217309	A/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.65	7.72	0.43	2.36e-13	Total cholesterol levels;
CESC	trans	rs6570726	0.791	rs414297	chr6:145887556	C/T	cg03826317	chr10:25465503	LOC100128811;GPR158	0.31	6.15	0.35	2.82e-9	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs12048904	0.505	rs10493936	chr1:101213335	A/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.7	-8.63	-0.47	5.64e-16	Multiple sclerosis;
CESC	cis	rs25645	0.502	rs7209742	chr17:38108708	A/G	cg17467752	chr17:38218738	THRA	0.41	5.11	0.3	6.17e-7	Myeloid white cell count;
CESC	cis	rs2882667	0.931	rs10044736	chr5:138320809	A/G	cg04439458	chr5:138467593	SIL1	0.29	5.14	0.3	5.24e-7	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs901683	1.000	rs35902429	chr10:46024335	T/C	cg16031567	chr10:46195673	NA	-0.77	-5.04	-0.3	8.57e-7	Red blood cell traits;Mean corpuscular volume;
CESC	cis	rs9487051	0.872	rs1111863	chr6:109611206	C/T	cg12927641	chr6:109611667	NA	0.45	6.77	0.38	8.18e-11	Reticulocyte fraction of red cells;
CESC	cis	rs60843830	0.964	rs17713568	chr2:242132	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.89	12.2	0.6	1.83e-27	Spherical equivalent (joint analysis main effects and education interaction);
CESC	trans	rs16893526	1.000	rs13214556	chr6:82496789	A/G	cg22476893	chr17:7210162	EIF5A	0.78	6.06	0.35	4.53e-9	Coronary heart disease;
CESC	trans	rs61931739	0.517	rs2636074	chr12:34064056	C/T	cg26384229	chr12:38710491	ALG10B	0.52	6.96	0.39	2.64e-11	Morning vs. evening chronotype;
CESC	cis	rs2033711	0.783	rs11671113	chr19:58958087	C/T	cg13877915	chr19:58951672	ZNF132	0.39	5.79	0.34	1.99e-8	Uric acid clearance;
CESC	trans	rs6572548	0.504	rs1956082	chr14:49665496	A/C	cg03947735	chr13:111090467	COL4A2	0.48	6.0	0.35	6.38e-9	Subjective well-being;
CESC	cis	rs2370759	1.000	rs2769241	chr10:32556229	T/C	cg01819863	chr10:32635814	EPC1	-1.17	-12.03	-0.59	6.79e-27	Sexual dysfunction (female);
CESC	cis	rs30380	0.632	rs149189	chr5:96137804	A/G	cg16492584	chr5:96139282	ERAP1	-0.48	-6.78	-0.38	7.83e-11	Cerebrospinal fluid biomarker levels;
CESC	cis	rs710216	0.917	rs900837	chr1:43412793	A/G	cg07803811	chr1:43423981	SLC2A1	-0.5	-5.47	-0.32	1.02e-7	Red cell distribution width;
CESC	cis	rs7683537	0.887	rs4540092	chr4:185633546	A/G	cg04058563	chr4:185651563	MLF1IP	0.63	6.89	0.39	3.95e-11	Systemic lupus erythematosus;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg12343791	chr22:39240109	NPTXR	-0.48	-6.37	-0.36	8.25e-10	Fibrinogen levels;
CESC	trans	rs61931739	0.500	rs11052966	chr12:34019826	C/T	cg26384229	chr12:38710491	ALG10B	0.47	6.49	0.37	4.23e-10	Morning vs. evening chronotype;
CESC	cis	rs9837602	0.507	rs793455	chr3:99526135	C/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.58	-9.06	-0.49	2.92e-17	Breast cancer;
CESC	cis	rs9902453	0.845	rs2628165	chr17:28121166	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	8.11	0.45	1.93e-14	Coffee consumption (cups per day);
CESC	cis	rs10129255	0.917	rs8022493	chr14:107190057	C/T	cg23076370	chr14:107095027	NA	-0.46	-5.95	-0.34	8.57e-9	Kawasaki disease;
CESC	cis	rs6763768	0.705	rs312483	chr3:53524051	A/G	cg07507251	chr3:52567010	NT5DC2	-0.33	-5.03	-0.3	9.22e-7	Bacterial meningitis;
CESC	cis	rs75477785	1.000	rs11119347	chr1:209983916	T/C	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.92	6.04	0.35	5.06e-9	Cleft lip with or without cleft palate;
CESC	cis	rs10089	1.000	rs6595806	chr5:127499764	A/T	cg19767477	chr5:127420684	SLC12A2	-0.38	-5.15	-0.3	5.16e-7	Ileal carcinoids;
CESC	cis	rs6754311	0.773	rs680428	chr2:136630757	A/G	cg07169764	chr2:136633963	MCM6	-0.7	-8.51	-0.46	1.28e-15	Mosquito bite size;
CESC	cis	rs2180341	0.883	rs6904630	chr6:127696869	A/G	cg24812749	chr6:127587940	RNF146	1.05	14.95	0.68	4.44e-37	Breast cancer;
CESC	cis	rs6456156	0.603	rs2345754	chr6:167484361	T/C	cg07741184	chr6:167504864	NA	0.37	6.36	0.36	8.83e-10	Primary biliary cholangitis;
CESC	cis	rs703842	0.616	rs4760171	chr12:58225904	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.55	6.74	0.38	1e-10	Multiple sclerosis;
CESC	cis	rs1799949	1.000	rs1399323	chr17:41332330	T/C	cg23758822	chr17:41437982	NA	1.04	16.01	0.7	7.99e-41	Menopause (age at onset);
CESC	cis	rs14403	0.519	rs3006917	chr1:243641971	C/T	cg21452805	chr1:244014465	NA	0.55	5.86	0.34	1.37e-8	Schizophrenia;
CESC	cis	rs17023223	0.537	rs12085616	chr1:119689148	A/C	cg05756136	chr1:119680316	WARS2	-0.46	-5.58	-0.32	6.01e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CESC	cis	rs3733585	0.631	rs4697707	chr4:10119787	G/T	cg00071950	chr4:10020882	SLC2A9	-0.62	-9.92	-0.52	6.42e-20	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs61931739	0.534	rs10844800	chr12:34230734	A/G	cg19457237	chr12:34500585	NA	-0.38	-5.29	-0.31	2.52e-7	Morning vs. evening chronotype;
CESC	cis	rs727563	0.635	rs5751141	chr22:42107745	A/G	cg17376030	chr22:41985996	PMM1	-0.77	-8.31	-0.45	5.13e-15	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs965469	0.696	rs6037570	chr20:3334292	C/A	cg25506879	chr20:3388711	C20orf194	-0.48	-5.15	-0.3	5.18e-7	IFN-related cytopenia;
CESC	trans	rs875971	0.737	rs7803424	chr7:65880605	T/C	cg26939375	chr7:64535504	NA	0.47	6.14	0.35	3.07e-9	Aortic root size;
CESC	cis	rs17095355	1.000	rs731793	chr10:111716667	C/G	cg00817464	chr10:111662876	XPNPEP1	0.46	5.4	0.31	1.47e-7	Biliary atresia;
CESC	cis	rs9487051	0.714	rs7774377	chr6:109602443	G/A	cg12927641	chr6:109611667	NA	-0.38	-5.66	-0.33	3.98e-8	Reticulocyte fraction of red cells;
CESC	cis	rs4523957	0.820	rs2209073	chr17:2205664	G/A	cg16513277	chr17:2031491	SMG6	0.59	7.77	0.43	1.78e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs796364	0.951	rs7565005	chr2:201013277	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.62	-6.2	-0.36	2.13e-9	Schizophrenia;
CESC	cis	rs7116495	0.609	rs10751191	chr11:71680920	C/T	cg07596299	chr11:71824057	C11orf51	-0.83	-5.36	-0.31	1.8e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg24739457	chr1:205821442	NA	0.42	5.42	0.32	1.35e-7	Menarche (age at onset);
CESC	cis	rs9302635	0.513	rs8061282	chr16:72155938	C/T	cg16558253	chr16:72132732	DHX38	-0.46	-6.04	-0.35	5.09e-9	Blood protein levels;
CESC	cis	rs9929218	0.551	rs9888942	chr16:68727572	A/G	cg02972257	chr16:68554789	NA	-0.44	-5.45	-0.32	1.15e-7	Colorectal cancer;
CESC	cis	rs9296736	0.890	rs9370258	chr6:53910988	T/G	cg04374786	chr6:53939321	C6orf142	0.34	5.3	0.31	2.46e-7	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs8018808	0.935	rs2364156	chr14:77916746	G/A	cg20045696	chr14:77926864	AHSA1	0.42	5.79	0.33	2.04e-8	Myeloid white cell count;
CESC	cis	rs9768139	0.935	rs10155946	chr7:158122116	C/T	cg06219351	chr7:158114137	PTPRN2	0.44	6.82	0.39	5.99e-11	Calcium levels;
CESC	trans	rs7980799	0.935	rs10732554	chr12:33533374	C/T	cg26384229	chr12:38710491	ALG10B	-0.47	-6.3	-0.36	1.26e-9	Heart rate;Heart rate variability traits (RMSSD);
CESC	cis	rs597539	0.727	rs632984	chr11:68620271	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.79	9.33	0.5	4.51e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs769267	0.965	rs2074303	chr19:19381755	C/T	cg03709012	chr19:19516395	GATAD2A	0.96	14.17	0.66	2.59e-34	Tonsillectomy;
CESC	cis	rs12586317	0.511	rs113770696	chr14:35444383	C/T	cg05294307	chr14:35346193	BAZ1A	-0.49	-5.37	-0.31	1.75e-7	Psoriasis;
CESC	cis	rs10465746	0.967	rs12732697	chr1:84349283	A/G	cg10977910	chr1:84465055	TTLL7	0.48	6.52	0.37	3.63e-10	Obesity-related traits;
CESC	cis	rs7635838	0.684	rs2606757	chr3:11358163	T/A	cg00170343	chr3:11313890	ATG7	0.54	7.83	0.43	1.15e-13	HDL cholesterol;
CESC	cis	rs938554	0.784	rs16868246	chr4:9978305	C/G	cg00071950	chr4:10020882	SLC2A9	0.47	5.68	0.33	3.54e-8	Blood metabolite levels;
CESC	cis	rs7191439	0.589	rs11076699	chr16:88756812	A/C	cg27087555	chr16:88793112	FAM38A	0.72	5.17	0.3	4.68e-7	Plateletcrit;
CESC	cis	rs8060686	0.623	rs56303487	chr16:68029739	C/T	cg26727032	chr16:67993705	SLC12A4	-0.59	-8.03	-0.44	3.27e-14	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs7086627	0.515	rs10887894	chr10:82209952	A/G	cg03267442	chr10:82210566	NA	-0.34	-5.6	-0.33	5.45e-8	Post bronchodilator FEV1;
CESC	trans	rs1285495	0.627	rs10912059	chr1:187354887	C/T	cg02739744	chr7:2613265	IQCE	0.5	6.76	0.38	8.66e-11	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
CESC	cis	rs73206853	0.841	rs55972509	chr12:110992755	T/C	cg12870014	chr12:110450643	ANKRD13A	0.63	5.29	0.31	2.51e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	trans	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg13565492	chr6:43139072	SRF	-0.74	-8.88	-0.48	1.02e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7264396	0.635	rs6121102	chr20:34544274	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.82	-11.49	-0.58	4.75e-25	Total cholesterol levels;
CESC	cis	rs17345786	0.511	rs1138818	chr3:101399583	C/G	cg12386194	chr3:101231763	SENP7	0.45	5.53	0.32	7.8e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs8005677	1.000	rs7145494	chr14:23399790	T/C	cg01529538	chr14:23388837	RBM23	0.51	6.84	0.39	5.51e-11	Cognitive ability (multi-trait analysis);
CESC	cis	rs4665809	1.000	rs10182857	chr2:26344411	C/T	cg27170947	chr2:26402098	FAM59B	-0.59	-7.07	-0.4	1.36e-11	Gut microbiome composition (summer);
CESC	cis	rs2230307	0.536	rs560659	chr1:100523536	A/G	cg24955406	chr1:100503596	HIAT1	-0.57	-5.7	-0.33	3.21e-8	Carotid intima media thickness;
CESC	cis	rs3096299	0.667	rs2965947	chr16:89518670	T/C	cg00750074	chr16:89608354	SPG7	-0.43	-6.22	-0.36	1.91e-9	Multiple myeloma (IgH translocation);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg12072290	chr12:124018993	RILPL1	0.42	6.03	0.35	5.41e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs112790992	1	rs112790992	chr14:105758217	A/C	cg13114125	chr14:105738426	BRF1	-0.71	-9.25	-0.49	7.96e-18	Platelet count;
CESC	cis	rs1707322	1.000	rs4298677	chr1:46306619	G/A	cg03146154	chr1:46216737	IPP	0.74	10.1	0.53	1.7e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs1065852	0.526	rs9611711	chr22:42410695	G/A	cg22189786	chr22:42395067	WBP2NL	0.41	5.22	0.31	3.55e-7	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
CESC	cis	rs748404	0.560	rs572837	chr15:43823813	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.55	7.09	0.4	1.2e-11	Lung cancer;
CESC	cis	rs7178909	0.933	rs7183156	chr15:90445446	A/G	cg19708238	chr15:90437601	AP3S2	0.43	5.89	0.34	1.19e-8	Common traits (Other);
CESC	cis	rs3858526	0.523	rs10769287	chr11:5884845	T/C	cg05234568	chr11:5960015	NA	-0.66	-9.65	-0.51	4.4e-19	DNA methylation (variation);
CESC	cis	rs660498	0.507	rs34467586	chr10:27742027	C/T	cg25705717	chr10:27608719	NA	0.46	5.72	0.33	2.83e-8	Asthma (childhood onset);
CESC	cis	rs34779708	0.931	rs2001893	chr10:35300623	G/A	cg04310649	chr10:35416472	CREM	-0.51	-6.14	-0.35	2.92e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs8077577	0.945	rs11654146	chr17:18076141	A/C	cg16794390	chr17:18148240	FLII	0.42	5.64	0.33	4.41e-8	Obesity-related traits;
CESC	cis	rs7914558	0.966	rs7908280	chr10:104816947	C/G	cg15744005	chr10:104629667	AS3MT	-0.34	-5.5	-0.32	8.8e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs727563	0.520	rs132773	chr22:42031768	T/A	cg03806693	chr22:41940476	POLR3H	1.05	12.5	0.61	1.69e-28	Crohn's disease;Inflammatory bowel disease;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg01187952	chr3:63850081	THOC7;ATXN7	-0.38	-6.03	-0.35	5.38e-9	Gambling;
CESC	cis	rs798554	1.000	rs798536	chr7:2766383	G/A	cg19346786	chr7:2764209	NA	-0.51	-7.45	-0.42	1.35e-12	Height;
CESC	cis	rs7959452	0.535	rs2305641	chr12:69646914	C/T	cg20891283	chr12:69753455	YEATS4	0.76	11.37	0.57	1.2e-24	Blood protein levels;
CESC	cis	rs9596863	0.950	rs7334923	chr13:54394765	G/T	ch.13.53330881F	chr13:54432880	NA	0.66	5.36	0.31	1.84e-7	Epilepsy and lamotrigine-induced maculopapular eruptions;
CESC	cis	rs2050392	0.517	rs2480299	chr10:30743197	G/A	cg18806716	chr10:30721971	MAP3K8	-0.5	-7.68	-0.43	3.1400000000000003e-13	Inflammatory bowel disease;
CESC	cis	rs2180341	0.843	rs4895821	chr6:127572761	T/A	cg24812749	chr6:127587940	RNF146	1.08	15.45	0.69	7.93e-39	Breast cancer;
CESC	cis	rs9487051	0.676	rs6925716	chr6:109597641	T/C	cg12927641	chr6:109611667	NA	-0.37	-5.51	-0.32	8.49e-8	Reticulocyte fraction of red cells;
CESC	cis	rs1552244	1.000	rs113522867	chr3:10154503	T/C	cg00166722	chr3:10149974	C3orf24	0.45	5.65	0.33	4.12e-8	Alzheimer's disease;
CESC	cis	rs7949030	0.588	rs2428548	chr11:62311462	A/G	cg02375832	chr11:62437615	C11orf48	-0.36	-5.34	-0.31	1.98e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs1878931	0.624	rs28089	chr16:3446937	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.79	-8.98	-0.48	5.1e-17	Body mass index (adult);
CESC	trans	rs11148252	0.595	rs4885325	chr13:53171317	C/T	cg18335740	chr13:41363409	SLC25A15	0.56	7.72	0.43	2.32e-13	Lewy body disease;
CESC	cis	rs910316	1.000	rs8003506	chr14:75586288	A/C	cg11812906	chr14:75593930	NEK9	-0.88	-14.15	-0.66	3.18e-34	Height;
CESC	cis	rs9910055	0.639	rs227583	chr17:42231698	C/G	cg08499158	chr17:42289980	UBTF	-0.52	-6.53	-0.37	3.27e-10	Total body bone mineral density;
CESC	cis	rs295140	0.507	rs1369842	chr2:201108987	C/A	cg23649088	chr2:200775458	C2orf69	-0.42	-5.76	-0.33	2.35e-8	QT interval;
CESC	cis	rs4665809	0.531	rs34081866	chr2:26475940	C/T	cg04944784	chr2:26401820	FAM59B	0.96	10.83	0.55	7.34e-23	Gut microbiome composition (summer);
CESC	cis	rs36051895	0.664	rs28378223	chr9:5113087	C/G	cg02405213	chr9:5042618	JAK2	-0.47	-5.88	-0.34	1.26e-8	Pediatric autoimmune diseases;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07257649	chr6:4776641	CDYL	0.61	7.09	0.4	1.2e-11	Gut microbiome composition (summer);
CESC	cis	rs4835473	0.932	rs1849128	chr4:144913735	C/T	cg25736465	chr4:144833511	NA	0.43	6.44	0.37	5.61e-10	Immature fraction of reticulocytes;
CESC	cis	rs57506017	0.585	rs7804234	chr7:12266814	A/G	cg23422036	chr7:12250390	TMEM106B	0.38	5.17	0.3	4.7e-7	Neuroticism;
CESC	cis	rs7618915	0.501	rs12486554	chr3:52742537	A/T	cg18337363	chr3:52569053	NT5DC2	0.29	5.11	0.3	6.24e-7	Bipolar disorder;
CESC	cis	rs1218582	0.772	rs4845682	chr1:154877105	T/C	cg09359103	chr1:154839909	KCNN3	-0.65	-12.33	-0.6	6.58e-28	Prostate cancer;
CESC	cis	rs9322193	0.923	rs12174349	chr6:150039148	G/A	cg09699651	chr6:150184138	LRP11	0.39	5.04	0.3	8.83e-7	Lung cancer;
CESC	cis	rs7666738	0.791	rs13120773	chr4:98972589	C/T	cg05340658	chr4:99064831	C4orf37	0.79	12.26	0.6	1.12e-27	Colonoscopy-negative controls vs population controls;
CESC	cis	rs921968	0.643	rs500317	chr2:219432953	G/C	cg02176678	chr2:219576539	TTLL4	0.41	7.13	0.4	9.62e-12	Mean corpuscular hemoglobin concentration;
CESC	cis	rs1005277	0.579	rs2474599	chr10:38438939	A/G	cg00409905	chr10:38381863	ZNF37A	-0.45	-5.96	-0.34	7.89e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs11098499	0.954	rs3733520	chr4:120423480	C/G	cg24375607	chr4:120327624	NA	0.46	5.75	0.33	2.42e-8	Corneal astigmatism;
CESC	cis	rs2456568	0.548	rs6483281	chr11:93661840	G/C	cg26875233	chr11:93583750	C11orf90	-0.33	-5.84	-0.34	1.52e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg02576381	chr5:159827164	C5orf54	0.45	6.25	0.36	1.59e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs7542091	1.000	rs7542091	chr1:210031948	G/C	cg21951975	chr1:209979733	IRF6	0.44	7.62	0.42	4.58e-13	Monobrow;
CESC	cis	rs9309473	0.948	rs7607892	chr2:73818707	C/T	cg20560298	chr2:73613845	ALMS1	-0.53	-7.03	-0.4	1.75e-11	Metabolite levels;
CESC	trans	rs7107217	1.000	rs1873872	chr11:129473993	A/T	cg05673432	chr3:15919505	NA	-0.54	-6.8	-0.39	7.11e-11	Breast cancer;Type 2 diabetes;
CESC	trans	rs1814175	0.817	rs2866863	chr11:49953242	C/T	cg03929089	chr4:120376271	NA	-0.93	-15.75	-0.7	6.66e-40	Height;
CESC	cis	rs8005677	0.798	rs4536383	chr14:23410926	T/C	cg01529538	chr14:23388837	RBM23	0.44	5.83	0.34	1.63e-8	Cognitive ability (multi-trait analysis);
CESC	cis	rs1552244	0.935	rs7652190	chr3:10105150	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.8	-10.21	-0.53	7.17e-21	Alzheimer's disease;
CESC	cis	rs11864453	0.713	rs3764312	chr16:72125733	A/C	cg16558253	chr16:72132732	DHX38	-0.56	-8.7	-0.47	3.62e-16	Fibrinogen levels;
CESC	cis	rs7524258	0.868	rs2412153	chr1:7272412	C/T	cg07173049	chr1:7289937	CAMTA1	0.37	5.5	0.32	8.98e-8	Tourette's syndrome or obsessive-compulsive disorder;
CESC	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg03188948	chr7:1209495	NA	0.47	6.1	0.35	3.7e-9	Longevity;Endometriosis;
CESC	cis	rs4455778	0.536	rs887451	chr7:48943352	T/C	cg26309511	chr7:48887640	NA	-0.35	-5.11	-0.3	6.1e-7	Lung cancer in never smokers;
CESC	cis	rs9733	0.519	rs10788792	chr1:150638572	T/G	cg09365446	chr1:150670422	GOLPH3L	0.41	5.77	0.33	2.22e-8	Tonsillectomy;
CESC	trans	rs17764205	0.777	rs17696630	chr19:3261995	A/G	cg04564646	chr1:113217655	MOV10	-0.8	-6.28	-0.36	1.4e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg02353165	chr6:42928485	GNMT	-0.83	-13.77	-0.65	6.71e-33	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs4362	0.934	rs4343	chr17:61566031	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.4	5.39	0.31	1.6e-7	Blood metabolite levels;
CESC	cis	rs13108904	0.870	rs12642797	chr4:1245990	G/A	cg00684032	chr4:1343700	KIAA1530	0.4	5.73	0.33	2.76e-8	Obesity-related traits;
CESC	cis	rs7777484	0.500	rs757787	chr7:2836355	G/A	cg09658497	chr7:2847517	GNA12	-0.44	-6.86	-0.39	4.8e-11	Height;
CESC	cis	rs1957429	0.808	rs7144718	chr14:65333831	G/A	cg23373153	chr14:65346875	NA	0.89	9.19	0.49	1.19e-17	Pediatric areal bone mineral density (radius);
CESC	cis	rs7678296	0.649	rs73128366	chr4:37241908	T/C	cg06805348	chr4:37245195	KIAA1239	0.53	5.79	0.33	2.04e-8	3-hydroxypropylmercapturic acid levels in smokers;
CESC	cis	rs12995849	0.714	rs6543342	chr2:106462256	T/C	cg16077055	chr2:106428750	NCK2	0.39	5.81	0.34	1.75e-8	Addiction;
CESC	cis	rs7582720	1.000	rs7582720	chr2:203753072	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.39	0.41	1.96e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	trans	rs17673138	0.631	rs17673099	chr8:32696905	A/C	cg05233373	chr2:161127261	NA	0.54	6.15	0.35	2.86e-9	Pharmacokinetics of olanzapine in severe mental disorder (concentration dose ratio);
CESC	cis	rs12079745	0.793	rs12061405	chr1:169208368	G/A	cg09363564	chr1:169337483	NME7;BLZF1	-1.13	-6.57	-0.37	2.58e-10	QT interval;
CESC	trans	rs1814175	0.645	rs11040702	chr11:50024827	C/T	cg03929089	chr4:120376271	NA	-0.91	-14.8	-0.67	1.58e-36	Height;
CESC	cis	rs4604732	0.588	rs4925551	chr1:247631724	T/A	cg12758973	chr1:247694275	LOC148824;OR2C3	0.48	5.96	0.34	7.9e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs7523050	0.643	rs67567504	chr1:109402580	C/A	cg08274380	chr1:109419600	GPSM2	0.86	5.69	0.33	3.36e-8	Fat distribution (HIV);
CESC	cis	rs1552244	1.000	rs7619340	chr3:10108178	C/T	cg08888203	chr3:10149979	C3orf24	0.53	6.72	0.38	1.11e-10	Alzheimer's disease;
CESC	cis	rs4319547	0.656	rs10744209	chr12:122931568	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.5	-5.77	-0.33	2.19e-8	Body mass index;
CESC	cis	rs34779708	0.931	rs4934700	chr10:35310842	A/G	cg03585969	chr10:35415529	CREM	0.76	10.03	0.52	2.79e-20	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs10927875	0.722	rs1763605	chr1:16338925	T/G	cg21385522	chr1:16154831	NA	0.62	7.51	0.42	9.21e-13	Dilated cardiomyopathy;
CESC	cis	rs3858526	0.523	rs10742818	chr11:5882535	T/C	cg05234568	chr11:5960015	NA	-0.65	-9.12	-0.49	1.91e-17	DNA methylation (variation);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25867694	chr22:31503597	SELM	0.59	6.52	0.37	3.45e-10	Gut microbiome composition (summer);
CESC	cis	rs4642101	0.618	rs11128614	chr3:12819212	A/G	cg05775895	chr3:12838266	CAND2	0.36	5.35	0.31	1.93e-7	QRS complex (12-leadsum);
CESC	cis	rs12477438	0.520	rs11695379	chr2:99742161	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.88	15.67	0.69	1.26e-39	Chronic sinus infection;
CESC	cis	rs2070488	0.965	rs13079145	chr3:38517992	T/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.95	17.58	0.73	2.16e-46	Electrocardiographic conduction measures;
CESC	cis	rs9486719	1.000	rs4077932	chr6:96905144	C/T	cg06623918	chr6:96969491	KIAA0776	-0.81	-8.3	-0.45	5.45e-15	Migraine;Coronary artery disease;
CESC	cis	rs1062177	1.000	rs2915878	chr5:151149662	A/G	cg00977110	chr5:151150581	G3BP1	0.66	7.09	0.4	1.25e-11	Preschool internalizing problems;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12357364	chr17:1557144	PRPF8	-0.55	-6.33	-0.36	1.02e-9	Gut microbiome composition (summer);
CESC	cis	rs12291225	0.679	rs11369	chr11:14288096	A/G	cg19336497	chr11:14380999	RRAS2	-0.37	-5.37	-0.31	1.72e-7	Sense of smell;
CESC	cis	rs853679	0.517	rs9380058	chr6:28127444	T/C	cg17949981	chr6:28129498	ZNF389	0.47	5.86	0.34	1.37e-8	Depression;
CESC	cis	rs7666738	0.830	rs732299	chr4:98995389	C/T	cg05340658	chr4:99064831	C4orf37	0.78	11.87	0.59	2.5e-26	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9948	0.529	rs62156222	chr2:97410988	C/A	cg01990225	chr2:97406019	LMAN2L	-0.98	-7.35	-0.41	2.39e-12	Erectile dysfunction and prostate cancer treatment;
CESC	cis	rs7772486	0.875	rs1960885	chr6:146325930	G/T	cg23711669	chr6:146136114	FBXO30	0.79	11.12	0.56	7.65e-24	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs10220309	0.501	rs2216086	chr14:80642320	C/T	cg08183125	chr14:80678293	DIO2	-0.43	-5.51	-0.32	8.66e-8	Lung function (FEV1);
CESC	cis	rs1552244	1.000	rs61077902	chr3:10126153	T/G	cg16606324	chr3:10149918	C3orf24	0.42	5.27	0.31	2.8e-7	Alzheimer's disease;
CESC	cis	rs12579753	0.879	rs11115007	chr12:82164673	A/T	cg23701643	chr12:82153290	PPFIA2	-0.36	-5.26	-0.31	2.92e-7	Resting heart rate;
CESC	cis	rs72781680	0.560	rs111310684	chr2:24265682	C/G	cg06627628	chr2:24431161	ITSN2	-0.65	-6.21	-0.36	2.08e-9	Lymphocyte counts;
CESC	cis	rs4474465	0.736	rs10899550	chr11:78256078	G/A	cg27205649	chr11:78285834	NARS2	0.42	5.32	0.31	2.16e-7	Alzheimer's disease (survival time);
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg05237023	chr16:75182837	ZFP1	0.56	7.22	0.41	5.41e-12	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs12893668	0.703	rs34026011	chr14:104050883	G/A	cg24130564	chr14:104152367	KLC1	-0.46	-5.75	-0.33	2.47e-8	Reticulocyte count;
CESC	cis	rs2032447	0.869	rs199752	chr6:26012875	C/T	cg18357526	chr6:26021779	HIST1H4A	0.77	10.74	0.55	1.47e-22	Intelligence (multi-trait analysis);
CESC	cis	rs3845702	0.736	rs3843323	chr2:180856459	T/C	cg01881094	chr2:180872142	CWC22	-1.08	-10.12	-0.53	1.5e-20	Schizophrenia;
CESC	cis	rs17854409	0.764	rs12625513	chr20:61475661	G/A	cg05147244	chr20:61493195	TCFL5	1.09	5.94	0.34	9.12e-9	Obesity-related traits;
CESC	cis	rs17666538	0.710	rs12716640	chr8:645376	A/C	cg07685180	chr8:600429	NA	0.59	5.2	0.3	3.9e-7	IgG glycosylation;
CESC	cis	rs72781680	0.611	rs72797818	chr2:24351107	G/A	cg06627628	chr2:24431161	ITSN2	-0.67	-6.45	-0.37	5.4e-10	Lymphocyte counts;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg01727434	chr2:152118530	RBM43	0.49	6.35	0.36	9.54e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs11711311	1.000	rs9826465	chr3:113432254	G/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.58	7.73	0.43	2.27e-13	IgG glycosylation;
CESC	cis	rs1801251	1.000	rs2012221	chr2:233566848	T/C	cg08000102	chr2:233561755	GIGYF2	0.66	9.02	0.48	3.78e-17	Coronary artery disease;
CESC	cis	rs28551159	1	rs28551159	chr6:26376368	A/G	cg14345882	chr6:26364793	BTN3A2	0.61	6.18	0.35	2.4e-9	Urinary tract infection frequency;
CESC	cis	rs7666738	0.830	rs17548431	chr4:98923768	C/G	cg03467027	chr4:99064603	C4orf37	0.46	5.59	0.32	5.78e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs72634258	0.554	rs4908705	chr1:7926401	C/T	cg00042356	chr1:8021962	PARK7	0.47	5.22	0.31	3.69e-7	Inflammatory bowel disease;
CESC	cis	rs9584850	0.915	rs7983438	chr13:99103317	T/C	cg22223119	chr13:99095684	FARP1	-0.37	-5.32	-0.31	2.16e-7	Neuroticism;
CESC	cis	rs3135063	0.847	rs1138690	chr4:3291401	G/T	cg00060484	chr4:3287598	NA	-0.33	-5.19	-0.3	4.12e-7	Blood protein levels;
CESC	cis	rs926938	0.505	rs2878573	chr1:115521602	A/G	cg12756093	chr1:115239321	AMPD1	0.45	6.15	0.35	2.84e-9	Autism;
CESC	cis	rs6076065	0.722	rs6048760	chr20:23345844	G/T	cg11657817	chr20:23433608	CST11	-0.38	-5.71	-0.33	2.96e-8	Facial morphology (factor 15, philtrum width);
CESC	cis	rs1552244	1.000	rs113153120	chr3:10156398	G/A	cg08888203	chr3:10149979	C3orf24	0.44	5.71	0.33	3.09e-8	Alzheimer's disease;
CESC	cis	rs2243480	0.831	rs57294491	chr7:65684901	T/A	cg12463550	chr7:65579703	CRCP	-0.73	-5.67	-0.33	3.81e-8	Diabetic kidney disease;
CESC	cis	rs2836974	0.739	rs12482181	chr21:40548852	A/G	cg11644478	chr21:40555479	PSMG1	1.01	16.75	0.72	1.91e-43	Cognitive function;
CESC	cis	rs6570726	0.791	rs422099	chr6:145806936	C/T	cg23711669	chr6:146136114	FBXO30	1.0	15.78	0.7	5.42e-40	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs868036	0.609	rs2278076	chr15:68099600	C/T	cg08079166	chr15:68083412	MAP2K5	0.41	5.66	0.33	3.85e-8	Restless legs syndrome;
CESC	cis	rs7412746	0.658	rs4970988	chr1:150950062	A/G	cg04414720	chr1:150670196	GOLPH3L	-0.46	-6.0	-0.35	6.29e-9	Melanoma;
CESC	cis	rs66530629	0.834	rs11249171	chr1:25073571	A/C	cg22509179	chr1:25234806	RUNX3	-0.48	-6.26	-0.36	1.56e-9	Plateletcrit;
CESC	cis	rs9768139	0.627	rs57920447	chr7:158121243	A/G	cg06219351	chr7:158114137	PTPRN2	-0.49	-7.53	-0.42	7.74e-13	Calcium levels;
CESC	cis	rs17376456	0.542	rs1982439	chr5:93160560	C/G	cg25358565	chr5:93447407	FAM172A	-0.7	-7.35	-0.41	2.52e-12	Diabetic retinopathy;
CESC	cis	rs533581	0.708	rs2968475	chr16:88976663	C/G	cg16701003	chr16:89028210	CBFA2T3	0.54	7.54	0.42	7.5e-13	Social autistic-like traits;
CESC	cis	rs1832871	0.711	rs12525147	chr6:158683509	A/G	cg07165851	chr6:158734300	TULP4	0.55	5.41	0.32	1.41e-7	Height;
CESC	cis	rs11958404	0.932	rs76601259	chr5:157430337	C/T	cg05962755	chr5:157440814	NA	0.63	6.63	0.38	1.87e-10	IgG glycosylation;
CESC	cis	rs75804782	0.641	rs72985387	chr2:239336589	G/A	cg18131467	chr2:239335373	ASB1	-0.67	-5.74	-0.33	2.54e-8	Morning vs. evening chronotype;Chronotype;
CESC	cis	rs7914558	0.966	rs1890185	chr10:104748718	A/G	cg08650961	chr10:104748594	CNNM2	0.33	5.35	0.31	1.92e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs854765	0.654	rs9911281	chr17:17762457	G/C	cg04398451	chr17:18023971	MYO15A	0.67	10.08	0.53	1.98e-20	Total body bone mineral density;
CESC	cis	rs12618769	0.597	rs3769725	chr2:99105967	A/G	cg10123293	chr2:99228465	UNC50	0.4	5.38	0.31	1.64e-7	Bipolar disorder;
CESC	cis	rs193541	0.632	rs34486978	chr5:122312543	G/A	cg19412675	chr5:122181750	SNX24	-0.46	-5.44	-0.32	1.22e-7	Glucose homeostasis traits;
CESC	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	13.67	0.64	1.44e-32	Prudent dietary pattern;
CESC	cis	rs9527	0.590	rs10883834	chr10:104881402	T/C	cg04362960	chr10:104952993	NT5C2	0.44	5.54	0.32	7.12e-8	Arsenic metabolism;
CESC	cis	rs4665809	0.941	rs1434079	chr2:26284670	C/G	cg22920501	chr2:26401640	FAM59B	-0.69	-8.44	-0.46	2.06e-15	Gut microbiome composition (summer);
CESC	cis	rs1559088	1.000	rs28803235	chr19:33561804	G/A	cg27124370	chr19:33622961	WDR88	0.41	5.04	0.3	8.46e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs7659604	0.540	rs4455438	chr4:122669550	G/A	cg19671926	chr4:122722719	EXOSC9	0.53	6.55	0.37	3e-10	Type 2 diabetes;
CESC	cis	rs35110281	0.641	rs9983670	chr21:45083425	A/G	cg01579765	chr21:45077557	HSF2BP	-0.53	-8.9	-0.48	9.29e-17	Mean corpuscular volume;
CESC	cis	rs7107174	1.000	rs7119933	chr11:78049750	A/C	cg02023728	chr11:77925099	USP35	0.39	5.54	0.32	7.12e-8	Testicular germ cell tumor;
CESC	cis	rs7617773	0.925	rs34513961	chr3:48173653	T/C	cg20734569	chr3:48348370	SPINK8	-0.37	-5.05	-0.3	8.23e-7	Coronary artery disease;
CESC	cis	rs2929278	0.561	rs62018952	chr15:44080737	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	-0.47	-7.35	-0.41	2.48e-12	Schizophrenia;
CESC	cis	rs1008375	0.797	rs6843530	chr4:17593605	G/T	cg02297831	chr4:17616191	MED28	0.5	6.23	0.36	1.81e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs7116495	1.000	rs4945435	chr11:71759219	C/T	cg10381502	chr11:71823885	C11orf51	-0.65	-5.48	-0.32	9.66e-8	Severe influenza A (H1N1) infection;
CESC	cis	rs12142240	0.698	rs7515598	chr1:46818479	C/T	cg10495392	chr1:46806563	NSUN4	0.57	6.27	0.36	1.47e-9	Menopause (age at onset);
CESC	cis	rs1355223	1.000	rs11602909	chr11:34768003	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.43	-5.62	-0.33	4.73e-8	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs863345	0.604	rs6689657	chr1:158462509	C/T	cg12129480	chr1:158549410	OR10X1	-0.36	-7.17	-0.4	7.29e-12	Pneumococcal bacteremia;
CESC	cis	rs7264396	0.790	rs6060562	chr20:34282053	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.65	6.96	0.39	2.62e-11	Total cholesterol levels;
CESC	cis	rs11098499	0.866	rs6857892	chr4:120282696	G/T	cg09307838	chr4:120376055	NA	0.87	12.16	0.6	2.41e-27	Corneal astigmatism;
CESC	cis	rs36051895	0.632	rs12684720	chr9:5150800	T/C	cg02405213	chr9:5042618	JAK2	-0.52	-6.45	-0.37	5.42e-10	Pediatric autoimmune diseases;
CESC	cis	rs910316	0.934	rs7141705	chr14:75655352	G/C	cg11812906	chr14:75593930	NEK9	-0.85	-13.94	-0.65	1.65e-33	Height;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg00298532	chr1:9790325	CLSTN1	0.47	6.38	0.36	8.03e-10	Fibrinogen levels;
CESC	cis	rs6120849	0.754	rs36003887	chr20:33589107	G/A	cg24642439	chr20:33292090	TP53INP2	0.67	6.62	0.38	1.94e-10	Protein C levels;
CESC	cis	rs7772486	0.641	rs67882056	chr6:146416301	T/C	cg23711669	chr6:146136114	FBXO30	0.84	11.1	0.56	9.14e-24	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9858542	0.953	rs9827708	chr3:49649989	C/G	cg03060546	chr3:49711283	APEH	-0.55	-6.65	-0.38	1.63e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs2243480	1.000	rs10807701	chr7:65724686	C/A	cg12463550	chr7:65579703	CRCP	-0.74	-5.73	-0.33	2.74e-8	Diabetic kidney disease;
CESC	trans	rs12265790	1.000	rs11253672	chr10:15928339	T/C	cg03460745	chr3:171966142	FNDC3B	0.75	6.02	0.35	5.81e-9	Cerebrospinal fluid t-tau:AB1-42 ratio;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg19091447	chr20:37555378	FAM83D	-0.47	-6.68	-0.38	1.37e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs6500602	0.627	rs11639998	chr16:4527109	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.42	5.84	0.34	1.56e-8	Schizophrenia;
CESC	cis	rs9788682	0.747	rs2036533	chr15:78781687	G/A	cg24631222	chr15:78858424	CHRNA5	0.64	7.65	0.43	3.69e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs11227306	0.902	rs625652	chr11:65641931	T/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.49	-5.45	-0.32	1.13e-7	DNA methylation (variation);
CESC	cis	rs9457247	1.000	rs2757042	chr6:167371234	A/T	cg25258033	chr6:167368657	RNASET2	-0.39	-5.98	-0.34	7.29e-9	Crohn's disease;
CESC	cis	rs853679	0.546	rs200989	chr6:27816442	A/G	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.87	7.44	0.42	1.39e-12	Depression;
CESC	cis	rs10751667	0.577	rs7946461	chr11:974035	A/G	cg20946044	chr11:1010712	AP2A2	-0.39	-5.32	-0.31	2.24e-7	Alzheimer's disease (late onset);
CESC	cis	rs172166	0.637	rs1225597	chr6:28162087	C/T	cg12963246	chr6:28129442	ZNF389	0.4	5.82	0.34	1.65e-8	Cardiac Troponin-T levels;
CESC	cis	rs9916302	0.904	rs4357971	chr17:37717280	C/T	cg15445000	chr17:37608096	MED1	0.42	6.83	0.39	5.67e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs1847202	0.859	rs4550778	chr3:72949198	G/A	cg25664220	chr3:72788482	NA	-0.37	-5.44	-0.32	1.2e-7	Motion sickness;
CESC	cis	rs8020095	0.571	rs8022657	chr14:67390499	C/T	cg19548862	chr14:67692701	FAM71D	-0.49	-6.01	-0.35	6.16e-9	Depression (quantitative trait);
CESC	cis	rs6570726	0.935	rs366308	chr6:145814532	T/A	cg23711669	chr6:146136114	FBXO30	0.82	12.29	0.6	8.74e-28	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg07269724	chr19:12904655	NA	-0.42	-6.14	-0.35	2.94e-9	Gambling;
CESC	cis	rs7412746	0.587	rs3849279	chr1:150944707	T/C	cg17724175	chr1:150552817	MCL1	0.34	5.3	0.31	2.39e-7	Melanoma;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg23850377	chr2:20251576	LAPTM4A	0.52	6.99	0.39	2.29e-11	Systemic lupus erythematosus;
CESC	cis	rs4727963	0.846	rs4574772	chr7:122701537	C/T	cg03640110	chr7:122635026	TAS2R16	-0.37	-5.7	-0.33	3.11e-8	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
CESC	cis	rs6580649	0.941	rs4760677	chr12:48449163	C/T	cg24011408	chr12:48396354	COL2A1	-0.42	-5.28	-0.31	2.67e-7	Lung cancer;
CESC	cis	rs514406	0.698	rs576891	chr1:53364976	A/G	cg06600287	chr1:53387719	ECHDC2	-0.27	-5.05	-0.3	8.13e-7	Monocyte count;
CESC	cis	rs9788682	0.747	rs2958719	chr15:78743029	G/A	cg24631222	chr15:78858424	CHRNA5	-0.61	-7.19	-0.4	6.65e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg06688411	chr11:65153958	FRMD8	-0.46	-6.44	-0.37	5.59e-10	Vertical cup-disc ratio;
CESC	cis	rs10857712	0.851	rs7913420	chr10:135213854	C/T	cg01444801	chr10:135216882	MTG1	-0.47	-5.41	-0.32	1.38e-7	Systemic lupus erythematosus;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg17322163	chr12:51632344	DAZAP2	0.46	6.06	0.35	4.75e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs2274273	0.870	rs10134339	chr14:55814380	T/C	cg04306507	chr14:55594613	LGALS3	0.32	6.31	0.36	1.19e-9	Protein biomarker;
CESC	cis	rs7044106	0.791	rs10984995	chr9:123479210	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.82	13.14	0.63	1.07e-30	Hip circumference adjusted for BMI;
CESC	trans	rs9435732	1.000	rs9435732	chr1:17308158	C/T	cg26354191	chr1:3547523	WDR8	-0.37	-6.22	-0.36	1.93e-9	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
CESC	trans	rs35110281	0.811	rs1122873	chr21:45044672	G/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.56	7.27	0.41	3.97e-12	Mean corpuscular volume;
CESC	cis	rs8177253	0.761	rs13079426	chr3:133522334	A/G	cg01448562	chr3:133502909	NA	-0.58	-8.46	-0.46	1.86e-15	Iron status biomarkers;
CESC	cis	rs6499255	0.857	rs11643926	chr16:69807282	A/G	cg15192750	chr16:69999425	NA	0.45	5.59	0.32	5.59e-8	IgE levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06406294	chr21:34915161	GART;SON	0.59	7.05	0.4	1.59e-11	Gut microbiome composition (summer);
CESC	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg03452623	chr4:187889614	NA	-0.94	-18.98	-0.76	2.61e-51	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs290268	1.000	rs188313	chr9:93548302	C/T	cg02608019	chr9:93564028	SYK	0.64	9.38	0.5	3.11e-18	Platelet count;
CESC	cis	rs68170813	0.559	rs1018946	chr7:106851754	T/C	cg02696742	chr7:106810147	HBP1	-0.52	-5.09	-0.3	6.84e-7	Coronary artery disease;
CESC	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg23034840	chr1:205782522	SLC41A1	-0.72	-9.76	-0.51	1.94e-19	Monocyte percentage of white cells;
CESC	cis	rs963731	0.649	rs4670272	chr2:39260468	A/C	cg04010122	chr2:39346883	SOS1	-0.7	-5.11	-0.3	6.16e-7	Corticobasal degeneration;
CESC	cis	rs7264396	0.563	rs2425130	chr20:34335059	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.63	6.72	0.38	1.08e-10	Total cholesterol levels;
CESC	cis	rs11734570	0.581	rs55958238	chr4:38604331	A/G	cg18361445	chr4:38666374	KLF3;FLJ13197	0.63	7.75	0.43	1.94e-13	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs911555	0.723	rs56227024	chr14:103861706	A/G	cg24130564	chr14:104152367	KLC1	0.45	6.3	0.36	1.27e-9	Intelligence (multi-trait analysis);
CESC	cis	rs6089829	0.926	rs1060489	chr20:61665921	C/T	cg16240275	chr20:61666158	NCRNA00029	0.5	8.94	0.48	6.65e-17	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs9399135	1.000	rs4896130	chr6:135355118	C/T	cg22676075	chr6:135203613	NA	0.49	6.89	0.39	4.03e-11	Red blood cell count;
CESC	cis	rs7771547	0.573	rs547026	chr6:36398616	G/A	cg07856975	chr6:36356162	ETV7	0.36	5.42	0.32	1.37e-7	Platelet distribution width;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg16672449	chr3:127842622	RUVBL1	0.52	6.94	0.39	2.95e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs9322193	0.886	rs2065663	chr6:150081467	A/G	cg04369109	chr6:150039330	LATS1	-0.46	-6.31	-0.36	1.2e-9	Lung cancer;
CESC	trans	rs61931739	0.500	rs6488213	chr12:34393319	C/T	cg26384229	chr12:38710491	ALG10B	0.54	7.75	0.43	2.01e-13	Morning vs. evening chronotype;
CESC	cis	rs780096	0.526	rs704791	chr2:27657167	T/C	cg12648201	chr2:27665141	KRTCAP3	-0.35	-6.56	-0.37	2.79e-10	Total body bone mineral density;
CESC	cis	rs8028182	0.636	rs11636031	chr15:75815758	T/C	cg20655648	chr15:75932815	IMP3	0.48	5.9	0.34	1.08e-8	Sudden cardiac arrest;
CESC	cis	rs736408	0.736	rs4687550	chr3:52823430	T/G	cg18404041	chr3:52824283	ITIH1	-0.48	-8.0	-0.44	3.77e-14	Bipolar disorder;
CESC	cis	rs4555082	0.874	rs78923231	chr14:105754033	C/T	cg06808227	chr14:105710500	BRF1	-0.52	-5.62	-0.33	4.87e-8	Mean platelet volume;Platelet distribution width;
CESC	trans	rs7937682	0.889	rs1789361	chr11:111485334	T/C	cg18187862	chr3:45730750	SACM1L	0.48	6.04	0.35	5.23e-9	Primary sclerosing cholangitis;
CESC	cis	rs4803468	0.934	rs11880674	chr19:41889423	A/T	cg14132834	chr19:41945861	ATP5SL	-0.55	-6.83	-0.39	5.87e-11	Height;
CESC	cis	rs2531992	0.800	rs1045476	chr16:4015313	A/G	cg05927578	chr16:4029543	ADCY9	0.46	6.1	0.35	3.72e-9	Waist circumference;
CESC	cis	rs752010	0.574	rs12130138	chr1:42117792	A/C	cg06885757	chr1:42089581	HIVEP3	0.48	7.61	0.42	4.72e-13	Lupus nephritis in systemic lupus erythematosus;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03350042	chr15:40733177	BAHD1	0.56	6.41	0.37	6.45e-10	Gut microbiome composition (summer);
CESC	cis	rs4927850	0.752	rs7618864	chr3:195749561	G/A	cg00031303	chr3:195681400	NA	0.43	5.43	0.32	1.26e-7	Pancreatic cancer;
CESC	cis	rs73206853	0.640	rs35026231	chr12:110832125	A/G	cg12870014	chr12:110450643	ANKRD13A	0.63	5.23	0.31	3.48e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs40363	0.672	rs1617722	chr16:3520806	C/T	cg05754148	chr16:3507555	NAT15	-0.56	-8.34	-0.46	4.02e-15	Tuberculosis;
CESC	cis	rs7666738	0.830	rs35276471	chr4:99068691	A/T	cg05340658	chr4:99064831	C4orf37	0.83	12.82	0.62	1.36e-29	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9818758	0.545	rs55921200	chr3:49189316	T/C	cg00383909	chr3:49044727	WDR6	0.93	5.4	0.31	1.51e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CESC	cis	rs1707322	0.648	rs4439382	chr1:46150805	C/T	cg05343316	chr1:45956843	TESK2	0.51	6.32	0.36	1.09e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7666738	0.830	rs59751489	chr4:98933802	A/G	cg17366294	chr4:99064904	C4orf37	0.61	8.56	0.47	9.36e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7762018	0.556	rs80250989	chr6:170105553	T/C	cg19338460	chr6:170058176	WDR27	-1.04	-8.47	-0.46	1.75e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg06786349	chr20:19815086	NA	-0.37	-6.18	-0.35	2.38e-9	Gambling;
CESC	cis	rs7762018	1.000	rs7746598	chr6:170084933	T/A	cg05834625	chr6:170176447	C6orf70	0.62	7.41	0.41	1.7e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs12042938	0.600	rs1865225	chr1:231763004	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.4	-5.09	-0.3	6.85e-7	Neuranatomic and neurocognitive phenotypes;
CESC	cis	rs8099014	0.861	rs2277722	chr18:56121280	G/C	cg19312305	chr18:56117016	MIR122	-0.27	-5.4	-0.31	1.51e-7	Platelet count;
CESC	cis	rs11785400	0.793	rs4336593	chr8:143739647	A/C	cg10596483	chr8:143751796	JRK	-0.44	-5.5	-0.32	8.81e-8	Schizophrenia;
CESC	cis	rs2836974	0.602	rs8130854	chr21:40707041	G/A	cg22974920	chr21:40686053	BRWD1	-0.42	-5.21	-0.3	3.77e-7	Cognitive function;
CESC	cis	rs9457247	0.602	rs2157388	chr6:167481912	G/A	cg07741184	chr6:167504864	NA	0.39	6.89	0.39	4.08e-11	Crohn's disease;
CESC	cis	rs9549367	0.713	rs9549682	chr13:113830181	C/T	cg18105134	chr13:113819100	PROZ	-0.7	-8.39	-0.46	2.95e-15	Platelet distribution width;
CESC	cis	rs1799949	0.501	rs35399157	chr17:41411602	G/C	cg05368731	chr17:41323189	NBR1	0.79	10.96	0.56	2.64e-23	Menopause (age at onset);
CESC	cis	rs7666738	0.830	rs3846444	chr4:99032888	T/C	cg17366294	chr4:99064904	C4orf37	0.62	8.95	0.48	6.32e-17	Colonoscopy-negative controls vs population controls;
CESC	cis	rs992157	0.687	rs10206984	chr2:219066980	C/T	cg00012203	chr2:219082015	ARPC2	0.86	12.41	0.61	3.6e-28	Colorectal cancer;
CESC	cis	rs8014204	0.762	rs973879	chr14:75297727	T/C	cg08847533	chr14:75593920	NEK9	0.43	5.6	0.33	5.27e-8	Caffeine consumption;
CESC	cis	rs9640161	0.789	rs2098053	chr7:150043205	G/A	cg27494647	chr7:150038898	RARRES2	0.44	5.24	0.31	3.36e-7	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs2243480	1.000	rs1964692	chr7:65454183	G/A	cg13147721	chr7:65941812	NA	-0.89	-8.55	-0.47	9.65e-16	Diabetic kidney disease;
CESC	cis	rs6879260	1.000	rs729568	chr5:179732350	C/T	cg23221052	chr5:179740743	GFPT2	0.54	7.41	0.41	1.66e-12	Height;
CESC	cis	rs12893668	0.543	rs12147645	chr14:104100208	T/A	cg24130564	chr14:104152367	KLC1	-0.5	-6.51	-0.37	3.71e-10	Reticulocyte count;
CESC	cis	rs6831352	0.918	rs7670638	chr4:100059807	G/C	cg13256891	chr4:100009986	ADH5	-0.75	-8.21	-0.45	9.89e-15	Alcohol dependence;
CESC	cis	rs6939532	0.648	rs9379862	chr6:26370707	T/C	cg14345882	chr6:26364793	BTN3A2	0.38	5.64	0.33	4.36e-8	Autism spectrum disorder or schizophrenia;
CESC	cis	rs1559088	0.847	rs7254758	chr19:33608047	T/A	cg27124370	chr19:33622961	WDR88	0.42	5.55	0.32	7.06e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs12887734	0.524	rs4906363	chr14:104210239	G/A	cg08213375	chr14:104286397	PPP1R13B	0.44	7.43	0.42	1.54e-12	Schizophrenia;Autism spectrum disorder or schizophrenia;
CESC	cis	rs2456568	0.709	rs7942444	chr11:93637160	G/A	cg26875233	chr11:93583750	C11orf90	0.29	5.15	0.3	5.2e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
CESC	cis	rs863345	0.625	rs4575081	chr1:158504837	C/A	cg12129480	chr1:158549410	OR10X1	-0.34	-6.84	-0.39	5.41e-11	Pneumococcal bacteremia;
CESC	cis	rs9905704	0.918	rs11656666	chr17:56929840	A/G	cg12560992	chr17:57184187	TRIM37	0.61	7.05	0.4	1.54e-11	Testicular germ cell tumor;
CESC	cis	rs7044106	0.762	rs3904197	chr9:123480378	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.36	5.94	0.34	9.08e-9	Hip circumference adjusted for BMI;
CESC	cis	rs7917772	0.560	rs7912339	chr10:104373758	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.39	5.41	0.32	1.43e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs1348850	0.526	rs2218575	chr2:178368997	C/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.68	6.17	0.35	2.52e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs4474465	1.000	rs7124092	chr11:78155086	T/C	cg27205649	chr11:78285834	NARS2	-0.42	-5.15	-0.3	4.98e-7	Alzheimer's disease (survival time);
CESC	trans	rs9354308	0.901	rs12197136	chr6:66590953	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.68	7.62	0.42	4.41e-13	Metabolite levels;
CESC	cis	rs12618769	0.597	rs2278214	chr2:99135738	A/G	cg10123293	chr2:99228465	UNC50	-0.4	-5.24	-0.31	3.28e-7	Bipolar disorder;
CESC	cis	rs1048238	0.506	rs10927866	chr1:16175317	C/T	cg22431228	chr1:16359049	CLCNKA	-0.36	-6.46	-0.37	4.99e-10	Systolic blood pressure;
CESC	cis	rs4975709	0.569	rs4975743	chr5:1859941	G/T	cg19770292	chr5:1868693	NA	0.31	5.18	0.3	4.34e-7	Cardiovascular disease risk factors;
CESC	cis	rs1799949	0.965	rs6503726	chr17:41284742	T/C	cg25072359	chr17:41440525	NA	0.48	7.31	0.41	3.19e-12	Menopause (age at onset);
CESC	cis	rs8141529	0.719	rs6005916	chr22:29233342	T/C	cg02153584	chr22:29168773	CCDC117	0.66	9.26	0.49	7.32e-18	Lymphocyte counts;
CESC	cis	rs524281	0.731	rs78578425	chr11:65810239	G/A	cg14036092	chr11:66035641	RAB1B	-0.57	-5.17	-0.3	4.52e-7	Electroencephalogram traits;
CESC	cis	rs1355223	0.506	rs11032898	chr11:34870111	C/G	cg11058730	chr11:34937778	PDHX;APIP	-0.55	-6.64	-0.38	1.81e-10	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs7412746	0.658	rs11204750	chr1:150939744	C/A	cg17724175	chr1:150552817	MCL1	0.38	5.85	0.34	1.42e-8	Melanoma;
CESC	cis	rs76878669	0.754	rs10896113	chr11:66117111	C/T	cg18002602	chr11:66138449	SLC29A2	-0.37	-5.07	-0.3	7.33e-7	Educational attainment (years of education);
CESC	cis	rs1552244	1.000	rs9827740	chr3:10120531	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	12.72	0.62	2.99e-29	Alzheimer's disease;
CESC	cis	rs17711722	0.522	rs62469933	chr7:65265639	G/A	cg12143784	chr7:64541923	NA	0.38	5.27	0.31	2.85e-7	Calcium levels;
CESC	cis	rs854765	0.583	rs8065563	chr17:17782404	A/G	cg04398451	chr17:18023971	MYO15A	-0.63	-8.62	-0.47	6.07e-16	Total body bone mineral density;
CESC	cis	rs12765878	1.000	rs12765878	chr10:105669622	C/T	cg11005552	chr10:105648138	OBFC1	-0.35	-5.1	-0.3	6.53e-7	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25195416	chr21:46696626	POFUT2	-0.61	-6.51	-0.37	3.81e-10	Gut microbiome composition (summer);
CESC	cis	rs7615952	0.599	rs7631268	chr3:125755664	T/A	cg04553112	chr3:125709451	NA	-0.51	-5.37	-0.31	1.7e-7	Blood pressure (smoking interaction);
CESC	cis	rs7613875	0.620	rs34312088	chr3:50032133	C/T	cg24308560	chr3:49941425	MST1R	-0.56	-7.83	-0.43	1.19e-13	Body mass index;
CESC	cis	rs798554	1.000	rs798550	chr7:2760609	A/G	cg19346786	chr7:2764209	NA	-0.47	-7.07	-0.4	1.41e-11	Height;
CESC	cis	rs75887402	0.793	rs10478580	chr5:122711168	C/T	cg27033705	chr5:122759302	CEP120	0.93	6.12	0.35	3.32e-9	Breast cancer;
CESC	cis	rs36051895	0.625	rs12340333	chr9:5176215	C/G	cg02405213	chr9:5042618	JAK2	-0.5	-6.46	-0.37	5.09e-10	Pediatric autoimmune diseases;
CESC	cis	rs9322193	0.923	rs4354168	chr6:150017778	C/T	cg07701084	chr6:150067640	NUP43	0.48	6.69	0.38	1.3e-10	Lung cancer;
CESC	cis	rs977987	1.000	rs62060550	chr16:75502252	C/T	cg03315344	chr16:75512273	CHST6	0.53	7.8	0.43	1.42e-13	Dupuytren's disease;
CESC	cis	rs7267979	1.000	rs8125868	chr20:25324410	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.85	-16.65	-0.71	4.48e-43	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs6087771	0.642	rs6060403	chr20:30221104	C/A	cg13852791	chr20:30311386	BCL2L1	0.67	7.77	0.43	1.7e-13	Subcortical brain region volumes;Putamen volume;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg23285320	chr19:36546349	THAP8;WDR62	-0.47	-6.91	-0.39	3.67e-11	Gambling;
CESC	trans	rs7246760	1.000	rs10419915	chr19:9890957	G/A	cg02900749	chr2:68251473	NA	-0.73	-6.78	-0.38	7.62e-11	Pursuit maintenance gain;
CESC	cis	rs7618915	0.524	rs35249778	chr3:52661640	G/C	cg18404041	chr3:52824283	ITIH1	-0.38	-6.45	-0.37	5.28e-10	Bipolar disorder;
CESC	cis	rs10927875	0.541	rs761759	chr1:16342350	A/T	cg22431228	chr1:16359049	CLCNKA	-0.52	-9.9	-0.52	7.22e-20	Dilated cardiomyopathy;
CESC	cis	rs7208859	0.623	rs1061342	chr17:29114463	G/A	cg14008862	chr17:28927542	LRRC37B2	0.66	5.26	0.31	2.93e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg09428623	chr2:68480128	PPP3R1	-0.49	-6.46	-0.37	4.9e-10	Height;
CESC	cis	rs9487051	0.676	rs6929438	chr6:109595506	C/T	cg01475377	chr6:109611718	NA	-0.44	-7.02	-0.4	1.9e-11	Reticulocyte fraction of red cells;
CESC	cis	rs1401999	1.000	rs4148579	chr3:183685249	T/C	cg01324343	chr3:183735012	ABCC5	0.63	13.39	0.64	1.36e-31	Anterior chamber depth;
CESC	trans	rs11039798	0.764	rs11039929	chr11:48703289	A/G	cg15704280	chr7:45808275	SEPT13	0.69	6.29	0.36	1.33e-9	Axial length;
CESC	cis	rs9916302	0.904	rs7501488	chr17:37576417	T/G	cg20243544	chr17:37824526	PNMT	0.51	6.39	0.37	7.25e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs9322193	0.962	rs9397357	chr6:150133601	G/A	cg13206674	chr6:150067644	NUP43	0.39	5.51	0.32	8.53e-8	Lung cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03739129	chr2:220252547	DNPEP	0.48	6.0	0.35	6.61e-9	Gut microbiome composition (summer);
CESC	cis	rs765787	0.530	rs11070451	chr15:45533541	T/C	cg24006582	chr15:45444508	DUOX1	-0.59	-7.23	-0.41	5.15e-12	Uric acid levels;
CESC	cis	rs10540	1.000	rs12421457	chr11:505780	T/C	cg03352830	chr11:487213	PTDSS2	0.73	7.02	0.4	1.85e-11	Body mass index;
CESC	cis	rs1799949	1.000	rs1545764	chr17:41424565	G/A	cg23758822	chr17:41437982	NA	1.05	15.6	0.69	2.24e-39	Menopause (age at onset);
CESC	cis	rs10822145	1	rs10822145	chr10:64934548	C/T	cg01631684	chr10:65280961	REEP3	-0.46	-5.58	-0.32	6.01e-8	Triglycerides;
CESC	cis	rs12497850	0.897	rs6446252	chr3:48911125	C/T	cg07636037	chr3:49044803	WDR6	1.03	18.76	0.76	1.49e-50	Parkinson's disease;
CESC	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg06873352	chr17:61820015	STRADA	0.73	12.96	0.62	4.25e-30	Prudent dietary pattern;
CESC	cis	rs10484885	0.752	rs72921948	chr6:90582560	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.9	-11.56	-0.58	2.77e-25	QRS interval (sulfonylurea treatment interaction);
CESC	trans	rs17685	0.753	rs55812043	chr7:75747241	T/C	cg19862616	chr7:65841803	NCRNA00174	0.83	11.92	0.59	1.67e-26	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs7772486	0.875	rs1960885	chr6:146325930	G/T	cg05347473	chr6:146136440	FBXO30	0.51	6.68	0.38	1.4e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs34779708	0.966	rs1057108	chr10:35484949	T/G	cg03585969	chr10:35415529	CREM	0.76	9.94	0.52	5.54e-20	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs7647973	0.771	rs9865051	chr3:49166069	C/T	cg06212747	chr3:49208901	KLHDC8B	0.56	6.05	0.35	5.05e-9	Menarche (age at onset);
CESC	cis	rs17401966	0.838	rs17034643	chr1:10332102	A/G	cg15208524	chr1:10270712	KIF1B	-0.39	-5.13	-0.3	5.67e-7	Hepatocellular carcinoma;
CESC	cis	rs4555082	0.874	rs2816620	chr14:105732704	G/T	cg06808227	chr14:105710500	BRF1	-0.56	-6.33	-0.36	1.04e-9	Mean platelet volume;Platelet distribution width;
CESC	cis	rs959260	0.623	rs4542691	chr17:73326965	T/C	cg20590849	chr17:73267439	MIF4GD	-0.43	-5.27	-0.31	2.86e-7	Systemic lupus erythematosus;
CESC	cis	rs7091068	0.522	rs866674	chr10:95487515	A/G	cg20715218	chr10:95462985	C10orf4	0.52	6.01	0.35	6.1e-9	Urinary tract infection frequency;
CESC	cis	rs1552244	0.816	rs17050701	chr3:10041554	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.85	11.02	0.56	1.64e-23	Alzheimer's disease;
CESC	cis	rs1046896	0.538	rs3803771	chr17:80687758	G/A	cg03115019	chr17:80708279	FN3K	-0.38	-5.63	-0.33	4.59e-8	Glycated hemoglobin levels;
CESC	trans	rs4332037	0.802	rs12113633	chr7:1932936	G/A	cg11693508	chr17:37793320	STARD3	0.64	6.17	0.35	2.59e-9	Bipolar disorder;
CESC	cis	rs34779708	0.931	rs4351760	chr10:35280254	A/G	cg03585969	chr10:35415529	CREM	0.77	10.3	0.53	3.84e-21	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs7552404	1.000	rs211723	chr1:76103030	C/T	cg22875332	chr1:76189707	ACADM	-0.59	-6.77	-0.38	8.24e-11	Blood metabolite levels;Acylcarnitine levels;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg02098460	chr2:114196058	CBWD2;LOC440839	-0.4	-6.06	-0.35	4.74e-9	Gambling;
CESC	cis	rs10463316	0.832	rs246482	chr5:150731857	C/G	cg03212797	chr5:150827313	SLC36A1	-0.42	-5.23	-0.31	3.48e-7	Metabolite levels (Pyroglutamine);
CESC	cis	rs6502050	0.799	rs7502533	chr17:80109778	A/G	cg11859384	chr17:80120422	CCDC57	-0.38	-5.11	-0.3	6.21e-7	Life satisfaction;
CESC	trans	rs11770686	0.967	rs4728289	chr7:75348505	C/T	cg10949413	chr6:26158832	HIST1H2BD	-0.41	-6.16	-0.35	2.7e-9	Essential tremor;
CESC	cis	rs7918232	0.800	rs7907981	chr10:27444329	T/C	cg14442939	chr10:27389572	ANKRD26	0.72	7.9	0.44	7.57e-14	Breast cancer;
CESC	cis	rs372883	0.648	rs15092	chr21:30718201	G/A	cg08807101	chr21:30365312	RNF160	-0.45	-5.18	-0.3	4.39e-7	Pancreatic cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10483393	chr16:18573498	NOMO2	0.58	6.67	0.38	1.52e-10	Gut microbiome composition (summer);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg05909891	chr12:19565983	NA	0.45	6.22	0.36	1.88e-9	Fibrinogen levels;
CESC	cis	rs875971	0.862	rs4718383	chr7:66108409	T/C	cg10691866	chr7:65817282	TPST1	0.3	5.05	0.3	8.38e-7	Aortic root size;
CESC	cis	rs1967309	0.625	rs730242	chr16:4070433	C/T	cg00061520	chr16:4070371	ADCY9	0.47	8.13	0.45	1.63e-14	Response to Dalcetrapib treatment in acute coronary syndrome;
CESC	cis	rs7216064	1.000	rs4569324	chr17:65872750	C/T	cg12091567	chr17:66097778	LOC651250	-0.84	-8.53	-0.46	1.13e-15	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs1215050	0.846	rs783923	chr4:98968686	C/T	cg05340658	chr4:99064831	C4orf37	-0.54	-6.73	-0.38	1.06e-10	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs4713118	0.662	rs156744	chr6:27967274	G/A	cg26335602	chr6:28129616	ZNF389	0.47	6.17	0.35	2.51e-9	Parkinson's disease;
CESC	cis	rs7917772	0.503	rs7100753	chr10:104300979	C/T	cg22532475	chr10:104410764	TRIM8	-0.34	-5.76	-0.33	2.3e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs644799	0.965	rs607039	chr11:95547086	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.53	6.41	0.37	6.77e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs477895	0.713	rs12787852	chr11:63954648	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.95	10.4	0.54	1.85e-21	Mean platelet volume;
CESC	cis	rs1559088	0.948	rs10406916	chr19:33590093	G/A	cg17764715	chr19:33622953	WDR88	0.49	6.32	0.36	1.11e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs2455799	0.613	rs11920540	chr3:15854608	G/A	cg16303742	chr3:15540471	COLQ	-0.37	-5.72	-0.33	2.8e-8	Mean platelet volume;
CESC	cis	rs9649213	0.593	rs10953255	chr7:97923198	A/G	cg21770322	chr7:97807741	LMTK2	0.57	8.64	0.47	5.23e-16	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs1707322	1.000	rs7532204	chr1:46485075	C/G	cg05343316	chr1:45956843	TESK2	-0.45	-5.54	-0.32	7.32e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs780096	0.525	rs13388159	chr2:27648284	A/T	cg02592271	chr2:27665507	KRTCAP3	-0.29	-5.76	-0.33	2.29e-8	Total body bone mineral density;
CESC	cis	rs1707322	0.656	rs9429172	chr1:46092476	C/G	cg05343316	chr1:45956843	TESK2	-0.52	-6.53	-0.37	3.41e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7552404	0.924	rs1694419	chr1:76219801	C/T	cg03433033	chr1:76189801	ACADM	0.67	8.88	0.48	1.02e-16	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs7799006	0.657	rs10447540	chr7:2301484	A/G	cg08027265	chr7:2291960	NA	-0.6	-10.21	-0.53	7.27e-21	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs9611565	0.694	rs202622	chr22:41825342	T/G	cg06481639	chr22:41940642	POLR3H	0.63	6.29	0.36	1.27e-9	Vitiligo;
CESC	cis	rs10883723	0.810	rs10748823	chr10:104274465	C/G	ch.10.2196322F	chr10:104248062	ACTR1A	0.42	5.16	0.3	4.76e-7	Allergic disease (asthma, hay fever or eczema);
CESC	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg03395511	chr6:291903	DUSP22	-0.71	-9.2	-0.49	1.13e-17	Menopause (age at onset);
CESC	cis	rs12666575	0.504	rs10226475	chr7:2226162	A/G	cg21782813	chr7:2030301	MAD1L1	0.44	6.36	0.36	8.79e-10	Schizophrenia;
CESC	cis	rs3733585	0.638	rs28715627	chr4:9958140	T/A	cg11266682	chr4:10021025	SLC2A9	-0.6	-11.09	-0.56	1.01e-23	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs2243480	1.000	rs7794661	chr7:65389730	T/C	cg18252515	chr7:66147081	NA	-1.09	-10.08	-0.53	1.87e-20	Diabetic kidney disease;
CESC	cis	rs9457247	1.000	rs439237	chr6:167391392	A/G	cg25258033	chr6:167368657	RNASET2	0.39	5.87	0.34	1.31e-8	Crohn's disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg17361593	chr6:87831888	NA	0.44	6.11	0.35	3.48e-9	Fibrinogen levels;
CESC	cis	rs9311474	0.508	rs4687546	chr3:52605943	T/A	cg18099408	chr3:52552593	STAB1	-0.36	-6.09	-0.35	4.06e-9	Electroencephalogram traits;
CESC	cis	rs3781454	1	rs3781454	chr10:126348565	G/A	cg20435097	chr10:126320824	FAM53B	-0.27	-5.09	-0.3	6.72e-7	White blood cell count;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg10267162	chr2:97001818	NCAPH	0.44	6.2	0.36	2.1e-9	Systemic lupus erythematosus;
CESC	cis	rs2456568	0.802	rs10831139	chr11:93640537	G/A	cg26875233	chr11:93583750	C11orf90	-0.29	-5.06	-0.3	7.7e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
CESC	cis	rs763121	0.853	rs7289577	chr22:39042214	C/G	cg21395723	chr22:39101663	GTPBP1	0.43	5.33	0.31	2.09e-7	Menopause (age at onset);
CESC	cis	rs1552244	1.000	rs3826	chr3:10141065	T/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	12.72	0.62	2.88e-29	Alzheimer's disease;
CESC	cis	rs9733	0.596	rs12086472	chr1:150697710	G/A	cg22823121	chr1:150693482	HORMAD1	0.47	6.96	0.39	2.6e-11	Tonsillectomy;
CESC	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg18402987	chr7:1209562	NA	0.76	7.57	0.42	6.04e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7666738	0.830	rs28785514	chr4:98959135	G/A	cg17366294	chr4:99064904	C4orf37	0.59	8.44	0.46	2.09e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4727963	0.792	rs59416413	chr7:122734516	C/A	cg03640110	chr7:122635026	TAS2R16	-0.39	-5.96	-0.34	8.01e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12821679	chr2:27249349	MAPRE3	-0.51	-6.64	-0.38	1.74e-10	Gut microbiome composition (summer);
CESC	cis	rs2668423	0.922	rs266805	chr19:1376723	C/T	cg02639931	chr19:1387894	NDUFS7	-0.48	-6.81	-0.39	6.66e-11	Nonalcoholic fatty liver disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20777956	chr18:60987812	BCL2	0.56	6.13	0.35	3.17e-9	Gut microbiome composition (summer);
CESC	cis	rs6460942	0.915	rs62448594	chr7:12442229	C/G	cg17427002	chr7:12443146	VWDE	-0.53	-5.18	-0.3	4.34e-7	Coronary artery disease;
CESC	cis	rs854765	0.547	rs6502632	chr17:17913057	A/G	cg09796270	chr17:17721594	SREBF1	0.4	5.54	0.32	7.42e-8	Total body bone mineral density;
CESC	cis	rs6460942	0.597	rs35589221	chr7:12535841	T/G	cg06484146	chr7:12443880	VWDE	-0.73	-7.77	-0.43	1.68e-13	Coronary artery disease;
CESC	cis	rs853679	0.517	rs56364346	chr6:28050762	T/G	cg18032046	chr6:28092343	ZSCAN16	-0.53	-6.09	-0.35	3.91e-9	Depression;
CESC	cis	rs10504229	1.000	rs114486414	chr8:58185103	G/A	cg05313129	chr8:58192883	C8orf71	-0.55	-6.29	-0.36	1.34e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs1670533	0.872	rs6854793	chr4:1055768	T/C	cg04106633	chr4:1044584	NA	0.4	5.09	0.3	6.7e-7	Recombination rate (females);
CESC	cis	rs4253772	0.514	rs11704878	chr22:46714664	C/T	cg18190219	chr22:46762943	CELSR1	-0.6	-5.84	-0.34	1.5e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs1348850	0.874	rs1348848	chr2:178358233	A/C	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.87	-13.05	-0.63	2.2e-30	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs7078219	0.524	rs1548963	chr10:101289703	C/G	cg09788492	chr10:101292477	NKX2-3	0.32	6.11	0.35	3.45e-9	Dental caries;
CESC	cis	rs9733	0.596	rs2867301	chr1:150653795	C/T	cg17724175	chr1:150552817	MCL1	0.44	7.21	0.41	5.8e-12	Tonsillectomy;
CESC	cis	rs2836974	0.899	rs114399588	chr21:40653958	G/A	cg11890956	chr21:40555474	PSMG1	1.11	17.92	0.74	1.38e-47	Cognitive function;
CESC	cis	rs12545109	0.643	rs1119707	chr8:57411548	T/C	cg09654669	chr8:57350985	NA	-0.54	-6.35	-0.36	9.45e-10	Obesity-related traits;
CESC	cis	rs7246657	0.943	rs10420430	chr19:37894194	C/G	cg23950597	chr19:37808831	NA	-0.62	-6.27	-0.36	1.43e-9	Coronary artery calcification;
CESC	cis	rs7246657	1.000	rs1529957	chr19:37739801	A/G	cg23950597	chr19:37808831	NA	-0.56	-6.1	-0.35	3.79e-9	Coronary artery calcification;
CESC	cis	rs12079745	0.793	rs12063056	chr1:169264107	G/A	cg09363564	chr1:169337483	NME7;BLZF1	-1.03	-6.26	-0.36	1.55e-9	QT interval;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg11897279	chr19:13044638	FARSA	-0.47	-6.14	-0.35	3.01e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs7923609	0.846	rs7073753	chr10:65062820	C/T	cg01631684	chr10:65280961	REEP3	-0.42	-5.34	-0.31	1.96e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7208859	0.673	rs79541516	chr17:29240583	C/T	cg19761014	chr17:28927070	LRRC37B2	0.73	5.78	0.33	2.06e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs1153858	1.000	rs56806728	chr15:45637814	A/G	cg21132104	chr15:45694354	SPATA5L1	0.82	11.02	0.56	1.72e-23	Homoarginine levels;
CESC	cis	rs514406	0.861	rs11206011	chr1:53235910	T/C	cg08736216	chr1:53307985	ZYG11A	0.32	5.74	0.33	2.59e-8	Monocyte count;
CESC	cis	rs1552244	1.000	rs67006488	chr3:10152993	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	12.69	0.61	3.82e-29	Alzheimer's disease;
CESC	cis	rs12497850	0.931	rs7626445	chr3:49114544	C/T	cg06212747	chr3:49208901	KLHDC8B	0.71	9.61	0.51	5.83e-19	Parkinson's disease;
CESC	cis	rs801193	0.660	rs10950049	chr7:66230860	T/C	cg18876405	chr7:65276391	NA	0.47	6.28	0.36	1.4e-9	Aortic root size;
CESC	cis	rs11252926	0.565	rs60553947	chr10:474284	T/C	cg18196295	chr10:418757	DIP2C	-0.53	-7.16	-0.4	7.94e-12	Psychosis in Alzheimer's disease;
CESC	cis	rs9311474	0.508	rs6788887	chr3:52605005	T/C	cg05564831	chr3:52568323	NT5DC2	0.47	7.46	0.42	1.24e-12	Electroencephalogram traits;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg04148091	chr16:81348876	GAN	-0.48	-6.28	-0.36	1.35e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs35160687	0.644	rs4832265	chr2:86488265	A/G	cg01119172	chr2:86362222	SNORD94;PTCD3	-0.39	-5.22	-0.31	3.59e-7	Night sleep phenotypes;
CESC	cis	rs3785574	0.962	rs2665842	chr17:61878535	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.1	19.47	0.77	5.16e-53	Height;
CESC	cis	rs501120	0.925	rs535949	chr10:44752330	A/C	cg09554077	chr10:44749378	NA	-0.51	-6.71	-0.38	1.16e-10	Coronary artery disease;Coronary heart disease;
CESC	cis	rs12291225	0.679	rs10832240	chr11:14304744	C/T	cg19336497	chr11:14380999	RRAS2	-0.37	-5.29	-0.31	2.58e-7	Sense of smell;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg14021555	chr22:43485536	TTLL1	0.46	6.02	0.35	5.71e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs9660180	0.868	rs12567685	chr1:1806647	T/C	cg20999797	chr1:1681921	NA	0.27	5.32	0.31	2.2e-7	Body mass index;
CESC	cis	rs16917546	0.967	rs10995243	chr10:64391208	G/C	cg03961010	chr10:64397487	ZNF365	-0.38	-6.15	-0.35	2.85e-9	Basal cell carcinoma;
CESC	cis	rs7084402	0.967	rs1658434	chr10:60328756	G/C	cg07615347	chr10:60278583	BICC1	0.59	9.2	0.49	1.08e-17	Refractive error;
CESC	cis	rs909002	0.703	rs4949460	chr1:32143138	A/G	cg13919466	chr1:32135498	COL16A1	0.34	5.9	0.34	1.13e-8	Intelligence (multi-trait analysis);
CESC	cis	rs7202877	0.610	rs7202284	chr16:75374346	A/T	cg04384234	chr16:75411784	CFDP1	-0.5	-6.01	-0.35	6.12e-9	Type 2 diabetes;Type 1 diabetes;
CESC	cis	rs3749237	0.595	rs1464566	chr3:49459376	T/C	cg06212747	chr3:49208901	KLHDC8B	0.51	6.87	0.39	4.52e-11	Resting heart rate;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg07385490	chr5:1318548	CLPTM1L	-0.36	-6.15	-0.35	2.77e-9	Gambling;
CESC	cis	rs7833790	0.777	rs1005850	chr8:82692255	G/A	cg23324259	chr8:82754387	SNX16	-0.44	-5.11	-0.3	6.11e-7	Diastolic blood pressure;
CESC	cis	rs7914558	1.000	rs6584540	chr10:104927634	A/G	cg15744005	chr10:104629667	AS3MT	-0.31	-5.04	-0.3	8.62e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs113835537	0.935	rs11550057	chr11:66392880	C/T	cg24851651	chr11:66362959	CCS	0.62	5.6	0.33	5.26e-8	Airway imaging phenotypes;
CESC	cis	rs4665809	1.000	rs6739061	chr2:26256147	C/T	cg25036284	chr2:26402008	FAM59B	-0.58	-6.71	-0.38	1.16e-10	Gut microbiome composition (summer);
CESC	cis	rs2070488	0.766	rs4679050	chr3:38482007	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.83	13.43	0.64	1e-31	Electrocardiographic conduction measures;
CESC	cis	rs3091242	0.933	rs61775167	chr1:25780893	A/G	cg12412775	chr1:25698385	RHCE	0.29	5.21	0.3	3.76e-7	Erythrocyte sedimentation rate;
CESC	trans	rs4927850	1.000	rs7625570	chr3:195747398	A/G	cg16724585	chr3:197361211	NA	-0.55	-6.95	-0.39	2.9e-11	Pancreatic cancer;
CESC	cis	rs8092503	0.536	rs8091336	chr18:52378707	C/A	cg12377874	chr18:52495404	RAB27B	-0.34	-5.12	-0.3	5.84e-7	Childhood body mass index;
CESC	cis	rs6963495	0.818	rs116457537	chr7:105152072	A/G	cg19920283	chr7:105172520	RINT1	0.67	6.36	0.36	8.79e-10	Bipolar disorder (body mass index interaction);
CESC	cis	rs11792861	0.926	rs56899598	chr9:111867271	A/G	cg13535736	chr9:111863775	C9orf5	-0.5	-6.62	-0.38	1.96e-10	Menarche (age at onset);
CESC	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.41	-5.27	-0.31	2.88e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7959452	0.535	rs10784771	chr12:69621264	A/G	cg20891283	chr12:69753455	YEATS4	0.75	10.83	0.55	7.16e-23	Blood protein levels;
CESC	cis	rs7937	0.693	rs17726276	chr19:41291119	A/G	cg09128733	chr19:41633906	CYP2F1	0.38	5.63	0.33	4.62e-8	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Chronic obstructive pulmonary disease;Emphysema imaging phenotypes;
CESC	cis	rs295137	0.836	rs10804097	chr2:201104924	A/T	cg23649088	chr2:200775458	C2orf69	0.43	5.71	0.33	2.97e-8	Asthma (bronchodilator response);
CESC	cis	rs2243480	1.000	rs316332	chr7:65604299	A/G	cg12463550	chr7:65579703	CRCP	0.75	5.96	0.34	8.2e-9	Diabetic kidney disease;
CESC	cis	rs4665809	0.531	rs3892649	chr2:26457267	T/G	cg04944784	chr2:26401820	FAM59B	0.96	10.5	0.54	8.76e-22	Gut microbiome composition (summer);
CESC	cis	rs1847202	0.859	rs6805260	chr3:72933767	C/T	cg25664220	chr3:72788482	NA	-0.43	-6.36	-0.36	8.99e-10	Motion sickness;
CESC	cis	rs7666738	0.830	rs7661264	chr4:98961574	G/A	cg18180107	chr4:99064573	C4orf37	0.4	5.14	0.3	5.26e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7520050	0.966	rs11211230	chr1:46406767	G/T	cg24296786	chr1:45957014	TESK2	0.44	5.49	0.32	9.64e-8	Red blood cell count;Reticulocyte count;
CESC	cis	rs1707322	1.000	rs10890382	chr1:46469674	A/G	cg03146154	chr1:46216737	IPP	0.76	10.05	0.53	2.46e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs977987	0.806	rs4888383	chr16:75386349	C/T	cg03315344	chr16:75512273	CHST6	0.4	5.81	0.34	1.74e-8	Dupuytren's disease;
CESC	cis	rs7703051	0.775	rs11957260	chr5:74608732	A/G	cg03227963	chr5:74354835	NA	-0.3	-5.51	-0.32	8.38e-8	LDL cholesterol;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
CESC	trans	rs875971	0.577	rs34888281	chr7:65585771	C/T	cg26939375	chr7:64535504	NA	-0.63	-8.33	-0.46	4.51e-15	Aortic root size;
CESC	cis	rs2439831	1.000	rs2439850	chr15:43784854	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.83	11.92	0.59	1.68e-26	Lung cancer in ever smokers;
CESC	cis	rs2836974	0.899	rs6517514	chr21:40527095	G/T	cg27266027	chr21:40555129	PSMG1	0.49	6.01	0.35	6.02e-9	Cognitive function;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg25005279	chr10:135113451	TUBGCP2	0.5	6.64	0.38	1.77e-10	Fibrinogen levels;
CESC	cis	rs1065852	0.526	rs7290907	chr22:42390209	G/A	cg22189786	chr22:42395067	WBP2NL	0.43	5.42	0.32	1.33e-7	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
CESC	cis	rs2760061	0.819	rs964941	chr1:228193857	G/A	cg18477163	chr1:228402036	OBSCN	0.32	5.62	0.33	4.95e-8	Diastolic blood pressure;
CESC	cis	rs3008870	0.583	rs2815369	chr1:67500894	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.99	10.98	0.56	2.3e-23	Lymphocyte percentage of white cells;
CESC	cis	rs1153858	1.000	rs1049503	chr15:45653707	T/C	cg14582100	chr15:45693742	SPATA5L1	0.42	5.97	0.34	7.62e-9	Homoarginine levels;
CESC	cis	rs651907	0.557	rs11917569	chr3:101355063	G/C	cg12386194	chr3:101231763	SENP7	0.44	5.37	0.31	1.71e-7	Colorectal cancer;
CESC	cis	rs7312933	0.558	rs1796381	chr12:42842475	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.53	7.14	0.4	9.03e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs6582630	0.555	rs7305352	chr12:38473800	T/C	cg26384229	chr12:38710491	ALG10B	0.72	10.64	0.55	3.12e-22	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs8062405	0.964	rs9972768	chr16:28861734	A/C	cg08761264	chr16:28874980	SH2B1	-0.47	-5.85	-0.34	1.42e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs939658	0.805	rs11638004	chr15:79425765	A/C	cg17916960	chr15:79447300	NA	-0.38	-6.29	-0.36	1.34e-9	Refractive error;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09377915	chr6:56295593	NA	-0.6	-7.5	-0.42	9.8e-13	Gut microbiome composition (summer);
CESC	cis	rs9322193	0.923	rs66516768	chr6:149993135	C/T	cg09699651	chr6:150184138	LRP11	0.4	5.12	0.3	5.83e-7	Lung cancer;
CESC	cis	rs889398	0.742	rs12446197	chr16:69854869	A/G	cg09409435	chr16:70099608	PDXDC2	-0.42	-5.22	-0.31	3.7e-7	Body mass index;
CESC	cis	rs6952808	0.692	rs12666575	chr7:2004421	C/T	cg02951883	chr7:2050386	MAD1L1	-0.5	-6.46	-0.37	4.94e-10	Bipolar disorder and schizophrenia;
CESC	cis	rs644799	1.000	rs3177463	chr11:95502128	G/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.94	14.84	0.67	1.14e-36	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	trans	rs1814175	0.817	rs10839465	chr11:49981554	C/A	cg15704280	chr7:45808275	SEPT13	-1.03	-21.34	-0.8	1.71e-59	Height;
CESC	cis	rs5753618	0.561	rs5753543	chr22:31685458	G/A	cg13145458	chr22:31556086	RNF185	0.49	5.48	0.32	9.7e-8	Colorectal cancer;
CESC	cis	rs7762018	0.607	rs7759404	chr6:170135728	A/G	cg05834625	chr6:170176447	C6orf70	0.64	7.32	0.41	3.01e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs4862750	0.872	rs6830828	chr4:187897472	T/G	cg06074448	chr4:187884817	NA	-0.37	-5.44	-0.32	1.21e-7	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs17401966	0.800	rs2039778	chr1:10354601	A/G	cg15208524	chr1:10270712	KIF1B	0.41	5.3	0.31	2.43e-7	Hepatocellular carcinoma;
CESC	cis	rs2904967	0.636	rs184734	chr11:64982203	T/C	cg23743554	chr11:65321226	LTBP3	-0.4	-5.17	-0.3	4.54e-7	Mean corpuscular volume;
CESC	cis	rs9311474	0.713	rs352170	chr3:52236077	A/G	cg07507251	chr3:52567010	NT5DC2	0.37	6.69	0.38	1.29e-10	Electroencephalogram traits;
CESC	cis	rs875971	0.522	rs1617484	chr7:65463095	G/A	cg26939375	chr7:64535504	NA	0.71	9.6	0.51	6.42e-19	Aortic root size;
CESC	cis	rs7818345	1.000	rs4430112	chr8:19293365	G/A	cg11303988	chr8:19266685	CSGALNACT1	0.35	6.31	0.36	1.16e-9	Language performance in older adults (adjusted for episodic memory);
CESC	cis	rs5769765	0.913	rs2319462	chr22:50263370	C/T	cg02269571	chr22:50332266	NA	0.46	6.28	0.36	1.39e-9	Schizophrenia;
CESC	cis	rs10927875	0.800	rs1627145	chr1:16328116	C/T	cg21385522	chr1:16154831	NA	0.65	7.87	0.44	9.26e-14	Dilated cardiomyopathy;
CESC	cis	rs78889164	0.840	rs3556	chr19:33878039	A/G	cg02272751	chr19:33882848	PEPD	-0.56	-8.07	-0.44	2.45e-14	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4927850	1.000	rs7630875	chr3:195753766	A/G	cg00031303	chr3:195681400	NA	0.42	5.26	0.31	2.98e-7	Pancreatic cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12665724	chr11:43364829	API5	-0.62	-7.51	-0.42	9.03e-13	Gut microbiome composition (summer);
CESC	cis	rs7662987	0.517	rs1311615	chr4:100012261	G/A	cg13256891	chr4:100009986	ADH5	0.75	8.06	0.44	2.55e-14	Smoking initiation;
CESC	trans	rs17764205	0.777	rs28729385	chr19:3258882	T/C	cg12868887	chr11:70244470	CTTN	0.72	6.0	0.35	6.46e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs9322193	0.923	rs9766037	chr6:149938057	A/C	cg07701084	chr6:150067640	NUP43	0.44	6.0	0.35	6.43e-9	Lung cancer;
CESC	cis	rs7589728	0.563	rs78685993	chr2:88447026	T/C	cg14558114	chr2:88469736	THNSL2	0.57	5.4	0.31	1.5e-7	Plasma clusterin levels;
CESC	cis	rs3733585	0.699	rs7694997	chr4:9947811	A/G	cg00071950	chr4:10020882	SLC2A9	-0.72	-11.75	-0.59	6.35e-26	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs854765	0.551	rs8070748	chr17:17859421	A/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.54	7.08	0.4	1.28e-11	Total body bone mineral density;
CESC	cis	rs6088580	0.524	rs1853056	chr20:33262058	C/T	cg24642439	chr20:33292090	TP53INP2	-0.45	-5.33	-0.31	2.08e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs28386778	0.734	rs12946669	chr17:62006007	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.8	11.12	0.56	8.08e-24	Prudent dietary pattern;
CESC	cis	rs12618769	0.597	rs3754891	chr2:99088018	T/C	cg10123293	chr2:99228465	UNC50	0.4	5.38	0.31	1.68e-7	Bipolar disorder;
CESC	cis	rs1577917	1.000	rs10455455	chr6:86670214	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-6.22	-0.36	1.91e-9	Response to antipsychotic treatment;
CESC	cis	rs6582630	0.537	rs2204006	chr12:38407098	A/G	cg13010199	chr12:38710504	ALG10B	0.45	5.86	0.34	1.39e-8	Drug-induced liver injury (flucloxacillin);
CESC	trans	rs4332037	0.707	rs56070303	chr7:1891015	C/T	cg11693508	chr17:37793320	STARD3	0.61	6.18	0.35	2.45e-9	Bipolar disorder;
CESC	trans	rs208520	0.837	rs208471	chr6:66916749	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.85	-10.02	-0.52	3.11e-20	Exhaled nitric oxide output;
CESC	cis	rs1348850	0.645	rs11887886	chr2:178425730	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.62	6.48	0.37	4.41e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs7818688	0.697	rs60003497	chr8:95983423	A/T	cg16049864	chr8:95962084	TP53INP1	0.55	5.55	0.32	6.92e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs9549260	0.755	rs7993233	chr13:41219434	T/A	cg21288729	chr13:41239152	FOXO1	0.67	8.77	0.47	2.16e-16	Red blood cell count;
CESC	cis	rs2299587	0.662	rs7816769	chr8:17768548	G/T	cg08627089	chr8:17753878	FGL1	0.39	5.17	0.3	4.68e-7	Economic and political preferences;
CESC	cis	rs7762018	0.891	rs7740218	chr6:170141552	G/A	cg13891659	chr6:170190454	C6orf122;C6orf208	0.65	6.46	0.37	5e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs7833790	0.963	rs72686466	chr8:82758928	G/T	cg02079420	chr8:82753780	SNX16	-0.58	-7.73	-0.43	2.18e-13	Diastolic blood pressure;
CESC	cis	rs367943	0.712	rs6594709	chr5:112700714	T/C	cg12552261	chr5:112820674	MCC	0.4	5.31	0.31	2.31e-7	Type 2 diabetes;
CESC	trans	rs801193	0.904	rs4718403	chr7:66242729	C/G	cg14393609	chr7:65229607	NA	0.47	6.33	0.36	1.05e-9	Aortic root size;
CESC	cis	rs875971	0.638	rs35986979	chr7:66088990	G/A	cg06456125	chr7:65229604	NA	-0.4	-5.17	-0.3	4.66e-7	Aortic root size;
CESC	cis	rs12497850	0.931	rs9311432	chr3:48850443	T/A	cg02487422	chr3:49467188	NICN1	0.4	5.11	0.3	6.09e-7	Parkinson's disease;
CESC	cis	rs9487051	0.837	rs9480920	chr6:109605322	C/A	cg12927641	chr6:109611667	NA	-0.43	-6.67	-0.38	1.51e-10	Reticulocyte fraction of red cells;
CESC	cis	rs13191362	0.507	rs2803051	chr6:163034979	G/A	cg06582575	chr6:163149167	PACRG;PARK2	-0.5	-6.24	-0.36	1.74e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs2997447	0.668	rs59978831	chr1:26446351	T/A	cg24596570	chr1:26146463	FAM54B;LOC646471	0.59	5.17	0.3	4.68e-7	QRS complex (12-leadsum);
CESC	cis	rs5758659	0.652	rs133336	chr22:42416303	C/T	cg15557168	chr22:42548783	NA	-0.45	-6.71	-0.38	1.19e-10	Cognitive function;
CESC	cis	rs7914558	1.000	rs12780843	chr10:104769335	G/C	cg08650961	chr10:104748594	CNNM2	0.33	5.52	0.32	8e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs3815700	0.841	rs10410895	chr19:33093655	T/G	cg02997394	chr19:33096574	ANKRD27	0.73	7.3	0.41	3.26e-12	Eosinophilic esophagitis;
CESC	cis	rs4713118	0.662	rs13218430	chr6:28029837	T/C	cg23281280	chr6:28129359	ZNF389	0.5	6.56	0.37	2.75e-10	Parkinson's disease;
CESC	cis	rs9916302	0.904	rs10852933	chr17:37698194	G/T	cg00129232	chr17:37814104	STARD3	-0.57	-7.44	-0.42	1.39e-12	Glomerular filtration rate (creatinine);
CESC	trans	rs1814175	0.791	rs10839395	chr11:49846274	G/T	cg15704280	chr7:45808275	SEPT13	-1.03	-20.17	-0.78	1.78e-55	Height;
CESC	cis	rs4862750	0.872	rs4862747	chr4:187877236	A/T	cg07414643	chr4:187882934	NA	-0.55	-7.9	-0.44	7.43e-14	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs3857067	0.806	rs28408270	chr4:95114572	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.65	-9.92	-0.52	6.18e-20	QT interval;
CESC	cis	rs9300255	0.739	rs11057210	chr12:123733799	A/G	cg00376283	chr12:123451042	ABCB9	0.7	8.61	0.47	6.56e-16	Neutrophil percentage of white cells;
CESC	cis	rs6088580	0.543	rs4911158	chr20:33239512	T/C	cg24642439	chr20:33292090	TP53INP2	-0.45	-5.36	-0.31	1.81e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs9815354	0.680	rs114714860	chr3:41882905	G/C	cg03022575	chr3:42003672	ULK4	0.45	5.26	0.31	2.97e-7	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs7210086	0.768	rs4072716	chr17:70640933	T/C	cg04206342	chr17:70636940	NA	-0.3	-5.84	-0.34	1.56e-8	Ulcerative colitis;
CESC	cis	rs28374715	0.662	rs513280	chr15:41482800	T/C	cg18705301	chr15:41695430	NDUFAF1	0.76	10.17	0.53	1.02e-20	Ulcerative colitis;
CESC	cis	rs9303280	0.901	rs12950743	chr17:38049233	T/C	cg19468946	chr17:37922297	IKZF3	-0.41	-5.54	-0.32	7.41e-8	Self-reported allergy;
CESC	cis	rs40363	0.951	rs250632	chr16:3523047	C/T	cg05754148	chr16:3507555	NAT15	0.67	7.46	0.42	1.24e-12	Tuberculosis;
CESC	cis	rs8077577	0.747	rs62072537	chr17:18216100	G/A	cg16794390	chr17:18148240	FLII	0.41	6.52	0.37	3.53e-10	Obesity-related traits;
CESC	cis	rs7662987	0.517	rs2602881	chr4:100040695	A/G	cg12011299	chr4:100065546	ADH4	0.6	6.56	0.37	2.83e-10	Smoking initiation;
CESC	cis	rs7107174	1.000	rs2510032	chr11:77968631	G/C	cg02023728	chr11:77925099	USP35	0.48	6.29	0.36	1.3e-9	Testicular germ cell tumor;
CESC	cis	rs7539624	0.588	rs10916634	chr1:223913858	C/T	cg10100437	chr1:223903862	CAPN2	0.37	5.16	0.3	4.74e-7	Schizophrenia;
CESC	cis	rs2243480	1.000	rs458291	chr7:65520479	C/A	cg13147721	chr7:65941812	NA	-0.88	-8.52	-0.46	1.19e-15	Diabetic kidney disease;
CESC	trans	rs7618501	0.633	rs2624843	chr3:49997963	G/A	cg21659725	chr3:3221576	CRBN	0.49	6.81	0.39	6.69e-11	Intelligence (multi-trait analysis);
CESC	cis	rs763121	0.853	rs2284073	chr22:39105948	T/C	cg06544989	chr22:39130855	UNC84B	0.51	9.82	0.52	1.27e-19	Menopause (age at onset);
CESC	cis	rs75477785	0.590	rs11119394	chr1:210194685	A/G	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.91	6.32	0.36	1.09e-9	Cleft lip with or without cleft palate;
CESC	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg18538332	chr22:24372958	LOC391322	-0.73	-10.57	-0.54	5.23e-22	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs16910800	0.689	rs56101126	chr11:23188861	T/A	cg20040320	chr11:23191996	NA	-0.67	-6.66	-0.38	1.53e-10	Cancer;
CESC	cis	rs9916302	0.904	rs3744348	chr17:37417575	C/G	cg15445000	chr17:37608096	MED1	0.4	6.52	0.37	3.63e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs9649213	0.727	rs12113294	chr7:97910637	C/G	cg24562669	chr7:97807699	LMTK2	0.37	5.09	0.3	6.95e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs1059312	0.808	rs4760533	chr12:129297651	A/G	cg09035930	chr12:129282057	SLC15A4	-0.67	-8.94	-0.48	6.63e-17	Systemic lupus erythematosus;
CESC	cis	rs6502050	0.769	rs9904237	chr17:80119664	G/A	cg11859384	chr17:80120422	CCDC57	-0.39	-5.34	-0.31	1.96e-7	Life satisfaction;
CESC	cis	rs9905704	0.647	rs2286299	chr17:57043367	T/G	cg12560992	chr17:57184187	TRIM37	0.62	7.93	0.44	6.35e-14	Testicular germ cell tumor;
CESC	cis	rs6088580	0.524	rs6142210	chr20:33223012	C/T	cg06115741	chr20:33292138	TP53INP2	-0.45	-5.25	-0.31	3.14e-7	Glomerular filtration rate (creatinine);
CESC	trans	rs17685	0.712	rs10952842	chr7:75780413	G/A	cg19862616	chr7:65841803	NCRNA00174	0.8	11.44	0.57	6.89e-25	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs4713118	0.662	rs149948	chr6:27974817	C/G	cg17221315	chr6:27791827	HIST1H4J	0.44	5.29	0.31	2.61e-7	Parkinson's disease;
CESC	cis	rs7301826	0.651	rs1973834	chr12:131280157	C/T	cg11011512	chr12:131303247	STX2	0.47	5.73	0.33	2.69e-8	Plasma plasminogen activator levels;
CESC	cis	rs1580019	0.563	rs4723169	chr7:32567577	G/A	cg07520158	chr7:32535189	LSM5;AVL9	0.52	6.61	0.38	2.16e-10	Cognitive ability;
CESC	cis	rs10504229	0.639	rs67996345	chr8:58117127	A/G	cg21724239	chr8:58056113	NA	0.58	5.95	0.34	8.29e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs11638352	0.661	rs2706490	chr15:44422238	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.56	-5.29	-0.31	2.53e-7	Lipoprotein phospholipase A2 activity in cardiovascular disease;
CESC	cis	rs2180341	0.960	rs9401953	chr6:127687574	G/A	cg24812749	chr6:127587940	RNF146	1.05	15.12	0.68	1.2e-37	Breast cancer;
CESC	cis	rs7000551	0.689	rs10110254	chr8:22309551	G/T	cg12081754	chr8:22256438	SLC39A14	0.41	5.45	0.32	1.16e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CESC	cis	rs9430161	0.611	rs34032547	chr1:11034374	C/G	cg27631724	chr1:11040367	C1orf127	0.38	6.21	0.36	2.02e-9	Ewing sarcoma;
CESC	cis	rs6466055	0.748	rs1204080	chr7:104988848	A/G	cg04380332	chr7:105027541	SRPK2	0.43	5.6	0.33	5.33e-8	Schizophrenia;
CESC	cis	rs703842	1.000	rs10877019	chr12:58172929	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	-0.72	-8.88	-0.48	1.07e-16	Multiple sclerosis;
CESC	cis	rs12477438	0.520	rs2516829	chr2:99773201	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.87	15.18	0.68	6.93e-38	Chronic sinus infection;
CESC	cis	rs7615952	0.576	rs4646748	chr3:125826329	G/A	cg06494592	chr3:125709126	NA	-0.5	-5.31	-0.31	2.38e-7	Blood pressure (smoking interaction);
CESC	cis	rs875971	0.660	rs801190	chr7:66033033	C/T	cg25985355	chr7:65971099	NA	0.33	5.52	0.32	7.94e-8	Aortic root size;
CESC	cis	rs1865760	0.532	rs9295687	chr6:26082710	T/C	cg17691542	chr6:26056736	HIST1H1C	0.42	5.57	0.32	6.13e-8	Height;
CESC	cis	rs34286592	1.000	rs28599680	chr16:29860685	A/C	cg27338089	chr16:29820515	MAZ	0.48	5.04	0.3	8.68e-7	Multiple sclerosis;
CESC	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg23034840	chr1:205782522	SLC41A1	0.68	8.32	0.46	4.7e-15	Menarche (age at onset);
CESC	cis	rs2115630	0.967	rs10438428	chr15:85330745	C/T	cg09876464	chr15:85330779	ZNF592	0.36	5.6	0.33	5.38e-8	P wave terminal force;
CESC	cis	rs875971	0.862	rs4718383	chr7:66108409	T/C	cg13147721	chr7:65941812	NA	0.38	5.36	0.31	1.77e-7	Aortic root size;
CESC	trans	rs7726839	0.540	rs12520279	chr5:657291	T/C	cg25482853	chr8:67687455	SGK3	0.93	9.54	0.51	9.85e-19	Obesity-related traits;
CESC	cis	rs7949030	0.688	rs2849031	chr11:62365665	G/A	cg23462726	chr11:62437636	C11orf83;C11orf48	0.41	5.42	0.32	1.33e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs270601	0.710	rs4705852	chr5:131602807	A/G	cg04518342	chr5:131593106	PDLIM4	0.4	5.95	0.34	8.64e-9	Acylcarnitine levels;
CESC	cis	rs6952808	0.529	rs73038442	chr7:2139457	C/T	cg08027265	chr7:2291960	NA	-0.45	-6.96	-0.39	2.71e-11	Bipolar disorder and schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02415717	chr17:45727607	KPNB1	0.57	6.74	0.38	1e-10	Gut microbiome composition (summer);
CESC	trans	rs7246657	0.943	rs3760825	chr19:37945601	C/T	cg24637308	chr11:6592297	DNHD1	0.54	6.34	0.36	1.01e-9	Coronary artery calcification;
CESC	cis	rs7212590	0.748	rs59685433	chr17:57891207	T/C	cg20303301	chr17:57937339	TUBD1	-0.59	-5.56	-0.32	6.49e-8	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs853679	0.517	rs9393896	chr6:28127703	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.57	-6.48	-0.37	4.36e-10	Depression;
CESC	cis	rs763014	0.865	rs2018789	chr16:632051	T/C	cg07343612	chr16:622815	PIGQ	-0.57	-8.23	-0.45	8.47e-15	Height;
CESC	cis	rs1008375	0.966	rs3796812	chr4:17582051	G/A	cg16339924	chr4:17578868	LAP3	0.62	7.84	0.43	1.09e-13	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs875971	0.862	rs6460290	chr7:65809106	G/A	cg10691866	chr7:65817282	TPST1	0.3	5.07	0.3	7.66e-7	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07120479	chr11:67033799	ADRBK1	0.59	6.61	0.38	2.07e-10	Gut microbiome composition (summer);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg10332367	chr16:2075476	SLC9A3R2	0.38	6.09	0.35	4.06e-9	Fibrinogen levels;
CESC	cis	rs7511006	0.893	rs5771104	chr22:50651839	C/T	cg07895657	chr22:50616420	PANX2	-0.36	-5.67	-0.33	3.69e-8	Obesity-related traits;
CESC	cis	rs2066819	1.000	rs773664	chr12:56702176	C/T	cg26734620	chr12:56694298	CS	-0.92	-9.33	-0.5	4.31e-18	Psoriasis vulgaris;
CESC	cis	rs524023	0.874	rs518053	chr11:64456099	C/T	cg07220939	chr11:64358617	SLC22A12	-0.35	-5.42	-0.32	1.36e-7	Urate levels in obese individuals;
CESC	cis	rs4819052	1.000	rs2838847	chr21:46670958	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.81	10.39	0.54	1.89e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg09820084	chr6:18387507	RNF144B	0.43	6.0	0.35	6.61e-9	Systemic lupus erythematosus;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg14765172	chr6:153304972	FBXO5	-0.52	-7.23	-0.41	5.29e-12	Gut microbiota (bacterial taxa);
CESC	cis	rs2243480	1.000	rs9769882	chr7:65642925	T/C	cg18252515	chr7:66147081	NA	1.36	13.62	0.64	2.24e-32	Diabetic kidney disease;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	ch.19.702771R	chr19:16673058	SLC35E1	-0.45	-6.17	-0.35	2.61e-9	Asthma;
CESC	cis	rs2486288	0.656	rs9920290	chr15:45548035	G/A	cg21132104	chr15:45694354	SPATA5L1	-0.54	-6.54	-0.37	3.21e-10	Glomerular filtration rate;
CESC	cis	rs4819052	0.851	rs2838831	chr21:46664775	C/T	cg11663144	chr21:46675770	NA	-0.63	-9.96	-0.52	4.72e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs2637266	1.000	rs11001830	chr10:78346396	G/A	cg18941641	chr10:78392320	NA	0.42	7.79	0.43	1.54e-13	Pulmonary function;
CESC	cis	rs7100689	0.646	rs10736345	chr10:82134140	C/T	cg00277334	chr10:82204260	NA	-0.57	-7.51	-0.42	9.08e-13	Post bronchodilator FEV1;
CESC	cis	rs2991971	0.810	rs781058	chr1:45935056	C/G	cg24296786	chr1:45957014	TESK2	-0.63	-9.17	-0.49	1.39e-17	High light scatter reticulocyte count;
CESC	cis	rs875971	0.862	rs12698526	chr7:65969105	T/C	cg19163074	chr7:65112434	INTS4L2	-0.42	-5.26	-0.31	2.93e-7	Aortic root size;
CESC	cis	rs6060717	0.536	rs11697024	chr20:34546500	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.79	-7.13	-0.4	9.32e-12	Hip circumference adjusted for BMI;
CESC	cis	rs7116495	0.881	rs615000	chr11:71802952	A/C	cg10381502	chr11:71823885	C11orf51	-0.64	-5.12	-0.3	5.87e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs61542988	0.570	rs7781074	chr7:22826360	A/G	cg11367502	chr7:22862612	TOMM7	-0.52	-6.14	-0.35	2.99e-9	Fibrinogen levels;
CESC	cis	rs7264396	0.790	rs6060526	chr20:34225302	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	-0.59	-6.43	-0.37	5.81e-10	Total cholesterol levels;
CESC	cis	rs9768139	0.708	rs10234067	chr7:158114542	C/T	cg06219351	chr7:158114137	PTPRN2	-0.56	-8.96	-0.48	5.77e-17	Calcium levels;
CESC	cis	rs7267979	1.000	rs6107047	chr20:25442097	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.83	15.81	0.7	4.28e-40	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7605827	0.930	rs10929376	chr2:15692856	A/T	cg19274914	chr2:15703543	NA	0.37	6.7	0.38	1.22e-10	Educational attainment (years of education);
CESC	cis	rs17253792	0.915	rs74580958	chr14:56181511	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.74	5.1	0.3	6.53e-7	Putamen volume;
CESC	cis	rs425277	0.565	rs3128293	chr1:2065339	A/G	cg19257562	chr1:2043853	PRKCZ	0.34	5.35	0.31	1.95e-7	Height;
CESC	cis	rs12145833	0.538	rs10754798	chr1:243309958	A/G	cg02356786	chr1:243265016	LOC731275	-0.69	-6.44	-0.37	5.61e-10	Obesity (early onset extreme);
CESC	cis	rs8177253	0.761	rs35332919	chr3:133519002	T/A	cg01448562	chr3:133502909	NA	-0.59	-8.58	-0.47	7.98e-16	Iron status biomarkers;
CESC	cis	rs4148883	0.504	rs9307238	chr4:100136182	A/G	cg13256891	chr4:100009986	ADH5	-0.51	-6.88	-0.39	4.27e-11	Alcohol dependence;
CESC	cis	rs72781680	0.611	rs72783636	chr2:24328706	C/T	cg08917208	chr2:24149416	ATAD2B	0.55	5.3	0.31	2.47e-7	Lymphocyte counts;
CESC	cis	rs896854	0.625	rs13281709	chr8:95972819	T/A	cg09323728	chr8:95962352	TP53INP1	-0.39	-8.53	-0.46	1.11e-15	Type 2 diabetes;
CESC	cis	rs12586317	0.548	rs12590678	chr14:35602956	C/T	cg16230307	chr14:35515116	FAM177A1	1.03	11.3	0.57	2e-24	Psoriasis;
CESC	cis	rs4474465	0.850	rs4482052	chr11:78263331	A/G	cg27205649	chr11:78285834	NARS2	0.43	5.31	0.31	2.3e-7	Alzheimer's disease (survival time);
CESC	cis	rs12681366	0.663	rs2930970	chr8:95464337	A/G	cg13257157	chr8:95487014	RAD54B	0.39	5.34	0.31	2.04e-7	Nonsyndromic cleft lip with cleft palate;
CESC	cis	rs7647973	0.580	rs11130184	chr3:49229930	C/T	cg06212747	chr3:49208901	KLHDC8B	0.73	11.08	0.56	1.07e-23	Menarche (age at onset);
CESC	cis	rs514406	0.929	rs557847	chr1:53333116	A/G	cg25767906	chr1:53392781	SCP2	-0.45	-5.7	-0.33	3.19e-8	Monocyte count;
CESC	cis	rs72945132	0.882	rs7928686	chr11:70134528	T/C	cg14191688	chr11:70257035	CTTN	0.41	5.19	0.3	4.24e-7	Coronary artery disease;
CESC	cis	rs736408	0.812	rs9324	chr3:52825585	T/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.15	0.35	2.87e-9	Bipolar disorder;
CESC	cis	rs7267979	0.966	rs6037103	chr20:25369095	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.84	-16.5	-0.71	1.44e-42	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7769051	0.522	rs34688576	chr6:133118214	C/T	cg07930552	chr6:133119739	C6orf192	1.14	7.79	0.43	1.5e-13	Type 2 diabetes nephropathy;
CESC	cis	rs780096	0.647	rs11682083	chr2:27752296	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.29	-5.66	-0.33	3.99e-8	Total body bone mineral density;
CESC	cis	rs7916697	0.520	rs4745957	chr10:70044702	A/G	cg06988349	chr10:69991859	ATOH7	-0.31	-5.08	-0.3	7.01e-7	Optic disc area;
CESC	cis	rs524281	0.773	rs4393319	chr11:66001878	A/T	cg14036092	chr11:66035641	RAB1B	-0.53	-5.31	-0.31	2.38e-7	Electroencephalogram traits;
CESC	cis	rs3785574	0.962	rs56295011	chr17:61850359	A/G	cg07677032	chr17:61819896	STRADA	0.42	5.23	0.31	3.42e-7	Height;
CESC	cis	rs2228479	0.850	rs11639925	chr16:89908250	C/T	cg04013166	chr16:89971882	TCF25	0.73	5.8	0.34	1.93e-8	Skin colour saturation;
CESC	cis	rs35110281	0.548	rs7276316	chr21:45029333	A/T	cg04455712	chr21:45112962	RRP1B	0.4	5.9	0.34	1.08e-8	Mean corpuscular volume;
CESC	cis	rs4975709	0.610	rs4975706	chr5:1860365	G/T	cg12288994	chr5:1860383	NA	0.42	7.0	0.4	2.04e-11	Cardiovascular disease risk factors;
CESC	cis	rs10751667	0.666	rs7396473	chr11:966181	T/C	cg20946044	chr11:1010712	AP2A2	-0.4	-5.46	-0.32	1.12e-7	Alzheimer's disease (late onset);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg16773294	chr8:55048378	MRPL15	0.45	6.32	0.36	1.08e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs10032549	0.627	rs10002170	chr4:77394139	G/C	cg20311846	chr4:77356250	SHROOM3	-0.26	-5.21	-0.3	3.87e-7	Glomerular filtration rate;
CESC	cis	rs6754311	0.551	rs2304599	chr2:136528004	C/G	cg15123519	chr2:136567270	LCT	0.32	5.63	0.33	4.67e-8	Mosquito bite size;
CESC	cis	rs9910055	0.552	rs4793084	chr17:42317371	G/T	cg13607699	chr17:42295918	UBTF	-0.85	-12.32	-0.6	6.83e-28	Total body bone mineral density;
CESC	trans	rs116095464	0.558	rs62344300	chr5:246336	A/G	cg00938859	chr5:1591904	SDHAP3	0.64	6.98	0.39	2.36e-11	Breast cancer;
CESC	cis	rs72634258	0.786	rs4405150	chr1:8173672	T/C	cg00042356	chr1:8021962	PARK7	-0.55	-5.93	-0.34	9.19e-9	Inflammatory bowel disease;
CESC	cis	rs9896933	0.732	rs590886	chr17:80767350	A/G	cg20578329	chr17:80767326	TBCD	0.73	8.42	0.46	2.38e-15	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
CESC	cis	rs1707322	0.721	rs10430123	chr1:46221440	T/C	cg06784218	chr1:46089804	CCDC17	0.43	7.58	0.42	5.65e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs11758351	1.000	rs17598927	chr6:26184640	C/G	cg01420254	chr6:26195488	NA	-0.73	-6.84	-0.39	5.54e-11	Gout;Renal underexcretion gout;
CESC	cis	rs17001868	0.527	rs11913132	chr22:40778778	A/G	cg07138101	chr22:40742427	ADSL	0.49	5.22	0.31	3.58e-7	Mammographic density (dense area);
CESC	cis	rs10751667	0.666	rs7936830	chr11:959686	A/G	cg06064525	chr11:970664	AP2A2	-0.47	-9.44	-0.5	2.07e-18	Alzheimer's disease (late onset);
CESC	cis	rs853679	0.882	rs9468287	chr6:28079741	G/T	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.79	7.22	0.41	5.41e-12	Depression;
CESC	cis	rs4780401	0.587	rs9931332	chr16:11807517	G/C	cg01061890	chr16:11836724	TXNDC11	-0.56	-7.59	-0.42	5.42e-13	Rheumatoid arthritis;
CESC	cis	rs7584330	0.737	rs10445707	chr2:238368751	A/G	cg14458575	chr2:238380390	NA	0.64	8.87	0.48	1.14e-16	Prostate cancer;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05889321	chr10:97416837	ALDH18A1	0.51	6.65	0.38	1.65e-10	Gut microbiota (bacterial taxa);
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg12474080	chr11:60929017	VPS37C	0.44	6.16	0.35	2.64e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs428668	0.523	rs10060607	chr5:150679304	A/C	cg11125805	chr5:150678162	SLC36A3	0.69	10.91	0.56	3.83e-23	Skin aging (microtopography measurement);
CESC	cis	rs858239	0.539	rs7791200	chr7:23182121	A/T	cg23682824	chr7:23144976	KLHL7	0.52	6.73	0.38	1.04e-10	Cerebrospinal fluid biomarker levels;
CESC	cis	rs3096299	0.606	rs8052103	chr16:89541243	A/T	cg02034447	chr16:89574710	SPG7	-0.48	-5.75	-0.33	2.42e-8	Multiple myeloma (IgH translocation);
CESC	cis	rs6460942	0.915	rs1595800	chr7:12439816	G/A	cg13733410	chr7:12443478	VWDE	-0.53	-5.47	-0.32	1.02e-7	Coronary artery disease;
CESC	cis	rs2836633	1.000	rs2836631	chr21:40065906	G/T	cg12884169	chr21:40033163	ERG	-0.33	-5.47	-0.32	1.05e-7	Coronary artery disease;
CESC	trans	rs9325144	0.513	rs12313652	chr12:38665412	G/A	cg23762105	chr12:34175262	ALG10	0.48	6.31	0.36	1.15e-9	Morning vs. evening chronotype;
CESC	cis	rs9322193	0.923	rs10782310	chr6:149943594	A/G	cg13206674	chr6:150067644	NUP43	0.41	5.77	0.33	2.21e-8	Lung cancer;
CESC	cis	rs10779751	0.922	rs2746638	chr1:11278125	T/C	cg08854313	chr1:11322531	MTOR	0.79	10.75	0.55	1.32e-22	Body mass index;
CESC	cis	rs941408	1.000	rs1736180	chr19:2796021	C/T	cg00079169	chr19:2811669	THOP1	0.45	6.44	0.37	5.47e-10	Total cholesterol levels;
CESC	cis	rs829883	0.664	rs249833	chr12:98832189	T/C	cg25150519	chr12:98850993	NA	0.87	14.77	0.67	1.95e-36	Colorectal adenoma (advanced);
CESC	cis	rs854765	0.547	rs4643387	chr17:17972973	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.57	7.98	0.44	4.39e-14	Total body bone mineral density;
CESC	cis	rs7829975	0.564	rs2976855	chr8:8301794	G/A	cg15556689	chr8:8085844	FLJ10661	0.62	7.95	0.44	5.39e-14	Mood instability;
CESC	cis	rs6831352	0.819	rs1230158	chr4:99990186	T/C	cg13256891	chr4:100009986	ADH5	0.69	8.15	0.45	1.43e-14	Alcohol dependence;
CESC	trans	rs7980799	0.967	rs7971226	chr12:33586881	C/T	cg26384229	chr12:38710491	ALG10B	0.53	7.21	0.4	5.74e-12	Heart rate;Heart rate variability traits (RMSSD);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07175945	chr5:32444062	ZFR	0.62	6.4	0.37	6.98e-10	Gut microbiome composition (summer);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg23093116	chr1:117489843	PTGFRN	0.45	6.45	0.37	5.41e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs1355223	0.506	rs7947848	chr11:34866220	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.54	-6.72	-0.38	1.12e-10	Systemic lupus erythematosus and Systemic sclerosis;
CESC	trans	rs916888	0.697	rs199516	chr17:44856485	C/T	cg22968622	chr17:43663579	NA	-1.19	-16.52	-0.71	1.26e-42	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs1801251	0.656	rs10211596	chr2:233699415	C/T	cg25237894	chr2:233734115	C2orf82	-0.29	-5.1	-0.3	6.48e-7	Coronary artery disease;
CESC	cis	rs6429082	0.818	rs167092	chr1:235642359	A/G	cg26050004	chr1:235667680	B3GALNT2	0.62	7.83	0.43	1.19e-13	Adiposity;
CESC	cis	rs262150	1.000	rs262149	chr7:158778256	A/G	cg19418458	chr7:158789849	NA	0.45	7.05	0.4	1.52e-11	Facial morphology (factor 20);
CESC	cis	rs7216064	1.000	rs1976053	chr17:65833002	C/G	cg07042672	chr17:66097459	LOC651250	-0.63	-7.92	-0.44	6.66e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs2836974	0.666	rs11910705	chr21:40685604	C/T	cg11644478	chr21:40555479	PSMG1	-0.8	-11.67	-0.58	1.12e-25	Cognitive function;
CESC	cis	rs6546550	0.935	rs4853027	chr2:70039224	A/G	cg02498382	chr2:70120550	SNRNP27	0.39	6.98	0.39	2.36e-11	Prevalent atrial fibrillation;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg16954204	chr6:20212978	MBOAT1	-0.47	-6.33	-0.36	1.05e-9	Asthma;
CESC	trans	rs1814175	0.935	rs11040438	chr11:49622521	G/A	cg03929089	chr4:120376271	NA	-0.87	-13.32	-0.63	2.44e-31	Height;
CESC	cis	rs7618915	1.000	rs3852064	chr3:52349412	G/T	cg18404041	chr3:52824283	ITIH1	-0.37	-5.1	-0.3	6.38e-7	Bipolar disorder;
CESC	trans	rs864643	0.773	rs11129837	chr3:39589963	A/G	cg14771734	chr5:79703670	ZFYVE16	0.46	6.01	0.35	6.03e-9	Attention deficit hyperactivity disorder;
CESC	cis	rs9322193	0.962	rs2065664	chr6:150083621	A/G	cg07701084	chr6:150067640	NUP43	0.39	5.24	0.31	3.36e-7	Lung cancer;
CESC	cis	rs1005277	0.522	rs289650	chr10:37975505	G/T	cg00409905	chr10:38381863	ZNF37A	-0.48	-6.64	-0.38	1.75e-10	Extrinsic epigenetic age acceleration;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg23490046	chr20:18487999	SEC23B	0.45	6.07	0.35	4.36e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs9926296	0.565	rs8055825	chr16:89832848	C/T	cg21285383	chr16:89894308	SPIRE2	0.32	5.74	0.33	2.6e-8	Vitiligo;
CESC	cis	rs896854	0.654	rs6982393	chr8:95980708	T/C	cg09323728	chr8:95962352	TP53INP1	-0.39	-8.29	-0.45	5.87e-15	Type 2 diabetes;
CESC	cis	rs7259376	0.905	rs8112246	chr19:22567447	C/T	cg02657401	chr19:22469223	NA	-0.25	-5.11	-0.3	6.31e-7	Menopause (age at onset);
CESC	cis	rs1395	0.778	rs11126918	chr2:27438710	G/A	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.44	5.8	0.34	1.84e-8	Blood metabolite levels;
CESC	cis	rs3741151	1.000	rs7129663	chr11:73045129	C/T	cg17517138	chr11:73019481	ARHGEF17	1.07	7.35	0.41	2.52e-12	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs2228479	0.541	rs9922515	chr16:89954138	G/C	cg04013166	chr16:89971882	TCF25	0.71	8.73	0.47	2.95e-16	Skin colour saturation;
CESC	cis	rs10751667	0.643	rs10902238	chr11:944810	G/A	cg06064525	chr11:970664	AP2A2	-0.52	-10.45	-0.54	1.21e-21	Alzheimer's disease (late onset);
CESC	cis	rs35306767	0.855	rs12781100	chr10:838636	C/T	cg10556349	chr10:835070	NA	0.7	6.04	0.35	5.24e-9	Eosinophil percentage of granulocytes;
CESC	cis	rs62064224	0.703	rs62065492	chr17:30822607	C/T	cg12855166	chr17:30846586	MYO1D	0.4	5.12	0.3	6.02e-7	Schizophrenia;
CESC	cis	rs709400	0.663	rs3742458	chr14:103950368	A/G	cg12935359	chr14:103987150	CKB	-0.51	-7.44	-0.42	1.39e-12	Body mass index;
CESC	trans	rs650950	0.528	rs646660	chr11:35528452	C/T	cg15448590	chr17:655563	ELP2P;GEMIN4	0.48	6.13	0.35	3.15e-9	Bronchopulmonary dysplasia;
CESC	cis	rs3820068	0.603	rs3766163	chr1:15986547	T/C	cg13390004	chr1:15929781	NA	0.34	5.47	0.32	1.04e-7	Systolic blood pressure;
CESC	cis	rs763014	0.865	rs710924	chr16:633353	T/C	cg00802000	chr16:706648	WDR90	-0.41	-6.12	-0.35	3.33e-9	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25312481	chr1:10459146	PGD	0.59	6.91	0.39	3.65e-11	Gut microbiome composition (summer);
CESC	cis	rs514406	0.825	rs6695819	chr1:53223366	T/C	cg24675658	chr1:53192096	ZYG11B	0.53	6.78	0.38	7.96e-11	Monocyte count;
CESC	cis	rs863345	0.604	rs7548349	chr1:158493726	C/T	cg12129480	chr1:158549410	OR10X1	-0.35	-6.86	-0.39	4.75e-11	Pneumococcal bacteremia;
CESC	cis	rs9623117	1.000	rs713639	chr22:40507282	T/C	cg05033341	chr22:40419857	FAM83F	-0.42	-5.13	-0.3	5.57e-7	Prostate cancer (SNP x SNP interaction);Prostate cancer;
CESC	cis	rs1620921	0.505	rs4708881	chr6:161203159	C/T	cg01280913	chr6:161186852	NA	-0.36	-5.26	-0.31	2.92e-7	Lipoprotein (a) - cholesterol levels;
CESC	cis	rs9322193	0.923	rs9322214	chr6:150025122	C/T	cg02462569	chr6:150064036	NUP43	-0.36	-5.11	-0.3	6.15e-7	Lung cancer;
CESC	cis	rs6088590	1.000	rs1998028	chr20:33344595	A/T	cg24642439	chr20:33292090	TP53INP2	0.85	11.81	0.59	3.81e-26	Coronary artery disease;
CESC	cis	rs1005277	0.579	rs116912400	chr10:38479207	G/T	cg25517755	chr10:38738941	LOC399744	-0.49	-6.35	-0.36	9.08e-10	Extrinsic epigenetic age acceleration;
CESC	trans	rs11039798	0.698	rs76315297	chr11:48240475	T/C	cg15704280	chr7:45808275	SEPT13	0.71	6.58	0.37	2.49e-10	Axial length;
CESC	cis	rs9837602	0.507	rs6803204	chr3:99680874	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.59	-7.14	-0.4	8.97e-12	Breast cancer;
CESC	cis	rs4472734	1.000	rs4615815	chr1:214604236	A/G	cg00063699	chr1:214624242	PTPN14	-0.34	-5.43	-0.32	1.26e-7	Height;
CESC	cis	rs258892	0.739	rs34667	chr5:72160050	T/C	cg21869765	chr5:72125136	TNPO1	0.44	5.55	0.32	6.92e-8	Small cell lung carcinoma;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11987090	chr1:22778442	ZBTB40	-0.64	-7.54	-0.42	7.31e-13	Gut microbiome composition (summer);
CESC	cis	rs4727027	0.901	rs6943937	chr7:148869915	A/G	cg23158103	chr7:148848205	ZNF398	-0.4	-6.32	-0.36	1.09e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs3781458	0.806	rs3781466	chr10:126328689	A/G	cg20435097	chr10:126320824	FAM53B	-0.31	-5.79	-0.34	1.96e-8	Male-pattern baldness;
CESC	cis	rs3820928	1.000	rs1346618	chr2:227771988	C/T	cg11843606	chr2:227700838	RHBDD1	0.42	5.65	0.33	4.16e-8	Pulmonary function;
CESC	trans	rs2727020	0.638	rs1164668	chr11:49330627	A/C	cg03929089	chr4:120376271	NA	0.79	11.67	0.58	1.14e-25	Coronary artery disease;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg03442064	chr6:41515050	FOXP4	-0.43	-6.51	-0.37	3.85e-10	Gambling;
CESC	cis	rs34779708	0.677	rs112355105	chr10:35550294	A/T	cg03585969	chr10:35415529	CREM	0.55	6.25	0.36	1.61e-9	Inflammatory bowel disease;Crohn's disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg22455250	chr17:73559202	LLGL2	0.44	6.45	0.37	5.43e-10	Fibrinogen levels;
CESC	cis	rs798766	1.000	rs3099555	chr4:1725651	T/C	cg07041428	chr4:1763019	NA	-0.41	-5.78	-0.33	2.05e-8	Bladder cancer;Urinary bladder cancer;
CESC	cis	rs2066819	1.000	rs2695789	chr12:56694261	C/A	cg26316697	chr12:56727976	PAN2	-0.69	-6.64	-0.38	1.74e-10	Psoriasis vulgaris;
CESC	cis	rs7312933	0.703	rs12371615	chr12:42563989	C/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.49	6.28	0.36	1.39e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs10504073	0.527	rs118032023	chr8:49926296	A/T	cg00325661	chr8:49890786	NA	0.53	8.13	0.45	1.62e-14	Blood metabolite ratios;
CESC	cis	rs1055129	0.655	rs7216615	chr17:73833910	T/C	cg08125733	chr17:73851984	WBP2	0.52	7.05	0.4	1.51e-11	White matter hyperintensity burden;
CESC	cis	rs7727544	0.660	rs272886	chr5:131665840	T/C	cg24060327	chr5:131705240	SLC22A5	-0.68	-8.94	-0.48	6.91e-17	Blood metabolite levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06753869	chr6:24667316	ACOT13;TTRAP	0.53	6.24	0.36	1.77e-9	Gut microbiome composition (summer);
CESC	cis	rs6540559	0.673	rs11805830	chr1:209984969	C/T	cg21951975	chr1:209979733	IRF6	0.62	7.7	0.43	2.7e-13	Cleft lip with or without cleft palate;
CESC	trans	rs11098499	0.909	rs7681214	chr4:120385320	C/A	cg25214090	chr10:38739885	LOC399744	0.7	9.93	0.52	5.63e-20	Corneal astigmatism;
CESC	cis	rs763121	0.853	rs35522482	chr22:39063015	C/A	cg21395723	chr22:39101663	GTPBP1	0.43	5.39	0.31	1.58e-7	Menopause (age at onset);
CESC	cis	rs2486288	0.656	rs62026703	chr15:45569929	G/T	cg09092052	chr15:45571596	NA	0.45	5.33	0.31	2.14e-7	Glomerular filtration rate;
CESC	cis	rs6570726	0.935	rs408723	chr6:145838535	A/G	cg05347473	chr6:146136440	FBXO30	0.49	6.69	0.38	1.3100000000000001e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1395	0.744	rs11686131	chr2:27508710	C/T	cg22903471	chr2:27725779	GCKR	-0.5	-6.08	-0.35	4.12e-9	Blood metabolite levels;
CESC	cis	rs1707322	0.717	rs2991989	chr1:46082965	C/T	cg06784218	chr1:46089804	CCDC17	-0.41	-7.08	-0.4	1.31e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs6740322	0.895	rs10196095	chr2:43571885	G/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.65	-6.93	-0.39	3.28e-11	Coronary artery disease;
CESC	cis	rs798502	0.541	rs2644307	chr7:2832973	G/A	cg09658497	chr7:2847517	GNA12	-0.47	-7.33	-0.41	2.76e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Inflammatory bowel disease;Waist circumference adjusted for BMI in non-smokers;Ulcerative colitis;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
CESC	cis	rs3733585	0.699	rs6449176	chr4:9967843	G/A	cg11266682	chr4:10021025	SLC2A9	-0.58	-10.94	-0.56	3.03e-23	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs7618915	0.547	rs35211965	chr3:52685305	C/G	cg07507251	chr3:52567010	NT5DC2	0.41	7.3	0.41	3.28e-12	Bipolar disorder;
CESC	cis	rs7666738	0.753	rs35146453	chr4:98902278	A/G	cg05340658	chr4:99064831	C4orf37	0.74	10.67	0.55	2.44e-22	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2952156	0.876	rs903501	chr17:37839493	T/C	cg07936489	chr17:37558343	FBXL20	-0.53	-6.45	-0.37	5.41e-10	Asthma;
CESC	cis	rs8141529	0.702	rs5762870	chr22:29261159	C/T	cg15103426	chr22:29168792	CCDC117	0.61	8.18	0.45	1.21e-14	Lymphocyte counts;
CESC	cis	rs7107174	0.892	rs4945273	chr11:78096977	T/C	cg02023728	chr11:77925099	USP35	0.47	6.23	0.36	1.83e-9	Testicular germ cell tumor;
CESC	cis	rs4566357	0.615	rs2272200	chr2:227912331	G/A	cg11843606	chr2:227700838	RHBDD1	-0.48	-6.59	-0.38	2.37e-10	Coronary artery disease;
CESC	cis	rs7116495	0.786	rs1573501	chr11:71735693	C/T	cg07596299	chr11:71824057	C11orf51	-0.85	-5.06	-0.3	7.92e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs250677	0.687	rs40523	chr5:148444186	A/T	cg18129178	chr5:148520854	ABLIM3	0.5	5.84	0.34	1.53e-8	Breast cancer;
CESC	cis	rs10823500	0.674	rs7089860	chr10:71992848	C/G	cg04118878	chr10:71993077	PPA1	0.51	5.97	0.34	7.56e-9	Blood protein levels;
CESC	cis	rs1355223	0.902	rs1773908	chr11:34743380	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.48	-6.44	-0.37	5.45e-10	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs875971	0.862	rs6955837	chr7:66043142	C/T	cg12463550	chr7:65579703	CRCP	-0.5	-6.34	-0.36	9.71e-10	Aortic root size;
CESC	cis	rs425277	0.606	rs12082939	chr1:2078922	C/T	cg16545954	chr1:2118288	C1orf86	0.36	7.1	0.4	1.13e-11	Height;
CESC	cis	rs910316	1.000	rs4899544	chr14:75546556	C/T	cg08847533	chr14:75593920	NEK9	0.99	18.86	0.76	6.94e-51	Height;
CESC	cis	rs2276314	0.857	rs16967327	chr18:33587036	C/T	cg19628046	chr18:33552617	C18orf21	0.51	5.68	0.33	3.59e-8	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs561341	0.714	rs75861674	chr17:30304317	A/G	cg00745463	chr17:30367425	LRRC37B	-0.67	-6.78	-0.38	7.66e-11	Hip circumference adjusted for BMI;
CESC	cis	rs4481887	0.741	rs6587467	chr1:248550976	T/G	cg26353448	chr1:248524236	OR2T4	-0.38	-5.29	-0.31	2.56e-7	Common traits (Other);
CESC	cis	rs6754311	0.731	rs7569057	chr2:136583958	A/C	cg07169764	chr2:136633963	MCM6	0.67	8.1	0.45	1.98e-14	Mosquito bite size;
CESC	cis	rs2456568	0.548	rs6483280	chr11:93661592	T/C	cg04235223	chr11:93583509	C11orf90	-0.37	-5.13	-0.3	5.55e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
CESC	cis	rs7071206	0.947	rs11002226	chr10:79399656	T/A	cg00983440	chr10:79422392	NA	-0.68	-8.07	-0.44	2.43e-14	Bone mineral density;
CESC	cis	rs3771570	1.000	rs16843590	chr2:242298228	G/A	cg21155796	chr2:242212141	HDLBP	0.59	5.11	0.3	6.19e-7	Prostate cancer;
CESC	cis	rs9811920	0.809	rs902159	chr3:99747445	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.47	7.87	0.44	9.11e-14	Axial length;
CESC	cis	rs6456156	0.586	rs1407315	chr6:167468659	A/G	cg23791538	chr6:167370224	RNASET2	-0.5	-6.47	-0.37	4.66e-10	Primary biliary cholangitis;
CESC	cis	rs4819052	1.000	rs13053002	chr21:46677854	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.9	11.95	0.59	1.3e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs9300255	0.544	rs1716157	chr12:123670473	T/C	cg05973401	chr12:123451056	ABCB9	0.49	5.49	0.32	9.51e-8	Neutrophil percentage of white cells;
CESC	trans	rs7980799	0.682	rs10844611	chr12:33603544	T/C	cg26384229	chr12:38710491	ALG10B	-0.53	-7.65	-0.43	3.76e-13	Heart rate;Heart rate variability traits (RMSSD);
CESC	cis	rs8078723	0.668	rs3859191	chr17:38128714	G/A	cg17467752	chr17:38218738	THRA	0.55	7.98	0.44	4.57e-14	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CESC	trans	rs73198271	0.653	rs10099808	chr8:8659873	A/G	cg23754772	chr18:12253859	CIDEA	0.32	6.04	0.35	5.08e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs2576037	0.899	rs2060417	chr18:44576486	C/A	cg19077165	chr18:44547161	KATNAL2	0.47	6.49	0.37	4.22e-10	Personality dimensions;
CESC	cis	rs12200560	0.505	rs211166	chr6:97068598	T/C	cg06623918	chr6:96969491	KIAA0776	0.52	6.64	0.38	1.76e-10	Coronary heart disease;
CESC	cis	rs4665809	0.590	rs35615763	chr2:26468778	C/G	cg22920501	chr2:26401640	FAM59B	0.91	10.33	0.54	3.07e-21	Gut microbiome composition (summer);
CESC	cis	rs7216064	0.954	rs8079291	chr17:65887622	A/G	cg07042672	chr17:66097459	LOC651250	-0.52	-5.4	-0.31	1.5e-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs11583043	1.000	rs11584222	chr1:101480110	G/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.52	5.78	0.33	2.1e-8	Ulcerative colitis;Inflammatory bowel disease;
CESC	cis	rs736408	0.812	rs1075653	chr3:52825528	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.43	5.72	0.33	2.87e-8	Bipolar disorder;
CESC	cis	rs7089973	0.604	rs7923693	chr10:116619566	A/G	cg23260525	chr10:116636907	FAM160B1	0.42	8.12	0.45	1.8e-14	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs7312933	0.966	rs6582375	chr12:42423185	A/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.42	5.53	0.32	7.51e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs6570726	0.755	rs2103633	chr6:145894021	C/T	cg23711669	chr6:146136114	FBXO30	0.97	14.77	0.67	2.05e-36	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs7937682	0.889	rs487985	chr11:111517908	G/A	cg18187862	chr3:45730750	SACM1L	0.51	6.47	0.37	4.81e-10	Primary sclerosing cholangitis;
CESC	cis	rs9815354	1.000	rs9855965	chr3:41860508	C/T	cg03022575	chr3:42003672	ULK4	0.45	5.06	0.3	7.71e-7	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs10129255	0.536	rs3944157	chr14:107138303	C/T	cg23076370	chr14:107095027	NA	-0.51	-7.15	-0.4	8.66e-12	Kawasaki disease;
CESC	cis	rs2274273	0.840	rs6573013	chr14:55735873	A/C	cg04306507	chr14:55594613	LGALS3	0.29	5.57	0.32	6.21e-8	Protein biomarker;
CESC	cis	rs2303745	0.589	rs1465576	chr19:17398487	G/A	cg02221750	chr19:17393354	ANKLE1	-0.52	-6.38	-0.36	8.01e-10	Systemic lupus erythematosus;
CESC	cis	rs2841277	0.676	rs10438247	chr14:105411781	G/A	cg14403583	chr14:105418241	AHNAK2	-0.61	-8.56	-0.47	9.32e-16	Rheumatoid arthritis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09765074	chr10:69634185	NA	-0.59	-7.58	-0.42	5.88e-13	Gut microbiome composition (summer);
CESC	cis	rs2836974	0.526	rs1888488	chr21:40686521	C/T	cg11890956	chr21:40555474	PSMG1	-0.92	-14.63	-0.67	6.36e-36	Cognitive function;
CESC	cis	rs6540559	0.740	rs2064163	chr1:210048819	G/T	cg09509183	chr1:209979624	IRF6	0.45	5.93	0.34	9.35e-9	Cleft lip with or without cleft palate;
CESC	trans	rs875971	0.964	rs6945032	chr7:65922486	C/T	cg26939375	chr7:64535504	NA	0.46	6.0	0.35	6.4e-9	Aortic root size;
CESC	cis	rs7666738	0.830	rs890470	chr4:98923435	A/C	cg05340658	chr4:99064831	C4orf37	0.82	12.2	0.6	1.81e-27	Colonoscopy-negative controls vs population controls;
CESC	cis	rs5769765	1.000	rs2319458	chr22:50236306	G/A	cg02269571	chr22:50332266	NA	-0.46	-5.92	-0.34	9.84e-9	Schizophrenia;
CESC	cis	rs9902453	0.967	rs12602065	chr17:28482488	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.62	8.08	0.44	2.37e-14	Coffee consumption (cups per day);
CESC	cis	rs6921919	0.562	rs13198809	chr6:28323702	G/A	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.85	5.59	0.32	5.74e-8	Autism spectrum disorder or schizophrenia;
CESC	cis	rs6088580	0.660	rs6087592	chr20:33114503	A/G	cg06115741	chr20:33292138	TP53INP2	0.44	5.5	0.32	8.99e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs875971	0.862	rs6955837	chr7:66043142	C/T	cg10691866	chr7:65817282	TPST1	0.33	5.47	0.32	1.02e-7	Aortic root size;
CESC	cis	rs3947	0.756	rs1613883	chr8:11699632	T/A	cg00262122	chr8:11665843	FDFT1	-0.5	-5.28	-0.31	2.75e-7	Blood protein levels;
CESC	cis	rs11098499	0.691	rs17009144	chr4:120270795	C/T	cg09307838	chr4:120376055	NA	-0.74	-10.1	-0.53	1.67e-20	Corneal astigmatism;
CESC	cis	rs2439831	0.850	rs10163054	chr15:44047638	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.7	8.06	0.44	2.56e-14	Lung cancer in ever smokers;
CESC	cis	rs6750795	0.542	rs1797388	chr2:232415981	T/G	cg19187155	chr2:232395269	NMUR1	0.65	11.47	0.58	5.35e-25	Height;
CESC	cis	rs1552244	0.816	rs56387520	chr3:10042782	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.74	-9.42	-0.5	2.37e-18	Alzheimer's disease;
CESC	cis	rs875971	0.898	rs6977501	chr7:65693342	T/C	cg10691866	chr7:65817282	TPST1	0.34	5.78	0.33	2.13e-8	Aortic root size;
CESC	cis	rs9457247	1.000	rs9457247	chr6:167392174	C/T	cg23791538	chr6:167370224	RNASET2	-0.6	-8.65	-0.47	4.96e-16	Crohn's disease;
CESC	cis	rs941873	0.772	rs7920127	chr10:81122914	T/C	cg09469691	chr10:81107165	PPIF	0.54	7.25	0.41	4.69e-12	Height;
CESC	trans	rs73568641	0.583	rs1892360	chr6:154111701	T/C	cg08374472	chr16:87445639	ZCCHC14	-0.48	-6.3	-0.36	1.2e-9	Methadone dose in opioid dependence;
CESC	trans	rs748404	0.631	rs7166812	chr15:43644760	T/C	cg24053811	chr14:70265306	SLC10A1	0.42	6.03	0.35	5.35e-9	Lung cancer;
CESC	cis	rs9303401	0.646	rs7217845	chr17:57236900	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.56	7.2	0.4	6.32e-12	Cognitive test performance;
CESC	cis	rs7584330	0.737	rs11886117	chr2:238361650	A/T	cg14458575	chr2:238380390	NA	0.54	7.55	0.42	7.05e-13	Prostate cancer;
CESC	cis	rs9733	0.596	rs72702556	chr1:150680115	C/T	cg18016565	chr1:150552671	MCL1	0.34	5.35	0.31	1.93e-7	Tonsillectomy;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg27194998	chr19:47217554	PRKD2	-0.47	-6.38	-0.36	7.66e-10	Fibrinogen levels;
CESC	cis	rs17376456	0.877	rs10059230	chr5:93450347	A/G	cg21475434	chr5:93447410	FAM172A	0.82	7.56	0.42	6.81e-13	Diabetic retinopathy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09845709	chr7:23571490	TRA2A	0.56	6.64	0.38	1.82e-10	Gut microbiome composition (summer);
CESC	cis	rs4851870	1.000	rs4851870	chr2:106437256	C/T	cg16077055	chr2:106428750	NCK2	-0.39	-5.1	-0.3	6.56e-7	Addiction;
CESC	cis	rs7666738	0.830	rs34870112	chr4:99045815	T/G	cg24818145	chr4:99064322	C4orf37	0.38	5.04	0.3	8.49e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2836974	0.897	rs1541102	chr21:40628765	C/T	cg11890956	chr21:40555474	PSMG1	1.19	21.95	0.8	1.5e-61	Cognitive function;
CESC	cis	rs10885582	0.809	rs10885579	chr10:116304958	C/T	cg17056676	chr10:116301354	ABLIM1	-0.29	-5.3	-0.31	2.4e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs731174	0.802	rs6426030	chr1:38188195	A/G	cg12339802	chr1:38156545	C1orf109	-0.58	-5.92	-0.34	9.96e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs4253772	0.591	rs6007748	chr22:46657798	A/G	cg24881330	chr22:46731750	TRMU	0.88	9.72	0.51	2.74e-19	LDL cholesterol;Cholesterol, total;
CESC	cis	rs17711722	0.701	rs55773927	chr7:65337902	T/C	cg14393609	chr7:65229607	NA	0.52	6.98	0.39	2.42e-11	Calcium levels;
CESC	cis	rs561341	1.000	rs2470267	chr17:30274132	G/A	cg12193833	chr17:30244370	NA	-0.61	-6.2	-0.36	2.19e-9	Hip circumference adjusted for BMI;
CESC	cis	rs796364	1.000	rs166845	chr2:200823360	T/A	cg23649088	chr2:200775458	C2orf69	0.55	5.33	0.31	2.14e-7	Schizophrenia;
CESC	cis	rs9902453	0.808	rs78154346	chr17:28169493	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	8.37	0.46	3.33e-15	Coffee consumption (cups per day);
CESC	cis	rs56235845	0.694	rs4976643	chr5:176760227	A/C	cg16006841	chr5:176797999	RGS14	0.46	5.62	0.33	4.82e-8	Hemoglobin concentration;Hematocrit;
CESC	trans	rs12339966	0.689	rs2821210	chr9:11680111	G/A	cg03904639	chr13:37677730	CSNK1A1L	0.39	5.99	0.35	6.65e-9	Systolic blood pressure;
CESC	cis	rs2777491	0.957	rs919961	chr15:41651721	A/G	cg02330683	chr15:41787940	ITPKA	0.42	6.24	0.36	1.7e-9	Ulcerative colitis;
CESC	cis	rs6674176	0.569	rs11210935	chr1:44369444	G/A	cg13606994	chr1:44402422	ARTN	-0.36	-5.22	-0.31	3.57e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg08270031	chr1:180472207	ACBD6	-0.45	-6.43	-0.37	5.92e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs4474465	0.920	rs10751291	chr11:78217687	T/C	cg01578073	chr11:78285783	NARS2	-0.46	-5.06	-0.3	7.99e-7	Alzheimer's disease (survival time);
CESC	cis	rs12681288	0.550	rs4410933	chr8:959581	A/G	cg04851639	chr8:1020857	NA	-0.29	-5.88	-0.34	1.2e-8	Schizophrenia;
CESC	cis	rs4900538	0.963	rs1885708	chr14:102960164	A/G	cg18135206	chr14:102964638	TECPR2	0.84	11.4	0.57	9.37e-25	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	cis	rs7044106	0.708	rs2416760	chr9:123374639	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.82	13.16	0.63	9.03e-31	Hip circumference adjusted for BMI;
CESC	cis	rs1218582	0.682	rs12144978	chr1:154850445	G/A	cg06221963	chr1:154839813	KCNN3	-0.65	-10.66	-0.55	2.59e-22	Prostate cancer;
CESC	cis	rs1832871	0.672	rs9457361	chr6:158771750	G/A	cg07165851	chr6:158734300	TULP4	0.58	6.19	0.36	2.31e-9	Height;
CESC	cis	rs34779708	0.966	rs57081218	chr10:35434608	A/G	cg04310649	chr10:35416472	CREM	-0.55	-6.64	-0.38	1.72e-10	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs10911232	0.507	rs4652763	chr1:182994084	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.84	13.19	0.63	6.74e-31	Hypertriglyceridemia;
CESC	cis	rs4819052	0.851	rs8126930	chr21:46671715	A/G	cg11663144	chr21:46675770	NA	-0.5	-7.83	-0.43	1.17e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs17376456	0.877	rs55832164	chr5:93436579	C/T	cg25358565	chr5:93447407	FAM172A	1.14	11.29	0.57	2.12e-24	Diabetic retinopathy;
CESC	cis	rs7618915	0.547	rs34173654	chr3:52634605	T/C	cg17372223	chr3:52568218	NT5DC2	0.43	6.39	0.37	7.25e-10	Bipolar disorder;
CESC	cis	rs3741151	0.686	rs7114376	chr11:73227361	T/C	cg17517138	chr11:73019481	ARHGEF17	0.58	5.16	0.3	4.76e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs698833	0.892	rs698831	chr2:44731117	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.48	5.59	0.32	5.61e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs11249608	0.511	rs58827878	chr5:178481936	C/G	cg21905437	chr5:178450457	ZNF879	0.51	6.52	0.37	3.48e-10	Pubertal anthropometrics;
CESC	cis	rs736408	0.511	rs12637632	chr3:52708073	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	7.31	0.41	3.09e-12	Bipolar disorder;
CESC	cis	rs9309473	0.528	rs11898362	chr2:73565293	G/A	cg20560298	chr2:73613845	ALMS1	-0.47	-6.45	-0.37	5.34e-10	Metabolite levels;
CESC	cis	rs2841277	0.708	rs4465542	chr14:105407798	A/G	cg17340268	chr14:105411764	AHNAK2	-0.49	-6.51	-0.37	3.84e-10	Rheumatoid arthritis;
CESC	cis	rs60871478	0.636	rs12534606	chr7:895928	A/G	cg05535760	chr7:792225	HEATR2	-0.78	-8.24	-0.45	8.16e-15	Cerebrospinal P-tau181p levels;
CESC	cis	rs1801251	0.963	rs13011298	chr2:233612996	A/G	cg08000102	chr2:233561755	GIGYF2	0.65	9.33	0.5	4.51e-18	Coronary artery disease;
CESC	cis	rs8031584	1.000	rs35239376	chr15:31290538	A/C	cg08109568	chr15:31115862	NA	-0.71	-8.86	-0.48	1.22e-16	Huntington's disease progression;
CESC	cis	rs9811920	0.809	rs796976	chr3:99621002	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.46	7.72	0.43	2.44e-13	Axial length;
CESC	cis	rs7666738	0.830	rs13144771	chr4:99026935	G/C	cg05340658	chr4:99064831	C4orf37	0.83	13.1	0.63	1.43e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs947211	0.948	rs12565968	chr1:205755046	A/G	cg14159672	chr1:205819179	PM20D1	-0.39	-5.13	-0.3	5.51e-7	Parkinson's disease;
CESC	trans	rs875971	0.964	rs11765965	chr7:65842221	A/G	cg26939375	chr7:64535504	NA	0.47	6.06	0.35	4.66e-9	Aortic root size;
CESC	cis	rs6439153	0.933	rs6799008	chr3:128717387	G/T	cg25356066	chr3:128598488	ACAD9	0.54	7.0	0.4	2.1e-11	Pneumococcal bacteremia;
CESC	cis	rs3820928	1.000	rs2163041	chr2:227772480	T/C	cg11843606	chr2:227700838	RHBDD1	-0.43	-5.74	-0.33	2.55e-8	Pulmonary function;
CESC	cis	rs9611565	0.681	rs5751094	chr22:41803279	C/T	cg03806693	chr22:41940476	POLR3H	1.04	12.37	0.61	4.76e-28	Vitiligo;
CESC	cis	rs2882667	0.858	rs11957527	chr5:138404895	T/C	cg04439458	chr5:138467593	SIL1	-0.37	-5.84	-0.34	1.53e-8	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs1348850	0.914	rs4893823	chr2:178285811	C/T	cg22681709	chr2:178499509	PDE11A	0.4	5.9	0.34	1.13e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs4973397	0.810	rs12993290	chr2:232279687	G/A	cg09339159	chr2:232260559	B3GNT7	0.6	5.95	0.34	8.45e-9	Anti-saccade response;
CESC	cis	rs7100689	0.646	rs9804236	chr10:82135100	T/C	cg00277334	chr10:82204260	NA	-0.57	-7.51	-0.42	9.08e-13	Post bronchodilator FEV1;
CESC	cis	rs664172	1	rs664172	chr15:78862762	G/A	cg24631222	chr15:78858424	CHRNA5	0.81	10.41	0.54	1.7e-21	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs2842992	0.830	rs2025189	chr6:160137518	C/T	cg11366901	chr6:160182831	ACAT2	0.84	11.06	0.56	1.28e-23	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs2836950	0.545	rs1888489	chr21:40533164	T/C	cg11890956	chr21:40555474	PSMG1	-0.67	-9.62	-0.51	5.62e-19	Menarche (age at onset);
CESC	cis	rs17376456	1.000	rs35184505	chr5:93561535	A/G	cg21475434	chr5:93447410	FAM172A	0.83	7.06	0.4	1.43e-11	Diabetic retinopathy;
CESC	cis	rs2734839	0.927	rs2734837	chr11:113286829	C/T	cg14159747	chr11:113255604	NA	0.3	5.4	0.31	1.52e-7	Information processing speed;
CESC	cis	rs10754283	0.967	rs7519971	chr1:90108743	G/A	cg21401794	chr1:90099060	LRRC8C	0.69	9.34	0.5	4.06e-18	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg22535103	chr8:58192502	C8orf71	-0.93	-10.39	-0.54	1.89e-21	Developmental language disorder (linguistic errors);
CESC	cis	rs4665809	0.938	rs6742226	chr2:26342537	A/G	cg26314531	chr2:26401878	FAM59B	-0.59	-6.64	-0.38	1.79e-10	Gut microbiome composition (summer);
CESC	cis	rs2228479	0.717	rs17226274	chr16:89850170	C/T	cg04013166	chr16:89971882	TCF25	0.78	7.26	0.41	4.33e-12	Skin colour saturation;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09969776	chr17:507582	VPS53	-0.63	-7.48	-0.42	1.1e-12	Gut microbiome composition (summer);
CESC	cis	rs6089584	0.566	rs11699442	chr20:60623268	A/G	cg24733560	chr20:60626293	TAF4	0.46	6.77	0.38	8.09e-11	Body mass index;
CESC	trans	rs7513165	0.935	rs4951316	chr1:204161490	C/T	cg04123578	chr16:4368124	NA	-0.36	-6.03	-0.35	5.35e-9	Psychosis proneness (hypomanic personality scale);Psychosis proneness (hypomanic personality scale and perceptual aberration scale);Psychosis proneness (hypomanic personality scale and revised social anhedonia scale);Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale);
CESC	cis	rs7264396	0.563	rs2425079	chr20:34298191	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.63	6.7	0.38	1.23e-10	Total cholesterol levels;
CESC	cis	rs12048904	0.964	rs17123467	chr1:101331760	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.51	6.52	0.37	3.5e-10	Multiple sclerosis;
CESC	cis	rs7949030	0.596	rs11231138	chr11:62316195	C/G	cg13298116	chr11:62369859	EML3;MTA2	0.63	9.16	0.49	1.42e-17	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs3785574	0.962	rs2247435	chr17:61892862	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.8	10.54	0.54	6.22e-22	Height;
CESC	cis	rs12478296	0.901	rs59477854	chr2:243015490	T/C	cg06360820	chr2:242988706	NA	-0.78	-9.65	-0.51	4.35e-19	Obesity-related traits;
CESC	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg17372223	chr3:52568218	NT5DC2	0.56	9.5	0.5	1.27e-18	Electroencephalogram traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25220428	chr6:19144084	NA	-0.55	-6.65	-0.38	1.63e-10	Gut microbiome composition (summer);
CESC	cis	rs6912958	0.559	rs446851	chr6:88043640	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.46	8.01	0.44	3.68e-14	Monocyte percentage of white cells;
CESC	cis	rs11122272	0.735	rs910824	chr1:231498773	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.55	-7.61	-0.42	4.76e-13	Hemoglobin concentration;
CESC	cis	rs4568518	0.619	rs6946266	chr7:18007588	G/C	cg03009463	chr7:17980271	SNX13	0.45	5.96	0.34	7.95e-9	Measles;
CESC	cis	rs9393777	0.513	rs13190754	chr6:26587406	G/A	cg12826209	chr6:26865740	GUSBL1	0.77	9.25	0.49	7.72e-18	Intelligence (multi-trait analysis);
CESC	cis	rs116095464	0.867	rs10061296	chr5:312253	G/A	cg12570787	chr5:219185	SDHA;CCDC127	0.62	5.04	0.3	8.7e-7	Breast cancer;
CESC	cis	rs2878628	0.596	rs57039206	chr3:52758570	T/A	cg18404041	chr3:52824283	ITIH1	-0.4	-6.81	-0.39	6.39e-11	Intelligence (multi-trait analysis);
CESC	cis	rs4665809	0.590	rs3792007	chr2:26497541	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.1	12.44	0.61	2.67e-28	Gut microbiome composition (summer);
CESC	cis	rs4423214	0.959	rs11606611	chr11:71164046	C/G	cg05163923	chr11:71159392	DHCR7	0.76	10.16	0.53	1.05e-20	Vitamin D levels;
CESC	cis	rs12145833	0.538	rs10926977	chr1:243411367	T/G	cg02356786	chr1:243265016	LOC731275	0.77	6.16	0.35	2.75e-9	Obesity (early onset extreme);
CESC	cis	rs7267979	1.000	rs2258884	chr20:25279539	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	18.72	0.75	2.09e-50	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7659604	0.676	rs6534323	chr4:122695888	G/A	cg06713675	chr4:122721982	EXOSC9	-0.42	-5.98	-0.34	7.1e-9	Type 2 diabetes;
CESC	cis	rs9908102	0.710	rs7211164	chr17:12917212	C/T	cg26162695	chr17:12921313	ELAC2	0.55	5.9	0.34	1.12e-8	Schizophrenia;
CESC	trans	rs561341	1.000	rs55736640	chr17:30333848	G/A	cg27661571	chr11:113659931	NA	-0.86	-7.61	-0.42	4.78e-13	Hip circumference adjusted for BMI;
CESC	cis	rs7927771	0.725	rs11039265	chr11:47523214	C/A	cg20135002	chr11:47629003	NA	-0.39	-5.03	-0.3	9.2e-7	Subjective well-being;
CESC	cis	rs7666738	0.830	rs10856936	chr4:99011319	T/C	cg03467027	chr4:99064603	C4orf37	0.44	5.52	0.32	7.98e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg04234412	chr22:24373322	LOC391322	-0.54	-7.66	-0.43	3.43e-13	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs798766	0.953	rs13123646	chr4:1740539	T/C	cg07041428	chr4:1763019	NA	-0.4	-5.67	-0.33	3.75e-8	Bladder cancer;Urinary bladder cancer;
CESC	cis	rs10504229	1.000	rs56344560	chr8:58180626	C/G	cg05313129	chr8:58192883	C8orf71	-0.48	-5.62	-0.33	4.83e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs897984	0.609	rs732172	chr16:31050033	C/T	cg02466173	chr16:30829666	NA	-0.42	-7.29	-0.41	3.49e-12	Dementia with Lewy bodies;
CESC	trans	rs17607347	0.542	rs8048181	chr16:72687065	C/T	cg19883748	chr14:71905595	NA	-0.4	-6.01	-0.35	6.14e-9	Intelligence (multi-trait analysis);
CESC	cis	rs59918340	0.728	rs10112337	chr8:142233573	A/G	cg16341495	chr8:142228727	SLC45A4	0.42	5.19	0.3	4.24e-7	Immature fraction of reticulocytes;
CESC	trans	rs61931739	0.927	rs1906135	chr12:34038103	C/A	cg26384229	chr12:38710491	ALG10B	-0.46	-6.16	-0.35	2.75e-9	Morning vs. evening chronotype;
CESC	cis	rs9303401	0.659	rs36093395	chr17:56957357	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.01	12.45	0.61	2.57e-28	Cognitive test performance;
CESC	cis	rs9300255	0.602	rs1790095	chr12:123681222	G/A	cg19016782	chr12:123741754	C12orf65	-0.44	-6.19	-0.36	2.33e-9	Neutrophil percentage of white cells;
CESC	cis	rs7927592	0.763	rs10896340	chr11:68312645	A/G	cg20283391	chr11:68216788	NA	0.43	5.38	0.31	1.67e-7	Total body bone mineral density;
CESC	cis	rs514406	0.893	rs476108	chr1:53317351	C/T	cg25767906	chr1:53392781	SCP2	-0.46	-6.03	-0.35	5.48e-9	Monocyte count;
CESC	cis	rs2243480	0.901	rs778693	chr7:65872345	T/G	cg12463550	chr7:65579703	CRCP	0.71	5.49	0.32	9.37e-8	Diabetic kidney disease;
CESC	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg17541715	chr7:1216824	NA	-0.38	-5.16	-0.3	4.91e-7	Longevity;Endometriosis;
CESC	trans	rs9987353	0.840	rs329994	chr8:9123233	A/G	cg06077741	chr3:43121458	C3orf39	0.47	6.03	0.35	5.35e-9	Recombination measurement;
CESC	cis	rs3008870	0.651	rs2815376	chr1:67508531	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.42	5.33	0.31	2.12e-7	Lymphocyte percentage of white cells;
CESC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg15830682	chr1:6298637	NA	-0.49	-6.35	-0.36	9.27e-10	Breast cancer;
CESC	cis	rs1215050	0.791	rs2658477	chr4:98850993	G/A	cg05340658	chr4:99064831	C4orf37	-0.5	-6.63	-0.38	1.92e-10	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs12049330	0.673	rs1608916	chr1:110055806	A/T	cg05049280	chr1:110155535	GNAT2	0.59	6.46	0.37	5.01e-10	Major depressive disorder;
CESC	cis	rs3733585	0.648	rs13103497	chr4:9979262	A/G	cg02734326	chr4:10020555	SLC2A9	0.43	6.1	0.35	3.83e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs1005277	0.505	rs7917943	chr10:38195811	T/A	cg00409905	chr10:38381863	ZNF37A	0.56	7.82	0.43	1.28e-13	Extrinsic epigenetic age acceleration;
CESC	cis	rs62064224	0.553	rs9915115	chr17:30684858	A/G	cg18200150	chr17:30822561	MYO1D	0.39	5.15	0.3	5.14e-7	Schizophrenia;
CESC	cis	rs10905065	0.930	rs10737012	chr10:5746686	G/A	cg11519256	chr10:5708881	ASB13	0.43	5.62	0.33	4.93e-8	Menopause (age at onset);
CESC	cis	rs853679	0.517	rs1904840	chr6:28108232	C/T	cg12963246	chr6:28129442	ZNF389	0.57	7.67	0.43	3.36e-13	Depression;
CESC	cis	rs8114671	0.836	rs62213676	chr20:33612676	T/A	cg06115741	chr20:33292138	TP53INP2	-0.44	-5.29	-0.31	2.53e-7	Height;
CESC	cis	rs2637266	0.967	rs4581393	chr10:78376123	A/C	cg18941641	chr10:78392320	NA	0.43	8.24	0.45	8.17e-15	Pulmonary function;
CESC	cis	rs9487051	0.676	rs1608044	chr6:109594076	T/C	cg01475377	chr6:109611718	NA	-0.44	-6.93	-0.39	3.18e-11	Reticulocyte fraction of red cells;
CESC	cis	rs3733585	0.648	rs35954357	chr4:9978758	G/C	cg11266682	chr4:10021025	SLC2A9	0.56	10.36	0.54	2.41e-21	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs2249625	0.523	rs2463707	chr6:72861732	G/A	cg18830697	chr6:72922368	RIMS1	-0.42	-6.22	-0.36	1.92e-9	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CESC	cis	rs10883723	0.810	rs17782574	chr10:104279394	G/A	cg22532475	chr10:104410764	TRIM8	-0.34	-5.88	-0.34	1.23e-8	Allergic disease (asthma, hay fever or eczema);
CESC	trans	rs17635075	0.590	rs57971645	chr4:167156182	G/A	cg17369527	chr13:28366702	GSX1	-0.56	-6.21	-0.36	2.06e-9	Obesity-related traits;
CESC	cis	rs736801	0.754	rs2706336	chr5:131799961	T/C	cg21138405	chr5:131827807	IRF1	0.37	5.61	0.33	5.2100000000000003e-08	Breast cancer;Mosquito bite size;
CESC	cis	rs6005807	0.543	rs6005866	chr22:29162940	A/G	cg15103426	chr22:29168792	CCDC117	0.5	5.08	0.3	7.15e-7	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg18548263	chr11:66383669	RBM14	-0.41	-6.18	-0.35	2.39e-9	Gambling;
CESC	cis	rs7662987	0.517	rs1154405	chr4:100008750	G/A	cg12011299	chr4:100065546	ADH4	0.6	6.61	0.38	2.11e-10	Smoking initiation;
CESC	cis	rs7613875	0.580	rs6808044	chr3:50136165	A/G	cg24110177	chr3:50126178	RBM5	0.56	7.58	0.42	5.81e-13	Body mass index;
CESC	cis	rs10208940	0.841	rs6731066	chr2:68796618	A/G	cg12452813	chr2:68675892	NA	0.54	5.35	0.31	1.88e-7	Urate levels in lean individuals;
CESC	trans	rs10507274	1.000	rs10507274	chr12:117160976	C/T	cg05266345	chr17:16439350	NA	0.71	6.07	0.35	4.47e-9	Neuroticism;
CESC	cis	rs3820068	0.705	rs59502343	chr1:15872617	T/C	cg17385448	chr1:15911702	AGMAT	0.36	5.66	0.33	3.96e-8	Systolic blood pressure;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15441230	chr15:44069583	ELL3	0.65	7.43	0.42	1.52e-12	Gut microbiome composition (summer);
CESC	cis	rs3768617	0.510	rs10911243	chr1:183075415	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.88	14.2	0.66	2.05e-34	Fuchs's corneal dystrophy;
CESC	cis	rs9911578	0.967	rs11079354	chr17:56594460	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	-0.41	-5.53	-0.32	7.63e-8	Intelligence (multi-trait analysis);
CESC	cis	rs916888	0.773	rs199451	chr17:44801784	G/A	cg17911788	chr17:44343683	NA	-0.62	-7.91	-0.44	7.07e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs616402	0.527	rs11584327	chr1:10578791	T/C	cg07384165	chr1:10488281	NA	-0.57	-8.34	-0.46	4.01e-15	Breast size;
CESC	cis	rs780096	0.526	rs1647267	chr2:27651054	A/T	cg22903471	chr2:27725779	GCKR	-0.52	-7.39	-0.41	1.88e-12	Total body bone mineral density;
CESC	cis	rs10885582	0.809	rs11196784	chr10:116305140	A/G	cg17056676	chr10:116301354	ABLIM1	-0.28	-5.11	-0.3	6.14e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs12541335	0.639	rs7003478	chr8:22201123	A/G	cg18135555	chr8:22132992	PIWIL2	0.24	5.3	0.31	2.47e-7	Hypertriglyceridemia;
CESC	cis	rs6429082	0.689	rs10925965	chr1:235708443	C/A	cg26050004	chr1:235667680	B3GALNT2	-0.49	-5.33	-0.31	2.14e-7	Adiposity;
CESC	cis	rs7666738	0.830	rs28451101	chr4:99001190	T/C	cg17366294	chr4:99064904	C4orf37	0.6	8.61	0.47	6.47e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs8077889	0.956	rs4793026	chr17:41850508	A/G	cg26893861	chr17:41843967	DUSP3	0.72	8.58	0.47	8.24e-16	Triglycerides;
CESC	cis	rs367615	0.679	rs4259216	chr5:108841817	A/G	cg17395555	chr5:108820864	NA	0.63	11.15	0.57	6.19e-24	Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs6499255	1.000	rs1139178	chr16:69781468	T/C	cg15192750	chr16:69999425	NA	0.45	5.52	0.32	8.26e-8	IgE levels;
CESC	cis	rs4713118	0.516	rs7739216	chr6:28079946	G/T	cg26335602	chr6:28129616	ZNF389	0.53	7.06	0.4	1.48e-11	Parkinson's disease;
CESC	cis	rs7551222	0.752	rs12130686	chr1:204554057	G/C	cg20240347	chr1:204465584	NA	-0.3	-6.02	-0.35	5.94e-9	Schizophrenia;
CESC	cis	rs7107174	1.000	rs4627115	chr11:78007873	T/G	cg02023728	chr11:77925099	USP35	0.5	6.69	0.38	1.33e-10	Testicular germ cell tumor;
CESC	cis	rs3008870	1.000	rs12132068	chr1:67451924	G/T	cg02640540	chr1:67518911	SLC35D1	-0.52	-5.59	-0.33	5.5e-8	Lymphocyte percentage of white cells;
CESC	cis	rs2191566	0.691	rs4803673	chr19:44584556	C/T	cg20607764	chr19:44506953	ZNF230	-0.42	-5.34	-0.31	2.03e-7	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs1050631	0.592	rs1789547	chr18:33725705	C/T	cg25426722	chr18:33708991	SLC39A6;ELP2	0.52	7.01	0.4	1.96e-11	Esophageal squamous cell cancer (length of survival);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10832168	chr17:61600389	KCNH6	0.59	6.26	0.36	1.52e-9	Gut microbiome composition (summer);
CESC	cis	rs703842	0.963	rs2291617	chr12:58166403	T/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.75	9.85	0.52	1.05e-19	Multiple sclerosis;
CESC	cis	rs9303401	0.659	rs34351230	chr17:56782555	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.03	12.82	0.62	1.31e-29	Cognitive test performance;
CESC	cis	rs9311474	0.508	rs6786043	chr3:52604861	A/G	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.33	5.99	0.35	6.83e-9	Electroencephalogram traits;
CESC	cis	rs17376456	0.877	rs10050465	chr5:93349963	C/A	cg21475434	chr5:93447410	FAM172A	0.79	6.98	0.39	2.39e-11	Diabetic retinopathy;
CESC	cis	rs3749237	1.000	rs6804655	chr3:49738945	C/T	cg03060546	chr3:49711283	APEH	0.64	7.42	0.41	1.59e-12	Resting heart rate;
CESC	cis	rs7949030	0.591	rs35156678	chr11:62369881	G/A	cg23462726	chr11:62437636	C11orf83;C11orf48	-0.42	-5.41	-0.32	1.37e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs2046867	0.818	rs17010184	chr3:72870242	A/T	cg25664220	chr3:72788482	NA	0.43	6.34	0.36	9.58e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CESC	cis	rs2304069	0.954	rs4705409	chr5:149414899	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.9	11.52	0.58	3.74e-25	HIV-1 control;
CESC	cis	rs7216064	1.000	rs62085992	chr17:65923083	T/A	cg07042672	chr17:66097459	LOC651250	-0.52	-5.35	-0.31	1.9e-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08898442	chr6:88183089	SLC35A1	0.6	7.0	0.4	2.14e-11	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19022476	chr8:145745884	LRRC14	-0.52	-6.17	-0.35	2.54e-9	Gut microbiome composition (summer);
CESC	cis	rs709400	0.643	rs11621777	chr14:104072090	A/G	cg12935359	chr14:103987150	CKB	-0.47	-6.02	-0.35	5.8e-9	Body mass index;
CESC	cis	rs911555	0.755	rs11620897	chr14:103944861	T/G	cg24130564	chr14:104152367	KLC1	-0.5	-6.58	-0.37	2.56e-10	Intelligence (multi-trait analysis);
CESC	trans	rs2623325	0.834	rs73134486	chr3:99129722	T/G	cg19595760	chr1:25948511	MAN1C1	-0.48	-6.28	-0.36	1.35e-9	Optic cup area;Vertical cup-disc ratio;
CESC	cis	rs863345	0.564	rs7540999	chr1:158504570	G/A	cg12129480	chr1:158549410	OR10X1	-0.34	-6.84	-0.39	5.41e-11	Pneumococcal bacteremia;
CESC	cis	rs7727544	0.636	rs2631365	chr5:131705949	T/C	cg07395648	chr5:131743802	NA	0.42	5.49	0.32	9.45e-8	Blood metabolite levels;
CESC	cis	rs875971	0.862	rs3926380	chr7:66080645	G/T	cg18876405	chr7:65276391	NA	-0.53	-7.2	-0.4	6.41e-12	Aortic root size;
CESC	cis	rs736408	0.509	rs13083798	chr3:52649748	A/G	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.38	7.36	0.41	2.29e-12	Bipolar disorder;
CESC	cis	rs11792861	0.962	rs3750452	chr9:111801353	T/C	cg13535736	chr9:111863775	C9orf5	-0.5	-6.58	-0.37	2.56e-10	Menarche (age at onset);
CESC	cis	rs8114671	0.967	rs6142324	chr20:33789043	C/T	cg06115741	chr20:33292138	TP53INP2	-0.42	-5.11	-0.3	6.06e-7	Height;
CESC	cis	rs1448094	0.817	rs7973694	chr12:86335589	A/G	cg02569458	chr12:86230093	RASSF9	0.46	6.43	0.37	5.95e-10	Major depressive disorder;
CESC	trans	rs61931739	0.500	rs11053066	chr12:34185318	G/A	cg13010199	chr12:38710504	ALG10B	0.48	5.99	0.35	6.66e-9	Morning vs. evening chronotype;
CESC	trans	rs17762452	1.000	rs2165888	chr17:2886122	A/G	cg20455774	chr4:1734371	TACC3	-0.46	-6.03	-0.35	5.56e-9	Lymphocyte counts;
CESC	cis	rs920590	0.758	rs35280191	chr8:19665214	A/C	cg01411142	chr8:19674711	INTS10	0.56	6.35	0.36	9.51e-10	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs6570726	0.577	rs403345	chr6:145845171	T/C	cg05347473	chr6:146136440	FBXO30	0.72	9.15	0.49	1.55e-17	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7070678	0.662	rs3780843	chr10:29818827	C/T	cg12329853	chr10:29834266	MIR604;SVIL	-0.4	-5.26	-0.31	3.03e-7	Platelet thrombus formation;
CESC	cis	rs72945132	0.882	rs113472486	chr11:70194945	C/G	cg00319359	chr11:70116639	PPFIA1	0.72	6.84	0.39	5.42e-11	Coronary artery disease;
CESC	cis	rs875971	0.545	rs73378304	chr7:65640747	G/A	cg11764359	chr7:65958608	NA	0.77	9.76	0.51	2.03e-19	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21205468	chr1:213031575	LQK1;FLVCR1	0.67	7.46	0.42	1.24e-12	Gut microbiome composition (summer);
CESC	cis	rs875971	0.862	rs1167390	chr7:65575893	G/A	cg11764359	chr7:65958608	NA	-0.79	-11.16	-0.57	5.72e-24	Aortic root size;
CESC	trans	rs11264799	0.636	rs6696922	chr1:157491322	G/A	cg00040427	chr19:14044197	PODNL1	-0.45	-6.21	-0.36	2.07e-9	IgA nephropathy;
CESC	cis	rs7177699	0.557	rs10083697	chr15:79124039	G/A	cg04896959	chr15:78267971	NA	0.32	5.04	0.3	8.74e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
CESC	cis	rs10504229	0.817	rs10504230	chr8:58197150	A/G	cg22535103	chr8:58192502	C8orf71	0.95	10.29	0.53	4.02e-21	Developmental language disorder (linguistic errors);
CESC	cis	rs2933343	0.729	rs813945	chr3:128660937	A/G	cg11901034	chr3:128598214	ACAD9	-0.36	-5.31	-0.31	2.33e-7	IgG glycosylation;
CESC	cis	rs9287719	0.649	rs10186984	chr2:10734192	C/G	cg00105475	chr2:10696890	NA	-0.4	-5.53	-0.32	7.86e-8	Prostate cancer;
CESC	cis	rs4243830	0.850	rs11122043	chr1:6580429	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.76	-8.3	-0.45	5.42e-15	Body mass index;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25951811	chr14:96858416	AK7	0.59	6.61	0.38	2.09e-10	Gut microbiome composition (summer);
CESC	cis	rs3126085	0.935	rs34188926	chr1:152293481	A/C	cg03465714	chr1:152285911	FLG	0.5	5.71	0.33	2.96e-8	Atopic dermatitis;
CESC	cis	rs7666738	0.830	rs17027058	chr4:98864671	G/A	cg03676636	chr4:99064102	C4orf37	0.34	5.12	0.3	5.86e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs875971	0.830	rs4718358	chr7:65973668	T/C	cg11764359	chr7:65958608	NA	0.96	15.41	0.69	1.05e-38	Aortic root size;
CESC	cis	rs67311347	0.544	rs2123998	chr3:40359005	C/G	cg09455208	chr3:40491958	NA	-0.39	-6.97	-0.39	2.51e-11	Renal cell carcinoma;
CESC	cis	rs9549367	0.577	rs3024711	chr13:113813268	A/G	cg00898013	chr13:113819073	PROZ	-0.5	-6.26	-0.36	1.55e-9	Platelet distribution width;
CESC	cis	rs116095464	0.558	rs10052012	chr5:231908	T/C	cg12570787	chr5:219185	SDHA;CCDC127	0.52	5.43	0.32	1.3e-7	Breast cancer;
CESC	cis	rs7503807	1.000	rs12939613	chr17:78588202	A/G	cg09596252	chr17:78655493	RPTOR	0.45	6.42	0.37	6.33e-10	Obesity;
CESC	cis	rs3820928	0.845	rs4234065	chr2:227882006	C/T	cg05526886	chr2:227700861	RHBDD1	-0.43	-5.48	-0.32	9.75e-8	Pulmonary function;
CESC	cis	rs16854884	0.657	rs13086088	chr3:143723942	G/A	cg06585982	chr3:143692056	C3orf58	0.51	6.73	0.38	1.02e-10	Economic and political preferences (feminism/equality);
CESC	cis	rs2519796	0.531	rs2519106	chr9:136807283	C/A	cg13751417	chr9:136814406	VAV2	-0.43	-5.73	-0.33	2.71e-8	Hematocrit;Hemoglobin concentration;
CESC	cis	rs10504229	0.953	rs17805380	chr8:58171128	C/A	cg14926445	chr8:58193284	C8orf71	-0.51	-5.47	-0.32	1.03e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs116095464	0.558	rs6872854	chr5:209038	G/T	cg10591111	chr5:226296	SDHA	-0.49	-6.21	-0.36	2.04e-9	Breast cancer;
CESC	cis	rs9487051	0.773	rs351749	chr6:109533353	A/T	cg01475377	chr6:109611718	NA	-0.44	-6.76	-0.38	8.56e-11	Reticulocyte fraction of red cells;
CESC	cis	rs4689388	0.926	rs11732178	chr4:6292643	G/C	cg14416269	chr4:6271139	WFS1	0.47	7.85	0.43	1.03e-13	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs17021463	0.844	rs17311008	chr4:95274653	A/G	cg11021082	chr4:95130006	SMARCAD1	0.53	7.71	0.43	2.53e-13	Testicular germ cell tumor;
CESC	trans	rs116095464	0.614	rs78905930	chr5:246560	G/A	cg00938859	chr5:1591904	SDHAP3	0.68	7.4	0.41	1.81e-12	Breast cancer;
CESC	cis	rs4819052	0.807	rs28715237	chr21:46673768	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.76	10.12	0.53	1.49e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs2425143	1.000	rs11700256	chr20:34372941	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.79	-7.11	-0.4	1.05e-11	Blood protein levels;
CESC	cis	rs3892630	0.824	rs35700505	chr19:33325006	C/T	cg13157960	chr19:33183277	NUDT19	0.54	5.17	0.3	4.52e-7	Red blood cell traits;
CESC	cis	rs1348850	0.958	rs4893941	chr2:178269531	A/T	cg22681709	chr2:178499509	PDE11A	-0.43	-6.18	-0.35	2.44e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs853679	0.599	rs149990	chr6:27998258	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.7	-5.6	-0.33	5.38e-8	Depression;
CESC	cis	rs854765	0.583	rs62064158	chr17:17826935	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.57	8.18	0.45	1.22e-14	Total body bone mineral density;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg26069066	chr20:44044698	PIGT	-0.42	-6.5	-0.37	3.87e-10	Gambling;
CESC	trans	rs61869271	0.871	rs6585310	chr10:116732726	G/A	cg17463145	chr7:79084011	MAGI2	0.31	6.24	0.36	1.72e-9	Tonsillectomy;
CESC	cis	rs34779708	0.931	rs35997236	chr10:35376690	C/T	cg04310649	chr10:35416472	CREM	-0.51	-6.06	-0.35	4.62e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs3741404	0.825	rs11603538	chr11:63986713	C/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.87	12.55	0.61	1.13e-28	Platelet count;
CESC	cis	rs9908102	0.637	rs8078508	chr17:12910523	G/A	cg26162695	chr17:12921313	ELAC2	0.52	5.71	0.33	3.04e-8	Schizophrenia;
CESC	trans	rs11098499	0.722	rs1814814	chr4:120258124	C/G	cg25214090	chr10:38739885	LOC399744	0.63	9.07	0.49	2.67e-17	Corneal astigmatism;
CESC	trans	rs2727020	0.656	rs7925524	chr11:49437542	G/A	cg15704280	chr7:45808275	SEPT13	-0.8	-10.4	-0.54	1.81e-21	Coronary artery disease;
CESC	cis	rs9649213	0.593	rs1076272	chr7:98031005	C/G	cg24562669	chr7:97807699	LMTK2	0.53	7.91	0.44	7.11e-14	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg18402987	chr7:1209562	NA	0.75	7.58	0.42	5.97e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs35306767	0.903	rs34270014	chr10:904666	T/C	cg20503657	chr10:835505	NA	0.76	7.51	0.42	8.89e-13	Eosinophil percentage of granulocytes;
CESC	trans	rs10463316	0.894	rs6579864	chr5:150762181	G/A	cg24389359	chr12:111284228	CCDC63	-0.33	-6.02	-0.35	5.68e-9	Metabolite levels (Pyroglutamine);
CESC	cis	rs933688	1.000	rs12655973	chr5:90736537	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.1	13.74	0.64	8.47e-33	Smoking behavior;
CESC	cis	rs9487051	0.714	rs7774390	chr6:109602461	C/G	cg12927641	chr6:109611667	NA	0.36	5.39	0.31	1.59e-7	Reticulocyte fraction of red cells;
CESC	cis	rs6915183	0.967	rs4504454	chr6:166706424	G/A	cg14022523	chr6:166756177	SFT2D1	0.54	7.18	0.4	6.82e-12	Longevity;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04876072	chr3:48594239	PFKFB4	0.56	6.6	0.38	2.27e-10	Gut microbiome composition (summer);
CESC	trans	rs877282	0.898	rs12358513	chr10:757571	A/G	cg22713356	chr15:30763199	NA	1.06	9.18	0.49	1.24e-17	Uric acid levels;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg12506373	chr2:27440548	CAD	0.5	6.81	0.39	6.48e-11	Systemic lupus erythematosus;
CESC	cis	rs17253792	0.822	rs75509578	chr14:56133493	G/A	cg01858014	chr14:56050164	KTN1	-0.86	-7.2	-0.4	6.37e-12	Putamen volume;
CESC	cis	rs2315504	0.605	rs2469816	chr17:39005954	C/T	cg05063374	chr17:38953512	KRT28	0.37	5.06	0.3	7.97e-7	Height;
CESC	cis	rs7851660	0.809	rs1561961	chr9:100667599	C/T	cg13688889	chr9:100608707	NA	-0.62	-8.72	-0.47	3.08e-16	Strep throat;
CESC	cis	rs113835537	0.529	rs116867234	chr11:66209024	C/T	cg24851651	chr11:66362959	CCS	0.53	6.31	0.36	1.19e-9	Airway imaging phenotypes;
CESC	trans	rs9325144	0.671	rs35817541	chr12:38975001	T/C	cg23762105	chr12:34175262	ALG10	0.48	6.41	0.37	6.48e-10	Morning vs. evening chronotype;
CESC	cis	rs6674176	0.628	rs4660758	chr1:44424879	A/C	cg13606994	chr1:44402422	ARTN	-0.37	-5.57	-0.32	6.41e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11636702	chr4:11370466	MIR572	-0.56	-6.95	-0.39	2.9e-11	Gut microbiome composition (summer);
CESC	cis	rs9733	0.566	rs112967224	chr1:150677263	G/A	cg17724175	chr1:150552817	MCL1	0.44	7.21	0.41	5.76e-12	Tonsillectomy;
CESC	cis	rs35110281	0.811	rs9980185	chr21:45057905	A/G	cg21573476	chr21:45109991	RRP1B	-0.49	-6.59	-0.38	2.32e-10	Mean corpuscular volume;
CESC	cis	rs892961	0.932	rs11658267	chr17:75411884	C/T	cg05865280	chr17:75406074	SEPT9	-0.6	-12.57	-0.61	9.64e-29	Airflow obstruction;
CESC	cis	rs6662572	0.737	rs10890356	chr1:46317924	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.44	-5.04	-0.3	8.65e-7	Blood protein levels;
CESC	cis	rs7149242	1.000	rs7149242	chr14:101159416	G/T	cg18089426	chr14:101175970	NA	0.35	5.67	0.33	3.79e-8	Platelet count;
CESC	cis	rs7584330	0.554	rs77194105	chr2:238436463	T/C	cg14458575	chr2:238380390	NA	0.73	6.61	0.38	2.09e-10	Prostate cancer;
CESC	trans	rs7837860	0.588	rs7011035	chr8:89299708	T/G	cg04391754	chr17:18022714	MYO15A	0.53	6.14	0.35	2.98e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs10463316	0.894	rs4099168	chr5:150766467	A/G	cg03212797	chr5:150827313	SLC36A1	-0.47	-6.2	-0.36	2.17e-9	Metabolite levels (Pyroglutamine);
CESC	cis	rs763121	0.925	rs4821815	chr22:39105707	G/A	cg14440974	chr22:39074834	NA	-0.36	-5.23	-0.31	3.41e-7	Menopause (age at onset);
CESC	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg01238044	chr22:24384105	GSTT1	-0.68	-8.96	-0.48	5.89e-17	Liver enzyme levels (gamma-glutamyl transferase);
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg04811502	chr14:21979673	METTL3	-0.44	-6.15	-0.35	2.87e-9	Asthma;
CESC	cis	rs10206020	0.921	rs72776302	chr2:1571383	G/A	cg12573674	chr2:1569213	NA	-0.47	-5.35	-0.31	1.93e-7	IgG glycosylation;
CESC	cis	rs6964587	1.000	rs926192	chr7:91671853	C/A	cg17063962	chr7:91808500	NA	0.56	7.79	0.43	1.53e-13	Breast cancer;
CESC	cis	rs34779708	0.931	rs4934533	chr10:35359619	A/G	cg04310649	chr10:35416472	CREM	-0.53	-6.43	-0.37	5.94e-10	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs9910055	0.529	rs228757	chr17:42164885	G/C	cg19774624	chr17:42201019	HDAC5	0.53	7.1	0.4	1.17e-11	Total body bone mineral density;
CESC	cis	rs4927850	0.958	rs1975582	chr3:195751439	G/T	cg01181863	chr3:195395398	SDHAP2	-0.47	-5.53	-0.32	7.83e-8	Pancreatic cancer;
CESC	cis	rs514406	0.505	rs6688064	chr1:53165609	C/T	cg24675658	chr1:53192096	ZYG11B	-0.54	-6.68	-0.38	1.41e-10	Monocyte count;
CESC	cis	rs1957429	0.614	rs7144637	chr14:65349709	A/G	cg23373153	chr14:65346875	NA	-0.9	-6.61	-0.38	2.11e-10	Pediatric areal bone mineral density (radius);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01249072	chr7:66147992	NA	-0.54	-6.66	-0.38	1.6e-10	Gut microbiome composition (summer);
CESC	cis	rs7208859	0.673	rs11652370	chr17:29097223	G/A	cg19761014	chr17:28927070	LRRC37B2	0.69	6.76	0.38	8.6e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs11867934	0.532	rs4399589	chr17:17114586	A/G	cg20098446	chr17:17120238	FLCN	0.35	5.41	0.32	1.43e-7	Diabetic retinopathy;
CESC	cis	rs595982	0.527	rs56021835	chr19:49369989	G/A	cg15549821	chr19:49342101	PLEKHA4	-0.68	-7.26	-0.41	4.3e-12	Red cell distribution width;
CESC	cis	rs3008870	1.000	rs2985825	chr1:67412822	T/G	cg08660285	chr1:67390436	MIER1;WDR78	1.04	14.57	0.67	9.76e-36	Lymphocyte percentage of white cells;
CESC	cis	rs2120019	0.938	rs3850093	chr15:75318482	A/G	cg09165964	chr15:75287851	SCAMP5	0.79	9.41	0.5	2.58e-18	Blood trace element (Zn levels);
CESC	cis	rs10752881	0.967	rs4652758	chr1:182975100	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.83	13.33	0.63	2.34e-31	Colorectal cancer;
CESC	cis	rs7914558	1.000	rs8139	chr10:104848123	G/A	cg04362960	chr10:104952993	NT5C2	0.48	6.3	0.36	1.22e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs9581857	0.579	rs76614377	chr13:27974251	A/T	cg01674679	chr13:27998804	GTF3A	-0.7	-5.54	-0.32	7.13e-8	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg00243897	chr12:122326549	PSMD9	-0.45	-6.16	-0.35	2.68e-9	Fibrinogen levels;
CESC	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg19536664	chr17:6899085	ALOX12	0.4	9.0	0.48	4.55e-17	Tonsillectomy;
CESC	cis	rs11122272	0.766	rs2790871	chr1:231543555	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.59	-7.97	-0.44	4.66e-14	Hemoglobin concentration;
CESC	cis	rs9303401	0.538	rs2240259	chr17:56458129	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.95	10.93	0.56	3.46e-23	Cognitive test performance;
CESC	cis	rs2836974	0.965	rs8131126	chr21:40655754	A/G	cg11890956	chr21:40555474	PSMG1	1.14	18.64	0.75	3.94e-50	Cognitive function;
CESC	cis	rs7044106	0.762	rs7849566	chr9:123460769	A/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.33	5.1	0.3	6.52e-7	Hip circumference adjusted for BMI;
CESC	trans	rs4596713	0.508	rs4076287	chr9:71755333	A/G	cg16512924	chr15:28394682	HERC2	0.49	6.3	0.36	1.25e-9	Headache;
CESC	cis	rs5753618	0.583	rs5753639	chr22:31870400	A/G	cg02404636	chr22:31891804	SFI1	-0.43	-6.01	-0.35	5.96e-9	Colorectal cancer;
CESC	cis	rs35570576	0.585	rs7216806	chr17:77538517	C/T	cg05749138	chr17:77536956	NA	-0.36	-5.08	-0.3	7.19e-7	Photic sneeze reflex;
CESC	cis	rs7208859	0.673	rs73277978	chr17:29191449	A/G	cg19761014	chr17:28927070	LRRC37B2	0.72	5.71	0.33	3.06e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs7666738	0.606	rs28625338	chr4:99076996	A/G	cg17366294	chr4:99064904	C4orf37	0.45	6.03	0.35	5.39e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs763014	0.931	rs10903017	chr16:627920	T/C	cg07343612	chr16:622815	PIGQ	-0.58	-8.47	-0.46	1.72e-15	Height;
CESC	cis	rs2072499	0.966	rs2842857	chr1:156168736	T/C	cg24450063	chr1:156163899	SLC25A44	1.09	23.41	0.82	1.83e-66	Testicular germ cell tumor;
CESC	cis	rs3733585	0.699	rs6449158	chr4:9960459	T/C	cg00071950	chr4:10020882	SLC2A9	-0.73	-11.83	-0.59	3.28e-26	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs1957429	0.901	rs7141985	chr14:65345670	C/T	cg23373153	chr14:65346875	NA	1.1	11.51	0.58	4.02e-25	Pediatric areal bone mineral density (radius);
CESC	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-1.11	-22.58	-0.81	1.05e-63	Prudent dietary pattern;
CESC	cis	rs6921919	0.583	rs9468355	chr6:28341877	A/G	cg21251018	chr6:28226885	NKAPL	0.31	5.35	0.31	1.93e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs6540559	0.543	rs672819	chr1:210436404	T/A	cg21951975	chr1:209979733	IRF6	0.48	6.03	0.35	5.59e-9	Cleft lip with or without cleft palate;
CESC	cis	rs17655565	1.000	rs2276399	chr12:52705269	G/A	cg08257133	chr12:52711352	KRT83	0.51	6.34	0.36	9.61e-10	Plasma amyloid beta peptide concentrations (ABx-42);
CESC	cis	rs9916302	0.768	rs11078900	chr17:37614641	C/T	cg07936489	chr17:37558343	FBXL20	-0.82	-12.22	-0.6	1.6e-27	Glomerular filtration rate (creatinine);
CESC	cis	rs902774	0.554	rs4919749	chr12:53358034	C/T	cg25025879	chr12:53359317	NA	-0.53	-7.01	-0.4	1.99e-11	Prostate cancer;
CESC	cis	rs5769765	0.955	rs9616204	chr22:50303530	T/C	cg02269571	chr22:50332266	NA	-0.56	-6.92	-0.39	3.35e-11	Schizophrenia;
CESC	cis	rs875971	0.505	rs6955582	chr7:65431686	A/G	cg05332525	chr7:65337924	VKORC1L1	0.49	6.13	0.35	3.2e-9	Aortic root size;
CESC	cis	rs67311347	1.000	rs951560	chr3:40463471	A/G	cg09455208	chr3:40491958	NA	0.44	7.57	0.42	6.1e-13	Renal cell carcinoma;
CESC	cis	rs780096	0.587	rs6743819	chr2:27567407	G/T	cg02592271	chr2:27665507	KRTCAP3	-0.3	-6.24	-0.36	1.77e-9	Total body bone mineral density;
CESC	cis	rs3087591	1.000	rs2905800	chr17:29531980	A/G	cg24425628	chr17:29625626	OMG;NF1	0.44	5.5	0.32	9.13e-8	Hip circumference;
CESC	cis	rs920590	0.684	rs59259846	chr8:19669468	C/G	cg17834443	chr8:19674713	INTS10	0.59	6.53	0.37	3.35e-10	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs270601	0.721	rs270621	chr5:131605821	C/A	cg18758796	chr5:131593413	PDLIM4	0.46	6.17	0.35	2.55e-9	Acylcarnitine levels;
CESC	cis	rs9911578	0.967	rs11079368	chr17:57086473	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.39	-5.06	-0.3	7.78e-7	Intelligence (multi-trait analysis);
CESC	cis	rs710216	0.912	rs11537640	chr1:43424519	T/G	cg22176566	chr1:43424700	SLC2A1	0.48	5.34	0.31	1.96e-7	Red cell distribution width;
CESC	cis	rs6089584	0.853	rs1740367	chr20:60574834	C/T	cg24733560	chr20:60626293	TAF4	0.42	5.62	0.33	4.76e-8	Body mass index;
CESC	cis	rs12477438	0.765	rs10193039	chr2:99692373	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.65	-9.04	-0.49	3.32e-17	Chronic sinus infection;
CESC	cis	rs9487051	0.802	rs6910696	chr6:109592329	A/T	cg21918786	chr6:109611834	NA	-0.4	-6.14	-0.35	3.02e-9	Reticulocyte fraction of red cells;
CESC	cis	rs698833	0.852	rs2241870	chr2:44549204	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.58	7.33	0.41	2.8e-12	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs938554	0.779	rs11735831	chr4:9951591	G/A	cg00071950	chr4:10020882	SLC2A9	-0.5	-5.82	-0.34	1.7e-8	Blood metabolite levels;
CESC	cis	rs9467711	0.720	rs9348716	chr6:26375658	G/A	cg14345882	chr6:26364793	BTN3A2	0.61	6.06	0.35	4.73e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs477895	0.629	rs7130030	chr11:63933733	T/G	cg04317338	chr11:64019027	PLCB3	0.88	9.12	0.49	1.91e-17	Mean platelet volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22333016	chr4:54244258	FIP1L1	0.61	7.08	0.4	1.27e-11	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20708961	chr19:22235256	ZNF257	-0.5	-6.24	-0.36	1.68e-9	Gut microbiome composition (summer);
CESC	trans	rs9858542	0.953	rs6446272	chr3:49463287	G/A	cg21659725	chr3:3221576	CRBN	-0.55	-6.52	-0.37	3.63e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs6740322	0.843	rs6727237	chr2:43562000	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.58	-6.39	-0.37	7.6e-10	Coronary artery disease;
CESC	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg24101359	chr6:42928495	GNMT	0.57	8.29	0.45	5.87e-15	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs1799949	1.000	rs11655505	chr17:41278377	G/A	cg23758822	chr17:41437982	NA	1.02	15.6	0.69	2.35e-39	Menopause (age at onset);
CESC	cis	rs2742417	0.603	rs2742370	chr3:45782098	T/C	cg04837898	chr3:45731254	SACM1L	-0.45	-5.8	-0.34	1.86e-8	Response to anti-depressant treatment in major depressive disorder;
CESC	cis	rs875971	0.756	rs2901210	chr7:66017505	G/A	cg18252515	chr7:66147081	NA	0.45	5.9	0.34	1.09e-8	Aortic root size;
CESC	cis	rs2380220	0.640	rs9320386	chr6:95994955	T/C	cg04719120	chr6:96025338	MANEA	0.55	5.4	0.32	1.45e-7	Behavioural disinhibition (generation interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02063551	chr15:75315956	PPCDC	0.58	6.14	0.35	2.96e-9	Gut microbiome composition (summer);
CESC	cis	rs6952808	0.595	rs3800916	chr7:2166072	C/T	cg02951883	chr7:2050386	MAD1L1	-0.45	-5.78	-0.33	2.06e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs8141529	0.732	rs11556025	chr22:29168755	T/C	cg15103426	chr22:29168792	CCDC117	0.7	9.76	0.51	1.98e-19	Lymphocyte counts;
CESC	cis	rs644148	0.836	rs2686770	chr19:44998773	A/G	cg15540054	chr19:45004280	ZNF180	-0.62	-6.7	-0.38	1.23e-10	Personality dimensions;
CESC	trans	rs9858542	0.953	rs11713474	chr3:49611457	A/G	cg21659725	chr3:3221576	CRBN	-0.52	-6.4	-0.37	6.83e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs9911578	0.967	rs6416932	chr17:57148991	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.4	5.16	0.3	4.9e-7	Intelligence (multi-trait analysis);
CESC	cis	rs6860806	0.603	rs112300250	chr5:131583292	G/A	cg22638593	chr5:131593259	PDLIM4	0.4	5.33	0.31	2.11e-7	Breast cancer;
CESC	cis	rs9394931	1.000	rs9394931	chr6:42873245	C/T	cg21280719	chr6:42927975	GNMT	0.27	5.87	0.34	1.33e-8	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid);
CESC	cis	rs3820068	0.608	rs6668919	chr1:16049893	A/G	cg18133145	chr1:16060689	PLEKHM2	0.41	5.17	0.3	4.54e-7	Systolic blood pressure;
CESC	cis	rs9902453	0.769	rs7210288	chr17:28243473	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.65	8.2	0.45	1.05e-14	Coffee consumption (cups per day);
CESC	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg06873352	chr17:61820015	STRADA	0.72	12.76	0.62	2.21e-29	Prudent dietary pattern;
CESC	cis	rs722599	0.683	rs8008475	chr14:75291900	C/T	cg11812906	chr14:75593930	NEK9	0.45	5.53	0.32	7.6e-8	IgG glycosylation;
CESC	trans	rs7307889	0.793	rs73047640	chr12:6008290	C/T	cg18407955	chr7:158110685	PTPRN2	-0.73	-6.28	-0.36	1.38e-9	Obesity-related traits;
CESC	cis	rs137699	0.687	rs4821887	chr22:39756985	C/T	cg05872129	chr22:39784769	NA	-0.63	-7.43	-0.42	1.51e-12	IgG glycosylation;
CESC	cis	rs6430585	0.583	rs2304370	chr2:136561735	G/A	cg07169764	chr2:136633963	MCM6	1.21	16.81	0.72	1.18e-43	Corneal structure;
CESC	cis	rs6674176	0.696	rs4448553	chr1:44411589	A/G	cg12908607	chr1:44402522	ARTN	-0.47	-6.92	-0.39	3.43e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs9486719	0.843	rs2103539	chr6:96844342	T/A	cg06623918	chr6:96969491	KIAA0776	0.78	7.39	0.41	1.89e-12	Migraine;Coronary artery disease;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg07450219	chr17:78428858	NA	-0.49	-6.08	-0.35	4.09e-9	Ulcerative colitis;
CESC	trans	rs6089829	0.925	rs11086152	chr20:61664656	T/C	cg23505145	chr19:12996616	KLF1	0.52	6.74	0.38	1e-10	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs60843830	1.000	rs62114548	chr2:274672	C/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.67	8.28	0.45	6.1e-15	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs11997175	0.546	rs11775414	chr8:33615826	A/G	ch.8.33884649F	chr8:33765107	NA	0.57	7.35	0.41	2.5e-12	Body mass index;
CESC	cis	rs4891159	0.548	rs2554830	chr18:74127702	A/G	cg24786174	chr18:74118243	ZNF516	0.84	15.89	0.7	2.23e-40	Longevity;
CESC	cis	rs13242816	1.000	rs62471202	chr7:116112562	G/A	cg04696780	chr7:116139425	CAV2	-0.58	-5.2	-0.3	4.08e-7	P wave duration;
CESC	cis	rs8014204	0.901	rs4899536	chr14:75316614	A/G	cg11812906	chr14:75593930	NEK9	-0.44	-5.48	-0.32	9.97e-8	Caffeine consumption;
CESC	trans	rs4349753	0.640	rs72804497	chr5:144083142	C/A	cg22407458	chr6:35109121	TCP11	0.5	6.31	0.36	1.18e-9	Photic sneeze reflex;
CESC	cis	rs13253111	1.000	rs62500888	chr8:28061823	A/G	cg26534493	chr8:28060551	NA	0.61	10.67	0.55	2.46e-22	Childhood body mass index;
CESC	cis	rs7100689	0.646	rs10887808	chr10:82137367	G/A	cg00277334	chr10:82204260	NA	-0.57	-7.51	-0.42	9.08e-13	Post bronchodilator FEV1;
CESC	cis	rs4727027	0.901	rs1534198	chr7:148772323	T/C	cg23158103	chr7:148848205	ZNF398	-0.41	-6.55	-0.37	2.9e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs12478296	1.000	rs12478296	chr2:243048760	A/G	cg06360820	chr2:242988706	NA	0.66	7.68	0.43	3.06e-13	Obesity-related traits;
CESC	cis	rs11677370	0.561	rs11687254	chr2:3830906	C/T	cg17052675	chr2:3827356	NA	-0.48	-6.22	-0.36	1.96e-9	Type 2 diabetes;
CESC	cis	rs9611565	0.500	rs10775759	chr22:42088158	T/C	cg06634786	chr22:41940651	POLR3H	0.6	6.18	0.35	2.39e-9	Vitiligo;
CESC	cis	rs7607369	0.536	rs12694443	chr2:219664977	G/T	cg02176678	chr2:219576539	TTLL4	-0.36	-6.44	-0.37	5.62e-10	Red blood cell count;Amyotrophic lateral sclerosis;
CESC	cis	rs910316	0.737	rs175080	chr14:75513828	G/A	cg08847533	chr14:75593920	NEK9	-0.89	-15.41	-0.69	1.09e-38	Height;
CESC	cis	rs9479482	1.000	rs9479482	chr6:150358012	T/C	cg03788504	chr6:150331562	NA	-0.38	-7.22	-0.41	5.37e-12	Alopecia areata;
CESC	cis	rs62158211	1.000	rs1807282	chr2:114110036	A/T	cg17784749	chr2:114082611	LOC440839	0.72	7.82	0.43	1.22e-13	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;
CESC	cis	rs2439831	1.000	rs550239	chr15:43720197	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.82	12.0	0.59	8.48e-27	Lung cancer in ever smokers;
CESC	cis	rs9303401	0.659	rs17822908	chr17:56801778	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.05	12.77	0.62	1.94e-29	Cognitive test performance;
CESC	cis	rs7116495	1.000	rs675185	chr11:71775572	T/G	cg10381502	chr11:71823885	C11orf51	-0.67	-5.66	-0.33	3.92e-8	Severe influenza A (H1N1) infection;
CESC	cis	rs4594175	0.962	rs4254242	chr14:51599184	A/C	cg23942311	chr14:51606299	NA	0.37	5.4	0.31	1.48e-7	Cancer;
CESC	cis	rs4728302	0.838	rs6974143	chr7:133603550	G/A	cg10665199	chr7:133106180	EXOC4	0.4	5.56	0.32	6.62e-8	Intelligence;Intelligence (multi-trait analysis);
CESC	cis	rs262150	0.579	rs4909110	chr7:158787332	C/T	cg23096020	chr7:158799433	NA	0.47	5.23	0.31	3.49e-7	Facial morphology (factor 20);
CESC	cis	rs1152591	1.000	rs1152591	chr14:64680848	A/G	cg21174375	chr14:64681225	SYNE2	0.47	6.27	0.36	1.45e-9	Atrial fibrillation;
CESC	cis	rs17095355	0.901	rs10884919	chr10:111757791	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.52	-5.99	-0.35	6.73e-9	Biliary atresia;
CESC	cis	rs2415984	0.600	rs2415958	chr14:46806262	C/G	cg14871534	chr14:47121158	RPL10L	-0.34	-5.06	-0.3	7.86e-7	Number of children ever born;
CESC	cis	rs9443645	0.901	rs2050662	chr6:79753073	G/C	cg05283184	chr6:79620031	NA	-0.44	-6.78	-0.38	7.67e-11	Intelligence (multi-trait analysis);
CESC	cis	rs8180040	0.764	rs62246375	chr3:47014464	G/A	cg27129171	chr3:47204927	SETD2	-0.66	-9.33	-0.5	4.26e-18	Colorectal cancer;
CESC	cis	rs9322193	0.923	rs10782317	chr6:150075047	C/T	cg04369109	chr6:150039330	LATS1	0.4	5.63	0.33	4.51e-8	Lung cancer;
CESC	cis	rs2797160	0.935	rs1739379	chr6:126012593	T/C	cg05901451	chr6:126070800	HEY2	0.46	6.56	0.37	2.81e-10	Endometrial cancer;
CESC	cis	rs7552404	1.000	rs4949879	chr1:76237143	G/A	cg03433033	chr1:76189801	ACADM	0.54	6.29	0.36	1.32e-9	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs9649213	0.574	rs3801251	chr7:98027618	T/C	cg24562669	chr7:97807699	LMTK2	0.53	7.91	0.44	7e-14	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs6142102	0.625	rs6142051	chr20:32533018	T/C	cg08999081	chr20:33150536	PIGU	0.34	5.14	0.3	5.46e-7	Skin pigmentation;
CESC	cis	rs425277	1.000	rs74877653	chr1:2065949	C/T	cg04315214	chr1:2043799	PRKCZ	-0.42	-5.91	-0.34	1.04e-8	Height;
CESC	trans	rs801193	0.761	rs2659888	chr7:66230171	T/G	cg14393609	chr7:65229607	NA	0.47	6.38	0.36	7.64e-10	Aortic root size;
CESC	cis	rs8068544	0.748	rs75881902	chr17:40156612	C/A	cg18442075	chr17:40169520	DNAJC7;NKIRAS2	-0.94	-8.43	-0.46	2.27e-15	Reticulocyte fraction of red cells;Reticulocyte count;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg04917373	chr1:231489252	C1orf124	0.4	6.08	0.35	4.14e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs1975974	1.000	rs67946006	chr17:21723940	T/C	cg18423549	chr17:21743878	NA	-0.51	-7.12	-0.4	1.04e-11	Psoriasis;
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg16338035	chr3:143691269	C3orf58	-0.43	-6.12	-0.35	3.42e-9	Vertical cup-disc ratio;
CESC	cis	rs4819052	0.851	rs28622522	chr21:46676599	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.94	14.0	0.65	1.02e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs13256369	0.851	rs12541477	chr8:8563895	G/A	cg00074818	chr8:8560427	CLDN23	0.38	5.46	0.32	1.1e-7	Obesity-related traits;
CESC	cis	rs7542091	0.704	rs1108628	chr1:210041150	A/G	cg22029157	chr1:209979665	IRF6	0.49	7.58	0.42	5.79e-13	Monobrow;
CESC	cis	rs7246657	0.943	rs12709813	chr19:37844983	G/A	cg23950597	chr19:37808831	NA	-0.55	-6.09	-0.35	3.96e-9	Coronary artery calcification;
CESC	cis	rs12479064	0.671	rs62155807	chr2:100076579	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.59	-6.89	-0.39	4.07e-11	Chronic sinus infection;
CESC	cis	rs2637266	1.000	rs2637267	chr10:78331803	A/G	cg18941641	chr10:78392320	NA	0.41	7.47	0.42	1.18e-12	Pulmonary function;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07235652	chr12:109531354	ALKBH2	0.55	6.35	0.36	9.56e-10	Gut microbiome composition (summer);
CESC	cis	rs989128	0.600	rs2240218	chr17:48630580	A/T	cg24438145	chr17:48624694	SPATA20	0.45	5.31	0.31	2.36e-7	Type 2 diabetes;
CESC	cis	rs4434138	0.568	rs6414569	chr3:52708075	A/T	cg05564831	chr3:52568323	NT5DC2	0.44	6.89	0.39	4.16e-11	Intelligence (multi-trait analysis);
CESC	cis	rs8114671	0.804	rs6060139	chr20:33566499	T/C	cg07148914	chr20:33460835	GGT7	0.43	5.53	0.32	7.59e-8	Height;
CESC	cis	rs12477438	0.520	rs4402818	chr2:99717608	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.88	15.54	0.69	3.79e-39	Chronic sinus infection;
CESC	cis	rs7412746	0.658	rs17660092	chr1:150797748	T/C	cg22823121	chr1:150693482	HORMAD1	0.45	6.35	0.36	9.55e-10	Melanoma;
CESC	cis	rs116095464	0.558	rs6555058	chr5:226376	C/T	cg10591111	chr5:226296	SDHA	0.49	5.94	0.34	9.13e-9	Breast cancer;
CESC	trans	rs763361	1.000	rs1790947	chr18:67527760	A/C	cg09273779	chr9:35605990	TESK1	0.44	6.05	0.35	5e-9	Type 1 diabetes;
CESC	cis	rs7618915	0.547	rs11714419	chr3:52628816	A/G	cg07507251	chr3:52567010	NT5DC2	0.41	7.24	0.41	4.75e-12	Bipolar disorder;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg06440065	chr19:30206617	C19orf12	-0.53	-7.22	-0.41	5.67e-12	Thyroid stimulating hormone;
CESC	cis	rs9309473	1.000	rs6755217	chr2:73641285	C/T	cg20560298	chr2:73613845	ALMS1	-0.55	-7.12	-0.4	1.02e-11	Metabolite levels;
CESC	cis	rs3806843	1.000	rs11167609	chr5:140200426	T/G	cg26395211	chr5:140044315	WDR55	-0.41	-5.13	-0.3	5.72e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs2952156	0.876	rs2313171	chr17:37833842	T/C	cg07936489	chr17:37558343	FBXL20	-0.61	-8.09	-0.44	2.2e-14	Asthma;
CESC	cis	rs801193	1.000	rs62466794	chr7:66191579	G/A	cg11764359	chr7:65958608	NA	0.71	9.39	0.5	2.85e-18	Aortic root size;
CESC	cis	rs514406	0.708	rs480299	chr1:53320274	G/T	cg16325326	chr1:53192061	ZYG11B	0.55	7.96	0.44	5e-14	Monocyte count;
CESC	cis	rs13242816	1.000	rs13247987	chr7:116113344	A/C	cg04696780	chr7:116139425	CAV2	-0.58	-5.2	-0.3	4.08e-7	P wave duration;
CESC	cis	rs875971	0.545	rs316324	chr7:65610614	A/G	cg18876405	chr7:65276391	NA	-0.51	-5.96	-0.34	8.21e-9	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26476595	chr16:2284284	E4F1	-0.56	-6.59	-0.38	2.32e-10	Gut microbiome composition (summer);
CESC	cis	rs8062405	1.000	rs7498555	chr16:28893571	T/C	cg05966235	chr16:28915196	ATP2A1	0.34	5.05	0.3	8.17e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	trans	rs11039798	0.588	rs10838970	chr11:48606267	G/T	cg15704280	chr7:45808275	SEPT13	0.61	6.29	0.36	1.32e-9	Axial length;
CESC	trans	rs17132261	0.661	rs80166325	chr5:109666675	C/T	cg14311597	chr17:2652531	MIR1253	-0.51	-6.06	-0.35	4.64e-9	Cardiac structure and function;Left ventricle wall thickness;
CESC	cis	rs1799949	1.000	rs8176233	chr17:41219804	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.66	9.08	0.49	2.51e-17	Menopause (age at onset);
CESC	cis	rs4665809	1.000	rs17040322	chr2:26351274	G/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.67	-7.53	-0.42	7.92e-13	Gut microbiome composition (summer);
CESC	cis	rs10754283	0.967	rs4658130	chr1:90113447	G/C	cg21401794	chr1:90099060	LRRC8C	0.69	9.34	0.5	4.06e-18	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs208520	0.874	rs208456	chr6:66907942	A/G	cg07460842	chr6:66804631	NA	-0.87	-10.33	-0.54	3.12e-21	Exhaled nitric oxide output;
CESC	cis	rs9611565	0.592	rs5751101	chr22:41828111	C/T	cg17376030	chr22:41985996	PMM1	-0.76	-8.01	-0.44	3.59e-14	Vitiligo;
CESC	cis	rs4950928	0.823	rs2486065	chr1:203167871	A/G	cg14085262	chr1:203155938	CHI3L1	-0.52	-5.68	-0.33	3.51e-8	YKL-40 levels;
CESC	cis	rs4888262	0.545	rs7184754	chr16:74667864	C/T	cg01733217	chr16:74700730	RFWD3	0.92	12.63	0.61	6.22e-29	Testicular germ cell tumor;
CESC	cis	rs13223928	0.651	rs4722435	chr7:3152962	C/T	cg19214707	chr7:3157722	NA	0.44	5.99	0.35	6.93e-9	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
CESC	cis	rs763121	0.819	rs138700	chr22:39129999	A/G	cg14440974	chr22:39074834	NA	-0.4	-5.61	-0.33	5.06e-8	Menopause (age at onset);
CESC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg06062125	chr4:76598767	G3BP2	-0.54	-6.42	-0.37	6.35e-10	Lung cancer in ever smokers;
CESC	cis	rs4819052	0.724	rs9753962	chr21:46661384	G/T	cg11663144	chr21:46675770	NA	-0.63	-10.02	-0.52	3.12e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs7680126	0.596	rs4637402	chr4:10045430	C/T	cg11266682	chr4:10021025	SLC2A9	0.53	7.0	0.39	2.14e-11	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	cis	rs1465370	0.692	rs2402996	chr7:130017003	C/T	cg04743876	chr7:130013617	NA	0.31	5.89	0.34	1.18e-8	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
CESC	cis	rs9814567	0.806	rs55835132	chr3:134325256	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.38	-5.06	-0.3	7.86e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs7914558	1.000	rs7920251	chr10:104950197	C/T	cg04362960	chr10:104952993	NT5C2	0.47	6.29	0.36	1.33e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs875971	0.862	rs4718377	chr7:66049678	C/T	cg11764359	chr7:65958608	NA	-0.78	-11.17	-0.57	5.37e-24	Aortic root size;
CESC	cis	rs854765	0.583	rs8070128	chr17:17804725	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.53	-7.38	-0.41	2.04e-12	Total body bone mineral density;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07065803	chr11:45921557	MAPK8IP1	0.52	6.0	0.35	6.38e-9	Gut microbiome composition (summer);
CESC	cis	rs3820928	1.000	rs4673173	chr2:227769493	A/C	cg05526886	chr2:227700861	RHBDD1	-0.44	-5.63	-0.33	4.63e-8	Pulmonary function;
CESC	trans	rs13098911	0.540	rs71615438	chr3:46039868	A/G	cg10236987	chr1:228114221	WNT9A	0.66	6.54	0.37	3.11e-10	Celiac disease;
CESC	cis	rs9611565	0.694	rs5758324	chr22:41787950	G/T	cg03806693	chr22:41940476	POLR3H	-0.79	-10.09	-0.53	1.81e-20	Vitiligo;
CESC	cis	rs853679	0.517	rs3757185	chr6:28107776	T/A	cg12963246	chr6:28129442	ZNF389	0.58	7.86	0.43	9.67e-14	Depression;
CESC	cis	rs2576037	0.562	rs9959877	chr18:44522293	T/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.48	-6.46	-0.37	5.03e-10	Personality dimensions;
CESC	cis	rs796364	0.616	rs2103094	chr2:200687954	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.55	5.06	0.3	7.93e-7	Schizophrenia;
CESC	cis	rs3749237	0.555	rs7637665	chr3:49552295	T/C	cg06212747	chr3:49208901	KLHDC8B	0.47	6.3	0.36	1.21e-9	Resting heart rate;
CESC	cis	rs7666738	0.830	rs7694889	chr4:98855596	T/C	cg05340658	chr4:99064831	C4orf37	0.74	10.7	0.55	1.97e-22	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7618915	0.547	rs11720432	chr3:52672742	T/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.36	6.45	0.37	5.14e-10	Bipolar disorder;
CESC	cis	rs72781680	1.000	rs56339200	chr2:24188194	C/A	cg20701182	chr2:24300061	SF3B14	0.64	5.74	0.33	2.56e-8	Lymphocyte counts;
CESC	cis	rs7216064	1.000	rs6504543	chr17:65837659	T/C	cg12091567	chr17:66097778	LOC651250	-0.81	-9.3	-0.5	5.41e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg26304593	chr6:42947056	PEX6	-0.43	-5.65	-0.33	4.24e-8	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs2050392	0.760	rs10826797	chr10:30690376	A/C	cg18806716	chr10:30721971	MAP3K8	-0.59	-8.82	-0.48	1.53e-16	Inflammatory bowel disease;
CESC	cis	rs17539620	0.624	rs62432735	chr6:154834055	T/C	cg20019720	chr6:154832845	CNKSR3	0.47	6.03	0.35	5.62e-9	Lipoprotein (a) levels;
CESC	trans	rs57221529	0.766	rs17563576	chr5:560476	A/G	cg25482853	chr8:67687455	SGK3	1.09	11.54	0.58	3.07e-25	Lung disease severity in cystic fibrosis;
CESC	trans	rs2749592	0.550	rs7081464	chr10:37883937	C/T	cg12057190	chr19:54976211	LENG9;CDC42EP5	-0.44	-6.35	-0.36	9.39e-10	Age-related hearing impairment (SNP x SNP interaction);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg26623551	chr16:14165028	MKL2	-0.51	-6.28	-0.36	1.38e-9	Ulcerative colitis;
CESC	cis	rs10088262	0.540	rs6988602	chr8:124788502	C/T	cg20713898	chr8:124780851	FAM91A1	0.58	7.11	0.4	1.09e-11	Pancreatic cancer;
CESC	cis	rs780096	0.526	rs780107	chr2:27684734	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.3	-5.57	-0.32	6.2e-8	Total body bone mineral density;
CESC	cis	rs2012796	0.956	rs6574646	chr14:81819809	A/G	cg02996355	chr14:81879375	NA	0.51	6.04	0.35	5.31e-9	Night sleep phenotypes;
CESC	cis	rs6741892	0.536	rs6761563	chr2:38891406	A/T	cg05604112	chr2:38893237	GALM	-0.55	-7.19	-0.4	6.65e-12	5-HTT brain serotonin transporter levels;
CESC	cis	rs10851478	0.872	rs10851479	chr15:49909741	C/T	cg08060515	chr15:49448048	GALK2;COPS2	0.43	5.26	0.31	3e-7	Oral cavity cancer;
CESC	cis	rs1401999	0.714	rs1533683	chr3:183635488	C/T	cg01324343	chr3:183735012	ABCC5	0.53	10.88	0.56	4.8e-23	Anterior chamber depth;
CESC	cis	rs9549260	0.755	rs2721071	chr13:41144507	G/A	cg21288729	chr13:41239152	FOXO1	0.67	8.54	0.46	1.07e-15	Red blood cell count;
CESC	cis	rs72829446	0.530	rs3853820	chr17:7396781	A/T	cg02795151	chr17:7402630	POLR2A	0.58	6.04	0.35	5.08e-9	Androgen levels;
CESC	cis	rs7216064	1.000	rs60432293	chr17:65860407	T/C	cg07042672	chr17:66097459	LOC651250	-0.57	-6.66	-0.38	1.55e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs5753618	0.539	rs1034588	chr22:31616301	A/G	cg13145458	chr22:31556086	RNF185	0.48	5.41	0.32	1.43e-7	Colorectal cancer;
CESC	cis	rs617791	0.530	rs55947178	chr11:65754230	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.38	-5.11	-0.3	6.15e-7	Breast cancer;
CESC	cis	rs3857536	0.776	rs4710316	chr6:66935097	T/A	cg07460842	chr6:66804631	NA	-0.42	-5.34	-0.31	1.96e-7	Blood trace element (Cu levels);
CESC	cis	rs7481584	0.581	rs399565	chr11:3061780	C/T	cg25174290	chr11:3078921	CARS	-0.51	-7.13	-0.4	9.46e-12	Calcium levels;
CESC	cis	rs2115630	0.691	rs2292462	chr15:85200754	G/T	cg12501888	chr15:85177176	SCAND2	-0.51	-6.8	-0.39	6.83e-11	P wave terminal force;
CESC	cis	rs11112613	0.653	rs59504344	chr12:105950837	C/T	cg03607813	chr12:105948248	NA	0.58	7.21	0.4	6.01e-12	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CESC	cis	rs7267979	1.000	rs884613	chr20:25288505	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.84	-16.13	-0.7	3.07e-41	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg07092213	chr7:1199455	ZFAND2A	-0.49	-5.3	-0.31	2.38e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7618915	0.547	rs13064064	chr3:52657002	T/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.29	5.18	0.3	4.42e-7	Bipolar disorder;
CESC	cis	rs7618915	0.571	rs6798246	chr3:52599922	G/A	cg07507251	chr3:52567010	NT5DC2	0.42	7.37	0.41	2.11e-12	Bipolar disorder;
CESC	cis	rs2228479	0.681	rs7199685	chr16:89959805	G/C	cg06558623	chr16:89946397	TCF25	0.55	5.52	0.32	7.88e-8	Skin colour saturation;
CESC	cis	rs4555082	0.874	rs28625632	chr14:105748849	G/T	cg06808227	chr14:105710500	BRF1	-0.55	-6.17	-0.35	2.56e-9	Mean platelet volume;Platelet distribution width;
CESC	cis	rs10504229	1.000	rs1961778	chr8:58168756	G/A	cg24829409	chr8:58192753	C8orf71	-0.75	-9.93	-0.52	5.93e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs5758511	0.596	rs55644935	chr22:42666069	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.57	8.62	0.47	6.07e-16	Birth weight;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg23358871	chr17:78121069	EIF4A3	0.43	6.0	0.35	6.35e-9	Systemic lupus erythematosus;
CESC	cis	rs12295403	0.964	rs61886869	chr11:18688508	C/T	cg09887367	chr11:18690185	NA	-0.39	-5.5	-0.32	8.85e-8	Ovarian reserve;
CESC	cis	rs7071206	0.947	rs4979905	chr10:79416367	C/T	cg07817648	chr10:79422355	NA	-0.87	-11.19	-0.57	4.47e-24	Bone mineral density;
CESC	cis	rs11696501	0.688	rs6094192	chr20:44297796	G/A	cg11783356	chr20:44313418	WFDC10B	-0.34	-5.29	-0.31	2.59e-7	Brain structure;
CESC	cis	rs2204008	0.837	rs11180482	chr12:38235950	G/A	cg13010199	chr12:38710504	ALG10B	0.49	6.1	0.35	3.78e-9	Bladder cancer;
CESC	cis	rs2836974	0.544	rs8128919	chr21:40711862	C/T	cg17971929	chr21:40555470	PSMG1	0.59	7.61	0.42	4.85e-13	Cognitive function;
CESC	cis	rs3960554	0.808	rs868555	chr7:75697418	G/A	cg17325771	chr7:75508891	RHBDD2	-0.35	-5.33	-0.31	2.07e-7	Eotaxin levels;
CESC	cis	rs7666738	0.753	rs7698541	chr4:98986351	T/A	cg05340658	chr4:99064831	C4orf37	0.8	12.42	0.61	3.31e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4704187	0.687	rs10051040	chr5:74501976	G/C	cg03227963	chr5:74354835	NA	0.29	5.27	0.31	2.77e-7	Response to amphetamines;
CESC	cis	rs7044106	0.791	rs735110	chr9:123488940	T/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.74	10.68	0.55	2.25e-22	Hip circumference adjusted for BMI;
CESC	trans	rs7246760	0.867	rs8102257	chr19:9830795	C/T	cg02900749	chr2:68251473	NA	-0.82	-7.4	-0.41	1.8e-12	Pursuit maintenance gain;
CESC	cis	rs9309473	0.519	rs2421545	chr2:73639476	T/C	cg20560298	chr2:73613845	ALMS1	0.49	7.05	0.4	1.52e-11	Metabolite levels;
CESC	trans	rs61931739	0.500	rs11053246	chr12:34516620	C/T	cg13010199	chr12:38710504	ALG10B	0.5	6.42	0.37	6.3e-10	Morning vs. evening chronotype;
CESC	cis	rs6933660	0.800	rs3800273	chr6:151759035	G/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.87	14.43	0.66	3.05e-35	Menarche (age at onset);
CESC	cis	rs748404	0.723	rs512431	chr15:43541939	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.52	-8.11	-0.45	1.86e-14	Lung cancer;
CESC	cis	rs4555082	0.874	rs2735828	chr14:105710486	C/A	cg10792982	chr14:105748885	BRF1	0.43	5.76	0.33	2.33e-8	Mean platelet volume;Platelet distribution width;
CESC	cis	rs780096	0.506	rs1728922	chr2:27644464	A/C	cg22903471	chr2:27725779	GCKR	-0.5	-7.16	-0.4	7.71e-12	Total body bone mineral density;
CESC	cis	rs17253792	0.822	rs10083431	chr14:56068348	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.77	5.98	0.34	7.23e-9	Putamen volume;
CESC	cis	rs6952808	0.717	rs12534679	chr7:1926745	G/A	cg02951883	chr7:2050386	MAD1L1	-0.41	-5.36	-0.31	1.82e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs710865	0.519	rs10753518	chr1:19483593	T/C	cg13387374	chr1:19411106	UBR4	0.52	6.96	0.39	2.65e-11	Brain structure;
CESC	cis	rs7666738	0.830	rs7672901	chr4:98938781	C/T	cg03467027	chr4:99064603	C4orf37	0.48	5.96	0.34	7.94e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7914558	0.966	rs7096269	chr10:104736721	A/G	cg15744005	chr10:104629667	AS3MT	-0.33	-5.23	-0.31	3.48e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs4974559	0.947	rs10018627	chr4:1356358	G/A	cg02980000	chr4:1222292	CTBP1	0.73	6.78	0.38	7.65e-11	Systolic blood pressure;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg24663397	chr14:55034535	SAMD4A	-0.48	-6.25	-0.36	1.6e-9	Fibrinogen levels;
CESC	cis	rs9910055	0.529	rs228765	chr17:42186422	C/T	cg19774624	chr17:42201019	HDAC5	0.58	7.84	0.43	1.07e-13	Total body bone mineral density;
CESC	cis	rs59918340	0.728	rs35257077	chr8:142235049	C/T	cg16341495	chr8:142228727	SLC45A4	0.42	5.06	0.3	7.7e-7	Immature fraction of reticulocytes;
CESC	cis	rs155076	0.938	rs536209	chr13:21847714	C/T	cg11317459	chr13:21872234	NA	-1.05	-11.58	-0.58	2.37e-25	White matter hyperintensity burden;
CESC	cis	rs7772486	0.754	rs9386133	chr6:146141213	A/G	cg23711669	chr6:146136114	FBXO30	0.87	12.78	0.62	1.84e-29	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2979489	0.891	rs2915594	chr8:30401367	T/C	cg26383811	chr8:30366931	RBPMS	-0.79	-9.91	-0.52	6.89e-20	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CESC	cis	rs13256369	1.000	rs883648	chr8:8569521	A/G	cg17143192	chr8:8559678	CLDN23	0.72	8.18	0.45	1.19e-14	Obesity-related traits;
CESC	cis	rs72781680	0.612	rs33913065	chr2:24344060	T/G	cg08917208	chr2:24149416	ATAD2B	0.57	5.52	0.32	8.27e-8	Lymphocyte counts;
CESC	cis	rs9297145	0.673	rs12531875	chr7:98724730	C/T	cg05967295	chr7:98741636	SMURF1	0.91	9.02	0.48	3.9e-17	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
CESC	cis	rs12477438	0.871	rs13396584	chr2:99611768	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.67	8.15	0.45	1.45e-14	Chronic sinus infection;
CESC	cis	rs1707322	0.682	rs3014241	chr1:46087879	A/G	cg06784218	chr1:46089804	CCDC17	-0.4	-6.94	-0.39	3.07e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs62432291	0.764	rs436743	chr6:159655102	A/G	cg14500486	chr6:159655392	FNDC1	-0.62	-6.21	-0.36	2.04e-9	Joint mobility (Beighton score);
CESC	cis	rs6445797	0.603	rs11706624	chr3:56584341	T/C	cg13792233	chr3:56591045	CCDC66	0.39	5.15	0.3	4.97e-7	Gastritis;
CESC	cis	rs7605827	0.930	rs918157	chr2:15657729	G/A	cg19274914	chr2:15703543	NA	0.37	6.65	0.38	1.65e-10	Educational attainment (years of education);
CESC	cis	rs425277	0.583	rs10910046	chr1:2041155	C/T	cg13918804	chr1:2043761	PRKCZ	0.27	5.18	0.3	4.31e-7	Height;
CESC	trans	rs11638815	0.954	rs11635442	chr15:83328542	C/G	cg25333056	chr10:135107159	TUBGCP2	-0.46	-6.0	-0.35	6.59e-9	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;
CESC	cis	rs597539	0.580	rs7935851	chr11:68731122	A/G	cg04772025	chr11:68637568	NA	0.49	5.62	0.33	4.92e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs372883	0.532	rs425989	chr21:30715275	T/C	cg24692254	chr21:30365293	RNF160	-0.48	-6.43	-0.37	6.02e-10	Pancreatic cancer;
CESC	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.93	13.79	0.65	5.71e-33	Prudent dietary pattern;
CESC	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg16132339	chr22:24313637	DDTL;DDT	0.39	5.92	0.34	9.84e-9	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs67311347	0.911	rs58282210	chr3:40417943	C/T	cg09455208	chr3:40491958	NA	0.52	8.88	0.48	1.01e-16	Renal cell carcinoma;
CESC	cis	rs7618915	0.501	rs7622694	chr3:52663882	G/A	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.36	6.58	0.37	2.5e-10	Bipolar disorder;
CESC	trans	rs2727020	0.595	rs10839286	chr11:49497063	C/A	cg15704280	chr7:45808275	SEPT13	-0.95	-16.98	-0.72	2.94e-44	Coronary artery disease;
CESC	cis	rs1799949	1.000	rs12944597	chr17:41187684	A/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.39	5.06	0.3	7.92e-7	Menopause (age at onset);
CESC	cis	rs6964587	0.626	rs6979235	chr7:91511776	T/C	cg17063962	chr7:91808500	NA	-0.45	-6.36	-0.36	9.03e-10	Breast cancer;
CESC	cis	rs1577917	1.000	rs1911553	chr6:86630892	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.42	-5.53	-0.32	7.75e-8	Response to antipsychotic treatment;
CESC	cis	rs8072100	0.935	rs78551919	chr17:45626002	A/C	cg08085267	chr17:45401833	C17orf57	0.46	6.12	0.35	3.37e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs1005277	0.579	rs2505197	chr10:38393310	T/C	cg25427524	chr10:38739819	LOC399744	-0.66	-9.5	-0.5	1.29e-18	Extrinsic epigenetic age acceleration;
CESC	cis	rs8014204	0.839	rs6574197	chr14:75331487	A/G	cg26191576	chr14:75389716	RPS6KL1	0.37	5.29	0.31	2.58e-7	Caffeine consumption;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg13910983	chr1:28241279	RPA2	-0.5	-7.19	-0.4	6.73e-12	Asthma;
CESC	cis	rs7666738	0.830	rs13102369	chr4:99045912	A/G	cg17366294	chr4:99064904	C4orf37	0.61	8.78	0.47	2.13e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs8018808	1.000	rs12101153	chr14:77863091	A/C	cg20045696	chr14:77926864	AHSA1	-0.43	-5.81	-0.34	1.82e-8	Myeloid white cell count;
CESC	cis	rs1728785	0.688	rs7203363	chr16:68587692	T/A	cg02972257	chr16:68554789	NA	-0.59	-6.69	-0.38	1.29e-10	Ulcerative colitis;
CESC	cis	rs780096	0.527	rs12471703	chr2:27738854	C/T	cg21248554	chr2:27665150	KRTCAP3	-0.37	-7.42	-0.41	1.64e-12	Total body bone mineral density;
CESC	cis	rs55728055	0.661	rs62237765	chr22:31956981	A/G	cg01338084	chr22:32026380	PISD	1.29	8.76	0.47	2.44e-16	Age-related hearing impairment;
CESC	cis	rs1008375	1.000	rs7659718	chr4:17638020	A/C	cg02297831	chr4:17616191	MED28	0.62	7.91	0.44	7.23e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs6502050	0.805	rs62078303	chr17:80085210	A/G	cg11859384	chr17:80120422	CCDC57	0.38	5.12	0.3	6.01e-7	Life satisfaction;
CESC	cis	rs8062405	0.573	rs7140	chr16:28995757	C/A	cg05966235	chr16:28915196	ATP2A1	-0.35	-5.04	-0.3	8.5e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs12530845	0.524	rs7795267	chr7:135308455	C/G	cg23117316	chr7:135346802	PL-5283	-0.52	-5.9	-0.34	1.1e-8	Red blood cell traits;
CESC	cis	rs910316	0.726	rs175040	chr14:75469555	A/G	cg08847533	chr14:75593920	NEK9	-0.9	-15.79	-0.7	4.7e-40	Height;
CESC	cis	rs9479482	1.000	rs9479405	chr6:150338065	G/A	cg03788504	chr6:150331562	NA	-0.36	-7.03	-0.4	1.8e-11	Alopecia areata;
CESC	cis	rs1218582	0.772	rs4845690	chr1:154886817	C/T	cg06221963	chr1:154839813	KCNN3	0.67	11.39	0.57	9.73e-25	Prostate cancer;
CESC	cis	rs116095464	0.558	rs10475136	chr5:232796	A/G	cg12570787	chr5:219185	SDHA;CCDC127	0.52	5.41	0.32	1.43e-7	Breast cancer;
CESC	cis	rs708547	0.874	rs1315006	chr4:57858193	C/T	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.6	-6.01	-0.35	6.09e-9	Response to bleomycin (chromatid breaks);
CESC	cis	rs72634258	0.519	rs36040967	chr1:7931804	A/G	cg00042356	chr1:8021962	PARK7	0.59	5.88	0.34	1.22e-8	Inflammatory bowel disease;
CESC	cis	rs17826219	0.500	rs28452421	chr17:29083980	G/A	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.91e-10	Body mass index;
CESC	cis	rs9322193	0.923	rs35961297	chr6:149989065	T/C	cg04369109	chr6:150039330	LATS1	-0.4	-5.51	-0.32	8.53e-8	Lung cancer;
CESC	cis	rs4803468	1.000	rs2241710	chr19:41912092	G/C	cg14132834	chr19:41945861	ATP5SL	-0.66	-8.12	-0.45	1.78e-14	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20962746	chr11:118436826	C11orf60	-0.59	-7.43	-0.42	1.48e-12	Gut microbiome composition (summer);
CESC	cis	rs11166927	1.000	rs10435690	chr8:140802093	C/T	cg16909799	chr8:140841666	TRAPPC9	0.55	8.27	0.45	6.75e-15	Pediatric non-alcoholic fatty liver disease activity score;
CESC	trans	rs11098499	0.866	rs12510451	chr4:120289143	C/T	cg25214090	chr10:38739885	LOC399744	0.65	9.11	0.49	2.04e-17	Corneal astigmatism;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg12169852	chr17:57231726	SKA2;PRR11	-0.43	-6.09	-0.35	3.88e-9	Asthma;
CESC	cis	rs1322639	0.614	rs6900964	chr6:169566763	A/G	cg03254818	chr6:169586852	NA	0.54	5.71	0.33	3.09e-8	Pulse pressure;
CESC	cis	rs7605827	0.930	rs12692263	chr2:15539206	G/A	cg19274914	chr2:15703543	NA	0.36	6.55	0.37	2.91e-10	Educational attainment (years of education);
CESC	cis	rs4713118	0.629	rs203888	chr6:28021589	C/T	cg23161317	chr6:28129485	ZNF389	0.44	5.72	0.33	2.86e-8	Parkinson's disease;
CESC	cis	rs2070433	0.539	rs1008549	chr21:47959698	C/T	cg12379764	chr21:47803548	PCNT	0.63	8.31	0.45	5.16e-15	Lymphocyte counts;
CESC	cis	rs7845219	0.544	rs4735331	chr8:95917958	C/T	cg13393036	chr8:95962371	TP53INP1	-0.42	-8.03	-0.44	3.25e-14	Type 2 diabetes;
CESC	cis	rs35306767	0.951	rs61833265	chr10:990143	C/T	cg25019033	chr10:957182	NA	-0.62	-6.92	-0.39	3.49e-11	Eosinophil percentage of granulocytes;
CESC	cis	rs1355223	0.525	rs7129517	chr11:34872236	A/C	cg11622362	chr11:34938112	PDHX;APIP	0.45	5.26	0.31	2.99e-7	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs2836974	0.644	rs11088472	chr21:40699376	A/C	cg11890956	chr21:40555474	PSMG1	-0.93	-14.9	-0.68	6.67e-37	Cognitive function;
CESC	cis	rs7666738	0.830	rs13138063	chr4:99050438	A/C	cg03676636	chr4:99064102	C4orf37	0.33	5.08	0.3	7.1e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1862618	0.853	rs832569	chr5:56154584	T/A	cg24549020	chr5:56110836	MAP3K1	0.68	7.64	0.43	3.9e-13	Initial pursuit acceleration;
CESC	cis	rs6736093	0.966	rs11692445	chr2:112704033	T/G	cg12686935	chr2:112915763	FBLN7	-0.42	-5.3	-0.31	2.49e-7	Coronary artery disease;
CESC	trans	rs7618501	0.633	rs6792892	chr3:49995518	T/C	cg21659725	chr3:3221576	CRBN	0.55	7.6	0.42	5.29e-13	Intelligence (multi-trait analysis);
CESC	cis	rs853679	0.517	rs9380056	chr6:28104476	C/T	cg23281280	chr6:28129359	ZNF389	0.59	8.16	0.45	1.34e-14	Depression;
CESC	cis	rs9322193	0.923	rs9322214	chr6:150025122	C/T	cg09699651	chr6:150184138	LRP11	0.41	5.13	0.3	5.62e-7	Lung cancer;
CESC	cis	rs2479106	0.854	rs4391495	chr9:126462986	G/C	cg16191174	chr9:126692580	DENND1A	0.47	6.39	0.37	7.36e-10	Polycystic ovary syndrome;
CESC	cis	rs2032447	0.670	rs198845	chr6:26107790	A/C	cg03264133	chr6:25882463	NA	-0.44	-6.42	-0.37	6.15e-10	Intelligence (multi-trait analysis);
CESC	cis	rs9549260	0.632	rs7323267	chr13:41204015	A/G	cg21288729	chr13:41239152	FOXO1	0.55	5.33	0.31	2.1e-7	Red blood cell count;
CESC	cis	rs6674176	1.000	rs6674176	chr1:44379957	G/A	cg13606994	chr1:44402422	ARTN	-0.4	-5.88	-0.34	1.2e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs9733	0.526	rs11204696	chr1:150658721	T/C	cg17724175	chr1:150552817	MCL1	0.45	7.33	0.41	2.84e-12	Tonsillectomy;
CESC	cis	rs72781680	0.898	rs72782136	chr2:24047344	A/G	cg08917208	chr2:24149416	ATAD2B	0.95	8.71	0.47	3.45e-16	Lymphocyte counts;
CESC	cis	rs7666738	0.830	rs62318503	chr4:98935479	T/C	cg05340658	chr4:99064831	C4orf37	0.82	12.54	0.61	1.29e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs72781680	0.528	rs56258075	chr2:24104256	C/G	cg20701182	chr2:24300061	SF3B14	0.64	5.82	0.34	1.73e-8	Lymphocyte counts;
CESC	cis	rs477895	0.653	rs11603212	chr11:63927810	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.86	-8.59	-0.47	7.5e-16	Mean platelet volume;
CESC	cis	rs1799949	1.000	rs12944430	chr17:41330820	C/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.38	5.04	0.3	8.73e-7	Menopause (age at onset);
CESC	cis	rs4595586	0.545	rs4768526	chr12:39402898	A/G	cg26384229	chr12:38710491	ALG10B	0.63	8.83	0.48	1.5e-16	Morning vs. evening chronotype;
CESC	cis	rs4604732	0.631	rs75320597	chr1:247626751	T/G	cg12758973	chr1:247694275	LOC148824;OR2C3	0.51	6.36	0.36	8.65e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs62229266	0.804	rs62230788	chr21:37380337	A/T	cg08632701	chr21:37451849	NA	-0.38	-5.07	-0.3	7.4e-7	Mitral valve prolapse;
CESC	cis	rs6831352	0.918	rs2851247	chr4:100046091	C/G	cg12011299	chr4:100065546	ADH4	-0.6	-6.46	-0.37	5.05e-10	Alcohol dependence;
CESC	cis	rs9486719	1.000	rs12205655	chr6:96891733	T/A	cg06623918	chr6:96969491	KIAA0776	-0.81	-8.29	-0.45	5.61e-15	Migraine;Coronary artery disease;
CESC	cis	rs798554	0.634	rs6978692	chr7:2857411	C/T	cg19717773	chr7:2847554	GNA12	-0.53	-8.48	-0.46	1.56e-15	Height;
CESC	cis	rs8044868	0.586	rs7200854	chr16:72083318	G/A	cg16558253	chr16:72132732	DHX38	-0.4	-6.32	-0.36	1.12e-9	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CESC	cis	rs875971	0.522	rs4718286	chr7:65292764	A/G	cg14393609	chr7:65229607	NA	0.52	6.97	0.39	2.47e-11	Aortic root size;
CESC	cis	rs34117943	1	rs34117943	chr16:68819642	C/CT	cg02972257	chr16:68554789	NA	0.45	5.22	0.31	3.62e-7	Mean corpuscular volume;
CESC	cis	rs4555082	0.874	rs2015978	chr14:105720134	G/C	cg27165867	chr14:105738592	BRF1	-0.51	-5.56	-0.32	6.63e-8	Mean platelet volume;Platelet distribution width;
CESC	cis	rs9583531	0.843	rs7999702	chr13:111382264	A/C	cg24331049	chr13:111365604	ING1	-0.75	-7.87	-0.44	8.93e-14	Coronary artery disease;
CESC	cis	rs7998202	0.561	rs442098	chr13:113353032	C/A	cg02820901	chr13:113351484	ATP11A	0.64	5.91	0.34	1.07e-8	Glycated hemoglobin levels;
CESC	cis	rs769267	0.965	rs2074550	chr19:19387743	A/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.57	7.2	0.4	6.13e-12	Tonsillectomy;
CESC	cis	rs858239	0.536	rs6961109	chr7:23252413	C/T	cg23682824	chr7:23144976	KLHL7	0.45	5.89	0.34	1.14e-8	Cerebrospinal fluid biomarker levels;
CESC	cis	rs7833790	1.000	rs7833790	chr8:82731157	T/C	cg17211192	chr8:82754475	SNX16	-0.65	-7.74	-0.43	2.1e-13	Diastolic blood pressure;
CESC	cis	rs929596	0.606	rs7604115	chr2:234658116	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.59	-7.32	-0.41	2.95e-12	Total bilirubin levels in HIV-1 infection;
CESC	cis	rs7618915	0.547	rs68021750	chr3:52624769	G/A	cg05564831	chr3:52568323	NT5DC2	0.45	6.97	0.39	2.55e-11	Bipolar disorder;
CESC	cis	rs950169	0.887	rs62029593	chr15:84955180	A/G	cg17507749	chr15:85114479	UBE2QP1	0.59	6.54	0.37	3.11e-10	Schizophrenia;
CESC	trans	rs7819412	0.668	rs4841507	chr8:11046394	C/G	cg15556689	chr8:8085844	FLJ10661	-0.47	-6.0	-0.35	6.4e-9	Triglycerides;
CESC	cis	rs668210	0.793	rs522553	chr11:65771669	T/C	cg02202077	chr11:65769826	EIF1AD;BANF1	0.68	7.46	0.42	1.26e-12	Cerebrospinal fluid biomarker levels;
CESC	cis	rs3091242	0.933	rs7541095	chr1:25761291	T/C	cg02931644	chr1:25747376	RHCE	0.39	6.56	0.37	2.87e-10	Erythrocyte sedimentation rate;
CESC	trans	rs12310956	0.532	rs7955514	chr12:33978737	G/A	cg26384229	chr12:38710491	ALG10B	0.58	8.12	0.45	1.8e-14	Morning vs. evening chronotype;
CESC	cis	rs9436116	1	rs9436116	chr1:150454724	G/T	cg09579323	chr1:150459698	TARS2	0.45	5.68	0.33	3.55e-8	Morning vs. evening chronotype;
CESC	trans	rs10489896	0.541	rs6682410	chr1:234570685	G/A	cg10395685	chr11:86085715	CCDC81	-0.42	-6.13	-0.35	3.19e-9	Cognitive test performance;
CESC	cis	rs11190604	1.000	rs10883501	chr10:102238326	A/G	cg07080220	chr10:102295463	HIF1AN	0.56	5.59	0.32	5.61e-8	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs936229	0.656	rs12898397	chr15:75130093	T/C	cg09165964	chr15:75287851	SCAMP5	0.47	6.38	0.36	7.92e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18231159	chr7:99214508	ZNF498	0.61	7.03	0.4	1.74e-11	Gut microbiome composition (summer);
CESC	cis	rs7618501	0.602	rs10049087	chr3:50123417	A/G	cg24308560	chr3:49941425	MST1R	0.6	8.61	0.47	6.53e-16	Intelligence (multi-trait analysis);
CESC	cis	rs2439831	1.000	rs2601014	chr15:43756013	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.8	9.89	0.52	7.9e-20	Lung cancer in ever smokers;
CESC	cis	rs9858542	0.951	rs1800668	chr3:49395757	G/A	cg03060546	chr3:49711283	APEH	-0.52	-5.96	-0.34	7.89e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.44	5.77	0.33	2.25e-8	Lymphocyte counts;
CESC	cis	rs6032067	0.852	rs6032064	chr20:43854827	A/G	cg10761708	chr20:43804764	PI3	0.5	6.15	0.35	2.83e-9	Blood protein levels;
CESC	cis	rs7615952	0.599	rs7652883	chr3:125707977	T/G	cg15145296	chr3:125709740	NA	-0.48	-5.25	-0.31	3.05e-7	Blood pressure (smoking interaction);
CESC	cis	rs1665050	0.534	rs35124643	chr15:59242001	A/G	cg05156742	chr15:59063176	FAM63B	0.49	6.19	0.36	2.33e-9	Atopic dermatitis;
CESC	cis	rs11608355	0.545	rs2302706	chr12:109894028	A/G	cg05360138	chr12:110035743	NA	0.82	8.92	0.48	7.93e-17	Neuroticism;
CESC	cis	rs9837602	1.000	rs9864437	chr3:99764754	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.54	7.56	0.42	6.43e-13	Breast cancer;
CESC	cis	rs7818345	0.967	rs4554480	chr8:19284072	G/A	cg11303988	chr8:19266685	CSGALNACT1	0.35	6.42	0.37	6.41e-10	Language performance in older adults (adjusted for episodic memory);
CESC	cis	rs3733585	0.648	rs13103497	chr4:9979262	A/G	cg00071950	chr4:10020882	SLC2A9	0.69	10.86	0.56	5.56e-23	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs6964587	0.773	rs12536421	chr7:92008220	A/G	cg17063962	chr7:91808500	NA	0.57	7.4	0.41	1.77e-12	Breast cancer;
CESC	cis	rs7116495	0.609	rs4944243	chr11:71674354	T/C	cg07596299	chr11:71824057	C11orf51	-0.83	-5.36	-0.31	1.8e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs7605827	0.897	rs34191114	chr2:15670691	C/A	cg19274914	chr2:15703543	NA	0.36	6.45	0.37	5.21e-10	Educational attainment (years of education);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg15260365	chr11:67771606	UNC93B1	-0.46	-6.72	-0.38	1.1e-10	Fibrinogen levels;
CESC	cis	rs1218582	0.600	rs72702224	chr1:154911689	G/A	cg06221963	chr1:154839813	KCNN3	-0.6	-9.5	-0.5	1.29e-18	Prostate cancer;
CESC	cis	rs2228479	0.681	rs62052184	chr16:89967217	T/C	cg06558623	chr16:89946397	TCF25	0.55	5.28	0.31	2.71e-7	Skin colour saturation;
CESC	cis	rs7818688	0.614	rs11783589	chr8:95845964	G/A	cg16049864	chr8:95962084	TP53INP1	0.52	5.48	0.32	9.71e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs7666738	0.723	rs35327100	chr4:98977788	C/A	cg17366294	chr4:99064904	C4orf37	0.59	8.43	0.46	2.31e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4253772	0.591	rs6007795	chr22:46686792	C/G	cg09491104	chr22:46646882	C22orf40	-0.63	-9.37	-0.5	3.4e-18	LDL cholesterol;Cholesterol, total;
CESC	cis	rs7618915	0.621	rs6788993	chr3:52605136	T/C	cg05564831	chr3:52568323	NT5DC2	0.47	7.48	0.42	1.08e-12	Bipolar disorder;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg25135259	chr10:115614956	NHLRC2;DCLRE1A	-0.48	-6.11	-0.35	3.56e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs561341	0.943	rs508566	chr17:30289861	G/C	cg12193833	chr17:30244370	NA	-0.75	-6.79	-0.38	7.44e-11	Hip circumference adjusted for BMI;
CESC	cis	rs6540559	0.673	rs4556361	chr1:210019654	C/G	cg23283495	chr1:209979779	IRF6	-0.44	-5.2	-0.3	4.05e-7	Cleft lip with or without cleft palate;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20021244	chr5:139944115	APBB3;SLC35A4	-0.63	-7.3	-0.41	3.36e-12	Gut microbiome composition (summer);
CESC	cis	rs1707322	0.721	rs4564187	chr1:46166861	G/C	cg06784218	chr1:46089804	CCDC17	0.43	7.58	0.42	5.65e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs76917914	0.820	rs7034147	chr9:100821691	T/G	cg03040243	chr9:100819229	NANS	0.48	5.38	0.31	1.65e-7	Immature fraction of reticulocytes;
CESC	cis	rs11677416	1.000	rs2856836	chr2:113532083	A/G	cg27083787	chr2:113543245	IL1A	0.59	7.34	0.41	2.58e-12	Response to antipsychotic treatment in schizophrenia (working memory);
CESC	cis	rs9926296	0.656	rs4522419	chr16:89853307	T/C	cg04287289	chr16:89883240	FANCA	0.63	7.98	0.44	4.52e-14	Vitiligo;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26488985	chr16:89584852	SPG7	-0.58	-7.02	-0.4	1.87e-11	Gut microbiome composition (summer);
CESC	cis	rs782590	0.818	rs2627765	chr2:55883317	G/T	cg18811423	chr2:55921094	PNPT1	0.77	12.26	0.6	1.09e-27	Metabolic syndrome;
CESC	cis	rs12701220	0.655	rs34696066	chr7:1140919	C/T	cg23978390	chr7:1156363	C7orf50	0.62	6.1	0.35	3.83e-9	Bronchopulmonary dysplasia;
CESC	cis	rs896854	0.625	rs13281709	chr8:95972819	T/A	cg13393036	chr8:95962371	TP53INP1	-0.48	-10.36	-0.54	2.51e-21	Type 2 diabetes;
CESC	cis	rs597539	0.652	rs646586	chr11:68681653	C/T	cg01988459	chr11:68622903	NA	0.47	6.76	0.38	8.55e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs116988415	0.539	rs11623956	chr14:65270391	G/A	cg25083366	chr14:65239357	SPTB	0.71	5.1	0.3	6.62e-7	Daytime sleep phenotypes;
CESC	cis	rs9611565	0.659	rs56319767	chr22:41933837	G/A	cg03806693	chr22:41940476	POLR3H	-1.21	-15.42	-0.69	9.91e-39	Vitiligo;
CESC	cis	rs4664304	0.597	rs979129	chr2:160840151	T/C	cg03641300	chr2:160917029	PLA2R1	-0.44	-6.07	-0.35	4.38e-9	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs7666738	0.830	rs6854594	chr4:99065312	A/T	cg24818145	chr4:99064322	C4orf37	0.39	5.04	0.3	8.74e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs936229	0.861	rs12441505	chr15:75107311	A/C	cg14664628	chr15:75095509	CSK	-1.01	-16.09	-0.7	4.25e-41	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg07944278	chr6:35699425	LOC285847	-0.49	-6.29	-0.36	1.3e-9	Ulcerative colitis;
CESC	cis	rs10089	0.951	rs736969	chr5:127466347	G/C	cg19767477	chr5:127420684	SLC12A2	-0.39	-5.23	-0.31	3.44e-7	Ileal carcinoids;
CESC	cis	rs9788333	0.888	rs35880230	chr13:21885972	A/G	cg06138931	chr13:21896616	NA	0.47	5.94	0.34	8.88e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs4423214	0.959	rs11606033	chr11:71154204	A/G	cg24826892	chr11:71159390	DHCR7	0.49	5.78	0.33	2.04e-8	Vitamin D levels;
CESC	cis	rs5743618	0.537	rs10017482	chr4:38765335	A/C	cg02016764	chr4:38805732	TLR1	-0.34	-5.21	-0.3	3.84e-7	Asthma;Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs25645	0.823	rs12453334	chr17:38153473	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.6	8.89	0.48	9.75e-17	Myeloid white cell count;
CESC	cis	rs1943345	0.519	rs11233504	chr11:82886525	A/G	cg07047830	chr11:82868014	PCF11	0.59	8.21	0.45	9.95e-15	Obesity-related traits;
CESC	cis	rs72766638	0.848	rs11789898	chr9:136925663	A/C	cg13789015	chr9:136890014	NCRNA00094	-0.46	-5.1	-0.3	6.35e-7	Mosquito bite size;
CESC	cis	rs28830936	1.000	rs11629485	chr15:41904569	C/T	cg11010575	chr15:42129464	JMJD7-PLA2G4B;JMJD7	-0.36	-5.09	-0.3	6.84e-7	Diastolic blood pressure;
CESC	cis	rs3824867	0.920	rs80241400	chr11:47453828	T/C	cg20307385	chr11:47447363	PSMC3	-0.49	-5.87	-0.34	1.27e-8	Mean corpuscular hemoglobin;
CESC	cis	rs6831352	1.000	rs6532798	chr4:100054827	C/T	cg21548116	chr4:100009993	ADH5	0.48	5.09	0.3	6.72e-7	Alcohol dependence;
CESC	cis	rs2191566	0.691	rs55771992	chr19:44588278	G/T	cg20607764	chr19:44506953	ZNF230	-0.4	-5.31	-0.31	2.28e-7	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs6582630	0.519	rs11519914	chr12:38287014	A/G	cg26384229	chr12:38710491	ALG10B	0.64	9.47	0.5	1.66e-18	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs854765	0.583	rs66531105	chr17:17809001	C/T	cg09796270	chr17:17721594	SREBF1	0.43	6.05	0.35	4.94e-9	Total body bone mineral density;
CESC	cis	rs2730245	0.959	rs2527201	chr7:158738611	G/T	cg24397884	chr7:158709396	WDR60	-0.89	-13.66	-0.64	1.65e-32	Height;
CESC	cis	rs9303401	0.659	rs61291849	chr17:56909867	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.01	12.45	0.61	2.57e-28	Cognitive test performance;
CESC	cis	rs11048434	0.698	rs1805745	chr12:9065226	A/T	cg23795048	chr12:9217529	LOC144571	0.36	5.7	0.33	3.24e-8	Sjögren's syndrome;
CESC	cis	rs9929218	0.501	rs12448999	chr16:68815549	T/A	cg02972257	chr16:68554789	NA	-0.43	-5.38	-0.31	1.68e-7	Colorectal cancer;
CESC	cis	rs2836950	0.501	rs62223052	chr21:40708702	A/C	cg11644478	chr21:40555479	PSMG1	-0.57	-7.75	-0.43	1.95e-13	Menarche (age at onset);
CESC	cis	rs863345	0.604	rs12059669	chr1:158501480	T/C	cg12129480	chr1:158549410	OR10X1	-0.34	-6.84	-0.39	5.41e-11	Pneumococcal bacteremia;
CESC	cis	rs9287719	0.967	rs7605461	chr2:10738134	G/A	cg00105475	chr2:10696890	NA	0.39	5.61	0.33	4.96e-8	Prostate cancer;
CESC	cis	rs11098499	0.955	rs35434465	chr4:120169378	C/G	cg09307838	chr4:120376055	NA	0.86	11.34	0.57	1.5e-24	Corneal astigmatism;
CESC	cis	rs4975616	0.869	rs455433	chr5:1336243	A/G	cg07493874	chr5:1342172	CLPTM1L	-0.41	-7.85	-0.43	1.02e-13	Lung cancer;
CESC	cis	rs4950928	0.887	rs7556099	chr1:203166198	C/G	cg14085262	chr1:203155938	CHI3L1	-0.52	-5.68	-0.33	3.51e-8	YKL-40 levels;
CESC	cis	rs12995491	0.933	rs7590305	chr2:88513131	C/T	cg07952391	chr2:88470173	THNSL2	-0.53	-7.7	-0.43	2.69e-13	Response to metformin (IC50);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg26566046	chr12:80083628	PAWR	0.46	6.44	0.37	5.69e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs7945705	0.869	rs2742471	chr11:9003953	C/T	cg09997546	chr11:8931473	C11orf17;ST5	-0.34	-5.76	-0.33	2.35e-8	Hemoglobin concentration;
CESC	cis	rs9916302	0.851	rs12936646	chr17:37647450	A/T	cg19468946	chr17:37922297	IKZF3	-0.39	-5.11	-0.3	6.24e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs9329289	0.510	rs28579610	chr10:2546080	C/A	cg15501526	chr10:2543763	NA	0.49	8.01	0.44	3.77e-14	Age-related hearing impairment;
CESC	cis	rs9660180	0.967	rs12044597	chr1:1708801	A/G	cg17747265	chr1:1875780	NA	-0.56	-9.05	-0.49	3.1e-17	Body mass index;
CESC	cis	rs1413885	0.549	rs1334879	chr1:65846051	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.46	6.14	0.35	3.05e-9	Anticoagulant levels;
CESC	cis	rs727505	0.954	rs55768077	chr7:124663216	A/G	cg23710748	chr7:124431027	NA	-0.41	-6.47	-0.37	4.68e-10	Lewy body disease;
CESC	cis	rs1348850	0.632	rs4470372	chr2:178505857	G/A	cg22681709	chr2:178499509	PDE11A	-0.56	-8.78	-0.47	2.11e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs6500395	0.962	rs1564980	chr16:48651377	A/T	cg04672837	chr16:48644449	N4BP1	0.49	5.98	0.34	7.31e-9	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs11190604	1.000	rs2495753	chr10:102325640	C/T	cg07080220	chr10:102295463	HIF1AN	0.62	5.57	0.32	6.31e-8	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs10484885	0.878	rs72921934	chr6:90579464	T/A	cg13799429	chr6:90582589	CASP8AP2	-0.79	-7.55	-0.42	7.1e-13	QRS interval (sulfonylurea treatment interaction);
CESC	cis	rs3820068	0.603	rs7529759	chr1:15977877	A/G	cg18133145	chr1:16060689	PLEKHM2	-0.4	-5.09	-0.3	6.65e-7	Systolic blood pressure;
CESC	cis	rs10751667	0.621	rs4075990	chr11:976614	T/C	cg06064525	chr11:970664	AP2A2	-0.47	-9.12	-0.49	1.9e-17	Alzheimer's disease (late onset);
CESC	trans	rs4756846	1.000	rs57463944	chr11:16400535	A/C	cg05579622	chr5:10618622	ANKRD33B	0.76	6.93	0.39	3.14e-11	Obesity and osteoporosis;
CESC	cis	rs708547	0.836	rs1277287	chr4:57853147	C/G	cg14719990	chr4:57843890	C4orf14;POLR2B	0.48	5.27	0.31	2.87e-7	Response to bleomycin (chromatid breaks);
CESC	cis	rs561341	0.883	rs7219239	chr17:30212016	A/G	cg19193384	chr17:30244184	NA	0.5	5.15	0.3	5.17e-7	Hip circumference adjusted for BMI;
CESC	cis	rs7552404	0.883	rs11161493	chr1:76206254	T/A	cg22875332	chr1:76189707	ACADM	0.72	10.03	0.52	2.87e-20	Blood metabolite levels;Acylcarnitine levels;
CESC	trans	rs4950322	0.570	rs4593887	chr1:146705892	T/C	cg04954894	chr8:38089920	DDHD2	-0.58	-6.17	-0.35	2.55e-9	Protein quantitative trait loci;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05622441	chr16:69419962	TERF2	0.54	6.59	0.38	2.33e-10	Gut microbiome composition (summer);
CESC	cis	rs9913156	0.793	rs56020376	chr17:4560909	A/G	cg00122941	chr17:4613640	ARRB2	0.85	9.99	0.52	3.79e-20	Lymphocyte counts;
CESC	cis	rs8114671	0.804	rs6060139	chr20:33566499	T/C	cg24642439	chr20:33292090	TP53INP2	0.45	5.37	0.31	1.72e-7	Height;
CESC	cis	rs1046896	0.538	rs3803771	chr17:80687758	G/A	cg02711726	chr17:80685570	FN3KRP	0.42	6.29	0.36	1.32e-9	Glycated hemoglobin levels;
CESC	cis	rs909674	0.731	rs4821897	chr22:39835587	A/G	cg25956985	chr22:39795188	MAP3K7IP1	-0.51	-5.07	-0.3	7.35e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs1577917	0.740	rs2842614	chr6:86306069	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.35	-5.03	-0.3	9.19e-7	Response to antipsychotic treatment;
CESC	cis	rs898097	0.812	rs56405605	chr17:80843663	T/C	cg15369054	chr17:80825471	TBCD	0.54	7.33	0.41	2.72e-12	Breast cancer;
CESC	cis	rs250677	0.687	rs250678	chr5:148434830	C/T	cg18129178	chr5:148520854	ABLIM3	-0.47	-5.45	-0.32	1.13e-7	Breast cancer;
CESC	cis	rs7259376	0.846	rs5014503	chr19:22568340	A/T	cg02657401	chr19:22469223	NA	-0.25	-5.1	-0.3	6.58e-7	Menopause (age at onset);
CESC	cis	rs3126085	0.935	rs12730241	chr1:152274016	G/A	cg03465714	chr1:152285911	FLG	0.51	5.87	0.34	1.32e-8	Atopic dermatitis;
CESC	cis	rs2295499	0.754	rs12499320	chr4:2703081	C/T	cg27239842	chr4:2403781	ZFYVE28	-0.32	-5.32	-0.31	2.17e-7	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
CESC	cis	rs12497850	0.931	rs7647813	chr3:48833348	G/T	cg07636037	chr3:49044803	WDR6	1.01	18.68	0.75	2.81e-50	Parkinson's disease;
CESC	cis	rs13108904	0.539	rs11247997	chr4:1361057	T/C	cg13395646	chr4:1353034	KIAA1530	-0.53	-6.35	-0.36	9.49e-10	Obesity-related traits;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg26878967	chr11:66459081	SPTBN2	0.5	7.01	0.4	1.93e-11	Fibrinogen levels;
CESC	cis	rs4253772	0.550	rs9615913	chr22:46668515	A/T	cg07012999	chr22:46692446	CN5H6.4;GTSE1	-0.52	-5.6	-0.33	5.45e-8	LDL cholesterol;Cholesterol, total;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg07213289	chr7:73610504	EIF4H	-0.44	-6.27	-0.36	1.48e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs6740322	0.696	rs11685054	chr2:43474295	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.73	-8.71	-0.47	3.34e-16	Coronary artery disease;
CESC	cis	rs7264396	0.790	rs6058288	chr20:34228680	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.84	11.84	0.59	3.11e-26	Total cholesterol levels;
CESC	cis	rs1670533	1.000	rs6812586	chr4:1069851	A/G	cg04106633	chr4:1044584	NA	0.4	5.11	0.3	6.07e-7	Recombination rate (females);
CESC	cis	rs8016982	0.617	rs2241621	chr14:81737076	G/T	cg01989461	chr14:81687754	GTF2A1	-0.59	-8.4	-0.46	2.66e-15	Schizophrenia;
CESC	cis	rs1348850	0.958	rs11689550	chr2:178456298	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.62	8.28	0.45	6.32e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs7618915	0.501	rs12486554	chr3:52742537	A/T	cg17372223	chr3:52568218	NT5DC2	0.42	6.2	0.36	2.11e-9	Bipolar disorder;
CESC	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg14820908	chr5:178986412	RUFY1	-0.5	-7.97	-0.44	4.85e-14	Lung cancer;
CESC	trans	rs1728785	0.818	rs1728772	chr16:68584526	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.61	7.48	0.42	1.11e-12	Ulcerative colitis;
CESC	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg06873352	chr17:61820015	STRADA	-0.68	-11.52	-0.58	3.69e-25	Prudent dietary pattern;
CESC	cis	rs763121	0.925	rs9835	chr22:39130971	A/G	cg14440974	chr22:39074834	NA	-0.35	-5.11	-0.3	6.17e-7	Menopause (age at onset);
CESC	cis	rs40363	0.723	rs2379831	chr16:3538927	T/C	cg22508957	chr16:3507546	NAT15	-0.69	-7.51	-0.42	8.87e-13	Tuberculosis;
CESC	cis	rs28647808	0.786	rs4962135	chr9:136256630	C/T	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.85	5.74	0.33	2.59e-8	Blood protein levels;
CESC	cis	rs727563	0.635	rs5751141	chr22:42107745	A/G	cg03806693	chr22:41940476	POLR3H	1.08	12.47	0.61	2.2e-28	Crohn's disease;Inflammatory bowel disease;
CESC	trans	rs7095944	0.644	rs965484	chr10:126453481	T/C	cg27222157	chr11:66382978	RBM14	0.38	6.13	0.35	3.17e-9	Asthma;
CESC	cis	rs79349575	0.783	rs4399576	chr17:47009835	G/A	cg16584676	chr17:46985605	UBE2Z	0.54	6.67	0.38	1.46e-10	Type 2 diabetes;
CESC	cis	rs208520	0.690	rs207094	chr6:66799009	G/A	cg07460842	chr6:66804631	NA	-1.0	-13.43	-0.64	1.05e-31	Exhaled nitric oxide output;
CESC	cis	rs7633770	0.786	rs1520489	chr3:46677519	A/G	cg11219411	chr3:46661640	NA	-0.37	-6.2	-0.36	2.12e-9	Coronary artery disease;
CESC	cis	rs5769765	0.773	rs7290751	chr22:50318312	T/C	cg26441486	chr22:50317300	CRELD2	0.48	5.78	0.33	2.13e-8	Schizophrenia;
CESC	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.56	0.37	2.73e-10	Prudent dietary pattern;
CESC	cis	rs68170813	0.559	rs10953531	chr7:106827867	A/G	cg02696742	chr7:106810147	HBP1	0.55	5.29	0.31	2.54e-7	Coronary artery disease;
CESC	cis	rs3793917	0.948	rs2284665	chr10:124226630	A/C	cg24884230	chr10:124216658	ARMS2	-0.29	-5.07	-0.3	7.6e-7	Age-related macular degeneration;
CESC	cis	rs13064411	0.735	rs10511326	chr3:113216325	T/C	cg18753928	chr3:113234510	CCDC52	-0.51	-6.24	-0.36	1.7e-9	Response to simvastatin treatment (PCSK9 protein level change);
CESC	cis	rs4642101	0.793	rs13086170	chr3:12832604	G/C	cg24848339	chr3:12840334	CAND2	0.35	5.41	0.32	1.4e-7	QRS complex (12-leadsum);
CESC	cis	rs11098499	0.754	rs7672778	chr4:120248585	A/G	cg09307838	chr4:120376055	NA	0.78	10.55	0.54	5.92e-22	Corneal astigmatism;
CESC	cis	rs698833	0.886	rs2304770	chr2:44569328	T/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	6.4	0.37	6.82e-10	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg19407570	chr11:61735476	FTH1	-0.46	-6.41	-0.37	6.53e-10	Fibrinogen levels;
CESC	cis	rs60843830	1.000	rs56167434	chr2:282137	G/C	cg00108164	chr2:264199	ACP1;SH3YL1	0.78	9.97	0.52	4.29e-20	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs11122272	0.735	rs2790873	chr1:231539685	A/G	cg06096015	chr1:231504339	EGLN1	0.41	5.89	0.34	1.15e-8	Hemoglobin concentration;
CESC	cis	rs1843834	0.755	rs10194591	chr2:225574276	T/A	cg22455342	chr2:225449267	CUL3	0.46	5.84	0.34	1.49e-8	IgE levels in asthmatics (D.p. specific);
CESC	cis	rs11098499	0.754	rs7672372	chr4:120248406	A/G	cg09307838	chr4:120376055	NA	0.78	10.54	0.54	6.4e-22	Corneal astigmatism;
CESC	cis	rs13191362	0.810	rs13200053	chr6:163011443	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.5	5.17	0.3	4.63e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs13382862	0.895	rs2289082	chr2:20881958	A/T	cg10553204	chr2:20871195	GDF7	0.34	5.12	0.3	5.92e-7	Abdominal aortic aneurysm;
CESC	cis	rs7044106	0.762	rs1547268	chr9:123408688	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.33	5.14	0.3	5.26e-7	Hip circumference adjusted for BMI;
CESC	cis	rs1451375	0.572	rs745042	chr7:50544138	A/G	cg14593290	chr7:50529359	DDC	-0.52	-5.94	-0.34	9.11e-9	Malaria;
CESC	cis	rs7904368	0.754	rs12269366	chr10:16850344	G/A	cg23933602	chr10:16859644	RSU1	0.67	6.17	0.35	2.54e-9	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
CESC	cis	rs684232	0.666	rs838373	chr17:567171	T/C	cg12384639	chr17:618140	VPS53	0.4	5.15	0.3	5.02e-7	Prostate cancer;
CESC	cis	rs7927771	0.524	rs10838732	chr11:47607940	C/G	cg20307385	chr11:47447363	PSMC3	0.64	8.77	0.47	2.17e-16	Subjective well-being;
CESC	cis	rs7412746	0.611	rs11803940	chr1:150685835	A/G	cg17724175	chr1:150552817	MCL1	0.45	7.41	0.41	1.75e-12	Melanoma;
CESC	cis	rs4689388	0.926	rs4308429	chr4:6294001	A/G	cg00701064	chr4:6280414	WFS1	0.68	11.71	0.58	8.68e-26	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	trans	rs13360092	1.000	rs76644223	chr5:50558191	C/T	cg03200537	chr16:87022121	NA	0.69	6.01	0.35	6.15e-9	Verbal declarative memory;
CESC	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg18765753	chr7:1198926	ZFAND2A	-0.47	-7.24	-0.41	4.99e-12	Longevity;Endometriosis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18804080	chr3:25705791	TOP2B	0.62	6.84	0.39	5.51e-11	Gut microbiome composition (summer);
CESC	cis	rs3008870	0.883	rs2755249	chr1:67493662	A/G	cg02640540	chr1:67518911	SLC35D1	0.52	5.56	0.32	6.48e-8	Lymphocyte percentage of white cells;
CESC	cis	rs2832191	0.646	rs2832214	chr21:30517127	C/T	cg08807101	chr21:30365312	RNF160	-0.47	-5.53	-0.32	7.85e-8	Dental caries;
CESC	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg06873352	chr17:61820015	STRADA	0.72	12.74	0.62	2.56e-29	Prudent dietary pattern;
CESC	cis	rs1316952	0.831	rs77732168	chr12:124392120	G/C	cg12597309	chr12:124393772	DNAH10	0.34	5.16	0.3	4.8e-7	Visceral adipose tissue adjusted for BMI;Visceral adipose tissue/subcutaneous adipose tissue ratio;
CESC	cis	rs72901758	0.768	rs55730737	chr17:76250777	T/A	cg26068271	chr17:76253126	NA	0.47	6.6	0.38	2.25e-10	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
CESC	cis	rs1044826	0.642	rs295479	chr3:139223865	C/T	cg00490450	chr3:139108681	COPB2	0.45	5.53	0.32	7.8e-8	Obesity-related traits;
CESC	cis	rs6061231	0.631	rs2427317	chr20:60975725	C/T	cg06197360	chr20:60970103	CABLES2	-0.4	-5.72	-0.33	2.89e-8	Colorectal cancer;
CESC	cis	rs9905704	0.681	rs4793948	chr17:56562062	G/A	cg12560992	chr17:57184187	TRIM37	-0.59	-5.68	-0.33	3.48e-8	Testicular germ cell tumor;
CESC	trans	rs997295	0.529	rs12592315	chr15:68040266	A/G	cg03031660	chr17:73257791	MRPS7;GGA3	0.47	6.11	0.35	3.49e-9	Motion sickness;
CESC	cis	rs4722166	0.695	rs7787893	chr7:22774437	A/G	cg05472934	chr7:22766657	IL6	0.65	8.85	0.48	1.31e-16	Lung cancer;
CESC	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg26338869	chr17:61819248	STRADA	0.69	9.1	0.49	2.22e-17	Prudent dietary pattern;
CESC	cis	rs4654899	1.000	rs7535895	chr1:21439239	T/A	cg05370193	chr1:21551575	ECE1	0.4	6.05	0.35	5.01e-9	Superior frontal gyrus grey matter volume;
CESC	cis	rs6088590	0.735	rs6060001	chr20:33294353	C/T	cg08999081	chr20:33150536	PIGU	-0.51	-7.79	-0.43	1.52e-13	Coronary artery disease;
CESC	cis	rs854765	0.547	rs2955384	chr17:17939573	C/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.47	6.2	0.36	2.12e-9	Total body bone mineral density;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05566397	chr7:104654900	MLL5;LOC100216545	-0.62	-7.39	-0.41	1.89e-12	Gut microbiome composition (summer);
CESC	cis	rs1371867	0.817	rs1660314	chr8:101332953	C/T	cg11906718	chr8:101322791	RNF19A	0.53	6.86	0.39	4.86e-11	Atrioventricular conduction;
CESC	cis	rs11792861	0.781	rs28361152	chr9:111727529	T/C	cg05043794	chr9:111880884	C9orf5	-0.38	-6.22	-0.36	1.88e-9	Menarche (age at onset);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg10671167	chr7:39988923	CDK13	-0.42	-6.08	-0.35	4.07e-9	Gambling;
CESC	cis	rs62236223	1	rs62236223	chr22:31863554	T/C	cg01338084	chr22:32026380	PISD	1.16	7.13	0.4	9.74e-12	Age-related hearing impairment;
CESC	cis	rs4665809	0.590	rs2303894	chr2:26508187	A/G	cg26314531	chr2:26401878	FAM59B	0.79	7.91	0.44	6.89e-14	Gut microbiome composition (summer);
CESC	cis	rs854765	0.647	rs7212447	chr17:17987067	G/A	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.47	5.97	0.34	7.49e-9	Total body bone mineral density;
CESC	cis	rs870825	0.616	rs4623061	chr4:185643161	A/C	cg04058563	chr4:185651563	MLF1IP	0.64	7.1	0.4	1.15e-11	Blood protein levels;
CESC	cis	rs1577917	0.958	rs13213899	chr6:86473140	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.52	-6.81	-0.39	6.5500000000000006e-11	Response to antipsychotic treatment;
CESC	cis	rs7824557	0.602	rs11784458	chr8:11204184	G/A	cg21775007	chr8:11205619	TDH	0.58	8.85	0.48	1.26e-16	Retinal vascular caliber;
CESC	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg24642844	chr7:1081250	C7orf50	-0.38	-5.07	-0.3	7.32e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs4689388	0.853	rs13108780	chr4:6294630	A/G	cg00701064	chr4:6280414	WFS1	0.68	11.71	0.58	8.68e-26	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs548181	0.668	rs579661	chr11:125474766	A/G	cg03464685	chr11:125439445	EI24	1.12	9.41	0.5	2.49e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs55823223	0.680	rs57287238	chr17:73850940	T/C	cg02397686	chr17:73851076	WBP2	0.59	7.45	0.42	1.29e-12	Psoriasis;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg19741408	chr1:90460434	ZNF326;LOC492303	-0.45	-6.48	-0.37	4.35e-10	Gambling;
CESC	cis	rs7193541	0.684	rs4888264	chr16:74681632	T/G	cg05580060	chr16:74700937	RFWD3	-0.5	-6.46	-0.37	5.01e-10	Multiple myeloma;
CESC	cis	rs1559088	0.947	rs10403238	chr19:33552405	A/G	cg17764715	chr19:33622953	WDR88	0.45	5.68	0.33	3.6e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	trans	rs3780486	0.846	rs4584234	chr9:33147479	G/A	cg20290983	chr6:43655470	MRPS18A	0.94	16.54	0.71	1.02e-42	IgG glycosylation;
CESC	cis	rs425277	0.606	rs2459984	chr1:2086312	A/G	cg12718519	chr1:2058417	PRKCZ	0.27	5.78	0.33	2.06e-8	Height;
CESC	cis	rs477692	0.569	rs1771448	chr10:131296201	A/G	cg05714579	chr10:131428358	MGMT	-0.41	-5.42	-0.32	1.31e-7	Response to temozolomide;
CESC	cis	rs9611565	0.659	rs9611610	chr22:41949259	A/G	cg03806693	chr22:41940476	POLR3H	-1.19	-14.75	-0.67	2.43e-36	Vitiligo;
CESC	cis	rs713587	0.776	rs1172294	chr2:25169200	A/G	cg01884057	chr2:25150051	NA	0.39	7.42	0.41	1.64e-12	Body mass index in non-asthmatics;
CESC	cis	rs57221529	0.600	rs11750269	chr5:666270	G/A	cg16447950	chr5:562315	NA	-0.62	-6.33	-0.36	1.02e-9	Lung disease severity in cystic fibrosis;
CESC	cis	rs921968	0.678	rs660432	chr2:219432127	C/T	cg02176678	chr2:219576539	TTLL4	0.39	6.8	0.39	6.94e-11	Mean corpuscular hemoglobin concentration;
CESC	cis	rs2228479	0.571	rs62052183	chr16:89966921	C/A	cg06558623	chr16:89946397	TCF25	1.05	8.66	0.47	4.66e-16	Skin colour saturation;
CESC	cis	rs78456975	1.000	rs11899027	chr2:1560414	G/C	cg26248373	chr2:1572462	NA	-0.59	-5.7	-0.33	3.11e-8	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs6912958	0.514	rs7767449	chr6:87887985	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.72	-10.35	-0.54	2.6e-21	Monocyte percentage of white cells;
CESC	cis	rs9487051	0.676	rs6925716	chr6:109597641	T/C	cg01475377	chr6:109611718	NA	-0.45	-7.04	-0.4	1.61e-11	Reticulocyte fraction of red cells;
CESC	cis	rs72781680	0.752	rs55859418	chr2:23904231	C/A	cg08917208	chr2:24149416	ATAD2B	1.18	10.67	0.55	2.49e-22	Lymphocyte counts;
CESC	trans	rs35146811	0.735	rs858512	chr7:99824453	A/G	cg13215871	chr17:75784724	NA	-0.34	-6.39	-0.37	7.46e-10	Coronary artery disease;
CESC	cis	rs7552404	0.924	rs7544117	chr1:76158246	A/G	cg22875332	chr1:76189707	ACADM	0.69	9.24	0.49	8.13e-18	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs2439831	0.850	rs2277531	chr15:44069069	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.68	7.88	0.44	8.75e-14	Lung cancer in ever smokers;
CESC	cis	rs3858526	0.584	rs10769270	chr11:5860563	T/C	cg13902645	chr11:5959945	NA	-0.67	-9.11	-0.49	2.14e-17	DNA methylation (variation);
CESC	cis	rs4819052	0.851	rs1056100	chr21:46678711	A/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.49	6.13	0.35	3.26e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs698813	0.774	rs2304769	chr2:44569474	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.53	6.25	0.36	1.62e-9	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
CESC	cis	rs1008375	1.000	rs28552744	chr4:17620165	A/G	cg04450456	chr4:17643702	FAM184B	0.39	5.68	0.33	3.54e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs7605827	0.930	rs6750232	chr2:15714958	C/T	cg19274914	chr2:15703543	NA	0.36	6.5	0.37	4.03e-10	Educational attainment (years of education);
CESC	cis	rs909674	0.731	rs6001594	chr22:39837472	C/T	cg01416388	chr22:39784598	NA	-0.62	-7.64	-0.42	3.97e-13	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs867529	0.620	rs335121	chr2:89084327	G/C	cg26627705	chr2:89060884	NA	0.41	5.66	0.33	3.86e-8	Height;
CESC	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg24503407	chr1:205819492	PM20D1	0.82	13.96	0.65	1.43e-33	Menarche (age at onset);
CESC	cis	rs2842992	0.747	rs9365095	chr6:160192928	T/G	cg26839252	chr6:160211577	TCP1;MRPL18	0.47	5.38	0.31	1.61e-7	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg18765753	chr7:1198926	ZFAND2A	-0.44	-5.52	-0.32	7.99e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7542091	0.704	rs1108628	chr1:210041150	A/G	cg23283495	chr1:209979779	IRF6	0.33	5.2	0.3	3.98e-7	Monobrow;
CESC	cis	rs116095464	0.558	rs28635197	chr5:279071	T/C	cg10591111	chr5:226296	SDHA	-0.53	-6.43	-0.37	6.03e-10	Breast cancer;
CESC	cis	rs9649213	0.593	rs7797943	chr7:97946902	T/C	cg21770322	chr7:97807741	LMTK2	0.55	8.3	0.45	5.37e-15	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs9911578	1.000	rs8067571	chr17:56868856	C/T	cg12560992	chr17:57184187	TRIM37	0.92	15.58	0.69	2.71e-39	Intelligence (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08161947	chr12:19592900	AEBP2	0.63	6.99	0.39	2.21e-11	Gut microbiome composition (summer);
CESC	cis	rs4704187	0.687	rs4704197	chr5:74537751	C/T	cg03227963	chr5:74354835	NA	0.27	5.04	0.3	8.67e-7	Response to amphetamines;
CESC	trans	rs1814175	0.645	rs1851849	chr11:50012164	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.42	-6.12	-0.35	3.32e-9	Height;
CESC	cis	rs875971	0.830	rs587360	chr7:65522698	C/A	cg26939375	chr7:64535504	NA	0.48	6.2	0.36	2.12e-9	Aortic root size;
CESC	cis	rs9322193	0.923	rs6913486	chr6:150026196	C/T	cg13206674	chr6:150067644	NUP43	-0.41	-5.66	-0.33	3.85e-8	Lung cancer;
CESC	cis	rs2066819	1.000	rs57279772	chr12:56698960	G/A	cg26734620	chr12:56694298	CS	1.07	6.58	0.37	2.56e-10	Psoriasis vulgaris;
CESC	cis	rs60871478	0.635	rs4311567	chr7:792295	T/C	cg00934597	chr7:893267	UNC84A	0.56	5.65	0.33	4.17e-8	Cerebrospinal P-tau181p levels;
CESC	cis	rs8017423	0.935	rs11159960	chr14:90740012	C/T	cg14092571	chr14:90743983	NA	0.56	8.49	0.46	1.54e-15	Mortality in heart failure;
CESC	cis	rs11098499	0.909	rs2127821	chr4:120394535	T/C	cg09307838	chr4:120376055	NA	0.94	13.95	0.65	1.51e-33	Corneal astigmatism;
CESC	cis	rs3733418	0.860	rs13141887	chr4:165950921	C/T	cg10852876	chr4:165953100	TRIM60	-0.47	-5.49	-0.32	9.39e-8	Obesity-related traits;
CESC	cis	rs9911578	0.967	rs12944948	chr17:56951474	A/G	cg05425664	chr17:57184151	TRIM37	-0.5	-6.94	-0.39	2.94e-11	Intelligence (multi-trait analysis);
CESC	cis	rs9926296	0.605	rs3743859	chr16:89846050	A/G	cg03388025	chr16:89894329	SPIRE2	-0.39	-7.6	-0.42	5.15e-13	Vitiligo;
CESC	cis	rs12050794	0.636	rs4506844	chr15:72509138	C/T	cg16672083	chr15:72433130	SENP8	0.45	6.62	0.38	1.99e-10	Metabolite levels (HVA/MHPG ratio);
CESC	cis	rs736408	0.609	rs13061423	chr3:52790213	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	6.81	0.39	6.69e-11	Bipolar disorder;
CESC	cis	rs67311347	1.000	rs28491638	chr3:40496263	T/C	cg09455208	chr3:40491958	NA	0.5	7.96	0.44	5.11e-14	Renal cell carcinoma;
CESC	cis	rs9487051	0.714	rs7774377	chr6:109602443	G/A	cg01475377	chr6:109611718	NA	-0.44	-6.97	-0.39	2.52e-11	Reticulocyte fraction of red cells;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg03093076	chr19:1390962	NDUFS7	0.48	6.27	0.36	1.5e-9	Fibrinogen levels;
CESC	cis	rs9926296	0.643	rs2159114	chr16:89831841	A/G	cg27121462	chr16:89883253	FANCA	0.52	6.32	0.36	1.1e-9	Vitiligo;
CESC	cis	rs4555082	1.000	rs7146012	chr14:105757566	G/A	cg13114125	chr14:105738426	BRF1	-0.75	-9.57	-0.51	7.69e-19	Mean platelet volume;Platelet distribution width;
CESC	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	10.08	0.53	1.93e-20	Prudent dietary pattern;
CESC	cis	rs8103278	0.507	rs7246377	chr19:46292259	G/A	cg14061069	chr19:46274453	DMPK	0.55	8.49	0.46	1.5e-15	Coronary artery disease;
CESC	cis	rs5167	0.504	rs7257476	chr19:45453165	C/T	cg09555818	chr19:45449301	APOC2	0.41	6.55	0.37	3.05e-10	Blood protein levels;
CESC	cis	rs4481887	0.861	rs4309013	chr1:248480768	C/T	cg00666640	chr1:248458726	OR2T12	0.36	5.98	0.34	7.16e-9	Common traits (Other);
CESC	cis	rs4689388	0.824	rs6446482	chr4:6295693	C/G	cg25554036	chr4:6271136	WFS1	0.52	8.46	0.46	1.79e-15	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs763121	0.819	rs4560233	chr22:38982442	A/T	cg06544989	chr22:39130855	UNC84B	0.47	8.01	0.44	3.77e-14	Menopause (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14620208	chr9:140652685	EHMT1	-0.66	-7.76	-0.43	1.8e-13	Gut microbiome composition (summer);
CESC	cis	rs11711311	0.911	rs3773681	chr3:113523901	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.72	10.17	0.53	1.02e-20	IgG glycosylation;
CESC	cis	rs66530629	0.874	rs7548438	chr1:25098341	C/T	cg22509179	chr1:25234806	RUNX3	-0.44	-5.64	-0.33	4.27e-8	Plateletcrit;
CESC	cis	rs8077889	1.000	rs2066725	chr17:41891473	A/G	cg26893861	chr17:41843967	DUSP3	0.78	10.32	0.54	3.4e-21	Triglycerides;
CESC	cis	rs2204008	0.777	rs2387813	chr12:38382091	A/C	cg26384229	chr12:38710491	ALG10B	0.69	10.49	0.54	8.95e-22	Bladder cancer;
CESC	cis	rs1008375	0.606	rs6828925	chr4:17561139	C/T	cg27347728	chr4:17578864	LAP3	0.41	5.17	0.3	4.67e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs1153858	1.000	rs12591058	chr15:45640172	T/C	cg14582100	chr15:45693742	SPATA5L1	0.42	6.08	0.35	4.2e-9	Homoarginine levels;
CESC	cis	rs4319547	0.737	rs10773176	chr12:122944713	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.57	-7.03	-0.4	1.75e-11	Body mass index;
CESC	cis	rs4835473	0.932	rs7666368	chr4:144706525	C/A	cg25736465	chr4:144833511	NA	-0.33	-5.43	-0.32	1.28e-7	Immature fraction of reticulocytes;
CESC	cis	rs7312933	0.932	rs10880220	chr12:42383046	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.39	5.09	0.3	6.77e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs8031584	0.651	rs28664821	chr15:31172323	G/A	cg14298792	chr15:30685198	CHRFAM7A	0.47	5.78	0.33	2.08e-8	Huntington's disease progression;
CESC	cis	rs7615952	0.599	rs6438953	chr3:125724951	T/C	cg15145296	chr3:125709740	NA	-0.45	-5.14	-0.3	5.34e-7	Blood pressure (smoking interaction);
CESC	cis	rs4566357	0.615	rs10190621	chr2:227914484	A/G	cg11843606	chr2:227700838	RHBDD1	-0.49	-6.8	-0.39	7.03e-11	Coronary artery disease;
CESC	cis	rs854765	0.575	rs7207821	chr17:17891781	A/G	cg16928487	chr17:17741425	SREBF1	-0.53	-8.72	-0.47	3.12e-16	Total body bone mineral density;
CESC	cis	rs7904368	0.951	rs7905776	chr10:16853609	C/T	cg23933602	chr10:16859644	RSU1	0.78	9.04	0.49	3.35e-17	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
CESC	cis	rs9611565	0.527	rs73178638	chr22:41942904	T/C	cg06481639	chr22:41940642	POLR3H	-0.7	-7.05	-0.4	1.52e-11	Vitiligo;
CESC	cis	rs35306767	0.903	rs11253504	chr10:956046	A/G	cg10556349	chr10:835070	NA	0.66	6.32	0.36	1.08e-9	Eosinophil percentage of granulocytes;
CESC	cis	rs798554	0.836	rs798526	chr7:2775542	G/C	cg18446336	chr7:2847575	GNA12	-0.39	-5.9	-0.34	1.11e-8	Height;
CESC	cis	rs77956314	0.818	rs12296869	chr12:117431203	G/A	cg02017074	chr12:117425053	FBXW8	-0.9	-8.49	-0.46	1.5e-15	Subcortical brain region volumes;Hippocampal volume;
CESC	cis	rs896854	0.654	rs4735340	chr8:95976251	A/T	cg26343298	chr8:95960752	TP53INP1	0.36	5.98	0.34	7.06e-9	Type 2 diabetes;
CESC	cis	rs6963495	0.818	rs6957192	chr7:105150255	A/C	cg19920283	chr7:105172520	RINT1	-0.66	-6.38	-0.36	7.85e-10	Bipolar disorder (body mass index interaction);
CESC	cis	rs7178572	0.568	rs28524916	chr15:77599002	T/A	cg22256960	chr15:77711686	NA	0.53	6.37	0.36	8.52e-10	Type 2 diabetes;
CESC	cis	rs763121	0.853	rs5757193	chr22:39034867	A/G	cg21395723	chr22:39101663	GTPBP1	-0.43	-5.18	-0.3	4.43e-7	Menopause (age at onset);
CESC	cis	rs4835473	0.897	rs13140654	chr4:144656886	A/G	cg25736465	chr4:144833511	NA	-0.36	-5.52	-0.32	7.97e-8	Immature fraction of reticulocytes;
CESC	cis	rs1568889	0.838	rs7127069	chr11:28325412	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.79	13.56	0.64	3.65e-32	Bipolar disorder;
CESC	cis	rs5758659	0.714	rs7245	chr22:42481849	G/A	cg04733989	chr22:42467013	NAGA	-0.42	-5.71	-0.33	3.01e-8	Cognitive function;
CESC	cis	rs644799	0.511	rs12791736	chr11:95475399	C/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.41	5.11	0.3	6.28e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs4555082	0.834	rs2816607	chr14:105718385	A/T	cg27165867	chr14:105738592	BRF1	-0.51	-5.45	-0.32	1.13e-7	Mean platelet volume;Platelet distribution width;
CESC	cis	rs6674176	0.628	rs2240447	chr1:44415415	C/T	cg13606994	chr1:44402422	ARTN	-0.37	-5.53	-0.32	7.66e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs9916302	0.706	rs4332770	chr17:37704712	T/C	cg07936489	chr17:37558343	FBXL20	-0.98	-11.47	-0.58	5.54e-25	Glomerular filtration rate (creatinine);
CESC	cis	rs4665809	1.000	rs4665309	chr2:26335502	T/C	cg25036284	chr2:26402008	FAM59B	-0.59	-6.88	-0.39	4.37e-11	Gut microbiome composition (summer);
CESC	cis	rs875971	0.660	rs28698552	chr7:66005018	A/G	cg11764359	chr7:65958608	NA	0.71	9.4	0.5	2.68e-18	Aortic root size;
CESC	cis	rs7116495	0.609	rs4944243	chr11:71674354	T/C	cg26138937	chr11:71823887	C11orf51	-1.25	-7.99	-0.44	4.19e-14	Severe influenza A (H1N1) infection;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20889476	chr12:72057658	THAP2;ZFC3H1	0.56	6.13	0.35	3.19e-9	Gut microbiome composition (summer);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg03474219	chr11:64072691	ESRRA	-0.4	-6.45	-0.37	5.39e-10	Gambling;
CESC	cis	rs8103278	1.000	rs7252126	chr19:46302374	T/A	cg14061069	chr19:46274453	DMPK	-0.4	-5.4	-0.31	1.51e-7	Coronary artery disease;
CESC	cis	rs7264396	0.676	rs6060727	chr20:34556000	G/A	cg17201900	chr20:34330562	RBM39	0.51	5.31	0.31	2.37e-7	Total cholesterol levels;
CESC	cis	rs950027	0.620	rs2461700	chr15:45640627	T/C	cg21132104	chr15:45694354	SPATA5L1	0.67	8.55	0.46	1.01e-15	Response to fenofibrate (adiponectin levels);
CESC	cis	rs11864453	0.713	rs7191127	chr16:72123992	G/T	cg16558253	chr16:72132732	DHX38	-0.56	-8.7	-0.47	3.62e-16	Fibrinogen levels;
CESC	cis	rs10504229	0.683	rs7838958	chr8:58136968	T/C	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs2290720	0.798	rs10778114	chr12:101745285	G/A	cg22051763	chr12:101673672	UTP20	-0.44	-5.52	-0.32	8.14e-8	Brain structure (hippocampal volume);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22976360	chr2:70528671	FAM136A	0.58	6.24	0.36	1.74e-9	Gut microbiome composition (summer);
CESC	cis	rs11098499	0.954	rs7656252	chr4:120404268	T/C	cg24375607	chr4:120327624	NA	0.45	5.52	0.32	8.1e-8	Corneal astigmatism;
CESC	cis	rs12220238	0.915	rs75467340	chr10:75907318	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.64	6.26	0.36	1.58e-9	Soluble interleukin-2 receptor subunit alpha;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22934568	chr3:48884614	PRKAR2A	0.59	6.7	0.38	1.24e-10	Gut microbiome composition (summer);
CESC	cis	rs6831352	0.819	rs1154401	chr4:100009738	G/C	cg13256891	chr4:100009986	ADH5	0.66	8.13	0.45	1.68e-14	Alcohol dependence;
CESC	cis	rs11864453	0.963	rs7185215	chr16:72034864	T/C	cg16558253	chr16:72132732	DHX38	-0.45	-6.59	-0.38	2.37e-10	Fibrinogen levels;
CESC	cis	rs4891159	0.513	rs2554831	chr18:74113513	C/G	cg24786174	chr18:74118243	ZNF516	0.85	15.75	0.7	7e-40	Longevity;
CESC	cis	rs2228479	0.850	rs17233448	chr16:89816424	G/T	cg00800038	chr16:89945340	TCF25	-0.91	-7.54	-0.42	7.39e-13	Skin colour saturation;
CESC	cis	rs875971	1.000	rs778722	chr7:65844828	T/C	cg10691866	chr7:65817282	TPST1	-0.34	-5.46	-0.32	1.12e-7	Aortic root size;
CESC	cis	rs9926296	0.712	rs2437957	chr16:89715648	G/A	cg04287289	chr16:89883240	FANCA	-0.48	-5.84	-0.34	1.48e-8	Vitiligo;
CESC	cis	rs9311474	0.659	rs7638808	chr3:52572056	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.38	-5.7	-0.33	3.19e-8	Electroencephalogram traits;
CESC	cis	rs1552244	0.882	rs13089863	chr3:10032259	G/T	cg08888203	chr3:10149979	C3orf24	-0.47	-5.39	-0.31	1.55e-7	Alzheimer's disease;
CESC	cis	rs6540559	1.000	rs6540559	chr1:209982025	G/A	cg25204440	chr1:209979598	IRF6	0.62	7.95	0.44	5.25e-14	Cleft lip with or without cleft palate;
CESC	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg04234412	chr22:24373322	LOC391322	-0.65	-9.77	-0.51	1.86e-19	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs7216064	0.532	rs8065296	chr17:66018562	T/A	cg12091567	chr17:66097778	LOC651250	0.86	11.3	0.57	1.95e-24	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs6831352	0.918	rs6813415	chr4:100048509	T/C	cg12011299	chr4:100065546	ADH4	-0.59	-6.52	-0.37	3.62e-10	Alcohol dependence;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17846100	chr22:43538986	MCAT	0.53	6.41	0.37	6.7e-10	Gut microbiome composition (summer);
CESC	cis	rs2635047	1.000	rs2684818	chr18:44712965	C/T	cg24371990	chr18:44770781	NA	0.34	5.46	0.32	1.08e-7	Educational attainment;
CESC	cis	rs11552708	0.504	rs8082166	chr17:7388728	G/C	cg02795151	chr17:7402630	POLR2A	0.55	5.86	0.34	1.41e-8	IgM levels;
CESC	trans	rs5756813	0.661	rs6000898	chr22:38202399	T/C	cg19894588	chr14:64061835	NA	-0.68	-8.42	-0.46	2.36e-15	Optic cup area;Vertical cup-disc ratio;
CESC	cis	rs514406	0.767	rs551591	chr1:53301876	A/G	cg08859206	chr1:53392774	SCP2	-0.63	-8.71	-0.47	3.46e-16	Monocyte count;
CESC	cis	rs9911578	0.967	rs1267542	chr17:56654690	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	-0.39	-5.19	-0.3	4.25e-7	Intelligence (multi-trait analysis);
CESC	cis	rs2204008	0.626	rs11520260	chr12:38330092	C/T	cg26384229	chr12:38710491	ALG10B	0.73	10.9	0.56	4.29e-23	Bladder cancer;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg19463885	chr2:242626846	DTYMK	0.49	6.33	0.36	1.03e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs807669	0.586	rs5746671	chr22:19160899	A/G	cg02655711	chr22:19163373	SLC25A1	0.44	6.24	0.36	1.7e-9	Metabolite levels;
CESC	cis	rs3820068	0.532	rs72647105	chr1:15935238	C/G	cg17385448	chr1:15911702	AGMAT	0.41	6.59	0.38	2.42e-10	Systolic blood pressure;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01750847	chr16:30007184	HIRIP3;INO80E	0.66	8.09	0.45	2.2e-14	Gut microbiome composition (summer);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg19742111	chr11:66460113	SPTBN2	0.53	7.37	0.41	2.11e-12	Fibrinogen levels;
CESC	cis	rs6032067	0.538	rs13041506	chr20:43739655	G/A	cg10761708	chr20:43804764	PI3	0.45	5.11	0.3	6.08e-7	Blood protein levels;
CESC	cis	rs1371867	0.875	rs1788173	chr8:101330939	A/G	cg11906718	chr8:101322791	RNF19A	-0.46	-5.97	-0.34	7.62e-9	Atrioventricular conduction;
CESC	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.56	-6.21	-0.36	2.06e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs77741769	0.529	rs3901854	chr12:121225526	C/T	cg02419362	chr12:121203948	SPPL3	0.35	5.72	0.33	2.83e-8	Mean corpuscular volume;
CESC	cis	rs11249608	0.548	rs17078991	chr5:178459426	A/C	cg01312482	chr5:178451176	ZNF879	-0.45	-6.08	-0.35	4.26e-9	Pubertal anthropometrics;
CESC	trans	rs765547	0.956	rs1992443	chr8:19853587	G/A	cg12649343	chr22:47023005	GRAMD4	-0.3	-6.12	-0.35	3.27e-9	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
CESC	cis	rs11785400	0.731	rs4294163	chr8:143730830	G/T	cg24634471	chr8:143751801	JRK	0.45	5.78	0.33	2.12e-8	Schizophrenia;
CESC	cis	rs1642645	0.831	rs6698877	chr1:42500436	T/C	cg16685388	chr1:42384056	HIVEP3	0.38	5.68	0.33	3.52e-8	Left ventricular obstructive tract defect (maternal effect);
CESC	cis	rs3857536	0.842	rs2188591	chr6:66939511	A/T	cg07460842	chr6:66804631	NA	-0.42	-5.34	-0.31	1.96e-7	Blood trace element (Cu levels);
CESC	cis	rs9649213	0.593	rs6955647	chr7:98004562	T/C	cg08684580	chr7:98029266	BAIAP2L1	-0.37	-5.98	-0.34	7.09e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7833986	0.534	rs17759244	chr8:57033768	A/G	cg26371346	chr8:56986568	SNORD54;RPS20	0.57	5.41	0.32	1.42e-7	Height;
CESC	cis	rs3820068	0.608	rs7552400	chr1:16035892	A/G	cg13390004	chr1:15929781	NA	0.33	5.13	0.3	5.64e-7	Systolic blood pressure;
CESC	cis	rs9322193	0.923	rs4421206	chr6:150004027	A/C	cg04369109	chr6:150039330	LATS1	-0.41	-5.75	-0.33	2.48e-8	Lung cancer;
CESC	cis	rs9302635	0.513	rs3812987	chr16:72158920	C/A	cg16558253	chr16:72132732	DHX38	-0.42	-5.41	-0.32	1.42e-7	Blood protein levels;
CESC	cis	rs7666738	0.830	rs7663661	chr4:99014761	A/G	cg05340658	chr4:99064831	C4orf37	0.8	12.51	0.61	1.52e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3785574	0.962	rs2247435	chr17:61892862	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.57	7.08	0.4	1.32e-11	Height;
CESC	cis	rs35110281	0.748	rs2838324	chr21:44999820	T/C	cg04455712	chr21:45112962	RRP1B	0.37	5.53	0.32	7.48e-8	Mean corpuscular volume;
CESC	cis	rs1707322	0.752	rs28890893	chr1:46186576	T/G	cg03146154	chr1:46216737	IPP	0.82	11.53	0.58	3.39e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7592578	0.771	rs12052514	chr2:191378170	C/T	cg10560079	chr2:191398806	TMEM194B	-0.61	-5.53	-0.32	7.74e-8	Diastolic blood pressure;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03794801	chr17:33817159	SLFN12L	-0.52	-6.25	-0.36	1.59e-9	Gut microbiome composition (summer);
CESC	cis	rs2439831	0.681	rs2278858	chr15:43632755	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.85	9.76	0.51	2.03e-19	Lung cancer in ever smokers;
CESC	cis	rs8002861	0.875	rs12872943	chr13:44410553	G/A	cg14210620	chr13:44453864	C13orf31;CCDC122	-0.42	-5.33	-0.31	2.16e-7	Leprosy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08201673	chr17:18167551	SMCR7	-0.61	-6.86	-0.39	4.99e-11	Gut microbiome composition (summer);
CESC	cis	rs7647973	0.848	rs4955411	chr3:49145304	A/G	cg07636037	chr3:49044803	WDR6	0.9	12.49	0.61	1.87e-28	Menarche (age at onset);
CESC	cis	rs13242816	1.000	rs36011826	chr7:116118336	G/A	cg04696780	chr7:116139425	CAV2	-0.58	-5.15	-0.3	5.21e-7	P wave duration;
CESC	cis	rs12681366	0.762	rs7831073	chr8:95354366	C/G	cg13257157	chr8:95487014	RAD54B	0.41	5.55	0.32	6.83e-8	Nonsyndromic cleft lip with cleft palate;
CESC	cis	rs2839186	0.967	rs2839191	chr21:47695395	C/G	cg10351095	chr21:47802916	PCNT	-0.47	-6.55	-0.37	2.89e-10	Testicular germ cell tumor;
CESC	cis	rs17784882	0.524	rs7433300	chr3:47120640	G/A	cg27129171	chr3:47204927	SETD2	0.64	9.09	0.49	2.35e-17	QT interval;
CESC	cis	rs4654899	0.772	rs7548269	chr1:21089472	T/C	cg05370193	chr1:21551575	ECE1	0.35	5.14	0.3	5.4e-7	Superior frontal gyrus grey matter volume;
CESC	cis	rs12500824	0.528	rs62303260	chr4:77286660	G/T	cg20311846	chr4:77356250	SHROOM3	0.37	6.86	0.39	4.82e-11	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05031202	chr17:7738649	NA	-0.68	-7.92	-0.44	6.63e-14	Gut microbiome composition (summer);
CESC	cis	rs2991971	0.869	rs2453404	chr1:46014735	A/G	cg06784218	chr1:46089804	CCDC17	-0.3	-5.11	-0.3	6.3e-7	High light scatter reticulocyte count;
CESC	cis	rs10752881	0.809	rs3738829	chr1:183113862	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.84	13.21	0.63	5.85e-31	Colorectal cancer;
CESC	cis	rs2573652	1.000	rs2727198	chr15:100513722	T/C	cg00587665	chr15:100533223	ADAMTS17	-0.34	-5.49	-0.32	9.48e-8	Height;
CESC	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.07	20.16	0.78	1.92e-55	Prudent dietary pattern;
CESC	cis	rs80130819	0.748	rs2409001	chr12:48594490	T/C	cg05342945	chr12:48394962	COL2A1	-0.57	-6.11	-0.35	3.6e-9	Prostate cancer;
CESC	cis	rs875971	0.508	rs10253883	chr7:66061138	T/C	cg19163074	chr7:65112434	INTS4L2	0.43	5.48	0.32	1.01e-7	Aortic root size;
CESC	cis	rs5758511	0.514	rs5751222	chr22:42517922	T/A	cg00645731	chr22:42541494	CYP2D7P1	0.63	9.78	0.52	1.69e-19	Birth weight;
CESC	cis	rs4308124	0.708	rs7585313	chr2:111975203	A/G	cg04571233	chr2:111982156	NA	-0.62	-6.89	-0.39	4.12e-11	Vitiligo;
CESC	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg01238044	chr22:24384105	GSTT1	-0.52	-6.54	-0.37	3.15e-10	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs780096	0.565	rs8179252	chr2:27746832	A/C	cg02592271	chr2:27665507	KRTCAP3	-0.3	-5.99	-0.35	6.92e-9	Total body bone mineral density;
CESC	cis	rs60871478	0.730	rs13222476	chr7:826630	T/C	cg13798912	chr7:905769	UNC84A	0.56	5.7	0.33	3.11e-8	Cerebrospinal P-tau181p levels;
CESC	cis	rs6088590	1.000	rs6120708	chr20:33335526	G/A	cg06115741	chr20:33292138	TP53INP2	0.57	7.02	0.4	1.83e-11	Coronary artery disease;
CESC	cis	rs7618915	0.547	rs68021750	chr3:52624769	G/A	cg18099408	chr3:52552593	STAB1	-0.31	-5.09	-0.3	6.68e-7	Bipolar disorder;
CESC	cis	rs78456975	0.506	rs10167704	chr2:1571037	G/C	cg26248373	chr2:1572462	NA	-0.6	-6.98	-0.39	2.43e-11	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs4076764	0.914	rs7536270	chr1:163377379	T/C	cg24596788	chr1:163392923	NA	-0.51	-7.52	-0.42	8.59e-13	Motion sickness;
CESC	cis	rs9362426	0.551	rs6912282	chr6:88103000	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.46	5.4	0.32	1.45e-7	Depressive episodes in bipolar disorder;
CESC	cis	rs11650776	1	rs11650776	chr17:37641402	G/A	cg15445000	chr17:37608096	MED1	0.41	6.76	0.38	8.83e-11	Lung function (FEV1);
CESC	cis	rs709400	0.832	rs55864158	chr14:104068579	G/A	cg24130564	chr14:104152367	KLC1	-0.43	-5.1	-0.3	6.5e-7	Body mass index;
CESC	cis	rs12597458	0.763	rs7195958	chr16:72036577	A/G	cg01557791	chr16:72042693	DHODH	0.81	12.44	0.61	2.76e-28	Prostate cancer;
CESC	cis	rs9303280	0.840	rs12939457	chr17:38032188	T/C	cg19468946	chr17:37922297	IKZF3	-0.41	-5.48	-0.32	1.01e-7	Self-reported allergy;
CESC	cis	rs2228479	0.850	rs17227064	chr16:89816314	A/G	cg19635926	chr16:89946313	TCF25	0.67	5.09	0.3	6.82e-7	Skin colour saturation;
CESC	cis	rs1707322	0.682	rs12041197	chr1:46104464	T/C	cg06784218	chr1:46089804	CCDC17	0.4	6.99	0.39	2.23e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9324022	0.929	rs1004574	chr14:101178067	C/G	cg18089426	chr14:101175970	NA	0.62	7.98	0.44	4.5e-14	Plateletcrit;
CESC	cis	rs6952808	0.825	rs34296663	chr7:1935245	C/T	cg21782813	chr7:2030301	MAD1L1	0.39	5.49	0.32	9.33e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs7937682	0.883	rs568506	chr11:111466429	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.9	-12.87	-0.62	9.33e-30	Primary sclerosing cholangitis;
CESC	cis	rs2073300	0.609	rs6137950	chr20:23418722	T/A	cg16736954	chr20:23401023	NAPB	0.78	5.78	0.33	2.05e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs13191362	1.000	rs67840803	chr6:163049048	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.53	5.9	0.34	1.12e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs9549367	0.577	rs3024713	chr13:113813321	G/A	cg00898013	chr13:113819073	PROZ	-0.49	-6.19	-0.36	2.27e-9	Platelet distribution width;
CESC	cis	rs6500395	1.000	rs7206647	chr16:48709220	G/C	cg04672837	chr16:48644449	N4BP1	-0.51	-6.53	-0.37	3.33e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs2573652	0.722	rs12904962	chr15:100544113	A/G	cg09918751	chr15:100517450	ADAMTS17	0.32	5.8	0.34	1.86e-8	Height;
CESC	cis	rs875971	0.723	rs28391294	chr7:65654315	T/C	cg18876405	chr7:65276391	NA	-0.53	-7.38	-0.41	2.09e-12	Aortic root size;
CESC	cis	rs7267979	1.000	rs6050599	chr20:25400240	T/C	cg08601574	chr20:25228251	PYGB	-0.37	-5.36	-0.31	1.77e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7666738	0.830	rs7698771	chr4:98986479	T/G	cg05340658	chr4:99064831	C4orf37	0.8	12.42	0.61	3.31e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9911578	0.967	rs1588322	chr17:56990099	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.41	5.41	0.32	1.38e-7	Intelligence (multi-trait analysis);
CESC	cis	rs6500395	0.775	rs1968903	chr16:48664014	C/T	cg04672837	chr16:48644449	N4BP1	0.49	6.27	0.36	1.46e-9	Response to tocilizumab in rheumatoid arthritis;
CESC	trans	rs35110281	0.626	rs162389	chr21:44936227	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.44	6.07	0.35	4.34e-9	Mean corpuscular volume;
CESC	trans	rs10463316	0.894	rs7723016	chr5:150764828	T/C	cg24389359	chr12:111284228	CCDC63	-0.33	-6.02	-0.35	5.68e-9	Metabolite levels (Pyroglutamine);
CESC	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.44	6.04	0.35	5.16e-9	Lymphocyte counts;
CESC	cis	rs9300255	0.602	rs1727296	chr12:123647725	G/C	cg05973401	chr12:123451056	ABCB9	0.5	5.81	0.34	1.79e-8	Neutrophil percentage of white cells;
CESC	cis	rs9560113	0.573	rs9560134	chr13:112244011	C/T	cg10483660	chr13:112241077	NA	0.42	6.99	0.39	2.21e-11	Menarche (age at onset);
CESC	cis	rs2204008	0.744	rs66474616	chr12:38461564	G/A	cg26384229	chr12:38710491	ALG10B	0.72	10.57	0.54	5.01e-22	Bladder cancer;
CESC	trans	rs899596	0.908	rs2127434	chr17:71737392	C/T	cg23413066	chr4:13548755	LOC285548	0.39	6.13	0.35	3.17e-9	Glucose homeostasis traits;
CESC	cis	rs4474465	0.850	rs4597089	chr11:78262244	A/G	cg27205649	chr11:78285834	NARS2	0.4	5.11	0.3	6.22e-7	Alzheimer's disease (survival time);
CESC	cis	rs9303280	0.806	rs2872507	chr17:38040763	C/T	cg20243544	chr17:37824526	PNMT	0.48	6.3	0.36	1.21e-9	Self-reported allergy;
CESC	cis	rs477692	0.692	rs12265758	chr10:131445144	A/G	cg24747557	chr10:131355152	MGMT	0.38	5.27	0.31	2.78e-7	Response to temozolomide;
CESC	cis	rs116095464	0.614	rs78905930	chr5:246560	G/A	cg22857025	chr5:266934	NA	-1.25	-16.91	-0.72	5.34e-44	Breast cancer;
CESC	cis	rs769267	1.000	rs2301669	chr19:19453560	C/A	cg15052019	chr19:19431593	KIAA0892;SF4	-0.41	-5.2	-0.3	3.93e-7	Tonsillectomy;
CESC	cis	rs1144333	0.850	rs1144341	chr1:76282659	T/G	cg22875332	chr1:76189707	ACADM	-0.54	-5.25	-0.31	3.11e-7	Attention function in attention deficit hyperactive disorder;
CESC	cis	rs2797160	0.875	rs12527010	chr6:125991507	A/G	cg05901451	chr6:126070800	HEY2	0.46	6.74	0.38	1.01e-10	Endometrial cancer;
CESC	cis	rs17376456	0.877	rs10057605	chr5:93443950	T/G	cg25358565	chr5:93447407	FAM172A	1.22	11.3	0.57	2.03e-24	Diabetic retinopathy;
CESC	cis	rs1559088	1.000	rs2161225	chr19:33551899	C/T	cg27124370	chr19:33622961	WDR88	0.43	5.47	0.32	1.04e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs796364	0.950	rs188146	chr2:200750444	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.84	8.22	0.45	9.15e-15	Schizophrenia;
CESC	cis	rs736408	0.511	rs12637632	chr3:52708073	A/T	cg05564831	chr3:52568323	NT5DC2	0.44	6.73	0.38	1.02e-10	Bipolar disorder;
CESC	cis	rs17001868	0.568	rs9611314	chr22:40735798	C/G	cg07138101	chr22:40742427	ADSL	0.55	5.26	0.31	3e-7	Mammographic density (dense area);
CESC	cis	rs4319547	0.695	rs10744211	chr12:122931820	A/G	cg23029597	chr12:123009494	RSRC2	-0.45	-5.08	-0.3	7.04e-7	Body mass index;
CESC	cis	rs7267979	0.868	rs6138553	chr20:25239233	G/A	cg08601574	chr20:25228251	PYGB	0.43	6.05	0.35	5.03e-9	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7799006	0.691	rs10447541	chr7:2301578	T/G	cg08027265	chr7:2291960	NA	-0.6	-10.21	-0.53	7.27e-21	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs12586317	0.547	rs13379372	chr14:35483882	A/C	cg05294307	chr14:35346193	BAZ1A	-0.51	-5.48	-0.32	1.01e-7	Psoriasis;
CESC	cis	rs17401966	0.838	rs12139981	chr1:10390696	T/C	cg15208524	chr1:10270712	KIF1B	0.39	5.03	0.3	8.95e-7	Hepatocellular carcinoma;
CESC	trans	rs2018683	0.707	rs1021691	chr7:28974496	C/T	cg19402173	chr7:128379420	CALU	-0.49	-6.51	-0.37	3.68e-10	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CESC	cis	rs11718455	0.960	rs6781618	chr3:44001933	C/T	cg08738300	chr3:44038990	NA	0.46	6.13	0.35	3.17e-9	Coronary artery disease;
CESC	trans	rs2018683	0.707	rs1874974	chr7:28967647	G/C	cg19402173	chr7:128379420	CALU	-0.53	-7.12	-0.4	1.04e-11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CESC	cis	rs4713118	0.621	rs4713134	chr6:28034121	T/C	cg23161317	chr6:28129485	ZNF389	0.51	6.38	0.36	7.9e-10	Parkinson's disease;
CESC	trans	rs2207136	0.771	rs7744992	chr6:50909541	G/A	cg06522515	chr3:184090630	THPO	-0.36	-6.19	-0.36	2.26e-9	Myopia;
CESC	cis	rs1144333	0.850	rs1146651	chr1:76273594	C/A	cg10523679	chr1:76189770	ACADM	-0.57	-5.44	-0.32	1.22e-7	Attention function in attention deficit hyperactive disorder;
CESC	trans	rs9693444	0.898	rs4732697	chr8:29519861	A/G	cg19318450	chr21:34852305	TMEM50B	-0.43	-6.42	-0.37	6.33e-10	Breast cancer;
CESC	cis	rs896854	1.000	rs13255935	chr8:95965685	C/A	cg26343298	chr8:95960752	TP53INP1	0.38	6.22	0.36	1.89e-9	Type 2 diabetes;
CESC	trans	rs7980799	0.935	rs1905427	chr12:33534368	T/C	cg26384229	chr12:38710491	ALG10B	-0.46	-6.25	-0.36	1.61e-9	Heart rate;Heart rate variability traits (RMSSD);
CESC	cis	rs9322193	0.576	rs7452592	chr6:150196581	A/G	cg01145232	chr6:150245071	RAET1G	0.5	5.55	0.32	6.97e-8	Lung cancer;
CESC	cis	rs10242455	0.702	rs73397447	chr7:99010949	G/T	cg18809830	chr7:99032528	PTCD1	-0.95	-6.5	-0.37	4e-10	Blood metabolite levels;
CESC	cis	rs8114671	0.836	rs2425006	chr20:33571228	T/G	cg24642439	chr20:33292090	TP53INP2	-0.43	-5.17	-0.3	4.68e-7	Height;
CESC	cis	rs4253772	0.591	rs9615934	chr22:46682310	C/G	cg24881330	chr22:46731750	TRMU	0.87	7.19	0.4	6.64e-12	LDL cholesterol;Cholesterol, total;
CESC	cis	rs853679	0.517	rs9348797	chr6:28137533	G/C	cg23161317	chr6:28129485	ZNF389	0.47	5.89	0.34	1.18e-8	Depression;
CESC	cis	rs748404	0.697	rs1095389	chr15:43566671	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	7.83	0.43	1.19e-13	Lung cancer;
CESC	cis	rs798554	0.959	rs798556	chr7:2759002	C/A	cg04166393	chr7:2884313	GNA12	0.52	6.58	0.37	2.5e-10	Height;
CESC	cis	rs2777491	1.000	rs7168177	chr15:41715585	A/G	cg20272979	chr15:41787780	ITPKA	0.45	6.68	0.38	1.42e-10	Ulcerative colitis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00711773	chr3:40351057	EIF1B	0.6	6.92	0.39	3.42e-11	Gut microbiome composition (summer);
CESC	cis	rs4566357	0.615	rs2396445	chr2:227917726	C/G	cg11843606	chr2:227700838	RHBDD1	-0.54	-7.0	-0.39	2.12e-11	Coronary artery disease;
CESC	cis	rs7937682	0.889	rs541198	chr11:111475340	A/G	cg22437258	chr11:111473054	SIK2	0.72	9.69	0.51	3.38e-19	Primary sclerosing cholangitis;
CESC	cis	rs17023223	0.581	rs10923750	chr1:119650795	T/G	cg05756136	chr1:119680316	WARS2	-0.46	-5.58	-0.32	5.88e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CESC	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg11965913	chr1:205819406	PM20D1	0.83	13.41	0.64	1.17e-31	Menarche (age at onset);
CESC	cis	rs10416265	0.502	rs7245411	chr19:33543029	A/T	cg17764715	chr19:33622953	WDR88	0.59	8.03	0.44	3.26e-14	Bone properties (heel);
CESC	cis	rs524023	0.958	rs2021860	chr11:64361384	G/T	cg07220939	chr11:64358617	SLC22A12	-0.36	-5.55	-0.32	7.08e-8	Urate levels in obese individuals;
CESC	cis	rs6952808	0.825	rs34296663	chr7:1935245	C/T	cg02951883	chr7:2050386	MAD1L1	-0.49	-6.51	-0.37	3.8e-10	Bipolar disorder and schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04136590	chr5:114505766	TRIM36	-0.59	-6.46	-0.37	4.85e-10	Gut microbiome composition (summer);
CESC	cis	rs67072384	0.818	rs12287481	chr11:72472336	A/C	cg04827223	chr11:72435913	ARAP1	0.71	7.01	0.4	1.97e-11	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
CESC	cis	rs9914578	1.000	rs9914577	chr17:2005130	C/T	cg16513277	chr17:2031491	SMG6	-0.58	-6.67	-0.38	1.51e-10	Body mass index;
CESC	cis	rs9811920	0.609	rs793447	chr3:99598278	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.64	10.11	0.53	1.53e-20	Axial length;
CESC	cis	rs7666738	0.606	rs28625338	chr4:99076996	A/G	cg07917127	chr4:99064746	C4orf37	0.4	5.05	0.3	8.3e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs116095464	0.558	rs7715108	chr5:264661	A/G	cg20965017	chr5:231967	SDHA	-0.48	-5.43	-0.32	1.25e-7	Breast cancer;
CESC	cis	rs875971	0.964	rs778735	chr7:65814809	C/A	cg11764359	chr7:65958608	NA	0.96	15.81	0.7	4.26e-40	Aortic root size;
CESC	cis	rs11190604	1.000	rs7477246	chr10:102261538	C/T	cg07080220	chr10:102295463	HIF1AN	0.69	6.6	0.38	2.19e-10	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs7851660	0.967	rs10818133	chr9:100610348	C/G	cg13688889	chr9:100608707	NA	-0.68	-10.64	-0.55	3.08e-22	Strep throat;
CESC	cis	rs6952407	1	rs6952407	chr7:66045512	A/G	cg18876405	chr7:65276391	NA	-0.58	-7.55	-0.42	6.9e-13	Cotinine glucuronidation;
CESC	cis	rs172166	0.611	rs203883	chr6:28078356	A/G	cg26335602	chr6:28129616	ZNF389	0.38	5.53	0.32	7.72e-8	Cardiac Troponin-T levels;
CESC	cis	rs10504229	0.565	rs7010503	chr8:58147127	G/A	cg02725872	chr8:58115012	NA	-0.36	-5.79	-0.34	1.99e-8	Developmental language disorder (linguistic errors);
CESC	trans	rs1223629	1.000	rs56682281	chr10:95943954	A/T	cg16346422	chr11:2920819	SLC22A18;SLC22A18AS	0.67	6.04	0.35	5.08e-9	Glucose homeostasis traits;
CESC	trans	rs17307778	0.706	rs10767363	chr11:25358065	T/C	cg22888484	chr20:37075185	SNHG11	-0.63	-6.07	-0.35	4.42e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs1552244	0.882	rs3755782	chr3:10029305	T/C	cg00149659	chr3:10157352	C3orf10	0.71	8.4	0.46	2.72e-15	Alzheimer's disease;
CESC	cis	rs7959452	1.000	rs2168029	chr12:69734641	A/C	cg14784868	chr12:69753453	YEATS4	0.56	7.54	0.42	7.52e-13	Blood protein levels;
CESC	cis	rs637571	0.522	rs528736	chr11:65705108	A/G	cg02202077	chr11:65769826	EIF1AD;BANF1	0.46	6.0	0.35	6.47e-9	Eosinophil percentage of white cells;
CESC	cis	rs3806843	1.000	rs11167609	chr5:140200426	T/G	cg16179182	chr5:140090404	VTRNA1-1	-0.4	-5.11	-0.3	6.18e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs9303401	0.614	rs34550282	chr17:57092788	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.9	11.27	0.57	2.59e-24	Cognitive test performance;
CESC	cis	rs72627123	0.867	rs112464051	chr14:74483975	C/T	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.78	5.82	0.34	1.74e-8	Morning vs. evening chronotype;
CESC	cis	rs4820539	1.000	rs4822358	chr22:23474795	A/G	cg14186256	chr22:23484241	RTDR1	0.83	15.07	0.68	1.76e-37	Bone mineral density;
CESC	trans	rs9467711	0.659	rs35680819	chr6:26455814	T/C	cg06606381	chr12:133084897	FBRSL1	-0.94	-6.86	-0.39	4.96e-11	Autism spectrum disorder or schizophrenia;
CESC	cis	rs28374715	0.532	rs28463309	chr15:41666716	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.01	-15.95	-0.7	1.34e-40	Ulcerative colitis;
CESC	cis	rs1568889	0.774	rs11030235	chr11:28212375	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.8	13.23	0.63	5.11e-31	Bipolar disorder;
CESC	cis	rs9311474	0.652	rs411457	chr3:52228150	A/T	cg15147215	chr3:52552868	STAB1	0.33	5.58	0.32	5.93e-8	Electroencephalogram traits;
CESC	cis	rs9616064	0.531	rs867212	chr22:47063330	C/T	cg05621596	chr22:47072043	GRAMD4	0.7	10.35	0.54	2.62e-21	Urate levels in obese individuals;
CESC	cis	rs7219451	0.655	rs8067028	chr17:38974029	G/A	cg17985300	chr17:38952333	KRT28	-0.32	-5.31	-0.31	2.33e-7	Glucose homeostasis traits;
CESC	cis	rs896854	0.967	rs2879813	chr8:95960947	A/G	cg09323728	chr8:95962352	TP53INP1	-0.44	-10.09	-0.53	1.8e-20	Type 2 diabetes;
CESC	cis	rs9916302	0.904	rs612194	chr17:37442707	T/A	cg19468946	chr17:37922297	IKZF3	0.42	5.48	0.32	9.97e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs6456156	0.792	rs10946212	chr6:167515947	C/G	cg07741184	chr6:167504864	NA	0.37	6.69	0.38	1.33e-10	Primary biliary cholangitis;
CESC	cis	rs863345	0.967	rs12753013	chr1:158505221	T/A	cg12129480	chr1:158549410	OR10X1	-0.31	-6.04	-0.35	5.32e-9	Pneumococcal bacteremia;
CESC	cis	rs10463316	0.832	rs1019467	chr5:150734323	A/G	cg03212797	chr5:150827313	SLC36A1	-0.52	-6.66	-0.38	1.58e-10	Metabolite levels (Pyroglutamine);
CESC	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg23708337	chr7:1209742	NA	0.53	5.34	0.31	1.98e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs1008375	0.933	rs10939757	chr4:17694125	T/C	cg02297831	chr4:17616191	MED28	0.47	5.72	0.33	2.91e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04284535	chr17:41624145	ETV4	-0.44	-6.22	-0.36	1.94e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs8077577	0.747	rs11867895	chr17:18146721	A/C	cg16794390	chr17:18148240	FLII	0.42	6.34	0.36	9.97e-10	Obesity-related traits;
CESC	cis	rs7937682	0.632	rs11214037	chr11:111773296	C/T	cg22437258	chr11:111473054	SIK2	-0.5	-5.55	-0.32	6.9e-8	Primary sclerosing cholangitis;
CESC	cis	rs9902453	0.730	rs4583306	chr17:28538715	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.59	-7.23	-0.41	5.27e-12	Coffee consumption (cups per day);
CESC	cis	rs6088580	0.624	rs6120645	chr20:33025171	C/T	cg08999081	chr20:33150536	PIGU	0.65	11.36	0.57	1.22e-24	Glomerular filtration rate (creatinine);
CESC	cis	rs2836974	0.568	rs377098	chr21:40535216	G/A	cg11890956	chr21:40555474	PSMG1	-0.97	-16.62	-0.71	5.65e-43	Cognitive function;
CESC	cis	rs7223966	1.000	rs8075061	chr17:61804723	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.68	0.38	1.4e-10	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs6089829	0.962	rs6062777	chr20:61663748	G/A	cg03213289	chr20:61660250	NA	0.39	6.07	0.35	4.42e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7520050	0.966	rs4660317	chr1:46326226	G/A	cg24296786	chr1:45957014	TESK2	0.43	5.41	0.32	1.4e-7	Red blood cell count;Reticulocyte count;
CESC	cis	rs13256369	0.951	rs13260947	chr8:8565883	A/G	cg18904891	chr8:8559673	CLDN23	0.72	8.39	0.46	2.85e-15	Obesity-related traits;
CESC	cis	rs10504229	0.683	rs11785258	chr8:58132893	A/G	cg21724239	chr8:58056113	NA	0.58	5.95	0.34	8.29e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs763014	0.932	rs35067229	chr16:649638	T/C	cg09263875	chr16:632152	PIGQ	0.69	12.03	0.59	6.76e-27	Height;
CESC	cis	rs2197308	0.765	rs11182900	chr12:37934009	C/T	cg13010199	chr12:38710504	ALG10B	0.53	6.81	0.39	6.71e-11	Morning vs. evening chronotype;
CESC	cis	rs637571	0.522	rs12797319	chr11:65735672	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.72	10.01	0.52	3.23e-20	Eosinophil percentage of white cells;
CESC	cis	rs1538970	0.739	rs4660863	chr1:45955868	T/C	cg24296786	chr1:45957014	TESK2	-0.46	-5.15	-0.3	4.97e-7	Platelet count;
CESC	cis	rs1348850	0.567	rs1405714	chr2:178538584	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.6	-7.99	-0.44	4.19e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs4819052	0.851	rs7279182	chr21:46656112	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.74	9.5	0.5	1.32e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs644148	0.679	rs2204119	chr19:44970975	T/C	cg15540054	chr19:45004280	ZNF180	-0.6	-6.46	-0.37	4.86e-10	Personality dimensions;
CESC	cis	rs9926296	0.712	rs258319	chr16:89732024	A/T	cg04287289	chr16:89883240	FANCA	-0.45	-5.55	-0.32	7.04e-8	Vitiligo;
CESC	cis	rs4843747	0.749	rs12102841	chr16:88072574	C/G	cg06374794	chr16:88002281	BANP	-0.38	-5.18	-0.3	4.35e-7	Menopause (age at onset);
CESC	cis	rs853679	0.517	rs4713152	chr6:28137454	G/A	cg20151795	chr6:28129481	ZNF389	0.41	5.3	0.31	2.46e-7	Depression;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04699474	chr19:9945708	PIN1	0.5	6.1	0.35	3.69e-9	Gut microbiome composition (summer);
CESC	cis	rs910316	0.967	rs8007539	chr14:75664953	T/C	cg16144293	chr14:75469539	EIF2B2	0.39	5.11	0.3	6.22e-7	Height;
CESC	cis	rs7243790	0.807	rs13380938	chr18:51895547	T/C	cg04730925	chr18:51795821	POLI	-0.43	-5.74	-0.33	2.54e-8	Diastolic blood pressure;
CESC	cis	rs10769945	0.679	rs7102920	chr11:1917872	C/T	cg06679296	chr11:1949032	TNNT3	0.3	5.2	0.3	3.95e-7	DNA methylation (variation);
CESC	cis	rs12477438	0.700	rs12467679	chr2:99654449	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.75	-10.87	-0.56	5.17e-23	Chronic sinus infection;
CESC	cis	rs3780486	0.505	rs10813959	chr9:33166234	C/T	cg13443165	chr9:33130375	B4GALT1	-0.48	-7.25	-0.41	4.52e-12	IgG glycosylation;
CESC	trans	rs10493340	0.597	rs72674242	chr1:63598265	A/G	cg01817204	chr3:123602957	MYLK	-0.52	-6.63	-0.38	1.85e-10	Blood pressure;
CESC	cis	rs916888	0.697	rs199516	chr17:44856485	C/T	cg17911788	chr17:44343683	NA	0.55	7.51	0.42	8.84e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs11190604	1.000	rs4919471	chr10:102299239	A/G	cg07080220	chr10:102295463	HIF1AN	0.66	6.07	0.35	4.53e-9	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs3892630	0.824	rs2287884	chr19:33321447	A/G	cg22980127	chr19:33182716	NUDT19	1.04	11.73	0.58	7.44e-26	Red blood cell traits;
CESC	cis	rs10504229	0.683	rs16921937	chr8:58145010	A/G	cg24829409	chr8:58192753	C8orf71	-0.55	-6.88	-0.39	4.4e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs1784581	0.802	rs6455787	chr6:162411378	G/A	cg17173639	chr6:162384350	PARK2	0.61	9.44	0.5	2.05e-18	Itch intensity from mosquito bite;
CESC	cis	rs2832191	0.633	rs2832166	chr21:30462395	G/C	cg08807101	chr21:30365312	RNF160	0.88	12.54	0.61	1.26e-28	Dental caries;
CESC	cis	rs2243480	1.000	rs781157	chr7:65478311	G/A	cg13147721	chr7:65941812	NA	-0.86	-8.36	-0.46	3.57e-15	Diabetic kidney disease;
CESC	cis	rs1538970	0.816	rs4633317	chr1:45985157	T/C	cg06784218	chr1:46089804	CCDC17	0.36	5.79	0.34	1.97e-8	Platelet count;
CESC	cis	rs734999	0.549	rs6667564	chr1:2520302	T/C	cg20673091	chr1:2541236	MMEL1	0.43	7.15	0.4	8.42e-12	Ulcerative colitis;
CESC	cis	rs7208859	0.623	rs73269923	chr17:29102571	C/T	cg19761014	chr17:28927070	LRRC37B2	0.79	6.28	0.36	1.37e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs3026101	0.671	rs58832024	chr17:5306536	G/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.42	5.6	0.33	5.31e-8	Body mass index;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg00653609	chr6:39082964	C6orf64	-0.47	-6.17	-0.35	2.61e-9	Height;
CESC	cis	rs7264396	0.561	rs6142470	chr20:34570579	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-6.98	-0.39	2.37e-11	Total cholesterol levels;
CESC	cis	rs1375194	0.582	rs13388224	chr2:33802902	T/C	cg04131969	chr2:33951647	MYADML	-0.51	-6.51	-0.37	3.76e-10	Response to antidepressants in depression;
CESC	cis	rs7666738	0.606	rs10006414	chr4:99101401	T/C	cg05340658	chr4:99064831	C4orf37	0.64	8.59	0.47	7.58e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs910316	0.934	rs4903278	chr14:75535019	C/A	cg11812906	chr14:75593930	NEK9	0.9	15.15	0.68	9.31e-38	Height;
CESC	cis	rs4481887	0.962	rs6686911	chr1:248476969	T/C	cg00666640	chr1:248458726	OR2T12	0.41	6.56	0.37	2.84e-10	Common traits (Other);
CESC	cis	rs7809950	0.953	rs2520267	chr7:107187497	T/C	cg23024343	chr7:107201750	COG5	-0.41	-5.65	-0.33	4.03e-8	Coronary artery disease;
CESC	cis	rs1153858	1.000	rs1890565	chr15:45663299	T/C	cg14582100	chr15:45693742	SPATA5L1	0.42	5.95	0.34	8.38e-9	Homoarginine levels;
CESC	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg26338869	chr17:61819248	STRADA	0.69	9.13	0.49	1.8e-17	Prudent dietary pattern;
CESC	cis	rs1316952	0.667	rs76411891	chr12:124388236	A/G	cg12597309	chr12:124393772	DNAH10	0.35	5.21	0.3	3.77e-7	Visceral adipose tissue adjusted for BMI;Visceral adipose tissue/subcutaneous adipose tissue ratio;
CESC	cis	rs7872515	0.536	rs28883017	chr9:94774870	T/C	cg01248375	chr9:94877805	SPTLC1	0.61	5.4	0.31	1.48e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs6772849	1.000	rs2713605	chr3:128307460	A/T	cg16766828	chr3:128327626	NA	-0.31	-5.06	-0.3	7.77e-7	Monocyte percentage of white cells;Monocyte count;
CESC	cis	rs7552404	0.691	rs1770890	chr1:76401117	A/G	cg22875332	chr1:76189707	ACADM	-0.54	-5.79	-0.34	1.94e-8	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs939658	0.805	rs2010524	chr15:79435825	G/T	cg17916960	chr15:79447300	NA	-0.38	-6.3	-0.36	1.24e-9	Refractive error;
CESC	cis	rs9611565	0.802	rs4822028	chr22:41789408	A/G	cg17376030	chr22:41985996	PMM1	0.52	5.74	0.33	2.62e-8	Vitiligo;
CESC	cis	rs9611565	0.649	rs202655	chr22:41841564	G/C	cg06481639	chr22:41940642	POLR3H	0.52	5.68	0.33	3.48e-8	Vitiligo;
CESC	cis	rs6860806	1.000	rs6860806	chr5:131640536	C/T	cg24060327	chr5:131705240	SLC22A5	0.4	5.16	0.3	4.74e-7	Breast cancer;
CESC	cis	rs4566357	0.615	rs10177528	chr2:227913706	G/A	cg05526886	chr2:227700861	RHBDD1	-0.47	-6.27	-0.36	1.45e-9	Coronary artery disease;
CESC	cis	rs1559088	0.948	rs10406916	chr19:33590093	G/A	cg27124370	chr19:33622961	WDR88	0.45	6.0	0.35	6.49e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs9811920	0.609	rs9872871	chr3:99658702	C/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.57	-6.84	-0.39	5.62e-11	Axial length;
CESC	cis	rs66887589	0.720	rs11724758	chr4:120239878	G/A	cg09307838	chr4:120376055	NA	0.57	7.68	0.43	3.06e-13	Diastolic blood pressure;
CESC	cis	rs6691722	0.503	rs3765428	chr1:24706113	G/A	cg18323236	chr1:24743029	NIPAL3	0.37	5.61	0.33	5.09e-8	Response to interferon beta in multiple sclerosis;
CESC	cis	rs6504950	0.566	rs7208403	chr17:53046667	C/A	cg19360675	chr17:53046073	COX11;STXBP4	0.43	5.53	0.32	7.75e-8	Breast cancer;
CESC	cis	rs7107174	1.000	rs58565853	chr11:78036707	C/T	cg02023728	chr11:77925099	USP35	0.45	6.35	0.36	9.35e-10	Testicular germ cell tumor;
CESC	cis	rs7474896	0.583	rs11011347	chr10:38019264	G/A	cg25427524	chr10:38739819	LOC399744	-0.49	-5.57	-0.32	6.36e-8	Obesity (extreme);
CESC	cis	rs7714584	1.000	rs1000113	chr5:150240076	C/T	cg22134413	chr5:150180641	NA	0.56	5.71	0.33	2.98e-8	Crohn's disease;
CESC	cis	rs10751667	0.580	rs7395515	chr11:1005160	C/T	cg20946044	chr11:1010712	AP2A2	-0.51	-6.88	-0.39	4.29e-11	Alzheimer's disease (late onset);
CESC	cis	rs4906332	0.811	rs2296487	chr14:103996205	T/C	cg19000871	chr14:103996768	TRMT61A	-0.35	-5.04	-0.3	8.56e-7	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15338675	chr6:28193028	ZNF193	0.66	7.43	0.42	1.46e-12	Gut microbiome composition (summer);
CESC	cis	rs6952808	0.929	rs12532128	chr7:1925454	T/C	cg23048001	chr7:2026167	MAD1L1	0.4	5.14	0.3	5.34e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs5753037	0.702	rs131301	chr22:30185889	A/T	cg01021169	chr22:30184971	ASCC2	-0.47	-6.68	-0.38	1.37e-10	Type 1 diabetes;
CESC	trans	rs12599106	0.707	rs2163977	chr16:34916134	A/G	cg01516881	chr6:292596	DUSP22	-0.79	-10.32	-0.54	3.34e-21	Menopause (age at onset);
CESC	cis	rs6540559	0.673	rs6540560	chr1:209982073	A/G	cg25204440	chr1:209979598	IRF6	-0.59	-6.36	-0.36	8.87e-10	Cleft lip with or without cleft palate;
CESC	cis	rs13191362	0.938	rs35211042	chr6:162998703	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.49	5.34	0.31	2.01e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs1552244	0.882	rs67895180	chr3:10026079	T/C	cg00166722	chr3:10149974	C3orf24	0.49	6.04	0.35	5.3e-9	Alzheimer's disease;
CESC	cis	rs2304069	0.909	rs30831	chr5:149359053	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.9	-10.84	-0.55	6.61e-23	HIV-1 control;
CESC	cis	rs7589342	0.894	rs6736932	chr2:106444854	A/G	cg16077055	chr2:106428750	NCK2	0.49	6.93	0.39	3.11e-11	Addiction;
CESC	cis	rs6088580	0.634	rs6059856	chr20:33057954	G/C	cg24642439	chr20:33292090	TP53INP2	0.52	6.87	0.39	4.68e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs12822507	0.868	rs61915599	chr12:12768409	A/G	cg09462578	chr12:12878428	APOLD1	-0.43	-5.32	-0.31	2.19e-7	Systemic lupus erythematosus;
CESC	cis	rs7586673	0.857	rs16845580	chr2:161920884	T/C	cg22496339	chr2:162101262	NA	0.51	6.77	0.38	8.09e-11	Intelligence (multi-trait analysis);
CESC	cis	rs6121246	0.529	rs6060142	chr20:30178028	A/G	cg13852791	chr20:30311386	BCL2L1	0.67	6.77	0.38	8.03e-11	Mean corpuscular hemoglobin;
CESC	cis	rs7412746	0.611	rs11204747	chr1:150927152	A/G	cg04414720	chr1:150670196	GOLPH3L	-0.44	-6.04	-0.35	5.25e-9	Melanoma;
CESC	cis	rs7811142	0.830	rs6979910	chr7:99940630	A/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.1	13.52	0.64	5.02e-32	Platelet count;
CESC	cis	rs3845702	0.736	rs9288045	chr2:180814194	G/A	cg01881094	chr2:180872142	CWC22	-1.05	-9.21	-0.49	9.96e-18	Schizophrenia;
CESC	cis	rs2836974	0.829	rs8128191	chr21:40527311	A/G	cg11644478	chr21:40555479	PSMG1	1.04	17.85	0.74	2.41e-47	Cognitive function;
CESC	cis	rs4481887	0.610	rs28763387	chr1:248559244	T/C	cg26353448	chr1:248524236	OR2T4	-0.37	-5.14	-0.3	5.42e-7	Common traits (Other);
CESC	cis	rs9788682	0.747	rs28480606	chr15:78762313	A/G	cg24631222	chr15:78858424	CHRNA5	0.61	7.16	0.4	8.13e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs1178968	1.000	rs13240408	chr7:72758023	T/C	cg25889504	chr7:72793014	NA	0.48	5.08	0.3	7.22e-7	Triglyceride levels;
CESC	trans	rs9693444	0.898	rs4732697	chr8:29519861	A/G	cg23666278	chr2:171785822	GORASP2	-0.41	-6.1	-0.35	3.8e-9	Breast cancer;
CESC	cis	rs2243480	0.711	rs2460426	chr7:65623129	A/G	cg12463550	chr7:65579703	CRCP	-0.73	-5.71	-0.33	3.1e-8	Diabetic kidney disease;
CESC	cis	rs863345	0.967	rs7520063	chr1:158470198	T/C	cg12129480	chr1:158549410	OR10X1	-0.31	-6.2	-0.36	2.14e-9	Pneumococcal bacteremia;
CESC	cis	rs754466	0.580	rs10430530	chr10:79582812	T/C	cg17075019	chr10:79541650	NA	-0.88	-14.01	-0.65	9.69e-34	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs7188697	0.922	rs28307	chr16:58577138	A/C	cg21335942	chr16:58549945	SETD6	0.45	5.33	0.31	2.13e-7	QT interval;
CESC	cis	rs7129220	0.588	rs7931957	chr11:10094304	G/A	cg01453529	chr11:10209919	SBF2	-0.47	-5.31	-0.31	2.32e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CESC	cis	rs9457247	0.967	rs2149083	chr6:167370971	G/C	cg07741184	chr6:167504864	NA	-0.3	-5.25	-0.31	3.1e-7	Crohn's disease;
CESC	cis	rs709400	0.663	rs28444993	chr14:103930564	T/C	cg12935359	chr14:103987150	CKB	-0.51	-7.42	-0.41	1.57e-12	Body mass index;
CESC	cis	rs17826219	0.568	rs11658027	chr17:29094882	A/G	cg19761014	chr17:28927070	LRRC37B2	-0.75	-6.23	-0.36	1.87e-9	Body mass index;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg26904991	chr16:8891722	PMM2;TMEM186	-0.41	-6.11	-0.35	3.47e-9	Gambling;
CESC	cis	rs790123	1.000	rs790123	chr3:122388993	T/C	cg17380795	chr3:122379686	NA	0.38	5.58	0.32	5.8e-8	Response to angiotensin II receptor blocker therapy;
CESC	cis	rs3820928	1.000	rs12615988	chr2:227769000	A/G	cg11843606	chr2:227700838	RHBDD1	-0.42	-5.66	-0.33	3.83e-8	Pulmonary function;
CESC	cis	rs763014	0.966	rs4984903	chr16:680695	A/G	cg07256732	chr16:621771	PIGQ	-0.31	-5.35	-0.31	1.91e-7	Height;
CESC	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg26338869	chr17:61819248	STRADA	0.71	9.47	0.5	1.6e-18	Prudent dietary pattern;
CESC	cis	rs2354432	0.505	rs3737845	chr1:146724408	A/G	cg25205988	chr1:146714368	CHD1L	0.99	8.27	0.45	6.59e-15	Mitochondrial DNA levels;
CESC	trans	rs4349753	0.640	rs10041987	chr5:144084954	G/A	cg22407458	chr6:35109121	TCP11	0.5	6.31	0.36	1.18e-9	Photic sneeze reflex;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06812225	chr1:204485782	MDM4	0.66	8.04	0.44	3.03e-14	Gut microbiome composition (summer);
CESC	cis	rs10479542	0.630	rs6879664	chr5:178974576	T/G	cg19626725	chr5:178986131	RUFY1	0.35	5.17	0.3	4.57e-7	Lung cancer;
CESC	cis	rs4919687	0.550	rs12784517	chr10:104464970	T/C	cg04362960	chr10:104952993	NT5C2	0.46	5.37	0.31	1.73e-7	Colorectal cancer;
CESC	cis	rs8067545	1.000	rs9891739	chr17:19942177	C/T	cg13482628	chr17:19912719	NA	0.43	5.78	0.33	2.08e-8	Schizophrenia;
CESC	cis	rs2710642	0.721	rs10177638	chr2:62887010	C/T	cg17519650	chr2:63277830	OTX1	0.49	6.19	0.36	2.27e-9	LDL cholesterol levels;LDL cholesterol;
CESC	cis	rs6460942	0.597	rs13221702	chr7:12519076	A/G	cg10578991	chr7:12443926	VWDE	0.49	5.19	0.3	4.16e-7	Coronary artery disease;
CESC	cis	rs875971	0.619	rs12533585	chr7:65984605	G/C	cg06456125	chr7:65229604	NA	0.39	5.08	0.3	7.17e-7	Aortic root size;
CESC	cis	rs9908102	0.653	rs8071829	chr17:12914517	G/A	cg26162695	chr17:12921313	ELAC2	0.51	5.47	0.32	1.03e-7	Schizophrenia;
CESC	cis	rs4704187	0.687	rs9293642	chr5:74365026	C/T	cg03227963	chr5:74354835	NA	0.31	5.82	0.34	1.66e-8	Response to amphetamines;
CESC	cis	rs830124	0.602	rs1630699	chr12:122386758	G/C	cg22168489	chr12:122356033	WDR66	-0.38	-5.05	-0.3	8.27e-7	Urinary metabolites;
CESC	cis	rs9972944	0.534	rs7208926	chr17:63863210	G/A	cg07283582	chr17:63770753	CCDC46	-0.34	-5.03	-0.3	9.04e-7	Total body bone mineral density;
CESC	cis	rs6546550	0.867	rs6738174	chr2:70150215	A/C	cg02498382	chr2:70120550	SNRNP27	-0.41	-7.26	-0.41	4.34e-12	Prevalent atrial fibrillation;
CESC	cis	rs61776719	0.500	rs11210866	chr1:38449565	T/C	cg04673462	chr1:38461896	NA	0.39	6.0	0.35	6.5e-9	Coronary artery disease;
CESC	cis	rs78889164	0.876	rs17570	chr19:33878837	G/A	cg02272751	chr19:33882848	PEPD	-0.57	-8.35	-0.46	3.73e-15	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs875971	0.545	rs67397473	chr7:65633305	A/G	cg11764359	chr7:65958608	NA	0.79	9.51	0.5	1.18e-18	Aortic root size;
CESC	cis	rs9322193	0.962	rs9322218	chr6:150103319	A/G	cg07701084	chr6:150067640	NUP43	0.4	5.48	0.32	9.87e-8	Lung cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07114478	chr16:3033714	NA	0.55	6.25	0.36	1.63e-9	Gut microbiome composition (summer);
CESC	cis	rs142802669	1	rs142802669	chr3:41869427	A/C	cg03022575	chr3:42003672	ULK4	0.48	5.51	0.32	8.52e-8	Immunoglobulin light chain (AL) amyloidosis;
CESC	cis	rs796364	0.906	rs281766	chr2:200820505	T/G	cg23649088	chr2:200775458	C2orf69	0.55	5.33	0.31	2.14e-7	Schizophrenia;
CESC	cis	rs6973256	0.568	rs7800126	chr7:133521356	A/C	cg10665199	chr7:133106180	EXOC4	0.44	6.14	0.35	3.04e-9	Intelligence (multi-trait analysis);
CESC	trans	rs208520	0.690	rs207081	chr6:66773742	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-12.55	-0.61	1.16e-28	Exhaled nitric oxide output;
CESC	cis	rs2842992	0.789	rs7758895	chr6:160193465	T/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.76	9.79	0.52	1.65e-19	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs9908102	0.740	rs58985615	chr17:12909988	C/A	cg26162695	chr17:12921313	ELAC2	0.52	5.67	0.33	3.77e-8	Schizophrenia;
CESC	cis	rs36051895	0.632	rs1360063	chr9:5167649	A/G	cg02405213	chr9:5042618	JAK2	-0.53	-6.14	-0.35	3.08e-9	Pediatric autoimmune diseases;
CESC	cis	rs9733	0.628	rs7540874	chr1:150702663	A/C	cg17724175	chr1:150552817	MCL1	0.45	7.31	0.41	3.17e-12	Tonsillectomy;
CESC	trans	rs17508449	0.819	rs77892281	chr1:114163617	A/T	cg15464363	chr22:32149800	DEPDC5	-0.68	-6.14	-0.35	3.03e-9	Leprosy;
CESC	cis	rs1003719	0.680	rs2835630	chr21:38521842	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.59	-8.0	-0.44	4.01e-14	Eye color traits;
CESC	cis	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg04267008	chr7:1944627	MAD1L1	-0.59	-7.18	-0.4	6.96e-12	Bipolar disorder and schizophrenia;
CESC	cis	rs2281558	0.876	rs2274890	chr20:25301022	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.61	8.17	0.45	1.31e-14	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;
CESC	cis	rs826838	1.000	rs11183747	chr12:38822595	A/G	cg13010199	chr12:38710504	ALG10B	-0.61	-8.63	-0.47	5.66e-16	Heart rate;
CESC	cis	rs10744422	1.000	rs2292134	chr12:123334033	C/G	cg25930673	chr12:123319894	HIP1R	-0.72	-5.73	-0.33	2.79e-8	Schizophrenia;
CESC	cis	rs10256972	0.721	rs6975972	chr7:1070468	A/G	cg04025307	chr7:1156635	C7orf50	0.48	7.52	0.42	8.34e-13	Longevity;Endometriosis;
CESC	cis	rs5771242	0.769	rs4838865	chr22:50664612	A/G	cg16473166	chr22:50639996	SELO	0.78	8.9	0.48	8.73e-17	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
CESC	cis	rs10754283	0.967	rs6698273	chr1:90106791	T/A	cg21401794	chr1:90099060	LRRC8C	0.69	9.34	0.5	4.06e-18	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs7264396	0.563	rs17093093	chr20:34380925	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.87	-9.7	-0.51	3.12e-19	Total cholesterol levels;
CESC	cis	rs3733585	0.783	rs13148371	chr4:10032561	C/T	cg11266682	chr4:10021025	SLC2A9	0.71	14.13	0.66	3.57e-34	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs4713118	0.621	rs4713132	chr6:28034035	A/G	cg26335602	chr6:28129616	ZNF389	0.48	6.14	0.35	3.05e-9	Parkinson's disease;
CESC	cis	rs853679	0.550	rs6901017	chr6:28152583	T/C	cg22143856	chr6:28129313	ZNF389	0.43	5.67	0.33	3.79e-8	Depression;
CESC	cis	rs9796	0.689	rs13329537	chr15:41449211	C/G	cg20272979	chr15:41787780	ITPKA	-0.33	-5.09	-0.3	6.75e-7	Menopause (age at onset);
CESC	cis	rs8016982	0.630	rs61980900	chr14:81686436	T/C	cg01989461	chr14:81687754	GTF2A1	0.75	11.71	0.58	8.36e-26	Schizophrenia;
CESC	cis	rs3733585	0.806	rs11723382	chr4:9954660	T/C	cg02734326	chr4:10020555	SLC2A9	-0.45	-6.82	-0.39	6.28e-11	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs11690935	0.959	rs7604918	chr2:172588094	G/A	cg13550731	chr2:172543902	DYNC1I2	-0.97	-14.97	-0.68	4e-37	Schizophrenia;
CESC	cis	rs7666738	0.830	rs28818218	chr4:98880575	A/C	cg17366294	chr4:99064904	C4orf37	0.56	7.87	0.44	9.04e-14	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2294693	0.898	rs6458195	chr6:40972498	A/T	cg14769373	chr6:40998127	UNC5CL	0.42	5.67	0.33	3.66e-8	Gastric cancer;Non-cardia gastric cancer;
CESC	cis	rs9457247	1.000	rs385863	chr6:167386615	C/G	cg07741184	chr6:167504864	NA	0.31	5.53	0.32	7.87e-8	Crohn's disease;
CESC	cis	rs2479106	0.892	rs12347057	chr9:126694094	T/A	cg16191174	chr9:126692580	DENND1A	0.51	7.0	0.4	2.04e-11	Polycystic ovary syndrome;
CESC	cis	rs4665809	1.000	rs750450	chr2:26324631	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.72	-8.14	-0.45	1.5e-14	Gut microbiome composition (summer);
CESC	cis	rs7520050	1.000	rs7540699	chr1:46338585	A/G	cg24296786	chr1:45957014	TESK2	0.43	5.41	0.32	1.4e-7	Red blood cell count;Reticulocyte count;
CESC	trans	rs61931739	0.500	rs34997501	chr12:34549828	C/G	cg26384229	chr12:38710491	ALG10B	0.72	10.84	0.55	6.43e-23	Morning vs. evening chronotype;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15262992	chr20:61442882	OGFR	-0.59	-6.85	-0.39	5.27e-11	Gut microbiome composition (summer);
CESC	cis	rs4853012	1.000	rs2280643	chr2:74358286	T/C	cg05890377	chr2:74357713	NA	0.71	8.95	0.48	6.36e-17	Gestational age at birth (maternal effect);
CESC	cis	rs60154123	0.730	rs590380	chr1:210463071	C/T	cg21951975	chr1:209979733	IRF6	0.42	5.46	0.32	1.09e-7	Coronary artery disease;
CESC	trans	rs7615952	0.932	rs9841157	chr3:125635655	C/A	cg07211511	chr3:129823064	LOC729375	-1.1	-13.63	-0.64	2.03e-32	Blood pressure (smoking interaction);
CESC	cis	rs9325144	0.560	rs11182979	chr12:38642562	C/A	cg26384229	chr12:38710491	ALG10B	-0.61	-8.58	-0.47	8.35e-16	Morning vs. evening chronotype;
CESC	cis	rs7666738	0.830	rs7697315	chr4:98938764	T/C	cg17366294	chr4:99064904	C4orf37	0.59	8.2	0.45	1.07e-14	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6977955	1.000	rs2189965	chr7:28172014	C/T	cg23620719	chr7:28220237	JAZF1	0.58	6.67	0.38	1.45e-10	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs873946	0.648	rs1548281	chr10:134552982	C/T	cg06453172	chr10:134556979	INPP5A	-0.41	-5.29	-0.31	2.54e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs780096	0.565	rs813592	chr2:27721971	T/C	cg24768116	chr2:27665128	KRTCAP3	-0.31	-5.8	-0.34	1.88e-8	Total body bone mineral density;
CESC	cis	rs9814567	0.806	rs11927540	chr3:134319455	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.39	-5.11	-0.3	6.3e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	trans	rs1382269	0.840	rs1478326	chr3:136964960	G/A	cg16900796	chr19:10755136	SLC44A2	-0.4	-6.15	-0.35	2.82e-9	Metabolite levels;
CESC	cis	rs4704187	0.640	rs74719230	chr5:74431888	G/C	cg03227963	chr5:74354835	NA	0.3	5.57	0.32	6.41e-8	Response to amphetamines;
CESC	cis	rs4665809	0.938	rs6742226	chr2:26342537	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.64	-7.14	-0.4	9.1e-12	Gut microbiome composition (summer);
CESC	cis	rs4727027	0.737	rs10278971	chr7:148780659	A/T	cg23583168	chr7:148888333	NA	-0.72	-10.06	-0.53	2.29e-20	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs2404602	0.716	rs12917430	chr15:76674360	T/C	cg22467129	chr15:76604101	ETFA	-0.37	-5.64	-0.33	4.44e-8	Blood metabolite levels;
CESC	cis	rs12410462	0.582	rs2872251	chr1:227647723	G/A	cg23173402	chr1:227635558	NA	0.55	5.41	0.32	1.41e-7	Major depressive disorder;
CESC	cis	rs10504229	0.683	rs7827881	chr8:58132137	C/T	cg02725872	chr8:58115012	NA	-0.45	-7.12	-0.4	1.02e-11	Developmental language disorder (linguistic errors);
CESC	trans	rs7618501	0.521	rs11130222	chr3:49901060	A/T	cg21659725	chr3:3221576	CRBN	0.47	6.19	0.36	2.26e-9	Intelligence (multi-trait analysis);
CESC	cis	rs9790314	0.967	rs336541	chr3:161056698	A/C	cg03342759	chr3:160939853	NMD3	-0.47	-6.07	-0.35	4.48e-9	Morning vs. evening chronotype;
CESC	cis	rs73206853	0.563	rs7301623	chr12:111170903	T/C	cg12870014	chr12:110450643	ANKRD13A	0.65	5.7	0.33	3.23e-8	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	trans	rs7937682	0.924	rs7924683	chr11:111555796	C/A	cg18187862	chr3:45730750	SACM1L	0.51	6.58	0.37	2.49e-10	Primary sclerosing cholangitis;
CESC	cis	rs9863	0.861	rs7973683	chr12:124449223	C/A	cg00084347	chr12:124393913	DNAH10	0.27	5.3	0.31	2.46e-7	White blood cell count;
CESC	cis	rs780096	0.565	rs813592	chr2:27721971	T/C	cg22903471	chr2:27725779	GCKR	-0.53	-7.5	-0.42	9.45e-13	Total body bone mineral density;
CESC	cis	rs7762018	0.769	rs7766146	chr6:170070135	A/T	cg05834625	chr6:170176447	C6orf70	0.52	5.64	0.33	4.31e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs6662572	0.641	rs4660891	chr1:46319447	T/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.44	-5.04	-0.3	8.65e-7	Blood protein levels;
CESC	cis	rs9311474	0.508	rs12637627	chr3:52619962	G/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.36	6.58	0.37	2.53e-10	Electroencephalogram traits;
CESC	cis	rs72901758	0.768	rs72901766	chr17:76245203	G/C	cg23302638	chr17:76210176	BIRC5	0.5	5.56	0.32	6.7e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
CESC	cis	rs1008375	0.866	rs2109518	chr4:17572162	G/A	cg27347728	chr4:17578864	LAP3	0.43	5.14	0.3	5.22e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs3091242	0.933	rs11802413	chr1:25760920	A/G	cg27572855	chr1:25598939	RHD	-0.44	-7.42	-0.41	1.63e-12	Erythrocyte sedimentation rate;
CESC	cis	rs5753037	0.585	rs36572	chr22:30200936	T/C	cg01021169	chr22:30184971	ASCC2	-0.55	-8.34	-0.46	4.1e-15	Type 1 diabetes;
CESC	cis	rs9303280	0.806	rs11078928	chr17:38064469	T/C	cg20243544	chr17:37824526	PNMT	0.53	6.79	0.39	7.3e-11	Self-reported allergy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01932459	chr6:109703513	CD164	0.59	6.85	0.39	5.1e-11	Gut microbiome composition (summer);
CESC	trans	rs1908814	0.516	rs13275143	chr8:11796990	T/A	cg15556689	chr8:8085844	FLJ10661	0.53	6.56	0.37	2.88e-10	Neuroticism;
CESC	cis	rs367943	0.672	rs1517207	chr5:112717245	G/A	cg12552261	chr5:112820674	MCC	0.39	5.22	0.31	3.62e-7	Type 2 diabetes;
CESC	cis	rs6032067	1.000	rs34885285	chr20:43804789	C/A	cg10761708	chr20:43804764	PI3	0.53	6.33	0.36	1.04e-9	Blood protein levels;
CESC	cis	rs6024905	0.722	rs2275954	chr20:36962667	C/T	cg07053727	chr20:36965646	BPI	-0.49	-7.35	-0.41	2.49e-12	Bipolar disorder and schizophrenia;
CESC	cis	rs67311347	0.866	rs3214006	chr3:40352134	C/T	cg09455208	chr3:40491958	NA	0.46	7.61	0.42	4.93e-13	Renal cell carcinoma;
CESC	cis	rs1949733	1.000	rs1357481	chr4:8496221	A/T	cg11789530	chr4:8429930	ACOX3	0.7	10.08	0.53	1.91e-20	Response to antineoplastic agents;
CESC	cis	rs11690935	0.959	rs1113389	chr2:172635365	C/T	cg13550731	chr2:172543902	DYNC1I2	-1.01	-16.63	-0.71	5.07e-43	Schizophrenia;
CESC	cis	rs13082711	0.863	rs35998108	chr3:27423427	G/A	cg02860705	chr3:27208620	NA	0.54	6.82	0.39	6.15e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CESC	cis	rs6912958	0.559	rs107690	chr6:88069352	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.48	-8.56	-0.47	9.42e-16	Monocyte percentage of white cells;
CESC	cis	rs1552244	1.000	rs35198334	chr3:10104553	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	11.71	0.58	8.58e-26	Alzheimer's disease;
CESC	cis	rs9926296	0.546	rs6500442	chr16:89828862	T/C	cg21285383	chr16:89894308	SPIRE2	0.33	5.98	0.35	7.03e-9	Vitiligo;
CESC	cis	rs561341	1.000	rs8073186	chr17:30244956	T/C	cg00745463	chr17:30367425	LRRC37B	-0.53	-5.37	-0.31	1.76e-7	Hip circumference adjusted for BMI;
CESC	cis	rs6963495	0.818	rs6961233	chr7:105150469	C/T	cg02135003	chr7:105160482	PUS7	-0.47	-5.61	-0.33	5.12e-8	Bipolar disorder (body mass index interaction);
CESC	cis	rs763014	0.931	rs59476302	chr16:629006	C/T	cg00802000	chr16:706648	WDR90	-0.42	-6.41	-0.37	6.52e-10	Height;
CESC	cis	rs4664308	0.618	rs17830755	chr2:160888835	T/C	cg03641300	chr2:160917029	PLA2R1	-0.59	-8.54	-0.46	1.04e-15	Idiopathic membranous nephropathy;
CESC	trans	rs877282	0.685	rs56234340	chr10:781339	A/G	cg22713356	chr15:30763199	NA	0.97	10.16	0.53	1.09e-20	Uric acid levels;
CESC	cis	rs7208859	0.623	rs8067338	chr17:29102345	T/C	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.17e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs2070433	0.500	rs9306156	chr21:47960493	T/C	cg12379764	chr21:47803548	PCNT	0.56	7.45	0.42	1.29e-12	Lymphocyte counts;
CESC	cis	rs4555082	0.957	rs2816628	chr14:105736134	T/G	cg27165867	chr14:105738592	BRF1	-0.48	-5.85	-0.34	1.47e-8	Mean platelet volume;Platelet distribution width;
CESC	cis	rs4919694	1.000	rs11191439	chr10:104638723	C/T	cg04362960	chr10:104952993	NT5C2	-0.75	-6.34	-0.36	9.85e-10	Arsenic metabolism;
CESC	cis	rs300703	0.654	rs435733	chr2:121222	A/G	cg21211680	chr2:198530	NA	-0.96	-9.78	-0.52	1.7e-19	Blood protein levels;
CESC	cis	rs12497850	1.000	rs12493578	chr3:48730116	C/T	cg03060546	chr3:49711283	APEH	-0.56	-6.38	-0.36	8.03e-10	Parkinson's disease;
CESC	trans	rs11098499	0.954	rs35063680	chr4:120387102	T/C	cg25214090	chr10:38739885	LOC399744	0.7	9.93	0.52	5.63e-20	Corneal astigmatism;
CESC	cis	rs7772486	0.686	rs6933161	chr6:146081369	G/A	cg23711669	chr6:146136114	FBXO30	-0.88	-13.18	-0.63	7.63e-31	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7091068	0.536	rs6583901	chr10:95409998	C/T	cg20715218	chr10:95462985	C10orf4	-0.48	-5.78	-0.33	2.14e-8	Urinary tract infection frequency;
CESC	trans	rs10242455	0.702	rs7794068	chr7:99146873	A/T	cg09045935	chr12:6379348	NA	0.83	7.11	0.4	1.08e-11	Blood metabolite levels;
CESC	cis	rs2236521	0.659	rs72487383	chr20:60889313	A/C	cg12382846	chr20:60892121	LAMA5	0.35	6.34	0.36	9.86e-10	Pelvic organ prolapse;
CESC	cis	rs6685188	0.920	rs6676110	chr1:205662977	G/A	cg14893161	chr1:205819251	PM20D1	-0.45	-6.18	-0.35	2.4e-9	White blood cell count (basophil);Basophil percentage of white cells;
CESC	cis	rs2243480	1.000	rs465359	chr7:65558164	C/T	cg13147721	chr7:65941812	NA	-0.98	-9.11	-0.49	2.06e-17	Diabetic kidney disease;
CESC	cis	rs1799949	1.000	rs1399323	chr17:41332330	T/C	cg25072359	chr17:41440525	NA	0.48	6.46	0.37	4.98e-10	Menopause (age at onset);
CESC	cis	rs17376456	0.877	rs17315943	chr5:93442830	T/C	cg21475434	chr5:93447410	FAM172A	0.85	7.6	0.42	5.01e-13	Diabetic retinopathy;
CESC	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	10.16	0.53	1.09e-20	Prudent dietary pattern;
CESC	cis	rs9322193	0.962	rs4816	chr6:150114745	G/A	cg04369109	chr6:150039330	LATS1	-0.39	-5.35	-0.31	1.93e-7	Lung cancer;
CESC	cis	rs4843747	0.636	rs11117358	chr16:88105053	T/A	cg03395651	chr16:88107091	BANP	0.46	5.34	0.31	1.98e-7	Menopause (age at onset);
CESC	cis	rs11203032	0.831	rs11203017	chr10:90948709	C/T	cg16672925	chr10:90967113	CH25H	0.72	7.16	0.4	7.78e-12	Heart failure;
CESC	cis	rs17826219	0.636	rs4055314	chr17:29079769	T/C	cg13385521	chr17:29058706	SUZ12P	0.81	6.51	0.37	3.84e-10	Body mass index;
CESC	trans	rs7246657	0.943	rs7248733	chr19:37996361	A/C	cg24637308	chr11:6592297	DNHD1	0.52	6.32	0.36	1.12e-9	Coronary artery calcification;
CESC	cis	rs751728	1.000	rs755496	chr6:33734376	C/G	cg25922239	chr6:33757077	LEMD2	0.5	6.73	0.38	1.05e-10	Crohn's disease;
CESC	cis	rs1862618	0.671	rs2591966	chr5:56233688	T/G	cg22800045	chr5:56110881	MAP3K1	-0.55	-7.15	-0.4	8.45e-12	Initial pursuit acceleration;
CESC	cis	rs5758659	0.714	rs5758589	chr22:42518382	A/G	cg04733989	chr22:42467013	NAGA	-0.45	-6.23	-0.36	1.83e-9	Cognitive function;
CESC	cis	rs9837602	0.938	rs9815439	chr3:99785206	G/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.46	6.79	0.38	7.54e-11	Breast cancer;
CESC	cis	rs4665809	0.590	rs1469523	chr2:26474631	T/A	cg26119090	chr2:26468346	HADHA;HADHB	1.1	12.71	0.62	3.31e-29	Gut microbiome composition (summer);
CESC	cis	rs8067354	0.574	rs2526353	chr17:57988607	G/T	cg13753209	chr17:57696993	CLTC	0.54	5.69	0.33	3.36e-8	Hemoglobin concentration;
CESC	cis	rs7191439	0.722	rs6500491	chr16:88783521	T/C	cg02389323	chr16:88786976	FAM38A	0.85	6.44	0.37	5.49e-10	Plateletcrit;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22060484	chr11:64646415	EHD1	0.58	6.79	0.38	7.5e-11	Gut microbiome composition (summer);
CESC	cis	rs2262909	0.962	rs73019844	chr19:22249925	T/C	cg11619707	chr19:22235551	ZNF257	0.33	5.17	0.3	4.65e-7	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
CESC	cis	rs3780486	0.505	rs10117038	chr9:33122626	T/C	cg13443165	chr9:33130375	B4GALT1	0.46	7.08	0.4	1.27e-11	IgG glycosylation;
CESC	cis	rs2952156	0.959	rs907087	chr17:37828787	G/A	cg07936489	chr17:37558343	FBXL20	-0.54	-6.4	-0.37	7.14e-10	Asthma;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg06538771	chr22:50636937	TRABD	0.48	7.05	0.4	1.56e-11	Fibrinogen levels;
CESC	trans	rs12310956	0.532	rs6488186	chr12:33974122	G/A	cg26384229	chr12:38710491	ALG10B	0.5	6.82	0.39	5.98e-11	Morning vs. evening chronotype;
CESC	cis	rs35306767	0.714	rs12777800	chr10:1070361	G/A	cg26597838	chr10:835615	NA	0.64	6.02	0.35	5.75e-9	Eosinophil percentage of granulocytes;
CESC	cis	rs7811142	1.000	rs7803454	chr7:99991548	C/T	cg11814155	chr7:99998594	ZCWPW1	0.53	5.14	0.3	5.31e-7	Platelet count;
CESC	cis	rs9787249	0.957	rs41267029	chr1:40214367	A/G	cg02773041	chr1:40204384	PPIE	0.53	7.56	0.42	6.49e-13	Blood protein levels;
CESC	cis	rs116095464	0.558	rs10056628	chr5:279512	G/A	cg22496380	chr5:211416	CCDC127	-0.99	-10.21	-0.53	7.52e-21	Breast cancer;
CESC	cis	rs4888262	0.545	rs7342732	chr16:74698716	A/C	cg01733217	chr16:74700730	RFWD3	0.91	12.9	0.62	7.31e-30	Testicular germ cell tumor;
CESC	cis	rs6963495	0.519	rs3892297	chr7:105152173	G/A	cg13798780	chr7:105162888	PUS7	0.75	7.67	0.43	3.27e-13	Bipolar disorder (body mass index interaction);
CESC	cis	rs7590720	1.000	rs934154	chr2:216901933	C/T	cg12620499	chr2:216877984	MREG	0.9	12.27	0.6	1.02e-27	Alcohol dependence;
CESC	cis	rs4713118	0.513	rs149950	chr6:28033039	T/G	cg23281280	chr6:28129359	ZNF389	0.37	5.47	0.32	1.06e-7	Parkinson's disease;
CESC	cis	rs67311347	0.868	rs10865895	chr3:40378677	C/T	cg24209194	chr3:40518798	ZNF619	0.4	5.1	0.3	6.35e-7	Renal cell carcinoma;
CESC	cis	rs17125944	0.686	rs12435704	chr14:53346574	T/C	cg00686598	chr14:53173677	PSMC6	-0.64	-5.58	-0.32	6.08e-8	Alzheimer's disease (late onset);
CESC	cis	rs9911578	0.935	rs304261	chr17:56813782	A/G	cg05425664	chr17:57184151	TRIM37	-0.5	-6.88	-0.39	4.25e-11	Intelligence (multi-trait analysis);
CESC	cis	rs11122272	0.735	rs2808601	chr1:231536571	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.5	-6.59	-0.38	2.31e-10	Hemoglobin concentration;
CESC	cis	rs2180341	0.960	rs9398842	chr6:127674662	T/C	cg27446573	chr6:127587934	RNF146	1.06	15.88	0.7	2.39e-40	Breast cancer;
CESC	cis	rs597539	0.652	rs514296	chr11:68654182	G/T	cg04772025	chr11:68637568	NA	0.5	6.14	0.35	2.92e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg08302209	chr14:92506076	TRIP11	0.48	6.09	0.35	3.96e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs3749237	0.595	rs1050088	chr3:49570882	C/T	cg07636037	chr3:49044803	WDR6	-0.56	-8.0	-0.44	3.89e-14	Resting heart rate;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07483432	chr12:72079704	TMEM19	-0.54	-6.22	-0.36	1.94e-9	Gut microbiome composition (summer);
CESC	cis	rs10510921	0.826	rs9825384	chr3:64893104	A/C	cg13520011	chr3:65339606	NA	-0.54	-5.23	-0.31	3.4e-7	Clozapine-induced agranulocytosis;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg02661095	chr16:1869158	HAGH	0.46	6.57	0.37	2.66e-10	Fibrinogen levels;
CESC	cis	rs2637266	0.667	rs7091526	chr10:78319770	A/G	cg18941641	chr10:78392320	NA	-0.31	-5.19	-0.3	4.14e-7	Pulmonary function;
CESC	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg03188948	chr7:1209495	NA	0.71	7.06	0.4	1.5e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs6460942	0.915	rs6966791	chr7:12439714	T/C	cg06484146	chr7:12443880	VWDE	-0.78	-9.1	-0.49	2.28e-17	Coronary artery disease;
CESC	cis	rs7143963	0.609	rs4906270	chr14:103364737	G/T	cg24154132	chr14:103367632	TRAF3	0.34	6.06	0.35	4.68e-9	Body mass index;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18029778	chr7:104654746	MLL5;LOC100216545	0.65	7.63	0.42	4.26e-13	Gut microbiome composition (summer);
CESC	cis	rs1322639	0.614	rs6940913	chr6:169563666	G/A	cg04662567	chr6:169592167	NA	-0.49	-5.19	-0.3	4.2e-7	Pulse pressure;
CESC	cis	rs3741404	0.609	rs666497	chr11:63869821	G/C	cg18225595	chr11:63971243	STIP1	0.51	6.7	0.38	1.24e-10	Platelet count;
CESC	cis	rs6460942	0.841	rs62448597	chr7:12449110	G/C	cg17427002	chr7:12443146	VWDE	-0.56	-5.85	-0.34	1.42e-8	Coronary artery disease;
CESC	trans	rs12356475	0.710	rs10822686	chr10:67733250	C/T	cg01095510	chr12:26267286	NA	0.47	6.01	0.35	6.01e-9	Psoriatic arthritis;
CESC	cis	rs798554	0.683	rs1182155	chr7:2902890	C/G	cg04166393	chr7:2884313	GNA12	0.59	7.7	0.43	2.77e-13	Height;
CESC	cis	rs9633740	0.545	rs2343306	chr10:82230146	A/G	cg00277334	chr10:82204260	NA	0.6	6.08	0.35	4.06e-9	Post bronchodilator FEV1;
CESC	cis	rs250677	0.522	rs6875902	chr5:148407893	C/A	cg18129178	chr5:148520854	ABLIM3	-0.45	-5.06	-0.3	7.92e-7	Breast cancer;
CESC	cis	rs10911232	0.507	rs4442336	chr1:182982538	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.83	13.25	0.63	4.4e-31	Hypertriglyceridemia;
CESC	cis	rs1799949	0.965	rs12950779	chr17:41306523	C/T	cg25072359	chr17:41440525	NA	0.44	5.85	0.34	1.43e-8	Menopause (age at onset);
CESC	trans	rs11098499	0.863	rs1155576	chr4:120450159	A/C	cg25214090	chr10:38739885	LOC399744	0.71	9.8	0.52	1.46e-19	Corneal astigmatism;
CESC	trans	rs116095464	0.558	rs7710005	chr5:233572	A/G	cg00938859	chr5:1591904	SDHAP3	0.66	7.18	0.4	6.97e-12	Breast cancer;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg13411962	chr8:28243934	ZNF395	-0.45	-6.04	-0.35	5.27e-9	Ulcerative colitis;
CESC	cis	rs2635047	0.713	rs17723389	chr18:44762307	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.42	5.64	0.33	4.37e-8	Educational attainment;
CESC	cis	rs473651	0.904	rs472247	chr2:239362573	G/A	cg21699342	chr2:239360505	ASB1	0.56	9.48	0.5	1.52e-18	Multiple system atrophy;
CESC	cis	rs7666738	0.830	rs113999196	chr4:99041961	C/T	cg18180107	chr4:99064573	C4orf37	0.41	5.29	0.31	2.51e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg06096824	chr1:51443952	NA	-0.48	-6.22	-0.36	1.94e-9	Fibrinogen levels;
CESC	cis	rs208520	1.000	rs72882086	chr6:66976671	G/A	cg07460842	chr6:66804631	NA	0.88	10.2	0.53	7.81e-21	Exhaled nitric oxide output;
CESC	cis	rs7666738	0.761	rs28758886	chr4:99059704	C/T	cg17366294	chr4:99064904	C4orf37	0.62	8.89	0.48	9.9900000000000006e-17	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7666738	0.830	rs1834647	chr4:98882915	G/A	cg17366294	chr4:99064904	C4orf37	0.56	7.79	0.43	1.48e-13	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04400940	chr3:150329548	SELT	-0.75	-8.46	-0.46	1.84e-15	Gut microbiome composition (summer);
CESC	cis	rs9649213	0.613	rs2286074	chr7:97952011	G/A	cg21770322	chr7:97807741	LMTK2	0.54	8.15	0.45	1.45e-14	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs2456568	0.548	rs7117597	chr11:93655091	A/G	cg26875233	chr11:93583750	C11orf90	-0.34	-5.89	-0.34	1.16e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
CESC	cis	rs7107174	1.000	rs7116698	chr11:77995191	T/C	cg02023728	chr11:77925099	USP35	0.48	6.68	0.38	1.41e-10	Testicular germ cell tumor;
CESC	cis	rs644799	1.000	rs514170	chr11:95556696	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	9.15	0.49	1.57e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs7811142	1.000	rs1000215	chr7:100004543	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.92	10.75	0.55	1.32e-22	Platelet count;
CESC	cis	rs1881797	1.000	rs1881796	chr1:247688931	G/A	cg05639522	chr1:247681581	NA	0.45	5.99	0.35	6.71e-9	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs1799949	0.896	rs33933393	chr17:41317432	C/T	cg23758822	chr17:41437982	NA	1.05	16.33	0.71	5.75e-42	Menopause (age at onset);
CESC	cis	rs4969178	0.965	rs2292643	chr17:76395421	G/A	cg05887092	chr17:76393375	PGS1	0.58	9.14	0.49	1.64e-17	HDL cholesterol levels;
CESC	cis	rs514406	0.893	rs499195	chr1:53344907	C/T	cg25767906	chr1:53392781	SCP2	-0.43	-5.47	-0.32	1.04e-7	Monocyte count;
CESC	cis	rs9486715	0.867	rs12207471	chr6:96963782	A/G	cg18709589	chr6:96969512	KIAA0776	0.44	6.18	0.35	2.4e-9	Headache;
CESC	cis	rs9929218	0.911	rs4783685	chr16:68834107	C/T	cg02972257	chr16:68554789	NA	0.51	5.85	0.34	1.43e-8	Colorectal cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27435660	chr10:5935953	FBXO18	-0.54	-6.5	-0.37	4.06e-10	Gut microbiome composition (summer);
CESC	cis	rs2204008	0.744	rs1115514	chr12:38280140	C/T	cg13010199	chr12:38710504	ALG10B	0.46	5.61	0.33	5.13e-8	Bladder cancer;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg18346038	chr20:33264828	PIGU	-0.46	-6.47	-0.37	4.63e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs736408	0.609	rs13087772	chr3:52782274	T/G	cg05564831	chr3:52568323	NT5DC2	0.44	6.69	0.38	1.3100000000000001e-10	Bipolar disorder;
CESC	cis	rs9303401	0.659	rs35564417	chr17:56718286	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.03	13.13	0.63	1.12e-30	Cognitive test performance;
CESC	cis	rs12822507	0.899	rs4763859	chr12:12787005	G/A	cg09462578	chr12:12878428	APOLD1	-0.44	-5.51	-0.32	8.36e-8	Systemic lupus erythematosus;
CESC	cis	rs4843747	0.671	rs8053377	chr16:88106465	A/G	cg06374794	chr16:88002281	BANP	0.41	5.29	0.31	2.62e-7	Menopause (age at onset);
CESC	cis	rs9287719	0.967	rs7355649	chr2:10748094	C/A	cg02196655	chr2:10830764	NOL10	-0.34	-5.16	-0.3	4.73e-7	Prostate cancer;
CESC	cis	rs3780486	0.846	rs3824458	chr9:33144809	C/T	cg13443165	chr9:33130375	B4GALT1	0.46	6.63	0.38	1.89e-10	IgG glycosylation;
CESC	cis	rs35955747	0.902	rs140074	chr22:31725634	C/G	cg02404636	chr22:31891804	SFI1	0.36	5.16	0.3	4.88e-7	Neutrophil count;Sum basophil neutrophil counts;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14942134	chr8:94929220	PDP1	0.56	6.66	0.38	1.61e-10	Gut microbiome composition (summer);
CESC	cis	rs8051149	0.688	rs55776570	chr16:87869516	C/G	cg01829163	chr16:87871160	SLC7A5	-0.57	-7.1	-0.4	1.17e-11	Blood metabolite levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19154858	chr13:48807339	ITM2B	0.56	6.67	0.38	1.48e-10	Gut microbiome composition (summer);
CESC	cis	rs6543140	0.964	rs6543138	chr2:103066132	G/A	cg04239558	chr2:103089729	SLC9A4	0.45	5.66	0.33	3.94e-8	Blood protein levels;
CESC	cis	rs782590	0.774	rs782637	chr2:55894247	T/C	cg18811423	chr2:55921094	PNPT1	0.78	12.91	0.62	6.55e-30	Metabolic syndrome;
CESC	cis	rs1801251	0.896	rs2305141	chr2:233684402	A/G	cg08000102	chr2:233561755	GIGYF2	-0.72	-11.24	-0.57	3.17e-24	Coronary artery disease;
CESC	cis	rs801193	0.569	rs6951302	chr7:66132512	T/C	cg10691866	chr7:65817282	TPST1	0.31	5.33	0.31	2.06e-7	Aortic root size;
CESC	cis	rs1552244	1.000	rs6793396	chr3:10110927	T/C	cg16606324	chr3:10149918	C3orf24	0.43	5.22	0.31	3.71e-7	Alzheimer's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07645736	chr6:137243249	SLC35D3	-0.58	-6.71	-0.38	1.16e-10	Gut microbiome composition (summer);
CESC	cis	rs8078723	0.677	rs11658328	chr17:38149236	T/C	cg17467752	chr17:38218738	THRA	-0.56	-8.52	-0.46	1.22e-15	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg15163040	chr3:167813423	GOLIM4	0.48	6.53	0.37	3.39e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs5758343	1	rs5758343	chr22:41816652	A/T	cg03806693	chr22:41940476	POLR3H	1.2	14.5	0.67	1.86e-35	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs4450798	0.793	rs28454765	chr3:13758013	A/G	cg23332027	chr3:13681764	NA	0.38	5.18	0.3	4.33e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs7617480	0.648	rs4858830	chr3:48734002	T/C	cg07636037	chr3:49044803	WDR6	0.76	9.61	0.51	6.12e-19	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CESC	cis	rs2131877	0.913	rs1874101	chr3:194849057	C/T	cg24618514	chr3:194868507	C3orf21	-0.43	-5.21	-0.3	3.84e-7	Non-small cell lung cancer;
CESC	trans	rs11098499	0.738	rs34965784	chr4:120361586	G/C	cg25214090	chr10:38739885	LOC399744	0.7	9.92	0.52	6.5e-20	Corneal astigmatism;
CESC	cis	rs7998202	0.775	rs282580	chr13:113357540	T/C	cg02820901	chr13:113351484	ATP11A	0.66	5.56	0.32	6.47e-8	Glycated hemoglobin levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21062897	chr14:50999680	MAP4K5;ATL1	0.63	7.72	0.43	2.38e-13	Gut microbiome composition (summer);
CESC	cis	rs911555	0.755	rs1116095	chr14:103931879	A/G	cg24130564	chr14:104152367	KLC1	0.48	6.26	0.36	1.53e-9	Intelligence (multi-trait analysis);
CESC	trans	rs3780486	0.718	rs3818593	chr9:33120706	A/G	cg20290983	chr6:43655470	MRPS18A	0.7	8.08	0.44	2.36e-14	IgG glycosylation;
CESC	cis	rs561341	0.714	rs55925849	chr17:30253085	C/T	cg00745463	chr17:30367425	LRRC37B	-0.85	-7.62	-0.42	4.38e-13	Hip circumference adjusted for BMI;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06610368	chr5:86564371	RASA1	0.55	6.36	0.36	9.05e-10	Gut microbiome composition (summer);
CESC	cis	rs7953508	0.506	rs930316	chr12:93967035	A/G	cg18151635	chr12:93972918	NA	-0.44	-5.87	-0.34	1.31e-8	Pubertal anthropometrics;
CESC	cis	rs4704187	0.595	rs7717337	chr5:74377001	T/C	cg03227963	chr5:74354835	NA	0.32	5.95	0.34	8.68e-9	Response to amphetamines;
CESC	cis	rs4835473	0.750	rs57610804	chr4:144895494	T/C	cg25736465	chr4:144833511	NA	0.39	5.97	0.34	7.43e-9	Immature fraction of reticulocytes;
CESC	cis	rs6952808	0.624	rs60137119	chr7:2083664	A/G	cg23048001	chr7:2026167	MAD1L1	0.47	6.08	0.35	4.08e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs11098499	0.955	rs35916640	chr4:120155852	T/C	cg09307838	chr4:120376055	NA	0.87	11.39	0.57	1.02e-24	Corneal astigmatism;
CESC	cis	rs9611565	0.765	rs767593	chr22:41779971	G/T	cg06481639	chr22:41940642	POLR3H	-0.63	-6.66	-0.38	1.55e-10	Vitiligo;
CESC	cis	rs12971120	0.891	rs12968731	chr18:72169708	G/T	cg25817165	chr18:72167213	CNDP2	-0.59	-7.2	-0.4	6.21e-12	Refractive error;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg06684987	chr19:45567721	SFRS16	0.53	6.93	0.39	3.13e-11	Fibrinogen levels;
CESC	cis	rs854765	0.647	rs4426402	chr17:17977926	C/T	cg04398451	chr17:18023971	MYO15A	0.78	11.61	0.58	1.85e-25	Total body bone mineral density;
CESC	cis	rs4713118	0.662	rs149946	chr6:27970031	A/C	cg12963246	chr6:28129442	ZNF389	-0.49	-6.35	-0.36	9.49e-10	Parkinson's disease;
CESC	cis	rs1348850	0.914	rs9789582	chr2:178330173	C/G	cg23306229	chr2:178417860	TTC30B	0.65	7.98	0.44	4.33e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs4975709	1.000	rs4975709	chr5:1877280	A/C	cg12288994	chr5:1860383	NA	0.35	5.84	0.34	1.52e-8	Cardiovascular disease risk factors;
CESC	cis	rs3796352	1.000	rs6445557	chr3:53083969	C/T	cg12962167	chr3:53033115	SFMBT1	-0.57	-5.78	-0.33	2.11e-8	Immune reponse to smallpox (secreted IL-2);
CESC	cis	rs12681288	0.748	rs2701935	chr8:1028618	T/A	cg15309053	chr8:964076	NA	0.38	6.03	0.35	5.42e-9	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21269758	chr1:25870003	LDLRAP1	0.54	6.32	0.36	1.13e-9	Gut microbiome composition (summer);
CESC	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg06074448	chr4:187884817	NA	-0.37	-5.43	-0.32	1.27e-7	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs67311347	0.911	rs9863737	chr3:40439836	C/T	cg09455208	chr3:40491958	NA	0.5	8.28	0.45	6.1e-15	Renal cell carcinoma;
CESC	cis	rs1062177	1.000	rs2964571	chr5:151171256	C/T	cg12924095	chr5:151150029	G3BP1	0.49	6.44	0.37	5.67e-10	Preschool internalizing problems;
CESC	cis	rs1552244	0.572	rs2054478	chr3:10172211	C/T	cg08888203	chr3:10149979	C3orf24	0.47	5.28	0.31	2.69e-7	Alzheimer's disease;
CESC	cis	rs506597	0.920	rs221797	chr7:100285974	A/C	cg10426581	chr7:100472382	SRRT	-0.69	-5.39	-0.31	1.57e-7	Pursuit maintenance gain in psychotic disorders;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg26384201	chr3:50336345	HYAL3;NAT6	-0.49	-7.13	-0.4	9.37e-12	Gut microbiota (bacterial taxa);
CESC	cis	rs644799	0.965	rs11021310	chr11:95502106	A/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.56	6.99	0.39	2.19e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs950169	0.845	rs4106951	chr15:84833394	C/G	cg17507749	chr15:85114479	UBE2QP1	0.55	6.25	0.36	1.66e-9	Schizophrenia;
CESC	cis	rs873946	0.557	rs34854637	chr10:134582962	A/G	cg18305652	chr10:134549665	INPP5A	0.46	6.58	0.37	2.48e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs6060717	0.610	rs1891154	chr20:34617129	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.58	-7.83	-0.43	1.17e-13	Hip circumference adjusted for BMI;
CESC	cis	rs34172651	0.917	rs1465422	chr16:24772486	C/T	cg06028605	chr16:24865363	SLC5A11	0.35	5.43	0.32	1.29e-7	Intelligence (multi-trait analysis);
CESC	cis	rs4076764	0.958	rs11590567	chr1:163396438	A/G	cg24596788	chr1:163392923	NA	-0.51	-7.44	-0.42	1.37e-12	Motion sickness;
CESC	cis	rs7772486	0.597	rs6570732	chr6:146245151	G/A	cg23711669	chr6:146136114	FBXO30	-0.94	-12.27	-0.6	1.06e-27	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1182196	0.502	rs757786	chr7:2836019	C/T	cg09658497	chr7:2847517	GNA12	-0.43	-6.86	-0.39	4.79e-11	Plateletcrit;
CESC	cis	rs2228479	0.850	rs17233455	chr16:89816407	A/G	cg14709524	chr16:89940631	TCF25	0.93	6.94	0.39	3.03e-11	Skin colour saturation;
CESC	cis	rs4819052	0.851	rs2330012	chr21:46658592	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.91	13.24	0.63	4.51e-31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs1881797	1.000	rs12081895	chr1:247686666	C/G	cg21399703	chr1:247681439	NA	0.55	7.37	0.41	2.13e-12	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs116095464	0.558	rs34629844	chr5:200829	A/G	cg16372103	chr5:203701	NA	0.51	5.66	0.33	4.01e-8	Breast cancer;
CESC	trans	rs1728785	1.000	rs12918865	chr16:68566546	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.61	7.42	0.41	1.57e-12	Ulcerative colitis;
CESC	cis	rs17001868	0.568	rs9611312	chr22:40734790	T/C	cg07138101	chr22:40742427	ADSL	0.54	5.18	0.3	4.49e-7	Mammographic density (dense area);
CESC	cis	rs2204008	0.837	rs11519926	chr12:38348992	G/A	cg26384229	chr12:38710491	ALG10B	0.73	10.65	0.55	2.87e-22	Bladder cancer;
CESC	trans	rs11098499	0.722	rs10025925	chr4:120271744	A/T	cg25214090	chr10:38739885	LOC399744	0.6	8.3	0.45	5.33e-15	Corneal astigmatism;
CESC	cis	rs7843479	0.930	rs4871903	chr8:21827833	C/T	cg17168535	chr8:21777572	XPO7	-0.47	-6.36	-0.36	9.05e-10	Mean corpuscular volume;
CESC	cis	rs12973672	0.812	rs12984022	chr19:35754011	A/C	cg12095397	chr19:35769544	USF2	0.5	5.96	0.34	7.98e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs938554	0.657	rs7660895	chr4:9985445	A/G	cg00071950	chr4:10020882	SLC2A9	0.45	5.79	0.33	2.03e-8	Blood metabolite levels;
CESC	cis	rs4746818	1.000	rs4746818	chr10:70884687	G/T	cg11621586	chr10:70884670	VPS26A	0.99	13.28	0.63	3.38e-31	Left atrial antero-posterior diameter;
CESC	trans	rs8026198	0.568	rs56670003	chr15:42548434	G/A	cg24724587	chr1:86044103	DDAH1	-0.58	-6.0	-0.35	6.4e-9	Fibrinogen levels;
CESC	cis	rs7618915	0.501	rs3733039	chr3:52719088	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.53	8.02	0.44	3.41e-14	Bipolar disorder;
CESC	cis	rs644799	0.965	rs499076	chr11:95546341	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.92	13.87	0.65	2.93e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	trans	rs17685	0.743	rs10277259	chr7:75802674	A/C	cg19862616	chr7:65841803	NCRNA00174	0.84	12.03	0.59	6.77e-27	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs35306767	0.761	rs11253559	chr10:1044809	T/C	cg20503657	chr10:835505	NA	0.7	6.32	0.36	1.07e-9	Eosinophil percentage of granulocytes;
CESC	cis	rs7542091	0.704	rs7550330	chr1:210044587	G/A	cg21951975	chr1:209979733	IRF6	0.47	8.25	0.45	7.51e-15	Monobrow;
CESC	cis	rs2072499	1.000	rs2241107	chr1:156182710	C/T	cg24450063	chr1:156163899	SLC25A44	-0.96	-18.22	-0.75	1.21e-48	Testicular germ cell tumor;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17875760	chr17:1802361	RPA1	-0.56	-6.72	-0.38	1.1e-10	Gut microbiome composition (summer);
CESC	cis	rs9911578	0.935	rs420878	chr17:56709077	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.4	5.46	0.32	1.12e-7	Intelligence (multi-trait analysis);
CESC	cis	rs2239547	0.522	rs2710345	chr3:52976075	T/C	cg11645453	chr3:52864694	ITIH4	-0.31	-5.13	-0.3	5.54e-7	Schizophrenia;
CESC	cis	rs748404	0.697	rs504417	chr15:43554226	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.51	7.98	0.44	4.38e-14	Lung cancer;
CESC	trans	rs2727020	0.523	rs7948958	chr11:49506749	G/A	cg15704280	chr7:45808275	SEPT13	0.83	10.19	0.53	8.77e-21	Coronary artery disease;
CESC	cis	rs9443645	0.901	rs9343843	chr6:79585625	C/T	cg05283184	chr6:79620031	NA	-0.44	-6.64	-0.38	1.74e-10	Intelligence (multi-trait analysis);
CESC	cis	rs7613875	0.580	rs2624819	chr3:50010571	G/T	cg24308560	chr3:49941425	MST1R	-0.59	-8.26	-0.45	6.88e-15	Body mass index;
CESC	cis	rs853679	0.517	rs1947863	chr6:28099344	G/A	cg22143856	chr6:28129313	ZNF389	0.52	6.77	0.38	8.31e-11	Depression;
CESC	cis	rs7587476	0.822	rs13018304	chr2:215682218	T/G	cg04004882	chr2:215674386	BARD1	0.53	5.94	0.34	8.87e-9	Neuroblastoma;
CESC	cis	rs3768617	0.782	rs10752893	chr1:183046261	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.66	9.15	0.49	1.56e-17	Fuchs's corneal dystrophy;
CESC	cis	rs1847202	0.592	rs13073005	chr3:72951007	C/T	cg25664220	chr3:72788482	NA	-0.38	-5.57	-0.32	6.3e-8	Motion sickness;
CESC	cis	rs875971	0.545	rs75577046	chr7:65958716	A/G	cg18876405	chr7:65276391	NA	0.48	5.52	0.32	8.28e-8	Aortic root size;
CESC	trans	rs916888	0.779	rs199528	chr17:44843136	C/T	cg22433210	chr17:43662623	NA	0.96	10.7	0.55	1.87e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12075144	chr3:155588060	GMPS	0.54	6.16	0.35	2.68e-9	Gut microbiome composition (summer);
CESC	cis	rs6912958	0.514	rs7767449	chr6:87887985	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.48	-8.19	-0.45	1.1e-14	Monocyte percentage of white cells;
CESC	trans	rs17685	0.712	rs1639620	chr7:75704090	A/G	cg19862616	chr7:65841803	NCRNA00174	0.85	12.47	0.61	2.13e-28	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs66887589	0.616	rs11098497	chr4:120187068	C/T	cg09307838	chr4:120376055	NA	0.68	9.52	0.5	1.13e-18	Diastolic blood pressure;
CESC	cis	rs3126085	0.560	rs3120666	chr1:152316981	G/C	cg03465714	chr1:152285911	FLG	0.42	5.04	0.3	8.66e-7	Atopic dermatitis;
CESC	cis	rs11112613	0.713	rs17041546	chr12:105950801	G/T	cg03607813	chr12:105948248	NA	-0.57	-7.28	-0.41	3.7e-12	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CESC	cis	rs116095464	0.558	rs2288459	chr5:231143	T/C	cg12570787	chr5:219185	SDHA;CCDC127	0.5	5.22	0.31	3.68e-7	Breast cancer;
CESC	cis	rs6570726	0.764	rs4896821	chr6:145896181	G/A	cg05347473	chr6:146136440	FBXO30	0.48	6.44	0.37	5.62e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs5750830	0.594	rs5757650	chr22:39778419	A/G	cg24399712	chr22:39784796	NA	-0.72	-10.38	-0.54	2.07e-21	Intelligence (multi-trait analysis);
CESC	cis	rs796364	0.806	rs35200468	chr2:201110368	G/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.7	-6.31	-0.36	1.14e-9	Schizophrenia;
CESC	cis	rs801193	1.000	rs1553609	chr7:66197139	T/C	cg06456125	chr7:65229604	NA	0.39	5.05	0.3	8.06e-7	Aortic root size;
CESC	cis	rs2806561	0.929	rs2867315	chr1:23541286	C/T	cg12483005	chr1:23474871	LUZP1	-0.33	-5.33	-0.31	2.07e-7	Height;
CESC	cis	rs7959452	0.640	rs11177599	chr12:69721970	G/A	cg14784868	chr12:69753453	YEATS4	0.73	10.44	0.54	1.35e-21	Blood protein levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26903090	chr16:3019041	PAQR4	0.56	6.65	0.38	1.65e-10	Gut microbiome composition (summer);
CESC	cis	rs9400271	0.632	rs9384703	chr6:109586803	A/G	cg01475377	chr6:109611718	NA	-0.47	-7.32	-0.41	2.95e-12	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
CESC	cis	rs2717559	0.542	rs11777634	chr8:143887957	C/T	cg17252645	chr8:143867129	LY6D	-0.31	-5.33	-0.31	2.07e-7	Urinary tract infection frequency;
CESC	cis	rs853679	0.517	rs9357065	chr6:28129580	T/C	cg08968635	chr6:28129556	ZNF389	0.39	5.17	0.3	4.51e-7	Depression;
CESC	cis	rs962856	1.000	rs979043	chr2:67566281	T/C	cg09028215	chr2:67624308	ETAA1	-0.4	-5.11	-0.3	6.05e-7	Pancreatic cancer;
CESC	cis	rs2652822	0.525	rs2053633	chr15:63505649	G/A	cg02713581	chr15:63449717	RPS27L	0.49	6.35	0.36	9.23e-10	Metabolic traits;
CESC	cis	rs1707322	0.721	rs10890336	chr1:46111056	C/T	cg06784218	chr1:46089804	CCDC17	0.43	7.4	0.41	1.77e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9300255	0.596	rs10732573	chr12:123743883	G/C	cg00376283	chr12:123451042	ABCB9	0.65	8.86	0.48	1.18e-16	Neutrophil percentage of white cells;
CESC	cis	rs68170813	0.559	rs17428071	chr7:106878200	C/G	cg02696742	chr7:106810147	HBP1	-0.52	-5.08	-0.3	7.2e-7	Coronary artery disease;
CESC	cis	rs10504229	0.906	rs73607868	chr8:58172482	T/C	cg22535103	chr8:58192502	C8orf71	-1.05	-13.27	-0.63	3.63e-31	Developmental language disorder (linguistic errors);
CESC	cis	rs17376456	0.877	rs10055340	chr5:93317644	T/C	cg21475434	chr5:93447410	FAM172A	0.75	6.78	0.38	7.96e-11	Diabetic retinopathy;
CESC	cis	rs7584330	0.518	rs77789507	chr2:238440972	C/T	cg14458575	chr2:238380390	NA	0.69	6.44	0.37	5.43e-10	Prostate cancer;
CESC	cis	rs12973672	0.812	rs10419959	chr19:35764705	G/A	cg12095397	chr19:35769544	USF2	0.51	6.18	0.35	2.4e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs10479542	0.721	rs6894113	chr5:178974789	G/C	cg14820908	chr5:178986412	RUFY1	0.42	6.11	0.35	3.55e-9	Lung cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23788167	chr9:74979561	ZFAND5	-0.57	-6.63	-0.38	1.92e-10	Gut microbiome composition (summer);
CESC	cis	rs722599	0.748	rs11623342	chr14:75347937	A/C	cg11812906	chr14:75593930	NEK9	-0.45	-5.43	-0.32	1.25e-7	IgG glycosylation;
CESC	cis	rs7666738	1.000	rs7666738	chr4:98968077	C/T	cg17366294	chr4:99064904	C4orf37	0.57	7.87	0.44	8.87e-14	Colonoscopy-negative controls vs population controls;
CESC	cis	rs72781680	1.000	rs72781663	chr2:24221694	C/G	cg08917208	chr2:24149416	ATAD2B	0.95	8.35	0.46	3.75e-15	Lymphocyte counts;
CESC	cis	rs2120019	1.000	rs60425110	chr15:75333000	T/A	cg17294928	chr15:75287854	SCAMP5	-0.74	-8.33	-0.46	4.42e-15	Blood trace element (Zn levels);
CESC	cis	rs9311474	0.597	rs6778735	chr3:52565100	T/C	cg07507251	chr3:52567010	NT5DC2	0.47	9.28	0.5	6.45e-18	Electroencephalogram traits;
CESC	cis	rs10504229	0.683	rs57866073	chr8:58139138	A/G	cg22535103	chr8:58192502	C8orf71	-0.81	-8.94	-0.48	6.75e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs1008375	0.932	rs7697329	chr4:17657853	C/A	cg16339924	chr4:17578868	LAP3	0.73	9.17	0.49	1.32e-17	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs4665809	0.549	rs62130460	chr2:26472718	T/C	cg25036284	chr2:26402008	FAM59B	0.76	7.75	0.43	1.97e-13	Gut microbiome composition (summer);
CESC	cis	rs1443512	0.796	rs1822437	chr12:54340077	A/G	cg17410650	chr12:54324560	NA	0.49	8.31	0.45	5.03e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
CESC	cis	rs2066819	1.000	rs59295315	chr12:56708576	G/A	cg26734620	chr12:56694298	CS	1.03	6.25	0.36	1.65e-9	Psoriasis vulgaris;
CESC	cis	rs40363	0.645	rs1690446	chr16:3519009	T/C	cg22508957	chr16:3507546	NAT15	0.59	9.56	0.51	8.29e-19	Tuberculosis;
CESC	cis	rs4906332	1.000	rs35344594	chr14:103955792	A/G	cg09975044	chr14:104007538	NA	0.47	6.39	0.37	7.49e-10	Coronary artery disease;
CESC	cis	rs4730250	0.707	rs61014091	chr7:106810107	A/C	cg02696742	chr7:106810147	HBP1	-0.59	-5.64	-0.33	4.37e-8	Osteoarthritis;
CESC	cis	rs16917546	1.000	rs12768538	chr10:64406358	C/G	cg03961010	chr10:64397487	ZNF365	0.37	6.05	0.35	5.01e-9	Basal cell carcinoma;
CESC	cis	rs769267	0.965	rs1010207	chr19:19416045	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.43	5.44	0.32	1.2e-7	Tonsillectomy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23318560	chr14:64854531	MTHFD1	-0.61	-7.11	-0.4	1.08e-11	Gut microbiome composition (summer);
CESC	cis	rs11122272	0.735	rs971534	chr1:231521971	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.57	-7.82	-0.43	1.29e-13	Hemoglobin concentration;
CESC	cis	rs3008870	1.000	rs2755248	chr1:67492624	A/G	cg02640540	chr1:67518911	SLC35D1	0.5	5.36	0.31	1.84e-7	Lymphocyte percentage of white cells;
CESC	trans	rs9987353	0.840	rs329994	chr8:9123233	A/G	cg18688230	chr12:89747628	DUSP6	-0.46	-6.01	-0.35	6.01e-9	Recombination measurement;
CESC	cis	rs35306767	0.903	rs35370435	chr10:898205	T/C	cg26597838	chr10:835615	NA	1.18	11.34	0.57	1.52e-24	Eosinophil percentage of granulocytes;
CESC	trans	rs459571	0.959	rs455381	chr9:136905577	C/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.6	-7.69	-0.43	2.96e-13	Platelet distribution width;
CESC	cis	rs9611565	0.559	rs13056262	chr22:42081921	A/G	cg06481639	chr22:41940642	POLR3H	0.57	5.74	0.33	2.58e-8	Vitiligo;
CESC	cis	rs73206853	0.609	rs61582364	chr12:110967847	T/G	cg12870014	chr12:110450643	ANKRD13A	0.65	5.65	0.33	4.09e-8	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs13191362	1.000	rs66789102	chr6:163104432	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.0	10.08	0.53	1.96e-20	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs9611565	0.592	rs5751139	chr22:42099981	G/C	cg06634786	chr22:41940651	POLR3H	0.66	6.64	0.38	1.73e-10	Vitiligo;
CESC	cis	rs2820292	0.619	rs12119907	chr1:201828755	T/C	cg06775570	chr1:201857621	SHISA4	-0.32	-5.1	-0.3	6.41e-7	Waist circumference;Body mass index (joint analysis main effects and smoking interaction);Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);
CESC	cis	rs28374715	0.578	rs13313520	chr15:41629127	T/G	cg02330683	chr15:41787940	ITPKA	0.48	5.69	0.33	3.35e-8	Ulcerative colitis;
CESC	cis	rs10779751	0.734	rs2791647	chr1:11132801	G/A	cg08854313	chr1:11322531	MTOR	0.76	10.24	0.53	5.91e-21	Body mass index;
CESC	cis	rs8028182	0.636	rs4075522	chr15:75864335	G/A	cg20655648	chr15:75932815	IMP3	0.49	6.06	0.35	4.75e-9	Sudden cardiac arrest;
CESC	cis	rs4268898	0.717	rs3731626	chr2:24427864	G/A	cg06627628	chr2:24431161	ITSN2	-0.89	-10.17	-0.53	9.85e-21	Asthma;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg01484320	chr1:109757057	SARS	-0.43	-6.1	-0.35	3.77e-9	Gambling;
CESC	cis	rs735396	0.770	rs1169301	chr12:121431300	C/T	cg25281562	chr12:121454272	C12orf43	0.53	6.68	0.38	1.43e-10	N-glycan levels;
CESC	cis	rs1008375	0.868	rs6816286	chr4:17698088	A/G	cg04450456	chr4:17643702	FAM184B	0.36	5.03	0.3	9.14e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs9911578	1.000	rs9892062	chr17:56976981	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.41	5.41	0.32	1.38e-7	Intelligence (multi-trait analysis);
CESC	cis	rs1707322	0.963	rs12076580	chr1:46258159	G/A	cg03146154	chr1:46216737	IPP	0.8	11.02	0.56	1.72e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2073016	0.925	rs2073014	chr6:41029109	C/T	cg14418226	chr6:40996092	UNC5CL	-0.48	-5.58	-0.32	6.07e-8	Progression free survival in metastatic colorectal cancer (CAPOX-B vs CAPOX-B plus cetuximab);
CESC	cis	rs875971	0.545	rs2420612	chr7:66001812	G/A	cg18527119	chr7:66119851	NA	-0.48	-5.22	-0.31	3.54e-7	Aortic root size;
CESC	cis	rs78366141	0.649	rs78179026	chr4:89657456	C/T	cg01026744	chr4:89619053	NAP1L5;HERC3	0.88	5.86	0.34	1.34e-8	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
CESC	cis	rs9611519	0.754	rs4820435	chr22:41652846	G/T	cg03806693	chr22:41940476	POLR3H	-0.74	-8.18	-0.45	1.17e-14	Neuroticism;
CESC	cis	rs35306767	0.953	rs12762973	chr10:960761	C/G	cg20503657	chr10:835505	NA	0.76	8.0	0.44	3.79e-14	Eosinophil percentage of granulocytes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10462529	chr17:78880748	RPTOR	-0.57	-6.9	-0.39	3.73e-11	Gut microbiome composition (summer);
CESC	cis	rs7959452	0.868	rs12812860	chr12:69746671	T/C	cg20891283	chr12:69753455	YEATS4	0.6	8.32	0.45	4.8e-15	Blood protein levels;
CESC	cis	rs7811142	1.000	rs6975729	chr7:100028187	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.78	6.78	0.38	7.61e-11	Platelet count;
CESC	cis	rs6582630	0.519	rs9738104	chr12:38338459	A/C	cg13010199	chr12:38710504	ALG10B	0.53	6.56	0.37	2.83e-10	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs769267	0.930	rs2301786	chr19:19413947	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.43	5.36	0.31	1.82e-7	Tonsillectomy;
CESC	cis	rs3857067	0.967	rs1904096	chr4:95012684	C/A	cg11021082	chr4:95130006	SMARCAD1	-0.5	-7.53	-0.42	8.12e-13	QT interval;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06288634	chr16:53164514	CHD9	0.54	6.24	0.36	1.73e-9	Gut microbiome composition (summer);
CESC	cis	rs514406	0.893	rs1242330	chr1:53396842	T/G	cg06600287	chr1:53387719	ECHDC2	-0.29	-5.08	-0.3	7e-7	Monocyte count;
CESC	cis	rs10791323	0.559	rs10750548	chr11:133729469	A/G	cg15485101	chr11:133734466	NA	0.36	5.84	0.34	1.56e-8	Childhood ear infection;
CESC	cis	rs9393777	0.513	rs7740197	chr6:26663478	C/T	cg14345882	chr6:26364793	BTN3A2	-0.41	-5.15	-0.3	5.2e-7	Intelligence (multi-trait analysis);
CESC	cis	rs17345786	0.911	rs10936707	chr3:101324063	G/A	cg12386194	chr3:101231763	SENP7	0.57	6.56	0.37	2.81e-10	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2242116	0.592	rs6442039	chr3:46960797	C/G	cg02527881	chr3:46936655	PTH1R	-0.43	-5.3	-0.31	2.44e-7	Birth weight;
CESC	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.63	7.15	0.4	8.37e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7666738	0.791	rs13111960	chr4:98976851	C/T	cg05340658	chr4:99064831	C4orf37	0.77	11.71	0.58	8.52e-26	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2963155	1.000	rs2963155	chr5:142756004	C/T	cg17617527	chr5:142782415	NR3C1	-0.49	-5.2	-0.3	3.99e-7	Breast cancer;
CESC	cis	rs9486719	0.947	rs12213375	chr6:96902134	A/G	cg18709589	chr6:96969512	KIAA0776	-0.56	-6.15	-0.35	2.88e-9	Migraine;Coronary artery disease;
CESC	cis	rs12893597	0.821	rs12896434	chr14:76816746	C/T	cg20290672	chr14:76816747	NA	-0.41	-5.87	-0.34	1.31e-8	Maximal oxygen uptake response;
CESC	cis	rs2836974	0.590	rs9974757	chr21:40617244	T/C	cg11890956	chr21:40555474	PSMG1	-0.94	-15.36	-0.69	1.62e-38	Cognitive function;
CESC	cis	rs910316	0.763	rs735452	chr14:75497984	A/G	cg08847533	chr14:75593920	NEK9	-0.95	-17.12	-0.72	9.25e-45	Height;
CESC	cis	rs7552404	1.000	rs942270	chr1:76177332	G/A	cg10523679	chr1:76189770	ACADM	0.69	7.83	0.43	1.15e-13	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs820218	0.743	rs3744000	chr17:73704333	C/T	cg01592526	chr17:73663357	RECQL5;SAP30BP	-0.39	-5.26	-0.31	2.93e-7	Rotator cuff tears;
CESC	cis	rs9911578	0.967	rs9907940	chr17:56663842	A/G	cg12560992	chr17:57184187	TRIM37	0.92	15.14	0.68	9.87e-38	Intelligence (multi-trait analysis);
CESC	cis	rs60843830	0.662	rs6721594	chr2:305203	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	-0.68	-8.94	-0.48	6.62e-17	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs1153858	1.000	rs12594857	chr15:45667178	A/G	cg14582100	chr15:45693742	SPATA5L1	0.42	5.95	0.34	8.38e-9	Homoarginine levels;
CESC	cis	rs1552244	0.935	rs7621551	chr3:10114205	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	11.94	0.59	1.43e-26	Alzheimer's disease;
CESC	trans	rs7107217	1.000	rs1873872	chr11:129473993	A/T	cg21518056	chr19:33183187	NUDT19	0.48	6.2	0.36	2.21e-9	Breast cancer;Type 2 diabetes;
CESC	cis	rs1670533	1.000	rs935970	chr4:1045323	C/G	cg04106633	chr4:1044584	NA	-0.42	-5.26	-0.31	3.04e-7	Recombination rate (females);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19319490	chr7:65447113	GUSB	0.57	7.29	0.41	3.62e-12	Gut microbiome composition (summer);
CESC	cis	rs7829975	0.714	rs59046059	chr8:8670736	C/A	cg15556689	chr8:8085844	FLJ10661	0.44	5.62	0.33	4.87e-8	Mood instability;
CESC	cis	rs910316	0.967	rs175505	chr14:75529619	C/T	cg15467112	chr14:75489610	MLH3	-0.34	-5.16	-0.3	4.9e-7	Height;
CESC	cis	rs6540556	0.635	rs17389184	chr1:209916789	C/T	cg05527609	chr1:210001259	C1orf107	-0.74	-7.53	-0.42	8.01e-13	Red blood cell count;
CESC	cis	rs4862750	0.758	rs2375915	chr4:187896255	A/C	cg07414643	chr4:187882934	NA	0.52	7.22	0.41	5.6e-12	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg13664146	chr17:71228606	C17orf80;FAM104A	0.44	6.03	0.35	5.39e-9	Tetralogy of Fallot;
CESC	cis	rs514406	0.505	rs447581	chr1:53177098	T/C	cg08859206	chr1:53392774	SCP2	-0.58	-7.94	-0.44	5.85e-14	Monocyte count;
CESC	cis	rs7412746	0.658	rs7526489	chr1:150726238	C/T	cg04414720	chr1:150670196	GOLPH3L	0.56	7.38	0.41	1.99e-12	Melanoma;
CESC	cis	rs7945705	0.935	rs2653567	chr11:8889630	T/C	cg09997546	chr11:8931473	C11orf17;ST5	-0.39	-6.8	-0.39	6.98e-11	Hemoglobin concentration;
CESC	cis	rs3820928	0.709	rs10178202	chr2:227914561	C/T	cg05526886	chr2:227700861	RHBDD1	-0.46	-5.35	-0.31	1.93e-7	Pulmonary function;
CESC	cis	rs1006703	0.544	rs10153291	chr17:3833740	G/A	cg06463185	chr17:3833770	ATP2A3	-0.66	-6.35	-0.36	9.3e-10	Glucose homeostasis traits;
CESC	cis	rs1862618	0.853	rs1559282	chr5:56099375	T/A	cg24531977	chr5:56204891	C5orf35	-0.83	-11.11	-0.56	8.79e-24	Initial pursuit acceleration;
CESC	cis	rs8114671	0.904	rs6060197	chr20:33654315	C/T	cg24642439	chr20:33292090	TP53INP2	-0.47	-5.7	-0.33	3.19e-8	Height;
CESC	cis	rs73206853	0.686	rs11829358	chr12:111126636	A/G	cg12870014	chr12:110450643	ANKRD13A	0.67	5.11	0.3	6.05e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs2228479	0.717	rs11649210	chr16:89807233	C/G	cg04287289	chr16:89883240	FANCA	0.65	5.93	0.34	9.41e-9	Skin colour saturation;
CESC	cis	rs116095464	0.558	rs10055405	chr5:265666	C/T	cg10591111	chr5:226296	SDHA	-0.52	-6.24	-0.36	1.7e-9	Breast cancer;
CESC	cis	rs3740713	1.000	rs16935432	chr11:18470487	G/A	cg23797887	chr11:18477753	LDHAL6A	-0.54	-5.21	-0.31	3.72e-7	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs2721195	0.967	rs748195	chr8:145682514	T/C	cg15320075	chr8:145703422	NA	0.64	8.66	0.47	4.66e-16	Age at first birth;
CESC	cis	rs4730250	0.707	rs6946931	chr7:106788621	G/T	cg02696742	chr7:106810147	HBP1	-0.55	-5.16	-0.3	4.91e-7	Osteoarthritis;
CESC	cis	rs2777491	1.000	rs2730057	chr15:41736275	C/A	cg20272979	chr15:41787780	ITPKA	0.44	6.4	0.37	7.03e-10	Ulcerative colitis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09039206	chr10:60028728	CISD1;IPMK	0.54	6.19	0.36	2.32e-9	Gut microbiome composition (summer);
CESC	cis	rs8018808	0.935	rs11623826	chr14:77912862	A/C	cg20045696	chr14:77926864	AHSA1	0.42	5.83	0.34	1.61e-8	Myeloid white cell count;
CESC	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	13.87	0.65	2.88e-33	Prudent dietary pattern;
CESC	trans	rs3780486	0.846	rs10738905	chr9:33123627	A/G	cg04842962	chr6:43655489	MRPS18A	0.99	19.07	0.76	1.21e-51	IgG glycosylation;
CESC	cis	rs13095912	1.000	rs6762208	chr3:185331165	A/C	cg11274856	chr3:185301563	NA	-0.37	-5.96	-0.34	8.1e-9	Systolic blood pressure;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg19872317	chr14:65346686	NA	-0.47	-6.27	-0.36	1.44e-9	Height;
CESC	cis	rs72945132	0.882	rs17160777	chr11:70163723	T/C	cg14191688	chr11:70257035	CTTN	0.42	5.34	0.31	1.95e-7	Coronary artery disease;
CESC	cis	rs3785574	0.962	rs2247435	chr17:61892862	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.1	19.27	0.76	2.4e-52	Height;
CESC	trans	rs9929218	0.953	rs9939049	chr16:68812301	A/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.6	-7.78	-0.43	1.6e-13	Colorectal cancer;
CESC	cis	rs6582630	0.519	rs1607868	chr12:38385512	G/T	cg13010199	chr12:38710504	ALG10B	0.47	6.05	0.35	4.84e-9	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs3008870	1.000	rs17497828	chr1:67452322	G/A	cg08660285	chr1:67390436	MIER1;WDR78	-1.02	-13.17	-0.63	7.98e-31	Lymphocyte percentage of white cells;
CESC	cis	rs1799949	0.965	rs11080034	chr17:41443014	T/C	cg05368731	chr17:41323189	NBR1	0.54	7.54	0.42	7.29e-13	Menopause (age at onset);
CESC	cis	rs258892	0.895	rs34660	chr5:72151858	T/A	cg21869765	chr5:72125136	TNPO1	0.44	5.55	0.32	6.92e-8	Small cell lung carcinoma;
CESC	cis	rs1348850	0.567	rs4893838	chr2:178531436	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.55	6.95	0.39	2.92e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs55788414	1.000	rs7499792	chr16:81184318	C/T	cg06400318	chr16:81190750	PKD1L2	-0.6	-6.77	-0.38	8.45e-11	Left ventricular obstructive tract defect (maternal effect);
CESC	cis	rs9905704	0.914	rs34556895	chr17:56826953	G/T	cg12560992	chr17:57184187	TRIM37	0.61	7.09	0.4	1.25e-11	Testicular germ cell tumor;
CESC	cis	rs6429082	0.755	rs291367	chr1:235690800	G/A	cg26050004	chr1:235667680	B3GALNT2	0.65	8.68	0.47	3.96e-16	Adiposity;
CESC	trans	rs61931739	0.817	rs11053071	chr12:34201400	A/G	cg26384229	chr12:38710491	ALG10B	0.46	6.3	0.36	1.2e-9	Morning vs. evening chronotype;
CESC	cis	rs8177253	0.901	rs9843728	chr3:133501407	C/T	cg12373951	chr3:133503437	NA	0.4	5.88	0.34	1.23e-8	Iron status biomarkers;
CESC	trans	rs8056446	0.710	rs8059793	chr16:78189298	A/C	cg19906694	chr5:60629770	ZSWIM6	0.49	6.26	0.36	1.53e-9	Pulmonary function (smoking interaction);
CESC	cis	rs7618915	0.501	rs3733041	chr3:52731598	T/C	cg07507251	chr3:52567010	NT5DC2	0.32	5.53	0.32	7.76e-8	Bipolar disorder;
CESC	cis	rs7937682	0.575	rs7127010	chr11:111770782	C/T	cg09085632	chr11:111637200	PPP2R1B	0.91	11.81	0.59	3.87e-26	Primary sclerosing cholangitis;
CESC	cis	rs6922893	1.000	rs7765509	chr6:71661689	A/T	cg10766373	chr6:71666121	B3GAT2	-0.34	-5.59	-0.32	5.77e-8	Obesity-related traits;
CESC	cis	rs6964587	0.626	rs7785941	chr7:91531024	T/C	cg17063962	chr7:91808500	NA	-0.45	-6.35	-0.36	9.5e-10	Breast cancer;
CESC	cis	rs9311474	0.597	rs13303	chr3:52558008	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.37	5.51	0.32	8.61e-8	Electroencephalogram traits;
CESC	cis	rs7267979	1.000	rs6115153	chr20:25325567	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.87	-18.09	-0.74	3.41e-48	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs853679	0.628	rs9368560	chr6:28159960	T/C	cg26335602	chr6:28129616	ZNF389	0.46	5.92	0.34	9.99e-9	Depression;
CESC	cis	rs796364	0.806	rs203767	chr2:200902411	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.85	-7.88	-0.44	8.7e-14	Schizophrenia;
CESC	cis	rs35306767	0.903	rs11253485	chr10:919362	C/T	cg25019033	chr10:957182	NA	-0.58	-6.21	-0.36	2.03e-9	Eosinophil percentage of granulocytes;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg09379601	chr19:12992224	DNASE2	0.52	6.89	0.39	4.08e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs5769765	0.955	rs5770750	chr22:50276828	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.46	5.32	0.31	2.21e-7	Schizophrenia;
CESC	cis	rs40363	0.723	rs2379831	chr16:3538927	T/C	cg00484396	chr16:3507460	NAT15	-0.56	-6.33	-0.36	1.04e-9	Tuberculosis;
CESC	cis	rs7811142	0.830	rs1063945	chr7:99930447	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.91	8.88	0.48	1.02e-16	Platelet count;
CESC	cis	rs1018836	0.923	rs6989123	chr8:91551234	A/T	cg16814680	chr8:91681699	NA	-0.71	-10.5	-0.54	8.8e-22	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs60843830	0.661	rs11674325	chr2:105517	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.51	6.08	0.35	4.11e-9	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs137699	0.652	rs2413589	chr22:39755689	C/T	cg24399712	chr22:39784796	NA	0.48	5.45	0.32	1.15e-7	IgG glycosylation;
CESC	cis	rs514406	0.679	rs960570	chr1:53237763	A/G	cg16325326	chr1:53192061	ZYG11B	-0.53	-7.96	-0.44	5.13e-14	Monocyte count;
CESC	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg07308232	chr7:1071921	C7orf50	-0.46	-6.27	-0.36	1.43e-9	Longevity;Endometriosis;
CESC	cis	rs6502050	0.799	rs7502524	chr17:80107261	C/T	cg11859384	chr17:80120422	CCDC57	-0.38	-5.11	-0.3	6.21e-7	Life satisfaction;
CESC	cis	rs9309473	1.000	rs7564890	chr2:73641853	T/C	cg20560298	chr2:73613845	ALMS1	-0.54	-7.09	-0.4	1.21e-11	Metabolite levels;
CESC	cis	rs3747547	0.892	rs17516779	chr9:37955265	A/G	cg13774184	chr9:37916125	SHB	0.74	6.52	0.37	3.49e-10	Metabolite levels (Dihydroxy docosatrienoic acid);
CESC	cis	rs1799949	0.965	rs4793233	chr17:41435437	G/C	cg06001716	chr17:41278141	BRCA1;NBR2	0.38	5.11	0.3	6.08e-7	Menopause (age at onset);
CESC	cis	rs9658691	0.607	rs9658757	chr10:90769455	T/C	cg03111039	chr10:90751583	FAS;ACTA2	-0.61	-5.3	-0.31	2.4e-7	Mosquito bite size;
CESC	trans	rs61931739	0.500	rs6488221	chr12:34525671	A/G	cg26384229	chr12:38710491	ALG10B	0.54	7.53	0.42	8.03e-13	Morning vs. evening chronotype;
CESC	cis	rs875971	0.862	rs6959268	chr7:65812966	G/A	cg10691866	chr7:65817282	TPST1	0.31	5.23	0.31	3.43e-7	Aortic root size;
CESC	cis	rs6570726	0.935	rs398060	chr6:145841515	C/T	cg05347473	chr6:146136440	FBXO30	-0.5	-6.73	-0.38	1.07e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7671266	0.747	rs6827946	chr4:10151335	T/C	cg00071950	chr4:10020882	SLC2A9	-0.52	-5.64	-0.33	4.4e-8	Cardiovascular disease risk factors;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04421424	chr19:57791681	ZNF460	0.55	7.2	0.4	6.28e-12	Gut microbiota (bacterial taxa);
CESC	cis	rs7605827	0.930	rs3954894	chr2:15517656	T/C	cg19274914	chr2:15703543	NA	0.35	6.11	0.35	3.61e-9	Educational attainment (years of education);
CESC	cis	rs4787484	0.593	rs12917712	chr16:29882490	A/G	cg01827781	chr16:29875145	LOC440356;CDIPT	-0.4	-5.43	-0.32	1.3e-7	Response to taxane treatment (placlitaxel);
CESC	cis	rs13256369	0.802	rs12153	chr8:8560909	G/C	cg17143192	chr8:8559678	CLDN23	0.76	8.64	0.47	5.49e-16	Obesity-related traits;
CESC	cis	rs9300255	0.602	rs1616131	chr12:123619838	G/A	cg19016782	chr12:123741754	C12orf65	-0.38	-5.15	-0.3	5.08e-7	Neutrophil percentage of white cells;
CESC	cis	rs713587	0.520	rs522806	chr2:25316584	C/A	cg01884057	chr2:25150051	NA	-0.3	-5.2	-0.3	4.01e-7	Body mass index in non-asthmatics;
CESC	cis	rs18122	0.660	rs7572001	chr2:67521908	A/G	cg09028215	chr2:67624308	ETAA1	-0.41	-5.11	-0.3	6.15e-7	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs4780401	0.755	rs7194034	chr16:11770777	A/G	cg01061890	chr16:11836724	TXNDC11	-0.41	-5.36	-0.31	1.85e-7	Rheumatoid arthritis;
CESC	cis	rs7635838	0.617	rs367745	chr3:11309274	T/C	cg00170343	chr3:11313890	ATG7	0.6	8.61	0.47	6.56e-16	HDL cholesterol;
CESC	cis	rs10504073	0.565	rs12056536	chr8:49890132	C/T	cg00325661	chr8:49890786	NA	-0.54	-8.14	-0.45	1.54e-14	Blood metabolite ratios;
CESC	cis	rs6665290	0.935	rs11588904	chr1:227196211	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.22	-32.88	-0.9	1.62e-95	Myeloid white cell count;
CESC	trans	rs9929218	0.608	rs35158985	chr16:68796746	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.62	-8.57	-0.47	8.77e-16	Colorectal cancer;
CESC	cis	rs4819052	0.851	rs2838836	chr21:46665875	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.75	10.02	0.52	2.97e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs3806843	0.735	rs813897	chr5:140070029	T/C	cg26395211	chr5:140044315	WDR55	0.47	5.94	0.34	9.08e-9	Depressive symptoms (multi-trait analysis);
CESC	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg18538332	chr22:24372958	LOC391322	-0.69	-9.81	-0.52	1.39e-19	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs8114671	0.662	rs6058146	chr20:33540529	A/G	cg07148914	chr20:33460835	GGT7	0.42	5.38	0.31	1.62e-7	Height;
CESC	cis	rs735396	0.965	rs2257962	chr12:121445808	T/C	cg02403541	chr12:121454288	C12orf43	0.64	9.27	0.49	6.87e-18	N-glycan levels;
CESC	cis	rs7247513	0.964	rs8105902	chr19:12718351	G/A	cg01871581	chr19:12707946	ZNF490	-0.85	-13.38	-0.64	1.49e-31	Bipolar disorder;
CESC	cis	rs7618915	0.570	rs13068293	chr3:52672167	C/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.48	6.93	0.39	3.29e-11	Bipolar disorder;
CESC	cis	rs5758511	0.680	rs1033460	chr22:42619308	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.59	8.71	0.47	3.36e-16	Birth weight;
CESC	cis	rs9311474	0.508	rs6805156	chr3:52609362	T/C	cg18404041	chr3:52824283	ITIH1	-0.39	-6.73	-0.38	1.03e-10	Electroencephalogram traits;
CESC	cis	rs1008375	0.898	rs4698620	chr4:17587361	C/T	cg02297831	chr4:17616191	MED28	0.51	6.18	0.35	2.44e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs3785574	0.962	rs2727329	chr17:61924566	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.11	19.31	0.76	1.86e-52	Height;
CESC	cis	rs1847202	0.826	rs11925587	chr3:72952227	A/G	cg25664220	chr3:72788482	NA	0.38	5.53	0.32	7.87e-8	Motion sickness;
CESC	cis	rs12530845	0.673	rs4269479	chr7:135332379	C/T	cg23117316	chr7:135346802	PL-5283	-0.55	-6.16	-0.35	2.7e-9	Red blood cell traits;
CESC	cis	rs6460942	1.000	rs73053531	chr7:12317474	T/C	cg06484146	chr7:12443880	VWDE	-0.81	-8.78	-0.47	2.13e-16	Coronary artery disease;
CESC	cis	rs713587	0.967	rs10182458	chr2:25150641	A/G	cg01884057	chr2:25150051	NA	0.43	8.07	0.44	2.54e-14	Body mass index in non-asthmatics;
CESC	cis	rs10392	0.543	rs1733	chr20:37581506	G/A	cg27552599	chr20:37590471	DHX35	0.38	5.53	0.32	7.59e-8	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
CESC	cis	rs801193	1.000	rs17566701	chr7:66193183	T/C	cg18876405	chr7:65276391	NA	0.61	8.12	0.45	1.78e-14	Aortic root size;
CESC	cis	rs875971	0.895	rs12698520	chr7:65918707	C/A	cg18876405	chr7:65276391	NA	0.51	6.82	0.39	6.25e-11	Aortic root size;
CESC	cis	rs11083475	0.607	rs6508816	chr19:39267783	G/A	cg26703956	chr19:39260304	NA	-0.29	-5.33	-0.31	2.08e-7	Heart rate;
CESC	cis	rs35110281	0.693	rs4819290	chr21:45122713	C/T	cg21573476	chr21:45109991	RRP1B	-0.58	-8.4	-0.46	2.69e-15	Mean corpuscular volume;
CESC	trans	rs208520	0.754	rs851592	chr6:66875175	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.99	-12.67	-0.61	4.31e-29	Exhaled nitric oxide output;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12952179	chr4:111866981	NA	-0.6	-6.78	-0.38	7.95e-11	Gut microbiome composition (summer);
CESC	cis	rs7116495	1.000	rs3750908	chr11:71822401	A/G	cg10381502	chr11:71823885	C11orf51	0.69	5.61	0.33	5.03e-8	Severe influenza A (H1N1) infection;
CESC	cis	rs5769765	0.773	rs7410291	chr22:50300078	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.49	-5.54	-0.32	7.17e-8	Schizophrenia;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05191435	chr6:7987870	MGC26597	-0.43	-6.15	-0.35	2.8e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs7267979	1.000	rs401166	chr20:25446308	C/G	cg08601574	chr20:25228251	PYGB	0.37	5.31	0.31	2.31e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs2456568	0.548	rs7113080	chr11:93657520	G/A	cg26875233	chr11:93583750	C11orf90	-0.33	-5.87	-0.34	1.28e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
CESC	cis	rs1551570	0.766	rs55752217	chr19:10218434	C/T	cg16327482	chr19:10226339	EIF3G	0.42	6.9	0.39	3.77e-11	Narcolepsy;
CESC	cis	rs875971	0.862	rs4718383	chr7:66108409	T/C	cg18252515	chr7:66147081	NA	0.52	6.96	0.39	2.64e-11	Aortic root size;
CESC	cis	rs9303401	0.615	rs7502342	chr17:56922629	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.01	12.69	0.61	3.78e-29	Cognitive test performance;
CESC	cis	rs992157	0.798	rs2382818	chr2:219155907	A/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.66	-8.74	-0.47	2.72e-16	Colorectal cancer;
CESC	cis	rs34375054	0.660	rs58624919	chr12:125596458	G/A	cg25124228	chr12:125621409	AACS	-0.56	-6.75	-0.38	9.19e-11	Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs2230307	0.536	rs6677998	chr1:100461046	G/A	cg24955406	chr1:100503596	HIAT1	0.55	5.48	0.32	9.85e-8	Carotid intima media thickness;
CESC	cis	rs10504229	0.679	rs17804870	chr8:58158071	A/G	cg24829409	chr8:58192753	C8orf71	-0.62	-6.32	-0.36	1.13e-9	Developmental language disorder (linguistic errors);
CESC	trans	rs1814175	0.740	rs10839439	chr11:49918240	C/T	cg03929089	chr4:120376271	NA	-0.93	-15.69	-0.69	1.12e-39	Height;
CESC	cis	rs863345	0.604	rs10908673	chr1:158503908	T/G	cg12129480	chr1:158549410	OR10X1	-0.34	-6.84	-0.39	5.41e-11	Pneumococcal bacteremia;
CESC	cis	rs4595586	0.870	rs10876208	chr12:39287667	G/T	cg26384229	chr12:38710491	ALG10B	-0.38	-5.46	-0.32	1.07e-7	Morning vs. evening chronotype;
CESC	cis	rs662064	0.962	rs648324	chr1:10556447	G/T	cg20482658	chr1:10539492	PEX14	-0.38	-7.66	-0.43	3.5e-13	Asthma;
CESC	cis	rs7819412	0.806	rs6980856	chr8:10938260	A/G	cg21775007	chr8:11205619	TDH	0.43	6.19	0.36	2.3e-9	Triglycerides;
CESC	trans	rs208520	0.837	rs208467	chr6:66914837	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.84	-9.91	-0.52	6.69e-20	Exhaled nitric oxide output;
CESC	cis	rs9287719	0.870	rs728135	chr2:10745132	A/C	cg00105475	chr2:10696890	NA	0.38	5.55	0.32	6.76e-8	Prostate cancer;
CESC	cis	rs798554	0.642	rs2533871	chr7:2883006	C/G	cg13628971	chr7:2884303	GNA12	0.64	8.77	0.47	2.21e-16	Height;
CESC	cis	rs3096299	0.658	rs4785679	chr16:89566113	G/T	cg08392591	chr16:89556376	ANKRD11	0.63	8.57	0.47	8.75e-16	Multiple myeloma (IgH translocation);
CESC	cis	rs6597981	0.675	rs4963120	chr11:825777	A/G	cg17628894	chr11:804452	LRDD	0.39	8.23	0.45	8.65e-15	Breast cancer;
CESC	cis	rs447735	0.565	rs10852626	chr16:89914633	T/G	cg27121462	chr16:89883253	FANCA	0.51	6.16	0.35	2.72e-9	Hemoglobin concentration;
CESC	cis	rs7267979	0.844	rs869358	chr20:25374674	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.79	-14.53	-0.67	1.38e-35	Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs4942242	0.640	rs9533563	chr13:44212127	A/G	cg19169023	chr15:41853346	TYRO3	-0.62	-7.85	-0.43	1.03e-13	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs896854	0.654	rs4735339	chr8:95974373	C/T	cg26343298	chr8:95960752	TP53INP1	0.36	5.98	0.34	7.06e-9	Type 2 diabetes;
CESC	cis	rs7429990	0.965	rs34380889	chr3:47947182	C/T	cg11946769	chr3:48343235	NME6	0.42	5.13	0.3	5.71e-7	Educational attainment (years of education);
CESC	cis	rs4665809	0.590	rs2289019	chr2:26420809	G/C	cg08470875	chr2:26401718	FAM59B	-0.73	-7.99	-0.44	4.05e-14	Gut microbiome composition (summer);
CESC	cis	rs10979	1.000	rs12215667	chr6:143893213	T/C	cg25407410	chr6:143891975	LOC285740	-0.61	-9.21	-0.49	1.01e-17	Hypospadias;
CESC	cis	rs6121246	0.559	rs6058465	chr20:30397691	G/A	cg13852791	chr20:30311386	BCL2L1	0.85	11.17	0.57	5.35e-24	Mean corpuscular hemoglobin;
CESC	cis	rs2204008	0.630	rs12306932	chr12:38242029	C/T	cg26384229	chr12:38710491	ALG10B	-0.44	-5.68	-0.33	3.59e-8	Bladder cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07355262	chr7:5347698	TNRC18	-0.53	-7.07	-0.4	1.36e-11	Gut microbiome composition (summer);
CESC	cis	rs1008375	0.966	rs6837664	chr4:17697835	G/C	cg15017067	chr4:17643749	FAM184B	0.36	5.13	0.3	5.58e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg17939001	chr1:197871836	C1orf53	-0.46	-6.04	-0.35	5.25e-9	Fibrinogen levels;
CESC	cis	rs6460942	0.597	rs35589221	chr7:12535841	T/G	cg20607287	chr7:12443886	VWDE	-0.72	-7.71	-0.43	2.51e-13	Coronary artery disease;
CESC	cis	rs7503807	0.967	rs12949279	chr17:78558411	T/C	cg09596252	chr17:78655493	RPTOR	0.46	6.36	0.36	8.67e-10	Obesity;
CESC	cis	rs875971	1.000	rs6961155	chr7:65933295	T/C	cg18876405	chr7:65276391	NA	0.51	6.82	0.39	6.05e-11	Aortic root size;
CESC	cis	rs902774	0.554	rs4503623	chr12:53353759	T/C	cg05393297	chr12:53359155	NA	-0.6	-8.54	-0.46	1.08e-15	Prostate cancer;
CESC	cis	rs6570726	0.870	rs370653	chr6:145823642	G/A	cg05347473	chr6:146136440	FBXO30	0.49	6.71	0.38	1.2e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6540559	0.932	rs764093	chr1:209983331	A/G	cg23283495	chr1:209979779	IRF6	0.51	7.55	0.42	7.09e-13	Cleft lip with or without cleft palate;
CESC	cis	rs1728785	0.901	rs698715	chr16:68560896	A/G	cg02972257	chr16:68554789	NA	-0.62	-6.95	-0.39	2.88e-11	Ulcerative colitis;
CESC	cis	rs7264396	0.513	rs3787169	chr20:34419884	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.85	-9.46	-0.5	1.73e-18	Total cholesterol levels;
CESC	cis	rs947211	0.846	rs823155	chr1:205762946	T/C	cg26354017	chr1:205819088	PM20D1	0.47	6.12	0.35	3.26e-9	Parkinson's disease;
CESC	cis	rs35110281	0.720	rs162394	chr21:44943550	C/G	cg01579765	chr21:45077557	HSF2BP	0.53	9.2	0.49	1.14e-17	Mean corpuscular volume;
CESC	cis	rs1008375	0.966	rs10489036	chr4:17697687	A/G	cg27347728	chr4:17578864	LAP3	0.45	5.32	0.31	2.21e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs12765878	0.934	rs58543155	chr10:105643244	G/A	cg11005552	chr10:105648138	OBFC1	0.35	5.1	0.3	6.34e-7	Coronary artery disease;
CESC	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg18099408	chr3:52552593	STAB1	-0.44	-8.08	-0.44	2.29e-14	Electroencephalogram traits;
CESC	cis	rs853679	0.882	rs4713140	chr6:28097193	C/T	cg19592336	chr6:28129416	ZNF389	0.52	5.19	0.3	4.1e-7	Depression;
CESC	cis	rs7258465	1.000	rs4808801	chr19:18571141	A/G	cg11102782	chr19:18549136	ISYNA1	-0.36	-5.06	-0.3	7.78e-7	Breast cancer;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg01372608	chr1:116185223	VANGL1	0.48	6.09	0.35	3.85e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs79976124	0.842	rs1548154	chr6:66624910	G/A	cg07460842	chr6:66804631	NA	0.72	8.45	0.46	1.91e-15	Type 2 diabetes;
CESC	cis	rs3859192	0.561	rs12453343	chr17:38181176	C/A	cg17344932	chr17:38183730	MED24;SNORD124	0.6	8.95	0.48	6.49e-17	White blood cell count;
CESC	cis	rs75064307	0.834	rs7636575	chr3:108115862	C/T	cg03329597	chr3:108125523	MYH15	-0.5	-5.72	-0.33	2.93e-8	Intelligence (multi-trait analysis);
CESC	cis	rs10979	1.000	rs12211659	chr6:143898348	G/T	cg25407410	chr6:143891975	LOC285740	-0.61	-9.2	-0.49	1.13e-17	Hypospadias;
CESC	cis	rs17376456	0.877	rs17083462	chr5:93462401	T/G	cg21475434	chr5:93447410	FAM172A	0.82	7.55	0.42	6.97e-13	Diabetic retinopathy;
CESC	cis	rs35306767	0.855	rs2050944	chr10:918910	T/C	cg20503657	chr10:835505	NA	0.78	7.64	0.42	4.09e-13	Eosinophil percentage of granulocytes;
CESC	cis	rs6693567	0.565	rs12736375	chr1:150411912	T/C	cg09579323	chr1:150459698	TARS2	0.49	6.12	0.35	3.3e-9	Migraine;
CESC	cis	rs7727544	0.684	rs274567	chr5:131714409	C/T	cg07395648	chr5:131743802	NA	0.45	5.95	0.34	8.3e-9	Blood metabolite levels;
CESC	cis	rs7666738	0.830	rs34916200	chr4:98851593	C/T	cg03467027	chr4:99064603	C4orf37	0.42	5.16	0.3	4.73e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10979	0.571	rs9386039	chr6:143916992	A/T	cg25407410	chr6:143891975	LOC285740	0.45	5.64	0.33	4.43e-8	Hypospadias;
CESC	cis	rs8014204	0.604	rs11625594	chr14:75389833	G/A	cg08847533	chr14:75593920	NEK9	0.6	7.59	0.42	5.58e-13	Caffeine consumption;
CESC	cis	rs6741892	0.536	rs11688977	chr2:38896631	C/T	cg00359181	chr2:38893519	GALM	-0.63	-8.83	-0.48	1.47e-16	5-HTT brain serotonin transporter levels;
CESC	cis	rs2836974	0.867	rs77959119	chr21:40542768	G/A	cg11890956	chr21:40555474	PSMG1	1.2	22.09	0.81	4.83e-62	Cognitive function;
CESC	cis	rs896854	0.548	rs574183	chr8:95973816	A/G	cg09323728	chr8:95962352	TP53INP1	0.34	6.42	0.37	6.29e-10	Type 2 diabetes;
CESC	cis	rs2952156	0.959	rs1565922	chr17:37831035	A/G	cg07936489	chr17:37558343	FBXL20	-0.54	-6.69	-0.38	1.3100000000000001e-10	Asthma;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg15312298	chr8:127570908	FAM84B	0.47	6.65	0.38	1.67e-10	Systemic lupus erythematosus;
CESC	cis	rs12142240	0.698	rs72677589	chr1:46817770	T/C	cg10495392	chr1:46806563	NSUN4	0.57	6.28	0.36	1.39e-9	Menopause (age at onset);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg12603476	chr10:82214649	TSPAN14	-0.46	-6.08	-0.35	4.28e-9	Fibrinogen levels;
CESC	cis	rs9486719	0.947	rs9398072	chr6:96911304	T/C	cg18709589	chr6:96969512	KIAA0776	0.48	5.72	0.33	2.9e-8	Migraine;Coronary artery disease;
CESC	cis	rs7666738	0.791	rs13128640	chr4:99003918	A/C	cg18180107	chr4:99064573	C4orf37	0.4	5.23	0.31	3.41e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9926296	0.509	rs2159113	chr16:89832083	C/T	cg03388025	chr16:89894329	SPIRE2	0.36	6.58	0.37	2.47e-10	Vitiligo;
CESC	cis	rs3858526	0.883	rs4758183	chr11:5925178	C/G	cg13902645	chr11:5959945	NA	-0.62	-7.4	-0.41	1.85e-12	DNA methylation (variation);
CESC	cis	rs7666738	0.830	rs6831588	chr4:98977356	T/G	cg03467027	chr4:99064603	C4orf37	0.43	5.4	0.31	1.49e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6500395	0.890	rs9936271	chr16:48601291	A/G	cg04672837	chr16:48644449	N4BP1	0.52	6.43	0.37	6.06e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20546810	chr20:2489835	ZNF343	0.58	6.11	0.35	3.61e-9	Gut microbiome composition (summer);
CESC	cis	rs9811920	0.638	rs793471	chr3:99546335	A/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.49	-5.86	-0.34	1.39e-8	Axial length;
CESC	cis	rs2694528	0.686	rs6885703	chr5:59862790	T/C	cg11474532	chr5:59995715	DEPDC1B	0.92	6.53	0.37	3.38e-10	Parkinson's disease;
CESC	cis	rs4332037	0.576	rs62434668	chr7:1866901	G/A	cg23422044	chr7:1970798	MAD1L1	-0.52	-5.2	-0.3	3.92e-7	Bipolar disorder;
CESC	cis	rs1538970	1.000	rs7417107	chr1:45831915	G/C	cg06784218	chr1:46089804	CCDC17	0.31	5.29	0.31	2.62e-7	Platelet count;
CESC	cis	rs733592	0.507	rs56129148	chr12:48485530	T/C	cg24011408	chr12:48396354	COL2A1	-0.5	-8.24	-0.45	7.94e-15	Plateletcrit;
CESC	cis	rs8050907	0.744	rs11866840	chr16:4536354	C/T	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.89	5.66	0.33	3.84e-8	Obesity-related traits;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg17675882	chr20:35374068	NDRG3	-0.48	-6.9	-0.39	3.88e-11	Gambling;
CESC	cis	rs34311866	0.808	rs748483	chr4:952409	A/G	cg07828340	chr4:882639	GAK	0.96	7.02	0.4	1.84e-11	Parkinson's disease;
CESC	cis	rs2836974	0.965	rs7354783	chr21:40652992	G/A	cg11644478	chr21:40555479	PSMG1	1.05	16.84	0.72	9.02e-44	Cognitive function;
CESC	cis	rs9916302	0.851	rs11078906	chr17:37662767	C/T	cg20243544	chr17:37824526	PNMT	0.5	6.37	0.36	8.22e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs4819052	0.765	rs2838827	chr21:46656146	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.91	12.69	0.61	3.88e-29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26736321	chr22:42196593	CCDC134	0.57	6.14	0.35	3.07e-9	Gut microbiome composition (summer);
CESC	cis	rs2354432	0.546	rs11240030	chr1:146882616	G/A	cg25205988	chr1:146714368	CHD1L	0.88	9.35	0.5	3.8e-18	Mitochondrial DNA levels;
CESC	cis	rs7178909	0.872	rs3931863	chr15:90433913	T/G	cg19708238	chr15:90437601	AP3S2	0.42	5.84	0.34	1.5e-8	Common traits (Other);
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg10392504	chr7:5464594	TNRC18	-0.49	-6.53	-0.37	3.35e-10	Height;
CESC	cis	rs3087591	0.708	rs67065748	chr17:29605631	T/A	cg24425628	chr17:29625626	OMG;NF1	0.42	5.25	0.31	3.14e-7	Hip circumference;
CESC	cis	rs708547	0.830	rs1713994	chr4:57868367	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.75	9.87	0.52	9.04e-20	Response to bleomycin (chromatid breaks);
CESC	cis	rs11098499	0.722	rs10006192	chr4:120263022	T/C	cg09307838	chr4:120376055	NA	0.75	9.88	0.52	8.38e-20	Corneal astigmatism;
CESC	cis	rs7267979	1.000	rs1888997	chr20:25298988	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.86	-16.78	-0.72	1.5e-43	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs2380220	0.808	rs2613553	chr6:95916704	A/G	cg15832292	chr6:96025679	MANEA	-0.65	-5.95	-0.34	8.46e-9	Behavioural disinhibition (generation interaction);
CESC	trans	rs1005277	0.577	rs4934906	chr10:38015028	C/T	cg12057190	chr19:54976211	LENG9;CDC42EP5	0.42	6.04	0.35	5.32e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs4665809	0.627	rs7562192	chr2:26469457	C/G	cg22920501	chr2:26401640	FAM59B	0.93	10.89	0.56	4.54e-23	Gut microbiome composition (summer);
CESC	cis	rs9911578	1.000	rs8071916	chr17:56660279	A/G	cg05425664	chr17:57184151	TRIM37	-0.47	-6.56	-0.37	2.87e-10	Intelligence (multi-trait analysis);
CESC	cis	rs2070488	0.804	rs13085153	chr3:38461279	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.81	13.28	0.63	3.43e-31	Electrocardiographic conduction measures;
CESC	cis	rs7618501	1.000	rs3749241	chr3:49744392	A/G	cg24308560	chr3:49941425	MST1R	0.49	6.69	0.38	1.29e-10	Intelligence (multi-trait analysis);
CESC	cis	rs7447593	0.666	rs10866705	chr5:176801131	G/T	cg17509989	chr5:176798049	RGS14	-0.59	-6.96	-0.39	2.74e-11	Urinary electrolytes (magnesium/calcium ratio);
CESC	cis	rs2072499	0.966	rs2853643	chr1:156184831	G/A	cg25208724	chr1:156163844	SLC25A44	0.95	15.35	0.69	1.82e-38	Testicular germ cell tumor;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17297071	chr21:26934424	MIR155HG	-0.58	-6.81	-0.39	6.45e-11	Gut microbiome composition (summer);
CESC	trans	rs1908814	0.516	rs4840597	chr8:11796068	A/C	cg15556689	chr8:8085844	FLJ10661	0.51	6.32	0.36	1.1e-9	Neuroticism;
CESC	cis	rs6580649	0.941	rs4760677	chr12:48449163	C/T	cg05342945	chr12:48394962	COL2A1	0.5	5.85	0.34	1.47e-8	Lung cancer;
CESC	trans	rs11098499	0.826	rs4472123	chr4:120236630	T/A	cg25214090	chr10:38739885	LOC399744	0.63	8.77	0.47	2.25e-16	Corneal astigmatism;
CESC	cis	rs1552244	1.000	rs68045038	chr3:10151828	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-10.9	-0.56	4.33e-23	Alzheimer's disease;
CESC	cis	rs6060987	1	rs6060987	chr20:30427077	T/A	cg13852791	chr20:30311386	BCL2L1	0.74	7.36	0.41	2.27e-12	Mean corpuscular volume;
CESC	cis	rs10129255	0.957	rs10136560	chr14:107195868	C/G	cg23076370	chr14:107095027	NA	-0.45	-5.31	-0.31	2.34e-7	Kawasaki disease;
CESC	cis	rs35306767	0.951	rs11253530	chr10:993729	T/C	cg20503657	chr10:835505	NA	0.76	7.78	0.43	1.65e-13	Eosinophil percentage of granulocytes;
CESC	cis	rs56036086	0.877	rs55958053	chr22:50647448	T/G	cg16473166	chr22:50639996	SELO	0.64	5.13	0.3	5.64e-7	Platelet count;Plateletcrit;
CESC	cis	rs1862618	0.573	rs2591962	chr5:56237155	G/A	cg18230493	chr5:56204884	C5orf35	0.8	9.57	0.51	8.02e-19	Initial pursuit acceleration;
CESC	cis	rs16854884	0.633	rs6779321	chr3:143736676	T/C	cg06585982	chr3:143692056	C3orf58	0.5	6.7	0.38	1.26e-10	Economic and political preferences (feminism/equality);
CESC	cis	rs7095944	0.614	rs1055256	chr10:126446592	A/G	cg08799069	chr10:126477246	METTL10	-0.35	-5.16	-0.3	4.81e-7	Asthma;
CESC	cis	rs9815354	0.716	rs76313799	chr3:41931751	A/C	cg03022575	chr3:42003672	ULK4	0.71	6.44	0.37	5.46e-10	Pulse pressure;Diastolic blood pressure;
CESC	trans	rs79527984	0.618	rs35526560	chr7:71741232	C/G	cg12318501	chr22:50919512	ADM2	-0.33	-6.11	-0.35	3.45e-9	Intelligence (multi-trait analysis);
CESC	cis	rs10089	1.000	rs4836367	chr5:127482592	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.78	10.51	0.54	8.08e-22	Ileal carcinoids;
CESC	cis	rs9311474	0.508	rs6805156	chr3:52609362	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.5	7.39	0.41	1.97e-12	Electroencephalogram traits;
CESC	cis	rs2479724	0.868	rs2249703	chr6:41814760	A/G	cg08135965	chr6:41755394	TOMM6	0.42	5.76	0.33	2.38e-8	Menarche (age at onset);
CESC	cis	rs9362426	0.708	rs7753821	chr6:88100010	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.51	6.11	0.35	3.49e-9	Depressive episodes in bipolar disorder;
CESC	cis	rs4919087	0.532	rs56189004	chr10:99086632	A/G	cg25902810	chr10:99078978	FRAT1	-0.49	-5.39	-0.31	1.55e-7	Monocyte count;
CESC	cis	rs6502050	0.805	rs11077970	chr17:80085916	C/T	cg23985595	chr17:80112537	CCDC57	0.42	6.55	0.37	2.99e-10	Life satisfaction;
CESC	cis	rs514406	0.505	rs440871	chr1:53173052	C/T	cg08859206	chr1:53392774	SCP2	-0.6	-8.01	-0.44	3.63e-14	Monocyte count;
CESC	cis	rs853679	0.550	rs6901017	chr6:28152583	T/C	cg12963246	chr6:28129442	ZNF389	0.51	7.03	0.4	1.8e-11	Depression;
CESC	cis	rs7772486	0.754	rs13214277	chr6:146136125	G/T	cg23711669	chr6:146136114	FBXO30	1.02	15.98	0.7	1.02e-40	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs12136530	0.625	rs4912086	chr1:19730181	A/G	cg01832549	chr1:19774989	CAPZB	-0.44	-6.27	-0.36	1.42e-9	Lead levels in blood;
CESC	cis	rs12348691	0.503	rs7048394	chr9:100605433	T/C	cg13688889	chr9:100608707	NA	-0.89	-13.55	-0.64	3.84e-32	Alopecia areata;
CESC	cis	rs4665809	1.000	rs6739061	chr2:26256147	C/T	cg22920501	chr2:26401640	FAM59B	-0.67	-8.04	-0.44	3.04e-14	Gut microbiome composition (summer);
CESC	cis	rs881375	0.678	rs10760129	chr9:123700183	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.52	7.52	0.42	8.42e-13	Rheumatoid arthritis;
CESC	cis	rs2455799	0.573	rs2455834	chr3:15753641	A/G	cg16303742	chr3:15540471	COLQ	-0.4	-6.29	-0.36	1.29e-9	Mean platelet volume;
CESC	cis	rs7809950	0.678	rs13230144	chr7:106909172	T/C	cg23024343	chr7:107201750	COG5	-0.55	-6.91	-0.39	3.58e-11	Coronary artery disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg22762088	chr20:33581493	MYH7B	0.47	7.12	0.4	9.99e-12	Fibrinogen levels;
CESC	cis	rs7647973	1.000	rs74471041	chr3:49542543	T/G	cg07636037	chr3:49044803	WDR6	-0.72	-10.25	-0.53	5.58e-21	Menarche (age at onset);
CESC	cis	rs9311474	0.659	rs7638808	chr3:52572056	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.44	-6.23	-0.36	1.79e-9	Electroencephalogram traits;
CESC	cis	rs7772486	0.790	rs1062067	chr6:146207563	A/G	cg23711669	chr6:146136114	FBXO30	0.92	13.35	0.63	1.96e-31	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2933343	0.621	rs789242	chr3:128585707	T/C	cg11901034	chr3:128598214	ACAD9	-0.37	-5.53	-0.32	7.56e-8	IgG glycosylation;
CESC	cis	rs11098499	0.779	rs6815934	chr4:120267310	T/C	cg09307838	chr4:120376055	NA	0.76	10.03	0.52	2.87e-20	Corneal astigmatism;
CESC	cis	rs1153858	1.000	rs7164602	chr15:45671325	A/G	cg21132104	chr15:45694354	SPATA5L1	0.86	11.62	0.58	1.67e-25	Homoarginine levels;
CESC	cis	rs447	1.000	rs6964546	chr7:83750271	T/C	cg22846510	chr7:83753280	SEMA3A	-0.45	-5.67	-0.33	3.8e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	trans	rs1814175	0.645	rs28549248	chr11:50042740	C/T	cg03929089	chr4:120376271	NA	-0.91	-14.92	-0.68	5.78e-37	Height;
CESC	cis	rs8077577	0.708	rs2290504	chr17:18136988	T/C	cg16794390	chr17:18148240	FLII	-0.43	-6.49	-0.37	4.23e-10	Obesity-related traits;
CESC	cis	rs9787249	0.533	rs1883648	chr1:40246535	T/G	cg02773041	chr1:40204384	PPIE	0.39	5.6	0.33	5.33e-8	Blood protein levels;
CESC	cis	rs9287719	0.967	rs12995159	chr2:10753323	C/T	cg02196655	chr2:10830764	NOL10	-0.37	-5.69	-0.33	3.39e-8	Prostate cancer;
CESC	cis	rs4665809	1.000	rs2891490	chr2:26325927	T/C	cg27170947	chr2:26402098	FAM59B	-0.58	-6.85	-0.39	5.18e-11	Gut microbiome composition (summer);
CESC	cis	rs3858526	0.523	rs10742818	chr11:5882535	T/C	cg13902645	chr11:5959945	NA	-0.67	-9.54	-0.51	9.62e-19	DNA methylation (variation);
CESC	cis	rs17253792	0.822	rs10137364	chr14:56059987	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.83	6.18	0.36	2.36e-9	Putamen volume;
CESC	cis	rs6842047	0.901	rs2102575	chr4:187131504	G/A	cg09526685	chr4:187126073	CYP4V2	0.72	5.85	0.34	1.48e-8	Blood protein levels;
CESC	cis	rs10129255	0.518	rs12590732	chr14:107187851	C/T	cg07958169	chr14:107095056	NA	0.53	8.32	0.46	4.69e-15	Kawasaki disease;
CESC	cis	rs9556958	0.708	rs4772092	chr13:99166614	A/G	cg20750642	chr13:99100586	FARP1	0.36	5.96	0.34	7.87e-9	Educational attainment (years of education);
CESC	cis	rs782590	0.967	rs10496050	chr2:55806313	C/T	cg18811423	chr2:55921094	PNPT1	0.79	12.77	0.62	2.03e-29	Metabolic syndrome;
CESC	cis	rs6120849	0.754	rs752448	chr20:33592248	C/T	cg24642439	chr20:33292090	TP53INP2	0.67	6.62	0.38	1.94e-10	Protein C levels;
CESC	cis	rs2836950	0.565	rs2836943	chr21:40592611	C/T	cg17971929	chr21:40555470	PSMG1	-0.55	-7.1	-0.4	1.15e-11	Menarche (age at onset);
CESC	cis	rs9291683	0.546	rs12504565	chr4:10045145	G/A	cg00071950	chr4:10020882	SLC2A9	0.81	13.65	0.64	1.7e-32	Bone mineral density;
CESC	cis	rs11638352	1.000	rs12900237	chr15:44330810	A/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.65	-6.07	-0.35	4.52e-9	Lipoprotein phospholipase A2 activity in cardiovascular disease;
CESC	cis	rs10504229	0.679	rs6474100	chr8:58031161	G/A	cg22535103	chr8:58192502	C8orf71	-0.61	-6.86	-0.39	4.87e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs3125734	0.633	rs7100297	chr10:63985100	T/C	cg09941381	chr10:64027924	RTKN2	-0.31	-5.11	-0.3	6.19e-7	Rheumatoid arthritis;
CESC	cis	rs728616	0.558	rs17616958	chr10:82137461	A/G	cg05935833	chr10:81318306	SFTPA2	-0.46	-5.66	-0.33	3.97e-8	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs1707322	0.721	rs11211158	chr1:46132850	C/G	cg06784218	chr1:46089804	CCDC17	0.43	7.48	0.42	1.07e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs1728785	0.818	rs1728772	chr16:68584526	C/T	cg02972257	chr16:68554789	NA	-0.54	-6.27	-0.36	1.45e-9	Ulcerative colitis;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg11922371	chr17:48226442	PPP1R9B	-0.42	-6.14	-0.35	3e-9	Gambling;
CESC	cis	rs12479064	0.724	rs4851203	chr2:99986932	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.63	-7.43	-0.42	1.53e-12	Chronic sinus infection;
CESC	cis	rs818427	0.896	rs712662	chr5:112222694	C/G	cg07820702	chr5:112228657	REEP5	0.44	5.46	0.32	1.08e-7	Total body bone mineral density;
CESC	cis	rs1143633	0.566	rs2708932	chr2:113690675	C/A	cg12858261	chr2:113808755	IL1F8	-0.44	-5.38	-0.31	1.64e-7	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs6032067	0.929	rs6017504	chr20:43818920	G/A	cg10761708	chr20:43804764	PI3	0.53	6.39	0.37	7.37e-10	Blood protein levels;
CESC	cis	rs11204677	1	rs11204677	chr1:150574695	C/G	cg13175981	chr1:150552382	MCL1	0.73	10.74	0.55	1.47e-22	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
CESC	cis	rs2243480	1.000	rs316325	chr7:65609518	G/A	cg18252515	chr7:66147081	NA	-1.41	-14.48	-0.66	2.11e-35	Diabetic kidney disease;
CESC	trans	rs853679	0.607	rs71559070	chr6:28038929	G/A	cg06606381	chr12:133084897	FBRSL1	-1.11	-8.0	-0.44	3.78e-14	Depression;
CESC	cis	rs7605827	0.930	rs6749663	chr2:15529705	T/G	cg19274914	chr2:15703543	NA	0.35	6.36	0.36	8.85e-10	Educational attainment (years of education);
CESC	cis	rs6540556	0.723	rs12060420	chr1:209906819	T/G	cg23920097	chr1:209922102	NA	-0.39	-5.06	-0.3	7.99e-7	Red blood cell count;
CESC	cis	rs875971	1.000	rs697970	chr7:65560052	G/C	cg18876405	chr7:65276391	NA	-0.57	-7.41	-0.41	1.66e-12	Aortic root size;
CESC	trans	rs12316797	0.708	rs12296488	chr12:43130547	A/G	cg08862033	chr2:6120613	LOC400940	-0.51	-6.24	-0.36	1.73e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CESC	cis	rs13256369	0.802	rs11249887	chr8:8562184	T/C	cg18904891	chr8:8559673	CLDN23	0.73	8.39	0.46	2.86e-15	Obesity-related traits;
CESC	cis	rs3733585	0.605	rs56178126	chr4:10123581	C/T	cg11266682	chr4:10021025	SLC2A9	-0.57	-10.21	-0.53	7.4e-21	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs1270639	0.778	rs2530403	chr7:157445639	C/T	cg13357408	chr7:157437802	PTPRN2	0.61	7.15	0.4	8.33e-12	Colorectal cancer;
CESC	cis	rs9914578	1.000	rs9915112	chr17:2007826	A/G	cg16513277	chr17:2031491	SMG6	-0.57	-6.62	-0.38	1.99e-10	Body mass index;
CESC	cis	rs12477438	0.834	rs1563108	chr2:99701153	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.72	-10.21	-0.53	7.64e-21	Chronic sinus infection;
CESC	cis	rs1003719	0.715	rs2156078	chr21:38546473	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.59	-7.98	-0.44	4.49e-14	Eye color traits;
CESC	trans	rs4843747	0.671	rs72818540	chr16:88078988	C/T	cg26811252	chr16:29126840	RRN3P2	0.7	9.84	0.52	1.11e-19	Menopause (age at onset);
CESC	trans	rs8073060	0.544	rs225274	chr17:33971221	C/T	cg19694781	chr19:47549865	TMEM160	0.71	7.51	0.42	9.29e-13	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	cis	rs3785574	0.962	rs2665840	chr17:61873307	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	-1.09	-19.45	-0.77	5.73e-53	Height;
CESC	cis	rs1568889	0.877	rs34351528	chr11:28304293	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.72	8.6	0.47	6.92e-16	Bipolar disorder;
CESC	cis	rs7267005	1.000	rs7272202	chr20:34489669	A/G	cg17201900	chr20:34330562	RBM39	-0.97	-5.21	-0.3	3.84e-7	Response to paliperidone in schizophrenia (Multivariate);
CESC	cis	rs7524258	0.868	rs1304712	chr1:7270538	C/T	cg07173049	chr1:7289937	CAMTA1	0.4	5.95	0.34	8.65e-9	Tourette's syndrome or obsessive-compulsive disorder;
CESC	cis	rs796364	1.000	rs769949	chr2:200729558	A/G	cg23649088	chr2:200775458	C2orf69	0.54	5.1	0.3	6.38e-7	Schizophrenia;
CESC	cis	rs4713118	0.587	rs61471148	chr6:28037032	T/A	cg18032046	chr6:28092343	ZSCAN16	-0.55	-5.98	-0.34	7.09e-9	Parkinson's disease;
CESC	cis	rs9612	1.000	rs2277745	chr19:44259077	C/T	cg08581076	chr19:44259116	C19orf61	0.63	7.37	0.41	2.21e-12	Exhaled nitric oxide output;
CESC	cis	rs4727027	0.834	rs7811446	chr7:148773226	G/T	cg23583168	chr7:148888333	NA	-0.78	-11.73	-0.58	7.14e-26	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs9322193	0.923	rs9800871	chr6:149965676	A/G	cg07701084	chr6:150067640	NUP43	0.46	6.48	0.37	4.5e-10	Lung cancer;
CESC	cis	rs4924935	1.000	rs35341640	chr17:18818228	G/A	cg26378065	chr17:18585709	ZNF286B	-0.52	-6.4	-0.37	6.95e-10	Pancreatic cancer;
CESC	cis	rs1218582	0.688	rs58629129	chr1:154910930	T/C	cg09359103	chr1:154839909	KCNN3	-0.59	-10.25	-0.53	5.57e-21	Prostate cancer;
CESC	cis	rs8017423	0.647	rs12895269	chr14:90822430	T/C	cg14092571	chr14:90743983	NA	0.44	6.77	0.38	8.12e-11	Mortality in heart failure;
CESC	cis	rs711245	0.545	rs848617	chr2:36811298	G/C	cg09467607	chr2:36825704	FEZ2	0.55	10.25	0.53	5.65e-21	Height;
CESC	cis	rs6502050	0.871	rs8082577	chr17:80070581	T/C	cg01763666	chr17:80159506	CCDC57	0.37	5.16	0.3	4.92e-7	Life satisfaction;
CESC	cis	rs4862750	0.872	rs9998172	chr4:187898773	T/C	cg22105103	chr4:187893119	NA	0.51	7.61	0.42	4.66e-13	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4664308	0.658	rs12987602	chr2:160960788	G/T	cg03641300	chr2:160917029	PLA2R1	-0.44	-6.23	-0.36	1.86e-9	Idiopathic membranous nephropathy;
CESC	cis	rs4722166	0.695	rs6946509	chr7:22809490	T/C	cg13104385	chr7:22767384	IL6	0.37	5.51	0.32	8.64e-8	Lung cancer;
CESC	cis	rs9715521	0.935	rs56025348	chr4:59836741	T/G	cg11281224	chr4:60001000	NA	-0.51	-6.6	-0.38	2.29e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs1355223	1.000	rs12792532	chr11:34765782	G/T	cg11058730	chr11:34937778	PDHX;APIP	-0.46	-6.09	-0.35	3.98e-9	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs454510	0.816	rs838987	chr1:120176127	A/G	cg16322792	chr1:120165303	ZNF697	0.46	7.31	0.41	3.2e-12	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
CESC	cis	rs36051895	0.632	rs12001334	chr9:5152604	C/A	cg02405213	chr9:5042618	JAK2	-0.52	-6.44	-0.37	5.58e-10	Pediatric autoimmune diseases;
CESC	cis	rs9399135	0.967	rs9389254	chr6:135330709	C/T	cg24558204	chr6:135376177	HBS1L	0.53	7.28	0.41	3.85e-12	Red blood cell count;
CESC	cis	rs1552244	1.000	rs33917318	chr3:10067797	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-10.79	-0.55	9.49e-23	Alzheimer's disease;
CESC	cis	rs12579753	0.672	rs4509857	chr12:82268017	C/T	cg23701643	chr12:82153290	PPFIA2	-0.35	-5.28	-0.31	2.76e-7	Resting heart rate;
CESC	cis	rs2576037	0.583	rs504668	chr18:44410749	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.52	-7.13	-0.4	9.42e-12	Personality dimensions;
CESC	cis	rs1355223	0.902	rs12802120	chr11:34747650	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.46	-6.07	-0.35	4.29e-9	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs8114671	0.562	rs2378294	chr20:33500378	G/A	cg07148914	chr20:33460835	GGT7	0.46	6.12	0.35	3.43e-9	Height;
CESC	cis	rs9399401	0.667	rs12213892	chr6:142702234	A/G	cg04461802	chr6:142623433	GPR126	0.36	5.4	0.31	1.52e-7	Chronic obstructive pulmonary disease;
CESC	cis	rs8005677	0.962	rs11157931	chr14:23403193	A/C	cg01529538	chr14:23388837	RBM23	0.5	6.74	0.38	9.9e-11	Cognitive ability (multi-trait analysis);
CESC	cis	rs9322193	0.962	rs3805753	chr6:150116798	C/T	cg05861140	chr6:150128134	PCMT1	-0.37	-5.34	-0.31	1.99e-7	Lung cancer;
CESC	cis	rs60733400	0.817	rs4648657	chr1:2560735	A/G	cg20673091	chr1:2541236	MMEL1	-0.47	-7.78	-0.43	1.64e-13	Multiple sclerosis;
CESC	cis	rs3106136	0.872	rs10033662	chr4:95239462	G/A	cg11021082	chr4:95130006	SMARCAD1	0.44	6.49	0.37	4.25e-10	Capecitabine sensitivity;
CESC	cis	rs2228479	0.867	rs75110337	chr16:89962635	C/A	cg06558623	chr16:89946397	TCF25	1.05	8.66	0.47	4.66e-16	Skin colour saturation;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg05780637	chr2:239989132	HDAC4	0.53	7.06	0.4	1.43e-11	Fibrinogen levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13248847	chr17:7137857	DVL2	0.65	8.13	0.45	1.68e-14	Gut microbiome composition (summer);
CESC	cis	rs801193	1.000	rs13239306	chr7:66136017	T/G	cg25985355	chr7:65971099	NA	0.32	5.27	0.31	2.78e-7	Aortic root size;
CESC	cis	rs1790761	0.587	rs4930431	chr11:67294308	C/T	cg24690094	chr11:67383802	NA	-0.36	-6.34	-0.36	9.92e-10	Mean corpuscular volume;
CESC	cis	rs12681288	0.578	rs56702775	chr8:968860	G/A	cg04851639	chr8:1020857	NA	-0.31	-6.08	-0.35	4.21e-9	Schizophrenia;
CESC	cis	rs3857536	0.776	rs9342535	chr6:66932963	C/T	cg07460842	chr6:66804631	NA	-0.42	-5.36	-0.31	1.8e-7	Blood trace element (Cu levels);
CESC	cis	rs3858526	0.959	rs11039723	chr11:5956002	G/C	cg05234568	chr11:5960015	NA	-0.62	-7.01	-0.4	1.97e-11	DNA methylation (variation);
CESC	cis	rs12930096	0.938	rs8048558	chr16:11678332	G/A	cg07439791	chr16:11680400	LITAF	0.61	5.63	0.33	4.68e-8	QT interval;
CESC	cis	rs2075371	0.796	rs12154724	chr7:133943443	G/A	cg11752832	chr7:134001865	SLC35B4	0.53	6.85	0.39	5.2e-11	Mean platelet volume;
CESC	cis	rs4853012	0.838	rs59570457	chr2:74344282	T/C	cg19729930	chr2:74357872	NA	0.86	12.95	0.62	4.69e-30	Gestational age at birth (maternal effect);
CESC	cis	rs7267979	1.000	rs2387884	chr20:25379069	C/T	cg08601574	chr20:25228251	PYGB	-0.38	-5.45	-0.32	1.13e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7666738	0.800	rs7683737	chr4:99070880	A/T	cg18180107	chr4:99064573	C4orf37	0.4	5.09	0.3	6.92e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3736485	0.966	rs1031664	chr15:51754897	C/A	cg08986416	chr15:51914746	DMXL2	-0.42	-5.35	-0.31	1.93e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs2204008	0.555	rs7310307	chr12:38107497	G/T	cg13010199	chr12:38710504	ALG10B	0.53	6.43	0.37	5.77e-10	Bladder cancer;
CESC	trans	rs629535	0.821	rs680993	chr8:70050247	G/A	cg21567404	chr3:27674614	NA	0.93	11.17	0.57	5.25e-24	Dupuytren's disease;
CESC	cis	rs41271951	0.512	rs12090246	chr1:151107496	G/A	cg11822372	chr1:151115635	SEMA6C	-0.64	-5.12	-0.3	5.84e-7	Blood protein levels;
CESC	cis	rs832540	0.898	rs702680	chr5:56220382	T/C	cg14703610	chr5:56206110	C5orf35	0.54	7.02	0.4	1.83e-11	Coronary artery disease;
CESC	cis	rs7666738	0.791	rs7377018	chr4:99034962	C/T	cg03676636	chr4:99064102	C4orf37	0.34	5.14	0.3	5.47e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4595586	0.545	rs12831116	chr12:39401456	C/T	cg26384229	chr12:38710491	ALG10B	0.63	8.92	0.48	7.92e-17	Morning vs. evening chronotype;
CESC	cis	rs1003719	0.680	rs3992	chr21:38505969	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-8.47	-0.46	1.69e-15	Eye color traits;
CESC	cis	rs9549260	0.755	rs7990923	chr13:41215972	A/G	cg21288729	chr13:41239152	FOXO1	0.65	8.62	0.47	6.27e-16	Red blood cell count;
CESC	cis	rs3740713	0.920	rs73438659	chr11:18455953	A/G	cg23797887	chr11:18477753	LDHAL6A	-0.53	-5.27	-0.31	2.89e-7	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg26338869	chr17:61819248	STRADA	0.68	8.89	0.48	9.81e-17	Prudent dietary pattern;
CESC	cis	rs8014204	0.762	rs8016389	chr14:75287554	T/C	cg08847533	chr14:75593920	NEK9	0.41	5.3	0.31	2.42e-7	Caffeine consumption;
CESC	cis	rs7520050	0.778	rs3013597	chr1:46128356	C/A	cg06784218	chr1:46089804	CCDC17	0.33	6.06	0.35	4.54e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs3820068	0.603	rs1980607	chr1:15975237	A/G	cg13390004	chr1:15929781	NA	0.34	5.58	0.32	6.07e-8	Systolic blood pressure;
CESC	cis	rs422421	1.000	rs434434	chr5:176516953	A/G	cg00618323	chr5:176515533	FGFR4	0.41	5.23	0.31	3.5e-7	Height;
CESC	cis	rs8031584	0.918	rs34095794	chr15:31269691	C/T	cg08109568	chr15:31115862	NA	-0.69	-9.06	-0.49	2.88e-17	Huntington's disease progression;
CESC	cis	rs736408	0.521	rs13074853	chr3:52779801	T/C	cg05564831	chr3:52568323	NT5DC2	0.45	7.02	0.4	1.83e-11	Bipolar disorder;
CESC	cis	rs2243480	1.000	rs778704	chr7:65863467	T/C	cg18252515	chr7:66147081	NA	-1.39	-14.18	-0.66	2.5e-34	Diabetic kidney disease;
CESC	cis	rs9287719	0.649	rs58633964	chr2:10736382	T/G	cg00105475	chr2:10696890	NA	0.37	5.22	0.31	3.6e-7	Prostate cancer;
CESC	cis	rs11098499	0.865	rs4001305	chr4:120359236	G/T	cg24375607	chr4:120327624	NA	0.46	5.77	0.33	2.18e-8	Corneal astigmatism;
CESC	cis	rs11958404	0.932	rs72816574	chr5:157429882	T/C	cg05962755	chr5:157440814	NA	0.62	6.53	0.37	3.41e-10	IgG glycosylation;
CESC	cis	rs2885135	0.559	rs1148455	chr1:13914230	A/G	cg04886857	chr1:13914270	PDPN	0.33	5.6	0.33	5.38e-8	Response to cytadine analogues (cytosine arabinoside);
CESC	cis	rs4862750	0.914	rs11943333	chr4:187872455	A/G	cg11301795	chr4:187892539	NA	-0.57	-8.88	-0.48	1.02e-16	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6570726	0.846	rs7773939	chr6:145927384	C/T	cg23711669	chr6:146136114	FBXO30	-0.83	-12.02	-0.59	7.45e-27	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6500395	0.926	rs1039343	chr16:48577507	T/G	cg04672837	chr16:48644449	N4BP1	0.49	5.98	0.34	7.28e-9	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs4819052	0.851	rs10470258	chr21:46658989	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.46	5.79	0.34	2e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs9894429	1.000	rs4074915	chr17:79579230	G/A	cg13777783	chr17:79615861	NA	0.35	5.78	0.33	2.09e-8	Eye color traits;
CESC	cis	rs6598955	0.671	rs57386998	chr1:26569821	G/A	cg19743891	chr1:26644573	UBXN11;CD52	0.38	5.44	0.32	1.21e-7	Obesity-related traits;
CESC	cis	rs7072216	0.763	rs6584202	chr10:100170383	G/A	cg26618903	chr10:100175079	PYROXD2	-0.36	-5.59	-0.32	5.65e-8	Metabolite levels;
CESC	cis	rs4843747	0.671	rs28679286	chr16:88106307	C/T	cg03395651	chr16:88107091	BANP	0.46	5.36	0.31	1.85e-7	Menopause (age at onset);
CESC	cis	rs889398	0.774	rs6499263	chr16:69890149	T/C	cg09409435	chr16:70099608	PDXDC2	0.42	5.27	0.31	2.9e-7	Body mass index;
CESC	cis	rs9911578	0.967	rs4932693	chr17:57110327	T/C	cg12560992	chr17:57184187	TRIM37	-1.01	-17.65	-0.74	1.26e-46	Intelligence (multi-trait analysis);
CESC	cis	rs8077577	0.895	rs3088233	chr17:18112675	C/T	cg16794390	chr17:18148240	FLII	0.41	5.64	0.33	4.37e-8	Obesity-related traits;
CESC	cis	rs35110281	0.632	rs9306160	chr21:45107562	T/C	cg04455712	chr21:45112962	RRP1B	0.47	7.2	0.4	6.15e-12	Mean corpuscular volume;
CESC	cis	rs754466	0.651	rs10824584	chr10:79625947	G/A	cg17075019	chr10:79541650	NA	-0.85	-13.12	-0.63	1.25e-30	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	7.83	0.43	1.17e-13	Prudent dietary pattern;
CESC	cis	rs2046867	0.862	rs6805234	chr3:72829869	A/G	cg25664220	chr3:72788482	NA	-0.38	-5.74	-0.33	2.54e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CESC	cis	rs831574	0.614	rs6806547	chr3:63893477	G/T	cg15342441	chr3:63893510	ATXN7	-0.43	-5.41	-0.32	1.42e-7	Metabolite levels (Dihydroxy docosatrienoic acid);
CESC	cis	rs1059312	1.000	rs7970815	chr12:129288366	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.73	-10.11	-0.53	1.56e-20	Systemic lupus erythematosus;
CESC	cis	rs9300255	0.602	rs941305	chr12:123715266	T/C	cg00376283	chr12:123451042	ABCB9	0.72	8.84	0.48	1.34e-16	Neutrophil percentage of white cells;
CESC	cis	rs2839186	0.771	rs2280959	chr21:47641996	C/G	cg10351095	chr21:47802916	PCNT	-0.45	-6.14	-0.35	2.98e-9	Testicular germ cell tumor;
CESC	cis	rs250677	0.958	rs36068	chr5:148417512	C/T	cg18129178	chr5:148520854	ABLIM3	-0.52	-5.8	-0.34	1.86e-8	Breast cancer;
CESC	cis	rs10788972	0.815	rs1981039	chr1:54555405	T/A	cg25741118	chr1:54482237	LDLRAD1	-0.22	-5.25	-0.31	3.19e-7	Parkinson disease and lewy body pathology;
CESC	cis	rs916888	0.647	rs199523	chr17:44848517	C/A	cg17911788	chr17:44343683	NA	0.42	6.52	0.37	3.45e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs1153858	1.000	rs11858495	chr15:45637662	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.42	-5.75	-0.33	2.51e-8	Homoarginine levels;
CESC	trans	rs875971	0.628	rs6974355	chr7:65841981	A/G	cg26939375	chr7:64535504	NA	0.65	8.48	0.46	1.55e-15	Aortic root size;
CESC	cis	rs11642862	0.901	rs11647243	chr16:30965308	G/A	cg02466173	chr16:30829666	NA	-0.57	-5.21	-0.3	3.81e-7	Tonsillectomy;
CESC	cis	rs57709857	0.957	rs56300324	chr8:38180561	T/G	cg01506891	chr8:38243824	LETM2	0.48	5.03	0.3	9.22e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs875971	0.862	rs778686	chr7:65835910	C/T	cg18876405	chr7:65276391	NA	0.5	6.85	0.39	5.28e-11	Aortic root size;
CESC	cis	rs4808199	0.948	rs2023883	chr19:19405480	G/A	cg03709012	chr19:19516395	GATAD2A	1.09	12.03	0.59	6.68e-27	Nonalcoholic fatty liver disease;
CESC	cis	rs1881744	1.000	rs11183943	chr12:47810498	G/T	cg18786123	chr12:47787067	NA	0.68	5.22	0.31	3.57e-7	Metabolite levels (HVA/5-HIAA ratio);
CESC	cis	rs7618915	0.501	rs11714030	chr3:52765882	C/T	cg17372223	chr3:52568218	NT5DC2	0.44	6.57	0.37	2.59e-10	Bipolar disorder;
CESC	cis	rs4253772	0.550	rs6007818	chr22:46703776	C/T	cg09491104	chr22:46646882	C22orf40	-0.52	-6.42	-0.37	6.22e-10	LDL cholesterol;Cholesterol, total;
CESC	cis	rs10504229	0.906	rs114627636	chr8:58173732	C/T	cg22535103	chr8:58192502	C8orf71	-1.06	-11.56	-0.58	2.66e-25	Developmental language disorder (linguistic errors);
CESC	cis	rs2050392	0.624	rs303450	chr10:30725337	C/A	cg25182066	chr10:30743637	MAP3K8	-0.45	-5.83	-0.34	1.6e-8	Inflammatory bowel disease;
CESC	cis	rs10504229	1.000	rs67039591	chr8:58174553	T/A	cg24829409	chr8:58192753	C8orf71	-0.76	-10.0	-0.52	3.53e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs9467711	0.606	rs9393710	chr6:26367833	A/G	cg14345882	chr6:26364793	BTN3A2	0.6	6.21	0.36	2.06e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs684232	0.583	rs10521106	chr17:510707	C/T	cg15660573	chr17:549704	VPS53	-0.79	-11.68	-0.58	1.08e-25	Prostate cancer;
CESC	cis	rs1552244	0.935	rs6805869	chr3:10119917	T/C	cg00166722	chr3:10149974	C3orf24	0.55	7.09	0.4	1.21e-11	Alzheimer's disease;
CESC	cis	rs10208940	0.920	rs35118992	chr2:68699460	G/A	cg12452813	chr2:68675892	NA	0.52	5.24	0.31	3.26e-7	Urate levels in lean individuals;
CESC	cis	rs35306767	0.715	rs17221456	chr10:1037234	T/C	cg26597838	chr10:835615	NA	0.66	5.91	0.34	1.04e-8	Eosinophil percentage of granulocytes;
CESC	cis	rs1448094	0.817	rs61929421	chr12:86342330	T/C	cg02569458	chr12:86230093	RASSF9	0.42	5.98	0.34	7.33e-9	Major depressive disorder;
CESC	cis	rs10463316	0.608	rs7700423	chr5:150769155	C/T	cg03212797	chr5:150827313	SLC36A1	-0.45	-5.88	-0.34	1.24e-8	Metabolite levels (Pyroglutamine);
CESC	cis	rs7666738	0.925	rs2865952	chr4:99040305	C/T	cg18180107	chr4:99064573	C4orf37	0.45	5.51	0.32	8.52e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7829975	0.511	rs2976906	chr8:8342415	A/T	cg06636001	chr8:8085503	FLJ10661	0.42	5.13	0.3	5.71e-7	Mood instability;
CESC	cis	rs7772486	0.790	rs4896852	chr6:146284621	T/C	cg05347473	chr6:146136440	FBXO30	-0.56	-7.17	-0.4	7.61e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs3862030	0.839	rs12570859	chr10:104257226	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.37	-5.23	-0.31	3.38e-7	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
CESC	cis	rs2749592	0.588	rs2504144	chr10:38383525	C/T	cg25517755	chr10:38738941	LOC399744	-0.43	-5.13	-0.3	5.53e-7	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs763121	0.819	rs5757169	chr22:39003495	G/A	cg06544989	chr22:39130855	UNC84B	0.51	9.34	0.5	4.01e-18	Menopause (age at onset);
CESC	cis	rs713587	0.563	rs7605335	chr2:25109317	G/A	cg01884057	chr2:25150051	NA	0.34	6.44	0.37	5.53e-10	Body mass index in non-asthmatics;
CESC	cis	rs7847628	0.550	rs12343516	chr9:123603469	A/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.78	12.61	0.61	7.2e-29	Birth weight;
CESC	cis	rs314370	1.000	rs12705089	chr7:100465355	C/T	cg10426581	chr7:100472382	SRRT	0.85	8.1	0.45	1.96e-14	Resting heart rate;
CESC	cis	rs6088590	0.542	rs6059956	chr20:33220070	A/G	cg24642439	chr20:33292090	TP53INP2	0.64	8.53	0.46	1.12e-15	Coronary artery disease;
CESC	cis	rs11792861	0.781	rs2297581	chr9:111755008	C/T	cg13535736	chr9:111863775	C9orf5	-0.47	-6.2	-0.36	2.17e-9	Menarche (age at onset);
CESC	cis	rs6740322	0.895	rs6760797	chr2:43559612	G/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.7	-7.29	-0.41	3.68e-12	Coronary artery disease;
CESC	cis	rs875971	0.928	rs2036263	chr7:65800197	C/T	cg10691866	chr7:65817282	TPST1	0.31	5.23	0.31	3.43e-7	Aortic root size;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg20250874	chr13:47127354	LRCH1	-0.47	-6.71	-0.38	1.15e-10	Gambling;
CESC	cis	rs34779708	0.966	rs11592567	chr10:35409369	C/T	cg04310649	chr10:35416472	CREM	-0.52	-6.25	-0.36	1.62e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs72781680	1.000	rs72788286	chr2:24098321	A/C	cg20701182	chr2:24300061	SF3B14	0.62	5.68	0.33	3.54e-8	Lymphocyte counts;
CESC	cis	rs6500395	0.925	rs9933148	chr16:48672099	C/T	cg04672837	chr16:48644449	N4BP1	0.51	6.28	0.36	1.35e-9	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs8060686	0.920	rs73594556	chr16:67925435	G/A	cg26727032	chr16:67993705	SLC12A4	-0.56	-6.46	-0.37	4.94e-10	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs9611565	0.559	rs9611619	chr22:41986714	C/T	cg17376030	chr22:41985996	PMM1	0.81	8.45	0.46	1.98e-15	Vitiligo;
CESC	cis	rs6570726	0.791	rs448939	chr6:145808320	T/C	cg05347473	chr6:146136440	FBXO30	0.48	6.32	0.36	1.12e-9	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9768139	0.901	rs56113702	chr7:158117938	C/T	cg24154853	chr7:158122151	PTPRN2	-0.38	-5.96	-0.34	8.14e-9	Calcium levels;
CESC	cis	rs6991838	0.584	rs16932245	chr8:66510045	A/C	cg13398993	chr8:66546079	ARMC1	-0.47	-5.59	-0.32	5.56e-8	Intelligence (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04618842	chr12:57472555	TMEM194A	-0.57	-6.95	-0.39	2.84e-11	Gut microbiome composition (summer);
CESC	cis	rs514406	0.893	rs1242317	chr1:53414766	T/C	cg24675658	chr1:53192096	ZYG11B	-0.53	-6.42	-0.37	6.12e-10	Monocyte count;
CESC	cis	rs9902453	0.868	rs9890075	chr17:28470464	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.65	8.29	0.45	5.59e-15	Coffee consumption (cups per day);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06090630	chr16:2827139	TCEB2	0.57	6.24	0.36	1.76e-9	Gut microbiome composition (summer);
CESC	cis	rs9287719	0.967	rs715247	chr2:10736291	A/G	cg00105475	chr2:10696890	NA	0.39	5.61	0.33	4.96e-8	Prostate cancer;
CESC	trans	rs116095464	0.558	rs10043002	chr5:226753	G/A	cg00938859	chr5:1591904	SDHAP3	0.62	6.74	0.38	9.67e-11	Breast cancer;
CESC	cis	rs3858526	0.959	rs11039723	chr11:5956002	G/C	cg13902645	chr11:5959945	NA	-0.67	-7.71	-0.43	2.52e-13	DNA methylation (variation);
CESC	cis	rs116095464	0.614	rs62344339	chr5:252995	T/G	cg22496380	chr5:211416	CCDC127	-0.73	-8.39	-0.46	2.99e-15	Breast cancer;
CESC	cis	rs7044106	0.791	rs10984994	chr9:123478769	A/T	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.64	-8.72	-0.47	3.05e-16	Hip circumference adjusted for BMI;
CESC	cis	rs6495122	0.699	rs3784789	chr15:75082552	C/G	cg14664628	chr15:75095509	CSK	-0.67	-9.29	-0.5	5.99e-18	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
CESC	cis	rs1008375	1.000	rs10805359	chr4:17684886	A/G	cg16339924	chr4:17578868	LAP3	0.51	6.57	0.37	2.67e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs12478296	0.786	rs13409307	chr2:242995499	G/C	cg06360820	chr2:242988706	NA	-0.74	-9.37	-0.5	3.4e-18	Obesity-related traits;
CESC	cis	rs9858542	0.953	rs71324979	chr3:49619651	T/C	cg07274523	chr3:49395745	GPX1	0.64	8.11	0.45	1.85e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs514406	0.893	rs476108	chr1:53317351	C/T	cg08736216	chr1:53307985	ZYG11A	-0.41	-6.9	-0.39	3.83e-11	Monocyte count;
CESC	cis	rs73001065	0.901	rs73004933	chr19:19675696	C/T	cg03709012	chr19:19516395	GATAD2A	0.95	5.74	0.33	2.62e-8	LDL cholesterol;
CESC	cis	rs8141529	0.956	rs132539	chr22:29304253	C/T	cg15103426	chr22:29168792	CCDC117	0.53	6.27	0.36	1.44e-9	Lymphocyte counts;
CESC	cis	rs55823223	0.564	rs936391	chr17:73847799	A/G	cg06969265	chr17:73775802	H3F3B	-0.48	-5.35	-0.31	1.92e-7	Psoriasis;
CESC	cis	rs6952808	0.531	rs3778991	chr7:2172455	G/A	cg05863683	chr7:1912471	MAD1L1	0.4	5.9	0.34	1.08e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs7267979	1.000	rs2482937	chr20:25340786	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.86	-16.6	-0.71	6.28e-43	Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs7107217	1.000	rs1873872	chr11:129473993	A/T	cg26532042	chr19:49468557	FTL	0.47	6.09	0.35	3.95e-9	Breast cancer;Type 2 diabetes;
CESC	cis	rs6430585	0.536	rs3213892	chr2:136552517	G/A	cg07169764	chr2:136633963	MCM6	1.3	17.95	0.74	1.12e-47	Corneal structure;
CESC	cis	rs3008870	0.727	rs2862729	chr1:67500828	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.61	7.95	0.44	5.54e-14	Lymphocyte percentage of white cells;
CESC	cis	rs2932538	0.961	rs6690292	chr1:113188419	C/T	cg22162597	chr1:113214053	CAPZA1	-0.45	-6.1	-0.35	3.79e-9	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CESC	cis	rs28647808	0.786	rs4962137	chr9:136256826	G/T	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.85	5.74	0.33	2.59e-8	Blood protein levels;
CESC	cis	rs1018836	0.923	rs9643308	chr8:91625399	A/C	cg16814680	chr8:91681699	NA	-0.72	-9.98	-0.52	3.92e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs2050392	0.590	rs17547917	chr10:30718303	G/A	cg18806716	chr10:30721971	MAP3K8	-0.62	-9.21	-0.49	1.01e-17	Inflammatory bowel disease;
CESC	cis	rs7588746	0.571	rs4673891	chr2:201156362	C/G	cg23649088	chr2:200775458	C2orf69	-0.43	-5.18	-0.3	4.32e-7	Bipolar disorder lithium response (continuous) or schizophrenia;
CESC	cis	rs798554	1.000	rs798545	chr7:2762386	C/T	cg13628971	chr7:2884303	GNA12	0.6	7.78	0.43	1.66e-13	Height;
CESC	cis	rs7552404	0.731	rs1689275	chr1:76409655	T/C	cg10523679	chr1:76189770	ACADM	-0.6	-6.31	-0.36	1.2e-9	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs7917772	0.636	rs4418737	chr10:104525123	A/G	cg04362960	chr10:104952993	NT5C2	0.45	5.11	0.3	6.07e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs4665809	0.590	rs13016300	chr2:26468365	G/C	cg04944784	chr2:26401820	FAM59B	0.96	10.55	0.54	5.79e-22	Gut microbiome composition (summer);
CESC	cis	rs7618915	0.547	rs4687636	chr3:52633929	G/A	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.31	5.52	0.32	7.94e-8	Bipolar disorder;
CESC	cis	rs7086627	0.515	rs4933390	chr10:82213081	A/C	cg03267442	chr10:82210566	NA	-0.34	-5.58	-0.32	6.06e-8	Post bronchodilator FEV1;
CESC	cis	rs13191362	1.000	rs13206253	chr6:163166902	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.66	6.88	0.39	4.28e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs9487051	0.676	rs4383852	chr6:109594475	G/A	cg21918786	chr6:109611834	NA	-0.37	-5.41	-0.32	1.39e-7	Reticulocyte fraction of red cells;
CESC	cis	rs12136530	0.636	rs4244001	chr1:19734368	C/T	cg01832549	chr1:19774989	CAPZB	-0.44	-6.25	-0.36	1.64e-9	Lead levels in blood;
CESC	cis	rs6088580	0.524	rs6142210	chr20:33223012	C/T	cg24642439	chr20:33292090	TP53INP2	-0.5	-5.97	-0.34	7.64e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs72627123	0.530	rs79371463	chr14:74474856	T/A	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.79	5.8	0.34	1.92e-8	Morning vs. evening chronotype;
CESC	trans	rs116095464	0.558	rs6878061	chr5:223072	A/G	cg00938859	chr5:1591904	SDHAP3	0.6	6.66	0.38	1.55e-10	Breast cancer;
CESC	cis	rs3733585	0.781	rs13103879	chr4:9972879	T/C	cg02734326	chr4:10020555	SLC2A9	-0.45	-6.66	-0.38	1.55e-10	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs3762637	1.000	rs28497203	chr3:122231819	T/C	cg24169773	chr3:122142474	KPNA1	-0.59	-6.91	-0.39	3.61e-11	LDL cholesterol levels;
CESC	cis	rs3793683	0.556	rs2803989	chr10:134560596	C/T	cg26818010	chr10:134567672	INPP5A	-0.65	-8.06	-0.44	2.7e-14	Migraine;
CESC	trans	rs61931739	0.500	rs6488215	chr12:34434803	A/T	cg26384229	chr12:38710491	ALG10B	0.54	7.46	0.42	1.25e-12	Morning vs. evening chronotype;
CESC	cis	rs514406	0.929	rs554301	chr1:53321948	A/T	cg08859206	chr1:53392774	SCP2	0.61	8.32	0.46	4.68e-15	Monocyte count;
CESC	cis	rs7618915	0.547	rs4130905	chr3:52709831	A/T	cg18404041	chr3:52824283	ITIH1	-0.4	-6.73	-0.38	1.07e-10	Bipolar disorder;
CESC	cis	rs67460515	0.500	rs9812507	chr3:160723393	G/A	cg03342759	chr3:160939853	NMD3	-0.43	-5.4	-0.32	1.45e-7	Parkinson's disease;
CESC	cis	rs3105593	1.000	rs12591751	chr15:50972497	G/A	cg08437265	chr15:50716283	USP8	0.46	6.11	0.35	3.5e-9	QT interval;
CESC	cis	rs1862618	0.853	rs252916	chr5:56121788	G/C	cg18230493	chr5:56204884	C5orf35	-0.72	-8.78	-0.47	2.09e-16	Initial pursuit acceleration;
CESC	cis	rs4665809	1.000	rs4665809	chr2:26251361	C/T	cg27170947	chr2:26402098	FAM59B	0.6	7.08	0.4	1.28e-11	Gut microbiome composition (summer);
CESC	cis	rs8062405	0.964	rs72793809	chr16:28832382	C/T	cg08761264	chr16:28874980	SH2B1	-0.47	-5.84	-0.34	1.55e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs10129255	0.957	rs12590667	chr14:107187462	A/G	cg23076370	chr14:107095027	NA	0.5	6.49	0.37	4.15e-10	Kawasaki disease;
CESC	cis	rs4474465	0.850	rs10751292	chr11:78242201	C/G	cg27205649	chr11:78285834	NARS2	0.44	5.42	0.32	1.33e-7	Alzheimer's disease (survival time);
CESC	cis	rs10791323	0.604	rs2851116	chr11:133705759	G/A	cg06766960	chr11:133703094	NA	-0.38	-5.41	-0.32	1.44e-7	Childhood ear infection;
CESC	cis	rs736408	0.509	rs3774349	chr3:52722335	A/C	cg07507251	chr3:52567010	NT5DC2	0.38	7.27	0.41	4.16e-12	Bipolar disorder;
CESC	trans	rs61931739	0.517	rs4104182	chr12:34081343	G/A	cg26384229	chr12:38710491	ALG10B	0.59	8.21	0.45	9.64e-15	Morning vs. evening chronotype;
CESC	cis	rs11563648	0.535	rs6467122	chr7:127001087	A/C	cg25922125	chr7:127225783	GCC1	-0.42	-5.16	-0.3	4.74e-7	Resting heart rate;
CESC	cis	rs763014	0.931	rs7199839	chr16:636126	T/C	cg00802000	chr16:706648	WDR90	-0.41	-6.19	-0.36	2.26e-9	Height;
CESC	cis	rs614226	1.000	rs1614223	chr12:120964043	T/C	cg01236616	chr12:121019343	POP5	1.55	19.98	0.78	8.29e-55	Type 1 diabetes nephropathy;
CESC	cis	rs6835098	0.923	rs7671278	chr4:174095769	A/G	cg08422745	chr4:174089978	GALNT7	-0.7	-9.22	-0.49	9.26e-18	Dementia and core Alzheimer's disease neuropathologic changes;
CESC	cis	rs977987	0.843	rs10514396	chr16:75422903	T/C	cg03315344	chr16:75512273	CHST6	0.4	5.73	0.33	2.68e-8	Dupuytren's disease;
CESC	cis	rs6088590	1.000	rs2295354	chr20:33356541	T/C	cg24642439	chr20:33292090	TP53INP2	0.85	11.78	0.59	4.73e-26	Coronary artery disease;
CESC	cis	rs9611565	0.765	rs132921	chr22:41812044	G/A	cg06481639	chr22:41940642	POLR3H	0.58	6.34	0.36	9.76e-10	Vitiligo;
CESC	cis	rs11676348	0.935	rs4674250	chr2:218977531	G/A	cg00012203	chr2:219082015	ARPC2	-0.54	-6.92	-0.39	3.37e-11	Ulcerative colitis;
CESC	cis	rs875971	0.545	rs67775320	chr7:65658779	T/C	cg11764359	chr7:65958608	NA	0.79	9.51	0.5	1.18e-18	Aortic root size;
CESC	cis	rs11997175	0.713	rs4733454	chr8:33651253	C/A	ch.8.33884649F	chr8:33765107	NA	0.55	6.77	0.38	8.32e-11	Body mass index;
CESC	cis	rs4629180	1.000	rs13031791	chr2:102108790	T/C	cg01388757	chr2:102091195	RFX8	0.44	6.75	0.38	9.06e-11	Chronic rhinosinusitis with nasal polyps;
CESC	trans	rs561341	1.000	rs555629	chr17:30294136	T/C	cg20587970	chr11:113659929	NA	-1.43	-18.65	-0.75	3.85e-50	Hip circumference adjusted for BMI;
CESC	cis	rs7647973	0.600	rs13064780	chr3:49274826	T/G	cg02487422	chr3:49467188	NICN1	0.39	5.3	0.31	2.38e-7	Menarche (age at onset);
CESC	cis	rs861020	0.630	rs655712	chr1:210006437	G/A	cg05527609	chr1:210001259	C1orf107	0.74	9.67	0.51	3.97e-19	Orofacial clefts;
CESC	cis	rs2290159	1.000	rs2290159	chr3:12628920	G/C	cg23032965	chr3:12705835	RAF1	0.49	5.44	0.32	1.22e-7	Cholesterol, total;
CESC	cis	rs6088580	0.634	rs6087588	chr20:33066369	T/C	cg06115741	chr20:33292138	TP53INP2	0.45	5.71	0.33	3.09e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs9486719	0.522	rs4839683	chr6:96851933	A/G	cg18709589	chr6:96969512	KIAA0776	0.43	5.11	0.3	6.19e-7	Migraine;Coronary artery disease;
CESC	cis	rs6088580	0.634	rs6088488	chr20:32992631	T/C	cg08999081	chr20:33150536	PIGU	-0.66	-11.72	-0.58	8.03e-26	Glomerular filtration rate (creatinine);
CESC	cis	rs7727544	0.716	rs4594848	chr5:131586598	C/A	cg14196790	chr5:131705035	SLC22A5	0.35	5.24	0.31	3.21e-7	Blood metabolite levels;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg12780433	chr3:159481918	SCHIP1	-0.5	-8.11	-0.45	1.85e-14	Gambling;
CESC	cis	rs9896933	0.732	rs590886	chr17:80767350	A/G	cg19500275	chr17:80737654	TBCD	-0.53	-5.51	-0.32	8.33e-8	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
CESC	cis	rs6570726	0.791	rs414600	chr6:145879606	G/A	cg05347473	chr6:146136440	FBXO30	0.57	7.26	0.41	4.21e-12	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg03592283	chr3:44666723	ZNF197	-0.44	-6.21	-0.36	2e-9	Fibrinogen levels;
CESC	cis	rs763121	0.853	rs138706	chr22:39137834	C/G	cg06544989	chr22:39130855	UNC84B	0.51	9.64	0.51	4.93e-19	Menopause (age at onset);
CESC	cis	rs6500395	0.963	rs4785528	chr16:48687908	A/C	cg04672837	chr16:48644449	N4BP1	-0.51	-6.37	-0.36	8.27e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs1008375	0.966	rs2872957	chr4:17651757	C/A	cg02297831	chr4:17616191	MED28	0.61	7.82	0.43	1.23e-13	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs7666738	0.830	rs2865989	chr4:99067532	G/A	cg05340658	chr4:99064831	C4orf37	0.83	12.82	0.62	1.36e-29	Colonoscopy-negative controls vs population controls;
CESC	cis	rs727505	0.607	rs67454509	chr7:124792500	A/G	cg23710748	chr7:124431027	NA	-0.4	-6.19	-0.36	2.33e-9	Lewy body disease;
CESC	cis	rs4713118	0.662	rs9357060	chr6:28024486	C/G	cg19592336	chr6:28129416	ZNF389	0.53	6.92	0.39	3.43e-11	Parkinson's disease;
CESC	cis	rs2075371	0.863	rs12707139	chr7:133954153	A/G	cg20476274	chr7:133979776	SLC35B4	0.62	8.9	0.48	8.88e-17	Mean platelet volume;
CESC	cis	rs55883249	1.000	rs76964971	chr2:9763904	C/A	cg23886495	chr2:9695866	ADAM17	0.61	5.51	0.32	8.64e-8	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
CESC	cis	rs11252926	0.603	rs11252670	chr10:529152	A/G	cg03684893	chr10:554711	DIP2C	0.43	6.46	0.37	4.97e-10	Psychosis in Alzheimer's disease;
CESC	cis	rs2072732	0.821	rs10909864	chr1:2948178	T/C	cg03976712	chr1:2946727	NA	0.32	5.47	0.32	1.07e-7	Plateletcrit;
CESC	cis	rs7666738	0.962	rs4699596	chr4:99012924	C/T	cg05340658	chr4:99064831	C4orf37	0.6	8.01	0.44	3.74e-14	Colonoscopy-negative controls vs population controls;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg21767207	chr19:36236454	PSENEN;U2AF1L4	0.45	6.14	0.35	2.98e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs34779708	0.931	rs2490663	chr10:35329735	A/G	cg04310649	chr10:35416472	CREM	0.5	6.21	0.36	2.07e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs854765	0.647	rs854769	chr17:18019011	A/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.43	-5.18	-0.3	4.43e-7	Total body bone mineral density;
CESC	cis	rs13095912	0.743	rs13076556	chr3:185339575	A/G	cg11274856	chr3:185301563	NA	0.37	5.51	0.32	8.61e-8	Systolic blood pressure;
CESC	cis	rs7618915	0.547	rs4130905	chr3:52709831	A/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.38	6.72	0.38	1.1e-10	Bipolar disorder;
CESC	cis	rs7072216	0.763	rs942803	chr10:100168631	G/T	cg26618903	chr10:100175079	PYROXD2	-0.37	-5.73	-0.33	2.79e-8	Metabolite levels;
CESC	cis	rs853679	0.546	rs200990	chr6:27815823	T/G	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.89	7.84	0.43	1.08e-13	Depression;
CESC	cis	rs3020736	0.500	rs28791586	chr22:42500483	A/G	cg15557168	chr22:42548783	NA	0.45	6.57	0.37	2.72e-10	Autism spectrum disorder or schizophrenia;
CESC	cis	rs3781458	0.803	rs11245321	chr10:126323279	C/T	cg20435097	chr10:126320824	FAM53B	0.29	5.31	0.31	2.31e-7	Male-pattern baldness;
CESC	cis	rs10504229	1.000	rs17217033	chr8:58180061	G/T	cg24829409	chr8:58192753	C8orf71	-0.76	-10.0	-0.52	3.53e-20	Developmental language disorder (linguistic errors);
CESC	trans	rs7819412	0.740	rs11250119	chr8:11037034	C/T	cg15556689	chr8:8085844	FLJ10661	-0.53	-6.81	-0.39	6.46e-11	Triglycerides;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11192808	chr8:101170185	SPAG1	0.62	7.42	0.41	1.58e-12	Gut microbiome composition (summer);
CESC	cis	rs9649213	0.593	rs12672092	chr7:97986557	C/A	cg00277769	chr7:97922759	BAIAP2L1	-0.33	-5.41	-0.32	1.41e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs798554	0.757	rs1182172	chr7:2878103	G/A	cg13628971	chr7:2884303	GNA12	0.61	7.39	0.41	1.98e-12	Height;
CESC	cis	rs2180341	0.824	rs9321076	chr6:127655614	G/A	cg24812749	chr6:127587940	RNF146	1.07	15.4	0.69	1.16e-38	Breast cancer;
CESC	cis	rs3125734	0.633	rs10761616	chr10:64009076	G/A	cg09941381	chr10:64027924	RTKN2	-0.31	-5.2	-0.3	4.09e-7	Rheumatoid arthritis;
CESC	cis	rs801193	0.636	rs10233806	chr7:66118248	G/C	cg10691866	chr7:65817282	TPST1	0.35	5.81	0.34	1.76e-8	Aortic root size;
CESC	cis	rs875971	0.522	rs7784623	chr7:65395034	T/G	cg18876405	chr7:65276391	NA	0.68	9.52	0.5	1.16e-18	Aortic root size;
CESC	trans	rs3942852	0.606	rs10734561	chr11:48097480	C/T	cg03929089	chr4:120376271	NA	-0.54	-6.41	-0.37	6.77e-10	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs11638352	1.000	rs2706481	chr15:44406317	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	-0.62	-5.65	-0.33	4.07e-8	Lipoprotein phospholipase A2 activity in cardiovascular disease;
CESC	cis	rs7429990	0.965	rs2882668	chr3:47980306	A/G	cg11946769	chr3:48343235	NME6	0.42	5.27	0.31	2.78e-7	Educational attainment (years of education);
CESC	cis	rs9811920	0.535	rs793481	chr3:99488742	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.34	-5.44	-0.32	1.19e-7	Axial length;
CESC	cis	rs2836974	0.583	rs2410124	chr21:40704760	C/G	cg11890956	chr21:40555474	PSMG1	-0.94	-15.03	-0.68	2.36e-37	Cognitive function;
CESC	cis	rs2236918	0.932	rs2526697	chr1:242040129	A/G	cg17736920	chr1:242011382	EXO1	-0.55	-7.21	-0.4	5.95e-12	Menopause (age at onset);
CESC	trans	rs7980799	0.682	rs10844612	chr12:33603676	T/C	cg26384229	chr12:38710491	ALG10B	-0.56	-8.03	-0.44	3.21e-14	Heart rate;Heart rate variability traits (RMSSD);
CESC	cis	rs11264213	0.901	rs72661623	chr1:36398368	G/A	cg27506609	chr1:36549197	TEKT2	0.66	5.59	0.32	5.62e-8	Schizophrenia;
CESC	cis	rs1957429	0.901	rs6573583	chr14:65351211	G/T	cg23373153	chr14:65346875	NA	0.96	11.49	0.58	4.43e-25	Pediatric areal bone mineral density (radius);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg08108911	chr1:157015297	ARHGEF11	-0.41	-6.18	-0.35	2.46e-9	Fibrinogen levels;
CESC	cis	rs2710642	0.962	rs4671051	chr2:63032696	A/T	cg17519650	chr2:63277830	OTX1	-0.53	-6.88	-0.39	4.29e-11	LDL cholesterol levels;LDL cholesterol;
CESC	cis	rs9486719	1.000	rs13210597	chr6:96969694	C/A	cg06623918	chr6:96969491	KIAA0776	-0.79	-8.2	-0.45	1.07e-14	Migraine;Coronary artery disease;
CESC	cis	rs7264396	0.635	rs2024854	chr20:34511189	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.61	7.2	0.4	6.24e-12	Total cholesterol levels;
CESC	cis	rs3026445	0.887	rs4766497	chr12:110950376	T/C	cg12870014	chr12:110450643	ANKRD13A	-0.41	-5.11	-0.3	6.2e-7	QT interval;
CESC	cis	rs8031584	0.678	rs798086	chr15:31129211	C/G	cg08704250	chr15:31115839	NA	0.64	8.42	0.46	2.39e-15	Huntington's disease progression;
CESC	cis	rs2717559	0.542	rs10956986	chr8:143886601	C/T	cg17252645	chr8:143867129	LY6D	-0.3	-5.36	-0.31	1.78e-7	Urinary tract infection frequency;
CESC	cis	rs736408	0.562	rs2072390	chr3:52780509	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	8.12	0.45	1.76e-14	Bipolar disorder;
CESC	cis	rs9640161	0.830	rs7800196	chr7:150061534	C/G	cg21361702	chr7:150065534	REPIN1	0.49	6.0	0.35	6.61e-9	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs3820068	0.581	rs58567918	chr1:15925823	A/G	cg16988262	chr1:15930761	NA	0.35	5.65	0.33	4.18e-8	Systolic blood pressure;
CESC	cis	rs11252926	0.673	rs816620	chr10:645916	A/G	cg16386425	chr10:429943	DIP2C	0.41	5.14	0.3	5.42e-7	Psychosis in Alzheimer's disease;
CESC	cis	rs10838687	0.610	rs4647737	chr11:47253244	T/G	cg25783544	chr11:47291846	MADD	0.59	6.84	0.39	5.38e-11	Proinsulin levels;
CESC	cis	rs1862618	0.853	rs10461617	chr5:56104308	A/G	cg12311346	chr5:56204834	C5orf35	-0.71	-8.79	-0.47	1.99e-16	Initial pursuit acceleration;
CESC	cis	rs34172651	0.517	rs7204288	chr16:24784531	A/G	cg04756594	chr16:24857601	SLC5A11	0.45	5.53	0.32	7.79e-8	Intelligence (multi-trait analysis);
CESC	cis	rs727505	1.000	rs10226033	chr7:124521430	C/A	cg23710748	chr7:124431027	NA	-0.48	-7.53	-0.42	8.1e-13	Lewy body disease;
CESC	cis	rs2477686	0.526	rs2477690	chr1:2395563	G/A	cg11214544	chr1:2391121	NA	-0.41	-6.28	-0.36	1.34e-9	Non-obstructive azoospermia;
CESC	cis	rs1153858	1.000	rs28679834	chr15:45616206	C/T	cg21132104	chr15:45694354	SPATA5L1	0.82	10.82	0.55	7.93e-23	Homoarginine levels;
CESC	cis	rs13256369	0.802	rs12541520	chr8:8564146	G/T	cg00074818	chr8:8560427	CLDN23	0.36	5.41	0.32	1.39e-7	Obesity-related traits;
CESC	cis	rs7208859	0.573	rs79505916	chr17:29062326	C/T	cg13385521	chr17:29058706	SUZ12P	0.81	6.51	0.37	3.66e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17213946	chr1:43997516	PTPRF	0.54	6.17	0.35	2.54e-9	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26371787	chr6:7910221	TXNDC5	0.61	7.41	0.41	1.65e-12	Gut microbiome composition (summer);
CESC	cis	rs920590	0.684	rs3899017	chr8:19669198	A/T	cg17834443	chr8:19674713	INTS10	0.59	6.47	0.37	4.61e-10	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs4604732	0.603	rs10925051	chr1:247641834	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.4	5.78	0.33	2.12e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs3008870	0.583	rs3008861	chr1:67396222	T/G	cg08660285	chr1:67390436	MIER1;WDR78	1.0	10.97	0.56	2.49e-23	Lymphocyte percentage of white cells;
CESC	cis	rs694739	1.000	rs646153	chr11:64089588	C/T	cg02228329	chr11:64053129	BAD;GPR137	0.72	9.21	0.49	1.06e-17	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CESC	cis	rs7772486	0.754	rs4896832	chr6:145964151	G/A	cg05347473	chr6:146136440	FBXO30	0.55	7.07	0.4	1.34e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs17854409	0.536	rs3765464	chr20:61485236	T/C	cg07645718	chr20:61493192	TCFL5	0.83	5.99	0.35	6.94e-9	Obesity-related traits;
CESC	cis	rs4642101	0.737	rs4299468	chr3:12825559	G/A	cg24848339	chr3:12840334	CAND2	0.38	5.94	0.34	8.89e-9	QRS complex (12-leadsum);
CESC	cis	rs7116495	0.881	rs598835	chr11:71797727	C/T	cg26138937	chr11:71823887	C11orf51	-0.86	-7.03	-0.4	1.75e-11	Severe influenza A (H1N1) infection;
CESC	cis	rs8062405	0.965	rs62037363	chr16:28865042	T/C	cg08761264	chr16:28874980	SH2B1	-0.47	-5.85	-0.34	1.42e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs1023500	0.506	rs6002625	chr22:42517689	A/G	cg15557168	chr22:42548783	NA	0.4	5.34	0.31	1.96e-7	Schizophrenia;
CESC	cis	rs62244186	0.566	rs6766221	chr3:44882784	C/T	cg15225532	chr3:44803084	KIF15;KIAA1143	0.43	5.58	0.32	5.99e-8	Depressive symptoms;
CESC	cis	rs10911232	0.507	rs28477876	chr1:183019882	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.87	13.5	0.64	6.03e-32	Hypertriglyceridemia;
CESC	cis	rs2742234	0.541	rs1317214	chr10:43733531	C/G	cg15436174	chr10:43711423	RASGEF1A	0.47	5.52	0.32	7.96e-8	Hirschsprung disease;
CESC	cis	rs2243480	1.000	rs1499613	chr7:65730860	G/A	cg13147721	chr7:65941812	NA	0.98	9.24	0.49	8.25e-18	Diabetic kidney disease;
CESC	cis	rs55883249	0.958	rs17362734	chr2:9730208	A/G	cg23886495	chr2:9695866	ADAM17	0.6	5.6	0.33	5.39e-8	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
CESC	cis	rs7246657	0.943	rs7255407	chr19:37933936	G/A	cg23950597	chr19:37808831	NA	-0.55	-5.99	-0.35	6.69e-9	Coronary artery calcification;
CESC	cis	rs7520050	0.966	rs6656992	chr1:46333068	C/G	cg24296786	chr1:45957014	TESK2	0.43	5.41	0.32	1.4e-7	Red blood cell count;Reticulocyte count;
CESC	cis	rs3762637	1.000	rs10049131	chr3:122202102	A/T	cg24169773	chr3:122142474	KPNA1	-0.54	-6.29	-0.36	1.28e-9	LDL cholesterol levels;
CESC	cis	rs7811142	1.000	rs11764818	chr7:100043055	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.0	9.53	0.51	1.03e-18	Platelet count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20367329	chr17:17399941	RASD1	0.57	6.06	0.35	4.55e-9	Gut microbiome composition (summer);
CESC	trans	rs4942242	0.574	rs9533557	chr13:44197487	C/G	cg19169023	chr15:41853346	TYRO3	0.58	7.2	0.4	6.27e-12	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs3815700	1.000	rs8109990	chr19:33095636	A/G	cg24916020	chr19:33096688	ANKRD27	0.59	5.72	0.33	2.85e-8	Eosinophilic esophagitis;
CESC	cis	rs706334	0.905	rs706333	chr4:140517700	A/G	cg22540532	chr4:140518177	NA	-0.4	-6.35	-0.36	9.21e-10	LDL peak particle diameter (total fat intake interaction);
CESC	cis	rs7980687	0.527	rs1626703	chr12:123710835	A/C	cg05973401	chr12:123451056	ABCB9	0.57	7.12	0.4	1.03e-11	Height;Educational attainment;Head circumference (infant);
CESC	cis	rs13256369	0.950	rs13255655	chr8:8577736	C/T	cg17143192	chr8:8559678	CLDN23	0.7	7.69	0.43	2.98e-13	Obesity-related traits;
CESC	cis	rs1976403	0.659	rs10799701	chr1:21820990	A/G	cg04349561	chr1:21808255	NBPF3	-0.38	-5.49	-0.32	9.63e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs12220238	1.000	rs10824090	chr10:75923446	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.63	6.43	0.37	5.9e-10	Soluble interleukin-2 receptor subunit alpha;
CESC	cis	rs2479724	0.901	rs33954419	chr6:41786136	A/G	cg08135965	chr6:41755394	TOMM6	0.41	5.49	0.32	9.53e-8	Menarche (age at onset);
CESC	cis	rs7555523	0.887	rs4657476	chr1:165732661	A/G	cg24409356	chr1:165738333	TMCO1	-0.92	-8.51	-0.46	1.29e-15	Intraocular pressure;Glaucoma (high intraocular pressure);
CESC	cis	rs8060686	0.641	rs7193935	chr16:68071147	C/T	cg26727032	chr16:67993705	SLC12A4	-0.52	-6.44	-0.37	5.46e-10	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs10129255	0.500	rs4774008	chr14:107137290	A/T	cg07470598	chr14:107239068	NA	0.37	5.22	0.31	3.68e-7	Kawasaki disease;
CESC	cis	rs780096	0.506	rs2950834	chr2:27627366	G/A	cg21248554	chr2:27665150	KRTCAP3	-0.34	-6.98	-0.39	2.34e-11	Total body bone mineral density;
CESC	cis	rs7301826	0.651	rs10773825	chr12:131298913	G/A	cg11011512	chr12:131303247	STX2	0.47	5.84	0.34	1.52e-8	Plasma plasminogen activator levels;
CESC	cis	rs875971	0.825	rs1000464	chr7:65777909	G/C	cg10691866	chr7:65817282	TPST1	0.31	5.34	0.31	2.05e-7	Aortic root size;
CESC	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.59	-6.55	-0.37	2.92e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs10463316	0.894	rs11167542	chr5:150760282	A/G	cg03212797	chr5:150827313	SLC36A1	0.44	5.67	0.33	3.78e-8	Metabolite levels (Pyroglutamine);
CESC	cis	rs962856	0.619	rs6739471	chr2:67585593	T/C	cg09028215	chr2:67624308	ETAA1	-0.44	-5.34	-0.31	1.97e-7	Pancreatic cancer;
CESC	trans	rs116095464	0.558	rs6555058	chr5:226376	C/T	cg00938859	chr5:1591904	SDHAP3	-0.59	-6.38	-0.36	7.76e-10	Breast cancer;
CESC	cis	rs637571	0.524	rs674363	chr11:65699134	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.46	-6.55	-0.37	2.93e-10	Eosinophil percentage of white cells;
CESC	cis	rs9543976	1.000	rs2296146	chr13:76143572	T/C	cg01531495	chr13:76123901	UCHL3	-0.55	-5.45	-0.32	1.14e-7	Diabetic retinopathy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04579203	chr1:87597566	LOC339524	0.61	7.27	0.41	4.08e-12	Gut microbiome composition (summer);
CESC	cis	rs11264213	0.901	rs584873	chr1:36431806	C/A	cg27506609	chr1:36549197	TEKT2	0.67	5.61	0.33	5.12e-8	Schizophrenia;
CESC	cis	rs9916302	0.808	rs12943928	chr17:37611330	G/A	cg19468946	chr17:37922297	IKZF3	-0.39	-5.08	-0.3	7.08e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs7772486	0.875	rs9399572	chr6:146362945	T/G	cg05347473	chr6:146136440	FBXO30	0.47	6.16	0.35	2.66e-9	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs13191362	1.000	rs55847707	chr6:163003414	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.88	9.16	0.49	1.46e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs854765	0.565	rs4072738	chr17:17884547	A/C	cg04398451	chr17:18023971	MYO15A	-0.6	-8.63	-0.47	5.68e-16	Total body bone mineral density;
CESC	cis	rs9902453	0.967	rs28792710	chr17:28450015	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	7.6	0.42	5.23e-13	Coffee consumption (cups per day);
CESC	cis	rs910316	1.000	rs12588240	chr14:75612083	C/A	cg16144293	chr14:75469539	EIF2B2	-0.39	-5.07	-0.3	7.52e-7	Height;
CESC	cis	rs6690583	0.623	rs12042160	chr1:85504516	A/G	cg22153463	chr1:85462885	MCOLN2	0.79	7.58	0.42	5.8e-13	Serum sulfate level;
CESC	cis	rs13191362	0.507	rs2849524	chr6:163127070	C/T	cg21926612	chr6:163149169	PACRG;PARK2	-0.56	-6.67	-0.38	1.47e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs1847202	0.859	rs13068268	chr3:72938132	G/A	cg25664220	chr3:72788482	NA	-0.42	-6.2	-0.36	2.1e-9	Motion sickness;
CESC	cis	rs910316	0.967	rs175479	chr14:75561871	A/C	cg11812906	chr14:75593930	NEK9	-0.88	-15.04	-0.68	2.26e-37	Height;
CESC	cis	rs3749237	0.964	rs2352967	chr3:49871641	C/T	cg03060546	chr3:49711283	APEH	0.65	7.65	0.43	3.83e-13	Resting heart rate;
CESC	cis	rs17761864	0.675	rs72815344	chr17:2046947	T/C	cg16513277	chr17:2031491	SMG6	0.41	5.18	0.3	4.35e-7	Esophageal cancer (squamous cell);
CESC	cis	rs6502050	0.723	rs11650635	chr17:80083816	T/C	cg11859384	chr17:80120422	CCDC57	0.38	5.22	0.31	3.67e-7	Life satisfaction;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg02306946	chr12:105630036	APPL2	-0.43	-6.3	-0.36	1.26e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs992157	0.835	rs34353396	chr2:219153982	T/C	cg00012203	chr2:219082015	ARPC2	-0.75	-9.65	-0.51	4.46e-19	Colorectal cancer;
CESC	trans	rs1814175	0.626	rs1722008	chr11:49897676	A/T	cg03929089	chr4:120376271	NA	-0.91	-15.01	-0.68	2.72e-37	Height;
CESC	cis	rs6964587	1.000	rs10488510	chr7:91660225	G/T	cg17063962	chr7:91808500	NA	0.56	7.69	0.43	2.93e-13	Breast cancer;
CESC	cis	rs7635838	0.785	rs2606735	chr3:11400714	A/C	cg00170343	chr3:11313890	ATG7	0.46	6.42	0.37	6.35e-10	HDL cholesterol;
CESC	cis	rs801193	0.569	rs4717315	chr7:66178325	C/T	cg11764359	chr7:65958608	NA	0.73	10.6	0.55	4.14e-22	Aortic root size;
CESC	cis	rs826838	1.000	rs4575342	chr12:38663831	G/A	cg26384229	chr12:38710491	ALG10B	0.82	14.26	0.66	1.22e-34	Heart rate;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg16139199	chr18:19180362	ESCO1	0.49	6.86	0.39	4.84e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs9633740	1.000	rs7900536	chr10:82253701	G/T	cg00277334	chr10:82204260	NA	-0.58	-6.0	-0.35	6.44e-9	Post bronchodilator FEV1;
CESC	cis	rs6089829	0.889	rs6090206	chr20:61668363	G/A	cg08564027	chr20:61660810	NA	0.91	15.41	0.69	1.11e-38	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs72781680	0.611	rs72797818	chr2:24351107	G/A	cg08917208	chr2:24149416	ATAD2B	0.61	5.85	0.34	1.43e-8	Lymphocyte counts;
CESC	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg22535103	chr8:58192502	C8orf71	-0.93	-10.39	-0.54	1.89e-21	Developmental language disorder (linguistic errors);
CESC	cis	rs6032067	0.777	rs2868236	chr20:43794070	G/A	cg11264863	chr20:43835661	SEMG1	0.5	5.35	0.31	1.86e-7	Blood protein levels;
CESC	cis	rs2072732	0.861	rs41334845	chr1:2950370	A/C	cg15211996	chr1:2936768	ACTRT2	-0.37	-5.5	-0.32	9.04e-8	Plateletcrit;
CESC	cis	rs1707322	0.721	rs11211165	chr1:46157906	C/T	cg03146154	chr1:46216737	IPP	0.82	11.58	0.58	2.25e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs5769765	0.955	rs9616368	chr22:50303533	C/G	cg02269571	chr22:50332266	NA	-0.56	-6.92	-0.39	3.35e-11	Schizophrenia;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg20272604	chr1:231004631	C1orf198	-0.44	-6.0	-0.35	6.5e-9	Fibrinogen levels;
CESC	cis	rs6860806	0.531	rs2631359	chr5:131707892	C/T	cg24060327	chr5:131705240	SLC22A5	0.76	10.64	0.55	2.96e-22	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00850453	chr7:12726919	ARL4A	0.55	6.7	0.38	1.26e-10	Gut microbiome composition (summer);
CESC	cis	rs8114671	0.562	rs6088646	chr20:33505937	T/C	cg24642439	chr20:33292090	TP53INP2	0.44	5.32	0.31	2.18e-7	Height;
CESC	cis	rs11864453	0.713	rs8051882	chr16:72142072	A/G	cg16558253	chr16:72132732	DHX38	0.54	8.28	0.45	6.06e-15	Fibrinogen levels;
CESC	cis	rs7301826	0.627	rs1077317	chr12:131314977	C/T	cg11011512	chr12:131303247	STX2	0.46	5.74	0.33	2.6e-8	Plasma plasminogen activator levels;
CESC	cis	rs7618915	0.547	rs34610878	chr3:52759169	G/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.49	0.37	4.1e-10	Bipolar disorder;
CESC	cis	rs9443189	0.615	rs602873	chr6:76323818	T/A	cg01950844	chr6:76311363	SENP6	0.88	9.44	0.5	2.07e-18	Prostate cancer;
CESC	cis	rs2985684	0.895	rs4900940	chr14:50075310	A/C	cg02151108	chr14:50098012	C14orf104	-0.41	-5.32	-0.31	2.17e-7	Carotid intima media thickness;
CESC	cis	rs28489187	0.706	rs233119	chr1:85788052	T/C	cg16011679	chr1:85725395	C1orf52	0.48	5.65	0.33	4.1e-8	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg09432136	chr19:1818466	REXO1	0.49	6.68	0.38	1.38e-10	Fibrinogen levels;
CESC	cis	rs1538970	0.962	rs7532762	chr1:45864695	C/A	cg05343316	chr1:45956843	TESK2	0.8	11.55	0.58	2.96e-25	Platelet count;
CESC	cis	rs7811142	1.000	rs74460138	chr7:100027339	C/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.78	6.78	0.38	7.61e-11	Platelet count;
CESC	cis	rs798502	0.522	rs7790322	chr7:2830498	C/T	cg04166393	chr7:2884313	GNA12	0.4	5.13	0.3	5.7e-7	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Inflammatory bowel disease;Waist circumference adjusted for BMI in non-smokers;Ulcerative colitis;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
CESC	cis	rs7116495	0.609	rs11235444	chr11:71831859	G/A	cg26138937	chr11:71823887	C11orf51	1.35	8.43	0.46	2.23e-15	Severe influenza A (H1N1) infection;
CESC	cis	rs899997	1.000	rs7182567	chr15:79045054	A/G	cg04896959	chr15:78267971	NA	0.4	5.91	0.34	1.04e-8	Coronary artery disease or large artery stroke;
CESC	cis	rs7666738	0.791	rs7660866	chr4:98961335	G/A	cg18180107	chr4:99064573	C4orf37	0.4	5.14	0.3	5.26e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3768617	1.000	rs1360704	chr1:183099380	C/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.65	-8.92	-0.48	7.7e-17	Fuchs's corneal dystrophy;
CESC	trans	rs7001362	0.935	rs13251567	chr8:140227205	C/T	cg18714679	chr5:40835242	RPL37	0.42	6.0	0.35	6.61e-9	Anti-saccade response;
CESC	cis	rs561341	1.000	rs8069199	chr17:30281845	A/G	cg12193833	chr17:30244370	NA	-0.59	-6.02	-0.35	5.78e-9	Hip circumference adjusted for BMI;
CESC	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	10.18	0.53	9.01e-21	Prudent dietary pattern;
CESC	cis	rs3087591	1.000	rs2107360	chr17:29697901	C/A	cg24425628	chr17:29625626	OMG;NF1	-0.45	-5.75	-0.33	2.5e-8	Hip circumference;
CESC	cis	rs896854	0.818	rs896855	chr8:95959808	A/G	cg13393036	chr8:95962371	TP53INP1	-0.53	-11.65	-0.58	1.3e-25	Type 2 diabetes;
CESC	cis	rs7523050	0.643	rs67091034	chr1:109402567	C/G	cg08274380	chr1:109419600	GPSM2	0.86	5.69	0.33	3.36e-8	Fat distribution (HIV);
CESC	trans	rs4335177	0.716	rs10978568	chr9:109391579	G/A	cg16874583	chr12:7781004	NA	-0.48	-6.29	-0.36	1.3e-9	Response to paliperidone in schizophrenia (positive Marder score);
CESC	cis	rs909674	0.818	rs8136980	chr22:39844574	G/A	cg05872129	chr22:39784769	NA	-0.8	-10.42	-0.54	1.58e-21	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs9926296	0.568	rs1230	chr16:89804855	A/G	cg04287289	chr16:89883240	FANCA	-0.92	-16.21	-0.71	1.64e-41	Vitiligo;
CESC	cis	rs593982	0.920	rs1151500	chr11:65481166	T/C	cg08755490	chr11:65554678	OVOL1	1.11	10.27	0.53	4.82e-21	Atopic dermatitis;
CESC	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg22907277	chr7:1156413	C7orf50	0.42	5.92	0.34	9.94e-9	Longevity;Endometriosis;
CESC	cis	rs597539	0.652	rs579136	chr11:68637476	C/G	cg18350739	chr11:68623251	NA	-0.46	-7.02	-0.4	1.88e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs6952808	0.594	rs3778969	chr7:2139990	A/G	cg08027265	chr7:2291960	NA	0.45	6.85	0.39	5.06e-11	Bipolar disorder and schizophrenia;
CESC	trans	rs7618501	0.633	rs35065728	chr3:50009176	T/C	cg21659725	chr3:3221576	CRBN	0.48	6.65	0.38	1.64e-10	Intelligence (multi-trait analysis);
CESC	cis	rs4849845	0.653	rs3933618	chr2:121035552	T/G	cg24070213	chr2:121070622	NA	0.43	6.33	0.36	1.07e-9	Mean platelet volume;
CESC	cis	rs3015497	0.646	rs2934698	chr14:51137883	G/C	cg26011998	chr14:51135199	SAV1	-0.58	-6.27	-0.36	1.47e-9	Mean platelet volume;
CESC	cis	rs6762	0.642	rs28692469	chr11:839675	T/C	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.66	-8.63	-0.47	5.87e-16	Mean platelet volume;
CESC	cis	rs2228479	0.702	rs11646374	chr16:89857935	G/A	cg00800038	chr16:89945340	TCF25	-0.9	-7.51	-0.42	9.25e-13	Skin colour saturation;
CESC	cis	rs6594499	0.872	rs7723819	chr5:110427347	A/G	cg04022379	chr5:110408740	TSLP	-0.32	-5.76	-0.33	2.28e-8	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs2486288	0.656	rs8041702	chr15:45547093	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.58	-6.86	-0.39	4.94e-11	Glomerular filtration rate;
CESC	cis	rs7937682	0.632	rs7128862	chr11:111755435	C/T	cg09085632	chr11:111637200	PPP2R1B	0.87	10.93	0.56	3.49e-23	Primary sclerosing cholangitis;
CESC	cis	rs9581857	0.725	rs9319366	chr13:28017722	C/T	cg01674679	chr13:27998804	GTF3A	-0.68	-5.41	-0.32	1.42e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
CESC	cis	rs28647808	1.000	rs2285482	chr9:136271792	G/T	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.9	5.73	0.33	2.75e-8	Blood protein levels;
CESC	cis	rs17253792	0.822	rs10148122	chr14:56146694	G/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.78	5.66	0.33	4e-8	Putamen volume;
CESC	cis	rs6933660	0.745	rs9322320	chr6:151751908	C/G	cg02564969	chr6:151773285	C6orf211;RMND1	0.61	8.46	0.46	1.89e-15	Menarche (age at onset);
CESC	cis	rs35306767	0.953	rs1539174	chr10:974870	C/G	cg10556349	chr10:835070	NA	0.47	5.06	0.3	7.68e-7	Eosinophil percentage of granulocytes;
CESC	cis	rs523522	0.962	rs3893104	chr12:120903936	G/A	cg12219531	chr12:120966889	COQ5	0.73	9.29	0.5	5.72e-18	High light scatter reticulocyte count;
CESC	cis	rs2289583	0.503	rs113742359	chr15:75261643	A/G	cg14664628	chr15:75095509	CSK	0.46	5.5	0.32	8.73e-8	Systemic lupus erythematosus;
CESC	cis	rs6500602	0.627	rs863501	chr16:4588394	G/C	cg08645402	chr16:4508243	NA	-0.42	-6.36	-0.36	9.03e-10	Schizophrenia;
CESC	cis	rs2249625	1.000	rs2463731	chr6:72920896	C/G	cg18830697	chr6:72922368	RIMS1	-0.44	-6.31	-0.36	1.17e-9	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CESC	cis	rs1364705	0.955	rs1346014	chr8:120224949	G/C	cg09273054	chr8:120220131	MAL2	0.59	6.82	0.39	6.02e-11	Hippocampal atrophy;
CESC	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg05552183	chr6:42928497	GNMT	0.82	13.78	0.65	6.26e-33	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs2380220	0.720	rs9398251	chr6:95984709	C/T	cg23517279	chr6:96025343	MANEA	0.51	5.43	0.32	1.3e-7	Behavioural disinhibition (generation interaction);
CESC	cis	rs875971	0.862	rs3926380	chr7:66080645	G/T	cg19163074	chr7:65112434	INTS4L2	0.42	5.28	0.31	2.63e-7	Aortic root size;
CESC	cis	rs425277	0.585	rs364677	chr1:2071765	A/G	cg04315214	chr1:2043799	PRKCZ	0.47	7.73	0.43	2.24e-13	Height;
CESC	cis	rs853679	0.517	rs4713148	chr6:28115921	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.6	-6.84	-0.39	5.51e-11	Depression;
CESC	cis	rs26868	0.766	rs26867	chr16:2249410	T/C	cg02248941	chr16:2239361	CASKIN1	0.39	6.2	0.36	2.19e-9	Height;
CESC	cis	rs1865721	0.656	rs727894	chr18:73137117	C/T	cg26385618	chr18:73139727	C18orf62	-0.46	-7.56	-0.42	6.49e-13	Intelligence;
CESC	cis	rs2404602	0.716	rs2164101	chr15:76749117	A/G	cg22467129	chr15:76604101	ETFA	-0.38	-5.81	-0.34	1.81e-8	Blood metabolite levels;
CESC	cis	rs684232	0.602	rs4968057	chr17:517521	T/A	cg12384639	chr17:618140	VPS53	0.43	5.51	0.32	8.37e-8	Prostate cancer;
CESC	cis	rs909002	0.830	rs7542583	chr1:32110813	A/G	cg13919466	chr1:32135498	COL16A1	-0.46	-8.3	-0.45	5.27e-15	Intelligence (multi-trait analysis);
CESC	cis	rs3820068	0.734	rs72645830	chr1:15889910	A/G	cg17385448	chr1:15911702	AGMAT	0.36	5.55	0.32	6.93e-8	Systolic blood pressure;
CESC	cis	rs4076764	0.801	rs6698738	chr1:163359918	G/A	cg24596788	chr1:163392923	NA	-0.4	-5.55	-0.32	6.85e-8	Motion sickness;
CESC	cis	rs72781680	0.611	rs36052574	chr2:24306587	A/C	cg06627628	chr2:24431161	ITSN2	-0.67	-6.33	-0.36	1.06e-9	Lymphocyte counts;
CESC	cis	rs116095464	0.558	rs1971229	chr5:268187	A/G	cg10591111	chr5:226296	SDHA	-0.52	-6.35	-0.36	9.51e-10	Breast cancer;
CESC	cis	rs1707322	0.721	rs10789468	chr1:46124558	A/G	cg06784218	chr1:46089804	CCDC17	0.4	7.21	0.4	6.01e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs1707322	0.758	rs10789474	chr1:46250040	G/T	cg03146154	chr1:46216737	IPP	0.81	11.3	0.57	1.99e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs763014	0.931	rs2071980	chr16:626346	A/C	cg00908189	chr16:619842	PIGQ	0.67	9.31	0.5	5.02e-18	Height;
CESC	cis	rs9611565	0.659	rs1810460	chr22:41927700	C/T	cg03806693	chr22:41940476	POLR3H	-1.24	-17.21	-0.73	4.56e-45	Vitiligo;
CESC	cis	rs8062405	0.723	rs4788079	chr16:28559363	C/A	cg07382826	chr16:28625726	SULT1A1	0.41	6.72	0.38	1.11e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs769267	0.895	rs2965189	chr19:19519518	G/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.57	7.6	0.42	5.01e-13	Tonsillectomy;
CESC	cis	rs7666738	0.830	rs2865978	chr4:99017946	G/T	cg03676636	chr4:99064102	C4orf37	0.33	5.15	0.3	5.05e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs921968	0.541	rs599973	chr2:219387273	C/G	cg02176678	chr2:219576539	TTLL4	0.5	9.08	0.49	2.49e-17	Mean corpuscular hemoglobin concentration;
CESC	cis	rs12130219	1.000	rs12733173	chr1:152173972	C/T	cg17718321	chr1:152188247	HRNR	0.41	5.4	0.32	1.46e-7	Inflammatory skin disease;
CESC	cis	rs6032067	1.000	rs6032069	chr20:43867388	C/T	cg10761708	chr20:43804764	PI3	-0.54	-6.69	-0.38	1.33e-10	Blood protein levels;
CESC	cis	rs4563143	0.663	rs10406794	chr19:29228056	C/T	cg12667521	chr19:29218732	NA	0.39	5.52	0.32	8.1e-8	Methadone dose in opioid dependence;
CESC	cis	rs13256369	0.901	rs12679831	chr8:8566411	T/G	cg18904891	chr8:8559673	CLDN23	0.7	8.04	0.44	3.06e-14	Obesity-related traits;
CESC	cis	rs4563143	0.663	rs73025068	chr19:29238998	G/A	cg12756686	chr19:29218302	NA	0.52	6.9	0.39	3.92e-11	Methadone dose in opioid dependence;
CESC	cis	rs7605827	0.930	rs2052437	chr2:15697819	A/G	cg19274914	chr2:15703543	NA	0.3	5.45	0.32	1.18e-7	Educational attainment (years of education);
CESC	cis	rs9291683	0.530	rs10939620	chr4:9946132	C/T	cg02734326	chr4:10020555	SLC2A9	-0.44	-6.45	-0.37	5.25e-10	Bone mineral density;
CESC	cis	rs66731853	0.557	rs576968	chr1:20901246	A/G	cg04087271	chr1:20915334	CDA	-0.38	-5.43	-0.32	1.26e-7	Mean corpuscular volume;
CESC	cis	rs7953249	0.807	rs2393791	chr12:121423956	A/G	cg02403541	chr12:121454288	C12orf43	0.5	6.92	0.39	3.4e-11	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
CESC	cis	rs4790333	0.562	rs2447104	chr17:2257532	C/T	cg02569219	chr17:2266849	SGSM2	0.38	5.09	0.3	6.96e-7	Proinsulin levels;
CESC	cis	rs2243480	1.000	rs36033484	chr7:65390558	T/G	cg12463550	chr7:65579703	CRCP	0.71	5.5	0.32	8.79e-8	Diabetic kidney disease;
CESC	cis	rs9291683	0.546	rs4575994	chr4:9997979	G/A	cg00071950	chr4:10020882	SLC2A9	0.78	12.58	0.61	8.94e-29	Bone mineral density;
CESC	cis	rs965469	0.901	rs6037586	chr20:3368114	G/A	cg25506879	chr20:3388711	C20orf194	-0.58	-6.14	-0.35	2.93e-9	IFN-related cytopenia;
CESC	cis	rs13191362	0.935	rs67889271	chr6:163045753	T/G	cg06582575	chr6:163149167	PACRG;PARK2	0.84	9.06	0.49	2.98e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs3106136	0.527	rs2664872	chr4:95146952	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.7	-11.56	-0.58	2.74e-25	Capecitabine sensitivity;
CESC	cis	rs9905704	0.918	rs2567901	chr17:56783255	C/T	cg12560992	chr17:57184187	TRIM37	0.59	7.06	0.4	1.45e-11	Testicular germ cell tumor;
CESC	cis	rs4665809	0.556	rs1560869	chr2:26417095	T/C	cg27170947	chr2:26402098	FAM59B	-0.84	-10.03	-0.52	2.88e-20	Gut microbiome composition (summer);
CESC	cis	rs12701220	0.655	rs7784403	chr7:1153077	G/A	cg04025307	chr7:1156635	C7orf50	0.44	5.17	0.3	4.55e-7	Bronchopulmonary dysplasia;
CESC	cis	rs55788414	0.932	rs34444956	chr16:81185412	C/T	cg06400318	chr16:81190750	PKD1L2	-0.6	-6.82	-0.39	6.19e-11	Left ventricular obstructive tract defect (maternal effect);
CESC	cis	rs853679	0.517	rs9368558	chr6:28133306	A/G	cg08968635	chr6:28129556	ZNF389	0.4	5.22	0.31	3.69e-7	Depression;
CESC	cis	rs6674176	0.597	rs4031031	chr1:44393533	C/T	cg23954153	chr1:44402353	ARTN	-0.37	-5.96	-0.34	8.23e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs9309473	1.000	rs56672945	chr2:73622663	C/T	cg20560298	chr2:73613845	ALMS1	-0.49	-6.49	-0.37	4.28e-10	Metabolite levels;
CESC	cis	rs73058052	0.597	rs11878568	chr19:50095961	T/C	cg09250473	chr19:50168907	IRF3;BCL2L12	0.5	5.64	0.33	4.47e-8	Fibrinogen levels;
CESC	cis	rs13191362	0.935	rs7769048	chr6:163010040	T/A	cg14584255	chr6:163149320	PACRG;PARK2	0.5	5.17	0.3	4.63e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	trans	rs4689592	0.546	rs2359012	chr4:7066053	A/C	cg07817883	chr1:32538562	TMEM39B	-0.53	-6.12	-0.35	3.37e-9	Monocyte percentage of white cells;
CESC	cis	rs7605827	0.930	rs7577436	chr2:15528281	C/T	cg19274914	chr2:15703543	NA	0.3	5.2	0.3	3.99e-7	Educational attainment (years of education);
CESC	cis	rs13256369	0.851	rs13256611	chr8:8564341	G/A	cg18904891	chr8:8559673	CLDN23	0.71	8.07	0.44	2.44e-14	Obesity-related traits;
CESC	cis	rs4595586	0.545	rs11615700	chr12:39365104	A/G	cg26384229	chr12:38710491	ALG10B	0.54	7.57	0.42	6.23e-13	Morning vs. evening chronotype;
CESC	cis	rs365132	0.875	rs691141	chr5:176323298	A/G	cg16309518	chr5:176445507	NA	0.37	5.26	0.31	3.01e-7	Menarche and menopause (age at onset);Menopause (age at onset);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg09377915	chr6:56295593	NA	0.43	6.26	0.36	1.58e-9	Fibrinogen levels;
CESC	cis	rs10744422	0.528	rs6489245	chr12:123360151	G/A	cg22842854	chr12:123319900	HIP1R	-0.67	-5.4	-0.32	1.45e-7	Schizophrenia;
CESC	cis	rs4975709	0.589	rs4975707	chr5:1864028	C/T	cg11168104	chr5:1857477	NA	-0.38	-5.78	-0.33	2.09e-8	Cardiovascular disease risk factors;
CESC	cis	rs4594175	0.707	rs4901102	chr14:51746605	C/T	cg23942311	chr14:51606299	NA	-0.33	-5.28	-0.31	2.63e-7	Cancer;
CESC	cis	rs853679	0.546	rs71537572	chr6:27970715	T/C	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.88	6.03	0.35	5.35e-9	Depression;
CESC	cis	rs9733	0.744	rs12126004	chr1:150889877	T/C	cg18016565	chr1:150552671	MCL1	-0.37	-5.79	-0.34	1.95e-8	Tonsillectomy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15087571	chr7:5462185	TNRC18	0.55	6.39	0.37	7.48e-10	Gut microbiome composition (summer);
CESC	cis	rs1862618	0.853	rs252902	chr5:56116085	A/G	cg03609598	chr5:56110824	MAP3K1	-0.49	-5.28	-0.31	2.69e-7	Initial pursuit acceleration;
CESC	cis	rs16854884	0.606	rs60676654	chr3:143734937	A/G	cg06585982	chr3:143692056	C3orf58	0.5	6.56	0.37	2.84e-10	Economic and political preferences (feminism/equality);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg15487600	chr1:155113158	DPM3	-0.45	-6.15	-0.35	2.78e-9	Fibrinogen levels;
CESC	cis	rs698833	0.892	rs1067371	chr2:44651982	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.46	5.87	0.34	1.3e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs4268898	0.931	rs55642516	chr2:24502305	A/G	cg08917208	chr2:24149416	ATAD2B	0.46	5.32	0.31	2.2e-7	Asthma;
CESC	cis	rs798554	0.759	rs2644291	chr7:2890456	T/C	cg04166393	chr7:2884313	GNA12	0.58	7.5	0.42	9.48e-13	Height;
CESC	trans	rs6828577	0.779	rs419292	chr4:119634130	T/C	cg05098011	chr1:151736092	OAZ3;MRPL9	0.48	6.02	0.35	5.93e-9	Perioperative myocardial infarction in coronary artery bypass surgery;
CESC	cis	rs6933660	0.683	rs6916340	chr6:151779064	T/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.71	10.42	0.54	1.61e-21	Menarche (age at onset);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg23063716	chr15:75743999	SIN3A	-0.44	-6.39	-0.37	7.6e-10	Fibrinogen levels;
CESC	cis	rs1182196	0.502	rs757786	chr7:2836019	C/T	cg19717773	chr7:2847554	GNA12	-0.67	-11.54	-0.58	3.05e-25	Plateletcrit;
CESC	cis	rs2274273	0.662	rs67215571	chr14:55673723	G/A	cg04306507	chr14:55594613	LGALS3	0.31	5.24	0.31	3.34e-7	Protein biomarker;
CESC	cis	rs863345	0.604	rs2317969	chr1:158491753	A/G	cg12129480	chr1:158549410	OR10X1	-0.35	-6.92	-0.39	3.36e-11	Pneumococcal bacteremia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12617538	chr9:69786570	NA	-0.52	-6.13	-0.35	3.13e-9	Gut microbiome composition (summer);
CESC	cis	rs2404602	0.647	rs11072612	chr15:76960984	A/T	cg00316803	chr15:76480434	C15orf27	0.37	5.36	0.31	1.77e-7	Blood metabolite levels;
CESC	cis	rs17826219	0.500	rs9891256	chr17:29072692	C/T	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.79e-10	Body mass index;
CESC	cis	rs11077998	0.967	rs4614761	chr17:80505809	C/T	cg10255544	chr17:80519551	FOXK2	0.53	8.37	0.46	3.31e-15	Reticulocyte fraction of red cells;
CESC	cis	rs11098499	0.866	rs12499602	chr4:120284387	T/A	cg09307838	chr4:120376055	NA	0.87	12.16	0.6	2.41e-27	Corneal astigmatism;
CESC	cis	rs12220238	0.908	rs10824124	chr10:75997360	C/G	cg19889307	chr10:75911429	ADK;AP3M1	0.64	6.22	0.36	1.89e-9	Soluble interleukin-2 receptor subunit alpha;
CESC	cis	rs1878931	0.507	rs11648783	chr16:3406626	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.69	8.64	0.47	5.55e-16	Body mass index (adult);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg25506288	chr19:49217868	MAMSTR	-0.45	-6.49	-0.37	4.15e-10	Gambling;
CESC	trans	rs11098499	0.908	rs71614449	chr4:120387055	C/T	cg25214090	chr10:38739885	LOC399744	0.7	9.93	0.52	5.63e-20	Corneal astigmatism;
CESC	cis	rs3857536	0.813	rs7766786	chr6:66932889	C/A	cg07460842	chr6:66804631	NA	-0.42	-5.36	-0.31	1.8e-7	Blood trace element (Cu levels);
CESC	cis	rs4819052	0.851	rs2838857	chr21:46681000	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.44	5.67	0.33	3.73e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs6502050	0.799	rs4789680	chr17:80100547	C/A	cg23985595	chr17:80112537	CCDC57	-0.42	-6.57	-0.37	2.72e-10	Life satisfaction;
CESC	cis	rs7923609	0.905	rs7088799	chr10:65016174	T/G	cg01631684	chr10:65280961	REEP3	-0.45	-5.64	-0.33	4.38e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs2952156	0.684	rs11658786	chr17:37815899	G/A	cg00129232	chr17:37814104	STARD3	-0.81	-12.35	-0.6	5.41e-28	Asthma;
CESC	cis	rs501120	1.000	rs534079	chr10:44752558	G/T	cg09554077	chr10:44749378	NA	0.52	6.89	0.39	3.96e-11	Coronary artery disease;Coronary heart disease;
CESC	trans	rs17685	0.753	rs4728586	chr7:75802869	T/C	cg19862616	chr7:65841803	NCRNA00174	0.84	12.03	0.59	6.77e-27	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs8020095	0.571	rs9323493	chr14:67546180	C/T	cg19548862	chr14:67692701	FAM71D	-0.51	-6.26	-0.36	1.57e-9	Depression (quantitative trait);
CESC	cis	rs7659604	0.521	rs4833235	chr4:122695136	C/A	cg19748678	chr4:122722346	EXOSC9	-0.45	-5.77	-0.33	2.17e-8	Type 2 diabetes;
CESC	cis	rs6547741	1.000	rs6547734	chr2:27830990	G/T	cg27432699	chr2:27873401	GPN1	0.49	6.94	0.39	3.02e-11	Oral cavity cancer;
CESC	cis	rs7819412	0.539	rs11250131	chr8:11251175	C/T	cg21775007	chr8:11205619	TDH	-0.48	-7.24	-0.41	4.72e-12	Triglycerides;
CESC	cis	rs9908102	0.740	rs73298504	chr17:12904102	C/T	cg26162695	chr17:12921313	ELAC2	0.5	5.49	0.32	9.61e-8	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03935544	chr7:42951740	C7orf25	0.58	6.46	0.37	4.99e-10	Gut microbiome composition (summer);
CESC	cis	rs5017598	1.000	rs5017598	chr6:169211494	A/G	cg05672967	chr6:169256475	NA	0.38	5.78	0.33	2.13e-8	Pediatric bone mineral density (femoral neck);Pediatric bone mineral density (hip);
CESC	cis	rs11250464	0.833	rs11250466	chr10:1409378	C/T	cg26394196	chr10:1453818	ADARB2	-0.41	-5.55	-0.32	6.86e-8	Radiation response;
CESC	cis	rs763014	0.931	rs56048717	chr16:634867	A/G	cg00802000	chr16:706648	WDR90	-0.4	-6.08	-0.35	4.11e-9	Height;
CESC	cis	rs9818758	0.607	rs9850917	chr3:49286983	A/G	cg00383909	chr3:49044727	WDR6	0.79	6.09	0.35	4e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CESC	cis	rs7605378	1.000	rs7577763	chr2:200681753	C/T	cg23649088	chr2:200775458	C2orf69	0.52	6.74	0.38	9.73e-11	Osteoporosis;
CESC	cis	rs8141529	0.764	rs8137969	chr22:29228484	G/C	cg15103426	chr22:29168792	CCDC117	0.68	9.65	0.51	4.52e-19	Lymphocyte counts;
CESC	cis	rs6502050	0.799	rs58538819	chr17:80107153	G/C	cg23985595	chr17:80112537	CCDC57	-0.42	-6.38	-0.36	7.89e-10	Life satisfaction;
CESC	cis	rs7219021	0.705	rs1962412	chr17:46970259	T/C	cg16584676	chr17:46985605	UBE2Z	0.61	7.58	0.42	5.82e-13	Schizophrenia or bipolar disorder;
CESC	cis	rs67460515	0.563	rs11922959	chr3:160828871	A/G	cg03342759	chr3:160939853	NMD3	-0.54	-6.87	-0.39	4.65e-11	Parkinson's disease;
CESC	cis	rs4819052	0.851	rs2877018	chr21:46658306	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.75	9.98	0.52	4.1e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs853679	0.517	rs9348793	chr6:28084189	G/A	cg08968635	chr6:28129556	ZNF389	0.4	5.36	0.31	1.84e-7	Depression;
CESC	cis	rs7762018	0.891	rs7740218	chr6:170141552	G/A	cg05834625	chr6:170176447	C6orf70	0.64	7.17	0.4	7.47e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs10504229	1.000	rs949848	chr8:58169125	A/G	cg14926445	chr8:58193284	C8orf71	-0.51	-5.47	-0.32	1.03e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs7408868	1.000	rs2074622	chr19:15277620	G/C	cg14696996	chr19:15285081	NOTCH3	1.11	11.94	0.59	1.43e-26	Pulse pressure;
CESC	cis	rs9649213	0.593	rs13307593	chr7:97986146	A/G	cg08684580	chr7:98029266	BAIAP2L1	-0.35	-5.8	-0.34	1.85e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7296418	0.885	rs1727305	chr12:123633382	T/C	cg00376283	chr12:123451042	ABCB9	0.68	9.62	0.51	5.43e-19	Platelet count;
CESC	cis	rs17376456	0.569	rs17083377	chr5:93164870	C/G	cg25358565	chr5:93447407	FAM172A	0.63	6.82	0.39	6.31e-11	Diabetic retinopathy;
CESC	trans	rs1945213	0.694	rs9888298	chr11:55865704	T/C	cg15704280	chr7:45808275	SEPT13	0.75	7.28	0.41	3.87e-12	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs2204008	0.837	rs11168387	chr12:37962818	G/A	cg26384229	chr12:38710491	ALG10B	-0.55	-7.78	-0.43	1.6e-13	Bladder cancer;
CESC	cis	rs6963495	0.818	rs118134111	chr7:105161229	A/C	cg13798780	chr7:105162888	PUS7	0.78	8.04	0.44	2.99e-14	Bipolar disorder (body mass index interaction);
CESC	cis	rs858239	0.539	rs4504540	chr7:23186198	C/G	cg23682824	chr7:23144976	KLHL7	0.5	6.56	0.37	2.77e-10	Cerebrospinal fluid biomarker levels;
CESC	cis	rs72945132	0.882	rs7941933	chr11:70123351	G/A	cg14191688	chr11:70257035	CTTN	0.42	5.12	0.3	5.84e-7	Coronary artery disease;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg23677363	chr1:111682944	DRAM2;CEPT1	-0.44	-6.39	-0.37	7.32e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs9858542	1.000	rs1131095	chr3:49714225	T/C	cg03060546	chr3:49711283	APEH	-0.57	-6.81	-0.39	6.44e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs2637266	0.905	rs2130796	chr10:78329712	C/G	cg18941641	chr10:78392320	NA	0.38	6.86	0.39	4.99e-11	Pulmonary function;
CESC	cis	rs11031096	0.711	rs61899755	chr11:4201317	G/T	cg18678763	chr11:4115507	RRM1	-0.39	-5.06	-0.3	7.72e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	cis	rs4555082	1.000	rs7146643	chr14:105757392	A/G	cg10792982	chr14:105748885	BRF1	0.38	5.45	0.32	1.18e-7	Mean platelet volume;Platelet distribution width;
CESC	cis	rs7208859	0.510	rs216402	chr17:28917126	A/T	cg14008862	chr17:28927542	LRRC37B2	0.76	5.66	0.33	3.93e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs7666738	0.830	rs28622458	chr4:98916651	A/G	cg17366294	chr4:99064904	C4orf37	0.56	7.68	0.43	3.1e-13	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00624375	chr12:110841656	ANAPC7	-0.57	-6.27	-0.36	1.44e-9	Gut microbiome composition (summer);
CESC	cis	rs12824058	0.831	rs7979497	chr12:130804706	C/T	cg23887609	chr12:130822674	PIWIL1	0.43	5.3	0.31	2.45e-7	Menopause (age at onset);
CESC	cis	rs8077889	0.956	rs55768269	chr17:41888997	C/T	cg26893861	chr17:41843967	DUSP3	0.82	9.6	0.51	6.18e-19	Triglycerides;
CESC	cis	rs17376456	0.877	rs17083460	chr5:93462354	A/G	cg21475434	chr5:93447410	FAM172A	0.82	7.56	0.42	6.81e-13	Diabetic retinopathy;
CESC	cis	rs9896933	0.778	rs80112422	chr17:80827719	G/T	cg20578329	chr17:80767326	TBCD	-0.75	-7.78	-0.43	1.62e-13	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
CESC	cis	rs4595586	0.545	rs2388176	chr12:39372357	G/A	cg26384229	chr12:38710491	ALG10B	0.54	7.53	0.42	7.85e-13	Morning vs. evening chronotype;
CESC	cis	rs4665809	0.590	rs1368902	chr2:26440576	T/C	cg26314531	chr2:26401878	FAM59B	-0.85	-9.04	-0.49	3.44e-17	Gut microbiome composition (summer);
CESC	cis	rs11690935	0.632	rs34531723	chr2:172564094	A/C	cg13550731	chr2:172543902	DYNC1I2	0.57	8.08	0.44	2.32e-14	Schizophrenia;
CESC	cis	rs10089	1.000	rs10060390	chr5:127452947	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.76	10.07	0.53	2.04e-20	Ileal carcinoids;
CESC	cis	rs757081	0.764	rs2051773	chr11:17365209	A/G	cg15432903	chr11:17409602	KCNJ11	-0.47	-5.74	-0.33	2.57e-8	Systolic blood pressure;
CESC	cis	rs57506017	0.585	rs6966915	chr7:12265988	C/T	cg23422036	chr7:12250390	TMEM106B	0.38	5.08	0.3	7.18e-7	Neuroticism;
CESC	cis	rs9287719	0.967	rs6432118	chr2:10749441	C/T	cg02196655	chr2:10830764	NOL10	-0.38	-5.79	-0.34	1.96e-8	Prostate cancer;
CESC	cis	rs7772486	0.875	rs12194437	chr6:146411440	A/G	cg05347473	chr6:146136440	FBXO30	0.51	6.68	0.38	1.37e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9322193	0.923	rs9383812	chr6:150033491	C/T	cg13206674	chr6:150067644	NUP43	0.46	6.73	0.38	1.03e-10	Lung cancer;
CESC	trans	rs2727020	0.576	rs1917321	chr11:49377760	A/C	cg03929089	chr4:120376271	NA	-0.59	-7.46	-0.42	1.23e-12	Coronary artery disease;
CESC	cis	rs7666738	0.830	rs10010698	chr4:98981594	C/T	cg17366294	chr4:99064904	C4orf37	0.58	8.39	0.46	2.88e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2180341	0.961	rs910720	chr6:127619070	T/C	cg24812749	chr6:127587940	RNF146	1.06	15.35	0.69	1.74e-38	Breast cancer;
CESC	cis	rs1448094	0.512	rs1584368	chr12:86245117	A/C	cg00310523	chr12:86230176	RASSF9	0.35	5.51	0.32	8.46e-8	Major depressive disorder;
CESC	cis	rs3768617	0.510	rs6691755	chr1:183099821	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.89	14.39	0.66	4.39e-35	Fuchs's corneal dystrophy;
CESC	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg08821792	chr21:34144507	C21orf49;C21orf66	0.51	6.45	0.37	5.27e-10	Myopia (pathological);
CESC	cis	rs7408868	0.611	rs11669982	chr19:15292366	C/T	cg14696996	chr19:15285081	NOTCH3	0.77	8.89	0.48	9.75e-17	Pulse pressure;
CESC	cis	rs9443645	0.901	rs7749916	chr6:79814192	A/G	cg05283184	chr6:79620031	NA	-0.44	-6.87	-0.39	4.5e-11	Intelligence (multi-trait analysis);
CESC	cis	rs2204008	0.837	rs1589395	chr12:38420405	C/T	cg13010199	chr12:38710504	ALG10B	0.47	6.1	0.35	3.7e-9	Bladder cancer;
CESC	cis	rs12134245	0.747	rs11164912	chr1:92005191	A/T	cg25838465	chr1:92012736	NA	-0.61	-8.8	-0.48	1.77e-16	Breast cancer;
CESC	cis	rs7223966	1.000	rs1877316	chr17:61766880	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.54	6.54	0.37	3.22e-10	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs523522	0.962	rs2233676	chr12:120933607	G/A	cg27279351	chr12:120934652	DYNLL1	0.69	9.11	0.49	2.02e-17	High light scatter reticulocyte count;
CESC	cis	rs9399135	0.967	rs1854865	chr6:135360300	C/G	cg22676075	chr6:135203613	NA	0.5	7.07	0.4	1.41e-11	Red blood cell count;
CESC	cis	rs2839186	1.000	rs2839181	chr21:47685939	A/G	cg11766577	chr21:47581405	C21orf56	-0.46	-6.13	-0.35	3.16e-9	Testicular germ cell tumor;
CESC	cis	rs9324022	0.929	rs9635298	chr14:101172542	C/T	cg18089426	chr14:101175970	NA	0.62	7.07	0.4	1.36e-11	Plateletcrit;
CESC	cis	rs4919087	0.748	rs701813	chr10:98975632	C/T	cg25902810	chr10:99078978	FRAT1	-0.45	-5.2	-0.3	3.96e-7	Monocyte count;
CESC	cis	rs9309473	1.000	rs6740223	chr2:73653332	T/C	cg20560298	chr2:73613845	ALMS1	-0.46	-6.2	-0.36	2.19e-9	Metabolite levels;
CESC	cis	rs7191439	0.858	rs11076701	chr16:88774525	A/G	cg02389323	chr16:88786976	FAM38A	1.0	8.46	0.46	1.77e-15	Plateletcrit;
CESC	cis	rs4955124	0.643	rs17028716	chr3:32041580	C/G	cg05935571	chr3:32023257	ZNF860;OSBPL10	-0.79	-6.37	-0.36	8.39e-10	Schizophrenia;
CESC	cis	rs6952808	0.792	rs12531315	chr7:1953650	C/G	cg22963979	chr7:1858916	MAD1L1	-0.39	-5.42	-0.32	1.37e-7	Bipolar disorder and schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13379408	chr18:11909052	MPPE1	0.7	8.24	0.45	8.24e-15	Gut microbiome composition (summer);
CESC	cis	rs514406	0.825	rs3863643	chr1:53224577	C/T	cg08736216	chr1:53307985	ZYG11A	0.42	7.11	0.4	1.06e-11	Monocyte count;
CESC	cis	rs3806843	0.868	rs2531345	chr5:140126781	T/G	cg26395211	chr5:140044315	WDR55	0.39	5.09	0.3	6.79e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs80282103	0.618	rs57514701	chr10:1146169	G/A	cg08668510	chr10:1095578	IDI1	0.77	6.35	0.36	9.51e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs7811142	0.830	rs7341507	chr7:99951315	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.92	9.01	0.48	4.18e-17	Platelet count;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg23436918	chr7:16685595	BZW2;ANKMY2	-0.48	-6.21	-0.36	1.99e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs7772486	0.875	rs9390371	chr6:146363180	A/G	cg23711669	chr6:146136114	FBXO30	0.76	11.14	0.56	6.6e-24	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6696846	0.936	rs12134724	chr1:205039288	T/C	cg00857998	chr1:205179979	DSTYK	0.53	6.56	0.37	2.79e-10	Red blood cell count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00346985	chr1:46940516	NA	-0.45	-6.15	-0.35	2.87e-9	Gut microbiome composition (summer);
CESC	cis	rs6687430	0.526	rs6688558	chr1:10611403	A/G	cg07384165	chr1:10488281	NA	-0.44	-5.93	-0.34	9.4e-9	Hand grip strength;
CESC	cis	rs7714584	1.000	rs10061105	chr5:150255185	C/G	cg22134413	chr5:150180641	NA	0.51	5.92	0.34	9.88e-9	Crohn's disease;
CESC	cis	rs7589728	0.563	rs12479338	chr2:88444513	C/T	cg14558114	chr2:88469736	THNSL2	0.57	5.43	0.32	1.29e-7	Plasma clusterin levels;
CESC	cis	rs10129255	0.536	rs6576201	chr14:107139713	A/G	cg07958169	chr14:107095056	NA	0.45	7.07	0.4	1.38e-11	Kawasaki disease;
CESC	cis	rs12971120	0.947	rs4891559	chr18:72170397	C/T	cg26446133	chr18:72167187	CNDP2	-0.76	-11.82	-0.59	3.53e-26	Refractive error;
CESC	cis	rs11785400	0.793	rs13255558	chr8:143748080	C/T	cg10596483	chr8:143751796	JRK	0.43	5.35	0.31	1.93e-7	Schizophrenia;
CESC	cis	rs8036030	0.604	rs11856835	chr15:74716174	G/A	cg14664628	chr15:75095509	CSK	-0.51	-6.23	-0.36	1.81e-9	Airflow obstruction;
CESC	cis	rs11792861	0.926	rs3750451	chr9:111822866	C/T	cg05043794	chr9:111880884	C9orf5	-0.39	-6.39	-0.37	7.26e-10	Menarche (age at onset);
CESC	trans	rs4921164	1.000	rs11950065	chr5:158543969	A/G	cg27516404	chr7:155640019	NA	0.39	6.18	0.35	2.44e-9	Gut microbiome composition (winter);
CESC	cis	rs9443645	0.901	rs1542977	chr6:79550307	G/T	cg05283184	chr6:79620031	NA	-0.43	-6.72	-0.38	1.1e-10	Intelligence (multi-trait analysis);
CESC	cis	rs7551222	0.752	rs12125533	chr1:204529302	A/C	cg20240347	chr1:204465584	NA	-0.28	-5.71	-0.33	2.96e-8	Schizophrenia;
CESC	cis	rs644799	1.000	rs473155	chr11:95596873	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.88	12.6	0.61	7.79e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs7191700	0.836	rs12708722	chr16:11428905	T/A	cg00044050	chr16:11439710	C16orf75	0.49	5.65	0.33	4.03e-8	Multiple sclerosis;
CESC	cis	rs2576037	0.796	rs2576043	chr18:44573476	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.45	5.79	0.34	1.95e-8	Personality dimensions;
CESC	cis	rs2204008	0.684	rs11514164	chr12:38036494	C/T	cg26384229	chr12:38710491	ALG10B	0.66	9.39	0.5	2.96e-18	Bladder cancer;
CESC	cis	rs17401966	1.000	rs12118323	chr1:10469641	A/G	cg15208524	chr1:10270712	KIF1B	0.41	5.16	0.3	4.86e-7	Hepatocellular carcinoma;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18242990	chr7:2884021	GNA12	0.56	6.38	0.36	7.79e-10	Gut microbiome composition (summer);
CESC	cis	rs3845702	0.736	rs72962575	chr2:180862133	C/G	cg01881094	chr2:180872142	CWC22	1.08	9.4	0.5	2.75e-18	Schizophrenia;
CESC	cis	rs561341	1.000	rs483301	chr17:30293398	G/T	cg00745463	chr17:30367425	LRRC37B	-0.85	-7.72	-0.43	2.36e-13	Hip circumference adjusted for BMI;
CESC	cis	rs9640161	0.750	rs3735167	chr7:150039555	C/T	cg21361702	chr7:150065534	REPIN1	0.57	5.92	0.34	9.9e-9	Blood protein levels;Circulating chemerin levels;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg26220259	chr1:44444688	B4GALT2	-0.52	-6.33	-0.36	1.03e-9	Ulcerative colitis;
CESC	trans	rs2115172	0.836	rs4835799	chr5:122762229	A/G	cg20566420	chr12:122327043	PSMD9	0.46	6.03	0.35	5.5e-9	Weight;
CESC	cis	rs875971	0.540	rs4717275	chr7:65265180	C/T	cg05332525	chr7:65337924	VKORC1L1	-0.51	-6.24	-0.36	1.75e-9	Aortic root size;
CESC	trans	rs2727020	0.558	rs1164675	chr11:49325972	C/T	cg15704280	chr7:45808275	SEPT13	0.82	12.23	0.6	1.45e-27	Coronary artery disease;
CESC	cis	rs9910055	0.550	rs113844752	chr17:42297631	C/A	cg13607699	chr17:42295918	UBTF	0.86	12.51	0.61	1.53e-28	Total body bone mineral density;
CESC	cis	rs6904897	0.563	rs4896117	chr6:135229400	T/C	cg22676075	chr6:135203613	NA	-0.66	-9.73	-0.51	2.54e-19	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	trans	rs9987353	0.518	rs4841110	chr8:9086023	C/T	cg06636001	chr8:8085503	FLJ10661	0.56	6.87	0.39	4.49e-11	Recombination measurement;
CESC	cis	rs763121	0.853	rs4821811	chr22:39075145	C/T	cg21395723	chr22:39101663	GTPBP1	0.42	5.25	0.31	3.14e-7	Menopause (age at onset);
CESC	cis	rs1691799	0.899	rs1168301	chr12:66736771	C/T	cg16791601	chr12:66731901	HELB	-0.61	-10.12	-0.53	1.39e-20	White blood cell count (basophil);
CESC	cis	rs1707322	0.963	rs10890371	chr1:46390897	T/G	cg03146154	chr1:46216737	IPP	0.72	9.82	0.52	1.31e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs904092	0.720	rs1618572	chr4:100195121	C/G	cg12011299	chr4:100065546	ADH4	0.54	6.3	0.36	1.26e-9	Alcohol dependence;
CESC	cis	rs875971	0.617	rs810400	chr7:66022889	G/C	cg25985355	chr7:65971099	NA	0.32	5.34	0.31	2e-7	Aortic root size;
CESC	cis	rs1847202	0.859	rs4550778	chr3:72949198	G/A	cg10804678	chr3:72788309	NA	-0.39	-5.25	-0.31	3.19e-7	Motion sickness;
CESC	cis	rs412000	0.553	rs2680702	chr17:56431549	A/G	cg25039879	chr17:56429692	SUPT4H1	0.6	7.59	0.42	5.55e-13	Primary tooth development (time to first tooth eruption);
CESC	cis	rs4919694	1.000	rs58700372	chr10:104800205	T/C	cg04362960	chr10:104952993	NT5C2	0.79	7.02	0.4	1.86e-11	Arsenic metabolism;
CESC	cis	rs12477438	0.798	rs1530996	chr2:99584079	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.73	-10.26	-0.53	5.33e-21	Chronic sinus infection;
CESC	cis	rs597539	0.652	rs507520	chr11:68666054	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.77	9.37	0.5	3.43e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs2576037	0.526	rs2571024	chr18:44557877	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.69	-10.89	-0.56	4.48e-23	Personality dimensions;
CESC	cis	rs2191566	0.887	rs55703004	chr19:44504781	T/G	cg20607764	chr19:44506953	ZNF230	-0.56	-7.01	-0.4	1.94e-11	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs9611565	0.625	rs73178625	chr22:41928320	G/C	cg06634786	chr22:41940651	POLR3H	-0.64	-6.73	-0.38	1.07e-10	Vitiligo;
CESC	cis	rs1062177	0.826	rs2053063	chr5:151166764	T/C	cg00977110	chr5:151150581	G3BP1	0.62	6.78	0.38	7.64e-11	Preschool internalizing problems;
CESC	cis	rs2425143	1.000	rs7273815	chr20:34232415	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.84	-7.65	-0.43	3.73e-13	Blood protein levels;
CESC	cis	rs9513593	1.000	rs9585019	chr13:99850487	T/C	cg21788972	chr13:99853209	UBAC2	0.64	7.39	0.41	1.97e-12	Psoriasis;
CESC	cis	rs208515	0.556	rs12201658	chr6:66678457	T/C	cg07460842	chr6:66804631	NA	0.85	10.63	0.55	3.24e-22	Exhaled nitric oxide levels;
CESC	cis	rs7918232	0.662	rs10741125	chr10:27288925	G/A	cg14240646	chr10:27532245	ACBD5	-0.49	-5.28	-0.31	2.7e-7	Breast cancer;
CESC	cis	rs1153858	1.000	rs9788780	chr15:45685487	T/A	cg21132104	chr15:45694354	SPATA5L1	0.86	11.62	0.58	1.71e-25	Homoarginine levels;
CESC	cis	rs28830936	0.966	rs62002090	chr15:42092326	C/T	cg11010575	chr15:42129464	JMJD7-PLA2G4B;JMJD7	-0.44	-5.79	-0.34	1.99e-8	Diastolic blood pressure;
CESC	cis	rs7666738	0.747	rs2865955	chr4:99040518	A/C	cg24818145	chr4:99064322	C4orf37	0.38	5.04	0.3	8.49e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9916302	0.904	rs3964723	chr17:37403979	C/T	cg15445000	chr17:37608096	MED1	0.38	6.07	0.35	4.33e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs66686620	1.000	rs13420940	chr2:69250234	C/T	cg12800200	chr2:69260302	ANTXR1	0.41	6.34	0.36	9.66e-10	Breast cancer;
CESC	cis	rs4481887	1.000	rs4244183	chr1:248471222	G/A	cg00666640	chr1:248458726	OR2T12	0.39	6.36	0.36	8.71e-10	Common traits (Other);
CESC	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg06873352	chr17:61820015	STRADA	0.73	12.81	0.62	1.47e-29	Prudent dietary pattern;
CESC	cis	rs7592578	0.771	rs4439990	chr2:191398353	A/C	cg10560079	chr2:191398806	TMEM194B	-0.66	-5.86	-0.34	1.35e-8	Diastolic blood pressure;
CESC	cis	rs2200578	1.000	rs7566277	chr2:99916242	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.53	5.87	0.34	1.33e-8	IgG glycosylation;
CESC	cis	rs6912958	0.712	rs2246113	chr6:88410050	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.46	-5.8	-0.34	1.9e-8	Monocyte percentage of white cells;
CESC	cis	rs7666738	0.723	rs35327100	chr4:98977788	C/A	cg03676636	chr4:99064102	C4orf37	0.34	5.2	0.3	3.93e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1799949	1.000	rs33945274	chr17:41280073	G/A	cg06001716	chr17:41278141	BRCA1;NBR2	0.39	5.28	0.31	2.75e-7	Menopause (age at onset);
CESC	cis	rs9309473	0.554	rs4330127	chr2:73581320	A/T	cg20560298	chr2:73613845	ALMS1	-0.45	-6.09	-0.35	3.94e-9	Metabolite levels;
CESC	cis	rs9300255	0.602	rs2695479	chr12:123689386	T/C	cg00376283	chr12:123451042	ABCB9	0.61	6.51	0.37	3.83e-10	Neutrophil percentage of white cells;
CESC	cis	rs11098499	0.866	rs13125526	chr4:120288019	G/A	cg09307838	chr4:120376055	NA	0.87	12.16	0.6	2.41e-27	Corneal astigmatism;
CESC	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	10.42	0.54	1.51e-21	Prudent dietary pattern;
CESC	cis	rs763014	0.966	rs4984903	chr16:680695	A/G	cg00908189	chr16:619842	PIGQ	0.64	8.97	0.48	5.42e-17	Height;
CESC	cis	rs9309473	0.500	rs2421582	chr2:73898420	A/G	cg20560298	chr2:73613845	ALMS1	0.53	7.35	0.41	2.52e-12	Metabolite levels;
CESC	cis	rs6762	0.642	rs28692469	chr11:839675	T/C	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.67	-8.37	-0.46	3.38e-15	Mean platelet volume;
CESC	cis	rs3947	0.950	rs1293331	chr8:11698436	C/T	cg00262122	chr8:11665843	FDFT1	-0.5	-5.17	-0.3	4.55e-7	Blood protein levels;
CESC	cis	rs9796	0.621	rs537244	chr15:41469313	G/T	cg18705301	chr15:41695430	NDUFAF1	0.44	6.46	0.37	4.86e-10	Menopause (age at onset);
CESC	cis	rs4450798	0.744	rs9653971	chr3:13749727	T/C	cg23332027	chr3:13681764	NA	0.4	5.29	0.31	2.58e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	trans	rs11098499	0.955	rs1511019	chr4:120166007	T/G	cg25214090	chr10:38739885	LOC399744	0.63	8.36	0.46	3.49e-15	Corneal astigmatism;
CESC	cis	rs60871478	0.545	rs35400476	chr7:795686	A/G	cg27478167	chr7:817139	HEATR2	-0.52	-6.12	-0.35	3.4e-9	Cerebrospinal P-tau181p levels;
CESC	cis	rs2070997	0.607	rs4504690	chr9:133663764	A/G	cg11464064	chr9:133710261	ABL1	0.58	6.88	0.39	4.42e-11	Response to amphetamines;
CESC	cis	rs10479542	0.702	rs13183521	chr5:178975606	A/G	cg26516362	chr5:178986906	RUFY1	-0.36	-5.25	-0.31	3.11e-7	Lung cancer;
CESC	cis	rs10504229	0.679	rs72649131	chr8:58054288	G/T	cg24829409	chr8:58192753	C8orf71	-0.51	-6.38	-0.36	7.84e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs7666738	0.830	rs2865981	chr4:99031493	G/A	cg03467027	chr4:99064603	C4orf37	0.48	6.04	0.35	5.14e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs939574	0.790	rs2276635	chr2:220087441	T/C	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.89	6.86	0.39	4.73e-11	Platelet distribution width;
CESC	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg23131131	chr22:24373011	LOC391322	-0.69	-9.95	-0.52	4.91e-20	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs9858542	0.537	rs35869135	chr3:49359102	A/G	cg00383909	chr3:49044727	WDR6	0.6	5.49	0.32	9.29e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs4332037	0.851	rs10268609	chr7:1962163	A/C	cg23422044	chr7:1970798	MAD1L1	-0.52	-5.44	-0.32	1.22e-7	Bipolar disorder;
CESC	cis	rs2228479	0.850	rs11639788	chr16:89807543	G/A	cg14709524	chr16:89940631	TCF25	0.91	6.86	0.39	4.91e-11	Skin colour saturation;
CESC	cis	rs4664308	0.618	rs4665138	chr2:160890427	C/T	cg03641300	chr2:160917029	PLA2R1	-0.6	-8.8	-0.48	1.82e-16	Idiopathic membranous nephropathy;
CESC	cis	rs477895	0.838	rs1058735	chr11:64000410	C/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.88	10.19	0.53	8.59e-21	Mean platelet volume;
CESC	cis	rs9611565	0.506	rs1984839	chr22:41685937	G/C	cg17376030	chr22:41985996	PMM1	0.48	5.39	0.31	1.58e-7	Vitiligo;
CESC	cis	rs1062177	1.000	rs17741826	chr5:151149262	C/T	cg12924095	chr5:151150029	G3BP1	-0.49	-6.43	-0.37	5.82e-10	Preschool internalizing problems;
CESC	cis	rs2836974	0.568	rs419469	chr21:40537234	C/T	cg17971929	chr21:40555470	PSMG1	0.86	12.55	0.61	1.16e-28	Cognitive function;
CESC	cis	rs3026101	0.671	rs56190856	chr17:5297149	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.43	5.65	0.33	4.03e-8	Body mass index;
CESC	cis	rs116095464	0.558	rs6555058	chr5:226376	C/T	cg22496380	chr5:211416	CCDC127	0.68	7.86	0.43	9.79e-14	Breast cancer;
CESC	trans	rs11148252	0.508	rs6561671	chr13:53182314	G/A	cg18335740	chr13:41363409	SLC25A15	0.58	8.17	0.45	1.24e-14	Lewy body disease;
CESC	cis	rs9649213	0.574	rs34717219	chr7:97962271	A/C	cg24562669	chr7:97807699	LMTK2	0.49	7.16	0.4	7.94e-12	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs722599	0.683	rs2058918	chr14:75288518	A/G	cg00095594	chr1:236228625	NID1	0.4	6.04	0.35	5.2e-9	IgG glycosylation;
CESC	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg24101359	chr6:42928495	GNMT	0.57	7.98	0.44	4.31e-14	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs2456568	0.900	rs2511399	chr11:93682156	C/T	cg26875233	chr11:93583750	C11orf90	0.28	5.04	0.3	8.65e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg00962125	chr14:24616485	PSME2;RNF31	-0.47	-6.06	-0.35	4.6e-9	Ulcerative colitis;
CESC	cis	rs8060686	0.641	rs76595854	chr16:68130233	T/C	cg26727032	chr16:67993705	SLC12A4	-0.54	-6.05	-0.35	4.92e-9	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs9911578	0.835	rs9788975	chr17:56460800	G/A	cg05425664	chr17:57184151	TRIM37	0.41	5.73	0.33	2.76e-8	Intelligence (multi-trait analysis);
CESC	trans	rs561341	1.000	rs537166	chr17:30326827	C/T	cg27661571	chr11:113659931	NA	-0.7	-7.12	-0.4	1.01e-11	Hip circumference adjusted for BMI;
CESC	cis	rs7131987	0.801	rs962866	chr12:29434147	A/G	cg09582351	chr12:29534625	ERGIC2	-0.31	-5.11	-0.3	6.29e-7	QT interval;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15249164	chr21:35288186	ATP5O	0.58	7.55	0.42	7.09e-13	Gut microbiome composition (summer);
CESC	cis	rs11098499	0.954	rs10006706	chr4:120409152	A/G	cg09307838	chr4:120376055	NA	0.92	12.92	0.62	6.07e-30	Corneal astigmatism;
CESC	trans	rs10776614	0.799	rs12358315	chr10:49765392	A/G	cg19218067	chr2:181235115	NA	0.49	6.0	0.35	6.35e-9	Self-employment;
CESC	cis	rs10425465	0.710	rs62125166	chr19:33884411	T/G	cg06856480	chr19:34850338	NA	0.51	5.07	0.3	7.65e-7	Schizophrenia;
CESC	cis	rs2180341	0.781	rs877102	chr6:127587086	T/C	cg27446573	chr6:127587934	RNF146	0.84	11.93	0.59	1.5e-26	Breast cancer;
CESC	cis	rs6964587	0.967	rs55801687	chr7:91762629	C/A	cg17063962	chr7:91808500	NA	0.59	8.13	0.45	1.69e-14	Breast cancer;
CESC	cis	rs951366	0.677	rs1775140	chr1:205672107	C/A	cg11965913	chr1:205819406	PM20D1	0.81	12.49	0.61	1.81e-28	Menarche (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13797019	chr14:105303134	NA	-0.59	-6.88	-0.39	4.2e-11	Gut microbiome composition (summer);
CESC	cis	rs155076	1.000	rs58519241	chr13:21845006	C/A	cg11317459	chr13:21872234	NA	-1.01	-11.12	-0.56	7.88e-24	White matter hyperintensity burden;
CESC	cis	rs2243480	0.803	rs55700941	chr7:65389800	T/A	cg25894440	chr7:65020034	NA	-0.64	-5.29	-0.31	2.53e-7	Diabetic kidney disease;
CESC	cis	rs6582630	0.519	rs11495373	chr12:38275470	T/C	cg26384229	chr12:38710491	ALG10B	0.68	9.7	0.51	3.2e-19	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs3820928	0.775	rs10179756	chr2:227897076	A/G	cg11843606	chr2:227700838	RHBDD1	-0.49	-6.47	-0.37	4.65e-10	Pulmonary function;
CESC	cis	rs7474896	0.583	rs1735621	chr10:38167723	G/T	cg25427524	chr10:38739819	LOC399744	0.49	5.52	0.32	8.07e-8	Obesity (extreme);
CESC	cis	rs1153858	0.621	rs1719237	chr15:45579822	G/A	cg09092052	chr15:45571596	NA	-0.45	-5.11	-0.3	6.26e-7	Homoarginine levels;
CESC	cis	rs4819052	0.851	rs2838845	chr21:46670812	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.41	5.05	0.3	8.12e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs2573652	0.674	rs11630583	chr15:100543355	G/A	cg00587665	chr15:100533223	ADAMTS17	-0.41	-6.75	-0.38	9.15e-11	Height;
CESC	cis	rs9322193	0.884	rs7744105	chr6:150170444	A/G	cg09699651	chr6:150184138	LRP11	0.5	6.5	0.37	3.89e-10	Lung cancer;
CESC	cis	rs8177253	0.965	rs3811658	chr3:133476852	C/T	cg12373951	chr3:133503437	NA	0.43	6.22	0.36	1.92e-9	Iron status biomarkers;
CESC	cis	rs2952156	0.883	rs12150603	chr17:37834715	G/A	cg20243544	chr17:37824526	PNMT	0.63	8.5	0.46	1.38e-15	Asthma;
CESC	cis	rs7615952	0.576	rs4646763	chr3:125822129	G/A	cg02807482	chr3:125708958	NA	-0.39	-5.11	-0.3	6.29e-7	Blood pressure (smoking interaction);
CESC	cis	rs2235642	0.787	rs2235646	chr16:1601287	A/G	cg08296037	chr16:1584118	IFT140;TMEM204	-0.31	-5.05	-0.3	8.1e-7	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00793990	chr12:132603671	EP400NL	-0.59	-7.07	-0.4	1.41e-11	Gut microbiome composition (summer);
CESC	cis	rs7772486	0.875	rs2814871	chr6:146312274	G/T	cg23711669	chr6:146136114	FBXO30	0.78	11.23	0.57	3.44e-24	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9443189	0.855	rs1321161	chr6:76454182	G/A	cg01950844	chr6:76311363	SENP6	-0.66	-7.06	-0.4	1.48e-11	Prostate cancer;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg15606692	chr11:124669480	C11orf61	-0.45	-6.35	-0.36	9.09e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs1552244	1.000	rs12374115	chr3:10134766	A/G	cg00166722	chr3:10149974	C3orf24	-0.43	-5.74	-0.33	2.58e-8	Alzheimer's disease;
CESC	cis	rs7605827	0.930	rs7605077	chr2:15546240	C/A	cg19274914	chr2:15703543	NA	0.38	6.79	0.39	7.26e-11	Educational attainment (years of education);
CESC	cis	rs9287719	0.934	rs4371336	chr2:10755723	C/A	cg00105475	chr2:10696890	NA	0.38	5.42	0.32	1.34e-7	Prostate cancer;
CESC	cis	rs7833986	0.501	rs2976036	chr8:57031721	G/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.57	7.28	0.41	3.83e-12	Height;
CESC	trans	rs9325144	0.647	rs870431	chr12:38953073	T/C	cg23762105	chr12:34175262	ALG10	0.48	6.45	0.37	5.35e-10	Morning vs. evening chronotype;
CESC	cis	rs929354	1.000	rs1182384	chr7:157040642	A/G	cg05182265	chr7:156933206	UBE3C	0.43	5.93	0.34	9.31e-9	Body mass index;
CESC	cis	rs875971	1.000	rs7781698	chr7:65896312	A/T	cg12463550	chr7:65579703	CRCP	0.57	7.16	0.4	8.19e-12	Aortic root size;
CESC	cis	rs4662945	0.525	rs28625431	chr2:130303333	A/G	cg05962382	chr2:130345044	NA	-0.5	-7.68	-0.43	3.16e-13	Response to cytidine analogues (gemcitabine);
CESC	cis	rs1862618	0.613	rs252889	chr5:56227069	C/A	cg12311346	chr5:56204834	C5orf35	-0.65	-8.84	-0.48	1.32e-16	Initial pursuit acceleration;
CESC	cis	rs367943	0.698	rs2195373	chr5:112998798	G/C	cg12552261	chr5:112820674	MCC	0.45	5.77	0.33	2.18e-8	Type 2 diabetes;
CESC	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg07414643	chr4:187882934	NA	0.54	7.39	0.41	1.87e-12	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs11098499	1.000	rs13116504	chr4:120209412	A/C	cg25214090	chr10:38739885	LOC399744	0.67	9.13	0.49	1.78e-17	Corneal astigmatism;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg01044692	chr2:208490024	FAM119A	-0.46	-6.22	-0.36	1.98e-9	Fibrinogen levels;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg14132868	chr11:18343680	HPS5;GTF2H1	-0.47	-6.54	-0.37	3.19e-10	Fibrinogen levels;
CESC	cis	rs78889164	0.910	rs79824755	chr19:33865323	G/T	cg02272751	chr19:33882848	PEPD	-0.52	-6.8	-0.39	7.1e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg24846343	chr22:24311635	DDTL	0.65	11.27	0.57	2.55e-24	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs9300255	0.596	rs11057202	chr12:123720775	G/T	cg19016782	chr12:123741754	C12orf65	-0.36	-5.32	-0.31	2.26e-7	Neutrophil percentage of white cells;
CESC	cis	rs7809950	0.773	rs9791733	chr7:107041730	T/C	cg23024343	chr7:107201750	COG5	-0.58	-7.33	-0.41	2.82e-12	Coronary artery disease;
CESC	cis	rs10870270	0.912	rs7079991	chr10:133736130	A/G	cg08754478	chr10:133766260	PPP2R2D	-0.62	-8.06	-0.44	2.63e-14	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs10744422	1.000	rs897385	chr12:123341297	A/G	cg25930673	chr12:123319894	HIP1R	-0.85	-6.42	-0.37	6.38e-10	Schizophrenia;
CESC	cis	rs4268898	0.527	rs72789910	chr2:24388609	T/G	cg08917208	chr2:24149416	ATAD2B	0.63	5.66	0.33	3.97e-8	Asthma;
CESC	cis	rs9814567	0.806	rs9824185	chr3:134324024	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.38	-5.06	-0.3	7.86e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs3096299	0.658	rs34590044	chr16:89543157	A/C	cg02034447	chr16:89574710	SPG7	0.47	6.06	0.35	4.61e-9	Multiple myeloma (IgH translocation);
CESC	cis	rs12410462	0.901	rs16847844	chr1:227638110	A/G	cg04117972	chr1:227635322	NA	0.62	6.26	0.36	1.53e-9	Major depressive disorder;
CESC	cis	rs7917772	0.503	rs61871067	chr10:104295382	C/T	ch.10.2196322F	chr10:104248062	ACTR1A	0.48	5.2	0.3	3.93e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs10504229	1.000	rs949848	chr8:58169125	A/G	cg22535103	chr8:58192502	C8orf71	-1.05	-13.27	-0.63	3.63e-31	Developmental language disorder (linguistic errors);
CESC	cis	rs12748961	0.557	rs823127	chr1:205713139	G/A	cg07167872	chr1:205819463	PM20D1	0.39	5.24	0.31	3.23e-7	White blood cell types;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg01356910	chr16:4323571	TFAP4	-0.53	-6.68	-0.38	1.41e-10	Ulcerative colitis;
CESC	cis	rs4654899	0.965	rs6692244	chr1:21396886	C/A	cg05370193	chr1:21551575	ECE1	0.39	5.91	0.34	1.06e-8	Superior frontal gyrus grey matter volume;
CESC	cis	rs9911578	0.935	rs9893351	chr17:57023326	G/A	cg05425664	chr17:57184151	TRIM37	-0.4	-5.52	-0.32	8.26e-8	Intelligence (multi-trait analysis);
CESC	cis	rs2721195	0.874	rs2721173	chr8:145744429	C/T	cg15857475	chr8:145742913	RECQL4;LRRC14	0.74	11.18	0.57	5.03e-24	Age at first birth;
CESC	trans	rs9987353	0.840	rs329994	chr8:9123233	A/G	cg18564448	chr14:77564276	KIAA1737	-0.49	-6.4	-0.37	7.19e-10	Recombination measurement;
CESC	cis	rs7084402	0.967	rs1820542	chr10:60315643	T/C	cg07615347	chr10:60278583	BICC1	0.59	8.89	0.48	9.83e-17	Refractive error;
CESC	cis	rs17023223	0.553	rs56234947	chr1:119707744	G/A	cg05756136	chr1:119680316	WARS2	-0.48	-5.78	-0.33	2.05e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CESC	cis	rs8180040	0.966	rs11130129	chr3:47489885	G/C	cg27129171	chr3:47204927	SETD2	-0.63	-9.47	-0.5	1.6e-18	Colorectal cancer;
CESC	cis	rs1669338	0.588	rs3931974	chr3:3186894	A/G	cg16797762	chr3:3221439	CRBN	0.6	6.14	0.35	2.93e-9	White matter integrity;
CESC	cis	rs2404602	0.735	rs2280306	chr15:76652258	C/G	cg23625390	chr15:77176239	SCAPER	-0.42	-5.62	-0.33	4.79e-8	Blood metabolite levels;
CESC	cis	rs2050392	0.931	rs2265189	chr10:30689316	C/T	cg18806716	chr10:30721971	MAP3K8	0.38	5.45	0.32	1.14e-7	Inflammatory bowel disease;
CESC	cis	rs7666738	0.830	rs6848397	chr4:98946738	A/G	cg17366294	chr4:99064904	C4orf37	0.6	8.53	0.46	1.15e-15	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13775627	chr19:15483883	AKAP8	-0.57	-6.48	-0.37	4.41e-10	Gut microbiome composition (summer);
CESC	cis	rs1552244	0.572	rs68121641	chr3:10165845	T/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.8	9.17	0.49	1.33e-17	Alzheimer's disease;
CESC	cis	rs933688	0.938	rs6869048	chr5:90664322	G/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.18	16.97	0.72	3.28e-44	Smoking behavior;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg25274881	chr12:49761165	SPATS2	0.46	6.23	0.36	1.8e-9	Thyroid stimulating hormone;
CESC	cis	rs10979	0.546	rs9496686	chr6:143908735	G/C	cg25407410	chr6:143891975	LOC285740	-0.49	-6.57	-0.37	2.58e-10	Hypospadias;
CESC	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.47	-5.39	-0.31	1.56e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs769267	0.930	rs3794993	chr19:19611550	G/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.43	5.64	0.33	4.33e-8	Tonsillectomy;
CESC	cis	rs8002861	0.905	rs6561149	chr13:44456782	T/G	cg19180546	chr13:44453867	C13orf31;CCDC122	-0.47	-6.02	-0.35	5.84e-9	Leprosy;
CESC	trans	rs1541692	0.507	rs250151	chr16:79591279	A/G	cg07251046	chr12:97791023	NA	0.41	6.19	0.36	2.23e-9	Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs9287719	0.967	rs11687023	chr2:10741412	G/A	cg00105475	chr2:10696890	NA	0.39	5.64	0.33	4.44e-8	Prostate cancer;
CESC	cis	rs9486719	0.948	rs11152970	chr6:96909077	A/G	cg06623918	chr6:96969491	KIAA0776	-0.8	-8.21	-0.45	9.55e-15	Migraine;Coronary artery disease;
CESC	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.53	-5.89	-0.34	1.19e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs68170813	0.559	rs6971675	chr7:106833797	G/A	cg02696742	chr7:106810147	HBP1	-0.53	-5.06	-0.3	7.95e-7	Coronary artery disease;
CESC	cis	rs561341	0.941	rs7215147	chr17:30266711	G/A	cg13647721	chr17:30228624	UTP6	0.53	5.45	0.32	1.17e-7	Hip circumference adjusted for BMI;
CESC	cis	rs711245	0.518	rs11886145	chr2:36825716	C/G	cg15105969	chr2:36825350	FEZ2	0.54	6.67	0.38	1.53e-10	Height;
CESC	cis	rs7714584	1.000	rs4958843	chr5:150224924	T/C	cg22134413	chr5:150180641	NA	0.52	5.64	0.33	4.31e-8	Crohn's disease;
CESC	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.07	10.75	0.55	1.35e-22	Platelet count;
CESC	cis	rs9309473	0.950	rs6546853	chr2:73833739	G/A	cg20560298	chr2:73613845	ALMS1	-0.45	-6.03	-0.35	5.44e-9	Metabolite levels;
CESC	cis	rs832540	0.656	rs832573	chr5:56159578	T/C	cg22800045	chr5:56110881	MAP3K1	0.44	5.36	0.31	1.84e-7	Coronary artery disease;
CESC	cis	rs7618915	0.501	rs9917834	chr3:52634619	A/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.7	0.38	1.22e-10	Bipolar disorder;
CESC	cis	rs12586317	0.547	rs3759548	chr14:35450333	C/T	cg16230307	chr14:35515116	FAM177A1	0.99	10.62	0.55	3.38e-22	Psoriasis;
CESC	cis	rs514406	0.708	rs536621	chr1:53309097	A/G	cg24675658	chr1:53192096	ZYG11B	-0.67	-9.52	-0.5	1.17e-18	Monocyte count;
CESC	cis	rs12926788	0.689	rs7186308	chr16:24848471	A/G	cg04756594	chr16:24857601	SLC5A11	0.47	5.75	0.33	2.44e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	trans	rs2235573	0.527	rs139884	chr22:38369976	A/G	cg19894588	chr14:64061835	NA	0.63	8.28	0.45	6.09e-15	Glioblastoma;Glioma;
CESC	trans	rs1973993	0.691	rs11165623	chr1:96893000	G/A	cg10631902	chr5:14652156	NA	0.56	8.07	0.44	2.4e-14	Weight;
CESC	cis	rs4919694	1.000	rs75219158	chr10:104747594	C/T	cg04362960	chr10:104952993	NT5C2	0.72	5.63	0.33	4.66e-8	Arsenic metabolism;
CESC	cis	rs473651	0.904	rs551859	chr2:239371836	T/C	cg21699342	chr2:239360505	ASB1	0.54	9.2	0.49	1.07e-17	Multiple system atrophy;
CESC	cis	rs60154123	0.614	rs646512	chr1:210453938	C/T	cg22029157	chr1:209979665	IRF6	-0.45	-5.96	-0.34	8.05e-9	Coronary artery disease;
CESC	trans	rs877282	0.898	rs35743076	chr10:758991	C/T	cg22713356	chr15:30763199	NA	1.13	10.93	0.56	3.42e-23	Uric acid levels;
CESC	cis	rs35110281	0.811	rs7275705	chr21:45056453	G/C	cg21573476	chr21:45109991	RRP1B	-0.5	-6.84	-0.39	5.38e-11	Mean corpuscular volume;
CESC	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg04025307	chr7:1156635	C7orf50	0.4	5.66	0.33	3.97e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs9329221	0.510	rs6995837	chr8:9975675	T/C	cg06636001	chr8:8085503	FLJ10661	0.49	6.2	0.36	2.18e-9	Neuroticism;
CESC	cis	rs1707322	1.000	rs4073847	chr1:46463012	A/C	cg03146154	chr1:46216737	IPP	-0.7	-9.32	-0.5	4.71e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs941408	1.000	rs1076447	chr19:2792128	C/G	cg00079169	chr19:2811669	THOP1	0.45	6.28	0.36	1.35e-9	Total cholesterol levels;
CESC	cis	rs854765	0.618	rs8066982	chr17:17851377	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.59	8.26	0.45	7.24e-15	Total body bone mineral density;
CESC	cis	rs1008375	1.000	rs10032326	chr4:17630717	A/T	cg16339924	chr4:17578868	LAP3	0.64	8.06	0.44	2.71e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs9814567	1.000	rs1138273	chr3:134261437	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.47	-6.37	-0.36	8.41e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs59948050	1	rs59948050	chr1:15915157	T/G	cg13390004	chr1:15929781	NA	0.41	5.13	0.3	5.68e-7	Morning vs. evening chronotype;
CESC	cis	rs12497850	0.931	rs4974087	chr3:48919232	A/G	cg03060546	chr3:49711283	APEH	0.43	5.27	0.31	2.85e-7	Parkinson's disease;
CESC	cis	rs11098499	0.954	rs1480931	chr4:120395809	G/T	cg09307838	chr4:120376055	NA	0.91	12.92	0.62	6.07e-30	Corneal astigmatism;
CESC	trans	rs6142102	0.812	rs6120440	chr20:32517585	A/G	cg09222884	chr3:49764367	IP6K1	0.55	6.3	0.36	1.25e-9	Skin pigmentation;
CESC	cis	rs27434	0.607	rs34750	chr5:96142806	G/C	cg16492584	chr5:96139282	ERAP1	-0.37	-5.31	-0.31	2.34e-7	Ankylosing spondylitis;
CESC	cis	rs910316	1.000	rs12879542	chr14:75507525	C/T	cg08847533	chr14:75593920	NEK9	0.99	18.02	0.74	6.08e-48	Height;
CESC	cis	rs7429990	0.965	rs319696	chr3:47943861	T/C	cg11946769	chr3:48343235	NME6	0.46	5.62	0.33	4.91e-8	Educational attainment (years of education);
CESC	cis	rs11676348	0.818	rs6436031	chr2:218979259	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.46	-6.04	-0.35	5.28e-9	Ulcerative colitis;
CESC	cis	rs9309473	0.500	rs6546862	chr2:73860348	G/A	cg20560298	chr2:73613845	ALMS1	0.51	7.22	0.41	5.57e-12	Metabolite levels;
CESC	cis	rs644799	0.511	rs12791736	chr11:95475399	C/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.65	9.04	0.49	3.47e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs8177179	0.967	rs10935085	chr3:133459735	C/T	cg18769074	chr3:133464867	TF	0.31	6.05	0.35	4.95e-9	Iron status biomarkers (transferrin levels);
CESC	cis	rs17376456	0.825	rs17372057	chr5:93071916	C/A	cg25358565	chr5:93447407	FAM172A	1.1	10.97	0.56	2.4e-23	Diabetic retinopathy;
CESC	cis	rs34779708	0.733	rs7914560	chr10:35548099	G/A	cg03585969	chr10:35415529	CREM	0.55	6.37	0.36	8.28e-10	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs752010	0.871	rs10789405	chr1:42101962	C/T	cg06885757	chr1:42089581	HIVEP3	0.49	7.94	0.44	5.63e-14	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg10150615	chr22:24372951	LOC391322	0.48	6.22	0.36	1.88e-9	Liver enzyme levels (gamma-glutamyl transferase);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg14118453	chr2:28613762	NA	0.44	6.05	0.35	4.95e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs9325144	0.647	rs12227834	chr12:38849246	G/C	cg26384229	chr12:38710491	ALG10B	-0.56	-7.89	-0.44	8.02e-14	Morning vs. evening chronotype;
CESC	trans	rs61931739	0.853	rs11053002	chr12:34083499	T/C	cg26384229	chr12:38710491	ALG10B	-0.45	-6.04	-0.35	5.32e-9	Morning vs. evening chronotype;
CESC	cis	rs2576037	0.796	rs2576043	chr18:44573476	C/G	cg19077165	chr18:44547161	KATNAL2	0.53	7.47	0.42	1.19e-12	Personality dimensions;
CESC	cis	rs1153858	1.000	rs4774579	chr15:45651803	G/A	cg14582100	chr15:45693742	SPATA5L1	0.42	5.97	0.34	7.62e-9	Homoarginine levels;
CESC	cis	rs6502050	0.769	rs9898542	chr17:80119682	C/T	cg11859384	chr17:80120422	CCDC57	-0.39	-5.34	-0.31	1.96e-7	Life satisfaction;
CESC	cis	rs2380220	0.576	rs7751219	chr6:96018915	G/A	cg04719120	chr6:96025338	MANEA	0.64	6.88	0.39	4.28e-11	Behavioural disinhibition (generation interaction);
CESC	cis	rs6088590	0.550	rs12624640	chr20:32952125	G/A	cg24642439	chr20:33292090	TP53INP2	0.64	8.14	0.45	1.6e-14	Coronary artery disease;
CESC	cis	rs10242455	0.702	rs917152	chr7:99004497	T/C	cg18809830	chr7:99032528	PTCD1	-0.91	-6.35	-0.36	9.52e-10	Blood metabolite levels;
CESC	cis	rs7188697	0.922	rs6499962	chr16:58610750	A/C	cg02549819	chr16:58548995	SETD6	0.44	5.43	0.32	1.26e-7	QT interval;
CESC	cis	rs8114671	0.527	rs6060068	chr20:33415820	T/A	cg06115741	chr20:33292138	TP53INP2	0.45	5.31	0.31	2.37e-7	Height;
CESC	cis	rs4474465	0.920	rs7396701	chr11:78202699	A/C	cg27205649	chr11:78285834	NARS2	0.44	5.62	0.33	4.83e-8	Alzheimer's disease (survival time);
CESC	cis	rs854765	0.583	rs9908832	chr17:17871068	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.65	9.38	0.5	3e-18	Total body bone mineral density;
CESC	cis	rs3105593	0.555	rs3131568	chr15:50757721	C/T	cg08437265	chr15:50716283	USP8	0.48	6.43	0.37	5.82e-10	QT interval;
CESC	cis	rs9393777	0.513	rs7754159	chr6:26620312	G/A	cg14345882	chr6:26364793	BTN3A2	0.42	5.3	0.31	2.41e-7	Intelligence (multi-trait analysis);
CESC	cis	rs1153858	1.000	rs67744121	chr15:45677237	C/G	cg21132104	chr15:45694354	SPATA5L1	0.86	11.62	0.58	1.67e-25	Homoarginine levels;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg13108601	chr6:41748242	FRS3;PRICKLE4	0.51	6.78	0.38	7.73e-11	Systemic lupus erythematosus;
CESC	cis	rs4481887	0.927	rs4292985	chr1:248473692	T/A	cg00666640	chr1:248458726	OR2T12	0.35	5.93	0.34	9.43e-9	Common traits (Other);
CESC	cis	rs3741404	0.609	rs592271	chr11:63872029	G/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.71	9.9	0.52	7.1e-20	Platelet count;
CESC	cis	rs7100689	0.753	rs2185426	chr10:82120887	G/A	cg00277334	chr10:82204260	NA	-0.59	-7.35	-0.41	2.39e-12	Post bronchodilator FEV1;
CESC	cis	rs13191362	0.935	rs73008456	chr6:163013697	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.5	5.17	0.3	4.63e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs9322193	0.736	rs3828701	chr6:150112199	C/T	cg13206674	chr6:150067644	NUP43	0.43	6.04	0.35	5.17e-9	Lung cancer;
CESC	cis	rs9457247	1.000	rs415890	chr6:167406633	C/G	cg25258033	chr6:167368657	RNASET2	-0.39	-5.9	-0.34	1.09e-8	Crohn's disease;
CESC	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg14926445	chr8:58193284	C8orf71	-0.54	-5.19	-0.3	4.14e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs7179456	0.545	rs2250583	chr15:59050382	C/T	cg05156742	chr15:59063176	FAM63B	-0.64	-8.46	-0.46	1.79e-15	Asperger disorder;
CESC	cis	rs7959452	0.562	rs11177630	chr12:69767963	G/C	cg14784868	chr12:69753453	YEATS4	0.85	13.23	0.63	5.24e-31	Blood protein levels;
CESC	cis	rs2836974	0.568	rs414850	chr21:40543337	A/C	cg17971929	chr21:40555470	PSMG1	0.86	12.77	0.62	1.93e-29	Cognitive function;
CESC	cis	rs597539	0.727	rs632984	chr11:68620271	C/T	cg04772025	chr11:68637568	NA	0.51	5.75	0.33	2.43e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs910316	0.737	rs2098251	chr14:75492696	G/A	cg11812906	chr14:75593930	NEK9	0.83	13.51	0.64	5.28e-32	Height;
CESC	cis	rs7666738	0.830	rs11935588	chr4:98979862	A/G	cg17366294	chr4:99064904	C4orf37	-0.57	-8.31	-0.45	5.08e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6089829	0.962	rs4809455	chr20:61660781	G/C	cg16240275	chr20:61666158	NCRNA00029	0.5	8.95	0.48	6.42e-17	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs3741404	0.895	rs1860368	chr11:63994692	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.89	-13.73	-0.64	9.32e-33	Platelet count;
CESC	cis	rs736408	0.634	rs11717836	chr3:52807736	A/G	cg17372223	chr3:52568218	NT5DC2	0.43	6.16	0.35	2.7e-9	Bipolar disorder;
CESC	cis	rs13191362	0.935	rs34063386	chr6:163041271	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.54	5.98	0.34	7.12e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs7727544	0.735	rs272875	chr5:131674888	T/C	cg24060327	chr5:131705240	SLC22A5	-0.66	-8.88	-0.48	1.04e-16	Blood metabolite levels;
CESC	cis	rs2576037	0.583	rs504668	chr18:44410749	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.35	5.69	0.33	3.38e-8	Personality dimensions;
CESC	cis	rs7618915	0.532	rs13060675	chr3:52674300	T/G	cg05564831	chr3:52568323	NT5DC2	0.45	6.84	0.39	5.32e-11	Bipolar disorder;
CESC	cis	rs26868	0.690	rs26835	chr16:2237549	C/T	cg02248941	chr16:2239361	CASKIN1	0.55	10.21	0.53	7.4e-21	Height;
CESC	cis	rs4862750	0.872	rs13143414	chr4:187878213	G/A	cg06074448	chr4:187884817	NA	-0.46	-7.12	-0.4	9.97e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7618915	0.501	rs7624716	chr3:52751534	T/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	5.81	0.34	1.79e-8	Bipolar disorder;
CESC	cis	rs9815354	0.680	rs73073280	chr3:42025772	T/C	cg03022575	chr3:42003672	ULK4	0.75	6.64	0.38	1.72e-10	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs875971	1.000	rs7789554	chr7:65946038	A/G	cg12463550	chr7:65579703	CRCP	0.56	7.09	0.4	1.2e-11	Aortic root size;
CESC	cis	rs9457247	0.967	rs2149083	chr6:167370971	G/C	cg23791538	chr6:167370224	RNASET2	0.61	8.62	0.47	6.14e-16	Crohn's disease;
CESC	cis	rs7980687	0.657	rs2851447	chr12:123665113	G/C	cg00376283	chr12:123451042	ABCB9	0.67	9.28	0.5	6.47e-18	Height;Educational attainment;Head circumference (infant);
CESC	cis	rs4711336	0.967	rs4711338	chr6:33660188	T/C	cg14003231	chr6:33640908	ITPR3	0.32	5.42	0.32	1.34e-7	Height;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg00549575	chr11:8008752	EIF3F	0.51	6.95	0.39	2.77e-11	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs4253772	0.550	rs6008613	chr22:46707924	G/T	cg10541313	chr22:46663664	TTC38	0.59	5.05	0.3	8.15e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs3820928	0.874	rs2272198	chr2:227893017	A/G	cg11843606	chr2:227700838	RHBDD1	0.44	5.41	0.32	1.44e-7	Pulmonary function;
CESC	cis	rs9905704	0.846	rs304262	chr17:56814456	A/G	cg12560992	chr17:57184187	TRIM37	0.62	7.77	0.43	1.77e-13	Testicular germ cell tumor;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg00602891	chr17:80408864	C17orf62	-0.49	-6.52	-0.37	3.44e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs9649213	0.555	rs6968193	chr7:97915902	C/T	cg08684580	chr7:98029266	BAIAP2L1	-0.33	-5.27	-0.31	2.79e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7923452	0.938	rs34930615	chr10:30761051	G/A	cg25182066	chr10:30743637	MAP3K8	0.49	5.44	0.32	1.19e-7	Itch intensity from mosquito bite;
CESC	cis	rs7618915	0.501	rs3733039	chr3:52719088	C/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	5.93	0.34	9.38e-9	Bipolar disorder;
CESC	cis	rs7542091	0.813	rs2049999	chr1:210031331	A/G	cg09509183	chr1:209979624	IRF6	0.36	5.03	0.3	8.96e-7	Monobrow;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg24103018	chr19:17420930	DDA1	-0.46	-6.02	-0.35	5.74e-9	Ulcerative colitis;
CESC	cis	rs3096299	0.606	rs4785674	chr16:89536613	A/G	cg16743903	chr16:89593216	SPG7	-0.47	-5.78	-0.33	2.06e-8	Multiple myeloma (IgH translocation);
CESC	cis	rs854765	0.547	rs4368210	chr17:17896090	A/G	cg16928487	chr17:17741425	SREBF1	0.53	8.96	0.48	6.08e-17	Total body bone mineral density;
CESC	cis	rs9479482	0.648	rs912558	chr6:150385730	G/T	cg03788504	chr6:150331562	NA	0.3	6.03	0.35	5.42e-9	Alopecia areata;
CESC	cis	rs9287719	0.774	rs4997811	chr2:10755538	T/C	cg00105475	chr2:10696890	NA	0.37	5.2	0.3	3.96e-7	Prostate cancer;
CESC	cis	rs6860806	0.661	rs2171247	chr5:131580234	G/T	cg24060327	chr5:131705240	SLC22A5	-0.41	-5.15	-0.3	5.16e-7	Breast cancer;
CESC	cis	rs7618501	0.521	rs55692411	chr3:49911155	G/A	cg24110177	chr3:50126178	RBM5	-0.54	-7.23	-0.41	5.23e-12	Intelligence (multi-trait analysis);
CESC	cis	rs2243480	1.000	rs466983	chr7:65520496	T/G	cg18252515	chr7:66147081	NA	-1.3	-13.17	-0.63	8.35e-31	Diabetic kidney disease;
CESC	cis	rs12476592	0.602	rs262538	chr2:63908025	A/T	cg17519650	chr2:63277830	OTX1	0.49	5.37	0.31	1.68e-7	Childhood ear infection;
CESC	cis	rs3793683	0.597	rs12767469	chr10:134587261	C/G	cg27286337	chr10:134555280	INPP5A	0.7	8.12	0.45	1.8e-14	Migraine;
CESC	cis	rs13064411	0.696	rs6798938	chr3:113218206	C/T	cg18753928	chr3:113234510	CCDC52	-0.53	-6.33	-0.36	1.05e-9	Response to simvastatin treatment (PCSK9 protein level change);
CESC	cis	rs10911251	0.546	rs944971	chr1:183112505	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.84	13.22	0.63	5.53e-31	Colorectal cancer;
CESC	cis	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg04267008	chr7:1944627	MAD1L1	-0.53	-6.57	-0.37	2.69e-10	Bipolar disorder and schizophrenia;
CESC	trans	rs12599106	0.707	rs2163977	chr16:34916134	A/G	cg07332563	chr6:291687	DUSP22	-0.63	-7.96	-0.44	4.97e-14	Menopause (age at onset);
CESC	cis	rs7666738	0.830	rs7678567	chr4:99057346	A/G	cg03467027	chr4:99064603	C4orf37	0.48	5.96	0.34	8.08e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1034591	0.715	rs12705991	chr7:114417612	A/C	cg05338976	chr7:114561850	MDFIC	-0.35	-5.04	-0.3	8.77e-7	Midgestational circulating levels of PBDEs (fetal genetic effect);
CESC	cis	rs11608355	0.597	rs10850070	chr12:109793882	A/G	cg19025524	chr12:109796872	NA	-0.54	-7.99	-0.44	4.03e-14	Neuroticism;
CESC	trans	rs11191205	0.644	rs10883665	chr10:103374233	G/A	cg12418535	chr2:119607192	EN1	-0.4	-6.0	-0.35	6.56e-9	Intelligence (multi-trait analysis);
CESC	cis	rs258892	0.895	rs10059897	chr5:72080538	C/T	cg21869765	chr5:72125136	TNPO1	-0.44	-5.52	-0.32	8.21e-8	Small cell lung carcinoma;
CESC	cis	rs1538970	0.962	rs9429072	chr1:45810091	C/T	cg24296786	chr1:45957014	TESK2	0.42	5.05	0.3	8.29e-7	Platelet count;
CESC	cis	rs875971	0.862	rs778724	chr7:65829291	T/C	cg11764359	chr7:65958608	NA	0.81	11.94	0.59	1.36e-26	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19476186	chr20:3869959	PANK2	0.55	6.24	0.36	1.69e-9	Gut microbiome composition (summer);
CESC	cis	rs6815814	0.950	rs113465719	chr4:38808045	A/T	cg02016764	chr4:38805732	TLR1	-0.63	-7.26	-0.41	4.22e-12	Breast cancer;
CESC	cis	rs7666738	0.830	rs11097605	chr4:98985167	T/C	cg03676636	chr4:99064102	C4orf37	0.33	5.13	0.3	5.6e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs12900413	0.687	rs28475471	chr15:90311749	C/T	cg24249390	chr15:90295951	MESP1	-0.41	-5.63	-0.33	4.51e-8	Coronary artery aneurysm in Kawasaki disease;
CESC	cis	rs4141404	0.737	rs5998067	chr22:32043630	C/T	cg00478049	chr22:31556069	RNF185	0.49	6.0	0.35	6.54e-9	Paclitaxel-induced neuropathy;
CESC	cis	rs56046484	0.956	rs2174218	chr15:85624656	C/G	cg08123816	chr15:85640762	PDE8A	0.48	6.05	0.35	4.86e-9	Testicular germ cell tumor;
CESC	cis	rs7216064	1.000	rs7221651	chr17:65832390	A/G	cg07042672	chr17:66097459	LOC651250	0.57	6.64	0.38	1.74e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	trans	rs4245128	0.862	rs1892978	chr11:112796011	G/T	cg10894232	chr8:11772343	NA	0.37	6.06	0.35	4.59e-9	Life satisfaction;
CESC	cis	rs9902453	0.904	rs7225686	chr17:28356744	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.67	-8.69	-0.47	3.79e-16	Coffee consumption (cups per day);
CESC	cis	rs12893668	0.673	rs2296482	chr14:104029819	T/G	cg24130564	chr14:104152367	KLC1	-0.48	-5.89	-0.34	1.19e-8	Reticulocyte count;
CESC	cis	rs6032067	0.929	rs62208428	chr20:43827578	A/C	cg10761708	chr20:43804764	PI3	0.53	6.36	0.36	8.83e-10	Blood protein levels;
CESC	cis	rs6815814	0.851	rs11466617	chr4:38780471	T/C	cg02016764	chr4:38805732	TLR1	-0.68	-8.15	-0.45	1.45e-14	Breast cancer;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg07322296	chr22:50661779	TUBGCP6	-0.44	-6.01	-0.35	6.15e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs2836974	0.568	rs2183573	chr21:40574305	A/G	cg17971929	chr21:40555470	PSMG1	-0.87	-12.9	-0.62	7.25e-30	Cognitive function;
CESC	cis	rs2760061	0.626	rs2527615	chr1:228119283	A/G	cg01973587	chr1:228161476	NA	0.37	5.66	0.33	3.89e-8	Diastolic blood pressure;
CESC	cis	rs798554	1.000	rs798548	chr7:2760935	A/G	cg19346786	chr7:2764209	NA	-0.47	-7.18	-0.4	7.19e-12	Height;
CESC	cis	rs10887741	0.646	rs1358863	chr10:89426508	T/G	cg13926569	chr10:89418898	PAPSS2	0.48	7.42	0.41	1.55e-12	Exercise (leisure time);
CESC	cis	rs3092073	0.624	rs11906879	chr20:44591324	C/T	cg00125455	chr20:44574271	PCIF1	-0.39	-6.3	-0.36	1.25e-9	Intelligence (multi-trait analysis);
CESC	cis	rs9611565	0.512	rs9607842	chr22:42192722	G/A	cg03806693	chr22:41940476	POLR3H	-1.16	-13.77	-0.65	6.87e-33	Vitiligo;
CESC	cis	rs2635047	0.615	rs9304343	chr18:44720664	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.42	-5.21	-0.3	3.89e-7	Educational attainment;
CESC	cis	rs172166	0.694	rs203876	chr6:28046673	T/C	cg23281280	chr6:28129359	ZNF389	0.43	6.41	0.37	6.46e-10	Cardiac Troponin-T levels;
CESC	cis	rs10540	1.000	rs71487292	chr11:486076	G/A	cg03576123	chr11:487126	PTDSS2	-1.12	-10.56	-0.54	5.45e-22	Body mass index;
CESC	cis	rs7772486	0.686	rs9390348	chr6:146044748	C/T	cg23711669	chr6:146136114	FBXO30	-0.87	-12.9	-0.62	7e-30	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg12476490	chr10:64576179	EGR2	-0.41	-6.29	-0.36	1.31e-9	Vertical cup-disc ratio;
CESC	cis	rs2073300	0.609	rs79250740	chr20:23417165	G/A	cg16736954	chr20:23401023	NAPB	0.78	5.78	0.33	2.05e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs11577318	0.853	rs3795684	chr1:26632781	C/T	cg18121669	chr1:26560928	CCDC21	0.43	5.1	0.3	6.41e-7	Granulocyte percentage of myeloid white cells;
CESC	cis	rs12188164	0.965	rs56146525	chr5:442571	A/C	cg26850624	chr5:429559	AHRR	-0.5	-6.69	-0.38	1.35e-10	Cystic fibrosis severity;
CESC	cis	rs1552244	0.810	rs7612908	chr3:10089148	A/G	cg08888203	chr3:10149979	C3orf24	0.51	6.39	0.37	7.29e-10	Alzheimer's disease;
CESC	cis	rs11764590	0.694	rs11773643	chr7:2104063	A/G	cg21782813	chr7:2030301	MAD1L1	-0.41	-5.3	-0.31	2.42e-7	Neuroticism;
CESC	cis	rs1707322	0.752	rs6662164	chr1:46146230	T/A	cg05343316	chr1:45956843	TESK2	0.48	5.97	0.34	7.4e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs4144743	0.938	rs55677902	chr17:45322572	G/T	cg18085866	chr17:45331354	ITGB3	-0.64	-7.01	-0.4	1.92e-11	Body mass index;
CESC	cis	rs4604732	0.631	rs12036460	chr1:247626928	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.57	7.17	0.4	7.39e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs4665809	1.000	rs4665819	chr2:26309073	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.7	-8.01	-0.44	3.69e-14	Gut microbiome composition (summer);
CESC	cis	rs60154123	0.667	rs650854	chr1:210465315	G/C	cg23283495	chr1:209979779	IRF6	0.42	5.46	0.32	1.08e-7	Coronary artery disease;
CESC	cis	rs4727963	0.846	rs2402626	chr7:122712358	C/T	cg03640110	chr7:122635026	TAS2R16	0.38	5.87	0.34	1.28e-8	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
CESC	cis	rs637571	0.522	rs491973	chr11:65727301	A/G	cg02202077	chr11:65769826	EIF1AD;BANF1	0.48	6.51	0.37	3.66e-10	Eosinophil percentage of white cells;
CESC	cis	rs4423214	0.650	rs2186777	chr11:71219803	C/A	cg05163923	chr11:71159392	DHCR7	0.73	9.19	0.49	1.19e-17	Vitamin D levels;
CESC	cis	rs644799	0.965	rs502521	chr11:95533557	T/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	13.69	0.64	1.25e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs4665809	0.877	rs35224700	chr2:26298037	T/C	cg26314531	chr2:26401878	FAM59B	0.7	7.47	0.42	1.17e-12	Gut microbiome composition (summer);
CESC	cis	rs9549367	0.789	rs3764125	chr13:113897648	A/G	cg18105134	chr13:113819100	PROZ	0.77	9.03	0.49	3.55e-17	Platelet distribution width;
CESC	cis	rs6831352	0.840	rs35073321	chr4:100053276	G/A	cg12011299	chr4:100065546	ADH4	-0.6	-6.62	-0.38	2.04e-10	Alcohol dependence;
CESC	cis	rs11645898	0.748	rs11647889	chr16:72052034	C/G	cg14768367	chr16:72042858	DHODH	-0.82	-6.66	-0.38	1.6e-10	Blood protein levels;
CESC	cis	rs9311474	0.629	rs13081028	chr3:52555316	G/A	cg07507251	chr3:52567010	NT5DC2	0.48	9.22	0.49	9.4e-18	Electroencephalogram traits;
CESC	cis	rs11657217	1.000	rs8081537	chr17:77708264	A/G	cg06901238	chr17:77706717	ENPP7	0.41	5.47	0.32	1.03e-7	Diastolic blood pressure response to hydrochlorothiazide in hypertension;
CESC	cis	rs7949030	0.588	rs2509961	chr11:62310909	T/C	cg23462726	chr11:62437636	C11orf83;C11orf48	-0.4	-5.4	-0.31	1.52e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs317689	0.658	rs479971	chr12:69672471	A/G	cg14784868	chr12:69753453	YEATS4	0.48	5.03	0.3	8.88e-7	Response to diuretic therapy;
CESC	cis	rs801193	1.000	rs2707856	chr7:66211010	A/T	cg10691866	chr7:65817282	TPST1	-0.33	-5.23	-0.31	3.46e-7	Aortic root size;
CESC	cis	rs9916302	0.851	rs11868029	chr17:37650304	A/G	cg00129232	chr17:37814104	STARD3	-0.51	-6.41	-0.37	6.79e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs11997175	0.766	rs60855034	chr8:33684732	G/A	ch.8.33884649F	chr8:33765107	NA	0.45	5.71	0.33	2.95e-8	Body mass index;
CESC	cis	rs798554	0.959	rs798556	chr7:2759002	C/A	cg19346786	chr7:2764209	NA	-0.46	-6.64	-0.38	1.78e-10	Height;
CESC	cis	rs7818688	1.000	rs11786380	chr8:96028136	A/G	cg16049864	chr8:95962084	TP53INP1	0.6	5.77	0.33	2.25e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg18635645	chr1:85667791	SYDE2	0.5	6.85	0.39	5.23e-11	Systemic lupus erythematosus;
CESC	cis	rs7666738	0.830	rs10017201	chr4:98983561	G/A	cg17366294	chr4:99064904	C4orf37	0.59	8.57	0.47	8.46e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2573652	1.000	rs1469829	chr15:100517332	A/G	cg00587665	chr15:100533223	ADAMTS17	-0.37	-5.81	-0.34	1.81e-8	Height;
CESC	cis	rs10129255	0.500	rs10143242	chr14:107137831	C/T	cg07958169	chr14:107095056	NA	-0.53	-8.53	-0.46	1.11e-15	Kawasaki disease;
CESC	cis	rs8180040	0.726	rs2061197	chr3:47001350	C/T	cg27129171	chr3:47204927	SETD2	-0.63	-8.62	-0.47	6.27e-16	Colorectal cancer;
CESC	cis	rs2708240	0.666	rs1861010	chr7:147601401	G/C	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.35	-5.77	-0.33	2.18e-8	QT interval (drug interaction);
CESC	cis	rs2749592	0.513	rs1208708	chr10:38085576	A/G	cg00409905	chr10:38381863	ZNF37A	-0.43	-5.91	-0.34	1.03e-8	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs5747327	0.874	rs713701	chr22:18131546	A/G	cg19898043	chr22:18121309	BCL2L13	-0.4	-5.04	-0.3	8.47e-7	Myeloid white cell count;Granulocyte count;
CESC	cis	rs34779708	0.966	rs34630580	chr10:35449228	A/G	cg03585969	chr10:35415529	CREM	0.76	10.16	0.53	1.1e-20	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs951366	1.000	rs4951261	chr1:205717823	A/C	cg14893161	chr1:205819251	PM20D1	-0.48	-6.6	-0.38	2.28e-10	Menarche (age at onset);
CESC	cis	rs734999	0.545	rs7368105	chr1:2556548	C/T	cg18854424	chr1:2615690	NA	0.31	5.91	0.34	1.08e-8	Ulcerative colitis;
CESC	cis	rs7605827	0.897	rs2241238	chr2:15656560	T/C	cg19274914	chr2:15703543	NA	0.37	6.65	0.38	1.65e-10	Educational attainment (years of education);
CESC	cis	rs7666738	0.830	rs6840766	chr4:99016260	C/G	cg05340658	chr4:99064831	C4orf37	0.8	12.51	0.61	1.52e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9926296	0.533	rs12102297	chr16:89812762	C/A	cg27121462	chr16:89883253	FANCA	0.82	12.28	0.6	9.91e-28	Vitiligo;
CESC	cis	rs7666738	0.830	rs10028505	chr4:98962310	C/A	cg05340658	chr4:99064831	C4orf37	0.8	12.39	0.61	3.96e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs524281	0.861	rs7929909	chr11:65951698	C/T	cg14036092	chr11:66035641	RAB1B	-0.56	-5.57	-0.32	6.24e-8	Electroencephalogram traits;
CESC	cis	rs12136530	0.593	rs12121242	chr1:19740609	G/C	cg01832549	chr1:19774989	CAPZB	-0.43	-6.13	-0.35	3.09e-9	Lead levels in blood;
CESC	cis	rs8062405	0.755	rs4787456	chr16:28559573	C/T	cg01378222	chr16:28622494	SULT1A1	0.3	5.14	0.3	5.27e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg10611753	chr15:55489541	RSL24D1	-0.5	-7.83	-0.43	1.15e-13	Gambling;
CESC	cis	rs2836950	0.565	rs4816617	chr21:40540690	T/C	cg11644478	chr21:40555479	PSMG1	-0.52	-7.16	-0.4	7.99e-12	Menarche (age at onset);
CESC	cis	rs11809207	0.501	rs2232654	chr1:26496870	A/G	cg00147160	chr1:26503991	CNKSR1	0.28	5.35	0.31	1.88e-7	Height;
CESC	cis	rs7772486	0.686	rs6570705	chr6:145961201	C/T	cg05347473	chr6:146136440	FBXO30	0.53	6.88	0.39	4.42e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs77861329	0.669	rs2878438	chr3:52103045	A/G	cg08692210	chr3:52188851	WDR51A	0.49	5.85	0.34	1.47e-8	Macrophage inflammatory protein 1b levels;
CESC	cis	rs1707322	1.000	rs1612419	chr1:46546945	T/C	cg05343316	chr1:45956843	TESK2	-0.47	-5.49	-0.32	9.29e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg11367841	chr11:47270567	NR1H3;ACP2	-0.43	-6.05	-0.35	4.99e-9	Gambling;
CESC	cis	rs9291683	0.527	rs73212848	chr4:10093299	T/C	cg00071950	chr4:10020882	SLC2A9	-0.67	-11.05	-0.56	1.36e-23	Bone mineral density;
CESC	cis	rs7274811	0.652	rs291686	chr20:32010851	T/C	cg21523528	chr20:32077966	CBFA2T2	-0.44	-5.15	-0.3	5.02e-7	Height;
CESC	cis	rs9911578	1.000	rs6503887	chr17:56993320	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.41	5.41	0.32	1.38e-7	Intelligence (multi-trait analysis);
CESC	cis	rs7635838	0.892	rs7644968	chr3:11489493	C/T	cg00170343	chr3:11313890	ATG7	0.42	5.68	0.33	3.57e-8	HDL cholesterol;
CESC	trans	rs523522	0.962	rs2235218	chr12:120888619	A/C	cg02849695	chr1:159869960	CCDC19	0.34	6.05	0.35	5.03e-9	High light scatter reticulocyte count;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg23041619	chr2:27435357	SLC5A6;C2orf28	-0.44	-6.89	-0.39	4.06e-11	Gambling;
CESC	cis	rs1348850	0.540	rs6737342	chr2:178419117	G/A	cg23306229	chr2:178417860	TTC30B	0.78	7.56	0.42	6.56e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs11168351	0.833	rs6580652	chr12:48447105	C/A	cg04545296	chr12:48745243	ZNF641	-0.36	-6.23	-0.36	1.86e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs7044106	0.762	rs4142158	chr9:123410819	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.76	10.99	0.56	2.15e-23	Hip circumference adjusted for BMI;
CESC	cis	rs736408	0.609	rs2336545	chr3:52787603	C/T	cg18404041	chr3:52824283	ITIH1	0.41	6.88	0.39	4.41e-11	Bipolar disorder;
CESC	cis	rs11690935	1.000	rs6721680	chr2:172543913	G/T	cg13550731	chr2:172543902	DYNC1I2	1.0	16.61	0.71	5.86e-43	Schizophrenia;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg24087447	chr12:133202758	POLE	0.49	6.7	0.38	1.22e-10	Fibrinogen levels;
CESC	cis	rs1448094	0.512	rs7970081	chr12:86243392	G/T	cg00310523	chr12:86230176	RASSF9	0.35	5.44	0.32	1.21e-7	Major depressive disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16512924	chr15:28394682	HERC2	-0.62	-6.78	-0.38	7.63e-11	Gut microbiome composition (summer);
CESC	trans	rs72996113	0.702	rs11224354	chr11:100519749	G/A	cg20136100	chr11:63974860	FERMT3	-0.52	-6.58	-0.37	2.56e-10	Reticulocyte fraction of red cells;Reticulocyte count;
CESC	cis	rs1797885	0.564	rs959088	chr3:12582138	G/C	cg26432171	chr3:12704882	RAF1	-0.53	-6.93	-0.39	3.27e-11	Immature fraction of reticulocytes;
CESC	cis	rs36051895	0.589	rs12682672	chr9:5187941	T/C	cg02405213	chr9:5042618	JAK2	-0.54	-6.6	-0.38	2.25e-10	Pediatric autoimmune diseases;
CESC	cis	rs7666738	0.830	rs4472144	chr4:98956494	G/A	cg03467027	chr4:99064603	C4orf37	0.44	5.51	0.32	8.58e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7851660	0.874	rs1955144	chr9:100634589	A/G	cg13688889	chr9:100608707	NA	-0.6	-8.55	-0.47	9.84e-16	Strep throat;
CESC	cis	rs763014	0.931	rs3752567	chr16:628130	A/G	cg07256732	chr16:621771	PIGQ	-0.3	-5.13	-0.3	5.48e-7	Height;
CESC	cis	rs12422267	0.536	rs11831679	chr12:132609960	C/T	cg09764611	chr12:132620959	NA	-0.52	-6.7	-0.38	1.28e-10	Plasma amyloid beta peptide concentrations (ABx-40);
CESC	cis	rs7552404	1.000	rs6593585	chr1:76140273	G/A	cg22875332	chr1:76189707	ACADM	0.66	7.84	0.43	1.1e-13	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs17376456	0.877	rs35075119	chr5:93385457	T/C	cg25358565	chr5:93447407	FAM172A	1.11	11.19	0.57	4.56e-24	Diabetic retinopathy;
CESC	cis	rs7084402	0.935	rs10763556	chr10:60341398	A/G	cg07615347	chr10:60278583	BICC1	-0.59	-9.17	-0.49	1.39e-17	Refractive error;
CESC	cis	rs11828289	0.660	rs17306398	chr11:23192235	G/T	cg20040320	chr11:23191996	NA	0.62	5.56	0.32	6.61e-8	Cancer;
CESC	cis	rs2243480	1.000	rs6958289	chr7:65657111	T/G	cg12463550	chr7:65579703	CRCP	-0.73	-5.66	-0.33	4.03e-8	Diabetic kidney disease;
CESC	cis	rs9611565	0.559	rs13056262	chr22:42081921	A/G	cg06634786	chr22:41940651	POLR3H	0.62	6.25	0.36	1.67e-9	Vitiligo;
CESC	cis	rs4819052	0.851	rs2838857	chr21:46681000	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.76	10.46	0.54	1.2e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg06203126	chr5:43313815	HMGCS1	-0.41	-6.2	-0.36	2.17e-9	Vertical cup-disc ratio;
CESC	cis	rs2073300	1.000	rs6132626	chr20:23444672	T/C	cg12062639	chr20:23401060	NAPB	0.91	6.41	0.37	6.71e-10	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs66887589	0.807	rs9799664	chr4:120326678	C/T	cg09307838	chr4:120376055	NA	0.52	7.01	0.4	1.95e-11	Diastolic blood pressure;
CESC	cis	rs2742234	0.541	rs10899782	chr10:43736361	A/T	cg15436174	chr10:43711423	RASGEF1A	0.45	5.13	0.3	5.72e-7	Hirschsprung disease;
CESC	cis	rs12477438	0.520	rs11677247	chr2:99756358	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	15.46	0.69	7.45e-39	Chronic sinus infection;
CESC	cis	rs12410462	0.581	rs7541809	chr1:227547299	G/A	cg10327440	chr1:227177885	CDC42BPA	-0.67	-5.69	-0.33	3.43e-8	Major depressive disorder;
CESC	cis	rs6540559	1.000	rs6659367	chr1:209982408	G/T	cg22442454	chr1:209979470	IRF6	0.5	6.22	0.36	1.98e-9	Cleft lip with or without cleft palate;
CESC	cis	rs9640161	0.750	rs1983440	chr7:150023941	G/C	cg21361702	chr7:150065534	REPIN1	0.51	5.86	0.34	1.37e-8	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs9921222	0.502	rs28461430	chr16:369562	G/A	cg00101154	chr16:420108	MRPL28	-0.44	-5.13	-0.3	5.68e-7	Bone mineral density (spine);Bone mineral density;
CESC	cis	rs5769765	1.000	rs8138941	chr22:50290678	G/A	cg26441486	chr22:50317300	CRELD2	0.38	5.32	0.31	2.17e-7	Schizophrenia;
CESC	cis	rs4481887	0.927	rs4381224	chr1:248456826	A/T	cg00666640	chr1:248458726	OR2T12	0.41	6.84	0.39	5.57e-11	Common traits (Other);
CESC	cis	rs4594175	0.926	rs11157800	chr14:51615502	A/T	cg23942311	chr14:51606299	NA	0.37	5.68	0.33	3.55e-8	Cancer;
CESC	cis	rs7223966	1.000	rs6504173	chr17:61735056	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.45	-5.56	-0.32	6.64e-8	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs11676348	0.811	rs13027120	chr2:219020914	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.42	5.4	0.31	1.47e-7	Ulcerative colitis;
CESC	cis	rs9402673	0.517	rs978036	chr6:135342903	C/T	cg24558204	chr6:135376177	HBS1L	0.52	7.29	0.41	3.48e-12	Reticulocyte count;High light scatter reticulocyte count;
CESC	cis	rs9926296	0.656	rs4522419	chr16:89853307	T/C	cg27121462	chr16:89883253	FANCA	0.55	6.49	0.37	4.14e-10	Vitiligo;
CESC	cis	rs8018808	0.902	rs8006688	chr14:77926649	G/A	cg20045696	chr14:77926864	AHSA1	0.42	5.75	0.33	2.45e-8	Myeloid white cell count;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg22866681	chr6:2685401	MYLK4	-0.46	-6.37	-0.36	8.24e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs8017423	1.000	rs8017423	chr14:90679910	A/G	cg14092571	chr14:90743983	NA	-0.57	-8.5	-0.46	1.44e-15	Mortality in heart failure;
CESC	cis	rs60843830	0.964	rs17713879	chr2:254215	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.86	11.77	0.59	5.28e-26	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs172166	0.637	rs1233691	chr6:28153897	T/G	cg17221315	chr6:27791827	HIST1H4J	0.43	5.72	0.33	2.88e-8	Cardiac Troponin-T levels;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04526987	chr8:131370329	ASAP1	-0.49	-6.82	-0.39	6.09e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs9611565	0.500	rs2011053	chr22:42121278	G/A	cg03806693	chr22:41940476	POLR3H	0.76	9.28	0.5	6.17e-18	Vitiligo;
CESC	cis	rs9910055	0.529	rs850851	chr17:42177674	C/T	cg13607699	chr17:42295918	UBTF	-0.44	-5.35	-0.31	1.89e-7	Total body bone mineral density;
CESC	cis	rs1552244	1.000	rs9875081	chr3:10083935	G/A	cg00166722	chr3:10149974	C3orf24	0.48	6.16	0.35	2.64e-9	Alzheimer's disease;
CESC	cis	rs7592578	0.679	rs4287794	chr2:191327147	T/C	cg10560079	chr2:191398806	TMEM194B	-0.55	-5.43	-0.32	1.28e-7	Diastolic blood pressure;
CESC	trans	rs7980799	0.682	rs1384599	chr12:33624579	G/A	cg26384229	chr12:38710491	ALG10B	-0.58	-8.26	-0.45	7.19e-15	Heart rate;Heart rate variability traits (RMSSD);
CESC	cis	rs3008870	1.000	rs2985822	chr1:67404910	T/G	cg08660285	chr1:67390436	MIER1;WDR78	1.02	14.14	0.66	3.43e-34	Lymphocyte percentage of white cells;
CESC	cis	rs875971	0.638	rs3898855	chr7:66036398	G/C	cg11764359	chr7:65958608	NA	-0.73	-9.8	-0.52	1.49e-19	Aortic root size;
CESC	cis	rs400736	0.602	rs11121090	chr1:8168634	A/G	cg25007680	chr1:8021821	PARK7	0.55	7.37	0.41	2.19e-12	Response to antidepressants and depression;
CESC	cis	rs7937682	0.889	rs558736	chr11:111500760	C/G	cg09085632	chr11:111637200	PPP2R1B	-1.0	-15.84	-0.7	3.11e-40	Primary sclerosing cholangitis;
CESC	cis	rs4727027	0.933	rs917123	chr7:148848358	G/A	cg23583168	chr7:148888333	NA	-0.81	-12.62	-0.61	6.75e-29	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs9322193	0.809	rs9479808	chr6:150072464	A/T	cg13206674	chr6:150067644	NUP43	0.45	6.44	0.37	5.65e-10	Lung cancer;
CESC	cis	rs2070488	0.775	rs7644530	chr3:38558316	C/T	cg24069376	chr3:38537580	EXOG	-0.34	-5.84	-0.34	1.49e-8	Electrocardiographic conduction measures;
CESC	cis	rs8044868	0.530	rs7189115	chr16:72098952	C/T	cg16558253	chr16:72132732	DHX38	-0.38	-5.87	-0.34	1.31e-8	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CESC	cis	rs10751667	0.666	rs10902235	chr11:938892	T/C	cg06064525	chr11:970664	AP2A2	-0.5	-10.04	-0.52	2.7e-20	Alzheimer's disease (late onset);
CESC	cis	rs7481584	0.564	rs7948848	chr11:2981896	G/A	cg25174290	chr11:3078921	CARS	-0.51	-6.67	-0.38	1.46e-10	Calcium levels;
CESC	cis	rs780096	0.526	rs2010087	chr2:27637235	C/T	cg02592271	chr2:27665507	KRTCAP3	-0.29	-5.74	-0.33	2.6e-8	Total body bone mineral density;
CESC	cis	rs12497850	0.797	rs61583136	chr3:49189195	C/T	cg02487422	chr3:49467188	NICN1	0.48	6.16	0.35	2.75e-9	Parkinson's disease;
CESC	trans	rs13398848	1.000	rs10190107	chr2:84201058	A/G	cg23262351	chr6:79576851	IRAK1BP1	0.68	6.01	0.35	6.2e-9	Conduct disorder (symptom count);Conduct disorder;
CESC	cis	rs4319547	1.000	rs4319547	chr12:123079035	A/G	cg23029597	chr12:123009494	RSRC2	-0.5	-5.55	-0.32	7.09e-8	Body mass index;
CESC	cis	rs67311347	1.000	rs4128740	chr3:40519532	C/A	cg24209194	chr3:40518798	ZNF619	0.49	6.1	0.35	3.73e-9	Renal cell carcinoma;
CESC	cis	rs2404602	0.692	rs12910382	chr15:77053442	A/C	cg22467129	chr15:76604101	ETFA	-0.34	-5.16	-0.3	4.84e-7	Blood metabolite levels;
CESC	cis	rs17601876	0.814	rs2899474	chr15:51562076	C/T	cg19946085	chr15:51559439	CYP19A1	-0.33	-5.2	-0.3	4.03e-7	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg11695030	chr19:34919128	UBA2	-0.44	-6.06	-0.35	4.57e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs225245	0.817	rs1049379	chr17:33998802	G/C	cg05299278	chr17:33885742	SLFN14	0.35	5.07	0.3	7.61e-7	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
CESC	cis	rs12956009	0.583	rs9653018	chr18:44895853	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.5	6.5	0.37	3.94e-10	Educational attainment (years of education);
CESC	cis	rs8062405	0.824	rs7191618	chr16:28565667	C/G	cg08761264	chr16:28874980	SH2B1	-0.42	-5.07	-0.3	7.33e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs5769765	0.730	rs62233964	chr22:50317410	C/G	cg26441486	chr22:50317300	CRELD2	0.47	5.66	0.33	3.99e-8	Schizophrenia;
CESC	cis	rs2625529	0.586	rs59975112	chr15:72423710	G/T	cg16672083	chr15:72433130	SENP8	0.44	6.7	0.38	1.21e-10	Red blood cell count;
CESC	cis	rs71403859	0.502	rs36122765	chr16:71504183	G/C	cg08717414	chr16:71523259	ZNF19	-0.99	-9.42	-0.5	2.36e-18	Post bronchodilator FEV1;
CESC	cis	rs5769707	0.846	rs5770610	chr22:50036897	A/C	cg20744362	chr22:50050164	C22orf34	0.48	8.27	0.45	6.61e-15	Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs78707713	0.841	rs78677622	chr10:71196698	C/T	cg12610070	chr10:71211762	TSPAN15	-0.44	-7.38	-0.41	2.08e-12	Venous thromboembolism;
CESC	cis	rs116095464	0.558	rs7725227	chr5:233517	G/A	cg22857025	chr5:266934	NA	-1.28	-18.71	-0.75	2.24e-50	Breast cancer;
CESC	cis	rs1003719	0.591	rs13046303	chr21:38551976	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.54	-6.96	-0.39	2.7e-11	Eye color traits;
CESC	cis	rs10170846	0.800	rs10194743	chr2:223518151	A/G	cg25565276	chr2:223520875	FARSB	0.55	7.71	0.43	2.51e-13	Schizophrenia (inflammation and infection response interaction);
CESC	cis	rs8060686	0.641	rs113502835	chr16:68238965	A/T	cg26727032	chr16:67993705	SLC12A4	-0.53	-5.95	-0.34	8.65e-9	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs17270561	0.609	rs17267614	chr6:25730027	A/C	cg17691542	chr6:26056736	HIST1H1C	0.41	5.34	0.31	1.96e-7	Iron status biomarkers;
CESC	cis	rs7666738	0.830	rs13129503	chr4:98987892	T/C	cg05340658	chr4:99064831	C4orf37	0.8	12.42	0.61	3.31e-28	Colonoscopy-negative controls vs population controls;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg03094905	chr4:52710562	DCUN1D4	-0.49	-6.18	-0.35	2.44e-9	Ulcerative colitis;
CESC	cis	rs6951245	0.744	rs1133122	chr7:1192572	C/A	cg16145915	chr7:1198662	ZFAND2A	-0.49	-5.45	-0.32	1.14e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7904368	0.754	rs12253908	chr10:16853358	T/C	cg23933602	chr10:16859644	RSU1	0.68	5.81	0.34	1.78e-8	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
CESC	cis	rs67478160	0.634	rs2368558	chr14:104230518	A/G	cg08213375	chr14:104286397	PPP1R13B	0.46	9.0	0.48	4.6e-17	Schizophrenia;
CESC	cis	rs13108904	0.518	rs4974602	chr4:1342391	C/T	cg00684032	chr4:1343700	KIAA1530	0.61	9.15	0.49	1.53e-17	Obesity-related traits;
CESC	cis	rs1008375	0.835	rs9760627	chr4:17651508	C/T	cg16339924	chr4:17578868	LAP3	0.63	7.85	0.43	1.04e-13	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs1707322	1.000	rs11211248	chr1:46476844	A/G	cg05343316	chr1:45956843	TESK2	0.43	5.24	0.31	3.24e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs11792861	0.926	rs1044905	chr9:111781495	G/A	cg14384093	chr9:111878565	C9orf5	-0.41	-5.05	-0.3	8.32e-7	Menarche (age at onset);
CESC	cis	rs7412746	0.611	rs2280627	chr1:150935872	A/G	cg22823121	chr1:150693482	HORMAD1	0.37	5.17	0.3	4.53e-7	Melanoma;
CESC	cis	rs9911578	0.741	rs2611776	chr17:56819636	G/T	cg12560992	chr17:57184187	TRIM37	0.92	15.09	0.68	1.43e-37	Intelligence (multi-trait analysis);
CESC	cis	rs72627123	0.867	rs73301475	chr14:74462868	C/T	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.77	5.34	0.31	2e-7	Morning vs. evening chronotype;
CESC	cis	rs9549367	0.756	rs2316463	chr13:113901406	C/T	cg00898013	chr13:113819073	PROZ	-0.52	-7.11	-0.4	1.07e-11	Platelet distribution width;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg22984404	chr17:30469399	RHOT1	-0.49	-6.52	-0.37	3.54e-10	Fibrinogen levels;
CESC	cis	rs4332037	0.950	rs56403963	chr7:1946130	C/G	cg23422044	chr7:1970798	MAD1L1	-0.53	-5.41	-0.32	1.44e-7	Bipolar disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00081347	chr17:78188837	SGSH	-0.56	-6.32	-0.36	1.08e-9	Gut microbiome composition (summer);
CESC	cis	rs13108904	0.870	rs12499546	chr4:1255194	C/T	cg00684032	chr4:1343700	KIAA1530	0.41	5.84	0.34	1.49e-8	Obesity-related traits;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg14857596	chr12:72233493	TBC1D15	-0.48	-6.75	-0.38	9.22e-11	Fibrinogen levels;
CESC	trans	rs9951602	0.512	rs7240758	chr18:76650677	T/C	cg02800362	chr5:177631904	HNRNPAB	0.66	8.66	0.47	4.55e-16	Obesity-related traits;
CESC	cis	rs6754311	0.608	rs3739020	chr2:136602491	T/G	cg15123519	chr2:136567270	LCT	-0.3	-5.14	-0.3	5.23e-7	Mosquito bite size;
CESC	cis	rs7618915	0.547	rs62253700	chr3:52625019	T/A	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.38	6.65	0.38	1.63e-10	Bipolar disorder;
CESC	cis	rs7618915	0.547	rs10865973	chr3:52718154	A/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.38	6.69	0.38	1.34e-10	Bipolar disorder;
CESC	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg24846343	chr22:24311635	DDTL	0.64	11.11	0.56	8.29e-24	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs7193541	0.684	rs4888265	chr16:74683737	T/C	cg01733217	chr16:74700730	RFWD3	1.05	20.24	0.78	1.07e-55	Multiple myeloma;
CESC	cis	rs9393777	0.513	rs9393737	chr6:26617306	A/G	cg14345882	chr6:26364793	BTN3A2	-0.39	-5.23	-0.31	3.5e-7	Intelligence (multi-trait analysis);
CESC	cis	rs11098499	0.954	rs6834796	chr4:120414693	A/C	cg24375607	chr4:120327624	NA	0.46	5.66	0.33	3.97e-8	Corneal astigmatism;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg03449406	chr14:35183687	CFL2	-0.49	-6.71	-0.38	1.21e-10	Ulcerative colitis;
CESC	cis	rs3768617	0.811	rs61808068	chr1:182979377	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.66	9.0	0.48	4.41e-17	Fuchs's corneal dystrophy;
CESC	cis	rs10504229	1.000	rs58371676	chr8:58189382	G/A	cg05313129	chr8:58192883	C8orf71	-0.55	-6.29	-0.36	1.34e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs172166	0.694	rs203877	chr6:28048624	T/C	cg17221315	chr6:27791827	HIST1H4J	0.46	6.09	0.35	3.98e-9	Cardiac Troponin-T levels;
CESC	cis	rs12142240	0.698	rs17361805	chr1:46813967	C/T	cg10495392	chr1:46806563	NSUN4	0.55	6.04	0.35	5.2e-9	Menopause (age at onset);
CESC	cis	rs7618915	0.798	rs353547	chr3:52268866	A/G	cg05564831	chr3:52568323	NT5DC2	-0.37	-5.34	-0.31	1.95e-7	Bipolar disorder;
CESC	cis	rs3733585	0.673	rs4292333	chr4:9953871	G/A	cg02734326	chr4:10020555	SLC2A9	-0.39	-5.64	-0.33	4.45e-8	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg19318889	chr4:1322082	MAEA	-0.6	-7.46	-0.42	1.28e-12	Longevity;
CESC	cis	rs2228479	0.702	rs17226841	chr16:89828484	C/T	cg06558623	chr16:89946397	TCF25	1.17	9.29	0.5	5.76e-18	Skin colour saturation;
CESC	cis	rs7666738	0.830	rs58367603	chr4:99015350	T/C	cg03467027	chr4:99064603	C4orf37	0.44	5.63	0.33	4.57e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9430161	0.611	rs12081181	chr1:11034165	T/G	cg02454025	chr1:11042201	C1orf127	0.96	15.32	0.69	2.28e-38	Ewing sarcoma;
CESC	cis	rs12188164	0.686	rs56279338	chr5:416118	G/A	cg26850624	chr5:429559	AHRR	-0.49	-6.72	-0.38	1.08e-10	Cystic fibrosis severity;
CESC	cis	rs2354432	0.607	rs55918563	chr1:146718973	G/C	cg25205988	chr1:146714368	CHD1L	-1.01	-8.47	-0.46	1.68e-15	Mitochondrial DNA levels;
CESC	cis	rs7219021	1.000	rs11657371	chr17:46843873	T/C	cg16584676	chr17:46985605	UBE2Z	-0.69	-7.57	-0.42	6.15e-13	Schizophrenia or bipolar disorder;
CESC	trans	rs61931739	0.534	rs1211286	chr12:34135581	T/C	cg26384229	chr12:38710491	ALG10B	0.51	6.8	0.39	6.9e-11	Morning vs. evening chronotype;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg06080712	chr22:32435515	NA	-0.5	-7.01	-0.4	1.94e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs6502050	0.799	rs12603050	chr17:80104631	A/G	cg11859384	chr17:80120422	CCDC57	-0.38	-5.11	-0.3	6.21e-7	Life satisfaction;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg09482975	chr15:55700768	CCPG1	-0.5	-6.4	-0.37	7.11e-10	Ulcerative colitis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06464452	chr4:77227879	STBD1	-0.56	-6.63	-0.38	1.82e-10	Gut microbiome composition (summer);
CESC	cis	rs920590	0.758	rs35280191	chr8:19665214	A/C	cg17834443	chr8:19674713	INTS10	0.61	6.92	0.39	3.49e-11	Acute lymphoblastic leukemia (childhood);
CESC	trans	rs8073060	0.544	rs9912939	chr17:34005264	T/G	cg19694781	chr19:47549865	TMEM160	-0.74	-6.91	-0.39	3.64e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	cis	rs4474465	0.850	rs4944203	chr11:78220629	A/C	cg27205649	chr11:78285834	NARS2	0.44	5.27	0.31	2.83e-7	Alzheimer's disease (survival time);
CESC	cis	rs832540	0.669	rs832539	chr5:56199386	A/C	cg22800045	chr5:56110881	MAP3K1	0.52	6.7	0.38	1.23e-10	Coronary artery disease;
CESC	cis	rs10504229	1.000	rs17805332	chr8:58169798	A/G	cg24829409	chr8:58192753	C8orf71	-0.74	-9.93	-0.52	5.7e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs10504229	0.724	rs58715581	chr8:58134568	A/G	cg24829409	chr8:58192753	C8orf71	-0.58	-7.2	-0.4	6.31e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs2730245	0.636	rs710421	chr7:158668575	T/C	cg01943577	chr7:158741284	NA	-0.47	-6.26	-0.36	1.57e-9	Height;
CESC	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg16132339	chr22:24313637	DDTL;DDT	0.38	5.87	0.34	1.33e-8	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg26338869	chr17:61819248	STRADA	0.68	8.87	0.48	1.08e-16	Prudent dietary pattern;
CESC	trans	rs1814175	0.558	rs5025146	chr11:49795724	C/G	cg03929089	chr4:120376271	NA	-0.89	-13.75	-0.65	7.56e-33	Height;
CESC	cis	rs11250464	0.736	rs5015512	chr10:1411923	T/C	cg26394196	chr10:1453818	ADARB2	-0.43	-5.76	-0.33	2.37e-8	Radiation response;
CESC	cis	rs317689	0.684	rs315125	chr12:69758884	C/T	cg20891283	chr12:69753455	YEATS4	0.64	7.44	0.42	1.42e-12	Response to diuretic therapy;
CESC	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg07677032	chr17:61819896	STRADA	-0.52	-6.99	-0.39	2.23e-11	Prudent dietary pattern;
CESC	cis	rs910316	0.737	rs175077	chr14:75506875	G/A	cg08847533	chr14:75593920	NEK9	-0.89	-14.97	-0.68	3.81e-37	Height;
CESC	cis	rs5758511	0.680	rs5758657	chr22:42618669	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.59	8.76	0.47	2.44e-16	Birth weight;
CESC	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	13.74	0.64	8.59e-33	Prudent dietary pattern;
CESC	cis	rs7551222	0.752	rs4951400	chr1:204534571	C/G	cg20240347	chr1:204465584	NA	-0.28	-5.66	-0.33	4.03e-8	Schizophrenia;
CESC	cis	rs9815354	0.812	rs57162396	chr3:41896031	G/A	cg03022575	chr3:42003672	ULK4	0.71	6.23	0.36	1.84e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs854765	0.618	rs9908017	chr17:17774422	C/T	cg04398451	chr17:18023971	MYO15A	0.64	9.37	0.5	3.2e-18	Total body bone mineral density;
CESC	cis	rs10870270	0.564	rs45519634	chr10:133782616	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.85	-7.59	-0.42	5.3e-13	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs1552244	1.000	rs2272123	chr3:10140115	G/A	cg00166722	chr3:10149974	C3orf24	0.47	5.97	0.34	7.77e-9	Alzheimer's disease;
CESC	cis	rs2477686	0.526	rs1998760	chr1:2397136	C/T	cg11214544	chr1:2391121	NA	-0.47	-7.24	-0.41	4.84e-12	Non-obstructive azoospermia;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg15104066	chr12:90102578	LOC338758	-0.46	-6.02	-0.35	5.84e-9	Fibrinogen levels;
CESC	cis	rs11711311	1.000	rs2242109	chr3:113434100	G/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.71	10.16	0.53	1.07e-20	IgG glycosylation;
CESC	cis	rs7560272	0.501	rs2421675	chr2:73955301	C/A	cg20560298	chr2:73613845	ALMS1	0.41	5.63	0.33	4.63e-8	Schizophrenia;
CESC	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg26354017	chr1:205819088	PM20D1	0.87	13.82	0.65	4.49e-33	Menarche (age at onset);
CESC	cis	rs40363	0.645	rs250633	chr16:3523002	C/T	cg00484396	chr16:3507460	NAT15	0.44	7.3	0.41	3.33e-12	Tuberculosis;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg08862778	chr1:11322643	MTOR	0.45	6.12	0.35	3.36e-9	Systemic lupus erythematosus;
CESC	cis	rs2249694	0.919	rs7093170	chr10:135402904	C/T	cg20169779	chr10:135381914	SYCE1	-0.41	-5.92	-0.34	9.89e-9	Obesity-related traits;
CESC	cis	rs9309473	0.950	rs11689588	chr2:73773691	A/G	cg20560298	chr2:73613845	ALMS1	-0.55	-6.97	-0.39	2.46e-11	Metabolite levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04653776	chr20:32399093	CHMP4B	0.58	6.67	0.38	1.48e-10	Gut microbiome composition (summer);
CESC	cis	rs763121	0.819	rs6001205	chr22:39100264	T/A	cg06022373	chr22:39101656	GTPBP1	0.91	14.38	0.66	4.71e-35	Menopause (age at onset);
CESC	cis	rs6952808	0.656	rs11764212	chr7:2067593	C/A	cg08027265	chr7:2291960	NA	-0.41	-6.25	-0.36	1.65e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs2180341	0.920	rs1073932	chr6:127682009	G/T	cg27446573	chr6:127587934	RNF146	1.06	15.88	0.7	2.39e-40	Breast cancer;
CESC	cis	rs2072499	0.778	rs2842868	chr1:156196407	A/C	cg25208724	chr1:156163844	SLC25A44	0.81	10.77	0.55	1.13e-22	Testicular germ cell tumor;
CESC	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg10150615	chr22:24372951	LOC391322	0.49	5.87	0.34	1.32e-8	Urinary 1,3-butadiene metabolite levels in smokers;
CESC	cis	rs10170846	0.893	rs1447108	chr2:223542231	A/G	cg25565276	chr2:223520875	FARSB	0.57	7.92	0.44	6.64e-14	Schizophrenia (inflammation and infection response interaction);
CESC	cis	rs9888739	0.920	rs12920597	chr16:31304382	C/T	cg15817542	chr16:31343056	ITGAM	-0.5	-5.41	-0.32	1.41e-7	Systemic lupus erythematosus;
CESC	cis	rs7666738	0.830	rs957742	chr4:99029409	C/T	cg24818145	chr4:99064322	C4orf37	0.39	5.09	0.3	6.95e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22907165	chr6:13328662	TBC1D7	0.61	7.15	0.4	8.51e-12	Gut microbiome composition (summer);
CESC	cis	rs3768617	0.510	rs3768624	chr1:183079252	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.88	14.14	0.66	3.44e-34	Fuchs's corneal dystrophy;
CESC	cis	rs2033711	0.870	rs3764534	chr19:58929136	G/A	cg26874164	chr19:58962979	ZNF324B	0.54	7.41	0.41	1.73e-12	Uric acid clearance;
CESC	cis	rs8114671	0.562	rs2064454	chr20:33496169	C/T	cg07148914	chr20:33460835	GGT7	0.52	6.79	0.39	7.24e-11	Height;
CESC	cis	rs2933343	0.761	rs789225	chr3:128600229	G/A	cg24203234	chr3:128598194	ACAD9	0.44	5.9	0.34	1.09e-8	IgG glycosylation;
CESC	trans	rs657452	0.722	rs1185222	chr1:49958961	C/T	cg17017335	chr3:97540665	NA	0.5	6.56	0.37	2.76e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs9611565	0.592	rs5758406	chr22:42076641	A/G	cg06634786	chr22:41940651	POLR3H	0.58	6.02	0.35	5.72e-9	Vitiligo;
CESC	trans	rs11039798	0.844	rs6485820	chr11:48264711	A/G	cg15704280	chr7:45808275	SEPT13	0.68	6.39	0.37	7.34e-10	Axial length;
CESC	cis	rs7267979	1.000	rs2500448	chr20:25404027	A/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.82	-15.49	-0.69	5.72e-39	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs863345	0.625	rs11264978	chr1:158447921	T/C	cg12129480	chr1:158549410	OR10X1	-0.36	-7.15	-0.4	8.56e-12	Pneumococcal bacteremia;
CESC	cis	rs514406	0.644	rs6662414	chr1:53198893	A/G	cg16325326	chr1:53192061	ZYG11B	-0.7	-11.15	-0.56	6.44e-24	Monocyte count;
CESC	cis	rs910316	0.935	rs2268620	chr14:75640403	G/A	cg08847533	chr14:75593920	NEK9	-0.99	-17.84	-0.74	2.57e-47	Height;
CESC	cis	rs7666738	0.753	rs11932536	chr4:98930105	A/G	cg03467027	chr4:99064603	C4orf37	0.46	5.6	0.33	5.39e-8	Colonoscopy-negative controls vs population controls;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg05366495	chr17:73915902	FBF1	0.44	6.21	0.36	2.03e-9	Fibrinogen levels;
CESC	cis	rs921968	0.565	rs13408305	chr2:219628183	G/A	cg02176678	chr2:219576539	TTLL4	-0.44	-7.73	-0.43	2.21e-13	Mean corpuscular hemoglobin concentration;
CESC	cis	rs67311347	1.000	rs72861689	chr3:40435890	A/G	cg24209194	chr3:40518798	ZNF619	0.53	7.08	0.4	1.31e-11	Renal cell carcinoma;
CESC	cis	rs7927771	0.524	rs10742817	chr11:47689343	A/G	cg20307385	chr11:47447363	PSMC3	-0.64	-9.1	-0.49	2.24e-17	Subjective well-being;
CESC	cis	rs6087990	0.814	rs2424895	chr20:31335978	C/T	cg13636640	chr20:31349939	DNMT3B	-0.79	-13.11	-0.63	1.33e-30	Ulcerative colitis;
CESC	cis	rs9486715	0.867	rs11152924	chr6:96877383	A/G	cg18709589	chr6:96969512	KIAA0776	0.45	6.46	0.37	5.05e-10	Headache;
CESC	cis	rs425277	1.000	rs262647	chr1:2095699	C/T	cg16545954	chr1:2118288	C1orf86	0.33	5.64	0.33	4.4e-8	Height;
CESC	cis	rs896854	0.654	rs13278601	chr8:95972974	G/C	cg26343298	chr8:95960752	TP53INP1	0.36	5.87	0.34	1.3e-8	Type 2 diabetes;
CESC	cis	rs34172651	0.517	rs874484	chr16:24803242	T/C	cg00339695	chr16:24857497	SLC5A11	0.53	6.61	0.38	2.07e-10	Intelligence (multi-trait analysis);
CESC	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg07167872	chr1:205819463	PM20D1	0.75	12.28	0.6	9.7e-28	Menarche (age at onset);
CESC	cis	rs9486715	0.867	rs4438964	chr6:96917563	T/G	cg18709589	chr6:96969512	KIAA0776	0.47	6.66	0.38	1.59e-10	Headache;
CESC	cis	rs2836974	0.863	rs6517519	chr21:40540245	A/G	cg11644478	chr21:40555479	PSMG1	1.03	16.93	0.72	4.47e-44	Cognitive function;
CESC	cis	rs7618915	0.501	rs6617	chr3:52740182	C/G	cg18404041	chr3:52824283	ITIH1	-0.39	-6.67	-0.38	1.5e-10	Bipolar disorder;
CESC	cis	rs2569991	0.636	rs361223	chr3:12922526	T/C	cg22481960	chr3:13008800	IQSEC1	-0.57	-6.88	-0.39	4.36e-11	Periodontitis (DPAL);
CESC	cis	rs9916302	0.851	rs11870631	chr17:37645129	C/T	cg07936489	chr17:37558343	FBXL20	-0.81	-11.96	-0.59	1.17e-26	Glomerular filtration rate (creatinine);
CESC	cis	rs896854	0.654	rs4735337	chr8:95973465	T/C	cg26343298	chr8:95960752	TP53INP1	0.37	6.06	0.35	4.58e-9	Type 2 diabetes;
CESC	cis	rs1707322	0.752	rs28812624	chr1:46203736	T/A	cg05343316	chr1:45956843	TESK2	0.51	6.32	0.36	1.09e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs6723226	0.552	rs62136336	chr2:32804106	G/A	cg02381751	chr2:32503542	YIPF4	0.81	10.88	0.56	4.75e-23	Intelligence (multi-trait analysis);
CESC	cis	rs7520050	0.966	rs7550746	chr1:46351719	T/A	cg03146154	chr1:46216737	IPP	-0.49	-6.42	-0.37	6.3e-10	Red blood cell count;Reticulocyte count;
CESC	cis	rs13108904	0.557	rs1680041	chr4:1238521	C/T	cg02475777	chr4:1388615	CRIPAK	-0.46	-5.95	-0.34	8.25e-9	Obesity-related traits;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg25177113	chr1:955463	AGRN	-0.46	-6.13	-0.35	3.1e-9	Fibrinogen levels;
CESC	cis	rs9457247	0.602	rs13204839	chr6:167471119	G/A	cg23791538	chr6:167370224	RNASET2	-0.52	-6.9	-0.39	3.81e-11	Crohn's disease;
CESC	cis	rs6546537	0.915	rs4852866	chr2:69829916	T/C	cg10773587	chr2:69614142	GFPT1	-0.43	-5.17	-0.3	4.58e-7	Serum thyroid-stimulating hormone levels;
CESC	trans	rs17685	0.712	rs2158867	chr7:75815141	C/A	cg19862616	chr7:65841803	NCRNA00174	0.82	11.63	0.58	1.6e-25	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs1178968	0.818	rs4717086	chr7:72777049	A/G	cg25889504	chr7:72793014	NA	0.47	5.03	0.3	8.91e-7	Triglyceride levels;
CESC	cis	rs4076764	0.958	rs11584957	chr1:163392937	C/T	cg24596788	chr1:163392923	NA	-0.52	-7.52	-0.42	8.31e-13	Motion sickness;
CESC	cis	rs965469	1.000	rs2236122	chr20:3305240	C/T	cg25506879	chr20:3388711	C20orf194	-0.53	-5.59	-0.32	5.77e-8	IFN-related cytopenia;
CESC	cis	rs13118159	0.801	rs7664474	chr4:1329116	T/A	cg02018176	chr4:1364513	KIAA1530	0.41	5.82	0.34	1.66e-8	Longevity;
CESC	cis	rs9486719	1.000	rs13210597	chr6:96969694	C/A	cg18709589	chr6:96969512	KIAA0776	-0.53	-5.83	-0.34	1.64e-8	Migraine;Coronary artery disease;
CESC	trans	rs7615952	0.688	rs17334074	chr3:125540460	A/G	cg07211511	chr3:129823064	LOC729375	0.79	8.99	0.48	4.67e-17	Blood pressure (smoking interaction);
CESC	cis	rs763121	0.853	rs5757166	chr22:38995385	G/T	cg06022373	chr22:39101656	GTPBP1	0.95	17.17	0.73	6.29e-45	Menopause (age at onset);
CESC	cis	rs9811920	0.809	rs13059754	chr3:99678490	C/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.47	-7.64	-0.42	4.04e-13	Axial length;
CESC	cis	rs2904967	0.562	rs239255	chr11:64987128	G/A	cg23743554	chr11:65321226	LTBP3	-0.4	-5.21	-0.3	3.82e-7	Mean corpuscular volume;
CESC	cis	rs7666738	0.830	rs17550735	chr4:99014076	T/G	cg03676636	chr4:99064102	C4orf37	0.33	5.16	0.3	4.86e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1008375	0.966	rs2302393	chr4:17654341	G/A	cg02297831	chr4:17616191	MED28	0.57	7.29	0.41	3.57e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs950776	0.667	rs57728226	chr15:78929350	G/C	cg06917634	chr15:78832804	PSMA4	0.56	6.65	0.38	1.62e-10	Sudden cardiac arrest;
CESC	cis	rs9291683	1.000	rs9291683	chr4:10324160	C/T	cg00071950	chr4:10020882	SLC2A9	0.52	7.81	0.43	1.36e-13	Bone mineral density;
CESC	cis	rs314370	0.818	rs12705091	chr7:100472380	C/T	cg10426581	chr7:100472382	SRRT	0.82	8.27	0.45	6.6e-15	Resting heart rate;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg19101460	chr15:59949499	GTF2A2	-0.49	-6.86	-0.39	4.9e-11	Asthma;
CESC	cis	rs892961	0.932	rs7216909	chr17:75405234	A/G	cg05865280	chr17:75406074	SEPT9	0.66	13.17	0.63	8e-31	Airflow obstruction;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13957827	chr4:164415471	C4orf43	0.6	6.32	0.36	1.12e-9	Gut microbiome composition (summer);
CESC	cis	rs10887741	0.646	rs10218939	chr10:89436853	A/G	cg13926569	chr10:89418898	PAPSS2	0.47	7.15	0.4	8.25e-12	Exercise (leisure time);
CESC	cis	rs916888	0.610	rs199454	chr17:44800110	G/A	cg01570182	chr17:44337453	NA	-0.63	-8.48	-0.46	1.63e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg18449345	chr7:30068347	PLEKHA8	-0.44	-6.49	-0.37	4.32e-10	Ulcerative colitis;
CESC	cis	rs763014	0.931	rs7192508	chr16:630367	C/T	cg00908189	chr16:619842	PIGQ	0.67	9.39	0.5	2.81e-18	Height;
CESC	cis	rs4713118	0.662	rs9380046	chr6:28030499	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.55	-6.22	-0.36	1.96e-9	Parkinson's disease;
CESC	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	13.65	0.64	1.8e-32	Prudent dietary pattern;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25618672	chr7:65939712	NA	-0.66	-7.25	-0.41	4.49e-12	Gut microbiome composition (summer);
CESC	trans	rs17508449	0.779	rs78703286	chr1:114148115	A/G	cg23028848	chr11:57092561	TNKS1BP1	-0.77	-6.14	-0.35	2.98e-9	Leprosy;
CESC	cis	rs10504229	0.683	rs16921807	chr8:58105967	C/T	cg22535103	chr8:58192502	C8orf71	-0.77	-8.76	-0.47	2.37e-16	Developmental language disorder (linguistic errors);
CESC	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	10.2	0.53	7.94e-21	Prudent dietary pattern;
CESC	cis	rs2404602	0.716	rs8039545	chr15:76707247	A/G	cg26408565	chr15:76604113	ETFA	-0.42	-6.08	-0.35	4.19e-9	Blood metabolite levels;
CESC	cis	rs11123610	0.520	rs12711962	chr2:3717985	C/T	cg19052272	chr2:3704530	ALLC	-0.47	-5.84	-0.34	1.51e-8	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CESC	cis	rs4535700	0.501	rs9642405	chr7:55978166	C/T	cg13278478	chr7:56160911	PHKG1	0.33	5.03	0.3	8.9e-7	Macular telangiectasia type 2;
CESC	cis	rs367943	0.698	rs13167361	chr5:112961789	C/G	cg12552261	chr5:112820674	MCC	0.44	5.66	0.33	3.85e-8	Type 2 diabetes;
CESC	cis	rs4132509	0.744	rs10927065	chr1:243914611	G/T	cg21452805	chr1:244014465	NA	0.56	6.82	0.39	6.3e-11	RR interval (heart rate);
CESC	cis	rs898097	0.691	rs7222745	chr17:80907253	C/T	cg10494973	chr17:80897199	TBCD	0.52	6.55	0.37	3.06e-10	Breast cancer;
CESC	trans	rs11039798	0.699	rs7120775	chr11:48266736	C/G	cg15704280	chr7:45808275	SEPT13	0.68	6.39	0.37	7.34e-10	Axial length;
CESC	cis	rs9660180	0.967	rs6664664	chr1:1751264	G/A	cg23982607	chr1:1823379	GNB1	-0.78	-12.68	-0.61	4.08e-29	Body mass index;
CESC	cis	rs2836974	0.966	rs2836977	chr21:40666066	T/C	cg27266027	chr21:40555129	PSMG1	0.45	5.29	0.31	2.59e-7	Cognitive function;
CESC	cis	rs78456975	1.000	rs6720874	chr2:1580504	A/G	cg26248373	chr2:1572462	NA	-0.51	-5.15	-0.3	4.99e-7	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs4561483	0.801	rs8061189	chr16:11951749	C/G	cg08843971	chr16:11963173	GSPT1	0.55	7.9	0.44	7.57e-14	Testicular germ cell tumor;
CESC	cis	rs9649213	0.593	rs6948540	chr7:97960066	A/G	cg21770322	chr7:97807741	LMTK2	0.54	8.17	0.45	1.26e-14	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs875971	0.545	rs801199	chr7:66025273	A/G	cg11764359	chr7:65958608	NA	-0.81	-9.98	-0.52	4.19e-20	Aortic root size;
CESC	cis	rs8060686	0.858	rs11553287	chr16:67905407	A/G	cg26727032	chr16:67993705	SLC12A4	-0.66	-9.7	-0.51	3.07e-19	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs853679	0.517	rs1947862	chr6:28105196	C/T	cg23161317	chr6:28129485	ZNF389	0.54	6.8	0.39	6.81e-11	Depression;
CESC	cis	rs7833790	0.963	rs10958046	chr8:82729210	A/G	cg17211192	chr8:82754475	SNX16	-0.71	-8.32	-0.45	4.8e-15	Diastolic blood pressure;
CESC	cis	rs13392177	0.647	rs6718220	chr2:219066518	T/C	cg00012203	chr2:219082015	ARPC2	-0.68	-8.55	-0.46	1.02e-15	Pyoderma gangrenosum in inflammatory bowel disease;
CESC	cis	rs6696846	0.749	rs6692170	chr1:205074019	G/A	cg00857998	chr1:205179979	DSTYK	0.5	6.79	0.39	7.13e-11	Red blood cell count;
CESC	cis	rs9303401	0.659	rs1864754	chr17:56688789	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	-1.02	-12.94	-0.62	5.18e-30	Cognitive test performance;
CESC	cis	rs10832963	1.000	rs7943121	chr11:18656062	G/C	cg20219074	chr11:18656078	SPTY2D1	0.8	11.7	0.58	9.24e-26	Breast cancer;
CESC	cis	rs7666738	0.716	rs114187620	chr4:98819534	T/A	cg17366294	chr4:99064904	C4orf37	0.55	7.5	0.42	9.71e-13	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7680126	0.596	rs4697714	chr4:10143786	A/T	cg00071950	chr4:10020882	SLC2A9	-0.51	-6.12	-0.35	3.32e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	cis	rs5760092	0.618	rs4461358	chr22:24260106	T/C	cg10150615	chr22:24372951	LOC391322	0.48	5.82	0.34	1.66e-8	Urinary 1,3-butadiene metabolite levels in smokers;
CESC	cis	rs7818688	0.697	rs11779698	chr8:95979764	C/G	cg16049864	chr8:95962084	TP53INP1	0.55	5.55	0.32	6.92e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14047321	chr14:62523576	SYT16	-0.63	-7.46	-0.42	1.23e-12	Gut microbiome composition (summer);
CESC	cis	rs4713118	0.513	rs183244	chr6:28031838	C/A	cg19592336	chr6:28129416	ZNF389	0.44	6.38	0.36	7.89e-10	Parkinson's disease;
CESC	trans	rs7246760	1.000	rs1592997	chr19:9900983	G/A	cg02900749	chr2:68251473	NA	-0.78	-7.1	-0.4	1.18e-11	Pursuit maintenance gain;
CESC	cis	rs7212590	0.618	rs7217337	chr17:58023417	C/T	cg20303301	chr17:57937339	TUBD1	-0.55	-5.57	-0.32	6.25e-8	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs8060686	0.516	rs9938020	chr16:68251784	C/G	cg26727032	chr16:67993705	SLC12A4	-0.51	-6.82	-0.39	6.18e-11	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs9311474	0.508	rs6786043	chr3:52604861	A/G	cg18404041	chr3:52824283	ITIH1	-0.39	-6.73	-0.38	1.06e-10	Electroencephalogram traits;
CESC	cis	rs4919694	1.000	rs79254677	chr10:104691567	A/G	cg04362960	chr10:104952993	NT5C2	0.79	6.69	0.38	1.35e-10	Arsenic metabolism;
CESC	trans	rs650950	0.528	rs646660	chr11:35528452	C/T	cg19041146	chr11:118401536	TMEM25;TTC36	0.46	6.37	0.36	8.47e-10	Bronchopulmonary dysplasia;
CESC	cis	rs4268898	0.722	rs7564420	chr2:24414002	C/T	cg06627628	chr2:24431161	ITSN2	-0.58	-7.42	-0.41	1.6e-12	Asthma;
CESC	cis	rs12188164	0.561	rs2721010	chr5:456915	A/G	cg16584290	chr5:462447	EXOC3	0.47	7.1	0.4	1.12e-11	Cystic fibrosis severity;
CESC	cis	rs12478296	0.901	rs67423532	chr2:243004719	A/G	cg06360820	chr2:242988706	NA	-0.73	-9.07	-0.49	2.7e-17	Obesity-related traits;
CESC	cis	rs4665809	0.627	rs13014338	chr2:26463024	C/T	cg04944784	chr2:26401820	FAM59B	0.96	10.55	0.54	5.79e-22	Gut microbiome composition (summer);
CESC	trans	rs9388451	0.591	rs1268792	chr6:126042124	G/A	cg05039488	chr6:79577232	IRAK1BP1	0.49	6.27	0.36	1.47e-9	Brugada syndrome;
CESC	cis	rs72781680	0.752	rs55806536	chr2:23912697	A/G	cg20701182	chr2:24300061	SF3B14	0.8	6.94	0.39	3.03e-11	Lymphocyte counts;
CESC	cis	rs9311474	0.607	rs4234633	chr3:52557038	C/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.29	5.19	0.3	4.29e-7	Electroencephalogram traits;
CESC	cis	rs13108904	0.967	rs13109112	chr4:1290481	C/A	cg22903657	chr4:1355424	KIAA1530	-0.37	-5.13	-0.3	5.71e-7	Obesity-related traits;
CESC	cis	rs780096	0.526	rs780106	chr2:27681598	A/C	cg21248554	chr2:27665150	KRTCAP3	-0.36	-7.38	-0.41	2.02e-12	Total body bone mineral density;
CESC	cis	rs10504229	0.724	rs58715581	chr8:58134568	A/G	cg02725872	chr8:58115012	NA	-0.45	-7.05	-0.4	1.52e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs3733585	0.648	rs7376155	chr4:9952588	C/T	cg11266682	chr4:10021025	SLC2A9	-0.58	-11.0	-0.56	2.04e-23	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs7165102	1.000	rs11632310	chr15:65882326	G/C	cg11441148	chr15:65824328	PTPLAD1	0.32	5.52	0.32	8.09e-8	Mean corpuscular hemoglobin;
CESC	cis	rs2576037	0.583	rs478820	chr18:44397782	G/A	cg19077165	chr18:44547161	KATNAL2	-0.61	-9.19	-0.49	1.2e-17	Personality dimensions;
CESC	trans	rs2018683	0.899	rs10479817	chr7:28978148	A/C	cg19402173	chr7:128379420	CALU	-0.54	-7.07	-0.4	1.4e-11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CESC	cis	rs853679	0.517	rs67878650	chr6:28142587	G/C	cg19592336	chr6:28129416	ZNF389	0.59	7.78	0.43	1.63e-13	Depression;
CESC	cis	rs1801251	0.752	rs2592126	chr2:233751377	A/G	cg25237894	chr2:233734115	C2orf82	-0.48	-8.44	-0.46	2.07e-15	Coronary artery disease;
CESC	cis	rs644799	1.000	rs544119	chr11:95538624	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.92	13.87	0.65	2.93e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs2235544	0.579	rs1537322	chr1:54482306	G/T	cg25741118	chr1:54482237	LDLRAD1	-0.22	-5.7	-0.33	3.23e-8	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
CESC	cis	rs57244997	0.725	rs7746052	chr6:162436267	G/A	cg17173639	chr6:162384350	PARK2	-0.5	-5.86	-0.34	1.4e-8	Mosquito bite size;
CESC	cis	rs10779751	0.734	rs1148485	chr1:11148759	G/A	cg08854313	chr1:11322531	MTOR	0.73	8.35	0.46	3.81e-15	Body mass index;
CESC	cis	rs7178909	0.902	rs28372736	chr15:90437858	T/C	cg19708238	chr15:90437601	AP3S2	0.43	6.19	0.36	2.25e-9	Common traits (Other);
CESC	cis	rs4713118	0.621	rs9368548	chr6:28034737	A/G	cg17949981	chr6:28129498	ZNF389	0.45	5.37	0.31	1.72e-7	Parkinson's disease;
CESC	cis	rs12477438	0.798	rs1580068	chr2:99649969	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.75	-10.87	-0.56	5.17e-23	Chronic sinus infection;
CESC	cis	rs1372520	0.577	rs2737021	chr4:90739992	T/A	cg15133208	chr4:90757351	SNCA	-0.4	-5.3	-0.31	2.43e-7	Neuroticism;
CESC	cis	rs12325245	0.536	rs8058781	chr16:58653838	G/A	cg05725404	chr16:58534157	NDRG4	-0.63	-5.32	-0.31	2.21e-7	Schizophrenia;
CESC	cis	rs7412746	0.658	rs72704682	chr1:150897677	A/T	cg17724175	chr1:150552817	MCL1	0.38	5.9	0.34	1.11e-8	Melanoma;
CESC	cis	rs3931020	0.548	rs17618340	chr1:75247617	G/A	cg21906852	chr1:75198582	TYW3;CRYZ	0.42	5.3	0.31	2.48e-7	Resistin levels;
CESC	cis	rs5758659	0.819	rs134871	chr22:42652716	A/G	cg15557168	chr22:42548783	NA	-0.36	-5.66	-0.33	3.92e-8	Cognitive function;
CESC	cis	rs67478160	0.643	rs12880821	chr14:104276049	C/T	cg08213375	chr14:104286397	PPP1R13B	0.52	9.81	0.52	1.42e-19	Schizophrenia;
CESC	cis	rs2836974	0.681	rs8128827	chr21:40710547	C/T	cg27266027	chr21:40555129	PSMG1	0.44	5.25	0.31	3.16e-7	Cognitive function;
CESC	cis	rs13191362	0.872	rs67712738	chr6:163245768	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.63	6.16	0.35	2.66e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs67478160	0.625	rs7141473	chr14:104316055	A/C	cg01849466	chr14:104193079	ZFYVE21	0.51	6.92	0.39	3.31e-11	Schizophrenia;
CESC	cis	rs7927771	0.965	rs3817335	chr11:47643891	T/A	cg18512352	chr11:47633146	NA	-0.6	-9.5	-0.5	1.32e-18	Subjective well-being;
CESC	trans	rs7837860	0.541	rs13248408	chr8:89285609	C/T	cg04391754	chr17:18022714	MYO15A	0.52	6.12	0.35	3.41e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs72781680	0.898	rs72786278	chr2:24063243	C/T	cg08917208	chr2:24149416	ATAD2B	0.93	8.48	0.46	1.57e-15	Lymphocyte counts;
CESC	cis	rs4563143	0.675	rs34113156	chr19:29270822	G/A	cg04546413	chr19:29218101	NA	0.56	7.91	0.44	6.84e-14	Methadone dose in opioid dependence;
CESC	cis	rs6088813	1.000	rs6142374	chr20:33985568	C/T	cg14752227	chr20:34000481	UQCC	-0.4	-5.08	-0.3	7.17e-7	Height;
CESC	cis	rs514406	0.798	rs504816	chr1:53307957	T/G	cg16325326	chr1:53192061	ZYG11B	0.73	11.05	0.56	1.33e-23	Monocyte count;
CESC	trans	rs7746199	0.736	rs34573979	chr6:27480526	C/T	cg01620082	chr3:125678407	NA	-0.78	-6.65	-0.38	1.71e-10	Gait speed in old age;Autism spectrum disorder or schizophrenia;
CESC	cis	rs2797160	0.651	rs1268093	chr6:126029235	C/T	cg05901451	chr6:126070800	HEY2	0.45	6.61	0.38	2.07e-10	Endometrial cancer;
CESC	cis	rs6032067	0.929	rs17424668	chr20:43809647	C/T	cg10761708	chr20:43804764	PI3	-0.53	-6.58	-0.37	2.53e-10	Blood protein levels;
CESC	cis	rs7429990	0.965	rs4858881	chr3:48123796	C/G	cg11946769	chr3:48343235	NME6	-0.44	-5.47	-0.32	1.02e-7	Educational attainment (years of education);
CESC	cis	rs2295499	0.933	rs9683585	chr4:2702804	C/G	cg08330972	chr4:2403930	ZFYVE28	-0.37	-6.15	-0.35	2.85e-9	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
CESC	cis	rs992157	0.767	rs2382822	chr2:219173327	T/C	cg00012203	chr2:219082015	ARPC2	-0.72	-9.33	-0.5	4.35e-18	Colorectal cancer;
CESC	cis	rs1005277	0.579	rs11011461	chr10:38431427	G/A	cg00409905	chr10:38381863	ZNF37A	-0.44	-5.87	-0.34	1.32e-8	Extrinsic epigenetic age acceleration;
CESC	cis	rs9322193	0.923	rs1934534	chr6:150033032	A/G	cg07701084	chr6:150067640	NUP43	0.47	6.62	0.38	1.97e-10	Lung cancer;
CESC	cis	rs11098499	0.954	rs10014845	chr4:120301077	T/G	cg24375607	chr4:120327624	NA	0.46	5.55	0.32	6.98e-8	Corneal astigmatism;
CESC	cis	rs4076764	0.535	rs4409627	chr1:163382050	A/G	cg24596788	chr1:163392923	NA	0.33	5.27	0.31	2.83e-7	Motion sickness;
CESC	cis	rs11098499	0.863	rs1552095	chr4:120460306	A/G	cg09307838	chr4:120376055	NA	0.94	12.51	0.61	1.52e-28	Corneal astigmatism;
CESC	cis	rs68170813	0.559	rs7981	chr7:106843133	G/C	cg02696742	chr7:106810147	HBP1	-0.53	-5.07	-0.3	7.63e-7	Coronary artery disease;
CESC	cis	rs6460942	0.687	rs74753576	chr7:12463926	G/A	cg06484146	chr7:12443880	VWDE	-0.75	-10.31	-0.54	3.55e-21	Coronary artery disease;
CESC	cis	rs8028182	0.525	rs9920028	chr15:75927717	G/A	cg20655648	chr15:75932815	IMP3	0.52	6.55	0.37	3.01e-10	Sudden cardiac arrest;
CESC	cis	rs34779708	0.931	rs17583009	chr10:35320915	T/C	cg04310649	chr10:35416472	CREM	-0.48	-5.8	-0.34	1.85e-8	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs11098499	0.863	rs11736416	chr4:120431661	C/T	cg24375607	chr4:120327624	NA	0.44	5.27	0.31	2.85e-7	Corneal astigmatism;
CESC	cis	rs9457247	0.935	rs9348211	chr6:167375173	G/C	cg23791538	chr6:167370224	RNASET2	0.58	8.26	0.45	7.1e-15	Crohn's disease;
CESC	cis	rs751728	0.544	rs2281820	chr6:33768897	A/G	cg25922239	chr6:33757077	LEMD2	0.44	5.83	0.34	1.57e-8	Crohn's disease;
CESC	trans	rs3749237	0.964	rs35210174	chr3:49812606	C/T	cg21659725	chr3:3221576	CRBN	0.53	6.23	0.36	1.84e-9	Resting heart rate;
CESC	cis	rs3857067	0.933	rs10023582	chr4:95035811	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.52	-7.81	-0.43	1.33e-13	QT interval;
CESC	cis	rs889312	0.500	rs33328	chr5:56143419	T/C	cg14703610	chr5:56206110	C5orf35	0.48	6.31	0.36	1.19e-9	Breast cancer;Breast cancer (early onset);
CESC	cis	rs1577917	0.771	rs7452605	chr6:86240951	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.55	7.67	0.43	3.2e-13	Response to antipsychotic treatment;
CESC	cis	rs6089829	0.926	rs7273917	chr20:61665975	G/A	cg16240275	chr20:61666158	NCRNA00029	0.5	8.93	0.48	7.38e-17	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs1348850	0.597	rs13014512	chr2:178470851	T/A	cg23306229	chr2:178417860	TTC30B	0.6	6.07	0.35	4.33e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs10883723	0.668	rs12414407	chr10:104387019	A/G	cg22532475	chr10:104410764	TRIM8	0.34	5.82	0.34	1.7e-8	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs6460942	0.659	rs28366613	chr7:12512167	C/T	cg06484146	chr7:12443880	VWDE	-0.67	-7.12	-0.4	1e-11	Coronary artery disease;
CESC	cis	rs9308433	0.529	rs4655246	chr1:214502898	G/C	cg06198575	chr1:214491504	SMYD2	0.47	5.49	0.32	9.23e-8	IgG glycosylation;
CESC	cis	rs367615	0.704	rs7704824	chr5:108850278	A/G	cg17395555	chr5:108820864	NA	0.52	8.79	0.48	1.96e-16	Colorectal cancer (SNP x SNP interaction);
CESC	trans	rs561341	1.000	rs113676348	chr17:30244327	A/G	cg20587970	chr11:113659929	NA	-1.11	-13.7	-0.64	1.19e-32	Hip circumference adjusted for BMI;
CESC	cis	rs2576037	0.583	rs545344	chr18:44367079	A/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.35	5.65	0.33	4.04e-8	Personality dimensions;
CESC	cis	rs9467773	1.000	rs9295695	chr6:26528250	C/T	cg11502198	chr6:26597334	ABT1	-0.37	-5.3	-0.31	2.48e-7	Intelligence (multi-trait analysis);
CESC	cis	rs798554	0.757	rs1713919	chr7:2864706	C/A	cg19346786	chr7:2764209	NA	-0.49	-7.07	-0.4	1.35e-11	Height;
CESC	cis	rs1163251	0.756	rs539799	chr1:120208472	C/T	cg19096424	chr1:120255104	PHGDH	0.43	5.59	0.32	5.58e-8	Blood metabolite levels;
CESC	cis	rs425277	0.606	rs2460001	chr1:2111030	T/C	cg24578937	chr1:2090814	PRKCZ	0.33	5.82	0.34	1.66e-8	Height;
CESC	cis	rs1018836	0.923	rs13277387	chr8:91633713	C/G	cg16814680	chr8:91681699	NA	-0.72	-10.41	-0.54	1.68e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg18965055	chr4:174291932	SAP30	-0.42	-6.87	-0.39	4.68e-11	Gambling;
CESC	cis	rs9311474	0.713	rs352170	chr3:52236077	A/G	cg18099408	chr3:52552593	STAB1	-0.32	-5.43	-0.32	1.28e-7	Electroencephalogram traits;
CESC	cis	rs875971	1.000	rs709595	chr7:65817333	G/C	cg10691866	chr7:65817282	TPST1	-0.33	-5.41	-0.32	1.44e-7	Aortic root size;
CESC	trans	rs116095464	0.510	rs10057501	chr5:239545	T/C	cg00938859	chr5:1591904	SDHAP3	0.64	7.02	0.4	1.84e-11	Breast cancer;
CESC	cis	rs2295499	0.643	rs2298965	chr4:2699655	C/G	cg27239842	chr4:2403781	ZFYVE28	0.3	5.08	0.3	7.11e-7	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
CESC	cis	rs12122100	0.526	rs12122534	chr1:146504399	A/G	cg02487331	chr1:146550467	NA	0.37	5.69	0.33	3.44e-8	HIV-1 control;
CESC	cis	rs4862750	0.872	rs6852907	chr4:187897094	A/C	cg10295955	chr4:187884368	NA	-1.08	-22.82	-0.81	1.67e-64	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24905370	chr5:74063138	NSA2;GFM2	-0.61	-7.13	-0.4	9.35e-12	Gut microbiome composition (summer);
CESC	cis	rs9287719	0.753	rs2018512	chr2:10759279	T/G	cg02196655	chr2:10830764	NOL10	-0.36	-5.59	-0.32	5.58e-8	Prostate cancer;
CESC	cis	rs12701220	0.655	rs6463317	chr7:1159243	G/A	cg04025307	chr7:1156635	C7orf50	0.47	5.75	0.33	2.51e-8	Bronchopulmonary dysplasia;
CESC	cis	rs35110281	0.591	rs86139	chr21:44932802	G/A	cg01579765	chr21:45077557	HSF2BP	-0.49	-8.29	-0.45	5.59e-15	Mean corpuscular volume;
CESC	cis	rs7659604	0.605	rs2071486	chr4:122740162	C/T	cg06713675	chr4:122721982	EXOSC9	-0.43	-6.09	-0.35	4.03e-9	Type 2 diabetes;
CESC	cis	rs5753618	0.539	rs2106294	chr22:31645759	C/T	cg02404636	chr22:31891804	SFI1	-0.4	-5.27	-0.31	2.87e-7	Colorectal cancer;
CESC	cis	rs11168618	0.567	rs7314569	chr12:48816981	G/T	cg24011408	chr12:48396354	COL2A1	0.36	5.69	0.33	3.33e-8	Adiponectin levels;
CESC	cis	rs875971	1.000	rs4718307	chr7:65610988	A/G	cg18876405	chr7:65276391	NA	-0.51	-6.96	-0.39	2.72e-11	Aortic root size;
CESC	cis	rs9291683	0.507	rs3775940	chr4:10025163	A/T	cg11266682	chr4:10021025	SLC2A9	0.66	13.19	0.63	7.23e-31	Bone mineral density;
CESC	trans	rs7690543	0.681	rs6552071	chr4:68002397	C/T	cg05505961	chr17:66375071	ARSG	-0.52	-6.09	-0.35	3.87e-9	Glucose homeostasis traits;
CESC	cis	rs4665809	0.590	rs3792007	chr2:26497541	C/T	cg22920501	chr2:26401640	FAM59B	0.89	9.91	0.52	6.61e-20	Gut microbiome composition (summer);
CESC	cis	rs10256972	0.786	rs3735686	chr7:1062527	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.49	-7.0	-0.4	2.08e-11	Longevity;Endometriosis;
CESC	cis	rs2404602	1.000	rs2404740	chr15:76852143	C/T	cg22467129	chr15:76604101	ETFA	-0.35	-5.25	-0.31	3.16e-7	Blood metabolite levels;
CESC	cis	rs4664304	0.789	rs2063439	chr2:160800101	C/A	cg03641300	chr2:160917029	PLA2R1	-0.41	-5.46	-0.32	1.1e-7	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs7264396	0.790	rs2425083	chr20:34300456	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.62	7.48	0.42	1.11e-12	Total cholesterol levels;
CESC	cis	rs1005277	0.579	rs2800485	chr10:38542588	G/A	cg00409905	chr10:38381863	ZNF37A	-0.5	-6.7	-0.38	1.27e-10	Extrinsic epigenetic age acceleration;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08740862	chr11:62314417	AHNAK	0.6	6.76	0.38	8.67e-11	Gut microbiome composition (summer);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg17817067	chr5:14713179	ANKH	0.45	6.15	0.35	2.81e-9	Fibrinogen levels;
CESC	cis	rs769267	0.896	rs7253807	chr19:19631444	A/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	7.47	0.42	1.2e-12	Tonsillectomy;
CESC	cis	rs7089973	0.604	rs1359079	chr10:116582502	A/G	cg03647239	chr10:116582469	FAM160B1	0.42	5.13	0.3	5.48e-7	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06629088	chr16:87984646	BANP	0.56	6.48	0.37	4.32e-10	Gut microbiome composition (summer);
CESC	cis	rs1707322	0.963	rs4508055	chr1:46257731	A/T	cg06784218	chr1:46089804	CCDC17	0.37	6.37	0.36	8.49e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7927771	0.929	rs12787646	chr11:47669665	T/C	cg05585544	chr11:47624801	NA	-0.47	-7.36	-0.41	2.36e-12	Subjective well-being;
CESC	cis	rs4969178	0.965	rs12451715	chr17:76397334	A/C	cg05887092	chr17:76393375	PGS1	0.58	9.22	0.49	9.9e-18	HDL cholesterol levels;
CESC	cis	rs4843747	0.671	rs28679286	chr16:88106307	C/T	cg06915872	chr16:87998081	BANP	0.44	5.24	0.31	3.36e-7	Menopause (age at onset);
CESC	trans	rs2235573	0.527	rs139886	chr22:38371328	C/T	cg19894588	chr14:64061835	NA	0.58	7.64	0.42	3.94e-13	Glioblastoma;Glioma;
CESC	cis	rs10911232	0.507	rs10797832	chr1:183044034	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.85	13.23	0.63	5.11e-31	Hypertriglyceridemia;
CESC	cis	rs9322193	0.962	rs9322219	chr6:150103399	C/T	cg05861140	chr6:150128134	PCMT1	-0.35	-5.07	-0.3	7.45e-7	Lung cancer;
CESC	cis	rs3785574	1.000	rs7223257	chr17:61787684	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.57	7.13	0.4	9.54e-12	Height;
CESC	cis	rs1670533	1.000	rs6599278	chr4:1058798	C/T	cg04106633	chr4:1044584	NA	0.42	5.43	0.32	1.3e-7	Recombination rate (females);
CESC	cis	rs10751667	0.666	rs11246357	chr11:963980	A/C	cg20946044	chr11:1010712	AP2A2	-0.39	-5.36	-0.31	1.82e-7	Alzheimer's disease (late onset);
CESC	cis	rs1510510	0.932	rs2136772	chr2:239492898	C/T	cg14780600	chr2:240281345	HDAC4	0.43	5.26	0.31	2.93e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09311964	chr17:40831349	NA	-0.58	-6.48	-0.37	4.41e-10	Gut microbiome composition (summer);
CESC	cis	rs34375054	0.738	rs10846834	chr12:125625570	A/G	cg21269045	chr12:125625041	AACS	-0.38	-5.88	-0.34	1.25e-8	Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs7666738	0.830	rs28456179	chr4:98991439	A/G	cg17366294	chr4:99064904	C4orf37	0.6	8.61	0.47	6.85e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs34172651	0.517	rs34172679	chr16:24840381	C/T	cg00339695	chr16:24857497	SLC5A11	0.54	6.74	0.38	9.94e-11	Intelligence (multi-trait analysis);
CESC	cis	rs6545883	0.929	rs2600663	chr2:61540687	A/G	cg15711740	chr2:61764176	XPO1	0.43	5.39	0.31	1.59e-7	Tuberculosis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03690763	chr11:133734501	NA	-0.45	-6.1	-0.35	3.82e-9	Gut microbiome composition (summer);
CESC	cis	rs722599	0.599	rs8003660	chr14:75227098	T/C	cg11812906	chr14:75593930	NEK9	0.45	5.49	0.32	9.6e-8	IgG glycosylation;
CESC	cis	rs2019216	0.542	rs1850564	chr17:21911794	T/C	cg22648282	chr17:21454238	C17orf51	-0.43	-5.61	-0.33	5.05e-8	Pelvic organ prolapse;
CESC	cis	rs13106227	0.550	rs11723732	chr4:77370557	A/G	cg20311846	chr4:77356250	SHROOM3	-0.31	-5.8	-0.34	1.87e-8	Eosinophilic esophagitis (pediatric);
CESC	cis	rs13191362	1.000	rs67042566	chr6:163006541	A/T	cg06582575	chr6:163149167	PACRG;PARK2	0.82	8.29	0.45	5.87e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	trans	rs208520	0.690	rs10455594	chr6:66737894	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.95	12.26	0.6	1.09e-27	Exhaled nitric oxide output;
CESC	cis	rs941408	0.515	rs12610096	chr19:2778129	C/T	cg06609049	chr19:2785107	THOP1	0.96	14.82	0.67	1.28e-36	Total cholesterol levels;
CESC	cis	rs2832077	0.527	rs2776210	chr21:30268558	A/G	cg08807101	chr21:30365312	RNF160	0.66	8.37	0.46	3.26e-15	Cognitive test performance;
CESC	cis	rs1670533	1.000	rs13107058	chr4:1054379	G/A	cg04106633	chr4:1044584	NA	0.41	5.23	0.31	3.36e-7	Recombination rate (females);
CESC	cis	rs7937682	0.924	rs499750	chr11:111513645	T/G	cg09085632	chr11:111637200	PPP2R1B	-0.99	-16.07	-0.7	5.11e-41	Primary sclerosing cholangitis;
CESC	cis	rs9837602	0.576	rs506186	chr3:99442753	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.44	-5.83	-0.34	1.58e-8	Breast cancer;
CESC	cis	rs8180040	0.620	rs6768722	chr3:47079112	G/A	cg27129171	chr3:47204927	SETD2	0.66	9.82	0.52	1.32e-19	Colorectal cancer;
CESC	trans	rs9858542	0.953	rs4625	chr3:49572140	A/G	cg21659725	chr3:3221576	CRBN	-0.52	-6.48	-0.37	4.43e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs400736	0.665	rs225104	chr1:8119903	A/G	cg25007680	chr1:8021821	PARK7	0.61	8.5	0.46	1.44e-15	Response to antidepressants and depression;
CESC	cis	rs1862618	0.529	rs978406	chr5:56259808	A/T	cg20203395	chr5:56204925	C5orf35	0.43	5.12	0.3	5.82e-7	Initial pursuit acceleration;
CESC	cis	rs3806843	0.966	rs2563267	chr5:140136913	C/T	cg26395211	chr5:140044315	WDR55	0.44	5.59	0.32	5.7e-8	Depressive symptoms (multi-trait analysis);
CESC	cis	rs34172651	0.517	rs8059004	chr16:24837905	G/A	cg00339695	chr16:24857497	SLC5A11	0.51	6.68	0.38	1.42e-10	Intelligence (multi-trait analysis);
CESC	cis	rs9322193	0.884	rs933055	chr6:150130837	A/G	cg07701084	chr6:150067640	NUP43	0.43	5.8	0.34	1.88e-8	Lung cancer;
CESC	cis	rs698833	0.819	rs2340809	chr2:44536249	A/G	cg04920474	chr2:44395004	PPM1B	0.37	5.19	0.3	4.24e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs12765878	1.000	rs2273698	chr10:105649158	G/A	cg11005552	chr10:105648138	OBFC1	0.35	5.06	0.3	7.92e-7	Coronary artery disease;
CESC	cis	rs2276314	0.857	rs59649576	chr18:33616075	G/T	cg05985134	chr18:33552581	C18orf21	0.63	7.59	0.42	5.58e-13	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs8060686	0.641	rs55682260	chr16:68057880	G/A	cg26727032	chr16:67993705	SLC12A4	-0.54	-6.13	-0.35	3.24e-9	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs6502050	0.842	rs62079996	chr17:80076862	A/G	cg11859384	chr17:80120422	CCDC57	0.4	5.5	0.32	8.88e-8	Life satisfaction;
CESC	cis	rs172166	0.637	rs1225595	chr6:28151340	A/T	cg17221315	chr6:27791827	HIST1H4J	0.44	5.78	0.33	2.06e-8	Cardiac Troponin-T levels;
CESC	cis	rs1832871	0.672	rs11751081	chr6:158761505	G/A	cg07165851	chr6:158734300	TULP4	0.58	6.2	0.36	2.1e-9	Height;
CESC	cis	rs7666738	0.791	rs34152299	chr4:98929862	G/C	cg03467027	chr4:99064603	C4orf37	0.46	5.6	0.33	5.39e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4713118	0.629	rs203890	chr6:28022248	T/C	cg23161317	chr6:28129485	ZNF389	0.49	6.18	0.35	2.42e-9	Parkinson's disease;
CESC	cis	rs13108904	0.901	rs4974594	chr4:1300480	C/T	cg16405210	chr4:1374714	KIAA1530	0.42	5.04	0.3	8.45e-7	Obesity-related traits;
CESC	cis	rs2439831	0.867	rs3809481	chr15:43662829	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.85	11.31	0.57	1.8e-24	Lung cancer in ever smokers;
CESC	cis	rs977987	0.902	rs34539062	chr16:75493279	C/A	cg03315344	chr16:75512273	CHST6	0.54	7.9	0.44	7.62e-14	Dupuytren's disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg07697635	chr5:77656183	SCAMP1	-0.49	-6.47	-0.37	4.81e-10	Fibrinogen levels;
CESC	cis	rs67311347	1.000	rs9822644	chr3:40426609	G/A	cg09455208	chr3:40491958	NA	0.49	7.91	0.44	6.79e-14	Renal cell carcinoma;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg15734422	chr10:121356865	TIAL1	-0.47	-6.52	-0.37	3.57e-10	Fibrinogen levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08740477	chr5:108084642	FER	0.57	6.31	0.36	1.18e-9	Gut microbiome composition (summer);
CESC	trans	rs11039798	1.000	rs7102865	chr11:48458361	A/C	cg15704280	chr7:45808275	SEPT13	0.69	6.58	0.37	2.56e-10	Axial length;
CESC	cis	rs1609391	0.561	rs9289523	chr3:136635589	C/G	cg15507776	chr3:136538369	TMEM22	0.83	12.21	0.6	1.69e-27	Neuroticism;
CESC	cis	rs7851660	0.874	rs1443436	chr9:100631298	T/A	cg13688889	chr9:100608707	NA	-0.6	-8.55	-0.47	9.84e-16	Strep throat;
CESC	cis	rs1799949	0.965	rs11650913	chr17:41331597	T/C	cg23758822	chr17:41437982	NA	1.03	15.5	0.69	5.3e-39	Menopause (age at onset);
CESC	cis	rs116095464	1.000	rs6555160	chr5:311669	A/G	cg10591111	chr5:226296	SDHA	0.55	5.15	0.3	5.17e-7	Breast cancer;
CESC	cis	rs736408	0.527	rs2577831	chr3:52628056	C/A	cg18337363	chr3:52569053	NT5DC2	0.33	6.47	0.37	4.7e-10	Bipolar disorder;
CESC	cis	rs10078	0.571	rs2561664	chr5:459793	T/C	cg08916839	chr5:415575	AHRR	0.58	6.73	0.38	1.06e-10	Fat distribution (HIV);
CESC	cis	rs7084402	0.935	rs10763558	chr10:60341934	A/C	cg07615347	chr10:60278583	BICC1	-0.55	-8.32	-0.46	4.76e-15	Refractive error;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg22614265	chr7:100425456	EPHB4	0.5	6.43	0.37	5.93e-10	Gut microbiota (bacterial taxa);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg07798137	chr1:17332259	ATP13A2	0.44	6.25	0.36	1.59e-9	Fibrinogen levels;
CESC	cis	rs11249608	0.789	rs7704963	chr5:178436854	A/G	cg10208897	chr5:178548229	ADAMTS2	0.35	5.22	0.31	3.63e-7	Pubertal anthropometrics;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06143244	chr16:22435202	RRN3P3	-0.64	-7.13	-0.4	9.31e-12	Gut microbiome composition (summer);
CESC	cis	rs7267979	1.000	rs6050555	chr20:25328543	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.86	-17.26	-0.73	3.06e-45	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs9915657	0.870	rs11077595	chr17:70130030	C/T	cg09344028	chr17:70110421	NA	0.35	6.17	0.35	2.53e-9	Thyroid hormone levels;
CESC	trans	rs931812	0.825	rs34153562	chr8:101893441	T/C	cg20993868	chr7:22813445	NA	0.55	7.52	0.42	8.52e-13	Attention deficit hyperactivity disorder and conduct disorder;
CESC	cis	rs875971	1.000	rs6970030	chr7:65968679	T/C	cg11764359	chr7:65958608	NA	0.96	15.25	0.68	3.95e-38	Aortic root size;
CESC	cis	rs3768617	0.510	rs12091137	chr1:183075732	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.86	14.06	0.65	6.34e-34	Fuchs's corneal dystrophy;
CESC	cis	rs3126085	1.000	rs3126097	chr1:152311026	G/A	cg03465714	chr1:152285911	FLG	0.41	5.2	0.3	4.06e-7	Atopic dermatitis;
CESC	cis	rs7264396	0.635	rs6060703	chr20:34529906	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.57	6.93	0.39	3.24e-11	Total cholesterol levels;
CESC	trans	rs2727020	0.734	rs1164663	chr11:49294723	A/T	cg15704280	chr7:45808275	SEPT13	0.79	10.49	0.54	9.39e-22	Coronary artery disease;
CESC	cis	rs2576037	0.583	rs2156049	chr18:44455717	G/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.34	5.42	0.32	1.34e-7	Personality dimensions;
CESC	cis	rs2979489	0.945	rs2979472	chr8:30291704	G/C	cg26383811	chr8:30366931	RBPMS	0.83	9.67	0.51	3.92e-19	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CESC	cis	rs7618915	0.547	rs12487591	chr3:52642936	A/T	cg18404041	chr3:52824283	ITIH1	-0.44	-7.04	-0.4	1.65e-11	Bipolar disorder;
CESC	cis	rs6963495	0.818	rs117907809	chr7:105168472	C/A	cg02135003	chr7:105160482	PUS7	-0.46	-5.44	-0.32	1.19e-7	Bipolar disorder (body mass index interaction);
CESC	cis	rs17826219	0.500	rs2874724	chr17:29072433	T/C	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.1e-10	Body mass index;
CESC	cis	rs17376456	1.000	rs12188453	chr5:93560807	G/T	cg25358565	chr5:93447407	FAM172A	-1.13	-10.51	-0.54	8.19e-22	Diabetic retinopathy;
CESC	trans	rs1549733	0.577	rs16857849	chr2:218418133	C/T	cg23408253	chr19:17438755	ANO8	-0.46	-6.01	-0.35	6.04e-9	Optic disc area;
CESC	cis	rs7771547	0.573	rs10440841	chr6:36399086	G/A	cg07856975	chr6:36356162	ETV7	-0.36	-5.38	-0.31	1.67e-7	Platelet distribution width;
CESC	cis	rs4819052	0.851	rs9974891	chr21:46680767	T/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.85	12.57	0.61	9.43e-29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs8073060	0.544	rs225283	chr17:33934912	A/G	cg19694781	chr19:47549865	TMEM160	-0.73	-7.03	-0.4	1.79e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	cis	rs9911578	0.935	rs9911753	chr17:56983174	G/A	cg12560992	chr17:57184187	TRIM37	0.81	12.55	0.61	1.15e-28	Intelligence (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26057283	chr7:73082469	VPS37D	0.58	6.89	0.39	3.96e-11	Gut microbiome composition (summer);
CESC	cis	rs17376456	0.877	rs66696214	chr5:93424533	G/A	cg25358565	chr5:93447407	FAM172A	1.18	11.22	0.57	3.75e-24	Diabetic retinopathy;
CESC	cis	rs34779708	0.766	rs7897088	chr10:35551567	G/T	cg04310649	chr10:35416472	CREM	-0.48	-5.38	-0.31	1.62e-7	Inflammatory bowel disease;Crohn's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06100147	chr7:143059260	FAM131B	0.54	6.07	0.35	4.37e-9	Gut microbiome composition (summer);
CESC	cis	rs56104184	0.723	rs116909499	chr19:49407733	C/T	cg15549821	chr19:49342101	PLEKHA4	-0.53	-5.47	-0.32	1.06e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	cis	rs2576037	0.583	rs641366	chr18:44430326	C/T	cg19077165	chr18:44547161	KATNAL2	-0.6	-9.21	-0.49	1.02e-17	Personality dimensions;
CESC	cis	rs11203032	0.831	rs9651495	chr10:90932381	G/A	cg16672925	chr10:90967113	CH25H	0.68	6.42	0.37	6.19e-10	Heart failure;
CESC	trans	rs61931739	0.500	rs7489130	chr12:34539674	C/A	cg13010199	chr12:38710504	ALG10B	0.51	6.58	0.37	2.47e-10	Morning vs. evening chronotype;
CESC	cis	rs7412746	0.658	rs72704652	chr1:150819470	A/G	cg17724175	chr1:150552817	MCL1	0.41	6.23	0.36	1.82e-9	Melanoma;
CESC	cis	rs4900109	0.590	rs4904870	chr14:92787008	A/G	cg06884470	chr14:92785924	NA	-0.29	-5.2	-0.3	4.04e-7	Iris characteristics;
CESC	cis	rs711830	1.000	rs2857540	chr2:177026698	G/T	cg13092806	chr2:177043255	NA	0.84	10.91	0.56	3.92e-23	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
CESC	cis	rs7044106	0.762	rs1867254	chr9:123429078	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.33	5.1	0.3	6.52e-7	Hip circumference adjusted for BMI;
CESC	cis	rs1005277	0.579	rs11011461	chr10:38431427	G/A	cg25427524	chr10:38739819	LOC399744	-0.66	-9.62	-0.51	5.39e-19	Extrinsic epigenetic age acceleration;
CESC	cis	rs1475911	1.000	rs2839465	chr21:43511232	C/T	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.4	-5.81	-0.34	1.78e-8	IgG glycosylation;
CESC	cis	rs938554	0.784	rs11726102	chr4:9951664	T/C	cg11266682	chr4:10021025	SLC2A9	-0.4	-5.42	-0.32	1.36e-7	Blood metabolite levels;
CESC	cis	rs2742234	0.541	rs12220534	chr10:43734306	G/T	cg15436174	chr10:43711423	RASGEF1A	-0.44	-5.35	-0.31	1.86e-7	Hirschsprung disease;
CESC	cis	rs6429082	0.634	rs3856245	chr1:235571428	G/A	cg26050004	chr1:235667680	B3GALNT2	-0.54	-6.77	-0.38	8.47e-11	Adiposity;
CESC	cis	rs2243480	1.000	rs316317	chr7:65613637	G/T	cg12463550	chr7:65579703	CRCP	0.75	5.84	0.34	1.56e-8	Diabetic kidney disease;
CESC	cis	rs2235544	0.639	rs6672989	chr1:54474472	T/C	cg25741118	chr1:54482237	LDLRAD1	-0.27	-6.57	-0.37	2.72e-10	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
CESC	cis	rs1552244	1.000	rs12152512	chr3:10143770	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.86	-12.2	-0.6	1.78e-27	Alzheimer's disease;
CESC	cis	rs4077515	0.967	rs11145874	chr9:139290011	G/A	cg14169450	chr9:139327907	INPP5E	0.39	5.59	0.32	5.78e-8	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs4728302	0.838	rs10224828	chr7:133591071	G/A	cg10665199	chr7:133106180	EXOC4	0.39	5.39	0.31	1.55e-7	Intelligence;Intelligence (multi-trait analysis);
CESC	cis	rs2952156	0.920	rs12940986	chr17:37836581	A/G	cg07936489	chr17:37558343	FBXL20	0.62	8.32	0.46	4.72e-15	Asthma;
CESC	cis	rs1799949	0.929	rs12937015	chr17:41307473	A/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.65	9.04	0.49	3.4e-17	Menopause (age at onset);
CESC	cis	rs1552244	0.882	rs66559400	chr3:10012551	G/A	cg00166722	chr3:10149974	C3orf24	0.46	5.67	0.33	3.8e-8	Alzheimer's disease;
CESC	cis	rs854765	0.647	rs7406744	chr17:17981938	C/G	cg04398451	chr17:18023971	MYO15A	-0.76	-11.22	-0.57	3.76e-24	Total body bone mineral density;
CESC	cis	rs7264396	0.790	rs6060565	chr20:34285442	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.87	-11.89	-0.59	2.02e-26	Total cholesterol levels;
CESC	trans	rs650950	0.528	rs646660	chr11:35528452	C/T	cg22858966	chr12:89919202	WDR51B;GALNT4	0.46	6.07	0.35	4.47e-9	Bronchopulmonary dysplasia;
CESC	cis	rs2629540	0.766	rs10794177	chr10:126407409	G/C	cg08799069	chr10:126477246	METTL10	0.59	7.49	0.42	1.02e-12	Cocaine dependence;
CESC	cis	rs9902453	0.904	rs4375718	chr17:28363642	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.74	-9.98	-0.52	4.18e-20	Coffee consumption (cups per day);
CESC	cis	rs2070677	1.000	rs2515641	chr10:135351362	T/C	cg20169779	chr10:135381914	SYCE1	0.65	7.69	0.43	2.94e-13	Gout;
CESC	cis	rs67478160	0.584	rs2295148	chr14:104195610	T/C	cg08213375	chr14:104286397	PPP1R13B	0.38	6.93	0.39	3.18e-11	Schizophrenia;
CESC	cis	rs11168351	0.864	rs10875743	chr12:48498413	C/T	cg04545296	chr12:48745243	ZNF641	-0.33	-5.64	-0.33	4.3e-8	Bipolar disorder and schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22788606	chr1:167424194	CD247	0.63	7.23	0.41	5.3e-12	Gut microbiome composition (summer);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg00630453	chr20:2821369	FAM113A;VPS16	-0.42	-6.05	-0.35	4.94e-9	Gambling;
CESC	cis	rs9911578	0.967	rs4598970	chr17:57076893	T/A	cg05425664	chr17:57184151	TRIM37	0.52	7.22	0.41	5.42e-12	Intelligence (multi-trait analysis);
CESC	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg19318889	chr4:1322082	MAEA	0.55	6.87	0.39	4.54e-11	Longevity;
CESC	cis	rs7560272	0.538	rs2012574	chr2:73928366	G/C	cg20560298	chr2:73613845	ALMS1	0.46	6.2	0.36	2.21e-9	Schizophrenia;
CESC	cis	rs514406	0.607	rs1930305	chr1:53195481	G/T	cg08736216	chr1:53307985	ZYG11A	0.4	6.35	0.36	9.55e-10	Monocyte count;
CESC	cis	rs2898681	0.874	rs59649036	chr4:53741175	T/C	cg00791764	chr4:53727839	RASL11B	0.36	5.25	0.31	3.12e-7	Optic nerve measurement (cup area);
CESC	cis	rs3820068	0.529	rs79570154	chr1:15990912	T/C	cg17385448	chr1:15911702	AGMAT	0.45	7.41	0.41	1.65e-12	Systolic blood pressure;
CESC	cis	rs61931739	0.500	rs11053269	chr12:34545307	A/G	cg06521331	chr12:34319734	NA	-0.36	-5.03	-0.3	9.01e-7	Morning vs. evening chronotype;
CESC	cis	rs116095464	0.558	rs10080225	chr5:232175	A/G	cg10591111	chr5:226296	SDHA	-0.53	-6.37	-0.36	8.13e-10	Breast cancer;
CESC	cis	rs28647808	0.618	rs7025970	chr9:136267173	G/A	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.82	5.46	0.32	1.11e-7	Blood protein levels;
CESC	cis	rs3096299	0.642	rs12934829	chr16:89523349	T/A	cg00750074	chr16:89608354	SPG7	-0.43	-6.18	-0.35	2.42e-9	Multiple myeloma (IgH translocation);
CESC	cis	rs887829	0.569	rs4663965	chr2:234650604	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.58	-7.68	-0.43	3.03e-13	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CESC	cis	rs4727963	0.846	rs1357946	chr7:122741080	G/T	cg03640110	chr7:122635026	TAS2R16	-0.36	-5.42	-0.32	1.32e-7	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
CESC	cis	rs6460942	1.000	rs62448562	chr7:12398785	T/C	cg06484146	chr7:12443880	VWDE	-0.81	-8.88	-0.48	1.05e-16	Coronary artery disease;
CESC	cis	rs67311347	1.000	rs4973878	chr3:40407565	C/T	cg24209194	chr3:40518798	ZNF619	0.46	6.06	0.35	4.69e-9	Renal cell carcinoma;
CESC	cis	rs763121	0.925	rs1043312	chr22:39131727	T/G	cg06544989	chr22:39130855	UNC84B	0.46	8.46	0.46	1.83e-15	Menopause (age at onset);
CESC	cis	rs2733201	1.000	rs12591537	chr15:44338263	T/A	cg27015174	chr15:43622946	ADAL;LCMT2	-0.65	-6.07	-0.35	4.52e-9	Lipoprotein phospholipase A2 activity in cardiovascular disease;
CESC	trans	rs4927850	0.723	rs7630825	chr3:195753740	T/C	cg16724585	chr3:197361211	NA	-0.57	-7.36	-0.41	2.33e-12	Pancreatic cancer;
CESC	cis	rs1008375	0.932	rs4235390	chr4:17696378	G/T	cg04450456	chr4:17643702	FAM184B	0.36	5.16	0.3	4.93e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs1348850	0.634	rs2293471	chr2:178487729	T/G	cg22681709	chr2:178499509	PDE11A	-0.48	-6.44	-0.37	5.58e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs7937682	0.883	rs1612013	chr11:111456293	A/G	cg22437258	chr11:111473054	SIK2	0.71	9.1	0.49	2.27e-17	Primary sclerosing cholangitis;
CESC	cis	rs2880765	0.835	rs7164106	chr15:86032590	T/C	cg19183879	chr15:85880815	NA	-0.25	-5.18	-0.3	4.49e-7	Coronary artery disease;
CESC	cis	rs10899021	1.000	rs11236193	chr11:74368307	T/C	cg25880958	chr11:74394337	NA	-0.75	-7.16	-0.4	7.74e-12	Response to metformin (IC50);
CESC	cis	rs9916302	0.904	rs8066704	chr17:37477218	C/T	cg07936489	chr17:37558343	FBXL20	0.8	11.43	0.57	7.13e-25	Glomerular filtration rate (creatinine);
CESC	cis	rs853679	0.517	rs11552219	chr6:28126834	C/T	cg19592336	chr6:28129416	ZNF389	0.61	8.03	0.44	3.13e-14	Depression;
CESC	cis	rs854765	0.647	rs854790	chr17:18028318	C/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.59	7.98	0.44	4.4e-14	Total body bone mineral density;
CESC	cis	rs643506	0.874	rs673679	chr11:111686800	C/T	cg09085632	chr11:111637200	PPP2R1B	0.41	5.37	0.31	1.73e-7	Breast cancer;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg06564473	chr11:601660	PHRF1	-0.43	-6.46	-0.37	4.92e-10	Gut microbiota (bacterial taxa);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20594226	chr2:87035716	CD8A	0.55	6.14	0.35	3.03e-9	Gut microbiome composition (summer);
CESC	cis	rs644799	0.710	rs3017756	chr11:95537358	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.77	10.82	0.55	8.02e-23	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs9399401	0.634	rs984932	chr6:142803037	C/T	cg04461802	chr6:142623433	GPR126	0.36	5.62	0.33	4.84e-8	Chronic obstructive pulmonary disease;
CESC	cis	rs12325245	0.536	rs12931124	chr16:58620063	G/A	cg02549819	chr16:58548995	SETD6	0.94	6.09	0.35	3.94e-9	Schizophrenia;
CESC	cis	rs7830933	0.955	rs57220043	chr8:23602763	A/T	cg04349084	chr8:23602677	NA	0.43	5.36	0.31	1.8e-7	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI in non-smokers;
CESC	cis	rs10504229	1.000	rs55787104	chr8:58178519	C/T	cg05313129	chr8:58192883	C8orf71	-0.55	-6.35	-0.36	9.17e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs2033711	0.840	rs4801590	chr19:58961813	G/C	cg00825309	chr19:58991885	ZNF446	-0.55	-8.04	-0.44	2.95e-14	Uric acid clearance;
CESC	cis	rs1881797	0.932	rs2387038	chr1:247674919	G/A	cg11166453	chr1:247681781	NA	0.45	5.61	0.33	4.99e-8	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs6754311	0.550	rs1438307	chr2:136499166	A/C	cg15123519	chr2:136567270	LCT	-0.29	-5.1	-0.3	6.45e-7	Mosquito bite size;
CESC	cis	rs7666738	0.830	rs13138920	chr4:99020786	A/G	cg05340658	chr4:99064831	C4orf37	0.82	12.99	0.62	3.34e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3015497	0.603	rs3015449	chr14:51078076	A/C	cg26011998	chr14:51135199	SAV1	-0.48	-5.43	-0.32	1.25e-7	Mean platelet volume;
CESC	cis	rs2635047	0.638	rs2668760	chr18:44682891	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.42	5.7	0.33	3.21e-8	Educational attainment;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg15540553	chr11:64018643	PLCB3	-0.46	-6.05	-0.35	4.87e-9	Ulcerative colitis;
CESC	cis	rs4319547	0.661	rs7398014	chr12:122943980	T/C	cg23029597	chr12:123009494	RSRC2	-0.48	-5.22	-0.31	3.53e-7	Body mass index;
CESC	cis	rs10788309	0.506	rs11599263	chr10:85824118	A/G	cg03623264	chr10:85672087	NA	0.36	5.09	0.3	6.73e-7	Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
CESC	cis	rs3126085	0.825	rs12045492	chr1:152253866	A/T	cg03465714	chr1:152285911	FLG	-0.45	-5.53	-0.32	7.71e-8	Atopic dermatitis;
CESC	cis	rs1278769	0.786	rs3742238	chr13:113540425	C/T	cg00823993	chr13:113535758	ATP11A	0.58	7.56	0.42	6.46e-13	Interstitial lung disease;
CESC	trans	rs561341	0.843	rs2028067	chr17:30239698	T/C	cg27661571	chr11:113659931	NA	-0.52	-6.08	-0.35	4.14e-9	Hip circumference adjusted for BMI;
CESC	cis	rs9549367	0.789	rs34568744	chr13:113894564	G/T	cg00898013	chr13:113819073	PROZ	-0.51	-6.94	-0.39	3.06e-11	Platelet distribution width;
CESC	cis	rs4654899	0.785	rs10916911	chr1:21290061	C/T	cg05370193	chr1:21551575	ECE1	0.36	5.4	0.31	1.49e-7	Superior frontal gyrus grey matter volume;
CESC	trans	rs35824328	0.706	rs76663547	chr2:215100054	A/G	cg05754377	chr7:36124944	NA	0.59	6.05	0.35	5.04e-9	HIV-associated neurocognitive disorder (mild neurocognitive disorder);
CESC	cis	rs4665809	1.000	rs4233710	chr2:26291565	G/A	cg27170947	chr2:26402098	FAM59B	-0.71	-8.27	-0.45	6.5e-15	Gut microbiome composition (summer);
CESC	cis	rs1348850	0.914	rs10170546	chr2:178248790	C/T	cg23306229	chr2:178417860	TTC30B	0.64	8.0	0.44	3.87e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs1799949	0.930	rs4445938	chr17:41337900	A/C	cg05368731	chr17:41323189	NBR1	0.77	10.72	0.55	1.69e-22	Menopause (age at onset);
CESC	cis	rs10504229	1.000	rs56350499	chr8:58178139	C/T	cg24829409	chr8:58192753	C8orf71	-0.76	-10.0	-0.52	3.53e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs853679	0.517	rs9295759	chr6:28124469	C/T	cg17949981	chr6:28129498	ZNF389	0.45	5.48	0.32	9.95e-8	Depression;
CESC	cis	rs9300255	0.602	rs1790126	chr12:123683563	C/T	cg19016782	chr12:123741754	C12orf65	-0.45	-6.4	-0.37	6.92e-10	Neutrophil percentage of white cells;
CESC	cis	rs7084402	0.934	rs1649021	chr10:60286028	C/T	cg07615347	chr10:60278583	BICC1	0.59	9.44	0.5	2.04e-18	Refractive error;
CESC	cis	rs1788820	0.957	rs1652342	chr18:21099583	C/T	cg14672496	chr18:21087552	C18orf8	0.53	7.19	0.4	6.58e-12	Body mass index;
CESC	cis	rs9487051	0.872	rs1111866	chr6:109610846	A/C	cg21918786	chr6:109611834	NA	0.41	6.21	0.36	2.06e-9	Reticulocyte fraction of red cells;
CESC	cis	rs7666738	0.830	rs2167892	chr4:99048503	G/C	cg18180107	chr4:99064573	C4orf37	0.41	5.29	0.31	2.51e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1552244	0.751	rs12715665	chr3:10021601	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.78	-9.93	-0.52	5.93e-20	Alzheimer's disease;
CESC	cis	rs9322193	0.884	rs7769115	chr6:150169932	C/T	cg04369109	chr6:150039330	LATS1	-0.38	-5.1	-0.3	6.52e-7	Lung cancer;
CESC	cis	rs10242455	0.702	rs78680379	chr7:99198573	G/A	cg25640893	chr7:99214727	ZNF498	1.26	7.15	0.4	8.32e-12	Blood metabolite levels;
CESC	cis	rs3820068	0.580	rs7556473	chr1:15996858	C/T	cg17385448	chr1:15911702	AGMAT	-0.41	-6.35	-0.36	9.45e-10	Systolic blood pressure;
CESC	cis	rs2645694	0.626	rs2645705	chr4:77830434	G/A	cg18351406	chr4:77819688	ANKRD56	0.53	6.34	0.36	9.71e-10	Emphysema distribution in smoking;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg08216050	chr16:704013	WDR90	0.46	6.09	0.35	3.89e-9	Fibrinogen levels;
CESC	cis	rs6540559	0.673	rs4556361	chr1:210019654	C/G	cg21951975	chr1:209979733	IRF6	-0.56	-7.09	-0.4	1.23e-11	Cleft lip with or without cleft palate;
CESC	cis	rs7932354	0.710	rs6485702	chr11:46898771	T/C	cg25783544	chr11:47291846	MADD	-0.39	-5.03	-0.3	8.94e-7	Bone mineral density (hip);Bone mineral density;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg07264050	chr8:48920858	UBE2V2	-0.47	-6.08	-0.35	4.16e-9	Ulcerative colitis;
CESC	cis	rs4727027	0.899	rs6464942	chr7:148826368	T/C	cg23583168	chr7:148888333	NA	-0.74	-10.89	-0.56	4.6e-23	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs6860806	0.507	rs2631364	chr5:131706914	C/G	cg07395648	chr5:131743802	NA	0.4	5.18	0.3	4.39e-7	Breast cancer;
CESC	cis	rs6879260	1.000	rs6879260	chr5:179731014	A/G	cg23221052	chr5:179740743	GFPT2	-0.59	-7.76	-0.43	1.89e-13	Height;
CESC	trans	rs11098499	0.644	rs3986377	chr4:120260270	G/A	cg25214090	chr10:38739885	LOC399744	0.61	8.64	0.47	5.49e-16	Corneal astigmatism;
CESC	trans	rs7902708	0.920	rs11003035	chr10:54428726	G/A	cg26219051	chr22:43739629	SCUBE1	-0.47	-6.05	-0.35	5e-9	Bone properties (heel);
CESC	cis	rs12188164	0.965	rs72717438	chr5:448663	C/T	cg26850624	chr5:429559	AHRR	-0.5	-6.67	-0.38	1.52e-10	Cystic fibrosis severity;
CESC	cis	rs7927771	0.524	rs7933184	chr11:47682402	C/T	cg20307385	chr11:47447363	PSMC3	0.62	8.65	0.47	5.03e-16	Subjective well-being;
CESC	cis	rs634534	0.532	rs12794370	chr11:65770413	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.45	6.75	0.38	9.17e-11	Sum eosinophil basophil counts;Eosinophil counts;
CESC	cis	rs977987	0.806	rs11643410	chr16:75428306	C/T	cg03315344	chr16:75512273	CHST6	0.4	5.7	0.33	3.21e-8	Dupuytren's disease;
CESC	trans	rs13098911	0.540	rs17215981	chr3:46124418	C/T	cg10236987	chr1:228114221	WNT9A	-0.61	-6.36	-0.36	8.64e-10	Celiac disease;
CESC	cis	rs9473147	0.543	rs9296559	chr6:47452270	T/C	cg20196966	chr6:47445060	CD2AP	0.4	5.19	0.3	4.26e-7	Platelet distribution width;Mean platelet volume;
CESC	cis	rs7666738	0.830	rs13124689	chr4:98961182	A/T	cg05340658	chr4:99064831	C4orf37	0.8	12.39	0.61	3.96e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2243480	0.522	rs431168	chr7:65511604	G/T	cg13147721	chr7:65941812	NA	-0.88	-6.59	-0.38	2.35e-10	Diabetic kidney disease;
CESC	cis	rs2011503	0.943	rs8102502	chr19:19652746	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.54	5.83	0.34	1.61e-8	Bipolar disorder;
CESC	cis	rs28830936	1.000	rs17678138	chr15:42043067	G/A	cg11010575	chr15:42129464	JMJD7-PLA2G4B;JMJD7	-0.37	-5.43	-0.32	1.25e-7	Diastolic blood pressure;
CESC	cis	rs7762018	0.660	rs41265385	chr6:170068086	C/T	cg13891659	chr6:170190454	C6orf122;C6orf208	0.56	5.43	0.32	1.25e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs16854884	0.837	rs7644767	chr3:143803092	C/G	cg06585982	chr3:143692056	C3orf58	0.44	5.44	0.32	1.24e-7	Economic and political preferences (feminism/equality);
CESC	cis	rs10911232	0.507	rs4651137	chr1:182994300	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.84	13.19	0.63	6.74e-31	Hypertriglyceridemia;
CESC	trans	rs7922314	0.571	rs61865691	chr10:64728320	C/T	cg06935979	chr1:232941706	KIAA1383	-0.66	-5.99	-0.35	6.67e-9	Cutaneous psoriasis;
CESC	cis	rs514406	0.505	rs12726160	chr1:53175099	A/G	cg24675658	chr1:53192096	ZYG11B	-0.56	-7.26	-0.41	4.43e-12	Monocyte count;
CESC	cis	rs9914988	0.887	rs11650282	chr17:27090741	C/G	cg20469991	chr17:27169893	C17orf63	-0.48	-5.25	-0.31	3.18e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CESC	cis	rs4423214	0.650	rs7940244	chr11:71221574	C/T	cg05163923	chr11:71159392	DHCR7	-0.76	-9.57	-0.51	7.73e-19	Vitamin D levels;
CESC	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg18402987	chr7:1209562	NA	0.76	7.79	0.43	1.5e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs561341	0.769	rs7217004	chr17:30178092	A/G	cg19193384	chr17:30244184	NA	0.6	5.7	0.33	3.19e-8	Hip circumference adjusted for BMI;
CESC	cis	rs7259376	0.837	rs16999542	chr19:22573092	A/C	cg02657401	chr19:22469223	NA	-0.26	-5.14	-0.3	5.27e-7	Menopause (age at onset);
CESC	trans	rs7922314	0.571	rs57110080	chr10:64736699	G/A	cg06935979	chr1:232941706	KIAA1383	-0.63	-6.12	-0.35	3.3e-9	Cutaneous psoriasis;
CESC	trans	rs2727020	0.729	rs4980439	chr11:49342246	G/C	cg03929089	chr4:120376271	NA	-0.79	-11.98	-0.59	9.9e-27	Coronary artery disease;
CESC	cis	rs2439831	0.867	rs2447208	chr15:43933895	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.64	7.89	0.44	7.73e-14	Lung cancer in ever smokers;
CESC	cis	rs8067354	0.645	rs28516945	chr17:57816578	T/C	cg02344993	chr17:57696989	CLTC	0.67	7.83	0.43	1.2e-13	Hemoglobin concentration;
CESC	cis	rs9916302	0.904	rs679995	chr17:37441679	A/T	cg15445000	chr17:37608096	MED1	-0.42	-6.81	-0.39	6.57e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs977987	0.806	rs35937717	chr16:75331567	C/A	cg03315344	chr16:75512273	CHST6	0.39	5.6	0.33	5.24e-8	Dupuytren's disease;
CESC	cis	rs12681288	0.676	rs17740799	chr8:1014327	C/T	cg15309053	chr8:964076	NA	-0.41	-7.04	-0.4	1.69e-11	Schizophrenia;
CESC	cis	rs2204008	0.692	rs11613378	chr12:38213138	T/A	cg13010199	chr12:38710504	ALG10B	0.54	6.69	0.38	1.28e-10	Bladder cancer;
CESC	cis	rs2836974	0.897	rs35386515	chr21:40532047	C/T	cg17971929	chr21:40555470	PSMG1	1.04	15.91	0.7	1.8e-40	Cognitive function;
CESC	cis	rs7927592	0.956	rs10896337	chr11:68284236	T/C	cg20283391	chr11:68216788	NA	-0.5	-6.03	-0.35	5.4e-9	Total body bone mineral density;
CESC	cis	rs1062177	1.000	rs72802204	chr5:151183183	T/C	cg00977110	chr5:151150581	G3BP1	0.63	6.88	0.39	4.37e-11	Preschool internalizing problems;
CESC	cis	rs1371867	0.846	rs1660347	chr8:101314980	G/A	cg11906718	chr8:101322791	RNF19A	0.54	6.93	0.39	3.1e-11	Atrioventricular conduction;
CESC	cis	rs9611565	0.685	rs169363	chr22:41853117	G/T	cg17376030	chr22:41985996	PMM1	-0.7	-7.54	-0.42	7.31e-13	Vitiligo;
CESC	cis	rs10097731	0.901	rs9298344	chr8:82043063	C/T	cg25230327	chr8:82042993	NA	-0.55	-6.22	-0.36	1.91e-9	Serum total protein level;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09452751	chr3:155572485	SLC33A1	0.61	6.79	0.38	7.29e-11	Gut microbiome composition (summer);
CESC	cis	rs9311474	0.508	rs7625743	chr3:52606366	C/G	cg17372223	chr3:52568218	NT5DC2	0.42	6.35	0.36	9.14e-10	Electroencephalogram traits;
CESC	cis	rs977987	0.806	rs4888391	chr16:75400746	C/T	cg03315344	chr16:75512273	CHST6	0.4	5.73	0.33	2.73e-8	Dupuytren's disease;
CESC	cis	rs67478160	0.643	rs2887282	chr14:104280734	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.46	-6.41	-0.37	6.58e-10	Schizophrenia;
CESC	cis	rs9926296	0.585	rs1800337	chr16:89845194	A/G	cg04287289	chr16:89883240	FANCA	0.91	16.04	0.7	6.43e-41	Vitiligo;
CESC	cis	rs2991971	0.967	rs10789465	chr1:45971759	T/C	cg24296786	chr1:45957014	TESK2	0.68	9.36	0.5	3.55e-18	High light scatter reticulocyte count;
CESC	cis	rs9858542	0.953	rs9837027	chr3:49597013	C/T	cg03060546	chr3:49711283	APEH	-0.51	-5.96	-0.34	7.9e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs7666738	0.830	rs60411337	chr4:99046617	T/C	cg03467027	chr4:99064603	C4orf37	0.47	5.98	0.34	7.19e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7264396	0.635	rs6060660	chr20:34476649	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.84	-11.5	-0.58	4.39e-25	Total cholesterol levels;
CESC	cis	rs9807841	0.592	rs10401513	chr19:10778763	A/T	cg17710535	chr19:10819994	QTRT1	0.37	5.12	0.3	5.82e-7	Inflammatory skin disease;
CESC	cis	rs7223966	1.000	rs8075422	chr17:61804686	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	7.32	0.41	3.01e-12	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs397969	0.646	rs17604987	chr17:19867331	A/T	cg12073167	chr17:19770448	ULK2	0.44	5.13	0.3	5.72e-7	Platelet count;
CESC	cis	rs10463316	0.817	rs3846713	chr5:150799739	C/T	cg03212797	chr5:150827313	SLC36A1	-0.52	-6.69	-0.38	1.3100000000000001e-10	Metabolite levels (Pyroglutamine);
CESC	cis	rs8017423	0.935	rs10147186	chr14:90779879	G/C	cg14092571	chr14:90743983	NA	-0.53	-8.12	-0.45	1.78e-14	Mortality in heart failure;
CESC	cis	rs6714016	0.600	rs12713004	chr2:23896049	A/G	cg20701182	chr2:24300061	SF3B14	-0.42	-5.15	-0.3	5.1e-7	Plateletcrit;
CESC	cis	rs2635047	0.747	rs9956387	chr18:44773382	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.43	5.79	0.34	2.01e-8	Educational attainment;
CESC	cis	rs853679	0.550	rs1150692	chr6:28173957	A/G	cg20151795	chr6:28129481	ZNF389	0.41	5.46	0.32	1.09e-7	Depression;
CESC	cis	rs10540	1.000	rs71487296	chr11:500282	G/A	cg03352830	chr11:487213	PTDSS2	0.72	6.98	0.39	2.31e-11	Body mass index;
CESC	cis	rs5763662	1.000	rs5763810	chr22:30541670	G/A	cg21388335	chr22:29999516	NF2	-0.74	-5.03	-0.3	9.22e-7	LDL cholesterol levels;LDL cholesterol;
CESC	cis	rs11112613	0.713	rs73184084	chr12:105952615	T/A	cg03607813	chr12:105948248	NA	0.59	7.41	0.41	1.75e-12	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CESC	cis	rs1707322	0.716	rs10890342	chr1:46157087	C/T	cg03146154	chr1:46216737	IPP	0.82	11.53	0.58	3.39e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs1218582	0.661	rs4845695	chr1:154911798	A/G	cg06221963	chr1:154839813	KCNN3	-0.59	-9.37	-0.5	3.4e-18	Prostate cancer;
CESC	trans	rs17508449	0.547	rs3195954	chr1:114354654	T/C	cg23028848	chr11:57092561	TNKS1BP1	-0.65	-6.01	-0.35	6.03e-9	Leprosy;
CESC	cis	rs2072732	0.861	rs55873718	chr1:2940012	A/G	cg03976712	chr1:2946727	NA	0.34	5.31	0.31	2.28e-7	Plateletcrit;
CESC	cis	rs4604732	0.588	rs74154678	chr1:247626202	A/T	cg12758973	chr1:247694275	LOC148824;OR2C3	0.51	6.36	0.36	8.65e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs9399137	0.507	rs7772031	chr6:135259734	G/A	cg22676075	chr6:135203613	NA	-0.57	-7.67	-0.43	3.36e-13	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg16636182	chr19:5112710	KDM4B	0.49	6.48	0.37	4.57e-10	Fibrinogen levels;
CESC	cis	rs1552244	0.808	rs7615088	chr3:10035896	A/T	cg00166722	chr3:10149974	C3orf24	0.48	5.98	0.34	7.06e-9	Alzheimer's disease;
CESC	cis	rs4835473	0.808	rs62339607	chr4:144712627	C/A	cg25736465	chr4:144833511	NA	-0.36	-5.84	-0.34	1.5e-8	Immature fraction of reticulocytes;
CESC	cis	rs3820928	0.904	rs4129884	chr2:227820943	G/A	cg05526886	chr2:227700861	RHBDD1	-0.4	-5.12	-0.3	5.97e-7	Pulmonary function;
CESC	cis	rs7613875	0.578	rs2526749	chr3:50076734	A/G	cg24308560	chr3:49941425	MST1R	0.6	8.72	0.47	3.17e-16	Body mass index;
CESC	cis	rs34779708	0.733	rs4934740	chr10:35547141	C/T	cg04310649	chr10:35416472	CREM	-0.45	-5.14	-0.3	5.34e-7	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs881375	0.933	rs1548784	chr9:123685280	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.39	5.24	0.31	3.22e-7	Rheumatoid arthritis;
CESC	cis	rs7617773	0.817	rs745116	chr3:48272536	T/G	cg11946769	chr3:48343235	NME6	0.79	10.77	0.55	1.16e-22	Coronary artery disease;
CESC	cis	rs2439831	1.000	rs9920763	chr15:43760508	T/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.94	9.77	0.51	1.81e-19	Lung cancer in ever smokers;
CESC	cis	rs965513	0.530	rs7357631	chr9:100528320	G/A	cg13688889	chr9:100608707	NA	-0.42	-5.48	-0.32	9.84e-8	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
CESC	cis	rs3820068	0.705	rs11584398	chr1:15880275	G/A	cg18192808	chr1:15853278	DNAJC16	0.47	5.69	0.33	3.33e-8	Systolic blood pressure;
CESC	cis	rs2274273	0.870	rs10144345	chr14:55847737	T/C	cg04306507	chr14:55594613	LGALS3	0.31	6.09	0.35	4.04e-9	Protein biomarker;
CESC	cis	rs644799	0.710	rs12272061	chr11:95524067	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.74	10.88	0.56	5.03e-23	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs7618501	0.699	rs1317154	chr3:49910084	T/C	cg24110177	chr3:50126178	RBM5	-0.46	-6.09	-0.35	4.06e-9	Intelligence (multi-trait analysis);
CESC	cis	rs12134040	0.646	rs10925102	chr1:236507727	G/T	cg21399712	chr1:236511386	NA	-0.37	-5.12	-0.3	5.78e-7	Urate levels (BMI interaction);
CESC	cis	rs736408	0.545	rs6445529	chr3:52662722	T/A	cg18337363	chr3:52569053	NT5DC2	0.28	5.07	0.3	7.31e-7	Bipolar disorder;
CESC	cis	rs763121	0.853	rs3747170	chr22:39067331	G/A	cg21395723	chr22:39101663	GTPBP1	0.42	5.33	0.31	2.15e-7	Menopause (age at onset);
CESC	cis	rs9311474	0.607	rs4475032	chr3:52560021	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.69	0.38	1.3100000000000001e-10	Electroencephalogram traits;
CESC	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.37	-5.49	-0.32	9.2e-8	Bipolar disorder;
CESC	cis	rs11650494	0.710	rs16948071	chr17:47468706	T/G	cg08112188	chr17:47440006	ZNF652	1.19	8.04	0.44	3.04e-14	Prostate cancer;
CESC	trans	rs3780486	0.718	rs10971418	chr9:33122024	A/C	cg20290983	chr6:43655470	MRPS18A	-0.69	-8.33	-0.46	4.52e-15	IgG glycosylation;
CESC	cis	rs863345	1.000	rs863351	chr1:158538663	G/T	cg12129480	chr1:158549410	OR10X1	-0.32	-6.42	-0.37	6.4e-10	Pneumococcal bacteremia;
CESC	cis	rs61776719	0.520	rs17465651	chr1:38418496	C/T	cg12658694	chr1:38397304	INPP5B	0.64	9.07	0.49	2.83e-17	Coronary artery disease;
CESC	trans	rs916888	0.647	rs199449	chr17:44808902	G/A	cg22433210	chr17:43662623	NA	0.61	8.0	0.44	3.78e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs7818345	0.967	rs13258090	chr8:19285726	A/G	cg11303988	chr8:19266685	CSGALNACT1	-0.37	-6.96	-0.39	2.67e-11	Language performance in older adults (adjusted for episodic memory);
CESC	cis	rs7666738	0.830	rs4699598	chr4:99019158	C/T	cg05340658	chr4:99064831	C4orf37	0.82	12.99	0.62	3.34e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs60154123	0.505	rs7540237	chr1:210053325	C/T	cg22029157	chr1:209979665	IRF6	0.72	7.3	0.41	3.39e-12	Coronary artery disease;
CESC	cis	rs7666738	0.830	rs1426666	chr4:99030887	A/G	cg17366294	chr4:99064904	C4orf37	0.62	8.95	0.48	6.32e-17	Colonoscopy-negative controls vs population controls;
CESC	cis	rs921968	0.541	rs581013	chr2:219432040	G/T	cg02176678	chr2:219576539	TTLL4	0.5	8.91	0.48	8.15e-17	Mean corpuscular hemoglobin concentration;
CESC	cis	rs4268898	0.662	rs74470633	chr2:24438712	A/G	cg08917208	chr2:24149416	ATAD2B	0.55	5.27	0.31	2.89e-7	Asthma;
CESC	cis	rs10504229	0.906	rs59336968	chr8:58176857	T/C	cg05313129	chr8:58192883	C8orf71	-0.55	-6.37	-0.36	8.42e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs11059919	1	rs11059919	chr12:129289190	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.71	-9.72	-0.51	2.64e-19	Systemic lupus erythematosus;
CESC	cis	rs9911578	0.933	rs2632508	chr17:56533235	G/A	cg05425664	chr17:57184151	TRIM37	-0.48	-6.62	-0.38	2.04e-10	Intelligence (multi-trait analysis);
CESC	cis	rs7762018	0.505	rs79843499	chr6:170068420	A/G	cg19338460	chr6:170058176	WDR27	-0.99	-8.06	-0.44	2.62e-14	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs1950626	0.743	rs1956734	chr14:101399830	A/T	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	-0.76	-9.68	-0.51	3.65e-19	Pelvic organ prolapse (moderate/severe);
CESC	cis	rs6894249	1.000	rs6894249	chr5:131797547	A/G	cg00255919	chr5:131827918	IRF1	0.37	6.13	0.35	3.16e-9	Asthma;
CESC	cis	rs11122272	0.735	rs2808591	chr1:231523421	G/A	cg06096015	chr1:231504339	EGLN1	0.43	6.18	0.35	2.46e-9	Hemoglobin concentration;
CESC	cis	rs6952808	0.601	rs3778978	chr7:2159817	A/G	cg04267008	chr7:1944627	MAD1L1	-0.6	-7.23	-0.41	5.11e-12	Bipolar disorder and schizophrenia;
CESC	cis	rs7618915	0.501	rs767418	chr3:52767427	C/T	cg18404041	chr3:52824283	ITIH1	-0.39	-6.63	-0.38	1.85e-10	Bipolar disorder;
CESC	cis	rs9916302	0.861	rs11078896	chr17:37415544	C/T	cg07936489	chr17:37558343	FBXL20	-0.77	-10.78	-0.55	1.03e-22	Glomerular filtration rate (creatinine);
CESC	cis	rs1461503	0.966	rs1461504	chr11:122845129	T/C	cg27398637	chr11:122830231	C11orf63	-0.55	-8.32	-0.45	4.77e-15	Menarche (age at onset);
CESC	cis	rs2742234	0.541	rs11238483	chr10:43728780	A/G	cg15436174	chr10:43711423	RASGEF1A	0.47	5.5	0.32	8.97e-8	Hirschsprung disease;
CESC	cis	rs3768617	0.565	rs3768626	chr1:183078462	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.88	14.14	0.66	3.44e-34	Fuchs's corneal dystrophy;
CESC	cis	rs9486719	0.947	rs9386648	chr6:97035656	T/C	cg18709589	chr6:96969512	KIAA0776	-0.5	-5.44	-0.32	1.21e-7	Migraine;Coronary artery disease;
CESC	cis	rs6952808	0.501	rs3778999	chr7:2180885	G/A	cg08027265	chr7:2291960	NA	-0.46	-7.17	-0.4	7.65e-12	Bipolar disorder and schizophrenia;
CESC	cis	rs1801251	1.000	rs12474040	chr2:233615345	T/G	cg25237894	chr2:233734115	C2orf82	0.45	7.97	0.44	4.79e-14	Coronary artery disease;
CESC	cis	rs9640161	0.789	rs28439010	chr7:150046276	C/T	cg10018233	chr7:150070692	REPIN1	0.36	5.17	0.3	4.71e-7	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs113835537	0.935	rs15969	chr11:66394387	C/T	cg22134325	chr11:66188745	NPAS4	0.5	5.76	0.33	2.27e-8	Airway imaging phenotypes;
CESC	cis	rs7666738	0.791	rs1830231	chr4:99026185	A/C	cg05340658	chr4:99064831	C4orf37	0.83	13.1	0.63	1.43e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs853679	0.517	rs9368554	chr6:28082711	T/C	cg23281280	chr6:28129359	ZNF389	0.58	7.93	0.44	6.31e-14	Depression;
CESC	cis	rs1577917	1.000	rs36096931	chr6:86693134	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-5.94	-0.34	8.79e-9	Response to antipsychotic treatment;
CESC	cis	rs7666738	0.830	rs35213297	chr4:98984049	T/C	cg05340658	chr4:99064831	C4orf37	0.76	11.43	0.57	7.54e-25	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7264396	0.635	rs6060720	chr20:34548336	A/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.52	6.2	0.36	2.18e-9	Total cholesterol levels;
CESC	cis	rs7829975	0.688	rs6601703	chr8:8380224	A/G	cg06636001	chr8:8085503	FLJ10661	0.51	6.26	0.36	1.53e-9	Mood instability;
CESC	cis	rs6580649	0.941	rs4760618	chr12:48434767	G/A	cg24011408	chr12:48396354	COL2A1	-0.41	-5.1	-0.3	6.53e-7	Lung cancer;
CESC	cis	rs72634258	0.945	rs1883679	chr1:8100451	T/G	cg00042356	chr1:8021962	PARK7	0.76	6.78	0.38	7.86e-11	Inflammatory bowel disease;
CESC	cis	rs6446731	0.734	rs10937921	chr4:3276491	C/T	cg08886695	chr4:3369023	RGS12	-0.35	-5.17	-0.3	4.53e-7	Mean platelet volume;
CESC	cis	rs2276314	0.947	rs16967319	chr18:33573525	A/G	cg19628046	chr18:33552617	C18orf21	0.54	5.77	0.33	2.17e-8	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs1395	0.778	rs11693001	chr2:27412744	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.44	5.85	0.34	1.44e-8	Blood metabolite levels;
CESC	cis	rs7666738	0.830	rs1405767	chr4:98965295	T/C	cg18180107	chr4:99064573	C4orf37	0.4	5.14	0.3	5.26e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs12971120	0.891	rs71359051	chr18:72169723	G/A	cg25817165	chr18:72167213	CNDP2	-0.58	-7.13	-0.4	9.45e-12	Refractive error;
CESC	cis	rs7666738	0.830	rs2865977	chr4:99017916	C/T	cg05340658	chr4:99064831	C4orf37	0.82	12.99	0.62	3.34e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs5758659	0.714	rs2413668	chr22:42505841	G/A	cg00645731	chr22:42541494	CYP2D7P1	0.32	5.55	0.32	6.8e-8	Cognitive function;
CESC	cis	rs780096	0.506	rs72819512	chr2:27614449	G/A	cg12648201	chr2:27665141	KRTCAP3	-0.33	-6.04	-0.35	5.19e-9	Total body bone mineral density;
CESC	cis	rs72781680	0.898	rs79023848	chr2:24038174	C/A	cg08917208	chr2:24149416	ATAD2B	1.13	10.18	0.53	9.42e-21	Lymphocyte counts;
CESC	cis	rs7666738	0.791	rs10010438	chr4:99022177	C/T	cg03676636	chr4:99064102	C4orf37	0.33	5.15	0.3	5.05e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6429637	0.582	rs37454	chr1:44294411	C/A	cg11704212	chr1:44303111	ST3GAL3	-0.41	-5.42	-0.32	1.32e-7	Intelligence (multi-trait analysis);
CESC	cis	rs826838	0.586	rs1843903	chr12:38627524	C/T	cg26384229	chr12:38710491	ALG10B	0.54	7.82	0.43	1.25e-13	Heart rate;
CESC	cis	rs7818688	0.614	rs7834966	chr8:95847196	G/T	cg16049864	chr8:95962084	TP53INP1	-0.49	-5.19	-0.3	4.16e-7	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg21605566	chr1:14075549	PRDM2	0.46	6.4	0.37	6.95e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs1865721	1.000	rs72977879	chr18:73193696	T/C	cg26385618	chr18:73139727	C18orf62	-0.51	-7.56	-0.42	6.81e-13	Intelligence;
CESC	cis	rs8060686	0.668	rs12448991	chr16:68218894	T/A	cg26727032	chr16:67993705	SLC12A4	-0.53	-5.99	-0.35	6.85e-9	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs7680126	0.633	rs4697745	chr4:10305081	G/A	cg00071950	chr4:10020882	SLC2A9	-0.49	-5.29	-0.31	2.53e-7	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg14926445	chr8:58193284	C8orf71	-0.54	-5.16	-0.3	4.76e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs28829049	1.000	rs28829049	chr1:19349281	C/T	cg13387374	chr1:19411106	UBR4	0.42	5.1	0.3	6.42e-7	QRS duration in Tripanosoma cruzi seropositivity;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg27279809	chr12:49183212	ADCY6	-0.44	-6.11	-0.35	3.47e-9	Fibrinogen levels;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg00721635	chr1:153572208	NA	-0.42	-6.03	-0.35	5.54e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7552404	0.731	rs1689275	chr1:76409655	T/C	cg22875332	chr1:76189707	ACADM	-0.57	-6.17	-0.35	2.5e-9	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs5167	0.525	rs10402642	chr19:45453878	G/A	cg13119609	chr19:45449297	APOC2	0.49	8.03	0.44	3.23e-14	Blood protein levels;
CESC	cis	rs5771069	0.933	rs137848	chr22:50440296	A/G	cg03721641	chr22:50451245	IL17REL	0.34	5.66	0.33	3.95e-8	Ulcerative colitis;
CESC	cis	rs2228479	0.850	rs117880578	chr16:89910230	C/G	cg04013166	chr16:89971882	TCF25	0.72	5.75	0.33	2.41e-8	Skin colour saturation;
CESC	cis	rs7824557	0.701	rs4568582	chr8:11160495	A/T	cg21775007	chr8:11205619	TDH	0.52	7.6	0.42	5.01e-13	Retinal vascular caliber;
CESC	cis	rs2735413	0.918	rs4309408	chr16:78071507	G/A	cg04733911	chr16:78082701	NA	-0.54	-8.96	-0.48	5.9e-17	Systolic blood pressure (alcohol consumption interaction);
CESC	cis	rs7666738	0.830	rs7657982	chr4:99044015	G/A	cg05340658	chr4:99064831	C4orf37	0.8	12.24	0.6	1.32e-27	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11098499	0.954	rs7654587	chr4:120388406	C/T	cg09307838	chr4:120376055	NA	0.95	13.96	0.65	1.42e-33	Corneal astigmatism;
CESC	cis	rs4665809	1.000	rs4665304	chr2:26313406	C/T	cg25036284	chr2:26402008	FAM59B	-0.58	-6.72	-0.38	1.09e-10	Gut microbiome composition (summer);
CESC	cis	rs12142240	0.698	rs17361819	chr1:46828109	A/G	cg00530320	chr1:46809349	NSUN4	0.6	8.01	0.44	3.75e-14	Menopause (age at onset);
CESC	cis	rs11249608	0.636	rs6888567	chr5:178449074	C/T	cg01312482	chr5:178451176	ZNF879	0.44	6.03	0.35	5.63e-9	Pubertal anthropometrics;
CESC	cis	rs6087990	0.865	rs6058859	chr20:31335157	A/G	cg13636640	chr20:31349939	DNMT3B	0.84	14.64	0.67	5.74e-36	Ulcerative colitis;
CESC	cis	rs2243480	1.000	rs34970380	chr7:65431493	C/T	cg18252515	chr7:66147081	NA	-1.2	-11.63	-0.58	1.53e-25	Diabetic kidney disease;
CESC	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg06873352	chr17:61820015	STRADA	-0.72	-12.78	-0.62	1.85e-29	Prudent dietary pattern;
CESC	cis	rs10504229	0.683	rs882429	chr8:58129292	A/G	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs6460942	0.915	rs17541464	chr7:12462675	A/G	cg02935154	chr7:12443704	VWDE	-0.57	-7.1	-0.4	1.17e-11	Coronary artery disease;
CESC	cis	rs6448317	0.954	rs35276311	chr4:24923493	C/T	cg21108841	chr4:24914750	CCDC149	-0.57	-6.85	-0.39	5.04e-11	Heschl's gyrus morphology;
CESC	cis	rs854765	0.718	rs6502629	chr17:17869642	A/G	cg04398451	chr17:18023971	MYO15A	-0.64	-8.63	-0.47	5.78e-16	Total body bone mineral density;
CESC	cis	rs12369179	1.000	rs12369179	chr12:122963550	C/T	cg18578876	chr12:123200353	GPR109B	-0.91	-7.16	-0.4	7.72e-12	Age-related diseases, mortality and associated endophenotypes;Age-related disease endophenotypes;
CESC	trans	rs3942852	0.726	rs10742836	chr11:48175831	G/A	cg15704280	chr7:45808275	SEPT13	-0.75	-8.67	-0.47	4.34e-16	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs2243480	0.522	rs431168	chr7:65511604	G/T	cg25894440	chr7:65020034	NA	-0.74	-5.19	-0.3	4.12e-7	Diabetic kidney disease;
CESC	cis	rs10979	1.000	rs34960207	chr6:143886398	C/T	cg25407410	chr6:143891975	LOC285740	-0.63	-9.62	-0.51	5.62e-19	Hypospadias;
CESC	cis	rs12291225	0.535	rs16930126	chr11:14404983	C/T	cg19336497	chr11:14380999	RRAS2	0.36	5.39	0.31	1.54e-7	Sense of smell;
CESC	cis	rs9359856	0.564	rs72913921	chr6:90328692	A/T	cg13799429	chr6:90582589	CASP8AP2	-0.63	-6.02	-0.35	5.88e-9	Bipolar disorder;
CESC	cis	rs7188697	0.845	rs1981960	chr16:58597289	C/G	cg21335942	chr16:58549945	SETD6	-0.45	-5.2	-0.3	4.06e-7	QT interval;
CESC	cis	rs703842	1.000	rs1599932	chr12:58177943	G/A	cg00677455	chr12:58241039	CTDSP2	0.52	6.62	0.38	2.03e-10	Multiple sclerosis;
CESC	cis	rs1218582	0.510	rs2878411	chr1:154823545	C/T	cg03351412	chr1:154909251	PMVK	0.53	6.35	0.36	9.17e-10	Prostate cancer;
CESC	cis	rs3812762	0.957	rs6484008	chr11:8754148	A/G	cg03980550	chr11:8754370	ST5	0.36	5.3	0.31	2.4e-7	Hypospadias;
CESC	cis	rs9649465	1.000	rs13225220	chr7:123371026	C/A	cg04330084	chr7:123175371	IQUB	-0.38	-5.18	-0.3	4.46e-7	Migraine;
CESC	cis	rs8070740	0.786	rs12761	chr17:5326145	C/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.51	6.44	0.37	5.73e-10	Menopause (age at onset);
CESC	cis	rs4665809	1.000	rs4665304	chr2:26313406	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.7	-7.98	-0.44	4.48e-14	Gut microbiome composition (summer);
CESC	cis	rs2370759	1.000	rs11599044	chr10:32615445	A/G	cg01819863	chr10:32635814	EPC1	1.14	12.39	0.61	4.11e-28	Sexual dysfunction (female);
CESC	cis	rs6963495	0.818	rs55825845	chr7:105166713	A/G	cg13798780	chr7:105162888	PUS7	0.78	8.02	0.44	3.36e-14	Bipolar disorder (body mass index interaction);
CESC	cis	rs951366	0.677	rs1775140	chr1:205672107	C/A	cg06877462	chr1:205807181	PM20D1	0.37	5.17	0.3	4.52e-7	Menarche (age at onset);
CESC	cis	rs10782582	0.593	rs11578480	chr1:76208989	T/G	cg22875332	chr1:76189707	ACADM	-0.45	-5.33	-0.31	2.13e-7	Daytime sleep phenotypes;
CESC	cis	rs853679	0.517	rs9380049	chr6:28048535	A/G	cg23281280	chr6:28129359	ZNF389	0.57	7.78	0.43	1.61e-13	Depression;
CESC	cis	rs2836950	0.545	rs1888489	chr21:40533164	T/C	cg11644478	chr21:40555479	PSMG1	-0.56	-7.67	-0.43	3.32e-13	Menarche (age at onset);
CESC	cis	rs6750047	0.546	rs985257	chr2:38283228	A/T	cg07380506	chr2:38303506	CYP1B1	-0.47	-6.03	-0.35	5.44e-9	Cutaneous malignant melanoma;Melanoma;
CESC	cis	rs13108904	0.650	rs3796618	chr4:1349602	T/A	cg19318889	chr4:1322082	MAEA	0.44	5.56	0.32	6.51e-8	Obesity-related traits;
CESC	cis	rs798554	0.680	rs2533889	chr7:2900309	G/C	cg04166393	chr7:2884313	GNA12	0.58	7.52	0.42	8.33e-13	Height;
CESC	cis	rs6460942	0.915	rs10267801	chr7:12451931	G/A	cg02935154	chr7:12443704	VWDE	-0.53	-6.58	-0.37	2.54e-10	Coronary artery disease;
CESC	cis	rs7605827	0.930	rs6431708	chr2:15638175	C/T	cg19274914	chr2:15703543	NA	0.37	6.64	0.38	1.76e-10	Educational attainment (years of education);
CESC	cis	rs2072499	0.966	rs2842882	chr1:156165342	T/G	cg24450063	chr1:156163899	SLC25A44	1.1	23.34	0.82	3.27e-66	Testicular germ cell tumor;
CESC	cis	rs7584330	0.695	rs6709497	chr2:238368925	C/T	cg14458575	chr2:238380390	NA	0.6	8.18	0.45	1.17e-14	Prostate cancer;
CESC	cis	rs7918232	0.607	rs1755401	chr10:27405763	A/C	cg14240646	chr10:27532245	ACBD5	-0.73	-5.6	-0.33	5.28e-8	Breast cancer;
CESC	cis	rs9303401	0.659	rs62081314	chr17:56778328	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	1.05	12.77	0.62	1.94e-29	Cognitive test performance;
CESC	cis	rs9322193	0.884	rs1108889	chr6:150166569	A/G	cg09699651	chr6:150184138	LRP11	0.47	5.86	0.34	1.35e-8	Lung cancer;
CESC	cis	rs62229266	0.626	rs7280896	chr21:37460906	G/A	cg08632701	chr21:37451849	NA	-0.54	-8.19	-0.45	1.14e-14	Mitral valve prolapse;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10380289	chr1:149399187	HIST2H2BF	-0.52	-6.18	-0.35	2.35e-9	Gut microbiome composition (summer);
CESC	cis	rs1401999	1.000	rs6802849	chr3:183698943	A/C	cg01324343	chr3:183735012	ABCC5	0.64	13.63	0.64	2.08e-32	Anterior chamber depth;
CESC	cis	rs6752107	0.967	rs3816234	chr2:234185999	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.49	6.69	0.38	1.3e-10	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs10857712	0.754	rs2297032	chr10:135234580	C/T	cg22671611	chr10:135291010	NA	-0.34	-5.09	-0.3	6.67e-7	Systemic lupus erythematosus;
CESC	cis	rs2963155	0.518	rs853177	chr5:142635460	A/G	cg17617527	chr5:142782415	NR3C1	0.84	7.84	0.43	1.08e-13	Breast cancer;
CESC	cis	rs7100689	0.622	rs2994389	chr10:82062257	C/G	cg00277334	chr10:82204260	NA	-0.61	-8.08	-0.44	2.35e-14	Post bronchodilator FEV1;
CESC	cis	rs9902453	0.967	rs7212741	chr17:28322941	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.64	7.92	0.44	6.76e-14	Coffee consumption (cups per day);
CESC	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.47	6.3	0.36	1.22e-9	Lymphocyte counts;
CESC	cis	rs9322193	0.923	rs2185352	chr6:150035776	T/G	cg09699651	chr6:150184138	LRP11	0.4	5.11	0.3	6.31e-7	Lung cancer;
CESC	cis	rs853679	0.542	rs9393892	chr6:28081394	A/G	cg17949981	chr6:28129498	ZNF389	0.47	5.93	0.34	9.24e-9	Depression;
CESC	trans	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg23590916	chr17:43697445	MGC57346	0.6	6.42	0.37	6.12e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	trans	rs2963826	0.589	rs298091	chr5:58996603	A/T	cg08862778	chr1:11322643	MTOR	0.47	6.26	0.36	1.5e-9	Obesity-related traits;
CESC	cis	rs7208859	0.524	rs77498725	chr17:29063986	C/T	cg13385521	chr17:29058706	SUZ12P	0.81	6.53	0.37	3.28e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs7210086	0.768	rs4075985	chr17:70640873	C/G	cg04206342	chr17:70636940	NA	-0.3	-5.84	-0.34	1.54e-8	Ulcerative colitis;
CESC	cis	rs861020	0.771	rs629150	chr1:209998467	C/T	cg05527609	chr1:210001259	C1orf107	1.08	14.81	0.67	1.4e-36	Orofacial clefts;
CESC	cis	rs896854	0.654	rs10429443	chr8:95971164	A/G	cg13393036	chr8:95962371	TP53INP1	-0.47	-10.01	-0.52	3.27e-20	Type 2 diabetes;
CESC	cis	rs875971	0.862	rs11763189	chr7:65983529	G/A	cg18252515	chr7:66147081	NA	-0.44	-5.64	-0.33	4.42e-8	Aortic root size;
CESC	cis	rs6860806	0.661	rs334902	chr5:131586559	C/G	cg18301423	chr5:131593218	PDLIM4	0.38	5.39	0.31	1.59e-7	Breast cancer;
CESC	cis	rs7666738	0.830	rs17027225	chr4:99028564	C/T	cg18180107	chr4:99064573	C4orf37	0.42	5.43	0.32	1.29e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4237845	0.788	rs6581157	chr12:58288793	C/T	cg02175503	chr12:58329896	NA	0.61	7.33	0.41	2.85e-12	Intelligence (multi-trait analysis);
CESC	cis	rs7959452	0.901	rs1384	chr12:69747834	C/T	cg20891283	chr12:69753455	YEATS4	0.6	8.51	0.46	1.3e-15	Blood protein levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23359810	chr10:51572113	NCOA4	-0.68	-8.35	-0.46	3.88e-15	Gut microbiome composition (summer);
CESC	cis	rs2066819	1.000	rs77120931	chr12:56646213	A/C	cg26734620	chr12:56694298	CS	1.03	6.78	0.38	7.71e-11	Psoriasis vulgaris;
CESC	cis	rs2075371	0.932	rs2598290	chr7:133987736	C/G	cg11752832	chr7:134001865	SLC35B4	0.55	7.23	0.41	5.27e-12	Mean platelet volume;
CESC	trans	rs2727020	0.786	rs10839263	chr11:49354462	A/G	cg15704280	chr7:45808275	SEPT13	-0.75	-9.28	-0.5	6.33e-18	Coronary artery disease;
CESC	cis	rs6933660	0.646	rs9397051	chr6:151778325	C/T	cg14416726	chr6:151773293	C6orf211;RMND1	-0.55	-7.36	-0.41	2.37e-12	Menarche (age at onset);
CESC	cis	rs4319547	0.656	rs10773075	chr12:122814236	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.48	-5.6	-0.33	5.34e-8	Body mass index;
CESC	cis	rs947211	0.898	rs1775146	chr1:205756168	A/G	cg14893161	chr1:205819251	PM20D1	0.39	5.12	0.3	5.9e-7	Parkinson's disease;
CESC	cis	rs6835098	0.962	rs10027704	chr4:174083107	T/C	cg08422745	chr4:174089978	GALNT7	-0.83	-11.79	-0.59	4.45e-26	Dementia and core Alzheimer's disease neuropathologic changes;
CESC	cis	rs6502050	0.805	rs11651863	chr17:80084539	T/C	cg23985595	chr17:80112537	CCDC57	0.41	6.46	0.37	5.01e-10	Life satisfaction;
CESC	cis	rs9916302	0.904	rs1966916	chr17:37425238	T/G	cg07936489	chr17:37558343	FBXL20	-0.8	-11.48	-0.58	5.11e-25	Glomerular filtration rate (creatinine);
CESC	cis	rs10242455	0.702	rs73397481	chr7:99030108	C/T	cg18809830	chr7:99032528	PTCD1	-0.82	-5.83	-0.34	1.6e-8	Blood metabolite levels;
CESC	cis	rs7666738	0.800	rs7684523	chr4:98983175	G/T	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.67e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11583043	0.918	rs6577216	chr1:101409972	C/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.55	6.27	0.36	1.44e-9	Ulcerative colitis;Inflammatory bowel disease;
CESC	cis	rs3785574	0.962	rs2727280	chr17:61918082	A/G	cg06420487	chr17:61919686	SMARCD2	0.45	5.24	0.31	3.34e-7	Height;
CESC	cis	rs6460942	0.818	rs7780083	chr7:12233647	C/T	cg06484146	chr7:12443880	VWDE	-0.47	-5.22	-0.31	3.54e-7	Coronary artery disease;
CESC	cis	rs7274811	0.779	rs13039908	chr20:32052070	G/A	cg21523528	chr20:32077966	CBFA2T2	0.59	6.99	0.39	2.18e-11	Height;
CESC	cis	rs12220238	1.000	rs4320897	chr10:76017732	C/G	cg19889307	chr10:75911429	ADK;AP3M1	0.6	5.92	0.34	1e-8	Soluble interleukin-2 receptor subunit alpha;
CESC	cis	rs17376456	0.569	rs7732578	chr5:93410244	C/T	cg25358565	chr5:93447407	FAM172A	-0.48	-5.6	-0.33	5.38e-8	Diabetic retinopathy;
CESC	trans	rs9858542	0.903	rs11917431	chr3:49644012	C/T	cg21659725	chr3:3221576	CRBN	-0.52	-6.35	-0.36	9.34e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs933688	1.000	rs7715402	chr5:90679504	T/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.94	12.6	0.61	7.96e-29	Smoking behavior;
CESC	cis	rs12497850	0.931	rs6446205	chr3:49035211	C/T	cg07636037	chr3:49044803	WDR6	1.05	19.44	0.77	6.31e-53	Parkinson's disease;
CESC	cis	rs35306767	0.903	rs11253467	chr10:901244	A/G	cg20503657	chr10:835505	NA	0.74	7.45	0.42	1.34e-12	Eosinophil percentage of granulocytes;
CESC	cis	rs34779708	0.702	rs4244995	chr10:35547175	A/G	cg03585969	chr10:35415529	CREM	0.55	6.37	0.36	8.28e-10	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs2594989	0.943	rs7622627	chr3:11357419	T/C	cg00170343	chr3:11313890	ATG7	0.59	5.25	0.31	3.1e-7	Circulating chemerin levels;
CESC	cis	rs4665809	0.549	rs3828255	chr2:26413252	G/A	cg27170947	chr2:26402098	FAM59B	0.75	8.39	0.46	2.88e-15	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06828538	chr7:5463627	TNRC18	-0.69	-8.38	-0.46	3.23e-15	Gut microbiome composition (summer);
CESC	trans	rs9929218	1.000	rs13333528	chr16:68790502	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.71	-8.86	-0.48	1.15e-16	Colorectal cancer;
CESC	trans	rs9693444	0.898	rs4732697	chr8:29519861	A/G	cg08874598	chr8:102217901	ZNF706	-0.42	-6.22	-0.36	1.94e-9	Breast cancer;
CESC	cis	rs35306767	0.903	rs11253493	chr10:936931	T/C	cg26597838	chr10:835615	NA	0.91	9.95	0.52	5.15e-20	Eosinophil percentage of granulocytes;
CESC	cis	rs6669072	0.669	rs814545	chr1:91240551	C/G	cg08895590	chr1:91227319	NA	-0.33	-5.73	-0.33	2.75e-8	Cognitive function;
CESC	cis	rs8014204	0.870	rs3742790	chr14:75308758	C/T	cg08847533	chr14:75593920	NEK9	-0.5	-6.46	-0.37	5.06e-10	Caffeine consumption;
CESC	cis	rs3796352	1.000	rs17052727	chr3:53070914	T/C	cg12962167	chr3:53033115	SFMBT1	0.55	5.04	0.3	8.53e-7	Immune reponse to smallpox (secreted IL-2);
CESC	cis	rs34779708	0.733	rs3853672	chr10:35549606	A/C	cg03585969	chr10:35415529	CREM	0.54	6.2	0.36	2.16e-9	Inflammatory bowel disease;Crohn's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08118908	chr16:15787920	NDE1	-0.55	-6.52	-0.37	3.55e-10	Gut microbiome composition (summer);
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg19782173	chr5:76383047	LOC728723;ZBED3	-0.49	-6.78	-0.38	7.77e-11	Asthma;
CESC	cis	rs7666738	0.830	rs2114425	chr4:99023967	T/C	cg03467027	chr4:99064603	C4orf37	0.47	5.94	0.34	9.15e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs174775	0.513	rs2283849	chr22:29743482	T/C	cg07256473	chr22:29710276	RASL10A	-0.48	-7.26	-0.41	4.39e-12	Immature fraction of reticulocytes;
CESC	cis	rs7666738	0.830	rs7691433	chr4:98968118	A/T	cg17366294	chr4:99064904	C4orf37	0.59	7.92	0.44	6.48e-14	Colonoscopy-negative controls vs population controls;
CESC	cis	rs72781680	0.948	rs72790326	chr2:24126153	C/T	cg08917208	chr2:24149416	ATAD2B	0.93	8.42	0.46	2.35e-15	Lymphocyte counts;
CESC	cis	rs34638657	0.797	rs11645045	chr16:82202137	G/A	cg09439754	chr16:82129088	HSD17B2	-0.35	-5.68	-0.33	3.63e-8	Lung adenocarcinoma;
CESC	cis	rs34638657	0.797	rs7203990	chr16:82185320	A/G	cg09439754	chr16:82129088	HSD17B2	-0.34	-5.29	-0.31	2.54e-7	Lung adenocarcinoma;
CESC	cis	rs7116495	0.541	rs579320	chr11:71794954	G/T	cg10381502	chr11:71823885	C11orf51	-0.66	-5.4	-0.31	1.51e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs7666738	0.515	rs13142498	chr4:98792443	G/T	cg05340658	chr4:99064831	C4orf37	0.54	6.59	0.38	2.39e-10	Colonoscopy-negative controls vs population controls;
CESC	cis	rs870825	0.616	rs28497285	chr4:185629169	G/A	cg04058563	chr4:185651563	MLF1IP	0.64	7.05	0.4	1.59e-11	Blood protein levels;
CESC	cis	rs9790314	0.846	rs9834659	chr3:160980947	A/C	cg03342759	chr3:160939853	NMD3	-0.51	-7.39	-0.41	1.96e-12	Morning vs. evening chronotype;
CESC	cis	rs919433	0.750	rs788010	chr2:198230949	T/C	cg03934865	chr2:198174659	NA	0.43	6.21	0.36	2.01e-9	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs2282802	0.635	rs199152	chr5:139539235	C/T	cg26211634	chr5:139558579	C5orf32	-0.42	-5.77	-0.33	2.23e-8	Intelligence (multi-trait analysis);
CESC	cis	rs6952808	0.929	rs34145223	chr7:1926237	G/A	cg05863683	chr7:1912471	MAD1L1	0.5	7.78	0.43	1.58e-13	Bipolar disorder and schizophrenia;
CESC	cis	rs12926788	0.542	rs11862971	chr16:24767574	C/A	cg06505273	chr16:24850292	NA	0.53	6.49	0.37	4.27e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs9457247	0.534	rs9347170	chr6:167405187	C/T	cg23791538	chr6:167370224	RNASET2	0.68	9.94	0.52	5.5e-20	Crohn's disease;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg27261837	chr1:146714163	CHD1L	-0.42	-6.11	-0.35	3.63e-9	Gambling;
CESC	cis	rs11098499	0.731	rs10015579	chr4:120271802	T/C	cg09307838	chr4:120376055	NA	0.77	10.31	0.54	3.49e-21	Corneal astigmatism;
CESC	trans	rs12599106	0.680	rs34728702	chr16:34896584	A/G	cg05064044	chr6:292385	DUSP22	-0.66	-8.23	-0.45	8.7e-15	Menopause (age at onset);
CESC	cis	rs60871478	0.636	rs4276575	chr7:900035	C/T	cg05535760	chr7:792225	HEATR2	-0.79	-8.61	-0.47	6.7e-16	Cerebrospinal P-tau181p levels;
CESC	cis	rs12079745	0.793	rs3766082	chr1:169215068	A/T	cg09363564	chr1:169337483	NME7;BLZF1	0.92	5.87	0.34	1.31e-8	QT interval;
CESC	cis	rs12618769	0.652	rs6736755	chr2:99204428	A/G	cg10123293	chr2:99228465	UNC50	-0.4	-5.27	-0.31	2.79e-7	Bipolar disorder;
CESC	cis	rs2836974	0.545	rs8128901	chr21:40710419	G/A	cg17971929	chr21:40555470	PSMG1	0.59	7.61	0.42	4.85e-13	Cognitive function;
CESC	cis	rs780096	0.506	rs1647265	chr2:27692261	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.29	-5.79	-0.34	2e-8	Total body bone mineral density;
CESC	cis	rs10504229	0.953	rs67677367	chr8:58175264	T/G	cg24829409	chr8:58192753	C8orf71	-0.76	-10.0	-0.52	3.53e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs1707322	0.752	rs3811435	chr1:46125790	C/A	cg06784218	chr1:46089804	CCDC17	0.43	7.48	0.42	1.07e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs1178968	0.901	rs799303	chr7:72804412	A/C	cg25889504	chr7:72793014	NA	-0.53	-5.65	-0.33	4.18e-8	Triglyceride levels;
CESC	cis	rs2262909	0.962	rs17459246	chr19:22278121	T/C	cg11619707	chr19:22235551	ZNF257	0.35	5.76	0.33	2.38e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
CESC	cis	rs9486715	0.838	rs7770889	chr6:96858453	C/T	cg18709589	chr6:96969512	KIAA0776	-0.42	-6.03	-0.35	5.62e-9	Headache;
CESC	cis	rs6460942	0.841	rs62448597	chr7:12449110	G/C	cg20607287	chr7:12443886	VWDE	-0.7	-8.49	-0.46	1.46e-15	Coronary artery disease;
CESC	cis	rs763014	0.898	rs8050792	chr16:656033	T/C	cg07256732	chr16:621771	PIGQ	-0.32	-5.54	-0.32	7.4e-8	Height;
CESC	cis	rs10838687	0.669	rs830084	chr11:47251652	T/C	cg25783544	chr11:47291846	MADD	-0.57	-6.69	-0.38	1.3100000000000001e-10	Proinsulin levels;
CESC	cis	rs1975974	0.872	rs17052352	chr17:21721972	A/G	cg18423549	chr17:21743878	NA	-0.52	-7.35	-0.41	2.47e-12	Psoriasis;
CESC	cis	rs1879734	0.731	rs11206198	chr1:54165910	C/A	cg23596471	chr1:54105337	GLIS1	0.35	5.58	0.32	5.97e-8	Mitral valve prolapse;
CESC	cis	rs7666738	0.716	rs2865982	chr4:99031661	T/G	cg24818145	chr4:99064322	C4orf37	0.39	5.09	0.3	6.95e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs650950	0.528	rs646660	chr11:35528452	C/T	cg08536481	chr12:123459152	ABCB9;OGFOD2	0.46	6.18	0.35	2.42e-9	Bronchopulmonary dysplasia;
CESC	cis	rs17711722	0.522	rs4642526	chr7:65216742	G/T	cg18876405	chr7:65276391	NA	0.45	6.04	0.35	5.11e-9	Calcium levels;
CESC	cis	rs9790314	0.967	rs9821201	chr3:160996155	G/C	cg03342759	chr3:160939853	NMD3	-0.45	-5.9	-0.34	1.08e-8	Morning vs. evening chronotype;
CESC	cis	rs1348850	0.526	rs6718769	chr2:178450909	T/C	cg22681709	chr2:178499509	PDE11A	-0.46	-5.05	-0.3	8.22e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs853679	0.517	rs9368555	chr6:28108967	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.55	-6.36	-0.36	8.66e-10	Depression;
CESC	cis	rs7811142	1.000	rs4989959	chr7:100032288	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.78	6.78	0.38	7.61e-11	Platelet count;
CESC	cis	rs875971	0.545	rs12670811	chr7:65823019	C/A	cg18876405	chr7:65276391	NA	0.51	6.0	0.35	6.35e-9	Aortic root size;
CESC	cis	rs4665809	0.878	rs35709953	chr2:26334997	G/A	cg22920501	chr2:26401640	FAM59B	0.72	8.09	0.45	2.15e-14	Gut microbiome composition (summer);
CESC	cis	rs4665809	0.816	rs2384359	chr2:26371364	T/C	cg08470875	chr2:26401718	FAM59B	-0.67	-7.34	-0.41	2.59e-12	Gut microbiome composition (summer);
CESC	cis	rs2710642	0.564	rs6752597	chr2:62823444	T/C	cg17519650	chr2:63277830	OTX1	0.48	6.38	0.36	7.95e-10	LDL cholesterol levels;LDL cholesterol;
CESC	cis	rs4819052	0.851	rs28616694	chr21:46674786	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.77	10.11	0.53	1.55e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs17431357	0.867	rs73225219	chr12:120953571	C/A	cg25045489	chr12:120971538	RNF10	-0.93	-5.37	-0.31	1.76e-7	Insulin resistance/response;
CESC	cis	rs67478160	0.595	rs12879501	chr14:104272634	G/T	cg08213375	chr14:104286397	PPP1R13B	0.54	10.66	0.55	2.51e-22	Schizophrenia;
CESC	cis	rs3740540	0.530	rs4297414	chr10:126292116	T/G	cg04949429	chr10:126290192	LHPP	0.41	5.51	0.32	8.5e-8	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
CESC	cis	rs9660180	0.934	rs34849348	chr1:1762757	C/T	cg03396347	chr1:1875803	NA	-0.43	-6.69	-0.38	1.33e-10	Body mass index;
CESC	trans	rs877282	1.000	rs11253370	chr10:773712	G/A	cg22713356	chr15:30763199	NA	1.12	11.27	0.57	2.42e-24	Uric acid levels;
CESC	cis	rs6088580	0.634	rs6120669	chr20:33105028	T/C	cg24642439	chr20:33292090	TP53INP2	0.5	6.57	0.37	2.61e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs1790761	0.559	rs10896190	chr11:67406123	T/C	cg24690094	chr11:67383802	NA	0.41	7.01	0.4	1.94e-11	Mean corpuscular volume;
CESC	cis	rs35110281	0.633	rs4819289	chr21:45120237	A/G	cg21573476	chr21:45109991	RRP1B	-0.58	-8.36	-0.46	3.54e-15	Mean corpuscular volume;
CESC	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	7.86	0.43	9.54e-14	Prudent dietary pattern;
CESC	cis	rs3768617	0.510	rs10797846	chr1:183087485	A/T	ch.1.3577855R	chr1:183094577	LAMC1	0.89	14.36	0.66	5.49e-35	Fuchs's corneal dystrophy;
CESC	cis	rs9322193	0.923	rs10872645	chr6:150063976	G/A	cg13206674	chr6:150067644	NUP43	0.41	5.72	0.33	2.81e-8	Lung cancer;
CESC	cis	rs4835473	0.932	rs4835476	chr4:144906670	T/G	cg25736465	chr4:144833511	NA	0.41	6.29	0.36	1.28e-9	Immature fraction of reticulocytes;
CESC	cis	rs13191362	1.000	rs68144677	chr6:163149024	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.09	11.12	0.56	7.8e-24	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.66	8.91	0.48	8.17e-17	Prudent dietary pattern;
CESC	cis	rs2228479	0.850	rs11647174	chr16:89958538	G/A	cg06558623	chr16:89946397	TCF25	1.17	9.37	0.5	3.29e-18	Skin colour saturation;
CESC	cis	rs2303745	0.544	rs6512181	chr19:17399213	T/G	cg22549504	chr19:17448937	GTPBP3	0.52	5.88	0.34	1.24e-8	Systemic lupus erythematosus;
CESC	cis	rs7845219	0.544	rs2123647	chr8:95931782	A/G	cg13393036	chr8:95962371	TP53INP1	0.42	8.03	0.44	3.14e-14	Type 2 diabetes;
CESC	cis	rs1348850	0.914	rs4893823	chr2:178285811	C/T	cg23306229	chr2:178417860	TTC30B	-0.67	-8.72	-0.47	3.11e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs9287719	0.837	rs4233882	chr2:10755564	A/G	cg00105475	chr2:10696890	NA	0.37	5.2	0.3	3.96e-7	Prostate cancer;
CESC	cis	rs875971	0.895	rs10447522	chr7:65796074	A/G	cg11764359	chr7:65958608	NA	-0.79	-11.58	-0.58	2.22e-25	Aortic root size;
CESC	cis	rs9322193	0.923	rs35830138	chr6:149989771	T/C	cg13206674	chr6:150067644	NUP43	0.43	6.15	0.35	2.83e-9	Lung cancer;
CESC	cis	rs208520	0.954	rs72884027	chr6:66995044	T/G	cg07460842	chr6:66804631	NA	0.88	9.99	0.52	3.87e-20	Exhaled nitric oxide output;
CESC	cis	rs739401	0.527	rs423236	chr11:3065916	C/T	cg08508325	chr11:3079039	CARS	-0.54	-10.23	-0.53	6.21e-21	Longevity;
CESC	cis	rs9486715	0.830	rs1475748	chr6:97034143	T/C	cg06623918	chr6:96969491	KIAA0776	-0.95	-14.99	-0.68	3.24e-37	Headache;
CESC	cis	rs1552244	1.000	rs722509	chr3:10102377	T/A	cg00149659	chr3:10157352	C3orf10	0.72	8.61	0.47	6.41e-16	Alzheimer's disease;
CESC	cis	rs13095912	0.889	rs6778977	chr3:185302532	T/G	cg11274856	chr3:185301563	NA	0.37	6.02	0.35	5.91e-9	Systolic blood pressure;
CESC	cis	rs10504229	1.000	rs112284078	chr8:58191640	A/G	cg24829409	chr8:58192753	C8orf71	-0.78	-10.21	-0.53	7.21e-21	Developmental language disorder (linguistic errors);
CESC	cis	rs6952808	0.501	rs4721429	chr7:2171704	T/C	cg23048001	chr7:2026167	MAD1L1	0.42	5.38	0.31	1.62e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs116095464	0.558	rs2162870	chr5:228129	G/A	cg22496380	chr5:211416	CCDC127	-0.74	-8.65	-0.47	5.2e-16	Breast cancer;
CESC	cis	rs9831754	0.906	rs9840031	chr3:78396140	C/T	cg06138941	chr3:78371609	NA	0.69	8.52	0.46	1.26e-15	Calcium levels;
CESC	cis	rs2404602	0.735	rs2454454	chr15:76823647	A/G	cg23625390	chr15:77176239	SCAPER	-0.4	-5.69	-0.33	3.31e-8	Blood metabolite levels;
CESC	cis	rs4683142	0.518	rs7653682	chr3:46029271	A/G	cg18004856	chr3:46029278	FYCO1	0.41	5.61	0.33	5.07e-8	Methadone dose in opioid dependence;
CESC	cis	rs3858526	0.523	rs10769289	chr11:5886607	C/T	cg05234568	chr11:5960015	NA	-0.66	-9.96	-0.52	4.63e-20	DNA methylation (variation);
CESC	cis	rs1799949	0.930	rs2298861	chr17:41176831	G/A	cg25072359	chr17:41440525	NA	0.49	6.41	0.37	6.64e-10	Menopause (age at onset);
CESC	cis	rs13191362	0.810	rs66921603	chr6:162996982	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.88	9.16	0.49	1.46e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs2354432	0.556	rs34602039	chr1:146850972	G/A	cg25205988	chr1:146714368	CHD1L	-1.07	-9.01	-0.48	4.13e-17	Mitochondrial DNA levels;
CESC	cis	rs4713118	0.621	rs9295756	chr6:28033396	G/T	cg26335602	chr6:28129616	ZNF389	0.48	6.07	0.35	4.39e-9	Parkinson's disease;
CESC	cis	rs4072980	0.545	rs12120737	chr1:38422544	C/T	cg12658694	chr1:38397304	INPP5B	0.65	8.98	0.48	5e-17	Coronary artery disease;
CESC	cis	rs7666738	0.830	rs732299	chr4:98995389	C/T	cg18180107	chr4:99064573	C4orf37	0.4	5.18	0.3	4.42e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4555082	0.794	rs2735827	chr14:105710600	T/A	cg13114125	chr14:105738426	BRF1	-0.8	-9.72	-0.51	2.68e-19	Mean platelet volume;Platelet distribution width;
CESC	cis	rs2952156	0.920	rs1476278	chr17:37836243	C/T	cg07936489	chr17:37558343	FBXL20	-0.6	-7.98	-0.44	4.39e-14	Asthma;
CESC	cis	rs2243480	1.000	rs56291018	chr7:65390339	G/A	cg18252515	chr7:66147081	NA	-1.18	-10.88	-0.56	5.02e-23	Diabetic kidney disease;
CESC	cis	rs9611565	0.659	rs73178626	chr22:41928371	T/G	cg06481639	chr22:41940642	POLR3H	-0.6	-6.28	-0.36	1.35e-9	Vitiligo;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24449463	chr1:168025552	DCAF6	-0.66	-7.71	-0.43	2.47e-13	Gut microbiome composition (summer);
CESC	cis	rs561341	0.556	rs542244	chr17:30307242	T/C	cg00745463	chr17:30367425	LRRC37B	-0.78	-7.07	-0.4	1.39e-11	Hip circumference adjusted for BMI;
CESC	trans	rs35110281	0.627	rs1436291	chr21:44965485	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.57	7.61	0.42	4.68e-13	Mean corpuscular volume;
CESC	cis	rs7208859	0.623	rs7217984	chr17:29092766	G/A	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.17e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs7100689	0.753	rs1856773	chr10:82060484	T/A	cg00277334	chr10:82204260	NA	-0.58	-7.31	-0.41	3.1e-12	Post bronchodilator FEV1;
CESC	cis	rs6456156	0.792	rs4710179	chr6:167513692	G/T	cg23791538	chr6:167370224	RNASET2	-0.39	-5.09	-0.3	6.69e-7	Primary biliary cholangitis;
CESC	cis	rs3096299	0.685	rs4785676	chr16:89553624	T/C	cg00750074	chr16:89608354	SPG7	-0.46	-6.6	-0.38	2.2e-10	Multiple myeloma (IgH translocation);
CESC	cis	rs1843834	0.898	rs2014887	chr2:225520082	A/G	cg22455342	chr2:225449267	CUL3	0.52	6.56	0.37	2.79e-10	IgE levels in asthmatics (D.p. specific);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg12951224	chr8:38126910	PPAPDC1B	0.49	6.32	0.36	1.13e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs1878931	0.520	rs2015640	chr16:3465018	G/C	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.74	-8.58	-0.47	8.04e-16	Body mass index (adult);
CESC	cis	rs13191362	0.935	rs66923841	chr6:163177317	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.59	5.69	0.33	3.44e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs9549367	0.789	rs71446682	chr13:113894908	A/G	cg00898013	chr13:113819073	PROZ	-0.51	-6.94	-0.39	3.06e-11	Platelet distribution width;
CESC	cis	rs6831352	0.918	rs4699714	chr4:100060538	A/G	cg12011299	chr4:100065546	ADH4	-0.59	-6.59	-0.38	2.35e-10	Alcohol dependence;
CESC	cis	rs875971	0.825	rs59466412	chr7:65565358	A/G	cg18876405	chr7:65276391	NA	-0.57	-7.55	-0.42	6.85e-13	Aortic root size;
CESC	cis	rs853679	0.517	rs35227624	chr6:28132726	A/G	cg20151795	chr6:28129481	ZNF389	0.44	5.55	0.32	6.85e-8	Depression;
CESC	cis	rs6502050	0.835	rs62078305	chr17:80085326	G/A	cg11859384	chr17:80120422	CCDC57	0.38	5.08	0.3	7.27e-7	Life satisfaction;
CESC	cis	rs1322639	0.614	rs6925950	chr6:169563958	A/G	cg04662567	chr6:169592167	NA	-0.5	-5.26	-0.31	2.93e-7	Pulse pressure;
CESC	cis	rs6973256	0.583	rs2345943	chr7:133340630	A/G	cg10665199	chr7:133106180	EXOC4	-0.48	-6.6	-0.38	2.18e-10	Intelligence (multi-trait analysis);
CESC	cis	rs1670533	1.000	rs2045066	chr4:1052401	C/T	cg04106633	chr4:1044584	NA	0.4	5.27	0.31	2.81e-7	Recombination rate (females);
CESC	cis	rs4595586	0.545	rs61939643	chr12:39378460	G/A	cg26384229	chr12:38710491	ALG10B	0.54	7.53	0.42	7.85e-13	Morning vs. evening chronotype;
CESC	cis	rs801193	1.000	rs1553610	chr7:66197233	T/C	cg06456125	chr7:65229604	NA	0.4	5.23	0.31	3.51e-7	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03970961	chr1:154292240	AQP10	-0.54	-7.47	-0.42	1.2e-12	Gut microbiome composition (summer);
CESC	cis	rs7589342	0.628	rs11886675	chr2:106409118	G/T	cg16077055	chr2:106428750	NCK2	0.54	6.84	0.39	5.44e-11	Addiction;
CESC	cis	rs854765	0.583	rs8075965	chr17:17853180	A/T	cg04398451	chr17:18023971	MYO15A	-0.69	-9.86	-0.52	9.76e-20	Total body bone mineral density;
CESC	cis	rs5753618	0.583	rs2273251	chr22:31843567	G/C	cg02404636	chr22:31891804	SFI1	0.4	5.43	0.32	1.3e-7	Colorectal cancer;
CESC	cis	rs3925075	1.000	rs4889543	chr16:31340216	C/T	cg02846316	chr16:31340340	ITGAM	0.43	6.68	0.38	1.41e-10	IgA nephropathy;
CESC	cis	rs7945705	0.935	rs1883098	chr11:8890594	G/A	cg09997546	chr11:8931473	C11orf17;ST5	-0.39	-6.75	-0.38	9.31e-11	Hemoglobin concentration;
CESC	cis	rs7937682	0.562	rs519850	chr11:111376888	A/T	cg09085632	chr11:111637200	PPP2R1B	-0.64	-8.59	-0.47	7.45e-16	Primary sclerosing cholangitis;
CESC	cis	rs1552244	0.935	rs41520445	chr3:10153141	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.88	-12.58	-0.61	9.2e-29	Alzheimer's disease;
CESC	cis	rs896854	0.738	rs527234	chr8:95963798	C/G	cg16049864	chr8:95962084	TP53INP1	0.64	10.1	0.53	1.72e-20	Type 2 diabetes;
CESC	cis	rs1707322	1.000	rs1707317	chr1:46510642	C/T	cg06784218	chr1:46089804	CCDC17	-0.35	-5.96	-0.34	7.81e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs12500824	0.564	rs62303261	chr4:77286929	C/T	cg20311846	chr4:77356250	SHROOM3	0.37	6.68	0.38	1.41e-10	Coronary artery disease;
CESC	cis	rs6662572	0.737	rs9429184	chr1:46524739	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.45	5.12	0.3	5.86e-7	Blood protein levels;
CESC	cis	rs7296418	0.961	rs4148862	chr12:123568619	A/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.33	-5.07	-0.3	7.65e-7	Platelet count;
CESC	cis	rs7833790	0.724	rs1054078	chr8:82712153	A/G	cg17211192	chr8:82754475	SNX16	-0.58	-7.38	-0.41	2.05e-12	Diastolic blood pressure;
CESC	cis	rs7188697	0.882	rs37054	chr16:58558989	C/T	cg02549819	chr16:58548995	SETD6	-0.42	-5.23	-0.31	3.45e-7	QT interval;
CESC	cis	rs11608355	0.515	rs7310945	chr12:109946012	G/A	cg05360138	chr12:110035743	NA	0.82	8.85	0.48	1.27e-16	Neuroticism;
CESC	cis	rs7923609	0.967	rs7085621	chr10:65208926	T/C	cg01631684	chr10:65280961	REEP3	-0.43	-5.39	-0.31	1.55e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs11608355	0.515	rs7311488	chr12:109930905	C/G	cg05360138	chr12:110035743	NA	-0.79	-8.46	-0.46	1.85e-15	Neuroticism;
CESC	cis	rs10214930	0.671	rs7799957	chr7:27882260	A/G	cg05786569	chr7:27702416	HIBADH	0.45	5.46	0.32	1.08e-7	Hypospadias;
CESC	cis	rs959260	0.925	rs9747801	chr17:73396572	C/T	cg12999837	chr17:73267436	MIF4GD	-0.48	-5.52	-0.32	8.2e-8	Systemic lupus erythematosus;
CESC	cis	rs1552244	1.000	rs17032299	chr3:10087638	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.78	-10.17	-0.53	9.95e-21	Alzheimer's disease;
CESC	cis	rs1348850	0.958	rs1545364	chr2:178462882	G/T	cg22681709	chr2:178499509	PDE11A	-0.34	-5.16	-0.3	4.86e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs35110281	0.715	rs2838320	chr21:44995037	A/G	cg01579765	chr21:45077557	HSF2BP	-0.53	-8.85	-0.48	1.32e-16	Mean corpuscular volume;
CESC	cis	rs965513	1.000	rs7028661	chr9:100538470	A/G	cg13688889	chr9:100608707	NA	-0.6	-8.47	-0.46	1.71e-15	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
CESC	cis	rs1670533	1.000	rs6850784	chr4:1059809	G/A	cg04106633	chr4:1044584	NA	0.4	5.19	0.3	4.15e-7	Recombination rate (females);
CESC	cis	rs1862618	0.853	rs252916	chr5:56121788	G/C	cg22800045	chr5:56110881	MAP3K1	0.82	10.18	0.53	9.04e-21	Initial pursuit acceleration;
CESC	cis	rs7635838	0.859	rs9812885	chr3:11508326	G/C	cg00170343	chr3:11313890	ATG7	0.42	5.64	0.33	4.38e-8	HDL cholesterol;
CESC	cis	rs7811142	1.000	rs67315960	chr7:100015124	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.01	9.83	0.52	1.21e-19	Platelet count;
CESC	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg11965913	chr1:205819406	PM20D1	0.76	11.83	0.59	3.37e-26	Menarche (age at onset);
CESC	cis	rs9916302	0.706	rs3744349	chr17:37414842	C/T	cg07936489	chr17:37558343	FBXL20	-0.87	-9.31	-0.5	5.09e-18	Glomerular filtration rate (creatinine);
CESC	cis	rs2228479	0.850	rs1108063	chr16:89893983	A/G	cg04013166	chr16:89971882	TCF25	0.67	5.46	0.32	1.08e-7	Skin colour saturation;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg08971769	chr10:75258327	USP54	-0.49	-6.37	-0.36	8.19e-10	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs10927875	0.632	rs2862162	chr1:16142960	A/C	cg05821634	chr1:16164109	FLJ37453	-0.35	-5.17	-0.3	4.72e-7	Dilated cardiomyopathy;
CESC	cis	rs6580649	0.941	rs3742074	chr12:48457385	C/T	cg05342945	chr12:48394962	COL2A1	0.5	5.85	0.34	1.47e-8	Lung cancer;
CESC	cis	rs57221529	0.825	rs7443550	chr5:578404	G/T	cg16447950	chr5:562315	NA	-0.64	-6.81	-0.39	6.59e-11	Lung disease severity in cystic fibrosis;
CESC	cis	rs9905704	0.645	rs17175543	chr17:56803598	G/T	cg12560992	chr17:57184187	TRIM37	0.63	5.88	0.34	1.21e-8	Testicular germ cell tumor;
CESC	cis	rs637571	0.522	rs566590	chr11:65754062	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.74	10.65	0.55	2.7e-22	Eosinophil percentage of white cells;
CESC	cis	rs7833790	0.654	rs7835342	chr8:82698092	A/G	cg07697082	chr8:82753677	SNX16	0.36	5.54	0.32	7.16e-8	Diastolic blood pressure;
CESC	trans	rs11250098	0.541	rs6997997	chr8:10766082	T/C	cg15556689	chr8:8085844	FLJ10661	-0.54	-6.26	-0.36	1.55e-9	Morning vs. evening chronotype;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg02872018	chr2:192746213	NA	-0.46	-6.57	-0.37	2.6200000000000003e-10	Thyroid stimulating hormone;
CESC	cis	rs9611565	0.592	rs28750375	chr22:41990644	A/C	cg06634786	chr22:41940651	POLR3H	-0.57	-6.24	-0.36	1.69e-9	Vitiligo;
CESC	trans	rs10242455	0.571	rs45532337	chr7:99310319	A/G	cg09045935	chr12:6379348	NA	0.73	6.54	0.37	3.14e-10	Blood metabolite levels;
CESC	cis	rs6089829	0.962	rs4809456	chr20:61660849	C/A	cg16240275	chr20:61666158	NCRNA00029	0.51	9.07	0.49	2.84e-17	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs6598163	0.712	rs10751695	chr12:132291061	A/C	cg00078996	chr12:132293329	NA	-0.45	-5.99	-0.35	6.77e-9	Migraine;
CESC	cis	rs7225151	0.518	rs56176579	chr17:5262253	C/T	cg24500398	chr17:5266808	RABEP1	-0.55	-6.69	-0.38	1.36e-10	Alzheimer's disease (late onset);
CESC	cis	rs60843830	1.000	rs11553746	chr2:272203	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.89	11.92	0.59	1.67e-26	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs225245	0.817	rs225297	chr17:33924587	G/A	cg05299278	chr17:33885742	SLFN14	0.38	5.46	0.32	1.08e-7	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
CESC	cis	rs1215050	0.740	rs783938	chr4:99010336	A/T	cg05340658	chr4:99064831	C4orf37	-0.53	-7.17	-0.4	7.67e-12	Waist-to-hip ratio adjusted for body mass index;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16759888	chr6:46620647	CYP39A1;SLC25A27	0.56	6.01	0.35	6.24e-9	Gut microbiome composition (summer);
CESC	cis	rs447735	0.566	rs258337	chr16:89720710	T/A	cg03605463	chr16:89740564	NA	0.43	5.31	0.31	2.3e-7	Hemoglobin concentration;
CESC	cis	rs5769707	0.846	rs5770610	chr22:50036897	A/C	cg05373962	chr22:49881684	NA	-0.4	-6.91	-0.39	3.65e-11	Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs7116495	0.737	rs661290	chr11:71766014	A/G	cg07596299	chr11:71824057	C11orf51	-0.85	-5.29	-0.31	2.51e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs9399137	0.507	rs13196486	chr6:135283874	C/G	cg22676075	chr6:135203613	NA	0.53	7.0	0.39	2.14e-11	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	cis	rs8114671	0.805	rs4616	chr20:33590358	C/T	cg06115741	chr20:33292138	TP53INP2	-0.46	-5.53	-0.32	7.8e-8	Height;
CESC	cis	rs67478160	0.595	rs12889993	chr14:104274294	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.51	-7.19	-0.4	6.56e-12	Schizophrenia;
CESC	cis	rs1843834	0.688	rs2396149	chr2:225601985	G/A	cg22455342	chr2:225449267	CUL3	0.4	5.19	0.3	4.22e-7	IgE levels in asthmatics (D.p. specific);
CESC	cis	rs11030122	0.661	rs10835561	chr11:4087594	C/T	cg18678763	chr11:4115507	RRM1	-0.47	-6.39	-0.37	7.47e-10	Mean platelet volume;Platelet distribution width;
CESC	cis	rs17253792	0.822	rs10083431	chr14:56068348	G/A	cg01858014	chr14:56050164	KTN1	-0.83	-7.03	-0.4	1.7e-11	Putamen volume;
CESC	cis	rs5758511	0.514	rs9607882	chr22:42567451	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.59	8.74	0.47	2.7e-16	Birth weight;
CESC	cis	rs3105593	1.000	rs11070798	chr15:50883263	T/C	cg08437265	chr15:50716283	USP8	0.42	5.49	0.32	9.52e-8	QT interval;
CESC	cis	rs7216064	0.684	rs7406031	chr17:66021753	C/T	cg07042672	chr17:66097459	LOC651250	0.63	8.27	0.45	6.65e-15	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs7553864	0.614	rs1886634	chr1:87614821	C/T	cg17420885	chr1:87600446	LOC339524	0.46	6.19	0.36	2.3e-9	Smoking behavior;
CESC	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	-1.11	-21.97	-0.8	1.23e-61	Prudent dietary pattern;
CESC	cis	rs910316	0.763	rs6574205	chr14:75453039	G/C	cg11812906	chr14:75593930	NEK9	0.8	12.79	0.62	1.77e-29	Height;
CESC	cis	rs9916302	0.784	rs4795382	chr17:37700860	A/G	cg15445000	chr17:37608096	MED1	0.42	6.91	0.39	3.53e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs6736093	0.796	rs4848980	chr2:112816348	A/G	cg12686935	chr2:112915763	FBLN7	-0.42	-5.63	-0.33	4.68e-8	Coronary artery disease;
CESC	cis	rs1707322	0.721	rs10890346	chr1:46223892	C/T	cg05343316	chr1:45956843	TESK2	-0.48	-6.01	-0.35	6.23e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs875971	0.830	rs28714531	chr7:65968237	G/A	cg10691866	chr7:65817282	TPST1	-0.33	-5.42	-0.32	1.34e-7	Aortic root size;
CESC	cis	rs7086627	0.515	rs10887899	chr10:82210214	G/A	cg00277334	chr10:82204260	NA	-0.9	-15.67	-0.69	1.3e-39	Post bronchodilator FEV1;
CESC	cis	rs1348850	0.574	rs10195917	chr2:178443121	C/T	cg22681709	chr2:178499509	PDE11A	-0.43	-5.36	-0.31	1.79e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs10870270	1.000	rs4880250	chr10:133773919	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.58	-7.47	-0.42	1.14e-12	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs7666738	0.791	rs13146909	chr4:98934198	C/T	cg05340658	chr4:99064831	C4orf37	0.82	12.54	0.61	1.29e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7129220	0.588	rs16907481	chr11:10144108	A/T	cg01453529	chr11:10209919	SBF2	-0.43	-5.22	-0.31	3.65e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08755283	chr5:118324104	DTWD2	0.6	7.32	0.41	3.03e-12	Gut microbiome composition (summer);
CESC	cis	rs7267979	1.000	rs6115168	chr20:25372891	C/A	cg08601574	chr20:25228251	PYGB	-0.38	-5.55	-0.32	6.83e-8	Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg22333016	chr4:54244258	FIP1L1	-0.49	-6.41	-0.37	6.79e-10	Ulcerative colitis;
CESC	cis	rs2295359	1.000	rs10889664	chr1:67635475	C/T	cg03340356	chr1:67600835	NA	0.34	5.4	0.31	1.47e-7	Psoriasis;
CESC	cis	rs2276314	1.000	rs16967317	chr18:33573400	A/G	cg05985134	chr18:33552581	C18orf21	0.64	7.39	0.41	1.9e-12	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs9733	0.536	rs6661415	chr1:150635869	G/A	cg22823121	chr1:150693482	HORMAD1	0.48	7.12	0.4	1.02e-11	Tonsillectomy;
CESC	cis	rs4835473	0.932	rs35055653	chr4:144675989	C/T	cg25736465	chr4:144833511	NA	-0.43	-6.5	-0.37	4.01e-10	Immature fraction of reticulocytes;
CESC	cis	rs7552404	0.731	rs61770556	chr1:76421902	T/C	cg10523679	chr1:76189770	ACADM	0.68	6.31	0.36	1.18e-9	Blood metabolite levels;Acylcarnitine levels;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg05671585	chr4:186064123	SLC25A4	-0.52	-6.23	-0.36	1.79e-9	Ulcerative colitis;
CESC	cis	rs10540	1.000	rs35255804	chr11:492617	G/A	cg03576123	chr11:487126	PTDSS2	-1.1	-11.01	-0.56	1.79e-23	Body mass index;
CESC	cis	rs763014	0.966	rs12935215	chr16:670605	T/C	cg07343612	chr16:622815	PIGQ	-0.57	-8.34	-0.46	4.2e-15	Height;
CESC	cis	rs72781680	1.000	rs72796329	chr2:24141912	G/A	cg20701182	chr2:24300061	SF3B14	0.63	5.67	0.33	3.79e-8	Lymphocyte counts;
CESC	cis	rs6499255	0.904	rs9929720	chr16:69557096	C/T	cg15192750	chr16:69999425	NA	-0.54	-6.29	-0.36	1.31e-9	IgE levels;
CESC	cis	rs2250402	0.510	rs2291619	chr15:40329033	C/T	cg20255370	chr15:40268687	EIF2AK4	0.61	5.61	0.33	5.05e-8	Corneal curvature;
CESC	cis	rs2243480	1.000	rs2533288	chr7:66056711	C/G	cg12463550	chr7:65579703	CRCP	0.72	5.62	0.33	4.87e-8	Diabetic kidney disease;
CESC	cis	rs6489785	0.735	rs12825746	chr12:121268033	A/C	cg02419362	chr12:121203948	SPPL3	0.35	5.52	0.32	8.19e-8	Longevity;Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs72781680	0.898	rs55846516	chr2:24158003	T/C	cg20701182	chr2:24300061	SF3B14	0.65	5.81	0.34	1.79e-8	Lymphocyte counts;
CESC	cis	rs2299587	0.554	rs17634704	chr8:17753306	A/G	cg08627089	chr8:17753878	FGL1	-0.39	-5.65	-0.33	4.15e-8	Economic and political preferences;
CESC	cis	rs12142240	0.698	rs66516678	chr1:46810112	G/T	cg10495392	chr1:46806563	NSUN4	0.59	6.34	0.36	9.65e-10	Menopause (age at onset);
CESC	cis	rs4450798	0.649	rs61179105	chr3:13791319	C/T	cg23332027	chr3:13681764	NA	0.38	5.13	0.3	5.63e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs9322193	0.884	rs1125	chr6:149979416	G/A	cg02462569	chr6:150064036	NUP43	-0.39	-5.74	-0.33	2.52e-8	Lung cancer;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg08403428	chr12:124899777	NCOR2	0.51	6.87	0.39	4.52e-11	Fibrinogen levels;
CESC	cis	rs7524258	0.900	rs2412151	chr1:7303216	G/C	cg07173049	chr1:7289937	CAMTA1	0.37	5.62	0.33	4.8e-8	Tourette's syndrome or obsessive-compulsive disorder;
CESC	cis	rs72634258	0.699	rs12128234	chr1:8170219	T/C	cg00042356	chr1:8021962	PARK7	-0.56	-5.99	-0.35	6.97e-9	Inflammatory bowel disease;
CESC	cis	rs7412746	0.658	rs3768015	chr1:150812954	C/T	cg04414720	chr1:150670196	GOLPH3L	0.57	7.68	0.43	3.18e-13	Melanoma;
CESC	cis	rs7666738	0.861	rs10018654	chr4:99002226	A/G	cg03467027	chr4:99064603	C4orf37	0.44	5.5	0.32	9.09e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7666738	0.830	rs6852015	chr4:99054373	C/A	cg05340658	chr4:99064831	C4orf37	0.82	12.88	0.62	8.44e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6582630	0.555	rs34884627	chr12:38443831	C/T	cg26384229	chr12:38710491	ALG10B	-0.44	-5.95	-0.34	8.28e-9	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs6032067	1.000	rs6032067	chr20:43864809	G/T	cg10761708	chr20:43804764	PI3	0.52	6.26	0.36	1.52e-9	Blood protein levels;
CESC	cis	rs2797160	1.000	rs9321050	chr6:126001568	A/G	cg05901451	chr6:126070800	HEY2	-0.46	-6.64	-0.38	1.76e-10	Endometrial cancer;
CESC	cis	rs9322193	0.962	rs9397357	chr6:150133601	G/A	cg07701084	chr6:150067640	NUP43	0.4	5.49	0.32	9.18e-8	Lung cancer;
CESC	cis	rs17641971	0.684	rs4873095	chr8:49990166	A/T	cg00325661	chr8:49890786	NA	0.39	5.5	0.32	8.94e-8	Blood metabolite levels;
CESC	cis	rs12545109	0.800	rs1440762	chr8:57410708	C/T	cg09654669	chr8:57350985	NA	-0.47	-6.5	-0.37	4.05e-10	Obesity-related traits;
CESC	cis	rs7851660	0.901	rs2401639	chr9:100607837	T/C	cg13688889	chr9:100608707	NA	-0.68	-10.61	-0.55	3.8e-22	Strep throat;
CESC	trans	rs561341	1.000	rs4795670	chr17:30244839	T/C	cg27661571	chr11:113659931	NA	-0.62	-6.6	-0.38	2.27e-10	Hip circumference adjusted for BMI;
CESC	cis	rs9908102	0.740	rs60875833	chr17:12912789	T/G	cg26162695	chr17:12921313	ELAC2	0.52	5.71	0.33	3.04e-8	Schizophrenia;
CESC	cis	rs6547741	1.000	rs6547740	chr2:27854369	C/T	cg21248554	chr2:27665150	KRTCAP3	0.24	5.1	0.3	6.55e-7	Oral cavity cancer;
CESC	trans	rs1814175	0.618	rs1851843	chr11:50021846	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.42	-6.13	-0.35	3.1e-9	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05593479	chr2:233415006	TIGD1;EIF4E2	-0.61	-7.52	-0.42	8.54e-13	Gut microbiome composition (summer);
CESC	trans	rs1814175	0.619	rs10769623	chr11:49865926	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.41	-6.15	-0.35	2.81e-9	Height;
CESC	trans	rs11039798	0.565	rs7118675	chr11:48532063	C/A	cg03929089	chr4:120376271	NA	0.61	6.02	0.35	5.81e-9	Axial length;
CESC	cis	rs76878669	0.561	rs7948058	chr11:66148111	T/A	cg18002602	chr11:66138449	SLC29A2	-0.41	-6.76	-0.38	8.55e-11	Educational attainment (years of education);
CESC	cis	rs875971	0.862	rs13232191	chr7:65986648	A/G	cg18252515	chr7:66147081	NA	-0.47	-6.08	-0.35	4.25e-9	Aortic root size;
CESC	cis	rs4716602	0.827	rs10270019	chr7:156158973	T/C	cg04090468	chr7:156181990	NA	0.4	5.15	0.3	5.18e-7	Anti-saccade response;
CESC	cis	rs1062177	0.826	rs2053063	chr5:151166764	T/C	cg12924095	chr5:151150029	G3BP1	0.45	5.97	0.34	7.43e-9	Preschool internalizing problems;
CESC	trans	rs17181170	0.523	rs62257771	chr3:87208290	C/T	ch.2.199792288R	chr2:200084043	NA	-0.46	-6.1	-0.35	3.78e-9	Prostate cancer;
CESC	cis	rs6061231	0.544	rs2427314	chr20:60973666	C/T	cg22633769	chr20:60982531	CABLES2	0.71	9.11	0.49	2.04e-17	Colorectal cancer;
CESC	cis	rs2075371	0.796	rs1646644	chr7:134011817	A/T	cg00033643	chr7:134001901	SLC35B4	0.41	5.1	0.3	6.33e-7	Mean platelet volume;
CESC	cis	rs4481887	0.604	rs4430368	chr1:248411573	A/G	cg00666640	chr1:248458726	OR2T12	0.42	6.45	0.37	5.31e-10	Common traits (Other);
CESC	cis	rs9359856	0.564	rs11961752	chr6:90481896	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.64	-6.06	-0.35	4.56e-9	Bipolar disorder;
CESC	cis	rs2033711	0.870	rs7409473	chr19:58939165	A/G	cg00825309	chr19:58991885	ZNF446	-0.55	-7.86	-0.43	9.42e-14	Uric acid clearance;
CESC	cis	rs6831352	0.918	rs2851248	chr4:100045974	A/G	cg13256891	chr4:100009986	ADH5	0.65	7.2	0.4	6.26e-12	Alcohol dependence;
CESC	cis	rs9796	0.649	rs8035828	chr15:41467287	T/A	cg18705301	chr15:41695430	NDUFAF1	-0.44	-6.42	-0.37	6.29e-10	Menopause (age at onset);
CESC	cis	rs709400	0.663	rs62007684	chr14:103894223	T/C	cg12935359	chr14:103987150	CKB	-0.56	-8.22	-0.45	8.94e-15	Body mass index;
CESC	cis	rs4253772	0.591	rs10854854	chr22:46684706	C/G	cg18190219	chr22:46762943	CELSR1	-0.51	-5.53	-0.32	7.6e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs2425143	1.000	rs2425143	chr20:34350666	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.8	-7.96	-0.44	5.07e-14	Blood protein levels;
CESC	cis	rs3858526	0.635	rs2045046	chr11:5875867	A/C	cg13902645	chr11:5959945	NA	-0.53	-5.7	-0.33	3.17e-8	DNA methylation (variation);
CESC	cis	rs2070488	0.965	rs1065800	chr3:38566480	C/T	cg24069376	chr3:38537580	EXOG	-0.45	-8.36	-0.46	3.55e-15	Electrocardiographic conduction measures;
CESC	cis	rs9303280	0.901	rs869402	chr17:38068043	C/T	cg19468946	chr17:37922297	IKZF3	-0.39	-5.54	-0.32	7.27e-8	Self-reported allergy;
CESC	cis	rs116095464	0.558	rs112343653	chr5:257174	G/A	cg20965017	chr5:231967	SDHA	-0.47	-5.22	-0.31	3.61e-7	Breast cancer;
CESC	cis	rs74781061	0.929	rs4887159	chr15:74865882	G/A	cg17294928	chr15:75287854	SCAMP5	-0.48	-5.15	-0.3	5.01e-7	Endometriosis;
CESC	cis	rs2230307	0.536	rs534252	chr1:100472604	A/G	cg24955406	chr1:100503596	HIAT1	0.55	5.48	0.32	9.85e-8	Carotid intima media thickness;
CESC	trans	rs12936587	0.538	rs1869771	chr17:17561094	C/A	cg00642494	chr5:76941749	NA	-0.41	-6.16	-0.35	2.71e-9	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
CESC	cis	rs1862618	0.853	rs9283717	chr5:56078659	G/A	cg12311346	chr5:56204834	C5orf35	-0.74	-9.03	-0.49	3.59e-17	Initial pursuit acceleration;
CESC	cis	rs4843747	0.641	rs11117353	chr16:88090895	A/G	cg06915872	chr16:87998081	BANP	0.46	5.54	0.32	7.21e-8	Menopause (age at onset);
CESC	cis	rs703842	0.616	rs4760171	chr12:58225904	A/G	cg02175503	chr12:58329896	NA	0.46	5.85	0.34	1.42e-8	Multiple sclerosis;
CESC	cis	rs7659604	0.702	rs6815790	chr4:122695385	A/C	cg20573242	chr4:122745356	CCNA2	0.51	6.31	0.36	1.15e-9	Type 2 diabetes;
CESC	cis	rs4699052	0.590	rs1356293	chr4:104288200	A/C	cg16532752	chr4:104119610	CENPE	-0.39	-5.49	-0.32	9.52e-8	Testicular germ cell tumor;
CESC	cis	rs6942756	0.713	rs691807	chr7:129076203	G/C	cg02491457	chr7:128862824	NA	-0.57	-7.67	-0.43	3.28e-13	White matter hyperintensity burden;
CESC	cis	rs7503807	0.967	rs12947696	chr17:78596793	C/T	cg09596252	chr17:78655493	RPTOR	0.52	7.69	0.43	2.93e-13	Obesity;
CESC	cis	rs7605827	0.930	rs7568874	chr2:15546361	T/C	cg19274914	chr2:15703543	NA	0.35	6.27	0.36	1.45e-9	Educational attainment (years of education);
CESC	cis	rs870825	0.655	rs28661636	chr4:185634218	A/C	cg04058563	chr4:185651563	MLF1IP	0.63	6.89	0.39	3.95e-11	Blood protein levels;
CESC	cis	rs2836974	0.897	rs3945	chr21:40566067	A/G	cg11644478	chr21:40555479	PSMG1	0.99	14.37	0.66	4.94e-35	Cognitive function;
CESC	cis	rs514406	0.893	rs499195	chr1:53344907	C/T	cg08859206	chr1:53392774	SCP2	-0.56	-7.37	-0.41	2.2e-12	Monocyte count;
CESC	cis	rs9325144	0.647	rs7316392	chr12:39064381	T/G	cg26384229	chr12:38710491	ALG10B	-0.51	-7.09	-0.4	1.22e-11	Morning vs. evening chronotype;
CESC	cis	rs731174	0.802	rs579908	chr1:38187447	A/G	cg12339802	chr1:38156545	C1orf109	-0.56	-5.68	-0.33	3.52e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs35306767	0.622	rs66462130	chr10:1022108	C/T	cg20503657	chr10:835505	NA	0.74	6.75	0.38	9.51e-11	Eosinophil percentage of granulocytes;
CESC	cis	rs7917772	0.503	rs11191326	chr10:104302959	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.54	7.49	0.42	9.98e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs2404602	0.647	rs35940181	chr15:77180019	G/A	cg23625390	chr15:77176239	SCAPER	-0.44	-6.04	-0.35	5.32e-9	Blood metabolite levels;
CESC	cis	rs7264396	0.563	rs2425136	chr20:34344782	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.9	-10.85	-0.55	6.29e-23	Total cholesterol levels;
CESC	cis	rs17854409	0.803	rs1063246	chr20:61472116	G/A	cg05147244	chr20:61493195	TCFL5	0.96	6.44	0.37	5.65e-10	Obesity-related traits;
CESC	cis	rs2273669	0.667	rs11153153	chr6:109356104	A/T	cg05315195	chr6:109294784	ARMC2	-0.67	-6.06	-0.35	4.74e-9	Prostate cancer;
CESC	cis	rs763121	0.853	rs5757253	chr22:39104320	C/T	cg06544989	chr22:39130855	UNC84B	0.51	9.77	0.51	1.9e-19	Menopause (age at onset);
CESC	cis	rs8072100	0.701	rs8075566	chr17:45771037	G/A	cg08085267	chr17:45401833	C17orf57	-0.42	-5.31	-0.31	2.33e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs962856	0.575	rs3770655	chr2:67632125	C/T	cg09028215	chr2:67624308	ETAA1	-0.43	-5.27	-0.31	2.86e-7	Pancreatic cancer;
CESC	cis	rs9790314	1.000	rs336569	chr3:161072346	T/G	cg03342759	chr3:160939853	NMD3	-0.47	-6.3	-0.36	1.26e-9	Morning vs. evening chronotype;
CESC	cis	rs7615952	0.576	rs6804482	chr3:125815762	C/T	cg18479299	chr3:125709523	NA	-0.47	-5.05	-0.3	8.2e-7	Blood pressure (smoking interaction);
CESC	cis	rs1577917	1.000	rs1415753	chr6:86753074	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.45	-5.85	-0.34	1.47e-8	Response to antipsychotic treatment;
CESC	cis	rs6439153	0.933	rs2630262	chr3:128677098	C/T	cg25356066	chr3:128598488	ACAD9	-0.51	-6.86	-0.39	4.74e-11	Pneumococcal bacteremia;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg02570054	chr12:49717017	TROAP	0.5	6.4	0.37	7.15e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs4819052	0.851	rs2838858	chr21:46681093	T/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.92	13.64	0.64	1.84e-32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg15383120	chr6:291909	DUSP22	-0.67	-8.61	-0.47	6.67e-16	Menopause (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13625205	chr1:151584902	SNX27	0.58	7.12	0.4	1.03e-11	Gut microbiome composition (summer);
CESC	cis	rs2735413	0.918	rs12931394	chr16:78081629	G/A	cg04733911	chr16:78082701	NA	-0.53	-9.01	-0.48	4.08e-17	Systolic blood pressure (alcohol consumption interaction);
CESC	cis	rs1801251	0.929	rs12694917	chr2:233707611	C/T	cg08000102	chr2:233561755	GIGYF2	-0.67	-9.8	-0.52	1.45e-19	Coronary artery disease;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg09360458	chr1:14075560	PRDM2	-0.54	-7.57	-0.42	6.04e-13	Gut microbiota (bacterial taxa);
CESC	cis	rs514406	0.861	rs7513052	chr1:53241360	C/T	cg25767906	chr1:53392781	SCP2	0.43	6.06	0.35	4.75e-9	Monocyte count;
CESC	trans	rs1814175	0.645	rs7952104	chr11:49964180	C/T	cg03929089	chr4:120376271	NA	-0.92	-15.24	-0.68	4.38e-38	Height;
CESC	cis	rs919433	0.783	rs3097383	chr2:198236887	A/G	cg03934865	chr2:198174659	NA	0.43	6.21	0.36	2.01e-9	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs116095464	0.558	rs55664502	chr5:270485	T/C	cg20965017	chr5:231967	SDHA	-0.45	-5.14	-0.3	5.34e-7	Breast cancer;
CESC	cis	rs2236918	0.664	rs1776158	chr1:242017658	C/T	cg17736920	chr1:242011382	EXO1	0.52	6.68	0.38	1.4e-10	Menopause (age at onset);
CESC	cis	rs35955747	0.869	rs8142988	chr22:31587158	T/C	cg25791279	chr22:32026902	PISD	-0.41	-5.11	-0.3	6.14e-7	Neutrophil count;Sum basophil neutrophil counts;
CESC	cis	rs826838	1.000	rs11183941	chr12:38851692	G/C	cg26384229	chr12:38710491	ALG10B	0.83	14.57	0.67	1.05e-35	Heart rate;
CESC	cis	rs6570726	0.818	rs9399555	chr6:145877554	T/C	cg23711669	chr6:146136114	FBXO30	0.87	12.91	0.62	6.56e-30	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs113835537	0.529	rs57634456	chr11:66250838	A/C	cg24851651	chr11:66362959	CCS	0.44	5.51	0.32	8.41e-8	Airway imaging phenotypes;
CESC	cis	rs9733	0.596	rs6685702	chr1:150656307	A/G	cg18016565	chr1:150552671	MCL1	0.33	5.14	0.3	5.34e-7	Tonsillectomy;
CESC	cis	rs7714584	1.000	rs73282209	chr5:150174959	G/A	cg22134413	chr5:150180641	NA	0.66	6.54	0.37	3.09e-10	Crohn's disease;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg06213876	chr16:16357187	NOMO3	0.48	6.09	0.35	4.01e-9	Thyroid stimulating hormone;
CESC	cis	rs40363	0.645	rs250627	chr16:3527050	G/A	cg21433313	chr16:3507492	NAT15	0.5	8.02	0.44	3.5e-14	Tuberculosis;
CESC	cis	rs7520050	0.966	rs12561806	chr1:46396776	C/T	cg24296786	chr1:45957014	TESK2	0.44	5.49	0.32	9.64e-8	Red blood cell count;Reticulocyte count;
CESC	cis	rs933688	1.000	rs12656350	chr5:90751343	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.9	10.12	0.53	1.41e-20	Smoking behavior;
CESC	cis	rs11696501	0.739	rs6104249	chr20:44250487	C/G	cg11783356	chr20:44313418	WFDC10B	0.33	5.27	0.31	2.88e-7	Brain structure;
CESC	trans	rs8057939	0.593	rs11860353	chr16:49409253	A/T	cg15532236	chr6:170188124	NA	0.5	6.1	0.35	3.75e-9	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs11098499	0.691	rs10010355	chr4:120261043	A/G	cg25214090	chr10:38739885	LOC399744	0.61	8.68	0.47	4.06e-16	Corneal astigmatism;
CESC	cis	rs9733	0.596	rs11803569	chr1:150664077	C/T	cg17724175	chr1:150552817	MCL1	0.44	7.23	0.41	5.25e-12	Tonsillectomy;
CESC	cis	rs9611565	0.729	rs137831	chr22:41903813	A/C	cg06634786	chr22:41940651	POLR3H	-0.5	-5.71	-0.33	2.99e-8	Vitiligo;
CESC	cis	rs1552244	1.000	rs7637888	chr3:10080722	T/C	cg00166722	chr3:10149974	C3orf24	0.46	5.88	0.34	1.21e-8	Alzheimer's disease;
CESC	cis	rs1270639	0.778	rs2906933	chr7:157450749	T/A	cg13357408	chr7:157437802	PTPRN2	0.6	6.65	0.38	1.7e-10	Colorectal cancer;
CESC	cis	rs4523957	0.651	rs7214741	chr17:2085598	C/T	cg16513277	chr17:2031491	SMG6	-0.69	-9.74	-0.51	2.3e-19	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs3820928	0.874	rs7582251	chr2:227791703	G/T	cg11843606	chr2:227700838	RHBDD1	-0.44	-5.87	-0.34	1.29e-8	Pulmonary function;
CESC	cis	rs9911578	1.000	rs1472288	chr17:56910720	G/A	cg05425664	chr17:57184151	TRIM37	-0.5	-6.92	-0.39	3.44e-11	Intelligence (multi-trait analysis);
CESC	cis	rs7216064	1.000	rs62084248	chr17:65874541	C/T	cg12091567	chr17:66097778	LOC651250	-0.86	-8.82	-0.48	1.55e-16	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs736408	0.716	rs2239550	chr3:52822509	G/C	cg07507251	chr3:52567010	NT5DC2	0.33	5.39	0.31	1.58e-7	Bipolar disorder;
CESC	cis	rs10540	1.000	rs12419716	chr11:503385	C/G	cg03934478	chr11:495069	RNH1	0.56	5.39	0.31	1.54e-7	Body mass index;
CESC	cis	rs1218582	0.803	rs7531728	chr1:154840516	C/A	cg06221963	chr1:154839813	KCNN3	-0.71	-11.86	-0.59	2.58e-26	Prostate cancer;
CESC	cis	rs2880765	0.805	rs11858817	chr15:86031260	C/T	cg19183879	chr15:85880815	NA	-0.25	-5.26	-0.31	3.03e-7	Coronary artery disease;
CESC	cis	rs371025208	1	rs371025208	chr20:43928602	TGGGTGTGTGTGTGTAGGG/T	cg10761708	chr20:43804764	PI3	0.46	5.81	0.34	1.76e-8	Parental longevity (mother's age at death);
CESC	cis	rs3793683	0.571	rs12781152	chr10:134590257	G/C	cg26818010	chr10:134567672	INPP5A	-0.91	-11.2	-0.57	4.4e-24	Migraine;
CESC	cis	rs11785400	0.928	rs750529	chr8:143744877	G/C	cg10596483	chr8:143751796	JRK	0.43	5.68	0.33	3.47e-8	Schizophrenia;
CESC	cis	rs3096299	0.933	rs3114848	chr16:89452771	G/A	cg02187348	chr16:89574699	SPG7	0.52	6.86	0.39	4.88e-11	Multiple myeloma (IgH translocation);
CESC	cis	rs67311347	0.955	rs4974067	chr3:40374551	C/T	cg24209194	chr3:40518798	ZNF619	0.4	5.24	0.31	3.29e-7	Renal cell carcinoma;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg10715820	chr1:17235063	NA	0.46	6.51	0.37	3.85e-10	Fibrinogen levels;
CESC	cis	rs875971	1.000	rs1144894	chr7:65542894	A/G	cg12463550	chr7:65579703	CRCP	-0.6	-7.4	-0.41	1.78e-12	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07277624	chr20:44035142	DBNDD2;SYS1-DBNDD2	0.59	6.76	0.38	8.68e-11	Gut microbiome composition (summer);
CESC	cis	rs11098499	0.909	rs6842762	chr4:120398236	A/T	cg24375607	chr4:120327624	NA	0.45	5.67	0.33	3.64e-8	Corneal astigmatism;
CESC	cis	rs10504229	1.000	rs114312649	chr8:58182539	C/G	cg14926445	chr8:58193284	C8orf71	-0.51	-5.52	-0.32	8.28e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs5750830	0.597	rs4821889	chr22:39777254	T/C	cg24399712	chr22:39784796	NA	-0.72	-10.59	-0.55	4.38e-22	Intelligence (multi-trait analysis);
CESC	cis	rs6541297	0.938	rs7551742	chr1:230290118	A/G	cg20703242	chr1:230279135	GALNT2	0.74	10.89	0.56	4.46e-23	Coronary artery disease;
CESC	cis	rs910316	0.763	rs175057	chr14:75489632	C/T	cg11812906	chr14:75593930	NEK9	-0.79	-12.22	-0.6	1.57e-27	Height;
CESC	cis	rs11098499	0.863	rs58452170	chr4:120459674	A/T	cg09307838	chr4:120376055	NA	0.9	12.15	0.6	2.72e-27	Corneal astigmatism;
CESC	cis	rs9325144	0.560	rs11183189	chr12:38683770	T/A	cg26384229	chr12:38710491	ALG10B	0.6	8.78	0.47	2e-16	Morning vs. evening chronotype;
CESC	cis	rs4629710	0.592	rs11758994	chr6:131582022	A/C	cg12606694	chr6:131520996	AKAP7	0.47	5.87	0.34	1.31e-8	Multiple myeloma (IgH translocation);
CESC	cis	rs801193	1.000	rs2707836	chr7:66160435	A/C	cg06456125	chr7:65229604	NA	0.4	5.23	0.31	3.51e-7	Aortic root size;
CESC	cis	rs9467711	0.606	rs34878490	chr6:26370572	C/T	cg12826209	chr6:26865740	GUSBL1	0.62	5.22	0.31	3.66e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs12479064	0.694	rs11896520	chr2:99995517	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.55	-6.51	-0.37	3.76e-10	Chronic sinus infection;
CESC	trans	rs7615952	0.599	rs67566088	chr3:125768973	C/A	cg07211511	chr3:129823064	LOC729375	-0.59	-6.53	-0.37	3.37e-10	Blood pressure (smoking interaction);
CESC	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.56	6.93	0.39	3.13e-11	Prudent dietary pattern;
CESC	cis	rs9457247	0.612	rs2237273	chr6:167443017	T/C	cg25258033	chr6:167368657	RNASET2	0.36	5.2	0.3	4.02e-7	Crohn's disease;
CESC	cis	rs9768139	0.733	rs35016950	chr7:158118710	C/A	cg24154853	chr7:158122151	PTPRN2	0.43	6.65	0.38	1.68e-10	Calcium levels;
CESC	cis	rs3768617	0.782	rs12146099	chr1:182968079	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.68	9.46	0.5	1.8e-18	Fuchs's corneal dystrophy;
CESC	cis	rs35110281	0.774	rs2838327	chr21:45018566	A/C	cg21573476	chr21:45109991	RRP1B	-0.45	-6.39	-0.37	7.53e-10	Mean corpuscular volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18876494	chr12:69004196	RAP1B	0.62	7.49	0.42	1.04e-12	Gut microbiome composition (summer);
CESC	cis	rs3857536	0.776	rs7765531	chr6:66932886	G/A	cg07460842	chr6:66804631	NA	-0.42	-5.36	-0.31	1.8e-7	Blood trace element (Cu levels);
CESC	cis	rs9616064	0.506	rs2542038	chr22:47059282	C/T	cg05621596	chr22:47072043	GRAMD4	-0.51	-8.19	-0.45	1.14e-14	Urate levels in obese individuals;
CESC	trans	rs35110281	0.720	rs230647	chr21:44919654	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.53	-6.63	-0.38	1.89e-10	Mean corpuscular volume;
CESC	trans	rs7902708	0.920	rs12266233	chr10:54424184	A/G	cg26219051	chr22:43739629	SCUBE1	-0.48	-6.19	-0.36	2.25e-9	Bone properties (heel);
CESC	cis	rs4975709	0.838	rs4975752	chr5:1880588	A/C	cg07747251	chr5:1868357	NA	0.31	5.12	0.3	5.75e-7	Cardiovascular disease risk factors;
CESC	cis	rs2243480	0.831	rs7806717	chr7:65393174	A/G	cg18252515	chr7:66147081	NA	1.06	9.79	0.52	1.67e-19	Diabetic kidney disease;
CESC	cis	rs6502050	0.835	rs8065210	chr17:80090960	G/A	cg23985595	chr17:80112537	CCDC57	-0.42	-6.6	-0.38	2.18e-10	Life satisfaction;
CESC	cis	rs854765	0.583	rs8078105	chr17:17853782	T/C	cg09796270	chr17:17721594	SREBF1	0.45	6.15	0.35	2.87e-9	Total body bone mineral density;
CESC	cis	rs7833790	0.929	rs10958048	chr8:82792914	C/T	cg27398817	chr8:82754497	SNX16	0.56	6.68	0.38	1.39e-10	Diastolic blood pressure;
CESC	cis	rs9486719	1.000	rs926276	chr6:96868735	C/T	cg18709589	chr6:96969512	KIAA0776	0.49	5.58	0.32	5.81e-8	Migraine;Coronary artery disease;
CESC	cis	rs6964587	0.810	rs408	chr7:91556284	A/G	cg01689657	chr7:91764605	CYP51A1	-0.29	-5.18	-0.3	4.38e-7	Breast cancer;
CESC	cis	rs7666738	0.830	rs7674095	chr4:99048158	T/A	cg18180107	chr4:99064573	C4orf37	0.41	5.29	0.31	2.51e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10504229	0.953	rs115634610	chr8:58190533	G/A	cg05313129	chr8:58192883	C8orf71	-0.55	-6.49	-0.37	4.09e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs7552404	0.655	rs1146646	chr1:76265500	G/A	cg10523679	chr1:76189770	ACADM	0.72	8.72	0.47	3.21e-16	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs6460942	0.915	rs1595802	chr7:12439672	C/T	cg19099843	chr7:12443191	VWDE	-0.51	-5.39	-0.31	1.59e-7	Coronary artery disease;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03193417	chr12:56583536	SMARCC2	0.49	6.1	0.35	3.84e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs7178572	0.568	rs1493700	chr15:77629060	T/C	cg22256960	chr15:77711686	NA	-0.54	-6.86	-0.39	4.9e-11	Type 2 diabetes;
CESC	cis	rs7520050	0.966	rs6669522	chr1:46397941	A/G	cg03146154	chr1:46216737	IPP	-0.47	-6.1	-0.35	3.66e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs1348850	0.632	rs13009207	chr2:178501632	A/G	cg22681709	chr2:178499509	PDE11A	-0.5	-8.05	-0.44	2.89e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs4253772	0.575	rs9615364	chr22:46797503	G/A	cg09491104	chr22:46646882	C22orf40	-0.49	-5.42	-0.32	1.32e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs9303401	0.659	rs17822807	chr17:56687190	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.02	11.73	0.58	7.25e-26	Cognitive test performance;
CESC	cis	rs4665809	1.000	rs4665819	chr2:26309073	A/G	cg25036284	chr2:26402008	FAM59B	-0.61	-7.08	-0.4	1.31e-11	Gut microbiome composition (summer);
CESC	cis	rs116095464	1.000	rs28416084	chr5:217640	G/A	cg22857025	chr5:266934	NA	-1.28	-14.18	-0.66	2.32e-34	Breast cancer;
CESC	cis	rs916888	0.779	rs199528	chr17:44843136	C/T	cg17911788	chr17:44343683	NA	-0.6	-7.81	-0.43	1.32e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs1448094	0.511	rs4492889	chr12:86146735	C/A	cg02569458	chr12:86230093	RASSF9	-0.42	-6.44	-0.37	5.67e-10	Major depressive disorder;
CESC	cis	rs2439831	0.702	rs2788	chr15:44064886	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.68	7.97	0.44	4.59e-14	Lung cancer in ever smokers;
CESC	cis	rs9818758	0.607	rs56004653	chr3:49072228	T/C	cg00383909	chr3:49044727	WDR6	0.89	5.24	0.31	3.23e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CESC	cis	rs7412746	0.611	rs10888398	chr1:150886782	A/G	cg17724175	chr1:150552817	MCL1	-0.33	-5.09	-0.3	6.86e-7	Melanoma;
CESC	cis	rs6963495	0.818	rs1721498	chr7:105178819	A/C	cg19920283	chr7:105172520	RINT1	-0.74	-8.52	-0.46	1.19e-15	Bipolar disorder (body mass index interaction);
CESC	cis	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg24642844	chr7:1081250	C7orf50	-0.73	-8.78	-0.47	2e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7666738	0.535	rs6850010	chr4:98971601	A/T	cg17366294	chr4:99064904	C4orf37	0.61	8.55	0.46	1.01e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2860975	0.967	rs11188134	chr10:96774255	G/C	cg09036531	chr10:96991505	NA	-0.34	-5.04	-0.3	8.46e-7	Immune response to smallpox vaccine (IL-6);
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg05382772	chr11:65686513	DRAP1;C11orf68	-0.5	-6.83	-0.39	5.8200000000000003e-11	Asthma;
CESC	cis	rs2303759	0.666	rs66967196	chr19:49808894	G/A	cg22307029	chr19:49891270	CCDC155	0.55	5.99	0.35	6.76e-9	Multiple sclerosis;
CESC	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg07092213	chr7:1199455	ZFAND2A	-0.48	-5.28	-0.31	2.67e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7208859	0.673	rs450585	chr17:28951039	G/A	cg14008862	chr17:28927542	LRRC37B2	0.71	6.42	0.37	6.33e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs1218582	0.772	rs4845693	chr1:154911257	A/G	cg09359103	chr1:154839909	KCNN3	0.67	12.57	0.61	9.74e-29	Prostate cancer;
CESC	trans	rs61931739	0.534	rs10844791	chr12:34211659	C/T	cg26384229	chr12:38710491	ALG10B	0.65	9.28	0.5	6.46e-18	Morning vs. evening chronotype;
CESC	cis	rs6754311	0.517	rs60453613	chr2:136527120	G/C	cg07169764	chr2:136633963	MCM6	0.97	12.24	0.6	1.31e-27	Mosquito bite size;
CESC	cis	rs6964587	1.000	rs10234071	chr7:91645152	C/G	cg17063962	chr7:91808500	NA	-0.57	-7.89	-0.44	8.09e-14	Breast cancer;
CESC	cis	rs6088590	0.502	rs6059861	chr20:33068563	A/T	cg24642439	chr20:33292090	TP53INP2	0.52	6.83	0.39	5.95e-11	Coronary artery disease;
CESC	cis	rs11203032	0.831	rs2211599	chr10:90929547	G/A	cg16672925	chr10:90967113	CH25H	0.7	6.65	0.38	1.62e-10	Heart failure;
CESC	cis	rs7809950	0.678	rs982447	chr7:106973534	T/C	cg23024343	chr7:107201750	COG5	-0.57	-7.3	-0.41	3.37e-12	Coronary artery disease;
CESC	cis	rs7692995	1.000	rs7662221	chr4:17966468	G/A	cg08925142	chr4:18023851	LCORL	-0.45	-5.13	-0.3	5.66e-7	Height;
CESC	cis	rs6088590	1.000	rs6088590	chr20:33313566	T/C	cg06115741	chr20:33292138	TP53INP2	0.58	7.14	0.4	9.16e-12	Coronary artery disease;
CESC	cis	rs3087591	1.000	rs12600974	chr17:29589360	A/G	cg24425628	chr17:29625626	OMG;NF1	0.43	5.21	0.31	3.73e-7	Hip circumference;
CESC	cis	rs858239	0.539	rs4377861	chr7:23185969	C/T	cg23682824	chr7:23144976	KLHL7	0.43	5.44	0.32	1.21e-7	Cerebrospinal fluid biomarker levels;
CESC	cis	rs4561483	0.798	rs33629	chr16:11997490	G/A	cg08843971	chr16:11963173	GSPT1	-0.41	-5.75	-0.33	2.47e-8	Testicular germ cell tumor;
CESC	cis	rs12220238	1.000	rs11000897	chr10:75911276	C/A	cg19889307	chr10:75911429	ADK;AP3M1	0.65	6.33	0.36	1.03e-9	Soluble interleukin-2 receptor subunit alpha;
CESC	cis	rs9291683	0.530	rs73227883	chr4:9979279	T/C	cg00071950	chr4:10020882	SLC2A9	0.79	14.43	0.66	3.23e-35	Bone mineral density;
CESC	trans	rs997295	0.592	rs8026627	chr15:67770306	G/T	cg05081167	chr6:156967138	NA	-0.28	-6.32	-0.36	1.11e-9	Motion sickness;
CESC	cis	rs7666738	0.830	rs13139024	chr4:99020700	C/T	cg03676636	chr4:99064102	C4orf37	0.33	5.15	0.3	5.05e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20285559	chr1:6688542	THAP3	-0.64	-7.53	-0.42	8.03e-13	Gut microbiome composition (summer);
CESC	cis	rs4563143	0.577	rs73025093	chr19:29254618	T/G	cg14983838	chr19:29218262	NA	0.5	6.16	0.35	2.67e-9	Methadone dose in opioid dependence;
CESC	cis	rs7666738	0.791	rs6840669	chr4:99016020	G/T	cg17366294	chr4:99064904	C4orf37	0.6	8.62	0.47	6.37e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs826838	0.904	rs11612004	chr12:39204282	G/A	cg26384229	chr12:38710491	ALG10B	0.78	13.13	0.63	1.09e-30	Heart rate;
CESC	cis	rs6060717	0.536	rs11696912	chr20:34497660	C/G	cg23207816	chr20:34252616	CPNE1;RBM12	-0.69	-6.2	-0.36	2.16e-9	Hip circumference adjusted for BMI;
CESC	cis	rs7829975	0.658	rs907181	chr8:8702875	T/C	cg06636001	chr8:8085503	FLJ10661	0.41	5.35	0.31	1.92e-7	Mood instability;
CESC	trans	rs6089829	0.926	rs1060491	chr20:61665817	C/A	cg23505145	chr19:12996616	KLF1	-0.52	-6.64	-0.38	1.82e-10	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs9611565	0.546	rs739134	chr22:42089623	T/C	cg06634786	chr22:41940651	POLR3H	0.61	6.26	0.36	1.54e-9	Vitiligo;
CESC	cis	rs7824557	0.545	rs2572380	chr8:11237477	A/G	cg21775007	chr8:11205619	TDH	-0.54	-8.07	-0.44	2.48e-14	Retinal vascular caliber;
CESC	cis	rs2836974	0.897	rs1984022	chr21:40596085	G/A	cg11644478	chr21:40555479	PSMG1	1.03	16.6	0.71	6.66e-43	Cognitive function;
CESC	cis	rs9309473	1.000	rs7558944	chr2:73810909	T/G	cg20560298	chr2:73613845	ALMS1	-0.53	-6.85	-0.39	5.01e-11	Metabolite levels;
CESC	cis	rs2412459	0.611	rs4924402	chr15:40245754	C/T	cg22077389	chr15:40226273	EIF2AK4	-0.47	-5.29	-0.31	2.61e-7	Response to haloperidol in psychosis;
CESC	cis	rs875971	0.862	rs801195	chr7:66026115	A/G	cg19163074	chr7:65112434	INTS4L2	0.42	5.25	0.31	3.16e-7	Aortic root size;
CESC	cis	rs798766	1.000	rs3099555	chr4:1725651	T/C	cg10756475	chr4:1757242	NA	0.46	6.22	0.36	1.92e-9	Bladder cancer;Urinary bladder cancer;
CESC	cis	rs896854	0.967	rs2879813	chr8:95960947	A/G	cg13393036	chr8:95962371	TP53INP1	-0.55	-12.59	-0.61	8.5e-29	Type 2 diabetes;
CESC	cis	rs2070677	0.935	rs4350328	chr10:135414948	G/A	cg20169779	chr10:135381914	SYCE1	-0.74	-9.65	-0.51	4.61e-19	Gout;
CESC	cis	rs4234798	1.000	rs4234797	chr4:7219907	C/T	cg18431297	chr4:7219810	SORCS2	0.44	6.85	0.39	5.13e-11	Insulin-like growth factors;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04908382	chr14:105415856	AHNAK2	-0.41	-6.22	-0.36	1.93e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs9486719	0.894	rs34826652	chr6:96899085	A/G	cg06623918	chr6:96969491	KIAA0776	-0.81	-8.3	-0.45	5.21e-15	Migraine;Coronary artery disease;
CESC	cis	rs858239	0.899	rs7794684	chr7:23310805	A/G	cg23682824	chr7:23144976	KLHL7	0.44	5.63	0.33	4.54e-8	Cerebrospinal fluid biomarker levels;
CESC	cis	rs853679	0.517	rs56310871	chr6:28044482	A/G	cg08968635	chr6:28129556	ZNF389	0.39	5.22	0.31	3.64e-7	Depression;
CESC	cis	rs1879734	0.731	rs11206197	chr1:54165831	A/G	cg23596471	chr1:54105337	GLIS1	0.33	5.43	0.32	1.3e-7	Mitral valve prolapse;
CESC	cis	rs2859741	0.565	rs12031540	chr1:37513757	C/T	cg09363841	chr1:37513479	NA	-0.55	-8.52	-0.46	1.24e-15	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
CESC	cis	rs317689	0.918	rs689415	chr12:69738139	A/G	cg20891283	chr12:69753455	YEATS4	-0.63	-7.14	-0.4	8.89e-12	Response to diuretic therapy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15641060	chr11:1977951	NA	-0.6	-6.91	-0.39	3.55e-11	Gut microbiome composition (summer);
CESC	cis	rs8020095	0.571	rs10136344	chr14:67410477	A/C	cg19548862	chr14:67692701	FAM71D	-0.49	-6.05	-0.35	5e-9	Depression (quantitative trait);
CESC	cis	rs6912958	0.728	rs6923230	chr6:88213949	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-6.62	-0.38	1.95e-10	Monocyte percentage of white cells;
CESC	cis	rs910316	0.934	rs8006587	chr14:75664939	A/G	cg16144293	chr14:75469539	EIF2B2	-0.38	-5.03	-0.3	9e-7	Height;
CESC	cis	rs10905065	0.827	rs7089100	chr10:5849877	C/G	cg11519256	chr10:5708881	ASB13	0.39	5.17	0.3	4.69e-7	Menopause (age at onset);
CESC	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg24503407	chr1:205819492	PM20D1	0.79	12.68	0.61	4.22e-29	Menarche (age at onset);
CESC	trans	rs116095464	0.558	rs7736600	chr5:231337	A/C	cg00938859	chr5:1591904	SDHAP3	0.63	6.87	0.39	4.48e-11	Breast cancer;
CESC	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.68	9.51	0.5	1.18e-18	Prudent dietary pattern;
CESC	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg02725872	chr8:58115012	NA	-0.42	-5.72	-0.33	2.88e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs17209837	0.607	rs45496691	chr7:87110795	C/A	cg00919237	chr7:87102261	ABCB4	-0.49	-6.5	-0.37	4.02e-10	Gallbladder cancer;
CESC	cis	rs7084402	1.000	rs1346301	chr10:60267310	G/A	cg07615347	chr10:60278583	BICC1	-0.61	-9.58	-0.51	7.18e-19	Refractive error;
CESC	cis	rs2836974	0.836	rs8129355	chr21:40579869	A/G	cg11644478	chr21:40555479	PSMG1	1.02	16.35	0.71	4.95e-42	Cognitive function;
CESC	cis	rs9322193	0.736	rs10457851	chr6:150096352	T/A	cg05861140	chr6:150128134	PCMT1	-0.37	-5.24	-0.31	3.23e-7	Lung cancer;
CESC	cis	rs10489525	0.560	rs10858062	chr1:115602563	A/G	cg12756093	chr1:115239321	AMPD1	-0.45	-5.44	-0.32	1.19e-7	Autism;
CESC	cis	rs1799949	1.000	rs8176202	chr17:41230228	G/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.43	5.89	0.34	1.14e-8	Menopause (age at onset);
CESC	cis	rs7666738	0.791	rs6833691	chr4:98951508	A/G	cg05340658	chr4:99064831	C4orf37	0.8	12.4	0.61	3.66e-28	Colonoscopy-negative controls vs population controls;
CESC	trans	rs10242455	0.557	rs2404487	chr7:99038057	G/A	cg09045935	chr12:6379348	NA	0.91	7.41	0.41	1.73e-12	Blood metabolite levels;
CESC	cis	rs1801251	1.000	rs6747645	chr2:233571033	C/T	cg08000102	chr2:233561755	GIGYF2	-0.68	-9.7	-0.51	3.11e-19	Coronary artery disease;
CESC	cis	rs3857536	0.813	rs6904511	chr6:66939102	A/C	cg07460842	chr6:66804631	NA	-0.42	-5.34	-0.31	1.96e-7	Blood trace element (Cu levels);
CESC	cis	rs2235642	0.928	rs1057610	chr16:1605537	T/C	cg07639376	chr16:1584516	IFT140;TMEM204	-0.32	-5.25	-0.31	3.11e-7	Coronary artery disease;
CESC	trans	rs6600671	0.934	rs67718113	chr1:121238910	C/T	cg17023122	chr1:144479586	NA	-0.51	-6.87	-0.39	4.58e-11	Hip geometry;
CESC	cis	rs7084402	0.967	rs1427200	chr10:60274928	C/T	cg07615347	chr10:60278583	BICC1	-0.57	-8.96	-0.48	6.01e-17	Refractive error;
CESC	cis	rs6815814	0.950	rs55830619	chr4:38807364	G/A	cg02016764	chr4:38805732	TLR1	-0.63	-7.11	-0.4	1.06e-11	Breast cancer;
CESC	cis	rs6430585	0.583	rs3769013	chr2:136556182	C/T	cg07169764	chr2:136633963	MCM6	1.24	18.81	0.76	1.03e-50	Corneal structure;
CESC	cis	rs34172651	0.502	rs12930727	chr16:24838497	G/T	cg06028605	chr16:24865363	SLC5A11	-0.34	-5.3	-0.31	2.39e-7	Intelligence (multi-trait analysis);
CESC	cis	rs7178572	0.568	rs12910480	chr15:77664212	G/C	cg22256960	chr15:77711686	NA	-0.53	-6.77	-0.38	8.05e-11	Type 2 diabetes;
CESC	cis	rs853679	0.517	rs35227624	chr6:28132726	A/G	cg08968635	chr6:28129556	ZNF389	0.4	5.22	0.31	3.69e-7	Depression;
CESC	cis	rs472402	0.560	rs6874005	chr5:6624371	C/T	cg10789808	chr5:6633262	NSUN2;SRD5A1	-0.46	-6.08	-0.35	4.1e-9	Response to amphetamines;
CESC	cis	rs12410462	1.000	rs16847833	chr1:227626662	G/A	cg04117972	chr1:227635322	NA	0.62	6.34	0.36	9.91e-10	Major depressive disorder;
CESC	cis	rs11055034	0.560	rs2024385	chr12:12888438	A/T	cg04607235	chr12:12878440	APOLD1	0.65	9.22	0.49	9.28e-18	Birth weight;
CESC	cis	rs9811920	0.638	rs796978	chr3:99564321	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.49	-6.11	-0.35	3.48e-9	Axial length;
CESC	cis	rs116095464	1.000	rs6879758	chr5:350277	G/C	cg22857025	chr5:266934	NA	-0.84	-5.33	-0.31	2.14e-7	Breast cancer;
CESC	cis	rs13034020	0.522	rs12988616	chr2:61244663	A/C	cg18625361	chr2:61244694	PEX13;PUS10	0.62	6.42	0.37	6.39e-10	Hodgkin's lymphoma;
CESC	cis	rs9894429	0.966	rs6565604	chr17:79589242	G/A	cg21984481	chr17:79567631	NPLOC4	-0.47	-7.63	-0.42	4.29e-13	Eye color traits;
CESC	cis	rs863345	0.548	rs1032352	chr1:158493154	C/T	cg12129480	chr1:158549410	OR10X1	-0.35	-6.86	-0.39	4.84e-11	Pneumococcal bacteremia;
CESC	cis	rs7605827	0.930	rs13017972	chr2:15699739	A/G	cg19274914	chr2:15703543	NA	0.37	6.58	0.37	2.43e-10	Educational attainment (years of education);
CESC	cis	rs950169	1.000	rs11638394	chr15:84778928	G/A	cg17507749	chr15:85114479	UBE2QP1	0.6	6.54	0.37	3.16e-10	Schizophrenia;
CESC	cis	rs1707322	0.721	rs6429575	chr1:46134216	G/C	cg06784218	chr1:46089804	CCDC17	0.43	7.48	0.42	1.07e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06857516	chr19:48205035	GLTSCR1	-0.6	-6.38	-0.36	7.94e-10	Gut microbiome composition (summer);
CESC	cis	rs9309711	0.689	rs4535075	chr2:3481716	T/C	cg10845886	chr2:3471009	TTC15	-0.67	-9.29	-0.5	5.87e-18	Neurofibrillary tangles;
CESC	cis	rs1461503	0.900	rs10892935	chr11:122838590	C/T	cg27398637	chr11:122830231	C11orf63	-0.56	-8.42	-0.46	2.35e-15	Menarche (age at onset);
CESC	trans	rs4927850	1.000	rs10881564	chr3:195750326	C/T	cg16724585	chr3:197361211	NA	-0.55	-7.03	-0.4	1.77e-11	Pancreatic cancer;
CESC	cis	rs8177179	0.967	rs6439436	chr3:133453779	C/T	cg18769074	chr3:133464867	TF	-0.3	-5.78	-0.33	2.08e-8	Iron status biomarkers (transferrin levels);
CESC	cis	rs10751667	0.600	rs4076915	chr11:1012464	C/G	cg01483505	chr11:975446	AP2A2	0.42	5.4	0.31	1.51e-7	Alzheimer's disease (late onset);
CESC	cis	rs7605827	0.930	rs1997305	chr2:15512383	T/C	cg19274914	chr2:15703543	NA	0.31	5.51	0.32	8.7e-8	Educational attainment (years of education);
CESC	cis	rs72945132	0.882	rs12278125	chr11:70134016	T/C	cg00319359	chr11:70116639	PPFIA1	0.78	7.74	0.43	2.13e-13	Coronary artery disease;
CESC	cis	rs360798	0.532	rs11125942	chr2:62966758	T/C	cg17519650	chr2:63277830	OTX1	-0.57	-7.48	-0.42	1.07e-12	Coronary artery disease;
CESC	cis	rs7208859	0.673	rs216409	chr17:28906269	C/T	cg19761014	chr17:28927070	LRRC37B2	-0.77	-7.28	-0.41	3.81e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs116095464	0.558	rs7715108	chr5:264661	A/G	cg12570787	chr5:219185	SDHA;CCDC127	0.53	5.49	0.32	9.44e-8	Breast cancer;
CESC	cis	rs6860806	0.661	rs334902	chr5:131586559	C/G	cg04518342	chr5:131593106	PDLIM4	0.4	5.97	0.34	7.4e-9	Breast cancer;
CESC	cis	rs2777491	1.000	rs1757455	chr15:41761332	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.65	-9.9	-0.52	7.01e-20	Ulcerative colitis;
CESC	cis	rs2303745	0.589	rs8103523	chr19:17398269	A/G	cg02221750	chr19:17393354	ANKLE1	-0.52	-6.28	-0.36	1.36e-9	Systemic lupus erythematosus;
CESC	cis	rs763121	0.853	rs3747170	chr22:39067331	G/A	cg06544989	chr22:39130855	UNC84B	0.49	8.54	0.46	1.06e-15	Menopause (age at onset);
CESC	cis	rs9473147	0.543	rs9349407	chr6:47453378	C/G	cg20196966	chr6:47445060	CD2AP	0.42	5.45	0.32	1.16e-7	Platelet distribution width;Mean platelet volume;
CESC	cis	rs4975709	0.589	rs4975745	chr5:1861058	G/C	cg11168104	chr5:1857477	NA	-0.38	-5.64	-0.33	4.27e-8	Cardiovascular disease risk factors;
CESC	cis	rs1008375	0.966	rs11947836	chr4:17697187	A/G	cg27347728	chr4:17578864	LAP3	-0.44	-5.19	-0.3	4.22e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	trans	rs10242455	0.557	rs73403272	chr7:99134208	T/G	cg09045935	chr12:6379348	NA	0.83	7.07	0.4	1.4e-11	Blood metabolite levels;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg18211447	chr14:102771717	RAGE	0.51	6.66	0.38	1.55e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs4975616	0.869	rs467095	chr5:1336221	T/C	cg07493874	chr5:1342172	CLPTM1L	-0.42	-7.89	-0.44	7.92e-14	Lung cancer;
CESC	cis	rs10189230	0.967	rs1367241	chr2:222353413	G/A	cg14652038	chr2:222343519	EPHA4	0.36	7.45	0.42	1.3e-12	Urate levels in lean individuals;
CESC	cis	rs9790314	0.540	rs35462273	chr3:160991877	C/T	cg03342759	chr3:160939853	NMD3	-0.53	-7.28	-0.41	3.89e-12	Morning vs. evening chronotype;
CESC	cis	rs7086627	0.507	rs7077907	chr10:82017082	A/G	cg00277334	chr10:82204260	NA	-0.44	-5.84	-0.34	1.52e-8	Post bronchodilator FEV1;
CESC	cis	rs62344088	0.590	rs7700533	chr5:180646	C/T	cg22857025	chr5:266934	NA	-1.03	-6.77	-0.38	8.21e-11	Asthma (childhood onset);
CESC	cis	rs2204008	0.805	rs3863360	chr12:37966432	C/T	cg13010199	chr12:38710504	ALG10B	0.46	5.75	0.33	2.48e-8	Bladder cancer;
CESC	cis	rs1218582	0.741	rs4339857	chr1:154888962	A/G	cg03351412	chr1:154909251	PMVK	0.7	9.51	0.5	1.21e-18	Prostate cancer;
CESC	cis	rs2710642	0.886	rs10153716	chr2:63007059	A/G	cg17519650	chr2:63277830	OTX1	-0.54	-7.2	-0.4	6.35e-12	LDL cholesterol levels;LDL cholesterol;
CESC	cis	rs2625529	0.556	rs55679065	chr15:72433395	C/T	cg16672083	chr15:72433130	SENP8	0.46	7.02	0.4	1.91e-11	Red blood cell count;
CESC	cis	rs4132509	1.000	rs10927067	chr1:243923244	C/T	cg21452805	chr1:244014465	NA	0.42	5.34	0.31	2.02e-7	RR interval (heart rate);
CESC	cis	rs712039	0.652	rs60112577	chr17:35833209	G/A	cg16670864	chr17:35848621	DUSP14	0.43	5.34	0.31	2.05e-7	Tuberculosis;
CESC	cis	rs597539	0.690	rs11228383	chr11:68623228	T/G	cg21963583	chr11:68658836	MRPL21	0.4	5.42	0.32	1.37e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs4722585	0.533	rs2049843	chr7:26196963	G/A	cg07876897	chr7:26191696	NFE2L3	0.42	5.25	0.31	3.15e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
CESC	cis	rs12497850	1.000	rs6788650	chr3:48749543	T/C	cg03060546	chr3:49711283	APEH	0.43	5.28	0.31	2.74e-7	Parkinson's disease;
CESC	cis	rs708547	1.000	rs708547	chr4:57821309	T/C	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.54	-5.39	-0.31	1.58e-7	Response to bleomycin (chromatid breaks);
CESC	cis	rs798554	1.000	rs798560	chr7:2758309	A/G	cg19346786	chr7:2764209	NA	-0.45	-6.56	-0.37	2.77e-10	Height;
CESC	cis	rs7615952	0.800	rs2062773	chr3:125639648	T/C	cg05084668	chr3:125655381	ALG1L	-0.45	-5.44	-0.32	1.21e-7	Blood pressure (smoking interaction);
CESC	cis	rs769267	0.896	rs10410664	chr19:19556651	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.46	5.94	0.34	8.86e-9	Tonsillectomy;
CESC	cis	rs4474465	1.000	rs11237511	chr11:78173606	C/T	cg27205649	chr11:78285834	NARS2	-0.41	-5.11	-0.3	6.27e-7	Alzheimer's disease (survival time);
CESC	cis	rs4689388	0.819	rs12649341	chr4:6294759	G/A	cg14416269	chr4:6271139	WFS1	0.46	7.76	0.43	1.79e-13	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs11030122	0.661	rs963998	chr11:4062803	A/G	cg18678763	chr11:4115507	RRM1	-0.46	-6.33	-0.36	1.03e-9	Mean platelet volume;Platelet distribution width;
CESC	cis	rs9611565	0.659	rs9607813	chr22:41941479	G/A	cg06481639	chr22:41940642	POLR3H	-0.62	-6.57	-0.37	2.59e-10	Vitiligo;
CESC	cis	rs10832963	0.961	rs10832954	chr11:18643559	G/A	cg20219074	chr11:18656078	SPTY2D1	0.8	11.77	0.59	5.17e-26	Breast cancer;
CESC	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg07677032	chr17:61819896	STRADA	0.45	6.05	0.35	5.02e-9	Prudent dietary pattern;
CESC	cis	rs9522267	0.535	rs914037	chr13:112235308	A/G	cg10483660	chr13:112241077	NA	-0.33	-5.78	-0.33	2.14e-8	Hepatitis;
CESC	cis	rs1707322	1.000	rs11211243	chr1:46455433	G/C	cg06784218	chr1:46089804	CCDC17	0.33	5.63	0.33	4.7e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs1559088	0.576	rs7251626	chr19:33578470	C/A	cg03563238	chr19:33554763	RHPN2	-0.32	-6.02	-0.35	5.81e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs1707322	0.686	rs2230659	chr1:46078884	C/T	cg06784218	chr1:46089804	CCDC17	-0.43	-7.41	-0.41	1.7e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs950776	0.593	rs555018	chr15:78879242	G/A	cg06917634	chr15:78832804	PSMA4	-0.6	-7.93	-0.44	6.15e-14	Sudden cardiac arrest;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21656672	chr7:2272667	MAD1L1	0.54	6.23	0.36	1.83e-9	Gut microbiome composition (summer);
CESC	cis	rs12142240	0.698	rs1984490	chr1:46858734	C/T	cg10495392	chr1:46806563	NSUN4	-0.53	-5.99	-0.35	6.67e-9	Menopause (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25469212	chr1:31769620	ZCCHC17;SNRNP40	0.56	6.6	0.38	2.19e-10	Gut microbiome composition (summer);
CESC	cis	rs72829446	0.530	rs9906913	chr17:7411360	G/A	cg02795151	chr17:7402630	POLR2A	0.63	6.81	0.39	6.57e-11	Androgen levels;
CESC	cis	rs950169	0.922	rs4586394	chr15:84822385	G/A	cg17507749	chr15:85114479	UBE2QP1	-0.55	-6.31	-0.36	1.2e-9	Schizophrenia;
CESC	trans	rs8057939	0.593	rs80233965	chr16:49406853	T/G	cg15532236	chr6:170188124	NA	0.55	6.43	0.37	5.91e-10	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs2243480	1.000	rs6460261	chr7:65215580	T/C	cg12463550	chr7:65579703	CRCP	-0.7	-5.35	-0.31	1.89e-7	Diabetic kidney disease;
CESC	cis	rs7223966	1.000	rs8066719	chr17:61825764	C/T	cg11494091	chr17:61959527	GH2	0.39	5.26	0.31	2.97e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs4803468	1.000	rs10409485	chr19:41920765	C/T	cg09537434	chr19:41945824	ATP5SL	1.05	18.8	0.76	1.09e-50	Height;
CESC	cis	rs748404	0.560	rs689797	chr15:43826557	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.48	7.33	0.41	2.74e-12	Lung cancer;
CESC	cis	rs7959452	0.590	rs11177628	chr12:69765421	G/A	cg22834771	chr12:69754056	YEATS4	-0.48	-6.38	-0.36	7.9e-10	Blood protein levels;
CESC	cis	rs5753037	0.702	rs140101	chr22:30128380	C/T	cg01021169	chr22:30184971	ASCC2	-0.41	-5.6	-0.33	5.49e-8	Type 1 diabetes;
CESC	cis	rs1799949	1.000	rs11657053	chr17:41191129	G/T	cg05368731	chr17:41323189	NBR1	0.79	10.58	0.55	4.63e-22	Menopause (age at onset);
CESC	trans	rs62103177	0.535	rs4799109	chr18:77675188	A/T	cg05926928	chr17:57297772	GDPD1	1.0	9.24	0.49	8.45e-18	Opioid sensitivity;
CESC	cis	rs9811920	0.965	rs9837131	chr3:99854514	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.45	7.3	0.41	3.35e-12	Axial length;
CESC	cis	rs10479542	0.549	rs4376229	chr5:179042971	A/G	cg19723775	chr5:179050963	HNRNPH1	0.5	6.5	0.37	4.05e-10	Lung cancer;
CESC	cis	rs2842992	0.789	rs2842969	chr6:160145364	C/T	cg11366901	chr6:160182831	ACAT2	0.84	10.96	0.56	2.59e-23	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs10504229	1.000	rs57186557	chr8:58177277	A/G	cg14926445	chr8:58193284	C8orf71	-0.51	-5.47	-0.32	1.03e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs7605827	0.897	rs1996518	chr2:15517419	A/G	cg19274914	chr2:15703543	NA	0.35	6.27	0.36	1.43e-9	Educational attainment (years of education);
CESC	cis	rs7552404	0.727	rs1144336	chr1:76277421	C/A	cg03433033	chr1:76189801	ACADM	0.62	6.78	0.38	7.6e-11	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs1865721	0.804	rs3745084	chr18:73142510	T/G	cg26385618	chr18:73139727	C18orf62	-0.51	-8.18	-0.45	1.2e-14	Intelligence;
CESC	cis	rs9814567	1.000	rs13089966	chr3:134279197	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.45	6.08	0.35	4.21e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs656900	0.715	rs673018	chr15:80115347	C/T	cg02196730	chr15:80188777	MTHFS	-0.41	-5.25	-0.31	3.06e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs7208859	0.573	rs60724269	chr17:29113273	G/T	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.79e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs736408	0.546	rs3733046	chr3:52621627	C/T	cg18337363	chr3:52569053	NT5DC2	0.29	5.32	0.31	2.2e-7	Bipolar disorder;
CESC	cis	rs12986413	0.624	rs2238599	chr19:2140009	C/T	cg09261902	chr19:2140048	AP3D1	0.34	5.44	0.32	1.24e-7	Height;
CESC	cis	rs2073300	1.000	rs6137971	chr20:23456429	G/T	cg12062639	chr20:23401060	NAPB	0.83	5.56	0.32	6.67e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs67311347	1.000	rs9860162	chr3:40403875	C/T	cg24209194	chr3:40518798	ZNF619	0.42	5.31	0.31	2.36e-7	Renal cell carcinoma;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15012766	chr1:41832369	NA	0.55	6.78	0.38	7.69e-11	Gut microbiome composition (summer);
CESC	cis	rs2204008	0.685	rs4556621	chr12:38187236	C/A	cg26384229	chr12:38710491	ALG10B	0.73	10.54	0.54	6.41e-22	Bladder cancer;
CESC	cis	rs9611565	0.625	rs9611606	chr22:41931074	A/G	cg06634786	chr22:41940651	POLR3H	-0.64	-6.69	-0.38	1.3e-10	Vitiligo;
CESC	cis	rs7762018	0.607	rs78941587	chr6:170061157	G/C	cg19338460	chr6:170058176	WDR27	-0.98	-8.2	-0.45	1.08e-14	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs60012524	1	rs60012524	chr2:99559117	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.72	-8.4	-0.46	2.78e-15	Chronic sinus infection;
CESC	cis	rs2836950	0.501	rs2056844	chr21:40670460	G/C	cg11890956	chr21:40555474	PSMG1	-0.6	-8.2	-0.45	1.04e-14	Menarche (age at onset);
CESC	cis	rs6714710	0.603	rs11690687	chr2:98461821	C/T	cg26665480	chr2:98280029	ACTR1B	0.57	8.07	0.44	2.38e-14	Posterior cortical atrophy and Alzheimer's disease;
CESC	trans	rs10028773	0.700	rs7690338	chr4:120256468	C/G	cg25214090	chr10:38739885	LOC399744	0.64	9.08	0.49	2.59e-17	Educational attainment;
CESC	cis	rs12541635	0.966	rs12681183	chr8:107007156	T/A	cg10147462	chr8:107024639	NA	0.42	5.96	0.34	7.89e-9	Age of smoking initiation;
CESC	cis	rs7666738	0.830	rs13110410	chr4:98920018	T/C	cg05340658	chr4:99064831	C4orf37	0.78	11.61	0.58	1.82e-25	Colonoscopy-negative controls vs population controls;
CESC	trans	rs765547	0.913	rs1992442	chr8:19853389	A/C	cg12649343	chr22:47023005	GRAMD4	-0.3	-6.12	-0.35	3.27e-9	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22253313	chr4:2011099	WHSC2	0.52	6.14	0.35	2.95e-9	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13341460	chr6:126307568	TRMT11	0.62	7.13	0.4	9.79e-12	Gut microbiome composition (summer);
CESC	trans	rs10411161	0.702	rs8113584	chr19:52383874	A/G	cg22319618	chr22:45562946	NUP50	-0.7	-6.78	-0.38	7.84e-11	Breast cancer;
CESC	cis	rs7584330	0.780	rs937395	chr2:238378749	T/C	cg14458575	chr2:238380390	NA	0.71	9.71	0.51	2.83e-19	Prostate cancer;
CESC	cis	rs10504229	1.000	rs17217082	chr8:58180918	G/A	cg22535103	chr8:58192502	C8orf71	-1.05	-13.27	-0.63	3.63e-31	Developmental language disorder (linguistic errors);
CESC	cis	rs5753618	0.504	rs5753669	chr22:31905819	T/G	cg13145458	chr22:31556086	RNF185	-0.48	-5.7	-0.33	3.12e-8	Colorectal cancer;
CESC	cis	rs2294693	0.581	rs2057000	chr6:41016952	A/C	cg14418226	chr6:40996092	UNC5CL	0.42	5.46	0.32	1.08e-7	Gastric cancer;Non-cardia gastric cancer;
CESC	cis	rs910316	1.000	rs13099	chr14:75599155	G/A	cg08847533	chr14:75593920	NEK9	-0.98	-18.77	-0.76	1.38e-50	Height;
CESC	cis	rs73206853	0.563	rs1973505	chr12:111160003	A/G	cg04375036	chr12:111181819	PPP1CC	0.5	5.23	0.31	3.46e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs858239	0.570	rs10242166	chr7:23162799	A/G	cg23682824	chr7:23144976	KLHL7	0.55	7.71	0.43	2.59e-13	Cerebrospinal fluid biomarker levels;
CESC	cis	rs4906332	1.000	rs12892062	chr14:103883512	A/G	cg09975044	chr14:104007538	NA	0.46	6.38	0.36	7.81e-10	Coronary artery disease;
CESC	cis	rs7937682	0.961	rs4935790	chr11:111633014	T/C	cg22437258	chr11:111473054	SIK2	-0.61	-6.68	-0.38	1.38e-10	Primary sclerosing cholangitis;
CESC	cis	rs7811142	0.887	rs111972532	chr7:100069088	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.07	10.18	0.53	9.37e-21	Platelet count;
CESC	cis	rs35306767	0.855	rs34318754	chr10:890714	G/A	cg10556349	chr10:835070	NA	0.75	6.1	0.35	3.75e-9	Eosinophil percentage of granulocytes;
CESC	cis	rs9300255	0.602	rs1716177	chr12:123655457	C/T	cg19016782	chr12:123741754	C12orf65	-0.45	-6.34	-0.36	9.76e-10	Neutrophil percentage of white cells;
CESC	cis	rs4900538	0.855	rs9788420	chr14:102839338	A/G	cg18135206	chr14:102964638	TECPR2	-0.75	-9.54	-0.51	1.02e-18	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	cis	rs10504229	1.000	rs17217082	chr8:58180918	G/A	cg24829409	chr8:58192753	C8orf71	-0.76	-10.0	-0.52	3.53e-20	Developmental language disorder (linguistic errors);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00369908	chr12:6772357	ING4	0.54	6.11	0.35	3.45e-9	Gut microbiome composition (summer);
CESC	cis	rs6460942	0.841	rs17443848	chr7:12443688	A/G	cg19099843	chr7:12443191	VWDE	-0.5	-6.19	-0.36	2.34e-9	Coronary artery disease;
CESC	cis	rs3096299	0.933	rs2965939	chr16:89493043	G/A	cg16743903	chr16:89593216	SPG7	-0.42	-5.41	-0.32	1.38e-7	Multiple myeloma (IgH translocation);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg20618750	chr5:149380010	HMGXB3;TIGD6	-0.45	-6.07	-0.35	4.41e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs16937	0.711	rs10751429	chr1:205107478	C/T	cg00857998	chr1:205179979	DSTYK	0.39	5.22	0.31	3.67e-7	Schizophrenia;
CESC	cis	rs2243480	1.000	rs313798	chr7:65493031	A/G	cg18252515	chr7:66147081	NA	-1.26	-12.38	-0.61	4.54e-28	Diabetic kidney disease;
CESC	cis	rs941873	0.772	rs7086293	chr10:81103247	T/C	cg08514558	chr10:81106712	PPIF	0.34	5.88	0.34	1.24e-8	Height;
CESC	cis	rs7666738	0.822	rs11097599	chr4:98959562	T/A	cg18180107	chr4:99064573	C4orf37	0.4	5.14	0.3	5.33e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs8133932	0.608	rs382195	chr21:47339222	G/A	cg14185626	chr21:47401492	COL6A1	-0.45	-5.09	-0.3	6.84e-7	Schizophrenia;
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg15721424	chr11:77850393	ALG8	-0.42	-6.17	-0.35	2.52e-9	Vertical cup-disc ratio;
CESC	cis	rs2559856	1.000	rs2559858	chr12:102089300	A/G	cg15068132	chr12:102092402	CHPT1	-0.43	-5.81	-0.34	1.77e-8	Blood protein levels;
CESC	cis	rs2072499	0.833	rs2758605	chr1:156200445	G/C	cg25208724	chr1:156163844	SLC25A44	0.83	13.18	0.63	7.63e-31	Testicular germ cell tumor;
CESC	cis	rs11638352	0.661	rs11857696	chr15:44366258	T/A	cg27015174	chr15:43622946	ADAL;LCMT2	-0.66	-6.27	-0.36	1.5e-9	Lipoprotein phospholipase A2 activity in cardiovascular disease;
CESC	cis	rs1005277	0.579	rs2749612	chr10:38488610	G/A	cg25427524	chr10:38739819	LOC399744	-0.7	-10.23	-0.53	6.45e-21	Extrinsic epigenetic age acceleration;
CESC	cis	rs10504229	0.683	rs7827881	chr8:58132137	C/T	cg24829409	chr8:58192753	C8orf71	-0.59	-7.31	-0.41	3.16e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs34421088	0.678	rs35928010	chr8:11591876	C/T	cg13293535	chr8:11597251	GATA4	0.31	5.76	0.33	2.39e-8	Neuroticism;
CESC	cis	rs72945132	0.882	rs7943840	chr11:70228615	C/A	cg00319359	chr11:70116639	PPFIA1	0.74	7.17	0.4	7.35e-12	Coronary artery disease;
CESC	cis	rs870825	0.616	rs10022834	chr4:185649431	A/G	cg04058563	chr4:185651563	MLF1IP	0.63	6.96	0.39	2.59e-11	Blood protein levels;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg12445378	chr8:48741753	PRKDC	-0.45	-6.26	-0.36	1.52e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs7089973	0.646	rs35453961	chr10:116638166	T/C	cg23260525	chr10:116636907	FAM160B1	0.37	6.62	0.38	2.03e-10	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs68170813	0.559	rs75007274	chr7:106814543	G/A	cg02696742	chr7:106810147	HBP1	-0.53	-5.06	-0.3	8e-7	Coronary artery disease;
CESC	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.39	7.44	0.42	1.44e-12	Electroencephalogram traits;
CESC	cis	rs4563143	0.634	rs113736470	chr19:29240125	G/A	cg14983838	chr19:29218262	NA	0.5	6.36	0.36	8.98e-10	Methadone dose in opioid dependence;
CESC	trans	rs78049276	0.688	rs1878406	chr4:148393664	C/T	cg13149281	chr14:23389818	RBM23;PRMT5	-0.65	-6.87	-0.39	4.63e-11	Pulse pressure;
CESC	cis	rs34779708	0.898	rs11595898	chr10:35326263	T/C	cg03585969	chr10:35415529	CREM	0.75	9.82	0.52	1.31e-19	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs760805	1.000	rs4648884	chr1:25261386	C/T	cg22509179	chr1:25234806	RUNX3	0.59	8.48	0.46	1.64e-15	Allergic disease (asthma, hay fever or eczema);
CESC	trans	rs208520	1.000	rs72882086	chr6:66976671	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.84	9.33	0.5	4.4e-18	Exhaled nitric oxide output;
CESC	cis	rs9325144	0.555	rs7955128	chr12:38684121	A/T	cg26384229	chr12:38710491	ALG10B	0.61	9.47	0.5	1.62e-18	Morning vs. evening chronotype;
CESC	cis	rs7613875	0.578	rs2526749	chr3:50076734	A/G	cg24110177	chr3:50126178	RBM5	0.58	8.17	0.45	1.28e-14	Body mass index;
CESC	cis	rs1707322	0.963	rs12022335	chr1:46402732	C/A	cg06784218	chr1:46089804	CCDC17	0.33	5.63	0.33	4.7e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs3806843	0.900	rs2262576	chr5:140135536	T/C	cg26395211	chr5:140044315	WDR55	0.4	5.2	0.3	4.03e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs1728785	1.000	rs1170434	chr16:68606590	A/G	cg02972257	chr16:68554789	NA	-0.68	-7.59	-0.42	5.63e-13	Ulcerative colitis;
CESC	cis	rs7811142	0.830	rs118119933	chr7:99939050	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.09	10.23	0.53	6.56e-21	Platelet count;
CESC	cis	rs7107174	0.748	rs11237458	chr11:78050849	A/T	cg02023728	chr11:77925099	USP35	0.38	5.49	0.32	9.3e-8	Testicular germ cell tumor;
CESC	cis	rs2243480	1.000	rs781150	chr7:65480973	C/T	cg13147721	chr7:65941812	NA	-0.91	-8.69	-0.47	3.87e-16	Diabetic kidney disease;
CESC	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.49	0.37	4.18e-10	Prudent dietary pattern;
CESC	cis	rs2075371	1.000	rs2598291	chr7:133988313	C/G	cg00033643	chr7:134001901	SLC35B4	0.44	5.62	0.33	4.89e-8	Mean platelet volume;
CESC	cis	rs11997175	0.583	rs7824990	chr8:33779934	A/G	ch.8.33884649F	chr8:33765107	NA	0.47	6.04	0.35	5.26e-9	Body mass index;
CESC	cis	rs870825	0.616	rs2003994	chr4:185636568	G/T	cg04058563	chr4:185651563	MLF1IP	0.62	6.86	0.39	4.91e-11	Blood protein levels;
CESC	cis	rs17125944	0.615	rs7150808	chr14:53304871	C/T	cg00686598	chr14:53173677	PSMC6	-0.71	-6.16	-0.35	2.63e-9	Alzheimer's disease (late onset);
CESC	cis	rs7666738	0.791	rs10005118	chr4:99038196	A/C	cg17366294	chr4:99064904	C4orf37	0.61	8.78	0.47	2.11e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs769267	0.965	rs2074296	chr19:19373689	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.4	5.05	0.3	8.25e-7	Tonsillectomy;
CESC	cis	rs7927771	1.000	rs11605774	chr11:47832793	G/A	cg18512352	chr11:47633146	NA	-0.6	-9.36	-0.5	3.59e-18	Subjective well-being;
CESC	cis	rs77972916	0.505	rs1322	chr2:43521167	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.64	-6.28	-0.36	1.38e-9	Granulocyte percentage of myeloid white cells;
CESC	cis	rs9473147	0.602	rs9296567	chr6:47553402	G/A	cg20196966	chr6:47445060	CD2AP	0.41	5.22	0.31	3.55e-7	Platelet distribution width;Mean platelet volume;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg21774377	chr6:34760070	UHRF1BP1	0.49	6.25	0.36	1.62e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs10883723	0.810	rs3740406	chr10:104272789	C/T	ch.10.2196322F	chr10:104248062	ACTR1A	0.42	5.16	0.3	4.76e-7	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs7264396	0.515	rs2425134	chr20:34339439	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.84	-10.41	-0.54	1.67e-21	Total cholesterol levels;
CESC	cis	rs1862618	0.853	rs832583	chr5:56178217	A/C	cg18230493	chr5:56204884	C5orf35	-0.73	-8.65	-0.47	4.94e-16	Initial pursuit acceleration;
CESC	cis	rs11112613	0.713	rs12321309	chr12:105943263	T/G	cg03607813	chr12:105948248	NA	0.6	6.77	0.38	8.3e-11	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CESC	trans	rs9325144	0.555	rs2387847	chr12:38687434	C/T	cg23762105	chr12:34175262	ALG10	-0.46	-6.15	-0.35	2.77e-9	Morning vs. evening chronotype;
CESC	cis	rs7395581	0.877	rs10838690	chr11:47335075	A/G	cg25783544	chr11:47291846	MADD	0.61	8.04	0.44	2.9e-14	HDL cholesterol;
CESC	cis	rs7666738	0.830	rs3896704	chr4:99034252	C/T	cg03676636	chr4:99064102	C4orf37	0.34	5.14	0.3	5.47e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23464032	chr5:145214937	PRELID2	0.57	6.29	0.36	1.29e-9	Gut microbiome composition (summer);
CESC	cis	rs6967414	1.000	rs6967414	chr7:6749758	G/A	cg00387323	chr7:6746715	ZNF12	0.62	6.65	0.38	1.68e-10	Hematocrit;Hemoglobin concentration;
CESC	trans	rs61931739	0.517	rs11053224	chr12:34484919	G/A	cg26384229	chr12:38710491	ALG10B	0.72	10.43	0.54	1.47e-21	Morning vs. evening chronotype;
CESC	cis	rs35110281	0.627	rs1436291	chr21:44965485	T/C	cg01579765	chr21:45077557	HSF2BP	-0.51	-8.35	-0.46	3.84e-15	Mean corpuscular volume;
CESC	cis	rs2075371	0.637	rs13245165	chr7:133951492	A/T	cg00033643	chr7:134001901	SLC35B4	0.4	5.14	0.3	5.22e-7	Mean platelet volume;
CESC	cis	rs4803468	0.967	rs7259900	chr19:41889429	A/T	cg08477640	chr19:41863820	B9D2	0.38	5.08	0.3	6.98e-7	Height;
CESC	cis	rs4853012	0.793	rs6723185	chr2:74344884	T/A	cg05776053	chr2:74358815	NA	0.4	5.04	0.3	8.64e-7	Gestational age at birth (maternal effect);
CESC	cis	rs2708240	0.560	rs4574770	chr7:147559736	C/T	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.39	-6.32	-0.36	1.08e-9	QT interval (drug interaction);
CESC	cis	rs1018836	0.923	rs13259842	chr8:91550819	A/G	cg16814680	chr8:91681699	NA	-0.71	-10.5	-0.54	8.8e-22	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs4664308	0.594	rs4665141	chr2:160890795	A/T	cg03641300	chr2:160917029	PLA2R1	-0.59	-8.54	-0.46	1.04e-15	Idiopathic membranous nephropathy;
CESC	cis	rs17376456	0.825	rs66564678	chr5:93165894	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.6	5.09	0.3	6.64e-7	Diabetic retinopathy;
CESC	cis	rs7949030	0.588	rs2509982	chr11:62312318	C/T	cg11742103	chr11:62369870	EML3;MTA2	0.57	8.62	0.47	6.29e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs2953174	0.786	rs2953145	chr2:241515596	C/G	cg07929629	chr2:241523174	NA	-0.48	-5.73	-0.33	2.74e-8	Bipolar disorder;
CESC	cis	rs4604732	0.631	rs60311891	chr1:247623127	C/T	cg12754571	chr1:247694271	LOC148824;OR2C3	0.42	5.16	0.3	4.96e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs4812048	0.602	rs59637156	chr20:57619618	T/C	cg14073986	chr20:57617431	SLMO2	0.83	7.46	0.42	1.22e-12	Mean platelet volume;
CESC	cis	rs1552244	1.000	rs4269070	chr3:10126083	C/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.85	-12.0	-0.59	8.92e-27	Alzheimer's disease;
CESC	cis	rs4481887	0.927	rs12731721	chr1:248474210	G/A	cg00666640	chr1:248458726	OR2T12	0.35	5.93	0.34	9.43e-9	Common traits (Other);
CESC	cis	rs10504229	1.000	rs58947041	chr8:58188934	G/A	cg14926445	chr8:58193284	C8orf71	-0.51	-5.52	-0.32	8.28e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs926938	0.563	rs360642	chr1:115425429	C/G	cg12756093	chr1:115239321	AMPD1	0.5	7.09	0.4	1.21e-11	Autism;
CESC	cis	rs74781061	0.929	rs76160708	chr15:74929242	A/G	cg17294928	chr15:75287854	SCAMP5	-0.49	-5.23	-0.31	3.42e-7	Endometriosis;
CESC	cis	rs12142240	0.667	rs45524035	chr1:46862780	C/T	cg10495392	chr1:46806563	NSUN4	0.56	6.17	0.35	2.61e-9	Menopause (age at onset);
CESC	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg06873352	chr17:61820015	STRADA	0.73	13.07	0.63	1.78e-30	Prudent dietary pattern;
CESC	cis	rs9388451	0.531	rs9401850	chr6:126151000	T/G	cg05901451	chr6:126070800	HEY2	-0.44	-5.89	-0.34	1.16e-8	Brugada syndrome;
CESC	cis	rs11229555	1.000	rs8373	chr11:58378424	A/G	cg15696309	chr11:58395628	NA	-0.43	-5.64	-0.33	4.3e-8	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CESC	trans	rs916888	0.821	rs199513	chr17:44856932	A/G	cg22968622	chr17:43663579	NA	-1.15	-15.19	-0.68	6.66e-38	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	trans	rs7618501	0.933	rs6809431	chr3:49804119	A/G	cg21659725	chr3:3221576	CRBN	0.83	13.56	0.64	3.67e-32	Intelligence (multi-trait analysis);
CESC	cis	rs727505	1.000	rs10246424	chr7:124494861	A/G	cg23710748	chr7:124431027	NA	-0.48	-7.64	-0.42	4.06e-13	Lewy body disease;
CESC	cis	rs7618915	0.547	rs11130315	chr3:52697163	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.5	7.23	0.41	5.08e-12	Bipolar disorder;
CESC	cis	rs738322	1.000	rs4379	chr22:38569171	T/C	cg25457927	chr22:38595422	NA	-0.3	-5.51	-0.32	8.66e-8	Cutaneous nevi;
CESC	cis	rs7598759	0.584	rs4973409	chr2:232311871	C/T	cg19187155	chr2:232395269	NMUR1	0.4	6.31	0.36	1.16e-9	Noise-induced hearing loss;
CESC	cis	rs1218582	0.774	rs4845681	chr1:154868055	G/T	cg09359103	chr1:154839909	KCNN3	-0.63	-12.09	-0.6	4.29e-27	Prostate cancer;
CESC	cis	rs3540	0.553	rs4031431	chr15:90990782	G/T	cg22089800	chr15:90895588	ZNF774	0.63	8.57	0.47	8.87e-16	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs56161922	0.730	rs74231794	chr1:207850717	G/A	cg09557387	chr1:207818395	CR1L	0.68	5.03	0.3	8.85e-7	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
CESC	cis	rs2235544	0.664	rs55766128	chr1:54477726	T/G	cg25741118	chr1:54482237	LDLRAD1	-0.25	-6.37	-0.36	8.38e-10	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
CESC	cis	rs4979906	1.000	rs11002242	chr10:79445873	G/C	cg07817648	chr10:79422355	NA	-0.46	-5.47	-0.32	1.02e-7	Mortality in heart failure;
CESC	cis	rs858239	1.000	rs166663	chr7:23316742	A/C	cg23682824	chr7:23144976	KLHL7	0.45	5.86	0.34	1.4e-8	Cerebrospinal fluid biomarker levels;
CESC	cis	rs3768617	0.966	rs6669796	chr1:183082825	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.65	8.99	0.48	4.91e-17	Fuchs's corneal dystrophy;
CESC	cis	rs826838	1.000	rs1963562	chr12:38662896	C/T	cg26384229	chr12:38710491	ALG10B	0.82	14.26	0.66	1.22e-34	Heart rate;
CESC	cis	rs2066819	1.000	rs76745316	chr12:56627652	A/C	cg26734620	chr12:56694298	CS	1.04	6.26	0.36	1.51e-9	Psoriasis vulgaris;
CESC	trans	rs3087243	0.755	rs231797	chr2:204706107	A/G	cg01841312	chr10:38069945	NA	0.37	6.23	0.36	1.85e-9	Rheumatoid arthritis;Hypothyroidism;Type 1 diabetes;
CESC	cis	rs4665809	0.590	rs4665319	chr2:26424583	A/C	cg26314531	chr2:26401878	FAM59B	-0.71	-8.09	-0.45	2.16e-14	Gut microbiome composition (summer);
CESC	cis	rs2637266	0.783	rs2395434	chr10:78476161	T/C	cg18941641	chr10:78392320	NA	0.4	7.58	0.42	5.65e-13	Pulmonary function;
CESC	cis	rs12983728	0.831	rs79222418	chr19:58664418	T/C	cg24884572	chr19:58661833	ZNF329	0.59	5.53	0.32	7.83e-8	Cholesterol, total;
CESC	cis	rs17533156	0.525	rs77932036	chr17:75207586	T/G	cg18815765	chr17:75136729	SEC14L1	0.63	6.32	0.36	1.09e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs6570726	0.935	rs400968	chr6:145819718	A/G	cg23711669	chr6:146136114	FBXO30	0.76	11.32	0.57	1.68e-24	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2273669	0.667	rs6918331	chr6:109317394	C/G	cg05315195	chr6:109294784	ARMC2	-0.66	-6.37	-0.36	8.17e-10	Prostate cancer;
CESC	cis	rs3126085	0.935	rs12726613	chr1:152185500	C/G	cg03465714	chr1:152285911	FLG	0.44	5.25	0.31	3.16e-7	Atopic dermatitis;
CESC	cis	rs10504229	1.000	rs73607871	chr8:58173007	T/C	cg22535103	chr8:58192502	C8orf71	-1.05	-13.27	-0.63	3.63e-31	Developmental language disorder (linguistic errors);
CESC	cis	rs7618915	0.501	rs62253740	chr3:52684128	A/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.75	0.38	9.1e-11	Bipolar disorder;
CESC	cis	rs16854884	0.657	rs920159	chr3:143753194	A/T	cg06585982	chr3:143692056	C3orf58	0.5	6.71	0.38	1.18e-10	Economic and political preferences (feminism/equality);
CESC	cis	rs1904096	0.506	rs10028613	chr4:95223698	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.62	-9.36	-0.5	3.52e-18	Type 2 diabetes;
CESC	cis	rs8062405	0.755	rs7186573	chr16:28587389	T/C	cg07382826	chr16:28625726	SULT1A1	0.4	6.63	0.38	1.93e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19909111	chr2:232329248	NCL	0.53	6.0	0.35	6.42e-9	Gut microbiome composition (summer);
CESC	cis	rs116161686	0.500	rs55871867	chr1:210051029	A/G	cg25204440	chr1:209979598	IRF6	0.64	6.07	0.35	4.36e-9	Coronary artery disease;
CESC	cis	rs55692468	0.606	rs6759772	chr2:153322724	C/T	cg04681845	chr2:153283485	FMNL2	-0.28	-5.79	-0.34	1.94e-8	Intraocular pressure;
CESC	cis	rs6952808	0.501	rs4721429	chr7:2171704	T/C	cg05863683	chr7:1912471	MAD1L1	0.41	6.05	0.35	4.95e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs9303401	0.921	rs34102441	chr17:56877414	A/G	cg12560992	chr17:57184187	TRIM37	0.49	5.54	0.32	7.42e-8	Cognitive test performance;
CESC	cis	rs10504229	0.906	rs58251024	chr8:58172259	G/C	cg22535103	chr8:58192502	C8orf71	-1.05	-13.16	-0.63	8.66e-31	Developmental language disorder (linguistic errors);
CESC	cis	rs9910055	0.659	rs7216294	chr17:42251095	T/C	cg19774624	chr17:42201019	HDAC5	-0.81	-12.45	-0.61	2.6e-28	Total body bone mineral density;
CESC	cis	rs1065852	0.526	rs2097561	chr22:42389431	T/C	cg22189786	chr22:42395067	WBP2NL	0.43	5.42	0.32	1.33e-7	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
CESC	cis	rs7264396	0.779	rs2425162	chr20:34429974	G/A	cg17201900	chr20:34330562	RBM39	0.51	5.14	0.3	5.24e-7	Total cholesterol levels;
CESC	cis	rs11098499	0.909	rs7681214	chr4:120385320	C/A	cg09307838	chr4:120376055	NA	0.95	13.96	0.65	1.42e-33	Corneal astigmatism;
CESC	cis	rs769267	0.965	rs1010207	chr19:19416045	T/C	cg15052019	chr19:19431593	KIAA0892;SF4	0.41	5.24	0.31	3.28e-7	Tonsillectomy;
CESC	cis	rs2243480	1.000	rs34933526	chr7:65383199	A/G	cg12463550	chr7:65579703	CRCP	0.7	5.58	0.32	5.87e-8	Diabetic kidney disease;
CESC	cis	rs4319547	1.000	rs1392236	chr12:123074890	C/G	cg23029597	chr12:123009494	RSRC2	-0.49	-5.4	-0.31	1.48e-7	Body mass index;
CESC	cis	rs909674	0.818	rs5757680	chr22:39844793	C/T	cg11247378	chr22:39784982	NA	0.56	7.97	0.44	4.89e-14	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs7017914	0.967	rs7819332	chr8:71668265	G/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.2	-0.3	3.94e-7	Bone mineral density;
CESC	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg07677032	chr17:61819896	STRADA	-0.43	-5.7	-0.33	3.16e-8	Prudent dietary pattern;
CESC	cis	rs748404	0.631	rs7166812	chr15:43644760	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.54	8.25	0.45	7.69e-15	Lung cancer;
CESC	cis	rs9287719	0.774	rs4997811	chr2:10755538	T/C	cg02196655	chr2:10830764	NOL10	-0.37	-5.51	-0.32	8.5e-8	Prostate cancer;
CESC	cis	rs9486719	0.948	rs2472904	chr6:96874962	T/G	cg18709589	chr6:96969512	KIAA0776	0.53	5.81	0.34	1.75e-8	Migraine;Coronary artery disease;
CESC	cis	rs2766692	1.000	rs2766692	chr14:100684192	C/T	cg14866419	chr14:100704911	YY1	0.62	7.93	0.44	6.23e-14	Electroencephalographic traits in alcoholism;
CESC	cis	rs11792861	0.926	rs11788825	chr9:111829757	T/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.46	6.04	0.35	5.3300000000000004e-09	Menarche (age at onset);
CESC	cis	rs7216064	1.000	rs7223930	chr17:65842186	G/A	cg12091567	chr17:66097778	LOC651250	-0.81	-9.14	-0.49	1.72e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs8067354	0.574	rs1291947	chr17:57996336	G/T	cg13753209	chr17:57696993	CLTC	0.52	5.7	0.33	3.21e-8	Hemoglobin concentration;
CESC	cis	rs7666738	0.830	rs4443293	chr4:99063120	G/A	cg17366294	chr4:99064904	C4orf37	0.62	8.8	0.48	1.82e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2243480	1.000	rs316312	chr7:65596491	T/G	cg13147721	chr7:65941812	NA	-0.99	-9.4	-0.5	2.68e-18	Diabetic kidney disease;
CESC	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.89	13.67	0.64	1.49e-32	Prudent dietary pattern;
CESC	cis	rs17376456	0.877	rs13173952	chr5:93307557	A/T	cg21475434	chr5:93447410	FAM172A	0.75	6.81	0.39	6.56e-11	Diabetic retinopathy;
CESC	cis	rs2463822	0.669	rs72919475	chr11:62042361	T/A	cg06239285	chr11:62104954	ASRGL1	-1.09	-8.77	-0.47	2.15e-16	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs7149337	0.805	rs2999355	chr14:51607084	A/G	cg23942311	chr14:51606299	NA	0.48	8.36	0.46	3.56e-15	Cancer;
CESC	cis	rs400736	0.930	rs370812	chr1:8075894	C/T	cg25007680	chr1:8021821	PARK7	0.71	10.26	0.53	5.13e-21	Response to antidepressants and depression;
CESC	cis	rs10504229	0.683	rs11774585	chr8:58132685	G/A	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs11958404	0.932	rs72816588	chr5:157434390	C/T	cg05962755	chr5:157440814	NA	0.62	6.56	0.37	2.74e-10	IgG glycosylation;
CESC	cis	rs748404	0.650	rs518234	chr15:43573421	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.53	8.3	0.45	5.45e-15	Lung cancer;
CESC	cis	rs2749592	0.588	rs2504144	chr10:38383525	C/T	cg00409905	chr10:38381863	ZNF37A	-0.55	-7.05	-0.4	1.56e-11	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs10899021	1.000	rs11236202	chr11:74376692	A/G	cg25880958	chr11:74394337	NA	-0.73	-6.74	-0.38	9.58e-11	Response to metformin (IC50);
CESC	cis	rs17666538	0.710	rs11987001	chr8:630755	T/C	cg23958373	chr8:599963	NA	0.77	5.48	0.32	9.95e-8	IgG glycosylation;
CESC	cis	rs854765	0.575	rs2955357	chr17:17946401	T/C	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.54	-7.02	-0.4	1.86e-11	Total body bone mineral density;
CESC	cis	rs790123	1.000	rs790113	chr3:122383276	T/A	cg17380795	chr3:122379686	NA	0.35	5.2	0.3	3.95e-7	Response to angiotensin II receptor blocker therapy;
CESC	cis	rs2963155	0.518	rs10482614	chr5:142782402	C/T	cg17617527	chr5:142782415	NR3C1	0.84	7.59	0.42	5.45e-13	Breast cancer;
CESC	cis	rs6460942	0.591	rs6942432	chr7:12338393	A/G	cg06484146	chr7:12443880	VWDE	-0.63	-7.0	-0.4	2.06e-11	Coronary artery disease;
CESC	cis	rs1451375	0.617	rs2329366	chr7:50544966	G/A	cg14593290	chr7:50529359	DDC	-0.54	-6.5	-0.37	4.05e-10	Malaria;
CESC	cis	rs2228479	0.867	rs76885005	chr16:89966668	A/G	cg14709524	chr16:89940631	TCF25	0.7	5.52	0.32	8.08e-8	Skin colour saturation;
CESC	cis	rs35306767	0.903	rs12769002	chr10:927666	C/G	cg10556349	chr10:835070	NA	-0.7	-6.0	-0.35	6.38e-9	Eosinophil percentage of granulocytes;
CESC	trans	rs815815	0.943	rs815811	chr2:47377472	A/G	cg07997434	chr2:238864969	NA	-0.48	-6.0	-0.35	6.4e-9	Dialysis-related mortality;
CESC	cis	rs7666738	0.830	rs60391193	chr4:98933912	T/G	cg17366294	chr4:99064904	C4orf37	0.61	8.56	0.47	9.36e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9311474	0.508	rs2878628	chr3:52584715	C/T	cg07507251	chr3:52567010	NT5DC2	-0.33	-5.59	-0.32	5.62e-8	Electroencephalogram traits;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg16247290	chr7:36429691	ANLN;KIAA0895	0.47	6.17	0.35	2.48e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs9457247	0.967	rs376097	chr6:167410878	A/G	cg23791538	chr6:167370224	RNASET2	-0.61	-8.81	-0.48	1.71e-16	Crohn's disease;
CESC	cis	rs4665809	0.590	rs4665321	chr2:26433801	A/C	cg27170947	chr2:26402098	FAM59B	-0.87	-9.77	-0.51	1.86e-19	Gut microbiome composition (summer);
CESC	cis	rs6502050	0.731	rs76421195	chr17:80109326	T/C	cg23985595	chr17:80112537	CCDC57	-0.42	-6.41	-0.37	6.63e-10	Life satisfaction;
CESC	cis	rs10479542	0.766	rs6894980	chr5:178974592	C/T	cg26516362	chr5:178986906	RUFY1	0.37	5.38	0.31	1.63e-7	Lung cancer;
CESC	cis	rs7666738	0.830	rs7662199	chr4:99019766	G/A	cg18180107	chr4:99064573	C4orf37	0.41	5.33	0.31	2.1e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7666738	0.800	rs11941885	chr4:99072921	A/C	cg03467027	chr4:99064603	C4orf37	0.46	5.6	0.33	5.25e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	7.7	0.43	2.77e-13	Prudent dietary pattern;
CESC	cis	rs34172651	0.517	rs3803716	chr16:24802325	C/T	cg02428538	chr16:24856791	SLC5A11	-0.48	-5.04	-0.3	8.68e-7	Intelligence (multi-trait analysis);
CESC	cis	rs9549367	0.713	rs3024745	chr13:113821598	A/G	cg00898013	chr13:113819073	PROZ	-0.54	-7.3	-0.41	3.29e-12	Platelet distribution width;
CESC	cis	rs4950322	0.570	rs72691097	chr1:146771388	C/T	cg22381352	chr1:146742008	CHD1L	-0.46	-5.05	-0.3	8.32e-7	Protein quantitative trait loci;
CESC	cis	rs477692	0.673	rs556253	chr10:131355781	G/A	cg24747557	chr10:131355152	MGMT	-0.39	-5.43	-0.32	1.3e-7	Response to temozolomide;
CESC	cis	rs1577917	1.000	rs35761942	chr6:86629504	C/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.49	-6.32	-0.36	1.09e-9	Response to antipsychotic treatment;
CESC	trans	rs916888	0.821	rs199509	chr17:44858728	G/A	cg10053473	chr17:62856997	LRRC37A3	0.65	7.33	0.41	2.74e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs6685188	0.920	rs6676110	chr1:205662977	G/A	cg11965913	chr1:205819406	PM20D1	-0.44	-6.13	-0.35	3.11e-9	White blood cell count (basophil);Basophil percentage of white cells;
CESC	cis	rs617219	0.889	rs1717567	chr5:78435762	C/T	cg22188827	chr5:78429774	NA	0.41	5.12	0.3	5.91e-7	Betaine levels in individuals undergoing cardiac evaluation;
CESC	cis	rs897984	0.762	rs4889599	chr16:30968589	C/T	cg00531865	chr16:30841666	NA	0.51	7.02	0.4	1.83e-11	Dementia with Lewy bodies;
CESC	cis	rs875971	0.638	rs801205	chr7:66022144	C/A	cg14393609	chr7:65229607	NA	-0.47	-6.31	-0.36	1.14e-9	Aortic root size;
CESC	cis	rs7829975	0.871	rs7829826	chr8:8578120	T/A	cg06636001	chr8:8085503	FLJ10661	-0.42	-5.38	-0.31	1.64e-7	Mood instability;
CESC	cis	rs910316	0.839	rs35977276	chr14:75637359	A/C	cg08847533	chr14:75593920	NEK9	-0.98	-17.94	-0.74	1.17e-47	Height;
CESC	cis	rs1552244	1.000	rs6781811	chr3:10121922	A/G	cg16606324	chr3:10149918	C3orf24	-0.42	-5.27	-0.31	2.9e-7	Alzheimer's disease;
CESC	cis	rs921968	0.541	rs578450	chr2:219401237	C/T	cg02176678	chr2:219576539	TTLL4	0.5	9.0	0.48	4.36e-17	Mean corpuscular hemoglobin concentration;
CESC	cis	rs1499972	0.941	rs62264779	chr3:117654731	G/T	cg07612923	chr3:117604196	NA	0.83	7.32	0.41	3.03e-12	Schizophrenia;
CESC	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg03188948	chr7:1209495	NA	0.58	6.69	0.38	1.3e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs589448	0.967	rs2617834	chr12:69753365	T/C	cg14784868	chr12:69753453	YEATS4	0.92	14.62	0.67	7.03e-36	Cerebrospinal fluid biomarker levels;
CESC	cis	rs2066819	0.892	rs117305040	chr12:56657888	A/G	cg26734620	chr12:56694298	CS	1.04	6.71	0.38	1.18e-10	Psoriasis vulgaris;
CESC	cis	rs7914558	1.000	rs11191539	chr10:104819770	A/G	cg04362960	chr10:104952993	NT5C2	0.47	6.32	0.36	1.11e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12199618	chr19:2353492	SPPL2B	-0.57	-6.73	-0.38	1.04e-10	Gut microbiome composition (summer);
CESC	cis	rs1552244	0.935	rs4441636	chr3:10083876	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.87	11.86	0.59	2.65e-26	Alzheimer's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02611874	chr10:46194725	NA	-0.55	-6.7	-0.38	1.27e-10	Gut microbiome composition (summer);
CESC	cis	rs4665809	1.000	rs6546744	chr2:26302161	A/G	cg27170947	chr2:26402098	FAM59B	-0.59	-7.09	-0.4	1.21e-11	Gut microbiome composition (summer);
CESC	trans	rs11098499	0.954	rs17005535	chr4:120411562	C/T	cg25214090	chr10:38739885	LOC399744	0.71	10.17	0.53	1.02e-20	Corneal astigmatism;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05851844	chr12:16035312	STRAP	0.56	6.27	0.36	1.46e-9	Gut microbiome composition (summer);
CESC	cis	rs72781680	0.898	rs72786279	chr2:24063266	C/T	cg08917208	chr2:24149416	ATAD2B	0.93	8.48	0.46	1.57e-15	Lymphocyte counts;
CESC	cis	rs12530845	0.623	rs73721677	chr7:135354238	C/A	cg23117316	chr7:135346802	PL-5283	-0.59	-6.39	-0.37	7.54e-10	Red blood cell traits;
CESC	cis	rs3106136	0.901	rs17376488	chr4:95226548	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.45	-6.56	-0.37	2.8e-10	Capecitabine sensitivity;
CESC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg01632322	chr19:4852205	PLIN3	-0.48	-6.03	-0.35	5.5e-9	Tetralogy of Fallot;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg04496106	chr17:41561072	DHX8	-0.45	-6.3	-0.36	1.26e-9	Gambling;
CESC	cis	rs10504229	0.679	rs56040464	chr8:58131603	G/A	cg24829409	chr8:58192753	C8orf71	-0.58	-7.2	-0.4	6.31e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	-1.11	-22.86	-0.81	1.3e-64	Prudent dietary pattern;
CESC	cis	rs9467711	0.606	rs12173854	chr6:26371679	A/G	cg14345882	chr6:26364793	BTN3A2	0.6	6.21	0.36	2.07e-9	Autism spectrum disorder or schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07851057	chr5:70751686	BDP1	0.6	6.65	0.38	1.63e-10	Gut microbiome composition (summer);
CESC	cis	rs1580019	0.844	rs4723159	chr7:32512804	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.91	13.04	0.63	2.42e-30	Cognitive ability;
CESC	cis	rs2070488	0.775	rs4407366	chr3:38521425	C/T	cg24069376	chr3:38537580	EXOG	0.32	5.27	0.31	2.88e-7	Electrocardiographic conduction measures;
CESC	cis	rs3204270	0.714	rs8074828	chr17:79657136	G/C	cg18367735	chr17:79674897	NA	0.66	5.62	0.33	4.87e-8	Dental caries;
CESC	cis	rs10504229	0.683	rs7822631	chr8:58130916	C/G	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs78456975	0.628	rs13426896	chr2:1554768	C/T	cg26248373	chr2:1572462	NA	-0.59	-6.01	-0.35	6.03e-9	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs7916697	0.947	rs9783176	chr10:70002393	A/T	cg06988349	chr10:69991859	ATOH7	0.38	6.4	0.37	6.94e-10	Optic disc area;
CESC	cis	rs7666738	0.606	rs4577589	chr4:99087858	A/G	cg17366294	chr4:99064904	C4orf37	0.43	5.71	0.33	3.05e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9815354	0.812	rs17217746	chr3:41926021	A/G	cg03022575	chr3:42003672	ULK4	0.71	6.44	0.37	5.46e-10	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs1552244	0.882	rs9312044	chr3:10037481	T/C	cg00149659	chr3:10157352	C3orf10	0.69	8.19	0.45	1.12e-14	Alzheimer's disease;
CESC	cis	rs7589728	0.858	rs79992736	chr2:88530575	A/C	cg07952391	chr2:88470173	THNSL2	0.58	6.78	0.38	7.56e-11	Plasma clusterin levels;
CESC	cis	rs2479724	0.792	rs7739064	chr6:41834037	C/A	cg17623882	chr6:41773611	USP49	-0.41	-6.01	-0.35	6.12e-9	Menarche (age at onset);
CESC	cis	rs858239	0.669	rs1618339	chr7:23229774	T/C	cg27449745	chr7:23145252	KLHL7	-0.41	-5.22	-0.31	3.59e-7	Cerebrospinal fluid biomarker levels;
CESC	cis	rs10752881	1.000	rs12028740	chr1:182985581	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.84	13.3	0.63	2.79e-31	Colorectal cancer;
CESC	cis	rs9311474	0.607	rs4475032	chr3:52560021	C/T	cg18404041	chr3:52824283	ITIH1	-0.38	-6.43	-0.37	5.88e-10	Electroencephalogram traits;
CESC	cis	rs963731	0.579	rs2373497	chr2:39288098	C/T	cg04010122	chr2:39346883	SOS1	-0.59	-5.4	-0.31	1.52e-7	Corticobasal degeneration;
CESC	cis	rs3888647	0.622	rs4758618	chr11:2995186	A/T	cg08508325	chr11:3079039	CARS	-0.5	-9.29	-0.5	5.75e-18	Type 2 diabetes;
CESC	cis	rs4604732	0.527	rs7546805	chr1:247627259	G/A	cg12758973	chr1:247694275	LOC148824;OR2C3	0.51	6.37	0.36	8.49e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs7917772	0.582	rs4917978	chr10:104366353	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.39	-5.28	-0.31	2.66e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs3736485	0.934	rs17609693	chr15:51868000	T/A	cg08986416	chr15:51914746	DMXL2	-0.4	-5.12	-0.3	5.86e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs3015469	0.584	rs1950730	chr14:50875828	C/T	cg26011998	chr14:51135199	SAV1	-0.55	-6.18	-0.36	2.35e-9	Plasma amyloid beta peptide concentrations (ABx-40);
CESC	cis	rs9291683	0.597	rs11723016	chr4:10126189	A/G	cg11266682	chr4:10021025	SLC2A9	-0.47	-8.53	-0.46	1.11e-15	Bone mineral density;
CESC	cis	rs1707322	0.963	rs12022335	chr1:46402732	C/A	cg05343316	chr1:45956843	TESK2	0.44	5.42	0.32	1.36e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs4665809	0.590	rs3806515	chr2:26466975	C/T	cg04944784	chr2:26401820	FAM59B	0.96	10.55	0.54	5.79e-22	Gut microbiome composition (summer);
CESC	cis	rs3749237	0.555	rs7637665	chr3:49552295	T/C	cg02487422	chr3:49467188	NICN1	0.56	8.08	0.44	2.33e-14	Resting heart rate;
CESC	trans	rs916888	0.773	rs199447	chr17:44812188	C/T	cg23590916	chr17:43697445	MGC57346	0.64	6.48	0.37	4.46e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs9910055	0.593	rs2905983	chr17:42212429	T/G	cg13607699	chr17:42295918	UBTF	-0.58	-7.46	-0.42	1.22e-12	Total body bone mineral density;
CESC	cis	rs12681366	0.734	rs4735288	chr8:95366544	C/T	cg13257157	chr8:95487014	RAD54B	0.39	5.42	0.32	1.33e-7	Nonsyndromic cleft lip with cleft palate;
CESC	cis	rs1552244	1.000	rs113771705	chr3:10075983	T/C	cg00149659	chr3:10157352	C3orf10	0.77	9.66	0.51	4.22e-19	Alzheimer's disease;
CESC	cis	rs3780486	0.846	rs7865745	chr9:33140976	A/G	cg13443165	chr9:33130375	B4GALT1	-0.43	-6.24	-0.36	1.72e-9	IgG glycosylation;
CESC	cis	rs7917772	0.503	rs7899576	chr10:104307504	G/A	ch.10.2196322F	chr10:104248062	ACTR1A	0.42	5.16	0.3	4.9e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs3806843	0.966	rs10060640	chr5:140211226	G/A	cg26395211	chr5:140044315	WDR55	-0.41	-5.13	-0.3	5.69e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs3796352	1.000	rs34244302	chr3:53102236	C/G	cg15956490	chr3:53032818	SFMBT1	0.63	5.15	0.3	5.18e-7	Immune reponse to smallpox (secreted IL-2);
CESC	cis	rs66887589	0.774	rs9307477	chr4:120421809	G/A	cg09307838	chr4:120376055	NA	0.54	7.29	0.41	3.49e-12	Diastolic blood pressure;
CESC	cis	rs9549367	0.713	rs56002882	chr13:113830694	T/C	cg18105134	chr13:113819100	PROZ	-0.68	-8.12	-0.45	1.75e-14	Platelet distribution width;
CESC	cis	rs7395581	0.918	rs61896050	chr11:47309063	T/C	cg25783544	chr11:47291846	MADD	0.62	8.26	0.45	7.05e-15	HDL cholesterol;
CESC	cis	rs7809950	0.678	rs77395658	chr7:107000651	G/A	cg23024343	chr7:107201750	COG5	-0.53	-6.76	-0.38	8.95e-11	Coronary artery disease;
CESC	cis	rs8077889	0.763	rs4792913	chr17:41854497	T/C	cg26893861	chr17:41843967	DUSP3	1.0	18.45	0.75	1.94e-49	Triglycerides;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg18900838	chr17:28804337	GOSR1	-0.51	-7.08	-0.4	1.29e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs9326248	0.530	rs7121347	chr11:116867209	G/T	cg01368799	chr11:117014884	PAFAH1B2	0.59	5.43	0.32	1.25e-7	Blood protein levels;
CESC	cis	rs9910055	0.762	rs7213436	chr17:42252163	A/G	cg13607699	chr17:42295918	UBTF	-0.59	-7.88	-0.44	8.46e-14	Total body bone mineral density;
CESC	cis	rs67311347	1.000	rs9875245	chr3:40442280	G/T	cg24209194	chr3:40518798	ZNF619	0.51	6.42	0.37	6.35e-10	Renal cell carcinoma;
CESC	cis	rs6032067	0.538	rs62206429	chr20:43730333	A/G	cg10761708	chr20:43804764	PI3	0.46	5.15	0.3	5.05e-7	Blood protein levels;
CESC	cis	rs8099014	0.725	rs12373325	chr18:56087648	C/T	cg12827950	chr18:55968429	NEDD4L	0.43	5.32	0.31	2.16e-7	Platelet count;
CESC	cis	rs62458065	0.513	rs10268149	chr7:32575499	T/C	cg20159608	chr7:32802032	NA	-0.55	-6.15	-0.35	2.89e-9	Metabolite levels (HVA/MHPG ratio);
CESC	cis	rs765787	0.530	rs1706830	chr15:45516229	G/A	cg24006582	chr15:45444508	DUOX1	-0.58	-7.12	-0.4	1.04e-11	Uric acid levels;
CESC	cis	rs2797160	0.547	rs10872298	chr6:125956348	A/C	cg05901451	chr6:126070800	HEY2	-0.39	-5.4	-0.32	1.46e-7	Endometrial cancer;
CESC	cis	rs7662987	0.517	rs2034696	chr4:100024322	C/G	cg12011299	chr4:100065546	ADH4	0.6	6.6	0.38	2.23e-10	Smoking initiation;
CESC	cis	rs6088590	1.000	rs6119530	chr20:33403930	A/G	cg08999081	chr20:33150536	PIGU	0.61	9.14	0.49	1.7e-17	Coronary artery disease;
CESC	cis	rs9300255	0.568	rs1790108	chr12:123636841	A/G	cg19016782	chr12:123741754	C12orf65	-0.4	-5.68	-0.33	3.46e-8	Neutrophil percentage of white cells;
CESC	cis	rs2625529	0.586	rs11639282	chr15:72435260	G/A	cg16672083	chr15:72433130	SENP8	0.42	6.45	0.37	5.42e-10	Red blood cell count;
CESC	cis	rs2243480	0.908	rs2460431	chr7:65622846	A/G	cg13147721	chr7:65941812	NA	0.97	9.19	0.49	1.2e-17	Diabetic kidney disease;
CESC	trans	rs7837860	0.588	rs17729482	chr8:89304297	T/A	cg04391754	chr17:18022714	MYO15A	0.54	6.21	0.36	2.02e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs950776	0.593	rs621849	chr15:78872861	G/A	cg24631222	chr15:78858424	CHRNA5	0.43	5.53	0.32	7.76e-8	Sudden cardiac arrest;
CESC	cis	rs9916302	0.904	rs4795355	chr17:37427382	C/T	cg00129232	chr17:37814104	STARD3	-0.55	-7.26	-0.41	4.23e-12	Glomerular filtration rate (creatinine);
CESC	cis	rs35306767	0.953	rs11253520	chr10:975961	C/G	cg20503657	chr10:835505	NA	-0.46	-5.65	-0.33	4.08e-8	Eosinophil percentage of granulocytes;
CESC	cis	rs9906944	0.707	rs9899931	chr17:47108282	G/A	cg09029085	chr17:47094198	IGF2BP1	0.26	5.11	0.3	6.26e-7	Intelligence (multi-trait analysis);Body fat percentage;
CESC	cis	rs2651899	0.902	rs1798246	chr1:3080855	A/C	cg22674798	chr1:3096360	PRDM16	0.34	6.58	0.37	2.53e-10	Migraine;
CESC	cis	rs295137	0.836	rs1217429	chr2:201094151	G/T	cg23649088	chr2:200775458	C2orf69	0.44	5.75	0.33	2.43e-8	Asthma (bronchodilator response);
CESC	cis	rs6952808	0.792	rs13224989	chr7:1953766	C/G	cg04267008	chr7:1944627	MAD1L1	-0.69	-9.11	-0.49	2.03e-17	Bipolar disorder and schizophrenia;
CESC	cis	rs1005224	0.963	rs2303345	chr14:76156609	A/G	cg25116370	chr14:76127843	TTLL5;C14orf1	0.41	5.56	0.32	6.51e-8	Large artery stroke;
CESC	cis	rs8050907	0.744	rs56235717	chr16:4524374	C/T	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.9	6.28	0.36	1.39e-9	Obesity-related traits;
CESC	cis	rs4969178	0.965	rs56658017	chr17:76396164	G/A	cg20026190	chr17:76395443	PGS1	0.49	7.81	0.43	1.34e-13	HDL cholesterol levels;
CESC	cis	rs7267979	1.000	rs4815424	chr20:25390284	T/C	cg08601574	chr20:25228251	PYGB	-0.37	-5.3	-0.31	2.45e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs3126085	0.935	rs991231	chr1:152211898	T/G	cg03465714	chr1:152285911	FLG	0.44	5.17	0.3	4.67e-7	Atopic dermatitis;
CESC	cis	rs7552404	1.000	rs4949872	chr1:76131392	C/G	cg10523679	chr1:76189770	ACADM	0.67	7.66	0.43	3.4e-13	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs9311474	1.000	rs7614727	chr3:52295895	C/T	cg05564831	chr3:52568323	NT5DC2	0.41	6.71	0.38	1.19e-10	Electroencephalogram traits;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg18570646	chr15:37391424	MEIS2	-0.43	-6.36	-0.36	9.01e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs9915657	0.870	rs12941066	chr17:70141226	C/T	cg06234051	chr17:70120541	SOX9	-0.43	-6.29	-0.36	1.32e-9	Thyroid hormone levels;
CESC	cis	rs2415984	0.579	rs2123129	chr14:46960920	G/T	cg14871534	chr14:47121158	RPL10L	-0.36	-5.41	-0.32	1.42e-7	Number of children ever born;
CESC	cis	rs1832871	0.655	rs4292552	chr6:158722888	G/A	cg07165851	chr6:158734300	TULP4	0.61	6.77	0.38	8.06e-11	Height;
CESC	cis	rs4964805	0.770	rs11111779	chr12:104185496	G/A	cg02344784	chr12:104178138	NT5DC3	0.38	5.29	0.31	2.56e-7	Attention deficit hyperactivity disorder;
CESC	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	22.35	0.81	6.51e-63	Prudent dietary pattern;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg13456812	chr6:167369504	RNASET2	0.5	6.72	0.38	1.14e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs56804039	1.000	rs67611618	chr8:8380939	T/C	cg15556689	chr8:8085844	FLJ10661	-0.49	-5.28	-0.31	2.66e-7	Cervical cancer;
CESC	cis	rs11098499	0.754	rs1511025	chr4:120240238	T/C	cg09307838	chr4:120376055	NA	0.79	10.77	0.55	1.17e-22	Corneal astigmatism;
CESC	cis	rs262150	0.659	rs2730275	chr7:158793397	A/G	cg10570241	chr7:158785291	NA	0.33	5.48	0.32	1.01e-7	Facial morphology (factor 20);
CESC	cis	rs2455799	0.573	rs2470520	chr3:15762920	C/T	cg16303742	chr3:15540471	COLQ	-0.39	-6.24	-0.36	1.76e-9	Mean platelet volume;
CESC	cis	rs1451375	0.583	rs3807556	chr7:50610536	G/A	cg14593290	chr7:50529359	DDC	0.52	6.26	0.36	1.53e-9	Malaria;
CESC	cis	rs28374715	0.681	rs7162231	chr15:41591859	G/A	cg02330683	chr15:41787940	ITPKA	0.48	5.73	0.33	2.77e-8	Ulcerative colitis;
CESC	cis	rs9611565	0.918	rs9611562	chr22:41760172	T/G	cg17376030	chr22:41985996	PMM1	0.65	6.9	0.39	3.73e-11	Vitiligo;
CESC	cis	rs1957429	0.901	rs1467570	chr14:65347858	A/G	cg23373153	chr14:65346875	NA	0.96	11.49	0.58	4.43e-25	Pediatric areal bone mineral density (radius);
CESC	cis	rs7666738	0.830	rs10000573	chr4:99048785	G/C	cg03467027	chr4:99064603	C4orf37	0.47	5.98	0.34	7.19e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs780096	0.526	rs11126999	chr2:27670307	G/A	cg21248554	chr2:27665150	KRTCAP3	-0.33	-6.7	-0.38	1.27e-10	Total body bone mineral density;
CESC	cis	rs847577	0.609	rs11765552	chr7:97822115	T/A	cg21770322	chr7:97807741	LMTK2	0.86	14.68	0.67	4.05e-36	Breast cancer;
CESC	cis	rs8177179	0.967	rs6782434	chr3:133438834	C/G	cg24879335	chr3:133465180	TF	0.46	8.72	0.47	3.07e-16	Iron status biomarkers (transferrin levels);
CESC	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	10.52	0.54	7.61e-22	Prudent dietary pattern;
CESC	cis	rs4665809	0.652	rs12611790	chr2:26404221	C/T	cg08470875	chr2:26401718	FAM59B	-0.71	-7.42	-0.41	1.6e-12	Gut microbiome composition (summer);
CESC	cis	rs10504229	0.728	rs17804335	chr8:58151428	G/T	cg02725872	chr8:58115012	NA	0.34	5.08	0.3	7.06e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs5769707	0.749	rs8137251	chr22:50036669	G/A	cg05373962	chr22:49881684	NA	-0.34	-5.57	-0.32	6.18e-8	Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg24503407	chr1:205819492	PM20D1	0.81	13.09	0.63	1.51e-30	Menarche (age at onset);
CESC	cis	rs7659604	0.521	rs9993206	chr4:122686957	A/G	cg19671926	chr4:122722719	EXOSC9	0.58	7.28	0.41	3.72e-12	Type 2 diabetes;
CESC	cis	rs2576037	0.562	rs612519	chr18:44379490	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.36	5.78	0.33	2.15e-8	Personality dimensions;
CESC	cis	rs2637266	0.935	rs2579728	chr10:78395598	A/G	cg18941641	chr10:78392320	NA	0.45	8.6	0.47	7.12e-16	Pulmonary function;
CESC	cis	rs896854	0.517	rs896851	chr8:95950251	T/C	cg23172400	chr8:95962367	TP53INP1	-0.39	-6.79	-0.38	7.52e-11	Type 2 diabetes;
CESC	cis	rs9911578	0.967	rs7222789	chr17:56819853	C/G	cg12560992	chr17:57184187	TRIM37	0.92	15.09	0.68	1.43e-37	Intelligence (multi-trait analysis);
CESC	cis	rs7847628	0.566	rs10739575	chr9:123606101	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.52	-5.4	-0.32	1.46e-7	Birth weight;
CESC	cis	rs6662572	0.737	rs75490316	chr1:46553785	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.47	5.11	0.3	6.21e-7	Blood protein levels;
CESC	cis	rs1552244	0.810	rs6809572	chr3:10100145	G/A	cg00149659	chr3:10157352	C3orf10	0.74	8.63	0.47	5.66e-16	Alzheimer's disease;
CESC	cis	rs9611565	0.659	rs9611602	chr22:41908405	T/C	cg17376030	chr22:41985996	PMM1	0.72	7.81	0.43	1.32e-13	Vitiligo;
CESC	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg06873352	chr17:61820015	STRADA	0.74	13.19	0.63	7.17e-31	Prudent dietary pattern;
CESC	trans	rs35110281	0.633	rs4819289	chr21:45120237	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.46	6.02	0.35	5.93e-9	Mean corpuscular volume;
CESC	cis	rs7580658	0.724	rs12623948	chr2:128001342	G/A	cg10021288	chr2:128175891	PROC	-0.39	-6.08	-0.35	4.23e-9	Protein C levels;
CESC	cis	rs7542091	0.506	rs992976	chr1:210066658	A/T	cg21951975	chr1:209979733	IRF6	-0.37	-6.09	-0.35	3.85e-9	Monobrow;
CESC	cis	rs7811142	1.000	rs11763511	chr7:100081944	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.01	11.17	0.57	5.56e-24	Platelet count;
CESC	cis	rs17401966	0.931	rs10492972	chr1:10353112	A/G	cg15208524	chr1:10270712	KIF1B	0.42	5.45	0.32	1.14e-7	Hepatocellular carcinoma;
CESC	cis	rs116095464	0.558	rs7714335	chr5:263513	T/C	cg22857025	chr5:266934	NA	-1.26	-15.32	-0.69	2.17e-38	Breast cancer;
CESC	cis	rs1799949	0.930	rs33968979	chr17:41297992	G/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.67	9.36	0.5	3.44e-18	Menopause (age at onset);
CESC	cis	rs9837602	0.938	rs10511177	chr3:99724873	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.46	-6.59	-0.38	2.36e-10	Breast cancer;
CESC	cis	rs7666738	0.830	rs2019163	chr4:99022747	C/T	cg17366294	chr4:99064904	C4orf37	0.61	8.76	0.47	2.35e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs909674	0.690	rs5750825	chr22:39831278	A/G	cg11247378	chr22:39784982	NA	-0.58	-8.53	-0.46	1.12e-15	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs74781061	0.929	rs8029099	chr15:74766770	A/C	cg17294928	chr15:75287854	SCAMP5	-0.5	-5.31	-0.31	2.35e-7	Endometriosis;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg26652484	chr3:57582327	ARF4	-0.44	-6.24	-0.36	1.71e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs17362650	1.000	rs4464248	chr2:9691320	A/G	cg12832956	chr2:9616023	IAH1	0.52	5.14	0.3	5.28e-7	Alcohol dependence (age at onset);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg13749939	chr11:796434	SLC25A22	-0.44	-6.62	-0.38	1.99e-10	Gambling;
CESC	cis	rs761746	0.672	rs10775716	chr22:31992645	C/T	cg25791279	chr22:32026902	PISD	0.57	5.77	0.33	2.26e-8	Intelligence;
CESC	cis	rs12477438	0.765	rs4851183	chr2:99629149	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.64	-8.73	-0.47	2.94e-16	Chronic sinus infection;
CESC	cis	rs7264396	0.635	rs2064724	chr20:34522520	T/C	cg17201900	chr20:34330562	RBM39	0.49	5.13	0.3	5.62e-7	Total cholesterol levels;
CESC	cis	rs2721195	0.549	rs2958492	chr8:145919126	C/T	cg15857475	chr8:145742913	RECQL4;LRRC14	0.41	5.43	0.32	1.26e-7	Age at first birth;
CESC	cis	rs3733585	0.725	rs10939636	chr4:9972640	T/G	cg11266682	chr4:10021025	SLC2A9	-0.58	-10.84	-0.55	6.42e-23	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs938554	0.779	rs11735831	chr4:9951591	G/A	cg11266682	chr4:10021025	SLC2A9	-0.4	-5.42	-0.32	1.36e-7	Blood metabolite levels;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg16857181	chr7:32931955	KBTBD2	0.52	6.68	0.38	1.44e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs7605827	0.930	rs13024118	chr2:15494640	A/T	cg19274914	chr2:15703543	NA	0.31	5.62	0.33	4.89e-8	Educational attainment (years of education);
CESC	cis	rs2228479	0.850	rs11076619	chr16:89831243	C/A	cg06558623	chr16:89946397	TCF25	1.17	9.29	0.5	5.84e-18	Skin colour saturation;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg25472998	chr6:10413233	TFAP2A	-0.49	-6.11	-0.35	3.5e-9	Ulcerative colitis;
CESC	cis	rs1348850	1.000	rs1348850	chr2:178418575	A/G	cg22681709	chr2:178499509	PDE11A	-0.4	-5.89	-0.34	1.17e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs10256972	1.000	rs10256972	chr7:1039003	G/T	cg04025307	chr7:1156635	C7orf50	-0.4	-6.53	-0.37	3.3e-10	Longevity;Endometriosis;
CESC	cis	rs875971	0.895	rs10755833	chr7:65913917	A/G	cg18876405	chr7:65276391	NA	0.51	6.82	0.39	6.05e-11	Aortic root size;
CESC	cis	rs11122272	0.735	rs2572254	chr1:231512593	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.54	-7.28	-0.41	3.86e-12	Hemoglobin concentration;
CESC	cis	rs2204008	0.775	rs12369238	chr12:38176051	A/G	cg26384229	chr12:38710491	ALG10B	0.68	9.53	0.51	1.08e-18	Bladder cancer;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg22025132	chr6:143771787	ADAT2;PEX3	-0.5	-6.79	-0.38	7.56e-11	Asthma;
CESC	cis	rs3820068	0.603	rs6429769	chr1:15968610	C/G	cg13390004	chr1:15929781	NA	0.34	5.61	0.33	5.11e-8	Systolic blood pressure;
CESC	cis	rs2180341	0.920	rs9401951	chr6:127671632	A/C	cg24812749	chr6:127587940	RNF146	1.06	15.02	0.68	2.7e-37	Breast cancer;
CESC	cis	rs9487051	0.872	rs9398197	chr6:109609988	C/A	cg21918786	chr6:109611834	NA	-0.4	-6.05	-0.35	5.03e-9	Reticulocyte fraction of red cells;
CESC	trans	rs7618501	0.602	rs2301166	chr3:50148305	C/G	cg21659725	chr3:3221576	CRBN	-0.5	-6.92	-0.39	3.32e-11	Intelligence (multi-trait analysis);
CESC	cis	rs2109514	0.774	rs6954077	chr7:116129153	G/A	cg12739419	chr7:116140593	CAV2	-0.38	-6.76	-0.38	8.91e-11	Prevalent atrial fibrillation;
CESC	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	22.35	0.81	6.51e-63	Prudent dietary pattern;
CESC	cis	rs17601876	0.814	rs12050767	chr15:51557257	T/C	cg19946085	chr15:51559439	CYP19A1	-0.35	-5.61	-0.33	5.08e-8	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
CESC	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg11494091	chr17:61959527	GH2	0.73	12.44	0.61	2.72e-28	Prudent dietary pattern;
CESC	cis	rs950169	0.840	rs62029595	chr15:84955301	C/T	cg17507749	chr15:85114479	UBE2QP1	0.59	6.5	0.37	4.03e-10	Schizophrenia;
CESC	cis	rs698813	0.572	rs4953076	chr2:44480950	G/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.47	5.3	0.31	2.41e-7	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
CESC	cis	rs1475911	0.744	rs12481958	chr21:43517269	A/G	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.37	-5.65	-0.33	4.18e-8	IgG glycosylation;
CESC	cis	rs28386778	0.669	rs12603821	chr17:62006432	G/A	cg07677032	chr17:61819896	STRADA	-0.47	-6.25	-0.36	1.67e-9	Prudent dietary pattern;
CESC	cis	rs11098499	0.865	rs9996417	chr4:120295862	T/C	cg24375607	chr4:120327624	NA	0.47	5.62	0.33	4.89e-8	Corneal astigmatism;
CESC	cis	rs10540	1.000	rs61876333	chr11:487136	G/A	cg03352830	chr11:487213	PTDSS2	0.72	6.64	0.38	1.73e-10	Body mass index;
CESC	cis	rs2996428	0.667	rs17412654	chr1:3758493	T/C	cg13057898	chr1:3703894	LRRC47	0.45	6.08	0.35	4.26e-9	Red cell distribution width;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg14995492	chr5:122971951	NA	-0.39	-6.29	-0.36	1.3e-9	Asthma;
CESC	cis	rs9581857	0.579	rs75326986	chr13:27997758	C/T	cg22138327	chr13:27999177	GTF3A	0.65	5.5	0.32	9.07e-8	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
CESC	cis	rs72945132	0.882	rs17160039	chr11:70145489	A/G	cg14191688	chr11:70257035	CTTN	0.42	5.34	0.31	1.95e-7	Coronary artery disease;
CESC	cis	rs9796	0.870	rs7181816	chr15:41358720	T/A	cg18705301	chr15:41695430	NDUFAF1	-0.45	-6.83	-0.39	5.74e-11	Menopause (age at onset);
CESC	cis	rs9649213	0.574	rs7802541	chr7:97933855	C/A	cg24562669	chr7:97807699	LMTK2	0.54	7.91	0.44	7.09e-14	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs12995491	0.569	rs6724281	chr2:88529531	T/G	cg14558114	chr2:88469736	THNSL2	-0.7	-10.12	-0.53	1.42e-20	Response to metformin (IC50);
CESC	cis	rs12497850	0.931	rs11705888	chr3:48817289	T/C	cg03060546	chr3:49711283	APEH	0.42	5.16	0.3	4.81e-7	Parkinson's disease;
CESC	cis	rs7618915	0.547	rs34610142	chr3:52708429	G/A	cg17372223	chr3:52568218	NT5DC2	0.44	6.57	0.37	2.69e-10	Bipolar disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13089318	chr1:80961776	NA	-0.59	-6.96	-0.39	2.62e-11	Gut microbiome composition (summer);
CESC	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg26304593	chr6:42947056	PEX6	-0.42	-5.32	-0.31	2.24e-7	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs10791323	0.569	rs10750542	chr11:133713436	T/C	cg15485101	chr11:133734466	NA	0.41	6.65	0.38	1.7e-10	Childhood ear infection;
CESC	trans	rs1493916	0.870	rs7239173	chr18:31395534	A/T	cg27147174	chr7:100797783	AP1S1	-0.54	-7.28	-0.41	3.85e-12	Life satisfaction;
CESC	trans	rs7615952	0.641	rs12487875	chr3:125787224	C/A	cg07211511	chr3:129823064	LOC729375	-0.57	-6.39	-0.37	7.57e-10	Blood pressure (smoking interaction);
CESC	cis	rs10504229	1.000	rs7007805	chr8:58179327	G/A	cg22535103	chr8:58192502	C8orf71	-1.05	-13.27	-0.63	3.63e-31	Developmental language disorder (linguistic errors);
CESC	cis	rs9322193	0.884	rs880245	chr6:150167398	A/G	cg04369109	chr6:150039330	LATS1	0.41	5.4	0.31	1.49e-7	Lung cancer;
CESC	cis	rs2073300	0.609	rs3736755	chr20:23377642	C/T	cg16736954	chr20:23401023	NAPB	0.78	6.0	0.35	6.37e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs62064224	0.791	rs11653160	chr17:30717222	A/G	cg09324608	chr17:30823087	MYO1D	0.49	7.32	0.41	2.94e-12	Schizophrenia;
CESC	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.48	-5.08	-0.3	7.1e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs1881797	1.000	rs12081895	chr1:247686666	C/G	cg11166453	chr1:247681781	NA	0.44	5.77	0.33	2.24e-8	Acute lymphoblastic leukemia (childhood);
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg27261837	chr1:146714163	CHD1L	0.49	6.7	0.38	1.28e-10	Systemic lupus erythematosus;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg02678462	chr19:5154735	NA	-0.52	-6.9	-0.39	3.91e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs7818688	0.578	rs11776489	chr8:95828458	G/A	cg16049864	chr8:95962084	TP53INP1	0.55	5.66	0.33	3.83e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs472402	0.580	rs3822430	chr5:6651970	A/G	cg10789808	chr5:6633262	NSUN2;SRD5A1	-0.55	-7.06	-0.4	1.43e-11	Response to amphetamines;
CESC	cis	rs3771570	1.000	rs55634485	chr2:242268994	T/C	cg21155796	chr2:242212141	HDLBP	0.6	5.11	0.3	6.17e-7	Prostate cancer;
CESC	cis	rs10504229	0.680	rs11777459	chr8:58044241	A/T	cg24829409	chr8:58192753	C8orf71	-0.53	-6.49	-0.37	4.3e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs9303401	0.580	rs12946396	chr17:57164195	T/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.0	12.4	0.61	3.86e-28	Cognitive test performance;
CESC	cis	rs2228479	1.000	rs4257207	chr16:89947861	T/A	cg14709524	chr16:89940631	TCF25	0.89	6.56	0.37	2.74e-10	Skin colour saturation;
CESC	cis	rs258892	0.793	rs34655	chr5:72147269	A/G	cg21869765	chr5:72125136	TNPO1	0.45	5.68	0.33	3.57e-8	Small cell lung carcinoma;
CESC	cis	rs4919687	0.550	rs12761195	chr10:104465374	T/C	cg04362960	chr10:104952993	NT5C2	0.46	5.37	0.31	1.73e-7	Colorectal cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01172114	chr10:5979283	FBXO18	-0.58	-6.16	-0.35	2.69e-9	Gut microbiome composition (summer);
CESC	cis	rs61931739	0.500	rs11053217	chr12:34470036	A/C	cg06521331	chr12:34319734	NA	-0.37	-5.04	-0.3	8.52e-7	Morning vs. evening chronotype;
CESC	cis	rs4953076	0.573	rs9973609	chr2:44450435	T/C	cg04920474	chr2:44395004	PPM1B	0.56	7.08	0.4	1.26e-11	Height;
CESC	cis	rs2991971	0.967	rs644915	chr1:46007002	T/C	cg06784218	chr1:46089804	CCDC17	-0.29	-5.09	-0.3	6.87e-7	High light scatter reticulocyte count;
CESC	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg24829409	chr8:58192753	C8orf71	-0.67	-7.99	-0.44	4.08e-14	Developmental language disorder (linguistic errors);
CESC	cis	rs10479542	0.784	rs7703730	chr5:178986632	C/A	cg26516362	chr5:178986906	RUFY1	-0.42	-6.53	-0.37	3.35e-10	Lung cancer;
CESC	trans	rs877282	0.898	rs34490091	chr10:765800	A/C	cg22713356	chr15:30763199	NA	1.16	11.28	0.57	2.37e-24	Uric acid levels;
CESC	cis	rs854765	0.547	rs4459604	chr17:17888549	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.57	7.78	0.43	1.65e-13	Total body bone mineral density;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05150023	chr5:42944267	NA	-0.48	-6.18	-0.35	2.36e-9	Gut microbiome composition (summer);
CESC	cis	rs780096	0.546	rs1060525	chr2:27635582	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.28	-5.23	-0.31	3.45e-7	Total body bone mineral density;
CESC	cis	rs7100689	0.556	rs6585971	chr10:82145057	G/C	cg00277334	chr10:82204260	NA	-0.58	-7.62	-0.42	4.52e-13	Post bronchodilator FEV1;
CESC	cis	rs8114671	0.562	rs4911449	chr20:33512236	T/G	cg24642439	chr20:33292090	TP53INP2	0.44	5.32	0.31	2.18e-7	Height;
CESC	cis	rs4843747	0.749	rs72818535	chr16:88074039	G/A	cg03395651	chr16:88107091	BANP	0.44	5.13	0.3	5.57e-7	Menopause (age at onset);
CESC	trans	rs9329221	0.650	rs657913	chr8:9882575	G/T	cg06636001	chr8:8085503	FLJ10661	-0.53	-6.81	-0.39	6.38e-11	Neuroticism;
CESC	cis	rs763121	0.853	rs5757226	chr22:39070550	T/C	cg06022373	chr22:39101656	GTPBP1	0.89	14.42	0.66	3.47e-35	Menopause (age at onset);
CESC	cis	rs820218	0.886	rs820202	chr17:73636623	G/A	cg01592526	chr17:73663357	RECQL5;SAP30BP	0.41	5.35	0.31	1.9e-7	Rotator cuff tears;
CESC	cis	rs11792861	0.816	rs2304779	chr9:111670513	C/T	cg13535736	chr9:111863775	C9orf5	0.46	6.22	0.36	1.97e-9	Menarche (age at onset);
CESC	cis	rs921968	0.565	rs2272189	chr2:219610322	G/A	cg02176678	chr2:219576539	TTLL4	-0.46	-8.14	-0.45	1.58e-14	Mean corpuscular hemoglobin concentration;
CESC	cis	rs4434138	0.594	rs7653028	chr3:52763000	A/T	cg05564831	chr3:52568323	NT5DC2	0.46	7.05	0.4	1.58e-11	Intelligence (multi-trait analysis);
CESC	cis	rs290986	1.000	rs290986	chr9:93563536	A/G	cg02608019	chr9:93564028	SYK	0.53	5.86	0.34	1.36e-8	Multiple sclerosis;
CESC	cis	rs317689	0.718	rs315130	chr12:69761444	T/C	cg20891283	chr12:69753455	YEATS4	0.64	7.44	0.42	1.42e-12	Response to diuretic therapy;
CESC	cis	rs13253111	0.624	rs4732844	chr8:28104473	A/G	cg26534493	chr8:28060551	NA	-0.47	-7.16	-0.4	8.15e-12	Childhood body mass index;
CESC	cis	rs6570726	0.967	rs450973	chr6:145863065	C/A	cg05347473	chr6:146136440	FBXO30	0.44	6.01	0.35	6.2e-9	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2760061	0.626	rs2796057	chr1:228124414	G/C	cg01973587	chr1:228161476	NA	0.38	5.84	0.34	1.49e-8	Diastolic blood pressure;
CESC	cis	rs853679	0.517	rs9393884	chr6:28046789	A/G	cg17221315	chr6:27791827	HIST1H4J	0.44	5.08	0.3	7.12e-7	Depression;
CESC	cis	rs854765	0.583	rs8080823	chr17:17864048	T/C	cg09796270	chr17:17721594	SREBF1	0.48	6.53	0.37	3.37e-10	Total body bone mineral density;
CESC	cis	rs372883	0.600	rs2832295	chr21:30739843	C/T	cg24692254	chr21:30365293	RNF160	0.58	7.23	0.41	5.32e-12	Pancreatic cancer;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg19541688	chr19:46289559	DMWD	0.47	6.28	0.36	1.39e-9	Fibrinogen levels;
CESC	cis	rs875971	0.706	rs1643374	chr7:65872682	T/A	cg11764359	chr7:65958608	NA	0.66	8.34	0.46	4.16e-15	Aortic root size;
CESC	cis	rs992157	0.717	rs3817266	chr2:219142594	C/T	cg00012203	chr2:219082015	ARPC2	-0.76	-9.55	-0.51	9.45e-19	Colorectal cancer;
CESC	cis	rs9549367	0.713	rs3024757	chr13:113823186	G/T	cg18105134	chr13:113819100	PROZ	-0.7	-8.34	-0.46	4.2e-15	Platelet distribution width;
CESC	cis	rs3892630	0.588	rs12610342	chr19:33250690	C/T	cg22980127	chr19:33182716	NUDT19	1.14	14.35	0.66	6.09e-35	Red blood cell traits;
CESC	cis	rs798554	0.757	rs1182188	chr7:2869985	T/C	cg19346786	chr7:2764209	NA	-0.42	-6.13	-0.35	3.18e-9	Height;
CESC	cis	rs1448094	0.511	rs34656916	chr12:86154658	G/C	cg02569458	chr12:86230093	RASSF9	0.51	7.7	0.43	2.65e-13	Major depressive disorder;
CESC	trans	rs864643	0.773	rs11129837	chr3:39589963	A/G	cg10663503	chr17:8126298	C17orf44	0.59	8.1	0.45	1.97e-14	Attention deficit hyperactivity disorder;
CESC	cis	rs1348850	0.526	rs2178017	chr2:178374788	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.68	6.07	0.35	4.42e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs2427308	0.607	rs1741635	chr20:60938197	C/G	cg09594475	chr20:60884601	LAMA5	-0.46	-5.16	-0.3	4.74e-7	Colorectal cancer;
CESC	trans	rs3780486	0.846	rs10113903	chr9:33122645	C/G	cg20290983	chr6:43655470	MRPS18A	-1.01	-19.01	-0.76	2.04e-51	IgG glycosylation;
CESC	cis	rs6570726	0.599	rs426371	chr6:145886469	A/G	cg05347473	chr6:146136440	FBXO30	-0.71	-9.16	-0.49	1.48e-17	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs12530845	0.623	rs73721681	chr7:135361917	A/G	cg23117316	chr7:135346802	PL-5283	-0.57	-6.18	-0.35	2.4e-9	Red blood cell traits;
CESC	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg18402987	chr7:1209562	NA	0.74	8.54	0.46	1.07e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7599312	0.534	rs7607363	chr2:213402705	A/G	cg16329650	chr2:213403929	ERBB4	0.58	8.43	0.46	2.31e-15	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs1580019	0.563	rs13244332	chr7:32537679	G/A	cg06627557	chr7:32535165	LSM5;AVL9	1.07	19.57	0.77	2.21e-53	Cognitive ability;
CESC	cis	rs7772486	0.790	rs2253880	chr6:146200774	T/C	cg05347473	chr6:146136440	FBXO30	0.55	7.26	0.41	4.4e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs13191362	0.872	rs13196631	chr6:163001588	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.5	5.17	0.3	4.64e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs7267979	1.000	rs7343481	chr20:25300113	C/T	cg08601574	chr20:25228251	PYGB	-0.39	-5.61	-0.33	5.09e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs963731	0.649	rs2278914	chr2:39218552	G/A	cg04010122	chr2:39346883	SOS1	-0.76	-5.57	-0.32	6.3e-8	Corticobasal degeneration;
CESC	cis	rs4568518	0.619	rs13238312	chr7:18008444	A/G	cg03009463	chr7:17980271	SNX13	0.44	5.83	0.34	1.58e-8	Measles;
CESC	cis	rs1215050	0.740	rs700739	chr4:99022546	A/G	cg05340658	chr4:99064831	C4orf37	-0.57	-7.6	-0.42	5.27e-13	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs10484885	0.824	rs72919981	chr6:90528977	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.75	-7.12	-0.4	1.03e-11	QRS interval (sulfonylurea treatment interaction);
CESC	cis	rs7666738	0.830	rs10021044	chr4:99002488	A/T	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.62e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2486288	0.656	rs7162022	chr15:45565253	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.55	-6.5	-0.37	4.05e-10	Glomerular filtration rate;
CESC	cis	rs838147	0.537	rs503279	chr19:49209010	C/T	cg21064579	chr19:49206444	FUT2	-0.43	-6.08	-0.35	4.15e-9	Dietary macronutrient intake;
CESC	cis	rs7618915	0.524	rs2028216	chr3:52680823	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.47	6.71	0.38	1.19e-10	Bipolar disorder;
CESC	cis	rs9733	0.596	rs1415148	chr1:150705755	G/A	cg09365446	chr1:150670422	GOLPH3L	0.42	5.84	0.34	1.55e-8	Tonsillectomy;
CESC	trans	rs2658782	0.826	rs1975820	chr11:93081815	G/A	cg03479527	chr8:145637966	SLC39A4	-0.42	-6.08	-0.35	4.2e-9	Pulmonary function decline;
CESC	cis	rs597539	0.617	rs672853	chr11:68636362	G/A	cg21963583	chr11:68658836	MRPL21	0.42	5.7	0.33	3.21e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs28829049	0.597	rs2066002	chr1:19504300	G/A	cg13387374	chr1:19411106	UBR4	0.43	5.41	0.32	1.43e-7	QRS duration in Tripanosoma cruzi seropositivity;
CESC	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg03188948	chr7:1209495	NA	0.7	6.68	0.38	1.4e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs3857067	0.806	rs2171379	chr4:95100243	A/T	cg11021082	chr4:95130006	SMARCAD1	-0.63	-9.49	-0.5	1.44e-18	QT interval;
CESC	trans	rs61931739	0.534	rs4931770	chr12:34044479	G/T	cg26384229	chr12:38710491	ALG10B	0.6	8.36	0.46	3.68e-15	Morning vs. evening chronotype;
CESC	cis	rs11098499	0.863	rs7669520	chr4:120515278	T/C	cg09307838	chr4:120376055	NA	0.91	12.63	0.61	6.02e-29	Corneal astigmatism;
CESC	cis	rs6696846	0.715	rs12139373	chr1:205054879	A/C	cg00857998	chr1:205179979	DSTYK	0.55	7.15	0.4	8.25e-12	Red blood cell count;
CESC	cis	rs6754311	0.628	rs309811	chr2:136625602	A/G	cg07169764	chr2:136633963	MCM6	-0.69	-8.54	-0.46	1.03e-15	Mosquito bite size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15965583	chr1:150601949	ENSA	0.51	6.25	0.36	1.59e-9	Gut microbiome composition (summer);
CESC	cis	rs6460942	1.000	rs6460938	chr7:12406808	T/G	cg02935154	chr7:12443704	VWDE	-0.56	-5.82	-0.34	1.71e-8	Coronary artery disease;
CESC	cis	rs1448094	0.512	rs7302741	chr12:86237127	C/T	cg19622623	chr12:86230825	RASSF9	-0.43	-5.28	-0.31	2.72e-7	Major depressive disorder;
CESC	cis	rs1799949	1.000	rs8176202	chr17:41230228	G/A	cg25072359	chr17:41440525	NA	0.47	6.36	0.36	8.75e-10	Menopause (age at onset);
CESC	cis	rs1005277	0.540	rs4934907	chr10:38015230	A/C	cg00409905	chr10:38381863	ZNF37A	-0.5	-6.82	-0.39	6.27e-11	Extrinsic epigenetic age acceleration;
CESC	cis	rs9910055	0.639	rs227583	chr17:42231698	C/G	cg13607699	chr17:42295918	UBTF	0.57	7.42	0.41	1.58e-12	Total body bone mineral density;
CESC	cis	rs2836950	0.840	rs12482317	chr21:40588241	A/G	cg17971929	chr21:40555470	PSMG1	-0.61	-7.53	-0.42	7.78e-13	Menarche (age at onset);
CESC	cis	rs1538970	0.781	rs12049503	chr1:46021556	G/T	cg05343316	chr1:45956843	TESK2	0.85	10.91	0.56	3.9e-23	Platelet count;
CESC	cis	rs6460942	0.659	rs6969309	chr7:12515847	T/C	cg02935154	chr7:12443704	VWDE	-0.54	-5.44	-0.32	1.23e-7	Coronary artery disease;
CESC	trans	rs1814175	0.817	rs1794164	chr11:49899610	T/C	cg03929089	chr4:120376271	NA	-0.93	-15.69	-0.69	1.12e-39	Height;
CESC	cis	rs4780401	0.632	rs7192366	chr16:11835209	C/G	cg01061890	chr16:11836724	TXNDC11	-0.58	-7.81	-0.43	1.3e-13	Rheumatoid arthritis;
CESC	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg06074448	chr4:187884817	NA	0.41	6.1	0.35	3.76e-9	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs875971	1.000	rs7789554	chr7:65946038	A/G	cg10691866	chr7:65817282	TPST1	-0.34	-5.62	-0.33	4.93e-8	Aortic root size;
CESC	cis	rs7843479	0.601	rs878873	chr8:21834581	T/C	cg17168535	chr8:21777572	XPO7	0.74	11.92	0.59	1.67e-26	Mean corpuscular volume;
CESC	cis	rs12497850	0.931	rs9311432	chr3:48850443	T/A	cg07636037	chr3:49044803	WDR6	1.02	18.99	0.76	2.3e-51	Parkinson's disease;
CESC	cis	rs875971	0.522	rs4502988	chr7:65297746	A/G	cg05332525	chr7:65337924	VKORC1L1	0.52	6.41	0.37	6.6e-10	Aortic root size;
CESC	cis	rs6500395	0.735	rs2883641	chr16:48664446	T/C	cg04672837	chr16:48644449	N4BP1	0.44	5.15	0.3	4.97e-7	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs17666538	0.539	rs1703925	chr8:608279	A/G	cg07234876	chr8:600039	NA	0.82	5.79	0.34	1.96e-8	IgG glycosylation;
CESC	cis	rs28647808	0.786	rs28458971	chr9:136255736	C/T	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.85	5.74	0.33	2.59e-8	Blood protein levels;
CESC	cis	rs4665809	0.590	rs13016807	chr2:26496186	G/C	cg27170947	chr2:26402098	FAM59B	0.81	8.91	0.48	8.12e-17	Gut microbiome composition (summer);
CESC	cis	rs4568518	0.616	rs11766489	chr7:18003670	T/C	cg03009463	chr7:17980271	SNX13	0.43	5.72	0.33	2.91e-8	Measles;
CESC	cis	rs854765	0.693	rs8079418	chr17:17924060	C/T	cg09796270	chr17:17721594	SREBF1	0.36	5.16	0.3	4.91e-7	Total body bone mineral density;
CESC	cis	rs2070488	0.761	rs6807940	chr3:38460062	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.7	9.91	0.52	6.66e-20	Electrocardiographic conduction measures;
CESC	cis	rs7618501	0.633	rs9853222	chr3:50022926	T/C	cg24308560	chr3:49941425	MST1R	-0.63	-9.02	-0.48	3.81e-17	Intelligence (multi-trait analysis);
CESC	cis	rs5769765	0.955	rs8138687	chr22:50291869	A/G	cg26441486	chr22:50317300	CRELD2	0.39	5.37	0.31	1.76e-7	Schizophrenia;
CESC	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg18110333	chr6:292329	DUSP22	-0.77	-10.46	-0.54	1.16e-21	Menopause (age at onset);
CESC	cis	rs8133932	0.621	rs1124309	chr21:47328767	C/A	cg14185626	chr21:47401492	COL6A1	0.46	5.11	0.3	6.13e-7	Schizophrenia;
CESC	cis	rs4144743	1.000	rs10438781	chr17:45323819	A/G	cg18085866	chr17:45331354	ITGB3	-0.66	-7.64	-0.43	3.87e-13	Body mass index;
CESC	trans	rs1814175	0.715	rs7479622	chr11:49673340	T/G	cg03929089	chr4:120376271	NA	-0.88	-13.46	-0.64	8.34e-32	Height;
CESC	cis	rs12188164	1.000	rs34847072	chr5:437862	G/C	cg26850624	chr5:429559	AHRR	-0.48	-6.63	-0.38	1.85e-10	Cystic fibrosis severity;
CESC	cis	rs9311474	0.508	rs3796353	chr3:52593230	C/T	cg07507251	chr3:52567010	NT5DC2	0.33	5.66	0.33	3.98e-8	Electroencephalogram traits;
CESC	trans	rs208520	0.690	rs851458	chr6:66813279	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.97	-13.03	-0.62	2.5e-30	Exhaled nitric oxide output;
CESC	cis	rs5753618	0.539	rs5753596	chr22:31787472	C/T	cg02404636	chr22:31891804	SFI1	-0.43	-6.25	-0.36	1.63e-9	Colorectal cancer;
CESC	cis	rs2109514	0.765	rs11769417	chr7:116103778	A/G	cg12739419	chr7:116140593	CAV2	-0.32	-5.71	-0.33	3.06e-8	Prevalent atrial fibrillation;
CESC	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg23034840	chr1:205782522	SLC41A1	0.77	10.75	0.55	1.3e-22	Monocyte percentage of white cells;
CESC	cis	rs8114671	0.562	rs6088653	chr20:33520321	T/C	cg07148914	chr20:33460835	GGT7	0.45	5.9	0.34	1.09e-8	Height;
CESC	cis	rs17039065	0.920	rs57121318	chr4:109456755	T/C	cg16022748	chr4:109541635	LOC285456;RPL34	0.63	5.78	0.33	2.08e-8	Gut microbiome composition (summer);
CESC	cis	rs2273669	0.667	rs12215381	chr6:109363217	C/T	cg05315195	chr6:109294784	ARMC2	-0.67	-6.33	-0.36	1.02e-9	Prostate cancer;
CESC	cis	rs4899554	0.640	rs1569328	chr14:75741751	A/G	cg18117039	chr14:75741733	NA	-0.43	-5.8	-0.34	1.85e-8	Inflammatory bowel disease;
CESC	cis	rs9300255	0.722	rs10773008	chr12:123800820	A/G	cg19016782	chr12:123741754	C12orf65	-0.43	-6.0	-0.35	6.54e-9	Neutrophil percentage of white cells;
CESC	cis	rs947211	0.948	rs12565968	chr1:205755046	A/G	cg24503407	chr1:205819492	PM20D1	-0.4	-5.32	-0.31	2.19e-7	Parkinson's disease;
CESC	cis	rs853679	0.517	rs34716816	chr6:28046169	C/A	cg20151795	chr6:28129481	ZNF389	0.44	5.59	0.33	5.5e-8	Depression;
CESC	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg12419862	chr22:24373484	LOC391322	-0.74	-10.49	-0.54	9.52e-22	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs9522267	0.535	rs9522299	chr13:112236013	C/A	cg10483660	chr13:112241077	NA	-0.33	-5.78	-0.33	2.14e-8	Hepatitis;
CESC	cis	rs6076065	0.748	rs6048781	chr20:23380027	T/C	cg11657817	chr20:23433608	CST11	0.4	6.1	0.35	3.7e-9	Facial morphology (factor 15, philtrum width);
CESC	cis	rs9911578	1.000	rs7342903	chr17:56914588	C/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.26	0.31	3.04e-7	Intelligence (multi-trait analysis);
CESC	cis	rs6860806	0.507	rs270608	chr5:131648406	C/T	cg04518342	chr5:131593106	PDLIM4	0.36	5.21	0.31	3.73e-7	Breast cancer;
CESC	cis	rs7586879	0.639	rs7567997	chr2:25096952	A/G	cg01884057	chr2:25150051	NA	0.38	7.48	0.42	1.12e-12	Body mass index;
CESC	cis	rs17125944	0.505	rs10483617	chr14:53202605	A/G	cg00686598	chr14:53173677	PSMC6	-1.14	-9.14	-0.49	1.66e-17	Alzheimer's disease (late onset);
CESC	cis	rs10504229	0.636	rs72649123	chr8:58045789	A/T	cg24829409	chr8:58192753	C8orf71	-0.51	-6.11	-0.35	3.63e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs1267303	0.642	rs11588450	chr1:47000996	C/T	cg25110126	chr1:46999211	NA	-0.77	-9.58	-0.51	7.52e-19	Monobrow;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04792727	chr1:231664260	TSNAX-DISC1;TSNAX	-0.56	-6.7	-0.38	1.25e-10	Gut microbiome composition (summer);
CESC	cis	rs514406	0.505	rs269290	chr1:53167027	A/T	cg08859206	chr1:53392774	SCP2	-0.6	-8.05	-0.44	2.89e-14	Monocyte count;
CESC	cis	rs67257959	0.739	rs10416982	chr19:17202933	C/A	cg16202187	chr19:17186497	HAUS8;MYO9B	0.43	5.19	0.3	4.26e-7	Selective IgA deficiency;
CESC	cis	rs2243480	1.000	rs57057549	chr7:65405738	A/G	cg25894440	chr7:65020034	NA	-0.64	-5.31	-0.31	2.33e-7	Diabetic kidney disease;
CESC	cis	rs897984	0.542	rs6565217	chr16:31083324	C/T	cg00531865	chr16:30841666	NA	-0.38	-5.44	-0.32	1.19e-7	Dementia with Lewy bodies;
CESC	cis	rs34638657	0.828	rs7194734	chr16:82199980	C/T	cg09439754	chr16:82129088	HSD17B2	-0.36	-5.38	-0.31	1.63e-7	Lung adenocarcinoma;
CESC	cis	rs7656342	0.636	rs10012880	chr4:9835480	T/C	cg11266682	chr4:10021025	SLC2A9	-0.34	-5.17	-0.3	4.59e-7	Gut microbiota (bacterial taxa);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg18163118	chr11:67250585	AIP	-0.45	-6.08	-0.35	4.26e-9	Fibrinogen levels;
CESC	cis	rs2404602	0.692	rs4886829	chr15:77091182	G/T	cg22467129	chr15:76604101	ETFA	-0.34	-5.17	-0.3	4.62e-7	Blood metabolite levels;
CESC	cis	rs71636778	0.543	rs12749822	chr1:27221963	T/C	cg12203394	chr1:27248618	NUDC	0.68	5.58	0.32	6.01e-8	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
CESC	cis	rs2296225	0.722	rs74840517	chr1:21049848	G/A	cg24673385	chr1:21051448	SH2D5	0.34	5.51	0.32	8.61e-8	Eosinophilic esophagitis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00162541	chr19:16607016	C19orf44;CALR3	-0.54	-6.07	-0.35	4.38e-9	Gut microbiome composition (summer);
CESC	cis	rs769267	0.930	rs9917108	chr19:19572785	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	7.4	0.41	1.78e-12	Tonsillectomy;
CESC	cis	rs1620921	0.524	rs12214168	chr6:161195801	C/T	cg01280913	chr6:161186852	NA	-0.4	-6.12	-0.35	3.42e-9	Lipoprotein (a) - cholesterol levels;
CESC	cis	rs9733	0.570	rs951281	chr1:150691122	A/C	cg04414720	chr1:150670196	GOLPH3L	0.62	8.86	0.48	1.21e-16	Tonsillectomy;
CESC	cis	rs2204008	0.713	rs12366709	chr12:38210179	G/A	cg13010199	chr12:38710504	ALG10B	0.54	6.69	0.38	1.28e-10	Bladder cancer;
CESC	cis	rs6088590	0.561	rs6059932	chr20:33175466	C/T	cg06115741	chr20:33292138	TP53INP2	0.51	6.53	0.37	3.27e-10	Coronary artery disease;
CESC	cis	rs1348850	0.914	rs4893957	chr2:178380409	A/G	cg23306229	chr2:178417860	TTC30B	0.65	8.07	0.44	2.52e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs9311474	0.581	rs13621	chr3:52558133	T/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.39	7.13	0.4	9.81e-12	Electroencephalogram traits;
CESC	cis	rs10504229	0.516	rs4361758	chr8:57990401	C/T	cg22535103	chr8:58192502	C8orf71	-0.48	-5.89	-0.34	1.16e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs1215050	0.740	rs2555390	chr4:98999112	A/G	cg05340658	chr4:99064831	C4orf37	-0.57	-7.62	-0.42	4.43e-13	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs6500602	0.702	rs11076834	chr16:4549583	C/G	cg08645402	chr16:4508243	NA	0.51	8.22	0.45	9.18e-15	Schizophrenia;
CESC	cis	rs35110281	1.000	rs35110281	chr21:45068947	T/A	cg04455712	chr21:45112962	RRP1B	0.39	5.68	0.33	3.58e-8	Mean corpuscular volume;
CESC	cis	rs9549367	0.789	rs71446682	chr13:113894908	A/G	cg18105134	chr13:113819100	PROZ	-0.66	-7.97	-0.44	4.85e-14	Platelet distribution width;
CESC	cis	rs11958404	1.000	rs56175756	chr5:157391080	T/C	cg05962755	chr5:157440814	NA	0.57	6.14	0.35	2.98e-9	IgG glycosylation;
CESC	cis	rs2635047	0.601	rs2684842	chr18:44725289	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.43	-5.93	-0.34	9.19e-9	Educational attainment;
CESC	cis	rs9300255	0.602	rs1790131	chr12:123701010	G/T	cg05973401	chr12:123451056	ABCB9	0.49	5.63	0.33	4.65e-8	Neutrophil percentage of white cells;
CESC	cis	rs7089973	0.604	rs35319791	chr10:116602296	C/A	cg23260525	chr10:116636907	FAM160B1	0.4	7.2	0.4	6.31e-12	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs7582720	1.000	rs72936852	chr2:203775475	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.38	0.41	1.99e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs736408	0.522	rs11130310	chr3:52674667	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.36	6.6	0.38	2.21e-10	Bipolar disorder;
CESC	cis	rs9611565	0.838	rs4239894	chr22:41745548	C/G	cg06481639	chr22:41940642	POLR3H	-0.68	-7.28	-0.41	3.84e-12	Vitiligo;
CESC	cis	rs3747547	0.642	rs112575018	chr9:38080747	G/A	cg13774184	chr9:37916125	SHB	-0.58	-5.38	-0.31	1.65e-7	Metabolite levels (Dihydroxy docosatrienoic acid);
CESC	cis	rs6463523	0.933	rs4724821	chr7:762544	C/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.98	14.98	0.68	3.54e-37	Subjective well-being;
CESC	cis	rs7429990	0.932	rs4293721	chr3:48045137	C/A	cg11946769	chr3:48343235	NME6	-0.44	-5.38	-0.31	1.63e-7	Educational attainment (years of education);
CESC	cis	rs7193541	0.646	rs7188880	chr16:74664810	A/T	cg01733217	chr16:74700730	RFWD3	1.06	20.86	0.79	7.73e-58	Multiple myeloma;
CESC	cis	rs11098499	0.954	rs11729521	chr4:120416788	T/C	cg24375607	chr4:120327624	NA	0.46	5.66	0.33	3.97e-8	Corneal astigmatism;
CESC	cis	rs2380220	0.574	rs9400526	chr6:95998441	T/C	cg04719120	chr6:96025338	MANEA	0.47	5.39	0.31	1.6e-7	Behavioural disinhibition (generation interaction);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg11664379	chr5:7289931	NA	-0.44	-6.83	-0.39	5.8e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs2303745	0.589	rs1965717	chr19:17398559	C/T	cg04248312	chr19:17393744	ANKLE1	-0.96	-15.14	-0.68	9.45e-38	Systemic lupus erythematosus;
CESC	cis	rs2075371	1.000	rs1862047	chr7:133978078	G/C	cg00033643	chr7:134001901	SLC35B4	0.42	5.47	0.32	1.04e-7	Mean platelet volume;
CESC	cis	rs561341	1.000	rs7210970	chr17:30262169	G/A	cg19193384	chr17:30244184	NA	-0.48	-5.52	-0.32	8.2e-8	Hip circumference adjusted for BMI;
CESC	cis	rs780096	0.505	rs12475426	chr2:27599132	G/A	cg17158414	chr2:27665306	KRTCAP3	-0.31	-5.86	-0.34	1.38e-8	Total body bone mineral density;
CESC	cis	rs4253772	0.530	rs11090865	chr22:46731689	G/T	cg24881330	chr22:46731750	TRMU	0.87	7.23	0.41	5.11e-12	LDL cholesterol;Cholesterol, total;
CESC	cis	rs703842	0.739	rs701008	chr12:58117645	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.46	5.78	0.33	2.12e-8	Multiple sclerosis;
CESC	cis	rs1385374	1.000	rs12311303	chr12:129301592	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.6	5.22	0.31	3.61e-7	Systemic lupus erythematosus;
CESC	cis	rs6582630	0.599	rs4882313	chr12:38454011	G/A	cg26384229	chr12:38710491	ALG10B	-0.44	-5.96	-0.34	7.9e-9	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs7631605	0.967	rs4678950	chr3:37253682	C/T	cg22985146	chr3:37219077	LRRFIP2	-0.33	-5.11	-0.3	6.25e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs8058578	0.943	rs7197770	chr16:30715908	T/C	cg02466173	chr16:30829666	NA	-0.4	-6.36	-0.36	8.58e-10	Multiple myeloma;
CESC	cis	rs3087591	1.000	rs12939853	chr17:29455021	G/A	cg24425628	chr17:29625626	OMG;NF1	0.42	5.17	0.3	4.57e-7	Hip circumference;
CESC	cis	rs10504229	0.645	rs6995814	chr8:58114159	C/T	cg21724239	chr8:58056113	NA	0.58	5.93	0.34	9.45e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs6815814	0.950	rs11725779	chr4:38811668	G/A	cg02016764	chr4:38805732	TLR1	-0.62	-7.43	-0.42	1.5e-12	Breast cancer;
CESC	cis	rs4148883	0.689	rs2851275	chr4:100024883	A/G	cg12011299	chr4:100065546	ADH4	0.65	9.73	0.51	2.53e-19	Alcohol dependence;
CESC	cis	rs2859741	0.967	rs507460	chr1:37493206	C/G	cg09363841	chr1:37513479	NA	0.65	10.56	0.54	5.51e-22	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
CESC	cis	rs7247513	0.930	rs35275129	chr19:12716493	G/A	cg01871581	chr19:12707946	ZNF490	-0.89	-15.19	-0.68	6.69e-38	Bipolar disorder;
CESC	cis	rs9322193	0.884	rs9383865	chr6:150173179	A/G	cg13206674	chr6:150067644	NUP43	0.38	5.12	0.3	5.81e-7	Lung cancer;
CESC	cis	rs782590	0.805	rs782578	chr2:55915904	A/C	cg18811423	chr2:55921094	PNPT1	0.8	12.89	0.62	7.51e-30	Metabolic syndrome;
CESC	cis	rs9322193	0.962	rs9689447	chr6:150110486	T/A	cg07701084	chr6:150067640	NUP43	0.42	5.78	0.33	2.07e-8	Lung cancer;
CESC	cis	rs2979489	0.891	rs4285443	chr8:30327317	A/G	cg26383811	chr8:30366931	RBPMS	-0.81	-10.05	-0.53	2.37e-20	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CESC	cis	rs6570726	0.846	rs446031	chr6:145885592	C/T	cg23711669	chr6:146136114	FBXO30	0.82	12.1	0.6	3.84e-27	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs3733585	0.674	rs7375643	chr4:9955239	A/G	cg00071950	chr4:10020882	SLC2A9	-0.78	-14.48	-0.66	2.06e-35	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs875971	0.862	rs6959268	chr7:65812966	G/A	cg18252515	chr7:66147081	NA	0.39	5.08	0.3	7.05e-7	Aortic root size;
CESC	cis	rs6598955	0.670	rs4659366	chr1:26542572	G/A	cg19743891	chr1:26644573	UBXN11;CD52	-0.26	-5.12	-0.3	5.98e-7	Obesity-related traits;
CESC	cis	rs4665809	1.000	rs4665299	chr2:26256840	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.83	-9.22	-0.49	9.93e-18	Gut microbiome composition (summer);
CESC	cis	rs9467773	0.549	rs9461273	chr6:26584526	A/G	cg11502198	chr6:26597334	ABT1	-0.4	-5.66	-0.33	3.88e-8	Intelligence (multi-trait analysis);
CESC	cis	rs1008375	0.932	rs4235390	chr4:17696378	G/T	cg15017067	chr4:17643749	FAM184B	0.37	5.21	0.3	3.74e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg06873352	chr17:61820015	STRADA	-0.74	-13.42	-0.64	1.08e-31	Prudent dietary pattern;
CESC	cis	rs9733	0.596	rs7529998	chr1:150662531	C/T	cg17724175	chr1:150552817	MCL1	0.44	7.23	0.41	5.25e-12	Tonsillectomy;
CESC	cis	rs1348850	0.567	rs2222711	chr2:178534110	G/T	cg22681709	chr2:178499509	PDE11A	-0.5	-7.37	-0.41	2.21e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs514406	0.861	rs10888755	chr1:53240829	A/G	cg08859206	chr1:53392774	SCP2	0.51	6.88	0.39	4.34e-11	Monocyte count;
CESC	cis	rs1552244	0.882	rs67895180	chr3:10026079	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.76	-9.64	-0.51	4.86e-19	Alzheimer's disease;
CESC	cis	rs892961	0.965	rs2411111	chr17:75402540	A/T	cg05865280	chr17:75406074	SEPT9	0.59	11.23	0.57	3.53e-24	Airflow obstruction;
CESC	cis	rs801193	0.569	rs4717315	chr7:66178325	C/T	cg18252515	chr7:66147081	NA	-0.48	-6.45	-0.37	5.25e-10	Aortic root size;
CESC	cis	rs6665290	0.835	rs11578479	chr1:227210888	A/T	cg10327440	chr1:227177885	CDC42BPA	-1.16	-24.11	-0.83	8.77e-69	Myeloid white cell count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17098857	chr11:82556674	PRCP	-0.58	-6.8	-0.39	7.05e-11	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17201535	chr8:145140563	GPAA1	-0.57	-6.51	-0.37	3.71e-10	Gut microbiome composition (summer);
CESC	cis	rs4481887	0.741	rs6587462	chr1:248539094	C/T	cg26353448	chr1:248524236	OR2T4	0.36	5.11	0.3	6.32e-7	Common traits (Other);
CESC	cis	rs9911578	0.967	rs11079354	chr17:56594460	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	-0.39	-5.16	-0.3	4.83e-7	Intelligence (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10801419	chr12:120632649	GCN1L1	0.58	6.25	0.36	1.62e-9	Gut microbiome composition (summer);
CESC	cis	rs8002861	0.846	rs12869355	chr13:44478193	A/C	cg14210620	chr13:44453864	C13orf31;CCDC122	0.42	5.41	0.32	1.44e-7	Leprosy;
CESC	cis	rs9611565	0.525	rs9611548	chr22:41704143	G/T	cg06634786	chr22:41940651	POLR3H	-0.49	-5.09	-0.3	6.88e-7	Vitiligo;
CESC	cis	rs4555082	0.874	rs760270	chr14:105737785	A/G	cg27165867	chr14:105738592	BRF1	-0.54	-5.87	-0.34	1.31e-8	Mean platelet volume;Platelet distribution width;
CESC	cis	rs6502050	0.835	rs9901076	chr17:80170020	G/A	cg01763666	chr17:80159506	CCDC57	-0.36	-5.04	-0.3	8.74e-7	Life satisfaction;
CESC	cis	rs1413885	0.549	rs7545720	chr1:65856443	G/T	cg14976592	chr1:65886160	LEPROT;LEPR	0.48	6.41	0.37	6.8e-10	Anticoagulant levels;
CESC	cis	rs7762018	0.943	rs7772889	chr6:170142458	T/C	cg13891659	chr6:170190454	C6orf122;C6orf208	0.67	6.66	0.38	1.61e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs34779708	0.897	rs7897827	chr10:35386237	C/T	cg04310649	chr10:35416472	CREM	-0.53	-6.52	-0.37	3.46e-10	Inflammatory bowel disease;Crohn's disease;
CESC	trans	rs10489896	0.541	rs11578044	chr1:234580945	G/T	cg10395685	chr11:86085715	CCDC81	-0.43	-6.38	-0.36	7.97e-10	Cognitive test performance;
CESC	trans	rs4906172	0.773	rs1190612	chr14:102520888	A/G	cg17920195	chr4:129149383	NA	0.31	6.01	0.35	5.99e-9	Menopause (age at onset);
CESC	cis	rs67311347	0.524	rs11129869	chr3:40259738	G/A	cg09455208	chr3:40491958	NA	0.35	5.5	0.32	9.03e-8	Renal cell carcinoma;
CESC	cis	rs736408	0.570	rs11130327	chr3:52793239	A/G	cg07507251	chr3:52567010	NT5DC2	0.42	7.2	0.4	6.24e-12	Bipolar disorder;
CESC	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.58	7.43	0.42	1.45e-12	Prudent dietary pattern;
CESC	cis	rs7216064	0.765	rs6504550	chr17:65894542	A/G	cg07042672	chr17:66097459	LOC651250	-0.56	-7.54	-0.42	7.47e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs3096299	0.728	rs1011749	chr16:89510869	G/C	cg02034447	chr16:89574710	SPG7	0.47	6.06	0.35	4.7e-9	Multiple myeloma (IgH translocation);
CESC	cis	rs9611565	0.506	rs2024566	chr22:41697338	A/G	cg06481639	chr22:41940642	POLR3H	-0.52	-5.74	-0.33	2.57e-8	Vitiligo;
CESC	cis	rs4253772	0.550	rs6007819	chr22:46704916	C/G	cg18190219	chr22:46762943	CELSR1	-0.59	-6.7	-0.38	1.23e-10	LDL cholesterol;Cholesterol, total;
CESC	cis	rs7927771	0.524	rs7929014	chr11:47776283	C/T	cg20307385	chr11:47447363	PSMC3	0.61	8.59	0.47	7.41e-16	Subjective well-being;
CESC	cis	rs9487051	0.872	rs9372211	chr6:109609648	C/T	cg01475377	chr6:109611718	NA	-0.51	-8.36	-0.46	3.66e-15	Reticulocyte fraction of red cells;
CESC	trans	rs28549925	0.590	rs9690302	chr7:16986964	C/T	cg12639933	chr12:57626296	SHMT2	0.95	6.1	0.35	3.83e-9	Congenital heart disease (maternal effect);Conotruncal heart defects (maternal effects);
CESC	cis	rs9549367	0.673	rs3024735	chr13:113819513	G/A	cg18105134	chr13:113819100	PROZ	-0.65	-7.7	-0.43	2.77e-13	Platelet distribution width;
CESC	cis	rs5758659	0.714	rs5751216	chr22:42508937	G/T	cg00645731	chr22:42541494	CYP2D7P1	0.31	5.39	0.31	1.55e-7	Cognitive function;
CESC	cis	rs798554	0.704	rs798531	chr7:2770067	G/C	cg09658497	chr7:2847517	GNA12	-0.36	-5.41	-0.32	1.38e-7	Height;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg09799789	chr1:245836746	KIF26B	-0.51	-6.9	-0.39	3.91e-11	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs17711722	0.701	rs55773927	chr7:65337902	T/C	cg11764359	chr7:65958608	NA	0.66	8.54	0.46	1.08e-15	Calcium levels;
CESC	cis	rs9611565	0.921	rs4822021	chr22:41726053	G/A	cg17376030	chr22:41985996	PMM1	0.5	5.46	0.32	1.1e-7	Vitiligo;
CESC	cis	rs3091242	0.933	rs10903129	chr1:25768937	A/G	cg27572855	chr1:25598939	RHD	0.43	7.22	0.41	5.42e-12	Erythrocyte sedimentation rate;
CESC	cis	rs4253772	0.550	rs6008615	chr22:46707928	G/A	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.66	6.3	0.36	1.26e-9	LDL cholesterol;Cholesterol, total;
CESC	cis	rs801193	0.569	rs10950050	chr7:66239588	A/C	cg11764359	chr7:65958608	NA	0.63	8.98	0.48	5.3e-17	Aortic root size;
CESC	cis	rs2635047	0.811	rs12956009	chr18:44768024	T/C	cg19077165	chr18:44547161	KATNAL2	-0.39	-5.11	-0.3	6.12e-7	Educational attainment;
CESC	cis	rs6120849	0.663	rs6119548	chr20:33552612	A/G	cg06115741	chr20:33292138	TP53INP2	0.53	5.04	0.3	8.81e-7	Protein C levels;
CESC	cis	rs3749237	0.595	rs1464566	chr3:49459376	T/C	cg02487422	chr3:49467188	NICN1	0.57	8.33	0.46	4.42e-15	Resting heart rate;
CESC	cis	rs2882667	0.858	rs10900856	chr5:138417746	C/T	cg04439458	chr5:138467593	SIL1	0.4	6.32	0.36	1.08e-9	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs769267	1.000	rs2301669	chr19:19453560	C/A	cg17414380	chr19:19431394	KIAA0892;SF4	-0.49	-6.06	-0.35	4.66e-9	Tonsillectomy;
CESC	trans	rs4942242	0.640	rs9533571	chr13:44230136	C/T	cg19169023	chr15:41853346	TYRO3	-0.6	-7.8	-0.43	1.41e-13	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs10883723	0.773	rs11191313	chr10:104278618	C/T	ch.10.2196322F	chr10:104248062	ACTR1A	0.49	5.38	0.31	1.62e-7	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs6831352	0.918	rs29001211	chr4:100051941	C/T	cg12011299	chr4:100065546	ADH4	-0.59	-6.52	-0.37	3.62e-10	Alcohol dependence;
CESC	cis	rs12541635	0.677	rs62527405	chr8:107058109	G/C	cg10147462	chr8:107024639	NA	0.43	6.41	0.37	6.55e-10	Age of smoking initiation;
CESC	cis	rs854765	0.647	rs7211714	chr17:17986955	A/G	cg04398451	chr17:18023971	MYO15A	-0.76	-11.15	-0.57	6.33e-24	Total body bone mineral density;
CESC	cis	rs365132	0.905	rs10068703	chr5:176377069	T/A	cg16309518	chr5:176445507	NA	-0.37	-5.36	-0.31	1.83e-7	Menarche and menopause (age at onset);Menopause (age at onset);
CESC	cis	rs875971	0.545	rs1638724	chr7:66040481	A/G	cg18876405	chr7:65276391	NA	-0.5	-5.84	-0.34	1.55e-8	Aortic root size;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg06493554	chr7:134001556	SLC35B4	-0.51	-6.33	-0.36	1.04e-9	Ulcerative colitis;
CESC	cis	rs66561647	0.895	rs9649959	chr8:128972721	C/T	cg05480350	chr8:128972681	MIR1205;PVT1	-0.57	-8.39	-0.46	2.88e-15	Hemoglobin concentration;
CESC	cis	rs1062177	1.000	rs12654573	chr5:151207473	T/G	cg12924095	chr5:151150029	G3BP1	0.43	5.61	0.33	5.12e-8	Preschool internalizing problems;
CESC	cis	rs3820068	0.603	rs998032	chr1:15989918	T/C	cg13390004	chr1:15929781	NA	0.34	5.51	0.32	8.39e-8	Systolic blood pressure;
CESC	cis	rs35306767	0.903	rs11253504	chr10:956046	A/G	cg25019033	chr10:957182	NA	-0.6	-6.42	-0.37	6.2e-10	Eosinophil percentage of granulocytes;
CESC	cis	rs10504229	0.679	rs7839948	chr8:58130607	A/G	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs6460942	0.597	rs12699381	chr7:12527026	G/A	cg20607287	chr7:12443886	VWDE	-0.71	-7.7	-0.43	2.69e-13	Coronary artery disease;
CESC	cis	rs7666738	0.830	rs28818180	chr4:98953625	A/G	cg03676636	chr4:99064102	C4orf37	0.33	5.11	0.3	6.05e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs61776719	0.520	rs17465651	chr1:38418496	C/T	cg04673462	chr1:38461896	NA	0.4	6.09	0.35	3.99e-9	Coronary artery disease;
CESC	cis	rs1577917	0.654	rs9450284	chr6:86199329	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.47	6.79	0.38	7.37e-11	Response to antipsychotic treatment;
CESC	cis	rs7618915	0.571	rs1961958	chr3:52585990	A/G	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.36	0.36	9.03e-10	Bipolar disorder;
CESC	cis	rs4243830	0.850	rs2063806	chr1:6610382	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.85	-8.42	-0.46	2.37e-15	Body mass index;
CESC	cis	rs6088580	0.524	rs2378251	chr20:33276750	C/T	cg07148914	chr20:33460835	GGT7	-0.41	-5.26	-0.31	2.96e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs2836974	0.533	rs4817999	chr21:40554355	C/A	cg11890956	chr21:40555474	PSMG1	-0.98	-16.55	-0.71	9.7e-43	Cognitive function;
CESC	cis	rs5750830	0.649	rs4821893	chr22:39797779	G/A	cg02038168	chr22:39784481	NA	-0.62	-7.79	-0.43	1.56e-13	Intelligence (multi-trait analysis);
CESC	cis	rs11969893	0.655	rs67724651	chr6:101417004	T/G	cg12253828	chr6:101329408	ASCC3	0.92	6.04	0.35	5.3e-9	Economic and political preferences (immigration/crime);
CESC	cis	rs7713065	0.765	rs11741543	chr5:131771315	G/T	cg10809880	chr5:131517096	NA	-0.46	-5.2	-0.3	3.92e-7	Lung function (FEV1/FVC);
CESC	cis	rs3793683	0.597	rs12783367	chr10:134587334	T/C	cg27286337	chr10:134555280	INPP5A	0.7	8.14	0.45	1.6e-14	Migraine;
CESC	cis	rs9300255	0.602	rs1716167	chr12:123651162	C/T	cg19016782	chr12:123741754	C12orf65	0.41	5.84	0.34	1.53e-8	Neutrophil percentage of white cells;
CESC	cis	rs2836974	0.602	rs8130854	chr21:40707041	G/A	cg11890956	chr21:40555474	PSMG1	-0.94	-15.31	-0.69	2.48e-38	Cognitive function;
CESC	cis	rs1008375	1.000	rs4698635	chr4:17630242	C/A	cg04450456	chr4:17643702	FAM184B	0.4	5.78	0.33	2.13e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs2836974	0.897	rs13339986	chr21:40605982	T/C	cg11890956	chr21:40555474	PSMG1	1.14	18.45	0.75	1.9e-49	Cognitive function;
CESC	cis	rs2404602	0.647	rs4886840	chr15:77179002	A/G	cg23625390	chr15:77176239	SCAPER	-0.45	-6.25	-0.36	1.68e-9	Blood metabolite levels;
CESC	cis	rs4925325	0.956	rs1776263	chr20:60515820	A/G	cg23262073	chr20:60523788	NA	-0.54	-7.45	-0.42	1.35e-12	Obesity-related traits;
CESC	cis	rs2439831	0.867	rs12323999	chr15:43683115	T/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.86	13.11	0.63	1.3e-30	Lung cancer in ever smokers;
CESC	cis	rs897984	0.645	rs9938550	chr16:30999142	A/G	cg02466173	chr16:30829666	NA	0.5	8.44	0.46	2.11e-15	Dementia with Lewy bodies;
CESC	cis	rs10752881	1.000	rs10797808	chr1:182979623	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.83	13.29	0.63	3.24e-31	Colorectal cancer;
CESC	cis	rs62283056	0.512	rs4568307	chr4:6284965	A/G	cg25554036	chr4:6271136	WFS1	0.52	7.21	0.41	5.76e-12	Cisplatin-induced ototoxicity;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07116015	chr17:27046591	RAB34;SNORD42B;RPL23A	0.63	7.03	0.4	1.8e-11	Gut microbiome composition (summer);
CESC	cis	rs8072100	0.840	rs9893901	chr17:45506682	T/G	cg08085267	chr17:45401833	C17orf57	-0.53	-7.16	-0.4	7.96e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs13191362	1.000	rs13200329	chr6:163004418	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.82	8.8	0.48	1.79e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs6740322	0.748	rs1549723	chr2:43460514	C/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.78	-8.38	-0.46	3.08e-15	Coronary artery disease;
CESC	cis	rs10504229	0.683	rs7460059	chr8:58111561	C/T	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs1005277	0.505	rs10827836	chr10:38215441	A/G	cg25427524	chr10:38739819	LOC399744	0.71	10.67	0.55	2.33e-22	Extrinsic epigenetic age acceleration;
CESC	trans	rs11098499	0.754	rs12506610	chr4:120241659	T/C	cg25214090	chr10:38739885	LOC399744	0.61	8.47	0.46	1.73e-15	Corneal astigmatism;
CESC	cis	rs1670533	1.000	rs11247971	chr4:1053580	A/G	cg04106633	chr4:1044584	NA	0.41	5.2	0.3	3.94e-7	Recombination rate (females);
CESC	cis	rs1799949	1.000	rs1799966	chr17:41223094	T/C	cg05368731	chr17:41323189	NBR1	0.8	11.13	0.56	7.38e-24	Menopause (age at onset);
CESC	cis	rs6121246	0.529	rs6060118	chr20:30171209	T/C	cg13852791	chr20:30311386	BCL2L1	0.7	7.17	0.4	7.61e-12	Mean corpuscular hemoglobin;
CESC	cis	rs644799	0.710	rs564480	chr11:95561741	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.78	11.15	0.57	6.38e-24	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs71403859	0.502	rs12927456	chr16:71505706	A/G	cg08717414	chr16:71523259	ZNF19	-1.02	-9.58	-0.51	7.51e-19	Post bronchodilator FEV1;
CESC	cis	rs2380220	0.720	rs9374178	chr6:95979974	G/T	cg23517279	chr6:96025343	MANEA	0.53	5.63	0.33	4.68e-8	Behavioural disinhibition (generation interaction);
CESC	cis	rs10870270	1.000	rs10870232	chr10:133738537	T/G	cg26149184	chr10:133730230	NA	0.37	5.06	0.3	7.88e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs13118159	0.641	rs4974598	chr4:1313220	C/T	cg19318889	chr4:1322082	MAEA	0.45	6.04	0.35	5.09e-9	Longevity;
CESC	cis	rs854765	1.000	rs854765	chr17:18012730	T/C	cg09796270	chr17:17721594	SREBF1	-0.38	-5.04	-0.3	8.65e-7	Total body bone mineral density;
CESC	cis	rs2228479	0.867	rs73276534	chr16:89950557	A/G	cg06558623	chr16:89946397	TCF25	0.6	5.98	0.34	7.29e-9	Skin colour saturation;
CESC	cis	rs9910055	0.639	rs227583	chr17:42231698	C/G	cg19774624	chr17:42201019	HDAC5	-0.9	-14.92	-0.68	5.71e-37	Total body bone mineral density;
CESC	cis	rs11579220	1	rs11579220	chr1:205144363	G/T	cg00857998	chr1:205179979	DSTYK	0.56	7.2	0.4	6.3e-12	White blood cell count (basophil);Basophil percentage of white cells;
CESC	cis	rs116095464	0.510	rs55750776	chr5:230467	T/C	cg22857025	chr5:266934	NA	-1.28	-18.8	-0.76	1.06e-50	Breast cancer;
CESC	cis	rs829883	1.000	rs829883	chr12:98879606	G/A	cg25150519	chr12:98850993	NA	0.68	9.06	0.49	2.94e-17	Colorectal adenoma (advanced);
CESC	cis	rs909674	0.818	rs8137426	chr22:39844350	T/G	cg02038168	chr22:39784481	NA	-0.64	-7.42	-0.41	1.63e-12	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs6580649	0.882	rs7133249	chr12:48456823	C/T	cg24011408	chr12:48396354	COL2A1	-0.42	-5.28	-0.31	2.67e-7	Lung cancer;
CESC	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	22.21	0.81	1.93e-62	Prudent dietary pattern;
CESC	cis	rs3733585	0.673	rs7375587	chr4:9954758	A/T	cg00071950	chr4:10020882	SLC2A9	0.72	11.94	0.59	1.37e-26	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs4819052	0.590	rs414743	chr21:46512075	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.58	6.36	0.36	8.66e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs9911578	0.935	rs117819974	chr17:57002324	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.4	5.28	0.31	2.68e-7	Intelligence (multi-trait analysis);
CESC	cis	rs10751667	0.666	rs7124480	chr11:971601	G/A	cg20946044	chr11:1010712	AP2A2	-0.39	-5.33	-0.31	2.09e-7	Alzheimer's disease (late onset);
CESC	cis	rs2295359	0.892	rs72676067	chr1:67658803	G/A	cg17031739	chr1:67600172	NA	0.4	5.25	0.31	3.18e-7	Psoriasis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08822737	chr17:71088851	SLC39A11	0.68	7.69	0.43	2.93e-13	Gut microbiome composition (summer);
CESC	cis	rs17376456	0.877	rs10073039	chr5:93467709	A/G	cg25358565	chr5:93447407	FAM172A	1.15	11.35	0.57	1.34e-24	Diabetic retinopathy;
CESC	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.65	7.48	0.42	1.09e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs9611565	0.649	rs202666	chr22:41814719	T/C	cg17376030	chr22:41985996	PMM1	-0.62	-6.64	-0.38	1.79e-10	Vitiligo;
CESC	cis	rs67311347	1.000	rs11716675	chr3:40485280	G/T	cg09455208	chr3:40491958	NA	0.44	7.54	0.42	7.53e-13	Renal cell carcinoma;
CESC	cis	rs9300255	0.602	rs1790126	chr12:123683563	C/T	cg00376283	chr12:123451042	ABCB9	0.71	8.92	0.48	7.69e-17	Neutrophil percentage of white cells;
CESC	cis	rs2204008	0.806	rs35534445	chr12:38279093	C/T	cg26384229	chr12:38710491	ALG10B	0.72	10.24	0.53	5.85e-21	Bladder cancer;
CESC	cis	rs6460942	0.818	rs116613169	chr7:12234669	T/C	cg20607287	chr7:12443886	VWDE	-0.59	-5.78	-0.33	2.05e-8	Coronary artery disease;
CESC	cis	rs13108904	0.967	rs12642396	chr4:1293055	C/A	cg22903657	chr4:1355424	KIAA1530	-0.38	-5.13	-0.3	5.55e-7	Obesity-related traits;
CESC	cis	rs6582630	0.555	rs61932279	chr12:38349096	C/T	cg26384229	chr12:38710491	ALG10B	-0.43	-5.57	-0.32	6.1e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs13108904	0.557	rs1250095	chr4:1239312	C/T	cg16405210	chr4:1374714	KIAA1530	0.76	10.61	0.55	3.67e-22	Obesity-related traits;
CESC	cis	rs17818399	0.962	rs2122715	chr2:46845849	A/G	cg06386533	chr2:46925753	SOCS5	0.48	5.53	0.32	7.57e-8	Height;
CESC	cis	rs400736	0.894	rs226242	chr1:8033468	G/A	cg25007680	chr1:8021821	PARK7	0.72	10.25	0.53	5.36e-21	Response to antidepressants and depression;
CESC	cis	rs9611565	0.559	rs4822049	chr22:41993496	G/A	cg03806693	chr22:41940476	POLR3H	-1.16	-13.06	-0.63	1.99e-30	Vitiligo;
CESC	cis	rs3857067	1.000	rs2865332	chr4:95013858	C/G	cg11021082	chr4:95130006	SMARCAD1	-0.5	-7.53	-0.42	8.12e-13	QT interval;
CESC	cis	rs116988415	0.584	rs75851540	chr14:65262909	C/T	cg25083366	chr14:65239357	SPTB	0.73	5.21	0.3	3.74e-7	Daytime sleep phenotypes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04269641	chr17:42422442	GRN	-0.55	-6.19	-0.36	2.26e-9	Gut microbiome composition (summer);
CESC	cis	rs921968	0.591	rs6717107	chr2:219588697	A/G	cg02176678	chr2:219576539	TTLL4	-0.43	-7.59	-0.42	5.51e-13	Mean corpuscular hemoglobin concentration;
CESC	cis	rs7762018	0.607	rs75964125	chr6:170054290	T/A	cg19338460	chr6:170058176	WDR27	-0.74	-6.34	-0.36	9.84e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs9868809	0.772	rs9809222	chr3:48714411	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.6	-5.19	-0.3	4.29e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs10788264	0.544	rs911786	chr10:124017583	C/G	cg09507567	chr10:124027408	NA	0.42	5.81	0.34	1.82e-8	Total body bone mineral density;
CESC	cis	rs17376456	0.877	rs34673483	chr5:93315079	C/A	cg21475434	chr5:93447410	FAM172A	0.75	6.65	0.38	1.67e-10	Diabetic retinopathy;
CESC	cis	rs2836950	0.545	rs2836952	chr21:40616651	G/C	cg17971929	chr21:40555470	PSMG1	-0.52	-6.67	-0.38	1.49e-10	Menarche (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21959036	chr4:129733057	PHF17	0.59	6.74	0.38	1e-10	Gut microbiome composition (summer);
CESC	cis	rs9926296	0.548	rs6500439	chr16:89808275	A/C	cg27121462	chr16:89883253	FANCA	0.8	11.72	0.58	7.88e-26	Vitiligo;
CESC	cis	rs854765	0.583	rs4244602	chr17:17841456	A/G	cg04398451	chr17:18023971	MYO15A	-0.66	-9.22	-0.49	9.48e-18	Total body bone mineral density;
CESC	cis	rs10751667	0.666	rs6597966	chr11:950750	T/C	cg20946044	chr11:1010712	AP2A2	-0.37	-5.08	-0.3	7.09e-7	Alzheimer's disease (late onset);
CESC	cis	rs10242455	0.702	rs41385645	chr7:98974038	A/T	cg25640893	chr7:99214727	ZNF498	0.87	5.77	0.33	2.15e-8	Blood metabolite levels;
CESC	cis	rs7843479	0.582	rs11779655	chr8:21794041	A/G	cg17168535	chr8:21777572	XPO7	-0.74	-12.43	-0.61	2.91e-28	Mean corpuscular volume;
CESC	cis	rs208520	1.000	rs12193164	chr6:66978962	C/T	cg07460842	chr6:66804631	NA	0.88	10.14	0.53	1.22e-20	Exhaled nitric oxide output;
CESC	cis	rs9937943	0.667	rs9938426	chr16:74523739	C/G	cg01733217	chr16:74700730	RFWD3	-0.61	-5.49	-0.32	9.2e-8	Neutrophil percentage of white cells;
CESC	cis	rs807669	0.525	rs2073740	chr22:19196112	A/C	cg02655711	chr22:19163373	SLC25A1	-0.43	-6.49	-0.37	4.16e-10	Metabolite levels;
CESC	cis	rs644799	0.648	rs1255181	chr11:95472148	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.45	6.12	0.35	3.39e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs4704187	0.687	rs1592948	chr5:74504152	G/A	cg03227963	chr5:74354835	NA	0.29	5.27	0.31	2.77e-7	Response to amphetamines;
CESC	cis	rs1005277	0.579	rs1780145	chr10:38537070	A/G	cg00409905	chr10:38381863	ZNF37A	-0.51	-6.77	-0.38	8.46e-11	Extrinsic epigenetic age acceleration;
CESC	cis	rs9733	0.519	rs2184833	chr1:150675483	C/T	cg09365446	chr1:150670422	GOLPH3L	0.41	5.75	0.33	2.5e-8	Tonsillectomy;
CESC	cis	rs9311474	0.659	rs7638808	chr3:52572056	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	0.35	5.18	0.3	4.33e-7	Electroencephalogram traits;
CESC	cis	rs6860806	0.631	rs6863548	chr5:131575920	G/A	cg22638593	chr5:131593259	PDLIM4	0.39	5.1	0.3	6.34e-7	Breast cancer;
CESC	cis	rs10504229	1.000	rs58371676	chr8:58189382	G/A	cg14926445	chr8:58193284	C8orf71	-0.51	-5.52	-0.32	8.28e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs780096	0.526	rs11127013	chr2:27692973	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.33	-6.7	-0.38	1.27e-10	Total body bone mineral density;
CESC	cis	rs2404602	0.684	rs1011084	chr15:77007480	C/G	cg23625390	chr15:77176239	SCAPER	-0.4	-5.2	-0.3	4e-7	Blood metabolite levels;
CESC	trans	rs1814175	0.817	rs10769598	chr11:49669326	C/G	cg03929089	chr4:120376271	NA	-0.93	-15.61	-0.69	2.13e-39	Height;
CESC	cis	rs4253772	0.591	rs6520010	chr22:46721223	G/A	cg10231785	chr22:46692440	CN5H6.4;GTSE1	0.57	5.91	0.34	1.07e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs870825	0.616	rs1401359	chr4:185640216	T/C	cg04058563	chr4:185651563	MLF1IP	0.66	7.21	0.4	5.94e-12	Blood protein levels;
CESC	cis	rs2477686	0.526	rs2477690	chr1:2395563	G/A	cg07700843	chr1:2391317	NA	-0.43	-7.23	-0.41	5.22e-12	Non-obstructive azoospermia;
CESC	cis	rs1395	0.813	rs11685326	chr2:27453679	A/G	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.45	5.93	0.34	9.64e-9	Blood metabolite levels;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg11702503	chr19:6215254	MLLT1	0.51	6.89	0.39	4.04e-11	Fibrinogen levels;
CESC	cis	rs7666738	0.830	rs10012271	chr4:99065154	A/C	cg05340658	chr4:99064831	C4orf37	0.84	13.04	0.63	2.35e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs12477438	0.798	rs1453561	chr2:99613924	C/T	cg08885076	chr2:99613938	TSGA10	-0.38	-5.06	-0.3	7.82e-7	Chronic sinus infection;
CESC	cis	rs35955747	0.869	rs28715	chr22:31730169	C/T	cg02404636	chr22:31891804	SFI1	0.37	5.14	0.3	5.31e-7	Neutrophil count;Sum basophil neutrophil counts;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05918473	chr13:32885580	ZAR1L	-0.51	-6.22	-0.36	1.88e-9	Gut microbiome composition (summer);
CESC	trans	rs4363385	0.626	rs11205192	chr1:153062767	C/T	cg25629905	chr12:26273008	BHLHE41	0.35	6.04	0.35	5.3e-9	Inflammatory skin disease;
CESC	cis	rs5758659	0.714	rs6002607	chr22:42496506	C/T	cg19513890	chr22:42538836	CYP2D7P1	0.38	5.63	0.33	4.62e-8	Cognitive function;
CESC	cis	rs524023	0.914	rs555456	chr11:64418259	T/C	cg07220939	chr11:64358617	SLC22A12	-0.35	-5.32	-0.31	2.23e-7	Urate levels in obese individuals;
CESC	cis	rs7666738	0.830	rs10028692	chr4:98962585	C/T	cg17366294	chr4:99064904	C4orf37	0.6	8.52	0.46	1.2e-15	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17537009	chr12:118814304	SUDS3	0.56	6.52	0.37	3.46e-10	Gut microbiome composition (summer);
CESC	cis	rs7552404	0.731	rs10873808	chr1:76406767	T/C	cg22875332	chr1:76189707	ACADM	0.65	6.44	0.37	5.54e-10	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs7904368	1.000	rs7904368	chr10:16858587	C/T	cg23933602	chr10:16859644	RSU1	0.77	9.41	0.5	2.5e-18	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
CESC	cis	rs6141600	0.540	rs1006296	chr20:34717718	T/C	cg07747181	chr20:34652970	NA	-0.37	-5.18	-0.3	4.5e-7	Height;Hip circumference;
CESC	cis	rs7078219	0.505	rs7893840	chr10:101293341	T/C	cg09788492	chr10:101292477	NKX2-3	0.32	5.99	0.35	6.65e-9	Dental caries;
CESC	cis	rs9595066	0.548	rs9562537	chr13:44755787	G/A	cg04068111	chr13:44716778	NA	-0.46	-5.92	-0.34	1.02e-8	Schizophrenia;
CESC	cis	rs57506017	0.585	rs2356065	chr7:12276885	T/C	cg23422036	chr7:12250390	TMEM106B	0.39	5.21	0.3	3.84e-7	Neuroticism;
CESC	trans	rs12356475	0.710	rs10822686	chr10:67733250	C/T	cg08043571	chr20:48100962	NA	0.5	6.13	0.35	3.18e-9	Psoriatic arthritis;
CESC	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.39	-5.94	-0.34	8.72e-9	Longevity;Endometriosis;
CESC	cis	rs4319547	0.728	rs61954974	chr12:123074169	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.58	-6.75	-0.38	9.5e-11	Body mass index;
CESC	trans	rs116095464	0.558	rs2162870	chr5:228129	G/A	cg00938859	chr5:1591904	SDHAP3	0.61	6.74	0.38	9.82e-11	Breast cancer;
CESC	cis	rs853679	0.517	rs4713143	chr6:28106759	A/C	cg22143856	chr6:28129313	ZNF389	0.52	6.77	0.38	8.31e-11	Depression;
CESC	cis	rs3008870	0.958	rs12131222	chr1:67438535	A/T	cg02640540	chr1:67518911	SLC35D1	-0.51	-5.58	-0.32	5.89e-8	Lymphocyte percentage of white cells;
CESC	cis	rs3096299	0.667	rs2965947	chr16:89518670	T/C	cg08392591	chr16:89556376	ANKRD11	0.58	7.96	0.44	5.01e-14	Multiple myeloma (IgH translocation);
CESC	cis	rs68092024	0.731	rs792840	chr3:99471251	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.42	6.77	0.38	8.49e-11	Cleft lip with or without cleft palate;
CESC	trans	rs28549925	0.590	rs1403802	chr7:16989793	G/C	cg12639933	chr12:57626296	SHMT2	0.95	6.1	0.35	3.83e-9	Congenital heart disease (maternal effect);Conotruncal heart defects (maternal effects);
CESC	cis	rs4523957	0.928	rs8066372	chr17:2180968	A/G	cg16513277	chr17:2031491	SMG6	-0.6	-8.21	-0.45	9.51e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22541143	chr4:84377292	HELQ;MRPS18C	0.61	7.28	0.41	3.82e-12	Gut microbiome composition (summer);
CESC	cis	rs3733585	0.699	rs6449157	chr4:9960442	G/A	cg00071950	chr4:10020882	SLC2A9	-0.73	-11.91	-0.59	1.82e-26	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs8005677	0.828	rs3794452	chr14:23386682	T/G	cg25600027	chr14:23388339	RBM23	-0.4	-5.04	-0.3	8.56e-7	Cognitive ability (multi-trait analysis);
CESC	cis	rs6987853	0.931	rs2923432	chr8:42395632	G/C	cg09913449	chr8:42400586	C8orf40	0.37	5.77	0.33	2.18e-8	Mean corpuscular hemoglobin concentration;
CESC	cis	rs1957429	0.901	rs17102320	chr14:65384693	T/C	cg23373153	chr14:65346875	NA	-0.9	-9.7	-0.51	3.21e-19	Pediatric areal bone mineral density (radius);
CESC	cis	rs10504229	1.000	rs66672857	chr8:58179817	G/C	cg24829409	chr8:58192753	C8orf71	-0.76	-10.0	-0.52	3.53e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs7666738	0.791	rs13111960	chr4:98976851	C/T	cg17366294	chr4:99064904	C4orf37	0.58	8.25	0.45	7.41e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3806843	0.900	rs116210441	chr5:140128649	T/A	cg26395211	chr5:140044315	WDR55	0.39	5.14	0.3	5.47e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs7666738	0.710	rs7674407	chr4:98838522	A/G	cg17366294	chr4:99064904	C4orf37	0.52	6.92	0.39	3.36e-11	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9322193	0.923	rs10872645	chr6:150063976	G/A	cg05861140	chr6:150128134	PCMT1	-0.35	-5.11	-0.3	6.19e-7	Lung cancer;
CESC	cis	rs4722166	0.508	rs2069832	chr7:22767433	A/G	cg05265849	chr7:22767390	IL6	0.5	6.5	0.37	3.86e-10	Lung cancer;
CESC	cis	rs4665809	0.590	rs6716858	chr2:26423414	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.91	-11.23	-0.57	3.39e-24	Gut microbiome composition (summer);
CESC	cis	rs6089584	0.853	rs1746280	chr20:60577821	C/G	cg18761221	chr20:60518478	NA	0.38	5.13	0.3	5.69e-7	Body mass index;
CESC	trans	rs9784649	0.760	rs17343923	chr5:25052414	G/A	cg08600765	chr20:34638493	LOC647979	-0.58	-6.28	-0.36	1.39e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs3096299	0.967	rs7205785	chr16:89458984	A/G	cg16743903	chr16:89593216	SPG7	-0.41	-5.25	-0.31	3.05e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs6942756	0.513	rs10954224	chr7:128893513	T/A	cg02491457	chr7:128862824	NA	0.5	7.3	0.41	3.41e-12	White matter hyperintensity burden;
CESC	cis	rs2721195	0.654	rs4610795	chr8:145881333	C/T	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.66	-9.68	-0.51	3.53e-19	Age at first birth;
CESC	cis	rs10504229	0.575	rs59424848	chr8:57999219	T/C	cg22535103	chr8:58192502	C8orf71	-0.56	-6.58	-0.37	2.48e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs9291683	0.551	rs62295971	chr4:9978142	G/A	cg02734326	chr4:10020555	SLC2A9	0.45	6.77	0.38	8.46e-11	Bone mineral density;
CESC	cis	rs7666738	0.830	rs11725095	chr4:99009711	T/A	cg17366294	chr4:99064904	C4orf37	0.6	8.62	0.47	6.37e-16	Colonoscopy-negative controls vs population controls;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg15110300	chr7:45039670	CCM2	-0.5	-6.05	-0.35	4.85e-9	Ulcerative colitis;
CESC	cis	rs763121	0.785	rs5750646	chr22:39013830	T/C	cg06544989	chr22:39130855	UNC84B	0.51	9.23	0.49	8.69e-18	Menopause (age at onset);
CESC	cis	rs2228479	0.850	rs12599473	chr16:89827435	A/C	cg06558623	chr16:89946397	TCF25	1.17	9.29	0.5	5.76e-18	Skin colour saturation;
CESC	cis	rs7208859	0.562	rs8078897	chr17:29106257	T/G	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.17e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs2075371	0.966	rs1901204	chr7:133985896	A/G	cg20476274	chr7:133979776	SLC35B4	0.63	9.08	0.49	2.53e-17	Mean platelet volume;
CESC	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	22.13	0.81	3.58e-62	Prudent dietary pattern;
CESC	cis	rs6546537	0.826	rs2704443	chr2:69889338	A/C	cg10773587	chr2:69614142	GFPT1	-0.57	-6.77	-0.38	8.37e-11	Serum thyroid-stimulating hormone levels;
CESC	cis	rs7649275	0.882	rs2612026	chr3:53776995	A/G	cg21503701	chr3:53781065	CACNA1D	-0.4	-5.46	-0.32	1.08e-7	Trans fatty acid levels;
CESC	cis	rs2735413	0.813	rs11644471	chr16:78077237	A/T	cg04733911	chr16:78082701	NA	-0.53	-9.01	-0.48	4.08e-17	Systolic blood pressure (alcohol consumption interaction);
CESC	cis	rs9300255	0.537	rs1619561	chr12:123620268	G/C	cg19016782	chr12:123741754	C12orf65	-0.37	-5.03	-0.3	8.85e-7	Neutrophil percentage of white cells;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg02567788	chr10:71992279	PPA1	-0.46	-6.41	-0.37	6.64e-10	Gambling;
CESC	cis	rs4906332	1.000	rs17617094	chr14:103893428	T/C	cg09975044	chr14:104007538	NA	0.46	6.38	0.36	7.81e-10	Coronary artery disease;
CESC	cis	rs11638352	1.000	rs1808509	chr15:44409539	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.59	-5.42	-0.32	1.33e-7	Lipoprotein phospholipase A2 activity in cardiovascular disease;
CESC	cis	rs4665809	0.941	rs11126336	chr2:26245931	C/T	cg26314531	chr2:26401878	FAM59B	-0.61	-6.68	-0.38	1.36e-10	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03576636	chr19:1918189	SCAMP4	-0.56	-6.47	-0.37	4.71e-10	Gut microbiome composition (summer);
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg04293180	chr8:144700367	TSTA3	0.49	6.83	0.39	5.88e-11	Systemic lupus erythematosus;
CESC	cis	rs5769765	0.818	rs8140681	chr22:50292081	C/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.45	-5.2	-0.3	4.01e-7	Schizophrenia;
CESC	cis	rs769267	0.965	rs8101938	chr19:19390497	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	7.34	0.41	2.56e-12	Tonsillectomy;
CESC	cis	rs11638352	0.661	rs2706486	chr15:44428982	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.55	-5.27	-0.31	2.83e-7	Lipoprotein phospholipase A2 activity in cardiovascular disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16724557	chr1:28907903	SNHG12;SNORA44;SNORA16A;SNORA61	-0.55	-6.15	-0.35	2.84e-9	Gut microbiome composition (summer);
CESC	cis	rs875971	0.540	rs1723268	chr7:65473080	A/C	cg11764359	chr7:65958608	NA	0.67	8.67	0.47	4.39e-16	Aortic root size;
CESC	cis	rs6502050	0.835	rs12950475	chr17:80118924	T/C	cg11859384	chr17:80120422	CCDC57	-0.39	-5.34	-0.31	1.98e-7	Life satisfaction;
CESC	cis	rs1198430	0.925	rs487859	chr1:23801101	T/C	cg22040403	chr1:23858016	E2F2	0.68	5.5	0.32	9.07e-8	Total cholesterol levels;
CESC	cis	rs910316	0.934	rs7141705	chr14:75655352	G/C	cg16144293	chr14:75469539	EIF2B2	0.39	5.1	0.3	6.6e-7	Height;
CESC	cis	rs7923609	0.967	rs7912893	chr10:65162000	T/A	cg01631684	chr10:65280961	REEP3	-0.44	-5.48	-0.32	9.84e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs1552244	0.572	rs67439440	chr3:10169503	C/T	cg00149659	chr3:10157352	C3orf10	0.99	12.05	0.59	6.02e-27	Alzheimer's disease;
CESC	cis	rs2637266	0.846	rs2637261	chr10:78320593	A/G	cg18941641	chr10:78392320	NA	-0.38	-6.95	-0.39	2.76e-11	Pulmonary function;
CESC	cis	rs10883723	0.703	rs7898410	chr10:104245858	T/C	ch.10.2196322F	chr10:104248062	ACTR1A	0.43	5.21	0.31	3.72e-7	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs12926788	0.542	rs11862971	chr16:24767574	C/A	cg06028605	chr16:24865363	SLC5A11	0.54	8.07	0.44	2.39e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	trans	rs1814175	0.562	rs1794130	chr11:49903764	T/A	cg11707556	chr5:10655725	ANKRD33B	-0.43	-6.36	-0.36	8.98e-10	Height;
CESC	cis	rs8014204	0.935	rs8010840	chr14:75355203	T/C	cg08847533	chr14:75593920	NEK9	-0.46	-5.73	-0.33	2.77e-8	Caffeine consumption;
CESC	cis	rs9872999	1	rs9872999	chr3:133457514	C/T	cg24879335	chr3:133465180	TF	0.45	8.68	0.47	4.14e-16	Iron status biomarkers;
CESC	cis	rs7523050	0.643	rs35665867	chr1:109395436	G/A	cg08274380	chr1:109419600	GPSM2	0.84	5.42	0.32	1.32e-7	Fat distribution (HIV);
CESC	cis	rs2273669	0.667	rs12201821	chr6:109340291	C/T	cg05315195	chr6:109294784	ARMC2	-0.67	-6.41	-0.37	6.73e-10	Prostate cancer;
CESC	trans	rs4843747	0.671	rs9933794	chr16:88116981	T/C	cg26811252	chr16:29126840	RRN3P2	0.69	9.53	0.51	1.05e-18	Menopause (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11629460	chr3:141457364	RNF7	-0.54	-6.11	-0.35	3.49e-9	Gut microbiome composition (summer);
CESC	cis	rs7582720	0.943	rs72932575	chr2:203866857	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.36	0.41	2.34e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	trans	rs7726839	0.540	rs61731455	chr5:665295	A/G	cg25482853	chr8:67687455	SGK3	0.97	9.73	0.51	2.43e-19	Obesity-related traits;
CESC	cis	rs2991971	0.967	rs2275276	chr1:45973928	C/T	cg05343316	chr1:45956843	TESK2	-0.52	-6.94	-0.39	3.09e-11	High light scatter reticulocyte count;
CESC	cis	rs2836974	1.000	rs28360661	chr21:40681972	G/C	cg11644478	chr21:40555479	PSMG1	0.96	13.39	0.64	1.44e-31	Cognitive function;
CESC	cis	rs896854	0.517	rs1011796	chr8:95951273	A/G	cg09323728	chr8:95962352	TP53INP1	0.36	6.57	0.37	2.64e-10	Type 2 diabetes;
CESC	cis	rs6120849	0.901	rs11696967	chr20:33743609	A/C	cg24642439	chr20:33292090	TP53INP2	0.63	6.69	0.38	1.35e-10	Protein C levels;
CESC	cis	rs7726839	0.526	rs11960159	chr5:568685	C/T	cg16447950	chr5:562315	NA	-0.64	-7.6	-0.42	5.22e-13	Obesity-related traits;
CESC	cis	rs60871478	0.786	rs62432898	chr7:826102	G/A	cg00934597	chr7:893267	UNC84A	0.53	5.44	0.32	1.19e-7	Cerebrospinal P-tau181p levels;
CESC	trans	rs941207	0.542	rs6581107	chr12:57194981	T/C	cg26462586	chr2:11164677	NA	0.38	6.1	0.35	3.74e-9	Platelet count;
CESC	cis	rs7833790	0.654	rs6415652	chr8:82702257	G/A	cg27398817	chr8:82754497	SNX16	-0.42	-5.32	-0.31	2.24e-7	Diastolic blood pressure;
CESC	cis	rs4319547	0.876	rs10846978	chr12:122964708	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.66	-7.7	-0.43	2.64e-13	Body mass index;
CESC	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	22.58	0.81	1.09e-63	Prudent dietary pattern;
CESC	cis	rs2760061	0.819	rs708111	chr1:228191365	G/A	cg02753203	chr1:228287806	NA	0.52	7.7	0.43	2.71e-13	Diastolic blood pressure;
CESC	cis	rs2204008	0.837	rs8189467	chr12:38241956	T/C	cg13010199	chr12:38710504	ALG10B	0.45	5.52	0.32	7.92e-8	Bladder cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12145552	chr21:43374218	C2CD2	0.66	7.54	0.42	7.66e-13	Gut microbiome composition (summer);
CESC	cis	rs9911578	1.000	rs654778	chr17:56736473	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.27	0.31	2.87e-7	Intelligence (multi-trait analysis);
CESC	cis	rs2276314	1.000	rs4573997	chr18:33552568	C/T	cg19628046	chr18:33552617	C18orf21	0.6	6.77	0.38	8.12e-11	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs7829975	0.688	rs7826660	chr8:8379107	C/A	cg06636001	chr8:8085503	FLJ10661	0.51	6.35	0.36	9.5e-10	Mood instability;
CESC	cis	rs9863	0.828	rs1187415	chr12:124491529	C/G	cg17562584	chr12:124393655	DNAH10	-0.31	-5.41	-0.32	1.42e-7	White blood cell count;
CESC	cis	rs7914558	1.000	rs10883824	chr10:104812897	A/G	cg04362960	chr10:104952993	NT5C2	0.48	6.45	0.37	5.35e-10	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	trans	rs17764205	0.777	rs17696630	chr19:3261995	A/G	cg12868887	chr11:70244470	CTTN	-0.75	-6.0	-0.35	6.55e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs11792861	0.781	rs28361106	chr9:111762385	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.55	7.15	0.4	8.6e-12	Menarche (age at onset);
CESC	cis	rs3820068	0.603	rs6696286	chr1:15968770	C/T	cg18133145	chr1:16060689	PLEKHM2	-0.41	-5.23	-0.31	3.41e-7	Systolic blood pressure;
CESC	cis	rs651907	0.535	rs34063583	chr3:101509948	C/T	cg12386194	chr3:101231763	SENP7	0.41	5.11	0.3	6.03e-7	Colorectal cancer;
CESC	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg23034840	chr1:205782522	SLC41A1	0.68	8.43	0.46	2.21e-15	Menarche (age at onset);
CESC	cis	rs3204270	0.714	rs7503307	chr17:79674929	C/G	cg18367735	chr17:79674897	NA	0.68	5.87	0.34	1.27e-8	Dental caries;
CESC	cis	rs9322193	0.886	rs10872652	chr6:150096439	C/T	cg04369109	chr6:150039330	LATS1	-0.39	-5.34	-0.31	2.01e-7	Lung cancer;
CESC	cis	rs7412746	0.597	rs868751	chr1:150669414	T/G	cg04414720	chr1:150670196	GOLPH3L	0.63	9.03	0.48	3.76e-17	Melanoma;
CESC	cis	rs2820292	0.967	rs2820290	chr1:201783682	A/G	cg11586189	chr1:201857591	SHISA4	0.32	5.3	0.31	2.44e-7	Waist circumference;Body mass index (joint analysis main effects and smoking interaction);Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);
CESC	cis	rs4478858	0.735	rs12134484	chr1:31823741	G/A	cg00250761	chr1:31883323	NA	-0.26	-5.06	-0.3	7.93e-7	Alcohol dependence;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg27551169	chr15:85383124	ALPK3	0.51	6.56	0.37	2.78e-10	Fibrinogen levels;
CESC	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.64	7.45	0.42	1.33e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs896854	0.540	rs2011567	chr8:95971920	G/A	cg26343298	chr8:95960752	TP53INP1	0.36	5.89	0.34	1.15e-8	Type 2 diabetes;
CESC	cis	rs6061231	0.837	rs6121558	chr20:60961365	A/G	cg22601191	chr20:60968625	CABLES2	0.53	6.61	0.38	2.16e-10	Colorectal cancer;
CESC	cis	rs4950322	0.570	rs72692905	chr1:146773253	C/T	cg22381352	chr1:146742008	CHD1L	-0.46	-5.05	-0.3	8.32e-7	Protein quantitative trait loci;
CESC	cis	rs6484504	0.532	rs11031332	chr11:31278962	T/C	cg14844989	chr11:31128820	NA	-0.41	-5.66	-0.33	3.89e-8	Red blood cell count;
CESC	cis	rs3540	0.512	rs7176518	chr15:91079637	C/T	cg10434728	chr15:90938212	IQGAP1	-0.39	-7.03	-0.4	1.74e-11	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs1153858	1.000	rs4775909	chr15:45643042	T/C	cg21132104	chr15:45694354	SPATA5L1	0.82	11.02	0.56	1.72e-23	Homoarginine levels;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg15926737	chr12:57853737	GLI1	-0.47	-6.56	-0.37	2.79e-10	Gambling;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg02656441	chr13:111367915	ING1	0.44	6.38	0.36	7.85e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs6088590	1.000	rs6119512	chr20:33306904	T/C	cg08999081	chr20:33150536	PIGU	0.6	9.27	0.49	6.6e-18	Coronary artery disease;
CESC	cis	rs11792861	0.816	rs11790105	chr9:111731785	T/C	cg05043794	chr9:111880884	C9orf5	-0.38	-6.25	-0.36	1.59e-9	Menarche (age at onset);
CESC	cis	rs1799949	0.859	rs11657004	chr17:41442751	A/G	cg05368731	chr17:41323189	NBR1	0.58	8.23	0.45	8.76e-15	Menopause (age at onset);
CESC	cis	rs644799	0.930	rs2186782	chr11:95649543	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.57	7.29	0.41	3.57e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs6912958	0.781	rs2300906	chr6:88207155	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.55	-7.33	-0.41	2.86e-12	Monocyte percentage of white cells;
CESC	cis	rs875971	0.830	rs587360	chr7:65522698	C/A	cg18876405	chr7:65276391	NA	0.55	7.39	0.41	1.98e-12	Aortic root size;
CESC	cis	rs738322	0.753	rs5756968	chr22:38595240	C/T	cg17652424	chr22:38574118	PLA2G6	0.3	5.26	0.31	2.98e-7	Cutaneous nevi;
CESC	cis	rs7412746	0.611	rs6660084	chr1:150748803	T/C	cg17724175	chr1:150552817	MCL1	0.42	6.36	0.36	8.99e-10	Melanoma;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05740071	chr10:35299094	CUL2	-0.43	-6.1	-0.35	3.71e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs17711722	0.740	rs7809991	chr7:65406218	A/G	cg18876405	chr7:65276391	NA	0.69	9.64	0.51	4.96e-19	Calcium levels;
CESC	cis	rs72780191	0.574	rs55836224	chr2:23895597	T/C	cg08917208	chr2:24149416	ATAD2B	0.72	7.35	0.41	2.45e-12	White blood cell count;
CESC	cis	rs72945132	0.882	rs7940090	chr11:70227824	C/G	cg00319359	chr11:70116639	PPFIA1	0.73	7.1	0.4	1.11e-11	Coronary artery disease;
CESC	trans	rs10463316	0.894	rs6880137	chr5:150755232	A/G	cg24389359	chr12:111284228	CCDC63	-0.34	-6.09	-0.35	3.93e-9	Metabolite levels (Pyroglutamine);
CESC	cis	rs9457247	0.765	rs9459849	chr6:167444160	G/T	cg23791538	chr6:167370224	RNASET2	-0.55	-7.68	-0.43	3.01e-13	Crohn's disease;
CESC	cis	rs2576037	0.526	rs607780	chr18:44417456	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.71	11.36	0.57	1.22e-24	Personality dimensions;
CESC	cis	rs13108904	0.870	rs13115355	chr4:1261576	G/A	cg00684032	chr4:1343700	KIAA1530	0.42	5.93	0.34	9.41e-9	Obesity-related traits;
CESC	cis	rs9443189	0.950	rs721264	chr6:76517896	G/A	cg01950844	chr6:76311363	SENP6	0.53	5.78	0.33	2.09e-8	Prostate cancer;
CESC	cis	rs7680126	0.596	rs12503603	chr4:10313757	T/G	cg00071950	chr4:10020882	SLC2A9	-0.5	-5.25	-0.31	3.06e-7	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	trans	rs11039798	0.511	rs7948129	chr11:48167828	G/A	cg15704280	chr7:45808275	SEPT13	-0.69	-6.85	-0.39	5.29e-11	Axial length;
CESC	cis	rs7666738	0.830	rs10029849	chr4:99059362	T/C	cg03467027	chr4:99064603	C4orf37	0.48	5.95	0.34	8.47e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs35110281	0.782	rs2838329	chr21:45023329	T/C	cg01579765	chr21:45077557	HSF2BP	-0.55	-9.22	-0.49	9.29e-18	Mean corpuscular volume;
CESC	cis	rs1879734	0.689	rs55786134	chr1:54171981	T/C	cg23596471	chr1:54105337	GLIS1	0.35	5.54	0.32	7.34e-8	Mitral valve prolapse;
CESC	cis	rs712039	0.652	rs853197	chr17:35848716	T/C	cg16670864	chr17:35848621	DUSP14	0.47	5.92	0.34	1.01e-8	Tuberculosis;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg25377665	chr17:36903811	PCGF2	-0.41	-6.21	-0.36	2.06e-9	Gambling;
CESC	cis	rs3733585	0.699	rs6449174	chr4:9966422	C/T	cg02734326	chr4:10020555	SLC2A9	-0.36	-5.06	-0.3	7.84e-7	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs73110464	0.609	rs4919752	chr12:53359229	G/C	cg16329197	chr12:53359506	NA	-0.71	-10.45	-0.54	1.28e-21	Cancer (pleiotropy);
CESC	cis	rs3768617	0.677	rs12739316	chr1:183052080	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.03	0.52	2.82e-20	Fuchs's corneal dystrophy;
CESC	trans	rs9325144	0.723	rs10161183	chr12:39182087	T/C	cg23762105	chr12:34175262	ALG10	0.45	6.14	0.35	3.01e-9	Morning vs. evening chronotype;
CESC	cis	rs4862750	0.872	rs9998172	chr4:187898773	T/C	cg03452623	chr4:187889614	NA	-0.88	-16.31	-0.71	7.08e-42	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg00276377	chr13:77601664	FBXL3	-0.45	-6.04	-0.35	5.21e-9	Fibrinogen levels;
CESC	cis	rs684232	0.649	rs838369	chr17:578180	T/C	cg15660573	chr17:549704	VPS53	-0.63	-8.63	-0.47	5.65e-16	Prostate cancer;
CESC	cis	rs9549367	0.789	rs9549695	chr13:113874814	A/G	cg00898013	chr13:113819073	PROZ	0.48	6.78	0.38	7.85e-11	Platelet distribution width;
CESC	cis	rs4713118	0.629	rs203887	chr6:28021269	C/T	cg26335602	chr6:28129616	ZNF389	0.45	5.43	0.32	1.25e-7	Parkinson's disease;
CESC	cis	rs71403859	0.667	rs12924650	chr16:71705908	C/T	cg08717414	chr16:71523259	ZNF19	-0.73	-6.39	-0.37	7.59e-10	Post bronchodilator FEV1;
CESC	cis	rs1799949	1.000	rs2037076	chr17:41305883	G/A	cg05368731	chr17:41323189	NBR1	0.79	11.23	0.57	3.39e-24	Menopause (age at onset);
CESC	cis	rs7589728	0.514	rs12465706	chr2:88467459	C/A	cg14558114	chr2:88469736	THNSL2	0.58	5.53	0.32	7.83e-8	Plasma clusterin levels;
CESC	cis	rs34779708	0.702	rs35969476	chr10:35544318	G/A	cg04310649	chr10:35416472	CREM	-0.47	-5.38	-0.31	1.67e-7	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs2777491	1.000	rs66538814	chr15:41685917	G/T	cg02330683	chr15:41787940	ITPKA	0.42	6.21	0.36	2.09e-9	Ulcerative colitis;
CESC	cis	rs17376456	0.877	rs10060462	chr5:93455073	C/T	cg21475434	chr5:93447410	FAM172A	0.9	7.81	0.43	1.31e-13	Diabetic retinopathy;
CESC	cis	rs12478296	0.901	rs7603560	chr2:243043256	C/T	cg06360820	chr2:242988706	NA	-0.92	-8.99	-0.48	4.94e-17	Obesity-related traits;
CESC	cis	rs9467773	0.595	rs12525810	chr6:26623511	T/TA	cg12292205	chr6:26970375	C6orf41	-0.53	-5.47	-0.32	1.02e-7	Intelligence (multi-trait analysis);
CESC	cis	rs12497850	0.931	rs9311432	chr3:48850443	T/A	cg03060546	chr3:49711283	APEH	0.44	5.38	0.31	1.61e-7	Parkinson's disease;
CESC	cis	rs853679	0.517	rs9368556	chr6:28131153	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.57	-6.49	-0.37	4.32e-10	Depression;
CESC	cis	rs16866061	1.000	rs3768886	chr2:225450161	G/C	cg12698349	chr2:225449008	CUL3	0.72	10.62	0.55	3.57e-22	Acute graft versus host disease in bone marrow transplantation (recipient effect);
CESC	cis	rs9894429	0.700	rs113915083	chr17:79552696	G/C	cg18240062	chr17:79603768	NPLOC4	-0.86	-12.51	-0.61	1.61e-28	Eye color traits;
CESC	cis	rs875971	0.862	rs778734	chr7:65814849	C/G	cg12463550	chr7:65579703	CRCP	0.47	6.08	0.35	4.21e-9	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22234827	chr1:154947116	CKS1B;SHC1	0.66	7.19	0.4	6.76e-12	Gut microbiome composition (summer);
CESC	cis	rs4835473	0.897	rs34380794	chr4:144656953	A/C	cg25736465	chr4:144833511	NA	-0.33	-5.25	-0.31	3.06e-7	Immature fraction of reticulocytes;
CESC	cis	rs72945132	0.714	rs72947077	chr11:70197431	A/G	cg00319359	chr11:70116639	PPFIA1	0.8	7.29	0.41	3.63e-12	Coronary artery disease;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg25978167	chr4:57301353	PAICS;PPAT	-0.47	-6.26	-0.36	1.55e-9	Height;
CESC	cis	rs200895692	1	rs200895692	chr1:43421956	CGCCTGTAATCCCAG/C	cg09824328	chr1:43425412	SLC2A1	-0.54	-5.61	-0.33	5.2e-8	Monocyte count;
CESC	trans	rs7326068	0.610	rs9552275	chr13:21337389	G/A	cg00192819	chr18:76486611	NA	0.43	6.13	0.35	3.11e-9	Schizophrenia, bipolar disorder and depression (combined);
CESC	cis	rs971768	0.892	rs62623403	chr22:17595175	C/T	cg06707910	chr22:17640812	CECR5;CECR4	-0.65	-5.96	-0.34	8.13e-9	Heschl's gyrus morphology;
CESC	cis	rs9916302	0.904	rs600010	chr17:37433517	T/C	cg19468946	chr17:37922297	IKZF3	-0.41	-5.3	-0.31	2.47e-7	Glomerular filtration rate (creatinine);
CESC	trans	rs57221529	0.766	rs4081847	chr5:574072	C/T	cg25482853	chr8:67687455	SGK3	1.05	10.38	0.54	2.11e-21	Lung disease severity in cystic fibrosis;
CESC	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg23978390	chr7:1156363	C7orf50	0.65	9.3	0.5	5.61e-18	Longevity;Endometriosis;
CESC	cis	rs11640734	0.619	rs2293586	chr16:89962394	A/G	cg04013166	chr16:89971882	TCF25	0.7	8.34	0.46	4.03e-15	Interleukin-17 levels;
CESC	cis	rs1552244	0.554	rs6762397	chr3:10007840	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.62	7.96	0.44	4.98e-14	Alzheimer's disease;
CESC	cis	rs7762018	0.607	rs3800544	chr6:170058374	C/T	cg19338460	chr6:170058176	WDR27	-0.78	-6.9	-0.39	3.74e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs9399137	0.507	rs6918512	chr6:135284839	T/G	cg22676075	chr6:135203613	NA	0.53	7.0	0.39	2.14e-11	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	cis	rs9916302	0.904	rs9905432	chr17:37555918	C/A	cg20243544	chr17:37824526	PNMT	-0.51	-6.5	-0.37	4.03e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs826838	1.000	rs11183469	chr12:38752311	G/A	cg13010199	chr12:38710504	ALG10B	0.62	8.74	0.47	2.7e-16	Heart rate;
CESC	cis	rs6540559	0.605	rs3753518	chr1:209977964	G/C	cg09509183	chr1:209979624	IRF6	0.56	5.8	0.34	1.9e-8	Cleft lip with or without cleft palate;
CESC	cis	rs5750830	0.649	rs5750822	chr22:39826788	C/T	cg24399712	chr22:39784796	NA	-0.82	-10.79	-0.55	9.78e-23	Intelligence (multi-trait analysis);
CESC	cis	rs854765	0.547	rs2955372	chr17:17970229	T/C	cg16928487	chr17:17741425	SREBF1	0.55	9.17	0.49	1.39e-17	Total body bone mineral density;
CESC	cis	rs10911232	0.507	rs6668980	chr1:183018857	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.87	13.5	0.64	6.03e-32	Hypertriglyceridemia;
CESC	cis	rs2180341	0.640	rs11154395	chr6:127629138	T/C	cg27446573	chr6:127587934	RNF146	0.64	8.54	0.46	1.07e-15	Breast cancer;
CESC	cis	rs863345	0.967	rs5009954	chr1:158530417	A/G	cg12129480	chr1:158549410	OR10X1	-0.32	-6.51	-0.37	3.8e-10	Pneumococcal bacteremia;
CESC	cis	rs977987	0.836	rs17685540	chr16:75323840	T/C	cg03315344	chr16:75512273	CHST6	0.37	5.35	0.31	1.94e-7	Dupuytren's disease;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg18433293	chr15:41576837	LOC729082	-0.46	-6.26	-0.36	1.52e-9	Asthma;
CESC	cis	rs56011263	0.687	rs4690293	chr4:706101	A/G	cg17689763	chr4:710664	PCGF3	-0.48	-6.39	-0.37	7.35e-10	White blood cell count;
CESC	cis	rs2249625	0.545	rs9791273	chr6:72891016	G/T	cg18830697	chr6:72922368	RIMS1	0.4	5.75	0.33	2.45e-8	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CESC	cis	rs4713118	0.513	rs183244	chr6:28031838	C/A	cg17221315	chr6:27791827	HIST1H4J	0.41	5.35	0.31	1.9e-7	Parkinson's disease;
CESC	cis	rs1008375	0.966	rs4698642	chr4:17679174	A/T	cg16339924	chr4:17578868	LAP3	0.49	6.24	0.36	1.72e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg02903691	chr16:18573200	NOMO2	-0.49	-6.34	-0.36	9.68e-10	Fibrinogen levels;
CESC	cis	rs9583531	0.689	rs9588247	chr13:111375571	G/T	cg24331049	chr13:111365604	ING1	-0.72	-10.28	-0.53	4.33e-21	Coronary artery disease;
CESC	cis	rs921968	0.643	rs678218	chr2:219379709	C/A	cg02176678	chr2:219576539	TTLL4	0.39	6.81	0.39	6.35e-11	Mean corpuscular hemoglobin concentration;
CESC	cis	rs863345	0.967	rs1592255	chr1:158470556	G/C	cg12129480	chr1:158549410	OR10X1	-0.31	-6.19	-0.36	2.34e-9	Pneumococcal bacteremia;
CESC	cis	rs2836974	0.897	rs34394827	chr21:40528087	T/C	cg11890956	chr21:40555474	PSMG1	1.17	22.39	0.81	4.79e-63	Cognitive function;
CESC	cis	rs2204008	0.774	rs7304438	chr12:38361146	T/G	cg26384229	chr12:38710491	ALG10B	0.73	10.95	0.56	2.81e-23	Bladder cancer;
CESC	cis	rs2996428	0.667	rs61768932	chr1:3765671	G/C	cg13057898	chr1:3703894	LRRC47	0.44	5.93	0.34	9.24e-9	Red cell distribution width;
CESC	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg24642844	chr7:1081250	C7orf50	-0.78	-9.49	-0.5	1.38e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7927771	0.524	rs7118747	chr11:47889545	C/T	cg18512352	chr11:47633146	NA	-0.36	-5.57	-0.32	6.22e-8	Subjective well-being;
CESC	cis	rs9660180	0.837	rs915292	chr1:1792157	A/C	cg13866156	chr1:1669148	SLC35E2	-0.51	-6.6	-0.38	2.17e-10	Body mass index;
CESC	cis	rs7264396	0.635	rs6058358	chr20:34492560	A/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.59	7.2	0.4	6.2e-12	Total cholesterol levels;
CESC	cis	rs875971	0.798	rs6460304	chr7:65964728	G/A	cg10691866	chr7:65817282	TPST1	-0.32	-5.25	-0.31	3.16e-7	Aortic root size;
CESC	cis	rs17711722	0.522	rs62469933	chr7:65265639	G/A	cg18876405	chr7:65276391	NA	0.47	6.25	0.36	1.6e-9	Calcium levels;
CESC	cis	rs1670533	1.000	rs604597	chr4:1094151	G/A	cg27284194	chr4:1044797	NA	-0.47	-6.01	-0.35	6.08e-9	Recombination rate (females);
CESC	cis	rs6933660	0.646	rs9397410	chr6:151770503	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.88	15.42	0.69	9.82e-39	Menarche (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14835113	chr13:111303423	CARS2	-0.68	-7.66	-0.43	3.49e-13	Gut microbiome composition (summer);
CESC	cis	rs875971	1.000	rs7789768	chr7:65938980	A/C	cg11764359	chr7:65958608	NA	0.97	15.5	0.69	5.25e-39	Aortic root size;
CESC	cis	rs10504229	1.000	rs76944716	chr8:58191643	T/C	cg22535103	chr8:58192502	C8orf71	-1.07	-13.22	-0.63	5.72e-31	Developmental language disorder (linguistic errors);
CESC	cis	rs873946	0.648	rs12782123	chr10:134554662	G/A	cg27297192	chr10:134578999	INPP5A	0.39	5.19	0.3	4.29e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs769267	0.930	rs6511038	chr19:19607564	A/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.47	5.84	0.34	1.51e-8	Tonsillectomy;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg27649522	chr12:12877729	APOLD1	0.48	6.22	0.36	1.88e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs3858526	0.920	rs11039698	chr11:5950907	C/T	cg13902645	chr11:5959945	NA	-0.66	-7.99	-0.44	4.26e-14	DNA methylation (variation);
CESC	cis	rs965469	0.779	rs6051683	chr20:3237822	G/C	cg25506879	chr20:3388711	C20orf194	-0.51	-5.57	-0.32	6.1e-8	IFN-related cytopenia;
CESC	cis	rs2637266	0.714	rs1965156	chr10:78450559	G/A	cg18941641	chr10:78392320	NA	0.43	7.8	0.43	1.43e-13	Pulmonary function;
CESC	cis	rs763121	0.853	rs5757232	chr22:39071677	C/T	cg21395723	chr22:39101663	GTPBP1	0.42	5.32	0.31	2.17e-7	Menopause (age at onset);
CESC	cis	rs854765	0.562	rs2955381	chr17:17945500	G/C	cg04398451	chr17:18023971	MYO15A	0.73	10.55	0.54	5.95e-22	Total body bone mineral density;
CESC	cis	rs3026101	0.578	rs3026142	chr17:5315089	G/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.44	5.83	0.34	1.6e-8	Body mass index;
CESC	cis	rs1728785	1.000	rs7202306	chr16:68587684	G/A	cg02972257	chr16:68554789	NA	-0.58	-6.56	-0.37	2.75e-10	Ulcerative colitis;
CESC	cis	rs3540	0.574	rs8035980	chr15:90974390	C/G	cg10434728	chr15:90938212	IQGAP1	0.39	7.12	0.4	1.02e-11	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs6546550	0.901	rs34586537	chr2:70163316	G/T	cg02498382	chr2:70120550	SNRNP27	0.42	7.31	0.41	3.24e-12	Prevalent atrial fibrillation;
CESC	cis	rs116095464	0.558	rs6555056	chr5:226222	T/C	cg20965017	chr5:231967	SDHA	-0.44	-5.04	-0.3	8.77e-7	Breast cancer;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg09901100	chr7:134867116	NA	0.51	6.8	0.39	6.81e-11	Fibrinogen levels;
CESC	cis	rs672059	0.513	rs627064	chr1:183165716	C/T	cg01949993	chr1:183155116	LAMC2	-0.29	-5.26	-0.31	2.91e-7	Hypertriglyceridemia;
CESC	cis	rs6570726	0.791	rs9497357	chr6:145912888	G/A	cg23711669	chr6:146136114	FBXO30	0.94	14.19	0.66	2.3e-34	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7680126	0.633	rs4698040	chr4:10352550	C/T	cg00071950	chr4:10020882	SLC2A9	-0.53	-5.86	-0.34	1.37e-8	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	cis	rs1568889	0.877	rs17310076	chr11:28147590	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.69	6.89	0.39	4e-11	Bipolar disorder;
CESC	cis	rs11252926	0.598	rs4881256	chr10:453831	T/A	cg18196295	chr10:418757	DIP2C	0.55	7.61	0.42	4.82e-13	Psychosis in Alzheimer's disease;
CESC	cis	rs3857067	1.000	rs2219755	chr4:95015684	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.52	-8.04	-0.44	3.04e-14	QT interval;
CESC	cis	rs11711311	0.955	rs34048496	chr3:113414121	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.66	8.82	0.48	1.54e-16	IgG glycosylation;
CESC	cis	rs6540559	1.000	rs4844895	chr1:209958580	T/C	cg12034118	chr1:209979487	IRF6	0.43	5.27	0.31	2.85e-7	Cleft lip with or without cleft palate;
CESC	cis	rs6582630	0.502	rs11520279	chr12:38360871	A/G	cg26384229	chr12:38710491	ALG10B	0.69	10.42	0.54	1.6e-21	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs854765	0.927	rs4925138	chr17:17992793	T/G	cg04398451	chr17:18023971	MYO15A	0.68	9.62	0.51	5.65e-19	Total body bone mineral density;
CESC	cis	rs11931598	0.511	rs4689576	chr4:7025523	T/C	cg26116260	chr4:7069785	GRPEL1	0.4	5.51	0.32	8.29e-8	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg14195377	chr11:60928647	VPS37C	-0.46	-6.27	-0.36	1.43e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs597539	0.652	rs686390	chr11:68656077	T/C	cg01988459	chr11:68622903	NA	-0.42	-5.76	-0.33	2.29e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs34779708	0.931	rs10437420	chr10:35335044	A/C	cg03585969	chr10:35415529	CREM	-0.77	-10.11	-0.53	1.57e-20	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs10782582	0.593	rs79552201	chr1:76215497	A/T	cg10523679	chr1:76189770	ACADM	-0.48	-5.59	-0.32	5.59e-8	Daytime sleep phenotypes;
CESC	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.48	-5.08	-0.3	7.1e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg14926445	chr8:58193284	C8orf71	-0.52	-5.26	-0.31	2.91e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs3105593	0.932	rs2414072	chr15:50850562	T/A	cg08437265	chr15:50716283	USP8	0.41	5.29	0.31	2.54e-7	QT interval;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02823137	chr17:79235689	SLC38A10	-0.61	-7.41	-0.41	1.66e-12	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.830	rs7691864	chr4:98971376	G/C	cg17366294	chr4:99064904	C4orf37	0.58	8.26	0.45	7.11e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4589502	0.502	rs2169460	chr15:67197240	A/G	cg12317470	chr15:67143691	NA	-0.8	-11.28	-0.57	2.39e-24	Lung cancer (smoking interaction);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg13784889	chr4:89513377	HERC3	0.5	6.42	0.37	6.37e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs1030877	0.515	rs920217	chr2:105904662	C/T	cg02079111	chr2:105885981	TGFBRAP1	-0.48	-6.3	-0.36	1.26e-9	Obesity-related traits;
CESC	cis	rs4704187	0.687	rs6862740	chr5:74405749	A/T	cg03227963	chr5:74354835	NA	0.32	5.94	0.34	8.7e-9	Response to amphetamines;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07011025	chr1:231114438	ARV1;TTC13	0.54	6.28	0.36	1.37e-9	Gut microbiome composition (summer);
CESC	cis	rs2708240	1.000	rs2247143	chr7:147581107	C/G	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.34	-5.55	-0.32	7.07e-8	QT interval (drug interaction);
CESC	cis	rs1879734	0.731	rs10888803	chr1:54160235	C/T	cg23596471	chr1:54105337	GLIS1	0.35	5.7	0.33	3.12e-8	Mitral valve prolapse;
CESC	cis	rs6952808	0.595	rs3778982	chr7:2166233	T/C	cg04267008	chr7:1944627	MAD1L1	-0.6	-7.2	-0.4	6.32e-12	Bipolar disorder and schizophrenia;
CESC	cis	rs2075371	0.863	rs1646635	chr7:134006728	T/C	cg11752832	chr7:134001865	SLC35B4	0.52	6.77	0.38	8.19e-11	Mean platelet volume;
CESC	cis	rs11098499	0.863	rs1480936	chr4:120462861	C/T	cg09307838	chr4:120376055	NA	0.9	12.35	0.6	5.71e-28	Corneal astigmatism;
CESC	cis	rs4481887	0.962	rs4369256	chr1:248492274	G/A	cg00666640	chr1:248458726	OR2T12	0.41	6.74	0.38	9.64e-11	Common traits (Other);
CESC	cis	rs898097	0.691	rs7222773	chr17:80907283	A/G	cg15664640	chr17:80829946	TBCD	0.38	5.41	0.32	1.42e-7	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12813709	chr11:576467	PHRF1;LOC143666	0.53	6.08	0.35	4.08e-9	Gut microbiome composition (summer);
CESC	cis	rs1256061	0.630	rs1256030	chr14:64747170	A/G	cg23250157	chr14:64679961	SYNE2	0.48	6.79	0.38	7.37e-11	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	trans	rs9354352	0.967	rs6455062	chr6:66694131	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.69	10.02	0.52	3.05e-20	Initial pursuit acceleration in psychotic disorders;
CESC	cis	rs73206853	0.764	rs59527539	chr12:110968119	A/G	cg04375036	chr12:111181819	PPP1CC	-0.54	-5.04	-0.3	8.83e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	trans	rs1814175	0.645	rs7115592	chr11:50013243	A/G	cg03929089	chr4:120376271	NA	-0.91	-14.65	-0.67	5.08e-36	Height;
CESC	cis	rs7811142	0.830	rs73401450	chr7:99981859	G/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.89	8.51	0.46	1.27e-15	Platelet count;
CESC	cis	rs561341	0.941	rs2428341	chr17:30317295	C/T	cg12193833	chr17:30244370	NA	-0.52	-5.99	-0.35	6.91e-9	Hip circumference adjusted for BMI;
CESC	cis	rs7937682	0.562	rs7938620	chr11:111366844	G/A	cg09085632	chr11:111637200	PPP2R1B	0.58	7.27	0.41	3.98e-12	Primary sclerosing cholangitis;
CESC	cis	rs9916302	0.851	rs12936996	chr17:37665554	A/G	cg20243544	chr17:37824526	PNMT	-0.5	-6.41	-0.37	6.81e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs4523957	0.928	rs11869805	chr17:2176532	A/G	cg16513277	chr17:2031491	SMG6	-0.59	-8.04	-0.44	3.02e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs4561483	0.583	rs11645213	chr16:11942924	C/A	cg08843971	chr16:11963173	GSPT1	0.47	6.49	0.37	4.21e-10	Testicular germ cell tumor;
CESC	cis	rs6964587	0.967	rs2299235	chr7:91627500	C/T	cg17063962	chr7:91808500	NA	0.57	7.86	0.43	9.99e-14	Breast cancer;
CESC	cis	rs644799	1.000	rs586238	chr11:95560371	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	14.31	0.66	8.38e-35	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs17376456	0.825	rs13182631	chr5:93115701	A/G	cg21475434	chr5:93447410	FAM172A	0.8	7.22	0.41	5.48e-12	Diabetic retinopathy;
CESC	cis	rs208520	0.874	rs208469	chr6:66915891	T/C	cg07460842	chr6:66804631	NA	-0.87	-10.57	-0.54	5.25e-22	Exhaled nitric oxide output;
CESC	cis	rs3916	1.000	rs34708625	chr12:121180019	T/C	cg21892295	chr12:121157589	UNC119B	-0.35	-5.07	-0.3	7.41e-7	Urinary metabolites (H-NMR features);
CESC	cis	rs2033711	0.870	rs11084545	chr19:58951693	G/C	cg13877915	chr19:58951672	ZNF132	0.4	5.88	0.34	1.24e-8	Uric acid clearance;
CESC	cis	rs921968	0.565	rs7562426	chr2:219605118	G/A	cg02176678	chr2:219576539	TTLL4	-0.47	-8.28	-0.45	6.04e-15	Mean corpuscular hemoglobin concentration;
CESC	cis	rs7412746	0.658	rs11204750	chr1:150939744	C/A	cg04414720	chr1:150670196	GOLPH3L	0.5	6.49	0.37	4.21e-10	Melanoma;
CESC	cis	rs2637266	0.935	rs1978927	chr10:78399786	A/T	cg18941641	chr10:78392320	NA	0.44	8.31	0.45	5.07e-15	Pulmonary function;
CESC	cis	rs9814567	1.000	rs4498009	chr3:134198008	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.45	-6.11	-0.35	3.53e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	trans	rs1945213	0.694	rs1384099	chr11:55866040	A/C	cg15704280	chr7:45808275	SEPT13	0.69	6.65	0.38	1.66e-10	Acute lymphoblastic leukemia (childhood);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg05255807	chr6:88411528	NCRNA00120;AKIRIN2	-0.48	-6.17	-0.35	2.54e-9	Ulcerative colitis;
CESC	cis	rs7927592	0.626	rs11228279	chr11:68309680	C/T	cg16797656	chr11:68205561	LRP5	-0.48	-7.41	-0.41	1.7e-12	Total body bone mineral density;
CESC	cis	rs9303401	0.615	rs35288118	chr17:56600748	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.0	11.19	0.57	4.8e-24	Cognitive test performance;
CESC	cis	rs6952808	0.500	rs3778996	chr7:2177190	G/A	cg05863683	chr7:1912471	MAD1L1	0.38	5.49	0.32	9.37e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs61008539	0.853	rs10950611	chr7:861094	G/T	cg00934597	chr7:893267	UNC84A	-0.49	-6.55	-0.37	2.95e-10	Perceived unattractiveness to mosquitoes;
CESC	cis	rs55883249	1.000	rs62119428	chr2:9743332	T/C	cg23886495	chr2:9695866	ADAM17	0.61	5.52	0.32	8.11e-8	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
CESC	cis	rs6696846	0.765	rs11576867	chr1:205064676	C/T	cg00857998	chr1:205179979	DSTYK	0.53	7.28	0.41	3.85e-12	Red blood cell count;
CESC	cis	rs727505	1.000	rs67585224	chr7:124537476	A/C	cg23710748	chr7:124431027	NA	-0.48	-7.5	-0.42	9.36e-13	Lewy body disease;
CESC	cis	rs9733	0.543	rs72702558	chr1:150683251	G/A	cg09365446	chr1:150670422	GOLPH3L	0.42	5.86	0.34	1.37e-8	Tonsillectomy;
CESC	cis	rs4304924	0.500	rs12585725	chr13:79220899	C/A	cg01819759	chr13:79234251	RNF219	0.41	5.3	0.31	2.4e-7	Large artery stroke;
CESC	trans	rs2764766	0.755	rs245310	chr5:127166633	C/T	cg15764593	chr10:829463	NA	0.4	6.27	0.36	1.42e-9	Schizophrenia;
CESC	cis	rs2204008	0.837	rs4432085	chr12:38181146	C/T	cg26384229	chr12:38710491	ALG10B	0.74	10.7	0.55	1.96e-22	Bladder cancer;
CESC	cis	rs11958404	0.929	rs79656592	chr5:157430291	G/A	cg05962755	chr5:157440814	NA	0.63	6.63	0.38	1.87e-10	IgG glycosylation;
CESC	cis	rs796364	0.806	rs74266489	chr2:201005732	G/A	cg23649088	chr2:200775458	C2orf69	-0.55	-5.04	-0.3	8.69e-7	Schizophrenia;
CESC	cis	rs875971	0.929	rs6970860	chr7:65976634	A/G	cg11764359	chr7:65958608	NA	0.96	15.25	0.68	3.95e-38	Aortic root size;
CESC	cis	rs7666738	0.830	rs4334758	chr4:98971875	A/G	cg17366294	chr4:99064904	C4orf37	0.59	8.43	0.46	2.31e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7561273	0.586	rs11900665	chr2:24298198	T/C	cg20701182	chr2:24300061	SF3B14	0.45	6.11	0.35	3.57e-9	Quantitative traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22512163	chr5:73205678	RGNEF	-0.58	-6.71	-0.38	1.19e-10	Gut microbiome composition (summer);
CESC	cis	rs2070997	0.667	rs7869508	chr9:133716802	T/C	cg11464064	chr9:133710261	ABL1	0.68	7.65	0.43	3.64e-13	Response to amphetamines;
CESC	cis	rs6912958	0.781	rs2207146	chr6:88180641	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.4	-5.19	-0.3	4.09e-7	Monocyte percentage of white cells;
CESC	cis	rs3617	0.652	rs60332615	chr3:52867595	C/A	cg07507251	chr3:52567010	NT5DC2	-0.32	-5.4	-0.31	1.5e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
CESC	cis	rs9660992	0.762	rs1172129	chr1:205244972	T/A	cg21643547	chr1:205240462	TMCC2	-0.46	-6.73	-0.38	1.05e-10	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs6933660	0.745	rs6557138	chr6:151732017	C/T	cg14262678	chr6:151773367	RMND1;C6orf211	0.66	9.32	0.5	4.58e-18	Menarche (age at onset);
CESC	cis	rs7666738	0.830	rs7663438	chr4:99014582	C/T	cg03467027	chr4:99064603	C4orf37	0.44	5.65	0.33	4.11e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1552244	0.882	rs6443276	chr3:10008905	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.86	11.17	0.57	5.32e-24	Alzheimer's disease;
CESC	cis	rs2276314	0.857	rs28375959	chr18:33601534	T/G	cg05985134	chr18:33552581	C18orf21	0.61	7.12	0.4	1.01e-11	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs898097	0.841	rs8074284	chr17:80909967	G/A	cg05255149	chr17:80675120	FN3KRP	0.45	5.14	0.3	5.47e-7	Breast cancer;
CESC	cis	rs7116495	0.609	rs79889241	chr11:71815585	T/C	cg18441811	chr11:71824068	C11orf51	0.82	5.16	0.3	4.89e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs17666538	0.585	rs4333567	chr8:636611	C/T	cg02524346	chr8:600233	NA	0.88	5.5	0.32	8.8e-8	IgG glycosylation;
CESC	cis	rs736408	0.677	rs678	chr3:52820981	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.45	5.95	0.34	8.48e-9	Bipolar disorder;
CESC	cis	rs9596863	1.000	rs35429587	chr13:54406523	T/A	ch.13.53330881F	chr13:54432880	NA	0.66	5.25	0.31	3.08e-7	Epilepsy and lamotrigine-induced maculopapular eruptions;
CESC	cis	rs270601	0.770	rs10463891	chr5:131597392	C/T	cg11843238	chr5:131593191	PDLIM4	-0.35	-5.11	-0.3	6.14e-7	Acylcarnitine levels;
CESC	cis	rs763014	0.931	rs56048717	chr16:634867	A/G	cg09263875	chr16:632152	PIGQ	0.67	11.45	0.58	6.39e-25	Height;
CESC	cis	rs9487051	0.676	rs1608042	chr6:109595631	G/A	cg12927641	chr6:109611667	NA	-0.37	-5.5	-0.32	8.91e-8	Reticulocyte fraction of red cells;
CESC	cis	rs3825932	0.701	rs1036937	chr15:79237180	C/A	cg25744700	chr15:79237217	CTSH	0.49	6.29	0.36	1.3e-9	Type 1 diabetes;
CESC	cis	rs933688	0.938	rs1477348	chr5:90707823	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.18	14.23	0.66	1.63e-34	Smoking behavior;
CESC	trans	rs2965280	0.793	rs8106201	chr19:34836889	C/T	cg05799317	chr6:165723796	C6orf118	0.81	6.0	0.35	6.45e-9	Colorectal cancer;
CESC	cis	rs6495122	0.618	rs4886413	chr15:75262310	G/C	cg14664628	chr15:75095509	CSK	-0.53	-6.69	-0.38	1.29e-10	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00111436	chr12:121837826	RNF34	0.66	8.06	0.44	2.59e-14	Gut microbiome composition (summer);
CESC	cis	rs1577917	0.958	rs12193904	chr6:86452703	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.53	-6.89	-0.39	4.05e-11	Response to antipsychotic treatment;
CESC	cis	rs9815354	0.812	rs73079324	chr3:41864564	T/C	cg03022575	chr3:42003672	ULK4	0.46	5.29	0.31	2.57e-7	Pulse pressure;Diastolic blood pressure;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04324509	chr3:101295624	PCNP	-0.53	-7.52	-0.42	8.35e-13	Gut microbiota (bacterial taxa);
CESC	cis	rs870825	0.616	rs10022818	chr4:185619282	A/G	cg04058563	chr4:185651563	MLF1IP	0.63	7.0	0.4	2.06e-11	Blood protein levels;
CESC	cis	rs4663969	0.873	rs759174	chr2:234668245	A/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.5	-6.47	-0.37	4.82e-10	Total bilirubin levels in HIV-1 infection;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg16528022	chr14:65438707	RAB15	-0.45	-6.06	-0.35	4.6e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs4594175	0.926	rs4318127	chr14:51624897	G/C	cg23942311	chr14:51606299	NA	0.39	5.93	0.34	9.29e-9	Cancer;
CESC	cis	rs7666738	0.830	rs28769113	chr4:98950371	T/G	cg17366294	chr4:99064904	C4orf37	0.59	8.52	0.46	1.24e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3820928	0.845	rs4234065	chr2:227882006	C/T	cg11843606	chr2:227700838	RHBDD1	-0.46	-6.09	-0.35	3.87e-9	Pulmonary function;
CESC	cis	rs3020736	0.500	rs6002603	chr22:42492362	C/G	cg15557168	chr22:42548783	NA	0.45	6.18	0.35	2.46e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs919433	0.662	rs2043018	chr2:198236958	G/A	cg10820045	chr2:198174542	NA	0.41	6.03	0.35	5.34e-9	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	trans	rs561341	0.783	rs512698	chr17:30292507	G/T	cg27661571	chr11:113659931	NA	-0.83	-7.66	-0.43	3.57e-13	Hip circumference adjusted for BMI;
CESC	cis	rs7312774	0.881	rs7309260	chr12:107313254	T/A	cg16260113	chr12:107380972	MTERFD3	0.64	6.06	0.35	4.62e-9	Severe influenza A (H1N1) infection;
CESC	cis	rs4237845	0.537	rs12312955	chr12:58265223	A/G	cg02175503	chr12:58329896	NA	0.49	5.85	0.34	1.43e-8	Intelligence (multi-trait analysis);
CESC	cis	rs78707713	0.836	rs77602872	chr10:71211734	G/A	cg12610070	chr10:71211762	TSPAN15	-0.4	-6.79	-0.39	7.15e-11	Venous thromboembolism;
CESC	cis	rs4665809	0.941	rs41285975	chr2:26351144	T/C	cg08470875	chr2:26401718	FAM59B	-0.47	-5.24	-0.31	3.31e-7	Gut microbiome composition (summer);
CESC	cis	rs7647973	0.925	rs4955439	chr3:49245645	G/T	cg13072238	chr3:49761600	GMPPB	0.39	5.06	0.3	7.87e-7	Menarche (age at onset);
CESC	cis	rs10924309	0.889	rs10802246	chr1:245858493	T/G	cg00036263	chr1:245852353	KIF26B	-0.42	-5.29	-0.31	2.54e-7	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
CESC	cis	rs9733	0.565	rs11804276	chr1:150685761	T/A	cg18016565	chr1:150552671	MCL1	0.35	5.36	0.31	1.86e-7	Tonsillectomy;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg21168982	chr1:28559030	DNAJC8	-0.44	-6.01	-0.35	6.07e-9	Asthma;
CESC	cis	rs9733	0.596	rs6587518	chr1:150661787	T/C	cg04414720	chr1:150670196	GOLPH3L	0.63	8.98	0.48	5.09e-17	Tonsillectomy;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg07611812	chr8:53627203	RB1CC1	-0.45	-6.16	-0.35	2.71e-9	Gambling;
CESC	trans	rs4824093	0.610	rs12106611	chr22:50242686	G/A	cg09872104	chr7:134855509	C7orf49	-0.95	-6.67	-0.38	1.52e-10	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs3820068	0.581	rs16851851	chr1:15929628	C/G	cg17385448	chr1:15911702	AGMAT	0.41	6.69	0.38	1.33e-10	Systolic blood pressure;
CESC	cis	rs62064224	0.714	rs11653974	chr17:30635002	T/C	cg18200150	chr17:30822561	MYO1D	0.4	5.42	0.32	1.31e-7	Schizophrenia;
CESC	cis	rs5758659	0.652	rs133322	chr22:42405659	A/G	cg04733989	chr22:42467013	NAGA	0.47	6.36	0.36	8.68e-10	Cognitive function;
CESC	cis	rs2249625	0.844	rs1830339	chr6:72877600	G/A	cg18830697	chr6:72922368	RIMS1	-0.39	-5.53	-0.32	7.7e-8	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CESC	cis	rs1559088	0.739	rs9304845	chr19:33592794	A/G	cg27124370	chr19:33622961	WDR88	0.45	5.97	0.34	7.78e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs9733	0.566	rs72702554	chr1:150678234	A/G	cg18016565	chr1:150552671	MCL1	0.34	5.33	0.31	2.07e-7	Tonsillectomy;
CESC	cis	rs11153306	0.818	rs7764009	chr6:111944596	G/T	cg22127309	chr6:111907043	TRAF3IP2	0.4	6.09	0.35	3.87e-9	Tonsillectomy;
CESC	cis	rs73206853	0.563	rs16940950	chr12:111136459	A/G	cg12870014	chr12:110450643	ANKRD13A	0.72	6.19	0.36	2.27e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs965469	1.000	rs6051806	chr20:3350319	C/T	cg25506879	chr20:3388711	C20orf194	-0.58	-6.17	-0.35	2.6e-9	IFN-related cytopenia;
CESC	cis	rs2115536	1.000	rs2903105	chr15:80189523	C/G	cg00225070	chr15:80189496	MTHFS	0.61	8.58	0.47	7.87e-16	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CESC	cis	rs9910055	0.529	rs400460	chr17:42182770	A/G	cg13607699	chr17:42295918	UBTF	-0.43	-5.58	-0.32	5.8e-8	Total body bone mineral density;
CESC	cis	rs7582720	1.000	rs72934751	chr2:203747522	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.39	0.41	1.96e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs34172651	0.687	rs8044992	chr16:24811207	T/C	cg06028605	chr16:24865363	SLC5A11	0.45	6.94	0.39	3.01e-11	Intelligence (multi-trait analysis);
CESC	cis	rs10851478	0.872	rs34246470	chr15:49796697	C/T	cg08060515	chr15:49448048	GALK2;COPS2	0.42	5.19	0.3	4.12e-7	Oral cavity cancer;
CESC	cis	rs9457247	0.765	rs9457251	chr6:167426707	T/C	cg23791538	chr6:167370224	RNASET2	-0.53	-7.32	-0.41	3.03e-12	Crohn's disease;
CESC	cis	rs1008375	1.000	rs10805357	chr4:17652352	G/A	cg16339924	chr4:17578868	LAP3	0.56	7.02	0.4	1.9e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs7666738	0.830	rs58367603	chr4:99015350	T/C	cg03676636	chr4:99064102	C4orf37	0.33	5.16	0.3	4.86e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10504073	0.647	rs1511359	chr8:50006448	T/A	cg00325661	chr8:49890786	NA	0.56	8.34	0.46	4.04e-15	Blood metabolite ratios;
CESC	cis	rs1784581	0.588	rs9346893	chr6:162417511	C/G	cg17173639	chr6:162384350	PARK2	0.57	8.72	0.47	3.12e-16	Itch intensity from mosquito bite;
CESC	cis	rs116095464	0.558	rs10057492	chr5:239503	T/C	cg10591111	chr5:226296	SDHA	-0.52	-6.32	-0.36	1.1e-9	Breast cancer;
CESC	cis	rs96067	0.711	rs272811	chr1:36634414	G/A	cg24686825	chr1:36642396	MAP7D1	-0.64	-8.17	-0.45	1.26e-14	Corneal structure;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09579959	chr1:228327934	GUK1	0.51	6.04	0.35	5.28e-9	Gut microbiome composition (summer);
CESC	cis	rs2072732	0.861	rs72856440	chr1:2956582	A/G	cg15211996	chr1:2936768	ACTRT2	0.33	5.91	0.34	1.07e-8	Plateletcrit;
CESC	cis	rs4704187	0.687	rs4235683	chr5:74415088	T/C	cg03227963	chr5:74354835	NA	0.31	5.7	0.33	3.22e-8	Response to amphetamines;
CESC	cis	rs7666738	0.606	rs7663216	chr4:99088385	A/C	cg24818145	chr4:99064322	C4orf37	0.4	5.24	0.31	3.27e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10504229	1.000	rs3814486	chr8:58191226	A/T	cg22535103	chr8:58192502	C8orf71	-1.05	-13.08	-0.63	1.71e-30	Developmental language disorder (linguistic errors);
CESC	cis	rs4642101	0.618	rs9877079	chr3:12821287	A/G	cg05775895	chr3:12838266	CAND2	0.41	6.33	0.36	1.04e-9	QRS complex (12-leadsum);
CESC	cis	rs17253792	0.822	rs11546	chr14:56146357	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.78	5.66	0.33	4e-8	Putamen volume;
CESC	cis	rs4423214	0.840	rs1792226	chr11:71176574	C/T	cg05163923	chr11:71159392	DHCR7	-0.65	-7.55	-0.42	6.91e-13	Vitamin D levels;
CESC	cis	rs1983170	0.736	rs13447479	chr1:91970464	T/G	cg02896835	chr1:92012615	NA	0.56	5.95	0.34	8.39e-9	Eosinophil percentage of white cells;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg25620125	chr11:61106775	DAK	0.47	6.16	0.35	2.66e-9	Fibrinogen levels;
CESC	cis	rs7580658	0.724	rs7568261	chr2:128117324	C/T	cg10021288	chr2:128175891	PROC	-0.37	-6.02	-0.35	5.86e-9	Protein C levels;
CESC	cis	rs4689388	0.679	rs1046316	chr4:6304087	A/G	cg00701064	chr4:6280414	WFS1	0.6	8.87	0.48	1.11e-16	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs854765	0.583	rs8070128	chr17:17804725	C/T	cg09796270	chr17:17721594	SREBF1	-0.46	-6.39	-0.37	7.6e-10	Total body bone mineral density;
CESC	trans	rs453301	0.571	rs330054	chr8:9088291	G/A	cg15556689	chr8:8085844	FLJ10661	-0.52	-6.57	-0.37	2.61e-10	Joint mobility (Beighton score);
CESC	trans	rs1728785	0.901	rs1103286	chr16:68578625	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.61	7.49	0.42	1.04e-12	Ulcerative colitis;
CESC	cis	rs12142240	0.698	rs12385697	chr1:46818898	T/C	cg10495392	chr1:46806563	NSUN4	0.57	6.27	0.36	1.47e-9	Menopause (age at onset);
CESC	cis	rs1153858	1.000	rs2056493	chr15:45648272	A/G	cg14582100	chr15:45693742	SPATA5L1	0.4	6.03	0.35	5.43e-9	Homoarginine levels;
CESC	cis	rs35110281	0.774	rs1378080	chr21:45011315	T/A	cg01579765	chr21:45077557	HSF2BP	-0.56	-9.34	-0.5	4.09e-18	Mean corpuscular volume;
CESC	cis	rs7584330	0.738	rs13398506	chr2:238374824	A/G	cg14458575	chr2:238380390	NA	0.62	8.3	0.45	5.37e-15	Prostate cancer;
CESC	cis	rs2070677	0.935	rs12261048	chr10:135407923	A/G	cg20169779	chr10:135381914	SYCE1	-0.77	-10.24	-0.53	5.89e-21	Gout;
CESC	cis	rs597539	0.652	rs579136	chr11:68637476	C/G	cg04772025	chr11:68637568	NA	0.55	6.49	0.37	4.17e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs10208940	0.920	rs7571506	chr2:68836317	C/A	cg12452813	chr2:68675892	NA	0.51	5.12	0.3	5.95e-7	Urate levels in lean individuals;
CESC	cis	rs1552244	0.882	rs13066757	chr3:10045030	C/A	cg00166722	chr3:10149974	C3orf24	0.48	5.95	0.34	8.39e-9	Alzheimer's disease;
CESC	cis	rs910316	0.687	rs175059	chr14:75490667	T/C	cg15467112	chr14:75489610	MLH3	-0.34	-5.26	-0.31	3.02e-7	Height;
CESC	cis	rs17711722	0.503	rs453835	chr7:65511159	T/A	cg18876405	chr7:65276391	NA	-0.53	-6.94	-0.39	2.97e-11	Calcium levels;
CESC	cis	rs4906332	1.000	rs4906327	chr14:103929039	C/T	cg09975044	chr14:104007538	NA	0.47	6.45	0.37	5.25e-10	Coronary artery disease;
CESC	cis	rs875971	0.642	rs35526611	chr7:66094008	C/T	cg25985355	chr7:65971099	NA	0.31	5.08	0.3	7e-7	Aortic root size;
CESC	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg06873352	chr17:61820015	STRADA	0.71	12.61	0.61	6.99e-29	Prudent dietary pattern;
CESC	cis	rs6860806	0.661	rs334902	chr5:131586559	C/G	cg24060327	chr5:131705240	SLC22A5	-0.4	-5.04	-0.3	8.52e-7	Breast cancer;
CESC	cis	rs7666738	0.830	rs10009943	chr4:99021475	G/A	cg03467027	chr4:99064603	C4orf37	0.46	5.81	0.34	1.8e-8	Colonoscopy-negative controls vs population controls;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg05380570	chr1:17866686	ARHGEF10L	-0.43	-6.2	-0.36	2.21e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs11166927	0.524	rs2035087	chr8:140831320	A/G	cg16909799	chr8:140841666	TRAPPC9	-0.62	-9.71	-0.51	2.79e-19	Pediatric non-alcoholic fatty liver disease activity score;
CESC	cis	rs7264396	0.790	rs2425115	chr20:34322418	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.85	-11.75	-0.59	5.91e-26	Total cholesterol levels;
CESC	cis	rs896854	1.000	rs13255935	chr8:95965685	C/A	cg16049864	chr8:95962084	TP53INP1	-0.71	-13.02	-0.62	2.84e-30	Type 2 diabetes;
CESC	cis	rs9790314	0.747	rs4616689	chr3:160856269	A/G	cg04691961	chr3:161091175	C3orf57	-0.4	-5.39	-0.31	1.52e-7	Morning vs. evening chronotype;
CESC	cis	rs1568889	0.838	rs1525717	chr11:28081205	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.8	13.5	0.64	5.83e-32	Bipolar disorder;
CESC	cis	rs2295499	0.643	rs59609182	chr4:2721530	C/T	cg08330972	chr4:2403930	ZFYVE28	-0.31	-5.18	-0.3	4.35e-7	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
CESC	cis	rs7584330	0.554	rs77956735	chr2:238399130	C/T	cg14458575	chr2:238380390	NA	0.66	5.47	0.32	1.06e-7	Prostate cancer;
CESC	cis	rs10751667	0.666	rs11246357	chr11:963980	A/C	cg06064525	chr11:970664	AP2A2	-0.47	-9.24	-0.49	8.25e-18	Alzheimer's disease (late onset);
CESC	cis	rs7927771	1.000	rs35624992	chr11:47615798	G/C	cg20307385	chr11:47447363	PSMC3	-0.53	-6.32	-0.36	1.07e-9	Subjective well-being;
CESC	cis	rs853679	0.517	rs9283884	chr6:28135660	C/G	cg26335602	chr6:28129616	ZNF389	-0.55	-7.15	-0.4	8.52e-12	Depression;
CESC	cis	rs5753618	0.504	rs8142121	chr22:31882785	G/A	cg00478049	chr22:31556069	RNF185	-0.46	-5.28	-0.31	2.66e-7	Colorectal cancer;
CESC	cis	rs2721195	0.967	rs748193	chr8:145682115	C/T	cg17328964	chr8:145687451	CYHR1	-0.57	-7.93	-0.44	6.05e-14	Age at first birth;
CESC	cis	rs735539	1.000	rs9506537	chr13:21280410	T/C	cg04906043	chr13:21280425	IL17D	0.39	6.0	0.35	6.3e-9	Dental caries;
CESC	cis	rs7615952	0.599	rs1044215	chr3:125725559	C/G	cg04553112	chr3:125709451	NA	-0.47	-5.34	-0.31	1.97e-7	Blood pressure (smoking interaction);
CESC	cis	rs13191362	1.000	rs35818596	chr6:163001874	C/G	cg14584255	chr6:163149320	PACRG;PARK2	0.5	5.17	0.3	4.64e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs12478296	0.786	rs28802397	chr2:243049730	G/A	cg06360820	chr2:242988706	NA	-0.66	-7.55	-0.42	7.07e-13	Obesity-related traits;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg04318602	chr14:53162623	ERO1L	0.47	6.09	0.35	3.98e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs6952808	0.531	rs4721441	chr7:2184060	A/G	cg21782813	chr7:2030301	MAD1L1	0.45	6.6	0.38	2.29e-10	Bipolar disorder and schizophrenia;
CESC	cis	rs1005277	0.505	rs200935	chr10:38132810	T/A	cg25427524	chr10:38739819	LOC399744	-0.68	-10.04	-0.52	2.67e-20	Extrinsic epigenetic age acceleration;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg17703834	chr19:13228980	TRMT1;NACC1	0.4	6.01	0.35	6.11e-9	Systemic lupus erythematosus;
CESC	cis	rs9487051	0.621	rs9374076	chr6:109597826	G/T	cg01475377	chr6:109611718	NA	-0.39	-5.04	-0.3	8.81e-7	Reticulocyte fraction of red cells;
CESC	cis	rs10905065	0.965	rs10752110	chr10:5837038	T/C	cg11519256	chr10:5708881	ASB13	0.44	6.11	0.35	3.51e-9	Menopause (age at onset);
CESC	cis	rs8070624	0.543	rs8068175	chr17:17874486	C/T	cg09796270	chr17:17721594	SREBF1	0.43	5.68	0.33	3.48e-8	Total body bone mineral density;
CESC	cis	rs1707322	0.752	rs28507722	chr1:46206540	A/G	cg03146154	chr1:46216737	IPP	0.82	11.53	0.58	3.39e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs6973256	0.637	rs12539993	chr7:133418799	C/T	cg10665199	chr7:133106180	EXOC4	0.44	6.18	0.35	2.47e-9	Intelligence (multi-trait analysis);
CESC	cis	rs34375054	0.660	rs57491100	chr12:125593010	C/T	cg25124228	chr12:125621409	AACS	-0.56	-6.63	-0.38	1.84e-10	Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs1728785	1.000	rs1170443	chr16:68573295	G/C	cg02972257	chr16:68554789	NA	-0.55	-6.34	-0.36	9.7e-10	Ulcerative colitis;
CESC	cis	rs7474896	0.526	rs1742235	chr10:38052256	T/C	cg25427524	chr10:38739819	LOC399744	-0.48	-5.26	-0.31	3.05e-7	Obesity (extreme);
CESC	cis	rs875971	0.862	rs4149461	chr7:65744732	T/C	cg18876405	chr7:65276391	NA	-0.49	-6.83	-0.39	5.72e-11	Aortic root size;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg11530914	chr16:67281528	FHOD1;SLC9A5	-0.44	-6.55	-0.37	3.06e-10	Gambling;
CESC	trans	rs2900976	0.773	rs4638819	chr2:71995202	A/T	cg01646268	chr11:14367071	RRAS2	-0.48	-6.31	-0.36	1.19e-9	Protein quantitative trait loci;
CESC	cis	rs6964587	1.000	rs10264666	chr7:91578639	G/A	cg17063962	chr7:91808500	NA	-0.54	-7.12	-0.4	9.86e-12	Breast cancer;
CESC	cis	rs1538970	0.816	rs34673142	chr1:45985561	G/A	cg03146154	chr1:46216737	IPP	0.47	5.43	0.32	1.3e-7	Platelet count;
CESC	cis	rs9487051	0.714	rs9487053	chr6:109619697	T/C	cg01475377	chr6:109611718	NA	-0.43	-6.68	-0.38	1.37e-10	Reticulocyte fraction of red cells;
CESC	cis	rs7617773	0.817	rs13072018	chr3:48320332	G/A	cg11946769	chr3:48343235	NME6	0.87	11.61	0.58	1.76e-25	Coronary artery disease;
CESC	cis	rs7107174	1.000	rs7127187	chr11:77995188	G/A	cg02023728	chr11:77925099	USP35	0.42	5.8	0.34	1.89e-8	Testicular germ cell tumor;
CESC	cis	rs1862618	0.671	rs2591968	chr5:56233541	A/G	cg24549020	chr5:56110836	MAP3K1	0.47	5.86	0.34	1.35e-8	Initial pursuit acceleration;
CESC	cis	rs5769765	1.000	rs768618	chr22:50286827	G/A	cg26441486	chr22:50317300	CRELD2	0.38	5.37	0.31	1.77e-7	Schizophrenia;
CESC	cis	rs6952808	0.609	rs6944877	chr7:1952582	T/G	cg04267008	chr7:1944627	MAD1L1	-0.59	-7.39	-0.41	1.96e-12	Bipolar disorder and schizophrenia;
CESC	cis	rs16910800	0.731	rs56768542	chr11:23191946	A/G	cg20040320	chr11:23191996	NA	-0.67	-6.66	-0.38	1.53e-10	Cancer;
CESC	cis	rs8177179	0.565	rs4355280	chr3:133468425	A/G	cg24879335	chr3:133465180	TF	0.34	5.84	0.34	1.49e-8	Iron status biomarkers (transferrin levels);
CESC	cis	rs5750830	0.649	rs5750813	chr22:39795228	G/C	cg24399712	chr22:39784796	NA	-0.81	-11.13	-0.56	7.1e-24	Intelligence (multi-trait analysis);
CESC	trans	rs2115172	0.836	rs4835799	chr5:122762229	A/G	cg00810945	chr16:21964237	UQCRC2	0.46	6.21	0.36	2.08e-9	Weight;
CESC	cis	rs738322	0.775	rs13056506	chr22:38580917	G/T	cg17652424	chr22:38574118	PLA2G6	0.3	5.15	0.3	5.07e-7	Cutaneous nevi;
CESC	cis	rs2645694	0.626	rs2703118	chr4:77823672	A/G	cg10057126	chr4:77819792	ANKRD56	0.58	8.4	0.46	2.79e-15	Emphysema distribution in smoking;
CESC	cis	rs9611565	0.592	rs4822046	chr22:41987543	G/A	cg06481639	chr22:41940642	POLR3H	-0.63	-6.28	-0.36	1.39e-9	Vitiligo;
CESC	cis	rs12497850	0.931	rs6446196	chr3:49004723	A/G	cg07636037	chr3:49044803	WDR6	1.08	19.57	0.77	2.17e-53	Parkinson's disease;
CESC	cis	rs12780046	0.536	rs4919291	chr10:101062614	G/A	cg27143070	chr10:101087766	CNNM1	0.36	5.37	0.31	1.72e-7	Non-glioblastoma glioma;
CESC	cis	rs2836974	0.644	rs719230	chr21:40676307	C/T	cg11890956	chr21:40555474	PSMG1	-0.95	-15.39	-0.69	1.26e-38	Cognitive function;
CESC	cis	rs1707322	1.000	rs4298677	chr1:46306619	G/A	cg05343316	chr1:45956843	TESK2	0.43	5.22	0.31	3.55e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs11758351	0.660	rs16891455	chr6:26230485	G/A	cg23601095	chr6:26197514	HIST1H3D	0.91	9.96	0.52	4.64e-20	Gout;Renal underexcretion gout;
CESC	cis	rs6430585	0.528	rs7573555	chr2:136694905	C/T	cg07169764	chr2:136633963	MCM6	-1.27	-20.1	-0.78	3.18e-55	Corneal structure;
CESC	cis	rs5753618	0.583	rs71324184	chr22:31752061	C/G	cg02404636	chr22:31891804	SFI1	0.44	6.48	0.37	4.57e-10	Colorectal cancer;
CESC	cis	rs7107174	1.000	rs10899485	chr11:78072383	C/T	cg02023728	chr11:77925099	USP35	-0.38	-5.47	-0.32	1.05e-7	Testicular germ cell tumor;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16257685	chr13:76124267	UCHL3	-0.54	-6.01	-0.35	5.96e-9	Gut microbiome composition (summer);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg07352798	chr5:141488591	NDFIP1	-0.42	-6.22	-0.36	1.98e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs919433	0.783	rs788011	chr2:198230771	A/G	cg10820045	chr2:198174542	NA	0.41	5.93	0.34	9.6e-9	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs6696846	0.740	rs11240369	chr1:205115099	G/A	cg00857998	chr1:205179979	DSTYK	0.57	7.45	0.42	1.28e-12	Red blood cell count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11342415	chr10:1034284	GTPBP4	0.58	6.33	0.36	1.07e-9	Gut microbiome composition (summer);
CESC	cis	rs4253772	0.591	rs9615348	chr22:46729338	C/G	cg18190219	chr22:46762943	CELSR1	-0.64	-5.89	-0.34	1.18e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs10540	1.000	rs35811812	chr11:498442	G/A	cg03576123	chr11:487126	PTDSS2	-1.04	-10.88	-0.56	4.82e-23	Body mass index;
CESC	cis	rs9549260	0.604	rs56302456	chr13:41295887	G/T	cg21288729	chr13:41239152	FOXO1	0.61	5.53	0.32	7.72e-8	Red blood cell count;
CESC	cis	rs4728302	0.534	rs6976069	chr7:133152898	T/C	cg10665199	chr7:133106180	EXOC4	0.52	7.21	0.4	5.91e-12	Intelligence;Intelligence (multi-trait analysis);
CESC	cis	rs9733	0.628	rs7540874	chr1:150702663	A/C	cg18016565	chr1:150552671	MCL1	0.34	5.28	0.31	2.67e-7	Tonsillectomy;
CESC	cis	rs1400745	0.756	rs799683	chr14:35349236	G/A	cg16230307	chr14:35515116	FAM177A1	0.44	5.24	0.31	3.35e-7	Monocyte count;
CESC	cis	rs4713675	0.565	rs4713670	chr6:33699882	C/T	cg14003231	chr6:33640908	ITPR3	-0.29	-5.1	-0.3	6.63e-7	Plateletcrit;
CESC	cis	rs2637266	0.756	rs2245335	chr10:78553265	T/C	cg18941641	chr10:78392320	NA	0.41	7.93	0.44	6.12e-14	Pulmonary function;
CESC	cis	rs7191439	0.858	rs2290902	chr16:88782676	A/G	cg27087555	chr16:88793112	FAM38A	-1.17	-9.73	-0.51	2.47e-19	Plateletcrit;
CESC	cis	rs4819052	0.788	rs4819051	chr21:46693128	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.92	13.78	0.65	6.16e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs12497850	1.000	rs12497850	chr3:48748989	G/T	cg06212747	chr3:49208901	KLHDC8B	0.61	8.07	0.44	2.45e-14	Parkinson's disease;
CESC	cis	rs3126085	0.935	rs2184951	chr1:152273168	T/G	cg03465714	chr1:152285911	FLG	0.51	5.87	0.34	1.32e-8	Atopic dermatitis;
CESC	cis	rs752010	0.695	rs11210509	chr1:42109311	A/G	cg06885757	chr1:42089581	HIVEP3	0.45	6.9	0.39	3.77e-11	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs9611565	0.512	rs132767	chr22:42009520	C/T	cg03806693	chr22:41940476	POLR3H	-0.97	-11.16	-0.57	6.04e-24	Vitiligo;
CESC	cis	rs35110281	0.627	rs1836855	chr21:44965414	C/G	cg01579765	chr21:45077557	HSF2BP	-0.53	-8.95	-0.48	6.49e-17	Mean corpuscular volume;
CESC	cis	rs208520	0.690	rs12201219	chr6:66748862	A/T	cg07460842	chr6:66804631	NA	0.96	12.71	0.62	3.3e-29	Exhaled nitric oxide output;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg02952711	chr10:134145586	LRRC27	-0.52	-6.9	-0.39	3.88e-11	Asthma;
CESC	cis	rs1729951	0.575	rs12494558	chr3:136678781	C/G	cg25687071	chr3:136751404	NA	0.39	5.22	0.31	3.66e-7	Neuroticism;
CESC	cis	rs7255436	0.965	rs12981318	chr19:8451430	G/A	cg10174797	chr19:8464628	RAB11B	0.39	5.57	0.32	6.11e-8	HDL cholesterol;
CESC	cis	rs9443645	0.810	rs9443637	chr6:79714708	C/T	cg05283184	chr6:79620031	NA	-0.39	-6.2	-0.36	2.16e-9	Intelligence (multi-trait analysis);
CESC	cis	rs2932538	0.922	rs17438324	chr1:113100573	C/T	cg22162597	chr1:113214053	CAPZA1	0.57	7.11	0.4	1.1e-11	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CESC	cis	rs4835473	0.932	rs4835013	chr4:144669638	C/T	cg25736465	chr4:144833511	NA	0.37	5.74	0.33	2.59e-8	Immature fraction of reticulocytes;
CESC	cis	rs10197940	0.638	rs2288193	chr2:152348842	T/A	cg06191203	chr2:152266755	RIF1	-0.46	-5.21	-0.3	3.86e-7	Lung cancer;
CESC	cis	rs9322193	0.962	rs9322223	chr6:150122645	G/A	cg13206674	chr6:150067644	NUP43	0.39	5.58	0.32	5.93e-8	Lung cancer;
CESC	cis	rs8111998	0.826	rs6511364	chr19:22765808	C/T	cg19914732	chr19:22715077	NA	-0.37	-5.18	-0.3	4.45e-7	Corneal structure;
CESC	cis	rs9311474	0.713	rs352169	chr3:52236762	C/T	cg05315796	chr3:52349193	DNAH1	0.3	5.34	0.31	2.01e-7	Electroencephalogram traits;
CESC	cis	rs9309473	1.000	rs11899740	chr2:73631212	G/A	cg20560298	chr2:73613845	ALMS1	-0.54	-7.0	-0.39	2.11e-11	Metabolite levels;
CESC	cis	rs10504229	0.683	rs11787247	chr8:58131528	G/T	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs9309473	0.687	rs11126399	chr2:73613341	G/A	cg20560298	chr2:73613845	ALMS1	-0.47	-6.2	-0.36	2.2e-9	Metabolite levels;
CESC	cis	rs6831352	0.918	rs7669636	chr4:100059312	G/A	cg12011299	chr4:100065546	ADH4	-0.6	-6.62	-0.38	2.04e-10	Alcohol dependence;
CESC	cis	rs748404	0.697	rs513970	chr15:43579566	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.53	8.36	0.46	3.69e-15	Lung cancer;
CESC	cis	rs4481887	1.000	rs7525344	chr1:248467565	C/T	cg00666640	chr1:248458726	OR2T12	-0.38	-6.62	-0.38	2.01e-10	Common traits (Other);
CESC	cis	rs7552404	0.691	rs61770550	chr1:76366966	C/T	cg03433033	chr1:76189801	ACADM	0.57	5.65	0.33	4.21e-8	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs11690935	1.000	rs3795999	chr2:172544483	A/G	cg13550731	chr2:172543902	DYNC1I2	0.94	14.58	0.67	9.17e-36	Schizophrenia;
CESC	cis	rs9322193	0.923	rs62441279	chr6:150042330	G/A	cg13206674	chr6:150067644	NUP43	0.45	6.53	0.37	3.37e-10	Lung cancer;
CESC	cis	rs3754214	0.836	rs12023277	chr1:150466737	A/G	cg09579323	chr1:150459698	TARS2	0.44	5.5	0.32	9e-8	Cerebrospinal fluid biomarker levels;
CESC	cis	rs1552244	1.000	rs6793396	chr3:10110927	T/C	cg08888203	chr3:10149979	C3orf24	0.53	6.72	0.38	1.11e-10	Alzheimer's disease;
CESC	cis	rs3806843	1.000	rs10057161	chr5:140156831	C/T	cg26395211	chr5:140044315	WDR55	-0.42	-5.35	-0.31	1.92e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs40363	0.723	rs4785936	chr16:3535116	A/G	cg00484396	chr16:3507460	NAT15	-0.58	-6.56	-0.37	2.88e-10	Tuberculosis;
CESC	cis	rs1577917	0.876	rs1582127	chr6:86697204	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.43	-5.59	-0.33	5.5e-8	Response to antipsychotic treatment;
CESC	cis	rs17688076	0.511	rs2418738	chr16:68122604	G/C	cg26727032	chr16:67993705	SLC12A4	-0.52	-6.3	-0.36	1.24e-9	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);
CESC	cis	rs892961	0.720	rs103458	chr17:75416031	A/G	cg05865280	chr17:75406074	SEPT9	0.59	11.38	0.57	1.04e-24	Airflow obstruction;
CESC	cis	rs965469	1.000	rs6037562	chr20:3326141	A/C	cg25506879	chr20:3388711	C20orf194	-0.54	-5.78	-0.33	2.14e-8	IFN-related cytopenia;
CESC	cis	rs1348850	0.914	rs1453370	chr2:178327727	C/T	cg23306229	chr2:178417860	TTC30B	0.65	8.0	0.44	4e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg06013127	chr17:27903940	GIT1	0.49	6.35	0.36	9.1e-10	Fibrinogen levels;
CESC	cis	rs769267	0.930	rs4808967	chr19:19640524	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.52	6.55	0.37	3.02e-10	Tonsillectomy;
CESC	cis	rs7772486	0.597	rs6570732	chr6:146245151	G/A	cg05347473	chr6:146136440	FBXO30	-0.76	-9.65	-0.51	4.49e-19	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6446731	0.517	rs2071667	chr4:3269926	C/A	cg08886695	chr4:3369023	RGS12	0.39	5.67	0.33	3.67e-8	Mean platelet volume;
CESC	cis	rs17376456	1.000	rs17376456	chr5:93557702	C/T	cg25358565	chr5:93447407	FAM172A	-1.18	-10.75	-0.55	1.34e-22	Diabetic retinopathy;
CESC	cis	rs7605827	0.930	rs4668923	chr2:15681227	G/A	cg19274914	chr2:15703543	NA	0.37	6.7	0.38	1.22e-10	Educational attainment (years of education);
CESC	cis	rs6866344	0.697	rs62392823	chr5:178126968	T/C	cg10224037	chr5:178157518	ZNF354A	0.67	7.38	0.41	2.09e-12	Neutrophil percentage of white cells;
CESC	cis	rs1552244	0.572	rs3894323	chr3:10168967	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.68	-7.65	-0.43	3.85e-13	Alzheimer's disease;
CESC	cis	rs7666738	0.830	rs10022389	chr4:99022229	T/C	cg03467027	chr4:99064603	C4orf37	0.46	5.81	0.34	1.8e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs17376456	0.877	rs10055741	chr5:93297187	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.61	5.34	0.31	1.98e-7	Diabetic retinopathy;
CESC	cis	rs734999	0.566	rs6664969	chr1:2534978	G/A	cg18854424	chr1:2615690	NA	0.27	5.21	0.3	3.79e-7	Ulcerative colitis;
CESC	cis	rs4820539	1.000	rs4820539	chr22:23477970	C/T	cg14186256	chr22:23484241	RTDR1	-0.78	-13.93	-0.65	1.85e-33	Bone mineral density;
CESC	cis	rs12497850	1.000	rs1352420	chr3:48757291	A/G	cg02487422	chr3:49467188	NICN1	0.43	5.53	0.32	7.81e-8	Parkinson's disease;
CESC	cis	rs9467711	0.606	rs66823108	chr6:26377939	G/A	cg12826209	chr6:26865740	GUSBL1	0.64	5.21	0.3	3.77e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.5	-6.31	-0.36	1.18e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2204008	0.805	rs7296063	chr12:37964775	T/G	cg13010199	chr12:38710504	ALG10B	0.52	6.55	0.37	3.01e-10	Bladder cancer;
CESC	cis	rs60871478	0.898	rs62432897	chr7:825429	A/G	cg15782153	chr7:917662	C7orf20	-0.47	-5.15	-0.3	5.12e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs7818688	0.697	rs78088250	chr8:95972718	G/A	cg16049864	chr8:95962084	TP53INP1	0.59	5.82	0.34	1.68e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs4660261	0.526	rs2040950	chr1:44315113	G/C	cg13606994	chr1:44402422	ARTN	-0.35	-5.16	-0.3	4.91e-7	Intelligence (multi-trait analysis);
CESC	cis	rs736408	0.505	rs2083180	chr3:52668119	G/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.61	8.81	0.48	1.71e-16	Bipolar disorder;
CESC	cis	rs35306767	0.904	rs10904584	chr10:983747	A/T	cg20503657	chr10:835505	NA	0.65	7.18	0.4	6.99e-12	Eosinophil percentage of granulocytes;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg10692753	chr16:23464628	COG7	-0.42	-6.03	-0.35	5.55e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs7296418	0.961	rs11608811	chr12:123529056	A/G	cg00376283	chr12:123451042	ABCB9	0.74	10.79	0.55	9.42e-23	Platelet count;
CESC	cis	rs425277	0.628	rs3128340	chr1:2047496	C/G	cg24578937	chr1:2090814	PRKCZ	-0.34	-5.73	-0.33	2.66e-8	Height;
CESC	cis	rs57221529	0.766	rs17497684	chr5:558307	T/C	cg16447950	chr5:562315	NA	-0.7	-7.76	-0.43	1.9e-13	Lung disease severity in cystic fibrosis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03992926	chr1:186344761	TPR;C1orf27;MIR548F1	0.59	6.92	0.39	3.33e-11	Gut microbiome composition (summer);
CESC	cis	rs35995292	0.534	rs28460817	chr7:38921917	T/C	cg19327137	chr7:38886074	VPS41	0.65	10.74	0.55	1.38e-22	Subjective well-being (multi-trait analysis);
CESC	cis	rs593982	0.719	rs555903	chr11:65466911	G/A	cg08755490	chr11:65554678	OVOL1	-1.16	-10.39	-0.54	2.03e-21	Atopic dermatitis;
CESC	cis	rs1395	0.778	rs60631624	chr2:27497815	T/G	cg22903471	chr2:27725779	GCKR	-0.5	-6.11	-0.35	3.47e-9	Blood metabolite levels;
CESC	cis	rs6460942	0.915	rs80345607	chr7:12442249	T/C	cg20607287	chr7:12443886	VWDE	-0.77	-9.04	-0.49	3.38e-17	Coronary artery disease;
CESC	cis	rs9486719	0.948	rs2092095	chr6:96870864	T/G	cg18709589	chr6:96969512	KIAA0776	0.53	5.81	0.34	1.75e-8	Migraine;Coronary artery disease;
CESC	cis	rs7552404	0.731	rs6699682	chr1:76340123	A/G	cg22875332	chr1:76189707	ACADM	-0.6	-6.39	-0.37	7.37e-10	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs3008870	1.000	rs2815370	chr1:67503727	A/G	cg02640540	chr1:67518911	SLC35D1	-0.53	-5.73	-0.33	2.7e-8	Lymphocyte percentage of white cells;
CESC	trans	rs9325144	0.647	rs12830095	chr12:38864199	C/T	cg23762105	chr12:34175262	ALG10	0.46	6.04	0.35	5.3e-9	Morning vs. evening chronotype;
CESC	cis	rs8017423	0.967	rs11627528	chr14:90719697	C/A	cg14092571	chr14:90743983	NA	0.57	8.73	0.47	2.9e-16	Mortality in heart failure;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17400366	chr19:10420311	ZGLP1	-0.54	-6.66	-0.38	1.53e-10	Gut microbiome composition (summer);
CESC	trans	rs4904167	0.841	rs12717596	chr14:84685302	A/C	cg06870609	chr15:89787223	FANCI	0.46	6.06	0.35	4.73e-9	Autism spectrum disorder or schizophrenia;
CESC	trans	rs7690543	0.581	rs1364982	chr4:67995472	A/G	cg05505961	chr17:66375071	ARSG	-0.51	-6.1	-0.35	3.79e-9	Glucose homeostasis traits;
CESC	cis	rs10504229	0.610	rs6987118	chr8:58147851	G/T	cg02725872	chr8:58115012	NA	-0.36	-5.79	-0.34	1.98e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs11764590	0.724	rs55789728	chr7:2107649	A/G	cg21782813	chr7:2030301	MAD1L1	-0.4	-5.16	-0.3	4.81e-7	Neuroticism;
CESC	cis	rs16921914	0.559	rs2985140	chr11:31315886	C/T	cg14844989	chr11:31128820	NA	0.38	5.3	0.31	2.42e-7	Bone mineral density (spine);
CESC	cis	rs4862750	0.872	rs6553029	chr4:187876470	G/T	cg11301795	chr4:187892539	NA	0.74	10.98	0.56	2.26e-23	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1799949	0.965	rs4239149	chr17:41328095	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	-0.47	-6.54	-0.37	3.19e-10	Menopause (age at onset);
CESC	cis	rs12477438	0.666	rs10179910	chr2:99658503	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.59	-7.87	-0.44	8.99e-14	Chronic sinus infection;
CESC	cis	rs12973672	0.812	rs28365133	chr19:35761519	A/G	cg12095397	chr19:35769544	USF2	0.49	5.83	0.34	1.59e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs7267979	1.000	rs448396	chr20:25440269	G/A	cg08601574	chr20:25228251	PYGB	0.37	5.31	0.31	2.31e-7	Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs1814175	0.645	rs1874969	chr11:49826700	G/A	cg15704280	chr7:45808275	SEPT13	-0.98	-17.89	-0.74	1.8e-47	Height;
CESC	cis	rs4972806	0.849	rs2857541	chr2:177029086	C/T	cg13092806	chr2:177043255	NA	0.46	6.87	0.39	4.45e-11	IgG glycosylation;
CESC	cis	rs4808199	0.689	rs12979148	chr19:19406869	T/C	cg03709012	chr19:19516395	GATAD2A	0.96	8.23	0.45	8.42e-15	Nonalcoholic fatty liver disease;
CESC	cis	rs7945705	0.747	rs2742480	chr11:8993130	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.41	-6.61	-0.38	2.08e-10	Hemoglobin concentration;
CESC	cis	rs7089973	0.584	rs758585	chr10:116582560	C/A	cg25233709	chr10:116636983	FAM160B1	0.36	5.82	0.34	1.65e-8	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs2243480	0.901	rs34807232	chr7:65965133	G/A	cg13147721	chr7:65941812	NA	-0.95	-8.98	-0.48	4.99e-17	Diabetic kidney disease;
CESC	cis	rs9733	0.596	rs6681990	chr1:150695929	A/G	cg09365446	chr1:150670422	GOLPH3L	0.42	5.84	0.34	1.55e-8	Tonsillectomy;
CESC	cis	rs6088590	0.561	rs6059934	chr20:33178324	G/T	cg06115741	chr20:33292138	TP53INP2	0.53	6.88	0.39	4.32e-11	Coronary artery disease;
CESC	cis	rs6499129	0.558	rs9934328	chr16:67573367	G/C	cg26727032	chr16:67993705	SLC12A4	-0.59	-7.21	-0.41	5.67e-12	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs2073300	1.000	rs2207988	chr20:23446000	C/A	cg12062639	chr20:23401060	NAPB	0.74	5.43	0.32	1.3e-7	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08478283	chr1:117076803	CD58	-0.74	-8.79	-0.48	1.96e-16	Gut microbiome composition (summer);
CESC	cis	rs501120	0.657	rs494207	chr10:44741256	G/A	cg09554077	chr10:44749378	NA	0.43	5.16	0.3	4.85e-7	Coronary artery disease;Coronary heart disease;
CESC	cis	rs6547741	1.000	rs6750943	chr2:27777904	T/G	cg27432699	chr2:27873401	GPN1	0.49	6.94	0.39	2.93e-11	Oral cavity cancer;
CESC	cis	rs17253792	0.822	rs28392709	chr14:56093685	G/A	cg01858014	chr14:56050164	KTN1	-0.85	-6.99	-0.39	2.22e-11	Putamen volume;
CESC	cis	rs2439831	0.850	rs7163245	chr15:43671294	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.92	11.23	0.57	3.34e-24	Lung cancer in ever smokers;
CESC	cis	rs6866344	0.570	rs6896799	chr5:178147014	G/C	cg03877680	chr5:178157825	ZNF354A	0.81	9.75	0.51	2.09e-19	Neutrophil percentage of white cells;
CESC	cis	rs2857078	0.627	rs1476512	chr17:42330122	C/T	cg13607699	chr17:42295918	UBTF	-0.65	-9.32	-0.5	4.77e-18	Red cell distribution width;Reticulocyte count;
CESC	cis	rs12618769	0.625	rs4850877	chr2:99112154	C/T	cg10123293	chr2:99228465	UNC50	0.39	5.13	0.3	5.6e-7	Bipolar disorder;
CESC	cis	rs875971	0.862	rs801195	chr7:66026115	A/G	cg10691866	chr7:65817282	TPST1	0.33	5.47	0.32	1.02e-7	Aortic root size;
CESC	cis	rs3733585	0.673	rs4560411	chr4:9953361	A/G	cg11266682	chr4:10021025	SLC2A9	-0.58	-11.0	-0.56	2.04e-23	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs1178968	1.000	rs2237285	chr7:72760213	C/T	cg25889504	chr7:72793014	NA	0.48	5.08	0.3	7.22e-7	Triglyceride levels;
CESC	cis	rs8103278	0.507	rs2041975	chr19:46238555	T/C	cg11657440	chr19:46296263	DMWD	0.78	11.83	0.59	3.36e-26	Coronary artery disease;
CESC	cis	rs6495122	0.532	rs2470890	chr15:75047426	C/T	cg14664628	chr15:75095509	CSK	-0.62	-7.99	-0.44	4.12e-14	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
CESC	cis	rs2040771	0.872	rs12485084	chr22:19162326	A/G	cg02655711	chr22:19163373	SLC25A1	0.42	6.15	0.35	2.87e-9	Metabolite levels (small molecules and protein measures);
CESC	trans	rs837841	0.864	rs1660903	chr2:130046679	C/G	cg05301181	chr10:35379533	CUL2	-0.46	-6.05	-0.35	4.94e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
CESC	cis	rs28647808	1.000	rs28478220	chr9:136273312	T/C	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.9	5.73	0.33	2.75e-8	Blood protein levels;
CESC	trans	rs527616	0.793	rs675150	chr18:24339719	C/T	cg05106058	chr4:172735924	GALNTL6	0.4	6.28	0.36	1.38e-9	Breast cancer;
CESC	cis	rs5758659	0.967	rs5758670	chr22:42636687	T/C	cg15557168	chr22:42548783	NA	-0.49	-7.82	-0.43	1.28e-13	Cognitive function;
CESC	trans	rs116095464	0.558	rs73031482	chr5:227594	G/A	cg00938859	chr5:1591904	SDHAP3	0.61	6.75	0.38	9.06e-11	Breast cancer;
CESC	cis	rs3741798	1.000	rs61922049	chr12:12497395	C/T	cg08615371	chr12:12503544	MANSC1	0.79	5.65	0.33	4.22e-8	Cerebrospinal fluid biomarker levels;
CESC	cis	rs7429990	0.932	rs6770477	chr3:48019258	A/G	cg11946769	chr3:48343235	NME6	-0.44	-5.38	-0.31	1.65e-7	Educational attainment (years of education);
CESC	trans	rs35110281	0.744	rs162398	chr21:44949285	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.49	6.57	0.37	2.65e-10	Mean corpuscular volume;
CESC	cis	rs2191566	0.664	rs3810406	chr19:44556381	G/T	cg20607764	chr19:44506953	ZNF230	-0.44	-5.64	-0.33	4.34e-8	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs2997447	0.761	rs74384164	chr1:26430379	C/T	cg24596570	chr1:26146463	FAM54B;LOC646471	0.6	5.14	0.3	5.43e-7	QRS complex (12-leadsum);
CESC	cis	rs7618915	0.547	rs6768697	chr3:52703615	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	6.93	0.39	3.13e-11	Bipolar disorder;
CESC	cis	rs6433857	0.657	rs10209994	chr2:181514955	A/C	cg23363182	chr2:181467187	NA	-0.46	-6.58	-0.37	2.49e-10	Body mass index;
CESC	cis	rs9814567	1.000	rs6806417	chr3:134211446	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.41	5.76	0.33	2.3e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs8068544	0.818	rs7209012	chr17:40161323	C/T	cg18442075	chr17:40169520	DNAJC7;NKIRAS2	-0.94	-8.43	-0.46	2.27e-15	Reticulocyte fraction of red cells;Reticulocyte count;
CESC	cis	rs8077577	0.708	rs3829589	chr17:18134266	T/C	cg16794390	chr17:18148240	FLII	-0.44	-6.58	-0.37	2.46e-10	Obesity-related traits;
CESC	cis	rs4332037	0.539	rs11764780	chr7:2020904	G/C	cg23422044	chr7:1970798	MAD1L1	-0.5	-5.38	-0.31	1.61e-7	Bipolar disorder;
CESC	cis	rs35306767	0.855	rs61830932	chr10:934183	T/C	cg20503657	chr10:835505	NA	0.8	8.18	0.45	1.16e-14	Eosinophil percentage of granulocytes;
CESC	cis	rs6570726	1.000	rs455109	chr6:145872665	C/T	cg05347473	chr6:146136440	FBXO30	0.43	5.83	0.34	1.63e-8	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs17711722	0.522	rs62469933	chr7:65265639	G/A	cg06263672	chr7:65235340	NA	0.4	5.09	0.3	6.86e-7	Calcium levels;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg24951396	chr12:125473687	DHX37	-0.46	-6.28	-0.36	1.38e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs6088580	0.634	rs7271970	chr20:32987666	A/G	cg06115741	chr20:33292138	TP53INP2	-0.47	-6.08	-0.35	4.13e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs16854884	0.657	rs12107291	chr3:143739547	T/C	cg06585982	chr3:143692056	C3orf58	0.5	6.71	0.38	1.18e-10	Economic and political preferences (feminism/equality);
CESC	cis	rs17376456	0.877	rs12716456	chr5:93397557	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.62	5.36	0.31	1.8e-7	Diabetic retinopathy;
CESC	cis	rs2120019	0.935	rs34913788	chr15:75372617	A/C	cg09165964	chr15:75287851	SCAMP5	-0.67	-8.12	-0.45	1.76e-14	Blood trace element (Zn levels);
CESC	cis	rs2228479	0.850	rs11649100	chr16:89798179	A/G	cg14709524	chr16:89940631	TCF25	0.78	5.43	0.32	1.3e-7	Skin colour saturation;
CESC	cis	rs2842992	0.747	rs733319	chr6:160221475	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.75	9.12	0.49	1.99e-17	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs2108225	0.714	rs929394	chr7:107437252	C/T	cg18560240	chr7:107437656	SLC26A3	-0.52	-7.22	-0.41	5.37e-12	Ulcerative colitis;
CESC	cis	rs5758659	0.904	rs5758653	chr22:42613485	G/T	cg04733989	chr22:42467013	NAGA	0.42	5.75	0.33	2.51e-8	Cognitive function;
CESC	cis	rs9322193	0.923	rs10782318	chr6:150075273	A/G	cg04369109	chr6:150039330	LATS1	-0.49	-6.73	-0.38	1.02e-10	Lung cancer;
CESC	cis	rs3741404	0.560	rs12362602	chr11:63908660	G/A	cg18225595	chr11:63971243	STIP1	-0.52	-7.3	-0.41	3.3e-12	Platelet count;
CESC	cis	rs9814567	1.000	rs6763088	chr3:134254989	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.45	6.08	0.35	4.21e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs9660180	0.967	rs11260623	chr1:1781456	G/T	cg23982607	chr1:1823379	GNB1	-0.76	-12.36	-0.6	5.22e-28	Body mass index;
CESC	cis	rs875971	0.929	rs778692	chr7:65872449	A/G	cg11764359	chr7:65958608	NA	0.98	15.79	0.7	4.71e-40	Aortic root size;
CESC	cis	rs2408955	0.568	rs12099462	chr12:48503104	T/C	cg24011408	chr12:48396354	COL2A1	-0.5	-7.63	-0.42	4.35e-13	Glycated hemoglobin levels;
CESC	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg05552183	chr6:42928497	GNMT	0.73	10.99	0.56	2.09e-23	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs17608059	0.710	rs8080167	chr17:13949828	G/A	cg27005118	chr17:13972210	COX10	-0.37	-5.62	-0.33	4.91e-8	Temperament;
CESC	cis	rs6540559	0.611	rs76766079	chr1:209997731	C/T	cg21951975	chr1:209979733	IRF6	0.59	6.72	0.38	1.1e-10	Cleft lip with or without cleft palate;
CESC	cis	rs2576037	0.583	rs4890698	chr18:44489725	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.51	-6.92	-0.39	3.47e-11	Personality dimensions;
CESC	cis	rs1707322	1.000	rs11211204	chr1:46317864	A/G	cg03146154	chr1:46216737	IPP	0.71	9.86	0.52	9.69e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs916888	0.687	rs199456	chr17:44797919	C/T	cg07870213	chr5:140052090	DND1	0.65	6.81	0.39	6.37e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs853679	0.517	rs55747925	chr6:28044337	T/C	cg17949981	chr6:28129498	ZNF389	0.45	5.62	0.33	4.9e-8	Depression;
CESC	cis	rs8031584	0.679	rs34017474	chr15:31230611	T/C	cg14829155	chr15:31115871	NA	-0.53	-7.27	-0.41	4.08e-12	Huntington's disease progression;
CESC	cis	rs1691799	0.831	rs6581678	chr12:66776656	A/G	cg16791601	chr12:66731901	HELB	-0.74	-13.0	-0.62	3.21e-30	White blood cell count (basophil);
CESC	cis	rs12497850	0.931	rs13064784	chr3:49135961	C/G	cg06212747	chr3:49208901	KLHDC8B	0.73	9.73	0.51	2.47e-19	Parkinson's disease;
CESC	cis	rs7208859	0.562	rs11650923	chr17:29008167	G/A	cg14008862	chr17:28927542	LRRC37B2	0.73	5.8	0.34	1.92e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs11683229	0.777	rs4671052	chr2:63139305	C/T	cg17519650	chr2:63277830	OTX1	0.68	5.88	0.34	1.25e-8	Protein quantitative trait loci;
CESC	cis	rs72781680	1.000	rs7355559	chr2:24256946	G/T	cg08917208	chr2:24149416	ATAD2B	-0.8	-7.63	-0.42	4.21e-13	Lymphocyte counts;
CESC	cis	rs7312774	0.748	rs12308071	chr12:107314539	T/A	cg16260113	chr12:107380972	MTERFD3	0.66	6.13	0.35	3.17e-9	Severe influenza A (H1N1) infection;
CESC	trans	rs2121875	0.638	rs10941660	chr5:44223787	G/C	cg09056876	chr6:156718398	NA	-0.48	-6.23	-0.36	1.8e-9	Prostate cancer;
CESC	cis	rs12477438	0.520	rs4588238	chr2:99749350	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.85	15.81	0.7	4.17e-40	Chronic sinus infection;
CESC	cis	rs6785206	0.892	rs6793907	chr3:128391626	A/G	cg16766828	chr3:128327626	NA	0.58	6.67	0.38	1.53e-10	Lymphocyte percentage of white cells;
CESC	cis	rs2842992	1.000	rs2758322	chr6:160075188	G/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.63	7.77	0.43	1.76e-13	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs72945132	0.882	rs7116059	chr11:70159690	G/T	cg14191688	chr11:70257035	CTTN	0.42	5.34	0.31	1.95e-7	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27445386	chr6:42897250	CNPY3	0.56	6.81	0.39	6.59e-11	Gut microbiome composition (summer);
CESC	cis	rs10782582	0.593	rs4646960	chr1:76211103	C/A	cg22875332	chr1:76189707	ACADM	-0.45	-5.32	-0.31	2.19e-7	Daytime sleep phenotypes;
CESC	cis	rs4253772	0.513	rs12171124	chr22:46710693	A/C	cg24881330	chr22:46731750	TRMU	0.81	7.26	0.41	4.22e-12	LDL cholesterol;Cholesterol, total;
CESC	cis	rs9430161	0.579	rs11121669	chr1:11039567	T/C	cg27631724	chr1:11040367	C1orf127	0.43	7.31	0.41	3.13e-12	Ewing sarcoma;
CESC	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg06877462	chr1:205807181	PM20D1	0.35	5.09	0.3	6.81e-7	Menarche (age at onset);
CESC	cis	rs9814567	1.000	rs6772896	chr3:134203347	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.45	-6.03	-0.35	5.44e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg25675027	chr19:1119071	SBNO2	0.44	6.34	0.36	9.65e-10	Gambling;
CESC	cis	rs3806843	0.735	rs6849	chr5:140086191	G/T	cg26395211	chr5:140044315	WDR55	0.48	6.13	0.35	3.17e-9	Depressive symptoms (multi-trait analysis);
CESC	cis	rs1538970	0.961	rs884962	chr1:45847981	G/A	cg05343316	chr1:45956843	TESK2	0.83	11.7	0.58	8.81e-26	Platelet count;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg03144560	chr20:55043299	C20orf43	-0.41	-6.08	-0.35	4.12e-9	Fibrinogen levels;
CESC	trans	rs12599106	0.680	rs34728702	chr16:34896584	A/G	cg26668828	chr6:292823	DUSP22	-0.72	-9.34	-0.5	4.23e-18	Menopause (age at onset);
CESC	cis	rs116095464	0.681	rs10060016	chr5:241100	T/C	cg22496380	chr5:211416	CCDC127	-0.74	-8.63	-0.47	5.66e-16	Breast cancer;
CESC	cis	rs7537052	0.669	rs2296263	chr1:36641729	C/T	cg24686825	chr1:36642396	MAP7D1	-0.57	-8.29	-0.45	5.68e-15	Schizophrenia;
CESC	cis	rs12530134	0.523	rs7762088	chr6:170794570	T/C	cg16453901	chr6:170730693	NA	-0.85	-5.97	-0.34	7.74e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs826838	0.967	rs11168985	chr12:39045983	A/C	cg26384229	chr12:38710491	ALG10B	-0.81	-13.45	-0.64	8.46e-32	Heart rate;
CESC	cis	rs116095464	0.558	rs1541822	chr5:269234	A/C	cg12570787	chr5:219185	SDHA;CCDC127	-0.51	-5.33	-0.31	2.09e-7	Breast cancer;
CESC	trans	rs12356475	0.710	rs10822686	chr10:67733250	C/T	cg12595990	chr12:49351331	ARF3	0.48	6.09	0.35	4.05e-9	Psoriatic arthritis;
CESC	cis	rs1448094	0.512	rs11503595	chr12:86244075	T/A	cg02569458	chr12:86230093	RASSF9	0.48	7.15	0.4	8.31e-12	Major depressive disorder;
CESC	cis	rs798554	0.959	rs798556	chr7:2759002	C/A	cg19717773	chr7:2847554	GNA12	-0.53	-7.63	-0.42	4.19e-13	Height;
CESC	cis	rs2075371	0.932	rs2598290	chr7:133987736	C/G	cg00033643	chr7:134001901	SLC35B4	0.44	5.71	0.33	3.05e-8	Mean platelet volume;
CESC	cis	rs40363	0.645	rs1690446	chr16:3519009	T/C	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.46	-5.63	-0.33	4.62e-8	Tuberculosis;
CESC	cis	rs9527	0.590	rs12775302	chr10:104911356	A/G	cg04362960	chr10:104952993	NT5C2	0.43	5.33	0.31	2.12e-7	Arsenic metabolism;
CESC	cis	rs11122272	0.705	rs2808599	chr1:231533482	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.56	-7.66	-0.43	3.45e-13	Hemoglobin concentration;
CESC	cis	rs10779751	0.649	rs1318348	chr1:11130418	A/G	cg08854313	chr1:11322531	MTOR	0.76	10.26	0.53	4.97e-21	Body mass index;
CESC	cis	rs7953508	0.711	rs11107116	chr12:93978504	G/T	cg18151635	chr12:93972918	NA	-0.37	-5.06	-0.3	7.76e-7	Pubertal anthropometrics;
CESC	cis	rs7618915	0.570	rs11130319	chr3:52755592	A/T	cg05564831	chr3:52568323	NT5DC2	0.45	6.75	0.38	9.12e-11	Bipolar disorder;
CESC	cis	rs9487051	0.676	rs4406271	chr6:109598213	G/A	cg21918786	chr6:109611834	NA	-0.38	-5.52	-0.32	8.19e-8	Reticulocyte fraction of red cells;
CESC	cis	rs875971	0.862	rs2024192	chr7:66041447	G/T	cg18252515	chr7:66147081	NA	0.46	5.96	0.34	8.03e-9	Aortic root size;
CESC	cis	rs9583531	0.600	rs1441042	chr13:111365589	T/G	cg24331049	chr13:111365604	ING1	0.82	12.31	0.6	7.59e-28	Coronary artery disease;
CESC	cis	rs11997175	0.655	rs7833512	chr8:33662884	C/T	ch.8.33884649F	chr8:33765107	NA	0.46	5.85	0.34	1.45e-8	Body mass index;
CESC	cis	rs7089973	0.523	rs11197017	chr10:116737738	C/A	cg23260525	chr10:116636907	FAM160B1	0.3	5.19	0.3	4.1e-7	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs854765	0.663	rs4925120	chr17:17754633	C/T	cg04398451	chr17:18023971	MYO15A	0.63	9.17	0.49	1.39e-17	Total body bone mineral density;
CESC	cis	rs57221529	0.766	rs56350081	chr5:583198	G/A	cg16447950	chr5:562315	NA	-0.62	-6.52	-0.37	3.51e-10	Lung disease severity in cystic fibrosis;
CESC	cis	rs6580649	0.943	rs9651993	chr12:48404692	G/A	cg24011408	chr12:48396354	COL2A1	0.41	5.08	0.3	7.17e-7	Lung cancer;
CESC	trans	rs11098499	0.863	rs12502389	chr4:120454191	A/G	cg25214090	chr10:38739885	LOC399744	0.7	9.62	0.51	5.47e-19	Corneal astigmatism;
CESC	cis	rs3820928	0.874	rs2177593	chr2:227833869	G/A	cg11843606	chr2:227700838	RHBDD1	-0.45	-5.74	-0.33	2.65e-8	Pulmonary function;
CESC	cis	rs2502731	0.539	rs3003615	chr9:130997892	C/T	cg13642260	chr9:130955380	CIZ1	0.46	6.74	0.38	9.57e-11	Attention deficit hyperactivity disorder;
CESC	cis	rs875971	0.862	rs13536	chr7:66019190	G/A	cg11764359	chr7:65958608	NA	-0.78	-11.22	-0.57	3.73e-24	Aortic root size;
CESC	cis	rs1050631	0.592	rs1785933	chr18:33719191	T/C	cg25426722	chr18:33708991	SLC39A6;ELP2	0.53	7.16	0.4	7.87e-12	Esophageal squamous cell cancer (length of survival);
CESC	cis	rs2836974	0.666	rs4624474	chr21:40686327	T/C	cg22974920	chr21:40686053	BRWD1	-0.45	-5.61	-0.33	4.99e-8	Cognitive function;
CESC	cis	rs12995491	0.731	rs17435439	chr2:88511391	A/G	cg07952391	chr2:88470173	THNSL2	-0.52	-7.76	-0.43	1.9e-13	Response to metformin (IC50);
CESC	cis	rs11690935	0.632	rs6723259	chr2:172622527	A/C	cg13550731	chr2:172543902	DYNC1I2	0.65	8.96	0.48	5.89e-17	Schizophrenia;
CESC	cis	rs7615952	0.932	rs3811679	chr3:125648283	A/G	cg05084668	chr3:125655381	ALG1L	-0.52	-6.04	-0.35	5.27e-9	Blood pressure (smoking interaction);
CESC	cis	rs6963495	0.818	rs55691539	chr7:105165774	T/C	cg13798780	chr7:105162888	PUS7	0.78	8.06	0.44	2.68e-14	Bipolar disorder (body mass index interaction);
CESC	cis	rs769267	0.895	rs2916069	chr19:19520358	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.46	6.05	0.35	4.83e-9	Tonsillectomy;
CESC	cis	rs1799949	0.965	rs8176161	chr17:41241390	C/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.44	6.24	0.36	1.71e-9	Menopause (age at onset);
CESC	cis	rs3780486	0.541	rs10738909	chr9:33148834	T/C	cg13443165	chr9:33130375	B4GALT1	0.48	7.35	0.41	2.46e-12	IgG glycosylation;
CESC	cis	rs11098499	0.779	rs10857066	chr4:120286596	C/T	cg09307838	chr4:120376055	NA	0.88	12.21	0.6	1.7e-27	Corneal astigmatism;
CESC	cis	rs35110281	0.666	rs2838348	chr21:45107285	C/G	cg21573476	chr21:45109991	RRP1B	0.57	8.35	0.46	3.76e-15	Mean corpuscular volume;
CESC	cis	rs6963495	0.818	rs73190183	chr7:105163022	G/A	cg02135003	chr7:105160482	PUS7	-0.46	-5.55	-0.32	6.92e-8	Bipolar disorder (body mass index interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18936800	chr18:44676962	HDHD2	0.58	6.33	0.36	1.04e-9	Gut microbiome composition (summer);
CESC	cis	rs6912958	0.605	rs2754247	chr6:88383571	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.32	-5.22	-0.31	3.59e-7	Monocyte percentage of white cells;
CESC	cis	rs2929278	0.617	rs694461	chr15:44096063	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.45	-7.06	-0.4	1.43e-11	Schizophrenia;
CESC	cis	rs6951245	0.882	rs56048221	chr7:1092533	A/G	cg24642844	chr7:1081250	C7orf50	-0.67	-8.66	-0.47	4.82e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs4930103	0.874	rs80047492	chr11:2025032	A/T	cg23202291	chr11:1979235	NA	0.39	5.78	0.33	2.11e-8	DNA methylation (parent-of-origin);DNA methylation (variation);
CESC	cis	rs727505	0.954	rs66871687	chr7:124670475	A/G	cg23710748	chr7:124431027	NA	-0.42	-6.62	-0.38	1.97e-10	Lewy body disease;
CESC	cis	rs360798	0.553	rs360804	chr2:62939397	C/T	cg17519650	chr2:63277830	OTX1	-0.53	-6.19	-0.36	2.28e-9	Coronary artery disease;
CESC	cis	rs1425132	0.642	rs1346019	chr7:37589526	A/G	cg15028436	chr7:37888078	TXNDC3	-0.31	-5.26	-0.31	2.95e-7	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
CESC	trans	rs11039798	1.000	rs3902927	chr11:48581457	C/T	cg15704280	chr7:45808275	SEPT13	0.66	6.21	0.36	2.01e-9	Axial length;
CESC	trans	rs319204	0.843	rs178549	chr5:146295990	A/G	cg01189915	chr7:128095027	C7orf68	-0.35	-6.1	-0.35	3.81e-9	Schizophrenia;
CESC	cis	rs4713118	0.586	rs6905516	chr6:28086478	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.58	-6.75	-0.38	9.45e-11	Parkinson's disease;
CESC	cis	rs7809950	1.000	rs2520265	chr7:107181231	A/G	cg23024343	chr7:107201750	COG5	-0.42	-5.83	-0.34	1.64e-8	Coronary artery disease;
CESC	cis	rs4664304	0.708	rs7564243	chr2:160726868	G/A	cg03641300	chr2:160917029	PLA2R1	-0.41	-5.41	-0.32	1.44e-7	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs763121	0.853	rs5757141	chr22:38957483	G/A	cg06544989	chr22:39130855	UNC84B	0.48	7.97	0.44	4.62e-14	Menopause (age at onset);
CESC	cis	rs651907	0.557	rs13069443	chr3:101373305	C/T	cg12386194	chr3:101231763	SENP7	0.44	5.45	0.32	1.15e-7	Colorectal cancer;
CESC	cis	rs17095355	1.000	rs11194940	chr10:111742223	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.45	-5.37	-0.31	1.73e-7	Biliary atresia;
CESC	cis	rs4970988	0.501	rs11204713	chr1:150694623	T/A	cg04414720	chr1:150670196	GOLPH3L	0.6	8.77	0.47	2.28e-16	Urate levels;
CESC	cis	rs2637266	0.597	rs846615	chr10:78548489	A/G	cg18941641	chr10:78392320	NA	-0.4	-7.55	-0.42	7.04e-13	Pulmonary function;
CESC	cis	rs2425143	0.730	rs6579259	chr20:34462550	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.66	5.7	0.33	3.16e-8	Blood protein levels;
CESC	cis	rs8017423	0.967	rs61231898	chr14:90691696	G/A	cg14092571	chr14:90743983	NA	-0.57	-8.19	-0.45	1.13e-14	Mortality in heart failure;
CESC	cis	rs7246657	0.943	rs10404920	chr19:37881556	T/C	cg23950597	chr19:37808831	NA	-0.61	-6.18	-0.35	2.39e-9	Coronary artery calcification;
CESC	cis	rs7851660	0.967	rs3758249	chr9:100614140	T/C	cg13688889	chr9:100608707	NA	-0.68	-10.54	-0.54	6.55e-22	Strep throat;
CESC	cis	rs10504229	0.906	rs2270609	chr8:58194684	G/A	cg05313129	chr8:58192883	C8orf71	-0.53	-6.07	-0.35	4.46e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs34375054	0.526	rs2343638	chr12:125677122	G/C	cg00522288	chr12:125625016	AACS	-0.33	-5.14	-0.3	5.44e-7	Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs72945132	0.882	rs11235967	chr11:70191691	T/C	cg00319359	chr11:70116639	PPFIA1	0.71	6.87	0.39	4.68e-11	Coronary artery disease;
CESC	cis	rs6933660	0.745	rs3800272	chr6:151744283	A/G	cg14262678	chr6:151773367	RMND1;C6orf211	-0.68	-9.35	-0.5	3.88e-18	Menarche (age at onset);
CESC	cis	rs7582720	1.000	rs114702158	chr2:203821793	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.36	0.41	2.34e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs11690935	0.885	rs6727017	chr2:172766847	T/A	cg13550731	chr2:172543902	DYNC1I2	-0.86	-12.68	-0.61	4.03e-29	Schizophrenia;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg07423838	chr7:73062350	NA	0.49	6.29	0.36	1.28e-9	Gut microbiota (bacterial taxa);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23173032	chr14:50359789	ARF6	0.59	6.98	0.39	2.33e-11	Gut microbiome composition (summer);
CESC	cis	rs7312774	0.618	rs4964510	chr12:107357251	A/G	cg16260113	chr12:107380972	MTERFD3	0.93	7.52	0.42	8.77e-13	Severe influenza A (H1N1) infection;
CESC	cis	rs72781680	0.612	rs33913065	chr2:24344060	T/G	cg20701182	chr2:24300061	SF3B14	0.92	10.62	0.55	3.63e-22	Lymphocyte counts;
CESC	cis	rs11190604	1.000	rs11190589	chr10:102275471	A/G	cg07080220	chr10:102295463	HIF1AN	0.66	6.16	0.35	2.7e-9	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs847577	0.748	rs55784506	chr7:97718201	G/A	cg21770322	chr7:97807741	LMTK2	0.64	10.36	0.54	2.38e-21	Breast cancer;
CESC	cis	rs9311474	0.713	rs352168	chr3:52237970	C/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.29	5.29	0.31	2.62e-7	Electroencephalogram traits;
CESC	cis	rs3106136	0.967	rs12643901	chr4:95145132	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.46	-7.01	-0.4	1.94e-11	Capecitabine sensitivity;
CESC	cis	rs17376456	0.504	rs6898507	chr5:93082343	C/T	cg25358565	chr5:93447407	FAM172A	0.68	7.24	0.41	5.01e-12	Diabetic retinopathy;
CESC	cis	rs853679	0.517	rs9348793	chr6:28084189	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.58	-6.75	-0.38	9.45e-11	Depression;
CESC	cis	rs9910055	0.683	rs7220138	chr17:42254011	C/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.74	10.2	0.53	8.14e-21	Total body bone mineral density;
CESC	cis	rs7811142	0.830	rs7792525	chr7:99972122	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.01	9.96	0.52	4.61e-20	Platelet count;
CESC	cis	rs473651	0.904	rs62196716	chr2:239356977	C/G	cg18131467	chr2:239335373	ASB1	0.99	20.18	0.78	1.72e-55	Multiple system atrophy;
CESC	cis	rs1975974	0.511	rs66766425	chr17:21755307	G/T	cg18423549	chr17:21743878	NA	-0.72	-9.92	-0.52	6.1e-20	Psoriasis;
CESC	cis	rs10789491	1.000	rs1258061	chr1:47105000	G/A	cg15501359	chr1:47185051	KIAA0494	-0.79	-8.66	-0.47	4.78e-16	Response to hepatitis C treatment;
CESC	cis	rs9322193	0.607	rs12527391	chr6:150203292	T/C	cg01145232	chr6:150245071	RAET1G	0.52	6.52	0.37	3.49e-10	Lung cancer;
CESC	cis	rs9815354	1.000	rs73079321	chr3:41863910	C/T	cg03022575	chr3:42003672	ULK4	0.49	5.52	0.32	7.99e-8	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs17376456	0.825	rs13161885	chr5:93071242	A/C	cg21475434	chr5:93447410	FAM172A	0.85	7.25	0.41	4.66e-12	Diabetic retinopathy;
CESC	cis	rs1048238	0.506	rs848194	chr1:16285342	G/A	cg22431228	chr1:16359049	CLCNKA	0.37	6.2	0.36	2.1e-9	Systolic blood pressure;
CESC	cis	rs938554	0.744	rs7675964	chr4:9941434	C/T	cg11266682	chr4:10021025	SLC2A9	-0.37	-5.89	-0.34	1.18e-8	Blood metabolite levels;
CESC	cis	rs909674	0.775	rs4821896	chr22:39833437	T/C	cg05872129	chr22:39784769	NA	-0.78	-10.4	-0.54	1.8e-21	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs9303401	0.659	rs62083362	chr17:56846464	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	1.01	12.5	0.61	1.71e-28	Cognitive test performance;
CESC	cis	rs3785574	0.962	rs2584632	chr17:61880641	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.1	19.47	0.77	5.16e-53	Height;
CESC	cis	rs2952156	0.883	rs12150603	chr17:37834715	G/A	cg00129232	chr17:37814104	STARD3	-0.78	-11.63	-0.58	1.51e-25	Asthma;
CESC	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg20887711	chr4:1340912	KIAA1530	0.77	10.4	0.54	1.88e-21	Longevity;
CESC	cis	rs9916302	0.904	rs679995	chr17:37441679	A/T	cg07936489	chr17:37558343	FBXL20	0.77	10.54	0.54	6.54e-22	Glomerular filtration rate (creatinine);
CESC	cis	rs3015497	0.603	rs3015443	chr14:51085208	C/T	cg26011998	chr14:51135199	SAV1	-0.48	-5.35	-0.31	1.92e-7	Mean platelet volume;
CESC	cis	rs10504073	0.647	rs4873098	chr8:50021041	T/C	cg00325661	chr8:49890786	NA	0.5	7.7	0.43	2.68e-13	Blood metabolite ratios;
CESC	trans	rs561341	1.000	rs72821952	chr17:30248133	T/A	cg20587970	chr11:113659929	NA	-1.4	-16.86	-0.72	7.67e-44	Hip circumference adjusted for BMI;
CESC	cis	rs7301826	0.603	rs7975825	chr12:131288444	C/T	cg11011512	chr12:131303247	STX2	0.45	5.44	0.32	1.2e-7	Plasma plasminogen activator levels;
CESC	cis	rs9300255	0.602	rs1716167	chr12:123651162	C/T	cg05973401	chr12:123451056	ABCB9	-0.51	-5.79	-0.34	1.94e-8	Neutrophil percentage of white cells;
CESC	cis	rs9457247	0.935	rs2757050	chr6:167377165	G/T	cg25258033	chr6:167368657	RNASET2	-0.42	-6.25	-0.36	1.63e-9	Crohn's disease;
CESC	cis	rs9457247	0.508	rs2285147	chr6:167505548	G/A	cg23791538	chr6:167370224	RNASET2	-0.49	-6.42	-0.37	6.12e-10	Crohn's disease;
CESC	cis	rs12497850	0.931	rs3774628	chr3:48801840	C/T	cg06641503	chr3:48959341	ARIH2	-0.33	-5.08	-0.3	7.01e-7	Parkinson's disease;
CESC	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg11494091	chr17:61959527	GH2	0.73	12.69	0.61	3.77e-29	Prudent dietary pattern;
CESC	cis	rs769267	0.965	rs4808937	chr19:19398005	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	7.46	0.42	1.24e-12	Tonsillectomy;
CESC	cis	rs17253792	0.822	rs28754619	chr14:56088394	G/A	cg01858014	chr14:56050164	KTN1	-0.83	-7.03	-0.4	1.7e-11	Putamen volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05379947	chr6:35436047	RPL10A	0.6	6.98	0.39	2.36e-11	Gut microbiome composition (summer);
CESC	cis	rs12597458	0.763	rs7195958	chr16:72036577	A/G	cg16558253	chr16:72132732	DHX38	0.38	5.44	0.32	1.2e-7	Prostate cancer;
CESC	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg04025307	chr7:1156635	C7orf50	0.58	9.93	0.52	5.64e-20	Longevity;Endometriosis;
CESC	cis	rs3931020	0.548	rs17618340	chr1:75247617	G/A	cg26855724	chr1:75198818	TYW3;CRYZ	0.52	6.57	0.37	2.7e-10	Resistin levels;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg06089844	chr16:68344779	PRMT7;SLC7A6OS	-0.5	-6.2	-0.36	2.14e-9	Ulcerative colitis;
CESC	cis	rs59698941	0.709	rs12163973	chr5:132226664	G/A	cg02081065	chr5:132209139	LEAP2	-0.52	-5.11	-0.3	6.08e-7	Apolipoprotein A-IV levels;
CESC	cis	rs80282103	0.618	rs10794720	chr10:1156165	A/G	cg08668510	chr10:1095578	IDI1	-0.67	-6.0	-0.35	6.46e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs826838	0.935	rs7301104	chr12:39182821	C/T	cg26384229	chr12:38710491	ALG10B	0.78	13.13	0.63	1.09e-30	Heart rate;
CESC	cis	rs3749237	0.555	rs2117939	chr3:49415179	C/A	cg03060546	chr3:49711283	APEH	0.75	11.32	0.57	1.68e-24	Resting heart rate;
CESC	cis	rs6032067	0.929	rs17425504	chr20:43880089	T/C	cg10761708	chr20:43804764	PI3	0.49	5.92	0.34	1.01e-8	Blood protein levels;
CESC	cis	rs921968	0.608	rs832817	chr2:219358603	C/T	cg02176678	chr2:219576539	TTLL4	0.43	7.54	0.42	7.27e-13	Mean corpuscular hemoglobin concentration;
CESC	cis	rs769267	0.930	rs4808965	chr19:19631655	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.45	5.61	0.33	5.1e-8	Tonsillectomy;
CESC	cis	rs763121	0.853	rs5750664	chr22:39072769	C/T	cg14440974	chr22:39074834	NA	-0.42	-5.89	-0.34	1.14e-8	Menopause (age at onset);
CESC	cis	rs7618915	0.547	rs34215106	chr3:52659124	T/C	cg07507251	chr3:52567010	NT5DC2	0.4	6.98	0.39	2.43e-11	Bipolar disorder;
CESC	cis	rs10206020	0.885	rs6720797	chr2:1574340	T/C	cg26248373	chr2:1572462	NA	-0.59	-6.93	-0.39	3.22e-11	IgG glycosylation;
CESC	cis	rs6540559	1.000	rs4844895	chr1:209958580	T/C	cg21951975	chr1:209979733	IRF6	0.61	9.29	0.5	6.01e-18	Cleft lip with or without cleft palate;
CESC	trans	rs875971	0.660	rs28698552	chr7:66005018	A/G	cg26939375	chr7:64535504	NA	0.64	8.73	0.47	2.85e-16	Aortic root size;
CESC	cis	rs7474896	0.507	rs2474555	chr10:38465220	G/C	cg25427524	chr10:38739819	LOC399744	-0.52	-5.13	-0.3	5.51e-7	Obesity (extreme);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14187204	chr20:18269147	ZNF133	0.58	6.22	0.36	1.95e-9	Gut microbiome composition (summer);
CESC	cis	rs2731664	0.792	rs335420	chr5:176898619	C/T	cg23176889	chr5:176863531	GRK6	0.64	11.78	0.59	4.81e-26	Intelligence (multi-trait analysis);
CESC	cis	rs7666738	0.830	rs13115356	chr4:98933171	T/C	cg17366294	chr4:99064904	C4orf37	0.6	8.22	0.45	9.04e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11640533	0.901	rs11862250	chr16:53415038	C/A	cg27158636	chr16:53407423	NA	0.43	5.73	0.33	2.67e-8	Intelligence (multi-trait analysis);
CESC	cis	rs1048238	0.506	rs6668183	chr1:16173814	G/C	cg21385522	chr1:16154831	NA	0.44	5.73	0.33	2.72e-8	Systolic blood pressure;
CESC	cis	rs6484504	0.625	rs7940420	chr11:31366700	T/A	cg14844989	chr11:31128820	NA	0.39	5.31	0.31	2.29e-7	Red blood cell count;
CESC	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg23034840	chr1:205782522	SLC41A1	0.6	6.84	0.39	5.58e-11	Menarche (age at onset);
CESC	cis	rs2197308	0.667	rs11181073	chr12:37898543	A/G	cg13010199	chr12:38710504	ALG10B	0.45	5.63	0.33	4.66e-8	Morning vs. evening chronotype;
CESC	trans	rs3942852	0.594	rs10769311	chr11:48094009	T/C	cg15704280	chr7:45808275	SEPT13	-0.73	-9.53	-0.51	1.06e-18	Acute lymphoblastic leukemia (childhood);
CESC	trans	rs78579285	0.544	rs11549835	chr16:88781073	G/A	cg15076811	chr1:11001038	NA	0.7	6.01	0.35	6.14e-9	Joint mobility (Beighton score);
CESC	cis	rs35306767	0.903	rs10508208	chr10:910983	C/T	cg10556349	chr10:835070	NA	0.53	5.2	0.3	3.93e-7	Eosinophil percentage of granulocytes;
CESC	cis	rs4474465	0.850	rs10793330	chr11:78269985	T/C	cg27205649	chr11:78285834	NARS2	0.44	5.69	0.33	3.28e-8	Alzheimer's disease (survival time);
CESC	cis	rs7772486	0.846	rs9373482	chr6:146363123	A/C	cg05347473	chr6:146136440	FBXO30	0.5	6.5	0.37	3.88e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs12130219	0.500	rs4845743	chr1:152184149	A/G	cg25272121	chr1:152190972	HRNR	-0.38	-5.82	-0.34	1.69e-8	Inflammatory skin disease;
CESC	cis	rs3858526	0.959	rs11039723	chr11:5956002	G/C	cg02574844	chr11:5959923	NA	-0.43	-5.15	-0.3	5.03e-7	DNA methylation (variation);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16593646	chr5:71616216	PTCD2;MRPS27	0.57	6.75	0.38	9.43e-11	Gut microbiome composition (summer);
CESC	cis	rs1538970	0.962	rs4660849	chr1:45819872	A/G	cg05343316	chr1:45956843	TESK2	-0.82	-11.17	-0.57	5.6e-24	Platelet count;
CESC	cis	rs13191362	0.688	rs73035006	chr6:162997083	G/T	cg21926612	chr6:163149169	PACRG;PARK2	0.88	9.16	0.49	1.46e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.46	6.05	0.35	5.01e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17197538	chr12:25404353	KRAS	-0.6	-6.98	-0.39	2.44e-11	Gut microbiome composition (summer);
CESC	cis	rs78456975	1.000	rs11903168	chr2:1560497	C/G	cg26248373	chr2:1572462	NA	-0.59	-5.7	-0.33	3.11e-8	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs7618915	0.571	rs12632381	chr3:52607685	G/A	cg18337363	chr3:52569053	NT5DC2	0.29	5.03	0.3	8.89e-7	Bipolar disorder;
CESC	cis	rs6669072	0.967	rs12130887	chr1:91240696	G/T	cg08895590	chr1:91227319	NA	-0.31	-5.04	-0.3	8.43e-7	Cognitive function;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13467950	chr10:74033549	DDIT4	0.64	7.4	0.41	1.82e-12	Gut microbiome composition (summer);
CESC	cis	rs875971	0.522	rs56028712	chr7:65466565	C/T	cg18876405	chr7:65276391	NA	0.69	9.6	0.51	6.27e-19	Aortic root size;
CESC	cis	rs6964587	0.836	rs757040	chr7:91552016	A/G	cg17063962	chr7:91808500	NA	-0.49	-5.69	-0.33	3.34e-8	Breast cancer;
CESC	cis	rs7605378	0.528	rs7592587	chr2:200786516	C/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.52	5.79	0.33	2.02e-8	Osteoporosis;
CESC	cis	rs9660992	0.710	rs1668869	chr1:205239779	G/C	cg00857998	chr1:205179979	DSTYK	0.47	5.35	0.31	1.87e-7	Mean corpuscular volume;Mean platelet volume;
CESC	trans	rs11098499	0.863	rs6835635	chr4:120458867	A/G	cg25214090	chr10:38739885	LOC399744	0.67	9.18	0.49	1.28e-17	Corneal astigmatism;
CESC	cis	rs12681288	0.676	rs7459467	chr8:999359	C/T	cg15309053	chr8:964076	NA	0.41	6.92	0.39	3.44e-11	Schizophrenia;
CESC	cis	rs116095464	0.558	rs9687898	chr5:253952	A/G	cg22857025	chr5:266934	NA	-1.29	-18.21	-0.75	1.29e-48	Breast cancer;
CESC	cis	rs34779708	0.966	rs4934537	chr10:35441512	C/T	cg03585969	chr10:35415529	CREM	0.76	10.0	0.52	3.56e-20	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs6893300	0.785	rs11738720	chr5:179154998	A/G	cg14593053	chr5:179126677	CANX	-0.47	-5.19	-0.3	4.12e-7	Resting heart rate;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09964670	chr19:5720572	TMEM146;LONP1	0.62	7.38	0.41	2.11e-12	Gut microbiome composition (summer);
CESC	cis	rs2629540	0.889	rs7090422	chr10:126439361	T/A	cg08799069	chr10:126477246	METTL10	-0.67	-9.16	-0.49	1.44e-17	Cocaine dependence;
CESC	cis	rs9549260	0.755	rs17061450	chr13:41183716	G/A	cg21288729	chr13:41239152	FOXO1	0.61	7.66	0.43	3.49e-13	Red blood cell count;
CESC	cis	rs1707322	0.721	rs4559551	chr1:46167533	T/C	cg03146154	chr1:46216737	IPP	0.81	11.37	0.57	1.12e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs6502050	1.000	rs6502050	chr17:80058236	C/G	cg23985595	chr17:80112537	CCDC57	0.4	6.14	0.35	3.01e-9	Life satisfaction;
CESC	cis	rs2228479	0.850	rs62056063	chr16:89903680	C/T	cg06558623	chr16:89946397	TCF25	1.12	8.22	0.45	9.28e-15	Skin colour saturation;
CESC	cis	rs2180341	1.000	rs9401950	chr6:127655485	C/T	cg24812749	chr6:127587940	RNF146	1.07	15.4	0.69	1.16e-38	Breast cancer;
CESC	cis	rs2243480	0.831	rs7806717	chr7:65393174	A/G	cg12463550	chr7:65579703	CRCP	-0.7	-5.58	-0.32	5.87e-8	Diabetic kidney disease;
CESC	cis	rs1003719	0.715	rs8130643	chr21:38551715	T/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.6	-8.13	-0.45	1.66e-14	Eye color traits;
CESC	cis	rs722599	0.715	rs11851433	chr14:75339450	C/T	cg11812906	chr14:75593930	NEK9	0.48	6.09	0.35	4.02e-9	IgG glycosylation;
CESC	cis	rs2243480	1.000	rs35391607	chr7:65360829	G/A	cg12463550	chr7:65579703	CRCP	0.69	5.62	0.33	4.79e-8	Diabetic kidney disease;
CESC	cis	rs9640161	0.789	rs3735172	chr7:150028958	C/T	cg10018233	chr7:150070692	REPIN1	-0.45	-7.22	-0.41	5.47e-12	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs875971	0.577	rs34888281	chr7:65585771	C/T	cg11764359	chr7:65958608	NA	-0.61	-7.55	-0.42	6.85e-13	Aortic root size;
CESC	cis	rs854765	0.663	rs3744115	chr17:17749822	G/A	cg04398451	chr17:18023971	MYO15A	0.64	9.16	0.49	1.44e-17	Total body bone mineral density;
CESC	cis	rs791888	1.000	rs791888	chr10:89412575	G/T	cg13926569	chr10:89418898	PAPSS2	-0.43	-6.18	-0.35	2.45e-9	Magnesium levels;
CESC	cis	rs634534	0.562	rs661335	chr11:65754061	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.44	6.53	0.37	3.42e-10	Sum eosinophil basophil counts;Eosinophil counts;
CESC	cis	rs1448094	0.512	rs61930861	chr12:86245023	G/T	cg19622623	chr12:86230825	RASSF9	-0.46	-5.89	-0.34	1.14e-8	Major depressive disorder;
CESC	cis	rs909674	0.515	rs9611170	chr22:39784845	G/C	cg02038168	chr22:39784481	NA	-0.67	-8.63	-0.47	5.82e-16	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs2243480	1.000	rs402418	chr7:65509469	G/A	cg12463550	chr7:65579703	CRCP	0.69	5.37	0.31	1.74e-7	Diabetic kidney disease;
CESC	cis	rs7178572	0.889	rs59153558	chr15:77806770	A/G	cg22256960	chr15:77711686	NA	-0.55	-7.0	-0.4	2.06e-11	Type 2 diabetes;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg25061763	chr12:62860430	MON2	-0.47	-6.02	-0.35	5.95e-9	Ulcerative colitis;
CESC	cis	rs769267	0.965	rs2905425	chr19:19475717	G/C	cg03709012	chr19:19516395	GATAD2A	-0.96	-14.42	-0.66	3.32e-35	Tonsillectomy;
CESC	cis	rs3204270	0.684	rs57405099	chr17:79637065	T/C	cg26965718	chr17:79658957	HGS	-0.73	-5.42	-0.32	1.31e-7	Dental caries;
CESC	cis	rs35306767	0.807	rs34527494	chr10:935192	T/C	cg26597838	chr10:835615	NA	1.16	11.43	0.57	7.45e-25	Eosinophil percentage of granulocytes;
CESC	trans	rs6572548	0.504	rs1956082	chr14:49665496	A/C	cg05923103	chr1:51701583	RNF11	-0.56	-6.27	-0.36	1.5e-9	Subjective well-being;
CESC	cis	rs73001065	0.636	rs28720066	chr19:19572220	G/T	cg03709012	chr19:19516395	GATAD2A	1.01	7.85	0.43	1.01e-13	LDL cholesterol;
CESC	cis	rs1862618	0.671	rs2034244	chr5:56242774	T/C	cg20203395	chr5:56204925	C5orf35	0.39	5.06	0.3	7.69e-7	Initial pursuit acceleration;
CESC	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg24101359	chr6:42928495	GNMT	0.55	7.88	0.44	8.37e-14	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs1008375	0.966	rs3775927	chr4:17599894	G/T	cg16339924	chr4:17578868	LAP3	0.65	8.26	0.45	6.87e-15	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs1843834	0.539	rs10177898	chr2:225437552	C/T	cg22509189	chr2:225307070	NA	-0.41	-5.46	-0.32	1.1e-7	IgE levels in asthmatics (D.p. specific);
CESC	cis	rs6570726	0.791	rs378937	chr6:145834745	C/T	cg05347473	chr6:146136440	FBXO30	0.51	6.65	0.38	1.69e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2014572	0.967	rs10418480	chr19:57755055	C/T	cg24459738	chr19:57751996	ZNF805	-0.55	-7.82	-0.43	1.23e-13	Hyperactive-impulsive symptoms;
CESC	cis	rs9549367	0.713	rs3024744	chr13:113821477	A/C	cg00898013	chr13:113819073	PROZ	-0.51	-7.17	-0.4	7.7e-12	Platelet distribution width;
CESC	cis	rs780094	0.544	rs2303370	chr2:27651375	C/T	cg12648201	chr2:27665141	KRTCAP3	-0.29	-5.7	-0.33	3.21e-8	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
CESC	cis	rs9487051	0.676	rs6903107	chr6:109597711	A/G	cg01475377	chr6:109611718	NA	-0.45	-7.04	-0.4	1.6e-11	Reticulocyte fraction of red cells;
CESC	cis	rs898097	0.812	rs56274787	chr17:80862682	C/T	cg15369054	chr17:80825471	TBCD	0.5	6.89	0.39	4.09e-11	Breast cancer;
CESC	cis	rs12325245	0.536	rs17821543	chr16:58540875	C/T	cg01152986	chr16:58549298	SETD6	0.87	5.83	0.34	1.64e-8	Schizophrenia;
CESC	cis	rs1059312	0.932	rs4760592	chr12:129287149	G/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.7	-9.54	-0.51	9.53e-19	Systemic lupus erythematosus;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16449816	chr17:55927528	MRPS23	0.57	6.59	0.38	2.38e-10	Gut microbiome composition (summer);
CESC	cis	rs7084402	0.935	rs1632584	chr10:60282078	T/C	cg07615347	chr10:60278583	BICC1	-0.59	-9.45	-0.5	1.81e-18	Refractive error;
CESC	cis	rs1405069	0.809	rs1046279	chr6:36932571	C/T	cg26433444	chr6:36932349	PI16	-0.41	-7.84	-0.43	1.08e-13	Chemerin levels;
CESC	cis	rs853679	0.546	rs13214023	chr6:28332141	A/G	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	-0.64	-5.05	-0.3	8.16e-7	Depression;
CESC	cis	rs6570726	0.935	rs407721	chr6:145871354	A/C	cg05347473	chr6:146136440	FBXO30	0.48	6.49	0.37	4.11e-10	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03535439	chr6:42981950	MEA1;KLHDC3	0.54	6.15	0.35	2.91e-9	Gut microbiome composition (summer);
CESC	cis	rs875971	0.505	rs2462573	chr7:65507392	C/T	cg08632164	chr7:65971372	NA	0.31	5.11	0.3	6.27e-7	Aortic root size;
CESC	cis	rs7824557	0.737	rs2293855	chr8:11177410	G/A	cg21775007	chr8:11205619	TDH	0.48	6.97	0.39	2.48e-11	Retinal vascular caliber;
CESC	cis	rs6938	0.514	rs35556055	chr15:75253414	G/A	cg09165964	chr15:75287851	SCAMP5	0.49	6.43	0.37	6.03e-10	Breast cancer;
CESC	cis	rs10924309	0.855	rs7413150	chr1:245858729	G/A	cg00036263	chr1:245852353	KIF26B	-0.41	-5.2	-0.3	3.9e-7	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
CESC	cis	rs1153858	1.000	rs2467863	chr15:45641880	G/A	cg21132104	chr15:45694354	SPATA5L1	0.85	11.46	0.58	5.76e-25	Homoarginine levels;
CESC	cis	rs1005277	0.579	rs2505241	chr10:38442421	T/C	cg25427524	chr10:38739819	LOC399744	-0.66	-9.68	-0.51	3.58e-19	Extrinsic epigenetic age acceleration;
CESC	cis	rs8133932	0.654	rs382303	chr21:47349284	G/A	cg14185626	chr21:47401492	COL6A1	-0.48	-5.36	-0.31	1.78e-7	Schizophrenia;
CESC	cis	rs714031	0.934	rs9607667	chr22:40077488	C/T	cg21377881	chr22:40064566	CACNA1I	-0.36	-5.81	-0.34	1.81e-8	Schizophrenia;
CESC	cis	rs1005277	0.505	rs719569	chr10:38154415	T/G	cg00409905	chr10:38381863	ZNF37A	0.56	7.73	0.43	2.28e-13	Extrinsic epigenetic age acceleration;
CESC	cis	rs10129255	0.500	rs2105989	chr14:107138216	C/T	cg07470598	chr14:107239068	NA	0.38	5.4	0.31	1.5e-7	Kawasaki disease;
CESC	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg03188948	chr7:1209495	NA	0.72	6.93	0.39	3.15e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs4713118	0.516	rs6931858	chr6:28078411	A/T	cg22143856	chr6:28129313	ZNF389	0.45	5.48	0.32	9.7e-8	Parkinson's disease;
CESC	cis	rs1538970	0.961	rs7543428	chr1:45839643	A/G	cg03146154	chr1:46216737	IPP	0.45	5.49	0.32	9.43e-8	Platelet count;
CESC	cis	rs7829975	0.659	rs4382480	chr8:8721473	C/T	cg06636001	chr8:8085503	FLJ10661	0.41	5.08	0.3	7.26e-7	Mood instability;
CESC	cis	rs736408	0.609	rs62255396	chr3:52782839	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.51	0.37	3.77e-10	Bipolar disorder;
CESC	cis	rs875971	0.862	rs17747530	chr7:65994729	G/C	cg19163074	chr7:65112434	INTS4L2	-0.43	-5.34	-0.31	2e-7	Aortic root size;
CESC	cis	rs7618915	0.501	rs12486554	chr3:52742537	A/T	cg05564831	chr3:52568323	NT5DC2	0.46	6.96	0.39	2.72e-11	Bipolar disorder;
CESC	cis	rs1552244	1.000	rs9879080	chr3:10084224	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-10.91	-0.56	3.8e-23	Alzheimer's disease;
CESC	cis	rs62229266	0.804	rs2835263	chr21:37430245	A/G	cg12218747	chr21:37451666	NA	0.39	5.53	0.32	7.61e-8	Mitral valve prolapse;
CESC	cis	rs2070488	0.930	rs928813	chr3:38528537	G/T	cg24069376	chr3:38537580	EXOG	0.49	8.96	0.48	5.98e-17	Electrocardiographic conduction measures;
CESC	cis	rs712039	0.652	rs34711199	chr17:35858039	C/T	cg16670864	chr17:35848621	DUSP14	0.45	5.68	0.33	3.6e-8	Tuberculosis;
CESC	cis	rs643506	0.874	rs663511	chr11:111710034	T/C	cg17089665	chr11:111648010	NA	-0.35	-5.1	-0.3	6.51e-7	Breast cancer;
CESC	cis	rs1862618	0.671	rs2591968	chr5:56233541	A/G	cg18230493	chr5:56204884	C5orf35	-0.59	-7.86	-0.43	9.52e-14	Initial pursuit acceleration;
CESC	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	6.92	0.39	3.36e-11	Bipolar disorder;
CESC	cis	rs2991971	0.967	rs7526665	chr1:46005832	G/T	cg15605315	chr1:45957053	TESK2	0.43	5.48	0.32	1.01e-7	High light scatter reticulocyte count;
CESC	cis	rs514406	0.644	rs1855127	chr1:53199594	A/G	cg08736216	chr1:53307985	ZYG11A	0.3	5.04	0.3	8.5e-7	Monocyte count;
CESC	cis	rs27434	0.660	rs42398	chr5:96120455	C/T	cg16492584	chr5:96139282	ERAP1	-0.49	-5.96	-0.34	8.01e-9	Ankylosing spondylitis;
CESC	cis	rs6723226	0.708	rs2754513	chr2:32782763	G/A	cg02381751	chr2:32503542	YIPF4	0.83	12.07	0.6	5.21e-27	Intelligence (multi-trait analysis);
CESC	cis	rs2180341	1.000	rs7776136	chr6:127638348	A/T	cg27446573	chr6:127587934	RNF146	1.11	16.48	0.71	1.76e-42	Breast cancer;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg19901472	chr1:29557379	MECR	-0.47	-6.07	-0.35	4.38e-9	Asthma;
CESC	cis	rs7666738	0.830	rs13137859	chr4:99050319	A/G	cg17366294	chr4:99064904	C4orf37	0.61	8.78	0.47	2.13e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1862618	0.853	rs252919	chr5:56124111	T/C	cg03609598	chr5:56110824	MAP3K1	-0.52	-5.57	-0.32	6.2e-8	Initial pursuit acceleration;
CESC	cis	rs12142240	0.698	rs41294456	chr1:46809782	T/C	cg00530320	chr1:46809349	NSUN4	0.6	7.98	0.44	4.48e-14	Menopause (age at onset);
CESC	cis	rs728616	0.558	rs34268041	chr10:82148639	A/G	cg05935833	chr10:81318306	SFTPA2	-0.44	-5.58	-0.32	5.92e-8	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs10504229	0.683	rs61201557	chr8:58138370	T/C	cg21724239	chr8:58056113	NA	0.58	5.95	0.34	8.29e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs763121	0.853	rs5750626	chr22:38977890	G/C	cg06544989	chr22:39130855	UNC84B	0.5	8.26	0.45	6.86e-15	Menopause (age at onset);
CESC	cis	rs875971	0.862	rs908915	chr7:65614651	G/T	cg12463550	chr7:65579703	CRCP	-0.5	-6.42	-0.37	6.11e-10	Aortic root size;
CESC	cis	rs7171869	1	rs7171869	chr15:78900909	A/G	cg24631222	chr15:78858424	CHRNA5	-0.81	-9.95	-0.52	4.93e-20	Post bronchodilator FEV1;
CESC	cis	rs1707322	0.827	rs10890347	chr1:46242332	A/T	cg06784218	chr1:46089804	CCDC17	-0.39	-6.58	-0.37	2.53e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19973604	chr17:73914282	FBF1	-0.56	-6.56	-0.37	2.87e-10	Gut microbiome composition (summer);
CESC	cis	rs727505	0.520	rs1454125	chr7:124862733	C/T	cg23710748	chr7:124431027	NA	-0.34	-5.17	-0.3	4.59e-7	Lewy body disease;
CESC	cis	rs4737010	0.511	rs7006871	chr8:41670952	A/G	cg08923054	chr8:41654455	ANK1	0.53	6.83	0.39	5.64e-11	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
CESC	cis	rs6499129	0.558	rs16957489	chr16:67651879	G/A	cg26727032	chr16:67993705	SLC12A4	-0.56	-6.44	-0.37	5.61e-10	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs4595586	0.525	rs4441057	chr12:39420620	T/A	cg13010199	chr12:38710504	ALG10B	0.43	5.25	0.31	3.17e-7	Morning vs. evening chronotype;
CESC	cis	rs7524258	0.778	rs12028181	chr1:7315085	C/T	cg07173049	chr1:7289937	CAMTA1	-0.33	-5.11	-0.3	6.13e-7	Tourette's syndrome or obsessive-compulsive disorder;
CESC	cis	rs9916302	0.904	rs6503519	chr17:37706578	A/G	cg20243544	chr17:37824526	PNMT	0.53	6.63	0.38	1.87e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs853679	0.517	rs9393893	chr6:28109262	T/C	cg23281280	chr6:28129359	ZNF389	0.59	8.07	0.44	2.52e-14	Depression;
CESC	cis	rs7020830	0.931	rs7027473	chr9:37132462	A/G	cg14294708	chr9:37120828	ZCCHC7	1.27	25.81	0.85	2.72e-74	Schizophrenia;
CESC	cis	rs12497850	0.863	rs4974084	chr3:48939080	G/A	cg02487422	chr3:49467188	NICN1	0.41	5.28	0.31	2.68e-7	Parkinson's disease;
CESC	cis	rs4233802	1.000	rs4425094	chr2:151139891	C/T	cg25300694	chr2:151184358	NA	0.88	7.6	0.42	5.07e-13	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
CESC	cis	rs514406	0.929	rs1672908	chr1:53340885	A/G	cg16325326	chr1:53192061	ZYG11B	0.8	12.22	0.6	1.6e-27	Monocyte count;
CESC	cis	rs17401966	1.000	rs2275424	chr1:10356562	C/A	cg15208524	chr1:10270712	KIF1B	0.51	6.57	0.37	2.66e-10	Hepatocellular carcinoma;
CESC	cis	rs4664308	0.840	rs17218566	chr2:161054748	C/T	cg03641300	chr2:160917029	PLA2R1	-0.65	-9.56	-0.51	8.34e-19	Idiopathic membranous nephropathy;
CESC	cis	rs12701220	0.894	rs34712249	chr7:1036634	C/T	cg26769984	chr7:1090371	C7orf50	0.65	7.37	0.41	2.24e-12	Bronchopulmonary dysplasia;
CESC	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.54	6.69	0.38	1.3100000000000001e-10	Prudent dietary pattern;
CESC	cis	rs4919087	0.715	rs2484880	chr10:98998355	T/C	cg25902810	chr10:99078978	FRAT1	-0.46	-5.2	-0.3	4.03e-7	Monocyte count;
CESC	cis	rs1670533	1.000	rs4690215	chr4:1054619	G/C	cg27284194	chr4:1044797	NA	0.46	5.85	0.34	1.42e-8	Recombination rate (females);
CESC	cis	rs597539	0.654	rs655816	chr11:68626405	A/G	cg01988459	chr11:68622903	NA	-0.41	-5.34	-0.31	2.04e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs6964587	1.000	rs10225892	chr7:91671020	A/G	cg17063962	chr7:91808500	NA	0.55	7.49	0.42	1.06e-12	Breast cancer;
CESC	cis	rs6493487	0.512	rs17521919	chr15:51291056	A/C	cg02338191	chr15:51200825	AP4E1	0.6	5.5	0.32	8.84e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs561341	1.000	rs535151	chr17:30317405	C/T	cg12193833	chr17:30244370	NA	-0.52	-5.95	-0.34	8.43e-9	Hip circumference adjusted for BMI;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg08537418	chr17:5342414	C1QBP	-0.45	-6.17	-0.35	2.53e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs4665809	0.589	rs4665841	chr2:26448950	G/A	cg25036284	chr2:26402008	FAM59B	-0.9	-10.54	-0.54	6.54e-22	Gut microbiome composition (summer);
CESC	cis	rs6754311	0.681	rs4954493	chr2:136609975	T/C	cg07169764	chr2:136633963	MCM6	-0.69	-8.48	-0.46	1.59e-15	Mosquito bite size;
CESC	cis	rs9815354	0.812	rs17217536	chr3:41923300	A/C	cg03022575	chr3:42003672	ULK4	0.68	5.92	0.34	9.93e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs514406	0.679	rs61768344	chr1:53229274	G/A	cg25767906	chr1:53392781	SCP2	0.53	7.67	0.43	3.35e-13	Monocyte count;
CESC	cis	rs514406	0.893	rs1242317	chr1:53414766	T/C	cg08736216	chr1:53307985	ZYG11A	-0.41	-6.53	-0.37	3.31e-10	Monocyte count;
CESC	cis	rs7044106	0.734	rs10491784	chr9:123432289	A/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.36	5.83	0.34	1.58e-8	Hip circumference adjusted for BMI;
CESC	trans	rs11039798	0.512	rs28453037	chr11:49006929	C/A	cg15704280	chr7:45808275	SEPT13	0.64	6.78	0.38	7.72e-11	Axial length;
CESC	cis	rs4253772	0.530	rs9627387	chr22:46684678	A/G	cg10231785	chr22:46692440	CN5H6.4;GTSE1	0.6	6.52	0.37	3.62e-10	LDL cholesterol;Cholesterol, total;
CESC	cis	rs8002861	0.875	rs12872943	chr13:44410553	G/A	cg19180546	chr13:44453867	C13orf31;CCDC122	-0.4	-5.08	-0.3	7.11e-7	Leprosy;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg25998860	chr5:126853954	PRRC1	-0.46	-6.82	-0.39	6.26e-11	Gambling;
CESC	cis	rs11098499	0.618	rs35265692	chr4:120325135	T/C	cg24375607	chr4:120327624	NA	0.48	5.89	0.34	1.15e-8	Corneal astigmatism;
CESC	cis	rs2797160	1.000	rs1777226	chr6:126017691	C/A	cg05901451	chr6:126070800	HEY2	0.46	6.48	0.37	4.56e-10	Endometrial cancer;
CESC	cis	rs7223966	0.618	rs9906903	chr17:61634508	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.46	5.03	0.3	9.16e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs3741151	0.773	rs73542952	chr11:73108556	A/G	cg17517138	chr11:73019481	ARHGEF17	0.98	7.14	0.4	8.86e-12	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs61931739	0.500	rs11053218	chr12:34474792	A/C	cg19457237	chr12:34500585	NA	0.38	5.2	0.3	3.93e-7	Morning vs. evening chronotype;
CESC	cis	rs8060686	0.641	rs112099181	chr16:68154230	T/C	cg26727032	chr16:67993705	SLC12A4	-0.51	-6.26	-0.36	1.59e-9	HDL cholesterol;Metabolic syndrome;
CESC	trans	rs7618501	1.000	rs7618519	chr3:49772708	A/T	cg21582582	chr3:182698605	DCUN1D1	-0.44	-6.01	-0.35	6.2e-9	Intelligence (multi-trait analysis);
CESC	cis	rs7811142	0.830	rs73401443	chr7:99977582	T/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.83	8.82	0.48	1.58e-16	Platelet count;
CESC	cis	rs9790314	0.905	rs7632797	chr3:161002694	C/T	cg03342759	chr3:160939853	NMD3	0.43	5.89	0.34	1.15e-8	Morning vs. evening chronotype;
CESC	cis	rs1008375	0.966	rs2315553	chr4:17627332	T/C	cg16339924	chr4:17578868	LAP3	0.66	8.49	0.46	1.48e-15	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs4148883	0.737	rs13148577	chr4:100060836	G/A	cg13256891	chr4:100009986	ADH5	0.56	7.34	0.41	2.64e-12	Alcohol dependence;
CESC	cis	rs8017423	0.967	rs1959002	chr14:90670994	T/A	cg14092571	chr14:90743983	NA	-0.55	-8.18	-0.45	1.2e-14	Mortality in heart failure;
CESC	cis	rs8114671	0.527	rs2295352	chr20:33320055	C/G	cg07148914	chr20:33460835	GGT7	-0.44	-5.59	-0.32	5.75e-8	Height;
CESC	cis	rs3096299	0.748	rs3102339	chr16:89442711	C/T	cg02187348	chr16:89574699	SPG7	0.57	7.41	0.41	1.74e-12	Multiple myeloma (IgH translocation);
CESC	cis	rs6866344	0.697	rs61247551	chr5:178133503	G/A	cg10224037	chr5:178157518	ZNF354A	0.67	7.34	0.41	2.64e-12	Neutrophil percentage of white cells;
CESC	cis	rs2929278	0.589	rs11638972	chr15:44074691	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.47	-7.26	-0.41	4.23e-12	Schizophrenia;
CESC	cis	rs7412746	0.611	rs16827671	chr1:150738759	T/C	cg04414720	chr1:150670196	GOLPH3L	0.56	7.4	0.41	1.78e-12	Melanoma;
CESC	cis	rs34172651	0.517	rs2287783	chr16:24831727	C/T	cg06028605	chr16:24865363	SLC5A11	0.53	7.72	0.43	2.45e-13	Intelligence (multi-trait analysis);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg10423910	chr5:127420075	SLC12A2;FLJ33630	0.5	6.3	0.36	1.26e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs6429082	0.875	rs4659524	chr1:235583354	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.4	-5.32	-0.31	2.21e-7	Adiposity;
CESC	cis	rs1552244	0.882	rs113268531	chr3:10167069	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.87	12.51	0.61	1.61e-28	Alzheimer's disease;
CESC	cis	rs6815814	0.851	rs17582921	chr4:38892649	T/C	cg02016764	chr4:38805732	TLR1	-0.57	-6.45	-0.37	5.26e-10	Breast cancer;
CESC	cis	rs12477438	0.748	rs10200974	chr2:99675227	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.61	-8.54	-0.46	1.04e-15	Chronic sinus infection;
CESC	trans	rs7615952	0.599	rs66532274	chr3:125731845	G/A	cg07211511	chr3:129823064	LOC729375	-0.59	-7.07	-0.4	1.37e-11	Blood pressure (smoking interaction);
CESC	cis	rs72720396	0.789	rs10922910	chr1:91199862	G/T	cg13456504	chr1:91191583	NA	0.49	7.07	0.4	1.38e-11	Morning vs. evening chronotype;Chronotype;
CESC	cis	rs3858526	0.959	rs61876224	chr11:5952859	G/A	cg05234568	chr11:5960015	NA	-0.64	-7.62	-0.42	4.55e-13	DNA methylation (variation);
CESC	cis	rs2370759	1.000	rs7910776	chr10:32639093	C/T	cg01819863	chr10:32635814	EPC1	1.1	10.93	0.56	3.25e-23	Sexual dysfunction (female);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19334895	chr19:18942619	UPF1	0.52	6.25	0.36	1.59e-9	Gut microbiome composition (summer);
CESC	cis	rs1799949	0.628	rs4474733	chr17:41433660	G/T	cg05368731	chr17:41323189	NBR1	0.71	8.26	0.45	7.18e-15	Menopause (age at onset);
CESC	cis	rs4689388	0.890	rs4688989	chr4:6290594	T/C	cg14416269	chr4:6271139	WFS1	0.46	7.71	0.43	2.49e-13	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg22105103	chr4:187893119	NA	0.49	6.86	0.39	4.89e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6540559	0.673	rs7525951	chr1:210018306	C/T	cg23283495	chr1:209979779	IRF6	-0.48	-5.53	-0.32	7.61e-8	Cleft lip with or without cleft palate;
CESC	cis	rs9300255	0.602	rs6488864	chr12:123618362	G/C	cg00376283	chr12:123451042	ABCB9	0.62	6.66	0.38	1.57e-10	Neutrophil percentage of white cells;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22918356	chr10:134496823	INPP5A	-0.68	-8.18	-0.45	1.22e-14	Gut microbiome composition (summer);
CESC	cis	rs6835098	1.000	rs6814857	chr4:174082805	T/A	cg08422745	chr4:174089978	GALNT7	-0.73	-9.49	-0.5	1.37e-18	Dementia and core Alzheimer's disease neuropathologic changes;
CESC	cis	rs11098499	0.754	rs1980027	chr4:120251577	C/T	cg09307838	chr4:120376055	NA	0.77	10.45	0.54	1.22e-21	Corneal astigmatism;
CESC	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg04025307	chr7:1156635	C7orf50	0.41	5.56	0.32	6.68e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs17376456	0.825	rs10061377	chr5:93174513	T/C	cg25358565	chr5:93447407	FAM172A	1.1	10.64	0.55	3.1e-22	Diabetic retinopathy;
CESC	cis	rs2836974	0.897	rs8132419	chr21:40527827	C/T	cg17971929	chr21:40555470	PSMG1	1.05	16.48	0.71	1.75e-42	Cognitive function;
CESC	cis	rs1799949	0.965	rs8176198	chr17:41230537	A/T	cg23758822	chr17:41437982	NA	0.79	11.1	0.56	9.08e-24	Menopause (age at onset);
CESC	cis	rs447735	0.587	rs7188458	chr16:89726484	A/G	cg04240660	chr16:89714849	CHMP1A	-0.36	-5.13	-0.3	5.66e-7	Hemoglobin concentration;
CESC	cis	rs7178909	0.872	rs10852124	chr15:90430464	C/T	cg19708238	chr15:90437601	AP3S2	0.4	5.68	0.33	3.54e-8	Common traits (Other);
CESC	cis	rs15676	0.733	rs2900269	chr9:131569878	G/T	cg00228799	chr9:131580591	ENDOG	0.5	6.0	0.35	6.44e-9	Blood metabolite levels;
CESC	cis	rs793571	0.669	rs714696	chr15:58962987	C/G	cg05156742	chr15:59063176	FAM63B	0.63	8.22	0.45	9.3e-15	Schizophrenia;
CESC	cis	rs2637266	0.967	rs2579748	chr10:78328313	T/C	cg18941641	chr10:78392320	NA	0.41	7.65	0.43	3.68e-13	Pulmonary function;
CESC	cis	rs780096	0.526	rs780102	chr2:27659491	T/C	cg21248554	chr2:27665150	KRTCAP3	-0.36	-7.38	-0.41	2.02e-12	Total body bone mineral density;
CESC	cis	rs514406	0.584	rs7524702	chr1:53197830	G/A	cg16325326	chr1:53192061	ZYG11B	-1.0	-17.64	-0.73	1.36e-46	Monocyte count;
CESC	cis	rs1218582	0.772	rs1109815	chr1:154909268	A/G	cg09359103	chr1:154839909	KCNN3	-0.65	-11.99	-0.59	9.49e-27	Prostate cancer;
CESC	cis	rs2842992	0.872	rs2758328	chr6:160090731	T/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.63	7.63	0.42	4.18e-13	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs2439831	1.000	rs2251538	chr15:43767209	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.89	10.48	0.54	9.91e-22	Lung cancer in ever smokers;
CESC	cis	rs5769707	0.732	rs135865	chr22:50004829	G/A	cg20744362	chr22:50050164	C22orf34	0.45	7.43	0.42	1.5e-12	Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs4665809	0.556	rs4665314	chr2:26415912	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.08	-13.27	-0.63	3.74e-31	Gut microbiome composition (summer);
CESC	cis	rs2658782	0.826	rs2925355	chr11:93090887	T/C	cg15737290	chr11:93063684	CCDC67	0.59	7.43	0.42	1.52e-12	Pulmonary function decline;
CESC	trans	rs6535028	1.000	rs4241953	chr4:135460904	G/C	cg04198210	chr15:74528606	CCDC33	-0.6	-6.01	-0.35	6.2e-9	Response to radiotherapy in prostate cancer (overall toxicity);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13180005	chr1:182360683	GLUL	0.59	6.58	0.37	2.47e-10	Gut microbiome composition (summer);
CESC	cis	rs13191362	1.000	rs34177053	chr6:163007772	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.49	5.36	0.31	1.82e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs9868809	0.881	rs9878063	chr3:48678971	T/G	cg07636037	chr3:49044803	WDR6	-0.6	-5.17	-0.3	4.73e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs916888	0.821	rs199506	chr17:44859031	A/G	cg01570182	chr17:44337453	NA	-0.88	-10.55	-0.54	5.83e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs10465746	0.747	rs1952066	chr1:84436456	T/C	cg10977910	chr1:84465055	TTLL7	0.52	7.13	0.4	9.46e-12	Obesity-related traits;
CESC	cis	rs1395	0.710	rs11682913	chr2:27473649	G/A	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.43	5.64	0.33	4.38e-8	Blood metabolite levels;
CESC	cis	rs4975709	0.589	rs4975745	chr5:1861058	G/C	cg15595755	chr5:1867978	NA	0.5	8.03	0.44	3.24e-14	Cardiovascular disease risk factors;
CESC	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg24642844	chr7:1081250	C7orf50	-0.76	-9.45	-0.5	1.94e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs644799	0.965	rs1944080	chr11:95503636	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.94	14.93	0.68	5.42e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs2637266	0.561	rs10824440	chr10:78489079	C/T	cg18941641	chr10:78392320	NA	-0.33	-5.31	-0.31	2.31e-7	Pulmonary function;
CESC	cis	rs3747547	1.000	rs7028246	chr9:37917602	A/G	cg13774184	chr9:37916125	SHB	-0.63	-5.83	-0.34	1.63e-8	Metabolite levels (Dihydroxy docosatrienoic acid);
CESC	trans	rs7937682	0.889	rs1784785	chr11:111483306	A/G	cg18187862	chr3:45730750	SACM1L	0.48	6.11	0.35	3.49e-9	Primary sclerosing cholangitis;
CESC	cis	rs6460942	0.597	rs12699388	chr7:12536336	T/C	cg06484146	chr7:12443880	VWDE	-0.73	-7.77	-0.43	1.68e-13	Coronary artery disease;
CESC	cis	rs9309473	0.519	rs12618600	chr2:73890682	T/C	cg20560298	chr2:73613845	ALMS1	0.51	7.15	0.4	8.44e-12	Metabolite levels;
CESC	cis	rs7618915	0.547	rs7642198	chr3:52677960	T/C	cg07507251	chr3:52567010	NT5DC2	0.4	7.06	0.4	1.49e-11	Bipolar disorder;
CESC	cis	rs7618915	0.547	rs11130311	chr3:52675005	T/C	cg18099408	chr3:52552593	STAB1	-0.3	-5.04	-0.3	8.71e-7	Bipolar disorder;
CESC	cis	rs9649213	0.593	rs56286037	chr7:98019522	C/T	cg24562669	chr7:97807699	LMTK2	0.52	7.57	0.42	6.02e-13	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7520050	0.778	rs3014216	chr1:46035760	A/T	cg06784218	chr1:46089804	CCDC17	0.33	5.99	0.35	6.85e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs9787249	0.915	rs6664570	chr1:40206298	G/A	cg19912559	chr1:40204330	PPIE	0.43	6.61	0.38	2.14e-10	Blood protein levels;
CESC	cis	rs8062405	0.755	rs7193402	chr16:28586127	A/G	cg01378222	chr16:28622494	SULT1A1	0.31	5.19	0.3	4.09e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs9911578	1.000	rs4793952	chr17:56608465	C/T	cg12560992	chr17:57184187	TRIM37	-0.93	-15.47	-0.69	6.8e-39	Intelligence (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01032946	chr16:30991033	SETD1A	-0.58	-6.04	-0.35	5.24e-9	Gut microbiome composition (summer);
CESC	cis	rs10504229	0.683	rs77548248	chr8:58117542	G/A	cg22535103	chr8:58192502	C8orf71	-0.8	-9.03	-0.49	3.55e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs2644899	0.859	rs2604893	chr19:41293543	A/G	cg24958765	chr19:41283667	RAB4B	-0.57	-6.36	-0.36	8.61e-10	Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs1799949	0.965	rs8176310	chr17:41199913	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.44	6.23	0.36	1.86e-9	Menopause (age at onset);
CESC	cis	rs4713118	0.662	rs149946	chr6:27970031	A/C	cg19592336	chr6:28129416	ZNF389	-0.54	-7.01	-0.4	1.92e-11	Parkinson's disease;
CESC	cis	rs60154123	0.505	rs2206043	chr1:210042983	G/A	cg21951975	chr1:209979733	IRF6	0.59	6.87	0.39	4.47e-11	Coronary artery disease;
CESC	cis	rs11690935	0.531	rs62183800	chr2:172867273	C/T	cg13550731	chr2:172543902	DYNC1I2	0.49	6.75	0.38	9.18e-11	Schizophrenia;
CESC	cis	rs75557865	1	rs75557865	chr3:121652141	G/A	cg20356878	chr3:121714668	ILDR1	0.45	6.57	0.37	2.71e-10	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs17711722	0.523	rs313812	chr7:65505043	T/C	cg18876405	chr7:65276391	NA	-0.47	-6.29	-0.36	1.31e-9	Calcium levels;
CESC	cis	rs66573146	1.000	rs55672215	chr4:6970529	T/C	cg00086871	chr4:6988644	TBC1D14	1.14	7.26	0.41	4.33e-12	Granulocyte percentage of myeloid white cells;
CESC	cis	rs11051970	0.592	rs7132235	chr12:32536303	T/A	cg24626660	chr12:32551988	NA	0.39	5.26	0.31	2.95e-7	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs9300255	0.596	rs11057202	chr12:123720775	G/T	cg05973401	chr12:123451056	ABCB9	0.46	5.56	0.32	6.62e-8	Neutrophil percentage of white cells;
CESC	cis	rs9733	0.596	rs12072339	chr1:150686099	A/G	cg18016565	chr1:150552671	MCL1	0.35	5.36	0.31	1.86e-7	Tonsillectomy;
CESC	cis	rs2249625	0.935	rs1852702	chr6:72908366	T/C	cg18830697	chr6:72922368	RIMS1	-0.42	-5.81	-0.34	1.78e-8	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CESC	cis	rs2933343	0.729	rs1680786	chr3:128644840	T/C	cg24203234	chr3:128598194	ACAD9	0.43	5.8	0.34	1.93e-8	IgG glycosylation;
CESC	cis	rs9914544	0.689	rs11078421	chr17:18804385	A/G	cg26378065	chr17:18585709	ZNF286B	0.43	5.85	0.34	1.41e-8	Educational attainment (years of education);
CESC	cis	rs6963495	0.818	rs115609508	chr7:105163716	C/A	cg13798780	chr7:105162888	PUS7	0.78	8.06	0.44	2.68e-14	Bipolar disorder (body mass index interaction);
CESC	cis	rs11645898	0.748	rs56387295	chr16:72055336	C/A	cg14768367	chr16:72042858	DHODH	-0.83	-6.78	-0.38	7.88e-11	Blood protein levels;
CESC	cis	rs2380220	0.606	rs4571572	chr6:96004823	T/C	cg15832292	chr6:96025679	MANEA	0.64	7.3	0.41	3.28e-12	Behavioural disinhibition (generation interaction);
CESC	cis	rs897984	0.542	rs3751855	chr16:31091209	T/C	cg00531865	chr16:30841666	NA	-0.39	-5.45	-0.32	1.18e-7	Dementia with Lewy bodies;
CESC	cis	rs16866061	1.000	rs72974263	chr2:225447371	C/T	cg12698349	chr2:225449008	CUL3	0.72	10.51	0.54	7.77e-22	Acute graft versus host disease in bone marrow transplantation (recipient effect);
CESC	cis	rs3762637	1.000	rs6790051	chr3:122192846	T/C	cg24169773	chr3:122142474	KPNA1	-0.54	-6.33	-0.36	1.04e-9	LDL cholesterol levels;
CESC	cis	rs7542091	0.635	rs7550733	chr1:210044968	G/A	cg22029157	chr1:209979665	IRF6	0.5	7.98	0.44	4.32e-14	Monobrow;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02957340	chr14:100070899	CCDC85C	0.61	6.86	0.39	4.76e-11	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23142731	chr12:50899018	DIP2B	0.6	6.62	0.38	1.94e-10	Gut microbiome composition (summer);
CESC	cis	rs72945132	0.882	rs7943547	chr11:70133282	C/A	cg00319359	chr11:70116639	PPFIA1	0.78	7.74	0.43	2.13e-13	Coronary artery disease;
CESC	cis	rs4948102	0.691	rs4470984	chr7:56033558	A/G	cg09872392	chr7:56161020	PHKG1	-0.46	-7.13	-0.4	9.57e-12	Plasma homocysteine levels (post-methionine load test);
CESC	cis	rs11098499	0.863	rs10013305	chr4:120450424	G/A	cg09307838	chr4:120376055	NA	0.91	12.54	0.61	1.24e-28	Corneal astigmatism;
CESC	cis	rs6496667	0.683	rs1869180	chr15:90895467	T/C	cg22089800	chr15:90895588	ZNF774	0.64	8.39	0.46	2.95e-15	Rheumatoid arthritis;
CESC	cis	rs2737618	0.674	rs2249150	chr1:200083654	G/A	cg21825944	chr1:200113062	NR5A2	-0.47	-7.26	-0.41	4.42e-12	Uric acid levels;
CESC	cis	rs7086627	0.515	rs4933390	chr10:82213081	A/C	cg00277334	chr10:82204260	NA	-0.91	-15.78	-0.7	5.2e-40	Post bronchodilator FEV1;
CESC	cis	rs7296418	0.885	rs1790104	chr12:123709409	C/T	cg00376283	chr12:123451042	ABCB9	0.67	9.59	0.51	6.84e-19	Platelet count;
CESC	cis	rs5167	0.525	rs10402642	chr19:45453878	G/A	cg20090143	chr19:45452003	APOC2	0.37	6.39	0.37	7.58e-10	Blood protein levels;
CESC	cis	rs7100689	0.784	rs4934153	chr10:82191255	T/C	cg00277334	chr10:82204260	NA	-0.62	-7.58	-0.42	5.88e-13	Post bronchodilator FEV1;
CESC	cis	rs13191362	1.000	rs71567659	chr6:163001736	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.5	5.17	0.3	4.64e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs10858047	0.883	rs761755	chr1:115222434	G/A	cg12756093	chr1:115239321	AMPD1	-0.52	-5.23	-0.31	3.44e-7	Autism;
CESC	cis	rs1538970	0.924	rs1007858	chr1:45912005	C/T	cg05343316	chr1:45956843	TESK2	0.89	12.04	0.59	6.22e-27	Platelet count;
CESC	trans	rs561341	1.000	rs501957	chr17:30314504	C/T	cg20587970	chr11:113659929	NA	-1.41	-18.06	-0.74	4.37e-48	Hip circumference adjusted for BMI;
CESC	cis	rs6831352	0.918	rs35784540	chr4:100061692	T/A	cg13256891	chr4:100009986	ADH5	-0.76	-8.27	-0.45	6.69e-15	Alcohol dependence;
CESC	cis	rs4849845	0.653	rs3925970	chr2:121018153	C/A	cg24070213	chr2:121070622	NA	0.44	6.36	0.36	8.64e-10	Mean platelet volume;
CESC	cis	rs7772486	0.875	rs9373485	chr6:146401429	A/T	cg05347473	chr6:146136440	FBXO30	0.49	6.65	0.38	1.63e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs734999	0.588	rs745368	chr1:2524205	C/T	cg20673091	chr1:2541236	MMEL1	0.43	6.9	0.39	3.84e-11	Ulcerative colitis;
CESC	trans	rs10174398	0.668	rs11887973	chr2:51242058	A/G	cg00888162	chr2:38152302	FAM82A1	-0.64	-6.16	-0.35	2.72e-9	Body mass index;
CESC	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg06873352	chr17:61820015	STRADA	0.7	12.62	0.61	6.49e-29	Prudent dietary pattern;
CESC	cis	rs1008375	0.900	rs3822235	chr4:17694916	C/T	cg02297831	chr4:17616191	MED28	-0.42	-5.21	-0.3	3.75e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs2250402	0.510	rs2898984	chr15:40324075	G/C	cg01081584	chr15:40268610	EIF2AK4	-0.57	-5.42	-0.32	1.33e-7	Corneal curvature;
CESC	cis	rs9649213	0.593	rs34534766	chr7:97920871	G/C	cg21770322	chr7:97807741	LMTK2	0.55	8.18	0.45	1.17e-14	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs736408	0.716	rs2239549	chr3:52823126	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.38	6.41	0.37	6.53e-10	Bipolar disorder;
CESC	cis	rs9831754	0.756	rs12714468	chr3:78445878	A/T	cg06138941	chr3:78371609	NA	-0.5	-6.12	-0.35	3.34e-9	Calcium levels;
CESC	cis	rs3733585	0.699	rs6449179	chr4:9969117	G/A	cg00071950	chr4:10020882	SLC2A9	-0.69	-11.47	-0.58	5.42e-25	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs863345	0.604	rs12133791	chr1:158506682	C/A	cg12129480	chr1:158549410	OR10X1	-0.34	-6.82	-0.39	6.1e-11	Pneumococcal bacteremia;
CESC	trans	rs6794880	0.778	rs75823133	chr3:84424374	T/G	cg03554283	chr8:76319451	NA	0.57	6.07	0.35	4.44e-9	Body mass index (joint analysis main effects and smoking interaction);BMI in non-smokers;BMI (adjusted for smoking behaviour);
CESC	cis	rs853679	0.517	rs9393894	chr6:28112562	A/G	cg22143856	chr6:28129313	ZNF389	0.52	6.53	0.37	3.27e-10	Depression;
CESC	cis	rs9910055	0.529	rs228757	chr17:42164885	G/C	cg13607699	chr17:42295918	UBTF	-0.45	-5.69	-0.33	3.39e-8	Total body bone mineral density;
CESC	cis	rs6860806	0.507	rs270606	chr5:131650867	A/G	cg24060327	chr5:131705240	SLC22A5	-0.74	-10.25	-0.53	5.64e-21	Breast cancer;
CESC	trans	rs1545843	0.593	rs4761082	chr12:84792755	T/G	cg03015433	chr16:56623111	MT3	-0.34	-6.12	-0.35	3.37e-9	Major depressive disorder;
CESC	trans	rs4843747	0.697	rs72818533	chr16:88073841	G/A	cg26811252	chr16:29126840	RRN3P2	0.7	9.74	0.51	2.28e-19	Menopause (age at onset);
CESC	trans	rs7819412	0.806	rs6980856	chr8:10938260	A/G	cg06636001	chr8:8085503	FLJ10661	0.52	6.54	0.37	3.07e-10	Triglycerides;
CESC	cis	rs10504229	0.636	rs77753517	chr8:58115897	C/T	cg21724239	chr8:58056113	NA	0.58	5.95	0.34	8.29e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs2425143	1.000	rs11699690	chr20:34271774	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.61	5.16	0.3	4.75e-7	Blood protein levels;
CESC	cis	rs6964587	0.869	rs10242792	chr7:91492103	A/C	cg17063962	chr7:91808500	NA	0.49	6.52	0.37	3.47e-10	Breast cancer;
CESC	cis	rs34779708	0.733	rs61449529	chr10:35543914	T/C	cg04310649	chr10:35416472	CREM	-0.47	-5.38	-0.31	1.67e-7	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs3820928	0.874	rs10195072	chr2:227794452	G/A	cg11843606	chr2:227700838	RHBDD1	-0.43	-5.63	-0.33	4.51e-8	Pulmonary function;
CESC	cis	rs4925325	0.956	rs1776263	chr20:60515820	A/G	cg06108461	chr20:60628389	TAF4	-0.5	-5.95	-0.34	8.26e-9	Obesity-related traits;
CESC	cis	rs763121	0.744	rs5757140	chr22:38957013	T/C	cg06544989	chr22:39130855	UNC84B	0.49	8.15	0.45	1.42e-14	Menopause (age at onset);
CESC	cis	rs7772486	0.719	rs702317	chr6:146005010	C/T	cg23711669	chr6:146136114	FBXO30	-0.99	-14.35	-0.66	5.95e-35	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9911578	0.803	rs8069033	chr17:57131581	T/A	cg05425664	chr17:57184151	TRIM37	0.53	7.36	0.41	2.26e-12	Intelligence (multi-trait analysis);
CESC	cis	rs34779708	0.733	rs12777960	chr10:35541026	C/A	cg03585969	chr10:35415529	CREM	0.56	6.42	0.37	6.15e-10	Inflammatory bowel disease;Crohn's disease;
CESC	trans	rs948562	0.744	rs113392266	chr11:58219751	C/G	cg24637035	chr12:120445227	CCDC64	-0.5	-6.06	-0.35	4.67e-9	Lymphoma;
CESC	cis	rs4713118	0.662	rs464312	chr6:27967591	T/A	cg23161317	chr6:28129485	ZNF389	0.46	6.19	0.36	2.32e-9	Parkinson's disease;
CESC	cis	rs7927771	1.000	rs11605774	chr11:47832793	G/A	cg20307385	chr11:47447363	PSMC3	-0.49	-5.98	-0.34	7.23e-9	Subjective well-being;
CESC	cis	rs7071206	0.947	rs716255	chr10:79419679	A/T	cg07817648	chr10:79422355	NA	-0.85	-10.89	-0.56	4.71e-23	Bone mineral density;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15498283	chr11:747520	TALDO1	0.56	6.37	0.36	8.55e-10	Gut microbiome composition (summer);
CESC	cis	rs1372520	0.567	rs2619349	chr4:90746646	G/T	cg15133208	chr4:90757351	SNCA	-0.4	-5.42	-0.32	1.34e-7	Neuroticism;
CESC	cis	rs10949834	1.000	rs11770302	chr7:73485252	G/C	cg07137043	chr7:73588983	EIF4H	-0.63	-5.24	-0.31	3.26e-7	Verbal memory performance (residualized delayed recall change);
CESC	cis	rs3820068	0.822	rs2901964	chr1:15792426	C/G	cg16988262	chr1:15930761	NA	0.35	5.54	0.32	7.38e-8	Systolic blood pressure;
CESC	cis	rs453301	0.682	rs2929451	chr8:9085295	A/T	cg06636001	chr8:8085503	FLJ10661	0.54	7.4	0.41	1.81e-12	Joint mobility (Beighton score);
CESC	cis	rs7618915	0.547	rs34610142	chr3:52708429	G/A	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.66	0.38	1.54e-10	Bipolar disorder;
CESC	cis	rs875971	0.790	rs10257911	chr7:65743770	A/G	cg18252515	chr7:66147081	NA	0.44	5.85	0.34	1.48e-8	Aortic root size;
CESC	trans	rs2488397	0.750	rs35939830	chr1:197561510	C/T	cg13426224	chr12:133196447	P2RX2	-0.46	-6.01	-0.35	6.2e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs7666738	0.830	rs6855393	chr4:99056534	T/C	cg03676636	chr4:99064102	C4orf37	0.34	5.15	0.3	5.06e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9303401	0.646	rs7213269	chr17:57237796	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.56	7.32	0.41	2.93e-12	Cognitive test performance;
CESC	cis	rs7179456	0.513	rs593742	chr15:59045774	A/G	cg05156742	chr15:59063176	FAM63B	0.55	6.74	0.38	9.99e-11	Asperger disorder;
CESC	cis	rs4523957	0.786	rs28524880	chr17:2125444	C/A	cg16513277	chr17:2031491	SMG6	-0.62	-8.67	-0.47	4.51e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs6445797	0.855	rs7646924	chr3:56570947	G/C	cg13792233	chr3:56591045	CCDC66	-0.38	-5.26	-0.31	2.98e-7	Gastritis;
CESC	cis	rs919433	0.889	rs787995	chr2:198216853	T/G	cg03934865	chr2:198174659	NA	0.44	6.47	0.37	4.71e-10	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs854765	0.822	rs1889014	chr17:17767165	C/T	cg04398451	chr17:18023971	MYO15A	0.6	8.25	0.45	7.68e-15	Total body bone mineral density;
CESC	cis	rs80130819	0.688	rs11168455	chr12:48592792	G/A	cg07561017	chr12:48398056	COL2A1	0.38	5.11	0.3	6.08e-7	Prostate cancer;
CESC	cis	rs738144	0.542	rs4303811	chr22:39157755	A/G	cg06022373	chr22:39101656	GTPBP1	-0.55	-5.3	-0.31	2.42e-7	IgG glycosylation;
CESC	cis	rs7618915	0.501	rs11714030	chr3:52765882	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.62	8.63	0.47	5.7e-16	Bipolar disorder;
CESC	cis	rs7945705	0.782	rs2742545	chr11:8884308	C/G	cg12365402	chr11:9010492	NRIP3	-0.33	-5.25	-0.31	3.14e-7	Hemoglobin concentration;
CESC	cis	rs17253792	0.822	rs75663029	chr14:56092385	T/C	cg01858014	chr14:56050164	KTN1	-0.85	-6.99	-0.39	2.22e-11	Putamen volume;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg08597319	chr8:103876573	AZIN1	-0.49	-6.22	-0.36	1.88e-9	Ulcerative colitis;
CESC	cis	rs787274	0.543	rs1324930	chr9:115634639	A/G	cg13803584	chr9:115635662	SNX30	0.64	5.98	0.34	7.3e-9	Age-related hearing impairment (SNP x SNP interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05543547	chr10:119135213	PDZD8	0.53	6.01	0.35	6.18e-9	Gut microbiome composition (summer);
CESC	cis	rs10504073	0.647	rs10808744	chr8:49988984	A/G	cg00325661	chr8:49890786	NA	0.54	7.92	0.44	6.4e-14	Blood metabolite ratios;
CESC	cis	rs10540	1.000	rs12788729	chr11:502371	G/A	cg03576123	chr11:487126	PTDSS2	-1.12	-11.21	-0.57	3.93e-24	Body mass index;
CESC	cis	rs7826238	0.566	rs2945886	chr8:8148270	C/G	cg06636001	chr8:8085503	FLJ10661	0.61	7.96	0.44	5e-14	Systolic blood pressure;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01985186	chr16:31448002	ZNF843	-0.5	-6.02	-0.35	5.81e-9	Gut microbiome composition (summer);
CESC	cis	rs7107174	1.000	rs2373115	chr11:78091150	G/T	cg02023728	chr11:77925099	USP35	0.41	6.01	0.35	6.21e-9	Testicular germ cell tumor;
CESC	cis	rs6580649	0.941	rs7312326	chr12:48480643	G/A	cg24011408	chr12:48396354	COL2A1	-0.4	-5.04	-0.3	8.67e-7	Lung cancer;
CESC	cis	rs780096	0.526	rs3845687	chr2:27689899	T/C	cg21248554	chr2:27665150	KRTCAP3	-0.37	-7.68	-0.43	3.02e-13	Total body bone mineral density;
CESC	cis	rs59574136	1	rs59574136	chr7:2036460	T/C	cg22963979	chr7:1858916	MAD1L1	-0.39	-5.32	-0.31	2.26e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs7385804	0.766	rs1734909	chr7:100309582	C/G	cg16850897	chr7:100343110	ZAN	0.47	6.41	0.37	6.69e-10	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
CESC	cis	rs6952808	0.692	rs56727870	chr7:2029940	T/C	cg23048001	chr7:2026167	MAD1L1	0.47	6.11	0.35	3.5e-9	Bipolar disorder and schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05815920	chr10:103880348	LDB1	0.56	6.31	0.36	1.17e-9	Gut microbiome composition (summer);
CESC	cis	rs11745587	0.539	rs6897597	chr5:131743465	C/T	cg21138405	chr5:131827807	IRF1	0.36	5.54	0.32	7.4e-8	Asthma;
CESC	trans	rs1814175	0.702	rs4881644	chr11:49786367	C/T	cg03929089	chr4:120376271	NA	-0.9	-14.71	-0.67	3.25e-36	Height;
CESC	trans	rs3087243	0.728	rs231734	chr2:204694280	G/A	cg01841312	chr10:38069945	NA	0.4	6.76	0.38	8.92e-11	Rheumatoid arthritis;Hypothyroidism;Type 1 diabetes;
CESC	cis	rs12477438	0.784	rs13407840	chr2:99569928	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.64	-8.59	-0.47	7.8e-16	Chronic sinus infection;
CESC	cis	rs6732160	0.564	rs1430346	chr2:73367245	T/C	cg01422370	chr2:73384389	NA	0.57	8.83	0.48	1.43e-16	Intelligence (multi-trait analysis);
CESC	trans	rs9467711	0.606	rs9379858	chr6:26367689	T/C	cg06606381	chr12:133084897	FBRSL1	-0.76	-6.86	-0.39	4.71e-11	Autism spectrum disorder or schizophrenia;
CESC	cis	rs4253772	0.550	rs715515	chr22:46720921	G/A	cg18190219	chr22:46762943	CELSR1	-0.59	-5.82	-0.34	1.71e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs11098499	0.954	rs10024844	chr4:120311528	A/G	cg24375607	chr4:120327624	NA	0.46	5.55	0.32	6.98e-8	Corneal astigmatism;
CESC	cis	rs9311474	0.569	rs7614981	chr3:52566914	G/T	cg17372223	chr3:52568218	NT5DC2	0.56	9.65	0.51	4.61e-19	Electroencephalogram traits;
CESC	cis	rs11690935	0.550	rs62183784	chr2:172866696	A/G	cg13550731	chr2:172543902	DYNC1I2	0.49	6.76	0.38	8.6e-11	Schizophrenia;
CESC	trans	rs17685	0.672	rs1639623	chr7:75707951	A/G	cg19862616	chr7:65841803	NCRNA00174	0.85	12.47	0.61	2.13e-28	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs4819052	0.851	rs2877019	chr21:46658647	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.46	5.77	0.33	2.18e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs12973672	0.812	rs12986033	chr19:35748782	A/G	cg12095397	chr19:35769544	USF2	0.49	5.97	0.34	7.44e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs965469	1.000	rs2236107	chr20:3285821	C/T	cg25506879	chr20:3388711	C20orf194	-0.57	-5.91	-0.34	1.04e-8	IFN-related cytopenia;
CESC	cis	rs2735413	0.875	rs8055298	chr16:78084868	C/G	cg04733911	chr16:78082701	NA	0.54	9.1	0.49	2.18e-17	Systolic blood pressure (alcohol consumption interaction);
CESC	trans	rs7604827	0.915	rs73072790	chr2:215330774	C/T	cg26520399	chr15:25332888	SNORD116-20;SNORD116-21	0.48	6.06	0.35	4.74e-9	PR interval;
CESC	cis	rs3741151	0.656	rs73550316	chr11:73299799	G/A	cg17517138	chr11:73019481	ARHGEF17	1.02	7.43	0.42	1.51e-12	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs656900	0.874	rs622506	chr15:80139195	A/C	cg02196730	chr15:80188777	MTHFS	-0.43	-5.52	-0.32	8.05e-8	Cerebrospinal P-tau181p levels;
CESC	cis	rs2115630	0.645	rs2292463	chr15:85175750	A/G	cg11189052	chr15:85197271	WDR73	-0.47	-6.36	-0.36	8.61e-10	P wave terminal force;
CESC	cis	rs4665809	1.000	rs4665298	chr2:26256378	G/A	cg04944784	chr2:26401820	FAM59B	-0.64	-7.31	-0.41	3.21e-12	Gut microbiome composition (summer);
CESC	cis	rs12586317	0.547	rs77262907	chr14:35495734	C/G	cg16230307	chr14:35515116	FAM177A1	0.99	10.61	0.55	3.72e-22	Psoriasis;
CESC	cis	rs1799949	1.000	rs8176109	chr17:41265776	A/G	cg25072359	chr17:41440525	NA	0.44	5.91	0.34	1.06e-8	Menopause (age at onset);
CESC	cis	rs7666738	0.791	rs13146909	chr4:98934198	C/T	cg03467027	chr4:99064603	C4orf37	0.48	5.91	0.34	1.03e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11166629	0.502	rs2439813	chr8:135669158	C/T	cg27224718	chr8:135614730	ZFAT	0.41	5.09	0.3	6.86e-7	Smoking quantity;
CESC	cis	rs79057730	0.528	rs6965219	chr7:821807	C/G	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.68	6.15	0.35	2.91e-9	Initial pursuit acceleration;
CESC	cis	rs2228479	0.717	rs2074904	chr16:89811546	A/G	cg04013166	chr16:89971882	TCF25	0.79	6.78	0.38	7.83e-11	Skin colour saturation;
CESC	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg22535103	chr8:58192502	C8orf71	-0.92	-10.16	-0.53	1.04e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs881375	0.900	rs2241003	chr9:123666777	G/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	5.94	0.34	8.87e-9	Rheumatoid arthritis;
CESC	cis	rs4481887	0.962	rs12037921	chr1:248454167	T/G	cg00666640	chr1:248458726	OR2T12	0.38	6.24	0.36	1.7e-9	Common traits (Other);
CESC	cis	rs9611565	0.694	rs5751107	chr22:41857812	A/G	cg06634786	chr22:41940651	POLR3H	0.72	7.39	0.41	1.94e-12	Vitiligo;
CESC	cis	rs6952808	0.609	rs12699453	chr7:1953056	C/T	cg05279229	chr7:1896384	MAD1L1	-0.39	-5.11	-0.3	6.13e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs6460942	0.915	rs62448599	chr7:12453764	C/T	cg20607287	chr7:12443886	VWDE	-0.77	-8.7	-0.47	3.63e-16	Coronary artery disease;
CESC	cis	rs9916302	0.706	rs8067511	chr17:37611352	C/T	cg07936489	chr17:37558343	FBXL20	-0.92	-9.65	-0.51	4.39e-19	Glomerular filtration rate (creatinine);
CESC	cis	rs7208859	0.573	rs56031503	chr17:29075665	T/C	cg14008862	chr17:28927542	LRRC37B2	0.65	5.19	0.3	4.21e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg16978263	chr3:160118452	SMC4;IFT80	0.48	6.11	0.35	3.54e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs896854	0.631	rs10097617	chr8:95961626	T/C	cg26343298	chr8:95960752	TP53INP1	0.35	5.83	0.34	1.57e-8	Type 2 diabetes;
CESC	cis	rs731174	0.802	rs502776	chr1:38182164	T/A	cg12339802	chr1:38156545	C1orf109	-0.5	-5.2	-0.3	4.01e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs13256369	0.708	rs11783670	chr8:8559394	G/A	cg17143192	chr8:8559678	CLDN23	0.77	8.63	0.47	5.79e-16	Obesity-related traits;
CESC	cis	rs7412746	0.658	rs59988025	chr1:150940358	C/T	cg04414720	chr1:150670196	GOLPH3L	0.5	6.49	0.37	4.21e-10	Melanoma;
CESC	cis	rs35955841	0.569	rs12437108	chr14:65309550	G/A	cg23373153	chr14:65346875	NA	0.44	5.76	0.33	2.32e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
CESC	cis	rs853679	0.517	rs9393896	chr6:28127703	C/T	cg23281280	chr6:28129359	ZNF389	0.59	7.91	0.44	6.86e-14	Depression;
CESC	cis	rs4665809	1.000	rs2384322	chr2:26291146	C/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.83	-9.25	-0.49	7.55e-18	Gut microbiome composition (summer);
CESC	cis	rs597539	0.652	rs553875	chr11:68695144	T/G	cg04772025	chr11:68637568	NA	0.57	6.59	0.38	2.35e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs1595825	0.891	rs7580003	chr2:198517893	C/T	cg10820045	chr2:198174542	NA	0.41	5.17	0.3	4.69e-7	Ulcerative colitis;
CESC	cis	rs1008375	1.000	rs10805358	chr4:17652450	A/C	cg16339924	chr4:17578868	LAP3	0.55	6.83	0.39	5.88e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs10504229	1.000	rs68076606	chr8:58191271	A/G	cg24829409	chr8:58192753	C8orf71	-0.76	-9.93	-0.52	5.87e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs7937682	1.000	rs12363179	chr11:111568091	G/A	cg22437258	chr11:111473054	SIK2	-0.68	-7.83	-0.43	1.19e-13	Primary sclerosing cholangitis;
CESC	trans	rs7656342	0.808	rs10003216	chr4:9766749	A/G	cg01814833	chr7:75623698	TMEM120A	-0.53	-6.05	-0.35	5.04e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs1879734	0.636	rs12080903	chr1:54178270	G/A	cg23596471	chr1:54105337	GLIS1	0.31	5.03	0.3	8.88e-7	Mitral valve prolapse;
CESC	cis	rs1003719	0.742	rs8129231	chr21:38501034	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.61	-8.21	-0.45	9.49e-15	Eye color traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09302448	chr16:67562672	FAM65A	0.62	7.13	0.4	9.71e-12	Gut microbiome composition (summer);
CESC	cis	rs854765	0.547	rs2955383	chr17:17941364	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.56	8.0	0.44	3.85e-14	Total body bone mineral density;
CESC	cis	rs12477438	0.520	rs4851187	chr2:99745860	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-16.29	-0.71	7.94e-42	Chronic sinus infection;
CESC	cis	rs10504229	0.636	rs72649133	chr8:58054681	G/A	cg24829409	chr8:58192753	C8orf71	-0.7	-7.79	-0.43	1.49e-13	Developmental language disorder (linguistic errors);
CESC	cis	rs6060717	0.610	rs2794382	chr20:34613651	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.5	6.32	0.36	1.13e-9	Hip circumference adjusted for BMI;
CESC	cis	rs4975709	0.801	rs3797063	chr5:1881549	A/T	cg12288994	chr5:1860383	NA	0.37	5.84	0.34	1.53e-8	Cardiovascular disease risk factors;
CESC	cis	rs12545109	0.765	rs2576589	chr8:57425647	C/T	cg09654669	chr8:57350985	NA	-0.61	-6.85	-0.39	5.2e-11	Obesity-related traits;
CESC	cis	rs2404602	0.563	rs12914005	chr15:76765667	A/G	cg26408565	chr15:76604113	ETFA	-0.43	-6.43	-0.37	5.86e-10	Blood metabolite levels;
CESC	cis	rs782590	0.967	rs1975484	chr2:55803167	T/A	cg18811423	chr2:55921094	PNPT1	0.8	12.92	0.62	6.23e-30	Metabolic syndrome;
CESC	cis	rs4423214	0.592	rs10898186	chr11:71188800	G/A	cg05163923	chr11:71159392	DHCR7	-0.54	-5.76	-0.33	2.36e-8	Vitamin D levels;
CESC	cis	rs9467773	0.620	rs2451738	chr6:26618459	A/T	cg24633756	chr6:26577808	NA	-0.37	-5.61	-0.33	5.13e-8	Intelligence (multi-trait analysis);
CESC	cis	rs12200560	0.505	rs211175	chr6:97073320	C/T	cg06623918	chr6:96969491	KIAA0776	0.5	6.43	0.37	5.95e-10	Coronary heart disease;
CESC	cis	rs863345	0.604	rs1342947	chr1:158459714	G/A	cg12129480	chr1:158549410	OR10X1	-0.36	-7.14	-0.4	8.93e-12	Pneumococcal bacteremia;
CESC	cis	rs9768139	0.903	rs28503558	chr7:158119568	C/T	cg06219351	chr7:158114137	PTPRN2	0.49	7.69	0.43	2.82e-13	Calcium levels;
CESC	cis	rs7811142	1.000	rs11559117	chr7:100076614	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.83	8.24	0.45	7.99e-15	Platelet count;
CESC	cis	rs2749592	0.550	rs7081464	chr10:37883937	C/T	cg25427524	chr10:38739819	LOC399744	0.54	7.36	0.41	2.31e-12	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs6912958	0.582	rs242285	chr6:88070743	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.5	8.8	0.48	1.8e-16	Monocyte percentage of white cells;
CESC	cis	rs2228479	0.850	rs2190808	chr16:89840856	C/T	cg00800038	chr16:89945340	TCF25	-0.92	-7.64	-0.42	4.02e-13	Skin colour saturation;
CESC	cis	rs2075671	0.855	rs11974395	chr7:100282538	G/A	cg16850897	chr7:100343110	ZAN	-0.7	-8.88	-0.48	1.04e-16	Other erythrocyte phenotypes;
CESC	cis	rs910316	0.737	rs28687415	chr14:75495482	T/C	cg08847533	chr14:75593920	NEK9	0.92	16.29	0.71	8.22e-42	Height;
CESC	cis	rs3806843	0.735	rs2563335	chr5:140044292	A/C	cg26395211	chr5:140044315	WDR55	-0.48	-6.06	-0.35	4.75e-9	Depressive symptoms (multi-trait analysis);
CESC	cis	rs1799949	1.000	rs12942277	chr17:41187974	G/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.39	5.06	0.3	7.92e-7	Menopause (age at onset);
CESC	cis	rs2014572	0.904	rs10412465	chr19:57753931	T/C	cg24459738	chr19:57751996	ZNF805	-0.57	-8.01	-0.44	3.74e-14	Hyperactive-impulsive symptoms;
CESC	cis	rs10256972	0.967	rs7799110	chr7:1039065	A/G	cg07308232	chr7:1071921	C7orf50	-0.41	-5.59	-0.32	5.56e-8	Longevity;Endometriosis;
CESC	cis	rs10876993	0.928	rs1689596	chr12:58053029	T/C	cg18357645	chr12:58087776	OS9	0.63	9.92	0.52	6.15e-20	Celiac disease or Rheumatoid arthritis;
CESC	cis	rs9457247	0.935	rs1794697	chr6:167395410	C/T	cg07741184	chr6:167504864	NA	0.29	5.18	0.3	4.34e-7	Crohn's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12498654	chr6:139456103	HECA	0.53	6.0	0.35	6.54e-9	Gut microbiome composition (summer);
CESC	cis	rs9581857	0.579	rs75872792	chr13:27996064	G/T	cg22138327	chr13:27999177	GTF3A	0.64	5.41	0.32	1.43e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
CESC	cis	rs3741151	0.773	rs7951072	chr11:73221721	G/A	cg17517138	chr11:73019481	ARHGEF17	0.98	7.25	0.41	4.61e-12	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs8049040	0.609	rs4258624	chr16:71467951	C/T	cg08717414	chr16:71523259	ZNF19	0.54	6.34	0.36	1.01e-9	Blood protein levels;
CESC	cis	rs4566357	0.595	rs1320406	chr2:227920474	C/T	cg11843606	chr2:227700838	RHBDD1	-0.51	-7.3	-0.41	3.4e-12	Coronary artery disease;
CESC	cis	rs11077998	0.933	rs6502121	chr17:80531314	A/G	cg10255544	chr17:80519551	FOXK2	0.55	8.73	0.47	2.83e-16	Reticulocyte fraction of red cells;
CESC	cis	rs3761218	0.738	rs4815604	chr20:3772913	C/T	cg25011176	chr20:3776985	CDC25B	-0.42	-5.52	-0.32	7.89e-8	Bipolar disorder;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg14546712	chr8:41478669	AGPAT6	0.53	6.94	0.39	2.94e-11	Fibrinogen levels;
CESC	cis	rs7223966	1.000	rs7223672	chr17:61720565	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.56	6.63	0.38	1.84e-10	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs11809207	0.501	rs3762460	chr1:26495550	A/G	cg00147160	chr1:26503991	CNKSR1	0.3	5.75	0.33	2.47e-8	Height;
CESC	cis	rs9948	0.786	rs62156230	chr2:97424915	A/G	cg01990225	chr2:97406019	LMAN2L	-0.86	-7.49	-0.42	1.03e-12	Erectile dysfunction and prostate cancer treatment;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03729566	chr7:1059678	C7orf50	-0.59	-6.62	-0.38	1.98e-10	Gut microbiome composition (summer);
CESC	cis	rs1729951	0.575	rs361243	chr3:136697786	C/T	cg25687071	chr3:136751404	NA	0.4	5.33	0.31	2.15e-7	Neuroticism;
CESC	cis	rs9467711	0.606	rs9379858	chr6:26367689	T/C	cg14345882	chr6:26364793	BTN3A2	0.6	6.21	0.36	2.06e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs7605827	0.897	rs11675604	chr2:15672901	C/T	cg19274914	chr2:15703543	NA	0.33	5.76	0.33	2.28e-8	Educational attainment (years of education);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09102409	chr8:134308734	NDRG1	-0.61	-7.49	-0.42	1.05e-12	Gut microbiome composition (summer);
CESC	cis	rs7914558	0.966	rs7921574	chr10:104840970	T/C	cg04362960	chr10:104952993	NT5C2	0.47	6.12	0.35	3.36e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs2282802	0.685	rs13170475	chr5:139671062	C/T	cg26211634	chr5:139558579	C5orf32	0.48	6.99	0.39	2.17e-11	Intelligence (multi-trait analysis);
CESC	cis	rs734999	0.505	rs4073285	chr1:2539796	C/T	cg18854424	chr1:2615690	NA	0.3	5.83	0.34	1.57e-8	Ulcerative colitis;
CESC	cis	rs4704187	0.687	rs7709707	chr5:74363575	T/G	cg03227963	chr5:74354835	NA	0.31	5.71	0.33	2.97e-8	Response to amphetamines;
CESC	cis	rs798554	0.797	rs1182184	chr7:2872446	G/A	cg04166393	chr7:2884313	GNA12	0.59	7.78	0.43	1.66e-13	Height;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg03488284	chr16:23607835	NDUFAB1	-0.47	-6.29	-0.36	1.31e-9	Fibrinogen levels;
CESC	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg11494091	chr17:61959527	GH2	0.73	12.52	0.61	1.41e-28	Prudent dietary pattern;
CESC	cis	rs1552244	0.608	rs3732962	chr3:10048951	T/C	cg00149659	chr3:10157352	C3orf10	0.53	6.51	0.37	3.81e-10	Alzheimer's disease;
CESC	trans	rs208520	0.609	rs208436	chr6:66897470	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.66	-8.07	-0.44	2.54e-14	Exhaled nitric oxide output;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg23262030	chr17:45918702	SCRN2	-0.48	-6.07	-0.35	4.29e-9	Ulcerative colitis;
CESC	cis	rs3820068	0.577	rs41270271	chr1:15913582	G/C	cg17385448	chr1:15911702	AGMAT	0.43	6.71	0.38	1.15e-10	Systolic blood pressure;
CESC	cis	rs798554	0.660	rs1182196	chr7:2866478	T/G	cg19717773	chr7:2847554	GNA12	-0.58	-9.13	-0.49	1.87e-17	Height;
CESC	cis	rs2997447	0.761	rs17356867	chr1:26448849	C/T	cg24596570	chr1:26146463	FAM54B;LOC646471	-0.59	-5.37	-0.31	1.76e-7	QRS complex (12-leadsum);
CESC	cis	rs12541335	0.590	rs11136002	chr8:22217082	C/T	cg18135555	chr8:22132992	PIWIL2	0.25	5.26	0.31	2.92e-7	Hypertriglyceridemia;
CESC	cis	rs7772486	0.720	rs6931553	chr6:146112348	T/C	cg05347473	chr6:146136440	FBXO30	-0.56	-7.08	-0.4	1.29e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4819052	0.808	rs2838825	chr21:46655651	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.91	12.86	0.62	9.49e-30	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs7833790	0.926	rs72686467	chr8:82758929	T/G	cg27398817	chr8:82754497	SNX16	0.56	6.44	0.37	5.68e-10	Diastolic blood pressure;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25886337	chr2:73441702	SMYD5	0.61	6.88	0.39	4.33e-11	Gut microbiome composition (summer);
CESC	cis	rs2070997	0.816	rs6597642	chr9:133725767	C/T	cg11464064	chr9:133710261	ABL1	0.55	5.57	0.32	6.37e-8	Response to amphetamines;
CESC	cis	rs7772486	0.875	rs2814875	chr6:146305810	G/A	cg23711669	chr6:146136114	FBXO30	0.9	13.1	0.63	1.45e-30	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs3733585	0.673	rs10000983	chr4:9951606	T/C	cg11266682	chr4:10021025	SLC2A9	-0.59	-11.13	-0.56	7.1e-24	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs3925075	1.000	rs4506917	chr16:31347350	T/G	cg02846316	chr16:31340340	ITGAM	0.41	6.52	0.37	3.54e-10	IgA nephropathy;
CESC	cis	rs56104184	0.775	rs55737338	chr19:49403141	A/G	cg15549821	chr19:49342101	PLEKHA4	-0.6	-5.99	-0.35	6.95e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	cis	rs9908102	0.740	rs55883319	chr17:12907513	G/C	cg26162695	chr17:12921313	ELAC2	0.51	5.64	0.33	4.33e-8	Schizophrenia;
CESC	cis	rs5753618	0.504	rs8142121	chr22:31882785	G/A	cg02404636	chr22:31891804	SFI1	0.4	5.3	0.31	2.39e-7	Colorectal cancer;
CESC	cis	rs4835473	0.831	rs4323050	chr4:144913259	T/C	cg25736465	chr4:144833511	NA	0.43	6.44	0.37	5.61e-10	Immature fraction of reticulocytes;
CESC	cis	rs13191362	1.000	rs13218900	chr6:163081638	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.0	10.3	0.53	3.82e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs12142240	0.698	rs41293285	chr1:46808426	C/T	cg00530320	chr1:46809349	NSUN4	0.6	7.98	0.44	4.48e-14	Menopause (age at onset);
CESC	cis	rs8050907	0.590	rs17137096	chr16:4558553	C/A	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.8	5.38	0.31	1.61e-7	Obesity-related traits;
CESC	cis	rs6500395	1.000	rs12919520	chr16:48705760	G/C	cg04672837	chr16:48644449	N4BP1	-0.51	-6.53	-0.37	3.33e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs727563	0.635	rs5758444	chr22:42133921	T/A	cg06634786	chr22:41940651	POLR3H	0.69	7.02	0.4	1.86e-11	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs9581857	0.579	rs75024088	chr13:27970105	G/T	cg01674679	chr13:27998804	GTF3A	-0.67	-5.25	-0.31	3.15e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
CESC	cis	rs2455799	0.574	rs2470534	chr3:15701054	C/G	cg16303742	chr3:15540471	COLQ	0.39	6.27	0.36	1.47e-9	Mean platelet volume;
CESC	cis	rs8060686	0.920	rs16942887	chr16:67928042	G/A	cg26727032	chr16:67993705	SLC12A4	-0.57	-6.74	-0.38	1e-10	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs514406	0.505	rs7543239	chr1:53162416	A/G	cg08736216	chr1:53307985	ZYG11A	-0.4	-6.79	-0.38	7.53e-11	Monocyte count;
CESC	cis	rs2075371	1.000	rs2598285	chr7:133971153	A/T	cg00033643	chr7:134001901	SLC35B4	0.41	5.28	0.31	2.7e-7	Mean platelet volume;
CESC	cis	rs6860806	0.661	rs28472559	chr5:131581611	G/A	cg22638593	chr5:131593259	PDLIM4	0.42	5.43	0.32	1.26e-7	Breast cancer;
CESC	cis	rs933688	1.000	rs4382199	chr5:90744228	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.1	12.03	0.59	6.99e-27	Smoking behavior;
CESC	cis	rs67311347	0.955	rs4973999	chr3:40460383	G/A	cg09455208	chr3:40491958	NA	0.45	7.84	0.43	1.1e-13	Renal cell carcinoma;
CESC	cis	rs60154123	0.730	rs587203	chr1:210463786	C/T	cg23283495	chr1:209979779	IRF6	0.38	5.11	0.3	6.31e-7	Coronary artery disease;
CESC	cis	rs7267979	0.932	rs6138600	chr20:25521346	A/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.76	13.66	0.64	1.58e-32	Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs7615952	0.641	rs7640158	chr3:125808011	G/A	cg07211511	chr3:129823064	LOC729375	-0.56	-6.22	-0.36	1.92e-9	Blood pressure (smoking interaction);
CESC	cis	rs9611565	0.512	rs715498	chr22:42148467	G/A	cg03806693	chr22:41940476	POLR3H	1.19	14.08	0.65	5.29e-34	Vitiligo;
CESC	cis	rs116095464	0.558	rs10080225	chr5:232175	A/G	cg12570787	chr5:219185	SDHA;CCDC127	0.52	5.41	0.32	1.43e-7	Breast cancer;
CESC	cis	rs3096299	0.900	rs2911258	chr16:89480760	A/G	cg16743903	chr16:89593216	SPG7	-0.42	-5.35	-0.31	1.93e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs6598955	0.666	rs12759434	chr1:26607123	C/T	cg00852783	chr1:26633632	UBXN11	0.42	6.11	0.35	3.58e-9	Obesity-related traits;
CESC	trans	rs916888	0.738	rs199515	chr17:44856641	C/G	cg23590916	chr17:43697445	MGC57346	-0.64	-7.02	-0.4	1.84e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16558908	chr1:33896237	NA	0.54	6.07	0.35	4.47e-9	Gut microbiome composition (summer);
CESC	cis	rs9549367	0.713	rs553316	chr13:113838015	A/G	cg18105134	chr13:113819100	PROZ	0.55	7.11	0.4	1.1e-11	Platelet distribution width;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg16248187	chr2:153191727	FMNL2	-0.5	-6.07	-0.35	4.46e-9	Ulcerative colitis;
CESC	cis	rs2197308	0.715	rs11181816	chr12:37911626	A/G	cg26384229	chr12:38710491	ALG10B	-0.55	-7.85	-0.43	1.02e-13	Morning vs. evening chronotype;
CESC	cis	rs3733585	0.648	rs35954357	chr4:9978758	G/C	cg00071950	chr4:10020882	SLC2A9	0.69	11.14	0.56	6.55e-24	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs796364	1.000	rs4263095	chr2:200830137	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.85	-8.67	-0.47	4.4e-16	Schizophrenia;
CESC	cis	rs1008375	1.000	rs2315561	chr4:17679695	C/T	cg16339924	chr4:17578868	LAP3	0.48	6.13	0.35	3.14e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs875971	0.545	rs3735147	chr7:65970528	A/C	cg18876405	chr7:65276391	NA	0.48	5.52	0.32	8.06e-8	Aortic root size;
CESC	cis	rs4319547	1.000	rs1392236	chr12:123074890	C/G	cg05707623	chr12:122985044	ZCCHC8	-0.58	-6.75	-0.38	9.4e-11	Body mass index;
CESC	cis	rs2243480	1.000	rs431318	chr7:65511597	G/A	cg25894440	chr7:65020034	NA	-0.61	-5.12	-0.3	5.79e-7	Diabetic kidney disease;
CESC	cis	rs9611565	0.921	rs2281332	chr22:41746212	T/C	cg06481639	chr22:41940642	POLR3H	-0.45	-5.25	-0.31	3.14e-7	Vitiligo;
CESC	cis	rs6460942	0.749	rs74834695	chr7:12464779	G/A	cg20607287	chr7:12443886	VWDE	-0.78	-9.15	-0.49	1.61e-17	Coronary artery disease;
CESC	cis	rs2075371	1.000	rs2544210	chr7:133971535	C/T	cg11752832	chr7:134001865	SLC35B4	0.52	6.73	0.38	1.04e-10	Mean platelet volume;
CESC	cis	rs2072732	0.821	rs12034766	chr1:2944038	A/G	cg03976712	chr1:2946727	NA	0.34	5.35	0.31	1.9e-7	Plateletcrit;
CESC	cis	rs7762018	0.514	rs60671539	chr6:170165981	A/G	cg00262263	chr6:170184901	NA	0.44	6.63	0.38	1.88e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs728616	0.867	rs12414096	chr10:81713629	A/G	cg05935833	chr10:81318306	SFTPA2	-0.51	-5.04	-0.3	8.51e-7	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs2228479	0.764	rs35518096	chr16:89961140	C/A	cg06558623	chr16:89946397	TCF25	0.69	6.1	0.35	3.69e-9	Skin colour saturation;
CESC	cis	rs3820068	0.581	rs6692489	chr1:15928517	A/G	cg13390004	chr1:15929781	NA	0.34	5.45	0.32	1.13e-7	Systolic blood pressure;
CESC	cis	rs7927592	0.913	rs12294029	chr11:68257059	A/C	cg20283391	chr11:68216788	NA	-0.53	-6.41	-0.37	6.5e-10	Total body bone mineral density;
CESC	cis	rs1059312	0.808	rs4482069	chr12:129294252	G/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.82	-12.1	-0.6	3.83e-27	Systemic lupus erythematosus;
CESC	trans	rs1814175	0.546	rs1614397	chr11:49913384	G/C	cg03929089	chr4:120376271	NA	-0.93	-15.69	-0.69	1.12e-39	Height;
CESC	cis	rs6570726	0.905	rs452770	chr6:145847162	T/C	cg05347473	chr6:146136440	FBXO30	0.49	6.62	0.38	1.96e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs10479542	0.892	rs7736163	chr5:178980316	G/C	cg05457628	chr5:178986728	RUFY1	0.51	7.68	0.43	3.09e-13	Lung cancer;
CESC	cis	rs698833	0.638	rs698786	chr2:44744897	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.42	5.18	0.3	4.3e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	trans	rs7615952	0.576	rs4646759	chr3:125822946	G/C	cg07211511	chr3:129823064	LOC729375	-0.57	-6.28	-0.36	1.38e-9	Blood pressure (smoking interaction);
CESC	cis	rs2963155	0.518	rs55817235	chr5:142765733	C/T	cg17617527	chr5:142782415	NR3C1	0.82	6.79	0.39	7.2e-11	Breast cancer;
CESC	cis	rs17711722	0.510	rs73142128	chr7:65331109	A/C	cg19163074	chr7:65112434	INTS4L2	-0.46	-5.5	-0.32	8.86e-8	Calcium levels;
CESC	cis	rs919433	0.926	rs787997	chr2:198216271	A/G	cg03934865	chr2:198174659	NA	0.44	6.49	0.37	4.2e-10	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs734999	0.545	rs4648356	chr1:2709164	C/A	cg20673091	chr1:2541236	MMEL1	0.48	7.84	0.43	1.07e-13	Ulcerative colitis;
CESC	cis	rs7959452	0.649	rs4761239	chr12:69776886	T/A	cg20891283	chr12:69753455	YEATS4	0.89	14.3	0.66	9.23e-35	Blood protein levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02588659	chr11:45826627	SLC35C1	0.63	6.87	0.39	4.67e-11	Gut microbiome composition (summer);
CESC	cis	rs11098499	0.818	rs10008791	chr4:120431469	A/C	cg24375607	chr4:120327624	NA	0.44	5.27	0.31	2.85e-7	Corneal astigmatism;
CESC	cis	rs113601626	1	rs113601626	chr2:24239189	T/TCCTGGC	cg08917208	chr2:24149416	ATAD2B	1.13	9.83	0.52	1.17e-19	Lymphocyte percentage of white cells;
CESC	cis	rs7188697	0.922	rs4471670	chr16:58601365	G/A	cg21335942	chr16:58549945	SETD6	-0.45	-5.2	-0.3	4.06e-7	QT interval;
CESC	cis	rs875971	1.000	rs2420168	chr7:65630631	C/G	cg18876405	chr7:65276391	NA	-0.53	-7.16	-0.4	7.93e-12	Aortic root size;
CESC	cis	rs2439831	0.867	rs2447211	chr15:43936351	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.69	8.5	0.46	1.35e-15	Lung cancer in ever smokers;
CESC	trans	rs6089829	0.890	rs6062775	chr20:61663650	T/C	cg23505145	chr19:12996616	KLF1	0.52	6.74	0.38	1e-10	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs2637266	0.905	rs34173296	chr10:78343389	C/T	cg18941641	chr10:78392320	NA	0.4	7.36	0.41	2.26e-12	Pulmonary function;
CESC	cis	rs7809950	0.678	rs2301801	chr7:106870746	T/C	cg23024343	chr7:107201750	COG5	-0.55	-7.01	-0.4	1.98e-11	Coronary artery disease;
CESC	cis	rs10170846	0.893	rs12614976	chr2:223542896	A/T	cg25565276	chr2:223520875	FARSB	0.57	7.92	0.44	6.64e-14	Schizophrenia (inflammation and infection response interaction);
CESC	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg11494091	chr17:61959527	GH2	0.72	12.38	0.61	4.46e-28	Prudent dietary pattern;
CESC	cis	rs9291683	0.588	rs2240722	chr4:10020757	A/G	cg11266682	chr4:10021025	SLC2A9	0.72	14.83	0.67	1.25e-36	Bone mineral density;
CESC	cis	rs1008375	0.966	rs7658240	chr4:17588950	A/G	cg02297831	chr4:17616191	MED28	-0.53	-6.26	-0.36	1.51e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs6430585	0.591	rs12466487	chr2:136407078	C/T	cg07169764	chr2:136633963	MCM6	-1.13	-11.55	-0.58	2.9e-25	Corneal structure;
CESC	cis	rs3767633	0.800	rs2880055	chr1:161922365	C/T	cg09175582	chr1:161736000	ATF6	0.77	6.62	0.38	1.95e-10	IgG glycosylation;
CESC	cis	rs897984	0.683	rs9932572	chr16:30841642	A/G	cg02466173	chr16:30829666	NA	-0.6	-11.55	-0.58	2.97e-25	Dementia with Lewy bodies;
CESC	trans	rs35110281	0.807	rs9984002	chr21:45061501	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.55	7.22	0.41	5.57e-12	Mean corpuscular volume;
CESC	cis	rs8062405	0.573	rs6565300	chr16:28993049	G/T	cg05966235	chr16:28915196	ATP2A1	0.36	5.2	0.3	4.04e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs9443645	0.527	rs1415859	chr6:79794858	A/G	cg05283184	chr6:79620031	NA	-0.39	-5.58	-0.32	5.88e-8	Intelligence (multi-trait analysis);
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg20930618	chr1:151162157	VPS72	-0.41	-6.13	-0.35	3.1e-9	Vertical cup-disc ratio;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg08492205	chr10:103879827	LDB1	-0.45	-6.1	-0.35	3.65e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs9916302	0.851	rs9909064	chr17:37500434	G/T	cg07936489	chr17:37558343	FBXL20	0.8	11.69	0.58	9.64e-26	Glomerular filtration rate (creatinine);
CESC	cis	rs16867321	0.950	rs4667228	chr2:181498824	T/A	cg23363182	chr2:181467187	NA	-0.43	-5.69	-0.33	3.39e-8	Obesity;
CESC	cis	rs7208859	0.623	rs80355557	chr17:29154421	C/T	cg19761014	chr17:28927070	LRRC37B2	0.72	5.91	0.34	1.03e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs6580649	0.883	rs4075913	chr12:48537624	A/G	cg05342945	chr12:48394962	COL2A1	-0.54	-6.26	-0.36	1.54e-9	Lung cancer;
CESC	cis	rs2637266	1.000	rs12251568	chr10:78345667	C/T	cg18941641	chr10:78392320	NA	0.42	7.79	0.43	1.54e-13	Pulmonary function;
CESC	cis	rs514406	0.661	rs550561	chr1:53375134	C/T	cg24675658	chr1:53192096	ZYG11B	-0.66	-9.13	-0.49	1.78e-17	Monocyte count;
CESC	cis	rs1986734	0.576	rs4624677	chr4:77420406	T/C	cg20311846	chr4:77356250	SHROOM3	-0.28	-5.68	-0.33	3.62e-8	Eosinophilic esophagitis (pediatric);Metabolite levels (small molecules and protein measures);
CESC	cis	rs2842992	0.724	rs9347340	chr6:160188891	C/T	cg26839252	chr6:160211577	TCP1;MRPL18	-0.43	-5.41	-0.32	1.39e-7	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs9457247	0.602	rs9457262	chr6:167473685	A/G	cg23791538	chr6:167370224	RNASET2	-0.52	-6.9	-0.39	3.81e-11	Crohn's disease;
CESC	cis	rs11139399	0.650	rs6559640	chr9:84349735	G/A	cg07852945	chr9:84303915	TLE1	0.37	5.51	0.32	8.35e-8	Hippocampal atrophy;
CESC	cis	rs6570726	0.935	rs419847	chr6:145827278	A/G	cg23711669	chr6:146136114	FBXO30	0.79	11.77	0.59	5.16e-26	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs62005083	1.000	rs62006778	chr14:74644121	A/G	cg05179529	chr14:74551516	LIN52;ALDH6A1	0.71	5.52	0.32	7.97e-8	Mean corpuscular volume;
CESC	cis	rs9908102	0.740	rs56375019	chr17:12909790	G/A	cg26162695	chr17:12921313	ELAC2	0.52	5.67	0.33	3.77e-8	Schizophrenia;
CESC	cis	rs35110281	0.748	rs4997353	chr21:45002329	A/C	cg04455712	chr21:45112962	RRP1B	0.39	5.84	0.34	1.53e-8	Mean corpuscular volume;
CESC	cis	rs4727027	0.631	rs62507511	chr7:148796080	C/A	cg23158103	chr7:148848205	ZNF398	-0.4	-6.31	-0.36	1.15e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs4555082	0.957	rs2735818	chr14:105714751	A/G	cg06808227	chr14:105710500	BRF1	-0.55	-6.73	-0.38	1.03e-10	Mean platelet volume;Platelet distribution width;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg12876261	chr7:56119223	PSPH;CCT6A	-0.44	-6.28	-0.36	1.35e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs34638657	0.827	rs6564996	chr16:82207542	T/C	cg09439754	chr16:82129088	HSD17B2	-0.37	-5.27	-0.31	2.84e-7	Lung adenocarcinoma;
CESC	cis	rs7809799	0.826	rs73147651	chr7:98781440	G/C	cg05967295	chr7:98741636	SMURF1	0.88	5.54	0.32	7.27e-8	Ulcerative colitis;
CESC	trans	rs11039798	0.557	rs4441015	chr11:49027070	A/G	cg15704280	chr7:45808275	SEPT13	0.68	6.88	0.39	4.2e-11	Axial length;
CESC	trans	rs9354308	0.840	rs1827157	chr6:66615761	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.65	7.07	0.4	1.36e-11	Metabolite levels;
CESC	cis	rs9527	0.571	rs4917985	chr10:104624072	C/T	cg04362960	chr10:104952993	NT5C2	0.48	5.97	0.34	7.73e-9	Arsenic metabolism;
CESC	cis	rs58688157	0.705	rs12795572	chr11:590999	G/A	cg02461776	chr11:598696	PHRF1	0.52	6.1	0.35	3.7e-9	Systemic lupus erythematosus;
CESC	cis	rs9549367	0.713	rs9549356	chr13:113851633	A/G	cg00898013	chr13:113819073	PROZ	-0.56	-7.55	-0.42	7.02e-13	Platelet distribution width;
CESC	cis	rs8014204	1.000	rs4553560	chr14:75334199	T/C	cg26191576	chr14:75389716	RPS6KL1	0.37	5.28	0.31	2.73e-7	Caffeine consumption;
CESC	cis	rs965469	0.779	rs6051752	chr20:3310452	C/T	cg25506879	chr20:3388711	C20orf194	-0.49	-5.41	-0.32	1.42e-7	IFN-related cytopenia;
CESC	cis	rs2479724	0.935	rs7753507	chr6:41784094	C/T	cg17623882	chr6:41773611	USP49	0.41	5.95	0.34	8.52e-9	Menarche (age at onset);
CESC	cis	rs34779708	0.733	rs4007271	chr10:35546611	C/T	cg04310649	chr10:35416472	CREM	-0.45	-5.14	-0.3	5.34e-7	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs4713118	0.527	rs4713151	chr6:28136356	G/A	cg22143856	chr6:28129313	ZNF389	0.46	5.83	0.34	1.58e-8	Parkinson's disease;
CESC	cis	rs7618915	0.571	rs6805539	chr3:52609710	T/A	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.38	6.73	0.38	1.02e-10	Bipolar disorder;
CESC	cis	rs2243480	1.000	rs34193460	chr7:65393110	A/G	cg18252515	chr7:66147081	NA	-1.23	-11.37	-0.57	1.14e-24	Diabetic kidney disease;
CESC	cis	rs1153858	1.000	rs12441971	chr15:45671957	A/T	cg14582100	chr15:45693742	SPATA5L1	0.42	5.95	0.34	8.38e-9	Homoarginine levels;
CESC	cis	rs72772090	0.539	rs111886458	chr5:96125047	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.57	-5.26	-0.31	3.01e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs1881797	1.000	rs10158379	chr1:247686352	C/A	cg21399703	chr1:247681439	NA	0.55	7.37	0.41	2.13e-12	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs698833	0.962	rs698828	chr2:44730577	A/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.49	6.05	0.35	4.93e-9	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs727505	0.607	rs59635547	chr7:124796371	A/C	cg23710748	chr7:124431027	NA	-0.39	-6.05	-0.35	4.87e-9	Lewy body disease;
CESC	cis	rs11098499	0.629	rs28369518	chr4:120271630	T/C	cg09307838	chr4:120376055	NA	0.77	10.19	0.53	8.72e-21	Corneal astigmatism;
CESC	trans	rs1814175	0.646	rs1722010	chr11:49897958	A/G	cg03929089	chr4:120376271	NA	-0.9	-14.75	-0.67	2.44e-36	Height;
CESC	cis	rs7044106	0.762	rs1470307	chr9:123433039	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.35	5.76	0.33	2.37e-8	Hip circumference adjusted for BMI;
CESC	cis	rs858239	0.636	rs28706766	chr7:23169834	T/A	cg23682824	chr7:23144976	KLHL7	0.48	6.64	0.38	1.75e-10	Cerebrospinal fluid biomarker levels;
CESC	cis	rs2952156	0.920	rs2517957	chr17:37838716	G/A	cg20243544	chr17:37824526	PNMT	0.62	8.16	0.45	1.36e-14	Asthma;
CESC	cis	rs2839186	0.588	rs2839140	chr21:47616080	G/A	cg00815214	chr21:47717953	NA	0.43	6.27	0.36	1.49e-9	Testicular germ cell tumor;
CESC	cis	rs1448094	0.512	rs12305828	chr12:86249153	C/G	cg02569458	chr12:86230093	RASSF9	0.49	7.27	0.41	3.98e-12	Major depressive disorder;
CESC	trans	rs11989744	1.000	rs17782264	chr8:23570489	C/T	cg03492747	chr16:86543808	FOXF1	0.6	7.07	0.4	1.38e-11	Waist-hip ratio;
CESC	cis	rs3806843	0.771	rs801174	chr5:140112712	C/T	cg26395211	chr5:140044315	WDR55	0.47	6.08	0.35	4.27e-9	Depressive symptoms (multi-trait analysis);
CESC	cis	rs9311474	0.508	rs2878628	chr3:52584715	C/T	cg18404041	chr3:52824283	ITIH1	0.36	6.13	0.35	3.21e-9	Electroencephalogram traits;
CESC	cis	rs10504229	0.639	rs112926738	chr8:58054939	A/G	cg02725872	chr8:58115012	NA	-0.41	-5.95	-0.34	8.38e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs9303401	0.580	rs12946396	chr17:57164195	T/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.0	12.81	0.62	1.44e-29	Cognitive test performance;
CESC	cis	rs6088580	0.634	rs3746455	chr20:32957216	G/A	cg24642439	chr20:33292090	TP53INP2	-0.51	-6.71	-0.38	1.18e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs2836974	0.897	rs12481860	chr21:40537836	T/A	cg27266027	chr21:40555129	PSMG1	0.47	5.63	0.33	4.49e-8	Cognitive function;
CESC	cis	rs4718428	0.705	rs4718422	chr7:66359269	A/G	cg12165864	chr7:66369176	NA	-0.66	-7.66	-0.43	3.45e-13	Corneal structure;
CESC	cis	rs4862750	0.872	rs13101408	chr4:187894777	G/A	cg10295955	chr4:187884368	NA	-1.07	-21.24	-0.79	3.82e-59	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6754311	0.731	rs7569057	chr2:136583958	A/C	cg15123519	chr2:136567270	LCT	-0.33	-5.62	-0.33	4.8e-8	Mosquito bite size;
CESC	cis	rs9322193	0.923	rs55993747	chr6:149943152	A/G	cg07701084	chr6:150067640	NUP43	0.44	6.15	0.35	2.83e-9	Lung cancer;
CESC	cis	rs1448094	0.512	rs11117060	chr12:86250788	G/T	cg02569458	chr12:86230093	RASSF9	-0.49	-7.38	-0.41	2e-12	Major depressive disorder;
CESC	cis	rs3785574	0.962	rs16947051	chr17:61790917	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.58	7.23	0.41	5.23e-12	Height;
CESC	trans	rs10488821	0.714	rs3781847	chr11:30518304	T/A	cg04407762	chr4:113442791	NA	-0.43	-6.07	-0.35	4.43e-9	QRS complex (12-leadsum);
CESC	cis	rs13191362	1.000	rs13191362	chr6:163033350	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.92	10.3	0.53	3.87e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs7666738	0.830	rs17558151	chr4:99048699	T/C	cg03676636	chr4:99064102	C4orf37	0.33	5.08	0.3	7.13e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7223966	1.000	rs8068603	chr17:61755211	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.46	-5.6	-0.33	5.23e-8	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs9926296	0.605	rs886951	chr16:89836865	A/G	cg07648498	chr16:89883185	FANCA	0.43	5.38	0.31	1.66e-7	Vitiligo;
CESC	cis	rs5753618	0.555	rs9609302	chr22:31895987	A/C	cg13145458	chr22:31556086	RNF185	-0.53	-6.25	-0.36	1.63e-9	Colorectal cancer;
CESC	cis	rs1215050	0.791	rs1025201	chr4:98902938	A/G	cg05340658	chr4:99064831	C4orf37	-0.53	-6.91	-0.39	3.69e-11	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs1552244	0.938	rs7647987	chr3:10140696	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.85	-12.15	-0.6	2.74e-27	Alzheimer's disease;
CESC	cis	rs853679	1.000	rs853685	chr6:28288785	C/T	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.67	6.96	0.39	2.68e-11	Depression;
CESC	cis	rs2645694	0.533	rs2645680	chr4:77820956	T/C	cg10057126	chr4:77819792	ANKRD56	0.59	8.71	0.47	3.45e-16	Emphysema distribution in smoking;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02546208	chr12:1100009	ERC1	0.55	6.0	0.35	6.32e-9	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21944557	chr1:179923876	CEP350	0.62	7.39	0.41	1.93e-12	Gut microbiome composition (summer);
CESC	cis	rs7223966	1.000	rs8081612	chr17:61724695	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.58	-7.46	-0.42	1.23e-12	Hip circumference adjusted for BMI;Body mass index;
CESC	trans	rs1814175	0.645	rs7103554	chr11:50027612	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.41	-6.01	-0.35	6.08e-9	Height;
CESC	cis	rs1395	0.778	rs34618115	chr2:27418289	G/A	cg22903471	chr2:27725779	GCKR	-0.42	-5.21	-0.3	3.81e-7	Blood metabolite levels;
CESC	cis	rs780096	0.546	rs1260320	chr2:27722416	A/G	cg22903471	chr2:27725779	GCKR	0.54	7.97	0.44	4.78e-14	Total body bone mineral density;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg08905662	chr7:102789948	NAPEPLD	-0.44	-6.12	-0.35	3.31e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs3733585	0.673	rs6850143	chr4:9958924	T/C	cg00071950	chr4:10020882	SLC2A9	-0.73	-11.79	-0.59	4.58e-26	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs1799949	0.965	rs799916	chr17:41243190	G/T	cg23758822	chr17:41437982	NA	-0.95	-15.74	-0.7	7.54e-40	Menopause (age at onset);
CESC	cis	rs6754311	0.731	rs6719488	chr2:136575199	G/T	cg15123519	chr2:136567270	LCT	0.33	5.62	0.33	4.81e-8	Mosquito bite size;
CESC	cis	rs2072732	0.808	rs56091202	chr1:2936803	A/G	cg15211996	chr1:2936768	ACTRT2	0.34	5.46	0.32	1.08e-7	Plateletcrit;
CESC	cis	rs7659604	0.540	rs28672860	chr4:122705051	G/A	cg19671926	chr4:122722719	EXOSC9	0.67	8.91	0.48	8.57e-17	Type 2 diabetes;
CESC	cis	rs6866344	0.570	rs56236920	chr5:178144617	C/T	cg03877680	chr5:178157825	ZNF354A	0.82	9.74	0.51	2.33e-19	Neutrophil percentage of white cells;
CESC	cis	rs7084402	0.935	rs1649068	chr10:60304864	A/C	cg07615347	chr10:60278583	BICC1	0.61	9.61	0.51	5.78e-19	Refractive error;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14182682	chr14:57857589	NAA30	-0.56	-6.31	-0.36	1.19e-9	Gut microbiome composition (summer);
CESC	cis	rs7223966	1.000	rs8064261	chr17:61705212	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.44	-5.07	-0.3	7.58e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs9549260	0.755	rs7985364	chr13:41179580	C/G	cg21288729	chr13:41239152	FOXO1	0.6	7.4	0.41	1.82e-12	Red blood cell count;
CESC	cis	rs9649465	1.000	rs6963231	chr7:123374766	A/G	cg04330084	chr7:123175371	IQUB	-0.38	-5.18	-0.3	4.46e-7	Migraine;
CESC	cis	rs7615952	0.599	rs6779141	chr3:125709995	A/T	cg15145296	chr3:125709740	NA	-0.49	-5.31	-0.31	2.36e-7	Blood pressure (smoking interaction);
CESC	cis	rs5758659	1.000	rs134902	chr22:42683997	C/T	cg05082376	chr22:42548792	NA	-0.34	-5.24	-0.31	3.28e-7	Cognitive function;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg23324888	chr5:111093475	C5orf13	-0.46	-6.37	-0.36	8.49e-10	Fibrinogen levels;
CESC	cis	rs7552404	0.807	rs2066183	chr1:76153745	A/G	cg22875332	chr1:76189707	ACADM	0.69	9.24	0.49	8.13e-18	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs9303401	0.527	rs12939313	chr17:56755616	A/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.01	11.02	0.56	1.64e-23	Cognitive test performance;
CESC	cis	rs1976403	0.659	rs10799701	chr1:21820990	A/G	cg02390115	chr1:21767211	NBPF3	0.39	5.66	0.33	3.95e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7772486	0.875	rs11155452	chr6:146424631	C/T	cg23711669	chr6:146136114	FBXO30	0.86	12.72	0.62	2.98e-29	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02265318	chr1:220960539	MOSC1	0.58	7.3	0.41	3.37e-12	Gut microbiome composition (summer);
CESC	trans	rs208520	0.690	rs1304672	chr6:66847973	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.88	9.27	0.49	6.82e-18	Exhaled nitric oxide output;
CESC	cis	rs6828523	0.698	rs4695984	chr4:175858796	C/T	cg14561282	chr4:175839468	ADAM29	0.46	5.42	0.32	1.32e-7	Breast cancer;
CESC	cis	rs258892	0.895	rs34155124	chr5:72060249	C/T	cg21869765	chr5:72125136	TNPO1	-0.43	-5.31	-0.31	2.33e-7	Small cell lung carcinoma;
CESC	cis	rs9916302	0.904	rs7503705	chr17:37669704	A/G	cg19468946	chr17:37922297	IKZF3	-0.39	-5.03	-0.3	9.14e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs17253792	0.822	rs78395034	chr14:56069783	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.76	5.39	0.31	1.56e-7	Putamen volume;
CESC	cis	rs7618501	0.633	rs2252833	chr3:50004209	C/T	cg24110177	chr3:50126178	RBM5	-0.55	-7.57	-0.42	6.07e-13	Intelligence (multi-trait analysis);
CESC	cis	rs13191362	0.935	rs35378894	chr6:163123933	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.09	11.08	0.56	1.09e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs12681288	0.862	rs935821	chr8:1022455	G/A	cg15309053	chr8:964076	NA	0.34	5.63	0.33	4.59e-8	Schizophrenia;
CESC	cis	rs853679	0.517	rs56364346	chr6:28050762	T/G	cg12963246	chr6:28129442	ZNF389	0.55	7.35	0.41	2.46e-12	Depression;
CESC	cis	rs7618501	1.000	rs4855862	chr3:49748833	C/T	cg24308560	chr3:49941425	MST1R	0.5	6.94	0.39	3.08e-11	Intelligence (multi-trait analysis);
CESC	cis	rs4566357	0.615	rs4675139	chr2:227908527	G/A	cg05526886	chr2:227700861	RHBDD1	-0.45	-5.87	-0.34	1.31e-8	Coronary artery disease;
CESC	cis	rs4722166	0.573	rs35436671	chr7:22775508	G/A	cg05472934	chr7:22766657	IL6	0.88	11.05	0.56	1.34e-23	Lung cancer;
CESC	cis	rs2933343	0.729	rs813732	chr3:128619357	C/T	cg25356066	chr3:128598488	ACAD9	0.62	8.43	0.46	2.2e-15	IgG glycosylation;
CESC	cis	rs2017305	0.834	rs12252761	chr10:70780296	C/T	cg01024728	chr10:70782572	NA	0.57	5.41	0.32	1.4e-7	Depression (quantitative trait);
CESC	cis	rs75804782	0.521	rs55915157	chr2:239424273	T/C	cg18131467	chr2:239335373	ASB1	-0.68	-5.54	-0.32	7.3e-8	Morning vs. evening chronotype;Chronotype;
CESC	cis	rs3820068	0.603	rs6668726	chr1:15962614	G/A	cg16988262	chr1:15930761	NA	0.34	5.48	0.32	9.82e-8	Systolic blood pressure;
CESC	cis	rs1707322	1.000	rs4660895	chr1:46329739	C/T	cg06784218	chr1:46089804	CCDC17	0.32	5.57	0.32	6.35e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg06489653	chr2:99061716	INPP4A	-0.39	-6.16	-0.35	2.68e-9	Gambling;
CESC	cis	rs1003719	0.715	rs58008706	chr21:38540506	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.59	-7.7	-0.43	2.7e-13	Eye color traits;
CESC	cis	rs561341	1.000	rs510264	chr17:30323414	A/G	cg12193833	chr17:30244370	NA	-0.76	-6.95	-0.39	2.87e-11	Hip circumference adjusted for BMI;
CESC	cis	rs1348850	0.914	rs4893944	chr2:178289357	G/T	cg23306229	chr2:178417860	TTC30B	0.59	7.51	0.42	8.78e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs10197940	0.662	rs10175134	chr2:152299355	G/A	cg06191203	chr2:152266755	RIF1	-0.45	-5.34	-0.31	2.02e-7	Lung cancer;
CESC	cis	rs9311474	0.508	rs1570	chr3:52586682	T/A	cg18337363	chr3:52569053	NT5DC2	0.28	5.05	0.3	8.27e-7	Electroencephalogram traits;
CESC	cis	rs6570726	0.935	rs386823	chr6:145841365	C/T	cg23711669	chr6:146136114	FBXO30	0.8	12.02	0.59	7.36e-27	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6594713	0.717	rs8180416	chr5:112868440	A/G	cg12552261	chr5:112820674	MCC	0.58	5.7	0.33	3.26e-8	Brain cytoarchitecture;
CESC	cis	rs9611565	0.504	rs5758452	chr22:42144927	G/A	cg06634786	chr22:41940651	POLR3H	0.49	5.58	0.32	5.82e-8	Vitiligo;
CESC	cis	rs61008539	0.821	rs10950789	chr7:897492	A/G	cg00475322	chr7:917719	C7orf20	0.5	7.39	0.41	1.92e-12	Perceived unattractiveness to mosquitoes;
CESC	trans	rs208520	0.690	rs12208310	chr6:66730108	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.95	12.24	0.6	1.32e-27	Exhaled nitric oxide output;
CESC	cis	rs709400	0.633	rs8013101	chr14:103951772	G/C	cg12935359	chr14:103987150	CKB	-0.51	-7.44	-0.42	1.39e-12	Body mass index;
CESC	cis	rs4555082	0.915	rs28594491	chr14:105758018	G/A	cg27165867	chr14:105738592	BRF1	-0.5	-5.38	-0.31	1.68e-7	Mean platelet volume;Platelet distribution width;
CESC	cis	rs7666738	0.830	rs28497822	chr4:98906873	C/T	cg03467027	chr4:99064603	C4orf37	0.42	5.14	0.3	5.39e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3960554	0.808	rs111764601	chr7:75706141	T/C	cg17325771	chr7:75508891	RHBDD2	-0.36	-5.37	-0.31	1.72e-7	Eotaxin levels;
CESC	cis	rs4722166	0.603	rs7801406	chr7:22788274	A/G	cg05265849	chr7:22767390	IL6	0.56	7.04	0.4	1.62e-11	Lung cancer;
CESC	trans	rs11039798	0.614	rs8188910	chr11:48825740	C/T	cg15704280	chr7:45808275	SEPT13	0.7	6.34	0.36	9.71e-10	Axial length;
CESC	cis	rs7666738	0.791	rs2865958	chr4:99040732	G/T	cg24818145	chr4:99064322	C4orf37	0.38	5.04	0.3	8.49e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6582630	0.519	rs10880576	chr12:38497693	T/C	cg26384229	chr12:38710491	ALG10B	0.64	9.62	0.51	5.39e-19	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs4835473	0.932	rs4835472	chr4:144903551	A/T	cg25736465	chr4:144833511	NA	0.4	6.12	0.35	3.42e-9	Immature fraction of reticulocytes;
CESC	cis	rs9814567	1.000	rs9871305	chr3:134213538	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.44	-5.99	-0.35	6.73e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs950027	0.620	rs1426932	chr15:45687256	T/C	cg21132104	chr15:45694354	SPATA5L1	0.66	8.53	0.46	1.12e-15	Response to fenofibrate (adiponectin levels);
CESC	cis	rs12711979	0.509	rs10200764	chr2:3827772	C/G	cg17052675	chr2:3827356	NA	-0.67	-11.23	-0.57	3.34e-24	Itch intensity from mosquito bite adjusted by bite size;
CESC	cis	rs9815354	0.812	rs17284472	chr3:41996304	A/G	cg03022575	chr3:42003672	ULK4	-0.7	-6.19	-0.36	2.3e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs12545109	0.800	rs1968551	chr8:57407760	T/C	cg09654669	chr8:57350985	NA	-0.56	-6.65	-0.38	1.67e-10	Obesity-related traits;
CESC	cis	rs9583531	0.600	rs2119479	chr13:111371181	A/C	cg15841412	chr13:111365552	ING1	0.52	6.71	0.38	1.19e-10	Coronary artery disease;
CESC	trans	rs12599106	0.625	rs12923277	chr16:34896261	G/A	cg21548813	chr6:291882	DUSP22	-0.73	-9.72	-0.51	2.63e-19	Menopause (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16522462	chr20:1875565	SIRPA	0.58	6.66	0.38	1.6e-10	Gut microbiome composition (summer);
CESC	cis	rs61776719	0.747	rs28428561	chr1:38434306	G/A	cg18451016	chr1:38461880	NA	-0.52	-7.82	-0.43	1.22e-13	Coronary artery disease;
CESC	cis	rs2839186	0.900	rs59828751	chr21:47708918	A/G	cg10351095	chr21:47802916	PCNT	-0.5	-6.8	-0.39	7.02e-11	Testicular germ cell tumor;
CESC	cis	rs4132509	1.000	rs10927076	chr1:243958293	A/G	cg21452805	chr1:244014465	NA	0.49	5.6	0.33	5.46e-8	RR interval (heart rate);
CESC	cis	rs7666738	0.546	rs62320963	chr4:98839297	A/G	cg05340658	chr4:99064831	C4orf37	0.54	6.4	0.37	7.1e-10	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7412746	0.634	rs7521592	chr1:150821691	A/C	cg09365446	chr1:150670422	GOLPH3L	0.39	5.21	0.3	3.87e-7	Melanoma;
CESC	cis	rs2230307	0.572	rs514090	chr1:100563186	C/G	cg24955406	chr1:100503596	HIAT1	0.53	5.25	0.31	3.18e-7	Carotid intima media thickness;
CESC	trans	rs6677604	1.000	rs12144939	chr1:196698945	G/T	cg02859443	chr16:53737878	RPGRIP1L;FTO	-0.63	-6.02	-0.35	5.87e-9	IgA nephropathy;Nephropathy;Blood protein levels;
CESC	cis	rs6867032	1.000	rs10462750	chr5:2012963	A/G	cg26168224	chr5:2018326	NA	0.91	17.17	0.73	5.99e-45	Gut microbiome composition (winter);
CESC	cis	rs782590	0.967	rs4672054	chr2:55773093	C/A	cg18811423	chr2:55921094	PNPT1	0.82	13.34	0.63	2.05e-31	Metabolic syndrome;
CESC	cis	rs2652822	0.525	rs2899691	chr15:63519088	T/A	cg02713581	chr15:63449717	RPS27L	0.51	6.49	0.37	4.3e-10	Metabolic traits;
CESC	cis	rs6456156	0.586	rs10946208	chr6:167459596	C/T	cg23791538	chr6:167370224	RNASET2	-0.53	-6.84	-0.39	5.4e-11	Primary biliary cholangitis;
CESC	cis	rs7851660	0.506	rs1912996	chr9:100598261	G/T	cg13688889	chr9:100608707	NA	-0.89	-13.11	-0.63	1.34e-30	Strep throat;
CESC	cis	rs9311474	0.632	rs6445528	chr3:52572447	C/T	cg05564831	chr3:52568323	NT5DC2	-0.47	-7.71	-0.43	2.47e-13	Electroencephalogram traits;
CESC	cis	rs6736093	0.863	rs35757708	chr2:112769902	T/C	cg12686935	chr2:112915763	FBLN7	-0.44	-5.66	-0.33	4.03e-8	Coronary artery disease;
CESC	cis	rs4253772	0.832	rs6008259	chr22:46633782	G/A	cg24881330	chr22:46731750	TRMU	0.75	8.11	0.45	1.92e-14	LDL cholesterol;Cholesterol, total;
CESC	cis	rs7589728	0.858	rs79992736	chr2:88530575	A/C	cg04511125	chr2:88470314	THNSL2	0.61	7.02	0.4	1.81e-11	Plasma clusterin levels;
CESC	cis	rs12893597	0.704	rs34065247	chr14:76834029	A/C	cg20290672	chr14:76816747	NA	-0.37	-5.24	-0.31	3.36e-7	Maximal oxygen uptake response;
CESC	cis	rs7940866	0.770	rs10750456	chr11:130819634	A/G	cg12179176	chr11:130786555	SNX19	0.7	10.51	0.54	7.74e-22	Schizophrenia;
CESC	cis	rs7927771	0.801	rs12798028	chr11:47604639	C/T	cg20307385	chr11:47447363	PSMC3	-0.42	-5.23	-0.31	3.38e-7	Subjective well-being;
CESC	cis	rs1018697	0.518	rs284846	chr10:104557290	T/C	cg04362960	chr10:104952993	NT5C2	-0.55	-6.24	-0.36	1.77e-9	Colorectal adenoma (advanced);
CESC	trans	rs1814175	0.817	rs1851860	chr11:49861310	A/C	cg03929089	chr4:120376271	NA	-0.87	-14.03	-0.65	8.19e-34	Height;
CESC	cis	rs8067354	0.872	rs2645466	chr17:57853214	A/C	cg13753209	chr17:57696993	CLTC	0.51	6.98	0.39	2.38e-11	Hemoglobin concentration;
CESC	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg14893161	chr1:205819251	PM20D1	0.87	15.37	0.69	1.47e-38	Menarche (age at onset);
CESC	cis	rs6460942	0.505	rs62448708	chr7:12328450	G/A	cg06484146	chr7:12443880	VWDE	-0.48	-5.56	-0.32	6.66e-8	Coronary artery disease;
CESC	cis	rs7103648	0.669	rs12577383	chr11:47774238	C/T	cg10504702	chr11:47789108	FNBP4	0.43	5.47	0.32	1.03e-7	Diastolic blood pressure;Systolic blood pressure;
CESC	cis	rs35123781	1.000	rs601324	chr5:139057179	C/G	cg10513866	chr5:139070639	NA	0.37	5.37	0.31	1.75e-7	Schizophrenia;
CESC	trans	rs801193	1.000	rs4717310	chr7:66161007	C/T	cg26939375	chr7:64535504	NA	0.64	8.67	0.47	4.39e-16	Aortic root size;
CESC	cis	rs4555082	0.834	rs11622165	chr14:105759761	C/A	cg06808227	chr14:105710500	BRF1	-0.49	-5.28	-0.31	2.72e-7	Mean platelet volume;Platelet distribution width;
CESC	cis	rs9914988	0.943	rs7215000	chr17:27088436	C/T	cg20469991	chr17:27169893	C17orf63	-0.48	-5.29	-0.31	2.56e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CESC	cis	rs1862618	0.853	rs252909	chr5:56121131	T/C	cg22800045	chr5:56110881	MAP3K1	0.84	10.23	0.53	6.66e-21	Initial pursuit acceleration;
CESC	cis	rs939658	0.728	rs8031638	chr15:79422726	C/T	cg17916960	chr15:79447300	NA	-0.32	-5.05	-0.3	8.14e-7	Refractive error;
CESC	cis	rs12824058	0.799	rs4759656	chr12:130815804	G/A	cg24838063	chr12:130822603	PIWIL1	0.63	8.58	0.47	7.91e-16	Menopause (age at onset);
CESC	cis	rs10845606	1.000	rs10845610	chr12:12839107	G/A	cg04607235	chr12:12878440	APOLD1	-0.74	-8.25	-0.45	7.65e-15	Systemic lupus erythematosus;
CESC	cis	rs7552404	1.000	rs28602663	chr1:76235355	C/T	cg03433033	chr1:76189801	ACADM	0.54	6.3	0.36	1.23e-9	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs17376456	1.000	rs13181660	chr5:93533658	A/G	cg21475434	chr5:93447410	FAM172A	0.85	7.64	0.42	4.02e-13	Diabetic retinopathy;
CESC	cis	rs34779708	0.966	rs10827492	chr10:35429825	A/G	cg04310649	chr10:35416472	CREM	0.51	6.34	0.36	9.74e-10	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs10479542	0.892	rs7736163	chr5:178980316	G/C	cg14820908	chr5:178986412	RUFY1	0.46	7.12	0.4	1.03e-11	Lung cancer;
CESC	cis	rs9902453	0.845	rs12601963	chr17:28246358	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.65	8.2	0.45	1.04e-14	Coffee consumption (cups per day);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04526987	chr8:131370329	ASAP1	-0.68	-8.34	-0.46	4.07e-15	Gut microbiome composition (summer);
CESC	cis	rs1707322	0.721	rs11211163	chr1:46153548	C/T	cg03146154	chr1:46216737	IPP	0.82	11.54	0.58	3.18e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs11997175	0.625	rs11777333	chr8:33596470	C/A	ch.8.33884649F	chr8:33765107	NA	0.51	6.29	0.36	1.34e-9	Body mass index;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03236184	chr10:89621862	PTEN;KILLIN	-0.63	-7.37	-0.41	2.21e-12	Gut microbiome composition (summer);
CESC	cis	rs763121	0.853	rs6001185	chr22:39052155	G/A	cg21395723	chr22:39101663	GTPBP1	0.43	5.39	0.31	1.54e-7	Menopause (age at onset);
CESC	trans	rs634534	0.622	rs501353	chr11:65739549	T/G	cg17712092	chr4:129076599	LARP1B	0.63	8.49	0.46	1.49e-15	Sum eosinophil basophil counts;Eosinophil counts;
CESC	cis	rs514406	0.644	rs6662414	chr1:53198893	A/G	cg25767906	chr1:53392781	SCP2	0.41	5.59	0.32	5.58e-8	Monocyte count;
CESC	cis	rs9902453	0.709	rs6505162	chr17:28444183	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	7.67	0.43	3.22e-13	Coffee consumption (cups per day);
CESC	cis	rs6665290	0.669	rs3768424	chr1:227177444	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.13	-25.31	-0.84	1.15e-72	Myeloid white cell count;
CESC	cis	rs9488822	0.676	rs12190737	chr6:116328128	C/A	cg26893134	chr6:116381904	FRK	0.25	5.98	0.34	7.06e-9	Cholesterol, total;LDL cholesterol;
CESC	cis	rs7267979	0.966	rs6083855	chr20:25405118	A/G	cg08601574	chr20:25228251	PYGB	-0.37	-5.43	-0.32	1.25e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs3741404	0.594	rs11231704	chr11:63898182	C/T	cg18225595	chr11:63971243	STIP1	-0.45	-5.73	-0.33	2.69e-8	Platelet count;
CESC	cis	rs10206020	0.921	rs9678719	chr2:1549628	A/G	cg26248373	chr2:1572462	NA	-0.58	-6.59	-0.38	2.38e-10	IgG glycosylation;
CESC	trans	rs11637445	0.677	rs11631864	chr15:68067762	T/C	cg14583481	chr3:118865028	C3orf30;IGSF11	-0.41	-6.08	-0.35	4.15e-9	Posterior cortical atrophy and Alzheimer's disease;
CESC	cis	rs3820068	0.705	rs74054769	chr1:15860147	A/C	cg18192808	chr1:15853278	DNAJC16	0.48	5.72	0.33	2.8e-8	Systolic blood pressure;
CESC	cis	rs1580019	0.563	rs2392071	chr7:32572536	G/A	cg06627557	chr7:32535165	LSM5;AVL9	1.07	17.82	0.74	3.15e-47	Cognitive ability;
CESC	cis	rs763014	0.931	rs3752567	chr16:628130	A/G	cg09263875	chr16:632152	PIGQ	0.67	10.99	0.56	2.17e-23	Height;
CESC	cis	rs11098499	0.754	rs714899	chr4:120243035	G/A	cg09307838	chr4:120376055	NA	0.8	10.89	0.56	4.48e-23	Corneal astigmatism;
CESC	cis	rs4555082	0.830	rs2255575	chr14:105727251	T/C	cg10792982	chr14:105748885	BRF1	0.42	5.59	0.32	5.74e-8	Mean platelet volume;Platelet distribution width;
CESC	cis	rs1005277	0.579	rs2504143	chr10:38383706	C/T	cg25517755	chr10:38738941	LOC399744	-0.48	-6.27	-0.36	1.47e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs35955747	0.934	rs5997966	chr22:31776246	C/T	cg25791279	chr22:32026902	PISD	-0.49	-5.91	-0.34	1.02e-8	Neutrophil count;Sum basophil neutrophil counts;
CESC	cis	rs2882667	0.824	rs11748097	chr5:138479887	C/A	cg04439458	chr5:138467593	SIL1	-0.38	-5.75	-0.33	2.5e-8	Age-related hearing impairment (SNP x SNP interaction);
CESC	trans	rs1814175	0.817	rs1390676	chr11:50056778	C/T	cg15704280	chr7:45808275	SEPT13	-1.05	-21.04	-0.79	1.87e-58	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03542721	chr8:22926253	TNFRSF10B	0.52	6.29	0.36	1.32e-9	Gut microbiome composition (summer);
CESC	cis	rs4642101	0.793	rs13086170	chr3:12832604	G/C	cg05775895	chr3:12838266	CAND2	0.35	5.3	0.31	2.41e-7	QRS complex (12-leadsum);
CESC	cis	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg20295408	chr7:1910781	MAD1L1	0.43	5.76	0.33	2.36e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs17384381	0.834	rs11161614	chr1:85898160	A/C	cg16011679	chr1:85725395	C1orf52	0.64	7.18	0.4	6.87e-12	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg07997682	chr22:41418886	NA	-0.46	-6.65	-0.38	1.71e-10	Gut microbiota (bacterial taxa);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01249735	chr7:156742241	NOM1	0.57	6.75	0.38	9.13e-11	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13547250	chr16:30107791	YPEL3	0.55	6.43	0.37	5.98e-10	Gut microbiome composition (summer);
CESC	cis	rs7527798	0.592	rs7539772	chr1:207833301	G/A	cg21110645	chr1:207815933	NA	-0.31	-5.41	-0.32	1.43e-7	Erythrocyte sedimentation rate;
CESC	cis	rs12476592	0.602	rs2421952	chr2:63749833	T/C	cg17519650	chr2:63277830	OTX1	-0.49	-5.64	-0.33	4.44e-8	Childhood ear infection;
CESC	cis	rs10504229	0.775	rs17805110	chr8:58161439	C/G	cg05313129	chr8:58192883	C8orf71	0.48	5.26	0.31	2.95e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs12479064	0.724	rs3792150	chr2:100041849	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.65	-7.7	-0.43	2.79e-13	Chronic sinus infection;
CESC	cis	rs6570726	0.935	rs906774	chr6:145813770	T/C	cg05347473	chr6:146136440	FBXO30	0.5	6.72	0.38	1.13e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6032067	0.929	rs17334064	chr20:43839197	T/C	cg10761708	chr20:43804764	PI3	0.5	5.91	0.34	1.02e-8	Blood protein levels;
CESC	cis	rs6754311	0.731	rs3769005	chr2:136603366	C/G	cg07169764	chr2:136633963	MCM6	-0.68	-8.38	-0.46	3.1e-15	Mosquito bite size;
CESC	cis	rs4862750	0.758	rs2375915	chr4:187896255	A/C	cg03452623	chr4:187889614	NA	-0.89	-15.18	-0.68	7.11e-38	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9311474	0.508	rs17052259	chr3:52593138	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.57	7.79	0.43	1.55e-13	Electroencephalogram traits;
CESC	cis	rs6963495	0.556	rs711427	chr7:105161755	T/G	cg13798780	chr7:105162888	PUS7	0.51	6.3	0.36	1.26e-9	Bipolar disorder (body mass index interaction);
CESC	cis	rs1862618	0.573	rs185220	chr5:56205357	A/G	cg12311346	chr5:56204834	C5orf35	-0.83	-10.23	-0.53	6.39e-21	Initial pursuit acceleration;
CESC	cis	rs6800768	1.000	rs6800768	chr3:24113252	T/C	cg10674438	chr3:24145617	LOC152024	-0.37	-5.59	-0.33	5.5e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25581932	chr17:7892150	NA	0.56	6.9	0.39	3.83e-11	Gut microbiome composition (summer);
CESC	cis	rs10208940	0.920	rs10211211	chr2:68718191	G/C	cg12452813	chr2:68675892	NA	0.52	5.24	0.31	3.26e-7	Urate levels in lean individuals;
CESC	cis	rs798554	0.759	rs1182189	chr7:2869522	G/A	cg19717773	chr7:2847554	GNA12	-0.56	-7.86	-0.43	9.86e-14	Height;
CESC	cis	rs9611565	0.579	rs73178621	chr22:41921665	A/G	cg03806693	chr22:41940476	POLR3H	-1.22	-15.27	-0.68	3.46e-38	Vitiligo;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg00318242	chr5:137548698	CDC23	0.47	6.4	0.37	7.14e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs9660180	0.967	rs61422524	chr1:1767565	C/A	cg23982607	chr1:1823379	GNB1	-0.76	-12.08	-0.6	4.49e-27	Body mass index;
CESC	cis	rs561341	0.941	rs2470236	chr17:30304940	G/C	cg19193384	chr17:30244184	NA	-0.6	-6.35	-0.36	9.57e-10	Hip circumference adjusted for BMI;
CESC	cis	rs963731	0.579	rs10190377	chr2:39250673	A/G	cg04010122	chr2:39346883	SOS1	-0.58	-5.17	-0.3	4.53e-7	Corticobasal degeneration;
CESC	cis	rs4665809	0.590	rs4665321	chr2:26433801	A/C	cg22920501	chr2:26401640	FAM59B	-0.9	-10.21	-0.53	7.46e-21	Gut microbiome composition (summer);
CESC	cis	rs710216	0.843	rs10890232	chr1:43416514	C/T	cg03128534	chr1:43423976	SLC2A1	0.61	7.74	0.43	2.04e-13	Red cell distribution width;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12855988	chr6:133135904	RPS12;SNORD101	0.53	6.26	0.36	1.58e-9	Gut microbiome composition (summer);
CESC	cis	rs2502731	0.539	rs3003610	chr9:130985525	G/A	cg09976142	chr9:130955436	CIZ1	0.41	6.63	0.38	1.83e-10	Attention deficit hyperactivity disorder;
CESC	cis	rs10504229	0.683	rs34859456	chr8:58117722	A/C	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg25509121	chr17:61851092	DDX42;CCDC47	-0.47	-6.38	-0.36	7.93e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs6582630	0.502	rs10880450	chr12:38440294	G/C	cg13010199	chr12:38710504	ALG10B	0.43	5.57	0.32	6.34e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs4718428	0.705	rs3800817	chr7:66263550	T/A	cg12165864	chr7:66369176	NA	-0.64	-7.35	-0.41	2.39e-12	Corneal structure;
CESC	cis	rs752010	0.841	rs58737163	chr1:42079821	G/T	cg06885757	chr1:42089581	HIVEP3	0.47	7.63	0.42	4.22e-13	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs801193	0.660	rs2659914	chr7:66156914	C/T	cg18876405	chr7:65276391	NA	0.47	6.29	0.36	1.27e-9	Aortic root size;
CESC	cis	rs514406	0.825	rs1242328	chr1:53396869	A/G	cg08736216	chr1:53307985	ZYG11A	-0.41	-6.69	-0.38	1.34e-10	Monocyte count;
CESC	cis	rs1552244	1.000	rs112847840	chr3:10101652	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	11.94	0.59	1.43e-26	Alzheimer's disease;
CESC	cis	rs1348850	0.914	rs4893938	chr2:178250095	T/C	cg23306229	chr2:178417860	TTC30B	0.64	8.26	0.45	7.09e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs290268	0.845	rs290266	chr9:93537952	T/A	cg02608019	chr9:93564028	SYK	0.57	8.39	0.46	2.91e-15	Platelet count;
CESC	cis	rs2050392	0.624	rs303447	chr10:30728464	T/C	cg02070205	chr10:30722105	MAP3K8	-0.46	-5.42	-0.32	1.33e-7	Inflammatory bowel disease;
CESC	cis	rs769267	0.965	rs8103496	chr19:19386015	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.43	5.33	0.31	2.11e-7	Tonsillectomy;
CESC	cis	rs9916302	0.904	rs587343	chr17:37440603	C/T	cg15445000	chr17:37608096	MED1	-0.4	-6.39	-0.37	7.58e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs11583043	0.874	rs41312668	chr1:101443582	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.5	5.51	0.32	8.64e-8	Ulcerative colitis;Inflammatory bowel disease;
CESC	cis	rs1949733	0.523	rs16842563	chr4:8545146	C/T	cg11789530	chr4:8429930	ACOX3	-0.52	-6.79	-0.38	7.45e-11	Response to antineoplastic agents;
CESC	cis	rs7520050	0.751	rs2991975	chr1:46024526	A/G	cg24296786	chr1:45957014	TESK2	0.5	6.33	0.36	1.03e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs3020736	0.500	rs6002605	chr22:42494335	A/G	cg15557168	chr22:42548783	NA	0.45	6.35	0.36	9.09e-10	Autism spectrum disorder or schizophrenia;
CESC	cis	rs453301	0.571	rs2929452	chr8:9084465	G/A	cg17143192	chr8:8559678	CLDN23	-0.46	-5.65	-0.33	4.11e-8	Joint mobility (Beighton score);
CESC	cis	rs8062405	1.000	rs62036622	chr16:28837203	T/G	cg05966235	chr16:28915196	ATP2A1	0.35	5.09	0.3	6.75e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs16867321	0.950	rs9677293	chr2:181499459	C/G	cg23363182	chr2:181467187	NA	-0.43	-5.69	-0.33	3.39e-8	Obesity;
CESC	trans	rs2898290	0.622	rs4840567	chr8:11347625	A/G	cg15556689	chr8:8085844	FLJ10661	-0.5	-6.03	-0.35	5.53e-9	Systolic blood pressure;
CESC	cis	rs1862618	0.802	rs33327	chr5:56142693	T/G	cg24549020	chr5:56110836	MAP3K1	0.68	7.72	0.43	2.37e-13	Initial pursuit acceleration;
CESC	cis	rs57221529	0.709	rs4957056	chr5:570105	T/C	cg09021430	chr5:549028	NA	-0.42	-5.08	-0.3	7.04e-7	Lung disease severity in cystic fibrosis;
CESC	cis	rs9322193	0.923	rs1413654	chr6:150105092	G/A	cg05861140	chr6:150128134	PCMT1	-0.36	-5.14	-0.3	5.22e-7	Lung cancer;
CESC	cis	rs959260	1.000	rs2117562	chr17:73369000	C/T	cg20590849	chr17:73267439	MIF4GD	-0.54	-6.32	-0.36	1.13e-9	Systemic lupus erythematosus;
CESC	cis	rs16854884	0.739	rs1075113	chr3:143760535	C/T	cg06585982	chr3:143692056	C3orf58	0.49	6.3	0.36	1.23e-9	Economic and political preferences (feminism/equality);
CESC	cis	rs4268898	0.571	rs1986478	chr2:24468545	G/A	cg06627628	chr2:24431161	ITSN2	-0.97	-11.05	-0.56	1.32e-23	Asthma;
CESC	cis	rs6121246	0.567	rs6060262	chr20:30193071	A/C	cg13852791	chr20:30311386	BCL2L1	0.67	6.71	0.38	1.2e-10	Mean corpuscular hemoglobin;
CESC	cis	rs736408	0.812	rs2270197	chr3:52824095	T/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	5.8	0.34	1.84e-8	Bipolar disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24993015	chr5:37371179	NUP155	0.58	6.56	0.37	2.74e-10	Gut microbiome composition (summer);
CESC	cis	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg09249682	chr7:17338253	AHR	-0.41	-5.3	-0.31	2.5e-7	Fibrinogen levels;
CESC	cis	rs4819052	0.918	rs2330013	chr21:46658662	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.82	10.4	0.54	1.81e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs10791097	0.967	rs1944142	chr11:130717440	C/T	cg14779329	chr11:130786720	SNX19	0.34	5.3	0.31	2.42e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs4843747	0.671	rs72818540	chr16:88078988	C/T	cg17633681	chr16:88106987	BANP	0.71	9.32	0.5	4.59e-18	Menopause (age at onset);
CESC	cis	rs17021463	0.676	rs11097421	chr4:95302915	T/C	cg11021082	chr4:95130006	SMARCAD1	0.52	7.21	0.4	5.93e-12	Testicular germ cell tumor;
CESC	cis	rs12048904	0.964	rs12027668	chr1:101330984	G/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.52	6.61	0.38	2.11e-10	Multiple sclerosis;
CESC	cis	rs6460942	0.505	rs73290446	chr7:12358133	T/G	cg20607287	chr7:12443886	VWDE	-0.57	-6.12	-0.35	3.31e-9	Coronary artery disease;
CESC	cis	rs12464559	0.522	rs7583060	chr2:152620943	C/A	cg01189475	chr2:152685088	ARL5A	0.7	6.72	0.38	1.13e-10	Response to cognitive-behavioural therapy in anxiety disorder;
CESC	cis	rs2732480	0.537	rs1061986	chr12:48736439	T/C	cg24011408	chr12:48396354	COL2A1	0.44	5.95	0.34	8.54e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs10883723	0.810	rs13287	chr10:104240438	A/G	cg22532475	chr10:104410764	TRIM8	-0.32	-5.35	-0.31	1.89e-7	Allergic disease (asthma, hay fever or eczema);
CESC	trans	rs12356475	0.710	rs10822686	chr10:67733250	C/T	cg00024472	chr17:47573864	NGFR	0.48	6.11	0.35	3.58e-9	Psoriatic arthritis;
CESC	cis	rs875971	0.965	rs6971509	chr7:65714970	G/T	cg12463550	chr7:65579703	CRCP	-0.53	-6.87	-0.39	4.46e-11	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16529530	chr1:32688001	EIF3I;C1orf91	0.6	6.61	0.38	2.13e-10	Gut microbiome composition (summer);
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg13483984	chr1:224580455	WDR26	0.4	6.04	0.35	5.06e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs2242116	0.796	rs4683296	chr3:46973820	G/C	cg02527881	chr3:46936655	PTH1R	0.52	7.3	0.41	3.29e-12	Birth weight;
CESC	cis	rs1008375	1.000	rs10939750	chr4:17692422	C/G	cg02297831	chr4:17616191	MED28	0.48	5.86	0.34	1.4e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs17253792	0.822	rs2274075	chr14:56096731	A/G	cg01858014	chr14:56050164	KTN1	-0.85	-6.99	-0.39	2.22e-11	Putamen volume;
CESC	cis	rs1387259	0.570	rs12368659	chr12:48562299	C/A	cg04545296	chr12:48745243	ZNF641	0.35	6.02	0.35	5.83e-9	Obstructive sleep apnea trait (apnea hypopnea index);
CESC	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg26338869	chr17:61819248	STRADA	0.73	9.52	0.5	1.11e-18	Prudent dietary pattern;
CESC	cis	rs1797885	0.934	rs299658	chr3:12552084	A/G	cg26432171	chr3:12704882	RAF1	-0.46	-5.63	-0.33	4.52e-8	Immature fraction of reticulocytes;
CESC	cis	rs2842992	0.513	rs7759086	chr6:160193853	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.76	10.89	0.56	4.42e-23	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs2836974	0.602	rs2836987	chr21:40706594	C/T	cg11890956	chr21:40555474	PSMG1	-0.93	-15.1	-0.68	1.32e-37	Cognitive function;
CESC	cis	rs13118159	0.934	rs4974553	chr4:1356911	G/A	cg13395646	chr4:1353034	KIAA1530	-0.38	-5.07	-0.3	7.66e-7	Longevity;
CESC	trans	rs8007846	0.569	rs4400971	chr14:66254578	A/C	cg24965984	chr10:113943723	GPAM	0.43	6.16	0.35	2.65e-9	Multiple sclerosis--Brain Glutamate Levels;
CESC	cis	rs9910055	0.615	rs189049	chr17:42197213	A/C	cg19774624	chr17:42201019	HDAC5	0.86	13.63	0.64	2.1e-32	Total body bone mineral density;
CESC	cis	rs4665809	1.000	rs10048683	chr2:26320519	C/T	cg27170947	chr2:26402098	FAM59B	-0.59	-7.11	-0.4	1.1e-11	Gut microbiome composition (summer);
CESC	cis	rs9611565	0.694	rs202656	chr22:41842203	T/A	cg03806693	chr22:41940476	POLR3H	1.19	14.41	0.66	3.63e-35	Vitiligo;
CESC	cis	rs10129255	0.912	rs35468694	chr14:107192436	A/C	cg07958169	chr14:107095056	NA	-0.4	-5.5	-0.32	8.83e-8	Kawasaki disease;
CESC	cis	rs1878931	0.697	rs1044390	chr16:3432594	T/A	cg26668626	chr16:3451006	ZNF174;ZNF434	1.07	18.3	0.75	6.4e-49	Body mass index (adult);
CESC	trans	rs11113894	0.579	rs11113845	chr12:108778298	A/G	cg24376434	chr1:170634859	PRRX1	-0.87	-6.61	-0.38	2.11e-10	Obesity-related traits;
CESC	trans	rs9693444	0.898	rs4732697	chr8:29519861	A/G	cg02683314	chr19:4182606	SIRT6;ANKRD24	-0.41	-6.0	-0.35	6.49e-9	Breast cancer;
CESC	cis	rs12477438	0.834	rs1563107	chr2:99701276	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.7	9.34	0.5	4.2e-18	Chronic sinus infection;
CESC	cis	rs8072100	0.840	rs9893901	chr17:45506682	T/G	cg25173405	chr17:45401733	C17orf57	-0.41	-5.44	-0.32	1.21e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs250677	0.687	rs250663	chr5:148453117	T/C	cg18129178	chr5:148520854	ABLIM3	-0.5	-5.77	-0.33	2.22e-8	Breast cancer;
CESC	cis	rs5760092	0.755	rs915589	chr22:24261004	C/T	cg09033563	chr22:24373618	LOC391322	0.52	5.93	0.34	9.44e-9	Urinary 1,3-butadiene metabolite levels in smokers;
CESC	cis	rs11098499	0.955	rs13114751	chr4:120156617	G/A	cg09307838	chr4:120376055	NA	0.87	11.45	0.58	6.04e-25	Corneal astigmatism;
CESC	cis	rs4481887	1.000	rs6683717	chr1:248476792	A/G	cg00666640	chr1:248458726	OR2T12	0.41	6.66	0.38	1.54e-10	Common traits (Other);
CESC	cis	rs10504229	1.000	rs73607863	chr8:58170178	A/G	cg05313129	chr8:58192883	C8orf71	-0.55	-6.29	-0.36	1.31e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs2737618	0.630	rs2821328	chr1:200082051	G/A	cg21825944	chr1:200113062	NR5A2	-0.47	-7.17	-0.4	7.64e-12	Uric acid levels;
CESC	trans	rs1545843	0.564	rs1459612	chr12:84890302	C/T	cg03015433	chr16:56623111	MT3	0.33	6.01	0.35	6.09e-9	Major depressive disorder;
CESC	cis	rs9992101	0.547	rs7654754	chr4:77409795	C/T	cg20311846	chr4:77356250	SHROOM3	-0.26	-5.11	-0.3	6.1e-7	Creatinine levels;
CESC	trans	rs634534	0.562	rs661335	chr11:65754061	G/A	cg17712092	chr4:129076599	LARP1B	0.72	9.89	0.52	7.93e-20	Sum eosinophil basophil counts;Eosinophil counts;
CESC	cis	rs9811920	0.609	rs4479633	chr3:99654510	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.59	-7.22	-0.41	5.61e-12	Axial length;
CESC	cis	rs7202877	0.611	rs56092808	chr16:75312716	A/T	cg04384234	chr16:75411784	CFDP1	-0.45	-5.23	-0.31	3.42e-7	Type 2 diabetes;Type 1 diabetes;
CESC	trans	rs7246657	0.882	rs13345148	chr19:37819631	A/G	cg24637308	chr11:6592297	DNHD1	0.53	6.15	0.35	2.8e-9	Coronary artery calcification;
CESC	cis	rs1050631	1.000	rs1050631	chr18:33694120	A/G	cg25426722	chr18:33708991	SLC39A6;ELP2	-0.41	-5.41	-0.32	1.42e-7	Esophageal squamous cell cancer (length of survival);
CESC	cis	rs875971	0.522	rs709604	chr7:65497434	A/G	cg26939375	chr7:64535504	NA	-0.77	-10.9	-0.56	4.36e-23	Aortic root size;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg18887839	chr14:67894263	NA	0.45	6.25	0.36	1.64e-9	Thyroid stimulating hormone;
CESC	cis	rs17253792	0.822	rs17832365	chr14:56153531	C/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.82	5.73	0.33	2.74e-8	Putamen volume;
CESC	cis	rs6754311	0.773	rs309180	chr2:136614255	A/G	cg15123519	chr2:136567270	LCT	-0.3	-5.15	-0.3	5.02e-7	Mosquito bite size;
CESC	cis	rs3806843	0.932	rs2563257	chr5:140140529	A/G	cg26395211	chr5:140044315	WDR55	0.39	5.17	0.3	4.51e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs7044106	0.762	rs4837790	chr9:123446325	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.36	5.83	0.34	1.58e-8	Hip circumference adjusted for BMI;
CESC	cis	rs7605827	0.897	rs13010658	chr2:15668468	A/G	cg19274914	chr2:15703543	NA	0.33	5.8	0.34	1.88e-8	Educational attainment (years of education);
CESC	cis	rs35306767	0.903	rs11253460	chr10:887382	C/G	cg25019033	chr10:957182	NA	-0.57	-6.13	-0.35	3.19e-9	Eosinophil percentage of granulocytes;
CESC	cis	rs936229	0.749	rs4886633	chr15:75178207	G/A	cg14664628	chr15:75095509	CSK	-0.72	-9.05	-0.49	3.28e-17	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CESC	cis	rs1862618	0.671	rs2591966	chr5:56233688	T/G	cg24549020	chr5:56110836	MAP3K1	-0.4	-5.03	-0.3	9.19e-7	Initial pursuit acceleration;
CESC	cis	rs28386778	0.965	rs2854154	chr17:61981696	C/A	cg06873352	chr17:61820015	STRADA	-0.68	-11.53	-0.58	3.38e-25	Prudent dietary pattern;
CESC	cis	rs7917772	0.503	rs7899576	chr10:104307504	G/A	cg22532475	chr10:104410764	TRIM8	-0.34	-5.93	-0.34	9.49e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs734999	0.572	rs2985857	chr1:2532624	C/T	cg18854424	chr1:2615690	NA	-0.27	-5.19	-0.3	4.11e-7	Ulcerative colitis;
CESC	trans	rs3749237	0.964	rs34522271	chr3:49808517	A/G	cg21659725	chr3:3221576	CRBN	0.53	6.28	0.36	1.39e-9	Resting heart rate;
CESC	cis	rs12477438	0.765	rs2278895	chr2:99613484	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.64	-8.73	-0.47	2.94e-16	Chronic sinus infection;
CESC	cis	rs4665809	0.590	rs36064164	chr2:26502768	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.09	11.83	0.59	3.18e-26	Gut microbiome composition (summer);
CESC	cis	rs9649213	0.574	rs34830366	chr7:97899535	G/T	cg21770322	chr7:97807741	LMTK2	0.58	8.5	0.46	1.36e-15	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs3785574	0.962	rs2584633	chr17:61879501	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.57	7.03	0.4	1.78e-11	Height;
CESC	cis	rs2576037	0.899	rs2246877	chr18:44577005	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.53	-7.2	-0.4	6.36e-12	Personality dimensions;
CESC	cis	rs35272691	1	rs35272691	chr17:38157841	T/C	cg17467752	chr17:38218738	THRA	-0.45	-5.94	-0.34	9.08e-9	White blood cell count (neutrophil);
CESC	cis	rs3857067	0.806	rs17374832	chr4:95114394	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.6	-9.12	-0.49	1.97e-17	QT interval;
CESC	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg16405210	chr4:1374714	KIAA1530	-0.91	-12.03	-0.59	6.78e-27	Longevity;
CESC	cis	rs853679	0.550	rs1233707	chr6:28172953	G/A	cg17949981	chr6:28129498	ZNF389	0.43	5.69	0.33	3.43e-8	Depression;
CESC	cis	rs6982240	0.569	rs6992286	chr8:142279412	G/A	cg27411547	chr8:142287226	NA	-0.55	-7.99	-0.44	4.17e-14	Tonsillectomy;
CESC	cis	rs7527798	0.592	rs12563520	chr1:207844062	C/T	cg21110645	chr1:207815933	NA	-0.33	-5.75	-0.33	2.4e-8	Erythrocyte sedimentation rate;
CESC	cis	rs7917772	0.503	rs11191342	chr10:104344450	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.53	7.47	0.42	1.15e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs6690583	0.562	rs76839162	chr1:85530021	A/G	cg22488158	chr1:85528044	WDR63	0.55	5.26	0.31	3.03e-7	Serum sulfate level;
CESC	cis	rs4790333	0.813	rs2005029	chr17:2255138	G/T	cg02569219	chr17:2266849	SGSM2	-0.39	-5.12	-0.3	5.98e-7	Proinsulin levels;
CESC	cis	rs73206853	0.764	rs28840785	chr12:110844920	C/G	cg12870014	chr12:110450643	ANKRD13A	0.63	5.18	0.3	4.34e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs360798	0.532	rs7573756	chr2:62990637	G/A	cg17519650	chr2:63277830	OTX1	-0.59	-7.61	-0.42	4.72e-13	Coronary artery disease;
CESC	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg18402987	chr7:1209562	NA	0.76	7.79	0.43	1.5e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs672059	0.548	rs500530	chr1:183254972	C/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.5	-5.91	-0.34	1.02e-8	Hypertriglyceridemia;
CESC	cis	rs9896933	0.830	rs607544	chr17:80768760	C/G	cg15369054	chr17:80825471	TBCD	0.47	5.2	0.3	3.98e-7	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
CESC	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.89	13.55	0.64	3.99e-32	Prudent dietary pattern;
CESC	cis	rs698833	0.886	rs2927433	chr2:44580737	T/A	cg04920474	chr2:44395004	PPM1B	0.37	5.04	0.3	8.75e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs875971	0.545	rs316328	chr7:65608838	A/G	cg11764359	chr7:65958608	NA	-0.73	-9.1	-0.49	2.27e-17	Aortic root size;
CESC	cis	rs798554	0.797	rs798491	chr7:2800521	A/G	cg13628971	chr7:2884303	GNA12	0.62	7.94	0.44	5.91e-14	Height;
CESC	cis	rs2243480	0.901	rs778687	chr7:65835819	G/A	cg18252515	chr7:66147081	NA	-1.39	-14.18	-0.66	2.5e-34	Diabetic kidney disease;
CESC	cis	rs7666738	0.830	rs10470951	chr4:99037051	G/A	cg18180107	chr4:99064573	C4orf37	0.41	5.29	0.31	2.52e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs12220238	1.000	rs12357530	chr10:75928654	C/A	cg19889307	chr10:75911429	ADK;AP3M1	0.63	6.1	0.35	3.78e-9	Soluble interleukin-2 receptor subunit alpha;
CESC	cis	rs17376456	0.825	rs13361613	chr5:93272176	C/T	cg21475434	chr5:93447410	FAM172A	0.74	6.16	0.35	2.67e-9	Diabetic retinopathy;
CESC	cis	rs116095464	0.558	rs10036253	chr5:238519	A/C	cg20965017	chr5:231967	SDHA	-0.47	-5.3	-0.31	2.49e-7	Breast cancer;
CESC	cis	rs7116495	0.609	rs10751191	chr11:71680920	C/T	cg18441811	chr11:71824068	C11orf51	-0.81	-5.3	-0.31	2.48e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs561341	0.882	rs2428337	chr17:30299467	C/T	cg00745463	chr17:30367425	LRRC37B	-0.81	-7.35	-0.41	2.5e-12	Hip circumference adjusted for BMI;
CESC	cis	rs3931020	0.530	rs6668736	chr1:75234550	C/T	cg21535942	chr1:75199100	CRYZ;TYW3	0.4	5.23	0.31	3.46e-7	Resistin levels;
CESC	cis	rs77741769	0.529	rs3213572	chr12:121205078	A/G	cg02419362	chr12:121203948	SPPL3	-0.35	-5.77	-0.33	2.18e-8	Mean corpuscular volume;
CESC	cis	rs977987	0.843	rs8056080	chr16:75410798	C/A	cg03315344	chr16:75512273	CHST6	0.4	5.73	0.33	2.78e-8	Dupuytren's disease;
CESC	cis	rs10504229	0.953	rs6990806	chr8:58183113	G/A	cg14926445	chr8:58193284	C8orf71	-0.51	-5.52	-0.32	8.28e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs6461049	0.800	rs3778977	chr7:2159746	C/T	cg04267008	chr7:1944627	MAD1L1	-0.53	-6.25	-0.36	1.61e-9	Schizophrenia;
CESC	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg03188948	chr7:1209495	NA	0.7	6.71	0.38	1.2e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg22271113	chr17:8370397	NDEL1	0.51	7.13	0.4	9.42e-12	Fibrinogen levels;
CESC	cis	rs9479482	1.000	rs11754987	chr6:150351204	G/A	cg03788504	chr6:150331562	NA	-0.38	-7.07	-0.4	1.38e-11	Alopecia areata;
CESC	cis	rs6456156	0.586	rs7746628	chr6:167483235	A/G	cg23791538	chr6:167370224	RNASET2	-0.51	-6.44	-0.37	5.67e-10	Primary biliary cholangitis;
CESC	cis	rs9858542	0.953	rs35169793	chr3:49423274	A/G	cg03060546	chr3:49711283	APEH	-0.54	-6.16	-0.35	2.67e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs4132509	1.000	rs4553169	chr1:243900640	G/A	cg21452805	chr1:244014465	NA	0.42	5.36	0.31	1.85e-7	RR interval (heart rate);
CESC	cis	rs941873	0.836	rs6480931	chr10:81108482	T/C	cg11057378	chr10:81107060	PPIF	0.35	5.57	0.32	6.2e-8	Height;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg24625240	chr11:126081434	RPUSD4;FAM118B	-0.45	-6.91	-0.39	3.61e-11	Gambling;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05099121	chr7:91764089	CYP51A1	0.51	6.09	0.35	3.99e-9	Gut microbiome composition (summer);
CESC	cis	rs4555082	0.874	rs2245329	chr14:105719181	T/C	cg10792982	chr14:105748885	BRF1	0.42	5.54	0.32	7.27e-8	Mean platelet volume;Platelet distribution width;
CESC	trans	rs2216164	0.933	rs2080414	chr12:68571817	A/T	cg27495728	chr7:99067116	NA	-0.35	-6.26	-0.36	1.56e-9	Alopecia areata;
CESC	trans	rs801193	1.000	rs2003301	chr7:66147656	G/C	cg26939375	chr7:64535504	NA	-0.63	-8.5	-0.46	1.4e-15	Aortic root size;
CESC	cis	rs6087990	0.899	rs6087999	chr20:31363774	A/G	cg13636640	chr20:31349939	DNMT3B	0.9	16.5	0.71	1.5e-42	Ulcerative colitis;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg21289763	chr17:78868835	RPTOR	0.41	6.01	0.35	6.22e-9	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs75575287	1.000	rs17120196	chr14:73206034	C/T	cg14758526	chr11:104879683	CASP5	-0.84	-6.06	-0.35	4.57e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
CESC	cis	rs111326718	1	rs111326718	chr10:104771211	A/AAAAAT	cg08650961	chr10:104748594	CNNM2	0.33	5.5	0.32	8.73e-8	Reticulocyte count;
CESC	cis	rs193541	0.642	rs42538	chr5:122292352	A/T	cg19412675	chr5:122181750	SNX24	0.45	5.34	0.31	2.03e-7	Glucose homeostasis traits;
CESC	cis	rs2235544	0.565	rs7513522	chr1:54465705	A/G	cg25741118	chr1:54482237	LDLRAD1	0.23	5.65	0.33	4.13e-8	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg21745091	chr11:118992183	HINFP	-0.44	-6.06	-0.35	4.7e-9	Fibrinogen levels;
CESC	cis	rs483180	0.512	rs606312	chr1:120222582	G/A	cg19096424	chr1:120255104	PHGDH	0.44	5.35	0.31	1.92e-7	Macular telangiectasia type 2;
CESC	cis	rs3820928	0.874	rs10210963	chr2:227821845	A/G	cg11843606	chr2:227700838	RHBDD1	-0.42	-5.58	-0.32	5.9e-8	Pulmonary function;
CESC	cis	rs6952808	0.789	rs35729895	chr7:1885069	C/T	cg04267008	chr7:1944627	MAD1L1	-0.6	-7.33	-0.41	2.73e-12	Bipolar disorder and schizophrenia;
CESC	cis	rs7551222	0.752	rs12566957	chr1:204556958	C/T	cg20240347	chr1:204465584	NA	-0.29	-5.95	-0.34	8.64e-9	Schizophrenia;
CESC	cis	rs270601	0.770	rs61352298	chr5:131600589	G/C	cg09877947	chr5:131593287	PDLIM4	0.48	6.32	0.36	1.11e-9	Acylcarnitine levels;
CESC	cis	rs826838	0.684	rs12367400	chr12:38618673	G/T	cg26384229	chr12:38710491	ALG10B	0.74	11.21	0.57	3.91e-24	Heart rate;
CESC	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-6.21	-0.36	2.01e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7927592	0.763	rs596494	chr11:68251054	T/G	cg20283391	chr11:68216788	NA	-0.47	-5.99	-0.35	6.92e-9	Total body bone mineral density;
CESC	trans	rs11098499	0.754	rs1546503	chr4:120241167	T/C	cg25214090	chr10:38739885	LOC399744	0.61	8.49	0.46	1.47e-15	Corneal astigmatism;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg15380607	chr6:138188545	TNFAIP3	-0.5	-6.45	-0.37	5.17e-10	Ulcerative colitis;
CESC	cis	rs2932538	0.961	rs3013441	chr1:113192605	C/T	cg22162597	chr1:113214053	CAPZA1	-0.55	-6.7	-0.38	1.24e-10	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CESC	cis	rs763121	0.853	rs2284073	chr22:39105948	T/C	cg06022373	chr22:39101656	GTPBP1	0.95	18.16	0.74	1.96e-48	Menopause (age at onset);
CESC	cis	rs801193	1.000	rs3778909	chr7:66255646	G/C	cg10691866	chr7:65817282	TPST1	-0.31	-5.08	-0.3	7.3e-7	Aortic root size;
CESC	cis	rs2836950	0.520	rs8130240	chr21:40538108	G/A	cg11890956	chr21:40555474	PSMG1	-0.69	-9.95	-0.52	5.08e-20	Menarche (age at onset);
CESC	cis	rs34330	0.562	rs7486387	chr12:12866911	G/A	cg04607235	chr12:12878440	APOLD1	-0.76	-8.34	-0.46	4.15e-15	Systemic lupus erythematosus;
CESC	cis	rs13256369	1.000	rs12547721	chr8:8570671	C/T	cg17143192	chr8:8559678	CLDN23	0.73	8.7	0.47	3.55e-16	Obesity-related traits;
CESC	trans	rs11098499	0.954	rs13133522	chr4:120324424	A/T	cg25214090	chr10:38739885	LOC399744	0.7	9.92	0.52	6.5e-20	Corneal astigmatism;
CESC	cis	rs4713118	0.597	rs172166	chr6:28020820	C/G	cg22143856	chr6:28129313	ZNF389	0.43	5.34	0.31	2.03e-7	Parkinson's disease;
CESC	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	10.54	0.54	6.46e-22	Prudent dietary pattern;
CESC	cis	rs9916302	0.904	rs1619021	chr17:37739274	G/A	cg15445000	chr17:37608096	MED1	0.39	6.05	0.35	4.91e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs7267979	1.000	rs2424700	chr20:25266513	A/G	cg08601574	chr20:25228251	PYGB	0.39	5.65	0.33	4.05e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs367615	0.918	rs10055528	chr5:108861129	G/T	cg17395555	chr5:108820864	NA	0.54	7.88	0.44	8.68e-14	Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs854765	0.583	rs7503334	chr17:17779458	C/T	cg09796270	chr17:17721594	SREBF1	-0.46	-6.46	-0.37	4.99e-10	Total body bone mineral density;
CESC	cis	rs4664304	0.966	rs925411	chr2:160745785	G/T	cg03641300	chr2:160917029	PLA2R1	-0.49	-6.99	-0.39	2.24e-11	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs561341	1.000	rs542132	chr17:30307193	A/T	cg23018236	chr17:30244563	NA	-0.52	-5.1	-0.3	6.39e-7	Hip circumference adjusted for BMI;
CESC	cis	rs4253772	0.515	rs8142080	chr22:46647429	G/T	cg10541313	chr22:46663664	TTC38	0.73	5.69	0.33	3.36e-8	LDL cholesterol;Cholesterol, total;
CESC	trans	rs4332037	0.950	rs11771828	chr7:1941003	T/C	cg11693508	chr17:37793320	STARD3	0.67	6.4	0.37	6.96e-10	Bipolar disorder;
CESC	cis	rs9910055	0.593	rs2905983	chr17:42212429	T/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.69	-9.14	-0.49	1.63e-17	Total body bone mineral density;
CESC	cis	rs2933343	0.700	rs1683787	chr3:128627021	C/T	cg25356066	chr3:128598488	ACAD9	-0.58	-8.19	-0.45	1.14e-14	IgG glycosylation;
CESC	cis	rs3960554	0.600	rs2302429	chr7:75614777	G/A	cg03214087	chr7:75624699	TMEM120A	-0.37	-5.47	-0.32	1.02e-7	Eotaxin levels;
CESC	cis	rs9355610	0.892	rs2247314	chr6:167370230	T/C	cg25258033	chr6:167368657	RNASET2	-0.4	-5.87	-0.34	1.27e-8	Graves' disease;
CESC	cis	rs514406	0.661	rs550561	chr1:53375134	C/T	cg06600287	chr1:53387719	ECHDC2	-0.27	-5.05	-0.3	8.13e-7	Monocyte count;
CESC	trans	rs801193	0.613	rs2016325	chr7:66323500	T/C	cg18876405	chr7:65276391	NA	-0.59	-7.53	-0.42	7.76e-13	Aortic root size;
CESC	cis	rs875971	0.862	rs6952182	chr7:65683317	T/G	cg12463550	chr7:65579703	CRCP	-0.52	-6.63	-0.38	1.84e-10	Aortic root size;
CESC	cis	rs568617	1.000	rs641018	chr11:65655393	G/C	cg19792802	chr11:65647270	CTSW	0.36	5.44	0.32	1.24e-7	Crohn's disease;
CESC	trans	rs2018683	0.707	rs4722875	chr7:28969632	A/G	cg19402173	chr7:128379420	CALU	-0.51	-6.84	-0.39	5.62e-11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CESC	cis	rs2820292	1.000	rs2494112	chr1:201787833	G/A	cg11586189	chr1:201857591	SHISA4	0.32	5.32	0.31	2.25e-7	Waist circumference;Body mass index (joint analysis main effects and smoking interaction);Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);
CESC	cis	rs4474465	0.541	rs11237527	chr11:78219664	C/A	cg27205649	chr11:78285834	NARS2	0.44	5.28	0.31	2.69e-7	Alzheimer's disease (survival time);
CESC	cis	rs9486715	1.000	rs9373985	chr6:97063522	C/G	cg06623918	chr6:96969491	KIAA0776	-0.88	-13.15	-0.63	9.55e-31	Headache;
CESC	cis	rs1009170	0.522	rs8004117	chr14:92638468	A/G	ch.14.1475328F	chr14:92585817	NDUFB1	0.44	5.06	0.3	7.88e-7	Dialysis-related mortality;
CESC	cis	rs2075371	0.673	rs35290398	chr7:134011773	C/T	cg11752832	chr7:134001865	SLC35B4	0.49	5.84	0.34	1.56e-8	Mean platelet volume;
CESC	cis	rs4713118	0.662	rs9380046	chr6:28030499	T/C	cg23161317	chr6:28129485	ZNF389	0.49	6.14	0.35	3.02e-9	Parkinson's disease;
CESC	cis	rs7762018	0.514	rs60671539	chr6:170165981	A/G	cg15038512	chr6:170123185	PHF10	0.45	6.07	0.35	4.44e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs9908102	0.710	rs4792313	chr17:12918296	T/C	cg26162695	chr17:12921313	ELAC2	0.56	6.04	0.35	5.13e-9	Schizophrenia;
CESC	cis	rs7131987	0.903	rs10843371	chr12:29414232	G/A	cg09582351	chr12:29534625	ERGIC2	-0.35	-5.59	-0.32	5.57e-8	QT interval;
CESC	cis	rs2154427	0.938	rs114440021	chr21:34202672	C/T	cg21871883	chr21:34145043	C21orf49;C21orf66	0.62	5.15	0.3	5.15e-7	Bilirubin levels;
CESC	trans	rs6089829	0.851	rs6122346	chr20:61661822	C/G	cg23505145	chr19:12996616	KLF1	0.52	6.7	0.38	1.24e-10	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs2836974	0.831	rs11911149	chr21:40528375	C/T	cg17971929	chr21:40555470	PSMG1	1.04	16.44	0.71	2.36e-42	Cognitive function;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg01522446	chr17:41150340	RPL27	0.49	6.83	0.39	5.93e-11	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs13256369	1.000	rs13266699	chr8:8570313	A/T	cg17143192	chr8:8559678	CLDN23	-0.7	-7.81	-0.43	1.3e-13	Obesity-related traits;
CESC	cis	rs1862618	0.853	rs10051747	chr5:56083289	C/A	cg24531977	chr5:56204891	C5orf35	-0.89	-11.1	-0.56	9.12e-24	Initial pursuit acceleration;
CESC	cis	rs1728785	1.000	rs1728773	chr16:68563644	A/C	cg02972257	chr16:68554789	NA	-0.55	-6.37	-0.36	8.21e-10	Ulcerative colitis;
CESC	cis	rs7560272	0.723	rs6722867	chr2:73816285	A/G	cg20560298	chr2:73613845	ALMS1	-0.5	-7.03	-0.4	1.74e-11	Schizophrenia;
CESC	cis	rs7666738	0.830	rs28416660	chr4:98899525	C/G	cg17366294	chr4:99064904	C4orf37	0.57	7.86	0.43	9.47e-14	Colonoscopy-negative controls vs population controls;
CESC	trans	rs3794271	0.706	rs9971816	chr12:20826911	C/T	cg05518939	chr3:121554459	IQCB1;EAF2	-0.45	-6.7	-0.38	1.21e-10	Response to TNF-alpha inhibitors in rheumatoid arthritis;
CESC	cis	rs2797160	1.000	rs1739373	chr6:126011509	A/G	cg05901451	chr6:126070800	HEY2	0.45	6.62	0.38	2e-10	Endometrial cancer;
CESC	cis	rs17376456	0.877	rs12374470	chr5:93481046	A/G	cg21475434	chr5:93447410	FAM172A	0.88	7.64	0.42	3.98e-13	Diabetic retinopathy;
CESC	cis	rs2832077	0.506	rs10222093	chr21:30163518	T/C	cg24692254	chr21:30365293	RNF160	-0.51	-6.02	-0.35	5.92e-9	Cognitive test performance;
CESC	cis	rs798554	0.959	rs798557	chr7:2758982	G/A	cg19717773	chr7:2847554	GNA12	-0.54	-7.66	-0.43	3.55e-13	Height;
CESC	cis	rs10504229	0.638	rs6981055	chr8:58113941	T/C	cg02725872	chr8:58115012	NA	-0.45	-7.04	-0.4	1.66e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs838147	0.507	rs1704773	chr19:49209566	A/G	cg21064579	chr19:49206444	FUT2	0.51	7.12	0.4	9.95e-12	Dietary macronutrient intake;
CESC	cis	rs1552244	1.000	rs6442150	chr3:10122575	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.8	-10.48	-0.54	9.87e-22	Alzheimer's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25907362	chr10:120937749	PRDX3	-0.63	-6.85	-0.39	5.25e-11	Gut microbiome composition (summer);
CESC	cis	rs62229266	0.804	rs62230821	chr21:37425116	C/T	cg12218747	chr21:37451666	NA	-0.42	-5.88	-0.34	1.23e-8	Mitral valve prolapse;
CESC	cis	rs9311474	0.607	rs28661185	chr3:52567188	G/T	cg18404041	chr3:52824283	ITIH1	-0.37	-6.26	-0.36	1.54e-9	Electroencephalogram traits;
CESC	cis	rs372883	0.638	rs371432	chr21:30710876	G/A	cg24692254	chr21:30365293	RNF160	-0.52	-6.55	-0.37	2.97e-10	Pancreatic cancer;
CESC	cis	rs5750830	0.621	rs5750810	chr22:39792943	A/G	cg11247378	chr22:39784982	NA	-0.59	-9.03	-0.49	3.52e-17	Intelligence (multi-trait analysis);
CESC	cis	rs4665809	1.000	rs7573118	chr2:26308086	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.7	-8.01	-0.44	3.69e-14	Gut microbiome composition (summer);
CESC	cis	rs4665809	0.567	rs12999875	chr2:26414847	A/C	cg04944784	chr2:26401820	FAM59B	0.94	10.66	0.55	2.64e-22	Gut microbiome composition (summer);
CESC	trans	rs1994135	0.565	rs1905240	chr12:33645009	A/G	cg26384229	chr12:38710491	ALG10B	-0.46	-6.28	-0.36	1.35e-9	Resting heart rate;
CESC	cis	rs7552404	0.924	rs7546641	chr1:76158035	T/C	cg22875332	chr1:76189707	ACADM	0.69	9.24	0.49	8.13e-18	Blood metabolite levels;Acylcarnitine levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08798701	chr3:129118382	RPL32P3	-0.55	-6.27	-0.36	1.43e-9	Gut microbiome composition (summer);
CESC	cis	rs9611565	0.729	rs169362	chr22:41827589	G/C	cg06634786	chr22:41940651	POLR3H	0.44	5.15	0.3	5.05e-7	Vitiligo;
CESC	trans	rs6543990	0.741	rs305191	chr2:36252564	C/T	cg04092111	chr11:58728533	NA	-0.41	-6.02	-0.35	5.87e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2651899	0.902	rs2742673	chr1:3080019	A/C	cg07622451	chr1:3079886	PRDM16	-0.31	-5.63	-0.33	4.51e-8	Migraine;
CESC	cis	rs1552244	0.882	rs2130813	chr3:10038706	A/C	cg08888203	chr3:10149979	C3orf24	0.48	6.09	0.35	3.99e-9	Alzheimer's disease;
CESC	cis	rs4820294	1.000	rs732856	chr22:38060691	C/G	cg21798802	chr22:38057573	PDXP	-0.46	-7.88	-0.44	8.53e-14	Fat distribution (HIV);
CESC	cis	rs6691722	1.000	rs6691722	chr1:24673866	A/G	cg02336364	chr1:24764700	NIPAL3	0.26	5.1	0.3	6.47e-7	Response to interferon beta in multiple sclerosis;
CESC	cis	rs3096299	0.566	rs4129126	chr16:89561475	A/C	cg02187348	chr16:89574699	SPG7	0.49	6.13	0.35	3.11e-9	Multiple myeloma (IgH translocation);
CESC	cis	rs736408	0.716	rs2239549	chr3:52823126	C/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.31	5.21	0.3	3.85e-7	Bipolar disorder;
CESC	cis	rs1799949	0.965	rs11657883	chr17:41330024	T/C	cg25072359	chr17:41440525	NA	0.5	6.75	0.38	9.44e-11	Menopause (age at onset);
CESC	cis	rs4595586	0.545	rs7972590	chr12:39376615	A/G	cg26384229	chr12:38710491	ALG10B	0.54	7.53	0.42	7.85e-13	Morning vs. evening chronotype;
CESC	cis	rs920590	0.684	rs57837509	chr8:19670088	A/G	cg17834443	chr8:19674713	INTS10	0.59	6.57	0.37	2.69e-10	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs7727544	0.735	rs274559	chr5:131720070	A/G	cg24060327	chr5:131705240	SLC22A5	0.7	9.59	0.51	7.1e-19	Blood metabolite levels;
CESC	cis	rs7618915	0.547	rs2336542	chr3:52710636	A/G	cg17372223	chr3:52568218	NT5DC2	0.44	6.63	0.38	1.88e-10	Bipolar disorder;
CESC	cis	rs548181	0.577	rs569766	chr11:125532369	G/A	cg03464685	chr11:125439445	EI24	0.89	7.67	0.43	3.32e-13	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs896854	0.967	rs10808671	chr8:95967372	A/G	cg09323728	chr8:95962352	TP53INP1	-0.42	-9.2	-0.49	1.09e-17	Type 2 diabetes;
CESC	trans	rs7617773	0.780	rs3731550	chr3:48206583	A/C	cg02094337	chr17:80542118	FOXK2	0.43	6.16	0.35	2.63e-9	Coronary artery disease;
CESC	cis	rs12765878	1.000	rs10883943	chr10:105651416	G/T	cg11005552	chr10:105648138	OBFC1	0.34	5.05	0.3	8.35e-7	Coronary artery disease;
CESC	cis	rs832540	0.552	rs702681	chr5:56218029	C/T	cg14703610	chr5:56206110	C5orf35	0.48	5.96	0.34	7.88e-9	Coronary artery disease;
CESC	cis	rs950776	0.518	rs11636131	chr15:78821606	C/T	cg24631222	chr15:78858424	CHRNA5	-0.42	-5.33	-0.31	2.09e-7	Sudden cardiac arrest;
CESC	cis	rs7666738	0.753	rs11097607	chr4:99011640	C/T	cg03676636	chr4:99064102	C4orf37	0.34	5.23	0.31	3.51e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6540559	1.000	rs6540559	chr1:209982025	G/A	cg23283495	chr1:209979779	IRF6	0.51	7.55	0.42	6.94e-13	Cleft lip with or without cleft palate;
CESC	cis	rs28386778	0.669	rs12603821	chr17:62006432	G/A	cg26338869	chr17:61819248	STRADA	-0.62	-7.85	-0.43	1.04e-13	Prudent dietary pattern;
CESC	cis	rs12950390	0.853	rs55745341	chr17:45855778	G/C	cg00777063	chr17:45855553	NA	-0.38	-5.64	-0.33	4.46e-8	IgG glycosylation;
CESC	cis	rs72781680	0.821	rs12616257	chr2:24135034	A/G	cg08917208	chr2:24149416	ATAD2B	0.56	5.6	0.33	5.47e-8	Lymphocyte counts;
CESC	cis	rs7666738	0.791	rs60028147	chr4:99046618	G/A	cg05340658	chr4:99064831	C4orf37	0.8	12.39	0.61	3.91e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4665809	0.567	rs6711402	chr2:26430983	A/G	cg04944784	chr2:26401820	FAM59B	-0.9	-9.7	-0.51	3.1400000000000002e-19	Gut microbiome composition (summer);
CESC	cis	rs4975616	0.843	rs4975615	chr5:1315343	C/T	cg26373071	chr5:1325741	CLPTM1L	-0.45	-7.05	-0.4	1.58e-11	Lung cancer;
CESC	cis	rs12477438	0.501	rs11123770	chr2:99825102	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.71	10.42	0.54	1.52e-21	Chronic sinus infection;
CESC	cis	rs2066819	1.000	rs75598973	chr12:56746558	C/T	cg26714650	chr12:56694279	CS	-1.39	-9.06	-0.49	2.88e-17	Psoriasis vulgaris;
CESC	cis	rs11048434	0.761	rs2377675	chr12:9124765	C/T	cg23795048	chr12:9217529	LOC144571	0.36	5.46	0.32	1.07e-7	Sjögren's syndrome;
CESC	cis	rs10789491	0.588	rs2099766	chr1:47193987	T/C	cg15501359	chr1:47185051	KIAA0494	0.68	6.75	0.38	9.35e-11	Response to hepatitis C treatment;
CESC	cis	rs12477438	0.715	rs6724476	chr2:99627316	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.62	-8.67	-0.47	4.43e-16	Chronic sinus infection;
CESC	cis	rs963731	0.649	rs79361942	chr2:39336315	G/A	cg04010122	chr2:39346883	SOS1	0.76	5.65	0.33	4.06e-8	Corticobasal degeneration;
CESC	cis	rs8078723	0.866	rs11078934	chr17:38189793	C/T	cg17467752	chr17:38218738	THRA	0.69	11.13	0.56	7.55e-24	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CESC	cis	rs6598955	0.543	rs6698557	chr1:26561220	G/C	cg04990556	chr1:26633338	UBXN11	0.83	9.48	0.5	1.56e-18	Obesity-related traits;
CESC	cis	rs798554	0.679	rs2644281	chr7:2886748	A/G	cg04166393	chr7:2884313	GNA12	0.59	8.08	0.44	2.29e-14	Height;
CESC	cis	rs7666738	0.830	rs13328042	chr4:99055406	A/G	cg05340658	chr4:99064831	C4orf37	0.83	12.83	0.62	1.27e-29	Colonoscopy-negative controls vs population controls;
CESC	cis	rs57506017	0.585	rs3807865	chr7:12250402	A/G	cg23422036	chr7:12250390	TMEM106B	-0.38	-5.11	-0.3	6.2e-7	Neuroticism;
CESC	cis	rs4727027	0.933	rs12532104	chr7:148864233	A/C	cg23158103	chr7:148848205	ZNF398	-0.42	-6.88	-0.39	4.26e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs2777491	0.574	rs1757468	chr15:41743574	T/A	cg20272979	chr15:41787780	ITPKA	0.42	5.18	0.3	4.44e-7	Ulcerative colitis;
CESC	cis	rs1546924	0.570	rs197419	chr1:112315450	G/T	cg23955903	chr1:112298873	DDX20;C1orf183	-0.44	-5.74	-0.33	2.65e-8	Body mass index;
CESC	cis	rs910316	0.967	rs35446981	chr14:75637351	A/T	cg08847533	chr14:75593920	NEK9	-0.97	-17.65	-0.74	1.22e-46	Height;
CESC	cis	rs4319547	0.656	rs7135419	chr12:122911861	T/A	cg05707623	chr12:122985044	ZCCHC8	-0.54	-6.17	-0.35	2.52e-9	Body mass index;
CESC	cis	rs1005224	0.927	rs8007792	chr14:76175666	C/A	cg25116370	chr14:76127843	TTLL5;C14orf1	-0.43	-5.83	-0.34	1.57e-8	Large artery stroke;
CESC	cis	rs41271951	0.512	rs34761930	chr1:151089523	T/C	cg11822372	chr1:151115635	SEMA6C	-0.63	-5.03	-0.3	9.12e-7	Blood protein levels;
CESC	cis	rs116095464	0.558	rs112343653	chr5:257174	G/A	cg10591111	chr5:226296	SDHA	-0.51	-6.15	-0.35	2.84e-9	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09912005	chr4:123300640	ADAD1	-0.58	-6.23	-0.36	1.83e-9	Gut microbiome composition (summer);
CESC	cis	rs9322193	0.962	rs6903998	chr6:150152493	T/C	cg04369109	chr6:150039330	LATS1	-0.44	-6.24	-0.36	1.7e-9	Lung cancer;
CESC	cis	rs72781680	0.582	rs72783611	chr2:24291445	C/T	cg08917208	chr2:24149416	ATAD2B	0.55	5.22	0.31	3.56e-7	Lymphocyte counts;
CESC	cis	rs854765	0.693	rs9907246	chr17:17770965	T/C	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.45	-5.83	-0.34	1.58e-8	Total body bone mineral density;
CESC	cis	rs16857609	0.628	rs2068972	chr2:218346451	A/G	cg03013118	chr2:218375971	DIRC3	0.28	5.28	0.31	2.7e-7	Breast cancer;Breast cancer (estrogen-receptor negative);
CESC	cis	rs4727027	0.866	rs1405124	chr7:148779618	C/T	cg23583168	chr7:148888333	NA	-0.79	-11.84	-0.59	3.12e-26	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs875971	0.862	rs778736	chr7:65813848	C/T	cg10691866	chr7:65817282	TPST1	-0.32	-5.42	-0.32	1.35e-7	Aortic root size;
CESC	cis	rs3749237	0.595	rs35701831	chr3:49515000	A/C	cg02487422	chr3:49467188	NICN1	0.56	8.19	0.45	1.12e-14	Resting heart rate;
CESC	cis	rs798554	0.591	rs757791	chr7:2867296	A/G	cg19717773	chr7:2847554	GNA12	-0.52	-7.99	-0.44	4.22e-14	Height;
CESC	cis	rs8062405	0.755	rs62034325	chr16:28538640	A/G	cg07382826	chr16:28625726	SULT1A1	0.4	6.64	0.38	1.73e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs7945705	0.818	rs2653613	chr11:8879105	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.41	-6.54	-0.37	3.16e-10	Hemoglobin concentration;
CESC	cis	rs7666738	0.546	rs10440329	chr4:98903735	C/T	cg17366294	chr4:99064904	C4orf37	0.51	6.53	0.37	3.27e-10	Colonoscopy-negative controls vs population controls;
CESC	cis	rs12220238	1.000	rs11000887	chr10:75897542	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.65	6.33	0.36	1.03e-9	Soluble interleukin-2 receptor subunit alpha;
CESC	trans	rs875971	1.000	rs4717292	chr7:65895598	G/A	cg26939375	chr7:64535504	NA	0.46	6.0	0.35	6.4e-9	Aortic root size;
CESC	cis	rs6842047	1.000	rs72647308	chr4:187135129	G/A	cg09526685	chr4:187126073	CYP4V2	-0.7	-5.91	-0.34	1.03e-8	Blood protein levels;
CESC	cis	rs1801251	0.574	rs2250660	chr2:233752551	G/C	cg25237894	chr2:233734115	C2orf82	-0.33	-5.44	-0.32	1.19e-7	Coronary artery disease;
CESC	cis	rs9322193	0.923	rs2342857	chr6:150130673	G/A	cg13206674	chr6:150067644	NUP43	0.42	5.82	0.34	1.66e-8	Lung cancer;
CESC	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg23708337	chr7:1209742	NA	0.52	5.14	0.3	5.37e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg11235426	chr6:292522	DUSP22	-0.73	-9.71	-0.51	2.89e-19	Menopause (age at onset);
CESC	cis	rs11792861	0.781	rs72607158	chr9:111763010	T/C	cg13535736	chr9:111863775	C9orf5	-0.46	-5.98	-0.35	7e-9	Menarche (age at onset);
CESC	cis	rs2652822	0.525	rs11632192	chr15:63515946	A/G	cg02713581	chr15:63449717	RPS27L	0.49	6.34	0.36	1e-9	Metabolic traits;
CESC	cis	rs66887589	0.967	rs3775842	chr4:120427732	G/A	cg09307838	chr4:120376055	NA	0.5	6.65	0.38	1.67e-10	Diastolic blood pressure;
CESC	cis	rs4843747	0.619	rs66508972	chr16:88086385	C/G	cg09044154	chr16:88155775	NA	-0.47	-5.22	-0.31	3.61e-7	Menopause (age at onset);
CESC	cis	rs4253772	0.591	rs11704586	chr22:46685274	T/C	cg18190219	chr22:46762943	CELSR1	-0.59	-5.46	-0.32	1.09e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs7618915	0.501	rs3733039	chr3:52719088	C/T	cg05564831	chr3:52568323	NT5DC2	0.46	7.33	0.41	2.88e-12	Bipolar disorder;
CESC	cis	rs2228479	0.702	rs3819574	chr16:89826630	G/A	cg00800038	chr16:89945340	TCF25	-0.92	-7.62	-0.42	4.38e-13	Skin colour saturation;
CESC	cis	rs875971	0.505	rs1167386	chr7:65513096	G/A	cg14393609	chr7:65229607	NA	-0.52	-7.14	-0.4	8.77e-12	Aortic root size;
CESC	cis	rs113835537	0.559	rs74933537	chr11:66274958	A/C	cg24851651	chr11:66362959	CCS	0.46	5.81	0.34	1.81e-8	Airway imaging phenotypes;
CESC	cis	rs3015469	0.751	rs12891224	chr14:51208143	T/G	cg26011998	chr14:51135199	SAV1	0.53	5.94	0.34	9.01e-9	Plasma amyloid beta peptide concentrations (ABx-40);
CESC	cis	rs8070740	0.898	rs4493114	chr17:5324207	G/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.51	6.28	0.36	1.35e-9	Menopause (age at onset);
CESC	cis	rs694739	1.000	rs499425	chr11:64105929	A/G	cg23796481	chr11:64053134	BAD;GPR137	-0.67	-8.62	-0.47	6.29e-16	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CESC	cis	rs2932538	0.961	rs6537746	chr1:113163529	C/T	cg22162597	chr1:113214053	CAPZA1	-0.58	-7.44	-0.42	1.42e-12	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg08007338	chr1:180123948	QSOX1	-0.45	-6.13	-0.35	3.11e-9	Fibrinogen levels;
CESC	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg17178900	chr1:205818956	PM20D1	0.79	12.22	0.6	1.59e-27	Menarche (age at onset);
CESC	cis	rs853679	0.517	rs9368558	chr6:28133306	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.57	-6.49	-0.37	4.32e-10	Depression;
CESC	cis	rs9443645	0.901	rs4415132	chr6:79554107	T/C	cg05283184	chr6:79620031	NA	-0.44	-6.88	-0.39	4.39e-11	Intelligence (multi-trait analysis);
CESC	trans	rs7615952	0.673	rs9841194	chr3:125635739	C/T	cg07211511	chr3:129823064	LOC729375	-0.89	-8.15	-0.45	1.47e-14	Blood pressure (smoking interaction);
CESC	trans	rs2975734	0.736	rs4841300	chr8:10112595	T/C	cg15556689	chr8:8085844	FLJ10661	-0.59	-6.73	-0.38	1.06e-10	Morning vs. evening chronotype;Chronotype;
CESC	cis	rs7666738	0.830	rs7663661	chr4:99014761	A/G	cg18180107	chr4:99064573	C4orf37	0.4	5.3	0.31	2.48e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7208859	0.623	rs1054400	chr17:29109954	A/G	cg19761014	chr17:28927070	LRRC37B2	0.77	6.37	0.36	8.1e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs9311474	0.502	rs4687624	chr3:52563572	C/T	cg05564831	chr3:52568323	NT5DC2	0.46	7.12	0.4	1e-11	Electroencephalogram traits;
CESC	cis	rs7264396	0.563	rs2425094	chr20:34306974	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.89	-10.65	-0.55	2.79e-22	Total cholesterol levels;
CESC	cis	rs7246657	0.943	rs7252346	chr19:37914682	G/A	cg23950597	chr19:37808831	NA	-0.55	-5.99	-0.35	6.69e-9	Coronary artery calcification;
CESC	cis	rs1008375	1.000	rs17507481	chr4:17620066	A/G	cg02297831	chr4:17616191	MED28	0.6	7.63	0.42	4.17e-13	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs798554	0.680	rs2533889	chr7:2900309	G/C	cg13628971	chr7:2884303	GNA12	0.6	7.87	0.44	9.16e-14	Height;
CESC	cis	rs9596863	0.898	rs9316658	chr13:54333620	C/T	ch.13.53330881F	chr13:54432880	NA	-0.59	-5.16	-0.3	4.78e-7	Epilepsy and lamotrigine-induced maculopapular eruptions;
CESC	cis	rs7666738	0.830	rs28619044	chr4:98789814	G/C	cg05340658	chr4:99064831	C4orf37	0.77	11.6	0.58	2.01e-25	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9325144	0.505	rs826893	chr12:39100536	A/G	cg26384229	chr12:38710491	ALG10B	-0.59	-9.44	-0.5	2.04e-18	Morning vs. evening chronotype;
CESC	cis	rs875971	0.862	rs1875057	chr7:65731855	A/G	cg18252515	chr7:66147081	NA	0.44	5.75	0.33	2.44e-8	Aortic root size;
CESC	cis	rs2412819	0.599	rs2470120	chr15:43929070	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.52	6.67	0.38	1.46e-10	Lung cancer;
CESC	cis	rs9815354	0.556	rs56201224	chr3:42004427	A/C	cg03022575	chr3:42003672	ULK4	0.64	5.83	0.34	1.62e-8	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs1008375	0.966	rs10939755	chr4:17693755	T/C	cg27347728	chr4:17578864	LAP3	0.42	5.08	0.3	7.24e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs73206853	0.764	rs56128816	chr12:110775609	T/C	cg12870014	chr12:110450643	ANKRD13A	0.66	5.59	0.32	5.61e-8	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	trans	rs7740797	0.967	rs3757291	chr6:155124583	G/T	cg11972327	chr1:8419796	RERE	-0.44	-6.05	-0.35	5.05e-9	Colorectal or endometrial cancer;
CESC	cis	rs11696501	0.694	rs7266372	chr20:44266635	T/C	cg11783356	chr20:44313418	WFDC10B	-0.34	-5.3	-0.31	2.44e-7	Brain structure;
CESC	cis	rs3820928	1.000	rs978909	chr2:227771389	A/C	cg05526886	chr2:227700861	RHBDD1	-0.44	-5.56	-0.32	6.65e-8	Pulmonary function;
CESC	cis	rs79349575	0.715	rs9894220	chr17:46989154	C/T	cg16584676	chr17:46985605	UBE2Z	0.71	9.18	0.49	1.25e-17	Type 2 diabetes;
CESC	cis	rs2836974	0.568	rs8130795	chr21:40549983	T/A	cg17971929	chr21:40555470	PSMG1	0.86	12.53	0.61	1.31e-28	Cognitive function;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16941144	chr14:45603841	FKBP3;FANCM	-0.54	-6.1	-0.35	3.69e-9	Gut microbiome composition (summer);
CESC	cis	rs2952156	0.883	rs8077172	chr17:37834977	G/T	cg07936489	chr17:37558343	FBXL20	-0.6	-7.98	-0.44	4.35e-14	Asthma;
CESC	cis	rs7216064	1.000	rs56404791	chr17:65893019	T/G	cg12091567	chr17:66097778	LOC651250	-0.71	-8.08	-0.44	2.37e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs11718455	0.960	rs11917885	chr3:44008013	A/G	cg08738300	chr3:44038990	NA	-0.45	-6.06	-0.35	4.56e-9	Coronary artery disease;
CESC	cis	rs2273669	0.667	rs12206606	chr6:109353519	C/A	cg05315195	chr6:109294784	ARMC2	-0.67	-6.33	-0.36	1.02e-9	Prostate cancer;
CESC	trans	rs61931739	0.500	rs11053249	chr12:34518834	A/T	cg13010199	chr12:38710504	ALG10B	0.5	6.42	0.37	6.3e-10	Morning vs. evening chronotype;
CESC	cis	rs10129255	1.000	rs8012033	chr14:107134871	T/A	cg23076370	chr14:107095027	NA	-0.41	-5.16	-0.3	4.85e-7	Kawasaki disease;
CESC	cis	rs7084402	0.870	rs1896245	chr10:60276083	T/G	cg07615347	chr10:60278583	BICC1	-0.59	-9.42	-0.5	2.33e-18	Refractive error;
CESC	cis	rs9354308	0.933	rs12203567	chr6:66589062	T/C	cg07460842	chr6:66804631	NA	0.66	7.47	0.42	1.16e-12	Metabolite levels;
CESC	cis	rs4689388	0.926	rs9998519	chr4:6292909	C/T	cg25554036	chr4:6271136	WFS1	0.53	8.74	0.47	2.69e-16	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs35955747	0.934	rs4820045	chr22:31785969	G/A	cg25791279	chr22:32026902	PISD	-0.44	-5.3	-0.31	2.42e-7	Neutrophil count;Sum basophil neutrophil counts;
CESC	cis	rs6543140	0.929	rs11465700	chr2:103057668	G/A	cg04239558	chr2:103089729	SLC9A4	0.48	6.04	0.35	5.17e-9	Blood protein levels;
CESC	trans	rs412658	0.668	rs7253490	chr19:22293706	A/C	cg05197062	chr11:11642011	GALNTL4	0.42	6.05	0.35	4.87e-9	Telomere length;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16988008	chr11:108463728	EXPH5	0.64	7.82	0.43	1.27e-13	Gut microbiome composition (summer);
CESC	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg21724239	chr8:58056113	NA	0.77	10.64	0.55	2.97e-22	Developmental language disorder (linguistic errors);
CESC	cis	rs11608355	0.618	rs2075435	chr12:109796832	C/T	cg19025524	chr12:109796872	NA	-0.58	-8.38	-0.46	3.14e-15	Neuroticism;
CESC	cis	rs9660180	0.967	rs6664664	chr1:1751264	G/A	cg20999797	chr1:1681921	NA	0.27	5.21	0.31	3.71e-7	Body mass index;
CESC	cis	rs7107174	1.000	rs10899453	chr11:77997482	A/C	cg02023728	chr11:77925099	USP35	0.51	7.03	0.4	1.74e-11	Testicular germ cell tumor;
CESC	cis	rs2408955	0.522	rs973398	chr12:48491048	A/G	cg24011408	chr12:48396354	COL2A1	-0.49	-7.34	-0.41	2.63e-12	Glycated hemoglobin levels;
CESC	cis	rs644148	0.738	rs2686767	chr19:44995037	G/C	cg15540054	chr19:45004280	ZNF180	-0.43	-5.35	-0.31	1.94e-7	Personality dimensions;
CESC	cis	rs780096	0.546	rs6547626	chr2:27646770	C/T	cg24768116	chr2:27665128	KRTCAP3	-0.29	-5.36	-0.31	1.82e-7	Total body bone mineral density;
CESC	cis	rs360798	0.553	rs7562734	chr2:63047973	G/C	cg17519650	chr2:63277830	OTX1	-0.59	-7.62	-0.42	4.45e-13	Coronary artery disease;
CESC	trans	rs10506458	0.688	rs73127095	chr12:63418283	T/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.08	-13.72	-0.64	9.72e-33	Hemostatic factors and hematological phenotypes;
CESC	cis	rs72781680	0.611	rs55905755	chr2:24330264	T/C	cg08917208	chr2:24149416	ATAD2B	0.61	5.78	0.33	2.1e-8	Lymphocyte counts;
CESC	cis	rs1801251	0.711	rs778339	chr2:233739678	T/C	cg08000102	chr2:233561755	GIGYF2	-0.6	-8.18	-0.45	1.16e-14	Coronary artery disease;
CESC	cis	rs9611565	0.659	rs1569516	chr22:41910244	C/T	cg06634786	chr22:41940651	POLR3H	-0.69	-7.1	-0.4	1.12e-11	Vitiligo;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg05556477	chr5:131705319	SLC22A5	-0.42	-6.09	-0.35	3.94e-9	Gambling;
CESC	cis	rs9811920	0.893	rs720688	chr3:99880569	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.43	6.99	0.39	2.28e-11	Axial length;
CESC	cis	rs2842992	0.915	rs1967802	chr6:160097791	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.64	7.74	0.43	2.05e-13	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs4665809	0.590	rs4665318	chr2:26424517	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.07	12.6	0.61	7.81e-29	Gut microbiome composition (summer);
CESC	trans	rs7837860	0.541	rs35658486	chr8:89279419	A/G	cg04391754	chr17:18022714	MYO15A	0.52	6.12	0.35	3.41e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg07677032	chr17:61819896	STRADA	0.45	5.93	0.34	9.39e-9	Prudent dietary pattern;
CESC	cis	rs12579753	0.692	rs9943807	chr12:82279404	T/A	cg23701643	chr12:82153290	PPFIA2	-0.36	-5.31	-0.31	2.36e-7	Resting heart rate;
CESC	cis	rs2204008	0.549	rs12312109	chr12:38228251	G/T	cg26384229	chr12:38710491	ALG10B	-0.47	-6.22	-0.36	1.89e-9	Bladder cancer;
CESC	cis	rs2625529	0.526	rs62022789	chr15:72564492	C/T	cg16672083	chr15:72433130	SENP8	0.42	6.36	0.36	8.62e-10	Red blood cell count;
CESC	cis	rs4665809	0.887	rs4665814	chr2:26273687	G/T	cg26314531	chr2:26401878	FAM59B	-0.6	-6.78	-0.38	7.95e-11	Gut microbiome composition (summer);
CESC	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.44	5.41	0.32	1.39e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs9291683	0.530	rs6449196	chr4:9973660	C/T	cg02734326	chr4:10020555	SLC2A9	-0.45	-6.77	-0.38	8.45e-11	Bone mineral density;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg07254608	chr8:41997973	NA	0.51	6.71	0.38	1.19e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs8067354	0.574	rs1296279	chr17:57965731	G/A	cg02344993	chr17:57696989	CLTC	0.54	5.6	0.33	5.31e-8	Hemoglobin concentration;
CESC	cis	rs11997175	0.550	rs10105616	chr8:33786830	G/A	ch.8.33884649F	chr8:33765107	NA	0.63	8.07	0.44	2.53e-14	Body mass index;
CESC	cis	rs193541	0.632	rs152038	chr5:122195846	G/A	cg19412675	chr5:122181750	SNX24	0.46	5.4	0.31	1.5e-7	Glucose homeostasis traits;
CESC	cis	rs6693567	0.545	rs4446975	chr1:150456169	C/T	cg09579323	chr1:150459698	TARS2	0.42	5.53	0.32	7.5e-8	Migraine;
CESC	cis	rs7412746	0.524	rs58304714	chr1:150831561	T/A	cg04414720	chr1:150670196	GOLPH3L	0.56	7.43	0.42	1.52e-12	Melanoma;
CESC	cis	rs947211	0.950	rs1775145	chr1:205756143	C/A	cg24503407	chr1:205819492	PM20D1	0.39	5.3	0.31	2.42e-7	Parkinson's disease;
CESC	cis	rs703842	1.000	rs10431505	chr12:58178589	A/G	cg18357645	chr12:58087776	OS9	-0.39	-5.52	-0.32	8.26e-8	Multiple sclerosis;
CESC	cis	rs35995292	0.534	rs10274968	chr7:38939254	C/T	cg19327137	chr7:38886074	VPS41	0.67	11.55	0.58	2.79e-25	Subjective well-being (multi-trait analysis);
CESC	cis	rs71277158	0.688	rs879161	chr3:169812115	A/G	cg04067573	chr3:169899625	PHC3	0.68	6.96	0.39	2.62e-11	Prostate cancer;
CESC	cis	rs1401999	1.000	rs2176824	chr3:183654029	C/G	cg01324343	chr3:183735012	ABCC5	0.66	14.04	0.65	7.57e-34	Anterior chamber depth;
CESC	cis	rs8017423	0.935	rs17260827	chr14:90732703	G/A	cg14092571	chr14:90743983	NA	0.57	8.49	0.46	1.49e-15	Mortality in heart failure;
CESC	cis	rs7208859	0.623	rs60890550	chr17:29030861	A/G	cg14008862	chr17:28927542	LRRC37B2	0.67	5.22	0.31	3.58e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs62458065	0.513	rs787220	chr7:32581139	C/G	cg20159608	chr7:32802032	NA	-0.55	-6.15	-0.35	2.89e-9	Metabolite levels (HVA/MHPG ratio);
CESC	cis	rs3096299	0.563	rs4600467	chr16:89562516	C/T	cg02187348	chr16:89574699	SPG7	0.66	9.26	0.49	7.27e-18	Multiple myeloma (IgH translocation);
CESC	cis	rs8018808	0.846	rs11624990	chr14:77943616	C/T	cg20045696	chr14:77926864	AHSA1	0.4	5.41	0.32	1.4e-7	Myeloid white cell count;
CESC	cis	rs4665809	0.590	rs1056389	chr2:26502875	T/C	cg04944784	chr2:26401820	FAM59B	0.95	9.94	0.52	5.28e-20	Gut microbiome composition (summer);
CESC	cis	rs4689388	0.926	rs4688987	chr4:6287329	C/T	cg14416269	chr4:6271139	WFS1	0.47	7.85	0.43	1.05e-13	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs1878931	0.624	rs1149492	chr16:3445239	A/G	cg02880119	chr16:3481970	NA	0.41	5.13	0.3	5.61e-7	Body mass index (adult);
CESC	cis	rs875971	0.617	rs810400	chr7:66022889	G/C	cg11764359	chr7:65958608	NA	-0.73	-9.8	-0.52	1.49e-19	Aortic root size;
CESC	cis	rs6540559	1.000	rs742215	chr1:209961023	A/T	cg21951975	chr1:209979733	IRF6	0.61	9.34	0.5	4.14e-18	Cleft lip with or without cleft palate;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01091156	chr16:87991122	BANP	-0.66	-7.79	-0.43	1.5700000000000001e-13	Gut microbiome composition (summer);
CESC	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg02353165	chr6:42928485	GNMT	0.85	13.6	0.64	2.68e-32	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs1799949	0.931	rs34410138	chr17:41279770	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.43	5.98	0.34	7.13e-9	Menopause (age at onset);
CESC	cis	rs9322193	0.962	rs12175575	chr6:150084487	G/A	cg13206674	chr6:150067644	NUP43	0.43	5.98	0.34	7.33e-9	Lung cancer;
CESC	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg22535103	chr8:58192502	C8orf71	-0.92	-10.19	-0.53	8.81e-21	Developmental language disorder (linguistic errors);
CESC	cis	rs9910055	0.659	rs7207464	chr17:42245033	C/T	cg19774624	chr17:42201019	HDAC5	-0.89	-14.85	-0.67	1.01e-36	Total body bone mineral density;
CESC	cis	rs7647973	0.626	rs4855845	chr3:49687043	T/C	cg06212747	chr3:49208901	KLHDC8B	0.65	7.85	0.43	1.01e-13	Menarche (age at onset);
CESC	trans	rs1945213	0.659	rs11227133	chr11:55836620	T/C	cg03929089	chr4:120376271	NA	0.76	7.26	0.41	4.31e-12	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs8017423	0.605	rs3742673	chr14:90735707	C/T	cg14092571	chr14:90743983	NA	-0.53	-8.17	-0.45	1.31e-14	Mortality in heart failure;
CESC	cis	rs6963495	0.745	rs75805443	chr7:105162828	A/G	cg13798780	chr7:105162888	PUS7	0.78	8.04	0.44	2.99e-14	Bipolar disorder (body mass index interaction);
CESC	cis	rs72781680	0.898	rs17462433	chr2:24012758	T/C	cg08917208	chr2:24149416	ATAD2B	0.95	8.71	0.47	3.45e-16	Lymphocyte counts;
CESC	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg04025307	chr7:1156635	C7orf50	0.51	8.46	0.46	1.8e-15	Longevity;Endometriosis;
CESC	cis	rs7618915	1.000	rs34569561	chr3:52287293	T/C	cg05564831	chr3:52568323	NT5DC2	0.4	5.62	0.33	4.82e-8	Bipolar disorder;
CESC	cis	rs6963495	0.818	rs73192124	chr7:105171528	C/T	cg02135003	chr7:105160482	PUS7	-0.46	-5.45	-0.32	1.13e-7	Bipolar disorder (body mass index interaction);
CESC	cis	rs7429990	0.932	rs9862913	chr3:48016172	T/C	cg11946769	chr3:48343235	NME6	0.43	5.2	0.3	4e-7	Educational attainment (years of education);
CESC	trans	rs61931739	0.500	rs7979769	chr12:34509522	C/T	cg13010199	chr12:38710504	ALG10B	0.5	6.42	0.37	6.3e-10	Morning vs. evening chronotype;
CESC	cis	rs11792861	0.816	rs2304779	chr9:111670513	C/T	cg05043794	chr9:111880884	C9orf5	0.33	5.47	0.32	1.03e-7	Menarche (age at onset);
CESC	cis	rs4665809	1.000	rs6546726	chr2:26275116	A/G	cg04944784	chr2:26401820	FAM59B	-0.68	-7.66	-0.43	3.57e-13	Gut microbiome composition (summer);
CESC	cis	rs1862618	0.802	rs194058	chr5:56188977	G/A	cg24549020	chr5:56110836	MAP3K1	0.6	6.65	0.38	1.67e-10	Initial pursuit acceleration;
CESC	cis	rs2236918	1.000	rs2236918	chr1:242017826	C/G	cg17736920	chr1:242011382	EXO1	-0.73	-10.02	-0.52	3.1e-20	Menopause (age at onset);
CESC	cis	rs1707322	1.000	rs7538978	chr1:46505054	C/T	cg03146154	chr1:46216737	IPP	-0.7	-9.56	-0.51	8.31e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9303401	0.659	rs36109237	chr17:56653834	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	1.02	12.93	0.62	5.59e-30	Cognitive test performance;
CESC	cis	rs10206020	0.921	rs10177509	chr2:1568536	T/C	cg26248373	chr2:1572462	NA	-0.57	-6.78	-0.38	7.9e-11	IgG glycosylation;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg15483030	chr1:5935144	NPHP4	0.48	6.1	0.35	3.82e-9	Fibrinogen levels;
CESC	cis	rs7091068	0.616	rs6583905	chr10:95504022	T/G	cg20715218	chr10:95462985	C10orf4	0.58	5.34	0.31	1.97e-7	Urinary tract infection frequency;
CESC	cis	rs34779708	0.649	rs34421369	chr10:35550275	G/C	cg03585969	chr10:35415529	CREM	0.54	6.19	0.36	2.3e-9	Inflammatory bowel disease;Crohn's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10517474	chr16:31470676	ARMC5	0.58	6.88	0.39	4.28e-11	Gut microbiome composition (summer);
CESC	cis	rs4975709	0.589	rs931508	chr5:1861224	C/G	cg14773178	chr5:1868261	NA	0.32	5.71	0.33	3.06e-8	Cardiovascular disease risk factors;
CESC	cis	rs1577917	0.727	rs9351065	chr6:86360428	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.54	-7.18	-0.4	7.14e-12	Response to antipsychotic treatment;
CESC	cis	rs473651	0.967	rs483042	chr2:239335320	A/G	cg18131467	chr2:239335373	ASB1	1.01	20.34	0.78	4.61e-56	Multiple system atrophy;
CESC	cis	rs734999	0.588	rs2843402	chr1:2528682	T/C	cg20673091	chr1:2541236	MMEL1	-0.44	-7.15	-0.4	8.55e-12	Ulcerative colitis;
CESC	cis	rs10743315	0.778	rs7397459	chr12:19377578	C/G	cg02471346	chr12:19282374	PLEKHA5	0.52	5.82	0.34	1.7e-8	Gut microbiota (bacterial taxa);
CESC	cis	rs8031584	0.678	rs798086	chr15:31129211	C/G	cg14829155	chr15:31115871	NA	0.74	10.23	0.53	6.51e-21	Huntington's disease progression;
CESC	cis	rs7666738	0.830	rs35951881	chr4:98999474	A/C	cg03467027	chr4:99064603	C4orf37	0.44	5.51	0.32	8.65e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2859741	0.528	rs59729868	chr1:37493710	G/A	cg09363841	chr1:37513479	NA	-0.51	-7.61	-0.42	4.96e-13	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
CESC	cis	rs73206853	0.764	rs68087637	chr12:110619797	T/C	cg12870014	chr12:110450643	ANKRD13A	0.65	5.77	0.33	2.21e-8	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs763014	0.898	rs1045277	chr16:633125	T/C	cg07343612	chr16:622815	PIGQ	-0.57	-8.23	-0.45	8.47e-15	Height;
CESC	cis	rs17253792	0.915	rs78089630	chr14:56178584	G/C	cg01858014	chr14:56050164	KTN1	-0.91	-7.03	-0.4	1.8e-11	Putamen volume;
CESC	cis	rs17376456	0.877	rs28418572	chr5:93144161	A/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.6	5.23	0.31	3.42e-7	Diabetic retinopathy;
CESC	cis	rs826838	0.935	rs1719855	chr12:39127242	C/T	cg13010199	chr12:38710504	ALG10B	-0.45	-6.26	-0.36	1.53e-9	Heart rate;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09797031	chr1:231473707	C1orf124;EXOC8	0.58	6.18	0.35	2.43e-9	Gut microbiome composition (summer);
CESC	cis	rs6088580	0.634	rs6120644	chr20:33023810	G/A	cg08999081	chr20:33150536	PIGU	0.65	11.36	0.57	1.22e-24	Glomerular filtration rate (creatinine);
CESC	trans	rs61931739	0.517	rs7139189	chr12:34319757	T/C	cg26384229	chr12:38710491	ALG10B	0.47	6.29	0.36	1.3e-9	Morning vs. evening chronotype;
CESC	cis	rs7412746	0.611	rs66847267	chr1:150875173	C/A	cg22823121	chr1:150693482	HORMAD1	0.36	5.1	0.3	6.36e-7	Melanoma;
CESC	cis	rs6570726	0.791	rs365869	chr6:145884751	C/T	cg23711669	chr6:146136114	FBXO30	1.02	15.57	0.69	2.89e-39	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1371867	0.846	rs1788199	chr8:101292854	A/G	cg11906718	chr8:101322791	RNF19A	0.54	6.93	0.39	3.24e-11	Atrioventricular conduction;
CESC	cis	rs17125944	0.542	rs75723366	chr14:53256882	T/C	cg00686598	chr14:53173677	PSMC6	1.33	11.53	0.58	3.4e-25	Alzheimer's disease (late onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06917231	chr6:28234854	ZNF187	0.57	6.86	0.39	4.81e-11	Gut microbiome composition (summer);
CESC	cis	rs3820068	0.581	rs72645890	chr1:15930602	A/G	cg17385448	chr1:15911702	AGMAT	0.41	6.69	0.38	1.33e-10	Systolic blood pressure;
CESC	cis	rs4665809	0.590	rs35727620	chr2:26458364	G/A	cg27170947	chr2:26402098	FAM59B	0.87	9.89	0.52	7.6e-20	Gut microbiome composition (summer);
CESC	cis	rs6500395	0.963	rs6500404	chr16:48690083	C/T	cg04672837	chr16:48644449	N4BP1	-0.51	-6.36	-0.36	8.64e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg06873352	chr17:61820015	STRADA	0.7	12.02	0.59	7.36e-27	Prudent dietary pattern;
CESC	cis	rs17376456	0.825	rs6877030	chr5:93201841	C/A	cg25358565	chr5:93447407	FAM172A	1.11	10.79	0.55	9.8e-23	Diabetic retinopathy;
CESC	cis	rs873946	0.564	rs2803991	chr10:134557068	A/G	cg26818010	chr10:134567672	INPP5A	-0.7	-8.73	-0.47	2.82e-16	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs7618501	0.573	rs2624824	chr3:50088266	T/C	cg24110177	chr3:50126178	RBM5	0.54	7.52	0.42	8.35e-13	Intelligence (multi-trait analysis);
CESC	cis	rs4975616	0.869	rs452384	chr5:1330840	T/C	cg26373071	chr5:1325741	CLPTM1L	0.43	6.92	0.39	3.37e-11	Lung cancer;
CESC	cis	rs7949030	0.653	rs2516634	chr11:62367186	G/A	cg23462726	chr11:62437636	C11orf83;C11orf48	0.41	5.42	0.32	1.35e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	trans	rs983392	0.679	rs7930318	chr11:60033371	C/T	cg13921652	chr1:144931966	PDE4DIP	0.48	6.12	0.35	3.29e-9	Alzheimer's disease (late onset);
CESC	cis	rs7589342	0.628	rs10496403	chr2:106419622	T/G	cg16077055	chr2:106428750	NCK2	0.56	7.13	0.4	9.6e-12	Addiction;
CESC	cis	rs12497850	0.931	rs4072859	chr3:49032205	G/C	cg07636037	chr3:49044803	WDR6	1.08	19.55	0.77	2.71e-53	Parkinson's disease;
CESC	cis	rs6032067	1.000	rs13041304	chr20:43811697	G/A	cg11264863	chr20:43835661	SEMG1	0.48	5.31	0.31	2.32e-7	Blood protein levels;
CESC	cis	rs965469	1.000	rs6051763	chr20:3321616	T/G	cg25506879	chr20:3388711	C20orf194	-0.51	-5.59	-0.32	5.65e-8	IFN-related cytopenia;
CESC	trans	rs2018683	0.707	rs917218	chr7:28975122	A/C	cg19402173	chr7:128379420	CALU	-0.46	-6.05	-0.35	4.94e-9	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg09567311	chr17:53316197	NA	0.47	6.87	0.39	4.55e-11	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs7666738	0.830	rs10014986	chr4:99000687	A/C	cg05340658	chr4:99064831	C4orf37	0.8	12.44	0.61	2.83e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4689592	0.554	rs3822270	chr4:7069804	C/A	cg06697600	chr4:7070879	GRPEL1	-0.49	-7.23	-0.41	5.09e-12	Monocyte percentage of white cells;
CESC	cis	rs79387448	0.701	rs10515921	chr2:102981018	T/G	cg09003973	chr2:102972529	NA	1.19	9.2	0.49	1.13e-17	Gut microbiota (bacterial taxa);
CESC	trans	rs11039798	0.582	rs1483119	chr11:48382334	A/G	cg15704280	chr7:45808275	SEPT13	-0.69	-6.75	-0.38	9.03e-11	Axial length;
CESC	cis	rs9916302	0.752	rs6503513	chr17:37561613	A/G	cg20243544	chr17:37824526	PNMT	-0.52	-5.87	-0.34	1.29e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs7666738	0.830	rs10031190	chr4:98908683	C/A	cg03467027	chr4:99064603	C4orf37	0.44	5.41	0.32	1.4e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs57221529	0.608	rs11749927	chr5:668842	C/T	cg16447950	chr5:562315	NA	-0.56	-6.39	-0.37	7.27e-10	Lung disease severity in cystic fibrosis;
CESC	cis	rs728616	0.681	rs17677908	chr10:82049603	A/G	cg05935833	chr10:81318306	SFTPA2	-0.44	-5.53	-0.32	7.71e-8	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs1552244	0.554	rs6768339	chr3:10006079	G/T	cg00149659	chr3:10157352	C3orf10	-0.56	-6.84	-0.39	5.34e-11	Alzheimer's disease;
CESC	cis	rs78366141	0.649	rs10428273	chr4:89672738	G/A	cg01026744	chr4:89619053	NAP1L5;HERC3	0.79	5.64	0.33	4.32e-8	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
CESC	cis	rs7666738	0.830	rs13113899	chr4:99050422	T/C	cg03467027	chr4:99064603	C4orf37	0.46	5.86	0.34	1.34e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9488822	0.676	rs12154016	chr6:116355188	C/T	cg26893134	chr6:116381904	FRK	0.25	6.08	0.35	4.16e-9	Cholesterol, total;LDL cholesterol;
CESC	cis	rs4689388	0.853	rs6446479	chr4:6291737	G/C	cg00701064	chr4:6280414	WFS1	0.68	11.32	0.57	1.77e-24	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs644799	0.965	rs545342	chr11:95545369	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.92	13.87	0.65	2.93e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs9902453	0.817	rs2628170	chr17:28056612	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.74	-9.63	-0.51	5.31e-19	Coffee consumption (cups per day);
CESC	cis	rs9611565	0.512	rs5751145	chr22:42133552	C/T	cg06481639	chr22:41940642	POLR3H	0.61	5.94	0.34	8.81e-9	Vitiligo;
CESC	cis	rs155076	1.000	rs9509638	chr13:21860193	G/A	cg11317459	chr13:21872234	NA	-1.08	-11.42	-0.57	7.79e-25	White matter hyperintensity burden;
CESC	cis	rs72945132	0.882	rs17853270	chr11:70200529	C/T	cg14191688	chr11:70257035	CTTN	0.44	5.31	0.31	2.37e-7	Coronary artery disease;
CESC	cis	rs9300255	0.602	rs10744147	chr12:123643729	A/G	cg00376283	chr12:123451042	ABCB9	0.57	6.44	0.37	5.55e-10	Neutrophil percentage of white cells;
CESC	cis	rs2281845	0.507	rs942703	chr1:201092979	A/G	cg06714761	chr1:201096289	NA	-0.43	-6.64	-0.38	1.77e-10	Permanent tooth development;
CESC	cis	rs597539	0.616	rs513476	chr11:68698996	C/T	cg21963583	chr11:68658836	MRPL21	0.4	5.64	0.33	4.32e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs1707322	0.752	rs11211145	chr1:46108491	A/C	cg06784218	chr1:46089804	CCDC17	0.4	6.62	0.38	2.02e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs863345	0.967	rs12081915	chr1:158533224	A/G	cg12129480	chr1:158549410	OR10X1	-0.33	-6.62	-0.38	1.93e-10	Pneumococcal bacteremia;
CESC	cis	rs514406	0.861	rs35581164	chr1:53271373	C/G	cg24675658	chr1:53192096	ZYG11B	-0.56	-7.08	-0.4	1.27e-11	Monocyte count;
CESC	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg07677032	chr17:61819896	STRADA	0.45	6.05	0.35	4.97e-9	Prudent dietary pattern;
CESC	cis	rs853679	0.517	rs11552219	chr6:28126834	C/T	cg17949981	chr6:28129498	ZNF389	0.45	5.57	0.32	6.26e-8	Depression;
CESC	cis	rs13336428	0.730	rs3946124	chr16:1525779	A/G	cg08008072	chr16:1524255	CLCN7	0.73	12.58	0.61	9.14e-29	Bone mineral density;
CESC	cis	rs295140	0.605	rs1436164	chr2:201158411	C/T	cg23649088	chr2:200775458	C2orf69	-0.4	-5.21	-0.31	3.71e-7	QT interval;
CESC	cis	rs2439831	0.867	rs6493085	chr15:43654182	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.9	10.46	0.54	1.12e-21	Lung cancer in ever smokers;
CESC	cis	rs11677416	1.000	rs6542092	chr2:113528322	C/G	cg27083787	chr2:113543245	IL1A	0.41	5.16	0.3	4.75e-7	Response to antipsychotic treatment in schizophrenia (working memory);
CESC	cis	rs10752881	0.967	rs12404594	chr1:182988027	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.8	12.34	0.6	6.01e-28	Colorectal cancer;
CESC	cis	rs17433780	0.504	rs7525985	chr1:89460948	C/T	cg09516651	chr1:89888402	LOC400759	0.47	6.47	0.37	4.81e-10	Carotid intima media thickness;
CESC	cis	rs801193	0.569	rs11772819	chr7:66217970	T/C	cg12463550	chr7:65579703	CRCP	0.49	6.31	0.36	1.17e-9	Aortic root size;
CESC	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	7.71	0.43	2.57e-13	Prudent dietary pattern;
CESC	cis	rs9322193	0.886	rs9767555	chr6:149968158	T/C	cg07701084	chr6:150067640	NUP43	0.4	5.44	0.32	1.19e-7	Lung cancer;
CESC	cis	rs4072980	0.545	rs16824518	chr1:38415315	A/C	cg17077180	chr1:38461687	NA	-0.39	-5.23	-0.31	3.45e-7	Coronary artery disease;
CESC	cis	rs6938	0.534	rs11854704	chr15:75221015	C/T	cg09165964	chr15:75287851	SCAMP5	0.45	6.02	0.35	5.86e-9	Breast cancer;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg09538139	chr9:127532208	NR6A1	-0.45	-6.23	-0.36	1.84e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs1348850	0.914	rs9789582	chr2:178330173	C/G	cg22681709	chr2:178499509	PDE11A	-0.43	-6.1	-0.35	3.67e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs3785574	0.886	rs62077504	chr17:61837734	A/G	cg06420487	chr17:61919686	SMARCD2	0.46	5.47	0.32	1.05e-7	Height;
CESC	cis	rs4547160	0.788	rs12227007	chr12:63484710	G/T	cg26727693	chr12:63544175	AVPR1A	-0.36	-5.22	-0.31	3.6e-7	Morning vs. evening chronotype;
CESC	cis	rs2294693	0.679	rs1534995	chr6:40960731	G/A	cg14418226	chr6:40996092	UNC5CL	0.45	5.08	0.3	7.03e-7	Gastric cancer;Non-cardia gastric cancer;
CESC	cis	rs12682352	0.652	rs1567398	chr8:8726804	A/C	cg15556689	chr8:8085844	FLJ10661	-0.49	-6.3	-0.36	1.25e-9	Neuroticism;
CESC	trans	rs2207136	0.835	rs568642	chr6:50904360	C/G	cg06522515	chr3:184090630	THPO	-0.36	-6.26	-0.36	1.56e-9	Myopia;
CESC	cis	rs2274273	0.624	rs7150234	chr14:55802181	A/G	cg04306507	chr14:55594613	LGALS3	0.29	5.12	0.3	5.74e-7	Protein biomarker;
CESC	trans	rs7246760	0.867	rs61580479	chr19:9782940	G/A	cg02900749	chr2:68251473	NA	-0.84	-7.5	-0.42	9.78e-13	Pursuit maintenance gain;
CESC	cis	rs6546550	0.901	rs10205487	chr2:70151471	C/T	cg02498382	chr2:70120550	SNRNP27	0.36	6.16	0.35	2.74e-9	Prevalent atrial fibrillation;
CESC	cis	rs875971	0.522	rs4718285	chr7:65292005	A/G	cg11764359	chr7:65958608	NA	0.67	8.6	0.47	7.12e-16	Aortic root size;
CESC	cis	rs2976388	0.566	rs13250661	chr8:143804134	C/T	cg20862496	chr8:143823734	SLURP1	0.34	5.35	0.31	1.92e-7	Urinary tract infection frequency;
CESC	cis	rs10979	0.557	rs9376767	chr6:143909380	G/A	cg25407410	chr6:143891975	LOC285740	-0.49	-6.47	-0.37	4.64e-10	Hypospadias;
CESC	cis	rs853679	1.000	rs6905391	chr6:28262686	G/A	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.67	6.93	0.39	3.12e-11	Depression;
CESC	trans	rs35110281	0.807	rs6518301	chr21:45016818	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.47	6.31	0.36	1.15e-9	Mean corpuscular volume;
CESC	trans	rs1814175	0.645	rs28454367	chr11:50045708	G/A	cg03929089	chr4:120376271	NA	-0.91	-14.92	-0.68	5.78e-37	Height;
CESC	cis	rs7811142	0.830	rs705866	chr7:99965285	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.71	6.1	0.35	3.74e-9	Platelet count;
CESC	cis	rs9291683	0.530	rs73227883	chr4:9979279	T/C	cg02734326	chr4:10020555	SLC2A9	0.46	6.84	0.39	5.39e-11	Bone mineral density;
CESC	cis	rs3858526	0.606	rs10838883	chr11:5952147	G/A	cg25319279	chr11:5960081	NA	0.41	6.11	0.35	3.51e-9	DNA methylation (variation);
CESC	cis	rs7827545	1.000	rs62523736	chr8:135560916	A/T	cg17885191	chr8:135476712	NA	0.47	6.31	0.36	1.18e-9	Hypertension (SNP x SNP interaction);
CESC	cis	rs8058578	1.000	rs7204278	chr16:30730274	A/G	cg00531865	chr16:30841666	NA	-0.44	-5.9	-0.34	1.11e-8	Multiple myeloma;
CESC	cis	rs7580658	0.963	rs10803585	chr2:128130108	G/A	cg10021288	chr2:128175891	PROC	-0.41	-6.47	-0.37	4.66e-10	Protein C levels;
CESC	cis	rs897984	0.542	rs7197717	chr16:31083075	A/C	cg00531865	chr16:30841666	NA	-0.37	-5.26	-0.31	2.92e-7	Dementia with Lewy bodies;
CESC	cis	rs477895	0.713	rs2282490	chr11:63962152	T/C	cg04317338	chr11:64019027	PLCB3	0.9	9.39	0.5	2.86e-18	Mean platelet volume;
CESC	trans	rs6923462	0.735	rs10498671	chr6:7797591	T/C	cg24010885	chr20:30102097	HM13	0.55	6.03	0.35	5.47e-9	Lung function (forced vital capacity);
CESC	cis	rs40363	0.645	rs4786421	chr16:3522303	A/G	cg22508957	chr16:3507546	NAT15	-0.59	-10.14	-0.53	1.26e-20	Tuberculosis;
CESC	cis	rs1267303	0.642	rs6670699	chr1:46997270	C/T	cg25110126	chr1:46999211	NA	1.06	11.5	0.58	4.25e-25	Monobrow;
CESC	cis	rs4812048	0.901	rs151358	chr20:57610059	C/A	cg14073986	chr20:57617431	SLMO2	0.5	5.06	0.3	7.92e-7	Mean platelet volume;
CESC	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg07414643	chr4:187882934	NA	0.48	6.94	0.39	2.96e-11	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs61931739	0.500	rs10844789	chr12:34202279	C/G	cg26384229	chr12:38710491	ALG10B	0.64	9.15	0.49	1.59e-17	Morning vs. evening chronotype;
CESC	cis	rs17125944	0.505	rs17125762	chr14:53289288	A/G	cg13660082	chr14:53194042	PSMC6	-0.84	-6.77	-0.38	8.02e-11	Alzheimer's disease (late onset);
CESC	cis	rs11792861	0.962	rs3750452	chr9:111801353	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.46	5.74	0.33	2.64e-8	Menarche (age at onset);
CESC	cis	rs2979489	0.945	rs12548554	chr8:30346544	G/A	cg26383811	chr8:30366931	RBPMS	-0.81	-9.65	-0.51	4.48e-19	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CESC	cis	rs4242434	0.699	rs878053	chr8:22483849	T/C	cg03733263	chr8:22462867	KIAA1967	0.73	10.33	0.54	3.13e-21	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04569364	chr19:57922590	ZNF17	0.47	6.02	0.35	5.91e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs4665809	1.000	rs4665811	chr2:26260017	A/G	cg08470875	chr2:26401718	FAM59B	-0.48	-5.2	-0.3	3.97e-7	Gut microbiome composition (summer);
CESC	cis	rs244293	0.931	rs2170942	chr17:53209515	A/C	cg19360675	chr17:53046073	COX11;STXBP4	-0.39	-5.09	-0.3	6.87e-7	Menarche (age at onset);
CESC	cis	rs7412746	0.503	rs72704639	chr1:150798335	A/C	cg17724175	chr1:150552817	MCL1	0.35	5.48	0.32	9.68e-8	Melanoma;
CESC	cis	rs4969178	0.965	rs12450500	chr17:76395750	C/T	cg20026190	chr17:76395443	PGS1	0.49	7.81	0.43	1.34e-13	HDL cholesterol levels;
CESC	cis	rs12497850	1.000	rs4858831	chr3:48735558	C/T	cg03060546	chr3:49711283	APEH	0.43	5.37	0.31	1.7e-7	Parkinson's disease;
CESC	cis	rs67257959	0.708	rs10406406	chr19:17198073	C/T	cg16202187	chr19:17186497	HAUS8;MYO9B	0.42	5.07	0.3	7.52e-7	Selective IgA deficiency;
CESC	cis	rs453301	0.686	rs10217044	chr8:8894752	A/G	cg15556689	chr8:8085844	FLJ10661	-0.49	-6.01	-0.35	6.06e-9	Joint mobility (Beighton score);
CESC	cis	rs3749237	0.595	rs4855864	chr3:49521974	C/T	cg07636037	chr3:49044803	WDR6	0.64	9.26	0.49	7.21e-18	Resting heart rate;
CESC	cis	rs67460515	0.563	rs4494975	chr3:160866768	C/T	cg03342759	chr3:160939853	NMD3	-0.53	-6.82	-0.39	6.25e-11	Parkinson's disease;
CESC	cis	rs782590	0.721	rs782641	chr2:55929294	C/T	cg18811423	chr2:55921094	PNPT1	0.76	11.62	0.58	1.68e-25	Metabolic syndrome;
CESC	cis	rs4689592	0.513	rs4689586	chr4:7067413	A/G	cg06697600	chr4:7070879	GRPEL1	-0.5	-7.34	-0.41	2.58e-12	Monocyte percentage of white cells;
CESC	cis	rs4835473	0.863	rs11735239	chr4:144610525	A/T	cg25736465	chr4:144833511	NA	-0.44	-6.52	-0.37	3.44e-10	Immature fraction of reticulocytes;
CESC	trans	rs9929218	0.954	rs35794312	chr16:68827785	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.63	-8.03	-0.44	3.1e-14	Colorectal cancer;
CESC	cis	rs3008870	0.920	rs3008860	chr1:67391003	G/C	cg02640540	chr1:67518911	SLC35D1	0.49	5.29	0.31	2.6e-7	Lymphocyte percentage of white cells;
CESC	cis	rs8180040	0.966	rs13075233	chr3:47420627	T/C	cg27129171	chr3:47204927	SETD2	0.64	9.85	0.52	1.05e-19	Colorectal cancer;
CESC	cis	rs12950390	0.853	rs67441169	chr17:45854462	T/G	cg00777063	chr17:45855553	NA	-0.39	-5.74	-0.33	2.62e-8	IgG glycosylation;
CESC	trans	rs875971	0.660	rs13224319	chr7:66007363	A/G	cg26939375	chr7:64535504	NA	0.63	8.63	0.47	5.93e-16	Aortic root size;
CESC	cis	rs7085104	0.700	rs743572	chr10:104597152	A/G	cg04362960	chr10:104952993	NT5C2	0.51	6.55	0.37	2.95e-10	Immature fraction of reticulocytes;Schizophrenia;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg03609269	chr1:53393023	SCP2	-0.43	-6.11	-0.35	3.61e-9	Gambling;
CESC	cis	rs1799949	0.930	rs34210004	chr17:41370337	A/T	cg25072359	chr17:41440525	NA	0.52	7.59	0.42	5.46e-13	Menopause (age at onset);
CESC	cis	rs7402982	0.625	rs4966011	chr15:99204006	G/A	cg03437748	chr15:99193247	IGF1R	0.62	8.25	0.45	7.46e-15	Birth weight;
CESC	cis	rs61776719	0.738	rs7555461	chr1:38444749	T/C	cg12658694	chr1:38397304	INPP5B	-0.76	-11.14	-0.56	6.69e-24	Coronary artery disease;
CESC	cis	rs9354308	0.933	rs55672811	chr6:66571730	G/A	cg07460842	chr6:66804631	NA	0.68	7.77	0.43	1.68e-13	Metabolite levels;
CESC	cis	rs735860	0.726	rs209517	chr6:53206989	A/T	cg10236188	chr6:53219634	NA	0.35	5.26	0.31	2.92e-7	Glaucoma;
CESC	cis	rs9309473	1.000	rs10496191	chr2:73673798	C/T	cg20560298	chr2:73613845	ALMS1	-0.46	-6.22	-0.36	1.95e-9	Metabolite levels;
CESC	cis	rs2011503	0.941	rs112253053	chr19:19425145	T/A	cg11584989	chr19:19387371	SF4	0.67	8.03	0.44	3.2e-14	Bipolar disorder;
CESC	cis	rs2070433	0.539	rs721131	chr21:47957767	T/C	cg12379764	chr21:47803548	PCNT	0.62	8.18	0.45	1.17e-14	Lymphocyte counts;
CESC	cis	rs9487051	0.676	rs9372208	chr6:109596168	A/G	cg21918786	chr6:109611834	NA	-0.38	-5.52	-0.32	8.19e-8	Reticulocyte fraction of red cells;
CESC	cis	rs9911578	0.935	rs2302189	chr17:56584205	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	-0.42	-5.3	-0.31	2.42e-7	Intelligence (multi-trait analysis);
CESC	cis	rs1152591	1.000	rs2738413	chr14:64679960	A/G	cg23250157	chr14:64679961	SYNE2	0.55	8.13	0.45	1.64e-14	Atrial fibrillation;
CESC	trans	rs66887589	0.616	rs11098498	chr4:120187119	T/C	cg25214090	chr10:38739885	LOC399744	0.44	6.14	0.35	3.05e-9	Diastolic blood pressure;
CESC	cis	rs27434	0.607	rs34753	chr5:96150911	C/T	cg16492584	chr5:96139282	ERAP1	-0.37	-5.43	-0.32	1.29e-7	Ankylosing spondylitis;
CESC	cis	rs611744	0.517	rs62537573	chr8:109269281	C/T	cg21045802	chr8:109455806	TTC35	0.56	6.95	0.39	2.89e-11	Dupuytren's disease;
CESC	cis	rs7208859	0.623	rs55938328	chr17:29117010	T/C	cg14008862	chr17:28927542	LRRC37B2	0.65	5.14	0.3	5.34e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs763014	0.931	rs11643039	chr16:634260	G/A	cg09263875	chr16:632152	PIGQ	0.67	11.3	0.57	1.94e-24	Height;
CESC	cis	rs1552244	1.000	rs17032283	chr3:10081545	C/G	cg00166722	chr3:10149974	C3orf24	0.48	6.41	0.37	6.72e-10	Alzheimer's disease;
CESC	cis	rs60871478	0.947	rs62432255	chr7:804219	G/A	cg27478167	chr7:817139	HEATR2	-0.49	-5.88	-0.34	1.23e-8	Cerebrospinal P-tau181p levels;
CESC	cis	rs875971	0.505	rs1167385	chr7:65513308	G/A	cg08632164	chr7:65971372	NA	0.31	5.11	0.3	6.27e-7	Aortic root size;
CESC	cis	rs1348850	0.645	rs4893963	chr2:178430747	A/G	cg23306229	chr2:178417860	TTC30B	-0.73	-8.13	-0.45	1.61e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs7589342	0.831	rs34554853	chr2:106448931	G/A	cg16077055	chr2:106428750	NCK2	0.49	6.98	0.39	2.34e-11	Addiction;
CESC	cis	rs400736	0.602	rs7553544	chr1:8165719	C/T	cg25007680	chr1:8021821	PARK7	-0.57	-6.24	-0.36	1.68e-9	Response to antidepressants and depression;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13446153	chr8:41435704	AGPAT6	0.53	6.09	0.35	4.05e-9	Gut microbiome composition (summer);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg15065896	chr3:37285038	GOLGA4	-0.46	-6.61	-0.38	2.04e-10	Gambling;
CESC	cis	rs875971	0.545	rs10950036	chr7:65818228	G/T	cg11764359	chr7:65958608	NA	0.8	10.0	0.52	3.53e-20	Aortic root size;
CESC	cis	rs13256369	0.851	rs13266562	chr8:8564065	T/C	cg18904891	chr8:8559673	CLDN23	0.73	8.12	0.45	1.74e-14	Obesity-related traits;
CESC	cis	rs2204008	0.811	rs12368410	chr12:38305705	C/T	cg26384229	chr12:38710491	ALG10B	0.72	10.16	0.53	1.08e-20	Bladder cancer;
CESC	cis	rs1707322	1.000	rs1768807	chr1:46510570	A/G	cg06784218	chr1:46089804	CCDC17	-0.33	-5.65	-0.33	4.08e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs6754311	0.731	rs218174	chr2:136658345	C/T	cg15123519	chr2:136567270	LCT	0.3	5.08	0.3	7.19e-7	Mosquito bite size;
CESC	cis	rs763121	0.853	rs2235230	chr22:39124467	A/G	cg21395723	chr22:39101663	GTPBP1	-0.43	-5.19	-0.3	4.24e-7	Menopause (age at onset);
CESC	cis	rs2635047	1.000	rs2684826	chr18:44679147	A/G	cg19077165	chr18:44547161	KATNAL2	-0.45	-6.03	-0.35	5.56e-9	Educational attainment;
CESC	cis	rs6674176	0.628	rs4660759	chr1:44432500	C/G	cg13606994	chr1:44402422	ARTN	-0.39	-5.79	-0.34	1.96e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs694739	1.000	rs499425	chr11:64105929	A/G	cg02228329	chr11:64053129	BAD;GPR137	-0.66	-8.33	-0.46	4.5e-15	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CESC	cis	rs1218582	0.772	rs12095061	chr1:154912968	A/T	cg16680214	chr1:154839983	KCNN3	-0.45	-6.95	-0.39	2.84e-11	Prostate cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14198950	chr1:153913380	DENND4B	-0.55	-6.54	-0.37	3.23e-10	Gut microbiome composition (summer);
CESC	cis	rs523522	0.962	rs55848094	chr12:120966659	G/A	cg12219531	chr12:120966889	COQ5	0.75	9.99	0.52	3.7e-20	High light scatter reticulocyte count;
CESC	cis	rs9399137	0.507	rs6940258	chr6:135366132	C/T	cg24558204	chr6:135376177	HBS1L	0.64	8.65	0.47	5.15e-16	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg17524854	chr12:67663046	CAND1	0.47	6.11	0.35	3.6e-9	Systemic lupus erythematosus;
CESC	cis	rs6580649	0.941	rs7296913	chr12:48488920	G/A	cg05342945	chr12:48394962	COL2A1	0.5	5.71	0.33	3.04e-8	Lung cancer;
CESC	trans	rs8073060	0.544	rs7211724	chr17:33993414	C/G	cg19694781	chr19:47549865	TMEM160	-0.75	-7.46	-0.42	1.21e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	cis	rs71403859	0.730	rs12447672	chr16:71715131	G/A	cg08717414	chr16:71523259	ZNF19	-0.73	-6.29	-0.36	1.31e-9	Post bronchodilator FEV1;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10382060	chr16:4853033	ROGDI	0.64	7.22	0.41	5.56e-12	Gut microbiome composition (summer);
CESC	cis	rs72781680	0.566	rs6714016	chr2:23899948	A/G	cg20701182	chr2:24300061	SF3B14	0.71	7.18	0.4	7.24e-12	Lymphocyte counts;
CESC	cis	rs1552244	0.810	rs35711405	chr3:10116939	C/T	cg00149659	chr3:10157352	C3orf10	0.77	9.07	0.49	2.81e-17	Alzheimer's disease;
CESC	cis	rs4969178	0.931	rs3826323	chr17:76400268	C/G	cg05887092	chr17:76393375	PGS1	0.58	9.26	0.49	7e-18	HDL cholesterol levels;
CESC	cis	rs9435341	0.965	rs9435441	chr1:107603330	C/G	cg09367891	chr1:107599246	PRMT6	-0.57	-7.28	-0.41	3.91e-12	Facial morphology (factor 21, depth of nasal alae);
CESC	cis	rs7818688	0.697	rs74633621	chr8:95981037	A/G	cg16049864	chr8:95962084	TP53INP1	0.55	5.55	0.32	6.92e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs763121	0.925	rs5757251	chr22:39100128	G/A	cg06544989	chr22:39130855	UNC84B	0.45	8.43	0.46	2.18e-15	Menopause (age at onset);
CESC	cis	rs2180341	0.924	rs9285459	chr6:127631113	T/C	cg27446573	chr6:127587934	RNF146	1.09	16.33	0.71	5.73e-42	Breast cancer;
CESC	cis	rs9894429	0.966	rs6565601	chr17:79580173	C/T	cg13777783	chr17:79615861	NA	-0.35	-5.79	-0.34	1.99e-8	Eye color traits;
CESC	cis	rs4665809	1.000	rs7588802	chr2:26277789	A/G	cg25036284	chr2:26402008	FAM59B	-0.71	-8.2	-0.45	1.05e-14	Gut microbiome composition (summer);
CESC	cis	rs1538970	1.000	rs2492840	chr1:45849792	C/A	cg05343316	chr1:45956843	TESK2	0.78	11.0	0.56	1.93e-23	Platelet count;
CESC	cis	rs10089	1.000	rs4836370	chr5:127499224	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.78	10.62	0.55	3.42e-22	Ileal carcinoids;
CESC	cis	rs4704187	0.687	rs10066946	chr5:74508021	T/A	cg03227963	chr5:74354835	NA	0.28	5.19	0.3	4.21e-7	Response to amphetamines;
CESC	cis	rs10256972	0.521	rs7457418	chr7:1110255	C/T	cg04025307	chr7:1156635	C7orf50	0.45	7.35	0.41	2.48e-12	Longevity;Endometriosis;
CESC	cis	rs6121246	0.512	rs6060941	chr20:30367383	C/T	cg13852791	chr20:30311386	BCL2L1	0.85	11.17	0.57	5.35e-24	Mean corpuscular hemoglobin;
CESC	cis	rs4563143	0.675	rs73025085	chr19:29247018	C/A	cg12667521	chr19:29218732	NA	0.48	6.4	0.37	6.97e-10	Methadone dose in opioid dependence;
CESC	cis	rs2742234	0.541	rs10899782	chr10:43736361	A/T	cg07801480	chr10:43725741	RASGEF1A	-0.4	-5.13	-0.3	5.71e-7	Hirschsprung disease;
CESC	cis	rs9399135	0.967	rs952674	chr6:135349157	A/G	cg22676075	chr6:135203613	NA	0.51	7.36	0.41	2.34e-12	Red blood cell count;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg09726469	chr1:150552014	MCL1	0.5	6.4	0.37	7.01e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs6967414	0.786	rs6948965	chr7:6758547	G/A	cg09896999	chr7:6746977	ZNF12	-0.52	-6.19	-0.36	2.31e-9	Hematocrit;Hemoglobin concentration;
CESC	cis	rs3740713	1.000	rs35593189	chr11:18468378	C/T	cg23797887	chr11:18477753	LDHAL6A	-0.53	-5.29	-0.31	2.59e-7	Amyotrophic lateral sclerosis (sporadic);
CESC	trans	rs12310956	0.532	rs1525903	chr12:33964163	T/C	cg26384229	chr12:38710491	ALG10B	0.52	7.15	0.4	8.38e-12	Morning vs. evening chronotype;
CESC	cis	rs2842992	0.692	rs1128661	chr6:160211554	T/G	cg26839252	chr6:160211577	TCP1;MRPL18	0.49	6.15	0.35	2.83e-9	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs9359856	0.510	rs2768936	chr6:90441851	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.7	-7.84	-0.43	1.11e-13	Bipolar disorder;
CESC	trans	rs1429606	1.000	rs12659535	chr5:87305069	A/C	cg12139725	chr1:38219781	EPHA10	0.63	6.7	0.38	1.26e-10	Number of children (6+ vs. 0 or 1);
CESC	cis	rs11098499	0.697	rs4373140	chr4:120307698	A/G	cg24375607	chr4:120327624	NA	0.46	5.55	0.32	6.98e-8	Corneal astigmatism;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15576692	chr20:18548019	LOC388789	0.59	6.63	0.38	1.84e-10	Gut microbiome composition (summer);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg01511534	chr16:3284640	ZNF200	-0.44	-6.62	-0.38	2.02e-10	Gambling;
CESC	cis	rs4919087	0.715	rs13439	chr10:99006083	C/T	cg25902810	chr10:99078978	FRAT1	-0.46	-5.26	-0.31	3e-7	Monocyte count;
CESC	cis	rs7818688	0.614	rs6989591	chr8:95874580	T/C	cg16049864	chr8:95962084	TP53INP1	0.51	5.26	0.31	2.91e-7	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21548869	chr14:105834472	PACS2	-0.53	-6.07	-0.35	4.37e-9	Gut microbiome composition (summer);
CESC	cis	rs6088590	0.735	rs2273684	chr20:33529766	G/T	cg06115741	chr20:33292138	TP53INP2	-0.5	-6.29	-0.36	1.34e-9	Coronary artery disease;
CESC	cis	rs6570726	0.791	rs425999	chr6:145819370	C/A	cg05347473	chr6:146136440	FBXO30	0.59	7.59	0.42	5.36e-13	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs796364	1.000	rs281771	chr2:200812202	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.8	-8.54	-0.46	1.05e-15	Schizophrenia;
CESC	trans	rs1973993	0.691	rs1980684	chr1:96890636	A/G	cg10631902	chr5:14652156	NA	0.61	9.46	0.5	1.72e-18	Weight;
CESC	trans	rs61931739	0.500	rs11053203	chr12:34456593	C/T	cg13010199	chr12:38710504	ALG10B	0.48	6.28	0.36	1.38e-9	Morning vs. evening chronotype;
CESC	cis	rs9931543	0.504	rs9922112	chr16:56314687	A/C	cg02433656	chr16:56322654	GNAO1	0.41	5.3	0.31	2.46e-7	Subjective well-being;
CESC	cis	rs258892	0.895	rs153320	chr5:72138452	C/T	cg21869765	chr5:72125136	TNPO1	-0.46	-5.87	-0.34	1.31e-8	Small cell lung carcinoma;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg19105362	chr10:71929497	SAR1A	0.46	6.27	0.36	1.5e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs11931598	0.514	rs10937779	chr4:7039326	G/A	cg19539972	chr4:7069911	GRPEL1	0.38	5.26	0.31	2.96e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
CESC	cis	rs7551222	0.752	rs4951393	chr1:204489557	A/C	cg20240347	chr1:204465584	NA	0.27	5.54	0.32	7.3e-8	Schizophrenia;
CESC	cis	rs1218582	0.741	rs6656494	chr1:154839799	A/G	cg06221963	chr1:154839813	KCNN3	-0.7	-12.21	-0.6	1.62e-27	Prostate cancer;
CESC	cis	rs10751667	0.961	rs6597951	chr11:991530	C/T	cg20946044	chr11:1010712	AP2A2	-0.46	-5.85	-0.34	1.43e-8	Alzheimer's disease (late onset);
CESC	cis	rs7666738	0.830	rs10516426	chr4:99035827	A/G	cg24818145	chr4:99064322	C4orf37	0.38	5.03	0.3	8.92e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7399018	1.000	rs7399018	chr12:51610365	C/T	cg25754956	chr12:51612065	POU6F1	-0.68	-7.65	-0.43	3.76e-13	Cisplatin-induced ototoxicity;
CESC	cis	rs765787	0.530	rs3759895	chr15:45543870	G/A	cg24006582	chr15:45444508	DUOX1	-0.6	-7.3	-0.41	3.41e-12	Uric acid levels;
CESC	cis	rs9487051	0.752	rs9372209	chr6:109601684	T/C	cg01475377	chr6:109611718	NA	-0.45	-7.12	-0.4	1e-11	Reticulocyte fraction of red cells;
CESC	cis	rs2276314	0.857	rs62101379	chr18:33584902	G/A	cg19628046	chr18:33552617	C18orf21	0.51	5.55	0.32	6.97e-8	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs7772486	0.654	rs1011597	chr6:146075672	A/C	cg05347473	chr6:146136440	FBXO30	-0.54	-7.07	-0.4	1.34e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9300255	0.602	rs1727315	chr12:123638930	A/G	cg19016782	chr12:123741754	C12orf65	0.41	5.76	0.33	2.3e-8	Neutrophil percentage of white cells;
CESC	cis	rs6939532	0.522	rs9366652	chr6:26354219	C/G	cg14345882	chr6:26364793	BTN3A2	0.39	6.26	0.36	1.54e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs7811142	1.000	rs7783550	chr7:99987805	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	-0.91	-9.32	-0.5	4.62e-18	Platelet count;
CESC	cis	rs2404602	0.619	rs7342603	chr15:76982625	C/T	cg22467129	chr15:76604101	ETFA	-0.34	-5.12	-0.3	5.9e-7	Blood metabolite levels;
CESC	cis	rs7107174	0.792	rs10751287	chr11:78072476	T/C	cg02023728	chr11:77925099	USP35	0.38	5.29	0.31	2.58e-7	Testicular germ cell tumor;
CESC	cis	rs734999	0.588	rs2843403	chr1:2529097	T/C	cg18854424	chr1:2615690	NA	-0.28	-5.61	-0.33	5.2100000000000003e-08	Ulcerative colitis;
CESC	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	21.56	0.8	3.13e-60	Prudent dietary pattern;
CESC	cis	rs2072499	1.000	rs2241108	chr1:156181007	C/G	cg25208724	chr1:156163844	SLC25A44	0.98	18.37	0.75	3.62e-49	Testicular germ cell tumor;
CESC	cis	rs1784581	0.706	rs9346895	chr6:162431168	T/C	cg17173639	chr6:162384350	PARK2	0.61	9.62	0.51	5.63e-19	Itch intensity from mosquito bite;
CESC	cis	rs35306767	0.953	rs11253521	chr10:976416	G/C	cg25019033	chr10:957182	NA	-0.64	-8.23	-0.45	8.48e-15	Eosinophil percentage of granulocytes;
CESC	cis	rs10504229	0.953	rs75545548	chr8:58172816	T/C	cg05313129	chr8:58192883	C8orf71	-0.55	-6.37	-0.36	8.42e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs7264396	0.790	rs6058290	chr20:34247702	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.64	7.7	0.43	2.63e-13	Total cholesterol levels;
CESC	cis	rs9611565	0.592	rs4481089	chr22:41980892	T/C	cg06481639	chr22:41940642	POLR3H	-0.56	-6.32	-0.36	1.13e-9	Vitiligo;
CESC	cis	rs4790333	0.531	rs2447107	chr17:2257864	A/G	cg02569219	chr17:2266849	SGSM2	0.39	5.15	0.3	5e-7	Proinsulin levels;
CESC	cis	rs4237845	0.537	rs7312623	chr12:58262523	G/T	cg02175503	chr12:58329896	NA	0.49	5.85	0.34	1.42e-8	Intelligence (multi-trait analysis);
CESC	trans	rs9914544	0.544	rs4244595	chr17:18677329	C/T	cg04702396	chr17:15466718	FAM18B2	0.48	6.07	0.35	4.3e-9	Educational attainment (years of education);
CESC	cis	rs18122	0.660	rs12479293	chr2:67521205	G/A	cg09028215	chr2:67624308	ETAA1	-0.41	-5.13	-0.3	5.5e-7	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs754466	1.000	rs2278218	chr10:79680399	G/A	cg17075019	chr10:79541650	NA	-0.76	-9.43	-0.5	2.22e-18	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs9303401	0.704	rs740605	chr17:56604811	C/T	cg12560992	chr17:57184187	TRIM37	0.57	7.24	0.41	4.75e-12	Cognitive test performance;
CESC	cis	rs7589342	0.839	rs1465639	chr2:106439181	T/C	cg16077055	chr2:106428750	NCK2	0.48	6.88	0.39	4.33e-11	Addiction;
CESC	cis	rs13118159	0.836	rs12647145	chr4:1338618	C/A	cg05025164	chr4:1340916	KIAA1530	0.42	5.72	0.33	2.82e-8	Longevity;
CESC	trans	rs561341	0.709	rs8068049	chr17:30183857	T/C	cg20587970	chr11:113659929	NA	1.01	10.34	0.54	2.85e-21	Hip circumference adjusted for BMI;
CESC	cis	rs9457247	1.000	rs2769352	chr6:167378619	A/G	cg25258033	chr6:167368657	RNASET2	-0.4	-6.11	-0.35	3.49e-9	Crohn's disease;
CESC	cis	rs7666738	0.830	rs28451001	chr4:98924544	T/A	cg03467027	chr4:99064603	C4orf37	0.46	5.59	0.32	5.78e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7666738	0.830	rs9994346	chr4:99037986	A/G	cg00999950	chr4:99064541	C4orf37	0.4	5.13	0.3	5.71e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4843747	0.697	rs72818533	chr16:88073841	G/A	cg06374794	chr16:88002281	BANP	0.41	5.3	0.31	2.42e-7	Menopause (age at onset);
CESC	cis	rs889312	0.500	rs832566	chr5:56151744	C/T	cg14703610	chr5:56206110	C5orf35	0.48	6.34	0.36	9.93e-10	Breast cancer;Breast cancer (early onset);
CESC	cis	rs763121	0.853	rs5750669	chr22:39080638	T/A	cg06544989	chr22:39130855	UNC84B	0.52	8.93	0.48	7.46e-17	Menopause (age at onset);
CESC	cis	rs62064224	0.638	rs9748130	chr17:30739113	A/G	cg18200150	chr17:30822561	MYO1D	0.4	5.18	0.3	4.45e-7	Schizophrenia;
CESC	cis	rs9287719	0.837	rs4233883	chr2:10755596	A/G	cg00105475	chr2:10696890	NA	0.38	5.44	0.32	1.23e-7	Prostate cancer;
CESC	cis	rs9911578	1.000	rs1472288	chr17:56910720	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.26	0.31	3.04e-7	Intelligence (multi-trait analysis);
CESC	cis	rs4253772	0.591	rs73886791	chr22:46687212	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.76	8.8	0.48	1.8e-16	LDL cholesterol;Cholesterol, total;
CESC	cis	rs7223966	1.000	rs11658740	chr17:61751069	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.56	6.69	0.38	1.33e-10	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs7769051	0.522	rs6934155	chr6:133124021	C/T	cg22852734	chr6:133119734	C6orf192	1.06	7.13	0.4	9.46e-12	Type 2 diabetes nephropathy;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg17966709	chr11:57435952	ZDHHC5	0.47	6.48	0.37	4.52e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs796364	0.806	rs6435040	chr2:200861161	T/G	cg23649088	chr2:200775458	C2orf69	0.59	5.34	0.31	1.95e-7	Schizophrenia;
CESC	cis	rs9914988	0.943	rs1035989	chr17:27143810	T/G	cg20469991	chr17:27169893	C17orf63	-0.48	-5.25	-0.31	3.18e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CESC	cis	rs7216064	1.000	rs62084208	chr17:65827443	C/T	cg12091567	chr17:66097778	LOC651250	-0.85	-8.46	-0.46	1.79e-15	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	trans	rs11098499	0.562	rs2389879	chr4:120557684	G/A	cg25214090	chr10:38739885	LOC399744	-0.57	-8.01	-0.44	3.6e-14	Corneal astigmatism;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg09267708	chr1:155883625	KIAA0907	-0.43	-6.17	-0.35	2.53e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs62064224	0.702	rs2302277	chr17:30791509	C/G	cg18200150	chr17:30822561	MYO1D	0.72	11.31	0.57	1.8e-24	Schizophrenia;
CESC	cis	rs1005277	0.563	rs2505215	chr10:38481273	A/G	cg25517755	chr10:38738941	LOC399744	-0.49	-6.35	-0.36	9.08e-10	Extrinsic epigenetic age acceleration;
CESC	cis	rs3126085	0.825	rs868303	chr1:152178563	C/A	cg26876637	chr1:152193138	HRNR	0.48	5.5	0.32	8.93e-8	Atopic dermatitis;
CESC	cis	rs9875589	0.509	rs2731337	chr3:14091440	G/C	cg19554555	chr3:13937349	NA	-0.45	-5.85	-0.34	1.41e-8	Ovarian reserve;
CESC	cis	rs7394190	0.748	rs2306327	chr10:75573778	A/T	cg07699608	chr10:75541558	CHCHD1	0.58	5.07	0.3	7.41e-7	Incident atrial fibrillation;
CESC	cis	rs7772486	0.754	rs4895682	chr6:146062861	G/A	cg05347473	chr6:146136440	FBXO30	-0.56	-7.08	-0.4	1.26e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs11792861	0.926	rs59904140	chr9:111910051	C/T	cg05043794	chr9:111880884	C9orf5	-0.39	-6.41	-0.37	6.65e-10	Menarche (age at onset);
CESC	cis	rs854765	0.583	rs10048206	chr17:17866897	A/G	cg09796270	chr17:17721594	SREBF1	0.45	6.15	0.35	2.87e-9	Total body bone mineral density;
CESC	cis	rs453301	0.571	rs2929454	chr8:9083854	A/C	cg15556689	chr8:8085844	FLJ10661	-0.52	-6.52	-0.37	3.6e-10	Joint mobility (Beighton score);
CESC	cis	rs11650494	0.710	rs76305536	chr17:47488913	G/A	cg08112188	chr17:47440006	ZNF652	1.12	7.22	0.41	5.4e-12	Prostate cancer;
CESC	cis	rs514406	0.505	rs431459	chr1:53183230	T/G	cg08736216	chr1:53307985	ZYG11A	-0.37	-6.27	-0.36	1.45e-9	Monocyte count;
CESC	cis	rs7927771	0.756	rs10742803	chr11:47439938	A/G	cg05585544	chr11:47624801	NA	0.41	6.14	0.35	3.01e-9	Subjective well-being;
CESC	cis	rs425277	0.585	rs3107157	chr1:2061969	A/G	cg04315214	chr1:2043799	PRKCZ	0.6	10.26	0.53	5.16e-21	Height;
CESC	cis	rs7666738	0.791	rs6853608	chr4:99047916	A/G	cg18180107	chr4:99064573	C4orf37	0.41	5.29	0.31	2.51e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs113835537	0.529	rs11227501	chr11:66274072	T/C	cg24851651	chr11:66362959	CCS	0.43	5.39	0.31	1.52e-7	Airway imaging phenotypes;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg10166735	chr16:1570449	IFT140	0.37	6.03	0.35	5.62e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs4862750	0.872	rs9997374	chr4:187877549	T/A	cg11301795	chr4:187892539	NA	-0.75	-11.96	-0.59	1.2e-26	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs13118159	0.836	rs2276903	chr4:1343405	A/G	cg01939980	chr4:1354348	KIAA1530	0.38	5.07	0.3	7.48e-7	Longevity;
CESC	cis	rs208520	0.789	rs9351549	chr6:66871851	A/G	cg07460842	chr6:66804631	NA	-0.99	-13.04	-0.63	2.24e-30	Exhaled nitric oxide output;
CESC	cis	rs1552244	0.572	rs68013239	chr3:10165711	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.79	8.79	0.47	1.98e-16	Alzheimer's disease;
CESC	cis	rs12477438	0.798	rs9679602	chr2:99577827	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.7	10.3	0.53	3.91e-21	Chronic sinus infection;
CESC	trans	rs4596713	0.507	rs10115134	chr9:71800562	T/C	cg16512924	chr15:28394682	HERC2	0.48	6.13	0.35	3.2e-9	Headache;
CESC	cis	rs4268898	1.000	rs6746005	chr2:24434345	G/A	cg06627628	chr2:24431161	ITSN2	0.63	7.39	0.41	1.89e-12	Asthma;
CESC	cis	rs5758659	0.652	rs5751195	chr22:42380001	A/C	cg15557168	chr22:42548783	NA	-0.42	-6.17	-0.35	2.61e-9	Cognitive function;
CESC	cis	rs2415984	0.562	rs61991051	chr14:46904538	C/A	cg14871534	chr14:47121158	RPL10L	0.43	6.07	0.35	4.41e-9	Number of children ever born;
CESC	cis	rs801193	1.000	rs10234018	chr7:66146284	A/T	cg11764359	chr7:65958608	NA	-0.66	-8.43	-0.46	2.25e-15	Aortic root size;
CESC	cis	rs10979	1.000	rs9403506	chr6:143887805	C/G	cg25407410	chr6:143891975	LOC285740	-0.61	-9.21	-0.49	1.04e-17	Hypospadias;
CESC	trans	rs61931739	1.000	rs12427279	chr12:34025898	T/G	cg26384229	chr12:38710491	ALG10B	-0.46	-6.14	-0.35	2.98e-9	Morning vs. evening chronotype;
CESC	cis	rs875971	0.862	rs6460307	chr7:66060871	A/G	cg19163074	chr7:65112434	INTS4L2	-0.46	-5.93	-0.34	9.36e-9	Aortic root size;
CESC	cis	rs7210086	0.948	rs72849451	chr17:70638565	C/T	cg04206342	chr17:70636940	NA	-0.35	-6.01	-0.35	6.05e-9	Ulcerative colitis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01849260	chr5:77072153	TBCA	0.55	6.22	0.36	1.93e-9	Gut microbiome composition (summer);
CESC	cis	rs2404602	0.647	rs36114653	chr15:77025393	G/A	cg23625390	chr15:77176239	SCAPER	-0.39	-5.12	-0.3	5.75e-7	Blood metabolite levels;
CESC	cis	rs2842992	0.747	rs9365095	chr6:160192928	T/G	cg11366901	chr6:160182831	ACAT2	0.83	10.41	0.54	1.65e-21	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs963731	0.649	rs4670905	chr2:39266134	A/T	cg04010122	chr2:39346883	SOS1	-0.72	-5.23	-0.31	3.38e-7	Corticobasal degeneration;
CESC	cis	rs12893668	0.638	rs11851616	chr14:104065600	G/A	cg08213375	chr14:104286397	PPP1R13B	0.33	5.18	0.3	4.43e-7	Reticulocyte count;
CESC	cis	rs651907	0.535	rs11714444	chr3:101513682	G/A	cg12386194	chr3:101231763	SENP7	0.41	5.11	0.3	6.03e-7	Colorectal cancer;
CESC	trans	rs35110281	0.712	rs167930	chr21:44946625	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.49	6.62	0.38	1.94e-10	Mean corpuscular volume;
CESC	cis	rs9359856	0.564	rs72915933	chr6:90441464	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.65	-6.52	-0.37	3.51e-10	Bipolar disorder;
CESC	cis	rs6964587	1.000	rs6944591	chr7:91642714	T/C	cg17063962	chr7:91808500	NA	0.56	7.76	0.43	1.79e-13	Breast cancer;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg00556029	chr1:32802033	MARCKSL1	-0.55	-7.32	-0.41	3.02e-12	Gut microbiota (bacterial taxa);
CESC	cis	rs7582720	1.000	rs115654617	chr2:203893999	C/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.36	0.41	2.34e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs514406	0.698	rs511599	chr1:53362818	T/C	cg24675658	chr1:53192096	ZYG11B	-0.66	-9.13	-0.49	1.78e-17	Monocyte count;
CESC	cis	rs250677	0.687	rs36043	chr5:148440983	G/A	cg18129178	chr5:148520854	ABLIM3	-0.5	-5.79	-0.34	1.98e-8	Breast cancer;
CESC	cis	rs6860806	0.695	rs6867282	chr5:131583120	G/C	cg18301423	chr5:131593218	PDLIM4	0.38	5.42	0.32	1.32e-7	Breast cancer;
CESC	cis	rs7927592	0.913	rs12284933	chr11:68319489	G/A	cg20283391	chr11:68216788	NA	-0.61	-7.36	-0.41	2.26e-12	Total body bone mineral density;
CESC	cis	rs11958404	0.932	rs6859470	chr5:157429505	T/G	cg05962755	chr5:157440814	NA	0.62	6.53	0.37	3.41e-10	IgG glycosylation;
CESC	cis	rs7225537	0.532	rs11551189	chr17:17062241	C/G	cg20098446	chr17:17120238	FLCN	0.33	5.14	0.3	5.4e-7	Mean platelet volume;
CESC	cis	rs7772486	0.875	rs9403763	chr6:146357655	A/G	cg05347473	chr6:146136440	FBXO30	0.5	6.51	0.37	3.72e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs17376456	0.877	rs10063045	chr5:93457584	A/T	cg21475434	chr5:93447410	FAM172A	0.9	7.47	0.42	1.18e-12	Diabetic retinopathy;
CESC	cis	rs55879323	1	rs55879323	chr1:152168740	C/T	cg09127314	chr1:152161683	NA	0.4	5.16	0.3	4.81e-7	Inflammatory skin disease;
CESC	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg18538332	chr22:24372958	LOC391322	-0.66	-9.82	-0.52	1.3e-19	Liver enzyme levels (gamma-glutamyl transferase);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12603476	chr10:82214649	TSPAN14	0.62	6.94	0.39	2.94e-11	Gut microbiome composition (summer);
CESC	cis	rs798554	0.759	rs2644309	chr7:2889034	T/C	cg18446336	chr7:2847575	GNA12	-0.36	-5.47	-0.32	1.03e-7	Height;
CESC	cis	rs7666738	0.546	rs13149516	chr4:98913030	T/A	cg05340658	chr4:99064831	C4orf37	0.6	7.49	0.42	1.06e-12	Colonoscopy-negative controls vs population controls;
CESC	trans	rs561341	1.000	rs15654	chr17:30326360	A/C	cg20587970	chr11:113659929	NA	-1.44	-18.71	-0.75	2.25e-50	Hip circumference adjusted for BMI;
CESC	cis	rs453301	0.598	rs2921383	chr8:8892221	C/T	cg06636001	chr8:8085503	FLJ10661	0.47	5.92	0.34	9.75e-9	Joint mobility (Beighton score);
CESC	cis	rs360798	0.512	rs1906198	chr2:62946658	C/T	cg17519650	chr2:63277830	OTX1	0.48	6.01	0.35	5.97e-9	Coronary artery disease;
CESC	cis	rs4555082	0.834	rs4412909	chr14:105759226	T/C	cg13114125	chr14:105738426	BRF1	-0.89	-10.98	-0.56	2.32e-23	Mean platelet volume;Platelet distribution width;
CESC	cis	rs7666738	0.861	rs5010991	chr4:98972179	A/G	cg03467027	chr4:99064603	C4orf37	0.43	5.4	0.31	1.49e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs748404	0.660	rs542898	chr15:43719392	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.57	7.55	0.42	7.19e-13	Lung cancer;
CESC	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg24101359	chr6:42928495	GNMT	0.61	9.62	0.51	5.66e-19	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs10256972	0.869	rs4720158	chr7:1040325	A/G	cg23978390	chr7:1156363	C7orf50	0.42	5.56	0.32	6.5e-8	Longevity;Endometriosis;
CESC	cis	rs12464483	0.591	rs72800120	chr2:30897122	G/A	cg07150166	chr2:30669952	LCLAT1	0.56	5.51	0.32	8.59e-8	Pre-treatment pain in head and neck squamous cell carcinoma;
CESC	cis	rs4780401	0.703	rs7193637	chr16:11764920	C/T	cg01061890	chr16:11836724	TXNDC11	-0.4	-5.17	-0.3	4.64e-7	Rheumatoid arthritis;
CESC	cis	rs736408	0.716	rs2239550	chr3:52822509	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.4	5.33	0.31	2.06e-7	Bipolar disorder;
CESC	trans	rs11098499	0.866	rs6847778	chr4:120293582	A/G	cg25214090	chr10:38739885	LOC399744	0.66	9.17	0.49	1.35e-17	Corneal astigmatism;
CESC	cis	rs6460942	1.000	rs62448566	chr7:12403662	G/A	cg17427002	chr7:12443146	VWDE	-0.52	-5.27	-0.31	2.82e-7	Coronary artery disease;
CESC	cis	rs10088262	0.629	rs12541177	chr8:124800273	G/T	cg02993010	chr8:124780839	FAM91A1	-0.67	-8.55	-0.46	1.01e-15	Pancreatic cancer;
CESC	cis	rs6089584	0.854	rs8117075	chr20:60613766	T/C	cg06108461	chr20:60628389	TAF4	-0.93	-14.44	-0.66	2.89e-35	Body mass index;
CESC	cis	rs1475911	1.000	rs2839466	chr21:43512324	A/G	cg19766460	chr21:43528205	UMODL1;C21orf128	-0.55	-6.37	-0.36	8.35e-10	IgG glycosylation;
CESC	cis	rs854765	0.583	rs7213225	chr17:17869111	T/C	cg09796270	chr17:17721594	SREBF1	0.45	6.17	0.35	2.61e-9	Total body bone mineral density;
CESC	cis	rs2710642	0.611	rs1534418	chr2:62883920	A/G	cg17519650	chr2:63277830	OTX1	-0.49	-5.86	-0.34	1.37e-8	LDL cholesterol levels;LDL cholesterol;
CESC	cis	rs56104184	0.779	rs17272666	chr19:49356294	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.8	-9.11	-0.49	2.04e-17	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	cis	rs7264396	0.623	rs78949029	chr20:34384964	C/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.66	6.57	0.37	2.65e-10	Total cholesterol levels;
CESC	cis	rs7524258	0.868	rs4908607	chr1:7269323	A/G	cg07173049	chr1:7289937	CAMTA1	0.4	6.06	0.35	4.56e-9	Tourette's syndrome or obsessive-compulsive disorder;
CESC	trans	rs875971	0.895	rs4718349	chr7:65909011	C/G	cg26939375	chr7:64535504	NA	0.47	6.04	0.35	5.27e-9	Aortic root size;
CESC	cis	rs782590	0.748	rs782634	chr2:55897700	T/C	cg18811423	chr2:55921094	PNPT1	0.77	12.5	0.61	1.74e-28	Metabolic syndrome;
CESC	cis	rs1461503	0.966	rs10892937	chr11:122841904	T/C	cg27398637	chr11:122830231	C11orf63	-0.55	-8.32	-0.45	4.77e-15	Menarche (age at onset);
CESC	cis	rs9487051	0.621	rs351722	chr6:109550939	A/G	cg01475377	chr6:109611718	NA	-0.38	-5.14	-0.3	5.22e-7	Reticulocyte fraction of red cells;
CESC	cis	rs10504229	0.679	rs75402323	chr8:58136227	A/G	cg24829409	chr8:58192753	C8orf71	-0.58	-7.2	-0.4	6.31e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs736408	0.609	rs13082960	chr3:52785168	A/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.55	0.37	2.95e-10	Bipolar disorder;
CESC	cis	rs9926296	0.605	rs7205053	chr16:89856763	G/C	cg27121462	chr16:89883253	FANCA	0.75	10.79	0.55	9.94e-23	Vitiligo;
CESC	cis	rs3126085	0.935	rs1552995	chr1:152171427	A/G	cg26876637	chr1:152193138	HRNR	0.45	5.18	0.3	4.29e-7	Atopic dermatitis;
CESC	cis	rs7224685	0.501	rs11649992	chr17:4026823	A/G	cg07607921	chr17:4047574	ZZEF1;CYB5D2	0.49	5.09	0.3	6.96e-7	Type 2 diabetes;
CESC	cis	rs12497850	0.931	rs9682444	chr3:48852639	A/G	cg02487422	chr3:49467188	NICN1	0.4	5.15	0.3	5.11e-7	Parkinson's disease;
CESC	cis	rs6912958	0.781	rs9450755	chr6:88303702	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-6.56	-0.37	2.82e-10	Monocyte percentage of white cells;
CESC	cis	rs8031584	0.958	rs34294266	chr15:31246840	A/G	cg08704250	chr15:31115839	NA	-0.63	-8.06	-0.44	2.6e-14	Huntington's disease progression;
CESC	cis	rs12971120	0.891	rs3794953	chr18:72180519	C/T	cg25817165	chr18:72167213	CNDP2	-0.61	-7.27	-0.41	3.94e-12	Refractive error;
CESC	trans	rs4741343	0.752	rs723968	chr9:14154231	T/C	cg03691418	chr17:80962847	B3GNTL1	-0.58	-6.09	-0.35	3.91e-9	Educational attainment (years of education);
CESC	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg23708337	chr7:1209742	NA	0.52	5.14	0.3	5.37e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg14347670	chr6:41908995	CCND3	0.47	6.14	0.35	2.96e-9	Tetralogy of Fallot;
CESC	cis	rs10242455	0.571	rs117370443	chr7:98975258	T/C	cg18809830	chr7:99032528	PTCD1	-0.73	-5.28	-0.31	2.71e-7	Blood metabolite levels;
CESC	cis	rs10540	1.000	rs61876332	chr11:487101	C/T	cg03576123	chr11:487126	PTDSS2	-1.08	-10.51	-0.54	7.9e-22	Body mass index;
CESC	cis	rs12681288	0.550	rs72507624	chr8:961324	G/A	cg04851639	chr8:1020857	NA	-0.32	-6.12	-0.35	3.33e-9	Schizophrenia;
CESC	cis	rs66887589	0.616	rs7659403	chr4:120207254	T/A	cg09307838	chr4:120376055	NA	0.68	9.52	0.5	1.13e-18	Diastolic blood pressure;
CESC	cis	rs7615952	0.641	rs4422257	chr3:125774363	A/G	cg06494592	chr3:125709126	NA	-0.49	-5.23	-0.31	3.48e-7	Blood pressure (smoking interaction);
CESC	cis	rs7613875	0.600	rs2856238	chr3:50158191	C/T	cg24110177	chr3:50126178	RBM5	-0.61	-8.72	-0.47	3.07e-16	Body mass index;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11310125	chr2:113239311	TTL	0.61	7.34	0.41	2.66e-12	Gut microbiome composition (summer);
CESC	cis	rs853679	0.517	rs9368555	chr6:28108967	T/C	cg20151795	chr6:28129481	ZNF389	0.45	5.84	0.34	1.5e-8	Depression;
CESC	cis	rs5750830	0.649	rs5750811	chr22:39793066	G/T	cg05872129	chr22:39784769	NA	0.81	10.76	0.55	1.25e-22	Intelligence (multi-trait analysis);
CESC	trans	rs561341	1.000	rs56903735	chr17:30254393	T/A	cg20587970	chr11:113659929	NA	-1.11	-13.56	-0.64	3.64e-32	Hip circumference adjusted for BMI;
CESC	cis	rs9660992	0.762	rs1668871	chr1:205237137	T/C	cg00857998	chr1:205179979	DSTYK	0.43	5.24	0.31	3.28e-7	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs12971120	0.891	rs2303463	chr18:72168608	G/A	cg25817165	chr18:72167213	CNDP2	-0.58	-7.09	-0.4	1.22e-11	Refractive error;
CESC	cis	rs10504229	0.683	rs34804288	chr8:58117570	C/A	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs9322193	0.923	rs1984111	chr6:150152856	G/A	cg07701084	chr6:150067640	NUP43	0.43	5.95	0.34	8.47e-9	Lung cancer;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg24156658	chr11:65122092	TIGD3	-0.45	-6.44	-0.37	5.56e-10	Asthma;
CESC	cis	rs10838687	0.673	rs59567949	chr11:47300155	G/A	cg25783544	chr11:47291846	MADD	0.56	6.52	0.37	3.53e-10	Proinsulin levels;
CESC	cis	rs4699052	0.963	rs4699057	chr4:104171123	A/G	cg16532752	chr4:104119610	CENPE	0.44	6.15	0.35	2.82e-9	Testicular germ cell tumor;
CESC	cis	rs9309473	0.607	rs7567017	chr2:73596270	C/T	cg20560298	chr2:73613845	ALMS1	-0.47	-6.56	-0.37	2.84e-10	Metabolite levels;
CESC	cis	rs7044106	0.762	rs1324473	chr9:123404610	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	-0.36	-5.82	-0.34	1.66e-8	Hip circumference adjusted for BMI;
CESC	cis	rs7618915	0.501	rs9917834	chr3:52634619	A/C	cg07507251	chr3:52567010	NT5DC2	0.32	5.5	0.32	8.74e-8	Bipolar disorder;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg16520737	chr19:1021368	C19orf6	-0.46	-6.18	-0.35	2.39e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs4664308	0.935	rs4637057	chr2:160950161	G/T	cg03641300	chr2:160917029	PLA2R1	-0.67	-9.84	-0.52	1.11e-19	Idiopathic membranous nephropathy;
CESC	cis	rs7605827	0.897	rs10202600	chr2:15514461	T/C	cg19274914	chr2:15703543	NA	0.32	5.55	0.32	6.84e-8	Educational attainment (years of education);
CESC	cis	rs11098499	0.738	rs10026493	chr4:120384194	C/G	cg24375607	chr4:120327624	NA	0.45	5.52	0.32	8.05e-8	Corneal astigmatism;
CESC	cis	rs10242455	0.867	rs2404769	chr7:99321716	T/C	cg07715041	chr7:99302981	CYP3A7	-0.43	-5.42	-0.32	1.36e-7	Blood metabolite levels;
CESC	cis	rs4948102	0.961	rs7776550	chr7:56092391	T/C	cg09872392	chr7:56161020	PHKG1	-0.43	-6.46	-0.37	5.11e-10	Plasma homocysteine levels (post-methionine load test);
CESC	cis	rs6952808	0.717	rs12534679	chr7:1926745	G/A	cg05863683	chr7:1912471	MAD1L1	0.48	7.35	0.41	2.39e-12	Bipolar disorder and schizophrenia;
CESC	cis	rs7666738	0.830	rs28497822	chr4:98906873	C/T	cg03676636	chr4:99064102	C4orf37	0.35	5.23	0.31	3.46e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3820928	0.874	rs13393902	chr2:227880554	A/G	cg11843606	chr2:227700838	RHBDD1	-0.46	-6.09	-0.35	3.87e-9	Pulmonary function;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg02576092	chr1:27668556	SYTL1	0.44	6.04	0.35	5.27e-9	Systemic lupus erythematosus;
CESC	cis	rs8177253	0.666	rs8177197	chr3:133469530	G/A	cg12373951	chr3:133503437	NA	0.37	5.09	0.3	6.7e-7	Iron status biomarkers;
CESC	cis	rs13191362	0.810	rs13209784	chr6:162961274	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.8	7.66	0.43	3.52e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs5769765	0.908	rs9616213	chr22:50317851	T/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.63	-6.44	-0.37	5.53e-10	Schizophrenia;
CESC	cis	rs9733	0.570	rs951281	chr1:150691122	A/C	cg09365446	chr1:150670422	GOLPH3L	0.42	5.86	0.34	1.37e-8	Tonsillectomy;
CESC	trans	rs9951602	0.512	rs12607938	chr18:76651887	A/C	cg02800362	chr5:177631904	HNRNPAB	0.61	8.34	0.46	4.07e-15	Obesity-related traits;
CESC	cis	rs2120019	0.938	rs8033925	chr15:75311959	A/G	cg09165964	chr15:75287851	SCAMP5	-0.77	-9.82	-0.52	1.29e-19	Blood trace element (Zn levels);
CESC	cis	rs7044106	0.791	rs10985001	chr9:123484232	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.7	10.3	0.53	3.82e-21	Hip circumference adjusted for BMI;
CESC	cis	rs34779708	0.733	rs3936503	chr10:35549257	A/G	cg03585969	chr10:35415529	CREM	-0.56	-6.85	-0.39	5.01e-11	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs6089584	1.000	rs6089581	chr20:60562394	G/A	cg13770153	chr20:60521292	NA	-0.45	-5.9	-0.34	1.12e-8	Body mass index;
CESC	cis	rs10504073	0.647	rs10808745	chr8:49989037	G/A	cg00325661	chr8:49890786	NA	0.55	8.05	0.44	2.78e-14	Blood metabolite ratios;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg16442450	chr15:69111511	ANP32A	-0.39	-6.23	-0.36	1.82e-9	Gambling;
CESC	trans	rs10463316	0.894	rs6579863	chr5:150761946	A/T	cg24389359	chr12:111284228	CCDC63	-0.33	-6.02	-0.35	5.68e-9	Metabolite levels (Pyroglutamine);
CESC	cis	rs7927592	0.763	rs1193699	chr11:68249480	C/G	cg01657329	chr11:68192670	LRP5	-0.45	-5.91	-0.34	1.05e-8	Total body bone mineral density;
CESC	cis	rs6740322	0.895	rs9309098	chr2:43554972	A/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.69	7.48	0.42	1.11e-12	Coronary artery disease;
CESC	cis	rs920590	0.684	rs59565447	chr8:19668430	A/T	cg03894339	chr8:19674705	INTS10	0.68	7.68	0.43	3.04e-13	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs6500395	0.926	rs11643272	chr16:48639723	T/C	cg04672837	chr16:48644449	N4BP1	0.5	6.07	0.35	4.3e-9	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs4819052	1.000	rs13053002	chr21:46677854	C/T	cg11663144	chr21:46675770	NA	-0.51	-7.08	-0.4	1.31e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs12458462	0.892	rs2242174	chr18:77458037	T/C	cg11879182	chr18:77439856	CTDP1	0.88	13.9	0.65	2.24e-33	Monocyte count;
CESC	cis	rs2625529	0.652	rs2929518	chr15:72332748	A/C	cg16672083	chr15:72433130	SENP8	0.44	6.71	0.38	1.18e-10	Red blood cell count;
CESC	cis	rs1799949	0.526	rs4352088	chr17:41414679	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.6	7.94	0.44	5.6e-14	Menopause (age at onset);
CESC	cis	rs763014	0.966	rs12935215	chr16:670605	T/C	cg09263875	chr16:632152	PIGQ	0.68	11.67	0.58	1.11e-25	Height;
CESC	cis	rs6540559	1.000	rs2235373	chr1:209963803	G/A	cg22029157	chr1:209979665	IRF6	0.71	10.13	0.53	1.34e-20	Cleft lip with or without cleft palate;
CESC	cis	rs7412746	0.597	rs868751	chr1:150669414	T/G	cg18016565	chr1:150552671	MCL1	0.33	5.09	0.3	6.65e-7	Melanoma;
CESC	cis	rs6499129	0.867	rs11859352	chr16:67390448	A/G	cg26727032	chr16:67993705	SLC12A4	-0.53	-5.83	-0.34	1.57e-8	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs736408	0.812	rs6778329	chr3:52824610	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.4	5.32	0.31	2.26e-7	Bipolar disorder;
CESC	cis	rs11098499	0.954	rs1546505	chr4:120241224	A/G	cg24375607	chr4:120327624	NA	0.44	5.4	0.31	1.49e-7	Corneal astigmatism;
CESC	cis	rs1045714	0.943	rs1045711	chr7:2653571	C/T	cg20813462	chr7:2646259	IQCE	0.71	5.79	0.34	1.98e-8	Urate levels in lean individuals;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15487600	chr1:155113158	DPM3	0.61	7.02	0.4	1.9e-11	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13323097	chr1:205649211	SLC45A3	0.57	6.81	0.39	6.52e-11	Gut microbiome composition (summer);
CESC	cis	rs1008375	0.966	rs4698621	chr4:17587565	C/T	cg27347728	chr4:17578864	LAP3	0.46	5.48	0.32	9.65e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs55728055	0.661	rs16989274	chr22:31955908	G/A	cg01338084	chr22:32026380	PISD	1.26	8.23	0.45	8.74e-15	Age-related hearing impairment;
CESC	cis	rs367943	0.712	rs10062004	chr5:112694914	T/C	cg12552261	chr5:112820674	MCC	0.41	5.37	0.31	1.73e-7	Type 2 diabetes;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg16529307	chr1:89990087	LRRC8B	-0.52	-6.68	-0.38	1.39e-10	Ulcerative colitis;
CESC	cis	rs360798	0.512	rs12989754	chr2:63020970	A/G	cg17519650	chr2:63277830	OTX1	-0.59	-7.79	-0.43	1.49e-13	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11781344	chr5:133706657	UBE2B	-0.63	-7.37	-0.41	2.24e-12	Gut microbiome composition (summer);
CESC	cis	rs3809566	1.000	rs4775610	chr15:63332057	C/T	cg05507819	chr15:63340323	TPM1	-0.52	-6.37	-0.36	8.15e-10	Platelet count;
CESC	cis	rs13064411	0.696	rs1386336	chr3:113144153	C/T	cg18753928	chr3:113234510	CCDC52	-0.45	-5.18	-0.3	4.37e-7	Response to simvastatin treatment (PCSK9 protein level change);
CESC	cis	rs6831352	0.918	rs4699713	chr4:100060513	C/T	cg13256891	chr4:100009986	ADH5	-0.75	-8.21	-0.45	9.89e-15	Alcohol dependence;
CESC	cis	rs4555082	0.794	rs2735827	chr14:105710600	T/A	cg27165867	chr14:105738592	BRF1	-0.5	-5.44	-0.32	1.23e-7	Mean platelet volume;Platelet distribution width;
CESC	cis	rs7772486	0.875	rs1330939	chr6:146308518	T/A	cg23711669	chr6:146136114	FBXO30	0.78	11.25	0.57	2.92e-24	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs3015469	0.671	rs2883951	chr14:51154493	C/T	cg26011998	chr14:51135199	SAV1	0.52	5.58	0.32	6.05e-8	Plasma amyloid beta peptide concentrations (ABx-40);
CESC	cis	rs9747201	1.000	rs9303020	chr17:80163247	C/T	cg09264619	chr17:80180166	NA	-0.46	-5.43	-0.32	1.29e-7	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs9611519	0.929	rs13055800	chr22:41440424	G/A	cg03806693	chr22:41940476	POLR3H	-0.56	-5.88	-0.34	1.22e-8	Neuroticism;
CESC	cis	rs7512552	0.809	rs1694363	chr1:150368677	T/G	cg15654264	chr1:150340011	RPRD2	0.42	5.51	0.32	8.49e-8	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs8114671	0.562	rs4911447	chr20:33479445	T/A	cg07148914	chr20:33460835	GGT7	0.45	5.92	0.34	9.9e-9	Height;
CESC	cis	rs79349575	0.687	rs12602179	chr17:47010034	G/T	cg16584676	chr17:46985605	UBE2Z	0.54	6.67	0.38	1.46e-10	Type 2 diabetes;
CESC	cis	rs9913156	0.793	rs72835633	chr17:4562643	C/T	cg19197139	chr17:4613644	ARRB2	0.92	10.46	0.54	1.18e-21	Lymphocyte counts;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg12296079	chr11:61849674	NA	0.49	6.15	0.35	2.85e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs2370759	0.945	rs10508773	chr10:32575444	C/T	cg05361325	chr10:32636312	EPC1	-0.55	-5.18	-0.3	4.39e-7	Sexual dysfunction (female);
CESC	cis	rs9611565	0.879	rs5758307	chr22:41750219	A/G	cg17376030	chr22:41985996	PMM1	0.43	5.03	0.3	9.17e-7	Vitiligo;
CESC	cis	rs4803468	0.901	rs3745292	chr19:41888506	A/G	cg09537434	chr19:41945824	ATP5SL	-1.02	-18.21	-0.75	1.31e-48	Height;
CESC	cis	rs7727544	0.735	rs272894	chr5:131662460	C/T	cg07395648	chr5:131743802	NA	-0.49	-6.5	-0.37	4.07e-10	Blood metabolite levels;
CESC	cis	rs853679	0.546	rs200953	chr6:27837267	T/C	cg17221315	chr6:27791827	HIST1H4J	0.63	5.22	0.31	3.65e-7	Depression;
CESC	cis	rs735860	0.726	rs209507	chr6:53194768	T/A	cg10236188	chr6:53219634	NA	0.34	5.12	0.3	5.91e-7	Glaucoma;
CESC	cis	rs4853012	0.838	rs72911122	chr2:74344119	C/G	cg01017244	chr2:74357527	NA	0.68	9.89	0.52	7.68e-20	Gestational age at birth (maternal effect);
CESC	cis	rs568617	0.953	rs658524	chr11:65647260	A/G	cg00576331	chr11:65640516	EFEMP2	0.45	5.3	0.31	2.48e-7	Crohn's disease;
CESC	trans	rs875971	1.000	rs1565531	chr7:65663113	T/A	cg26939375	chr7:64535504	NA	-0.46	-6.09	-0.35	4e-9	Aortic root size;
CESC	cis	rs7264396	1.000	rs6060479	chr20:34165723	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	0.54	6.47	0.37	4.67e-10	Total cholesterol levels;
CESC	cis	rs7666738	0.791	rs2865953	chr4:99040319	C/T	cg24818145	chr4:99064322	C4orf37	0.38	5.05	0.3	8.28e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs8064299	0.967	rs878907	chr17:72769694	A/G	cg25054828	chr17:72772726	NAT9;TMEM104	0.64	9.21	0.49	9.94e-18	Monocyte count;
CESC	cis	rs3785574	0.962	rs8066463	chr17:61818390	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.1	19.24	0.76	3.09e-52	Height;
CESC	cis	rs801193	1.000	rs2286684	chr7:66129830	G/T	cg06456125	chr7:65229604	NA	-0.39	-5.09	-0.3	6.82e-7	Aortic root size;
CESC	cis	rs4665809	0.567	rs6546848	chr2:26444414	G/C	cg25036284	chr2:26402008	FAM59B	-0.88	-9.99	-0.52	3.79e-20	Gut microbiome composition (summer);
CESC	cis	rs909674	0.734	rs5757675	chr22:39838892	G/T	cg05872129	chr22:39784769	NA	-0.77	-10.31	-0.54	3.54e-21	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs10078	0.571	rs2721014	chr5:463539	G/A	cg08916839	chr5:415575	AHRR	0.58	6.76	0.38	8.54e-11	Fat distribution (HIV);
CESC	cis	rs8060686	0.623	rs7205935	chr16:68152157	A/G	cg26727032	chr16:67993705	SLC12A4	-0.59	-8.1	-0.45	2.03e-14	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs7618915	0.547	rs34537256	chr3:52657472	A/G	cg07507251	chr3:52567010	NT5DC2	0.41	7.2	0.4	6.38e-12	Bipolar disorder;
CESC	trans	rs7107217	1.000	rs1873872	chr11:129473993	A/T	cg14748682	chr11:6624841	ILK;RRP8	0.49	6.19	0.36	2.23e-9	Breast cancer;Type 2 diabetes;
CESC	cis	rs754466	0.580	rs2289309	chr10:79571108	C/T	cg17075019	chr10:79541650	NA	-0.87	-13.8	-0.65	5.26e-33	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs2836974	0.555	rs35909862	chr21:40621158	G/A	cg11644478	chr21:40555479	PSMG1	-0.84	-12.59	-0.61	8.41e-29	Cognitive function;
CESC	cis	rs11122272	0.735	rs2790881	chr1:231534181	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.56	-7.66	-0.43	3.45e-13	Hemoglobin concentration;
CESC	cis	rs28386778	0.830	rs7209321	chr17:61855668	A/C	cg11494091	chr17:61959527	GH2	0.74	12.59	0.61	8.53e-29	Prudent dietary pattern;
CESC	trans	rs2693676	0.504	rs1257491	chr14:99603939	T/C	cg17465227	chr4:47427752	GABRB1	0.55	6.25	0.36	1.68e-9	Corneal curvature;
CESC	cis	rs977987	0.806	rs12930768	chr16:75464500	T/C	cg03315344	chr16:75512273	CHST6	0.41	5.91	0.34	1.07e-8	Dupuytren's disease;
CESC	cis	rs2075371	0.734	rs13225086	chr7:134011411	C/T	cg11752832	chr7:134001865	SLC35B4	0.5	5.99	0.35	6.84e-9	Mean platelet volume;
CESC	cis	rs910316	1.000	rs2268617	chr14:75608728	G/A	cg08847533	chr14:75593920	NEK9	1.0	19.26	0.76	2.69e-52	Height;
CESC	cis	rs1691799	0.899	rs1168351	chr12:66752505	A/G	cg16791601	chr12:66731901	HELB	-0.78	-13.93	-0.65	1.79e-33	White blood cell count (basophil);
CESC	cis	rs2243480	1.000	rs58062456	chr7:65394852	G/T	cg12463550	chr7:65579703	CRCP	0.7	5.7	0.33	3.21e-8	Diabetic kidney disease;
CESC	cis	rs17666538	0.585	rs4448252	chr8:615597	A/G	cg07234876	chr8:600039	NA	0.81	5.83	0.34	1.62e-8	IgG glycosylation;
CESC	cis	rs8020095	0.706	rs8006552	chr14:67294069	C/G	cg19548862	chr14:67692701	FAM71D	-0.42	-5.67	-0.33	3.7e-8	Depression (quantitative trait);
CESC	cis	rs10788264	0.504	rs1034533	chr10:124032434	A/G	cg09507567	chr10:124027408	NA	0.43	6.0	0.35	6.31e-9	Total body bone mineral density;
CESC	cis	rs4566357	0.615	rs12621808	chr2:227909522	A/C	cg05526886	chr2:227700861	RHBDD1	-0.44	-5.74	-0.33	2.57e-8	Coronary artery disease;
CESC	cis	rs9311474	0.508	rs11720159	chr3:52617802	T/G	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.33	5.97	0.34	7.45e-9	Electroencephalogram traits;
CESC	cis	rs17376456	0.757	rs10066431	chr5:93198204	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.6	5.05	0.3	8.28e-7	Diabetic retinopathy;
CESC	cis	rs7267979	0.932	rs424487	chr20:25468131	C/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.79	14.62	0.67	6.72e-36	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs870825	0.655	rs35764203	chr4:185639078	C/A	cg04058563	chr4:185651563	MLF1IP	0.64	7.07	0.4	1.39e-11	Blood protein levels;
CESC	cis	rs2243480	0.522	rs73150635	chr7:65972490	C/T	cg13147721	chr7:65941812	NA	-0.86	-6.38	-0.36	7.85e-10	Diabetic kidney disease;
CESC	cis	rs9733	0.596	rs72700897	chr1:150626038	C/G	cg04414720	chr1:150670196	GOLPH3L	0.63	9.04	0.49	3.47e-17	Tonsillectomy;
CESC	cis	rs12410462	0.681	rs6670816	chr1:227610592	G/T	cg04117972	chr1:227635322	NA	-0.73	-6.9	-0.39	3.72e-11	Major depressive disorder;
CESC	cis	rs2658782	0.789	rs3020076	chr11:93141058	C/T	cg15737290	chr11:93063684	CCDC67	0.48	5.83	0.34	1.61e-8	Pulmonary function decline;
CESC	cis	rs477692	0.612	rs58103386	chr10:131319958	C/A	cg05714579	chr10:131428358	MGMT	0.41	5.36	0.31	1.83e-7	Response to temozolomide;
CESC	cis	rs5769765	0.773	rs58375955	chr22:50312630	A/G	cg26441486	chr22:50317300	CRELD2	0.42	5.24	0.31	3.33e-7	Schizophrenia;
CESC	cis	rs4555082	0.957	rs2735818	chr14:105714751	A/G	cg13114125	chr14:105738426	BRF1	-0.68	-8.41	-0.46	2.62e-15	Mean platelet volume;Platelet distribution width;
CESC	cis	rs3096299	0.874	rs3102342	chr16:89451575	T/C	cg02187348	chr16:89574699	SPG7	0.55	7.34	0.41	2.64e-12	Multiple myeloma (IgH translocation);
CESC	cis	rs875971	0.929	rs778712	chr7:65849978	C/T	cg12463550	chr7:65579703	CRCP	0.59	7.54	0.42	7.73e-13	Aortic root size;
CESC	cis	rs1577917	0.771	rs7742201	chr6:86432930	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.56	-7.92	-0.44	6.58e-14	Response to antipsychotic treatment;
CESC	cis	rs514406	0.861	rs503296	chr1:53283088	A/G	cg16325326	chr1:53192061	ZYG11B	-0.9	-15.35	-0.69	1.76e-38	Monocyte count;
CESC	cis	rs853679	0.517	rs9368555	chr6:28108967	T/C	cg26335602	chr6:28129616	ZNF389	0.54	7.14	0.4	8.92e-12	Depression;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06891939	chr7:56950307	NA	-0.56	-6.6	-0.38	2.19e-10	Gut microbiome composition (summer);
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg04100724	chr12:92539208	BTG1	-0.48	-6.65	-0.38	1.7e-10	Height;
CESC	cis	rs1005224	0.895	rs11624114	chr14:76131800	A/G	cg25116370	chr14:76127843	TTLL5;C14orf1	-0.4	-5.36	-0.31	1.78e-7	Large artery stroke;
CESC	cis	rs7772486	0.790	rs9497425	chr6:146234197	G/A	cg23711669	chr6:146136114	FBXO30	-0.82	-11.64	-0.58	1.47e-25	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9581857	0.725	rs1924074	chr13:28015387	C/G	cg22138327	chr13:27999177	GTF3A	-0.67	-5.42	-0.32	1.36e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
CESC	cis	rs74781061	1.000	rs11072488	chr15:74786358	T/C	cg17294928	chr15:75287854	SCAMP5	-0.47	-5.04	-0.3	8.43e-7	Endometriosis;
CESC	cis	rs4713118	0.586	rs6905516	chr6:28086478	A/G	cg22143856	chr6:28129313	ZNF389	0.52	6.71	0.38	1.21e-10	Parkinson's disease;
CESC	cis	rs4699052	0.590	rs28728298	chr4:104282850	A/T	cg16532752	chr4:104119610	CENPE	-0.37	-5.3	-0.31	2.46e-7	Testicular germ cell tumor;
CESC	cis	rs28386778	0.965	rs2854154	chr17:61981696	C/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.69	-9.37	-0.5	3.23e-18	Prudent dietary pattern;
CESC	cis	rs78707713	0.841	rs12242391	chr10:71201504	C/T	cg12610070	chr10:71211762	TSPAN15	-0.41	-7.22	-0.41	5.39e-12	Venous thromboembolism;
CESC	cis	rs34330	0.562	rs11055024	chr12:12858969	A/G	cg09462578	chr12:12878428	APOLD1	-0.79	-8.49	-0.46	1.48e-15	Systemic lupus erythematosus;
CESC	cis	rs6540559	1.000	rs6540559	chr1:209982025	G/A	cg21951975	chr1:209979733	IRF6	0.6	9.55	0.51	9.28e-19	Cleft lip with or without cleft palate;
CESC	cis	rs28374715	0.681	rs7162231	chr15:41591859	G/A	cg20272979	chr15:41787780	ITPKA	0.43	5.17	0.3	4.65e-7	Ulcerative colitis;
CESC	cis	rs2380220	0.606	rs4559095	chr6:95994154	A/C	cg04719120	chr6:96025338	MANEA	0.46	5.21	0.3	3.88e-7	Behavioural disinhibition (generation interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10826053	chr4:108641834	PAPSS1	-0.59	-6.71	-0.38	1.19e-10	Gut microbiome composition (summer);
CESC	cis	rs10754283	0.934	rs7529653	chr1:90111851	G/A	cg21401794	chr1:90099060	LRRC8C	0.69	9.34	0.5	4.06e-18	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs7827545	0.545	rs4909477	chr8:135562976	A/G	cg17885191	chr8:135476712	NA	0.57	6.1	0.35	3.79e-9	Hypertension (SNP x SNP interaction);
CESC	trans	rs73198271	0.640	rs7838012	chr8:8656630	A/G	cg23754772	chr18:12253859	CIDEA	-0.34	-6.26	-0.36	1.55e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs1707322	0.752	rs4660880	chr1:46111040	C/T	cg05343316	chr1:45956843	TESK2	0.51	6.27	0.36	1.49e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs8050907	0.744	rs1345430	chr16:4527961	G/A	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.9	6.28	0.36	1.39e-9	Obesity-related traits;
CESC	cis	rs4862750	0.914	rs11945845	chr4:187874136	T/C	cg07414643	chr4:187882934	NA	0.53	7.37	0.41	2.15e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs55883249	1.000	rs62119423	chr2:9726601	C/T	cg23886495	chr2:9695866	ADAM17	0.6	5.6	0.33	5.39e-8	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21397993	chr1:243418055	CEP170;SDCCAG8	0.55	6.13	0.35	3.19e-9	Gut microbiome composition (summer);
CESC	cis	rs40363	0.720	rs4453493	chr16:3533881	T/C	cg21433313	chr16:3507492	NAT15	-0.56	-8.71	-0.47	3.39e-16	Tuberculosis;
CESC	cis	rs11764590	0.724	rs55669426	chr7:2090129	G/C	cg21782813	chr7:2030301	MAD1L1	-0.41	-5.26	-0.31	2.9e-7	Neuroticism;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02993890	chr14:50087996	RPL36AL;MGAT2	0.55	6.09	0.35	3.87e-9	Gut microbiome composition (summer);
CESC	cis	rs6968419	0.755	rs6948556	chr7:115895433	T/C	cg02561103	chr7:115862891	TES	-0.41	-5.33	-0.31	2.13e-7	Intraocular pressure;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg07869135	chr8:123794843	ZHX2	0.47	6.05	0.35	4.91e-9	Systemic lupus erythematosus;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg04091837	chr21:47809310	PCNT	0.42	6.13	0.35	3.1e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs2637266	0.935	rs2579774	chr10:78402253	T/C	cg18941641	chr10:78392320	NA	0.45	8.65	0.47	4.9e-16	Pulmonary function;
CESC	cis	rs2842992	0.789	rs4276525	chr6:160193612	G/A	cg26839252	chr6:160211577	TCP1;MRPL18	0.46	5.26	0.31	3.04e-7	Age-related macular degeneration (geographic atrophy);
CESC	trans	rs11098499	0.754	rs12711071	chr4:120240934	A/G	cg25214090	chr10:38739885	LOC399744	0.57	7.73	0.43	2.3e-13	Corneal astigmatism;
CESC	cis	rs8072100	0.607	rs9894594	chr17:45461383	A/G	cg25173405	chr17:45401733	C17orf57	-0.43	-5.42	-0.32	1.36e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs727505	1.000	rs67939974	chr7:124554364	C/T	cg23710748	chr7:124431027	NA	-0.48	-7.38	-0.41	2.09e-12	Lewy body disease;
CESC	cis	rs4237845	0.591	rs4760344	chr12:58320783	A/T	cg02175503	chr12:58329896	NA	0.8	10.69	0.55	2e-22	Intelligence (multi-trait analysis);
CESC	cis	rs9926296	0.568	rs7203907	chr16:89833774	C/G	cg21285383	chr16:89894308	SPIRE2	0.33	5.82	0.34	1.73e-8	Vitiligo;
CESC	cis	rs6582630	0.599	rs8175936	chr12:38426315	C/G	cg26384229	chr12:38710491	ALG10B	-0.44	-5.95	-0.34	8.28e-9	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs1862618	0.671	rs832531	chr5:56228401	A/G	cg24531977	chr5:56204891	C5orf35	-0.67	-9.38	-0.5	3.04e-18	Initial pursuit acceleration;
CESC	trans	rs2717463	0.639	rs4399374	chr12:80814828	A/G	cg08548409	chr3:61550635	PTPRG	0.77	6.27	0.36	1.48e-9	Positive affect;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg05922971	chr5:43121458	ZNF131	-0.46	-6.13	-0.35	3.18e-9	Ulcerative colitis;
CESC	cis	rs3857067	0.806	rs17302300	chr4:95109177	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.59	-8.92	-0.48	7.87e-17	QT interval;
CESC	trans	rs561341	1.000	rs7216102	chr17:30259450	A/G	cg27661571	chr11:113659931	NA	-0.53	-6.04	-0.35	5.29e-9	Hip circumference adjusted for BMI;
CESC	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg26338869	chr17:61819248	STRADA	0.7	9.26	0.49	7.46e-18	Prudent dietary pattern;
CESC	cis	rs66569888	0.754	rs6719028	chr2:106895212	T/C	cg16099169	chr2:106886729	NA	0.71	8.71	0.47	3.26e-16	Facial morphology (factor 23);
CESC	cis	rs17401966	1.000	rs35837142	chr1:10322358	C/G	cg15208524	chr1:10270712	KIF1B	0.5	6.47	0.37	4.65e-10	Hepatocellular carcinoma;
CESC	cis	rs1847202	0.859	rs7634316	chr3:72941452	C/G	cg25664220	chr3:72788482	NA	0.41	5.84	0.34	1.5e-8	Motion sickness;
CESC	cis	rs875971	0.862	rs6960446	chr7:65733259	A/G	cg12463550	chr7:65579703	CRCP	-0.47	-5.96	-0.34	7.88e-9	Aortic root size;
CESC	cis	rs6540559	0.932	rs764093	chr1:209983331	A/G	cg22442454	chr1:209979470	IRF6	0.51	6.28	0.36	1.38e-9	Cleft lip with or without cleft palate;
CESC	cis	rs7726839	0.540	rs3749618	chr5:602650	A/G	cg16447950	chr5:562315	NA	-0.58	-6.02	-0.35	5.91e-9	Obesity-related traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09426994	chr11:118478258	PHLDB1	0.55	6.29	0.36	1.29e-9	Gut microbiome composition (summer);
CESC	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-6.21	-0.36	2.01e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00560284	chr12:49783222	SPATS2	-0.67	-7.57	-0.42	6.17e-13	Gut microbiome composition (summer);
CESC	cis	rs7408868	0.908	rs45591935	chr19:15277006	T/C	cg14696996	chr19:15285081	NOTCH3	1.11	11.48	0.58	4.81e-25	Pulse pressure;
CESC	cis	rs7219021	0.739	rs4793993	chr17:47008546	C/T	cg16584676	chr17:46985605	UBE2Z	-0.61	-6.92	-0.39	3.46e-11	Schizophrenia or bipolar disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04284535	chr17:41624145	ETV4	-0.59	-7.02	-0.4	1.86e-11	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.861	rs5010991	chr4:98972179	A/G	cg05340658	chr4:99064831	C4orf37	0.79	12.26	0.6	1.12e-27	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9831754	1.000	rs3946823	chr3:78353052	G/A	cg06138941	chr3:78371609	NA	-0.75	-8.54	-0.46	1.09e-15	Calcium levels;
CESC	cis	rs9911578	1.000	rs12453459	chr17:56624291	C/T	cg05425664	chr17:57184151	TRIM37	0.5	7.06	0.4	1.5e-11	Intelligence (multi-trait analysis);
CESC	cis	rs3857067	1.000	rs3846291	chr4:95026735	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.52	-7.99	-0.44	4.19e-14	QT interval;
CESC	cis	rs1728785	1.000	rs8058145	chr16:68584090	G/A	cg02972257	chr16:68554789	NA	-0.54	-6.27	-0.36	1.45e-9	Ulcerative colitis;
CESC	cis	rs9916302	0.904	rs1077715	chr17:37683548	A/T	cg07936489	chr17:37558343	FBXL20	-0.81	-11.7	-0.58	9.17e-26	Glomerular filtration rate (creatinine);
CESC	cis	rs8141529	0.748	rs5997412	chr22:29276747	G/A	cg15103426	chr22:29168792	CCDC117	0.6	7.59	0.42	5.42e-13	Lymphocyte counts;
CESC	cis	rs10979	0.597	rs9496687	chr6:143908815	A/G	cg25407410	chr6:143891975	LOC285740	-0.53	-6.93	-0.39	3.25e-11	Hypospadias;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03338968	chr1:3731507	KIAA0562	-0.48	-6.03	-0.35	5.58e-9	Gut microbiome composition (summer);
CESC	cis	rs921968	0.541	rs687747	chr2:219399627	T/C	cg02176678	chr2:219576539	TTLL4	0.5	9.0	0.48	4.36e-17	Mean corpuscular hemoglobin concentration;
CESC	cis	rs875971	1.000	rs6945843	chr7:65734783	G/A	cg11764359	chr7:65958608	NA	-0.94	-15.28	-0.68	3.2e-38	Aortic root size;
CESC	cis	rs7219021	0.886	rs9897440	chr17:46868142	C/G	cg16584676	chr17:46985605	UBE2Z	-0.57	-6.6	-0.38	2.17e-10	Schizophrenia or bipolar disorder;
CESC	cis	rs6964587	0.869	rs13237856	chr7:91551788	G/A	cg01689657	chr7:91764605	CYP51A1	-0.29	-5.17	-0.3	4.57e-7	Breast cancer;
CESC	cis	rs113835537	0.529	rs116867234	chr11:66209024	C/T	cg22134325	chr11:66188745	NPAS4	0.44	6.7	0.38	1.22e-10	Airway imaging phenotypes;
CESC	cis	rs939574	0.790	rs79225383	chr2:220093972	C/A	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.88	7.38	0.41	2e-12	Platelet distribution width;
CESC	cis	rs3008870	1.000	rs1925408	chr1:67365034	C/T	cg02640540	chr1:67518911	SLC35D1	0.48	5.12	0.3	5.81e-7	Lymphocyte percentage of white cells;
CESC	trans	rs2727020	0.587	rs1164658	chr11:49298551	C/A	cg15704280	chr7:45808275	SEPT13	0.87	14.55	0.67	1.19e-35	Coronary artery disease;
CESC	cis	rs7914558	1.000	rs10883826	chr10:104830819	A/G	cg04362960	chr10:104952993	NT5C2	0.46	6.16	0.35	2.62e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs11583043	1.000	rs3861734	chr1:101489461	A/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.51	5.63	0.33	4.65e-8	Ulcerative colitis;Inflammatory bowel disease;
CESC	cis	rs6060717	0.536	rs6060664	chr20:34478884	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.66	5.7	0.33	3.16e-8	Hip circumference adjusted for BMI;
CESC	cis	rs4689592	0.503	rs3857180	chr4:7073899	T/G	cg06697600	chr4:7070879	GRPEL1	0.53	6.48	0.37	4.39e-10	Monocyte percentage of white cells;
CESC	cis	rs7666738	0.830	rs7679299	chr4:99057620	C/A	cg03676636	chr4:99064102	C4orf37	0.34	5.1	0.3	6.47e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2842992	0.789	rs2146163	chr6:160224346	T/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.77	9.43	0.5	2.1e-18	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs9487051	0.872	rs9480923	chr6:109607369	G/C	cg01475377	chr6:109611718	NA	-0.52	-8.56	-0.47	9.05e-16	Reticulocyte fraction of red cells;
CESC	cis	rs453301	0.686	rs3895823	chr8:8873646	T/C	cg15556689	chr8:8085844	FLJ10661	-0.47	-5.62	-0.33	4.95e-8	Joint mobility (Beighton score);
CESC	cis	rs12477438	0.501	rs2516833	chr2:99777405	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.77	12.84	0.62	1.16e-29	Chronic sinus infection;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg26913791	chr1:47134196	ATPAF1	-0.5	-6.37	-0.36	8.16e-10	Ulcerative colitis;
CESC	cis	rs11690935	0.632	rs11690807	chr2:172628120	G/A	cg13550731	chr2:172543902	DYNC1I2	0.62	8.72	0.47	3.14e-16	Schizophrenia;
CESC	cis	rs1552244	1.000	rs7652935	chr3:10151138	T/C	cg08888203	chr3:10149979	C3orf24	0.47	5.91	0.34	1.05e-8	Alzheimer's disease;
CESC	cis	rs6570726	0.791	rs435671	chr6:145881215	A/G	cg23711669	chr6:146136114	FBXO30	0.98	15.12	0.68	1.11e-37	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9457247	0.935	rs1187530	chr6:167376812	C/T	cg07741184	chr6:167504864	NA	-0.3	-5.38	-0.31	1.62e-7	Crohn's disease;
CESC	cis	rs7914558	0.901	rs35525740	chr10:104941112	A/T	cg04362960	chr10:104952993	NT5C2	0.47	6.21	0.36	2.01e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs6860806	0.661	rs334902	chr5:131586559	C/G	cg11843238	chr5:131593191	PDLIM4	0.36	5.21	0.31	3.71e-7	Breast cancer;
CESC	cis	rs7512552	0.809	rs2794679	chr1:150324857	G/A	cg15654264	chr1:150340011	RPRD2	0.39	5.24	0.31	3.25e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs4006360	0.505	rs8067313	chr17:39290306	G/T	cg18442075	chr17:40169520	DNAJC7;NKIRAS2	-0.4	-5.07	-0.3	7.45e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs651907	0.557	rs7651721	chr3:101393583	C/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.46	5.82	0.34	1.69e-8	Colorectal cancer;
CESC	cis	rs7582720	1.000	rs72936872	chr2:203790889	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.38	0.41	1.99e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	trans	rs1493916	0.870	rs1389531	chr18:31386616	C/T	cg27147174	chr7:100797783	AP1S1	-0.49	-6.87	-0.39	4.48e-11	Life satisfaction;
CESC	cis	rs10489202	0.632	rs202268	chr1:167927339	T/C	cg24449463	chr1:168025552	DCAF6	-0.44	-5.56	-0.32	6.55e-8	Schizophrenia;
CESC	cis	rs7582720	1.000	rs6725887	chr2:203745885	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	-0.85	-7.0	-0.39	2.13e-11	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs854765	0.583	rs2350977	chr17:17802779	A/G	cg09796270	chr17:17721594	SREBF1	0.43	5.84	0.34	1.49e-8	Total body bone mineral density;
CESC	cis	rs3785574	0.962	rs56295011	chr17:61850359	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.11	19.72	0.77	6.87e-54	Height;
CESC	cis	rs7618915	0.501	rs6804145	chr3:52694198	C/T	cg07507251	chr3:52567010	NT5DC2	0.32	5.56	0.32	6.75e-8	Bipolar disorder;
CESC	cis	rs9902453	0.765	rs3102560	chr17:28029938	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.77	10.47	0.54	1.11e-21	Coffee consumption (cups per day);
CESC	cis	rs2228479	0.850	rs74251570	chr16:89910068	C/A	cg04013166	chr16:89971882	TCF25	0.72	5.75	0.33	2.41e-8	Skin colour saturation;
CESC	cis	rs1005224	0.963	rs2302592	chr14:76129287	C/G	cg25116370	chr14:76127843	TTLL5;C14orf1	0.39	5.21	0.3	3.74e-7	Large artery stroke;
CESC	cis	rs7208859	0.623	rs216446	chr17:28933718	T/G	cg13385521	chr17:29058706	SUZ12P	0.77	5.67	0.33	3.8e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs9837602	1.000	rs7610486	chr3:99732564	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.54	7.51	0.42	9.05e-13	Breast cancer;
CESC	cis	rs1448094	0.511	rs17345272	chr12:86165334	A/C	cg00310523	chr12:86230176	RASSF9	0.35	5.71	0.33	3.05e-8	Major depressive disorder;
CESC	cis	rs12220238	1.000	rs7096553	chr10:75957835	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.6	5.48	0.32	9.99e-8	Soluble interleukin-2 receptor subunit alpha;
CESC	cis	rs2204008	0.569	rs11495449	chr12:37995753	C/T	cg26384229	chr12:38710491	ALG10B	0.74	10.87	0.56	5.15e-23	Bladder cancer;
CESC	cis	rs72781680	0.678	rs2551341	chr2:24014778	G/T	cg08917208	chr2:24149416	ATAD2B	0.61	5.99	0.35	6.76e-9	Lymphocyte counts;
CESC	cis	rs34779708	0.931	rs34876468	chr10:35424450	G/A	cg03585969	chr10:35415529	CREM	0.76	10.09	0.53	1.81e-20	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs6496667	0.557	rs2589951	chr15:90958392	T/C	cg22089800	chr15:90895588	ZNF774	0.43	5.63	0.33	4.61e-8	Rheumatoid arthritis;
CESC	cis	rs4665809	0.590	rs4665313	chr2:26415897	A/G	cg08470875	chr2:26401718	FAM59B	-0.71	-7.68	-0.43	3.13e-13	Gut microbiome composition (summer);
CESC	cis	rs9309473	1.000	rs7585004	chr2:73666645	C/G	cg20560298	chr2:73613845	ALMS1	-0.45	-5.91	-0.34	1.06e-8	Metabolite levels;
CESC	cis	rs709400	1.000	rs61995780	chr14:104120612	A/G	cg24130564	chr14:104152367	KLC1	-0.42	-5.42	-0.32	1.36e-7	Body mass index;
CESC	trans	rs2727020	0.573	rs7925419	chr11:49231859	C/T	cg00717180	chr2:96193071	NA	-0.48	-6.82	-0.39	6.01e-11	Coronary artery disease;
CESC	cis	rs7937682	1.000	rs4936661	chr11:111587495	G/A	cg09085632	chr11:111637200	PPP2R1B	1.09	15.25	0.68	4.08e-38	Primary sclerosing cholangitis;
CESC	cis	rs7267979	1.000	rs422424	chr20:25445446	G/C	cg08601574	chr20:25228251	PYGB	0.37	5.31	0.31	2.31e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs6783573	0.510	rs11718490	chr3:46628763	C/T	cg21489266	chr3:46619131	LRRC2;TDGF1	-0.46	-6.5	-0.37	4.02e-10	Cerebrospinal fluid biomarker levels;
CESC	cis	rs7615952	0.576	rs6804482	chr3:125815762	C/T	cg06494592	chr3:125709126	NA	-0.52	-5.56	-0.32	6.58e-8	Blood pressure (smoking interaction);
CESC	cis	rs921968	0.565	rs6436070	chr2:219597960	A/G	cg02176678	chr2:219576539	TTLL4	-0.45	-8.11	-0.45	1.85e-14	Mean corpuscular hemoglobin concentration;
CESC	cis	rs4927850	0.918	rs4361313	chr3:195752260	A/G	cg00031303	chr3:195681400	NA	0.46	5.81	0.34	1.74e-8	Pancreatic cancer;
CESC	cis	rs17253792	0.822	rs10083499	chr14:56066590	T/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.83	6.18	0.36	2.36e-9	Putamen volume;
CESC	cis	rs6060960	0.502	rs6057968	chr20:30082779	A/T	cg13852791	chr20:30311386	BCL2L1	0.5	5.22	0.31	3.66e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg21871583	chr3:15374148	SH3BP5	-0.43	-6.25	-0.36	1.6e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs9790314	0.502	rs34972965	chr3:160984296	G/A	cg03342759	chr3:160939853	NMD3	-0.54	-7.7	-0.43	2.68e-13	Morning vs. evening chronotype;
CESC	cis	rs4132509	1.000	rs6681863	chr1:243982709	C/G	cg21452805	chr1:244014465	NA	0.5	6.21	0.36	2.09e-9	RR interval (heart rate);
CESC	cis	rs2014572	0.967	rs8106734	chr19:57763546	C/T	cg12963866	chr19:57752005	ZNF805	-0.47	-6.41	-0.37	6.66e-10	Hyperactive-impulsive symptoms;
CESC	cis	rs3785574	0.962	rs2247435	chr17:61892862	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.57	6.99	0.39	2.29e-11	Height;
CESC	cis	rs950776	0.518	rs12900783	chr15:78815523	G/A	cg24631222	chr15:78858424	CHRNA5	-0.4	-5.18	-0.3	4.45e-7	Sudden cardiac arrest;
CESC	cis	rs270601	0.770	rs1007602	chr5:131602166	T/C	cg09877947	chr5:131593287	PDLIM4	0.48	6.32	0.36	1.11e-9	Acylcarnitine levels;
CESC	cis	rs473651	0.935	rs578510	chr2:239343140	C/T	cg21699342	chr2:239360505	ASB1	0.55	9.41	0.5	2.44e-18	Multiple system atrophy;
CESC	cis	rs10504229	0.817	rs78138632	chr8:58191341	G/T	cg24829409	chr8:58192753	C8orf71	-0.74	-8.46	-0.46	1.77e-15	Developmental language disorder (linguistic errors);
CESC	cis	rs1799949	1.000	rs8176297	chr17:41203325	T/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.64	8.65	0.47	4.88e-16	Menopause (age at onset);
CESC	cis	rs1707322	1.000	rs785507	chr1:46541558	C/T	cg05343316	chr1:45956843	TESK2	-0.48	-5.66	-0.33	3.94e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs4689388	0.926	rs4688986	chr4:6285797	C/A	cg14416269	chr4:6271139	WFS1	0.49	8.17	0.45	1.26e-14	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs8031584	0.918	rs34331396	chr15:31248736	C/G	cg08704250	chr15:31115839	NA	-0.63	-8.23	-0.45	8.79e-15	Huntington's disease progression;
CESC	cis	rs992157	0.735	rs13392177	chr2:219112956	C/T	cg00012203	chr2:219082015	ARPC2	-0.8	-11.49	-0.58	4.77e-25	Colorectal cancer;
CESC	cis	rs3809566	0.526	rs35829897	chr15:63334688	G/C	cg05507819	chr15:63340323	TPM1	-0.79	-7.76	-0.43	1.85e-13	Platelet count;
CESC	cis	rs28647808	0.748	rs28502181	chr9:136257792	T/G	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.85	5.75	0.33	2.45e-8	Blood protein levels;
CESC	cis	rs854765	0.583	rs8078105	chr17:17853782	T/C	cg16928487	chr17:17741425	SREBF1	-0.57	-9.57	-0.51	7.66e-19	Total body bone mineral density;
CESC	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg11905131	chr22:24372483	LOC391322	0.7	10.0	0.52	3.49e-20	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs7091068	0.518	rs1572772	chr10:95432862	A/G	cg20715218	chr10:95462985	C10orf4	-0.47	-5.96	-0.34	8.08e-9	Urinary tract infection frequency;
CESC	cis	rs2576037	0.583	rs892586	chr18:44560429	C/A	cg19077165	chr18:44547161	KATNAL2	0.65	9.84	0.52	1.13e-19	Personality dimensions;
CESC	cis	rs7927771	0.864	rs3781626	chr11:47442893	A/T	cg05585544	chr11:47624801	NA	-0.41	-6.05	-0.35	4.91e-9	Subjective well-being;
CESC	cis	rs7618915	0.501	rs1866268	chr3:52719398	C/A	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.81	0.39	6.64e-11	Bipolar disorder;
CESC	cis	rs9916302	0.904	rs4795384	chr17:37716771	C/G	cg15445000	chr17:37608096	MED1	0.4	6.21	0.36	2.02e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs6582630	0.531	rs3850000	chr12:38483752	T/C	cg26384229	chr12:38710491	ALG10B	0.71	10.82	0.55	7.82e-23	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs6977955	0.877	rs9648346	chr7:28160113	C/G	cg23620719	chr7:28220237	JAZF1	0.44	5.04	0.3	8.53e-7	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs1577917	1.000	rs12196411	chr6:86779762	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-6.2	-0.36	2.14e-9	Response to antipsychotic treatment;
CESC	cis	rs3820068	0.581	rs61056912	chr1:15926296	A/G	cg17385448	chr1:15911702	AGMAT	0.44	7.16	0.4	7.97e-12	Systolic blood pressure;
CESC	cis	rs1879734	0.731	rs6665257	chr1:54161087	T/C	cg23596471	chr1:54105337	GLIS1	0.32	5.45	0.32	1.13e-7	Mitral valve prolapse;
CESC	cis	rs561341	0.783	rs512698	chr17:30292507	G/T	cg19193384	chr17:30244184	NA	-0.69	-6.46	-0.37	4.99e-10	Hip circumference adjusted for BMI;
CESC	cis	rs9322193	0.923	rs10782317	chr6:150075047	C/T	cg07701084	chr6:150067640	NUP43	-0.47	-6.65	-0.38	1.7e-10	Lung cancer;
CESC	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.61	0.38	2.1e-10	Prudent dietary pattern;
CESC	cis	rs9815354	0.767	rs73081341	chr3:41900335	A/T	cg03022575	chr3:42003672	ULK4	0.56	5.58	0.32	5.87e-8	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs7618915	0.547	rs34173654	chr3:52634605	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.47	6.69	0.38	1.35e-10	Bipolar disorder;
CESC	cis	rs3820928	1.000	rs10210763	chr2:227776029	G/T	cg11843606	chr2:227700838	RHBDD1	-0.43	-5.74	-0.33	2.55e-8	Pulmonary function;
CESC	cis	rs75477785	0.590	rs10489346	chr1:210235308	A/G	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.91	6.32	0.36	1.09e-9	Cleft lip with or without cleft palate;
CESC	trans	rs11264799	0.765	rs7531547	chr1:157623267	G/T	cg22691776	chr3:15032403	NR2C2	0.33	6.1	0.35	3.7e-9	IgA nephropathy;
CESC	cis	rs1153858	1.000	rs1288775	chr15:45661678	T/A	cg21132104	chr15:45694354	SPATA5L1	0.77	10.24	0.53	5.86e-21	Homoarginine levels;
CESC	cis	rs7577696	0.568	rs177082	chr2:32438350	A/T	cg02381751	chr2:32503542	YIPF4	0.46	5.16	0.3	4.77e-7	Inflammatory biomarkers;
CESC	cis	rs7044106	0.500	rs56725168	chr9:123492576	T/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.75	11.04	0.56	1.49e-23	Hip circumference adjusted for BMI;
CESC	cis	rs7914558	0.966	rs56946876	chr10:104653545	T/C	cg04362960	chr10:104952993	NT5C2	0.46	5.99	0.35	6.65e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs1577917	0.771	rs4383777	chr6:86435960	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.36	5.09	0.3	6.94e-7	Response to antipsychotic treatment;
CESC	trans	rs87938	1.000	rs376362	chr3:41111939	A/T	cg27294816	chr19:54372713	MYADM	0.37	6.22	0.36	1.88e-9	Bone mineral density (hip);
CESC	cis	rs597539	0.652	rs513615	chr11:68705504	G/T	cg21963583	chr11:68658836	MRPL21	0.38	5.13	0.3	5.62e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs7618501	1.000	rs11130221	chr3:49819102	C/G	cg24308560	chr3:49941425	MST1R	-0.5	-6.8	-0.39	7.06e-11	Intelligence (multi-trait analysis);
CESC	cis	rs752010	0.574	rs10890157	chr1:42117689	C/G	cg06885757	chr1:42089581	HIVEP3	0.48	7.61	0.42	4.72e-13	Lupus nephritis in systemic lupus erythematosus;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22483286	chr7:72727303	TRIM50	-0.58	-7.17	-0.4	7.45e-12	Gut microbiome composition (summer);
CESC	cis	rs9487023	1	rs9487023	chr6:109590004	A/G	cg21918786	chr6:109611834	NA	-0.36	-5.25	-0.31	3.12e-7	Red blood cell count;Mean corpuscular hemoglobin concentration;Neutrophil percentage of white cells;Lymphocyte percentage of white cells;Mean corpuscular hemoglobin;High light scatter reticulocyte percentage of red cells;Mean corpuscular volume;
CESC	cis	rs798554	0.679	rs1636250	chr7:2884433	T/C	cg19717773	chr7:2847554	GNA12	-0.47	-6.75	-0.38	9.38e-11	Height;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg26586917	chr4:153899740	FHDC1	-0.41	-6.18	-0.35	2.35e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs901683	1.000	rs36070535	chr10:46022238	T/C	cg16031567	chr10:46195673	NA	-0.77	-5.04	-0.3	8.57e-7	Red blood cell traits;Mean corpuscular volume;
CESC	cis	rs826838	1.000	rs11183214	chr12:38692938	C/T	cg13010199	chr12:38710504	ALG10B	0.61	8.84	0.48	1.32e-16	Heart rate;
CESC	cis	rs77956314	0.515	rs9804817	chr12:117440220	G/A	cg16111737	chr12:117408163	FBXW8	0.45	5.34	0.31	1.98e-7	Subcortical brain region volumes;Hippocampal volume;
CESC	cis	rs66887589	0.967	rs2892869	chr4:120521297	T/C	cg09307838	chr4:120376055	NA	-0.51	-6.85	-0.39	5.19e-11	Diastolic blood pressure;
CESC	cis	rs769267	0.965	rs2017964	chr19:19387149	T/C	cg03709012	chr19:19516395	GATAD2A	0.96	14.18	0.66	2.35e-34	Tonsillectomy;
CESC	cis	rs6088580	0.634	rs2225837	chr20:33005634	C/T	cg08999081	chr20:33150536	PIGU	-0.65	-11.29	-0.57	2.22e-24	Glomerular filtration rate (creatinine);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04266929	chr5:54522528	NA	0.52	6.08	0.35	4.08e-9	Gut microbiome composition (summer);
CESC	cis	rs59574136	1	rs59574136	chr7:2036460	T/C	cg02951883	chr7:2050386	MAD1L1	-0.58	-7.94	-0.44	5.88e-14	Autism spectrum disorder or schizophrenia;
CESC	cis	rs7084402	0.967	rs1658483	chr10:60288933	C/T	cg07615347	chr10:60278583	BICC1	0.6	9.41	0.5	2.54e-18	Refractive error;
CESC	trans	rs801193	1.000	rs62466794	chr7:66191579	G/A	cg26939375	chr7:64535504	NA	0.64	8.67	0.47	4.39e-16	Aortic root size;
CESC	cis	rs870825	0.616	rs55674580	chr4:185626605	C/G	cg04058563	chr4:185651563	MLF1IP	0.64	7.05	0.4	1.59e-11	Blood protein levels;
CESC	cis	rs1707322	1.000	rs6661500	chr1:46465662	T/C	cg06784218	chr1:46089804	CCDC17	0.35	5.95	0.34	8.32e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs780096	0.506	rs8395	chr2:27715207	T/A	cg24768116	chr2:27665128	KRTCAP3	-0.29	-5.35	-0.31	1.89e-7	Total body bone mineral density;
CESC	cis	rs7246657	1.000	rs35398388	chr19:37740358	A/G	cg23950597	chr19:37808831	NA	-0.61	-6.37	-0.36	8.38e-10	Coronary artery calcification;
CESC	cis	rs13108904	0.901	rs13124847	chr4:1278206	A/G	cg00684032	chr4:1343700	KIAA1530	0.4	5.56	0.32	6.51e-8	Obesity-related traits;
CESC	cis	rs12930096	1.000	rs12444633	chr16:11677857	A/C	cg07439791	chr16:11680400	LITAF	0.61	5.59	0.32	5.69e-8	QT interval;
CESC	cis	rs2455799	0.634	rs62243670	chr3:15918990	C/T	cg16303742	chr3:15540471	COLQ	-0.37	-5.69	-0.33	3.27e-8	Mean platelet volume;
CESC	cis	rs11638352	1.000	rs1820485	chr15:44430332	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	-0.56	-5.29	-0.31	2.53e-7	Lipoprotein phospholipase A2 activity in cardiovascular disease;
CESC	cis	rs2880765	0.743	rs8028240	chr15:86013248	A/G	cg10818794	chr15:86012489	AKAP13	-0.34	-5.31	-0.31	2.33e-7	Coronary artery disease;
CESC	trans	rs208520	0.661	rs851466	chr6:66840476	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.99	-13.08	-0.63	1.69e-30	Exhaled nitric oxide output;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg18505939	chr19:36427426	LRFN3	-0.44	-6.8	-0.39	7.11e-11	Gambling;
CESC	cis	rs875971	0.862	rs801204	chr7:66022921	T/C	cg10691866	chr7:65817282	TPST1	0.33	5.51	0.32	8.51e-8	Aortic root size;
CESC	cis	rs6580649	0.771	rs1034762	chr12:48389643	G/T	cg24011408	chr12:48396354	COL2A1	-0.4	-5.17	-0.3	4.54e-7	Lung cancer;
CESC	cis	rs2842992	0.724	rs2273823	chr6:160211485	T/C	cg11366901	chr6:160182831	ACAT2	0.64	8.17	0.45	1.24e-14	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs17376456	0.877	rs28575883	chr5:93346035	T/C	cg25358565	chr5:93447407	FAM172A	1.09	10.4	0.54	1.88e-21	Diabetic retinopathy;
CESC	cis	rs10461617	0.617	rs1423623	chr5:56065575	A/G	cg24531977	chr5:56204891	C5orf35	0.69	9.27	0.49	6.83e-18	Type 2 diabetes;
CESC	cis	rs34779708	0.931	rs6481935	chr10:35342959	C/T	cg04310649	chr10:35416472	CREM	-0.53	-6.42	-0.37	6.1e-10	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.56	-6.25	-0.36	1.67e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs9916302	0.706	rs8182252	chr17:37727950	T/C	cg00129232	chr17:37814104	STARD3	0.54	6.1	0.35	3.84e-9	Glomerular filtration rate (creatinine);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg08487038	chr9:6413045	UHRF2	0.5	6.35	0.36	9.23e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg01831166	chr2:198570100	MARS2	0.56	7.2	0.4	6.17e-12	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs1153858	1.000	rs12439274	chr15:45636667	A/G	cg21132104	chr15:45694354	SPATA5L1	0.83	11.19	0.57	4.65e-24	Homoarginine levels;
CESC	cis	rs9300255	0.596	rs10732573	chr12:123743883	G/C	cg19016782	chr12:123741754	C12orf65	-0.37	-5.68	-0.33	3.55e-8	Neutrophil percentage of white cells;
CESC	cis	rs11792861	0.816	rs72607157	chr9:111748001	T/G	cg13535736	chr9:111863775	C9orf5	-0.47	-6.16	-0.35	2.73e-9	Menarche (age at onset);
CESC	cis	rs6942756	1.000	rs6467233	chr7:128868656	C/T	cg02491457	chr7:128862824	NA	-0.71	-10.14	-0.53	1.27e-20	White matter hyperintensity burden;
CESC	cis	rs875971	0.862	rs6944374	chr7:65686929	C/G	cg11764359	chr7:65958608	NA	-0.72	-9.69	-0.51	3.32e-19	Aortic root size;
CESC	cis	rs4665809	1.000	rs4233708	chr2:26291345	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.67	-7.6	-0.42	4.99e-13	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26582338	chr3:155523741	C3orf33	-0.56	-6.04	-0.35	5.12e-9	Gut microbiome composition (summer);
CESC	cis	rs2346177	0.967	rs4953374	chr2:46654401	T/C	cg26688816	chr2:46740690	ATP6V1E2	-0.43	-5.18	-0.3	4.37e-7	HDL cholesterol;
CESC	cis	rs769267	1.000	rs2074090	chr19:19449686	G/T	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.43	-5.43	-0.32	1.24e-7	Tonsillectomy;
CESC	cis	rs3093024	0.935	rs10946216	chr6:167538897	T/C	cg23791538	chr6:167370224	RNASET2	0.42	5.19	0.3	4.27e-7	Rheumatoid arthritis;
CESC	cis	rs9815354	0.812	rs73071242	chr3:41993011	T/C	cg03022575	chr3:42003672	ULK4	0.67	5.88	0.34	1.23e-8	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs7309	0.622	rs4664396	chr2:161901650	C/T	cg16506815	chr2:162101123	NA	-0.38	-5.05	-0.3	8.15e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
CESC	cis	rs1003719	0.762	rs11701556	chr21:38455153	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.62	8.67	0.47	4.41e-16	Eye color traits;
CESC	cis	rs2361718	0.500	rs8068856	chr17:78100731	A/G	cg21238619	chr17:78079768	GAA	-0.36	-5.44	-0.32	1.21e-7	Yeast infection;
CESC	cis	rs4253772	0.515	rs74766656	chr22:46662497	A/G	cg10541313	chr22:46663664	TTC38	0.72	5.84	0.34	1.54e-8	LDL cholesterol;Cholesterol, total;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21317132	chr2:65215566	SLC1A4	-0.55	-6.15	-0.35	2.78e-9	Gut microbiome composition (summer);
CESC	cis	rs9399401	0.614	rs262125	chr6:142838355	A/T	cg03128060	chr6:142623767	GPR126	0.33	5.42	0.32	1.35e-7	Chronic obstructive pulmonary disease;
CESC	cis	rs13242816	1.000	rs17138708	chr7:116109062	T/G	cg04696780	chr7:116139425	CAV2	-0.63	-5.71	-0.33	2.98e-8	P wave duration;
CESC	cis	rs4555082	0.834	rs11849607	chr14:105745383	G/A	cg06808227	chr14:105710500	BRF1	-0.57	-6.55	-0.37	3.02e-10	Mean platelet volume;Platelet distribution width;
CESC	cis	rs60843830	1.000	rs3828165	chr2:220889	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.78	9.79	0.52	1.63e-19	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs12824058	0.831	rs4759658	chr12:130815872	C/T	cg26677194	chr12:130822605	PIWIL1	0.52	6.82	0.39	6.23e-11	Menopause (age at onset);
CESC	cis	rs3785574	0.962	rs7219920	chr17:61811642	C/G	cg06873352	chr17:61820015	STRADA	0.49	7.24	0.41	4.86e-12	Height;
CESC	cis	rs9916302	0.861	rs11078896	chr17:37415544	C/T	cg15445000	chr17:37608096	MED1	0.4	6.54	0.37	3.13e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs11229555	1.000	rs11229545	chr11:58386650	A/G	cg15696309	chr11:58395628	NA	-0.43	-5.64	-0.33	4.3e-8	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs6963495	0.818	rs17343556	chr7:105151272	C/T	cg13798780	chr7:105162888	PUS7	0.76	7.84	0.43	1.12e-13	Bipolar disorder (body mass index interaction);
CESC	cis	rs7659604	0.539	rs7660548	chr4:122730821	G/C	cg19748678	chr4:122722346	EXOSC9	0.78	9.69	0.51	3.39e-19	Type 2 diabetes;
CESC	cis	rs2073300	0.609	rs6137931	chr20:23376875	G/C	cg16736954	chr20:23401023	NAPB	0.8	6.25	0.36	1.67e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs7584330	0.737	rs60187585	chr2:238365159	C/T	cg14458575	chr2:238380390	NA	0.62	8.39	0.46	3.03e-15	Prostate cancer;
CESC	cis	rs9388451	0.626	rs1343115	chr6:126069817	C/G	cg05901451	chr6:126070800	HEY2	-0.61	-9.27	-0.49	6.65e-18	Brugada syndrome;
CESC	cis	rs155076	0.711	rs4770131	chr13:21897468	A/G	cg06138931	chr13:21896616	NA	0.68	6.52	0.37	3.56e-10	White matter hyperintensity burden;
CESC	cis	rs875971	0.862	rs11984115	chr7:65773859	C/T	cg11764359	chr7:65958608	NA	-0.78	-11.58	-0.58	2.21e-25	Aortic root size;
CESC	cis	rs9733	0.818	rs12130363	chr1:150688596	T/C	cg18016565	chr1:150552671	MCL1	-0.35	-5.89	-0.34	1.15e-8	Tonsillectomy;
CESC	cis	rs13191362	1.000	rs35583420	chr6:163214327	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.97	9.11	0.49	2.06e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	trans	rs561341	1.000	rs497479	chr17:30328605	C/T	cg20587970	chr11:113659929	NA	-1.39	-18.35	-0.75	4.13e-49	Hip circumference adjusted for BMI;
CESC	cis	rs9400467	0.506	rs12199233	chr6:111592317	G/A	cg15721981	chr6:111408429	SLC16A10	0.53	5.11	0.3	6.28e-7	Blood metabolite levels;Amino acid levels;
CESC	cis	rs7659604	0.702	rs58649165	chr4:122693752	C/A	cg06713675	chr4:122721982	EXOSC9	-0.39	-5.64	-0.33	4.43e-8	Type 2 diabetes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08555013	chr4:83932063	LIN54	0.6	6.46	0.37	4.92e-10	Gut microbiome composition (summer);
CESC	cis	rs4665809	0.652	rs6727974	chr2:26524639	A/G	cg27170947	chr2:26402098	FAM59B	0.61	7.09	0.4	1.19e-11	Gut microbiome composition (summer);
CESC	cis	rs910316	0.737	rs175080	chr14:75513828	G/A	cg11812906	chr14:75593930	NEK9	-0.82	-13.36	-0.63	1.72e-31	Height;
CESC	cis	rs644799	0.710	rs522536	chr11:95528714	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.77	10.82	0.55	8.02e-23	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs6121246	0.559	rs6060950	chr20:30378031	T/C	cg13852791	chr20:30311386	BCL2L1	0.85	11.17	0.57	5.35e-24	Mean corpuscular hemoglobin;
CESC	cis	rs78456975	0.506	rs10167704	chr2:1571037	G/C	cg12573674	chr2:1569213	NA	-0.47	-5.35	-0.31	1.93e-7	Placebo response in major depressive disorder (% change in symptom score);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg13503583	chr14:105282271	NA	-0.51	-6.6	-0.38	2.28e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs7243790	0.837	rs1992129	chr18:51946093	G/T	cg04730925	chr18:51795821	POLI	-0.43	-5.76	-0.33	2.33e-8	Diastolic blood pressure;
CESC	trans	rs7618501	0.699	rs2681781	chr3:49898273	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.49	6.8	0.39	6.79e-11	Intelligence (multi-trait analysis);
CESC	cis	rs1348850	0.526	rs6723063	chr2:178491398	C/T	cg22681709	chr2:178499509	PDE11A	-0.52	-5.36	-0.31	1.82e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11388866	chr21:40752116	WRB	0.63	7.13	0.4	9.61e-12	Gut microbiome composition (summer);
CESC	cis	rs6912958	0.781	rs2300906	chr6:88207155	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.36	-5.93	-0.34	9.18e-9	Monocyte percentage of white cells;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg03044510	chr21:27107978	ATP5J;GABPA	0.47	6.26	0.36	1.53e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs151227923	1	rs151227923	chr7:155106564	C/T	cg14927855	chr7:155151427	NA	0.49	8.0	0.44	3.96e-14	Stem cell growth factor beta levels;
CESC	cis	rs4727963	0.765	rs6971635	chr7:122704188	C/T	cg03640110	chr7:122635026	TAS2R16	0.41	6.49	0.37	4.11e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
CESC	cis	rs11690935	0.686	rs10165126	chr2:172820315	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.67	-9.93	-0.52	5.85e-20	Schizophrenia;
CESC	cis	rs3820068	0.581	rs72645871	chr1:15926142	G/A	cg17385448	chr1:15911702	AGMAT	0.41	6.69	0.38	1.33e-10	Systolic blood pressure;
CESC	cis	rs1707322	1.000	rs34446427	chr1:46417655	A/C	cg03146154	chr1:46216737	IPP	0.72	9.82	0.52	1.31e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs34638657	0.673	rs62045961	chr16:82199723	A/G	cg09439754	chr16:82129088	HSD17B2	-0.37	-6.42	-0.37	6.31e-10	Lung adenocarcinoma;
CESC	cis	rs875971	0.862	rs6960446	chr7:65733259	A/G	cg11764359	chr7:65958608	NA	-0.79	-11.67	-0.58	1.16e-25	Aortic root size;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg04653284	chr16:28875071	SH2B1	-0.51	-6.16	-0.35	2.69e-9	Ulcerative colitis;
CESC	cis	rs10540	1.000	rs79440439	chr11:478147	A/C	cg03934478	chr11:495069	RNH1	0.52	5.05	0.3	8.42e-7	Body mass index;
CESC	cis	rs2180341	0.804	rs6902233	chr6:127555963	A/G	cg24812749	chr6:127587940	RNF146	0.95	11.43	0.57	7.26e-25	Breast cancer;
CESC	cis	rs6540556	0.723	rs10863785	chr1:209908876	C/T	cg23920097	chr1:209922102	NA	0.39	5.07	0.3	7.64e-7	Red blood cell count;
CESC	cis	rs5750830	0.649	rs4821893	chr22:39797779	G/A	cg11247378	chr22:39784982	NA	-0.63	-9.31	-0.5	5.01e-18	Intelligence (multi-trait analysis);
CESC	cis	rs9649213	0.593	rs7776638	chr7:97993506	C/T	cg21770322	chr7:97807741	LMTK2	0.57	8.84	0.48	1.39e-16	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs2204008	0.748	rs11514352	chr12:38246954	C/T	cg26384229	chr12:38710491	ALG10B	0.71	10.11	0.53	1.52e-20	Bladder cancer;
CESC	cis	rs7264396	0.580	rs6119655	chr20:34412049	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.81	-10.45	-0.54	1.21e-21	Total cholesterol levels;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg11150667	chr3:195595368	TNK2	0.48	6.31	0.36	1.14e-9	Fibrinogen levels;
CESC	cis	rs6775745	0.654	rs1976992	chr3:131779012	G/A	cg12213930	chr3:131751605	CPNE4	0.48	5.5	0.32	8.82e-8	Neutrophil count;
CESC	cis	rs503341	0.756	rs11231591	chr11:63587986	G/T	cg04362095	chr11:63592001	C11orf84	-0.56	-7.98	-0.44	4.36e-14	Pulse pressure;
CESC	cis	rs6433857	0.505	rs7561255	chr2:181369216	A/G	cg23363182	chr2:181467187	NA	-0.42	-5.96	-0.34	7.9e-9	Body mass index;
CESC	cis	rs3733585	0.699	rs6449171	chr4:9965998	C/T	cg11266682	chr4:10021025	SLC2A9	0.58	10.41	0.54	1.67e-21	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs2274273	0.588	rs11158037	chr14:55832152	C/A	cg04306507	chr14:55594613	LGALS3	0.29	5.17	0.3	4.65e-7	Protein biomarker;
CESC	cis	rs73206853	0.686	rs73206895	chr12:110879968	A/G	cg12870014	chr12:110450643	ANKRD13A	0.63	5.18	0.3	4.34e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs11098499	0.866	rs13105020	chr4:120285688	G/T	cg09307838	chr4:120376055	NA	0.87	12.16	0.6	2.41e-27	Corneal astigmatism;
CESC	cis	rs4642101	0.662	rs57411588	chr3:12820384	C/G	cg24848339	chr3:12840334	CAND2	0.38	6.02	0.35	5.8e-9	QRS complex (12-leadsum);
CESC	cis	rs1348850	0.526	rs6723014	chr2:178410586	G/A	cg22681709	chr2:178499509	PDE11A	-0.5	-5.3	-0.31	2.44e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs10791097	0.694	rs7106995	chr11:130758152	G/T	cg12179176	chr11:130786555	SNX19	0.65	10.09	0.53	1.76e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs9611519	0.565	rs8135524	chr22:41436442	T/C	cg03806693	chr22:41940476	POLR3H	-0.51	-6.0	-0.35	6.59e-9	Neuroticism;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27007625	chr2:240896183	NA	-0.6	-6.48	-0.37	4.55e-10	Gut microbiome composition (summer);
CESC	trans	rs9945268	0.964	rs7227150	chr18:59331815	A/G	cg24536146	chr1:207997166	NA	-0.4	-6.31	-0.36	1.19e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs7084402	0.764	rs2033149	chr10:60264741	A/T	cg07615347	chr10:60278583	BICC1	0.59	9.22	0.49	9.73e-18	Refractive error;
CESC	cis	rs3126085	0.935	rs4361987	chr1:152229701	A/G	cg03465714	chr1:152285911	FLG	-0.46	-5.7	-0.33	3.14e-8	Atopic dermatitis;
CESC	cis	rs6693567	0.545	rs1566225	chr1:150415990	G/C	cg09579323	chr1:150459698	TARS2	0.48	6.0	0.35	6.34e-9	Migraine;
CESC	cis	rs270601	0.913	rs273916	chr5:131659830	C/A	cg24060327	chr5:131705240	SLC22A5	-0.77	-10.78	-0.55	1.05e-22	Acylcarnitine levels;
CESC	cis	rs4909189	1.000	rs4909189	chr7:158136986	A/T	cg27057461	chr7:158136379	PTPRN2	0.38	5.25	0.31	3.15e-7	Response to amphetamines;
CESC	cis	rs919433	0.889	rs788001	chr2:198213720	C/T	cg20885578	chr2:198174922	NA	0.4	5.42	0.32	1.31e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs5753618	0.583	rs5753601	chr22:31798259	G/T	cg13145458	chr22:31556086	RNF185	-0.5	-5.96	-0.34	7.96e-9	Colorectal cancer;
CESC	cis	rs6732160	0.656	rs2043093	chr2:73407342	G/C	cg01422370	chr2:73384389	NA	0.45	7.6	0.42	5.07e-13	Intelligence (multi-trait analysis);
CESC	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg06074448	chr4:187884817	NA	-0.38	-5.52	-0.32	8.08e-8	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4975616	0.843	rs4975615	chr5:1315343	C/T	cg07493874	chr5:1342172	CLPTM1L	0.37	6.83	0.39	5.81e-11	Lung cancer;
CESC	cis	rs4664308	1.000	rs10929966	chr2:160908341	C/T	cg03641300	chr2:160917029	PLA2R1	-0.67	-10.16	-0.53	1.08e-20	Idiopathic membranous nephropathy;
CESC	cis	rs3793683	0.545	rs12784407	chr10:134589631	A/G	cg27286337	chr10:134555280	INPP5A	0.7	8.03	0.44	3.21e-14	Migraine;
CESC	cis	rs6032067	0.673	rs4522674	chr20:43893276	T/C	cg10761708	chr20:43804764	PI3	0.41	5.14	0.3	5.43e-7	Blood protein levels;
CESC	cis	rs938554	0.692	rs13125209	chr4:9982044	A/C	cg11266682	chr4:10021025	SLC2A9	0.36	5.03	0.3	8.88e-7	Blood metabolite levels;
CESC	cis	rs4851551	0.543	rs62156407	chr2:102824622	C/T	cg09363443	chr2:102758946	NA	0.65	5.26	0.31	2.94e-7	Blood protein levels;
CESC	cis	rs4853012	0.838	rs12619982	chr2:74356022	G/A	cg05890377	chr2:74357713	NA	0.8	10.16	0.53	1.06e-20	Gestational age at birth (maternal effect);
CESC	cis	rs7914558	0.752	rs7896519	chr10:104866863	C/T	cg04362960	chr10:104952993	NT5C2	0.46	5.81	0.34	1.74e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs546131	0.928	rs572690	chr11:34833614	A/G	cg06937548	chr11:34938143	PDHX;APIP	0.52	6.59	0.38	2.38e-10	Lung disease severity in cystic fibrosis;
CESC	cis	rs9916302	0.861	rs11658219	chr17:37709782	G/A	cg20243544	chr17:37824526	PNMT	0.48	5.91	0.34	1.07e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs11969893	0.649	rs9485415	chr6:101279459	C/T	cg12253828	chr6:101329408	ASCC3	0.94	8.23	0.45	8.37e-15	Economic and political preferences (immigration/crime);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15424593	chr16:34777963	NA	-0.5	-6.38	-0.36	7.96e-10	Gut microbiome composition (summer);
CESC	cis	rs9549367	0.713	rs11620600	chr13:113829090	G/A	cg18105134	chr13:113819100	PROZ	-0.71	-8.53	-0.46	1.13e-15	Platelet distribution width;
CESC	cis	rs7772486	0.686	rs857879	chr6:145974043	C/A	cg05347473	chr6:146136440	FBXO30	-0.53	-6.97	-0.39	2.51e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4930103	0.935	rs2071095	chr11:2020627	C/A	cg23202291	chr11:1979235	NA	0.35	5.04	0.3	8.79e-7	DNA methylation (parent-of-origin);DNA methylation (variation);
CESC	cis	rs3733585	0.673	rs10000983	chr4:9951606	T/C	cg00071950	chr4:10020882	SLC2A9	-0.7	-11.53	-0.58	3.42e-25	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs3888647	0.561	rs4758617	chr11:2995185	T/A	cg25174290	chr11:3078921	CARS	0.52	7.06	0.4	1.48e-11	Type 2 diabetes;
CESC	cis	rs9430161	0.579	rs7542158	chr1:11040193	G/A	cg02454025	chr1:11042201	C1orf127	0.87	13.72	0.64	9.82e-33	Ewing sarcoma;
CESC	cis	rs6732160	0.809	rs13387480	chr2:73371007	C/T	cg01422370	chr2:73384389	NA	0.42	7.2	0.4	6.17e-12	Intelligence (multi-trait analysis);
CESC	cis	rs40363	0.645	rs250630	chr16:3524242	C/T	cg21433313	chr16:3507492	NAT15	0.51	8.54	0.46	1.1e-15	Tuberculosis;
CESC	cis	rs7267979	0.932	rs367666	chr20:25449818	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.83	15.78	0.7	5.17e-40	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs6088580	0.609	rs2378205	chr20:33110803	C/G	cg06115741	chr20:33292138	TP53INP2	0.45	5.8	0.34	1.88e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs10504229	0.724	rs72650827	chr8:58126884	A/T	cg21724239	chr8:58056113	NA	0.57	5.76	0.33	2.29e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs1008375	0.966	rs4515155	chr4:17696477	G/T	cg15017067	chr4:17643749	FAM184B	0.37	5.21	0.3	3.74e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	trans	rs324780	0.506	rs370604	chr12:83926427	C/T	cg22140261	chr22:42466895	NAGA	-0.48	-6.12	-0.35	3.34e-9	Vertical cup-disc ratio;
CESC	cis	rs12079745	1.000	rs12076510	chr1:169162084	A/G	cg09363564	chr1:169337483	NME7;BLZF1	-0.71	-5.51	-0.32	8.29e-8	QT interval;
CESC	cis	rs9322193	0.923	rs2297930	chr6:150039496	T/C	cg04369109	chr6:150039330	LATS1	-0.42	-5.83	-0.34	1.61e-8	Lung cancer;
CESC	cis	rs10504229	0.636	rs77753517	chr8:58115897	C/T	cg24829409	chr8:58192753	C8orf71	-0.58	-7.2	-0.4	6.31e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs2073300	1.000	rs6137961	chr20:23443102	G/T	cg12062639	chr20:23401060	NAPB	0.91	6.41	0.37	6.51e-10	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs4660306	1.000	rs4660870	chr1:45995231	T/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.51	-6.54	-0.37	3.07e-10	Homocysteine levels;
CESC	cis	rs6963495	0.872	rs1569134	chr7:105158228	T/C	cg13798780	chr7:105162888	PUS7	0.78	8.04	0.44	2.99e-14	Bipolar disorder (body mass index interaction);
CESC	cis	rs34330	0.562	rs11055024	chr12:12858969	A/G	cg04607235	chr12:12878440	APOLD1	-0.84	-9.1	-0.49	2.3e-17	Systemic lupus erythematosus;
CESC	cis	rs116095464	0.558	rs7715108	chr5:264661	A/G	cg10591111	chr5:226296	SDHA	-0.52	-6.35	-0.36	9.51e-10	Breast cancer;
CESC	cis	rs4566357	1.000	rs2177597	chr2:227922546	C/T	cg11843606	chr2:227700838	RHBDD1	-0.42	-5.28	-0.31	2.71e-7	Coronary artery disease;
CESC	cis	rs10540	1.000	rs117339389	chr11:505025	T/A	cg03352830	chr11:487213	PTDSS2	0.75	7.18	0.4	7.06e-12	Body mass index;
CESC	cis	rs7618501	0.521	rs2883059	chr3:49902160	C/T	cg24308560	chr3:49941425	MST1R	0.63	9.28	0.5	6.27e-18	Intelligence (multi-trait analysis);
CESC	cis	rs1799949	1.000	rs4793191	chr17:41204377	A/G	cg05368731	chr17:41323189	NBR1	0.75	10.35	0.54	2.72e-21	Menopause (age at onset);
CESC	cis	rs7666738	1.000	rs880471	chr4:98922541	C/T	cg17366294	chr4:99064904	C4orf37	0.51	6.62	0.38	1.93e-10	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9486715	0.758	rs2971610	chr6:97027380	C/T	cg18709589	chr6:96969512	KIAA0776	-0.45	-6.39	-0.37	7.52e-10	Headache;
CESC	cis	rs7666738	0.830	rs7664169	chr4:99037859	C/T	cg24818145	chr4:99064322	C4orf37	-0.39	-5.18	-0.3	4.46e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg17377491	chr11:112096999	PTS	-0.42	-6.09	-0.35	3.99e-9	Gambling;
CESC	cis	rs17376456	0.569	rs7713956	chr5:93133185	T/C	cg25358565	chr5:93447407	FAM172A	-0.71	-7.57	-0.42	6.21e-13	Diabetic retinopathy;
CESC	cis	rs17666538	0.585	rs6559064	chr8:623061	G/A	cg23958373	chr8:599963	NA	0.82	5.92	0.34	1.02e-8	IgG glycosylation;
CESC	cis	rs7107174	0.579	rs10793299	chr11:78018954	T/A	cg02023728	chr11:77925099	USP35	0.48	6.27	0.36	1.46e-9	Testicular germ cell tumor;
CESC	cis	rs709400	0.930	rs10134399	chr14:104083457	G/A	cg12935359	chr14:103987150	CKB	-0.44	-5.61	-0.33	5.14e-8	Body mass index;
CESC	cis	rs3892630	0.588	rs12610342	chr19:33250690	C/T	cg13157960	chr19:33183277	NUDT19	0.54	5.31	0.31	2.32e-7	Red blood cell traits;
CESC	cis	rs7178909	0.872	rs28468074	chr15:90435600	C/T	cg19708238	chr15:90437601	AP3S2	0.43	6.23	0.36	1.86e-9	Common traits (Other);
CESC	cis	rs2832191	0.692	rs8134627	chr21:30349069	C/T	cg08807101	chr21:30365312	RNF160	-0.91	-14.05	-0.65	6.69e-34	Dental caries;
CESC	cis	rs9926296	0.682	rs467357	chr16:89717397	A/G	cg03605463	chr16:89740564	NA	0.66	7.83	0.43	1.14e-13	Vitiligo;
CESC	cis	rs2777491	0.915	rs7178777	chr15:41634588	C/A	cg02330683	chr15:41787940	ITPKA	0.44	6.51	0.37	3.74e-10	Ulcerative colitis;
CESC	cis	rs8062405	0.824	rs4788084	chr16:28539848	C/T	cg07382826	chr16:28625726	SULT1A1	0.31	5.05	0.3	8.32e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs3820068	0.603	rs72645887	chr1:15929905	G/C	cg13390004	chr1:15929781	NA	0.35	5.58	0.32	5.83e-8	Systolic blood pressure;
CESC	cis	rs59574136	1	rs59574136	chr7:2036460	T/C	cg08027265	chr7:2291960	NA	-0.36	-5.48	-0.32	1e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs7811142	1.000	rs11766752	chr7:100073292	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.87	9.17	0.49	1.38e-17	Platelet count;
CESC	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.48	-5.2	-0.3	4.05e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs1030877	0.515	rs2576736	chr2:105890971	C/T	cg02079111	chr2:105885981	TGFBRAP1	0.5	6.52	0.37	3.61e-10	Obesity-related traits;
CESC	cis	rs6964587	0.839	rs17731846	chr7:91440342	A/G	cg17063962	chr7:91808500	NA	0.48	6.19	0.36	2.22e-9	Breast cancer;
CESC	cis	rs7714584	1.000	rs7736873	chr5:150258482	T/C	cg22134413	chr5:150180641	NA	0.48	5.35	0.31	1.86e-7	Crohn's disease;
CESC	cis	rs9473147	0.543	rs1004173	chr6:47445017	C/T	cg20196966	chr6:47445060	CD2AP	0.39	5.03	0.3	9.22e-7	Platelet distribution width;Mean platelet volume;
CESC	cis	rs1008375	1.000	rs56974987	chr4:17627856	G/A	cg15017067	chr4:17643749	FAM184B	0.4	5.77	0.33	2.23e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs80282103	0.618	rs11816485	chr10:1147974	T/C	cg08668510	chr10:1095578	IDI1	0.76	6.28	0.36	1.36e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs9640161	0.789	rs13223702	chr7:150058968	G/A	cg17279839	chr7:150038598	RARRES2	0.48	5.75	0.33	2.51e-8	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs875971	0.660	rs801211	chr7:66015689	T/G	cg18876405	chr7:65276391	NA	-0.57	-7.75	-0.43	1.97e-13	Aortic root size;
CESC	cis	rs7296418	0.961	rs1790121	chr12:123604492	G/A	cg00376283	chr12:123451042	ABCB9	0.72	10.31	0.54	3.58e-21	Platelet count;
CESC	cis	rs208520	0.690	rs176289	chr6:66766522	C/T	cg07460842	chr6:66804631	NA	-0.96	-13.07	-0.63	1.89e-30	Exhaled nitric oxide output;
CESC	cis	rs853679	0.517	rs9468292	chr6:28095355	G/A	cg20151795	chr6:28129481	ZNF389	0.44	5.74	0.33	2.6e-8	Depression;
CESC	cis	rs7647973	0.600	rs13064780	chr3:49274826	T/G	cg06212747	chr3:49208901	KLHDC8B	0.7	10.45	0.54	1.24e-21	Menarche (age at onset);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg14839905	chr11:68183723	LRP5	0.47	6.18	0.35	2.35e-9	Fibrinogen levels;
CESC	cis	rs826838	0.900	rs1403523	chr12:39130570	T/A	cg13010199	chr12:38710504	ALG10B	-0.45	-6.27	-0.36	1.48e-9	Heart rate;
CESC	trans	rs7866350	0.604	rs1935389	chr9:100994470	A/G	cg04238871	chr10:126431886	FAM53B	0.44	6.06	0.35	4.63e-9	Post-traumatic stress disorder;
CESC	cis	rs3820928	0.839	rs10197773	chr2:227824835	G/A	cg11843606	chr2:227700838	RHBDD1	-0.44	-5.67	-0.33	3.79e-8	Pulmonary function;
CESC	cis	rs9640161	0.789	rs6964110	chr7:150041836	A/C	cg27494647	chr7:150038898	RARRES2	0.43	5.64	0.33	4.26e-8	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg07677032	chr17:61819896	STRADA	0.41	5.37	0.31	1.75e-7	Prudent dietary pattern;
CESC	cis	rs17433780	0.897	rs17434151	chr1:89500526	G/T	cg09516651	chr1:89888402	LOC400759	0.68	9.56	0.51	8.55e-19	Carotid intima media thickness;
CESC	cis	rs829661	0.947	rs829665	chr2:30724701	T/A	cg17749961	chr2:30669863	LCLAT1	1.05	9.57	0.51	7.98e-19	Midgestational circulating levels of PBDEs (fetal genetic effect);
CESC	cis	rs35110281	0.805	rs2838330	chr21:45023876	T/A	cg21573476	chr21:45109991	RRP1B	-0.46	-6.34	-0.36	9.62e-10	Mean corpuscular volume;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg09709060	chr11:95522957	CEP57;FAM76B	0.58	7.64	0.42	3.93e-13	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs2030746	1.000	rs2030746	chr2:121309488	C/T	cg15455772	chr8:33269701	FUT10	0.43	6.03	0.35	5.45e-9	LDL cholesterol;Total cholesterol levels;LDL cholesterol levels;
CESC	trans	rs916888	0.773	rs199457	chr17:44795469	C/T	cg10053473	chr17:62856997	LRRC37A3	-0.72	-7.62	-0.42	4.44e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs2625529	0.617	rs3784313	chr15:72187519	G/T	cg16672083	chr15:72433130	SENP8	0.45	6.77	0.38	8.17e-11	Red blood cell count;
CESC	trans	rs2120243	0.647	rs7632702	chr3:157145903	C/T	cg23109721	chr2:106886537	NA	-0.39	-6.13	-0.35	3.14e-9	Hepatocellular carcinoma in hepatitis B infection;
CESC	cis	rs1832871	0.672	rs9457345	chr6:158743098	A/G	cg07165851	chr6:158734300	TULP4	0.59	6.41	0.37	6.63e-10	Height;
CESC	cis	rs722599	0.748	rs61978948	chr14:75363369	G/A	cg11812906	chr14:75593930	NEK9	-0.47	-5.61	-0.33	5.15e-8	IgG glycosylation;
CESC	cis	rs1559088	0.847	rs3786933	chr19:33602881	C/T	cg27124370	chr19:33622961	WDR88	0.45	5.86	0.34	1.34e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs2932538	0.883	rs6701351	chr1:113139196	G/A	cg22162597	chr1:113214053	CAPZA1	0.49	6.56	0.37	2.84e-10	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CESC	cis	rs116095464	0.558	rs10079760	chr5:230778	A/G	cg10591111	chr5:226296	SDHA	-0.52	-6.53	-0.37	3.4e-10	Breast cancer;
CESC	cis	rs6500602	0.727	rs4786510	chr16:4571247	A/G	cg08645402	chr16:4508243	NA	0.54	8.71	0.47	3.29e-16	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25386411	chr1:232766478	NA	0.55	6.06	0.35	4.55e-9	Gut microbiome composition (summer);
CESC	cis	rs7520050	0.807	rs4660312	chr1:46110572	A/G	cg03146154	chr1:46216737	IPP	0.52	6.88	0.39	4.28e-11	Red blood cell count;Reticulocyte count;
CESC	cis	rs3768617	0.510	rs7525917	chr1:183065406	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.85	13.25	0.63	4.47e-31	Fuchs's corneal dystrophy;
CESC	cis	rs820218	0.892	rs820215	chr17:73693810	A/G	cg01592526	chr17:73663357	RECQL5;SAP30BP	-0.48	-6.54	-0.37	3.09e-10	Rotator cuff tears;
CESC	cis	rs10504229	0.953	rs66815941	chr8:58187306	C/T	cg05313129	chr8:58192883	C8orf71	-0.55	-6.29	-0.36	1.34e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs9916302	0.851	rs11868029	chr17:37650304	A/G	cg07936489	chr17:37558343	FBXL20	-0.79	-11.12	-0.56	7.81e-24	Glomerular filtration rate (creatinine);
CESC	cis	rs10927875	0.518	rs1763597	chr1:16343297	C/T	cg22431228	chr1:16359049	CLCNKA	-0.52	-9.9	-0.52	7.22e-20	Dilated cardiomyopathy;
CESC	cis	rs4819052	0.851	rs28501512	chr21:46676702	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.47	5.84	0.34	1.49e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07353731	chr12:123341735	HIP1R	-0.65	-7.4	-0.41	1.86e-12	Gut microbiome composition (summer);
CESC	cis	rs7223966	1.000	rs8077265	chr17:61732727	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	7.55	0.42	7e-13	Hip circumference adjusted for BMI;Body mass index;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03028685	chr10:99078963	FRAT1	0.58	6.82	0.39	6.22e-11	Gut microbiome composition (summer);
CESC	cis	rs4481887	1.000	rs7527822	chr1:248467301	A/G	cg00666640	chr1:248458726	OR2T12	0.38	6.73	0.38	1.03e-10	Common traits (Other);
CESC	cis	rs40363	0.645	rs4786421	chr16:3522303	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.53	7.0	0.4	2.08e-11	Tuberculosis;
CESC	cis	rs8114671	0.662	rs6088664	chr20:33551100	G/A	cg07148914	chr20:33460835	GGT7	0.44	5.66	0.33	3.83e-8	Height;
CESC	cis	rs2243480	0.901	rs73142137	chr7:65343442	A/T	cg12463550	chr7:65579703	CRCP	0.69	5.53	0.32	7.85e-8	Diabetic kidney disease;
CESC	cis	rs875971	0.767	rs61348003	chr7:66005934	C/T	cg11764359	chr7:65958608	NA	0.79	11.32	0.57	1.67e-24	Aortic root size;
CESC	cis	rs7666738	0.830	rs13122054	chr4:98972974	G/A	cg03467027	chr4:99064603	C4orf37	0.43	5.48	0.32	1.01e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2288912	0.807	rs3760626	chr19:45457105	A/G	cg09555818	chr19:45449301	APOC2	0.41	6.54	0.37	3.08e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs2354432	1.000	rs7514864	chr1:146690102	T/C	cg25205988	chr1:146714368	CHD1L	1.08	11.4	0.57	8.97e-25	Mitochondrial DNA levels;
CESC	cis	rs9790314	0.580	rs10936227	chr3:161043869	A/C	cg03342759	chr3:160939853	NMD3	-0.44	-6.28	-0.36	1.41e-9	Morning vs. evening chronotype;
CESC	cis	rs4665809	0.525	rs4665324	chr2:26447147	A/C	cg04944784	chr2:26401820	FAM59B	-0.96	-10.5	-0.54	8.76e-22	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23477849	chr19:5698492	LONP1	-0.57	-6.45	-0.37	5.17e-10	Gut microbiome composition (summer);
CESC	cis	rs6866344	0.697	rs11749438	chr5:178131245	C/T	cg10224037	chr5:178157518	ZNF354A	0.67	7.44	0.42	1.39e-12	Neutrophil percentage of white cells;
CESC	cis	rs10504229	0.683	rs55807014	chr8:58131801	T/C	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg27094323	chr7:1216898	NA	-0.37	-5.18	-0.3	4.4e-7	Longevity;Endometriosis;
CESC	cis	rs2425143	1.000	rs2378409	chr20:34392464	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.79	-7.16	-0.4	7.72e-12	Blood protein levels;
CESC	cis	rs9487051	0.714	rs1546722	chr6:109625797	A/G	cg01475377	chr6:109611718	NA	-0.43	-6.66	-0.38	1.6e-10	Reticulocyte fraction of red cells;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06551493	chr7:77166702	PTPN12	0.53	6.39	0.37	7.53e-10	Gut microbiome composition (summer);
CESC	cis	rs2014572	1.000	rs2014572	chr19:57760018	G/A	cg12963866	chr19:57752005	ZNF805	-0.47	-6.28	-0.36	1.38e-9	Hyperactive-impulsive symptoms;
CESC	trans	rs941207	0.542	rs6581106	chr12:57190543	G/A	cg26462586	chr2:11164677	NA	0.38	6.1	0.35	3.66e-9	Platelet count;
CESC	cis	rs3204270	0.500	rs62077175	chr17:79649568	G/T	cg26965718	chr17:79658957	HGS	-0.74	-5.65	-0.33	4.16e-8	Dental caries;
CESC	cis	rs950776	0.616	rs12901300	chr15:78892952	G/A	cg06917634	chr15:78832804	PSMA4	0.56	7.26	0.41	4.24e-12	Sudden cardiac arrest;
CESC	cis	rs11098499	0.604	rs17051352	chr4:120581427	G/A	cg09307838	chr4:120376055	NA	0.75	9.29	0.5	6.05e-18	Corneal astigmatism;
CESC	cis	rs9393777	0.513	rs13215020	chr6:26656073	G/A	cg12826209	chr6:26865740	GUSBL1	0.73	8.13	0.45	1.7e-14	Intelligence (multi-trait analysis);
CESC	cis	rs6496667	0.510	rs7495784	chr15:91068882	T/C	cg10434728	chr15:90938212	IQGAP1	-0.33	-5.27	-0.31	2.77e-7	Rheumatoid arthritis;
CESC	cis	rs78456975	1.000	rs13414537	chr2:1556330	C/T	cg26248373	chr2:1572462	NA	-0.58	-5.22	-0.31	3.68e-7	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs4253772	0.550	rs715515	chr22:46720921	G/A	cg24881330	chr22:46731750	TRMU	0.78	5.94	0.34	9.12e-9	LDL cholesterol;Cholesterol, total;
CESC	cis	rs7927592	0.513	rs653056	chr11:68203625	T/C	cg01657329	chr11:68192670	LRP5	-0.55	-7.23	-0.41	5.07e-12	Total body bone mineral density;
CESC	cis	rs3126085	0.935	rs1496045	chr1:152184704	C/T	cg26876637	chr1:152193138	HRNR	0.48	5.44	0.32	1.21e-7	Atopic dermatitis;
CESC	cis	rs27434	0.529	rs34757	chr5:96152588	T/C	cg16492584	chr5:96139282	ERAP1	-0.37	-5.35	-0.31	1.89e-7	Ankylosing spondylitis;
CESC	cis	rs561341	1.000	rs72821952	chr17:30248133	T/A	cg00745463	chr17:30367425	LRRC37B	-0.81	-7.22	-0.41	5.54e-12	Hip circumference adjusted for BMI;
CESC	cis	rs875971	0.965	rs28682868	chr7:65689809	C/T	cg12463550	chr7:65579703	CRCP	-0.57	-7.38	-0.41	2.02e-12	Aortic root size;
CESC	cis	rs7116495	0.609	rs1548348	chr11:71750917	A/G	cg26138937	chr11:71823887	C11orf51	-1.24	-7.4	-0.41	1.82e-12	Severe influenza A (H1N1) infection;
CESC	cis	rs9910055	0.708	rs2631298	chr17:42219832	T/C	cg19774624	chr17:42201019	HDAC5	-0.89	-14.35	-0.66	6.3e-35	Total body bone mineral density;
CESC	cis	rs10504229	0.683	rs11785260	chr8:58132906	A/G	cg02725872	chr8:58115012	NA	-0.45	-7.05	-0.4	1.52e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs72945132	0.882	rs55758686	chr11:70172204	C/T	cg14191688	chr11:70257035	CTTN	0.43	5.46	0.32	1.11e-7	Coronary artery disease;
CESC	cis	rs8072100	0.790	rs34200664	chr17:45744652	C/T	cg08085267	chr17:45401833	C17orf57	0.44	5.54	0.32	7.36e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs8072100	0.576	rs7216112	chr17:45406345	C/T	cg08085267	chr17:45401833	C17orf57	0.65	8.29	0.45	5.66e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs10911232	0.507	rs10752890	chr1:183021910	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.87	13.43	0.64	1.05e-31	Hypertriglyceridemia;
CESC	cis	rs921968	0.643	rs2278530	chr2:219501133	G/A	cg02176678	chr2:219576539	TTLL4	0.46	8.34	0.46	4.1e-15	Mean corpuscular hemoglobin concentration;
CESC	cis	rs2880765	0.835	rs11633604	chr15:86031579	T/G	cg19183879	chr15:85880815	NA	-0.25	-5.26	-0.31	3.03e-7	Coronary artery disease;
CESC	cis	rs6426558	0.537	rs6699828	chr1:227274591	T/C	cg10327440	chr1:227177885	CDC42BPA	0.47	5.75	0.33	2.42e-8	Neutrophil percentage of white cells;
CESC	cis	rs8078723	0.690	rs3785549	chr17:38149724	T/C	cg17467752	chr17:38218738	THRA	-0.56	-8.52	-0.46	1.22e-15	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CESC	cis	rs9733	0.818	rs4970926	chr1:150673684	T/C	cg13175981	chr1:150552382	MCL1	0.62	9.23	0.49	9.09e-18	Tonsillectomy;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg09123307	chr7:6746650	ZNF12	-0.5	-6.44	-0.37	5.67e-10	Ulcerative colitis;
CESC	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.6	0.38	2.17e-10	Prudent dietary pattern;
CESC	cis	rs7674212	0.539	rs6815783	chr4:104122146	A/C	cg16532752	chr4:104119610	CENPE	-0.4	-5.48	-0.32	1.01e-7	Type 2 diabetes;
CESC	cis	rs28489187	0.597	rs506082	chr1:85899215	A/C	cg16011679	chr1:85725395	C1orf52	-0.44	-5.28	-0.31	2.7e-7	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	cis	rs3106136	0.934	rs4693004	chr4:95168456	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.45	-6.8	-0.39	6.94e-11	Capecitabine sensitivity;
CESC	cis	rs41307935	0.722	rs12724052	chr1:27234682	G/A	cg12203394	chr1:27248618	NUDC	0.65	5.51	0.32	8.6e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs1707322	0.928	rs7527244	chr1:46368772	A/G	cg06784218	chr1:46089804	CCDC17	0.32	5.52	0.32	8.1e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs6537837	0.838	rs12046010	chr1:110104189	A/C	cg05049280	chr1:110155535	GNAT2	0.41	5.74	0.33	2.62e-8	Major depressive disorder;
CESC	cis	rs9831754	0.756	rs6548554	chr3:78423185	C/T	cg06138941	chr3:78371609	NA	-0.52	-6.53	-0.37	3.29e-10	Calcium levels;
CESC	trans	rs3780486	1.000	rs3780486	chr9:33139453	C/T	cg20290983	chr6:43655470	MRPS18A	0.85	12.23	0.6	1.45e-27	IgG glycosylation;
CESC	cis	rs4423214	0.559	rs10898203	chr11:71203436	C/T	cg24826892	chr11:71159390	DHCR7	-0.54	-5.12	-0.3	5.94e-7	Vitamin D levels;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg27220681	chr17:685915	RNMTL1;GLOD4	-0.49	-6.5	-0.37	3.99e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs8031584	0.958	rs11629793	chr15:31238423	G/A	cg14829155	chr15:31115871	NA	-0.7	-9.48	-0.5	1.52e-18	Huntington's disease progression;
CESC	cis	rs6912958	0.781	rs9444504	chr6:88181046	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.45	-6.14	-0.35	3.01e-9	Monocyte percentage of white cells;
CESC	cis	rs11098499	0.863	rs6858592	chr4:120458692	G/A	cg24375607	chr4:120327624	NA	0.42	5.05	0.3	8.24e-7	Corneal astigmatism;
CESC	cis	rs2075371	0.932	rs2544215	chr7:133987896	T/C	cg00033643	chr7:134001901	SLC35B4	0.43	5.56	0.32	6.56e-8	Mean platelet volume;
CESC	trans	rs61931739	0.500	rs11053261	chr12:34530810	C/T	cg26384229	chr12:38710491	ALG10B	0.72	10.84	0.55	6.43e-23	Morning vs. evening chronotype;
CESC	cis	rs4665809	0.556	rs4665322	chr2:26434605	C/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.97	-11.12	-0.56	7.79e-24	Gut microbiome composition (summer);
CESC	cis	rs116095464	0.558	rs7736600	chr5:231337	A/C	cg10591111	chr5:226296	SDHA	-0.51	-6.18	-0.35	2.44e-9	Breast cancer;
CESC	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	13.62	0.64	2.2e-32	Prudent dietary pattern;
CESC	cis	rs748404	0.588	rs2255410	chr15:43831097	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.54	6.95	0.39	2.87e-11	Lung cancer;
CESC	cis	rs1215050	0.782	rs6853916	chr4:98653387	C/T	cg05340658	chr4:99064831	C4orf37	-0.47	-6.04	-0.35	5.08e-9	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs7605827	0.930	rs11889160	chr2:15605509	C/T	cg19274914	chr2:15703543	NA	0.35	6.33	0.36	1.05e-9	Educational attainment (years of education);
CESC	cis	rs1707322	1.000	rs10890355	chr1:46317348	G/A	cg06784218	chr1:46089804	CCDC17	0.32	5.57	0.32	6.35e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg22122542	chr4:113486179	C4orf21	0.41	6.3	0.36	1.24e-9	Gambling;
CESC	cis	rs7481584	0.624	rs449164	chr11:3053454	C/T	cg25174290	chr11:3078921	CARS	-0.43	-6.04	-0.35	5.18e-9	Calcium levels;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg00254426	chr21:30374028	NA	0.4	6.06	0.35	4.67e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs9486719	1.000	rs2142652	chr6:96868504	A/C	cg18709589	chr6:96969512	KIAA0776	0.53	5.81	0.34	1.75e-8	Migraine;Coronary artery disease;
CESC	cis	rs7819412	0.668	rs4841507	chr8:11046394	C/G	cg21775007	chr8:11205619	TDH	-0.38	-5.62	-0.33	4.96e-8	Triglycerides;
CESC	cis	rs8031584	0.678	rs798127	chr15:31117403	T/C	cg14829155	chr15:31115871	NA	0.76	10.65	0.55	2.87e-22	Huntington's disease progression;
CESC	cis	rs4819052	0.765	rs2838852	chr21:46677037	C/A	cg11663144	chr21:46675770	NA	-0.63	-9.74	-0.51	2.28e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs61990749	0.500	rs8011337	chr14:78272626	T/G	cg23188588	chr14:78226832	SNW1;C14orf178	0.5	5.15	0.3	5.07e-7	Fibroblast growth factor basic levels;
CESC	cis	rs910316	1.000	rs175442	chr14:75603564	T/C	cg11812906	chr14:75593930	NEK9	-0.87	-14.98	-0.68	3.74e-37	Height;
CESC	cis	rs7552404	0.960	rs4949877	chr1:76201668	C/G	cg10523679	chr1:76189770	ACADM	0.74	8.74	0.47	2.79e-16	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs9318086	0.712	rs9510916	chr13:24442789	C/T	cg25267304	chr13:24462978	PCOTH;MIPEP	0.42	5.82	0.34	1.69e-8	Myopia (pathological);
CESC	cis	rs2688608	0.620	rs7076525	chr10:75512797	C/T	cg23231163	chr10:75533350	FUT11	-0.37	-5.65	-0.33	4.06e-8	Inflammatory bowel disease;
CESC	trans	rs3942852	0.955	rs6485809	chr11:48112468	C/T	cg15704280	chr7:45808275	SEPT13	-0.68	-7.52	-0.42	8.24e-13	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs7772486	0.875	rs2777483	chr6:146329235	A/G	cg23711669	chr6:146136114	FBXO30	0.81	11.45	0.58	6.31e-25	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs875971	1.000	rs4717292	chr7:65895598	G/A	cg12463550	chr7:65579703	CRCP	0.56	7.09	0.4	1.2e-11	Aortic root size;
CESC	cis	rs8060686	0.920	rs2271293	chr16:67902070	A/G	cg26727032	chr16:67993705	SLC12A4	0.55	5.92	0.34	9.84e-9	HDL cholesterol;Metabolic syndrome;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg23300289	chr9:132146083	NA	0.48	6.4	0.37	6.92e-10	Systemic lupus erythematosus;
CESC	cis	rs2108622	0.647	rs111427692	chr19:15977479	A/T	cg13772218	chr19:15982569	NA	0.29	5.69	0.33	3.28e-8	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CESC	cis	rs4666360	1.000	rs10196396	chr2:20337035	C/T	cg23291376	chr2:20336282	NA	0.37	6.34	0.36	9.68e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel);
CESC	cis	rs4555082	0.874	rs28625632	chr14:105748849	G/T	cg13114125	chr14:105738426	BRF1	-0.86	-10.36	-0.54	2.37e-21	Mean platelet volume;Platelet distribution width;
CESC	cis	rs854765	0.663	rs4925120	chr17:17754633	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.48	-6.85	-0.39	5.21e-11	Total body bone mineral density;
CESC	cis	rs1185460	1.000	rs1185460	chr11:118943433	C/T	cg23280166	chr11:118938394	VPS11	-0.52	-6.6	-0.38	2.22e-10	Coronary artery disease;
CESC	cis	rs798554	0.757	rs1183085	chr7:2875570	G/A	cg13628971	chr7:2884303	GNA12	0.59	7.53	0.42	8.17e-13	Height;
CESC	cis	rs854765	0.583	rs7207395	chr17:17819335	C/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.51	6.57	0.37	2.65e-10	Total body bone mineral density;
CESC	cis	rs9457247	1.000	rs400176	chr6:167406238	T/C	cg07741184	chr6:167504864	NA	0.29	5.31	0.31	2.32e-7	Crohn's disease;
CESC	cis	rs8070624	0.543	rs4299203	chr17:17878159	T/G	cg09796270	chr17:17721594	SREBF1	0.43	5.68	0.33	3.48e-8	Total body bone mineral density;
CESC	cis	rs2730245	0.527	rs924910	chr7:158672272	C/T	cg24397884	chr7:158709396	WDR60	0.85	8.81	0.48	1.67e-16	Height;
CESC	trans	rs1814175	0.746	rs10839429	chr11:49906845	G/A	cg15704280	chr7:45808275	SEPT13	-1.03	-21.21	-0.79	4.77e-59	Height;
CESC	cis	rs7917772	0.582	rs10883738	chr10:104321721	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.42	5.71	0.33	3.08e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs11792861	0.962	rs3829084	chr9:111801724	C/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	-0.45	-5.71	-0.33	3.01e-8	Menarche (age at onset);
CESC	cis	rs9457247	0.663	rs6456143	chr6:167415440	C/A	cg23791538	chr6:167370224	RNASET2	-0.57	-7.68	-0.43	3e-13	Crohn's disease;
CESC	cis	rs425277	0.500	rs908744	chr1:2038893	G/A	cg19257562	chr1:2043853	PRKCZ	0.34	5.67	0.33	3.77e-8	Height;
CESC	cis	rs7618915	0.501	rs12486554	chr3:52742537	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.56	7.54	0.42	7.46e-13	Bipolar disorder;
CESC	cis	rs7586879	0.575	rs6706316	chr2:25128351	C/G	cg01884057	chr2:25150051	NA	0.37	7.06	0.4	1.44e-11	Body mass index;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg04844016	chr2:65659148	SPRED2	-0.49	-7.4	-0.41	1.83e-12	Gambling;
CESC	cis	rs7927771	0.965	rs35184771	chr11:47475189	G/T	cg18512352	chr11:47633146	NA	-0.59	-8.87	-0.48	1.15e-16	Subjective well-being;
CESC	cis	rs6754311	0.731	rs12988076	chr2:136569848	C/A	cg15123519	chr2:136567270	LCT	0.33	5.62	0.33	4.81e-8	Mosquito bite size;
CESC	cis	rs12497850	0.865	rs13072911	chr3:48962128	T/G	cg07636037	chr3:49044803	WDR6	1.03	19.7	0.77	7.94e-54	Parkinson's disease;
CESC	cis	rs2033732	0.826	rs12546578	chr8:85085268	A/T	cg05716166	chr8:85095498	RALYL	-0.31	-5.05	-0.3	8.31e-7	Body mass index;
CESC	cis	rs6456156	0.586	rs10946209	chr6:167480991	G/A	cg23791538	chr6:167370224	RNASET2	-0.54	-7.02	-0.4	1.83e-11	Primary biliary cholangitis;
CESC	cis	rs1799949	0.930	rs3092987	chr17:41222723	T/C	cg25072359	chr17:41440525	NA	0.49	6.51	0.37	3.68e-10	Menopause (age at onset);
CESC	cis	rs7666738	0.830	rs58367603	chr4:99015350	T/C	cg17366294	chr4:99064904	C4orf37	0.6	8.62	0.47	6.37e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7107174	1.000	rs11237460	chr11:78056274	G/A	cg02023728	chr11:77925099	USP35	0.4	5.79	0.34	2e-8	Testicular germ cell tumor;
CESC	cis	rs3093024	0.595	rs4412174	chr6:167476066	A/G	cg07741184	chr6:167504864	NA	0.38	6.7	0.38	1.22e-10	Rheumatoid arthritis;
CESC	cis	rs2235544	0.588	rs638749	chr1:54450490	A/G	cg25741118	chr1:54482237	LDLRAD1	0.23	5.84	0.34	1.55e-8	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
CESC	cis	rs1185460	0.546	rs549893	chr11:118959732	A/G	cg23280166	chr11:118938394	VPS11	-0.37	-5.27	-0.31	2.78e-7	Coronary artery disease;
CESC	cis	rs9596863	0.950	rs6561749	chr13:54435195	G/C	ch.13.53330881F	chr13:54432880	NA	-0.62	-5.31	-0.31	2.33e-7	Epilepsy and lamotrigine-induced maculopapular eruptions;
CESC	cis	rs55788414	0.932	rs8043592	chr16:81182537	A/G	cg06400318	chr16:81190750	PKD1L2	-0.59	-7.04	-0.4	1.62e-11	Left ventricular obstructive tract defect (maternal effect);
CESC	cis	rs2276314	0.857	rs28530656	chr18:33588700	C/T	cg19628046	chr18:33552617	C18orf21	-0.51	-5.94	-0.34	8.89e-9	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs962856	0.619	rs6546298	chr2:67581853	T/G	cg09028215	chr2:67624308	ETAA1	-0.44	-5.29	-0.31	2.56e-7	Pancreatic cancer;
CESC	cis	rs2836974	0.965	rs2836967	chr21:40639102	T/G	cg27266027	chr21:40555129	PSMG1	0.43	5.11	0.3	6.04e-7	Cognitive function;
CESC	cis	rs9611565	0.592	rs5758405	chr22:42076381	C/A	cg06481639	chr22:41940642	POLR3H	0.6	6.3	0.36	1.21e-9	Vitiligo;
CESC	cis	rs13223928	0.621	rs10228451	chr7:3150859	C/G	cg19214707	chr7:3157722	NA	0.43	5.85	0.34	1.46e-8	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
CESC	cis	rs7818688	1.000	rs10100089	chr8:96025093	T/A	cg16049864	chr8:95962084	TP53INP1	0.6	5.77	0.33	2.25e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs2645424	1.000	rs2645424	chr8:11684463	A/G	cg21281001	chr8:11725306	CTSB	-0.42	-5.03	-0.3	9.1e-7	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);
CESC	cis	rs7412746	0.524	rs58304714	chr1:150831561	T/A	cg09365446	chr1:150670422	GOLPH3L	0.38	5.05	0.3	8.07e-7	Melanoma;
CESC	cis	rs7949030	0.653	rs17773169	chr11:62318530	G/T	cg23462726	chr11:62437636	C11orf83;C11orf48	-0.4	-5.48	-0.32	9.84e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	trans	rs9325144	0.647	rs35138700	chr12:38804474	C/T	cg23762105	chr12:34175262	ALG10	0.46	6.04	0.35	5.29e-9	Morning vs. evening chronotype;
CESC	cis	rs12142240	0.698	rs56063031	chr1:46825433	C/T	cg10495392	chr1:46806563	NSUN4	0.58	6.32	0.36	1.09e-9	Menopause (age at onset);
CESC	cis	rs7666738	0.688	rs4632667	chr4:98748299	A/G	cg05340658	chr4:99064831	C4orf37	0.55	5.64	0.33	4.29e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9649213	0.593	rs2240349	chr7:97984663	C/T	cg00277769	chr7:97922759	BAIAP2L1	-0.33	-5.41	-0.32	1.41e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg06873352	chr17:61820015	STRADA	-0.69	-11.9	-0.59	1.84e-26	Prudent dietary pattern;
CESC	cis	rs2880765	0.835	rs7174323	chr15:86049719	A/C	cg10818794	chr15:86012489	AKAP13	-0.34	-5.22	-0.31	3.68e-7	Coronary artery disease;
CESC	cis	rs2629540	0.889	rs17624662	chr10:126408146	A/C	cg08799069	chr10:126477246	METTL10	0.59	7.49	0.42	1.02e-12	Cocaine dependence;
CESC	cis	rs3931020	0.671	rs1327088	chr1:75255491	A/G	cg00121533	chr1:75199117	CRYZ;TYW3	0.39	5.14	0.3	5.28e-7	Resistin levels;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg19040509	chr17:72199640	RPL38	0.46	6.57	0.37	2.69e-10	Systemic lupus erythematosus;
CESC	cis	rs4523957	0.614	rs7219693	chr17:2061101	C/A	cg16513277	chr17:2031491	SMG6	-0.7	-9.84	-0.52	1.09e-19	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	trans	rs916888	0.773	rs199533	chr17:44828931	G/A	cg01341218	chr17:43662625	NA	0.93	11.18	0.57	4.86e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	trans	rs2727020	0.894	rs2866361	chr11:49372481	A/G	cg15704280	chr7:45808275	SEPT13	-0.76	-9.38	-0.5	2.98e-18	Coronary artery disease;
CESC	cis	rs7824557	0.602	rs10110557	chr8:11207508	T/C	cg21775007	chr8:11205619	TDH	0.57	8.65	0.47	5.01e-16	Retinal vascular caliber;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19683962	chr4:108852534	CYP2U1	0.61	7.41	0.41	1.71e-12	Gut microbiome composition (summer);
CESC	cis	rs2337406	0.714	rs7145254	chr14:107226016	A/G	cg07958169	chr14:107095056	NA	-0.48	-5.37	-0.31	1.7e-7	Alzheimer's disease (late onset);
CESC	cis	rs7408868	1.000	rs2074618	chr19:15276143	C/T	cg14696996	chr19:15285081	NOTCH3	1.12	11.59	0.58	2.09e-25	Pulse pressure;
CESC	cis	rs34172651	0.517	rs2303084	chr16:24834581	G/C	cg02428538	chr16:24856791	SLC5A11	-0.6	-6.06	-0.35	4.63e-9	Intelligence (multi-trait analysis);
CESC	trans	rs6073597	1.000	rs6031980	chr20:43714384	C/T	cg08587820	chr3:5020949	BHLHE40	0.48	6.45	0.37	5.28e-10	Positive affect;
CESC	cis	rs910316	0.737	rs175065	chr14:75494983	T/C	cg15467112	chr14:75489610	MLH3	-0.34	-5.14	-0.3	5.43e-7	Height;
CESC	cis	rs3806933	0.522	rs11241095	chr5:110439509	A/G	cg04022379	chr5:110408740	TSLP	0.46	7.55	0.42	6.96e-13	Eosinophilic esophagitis;
CESC	cis	rs11122272	0.735	rs2790878	chr1:231534390	T/C	cg06096015	chr1:231504339	EGLN1	0.39	5.45	0.32	1.16e-7	Hemoglobin concentration;
CESC	cis	rs2839186	0.559	rs2277826	chr21:47639492	C/G	cg00612595	chr21:47717864	NA	0.36	5.08	0.3	7.06e-7	Testicular germ cell tumor;
CESC	cis	rs1847202	0.859	rs4566476	chr3:72948995	G/C	cg25664220	chr3:72788482	NA	-0.37	-5.46	-0.32	1.08e-7	Motion sickness;
CESC	cis	rs7103648	0.897	rs35032070	chr11:47408592	G/A	cg03711944	chr11:47377212	SPI1	-0.36	-5.8	-0.34	1.85e-8	Diastolic blood pressure;Systolic blood pressure;
CESC	cis	rs829661	0.532	rs7602714	chr2:30789607	C/G	cg12454169	chr2:30669597	LCLAT1	-0.4	-5.07	-0.3	7.51e-7	Midgestational circulating levels of PBDEs (fetal genetic effect);
CESC	cis	rs736408	0.540	rs4687637	chr3:52634092	C/T	cg05564831	chr3:52568323	NT5DC2	0.47	7.35	0.41	2.54e-12	Bipolar disorder;
CESC	cis	rs9486715	1.000	rs9398148	chr6:97063555	A/G	cg06623918	chr6:96969491	KIAA0776	-0.89	-13.28	-0.63	3.27e-31	Headache;
CESC	cis	rs7552404	0.889	rs1250874	chr1:76190978	A/G	cg10523679	chr1:76189770	ACADM	0.75	10.09	0.53	1.83e-20	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs514406	0.929	rs2607095	chr1:53325639	T/C	cg08859206	chr1:53392774	SCP2	-0.64	-8.55	-0.47	9.9e-16	Monocyte count;
CESC	cis	rs2380220	0.576	rs4498363	chr6:96042338	A/C	cg04719120	chr6:96025338	MANEA	0.62	6.61	0.38	2.14e-10	Behavioural disinhibition (generation interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15801215	chr6:130341195	L3MBTL3	-0.6	-6.25	-0.36	1.59e-9	Gut microbiome composition (summer);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg09266924	chr15:29034669	NA	0.42	6.11	0.35	3.51e-9	Fibrinogen levels;
CESC	cis	rs2262909	0.548	rs7249672	chr19:22301523	C/T	cg07498013	chr19:22123504	NA	-0.32	-5.06	-0.3	7.86e-7	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
CESC	cis	rs7086627	0.515	rs11202959	chr10:82209672	A/G	cg03267442	chr10:82210566	NA	-0.34	-5.6	-0.33	5.45e-8	Post bronchodilator FEV1;
CESC	cis	rs7824557	0.806	rs6601574	chr8:11094885	G/A	cg21775007	chr8:11205619	TDH	-0.36	-5.22	-0.31	3.7e-7	Retinal vascular caliber;
CESC	cis	rs7666738	0.830	rs6532720	chr4:99043781	C/T	cg05340658	chr4:99064831	C4orf37	0.82	12.88	0.62	8.44e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3741404	0.672	rs4980524	chr11:63959259	A/C	cg04317338	chr11:64019027	PLCB3	0.41	5.11	0.3	6.03e-7	Platelet count;
CESC	cis	rs4919044	0.756	rs835257	chr10:94779801	T/A	cg26979504	chr10:94451518	HHEX	-0.47	-5.15	-0.3	5.16e-7	Coronary artery disease;
CESC	cis	rs950776	0.518	rs12903129	chr15:78819606	C/T	cg24631222	chr15:78858424	CHRNA5	-0.4	-5.2	-0.3	4.08e-7	Sudden cardiac arrest;
CESC	cis	rs3026101	0.578	rs55747983	chr17:5297742	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.43	5.68	0.33	3.57e-8	Body mass index;
CESC	cis	rs9325144	0.555	rs2387847	chr12:38687434	C/T	cg26384229	chr12:38710491	ALG10B	0.58	8.59	0.47	7.74e-16	Morning vs. evening chronotype;
CESC	cis	rs6032067	0.632	rs62208389	chr20:43794783	A/T	cg10761708	chr20:43804764	PI3	0.56	6.55	0.37	3.01e-10	Blood protein levels;
CESC	cis	rs7618915	0.501	rs9917834	chr3:52634619	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	7.55	0.42	7.15e-13	Bipolar disorder;
CESC	cis	rs7937682	0.889	rs493865	chr11:111495178	A/C	cg22437258	chr11:111473054	SIK2	0.71	9.55	0.51	8.99e-19	Primary sclerosing cholangitis;
CESC	cis	rs9733	0.526	rs11204698	chr1:150659545	G/A	cg04414720	chr1:150670196	GOLPH3L	0.63	9.03	0.48	3.76e-17	Tonsillectomy;
CESC	cis	rs7772486	0.875	rs10872582	chr6:146373061	G/A	cg05347473	chr6:146136440	FBXO30	0.48	6.46	0.37	4.85e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs8018808	0.935	rs11627016	chr14:77881138	T/C	cg20045696	chr14:77926864	AHSA1	0.42	5.84	0.34	1.56e-8	Myeloid white cell count;
CESC	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	22.53	0.81	1.67e-63	Prudent dietary pattern;
CESC	cis	rs7833986	0.501	rs2953911	chr8:56948009	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.61	7.55	0.42	6.89e-13	Height;
CESC	cis	rs8180040	1.000	rs811115	chr3:47322133	C/T	cg27129171	chr3:47204927	SETD2	0.66	10.09	0.53	1.82e-20	Colorectal cancer;
CESC	cis	rs9910055	0.762	rs2526020	chr17:42216588	G/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.65	8.58	0.47	8.13e-16	Total body bone mineral density;
CESC	cis	rs2262909	0.925	rs404822	chr19:22215967	A/C	cg11619707	chr19:22235551	ZNF257	-0.36	-5.84	-0.34	1.5e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
CESC	cis	rs875971	0.545	rs73142245	chr7:65691649	A/G	cg11764359	chr7:65958608	NA	0.8	8.97	0.48	5.49e-17	Aortic root size;
CESC	cis	rs698833	0.620	rs1067354	chr2:44663675	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.45	5.03	0.3	8.86e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs896854	0.654	rs896847	chr8:95972551	G/A	cg16049864	chr8:95962084	TP53INP1	-0.65	-11.35	-0.57	1.31e-24	Type 2 diabetes;
CESC	trans	rs2018683	0.707	rs1021690	chr7:28974488	A/G	cg19402173	chr7:128379420	CALU	-0.49	-6.51	-0.37	3.68e-10	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CESC	cis	rs3857536	0.566	rs208463	chr6:66913962	T/A	cg07460842	chr6:66804631	NA	-0.62	-7.72	-0.43	2.4e-13	Blood trace element (Cu levels);
CESC	cis	rs4901847	0.643	rs7153396	chr14:58596356	C/T	cg15908186	chr14:58618357	C14orf37	-0.35	-5.19	-0.3	4.23e-7	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs780096	0.546	rs8179225	chr2:27737181	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.35	-6.24	-0.36	1.7e-9	Total body bone mineral density;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg25228510	chr10:62538235	CDK1;CDC2	0.44	6.24	0.36	1.68e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs3762637	0.882	rs7630833	chr3:122190424	C/T	cg24169773	chr3:122142474	KPNA1	-0.53	-6.17	-0.35	2.56e-9	LDL cholesterol levels;
CESC	cis	rs10484885	0.878	rs72921959	chr6:90591326	C/G	cg13799429	chr6:90582589	CASP8AP2	-0.8	-7.56	-0.42	6.5e-13	QRS interval (sulfonylurea treatment interaction);
CESC	cis	rs6732160	0.691	rs4536673	chr2:73413462	A/T	cg01422370	chr2:73384389	NA	0.42	7.15	0.4	8.6e-12	Intelligence (multi-trait analysis);
CESC	cis	rs820218	0.962	rs820129	chr17:73668107	A/G	cg01592526	chr17:73663357	RECQL5;SAP30BP	0.47	6.09	0.35	3.9e-9	Rotator cuff tears;
CESC	cis	rs6952808	0.717	rs12534679	chr7:1926745	G/A	cg04267008	chr7:1944627	MAD1L1	-0.49	-5.91	-0.34	1.03e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs9916302	0.851	rs11078907	chr17:37662954	C/T	cg20243544	chr17:37824526	PNMT	0.51	6.5	0.37	3.97e-10	Glomerular filtration rate (creatinine);
CESC	trans	rs61931739	0.500	rs11053066	chr12:34185318	G/A	cg26384229	chr12:38710491	ALG10B	0.65	9.11	0.49	2.1e-17	Morning vs. evening chronotype;
CESC	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg23102388	chr7:1867652	MAD1L1	-0.34	-5.11	-0.3	6.07e-7	Bipolar disorder and schizophrenia;
CESC	trans	rs208520	0.634	rs3909071	chr6:66836947	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.96	-12.54	-0.61	1.29e-28	Exhaled nitric oxide output;
CESC	cis	rs6964587	0.869	rs10256780	chr7:91527176	T/A	cg17063962	chr7:91808500	NA	-0.54	-7.24	-0.41	4.76e-12	Breast cancer;
CESC	cis	rs12497850	0.931	rs4974080	chr3:49030828	A/C	cg07636037	chr3:49044803	WDR6	1.08	19.78	0.77	4.02e-54	Parkinson's disease;
CESC	cis	rs6424115	0.729	rs561733	chr1:24049595	T/G	cg15997130	chr1:24165203	NA	0.42	5.61	0.33	4.99e-8	Immature fraction of reticulocytes;
CESC	cis	rs6060717	0.610	rs2794382	chr20:34613651	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-7.92	-0.44	6.36e-14	Hip circumference adjusted for BMI;
CESC	cis	rs4665809	0.531	rs12990692	chr2:26464939	C/T	cg08470875	chr2:26401718	FAM59B	0.76	8.06	0.44	2.69e-14	Gut microbiome composition (summer);
CESC	cis	rs763121	0.853	rs2413546	chr22:39107001	G/A	cg06022373	chr22:39101656	GTPBP1	0.91	14.57	0.67	9.91e-36	Menopause (age at onset);
CESC	cis	rs3092073	0.624	rs11696623	chr20:44580380	C/T	cg00981651	chr20:44574847	PCIF1	0.37	5.51	0.32	8.6e-8	Intelligence (multi-trait analysis);
CESC	cis	rs4713118	0.662	rs9357060	chr6:28024486	C/G	cg23281280	chr6:28129359	ZNF389	0.49	6.54	0.37	3.24e-10	Parkinson's disease;
CESC	cis	rs55794721	0.543	rs1293260	chr1:25709104	C/G	cg12412775	chr1:25698385	RHCE	-0.31	-5.55	-0.32	6.93e-8	Plateletcrit;Mean corpuscular volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24931596	chr1:109968772	PSMA5	0.6	7.09	0.4	1.21e-11	Gut microbiome composition (summer);
CESC	trans	rs6445797	0.632	rs4681963	chr3:56687637	C/T	cg15444621	chr13:113611794	NA	0.34	6.08	0.35	4.13e-9	Gastritis;
CESC	cis	rs13102973	0.965	rs11730310	chr4:135861925	A/G	cg14419869	chr4:135874104	NA	0.34	5.37	0.31	1.72e-7	Subjective well-being;
CESC	cis	rs3733585	0.673	rs6843873	chr4:9958788	A/C	cg02734326	chr4:10020555	SLC2A9	-0.43	-5.99	-0.35	6.72e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs40363	0.645	rs6501177	chr16:3523681	C/T	cg22508957	chr16:3507546	NAT15	0.57	9.5	0.5	1.31e-18	Tuberculosis;
CESC	cis	rs1975974	1.000	rs4889732	chr17:21721443	T/C	cg18423549	chr17:21743878	NA	-0.5	-6.94	-0.39	2.92e-11	Psoriasis;
CESC	cis	rs10131894	0.635	rs174997	chr14:75434806	G/A	cg11812906	chr14:75593930	NEK9	-0.67	-10.05	-0.53	2.41e-20	Coronary artery disease;
CESC	trans	rs7937682	0.889	rs564086	chr11:111501079	C/G	cg18187862	chr3:45730750	SACM1L	0.5	6.39	0.37	7.26e-10	Primary sclerosing cholangitis;
CESC	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg24642844	chr7:1081250	C7orf50	-0.77	-9.63	-0.51	5.27e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09036558	chr16:69973001	WWP2	-0.68	-7.8	-0.43	1.43e-13	Gut microbiome composition (summer);
CESC	cis	rs6089584	0.888	rs6089624	chr20:60619907	C/G	cg24733560	chr20:60626293	TAF4	0.45	6.54	0.37	3.1e-10	Body mass index;
CESC	cis	rs11166629	1.000	rs935119	chr8:135638353	C/T	cg27224718	chr8:135614730	ZFAT	-0.46	-5.65	-0.33	4.21e-8	Smoking quantity;
CESC	cis	rs12142240	0.698	rs4372193	chr1:46853233	G/T	cg10495392	chr1:46806563	NSUN4	0.56	6.15	0.35	2.86e-9	Menopause (age at onset);
CESC	cis	rs7267979	1.000	rs422844	chr20:25445591	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.86	17.57	0.73	2.33e-46	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs4919694	1.000	rs76892505	chr10:104719290	G/A	cg04362960	chr10:104952993	NT5C2	0.76	5.99	0.35	6.7e-9	Arsenic metabolism;
CESC	cis	rs56104184	0.775	rs55981795	chr19:49401952	A/C	cg21252483	chr19:49399788	TULP2	-0.52	-5.69	-0.33	3.36e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	cis	rs798554	0.836	rs13243214	chr7:2817455	G/T	cg09658497	chr7:2847517	GNA12	-0.42	-5.69	-0.33	3.35e-8	Height;
CESC	cis	rs736801	0.607	rs11746555	chr5:131727033	G/A	cg14196790	chr5:131705035	SLC22A5	0.34	5.16	0.3	4.96e-7	Breast cancer;Mosquito bite size;
CESC	cis	rs7615952	0.641	rs7618515	chr3:125790578	C/T	cg06494592	chr3:125709126	NA	-0.51	-5.46	-0.32	1.12e-7	Blood pressure (smoking interaction);
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg05719672	chr15:91446576	MAN2A2	0.43	6.18	0.35	2.44e-9	Systemic lupus erythematosus;
CESC	cis	rs919433	0.963	rs1896854	chr2:198147776	G/T	cg10820045	chr2:198174542	NA	-0.41	-6.28	-0.36	1.36e-9	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs5758659	0.652	rs133336	chr22:42416303	C/T	cg04733989	chr22:42467013	NAGA	0.4	5.32	0.31	2.26e-7	Cognitive function;
CESC	cis	rs7103648	0.630	rs7934481	chr11:47883337	C/T	cg10504702	chr11:47789108	FNBP4	0.42	5.23	0.31	3.48e-7	Diastolic blood pressure;Systolic blood pressure;
CESC	cis	rs28655083	0.957	rs2171096	chr16:77079043	T/C	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.4	-5.24	-0.31	3.21e-7	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7512552	0.809	rs1694377	chr1:150293153	A/G	cg15654264	chr1:150340011	RPRD2	0.41	5.31	0.31	2.31e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs13004237	1	rs13004237	chr2:172833139	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.73	-10.52	-0.54	7.25e-22	Schizophrenia;
CESC	cis	rs6679073	1.000	rs10494874	chr1:205754688	C/G	cg24503407	chr1:205819492	PM20D1	0.39	5.33	0.31	2.13e-7	Prostate-specific antigen levels;
CESC	cis	rs2380220	0.606	rs9488080	chr6:96006973	A/G	cg15832292	chr6:96025679	MANEA	0.63	7.18	0.4	6.98e-12	Behavioural disinhibition (generation interaction);
CESC	cis	rs57506017	0.585	rs1468802	chr7:12276011	G/A	cg23422036	chr7:12250390	TMEM106B	0.39	5.24	0.31	3.35e-7	Neuroticism;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21581312	chr15:35529473	LOC723972	-0.66	-7.82	-0.43	1.27e-13	Gut microbiome composition (summer);
CESC	cis	rs3862260	0.509	rs3795662	chr1:120165135	G/T	cg16322792	chr1:120165303	ZNF697	0.58	10.95	0.56	2.82e-23	Systemic lupus erythematosus;
CESC	cis	rs1691799	0.867	rs1168311	chr12:66725912	A/C	cg16791601	chr12:66731901	HELB	0.72	12.31	0.6	7.35e-28	White blood cell count (basophil);
CESC	cis	rs75229567	0.717	rs17107156	chr12:70234066	A/G	cg10114359	chr12:70132523	RAB3IP	-0.84	-6.37	-0.36	8.36e-10	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
CESC	cis	rs6690583	0.573	rs7547317	chr1:85456961	T/G	cg22153463	chr1:85462885	MCOLN2	0.77	7.18	0.4	6.91e-12	Serum sulfate level;
CESC	cis	rs4629180	0.675	rs10183203	chr2:102095080	C/T	cg04415270	chr2:102091202	RFX8	0.33	5.74	0.33	2.63e-8	Chronic rhinosinusitis with nasal polyps;
CESC	cis	rs2014572	0.967	rs10421632	chr19:57764770	G/A	cg24459738	chr19:57751996	ZNF805	-0.53	-7.57	-0.42	6.02e-13	Hyperactive-impulsive symptoms;
CESC	cis	rs763121	0.853	rs2281021	chr22:39064667	T/C	cg06544989	chr22:39130855	UNC84B	0.48	8.4	0.46	2.69e-15	Menopause (age at onset);
CESC	cis	rs2236918	1.000	rs2797605	chr1:242025245	A/T	cg17736920	chr1:242011382	EXO1	0.71	9.05	0.49	3.1e-17	Menopause (age at onset);
CESC	cis	rs12477438	0.520	rs6542865	chr2:99764521	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	15.46	0.69	7.45e-39	Chronic sinus infection;
CESC	cis	rs1559088	0.847	rs2287680	chr19:33608566	A/G	cg17764715	chr19:33622953	WDR88	-0.47	-6.05	-0.35	4.91e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs74181299	0.620	rs6546123	chr2:65303582	T/C	cg05010058	chr2:65284262	CEP68	-0.32	-5.33	-0.31	2.1e-7	Pulse pressure;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg02664216	chr12:19592651	AEBP2	-0.45	-6.02	-0.35	5.78e-9	Height;
CESC	cis	rs3820928	0.874	rs116652884	chr2:227902285	C/T	cg05526886	chr2:227700861	RHBDD1	-0.45	-5.66	-0.33	3.98e-8	Pulmonary function;
CESC	cis	rs6598955	0.724	rs7526545	chr1:26569990	C/A	cg00852783	chr1:26633632	UBXN11	0.42	6.22	0.36	1.89e-9	Obesity-related traits;
CESC	cis	rs910316	0.591	rs7157158	chr14:75457238	A/G	cg08847533	chr14:75593920	NEK9	0.9	15.58	0.69	2.7e-39	Height;
CESC	cis	rs6866344	0.697	rs17184281	chr5:178127563	G/A	cg10224037	chr5:178157518	ZNF354A	0.68	7.51	0.42	8.94e-13	Neutrophil percentage of white cells;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	ch.13.1524792R	chr13:99552827	DOCK9	-0.51	-6.11	-0.35	3.45e-9	Gut microbiome composition (summer);
CESC	cis	rs4555082	0.874	rs56263609	chr14:105756944	C/T	cg27165867	chr14:105738592	BRF1	-0.5	-5.2	-0.3	4.05e-7	Mean platelet volume;Platelet distribution width;
CESC	cis	rs2625529	0.504	rs11072349	chr15:72464471	T/C	cg16672083	chr15:72433130	SENP8	0.45	6.79	0.39	7.29e-11	Red blood cell count;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg19560052	chr20:60813453	OSBPL2	0.46	6.0	0.35	6.59e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs7267979	1.000	rs6050626	chr20:25428261	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.87	18.11	0.74	2.94e-48	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg04267008	chr7:1944627	MAD1L1	-0.71	-9.05	-0.49	3.25e-17	Bipolar disorder and schizophrenia;
CESC	cis	rs80130819	0.515	rs1476608	chr12:48493731	C/T	cg05342945	chr12:48394962	COL2A1	-0.5	-5.87	-0.34	1.28e-8	Prostate cancer;
CESC	cis	rs12477438	0.520	rs2516827	chr2:99772565	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.85	15.81	0.7	4.17e-40	Chronic sinus infection;
CESC	cis	rs10504229	0.683	rs67048677	chr8:58140023	C/G	cg22535103	chr8:58192502	C8orf71	-0.8	-9.09	-0.49	2.46e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs2658782	0.666	rs2925361	chr11:93098823	G/A	cg15737290	chr11:93063684	CCDC67	0.57	7.26	0.41	4.36e-12	Pulmonary function decline;
CESC	cis	rs2228479	0.850	rs11649100	chr16:89798179	A/G	cg00800038	chr16:89945340	TCF25	-0.74	-5.68	-0.33	3.6e-8	Skin colour saturation;
CESC	cis	rs1559088	0.546	rs11881543	chr19:33559372	T/G	cg27124370	chr19:33622961	WDR88	0.54	7.48	0.42	1.13e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs4072980	0.545	rs12120737	chr1:38422544	C/T	cg18451016	chr1:38461880	NA	0.4	5.67	0.33	3.78e-8	Coronary artery disease;
CESC	cis	rs2361718	0.521	rs2361724	chr17:78099114	G/A	cg27427491	chr17:78079615	GAA	-0.4	-5.88	-0.34	1.2e-8	Yeast infection;
CESC	cis	rs7618915	0.547	rs33967311	chr3:52683864	G/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.34	6.38	0.36	7.99e-10	Bipolar disorder;
CESC	cis	rs270601	0.770	rs932019	chr5:131599370	T/C	cg18758796	chr5:131593413	PDLIM4	0.5	7.41	0.41	1.74e-12	Acylcarnitine levels;
CESC	cis	rs2730245	0.550	rs2657364	chr7:158683825	T/C	cg24397884	chr7:158709396	WDR60	0.82	12.85	0.62	1.06e-29	Height;
CESC	cis	rs2228479	0.850	rs1800355	chr16:89813194	C/T	cg04013166	chr16:89971882	TCF25	0.78	6.65	0.38	1.72e-10	Skin colour saturation;
CESC	cis	rs17376456	0.877	rs7701011	chr5:93311456	G/A	cg21475434	chr5:93447410	FAM172A	0.76	6.88	0.39	4.31e-11	Diabetic retinopathy;
CESC	cis	rs9649213	0.574	rs3801251	chr7:98027618	T/C	cg00277769	chr7:97922759	BAIAP2L1	-0.31	-5.14	-0.3	5.46e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs2439831	0.681	rs3742969	chr15:43621947	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	13.12	0.63	1.26e-30	Lung cancer in ever smokers;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19408915	chr1:172412924	C1orf105;PIGC	0.53	6.26	0.36	1.5e-9	Gut microbiome composition (summer);
CESC	cis	rs6461049	0.638	rs3778994	chr7:2175855	G/T	cg08027265	chr7:2291960	NA	-0.41	-6.4	-0.37	6.89e-10	Schizophrenia;
CESC	cis	rs765787	0.530	rs16941017	chr15:45543281	T/C	cg24006582	chr15:45444508	DUOX1	-0.6	-7.4	-0.41	1.83e-12	Uric acid levels;
CESC	cis	rs4975709	0.589	rs4975746	chr5:1861069	G/A	cg19770292	chr5:1868693	NA	0.3	5.05	0.3	8.04e-7	Cardiovascular disease risk factors;
CESC	cis	rs4595586	0.525	rs12809307	chr12:39365927	A/G	cg26384229	chr12:38710491	ALG10B	0.54	7.57	0.42	6.23e-13	Morning vs. evening chronotype;
CESC	cis	rs2380220	0.576	rs7751219	chr6:96018915	G/A	cg23517279	chr6:96025343	MANEA	0.54	5.29	0.31	2.57e-7	Behavioural disinhibition (generation interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26865258	chr19:47551991	TMEM160	0.58	6.11	0.35	3.54e-9	Gut microbiome composition (summer);
CESC	cis	rs1862618	0.853	rs33326	chr5:56142601	G/A	cg22800045	chr5:56110881	MAP3K1	0.83	9.99	0.52	3.69e-20	Initial pursuit acceleration;
CESC	cis	rs3091242	0.967	rs3093614	chr1:25677844	T/A	cg12412775	chr1:25698385	RHCE	0.32	5.7	0.33	3.14e-8	Erythrocyte sedimentation rate;
CESC	cis	rs2249694	0.960	rs7075572	chr10:135404358	T/C	cg20169779	chr10:135381914	SYCE1	-0.39	-5.64	-0.33	4.42e-8	Obesity-related traits;
CESC	cis	rs1879734	0.689	rs12097598	chr1:54170801	C/G	cg23596471	chr1:54105337	GLIS1	0.35	5.58	0.32	5.97e-8	Mitral valve prolapse;
CESC	cis	rs6831352	0.918	rs1126672	chr4:100047812	G/A	cg12011299	chr4:100065546	ADH4	-0.59	-6.52	-0.37	3.62e-10	Alcohol dependence;
CESC	cis	rs34779708	0.931	rs11010067	chr10:35295431	C/G	cg03585969	chr10:35415529	CREM	-0.74	-9.87	-0.52	8.82e-20	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs116095464	0.558	rs13357299	chr5:242211	T/C	cg22496380	chr5:211416	CCDC127	-0.72	-8.46	-0.46	1.87e-15	Breast cancer;
CESC	cis	rs922182	0.569	rs7180050	chr15:64263784	G/A	cg24729988	chr15:64271149	DAPK2	0.4	5.32	0.31	2.21e-7	Blood protein levels;
CESC	cis	rs2760061	0.626	rs592736	chr1:228116831	A/G	cg01973587	chr1:228161476	NA	0.33	5.19	0.3	4.15e-7	Diastolic blood pressure;
CESC	cis	rs7927771	0.524	rs11039392	chr11:47798753	A/G	cg18512352	chr11:47633146	NA	0.34	5.24	0.31	3.35e-7	Subjective well-being;
CESC	cis	rs79349575	0.783	rs59270107	chr17:47026185	A/T	cg26022315	chr17:47021804	SNF8	0.39	5.16	0.3	4.94e-7	Type 2 diabetes;
CESC	cis	rs9611565	0.525	rs9611549	chr22:41705909	C/G	cg06634786	chr22:41940651	POLR3H	-0.5	-5.35	-0.31	1.91e-7	Vitiligo;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03915945	chr6:155635934	TFB1M	0.61	7.37	0.41	2.23e-12	Gut microbiome composition (summer);
CESC	cis	rs12476592	0.602	rs10469945	chr2:63816776	T/C	cg17519650	chr2:63277830	OTX1	-0.45	-5.12	-0.3	5.75e-7	Childhood ear infection;
CESC	cis	rs7618915	0.501	rs2109634	chr3:52752075	T/G	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	5.81	0.34	1.79e-8	Bipolar disorder;
CESC	cis	rs6582630	0.638	rs12425531	chr12:38550387	A/G	cg26384229	chr12:38710491	ALG10B	-0.39	-5.19	-0.3	4.22e-7	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs67311347	0.910	rs7617361	chr3:40373259	G/T	cg09455208	chr3:40491958	NA	0.45	7.96	0.44	5.05e-14	Renal cell carcinoma;
CESC	cis	rs854765	0.583	rs4413022	chr17:17858280	G/C	cg16928487	chr17:17741425	SREBF1	-0.57	-9.58	-0.51	7.39e-19	Total body bone mineral density;
CESC	cis	rs6687430	0.532	rs9430149	chr1:10612820	G/C	cg20482658	chr1:10539492	PEX14	0.39	8.02	0.44	3.52e-14	Hand grip strength;
CESC	cis	rs1790761	0.505	rs7938563	chr11:67304131	A/G	cg00290607	chr11:67383545	NA	-0.38	-5.63	-0.33	4.55e-8	Mean corpuscular volume;
CESC	cis	rs910316	0.737	rs108622	chr14:75481908	A/G	cg16144293	chr14:75469539	EIF2B2	0.39	5.11	0.3	6.28e-7	Height;
CESC	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg06873352	chr17:61820015	STRADA	0.72	12.67	0.61	4.43e-29	Prudent dietary pattern;
CESC	cis	rs6424115	1.000	rs4237	chr1:24114129	C/T	cg15997130	chr1:24165203	NA	0.5	7.05	0.4	1.55e-11	Immature fraction of reticulocytes;
CESC	cis	rs3824867	0.920	rs7107853	chr11:47453518	T/C	cg20307385	chr11:47447363	PSMC3	-0.49	-5.94	-0.34	9.16e-9	Mean corpuscular hemoglobin;
CESC	cis	rs2354432	0.607	rs11587707	chr1:146707186	T/C	cg25205988	chr1:146714368	CHD1L	-1.02	-8.03	-0.44	3.16e-14	Mitochondrial DNA levels;
CESC	cis	rs7618915	1.000	rs3852064	chr3:52349412	G/T	cg07507251	chr3:52567010	NT5DC2	0.42	6.12	0.35	3.32e-9	Bipolar disorder;
CESC	cis	rs7772486	0.875	rs2224121	chr6:146343214	G/A	cg23711669	chr6:146136114	FBXO30	0.84	12.07	0.6	4.9e-27	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs10489525	0.599	rs7516121	chr1:115604317	A/G	cg01522456	chr1:115632236	TSPAN2	0.47	5.61	0.33	5.03e-8	Autism;
CESC	trans	rs7618501	1.000	rs11709680	chr3:49745188	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.58	-8.43	-0.46	2.17e-15	Intelligence (multi-trait analysis);
CESC	cis	rs367943	1.000	rs348948	chr5:112822452	A/C	cg12552261	chr5:112820674	MCC	-0.63	-7.96	-0.44	4.96e-14	Type 2 diabetes;
CESC	cis	rs897080	0.515	rs1067333	chr2:44626710	C/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.49	5.82	0.34	1.67e-8	Height;
CESC	cis	rs36051895	0.622	rs12686652	chr9:5071942	C/G	cg02405213	chr9:5042618	JAK2	-0.51	-6.19	-0.36	2.28e-9	Pediatric autoimmune diseases;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06931193	chr6:107781130	PDSS2	0.56	6.43	0.37	5.83e-10	Gut microbiome composition (summer);
CESC	cis	rs1707322	0.964	rs10437063	chr1:46273666	G/A	cg03146154	chr1:46216737	IPP	0.71	9.86	0.52	9.77e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs1059312	0.966	rs2291349	chr12:129284248	T/C	cg09035930	chr12:129282057	SLC15A4	0.78	11.04	0.56	1.46e-23	Systemic lupus erythematosus;
CESC	cis	rs910316	0.737	rs175084	chr14:75519175	C/T	cg16144293	chr14:75469539	EIF2B2	0.39	5.14	0.3	5.39e-7	Height;
CESC	cis	rs11971779	0.793	rs4732366	chr7:139027845	G/C	cg07862535	chr7:139043722	LUC7L2	0.49	5.55	0.32	6.82e-8	Diisocyanate-induced asthma;
CESC	cis	rs34779708	0.931	rs35126129	chr10:35452141	G/A	cg04310649	chr10:35416472	CREM	-0.53	-6.4	-0.37	7.07e-10	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs597539	0.616	rs631001	chr11:68642974	C/T	cg04772025	chr11:68637568	NA	0.53	5.97	0.34	7.49e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs7178572	0.568	rs12913233	chr15:77543297	C/T	cg22256960	chr15:77711686	NA	-0.53	-6.78	-0.38	7.79e-11	Type 2 diabetes;
CESC	cis	rs10185178	1.000	rs10185178	chr2:171356274	A/G	cg21128415	chr2:171359116	MYO3B	-1.07	-8.89	-0.48	9.93e-17	Coronary artery aneurysm in Kawasaki disease;
CESC	cis	rs963731	0.649	rs4142729	chr2:39222915	A/G	cg04010122	chr2:39346883	SOS1	-0.77	-5.4	-0.31	1.51e-7	Corticobasal degeneration;
CESC	cis	rs7631605	0.905	rs11711968	chr3:37224967	C/G	cg22985146	chr3:37219077	LRRFIP2	-0.32	-5.24	-0.31	3.21e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs1941023	0.503	rs11230288	chr11:60128968	G/A	cg08716584	chr11:60157161	MS4A7	-0.51	-8.18	-0.45	1.2e-14	Congenital heart disease (maternal effect);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17424859	chr6:71319002	NA	-0.62	-7.41	-0.41	1.72e-12	Gut microbiome composition (summer);
CESC	cis	rs71403859	0.803	rs17282500	chr16:71633653	C/A	cg08717414	chr16:71523259	ZNF19	-0.79	-6.93	-0.39	3.26e-11	Post bronchodilator FEV1;
CESC	cis	rs7312933	0.558	rs61926593	chr12:42818912	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.5	6.41	0.37	6.61e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs7100689	0.646	rs10749579	chr10:82140959	C/T	cg00277334	chr10:82204260	NA	-0.59	-7.81	-0.43	1.36e-13	Post bronchodilator FEV1;
CESC	cis	rs6748734	0.600	rs10933510	chr2:241826754	G/A	cg04034577	chr2:241836375	C2orf54	-0.29	-5.08	-0.3	7.16e-7	Urinary metabolites;
CESC	cis	rs13191362	0.507	rs2803083	chr6:163111199	A/C	cg14584255	chr6:163149320	PACRG;PARK2	0.45	5.79	0.34	1.99e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs3126085	0.935	rs7537637	chr1:152223335	T/A	cg03465714	chr1:152285911	FLG	-0.42	-5.16	-0.3	4.84e-7	Atopic dermatitis;
CESC	cis	rs2933343	0.700	rs2249514	chr3:128643812	C/T	cg25356066	chr3:128598488	ACAD9	0.6	8.44	0.46	2.09e-15	IgG glycosylation;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02620388	chr7:100271115	GNB2	0.55	6.34	0.36	1e-9	Gut microbiome composition (summer);
CESC	cis	rs7937682	0.921	rs4616071	chr11:111440865	C/G	cg09085632	chr11:111637200	PPP2R1B	0.91	10.72	0.55	1.59e-22	Primary sclerosing cholangitis;
CESC	cis	rs826838	0.872	rs826878	chr12:39088837	A/T	cg13010199	chr12:38710504	ALG10B	-0.37	-5.04	-0.3	8.58e-7	Heart rate;
CESC	cis	rs875971	0.545	rs1065265	chr7:65841203	C/T	cg25405998	chr7:65216604	CCT6P1	0.51	5.52	0.32	8.13e-8	Aortic root size;
CESC	cis	rs274567	0.501	rs272855	chr5:131687175	C/T	cg24060327	chr5:131705240	SLC22A5	-0.75	-10.45	-0.54	1.25e-21	Blood metabolite levels;
CESC	cis	rs9311474	1.000	rs7629072	chr3:52305633	C/T	cg18099408	chr3:52552593	STAB1	-0.3	-5.13	-0.3	5.48e-7	Electroencephalogram traits;
CESC	cis	rs7666738	0.791	rs10010438	chr4:99022177	C/T	cg18180107	chr4:99064573	C4orf37	0.41	5.39	0.31	1.57e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7927771	1.000	rs11039390	chr11:47796295	C/G	cg05585544	chr11:47624801	NA	-0.5	-7.86	-0.43	9.61e-14	Subjective well-being;
CESC	cis	rs1707322	1.000	rs11211237	chr1:46447329	G/C	cg03146154	chr1:46216737	IPP	0.72	9.82	0.52	1.31e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs10504229	1.000	rs57261109	chr8:58172152	C/T	cg22535103	chr8:58192502	C8orf71	-1.05	-13.27	-0.63	3.63e-31	Developmental language disorder (linguistic errors);
CESC	cis	rs897080	0.515	rs1067398	chr2:44678882	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.47	5.51	0.32	8.33e-8	Height;
CESC	cis	rs7937682	0.640	rs587010	chr11:111425658	C/A	cg09085632	chr11:111637200	PPP2R1B	-0.76	-10.13	-0.53	1.34e-20	Primary sclerosing cholangitis;
CESC	cis	rs2109514	0.902	rs28495552	chr7:116113744	C/G	cg12739419	chr7:116140593	CAV2	-0.38	-6.85	-0.39	5.19e-11	Prevalent atrial fibrillation;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21140054	chr3:42632404	SS18L2	0.54	6.29	0.36	1.29e-9	Gut microbiome composition (summer);
CESC	cis	rs9640161	0.742	rs2159236	chr7:150017214	A/G	cg10018233	chr7:150070692	REPIN1	0.46	7.36	0.41	2.3e-12	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg07677032	chr17:61819896	STRADA	-0.46	-6.25	-0.36	1.63e-9	Prudent dietary pattern;
CESC	cis	rs1790761	0.520	rs12805884	chr11:67387977	G/A	cg00290607	chr11:67383545	NA	-0.39	-5.38	-0.31	1.61e-7	Mean corpuscular volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17895870	chr19:16254474	HSH2D	0.57	6.7	0.38	1.24e-10	Gut microbiome composition (summer);
CESC	trans	rs123509	0.874	rs339683	chr3:42788511	G/T	cg22035501	chr5:112073398	APC	0.57	6.11	0.35	3.62e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg10252516	chr19:56671462	ZNF444	0.49	6.42	0.37	6.3e-10	Fibrinogen levels;
CESC	cis	rs5769765	0.740	rs2103932	chr22:50272515	A/G	cg26441486	chr22:50317300	CRELD2	-0.38	-5.31	-0.31	2.32e-7	Schizophrenia;
CESC	cis	rs3820068	0.581	rs72645864	chr1:15921153	C/T	cg17385448	chr1:15911702	AGMAT	0.42	6.72	0.38	1.13e-10	Systolic blood pressure;
CESC	cis	rs6736093	1.000	rs7604403	chr2:112656652	G/A	cg12686935	chr2:112915763	FBLN7	-0.42	-5.18	-0.3	4.48e-7	Coronary artery disease;
CESC	cis	rs250677	0.522	rs1432801	chr5:148390979	T/C	cg18129178	chr5:148520854	ABLIM3	-0.47	-5.22	-0.31	3.57e-7	Breast cancer;
CESC	cis	rs875971	1.000	rs7781698	chr7:65896312	A/T	cg18876405	chr7:65276391	NA	0.49	6.52	0.37	3.5e-10	Aortic root size;
CESC	trans	rs12265790	1.000	rs11253670	chr10:15928012	G/A	cg03460745	chr3:171966142	FNDC3B	0.75	6.19	0.36	2.25e-9	Cerebrospinal fluid t-tau:AB1-42 ratio;
CESC	cis	rs10504229	0.683	rs73603874	chr8:58108340	G/A	cg24829409	chr8:58192753	C8orf71	-0.56	-7.01	-0.4	1.97e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs9467711	0.606	rs28360517	chr6:26602453	A/G	cg12826209	chr6:26865740	GUSBL1	0.67	6.06	0.35	4.68e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs9649213	0.593	rs6947208	chr7:97912204	C/T	cg21770322	chr7:97807741	LMTK2	0.54	7.91	0.44	6.97e-14	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs1790761	0.658	rs684928	chr11:67329742	G/A	cg24690094	chr11:67383802	NA	0.36	5.85	0.34	1.43e-8	Mean corpuscular volume;
CESC	cis	rs67366981	0.925	rs66846709	chr14:77692812	G/A	cg22824376	chr14:77648248	TMEM63C	0.64	5.32	0.31	2.23e-7	Obsessive-compulsive symptoms;
CESC	cis	rs7772486	0.875	rs2814873	chr6:146308932	T/C	cg05347473	chr6:146136440	FBXO30	0.56	7.37	0.41	2.14e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4665809	1.000	rs11678157	chr2:26321526	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.68	-7.7	-0.43	2.76e-13	Gut microbiome composition (summer);
CESC	cis	rs1707322	0.656	rs9429172	chr1:46092476	C/G	cg03146154	chr1:46216737	IPP	-0.79	-11.05	-0.56	1.36e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7666738	0.830	rs4401456	chr4:98959902	C/T	cg18180107	chr4:99064573	C4orf37	0.4	5.14	0.3	5.26e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs826838	0.585	rs4363678	chr12:38624514	G/A	cg26384229	chr12:38710491	ALG10B	0.46	6.6	0.38	2.27e-10	Heart rate;
CESC	cis	rs9611565	0.512	rs9611672	chr22:42209922	A/G	cg03806693	chr22:41940476	POLR3H	-1.18	-13.57	-0.64	3.29e-32	Vitiligo;
CESC	cis	rs7264396	0.790	rs6060516	chr20:34214368	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.87	-11.51	-0.58	4.04e-25	Total cholesterol levels;
CESC	cis	rs7412746	0.658	rs4970987	chr1:150949682	T/C	cg04414720	chr1:150670196	GOLPH3L	0.49	6.45	0.37	5.22e-10	Melanoma;
CESC	cis	rs11711311	0.911	rs9817327	chr3:113478500	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.72	10.24	0.53	5.93e-21	IgG glycosylation;
CESC	cis	rs9733	0.596	rs72702580	chr1:150691285	A/T	cg09365446	chr1:150670422	GOLPH3L	0.42	5.86	0.34	1.37e-8	Tonsillectomy;
CESC	cis	rs35110281	0.627	rs56369437	chr21:44970275	A/G	cg01579765	chr21:45077557	HSF2BP	-0.5	-8.45	-0.46	2.01e-15	Mean corpuscular volume;
CESC	cis	rs559928	0.548	rs11231713	chr11:63931849	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.66	5.44	0.32	1.2e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CESC	cis	rs2439831	1.000	rs2256764	chr15:43735763	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.92	9.53	0.51	1.06e-18	Lung cancer in ever smokers;
CESC	cis	rs1552244	0.572	rs6797536	chr3:10168802	C/T	cg08888203	chr3:10149979	C3orf24	-0.47	-5.19	-0.3	4.16e-7	Alzheimer's disease;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg22108864	chr8:26307427	NA	0.5	6.52	0.37	3.45e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs61931739	0.817	rs7963318	chr12:34244929	C/G	cg19457237	chr12:34500585	NA	0.4	5.74	0.33	2.58e-8	Morning vs. evening chronotype;
CESC	trans	rs916888	0.610	rs199442	chr17:44820122	G/A	cg22968622	chr17:43663579	NA	0.78	10.72	0.55	1.68e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs7937682	0.883	rs12366001	chr11:111433916	A/G	cg09085632	chr11:111637200	PPP2R1B	0.97	13.15	0.63	9.55e-31	Primary sclerosing cholangitis;
CESC	cis	rs1799949	1.000	rs8077486	chr17:41212805	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	6.95	0.39	2.79e-11	Menopause (age at onset);
CESC	cis	rs667920	0.557	rs35849216	chr3:136327569	C/T	cg15507776	chr3:136538369	TMEM22	-0.71	-5.63	-0.33	4.58e-8	Coronary artery disease;
CESC	cis	rs4332037	0.805	rs10278591	chr7:1921362	A/G	cg23422044	chr7:1970798	MAD1L1	0.6	7.65	0.43	3.83e-13	Bipolar disorder;
CESC	cis	rs9905704	0.718	rs72826360	chr17:56664395	T/G	cg12560992	chr17:57184187	TRIM37	0.64	5.96	0.34	8.03e-9	Testicular germ cell tumor;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg19273467	chr1:32110819	PEF1	0.5	6.33	0.36	1.03e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs6860806	0.661	rs2136188	chr5:131577514	A/G	cg11843238	chr5:131593191	PDLIM4	-0.37	-5.34	-0.31	1.99e-7	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17838705	chr1:112298602	DDX20;C1orf183	0.6	7.46	0.42	1.26e-12	Gut microbiome composition (summer);
CESC	cis	rs727505	1.000	rs10233385	chr7:124498707	C/G	cg23710748	chr7:124431027	NA	-0.48	-7.52	-0.42	8.73e-13	Lewy body disease;
CESC	cis	rs3020736	0.500	rs6519306	chr22:42501217	T/C	cg04733989	chr22:42467013	NAGA	-0.79	-12.03	-0.59	6.75e-27	Autism spectrum disorder or schizophrenia;
CESC	cis	rs4604732	0.536	rs12058821	chr1:247649651	G/T	cg12754571	chr1:247694271	LOC148824;OR2C3	0.42	5.34	0.31	1.98e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	trans	rs1945213	0.694	rs11227113	chr11:55828024	C/T	cg03929089	chr4:120376271	NA	0.76	7.23	0.41	5.06e-12	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs12930096	1.000	rs12929430	chr16:11679467	C/T	cg07439791	chr16:11680400	LITAF	0.61	6.14	0.35	2.95e-9	QT interval;
CESC	cis	rs7733403	1	rs7733403	chr5:140154215	A/G	cg16179182	chr5:140090404	VTRNA1-1	-0.41	-5.36	-0.31	1.82e-7	Schizophrenia;
CESC	cis	rs10887741	0.646	rs12257469	chr10:89437129	G/A	cg13926569	chr10:89418898	PAPSS2	0.5	8.14	0.45	1.54e-14	Exercise (leisure time);
CESC	cis	rs12500824	0.564	rs62300855	chr4:77281889	G/C	cg20311846	chr4:77356250	SHROOM3	0.37	6.88	0.39	4.32e-11	Coronary artery disease;
CESC	cis	rs7666738	0.861	rs28821920	chr4:98962743	T/C	cg17366294	chr4:99064904	C4orf37	0.6	8.52	0.46	1.2e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1023500	0.573	rs133382	chr22:42471774	C/T	cg04733989	chr22:42467013	NAGA	0.79	12.05	0.59	5.98e-27	Schizophrenia;
CESC	cis	rs7223966	1.000	rs8074771	chr17:61735865	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.44	-5.16	-0.3	4.73e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs769267	0.931	rs15622	chr19:19468734	G/A	cg03709012	chr19:19516395	GATAD2A	-0.98	-14.29	-0.66	1.02e-34	Tonsillectomy;
CESC	cis	rs7116495	0.786	rs610004	chr11:71797939	C/T	cg26138937	chr11:71823887	C11orf51	-0.86	-7.03	-0.4	1.75e-11	Severe influenza A (H1N1) infection;
CESC	cis	rs10461617	0.541	rs860581	chr5:56150537	A/G	cg24549020	chr5:56110836	MAP3K1	0.67	6.19	0.36	2.25e-9	Type 2 diabetes;
CESC	cis	rs9926296	0.744	rs154657	chr16:89708096	A/G	cg04287289	chr16:89883240	FANCA	0.47	5.9	0.34	1.09e-8	Vitiligo;
CESC	cis	rs2239547	0.522	rs6770957	chr3:52995416	T/C	cg11645453	chr3:52864694	ITIH4	0.33	5.55	0.32	7.04e-8	Schizophrenia;
CESC	cis	rs561341	1.000	rs527256	chr17:30321293	C/G	cg12193833	chr17:30244370	NA	-0.72	-6.68	-0.38	1.42e-10	Hip circumference adjusted for BMI;
CESC	cis	rs300703	0.639	rs397719	chr2:204870	T/G	cg21211680	chr2:198530	NA	0.96	10.54	0.54	6.42e-22	Blood protein levels;
CESC	cis	rs7927771	0.524	rs6485786	chr11:47837408	G/C	cg20307385	chr11:47447363	PSMC3	0.62	8.62	0.47	6.37e-16	Subjective well-being;
CESC	cis	rs8031584	0.651	rs28664821	chr15:31172323	G/A	cg08109568	chr15:31115862	NA	0.8	11.8	0.59	4.17e-26	Huntington's disease progression;
CESC	cis	rs1008375	0.966	rs2010053	chr4:17583806	A/C	cg27347728	chr4:17578864	LAP3	0.43	5.18	0.3	4.42e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs1552244	0.872	rs115331527	chr3:10154504	G/A	cg08888203	chr3:10149979	C3orf24	0.47	6.14	0.35	3.04e-9	Alzheimer's disease;
CESC	cis	rs7851660	0.967	rs907577	chr9:100615117	C/T	cg13688889	chr9:100608707	NA	-0.69	-10.57	-0.54	4.92e-22	Strep throat;
CESC	cis	rs863345	0.604	rs10908661	chr1:158466990	T/A	cg12129480	chr1:158549410	OR10X1	-0.33	-6.58	-0.37	2.53e-10	Pneumococcal bacteremia;
CESC	cis	rs3820928	0.874	rs2228557	chr2:227872182	G/A	cg11843606	chr2:227700838	RHBDD1	-0.47	-6.05	-0.35	4.92e-9	Pulmonary function;
CESC	cis	rs2249625	1.000	rs2463698	chr6:72923936	A/G	cg18830697	chr6:72922368	RIMS1	-0.45	-6.43	-0.37	6.06e-10	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CESC	cis	rs13191362	0.935	rs67337490	chr6:162953961	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.8	7.66	0.43	3.61e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs1005277	0.579	rs176880	chr10:38401417	C/G	cg25517755	chr10:38738941	LOC399744	0.44	5.72	0.33	2.81e-8	Extrinsic epigenetic age acceleration;
CESC	cis	rs11871801	0.517	rs645692	chr17:40701073	C/T	cg14558262	chr17:40713999	COASY	0.53	6.14	0.35	3.08e-9	Crohn's disease;
CESC	cis	rs7586673	1.000	rs16845584	chr2:161923830	C/T	cg08807892	chr2:162101083	NA	-0.47	-6.29	-0.36	1.31e-9	Intelligence (multi-trait analysis);
CESC	cis	rs7618915	0.501	rs1468638	chr3:52748058	T/C	cg18404041	chr3:52824283	ITIH1	-0.4	-6.76	-0.38	8.51e-11	Bipolar disorder;
CESC	cis	rs9467711	0.591	rs17586553	chr6:25928775	C/T	cg21479132	chr6:26055353	NA	0.91	9.03	0.48	3.74e-17	Autism spectrum disorder or schizophrenia;
CESC	cis	rs9916302	0.851	rs11078904	chr17:37650569	G/A	cg20243544	chr17:37824526	PNMT	0.51	6.5	0.37	3.97e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs634534	0.622	rs624273	chr11:65712413	A/G	cg26695010	chr11:65641043	EFEMP2	-0.44	-5.43	-0.32	1.29e-7	Sum eosinophil basophil counts;Eosinophil counts;
CESC	cis	rs25645	0.771	rs11078936	chr17:38197914	T/C	cg17467752	chr17:38218738	THRA	-0.53	-6.77	-0.38	8.22e-11	Myeloid white cell count;
CESC	cis	rs1451375	0.572	rs12666409	chr7:50634976	A/T	cg14593290	chr7:50529359	DDC	-0.44	-5.27	-0.31	2.79e-7	Malaria;
CESC	cis	rs2070488	0.736	rs2070988	chr3:38437835	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.68	9.56	0.51	8.31e-19	Electrocardiographic conduction measures;
CESC	trans	rs8073060	0.586	rs8064895	chr17:34001121	T/C	cg19694781	chr19:47549865	TMEM160	-0.74	-6.91	-0.39	3.64e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	cis	rs769267	0.929	rs2965180	chr19:19491973	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	-0.58	-7.57	-0.42	6.29e-13	Tonsillectomy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11653948	chr11:2421970	NA	0.55	6.59	0.38	2.43e-10	Gut microbiome composition (summer);
CESC	cis	rs7107174	1.000	rs7116611	chr11:78030046	A/G	cg02023728	chr11:77925099	USP35	0.47	6.47	0.37	4.75e-10	Testicular germ cell tumor;
CESC	cis	rs8103278	0.507	rs62111759	chr19:46296230	A/T	cg06577658	chr19:46296270	DMWD	0.47	5.59	0.33	5.5e-8	Coronary artery disease;
CESC	cis	rs12906542	0.507	rs4395040	chr15:78282533	G/A	cg22832135	chr15:78370102	TBC1D2B	0.49	5.05	0.3	8.04e-7	Breast cancer;
CESC	cis	rs9322193	0.923	rs10782317	chr6:150075047	C/T	cg13206674	chr6:150067644	NUP43	-0.46	-6.67	-0.38	1.52e-10	Lung cancer;
CESC	cis	rs34779708	0.931	rs4934709	chr10:35339324	A/C	cg03585969	chr10:35415529	CREM	-0.71	-9.07	-0.49	2.73e-17	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs7647973	0.626	rs9830730	chr3:49675875	G/C	cg07636037	chr3:49044803	WDR6	0.53	6.34	0.36	9.78e-10	Menarche (age at onset);
CESC	cis	rs79839061	0.656	rs11726912	chr4:887868	A/C	cg07828340	chr4:882639	GAK	1.07	8.55	0.47	9.76e-16	Intelligence (multi-trait analysis);
CESC	cis	rs3785574	0.962	rs2727331	chr17:61926990	G/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.79	10.4	0.54	1.83e-21	Height;
CESC	cis	rs7851660	0.809	rs12004762	chr9:100652755	A/G	cg13688889	chr9:100608707	NA	-0.63	-8.96	-0.48	5.96e-17	Strep throat;
CESC	cis	rs7116495	0.609	rs2852365	chr11:71715218	T/C	cg26138937	chr11:71823887	C11orf51	-1.22	-8.14	-0.45	1.52e-14	Severe influenza A (H1N1) infection;
CESC	trans	rs3925158	0.510	rs4955398	chr3:38301161	T/C	cg23247845	chr10:3679085	NA	0.61	6.0	0.35	6.39e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs938554	0.501	rs7671266	chr4:10056376	C/T	cg00071950	chr4:10020882	SLC2A9	-0.68	-8.29	-0.45	5.91e-15	Blood metabolite levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15549927	chr7:153749756	DPP6	-0.48	-6.05	-0.35	4.83e-9	Gut microbiome composition (summer);
CESC	cis	rs9910055	0.659	rs2251165	chr17:42234748	T/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.72	9.83	0.52	1.18e-19	Total body bone mineral density;
CESC	cis	rs870825	0.616	rs3184982	chr4:185615768	T/G	cg04058563	chr4:185651563	MLF1IP	0.65	7.14	0.4	9.11e-12	Blood protein levels;
CESC	cis	rs9910055	0.659	rs6503488	chr17:42246158	T/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.68	9.05	0.49	3.11e-17	Total body bone mineral density;
CESC	cis	rs854765	0.551	rs12600546	chr17:17867614	A/G	cg16928487	chr17:17741425	SREBF1	-0.57	-9.55	-0.51	9.29e-19	Total body bone mineral density;
CESC	cis	rs4665809	0.941	rs41285975	chr2:26351144	T/C	cg26314531	chr2:26401878	FAM59B	-0.62	-6.99	-0.39	2.29e-11	Gut microbiome composition (summer);
CESC	cis	rs72781680	1.000	rs12617839	chr2:24166277	A/T	cg08917208	chr2:24149416	ATAD2B	0.94	8.58	0.47	7.87e-16	Lymphocyte counts;
CESC	trans	rs11098499	0.865	rs3956464	chr4:120256764	T/C	cg25214090	chr10:38739885	LOC399744	0.64	9.08	0.49	2.59e-17	Corneal astigmatism;
CESC	cis	rs9300255	0.537	rs1619561	chr12:123620268	G/C	cg00376283	chr12:123451042	ABCB9	0.74	8.99	0.48	4.76e-17	Neutrophil percentage of white cells;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00281600	chr7:149322071	ZNF767	0.57	6.29	0.36	1.33e-9	Gut microbiome composition (summer);
CESC	cis	rs2797160	0.935	rs12717178	chr6:126016499	G/A	cg05901451	chr6:126070800	HEY2	0.45	6.45	0.37	5.3e-10	Endometrial cancer;
CESC	cis	rs926938	0.618	rs904292	chr1:115358421	C/T	cg12756093	chr1:115239321	AMPD1	0.44	5.92	0.34	9.88e-9	Autism;
CESC	cis	rs769267	0.930	rs10422819	chr19:19643028	C/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.46	5.65	0.33	4.07e-8	Tonsillectomy;
CESC	cis	rs9399135	1.000	rs6569988	chr6:135352303	C/A	cg22676075	chr6:135203613	NA	0.48	6.69	0.38	1.36e-10	Red blood cell count;
CESC	cis	rs7618915	0.571	rs34954168	chr3:52612159	C/T	cg05564831	chr3:52568323	NT5DC2	0.46	6.98	0.39	2.32e-11	Bipolar disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17809632	chr2:27435717	SLC5A6;C2orf28	-0.55	-6.35	-0.36	9.25e-10	Gut microbiome composition (summer);
CESC	cis	rs1008375	0.966	rs3796813	chr4:17591648	A/G	cg16339924	chr4:17578868	LAP3	0.7	9.26	0.49	7.03e-18	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs8072100	0.967	rs2317826	chr17:45730899	C/T	cg08085267	chr17:45401833	C17orf57	-0.43	-5.75	-0.33	2.45e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs11785400	0.793	rs11785012	chr8:143748355	G/A	cg24634471	chr8:143751801	JRK	0.46	5.77	0.33	2.25e-8	Schizophrenia;
CESC	cis	rs2737618	0.674	rs2821334	chr1:200093887	G/T	cg21825944	chr1:200113062	NR5A2	-0.42	-6.36	-0.36	8.88e-10	Uric acid levels;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg00475815	chr3:196594767	SENP5	-0.42	-6.02	-0.35	5.72e-9	Ulcerative colitis;
CESC	cis	rs6991838	0.550	rs12335006	chr8:66531629	T/C	cg13398993	chr8:66546079	ARMC1	0.46	5.65	0.33	4.19e-8	Intelligence (multi-trait analysis);
CESC	cis	rs6429082	0.871	rs6675944	chr1:235572669	C/T	cg26050004	chr1:235667680	B3GALNT2	0.39	5.31	0.31	2.37e-7	Adiposity;
CESC	cis	rs5769765	0.908	rs138866	chr22:50205903	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.45	5.12	0.3	5.82e-7	Schizophrenia;
CESC	cis	rs611744	0.870	rs634216	chr8:109174803	A/G	cg21045802	chr8:109455806	TTC35	0.46	5.57	0.32	6.24e-8	Dupuytren's disease;
CESC	cis	rs3820068	0.705	rs41486146	chr1:15900517	A/G	cg17385448	chr1:15911702	AGMAT	-0.39	-5.79	-0.34	1.99e-8	Systolic blood pressure;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05241309	chr16:67691486	ACD	-0.59	-6.64	-0.38	1.8e-10	Gut microbiome composition (summer);
CESC	cis	rs9908102	0.740	rs8078710	chr17:12910662	G/A	cg26162695	chr17:12921313	ELAC2	0.52	5.71	0.33	3.04e-8	Schizophrenia;
CESC	cis	rs1775715	0.737	rs2808072	chr10:32205504	A/T	cg18675610	chr10:32216311	ARHGAP12	0.36	5.55	0.32	6.84e-8	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs763014	0.865	rs8909	chr16:633851	T/C	cg09263875	chr16:632152	PIGQ	0.65	10.73	0.55	1.53e-22	Height;
CESC	cis	rs9733	0.715	rs7534124	chr1:150739073	C/T	cg22823121	chr1:150693482	HORMAD1	-0.39	-5.85	-0.34	1.41e-8	Tonsillectomy;
CESC	cis	rs514406	0.708	rs480299	chr1:53320274	G/T	cg08736216	chr1:53307985	ZYG11A	-0.39	-6.79	-0.39	7.28e-11	Monocyte count;
CESC	cis	rs4862750	0.794	rs7672272	chr4:187896774	T/G	cg07414643	chr4:187882934	NA	0.55	8.01	0.44	3.75e-14	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs13118159	0.742	rs34947293	chr4:1335034	T/C	cg00684032	chr4:1343700	KIAA1530	0.36	5.56	0.32	6.59e-8	Longevity;
CESC	cis	rs798554	0.836	rs2260230	chr7:2822986	T/A	cg19717773	chr7:2847554	GNA12	-0.57	-8.08	-0.44	2.27e-14	Height;
CESC	cis	rs4948523	0.530	rs11006182	chr10:60309128	G/A	cg07615347	chr10:60278583	BICC1	-0.57	-8.14	-0.45	1.59e-14	Myopia;
CESC	cis	rs2439831	0.850	rs28413704	chr15:44148427	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.68	7.43	0.42	1.45e-12	Lung cancer in ever smokers;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07508942	chr7:5267994	WIPI2	-0.55	-6.0	-0.35	6.6e-9	Gut microbiome composition (summer);
CESC	cis	rs2120019	0.938	rs5020842	chr15:75322310	T/C	cg09165964	chr15:75287851	SCAMP5	-0.86	-10.97	-0.56	2.39e-23	Blood trace element (Zn levels);
CESC	cis	rs9394152	0.845	rs9296092	chr6:33478496	C/T	cg13560919	chr6:33536144	NA	-0.48	-7.61	-0.42	4.71e-13	Age at smoking initiation in chronic obstructive pulmonary disease;
CESC	cis	rs992157	0.798	rs10193383	chr2:219157692	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.68	9.02	0.48	3.81e-17	Colorectal cancer;
CESC	cis	rs2180341	0.782	rs6912750	chr6:127723081	A/T	cg27446573	chr6:127587934	RNF146	0.8	11.46	0.58	5.73e-25	Breast cancer;
CESC	trans	rs1814175	0.645	rs11040671	chr11:49958776	G/A	cg03929089	chr4:120376271	NA	-0.92	-15.24	-0.68	4.38e-38	Height;
CESC	cis	rs8050907	0.744	rs28680621	chr16:4518994	G/A	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.93	6.54	0.37	3.14e-10	Obesity-related traits;
CESC	cis	rs2839186	0.770	rs2280956	chr21:47642323	C/G	cg10351095	chr21:47802916	PCNT	0.43	5.87	0.34	1.31e-8	Testicular germ cell tumor;
CESC	cis	rs7666738	0.830	rs13118892	chr4:98968497	T/C	cg03676636	chr4:99064102	C4orf37	0.34	5.2	0.3	4.04e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2066819	0.892	rs112931321	chr12:56667894	C/T	cg26714650	chr12:56694279	CS	-1.51	-10.33	-0.54	3.09e-21	Psoriasis vulgaris;
CESC	cis	rs796364	0.577	rs7574287	chr2:200680999	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.57	5.23	0.31	3.39e-7	Schizophrenia;
CESC	cis	rs992157	0.735	rs13430006	chr2:219113089	A/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.67	-9.18	-0.49	1.3e-17	Colorectal cancer;
CESC	cis	rs7829975	0.593	rs2921077	chr8:8304502	C/T	cg15556689	chr8:8085844	FLJ10661	0.64	8.72	0.47	3.04e-16	Mood instability;
CESC	cis	rs7552404	0.731	rs5745458	chr1:76345429	G/A	cg03433033	chr1:76189801	ACADM	-0.58	-5.97	-0.34	7.72e-9	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs3806843	0.900	rs2337983	chr5:140136808	G/A	cg26395211	chr5:140044315	WDR55	0.43	5.46	0.32	1.07e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs13256369	0.851	rs13249700	chr8:8563637	C/T	cg18904891	chr8:8559673	CLDN23	0.73	8.11	0.45	1.94e-14	Obesity-related traits;
CESC	cis	rs977987	0.778	rs62059846	chr16:75430809	T/A	cg03315344	chr16:75512273	CHST6	0.4	5.71	0.33	3e-8	Dupuytren's disease;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg20194871	chr2:97779411	ANKRD36	-0.47	-6.17	-0.35	2.57e-9	Asthma;
CESC	cis	rs1799949	0.501	rs2343819	chr17:41409653	T/G	cg05368731	chr17:41323189	NBR1	0.79	10.96	0.56	2.64e-23	Menopause (age at onset);
CESC	cis	rs7089973	0.624	rs11196930	chr10:116583596	C/T	cg25233709	chr10:116636983	FAM160B1	0.35	5.48	0.32	1.01e-7	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs11792861	0.591	rs2275641	chr9:111696389	G/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.63	9.77	0.51	1.92e-19	Menarche (age at onset);
CESC	cis	rs9467711	0.606	rs2235251	chr6:26431982	C/T	cg14345882	chr6:26364793	BTN3A2	0.61	5.84	0.34	1.56e-8	Autism spectrum disorder or schizophrenia;
CESC	cis	rs17711722	0.640	rs13237956	chr7:65318029	G/A	cg06456125	chr7:65229604	NA	0.44	5.75	0.33	2.47e-8	Calcium levels;
CESC	cis	rs3780486	0.718	rs10971418	chr9:33122024	A/C	cg13443165	chr9:33130375	B4GALT1	-0.43	-5.27	-0.31	2.8e-7	IgG glycosylation;
CESC	cis	rs11122272	0.735	rs2790885	chr1:231529925	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.56	-7.66	-0.43	3.45e-13	Hemoglobin concentration;
CESC	cis	rs12586317	0.547	rs28589276	chr14:35478865	A/G	cg05294307	chr14:35346193	BAZ1A	-0.51	-5.45	-0.32	1.16e-7	Psoriasis;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg26606899	chr16:1802252	MAPK8IP3	0.49	6.48	0.37	4.37e-10	Fibrinogen levels;
CESC	cis	rs11750568	0.967	rs890699	chr5:178511846	A/G	cg10208897	chr5:178548229	ADAMTS2	-0.41	-5.74	-0.33	2.52e-8	Height;
CESC	cis	rs1153858	1.000	rs12909158	chr15:45621174	A/G	cg21132104	chr15:45694354	SPATA5L1	0.83	11.01	0.56	1.8e-23	Homoarginine levels;
CESC	trans	rs2502399	0.689	rs2502372	chr6:113504554	A/G	cg00285294	chr7:1089767	C7orf50	-0.35	-6.64	-0.38	1.75e-10	Plasma clusterin levels;
CESC	cis	rs7666738	0.830	rs7682991	chr4:98982595	C/A	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.67e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6459788	0.692	rs10807645	chr7:157258979	T/C	cg03453431	chr7:157225567	NA	0.34	5.78	0.33	2.12e-8	Epstein-Barr virus copy number in lymphoblastoid cell lines;
CESC	cis	rs10540	1.000	rs117339389	chr11:505025	T/A	cg03934478	chr11:495069	RNH1	0.55	5.25	0.31	3.06e-7	Body mass index;
CESC	trans	rs7672847	0.547	rs7693196	chr4:170474693	C/T	cg19308436	chr1:237949471	RYR2	0.65	6.9	0.39	3.89e-11	Subjective well-being;
CESC	cis	rs1862618	0.620	rs2591967	chr5:56233551	C/G	cg24549020	chr5:56110836	MAP3K1	-0.48	-6.08	-0.35	4.11e-9	Initial pursuit acceleration;
CESC	cis	rs7621025	0.505	rs34613715	chr3:136455007	A/T	cg15507776	chr3:136538369	TMEM22	-0.8	-7.14	-0.4	9.13e-12	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
CESC	cis	rs7615952	0.576	rs2276727	chr3:125826243	C/T	cg06494592	chr3:125709126	NA	-0.49	-5.32	-0.31	2.23e-7	Blood pressure (smoking interaction);
CESC	cis	rs832540	0.898	rs331497	chr5:56251660	G/T	cg24531977	chr5:56204891	C5orf35	0.4	5.04	0.3	8.73e-7	Coronary artery disease;
CESC	cis	rs6597981	0.592	rs10902218	chr11:743813	C/T	cg21775979	chr11:780331	NA	0.38	5.78	0.33	2.12e-8	Breast cancer;
CESC	cis	rs7116495	1.000	rs541022	chr11:71783056	G/A	cg26138937	chr11:71823887	C11orf51	-0.72	-6.35	-0.36	9.41e-10	Severe influenza A (H1N1) infection;
CESC	cis	rs875971	0.862	rs12537823	chr7:65720884	C/T	cg18876405	chr7:65276391	NA	0.52	7.33	0.41	2.8e-12	Aortic root size;
CESC	cis	rs6831352	0.918	rs13129488	chr4:100053025	G/T	cg12011299	chr4:100065546	ADH4	-0.59	-6.52	-0.37	3.62e-10	Alcohol dependence;
CESC	trans	rs9319321	0.571	rs9512419	chr13:27415593	A/T	cg14332112	chr6:47277683	TNFRSF21	-0.49	-6.22	-0.36	1.97e-9	Asthma (toluene diisocyanate-induced);
CESC	cis	rs6032067	0.777	rs2868237	chr20:43794189	C/T	cg11264863	chr20:43835661	SEMG1	0.5	5.35	0.31	1.86e-7	Blood protein levels;
CESC	cis	rs3784262	0.904	rs12901462	chr15:58316487	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.31	-5.05	-0.3	8.08e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
CESC	cis	rs4819052	0.724	rs9753962	chr21:46661384	G/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.46	5.79	0.34	2e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs9611565	0.694	rs202639	chr22:41856137	T/A	cg06481639	chr22:41940642	POLR3H	0.64	6.52	0.37	3.61e-10	Vitiligo;
CESC	cis	rs7772486	0.790	rs80050589	chr6:146230454	T/C	cg05347473	chr6:146136440	FBXO30	-0.57	-7.31	-0.41	3.07e-12	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs7911712	0.565	rs2477529	chr10:45250582	C/G	cg12743970	chr17:64536520	PRKCA	-0.63	-6.02	-0.35	5.68e-9	Emphysema-related traits;
CESC	cis	rs10751667	0.666	rs7395823	chr11:942701	T/C	cg20946044	chr11:1010712	AP2A2	-0.39	-5.44	-0.32	1.23e-7	Alzheimer's disease (late onset);
CESC	cis	rs68170813	0.559	rs77829121	chr7:106968470	A/G	cg02696742	chr7:106810147	HBP1	-0.54	-5.17	-0.3	4.64e-7	Coronary artery disease;
CESC	cis	rs9916302	0.706	rs7503081	chr17:37482673	A/G	cg07936489	chr17:37558343	FBXL20	0.94	10.63	0.55	3.23e-22	Glomerular filtration rate (creatinine);
CESC	cis	rs2836974	0.568	rs452377	chr21:40537183	T/C	cg27266027	chr21:40555129	PSMG1	0.4	5.13	0.3	5.63e-7	Cognitive function;
CESC	cis	rs6502050	0.835	rs34199331	chr17:80134487	C/T	cg23985595	chr17:80112537	CCDC57	-0.41	-6.42	-0.37	6.39e-10	Life satisfaction;
CESC	cis	rs6967414	0.786	rs9639026	chr7:6746736	A/G	cg00387323	chr7:6746715	ZNF12	0.69	6.89	0.39	4.06e-11	Hematocrit;Hemoglobin concentration;
CESC	cis	rs2303745	0.589	rs8103523	chr19:17398269	A/G	cg04248312	chr19:17393744	ANKLE1	-0.92	-14.73	-0.67	2.83e-36	Systemic lupus erythematosus;
CESC	cis	rs3020736	0.500	rs7364293	chr22:42506370	C/T	cg04733989	chr22:42467013	NAGA	-0.83	-12.49	-0.61	1.9e-28	Autism spectrum disorder or schizophrenia;
CESC	cis	rs17401966	0.838	rs61775887	chr1:10284733	T/C	cg15208524	chr1:10270712	KIF1B	0.42	5.45	0.32	1.14e-7	Hepatocellular carcinoma;
CESC	cis	rs941873	0.868	rs2233718	chr10:81108956	A/G	cg09469691	chr10:81107165	PPIF	0.54	7.29	0.41	3.65e-12	Height;
CESC	cis	rs6088580	0.634	rs6087587	chr20:33058628	G/T	cg06115741	chr20:33292138	TP53INP2	0.47	6.09	0.35	4.03e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs1129187	0.837	rs3763236	chr6:42902508	C/T	cg24101359	chr6:42928495	GNMT	-0.45	-6.79	-0.38	7.55e-11	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs72634258	0.945	rs12757968	chr1:8106201	A/G	cg00042356	chr1:8021962	PARK7	0.8	7.14	0.4	9.2e-12	Inflammatory bowel disease;
CESC	cis	rs8180040	0.620	rs7373821	chr3:47080127	A/C	cg27129171	chr3:47204927	SETD2	0.66	9.82	0.52	1.32e-19	Colorectal cancer;
CESC	cis	rs9311474	0.713	rs352167	chr3:52238656	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	-0.29	-5.22	-0.31	3.69e-7	Electroencephalogram traits;
CESC	cis	rs7786808	0.649	rs6459879	chr7:158211792	C/G	cg09998033	chr7:158218633	PTPRN2	-0.37	-5.41	-0.32	1.43e-7	Obesity-related traits;
CESC	cis	rs9322193	0.651	rs9322188	chr6:149909491	A/G	cg07701084	chr6:150067640	NUP43	-0.41	-5.65	-0.33	4.23e-8	Lung cancer;
CESC	cis	rs921968	0.565	rs608047	chr2:219615910	A/C	cg02176678	chr2:219576539	TTLL4	0.39	6.87	0.39	4.68e-11	Mean corpuscular hemoglobin concentration;
CESC	cis	rs11122272	0.735	rs2486730	chr1:231534987	T/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.56	-7.66	-0.43	3.45e-13	Hemoglobin concentration;
CESC	cis	rs2180341	1.000	rs9285460	chr6:127640190	A/G	cg24812749	chr6:127587940	RNF146	1.07	15.48	0.69	6.31e-39	Breast cancer;
CESC	cis	rs634534	0.562	rs661335	chr11:65754061	G/A	cg02202077	chr11:65769826	EIF1AD;BANF1	0.45	6.02	0.35	5.67e-9	Sum eosinophil basophil counts;Eosinophil counts;
CESC	cis	rs9549367	0.713	rs4907599	chr13:113861441	C/T	cg00898013	chr13:113819073	PROZ	0.44	6.61	0.38	2.15e-10	Platelet distribution width;
CESC	cis	rs7762018	1.000	rs41265383	chr6:170068025	T/C	cg13891659	chr6:170190454	C6orf122;C6orf208	0.52	5.34	0.31	2e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs870825	0.616	rs7667449	chr4:185641711	T/C	cg04058563	chr4:185651563	MLF1IP	0.65	7.14	0.4	9.06e-12	Blood protein levels;
CESC	cis	rs7267979	0.966	rs3002698	chr20:25303379	C/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.86	-16.78	-0.72	1.5e-43	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs738322	1.000	rs133009	chr22:38569653	G/C	cg25457927	chr22:38595422	NA	-0.3	-5.51	-0.32	8.66e-8	Cutaneous nevi;
CESC	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.64	7.45	0.42	1.33e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg11668638	chr6:42952412	PPP2R5D	0.46	6.19	0.36	2.26e-9	Systemic lupus erythematosus;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg19906694	chr5:60629770	ZSWIM6	-0.47	-6.19	-0.36	2.34e-9	Fibrinogen levels;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg25682936	chr1:38455768	SF3A3	-0.44	-6.18	-0.35	2.38e-9	Gambling;
CESC	cis	rs6964587	0.869	rs2013334	chr7:91549657	G/A	cg17063962	chr7:91808500	NA	-0.53	-7.09	-0.4	1.21e-11	Breast cancer;
CESC	cis	rs6088590	1.000	rs6088595	chr20:33358499	T/A	cg06115741	chr20:33292138	TP53INP2	0.59	7.02	0.4	1.84e-11	Coronary artery disease;
CESC	cis	rs7246657	0.943	rs10415024	chr19:37814724	A/G	cg23950597	chr19:37808831	NA	-0.6	-6.08	-0.35	4.27e-9	Coronary artery calcification;
CESC	cis	rs875971	0.628	rs6974355	chr7:65841981	A/G	cg14393609	chr7:65229607	NA	0.43	5.46	0.32	1.12e-7	Aortic root size;
CESC	cis	rs11864453	0.612	rs12708925	chr16:72122706	A/T	cg16558253	chr16:72132732	DHX38	-0.54	-8.41	-0.46	2.65e-15	Fibrinogen levels;
CESC	cis	rs10885582	0.754	rs10749167	chr10:116300041	G/C	cg17056676	chr10:116301354	ABLIM1	-0.29	-5.33	-0.31	2.14e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg04025307	chr7:1156635	C7orf50	0.53	8.92	0.48	8.11e-17	Longevity;Endometriosis;
CESC	cis	rs898097	0.578	rs2380173	chr17:80909157	G/T	cg20271620	chr17:80763330	TBCD	0.43	5.71	0.33	2.98e-8	Breast cancer;
CESC	cis	rs5753037	0.585	rs5752962	chr22:30188245	A/C	cg01021169	chr22:30184971	ASCC2	-0.56	-8.59	-0.47	7.73e-16	Type 1 diabetes;
CESC	trans	rs864643	0.773	rs11129837	chr3:39589963	A/G	cg17878204	chr1:145611075	RNF115;POLR3C	0.48	6.13	0.35	3.23e-9	Attention deficit hyperactivity disorder;
CESC	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.66	-8.77	-0.47	2.21e-16	Longevity;Endometriosis;
CESC	cis	rs2637266	0.703	rs846646	chr10:78515883	C/T	cg18941641	chr10:78392320	NA	0.38	7.5	0.42	9.82e-13	Pulmonary function;
CESC	cis	rs1862618	0.853	rs860580	chr5:56149429	G/T	cg12311346	chr5:56204834	C5orf35	0.69	8.7	0.47	3.65e-16	Initial pursuit acceleration;
CESC	cis	rs7666738	0.830	rs4345191	chr4:98945408	A/G	cg17366294	chr4:99064904	C4orf37	0.6	8.53	0.46	1.15e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11723261	0.582	rs11248005	chr4:166615	C/T	cg12746427	chr4:53362	ZNF718;ZNF595	0.44	5.57	0.32	6.39e-8	Immune response to smallpox vaccine (IL-6);
CESC	cis	rs660498	0.516	rs638324	chr10:27730261	A/C	cg08398567	chr10:27609333	NA	0.36	5.13	0.3	5.71e-7	Asthma (childhood onset);
CESC	cis	rs6502050	0.667	rs9892469	chr17:80093657	T/C	cg23985595	chr17:80112537	CCDC57	-0.42	-6.6	-0.38	2.19e-10	Life satisfaction;
CESC	cis	rs832540	0.898	rs702680	chr5:56220382	T/C	cg12311346	chr5:56204834	C5orf35	-0.42	-5.27	-0.31	2.79e-7	Coronary artery disease;
CESC	cis	rs113835537	0.935	rs79106199	chr11:66420518	T/C	cg22134325	chr11:66188745	NPAS4	0.51	5.84	0.34	1.55e-8	Airway imaging phenotypes;
CESC	cis	rs4243830	1.000	rs12401795	chr1:6594773	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	0.78	6.22	0.36	1.95e-9	Body mass index;
CESC	cis	rs4665809	0.556	rs6730311	chr2:26419474	C/T	cg25036284	chr2:26402008	FAM59B	-0.89	-10.85	-0.55	6.05e-23	Gut microbiome composition (summer);
CESC	cis	rs929354	0.739	rs12533082	chr7:157014172	T/A	cg05182265	chr7:156933206	UBE3C	-0.5	-7.39	-0.41	1.88e-12	Body mass index;
CESC	cis	rs2073300	0.609	rs3746733	chr20:23349749	C/T	cg16736954	chr20:23401023	NAPB	0.72	5.54	0.32	7.47e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21646326	chr4:77227811	STBD1	0.62	7.29	0.41	3.57e-12	Gut microbiome composition (summer);
CESC	cis	rs8060686	0.920	rs73591955	chr16:67782568	G/T	cg26727032	chr16:67993705	SLC12A4	-0.57	-6.22	-0.36	1.92e-9	HDL cholesterol;Metabolic syndrome;
CESC	trans	rs17685	0.712	rs4552844	chr7:75718095	A/G	cg19862616	chr7:65841803	NCRNA00174	0.85	12.47	0.61	2.13e-28	Coffee consumption;Coffee consumption (cups per day);
CESC	trans	rs11098499	0.754	rs10212714	chr4:120254302	T/C	cg25214090	chr10:38739885	LOC399744	0.64	8.81	0.48	1.68e-16	Corneal astigmatism;
CESC	cis	rs7927771	0.832	rs10769258	chr11:47391039	C/T	cg20307385	chr11:47447363	PSMC3	0.56	6.65	0.38	1.65e-10	Subjective well-being;
CESC	cis	rs6582630	0.519	rs11182021	chr12:38443709	A/T	cg26384229	chr12:38710491	ALG10B	-0.64	-9.48	-0.5	1.5e-18	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg18402987	chr7:1209562	NA	0.76	7.79	0.43	1.5e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2404602	0.716	rs12907805	chr15:76690606	C/T	cg22467129	chr15:76604101	ETFA	-0.38	-5.75	-0.33	2.43e-8	Blood metabolite levels;
CESC	cis	rs4803468	1.000	rs2231940	chr19:41944237	T/C	cg09537434	chr19:41945824	ATP5SL	1.12	21.48	0.8	5.84e-60	Height;
CESC	cis	rs7568458	0.709	rs11895401	chr2:85753847	C/T	cg02493740	chr2:85810744	VAMP5	-0.57	-8.48	-0.46	1.57e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CESC	cis	rs7072216	0.763	rs7911036	chr10:100167015	A/T	cg26618903	chr10:100175079	PYROXD2	-0.36	-5.49	-0.32	9.42e-8	Metabolite levels;
CESC	cis	rs2795502	0.873	rs1891324	chr10:43399581	A/G	cg27426351	chr10:43362370	NA	0.49	5.97	0.34	7.63e-9	Blood protein levels;
CESC	cis	rs514406	0.505	rs269289	chr1:53167151	A/C	cg08859206	chr1:53392774	SCP2	-0.59	-8.23	-0.45	8.65e-15	Monocyte count;
CESC	cis	rs4253772	0.637	rs6008339	chr22:46650846	C/T	cg24881330	chr22:46731750	TRMU	0.89	10.09	0.53	1.86e-20	LDL cholesterol;Cholesterol, total;
CESC	cis	rs1008375	0.931	rs10008337	chr4:17593849	G/C	cg16339924	chr4:17578868	LAP3	0.73	9.5	0.5	1.31e-18	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs870825	0.860	rs72703527	chr4:185605997	C/A	cg04058563	chr4:185651563	MLF1IP	0.54	5.24	0.31	3.27e-7	Blood protein levels;
CESC	cis	rs6570726	0.791	rs425999	chr6:145819370	C/A	cg23711669	chr6:146136114	FBXO30	1.02	16.0	0.7	8.93e-41	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs854765	0.693	rs8080061	chr17:17776389	C/T	cg04398451	chr17:18023971	MYO15A	0.64	9.38	0.5	3.08e-18	Total body bone mineral density;
CESC	cis	rs13130787	0.606	rs1370821	chr4:94943383	C/T	cg11021082	chr4:95130006	SMARCAD1	0.45	6.26	0.36	1.55e-9	Colorectal cancer;
CESC	cis	rs3768617	0.510	rs2296293	chr1:183095477	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.89	14.39	0.66	4.39e-35	Fuchs's corneal dystrophy;
CESC	cis	rs11677416	1.000	rs34015482	chr2:113525745	A/G	cg27083787	chr2:113543245	IL1A	0.58	7.33	0.41	2.81e-12	Response to antipsychotic treatment in schizophrenia (working memory);
CESC	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg11494091	chr17:61959527	GH2	0.73	12.55	0.61	1.13e-28	Prudent dietary pattern;
CESC	cis	rs10242455	0.702	rs115279860	chr7:98994492	C/T	cg25640893	chr7:99214727	ZNF498	1.07	6.42	0.37	6.22e-10	Blood metabolite levels;
CESC	cis	rs2014572	0.967	rs11667407	chr19:57763122	C/T	cg24459738	chr19:57751996	ZNF805	-0.53	-7.54	-0.42	7.48e-13	Hyperactive-impulsive symptoms;
CESC	cis	rs9467711	0.606	rs2073530	chr6:26375243	T/C	cg12826209	chr6:26865740	GUSBL1	0.65	5.35	0.31	1.88e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs4563143	0.647	rs117442062	chr19:29256823	A/T	cg12667521	chr19:29218732	NA	0.48	6.28	0.36	1.37e-9	Methadone dose in opioid dependence;
CESC	cis	rs561341	0.740	rs11080174	chr17:30208521	C/A	cg13647721	chr17:30228624	UTP6	-0.76	-9.3	-0.5	5.52e-18	Hip circumference adjusted for BMI;
CESC	cis	rs61332075	0.518	rs56171132	chr2:239378856	C/T	cg18131467	chr2:239335373	ASB1	-0.74	-6.11	-0.35	3.58e-9	Lung function (FEV1/FVC);
CESC	cis	rs1395	0.778	rs1978881	chr2:27400850	C/A	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.42	5.5	0.32	8.91e-8	Blood metabolite levels;
CESC	cis	rs4713118	0.662	rs149901	chr6:27965503	C/T	cg19592336	chr6:28129416	ZNF389	0.47	6.44	0.37	5.49e-10	Parkinson's disease;
CESC	cis	rs7666738	0.830	rs10028505	chr4:98962310	C/A	cg18180107	chr4:99064573	C4orf37	0.4	5.14	0.3	5.26e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3105593	0.635	rs3131567	chr15:50757930	A/T	cg05456662	chr15:50716270	USP8	0.41	5.53	0.32	7.86e-8	QT interval;
CESC	cis	rs7618915	0.547	rs12496634	chr3:52709259	A/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	5.69	0.33	3.44e-8	Bipolar disorder;
CESC	cis	rs801193	0.967	rs34356500	chr7:66236607	G/T	cg11764359	chr7:65958608	NA	0.65	8.21	0.45	9.47e-15	Aortic root size;
CESC	cis	rs7100689	0.646	rs1340384	chr10:82088702	T/A	cg00277334	chr10:82204260	NA	-0.6	-7.96	-0.44	4.91e-14	Post bronchodilator FEV1;
CESC	cis	rs7618915	0.547	rs2336542	chr3:52710636	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.5	7.27	0.41	4.02e-12	Bipolar disorder;
CESC	cis	rs7250872	0.647	rs2304612	chr19:1817866	A/G	cg02747822	chr19:1826707	REXO1	-0.37	-5.15	-0.3	5.13e-7	Bipolar disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15900544	chr1:153606818	C1orf77;S100A13	0.58	6.09	0.35	3.94e-9	Gut microbiome composition (summer);
CESC	cis	rs3892630	0.588	rs7248798	chr19:33303684	G/T	cg13157960	chr19:33183277	NUDT19	0.55	5.59	0.32	5.67e-8	Red blood cell traits;
CESC	cis	rs2439831	0.867	rs12324572	chr15:43636200	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.84	12.56	0.61	1.02e-28	Lung cancer in ever smokers;
CESC	cis	rs57506017	0.628	rs2302635	chr7:12270625	G/A	cg23422036	chr7:12250390	TMEM106B	0.39	5.17	0.3	4.56e-7	Neuroticism;
CESC	cis	rs9733	0.596	rs7549795	chr1:150656873	G/A	cg22823121	chr1:150693482	HORMAD1	0.48	7.09	0.4	1.21e-11	Tonsillectomy;
CESC	cis	rs8014204	1.000	rs8014204	chr14:75322794	A/G	cg08847533	chr14:75593920	NEK9	0.48	6.08	0.35	4.26e-9	Caffeine consumption;
CESC	cis	rs9487051	1.000	rs9400273	chr6:109632799	A/G	cg01475377	chr6:109611718	NA	-0.41	-6.16	-0.35	2.7e-9	Reticulocyte fraction of red cells;
CESC	cis	rs12973672	0.812	rs12979058	chr19:35750684	G/A	cg12095397	chr19:35769544	USF2	0.5	6.0	0.35	6.44e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs28829049	0.597	rs12745238	chr1:19393710	C/T	cg13387374	chr1:19411106	UBR4	0.44	5.62	0.33	4.73e-8	QRS duration in Tripanosoma cruzi seropositivity;
CESC	cis	rs829880	0.558	rs249821	chr12:98897811	T/C	cg25150519	chr12:98850993	NA	0.51	5.97	0.34	7.65e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs875971	0.571	rs160641	chr7:65577346	G/A	cg19163074	chr7:65112434	INTS4L2	0.47	5.05	0.3	8.31e-7	Aortic root size;
CESC	cis	rs5758659	1.000	rs5751255	chr22:42648408	C/T	cg04733989	chr22:42467013	NAGA	0.41	5.6	0.33	5.42e-8	Cognitive function;
CESC	cis	rs12824058	0.798	rs7968728	chr12:130804696	T/A	cg23887609	chr12:130822674	PIWIL1	0.43	5.3	0.31	2.45e-7	Menopause (age at onset);
CESC	cis	rs1448094	0.512	rs11117060	chr12:86250788	G/T	cg00310523	chr12:86230176	RASSF9	-0.35	-5.49	-0.32	9.21e-8	Major depressive disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19319069	chr7:129593010	UBE2H	-0.6	-7.05	-0.4	1.57e-11	Gut microbiome composition (summer);
CESC	cis	rs12477438	0.520	rs13798	chr2:99813614	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.88	15.95	0.7	1.34e-40	Chronic sinus infection;
CESC	cis	rs8017423	0.967	rs7142513	chr14:90705182	T/C	cg14092571	chr14:90743983	NA	-0.55	-8.08	-0.44	2.37e-14	Mortality in heart failure;
CESC	cis	rs2404618	0.624	rs7012381	chr8:1475357	C/T	cg13402656	chr8:1511478	DLGAP2	-0.48	-6.69	-0.38	1.3100000000000001e-10	Lung cancer;
CESC	cis	rs858239	0.600	rs10256524	chr7:23144947	T/C	cg23682824	chr7:23144976	KLHL7	0.54	7.7	0.43	2.72e-13	Cerebrospinal fluid biomarker levels;
CESC	cis	rs1862618	0.671	rs832531	chr5:56228401	A/G	cg22800045	chr5:56110881	MAP3K1	0.57	7.53	0.42	8.21e-13	Initial pursuit acceleration;
CESC	cis	rs796364	0.662	rs11687313	chr2:201146399	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.71	-5.11	-0.3	6.16e-7	Schizophrenia;
CESC	cis	rs7605827	0.930	rs13015492	chr2:15505716	G/A	cg19274914	chr2:15703543	NA	0.32	5.76	0.33	2.33e-8	Educational attainment (years of education);
CESC	cis	rs73206853	0.841	rs73191828	chr12:110946121	G/A	cg12870014	chr12:110450643	ANKRD13A	0.63	5.22	0.31	3.56e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs7267979	1.000	rs6050617	chr20:25421648	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.87	18.11	0.74	3e-48	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs1499614	1.000	rs2707828	chr7:66171377	G/A	cg13147721	chr7:65941812	NA	-0.94	-8.9	-0.48	9.08e-17	Gout;
CESC	cis	rs61931739	0.534	rs10844816	chr12:34248533	C/A	cg19457237	chr12:34500585	NA	-0.38	-5.34	-0.31	2.02e-7	Morning vs. evening chronotype;
CESC	cis	rs1707322	0.721	rs11211149	chr1:46112218	T/C	cg05343316	chr1:45956843	TESK2	0.5	6.18	0.35	2.46e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs1046896	0.627	rs7225515	chr17:80795783	C/T	cg02711726	chr17:80685570	FN3KRP	-0.43	-5.72	-0.33	2.8e-8	Glycated hemoglobin levels;
CESC	cis	rs73206853	0.563	rs34378671	chr12:111163204	C/T	cg12870014	chr12:110450643	ANKRD13A	0.64	5.66	0.33	3.91e-8	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	trans	rs12310956	0.532	rs1852226	chr12:33962940	G/A	cg26384229	chr12:38710491	ALG10B	0.48	6.68	0.38	1.37e-10	Morning vs. evening chronotype;
CESC	cis	rs10489525	0.599	rs17033129	chr1:115611539	C/T	cg12756093	chr1:115239321	AMPD1	-0.45	-5.59	-0.32	5.56e-8	Autism;
CESC	cis	rs4955124	0.818	rs4955220	chr3:32043207	A/G	cg05935571	chr3:32023257	ZNF860;OSBPL10	0.66	5.29	0.31	2.5e-7	Schizophrenia;
CESC	cis	rs2288912	0.807	rs10423208	chr19:45453656	G/A	cg20090143	chr19:45452003	APOC2	0.37	6.39	0.37	7.58e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs344364	0.511	rs2982449	chr16:1947878	C/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.55	-6.2	-0.36	2.15e-9	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs10129255	0.500	rs6576225	chr14:107186359	G/C	cg23076370	chr14:107095027	NA	-0.65	-9.67	-0.51	3.98e-19	Kawasaki disease;
CESC	cis	rs1008375	1.000	rs4698651	chr4:17694223	A/G	cg16339924	chr4:17578868	LAP3	0.58	7.08	0.4	1.33e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs56114371	0.777	rs200483	chr6:27774824	C/T	cg02228804	chr6:27775720	HIST1H2AI;HIST1H2BL	0.61	5.64	0.33	4.37e-8	Breast cancer;
CESC	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg21226059	chr5:178986404	RUFY1	0.52	8.09	0.44	2.18e-14	Lung cancer;
CESC	trans	rs2797160	0.651	rs1268067	chr6:126036621	T/C	cg05039488	chr6:79577232	IRAK1BP1	0.48	6.44	0.37	5.59e-10	Endometrial cancer;
CESC	cis	rs6598955	0.640	rs6667826	chr1:26531408	T/C	cg00852783	chr1:26633632	UBXN11	0.4	5.85	0.34	1.41e-8	Obesity-related traits;
CESC	cis	rs1005277	0.579	rs2505196	chr10:38393563	G/A	cg25427524	chr10:38739819	LOC399744	-0.66	-9.5	-0.5	1.29e-18	Extrinsic epigenetic age acceleration;
CESC	cis	rs7584330	0.657	rs7599658	chr2:238352898	A/C	cg14458575	chr2:238380390	NA	-0.66	-9.26	-0.49	7.41e-18	Prostate cancer;
CESC	cis	rs10504229	0.679	rs16921606	chr8:58034477	A/C	cg24829409	chr8:58192753	C8orf71	-0.42	-5.53	-0.32	7.58e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs832540	0.519	rs10940518	chr5:56270794	C/T	cg14703610	chr5:56206110	C5orf35	0.53	6.86	0.39	4.71e-11	Coronary artery disease;
CESC	cis	rs6732160	0.588	rs2043101	chr2:73374050	A/G	cg01422370	chr2:73384389	NA	0.58	9.54	0.51	9.53e-19	Intelligence (multi-trait analysis);
CESC	cis	rs9430161	0.579	rs7542164	chr1:11040223	G/A	cg02454025	chr1:11042201	C1orf127	0.87	13.72	0.64	9.82e-33	Ewing sarcoma;
CESC	trans	rs10028773	0.700	rs35653026	chr4:120248378	A/G	cg25214090	chr10:38739885	LOC399744	0.62	8.36	0.46	3.48e-15	Educational attainment;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg09419297	chr15:77712428	HMG20A	-0.45	-6.09	-0.35	3.97e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs7605378	0.528	rs7592587	chr2:200786516	C/G	cg23649088	chr2:200775458	C2orf69	0.71	8.81	0.48	1.64e-16	Osteoporosis;
CESC	cis	rs4253772	0.575	rs9615364	chr22:46797503	G/A	cg18190219	chr22:46762943	CELSR1	-0.6	-6.22	-0.36	1.97e-9	LDL cholesterol;Cholesterol, total;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23323137	chr6:42532021	UBR2	0.57	6.46	0.37	4.94e-10	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.830	rs13122054	chr4:98972974	G/A	cg05340658	chr4:99064831	C4orf37	0.8	12.36	0.6	5.3e-28	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11098499	0.863	rs11736416	chr4:120431661	C/T	cg25214090	chr10:38739885	LOC399744	0.7	9.62	0.51	5.54e-19	Corneal astigmatism;
CESC	cis	rs35110281	0.805	rs2838317	chr21:44991791	A/C	cg21573476	chr21:45109991	RRP1B	-0.43	-5.96	-0.34	8.16e-9	Mean corpuscular volume;
CESC	cis	rs875971	1.000	rs6460296	chr7:65895139	C/T	cg12463550	chr7:65579703	CRCP	0.57	7.2	0.4	6.12e-12	Aortic root size;
CESC	cis	rs7666738	0.830	rs957742	chr4:99029409	C/T	cg05340658	chr4:99064831	C4orf37	0.83	13.1	0.63	1.43e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg18538332	chr22:24372958	LOC391322	-0.74	-10.81	-0.55	8.55e-23	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs6499129	0.867	rs1862689	chr16:67419152	C/T	cg26727032	chr16:67993705	SLC12A4	-0.5	-5.62	-0.33	4.95e-8	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs6831352	0.918	rs3919370	chr4:100064326	A/T	cg13256891	chr4:100009986	ADH5	-0.73	-7.79	-0.43	1.52e-13	Alcohol dependence;
CESC	cis	rs796364	0.806	rs79725795	chr2:201083534	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.7	-6.12	-0.35	3.32e-9	Schizophrenia;
CESC	cis	rs9911578	0.935	rs9911753	chr17:56983174	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.4	5.31	0.31	2.36e-7	Intelligence (multi-trait analysis);
CESC	cis	rs9916302	0.706	rs12937013	chr17:37665571	G/A	cg07936489	chr17:37558343	FBXL20	-0.91	-9.97	-0.52	4.37e-20	Glomerular filtration rate (creatinine);
CESC	cis	rs17666538	1.000	rs59631161	chr8:587808	G/T	cg13264159	chr8:625131	ERICH1	0.74	5.14	0.3	5.34e-7	IgG glycosylation;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg12105361	chr19:10216875	PPAN-P2RY11;SNORD105;PPAN	-0.47	-6.14	-0.35	2.97e-9	Asthma;
CESC	trans	rs7618501	0.699	rs2777888	chr3:49898000	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.49	6.8	0.39	6.79e-11	Intelligence (multi-trait analysis);
CESC	cis	rs12220238	1.000	rs10824078	chr10:75892120	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.64	6.23	0.36	1.87e-9	Soluble interleukin-2 receptor subunit alpha;
CESC	cis	rs2898681	0.561	rs2200225	chr4:53738411	A/G	cg00791764	chr4:53727839	RASL11B	0.45	5.45	0.32	1.13e-7	Optic nerve measurement (cup area);
CESC	cis	rs875971	0.862	rs17747530	chr7:65994729	G/C	cg10691866	chr7:65817282	TPST1	-0.33	-5.39	-0.31	1.58e-7	Aortic root size;
CESC	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg21280719	chr6:42927975	GNMT	-0.27	-6.08	-0.35	4.09e-9	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs7020830	0.858	rs67036212	chr9:37133538	A/G	cg14294708	chr9:37120828	ZCCHC7	1.25	23.68	0.82	2.39e-67	Schizophrenia;
CESC	trans	rs1908814	0.510	rs57655799	chr8:11782417	A/C	cg15556689	chr8:8085844	FLJ10661	0.51	6.21	0.36	1.99e-9	Neuroticism;
CESC	cis	rs6963495	0.818	rs73190167	chr7:105160418	A/G	cg02135003	chr7:105160482	PUS7	-0.46	-5.55	-0.32	6.92e-8	Bipolar disorder (body mass index interaction);
CESC	cis	rs4466137	1.000	rs4466137	chr5:82985739	A/C	cg16102102	chr5:83017553	HAPLN1	-0.42	-6.36	-0.36	8.92e-10	Prostate cancer;
CESC	cis	rs4588572	0.615	rs4143070	chr5:77769094	G/C	cg11547950	chr5:77652471	NA	-0.4	-5.47	-0.32	1.07e-7	Triglycerides;
CESC	cis	rs739401	0.611	rs494427	chr11:3048140	A/G	cg08508325	chr11:3079039	CARS	-0.51	-10.01	-0.52	3.22e-20	Longevity;
CESC	cis	rs9443189	1.000	rs6905047	chr6:76498109	C/T	cg01950844	chr6:76311363	SENP6	0.62	5.97	0.34	7.42e-9	Prostate cancer;
CESC	cis	rs3096299	0.685	rs4785571	chr16:89565169	A/G	cg16743903	chr16:89593216	SPG7	-0.49	-6.5	-0.37	3.95e-10	Multiple myeloma (IgH translocation);
CESC	cis	rs644799	1.000	rs1944074	chr11:95511445	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.71	9.55	0.51	8.96e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs2294693	0.947	rs6924722	chr6:41002195	C/T	cg14418226	chr6:40996092	UNC5CL	-0.45	-5.81	-0.34	1.75e-8	Gastric cancer;Non-cardia gastric cancer;
CESC	cis	rs6951245	0.882	rs10256720	chr7:1210825	C/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.51	5.75	0.33	2.42e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs1218582	0.774	rs11264284	chr1:154875793	C/T	cg03351412	chr1:154909251	PMVK	0.6	7.73	0.43	2.26e-13	Prostate cancer;
CESC	cis	rs2404602	0.583	rs12898415	chr15:76574232	C/T	cg05617483	chr15:76483344	C15orf27	0.4	5.34	0.31	2.01e-7	Blood metabolite levels;
CESC	cis	rs9487051	0.768	rs442405	chr6:109526980	T/G	cg01475377	chr6:109611718	NA	-0.44	-6.66	-0.38	1.56e-10	Reticulocyte fraction of red cells;
CESC	cis	rs7107174	1.000	rs10899465	chr11:78013588	G/A	cg02023728	chr11:77925099	USP35	0.49	6.42	0.37	6.18e-10	Testicular germ cell tumor;
CESC	cis	rs11122272	0.668	rs2808616	chr1:231554993	C/G	cg06096015	chr1:231504339	EGLN1	-0.39	-5.65	-0.33	4.21e-8	Hemoglobin concentration;
CESC	cis	rs7666738	0.893	rs11729640	chr4:99052699	C/T	cg05340658	chr4:99064831	C4orf37	0.82	12.88	0.62	8.44e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7851660	0.809	rs3808893	chr9:100663745	C/T	cg13688889	chr9:100608707	NA	-0.62	-8.87	-0.48	1.11e-16	Strep throat;
CESC	cis	rs1348850	0.918	rs12463893	chr2:178448559	G/T	cg23306229	chr2:178417860	TTC30B	0.55	7.17	0.4	7.52e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs4660306	0.961	rs4660867	chr1:45986484	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.61	-7.72	-0.43	2.33e-13	Homocysteine levels;
CESC	cis	rs3087591	0.960	rs1013947	chr17:29530362	C/T	cg24425628	chr17:29625626	OMG;NF1	0.43	5.35	0.31	1.9e-7	Hip circumference;
CESC	cis	rs10504229	0.683	rs56196593	chr8:58141898	G/A	cg22535103	chr8:58192502	C8orf71	-0.82	-9.22	-0.49	9.72e-18	Developmental language disorder (linguistic errors);
CESC	cis	rs6499255	0.951	rs56282083	chr16:69825728	C/T	cg15192750	chr16:69999425	NA	0.43	5.35	0.31	1.91e-7	IgE levels;
CESC	cis	rs6087771	0.650	rs6060395	chr20:30219823	G/C	cg13852791	chr20:30311386	BCL2L1	0.67	7.84	0.43	1.11e-13	Subcortical brain region volumes;Putamen volume;
CESC	trans	rs17685	0.753	rs1639609	chr7:75683581	T/C	cg19862616	chr7:65841803	NCRNA00174	0.83	12.38	0.61	4.45e-28	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs60871478	1.000	rs4720917	chr7:806998	C/G	cg05535760	chr7:792225	HEATR2	0.87	10.97	0.56	2.5e-23	Cerebrospinal P-tau181p levels;
CESC	cis	rs2836974	0.584	rs6517535	chr21:40653352	G/C	cg17971929	chr21:40555470	PSMG1	-0.87	-12.61	-0.61	6.96e-29	Cognitive function;
CESC	cis	rs453301	0.507	rs2929306	chr8:9084909	C/T	cg06636001	chr8:8085503	FLJ10661	-0.54	-7.0	-0.39	2.15e-11	Joint mobility (Beighton score);
CESC	cis	rs4268898	1.000	rs6707781	chr2:24441883	T/G	cg06627628	chr2:24431161	ITSN2	0.66	8.08	0.44	2.26e-14	Asthma;
CESC	cis	rs9487051	0.714	rs13209277	chr6:109624963	T/A	cg12927641	chr6:109611667	NA	-0.41	-6.13	-0.35	3.09e-9	Reticulocyte fraction of red cells;
CESC	cis	rs9388451	0.587	rs1739385	chr6:126099939	G/A	cg05901451	chr6:126070800	HEY2	-0.57	-8.24	-0.45	7.88e-15	Brugada syndrome;
CESC	cis	rs4835473	0.669	rs75704080	chr4:144700219	A/T	cg25736465	chr4:144833511	NA	-0.33	-5.18	-0.3	4.42e-7	Immature fraction of reticulocytes;
CESC	cis	rs7607369	0.580	rs7594289	chr2:219652286	A/G	cg02176678	chr2:219576539	TTLL4	-0.49	-8.59	-0.47	7.42e-16	Red blood cell count;Amyotrophic lateral sclerosis;
CESC	cis	rs12477438	0.798	rs6705821	chr2:99602832	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-10.57	-0.54	5.22e-22	Chronic sinus infection;
CESC	cis	rs7772486	0.701	rs697056	chr6:146003897	C/T	cg05347473	chr6:146136440	FBXO30	-0.56	-6.87	-0.39	4.53e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs801193	0.569	rs2707824	chr7:66189243	A/G	cg18252515	chr7:66147081	NA	-0.47	-6.41	-0.37	6.57e-10	Aortic root size;
CESC	trans	rs1219515	0.614	rs1696821	chr10:123463056	G/A	cg09033641	chr16:89436838	ANKRD11	0.54	6.13	0.35	3.21e-9	Magnesium levels;
CESC	cis	rs6087990	0.965	rs2424899	chr20:31343543	A/C	cg13636640	chr20:31349939	DNMT3B	0.9	16.32	0.71	6.41e-42	Ulcerative colitis;
CESC	cis	rs698833	0.828	rs4952710	chr2:44524575	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.46	5.83	0.34	1.63e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs1707322	0.721	rs56255771	chr1:46224319	C/T	cg05343316	chr1:45956843	TESK2	0.47	6.02	0.35	5.8e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs10504229	1.000	rs59071610	chr8:58186301	A/C	cg14926445	chr8:58193284	C8orf71	-0.51	-5.52	-0.32	8.28e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs9291683	0.530	rs13115193	chr4:9982191	C/T	cg02734326	chr4:10020555	SLC2A9	0.46	6.9	0.39	3.73e-11	Bone mineral density;
CESC	cis	rs9916302	0.706	rs2338799	chr17:37513941	G/A	cg07936489	chr17:37558343	FBXL20	0.89	9.69	0.51	3.45e-19	Glomerular filtration rate (creatinine);
CESC	cis	rs780096	0.565	rs10169261	chr2:27727314	C/T	cg24768116	chr2:27665128	KRTCAP3	-0.34	-6.23	-0.36	1.8e-9	Total body bone mineral density;
CESC	cis	rs9581857	0.579	rs3759434	chr13:27997700	A/C	cg01674679	chr13:27998804	GTF3A	-0.63	-6.3	-0.36	1.26e-9	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
CESC	cis	rs7811142	1.000	rs4989959	chr7:100032288	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.0	9.63	0.51	5.12e-19	Platelet count;
CESC	cis	rs898097	0.812	rs7406011	chr17:80829980	C/T	cg08704611	chr17:80376099	HEXDC;C17orf101	-0.43	-5.06	-0.3	7.89e-7	Breast cancer;
CESC	cis	rs11676348	0.811	rs13027120	chr2:219020914	C/T	cg00012203	chr2:219082015	ARPC2	0.54	6.89	0.39	4.03e-11	Ulcerative colitis;
CESC	cis	rs524281	0.861	rs485857	chr11:65959519	A/G	cg14036092	chr11:66035641	RAB1B	-0.49	-5.5	-0.32	9.06e-8	Electroencephalogram traits;
CESC	cis	rs34779708	0.931	rs4934710	chr10:35350416	T/C	cg04310649	chr10:35416472	CREM	-0.49	-5.87	-0.34	1.31e-8	Inflammatory bowel disease;Crohn's disease;
CESC	trans	rs61931739	0.534	rs11053075	chr12:34207009	A/G	cg26384229	chr12:38710491	ALG10B	-0.63	-9.08	-0.49	2.55e-17	Morning vs. evening chronotype;
CESC	cis	rs12541635	0.677	rs12546875	chr8:107012915	C/T	cg10147462	chr8:107024639	NA	0.48	7.12	0.4	1.03e-11	Age of smoking initiation;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12833323	chr8:145180747	NA	-0.55	-6.06	-0.35	4.66e-9	Gut microbiome composition (summer);
CESC	cis	rs2637266	0.905	rs3923669	chr10:78375047	T/C	cg18941641	chr10:78392320	NA	0.43	8.26	0.45	6.94e-15	Pulmonary function;
CESC	cis	rs8114671	0.869	rs2145559	chr20:33651725	G/A	cg07148914	chr20:33460835	GGT7	-0.41	-5.24	-0.31	3.28e-7	Height;
CESC	cis	rs703842	1.000	rs10783847	chr12:58196447	G/A	cg00599273	chr12:58146742	CDK4	0.33	5.04	0.3	8.52e-7	Multiple sclerosis;
CESC	cis	rs13118159	0.836	rs2293630	chr4:1342521	G/A	cg01939980	chr4:1354348	KIAA1530	0.41	5.53	0.32	7.61e-8	Longevity;
CESC	cis	rs1552244	0.572	rs7645759	chr3:10157368	C/T	cg00149659	chr3:10157352	C3orf10	1.01	11.49	0.58	4.52e-25	Alzheimer's disease;
CESC	cis	rs8005677	1.000	rs1043209	chr14:23373986	A/G	cg25600027	chr14:23388339	RBM23	0.42	5.11	0.3	6.24e-7	Cognitive ability (multi-trait analysis);
CESC	trans	rs9987353	0.840	rs329994	chr8:9123233	A/G	cg17001531	chr1:16825540	NA	-0.43	-6.12	-0.35	3.39e-9	Recombination measurement;
CESC	cis	rs9611565	0.729	rs73176689	chr22:41782633	T/C	cg06481639	chr22:41940642	POLR3H	-0.67	-7.01	-0.4	1.95e-11	Vitiligo;
CESC	cis	rs938554	0.784	rs10939638	chr4:9977675	T/A	cg00071950	chr4:10020882	SLC2A9	0.48	5.68	0.33	3.49e-8	Blood metabolite levels;
CESC	cis	rs4253772	0.637	rs36125344	chr22:46655779	G/C	cg00784671	chr22:46762841	CELSR1	-0.52	-5.49	-0.32	9.24e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs3540	0.533	rs12916560	chr15:91056259	A/C	cg22089800	chr15:90895588	ZNF774	-0.61	-8.11	-0.45	1.93e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs875971	0.545	rs4718364	chr7:66001340	C/A	cg25405998	chr7:65216604	CCT6P1	0.46	5.21	0.3	3.87e-7	Aortic root size;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg14849479	chr5:60039648	NA	0.41	6.1	0.35	3.83e-9	Fibrinogen levels;
CESC	cis	rs7178572	0.568	rs11857294	chr15:77596725	C/T	cg22256960	chr15:77711686	NA	-0.53	-6.6	-0.38	2.26e-10	Type 2 diabetes;
CESC	trans	rs9929218	1.000	rs12930371	chr16:68802936	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.63	8.47	0.46	1.75e-15	Colorectal cancer;
CESC	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg07157834	chr1:205819609	PM20D1	0.71	11.02	0.56	1.73e-23	Menarche (age at onset);
CESC	cis	rs6089829	0.962	rs6062777	chr20:61663748	G/A	cg16240275	chr20:61666158	NCRNA00029	0.5	8.97	0.48	5.67e-17	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs780096	0.526	rs3845686	chr2:27655447	T/G	cg22903471	chr2:27725779	GCKR	-0.55	-7.72	-0.43	2.43e-13	Total body bone mineral density;
CESC	cis	rs6541297	0.941	rs2144299	chr1:230280366	A/G	cg05784532	chr1:230284198	GALNT2	0.47	5.38	0.31	1.63e-7	Coronary artery disease;
CESC	cis	rs736801	0.780	rs12521868	chr5:131784393	A/C	cg07395648	chr5:131743802	NA	0.44	5.48	0.32	1.01e-7	Breast cancer;Mosquito bite size;
CESC	cis	rs1448094	0.512	rs6539931	chr12:86247473	C/T	cg19622623	chr12:86230825	RASSF9	-0.46	-5.89	-0.34	1.14e-8	Major depressive disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13986503	chr11:126152983	TIRAP	0.58	7.04	0.4	1.64e-11	Gut microbiome composition (summer);
CESC	trans	rs6794880	0.943	rs1482385	chr3:84459213	G/T	cg03554283	chr8:76319451	NA	-0.56	-6.08	-0.35	4.27e-9	Body mass index (joint analysis main effects and smoking interaction);BMI in non-smokers;BMI (adjusted for smoking behaviour);
CESC	cis	rs514406	0.825	rs497535	chr1:53284677	A/G	cg24675658	chr1:53192096	ZYG11B	0.56	7.04	0.4	1.63e-11	Monocyte count;
CESC	cis	rs7560272	0.501	rs6750494	chr2:73946496	G/A	cg20560298	chr2:73613845	ALMS1	0.41	5.61	0.33	5.1e-8	Schizophrenia;
CESC	cis	rs7640424	0.628	rs7628325	chr3:107816314	G/A	cg09227934	chr3:107805635	CD47	-0.47	-5.77	-0.33	2.24e-8	Body mass index;
CESC	cis	rs4820294	1.000	rs78974622	chr22:38059925	A/C	cg21798802	chr22:38057573	PDXP	0.46	7.88	0.44	8.53e-14	Fat distribution (HIV);
CESC	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg06873352	chr17:61820015	STRADA	0.73	12.83	0.62	1.19e-29	Prudent dietary pattern;
CESC	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg22535103	chr8:58192502	C8orf71	-0.94	-9.92	-0.52	6.46e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs10791097	0.678	rs10894272	chr11:130731081	A/G	cg12179176	chr11:130786555	SNX19	0.55	8.38	0.46	3.14e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs72781680	0.752	rs56152044	chr2:23927680	A/G	cg20701182	chr2:24300061	SF3B14	0.81	7.13	0.4	9.6e-12	Lymphocyte counts;
CESC	cis	rs6963495	0.585	rs1706923	chr7:105221097	A/G	cg13798780	chr7:105162888	PUS7	0.54	6.76	0.38	8.58e-11	Bipolar disorder (body mass index interaction);
CESC	cis	rs8017423	0.967	rs61989980	chr14:90727635	C/T	cg14092571	chr14:90743983	NA	-0.55	-8.17	-0.45	1.24e-14	Mortality in heart failure;
CESC	cis	rs7520050	0.966	rs7556615	chr1:46461369	G/A	cg03146154	chr1:46216737	IPP	-0.48	-6.16	-0.35	2.71e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs4953076	0.573	rs13008237	chr2:44404902	A/G	cg04920474	chr2:44395004	PPM1B	0.55	7.07	0.4	1.37e-11	Height;
CESC	cis	rs7618915	0.533	rs35107891	chr3:52613656	G/C	cg17372223	chr3:52568218	NT5DC2	0.43	6.34	0.36	1e-9	Bipolar disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08717488	chr1:205238158	TMCC2	-0.61	-6.75	-0.38	9.17e-11	Gut microbiome composition (summer);
CESC	cis	rs5758659	0.904	rs134877	chr22:42662371	C/T	cg04733989	chr22:42467013	NAGA	0.42	5.81	0.34	1.78e-8	Cognitive function;
CESC	cis	rs977987	0.843	rs7499872	chr16:75426529	G/A	cg03315344	chr16:75512273	CHST6	0.4	5.73	0.33	2.68e-8	Dupuytren's disease;
CESC	trans	rs561341	1.000	rs546519	chr17:30297682	T/G	cg27661571	chr11:113659931	NA	-0.72	-7.36	-0.41	2.36e-12	Hip circumference adjusted for BMI;
CESC	cis	rs2576037	0.562	rs477826	chr18:44397649	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.78	12.9	0.62	7.29e-30	Personality dimensions;
CESC	cis	rs2836950	0.527	rs2836948	chr21:40599677	T/C	cg17971929	chr21:40555470	PSMG1	-0.55	-7.16	-0.4	8.14e-12	Menarche (age at onset);
CESC	cis	rs597539	0.652	rs559032	chr11:68710847	G/T	cg21963583	chr11:68658836	MRPL21	0.43	6.33	0.36	1.03e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs6952808	0.689	rs12670737	chr7:2046830	C/T	cg05863683	chr7:1912471	MAD1L1	0.47	7.18	0.4	7e-12	Bipolar disorder and schizophrenia;
CESC	cis	rs1707322	0.721	rs10890341	chr1:46147240	C/A	cg03146154	chr1:46216737	IPP	0.82	11.53	0.58	3.39e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs6912958	0.512	rs910563	chr6:88058885	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.47	8.18	0.45	1.18e-14	Monocyte percentage of white cells;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03988675	chr1:14075428	PRDM2	-0.45	-6.2	-0.36	2.18e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs8031584	0.736	rs11635775	chr15:31160640	A/G	cg08704250	chr15:31115839	NA	-0.63	-8.2	-0.45	1.06e-14	Huntington's disease progression;
CESC	cis	rs769267	0.965	rs2023882	chr19:19405405	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.43	5.27	0.31	2.88e-7	Tonsillectomy;
CESC	cis	rs6545883	0.895	rs2442029	chr2:61679552	G/T	cg15711740	chr2:61764176	XPO1	-0.4	-5.22	-0.31	3.61e-7	Tuberculosis;
CESC	cis	rs9815354	0.812	rs73073230	chr3:42008263	G/A	cg03022575	chr3:42003672	ULK4	0.69	6.24	0.36	1.72e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs9479482	1.000	rs9478380	chr6:150354665	A/G	cg03788504	chr6:150331562	NA	0.36	6.53	0.37	3.3e-10	Alopecia areata;
CESC	cis	rs7503807	0.701	rs1485329	chr17:78643561	A/G	cg09596252	chr17:78655493	RPTOR	0.42	5.77	0.33	2.19e-8	Obesity;
CESC	cis	rs3741489	1.000	rs75810241	chr12:133365186	G/A	cg01499426	chr12:133417423	CHFR	1.07	6.1	0.35	3.79e-9	Cognitive function;
CESC	cis	rs4319547	0.695	rs10773167	chr12:122934001	C/T	cg23029597	chr12:123009494	RSRC2	-0.48	-5.19	-0.3	4.24e-7	Body mass index;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16873973	chr7:5920535	OCM	-0.42	-6.12	-0.35	3.43e-9	Gut microbiome composition (summer);
CESC	cis	rs6952808	0.500	rs3778996	chr7:2177190	G/A	cg21782813	chr7:2030301	MAD1L1	0.49	7.05	0.4	1.52e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs11252926	0.507	rs4881199	chr10:428090	C/G	cg16386425	chr10:429943	DIP2C	-0.57	-7.5	-0.42	9.73e-13	Psychosis in Alzheimer's disease;
CESC	cis	rs6032067	0.929	rs6032055	chr20:43833336	C/T	cg10761708	chr20:43804764	PI3	0.52	6.3	0.36	1.27e-9	Blood protein levels;
CESC	cis	rs9649213	0.593	rs2107716	chr7:97944744	G/A	cg08684580	chr7:98029266	BAIAP2L1	-0.36	-5.82	-0.34	1.69e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs9322193	0.962	rs2065664	chr6:150083621	A/G	cg13206674	chr6:150067644	NUP43	0.41	5.64	0.33	4.37e-8	Lung cancer;
CESC	cis	rs9916302	0.904	rs8077104	chr17:37530510	A/G	cg00129232	chr17:37814104	STARD3	0.57	7.44	0.42	1.38e-12	Glomerular filtration rate (creatinine);
CESC	cis	rs2204008	0.594	rs2711545	chr12:38061039	C/T	cg26384229	chr12:38710491	ALG10B	0.44	5.96	0.34	7.93e-9	Bladder cancer;
CESC	cis	rs4077515	0.967	rs10781500	chr9:139269338	A/G	cg14169450	chr9:139327907	INPP5E	-0.34	-5.03	-0.3	9.17e-7	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs3093024	0.967	rs1571878	chr6:167540842	C/T	cg07741184	chr6:167504864	NA	-0.33	-5.56	-0.32	6.49e-8	Rheumatoid arthritis;
CESC	cis	rs1065852	0.510	rs5751247	chr22:42633054	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.38	6.21	0.36	2.08e-9	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
CESC	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg07677032	chr17:61819896	STRADA	0.46	6.21	0.36	2.06e-9	Prudent dietary pattern;
CESC	trans	rs11098499	0.863	rs12508173	chr4:120318526	T/C	cg25214090	chr10:38739885	LOC399744	0.7	9.7	0.51	3.1400000000000002e-19	Corneal astigmatism;
CESC	cis	rs1003719	0.762	rs2835590	chr21:38463406	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.63	8.77	0.47	2.14e-16	Eye color traits;
CESC	cis	rs72772090	0.539	rs11750464	chr5:96113031	C/T	cg17330273	chr5:96107758	CAST;ERAP1	0.59	5.11	0.3	6.29e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs9381040	1.000	rs2093395	chr6:41155026	C/G	cg03526776	chr6:41159608	TREML2	-0.39	-6.54	-0.37	3.18e-10	Alzheimer's disease (late onset);
CESC	cis	rs17023223	0.537	rs12086686	chr1:119689084	T/A	cg05756136	chr1:119680316	WARS2	-0.46	-5.58	-0.32	6.01e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CESC	cis	rs7666738	0.830	rs13110498	chr4:98959150	G/A	cg17366294	chr4:99064904	C4orf37	0.59	8.44	0.46	2.09e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs12530845	0.943	rs55889179	chr7:135331631	C/T	cg23117316	chr7:135346802	PL-5283	-0.45	-5.58	-0.32	6.05e-8	Red blood cell traits;
CESC	cis	rs12142240	0.698	rs1135460	chr1:46815970	T/C	cg00530320	chr1:46809349	NSUN4	0.58	7.89	0.44	8.17e-14	Menopause (age at onset);
CESC	cis	rs854765	0.547	rs2955378	chr17:17930253	G/A	cg09796270	chr17:17721594	SREBF1	0.38	5.3	0.31	2.5e-7	Total body bone mineral density;
CESC	cis	rs10465746	0.935	rs942848	chr1:84427707	G/C	cg10977910	chr1:84465055	TTLL7	0.46	6.18	0.35	2.45e-9	Obesity-related traits;
CESC	cis	rs753778	0.667	rs10103731	chr8:142206068	C/T	cg23750338	chr8:142222470	SLC45A4	0.36	5.14	0.3	5.35e-7	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	cis	rs941873	0.835	rs4246944	chr10:81105684	C/T	cg11057378	chr10:81107060	PPIF	0.32	5.12	0.3	5.94e-7	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13063101	chr1:119914432	HAO2	0.51	6.26	0.36	1.58e-9	Gut microbiome composition (summer);
CESC	cis	rs202629	1	rs202629	chr22:41849975	C/T	cg06634786	chr22:41940651	POLR3H	0.59	6.39	0.37	7.33e-10	Cannabis dependence symptom count;
CESC	cis	rs1008375	0.900	rs13144986	chr4:17675019	C/A	cg27347728	chr4:17578864	LAP3	-0.48	-5.3	-0.31	2.49e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs11785400	1.000	rs10108059	chr8:143750028	G/T	cg24634471	chr8:143751801	JRK	-0.47	-6.13	-0.35	3.26e-9	Schizophrenia;
CESC	cis	rs7000551	0.725	rs2461489	chr8:22370253	G/A	cg12081754	chr8:22256438	SLC39A14	0.45	6.02	0.35	5.74e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CESC	cis	rs7412746	0.658	rs11582281	chr1:150826831	T/C	cg04414720	chr1:150670196	GOLPH3L	0.56	7.41	0.41	1.7e-12	Melanoma;
CESC	cis	rs9916302	0.904	rs6503519	chr17:37706578	A/G	cg07936489	chr17:37558343	FBXL20	-0.8	-11.36	-0.57	1.25e-24	Glomerular filtration rate (creatinine);
CESC	cis	rs11098499	0.863	rs3736115	chr4:120488703	A/G	cg24375607	chr4:120327624	NA	-0.45	-5.34	-0.31	2.05e-7	Corneal astigmatism;
CESC	cis	rs6089584	0.850	rs6142938	chr20:60627723	A/C	cg06108461	chr20:60628389	TAF4	-0.92	-14.32	-0.66	7.92e-35	Body mass index;
CESC	cis	rs9768139	0.733	rs921617	chr7:158118198	A/G	cg27057461	chr7:158136379	PTPRN2	-0.33	-5.17	-0.3	4.6e-7	Calcium levels;
CESC	cis	rs9300255	0.602	rs1716177	chr12:123655457	C/T	cg00376283	chr12:123451042	ABCB9	0.7	8.57	0.47	8.55e-16	Neutrophil percentage of white cells;
CESC	cis	rs9611565	0.512	rs139566	chr22:42199277	A/G	cg06634786	chr22:41940651	POLR3H	-0.67	-6.64	-0.38	1.74e-10	Vitiligo;
CESC	cis	rs28647808	1.000	rs2285483	chr9:136271838	G/A	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.9	5.73	0.33	2.75e-8	Blood protein levels;
CESC	cis	rs477895	0.639	rs35858916	chr11:63950529	T/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.95	10.4	0.54	1.85e-21	Mean platelet volume;
CESC	cis	rs1005277	0.522	rs9417256	chr10:37976990	A/G	cg25517755	chr10:38738941	LOC399744	-0.42	-5.42	-0.32	1.35e-7	Extrinsic epigenetic age acceleration;
CESC	cis	rs425277	0.583	rs1467217	chr1:2045165	G/A	cg13918804	chr1:2043761	PRKCZ	0.28	5.31	0.31	2.31e-7	Height;
CESC	cis	rs4237845	0.537	rs59401446	chr12:58259564	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.51	5.72	0.33	2.82e-8	Intelligence (multi-trait analysis);
CESC	cis	rs477692	0.647	rs524804	chr10:131430686	G/A	cg05714579	chr10:131428358	MGMT	-0.6	-8.72	-0.47	3.18e-16	Response to temozolomide;
CESC	cis	rs6570726	0.516	rs9322025	chr6:145729196	C/T	cg23711669	chr6:146136114	FBXO30	0.52	6.65	0.38	1.69e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs763014	0.966	rs4984677	chr16:671682	A/G	cg00802000	chr16:706648	WDR90	-0.43	-6.55	-0.37	3.05e-10	Height;
CESC	cis	rs459571	0.959	rs2520100	chr9:136918137	A/T	cg13789015	chr9:136890014	NCRNA00094	0.57	8.06	0.44	2.59e-14	Platelet distribution width;
CESC	cis	rs727563	0.635	rs2899348	chr22:42164516	C/G	cg17376030	chr22:41985996	PMM1	-0.79	-8.37	-0.46	3.43e-15	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs3785574	0.962	rs57553639	chr17:61848499	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.81	10.76	0.55	1.2e-22	Height;
CESC	cis	rs13040088	1.000	rs6090159	chr20:61531351	C/G	cg23096297	chr20:61557774	DIDO1	0.89	10.14	0.53	1.26e-20	Menopause (age at onset);
CESC	cis	rs7824557	0.568	rs35747588	chr8:11206627	C/G	cg21775007	chr8:11205619	TDH	0.58	8.81	0.48	1.71e-16	Retinal vascular caliber;
CESC	cis	rs597539	0.652	rs592697	chr11:68650064	G/A	cg01988459	chr11:68622903	NA	-0.39	-5.42	-0.32	1.37e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg04234412	chr22:24373322	LOC391322	-0.61	-8.69	-0.47	3.86e-16	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs6570726	0.791	rs4896820	chr6:145894957	T/C	cg23711669	chr6:146136114	FBXO30	0.83	12.51	0.61	1.62e-28	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7937682	0.883	rs12804962	chr11:111442683	A/T	cg09085632	chr11:111637200	PPP2R1B	0.89	12.45	0.61	2.58e-28	Primary sclerosing cholangitis;
CESC	cis	rs2991971	0.934	rs11580609	chr1:45975856	C/G	cg05343316	chr1:45956843	TESK2	-0.51	-6.75	-0.38	9.49e-11	High light scatter reticulocyte count;
CESC	cis	rs9527	0.590	rs2182348	chr10:104872684	A/G	cg04362960	chr10:104952993	NT5C2	0.44	5.54	0.32	7.12e-8	Arsenic metabolism;
CESC	cis	rs7927771	1.000	rs9909	chr11:47799775	C/G	cg20307385	chr11:47447363	PSMC3	-0.51	-6.24	-0.36	1.7e-9	Subjective well-being;
CESC	trans	rs7666738	0.830	rs4292341	chr4:98959724	C/T	cg01391346	chr6:99873300	SFRS18	0.41	6.11	0.35	3.58e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10191773	0.589	rs72833410	chr2:113054119	G/A	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.68	-7.37	-0.41	2.23e-12	Yeast infection;
CESC	cis	rs60871478	1.000	rs34761279	chr7:794471	A/G	cg05535760	chr7:792225	HEATR2	0.96	10.78	0.55	1.04e-22	Cerebrospinal P-tau181p levels;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg17298437	chr19:5805096	NA	-0.48	-6.17	-0.35	2.53e-9	Ulcerative colitis;
CESC	cis	rs796364	0.951	rs10931888	chr2:201022952	T/G	cg23649088	chr2:200775458	C2orf69	-0.52	-5.09	-0.3	6.65e-7	Schizophrenia;
CESC	cis	rs637571	0.607	rs574586	chr11:65697083	G/A	cg02202077	chr11:65769826	EIF1AD;BANF1	0.46	5.83	0.34	1.63e-8	Eosinophil percentage of white cells;
CESC	cis	rs6540559	0.673	rs926346	chr1:209962204	A/T	cg23283495	chr1:209979779	IRF6	0.53	6.34	0.36	9.65e-10	Cleft lip with or without cleft palate;
CESC	cis	rs2760061	0.583	rs1774757	chr1:228211135	C/G	cg02753203	chr1:228287806	NA	0.8	11.29	0.57	2.17e-24	Diastolic blood pressure;
CESC	cis	rs3820928	0.967	rs4675113	chr2:227766339	G/A	cg05526886	chr2:227700861	RHBDD1	-0.43	-5.63	-0.33	4.53e-8	Pulmonary function;
CESC	cis	rs9549260	0.620	rs9532580	chr13:41244260	T/C	cg21288729	chr13:41239152	FOXO1	0.58	6.3	0.36	1.23e-9	Red blood cell count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10795676	chr6:26370623	BTN3A2	-0.57	-6.59	-0.38	2.34e-10	Gut microbiome composition (summer);
CESC	cis	rs7408868	1.000	rs7250232	chr19:15277199	C/T	cg14696996	chr19:15285081	NOTCH3	0.89	8.5	0.46	1.42e-15	Pulse pressure;
CESC	cis	rs7267979	1.000	rs4815408	chr20:25346678	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.85	-16.53	-0.71	1.11e-42	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs829883	1.000	rs249819	chr12:98897265	T/A	cg25150519	chr12:98850993	NA	0.66	8.75	0.47	2.57e-16	Colorectal adenoma (advanced);
CESC	cis	rs5769765	0.865	rs10854860	chr22:50320029	G/T	cg02269571	chr22:50332266	NA	-0.55	-6.42	-0.37	6.1e-10	Schizophrenia;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg15605918	chr19:3501056	DOHH	-0.45	-6.17	-0.35	2.57e-9	Thyroid stimulating hormone;
CESC	cis	rs12530845	0.623	rs7798256	chr7:135344211	C/A	cg23117316	chr7:135346802	PL-5283	-0.6	-6.51	-0.37	3.73e-10	Red blood cell traits;
CESC	cis	rs7903847	0.642	rs2275090	chr10:99148151	A/G	cg20016023	chr10:99160130	RRP12	-0.29	-5.06	-0.3	7.89e-7	Granulocyte percentage of myeloid white cells;
CESC	trans	rs11088226	0.681	rs2833891	chr21:33928821	A/G	cg09050820	chr6:167586206	TCP10L2	0.82	8.68	0.47	4.09e-16	Gastritis;
CESC	cis	rs4253772	1.000	rs4253772	chr22:46627603	C/T	cg18190219	chr22:46762943	CELSR1	-0.67	-5.9	-0.34	1.11e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs3096299	0.503	rs4785677	chr16:89555101	A/G	cg16743903	chr16:89593216	SPG7	-0.41	-5.09	-0.3	6.76e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs7044106	0.762	rs10491783	chr9:123450155	C/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.36	5.83	0.34	1.58e-8	Hip circumference adjusted for BMI;
CESC	cis	rs3785574	0.962	rs58131426	chr17:61854375	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.58	7.15	0.4	8.26e-12	Height;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg13456812	chr6:167369504	RNASET2	-0.48	-6.6	-0.38	2.18e-10	Height;
CESC	cis	rs8072100	0.754	rs8081717	chr17:45653921	T/A	cg08085267	chr17:45401833	C17orf57	0.44	5.9	0.34	1.12e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs227584	0.663	rs3180912	chr17:42259463	A/G	cg13607699	chr17:42295918	UBTF	0.42	5.44	0.32	1.23e-7	Bone mineral density (hip);Bone mineral density;
CESC	cis	rs7666738	0.753	rs10004827	chr4:99037953	A/C	cg05340658	chr4:99064831	C4orf37	0.82	12.87	0.62	9.38e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs796364	1.000	rs10178177	chr2:200829993	G/A	cg23649088	chr2:200775458	C2orf69	0.55	5.33	0.31	2.14e-7	Schizophrenia;
CESC	cis	rs1552244	0.872	rs6803517	chr3:10065426	C/T	cg00149659	chr3:10157352	C3orf10	0.75	9.05	0.49	3.07e-17	Alzheimer's disease;
CESC	cis	rs79976124	0.879	rs78012385	chr6:66618091	G/A	cg07460842	chr6:66804631	NA	0.75	8.76	0.47	2.39e-16	Type 2 diabetes;
CESC	cis	rs3791556	0.661	rs3791539	chr2:240102327	C/T	cg03281426	chr2:240109471	HDAC4	0.5	5.98	0.34	7.23e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg01688141	chr8:23539808	NKX3-1	-0.44	-6.23	-0.36	1.81e-9	Gambling;
CESC	cis	rs4474465	0.831	rs7121299	chr11:78189133	G/T	cg27205649	chr11:78285834	NARS2	-0.42	-5.23	-0.31	3.4e-7	Alzheimer's disease (survival time);
CESC	cis	rs9457247	1.000	rs415842	chr6:167406681	G/A	cg07741184	chr6:167504864	NA	0.29	5.31	0.31	2.32e-7	Crohn's disease;
CESC	cis	rs9788682	0.947	rs12439240	chr15:78829091	T/C	cg06917634	chr15:78832804	PSMA4	-0.58	-6.94	-0.39	2.92e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs926938	0.584	rs2798663	chr1:115363582	G/A	cg12756093	chr1:115239321	AMPD1	0.43	5.9	0.34	1.09e-8	Autism;
CESC	cis	rs7412746	0.658	rs72704682	chr1:150897677	A/T	cg04414720	chr1:150670196	GOLPH3L	0.51	6.76	0.38	8.61e-11	Melanoma;
CESC	cis	rs9290065	0.538	rs6809206	chr3:160755708	G/A	cg03342759	chr3:160939853	NMD3	-0.38	-5.12	-0.3	5.91e-7	Kawasaki disease;
CESC	cis	rs7312774	0.618	rs4964513	chr12:107375758	T/C	cg16260113	chr12:107380972	MTERFD3	0.97	7.63	0.42	4.27e-13	Severe influenza A (H1N1) infection;
CESC	cis	rs35110281	0.632	rs9306160	chr21:45107562	T/C	cg01579765	chr21:45077557	HSF2BP	-0.54	-8.95	-0.48	6.29e-17	Mean corpuscular volume;
CESC	cis	rs7659604	1.000	rs7660078	chr4:122665577	G/T	cg19671926	chr4:122722719	EXOSC9	-0.49	-5.95	-0.34	8.28e-9	Type 2 diabetes;
CESC	cis	rs116095464	0.558	rs10075018	chr5:239175	G/A	cg22857025	chr5:266934	NA	-1.27	-18.31	-0.75	6.06e-49	Breast cancer;
CESC	trans	rs916888	0.687	rs199456	chr17:44797919	C/T	cg22968622	chr17:43663579	NA	1.36	18.72	0.75	2.16e-50	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs56104184	0.775	rs117016425	chr19:49400216	C/T	cg15549821	chr19:49342101	PLEKHA4	-0.6	-5.99	-0.35	6.95e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	trans	rs11098499	0.909	rs71614422	chr4:120359340	G/A	cg25214090	chr10:38739885	LOC399744	0.71	10.01	0.52	3.2e-20	Corneal astigmatism;
CESC	cis	rs4423214	0.921	rs12807827	chr11:71203790	A/C	cg24826892	chr11:71159390	DHCR7	0.45	5.16	0.3	4.88e-7	Vitamin D levels;
CESC	cis	rs7959452	0.640	rs1598543	chr12:69688757	G/T	cg20891283	chr12:69753455	YEATS4	0.75	11.01	0.56	1.86e-23	Blood protein levels;
CESC	cis	rs10845606	1.000	rs10845605	chr12:12833468	T/C	cg04607235	chr12:12878440	APOLD1	-0.71	-7.86	-0.43	9.54e-14	Systemic lupus erythematosus;
CESC	cis	rs9457247	0.967	rs377753	chr6:167389496	A/T	cg07741184	chr6:167504864	NA	0.31	5.53	0.32	7.87e-8	Crohn's disease;
CESC	cis	rs6087990	0.765	rs6058900	chr20:31400673	T/C	cg13636640	chr20:31349939	DNMT3B	0.9	15.0	0.68	3.16e-37	Ulcerative colitis;
CESC	cis	rs7527798	0.592	rs11118282	chr1:207832402	G/A	cg21110645	chr1:207815933	NA	-0.32	-5.62	-0.33	4.92e-8	Erythrocyte sedimentation rate;
CESC	cis	rs61931739	0.517	rs34760282	chr12:34153711	G/T	cg19457237	chr12:34500585	NA	-0.39	-5.35	-0.31	1.93e-7	Morning vs. evening chronotype;
CESC	cis	rs933688	0.759	rs1423593	chr5:90752351	T/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.12	12.64	0.61	5.66e-29	Smoking behavior;
CESC	cis	rs9467711	0.523	rs9379853	chr6:26357635	A/G	cg14345882	chr6:26364793	BTN3A2	0.59	6.06	0.35	4.66e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs9916302	0.904	rs7223438	chr17:37521355	T/C	cg00129232	chr17:37814104	STARD3	0.52	6.49	0.37	4.19e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs6782228	1.000	rs6775011	chr3:128396483	T/C	cg15607142	chr3:128420513	NA	-0.38	-5.19	-0.3	4.24e-7	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
CESC	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg24846343	chr22:24311635	DDTL	0.6	10.01	0.52	3.34e-20	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs10489202	0.632	rs413168	chr1:168005789	C/G	cg24449463	chr1:168025552	DCAF6	-0.4	-5.12	-0.3	5.94e-7	Schizophrenia;
CESC	cis	rs1552244	0.935	rs6805869	chr3:10119917	T/C	cg16606324	chr3:10149918	C3orf24	0.43	5.36	0.31	1.81e-7	Alzheimer's disease;
CESC	cis	rs910316	0.967	rs4899549	chr14:75647494	G/A	cg08847533	chr14:75593920	NEK9	-0.94	-16.62	-0.71	5.67e-43	Height;
CESC	trans	rs8007846	0.569	rs4400971	chr14:66254578	A/C	cg05684300	chr4:102267366	PPP3CA	0.47	6.48	0.37	4.36e-10	Multiple sclerosis--Brain Glutamate Levels;
CESC	cis	rs9303401	0.659	rs7224276	chr17:56897827	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.01	12.68	0.61	4.11e-29	Cognitive test performance;
CESC	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg22535103	chr8:58192502	C8orf71	-0.92	-10.19	-0.53	8.81e-21	Developmental language disorder (linguistic errors);
CESC	cis	rs9916302	0.821	rs1966915	chr17:37425262	A/C	cg07936489	chr17:37558343	FBXL20	-0.8	-11.48	-0.58	5.11e-25	Glomerular filtration rate (creatinine);
CESC	cis	rs826838	0.616	rs2200605	chr12:38624088	G/A	cg26384229	chr12:38710491	ALG10B	0.47	6.69	0.38	1.34e-10	Heart rate;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg14311538	chr9:139348775	SEC16A	0.5	6.64	0.38	1.75e-10	Fibrinogen levels;
CESC	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	10.25	0.53	5.71e-21	Prudent dietary pattern;
CESC	cis	rs7659604	1.000	rs6823488	chr4:122664819	A/G	cg19671926	chr4:122722719	EXOSC9	-0.43	-5.27	-0.31	2.78e-7	Type 2 diabetes;
CESC	cis	rs12134245	1.000	rs12134245	chr1:92021464	C/T	cg25838465	chr1:92012736	NA	-0.38	-5.17	-0.3	4.59e-7	Breast cancer;
CESC	cis	rs7246657	0.943	rs2291004	chr19:37997952	C/A	cg23950597	chr19:37808831	NA	-0.62	-6.38	-0.36	7.88e-10	Coronary artery calcification;
CESC	cis	rs7680126	0.672	rs4697957	chr4:10182254	A/G	cg00071950	chr4:10020882	SLC2A9	-0.51	-5.53	-0.32	7.58e-8	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg12592965	chr5:177631661	HNRNPAB	-0.5	-6.71	-0.38	1.18e-10	Fibrinogen levels;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg24615751	chr1:40723984	ZMPSTE24	-0.44	-6.06	-0.35	4.55e-9	Asthma;
CESC	cis	rs57506017	0.585	rs1042949	chr7:12272116	C/G	cg23422036	chr7:12250390	TMEM106B	0.39	5.17	0.3	4.57e-7	Neuroticism;
CESC	cis	rs6461049	0.765	rs10224497	chr7:2149967	A/G	cg05863683	chr7:1912471	MAD1L1	0.37	5.4	0.31	1.46e-7	Schizophrenia;
CESC	cis	rs4843747	0.671	rs28679286	chr16:88106307	C/T	cg17633681	chr16:88106987	BANP	0.76	10.51	0.54	8.01e-22	Menopause (age at onset);
CESC	trans	rs11098499	0.865	rs11722183	chr4:120280597	A/C	cg25214090	chr10:38739885	LOC399744	0.68	9.35	0.5	3.7e-18	Corneal astigmatism;
CESC	cis	rs11971779	1.000	rs75919582	chr7:139054919	G/A	cg07862535	chr7:139043722	LUC7L2	0.55	5.19	0.3	4.12e-7	Diisocyanate-induced asthma;
CESC	cis	rs7618915	0.501	rs11130308	chr3:52639257	G/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.7	0.38	1.22e-10	Bipolar disorder;
CESC	cis	rs3204270	0.759	rs8071492	chr17:79682650	G/A	cg18367735	chr17:79674897	NA	0.74	6.59	0.38	2.39e-10	Dental caries;
CESC	cis	rs10861342	1.000	rs11112368	chr12:105494218	T/C	cg23923672	chr12:105501055	KIAA1033	0.69	5.91	0.34	1.07e-8	IgG glycosylation;
CESC	cis	rs832540	0.618	rs2548663	chr5:56172778	G/A	cg12311346	chr5:56204834	C5orf35	-0.47	-5.63	-0.33	4.59e-8	Coronary artery disease;
CESC	cis	rs6860806	0.531	rs274556	chr5:131722075	A/G	cg18758796	chr5:131593413	PDLIM4	-0.42	-5.75	-0.33	2.45e-8	Breast cancer;
CESC	cis	rs7208859	0.573	rs7223803	chr17:29077193	A/G	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.1e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs12220238	1.000	rs4745740	chr10:75942469	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.61	5.82	0.34	1.69e-8	Soluble interleukin-2 receptor subunit alpha;
CESC	cis	rs9733	0.650	rs1971378	chr1:150597261	C/T	cg17724175	chr1:150552817	MCL1	-0.32	-5.26	-0.31	2.93e-7	Tonsillectomy;
CESC	cis	rs1843834	0.505	rs3820763	chr2:225347270	A/G	cg12698349	chr2:225449008	CUL3	-0.59	-8.44	-0.46	2.1e-15	IgE levels in asthmatics (D.p. specific);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12588476	chr7:99647494	ZSCAN21	0.69	8.13	0.45	1.7e-14	Gut microbiome composition (summer);
CESC	cis	rs4849845	0.889	rs4849846	chr2:121026891	T/C	cg24070213	chr2:121070622	NA	0.39	5.04	0.3	8.71e-7	Mean platelet volume;
CESC	cis	rs8177253	0.665	rs12639304	chr3:133441594	A/T	cg16262614	chr3:133464971	TF	0.29	5.14	0.3	5.29e-7	Iron status biomarkers;
CESC	cis	rs7605827	0.930	rs4668446	chr2:15516020	C/T	cg19274914	chr2:15703543	NA	0.31	5.39	0.31	1.55e-7	Educational attainment (years of education);
CESC	cis	rs1862618	0.713	rs832550	chr5:56182589	C/T	cg24549020	chr5:56110836	MAP3K1	0.66	7.45	0.42	1.29e-12	Initial pursuit acceleration;
CESC	cis	rs71444571	1	rs71444571	chr12:123771015	G/A	cg00376283	chr12:123451042	ABCB9	-0.62	-6.4	-0.37	7.02e-10	Lymphocyte percentage of white cells;
CESC	cis	rs72829446	0.556	rs12936464	chr17:7403942	A/C	cg02795151	chr17:7402630	POLR2A	-0.57	-6.68	-0.38	1.42e-10	Androgen levels;
CESC	cis	rs3015497	0.506	rs6572689	chr14:51168325	T/C	cg26011998	chr14:51135199	SAV1	-0.55	-6.15	-0.35	2.8e-9	Mean platelet volume;
CESC	cis	rs9322193	0.923	rs62439840	chr6:149995775	G/A	cg07701084	chr6:150067640	NUP43	0.41	5.41	0.32	1.41e-7	Lung cancer;
CESC	cis	rs754466	0.651	rs11815015	chr10:79625482	C/T	cg17075019	chr10:79541650	NA	-0.86	-13.15	-0.63	9.74e-31	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs12887734	0.524	rs4906363	chr14:104210239	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.44	-5.46	-0.32	1.1e-7	Schizophrenia;Autism spectrum disorder or schizophrenia;
CESC	cis	rs7680126	0.596	rs10939723	chr4:10139105	G/T	cg11266682	chr4:10021025	SLC2A9	-0.38	-5.25	-0.31	3.17e-7	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	cis	rs10754283	0.901	rs4520403	chr1:90112840	T/G	cg21401794	chr1:90099060	LRRC8C	0.69	9.34	0.5	4.06e-18	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs3820068	0.608	rs12092485	chr1:16048038	A/G	cg17385448	chr1:15911702	AGMAT	0.37	5.78	0.33	2.06e-8	Systolic blood pressure;
CESC	cis	rs868036	0.756	rs2241421	chr15:68082825	G/A	cg08079166	chr15:68083412	MAP2K5	0.45	7.05	0.4	1.53e-11	Restless legs syndrome;
CESC	cis	rs12618769	0.597	rs6753515	chr2:99128965	T/A	cg10123293	chr2:99228465	UNC50	0.4	5.38	0.31	1.64e-7	Bipolar disorder;
CESC	cis	rs61996546	0.622	rs12901009	chr15:26855181	C/G	cg14859324	chr15:26874363	GABRB3	-0.37	-5.06	-0.3	7.97e-7	Response to methotrexate in juvenile idiopathic arthritis;
CESC	cis	rs7216064	1.000	rs4790908	chr17:65852907	T/G	cg07042672	chr17:66097459	LOC651250	-0.57	-6.56	-0.37	2.74e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs6088580	0.634	rs6059867	chr20:33078103	C/T	cg08999081	chr20:33150536	PIGU	0.66	11.68	0.58	1.03e-25	Glomerular filtration rate (creatinine);
CESC	cis	rs2933343	0.621	rs4927921	chr3:128568868	A/G	cg24203234	chr3:128598194	ACAD9	-0.47	-6.58	-0.37	2.51e-10	IgG glycosylation;
CESC	cis	rs228437	1.000	rs6928242	chr6:134936389	T/G	cg24504307	chr6:134963096	NA	0.56	5.98	0.34	7.38e-9	Melanoma;
CESC	cis	rs939574	0.722	rs115402093	chr2:220096128	C/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.87	7.02	0.4	1.85e-11	Platelet distribution width;
CESC	cis	rs2836974	0.583	rs9636957	chr21:40705847	G/A	cg11890956	chr21:40555474	PSMG1	-0.93	-15.11	-0.68	1.23e-37	Cognitive function;
CESC	cis	rs3857067	1.000	rs2865330	chr4:95004716	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.52	-8.04	-0.44	3e-14	QT interval;
CESC	cis	rs2075671	0.857	rs11772849	chr7:100308412	G/A	cg20848291	chr7:100343083	ZAN	-0.73	-9.16	-0.49	1.5e-17	Other erythrocyte phenotypes;
CESC	cis	rs7605827	0.866	rs13014988	chr2:15498404	C/T	cg19274914	chr2:15703543	NA	0.31	5.63	0.33	4.57e-8	Educational attainment (years of education);
CESC	cis	rs2404618	0.593	rs7815979	chr8:1484887	A/G	cg13402656	chr8:1511478	DLGAP2	-0.55	-8.01	-0.44	3.57e-14	Lung cancer;
CESC	cis	rs6963495	0.745	rs75805443	chr7:105162828	A/G	cg02135003	chr7:105160482	PUS7	-0.46	-5.55	-0.32	6.92e-8	Bipolar disorder (body mass index interaction);
CESC	cis	rs3806843	1.000	rs6898939	chr5:140169355	C/A	cg16179182	chr5:140090404	VTRNA1-1	-0.4	-5.19	-0.3	4.21e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs9325144	0.600	rs12424410	chr12:38758035	A/T	cg26384229	chr12:38710491	ALG10B	-0.57	-7.91	-0.44	6.79e-14	Morning vs. evening chronotype;
CESC	cis	rs4665809	0.627	rs13014338	chr2:26463024	C/T	cg26314531	chr2:26401878	FAM59B	0.85	9.04	0.49	3.44e-17	Gut microbiome composition (summer);
CESC	cis	rs660498	0.507	rs765700	chr10:27734885	G/A	cg25705717	chr10:27608719	NA	0.48	5.82	0.34	1.73e-8	Asthma (childhood onset);
CESC	cis	rs4665809	0.818	rs35413760	chr2:26267137	C/A	cg22920501	chr2:26401640	FAM59B	0.72	8.03	0.44	3.27e-14	Gut microbiome composition (summer);
CESC	cis	rs6456156	0.586	rs2345753	chr6:167484344	T/A	cg23791538	chr6:167370224	RNASET2	-0.51	-6.44	-0.37	5.67e-10	Primary biliary cholangitis;
CESC	cis	rs644799	1.000	rs11021319	chr11:95523123	C/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.92	14.22	0.66	1.74e-34	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs875971	0.929	rs10950041	chr7:65973875	T/C	cg12463550	chr7:65579703	CRCP	0.57	7.18	0.4	6.93e-12	Aortic root size;
CESC	cis	rs910316	0.967	rs4903293	chr14:75656568	A/G	cg08847533	chr14:75593920	NEK9	-0.94	-16.53	-0.71	1.17e-42	Height;
CESC	trans	rs6084875	0.641	rs6052810	chr20:4722964	A/C	cg10192164	chr16:30419175	ZNF771	-0.51	-6.18	-0.35	2.44e-9	Systemic lupus erythematosus;
CESC	cis	rs2439831	0.681	rs1549523	chr15:43624189	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.91	10.95	0.56	2.88e-23	Lung cancer in ever smokers;
CESC	cis	rs9814567	1.000	rs6766897	chr3:134191303	C/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.41	-5.64	-0.33	4.25e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs2576037	0.526	rs626217	chr18:44429182	T/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.71	11.5	0.58	4.37e-25	Personality dimensions;
CESC	cis	rs2455799	0.573	rs2455833	chr3:15752830	T/C	cg09340198	chr3:15902540	ANKRD28	-0.33	-5.27	-0.31	2.87e-7	Mean platelet volume;
CESC	cis	rs2455799	0.613	rs3856830	chr3:15806520	A/C	cg16303742	chr3:15540471	COLQ	-0.4	-6.23	-0.36	1.83e-9	Mean platelet volume;
CESC	cis	rs6667605	0.506	rs10797440	chr1:2541269	A/G	cg18854424	chr1:2615690	NA	0.3	6.01	0.35	6.23e-9	Inflammatory bowel disease;Ulcerative colitis;
CESC	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg06873352	chr17:61820015	STRADA	0.71	12.48	0.61	2.02e-28	Prudent dietary pattern;
CESC	cis	rs875971	0.825	rs59466412	chr7:65565358	A/G	cg12463550	chr7:65579703	CRCP	-0.54	-6.65	-0.38	1.65e-10	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05246657	chr6:52930357	FBXO9	0.53	6.01	0.35	6.23e-9	Gut microbiome composition (summer);
CESC	cis	rs2011503	1.000	rs4808206	chr19:19645645	C/A	cg11584989	chr19:19387371	SF4	0.61	6.98	0.39	2.41e-11	Bipolar disorder;
CESC	cis	rs6545883	0.931	rs7557230	chr2:61736652	A/T	cg15711740	chr2:61764176	XPO1	-0.43	-5.35	-0.31	1.91e-7	Tuberculosis;
CESC	cis	rs10463316	0.817	rs6895187	chr5:150775909	G/A	cg03212797	chr5:150827313	SLC36A1	-0.45	-5.94	-0.34	9.07e-9	Metabolite levels (Pyroglutamine);
CESC	cis	rs3857067	1.000	rs7685048	chr4:95027784	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.53	-8.12	-0.45	1.77e-14	QT interval;
CESC	cis	rs9910055	0.573	rs228768	chr17:42191893	A/C	cg10896456	chr17:42255109	ASB16;C17orf65	0.37	5.36	0.31	1.79e-7	Total body bone mineral density;
CESC	cis	rs317689	0.581	rs315132	chr12:69761996	G/C	cg20891283	chr12:69753455	YEATS4	0.75	10.03	0.52	2.83e-20	Response to diuretic therapy;
CESC	cis	rs718433	0.584	rs1002180	chr14:22217052	C/T	cg02257791	chr14:22217085	NA	-0.32	-5.08	-0.3	7.27e-7	Intraocular pressure;
CESC	cis	rs6690583	1.000	rs6690583	chr1:85466337	A/G	cg22153463	chr1:85462885	MCOLN2	-0.77	-9.39	-0.5	2.81e-18	Serum sulfate level;
CESC	cis	rs2721195	0.626	rs59464125	chr8:145857786	G/A	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.67	-9.69	-0.51	3.4e-19	Age at first birth;
CESC	cis	rs2439831	0.867	rs4583210	chr15:43660925	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.92	11.29	0.57	2.11e-24	Lung cancer in ever smokers;
CESC	cis	rs6860806	0.695	rs6867282	chr5:131583120	G/C	cg18758796	chr5:131593413	PDLIM4	0.46	6.48	0.37	4.48e-10	Breast cancer;
CESC	cis	rs262150	0.659	rs2527236	chr7:158796644	C/T	cg10570241	chr7:158785291	NA	0.31	5.25	0.31	3.15e-7	Facial morphology (factor 20);
CESC	trans	rs459571	0.920	rs2520094	chr9:136919985	A/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.63	-8.22	-0.45	8.91e-15	Platelet distribution width;
CESC	cis	rs3733585	0.664	rs17245436	chr4:9958169	A/G	cg00071950	chr4:10020882	SLC2A9	-0.72	-11.7	-0.58	8.89e-26	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs3126085	0.935	rs3126091	chr1:152307338	T/C	cg03465714	chr1:152285911	FLG	0.41	5.18	0.3	4.36e-7	Atopic dermatitis;
CESC	cis	rs6709815	0.902	rs13020432	chr2:219668211	C/T	cg02176678	chr2:219576539	TTLL4	-0.34	-5.81	-0.34	1.77e-8	Reticulocyte count;High light scatter reticulocyte count;
CESC	cis	rs853679	0.550	rs9295762	chr6:28155418	C/T	cg22143856	chr6:28129313	ZNF389	-0.42	-5.56	-0.32	6.72e-8	Depression;
CESC	cis	rs6121246	0.909	rs6060923	chr20:30336655	A/C	cg13852791	chr20:30311386	BCL2L1	0.82	8.74	0.47	2.63e-16	Mean corpuscular hemoglobin;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg01088093	chr15:75748402	SIN3A	-0.39	-6.24	-0.36	1.68e-9	Gambling;
CESC	cis	rs7726839	0.794	rs6883536	chr5:599274	G/A	cg16447950	chr5:562315	NA	-0.49	-5.72	-0.33	2.88e-8	Obesity-related traits;
CESC	cis	rs11997175	0.625	rs7825931	chr8:33583627	A/C	ch.8.33884649F	chr8:33765107	NA	-0.49	-5.84	-0.34	1.51e-8	Body mass index;
CESC	cis	rs4148883	0.689	rs2851275	chr4:100024883	A/G	cg13256891	chr4:100009986	ADH5	0.54	7.3	0.41	3.37e-12	Alcohol dependence;
CESC	cis	rs6987853	0.661	rs4641053	chr8:42352161	G/A	cg09913449	chr8:42400586	C8orf40	-0.36	-5.9	-0.34	1.11e-8	Mean corpuscular hemoglobin concentration;
CESC	cis	rs7552404	0.824	rs1251079	chr1:76189445	C/T	cg10523679	chr1:76189770	ACADM	0.87	13.69	0.64	1.21e-32	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs941873	0.836	rs6480931	chr10:81108482	T/C	cg09469691	chr10:81107165	PPIF	0.53	7.02	0.4	1.82e-11	Height;
CESC	cis	rs7129220	0.588	rs7124925	chr11:10143700	G/A	cg01453529	chr11:10209919	SBF2	-0.48	-5.63	-0.33	4.67e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CESC	cis	rs6785206	0.614	rs2712430	chr3:128337438	A/C	cg16766828	chr3:128327626	NA	-0.63	-6.49	-0.37	4.31e-10	Lymphocyte percentage of white cells;
CESC	cis	rs7267979	0.932	rs417110	chr20:25458297	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.78	14.78	0.67	1.87e-36	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs4588572	0.645	rs10059940	chr5:77680873	T/C	cg11547950	chr5:77652471	NA	0.46	5.91	0.34	1.06e-8	Triglycerides;
CESC	cis	rs7811142	0.830	rs3087502	chr7:99955364	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.08	11.0	0.56	1.98e-23	Platelet count;
CESC	cis	rs59918340	0.616	rs3739222	chr8:142205904	C/G	cg18755752	chr8:142205143	DENND3	-0.48	-6.55	-0.37	3.01e-10	Immature fraction of reticulocytes;
CESC	cis	rs1371867	0.875	rs1612773	chr8:101337818	G/C	cg11906718	chr8:101322791	RNF19A	0.48	6.1	0.35	3.7e-9	Atrioventricular conduction;
CESC	cis	rs7666738	0.830	rs13138438	chr4:99050545	C/A	cg03467027	chr4:99064603	C4orf37	0.47	5.98	0.34	7.19e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2404602	0.647	rs11072607	chr15:76908529	C/T	cg23625390	chr15:77176239	SCAPER	-0.45	-6.17	-0.35	2.48e-9	Blood metabolite levels;
CESC	cis	rs9322193	0.962	rs9397022	chr6:150133188	C/T	cg07701084	chr6:150067640	NUP43	0.4	5.49	0.32	9.18e-8	Lung cancer;
CESC	cis	rs2243480	1.000	rs466983	chr7:65520496	T/G	cg12463550	chr7:65579703	CRCP	0.68	5.42	0.32	1.36e-7	Diabetic kidney disease;
CESC	cis	rs9322193	0.962	rs6914319	chr6:150127440	G/A	cg05861140	chr6:150128134	PCMT1	-0.36	-5.21	-0.3	3.76e-7	Lung cancer;
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg19245296	chr20:10015646	ANKRD5	0.41	6.05	0.35	4.92e-9	Vertical cup-disc ratio;
CESC	trans	rs7902708	0.920	rs7895388	chr10:54423387	A/G	cg26219051	chr22:43739629	SCUBE1	-0.48	-6.19	-0.36	2.25e-9	Bone properties (heel);
CESC	cis	rs796364	1.000	rs281774	chr2:200814572	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.87	8.59	0.47	7.81e-16	Schizophrenia;
CESC	cis	rs11792861	0.926	rs72607173	chr9:111879398	T/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.42	5.31	0.31	2.28e-7	Menarche (age at onset);
CESC	cis	rs3540	0.618	rs11609	chr15:91043765	C/G	cg22089800	chr15:90895588	ZNF774	-0.62	-8.14	-0.45	1.56e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs4642101	0.611	rs6442331	chr3:12820636	T/G	cg24848339	chr3:12840334	CAND2	0.41	6.36	0.36	8.91e-10	QRS complex (12-leadsum);
CESC	cis	rs4072980	0.545	rs11210870	chr1:38449910	T/C	cg18451016	chr1:38461880	NA	-0.41	-5.64	-0.33	4.36e-8	Coronary artery disease;
CESC	cis	rs597539	0.616	rs473997	chr11:68639481	C/T	cg01988459	chr11:68622903	NA	-0.42	-5.43	-0.32	1.27e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs6460942	0.597	rs13232817	chr7:12551909	C/A	cg02935154	chr7:12443704	VWDE	-0.55	-5.24	-0.31	3.31e-7	Coronary artery disease;
CESC	cis	rs3806843	0.735	rs2530240	chr5:140060547	T/C	cg16179182	chr5:140090404	VTRNA1-1	0.39	5.11	0.3	6.21e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs10242455	0.867	rs2037499	chr7:99312653	C/G	cg07715041	chr7:99302981	CYP3A7	-0.43	-5.42	-0.32	1.36e-7	Blood metabolite levels;
CESC	cis	rs7811142	0.830	rs7341507	chr7:99951315	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.06	10.91	0.56	3.9e-23	Platelet count;
CESC	cis	rs3820068	0.562	rs10927841	chr1:16045261	T/C	cg13390004	chr1:15929781	NA	0.34	5.19	0.3	4.22e-7	Systolic blood pressure;
CESC	cis	rs4253772	0.637	rs9627295	chr22:46650100	C/T	cg09491104	chr22:46646882	C22orf40	-0.59	-9.15	-0.49	1.58e-17	LDL cholesterol;Cholesterol, total;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg23681110	chr8:140847721	TRAPPC9	0.46	6.14	0.35	2.94e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07613930	chr12:117316665	HRK	-0.66	-8.15	-0.45	1.47e-14	Gut microbiome composition (summer);
CESC	cis	rs4665809	0.627	rs1465720	chr2:26412638	G/T	cg27170947	chr2:26402098	FAM59B	-0.82	-9.69	-0.51	3.29e-19	Gut microbiome composition (summer);
CESC	cis	rs7772486	0.566	rs735536	chr6:146036832	A/C	cg05347473	chr6:146136440	FBXO30	-0.53	-6.99	-0.39	2.19e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9581857	0.725	rs9581853	chr13:28016236	T/C	cg22138327	chr13:27999177	GTF3A	0.67	5.46	0.32	1.12e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
CESC	cis	rs9311474	0.629	rs13081028	chr3:52555316	G/A	cg17372223	chr3:52568218	NT5DC2	0.55	9.24	0.49	8.55e-18	Electroencephalogram traits;
CESC	cis	rs35306767	0.903	rs7074642	chr10:878359	A/G	cg25019033	chr10:957182	NA	-0.58	-6.3	-0.36	1.2e-9	Eosinophil percentage of granulocytes;
CESC	cis	rs12142240	0.698	rs17361791	chr1:46812519	A/G	cg00530320	chr1:46809349	NSUN4	0.58	7.85	0.43	1.05e-13	Menopause (age at onset);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg00840257	chr16:8963031	CARHSP1	-0.48	-6.08	-0.35	4.08e-9	Ulcerative colitis;
CESC	cis	rs4819052	0.851	rs7281263	chr21:46695606	T/C	cg11663144	chr21:46675770	NA	-0.62	-9.82	-0.52	1.27e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04840494	chr5:79550959	SERINC5	-0.63	-7.29	-0.41	3.6e-12	Gut microbiome composition (summer);
CESC	cis	rs2243480	1.000	rs781156	chr7:65479141	C/A	cg13147721	chr7:65941812	NA	-0.89	-8.55	-0.47	9.65e-16	Diabetic kidney disease;
CESC	cis	rs9640161	0.750	rs3800780	chr7:150027284	C/A	cg17279839	chr7:150038598	RARRES2	0.43	5.19	0.3	4.24e-7	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs4665809	0.877	rs35224700	chr2:26298037	T/C	cg22920501	chr2:26401640	FAM59B	0.72	8.12	0.45	1.74e-14	Gut microbiome composition (summer);
CESC	cis	rs3857067	0.967	rs7668980	chr4:95037320	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.52	-7.95	-0.44	5.37e-14	QT interval;
CESC	trans	rs17685	0.753	rs6951943	chr7:75772452	A/G	cg19862616	chr7:65841803	NCRNA00174	0.85	12.4	0.61	3.88e-28	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs910316	0.874	rs61980828	chr14:75630378	G/A	cg08847533	chr14:75593920	NEK9	-1.01	-18.52	-0.75	1.04e-49	Height;
CESC	cis	rs778371	0.676	rs13024330	chr2:233715487	A/G	cg08000102	chr2:233561755	GIGYF2	0.81	12.42	0.61	3.19e-28	Schizophrenia;
CESC	cis	rs1559088	0.600	rs7255229	chr19:33562807	A/G	cg27124370	chr19:33622961	WDR88	0.54	7.5	0.42	9.47e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs7246657	0.943	rs4452075	chr19:37879589	A/G	cg23950597	chr19:37808831	NA	-0.55	-5.97	-0.34	7.77e-9	Coronary artery calcification;
CESC	cis	rs2576037	0.526	rs4258717	chr18:44456954	T/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.32	5.14	0.3	5.31e-7	Personality dimensions;
CESC	cis	rs4665809	0.567	rs6546848	chr2:26444414	G/C	cg04944784	chr2:26401820	FAM59B	-0.96	-10.83	-0.55	7.34e-23	Gut microbiome composition (summer);
CESC	cis	rs4711336	1.000	rs764754	chr6:33658310	C/T	cg14003231	chr6:33640908	ITPR3	0.32	5.46	0.32	1.07e-7	Height;
CESC	cis	rs546131	0.928	rs552868	chr11:34830694	G/A	cg06937548	chr11:34938143	PDHX;APIP	0.53	6.72	0.38	1.09e-10	Lung disease severity in cystic fibrosis;
CESC	cis	rs7811142	1.000	rs74460138	chr7:100027339	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.0	9.63	0.51	5.12e-19	Platelet count;
CESC	cis	rs7247513	0.701	rs8107642	chr19:12766370	C/T	cg06417478	chr19:12876846	HOOK2	0.43	5.25	0.31	3.11e-7	Bipolar disorder;
CESC	cis	rs62005083	1.000	rs62006760	chr14:74615095	G/A	cg05179529	chr14:74551516	LIN52;ALDH6A1	0.74	5.42	0.32	1.34e-7	Mean corpuscular volume;
CESC	cis	rs2243480	1.000	rs4145008	chr7:65647511	T/G	cg12463550	chr7:65579703	CRCP	-0.73	-5.66	-0.33	4.03e-8	Diabetic kidney disease;
CESC	trans	rs561341	0.883	rs72821942	chr17:30234460	C/T	cg20587970	chr11:113659929	NA	-1.09	-13.14	-0.63	1.04e-30	Hip circumference adjusted for BMI;
CESC	cis	rs10479542	0.929	rs10078796	chr5:178978883	T/A	cg00080972	chr5:178986291	RUFY1	0.44	7.02	0.4	1.88e-11	Lung cancer;
CESC	cis	rs6439153	0.967	rs61480393	chr3:128699759	T/C	cg25356066	chr3:128598488	ACAD9	0.51	6.5	0.37	3.9e-10	Pneumococcal bacteremia;
CESC	cis	rs2404602	0.608	rs17361504	chr15:76601871	A/G	cg26408565	chr15:76604113	ETFA	-0.4	-5.89	-0.34	1.19e-8	Blood metabolite levels;
CESC	cis	rs896854	0.738	rs509594	chr8:95967156	C/G	cg13393036	chr8:95962371	TP53INP1	0.47	9.09	0.49	2.33e-17	Type 2 diabetes;
CESC	cis	rs2635047	0.542	rs2684814	chr18:44754103	C/T	cg24371990	chr18:44770781	NA	-0.34	-5.51	-0.32	8.31e-8	Educational attainment;
CESC	cis	rs5758659	0.967	rs5751250	chr22:42639645	T/G	cg15557168	chr22:42548783	NA	-0.49	-7.72	-0.43	2.34e-13	Cognitive function;
CESC	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg23131131	chr22:24373011	LOC391322	-0.76	-11.11	-0.56	8.7e-24	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs6089584	0.850	rs881993	chr20:60623862	A/G	cg13770153	chr20:60521292	NA	-0.5	-6.58	-0.37	2.55e-10	Body mass index;
CESC	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	10.31	0.54	3.45e-21	Prudent dietary pattern;
CESC	cis	rs8060686	0.545	rs8056649	chr16:68260083	A/G	cg26727032	chr16:67993705	SLC12A4	0.44	5.49	0.32	9.33e-8	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs896854	0.967	rs2879813	chr8:95960947	A/G	cg23172400	chr8:95962367	TP53INP1	-0.5	-11.1	-0.56	9.09e-24	Type 2 diabetes;
CESC	cis	rs7666738	0.830	rs11942114	chr4:99066261	C/G	cg17366294	chr4:99064904	C4orf37	0.6	8.49	0.46	1.46e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs72945132	0.882	rs55738915	chr11:70190019	C/T	cg00319359	chr11:70116639	PPFIA1	0.79	7.41	0.41	1.66e-12	Coronary artery disease;
CESC	cis	rs4654899	0.802	rs12401413	chr1:21236503	T/C	cg05370193	chr1:21551575	ECE1	0.38	5.55	0.32	6.84e-8	Superior frontal gyrus grey matter volume;
CESC	trans	rs7980799	0.654	rs1482987	chr12:33614283	G/C	cg26384229	chr12:38710491	ALG10B	-0.55	-7.87	-0.44	9.24e-14	Heart rate;Heart rate variability traits (RMSSD);
CESC	cis	rs1912483	0.505	rs11079772	chr17:45393739	A/C	cg25173405	chr17:45401733	C17orf57	0.44	5.16	0.3	4.96e-7	Coronary artery disease;
CESC	cis	rs711245	0.670	rs7560321	chr2:36822318	C/G	cg10546459	chr2:36825355	FEZ2	-0.44	-5.3	-0.31	2.43e-7	Height;
CESC	cis	rs4132509	0.739	rs10803150	chr1:243822600	C/T	cg21452805	chr1:244014465	NA	0.59	6.57	0.37	2.72e-10	RR interval (heart rate);
CESC	cis	rs72781680	0.848	rs6754694	chr2:24155448	T/C	cg08917208	chr2:24149416	ATAD2B	0.95	8.51	0.46	1.27e-15	Lymphocyte counts;
CESC	cis	rs34375054	0.660	rs12578446	chr12:125605887	A/G	cg25124228	chr12:125621409	AACS	-0.56	-6.74	-0.38	1e-10	Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs3857067	1.000	rs3846292	chr4:95027717	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.53	-8.12	-0.45	1.77e-14	QT interval;
CESC	cis	rs1008375	0.966	rs6825133	chr4:17577776	C/T	cg27347728	chr4:17578864	LAP3	0.43	5.11	0.3	6.18e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	trans	rs60380162	0.963	rs28379534	chr1:87709437	G/C	cg20163645	chr8:1900353	ARHGEF10	-0.43	-6.0	-0.35	6.63e-9	Loneliness (linear analysis);
CESC	cis	rs7267979	1.000	rs6083828	chr20:25369918	T/C	cg08601574	chr20:25228251	PYGB	-0.38	-5.53	-0.32	7.83e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs523522	0.962	rs10849759	chr12:120994488	T/A	cg12219531	chr12:120966889	COQ5	0.75	9.81	0.52	1.43e-19	High light scatter reticulocyte count;
CESC	cis	rs9287719	0.615	rs12613769	chr2:10742290	C/T	cg00105475	chr2:10696890	NA	0.37	5.06	0.3	7.79e-7	Prostate cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11527367	chr1:144612646	C1orf152	-0.64	-7.94	-0.44	5.59e-14	Gut microbiome composition (summer);
CESC	cis	rs4835473	0.798	rs34353812	chr4:144895102	T/A	cg25736465	chr4:144833511	NA	0.38	5.7	0.33	3.22e-8	Immature fraction of reticulocytes;
CESC	cis	rs7017914	0.840	rs13254851	chr8:71689034	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.2	-0.3	3.94e-7	Bone mineral density;
CESC	cis	rs6540559	1.000	rs2235373	chr1:209963803	G/A	cg10074409	chr1:209979377	IRF6	0.37	5.96	0.34	7.83e-9	Cleft lip with or without cleft palate;
CESC	cis	rs2479106	0.591	rs7852243	chr9:126417340	A/G	cg16191174	chr9:126692580	DENND1A	-0.4	-5.69	-0.33	3.31e-8	Polycystic ovary syndrome;
CESC	cis	rs6964587	0.626	rs12704631	chr7:91523525	T/C	cg17063962	chr7:91808500	NA	-0.46	-6.48	-0.37	4.55e-10	Breast cancer;
CESC	cis	rs875971	0.638	rs10278816	chr7:66036987	T/C	cg14393609	chr7:65229607	NA	-0.47	-6.31	-0.36	1.16e-9	Aortic root size;
CESC	cis	rs6461049	0.800	rs3800913	chr7:2163237	A/G	cg05863683	chr7:1912471	MAD1L1	0.4	5.89	0.34	1.18e-8	Schizophrenia;
CESC	cis	rs1008375	0.932	rs6835077	chr4:17653285	A/T	cg02297831	chr4:17616191	MED28	0.65	8.09	0.44	2.2e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs60733400	0.500	rs72644697	chr1:2533605	G/A	cg18854424	chr1:2615690	NA	0.27	5.23	0.31	3.43e-7	Multiple sclerosis;
CESC	cis	rs11078597	0.671	rs34599286	chr17:1645747	C/A	cg18436246	chr17:1640651	WDR81	0.62	7.59	0.42	5.36e-13	Serum albumin level;
CESC	cis	rs4713118	0.662	rs464312	chr6:27967591	T/A	cg17221315	chr6:27791827	HIST1H4J	0.44	5.31	0.31	2.27e-7	Parkinson's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10332367	chr16:2075476	SLC9A3R2	-0.47	-6.2	-0.36	2.15e-9	Gut microbiome composition (summer);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg07434447	chr7:74489725	WBSCR16	-0.48	-6.57	-0.37	2.71e-10	Fibrinogen levels;
CESC	cis	rs10871290	0.881	rs7498574	chr16:74472661	A/G	cg01733217	chr16:74700730	RFWD3	-0.67	-8.85	-0.48	1.27e-16	Breast cancer;
CESC	cis	rs73206853	0.534	rs7131996	chr12:111073276	C/A	cg12870014	chr12:110450643	ANKRD13A	0.63	5.68	0.33	3.53e-8	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs9300255	0.739	rs1533703	chr12:123742093	T/G	cg05973401	chr12:123451056	ABCB9	0.49	5.52	0.32	8.03e-8	Neutrophil percentage of white cells;
CESC	cis	rs763121	0.819	rs6001205	chr22:39100264	T/A	cg21395723	chr22:39101663	GTPBP1	0.44	5.44	0.32	1.2e-7	Menopause (age at onset);
CESC	trans	rs875971	0.660	rs10272357	chr7:66063074	G/A	cg26939375	chr7:64535504	NA	-0.64	-8.62	-0.47	6.24e-16	Aortic root size;
CESC	cis	rs11690935	0.885	rs6725388	chr2:172730015	G/C	cg13550731	chr2:172543902	DYNC1I2	-0.86	-13.3	-0.63	2.97e-31	Schizophrenia;
CESC	cis	rs1008375	0.966	rs1476836	chr4:17585014	G/C	cg02297831	chr4:17616191	MED28	0.51	6.18	0.35	2.44e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs4689388	0.926	rs4689394	chr4:6291003	C/G	cg00701064	chr4:6280414	WFS1	-0.67	-11.4	-0.57	9.44e-25	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs4253772	0.550	rs12165597	chr22:46705584	A/G	cg09491104	chr22:46646882	C22orf40	-0.51	-6.16	-0.35	2.69e-9	LDL cholesterol;Cholesterol, total;
CESC	cis	rs7772486	0.764	rs7745696	chr6:146162829	T/C	cg05347473	chr6:146136440	FBXO30	0.55	7.26	0.41	4.4e-12	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09659697	chr5:54529994	CCNO	-0.55	-6.38	-0.36	8.08e-10	Gut microbiome composition (summer);
CESC	cis	rs763121	0.814	rs5757212	chr22:39053757	G/C	cg06022373	chr22:39101656	GTPBP1	0.95	17.52	0.73	3.72e-46	Menopause (age at onset);
CESC	cis	rs1801251	0.963	rs13424351	chr2:233573629	A/G	cg25237894	chr2:233734115	C2orf82	0.49	8.29	0.45	5.67e-15	Coronary artery disease;
CESC	cis	rs13242816	1.000	rs34936262	chr7:116160022	G/A	cg04696780	chr7:116139425	CAV2	-0.61	-5.55	-0.32	7.01e-8	P wave duration;
CESC	cis	rs1059312	1.000	rs1059312	chr12:129278864	A/G	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.61	8.23	0.45	8.64e-15	Systemic lupus erythematosus;
CESC	cis	rs6594499	0.872	rs13178997	chr5:110444249	G/T	cg04022379	chr5:110408740	TSLP	0.34	5.95	0.34	8.43e-9	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs769267	0.930	rs3752151	chr19:19616026	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.51	6.38	0.36	8.06e-10	Tonsillectomy;
CESC	cis	rs698813	0.572	rs6544749	chr2:44478077	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.48	5.44	0.32	1.19e-7	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
CESC	cis	rs9943753	0.508	rs7958071	chr12:109836089	G/A	cg19025524	chr12:109796872	NA	-0.47	-6.67	-0.38	1.45e-10	HDL cholesterol;
CESC	trans	rs931812	0.895	rs4734013	chr8:101908687	A/C	cg20993868	chr7:22813445	NA	0.57	8.09	0.45	2.11e-14	Attention deficit hyperactivity disorder and conduct disorder;
CESC	cis	rs7618915	0.501	rs13085775	chr3:52678370	C/T	cg07507251	chr3:52567010	NT5DC2	0.32	5.58	0.32	5.88e-8	Bipolar disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13830646	chr11:65668067	FOSL1	0.56	6.98	0.39	2.34e-11	Gut microbiome composition (summer);
CESC	cis	rs763014	0.865	rs8675	chr16:633843	A/G	cg07343612	chr16:622815	PIGQ	-0.55	-7.95	-0.44	5.41e-14	Height;
CESC	cis	rs11252926	0.673	rs7096559	chr10:499188	C/T	cg18196295	chr10:418757	DIP2C	0.5	6.79	0.38	7.44e-11	Psychosis in Alzheimer's disease;
CESC	cis	rs611744	0.625	rs4735055	chr8:109286642	G/A	cg21045802	chr8:109455806	TTC35	0.48	5.87	0.34	1.29e-8	Dupuytren's disease;
CESC	cis	rs17376456	0.877	rs10476601	chr5:93402522	G/A	cg21475434	chr5:93447410	FAM172A	0.82	7.28	0.41	3.91e-12	Diabetic retinopathy;
CESC	cis	rs5758659	0.714	rs5751216	chr22:42508937	G/T	cg15557168	chr22:42548783	NA	0.42	6.46	0.37	4.94e-10	Cognitive function;
CESC	cis	rs9611565	0.659	rs73178641	chr22:41952075	A/T	cg06481639	chr22:41940642	POLR3H	-0.63	-6.54	-0.37	3.09e-10	Vitiligo;
CESC	cis	rs72781680	0.611	rs56113233	chr2:24341085	A/C	cg08917208	chr2:24149416	ATAD2B	0.62	5.98	0.34	7.28e-9	Lymphocyte counts;
CESC	cis	rs2758596	0.850	rs2842879	chr1:156163695	G/T	cg25208724	chr1:156163844	SLC25A44	0.65	6.24	0.36	1.72e-9	Paclitaxel disposition in epithelial ovarian cancer;
CESC	cis	rs17401966	0.931	rs4846205	chr1:10310214	A/T	cg15208524	chr1:10270712	KIF1B	0.41	5.25	0.31	3.14e-7	Hepatocellular carcinoma;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00703902	chr7:5253016	WIPI2	0.52	6.04	0.35	5.21e-9	Gut microbiome composition (summer);
CESC	cis	rs1018836	0.599	rs9643295	chr8:91492283	T/G	cg16814680	chr8:91681699	NA	-0.55	-7.75	-0.43	1.91e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs873946	0.586	rs12767391	chr10:134573844	A/G	cg18305652	chr10:134549665	INPP5A	-0.42	-6.03	-0.35	5.43e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs6594499	0.872	rs10038177	chr5:110436450	C/T	cg04022379	chr5:110408740	TSLP	0.34	6.22	0.36	1.9e-9	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs9811920	0.609	rs10936005	chr3:99674093	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.6	-9.71	-0.51	2.92e-19	Axial length;
CESC	cis	rs6860806	0.695	rs11952099	chr5:131576772	A/G	cg12564285	chr5:131593104	PDLIM4	0.4	6.13	0.35	3.15e-9	Breast cancer;
CESC	cis	rs3806843	1.000	rs2337985	chr5:140157861	T/C	cg26395211	chr5:140044315	WDR55	-0.42	-5.41	-0.32	1.41e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs3785574	0.962	rs2727324	chr17:61922102	G/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.59	7.49	0.42	1.05e-12	Height;
CESC	cis	rs947211	0.846	rs708726	chr1:205762139	G/T	cg14893161	chr1:205819251	PM20D1	-0.42	-5.83	-0.34	1.64e-8	Parkinson's disease;
CESC	cis	rs11252926	0.589	rs12359901	chr10:475068	A/G	cg16386425	chr10:429943	DIP2C	0.48	5.99	0.35	6.99e-9	Psychosis in Alzheimer's disease;
CESC	cis	rs7829975	0.777	rs560544	chr8:8637429	G/A	cg15556689	chr8:8085844	FLJ10661	-0.45	-5.68	-0.33	3.53e-8	Mood instability;
CESC	cis	rs9863	0.828	rs12833624	chr12:124476873	C/T	cg00084347	chr12:124393913	DNAH10	0.26	5.06	0.3	7.9e-7	White blood cell count;
CESC	cis	rs7666738	0.800	rs2865988	chr4:99067807	T/C	cg17366294	chr4:99064904	C4orf37	0.61	8.5	0.46	1.41e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs897984	0.806	rs11640534	chr16:30949515	G/A	cg02466173	chr16:30829666	NA	0.48	8.19	0.45	1.15e-14	Dementia with Lewy bodies;
CESC	trans	rs7246760	0.867	rs67539464	chr19:9832424	C/G	cg02900749	chr2:68251473	NA	-0.8	-7.31	-0.41	3.22e-12	Pursuit maintenance gain;
CESC	cis	rs769267	0.895	rs2965183	chr19:19545696	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.47	6.08	0.35	4.06e-9	Tonsillectomy;
CESC	cis	rs3125734	0.660	rs10733769	chr10:63974255	G/T	cg09941381	chr10:64027924	RTKN2	-0.32	-5.17	-0.3	4.51e-7	Rheumatoid arthritis;
CESC	cis	rs7843479	0.506	rs7818430	chr8:21798429	C/T	cg17168535	chr8:21777572	XPO7	0.76	12.74	0.62	2.53e-29	Mean corpuscular volume;
CESC	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-6.21	-0.36	2.01e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs8044868	0.512	rs10048144	chr16:72052891	C/G	cg16558253	chr16:72132732	DHX38	-0.37	-5.69	-0.33	3.31e-8	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CESC	cis	rs2354432	0.607	rs11239980	chr1:146782698	G/A	cg25205988	chr1:146714368	CHD1L	-1.0	-8.9	-0.48	9.01e-17	Mitochondrial DNA levels;
CESC	cis	rs35110281	0.667	rs4819291	chr21:45123139	G/A	cg04455712	chr21:45112962	RRP1B	0.51	7.8	0.43	1.44e-13	Mean corpuscular volume;
CESC	trans	rs17685	0.753	rs10233282	chr7:75790081	C/T	cg19862616	chr7:65841803	NCRNA00174	0.84	12.03	0.59	6.77e-27	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs2760061	0.598	rs1774755	chr1:228115282	T/G	cg02753203	chr1:228287806	NA	-0.5	-7.24	-0.41	4.83e-12	Diastolic blood pressure;
CESC	cis	rs6964587	0.626	rs68009402	chr7:91516226	G/A	cg17063962	chr7:91808500	NA	-0.46	-6.48	-0.37	4.5e-10	Breast cancer;
CESC	cis	rs72634258	0.945	rs225120	chr1:8046378	C/T	cg00042356	chr1:8021962	PARK7	0.59	6.3	0.36	1.25e-9	Inflammatory bowel disease;
CESC	cis	rs921968	0.643	rs864990	chr2:219494037	G/A	cg02176678	chr2:219576539	TTLL4	0.39	6.64	0.38	1.79e-10	Mean corpuscular hemoglobin concentration;
CESC	cis	rs11122272	0.735	rs2437149	chr1:231490105	C/T	cg06096015	chr1:231504339	EGLN1	0.42	6.12	0.35	3.3e-9	Hemoglobin concentration;
CESC	cis	rs6429082	0.875	rs2291688	chr1:235594250	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.41	-5.29	-0.31	2.51e-7	Adiposity;
CESC	cis	rs4234798	0.500	rs7661066	chr4:7219878	C/T	cg18431297	chr4:7219810	SORCS2	0.56	9.37	0.5	3.28e-18	Insulin-like growth factors;
CESC	trans	rs35110281	0.627	rs6518268	chr21:44967448	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.56	7.52	0.42	8.61e-13	Mean corpuscular volume;
CESC	cis	rs35110281	0.667	rs7282122	chr21:45082365	G/A	cg04455712	chr21:45112962	RRP1B	0.47	7.61	0.42	4.67e-13	Mean corpuscular volume;
CESC	cis	rs3825932	0.736	rs1036939	chr15:79237324	C/A	cg25744700	chr15:79237217	CTSH	0.48	6.35	0.36	9.31e-10	Type 1 diabetes;
CESC	cis	rs4642101	0.640	rs9877049	chr3:12821231	A/G	cg05775895	chr3:12838266	CAND2	0.41	6.3	0.36	1.23e-9	QRS complex (12-leadsum);
CESC	cis	rs1950626	0.750	rs72700530	chr14:101429459	G/C	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.82	11.2	0.57	4.23e-24	Pelvic organ prolapse (moderate/severe);
CESC	cis	rs875971	1.000	rs2077593	chr7:65892530	A/G	cg18876405	chr7:65276391	NA	0.51	6.68	0.38	1.39e-10	Aortic root size;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg17249942	chr21:45660288	ICOSLG	-0.48	-6.27	-0.36	1.42e-9	Fibrinogen levels;
CESC	trans	rs11971186	0.924	rs3919444	chr7:126473588	C/T	cg10894441	chr11:111169905	C11orf92;C11orf93	-0.46	-6.0	-0.35	6.57e-9	Chemerin levels;
CESC	cis	rs9467711	0.606	rs67234939	chr6:26530419	A/G	cg12826209	chr6:26865740	GUSBL1	0.59	5.27	0.31	2.84e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg21280719	chr6:42927975	GNMT	-0.3	-7.06	-0.4	1.44e-11	Alzheimer's disease in APOE e4+ carriers;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10066545	chr7:66072065	NA	-0.48	-6.01	-0.35	6e-9	Gut microbiome composition (summer);
CESC	cis	rs3008870	1.000	rs3008854	chr1:67385951	T/C	cg02640540	chr1:67518911	SLC35D1	0.48	5.19	0.3	4.09e-7	Lymphocyte percentage of white cells;
CESC	cis	rs7095944	0.585	rs11245357	chr10:126452042	A/G	cg08799069	chr10:126477246	METTL10	-0.35	-5.14	-0.3	5.46e-7	Asthma;
CESC	cis	rs7219021	0.961	rs9906942	chr17:46864634	G/A	cg16584676	chr17:46985605	UBE2Z	-0.56	-6.31	-0.36	1.14e-9	Schizophrenia or bipolar disorder;
CESC	cis	rs5167	0.506	rs11669173	chr19:45492559	G/A	cg13119609	chr19:45449297	APOC2	-0.51	-7.69	-0.43	2.89e-13	Blood protein levels;
CESC	cis	rs6952808	0.500	rs3800902	chr7:2144378	C/T	cg23048001	chr7:2026167	MAD1L1	0.44	5.73	0.33	2.73e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs1348850	0.914	rs4893950	chr2:178304885	T/C	cg23306229	chr2:178417860	TTC30B	0.64	7.97	0.44	4.59e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs10504229	1.000	rs17216957	chr8:58179893	C/T	cg14926445	chr8:58193284	C8orf71	-0.51	-5.47	-0.32	1.03e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs7914558	0.966	rs11191438	chr10:104637864	C/G	cg08650961	chr10:104748594	CNNM2	0.35	5.87	0.34	1.27e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs2243480	1.000	rs313809	chr7:65499983	G/A	cg13147721	chr7:65941812	NA	-0.91	-8.69	-0.47	3.87e-16	Diabetic kidney disease;
CESC	cis	rs477895	1.000	rs477895	chr11:64048912	C/T	cg04317338	chr11:64019027	PLCB3	-0.52	-5.07	-0.3	7.4e-7	Mean platelet volume;
CESC	cis	rs2066819	1.000	rs2066819	chr12:56750204	C/T	cg26714650	chr12:56694279	CS	-1.39	-9.06	-0.49	2.88e-17	Psoriasis vulgaris;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07264050	chr8:48920858	UBE2V2	0.63	7.58	0.42	5.75e-13	Gut microbiome composition (summer);
CESC	cis	rs6502050	0.842	rs7211808	chr17:80071244	T/C	cg23985595	chr17:80112537	CCDC57	0.4	6.35	0.36	9.15e-10	Life satisfaction;
CESC	cis	rs2742234	0.955	rs2503841	chr10:43675721	C/T	cg07801480	chr10:43725741	RASGEF1A	0.39	5.69	0.33	3.31e-8	Hirschsprung disease;
CESC	cis	rs12586317	0.557	rs8004288	chr14:35679288	A/G	cg16230307	chr14:35515116	FAM177A1	0.42	5.22	0.31	3.57e-7	Psoriasis;
CESC	trans	rs17508449	0.819	rs4839331	chr1:114161631	A/G	cg23028848	chr11:57092561	TNKS1BP1	-0.74	-6.0	-0.35	6.52e-9	Leprosy;
CESC	cis	rs13191362	1.000	rs73035021	chr6:163000716	C/A	cg21926612	chr6:163149169	PACRG;PARK2	0.88	9.16	0.49	1.46e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	trans	rs7839040	0.698	rs13277577	chr8:82931310	C/T	cg14472086	chr9:107730925	NA	-0.48	-6.45	-0.37	5.4e-10	Response to methotrexate in juvenile idiopathic arthritis;
CESC	cis	rs3857067	0.806	rs12513267	chr4:95109545	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.59	-8.92	-0.48	7.87e-17	QT interval;
CESC	cis	rs9916302	0.904	rs7503705	chr17:37669704	A/G	cg20243544	chr17:37824526	PNMT	0.51	6.4	0.37	6.86e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs7666738	0.830	rs7663438	chr4:99014582	C/T	cg18180107	chr4:99064573	C4orf37	0.4	5.28	0.31	2.64e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3796392	1	rs3796392	chr3:129137127	G/A	cg18113058	chr3:129116479	RPL32P3;SNORA7B	1.12	5.99	0.35	6.85e-9	Diisocyanate-induced asthma;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg06066128	chr3:47018377	CCDC12	-0.49	-6.13	-0.35	3.22e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs6430585	0.702	rs2304601	chr2:136528034	C/A	cg07169764	chr2:136633963	MCM6	1.26	16.5	0.71	1.45e-42	Corneal structure;
CESC	cis	rs6728642	0.614	rs113485946	chr2:97866442	T/C	cg26665480	chr2:98280029	ACTR1B	-0.92	-6.97	-0.39	2.47e-11	Bipolar disorder lithium response (continuous) or schizophrenia;
CESC	cis	rs6964587	1.000	rs756647	chr7:91586389	A/G	cg17063962	chr7:91808500	NA	0.58	7.89	0.44	7.72e-14	Breast cancer;
CESC	cis	rs3820928	0.874	rs4234063	chr2:227828335	A/T	cg11843606	chr2:227700838	RHBDD1	0.47	6.11	0.35	3.58e-9	Pulmonary function;
CESC	cis	rs66573146	0.572	rs66734745	chr4:6948765	T/C	cg00086871	chr4:6988644	TBC1D14	1.03	6.85	0.39	5.16e-11	Granulocyte percentage of myeloid white cells;
CESC	cis	rs7917772	0.536	rs12357172	chr10:104388549	C/T	ch.10.2196322F	chr10:104248062	ACTR1A	0.51	5.47	0.32	1.06e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg05313129	chr8:58192883	C8orf71	-0.47	-5.13	-0.3	5.63e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs55794721	0.543	rs1293260	chr1:25709104	C/G	cg03538708	chr1:25844672	NA	-0.35	-5.21	-0.3	3.85e-7	Plateletcrit;Mean corpuscular volume;
CESC	cis	rs7772486	0.654	rs6928007	chr6:146074941	G/A	cg23711669	chr6:146136114	FBXO30	-0.87	-12.87	-0.62	8.94e-30	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6570726	0.738	rs6925594	chr6:145898454	T/C	cg05347473	chr6:146136440	FBXO30	0.59	7.78	0.43	1.59e-13	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs17666538	0.591	rs2878547	chr8:603416	G/A	cg07685180	chr8:600429	NA	0.6	5.13	0.3	5.73e-7	IgG glycosylation;
CESC	cis	rs2032447	0.670	rs198834	chr6:26114372	G/A	cg18357526	chr6:26021779	HIST1H4A	-0.61	-8.53	-0.46	1.13e-15	Intelligence (multi-trait analysis);
CESC	cis	rs9291683	0.588	rs12506364	chr4:10023448	C/T	cg02734326	chr4:10020555	SLC2A9	0.48	6.9	0.39	3.89e-11	Bone mineral density;
CESC	cis	rs4925386	1.000	rs4925386	chr20:60921044	C/T	cg22633769	chr20:60982531	CABLES2	0.42	5.07	0.3	7.46e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CESC	trans	rs916888	0.821	rs199505	chr17:44859410	A/G	cg22968622	chr17:43663579	NA	-1.19	-16.0	-0.7	8.93e-41	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs2576037	0.562	rs9959877	chr18:44522293	T/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.36	5.72	0.33	2.9e-8	Personality dimensions;
CESC	trans	rs9929218	0.551	rs3785133	chr16:68728611	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.89	14.92	0.68	5.68e-37	Colorectal cancer;
CESC	cis	rs4689388	0.782	rs4262051	chr4:6281775	G/A	cg14416269	chr4:6271139	WFS1	0.47	7.54	0.42	7.67e-13	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs6963495	0.818	rs6944787	chr7:105147309	C/T	cg19920283	chr7:105172520	RINT1	0.66	6.28	0.36	1.36e-9	Bipolar disorder (body mass index interaction);
CESC	trans	rs7944735	0.767	rs1017875	chr11:47999218	C/T	cg15704280	chr7:45808275	SEPT13	0.59	6.16	0.35	2.74e-9	Intraocular pressure;
CESC	cis	rs13191362	1.000	rs34918316	chr6:163005386	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.82	8.35	0.46	3.97e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs6456156	0.586	rs12213801	chr6:167474084	T/A	cg07741184	chr6:167504864	NA	0.37	6.39	0.37	7.28e-10	Primary biliary cholangitis;
CESC	cis	rs780096	0.565	rs11681351	chr2:27743423	G/A	cg24768116	chr2:27665128	KRTCAP3	-0.31	-5.62	-0.33	4.71e-8	Total body bone mineral density;
CESC	cis	rs736408	0.540	rs4687637	chr3:52634092	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.56	7.85	0.43	1.05e-13	Bipolar disorder;
CESC	cis	rs9929218	0.529	rs2296404	chr16:68729525	C/T	cg01251360	chr16:68772225	CDH1	-0.23	-5.12	-0.3	6.01e-7	Colorectal cancer;
CESC	cis	rs6540556	0.608	rs7532324	chr1:209918090	C/T	cg05527609	chr1:210001259	C1orf107	-0.58	-6.93	-0.39	3.18e-11	Red blood cell count;
CESC	cis	rs1707322	0.691	rs61784799	chr1:46177748	A/G	cg06784218	chr1:46089804	CCDC17	-0.41	-7.21	-0.41	5.75e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs514406	0.929	rs557847	chr1:53333116	A/G	cg08859206	chr1:53392774	SCP2	-0.64	-8.62	-0.47	6.22e-16	Monocyte count;
CESC	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg03188948	chr7:1209495	NA	0.71	7.06	0.4	1.5e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11166348	chr1:7740267	CAMTA1	0.51	6.09	0.35	3.95e-9	Gut microbiome composition (summer);
CESC	cis	rs9649213	0.593	rs13232181	chr7:97935671	C/G	cg00277769	chr7:97922759	BAIAP2L1	-0.32	-5.14	-0.3	5.22e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs9311474	0.508	rs4687546	chr3:52605943	T/A	cg17372223	chr3:52568218	NT5DC2	0.4	5.93	0.34	9.47e-9	Electroencephalogram traits;
CESC	cis	rs736408	0.736	rs4687550	chr3:52823430	T/G	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.34	5.78	0.33	2.1e-8	Bipolar disorder;
CESC	cis	rs6540559	0.673	rs6540560	chr1:209982073	A/G	cg23283495	chr1:209979779	IRF6	-0.49	-6.06	-0.35	4.54e-9	Cleft lip with or without cleft palate;
CESC	cis	rs7680126	0.632	rs6834645	chr4:10150174	G/A	cg00071950	chr4:10020882	SLC2A9	-0.61	-6.53	-0.37	3.41e-10	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	trans	rs7615952	0.611	rs2947646	chr3:125593602	C/T	cg07211511	chr3:129823064	LOC729375	0.8	7.66	0.43	3.46e-13	Blood pressure (smoking interaction);
CESC	cis	rs7692995	1.000	rs6840868	chr4:17939331	C/T	cg08925142	chr4:18023851	LCORL	-0.45	-5.28	-0.31	2.65e-7	Height;
CESC	cis	rs868036	1.000	rs1026732	chr15:68095085	C/T	cg08079166	chr15:68083412	MAP2K5	0.44	7.06	0.4	1.5e-11	Restless legs syndrome;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09567311	chr17:53316197	NA	-0.54	-6.42	-0.37	6.39e-10	Gut microbiome composition (summer);
CESC	cis	rs853679	0.550	rs1150692	chr6:28173957	A/G	cg21251018	chr6:28226885	NKAPL	0.35	5.29	0.31	2.57e-7	Depression;
CESC	cis	rs1348850	0.872	rs4893825	chr2:178298687	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.77	10.18	0.53	9.32e-21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs9834373	0.853	rs13322529	chr3:78495795	A/G	cg06138941	chr3:78371609	NA	-0.42	-5.12	-0.3	5.77e-7	Protein quantitative trait loci;
CESC	cis	rs17209837	0.607	rs60040620	chr7:87085379	C/A	cg00919237	chr7:87102261	ABCB4	-0.51	-6.58	-0.37	2.45e-10	Gallbladder cancer;
CESC	cis	rs35110281	0.840	rs7276633	chr21:45078800	C/T	cg01579765	chr21:45077557	HSF2BP	-0.58	-9.91	-0.52	6.67e-20	Mean corpuscular volume;
CESC	cis	rs2180341	0.781	rs7760652	chr6:127572096	A/G	cg27446573	chr6:127587934	RNF146	0.83	11.71	0.58	8.67e-26	Breast cancer;
CESC	trans	rs7840128	1.000	rs2720743	chr8:3677684	C/T	cg00270497	chr6:84562908	RIPPLY2	-0.79	-6.58	-0.37	2.44e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs6089584	0.888	rs6061973	chr20:60610870	C/T	cg13770153	chr20:60521292	NA	-0.44	-5.68	-0.33	3.6e-8	Body mass index;
CESC	cis	rs7949030	0.626	rs7124057	chr11:62334096	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.64	9.47	0.5	1.65e-18	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs9649213	0.593	rs6465673	chr7:97968887	C/T	cg08684580	chr7:98029266	BAIAP2L1	-0.35	-5.76	-0.33	2.37e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs6540559	1.000	rs7522250	chr1:209962539	T/C	cg21951975	chr1:209979733	IRF6	0.6	9.37	0.5	3.31e-18	Cleft lip with or without cleft palate;
CESC	cis	rs7666738	0.830	rs13138059	chr4:99050430	A/G	cg03676636	chr4:99064102	C4orf37	0.33	5.08	0.3	7.1e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs67478160	0.654	rs11628240	chr14:104218135	A/G	cg08213375	chr14:104286397	PPP1R13B	0.55	11.04	0.56	1.4e-23	Schizophrenia;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg22717323	chr7:2094977	MAD1L1	0.4	6.2	0.36	2.17e-9	Fibrinogen levels;
CESC	cis	rs2540647	0.706	rs2518804	chr22:18975504	A/C	cg12798833	chr22:18958832	DGCR5	0.5	5.45	0.32	1.15e-7	Blood metabolite ratios;
CESC	trans	rs9467711	0.790	rs1979	chr6:26377591	G/T	cg06606381	chr12:133084897	FBRSL1	-0.74	-6.73	-0.38	1.05e-10	Autism spectrum disorder or schizophrenia;
CESC	cis	rs3780486	0.846	rs10738905	chr9:33123627	A/G	cg13443165	chr9:33130375	B4GALT1	0.43	6.23	0.36	1.86e-9	IgG glycosylation;
CESC	cis	rs897080	0.552	rs1067377	chr2:44648239	T/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	5.91	0.34	1.07e-8	Height;
CESC	cis	rs6963495	0.615	rs2697021	chr7:105151029	A/C	cg13798780	chr7:105162888	PUS7	0.5	6.09	0.35	4.04e-9	Bipolar disorder (body mass index interaction);
CESC	cis	rs1003719	0.788	rs2835600	chr21:38468958	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.63	8.77	0.47	2.14e-16	Eye color traits;
CESC	cis	rs7927771	1.000	rs12787330	chr11:47812311	C/T	cg05585544	chr11:47624801	NA	-0.49	-7.71	-0.43	2.62e-13	Subjective well-being;
CESC	cis	rs11077998	0.967	rs4789788	chr17:80510285	C/T	cg10255544	chr17:80519551	FOXK2	-0.52	-8.56	-0.47	9.1e-16	Reticulocyte fraction of red cells;
CESC	cis	rs9837602	1.000	rs6799379	chr3:99762840	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.49	7.14	0.4	8.96e-12	Breast cancer;
CESC	cis	rs10504229	1.000	rs34616626	chr8:58184650	C/T	cg24829409	chr8:58192753	C8orf71	-0.76	-9.93	-0.52	5.87e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs6460942	1.000	rs112794590	chr7:12319426	G/A	cg02935154	chr7:12443704	VWDE	-0.59	-5.84	-0.34	1.5e-8	Coronary artery disease;
CESC	cis	rs854765	0.693	rs8079418	chr17:17924060	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.4	5.58	0.32	5.93e-8	Total body bone mineral density;
CESC	cis	rs13256369	1.000	rs9329166	chr8:8576655	C/T	cg17143192	chr8:8559678	CLDN23	0.66	7.49	0.42	1.01e-12	Obesity-related traits;
CESC	cis	rs12681366	0.537	rs2919664	chr8:95468713	A/G	cg13257157	chr8:95487014	RAD54B	0.45	5.47	0.32	1.02e-7	Nonsyndromic cleft lip with cleft palate;
CESC	cis	rs710216	0.917	rs900837	chr1:43412793	A/G	cg03128534	chr1:43423976	SLC2A1	-0.56	-6.49	-0.37	4.09e-10	Red cell distribution width;
CESC	cis	rs4819052	0.851	rs9754134	chr21:46661751	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.75	9.98	0.52	4.1e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs798554	0.757	rs1182198	chr7:2862906	C/T	cg09658497	chr7:2847517	GNA12	-0.43	-5.93	-0.34	9.31e-9	Height;
CESC	trans	rs2018683	1.000	rs740252	chr7:28997765	C/G	cg19402173	chr7:128379420	CALU	-0.66	-8.73	-0.47	2.87e-16	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CESC	cis	rs7937682	0.961	rs491937	chr11:111494947	A/T	cg09085632	chr11:111637200	PPP2R1B	-0.91	-13.98	-0.65	1.22e-33	Primary sclerosing cholangitis;
CESC	cis	rs7605378	0.528	rs1704191	chr2:200816393	C/A	cg23649088	chr2:200775458	C2orf69	0.72	8.93	0.48	7.24e-17	Osteoporosis;
CESC	cis	rs7084402	0.967	rs1658427	chr10:60331504	G/A	cg07615347	chr10:60278583	BICC1	0.59	9.22	0.49	9.62e-18	Refractive error;
CESC	cis	rs9314323	0.798	rs2019239	chr8:26217354	G/A	cg11498726	chr8:26250323	BNIP3L	-0.44	-6.47	-0.37	4.7e-10	Red cell distribution width;
CESC	cis	rs6893300	0.524	rs12522926	chr5:179214818	G/A	cg14593053	chr5:179126677	CANX	0.53	7.87	0.44	8.9e-14	Resting heart rate;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg12977448	chr10:14920832	SUV39H2	-0.42	-6.1	-0.35	3.79e-9	Gambling;
CESC	cis	rs568617	1.000	rs687672	chr11:65649984	T/C	cg04055107	chr11:65626734	MUS81;CFL1	-0.67	-7.06	-0.4	1.43e-11	Crohn's disease;
CESC	cis	rs7666738	0.830	rs7659593	chr4:98934823	T/C	cg17366294	chr4:99064904	C4orf37	0.61	8.56	0.47	9.36e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2932538	0.922	rs6668533	chr1:113064468	C/T	cg22162597	chr1:113214053	CAPZA1	0.55	6.83	0.39	5.8e-11	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CESC	cis	rs4969178	0.965	rs56658017	chr17:76396164	G/A	cg05887092	chr17:76393375	PGS1	0.58	9.22	0.49	9.9e-18	HDL cholesterol levels;
CESC	trans	rs11096990	0.964	rs6831700	chr4:39256964	G/T	cg24474409	chr7:150021518	ACTR3C;LRRC61	-0.38	-6.05	-0.35	4.89e-9	Cognitive function;
CESC	cis	rs2404602	0.692	rs12437733	chr15:77155562	A/G	cg26408565	chr15:76604113	ETFA	-0.39	-5.68	-0.33	3.6e-8	Blood metabolite levels;
CESC	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.55	-6.13	-0.35	3.19e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7945705	0.791	rs6484484	chr11:8817206	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.33	5.16	0.3	4.93e-7	Hemoglobin concentration;
CESC	cis	rs2721195	0.967	rs748195	chr8:145682514	T/C	cg17328964	chr8:145687451	CYHR1	-0.57	-7.72	-0.43	2.34e-13	Age at first birth;
CESC	trans	rs17716202	0.702	rs16885766	chr5:55892229	A/G	cg14306956	chr9:37027384	PAX5	-0.53	-6.02	-0.35	5.7e-9	Psychosis in Alzheimer's disease;
CESC	cis	rs694739	0.796	rs479777	chr11:64107477	A/G	cg23796481	chr11:64053134	BAD;GPR137	0.67	8.37	0.46	3.26e-15	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CESC	cis	rs1620921	0.505	rs2115870	chr6:161207992	A/G	cg01280913	chr6:161186852	NA	-0.38	-5.69	-0.33	3.37e-8	Lipoprotein (a) - cholesterol levels;
CESC	cis	rs17431357	1.000	rs76230314	chr12:120930908	C/T	cg25045489	chr12:120971538	RNF10	-0.93	-5.46	-0.32	1.1e-7	Insulin resistance/response;
CESC	cis	rs902774	0.515	rs2363635	chr12:53354622	T/C	cg05393297	chr12:53359155	NA	-0.63	-8.77	-0.47	2.24e-16	Prostate cancer;
CESC	cis	rs9467711	0.606	rs9358930	chr6:26357011	C/T	cg14345882	chr6:26364793	BTN3A2	0.59	6.06	0.35	4.66e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs698833	0.828	rs2165421	chr2:44526010	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.48	6.1	0.35	3.79e-9	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs9831754	1.000	rs9855903	chr3:78347988	C/A	cg06138941	chr3:78371609	NA	-0.78	-8.75	-0.47	2.54e-16	Calcium levels;
CESC	cis	rs7044106	0.791	rs2416799	chr9:123480866	G/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.84	13.65	0.64	1.68e-32	Hip circumference adjusted for BMI;
CESC	cis	rs10823500	0.604	rs10762345	chr10:71939374	A/G	cg04118878	chr10:71993077	PPA1	0.43	5.13	0.3	5.55e-7	Blood protein levels;
CESC	cis	rs7666738	0.753	rs28390295	chr4:99028497	C/A	cg24818145	chr4:99064322	C4orf37	0.39	5.09	0.3	6.95e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs919433	0.857	rs36071109	chr2:198183191	C/A	cg03934865	chr2:198174659	NA	-0.42	-5.83	-0.34	1.57e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs10504229	0.679	rs10504217	chr8:58037522	A/G	cg22535103	chr8:58192502	C8orf71	-0.6	-6.76	-0.38	8.68e-11	Developmental language disorder (linguistic errors);
CESC	trans	rs2502399	0.652	rs1321021	chr6:113505786	T/C	cg00285294	chr7:1089767	C7orf50	-0.35	-6.31	-0.36	1.14e-9	Plasma clusterin levels;
CESC	cis	rs6831352	0.918	rs13138294	chr4:100062675	T/G	cg12011299	chr4:100065546	ADH4	-0.6	-6.7	-0.38	1.25e-10	Alcohol dependence;
CESC	cis	rs8072100	0.701	rs6503807	chr17:45772932	T/C	cg08085267	chr17:45401833	C17orf57	-0.43	-5.45	-0.32	1.12e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs12586317	0.547	rs116499019	chr14:35441931	T/C	cg05294307	chr14:35346193	BAZ1A	-0.49	-5.37	-0.31	1.75e-7	Psoriasis;
CESC	cis	rs7666738	0.830	rs9992391	chr4:98916052	G/A	cg05340658	chr4:99064831	C4orf37	0.76	11.21	0.57	4.1e-24	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7412746	0.597	rs868751	chr1:150669414	T/G	cg17724175	chr1:150552817	MCL1	0.45	7.33	0.41	2.84e-12	Melanoma;
CESC	cis	rs9549367	0.737	rs71446680	chr13:113894846	C/T	cg18105134	chr13:113819100	PROZ	-0.71	-8.63	-0.47	5.81e-16	Platelet distribution width;
CESC	cis	rs12541635	0.934	rs7008840	chr8:107016404	T/C	cg10147462	chr8:107024639	NA	0.42	5.87	0.34	1.31e-8	Age of smoking initiation;
CESC	cis	rs12410462	0.892	rs35341041	chr1:227653885	G/A	cg23173402	chr1:227635558	NA	0.55	5.41	0.32	1.41e-7	Major depressive disorder;
CESC	cis	rs6456156	0.586	rs1358882	chr6:167467101	G/A	cg23791538	chr6:167370224	RNASET2	-0.49	-6.37	-0.36	8.13e-10	Primary biliary cholangitis;
CESC	cis	rs2549003	1.000	rs9282761	chr5:131822224	T/C	cg02551604	chr5:131831745	NA	-0.37	-5.27	-0.31	2.81e-7	Asthma (sex interaction);
CESC	cis	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg13769605	chr2:12857067	TRIB2	0.42	5.83	0.34	1.65e-8	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs1799949	1.000	rs2037075	chr17:41305826	G/T	cg25072359	chr17:41440525	NA	0.46	6.06	0.35	4.72e-9	Menopause (age at onset);
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg16157530	chr2:105654526	MRPS9	0.43	6.05	0.35	4.91e-9	Vertical cup-disc ratio;
CESC	cis	rs9910055	0.530	rs7222349	chr17:42304644	C/T	cg19774624	chr17:42201019	HDAC5	-0.6	-8.52	-0.46	1.24e-15	Total body bone mineral density;
CESC	cis	rs734999	0.566	rs12748729	chr1:2558740	C/T	cg20673091	chr1:2541236	MMEL1	-0.48	-8.01	-0.44	3.71e-14	Ulcerative colitis;
CESC	cis	rs892961	0.932	rs3987886	chr17:75414980	A/G	cg05865280	chr17:75406074	SEPT9	0.63	12.78	0.62	1.79e-29	Airflow obstruction;
CESC	cis	rs4975616	0.686	rs37008	chr5:1351538	C/T	cg26373071	chr5:1325741	CLPTM1L	0.42	6.77	0.38	8.03e-11	Lung cancer;
CESC	cis	rs921968	0.541	rs6720403	chr2:219294258	A/C	cg02176678	chr2:219576539	TTLL4	-0.48	-8.4	-0.46	2.8e-15	Mean corpuscular hemoglobin concentration;
CESC	trans	rs57221529	0.545	rs55955015	chr5:575182	A/G	cg25482853	chr8:67687455	SGK3	1.01	10.19	0.53	8.63e-21	Lung disease severity in cystic fibrosis;
CESC	cis	rs4654899	1.000	rs4654905	chr1:21509558	A/G	cg05370193	chr1:21551575	ECE1	0.41	6.22	0.36	1.96e-9	Superior frontal gyrus grey matter volume;
CESC	cis	rs2404602	0.684	rs28895952	chr15:76856776	A/G	cg23625390	chr15:77176239	SCAPER	-0.44	-6.13	-0.35	3.24e-9	Blood metabolite levels;
CESC	cis	rs3796619	1.000	rs4974601	chr4:1095410	G/A	cg27284194	chr4:1044797	NA	0.38	5.74	0.33	2.58e-8	Recombination rate (males);
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg09196456	chr19:1390694	NDUFS7	0.43	6.17	0.35	2.6e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs11190604	1.000	rs7088512	chr10:102303498	G/T	cg07080220	chr10:102295463	HIF1AN	0.56	5.42	0.32	1.35e-7	Palmitoleic acid (16:1n-7) levels;
CESC	trans	rs7741085	0.872	rs11755164	chr6:44639184	A/G	cg04735960	chr13:21006388	CRYL1	-0.45	-6.13	-0.35	3.18e-9	Total body bone mineral density;
CESC	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.16	11.93	0.59	1.55e-26	Platelet count;
CESC	cis	rs7000551	0.725	rs2469757	chr8:22360938	C/T	cg12081754	chr8:22256438	SLC39A14	0.39	5.31	0.31	2.33e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CESC	cis	rs60154123	0.505	rs76101197	chr1:210044089	T/C	cg23283495	chr1:209979779	IRF6	0.53	5.68	0.33	3.56e-8	Coronary artery disease;
CESC	cis	rs35306767	0.903	rs11816064	chr10:931176	A/C	cg20503657	chr10:835505	NA	0.77	8.0	0.44	3.93e-14	Eosinophil percentage of granulocytes;
CESC	cis	rs55794721	0.543	rs1293260	chr1:25709104	C/G	cg27572855	chr1:25598939	RHD	0.5	8.4	0.46	2.68e-15	Plateletcrit;Mean corpuscular volume;
CESC	cis	rs55882075	0.535	rs67484565	chr5:179110574	G/T	cg14593053	chr5:179126677	CANX	0.46	5.91	0.34	1.07e-8	Monocyte percentage of white cells;
CESC	cis	rs1801251	0.778	rs2250665	chr2:233752639	A/T	cg08000102	chr2:233561755	GIGYF2	-0.57	-7.79	-0.43	1.52e-13	Coronary artery disease;
CESC	cis	rs7149337	0.717	rs4309324	chr14:51606336	A/T	cg23942311	chr14:51606299	NA	-0.55	-9.72	-0.51	2.68e-19	Cancer;
CESC	cis	rs3770081	1.000	rs6724025	chr2:86200835	A/G	cg01119172	chr2:86362222	SNORD94;PTCD3	0.65	5.11	0.3	6.12e-7	Facial emotion recognition (sad faces);
CESC	cis	rs7666738	0.830	rs7661264	chr4:98961574	G/A	cg03676636	chr4:99064102	C4orf37	0.33	5.14	0.3	5.39e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2549003	1.000	rs17848418	chr5:131821188	C/T	cg00255919	chr5:131827918	IRF1	0.51	8.68	0.47	4.19e-16	Asthma (sex interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02674305	chr20:34359915	PHF20	-0.69	-8.71	-0.47	3.44e-16	Gut microbiome composition (summer);
CESC	cis	rs9733	0.519	rs11204717	chr1:150709129	T/A	cg09365446	chr1:150670422	GOLPH3L	0.42	5.81	0.34	1.8e-8	Tonsillectomy;
CESC	cis	rs9322193	0.926	rs9383546	chr6:150143879	T/A	cg13206674	chr6:150067644	NUP43	0.4	5.57	0.32	6.36e-8	Lung cancer;
CESC	cis	rs4481887	0.893	rs4297335	chr1:248473421	C/T	cg00666640	chr1:248458726	OR2T12	0.36	6.12	0.35	3.33e-9	Common traits (Other);
CESC	cis	rs9611519	0.580	rs8138349	chr22:41412723	C/T	cg03806693	chr22:41940476	POLR3H	-0.51	-6.04	-0.35	5.18e-9	Neuroticism;
CESC	cis	rs7582720	0.943	rs72932560	chr2:203847417	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.36	0.41	2.34e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg07157834	chr1:205819609	PM20D1	0.7	10.74	0.55	1.37e-22	Menarche (age at onset);
CESC	trans	rs3087243	0.755	rs3115969	chr2:204694805	T/C	cg01841312	chr10:38069945	NA	0.38	6.33	0.36	1.03e-9	Rheumatoid arthritis;Hypothyroidism;Type 1 diabetes;
CESC	cis	rs6714710	0.603	rs34974566	chr2:98552299	C/G	cg26665480	chr2:98280029	ACTR1B	0.58	7.99	0.44	4.15e-14	Posterior cortical atrophy and Alzheimer's disease;
CESC	cis	rs9733	0.596	rs12085275	chr1:150650265	T/C	cg22823121	chr1:150693482	HORMAD1	0.48	7.09	0.4	1.21e-11	Tonsillectomy;
CESC	cis	rs2180341	0.961	rs7775493	chr6:127615000	C/A	cg27446573	chr6:127587934	RNF146	1.08	16.13	0.7	3.14e-41	Breast cancer;
CESC	cis	rs854765	0.583	rs4244602	chr17:17841456	A/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.5	6.38	0.37	7.73e-10	Total body bone mineral density;
CESC	cis	rs7945705	0.967	rs10769973	chr11:8928615	C/G	cg12365402	chr11:9010492	NRIP3	0.4	6.09	0.35	3.86e-9	Hemoglobin concentration;
CESC	cis	rs950169	0.920	rs12915390	chr15:84792069	T/C	cg17507749	chr15:85114479	UBE2QP1	0.62	6.89	0.39	4e-11	Schizophrenia;
CESC	cis	rs6674176	0.660	rs12726706	chr1:44399942	G/A	cg23954153	chr1:44402353	ARTN	-0.35	-5.51	-0.32	8.56e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs921968	0.565	rs6723334	chr2:219629303	C/T	cg02176678	chr2:219576539	TTLL4	0.42	7.5	0.42	9.58e-13	Mean corpuscular hemoglobin concentration;
CESC	cis	rs514406	0.679	rs61768344	chr1:53229274	G/A	cg08736216	chr1:53307985	ZYG11A	0.35	6.25	0.36	1.65e-9	Monocyte count;
CESC	cis	rs9902453	0.791	rs2628166	chr17:28113123	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.66	-8.47	-0.46	1.74e-15	Coffee consumption (cups per day);
CESC	cis	rs9916302	0.800	rs8081220	chr17:37473157	A/C	cg15445000	chr17:37608096	MED1	-0.4	-6.38	-0.36	7.99e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs3857067	0.773	rs10023115	chr4:95095502	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.61	-9.04	-0.49	3.47e-17	QT interval;
CESC	cis	rs7412746	0.658	rs1027699	chr1:150811712	T/C	cg22823121	chr1:150693482	HORMAD1	0.45	6.38	0.36	7.78e-10	Melanoma;
CESC	cis	rs7552404	0.727	rs5745433	chr1:76333163	T/G	cg03433033	chr1:76189801	ACADM	0.63	6.35	0.36	9.5e-10	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs9447004	0.557	rs2173854	chr6:74426775	T/A	cg23004174	chr6:74404879	CD109	0.35	5.07	0.3	7.63e-7	Blood protein levels;Calcium levels;
CESC	cis	rs2806561	0.894	rs1738475	chr1:23536891	C/G	cg12483005	chr1:23474871	LUZP1	0.32	5.15	0.3	4.99e-7	Height;
CESC	cis	rs6570726	0.935	rs372378	chr6:145816227	A/G	cg23711669	chr6:146136114	FBXO30	0.82	12.29	0.6	8.74e-28	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7618915	0.501	rs3774366	chr3:52641255	T/C	cg17372223	chr3:52568218	NT5DC2	0.41	6.32	0.36	1.11e-9	Bipolar disorder;
CESC	cis	rs9443189	0.570	rs659807	chr6:76293435	C/A	cg01950844	chr6:76311363	SENP6	0.87	9.54	0.51	9.61e-19	Prostate cancer;
CESC	cis	rs7089973	0.624	rs11196940	chr10:116593791	T/G	cg25233709	chr10:116636983	FAM160B1	0.39	6.13	0.35	3.22e-9	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18073432	chr5:86180679	NA	-0.56	-6.78	-0.38	7.68e-11	Gut microbiome composition (summer);
CESC	cis	rs1707322	1.000	rs4660328	chr1:46444831	G/T	cg05343316	chr1:45956843	TESK2	0.44	5.42	0.32	1.36e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2836950	0.501	rs4818019	chr21:40694456	T/A	cg17971929	chr21:40555470	PSMG1	-0.59	-7.65	-0.43	3.67e-13	Menarche (age at onset);
CESC	cis	rs8180040	1.000	rs295458	chr3:47385585	C/A	cg27129171	chr3:47204927	SETD2	0.66	10.0	0.52	3.6e-20	Colorectal cancer;
CESC	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg26338869	chr17:61819248	STRADA	0.69	8.69	0.47	3.91e-16	Prudent dietary pattern;
CESC	cis	rs9910055	0.659	rs112114764	chr17:42201041	G/T	cg19774624	chr17:42201019	HDAC5	0.9	14.87	0.67	8.64e-37	Total body bone mineral density;
CESC	cis	rs2033711	0.840	rs4801590	chr19:58961813	G/C	cg13877915	chr19:58951672	ZNF132	0.37	5.53	0.32	7.56e-8	Uric acid clearance;
CESC	cis	rs3784262	1.000	rs4646627	chr15:58255305	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.31	-5.13	-0.3	5.51e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
CESC	cis	rs735396	0.770	rs1169300	chr12:121431225	G/A	cg25281562	chr12:121454272	C12orf43	0.53	6.68	0.38	1.43e-10	N-glycan levels;
CESC	cis	rs10206020	0.879	rs72778007	chr2:1573178	C/T	cg12573674	chr2:1569213	NA	-0.47	-5.42	-0.32	1.33e-7	IgG glycosylation;
CESC	cis	rs4722166	0.630	rs2091115	chr7:22810166	G/T	cg13104385	chr7:22767384	IL6	0.41	5.56	0.32	6.6e-8	Lung cancer;
CESC	trans	rs6456042	0.893	rs3099312	chr6:166557339	T/C	cg01261503	chr17:62493599	POLG2	-0.44	-6.3	-0.36	1.2e-9	Asthma;
CESC	cis	rs3916	0.911	rs3999408	chr12:121167387	C/T	cg21892295	chr12:121157589	UNC119B	-0.36	-5.24	-0.31	3.35e-7	Urinary metabolites (H-NMR features);
CESC	cis	rs875971	0.929	rs778712	chr7:65849978	C/T	cg11764359	chr7:65958608	NA	0.96	15.23	0.68	4.87e-38	Aortic root size;
CESC	cis	rs2230307	0.536	rs2893426	chr1:100528200	G/T	cg24955406	chr1:100503596	HIAT1	0.55	5.37	0.31	1.76e-7	Carotid intima media thickness;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg17670436	chr10:3374199	NA	-0.45	-6.19	-0.36	2.23e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs2274273	1.000	rs67098772	chr14:55595242	G/A	cg04306507	chr14:55594613	LGALS3	0.28	5.15	0.3	5.13e-7	Protein biomarker;
CESC	cis	rs694739	0.796	rs479777	chr11:64107477	A/G	cg02228329	chr11:64053129	BAD;GPR137	0.72	9.32	0.5	4.74e-18	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CESC	cis	rs9914266	1	rs9914266	chr17:2133250	T/C	cg16513277	chr17:2031491	SMG6	-0.63	-8.99	-0.48	4.73e-17	Myocardial infarction;
CESC	cis	rs933688	1.000	rs7720132	chr5:90745105	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.95	11.04	0.56	1.47e-23	Smoking behavior;
CESC	cis	rs1008375	1.000	rs10939756	chr4:17693867	C/T	cg16339924	chr4:17578868	LAP3	0.58	7.22	0.41	5.37e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs6570726	0.846	rs453834	chr6:145886261	T/C	cg23711669	chr6:146136114	FBXO30	0.85	13.03	0.62	2.59e-30	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs113835537	0.529	rs117112180	chr11:66293273	A/G	cg24851651	chr11:66362959	CCS	0.53	6.07	0.35	4.43e-9	Airway imaging phenotypes;
CESC	cis	rs6662572	1.000	rs56251392	chr1:46210829	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.51	5.55	0.32	7.08e-8	Blood protein levels;
CESC	trans	rs11148252	0.595	rs9526974	chr13:53251040	C/G	cg18335740	chr13:41363409	SLC25A15	0.51	6.83	0.39	5.79e-11	Lewy body disease;
CESC	cis	rs2014572	0.967	rs10411941	chr19:57762886	C/T	cg12963866	chr19:57752005	ZNF805	-0.47	-6.35	-0.36	9.56e-10	Hyperactive-impulsive symptoms;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07159286	chr12:133779169	ZNF268	-0.56	-6.4	-0.37	6.84e-10	Gut microbiome composition (summer);
CESC	cis	rs2228479	0.850	rs45524643	chr16:89815824	G/A	cg14709524	chr16:89940631	TCF25	0.93	6.94	0.39	3.03e-11	Skin colour saturation;
CESC	cis	rs7312933	1.000	rs3229	chr12:42475888	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.38	5.05	0.3	8.32e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs4555082	0.874	rs2816621	chr14:105732762	A/T	cg27165867	chr14:105738592	BRF1	-0.55	-5.92	-0.34	9.91e-9	Mean platelet volume;Platelet distribution width;
CESC	cis	rs1218582	0.596	rs11264275	chr1:154825270	G/T	cg09359103	chr1:154839909	KCNN3	0.46	7.72	0.43	2.39e-13	Prostate cancer;
CESC	cis	rs13118159	0.550	rs4974614	chr4:1373489	A/G	cg02071572	chr4:1403502	NA	0.38	5.61	0.33	5.2e-8	Longevity;
CESC	cis	rs7474896	0.537	rs1208683	chr10:38093723	A/G	cg25427524	chr10:38739819	LOC399744	0.46	5.03	0.3	8.97e-7	Obesity (extreme);
CESC	cis	rs4319547	0.876	rs10846978	chr12:122964708	T/C	cg23029597	chr12:123009494	RSRC2	-0.5	-5.52	-0.32	7.88e-8	Body mass index;
CESC	cis	rs6724607	1.000	rs13006708	chr2:191471428	G/A	cg21644426	chr2:191273491	MFSD6	-0.49	-6.68	-0.38	1.42e-10	Pulse pressure;
CESC	cis	rs9583531	0.600	rs9555726	chr13:111368316	C/T	cg24331049	chr13:111365604	ING1	0.67	9.59	0.51	7.01e-19	Coronary artery disease;
CESC	cis	rs11718455	0.960	rs35277738	chr3:44006732	T/C	cg08738300	chr3:44038990	NA	0.46	6.14	0.35	3.03e-9	Coronary artery disease;
CESC	cis	rs4819052	1.000	rs2838847	chr21:46670958	G/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.55	6.63	0.38	1.86e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs6964587	0.621	rs38798	chr7:92044539	C/A	cg17063962	chr7:91808500	NA	-0.52	-7.49	-0.42	1.05e-12	Breast cancer;
CESC	cis	rs611744	0.523	rs13253581	chr8:109343105	A/G	cg21045802	chr8:109455806	TTC35	0.58	7.04	0.4	1.69e-11	Dupuytren's disease;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg09068198	chr2:65357064	RAB1A	-0.47	-6.89	-0.39	4.05e-11	Gambling;
CESC	cis	rs7216064	1.000	rs62084246	chr17:65867911	G/C	cg07042672	chr17:66097459	LOC651250	-0.54	-5.59	-0.32	5.61e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	trans	rs7615952	0.599	rs16834938	chr3:125706046	C/T	cg07211511	chr3:129823064	LOC729375	-0.54	-6.56	-0.37	2.75e-10	Blood pressure (smoking interaction);
CESC	cis	rs4665809	1.000	rs6739061	chr2:26256147	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.69	-7.85	-0.43	1.04e-13	Gut microbiome composition (summer);
CESC	cis	rs9837602	1.000	rs6806178	chr3:99780393	A/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.46	6.78	0.38	8e-11	Breast cancer;
CESC	cis	rs4268898	0.896	rs2702042	chr2:24546542	C/T	cg20701182	chr2:24300061	SF3B14	0.47	5.85	0.34	1.44e-8	Asthma;
CESC	cis	rs4253772	0.515	rs7287164	chr22:46781008	T/C	cg24881330	chr22:46731750	TRMU	0.8	5.49	0.32	9.33e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs853679	0.517	rs9357066	chr6:28129831	T/C	cg08968635	chr6:28129556	ZNF389	0.4	5.22	0.31	3.69e-7	Depression;
CESC	cis	rs3857067	1.000	rs3857068	chr4:95026494	C/G	cg11021082	chr4:95130006	SMARCAD1	0.54	8.45	0.46	1.98e-15	QT interval;
CESC	cis	rs6860806	0.661	rs28472559	chr5:131581611	G/A	cg18758796	chr5:131593413	PDLIM4	0.46	6.4	0.37	7.1e-10	Breast cancer;
CESC	cis	rs7119038	0.731	rs28409215	chr11:118679304	G/A	cg19308663	chr11:118741387	NA	0.4	5.03	0.3	9e-7	Sjögren's syndrome;
CESC	cis	rs1371867	0.641	rs1788209	chr8:101337056	C/T	cg11906718	chr8:101322791	RNF19A	0.48	6.22	0.36	1.97e-9	Atrioventricular conduction;
CESC	cis	rs801193	0.591	rs721717	chr7:66130292	G/T	cg18252515	chr7:66147081	NA	0.48	6.47	0.37	4.62e-10	Aortic root size;
CESC	cis	rs2180341	1.000	rs9375499	chr6:127618072	T/C	cg27446573	chr6:127587934	RNF146	1.08	16.13	0.7	3.14e-41	Breast cancer;
CESC	cis	rs10465746	0.967	rs12118434	chr1:84328629	C/T	cg10977910	chr1:84465055	TTLL7	0.47	6.49	0.37	4.22e-10	Obesity-related traits;
CESC	cis	rs9308433	0.553	rs1048791	chr1:214511519	T/C	cg06198575	chr1:214491504	SMYD2	0.44	5.05	0.3	8.27e-7	IgG glycosylation;
CESC	cis	rs7666738	0.830	rs7659420	chr4:98878714	G/C	cg05340658	chr4:99064831	C4orf37	0.78	11.69	0.58	9.42e-26	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9308731	1.000	rs13396983	chr2:111900598	A/G	cg04202892	chr2:111875749	ACOXL	0.37	5.37	0.31	1.71e-7	Chronic lymphocytic leukemia;
CESC	cis	rs13095912	1.000	rs6784842	chr3:185342723	C/T	cg11274856	chr3:185301563	NA	0.34	5.43	0.32	1.31e-7	Systolic blood pressure;
CESC	cis	rs4727027	0.769	rs10952797	chr7:148816722	A/T	cg23583168	chr7:148888333	NA	-0.78	-12.25	-0.6	1.2100000000000001e-27	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs6448317	0.863	rs2695228	chr4:24901985	C/T	cg21108841	chr4:24914750	CCDC149	0.49	6.14	0.35	3.07e-9	Heschl's gyrus morphology;
CESC	trans	rs921968	0.541	rs593888	chr2:219427597	A/G	cg15547669	chr20:2781122	CPXM1	0.36	6.04	0.35	5.31e-9	Mean corpuscular hemoglobin concentration;
CESC	cis	rs1448094	0.717	rs60713909	chr12:86294469	C/G	cg02569458	chr12:86230093	RASSF9	0.36	5.14	0.3	5.46e-7	Major depressive disorder;
CESC	cis	rs6732160	0.838	rs13411380	chr2:73382846	G/C	cg01422370	chr2:73384389	NA	0.44	7.58	0.42	5.89e-13	Intelligence (multi-trait analysis);
CESC	cis	rs4835473	0.897	rs4835095	chr4:144881584	A/T	cg25736465	chr4:144833511	NA	0.41	6.05	0.35	4.79e-9	Immature fraction of reticulocytes;
CESC	trans	rs3942852	0.726	rs1503171	chr11:48175152	T/C	cg15704280	chr7:45808275	SEPT13	-0.75	-8.6	-0.47	7.22e-16	Acute lymphoblastic leukemia (childhood);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg15831200	chr1:110765724	KCNC4	0.35	6.0	0.35	6.29e-9	Gambling;
CESC	cis	rs2033711	0.870	rs4801270	chr19:58932762	C/A	cg13877915	chr19:58951672	ZNF132	0.39	5.81	0.34	1.83e-8	Uric acid clearance;
CESC	cis	rs9303401	0.703	rs8072182	chr17:57211213	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.57	7.56	0.42	6.48e-13	Cognitive test performance;
CESC	cis	rs7659604	0.605	rs1507994	chr4:122749541	C/T	cg06713675	chr4:122721982	EXOSC9	-0.44	-6.13	-0.35	3.23e-9	Type 2 diabetes;
CESC	cis	rs12079745	0.590	rs35144581	chr1:169183588	C/T	cg09363564	chr1:169337483	NME7;BLZF1	-0.99	-6.11	-0.35	3.47e-9	QT interval;
CESC	cis	rs78456975	0.943	rs10470006	chr2:1580971	A/C	cg26248373	chr2:1572462	NA	-0.51	-5.19	-0.3	4.24e-7	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg23131131	chr22:24373011	LOC391322	-0.69	-9.45	-0.5	1.87e-18	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs11792861	0.888	rs11794648	chr9:111829792	C/T	cg13535736	chr9:111863775	C9orf5	-0.49	-6.64	-0.38	1.75e-10	Menarche (age at onset);
CESC	trans	rs7618501	0.699	rs6446187	chr3:49907111	C/A	cg21659725	chr3:3221576	CRBN	0.58	8.2	0.45	1.04e-14	Intelligence (multi-trait analysis);
CESC	cis	rs798554	0.660	rs2527692	chr7:2856533	G/A	cg09658497	chr7:2847517	GNA12	-0.35	-5.25	-0.31	3.07e-7	Height;
CESC	trans	rs561341	0.882	rs2428337	chr17:30299467	C/T	cg20587970	chr11:113659929	NA	-1.43	-18.65	-0.75	3.85e-50	Hip circumference adjusted for BMI;
CESC	cis	rs1062177	0.756	rs2964587	chr5:151119972	C/T	cg12924095	chr5:151150029	G3BP1	-0.43	-5.34	-0.31	2e-7	Preschool internalizing problems;
CESC	cis	rs55728055	0.661	rs16989278	chr22:31957167	A/G	cg01338084	chr22:32026380	PISD	1.26	8.23	0.45	8.62e-15	Age-related hearing impairment;
CESC	cis	rs4523957	0.928	rs452363	chr17:2194028	T/C	cg16513277	chr17:2031491	SMG6	0.59	8.08	0.44	2.29e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.52	7.06	0.4	1.46e-11	Lymphocyte counts;
CESC	cis	rs2439831	0.850	rs3816792	chr15:44116986	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.66	-6.06	-0.35	4.62e-9	Lung cancer in ever smokers;
CESC	cis	rs875971	0.862	rs13536	chr7:66019190	G/A	cg18876405	chr7:65276391	NA	-0.53	-7.22	-0.41	5.6e-12	Aortic root size;
CESC	cis	rs4132509	0.566	rs1578275	chr1:243680442	C/G	cg21452805	chr1:244014465	NA	-0.55	-6.19	-0.36	2.33e-9	RR interval (heart rate);
CESC	cis	rs3091242	0.967	rs1053438	chr1:25687901	T/C	cg03538708	chr1:25844672	NA	0.37	5.43	0.32	1.3e-7	Erythrocyte sedimentation rate;
CESC	cis	rs2688608	0.560	rs10128354	chr10:75470045	T/C	cg23231163	chr10:75533350	FUT11	-0.36	-5.53	-0.32	7.78e-8	Inflammatory bowel disease;
CESC	cis	rs1790761	0.504	rs61894496	chr11:67391907	C/T	cg00290607	chr11:67383545	NA	0.5	7.39	0.41	1.91e-12	Mean corpuscular volume;
CESC	trans	rs7819412	0.505	rs67849263	chr8:11007544	G/T	cg15556689	chr8:8085844	FLJ10661	-0.54	-6.27	-0.36	1.46e-9	Triglycerides;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17004975	chr10:81743287	NA	-0.58	-7.21	-0.4	5.71e-12	Gut microbiome composition (summer);
CESC	cis	rs3768617	0.510	rs10797844	chr1:183082067	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.87	14.13	0.66	3.47e-34	Fuchs's corneal dystrophy;
CESC	cis	rs2573652	1.000	rs2727196	chr15:100513529	C/T	cg09918751	chr15:100517450	ADAMTS17	-0.39	-7.61	-0.42	4.79e-13	Height;
CESC	cis	rs8070128	0.534	rs2955350	chr17:17953548	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.62	-8.81	-0.48	1.7e-16	Total body bone mineral density;
CESC	cis	rs12497850	0.897	rs9850134	chr3:48957147	A/G	cg06212747	chr3:49208901	KLHDC8B	0.68	9.34	0.5	3.96e-18	Parkinson's disease;
CESC	cis	rs7523050	0.643	rs12741194	chr1:109400390	T/C	cg08274380	chr1:109419600	GPSM2	0.83	5.58	0.32	5.89e-8	Fat distribution (HIV);
CESC	trans	rs208520	0.837	rs208498	chr6:66931560	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.81	-9.62	-0.51	5.57e-19	Exhaled nitric oxide output;
CESC	cis	rs763121	0.853	rs35565791	chr22:39063011	C/A	cg06022373	chr22:39101656	GTPBP1	0.88	13.95	0.65	1.51e-33	Menopause (age at onset);
CESC	cis	rs561341	1.000	rs501312	chr17:30329066	A/G	cg00745463	chr17:30367425	LRRC37B	-0.83	-7.54	-0.42	7.69e-13	Hip circumference adjusted for BMI;
CESC	cis	rs6121246	0.954	rs6060992	chr20:30431255	G/T	cg13852791	chr20:30311386	BCL2L1	0.75	7.38	0.41	2.1e-12	Mean corpuscular hemoglobin;
CESC	cis	rs72945132	0.882	rs67529561	chr11:70162055	G/T	cg00319359	chr11:70116639	PPFIA1	0.78	7.71	0.43	2.52e-13	Coronary artery disease;
CESC	cis	rs2243480	1.000	rs6460274	chr7:65628484	T/A	cg12463550	chr7:65579703	CRCP	-0.73	-5.71	-0.33	3.1e-8	Diabetic kidney disease;
CESC	cis	rs473651	0.967	rs483042	chr2:239335320	A/G	cg21699342	chr2:239360505	ASB1	0.54	9.13	0.49	1.82e-17	Multiple system atrophy;
CESC	cis	rs11608355	0.545	rs11609019	chr12:109895958	G/A	cg05360138	chr12:110035743	NA	0.82	8.92	0.48	7.93e-17	Neuroticism;
CESC	cis	rs258892	0.793	rs34657	chr5:72148196	G/A	cg21869765	chr5:72125136	TNPO1	0.44	5.55	0.32	6.92e-8	Small cell lung carcinoma;
CESC	cis	rs2836950	0.520	rs1980407	chr21:40543961	T/C	cg17971929	chr21:40555470	PSMG1	-0.6	-8.02	-0.44	3.31e-14	Menarche (age at onset);
CESC	cis	rs9908102	0.740	rs11545302	chr17:12899963	T/C	cg26162695	chr17:12921313	ELAC2	0.52	5.75	0.33	2.5e-8	Schizophrenia;
CESC	cis	rs67460515	0.527	rs34221255	chr3:160854123	T/C	cg03342759	chr3:160939853	NMD3	-0.41	-5.38	-0.31	1.66e-7	Parkinson's disease;
CESC	cis	rs10504229	0.724	rs16922734	chr8:58111192	C/T	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs11792861	0.926	rs72607163	chr9:111803128	G/T	cg05043794	chr9:111880884	C9orf5	-0.4	-6.63	-0.38	1.86e-10	Menarche (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05205601	chr15:64885318	ZNF609	-0.53	-6.13	-0.35	3.17e-9	Gut microbiome composition (summer);
CESC	cis	rs9308433	0.553	rs11120299	chr1:214509407	C/A	cg06198575	chr1:214491504	SMYD2	0.48	5.79	0.34	2.01e-8	IgG glycosylation;
CESC	cis	rs17641971	0.599	rs2385230	chr8:50015755	A/G	cg00325661	chr8:49890786	NA	0.38	5.33	0.31	2.15e-7	Blood metabolite levels;
CESC	cis	rs4819052	0.851	rs7279182	chr21:46656112	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.47	5.65	0.33	4.1e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs9951602	0.573	rs8098953	chr18:76648734	A/G	cg02800362	chr5:177631904	HNRNPAB	0.65	8.65	0.47	5.07e-16	Obesity-related traits;
CESC	cis	rs4595586	0.545	rs12812262	chr12:39392567	T/A	cg26384229	chr12:38710491	ALG10B	0.54	7.64	0.42	3.96e-13	Morning vs. evening chronotype;
CESC	cis	rs7100689	0.577	rs9285726	chr10:82035150	A/T	cg09936400	chr10:82049201	MAT1A	0.4	5.85	0.34	1.43e-8	Post bronchodilator FEV1;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg20340149	chr2:122407145	CLASP1	-0.46	-6.66	-0.38	1.55e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs13191362	0.507	rs13212746	chr6:163203092	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.47	5.53	0.32	7.67e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	trans	rs6931865	0.508	rs55767626	chr6:144065552	A/G	cg02864954	chr6:154535553	IPCEF1;OPRM1	0.39	6.36	0.36	8.74e-10	Erectile dysfunction in type 1 diabetes;
CESC	cis	rs9911578	0.935	rs302873	chr17:56769481	C/G	cg05425664	chr17:57184151	TRIM37	-0.52	-7.11	-0.4	1.07e-11	Intelligence (multi-trait analysis);
CESC	cis	rs2901656	0.502	rs9425601	chr1:172377262	G/A	cg03748243	chr1:172413542	C1orf105;PIGC	-0.4	-5.49	-0.32	9.18e-8	Red cell distribution width;Platelet distribution width;
CESC	cis	rs3785574	0.962	rs2584630	chr17:61887561	T/A	cg06420487	chr17:61919686	SMARCD2	0.44	5.29	0.31	2.53e-7	Height;
CESC	cis	rs853679	0.517	rs9380058	chr6:28127444	T/C	cg26335602	chr6:28129616	ZNF389	0.53	6.95	0.39	2.83e-11	Depression;
CESC	cis	rs2228479	0.850	rs62054640	chr16:89823157	C/T	cg00800038	chr16:89945340	TCF25	-0.91	-7.54	-0.42	7.39e-13	Skin colour saturation;
CESC	cis	rs4953076	0.613	rs11124981	chr2:44462133	A/T	cg04920474	chr2:44395004	PPM1B	0.6	7.75	0.43	1.92e-13	Height;
CESC	cis	rs10129255	0.957	rs8005468	chr14:107142448	C/T	cg07958169	chr14:107095056	NA	-0.38	-5.21	-0.3	3.79e-7	Kawasaki disease;
CESC	cis	rs9549260	0.564	rs4941989	chr13:41299687	T/C	cg21288729	chr13:41239152	FOXO1	0.59	7.63	0.42	4.25e-13	Red blood cell count;
CESC	cis	rs780096	0.525	rs13388159	chr2:27648284	A/T	cg24768116	chr2:27665128	KRTCAP3	-0.29	-5.28	-0.31	2.7e-7	Total body bone mineral density;
CESC	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.44	-5.81	-0.34	1.83e-8	Longevity;Endometriosis;
CESC	cis	rs7552404	0.731	rs1493367	chr1:76344011	C/A	cg22875332	chr1:76189707	ACADM	-0.58	-6.06	-0.35	4.53e-9	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs7208859	0.524	rs77498725	chr17:29063986	C/T	cg19761014	chr17:28927070	LRRC37B2	0.76	6.25	0.36	1.66e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	trans	rs801193	0.935	rs2659899	chr7:66186721	A/G	cg26939375	chr7:64535504	NA	0.64	8.67	0.47	4.39e-16	Aortic root size;
CESC	trans	rs650950	0.528	rs646660	chr11:35528452	C/T	cg04203298	chr11:59521722	STX3	0.44	6.22	0.36	1.91e-9	Bronchopulmonary dysplasia;
CESC	cis	rs7089973	0.872	rs7918388	chr10:116614563	T/C	cg23260525	chr10:116636907	FAM160B1	0.38	6.37	0.36	8.29e-10	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs2549003	1.000	rs7735073	chr5:131815357	G/A	cg02551604	chr5:131831745	NA	-0.36	-5.08	-0.3	7.22e-7	Asthma (sex interaction);
CESC	cis	rs2637266	0.783	rs7900420	chr10:78476543	T/C	cg18941641	chr10:78392320	NA	0.4	7.59	0.42	5.51e-13	Pulmonary function;
CESC	cis	rs1005277	0.579	rs2474572	chr10:38385316	A/G	cg00409905	chr10:38381863	ZNF37A	-0.52	-7.13	-0.4	9.34e-12	Extrinsic epigenetic age acceleration;
CESC	cis	rs4819052	0.807	rs1075788	chr21:46666564	T/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.47	6.0	0.35	6.55e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs4862750	0.872	rs13101408	chr4:187894777	G/A	cg11301795	chr4:187892539	NA	-0.74	-11.64	-0.58	1.46e-25	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7772486	0.754	rs864148	chr6:145976675	T/C	cg23711669	chr6:146136114	FBXO30	-0.98	-15.11	-0.68	1.2e-37	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7903847	0.692	rs7900255	chr10:99157575	G/A	cg20016023	chr10:99160130	RRP12	-0.3	-5.19	-0.3	4.18e-7	Granulocyte percentage of myeloid white cells;
CESC	cis	rs258892	0.895	rs34782328	chr5:72060974	T/C	cg21869765	chr5:72125136	TNPO1	-0.43	-5.35	-0.31	1.93e-7	Small cell lung carcinoma;
CESC	cis	rs60871478	0.898	rs4720929	chr7:808009	T/C	cg05535760	chr7:792225	HEATR2	0.88	11.01	0.56	1.78e-23	Cerebrospinal P-tau181p levels;
CESC	cis	rs2836974	0.739	rs12482181	chr21:40548852	A/G	cg27266027	chr21:40555129	PSMG1	0.43	5.17	0.3	4.72e-7	Cognitive function;
CESC	trans	rs1814175	0.791	rs7395713	chr11:49877887	A/G	cg15704280	chr7:45808275	SEPT13	-1.03	-20.77	-0.79	1.6e-57	Height;
CESC	cis	rs6912958	0.559	rs242281	chr6:88048916	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.72	10.99	0.56	2.06e-23	Monocyte percentage of white cells;
CESC	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg11494091	chr17:61959527	GH2	0.72	12.38	0.61	4.46e-28	Prudent dietary pattern;
CESC	cis	rs798554	0.679	rs11973498	chr7:2886873	C/A	cg19717773	chr7:2847554	GNA12	-0.44	-6.46	-0.37	4.99e-10	Height;
CESC	cis	rs7666738	0.830	rs1120708	chr4:98931260	G/C	cg03467027	chr4:99064603	C4orf37	0.46	5.6	0.33	5.39e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs17253792	0.822	rs28831725	chr14:56087569	C/T	cg01858014	chr14:56050164	KTN1	-0.85	-6.99	-0.39	2.22e-11	Putamen volume;
CESC	cis	rs7267979	0.903	rs6132819	chr20:25218618	C/G	cg08601574	chr20:25228251	PYGB	0.42	5.88	0.34	1.23e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7666738	0.830	rs10019087	chr4:99030211	C/T	cg03467027	chr4:99064603	C4orf37	0.49	6.18	0.35	2.44e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7580658	0.676	rs58475809	chr2:128002650	A/G	cg10021288	chr2:128175891	PROC	-0.37	-6.03	-0.35	5.53e-9	Protein C levels;
CESC	cis	rs977987	0.815	rs11149818	chr16:75419373	G/A	cg03315344	chr16:75512273	CHST6	0.4	5.77	0.33	2.22e-8	Dupuytren's disease;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg08718230	chr6:21596358	SOX4	-0.49	-6.47	-0.37	4.62e-10	Ulcerative colitis;
CESC	cis	rs7927592	0.830	rs10896339	chr11:68302846	G/C	cg16797656	chr11:68205561	LRP5	0.41	6.15	0.35	2.76e-9	Total body bone mineral density;
CESC	cis	rs6460942	1.000	rs77494477	chr7:12315302	A/T	cg20607287	chr7:12443886	VWDE	-0.79	-8.51	-0.46	1.32e-15	Coronary artery disease;
CESC	cis	rs7914558	0.966	rs4917997	chr10:104945213	A/G	cg04362960	chr10:104952993	NT5C2	0.46	6.16	0.35	2.74e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs1707322	0.717	rs1547925	chr1:46085356	C/T	cg03146154	chr1:46216737	IPP	-0.78	-10.93	-0.56	3.39e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg16087482	chr17:79683232	SLC25A10	0.41	6.38	0.36	7.85e-10	Fibrinogen levels;
CESC	trans	rs6479874	0.920	rs7893612	chr10:52761458	G/A	cg14115756	chr9:125795935	GPR21;RABGAP1	0.68	6.0	0.35	6.41e-9	Migraine;
CESC	cis	rs2243480	1.000	rs56291018	chr7:65390339	G/A	cg13147721	chr7:65941812	NA	-0.88	-8.15	-0.45	1.47e-14	Diabetic kidney disease;
CESC	trans	rs673604	0.505	rs676614	chr1:36107510	G/T	cg01420088	chr10:101491661	CUTC;COX15	0.54	6.04	0.35	5.18e-9	Endometrial cancer;
CESC	cis	rs4563143	0.514	rs73029079	chr19:29294903	A/G	cg12756686	chr19:29218302	NA	0.54	6.27	0.36	1.46e-9	Methadone dose in opioid dependence;
CESC	cis	rs7267979	0.706	rs6037069	chr20:25234166	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.79	15.3	0.68	2.73e-38	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7678296	0.649	rs60691639	chr4:37239925	T/C	cg06805348	chr4:37245195	KIAA1239	0.53	5.79	0.33	2.04e-8	3-hydroxypropylmercapturic acid levels in smokers;
CESC	cis	rs2011503	0.941	rs11555053	chr19:19390185	G/A	cg11584989	chr19:19387371	SF4	0.61	7.3	0.41	3.41e-12	Bipolar disorder;
CESC	cis	rs12824058	0.831	rs11609362	chr12:130810526	T/C	cg23887609	chr12:130822674	PIWIL1	0.45	5.82	0.34	1.69e-8	Menopause (age at onset);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg00688900	chr17:34901364	GGNBP2	0.42	6.03	0.35	5.56e-9	Fibrinogen levels;
CESC	cis	rs870825	0.616	rs2141257	chr4:185609463	C/T	cg04058563	chr4:185651563	MLF1IP	-0.63	-6.14	-0.35	3.01e-9	Blood protein levels;
CESC	cis	rs1799949	1.000	rs8176083	chr17:41275151	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.64	8.61	0.47	6.49e-16	Menopause (age at onset);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg15092787	chr17:74581715	ST6GALNAC2	-0.48	-6.49	-0.37	4.08e-10	Fibrinogen levels;
CESC	cis	rs9309473	1.000	rs10187192	chr2:73713500	T/C	cg20560298	chr2:73613845	ALMS1	-0.55	-6.86	-0.39	4.78e-11	Metabolite levels;
CESC	cis	rs11122272	0.675	rs1416913	chr1:231533206	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.56	-7.66	-0.43	3.45e-13	Hemoglobin concentration;
CESC	cis	rs6062302	0.522	rs13043255	chr20:62218916	C/G	cg06363034	chr20:62225388	GMEB2	-0.51	-6.57	-0.37	2.68e-10	Glioblastoma;
CESC	cis	rs3008870	0.920	rs2755253	chr1:67470843	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.77	10.52	0.54	7.66e-22	Lymphocyte percentage of white cells;
CESC	cis	rs6963495	0.818	rs73192115	chr7:105169605	T/A	cg02135003	chr7:105160482	PUS7	-0.46	-5.5	-0.32	9.1e-8	Bipolar disorder (body mass index interaction);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg10217975	chr3:52091484	DUSP7	-0.47	-6.3	-0.36	1.21e-9	Fibrinogen levels;
CESC	cis	rs71403859	0.502	rs12708914	chr16:71470636	G/A	cg08717414	chr16:71523259	ZNF19	-0.7	-7.23	-0.41	5.03e-12	Post bronchodilator FEV1;
CESC	cis	rs13191362	0.935	rs34934114	chr6:163082480	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.62	6.4	0.37	7.19e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs870825	0.698	rs7673203	chr4:185625397	T/C	cg04058563	chr4:185651563	MLF1IP	0.64	7.05	0.4	1.59e-11	Blood protein levels;
CESC	cis	rs6088590	1.000	rs6120750	chr20:33465289	A/C	cg06115741	chr20:33292138	TP53INP2	0.63	7.65	0.43	3.83e-13	Coronary artery disease;
CESC	cis	rs1044826	0.642	rs295473	chr3:139215585	T/C	cg00490450	chr3:139108681	COPB2	0.45	5.53	0.32	7.8e-8	Obesity-related traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01708236	chr6:44233446	NFKBIE	0.64	7.02	0.4	1.9e-11	Gut microbiome composition (summer);
CESC	cis	rs1448094	0.512	rs7957170	chr12:86243282	A/G	cg02569458	chr12:86230093	RASSF9	0.49	7.22	0.41	5.67e-12	Major depressive disorder;
CESC	cis	rs7246657	0.943	rs2112923	chr19:37940327	C/T	cg23950597	chr19:37808831	NA	-0.55	-5.99	-0.35	6.69e-9	Coronary artery calcification;
CESC	cis	rs1799949	0.965	rs8176193	chr17:41231516	C/T	cg06001716	chr17:41278141	BRCA1;NBR2	0.38	5.29	0.31	2.61e-7	Menopause (age at onset);
CESC	cis	rs896854	0.684	rs2340534	chr8:95992330	G/A	cg16049864	chr8:95962084	TP53INP1	-0.64	-11.35	-0.57	1.34e-24	Type 2 diabetes;
CESC	trans	rs6445797	0.632	rs2291499	chr3:56658481	G/C	cg15444621	chr13:113611794	NA	0.34	6.1	0.35	3.64e-9	Gastritis;
CESC	cis	rs10504229	0.683	rs11786043	chr8:58133174	T/C	cg02725872	chr8:58115012	NA	-0.45	-7.05	-0.4	1.52e-11	Developmental language disorder (linguistic errors);
CESC	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg03395511	chr6:291903	DUSP22	-0.73	-9.54	-0.51	1.01e-18	Menopause (age at onset);
CESC	cis	rs17376456	0.825	rs10038828	chr5:93124056	C/T	cg25358565	chr5:93447407	FAM172A	1.11	10.66	0.55	2.6e-22	Diabetic retinopathy;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg12444081	chr17:16521159	NA	-0.46	-6.37	-0.36	8.21e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.64	7.45	0.42	1.33e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs861020	0.959	rs658860	chr1:209990549	C/T	cg05527609	chr1:210001259	C1orf107	1.08	13.26	0.63	4.16e-31	Orofacial clefts;
CESC	cis	rs7666738	0.861	rs5014702	chr4:99052102	C/A	cg05340658	chr4:99064831	C4orf37	0.81	12.4	0.61	3.83e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10979	0.571	rs7764231	chr6:143919151	C/G	cg25407410	chr6:143891975	LOC285740	-0.47	-5.85	-0.34	1.42e-8	Hypospadias;
CESC	cis	rs2439831	0.850	rs694985	chr15:43813387	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.78	8.47	0.46	1.69e-15	Lung cancer in ever smokers;
CESC	cis	rs9487051	0.621	rs351750	chr6:109533385	T/C	cg01475377	chr6:109611718	NA	-0.39	-5.16	-0.3	4.76e-7	Reticulocyte fraction of red cells;
CESC	cis	rs9837602	0.507	rs793453	chr3:99529095	A/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.51	-6.17	-0.35	2.48e-9	Breast cancer;
CESC	cis	rs875971	0.540	rs35510581	chr7:65578777	G/A	cg11764359	chr7:65958608	NA	-0.64	-8.11	-0.45	1.9e-14	Aortic root size;
CESC	cis	rs2797685	0.853	rs707462	chr1:7849880	A/G	cg04725166	chr1:7887271	PER3	-0.44	-6.24	-0.36	1.7e-9	Crohn's disease;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	ch.1.2648414R	chr1:113158148	ST7L	-0.47	-6.0	-0.35	6.37e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs6502050	0.799	rs28376857	chr17:80104351	G/A	cg11859384	chr17:80120422	CCDC57	-0.38	-5.11	-0.3	6.21e-7	Life satisfaction;
CESC	trans	rs208520	1.000	rs208527	chr6:66957209	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.85	-9.42	-0.5	2.36e-18	Exhaled nitric oxide output;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg06397510	chr1:32403634	PTP4A2	-0.48	-6.42	-0.37	6.27e-10	Ulcerative colitis;
CESC	cis	rs6499255	1.000	rs12925371	chr16:69773885	G/A	cg15192750	chr16:69999425	NA	0.54	6.48	0.37	4.42e-10	IgE levels;
CESC	cis	rs7903847	0.642	rs11189200	chr10:99156273	C/G	cg20016023	chr10:99160130	RRP12	-0.3	-5.19	-0.3	4.18e-7	Granulocyte percentage of myeloid white cells;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg01604348	chr19:54663591	LENG1	0.46	6.41	0.37	6.58e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs11645898	0.688	rs437638	chr16:72095452	C/T	cg14768367	chr16:72042858	DHODH	-0.79	-6.25	-0.36	1.65e-9	Blood protein levels;
CESC	trans	rs61931739	0.517	rs10844830	chr12:34308133	C/T	cg26384229	chr12:38710491	ALG10B	0.44	6.01	0.35	6.07e-9	Morning vs. evening chronotype;
CESC	cis	rs9811920	0.609	rs793466	chr3:99609837	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.64	10.11	0.53	1.53e-20	Axial length;
CESC	cis	rs8077889	0.672	rs4793028	chr17:41857212	T/C	cg26893861	chr17:41843967	DUSP3	1.01	18.86	0.76	6.61e-51	Triglycerides;
CESC	cis	rs1051424	0.651	rs1292063	chr17:57907768	T/A	cg13753209	chr17:57696993	CLTC	-0.67	-8.48	-0.46	1.6e-15	Obesity-related traits;
CESC	cis	rs6860806	0.507	rs273915	chr5:131660119	G/C	cg07395648	chr5:131743802	NA	-0.43	-5.64	-0.33	4.43e-8	Breast cancer;
CESC	cis	rs6088580	0.561	rs3761147	chr20:32996689	G/T	cg08999081	chr20:33150536	PIGU	-0.63	-10.83	-0.55	7.31e-23	Glomerular filtration rate (creatinine);
CESC	cis	rs4803468	1.000	rs11883104	chr19:41923799	T/C	cg14132834	chr19:41945861	ATP5SL	-0.68	-8.39	-0.46	2.9e-15	Height;
CESC	cis	rs854765	0.547	rs2955370	chr17:17966945	C/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.48	-6.15	-0.35	2.87e-9	Total body bone mineral density;
CESC	cis	rs4594175	0.926	rs9323206	chr14:51621800	C/T	cg23942311	chr14:51606299	NA	0.41	6.23	0.36	1.78e-9	Cancer;
CESC	cis	rs6952808	0.595	rs3778983	chr7:2166319	T/G	cg04267008	chr7:1944627	MAD1L1	-0.54	-6.51	-0.37	3.78e-10	Bipolar disorder and schizophrenia;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg23939166	chr14:55032812	NA	-0.45	-6.13	-0.35	3.17e-9	Asthma;
CESC	cis	rs3785574	0.962	rs2727280	chr17:61918082	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.06	16.57	0.71	8.06e-43	Height;
CESC	cis	rs921968	0.541	rs488767	chr2:219466860	G/T	cg02176678	chr2:219576539	TTLL4	0.44	7.6	0.42	5.18e-13	Mean corpuscular hemoglobin concentration;
CESC	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.63	7.15	0.4	8.37e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs73206853	0.764	rs73206857	chr12:110767721	T/A	cg04375036	chr12:111181819	PPP1CC	-0.55	-5.04	-0.3	8.52e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs5753618	0.561	rs2283879	chr22:31638448	G/A	cg13145458	chr22:31556086	RNF185	0.46	5.21	0.3	3.86e-7	Colorectal cancer;
CESC	trans	rs62103177	0.759	rs9956512	chr18:77607517	G/A	cg05926928	chr17:57297772	GDPD1	1.14	11.63	0.58	1.58e-25	Opioid sensitivity;
CESC	cis	rs4332037	0.754	rs62436669	chr7:1926636	G/A	cg23422044	chr7:1970798	MAD1L1	-0.58	-6.06	-0.35	4.66e-9	Bipolar disorder;
CESC	cis	rs447	1.000	rs6978184	chr7:83778360	C/T	cg22846510	chr7:83753280	SEMA3A	-0.42	-5.08	-0.3	7e-7	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs6121246	0.609	rs6089054	chr20:30323141	A/G	cg13852791	chr20:30311386	BCL2L1	0.81	10.36	0.54	2.4e-21	Mean corpuscular hemoglobin;
CESC	cis	rs7103648	0.669	rs7131262	chr11:47836302	T/A	cg10504702	chr11:47789108	FNBP4	0.43	5.34	0.31	2.03e-7	Diastolic blood pressure;Systolic blood pressure;
CESC	cis	rs2733201	1.000	rs4419034	chr15:44348400	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	-0.66	-6.28	-0.36	1.39e-9	Lipoprotein phospholipase A2 activity in cardiovascular disease;
CESC	cis	rs7202877	0.706	rs247443	chr16:75465073	G/C	cg04384234	chr16:75411784	CFDP1	0.49	5.77	0.33	2.24e-8	Type 2 diabetes;Type 1 diabetes;
CESC	cis	rs1799949	1.000	rs8176212	chr17:41226601	G/C	cg06001716	chr17:41278141	BRCA1;NBR2	0.4	5.35	0.31	1.87e-7	Menopause (age at onset);
CESC	cis	rs1448094	0.511	rs10863071	chr12:86145813	A/G	cg02569458	chr12:86230093	RASSF9	-0.43	-6.65	-0.38	1.65e-10	Major depressive disorder;
CESC	cis	rs4481887	0.741	rs7540715	chr1:248544206	C/T	cg26353448	chr1:248524236	OR2T4	-0.37	-5.12	-0.3	5.85e-7	Common traits (Other);
CESC	cis	rs2735413	0.709	rs1319049	chr16:78084610	T/G	cg04733911	chr16:78082701	NA	0.52	8.4	0.46	2.69e-15	Systolic blood pressure (alcohol consumption interaction);
CESC	cis	rs4906332	0.933	rs35999760	chr14:103924481	A/C	cg09975044	chr14:104007538	NA	0.47	6.45	0.37	5.25e-10	Coronary artery disease;
CESC	cis	rs11764590	0.666	rs3996325	chr7:2053747	T/C	cg21782813	chr7:2030301	MAD1L1	-0.42	-5.27	-0.31	2.84e-7	Neuroticism;
CESC	cis	rs6537837	0.838	rs6663547	chr1:110114229	A/C	cg05049280	chr1:110155535	GNAT2	0.4	5.69	0.33	3.32e-8	Major depressive disorder;
CESC	cis	rs9612	1.000	rs58896392	chr19:44269142	G/A	cg08581076	chr19:44259116	C19orf61	0.53	6.05	0.35	4.88e-9	Exhaled nitric oxide output;
CESC	trans	rs11098499	0.754	rs12506487	chr4:120271361	T/G	cg25214090	chr10:38739885	LOC399744	0.6	8.3	0.45	5.33e-15	Corneal astigmatism;
CESC	cis	rs10754283	0.967	rs10922680	chr1:90101326	C/T	cg21401794	chr1:90099060	LRRC8C	-0.67	-9.02	-0.48	3.79e-17	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs7412746	0.611	rs72704679	chr1:150897477	C/T	cg22823121	chr1:150693482	HORMAD1	0.36	5.05	0.3	8.1e-7	Melanoma;
CESC	cis	rs920590	0.758	rs7011322	chr8:19661937	C/T	cg01411142	chr8:19674711	INTS10	0.52	5.86	0.34	1.39e-8	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs7647973	0.710	rs1491983	chr3:49639803	G/T	cg03060546	chr3:49711283	APEH	0.64	7.34	0.41	2.55e-12	Menarche (age at onset);
CESC	cis	rs16854884	0.632	rs35716467	chr3:143684993	C/A	cg01302019	chr3:143689584	C3orf58	-0.34	-5.17	-0.3	4.54e-7	Economic and political preferences (feminism/equality);
CESC	cis	rs7561273	0.609	rs2160943	chr2:24288775	G/A	cg20701182	chr2:24300061	SF3B14	0.45	6.03	0.35	5.41e-9	Quantitative traits;
CESC	cis	rs875971	1.000	rs2077593	chr7:65892530	A/G	cg12463550	chr7:65579703	CRCP	0.57	7.21	0.4	5.88e-12	Aortic root size;
CESC	cis	rs7202877	0.706	rs4888375	chr16:75322356	T/C	cg04384234	chr16:75411784	CFDP1	-0.46	-5.29	-0.31	2.55e-7	Type 2 diabetes;Type 1 diabetes;
CESC	cis	rs11958404	0.932	rs56065211	chr5:157439386	C/T	cg05962755	chr5:157440814	NA	0.62	6.66	0.38	1.57e-10	IgG glycosylation;
CESC	cis	rs1949733	0.523	rs56053534	chr4:8542876	G/A	cg11789530	chr4:8429930	ACOX3	-0.58	-7.21	-0.41	5.71e-12	Response to antineoplastic agents;
CESC	trans	rs116095464	0.558	rs56043030	chr5:220917	A/G	cg00938859	chr5:1591904	SDHAP3	0.6	6.66	0.38	1.55e-10	Breast cancer;
CESC	cis	rs12545109	0.732	rs1973629	chr8:57429583	A/G	cg09654669	chr8:57350985	NA	-0.62	-7.17	-0.4	7.37e-12	Obesity-related traits;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg13789711	chr9:139743225	PHPT1	0.51	7.06	0.4	1.42e-11	Systemic lupus erythematosus;
CESC	cis	rs2576037	0.526	rs10853547	chr18:44530548	A/C	cg19077165	chr18:44547161	KATNAL2	-0.52	-7.67	-0.43	3.34e-13	Personality dimensions;
CESC	cis	rs763121	0.889	rs2267390	chr22:38889657	C/T	cg14440974	chr22:39074834	NA	-0.38	-5.16	-0.3	4.84e-7	Menopause (age at onset);
CESC	cis	rs2404602	0.692	rs67570291	chr15:77020502	T/C	cg22467129	chr15:76604101	ETFA	-0.34	-5.16	-0.3	4.84e-7	Blood metabolite levels;
CESC	cis	rs79149102	0.649	rs1531162	chr15:75111984	C/T	cg09165964	chr15:75287851	SCAMP5	-0.69	-5.44	-0.32	1.21e-7	Lung cancer;
CESC	cis	rs7927771	0.524	rs61895760	chr11:47794538	G/C	cg20307385	chr11:47447363	PSMC3	0.61	8.64	0.47	5.45e-16	Subjective well-being;
CESC	cis	rs12347191	0.500	rs1912998	chr9:100621386	T/C	cg13688889	chr9:100608707	NA	-0.91	-13.42	-0.64	1.07e-31	Orofacial clefts;
CESC	cis	rs798554	0.836	rs13243214	chr7:2817455	G/T	cg18446336	chr7:2847575	GNA12	-0.39	-5.63	-0.33	4.55e-8	Height;
CESC	cis	rs4889855	0.530	rs8080678	chr17:78544003	G/T	cg16591659	chr17:78472290	NA	0.37	6.18	0.35	2.45e-9	Fractional excretion of uric acid;
CESC	cis	rs2073300	0.609	rs3746733	chr20:23349749	C/T	cg12062639	chr20:23401060	NAPB	0.98	7.92	0.44	6.56e-14	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs643506	0.817	rs658373	chr11:111682991	T/C	cg09085632	chr11:111637200	PPP2R1B	0.41	5.45	0.32	1.13e-7	Breast cancer;
CESC	cis	rs7818688	1.000	rs28440026	chr8:96026744	C/G	cg16049864	chr8:95962084	TP53INP1	0.6	5.77	0.33	2.25e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs7618501	0.665	rs7621352	chr3:50070763	A/C	cg24308560	chr3:49941425	MST1R	0.62	9.1	0.49	2.24e-17	Intelligence (multi-trait analysis);
CESC	cis	rs6429082	0.597	rs6683978	chr1:235541425	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.54	-6.73	-0.38	1.02e-10	Adiposity;
CESC	cis	rs11658309	1	rs11658309	chr17:17762247	T/G	cg09796270	chr17:17721594	SREBF1	-0.43	-6.15	-0.35	2.77e-9	Strep throat;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25910647	chr15:62539093	NA	-0.64	-7.57	-0.42	6.19e-13	Gut microbiome composition (summer);
CESC	cis	rs938554	0.571	rs4144	chr4:10016322	T/C	cg11266682	chr4:10021025	SLC2A9	0.56	7.75	0.43	2.03e-13	Blood metabolite levels;
CESC	cis	rs12477438	0.765	rs28648058	chr2:99696417	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.62	-8.62	-0.47	6.05e-16	Chronic sinus infection;
CESC	cis	rs2439831	1.000	rs2467739	chr15:43740196	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.88	10.56	0.54	5.55e-22	Lung cancer in ever smokers;
CESC	cis	rs10203711	0.966	rs4998694	chr2:239564713	C/T	cg14580085	chr2:239553406	NA	0.34	5.08	0.3	7.02e-7	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7412746	0.571	rs12402939	chr1:150615094	A/C	cg22823121	chr1:150693482	HORMAD1	0.47	6.66	0.38	1.6e-10	Melanoma;
CESC	cis	rs4604732	0.631	rs74154676	chr1:247625894	T/C	cg12754571	chr1:247694271	LOC148824;OR2C3	0.44	5.44	0.32	1.21e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs4727027	0.901	rs34201592	chr7:148842403	C/G	cg23583168	chr7:148888333	NA	-0.73	-10.81	-0.55	8.24e-23	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs1499972	0.938	rs843854	chr3:117757755	A/G	cg07612923	chr3:117604196	NA	0.75	5.65	0.33	4.12e-8	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26312950	chr7:5391498	TNRC18	-0.56	-6.13	-0.35	3.25e-9	Gut microbiome composition (summer);
CESC	cis	rs1372520	0.684	rs1442144	chr4:90736113	T/C	cg15133208	chr4:90757351	SNCA	-0.42	-5.74	-0.33	2.57e-8	Neuroticism;
CESC	cis	rs10832963	0.924	rs10500834	chr11:18638712	A/T	cg20219074	chr11:18656078	SPTY2D1	0.8	11.77	0.59	5.17e-26	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00563768	chr17:34174170	TAF15	-0.56	-6.97	-0.39	2.53e-11	Gut microbiome composition (summer);
CESC	cis	rs155076	1.000	rs195570	chr13:21867580	T/G	cg11317459	chr13:21872234	NA	-1.12	-12.77	-0.62	1.94e-29	White matter hyperintensity burden;
CESC	cis	rs736408	0.812	rs1076425	chr3:52825462	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.45	6.05	0.35	4.97e-9	Bipolar disorder;
CESC	cis	rs703842	1.000	rs2072052	chr12:58146719	A/C	cg18357645	chr12:58087776	OS9	-0.43	-6.13	-0.35	3.17e-9	Multiple sclerosis;
CESC	cis	rs4665809	1.000	rs1550381	chr2:26266946	A/G	cg22920501	chr2:26401640	FAM59B	-0.69	-8.22	-0.45	9.07e-15	Gut microbiome composition (summer);
CESC	cis	rs76878669	0.561	rs4244813	chr11:66129488	G/C	cg18002602	chr11:66138449	SLC29A2	0.4	6.65	0.38	1.71e-10	Educational attainment (years of education);
CESC	cis	rs7071206	0.704	rs11002234	chr10:79434458	A/G	cg07817648	chr10:79422355	NA	-0.69	-8.68	-0.47	4.16e-16	Bone mineral density;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05087722	chr2:241404981	GPC1	-0.57	-6.6	-0.38	2.17e-10	Gut microbiome composition (summer);
CESC	cis	rs4253772	0.530	rs79354880	chr22:46746419	C/A	cg00784671	chr22:46762841	CELSR1	-0.65	-6.26	-0.36	1.51e-9	LDL cholesterol;Cholesterol, total;
CESC	trans	rs208520	0.507	rs9453585	chr6:66796668	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.08	-23.22	-0.82	7.87e-66	Exhaled nitric oxide output;
CESC	cis	rs67311347	1.000	rs73078163	chr3:40479958	C/T	cg24209194	chr3:40518798	ZNF619	0.51	6.2	0.36	2.18e-9	Renal cell carcinoma;
CESC	cis	rs9457247	1.000	rs402749	chr6:167386104	C/T	cg23791538	chr6:167370224	RNASET2	-0.6	-8.65	-0.47	4.96e-16	Crohn's disease;
CESC	cis	rs2952156	0.959	rs1495102	chr17:37832093	T/C	cg00129232	chr17:37814104	STARD3	-0.71	-9.32	-0.5	4.68e-18	Asthma;
CESC	cis	rs8114671	0.562	rs6087653	chr20:33522054	T/C	cg24642439	chr20:33292090	TP53INP2	0.43	5.19	0.3	4.19e-7	Height;
CESC	cis	rs3845702	0.736	rs6727890	chr2:180832675	T/C	cg01881094	chr2:180872142	CWC22	-1.02	-9.36	-0.5	3.69e-18	Schizophrenia;
CESC	cis	rs754466	0.580	rs10824575	chr10:79549047	A/G	cg17075019	chr10:79541650	NA	-0.86	-13.56	-0.64	3.65e-32	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs929354	0.742	rs62491945	chr7:156955580	G/A	cg05182265	chr7:156933206	UBE3C	-0.5	-7.29	-0.41	3.49e-12	Body mass index;
CESC	cis	rs13191362	1.000	rs67094146	chr6:163145412	G/C	cg06582575	chr6:163149167	PACRG;PARK2	0.75	7.87	0.44	9.12e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs6693567	0.565	rs2264417	chr1:150368501	C/T	cg09579323	chr1:150459698	TARS2	0.48	6.03	0.35	5.58e-9	Migraine;
CESC	cis	rs367615	0.918	rs10070104	chr5:108866438	C/T	cg17395555	chr5:108820864	NA	-0.55	-8.22	-0.45	9.28e-15	Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg04025307	chr7:1156635	C7orf50	0.6	10.36	0.54	2.53e-21	Longevity;Endometriosis;
CESC	cis	rs2243480	1.000	rs316321	chr7:65611613	G/A	cg12463550	chr7:65579703	CRCP	0.75	5.84	0.34	1.56e-8	Diabetic kidney disease;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg10579840	chr8:99306110	NIPAL2	-0.44	-6.14	-0.35	3.05e-9	Gambling;
CESC	cis	rs13191362	1.000	rs35754151	chr6:163074867	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.87	7.82	0.43	1.29e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs2295499	0.816	rs9683572	chr4:2702698	C/T	cg08330972	chr4:2403930	ZFYVE28	-0.32	-5.21	-0.3	3.75e-7	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11585767	chr3:112280782	ATG3;SLC35A5	0.5	6.21	0.36	2.08e-9	Gut microbiome composition (summer);
CESC	trans	rs1728785	0.901	rs6499186	chr16:68660565	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.7	7.71	0.43	2.54e-13	Ulcerative colitis;
CESC	cis	rs6460942	1.000	rs6944134	chr7:12418036	T/C	cg02935154	chr7:12443704	VWDE	-0.59	-6.39	-0.37	7.23e-10	Coronary artery disease;
CESC	cis	rs7959452	0.640	rs4761233	chr12:69722880	T/C	cg20891283	chr12:69753455	YEATS4	0.77	11.25	0.57	3.01e-24	Blood protein levels;
CESC	cis	rs919433	0.963	rs2043016	chr2:198146381	C/T	cg03934865	chr2:198174659	NA	-0.49	-7.43	-0.42	1.47e-12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs4704187	0.687	rs4340901	chr5:74404905	C/T	cg03227963	chr5:74354835	NA	0.32	5.94	0.34	8.7e-9	Response to amphetamines;
CESC	cis	rs13064411	0.696	rs869343	chr3:113226705	C/T	cg18753928	chr3:113234510	CCDC52	-0.5	-6.13	-0.35	3.23e-9	Response to simvastatin treatment (PCSK9 protein level change);
CESC	cis	rs62229266	0.804	rs12483151	chr21:37419578	C/T	cg12218747	chr21:37451666	NA	-0.4	-5.72	-0.33	2.82e-8	Mitral valve prolapse;
CESC	cis	rs7666738	0.830	rs11097605	chr4:98985167	T/C	cg17366294	chr4:99064904	C4orf37	0.58	8.39	0.46	2.88e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1008375	0.932	rs11941874	chr4:17666416	C/T	cg16339924	chr4:17578868	LAP3	-0.64	-7.58	-0.42	5.95e-13	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs7618915	0.501	rs6804145	chr3:52694198	C/T	cg18337363	chr3:52569053	NT5DC2	0.28	5.24	0.31	3.22e-7	Bipolar disorder;
CESC	cis	rs7666738	0.800	rs13107586	chr4:99028788	G/C	cg18180107	chr4:99064573	C4orf37	0.42	5.43	0.32	1.29e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9399135	0.660	rs4267967	chr6:135272477	T/G	cg22676075	chr6:135203613	NA	0.51	7.06	0.4	1.46e-11	Red blood cell count;
CESC	cis	rs2985684	0.802	rs10150823	chr14:50051751	C/T	cg04989706	chr14:50066350	PPIL5	-0.45	-5.05	-0.3	8.24e-7	Carotid intima media thickness;
CESC	cis	rs412050	0.696	rs41283227	chr22:22275524	C/T	cg17089214	chr22:22089827	YPEL1	0.69	5.88	0.34	1.24e-8	Attention deficit hyperactivity disorder;
CESC	cis	rs17209837	0.831	rs56223611	chr7:87083157	C/A	cg00919237	chr7:87102261	ABCB4	-0.53	-6.03	-0.35	5.36e-9	Gallbladder cancer;
CESC	cis	rs6982240	0.514	rs72681579	chr8:142263074	G/A	cg27411547	chr8:142287226	NA	-0.53	-7.27	-0.41	4.07e-12	Tonsillectomy;
CESC	cis	rs75064307	0.834	rs9288870	chr3:108113469	G/C	cg03329597	chr3:108125523	MYH15	0.51	5.77	0.33	2.17e-8	Intelligence (multi-trait analysis);
CESC	cis	rs561341	0.941	rs4525554	chr17:30312819	T/C	cg00745463	chr17:30367425	LRRC37B	-0.78	-7.09	-0.4	1.2e-11	Hip circumference adjusted for BMI;
CESC	cis	rs662064	1.000	rs662064	chr1:10557251	T/C	cg20482658	chr1:10539492	PEX14	-0.36	-7.09	-0.4	1.24e-11	Asthma;
CESC	cis	rs7918232	0.941	rs1085782	chr10:27440517	G/A	cg14442939	chr10:27389572	ANKRD26	-0.67	-6.45	-0.37	5.34e-10	Breast cancer;
CESC	cis	rs2637266	0.777	rs2637254	chr10:78312002	G/A	cg18941641	chr10:78392320	NA	0.34	6.14	0.35	2.94e-9	Pulmonary function;
CESC	cis	rs709400	0.598	rs11627529	chr14:104004557	C/T	cg12935359	chr14:103987150	CKB	-0.55	-7.91	-0.44	6.94e-14	Body mass index;
CESC	cis	rs4332037	0.538	rs6951956	chr7:1934131	C/T	cg23422044	chr7:1970798	MAD1L1	-0.43	-5.5	-0.32	9.08e-8	Bipolar disorder;
CESC	cis	rs9905704	0.918	rs302857	chr17:56692387	C/G	cg12560992	chr17:57184187	TRIM37	0.59	6.98	0.39	2.34e-11	Testicular germ cell tumor;
CESC	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg21724239	chr8:58056113	NA	0.6	5.54	0.32	7.11e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs896854	0.684	rs10099059	chr8:95986972	G/C	cg13393036	chr8:95962371	TP53INP1	-0.49	-10.71	-0.55	1.73e-22	Type 2 diabetes;
CESC	cis	rs1881797	1.000	rs12071797	chr1:247686871	A/G	cg05639522	chr1:247681581	NA	0.46	6.02	0.35	5.84e-9	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs8177253	0.761	rs35332919	chr3:133519002	T/A	cg11941060	chr3:133502564	NA	-0.52	-7.18	-0.4	7.03e-12	Iron status biomarkers;
CESC	cis	rs4253772	0.550	rs9615949	chr22:46722531	C/T	cg18190219	chr22:46762943	CELSR1	-0.53	-5.5	-0.32	9.1e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs897984	0.762	rs11150601	chr16:30977799	G/A	cg00531865	chr16:30841666	NA	0.51	7.02	0.4	1.83e-11	Dementia with Lewy bodies;
CESC	cis	rs17433780	0.928	rs10922533	chr1:89456659	C/G	cg09516651	chr1:89888402	LOC400759	0.66	8.99	0.48	4.92e-17	Carotid intima media thickness;
CESC	cis	rs2012796	0.743	rs8020575	chr14:81859521	G/A	cg02996355	chr14:81879375	NA	0.62	7.72	0.43	2.44e-13	Night sleep phenotypes;
CESC	cis	rs13256369	1.000	rs885000	chr8:8568875	G/T	cg18904891	chr8:8559673	CLDN23	0.66	7.24	0.41	4.75e-12	Obesity-related traits;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg16242888	chr9:34179479	UBAP1	0.5	6.39	0.37	7.48e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs7267979	1.000	rs11087521	chr20:25440648	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.82	15.34	0.69	1.94e-38	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs1348850	0.526	rs59972556	chr2:178399561	A/G	cg22681709	chr2:178499509	PDE11A	-0.49	-5.23	-0.31	3.39e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs148734725	1	rs148734725	chr3:49406708	G/A	cg07274523	chr3:49395745	GPX1	0.68	8.49	0.46	1.55e-15	Educational attainment (college completion);
CESC	cis	rs941408	0.515	rs1640265	chr19:2784405	C/T	cg06609049	chr19:2785107	THOP1	0.85	12.84	0.62	1.16e-29	Total cholesterol levels;
CESC	cis	rs7772486	0.641	rs9390370	chr6:146357569	C/T	cg05347473	chr6:146136440	FBXO30	0.64	8.09	0.45	2.15e-14	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs910316	1.000	rs4903275	chr14:75512509	C/T	cg11812906	chr14:75593930	NEK9	0.89	14.59	0.67	8.27e-36	Height;
CESC	trans	rs747782	0.646	rs61914719	chr11:48059091	C/T	cg15704280	chr7:45808275	SEPT13	0.68	6.07	0.35	4.48e-9	Intraocular pressure;
CESC	cis	rs208520	1.000	rs12190773	chr6:66968194	T/C	cg07460842	chr6:66804631	NA	0.9	10.34	0.54	2.79e-21	Exhaled nitric oxide output;
CESC	cis	rs2279817	0.863	rs28481933	chr1:18026277	A/G	cg21791023	chr1:18019539	ARHGEF10L	0.55	8.07	0.44	2.53e-14	Neuroticism;
CESC	cis	rs1552244	1.000	rs35993975	chr3:10067794	A/G	cg00166722	chr3:10149974	C3orf24	0.53	6.37	0.36	8.45e-10	Alzheimer's disease;
CESC	cis	rs13191362	1.000	rs35575481	chr6:163007746	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.87	9.04	0.49	3.35e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs9917256	0.831	rs908594	chr2:169133796	A/G	cg07857142	chr2:169103971	STK39	0.54	5.03	0.3	9.04e-7	Parkinson's disease;
CESC	cis	rs7827545	1.000	rs6992097	chr8:135565844	G/A	cg17885191	chr8:135476712	NA	0.48	6.36	0.36	8.96e-10	Hypertension (SNP x SNP interaction);
CESC	cis	rs9487051	0.872	rs9487033	chr6:109605388	C/G	cg21918786	chr6:109611834	NA	0.38	5.79	0.33	2.02e-8	Reticulocyte fraction of red cells;
CESC	cis	rs2977993	1	rs2977993	chr9:131608786	G/A	cg00228799	chr9:131580591	ENDOG	0.45	5.56	0.32	6.55e-8	Schizophrenia;
CESC	cis	rs769267	0.930	rs3794993	chr19:19611550	G/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	7.58	0.42	5.75e-13	Tonsillectomy;
CESC	cis	rs1801251	1.000	rs283479	chr2:233648754	A/G	cg08000102	chr2:233561755	GIGYF2	0.67	9.28	0.5	6.17e-18	Coronary artery disease;
CESC	cis	rs2273669	0.667	rs2356575	chr6:109367255	T/C	cg05315195	chr6:109294784	ARMC2	-0.67	-6.33	-0.36	1.02e-9	Prostate cancer;
CESC	cis	rs798554	1.000	rs798540	chr7:2764130	G/A	cg13628971	chr7:2884303	GNA12	0.59	7.57	0.42	6.06e-13	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01833398	chr12:53894760	TARBP2;MAP3K12	0.65	7.29	0.41	3.54e-12	Gut microbiome composition (summer);
CESC	cis	rs7089973	0.584	rs6585300	chr10:116639889	A/C	cg23260525	chr10:116636907	FAM160B1	0.42	8.02	0.44	3.46e-14	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs7940866	0.834	rs1594821	chr11:130835883	C/T	cg12179176	chr11:130786555	SNX19	0.62	9.08	0.49	2.66e-17	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15844154	chr10:75173990	ANXA7	-0.62	-6.75	-0.38	9.46e-11	Gut microbiome composition (summer);
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg24249734	chr3:127872125	EEFSEC	-0.52	-6.88	-0.39	4.37e-11	Height;
CESC	cis	rs9443645	0.901	rs9448590	chr6:79606429	C/G	cg05283184	chr6:79620031	NA	-0.43	-6.5	-0.37	3.91e-10	Intelligence (multi-trait analysis);
CESC	cis	rs2439831	0.681	rs1549523	chr15:43624189	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	13.2	0.63	6.62e-31	Lung cancer in ever smokers;
CESC	cis	rs1983170	1.000	rs597288	chr1:91999296	C/T	cg21854759	chr1:92012499	NA	0.52	5.66	0.33	3.99e-8	Eosinophil percentage of white cells;
CESC	trans	rs604222	0.508	rs9878726	chr3:193577995	C/T	cg18397450	chr14:105830631	PACS2	-0.4	-6.02	-0.35	5.82e-9	Major depressive disorder;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg21654404	chr12:118814431	SUDS3	-0.5	-6.37	-0.36	8.3e-10	Ulcerative colitis;
CESC	cis	rs4566357	0.595	rs6707159	chr2:227909339	T/A	cg05526886	chr2:227700861	RHBDD1	-0.47	-6.13	-0.35	3.1e-9	Coronary artery disease;
CESC	cis	rs17826219	0.706	rs55764512	chr17:29085758	G/A	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.17e-10	Body mass index;
CESC	cis	rs637571	0.522	rs606978	chr11:65711517	A/C	cg02202077	chr11:65769826	EIF1AD;BANF1	0.47	6.19	0.36	2.3e-9	Eosinophil percentage of white cells;
CESC	cis	rs1905108	0.510	rs12544004	chr8:49543160	T/C	cg15397374	chr8:49647703	EFCAB1	0.31	5.27	0.31	2.85e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs748404	0.578	rs576557	chr15:43597737	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.56	8.89	0.48	9.41e-17	Lung cancer;
CESC	cis	rs7615952	0.641	rs60839048	chr3:125807938	G/A	cg18479299	chr3:125709523	NA	-0.48	-5.06	-0.3	7.98e-7	Blood pressure (smoking interaction);
CESC	cis	rs1218582	0.710	rs9793588	chr1:154878878	C/G	cg03351412	chr1:154909251	PMVK	0.69	9.38	0.5	3.14e-18	Prostate cancer;
CESC	cis	rs6500602	0.701	rs8129	chr16:4562351	A/G	cg08645402	chr16:4508243	NA	0.42	6.41	0.37	6.74e-10	Schizophrenia;
CESC	cis	rs2839186	0.564	rs4819215	chr21:47623573	G/A	cg12516959	chr21:47718080	NA	-0.4	-5.8	-0.34	1.87e-8	Testicular germ cell tumor;
CESC	cis	rs1055129	0.560	rs2305913	chr17:73922941	T/C	cg10935138	chr17:73851978	WBP2	0.42	5.17	0.3	4.59e-7	White matter hyperintensity burden;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06623486	chr1:162531613	UAP1	0.62	7.56	0.42	6.69e-13	Gut microbiome composition (summer);
CESC	cis	rs6582630	0.502	rs1607867	chr12:38385463	C/T	cg26384229	chr12:38710491	ALG10B	0.73	11.15	0.57	6.25e-24	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs2066819	1.000	rs11171803	chr12:56718422	T/C	cg26714650	chr12:56694279	CS	-1.48	-9.9	-0.52	7.03e-20	Psoriasis vulgaris;
CESC	trans	rs11098499	0.863	rs2127823	chr4:120485670	G/T	cg25214090	chr10:38739885	LOC399744	0.67	9.07	0.49	2.85e-17	Corneal astigmatism;
CESC	cis	rs1144333	1.000	rs60144605	chr1:76359699	A/C	cg22875332	chr1:76189707	ACADM	0.52	5.04	0.3	8.65e-7	Attention function in attention deficit hyperactive disorder;
CESC	cis	rs1124376	1.000	rs9828701	chr3:20149203	A/G	cg05072819	chr3:20081367	KAT2B	0.47	5.14	0.3	5.39e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs9814567	0.722	rs13083717	chr3:134348796	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.46	5.71	0.33	3.01e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs4523957	0.651	rs7223390	chr17:2085653	T/C	cg16513277	chr17:2031491	SMG6	-0.71	-10.17	-0.53	1.04e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs7833790	0.654	rs6415652	chr8:82702257	G/A	cg17211192	chr8:82754475	SNX16	-0.58	-7.62	-0.42	4.64e-13	Diastolic blood pressure;
CESC	cis	rs12479064	0.724	rs3792150	chr2:100041849	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.58	-7.01	-0.4	1.98e-11	Chronic sinus infection;
CESC	cis	rs7647973	1.000	rs13096474	chr3:49443081	C/T	cg07636037	chr3:49044803	WDR6	-0.71	-10.03	-0.52	2.87e-20	Menarche (age at onset);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg15703646	chr7:100209939	MOSPD3	-0.42	-6.14	-0.35	2.96e-9	Gambling;
CESC	cis	rs8114671	0.967	rs34515766	chr20:33785221	C/G	cg06115741	chr20:33292138	TP53INP2	-0.42	-5.11	-0.3	6.06e-7	Height;
CESC	cis	rs12765878	0.934	rs11191841	chr10:105639611	C/T	cg11005552	chr10:105648138	OBFC1	-0.38	-5.52	-0.32	8e-8	Coronary artery disease;
CESC	cis	rs9549260	0.620	rs4325427	chr13:41216534	C/T	cg21288729	chr13:41239152	FOXO1	0.66	8.68	0.47	4.2e-16	Red blood cell count;
CESC	cis	rs2795502	0.515	rs116848302	chr10:43367783	G/A	cg20628663	chr10:43360327	NA	0.57	5.1	0.3	6.44e-7	Blood protein levels;
CESC	cis	rs2576037	0.526	rs2571024	chr18:44557877	G/T	cg19077165	chr18:44547161	KATNAL2	0.54	8.01	0.44	3.56e-14	Personality dimensions;
CESC	cis	rs30380	0.553	rs152280	chr5:96161942	T/G	cg16492584	chr5:96139282	ERAP1	-0.41	-5.62	-0.33	4.9e-8	Cerebrospinal fluid biomarker levels;
CESC	cis	rs7660520	0.524	rs4862100	chr4:183732709	G/T	cg09197432	chr4:183729176	NA	0.58	5.59	0.32	5.75e-8	Pediatric autoimmune diseases;
CESC	cis	rs4076764	1.000	rs7540279	chr1:163429970	A/T	cg06092702	chr1:163392909	NA	-0.37	-5.39	-0.31	1.57e-7	Motion sickness;
CESC	cis	rs7215564	0.822	rs10871488	chr17:78739079	T/C	cg11222173	chr17:78748019	RPTOR	0.55	5.04	0.3	8.62e-7	Myopia (pathological);
CESC	trans	rs17685	0.702	rs6960598	chr7:75772991	T/C	cg19862616	chr7:65841803	NCRNA00174	0.8	11.44	0.57	6.89e-25	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs2243480	0.908	rs4718273	chr7:65216099	G/A	cg18252515	chr7:66147081	NA	1.21	11.36	0.57	1.3e-24	Diabetic kidney disease;
CESC	cis	rs7552404	1.000	rs437298	chr1:76113770	T/C	cg10523679	chr1:76189770	ACADM	-0.65	-7.28	-0.41	3.82e-12	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs11098499	0.863	rs36040693	chr4:120477616	A/G	cg09307838	chr4:120376055	NA	0.91	12.68	0.61	4e-29	Corneal astigmatism;
CESC	cis	rs1008375	0.966	rs1860599	chr4:17638900	T/C	cg02297831	chr4:17616191	MED28	0.54	6.85	0.39	5.05e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs9926296	0.546	rs7187436	chr16:89845110	A/T	cg04287289	chr16:89883240	FANCA	0.9	15.27	0.68	3.27e-38	Vitiligo;
CESC	cis	rs4132509	0.793	rs34477525	chr1:243966454	T/A	cg21452805	chr1:244014465	NA	0.5	6.25	0.36	1.59e-9	RR interval (heart rate);
CESC	cis	rs4862750	0.914	rs9995391	chr4:187873749	A/T	cg03647317	chr4:187891568	NA	0.37	5.32	0.31	2.17e-7	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs60871478	0.735	rs4721501	chr7:862166	G/T	cg05535760	chr7:792225	HEATR2	-0.81	-8.41	-0.46	2.63e-15	Cerebrospinal P-tau181p levels;
CESC	cis	rs2576037	0.526	rs10853545	chr18:44475220	A/T	cg19077165	chr18:44547161	KATNAL2	-0.54	-7.79	-0.43	1.53e-13	Personality dimensions;
CESC	cis	rs9512730	0.527	rs11619722	chr13:27998600	T/C	cg08193333	chr13:27998609	GTF3A	0.54	6.35	0.36	9.52e-10	Schizophrenia;
CESC	cis	rs875971	0.800	rs427557	chr7:65519250	A/G	cg26939375	chr7:64535504	NA	0.48	6.2	0.36	2.12e-9	Aortic root size;
CESC	cis	rs9583531	0.600	rs6492303	chr13:111356800	G/A	cg24331049	chr13:111365604	ING1	0.73	10.7	0.55	1.9e-22	Coronary artery disease;
CESC	trans	rs4308128	0.657	rs272049	chr2:116622022	C/A	cg17910586	chr3:52479098	SEMA3G	-0.43	-6.04	-0.35	5.13e-9	Suicide attempts in major depressive disorder;
CESC	cis	rs7580658	0.929	rs4150477	chr2:128032546	A/G	cg10021288	chr2:128175891	PROC	0.42	6.7	0.38	1.27e-10	Protein C levels;
CESC	cis	rs8177253	1.000	rs8177261	chr3:133480588	A/C	cg01448562	chr3:133502909	NA	-0.42	-5.9	-0.34	1.09e-8	Iron status biomarkers;
CESC	cis	rs1008375	0.966	rs4515155	chr4:17696477	G/T	cg16339924	chr4:17578868	LAP3	0.59	7.41	0.41	1.69e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs67311347	1.000	rs56291770	chr3:40515370	T/C	cg24209194	chr3:40518798	ZNF619	0.5	6.15	0.35	2.84e-9	Renal cell carcinoma;
CESC	cis	rs3733585	0.699	rs6449179	chr4:9969117	G/A	cg11266682	chr4:10021025	SLC2A9	-0.57	-10.92	-0.56	3.5e-23	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs10504229	0.683	rs7464038	chr8:58111908	T/C	cg02725872	chr8:58115012	NA	-0.48	-7.47	-0.42	1.14e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs6500395	1.000	rs7195684	chr16:48710750	G/A	cg04672837	chr16:48644449	N4BP1	-0.51	-6.53	-0.37	3.33e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs875971	0.508	rs10950045	chr7:66066373	T/C	cg06456125	chr7:65229604	NA	-0.4	-5.58	-0.32	5.82e-8	Aortic root size;
CESC	cis	rs875971	0.862	rs6460282	chr7:65691246	T/C	cg12463550	chr7:65579703	CRCP	-0.53	-6.69	-0.38	1.36e-10	Aortic root size;
CESC	cis	rs62432291	0.681	rs418859	chr6:159649695	A/T	cg14500486	chr6:159655392	FNDC1	0.6	6.01	0.35	6.09e-9	Joint mobility (Beighton score);
CESC	cis	rs9908102	0.740	rs733889	chr17:12918118	A/G	cg26162695	chr17:12921313	ELAC2	0.56	6.04	0.35	5.13e-9	Schizophrenia;
CESC	cis	rs317689	0.613	rs315112	chr12:69785926	T/A	cg20891283	chr12:69753455	YEATS4	0.72	9.58	0.51	7.42e-19	Response to diuretic therapy;
CESC	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg06873352	chr17:61820015	STRADA	0.73	13.07	0.63	1.78e-30	Prudent dietary pattern;
CESC	cis	rs2204008	0.744	rs66474616	chr12:38461564	G/A	cg13010199	chr12:38710504	ALG10B	0.53	6.71	0.38	1.14e-10	Bladder cancer;
CESC	cis	rs1707322	0.964	rs785508	chr1:46527159	G/A	cg05343316	chr1:45956843	TESK2	-0.42	-5.05	-0.3	8.16e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs6502050	0.835	rs8079389	chr17:80158656	T/G	cg23985595	chr17:80112537	CCDC57	-0.4	-6.37	-0.36	8.38e-10	Life satisfaction;
CESC	cis	rs7772486	0.720	rs6901888	chr6:146023144	A/G	cg05347473	chr6:146136440	FBXO30	-0.57	-7.25	-0.41	4.46e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs769267	0.965	rs735273	chr19:19385411	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.43	5.33	0.31	2.11e-7	Tonsillectomy;
CESC	cis	rs35110281	0.782	rs2051407	chr21:45079245	T/C	cg21573476	chr21:45109991	RRP1B	-0.51	-7.14	-0.4	8.91e-12	Mean corpuscular volume;
CESC	cis	rs17039065	0.920	rs17039101	chr4:109434632	C/G	cg16022748	chr4:109541635	LOC285456;RPL34	0.67	6.15	0.35	2.81e-9	Gut microbiome composition (summer);
CESC	cis	rs1552244	1.000	rs35993975	chr3:10067794	A/G	cg08888203	chr3:10149979	C3orf24	0.52	6.28	0.36	1.38e-9	Alzheimer's disease;
CESC	cis	rs7429990	0.965	rs35199727	chr3:47946708	T/C	cg11946769	chr3:48343235	NME6	0.46	5.59	0.32	5.54e-8	Educational attainment (years of education);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11913104	chr19:13056743	RAD23A	0.59	6.51	0.37	3.85e-10	Gut microbiome composition (summer);
CESC	cis	rs7116495	1.000	rs73539529	chr11:71815596	T/C	cg26138937	chr11:71823887	C11orf51	0.86	6.88	0.39	4.18e-11	Severe influenza A (H1N1) infection;
CESC	cis	rs7809950	0.678	rs7790080	chr7:107031322	G/A	cg23024343	chr7:107201750	COG5	-0.58	-7.26	-0.41	4.42e-12	Coronary artery disease;
CESC	cis	rs55794721	0.509	rs6699113	chr1:25777743	C/T	cg03538708	chr1:25844672	NA	-0.41	-6.27	-0.36	1.48e-9	Plateletcrit;Mean corpuscular volume;
CESC	cis	rs6736093	1.000	rs10496439	chr2:112664631	C/G	cg12686935	chr2:112915763	FBLN7	-0.42	-5.35	-0.31	1.91e-7	Coronary artery disease;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg26531923	chr6:24646364	KIAA0319	-0.47	-6.0	-0.35	6.28e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs9399401	0.667	rs17071756	chr6:142715195	C/T	cg04461802	chr6:142623433	GPR126	-0.39	-5.64	-0.33	4.41e-8	Chronic obstructive pulmonary disease;
CESC	cis	rs909674	0.734	rs5757675	chr22:39838892	G/T	cg11247378	chr22:39784982	NA	-0.59	-8.61	-0.47	6.52e-16	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs710865	0.541	rs4066014	chr1:19555783	A/G	cg13387374	chr1:19411106	UBR4	0.47	5.73	0.33	2.7e-8	Brain structure;
CESC	cis	rs7666738	0.830	rs880472	chr4:98922595	C/A	cg17366294	chr4:99064904	C4orf37	0.6	8.23	0.45	8.65e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9457247	0.967	rs402191	chr6:167405553	T/C	cg25258033	chr6:167368657	RNASET2	0.39	5.89	0.34	1.15e-8	Crohn's disease;
CESC	cis	rs7918232	0.941	rs7907988	chr10:27444344	T/G	cg14442939	chr10:27389572	ANKRD26	0.66	6.3	0.36	1.27e-9	Breast cancer;
CESC	cis	rs7084402	1.000	rs12259315	chr10:60266152	T/C	cg07615347	chr10:60278583	BICC1	-0.58	-8.92	-0.48	8.11e-17	Refractive error;
CESC	cis	rs826838	1.000	rs826891	chr12:39100824	A/G	cg13010199	chr12:38710504	ALG10B	-0.4	-5.54	-0.32	7.42e-8	Heart rate;
CESC	cis	rs1670533	1.000	rs7673898	chr4:1056569	C/A	cg04106633	chr4:1044584	NA	0.41	5.19	0.3	4.11e-7	Recombination rate (females);
CESC	cis	rs2635047	0.811	rs17785419	chr18:44765469	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.46	-6.27	-0.36	1.48e-9	Educational attainment;
CESC	cis	rs9287719	0.745	rs4997810	chr2:10755540	T/A	cg02196655	chr2:10830764	NOL10	-0.37	-5.51	-0.32	8.5e-8	Prostate cancer;
CESC	cis	rs10504229	0.639	rs2318146	chr8:58114873	T/G	cg24829409	chr8:58192753	C8orf71	-0.58	-7.2	-0.4	6.31e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs6502050	0.865	rs8073679	chr17:80155343	G/A	cg23985595	chr17:80112537	CCDC57	-0.39	-6.26	-0.36	1.53e-9	Life satisfaction;
CESC	cis	rs858239	0.568	rs6970694	chr7:23250828	T/C	cg23682824	chr7:23144976	KLHL7	0.46	5.88	0.34	1.23e-8	Cerebrospinal fluid biomarker levels;
CESC	cis	rs644799	0.862	rs1150361	chr11:95633805	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.6	7.68	0.43	3.1e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg00974149	chr17:56296512	MKS1	-0.43	-6.01	-0.35	6.18e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs2228479	0.850	rs2302162	chr16:89845287	A/G	cg04013166	chr16:89971882	TCF25	0.78	6.68	0.38	1.41e-10	Skin colour saturation;
CESC	trans	rs9650657	0.537	rs11250092	chr8:10786543	A/G	cg15556689	chr8:8085844	FLJ10661	0.54	6.55	0.37	2.92e-10	Neuroticism;
CESC	cis	rs644799	0.930	rs3802764	chr11:95514599	T/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.55	6.93	0.39	3.22e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05439191	chr3:9791515	OGG1	0.58	6.11	0.35	3.62e-9	Gut microbiome composition (summer);
CESC	cis	rs3820068	0.580	rs61169376	chr1:16003832	A/G	cg17385448	chr1:15911702	AGMAT	0.39	6.22	0.36	1.94e-9	Systolic blood pressure;
CESC	cis	rs1799949	1.000	rs8176242	chr17:41217874	C/T	cg23758822	chr17:41437982	NA	1.03	15.37	0.69	1.52e-38	Menopause (age at onset);
CESC	cis	rs7824557	0.564	rs12547100	chr8:11242632	G/A	cg21775007	chr8:11205619	TDH	-0.5	-7.41	-0.41	1.66e-12	Retinal vascular caliber;
CESC	cis	rs1552244	1.000	rs7615646	chr3:10089773	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.8	-10.21	-0.53	7.17e-21	Alzheimer's disease;
CESC	cis	rs35306767	0.953	rs1106064	chr10:957211	G/A	cg26597838	chr10:835615	NA	0.82	9.53	0.51	1.07e-18	Eosinophil percentage of granulocytes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24074884	chr19:17356310	NR2F6	0.46	5.99	0.35	6.71e-9	Gut microbiome composition (summer);
CESC	cis	rs9394438	0.628	rs2153947	chr6:37544930	A/G	cg00985040	chr6:37553208	NA	-0.33	-5.38	-0.31	1.62e-7	IgG glycosylation;
CESC	cis	rs3858526	0.883	rs11039686	chr11:5948725	T/C	cg13902645	chr11:5959945	NA	-0.68	-8.25	-0.45	7.64e-15	DNA methylation (variation);
CESC	cis	rs2204008	0.837	rs12369089	chr12:38060263	G/A	cg26384229	chr12:38710491	ALG10B	0.73	10.64	0.55	3.1e-22	Bladder cancer;
CESC	cis	rs1401999	1.000	rs6443926	chr3:183706630	A/C	cg01324343	chr3:183735012	ABCC5	0.64	13.64	0.64	1.94e-32	Anterior chamber depth;
CESC	cis	rs2404602	0.669	rs12438540	chr15:76943213	C/G	cg22467129	chr15:76604101	ETFA	-0.35	-5.21	-0.3	3.89e-7	Blood metabolite levels;
CESC	cis	rs10791097	0.677	rs11222359	chr11:130730648	A/G	cg09137382	chr11:130731461	NA	0.39	5.86	0.34	1.38e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg23359810	chr10:51572113	NCOA4	0.39	6.08	0.35	4.07e-9	Gambling;
CESC	cis	rs4955124	0.558	rs12632509	chr3:32024275	T/C	cg05935571	chr3:32023257	ZNF860;OSBPL10	1.01	8.09	0.45	2.1e-14	Schizophrenia;
CESC	cis	rs736408	0.688	rs2239551	chr3:52818579	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	-0.44	-6.05	-0.35	4.93e-9	Bipolar disorder;
CESC	cis	rs1983891	0.742	rs9369295	chr6:41564026	G/C	cg20194872	chr6:41519635	FOXP4	0.44	6.16	0.35	2.74e-9	Prostate cancer;
CESC	cis	rs2295499	0.643	rs12509102	chr4:2710962	G/C	cg27239842	chr4:2403781	ZFYVE28	-0.34	-5.82	-0.34	1.69e-8	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
CESC	cis	rs1048238	0.548	rs848217	chr1:16272250	A/G	cg22431228	chr1:16359049	CLCNKA	0.46	8.63	0.47	5.65e-16	Systolic blood pressure;
CESC	cis	rs9486719	1.000	rs10457159	chr6:96993139	G/A	cg06623918	chr6:96969491	KIAA0776	-0.79	-8.2	-0.45	1.07e-14	Migraine;Coronary artery disease;
CESC	cis	rs1215050	0.818	rs6532703	chr4:98777486	A/T	cg05340658	chr4:99064831	C4orf37	0.54	6.42	0.37	6.44e-10	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs9326248	0.569	rs4938315	chr11:116731205	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.57	5.35	0.31	1.93e-7	Blood protein levels;
CESC	cis	rs9457247	0.967	rs377753	chr6:167389496	A/T	cg23791538	chr6:167370224	RNASET2	-0.6	-8.65	-0.47	4.96e-16	Crohn's disease;
CESC	cis	rs2235642	0.787	rs2235646	chr16:1601287	A/G	cg03715980	chr16:1756201	MAPK8IP3	0.39	5.03	0.3	8.87e-7	Coronary artery disease;
CESC	cis	rs826838	0.967	rs7965656	chr12:38807244	G/A	cg26384229	chr12:38710491	ALG10B	0.81	13.62	0.64	2.28e-32	Heart rate;
CESC	cis	rs9788682	1.000	rs7181245	chr15:78814389	C/T	cg24631222	chr15:78858424	CHRNA5	0.73	9.27	0.49	6.82e-18	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs208520	0.955	rs12202599	chr6:67001573	A/G	cg07460842	chr6:66804631	NA	0.77	8.99	0.48	4.98e-17	Exhaled nitric oxide output;
CESC	cis	rs67460515	0.500	rs9822435	chr3:160748068	A/T	cg03342759	chr3:160939853	NMD3	-0.5	-6.06	-0.35	4.78e-9	Parkinson's disease;
CESC	cis	rs9303280	0.754	rs3816470	chr17:37985801	A/G	cg20243544	chr17:37824526	PNMT	0.52	7.03	0.4	1.74e-11	Self-reported allergy;
CESC	cis	rs7605827	0.930	rs2052435	chr2:15687306	A/T	cg19274914	chr2:15703543	NA	0.3	5.39	0.31	1.59e-7	Educational attainment (years of education);
CESC	cis	rs2180341	0.814	rs9321085	chr6:127735361	T/C	cg27446573	chr6:127587934	RNF146	0.83	12.03	0.59	6.99e-27	Breast cancer;
CESC	cis	rs60154123	0.730	rs652256	chr1:210465017	T/C	cg22029157	chr1:209979665	IRF6	0.48	5.88	0.34	1.21e-8	Coronary artery disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg13444131	chr19:40322546	DYRK1B	0.5	6.91	0.39	3.61e-11	Fibrinogen levels;
CESC	cis	rs6977660	0.507	rs28402966	chr7:19774469	A/C	cg07541023	chr7:19748670	TWISTNB	0.8	7.2	0.4	6.34e-12	Thyroid stimulating hormone;
CESC	cis	rs7552404	0.731	rs6699682	chr1:76340123	A/G	cg03433033	chr1:76189801	ACADM	-0.6	-6.31	-0.36	1.15e-9	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs10504229	0.683	rs6995355	chr8:58113870	C/T	cg21724239	chr8:58056113	NA	0.58	5.93	0.34	9.45e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs873946	0.564	rs12263364	chr10:134555548	G/T	cg27286337	chr10:134555280	INPP5A	0.59	6.9	0.39	3.78e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs2033711	0.870	rs4801583	chr19:58918405	A/G	cg26874164	chr19:58962979	ZNF324B	0.54	7.55	0.42	6.95e-13	Uric acid clearance;
CESC	cis	rs514406	0.825	rs6693210	chr1:53223398	A/G	cg08859206	chr1:53392774	SCP2	0.53	6.93	0.39	3.16e-11	Monocyte count;
CESC	cis	rs1215050	0.740	rs804051	chr4:98935935	A/T	cg05340658	chr4:99064831	C4orf37	-0.56	-7.47	-0.42	1.16e-12	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs36051895	0.623	rs7025005	chr9:5261794	T/C	cg02405213	chr9:5042618	JAK2	-0.52	-6.49	-0.37	4.26e-10	Pediatric autoimmune diseases;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26512406	chr16:28223152	XPO6	0.64	7.58	0.42	5.83e-13	Gut microbiome composition (summer);
CESC	cis	rs907612	0.638	rs11041476	chr11:1875067	C/T	cg07277017	chr11:1874093	LSP1	0.35	5.76	0.33	2.29e-8	Monocyte percentage of white cells;Monocyte count;Granulocyte percentage of myeloid white cells;
CESC	cis	rs6570726	0.791	rs6923074	chr6:145893332	T/C	cg23711669	chr6:146136114	FBXO30	0.97	14.77	0.67	2.05e-36	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7635838	0.684	rs2594968	chr3:11352442	T/C	cg00170343	chr3:11313890	ATG7	0.54	7.66	0.43	3.45e-13	HDL cholesterol;
CESC	cis	rs11997175	0.646	rs7386741	chr8:33769709	A/G	ch.8.33884649F	chr8:33765107	NA	0.43	5.17	0.3	4.58e-7	Body mass index;
CESC	cis	rs760805	0.900	rs1005733	chr1:25261960	T/A	cg22509179	chr1:25234806	RUNX3	-0.69	-10.07	-0.53	2.08e-20	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs873946	0.648	rs12771651	chr10:134554482	C/A	cg18305652	chr10:134549665	INPP5A	0.48	6.9	0.39	3.86e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs3733585	0.673	rs6449156	chr4:9956712	G/C	cg00071950	chr4:10020882	SLC2A9	-0.72	-11.68	-0.58	1.03e-25	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs9611565	0.694	rs2142505	chr22:41820541	A/G	cg06481639	chr22:41940642	POLR3H	0.64	6.43	0.37	5.82e-10	Vitiligo;
CESC	cis	rs7959452	0.590	rs28778648	chr12:69771911	C/A	cg14784868	chr12:69753453	YEATS4	0.84	13.23	0.63	5.07e-31	Blood protein levels;
CESC	cis	rs858239	0.539	rs6971673	chr7:23159523	C/G	cg23682824	chr7:23144976	KLHL7	0.54	7.4	0.41	1.79e-12	Cerebrospinal fluid biomarker levels;
CESC	cis	rs4853012	0.838	rs59570457	chr2:74344282	T/C	cg01017244	chr2:74357527	NA	0.68	9.91	0.52	6.99e-20	Gestational age at birth (maternal effect);
CESC	cis	rs9916302	0.851	rs2338795	chr17:37399364	T/G	cg15445000	chr17:37608096	MED1	0.4	6.54	0.37	3.24e-10	Glomerular filtration rate (creatinine);
CESC	trans	rs35110281	0.776	rs1073522	chr21:45009219	T/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.59	7.86	0.43	9.43e-14	Mean corpuscular volume;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg08389503	chr7:6204983	CYTH3	0.44	6.06	0.35	4.53e-9	Fibrinogen levels;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg13778778	chr20:35808076	C20orf132;RPN2	-0.5	-6.48	-0.37	4.39e-10	Ulcerative colitis;
CESC	cis	rs7605827	0.897	rs10166429	chr2:15514472	A/C	cg19274914	chr2:15703543	NA	0.32	5.55	0.32	6.84e-8	Educational attainment (years of education);
CESC	cis	rs870825	0.655	rs35397385	chr4:185639095	C/T	cg04058563	chr4:185651563	MLF1IP	0.64	7.07	0.4	1.39e-11	Blood protein levels;
CESC	cis	rs7618915	0.570	rs11130319	chr3:52755592	A/T	cg18099408	chr3:52552593	STAB1	-0.32	-5.25	-0.31	3.08e-7	Bipolar disorder;
CESC	cis	rs12410462	0.681	rs114950580	chr1:227673334	G/C	cg23173402	chr1:227635558	NA	0.69	5.31	0.31	2.27e-7	Major depressive disorder;
CESC	cis	rs9611565	0.659	rs12483998	chr22:41935362	A/G	cg06634786	chr22:41940651	POLR3H	-0.67	-6.82	-0.39	6.3e-11	Vitiligo;
CESC	cis	rs1799949	1.000	rs4793212	chr17:41302750	T/C	cg25072359	chr17:41440525	NA	0.46	6.1	0.35	3.77e-9	Menopause (age at onset);
CESC	trans	rs1814175	0.529	rs10839396	chr11:49852406	G/T	cg15704280	chr7:45808275	SEPT13	0.88	12.57	0.61	9.61e-29	Height;
CESC	cis	rs9487051	0.604	rs9320282	chr6:109619377	A/G	cg12927641	chr6:109611667	NA	-0.35	-5.12	-0.3	5.81e-7	Reticulocyte fraction of red cells;
CESC	cis	rs2243480	1.000	rs34933526	chr7:65383199	A/G	cg13147721	chr7:65941812	NA	-0.85	-8.1	-0.45	2e-14	Diabetic kidney disease;
CESC	cis	rs7259376	0.936	rs2099354	chr19:22539532	C/A	cg02657401	chr19:22469223	NA	-0.25	-5.05	-0.3	8.16e-7	Menopause (age at onset);
CESC	cis	rs10949834	1.000	rs10949835	chr7:73488922	A/G	cg07137043	chr7:73588983	EIF4H	-0.68	-5.39	-0.31	1.53e-7	Verbal memory performance (residualized delayed recall change);
CESC	cis	rs57244997	0.860	rs9458425	chr6:162376946	C/T	cg17173639	chr6:162384350	PARK2	-0.75	-7.63	-0.42	4.27e-13	Mosquito bite size;
CESC	cis	rs6540559	0.673	rs926346	chr1:209962204	A/T	cg21951975	chr1:209979733	IRF6	0.62	7.75	0.43	2.01e-13	Cleft lip with or without cleft palate;
CESC	cis	rs7927771	0.832	rs7940536	chr11:47395240	G/A	cg18512352	chr11:47633146	NA	0.49	7.01	0.4	2.02e-11	Subjective well-being;
CESC	cis	rs4808199	1.000	rs7258508	chr19:19475469	T/C	cg03709012	chr19:19516395	GATAD2A	1.08	12.88	0.62	8.56e-30	Nonalcoholic fatty liver disease;
CESC	cis	rs690037	0.641	rs538525	chr3:16376279	A/G	cg23474789	chr3:16306055	DPH3;OXNAD1	0.51	6.89	0.39	4.06e-11	Optic nerve measurement (cup-to-disc ratio);Optic nerve measurement (cup area);
CESC	cis	rs35995292	0.553	rs2392605	chr7:38924670	T/C	cg19327137	chr7:38886074	VPS41	0.64	10.39	0.54	1.98e-21	Subjective well-being (multi-trait analysis);
CESC	trans	rs57221529	0.713	rs12521091	chr5:590710	G/T	cg25482853	chr8:67687455	SGK3	0.97	9.68	0.51	3.51e-19	Lung disease severity in cystic fibrosis;
CESC	cis	rs7666738	0.830	rs4292342	chr4:98959870	A/T	cg03467027	chr4:99064603	C4orf37	0.44	5.43	0.32	1.31e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6570726	0.935	rs452552	chr6:145820781	G/A	cg23711669	chr6:146136114	FBXO30	0.81	12.04	0.59	6.44e-27	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9457247	0.935	rs1044059	chr6:167369897	C/A	cg07741184	chr6:167504864	NA	-0.31	-5.47	-0.32	1.03e-7	Crohn's disease;
CESC	cis	rs950776	0.518	rs4886571	chr15:78833758	G/A	cg06917634	chr15:78832804	PSMA4	-0.79	-12.1	-0.6	4.1e-27	Sudden cardiac arrest;
CESC	cis	rs7666738	0.830	rs13134819	chr4:98919885	G/C	cg05340658	chr4:99064831	C4orf37	0.78	11.64	0.58	1.43e-25	Colonoscopy-negative controls vs population controls;
CESC	cis	rs5753618	0.607	rs5753621	chr22:31847647	T/C	cg13145458	chr22:31556086	RNF185	-0.5	-5.89	-0.34	1.16e-8	Colorectal cancer;
CESC	cis	rs11098499	0.575	rs907205	chr4:120238664	G/C	cg09307838	chr4:120376055	NA	0.79	10.77	0.55	1.17e-22	Corneal astigmatism;
CESC	cis	rs13392177	0.684	rs62185965	chr2:219073779	T/C	cg00012203	chr2:219082015	ARPC2	-0.66	-8.2	-0.45	1.01e-14	Pyoderma gangrenosum in inflammatory bowel disease;
CESC	cis	rs9916302	0.706	rs7503377	chr17:37708841	A/G	cg20243544	chr17:37824526	PNMT	0.57	5.56	0.32	6.59e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs4523957	0.890	rs9900379	chr17:2101134	G/A	cg16513277	chr17:2031491	SMG6	-0.66	-9.11	-0.49	2.04e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg23963070	chr1:1162176	SDF4	0.45	6.01	0.35	5.95e-9	Fibrinogen levels;
CESC	cis	rs6570726	1.000	rs1935615	chr6:145921117	G/T	cg05347473	chr6:146136440	FBXO30	0.41	5.55	0.32	6.9e-8	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs798554	0.797	rs798491	chr7:2800521	A/G	cg19346786	chr7:2764209	NA	-0.5	-7.22	-0.41	5.54e-12	Height;
CESC	cis	rs2297440	0.530	rs34533955	chr20:62233020	A/C	cg09650180	chr20:62225654	GMEB2	-0.82	-9.27	-0.49	6.91e-18	Glioma;Non-glioblastoma glioma;Glioblastoma;
CESC	cis	rs858239	0.601	rs3735228	chr7:23170427	T/G	cg23682824	chr7:23144976	KLHL7	0.54	7.55	0.42	6.83e-13	Cerebrospinal fluid biomarker levels;
CESC	cis	rs1775148	1	rs1775148	chr1:205757824	C/T	cg24503407	chr1:205819492	PM20D1	0.45	6.6	0.38	2.26e-10	Prostate cancer;
CESC	cis	rs7772486	0.659	rs9376957	chr6:146011064	C/T	cg23711669	chr6:146136114	FBXO30	-0.88	-12.63	-0.61	6.23e-29	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4919087	0.748	rs1147600	chr10:98981643	T/C	cg25902810	chr10:99078978	FRAT1	-0.52	-5.82	-0.34	1.71e-8	Monocyte count;
CESC	cis	rs7089973	0.836	rs1966384	chr10:116627910	G/T	cg23260525	chr10:116636907	FAM160B1	0.37	6.3	0.36	1.26e-9	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs9611565	0.559	rs5758428	chr22:42106216	G/A	cg17376030	chr22:41985996	PMM1	-0.78	-8.43	-0.46	2.23e-15	Vitiligo;
CESC	cis	rs6461049	0.800	rs3800909	chr7:2159594	C/G	cg05863683	chr7:1912471	MAD1L1	0.4	5.89	0.34	1.16e-8	Schizophrenia;
CESC	cis	rs2594989	0.943	rs346072	chr3:11306851	A/G	cg00170343	chr3:11313890	ATG7	-0.55	-5.06	-0.3	7.92e-7	Circulating chemerin levels;
CESC	trans	rs1814175	0.541	rs12287397	chr11:49819799	G/A	cg03929089	chr4:120376271	NA	-0.91	-15.19	-0.68	6.5e-38	Height;
CESC	cis	rs7589342	0.831	rs10169998	chr2:106452253	A/G	cg16077055	chr2:106428750	NCK2	0.49	6.83	0.39	5.65e-11	Addiction;
CESC	cis	rs4819052	0.851	rs28501512	chr21:46676702	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.76	10.1	0.53	1.62e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg12817154	chr4:864995	GAK	0.48	6.38	0.36	7.73e-10	Fibrinogen levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05929132	chr15:66586024	DIS3L	0.6	7.22	0.41	5.58e-12	Gut microbiome composition (summer);
CESC	cis	rs1008375	1.000	rs11722037	chr4:17683811	G/A	cg16339924	chr4:17578868	LAP3	0.49	6.27	0.36	1.44e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02528389	chr5:143550332	YIPF5;KCTD16	0.56	6.13	0.35	3.12e-9	Gut microbiome composition (summer);
CESC	cis	rs593982	0.920	rs4930298	chr11:65448108	T/A	cg08755490	chr11:65554678	OVOL1	-1.17	-8.74	-0.47	2.66e-16	Atopic dermatitis;
CESC	cis	rs7665939	1.000	rs72709217	chr4:190113079	C/T	cg14840187	chr4:190284988	NA	-0.63	-6.2	-0.36	2.12e-9	Amyotrophic lateral sclerosis;
CESC	cis	rs11098499	0.779	rs72918579	chr4:120333222	G/C	cg24375607	chr4:120327624	NA	0.47	5.71	0.33	3.03e-8	Corneal astigmatism;
CESC	cis	rs6951245	0.882	rs56048221	chr7:1092533	A/G	cg23708337	chr7:1209742	NA	0.49	5.21	0.3	3.82e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs10463316	0.779	rs6861968	chr5:150817725	C/T	cg03212797	chr5:150827313	SLC36A1	-0.44	-5.74	-0.33	2.54e-8	Metabolite levels (Pyroglutamine);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24117723	chr11:77185398	PAK1	0.59	6.5	0.37	4.03e-10	Gut microbiome composition (summer);
CESC	cis	rs8017423	0.935	rs7154695	chr14:90795705	C/G	cg14092571	chr14:90743983	NA	-0.53	-7.63	-0.42	4.19e-13	Mortality in heart failure;
CESC	cis	rs10744422	1.000	rs4759355	chr12:123316566	A/G	cg25930673	chr12:123319894	HIP1R	-0.67	-5.41	-0.32	1.42e-7	Schizophrenia;
CESC	cis	rs12586317	0.553	rs3809448	chr14:35515096	C/T	cg05294307	chr14:35346193	BAZ1A	-0.57	-5.82	-0.34	1.71e-8	Psoriasis;
CESC	cis	rs763121	0.853	rs2076028	chr22:39150450	G/A	cg06022373	chr22:39101656	GTPBP1	0.92	15.32	0.69	2.23e-38	Menopause (age at onset);
CESC	cis	rs367943	0.608	rs4705564	chr5:112980196	G/C	cg12552261	chr5:112820674	MCC	0.39	5.03	0.3	8.99e-7	Type 2 diabetes;
CESC	cis	rs4595586	0.545	rs12812959	chr12:39371197	T/C	cg26384229	chr12:38710491	ALG10B	0.53	7.51	0.42	8.86e-13	Morning vs. evening chronotype;
CESC	cis	rs9522267	0.535	rs4773392	chr13:112227358	A/G	cg10483660	chr13:112241077	NA	0.34	6.09	0.35	3.85e-9	Hepatitis;
CESC	cis	rs295140	0.546	rs295119	chr2:201117944	C/T	cg23649088	chr2:200775458	C2orf69	0.46	5.98	0.34	7.23e-9	QT interval;
CESC	cis	rs875971	0.862	rs1083554	chr7:65852341	T/C	cg18876405	chr7:65276391	NA	0.53	7.32	0.41	3.01e-12	Aortic root size;
CESC	cis	rs11785400	1.000	rs3824208	chr8:143743653	C/G	cg10596483	chr8:143751796	JRK	0.43	5.65	0.33	4.1e-8	Schizophrenia;
CESC	cis	rs7551222	0.752	rs12039454	chr1:204542580	C/T	cg20240347	chr1:204465584	NA	0.27	5.45	0.32	1.16e-7	Schizophrenia;
CESC	cis	rs7255436	0.965	rs11668346	chr19:8450854	A/T	cg16745616	chr19:8428856	ANGPTL4	-0.36	-5.49	-0.32	9.22e-8	HDL cholesterol;
CESC	cis	rs4450131	0.522	rs11245323	chr10:126344624	C/T	cg20435097	chr10:126320824	FAM53B	0.29	5.23	0.31	3.43e-7	White blood cell count (basophil);
CESC	cis	rs2073300	0.609	rs6132609	chr20:23400412	A/C	cg16736954	chr20:23401023	NAPB	0.77	5.65	0.33	4.24e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs9308731	0.591	rs7569300	chr2:111944873	G/A	cg04202892	chr2:111875749	ACOXL	0.37	5.17	0.3	4.61e-7	Chronic lymphocytic leukemia;
CESC	cis	rs79349575	0.651	rs4378658	chr17:46993370	G/A	cg16584676	chr17:46985605	UBE2Z	0.53	6.6	0.38	2.25e-10	Type 2 diabetes;
CESC	cis	rs4654899	0.802	rs6426648	chr1:21179527	A/G	cg05370193	chr1:21551575	ECE1	0.37	5.41	0.32	1.41e-7	Superior frontal gyrus grey matter volume;
CESC	cis	rs826838	1.000	rs1963562	chr12:38662896	C/T	cg13010199	chr12:38710504	ALG10B	0.59	8.31	0.45	4.93e-15	Heart rate;
CESC	trans	rs2797160	0.651	rs1343121	chr6:126036184	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.53	7.17	0.4	7.49e-12	Endometrial cancer;
CESC	cis	rs28374715	0.528	rs28492932	chr15:41624397	G/C	cg20272979	chr15:41787780	ITPKA	0.47	5.57	0.32	6.19e-8	Ulcerative colitis;
CESC	cis	rs753778	0.667	rs6578153	chr8:142209543	C/T	cg18755752	chr8:142205143	DENND3	-0.64	-9.53	-0.51	1.04e-18	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	cis	rs965469	0.545	rs6051846	chr20:3403824	A/G	cg25506879	chr20:3388711	C20orf194	0.56	6.93	0.39	3.16e-11	IFN-related cytopenia;
CESC	cis	rs1448094	0.511	rs11117023	chr12:86145329	G/A	cg02569458	chr12:86230093	RASSF9	-0.42	-6.44	-0.37	5.67e-10	Major depressive disorder;
CESC	cis	rs6500395	0.926	rs11645193	chr16:48594229	C/T	cg04672837	chr16:48644449	N4BP1	0.46	5.54	0.32	7.22e-8	Response to tocilizumab in rheumatoid arthritis;
CESC	trans	rs1814175	0.935	rs10839329	chr11:49694206	G/A	cg03929089	chr4:120376271	NA	-0.87	-13.35	-0.63	1.93e-31	Height;
CESC	cis	rs1707322	0.721	rs11211158	chr1:46132850	C/G	cg05343316	chr1:45956843	TESK2	0.5	6.12	0.35	3.43e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs6963495	0.592	rs114793754	chr7:105152162	G/C	cg13798780	chr7:105162888	PUS7	0.76	7.77	0.43	1.79e-13	Bipolar disorder (body mass index interaction);
CESC	cis	rs4974559	0.948	rs3856982	chr4:1328863	C/T	cg02980000	chr4:1222292	CTBP1	-0.66	-7.79	-0.43	1.56e-13	Systolic blood pressure;
CESC	cis	rs7264396	0.563	rs7268195	chr20:34339854	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.89	-10.73	-0.55	1.51e-22	Total cholesterol levels;
CESC	trans	rs1814175	0.645	rs10839382	chr11:49823172	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.44	-6.32	-0.36	1.09e-9	Height;
CESC	cis	rs9905704	0.801	rs2013182	chr17:56637770	G/A	cg12560992	chr17:57184187	TRIM37	-0.62	-7.63	-0.42	4.34e-13	Testicular germ cell tumor;
CESC	cis	rs875971	0.862	rs10274883	chr7:66116091	C/T	cg10691866	chr7:65817282	TPST1	0.31	5.34	0.31	2e-7	Aortic root size;
CESC	cis	rs11030122	0.702	rs17081	chr11:3987830	A/G	cg18678763	chr11:4115507	RRM1	0.46	6.07	0.35	4.38e-9	Mean platelet volume;Platelet distribution width;
CESC	cis	rs7923609	0.934	rs2893919	chr10:65134778	G/A	cg01631684	chr10:65280961	REEP3	-0.42	-5.18	-0.3	4.35e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs6748734	1.000	rs6748734	chr2:241837452	A/G	cg15164180	chr2:241846931	NA	-0.35	-5.21	-0.3	3.77e-7	Urinary metabolites;
CESC	cis	rs9948	0.655	rs62152785	chr2:97459403	A/T	cg01990225	chr2:97406019	LMAN2L	-0.89	-7.17	-0.4	7.42e-12	Erectile dysfunction and prostate cancer treatment;
CESC	cis	rs921968	0.541	rs7574429	chr2:219498759	T/G	cg02176678	chr2:219576539	TTLL4	0.47	8.29	0.45	5.7e-15	Mean corpuscular hemoglobin concentration;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11255513	chr11:113644528	ZW10	-0.57	-6.47	-0.37	4.66e-10	Gut microbiome composition (summer);
CESC	cis	rs2066819	1.000	rs2629447	chr12:56700809	G/A	cg26714650	chr12:56694279	CS	1.28	15.86	0.7	2.7e-40	Psoriasis vulgaris;
CESC	cis	rs539096	0.566	rs3011220	chr1:44308867	A/G	cg13606994	chr1:44402422	ARTN	-0.36	-5.55	-0.32	6.9e-8	Intelligence (multi-trait analysis);
CESC	cis	rs1801251	1.000	rs1044480	chr2:233633736	A/G	cg08000102	chr2:233561755	GIGYF2	0.65	9.21	0.49	1.01e-17	Coronary artery disease;
CESC	cis	rs11098499	0.909	rs28555550	chr4:120211040	C/G	cg09307838	chr4:120376055	NA	0.88	11.91	0.59	1.75e-26	Corneal astigmatism;
CESC	cis	rs2070488	0.775	rs4679066	chr3:38568527	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.78	-12.87	-0.62	9.13e-30	Electrocardiographic conduction measures;
CESC	cis	rs8072100	0.870	rs10432035	chr17:45624913	G/C	cg08085267	chr17:45401833	C17orf57	0.42	5.37	0.31	1.74e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs2337406	0.714	rs8022729	chr14:107225161	C/T	cg23076370	chr14:107095027	NA	0.55	5.82	0.34	1.68e-8	Alzheimer's disease (late onset);
CESC	cis	rs72781680	0.593	rs72797817	chr2:24350569	A/G	cg06627628	chr2:24431161	ITSN2	-0.68	-6.64	-0.38	1.76e-10	Lymphocyte counts;
CESC	cis	rs2108622	0.727	rs3093193	chr19:15991914	C/G	cg13772218	chr19:15982569	NA	0.31	6.07	0.35	4.46e-9	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CESC	cis	rs644799	1.000	rs586238	chr11:95560371	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.71	9.29	0.5	5.89e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs4253772	0.591	rs9615348	chr22:46729338	C/G	cg10541313	chr22:46663664	TTC38	0.73	5.21	0.3	3.86e-7	LDL cholesterol;Cholesterol, total;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg15915129	chr11:124933008	SLC37A2	0.46	6.12	0.35	3.39e-9	Systemic lupus erythematosus;
CESC	cis	rs7945705	0.747	rs1123936	chr11:9003306	A/G	cg12365402	chr11:9010492	NRIP3	-0.42	-7.18	-0.4	7.05e-12	Hemoglobin concentration;
CESC	cis	rs1707322	0.963	rs4660900	chr1:46419605	T/C	cg05343316	chr1:45956843	TESK2	0.44	5.42	0.32	1.36e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7666738	0.830	rs6848397	chr4:98946738	A/G	cg03676636	chr4:99064102	C4orf37	0.34	5.11	0.3	6.15e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7044106	0.762	rs10984974	chr9:123421556	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.81	12.73	0.62	2.71e-29	Hip circumference adjusted for BMI;
CESC	cis	rs55871839	0.547	rs3780001	chr8:59872615	G/T	cg07426533	chr8:59803705	TOX	-0.45	-5.8	-0.34	1.88e-8	Pneumonia;
CESC	cis	rs8141529	0.748	rs6005936	chr22:29289250	T/C	cg02153584	chr22:29168773	CCDC117	0.58	7.78	0.43	1.5700000000000001e-13	Lymphocyte counts;
CESC	trans	rs61931739	0.500	rs28624237	chr12:34457171	G/T	cg13010199	chr12:38710504	ALG10B	0.48	6.28	0.36	1.38e-9	Morning vs. evening chronotype;
CESC	cis	rs6430585	0.583	rs3754689	chr2:136590746	C/T	cg07169764	chr2:136633963	MCM6	1.18	17.34	0.73	1.59e-45	Corneal structure;
CESC	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg10295955	chr4:187884368	NA	-1.04	-21.24	-0.79	3.96e-59	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs11039798	0.588	rs6485891	chr11:48612024	T/A	cg15704280	chr7:45808275	SEPT13	0.61	6.29	0.36	1.32e-9	Axial length;
CESC	cis	rs12477438	0.520	rs6542869	chr2:99783403	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.91	15.64	0.69	1.66e-39	Chronic sinus infection;
CESC	trans	rs1814175	0.817	rs1996982	chr11:49972619	G/T	cg03929089	chr4:120376271	NA	-0.93	-16.32	-0.71	6.51e-42	Height;
CESC	cis	rs7216064	1.000	rs9912770	chr17:65868233	C/T	cg07042672	chr17:66097459	LOC651250	-0.57	-6.57	-0.37	2.69e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs2832191	0.933	rs2832236	chr21:30547602	C/T	cg08807101	chr21:30365312	RNF160	-0.57	-7.58	-0.42	5.96e-13	Dental caries;
CESC	cis	rs897984	0.644	rs73524556	chr16:30823162	G/A	cg02466173	chr16:30829666	NA	-0.59	-11.47	-0.58	5.58e-25	Dementia with Lewy bodies;
CESC	trans	rs17536732	0.685	rs80229139	chr4:162856305	T/A	cg12177677	chr2:158300475	CYTIP	-0.63	-6.2	-0.36	2.17e-9	Risky sexual behaviors (alcohol dependence interaction);
CESC	cis	rs858239	0.601	rs4440529	chr7:23168751	G/C	cg23682824	chr7:23144976	KLHL7	0.54	7.37	0.41	2.14e-12	Cerebrospinal fluid biomarker levels;
CESC	cis	rs1448094	0.817	rs10863122	chr12:86346047	T/C	cg02569458	chr12:86230093	RASSF9	0.39	5.64	0.33	4.25e-8	Major depressive disorder;
CESC	cis	rs4713118	0.629	rs149899	chr6:28019979	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.51	-5.82	-0.34	1.73e-8	Parkinson's disease;
CESC	cis	rs7666738	0.570	rs10032272	chr4:99095601	T/C	cg05340658	chr4:99064831	C4orf37	0.63	8.46	0.46	1.84e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs17253792	0.822	rs2274075	chr14:56096731	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.79	5.91	0.34	1.06e-8	Putamen volume;
CESC	cis	rs9303280	0.747	rs1453559	chr17:38020419	T/C	cg19468946	chr17:37922297	IKZF3	-0.4	-5.47	-0.32	1.05e-7	Self-reported allergy;
CESC	cis	rs875971	0.830	rs6950137	chr7:65976610	G/A	cg10691866	chr7:65817282	TPST1	-0.32	-5.25	-0.31	3.16e-7	Aortic root size;
CESC	cis	rs4629710	0.592	rs11154622	chr6:131547578	C/T	cg12606694	chr6:131520996	AKAP7	0.46	5.66	0.33	3.86e-8	Multiple myeloma (IgH translocation);
CESC	cis	rs875971	0.862	rs6460293	chr7:65810192	C/A	cg18876405	chr7:65276391	NA	-0.53	-7.27	-0.41	4.11e-12	Aortic root size;
CESC	cis	rs4819052	1.000	rs9306123	chr21:46709922	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.93	12.47	0.61	2.14e-28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs6500602	0.647	rs1641868	chr16:4594503	G/C	cg08645402	chr16:4508243	NA	0.49	7.81	0.43	1.31e-13	Schizophrenia;
CESC	cis	rs2576037	0.526	rs564113	chr18:44364389	A/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.54	-7.45	-0.42	1.33e-12	Personality dimensions;
CESC	cis	rs7084402	0.967	rs1658447	chr10:60313174	G/A	cg07615347	chr10:60278583	BICC1	0.61	9.59	0.51	7.04e-19	Refractive error;
CESC	cis	rs6580649	0.883	rs4760621	chr12:48561262	A/G	cg05342945	chr12:48394962	COL2A1	-0.5	-5.93	-0.34	9.25e-9	Lung cancer;
CESC	cis	rs8180040	0.726	rs1463393	chr3:46994987	G/A	cg27129171	chr3:47204927	SETD2	-0.63	-8.95	-0.48	6.47e-17	Colorectal cancer;
CESC	cis	rs10540	0.908	rs1044707	chr11:491334	G/T	cg03576123	chr11:487126	PTDSS2	1.1	10.95	0.56	2.87e-23	Body mass index;
CESC	cis	rs11048434	0.687	rs12814670	chr12:9060025	C/T	cg23795048	chr12:9217529	LOC144571	0.37	5.8	0.34	1.87e-8	Sjögren's syndrome;
CESC	cis	rs6580649	1.000	rs7132668	chr12:48405860	C/T	cg24011408	chr12:48396354	COL2A1	0.43	5.45	0.32	1.15e-7	Lung cancer;
CESC	cis	rs460214	0.539	rs55819392	chr21:40038207	G/A	cg05519781	chr21:40033154	ERG	-0.46	-5.57	-0.32	6.13e-8	Response to cognitive-behavioural therapy in anxiety disorder;
CESC	cis	rs9915657	0.933	rs4793272	chr17:70139257	A/T	cg09344028	chr17:70110421	NA	0.32	6.02	0.35	5.66e-9	Thyroid hormone levels;
CESC	cis	rs17376456	0.825	rs10214278	chr5:93237679	C/T	cg25358565	chr5:93447407	FAM172A	-1.07	-9.7	-0.51	3.21e-19	Diabetic retinopathy;
CESC	cis	rs798554	0.679	rs7807978	chr7:2814635	C/T	cg13628971	chr7:2884303	GNA12	0.41	5.46	0.32	1.11e-7	Height;
CESC	trans	rs11098499	0.866	rs13125526	chr4:120288019	G/A	cg25214090	chr10:38739885	LOC399744	0.65	9.11	0.49	2.04e-17	Corneal astigmatism;
CESC	cis	rs7582720	1.000	rs72936846	chr2:203774734	G/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.39	0.41	1.96e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs2635047	0.713	rs28666933	chr18:44762408	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.42	5.64	0.33	4.37e-8	Educational attainment;
CESC	cis	rs748404	0.697	rs564946	chr15:43556272	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.61	7.83	0.43	1.19e-13	Lung cancer;
CESC	cis	rs2760061	0.583	rs708113	chr1:228192753	T/A	cg02753203	chr1:228287806	NA	0.72	11.27	0.57	2.57e-24	Diastolic blood pressure;
CESC	cis	rs1185460	0.967	rs1184902	chr11:118945337	A/G	cg01677386	chr11:118938358	VPS11	-0.44	-5.4	-0.32	1.45e-7	Coronary artery disease;
CESC	cis	rs477895	0.653	rs3824854	chr11:63885305	C/T	cg18225595	chr11:63971243	STIP1	0.55	5.41	0.32	1.39e-7	Mean platelet volume;
CESC	cis	rs7613875	0.620	rs11721204	chr3:49982765	C/T	cg24308560	chr3:49941425	MST1R	-0.55	-7.61	-0.42	4.87e-13	Body mass index;
CESC	cis	rs28489187	0.617	rs233112	chr1:85785751	C/T	cg16011679	chr1:85725395	C1orf52	-0.43	-5.3	-0.31	2.46e-7	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	cis	rs11098499	0.820	rs6829903	chr4:120506884	C/T	cg24375607	chr4:120327624	NA	0.46	5.48	0.32	1.01e-7	Corneal astigmatism;
CESC	cis	rs1728785	1.000	rs1170439	chr16:68608511	T/C	cg02972257	chr16:68554789	NA	-0.61	-6.93	-0.39	3.25e-11	Ulcerative colitis;
CESC	cis	rs9811920	0.809	rs13059754	chr3:99678490	C/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.44	-5.65	-0.33	4.05e-8	Axial length;
CESC	trans	rs9987353	0.840	rs329994	chr8:9123233	A/G	cg00917603	chr5:140209956	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.41	6.23	0.36	1.85e-9	Recombination measurement;
CESC	trans	rs74054849	0.850	rs72879500	chr1:16033853	G/A	cg06826283	chr7:600452	PRKAR1B	0.69	6.1	0.35	3.76e-9	Alcoholic chronic pancreatitis;
CESC	cis	rs6938	0.534	rs8025447	chr15:75192222	T/G	cg14664628	chr15:75095509	CSK	-0.56	-7.57	-0.42	6.12e-13	Breast cancer;
CESC	cis	rs8114671	0.562	rs4911161	chr20:33402231	C/T	cg08999081	chr20:33150536	PIGU	0.4	5.67	0.33	3.74e-8	Height;
CESC	cis	rs2228479	0.717	rs9282682	chr16:89805794	A/G	cg00800038	chr16:89945340	TCF25	-0.61	-6.18	-0.36	2.38e-9	Skin colour saturation;
CESC	cis	rs7296418	0.961	rs1727307	chr12:123575742	A/G	cg00376283	chr12:123451042	ABCB9	0.72	10.03	0.52	2.88e-20	Platelet count;
CESC	cis	rs12541635	0.934	rs2115703	chr8:107045935	C/G	cg10147462	chr8:107024639	NA	0.42	5.97	0.34	7.51e-9	Age of smoking initiation;
CESC	cis	rs2228479	0.541	rs13335395	chr16:89952843	T/A	cg04013166	chr16:89971882	TCF25	0.72	8.57	0.47	8.47e-16	Skin colour saturation;
CESC	cis	rs2635047	1.000	rs2684841	chr18:44724262	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.49	6.74	0.38	1.01e-10	Educational attainment;
CESC	cis	rs2050392	0.624	rs303435	chr10:30731491	T/C	cg18806716	chr10:30721971	MAP3K8	-0.62	-9.31	-0.5	5.02e-18	Inflammatory bowel disease;
CESC	cis	rs1799949	0.930	rs35292991	chr17:41334016	C/A	cg25072359	chr17:41440525	NA	0.5	6.77	0.38	8.41e-11	Menopause (age at onset);
CESC	cis	rs11190604	1.000	rs3793771	chr10:102222957	C/G	cg07080220	chr10:102295463	HIF1AN	0.55	5.6	0.33	5.35e-8	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs8076336	1	rs8076336	chr17:18212614	A/C	cg16794390	chr17:18148240	FLII	0.41	7.04	0.4	1.65e-11	Parental longevity (combined parental age at death);
CESC	cis	rs9311474	0.607	rs13076398	chr3:52573096	G/A	cg18404041	chr3:52824283	ITIH1	-0.35	-5.99	-0.35	6.8e-9	Electroencephalogram traits;
CESC	cis	rs7210086	0.768	rs72849445	chr17:70637985	T/G	cg04206342	chr17:70636940	NA	-0.31	-6.09	-0.35	4.05e-9	Ulcerative colitis;
CESC	cis	rs2204008	0.618	rs8186932	chr12:38338386	G/A	cg26384229	chr12:38710491	ALG10B	-0.45	-5.82	-0.34	1.72e-8	Bladder cancer;
CESC	cis	rs4819052	0.851	rs7275468	chr21:46656499	C/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.81	11.33	0.57	1.59e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs5753618	0.583	rs2273251	chr22:31843567	G/C	cg13145458	chr22:31556086	RNF185	-0.51	-6.04	-0.35	5.17e-9	Colorectal cancer;
CESC	cis	rs9768139	0.733	rs12698208	chr7:158117575	C/T	cg06219351	chr7:158114137	PTPRN2	-0.44	-6.86	-0.39	4.87e-11	Calcium levels;
CESC	cis	rs6032067	0.777	rs34916007	chr20:43782952	T/G	cg11264863	chr20:43835661	SEMG1	0.5	5.35	0.31	1.89e-7	Blood protein levels;
CESC	cis	rs941408	1.000	rs2260416	chr19:2796355	G/A	cg06609049	chr19:2785107	THOP1	0.71	10.27	0.53	4.74e-21	Total cholesterol levels;
CESC	cis	rs317689	0.876	rs547332	chr12:69743639	C/G	cg20891283	chr12:69753455	YEATS4	0.66	8.34	0.46	4.23e-15	Response to diuretic therapy;
CESC	cis	rs9814567	0.964	rs6772406	chr3:134210183	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.43	-5.98	-0.34	7.11e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs514406	0.505	rs269292	chr1:53187911	T/C	cg08736216	chr1:53307985	ZYG11A	-0.38	-6.25	-0.36	1.65e-9	Monocyte count;
CESC	cis	rs924607	0.966	rs1709554	chr5:637443	A/G	cg09021430	chr5:549028	NA	-0.39	-6.88	-0.39	4.32e-11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03272279	chr8:74791249	UBE2W	0.68	7.77	0.43	1.76e-13	Gut microbiome composition (summer);
CESC	trans	rs61931739	0.500	rs3924704	chr12:34557833	C/T	cg26384229	chr12:38710491	ALG10B	0.72	10.67	0.55	2.39e-22	Morning vs. evening chronotype;
CESC	cis	rs561341	1.000	rs561341	chr17:30316385	T/G	cg23018236	chr17:30244563	NA	-0.52	-5.1	-0.3	6.39e-7	Hip circumference adjusted for BMI;
CESC	trans	rs4589258	0.737	rs7110548	chr11:90397761	A/G	cg04115680	chr7:75889229	SRRM3	0.34	5.99	0.35	6.67e-9	Intelligence (multi-trait analysis);
CESC	cis	rs965469	0.779	rs6051693	chr20:3244449	T/G	cg25506879	chr20:3388711	C20orf194	-0.51	-5.57	-0.32	6.1e-8	IFN-related cytopenia;
CESC	cis	rs801193	1.000	rs11773829	chr7:66141074	G/A	cg06456125	chr7:65229604	NA	-0.39	-5.06	-0.3	7.77e-7	Aortic root size;
CESC	cis	rs2836974	0.966	rs2836977	chr21:40666066	T/C	cg11890956	chr21:40555474	PSMG1	1.17	21.56	0.8	3.08e-60	Cognitive function;
CESC	cis	rs826838	0.967	rs980572	chr12:39127673	A/C	cg13010199	chr12:38710504	ALG10B	0.43	5.73	0.33	2.7e-8	Heart rate;
CESC	cis	rs17376456	0.825	rs17374166	chr5:93238655	T/C	cg25358565	chr5:93447407	FAM172A	1.1	10.58	0.54	4.84e-22	Diabetic retinopathy;
CESC	cis	rs9303401	1.000	rs6503877	chr17:56841948	C/T	cg12560992	chr17:57184187	TRIM37	0.49	5.54	0.32	7.42e-8	Cognitive test performance;
CESC	cis	rs9905704	0.647	rs2108435	chr17:57102133	T/C	cg12560992	chr17:57184187	TRIM37	-0.66	-8.39	-0.46	2.97e-15	Testicular germ cell tumor;
CESC	cis	rs9863	0.828	rs11057412	chr12:124489142	G/C	cg00084347	chr12:124393913	DNAH10	0.26	5.11	0.3	6.2e-7	White blood cell count;
CESC	cis	rs2835872	0.733	rs1787400	chr21:39038217	G/C	cg06728970	chr21:39037746	KCNJ6	0.3	5.59	0.32	5.72e-8	Electroencephalographic traits in alcoholism;
CESC	cis	rs798554	0.797	rs798487	chr7:2802943	G/A	cg19346786	chr7:2764209	NA	-0.5	-7.17	-0.4	7.34e-12	Height;
CESC	cis	rs9487051	0.735	rs1761608	chr6:109517706	G/A	cg01475377	chr6:109611718	NA	-0.37	-5.52	-0.32	8.15e-8	Reticulocyte fraction of red cells;
CESC	cis	rs9733	0.628	rs11807409	chr1:150683423	C/T	cg22823121	chr1:150693482	HORMAD1	0.48	7.11	0.4	1.11e-11	Tonsillectomy;
CESC	cis	rs1448094	0.512	rs61930862	chr12:86246567	A/G	cg00310523	chr12:86230176	RASSF9	0.35	5.46	0.32	1.1e-7	Major depressive disorder;
CESC	cis	rs67311347	1.000	rs73080137	chr3:40516412	A/G	cg01475735	chr3:40494733	NA	-0.41	-5.14	-0.3	5.28e-7	Renal cell carcinoma;
CESC	cis	rs6545883	0.859	rs2694644	chr2:61604856	A/T	cg15711740	chr2:61764176	XPO1	0.4	5.03	0.3	9.13e-7	Tuberculosis;
CESC	cis	rs1707322	0.721	rs10890341	chr1:46147240	C/A	cg06784218	chr1:46089804	CCDC17	0.41	7.21	0.41	5.75e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs6912958	0.754	rs4587143	chr6:88292291	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-6.52	-0.37	3.6e-10	Monocyte percentage of white cells;
CESC	cis	rs10979	0.965	rs9390109	chr6:143892806	T/C	cg25407410	chr6:143891975	LOC285740	-0.61	-9.21	-0.49	1.01e-17	Hypospadias;
CESC	cis	rs4665809	0.549	rs62130460	chr2:26472718	T/C	cg26314531	chr2:26401878	FAM59B	0.76	7.54	0.42	7.31e-13	Gut microbiome composition (summer);
CESC	cis	rs11509880	0.606	rs11971133	chr7:12256548	T/C	cg23422036	chr7:12250390	TMEM106B	0.39	5.23	0.31	3.36e-7	Coronary artery disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg14529598	chr4:8098851	ABLIM2	0.39	6.13	0.35	3.15e-9	Fibrinogen levels;
CESC	cis	rs13191362	1.000	rs34052221	chr6:163160803	G/A	cg06582575	chr6:163149167	PACRG;PARK2	1.04	10.24	0.53	6.17e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs8082590	1	rs8082590	chr17:17958402	G/A	cg09796270	chr17:17721594	SREBF1	-0.38	-5.12	-0.3	5.97e-7	Schizophrenia;
CESC	cis	rs15676	0.853	rs2259043	chr9:131607921	A/G	cg00228799	chr9:131580591	ENDOG	0.44	5.48	0.32	9.79e-8	Blood metabolite levels;
CESC	cis	rs2070488	0.965	rs4679060	chr3:38536261	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.95	-17.92	-0.74	1.34e-47	Electrocardiographic conduction measures;
CESC	cis	rs6952808	0.792	rs12536261	chr7:1953571	G/A	cg22963979	chr7:1858916	MAD1L1	-0.39	-5.42	-0.32	1.37e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs7666738	0.830	rs11729753	chr4:98803267	T/A	cg17366294	chr4:99064904	C4orf37	0.58	8.12	0.45	1.73e-14	Colonoscopy-negative controls vs population controls;
CESC	cis	rs16867321	0.627	rs2194687	chr2:181577170	G/A	cg23363182	chr2:181467187	NA	0.45	6.6	0.38	2.21e-10	Obesity;
CESC	cis	rs17125944	0.572	rs79312783	chr14:53250296	A/T	cg13660082	chr14:53194042	PSMC6	-0.67	-5.97	-0.34	7.59e-9	Alzheimer's disease (late onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00041467	chr2:122494276	MKI67IP	0.58	6.63	0.38	1.91e-10	Gut microbiome composition (summer);
CESC	cis	rs2455799	0.552	rs1472697	chr3:15750268	G/A	cg09340198	chr3:15902540	ANKRD28	-0.33	-5.15	-0.3	5.13e-7	Mean platelet volume;
CESC	cis	rs7224314	1.000	rs62084076	chr17:65383102	G/A	cg01507342	chr17:65387096	PITPNC1	-0.46	-5.6	-0.33	5.31e-8	Diisocyanate-induced asthma;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg17378273	chr11:45169082	PRDM11	-0.45	-6.28	-0.36	1.39e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs870825	0.616	rs1401358	chr4:185640057	C/T	cg04058563	chr4:185651563	MLF1IP	0.63	7.34	0.41	2.68e-12	Blood protein levels;
CESC	cis	rs4665809	1.000	rs750451	chr2:26324241	G/A	cg08470875	chr2:26401718	FAM59B	-0.47	-5.19	-0.3	4.23e-7	Gut microbiome composition (summer);
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg02400751	chr11:74459640	RNF169	-0.44	-6.02	-0.35	5.69e-9	Asthma;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg07203573	chr17:73201765	NUP85	-0.52	-6.34	-0.36	9.94e-10	Ulcerative colitis;
CESC	cis	rs9916302	0.904	rs6503506	chr17:37524653	C/A	cg00129232	chr17:37814104	STARD3	0.59	7.98	0.44	4.33e-14	Glomerular filtration rate (creatinine);
CESC	trans	rs11148252	0.595	rs4884522	chr13:53053768	C/A	cg18335740	chr13:41363409	SLC25A15	0.56	7.62	0.42	4.45e-13	Lewy body disease;
CESC	cis	rs4253772	0.591	rs6008538	chr22:46685963	G/A	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.78	8.9	0.48	8.95e-17	LDL cholesterol;Cholesterol, total;
CESC	cis	rs801193	0.591	rs4506088	chr7:66135457	G/A	cg12463550	chr7:65579703	CRCP	-0.5	-6.46	-0.37	4.91e-10	Aortic root size;
CESC	cis	rs9911578	0.740	rs368243	chr17:56708979	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.43	5.76	0.33	2.31e-8	Intelligence (multi-trait analysis);
CESC	cis	rs2832191	0.646	rs2832214	chr21:30517127	C/T	cg24692254	chr21:30365293	RNF160	-0.56	-7.08	-0.4	1.32e-11	Dental caries;
CESC	cis	rs597539	0.652	rs507520	chr11:68666054	C/T	cg04772025	chr11:68637568	NA	0.52	6.06	0.35	4.6e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs597539	0.690	rs608810	chr11:68624118	G/C	cg18350739	chr11:68623251	NA	-0.45	-6.5	-0.37	3.89e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs3026101	0.671	rs1071705	chr17:5290033	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.44	5.8	0.34	1.9e-8	Body mass index;
CESC	cis	rs7129220	0.588	rs60257382	chr11:10122172	C/T	cg01453529	chr11:10209919	SBF2	-0.48	-5.38	-0.31	1.67e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CESC	cis	rs6444746	1.000	rs6444746	chr3:193495155	A/G	cg22553634	chr3:193489233	NA	-0.42	-5.49	-0.32	9.61e-8	Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
CESC	cis	rs17125944	0.686	rs77625717	chr14:53336544	T/C	cg00686598	chr14:53173677	PSMC6	0.94	6.6	0.38	2.19e-10	Alzheimer's disease (late onset);
CESC	cis	rs2066819	1.000	rs11575234	chr12:56744276	C/G	cg26734620	chr12:56694298	CS	0.88	8.73	0.47	2.85e-16	Psoriasis vulgaris;
CESC	trans	rs2764766	0.721	rs245192	chr5:127188220	C/T	cg15764593	chr10:829463	NA	-0.4	-6.19	-0.36	2.33e-9	Schizophrenia;
CESC	cis	rs4727027	0.782	rs10245343	chr7:148796333	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.49	5.77	0.33	2.25e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs1707322	0.752	rs4607935	chr1:46117161	C/T	cg06784218	chr1:46089804	CCDC17	0.41	7.12	0.4	1.04e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2576037	0.583	rs9916891	chr18:44493521	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.37	6.01	0.35	5.99e-9	Personality dimensions;
CESC	cis	rs10791323	0.569	rs2282602	chr11:133714522	G/A	cg15485101	chr11:133734466	NA	0.41	6.65	0.38	1.66e-10	Childhood ear infection;
CESC	cis	rs6547741	1.000	rs6706610	chr2:27778091	G/A	cg27432699	chr2:27873401	GPN1	0.49	6.86	0.39	4.85e-11	Oral cavity cancer;
CESC	cis	rs7618915	0.571	rs11130307	chr3:52607682	G/A	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	5.67	0.33	3.7e-8	Bipolar disorder;
CESC	cis	rs78707713	0.841	rs10998780	chr10:71201735	A/T	cg12610070	chr10:71211762	TSPAN15	-0.36	-6.41	-0.37	6.68e-10	Venous thromboembolism;
CESC	cis	rs11098499	0.909	rs11723757	chr4:120299669	C/T	cg24375607	chr4:120327624	NA	0.46	5.55	0.32	6.98e-8	Corneal astigmatism;
CESC	cis	rs1691799	0.867	rs1183274	chr12:66732057	C/G	cg16791601	chr12:66731901	HELB	-0.75	-12.95	-0.62	4.83e-30	White blood cell count (basophil);
CESC	cis	rs9733	0.628	rs72700895	chr1:150626029	C/T	cg17724175	chr1:150552817	MCL1	0.44	7.21	0.41	5.75e-12	Tonsillectomy;
CESC	cis	rs4819052	0.851	rs13048789	chr21:46660714	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.91	13.24	0.63	4.51e-31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs561341	0.941	rs112569713	chr17:30271738	C/T	cg27661571	chr11:113659931	NA	-0.71	-7.27	-0.41	4.13e-12	Hip circumference adjusted for BMI;
CESC	cis	rs1538970	0.816	rs34673142	chr1:45985561	G/A	cg05343316	chr1:45956843	TESK2	0.92	12.54	0.61	1.2e-28	Platelet count;
CESC	cis	rs7216064	1.000	rs4271626	chr17:65930133	G/A	cg07042672	chr17:66097459	LOC651250	-0.55	-5.96	-0.34	8.12e-9	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs7772486	0.875	rs2814872	chr6:146310234	T/C	cg05347473	chr6:146136440	FBXO30	0.56	7.37	0.41	2.14e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6439153	0.933	rs900381	chr3:128713455	C/G	cg25356066	chr3:128598488	ACAD9	0.51	6.57	0.37	2.65e-10	Pneumococcal bacteremia;
CESC	cis	rs4555082	0.872	rs7153832	chr14:105730563	G/T	cg13114125	chr14:105738426	BRF1	-0.78	-10.03	-0.52	2.81e-20	Mean platelet volume;Platelet distribution width;
CESC	cis	rs12541635	0.966	rs4734895	chr8:107002604	A/G	cg10147462	chr8:107024639	NA	0.41	5.69	0.33	3.3e-8	Age of smoking initiation;
CESC	cis	rs9291683	0.538	rs11727199	chr4:10036190	C/T	cg00071950	chr4:10020882	SLC2A9	0.83	14.43	0.66	3.23e-35	Bone mineral density;
CESC	cis	rs950027	0.620	rs872192	chr15:45614502	A/G	cg21132104	chr15:45694354	SPATA5L1	0.68	8.67	0.47	4.44e-16	Response to fenofibrate (adiponectin levels);
CESC	cis	rs7666738	0.830	rs17558193	chr4:99049593	A/G	cg03676636	chr4:99064102	C4orf37	0.33	5.12	0.3	5.93e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs72781680	0.898	rs6712524	chr2:24083925	T/C	cg08917208	chr2:24149416	ATAD2B	0.92	8.46	0.46	1.78e-15	Lymphocyte counts;
CESC	cis	rs651907	0.514	rs34301719	chr3:101417993	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.47	5.91	0.34	1.03e-8	Colorectal cancer;
CESC	cis	rs10870270	1.000	rs11146338	chr10:133770291	C/G	cg17892150	chr10:133769511	PPP2R2D	-0.86	-12.56	-0.61	1.08e-28	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs17826219	0.636	rs79565452	chr17:29142841	T/C	cg14008862	chr17:28927542	LRRC37B2	0.65	5.14	0.3	5.47e-7	Body mass index;
CESC	cis	rs763014	0.966	rs4144003	chr16:645968	C/T	cg07256732	chr16:621771	PIGQ	-0.3	-5.1	-0.3	6.42e-7	Height;
CESC	cis	rs1348850	0.918	rs4893966	chr2:178470138	A/G	cg22681709	chr2:178499509	PDE11A	-0.37	-5.35	-0.31	1.89e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs45535039	0.961	rs7120073	chr11:119112898	T/C	cg16724696	chr11:118992527	HINFP	0.43	5.29	0.31	2.51e-7	Plateletcrit;
CESC	cis	rs3820928	0.874	rs1917122	chr2:227835681	C/T	cg11843606	chr2:227700838	RHBDD1	-0.45	-5.77	-0.33	2.22e-8	Pulmonary function;
CESC	cis	rs3096299	0.719	rs2911265	chr16:89511328	G/A	cg02034447	chr16:89574710	SPG7	0.47	5.99	0.35	6.82e-9	Multiple myeloma (IgH translocation);
CESC	cis	rs17666538	0.585	rs1669615	chr8:616665	T/C	cg02524346	chr8:600233	NA	0.85	6.12	0.35	3.39e-9	IgG glycosylation;
CESC	cis	rs3981351	0.797	rs61866461	chr10:115454862	C/A	cg24846397	chr10:115438155	CASP7	-0.36	-5.13	-0.3	5.49e-7	Obesity-related traits;
CESC	cis	rs7267979	0.903	rs6115118	chr20:25246734	G/A	cg08601574	chr20:25228251	PYGB	0.42	5.9	0.34	1.12e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs10504229	0.639	rs112926738	chr8:58054939	A/G	cg24829409	chr8:58192753	C8orf71	-0.58	-6.75	-0.38	9.05e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs7692995	1.000	rs73098845	chr4:17940718	C/A	cg08925142	chr4:18023851	LCORL	-0.46	-5.32	-0.31	2.26e-7	Height;
CESC	cis	rs7811142	0.562	rs7786844	chr7:99934008	T/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.1	13.5	0.64	6.04e-32	Platelet count;
CESC	cis	rs3617	0.573	rs4687680	chr3:52907372	G/A	cg07507251	chr3:52567010	NT5DC2	0.33	5.44	0.32	1.19e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
CESC	cis	rs1552244	1.000	rs6772315	chr3:10113644	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	11.94	0.59	1.43e-26	Alzheimer's disease;
CESC	cis	rs1008375	1.000	rs4698648	chr4:17692715	C/G	cg16339924	chr4:17578868	LAP3	0.6	7.44	0.42	1.45e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs116095464	0.558	rs60251075	chr5:245292	T/C	cg22496380	chr5:211416	CCDC127	-0.74	-8.63	-0.47	5.66e-16	Breast cancer;
CESC	cis	rs7833790	1.000	rs7460277	chr8:82709777	T/C	cg02079420	chr8:82753780	SNX16	0.57	7.65	0.43	3.67e-13	Diastolic blood pressure;
CESC	cis	rs1552244	0.882	rs13099507	chr3:10031603	G/A	cg08888203	chr3:10149979	C3orf24	0.5	6.02	0.35	5.84e-9	Alzheimer's disease;
CESC	cis	rs16973500	1.000	rs16973500	chr16:71965196	C/T	cg09427745	chr16:71932006	KIAA0174	-0.52	-5.33	-0.31	2.13e-7	Response to anti-TNF therapy in rheumatoid arthritis;Attention deficit hyperactivity disorder and conduct disorder;
CESC	cis	rs2072499	0.966	rs2842857	chr1:156168736	T/C	cg06970220	chr1:156163860	SLC25A44	0.38	5.25	0.31	3.16e-7	Testicular germ cell tumor;
CESC	cis	rs2952156	0.920	rs1565920	chr17:37831613	G/A	cg00129232	chr17:37814104	STARD3	-0.78	-10.99	-0.56	2.12e-23	Asthma;
CESC	cis	rs7089973	0.604	rs11196936	chr10:116588630	C/T	cg23260525	chr10:116636907	FAM160B1	0.4	7.19	0.4	6.76e-12	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs7560272	0.501	rs11894953	chr2:73964631	A/G	cg20560298	chr2:73613845	ALMS1	-0.41	-5.66	-0.33	3.97e-8	Schizophrenia;
CESC	cis	rs7666738	0.791	rs4699324	chr4:98967496	G/A	cg03676636	chr4:99064102	C4orf37	0.33	5.17	0.3	4.54e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs7107217	1.000	rs1873872	chr11:129473993	A/T	cg16714605	chr19:10765132	ILF3;LOC147727	0.44	6.16	0.35	2.62e-9	Breast cancer;Type 2 diabetes;
CESC	cis	rs208520	0.690	rs4710564	chr6:66823478	A/G	cg07460842	chr6:66804631	NA	0.92	10.96	0.56	2.59e-23	Exhaled nitric oxide output;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12177922	chr1:154245232	HAX1	0.57	7.3	0.41	3.34e-12	Gut microbiome composition (summer);
CESC	cis	rs853679	0.546	rs200981	chr6:27833174	A/G	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.87	7.6	0.42	5.06e-13	Depression;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02051553	chr1:10044519	NMNAT1	-0.59	-7.06	-0.4	1.48e-11	Gut microbiome composition (summer);
CESC	cis	rs60154123	0.505	rs1319435	chr1:210047618	C/T	cg21951975	chr1:209979733	IRF6	-0.58	-6.27	-0.36	1.47e-9	Coronary artery disease;
CESC	cis	rs1448094	0.511	rs11117042	chr12:86207547	G/T	cg00310523	chr12:86230176	RASSF9	0.38	5.9	0.34	1.11e-8	Major depressive disorder;
CESC	cis	rs6912958	0.559	rs395358	chr6:88057924	T/C	cg04972856	chr6:88032051	C6orf162;GJB7	0.35	5.74	0.33	2.6e-8	Monocyte percentage of white cells;
CESC	cis	rs4665809	0.618	rs7579199	chr2:26266496	G/A	cg08470875	chr2:26401718	FAM59B	-0.48	-5.21	-0.3	3.8e-7	Gut microbiome composition (summer);
CESC	cis	rs2228479	1.000	rs62052213	chr16:89991963	C/T	cg00800038	chr16:89945340	TCF25	-0.92	-7.39	-0.41	1.97e-12	Skin colour saturation;
CESC	trans	rs7039247	0.659	rs12352824	chr9:1267148	C/T	cg04148091	chr16:81348876	GAN	0.45	6.04	0.35	5.13e-9	Stem cell factor levels;
CESC	cis	rs2455799	0.613	rs3924773	chr3:15796853	G/A	cg09340198	chr3:15902540	ANKRD28	-0.33	-5.16	-0.3	4.94e-7	Mean platelet volume;
CESC	trans	rs2963826	0.589	rs298091	chr5:58996603	A/T	cg08052428	chr9:135996421	RALGDS	0.47	6.18	0.35	2.4e-9	Obesity-related traits;
CESC	cis	rs11098499	0.954	rs7437420	chr4:120312903	A/G	cg24375607	chr4:120327624	NA	0.46	5.55	0.32	6.98e-8	Corneal astigmatism;
CESC	cis	rs7666738	0.830	rs28887893	chr4:98963006	G/A	cg17366294	chr4:99064904	C4orf37	0.6	8.52	0.46	1.2e-15	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10802521	chr3:52805072	NEK4	0.57	6.26	0.36	1.53e-9	Gut microbiome composition (summer);
CESC	cis	rs7193541	0.694	rs8061942	chr16:74691362	C/T	cg01733217	chr16:74700730	RFWD3	1.05	20.24	0.78	1.06e-55	Multiple myeloma;
CESC	cis	rs40363	0.645	rs1690447	chr16:3519211	T/C	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.46	-5.63	-0.33	4.62e-8	Tuberculosis;
CESC	cis	rs533581	0.873	rs555191	chr16:88978850	C/T	cg16701003	chr16:89028210	CBFA2T3	0.6	8.5	0.46	1.41e-15	Social autistic-like traits;
CESC	cis	rs7216064	1.000	rs8071463	chr17:65938655	C/T	cg12091567	chr17:66097778	LOC651250	0.69	7.54	0.42	7.42e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs734999	0.545	rs28690427	chr1:2571823	A/G	cg20673091	chr1:2541236	MMEL1	-0.48	-8.03	-0.44	3.11e-14	Ulcerative colitis;
CESC	cis	rs2576037	0.583	rs11659693	chr18:44458733	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.52	-7.14	-0.4	9.22e-12	Personality dimensions;
CESC	cis	rs736408	0.546	rs3733046	chr3:52621627	C/T	cg18099408	chr3:52552593	STAB1	-0.31	-5.18	-0.3	4.46e-7	Bipolar disorder;
CESC	cis	rs748404	0.604	rs2278857	chr15:43632549	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.56	8.76	0.47	2.39e-16	Lung cancer;
CESC	cis	rs9549367	0.756	rs9549702	chr13:113881944	T/G	cg00898013	chr13:113819073	PROZ	-0.52	-7.32	-0.41	2.88e-12	Platelet distribution width;
CESC	cis	rs7044106	0.734	rs12553070	chr9:123485266	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.34	5.47	0.32	1.06e-7	Hip circumference adjusted for BMI;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg09212610	chr15:90892496	GABARAPL3	0.52	7.32	0.41	3.05e-12	Fibrinogen levels;
CESC	cis	rs7824557	0.603	rs2246606	chr8:11219334	G/A	cg21775007	chr8:11205619	TDH	0.56	7.98	0.44	4.53e-14	Retinal vascular caliber;
CESC	cis	rs7818345	0.967	rs4391454	chr8:19275653	T/C	cg11303988	chr8:19266685	CSGALNACT1	0.34	6.19	0.36	2.31e-9	Language performance in older adults (adjusted for episodic memory);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04343394	chr6:10695072	C6orf52;PAK1IP1	0.56	6.55	0.37	3.04e-10	Gut microbiome composition (summer);
CESC	cis	rs1448094	0.533	rs7307617	chr12:86151317	T/C	cg02569458	chr12:86230093	RASSF9	-0.42	-6.48	-0.37	4.48e-10	Major depressive disorder;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04100724	chr12:92539208	BTG1	0.5	6.68	0.38	1.42e-10	Gut microbiota (bacterial taxa);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg16924120	chr12:118814149	SUDS3	-0.46	-6.66	-0.38	1.58e-10	Gambling;
CESC	cis	rs6674176	0.597	rs4031031	chr1:44393533	C/T	cg13606994	chr1:44402422	ARTN	-0.41	-6.5	-0.37	3.91e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25851803	chr17:79481404	NA	-0.58	-6.55	-0.37	2.92e-10	Gut microbiome composition (summer);
CESC	cis	rs8060686	0.858	rs1109166	chr16:67977382	T/C	cg26727032	chr16:67993705	SLC12A4	-0.62	-8.97	-0.48	5.52e-17	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs561341	0.941	rs7215147	chr17:30266711	G/A	cg19193384	chr17:30244184	NA	-0.5	-5.87	-0.34	1.29e-8	Hip circumference adjusted for BMI;
CESC	cis	rs1050631	0.960	rs1789516	chr18:33691688	T/A	cg25426722	chr18:33708991	SLC39A6;ELP2	0.44	5.7	0.33	3.22e-8	Esophageal squamous cell cancer (length of survival);
CESC	cis	rs3741798	1.000	rs55865572	chr12:12497333	T/C	cg08615371	chr12:12503544	MANSC1	0.79	5.65	0.33	4.22e-8	Cerebrospinal fluid biomarker levels;
CESC	cis	rs9467711	0.606	rs9379857	chr6:26367654	G/C	cg12826209	chr6:26865740	GUSBL1	0.62	5.22	0.31	3.66e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs2075371	0.863	rs12672691	chr7:133954431	C/T	cg11752832	chr7:134001865	SLC35B4	0.51	6.55	0.37	3.04e-10	Mean platelet volume;
CESC	cis	rs7904368	0.951	rs7074647	chr10:16855455	T/C	cg23933602	chr10:16859644	RSU1	0.79	8.26	0.45	6.99e-15	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
CESC	cis	rs728616	0.614	rs17678338	chr10:82098146	C/T	cg05935833	chr10:81318306	SFTPA2	-0.48	-6.05	-0.35	4.99e-9	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs11676348	0.755	rs13410318	chr2:219022910	T/G	cg00012203	chr2:219082015	ARPC2	0.57	7.33	0.41	2.75e-12	Ulcerative colitis;
CESC	cis	rs2243480	1.000	rs313802	chr7:65516373	A/G	cg18252515	chr7:66147081	NA	-1.25	-12.55	-0.61	1.18e-28	Diabetic kidney disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03517506	chr2:97778174	ANKRD36	-0.56	-7.14	-0.4	9.03e-12	Gut microbiome composition (summer);
CESC	cis	rs7937682	0.961	rs11828343	chr11:111491322	A/G	cg09085632	chr11:111637200	PPP2R1B	0.91	12.11	0.6	3.68e-27	Primary sclerosing cholangitis;
CESC	cis	rs1552244	0.810	rs6809572	chr3:10100145	G/A	cg08888203	chr3:10149979	C3orf24	0.53	6.52	0.37	3.48e-10	Alzheimer's disease;
CESC	cis	rs17021463	0.673	rs17377118	chr4:95285622	G/A	cg11021082	chr4:95130006	SMARCAD1	0.5	6.9	0.39	3.75e-11	Testicular germ cell tumor;
CESC	cis	rs3126085	0.877	rs1552992	chr1:152171625	C/G	cg03465714	chr1:152285911	FLG	-0.43	-5.28	-0.31	2.72e-7	Atopic dermatitis;
CESC	cis	rs10905065	0.965	rs10737019	chr10:5783733	G/A	cg11519256	chr10:5708881	ASB13	0.45	6.04	0.35	5.07e-9	Menopause (age at onset);
CESC	cis	rs1153858	1.000	rs7179743	chr15:45638331	G/C	cg14582100	chr15:45693742	SPATA5L1	0.42	6.08	0.35	4.2e-9	Homoarginine levels;
CESC	cis	rs7264396	0.563	rs2425130	chr20:34335059	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.89	-10.73	-0.55	1.57e-22	Total cholesterol levels;
CESC	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg24503407	chr1:205819492	PM20D1	0.82	13.21	0.63	5.8e-31	Menarche (age at onset);
CESC	cis	rs7208859	0.673	rs7211776	chr17:29120196	T/G	cg04154034	chr17:28927549	LRRC37B2	0.55	5.24	0.31	3.25e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs425277	0.583	rs4648807	chr1:2040898	A/G	cg16545954	chr1:2118288	C1orf86	-0.3	-5.85	-0.34	1.46e-8	Height;
CESC	cis	rs6952808	0.692	rs59619245	chr7:2068630	C/T	cg02951883	chr7:2050386	MAD1L1	-0.53	-7.08	-0.4	1.29e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs4727027	0.933	rs917122	chr7:148848257	T/C	cg23583168	chr7:148888333	NA	-0.81	-12.66	-0.61	4.98e-29	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs12791968	0.765	rs2279359	chr11:44999605	A/G	cg11846598	chr11:44996168	LOC221122	0.46	5.64	0.33	4.25e-8	Inhibitory control;
CESC	cis	rs6460942	1.000	rs62448562	chr7:12398785	T/C	cg02935154	chr7:12443704	VWDE	-0.58	-5.83	-0.34	1.62e-8	Coronary artery disease;
CESC	cis	rs8067354	0.574	rs1292043	chr17:57934169	A/G	cg02344993	chr17:57696989	CLTC	0.57	5.91	0.34	1.03e-8	Hemoglobin concentration;
CESC	cis	rs1707322	0.686	rs1084086	chr1:46041100	A/C	cg06784218	chr1:46089804	CCDC17	-0.41	-7.23	-0.41	5.17e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs704795	0.805	rs1728926	chr2:27612937	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.28	-5.64	-0.33	4.41e-8	Menopause (age at onset);
CESC	cis	rs13256369	1.000	rs13282915	chr8:8570891	T/G	cg18904891	chr8:8559673	CLDN23	0.7	8.26	0.45	7.1e-15	Obesity-related traits;
CESC	cis	rs7927592	0.913	rs12285993	chr11:68302538	A/G	cg20283391	chr11:68216788	NA	-0.62	-7.44	-0.42	1.42e-12	Total body bone mineral density;
CESC	cis	rs12530845	0.673	rs73721607	chr7:135335822	C/T	cg23117316	chr7:135346802	PL-5283	-0.55	-6.16	-0.35	2.7e-9	Red blood cell traits;
CESC	cis	rs78707713	0.512	rs35793747	chr10:71182165	A/G	cg12610070	chr10:71211762	TSPAN15	-0.37	-7.75	-0.43	1.98e-13	Venous thromboembolism;
CESC	cis	rs853679	0.607	rs13197574	chr6:28060239	T/C	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.83	5.09	0.3	6.76e-7	Depression;
CESC	cis	rs677665	0.537	rs72641832	chr1:9336116	C/A	cg25755851	chr1:9335794	NA	0.97	14.24	0.66	1.49e-34	Eosinophil percentage of white cells;
CESC	cis	rs36051895	0.587	rs7035915	chr9:5238253	C/T	cg02405213	chr9:5042618	JAK2	-0.56	-6.81	-0.39	6.66e-11	Pediatric autoimmune diseases;
CESC	cis	rs7818345	1.000	rs7833166	chr8:19294634	C/T	cg11303988	chr8:19266685	CSGALNACT1	0.35	6.31	0.36	1.14e-9	Language performance in older adults (adjusted for episodic memory);
CESC	cis	rs2668423	0.922	rs3826942	chr19:1360575	A/G	cg02639931	chr19:1387894	NDUFS7	0.46	7.04	0.4	1.64e-11	Nonalcoholic fatty liver disease;
CESC	cis	rs9300255	0.537	rs1790101	chr12:123704844	T/C	cg05973401	chr12:123451056	ABCB9	0.5	5.68	0.33	3.48e-8	Neutrophil percentage of white cells;
CESC	cis	rs4268898	0.662	rs2891382	chr2:24511491	C/G	cg06627628	chr2:24431161	ITSN2	-0.96	-11.13	-0.56	7.18e-24	Asthma;
CESC	trans	rs7819412	0.521	rs2409720	chr8:11037903	A/C	cg06636001	chr8:8085503	FLJ10661	-0.55	-6.53	-0.37	3.25e-10	Triglycerides;
CESC	cis	rs7481584	0.626	rs2071103	chr11:3040087	C/T	cg08508325	chr11:3079039	CARS	0.29	5.03	0.3	8.92e-7	Calcium levels;
CESC	cis	rs35146811	0.771	rs6465762	chr7:99620554	G/A	cg22906224	chr7:99728672	NA	0.49	5.77	0.33	2.23e-8	Coronary artery disease;
CESC	cis	rs7223966	1.000	rs7216798	chr17:61740963	G/A	cg11494091	chr17:61959527	GH2	0.38	5.35	0.31	1.93e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs6460942	0.915	rs17444141	chr7:12460971	T/G	cg20607287	chr7:12443886	VWDE	-0.78	-9.15	-0.49	1.61e-17	Coronary artery disease;
CESC	cis	rs7044106	0.762	rs3903886	chr9:123383646	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.77	-12.08	-0.6	4.56e-27	Hip circumference adjusted for BMI;
CESC	cis	rs6502050	0.731	rs9892653	chr17:80100191	G/T	cg23985595	chr17:80112537	CCDC57	-0.42	-6.57	-0.37	2.72e-10	Life satisfaction;
CESC	cis	rs9300255	0.568	rs1627724	chr12:123638580	T/A	cg19016782	chr12:123741754	C12orf65	-0.4	-5.74	-0.33	2.64e-8	Neutrophil percentage of white cells;
CESC	cis	rs854765	0.583	rs8065970	chr17:17858771	A/G	cg16928487	chr17:17741425	SREBF1	-0.57	-9.57	-0.51	7.66e-19	Total body bone mineral density;
CESC	cis	rs7267979	1.000	rs11100	chr20:25281184	G/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	18.72	0.75	2.09e-50	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs10791323	0.628	rs10750543	chr11:133718467	G/A	cg15485101	chr11:133734466	NA	0.36	5.89	0.34	1.17e-8	Childhood ear infection;
CESC	cis	rs8014204	1.000	rs8014204	chr14:75322794	A/G	cg11812906	chr14:75593930	NEK9	0.44	5.48	0.32	1.01e-7	Caffeine consumption;
CESC	cis	rs7845219	0.544	rs9643352	chr8:95918288	C/T	cg09323728	chr8:95962352	TP53INP1	-0.32	-6.23	-0.36	1.8e-9	Type 2 diabetes;
CESC	cis	rs2191566	0.691	rs8104605	chr19:44589016	C/T	cg20607764	chr19:44506953	ZNF230	0.45	5.6	0.33	5.31e-8	Acute lymphoblastic leukemia (childhood);
CESC	trans	rs916888	0.610	rs199454	chr17:44800110	G/A	cg01341218	chr17:43662625	NA	-0.52	-6.78	-0.38	7.67e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs6901004	0.772	rs191632	chr6:111544882	C/T	cg15721981	chr6:111408429	SLC16A10	-0.36	-5.18	-0.3	4.3e-7	Blood metabolite levels;
CESC	cis	rs11711311	1.000	rs9863050	chr3:113508888	C/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.69	9.48	0.5	1.48e-18	IgG glycosylation;
CESC	cis	rs4665809	0.652	rs6727974	chr2:26524639	A/G	cg26119090	chr2:26468346	HADHA;HADHB	0.62	6.63	0.38	1.93e-10	Gut microbiome composition (summer);
CESC	cis	rs6840258	0.825	rs72667751	chr4:87936379	C/T	cg08197287	chr4:87952173	AFF1	-0.4	-5.4	-0.31	1.48e-7	Mean corpuscular volume;Basophil percentage of granulocytes;
CESC	cis	rs7818688	1.000	rs6985880	chr8:96027599	A/G	cg16049864	chr8:95962084	TP53INP1	0.6	5.77	0.33	2.25e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	trans	rs459571	0.959	rs416390	chr9:136908549	C/G	cg09836344	chr4:1243392	C4orf42;CTBP1	0.66	8.78	0.47	2.08e-16	Platelet distribution width;
CESC	cis	rs9322193	0.923	rs4870529	chr6:150037572	A/G	cg04369109	chr6:150039330	LATS1	-0.39	-5.43	-0.32	1.28e-7	Lung cancer;
CESC	cis	rs1707322	1.000	rs11211244	chr1:46456673	G/A	cg05343316	chr1:45956843	TESK2	0.44	5.42	0.32	1.36e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs17125944	0.686	rs77650471	chr14:53364307	C/T	cg00686598	chr14:53173677	PSMC6	0.96	7.21	0.41	5.77e-12	Alzheimer's disease (late onset);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg13762774	chr10:32048991	NA	-0.46	-6.81	-0.39	6.37e-11	Gambling;
CESC	cis	rs55728055	0.661	rs62237798	chr22:31976839	G/T	cg01338084	chr22:32026380	PISD	1.22	8.02	0.44	3.48e-14	Age-related hearing impairment;
CESC	cis	rs9916302	0.904	rs10221223	chr17:37489100	T/G	cg15445000	chr17:37608096	MED1	-0.42	-6.67	-0.38	1.49e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs7208859	0.623	rs9899692	chr17:29156939	C/T	cg19761014	chr17:28927070	LRRC37B2	0.74	6.03	0.35	5.43e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs2299587	0.623	rs7816738	chr8:17768482	A/G	cg08627089	chr8:17753878	FGL1	-0.4	-5.44	-0.32	1.19e-7	Economic and political preferences;
CESC	cis	rs9910055	0.659	rs227578	chr17:42210189	C/A	cg19774624	chr17:42201019	HDAC5	0.9	15.0	0.68	3.16e-37	Total body bone mineral density;
CESC	cis	rs7116495	0.609	rs2503	chr11:71719403	C/T	cg07596299	chr11:71824057	C11orf51	0.74	5.16	0.3	4.92e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs6500395	1.000	rs6500397	chr16:48642235	T/C	cg04672837	chr16:48644449	N4BP1	0.51	6.21	0.36	2.03e-9	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs10465746	0.901	rs17475760	chr1:84398435	A/T	cg10977910	chr1:84465055	TTLL7	0.47	6.39	0.37	7.37e-10	Obesity-related traits;
CESC	trans	rs17685	0.753	rs1637045	chr7:75703895	T/C	cg19862616	chr7:65841803	NCRNA00174	0.87	12.74	0.62	2.5e-29	Coffee consumption;Coffee consumption (cups per day);
CESC	trans	rs7427021	0.967	rs11709545	chr3:163737754	A/C	cg07975705	chr5:114961891	TMED7-TICAM2;TMED7	-0.42	-6.14	-0.35	3.03e-9	Bipolar disorder;
CESC	trans	rs11098499	0.691	rs12502524	chr4:120271414	G/A	cg25214090	chr10:38739885	LOC399744	0.6	8.3	0.45	5.33e-15	Corneal astigmatism;
CESC	trans	rs72996113	0.702	rs78901113	chr11:100568439	G/A	cg01999051	chr6:166797738	BRP44L	0.7	6.08	0.35	4.17e-9	Reticulocyte fraction of red cells;Reticulocyte count;
CESC	cis	rs2549003	1.000	rs6873426	chr5:131818631	G/T	cg21138405	chr5:131827807	IRF1	0.54	9.25	0.49	8e-18	Asthma (sex interaction);
CESC	cis	rs6964587	0.655	rs6965864	chr7:91595596	A/G	cg17063962	chr7:91808500	NA	0.46	6.49	0.37	4.29e-10	Breast cancer;
CESC	cis	rs2836974	0.533	rs418298	chr21:40536654	A/T	cg11644478	chr21:40555479	PSMG1	0.83	12.83	0.62	1.29e-29	Cognitive function;
CESC	cis	rs1799949	1.000	rs11653069	chr17:41283377	C/T	cg25072359	chr17:41440525	NA	0.43	5.83	0.34	1.61e-8	Menopause (age at onset);
CESC	cis	rs72781680	0.898	rs112985192	chr2:24102797	G/A	cg20701182	chr2:24300061	SF3B14	0.63	5.72	0.33	2.93e-8	Lymphocyte counts;
CESC	cis	rs1832871	0.672	rs12529235	chr6:158766950	A/G	cg07165851	chr6:158734300	TULP4	0.58	6.19	0.36	2.31e-9	Height;
CESC	cis	rs2075371	0.966	rs2544225	chr7:133995838	A/C	cg20476274	chr7:133979776	SLC35B4	0.67	9.82	0.52	1.26e-19	Mean platelet volume;
CESC	cis	rs1448094	0.512	rs7960130	chr12:86243191	T/C	cg19622623	chr12:86230825	RASSF9	-0.46	-5.89	-0.34	1.2e-8	Major depressive disorder;
CESC	cis	rs34286592	0.929	rs9939514	chr16:29855731	G/A	cg27338089	chr16:29820515	MAZ	0.48	5.04	0.3	8.68e-7	Multiple sclerosis;
CESC	cis	rs1577917	0.740	rs2842604	chr6:86336300	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.52	-6.94	-0.39	2.99e-11	Response to antipsychotic treatment;
CESC	cis	rs2370759	1.000	rs79578760	chr10:32611264	C/A	cg01819863	chr10:32635814	EPC1	1.16	12.51	0.61	1.58e-28	Sexual dysfunction (female);
CESC	cis	rs1707322	1.000	rs4539075	chr1:46358010	C/T	cg03146154	chr1:46216737	IPP	0.71	9.86	0.52	9.69e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs736408	0.609	rs1029871	chr3:52797634	G/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.3	0.36	1.22e-9	Bipolar disorder;
CESC	cis	rs9486715	1.000	rs9373985	chr6:97063522	C/G	cg18709589	chr6:96969512	KIAA0776	-0.46	-6.39	-0.37	7.34e-10	Headache;
CESC	cis	rs6674176	0.660	rs12726706	chr1:44399942	G/A	cg12908607	chr1:44402522	ARTN	-0.49	-7.35	-0.41	2.39e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs9916302	0.904	rs6503503	chr17:37514373	G/A	cg07936489	chr17:37558343	FBXL20	0.78	10.7	0.55	1.93e-22	Glomerular filtration rate (creatinine);
CESC	cis	rs861020	0.677	rs2049998	chr1:210031154	C/T	cg05527609	chr1:210001259	C1orf107	-1.02	-12.03	-0.59	6.72e-27	Orofacial clefts;
CESC	cis	rs1008375	0.932	rs6449315	chr4:17590219	A/G	cg02297831	chr4:17616191	MED28	0.54	6.26	0.36	1.5e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs7918232	0.943	rs4747584	chr10:27373333	G/A	cg14442939	chr10:27389572	ANKRD26	0.7	6.5	0.37	4.04e-10	Breast cancer;
CESC	cis	rs13294100	0.929	rs10435770	chr9:17581168	C/G	cg11213383	chr9:17579734	SH3GL2	-0.36	-5.58	-0.32	5.98e-8	Parkinson's disease;
CESC	cis	rs1153858	1.000	rs4627277	chr15:45652768	C/A	cg21132104	chr15:45694354	SPATA5L1	0.85	11.64	0.58	1.47e-25	Homoarginine levels;
CESC	trans	rs7937682	0.889	rs493865	chr11:111495178	A/C	cg18187862	chr3:45730750	SACM1L	0.47	5.99	0.35	6.68e-9	Primary sclerosing cholangitis;
CESC	cis	rs9583531	0.600	rs6492305	chr13:111361400	C/T	cg15841412	chr13:111365552	ING1	0.52	6.74	0.38	1.01e-10	Coronary artery disease;
CESC	cis	rs11030122	0.702	rs17279635	chr11:3973083	A/C	cg18678763	chr11:4115507	RRM1	0.48	6.48	0.37	4.42e-10	Mean platelet volume;Platelet distribution width;
CESC	cis	rs270601	0.739	rs3900945	chr5:131592870	T/C	cg11843238	chr5:131593191	PDLIM4	0.38	5.6	0.33	5.25e-8	Acylcarnitine levels;
CESC	cis	rs832540	0.669	rs832539	chr5:56199386	A/C	cg24549020	chr5:56110836	MAP3K1	0.41	5.13	0.3	5.53e-7	Coronary artery disease;
CESC	cis	rs7264396	0.528	rs7273880	chr20:34551507	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.52	6.2	0.36	2.18e-9	Total cholesterol levels;
CESC	cis	rs12142240	0.698	rs41294478	chr1:46818442	G/A	cg00530320	chr1:46809349	NSUN4	0.58	7.89	0.44	8.15e-14	Menopause (age at onset);
CESC	cis	rs11252926	0.966	rs61831030	chr10:578869	C/T	cg16386425	chr10:429943	DIP2C	0.47	5.04	0.3	8.44e-7	Psychosis in Alzheimer's disease;
CESC	cis	rs1348850	1.000	rs3927978	chr2:178443854	A/G	cg22681709	chr2:178499509	PDE11A	0.36	5.6	0.33	5.35e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12730826	chr1:205179972	DSTYK	0.55	6.04	0.35	5.26e-9	Gut microbiome composition (summer);
CESC	cis	rs9467711	0.606	rs9379858	chr6:26367689	T/C	cg12826209	chr6:26865740	GUSBL1	0.62	5.22	0.31	3.66e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs9914988	0.832	rs12946132	chr17:27157362	T/C	cg20469991	chr17:27169893	C17orf63	-0.48	-5.25	-0.31	3.18e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CESC	cis	rs7659604	0.540	rs4833775	chr4:122716826	T/C	cg19748678	chr4:122722346	EXOSC9	-0.43	-5.3	-0.31	2.47e-7	Type 2 diabetes;
CESC	cis	rs7772486	0.902	rs1331643	chr6:146398873	T/A	cg05347473	chr6:146136440	FBXO30	0.47	6.54	0.37	3.1e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs5757676	1.000	rs5757676	chr22:39841700	T/C	cg24399712	chr22:39784796	NA	-0.81	-8.7	-0.47	3.49e-16	IgG glycosylation;
CESC	trans	rs61931739	0.500	rs7955247	chr12:34126580	G/A	cg26384229	chr12:38710491	ALG10B	0.6	8.43	0.46	2.28e-15	Morning vs. evening chronotype;
CESC	cis	rs7666738	0.830	rs7659006	chr4:98934529	T/C	cg17366294	chr4:99064904	C4orf37	0.61	8.56	0.47	9.36e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs477895	0.653	rs72918475	chr11:63878644	G/C	cg04317338	chr11:64019027	PLCB3	0.82	8.4	0.46	2.83e-15	Mean platelet volume;
CESC	cis	rs870825	0.860	rs72703521	chr4:185603080	T/C	cg04058563	chr4:185651563	MLF1IP	0.54	5.24	0.31	3.27e-7	Blood protein levels;
CESC	cis	rs13191362	1.000	rs67646369	chr6:163003233	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.88	9.16	0.49	1.46e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	trans	rs4950322	0.542	rs56080828	chr1:146655026	G/A	cg04954894	chr8:38089920	DDHD2	-0.62	-6.39	-0.37	7.45e-10	Protein quantitative trait loci;
CESC	cis	rs1801251	1.000	rs36007169	chr2:233621834	A/G	cg08000102	chr2:233561755	GIGYF2	0.67	9.48	0.5	1.53e-18	Coronary artery disease;
CESC	cis	rs875971	0.545	rs10950027	chr7:65634151	C/T	cg19163074	chr7:65112434	INTS4L2	-0.46	-5.05	-0.3	8.07e-7	Aortic root size;
CESC	cis	rs6977955	0.838	rs917115	chr7:28172586	T/C	cg23620719	chr7:28220237	JAZF1	0.53	5.99	0.35	6.92e-9	Allergic disease (asthma, hay fever or eczema);
CESC	trans	rs208520	0.690	rs12202805	chr6:66703903	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.94	-12.44	-0.61	2.68e-28	Exhaled nitric oxide output;
CESC	cis	rs858239	0.601	rs73272048	chr7:23152653	C/G	cg23682824	chr7:23144976	KLHL7	0.55	7.73	0.43	2.24e-13	Cerebrospinal fluid biomarker levels;
CESC	cis	rs11864453	0.713	rs9925763	chr16:72142595	C/A	cg01557791	chr16:72042693	DHODH	-0.48	-6.32	-0.36	1.08e-9	Fibrinogen levels;
CESC	cis	rs7927771	0.832	rs10838704	chr11:47424717	T/C	cg05585544	chr11:47624801	NA	-0.51	-7.28	-0.41	3.77e-12	Subjective well-being;
CESC	cis	rs1144333	0.737	rs1144339	chr1:76280543	A/G	cg10523679	chr1:76189770	ACADM	-0.57	-5.44	-0.32	1.22e-7	Attention function in attention deficit hyperactive disorder;
CESC	cis	rs4853012	0.838	rs58759652	chr2:74344902	A/T	cg05890377	chr2:74357713	NA	0.77	10.42	0.54	1.51e-21	Gestational age at birth (maternal effect);
CESC	cis	rs13108904	0.517	rs4974551	chr4:1336410	C/A	cg00684032	chr4:1343700	KIAA1530	0.56	8.52	0.46	1.19e-15	Obesity-related traits;
CESC	cis	rs910316	0.763	rs175047	chr14:75479039	C/G	cg08847533	chr14:75593920	NEK9	-0.9	-15.92	-0.7	1.65e-40	Height;
CESC	cis	rs7666738	0.830	rs34890015	chr4:99023769	A/T	cg17366294	chr4:99064904	C4orf37	0.61	8.77	0.47	2.15e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9911578	0.867	rs4793941	chr17:56472366	G/A	cg25039879	chr17:56429692	SUPT4H1	-0.39	-5.1	-0.3	6.37e-7	Intelligence (multi-trait analysis);
CESC	cis	rs910316	0.699	rs175039	chr14:75468950	G/C	cg16144293	chr14:75469539	EIF2B2	0.43	5.67	0.33	3.79e-8	Height;
CESC	trans	rs116095464	0.558	rs10052012	chr5:231908	T/C	cg00938859	chr5:1591904	SDHAP3	0.63	6.87	0.39	4.49e-11	Breast cancer;
CESC	cis	rs9649465	0.561	rs2429618	chr7:123421662	G/A	cg03229431	chr7:123269106	ASB15	0.4	5.59	0.32	5.75e-8	Migraine;
CESC	cis	rs2841277	0.676	rs10438246	chr14:105410183	T/C	cg14403583	chr14:105418241	AHNAK2	-0.58	-8.06	-0.44	2.55e-14	Rheumatoid arthritis;
CESC	cis	rs4908768	0.501	rs1024197	chr1:8537058	C/G	cg00120948	chr1:8484417	RERE	-0.34	-5.23	-0.31	3.51e-7	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
CESC	trans	rs11098499	0.754	rs34425882	chr4:120253177	G/A	cg25214090	chr10:38739885	LOC399744	0.62	8.7	0.47	3.58e-16	Corneal astigmatism;
CESC	trans	rs10242455	0.702	rs73397481	chr7:99030108	C/T	cg09045935	chr12:6379348	NA	0.9	6.02	0.35	5.93e-9	Blood metabolite levels;
CESC	cis	rs9926296	0.607	rs11076629	chr16:89875259	T/C	cg27121462	chr16:89883253	FANCA	0.57	7.08	0.4	1.28e-11	Vitiligo;
CESC	cis	rs2963155	0.518	rs853178	chr5:142634799	C/T	cg17617527	chr5:142782415	NR3C1	0.84	7.69	0.43	2.95e-13	Breast cancer;
CESC	cis	rs7959452	0.590	rs7968629	chr12:69782857	G/A	cg22834771	chr12:69754056	YEATS4	-0.48	-6.46	-0.37	4.87e-10	Blood protein levels;
CESC	cis	rs9354308	0.899	rs2814094	chr6:66536275	G/T	cg07460842	chr6:66804631	NA	-0.56	-6.45	-0.37	5.17e-10	Metabolite levels;
CESC	cis	rs11098499	0.566	rs7664440	chr4:120578540	A/G	cg09307838	chr4:120376055	NA	0.75	9.42	0.5	2.26e-18	Corneal astigmatism;
CESC	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg18538332	chr22:24372958	LOC391322	-0.78	-11.44	-0.58	6.57e-25	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs798554	0.610	rs1182173	chr7:2878016	C/G	cg13628971	chr7:2884303	GNA12	0.38	5.11	0.3	6.26e-7	Height;
CESC	trans	rs9388451	0.626	rs3799708	chr6:126078530	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.66	-9.21	-0.49	1e-17	Brugada syndrome;
CESC	cis	rs12464559	0.579	rs2293221	chr2:152653380	C/T	cg01189475	chr2:152685088	ARL5A	0.66	5.81	0.34	1.74e-8	Response to cognitive-behavioural therapy in anxiety disorder;
CESC	cis	rs9322193	0.962	rs9765929	chr6:150090816	T/C	cg07701084	chr6:150067640	NUP43	0.44	5.92	0.34	9.71e-9	Lung cancer;
CESC	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg10150615	chr22:24372951	LOC391322	-0.59	-8.05	-0.44	2.87e-14	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs3793683	0.928	rs10781585	chr10:134553369	C/A	cg18305652	chr10:134549665	INPP5A	-0.34	-5.41	-0.32	1.4e-7	Migraine;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg13777502	chr17:66031814	KPNA2	-0.46	-6.76	-0.38	9.02e-11	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs9467773	0.549	rs9461273	chr6:26584526	A/G	cg26531700	chr6:26746687	NA	0.35	5.36	0.31	1.78e-7	Intelligence (multi-trait analysis);
CESC	cis	rs9325144	0.647	rs4616077	chr12:39092364	T/C	cg26384229	chr12:38710491	ALG10B	-0.5	-6.9	-0.39	3.79e-11	Morning vs. evening chronotype;
CESC	cis	rs7267979	0.966	rs2263204	chr20:25377688	A/T	cg08601574	chr20:25228251	PYGB	-0.36	-5.05	-0.3	8.36e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs1577917	0.771	rs9362230	chr6:86305013	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.56	-7.8	-0.43	1.46e-13	Response to antipsychotic treatment;
CESC	cis	rs9486715	0.867	rs4839687	chr6:96951732	C/A	cg06623918	chr6:96969491	KIAA0776	0.93	14.38	0.66	4.75e-35	Headache;
CESC	cis	rs7312933	1.000	rs10880230	chr12:42450253	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.41	5.36	0.31	1.81e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs2806561	0.765	rs4333826	chr1:23517514	C/T	cg12483005	chr1:23474871	LUZP1	0.38	6.0	0.35	6.44e-9	Height;
CESC	cis	rs425277	0.606	rs262663	chr1:2084598	T/C	cg24578937	chr1:2090814	PRKCZ	0.36	6.49	0.37	4.11e-10	Height;
CESC	cis	rs914615	0.552	rs4971089	chr1:155142927	A/G	cg02153340	chr1:155202674	NA	-0.37	-5.39	-0.31	1.54e-7	Urinary albumin-to-creatinine ratio;
CESC	cis	rs769267	0.930	rs3794990	chr19:19610030	A/G	cg03709012	chr19:19516395	GATAD2A	1.01	15.71	0.69	9.73e-40	Tonsillectomy;
CESC	cis	rs73206853	0.764	rs970228	chr12:111070169	G/C	cg12870014	chr12:110450643	ANKRD13A	0.64	5.49	0.32	9.25e-8	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14337668	chr9:99883682	NA	-0.47	-6.42	-0.37	6.09e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs11098499	0.564	rs11098507	chr4:120288286	G/A	cg24375607	chr4:120327624	NA	0.42	5.2	0.3	3.94e-7	Corneal astigmatism;
CESC	cis	rs1552244	1.000	rs12152515	chr3:10143976	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	12.89	0.62	7.89e-30	Alzheimer's disease;
CESC	cis	rs10779751	1.000	rs718206	chr1:11294474	T/A	cg08854313	chr1:11322531	MTOR	0.79	10.7	0.55	1.85e-22	Body mass index;
CESC	cis	rs1801251	1.000	rs4973054	chr2:233710713	G/C	cg08000102	chr2:233561755	GIGYF2	-0.69	-9.93	-0.52	5.72e-20	Coronary artery disease;
CESC	cis	rs7959452	0.535	rs7133487	chr12:69774377	G/A	cg14784868	chr12:69753453	YEATS4	0.84	13.42	0.64	1.11e-31	Blood protein levels;
CESC	cis	rs897080	0.515	rs1067346	chr2:44618811	C/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.51	5.94	0.34	8.71e-9	Height;
CESC	cis	rs11098499	0.588	rs2389874	chr4:120554991	A/G	cg09307838	chr4:120376055	NA	-0.66	-8.66	-0.47	4.83e-16	Corneal astigmatism;
CESC	cis	rs477692	0.544	rs7904404	chr10:131447612	G/A	cg24747557	chr10:131355152	MGMT	0.46	6.19	0.36	2.33e-9	Response to temozolomide;
CESC	cis	rs12617721	0.574	rs6542754	chr2:99025400	C/T	cg10123293	chr2:99228465	UNC50	0.4	5.37	0.31	1.76e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs7833986	0.534	rs72653928	chr8:56907735	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.58	7.23	0.41	5.33e-12	Height;
CESC	cis	rs62229266	0.563	rs6517325	chr21:37434978	T/C	cg08632701	chr21:37451849	NA	-0.4	-5.49	-0.32	9.62e-8	Mitral valve prolapse;
CESC	cis	rs9611565	0.559	rs739136	chr22:42100275	C/T	cg06481639	chr22:41940642	POLR3H	-0.59	-5.91	-0.34	1.05e-8	Vitiligo;
CESC	cis	rs6500602	0.702	rs11645519	chr16:4538989	G/A	cg08645402	chr16:4508243	NA	0.57	9.27	0.49	6.82e-18	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17961057	chr2:74645699	C2orf81	-0.61	-7.26	-0.41	4.34e-12	Gut microbiome composition (summer);
CESC	cis	rs694739	0.930	rs574087	chr11:64102948	A/G	cg02228329	chr11:64053129	BAD;GPR137	0.71	9.08	0.49	2.64e-17	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CESC	cis	rs514406	0.505	rs269287	chr1:53168842	T/C	cg24675658	chr1:53192096	ZYG11B	-0.52	-6.56	-0.37	2.89e-10	Monocyte count;
CESC	cis	rs8060686	0.565	rs55857142	chr16:68236741	A/T	cg26727032	chr16:67993705	SLC12A4	-0.52	-5.73	-0.33	2.72e-8	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs962856	0.964	rs600388	chr2:67656809	A/G	cg09028215	chr2:67624308	ETAA1	-0.39	-5.23	-0.31	3.39e-7	Pancreatic cancer;
CESC	cis	rs6032067	0.641	rs34638860	chr20:43765839	C/T	cg10761708	chr20:43804764	PI3	0.54	6.07	0.35	4.4e-9	Blood protein levels;
CESC	cis	rs6089829	0.962	rs6122344	chr20:61661738	C/T	cg03213289	chr20:61660250	NA	0.39	6.06	0.35	4.64e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs4835473	0.864	rs13101482	chr4:144910616	G/A	cg25736465	chr4:144833511	NA	0.42	6.43	0.37	6.02e-10	Immature fraction of reticulocytes;
CESC	cis	rs28374715	0.528	rs7178360	chr15:41631175	T/A	cg20272979	chr15:41787780	ITPKA	0.46	5.44	0.32	1.19e-7	Ulcerative colitis;
CESC	cis	rs2635047	0.638	rs2571008	chr18:44649950	T/C	cg19077165	chr18:44547161	KATNAL2	-0.37	-5.04	-0.3	8.63e-7	Educational attainment;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg08732623	chr10:127408269	C10orf137	-0.45	-6.21	-0.36	2.03e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs4243830	1.000	rs11809957	chr1:6584420	C/A	cg22792644	chr1:6614718	TAS1R1;NOL9	0.69	5.84	0.34	1.5e-8	Body mass index;
CESC	cis	rs11123610	0.520	rs12996655	chr2:3720900	G/A	cg19052272	chr2:3704530	ALLC	-0.48	-5.92	-0.34	1.01e-8	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CESC	cis	rs73206853	0.640	rs871921	chr12:111115113	G/C	cg12870014	chr12:110450643	ANKRD13A	0.76	7.62	0.42	4.46e-13	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs10791097	0.694	rs2236717	chr11:130739887	G/T	cg12179176	chr11:130786555	SNX19	0.64	10.04	0.52	2.69e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs11098499	0.909	rs28884220	chr4:120307211	A/G	cg24375607	chr4:120327624	NA	0.46	5.55	0.32	6.98e-8	Corneal astigmatism;
CESC	cis	rs10911251	0.546	rs2027085	chr1:183108611	G/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.82	-12.85	-0.62	1.04e-29	Colorectal cancer;
CESC	cis	rs6577655	0.517	rs62525562	chr8:135587076	C/T	cg17885191	chr8:135476712	NA	0.45	5.1	0.3	6.63e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CESC	cis	rs5758659	0.652	rs133301	chr22:42390093	C/T	cg15557168	chr22:42548783	NA	-0.43	-6.29	-0.36	1.27e-9	Cognitive function;
CESC	cis	rs7178572	0.568	rs1191196	chr15:77646504	C/T	cg22256960	chr15:77711686	NA	0.54	6.65	0.38	1.67e-10	Type 2 diabetes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10807698	chr14:103243805	TRAF3	0.66	7.69	0.43	2.91e-13	Gut microbiome composition (summer);
CESC	cis	rs7851660	0.967	rs1443434	chr9:100617479	G/T	cg13688889	chr9:100608707	NA	-0.69	-10.57	-0.54	4.92e-22	Strep throat;
CESC	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.5	0.37	3.98e-10	Prudent dietary pattern;
CESC	cis	rs6138458	1.000	rs11906373	chr20:24938832	A/G	cg06937882	chr20:24974362	C20orf3	-0.35	-5.05	-0.3	8.34e-7	Blood protein levels;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05330668	chr14:24836090	NFATC4	-0.47	-6.55	-0.37	2.99e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs7666738	0.830	rs34890015	chr4:99023769	A/T	cg05340658	chr4:99064831	C4orf37	0.82	12.87	0.62	9.16e-30	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19877921	chr17:61904685	PSMC5;FTSJ3	0.53	6.12	0.35	3.29e-9	Gut microbiome composition (summer);
CESC	cis	rs258892	0.895	rs36040109	chr5:72050659	A/G	cg21869765	chr5:72125136	TNPO1	-0.41	-5.3	-0.31	2.49e-7	Small cell lung carcinoma;
CESC	cis	rs9532580	0.710	rs9577090	chr13:41225228	G/T	cg21288729	chr13:41239152	FOXO1	0.65	8.35	0.46	3.76e-15	Mean corpuscular hemoglobin;
CESC	cis	rs12765878	1.000	rs4918067	chr10:105644636	A/C	cg11005552	chr10:105648138	OBFC1	0.36	5.29	0.31	2.51e-7	Coronary artery disease;
CESC	cis	rs2836974	0.897	rs8128102	chr21:40606414	G/A	cg11890956	chr21:40555474	PSMG1	1.17	21.95	0.8	1.41e-61	Cognitive function;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01029985	chr19:40932112	SERTAD1	-0.55	-6.26	-0.36	1.5e-9	Gut microbiome composition (summer);
CESC	cis	rs2191566	0.576	rs370809	chr19:44493830	C/T	cg20607764	chr19:44506953	ZNF230	0.44	5.58	0.32	5.9e-8	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs778371	0.723	rs12619195	chr2:233678326	G/A	cg08000102	chr2:233561755	GIGYF2	-0.84	-14.27	-0.66	1.18e-34	Schizophrenia;
CESC	cis	rs7589728	0.563	rs12479338	chr2:88444513	C/T	cg18490616	chr2:88469792	THNSL2	0.55	5.29	0.31	2.59e-7	Plasma clusterin levels;
CESC	cis	rs7666738	0.830	rs1527517	chr4:98931907	C/T	cg03467027	chr4:99064603	C4orf37	0.46	5.6	0.33	5.39e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs34779708	0.931	rs2384289	chr10:35343525	G/A	cg03585969	chr10:35415529	CREM	0.78	10.21	0.53	7.36e-21	Inflammatory bowel disease;Crohn's disease;
CESC	trans	rs7937682	1.000	rs10502147	chr11:111569931	G/A	cg18187862	chr3:45730750	SACM1L	-0.53	-6.07	-0.35	4.52e-9	Primary sclerosing cholangitis;
CESC	cis	rs919433	0.854	rs787994	chr2:198223121	T/C	cg20885578	chr2:198174922	NA	0.4	5.37	0.31	1.73e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs7000551	0.715	rs12544074	chr8:22338378	A/G	cg12081754	chr8:22256438	SLC39A14	0.45	6.09	0.35	3.97e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CESC	cis	rs3771570	1.000	rs1056801	chr2:242292307	T/C	cg21155796	chr2:242212141	HDLBP	0.6	5.18	0.3	4.5e-7	Prostate cancer;
CESC	cis	rs7615952	0.576	rs6780025	chr3:125815624	A/C	cg02807482	chr3:125708958	NA	-0.4	-5.17	-0.3	4.73e-7	Blood pressure (smoking interaction);
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg04524006	chr5:111093197	C5orf13	-0.5	-6.39	-0.37	7.28e-10	Asthma;
CESC	cis	rs13118159	0.550	rs4974614	chr4:1373489	A/G	cg20887711	chr4:1340912	KIAA1530	0.85	11.41	0.57	8.51e-25	Longevity;
CESC	cis	rs12618769	0.597	rs1847550	chr2:99052299	C/T	cg10123293	chr2:99228465	UNC50	0.41	5.42	0.32	1.31e-7	Bipolar disorder;
CESC	cis	rs17253792	0.822	rs10145687	chr14:56124384	T/C	cg01858014	chr14:56050164	KTN1	-0.71	-6.19	-0.36	2.22e-9	Putamen volume;
CESC	cis	rs7829975	0.514	rs2920991	chr8:8259117	T/A	cg15556689	chr8:8085844	FLJ10661	0.59	7.85	0.43	1.06e-13	Mood instability;
CESC	cis	rs7589342	0.628	rs12996286	chr2:106399667	A/G	cg16077055	chr2:106428750	NCK2	0.51	6.18	0.36	2.34e-9	Addiction;
CESC	cis	rs6426558	0.537	rs2718193	chr1:227404672	C/G	cg10327440	chr1:227177885	CDC42BPA	0.45	5.53	0.32	7.58e-8	Neutrophil percentage of white cells;
CESC	cis	rs6087990	0.899	rs4911107	chr20:31374991	G/A	cg13636640	chr20:31349939	DNMT3B	0.89	15.31	0.69	2.42e-38	Ulcerative colitis;
CESC	cis	rs763121	0.853	rs5757213	chr22:39053888	C/T	cg06022373	chr22:39101656	GTPBP1	0.88	13.91	0.65	2.06e-33	Menopause (age at onset);
CESC	cis	rs9308433	0.529	rs59864830	chr1:214474889	A/G	cg06198575	chr1:214491504	SMYD2	0.46	5.25	0.31	3.08e-7	IgG glycosylation;
CESC	cis	rs11098499	0.863	rs10034450	chr4:120455649	A/G	cg09307838	chr4:120376055	NA	0.91	12.54	0.61	1.24e-28	Corneal astigmatism;
CESC	cis	rs7618915	0.571	rs1961958	chr3:52585990	A/G	cg17372223	chr3:52568218	NT5DC2	0.42	6.19	0.36	2.24e-9	Bipolar disorder;
CESC	cis	rs875971	0.862	rs1083554	chr7:65852341	T/C	cg19163074	chr7:65112434	INTS4L2	-0.41	-5.11	-0.3	6.29e-7	Aortic root size;
CESC	cis	rs9488822	0.636	rs10872142	chr6:116369052	C/A	cg05304507	chr6:116381966	FRK	0.26	6.75	0.38	9.45e-11	Cholesterol, total;LDL cholesterol;
CESC	cis	rs6502050	0.835	rs7503189	chr17:80099486	C/A	cg23985595	chr17:80112537	CCDC57	-0.42	-6.57	-0.37	2.72e-10	Life satisfaction;
CESC	cis	rs11583043	0.918	rs6693456	chr1:101424561	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.49	5.51	0.32	8.62e-8	Ulcerative colitis;Inflammatory bowel disease;
CESC	cis	rs9322193	0.923	rs9478291	chr6:150050570	A/G	cg09699651	chr6:150184138	LRP11	0.4	5.15	0.3	4.99e-7	Lung cancer;
CESC	cis	rs561341	1.000	rs484175	chr17:30309041	G/A	cg00745463	chr17:30367425	LRRC37B	-0.78	-7.09	-0.4	1.2e-11	Hip circumference adjusted for BMI;
CESC	cis	rs35306767	0.903	rs11812523	chr10:915638	C/T	cg26597838	chr10:835615	NA	0.87	9.15	0.49	1.55e-17	Eosinophil percentage of granulocytes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01861349	chr15:75198956	C15orf17	0.54	6.22	0.36	1.94e-9	Gut microbiome composition (summer);
CESC	cis	rs4319547	0.661	rs10846830	chr12:122897220	C/G	cg05707623	chr12:122985044	ZCCHC8	-0.53	-6.11	-0.35	3.47e-9	Body mass index;
CESC	cis	rs7336332	0.598	rs75439483	chr13:28010512	A/G	cg01674679	chr13:27998804	GTF3A	-0.58	-5.34	-0.31	2.04e-7	Weight;
CESC	cis	rs9311474	0.508	rs7652191	chr3:52610415	T/C	cg18099408	chr3:52552593	STAB1	-0.31	-5.23	-0.31	3.4e-7	Electroencephalogram traits;
CESC	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.62	0.38	1.94e-10	Prudent dietary pattern;
CESC	cis	rs7666738	0.830	rs10031751	chr4:98939134	G/A	cg17366294	chr4:99064904	C4orf37	0.61	8.56	0.47	9.36e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9399135	0.869	rs9402675	chr6:135325794	C/G	cg24558204	chr6:135376177	HBS1L	0.53	7.28	0.41	3.85e-12	Red blood cell count;
CESC	cis	rs9788682	0.747	rs938682	chr15:78896547	A/G	cg24631222	chr15:78858424	CHRNA5	0.78	9.77	0.51	1.92e-19	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs9611565	0.918	rs9611562	chr22:41760172	T/G	cg06481639	chr22:41940642	POLR3H	-0.7	-7.37	-0.41	2.23e-12	Vitiligo;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg13822231	chr9:133588088	ABL1	-0.47	-6.17	-0.35	2.53e-9	Fibrinogen levels;
CESC	cis	rs34330	0.562	rs7486387	chr12:12866911	G/A	cg09462578	chr12:12878428	APOLD1	-0.7	-7.61	-0.42	4.78e-13	Systemic lupus erythematosus;
CESC	cis	rs10504229	0.683	rs6995355	chr8:58113870	C/T	cg02725872	chr8:58115012	NA	-0.45	-7.04	-0.4	1.66e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs4665809	1.000	rs4665817	chr2:26305167	G/A	cg27170947	chr2:26402098	FAM59B	-0.72	-8.31	-0.45	5.18e-15	Gut microbiome composition (summer);
CESC	cis	rs17253792	0.822	rs17746033	chr14:56061837	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.85	6.13	0.35	3.15e-9	Putamen volume;
CESC	cis	rs6089584	0.546	rs6061980	chr20:60618877	G/A	cg06108461	chr20:60628389	TAF4	-0.59	-7.99	-0.44	4.06e-14	Body mass index;
CESC	trans	rs4756846	1.000	rs17554911	chr11:16432694	A/G	cg05579622	chr5:10618622	ANKRD33B	0.76	6.91	0.39	3.7e-11	Obesity and osteoporosis;
CESC	cis	rs8141529	0.748	rs1318026	chr22:29283518	A/G	cg02153584	chr22:29168773	CCDC117	0.6	7.84	0.43	1.13e-13	Lymphocyte counts;
CESC	cis	rs6062302	0.522	rs914558	chr20:62216976	A/G	cg09650180	chr20:62225654	GMEB2	-0.8	-8.92	-0.48	7.9e-17	Glioblastoma;
CESC	cis	rs826838	0.510	rs10506129	chr12:39224242	A/T	cg26384229	chr12:38710491	ALG10B	0.7	10.51	0.54	7.69e-22	Heart rate;
CESC	cis	rs7953249	0.807	rs2393775	chr12:121424574	G/A	cg02403541	chr12:121454288	C12orf43	-0.51	-6.84	-0.39	5.58e-11	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
CESC	cis	rs9916302	0.904	rs7223331	chr17:37482930	A/G	cg15445000	chr17:37608096	MED1	-0.41	-6.8	-0.39	6.8e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs919433	0.783	rs788014	chr2:198228997	G/A	cg20885578	chr2:198174922	NA	0.4	5.2	0.3	4.09e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs8177253	0.574	rs6775042	chr3:133442245	G/T	cg24879335	chr3:133465180	TF	0.36	6.37	0.36	8.47e-10	Iron status biomarkers;
CESC	cis	rs10504229	0.639	rs2318146	chr8:58114873	T/G	cg21724239	chr8:58056113	NA	0.58	5.95	0.34	8.29e-9	Developmental language disorder (linguistic errors);
CESC	trans	rs1545843	0.568	rs11116351	chr12:84775744	T/C	cg03015433	chr16:56623111	MT3	-0.33	-6.05	-0.35	4.9e-9	Major depressive disorder;
CESC	cis	rs7592578	0.599	rs62180992	chr2:191285732	A/G	cg10560079	chr2:191398806	TMEM194B	-0.6	-5.73	-0.33	2.73e-8	Diastolic blood pressure;
CESC	cis	rs858239	0.536	rs6956974	chr7:23252318	C/G	cg23682824	chr7:23144976	KLHL7	-0.43	-5.64	-0.33	4.28e-8	Cerebrospinal fluid biomarker levels;
CESC	cis	rs5769707	0.632	rs135876	chr22:50013573	A/G	cg20744362	chr22:50050164	C22orf34	0.36	5.05	0.3	8.22e-7	Monocyte count;Monocyte percentage of white cells;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg10387901	chr3:15106641	MRPS25	-0.45	-6.55	-0.37	2.97e-10	Gambling;
CESC	cis	rs28489187	0.597	rs233053	chr1:85839507	G/A	cg16011679	chr1:85725395	C1orf52	0.44	5.3	0.31	2.44e-7	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	cis	rs9303401	0.659	rs12944971	chr17:56988801	A/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.96	10.69	0.55	2.11e-22	Cognitive test performance;
CESC	cis	rs853679	0.517	rs4713150	chr6:28136212	G/A	cg17949981	chr6:28129498	ZNF389	0.42	5.24	0.31	3.27e-7	Depression;
CESC	cis	rs941873	0.772	rs7086293	chr10:81103247	T/C	cg11057378	chr10:81107060	PPIF	0.36	5.89	0.34	1.18e-8	Height;
CESC	cis	rs11650494	0.908	rs9907478	chr17:47395729	C/T	cg08112188	chr17:47440006	ZNF652	1.29	8.63	0.47	5.85e-16	Prostate cancer;
CESC	trans	rs7107217	1.000	rs1873872	chr11:129473993	A/T	cg20284698	chr3:48956327	C3orf71;ARIH2	0.44	6.02	0.35	5.91e-9	Breast cancer;Type 2 diabetes;
CESC	cis	rs12134245	0.776	rs625525	chr1:91997593	C/T	cg07090678	chr1:91966139	CDC7	0.38	5.33	0.31	2.08e-7	Breast cancer;
CESC	cis	rs36051895	0.632	rs62541916	chr9:5151904	C/A	cg02405213	chr9:5042618	JAK2	-0.53	-6.57	-0.37	2.66e-10	Pediatric autoimmune diseases;
CESC	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg25934064	chr3:52569026	NT5DC2	0.27	5.69	0.33	3.39e-8	Electroencephalogram traits;
CESC	cis	rs7666738	0.830	rs13125432	chr4:98961253	G/A	cg03676636	chr4:99064102	C4orf37	0.33	5.14	0.3	5.39e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs10895547	0.565	rs492441	chr11:103792570	C/T	cg23613023	chr12:115353932	NA	-0.36	-6.03	-0.35	5.53e-9	LDL cholesterol;
CESC	cis	rs7116495	1.000	rs7116495	chr11:71762085	C/T	cg10381502	chr11:71823885	C11orf51	-0.66	-5.35	-0.31	1.89e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs2841277	0.509	rs11850949	chr14:105408827	A/C	cg19901468	chr14:105411992	AHNAK2	-0.63	-9.05	-0.49	3.14e-17	Rheumatoid arthritis;
CESC	cis	rs875971	0.862	rs35034167	chr7:65580166	C/G	cg11764359	chr7:65958608	NA	-0.79	-11.16	-0.57	5.72e-24	Aortic root size;
CESC	cis	rs778371	0.958	rs778341	chr2:233728801	C/A	cg08000102	chr2:233561755	GIGYF2	-0.81	-11.29	-0.57	2.19e-24	Schizophrenia;
CESC	cis	rs7552404	0.731	rs11161857	chr1:76370228	G/C	cg10523679	chr1:76189770	ACADM	0.64	6.11	0.35	3.63e-9	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs7160336	0.641	rs17782448	chr14:74682701	G/C	cg08255017	chr14:74727001	VSX2	-0.38	-5.6	-0.33	5.35e-8	Blood protein levels;
CESC	cis	rs155076	0.711	rs4769158	chr13:21881975	T/C	cg11317459	chr13:21872234	NA	1.2	15.33	0.69	2.11e-38	White matter hyperintensity burden;
CESC	trans	rs8073060	0.505	rs225276	chr17:33973034	T/C	cg19694781	chr19:47549865	TMEM160	-0.73	-7.03	-0.4	1.79e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	cis	rs1707322	1.000	rs785469	chr1:46521091	C/T	cg06784218	chr1:46089804	CCDC17	-0.33	-5.65	-0.33	4.08e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs447735	0.565	rs10852626	chr16:89914633	T/G	cg03605463	chr16:89740564	NA	-0.45	-5.12	-0.3	5.82e-7	Hemoglobin concentration;
CESC	cis	rs10504229	0.679	rs75402323	chr8:58136227	A/G	cg21724239	chr8:58056113	NA	0.58	5.95	0.34	8.29e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs9302635	0.640	rs9933009	chr16:72190650	G/A	cg01557791	chr16:72042693	DHODH	-0.49	-5.68	-0.33	3.57e-8	Blood protein levels;
CESC	cis	rs11249608	0.548	rs10516150	chr5:178459169	G/C	cg01312482	chr5:178451176	ZNF879	-0.45	-6.08	-0.35	4.26e-9	Pubertal anthropometrics;
CESC	trans	rs2472476	0.900	rs2472479	chr9:107525165	G/T	cg14553338	chr2:66689807	MEIS1	0.46	6.41	0.37	6.74e-10	Obesity-related traits;
CESC	cis	rs863345	0.604	rs10908666	chr1:158500098	G/T	cg12129480	chr1:158549410	OR10X1	-0.34	-6.84	-0.39	5.49e-11	Pneumococcal bacteremia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21951070	chr3:185826924	ETV5	0.59	6.05	0.35	5.02e-9	Gut microbiome composition (summer);
CESC	trans	rs4824093	0.610	rs13340054	chr22:50311726	G/A	cg09872104	chr7:134855509	C7orf49	-0.86	-6.13	-0.35	3.09e-9	Amyotrophic lateral sclerosis (sporadic);
CESC	trans	rs12356475	0.710	rs10822686	chr10:67733250	C/T	cg00097228	chr1:63783167	NA	0.51	6.12	0.35	3.41e-9	Psoriatic arthritis;
CESC	cis	rs7818345	1.000	rs7835461	chr8:19307051	C/T	cg11303988	chr8:19266685	CSGALNACT1	0.35	6.11	0.35	3.48e-9	Language performance in older adults (adjusted for episodic memory);
CESC	cis	rs67072384	0.818	rs1872128	chr11:72465526	C/T	cg04827223	chr11:72435913	ARAP1	-0.7	-7.1	-0.4	1.16e-11	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg18190547	chr1:249142064	ZNF672	0.51	7.18	0.4	6.87e-12	Fibrinogen levels;
CESC	cis	rs4268898	0.662	rs9917355	chr2:24433400	C/T	cg08917208	chr2:24149416	ATAD2B	0.55	5.27	0.31	2.89e-7	Asthma;
CESC	cis	rs780096	0.526	rs780112	chr2:27665361	C/G	cg02592271	chr2:27665507	KRTCAP3	-0.29	-5.79	-0.34	2e-8	Total body bone mineral density;
CESC	cis	rs769267	1.000	rs12985655	chr19:19442434	G/A	cg03709012	chr19:19516395	GATAD2A	-0.97	-14.38	-0.66	4.86e-35	Tonsillectomy;
CESC	cis	rs10504229	1.000	rs1961778	chr8:58168756	G/A	cg05313129	chr8:58192883	C8orf71	-0.54	-6.21	-0.36	1.99e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs7520050	0.966	rs7515491	chr1:46355079	A/G	cg03146154	chr1:46216737	IPP	-0.49	-6.43	-0.37	5.9e-10	Red blood cell count;Reticulocyte count;
CESC	cis	rs4849845	0.598	rs3933620	chr2:121034936	A/T	cg24070213	chr2:121070622	NA	0.44	6.41	0.37	6.46e-10	Mean platelet volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26571942	chr2:30455099	LBH	0.55	6.24	0.36	1.75e-9	Gut microbiome composition (summer);
CESC	cis	rs10504073	0.669	rs12548464	chr8:50023867	C/T	cg00325661	chr8:49890786	NA	0.5	7.49	0.42	1.02e-12	Blood metabolite ratios;
CESC	cis	rs6952808	0.692	rs56727870	chr7:2029940	T/C	cg02951883	chr7:2050386	MAD1L1	-0.58	-7.77	-0.43	1.72e-13	Bipolar disorder and schizophrenia;
CESC	cis	rs1799949	1.000	rs8176077	chr17:41276348	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.67	9.34	0.5	3.98e-18	Menopause (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23039201	chr2:27851887	GPN1;CCDC121	0.65	8.02	0.44	3.39e-14	Gut microbiome composition (summer);
CESC	cis	rs7223966	1.000	rs17549954	chr17:61707032	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.53	6.16	0.35	2.7e-9	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs9640161	0.750	rs73170185	chr7:150030191	C/A	cg21361702	chr7:150065534	REPIN1	0.54	5.89	0.34	1.18e-8	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs35306767	0.715	rs1250891	chr10:1040159	G/C	cg20503657	chr10:835505	NA	0.67	6.06	0.35	4.55e-9	Eosinophil percentage of granulocytes;
CESC	cis	rs6088580	0.634	rs6059878	chr20:33087166	A/T	cg08999081	chr20:33150536	PIGU	0.65	11.26	0.57	2.65e-24	Glomerular filtration rate (creatinine);
CESC	cis	rs9486719	1.000	rs12213426	chr6:96896035	T/C	cg18709589	chr6:96969512	KIAA0776	-0.54	-5.87	-0.34	1.3e-8	Migraine;Coronary artery disease;
CESC	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.53	-7.21	-0.4	5.87e-12	Lymphocyte counts;
CESC	cis	rs9297145	0.673	rs62473003	chr7:98725660	A/G	cg05967295	chr7:98741636	SMURF1	0.91	8.99	0.48	4.78e-17	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
CESC	cis	rs1448094	0.511	rs17279240	chr12:86162550	A/T	cg00310523	chr12:86230176	RASSF9	0.35	5.59	0.32	5.75e-8	Major depressive disorder;
CESC	cis	rs34311866	0.808	rs4583705	chr4:973036	C/T	cg07828340	chr4:882639	GAK	0.88	6.92	0.39	3.33e-11	Parkinson's disease;
CESC	cis	rs9768139	1.000	rs9768139	chr7:158120731	G/A	cg24154853	chr7:158122151	PTPRN2	-0.38	-5.95	-0.34	8.6e-9	Calcium levels;
CESC	cis	rs12410462	0.901	rs1120000	chr1:227659615	T/C	cg04117972	chr1:227635322	NA	0.63	6.27	0.36	1.47e-9	Major depressive disorder;
CESC	trans	rs6089829	0.855	rs6090203	chr20:61663632	G/A	cg23505145	chr19:12996616	KLF1	0.52	6.74	0.38	1e-10	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs875971	0.862	rs6944374	chr7:65686929	C/G	cg18876405	chr7:65276391	NA	-0.55	-7.48	-0.42	1.11e-12	Aortic root size;
CESC	trans	rs10463316	0.894	rs13361316	chr5:150765593	T/C	cg24389359	chr12:111284228	CCDC63	-0.34	-6.2	-0.36	2.19e-9	Metabolite levels (Pyroglutamine);
CESC	cis	rs9309711	0.621	rs7586472	chr2:3473670	G/A	cg10845886	chr2:3471009	TTC15	-0.63	-8.64	-0.47	5.3e-16	Neurofibrillary tangles;
CESC	cis	rs2440129	0.611	rs1042356	chr17:6902743	G/A	cg19536664	chr17:6899085	ALOX12	0.39	8.6	0.47	7.07e-16	Tonsillectomy;
CESC	cis	rs8014204	0.753	rs6574199	chr14:75356103	T/C	cg08847533	chr14:75593920	NEK9	-0.44	-5.4	-0.32	1.45e-7	Caffeine consumption;
CESC	cis	rs898097	0.578	rs6502021	chr17:80907728	T/C	cg10494973	chr17:80897199	TBCD	-0.48	-6.04	-0.35	5.14e-9	Breast cancer;
CESC	cis	rs10911232	0.507	rs10797822	chr1:183017769	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.87	13.5	0.64	5.78e-32	Hypertriglyceridemia;
CESC	cis	rs10256972	0.621	rs2280725	chr7:1087426	G/T	cg23978390	chr7:1156363	C7orf50	0.47	6.41	0.37	6.75e-10	Longevity;Endometriosis;
CESC	cis	rs9517313	0.551	rs2274051	chr13:99091634	A/G	cg07423050	chr13:99094983	FARP1	0.36	6.35	0.36	9.47e-10	Neuroticism;
CESC	cis	rs55882075	0.537	rs62406698	chr5:179110429	C/T	cg14593053	chr5:179126677	CANX	0.54	6.91	0.39	3.62e-11	Monocyte percentage of white cells;
CESC	cis	rs7116495	0.609	rs2155145	chr11:71719619	G/T	cg10381502	chr11:71823885	C11orf51	-1.16	-7.71	-0.43	2.62e-13	Severe influenza A (H1N1) infection;
CESC	cis	rs9322193	0.923	rs12211511	chr6:150066342	G/C	cg07701084	chr6:150067640	NUP43	0.43	5.81	0.34	1.78e-8	Lung cancer;
CESC	cis	rs1580019	0.587	rs6968990	chr7:32552159	C/T	cg06627557	chr7:32535165	LSM5;AVL9	-1.04	-17.38	-0.73	1.12e-45	Cognitive ability;
CESC	cis	rs875971	0.545	rs2460427	chr7:65619205	T/C	cg19163074	chr7:65112434	INTS4L2	0.46	5.05	0.3	8.07e-7	Aortic root size;
CESC	cis	rs7772486	0.692	rs1577916	chr6:146069789	G/A	cg05347473	chr6:146136440	FBXO30	-0.54	-7.0	-0.4	2.06e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9905704	0.633	rs2632511	chr17:56490989	G/A	cg12560992	chr17:57184187	TRIM37	0.62	5.62	0.33	4.95e-8	Testicular germ cell tumor;
CESC	cis	rs7811142	0.943	rs11769886	chr7:99998607	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.77	6.63	0.38	1.87e-10	Platelet count;
CESC	cis	rs2301436	0.512	rs6925969	chr6:167501738	C/A	cg23791538	chr6:167370224	RNASET2	-0.53	-6.66	-0.38	1.59e-10	Crohn's disease;
CESC	cis	rs10851478	0.802	rs7162741	chr15:49905410	A/G	cg08060515	chr15:49448048	GALK2;COPS2	0.43	5.26	0.31	3e-7	Oral cavity cancer;
CESC	cis	rs4665809	1.000	rs6729757	chr2:26285102	A/G	cg27170947	chr2:26402098	FAM59B	-0.6	-7.23	-0.41	5.28e-12	Gut microbiome composition (summer);
CESC	cis	rs6740322	0.696	rs10188539	chr2:43484675	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.77	-8.39	-0.46	2.95e-15	Coronary artery disease;
CESC	cis	rs7089973	0.523	rs7093330	chr10:116744574	T/A	cg23260525	chr10:116636907	FAM160B1	0.3	5.24	0.31	3.21e-7	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs77972916	0.505	rs6727824	chr2:43528377	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.63	-6.01	-0.35	6.27e-9	Granulocyte percentage of myeloid white cells;
CESC	cis	rs17376456	1.000	rs13174700	chr5:93554644	G/A	cg21475434	chr5:93447410	FAM172A	0.88	7.46	0.42	1.25e-12	Diabetic retinopathy;
CESC	cis	rs7520050	0.667	rs11211176	chr1:46223086	C/T	cg06784218	chr1:46089804	CCDC17	-0.36	-6.48	-0.37	4.5e-10	Red blood cell count;Reticulocyte count;
CESC	cis	rs796364	0.951	rs2881593	chr2:201000347	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.62	-6.46	-0.37	4.94e-10	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12309172	chr15:91454691	MAN2A2	-0.52	-6.48	-0.37	4.45e-10	Gut microbiome composition (summer);
CESC	cis	rs6460942	0.915	rs75732743	chr7:12454095	C/T	cg10578991	chr7:12443926	VWDE	-0.5	-5.52	-0.32	7.93e-8	Coronary artery disease;
CESC	cis	rs7412746	0.553	rs59337856	chr1:150746406	G/T	cg04414720	chr1:150670196	GOLPH3L	0.58	7.55	0.42	7.07e-13	Melanoma;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg24641125	chr21:40721130	HMGN1	-0.46	-6.09	-0.35	3.86e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs8005677	1.000	rs1951119	chr14:23388326	A/C	cg01529538	chr14:23388837	RBM23	0.51	6.88	0.39	4.29e-11	Cognitive ability (multi-trait analysis);
CESC	cis	rs7103648	0.695	rs7933019	chr11:47509137	G/C	cg10504702	chr11:47789108	FNBP4	0.42	5.2	0.3	4.01e-7	Diastolic blood pressure;Systolic blood pressure;
CESC	trans	rs61931739	0.500	rs34418276	chr12:34535976	C/T	cg13010199	chr12:38710504	ALG10B	0.5	6.31	0.36	1.16e-9	Morning vs. evening chronotype;
CESC	cis	rs4282054	0.631	rs13081155	chr3:52732429	A/G	cg18099408	chr3:52552593	STAB1	-0.35	-6.35	-0.36	9.06e-10	Cognitive function;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg08118649	chr12:99038419	APAF1;IKBIP	0.48	6.21	0.36	2.08e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs77956314	0.515	rs10850741	chr12:117432004	A/G	cg02017074	chr12:117425053	FBXW8	0.78	8.49	0.46	1.46e-15	Subcortical brain region volumes;Hippocampal volume;
CESC	cis	rs1008375	0.933	rs6449324	chr4:17694880	G/C	cg02297831	chr4:17616191	MED28	0.43	5.27	0.31	2.79e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs780096	0.526	rs13472	chr2:27600239	G/A	cg02592271	chr2:27665507	KRTCAP3	-0.26	-5.12	-0.3	5.96e-7	Total body bone mineral density;
CESC	cis	rs8062405	0.755	rs4788076	chr16:28570005	C/T	cg01378222	chr16:28622494	SULT1A1	0.31	5.15	0.3	5.01e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs10197940	0.789	rs2444256	chr2:152280365	C/T	cg19508488	chr2:152266495	RIF1	0.43	5.19	0.3	4.1e-7	Lung cancer;
CESC	cis	rs7264396	0.635	rs6058382	chr20:34553948	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.52	6.18	0.36	2.37e-9	Total cholesterol levels;
CESC	cis	rs1862618	0.671	rs2591964	chr5:56236900	T/G	cg12311346	chr5:56204834	C5orf35	0.65	8.75	0.47	2.51e-16	Initial pursuit acceleration;
CESC	trans	rs17057718	1.000	rs2035656	chr3:57125101	A/C	cg04869497	chr17:20059225	CYTSB	-0.56	-5.99	-0.35	6.63e-9	Cerebrospinal fluid biomarker levels;
CESC	cis	rs11785400	1.000	rs3735994	chr8:143742683	C/T	cg24634471	chr8:143751801	JRK	0.47	6.21	0.36	2e-9	Schizophrenia;
CESC	trans	rs7178375	1.000	rs28881289	chr15:31223955	A/G	cg04373760	chr16:53404718	NA	0.54	7.26	0.41	4.39e-12	Hypertriglyceridemia;
CESC	cis	rs6963495	0.818	rs17343556	chr7:105151272	C/T	cg19920283	chr7:105172520	RINT1	0.67	6.33	0.36	1.02e-9	Bipolar disorder (body mass index interaction);
CESC	cis	rs561341	0.883	rs4450460	chr17:30201309	C/T	cg13647721	chr17:30228624	UTP6	-0.62	-5.83	-0.34	1.63e-8	Hip circumference adjusted for BMI;
CESC	cis	rs1784581	0.855	rs1893101	chr6:162384371	G/C	cg17173639	chr6:162384350	PARK2	-0.81	-13.3	-0.63	2.97e-31	Itch intensity from mosquito bite;
CESC	cis	rs8062405	0.756	rs151301	chr16:28497059	T/A	cg08761264	chr16:28874980	SH2B1	-0.45	-5.26	-0.31	3.03e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs9815354	0.812	rs73830532	chr3:41898814	T/C	cg03022575	chr3:42003672	ULK4	0.71	6.23	0.36	1.84e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs875971	0.862	rs6460279	chr7:65662761	T/C	cg18252515	chr7:66147081	NA	0.46	5.97	0.34	7.62e-9	Aortic root size;
CESC	cis	rs13256369	0.755	rs12550057	chr8:8562268	G/A	cg00074818	chr8:8560427	CLDN23	0.36	5.22	0.31	3.64e-7	Obesity-related traits;
CESC	cis	rs734999	0.545	rs4648565	chr1:2570023	A/G	cg18854424	chr1:2615690	NA	-0.3	-5.88	-0.34	1.2e-8	Ulcerative colitis;
CESC	cis	rs2440129	0.611	rs11571335	chr17:6904263	C/T	cg19536664	chr17:6899085	ALOX12	0.39	8.73	0.47	2.97e-16	Tonsillectomy;
CESC	cis	rs35306767	0.903	rs12244253	chr10:889320	G/T	cg20503657	chr10:835505	NA	0.79	7.99	0.44	4.07e-14	Eosinophil percentage of granulocytes;
CESC	cis	rs1865760	0.566	rs1971509	chr6:26085777	T/C	cg17691542	chr6:26056736	HIST1H1C	0.42	5.57	0.32	6.13e-8	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10534439	chr2:69969029	ANXA4	0.7	8.38	0.46	3.08e-15	Gut microbiome composition (summer);
CESC	cis	rs11122272	0.525	rs2749713	chr1:231537921	T/C	cg06096015	chr1:231504339	EGLN1	0.43	6.08	0.35	4.28e-9	Hemoglobin concentration;
CESC	cis	rs9788682	0.748	rs569207	chr15:78873119	A/G	cg24631222	chr15:78858424	CHRNA5	-0.8	-10.06	-0.53	2.25e-20	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs8067545	0.611	rs2703786	chr17:20156369	T/C	cg13482628	chr17:19912719	NA	-0.41	-5.51	-0.32	8.66e-8	Schizophrenia;
CESC	cis	rs2760061	0.598	rs605410	chr1:228116281	A/G	cg02753203	chr1:228287806	NA	-0.49	-7.18	-0.4	7.11e-12	Diastolic blood pressure;
CESC	cis	rs7833986	0.501	rs72653981	chr8:57027814	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.57	7.28	0.41	3.83e-12	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19905880	chr11:67049324	ADRBK1	-0.52	-6.08	-0.35	4.15e-9	Gut microbiome composition (summer);
CESC	cis	rs112158604	1	rs112158604	chr1:150696792	TCTTCTGCAG/T	cg13175981	chr1:150552382	MCL1	0.62	9.02	0.48	3.95e-17	Lymphocyte counts;
CESC	cis	rs9318086	0.901	rs7336730	chr13:24452104	T/G	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.41	-5.97	-0.34	7.55e-9	Myopia (pathological);
CESC	cis	rs992157	0.798	rs10206064	chr2:219157959	T/C	cg00012203	chr2:219082015	ARPC2	0.75	9.7	0.51	3.1e-19	Colorectal cancer;
CESC	cis	rs12142240	0.698	rs45449893	chr1:46859024	A/G	cg00530320	chr1:46809349	NSUN4	0.6	8.27	0.45	6.54e-15	Menopause (age at onset);
CESC	trans	rs9467711	0.606	rs9379899	chr6:26603015	T/A	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.73	6.12	0.35	3.38e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs6484504	0.532	rs1929019	chr11:31267030	C/T	cg14844989	chr11:31128820	NA	-0.41	-5.82	-0.34	1.73e-8	Red blood cell count;
CESC	cis	rs8072100	0.905	rs9895274	chr17:45539117	C/T	cg25173405	chr17:45401733	C17orf57	-0.41	-5.49	-0.32	9.29e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg10824722	chr1:206506826	NA	0.45	6.74	0.38	9.94e-11	Fibrinogen levels;
CESC	cis	rs3096299	0.685	rs12446145	chr16:89542695	C/T	cg02187348	chr16:89574699	SPG7	0.64	9.02	0.48	4.03e-17	Multiple myeloma (IgH translocation);
CESC	cis	rs7618915	0.501	rs6804145	chr3:52694198	C/T	cg18404041	chr3:52824283	ITIH1	-0.38	-6.51	-0.37	3.7e-10	Bipolar disorder;
CESC	cis	rs651907	0.557	rs2288272	chr3:101378476	C/T	cg12386194	chr3:101231763	SENP7	0.45	5.6	0.33	5.44e-8	Colorectal cancer;
CESC	cis	rs2380220	0.935	rs7744491	chr6:95994980	T/G	cg04719120	chr6:96025338	MANEA	0.55	5.4	0.32	1.45e-7	Behavioural disinhibition (generation interaction);
CESC	cis	rs7666738	0.791	rs11729596	chr4:99045461	A/G	cg05340658	chr4:99064831	C4orf37	0.82	12.88	0.62	8.44e-30	Colonoscopy-negative controls vs population controls;
CESC	trans	rs5758511	0.731	rs58302269	chr22:42351309	G/A	cg15080870	chr19:47770746	CCDC9	0.5	6.19	0.36	2.26e-9	Birth weight;
CESC	cis	rs1707322	0.648	rs4439382	chr1:46150805	C/T	cg03146154	chr1:46216737	IPP	0.82	11.53	0.58	3.39e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7615952	0.576	rs1127717	chr3:125826059	T/C	cg06494592	chr3:125709126	NA	-0.5	-5.51	-0.32	8.69e-8	Blood pressure (smoking interaction);
CESC	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg18402987	chr7:1209562	NA	0.57	6.64	0.38	1.72e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs881375	0.702	rs3761847	chr9:123690239	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.39	5.57	0.32	6.41e-8	Rheumatoid arthritis;
CESC	cis	rs10504229	0.683	rs11786523	chr8:58131319	G/C	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	trans	rs561341	1.000	rs117029332	chr17:30266085	C/G	cg27661571	chr11:113659931	NA	-0.83	-7.82	-0.43	1.26e-13	Hip circumference adjusted for BMI;
CESC	cis	rs17253792	0.822	rs117050012	chr14:56038729	G/T	cg01858014	chr14:56050164	KTN1	-0.99	-7.46	-0.42	1.21e-12	Putamen volume;
CESC	cis	rs7216064	0.953	rs62086044	chr17:65970837	G/T	cg07042672	chr17:66097459	LOC651250	-0.58	-6.52	-0.37	3.49e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08255233	chr6:87607178	NA	-0.58	-7.64	-0.42	3.85e-13	Gut microbiome composition (summer);
CESC	cis	rs7116495	1.000	rs493065	chr11:71796929	T/C	cg26138937	chr11:71823887	C11orf51	-0.86	-7.03	-0.4	1.75e-11	Severe influenza A (H1N1) infection;
CESC	cis	rs11098499	0.954	rs6834796	chr4:120414693	A/C	cg09307838	chr4:120376055	NA	0.93	13.06	0.63	2.03e-30	Corneal astigmatism;
CESC	cis	rs7927592	0.913	rs11228276	chr11:68307525	A/G	cg20283391	chr11:68216788	NA	-0.62	-7.45	-0.42	1.31e-12	Total body bone mineral density;
CESC	cis	rs668210	0.793	rs622779	chr11:65744247	G/A	cg02202077	chr11:65769826	EIF1AD;BANF1	-0.66	-6.52	-0.37	3.55e-10	Cerebrospinal fluid biomarker levels;
CESC	cis	rs7247513	0.639	rs12984441	chr19:12760287	A/C	cg01871581	chr19:12707946	ZNF490	-0.81	-12.65	-0.61	5.37e-29	Bipolar disorder;
CESC	cis	rs1005277	0.602	rs1780141	chr10:38504299	T/C	cg00409905	chr10:38381863	ZNF37A	-0.52	-7.04	-0.4	1.69e-11	Extrinsic epigenetic age acceleration;
CESC	trans	rs677673	1.000	rs67438213	chr20:10476532	T/G	cg16021678	chr13:55475951	NA	0.51	6.4	0.37	7.15e-10	Body mass index (change over time) in chronic obstructive pulmonary disease;
CESC	cis	rs3820068	0.581	rs6692461	chr1:15928449	A/G	cg17385448	chr1:15911702	AGMAT	0.44	7.16	0.4	7.97e-12	Systolic blood pressure;
CESC	cis	rs9611519	0.780	rs1983631	chr22:41644074	C/T	cg03806693	chr22:41940476	POLR3H	-0.69	-7.8	-0.43	1.38e-13	Neuroticism;
CESC	cis	rs3785574	0.962	rs2597632	chr17:61894739	A/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.57	6.99	0.39	2.29e-11	Height;
CESC	cis	rs796364	0.906	rs281789	chr2:200780698	T/G	cg23649088	chr2:200775458	C2orf69	0.56	5.26	0.31	3e-7	Schizophrenia;
CESC	cis	rs9513627	0.833	rs4605005	chr13:100132471	T/C	cg25919922	chr13:100150906	NA	0.68	5.77	0.33	2.16e-8	Obesity-related traits;
CESC	cis	rs6598955	0.617	rs11247883	chr1:26576247	T/G	cg19743891	chr1:26644573	UBXN11;CD52	0.37	5.19	0.3	4.16e-7	Obesity-related traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07207937	chr4:78783799	MRPL1	-0.55	-6.11	-0.35	3.45e-9	Gut microbiome composition (summer);
CESC	cis	rs736408	0.540	rs4687637	chr3:52634092	C/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.31	5.68	0.33	3.59e-8	Bipolar disorder;
CESC	trans	rs9354308	0.901	rs2814121	chr6:66566915	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.71	7.96	0.44	5.21e-14	Metabolite levels;
CESC	cis	rs1799949	1.000	rs8176103	chr17:41267050	G/A	cg23758822	chr17:41437982	NA	1.01	15.25	0.68	3.9e-38	Menopause (age at onset);
CESC	cis	rs5769765	0.908	rs4074304	chr22:50309446	G/A	cg02269571	chr22:50332266	NA	-0.57	-6.99	-0.39	2.29e-11	Schizophrenia;
CESC	cis	rs6540556	0.769	rs627670	chr1:209929299	G/A	cg05527609	chr1:210001259	C1orf107	0.49	5.89	0.34	1.17e-8	Red blood cell count;
CESC	cis	rs11190604	1.000	rs11190556	chr10:102209223	G/A	cg07080220	chr10:102295463	HIF1AN	0.55	5.51	0.32	8.5e-8	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs4969178	0.965	rs8072632	chr17:76397830	T/C	cg20026190	chr17:76395443	PGS1	0.49	7.79	0.43	1.51e-13	HDL cholesterol levels;
CESC	cis	rs644799	0.648	rs1255176	chr11:95471465	A/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.42	5.73	0.33	2.78e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs2228479	0.867	rs62052185	chr16:89969254	C/T	cg14709524	chr16:89940631	TCF25	0.72	5.44	0.32	1.24e-7	Skin colour saturation;
CESC	cis	rs3008870	1.000	rs6673462	chr1:67461857	A/C	cg02640540	chr1:67518911	SLC35D1	-0.51	-5.58	-0.32	5.89e-8	Lymphocyte percentage of white cells;
CESC	cis	rs7824557	0.806	rs7007394	chr8:11094566	G/A	cg21775007	chr8:11205619	TDH	-0.36	-5.21	-0.31	3.73e-7	Retinal vascular caliber;
CESC	cis	rs7116495	0.609	rs4387373	chr11:71774908	A/G	cg26138937	chr11:71823887	C11orf51	-1.32	-8.2	-0.45	1.04e-14	Severe influenza A (H1N1) infection;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg16682046	chr11:82612617	PRCP;C11orf82	0.47	6.0	0.35	6.52e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs2072732	0.904	rs12044831	chr1:2964397	A/C	cg15211996	chr1:2936768	ACTRT2	0.34	5.44	0.32	1.2e-7	Plateletcrit;
CESC	cis	rs7116495	1.000	rs10793016	chr11:71755063	A/G	cg26138937	chr11:71823887	C11orf51	0.76	6.44	0.37	5.6e-10	Severe influenza A (H1N1) infection;
CESC	cis	rs3096299	0.967	rs2965935	chr16:89481274	C/T	cg08392591	chr16:89556376	ANKRD11	-0.38	-5.06	-0.3	7.77e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs4665809	0.590	rs2891496	chr2:26452605	G/A	cg08470875	chr2:26401718	FAM59B	0.75	7.82	0.43	1.26e-13	Gut microbiome composition (summer);
CESC	cis	rs9443189	1.000	rs1280047	chr6:76527791	A/G	cg01950844	chr6:76311363	SENP6	0.64	6.66	0.38	1.61e-10	Prostate cancer;
CESC	cis	rs7809950	0.862	rs12112877	chr7:106941324	T/C	cg23024343	chr7:107201750	COG5	-0.37	-5.1	-0.3	6.42e-7	Coronary artery disease;
CESC	cis	rs780096	0.546	rs715325	chr2:27725572	C/A	cg22903471	chr2:27725779	GCKR	-0.55	-7.53	-0.42	8.1e-13	Total body bone mineral density;
CESC	cis	rs4722166	0.564	rs1800797	chr7:22766221	A/G	cg05472934	chr7:22766657	IL6	0.8	10.22	0.53	6.78e-21	Lung cancer;
CESC	cis	rs8018808	0.935	rs958463	chr14:77886721	G/T	cg20045696	chr14:77926864	AHSA1	0.47	6.59	0.38	2.42e-10	Myeloid white cell count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25886382	chr13:26760664	NA	0.55	6.64	0.38	1.78e-10	Gut microbiome composition (summer);
CESC	cis	rs898097	0.528	rs2243523	chr17:80680449	G/T	cg05255149	chr17:80675120	FN3KRP	-0.5	-6.42	-0.37	6.24e-10	Breast cancer;
CESC	cis	rs425277	0.958	rs7546523	chr1:2043792	G/A	cg16545954	chr1:2118288	C1orf86	0.32	5.25	0.31	3.15e-7	Height;
CESC	trans	rs6542647	0.678	rs17582650	chr2:4855471	A/G	cg06797068	chr6:74104600	DDX43	0.69	6.17	0.35	2.52e-9	Left ventricular obstructive tract defect (inherited effect);
CESC	cis	rs9309473	0.950	rs6546860	chr2:73844249	G/A	cg20560298	chr2:73613845	ALMS1	-0.43	-5.74	-0.33	2.55e-8	Metabolite levels;
CESC	cis	rs3785574	1.000	rs7223257	chr17:61787684	T/C	cg06873352	chr17:61820015	STRADA	0.49	7.2	0.4	6.26e-12	Height;
CESC	cis	rs7666738	0.830	rs60391193	chr4:98933912	T/G	cg03467027	chr4:99064603	C4orf37	0.48	5.91	0.34	1.03e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs72945132	0.882	rs72949078	chr11:70217708	T/C	cg00319359	chr11:70116639	PPFIA1	0.76	7.17	0.4	7.33e-12	Coronary artery disease;
CESC	cis	rs6541297	0.703	rs637180	chr1:230311677	G/A	cg20703242	chr1:230279135	GALNT2	-0.43	-5.59	-0.33	5.51e-8	Coronary artery disease;
CESC	cis	rs1552244	0.808	rs17032306	chr3:10091399	C/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.82	-10.8	-0.55	9.24e-23	Alzheimer's disease;
CESC	cis	rs9457247	1.000	rs408080	chr6:167392522	T/C	cg25258033	chr6:167368657	RNASET2	0.38	5.76	0.33	2.31e-8	Crohn's disease;
CESC	cis	rs3749237	0.595	rs7637999	chr3:49535115	C/T	cg02487422	chr3:49467188	NICN1	0.56	8.19	0.45	1.09e-14	Resting heart rate;
CESC	cis	rs12477438	0.501	rs12619780	chr2:99707307	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.78	13.35	0.63	2e-31	Chronic sinus infection;
CESC	cis	rs2273669	0.667	rs112319185	chr6:109305318	T/C	cg05315195	chr6:109294784	ARMC2	-0.65	-6.08	-0.35	4.15e-9	Prostate cancer;
CESC	cis	rs17711722	0.503	rs453835	chr7:65511159	T/A	cg26939375	chr7:64535504	NA	-0.63	-8.45	-0.46	1.96e-15	Calcium levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.54	6.01	0.35	5.96e-9	Gut microbiome composition (summer);
CESC	cis	rs2635047	1.000	rs2684825	chr18:44666415	T/C	cg19077165	chr18:44547161	KATNAL2	-0.45	-6.05	-0.35	5e-9	Educational attainment;
CESC	cis	rs7605827	0.930	rs12692262	chr2:15539084	A/G	cg19274914	chr2:15703543	NA	0.35	6.27	0.36	1.45e-9	Educational attainment (years of education);
CESC	cis	rs8067354	0.645	rs2645491	chr17:57877049	C/T	cg02344993	chr17:57696989	CLTC	0.67	8.28	0.45	6.3e-15	Hemoglobin concentration;
CESC	trans	rs3942852	0.868	rs7118226	chr11:48106267	T/G	cg15704280	chr7:45808275	SEPT13	-0.66	-7.67	-0.43	3.3e-13	Acute lymphoblastic leukemia (childhood);
CESC	trans	rs61931739	0.534	rs1852222	chr12:34008665	C/A	cg26384229	chr12:38710491	ALG10B	0.48	6.57	0.37	2.6e-10	Morning vs. evening chronotype;
CESC	cis	rs2836974	0.666	rs12626405	chr21:40663121	G/T	cg11644478	chr21:40555479	PSMG1	-0.82	-12.16	-0.6	2.48e-27	Cognitive function;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg08126158	chr2:183963421	DUSP19	0.39	6.13	0.35	3.23e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs9311474	0.581	rs13621	chr3:52558133	T/C	cg05564831	chr3:52568323	NT5DC2	0.46	7.34	0.41	2.57e-12	Electroencephalogram traits;
CESC	cis	rs763014	0.898	rs8060921	chr16:635988	C/A	cg07343612	chr16:622815	PIGQ	-0.55	-7.99	-0.44	4.25e-14	Height;
CESC	cis	rs8038465	0.622	rs710086	chr15:73877001	C/T	cg15420318	chr15:73925796	NPTN	0.49	6.93	0.39	3.26e-11	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs12142240	0.698	rs45517837	chr1:46859225	A/G	cg00530320	chr1:46809349	NSUN4	0.6	8.27	0.45	6.54e-15	Menopause (age at onset);
CESC	cis	rs9303401	0.580	rs34076823	chr17:57114497	C/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.86	10.68	0.55	2.3e-22	Cognitive test performance;
CESC	cis	rs6580649	0.882	rs2286022	chr12:48436647	G/A	cg05342945	chr12:48394962	COL2A1	0.53	6.0	0.35	6.38e-9	Lung cancer;
CESC	cis	rs13108904	0.560	rs11247994	chr4:1343720	G/A	cg22903657	chr4:1355424	KIAA1530	-0.38	-5.16	-0.3	4.96e-7	Obesity-related traits;
CESC	cis	rs8060686	0.545	rs12444188	chr16:68282077	G/A	cg26727032	chr16:67993705	SLC12A4	-0.52	-5.6	-0.33	5.23e-8	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs3733585	0.699	rs6844787	chr4:9959233	A/G	cg00071950	chr4:10020882	SLC2A9	-0.73	-11.79	-0.59	4.58e-26	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs801193	0.967	rs3800823	chr7:66147110	C/A	cg11764359	chr7:65958608	NA	-0.63	-8.0	-0.44	4.01e-14	Aortic root size;
CESC	cis	rs11792861	0.619	rs2289480	chr9:111705501	A/C	cg13535736	chr9:111863775	C9orf5	-0.39	-5.67	-0.33	3.82e-8	Menarche (age at onset);
CESC	cis	rs9311474	0.581	rs4687626	chr3:52569098	G/A	cg05564831	chr3:52568323	NT5DC2	0.47	7.34	0.41	2.68e-12	Electroencephalogram traits;
CESC	trans	rs7824557	0.510	rs4841524	chr8:11243126	C/G	cg06636001	chr8:8085503	FLJ10661	-0.49	-6.05	-0.35	4.95e-9	Retinal vascular caliber;
CESC	cis	rs9583531	0.600	rs6492306	chr13:111361693	G/A	cg24331049	chr13:111365604	ING1	0.71	10.89	0.56	4.48e-23	Coronary artery disease;
CESC	cis	rs2228479	1.000	rs62052180	chr16:89963289	C/G	cg04013166	chr16:89971882	TCF25	0.76	6.94	0.39	3.06e-11	Skin colour saturation;
CESC	cis	rs4594175	0.926	rs114230179	chr14:51601974	C/T	cg23942311	chr14:51606299	NA	0.4	5.94	0.34	9.07e-9	Cancer;
CESC	cis	rs7973683	0.541	rs6488910	chr12:124393697	G/T	cg00084347	chr12:124393913	DNAH10	0.29	6.19	0.36	2.23e-9	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
CESC	cis	rs3785574	0.962	rs2665840	chr17:61873307	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.58	-7.33	-0.41	2.75e-12	Height;
CESC	cis	rs7666738	0.830	rs10001702	chr4:99065160	T/G	cg03676636	chr4:99064102	C4orf37	0.33	5.04	0.3	8.47e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs514406	0.644	rs7530078	chr1:53204861	G/T	cg08736216	chr1:53307985	ZYG11A	0.3	5.05	0.3	8.16e-7	Monocyte count;
CESC	cis	rs3617	0.591	rs11918800	chr3:52868145	G/A	cg11645453	chr3:52864694	ITIH4	-0.26	-5.18	-0.3	4.48e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
CESC	cis	rs72781680	0.752	rs72796119	chr2:23917179	C/T	cg08917208	chr2:24149416	ATAD2B	1.13	10.24	0.53	5.87e-21	Lymphocyte counts;
CESC	cis	rs6831352	0.918	rs7670060	chr4:100059568	G/T	cg13256891	chr4:100009986	ADH5	-0.77	-8.49	-0.46	1.5e-15	Alcohol dependence;
CESC	cis	rs28374715	0.578	rs7165914	chr15:41632451	C/T	cg20272979	chr15:41787780	ITPKA	0.46	5.5	0.32	8.78e-8	Ulcerative colitis;
CESC	cis	rs7000551	0.715	rs2443502	chr8:22340499	G/A	cg12081754	chr8:22256438	SLC39A14	0.4	5.31	0.31	2.34e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CESC	trans	rs9951602	0.512	rs9946138	chr18:76654608	A/G	cg02800362	chr5:177631904	HNRNPAB	0.66	8.63	0.47	5.9e-16	Obesity-related traits;
CESC	cis	rs9894429	0.646	rs6565609	chr17:79592267	G/A	cg21984481	chr17:79567631	NPLOC4	-0.34	-5.19	-0.3	4.21e-7	Eye color traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15238467	chr12:57522045	LRP1	0.55	6.06	0.35	4.64e-9	Gut microbiome composition (summer);
CESC	cis	rs870825	0.549	rs28579266	chr4:185627262	T/C	cg04058563	chr4:185651563	MLF1IP	0.64	7.05	0.4	1.59e-11	Blood protein levels;
CESC	cis	rs425277	1.000	rs262657	chr1:2088577	G/A	cg24578937	chr1:2090814	PRKCZ	0.55	9.53	0.51	1.09e-18	Height;
CESC	cis	rs1552244	1.000	rs7619340	chr3:10108178	C/T	cg00149659	chr3:10157352	C3orf10	0.72	8.61	0.47	6.41e-16	Alzheimer's disease;
CESC	cis	rs7762018	1.000	rs74900588	chr6:170102180	A/C	cg13891659	chr6:170190454	C6orf122;C6orf208	0.55	5.7	0.33	3.26e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs9768139	0.708	rs10234067	chr7:158114542	C/T	cg25566285	chr7:158114605	PTPRN2	0.54	9.09	0.49	2.33e-17	Calcium levels;
CESC	cis	rs62344088	0.590	rs2115276	chr5:169829	C/G	cg22857025	chr5:266934	NA	-1.2	-8.17	-0.45	1.24e-14	Asthma (childhood onset);
CESC	cis	rs4665809	0.590	rs2289019	chr2:26420809	G/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.09	-13.46	-0.64	8.09e-32	Gut microbiome composition (summer);
CESC	cis	rs8031584	0.958	rs61997079	chr15:31238271	G/C	cg14298792	chr15:30685198	CHRFAM7A	-0.46	-5.51	-0.32	8.59e-8	Huntington's disease progression;
CESC	cis	rs5995756	0.761	rs1534883	chr22:40005425	T/C	cg03390717	chr22:39966585	CACNA1I	-0.36	-6.18	-0.35	2.4e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs12477438	0.798	rs2309524	chr2:99659510	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-11.0	-0.56	1.96e-23	Chronic sinus infection;
CESC	cis	rs9911578	0.935	rs2302189	chr17:56584205	A/C	cg12560992	chr17:57184187	TRIM37	-0.92	-14.34	-0.66	6.66e-35	Intelligence (multi-trait analysis);
CESC	cis	rs853679	0.517	rs17774663	chr6:28120898	G/A	cg26335602	chr6:28129616	ZNF389	0.53	6.82	0.39	6.19e-11	Depression;
CESC	cis	rs6942756	1.000	rs2012919	chr7:128890812	C/T	cg02491457	chr7:128862824	NA	-0.7	-10.09	-0.53	1.75e-20	White matter hyperintensity burden;
CESC	cis	rs10782582	0.593	rs79552201	chr1:76215497	A/T	cg22875332	chr1:76189707	ACADM	-0.45	-5.32	-0.31	2.19e-7	Daytime sleep phenotypes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16479401	chr4:83956051	COPS4	-0.57	-6.61	-0.38	2.15e-10	Gut microbiome composition (summer);
CESC	cis	rs4665809	0.627	rs1465720	chr2:26412638	G/T	cg04944784	chr2:26401820	FAM59B	-0.91	-10.44	-0.54	1.36e-21	Gut microbiome composition (summer);
CESC	cis	rs9486719	1.000	rs2145535	chr6:97034715	G/A	cg06623918	chr6:96969491	KIAA0776	-0.8	-8.21	-0.45	9.56e-15	Migraine;Coronary artery disease;
CESC	cis	rs7552404	0.924	rs1498317	chr1:76171984	A/C	cg22875332	chr1:76189707	ACADM	0.69	9.3	0.5	5.49e-18	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs1371867	0.846	rs1660327	chr8:101292206	A/C	cg11906718	chr8:101322791	RNF19A	0.54	6.93	0.39	3.24e-11	Atrioventricular conduction;
CESC	cis	rs7914558	0.933	rs1538204	chr10:104733893	T/A	cg04362960	chr10:104952993	NT5C2	0.45	5.76	0.33	2.33e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs11122272	0.701	rs2883799	chr1:231531166	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.56	-7.66	-0.43	3.45e-13	Hemoglobin concentration;
CESC	cis	rs17125944	0.615	rs17125798	chr14:53319905	G/A	cg00686598	chr14:53173677	PSMC6	0.98	7.08	0.4	1.29e-11	Alzheimer's disease (late onset);
CESC	cis	rs1034435	0.755	rs6007871	chr22:48894392	C/G	cg05992904	chr22:48892994	FAM19A5	-0.57	-9.64	-0.51	4.75e-19	Late-onset Alzheimer's disease;
CESC	cis	rs501120	0.929	rs605425	chr10:44750669	T/C	cg09554077	chr10:44749378	NA	0.52	6.89	0.39	4.12e-11	Coronary artery disease;Coronary heart disease;
CESC	cis	rs67311347	1.000	rs73080138	chr3:40516417	A/G	cg01475735	chr3:40494733	NA	-0.42	-5.4	-0.32	1.46e-7	Renal cell carcinoma;
CESC	cis	rs763121	0.853	rs5750627	chr22:38982321	A/G	cg06022373	chr22:39101656	GTPBP1	0.93	16.41	0.71	2.96e-42	Menopause (age at onset);
CESC	cis	rs6598955	0.724	rs12754536	chr1:26639605	T/C	cg00852783	chr1:26633632	UBXN11	0.43	6.31	0.36	1.14e-9	Obesity-related traits;
CESC	cis	rs1552244	0.938	rs67667957	chr3:10167264	G/C	cg00149659	chr3:10157352	C3orf10	0.72	9.27	0.49	6.61e-18	Alzheimer's disease;
CESC	cis	rs7412746	0.658	rs4537557	chr1:150734436	A/G	cg09365446	chr1:150670422	GOLPH3L	0.39	5.11	0.3	6.21e-7	Melanoma;
CESC	cis	rs4843747	0.636	rs4075597	chr16:88107590	C/A	cg17633681	chr16:88106987	BANP	0.72	9.54	0.51	9.75e-19	Menopause (age at onset);
CESC	cis	rs6570726	0.755	rs2103633	chr6:145894021	C/T	cg05347473	chr6:146136440	FBXO30	0.59	7.63	0.42	4.24e-13	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs698833	0.669	rs1584885	chr2:44647038	A/C	cg02912187	chr19:18314776	RAB3A	-0.44	-6.03	-0.35	5.55e-9	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs7666738	0.830	rs34461023	chr4:99023751	C/T	cg18180107	chr4:99064573	C4orf37	0.42	5.44	0.32	1.2e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2710642	0.545	rs1406002	chr2:62807091	A/C	cg17519650	chr2:63277830	OTX1	0.47	6.26	0.36	1.53e-9	LDL cholesterol levels;LDL cholesterol;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg13415434	chr3:49044522	P4HTM;WDR6	0.47	6.03	0.35	5.43e-9	Gut microbiota (bacterial taxa);
CESC	trans	rs76747430	0.528	rs5750913	chr22:40640285	A/G	cg26752003	chr8:145688521	CYHR1	0.48	6.07	0.35	4.33e-9	Facial morphology (factor 20);
CESC	cis	rs6032067	0.929	rs6032044	chr20:43819416	C/A	cg11264863	chr20:43835661	SEMG1	0.48	5.29	0.31	2.53e-7	Blood protein levels;
CESC	cis	rs9300255	0.739	rs10846491	chr12:123753492	C/G	cg05973401	chr12:123451056	ABCB9	0.51	5.88	0.34	1.24e-8	Neutrophil percentage of white cells;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19726959	chr15:75094782	CSK	-0.52	-6.14	-0.35	3.05e-9	Gut microbiome composition (summer);
CESC	cis	rs6570726	0.791	rs11759979	chr6:145918881	C/T	cg23711669	chr6:146136114	FBXO30	0.94	14.11	0.66	4.13e-34	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2046867	0.818	rs1502757	chr3:72864161	C/T	cg25664220	chr3:72788482	NA	-0.47	-6.89	-0.39	4.1e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CESC	cis	rs1059312	1.000	rs7135854	chr12:129279988	G/C	cg09035930	chr12:129282057	SLC15A4	0.76	10.73	0.55	1.59e-22	Systemic lupus erythematosus;
CESC	cis	rs12042052	1.000	rs72754230	chr1:232935071	A/G	cg06935979	chr1:232941706	KIAA1383	0.75	6.09	0.35	4.02e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CESC	cis	rs367943	0.712	rs26961	chr5:112736779	A/G	cg12552261	chr5:112820674	MCC	0.4	5.32	0.31	2.21e-7	Type 2 diabetes;
CESC	cis	rs7107174	1.000	rs10899467	chr11:78014057	G/T	cg02023728	chr11:77925099	USP35	0.43	5.66	0.33	4e-8	Testicular germ cell tumor;
CESC	cis	rs7666738	0.830	rs6852015	chr4:99054373	C/A	cg24818145	chr4:99064322	C4orf37	0.38	5.04	0.3	8.49e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11792861	0.591	rs2275641	chr9:111696389	G/C	cg05043794	chr9:111880884	C9orf5	-0.3	-5.43	-0.32	1.28e-7	Menarche (age at onset);
CESC	cis	rs35110281	0.666	rs2838348	chr21:45107285	C/G	cg04455712	chr21:45112962	RRP1B	-0.48	-7.52	-0.42	8.48e-13	Mean corpuscular volume;
CESC	cis	rs1957429	0.901	rs1957435	chr14:65349697	G/A	cg23373153	chr14:65346875	NA	0.96	11.49	0.58	4.43e-25	Pediatric areal bone mineral density (radius);
CESC	cis	rs11123694	1.000	rs11123694	chr2:109064563	C/T	cg01745370	chr2:109065127	GCC2	0.37	5.61	0.33	5.02e-8	Mean platelet volume;
CESC	cis	rs9322193	0.962	rs9767122	chr6:150104689	T/G	cg04369109	chr6:150039330	LATS1	-0.4	-5.4	-0.31	1.48e-7	Lung cancer;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg17740632	chr19:58892104	ZNF837	-0.45	-6.21	-0.36	2.03e-9	Fibrinogen levels;
CESC	cis	rs875971	0.660	rs801192	chr7:66031952	C/G	cg18876405	chr7:65276391	NA	-0.59	-7.97	-0.44	4.6e-14	Aortic root size;
CESC	cis	rs6963495	0.818	rs56055535	chr7:105163574	C/A	cg13798780	chr7:105162888	PUS7	0.78	8.06	0.44	2.68e-14	Bipolar disorder (body mass index interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17902007	chr13:101184847	A2LD1	-0.62	-7.06	-0.4	1.43e-11	Gut microbiome composition (summer);
CESC	cis	rs7520050	0.807	rs4660312	chr1:46110572	A/G	cg06784218	chr1:46089804	CCDC17	0.33	5.95	0.34	8.33e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs7552404	0.924	rs12136754	chr1:76230232	C/A	cg10523679	chr1:76189770	ACADM	0.77	10.51	0.54	8.08e-22	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs7605827	0.897	rs4668922	chr2:15675130	C/T	cg19274914	chr2:15703543	NA	0.38	6.79	0.38	7.31e-11	Educational attainment (years of education);
CESC	cis	rs714031	0.934	rs5757768	chr22:40071322	G/A	cg21377881	chr22:40064566	CACNA1I	-0.4	-6.47	-0.37	4.69e-10	Schizophrenia;
CESC	cis	rs9811920	0.609	rs793467	chr3:99539664	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.47	5.73	0.33	2.79e-8	Axial length;
CESC	cis	rs11098499	0.865	rs28753180	chr4:120405367	A/T	cg09307838	chr4:120376055	NA	0.93	13.07	0.63	1.78e-30	Corneal astigmatism;
CESC	cis	rs9486719	1.000	rs9373978	chr6:97056255	T/C	cg18709589	chr6:96969512	KIAA0776	-0.52	-5.71	-0.33	3.09e-8	Migraine;Coronary artery disease;
CESC	cis	rs35306767	0.715	rs1871622	chr10:1049309	T/G	cg25019033	chr10:957182	NA	-0.56	-5.57	-0.32	6.34e-8	Eosinophil percentage of granulocytes;
CESC	cis	rs6963495	0.818	rs56177071	chr7:105165648	C/T	cg19920283	chr7:105172520	RINT1	0.7	6.66	0.38	1.58e-10	Bipolar disorder (body mass index interaction);
CESC	cis	rs2573652	1.000	rs7163481	chr15:100516916	C/G	cg09918751	chr15:100517450	ADAMTS17	0.42	8.07	0.44	2.39e-14	Height;
CESC	cis	rs9926296	0.542	rs12599531	chr16:89909401	C/T	cg27121462	chr16:89883253	FANCA	-0.51	-6.1	-0.35	3.66e-9	Vitiligo;
CESC	cis	rs12478296	0.901	rs73007142	chr2:243010852	T/C	cg06360820	chr2:242988706	NA	-1.04	-10.22	-0.53	7.03e-21	Obesity-related traits;
CESC	cis	rs9916302	0.904	rs12600751	chr17:37553651	G/C	cg15445000	chr17:37608096	MED1	-0.39	-5.95	-0.34	8.41e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg24642844	chr7:1081250	C7orf50	-0.77	-9.63	-0.51	5.27e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs6502050	0.723	rs11650633	chr17:80083807	T/C	cg11859384	chr17:80120422	CCDC57	0.38	5.21	0.3	3.88e-7	Life satisfaction;
CESC	cis	rs8103278	0.507	rs8112282	chr19:46265029	C/T	cg11657440	chr19:46296263	DMWD	0.77	11.86	0.59	2.57e-26	Coronary artery disease;
CESC	cis	rs75477785	0.590	rs72649949	chr1:210244351	A/G	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.92	6.23	0.36	1.82e-9	Cleft lip with or without cleft palate;
CESC	cis	rs8177179	0.967	rs6439436	chr3:133453779	C/T	cg16262614	chr3:133464971	TF	-0.39	-7.78	-0.43	1.66e-13	Iron status biomarkers (transferrin levels);
CESC	cis	rs6582630	0.599	rs8189525	chr12:38424982	A/C	cg26384229	chr12:38710491	ALG10B	0.41	5.58	0.32	6.04e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs7917772	0.545	rs3934960	chr10:104355275	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.4	-5.4	-0.31	1.49e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs854765	0.619	rs4561528	chr17:17979099	C/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.51	6.52	0.37	3.59e-10	Total body bone mineral density;
CESC	cis	rs7089973	0.604	rs11196936	chr10:116588630	C/T	cg03647239	chr10:116582469	FAM160B1	0.43	5.29	0.31	2.6e-7	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs7674212	0.539	rs6533056	chr4:104120997	T/C	cg16532752	chr4:104119610	CENPE	-0.4	-5.48	-0.32	1.01e-7	Type 2 diabetes;
CESC	cis	rs9303401	0.573	rs35104446	chr17:57180234	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.89	11.2	0.57	4.21e-24	Cognitive test performance;
CESC	cis	rs17666538	0.539	rs1703925	chr8:608279	A/G	cg13264159	chr8:625131	ERICH1	-0.69	-5.15	-0.3	5.02e-7	IgG glycosylation;
CESC	cis	rs9291683	0.552	rs10939655	chr4:10014642	A/T	cg11266682	chr4:10021025	SLC2A9	0.72	14.87	0.67	8.7e-37	Bone mineral density;
CESC	cis	rs2180341	1.000	rs6904520	chr6:127629802	T/C	cg24812749	chr6:127587940	RNF146	1.07	15.48	0.69	6e-39	Breast cancer;
CESC	cis	rs6088580	0.524	rs6087612	chr20:33230822	T/G	cg08999081	chr20:33150536	PIGU	-0.44	-6.19	-0.36	2.33e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs2276314	1.000	rs9304154	chr18:33562227	C/T	cg19628046	chr18:33552617	C18orf21	0.53	5.72	0.33	2.83e-8	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs6963495	0.872	rs1569134	chr7:105158228	T/C	cg19920283	chr7:105172520	RINT1	0.69	6.56	0.37	2.85e-10	Bipolar disorder (body mass index interaction);
CESC	cis	rs748404	0.631	rs2467745	chr15:43722742	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.57	7.62	0.42	4.42e-13	Lung cancer;
CESC	cis	rs2732480	0.517	rs2634676	chr12:48738236	A/G	cg04545296	chr12:48745243	ZNF641	0.44	7.23	0.41	5.12e-12	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs9790314	1.000	rs7653233	chr3:160992033	G/A	cg03342759	chr3:160939853	NMD3	-0.53	-7.24	-0.41	4.97e-12	Morning vs. evening chronotype;
CESC	cis	rs875971	1.000	rs12532998	chr7:65967459	A/C	cg11764359	chr7:65958608	NA	0.96	15.27	0.68	3.49e-38	Aortic root size;
CESC	cis	rs7914558	0.505	rs12260436	chr10:104741114	A/C	cg04362960	chr10:104952993	NT5C2	0.53	6.29	0.36	1.33e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs6570726	0.935	rs390252	chr6:145856896	A/G	cg23711669	chr6:146136114	FBXO30	0.8	11.74	0.58	6.58e-26	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs889398	0.802	rs12598642	chr16:69848772	A/G	cg09409435	chr16:70099608	PDXDC2	-0.4	-5.06	-0.3	7.91e-7	Body mass index;
CESC	cis	rs6835098	1.000	rs28477433	chr4:174085820	T/C	cg08422745	chr4:174089978	GALNT7	-0.84	-12.19	-0.6	1.92e-27	Dementia and core Alzheimer's disease neuropathologic changes;
CESC	cis	rs208520	0.690	rs12208977	chr6:66725257	G/A	cg07460842	chr6:66804631	NA	0.96	12.77	0.62	2e-29	Exhaled nitric oxide output;
CESC	cis	rs7247513	0.639	rs12984441	chr19:12760287	A/C	cg06417478	chr19:12876846	HOOK2	0.43	5.36	0.31	1.86e-7	Bipolar disorder;
CESC	cis	rs2243480	1.000	rs34815098	chr7:65292254	A/C	cg18252515	chr7:66147081	NA	-1.01	-9.72	-0.51	2.6e-19	Diabetic kidney disease;
CESC	trans	rs916888	0.773	rs199457	chr17:44795469	C/T	cg23590916	chr17:43697445	MGC57346	0.65	6.44	0.37	5.62e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs3738443	0.594	rs6664697	chr1:247380610	A/T	cg07706540	chr1:247373924	NA	0.47	5.74	0.33	2.61e-8	Alcohol dependence;
CESC	cis	rs7833790	0.724	rs10958045	chr8:82722994	T/C	cg06027949	chr8:82754900	SNX16	-0.44	-5.24	-0.31	3.31e-7	Diastolic blood pressure;
CESC	cis	rs4660306	1.000	rs2993259	chr1:46001550	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.6	-7.53	-0.42	8.05e-13	Homocysteine levels;
CESC	cis	rs4243830	0.850	rs1114661	chr1:6596871	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.98	-9.9	-0.52	7.19e-20	Body mass index;
CESC	cis	rs6732160	0.691	rs2007191	chr2:73421463	T/G	cg01422370	chr2:73384389	NA	0.43	7.29	0.41	3.57e-12	Intelligence (multi-trait analysis);
CESC	cis	rs514406	0.755	rs11206015	chr1:53242187	T/C	cg25767906	chr1:53392781	SCP2	0.43	6.06	0.35	4.75e-9	Monocyte count;
CESC	trans	rs2115172	0.836	rs4835799	chr5:122762229	A/G	cg04621255	chr9:131581398	ENDOG	0.44	6.01	0.35	5.98e-9	Weight;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg15739904	chr8:125313885	NA	-0.48	-6.37	-0.36	8.35e-10	Asthma;
CESC	cis	rs798554	0.836	rs798490	chr7:2801542	C/T	cg09658497	chr7:2847517	GNA12	-0.43	-6.15	-0.35	2.77e-9	Height;
CESC	trans	rs916888	0.821	rs199525	chr17:44847834	T/G	cg23590916	chr17:43697445	MGC57346	0.65	6.58	0.37	2.51e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg00292435	chr9:91925643	CKS2	-0.43	-6.35	-0.36	9.2e-10	Gambling;
CESC	cis	rs11098499	0.913	rs35271032	chr4:120156659	C/T	cg09307838	chr4:120376055	NA	0.87	11.45	0.58	6.04e-25	Corneal astigmatism;
CESC	cis	rs10504229	0.815	rs16921955	chr8:58164553	C/T	cg05313129	chr8:58192883	C8orf71	-0.43	-5.09	-0.3	6.71e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs2204008	0.576	rs11519979	chr12:37999413	C/T	cg26384229	chr12:38710491	ALG10B	0.74	10.71	0.55	1.77e-22	Bladder cancer;
CESC	cis	rs1580019	0.922	rs59938271	chr7:32484844	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.89	12.23	0.6	1.43e-27	Cognitive ability;
CESC	cis	rs35110281	0.782	rs4818856	chr21:45043495	A/G	cg01579765	chr21:45077557	HSF2BP	-0.55	-9.2	-0.49	1.12e-17	Mean corpuscular volume;
CESC	cis	rs2361718	0.500	rs4889970	chr17:78096086	C/T	cg14949292	chr17:78079608	GAA	0.36	5.13	0.3	5.5e-7	Yeast infection;
CESC	cis	rs7165102	0.895	rs1699937	chr15:65791579	T/C	cg11441148	chr15:65824328	PTPLAD1	-0.31	-5.21	-0.3	3.74e-7	Mean corpuscular hemoglobin;
CESC	cis	rs7666738	0.830	rs116103936	chr4:98954531	T/C	cg05340658	chr4:99064831	C4orf37	0.8	12.4	0.61	3.76e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7412746	0.658	rs72704652	chr1:150819470	A/G	cg09365446	chr1:150670422	GOLPH3L	0.4	5.31	0.31	2.34e-7	Melanoma;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg20617956	chr10:82168530	C10orf58	-0.47	-6.65	-0.38	1.64e-10	Height;
CESC	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg22105103	chr4:187893119	NA	0.49	6.86	0.39	4.89e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs8017423	0.935	rs7158410	chr14:90704370	T/C	cg14092571	chr14:90743983	NA	-0.56	-8.31	-0.45	4.95e-15	Mortality in heart failure;
CESC	cis	rs748404	0.660	rs694725	chr15:43756210	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.57	7.49	0.42	1.01e-12	Lung cancer;
CESC	cis	rs10752881	1.000	rs10797802	chr1:182973158	A/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.85	-13.52	-0.64	4.8e-32	Colorectal cancer;
CESC	cis	rs4713118	0.662	rs149900	chr6:28014597	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.53	-5.74	-0.33	2.55e-8	Parkinson's disease;
CESC	cis	rs2204008	0.748	rs7312204	chr12:38334909	T/C	cg26384229	chr12:38710491	ALG10B	0.65	9.63	0.51	5.06e-19	Bladder cancer;
CESC	cis	rs57506017	0.585	rs1020006	chr7:12255664	G/A	cg23422036	chr7:12250390	TMEM106B	0.39	5.23	0.31	3.36e-7	Neuroticism;
CESC	cis	rs4819052	1.000	rs733738	chr21:46666396	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.87	-11.68	-0.58	1.08e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs116095464	0.558	rs6555055	chr5:226160	A/C	cg10591111	chr5:226296	SDHA	-0.53	-6.61	-0.38	2.15e-10	Breast cancer;
CESC	cis	rs11650494	0.831	rs73324348	chr17:47455752	G/A	cg08112188	chr17:47440006	ZNF652	1.04	8.0	0.44	3.86e-14	Prostate cancer;
CESC	cis	rs6543140	0.964	rs1523206	chr2:103070175	A/T	cg04239558	chr2:103089729	SLC9A4	0.47	5.99	0.35	6.67e-9	Blood protein levels;
CESC	trans	rs941207	0.542	rs2888095	chr12:57187473	C/T	cg26462586	chr2:11164677	NA	0.38	6.02	0.35	5.82e-9	Platelet count;
CESC	cis	rs6732160	0.574	rs1991612	chr2:73480501	G/C	cg01422370	chr2:73384389	NA	0.44	7.54	0.42	7.49e-13	Intelligence (multi-trait analysis);
CESC	cis	rs1065852	0.526	rs2097562	chr22:42389500	T/C	cg22189786	chr22:42395067	WBP2NL	0.43	5.42	0.32	1.33e-7	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
CESC	trans	rs1373453	0.908	rs2277389	chr12:70066856	C/T	cg19702771	chr4:82058885	PRKG2	0.74	6.04	0.35	5.28e-9	Orofacial clefts;
CESC	cis	rs854765	0.964	rs854764	chr17:18011750	A/G	cg16928487	chr17:17741425	SREBF1	0.61	9.81	0.52	1.41e-19	Total body bone mineral density;
CESC	cis	rs2243480	1.000	rs781142	chr7:65438778	C/T	cg13147721	chr7:65941812	NA	-0.87	-8.63	-0.47	5.76e-16	Diabetic kidney disease;
CESC	cis	rs1799949	1.000	rs1960605	chr17:41305397	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.66	9.22	0.49	9.27e-18	Menopause (age at onset);
CESC	cis	rs76878669	0.561	rs4930362	chr11:66154360	T/C	cg18002602	chr11:66138449	SLC29A2	0.4	6.76	0.38	8.68e-11	Educational attainment (years of education);
CESC	cis	rs2425143	0.818	rs73902932	chr20:34489009	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.68	5.87	0.34	1.33e-8	Blood protein levels;
CESC	cis	rs4604732	0.588	rs74154678	chr1:247626202	A/T	cg12754571	chr1:247694271	LOC148824;OR2C3	0.44	5.44	0.32	1.21e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs9910055	0.573	rs113184718	chr17:42206543	A/T	cg13607699	chr17:42295918	UBTF	-0.6	-7.82	-0.43	1.23e-13	Total body bone mineral density;
CESC	cis	rs8031584	0.918	rs61997139	chr15:31273602	C/G	cg14829155	chr15:31115871	NA	-0.71	-9.41	-0.5	2.52e-18	Huntington's disease progression;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15427160	chr3:186524114	RFC4	0.57	6.05	0.35	4.86e-9	Gut microbiome composition (summer);
CESC	cis	rs12530845	1.000	rs56060450	chr7:135331777	C/T	cg23117316	chr7:135346802	PL-5283	-0.41	-5.29	-0.31	2.52e-7	Red blood cell traits;
CESC	cis	rs4803455	0.565	rs2241713	chr19:41869468	C/G	cg09537434	chr19:41945824	ATP5SL	0.69	9.91	0.52	6.84e-20	Migraine;Coronary artery disease;
CESC	cis	rs4665809	0.590	rs13006973	chr2:26454707	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.1	12.68	0.61	4e-29	Gut microbiome composition (summer);
CESC	cis	rs2354432	0.891	rs2165743	chr1:146690319	C/T	cg25205988	chr1:146714368	CHD1L	1.08	11.4	0.57	8.97e-25	Mitochondrial DNA levels;
CESC	cis	rs287982	1.000	rs287979	chr2:9970967	T/C	cg10881225	chr2:9984929	TAF1B	-0.39	-5.12	-0.3	5.88e-7	Nonsyndromic cleft lip with cleft palate;
CESC	cis	rs12121840	0.790	rs16847083	chr1:165534130	C/T	cg16553119	chr1:165599451	MGST3	0.43	5.04	0.3	8.72e-7	Interleukin-1-receptor antagonist levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00383909	chr3:49044727	WDR6	-0.62	-7.02	-0.4	1.86e-11	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19598685	chr12:109592525	ACACB	0.57	6.9	0.39	3.87e-11	Gut microbiome composition (summer);
CESC	cis	rs6460942	1.000	rs117657017	chr7:12318891	T/C	cg20607287	chr7:12443886	VWDE	-0.79	-8.51	-0.46	1.32e-15	Coronary artery disease;
CESC	cis	rs8002861	0.846	rs56408817	chr13:44471983	A/G	cg14210620	chr13:44453864	C13orf31;CCDC122	-0.44	-5.48	-0.32	9.92e-8	Leprosy;
CESC	cis	rs4835473	0.932	rs6843671	chr4:144693194	T/G	cg25736465	chr4:144833511	NA	-0.33	-5.15	-0.3	5e-7	Immature fraction of reticulocytes;
CESC	cis	rs10504229	0.639	rs2318146	chr8:58114873	T/G	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs751728	0.664	rs6929696	chr6:33759290	C/T	cg25922239	chr6:33757077	LEMD2	-0.43	-6.01	-0.35	6.02e-9	Crohn's disease;
CESC	cis	rs7208859	0.573	rs216443	chr17:28931871	A/G	cg19761014	chr17:28927070	LRRC37B2	0.81	6.39	0.37	7.41e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs7520050	0.807	rs28844317	chr1:46209207	T/C	cg24296786	chr1:45957014	TESK2	-0.48	-6.19	-0.36	2.27e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs17253792	0.822	rs17747083	chr14:56110594	T/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.79	6.04	0.35	5.13e-9	Putamen volume;
CESC	cis	rs7665939	0.932	rs66626876	chr4:190101569	T/G	cg14840187	chr4:190284988	NA	-0.64	-6.6	-0.38	2.28e-10	Amyotrophic lateral sclerosis;
CESC	cis	rs1048238	0.818	rs945421	chr1:16345393	T/C	cg21214613	chr1:16344536	HSPB7	0.32	5.25	0.31	3.08e-7	Systolic blood pressure;
CESC	cis	rs9911578	0.967	rs302842	chr17:56728102	C/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.27	0.31	2.87e-7	Intelligence (multi-trait analysis);
CESC	cis	rs8018808	1.000	rs4899652	chr14:77848972	A/G	cg20045696	chr14:77926864	AHSA1	-0.43	-5.81	-0.34	1.82e-8	Myeloid white cell count;
CESC	cis	rs2996428	0.667	rs11576900	chr1:3770914	A/G	cg13057898	chr1:3703894	LRRC47	0.44	5.98	0.34	7.28e-9	Red cell distribution width;
CESC	cis	rs1355223	0.545	rs12278318	chr11:34876507	C/G	cg11058730	chr11:34937778	PDHX;APIP	-0.55	-6.59	-0.38	2.37e-10	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs7264396	0.690	rs2425171	chr20:34443173	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.85	-11.51	-0.58	3.81e-25	Total cholesterol levels;
CESC	trans	rs3780486	0.846	rs2209948	chr9:33138247	G/A	cg04842962	chr6:43655489	MRPS18A	1.0	18.82	0.76	9.47e-51	IgG glycosylation;
CESC	cis	rs2073300	0.609	rs6132617	chr20:23420151	G/C	cg12062639	chr20:23401060	NAPB	0.89	7.28	0.41	3.91e-12	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs7212590	0.748	rs7223057	chr17:57936438	G/C	cg20303301	chr17:57937339	TUBD1	-0.53	-5.24	-0.31	3.3e-7	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs9916302	0.718	rs10445306	chr17:37591422	A/G	cg00129232	chr17:37814104	STARD3	-0.56	-7.4	-0.41	1.85e-12	Glomerular filtration rate (creatinine);
CESC	cis	rs7666738	0.861	rs5014702	chr4:99052102	C/A	cg03467027	chr4:99064603	C4orf37	0.47	5.94	0.34	8.77e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7274811	0.744	rs209665	chr20:32128889	T/G	cg21523528	chr20:32077966	CBFA2T2	0.43	5.21	0.31	3.73e-7	Height;
CESC	cis	rs9815354	1.000	rs9875083	chr3:41775786	T/A	cg03022575	chr3:42003672	ULK4	0.55	5.41	0.32	1.39e-7	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs11098499	0.908	rs11098527	chr4:120399906	A/G	cg09307838	chr4:120376055	NA	0.92	12.88	0.62	8.65e-30	Corneal astigmatism;
CESC	cis	rs7615952	0.576	rs12497295	chr3:125818650	G/A	cg04553112	chr3:125709451	NA	-0.54	-5.82	-0.34	1.71e-8	Blood pressure (smoking interaction);
CESC	cis	rs7914558	0.966	rs10450373	chr10:104728616	T/C	cg04362960	chr10:104952993	NT5C2	0.44	5.74	0.33	2.57e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs708547	0.647	rs1718830	chr4:57888510	T/C	cg16868167	chr4:57843880	C4orf14;POLR2B	0.48	6.67	0.38	1.48e-10	Response to bleomycin (chromatid breaks);
CESC	cis	rs4713118	0.587	rs9393899	chr6:28133528	G/C	cg12963246	chr6:28129442	ZNF389	0.56	7.38	0.41	1.99e-12	Parkinson's disease;
CESC	cis	rs9910055	0.762	rs227579	chr17:42223134	A/T	cg10896456	chr17:42255109	ASB16;C17orf65	-0.46	-6.9	-0.39	3.86e-11	Total body bone mineral density;
CESC	cis	rs4975709	0.589	rs1466606	chr5:1865055	C/T	cg12288994	chr5:1860383	NA	0.42	7.1	0.4	1.12e-11	Cardiovascular disease risk factors;
CESC	cis	rs4665809	0.589	rs4665842	chr2:26448954	A/G	cg27170947	chr2:26402098	FAM59B	-0.87	-9.83	-0.52	1.2e-19	Gut microbiome composition (summer);
CESC	cis	rs1499614	1.000	rs1882655	chr7:66147057	T/C	cg18252515	chr7:66147081	NA	1.42	14.47	0.66	2.33e-35	Gout;
CESC	cis	rs13118159	0.550	rs4974614	chr4:1373489	A/G	cg16405210	chr4:1374714	KIAA1530	-0.98	-13.46	-0.64	7.93e-32	Longevity;
CESC	cis	rs3806843	0.966	rs6579965	chr5:140168811	T/G	cg26395211	chr5:140044315	WDR55	-0.42	-5.43	-0.32	1.26e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs6582630	0.593	rs11182590	chr12:38574274	A/T	cg26384229	chr12:38710491	ALG10B	0.52	7.36	0.41	2.25e-12	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs7937682	0.562	rs527847	chr11:111369132	A/C	cg22437258	chr11:111473054	SIK2	-0.47	-5.97	-0.34	7.65e-9	Primary sclerosing cholangitis;
CESC	cis	rs597539	0.652	rs660614	chr11:68659488	G/A	cg01988459	chr11:68622903	NA	-0.4	-5.5	-0.32	8.8e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs75804782	0.641	rs3769124	chr2:239349362	G/A	cg18131467	chr2:239335373	ASB1	-0.66	-5.83	-0.34	1.58e-8	Morning vs. evening chronotype;Chronotype;
CESC	cis	rs3820068	0.603	rs7536654	chr1:15989141	C/G	cg13390004	chr1:15929781	NA	0.31	5.17	0.3	4.66e-7	Systolic blood pressure;
CESC	cis	rs17826219	0.568	rs7213925	chr17:29121634	A/G	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.79e-10	Body mass index;
CESC	cis	rs11711311	1.000	rs7633832	chr3:113472292	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.72	10.06	0.53	2.24e-20	IgG glycosylation;
CESC	cis	rs2635047	0.967	rs3816125	chr18:44601611	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.56	-6.97	-0.39	2.49e-11	Educational attainment;
CESC	trans	rs61931739	0.500	rs11053248	chr12:34518011	G/A	cg13010199	chr12:38710504	ALG10B	0.5	6.42	0.37	6.3e-10	Morning vs. evening chronotype;
CESC	cis	rs8067545	0.611	rs1992561	chr17:20219119	G/A	cg13482628	chr17:19912719	NA	-0.39	-5.06	-0.3	8.02e-7	Schizophrenia;
CESC	cis	rs929354	0.772	rs6459738	chr7:156998532	T/G	cg05182265	chr7:156933206	UBE3C	-0.51	-7.47	-0.42	1.2e-12	Body mass index;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24034568	chr3:184080707	CLCN2;POLR2H	0.67	7.74	0.43	2.08e-13	Gut microbiome composition (summer);
CESC	cis	rs2115630	0.846	rs8024538	chr15:85368419	A/T	cg11189052	chr15:85197271	WDR73	-0.43	-5.65	-0.33	4.2e-8	P wave terminal force;
CESC	cis	rs116095464	0.558	rs9688045	chr5:254035	T/C	cg22496380	chr5:211416	CCDC127	-0.73	-8.39	-0.46	2.99e-15	Breast cancer;
CESC	cis	rs1552244	1.000	rs113771705	chr3:10075983	T/C	cg08888203	chr3:10149979	C3orf24	0.46	5.9	0.34	1.11e-8	Alzheimer's disease;
CESC	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.55	0.37	2.91e-10	Prudent dietary pattern;
CESC	cis	rs514406	0.698	rs522259	chr1:53365481	A/G	cg25767906	chr1:53392781	SCP2	-0.54	-7.48	-0.42	1.08e-12	Monocyte count;
CESC	cis	rs9796	0.621	rs2918462	chr15:41481254	A/G	cg20272979	chr15:41787780	ITPKA	-0.34	-5.15	-0.3	4.97e-7	Menopause (age at onset);
CESC	cis	rs7107174	1.000	rs2510050	chr11:77982564	A/G	cg02023728	chr11:77925099	USP35	0.47	6.49	0.37	4.19e-10	Testicular germ cell tumor;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg09164920	chr16:4526354	HMOX2;NMRAL1	-0.55	-7.35	-0.41	2.44e-12	Asthma;
CESC	trans	rs6089829	0.851	rs4809460	chr20:61661355	T/C	cg23505145	chr19:12996616	KLF1	0.52	6.7	0.38	1.24e-10	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs2797160	1.000	rs1739380	chr6:126012858	T/C	cg05901451	chr6:126070800	HEY2	0.46	6.56	0.37	2.81e-10	Endometrial cancer;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg09333812	chr10:99052472	ARHGAP19	-0.48	-6.62	-0.38	1.97e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs6570726	0.791	rs385729	chr6:145855465	T/C	cg05347473	chr6:146136440	FBXO30	0.57	7.3	0.41	3.36e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs801193	0.548	rs2659891	chr7:66201114	A/G	cg10691866	chr7:65817282	TPST1	-0.32	-5.45	-0.32	1.15e-7	Aortic root size;
CESC	cis	rs798554	0.959	rs798558	chr7:2758935	T/G	cg18446336	chr7:2847575	GNA12	-0.38	-5.75	-0.33	2.51e-8	Height;
CESC	cis	rs8103278	0.507	rs16939	chr19:46276056	C/A	cg06577658	chr19:46296270	DMWD	0.42	5.09	0.3	6.69e-7	Coronary artery disease;
CESC	cis	rs6860806	0.661	rs2136188	chr5:131577514	A/G	cg18758796	chr5:131593413	PDLIM4	-0.46	-6.58	-0.37	2.56e-10	Breast cancer;
CESC	cis	rs10733682	0.715	rs3814119	chr9:129462901	A/G	cg00232160	chr9:129468157	NA	0.38	6.12	0.35	3.4e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs10465746	0.935	rs12410617	chr1:84379461	G/C	cg10977910	chr1:84465055	TTLL7	0.47	6.37	0.36	8.21e-10	Obesity-related traits;
CESC	cis	rs4595586	1.000	rs4595586	chr12:39225991	A/T	cg26384229	chr12:38710491	ALG10B	-0.4	-5.61	-0.33	5.12e-8	Morning vs. evening chronotype;
CESC	cis	rs9311474	0.713	rs352165	chr3:52242902	A/G	cg05564831	chr3:52568323	NT5DC2	0.39	6.09	0.35	3.89e-9	Electroencephalogram traits;
CESC	cis	rs7103648	0.643	rs12365079	chr11:47696596	A/T	cg10504702	chr11:47789108	FNBP4	0.44	5.52	0.32	8.2e-8	Diastolic blood pressure;Systolic blood pressure;
CESC	cis	rs2836974	0.931	rs2836968	chr21:40642386	A/G	cg11890956	chr21:40555474	PSMG1	1.2	22.3	0.81	9.49e-63	Cognitive function;
CESC	cis	rs798766	0.723	rs3134865	chr4:1723279	T/C	cg05874882	chr4:1763078	NA	-0.6	-8.45	-0.46	1.98e-15	Bladder cancer;Urinary bladder cancer;
CESC	cis	rs79349575	0.783	rs17708633	chr17:47011620	C/G	cg26022315	chr17:47021804	SNF8	0.39	5.16	0.3	4.94e-7	Type 2 diabetes;
CESC	cis	rs875971	0.660	rs801211	chr7:66015689	T/G	cg11764359	chr7:65958608	NA	-0.73	-9.8	-0.52	1.49e-19	Aortic root size;
CESC	trans	rs801193	0.591	rs9986881	chr7:66173040	A/G	cg26939375	chr7:64535504	NA	0.49	6.47	0.37	4.67e-10	Aortic root size;
CESC	cis	rs56775891	1.000	rs4799088	chr18:77573548	A/G	cg13263691	chr18:77568018	NA	0.46	6.82	0.39	6.12e-11	Schizophrenia;
CESC	cis	rs4819052	0.851	rs1056100	chr21:46678711	A/C	cg11663144	chr21:46675770	NA	-0.52	-7.66	-0.43	3.51e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs595018	0.505	rs11230501	chr11:60598075	G/A	cg07268726	chr11:60701918	TMEM132A	-0.5	-5.66	-0.33	3.9e-8	Wegener's granulomatosis;
CESC	cis	rs12472274	0.646	rs2305171	chr2:239097140	G/A	cg17459225	chr2:239074497	NA	0.5	5.89	0.34	1.17e-8	Phospholipid levels (plasma);
CESC	cis	rs7635838	0.620	rs1666988	chr3:11284950	A/G	cg00170343	chr3:11313890	ATG7	0.51	7.08	0.4	1.26e-11	HDL cholesterol;
CESC	cis	rs3812762	0.833	rs35670750	chr11:8782444	T/C	cg03980550	chr11:8754370	ST5	-0.41	-5.58	-0.32	5.95e-8	Hypospadias;
CESC	cis	rs36051895	0.623	rs4358852	chr9:5251238	C/T	cg02405213	chr9:5042618	JAK2	-0.53	-6.45	-0.37	5.36e-10	Pediatric autoimmune diseases;
CESC	cis	rs2836950	0.565	rs2150414	chr21:40614988	A/G	cg11890956	chr21:40555474	PSMG1	-0.67	-9.24	-0.49	8.2e-18	Menarche (age at onset);
CESC	cis	rs115056730	0.520	rs113247402	chr2:98168573	T/C	cg26665480	chr2:98280029	ACTR1B	-0.93	-6.48	-0.37	4.37e-10	Monocyte chemoattractant protein-3 levels;
CESC	cis	rs6570726	0.643	rs9403735	chr6:145936591	C/T	cg23711669	chr6:146136114	FBXO30	0.97	14.71	0.67	3.19e-36	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7786877	0.626	rs11983745	chr7:100223678	T/C	cg16850897	chr7:100343110	ZAN	-0.62	-6.62	-0.38	1.99e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs425277	0.583	rs10910046	chr1:2041155	C/T	cg19257562	chr1:2043853	PRKCZ	0.35	5.75	0.33	2.43e-8	Height;
CESC	cis	rs2777491	1.000	rs7167729	chr15:41721042	G/A	cg20272979	chr15:41787780	ITPKA	0.45	6.68	0.38	1.39e-10	Ulcerative colitis;
CESC	cis	rs3806843	0.676	rs778593	chr5:140027216	T/C	cg16179182	chr5:140090404	VTRNA1-1	0.44	5.61	0.33	5.07e-8	Depressive symptoms (multi-trait analysis);
CESC	cis	rs5769765	0.908	rs138889	chr22:50226673	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.46	-5.19	-0.3	4.28e-7	Schizophrenia;
CESC	cis	rs2769264	0.505	rs11801791	chr1:151387508	C/T	cg18801370	chr1:151430492	POGZ	0.55	6.9	0.39	3.88e-11	Blood trace element (Cu levels);
CESC	cis	rs989978	0.532	rs10883364	chr10:101287586	A/G	cg09788492	chr10:101292477	NKX2-3	0.31	5.03	0.3	8.88e-7	Red blood cell count;
CESC	cis	rs55788414	0.932	rs12103403	chr16:81185904	C/A	cg06400318	chr16:81190750	PKD1L2	-0.57	-6.54	-0.37	3.21e-10	Left ventricular obstructive tract defect (maternal effect);
CESC	cis	rs830124	0.571	rs1667586	chr12:122382179	A/G	cg22168489	chr12:122356033	WDR66	-0.39	-5.14	-0.3	5.32e-7	Urinary metabolites;
CESC	cis	rs7301826	1.000	rs1106369	chr12:131300095	G/T	cg11011512	chr12:131303247	STX2	0.41	5.22	0.31	3.53e-7	Plasma plasminogen activator levels;
CESC	cis	rs10504229	0.596	rs7004566	chr8:58115602	G/C	cg02725872	chr8:58115012	NA	-0.45	-7.05	-0.4	1.52e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs1707322	1.000	rs4660896	chr1:46372416	A/G	cg03146154	chr1:46216737	IPP	0.71	9.86	0.52	9.69e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs10876993	0.893	rs1678504	chr12:58085498	G/C	cg18357645	chr12:58087776	OS9	0.65	10.98	0.56	2.31e-23	Celiac disease or Rheumatoid arthritis;
CESC	cis	rs4713118	0.515	rs9368549	chr6:28050047	T/A	cg23281280	chr6:28129359	ZNF389	0.57	7.78	0.43	1.61e-13	Parkinson's disease;
CESC	cis	rs117623576	0.941	rs17230152	chr10:32431969	A/G	cg03047570	chr10:32398778	NA	-0.61	-5.56	-0.32	6.59e-8	Anti-saccade response;
CESC	cis	rs7618915	0.501	rs1866268	chr3:52719398	C/A	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	5.93	0.34	9.38e-9	Bipolar disorder;
CESC	cis	rs854765	0.583	rs7503334	chr17:17779458	C/T	cg16928487	chr17:17741425	SREBF1	0.61	10.65	0.55	2.81e-22	Total body bone mineral density;
CESC	cis	rs2645694	0.626	rs2703151	chr4:77834095	A/G	cg10057126	chr4:77819792	ANKRD56	0.46	6.44	0.37	5.58e-10	Emphysema distribution in smoking;
CESC	cis	rs4073582	0.595	rs3016319	chr11:65981846	C/T	cg14036092	chr11:66035641	RAB1B	0.55	7.59	0.42	5.59e-13	Gout;
CESC	cis	rs11055008	0.620	rs2111941	chr12:12829404	A/T	cg04607235	chr12:12878440	APOLD1	0.5	6.58	0.37	2.5e-10	Pulse pressure;
CESC	cis	rs12995491	0.569	rs6724281	chr2:88529531	T/G	cg04511125	chr2:88470314	THNSL2	-0.71	-10.38	-0.54	2.19e-21	Response to metformin (IC50);
CESC	cis	rs9894429	1.000	rs7503679	chr17:79583843	G/C	cg21984481	chr17:79567631	NPLOC4	-0.49	-8.04	-0.44	2.97e-14	Eye color traits;
CESC	trans	rs877282	0.898	rs11253349	chr10:765897	C/G	cg22713356	chr15:30763199	NA	1.16	11.35	0.57	1.37e-24	Uric acid levels;
CESC	cis	rs2204008	0.665	rs11495668	chr12:38221018	C/T	cg13010199	chr12:38710504	ALG10B	0.53	6.65	0.38	1.69e-10	Bladder cancer;
CESC	cis	rs2842992	0.915	rs2758321	chr6:160071611	C/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.62	7.54	0.42	7.41e-13	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs1185460	0.967	rs1786141	chr11:118938315	C/T	cg01677386	chr11:118938358	VPS11	-0.47	-6.03	-0.35	5.54e-9	Coronary artery disease;
CESC	cis	rs595982	0.517	rs10404905	chr19:49406175	A/T	cg21252483	chr19:49399788	TULP2	0.35	5.18	0.3	4.47e-7	Red cell distribution width;
CESC	cis	rs6842047	1.000	rs9995366	chr4:187131384	T/C	cg23442198	chr4:187126114	CYP4V2	0.57	5.07	0.3	7.49e-7	Blood protein levels;
CESC	cis	rs7927592	0.871	rs871212	chr11:68348695	T/A	cg16797656	chr11:68205561	LRP5	0.39	5.36	0.31	1.82e-7	Total body bone mineral density;
CESC	cis	rs7726839	0.526	rs55647623	chr5:567747	T/C	cg09021430	chr5:549028	NA	-0.47	-6.34	-0.36	9.81e-10	Obesity-related traits;
CESC	cis	rs36051895	0.589	rs6476947	chr9:5204279	A/G	cg02405213	chr9:5042618	JAK2	-0.49	-5.69	-0.33	3.41e-8	Pediatric autoimmune diseases;
CESC	cis	rs977987	0.835	rs3851734	chr16:75371920	T/C	cg03315344	chr16:75512273	CHST6	0.4	5.64	0.33	4.32e-8	Dupuytren's disease;
CESC	cis	rs950027	0.549	rs9920634	chr15:45596546	G/T	cg21132104	chr15:45694354	SPATA5L1	-0.58	-6.96	-0.39	2.61e-11	Response to fenofibrate (adiponectin levels);
CESC	cis	rs2742234	0.590	rs2435339	chr10:43642173	G/C	cg07801480	chr10:43725741	RASGEF1A	0.42	5.31	0.31	2.34e-7	Hirschsprung disease;
CESC	cis	rs45535039	1.000	rs4938643	chr11:119119045	C/T	cg16724696	chr11:118992527	HINFP	0.43	5.29	0.31	2.61e-7	Plateletcrit;
CESC	cis	rs11078917	1	rs11078917	chr17:37746359	A/C	cg15445000	chr17:37608096	MED1	0.34	5.18	0.3	4.33e-7	Mean corpuscular volume;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg06832064	chr1:150551018	MCL1	-0.46	-6.59	-0.38	2.36e-10	Gambling;
CESC	cis	rs7833986	0.501	rs2719227	chr8:57043794	A/G	cg26371346	chr8:56986568	SNORD54;RPS20	-0.56	-5.14	-0.3	5.46e-7	Height;
CESC	cis	rs13720	0.673	rs163802	chr20:57578852	C/G	cg23907860	chr20:57583709	CTSZ	-0.47	-5.79	-0.34	1.98e-8	Platelet distribution width;
CESC	cis	rs9457247	0.967	rs377753	chr6:167389496	A/T	cg25258033	chr6:167368657	RNASET2	0.39	5.87	0.34	1.31e-8	Crohn's disease;
CESC	cis	rs644799	0.562	rs1313288	chr11:95520695	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.61	8.27	0.45	6.69e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs4665809	0.590	rs962217	chr2:26438276	T/C	cg22920501	chr2:26401640	FAM59B	-0.9	-10.16	-0.53	1.09e-20	Gut microbiome composition (summer);
CESC	cis	rs9733	0.596	rs72702552	chr1:150677462	G/A	cg22823121	chr1:150693482	HORMAD1	0.48	7.07	0.4	1.36e-11	Tonsillectomy;
CESC	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.49	-6.15	-0.35	2.92e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs963731	0.649	rs297137	chr2:39305721	T/C	cg04010122	chr2:39346883	SOS1	-0.76	-5.74	-0.33	2.65e-8	Corticobasal degeneration;
CESC	cis	rs5753618	0.555	rs5749286	chr22:31900359	G/T	cg02404636	chr22:31891804	SFI1	0.42	5.73	0.33	2.75e-8	Colorectal cancer;
CESC	cis	rs17293817	0.589	rs115985668	chr10:1419403	G/A	cg04271617	chr10:1416546	ADARB2	0.36	5.73	0.33	2.68e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs9611565	0.592	rs5751101	chr22:41828111	C/T	cg03806693	chr22:41940476	POLR3H	1.2	14.31	0.66	8.32e-35	Vitiligo;
CESC	cis	rs7851660	0.679	rs4297160	chr9:100585506	G/A	cg13688889	chr9:100608707	NA	-0.61	-9.31	-0.5	4.99e-18	Strep throat;
CESC	cis	rs854765	0.547	rs2955377	chr17:17932818	G/A	cg16928487	chr17:17741425	SREBF1	-0.53	-8.99	-0.48	4.71e-17	Total body bone mineral density;
CESC	trans	rs916888	0.821	rs199505	chr17:44859410	A/G	cg27125505	chr17:43679177	LOC644172	-0.48	-6.62	-0.38	2.01e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs5769765	0.862	rs138857	chr22:50199589	C/T	cg02269571	chr22:50332266	NA	-0.46	-5.72	-0.33	2.9e-8	Schizophrenia;
CESC	cis	rs9487051	0.597	rs351718	chr6:109552918	G/A	cg01475377	chr6:109611718	NA	-0.4	-5.35	-0.31	1.92e-7	Reticulocyte fraction of red cells;
CESC	cis	rs7267979	1.000	rs7018	chr20:25278261	A/G	cg08601574	chr20:25228251	PYGB	0.38	5.54	0.32	7.26e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs4819052	0.851	rs2838845	chr21:46670812	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.72	9.4	0.5	2.65e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs8063761	1.000	rs8063761	chr16:90027626	A/T	cg12064134	chr16:90016061	DEF8	0.4	5.31	0.31	2.27e-7	Squamous cell carcinoma;
CESC	cis	rs42648	0.935	rs42668	chr7:89986525	A/C	cg23697855	chr7:89950296	NA	0.27	5.12	0.3	5.75e-7	Homocysteine levels;
CESC	cis	rs863345	0.604	rs7518808	chr1:158491820	G/A	cg12129480	chr1:158549410	OR10X1	-0.34	-6.85	-0.39	5.17e-11	Pneumococcal bacteremia;
CESC	cis	rs3892630	0.757	rs8109823	chr19:33183316	A/G	cg22980127	chr19:33182716	NUDT19	1.02	11.67	0.58	1.15e-25	Red blood cell traits;
CESC	cis	rs6952808	0.601	rs3800882	chr7:2120758	G/A	cg23048001	chr7:2026167	MAD1L1	0.46	6.05	0.35	4.97e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs4454254	0.901	rs10088129	chr8:141060242	A/G	cg06693505	chr8:141057453	TRAPPC9	0.31	5.27	0.31	2.76e-7	Pulse pressure;
CESC	cis	rs72781680	0.898	rs72786298	chr2:24083011	C/T	cg08917208	chr2:24149416	ATAD2B	1.13	10.29	0.53	3.99e-21	Lymphocyte counts;
CESC	cis	rs6480314	0.831	rs10733840	chr10:69980221	A/G	cg06988349	chr10:69991859	ATOH7	-0.33	-5.23	-0.31	3.38e-7	Optic nerve measurement (disc area);
CESC	cis	rs7520050	0.933	rs6656022	chr1:46394315	A/G	cg03146154	chr1:46216737	IPP	-0.47	-6.1	-0.35	3.66e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs2731664	0.792	rs335466	chr5:176889530	C/A	cg23176889	chr5:176863531	GRK6	-0.64	-11.29	-0.57	2.1e-24	Intelligence (multi-trait analysis);
CESC	cis	rs72781680	0.752	rs7578606	chr2:23902360	T/C	cg20701182	chr2:24300061	SF3B14	0.8	6.92	0.39	3.33e-11	Lymphocyte counts;
CESC	cis	rs778371	0.697	rs4973564	chr2:233718440	A/G	cg08000102	chr2:233561755	GIGYF2	-0.84	-14.34	-0.66	6.47e-35	Schizophrenia;
CESC	cis	rs7613875	0.578	rs4688753	chr3:50074773	A/G	cg24110177	chr3:50126178	RBM5	0.58	8.17	0.45	1.28e-14	Body mass index;
CESC	cis	rs1048238	0.846	rs945422	chr1:16345619	T/C	cg21214613	chr1:16344536	HSPB7	0.31	5.04	0.3	8.71e-7	Systolic blood pressure;
CESC	cis	rs10927875	0.632	rs10927863	chr1:16165247	C/A	cg18973939	chr1:16164122	FLJ37453	0.36	5.46	0.32	1.07e-7	Dilated cardiomyopathy;
CESC	cis	rs7666738	0.753	rs34164013	chr4:98976333	A/G	cg03467027	chr4:99064603	C4orf37	0.43	5.4	0.31	1.49e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17340548	chr19:46185070	GIPR	0.63	7.53	0.42	7.97e-13	Gut microbiome composition (summer);
CESC	cis	rs12476592	0.602	rs6736029	chr2:63789170	G/A	cg17519650	chr2:63277830	OTX1	-0.48	-5.42	-0.32	1.34e-7	Childhood ear infection;
CESC	cis	rs7017914	0.967	rs6993170	chr8:71693519	A/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.44	-5.61	-0.33	4.99e-8	Bone mineral density;
CESC	trans	rs7618501	0.633	rs6446189	chr3:50008566	A/G	cg21659725	chr3:3221576	CRBN	0.52	7.18	0.4	7.23e-12	Intelligence (multi-trait analysis);
CESC	cis	rs79349575	0.783	rs12602746	chr17:47031741	A/C	cg16584676	chr17:46985605	UBE2Z	0.54	6.67	0.38	1.46e-10	Type 2 diabetes;
CESC	cis	rs9309473	0.500	rs6757996	chr2:73772251	G/A	cg20560298	chr2:73613845	ALMS1	-0.52	-7.35	-0.41	2.42e-12	Metabolite levels;
CESC	cis	rs60154123	0.772	rs614167	chr1:210425895	T/C	cg22029157	chr1:209979665	IRF6	0.5	5.75	0.33	2.5e-8	Coronary artery disease;
CESC	cis	rs6460942	0.597	rs7808537	chr7:12520913	G/C	cg20607287	chr7:12443886	VWDE	-0.7	-7.58	-0.42	5.83e-13	Coronary artery disease;
CESC	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg05552183	chr6:42928497	GNMT	-0.75	-12.03	-0.59	7.05e-27	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs7258465	1.000	rs7252707	chr19:18612257	G/A	cg25828334	chr19:18545568	ISYNA1	-0.35	-5.42	-0.32	1.36e-7	Breast cancer;
CESC	trans	rs7902708	0.920	rs11003015	chr10:54427337	T/G	cg26219051	chr22:43739629	SCUBE1	-0.48	-6.19	-0.36	2.25e-9	Bone properties (heel);
CESC	cis	rs2836633	1.000	rs2836634	chr21:40068230	T/A	cg05519781	chr21:40033154	ERG	0.59	9.22	0.49	9.41e-18	Coronary artery disease;
CESC	cis	rs7927592	0.763	rs10791982	chr11:68337664	T/G	cg20283391	chr11:68216788	NA	0.43	5.36	0.31	1.79e-7	Total body bone mineral density;
CESC	cis	rs2070677	1.000	rs4301745	chr10:135421636	T/G	cg20169779	chr10:135381914	SYCE1	-0.74	-9.88	-0.52	8.58e-20	Gout;
CESC	cis	rs7552404	0.727	rs2172508	chr1:76320215	A/G	cg10523679	chr1:76189770	ACADM	0.68	6.49	0.37	4.14e-10	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs7647973	0.710	rs12637313	chr3:49645458	A/G	cg03060546	chr3:49711283	APEH	0.64	7.27	0.41	4.1e-12	Menarche (age at onset);
CESC	trans	rs11098499	0.955	rs35916640	chr4:120155852	T/C	cg25214090	chr10:38739885	LOC399744	0.65	8.59	0.47	7.54e-16	Corneal astigmatism;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg02933375	chr17:78858828	RPTOR	0.53	7.03	0.4	1.77e-11	Fibrinogen levels;
CESC	cis	rs10504229	0.679	rs16921688	chr8:58054659	T/C	cg24829409	chr8:58192753	C8orf71	-0.58	-6.75	-0.38	9.05e-11	Developmental language disorder (linguistic errors);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15997374	chr11:64666193	ATG2A	-0.55	-6.11	-0.35	3.63e-9	Gut microbiome composition (summer);
CESC	cis	rs9549367	0.789	rs2287251	chr13:113889499	A/G	cg18105134	chr13:113819100	PROZ	-0.65	-7.73	-0.43	2.24e-13	Platelet distribution width;
CESC	cis	rs10129255	0.957	rs10137980	chr14:107183974	G/C	cg23076370	chr14:107095027	NA	-0.46	-6.01	-0.35	6.16e-9	Kawasaki disease;
CESC	cis	rs7520050	0.807	rs12025621	chr1:46228391	G/A	cg06784218	chr1:46089804	CCDC17	-0.31	-5.59	-0.32	5.66e-8	Red blood cell count;Reticulocyte count;
CESC	cis	rs1577917	1.000	rs11759855	chr6:86610841	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-5.91	-0.34	1.05e-8	Response to antipsychotic treatment;
CESC	cis	rs17376456	0.877	rs12109629	chr5:93359702	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.6	5.2	0.3	3.98e-7	Diabetic retinopathy;
CESC	cis	rs9894429	0.624	rs9910935	chr17:79613949	T/C	cg13777783	chr17:79615861	NA	-0.38	-5.91	-0.34	1.05e-8	Eye color traits;
CESC	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.58	7.51	0.42	8.95e-13	Prudent dietary pattern;
CESC	cis	rs7811142	0.562	rs7786844	chr7:99934008	T/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.91	10.16	0.53	1.1e-20	Platelet count;
CESC	cis	rs10504229	0.724	rs73603871	chr8:58107612	A/G	cg24829409	chr8:58192753	C8orf71	-0.56	-7.01	-0.4	1.97e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs4523957	0.719	rs1532292	chr17:2097483	T/G	cg16513277	chr17:2031491	SMG6	-0.57	-7.84	-0.43	1.08e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs9309473	0.847	rs13538	chr2:73868328	A/G	cg20560298	chr2:73613845	ALMS1	-0.53	-6.77	-0.38	8.13e-11	Metabolite levels;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg21989094	chr19:39421295	MRPS12;SARS2	-0.46	-6.53	-0.37	3.38e-10	Gambling;
CESC	trans	rs7246657	1.000	rs1823061	chr19:37800626	G/A	cg01833234	chr11:6592585	DNHD1	0.54	6.13	0.35	3.19e-9	Coronary artery calcification;
CESC	cis	rs6963495	0.818	rs55740553	chr7:105159551	A/G	cg13798780	chr7:105162888	PUS7	0.78	8.04	0.44	2.99e-14	Bipolar disorder (body mass index interaction);
CESC	cis	rs801193	1.000	rs2707845	chr7:66198798	C/T	cg11764359	chr7:65958608	NA	0.69	9.1	0.49	2.27e-17	Aortic root size;
CESC	cis	rs847577	0.587	rs34307903	chr7:97728449	C/A	cg21770322	chr7:97807741	LMTK2	0.83	14.06	0.65	6.11e-34	Breast cancer;
CESC	cis	rs6693567	0.565	rs1776275	chr1:150269437	G/T	cg09579323	chr1:150459698	TARS2	-0.47	-6.04	-0.35	5.18e-9	Migraine;
CESC	cis	rs6460942	0.908	rs6948654	chr7:12418546	T/A	cg20607287	chr7:12443886	VWDE	-0.73	-8.95	-0.48	6.59e-17	Coronary artery disease;
CESC	cis	rs910316	1.000	rs12590452	chr14:75548756	T/C	cg08847533	chr14:75593920	NEK9	1.02	20.23	0.78	1.12e-55	Height;
CESC	cis	rs56235845	0.964	rs11741640	chr5:176792743	G/A	cg06060754	chr5:176797920	RGS14	0.49	5.14	0.3	5.3e-7	Hemoglobin concentration;Hematocrit;
CESC	cis	rs6952808	0.582	rs10479762	chr7:2045351	T/C	cg21782813	chr7:2030301	MAD1L1	-0.4	-5.62	-0.33	4.71e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs2303759	0.709	rs10422677	chr19:49824290	C/T	cg22590775	chr19:49891494	CCDC155	0.45	5.04	0.3	8.62e-7	Multiple sclerosis;
CESC	cis	rs7914558	0.966	rs11191518	chr10:104782853	C/G	cg15744005	chr10:104629667	AS3MT	-0.33	-5.42	-0.32	1.33e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg06522697	chr10:121356224	TIAL1	-0.43	-6.04	-0.35	5.27e-9	Fibrinogen levels;
CESC	cis	rs4728302	0.934	rs10258052	chr7:133635874	T/C	cg10665199	chr7:133106180	EXOC4	-0.37	-5.04	-0.3	8.52e-7	Intelligence;Intelligence (multi-trait analysis);
CESC	cis	rs2836974	0.897	rs8132295	chr21:40527774	A/G	cg17971929	chr21:40555470	PSMG1	-1.03	-16.37	-0.71	4.3e-42	Cognitive function;
CESC	cis	rs7618915	0.501	rs34157897	chr3:52716937	T/C	cg17372223	chr3:52568218	NT5DC2	0.43	6.65	0.38	1.62e-10	Bipolar disorder;
CESC	cis	rs9303401	0.659	rs12600349	chr17:57054245	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	-0.98	-12.11	-0.6	3.72e-27	Cognitive test performance;
CESC	cis	rs1552244	0.572	rs3774208	chr3:10164722	T/G	cg00149659	chr3:10157352	C3orf10	1.0	11.96	0.59	1.22e-26	Alzheimer's disease;
CESC	cis	rs9915657	0.660	rs2241170	chr17:70070989	G/C	cg09344028	chr17:70110421	NA	0.39	7.08	0.4	1.32e-11	Thyroid hormone levels;
CESC	cis	rs6901004	0.803	rs193282	chr6:111543067	G/A	cg15721981	chr6:111408429	SLC16A10	-0.35	-5.07	-0.3	7.41e-7	Blood metabolite levels;
CESC	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg11494091	chr17:61959527	GH2	0.72	12.17	0.6	2.32e-27	Prudent dietary pattern;
CESC	cis	rs4242434	0.927	rs2291232	chr8:22464064	A/G	cg03733263	chr8:22462867	KIAA1967	0.93	14.86	0.67	9.8e-37	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CESC	cis	rs1707322	1.000	rs946524	chr1:46487560	A/G	cg06784218	chr1:46089804	CCDC17	-0.33	-5.6	-0.33	5.27e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs763014	0.898	rs1045277	chr16:633125	T/C	cg07256732	chr16:621771	PIGQ	-0.3	-5.14	-0.3	5.22e-7	Height;
CESC	cis	rs9818758	0.607	rs9847839	chr3:49289003	T/C	cg00383909	chr3:49044727	WDR6	0.79	6.09	0.35	4e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CESC	cis	rs4699052	1.000	rs7694190	chr4:104168017	A/G	cg16532752	chr4:104119610	CENPE	-0.37	-5.04	-0.3	8.58e-7	Testicular germ cell tumor;
CESC	cis	rs8077577	0.689	rs62072543	chr17:18243872	G/A	cg16794390	chr17:18148240	FLII	0.41	6.42	0.37	6.22e-10	Obesity-related traits;
CESC	cis	rs7937682	0.883	rs566647	chr11:111466607	A/G	cg22437258	chr11:111473054	SIK2	-0.75	-9.18	-0.49	1.27e-17	Primary sclerosing cholangitis;
CESC	cis	rs3820068	0.581	rs72645871	chr1:15926142	G/A	cg16988262	chr1:15930761	NA	0.35	5.65	0.33	4.18e-8	Systolic blood pressure;
CESC	cis	rs73206853	0.544	rs55752061	chr12:111126096	G/C	cg12870014	chr12:110450643	ANKRD13A	0.71	5.24	0.31	3.26e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs735396	0.731	rs1182933	chr12:121454622	C/T	cg25281562	chr12:121454272	C12orf43	0.52	6.49	0.37	4.18e-10	N-glycan levels;
CESC	trans	rs916888	0.821	rs199504	chr17:44861003	C/T	cg27125505	chr17:43679177	LOC644172	-0.5	-6.85	-0.39	5.1e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs6500602	0.727	rs4786515	chr16:4578133	T/A	cg08645402	chr16:4508243	NA	0.51	8.37	0.46	3.41e-15	Schizophrenia;
CESC	cis	rs7927771	0.864	rs2868459	chr11:47454972	C/G	cg05585544	chr11:47624801	NA	-0.49	-7.17	-0.4	7.46e-12	Subjective well-being;
CESC	cis	rs314370	0.521	rs314308	chr7:100420878	C/T	cg10426581	chr7:100472382	SRRT	0.49	5.44	0.32	1.21e-7	Resting heart rate;
CESC	cis	rs2455799	0.552	rs2470540	chr3:15718652	T/A	cg16303742	chr3:15540471	COLQ	-0.33	-5.16	-0.3	4.94e-7	Mean platelet volume;
CESC	cis	rs10504229	1.000	rs57624567	chr8:58176995	T/C	cg24829409	chr8:58192753	C8orf71	-0.76	-10.0	-0.52	3.53e-20	Developmental language disorder (linguistic errors);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04103315	chr3:42642047	NKTR	0.61	6.57	0.37	2.67e-10	Gut microbiome composition (summer);
CESC	cis	rs9916302	0.851	rs11078904	chr17:37650569	G/A	cg15445000	chr17:37608096	MED1	0.41	6.76	0.38	8.83e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs7412746	0.658	rs4970982	chr1:150865084	G/C	cg18016565	chr1:150552671	MCL1	0.34	5.07	0.3	7.52e-7	Melanoma;
CESC	trans	rs10411161	0.702	rs10423835	chr19:52387322	A/G	cg22319618	chr22:45562946	NUP50	-0.73	-7.14	-0.4	8.9e-12	Breast cancer;
CESC	cis	rs873946	0.586	rs12782567	chr10:134576709	C/G	cg18305652	chr10:134549665	INPP5A	-0.43	-6.0	-0.35	6.52e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs116095464	0.558	rs10043002	chr5:226753	G/A	cg20965017	chr5:231967	SDHA	-0.45	-5.15	-0.3	5.04e-7	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12435584	chr6:107780425	PDSS2	0.56	6.38	0.36	7.99e-10	Gut microbiome composition (summer);
CESC	cis	rs6580649	0.941	rs12580764	chr12:48453882	G/A	cg24011408	chr12:48396354	COL2A1	-0.42	-5.28	-0.31	2.67e-7	Lung cancer;
CESC	cis	rs34779708	0.966	rs35814343	chr10:35427714	G/T	cg03585969	chr10:35415529	CREM	0.76	10.09	0.53	1.81e-20	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs4665809	0.590	rs4665313	chr2:26415897	A/G	cg25036284	chr2:26402008	FAM59B	-0.82	-9.43	-0.5	2.23e-18	Gut microbiome composition (summer);
CESC	cis	rs8114671	0.836	rs6058154	chr20:33585834	C/T	cg24642439	chr20:33292090	TP53INP2	-0.51	-6.27	-0.36	1.45e-9	Height;
CESC	cis	rs9815354	1.000	rs17063649	chr3:41863406	C/T	cg03022575	chr3:42003672	ULK4	0.49	5.51	0.32	8.46e-8	Pulse pressure;Diastolic blood pressure;
CESC	trans	rs2963826	0.589	rs298091	chr5:58996603	A/T	cg11522767	chr6:157342961	ARID1B	0.48	6.31	0.36	1.18e-9	Obesity-related traits;
CESC	cis	rs1707322	0.752	rs11211152	chr1:46114157	C/T	cg05343316	chr1:45956843	TESK2	0.51	6.24	0.36	1.7e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9640161	0.789	rs13223702	chr7:150058968	G/A	cg21361702	chr7:150065534	REPIN1	0.61	6.62	0.38	1.93e-10	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs68170813	0.641	rs1978085	chr7:107095216	T/C	cg02696742	chr7:106810147	HBP1	-0.56	-5.26	-0.31	3.03e-7	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01140579	chr3:48541502	SHISA5	0.51	6.2	0.36	2.12e-9	Gut microbiome composition (summer);
CESC	cis	rs6964587	0.967	rs10248102	chr7:91699779	G/A	cg17063962	chr7:91808500	NA	0.6	8.37	0.46	3.45e-15	Breast cancer;
CESC	trans	rs7824557	0.525	rs12682349	chr8:11245303	C/G	cg06636001	chr8:8085503	FLJ10661	0.49	6.18	0.35	2.47e-9	Retinal vascular caliber;
CESC	cis	rs2286503	0.901	rs10950922	chr7:22854006	C/T	cg13679077	chr7:22862647	TOMM7	0.4	5.07	0.3	7.52e-7	Fibrinogen;
CESC	cis	rs9322193	0.962	rs12175575	chr6:150084487	G/A	cg04369109	chr6:150039330	LATS1	-0.39	-5.27	-0.31	2.82e-7	Lung cancer;
CESC	cis	rs8060686	0.858	rs7187289	chr16:67967878	A/C	cg26727032	chr16:67993705	SLC12A4	-0.64	-9.33	-0.5	4.45e-18	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs4805272	0.626	rs12608533	chr19:29331405	C/G	cg12756686	chr19:29218302	NA	0.42	5.87	0.34	1.3e-8	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
CESC	cis	rs6963495	0.818	rs73190161	chr7:105156871	C/T	cg19920283	chr7:105172520	RINT1	0.69	6.56	0.37	2.85e-10	Bipolar disorder (body mass index interaction);
CESC	cis	rs7692995	1.000	rs16896074	chr4:17947873	T/C	cg08925142	chr4:18023851	LCORL	-0.44	-5.1	-0.3	6.36e-7	Height;
CESC	cis	rs736408	0.562	rs12497998	chr3:52793602	C/T	cg07507251	chr3:52567010	NT5DC2	0.33	5.55	0.32	6.9e-8	Bipolar disorder;
CESC	cis	rs5769765	0.817	rs8142561	chr22:50291750	T/C	cg26441486	chr22:50317300	CRELD2	0.39	5.37	0.31	1.76e-7	Schizophrenia;
CESC	cis	rs6460942	0.841	rs17444203	chr7:12461864	C/G	cg16278512	chr7:12443529	VWDE	0.46	5.38	0.31	1.62e-7	Coronary artery disease;
CESC	cis	rs2668423	0.502	rs7254913	chr19:1388320	A/G	cg02639931	chr19:1387894	NDUFS7	0.69	15.0	0.68	2.98e-37	Nonalcoholic fatty liver disease;
CESC	cis	rs3820068	0.705	rs951225	chr1:15826292	G/A	cg17385448	chr1:15911702	AGMAT	0.39	6.18	0.35	2.44e-9	Systolic blood pressure;
CESC	cis	rs858239	0.600	rs10488077	chr7:23144182	A/T	cg23682824	chr7:23144976	KLHL7	0.51	6.8	0.39	7.07e-11	Cerebrospinal fluid biomarker levels;
CESC	cis	rs875971	1.000	rs6979382	chr7:65886375	C/T	cg12463550	chr7:65579703	CRCP	0.56	7.16	0.4	8.17e-12	Aortic root size;
CESC	cis	rs8014204	0.836	rs8021280	chr14:75290018	C/G	cg08847533	chr14:75593920	NEK9	0.47	6.01	0.35	6.18e-9	Caffeine consumption;
CESC	cis	rs7814319	0.646	rs938828	chr8:97316821	A/C	cg20787634	chr8:97240163	UQCRB	-0.57	-7.28	-0.41	3.75e-12	Lung function (FVC);
CESC	cis	rs7818688	1.000	rs7818688	chr8:96024082	C/A	cg16049864	chr8:95962084	TP53INP1	0.61	5.77	0.33	2.17e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs798554	0.797	rs798491	chr7:2800521	A/G	cg19717773	chr7:2847554	GNA12	-0.56	-7.87	-0.44	8.93e-14	Height;
CESC	cis	rs2046867	0.862	rs6778168	chr3:72840206	T/A	cg25664220	chr3:72788482	NA	-0.38	-5.69	-0.33	3.42e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CESC	cis	rs7618915	0.571	rs12487445	chr3:52618319	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	6.64	0.38	1.79e-10	Bipolar disorder;
CESC	cis	rs875971	1.000	rs6958277	chr7:65979349	A/G	cg10691866	chr7:65817282	TPST1	-0.36	-5.92	-0.34	9.82e-9	Aortic root size;
CESC	cis	rs3857536	0.776	rs9294687	chr6:66942919	C/T	cg07460842	chr6:66804631	NA	-0.41	-5.28	-0.31	2.71e-7	Blood trace element (Cu levels);
CESC	cis	rs600231	0.706	rs3782091	chr11:65336483	G/T	cg21890820	chr11:65308645	LTBP3	-0.4	-5.1	-0.3	6.4e-7	Bone mineral density;
CESC	cis	rs13256369	1.000	rs4841017	chr8:8577093	A/G	cg17143192	chr8:8559678	CLDN23	0.67	8.16	0.45	1.4e-14	Obesity-related traits;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg09041756	chr7:5570314	ACTB	-0.5	-6.84	-0.39	5.55e-11	Fibrinogen levels;
CESC	cis	rs11122272	0.735	rs2486735	chr1:231521778	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.57	-7.82	-0.43	1.29e-13	Hemoglobin concentration;
CESC	cis	rs854765	0.583	rs4534911	chr17:17852330	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.57	7.66	0.43	3.56e-13	Total body bone mineral density;
CESC	cis	rs6484504	0.576	rs2756191	chr11:31135882	A/T	cg14844989	chr11:31128820	NA	0.42	6.02	0.35	5.86e-9	Red blood cell count;
CESC	cis	rs9790314	0.521	rs60625846	chr3:161084525	G/T	cg04691961	chr3:161091175	C3orf57	-0.37	-5.11	-0.3	6.18e-7	Morning vs. evening chronotype;
CESC	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.51	0.37	3.75e-10	Prudent dietary pattern;
CESC	cis	rs9916302	0.904	rs7216086	chr17:37709422	G/A	cg07936489	chr17:37558343	FBXL20	-0.81	-11.8	-0.59	4.2e-26	Glomerular filtration rate (creatinine);
CESC	cis	rs17401966	0.931	rs10864448	chr1:10277497	A/T	cg15208524	chr1:10270712	KIF1B	0.47	6.0	0.35	6.47e-9	Hepatocellular carcinoma;
CESC	cis	rs1395	0.778	rs724311	chr2:27441645	A/G	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.44	5.92	0.34	1.01e-8	Blood metabolite levels;
CESC	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg17178900	chr1:205818956	PM20D1	0.78	12.92	0.62	5.92e-30	Menarche (age at onset);
CESC	cis	rs9649213	0.593	rs6961438	chr7:98005849	T/C	cg21770322	chr7:97807741	LMTK2	0.57	8.63	0.47	5.93e-16	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs748404	0.660	rs2249952	chr15:43720533	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.57	7.55	0.42	7.19e-13	Lung cancer;
CESC	cis	rs10465746	0.967	rs942849	chr1:84427499	G/A	cg10977910	chr1:84465055	TTLL7	0.46	6.18	0.35	2.45e-9	Obesity-related traits;
CESC	cis	rs769267	1.000	rs7246748	chr19:19433105	C/T	cg15052019	chr19:19431593	KIAA0892;SF4	-0.42	-5.39	-0.31	1.53e-7	Tonsillectomy;
CESC	cis	rs832540	0.931	rs832399	chr5:56222358	A/T	cg12311346	chr5:56204834	C5orf35	-0.43	-5.38	-0.31	1.66e-7	Coronary artery disease;
CESC	cis	rs9733	0.596	rs7418501	chr1:150711896	A/T	cg09365446	chr1:150670422	GOLPH3L	0.4	5.6	0.33	5.44e-8	Tonsillectomy;
CESC	cis	rs8103278	1.000	rs8108864	chr19:46301671	G/A	cg14061069	chr19:46274453	DMPK	-0.37	-5.07	-0.3	7.38e-7	Coronary artery disease;
CESC	cis	rs208520	0.690	rs4710311	chr6:66823223	C/T	cg07460842	chr6:66804631	NA	-0.86	-11.82	-0.59	3.51e-26	Exhaled nitric oxide output;
CESC	cis	rs11122272	0.735	rs2739515	chr1:231514681	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.57	-7.82	-0.43	1.29e-13	Hemoglobin concentration;
CESC	cis	rs34779708	0.931	rs34954932	chr10:35410807	G/T	cg03585969	chr10:35415529	CREM	0.77	10.36	0.54	2.41e-21	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs1538970	0.962	rs7532762	chr1:45864695	C/A	cg06784218	chr1:46089804	CCDC17	0.31	5.33	0.31	2.13e-7	Platelet count;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg15353389	chr12:120525027	CCDC64	0.48	6.59	0.38	2.43e-10	Systemic lupus erythematosus;
CESC	cis	rs6120849	0.754	rs6088686	chr20:33623437	C/T	cg06115741	chr20:33292138	TP53INP2	0.53	5.05	0.3	8.15e-7	Protein C levels;
CESC	trans	rs11098499	0.754	rs7672594	chr4:120248543	A/C	cg25214090	chr10:38739885	LOC399744	0.62	8.71	0.47	3.41e-16	Corneal astigmatism;
CESC	cis	rs2262909	0.962	rs73021832	chr19:22316144	G/C	cg11619707	chr19:22235551	ZNF257	0.34	5.48	0.32	1e-7	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
CESC	trans	rs10500991	0.737	rs11602503	chr11:24879440	T/C	cg07129253	chr8:30890560	PURG;WRN	-0.54	-6.74	-0.38	1.01e-10	Iron status biomarkers;
CESC	cis	rs367615	0.552	rs2416210	chr5:108741137	C/T	cg17395555	chr5:108820864	NA	-0.45	-7.45	-0.42	1.34e-12	Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs7666738	0.830	rs4699590	chr4:98974030	A/C	cg17366294	chr4:99064904	C4orf37	0.59	8.43	0.46	2.31e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs681343	1.000	rs681343	chr19:49206462	C/T	cg21064579	chr19:49206444	FUT2	0.52	7.39	0.41	1.98e-12	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
CESC	cis	rs9929218	0.953	rs9927329	chr16:68750331	C/T	cg02972257	chr16:68554789	NA	0.56	6.46	0.37	4.87e-10	Colorectal cancer;
CESC	cis	rs3096299	0.933	rs2965938	chr16:89491336	C/T	cg00750074	chr16:89608354	SPG7	-0.39	-5.62	-0.33	4.73e-8	Multiple myeloma (IgH translocation);
CESC	cis	rs778371	0.624	rs6733495	chr2:233616709	A/G	cg08000102	chr2:233561755	GIGYF2	0.83	14.46	0.66	2.52e-35	Schizophrenia;
CESC	cis	rs734999	0.549	rs3828154	chr1:2524943	G/A	cg18854424	chr1:2615690	NA	0.28	5.48	0.32	1.01e-7	Ulcerative colitis;
CESC	cis	rs853679	0.513	rs9468296	chr6:28113730	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.58	-6.6	-0.38	2.25e-10	Depression;
CESC	cis	rs2243480	0.803	rs36127118	chr7:65565505	A/G	cg12463550	chr7:65579703	CRCP	0.75	5.83	0.34	1.63e-8	Diabetic kidney disease;
CESC	cis	rs12478296	1.000	rs60533128	chr2:243028088	A/G	cg06360820	chr2:242988706	NA	-1.01	-9.22	-0.49	9.77e-18	Obesity-related traits;
CESC	cis	rs3850699	0.886	rs12773833	chr10:104418350	C/T	cg04362960	chr10:104952993	NT5C2	0.45	5.53	0.32	7.68e-8	Prostate cancer;
CESC	trans	rs2321882	0.958	rs6561986	chr13:59393763	C/T	cg20914879	chr14:56566808	NA	-0.43	-6.17	-0.35	2.51e-9	Body mass index;
CESC	cis	rs4950928	0.774	rs4950931	chr1:203164075	G/A	cg14085262	chr1:203155938	CHI3L1	-0.48	-5.3	-0.31	2.43e-7	YKL-40 levels;
CESC	cis	rs896854	0.625	rs7823886	chr8:95986459	A/T	cg13393036	chr8:95962371	TP53INP1	-0.47	-9.94	-0.52	5.45e-20	Type 2 diabetes;
CESC	cis	rs1348850	0.567	rs3770009	chr2:178536544	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.56	6.78	0.38	7.63e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs668210	0.793	rs586921	chr11:65747701	G/A	cg02202077	chr11:65769826	EIF1AD;BANF1	-0.64	-6.04	-0.35	5.25e-9	Cerebrospinal fluid biomarker levels;
CESC	cis	rs472402	0.540	rs2288445	chr5:6620092	C/T	cg10789808	chr5:6633262	NSUN2;SRD5A1	-0.5	-6.51	-0.37	3.79e-10	Response to amphetamines;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17367356	chr11:45907078	MAPK8IP1	0.61	6.71	0.38	1.19e-10	Gut microbiome composition (summer);
CESC	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg02725872	chr8:58115012	NA	-0.42	-5.88	-0.34	1.25e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs1728785	0.688	rs698729	chr16:68624205	G/C	cg02972257	chr16:68554789	NA	-0.64	-7.22	-0.41	5.58e-12	Ulcerative colitis;
CESC	cis	rs62005083	1.000	rs62006761	chr14:74616299	T/A	cg05179529	chr14:74551516	LIN52;ALDH6A1	0.74	5.42	0.32	1.34e-7	Mean corpuscular volume;
CESC	trans	rs208520	0.690	rs207094	chr6:66799009	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.99	-12.82	-0.62	1.32e-29	Exhaled nitric oxide output;
CESC	cis	rs6570726	1.000	rs450076	chr6:145847655	G/T	cg23711669	chr6:146136114	FBXO30	0.76	11.25	0.57	2.92e-24	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs11958404	0.615	rs10061079	chr5:157449968	G/C	cg05962755	chr5:157440814	NA	0.38	5.65	0.33	4.06e-8	IgG glycosylation;
CESC	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg24642844	chr7:1081250	C7orf50	-0.74	-8.83	-0.48	1.46e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs9611519	0.929	rs73174660	chr22:41437304	T/C	cg03806693	chr22:41940476	POLR3H	-0.56	-5.88	-0.34	1.22e-8	Neuroticism;
CESC	cis	rs4253772	0.591	rs6008384	chr22:46655948	T/C	cg10231785	chr22:46692440	CN5H6.4;GTSE1	0.49	5.14	0.3	5.39e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs13256369	1.000	rs13256369	chr8:8577379	T/C	cg18904891	chr8:8559673	CLDN23	0.69	8.05	0.44	2.87e-14	Obesity-related traits;
CESC	cis	rs8180040	0.932	rs62246474	chr3:47398130	C/T	cg27129171	chr3:47204927	SETD2	-0.68	-10.45	-0.54	1.24e-21	Colorectal cancer;
CESC	cis	rs4665809	1.000	rs1550382	chr2:26266877	T/G	cg25036284	chr2:26402008	FAM59B	-0.59	-6.7	-0.38	1.23e-10	Gut microbiome composition (summer);
CESC	cis	rs78456975	0.600	rs72776256	chr2:1529595	C/A	cg01028140	chr2:1542097	TPO	-0.61	-5.79	-0.33	2.02e-8	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs10267417	0.514	rs2072184	chr7:19748883	A/G	cg07541023	chr7:19748670	TWISTNB	0.86	8.92	0.48	7.92e-17	Night sleep phenotypes;
CESC	cis	rs875971	0.862	rs1167390	chr7:65575893	G/A	cg18876405	chr7:65276391	NA	-0.55	-7.4	-0.41	1.75e-12	Aortic root size;
CESC	cis	rs9287719	0.934	rs6721510	chr2:10751046	T/C	cg00105475	chr2:10696890	NA	0.38	5.57	0.32	6.34e-8	Prostate cancer;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg10990685	chr12:120720139	NME2P1	0.53	7.04	0.4	1.65e-11	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs875971	1.000	rs10215948	chr7:65747786	G/A	cg11764359	chr7:65958608	NA	-0.93	-15.42	-0.69	1.01e-38	Aortic root size;
CESC	cis	rs62064224	0.720	rs8078837	chr17:30763537	A/G	cg25809561	chr17:30822961	MYO1D	0.62	9.08	0.49	2.59e-17	Schizophrenia;
CESC	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.57	-8.7	-0.47	3.58e-16	Longevity;Endometriosis;
CESC	trans	rs10411161	0.702	rs6509592	chr19:52393150	G/A	cg22319618	chr22:45562946	NUP50	-0.74	-7.34	-0.41	2.7e-12	Breast cancer;
CESC	cis	rs4555082	0.957	rs10140586	chr14:105749582	A/G	cg06808227	chr14:105710500	BRF1	-0.53	-6.56	-0.37	2.88e-10	Mean platelet volume;Platelet distribution width;
CESC	cis	rs2439831	0.850	rs8032649	chr15:44134922	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.6	-5.47	-0.32	1.06e-7	Lung cancer in ever smokers;
CESC	cis	rs9322193	0.923	rs9404048	chr6:149937324	C/T	cg13206674	chr6:150067644	NUP43	0.41	5.87	0.34	1.31e-8	Lung cancer;
CESC	cis	rs17021463	0.673	rs17565759	chr4:95280763	C/T	cg11021082	chr4:95130006	SMARCAD1	0.5	6.91	0.39	3.66e-11	Testicular germ cell tumor;
CESC	cis	rs4948102	0.642	rs6593297	chr7:56122058	A/T	cg09872392	chr7:56161020	PHKG1	0.44	7.21	0.4	5.83e-12	Plasma homocysteine levels (post-methionine load test);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg03931927	chr7:65215969	CCT6P1	-0.47	-6.62	-0.38	1.97e-10	Fibrinogen levels;
CESC	cis	rs9487051	0.652	rs13210424	chr6:109598737	G/A	cg01475377	chr6:109611718	NA	-0.44	-6.88	-0.39	4.24e-11	Reticulocyte fraction of red cells;
CESC	cis	rs2806561	0.514	rs7519093	chr1:23541078	A/T	cg19743168	chr1:23544995	NA	-0.37	-5.76	-0.33	2.32e-8	Height;
CESC	cis	rs7586879	0.639	rs6749170	chr2:25110962	A/G	cg01884057	chr2:25150051	NA	0.37	7.13	0.4	9.47e-12	Body mass index;
CESC	trans	rs2018683	0.624	rs2286220	chr7:28998699	G/C	cg19402173	chr7:128379420	CALU	-0.58	-7.07	-0.4	1.36e-11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CESC	cis	rs10242455	0.702	rs73405247	chr7:99159174	C/G	cg25640893	chr7:99214727	ZNF498	0.78	5.5	0.32	8.75e-8	Blood metabolite levels;
CESC	cis	rs60154123	0.505	rs115881613	chr1:210040369	C/T	cg22029157	chr1:209979665	IRF6	0.72	7.16	0.4	8.04e-12	Coronary artery disease;
CESC	cis	rs1552244	0.882	rs17050660	chr3:10001772	A/G	cg00149659	chr3:10157352	C3orf10	-0.61	-7.54	-0.42	7.57e-13	Alzheimer's disease;
CESC	cis	rs8018808	0.935	rs1061629	chr14:77926011	A/G	cg20045696	chr14:77926864	AHSA1	-0.41	-5.44	-0.32	1.23e-7	Myeloid white cell count;
CESC	cis	rs6752107	1.000	rs2241879	chr2:234183468	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.49	6.7	0.38	1.25e-10	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs9733	0.744	rs2039590	chr1:150813315	G/A	cg13175981	chr1:150552382	MCL1	0.49	6.75	0.38	9.09e-11	Tonsillectomy;
CESC	cis	rs12497850	0.931	rs9755490	chr3:48871664	A/C	cg03060546	chr3:49711283	APEH	0.45	5.5	0.32	9e-8	Parkinson's disease;
CESC	cis	rs2425143	1.000	rs17093027	chr20:34319118	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.8	-7.49	-0.42	1.03e-12	Blood protein levels;
CESC	cis	rs1728785	1.000	rs698719	chr16:68560125	C/T	cg02972257	chr16:68554789	NA	-0.56	-6.46	-0.37	5.11e-10	Ulcerative colitis;
CESC	cis	rs1218582	0.741	rs10908447	chr1:154869742	C/T	cg09359103	chr1:154839909	KCNN3	-0.64	-11.52	-0.58	3.75e-25	Prostate cancer;
CESC	cis	rs1034435	0.755	rs5768679	chr22:48892847	T/G	cg05992904	chr22:48892994	FAM19A5	-0.57	-9.8	-0.52	1.53e-19	Late-onset Alzheimer's disease;
CESC	trans	rs1814175	0.527	rs7128827	chr11:49665644	C/T	cg03929089	chr4:120376271	NA	0.75	8.78	0.47	2.11e-16	Height;
CESC	cis	rs853679	0.517	rs9393884	chr6:28046789	A/G	cg12963246	chr6:28129442	ZNF389	0.59	8.01	0.44	3.74e-14	Depression;
CESC	cis	rs7666738	0.830	rs11725095	chr4:99009711	T/A	cg03676636	chr4:99064102	C4orf37	0.33	5.16	0.3	4.86e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7216064	0.906	rs1976052	chr17:65830578	C/T	cg07042672	chr17:66097459	LOC651250	-0.5	-5.06	-0.3	7.79e-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs769267	0.965	rs2315024	chr19:19423817	T/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.44	5.53	0.32	7.7e-8	Tonsillectomy;
CESC	cis	rs763014	0.931	rs7191939	chr16:630089	C/T	cg09263875	chr16:632152	PIGQ	0.66	10.93	0.56	3.24e-23	Height;
CESC	trans	rs17764205	0.929	rs10421936	chr19:3256484	C/T	cg27384338	chr17:2031545	SMG6	-0.64	-6.08	-0.35	4.2e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs2576037	0.523	rs590923	chr18:44404259	G/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.78	12.78	0.62	1.82e-29	Personality dimensions;
CESC	cis	rs12348691	0.503	rs1348386	chr9:100612807	A/G	cg13688889	chr9:100608707	NA	-0.9	-13.36	-0.63	1.76e-31	Alopecia areata;
CESC	cis	rs7246657	0.943	rs1559229	chr19:37876197	T/C	cg23950597	chr19:37808831	NA	-0.55	-6.06	-0.35	4.78e-9	Coronary artery calcification;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg19980912	chr5:133304180	C5orf15	-0.45	-6.25	-0.36	1.65e-9	Fibrinogen levels;
CESC	cis	rs4319547	0.774	rs7954006	chr12:123131824	A/C	cg05707623	chr12:122985044	ZCCHC8	0.48	5.76	0.33	2.35e-8	Body mass index;
CESC	cis	rs3096299	0.967	rs2965935	chr16:89481274	C/T	cg02187348	chr16:89574699	SPG7	-0.58	-8.11	-0.45	1.9e-14	Multiple myeloma (IgH translocation);
CESC	cis	rs1005277	0.557	rs1854563	chr10:38434961	G/A	cg25517755	chr10:38738941	LOC399744	-0.49	-6.35	-0.36	9.09e-10	Extrinsic epigenetic age acceleration;
CESC	trans	rs3780486	0.846	rs6476399	chr9:33123013	A/G	cg20290983	chr6:43655470	MRPS18A	0.98	18.34	0.75	4.45e-49	IgG glycosylation;
CESC	cis	rs4595586	0.505	rs76485055	chr12:39358294	A/G	cg26384229	chr12:38710491	ALG10B	0.54	7.54	0.42	7.28e-13	Morning vs. evening chronotype;
CESC	cis	rs753778	0.667	rs6578153	chr8:142209543	C/T	cg23750338	chr8:142222470	SLC45A4	0.38	5.55	0.32	6.98e-8	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	cis	rs11608355	0.515	rs11609921	chr12:109918405	A/G	cg05360138	chr12:110035743	NA	0.81	8.75	0.47	2.52e-16	Neuroticism;
CESC	cis	rs2236918	1.000	rs735943	chr1:242030151	C/T	cg17736920	chr1:242011382	EXO1	-0.66	-8.95	-0.48	6.54e-17	Menopause (age at onset);
CESC	cis	rs13064411	0.696	rs6438161	chr3:113227637	G/A	cg18753928	chr3:113234510	CCDC52	-0.5	-6.13	-0.35	3.23e-9	Response to simvastatin treatment (PCSK9 protein level change);
CESC	cis	rs6831352	0.851	rs1230164	chr4:99986023	C/G	cg13256891	chr4:100009986	ADH5	0.63	6.75	0.38	9.24e-11	Alcohol dependence;
CESC	cis	rs11122272	0.735	rs2790884	chr1:231531932	A/G	cg06096015	chr1:231504339	EGLN1	0.43	6.15	0.35	2.9e-9	Hemoglobin concentration;
CESC	cis	rs34779708	0.966	rs12762493	chr10:35471873	G/A	cg04310649	chr10:35416472	CREM	-0.54	-6.54	-0.37	3.16e-10	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs17407555	0.601	rs73229828	chr4:10026833	A/G	cg00071950	chr4:10020882	SLC2A9	-0.58	-5.86	-0.34	1.36e-8	Schizophrenia (age at onset);
CESC	cis	rs7959452	0.868	rs10878967	chr12:69740869	T/C	cg20891283	chr12:69753455	YEATS4	0.6	8.51	0.46	1.3e-15	Blood protein levels;
CESC	cis	rs798554	0.686	rs2527690	chr7:2854250	C/T	cg13628971	chr7:2884303	GNA12	0.42	5.54	0.32	7.32e-8	Height;
CESC	cis	rs2273669	0.667	rs111523655	chr6:109301664	G/A	cg05315195	chr6:109294784	ARMC2	-0.65	-6.08	-0.35	4.15e-9	Prostate cancer;
CESC	cis	rs28829049	0.570	rs12060125	chr1:19391108	A/G	cg13387374	chr1:19411106	UBR4	-0.42	-5.54	-0.32	7.27e-8	QRS duration in Tripanosoma cruzi seropositivity;
CESC	cis	rs9911578	1.000	rs12453049	chr17:56611372	C/T	cg12560992	chr17:57184187	TRIM37	-0.93	-15.59	-0.69	2.43e-39	Intelligence (multi-trait analysis);
CESC	cis	rs7727544	0.735	rs272879	chr5:131670546	C/G	cg07395648	chr5:131743802	NA	-0.46	-6.06	-0.35	4.78e-9	Blood metabolite levels;
CESC	cis	rs1862618	0.802	rs33327	chr5:56142693	T/G	cg18230493	chr5:56204884	C5orf35	-0.74	-8.84	-0.48	1.37e-16	Initial pursuit acceleration;
CESC	trans	rs561341	1.000	rs506766	chr17:30289659	T/C	cg27661571	chr11:113659931	NA	-0.8	-6.98	-0.39	2.37e-11	Hip circumference adjusted for BMI;
CESC	cis	rs7264396	0.790	rs6058294	chr20:34259396	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.66	7.92	0.44	6.7e-14	Total cholesterol levels;
CESC	cis	rs11785400	1.000	rs11785400	chr8:143730456	C/T	cg10596483	chr8:143751796	JRK	0.41	5.41	0.32	1.43e-7	Schizophrenia;
CESC	trans	rs7726839	0.540	rs72705030	chr5:645562	C/T	cg25482853	chr8:67687455	SGK3	1.01	10.42	0.54	1.61e-21	Obesity-related traits;
CESC	cis	rs1552244	1.000	rs7631678	chr3:10078816	T/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.87	11.84	0.59	2.99e-26	Alzheimer's disease;
CESC	cis	rs425277	0.628	rs3107147	chr1:2048729	G/A	cg23803603	chr1:2058230	PRKCZ	-0.35	-6.16	-0.35	2.74e-9	Height;
CESC	cis	rs4330281	0.702	rs10433561	chr3:17803996	T/G	cg20981856	chr3:17787350	NA	0.38	5.35	0.31	1.87e-7	Schizophrenia;
CESC	cis	rs4713118	0.586	rs6905516	chr6:28086478	A/G	cg23161317	chr6:28129485	ZNF389	0.51	6.53	0.37	3.44e-10	Parkinson's disease;
CESC	cis	rs9926296	0.572	rs8046872	chr16:89841552	T/C	cg04287289	chr16:89883240	FANCA	0.59	7.91	0.44	7.09e-14	Vitiligo;
CESC	cis	rs12142240	0.659	rs17361873	chr1:46832686	A/G	cg00530320	chr1:46809349	NSUN4	0.6	8.08	0.44	2.37e-14	Menopause (age at onset);
CESC	cis	rs7312933	1.000	rs11181328	chr12:42504679	T/G	cg01256987	chr12:42539512	GXYLT1	-0.34	-5.13	-0.3	5.66e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs7296418	0.699	rs11057219	chr12:123750073	T/C	cg05973401	chr12:123451056	ABCB9	0.46	5.93	0.34	9.46e-9	Platelet count;
CESC	cis	rs9486719	1.000	rs72931061	chr6:96880285	G/A	cg18709589	chr6:96969512	KIAA0776	-0.53	-5.81	-0.34	1.75e-8	Migraine;Coronary artery disease;
CESC	cis	rs9733	0.596	rs72702585	chr1:150696427	G/A	cg09365446	chr1:150670422	GOLPH3L	0.42	5.84	0.34	1.55e-8	Tonsillectomy;
CESC	cis	rs7592578	0.664	rs10931461	chr2:191405280	T/A	cg10560079	chr2:191398806	TMEM194B	0.66	5.89	0.34	1.14e-8	Diastolic blood pressure;
CESC	cis	rs9388451	0.772	rs1268064	chr6:126042578	G/A	cg05901451	chr6:126070800	HEY2	0.6	8.58	0.47	8.27e-16	Brugada syndrome;
CESC	cis	rs6762	0.748	rs7929032	chr11:839078	G/A	cg23754390	chr11:835074	CD151	0.31	5.28	0.31	2.75e-7	Mean platelet volume;
CESC	cis	rs7084402	1.000	rs28426375	chr10:60285478	T/A	cg07615347	chr10:60278583	BICC1	0.61	9.7	0.51	3.12e-19	Refractive error;
CESC	cis	rs17384381	0.953	rs12717763	chr1:85808164	A/T	cg16011679	chr1:85725395	C1orf52	0.81	8.44	0.46	2.12e-15	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs3785574	1.000	rs3785574	chr17:61763185	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	1.06	16.15	0.7	2.57e-41	Height;
CESC	trans	rs9693444	0.898	rs4732697	chr8:29519861	A/G	cg09474081	chr11:94501387	AMOTL1	-0.42	-6.3	-0.36	1.21e-9	Breast cancer;
CESC	cis	rs4704187	0.687	rs4389672	chr5:74368642	G/T	cg03227963	chr5:74354835	NA	0.31	5.79	0.34	1.99e-8	Response to amphetamines;
CESC	cis	rs172166	0.637	rs1071893	chr6:28167635	G/C	cg21251018	chr6:28226885	NKAPL	0.35	5.63	0.33	4.61e-8	Cardiac Troponin-T levels;
CESC	cis	rs801193	0.548	rs2659904	chr7:66178602	C/A	cg11764359	chr7:65958608	NA	0.87	13.23	0.63	4.93e-31	Aortic root size;
CESC	cis	rs11190604	1.000	rs35106985	chr10:102307542	T/C	cg07080220	chr10:102295463	HIF1AN	0.63	6.0	0.35	6.54e-9	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs2204008	0.805	rs11169513	chr12:37988640	G/A	cg26384229	chr12:38710491	ALG10B	0.74	10.83	0.55	6.91e-23	Bladder cancer;
CESC	cis	rs6502050	0.835	rs8065556	chr17:80091176	G/C	cg01763666	chr17:80159506	CCDC57	-0.37	-5.1	-0.3	6.49e-7	Life satisfaction;
CESC	cis	rs9916302	0.904	rs2024073	chr17:37471330	T/G	cg07936489	chr17:37558343	FBXL20	0.77	10.94	0.56	3.02e-23	Glomerular filtration rate (creatinine);
CESC	cis	rs9388451	0.874	rs13209968	chr6:126089285	G/C	cg10911889	chr6:126070802	HEY2	0.39	5.31	0.31	2.3e-7	Brugada syndrome;
CESC	cis	rs875971	0.516	rs6945322	chr7:65336056	T/C	cg06456125	chr7:65229604	NA	0.44	5.73	0.33	2.7e-8	Aortic root size;
CESC	cis	rs1799949	1.000	rs8176297	chr17:41203325	T/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.41	5.6	0.33	5.36e-8	Menopause (age at onset);
CESC	cis	rs7937682	0.889	rs12360825	chr11:111528786	A/T	cg09085632	chr11:111637200	PPP2R1B	-0.97	-15.5	-0.69	5.25e-39	Primary sclerosing cholangitis;
CESC	cis	rs3733585	0.563	rs881971	chr4:9930962	A/G	cg11266682	chr4:10021025	SLC2A9	-0.52	-9.6	-0.51	6.34e-19	Cleft plate (environmental tobacco smoke interaction);
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg05515957	chr12:14956570	WBP11;C12orf60	-0.42	-6.46	-0.37	5.12e-10	Vertical cup-disc ratio;
CESC	cis	rs8040855	0.627	rs11632175	chr15:85611680	T/A	cg08123816	chr15:85640762	PDE8A	-0.41	-6.08	-0.35	4.18e-9	Bulimia nervosa;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg24132523	chr1:145827062	GPR89A	-0.47	-6.53	-0.37	3.42e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs7618915	0.547	rs62253703	chr3:52632357	T/C	cg05564831	chr3:52568323	NT5DC2	0.45	6.96	0.39	2.68e-11	Bipolar disorder;
CESC	cis	rs1862618	0.853	rs252910	chr5:56192983	G/A	cg12311346	chr5:56204834	C5orf35	-0.81	-9.5	-0.5	1.33e-18	Initial pursuit acceleration;
CESC	cis	rs5750830	0.594	rs6001587	chr22:39819008	T/C	cg01416388	chr22:39784598	NA	-0.58	-7.11	-0.4	1.1e-11	Intelligence (multi-trait analysis);
CESC	cis	rs7811142	0.775	rs6946768	chr7:99954393	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.09	10.22	0.53	6.88e-21	Platelet count;
CESC	cis	rs4713118	0.512	rs2622319	chr6:28120401	G/C	cg18032046	chr6:28092343	ZSCAN16	-0.5	-6.43	-0.37	5.82e-10	Parkinson's disease;
CESC	cis	rs2072732	0.861	rs3795262	chr1:2938697	A/C	cg15211996	chr1:2936768	ACTRT2	0.33	5.46	0.32	1.1e-7	Plateletcrit;
CESC	cis	rs11676348	0.755	rs1008562	chr2:219026972	G/C	cg20019365	chr2:219134978	PNKD;AAMP	0.43	5.52	0.32	7.92e-8	Ulcerative colitis;
CESC	cis	rs2070488	0.965	rs2051215	chr3:38560345	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.9	-16.74	-0.72	2.14e-43	Electrocardiographic conduction measures;
CESC	cis	rs7666738	0.830	rs7673880	chr4:99057262	A/G	cg03467027	chr4:99064603	C4orf37	0.49	6.16	0.35	2.65e-9	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg15604170	chr13:19203463	NA	-0.42	-6.47	-0.37	4.7e-10	Asthma;
CESC	cis	rs13191362	0.872	rs73017702	chr6:163257695	C/A	cg06582575	chr6:163149167	PACRG;PARK2	0.69	6.68	0.38	1.41e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs9926296	0.605	rs12448860	chr16:89849629	T/A	cg04287289	chr16:89883240	FANCA	0.9	15.3	0.68	2.55e-38	Vitiligo;
CESC	cis	rs7772486	0.875	rs2748501	chr6:146312258	G/A	cg23711669	chr6:146136114	FBXO30	0.9	13.01	0.62	3.07e-30	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs11122272	0.735	rs973252	chr1:231520802	A/G	cg06096015	chr1:231504339	EGLN1	0.43	6.18	0.35	2.46e-9	Hemoglobin concentration;
CESC	cis	rs8018808	1.000	rs4903577	chr14:77847258	C/T	cg20045696	chr14:77926864	AHSA1	-0.4	-5.37	-0.31	1.68e-7	Myeloid white cell count;
CESC	cis	rs7216064	0.953	rs8073510	chr17:65839210	A/G	cg12091567	chr17:66097778	LOC651250	-0.86	-8.83	-0.48	1.49e-16	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs11122272	0.735	rs2808585	chr1:231514218	C/T	cg06096015	chr1:231504339	EGLN1	0.43	6.18	0.35	2.46e-9	Hemoglobin concentration;
CESC	cis	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg05564831	chr3:52568323	NT5DC2	-0.38	-5.32	-0.31	2.19e-7	Bipolar disorder;
CESC	cis	rs6121246	0.567	rs2889488	chr20:30185758	G/A	cg13852791	chr20:30311386	BCL2L1	0.67	6.71	0.38	1.2e-10	Mean corpuscular hemoglobin;
CESC	cis	rs11098499	0.863	rs3775858	chr4:120486028	A/G	cg09307838	chr4:120376055	NA	0.91	12.54	0.61	1.27e-28	Corneal astigmatism;
CESC	cis	rs2249694	0.586	rs9418987	chr10:135324409	A/G	cg20169779	chr10:135381914	SYCE1	0.4	5.29	0.31	2.52e-7	Obesity-related traits;
CESC	cis	rs6032067	0.852	rs17333180	chr20:43803708	C/A	cg10761708	chr20:43804764	PI3	0.55	6.55	0.37	2.91e-10	Blood protein levels;
CESC	cis	rs7666738	0.830	rs7661264	chr4:98961574	G/A	cg03467027	chr4:99064603	C4orf37	0.44	5.57	0.32	6.41e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs13191362	0.507	rs2846519	chr6:163045463	G/A	cg06582575	chr6:163149167	PACRG;PARK2	-0.47	-5.87	-0.34	1.28e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs4268898	0.722	rs12185638	chr2:24382030	C/G	cg06627628	chr2:24431161	ITSN2	0.52	6.77	0.38	8.5e-11	Asthma;
CESC	cis	rs2836974	0.800	rs73221174	chr21:40540939	T/C	cg11644478	chr21:40555479	PSMG1	0.99	15.29	0.68	2.91e-38	Cognitive function;
CESC	cis	rs155076	0.938	rs485361	chr13:21845826	G/T	cg11317459	chr13:21872234	NA	-1.01	-11.12	-0.56	7.88e-24	White matter hyperintensity burden;
CESC	cis	rs10870270	1.000	rs10870292	chr10:133770782	G/C	cg08754478	chr10:133766260	PPP2R2D	-0.58	-7.52	-0.42	8.66e-13	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs6963495	0.818	rs818621	chr7:105173029	T/C	cg02135003	chr7:105160482	PUS7	-0.44	-5.98	-0.34	7.1e-9	Bipolar disorder (body mass index interaction);
CESC	cis	rs736408	0.527	rs2577831	chr3:52628056	C/A	cg07507251	chr3:52567010	NT5DC2	0.38	7.27	0.41	3.99e-12	Bipolar disorder;
CESC	cis	rs17818399	0.926	rs13032670	chr2:46830794	C/T	cg02822958	chr2:46747628	ATP6V1E2	0.47	5.64	0.33	4.45e-8	Height;
CESC	cis	rs9910055	0.659	rs227580	chr17:42223068	C/T	cg13607699	chr17:42295918	UBTF	-0.57	-7.31	-0.41	3.2e-12	Total body bone mineral density;
CESC	cis	rs3617	0.573	rs9810807	chr3:52924227	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	-0.31	-5.26	-0.31	3.03e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
CESC	cis	rs11250464	0.833	rs4554799	chr10:1407728	C/T	cg08668359	chr10:1443807	ADARB2	0.6	7.32	0.41	2.89e-12	Radiation response;
CESC	cis	rs7903847	0.642	rs11814021	chr10:99158386	A/G	cg20016023	chr10:99160130	RRP12	-0.3	-5.17	-0.3	4.63e-7	Granulocyte percentage of myeloid white cells;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10735211	chr4:4310922	ZNF509	-0.59	-7.13	-0.4	9.8e-12	Gut microbiome composition (summer);
CESC	cis	rs9291683	0.546	rs13110307	chr4:10044364	T/C	cg02734326	chr4:10020555	SLC2A9	0.45	6.19	0.36	2.29e-9	Bone mineral density;
CESC	cis	rs6714710	0.603	rs7421146	chr2:98552271	G/C	cg26665480	chr2:98280029	ACTR1B	0.67	8.99	0.48	4.92e-17	Posterior cortical atrophy and Alzheimer's disease;
CESC	cis	rs3809566	0.637	rs8026047	chr15:63323347	C/G	cg12160578	chr15:63334699	TPM1	0.45	5.52	0.32	8.13e-8	Platelet count;
CESC	cis	rs7659604	0.592	rs56077950	chr4:122721412	C/T	cg06713675	chr4:122721982	EXOSC9	-0.51	-7.04	-0.4	1.65e-11	Type 2 diabetes;
CESC	cis	rs832540	0.629	rs10940512	chr5:56082094	G/C	cg12311346	chr5:56204834	C5orf35	-0.47	-5.73	-0.33	2.67e-8	Coronary artery disease;
CESC	cis	rs7615952	0.576	rs12497295	chr3:125818650	G/A	cg06494592	chr3:125709126	NA	-0.51	-5.44	-0.32	1.22e-7	Blood pressure (smoking interaction);
CESC	cis	rs1552244	1.000	rs3826	chr3:10141065	T/G	cg00166722	chr3:10149974	C3orf24	0.46	5.89	0.34	1.18e-8	Alzheimer's disease;
CESC	cis	rs854765	0.583	rs4077198	chr17:17834563	T/C	cg09796270	chr17:17721594	SREBF1	0.43	6.05	0.35	4.9e-9	Total body bone mineral density;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg02574861	chr17:3912370	ZZEF1	0.49	6.58	0.37	2.54e-10	Fibrinogen levels;
CESC	cis	rs7659604	0.676	rs4077102	chr4:122699830	A/G	cg19748678	chr4:122722346	EXOSC9	0.72	9.4	0.5	2.74e-18	Type 2 diabetes;
CESC	cis	rs1568889	1.000	rs11603799	chr11:28196488	T/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.77	10.58	0.54	4.76e-22	Bipolar disorder;
CESC	cis	rs11048434	0.761	rs1805765	chr12:9094548	A/G	cg23795048	chr12:9217529	LOC144571	0.38	5.88	0.34	1.25e-8	Sjögren's syndrome;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27067419	chr5:54830434	PPAP2A;RNF138P1	0.63	7.86	0.43	9.83e-14	Gut microbiome composition (summer);
CESC	trans	rs5758511	0.773	rs10154700	chr22:42365073	G/T	cg15080870	chr19:47770746	CCDC9	0.5	6.19	0.36	2.26e-9	Birth weight;
CESC	cis	rs35110281	0.627	rs6518268	chr21:44967448	A/G	cg01579765	chr21:45077557	HSF2BP	-0.49	-8.04	-0.44	2.93e-14	Mean corpuscular volume;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg16010370	chr3:53290200	TKT	0.46	6.59	0.38	2.36e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs116095464	0.558	rs7725227	chr5:233517	G/A	cg12570787	chr5:219185	SDHA;CCDC127	0.5	5.24	0.31	3.35e-7	Breast cancer;
CESC	cis	rs2839186	0.771	rs2280957	chr21:47642272	A/G	cg13012494	chr21:47604986	C21orf56	-0.45	-5.99	-0.35	6.77e-9	Testicular germ cell tumor;
CESC	cis	rs9649213	0.593	rs736753	chr7:97931489	G/T	cg00277769	chr7:97922759	BAIAP2L1	-0.34	-5.62	-0.33	4.89e-8	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg27391037	chr22:18560705	PEX26	-0.44	-6.27	-0.36	1.44e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs9916302	0.605	rs12938099	chr17:37612910	T/G	cg07936489	chr17:37558343	FBXL20	-0.91	-9.97	-0.52	4.37e-20	Glomerular filtration rate (creatinine);
CESC	cis	rs4862750	0.832	rs6836076	chr4:187899660	A/C	cg03647317	chr4:187891568	NA	-0.37	-5.56	-0.32	6.44e-8	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7949030	0.591	rs35880596	chr11:62369884	C/G	cg13298116	chr11:62369859	EML3;MTA2	0.64	9.19	0.49	1.22e-17	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs6088580	0.634	rs6059860	chr20:33063830	A/C	cg24642439	chr20:33292090	TP53INP2	0.52	6.9	0.39	3.77e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs5750830	0.649	rs5750822	chr22:39826788	C/T	cg05872129	chr22:39784769	NA	-0.84	-11.18	-0.57	5.16e-24	Intelligence (multi-trait analysis);
CESC	cis	rs7116495	1.000	rs10898814	chr11:71736505	T/C	cg26138937	chr11:71823887	C11orf51	-0.76	-6.07	-0.35	4.41e-9	Severe influenza A (H1N1) infection;
CESC	cis	rs11997175	0.624	rs4621768	chr8:33677452	T/C	ch.8.33884649F	chr8:33765107	NA	0.58	7.44	0.42	1.44e-12	Body mass index;
CESC	cis	rs2180341	0.618	rs6683	chr6:127610021	G/A	cg27446573	chr6:127587934	RNF146	0.62	8.52	0.46	1.22e-15	Breast cancer;
CESC	cis	rs9486715	1.000	rs9486725	chr6:97061159	C/T	cg18709589	chr6:96969512	KIAA0776	-0.46	-6.36	-0.36	8.93e-10	Headache;
CESC	cis	rs1336900	0.641	rs6587756	chr1:150546865	A/T	cg22823121	chr1:150693482	HORMAD1	-0.4	-5.43	-0.32	1.25e-7	Blood protein levels;
CESC	cis	rs270601	0.739	rs3900945	chr5:131592870	T/C	cg04518342	chr5:131593106	PDLIM4	0.43	6.61	0.38	2.05e-10	Acylcarnitine levels;
CESC	cis	rs6582630	0.519	rs7305545	chr12:38349223	G/A	cg13010199	chr12:38710504	ALG10B	0.48	6.06	0.35	4.62e-9	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs896854	0.684	rs10099941	chr8:95987008	C/T	cg13393036	chr8:95962371	TP53INP1	-0.49	-10.71	-0.55	1.73e-22	Type 2 diabetes;
CESC	cis	rs72627123	0.867	rs73303129	chr14:74489244	A/T	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.73	5.65	0.33	4.06e-8	Morning vs. evening chronotype;
CESC	cis	rs1801251	0.727	rs13029336	chr2:233569935	A/G	cg08000102	chr2:233561755	GIGYF2	-0.65	-9.58	-0.51	7.27e-19	Coronary artery disease;
CESC	trans	rs958685	0.766	rs3771503	chr2:70712241	A/G	cg20996124	chr1:1144203	NA	-0.41	-6.06	-0.35	4.59e-9	Hand grip strength;
CESC	cis	rs7267979	1.000	rs6515651	chr20:25414539	T/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.83	-16.43	-0.71	2.68e-42	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs4843747	0.619	rs66508972	chr16:88086385	C/G	cg06915872	chr16:87998081	BANP	0.45	5.26	0.31	2.94e-7	Menopause (age at onset);
CESC	cis	rs798554	1.000	rs798554	chr7:2759795	C/T	cg04166393	chr7:2884313	GNA12	0.53	6.76	0.38	8.84e-11	Height;
CESC	trans	rs35883536	1.000	rs1932351	chr1:101142049	C/T	cg16931499	chr17:42786676	DBF4B	0.42	6.26	0.36	1.57e-9	Monocyte count;
CESC	cis	rs367943	0.698	rs2115206	chr5:112999058	A/T	cg12552261	chr5:112820674	MCC	0.44	5.77	0.33	2.21e-8	Type 2 diabetes;
CESC	cis	rs16854884	0.657	rs6766685	chr3:143736916	C/T	cg06585982	chr3:143692056	C3orf58	0.5	6.7	0.38	1.26e-10	Economic and political preferences (feminism/equality);
CESC	cis	rs12681366	0.708	rs13280849	chr8:95396959	C/A	cg13257157	chr8:95487014	RAD54B	0.38	5.14	0.3	5.22e-7	Nonsyndromic cleft lip with cleft palate;
CESC	cis	rs7586673	0.578	rs6723840	chr2:161879615	G/T	cg22496339	chr2:162101262	NA	0.47	6.01	0.35	6.14e-9	Intelligence (multi-trait analysis);
CESC	cis	rs1691799	0.899	rs1168300	chr12:66736467	C/A	cg16791601	chr12:66731901	HELB	-0.75	-13.03	-0.62	2.51e-30	White blood cell count (basophil);
CESC	cis	rs7923609	0.936	rs4405189	chr10:65013935	A/G	cg01631684	chr10:65280961	REEP3	-0.45	-5.53	-0.32	7.73e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs2880765	0.743	rs8032488	chr15:86012768	T/C	cg10818794	chr15:86012489	AKAP13	-0.34	-5.26	-0.31	2.99e-7	Coronary artery disease;
CESC	cis	rs1499972	0.938	rs864199	chr3:117755612	T/C	cg07612923	chr3:117604196	NA	-0.81	-6.04	-0.35	5.25e-9	Schizophrenia;
CESC	cis	rs3126085	0.935	rs1353436	chr1:152172658	G/A	cg26876637	chr1:152193138	HRNR	0.44	5.11	0.3	6.25e-7	Atopic dermatitis;
CESC	cis	rs2115630	0.645	rs1107179	chr15:85198362	A/C	cg11189052	chr15:85197271	WDR73	0.52	7.04	0.4	1.66e-11	P wave terminal force;
CESC	cis	rs9486715	0.929	rs2025044	chr6:97067028	A/G	cg06623918	chr6:96969491	KIAA0776	-0.88	-12.55	-0.61	1.13e-28	Headache;
CESC	cis	rs2011503	0.714	rs113980591	chr19:19565357	G/A	cg11584989	chr19:19387371	SF4	0.62	6.89	0.39	4.07e-11	Bipolar disorder;
CESC	cis	rs9488822	0.596	rs6568921	chr6:116373616	C/T	cg18764771	chr6:116381957	FRK	0.22	5.14	0.3	5.3e-7	Cholesterol, total;LDL cholesterol;
CESC	cis	rs4253772	1.000	rs4253766	chr22:46623905	C/T	cg09491104	chr22:46646882	C22orf40	-0.55	-6.41	-0.37	6.62e-10	LDL cholesterol;Cholesterol, total;
CESC	cis	rs2439831	0.850	rs68079546	chr15:44136957	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.67	7.46	0.42	1.21e-12	Lung cancer in ever smokers;
CESC	cis	rs9863	0.827	rs12823740	chr12:124458002	C/A	cg17562584	chr12:124393655	DNAH10	0.31	5.34	0.31	2.04e-7	White blood cell count;
CESC	cis	rs18122	0.632	rs1483333	chr2:67530280	C/T	cg09028215	chr2:67624308	ETAA1	-0.43	-5.28	-0.31	2.67e-7	Waist-to-hip ratio adjusted for body mass index;
CESC	trans	rs12310956	0.515	rs115836245	chr12:33951369	T/C	cg26384229	chr12:38710491	ALG10B	0.45	6.39	0.37	7.33e-10	Morning vs. evening chronotype;
CESC	cis	rs9926296	0.548	rs6500439	chr16:89808275	A/C	cg03388025	chr16:89894329	SPIRE2	0.4	7.7	0.43	2.69e-13	Vitiligo;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16263627	chr15:100339283	C15orf51	-0.66	-7.88	-0.44	8.52e-14	Gut microbiome composition (summer);
CESC	cis	rs1707322	0.721	rs11211163	chr1:46153548	C/T	cg05343316	chr1:45956843	TESK2	0.51	6.2	0.36	2.19e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs6912958	0.754	rs4587143	chr6:88292291	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.33	-5.34	-0.31	1.99e-7	Monocyte percentage of white cells;
CESC	cis	rs7680126	0.633	rs55766779	chr4:10287039	C/T	cg00071950	chr4:10020882	SLC2A9	-0.55	-6.07	-0.35	4.32e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	cis	rs10504229	0.683	rs56408763	chr8:58137276	G/A	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs4969178	0.965	rs11077362	chr17:76397219	A/T	cg20026190	chr17:76395443	PGS1	0.49	7.81	0.43	1.34e-13	HDL cholesterol levels;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg00840257	chr16:8963031	CARHSP1	-0.44	-6.03	-0.35	5.47e-9	Fibrinogen levels;
CESC	cis	rs561341	1.000	rs757009	chr17:30243937	A/G	cg12193833	chr17:30244370	NA	-0.52	-5.82	-0.34	1.69e-8	Hip circumference adjusted for BMI;
CESC	cis	rs7223966	1.000	rs8078862	chr17:61854068	C/T	cg11494091	chr17:61959527	GH2	0.38	5.18	0.3	4.33e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs2274273	0.662	rs67092614	chr14:55672055	G/A	cg04306507	chr14:55594613	LGALS3	0.31	5.24	0.31	3.34e-7	Protein biomarker;
CESC	cis	rs4819052	0.819	rs13046807	chr21:46672286	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.78	10.35	0.54	2.63e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs7631605	0.905	rs1468712	chr3:37106013	C/T	cg22985146	chr3:37219077	LRRFIP2	0.34	5.51	0.32	8.43e-8	Cerebrospinal P-tau181p levels;
CESC	cis	rs9311474	0.581	rs13621	chr3:52558133	T/C	cg07507251	chr3:52567010	NT5DC2	0.45	8.39	0.46	2.84e-15	Electroencephalogram traits;
CESC	cis	rs208520	1.000	rs72882100	chr6:66981495	G/C	cg07460842	chr6:66804631	NA	0.87	10.16	0.53	1.1e-20	Exhaled nitric oxide output;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg14753042	chr7:55714413	LOC442308	-0.48	-6.5	-0.37	3.94e-10	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7089973	0.604	rs11196942	chr10:116596872	G/A	cg23260525	chr10:116636907	FAM160B1	0.42	7.66	0.43	3.53e-13	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs9926296	0.585	rs1800337	chr16:89845194	A/G	cg21285383	chr16:89894308	SPIRE2	0.32	5.69	0.33	3.3e-8	Vitiligo;
CESC	cis	rs17293817	0.562	rs7070629	chr10:1424938	A/G	cg04271617	chr10:1416546	ADARB2	-0.32	-5.31	-0.31	2.32e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs2034088	0.833	rs11247554	chr17:407465	C/A	cg13332499	chr17:408570	NA	0.52	9.08	0.49	2.54e-17	Hip circumference adjusted for BMI;
CESC	cis	rs3815700	1.000	rs8109885	chr19:33095557	A/G	cg02997394	chr19:33096574	ANKRD27	0.71	7.09	0.4	1.21e-11	Eosinophilic esophagitis;
CESC	cis	rs13191362	0.938	rs13208970	chr6:163006368	G/T	cg06582575	chr6:163149167	PACRG;PARK2	0.78	8.21	0.45	9.97e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	trans	rs2115172	0.836	rs4835799	chr5:122762229	A/G	cg26462404	chr19:2270807	OAZ1	0.46	6.2	0.36	2.21e-9	Weight;
CESC	cis	rs72945132	1.000	rs72945127	chr11:70107650	A/G	cg14191688	chr11:70257035	CTTN	0.42	5.22	0.31	3.61e-7	Coronary artery disease;
CESC	cis	rs477692	0.905	rs4751106	chr10:131424653	G/T	cg26102564	chr10:131424627	MGMT	-0.35	-5.22	-0.31	3.64e-7	Response to temozolomide;
CESC	cis	rs9393777	0.513	rs9379905	chr6:26630990	G/A	cg12826209	chr6:26865740	GUSBL1	0.75	8.82	0.48	1.62e-16	Intelligence (multi-trait analysis);
CESC	cis	rs2011503	0.941	rs10403273	chr19:19372968	C/G	cg11584989	chr19:19387371	SF4	0.54	6.42	0.37	6.34e-10	Bipolar disorder;
CESC	cis	rs17376456	0.569	rs7729807	chr5:93104089	C/T	cg25358565	chr5:93447407	FAM172A	0.67	7.04	0.4	1.66e-11	Diabetic retinopathy;
CESC	cis	rs9325144	0.505	rs7955162	chr12:38711658	G/A	cg26384229	chr12:38710491	ALG10B	0.69	11.89	0.59	2.07e-26	Morning vs. evening chronotype;
CESC	cis	rs9300255	0.602	rs11057192	chr12:123693420	T/C	cg19016782	chr12:123741754	C12orf65	-0.45	-6.51	-0.37	3.65e-10	Neutrophil percentage of white cells;
CESC	cis	rs7666738	0.830	rs10007261	chr4:98926155	C/T	cg17366294	chr4:99064904	C4orf37	0.6	8.23	0.45	8.65e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs875971	0.825	rs66981195	chr7:66079035	C/A	cg12463550	chr7:65579703	CRCP	-0.53	-6.77	-0.38	8.05e-11	Aortic root size;
CESC	cis	rs12541335	0.639	rs7003478	chr8:22201123	A/G	cg02788857	chr8:22132959	PIWIL2	0.32	5.68	0.33	3.54e-8	Hypertriglyceridemia;
CESC	trans	rs11992162	0.967	rs4841661	chr8:11832769	T/C	cg15556689	chr8:8085844	FLJ10661	0.55	6.28	0.36	1.37e-9	Monocyte count;
CESC	cis	rs9733	0.519	rs7521898	chr1:150707596	G/A	cg04414720	chr1:150670196	GOLPH3L	0.61	8.81	0.48	1.72e-16	Tonsillectomy;
CESC	cis	rs3733585	0.638	rs28715627	chr4:9958140	T/A	cg02734326	chr4:10020555	SLC2A9	-0.43	-5.93	-0.34	9.22e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs8141529	0.732	rs5762788	chr22:29174770	G/T	cg02153584	chr22:29168773	CCDC117	0.72	10.17	0.53	9.68e-21	Lymphocyte counts;
CESC	cis	rs644799	1.000	rs2508289	chr11:95624669	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.83	11.71	0.58	8.53e-26	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs7666738	0.830	rs7689495	chr4:98920152	T/C	cg05340658	chr4:99064831	C4orf37	0.78	11.59	0.58	2.05e-25	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4665809	0.590	rs36064164	chr2:26502768	C/T	cg08470875	chr2:26401718	FAM59B	0.71	7.06	0.4	1.43e-11	Gut microbiome composition (summer);
CESC	cis	rs3796352	1.000	rs71301809	chr3:53090312	C/T	cg12962167	chr3:53033115	SFMBT1	0.7	6.13	0.35	3.23e-9	Immune reponse to smallpox (secreted IL-2);
CESC	cis	rs2075371	1.000	rs2598292	chr7:133988584	C/G	cg20476274	chr7:133979776	SLC35B4	0.67	9.79	0.52	1.65e-19	Mean platelet volume;
CESC	cis	rs8005677	1.000	rs2295685	chr14:23398153	A/G	cg01529538	chr14:23388837	RBM23	0.51	6.84	0.39	5.51e-11	Cognitive ability (multi-trait analysis);
CESC	cis	rs10504229	0.683	rs34859456	chr8:58117722	A/C	cg24829409	chr8:58192753	C8orf71	-0.58	-7.2	-0.4	6.31e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs6693567	0.565	rs1262432	chr1:150371839	C/A	cg09579323	chr1:150459698	TARS2	0.48	6.03	0.35	5.61e-9	Migraine;
CESC	trans	rs916888	0.773	rs199451	chr17:44801784	G/A	cg01341218	chr17:43662625	NA	0.93	10.8	0.55	9.11e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs344364	0.511	rs2982446	chr16:1947153	C/T	cg26617929	chr16:1858877	NA	-0.49	-5.15	-0.3	5.09e-7	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs10911232	0.507	rs7547953	chr1:183031641	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.87	13.59	0.64	2.82e-32	Hypertriglyceridemia;
CESC	cis	rs1475911	1.000	rs17114359	chr21:43510437	A/C	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.35	-5.17	-0.3	4.7e-7	IgG glycosylation;
CESC	cis	rs7727544	0.735	rs2569266	chr5:131706791	T/C	cg24060327	chr5:131705240	SLC22A5	0.68	9.2	0.49	1.14e-17	Blood metabolite levels;
CESC	cis	rs2836974	0.563	rs997147	chr21:40695325	A/G	cg11890956	chr21:40555474	PSMG1	-0.92	-14.57	-0.67	1.03e-35	Cognitive function;
CESC	cis	rs854765	0.547	rs8075189	chr17:17901946	C/G	cg16928487	chr17:17741425	SREBF1	-0.58	-10.22	-0.53	6.92e-21	Total body bone mineral density;
CESC	cis	rs9596863	1.000	rs1379831	chr13:54418506	C/G	ch.13.53330881F	chr13:54432880	NA	0.62	5.38	0.31	1.64e-7	Epilepsy and lamotrigine-induced maculopapular eruptions;
CESC	cis	rs2180341	0.842	rs9375492	chr6:127545492	C/T	cg27446573	chr6:127587934	RNF146	-1.01	-12.64	-0.61	5.73e-29	Breast cancer;
CESC	cis	rs870825	0.616	rs28618216	chr4:185648998	T/C	cg04058563	chr4:185651563	MLF1IP	0.63	6.96	0.39	2.59e-11	Blood protein levels;
CESC	cis	rs4689388	0.926	rs4308429	chr4:6294001	A/G	cg25554036	chr4:6271136	WFS1	0.51	8.37	0.46	3.31e-15	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs1878931	0.582	rs27239	chr16:3442140	T/C	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.7	-8.38	-0.46	3.13e-15	Body mass index (adult);
CESC	cis	rs76878669	0.561	rs1039594	chr11:66131149	C/T	cg18002602	chr11:66138449	SLC29A2	0.4	6.65	0.38	1.71e-10	Educational attainment (years of education);
CESC	cis	rs9916302	0.904	rs9898170	chr17:37510092	T/C	cg15445000	chr17:37608096	MED1	-0.41	-6.6	-0.38	2.18e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs656900	0.874	rs642697	chr15:80121160	C/T	cg02196730	chr15:80188777	MTHFS	-0.4	-5.13	-0.3	5.73e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs514406	0.584	rs11205997	chr1:53195271	G/C	cg08859206	chr1:53392774	SCP2	0.57	7.13	0.4	9.66e-12	Monocyte count;
CESC	cis	rs3091242	0.933	rs909833	chr1:25754140	C/G	cg12412775	chr1:25698385	RHCE	-0.29	-5.18	-0.3	4.39e-7	Erythrocyte sedimentation rate;
CESC	cis	rs8014204	0.901	rs2080087	chr14:75365062	C/T	cg08847533	chr14:75593920	NEK9	0.44	5.38	0.31	1.61e-7	Caffeine consumption;
CESC	cis	rs9858542	0.953	rs4625	chr3:49572140	A/G	cg03060546	chr3:49711283	APEH	-0.5	-5.96	-0.34	8.2e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs854765	0.583	rs9890341	chr17:17823175	G/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.57	8.18	0.45	1.22e-14	Total body bone mineral density;
CESC	cis	rs703842	1.000	rs703842	chr12:58162739	C/T	cg00677455	chr12:58241039	CTDSP2	-0.52	-6.94	-0.39	2.96e-11	Multiple sclerosis;
CESC	cis	rs7527798	0.571	rs11118237	chr1:207818719	G/A	cg21110645	chr1:207815933	NA	-0.32	-5.43	-0.32	1.3e-7	Erythrocyte sedimentation rate;
CESC	cis	rs561341	0.769	rs8074383	chr17:30178793	C/T	cg19193384	chr17:30244184	NA	0.6	5.7	0.33	3.19e-8	Hip circumference adjusted for BMI;
CESC	cis	rs896854	0.967	rs13257021	chr8:95965695	A/G	cg26343298	chr8:95960752	TP53INP1	0.36	5.86	0.34	1.35e-8	Type 2 diabetes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07926531	chr1:33546695	ADC	0.64	7.35	0.41	2.39e-12	Gut microbiome composition (summer);
CESC	cis	rs9911578	0.839	rs7208505	chr17:57187729	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.4	5.35	0.31	1.87e-7	Intelligence (multi-trait analysis);
CESC	cis	rs6938	0.618	rs11857695	chr15:75165751	G/T	cg14664628	chr15:75095509	CSK	-0.58	-8.1	-0.45	2.07e-14	Breast cancer;
CESC	cis	rs35955747	0.902	rs5997932	chr22:31668154	C/G	cg25791279	chr22:32026902	PISD	-0.5	-5.96	-0.34	7.84e-9	Neutrophil count;Sum basophil neutrophil counts;
CESC	cis	rs909674	0.818	rs7364148	chr22:39842165	T/C	cg05872129	chr22:39784769	NA	-0.81	-9.95	-0.52	5.1e-20	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs7552167	1.000	rs7552167	chr1:24518643	A/G	cg01960748	chr1:24522592	NA	-0.44	-5.9	-0.34	1.11e-8	Psoriasis vulgaris;
CESC	cis	rs17376456	0.877	rs34184666	chr5:93444584	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.6	5.11	0.3	6.27e-7	Diabetic retinopathy;
CESC	cis	rs7219021	0.705	rs11869991	chr17:47027763	C/T	cg16584676	chr17:46985605	UBE2Z	-0.61	-6.99	-0.39	2.2e-11	Schizophrenia or bipolar disorder;
CESC	cis	rs7618915	0.532	rs13060675	chr3:52674300	T/G	cg18099408	chr3:52552593	STAB1	-0.31	-5.09	-0.3	6.65e-7	Bipolar disorder;
CESC	cis	rs6912958	0.500	rs2025486	chr6:87796886	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.39	-5.85	-0.34	1.42e-8	Monocyte percentage of white cells;
CESC	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg07157834	chr1:205819609	PM20D1	0.74	11.29	0.57	2.21e-24	Menarche (age at onset);
CESC	cis	rs17376456	0.778	rs72786662	chr5:93137630	C/T	cg21475434	chr5:93447410	FAM172A	0.85	7.25	0.41	4.66e-12	Diabetic retinopathy;
CESC	cis	rs7131987	0.874	rs10843366	chr12:29407903	T/C	cg09582351	chr12:29534625	ERGIC2	-0.35	-5.59	-0.32	5.57e-8	QT interval;
CESC	cis	rs4665809	1.000	rs4665305	chr2:26313524	C/T	cg25036284	chr2:26402008	FAM59B	-0.59	-6.69	-0.38	1.35e-10	Gut microbiome composition (summer);
CESC	cis	rs2228479	0.681	rs3212346	chr16:89982358	G/A	cg04013166	chr16:89971882	TCF25	0.77	9.0	0.48	4.63e-17	Skin colour saturation;
CESC	cis	rs2429369	0.528	rs2526376	chr17:56427142	A/C	cg12560992	chr17:57184187	TRIM37	0.59	7.69	0.43	2.96e-13	Cognitive function;
CESC	cis	rs736408	0.545	rs6445529	chr3:52662722	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	7.73	0.43	2.26e-13	Bipolar disorder;
CESC	cis	rs4654899	0.758	rs6658679	chr1:21376451	T/C	cg05370193	chr1:21551575	ECE1	0.35	5.34	0.31	2.04e-7	Superior frontal gyrus grey matter volume;
CESC	cis	rs17001868	0.568	rs470113	chr22:40729614	A/G	cg07138101	chr22:40742427	ADSL	0.57	5.52	0.32	8.18e-8	Mammographic density (dense area);
CESC	cis	rs7945705	0.818	rs1988708	chr11:8882893	C/A	cg09997546	chr11:8931473	C11orf17;ST5	-0.37	-6.41	-0.37	6.74e-10	Hemoglobin concentration;
CESC	cis	rs9399135	0.967	rs9389251	chr6:135325717	A/G	cg24558204	chr6:135376177	HBS1L	0.53	7.28	0.41	3.85e-12	Red blood cell count;
CESC	cis	rs708547	0.624	rs1277284	chr4:57855361	T/G	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.51	-6.97	-0.39	2.51e-11	Response to bleomycin (chromatid breaks);
CESC	cis	rs617791	0.530	rs735942	chr11:65749337	A/G	cg09783858	chr11:65769428	EIF1AD;BANF1	0.53	6.35	0.36	9.55e-10	Breast cancer;
CESC	cis	rs1552244	0.882	rs13074282	chr3:10024699	T/G	cg08888203	chr3:10149979	C3orf24	0.49	6.17	0.35	2.49e-9	Alzheimer's disease;
CESC	cis	rs514406	0.505	rs425520	chr1:53179805	C/G	cg27535305	chr1:53392650	SCP2	-0.32	-5.19	-0.3	4.2e-7	Monocyte count;
CESC	cis	rs3799378	0.579	rs9348715	chr6:26375642	C/G	cg14345882	chr6:26364793	BTN3A2	0.37	5.84	0.34	1.56e-8	Intelligence (multi-trait analysis);
CESC	cis	rs12477438	0.501	rs9941561	chr2:99753829	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.91	15.68	0.69	1.18e-39	Chronic sinus infection;
CESC	trans	rs61931739	0.500	rs35030191	chr12:34548865	C/T	cg13010199	chr12:38710504	ALG10B	0.51	6.58	0.37	2.47e-10	Morning vs. evening chronotype;
CESC	cis	rs2425143	1.000	rs7261284	chr20:34244104	T/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.61	5.17	0.3	4.59e-7	Blood protein levels;
CESC	cis	rs6831352	0.918	rs1042364	chr4:100045574	T/C	cg13256891	chr4:100009986	ADH5	0.74	8.13	0.45	1.63e-14	Alcohol dependence;
CESC	cis	rs1008375	0.966	rs2010053	chr4:17583806	A/C	cg02297831	chr4:17616191	MED28	0.5	6.12	0.35	3.42e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs1707322	1.000	rs4660332	chr1:46461418	T/A	cg05343316	chr1:45956843	TESK2	0.5	6.13	0.35	3.11e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7666738	0.830	rs34412187	chr4:99010454	A/G	cg05340658	chr4:99064831	C4orf37	0.8	12.51	0.61	1.52e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6089584	0.566	rs2146852	chr20:60616492	T/G	cg24733560	chr20:60626293	TAF4	0.49	7.22	0.41	5.59e-12	Body mass index;
CESC	cis	rs116095464	0.867	rs10061296	chr5:312253	G/A	cg22857025	chr5:266934	NA	-1.21	-10.57	-0.54	4.96e-22	Breast cancer;
CESC	cis	rs1018836	0.923	rs7833025	chr8:91568470	G/C	cg16814680	chr8:91681699	NA	-0.72	-10.29	-0.53	4.01e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs4803468	0.967	rs3213860	chr19:41920211	T/C	cg09537434	chr19:41945824	ATP5SL	-1.08	-18.9	-0.76	4.86e-51	Height;
CESC	cis	rs9788333	0.962	rs12584792	chr13:21887208	C/T	cg06138931	chr13:21896616	NA	0.47	5.94	0.34	8.88e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs10504229	0.906	rs903718	chr8:58167726	A/G	cg22535103	chr8:58192502	C8orf71	-0.93	-12.03	-0.59	6.97e-27	Developmental language disorder (linguistic errors);
CESC	cis	rs926392	0.533	rs6129162	chr20:37683195	G/A	cg16355469	chr20:37678765	NA	0.59	7.12	0.4	1.01e-11	Dialysis-related mortality;
CESC	cis	rs4819052	0.808	rs2246697	chr21:46689999	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.45	5.67	0.33	3.77e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs11583043	0.708	rs10493942	chr1:101545482	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.49	5.17	0.3	4.67e-7	Ulcerative colitis;Inflammatory bowel disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00713953	chr2:220462525	STK11IP	0.54	6.34	0.36	9.86e-10	Gut microbiome composition (summer);
CESC	cis	rs910316	1.000	rs175512	chr14:75523382	T/C	cg08847533	chr14:75593920	NEK9	-1.0	-19.03	-0.76	1.79e-51	Height;
CESC	cis	rs116095464	0.681	rs10060016	chr5:241100	T/C	cg22857025	chr5:266934	NA	-1.27	-18.37	-0.75	3.49e-49	Breast cancer;
CESC	cis	rs1862618	0.511	rs2591952	chr5:56120769	T/A	cg03609598	chr5:56110824	MAP3K1	-0.51	-5.54	-0.32	7.18e-8	Initial pursuit acceleration;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg08678925	chr15:85358595	ALPK3	-0.43	-6.26	-0.36	1.52e-9	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs11696501	0.739	rs6073846	chr20:44296323	G/T	cg10864404	chr6:43395769	NA	0.53	6.45	0.37	5.32e-10	Brain structure;
CESC	cis	rs9560113	0.550	rs1163632	chr13:112231530	T/C	cg10483660	chr13:112241077	NA	-0.44	-7.63	-0.42	4.14e-13	Menarche (age at onset);
CESC	cis	rs853679	0.824	rs34712084	chr6:28043828	A/G	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.79	6.72	0.38	1.1e-10	Depression;
CESC	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg22535103	chr8:58192502	C8orf71	-0.92	-10.16	-0.53	1.04e-20	Developmental language disorder (linguistic errors);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10378898	chr14:55738124	FBXO34	0.62	7.07	0.4	1.4e-11	Gut microbiome composition (summer);
CESC	cis	rs898097	0.841	rs55810435	chr17:80836722	G/C	cg15369054	chr17:80825471	TBCD	0.55	7.64	0.42	3.91e-13	Breast cancer;
CESC	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.62	6.85	0.39	5e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs10504229	1.000	rs72650892	chr8:58179714	A/G	cg14926445	chr8:58193284	C8orf71	-0.51	-5.47	-0.32	1.03e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs6963495	0.818	rs73190156	chr7:105153567	C/T	cg19920283	chr7:105172520	RINT1	0.69	6.56	0.37	2.85e-10	Bipolar disorder (body mass index interaction);
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg24858658	chr1:33502741	AK2	-0.44	-6.05	-0.35	5.04e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs2033711	0.755	rs4801587	chr19:58936679	C/A	cg11952622	chr19:58962976	ZNF324B	0.44	5.81	0.34	1.83e-8	Uric acid clearance;
CESC	cis	rs763121	0.853	rs5750669	chr22:39080638	T/A	cg06022373	chr22:39101656	GTPBP1	0.9	13.91	0.65	2.08e-33	Menopause (age at onset);
CESC	cis	rs2408955	0.500	rs12816820	chr12:48558325	A/G	cg04545296	chr12:48745243	ZNF641	0.34	5.78	0.33	2.04e-8	Glycated hemoglobin levels;
CESC	cis	rs7264396	0.635	rs6060696	chr20:34522060	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.8	-11.03	-0.56	1.57e-23	Total cholesterol levels;
CESC	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg10819733	chr22:24237672	NA	-0.41	-5.83	-0.34	1.64e-8	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs6752107	1.000	rs12994997	chr2:234173503	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.48	6.67	0.38	1.52e-10	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs9611565	0.918	rs4822024	chr22:41757647	G/A	cg06634786	chr22:41940651	POLR3H	-0.64	-6.69	-0.38	1.35e-10	Vitiligo;
CESC	cis	rs6582630	0.519	rs8189618	chr12:38276281	A/C	cg26384229	chr12:38710491	ALG10B	0.68	9.7	0.51	3.2e-19	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs2901656	0.652	rs3213563	chr1:172412995	T/C	cg03748243	chr1:172413542	C1orf105;PIGC	0.54	8.28	0.45	5.98e-15	Red cell distribution width;Platelet distribution width;
CESC	cis	rs3796352	1.000	rs59583591	chr3:53119581	T/C	cg12962167	chr3:53033115	SFMBT1	0.5	5.23	0.31	3.38e-7	Immune reponse to smallpox (secreted IL-2);
CESC	cis	rs1387259	0.859	rs2054905	chr12:48687951	A/G	cg24011408	chr12:48396354	COL2A1	0.43	5.96	0.34	7.85e-9	Obstructive sleep apnea trait (apnea hypopnea index);
CESC	cis	rs748404	0.690	rs2244981	chr15:43752751	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	8.19	0.45	1.12e-14	Lung cancer;
CESC	trans	rs9354352	0.784	rs2062327	chr6:66689923	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.7	-9.86	-0.52	9.73e-20	Initial pursuit acceleration in psychotic disorders;
CESC	cis	rs9322193	0.923	rs9766886	chr6:149958184	T/C	cg07701084	chr6:150067640	NUP43	0.45	6.39	0.37	7.37e-10	Lung cancer;
CESC	cis	rs117623576	0.941	rs11008775	chr10:32410307	T/C	cg03047570	chr10:32398778	NA	-0.73	-7.75	-0.43	1.96e-13	Anti-saccade response;
CESC	cis	rs977987	0.806	rs2285225	chr16:75429252	T/C	cg03315344	chr16:75512273	CHST6	0.4	5.71	0.33	3e-8	Dupuytren's disease;
CESC	cis	rs140364877	1	rs140364877	chr7:1885178	C/T	cg04267008	chr7:1944627	MAD1L1	-0.6	-7.31	-0.41	3.12e-12	Autism spectrum disorder or schizophrenia;
CESC	cis	rs6502050	0.814	rs62079997	chr17:80076888	C/T	cg23985595	chr17:80112537	CCDC57	0.41	6.42	0.37	6.41e-10	Life satisfaction;
CESC	cis	rs9914988	0.943	rs66588554	chr17:27141110	A/G	cg20469991	chr17:27169893	C17orf63	-0.48	-5.25	-0.31	3.18e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CESC	cis	rs897984	0.806	rs10782001	chr16:30942625	G/A	cg02466173	chr16:30829666	NA	0.49	8.33	0.46	4.26e-15	Dementia with Lewy bodies;
CESC	cis	rs11583043	0.918	rs6577216	chr1:101409972	C/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.45	5.09	0.3	6.75e-7	Ulcerative colitis;Inflammatory bowel disease;
CESC	cis	rs7598759	0.548	rs1823328	chr2:232355184	G/A	cg19187155	chr2:232395269	NMUR1	0.62	10.27	0.53	4.87e-21	Noise-induced hearing loss;
CESC	cis	rs863345	0.604	rs11264997	chr1:158485482	C/T	cg12129480	chr1:158549410	OR10X1	-0.35	-6.91	-0.39	3.53e-11	Pneumococcal bacteremia;
CESC	cis	rs2439831	0.850	rs12440573	chr15:44108997	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.69	7.71	0.43	2.55e-13	Lung cancer in ever smokers;
CESC	cis	rs4664293	1.000	rs12692554	chr2:160451288	G/A	cg08347373	chr2:160653686	CD302	-0.32	-5.32	-0.31	2.19e-7	Monocyte percentage of white cells;
CESC	cis	rs1552244	0.882	rs3755783	chr3:10029289	A/G	cg08888203	chr3:10149979	C3orf24	0.52	6.09	0.35	3.95e-9	Alzheimer's disease;
CESC	cis	rs7165102	0.965	rs28754459	chr15:65990096	T/C	cg11441148	chr15:65824328	PTPLAD1	0.3	5.04	0.3	8.68e-7	Mean corpuscular hemoglobin;
CESC	cis	rs2404602	0.716	rs56216512	chr15:76686936	T/C	cg22467129	chr15:76604101	ETFA	-0.37	-5.48	-0.32	9.79e-8	Blood metabolite levels;
CESC	cis	rs12681366	0.563	rs6999103	chr8:95482537	G/A	cg13257157	chr8:95487014	RAD54B	0.45	5.44	0.32	1.22e-7	Nonsyndromic cleft lip with cleft palate;
CESC	cis	rs933688	1.000	rs10073935	chr5:90742188	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.96	12.76	0.62	2.16e-29	Smoking behavior;
CESC	cis	rs863345	0.604	rs6666805	chr1:158498305	G/C	cg12129480	chr1:158549410	OR10X1	-0.34	-6.85	-0.39	5.15e-11	Pneumococcal bacteremia;
CESC	cis	rs7552404	1.000	rs1498312	chr1:76177849	C/T	cg22875332	chr1:76189707	ACADM	0.66	7.82	0.43	1.24e-13	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs1506636	1.000	rs2429619	chr7:123425599	C/G	cg03229431	chr7:123269106	ASB15	0.49	6.56	0.37	2.83e-10	Plateletcrit;Platelet count;
CESC	trans	rs1814175	0.669	rs11040473	chr11:49703813	C/T	cg03929089	chr4:120376271	NA	-0.72	-9.21	-0.49	1.04e-17	Height;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg11118357	chr8:67525492	MYBL1	-0.47	-6.13	-0.35	3.23e-9	Ulcerative colitis;
CESC	cis	rs12926788	0.689	rs34365165	chr16:24856208	G/A	cg06028605	chr16:24865363	SLC5A11	0.54	7.55	0.42	7.16e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs17428076	0.874	rs12619041	chr2:172600716	A/C	cg13550731	chr2:172543902	DYNC1I2	-0.46	-5.11	-0.3	6.17e-7	Myopia;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg25101327	chr2:119981142	STEAP3	-0.46	-6.34	-0.36	9.66e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs2463822	1.000	rs11231050	chr11:62131660	C/G	cg06239285	chr11:62104954	ASRGL1	-0.94	-8.25	-0.45	7.44e-15	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs12701220	0.655	rs10241018	chr7:1144774	G/C	cg04025307	chr7:1156635	C7orf50	0.44	5.31	0.31	2.33e-7	Bronchopulmonary dysplasia;
CESC	cis	rs8040855	0.627	rs72757059	chr15:85603149	C/T	cg08123816	chr15:85640762	PDE8A	-0.37	-5.56	-0.32	6.5e-8	Bulimia nervosa;
CESC	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	10.31	0.54	3.43e-21	Prudent dietary pattern;
CESC	cis	rs4919694	1.000	rs12266291	chr10:104806884	G/A	cg04362960	chr10:104952993	NT5C2	0.79	7.08	0.4	1.27e-11	Arsenic metabolism;
CESC	cis	rs4654899	0.758	rs7521711	chr1:21400218	A/G	cg05370193	chr1:21551575	ECE1	0.36	5.48	0.32	1e-7	Superior frontal gyrus grey matter volume;
CESC	cis	rs9649213	0.593	rs12704982	chr7:97926053	C/T	cg21770322	chr7:97807741	LMTK2	0.54	8.13	0.45	1.67e-14	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7666738	0.830	rs28417716	chr4:98864859	C/T	cg03467027	chr4:99064603	C4orf37	0.42	5.16	0.3	4.73e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg21989500	chr16:23607577	NDUFAB1	-0.43	-6.32	-0.36	1.1e-9	Gambling;
CESC	cis	rs7666738	0.830	rs13110410	chr4:98920018	T/C	cg03467027	chr4:99064603	C4orf37	0.43	5.33	0.31	2.06e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs8073060	0.586	rs225280	chr17:33976296	C/T	cg19694781	chr19:47549865	TMEM160	-0.73	-7.03	-0.4	1.79e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	cis	rs2180341	0.618	rs11154396	chr6:127638911	C/T	cg27446573	chr6:127587934	RNF146	0.62	8.56	0.47	9.22e-16	Breast cancer;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg17584303	chr4:1657192	FAM53A	0.45	6.15	0.35	2.79e-9	Fibrinogen levels;
CESC	cis	rs13191362	1.000	rs66529337	chr6:163005662	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.78	8.21	0.45	9.97e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs2455799	0.613	rs2470537	chr3:15716898	C/T	cg16303742	chr3:15540471	COLQ	-0.34	-5.32	-0.31	2.18e-7	Mean platelet volume;
CESC	cis	rs4711336	0.935	rs3818525	chr6:33660779	A/G	cg15676125	chr6:33679581	C6orf125	0.34	5.04	0.3	8.58e-7	Height;
CESC	cis	rs9916302	0.851	rs7225096	chr17:37664443	T/C	cg15445000	chr17:37608096	MED1	0.41	6.76	0.38	8.83e-11	Glomerular filtration rate (creatinine);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19138325	chr12:129429698	GLT1D1	-0.57	-7.21	-0.4	6.03e-12	Gut microbiome composition (summer);
CESC	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg26338869	chr17:61819248	STRADA	0.67	8.75	0.47	2.55e-16	Prudent dietary pattern;
CESC	cis	rs8141529	0.732	rs6005881	chr22:29183133	A/G	cg15103426	chr22:29168792	CCDC117	0.69	9.96	0.52	4.85e-20	Lymphocyte counts;
CESC	cis	rs644799	1.000	rs617999	chr11:95589935	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.69	8.73	0.47	2.91e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs7843479	0.601	rs3824338	chr8:21864540	A/C	cg17168535	chr8:21777572	XPO7	0.7	11.09	0.56	9.93e-24	Mean corpuscular volume;
CESC	cis	rs4713118	0.513	rs149955	chr6:28036225	G/C	cg23281280	chr6:28129359	ZNF389	0.4	5.7	0.33	3.25e-8	Parkinson's disease;
CESC	cis	rs116095464	0.558	rs1541822	chr5:269234	A/C	cg22496380	chr5:211416	CCDC127	0.69	7.87	0.44	8.94e-14	Breast cancer;
CESC	cis	rs6540556	0.608	rs12129718	chr1:209912540	C/T	cg05527609	chr1:210001259	C1orf107	-0.55	-6.35	-0.36	9.43e-10	Red blood cell count;
CESC	cis	rs35110281	0.627	rs11701746	chr21:44975137	C/T	cg21573476	chr21:45109991	RRP1B	-0.4	-5.5	-0.32	9.09e-8	Mean corpuscular volume;
CESC	cis	rs9611565	0.568	rs5751159	chr22:42175365	G/A	cg03806693	chr22:41940476	POLR3H	0.78	9.34	0.5	3.97e-18	Vitiligo;
CESC	cis	rs2075371	0.611	rs12707154	chr7:134015832	C/T	cg20476274	chr7:133979776	SLC35B4	0.58	7.72	0.43	2.35e-13	Mean platelet volume;
CESC	cis	rs873946	0.590	rs12259699	chr10:134549692	A/G	cg06453172	chr10:134556979	INPP5A	-0.4	-5.43	-0.32	1.3e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs736408	0.609	rs2268025	chr3:52795224	A/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.25	0.36	1.63e-9	Bipolar disorder;
CESC	cis	rs2425143	1.000	rs6060588	chr20:34337480	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.6	5.15	0.3	5.14e-7	Blood protein levels;
CESC	trans	rs1814175	0.746	rs10839429	chr11:49906845	G/A	cg03929089	chr4:120376271	NA	-0.93	-16.26	-0.71	1.03e-41	Height;
CESC	cis	rs6831352	0.879	rs29001215	chr4:100051722	T/C	cg12011299	chr4:100065546	ADH4	-0.59	-6.52	-0.37	3.62e-10	Alcohol dependence;
CESC	cis	rs9649213	0.593	rs1468338	chr7:97951118	T/C	cg08684580	chr7:98029266	BAIAP2L1	-0.35	-5.69	-0.33	3.38e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs514406	0.667	rs10788942	chr1:53210521	A/T	cg24675658	chr1:53192096	ZYG11B	0.64	8.96	0.48	5.89e-17	Monocyte count;
CESC	cis	rs11122272	0.766	rs2790872	chr1:231540543	A/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.48	-6.32	-0.36	1.08e-9	Hemoglobin concentration;
CESC	cis	rs2455799	0.613	rs6795100	chr3:15793798	C/T	cg09340198	chr3:15902540	ANKRD28	-0.33	-5.16	-0.3	4.94e-7	Mean platelet volume;
CESC	cis	rs9549260	0.755	rs4941987	chr13:41195992	T/C	cg21288729	chr13:41239152	FOXO1	0.62	7.9	0.44	7.34e-14	Red blood cell count;
CESC	cis	rs910316	0.687	rs11627442	chr14:75669649	A/G	cg08847533	chr14:75593920	NEK9	-0.83	-13.0	-0.62	3.11e-30	Height;
CESC	cis	rs1215050	0.740	rs700739	chr4:99022546	A/G	cg17366294	chr4:99064904	C4orf37	-0.4	-5.26	-0.31	3e-7	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg20119798	chr7:94954144	PON1	-0.38	-5.58	-0.32	5.95e-8	Paraoxonase activity;
CESC	cis	rs12477438	0.822	rs6727170	chr2:99588042	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.65	-7.95	-0.44	5.43e-14	Chronic sinus infection;
CESC	cis	rs3768617	1.000	rs3768617	chr1:183092500	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.65	9.22	0.49	9.46e-18	Fuchs's corneal dystrophy;
CESC	cis	rs7927771	0.832	rs11605672	chr11:47413733	A/G	cg05585544	chr11:47624801	NA	-0.5	-7.5	-0.42	9.62e-13	Subjective well-being;
CESC	cis	rs644799	0.965	rs502521	chr11:95533557	T/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	9.13	0.49	1.83e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs11690935	0.851	rs7581072	chr2:172859849	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.79	-10.76	-0.55	1.25e-22	Schizophrenia;
CESC	cis	rs6866344	0.570	rs56236920	chr5:178144617	C/T	cg10224037	chr5:178157518	ZNF354A	0.73	8.42	0.46	2.41e-15	Neutrophil percentage of white cells;
CESC	cis	rs3768617	0.510	rs10797852	chr1:183101302	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.89	14.34	0.66	6.72e-35	Fuchs's corneal dystrophy;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg13917004	chr19:42462874	RABAC1	-0.48	-6.24	-0.36	1.76e-9	Height;
CESC	cis	rs6963495	0.818	rs73190151	chr7:105152887	C/T	cg19920283	chr7:105172520	RINT1	0.69	6.54	0.37	3.09e-10	Bipolar disorder (body mass index interaction);
CESC	trans	rs7839040	0.662	rs7840956	chr8:82929514	C/A	cg14472086	chr9:107730925	NA	-0.48	-6.33	-0.36	1.03e-9	Response to methotrexate in juvenile idiopathic arthritis;
CESC	cis	rs2991971	0.967	rs12133294	chr1:45988764	C/T	cg05343316	chr1:45956843	TESK2	-0.5	-6.51	-0.37	3.84e-10	High light scatter reticulocyte count;
CESC	cis	rs1509123	0.609	rs56161809	chr17:6705360	A/T	cg12642237	chr17:6703447	TEKT1	-0.62	-5.08	-0.3	7.26e-7	Blood metabolite levels;
CESC	cis	rs7762018	1.000	rs11961560	chr6:170130121	T/C	cg13891659	chr6:170190454	C6orf122;C6orf208	0.6	6.14	0.35	3.04e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs597539	0.652	rs514833	chr11:68657734	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.79	10.29	0.53	4.1e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs6987853	0.787	rs2923442	chr8:42435493	T/C	cg09913449	chr8:42400586	C8orf40	0.45	7.54	0.42	7.31e-13	Mean corpuscular hemoglobin concentration;
CESC	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-6.22	-0.36	1.95e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs9876781	0.559	rs13073692	chr3:48403302	C/T	cg11946769	chr3:48343235	NME6	0.4	5.05	0.3	8.28e-7	Longevity;
CESC	cis	rs2361718	0.500	rs8064429	chr17:78096187	A/C	cg21238619	chr17:78079768	GAA	-0.41	-6.17	-0.35	2.54e-9	Yeast infection;
CESC	cis	rs7727544	0.716	rs11949055	chr5:131576737	T/C	cg14196790	chr5:131705035	SLC22A5	0.36	5.29	0.31	2.58e-7	Blood metabolite levels;
CESC	cis	rs2066819	0.818	rs703830	chr12:56701872	T/C	cg26734620	chr12:56694298	CS	-0.92	-9.33	-0.5	4.31e-18	Psoriasis vulgaris;
CESC	cis	rs896854	0.902	rs896852	chr8:95960886	G/T	cg26343298	chr8:95960752	TP53INP1	0.37	5.94	0.34	8.73e-9	Type 2 diabetes;
CESC	cis	rs780096	0.587	rs1049817	chr2:27550967	A/G	cg22903471	chr2:27725779	GCKR	-0.46	-6.43	-0.37	5.8e-10	Total body bone mineral density;
CESC	cis	rs208520	0.690	rs1233103	chr6:66855943	T/G	cg07460842	chr6:66804631	NA	-1.01	-13.48	-0.64	6.84e-32	Exhaled nitric oxide output;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03041730	chr4:903314	GAK	-0.58	-6.17	-0.35	2.58e-9	Gut microbiome composition (summer);
CESC	cis	rs2014572	0.875	rs10405008	chr19:57753643	C/G	cg12963866	chr19:57752005	ZNF805	0.44	5.94	0.34	8.71e-9	Hyperactive-impulsive symptoms;
CESC	cis	rs1832871	0.672	rs12525675	chr6:158708749	A/T	cg07165851	chr6:158734300	TULP4	0.61	6.68	0.38	1.38e-10	Height;
CESC	cis	rs9611565	0.659	rs9607812	chr22:41941243	G/A	cg06634786	chr22:41940651	POLR3H	-0.64	-6.72	-0.38	1.11e-10	Vitiligo;
CESC	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg24846343	chr22:24311635	DDTL	0.46	7.28	0.41	3.76e-12	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs7552404	0.696	rs12140121	chr1:76455001	A/G	cg10523679	chr1:76189770	ACADM	0.64	6.24	0.36	1.71e-9	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs4253772	0.591	rs6007747	chr22:46657261	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.7	8.29	0.45	5.64e-15	LDL cholesterol;Cholesterol, total;
CESC	cis	rs1023500	0.505	rs134899	chr22:42683030	T/G	cg04733989	chr22:42467013	NAGA	0.61	9.3	0.5	5.44e-18	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18052550	chr4:166201661	GK3P;KLHL2	-0.61	-7.53	-0.42	7.89e-13	Gut microbiome composition (summer);
CESC	cis	rs10504229	1.000	rs67039591	chr8:58174553	T/A	cg22535103	chr8:58192502	C8orf71	-1.05	-13.27	-0.63	3.63e-31	Developmental language disorder (linguistic errors);
CESC	cis	rs881375	0.678	rs4836834	chr9:123665901	T/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.47	6.78	0.38	7.79e-11	Rheumatoid arthritis;
CESC	cis	rs11583043	0.708	rs6577227	chr1:101562132	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.5	5.47	0.32	1.03e-7	Ulcerative colitis;Inflammatory bowel disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07172676	chr8:144997714	PLEC1	-0.57	-6.43	-0.37	6.06e-10	Gut microbiome composition (summer);
CESC	cis	rs6867032	1.000	rs4413568	chr5:2016894	A/G	cg26168224	chr5:2018326	NA	1.05	23.85	0.83	6.36e-68	Gut microbiome composition (winter);
CESC	cis	rs798554	0.959	rs798557	chr7:2758982	G/A	cg18446336	chr7:2847575	GNA12	-0.37	-5.49	-0.32	9.37e-8	Height;
CESC	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg26338869	chr17:61819248	STRADA	0.68	8.87	0.48	1.08e-16	Prudent dietary pattern;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06080712	chr22:32435515	NA	-0.59	-6.94	-0.39	2.96e-11	Gut microbiome composition (summer);
CESC	cis	rs4713118	0.586	rs6905522	chr6:28086479	A/C	cg12963246	chr6:28129442	ZNF389	0.56	7.63	0.42	4.26e-13	Parkinson's disease;
CESC	cis	rs6952808	0.929	rs11761270	chr7:1923695	C/T	cg21782813	chr7:2030301	MAD1L1	0.43	6.05	0.35	4.98e-9	Bipolar disorder and schizophrenia;
CESC	trans	rs11098499	0.908	rs28499576	chr4:120386677	G/A	cg25214090	chr10:38739885	LOC399744	0.7	9.98	0.52	4.04e-20	Corneal astigmatism;
CESC	cis	rs959260	1.000	rs12604003	chr17:73399598	G/A	cg12999837	chr17:73267436	MIF4GD	-0.52	-5.87	-0.34	1.3e-8	Systemic lupus erythematosus;
CESC	cis	rs11191270	0.590	rs12569901	chr10:104025410	C/G	cg15320455	chr10:103880129	LDB1	0.61	5.86	0.34	1.38e-8	Intelligence (multi-trait analysis);
CESC	cis	rs4700695	0.668	rs166180	chr5:65499225	C/T	cg21114390	chr5:65439923	SFRS12	-0.48	-5.85	-0.34	1.48e-8	Facial morphology (factor 19);
CESC	cis	rs11630290	0.592	rs1039818	chr15:64155296	A/G	cg12036633	chr15:63758958	NA	0.45	5.44	0.32	1.21e-7	Iris characteristics;
CESC	cis	rs6938	0.534	rs11636892	chr15:75266049	G/C	cg14664628	chr15:75095509	CSK	-0.53	-6.71	-0.38	1.17e-10	Breast cancer;
CESC	cis	rs5769765	1.000	rs4597652	chr22:50270570	A/G	cg26441486	chr22:50317300	CRELD2	-0.39	-5.5	-0.32	8.72e-8	Schizophrenia;
CESC	cis	rs644799	0.930	rs631099	chr11:95563482	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	9.15	0.49	1.57e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs7666738	0.830	rs957742	chr4:99029409	C/T	cg17366294	chr4:99064904	C4orf37	0.62	8.95	0.48	6.32e-17	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7188697	0.921	rs12445577	chr16:58587164	T/C	cg02549819	chr16:58548995	SETD6	0.43	5.38	0.31	1.64e-7	QT interval;
CESC	cis	rs3105593	1.000	rs11637228	chr15:50899972	G/T	cg08437265	chr15:50716283	USP8	0.41	5.37	0.31	1.76e-7	QT interval;
CESC	cis	rs9837602	0.938	rs9814359	chr3:99797013	C/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.45	6.39	0.37	7.39e-10	Breast cancer;
CESC	cis	rs9322193	0.962	rs6899661	chr6:150139229	T/C	cg04369109	chr6:150039330	LATS1	-0.4	-5.49	-0.32	9.42e-8	Lung cancer;
CESC	cis	rs2066819	1.000	rs11575229	chr12:56750737	C/T	cg26734620	chr12:56694298	CS	0.97	5.8	0.34	1.92e-8	Psoriasis vulgaris;
CESC	cis	rs6728642	1.000	rs6728642	chr2:97607071	A/G	cg26665480	chr2:98280029	ACTR1B	-0.65	-6.53	-0.37	3.32e-10	Bipolar disorder lithium response (continuous) or schizophrenia;
CESC	cis	rs796364	0.806	rs78527234	chr2:200913453	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.84	-7.75	-0.43	1.94e-13	Schizophrenia;
CESC	cis	rs589448	0.535	rs12423794	chr12:69713018	G/A	cg14784868	chr12:69753453	YEATS4	0.77	10.88	0.56	4.75e-23	Cerebrospinal fluid biomarker levels;
CESC	cis	rs9611565	0.559	rs12483860	chr22:41961916	C/T	cg06481639	chr22:41940642	POLR3H	-0.57	-6.38	-0.36	7.88e-10	Vitiligo;
CESC	cis	rs9649213	0.593	rs6967457	chr7:97912221	T/G	cg24562669	chr7:97807699	LMTK2	0.51	7.27	0.41	4.05e-12	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs10992471	0.756	rs10992319	chr9:95127895	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.45	-5.68	-0.33	3.52e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CESC	cis	rs4891159	0.513	rs35534021	chr18:74130523	G/A	cg24786174	chr18:74118243	ZNF516	0.83	15.52	0.69	4.35e-39	Longevity;
CESC	cis	rs9309473	0.519	rs13022145	chr2:73863473	G/A	cg20560298	chr2:73613845	ALMS1	0.48	6.77	0.38	8.49e-11	Metabolite levels;
CESC	cis	rs926938	0.563	rs360630	chr1:115415132	C/T	cg12756093	chr1:115239321	AMPD1	0.45	6.01	0.35	6.15e-9	Autism;
CESC	cis	rs2295499	0.754	rs12499258	chr4:2715758	G/A	cg27239842	chr4:2403781	ZFYVE28	-0.33	-5.55	-0.32	6.84e-8	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
CESC	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg03647317	chr4:187891568	NA	-0.44	-6.71	-0.38	1.15e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9309473	1.000	rs10190219	chr2:73658331	C/T	cg20560298	chr2:73613845	ALMS1	-0.53	-6.95	-0.39	2.86e-11	Metabolite levels;
CESC	trans	rs9354308	0.903	rs9360158	chr6:66558164	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.5	-6.02	-0.35	5.86e-9	Metabolite levels;
CESC	cis	rs6723226	0.750	rs1033751	chr2:32695759	T/C	cg02381751	chr2:32503542	YIPF4	0.53	6.82	0.39	6.05e-11	Intelligence (multi-trait analysis);
CESC	cis	rs514406	0.505	rs374662	chr1:53164549	C/A	cg16325326	chr1:53192061	ZYG11B	0.9	15.66	0.69	1.42e-39	Monocyte count;
CESC	cis	rs116979167	0.514	rs1706915	chr7:105196437	A/G	cg19920283	chr7:105172520	RINT1	0.5	5.7	0.33	3.17e-8	Bipolar disorder (body mass index interaction);
CESC	cis	rs6952808	0.529	rs73038442	chr7:2139457	C/T	cg05863683	chr7:1912471	MAD1L1	0.37	5.42	0.32	1.35e-7	Bipolar disorder and schizophrenia;
CESC	trans	rs1814175	0.817	rs2866545	chr11:49630824	A/C	cg03929089	chr4:120376271	NA	-0.9	-14.83	-0.67	1.19e-36	Height;
CESC	cis	rs8114671	0.836	rs6060140	chr20:33566507	G/A	cg07148914	chr20:33460835	GGT7	0.43	5.58	0.32	6e-8	Height;
CESC	cis	rs9611565	0.512	rs139566	chr22:42199277	A/G	cg06481639	chr22:41940642	POLR3H	-0.58	-5.82	-0.34	1.68e-8	Vitiligo;
CESC	cis	rs1552244	0.882	rs35056669	chr3:10014171	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.76	-9.51	-0.5	1.23e-18	Alzheimer's disease;
CESC	cis	rs10203711	0.966	rs4998693	chr2:239564753	G/T	cg14580085	chr2:239553406	NA	0.34	5.16	0.3	4.74e-7	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs10504229	1.000	rs114486414	chr8:58185103	G/A	cg22535103	chr8:58192502	C8orf71	-1.05	-13.08	-0.63	1.71e-30	Developmental language disorder (linguistic errors);
CESC	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg24642844	chr7:1081250	C7orf50	-0.75	-9.03	-0.49	3.61e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs6598955	0.543	rs6690461	chr1:26543097	T/A	cg04990556	chr1:26633338	UBXN11	0.82	9.16	0.49	1.45e-17	Obesity-related traits;
CESC	cis	rs4975616	0.714	rs37007	chr5:1352372	G/C	cg07493874	chr5:1342172	CLPTM1L	-0.42	-7.83	-0.43	1.18e-13	Lung cancer;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg19586661	chr11:66079705	NA	-0.54	-7.21	-0.4	5.85e-12	Ulcerative colitis;
CESC	cis	rs2032447	0.670	rs198845	chr6:26107790	A/C	cg12310025	chr6:25882481	NA	-0.44	-6.38	-0.36	7.94e-10	Intelligence (multi-trait analysis);
CESC	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.38	-5.23	-0.31	3.39e-7	Lymphocyte counts;
CESC	cis	rs7647973	0.807	rs4955416	chr3:49108428	T/C	cg06212747	chr3:49208901	KLHDC8B	0.52	6.23	0.36	1.81e-9	Menarche (age at onset);
CESC	cis	rs2295499	0.673	rs55993221	chr4:2704910	G/T	cg27239842	chr4:2403781	ZFYVE28	-0.34	-5.66	-0.33	3.98e-8	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
CESC	cis	rs4862750	0.872	rs6836781	chr4:187899701	G/A	cg06074448	chr4:187884817	NA	-0.37	-5.43	-0.32	1.27e-7	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9322193	0.923	rs9767652	chr6:150055638	A/T	cg04369109	chr6:150039330	LATS1	-0.46	-6.46	-0.37	4.96e-10	Lung cancer;
CESC	cis	rs1008375	0.966	rs3775925	chr4:17588437	A/G	cg16339924	chr4:17578868	LAP3	0.74	9.63	0.51	5.26e-19	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs11122272	0.668	rs2472261	chr1:231505701	G/A	cg06096015	chr1:231504339	EGLN1	0.39	5.57	0.32	6.39e-8	Hemoglobin concentration;
CESC	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg26354017	chr1:205819088	PM20D1	0.84	13.62	0.64	2.19e-32	Menarche (age at onset);
CESC	cis	rs7208859	0.623	rs9916725	chr17:29107471	A/C	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.17e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs3026101	0.534	rs57303034	chr17:5319003	G/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.4	5.22	0.31	3.64e-7	Body mass index;
CESC	cis	rs7829975	0.682	rs7013471	chr8:8687325	A/G	cg15556689	chr8:8085844	FLJ10661	-0.44	-5.41	-0.32	1.44e-7	Mood instability;
CESC	cis	rs6543140	0.964	rs7561351	chr2:103077780	A/G	cg04239558	chr2:103089729	SLC9A4	0.47	6.16	0.35	2.64e-9	Blood protein levels;
CESC	cis	rs3733585	0.699	rs4408959	chr4:9948868	C/T	cg00071950	chr4:10020882	SLC2A9	-0.72	-11.95	-0.59	1.27e-26	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs10504229	1.000	rs67388517	chr8:58176617	C/A	cg05313129	chr8:58192883	C8orf71	-0.55	-6.37	-0.36	8.42e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs8031584	0.918	rs1425292	chr15:31285422	G/A	cg14298792	chr15:30685198	CHRFAM7A	-0.45	-5.33	-0.31	2.08e-7	Huntington's disease progression;
CESC	cis	rs10504229	1.000	rs59383954	chr8:58189689	G/A	cg14926445	chr8:58193284	C8orf71	-0.51	-5.52	-0.32	8.28e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs6912958	0.781	rs7757636	chr6:88256092	T/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.53	-7.12	-0.4	9.94e-12	Monocyte percentage of white cells;
CESC	trans	rs7615952	0.599	rs2270986	chr3:125701099	T/C	cg07211511	chr3:129823064	LOC729375	-0.55	-6.3	-0.36	1.2e-9	Blood pressure (smoking interaction);
CESC	cis	rs9322193	0.923	rs4870267	chr6:149992708	C/G	cg13206674	chr6:150067644	NUP43	0.44	6.35	0.36	9.48e-10	Lung cancer;
CESC	cis	rs561341	0.714	rs474455	chr17:30312465	A/T	cg00745463	chr17:30367425	LRRC37B	-0.68	-6.9	-0.39	3.9e-11	Hip circumference adjusted for BMI;
CESC	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg15112475	chr7:1198522	ZFAND2A	-0.45	-7.28	-0.41	3.84e-12	Longevity;Endometriosis;
CESC	cis	rs1568889	0.838	rs11030230	chr11:28174631	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.8	13.46	0.64	8.14e-32	Bipolar disorder;
CESC	cis	rs4665809	0.878	rs4665826	chr2:26367503	A/T	cg27170947	chr2:26402098	FAM59B	0.78	9.28	0.5	6.33e-18	Gut microbiome composition (summer);
CESC	cis	rs17711722	0.510	rs11767457	chr7:65290615	C/T	cg25405998	chr7:65216604	CCT6P1	0.52	6.56	0.37	2.75e-10	Calcium levels;
CESC	cis	rs6701037	0.555	rs10912899	chr1:175120715	C/T	cg00321850	chr1:175162397	KIAA0040	0.45	6.48	0.37	4.35e-10	Alcohol dependence;
CESC	cis	rs782590	1.000	rs782590	chr2:55843413	C/T	cg18811423	chr2:55921094	PNPT1	0.79	12.71	0.62	3.13e-29	Metabolic syndrome;
CESC	cis	rs10751667	0.666	rs6597962	chr11:976351	C/T	cg06064525	chr11:970664	AP2A2	-0.51	-9.99	-0.52	3.83e-20	Alzheimer's disease (late onset);
CESC	trans	rs9325144	0.671	rs7485963	chr12:38768254	C/G	cg10679878	chr6:156759499	NA	-0.34	-6.09	-0.35	4.05e-9	Morning vs. evening chronotype;
CESC	cis	rs9916302	0.851	rs9909064	chr17:37500434	G/T	cg00129232	chr17:37814104	STARD3	0.57	7.67	0.43	3.29e-13	Glomerular filtration rate (creatinine);
CESC	trans	rs877282	0.945	rs34367686	chr10:791868	G/C	cg22713356	chr15:30763199	NA	1.32	13.44	0.64	9.25e-32	Uric acid levels;
CESC	cis	rs1348850	0.914	rs7591807	chr2:178252986	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.9	13.34	0.63	2.02e-31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs12586317	0.514	rs61100068	chr14:35400232	A/T	cg16230307	chr14:35515116	FAM177A1	1.08	10.96	0.56	2.63e-23	Psoriasis;
CESC	cis	rs7264396	0.790	rs6058283	chr20:34216276	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.65	7.65	0.43	3.84e-13	Total cholesterol levels;
CESC	cis	rs73019876	0.869	rs2522092	chr19:22126992	G/T	cg11619707	chr19:22235551	ZNF257	-0.29	-5.22	-0.31	3.61e-7	Testicular germ cell tumor;
CESC	cis	rs9818941	0.910	rs9825122	chr3:157672947	T/C	cg08654915	chr3:157813417	NA	-0.44	-7.72	-0.43	2.34e-13	Height;
CESC	cis	rs11574514	1.000	rs28679372	chr16:67882932	C/T	cg01866162	chr16:67596514	CTCF	-0.96	-5.57	-0.32	6.39e-8	Crohn's disease;
CESC	cis	rs2243480	1.000	rs160646	chr7:65556280	C/T	cg18252515	chr7:66147081	NA	-1.39	-13.8	-0.65	5.05e-33	Diabetic kidney disease;
CESC	cis	rs7726839	0.540	rs4957080	chr5:644552	A/C	cg16447950	chr5:562315	NA	0.56	6.13	0.35	3.2e-9	Obesity-related traits;
CESC	cis	rs9660992	0.639	rs1151786	chr1:205227760	G/C	cg00857998	chr1:205179979	DSTYK	0.49	5.7	0.33	3.24e-8	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs67311347	1.000	rs9822644	chr3:40426609	G/A	cg24209194	chr3:40518798	ZNF619	0.5	6.24	0.36	1.74e-9	Renal cell carcinoma;
CESC	trans	rs8073060	0.586	rs225307	chr17:33918311	A/G	cg19694781	chr19:47549865	TMEM160	0.72	6.95	0.39	2.85e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	cis	rs7178572	0.524	rs11853287	chr15:77399371	A/G	cg22256960	chr15:77711686	NA	-0.54	-6.84	-0.39	5.62e-11	Type 2 diabetes;
CESC	cis	rs4237845	0.537	rs10877031	chr12:58266695	A/G	cg02175503	chr12:58329896	NA	0.51	6.08	0.35	4.27e-9	Intelligence (multi-trait analysis);
CESC	trans	rs10242455	0.702	rs2293256	chr7:99057701	A/G	cg09045935	chr12:6379348	NA	-0.7	-6.02	-0.35	5.93e-9	Blood metabolite levels;
CESC	cis	rs6748734	0.625	rs4675871	chr2:241823849	G/A	cg04034577	chr2:241836375	C2orf54	-0.32	-5.63	-0.33	4.69e-8	Urinary metabolites;
CESC	cis	rs9796	0.870	rs28581803	chr15:41326513	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.46	-6.84	-0.39	5.38e-11	Menopause (age at onset);
CESC	cis	rs9733	0.596	rs17606613	chr1:150683015	C/T	cg17724175	chr1:150552817	MCL1	0.45	7.31	0.41	3.23e-12	Tonsillectomy;
CESC	cis	rs10754283	0.905	rs7519969	chr1:90108721	G/C	cg21401794	chr1:90099060	LRRC8C	0.69	9.34	0.5	4.06e-18	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs7666738	0.861	rs28821920	chr4:98962743	T/C	cg05340658	chr4:99064831	C4orf37	0.8	12.39	0.61	3.96e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs34779708	0.966	rs12765038	chr10:35416513	G/C	cg03585969	chr10:35415529	CREM	0.77	10.24	0.53	5.78e-21	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs9611565	0.512	rs139572	chr22:42214532	C/T	cg03806693	chr22:41940476	POLR3H	-1.05	-11.19	-0.57	4.52e-24	Vitiligo;
CESC	cis	rs17711722	0.740	rs7809991	chr7:65406218	A/G	cg11987759	chr7:65425863	GUSB	-0.47	-6.42	-0.37	6.18e-10	Calcium levels;
CESC	cis	rs35110281	0.807	rs28840140	chr21:45039163	T/C	cg01579765	chr21:45077557	HSF2BP	-0.59	-10.12	-0.53	1.43e-20	Mean corpuscular volume;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg08464520	chr19:56104287	FIZ1	0.47	6.36	0.36	8.59e-10	Fibrinogen levels;
CESC	trans	rs7615952	0.741	rs13314845	chr3:125644782	C/T	cg07211511	chr3:129823064	LOC729375	-1.13	-15.5	-0.69	5.37e-39	Blood pressure (smoking interaction);
CESC	cis	rs7191439	0.728	rs8043637	chr16:88781125	T/C	cg27087555	chr16:88793112	FAM38A	-1.1	-9.05	-0.49	3.07e-17	Plateletcrit;
CESC	cis	rs11098499	0.866	rs13105020	chr4:120285688	G/T	cg24375607	chr4:120327624	NA	0.42	5.19	0.3	4.19e-7	Corneal astigmatism;
CESC	cis	rs11209002	0.567	rs2755269	chr1:67541065	T/C	cg02640540	chr1:67518911	SLC35D1	0.47	5.39	0.31	1.52e-7	Crohn's disease;
CESC	cis	rs8070624	0.543	rs11078409	chr17:17876296	C/G	cg04398451	chr17:18023971	MYO15A	-0.75	-10.67	-0.55	2.48e-22	Total body bone mineral density;
CESC	cis	rs6693567	0.565	rs1313569	chr1:150344171	G/A	cg09579323	chr1:150459698	TARS2	0.47	6.05	0.35	4.99e-9	Migraine;
CESC	cis	rs561341	0.941	rs4525554	chr17:30312819	T/C	cg19193384	chr17:30244184	NA	-0.67	-6.36	-0.36	8.74e-10	Hip circumference adjusted for BMI;
CESC	cis	rs13108904	0.934	rs13115173	chr4:1316824	T/C	cg22903657	chr4:1355424	KIAA1530	-0.38	-5.26	-0.31	2.94e-7	Obesity-related traits;
CESC	cis	rs1707322	0.721	rs4564187	chr1:46166861	G/C	cg05343316	chr1:45956843	TESK2	0.51	6.2	0.36	2.19e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs736408	0.609	rs13082960	chr3:52785168	A/C	cg17372223	chr3:52568218	NT5DC2	0.45	6.61	0.38	2.11e-10	Bipolar disorder;
CESC	cis	rs7666738	0.830	rs35822567	chr4:98654138	G/A	cg03467027	chr4:99064603	C4orf37	0.44	5.39	0.31	1.52e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2839186	0.814	rs12482209	chr21:47664275	C/G	cg05896524	chr21:47604654	C21orf56	-0.4	-5.18	-0.3	4.41e-7	Testicular germ cell tumor;
CESC	cis	rs11864453	0.560	rs6499561	chr16:72148404	A/G	cg01557791	chr16:72042693	DHODH	-0.47	-6.34	-0.36	9.86e-10	Fibrinogen levels;
CESC	cis	rs1348850	0.597	rs13014417	chr2:178417835	T/G	cg22681709	chr2:178499509	PDE11A	-0.53	-6.46	-0.37	5.11e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs2657888	0.899	rs7300877	chr12:56933233	C/A	cg23002907	chr12:56915593	RBMS2	0.4	5.22	0.31	3.53e-7	Adiponectin levels;
CESC	cis	rs6964587	1.000	rs12704635	chr7:91737324	T/G	cg17063962	chr7:91808500	NA	0.56	7.69	0.43	2.96e-13	Breast cancer;
CESC	cis	rs4727963	0.846	rs6968535	chr7:122715438	C/T	cg03640110	chr7:122635026	TAS2R16	-0.39	-6.04	-0.35	5.11e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
CESC	cis	rs34779708	0.931	rs11010101	chr10:35411045	T/A	cg04310649	chr10:35416472	CREM	-0.55	-6.76	-0.38	8.85e-11	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs950776	0.616	rs495090	chr15:78870003	A/G	cg06917634	chr15:78832804	PSMA4	-0.5	-6.19	-0.36	2.26e-9	Sudden cardiac arrest;
CESC	cis	rs6009527	1.000	rs2318942	chr22:49573505	G/A	cg12746016	chr22:49560550	NA	0.35	5.13	0.3	5.61e-7	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);
CESC	cis	rs4970988	0.787	rs1532770	chr1:150725335	G/T	cg04414720	chr1:150670196	GOLPH3L	0.57	7.47	0.42	1.2e-12	Urate levels;
CESC	trans	rs7824557	0.564	rs2572400	chr8:11234367	T/G	cg06636001	chr8:8085503	FLJ10661	-0.49	-6.07	-0.35	4.52e-9	Retinal vascular caliber;
CESC	cis	rs208520	0.661	rs704519	chr6:66801136	T/C	cg07460842	chr6:66804631	NA	-0.99	-13.28	-0.63	3.36e-31	Exhaled nitric oxide output;
CESC	cis	rs875971	0.508	rs10242423	chr7:66059175	A/G	cg06456125	chr7:65229604	NA	-0.4	-5.59	-0.32	5.76e-8	Aortic root size;
CESC	trans	rs801193	1.000	rs7785213	chr7:66138978	A/C	cg26939375	chr7:64535504	NA	-0.64	-8.64	-0.47	5.52e-16	Aortic root size;
CESC	cis	rs6831352	0.589	rs2602836	chr4:100014805	C/T	cg12011299	chr4:100065546	ADH4	-0.75	-10.87	-0.56	5.26e-23	Alcohol dependence;
CESC	cis	rs12042052	1.000	rs72752168	chr1:232922800	G/A	cg00951395	chr1:232941775	KIAA1383	0.71	6.48	0.37	4.51e-10	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CESC	cis	rs9611565	0.506	rs1984839	chr22:41685937	G/C	cg03806693	chr22:41940476	POLR3H	-0.79	-9.05	-0.49	3.08e-17	Vitiligo;
CESC	cis	rs757110	0.933	rs4148646	chr11:17415190	C/G	cg11839944	chr11:17409644	KCNJ11	0.38	5.05	0.3	8.1e-7	Type 2 diabetes;
CESC	trans	rs637571	0.512	rs660118	chr11:65735174	G/C	cg17712092	chr4:129076599	LARP1B	0.75	10.32	0.54	3.36e-21	Eosinophil percentage of white cells;
CESC	cis	rs11722228	0.521	rs56403947	chr4:10112529	T/G	cg14348967	chr4:10160060	NA	-0.41	-5.15	-0.3	5.13e-7	Gout;Urate levels;Serum uric acid levels;
CESC	cis	rs6582630	0.634	rs10748443	chr12:38734062	G/T	cg26384229	chr12:38710491	ALG10B	0.56	8.04	0.44	3.07e-14	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs7809950	0.817	rs34325395	chr7:107113808	C/G	cg23024343	chr7:107201750	COG5	-0.6	-7.8	-0.43	1.43e-13	Coronary artery disease;
CESC	cis	rs9549367	0.737	rs11619691	chr13:113904636	T/C	cg00898013	chr13:113819073	PROZ	-0.53	-7.21	-0.41	5.74e-12	Platelet distribution width;
CESC	cis	rs780096	0.526	rs4582	chr2:27604279	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.29	-5.39	-0.31	1.55e-7	Total body bone mineral density;
CESC	cis	rs1728785	1.000	rs7118	chr16:68600855	G/T	cg02972257	chr16:68554789	NA	-0.59	-6.75	-0.38	9.22e-11	Ulcerative colitis;
CESC	cis	rs4665809	1.000	rs10182857	chr2:26344411	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.67	-7.53	-0.42	7.92e-13	Gut microbiome composition (summer);
CESC	cis	rs7618915	0.501	rs2159644	chr3:52774530	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.56	0.37	2.76e-10	Bipolar disorder;
CESC	cis	rs5167	0.504	rs8100120	chr19:45466058	T/C	cg09555818	chr19:45449301	APOC2	0.39	6.18	0.35	2.46e-9	Blood protein levels;
CESC	cis	rs798554	1.000	rs798548	chr7:2760935	A/G	cg18446336	chr7:2847575	GNA12	-0.36	-5.65	-0.33	4.18e-8	Height;
CESC	cis	rs1008375	1.000	rs10805359	chr4:17684886	A/G	cg02297831	chr4:17616191	MED28	0.44	5.64	0.33	4.43e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs6032067	0.929	rs56168207	chr20:43803971	C/T	cg10761708	chr20:43804764	PI3	0.53	6.29	0.36	1.28e-9	Blood protein levels;
CESC	cis	rs9815354	1.000	rs1716661	chr3:41962818	C/T	cg03022575	chr3:42003672	ULK4	-0.46	-5.45	-0.32	1.15e-7	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs3796352	1.000	rs7625448	chr3:53120766	C/A	cg12962167	chr3:53033115	SFMBT1	0.53	5.44	0.32	1.22e-7	Immune reponse to smallpox (secreted IL-2);
CESC	cis	rs2288073	1.000	rs2288073	chr2:24413298	C/T	cg06627628	chr2:24431161	ITSN2	0.78	9.23	0.49	8.93e-18	Venous thromboembolism (SNP x SNP interaction);
CESC	cis	rs6951245	0.580	rs10257426	chr7:1213694	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.44	-5.27	-0.31	2.88e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs938554	0.736	rs4697699	chr4:9945722	T/C	cg11266682	chr4:10021025	SLC2A9	-0.38	-5.17	-0.3	4.57e-7	Blood metabolite levels;
CESC	cis	rs12137294	0.866	rs896320	chr1:205205347	T/C	cg21643547	chr1:205240462	TMCC2	-0.35	-5.58	-0.32	6.09e-8	Red cell distribution width;
CESC	cis	rs769267	1.000	rs12985655	chr19:19442434	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.65	-8.42	-0.46	2.42e-15	Tonsillectomy;
CESC	cis	rs1691799	0.899	rs1168292	chr12:66732660	C/T	cg16791601	chr12:66731901	HELB	-0.75	-12.9	-0.62	7.25e-30	White blood cell count (basophil);
CESC	cis	rs2712184	0.729	rs2541397	chr2:217646693	G/A	cg05032264	chr2:217675019	NA	-0.35	-5.32	-0.31	2.26e-7	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
CESC	cis	rs1950626	0.615	rs12893486	chr14:101463800	C/A	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.84	9.79	0.52	1.62e-19	Pelvic organ prolapse (moderate/severe);
CESC	cis	rs780096	0.587	rs10205219	chr2:27568565	T/C	cg12648201	chr2:27665141	KRTCAP3	-0.34	-6.39	-0.37	7.61e-10	Total body bone mineral density;
CESC	cis	rs7078219	0.505	rs10883371	chr10:101292455	G/T	cg09788492	chr10:101292477	NKX2-3	0.33	6.32	0.36	1.12e-9	Dental caries;
CESC	cis	rs9902453	0.757	rs12453308	chr17:28441604	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.62	7.88	0.44	8.34e-14	Coffee consumption (cups per day);
CESC	cis	rs270601	0.690	rs162907	chr5:131580152	A/G	cg18301423	chr5:131593218	PDLIM4	-0.4	-5.56	-0.32	6.68e-8	Acylcarnitine levels;
CESC	cis	rs7582720	0.806	rs72926770	chr2:203798585	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.38	0.41	1.99e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs1799949	1.000	rs8176133	chr17:41257458	A/C	cg05368731	chr17:41323189	NBR1	0.77	10.78	0.55	1.02e-22	Menopause (age at onset);
CESC	cis	rs858239	0.539	rs6949363	chr7:23192394	A/G	cg23682824	chr7:23144976	KLHL7	0.5	6.78	0.38	7.91e-11	Cerebrospinal fluid biomarker levels;
CESC	cis	rs80130819	0.636	rs2732470	chr12:48664757	T/G	cg05342945	chr12:48394962	COL2A1	-0.48	-5.22	-0.31	3.6e-7	Prostate cancer;
CESC	cis	rs62064224	0.703	rs62065492	chr17:30822607	C/T	cg18200150	chr17:30822561	MYO1D	0.75	12.22	0.6	1.55e-27	Schizophrenia;
CESC	trans	rs801193	0.967	rs1110414	chr7:66205582	A/G	cg26939375	chr7:64535504	NA	0.64	8.77	0.47	2.19e-16	Aortic root size;
CESC	cis	rs7587476	0.784	rs13032278	chr2:215698034	G/A	cg04004882	chr2:215674386	BARD1	0.5	5.42	0.32	1.36e-7	Neuroblastoma;
CESC	cis	rs7772486	0.720	rs6570713	chr6:146075085	G/A	cg05347473	chr6:146136440	FBXO30	-0.57	-7.36	-0.41	2.27e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2204008	0.715	rs3899385	chr12:38169880	C/G	cg26384229	chr12:38710491	ALG10B	0.72	10.46	0.54	1.18e-21	Bladder cancer;
CESC	cis	rs1862618	0.853	rs33322	chr5:56175226	A/G	cg12311346	chr5:56204834	C5orf35	-0.74	-8.84	-0.48	1.38e-16	Initial pursuit acceleration;
CESC	cis	rs1448094	0.511	rs58742237	chr12:86166444	C/T	cg00310523	chr12:86230176	RASSF9	0.41	6.17	0.35	2.61e-9	Major depressive disorder;
CESC	cis	rs7143963	0.609	rs7140494	chr14:103291698	C/T	cg24154132	chr14:103367632	TRAF3	-0.36	-6.58	-0.37	2.52e-10	Body mass index;
CESC	cis	rs4713118	0.513	rs1225591	chr6:28148752	G/A	cg19592336	chr6:28129416	ZNF389	0.47	6.85	0.39	5.17e-11	Parkinson's disease;
CESC	cis	rs854765	0.583	rs9913724	chr17:17819101	A/G	cg16928487	chr17:17741425	SREBF1	-0.56	-9.74	-0.51	2.34e-19	Total body bone mineral density;
CESC	cis	rs7917772	0.503	rs10748825	chr10:104293609	A/G	cg22532475	chr10:104410764	TRIM8	-0.34	-5.81	-0.34	1.82e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs921968	0.541	rs3845835	chr2:219342284	T/C	cg02176678	chr2:219576539	TTLL4	-0.55	-9.81	-0.52	1.36e-19	Mean corpuscular hemoglobin concentration;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14520079	chr3:106825871	NA	-0.65	-7.46	-0.42	1.26e-12	Gut microbiome composition (summer);
CESC	cis	rs9611565	0.559	rs13056262	chr22:42081921	A/G	cg17376030	chr22:41985996	PMM1	-0.79	-8.55	-0.47	9.65e-16	Vitiligo;
CESC	cis	rs6032067	0.850	rs34274189	chr20:43864298	G/T	cg10761708	chr20:43804764	PI3	0.49	5.55	0.32	6.82e-8	Blood protein levels;
CESC	cis	rs35110281	0.776	rs2838316	chr21:44990036	C/T	cg21573476	chr21:45109991	RRP1B	-0.46	-6.29	-0.36	1.31e-9	Mean corpuscular volume;
CESC	cis	rs3091242	0.933	rs12402120	chr1:25751632	C/T	cg27572855	chr1:25598939	RHD	0.45	7.53	0.42	7.96e-13	Erythrocyte sedimentation rate;
CESC	cis	rs477895	0.713	rs35095324	chr11:63948412	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.95	10.4	0.54	1.85e-21	Mean platelet volume;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg27026831	chr7:72971748	BCL7B	-0.51	-6.07	-0.35	4.4e-9	Ulcerative colitis;
CESC	cis	rs703842	1.000	rs10783848	chr12:58196528	G/A	cg00677455	chr12:58241039	CTDSP2	0.53	6.97	0.39	2.45e-11	Multiple sclerosis;
CESC	cis	rs1983891	0.742	rs6920495	chr6:41554182	A/G	cg20194872	chr6:41519635	FOXP4	0.48	6.77	0.38	8.28e-11	Prostate cancer;
CESC	cis	rs3820068	0.581	rs72645889	chr1:15930251	T/G	cg16988262	chr1:15930761	NA	0.35	5.65	0.33	4.18e-8	Systolic blood pressure;
CESC	cis	rs7412746	0.658	rs8444	chr1:150938571	G/A	cg17724175	chr1:150552817	MCL1	0.38	5.83	0.34	1.58e-8	Melanoma;
CESC	trans	rs7937682	0.824	rs510866	chr11:111484113	A/C	cg18187862	chr3:45730750	SACM1L	0.48	6.03	0.35	5.37e-9	Primary sclerosing cholangitis;
CESC	cis	rs2425143	1.000	rs12480408	chr20:34234800	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.84	-7.67	-0.43	3.27e-13	Blood protein levels;
CESC	cis	rs6594499	0.872	rs7702774	chr5:110460851	G/T	cg04022379	chr5:110408740	TSLP	0.33	6.01	0.35	5.98e-9	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg07677032	chr17:61819896	STRADA	0.5	6.7	0.38	1.25e-10	Prudent dietary pattern;
CESC	cis	rs9733	0.596	rs6692960	chr1:150695965	G/A	cg04414720	chr1:150670196	GOLPH3L	0.62	8.8	0.48	1.76e-16	Tonsillectomy;
CESC	cis	rs7364180	0.515	rs6002503	chr22:42208672	A/G	cg03806693	chr22:41940476	POLR3H	-0.5	-6.14	-0.35	2.97e-9	Alzheimer's disease biomarkers;
CESC	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.48	6.24	0.36	1.71e-9	Lymphocyte counts;
CESC	cis	rs72781680	0.898	rs72796166	chr2:23939311	G/C	cg08917208	chr2:24149416	ATAD2B	1.1	10.15	0.53	1.18e-20	Lymphocyte counts;
CESC	cis	rs2735413	0.560	rs73562716	chr16:78126415	A/G	cg04733911	chr16:78082701	NA	0.43	6.06	0.35	4.54e-9	Systolic blood pressure (alcohol consumption interaction);
CESC	trans	rs9929218	1.000	rs9282650	chr16:68809640	T/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.61	-8.03	-0.44	3.1e-14	Colorectal cancer;
CESC	cis	rs4835473	0.897	rs35377051	chr4:144658780	A/G	cg25736465	chr4:144833511	NA	-0.34	-5.3	-0.31	2.46e-7	Immature fraction of reticulocytes;
CESC	cis	rs71277158	0.688	rs76646441	chr3:169885103	A/G	cg04067573	chr3:169899625	PHC3	0.71	7.12	0.4	9.93e-12	Prostate cancer;
CESC	cis	rs760805	0.932	rs1005734	chr1:25262022	C/A	cg22509179	chr1:25234806	RUNX3	-0.68	-9.96	-0.52	4.52e-20	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs1003719	0.788	rs2835597	chr21:38466539	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.63	8.77	0.47	2.14e-16	Eye color traits;
CESC	cis	rs9584850	0.789	rs7988345	chr13:99117685	A/G	cg22223119	chr13:99095684	FARP1	-0.35	-5.03	-0.3	8.85e-7	Neuroticism;
CESC	cis	rs7586673	0.930	rs7591506	chr2:161960925	T/G	cg16506815	chr2:162101123	NA	0.44	6.0	0.35	6.4e-9	Intelligence (multi-trait analysis);
CESC	cis	rs7666738	0.546	rs28590002	chr4:98722642	C/T	cg05340658	chr4:99064831	C4orf37	0.59	7.36	0.41	2.32e-12	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7786808	0.741	rs11769149	chr7:158227127	A/G	cg09998033	chr7:158218633	PTPRN2	0.41	6.1	0.35	3.84e-9	Obesity-related traits;
CESC	cis	rs9905704	0.881	rs695137	chr17:56776663	G/A	cg12560992	chr17:57184187	TRIM37	0.59	7.01	0.4	1.92e-11	Testicular germ cell tumor;
CESC	cis	rs4523957	0.690	rs4790884	chr17:2105299	G/C	cg16513277	chr17:2031491	SMG6	-0.67	-9.25	-0.49	7.79e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs909002	0.800	rs6703093	chr1:32093561	C/T	cg13919466	chr1:32135498	COL16A1	-0.46	-8.27	-0.45	6.37e-15	Intelligence (multi-trait analysis);
CESC	cis	rs3026101	0.671	rs12602074	chr17:5302778	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.42	5.6	0.33	5.31e-8	Body mass index;
CESC	cis	rs7666738	0.535	rs6850010	chr4:98971601	A/T	cg18180107	chr4:99064573	C4orf37	0.4	5.16	0.3	4.82e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11608355	0.538	rs11611957	chr12:109801803	A/G	cg19025524	chr12:109796872	NA	-0.51	-7.31	-0.41	3.06e-12	Neuroticism;
CESC	cis	rs12893668	0.572	rs4906356	chr14:104138701	C/T	cg24130564	chr14:104152367	KLC1	-0.49	-6.46	-0.37	4.98e-10	Reticulocyte count;
CESC	trans	rs1493916	0.967	rs9953765	chr18:31399464	A/G	cg27147174	chr7:100797783	AP1S1	-0.52	-7.1	-0.4	1.14e-11	Life satisfaction;
CESC	cis	rs12479064	0.724	rs2309618	chr2:99974473	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.66	-7.8	-0.43	1.4e-13	Chronic sinus infection;
CESC	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg20887711	chr4:1340912	KIAA1530	0.85	11.49	0.58	4.64e-25	Longevity;
CESC	cis	rs11711311	1.000	rs2566968	chr3:113474154	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.58	7.64	0.42	4.1e-13	IgG glycosylation;
CESC	cis	rs7811142	0.830	rs6948685	chr7:99970188	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.89	8.51	0.46	1.27e-15	Platelet count;
CESC	cis	rs11650494	0.522	rs117821438	chr17:47325867	A/T	cg08112188	chr17:47440006	ZNF652	1.04	6.47	0.37	4.69e-10	Prostate cancer;
CESC	cis	rs11792861	0.926	rs10512391	chr9:111809530	A/G	cg13535736	chr9:111863775	C9orf5	-0.46	-5.77	-0.33	2.25e-8	Menarche (age at onset);
CESC	cis	rs9359856	0.510	rs6937789	chr6:90468775	C/G	cg13799429	chr6:90582589	CASP8AP2	0.67	7.27	0.41	3.97e-12	Bipolar disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13581034	chr5:174906090	SFXN1	-0.57	-6.15	-0.35	2.92e-9	Gut microbiome composition (summer);
CESC	cis	rs8005677	0.798	rs35615180	chr14:23404389	T/C	cg01529538	chr14:23388837	RBM23	0.43	5.69	0.33	3.3e-8	Cognitive ability (multi-trait analysis);
CESC	cis	rs4927850	0.881	rs7624638	chr3:195748729	C/T	cg00031303	chr3:195681400	NA	0.47	5.87	0.34	1.27e-8	Pancreatic cancer;
CESC	cis	rs10129255	0.957	rs10142918	chr14:107190443	C/A	cg07958169	chr14:107095056	NA	-0.39	-5.3	-0.31	2.47e-7	Kawasaki disease;
CESC	trans	rs7246657	0.765	rs7247259	chr19:37851090	T/C	cg24637308	chr11:6592297	DNHD1	0.53	6.17	0.35	2.55e-9	Coronary artery calcification;
CESC	cis	rs8027181	0.804	rs34661924	chr15:72994564	A/G	cg25632853	chr15:73088954	NA	0.3	5.28	0.31	2.74e-7	Triglyceride levels;
CESC	cis	rs7301826	0.651	rs4759525	chr12:131316281	T/C	cg11011512	chr12:131303247	STX2	0.46	5.74	0.33	2.6e-8	Plasma plasminogen activator levels;
CESC	cis	rs847577	0.609	rs6465657	chr7:97816327	C/T	cg24562669	chr7:97807699	LMTK2	0.83	13.57	0.64	3.36e-32	Breast cancer;
CESC	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg03188948	chr7:1209495	NA	0.74	7.3	0.41	3.27e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs11098499	0.863	rs10009626	chr4:120470005	T/C	cg09307838	chr4:120376055	NA	0.91	12.73	0.62	2.82e-29	Corneal astigmatism;
CESC	cis	rs875971	0.964	rs778708	chr7:65856319	T/C	cg18876405	chr7:65276391	NA	0.52	6.87	0.39	4.49e-11	Aortic root size;
CESC	cis	rs8014204	0.905	rs8014289	chr14:75377352	A/G	cg08847533	chr14:75593920	NEK9	-0.47	-5.8	-0.34	1.86e-8	Caffeine consumption;
CESC	cis	rs7552404	0.924	rs1498317	chr1:76171984	A/C	cg10523679	chr1:76189770	ACADM	0.76	10.05	0.53	2.4e-20	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs7091068	0.522	rs10882323	chr10:95483280	T/C	cg20715218	chr10:95462985	C10orf4	0.5	5.89	0.34	1.14e-8	Urinary tract infection frequency;
CESC	cis	rs2742234	0.955	rs2435384	chr10:43673731	G/T	cg07801480	chr10:43725741	RASGEF1A	0.37	5.29	0.31	2.58e-7	Hirschsprung disease;
CESC	cis	rs9660992	0.710	rs1668873	chr1:205235990	G/A	cg21643547	chr1:205240462	TMCC2	-0.49	-6.67	-0.38	1.45e-10	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs1707322	1.000	rs4660889	chr1:46297331	C/T	cg06784218	chr1:46089804	CCDC17	0.32	5.47	0.32	1.02e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs1707322	0.963	rs10890373	chr1:46393755	A/C	cg05343316	chr1:45956843	TESK2	0.51	6.24	0.36	1.71e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs8063761	0.640	rs4785760	chr16:90051438	G/A	cg08547343	chr16:90038815	CENPBD1;AFG3L1	0.65	9.59	0.51	6.71e-19	Squamous cell carcinoma;
CESC	cis	rs11792861	0.816	rs28361186	chr9:111704064	G/A	cg13535736	chr9:111863775	C9orf5	-0.47	-6.26	-0.36	1.57e-9	Menarche (age at onset);
CESC	cis	rs7937682	0.889	rs1789355	chr11:111499718	T/C	cg22437258	chr11:111473054	SIK2	0.7	9.18	0.49	1.31e-17	Primary sclerosing cholangitis;
CESC	cis	rs6951245	0.542	rs28460147	chr7:1217192	G/A	cg18402987	chr7:1209562	NA	0.77	8.33	0.46	4.24e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg22776125	chr6:167041314	RPS6KA2	0.54	7.13	0.4	9.79e-12	Gut microbiota (bacterial taxa);
CESC	cis	rs9916302	0.706	rs649180	chr17:37464959	A/C	cg07936489	chr17:37558343	FBXL20	0.95	10.45	0.54	1.24e-21	Glomerular filtration rate (creatinine);
CESC	cis	rs1707322	1.000	rs10789485	chr1:46407308	C/T	cg05343316	chr1:45956843	TESK2	0.5	6.13	0.35	3.11e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs8114671	0.742	rs6058161	chr20:33620026	C/T	cg07148914	chr20:33460835	GGT7	-0.41	-5.31	-0.31	2.28e-7	Height;
CESC	cis	rs1878931	0.582	rs9921152	chr16:3421199	A/G	cg02880119	chr16:3481970	NA	-0.4	-5.22	-0.31	3.67e-7	Body mass index (adult);
CESC	cis	rs2425143	1.000	rs6060557	chr20:34270266	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.83	-7.53	-0.42	8.04e-13	Blood protein levels;
CESC	trans	rs4671386	0.901	rs2160068	chr2:60522090	T/C	cg24386296	chr4:1723849	TMEM129;TACC3	0.51	6.39	0.37	7.28e-10	Acne (severe);
CESC	cis	rs2425143	1.000	rs117010355	chr20:34343442	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.84	-7.55	-0.42	6.87e-13	Blood protein levels;
CESC	cis	rs853679	0.546	rs200953	chr6:27837267	T/C	cg26587870	chr6:27730563	NA	-0.59	-5.3	-0.31	2.44e-7	Depression;
CESC	cis	rs3091242	0.933	rs11249251	chr1:25770188	C/G	cg03538708	chr1:25844672	NA	-0.38	-5.69	-0.33	3.37e-8	Erythrocyte sedimentation rate;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg18216292	chr1:155920810	ARHGEF2	0.49	6.82	0.39	6.08e-11	Fibrinogen levels;
CESC	cis	rs7666738	0.830	rs7687958	chr4:99014495	T/C	cg05340658	chr4:99064831	C4orf37	0.8	12.51	0.61	1.52e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9649213	0.593	rs6465665	chr7:97934150	T/C	cg08684580	chr7:98029266	BAIAP2L1	-0.35	-5.55	-0.32	6.86e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7586879	0.638	rs10203482	chr2:25136916	T/C	cg01884057	chr2:25150051	NA	0.41	7.92	0.44	6.63e-14	Body mass index;
CESC	cis	rs3785574	0.924	rs2727292	chr17:61893747	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.8	10.54	0.54	6.22e-22	Height;
CESC	cis	rs9303401	0.659	rs16943176	chr17:56769887	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.05	12.77	0.62	1.94e-29	Cognitive test performance;
CESC	cis	rs2718058	0.519	rs2722242	chr7:37873610	A/G	cg24998770	chr7:37888106	TXNDC3	-0.32	-5.12	-0.3	5.88e-7	Alzheimer's disease (late onset);
CESC	cis	rs365132	0.818	rs251843	chr5:176476106	A/G	cg16309518	chr5:176445507	NA	-0.38	-5.53	-0.32	7.74e-8	Menarche and menopause (age at onset);Menopause (age at onset);
CESC	cis	rs62103177	0.608	rs551643	chr18:77838970	C/G	cg12964065	chr18:77638022	KCNG2	-0.44	-5.13	-0.3	5.53e-7	Opioid sensitivity;
CESC	cis	rs16957304	1.000	rs3868143	chr16:67328453	C/T	cg26727032	chr16:67993705	SLC12A4	0.52	5.2	0.3	4.04e-7	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
CESC	cis	rs2072732	0.821	rs58052947	chr1:2950094	T/C	cg03976712	chr1:2946727	NA	0.32	5.45	0.32	1.13e-7	Plateletcrit;
CESC	cis	rs8017423	0.967	rs12889636	chr14:90689953	A/C	cg14092571	chr14:90743983	NA	0.52	7.58	0.42	6e-13	Mortality in heart failure;
CESC	cis	rs9611565	0.694	rs202637	chr22:41853928	A/G	cg17376030	chr22:41985996	PMM1	-0.7	-7.2	-0.4	6.1e-12	Vitiligo;
CESC	cis	rs9322193	0.923	rs12526675	chr6:150050676	A/C	cg00933542	chr6:150070202	PCMT1	-0.31	-5.33	-0.31	2.14e-7	Lung cancer;
CESC	cis	rs11122272	0.735	rs2437147	chr1:231516756	T/C	cg06096015	chr1:231504339	EGLN1	0.43	6.18	0.35	2.46e-9	Hemoglobin concentration;
CESC	cis	rs17666538	0.535	rs1669658	chr8:607380	A/G	cg23958373	chr8:599963	NA	0.81	6.21	0.36	2.04e-9	IgG glycosylation;
CESC	cis	rs10918270	0.838	rs9783050	chr1:161936020	A/G	cg19735514	chr1:161762739	ATF6	-0.38	-5.6	-0.33	5.26e-8	Parkinson's disease (age of onset);
CESC	cis	rs1580019	0.587	rs9638880	chr7:32552401	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.52	6.68	0.38	1.44e-10	Cognitive ability;
CESC	cis	rs1003719	0.788	rs2156076	chr21:38452634	G/T	cg10648535	chr21:38446584	PIGP;TTC3	0.64	8.79	0.48	1.93e-16	Eye color traits;
CESC	cis	rs7666738	0.822	rs979946	chr4:98921235	C/A	cg05340658	chr4:99064831	C4orf37	0.79	11.76	0.59	5.78e-26	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1008375	1.000	rs28497813	chr4:17685503	A/G	cg16339924	chr4:17578868	LAP3	0.51	6.55	0.37	2.98e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs2625529	0.878	rs16956302	chr15:72136243	C/T	cg16672083	chr15:72433130	SENP8	-0.43	-5.34	-0.31	1.95e-7	Red blood cell count;
CESC	cis	rs17125944	1.000	rs17125924	chr14:53391680	A/G	cg00686598	chr14:53173677	PSMC6	0.8	5.79	0.33	2.02e-8	Alzheimer's disease (late onset);
CESC	cis	rs10504229	0.953	rs66815941	chr8:58187306	C/T	cg22535103	chr8:58192502	C8orf71	-1.05	-13.08	-0.63	1.71e-30	Developmental language disorder (linguistic errors);
CESC	cis	rs763121	0.888	rs2235229	chr22:39124912	A/G	cg06544989	chr22:39130855	UNC84B	0.43	8.07	0.44	2.5e-14	Menopause (age at onset);
CESC	cis	rs853679	0.542	rs6934769	chr6:28090931	A/G	cg26335602	chr6:28129616	ZNF389	0.53	7.09	0.4	1.19e-11	Depression;
CESC	cis	rs654950	0.901	rs1885654	chr1:42007188	C/A	cg06885757	chr1:42089581	HIVEP3	-0.63	-9.94	-0.52	5.5e-20	Airway imaging phenotypes;
CESC	cis	rs28374715	0.578	rs72739630	chr15:41631064	G/A	cg20272979	chr15:41787780	ITPKA	0.44	5.2	0.3	4.02e-7	Ulcerative colitis;
CESC	cis	rs4561483	0.815	rs11646545	chr16:11934594	T/G	cg08843971	chr16:11963173	GSPT1	0.52	7.46	0.42	1.23e-12	Testicular germ cell tumor;
CESC	cis	rs7726839	0.540	rs11750321	chr5:599196	C/T	cg16447950	chr5:562315	NA	-0.6	-6.05	-0.35	4.91e-9	Obesity-related traits;
CESC	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg16132339	chr22:24313637	DDTL;DDT	0.41	6.22	0.36	1.9e-9	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs7827545	1.000	rs6578229	chr8:135562453	T/G	cg17885191	chr8:135476712	NA	0.45	6.05	0.35	4.94e-9	Hypertension (SNP x SNP interaction);
CESC	trans	rs8026198	0.568	rs1659213	chr15:42624699	C/T	cg13954090	chr10:73533106	CDH23;C10orf54	-0.7	-6.11	-0.35	3.47e-9	Fibrinogen levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19955521	chr10:1102667	WDR37	0.57	6.88	0.39	4.21e-11	Gut microbiome composition (summer);
CESC	cis	rs11203032	0.901	rs7098394	chr10:90960906	T/A	cg16672925	chr10:90967113	CH25H	0.75	7.18	0.4	7.13e-12	Heart failure;
CESC	cis	rs7824557	0.564	rs13260727	chr8:11232860	A/G	cg21775007	chr8:11205619	TDH	0.49	7.02	0.4	1.83e-11	Retinal vascular caliber;
CESC	cis	rs853679	0.542	rs6934769	chr6:28090931	A/G	cg12963246	chr6:28129442	ZNF389	0.56	7.62	0.42	4.43e-13	Depression;
CESC	cis	rs16937	0.574	rs10900455	chr1:205123534	T/C	cg00857998	chr1:205179979	DSTYK	0.4	5.35	0.31	1.92e-7	Schizophrenia;
CESC	cis	rs76878669	0.538	rs73489638	chr11:66127639	C/T	cg18002602	chr11:66138449	SLC29A2	-0.41	-6.77	-0.38	8.14e-11	Educational attainment (years of education);
CESC	cis	rs853679	0.517	rs4713152	chr6:28137454	G/A	cg12963246	chr6:28129442	ZNF389	0.54	7.12	0.4	1.02e-11	Depression;
CESC	cis	rs4561483	0.801	rs33637	chr16:11989875	A/T	cg08843971	chr16:11963173	GSPT1	-0.56	-8.18	-0.45	1.23e-14	Testicular germ cell tumor;
CESC	cis	rs6502050	0.835	rs7405738	chr17:80084227	A/G	cg23985595	chr17:80112537	CCDC57	0.42	6.55	0.37	2.99e-10	Life satisfaction;
CESC	cis	rs514406	0.505	rs437954	chr1:53173321	C/G	cg16325326	chr1:53192061	ZYG11B	0.93	16.13	0.7	3.13e-41	Monocyte count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24849267	chr2:172374169	NA	-0.56	-6.28	-0.36	1.36e-9	Gut microbiome composition (summer);
CESC	cis	rs459571	0.916	rs467303	chr9:136904835	C/T	cg13789015	chr9:136890014	NCRNA00094	0.54	7.69	0.43	2.98e-13	Platelet distribution width;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06895349	chr6:26197261	HIST1H3D	0.56	6.34	0.36	9.82e-10	Gut microbiome composition (summer);
CESC	cis	rs8072100	0.967	rs12452315	chr17:45479446	G/T	cg25173405	chr17:45401733	C17orf57	0.39	5.26	0.31	2.91e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs34172651	0.517	rs2303083	chr16:24835168	G/A	cg04756594	chr16:24857601	SLC5A11	0.48	5.22	0.31	3.7e-7	Intelligence (multi-trait analysis);
CESC	cis	rs4253772	0.530	rs113258957	chr22:46663678	G/C	cg10541313	chr22:46663664	TTC38	0.71	5.69	0.33	3.36e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs6439153	0.933	rs7648877	chr3:128709980	T/C	cg24203234	chr3:128598194	ACAD9	0.43	5.59	0.32	5.56e-8	Pneumococcal bacteremia;
CESC	cis	rs9303280	0.901	rs9901146	chr17:38043343	G/A	cg19468946	chr17:37922297	IKZF3	-0.42	-5.63	-0.33	4.53e-8	Self-reported allergy;
CESC	cis	rs1799949	1.000	rs8176220	chr17:41222462	A/G	cg23758822	chr17:41437982	NA	1.03	15.62	0.69	2.01e-39	Menopause (age at onset);
CESC	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg12912258	chr5:131630175	SLC22A4	0.48	6.38	0.36	7.92e-10	Myopia (pathological);
CESC	cis	rs6433857	0.505	rs12471899	chr2:181369856	C/T	cg23363182	chr2:181467187	NA	-0.42	-5.87	-0.34	1.28e-8	Body mass index;
CESC	cis	rs2243480	1.000	rs4718269	chr7:65200778	C/G	cg12463550	chr7:65579703	CRCP	-0.65	-5.08	-0.3	6.99e-7	Diabetic kidney disease;
CESC	cis	rs1124376	1.000	rs1124376	chr3:20108546	A/G	cg05072819	chr3:20081367	KAT2B	-0.59	-6.16	-0.35	2.62e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs6963495	0.556	rs711433	chr7:105153191	A/G	cg13798780	chr7:105162888	PUS7	-0.49	-6.07	-0.35	4.39e-9	Bipolar disorder (body mass index interaction);
CESC	cis	rs7208859	0.673	rs11653955	chr17:29033292	C/A	cg13385521	chr17:29058706	SUZ12P	0.82	6.37	0.36	8.09e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs1595825	0.945	rs73058818	chr2:198862600	C/T	cg00982548	chr2:198649783	BOLL	-0.49	-5.58	-0.32	5.98e-8	Ulcerative colitis;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg03971247	chr2:46841077	PIGF	0.38	6.29	0.36	1.34e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs644799	0.542	rs10831416	chr11:95467220	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.5	6.53	0.37	3.28e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs1218582	0.774	rs4845680	chr1:154863195	A/G	cg16680214	chr1:154839983	KCNN3	-0.45	-6.94	-0.39	2.95e-11	Prostate cancer;
CESC	cis	rs6860806	0.531	rs272888	chr5:131665423	T/C	cg24060327	chr5:131705240	SLC22A5	-0.78	-11.01	-0.56	1.85e-23	Breast cancer;
CESC	cis	rs853679	0.574	rs1233705	chr6:28166447	C/G	cg23161317	chr6:28129485	ZNF389	0.44	5.72	0.33	2.8e-8	Depression;
CESC	cis	rs5769765	0.862	rs9616381	chr22:50312382	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.58	-6.21	-0.36	2.01e-9	Schizophrenia;
CESC	cis	rs1957429	0.614	rs73279812	chr14:65348012	G/A	cg23373153	chr14:65346875	NA	-0.9	-6.61	-0.38	2.11e-10	Pediatric areal bone mineral density (radius);
CESC	trans	rs12429889	0.831	rs11620053	chr13:74751444	T/C	cg03455107	chr17:54509207	ANKFN1	0.34	6.03	0.35	5.36e-9	Sudden cardiac arrest;
CESC	cis	rs733592	0.560	rs2158515	chr12:48507668	T/C	cg04545296	chr12:48745243	ZNF641	-0.29	-5.29	-0.31	2.55e-7	Plateletcrit;
CESC	trans	rs11098499	0.645	rs72676059	chr4:120290828	C/G	cg25214090	chr10:38739885	LOC399744	0.65	9.11	0.49	2.04e-17	Corneal astigmatism;
CESC	cis	rs916888	0.610	rs142167	chr17:44795234	C/T	cg01570182	chr17:44337453	NA	-0.68	-9.33	-0.5	4.28e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs2197308	0.619	rs4002730	chr12:37876400	T/C	cg26384229	chr12:38710491	ALG10B	0.74	10.98	0.56	2.29e-23	Morning vs. evening chronotype;
CESC	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	13.65	0.64	1.8e-32	Prudent dietary pattern;
CESC	cis	rs9911578	1.000	rs8067571	chr17:56868856	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.24	0.31	3.23e-7	Intelligence (multi-trait analysis);
CESC	cis	rs765787	0.530	rs4270107	chr15:45535350	A/G	cg24006582	chr15:45444508	DUOX1	-0.59	-7.23	-0.41	5.15e-12	Uric acid levels;
CESC	cis	rs2974760	0.606	rs6600143	chr16:201389	A/C	cg08400316	chr16:204221	HBZ	-0.65	-11.11	-0.56	8.51e-24	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	cis	rs1448094	0.511	rs11610371	chr12:86163487	A/G	cg00310523	chr12:86230176	RASSF9	0.35	5.76	0.33	2.3e-8	Major depressive disorder;
CESC	cis	rs10927875	0.632	rs10927863	chr1:16165247	C/A	cg21385522	chr1:16154831	NA	-1.02	-17.11	-0.72	1.05e-44	Dilated cardiomyopathy;
CESC	cis	rs9291683	0.546	rs4529049	chr4:10045389	C/T	cg11266682	chr4:10021025	SLC2A9	0.65	12.39	0.61	3.92e-28	Bone mineral density;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg17609050	chr7:92861606	CCDC132	-0.43	-6.11	-0.35	3.53e-9	Gambling;
CESC	cis	rs10504073	0.584	rs11784268	chr8:49956339	T/G	cg00325661	chr8:49890786	NA	0.59	8.9	0.48	9.3e-17	Blood metabolite ratios;
CESC	cis	rs2243480	1.000	rs451396	chr7:65484074	T/A	cg18252515	chr7:66147081	NA	-1.19	-11.57	-0.58	2.56e-25	Diabetic kidney disease;
CESC	cis	rs7615952	0.611	rs2947646	chr3:125593602	C/T	cg05084668	chr3:125655381	ALG1L	0.73	7.89	0.44	7.91e-14	Blood pressure (smoking interaction);
CESC	cis	rs7395581	0.879	rs3758673	chr11:47278917	C/T	cg25783544	chr11:47291846	MADD	0.6	7.8	0.43	1.47e-13	HDL cholesterol;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20725539	chr19:9695373	ZNF121	0.57	6.5	0.37	4.02e-10	Gut microbiome composition (summer);
CESC	cis	rs40363	0.645	rs1690447	chr16:3519211	T/C	cg21433313	chr16:3507492	NAT15	0.5	7.85	0.43	1.02e-13	Tuberculosis;
CESC	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	13.6	0.64	2.58e-32	Prudent dietary pattern;
CESC	cis	rs6502050	0.842	rs62079996	chr17:80076862	A/G	cg23985595	chr17:80112537	CCDC57	0.41	6.42	0.37	6.41e-10	Life satisfaction;
CESC	cis	rs9522267	0.535	rs7329118	chr13:112232693	C/T	cg10483660	chr13:112241077	NA	-0.33	-5.83	-0.34	1.65e-8	Hepatitis;
CESC	cis	rs6088580	0.634	rs4258875	chr20:32924895	C/A	cg24642439	chr20:33292090	TP53INP2	-0.52	-6.77	-0.38	8.14e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs3733585	0.648	rs7378305	chr4:9954893	C/T	cg02734326	chr4:10020555	SLC2A9	-0.41	-5.79	-0.33	2.02e-8	Cleft plate (environmental tobacco smoke interaction);
CESC	trans	rs459571	0.959	rs461462	chr9:136911272	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.57	-7.48	-0.42	1.1e-12	Platelet distribution width;
CESC	cis	rs35110281	0.782	rs1454651	chr21:45012476	A/G	cg04455712	chr21:45112962	RRP1B	0.39	5.96	0.34	7.84e-9	Mean corpuscular volume;
CESC	cis	rs6723226	0.721	rs3769600	chr2:32616879	G/A	cg02381751	chr2:32503542	YIPF4	-0.54	-6.79	-0.39	7.3e-11	Intelligence (multi-trait analysis);
CESC	cis	rs1270639	0.722	rs6950817	chr7:157439636	A/G	cg13357408	chr7:157437802	PTPRN2	0.61	6.99	0.39	2.24e-11	Colorectal cancer;
CESC	cis	rs798554	0.610	rs2644297	chr7:2858906	A/C	cg13628971	chr7:2884303	GNA12	0.41	5.47	0.32	1.06e-7	Height;
CESC	cis	rs8020095	0.571	rs7156852	chr14:67340549	T/G	cg19548862	chr14:67692701	FAM71D	-0.5	-6.06	-0.35	4.73e-9	Depression (quantitative trait);
CESC	cis	rs17253792	0.545	rs12893676	chr14:56016159	G/A	cg01858014	chr14:56050164	KTN1	-0.87	-6.37	-0.36	8.34e-10	Putamen volume;
CESC	cis	rs2777491	0.872	rs61037359	chr15:41585926	T/C	cg02330683	chr15:41787940	ITPKA	0.42	6.21	0.36	2e-9	Ulcerative colitis;
CESC	cis	rs4862750	0.832	rs10007858	chr4:187877492	A/G	cg10295955	chr4:187884368	NA	-1.05	-19.92	-0.77	1.36e-54	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4595586	0.525	rs34204378	chr12:39425759	C/T	cg13010199	chr12:38710504	ALG10B	0.43	5.19	0.3	4.24e-7	Morning vs. evening chronotype;
CESC	cis	rs7208859	0.673	rs9907197	chr17:29018263	C/T	cg19761014	chr17:28927070	LRRC37B2	0.67	5.99	0.35	6.81e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs61776719	0.747	rs28428561	chr1:38434306	G/A	cg17077180	chr1:38461687	NA	-0.55	-8.49	-0.46	1.48e-15	Coronary artery disease;
CESC	cis	rs4862750	0.914	rs1863405	chr4:187874528	G/T	cg07414643	chr4:187882934	NA	-0.53	-7.57	-0.42	6.21e-13	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs898097	0.841	rs4986122	chr17:80825500	C/T	cg05255149	chr17:80675120	FN3KRP	-0.48	-5.64	-0.33	4.28e-8	Breast cancer;
CESC	cis	rs875971	1.000	rs11971949	chr7:65626014	A/G	cg11764359	chr7:65958608	NA	-0.93	-14.88	-0.67	8.32e-37	Aortic root size;
CESC	cis	rs9291683	0.597	rs11723016	chr4:10126189	A/G	cg00071950	chr4:10020882	SLC2A9	-0.55	-8.51	-0.46	1.33e-15	Bone mineral density;
CESC	cis	rs514406	0.793	rs12081018	chr1:53217542	C/A	cg27535305	chr1:53392650	SCP2	0.32	5.68	0.33	3.6e-8	Monocyte count;
CESC	cis	rs10504229	0.683	rs6999984	chr8:58115079	G/A	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs3960554	0.808	rs13438599	chr7:75768022	G/A	cg17325771	chr7:75508891	RHBDD2	-0.34	-5.06	-0.3	7.71e-7	Eotaxin levels;
CESC	cis	rs9768139	0.708	rs11771764	chr7:158119871	A/G	cg27057461	chr7:158136379	PTPRN2	-0.34	-5.29	-0.31	2.58e-7	Calcium levels;
CESC	cis	rs7618915	0.547	rs3774365	chr3:52642487	T/C	cg17372223	chr3:52568218	NT5DC2	0.43	6.34	0.36	9.62e-10	Bipolar disorder;
CESC	cis	rs14057	0.896	rs2232460	chr1:6659505	G/A	cg06778853	chr1:6672620	PHF13	-0.27	-5.04	-0.3	8.74e-7	Systolic blood pressure;
CESC	cis	rs2243480	1.000	rs1546059	chr7:65654709	C/A	cg12463550	chr7:65579703	CRCP	-0.73	-5.66	-0.33	4.03e-8	Diabetic kidney disease;
CESC	cis	rs780096	0.526	rs4582	chr2:27604279	A/G	cg22903471	chr2:27725779	GCKR	-0.5	-7.11	-0.4	1.08e-11	Total body bone mineral density;
CESC	cis	rs9926296	0.712	rs258319	chr16:89732024	A/T	cg27121462	chr16:89883253	FANCA	-0.46	-5.38	-0.31	1.66e-7	Vitiligo;
CESC	cis	rs7666738	0.830	rs35531558	chr4:98938217	A/G	cg05340658	chr4:99064831	C4orf37	0.82	12.54	0.61	1.29e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs131777	0.575	rs963980	chr22:51022117	C/A	cg00083937	chr22:51039805	MAPK8IP2	0.4	5.73	0.33	2.72e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	cis	rs6460942	0.908	rs77034890	chr7:12244506	A/T	cg20607287	chr7:12443886	VWDE	-0.62	-6.03	-0.35	5.41e-9	Coronary artery disease;
CESC	cis	rs6860806	0.507	rs635620	chr5:131720263	A/G	cg24060327	chr5:131705240	SLC22A5	0.76	10.91	0.56	3.9699999999999997e-23	Breast cancer;
CESC	cis	rs478304	0.934	rs12801731	chr11:65549606	T/C	cg08755490	chr11:65554678	OVOL1	0.52	6.73	0.38	1.03e-10	Acne (severe);
CESC	cis	rs11958404	1.000	rs72816538	chr5:157414303	A/G	cg05962755	chr5:157440814	NA	0.52	6.01	0.35	6.19e-9	IgG glycosylation;
CESC	cis	rs3857536	0.813	rs4710581	chr6:66939954	T/C	cg07460842	chr6:66804631	NA	-0.42	-5.34	-0.31	1.96e-7	Blood trace element (Cu levels);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01499736	chr6:36164655	BRPF3	0.58	6.78	0.38	7.78e-11	Gut microbiome composition (summer);
CESC	cis	rs3741151	1.000	rs7125978	chr11:73039229	G/A	cg17517138	chr11:73019481	ARHGEF17	0.62	5.33	0.31	2.12e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs35110281	0.715	rs2838320	chr21:44995037	A/G	cg21573476	chr21:45109991	RRP1B	-0.47	-6.64	-0.38	1.8e-10	Mean corpuscular volume;
CESC	cis	rs1018836	0.884	rs2073640	chr8:91594853	A/G	cg16814680	chr8:91681699	NA	-0.71	-10.37	-0.54	2.21e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs933688	1.000	rs332544	chr5:90778848	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.03	13.78	0.65	6.06e-33	Smoking behavior;
CESC	cis	rs977987	0.843	rs4888427	chr16:75478447	A/G	cg03315344	chr16:75512273	CHST6	0.43	6.23	0.36	1.77e-9	Dupuytren's disease;
CESC	cis	rs801193	0.967	rs1110414	chr7:66205582	A/G	cg06456125	chr7:65229604	NA	0.4	5.23	0.31	3.51e-7	Aortic root size;
CESC	trans	rs12339966	0.643	rs2586341	chr9:11678273	G/T	cg03904639	chr13:37677730	CSNK1A1L	0.39	6.06	0.35	4.67e-9	Systolic blood pressure;
CESC	cis	rs7615952	0.599	rs12496921	chr3:125701948	C/G	cg04553112	chr3:125709451	NA	-0.5	-5.48	-0.32	9.86e-8	Blood pressure (smoking interaction);
CESC	cis	rs55883249	1.000	rs57234614	chr2:9756379	T/C	cg23886495	chr2:9695866	ADAM17	0.62	5.66	0.33	3.83e-8	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04723601	chr11:60681193	TMEM109	-0.56	-6.39	-0.37	7.58e-10	Gut microbiome composition (summer);
CESC	cis	rs6662572	1.000	rs72688452	chr1:46092365	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.52	5.73	0.33	2.66e-8	Blood protein levels;
CESC	cis	rs7264396	0.635	rs6060682	chr20:34506331	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.81	-11.22	-0.57	3.58e-24	Total cholesterol levels;
CESC	cis	rs4561483	0.549	rs6498251	chr16:11952290	A/G	cg08843971	chr16:11963173	GSPT1	0.52	7.26	0.41	4.2e-12	Testicular germ cell tumor;
CESC	cis	rs6502050	0.835	rs9900072	chr17:80114360	C/G	cg23985595	chr17:80112537	CCDC57	-0.41	-6.57	-0.37	2.63e-10	Life satisfaction;
CESC	cis	rs4862750	0.872	rs6836781	chr4:187899701	G/A	cg03452623	chr4:187889614	NA	-0.88	-16.16	-0.7	2.39e-41	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2197308	0.740	rs11182967	chr12:37935140	A/C	cg13010199	chr12:38710504	ALG10B	0.53	6.81	0.39	6.71e-11	Morning vs. evening chronotype;
CESC	cis	rs3820068	0.705	rs72643694	chr1:15860185	C/T	cg18192808	chr1:15853278	DNAJC16	0.48	5.91	0.34	1.03e-8	Systolic blood pressure;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg12102766	chr2:105954037	C2orf49	-0.53	-6.64	-0.38	1.77e-10	Ulcerative colitis;
CESC	cis	rs9512730	0.553	rs1007701	chr13:28049143	C/G	cg08193333	chr13:27998609	GTF3A	-0.45	-5.32	-0.31	2.18e-7	Schizophrenia;
CESC	cis	rs11168351	0.927	rs7971880	chr12:48391055	C/T	cg24011408	chr12:48396354	COL2A1	0.53	8.08	0.44	2.23e-14	Bipolar disorder and schizophrenia;
CESC	cis	rs7666738	0.753	rs13111199	chr4:98953705	A/G	cg03467027	chr4:99064603	C4orf37	0.45	5.61	0.33	4.97e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg21280719	chr6:42927975	GNMT	-0.29	-6.75	-0.38	9.55e-11	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs3096299	0.658	rs4785679	chr16:89566113	G/T	cg02034447	chr16:89574710	SPG7	0.55	6.99	0.39	2.17e-11	Multiple myeloma (IgH translocation);
CESC	cis	rs561341	0.556	rs542244	chr17:30307242	T/C	cg12193833	chr17:30244370	NA	-0.7	-6.48	-0.37	4.5e-10	Hip circumference adjusted for BMI;
CESC	cis	rs868036	0.609	rs13329413	chr15:68097126	C/T	cg08079166	chr15:68083412	MAP2K5	0.42	5.8	0.34	1.86e-8	Restless legs syndrome;
CESC	cis	rs11098499	0.863	rs9884402	chr4:120489982	A/G	cg24375607	chr4:120327624	NA	0.46	5.59	0.32	5.73e-8	Corneal astigmatism;
CESC	cis	rs854765	0.964	rs72827413	chr17:17988299	C/T	cg16928487	chr17:17741425	SREBF1	0.57	9.73	0.51	2.47e-19	Total body bone mineral density;
CESC	cis	rs2933343	0.951	rs789218	chr3:128592670	G/A	cg25356066	chr3:128598488	ACAD9	0.57	6.87	0.39	4.45e-11	IgG glycosylation;
CESC	trans	rs2623325	0.874	rs6440580	chr3:99111135	A/G	cg19595760	chr1:25948511	MAN1C1	0.46	6.09	0.35	3.98e-9	Optic cup area;Vertical cup-disc ratio;
CESC	cis	rs875971	0.505	rs2462573	chr7:65507392	C/T	cg06456125	chr7:65229604	NA	-0.48	-6.33	-0.36	1.04e-9	Aortic root size;
CESC	cis	rs3820928	0.804	rs4144327	chr2:227790262	C/T	cg11843606	chr2:227700838	RHBDD1	-0.44	-5.87	-0.34	1.29e-8	Pulmonary function;
CESC	cis	rs11122272	0.735	rs2437147	chr1:231516756	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.57	-7.82	-0.43	1.29e-13	Hemoglobin concentration;
CESC	cis	rs11098499	0.954	rs11940028	chr4:120411907	T/C	cg24375607	chr4:120327624	NA	0.46	5.63	0.33	4.52e-8	Corneal astigmatism;
CESC	cis	rs1348850	0.632	rs13009207	chr2:178501632	A/G	cg23306229	chr2:178417860	TTC30B	0.58	7.61	0.42	4.82e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs4689592	0.503	rs4689064	chr4:7055603	A/G	cg26116260	chr4:7069785	GRPEL1	-0.83	-9.37	-0.5	3.38e-18	Monocyte percentage of white cells;
CESC	cis	rs947211	0.898	rs10900524	chr1:205748309	G/A	cg17178900	chr1:205818956	PM20D1	0.41	5.27	0.31	2.9e-7	Parkinson's disease;
CESC	cis	rs1707322	1.000	rs6429580	chr1:46275648	A/G	cg03146154	chr1:46216737	IPP	0.73	10.13	0.53	1.3e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs2797160	0.935	rs1739372	chr6:126011325	G/A	cg05039488	chr6:79577232	IRAK1BP1	0.45	5.99	0.35	6.67e-9	Endometrial cancer;
CESC	cis	rs6060717	0.536	rs2425104	chr20:34312346	C/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.61	5.29	0.31	2.61e-7	Hip circumference adjusted for BMI;
CESC	cis	rs3820928	0.934	rs16822890	chr2:227761477	G/A	cg05526886	chr2:227700861	RHBDD1	-0.42	-5.5	-0.32	8.95e-8	Pulmonary function;
CESC	cis	rs9911578	0.967	rs2429369	chr17:56501420	A/G	cg12560992	chr17:57184187	TRIM37	0.92	15.73	0.69	7.77e-40	Intelligence (multi-trait analysis);
CESC	cis	rs11792861	0.781	rs874864	chr9:111728718	C/T	cg05043794	chr9:111880884	C9orf5	-0.38	-6.6	-0.38	2.22e-10	Menarche (age at onset);
CESC	cis	rs425277	1.000	rs262676	chr1:2078482	T/A	cg04315214	chr1:2043799	PRKCZ	-0.38	-5.3	-0.31	2.42e-7	Height;
CESC	cis	rs6089829	0.962	rs3746749	chr20:61667333	T/C	cg08564027	chr20:61660810	NA	0.9	15.44	0.69	8.75e-39	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs6496667	0.557	rs2601201	chr15:90958000	C/T	cg10434728	chr15:90938212	IQGAP1	0.33	5.76	0.33	2.33e-8	Rheumatoid arthritis;
CESC	cis	rs8031584	0.918	rs1425292	chr15:31285422	G/A	cg14829155	chr15:31115871	NA	-0.73	-9.78	-0.51	1.78e-19	Huntington's disease progression;
CESC	cis	rs96067	0.711	rs795047	chr1:36637708	C/T	cg24686825	chr1:36642396	MAP7D1	0.43	5.95	0.34	8.34e-9	Corneal structure;
CESC	cis	rs7927771	0.864	rs55927797	chr11:47446292	A/T	cg20307385	chr11:47447363	PSMC3	-0.62	-7.42	-0.41	1.58e-12	Subjective well-being;
CESC	cis	rs9486715	0.867	rs9373907	chr6:96981189	G/A	cg18709589	chr6:96969512	KIAA0776	0.46	6.47	0.37	4.7e-10	Headache;
CESC	cis	rs2180341	0.920	rs4472373	chr6:127705983	G/A	cg24812749	chr6:127587940	RNF146	1.05	14.91	0.68	6.23e-37	Breast cancer;
CESC	cis	rs2731664	0.792	rs2630764	chr5:176880085	C/T	cg23176889	chr5:176863531	GRK6	-0.66	-11.73	-0.58	6.91e-26	Intelligence (multi-trait analysis);
CESC	cis	rs4566357	0.615	rs12618793	chr2:227909552	T/C	cg11843606	chr2:227700838	RHBDD1	-0.48	-6.54	-0.37	3.2e-10	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08494708	chr6:108881870	FOXO3	0.62	7.41	0.41	1.71e-12	Gut microbiome composition (summer);
CESC	cis	rs3820928	1.000	rs11692572	chr2:227774503	C/G	cg05526886	chr2:227700861	RHBDD1	-0.43	-5.51	-0.32	8.62e-8	Pulmonary function;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg15731816	chr14:75230414	YLPM1	0.51	6.85	0.39	5.11e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs4073582	0.595	rs1115508	chr11:65923149	A/G	cg14036092	chr11:66035641	RAB1B	0.55	7.83	0.43	1.17e-13	Gout;
CESC	cis	rs10838687	0.736	rs7120158	chr11:47265194	G/C	cg25783544	chr11:47291846	MADD	0.57	6.63	0.38	1.91e-10	Proinsulin levels;
CESC	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg02353165	chr6:42928485	GNMT	0.88	15.24	0.68	4.23e-38	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs9787249	0.957	rs10888958	chr1:40211737	T/C	cg24920358	chr1:40204285	PPIE	0.42	6.37	0.36	8.16e-10	Blood protein levels;
CESC	cis	rs7631605	0.905	rs1399178	chr3:37258669	G/A	cg22985146	chr3:37219077	LRRFIP2	-0.35	-5.51	-0.32	8.64e-8	Cerebrospinal P-tau181p levels;
CESC	cis	rs637571	0.522	rs7105628	chr11:65763067	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.43	6.36	0.36	8.58e-10	Eosinophil percentage of white cells;
CESC	cis	rs6088590	0.687	rs6088580	chr20:33285053	G/C	cg06115741	chr20:33292138	TP53INP2	0.52	6.49	0.37	4.1e-10	Coronary artery disease;
CESC	cis	rs7666738	0.830	rs7678250	chr4:98922109	G/A	cg03467027	chr4:99064603	C4orf37	0.46	5.59	0.32	5.78e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1862618	0.573	rs1550821	chr5:56242323	C/T	cg12311346	chr5:56204834	C5orf35	0.87	10.7	0.55	1.85e-22	Initial pursuit acceleration;
CESC	cis	rs2688608	0.592	rs11000760	chr10:75493734	G/A	cg23231163	chr10:75533350	FUT11	-0.34	-5.27	-0.31	2.82e-7	Inflammatory bowel disease;
CESC	trans	rs1814175	0.817	rs28502006	chr11:50049930	T/C	cg15704280	chr7:45808275	SEPT13	-1.05	-21.04	-0.79	1.87e-58	Height;
CESC	cis	rs11098499	0.954	rs3733520	chr4:120423480	C/G	cg09307838	chr4:120376055	NA	0.96	13.89	0.65	2.55e-33	Corneal astigmatism;
CESC	cis	rs7044106	0.762	rs10760115	chr9:123476952	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.69	10.12	0.53	1.48e-20	Hip circumference adjusted for BMI;
CESC	cis	rs12545109	0.879	rs1581129	chr8:57377476	T/C	cg09654669	chr8:57350985	NA	-0.57	-6.67	-0.38	1.46e-10	Obesity-related traits;
CESC	cis	rs6493487	0.512	rs7170364	chr15:51123027	G/A	cg02338191	chr15:51200825	AP4E1	0.51	5.19	0.3	4.29e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs7937682	0.632	rs10789850	chr11:111750829	C/T	cg22437258	chr11:111473054	SIK2	-0.49	-5.46	-0.32	1.1e-7	Primary sclerosing cholangitis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03569283	chr8:142222314	SLC45A4	-0.55	-6.39	-0.37	7.52e-10	Gut microbiome composition (summer);
CESC	cis	rs1865760	0.566	rs1971509	chr6:26085777	T/C	cg16482183	chr6:26056742	HIST1H1C	0.38	5.11	0.3	6.19e-7	Height;
CESC	cis	rs9316337	0.557	rs9509659	chr13:21924162	A/G	cg18095732	chr13:22033692	ZDHHC20	-0.47	-5.78	-0.33	2.1e-8	Schizophrenia;
CESC	cis	rs9910055	0.659	rs2251165	chr17:42234748	T/C	cg13607699	chr17:42295918	UBTF	0.56	7.28	0.41	3.88e-12	Total body bone mineral density;
CESC	cis	rs116095464	0.558	rs59284383	chr5:284525	C/G	cg12570787	chr5:219185	SDHA;CCDC127	0.52	5.41	0.32	1.38e-7	Breast cancer;
CESC	cis	rs10197940	0.624	rs4461258	chr2:152429679	A/G	cg19508488	chr2:152266495	RIF1	-0.46	-5.06	-0.3	8e-7	Lung cancer;
CESC	cis	rs7666738	0.518	rs13133925	chr4:98706398	G/T	cg17366294	chr4:99064904	C4orf37	0.49	6.11	0.35	3.59e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs8002861	0.905	rs12853286	chr13:44446817	A/G	cg14210620	chr13:44453864	C13orf31;CCDC122	-0.45	-5.64	-0.33	4.33e-8	Leprosy;
CESC	cis	rs9811920	0.609	rs2452320	chr3:99645216	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.59	7.22	0.41	5.61e-12	Axial length;
CESC	cis	rs9322193	0.962	rs2342861	chr6:150098697	C/T	cg13206674	chr6:150067644	NUP43	0.41	5.68	0.33	3.47e-8	Lung cancer;
CESC	trans	rs61931739	0.517	rs2101396	chr12:34048927	T/A	cg26384229	chr12:38710491	ALG10B	0.51	6.94	0.39	2.97e-11	Morning vs. evening chronotype;
CESC	cis	rs4665809	0.818	rs35413760	chr2:26267137	C/A	cg26119090	chr2:26468346	HADHA;HADHB	0.81	8.71	0.47	3.25e-16	Gut microbiome composition (summer);
CESC	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg24503407	chr1:205819492	PM20D1	0.79	12.46	0.61	2.34e-28	Menarche (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09804439	chr17:40540457	STAT3	0.54	6.12	0.35	3.35e-9	Gut microbiome composition (summer);
CESC	cis	rs1552244	0.748	rs9862221	chr3:10059658	G/T	cg13047869	chr3:10149882	C3orf24	0.43	5.27	0.31	2.85e-7	Alzheimer's disease;
CESC	cis	rs12762955	0.561	rs7918118	chr10:1042823	C/A	cg06753689	chr10:1034030	GTPBP4	0.5	5.05	0.3	8.33e-7	Response to angiotensin II receptor blocker therapy;
CESC	cis	rs7980687	0.574	rs10744149	chr12:123708490	T/A	cg05973401	chr12:123451056	ABCB9	0.47	5.29	0.31	2.63e-7	Height;Educational attainment;Head circumference (infant);
CESC	cis	rs6120849	0.754	rs17319032	chr20:33643296	T/C	cg24642439	chr20:33292090	TP53INP2	0.68	6.77	0.38	8.46e-11	Protein C levels;
CESC	cis	rs7584330	0.704	rs72620821	chr2:238362615	C/A	cg14458575	chr2:238380390	NA	0.89	11.75	0.59	5.91e-26	Prostate cancer;
CESC	cis	rs7589728	0.620	rs76687350	chr2:88473832	G/A	cg18490616	chr2:88469792	THNSL2	0.54	5.07	0.3	7.54e-7	Plasma clusterin levels;
CESC	cis	rs870825	0.587	rs35377170	chr4:185639728	T/C	cg04058563	chr4:185651563	MLF1IP	0.64	7.09	0.4	1.21e-11	Blood protein levels;
CESC	cis	rs3733585	0.673	rs4467564	chr4:9953472	G/T	cg02734326	chr4:10020555	SLC2A9	-0.39	-5.64	-0.33	4.45e-8	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs2576037	0.526	rs1539878	chr18:44523004	T/C	cg19077165	chr18:44547161	KATNAL2	-0.53	-7.75	-0.43	1.94e-13	Personality dimensions;
CESC	cis	rs7772486	0.875	rs9322044	chr6:146369608	T/C	cg05347473	chr6:146136440	FBXO30	0.5	6.5	0.37	3.88e-10	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00841781	chr22:51021511	LOC100144603;CHKB-CPT1B;CHKB	0.56	6.16	0.35	2.62e-9	Gut microbiome composition (summer);
CESC	cis	rs7772486	0.875	rs2777479	chr6:146309178	C/A	cg05347473	chr6:146136440	FBXO30	0.54	7.04	0.4	1.66e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs10465746	0.967	rs12757632	chr1:84416408	T/C	cg10977910	chr1:84465055	TTLL7	0.49	6.58	0.37	2.51e-10	Obesity-related traits;
CESC	cis	rs13343954	0.518	rs8106293	chr19:33536376	C/T	cg17764715	chr19:33622953	WDR88	0.55	7.54	0.42	7.64e-13	Colorectal cancer;
CESC	cis	rs733592	0.965	rs1978161	chr12:48467721	A/G	cg24011408	chr12:48396354	COL2A1	-0.51	-7.81	-0.43	1.36e-13	Plateletcrit;
CESC	cis	rs11677370	0.561	rs13015012	chr2:3821252	C/G	cg17052675	chr2:3827356	NA	0.41	5.31	0.31	2.37e-7	Type 2 diabetes;
CESC	cis	rs9487051	0.676	rs7773213	chr6:109601885	C/T	cg21918786	chr6:109611834	NA	-0.39	-5.74	-0.33	2.56e-8	Reticulocyte fraction of red cells;
CESC	cis	rs10504229	0.953	rs66815941	chr8:58187306	C/T	cg14926445	chr8:58193284	C8orf71	-0.51	-5.52	-0.32	8.28e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs2115630	0.645	rs4842978	chr15:85197253	T/C	cg12501888	chr15:85177176	SCAND2	-0.46	-6.06	-0.35	4.58e-9	P wave terminal force;
CESC	cis	rs9309711	0.922	rs11679058	chr2:3483813	C/G	cg10845886	chr2:3471009	TTC15	-0.89	-12.76	-0.62	2.13e-29	Neurofibrillary tangles;
CESC	cis	rs7568498	0.517	rs11678856	chr2:161925443	C/T	cg22496339	chr2:162101262	NA	-0.52	-5.62	-0.33	4.95e-8	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);
CESC	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	-0.54	-6.76	-0.38	8.91e-11	Prudent dietary pattern;
CESC	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg07308232	chr7:1071921	C7orf50	-0.48	-6.89	-0.39	4.16e-11	Longevity;Endometriosis;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg14895945	chr19:12889086	NA	-0.49	-6.62	-0.38	1.96e-10	Asthma;
CESC	cis	rs7843479	0.509	rs3758156	chr8:21770796	A/G	cg17168535	chr8:21777572	XPO7	0.63	9.46	0.5	1.74e-18	Mean corpuscular volume;
CESC	cis	rs7762018	1.000	rs4509126	chr6:170068058	A/G	cg05834625	chr6:170176447	C6orf70	0.62	7.35	0.41	2.48e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs2228479	0.850	rs74251570	chr16:89910068	C/A	cg00800038	chr16:89945340	TCF25	-0.89	-6.89	-0.39	4.13e-11	Skin colour saturation;
CESC	cis	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg13880726	chr7:1868755	MAD1L1	-0.5	-6.73	-0.38	1.02e-10	Bipolar disorder and schizophrenia;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg14797243	chr11:68671428	IGHMBP2;MRPL21	0.5	6.68	0.38	1.41e-10	Systemic lupus erythematosus;
CESC	cis	rs12497850	0.805	rs6446198	chr3:49007638	T/A	cg02487422	chr3:49467188	NICN1	0.46	5.84	0.34	1.53e-8	Parkinson's disease;
CESC	cis	rs9486715	1.000	rs2273621	chr6:97058553	A/G	cg06623918	chr6:96969491	KIAA0776	-0.89	-12.98	-0.62	3.77e-30	Headache;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg02458088	chr16:77228411	MON1B	0.47	6.29	0.36	1.29e-9	Fibrinogen levels;
CESC	cis	rs798554	1.000	rs798554	chr7:2759795	C/T	cg19717773	chr7:2847554	GNA12	-0.53	-7.62	-0.42	4.54e-13	Height;
CESC	cis	rs1904096	0.506	rs6841121	chr4:95222995	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.62	-10.1	-0.53	1.67e-20	Type 2 diabetes;
CESC	cis	rs896854	0.967	rs10808671	chr8:95967372	A/G	cg23172400	chr8:95962367	TP53INP1	-0.47	-9.92	-0.52	6.36e-20	Type 2 diabetes;
CESC	cis	rs3008870	0.755	rs4655661	chr1:67408828	A/C	cg08660285	chr1:67390436	MIER1;WDR78	0.63	8.34	0.46	4.16e-15	Lymphocyte percentage of white cells;
CESC	cis	rs2576037	0.526	rs4890703	chr18:44522037	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.57	7.98	0.44	4.5e-14	Personality dimensions;
CESC	cis	rs1552244	1.000	rs56394721	chr3:10150795	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	12.3	0.6	8.13e-28	Alzheimer's disease;
CESC	cis	rs6840360	0.533	rs13121190	chr4:152729072	T/G	cg22705602	chr4:152727874	NA	0.37	5.07	0.3	7.32e-7	Intelligence (multi-trait analysis);
CESC	cis	rs6060717	0.610	rs2590964	chr20:34613376	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-7.92	-0.44	6.36e-14	Hip circumference adjusted for BMI;
CESC	cis	rs950169	0.723	rs17589320	chr15:84919996	C/A	cg17507749	chr15:85114479	UBE2QP1	0.57	6.33	0.36	1.07e-9	Schizophrenia;
CESC	cis	rs11031096	0.502	rs720571	chr11:4001328	G/T	cg18678763	chr11:4115507	RRM1	-0.48	-6.47	-0.37	4.8e-10	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	cis	rs10504229	0.683	rs72650839	chr8:58130029	C/T	cg21724239	chr8:58056113	NA	0.58	5.95	0.34	8.51e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs2625529	0.775	rs16956273	chr15:72117102	C/T	cg16672083	chr15:72433130	SENP8	-0.49	-7.32	-0.41	2.92e-12	Red blood cell count;
CESC	cis	rs4604732	0.536	rs12074913	chr1:247631607	G/T	cg12758973	chr1:247694275	LOC148824;OR2C3	0.48	5.96	0.34	7.9e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs853679	0.517	rs4711164	chr6:28115156	C/T	cg19592336	chr6:28129416	ZNF389	0.62	8.12	0.45	1.77e-14	Depression;
CESC	trans	rs11098499	0.730	rs78971550	chr4:120281041	C/T	cg25214090	chr10:38739885	LOC399744	0.67	9.02	0.48	3.81e-17	Corneal astigmatism;
CESC	cis	rs514406	0.505	rs427319	chr1:53178807	T/G	cg08859206	chr1:53392774	SCP2	-0.56	-7.4	-0.41	1.83e-12	Monocyte count;
CESC	cis	rs941873	0.838	rs2233713	chr10:81107135	A/C	cg09469691	chr10:81107165	PPIF	0.59	7.98	0.44	4.31e-14	Height;
CESC	cis	rs7267979	0.844	rs6083851	chr20:25401235	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.79	-14.64	-0.67	5.69e-36	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs3741151	0.773	rs58564192	chr11:73228904	G/A	cg17517138	chr11:73019481	ARHGEF17	1.05	7.72	0.43	2.46e-13	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs7089973	0.836	rs1046492	chr10:116624067	C/T	cg23260525	chr10:116636907	FAM160B1	0.38	6.47	0.37	4.62e-10	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs78889164	0.614	rs8111593	chr19:33851076	G/A	cg02272751	chr19:33882848	PEPD	-0.37	-5.48	-0.32	9.97e-8	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs317689	0.684	rs315125	chr12:69758884	C/T	cg14784868	chr12:69753453	YEATS4	0.64	7.44	0.42	1.36e-12	Response to diuretic therapy;
CESC	cis	rs4665809	0.590	rs7604564	chr2:26501953	C/A	cg08470875	chr2:26401718	FAM59B	0.7	7.23	0.41	5.17e-12	Gut microbiome composition (summer);
CESC	trans	rs826838	0.709	rs4882355	chr12:38721462	A/T	cg23762105	chr12:34175262	ALG10	-0.48	-6.38	-0.36	7.96e-10	Heart rate;
CESC	cis	rs7552404	0.807	rs2066183	chr1:76153745	A/G	cg10523679	chr1:76189770	ACADM	0.76	9.99	0.52	3.63e-20	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs7116495	1.000	rs4945434	chr11:71759087	A/G	cg26138937	chr11:71823887	C11orf51	0.91	7.39	0.41	1.86e-12	Severe influenza A (H1N1) infection;
CESC	cis	rs897984	0.609	rs12445650	chr16:31044897	G/A	cg02466173	chr16:30829666	NA	-0.39	-6.7	-0.38	1.28e-10	Dementia with Lewy bodies;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg05707704	chr2:73144283	EMX1	-0.48	-6.62	-0.38	1.93e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs727563	0.638	rs5996058	chr22:42141452	A/G	cg17376030	chr22:41985996	PMM1	-0.79	-8.34	-0.46	4.18e-15	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs11785400	0.793	rs11543967	chr8:143739435	A/G	cg10596483	chr8:143751796	JRK	-0.43	-5.27	-0.31	2.88e-7	Schizophrenia;
CESC	cis	rs861020	0.582	rs630065	chr1:209998662	C/T	cg05527609	chr1:210001259	C1orf107	0.74	9.63	0.51	5.29e-19	Orofacial clefts;
CESC	cis	rs3820928	0.874	rs10194663	chr2:227875369	T/A	cg11843606	chr2:227700838	RHBDD1	-0.46	-5.8	-0.34	1.84e-8	Pulmonary function;
CESC	cis	rs597539	0.518	rs35093305	chr11:68730729	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.78	9.5	0.5	1.34e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	ch.13.1524792R	chr13:99552827	DOCK9	0.46	6.8	0.39	7.07e-11	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs7219021	0.674	rs9904761	chr17:46956830	C/G	cg16584676	chr17:46985605	UBE2Z	-0.57	-6.85	-0.39	5.06e-11	Schizophrenia or bipolar disorder;
CESC	cis	rs1348850	0.872	rs13004955	chr2:178398923	A/T	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.82	-11.06	-0.56	1.29e-23	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07020338	chr15:41099895	ZFYVE19;DNAJC17	0.57	6.02	0.35	5.91e-9	Gut microbiome composition (summer);
CESC	cis	rs116095464	0.542	rs28650039	chr5:273954	C/A	cg20965017	chr5:231967	SDHA	-0.49	-5.48	-0.32	9.73e-8	Breast cancer;
CESC	cis	rs1045714	0.779	rs3735113	chr7:2651563	G/A	cg20813462	chr7:2646259	IQCE	0.66	5.62	0.33	4.95e-8	Urate levels in lean individuals;
CESC	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg07308232	chr7:1071921	C7orf50	-0.43	-6.03	-0.35	5.52e-9	Longevity;Endometriosis;
CESC	cis	rs1475911	1.000	rs17114359	chr21:43510437	A/C	cg19766460	chr21:43528205	UMODL1;C21orf128	0.53	5.93	0.34	9.52e-9	IgG glycosylation;
CESC	cis	rs17384381	0.700	rs11161616	chr1:85907625	A/G	cg16011679	chr1:85725395	C1orf52	-0.61	-6.43	-0.37	6.03e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7412746	0.658	rs59988025	chr1:150940358	C/T	cg17724175	chr1:150552817	MCL1	0.38	5.85	0.34	1.42e-8	Melanoma;
CESC	cis	rs5769765	0.865	rs3788730	chr22:50244695	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	0.47	5.47	0.32	1.07e-7	Schizophrenia;
CESC	cis	rs9837602	0.872	rs4928234	chr3:99704861	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.53	-7.24	-0.41	4.82e-12	Breast cancer;
CESC	cis	rs28386778	0.830	rs7209321	chr17:61855668	A/C	cg06873352	chr17:61820015	STRADA	0.73	12.93	0.62	5.59e-30	Prudent dietary pattern;
CESC	cis	rs853679	0.517	rs17774663	chr6:28120898	G/A	cg23161317	chr6:28129485	ZNF389	0.53	6.51	0.37	3.8e-10	Depression;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg03330302	chr2:26468406	HADHA;HADHB	0.45	6.51	0.37	3.75e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs2842992	0.672	rs7738253	chr6:160193917	G/T	cg26839252	chr6:160211577	TCP1;MRPL18	0.49	5.42	0.32	1.32e-7	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs4148883	0.603	rs6833176	chr4:100131163	G/C	cg13256891	chr4:100009986	ADH5	-0.46	-6.08	-0.35	4.13e-9	Alcohol dependence;
CESC	cis	rs6977660	0.507	rs72591449	chr7:19775443	T/C	cg07541023	chr7:19748670	TWISTNB	0.8	7.21	0.4	6.02e-12	Thyroid stimulating hormone;
CESC	cis	rs514406	0.679	rs11585495	chr1:53244331	T/C	cg27535305	chr1:53392650	SCP2	0.35	6.23	0.36	1.78e-9	Monocyte count;
CESC	trans	rs11165623	0.792	rs13375510	chr1:96920723	A/G	cg10631902	chr5:14652156	NA	-0.55	-8.26	-0.45	7.06e-15	Hip circumference;Waist circumference;
CESC	cis	rs709400	1.000	rs6593	chr14:104163282	G/A	cg12935359	chr14:103987150	CKB	-0.46	-6.21	-0.36	2.08e-9	Body mass index;
CESC	cis	rs2742234	0.554	rs1254963	chr10:43696086	C/T	cg07801480	chr10:43725741	RASGEF1A	-0.41	-5.33	-0.31	2.14e-7	Hirschsprung disease;
CESC	cis	rs9926296	0.605	rs8046243	chr16:89852133	A/G	cg21285383	chr16:89894308	SPIRE2	0.31	5.47	0.32	1.03e-7	Vitiligo;
CESC	cis	rs62103177	0.810	rs62103188	chr18:77627661	G/A	cg12964065	chr18:77638022	KCNG2	0.58	5.46	0.32	1.07e-7	Opioid sensitivity;
CESC	cis	rs853679	0.517	rs9380065	chr6:28144751	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.56	-6.42	-0.37	6.22e-10	Depression;
CESC	cis	rs963731	0.649	rs1377861	chr2:39293858	T/C	cg04010122	chr2:39346883	SOS1	-0.78	-5.91	-0.34	1.06e-8	Corticobasal degeneration;
CESC	cis	rs10751667	0.643	rs7396407	chr11:929374	A/T	cg06064525	chr11:970664	AP2A2	-0.52	-10.25	-0.53	5.74e-21	Alzheimer's disease (late onset);
CESC	cis	rs8067354	0.872	rs1292060	chr17:57913849	A/G	cg13753209	chr17:57696993	CLTC	0.48	6.62	0.38	1.99e-10	Hemoglobin concentration;
CESC	cis	rs977987	0.585	rs62059845	chr16:75430713	A/G	cg03315344	chr16:75512273	CHST6	0.4	5.71	0.33	3e-8	Dupuytren's disease;
CESC	cis	rs8141529	0.748	rs1318025	chr22:29283757	C/T	cg02153584	chr22:29168773	CCDC117	0.59	7.62	0.42	4.62e-13	Lymphocyte counts;
CESC	cis	rs7072216	0.763	rs45523432	chr10:100167436	T/C	cg26618903	chr10:100175079	PYROXD2	-0.36	-5.49	-0.32	9.42e-8	Metabolite levels;
CESC	cis	rs6570726	0.935	rs385134	chr6:145851005	C/T	cg23711669	chr6:146136114	FBXO30	0.8	11.89	0.59	2e-26	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs854765	0.583	rs8065563	chr17:17782404	A/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.51	6.51	0.37	3.71e-10	Total body bone mineral density;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg01628954	chr18:60190696	ZCCHC2	-0.46	-6.79	-0.38	7.16e-11	Gambling;
CESC	cis	rs10504229	0.906	rs61638902	chr8:58193511	A/C	cg05313129	chr8:58192883	C8orf71	-0.54	-6.58	-0.37	2.56e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs9911578	0.900	rs4793593	chr17:56892699	C/G	cg05425664	chr17:57184151	TRIM37	0.48	6.73	0.38	1.06e-10	Intelligence (multi-trait analysis);
CESC	cis	rs6429082	1.000	rs6429082	chr1:235600129	C/T	cg26050004	chr1:235667680	B3GALNT2	0.45	6.0	0.35	6.47e-9	Adiposity;
CESC	cis	rs13095912	1.000	rs2034343	chr3:185337854	A/T	cg11274856	chr3:185301563	NA	0.33	5.25	0.31	3.19e-7	Systolic blood pressure;
CESC	cis	rs875971	0.755	rs10228885	chr7:65780529	C/G	cg18876405	chr7:65276391	NA	-0.53	-7.3	-0.41	3.35e-12	Aortic root size;
CESC	cis	rs6500395	1.000	rs9933187	chr16:48556573	A/C	cg04672837	chr16:48644449	N4BP1	-0.47	-5.57	-0.32	6.29e-8	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs514406	0.755	rs10888754	chr1:53228751	C/G	cg16325326	chr1:53192061	ZYG11B	-0.71	-11.92	-0.59	1.62e-26	Monocyte count;
CESC	cis	rs6089584	0.507	rs6061990	chr20:60628429	T/G	cg24733560	chr20:60626293	TAF4	0.44	6.55	0.37	2.93e-10	Body mass index;
CESC	cis	rs6701037	0.566	rs4344281	chr1:175135376	C/T	cg00321850	chr1:175162397	KIAA0040	0.44	6.32	0.36	1.11e-9	Alcohol dependence;
CESC	cis	rs3815700	1.000	rs8108840	chr19:33094452	A/C	cg02997394	chr19:33096574	ANKRD27	0.68	6.36	0.36	8.94e-10	Eosinophilic esophagitis;
CESC	cis	rs10851478	0.872	rs6493372	chr15:49758729	T/C	cg08060515	chr15:49448048	GALK2;COPS2	0.42	5.16	0.3	4.79e-7	Oral cavity cancer;
CESC	cis	rs2073300	1.000	rs6137960	chr20:23442886	G/A	cg12062639	chr20:23401060	NAPB	0.91	6.41	0.37	6.71e-10	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs4481887	1.000	rs10888360	chr1:248479282	G/A	cg00666640	chr1:248458726	OR2T12	0.39	6.34	0.36	9.68e-10	Common traits (Other);
CESC	cis	rs2425143	1.000	rs10485510	chr20:34445164	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.79	-7.16	-0.4	7.86e-12	Blood protein levels;
CESC	cis	rs6594499	1.000	rs1438673	chr5:110467499	C/T	cg04022379	chr5:110408740	TSLP	0.3	5.14	0.3	5.35e-7	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs12134245	0.776	rs625525	chr1:91997593	C/T	cg02896835	chr1:92012615	NA	-0.56	-7.79	-0.43	1.51e-13	Breast cancer;
CESC	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg26338869	chr17:61819248	STRADA	0.71	9.41	0.5	2.51e-18	Prudent dietary pattern;
CESC	cis	rs7264396	0.673	rs2425163	chr20:34432670	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.61	7.24	0.41	4.81e-12	Total cholesterol levels;
CESC	cis	rs7000551	0.715	rs1600877	chr8:22378118	C/T	cg12081754	chr8:22256438	SLC39A14	0.41	5.46	0.32	1.08e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CESC	cis	rs7605827	0.930	rs2287276	chr2:15660254	A/G	cg19274914	chr2:15703543	NA	0.37	6.67	0.38	1.47e-10	Educational attainment (years of education);
CESC	cis	rs769267	0.930	rs1054930	chr19:19648346	G/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.56	7.0	0.4	2.1e-11	Tonsillectomy;
CESC	cis	rs2228479	0.717	rs17226274	chr16:89850170	C/T	cg14709524	chr16:89940631	TCF25	0.82	6.43	0.37	6.08e-10	Skin colour saturation;
CESC	cis	rs12477438	0.501	rs11692336	chr2:99740606	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.78	12.89	0.62	7.58e-30	Chronic sinus infection;
CESC	trans	rs1557351	0.723	rs6566850	chr18:54723394	T/C	cg11433624	chr6:7146702	RREB1	0.37	6.06	0.35	4.6e-9	Multiple sclerosis (age of onset);
CESC	cis	rs12137294	0.794	rs1172160	chr1:205207015	G/A	cg21643547	chr1:205240462	TMCC2	-0.35	-5.65	-0.33	4.24e-8	Red cell distribution width;
CESC	cis	rs9487051	0.652	rs9372210	chr6:109601703	G/C	cg21918786	chr6:109611834	NA	-0.37	-5.39	-0.31	1.55e-7	Reticulocyte fraction of red cells;
CESC	cis	rs6570726	0.967	rs7772286	chr6:145930423	A/T	cg23711669	chr6:146136114	FBXO30	-0.81	-11.73	-0.58	7.17e-26	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9309473	0.500	rs4852953	chr2:73869908	G/A	cg20560298	chr2:73613845	ALMS1	0.46	6.36	0.36	8.78e-10	Metabolite levels;
CESC	cis	rs9815354	0.812	rs73071352	chr3:41828300	A/G	cg03022575	chr3:42003672	ULK4	0.7	6.04	0.35	5.26e-9	Pulse pressure;Diastolic blood pressure;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg23668004	chr7:4784903	FOXK1	-0.41	-6.29	-0.36	1.3e-9	Gambling;
CESC	cis	rs7615952	0.611	rs35321002	chr3:125612065	G/C	cg05084668	chr3:125655381	ALG1L	-0.6	-6.54	-0.37	3.1e-10	Blood pressure (smoking interaction);
CESC	cis	rs4835473	0.831	rs2667353	chr4:144881615	G/C	cg25736465	chr4:144833511	NA	0.41	6.05	0.35	4.79e-9	Immature fraction of reticulocytes;
CESC	trans	rs6499188	0.522	rs8046299	chr16:68672346	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.63	7.64	0.42	3.93e-13	Ulcerative colitis;
CESC	cis	rs2075371	0.734	rs13225086	chr7:134011411	C/T	cg20476274	chr7:133979776	SLC35B4	0.58	7.59	0.42	5.33e-13	Mean platelet volume;
CESC	cis	rs1799949	1.000	rs11657835	chr17:41291953	C/G	cg23758822	chr17:41437982	NA	1.01	15.21	0.68	5.44e-38	Menopause (age at onset);
CESC	cis	rs6732160	0.619	rs12105975	chr2:73406049	T/A	cg01422370	chr2:73384389	NA	0.42	6.77	0.38	8.44e-11	Intelligence (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20974885	chr3:183966734	ALG3;ECE2	0.77	8.69	0.47	3.73e-16	Gut microbiome composition (summer);
CESC	cis	rs6580649	1.000	rs10783227	chr12:48400617	C/T	cg24011408	chr12:48396354	COL2A1	0.4	5.17	0.3	4.63e-7	Lung cancer;
CESC	cis	rs6831352	0.918	rs13110176	chr4:100062430	C/T	cg12011299	chr4:100065546	ADH4	0.56	6.34	0.36	9.9e-10	Alcohol dependence;
CESC	cis	rs116095464	0.558	rs62347677	chr5:227453	A/G	cg22496380	chr5:211416	CCDC127	-0.74	-8.71	-0.47	3.44e-16	Breast cancer;
CESC	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg11494091	chr17:61959527	GH2	0.73	12.48	0.61	2.02e-28	Prudent dietary pattern;
CESC	cis	rs72627123	0.867	rs17094448	chr14:74440119	A/G	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.76	5.04	0.3	8.57e-7	Morning vs. evening chronotype;
CESC	cis	rs1707322	1.000	rs6676982	chr1:46275401	A/T	cg05343316	chr1:45956843	TESK2	0.44	5.53	0.32	7.85e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs3820068	0.581	rs6692489	chr1:15928517	A/G	cg16988262	chr1:15930761	NA	0.33	5.35	0.31	1.89e-7	Systolic blood pressure;
CESC	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.52	7.22	0.41	5.43e-12	Lymphocyte counts;
CESC	trans	rs7615952	0.673	rs7632557	chr3:125634881	G/C	cg07211511	chr3:129823064	LOC729375	-1.1	-13.65	-0.64	1.67e-32	Blood pressure (smoking interaction);
CESC	cis	rs9549260	0.709	rs2721072	chr13:41144919	G/A	cg21288729	chr13:41239152	FOXO1	0.67	8.49	0.46	1.54e-15	Red blood cell count;
CESC	cis	rs7116495	0.609	rs949326	chr11:71730306	A/G	cg26138937	chr11:71823887	C11orf51	1.04	7.01	0.4	1.96e-11	Severe influenza A (H1N1) infection;
CESC	cis	rs9287719	0.967	rs7566767	chr2:10754663	T/C	cg02196655	chr2:10830764	NOL10	-0.37	-5.58	-0.32	5.98e-8	Prostate cancer;
CESC	trans	rs11098499	0.754	rs11724409	chr4:120252361	A/G	cg25214090	chr10:38739885	LOC399744	0.62	8.7	0.47	3.58e-16	Corneal astigmatism;
CESC	cis	rs7580658	0.680	rs2069931	chr2:128185569	C/T	cg10021288	chr2:128175891	PROC	-0.41	-6.14	-0.35	2.94e-9	Protein C levels;
CESC	cis	rs704795	0.902	rs11887784	chr2:27679919	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.28	-5.07	-0.3	7.42e-7	Menopause (age at onset);
CESC	cis	rs116979167	0.630	rs56230603	chr7:105165268	A/G	cg13798780	chr7:105162888	PUS7	0.78	8.04	0.44	2.99e-14	Bipolar disorder (body mass index interaction);
CESC	cis	rs6860806	0.632	rs4330455	chr5:131586349	T/C	cg18758796	chr5:131593413	PDLIM4	0.45	6.31	0.36	1.14e-9	Breast cancer;
CESC	cis	rs9549367	0.789	rs9549699	chr13:113878263	T/A	cg18105134	chr13:113819100	PROZ	-0.66	-8.24	-0.45	8.04e-15	Platelet distribution width;
CESC	cis	rs7584330	0.868	rs58057291	chr2:238395479	T/A	cg14458575	chr2:238380390	NA	0.75	10.47	0.54	1.05e-21	Prostate cancer;
CESC	trans	rs9467711	0.606	rs9366653	chr6:26354247	G/A	cg06606381	chr12:133084897	FBRSL1	-0.77	-7.0	-0.4	2.04e-11	Autism spectrum disorder or schizophrenia;
CESC	trans	rs10895547	0.527	rs566033	chr11:103790856	A/G	cg23613023	chr12:115353932	NA	-0.38	-6.16	-0.35	2.7e-9	LDL cholesterol;
CESC	cis	rs2066819	1.000	rs11171803	chr12:56718422	T/C	cg26734620	chr12:56694298	CS	1.03	6.25	0.36	1.65e-9	Psoriasis vulgaris;
CESC	cis	rs7552404	0.920	rs2788654	chr1:76219569	C/T	cg03433033	chr1:76189801	ACADM	0.71	9.78	0.52	1.68e-19	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs10504229	0.639	rs11781834	chr8:58133422	C/T	cg21724239	chr8:58056113	NA	0.55	5.6	0.33	5.43e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs1707322	0.686	rs2050376	chr1:46078630	C/T	cg06784218	chr1:46089804	CCDC17	0.42	7.43	0.42	1.52e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs62103177	0.733	rs62096747	chr18:77619568	A/G	cg05926928	chr17:57297772	GDPD1	1.2	10.71	0.55	1.82e-22	Opioid sensitivity;
CESC	cis	rs9790314	1.000	rs336577	chr3:161066294	C/T	cg03342759	chr3:160939853	NMD3	-0.49	-6.43	-0.37	6.04e-10	Morning vs. evening chronotype;
CESC	cis	rs9649213	0.593	rs1132971	chr7:97921533	A/G	cg00277769	chr7:97922759	BAIAP2L1	-0.34	-5.57	-0.32	6.1e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs2979489	0.891	rs2915590	chr8:30393334	A/G	cg26383811	chr8:30366931	RBPMS	-0.78	-9.72	-0.51	2.78e-19	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CESC	cis	rs6121246	0.528	rs6060252	chr20:30191084	A/G	cg13852791	chr20:30311386	BCL2L1	0.58	5.56	0.32	6.65e-8	Mean corpuscular hemoglobin;
CESC	cis	rs400736	0.562	rs7551900	chr1:8178526	A/C	cg25007680	chr1:8021821	PARK7	-0.55	-6.86	-0.39	4.91e-11	Response to antidepressants and depression;
CESC	cis	rs736408	0.634	rs11717836	chr3:52807736	A/G	cg18099408	chr3:52552593	STAB1	-0.32	-5.15	-0.3	5.11e-7	Bipolar disorder;
CESC	cis	rs12497850	0.931	rs13064911	chr3:48952385	A/G	cg06212747	chr3:49208901	KLHDC8B	0.66	8.81	0.48	1.65e-16	Parkinson's disease;
CESC	cis	rs7552404	1.000	rs12126607	chr1:76217097	G/A	cg22875332	chr1:76189707	ACADM	0.64	7.7	0.43	2.76e-13	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs1580019	0.961	rs11765387	chr7:32494790	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.72	10.07	0.53	2.04e-20	Cognitive ability;
CESC	cis	rs8014204	0.836	rs888413	chr14:75267396	C/T	cg11812906	chr14:75593930	NEK9	0.42	5.14	0.3	5.35e-7	Caffeine consumption;
CESC	cis	rs1847505	0.609	rs9538998	chr13:61571160	A/G	cg25164009	chr13:61490935	NA	-0.4	-5.41	-0.32	1.4e-7	Polychlorinated biphenyl levels;
CESC	cis	rs3733585	0.605	rs56178126	chr4:10123581	C/T	cg02734326	chr4:10020555	SLC2A9	-0.38	-5.13	-0.3	5.48e-7	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs9649465	0.688	rs34967330	chr7:123318560	A/C	cg04330084	chr7:123175371	IQUB	-0.39	-5.26	-0.31	2.95e-7	Migraine;
CESC	cis	rs10838687	0.800	rs10838689	chr11:47334524	C/T	cg25783544	chr11:47291846	MADD	0.5	5.39	0.31	1.55e-7	Proinsulin levels;
CESC	cis	rs2282802	0.585	rs2189659	chr5:139697220	C/A	cg26211634	chr5:139558579	C5orf32	-0.46	-6.6	-0.38	2.21e-10	Intelligence (multi-trait analysis);
CESC	cis	rs4819052	0.851	rs2838849	chr21:46671027	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.75	9.89	0.52	7.53e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs9926296	0.605	rs12448860	chr16:89849629	T/A	cg03388025	chr16:89894329	SPIRE2	0.39	7.39	0.41	1.94e-12	Vitiligo;
CESC	cis	rs798554	0.757	rs2644312	chr7:2841164	G/A	cg04166393	chr7:2884313	GNA12	0.63	8.01	0.44	3.75e-14	Height;
CESC	cis	rs13256369	0.802	rs35382339	chr8:8559255	G/A	cg00074818	chr8:8560427	CLDN23	0.37	5.18	0.3	4.44e-7	Obesity-related traits;
CESC	cis	rs7116495	0.609	rs7942626	chr11:71703849	G/A	cg26138937	chr11:71823887	C11orf51	-1.22	-8.09	-0.45	2.15e-14	Severe influenza A (H1N1) infection;
CESC	cis	rs2204008	0.537	rs11170128	chr12:38006632	G/A	cg13010199	chr12:38710504	ALG10B	0.54	6.77	0.38	8.14e-11	Bladder cancer;
CESC	cis	rs7412746	0.611	rs11803940	chr1:150685835	A/G	cg18016565	chr1:150552671	MCL1	0.34	5.29	0.31	2.53e-7	Melanoma;
CESC	cis	rs6500395	1.000	rs8052073	chr16:48682696	T/C	cg04672837	chr16:48644449	N4BP1	0.51	6.36	0.36	8.64e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs9858542	0.953	rs1801143	chr3:49570200	C/T	cg07274523	chr3:49395745	GPX1	0.66	8.17	0.45	1.23e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs6500395	0.775	rs7185541	chr16:48664681	A/G	cg04672837	chr16:48644449	N4BP1	0.49	6.27	0.36	1.46e-9	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs2191566	0.664	rs7251083	chr19:44551866	G/T	cg20607764	chr19:44506953	ZNF230	-0.44	-5.64	-0.33	4.34e-8	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs7618915	0.501	rs62253740	chr3:52684128	A/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	5.85	0.34	1.46e-8	Bipolar disorder;
CESC	cis	rs4665809	1.000	rs6739061	chr2:26256147	C/T	cg26314531	chr2:26401878	FAM59B	-0.61	-6.91	-0.39	3.66e-11	Gut microbiome composition (summer);
CESC	cis	rs5769765	0.908	rs2319464	chr22:50265777	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.46	5.31	0.31	2.35e-7	Schizophrenia;
CESC	cis	rs8092503	0.951	rs12457769	chr18:52499801	T/G	cg12377874	chr18:52495404	RAB27B	0.37	6.11	0.35	3.62e-9	Childhood body mass index;
CESC	cis	rs7666738	0.830	rs4334758	chr4:98971875	A/G	cg05340658	chr4:99064831	C4orf37	0.79	12.26	0.6	1.12e-27	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6088590	0.561	rs3891369	chr20:33161127	C/T	cg06115741	chr20:33292138	TP53INP2	0.52	6.74	0.38	1e-10	Coronary artery disease;
CESC	cis	rs12479064	0.694	rs11896520	chr2:99995517	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.64	-7.34	-0.41	2.6e-12	Chronic sinus infection;
CESC	cis	rs6938	0.534	rs12907898	chr15:75207872	C/T	cg14664628	chr15:75095509	CSK	-0.54	-7.22	-0.41	5.37e-12	Breast cancer;
CESC	cis	rs8017423	0.647	rs11626821	chr14:90824945	A/G	cg14092571	chr14:90743983	NA	0.44	6.77	0.38	8.12e-11	Mortality in heart failure;
CESC	cis	rs896854	0.517	rs1011796	chr8:95951273	A/G	cg16049864	chr8:95962084	TP53INP1	0.54	7.6	0.42	4.98e-13	Type 2 diabetes;
CESC	cis	rs7605827	0.930	rs4668445	chr2:15515838	C/T	cg19274914	chr2:15703543	NA	0.32	5.7	0.33	3.17e-8	Educational attainment (years of education);
CESC	cis	rs7560272	0.501	rs17350188	chr2:73964842	C/G	cg20560298	chr2:73613845	ALMS1	-0.44	-5.95	-0.34	8.45e-9	Schizophrenia;
CESC	cis	rs1153858	0.723	rs11855527	chr15:45606685	G/A	cg21132104	chr15:45694354	SPATA5L1	-0.72	-9.29	-0.5	5.8e-18	Homoarginine levels;
CESC	cis	rs4665809	0.567	rs6546848	chr2:26444414	G/C	cg08470875	chr2:26401718	FAM59B	-0.76	-8.06	-0.44	2.69e-14	Gut microbiome composition (summer);
CESC	cis	rs17125944	0.615	rs2025632	chr14:53294319	T/C	cg00686598	chr14:53173677	PSMC6	-0.69	-5.95	-0.34	8.3e-9	Alzheimer's disease (late onset);
CESC	cis	rs941873	0.868	rs2233718	chr10:81108956	A/G	cg11057378	chr10:81107060	PPIF	0.31	5.05	0.3	8.43e-7	Height;
CESC	cis	rs909674	0.818	rs8137426	chr22:39844350	T/G	cg01416388	chr22:39784598	NA	-0.61	-7.09	-0.4	1.25e-11	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs7089973	0.584	rs4752255	chr10:116576790	C/T	cg25233709	chr10:116636983	FAM160B1	0.35	5.55	0.32	6.87e-8	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs9457247	0.663	rs6456143	chr6:167415440	C/A	cg25258033	chr6:167368657	RNASET2	0.37	5.39	0.31	1.56e-7	Crohn's disease;
CESC	cis	rs3096299	0.658	rs4291902	chr16:89560315	G/C	cg00750074	chr16:89608354	SPG7	-0.43	-6.18	-0.35	2.41e-9	Multiple myeloma (IgH translocation);
CESC	cis	rs9929218	1.000	rs13334294	chr16:68809278	A/C	cg02972257	chr16:68554789	NA	0.43	5.12	0.3	5.89e-7	Colorectal cancer;
CESC	cis	rs1799949	1.000	rs1960605	chr17:41305397	C/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.45	6.26	0.36	1.57e-9	Menopause (age at onset);
CESC	cis	rs3106136	0.967	rs17310266	chr4:95177051	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.45	-6.72	-0.38	1.14e-10	Capecitabine sensitivity;
CESC	cis	rs2404602	0.735	rs56246286	chr15:76690731	C/T	cg23625390	chr15:77176239	SCAPER	-0.43	-5.94	-0.34	8.72e-9	Blood metabolite levels;
CESC	trans	rs9929218	1.000	rs67359183	chr16:68814204	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.64	-8.36	-0.46	3.57e-15	Colorectal cancer;
CESC	cis	rs704795	0.775	rs4665975	chr2:27626017	A/T	cg22903471	chr2:27725779	GCKR	-0.56	-8.05	-0.44	2.81e-14	Menopause (age at onset);
CESC	cis	rs7264396	0.836	rs6058282	chr20:34212590	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.87	-11.33	-0.57	1.56e-24	Total cholesterol levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01083584	chr19:14629193	DNAJB1	0.53	6.34	0.36	1.01e-9	Gut microbiome composition (summer);
CESC	trans	rs6021270	0.850	rs1987430	chr20:50134174	G/A	cg05339727	chr2:165812079	SLC38A11	-0.79	-6.11	-0.35	3.45e-9	Self-reported allergy;
CESC	cis	rs863345	0.967	rs863355	chr1:158542595	T/G	cg12129480	chr1:158549410	OR10X1	-0.32	-6.36	-0.36	8.9e-10	Pneumococcal bacteremia;
CESC	cis	rs34779708	0.966	rs12775548	chr10:35479504	G/T	cg03585969	chr10:35415529	CREM	0.71	9.19	0.49	1.21e-17	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs6912958	0.559	rs499373	chr6:88042062	A/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.76	11.09	0.56	9.87e-24	Monocyte percentage of white cells;
CESC	trans	rs66573146	1.000	rs56178503	chr4:6961748	C/T	cg07817883	chr1:32538562	TMEM39B	1.51	9.21	0.49	1.06e-17	Granulocyte percentage of myeloid white cells;
CESC	cis	rs7084402	0.902	rs1593670	chr10:60300766	C/G	cg07615347	chr10:60278583	BICC1	0.6	9.46	0.5	1.77e-18	Refractive error;
CESC	cis	rs9837602	0.507	rs793452	chr3:99529523	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.52	6.3	0.36	1.26e-9	Breast cancer;
CESC	cis	rs6460942	0.915	rs1595800	chr7:12439816	G/A	cg10578991	chr7:12443926	VWDE	-0.45	-5.11	-0.3	6.15e-7	Coronary artery disease;
CESC	cis	rs12313068	0.600	rs7136207	chr12:110491487	T/C	cg12870014	chr12:110450643	ANKRD13A	0.86	9.68	0.51	3.61e-19	Intelligence (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20980112	chr1:155108432	RAG1AP1	0.62	7.06	0.4	1.45e-11	Gut microbiome composition (summer);
CESC	trans	rs17508449	0.819	rs4839332	chr1:114162191	G/T	cg23028848	chr11:57092561	TNKS1BP1	-0.82	-6.49	-0.37	4.21e-10	Leprosy;
CESC	cis	rs875971	1.000	rs7783613	chr7:65805261	C/T	cg11764359	chr7:65958608	NA	-0.94	-15.34	-0.69	1.97e-38	Aortic root size;
CESC	cis	rs35955747	0.902	rs5997919	chr22:31623442	A/G	cg25791279	chr22:32026902	PISD	-0.48	-5.75	-0.33	2.44e-8	Neutrophil count;Sum basophil neutrophil counts;
CESC	cis	rs959260	1.000	rs7216423	chr17:73365671	T/C	cg12999837	chr17:73267436	MIF4GD	-0.47	-5.46	-0.32	1.1e-7	Systemic lupus erythematosus;
CESC	cis	rs832540	0.512	rs33320	chr5:56206529	C/T	cg14703610	chr5:56206110	C5orf35	0.43	5.38	0.31	1.62e-7	Coronary artery disease;
CESC	cis	rs2836974	0.899	rs8127087	chr21:40544502	C/T	cg11644478	chr21:40555479	PSMG1	1.03	16.69	0.72	3.03e-43	Cognitive function;
CESC	cis	rs2204008	0.805	rs11179579	chr12:38213957	A/C	cg26384229	chr12:38710491	ALG10B	0.71	10.3	0.53	3.96e-21	Bladder cancer;
CESC	cis	rs854765	0.583	rs9635697	chr17:17870394	T/A	cg09796270	chr17:17721594	SREBF1	0.45	6.17	0.35	2.61e-9	Total body bone mineral density;
CESC	cis	rs2439831	0.764	rs12324584	chr15:43683446	G/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.91	10.89	0.56	4.69e-23	Lung cancer in ever smokers;
CESC	trans	rs1814175	0.645	rs7103554	chr11:50027612	G/A	cg03929089	chr4:120376271	NA	-0.9	-14.7	-0.67	3.47e-36	Height;
CESC	cis	rs4975709	0.838	rs4975752	chr5:1880588	A/C	cg17650747	chr5:1873721	NA	0.39	5.24	0.31	3.21e-7	Cardiovascular disease risk factors;
CESC	cis	rs7312774	0.618	rs12316476	chr12:107343326	C/G	cg16260113	chr12:107380972	MTERFD3	0.81	7.42	0.41	1.55e-12	Severe influenza A (H1N1) infection;
CESC	cis	rs3126085	0.935	rs11204934	chr1:152176848	C/A	cg03465714	chr1:152285911	FLG	0.47	5.55	0.32	6.93e-8	Atopic dermatitis;
CESC	trans	rs1557351	0.569	rs2027701	chr18:54725195	C/T	cg11433624	chr6:7146702	RREB1	-0.36	-6.06	-0.35	4.54e-9	Multiple sclerosis (age of onset);
CESC	cis	rs4704187	0.687	rs6879894	chr5:74498164	C/A	cg03227963	chr5:74354835	NA	0.28	5.18	0.3	4.33e-7	Response to amphetamines;
CESC	cis	rs1009181	0.585	rs9379827	chr6:26153335	G/T	cg17691542	chr6:26056736	HIST1H1C	0.51	5.24	0.31	3.36e-7	Childhood ear infection;
CESC	cis	rs7532866	0.885	rs7517224	chr1:26731029	A/G	cg17456097	chr1:26900765	RPS6KA1	-0.47	-6.04	-0.35	5.23e-9	Height;
CESC	cis	rs4665809	1.000	rs6709595	chr2:26259885	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.69	-7.83	-0.43	1.19e-13	Gut microbiome composition (summer);
CESC	cis	rs12477438	0.520	rs11692699	chr2:99730657	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.88	15.61	0.69	2.15e-39	Chronic sinus infection;
CESC	cis	rs116095464	0.510	rs10057501	chr5:239545	T/C	cg22496380	chr5:211416	CCDC127	-0.74	-8.66	-0.47	4.75e-16	Breast cancer;
CESC	cis	rs9611565	0.643	rs202634	chr22:41809623	A/G	cg06634786	chr22:41940651	POLR3H	0.73	7.46	0.42	1.23e-12	Vitiligo;
CESC	cis	rs9303401	0.659	rs56162835	chr17:56687315	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	1.04	13.0	0.62	3.27e-30	Cognitive test performance;
CESC	trans	rs9858542	1.000	rs9836291	chr3:49697459	G/A	cg21659725	chr3:3221576	CRBN	-0.54	-6.63	-0.38	1.89e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs4835473	0.868	rs66634585	chr4:144655761	C/G	cg25736465	chr4:144833511	NA	-0.33	-5.23	-0.31	3.44e-7	Immature fraction of reticulocytes;
CESC	cis	rs1799949	0.965	rs33961729	chr17:41287924	C/A	cg05368731	chr17:41323189	NBR1	0.79	10.91	0.56	4.06e-23	Menopause (age at onset);
CESC	cis	rs6088590	1.000	rs6120705	chr20:33313740	T/C	cg06115741	chr20:33292138	TP53INP2	0.59	7.32	0.41	2.95e-12	Coronary artery disease;
CESC	trans	rs3780486	0.801	rs3780495	chr9:33125942	A/C	cg04842962	chr6:43655489	MRPS18A	1.0	19.11	0.76	8.81e-52	IgG glycosylation;
CESC	cis	rs3820068	0.532	rs74057713	chr1:15944620	G/C	cg13390004	chr1:15929781	NA	0.36	5.92	0.34	9.92e-9	Systolic blood pressure;
CESC	cis	rs826838	0.868	rs864324	chr12:39122853	A/G	cg13010199	chr12:38710504	ALG10B	0.41	5.65	0.33	4.04e-8	Heart rate;
CESC	cis	rs736408	0.609	rs13082960	chr3:52785168	A/C	cg18404041	chr3:52824283	ITIH1	-0.41	-6.79	-0.38	7.34e-11	Bipolar disorder;
CESC	cis	rs2108225	0.900	rs7805114	chr7:107450033	G/T	cg18560240	chr7:107437656	SLC26A3	0.39	5.34	0.31	2.05e-7	Ulcerative colitis;
CESC	cis	rs9815354	0.680	rs73073250	chr3:42016559	G/T	cg03022575	chr3:42003672	ULK4	0.74	6.64	0.38	1.79e-10	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs2979489	0.891	rs4449748	chr8:30304402	A/G	cg26383811	chr8:30366931	RBPMS	0.82	9.6	0.51	6.26e-19	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CESC	cis	rs9894429	1.000	rs9748176	chr17:79584043	C/G	cg13777783	chr17:79615861	NA	-0.35	-5.81	-0.34	1.83e-8	Eye color traits;
CESC	cis	rs826838	0.935	rs1160162	chr12:38959795	G/A	cg13010199	chr12:38710504	ALG10B	0.58	8.14	0.45	1.56e-14	Heart rate;
CESC	cis	rs6502050	0.835	rs4789675	chr17:80123144	G/A	cg23985595	chr17:80112537	CCDC57	-0.41	-6.57	-0.37	2.6200000000000003e-10	Life satisfaction;
CESC	cis	rs8018808	0.902	rs176773	chr14:77882456	C/T	cg20045696	chr14:77926864	AHSA1	0.42	5.84	0.34	1.56e-8	Myeloid white cell count;
CESC	cis	rs116988415	0.584	rs74331120	chr14:65244595	G/A	cg25083366	chr14:65239357	SPTB	0.75	5.47	0.32	1.02e-7	Daytime sleep phenotypes;
CESC	cis	rs798554	0.959	rs798557	chr7:2758982	G/A	cg19346786	chr7:2764209	NA	-0.47	-6.76	-0.38	9.02e-11	Height;
CESC	trans	rs9784649	0.771	rs72755810	chr5:25039139	A/C	cg08600765	chr20:34638493	LOC647979	-0.55	-6.27	-0.36	1.48e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26561342	chr1:45241260	SNORD55;RPS8;SNORD46	0.53	6.57	0.37	2.71e-10	Gut microbiome composition (summer);
CESC	cis	rs5167	0.504	rs3760629	chr19:45458146	A/C	cg20090143	chr19:45452003	APOC2	0.33	5.82	0.34	1.66e-8	Blood protein levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11259409	chr11:1331124	LOC255512;TOLLIP	0.59	6.99	0.39	2.22e-11	Gut microbiome composition (summer);
CESC	cis	rs8099014	0.814	rs4245272	chr18:56115145	T/A	cg19312305	chr18:56117016	MIR122	-0.26	-5.21	-0.3	3.83e-7	Platelet count;
CESC	cis	rs514406	0.661	rs550561	chr1:53375134	C/T	cg16325326	chr1:53192061	ZYG11B	0.53	7.5	0.42	9.67e-13	Monocyte count;
CESC	cis	rs208515	0.525	rs10755508	chr6:66675790	T/C	cg07460842	chr6:66804631	NA	0.85	10.63	0.55	3.24e-22	Exhaled nitric oxide levels;
CESC	cis	rs950169	1.000	rs35658069	chr15:84780146	C/T	cg17507749	chr15:85114479	UBE2QP1	0.6	6.61	0.38	2.08e-10	Schizophrenia;
CESC	cis	rs7615952	0.641	rs12495947	chr3:125771698	C/T	cg02807482	chr3:125708958	NA	-0.4	-5.2	-0.3	3.94e-7	Blood pressure (smoking interaction);
CESC	trans	rs650950	0.528	rs646660	chr11:35528452	C/T	cg09265274	chr17:48585635	MYCBPAP	-0.45	-6.2	-0.36	2.19e-9	Bronchopulmonary dysplasia;
CESC	cis	rs7927771	0.832	rs4752994	chr11:47411065	A/T	cg20307385	chr11:47447363	PSMC3	0.62	7.61	0.42	4.7e-13	Subjective well-being;
CESC	cis	rs1862618	0.525	rs2662021	chr5:56261691	C/T	cg24531977	chr5:56204891	C5orf35	0.87	11.43	0.57	7.36e-25	Initial pursuit acceleration;
CESC	cis	rs12188164	0.965	rs72717430	chr5:444502	T/C	cg26850624	chr5:429559	AHRR	-0.5	-6.67	-0.38	1.52e-10	Cystic fibrosis severity;
CESC	cis	rs11997175	0.574	rs7001404	chr8:33645219	G/A	ch.8.33884649F	chr8:33765107	NA	0.65	8.33	0.46	4.47e-15	Body mass index;
CESC	cis	rs2708240	0.689	rs2710114	chr7:147598021	A/G	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.35	-5.66	-0.33	3.93e-8	QT interval (drug interaction);
CESC	cis	rs3888647	0.561	rs4758617	chr11:2995185	T/A	cg08508325	chr11:3079039	CARS	-0.5	-9.29	-0.5	5.75e-18	Type 2 diabetes;
CESC	cis	rs9486719	0.802	rs2983896	chr6:97029871	G/A	cg06623918	chr6:96969491	KIAA0776	-0.9	-10.79	-0.55	9.98e-23	Migraine;Coronary artery disease;
CESC	cis	rs9399135	0.660	rs4472368	chr6:135274232	A/G	cg22676075	chr6:135203613	NA	0.48	6.5	0.37	4.04e-10	Red blood cell count;
CESC	cis	rs9911578	1.000	rs7215808	chr17:56940742	G/C	cg05425664	chr17:57184151	TRIM37	-0.5	-6.95	-0.39	2.8e-11	Intelligence (multi-trait analysis);
CESC	cis	rs4481887	0.830	rs4916126	chr1:248466604	G/A	cg00666640	chr1:248458726	OR2T12	0.39	6.37	0.36	8.47e-10	Common traits (Other);
CESC	cis	rs7259376	0.902	rs4932763	chr19:22603922	C/A	cg02657401	chr19:22469223	NA	0.26	5.07	0.3	7.61e-7	Menopause (age at onset);
CESC	cis	rs4253772	0.550	rs9615951	chr22:46728056	C/A	cg24881330	chr22:46731750	TRMU	0.78	6.4	0.37	6.94e-10	LDL cholesterol;Cholesterol, total;
CESC	cis	rs4689388	0.856	rs4308430	chr4:6294095	A/G	cg25554036	chr4:6271136	WFS1	0.51	8.34	0.46	4.21e-15	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs7264396	0.635	rs6060720	chr20:34548336	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.77	-10.35	-0.54	2.7e-21	Total cholesterol levels;
CESC	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.59	6.88	0.39	4.21e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs12477438	0.520	rs2516829	chr2:99773201	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.91	15.51	0.69	4.65e-39	Chronic sinus infection;
CESC	cis	rs4535700	0.501	rs10227764	chr7:56012422	A/C	cg09872392	chr7:56161020	PHKG1	0.4	5.78	0.33	2.1e-8	Macular telangiectasia type 2;
CESC	cis	rs919433	0.783	rs55725278	chr2:198238223	C/T	cg10820045	chr2:198174542	NA	0.41	5.98	0.34	7.19e-9	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs9325144	0.541	rs7303395	chr12:38664124	C/T	cg26384229	chr12:38710491	ALG10B	-0.6	-8.49	-0.46	1.45e-15	Morning vs. evening chronotype;
CESC	cis	rs4588572	0.644	rs6873144	chr5:77741784	C/T	cg11547950	chr5:77652471	NA	-0.4	-5.56	-0.32	6.42e-8	Triglycerides;
CESC	cis	rs372883	0.600	rs1153277	chr21:30666867	A/T	cg24692254	chr21:30365293	RNF160	-0.59	-7.61	-0.42	4.74e-13	Pancreatic cancer;
CESC	cis	rs12325245	0.536	rs71375919	chr16:58547522	C/T	cg02549819	chr16:58548995	SETD6	0.95	6.25	0.36	1.67e-9	Schizophrenia;
CESC	cis	rs72772090	0.539	rs72773917	chr5:96111302	A/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.6	-5.03	-0.3	8.86e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs514406	0.667	rs10788942	chr1:53210521	A/T	cg08859206	chr1:53392774	SCP2	0.63	9.27	0.49	6.72e-18	Monocyte count;
CESC	cis	rs12540874	0.698	rs3807566	chr7:50564204	G/T	cg18232548	chr7:50535776	DDC	-0.42	-5.89	-0.34	1.16e-8	Systemic sclerosis;
CESC	cis	rs12887734	0.546	rs4906376	chr14:104272165	A/C	cg08213375	chr14:104286397	PPP1R13B	0.38	6.41	0.37	6.71e-10	Schizophrenia;Autism spectrum disorder or schizophrenia;
CESC	cis	rs2075371	0.637	rs13245165	chr7:133951492	A/T	cg20476274	chr7:133979776	SLC35B4	0.62	8.9	0.48	8.88e-17	Mean platelet volume;
CESC	cis	rs365132	0.875	rs4976665	chr5:176352736	C/T	cg16309518	chr5:176445507	NA	-0.37	-5.33	-0.31	2.09e-7	Menarche and menopause (age at onset);Menopause (age at onset);
CESC	cis	rs6088590	0.523	rs6059913	chr20:33143288	G/A	cg08999081	chr20:33150536	PIGU	0.7	12.47	0.61	2.17e-28	Coronary artery disease;
CESC	cis	rs523522	0.962	rs3742052	chr12:120966921	A/G	cg12219531	chr12:120966889	COQ5	0.75	9.99	0.52	3.7e-20	High light scatter reticulocyte count;
CESC	cis	rs13031619	0.660	rs34855424	chr2:3702780	C/A	cg19052272	chr2:3704530	ALLC	-0.79	-8.83	-0.48	1.5e-16	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CESC	cis	rs7267979	0.565	rs6107060	chr20:25592476	C/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.7	11.68	0.58	1.05e-25	Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs10517270	0.744	rs10028228	chr4:33212652	A/G	cg20709895	chr11:43965598	NA	0.62	6.45	0.37	5.4e-10	Alzheimer's disease (age of onset);
CESC	cis	rs738322	1.000	rs4382	chr22:38570842	T/C	cg17652424	chr22:38574118	PLA2G6	-0.34	-6.04	-0.35	5.08e-9	Cutaneous nevi;
CESC	trans	rs11098499	0.954	rs3733523	chr4:120423719	C/T	cg25214090	chr10:38739885	LOC399744	0.7	9.78	0.51	1.7e-19	Corneal astigmatism;
CESC	cis	rs2519796	0.531	rs2519804	chr9:136805739	G/A	cg13751417	chr9:136814406	VAV2	-0.43	-5.67	-0.33	3.79e-8	Hematocrit;Hemoglobin concentration;
CESC	trans	rs877282	0.945	rs17293517	chr10:778770	C/T	cg22713356	chr15:30763199	NA	1.32	13.38	0.63	1.51e-31	Uric acid levels;
CESC	cis	rs12121840	0.790	rs6657863	chr1:165546671	G/A	cg16553119	chr1:165599451	MGST3	-0.43	-5.55	-0.32	6.91e-8	Interleukin-1-receptor antagonist levels;
CESC	cis	rs7512552	0.839	rs11587116	chr1:150451898	A/T	cg15654264	chr1:150340011	RPRD2	0.39	5.2	0.3	3.98e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs9929218	0.954	rs4552018	chr16:68822854	T/G	cg02972257	chr16:68554789	NA	0.45	5.39	0.31	1.58e-7	Colorectal cancer;
CESC	cis	rs2011503	0.941	rs56044734	chr19:19366927	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.53	5.43	0.32	1.3e-7	Bipolar disorder;
CESC	cis	rs7084402	0.967	rs1649025	chr10:60281584	C/G	cg07615347	chr10:60278583	BICC1	-0.6	-9.49	-0.5	1.43e-18	Refractive error;
CESC	cis	rs3806843	0.735	rs801167	chr5:140081423	A/G	cg26395211	chr5:140044315	WDR55	-0.45	-5.67	-0.33	3.74e-8	Depressive symptoms (multi-trait analysis);
CESC	cis	rs7259376	0.869	rs10402396	chr19:22601809	G/C	cg02657401	chr19:22469223	NA	0.26	5.12	0.3	5.79e-7	Menopause (age at onset);
CESC	cis	rs1552244	0.832	rs3732968	chr3:10013273	A/G	cg00166722	chr3:10149974	C3orf24	0.48	5.97	0.34	7.76e-9	Alzheimer's disease;
CESC	cis	rs7937682	0.961	rs11828343	chr11:111491322	A/G	cg22437258	chr11:111473054	SIK2	-0.69	-8.26	-0.45	7.19e-15	Primary sclerosing cholangitis;
CESC	cis	rs7666738	0.830	rs60411337	chr4:99046617	T/C	cg17366294	chr4:99064904	C4orf37	0.61	8.78	0.47	2.13e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2011503	1.000	rs75453386	chr19:19637781	C/T	cg11584989	chr19:19387371	SF4	0.61	7.03	0.4	1.79e-11	Bipolar disorder;
CESC	cis	rs60871478	0.945	rs62432254	chr7:804175	C/T	cg27478167	chr7:817139	HEATR2	-0.49	-5.88	-0.34	1.23e-8	Cerebrospinal P-tau181p levels;
CESC	cis	rs3785574	0.962	rs56295011	chr17:61850359	A/G	cg06420487	chr17:61919686	SMARCD2	0.47	5.59	0.32	5.64e-8	Height;
CESC	cis	rs2228479	0.717	rs2074904	chr16:89811546	A/G	cg06558623	chr16:89946397	TCF25	1.19	9.55	0.51	8.99e-19	Skin colour saturation;
CESC	cis	rs977987	0.872	rs10781976	chr16:75314838	G/T	cg03315344	chr16:75512273	CHST6	0.38	5.41	0.32	1.39e-7	Dupuytren's disease;
CESC	cis	rs477895	0.713	rs2282490	chr11:63962152	T/C	cg18225595	chr11:63971243	STIP1	0.52	5.19	0.3	4.19e-7	Mean platelet volume;
CESC	cis	rs7412746	0.622	rs11552229	chr1:150783985	T/C	cg22823121	chr1:150693482	HORMAD1	0.47	6.64	0.38	1.73e-10	Melanoma;
CESC	cis	rs853679	0.517	rs9357066	chr6:28129831	T/C	cg22143856	chr6:28129313	ZNF389	0.49	6.24	0.36	1.73e-9	Depression;
CESC	cis	rs3733585	0.673	rs6836706	chr4:9964251	T/A	cg11266682	chr4:10021025	SLC2A9	-0.6	-11.2	-0.57	4.42e-24	Cleft plate (environmental tobacco smoke interaction);
CESC	trans	rs801193	0.967	rs2707853	chr7:66214010	G/A	cg26939375	chr7:64535504	NA	0.64	8.67	0.47	4.31e-16	Aortic root size;
CESC	cis	rs962856	0.964	rs5022017	chr2:67619177	G/A	cg09028215	chr2:67624308	ETAA1	-0.4	-5.33	-0.31	2.07e-7	Pancreatic cancer;
CESC	cis	rs9611565	0.729	rs2413646	chr22:41906325	C/T	cg06634786	chr22:41940651	POLR3H	-0.7	-7.13	-0.4	9.69e-12	Vitiligo;
CESC	cis	rs7084402	0.967	rs1658467	chr10:60295316	A/G	cg07615347	chr10:60278583	BICC1	0.6	9.42	0.5	2.35e-18	Refractive error;
CESC	cis	rs875971	1.000	rs10244498	chr7:66116056	A/G	cg18876405	chr7:65276391	NA	0.49	6.67	0.38	1.46e-10	Aortic root size;
CESC	cis	rs4523957	0.583	rs2760738	chr17:2024600	A/G	cg16513277	chr17:2031491	SMG6	-0.71	-10.08	-0.53	1.96e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs1218582	0.772	rs4240875	chr1:154885782	G/A	cg06221963	chr1:154839813	KCNN3	-0.66	-11.23	-0.57	3.52e-24	Prostate cancer;
CESC	cis	rs10242455	0.717	rs2741872	chr7:99339776	A/T	cg07715041	chr7:99302981	CYP3A7	-0.45	-5.32	-0.31	2.25e-7	Blood metabolite levels;
CESC	cis	rs754466	0.651	rs11002316	chr10:79617511	C/G	cg17075019	chr10:79541650	NA	-0.87	-13.72	-0.64	1.01e-32	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs875971	0.564	rs313804	chr7:65514622	A/G	cg18876405	chr7:65276391	NA	0.56	7.47	0.42	1.15e-12	Aortic root size;
CESC	trans	rs2391518	0.639	rs2952860	chr4:130782065	A/G	cg04981619	chr2:43328122	NA	0.38	6.0	0.35	6.59e-9	Body mass index;
CESC	cis	rs9309473	0.519	rs7606947	chr2:73909818	C/T	cg20560298	chr2:73613845	ALMS1	-0.5	-7.03	-0.4	1.77e-11	Metabolite levels;
CESC	cis	rs7116495	0.609	rs595062	chr11:71809635	C/T	cg10381502	chr11:71823885	C11orf51	1.05	6.51	0.37	3.78e-10	Severe influenza A (H1N1) infection;
CESC	cis	rs11098499	0.863	rs3822190	chr4:120428098	G/A	cg09307838	chr4:120376055	NA	0.95	13.17	0.63	8.54e-31	Corneal astigmatism;
CESC	cis	rs7666738	0.830	rs880470	chr4:98922522	A/T	cg17366294	chr4:99064904	C4orf37	0.6	8.23	0.45	8.65e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7937682	0.587	rs571594	chr11:111359334	A/G	cg22437258	chr11:111473054	SIK2	-0.44	-5.52	-0.32	8.22e-8	Primary sclerosing cholangitis;
CESC	trans	rs1814175	0.645	rs28839231	chr11:50044292	G/T	cg15704280	chr7:45808275	SEPT13	-1.01	-18.71	-0.75	2.23e-50	Height;
CESC	cis	rs12477438	0.501	rs12613624	chr2:99732741	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.8	-12.74	-0.62	2.5e-29	Chronic sinus infection;
CESC	cis	rs4474465	0.736	rs10899542	chr11:78246572	T/G	cg27205649	chr11:78285834	NARS2	0.44	5.33	0.31	2.12e-7	Alzheimer's disease (survival time);
CESC	cis	rs7412746	0.611	rs4970931	chr1:150910727	G/A	cg22823121	chr1:150693482	HORMAD1	0.36	5.12	0.3	5.88e-7	Melanoma;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg12129596	chr19:55770037	SAPS1	-0.45	-6.58	-0.37	2.51e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg24829409	chr8:58192753	C8orf71	-0.67	-8.18	-0.45	1.19e-14	Developmental language disorder (linguistic errors);
CESC	cis	rs9303401	0.659	rs34351230	chr17:56782555	C/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.05	12.77	0.62	1.94e-29	Cognitive test performance;
CESC	cis	rs10191773	0.589	rs6761440	chr2:112959193	G/A	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.74	-7.2	-0.4	6.14e-12	Yeast infection;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg26918957	chr8:22926800	TNFRSF10B	-0.45	-6.24	-0.36	1.7e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs854765	0.583	rs7213225	chr17:17869111	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.59	8.22	0.45	9.43e-15	Total body bone mineral density;
CESC	cis	rs9296736	0.922	rs625899	chr6:53957588	C/T	cg04374786	chr6:53939321	C6orf142	-0.32	-5.19	-0.3	4.16e-7	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs116095464	0.558	rs6869925	chr5:264036	A/G	cg10591111	chr5:226296	SDHA	-0.52	-6.35	-0.36	9.51e-10	Breast cancer;
CESC	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.49	-6.15	-0.35	2.92e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs10256972	0.685	rs10263665	chr7:1110628	A/G	cg04025307	chr7:1156635	C7orf50	0.45	7.29	0.41	3.56e-12	Longevity;Endometriosis;
CESC	cis	rs6500395	0.925	rs12920170	chr16:48701530	A/G	cg04672837	chr16:48644449	N4BP1	-0.51	-6.36	-0.36	8.64e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs62229266	0.804	rs2835259	chr21:37425302	T/C	cg08632701	chr21:37451849	NA	-0.38	-5.2	-0.3	3.96e-7	Mitral valve prolapse;
CESC	cis	rs2790457	0.958	rs2772432	chr10:28894295	G/A	cg04045419	chr10:28823091	WAC	-0.43	-5.16	-0.3	4.76e-7	Multiple myeloma;
CESC	trans	rs7656342	0.808	rs10003216	chr4:9766749	A/G	cg06772157	chr7:100728711	TRIM56	-0.53	-6.24	-0.36	1.68e-9	Gut microbiota (bacterial taxa);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16931877	chr3:32726605	CNOT10	0.64	7.16	0.4	7.98e-12	Gut microbiome composition (summer);
CESC	cis	rs6502050	0.626	rs11868521	chr17:80100195	T/G	cg23985595	chr17:80112537	CCDC57	0.36	5.18	0.3	4.33e-7	Life satisfaction;
CESC	cis	rs1055129	0.560	rs9891076	chr17:73911715	C/T	cg02678768	chr17:74002944	EVPL	0.42	5.93	0.34	9.62e-9	White matter hyperintensity burden;
CESC	cis	rs10870270	0.956	rs10870281	chr10:133762642	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.87	-12.75	-0.62	2.25e-29	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09882061	chr5:175874675	FAF2	0.59	6.56	0.37	2.75e-10	Gut microbiome composition (summer);
CESC	cis	rs6860806	0.507	rs635619	chr5:131720265	G/A	cg18758796	chr5:131593413	PDLIM4	-0.41	-5.74	-0.33	2.61e-8	Breast cancer;
CESC	cis	rs17253792	0.822	rs113692713	chr14:56087424	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.76	5.39	0.31	1.56e-7	Putamen volume;
CESC	cis	rs5753037	0.653	rs140133	chr22:30152522	G/C	cg01021169	chr22:30184971	ASCC2	-0.44	-6.21	-0.36	2.09e-9	Type 1 diabetes;
CESC	cis	rs7116495	0.737	rs661290	chr11:71766014	A/G	cg26138937	chr11:71823887	C11orf51	-1.18	-7.09	-0.4	1.25e-11	Severe influenza A (H1N1) infection;
CESC	cis	rs6466055	0.720	rs35757884	chr7:105020534	G/T	cg04380332	chr7:105027541	SRPK2	-0.42	-5.36	-0.31	1.81e-7	Schizophrenia;
CESC	cis	rs1448094	0.512	rs56082822	chr12:86255475	C/T	cg19622623	chr12:86230825	RASSF9	-0.48	-6.11	-0.35	3.64e-9	Major depressive disorder;
CESC	cis	rs4713118	0.629	rs172165	chr6:28020814	T/G	cg12963246	chr6:28129442	ZNF389	0.49	6.34	0.36	9.71e-10	Parkinson's disease;
CESC	cis	rs9291683	0.588	rs2240724	chr4:10021290	G/C	cg11266682	chr4:10021025	SLC2A9	0.71	14.8	0.67	1.56e-36	Bone mineral density;
CESC	cis	rs8180040	0.701	rs13066214	chr3:47033937	C/T	cg27129171	chr3:47204927	SETD2	0.67	9.93	0.52	5.88e-20	Colorectal cancer;
CESC	cis	rs4975709	0.589	rs4975707	chr5:1864028	C/T	cg19770292	chr5:1868693	NA	0.3	5.18	0.3	4.47e-7	Cardiovascular disease risk factors;
CESC	cis	rs4835473	0.932	rs6813011	chr4:144835649	G/T	cg25736465	chr4:144833511	NA	0.41	6.21	0.36	2.09e-9	Immature fraction of reticulocytes;
CESC	cis	rs5417	0.788	rs2654185	chr17:7183362	G/T	cg25256661	chr17:7137939	DVL2	0.53	7.3	0.41	3.27e-12	Diastolic blood pressure;
CESC	cis	rs3106136	0.967	rs4693377	chr4:95157256	G/C	cg11021082	chr4:95130006	SMARCAD1	-0.46	-6.98	-0.39	2.33e-11	Capecitabine sensitivity;
CESC	cis	rs1008375	0.966	rs2315553	chr4:17627332	T/C	cg04450456	chr4:17643702	FAM184B	0.38	5.44	0.32	1.2e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs10504229	0.906	rs113857287	chr8:58191683	T/C	cg22535103	chr8:58192502	C8orf71	-1.06	-13.14	-0.63	1.04e-30	Developmental language disorder (linguistic errors);
CESC	cis	rs4665809	1.000	rs4665309	chr2:26335502	T/C	cg22920501	chr2:26401640	FAM59B	-0.67	-8.09	-0.44	2.22e-14	Gut microbiome composition (summer);
CESC	cis	rs1707322	0.686	rs1541131	chr1:46084934	G/A	cg06784218	chr1:46089804	CCDC17	-0.41	-7.15	-0.4	8.63e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs2908835	0.705	rs35428220	chr12:11644192	G/T	cg09915232	chr8:1879280	ARHGEF10	-0.64	-6.26	-0.36	1.52e-9	Information processing speed;
CESC	cis	rs17641971	0.684	rs4873100	chr8:50025772	G/A	cg00325661	chr8:49890786	NA	0.38	5.35	0.31	1.9e-7	Blood metabolite levels;
CESC	cis	rs262150	0.837	rs2657404	chr7:158783155	C/T	cg09640425	chr7:158790006	NA	-0.4	-6.44	-0.37	5.44e-10	Facial morphology (factor 20);
CESC	cis	rs72781680	0.566	rs72796106	chr2:23901362	A/C	cg20701182	chr2:24300061	SF3B14	0.75	7.56	0.42	6.46e-13	Lymphocyte counts;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg22185043	chr18:12947723	SEH1L	-0.44	-6.1	-0.35	3.72e-9	Fibrinogen levels;
CESC	cis	rs9815354	0.812	rs73077359	chr3:41850016	G/A	cg03022575	chr3:42003672	ULK4	0.7	6.04	0.35	5.26e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs9859260	0.744	rs492288	chr3:195784210	C/T	cg12923728	chr3:195709715	SDHAP1	0.54	6.96	0.39	2.68e-11	Mean corpuscular volume;
CESC	cis	rs9906944	0.864	rs9902512	chr17:47094274	C/G	cg09029085	chr17:47094198	IGF2BP1	0.26	5.11	0.3	6.12e-7	Intelligence (multi-trait analysis);Body fat percentage;
CESC	cis	rs60871478	0.636	rs61441144	chr7:897784	C/T	cg13798912	chr7:905769	UNC84A	-0.54	-5.43	-0.32	1.29e-7	Cerebrospinal P-tau181p levels;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg27491609	chr17:62779607	LOC146880	0.47	6.6	0.38	2.17e-10	Fibrinogen levels;
CESC	cis	rs28673728	0.868	rs28380108	chr1:38409103	G/C	cg04673462	chr1:38461896	NA	0.39	5.92	0.34	9.68e-9	Red cell distribution width;
CESC	cis	rs9611565	0.512	rs5758436	chr22:42124265	C/T	cg06634786	chr22:41940651	POLR3H	0.65	6.57	0.37	2.6200000000000003e-10	Vitiligo;
CESC	cis	rs4474465	1.000	rs11237500	chr11:78163636	G/A	cg02023728	chr11:77925099	USP35	0.39	5.04	0.3	8.78e-7	Alzheimer's disease (survival time);
CESC	cis	rs8177253	1.000	rs8177272	chr3:133482870	C/T	cg11941060	chr3:133502564	NA	-0.47	-6.33	-0.36	1.04e-9	Iron status biomarkers;
CESC	cis	rs922692	0.715	rs11072803	chr15:79077878	G/A	cg04896959	chr15:78267971	NA	0.35	5.1	0.3	6.61e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
CESC	cis	rs10751667	0.666	rs7936830	chr11:959686	A/G	cg01483505	chr11:975446	AP2A2	0.37	5.09	0.3	6.77e-7	Alzheimer's disease (late onset);
CESC	cis	rs12220238	1.000	rs10824088	chr10:75921490	G/C	cg19889307	chr10:75911429	ADK;AP3M1	0.64	6.09	0.35	4.01e-9	Soluble interleukin-2 receptor subunit alpha;
CESC	cis	rs6714710	0.603	rs2278700	chr2:98427382	T/C	cg26665480	chr2:98280029	ACTR1B	0.56	7.96	0.44	5.02e-14	Posterior cortical atrophy and Alzheimer's disease;
CESC	trans	rs916888	0.821	rs199514	chr17:44856881	G/A	cg01341218	chr17:43662625	NA	-0.87	-10.48	-0.54	9.93e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17482391	chr1:110881020	RBM15	0.52	6.14	0.35	3.06e-9	Gut microbiome composition (summer);
CESC	cis	rs561341	1.000	rs561341	chr17:30316385	T/G	cg00745463	chr17:30367425	LRRC37B	-0.78	-7.09	-0.4	1.2e-11	Hip circumference adjusted for BMI;
CESC	cis	rs1552244	0.882	rs17050660	chr3:10001772	A/G	cg00166722	chr3:10149974	C3orf24	-0.45	-5.94	-0.34	8.84e-9	Alzheimer's disease;
CESC	cis	rs9916302	0.904	rs2061342	chr17:37405657	T/G	cg00129232	chr17:37814104	STARD3	-0.57	-7.33	-0.41	2.77e-12	Glomerular filtration rate (creatinine);
CESC	cis	rs8114671	0.562	rs6088655	chr20:33527838	A/G	cg06115741	chr20:33292138	TP53INP2	0.48	5.78	0.33	2.13e-8	Height;
CESC	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	10.31	0.54	3.45e-21	Prudent dietary pattern;
CESC	cis	rs896854	0.967	rs13257021	chr8:95965695	A/G	cg16049864	chr8:95962084	TP53INP1	-0.69	-12.32	-0.6	6.82e-28	Type 2 diabetes;
CESC	cis	rs40363	0.723	rs8060367	chr16:3537919	C/A	cg22508957	chr16:3507546	NAT15	-0.69	-7.52	-0.42	8.76e-13	Tuberculosis;
CESC	cis	rs9303401	0.580	rs34076823	chr17:57114497	C/G	cg12560992	chr17:57184187	TRIM37	0.5	5.2	0.3	3.94e-7	Cognitive test performance;
CESC	cis	rs6594713	0.717	rs17331844	chr5:112914426	G/T	cg12552261	chr5:112820674	MCC	0.57	5.55	0.32	6.94e-8	Brain cytoarchitecture;
CESC	trans	rs7656342	0.808	rs10003216	chr4:9766749	A/G	cg23965352	chr5:92603043	NA	-0.46	-6.25	-0.36	1.59e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs2294693	0.947	rs9349176	chr6:40989525	C/T	cg14769373	chr6:40998127	UNC5CL	-0.47	-6.59	-0.38	2.41e-10	Gastric cancer;Non-cardia gastric cancer;
CESC	cis	rs13108904	0.517	rs13128825	chr4:1334007	G/A	cg22903657	chr4:1355424	KIAA1530	-0.4	-5.67	-0.33	3.82e-8	Obesity-related traits;
CESC	cis	rs9457247	0.967	rs1187532	chr6:167382020	G/A	cg23791538	chr6:167370224	RNASET2	-0.6	-8.65	-0.47	5.12e-16	Crohn's disease;
CESC	trans	rs3780486	1.000	rs10813951	chr9:33128021	C/T	cg04842962	chr6:43655489	MRPS18A	-0.91	-13.82	-0.65	4.43e-33	IgG glycosylation;
CESC	cis	rs739401	0.595	rs6578305	chr11:3001120	C/T	cg08508325	chr11:3079039	CARS	-0.49	-9.26	-0.49	7.24e-18	Longevity;
CESC	cis	rs6754311	0.731	rs12615624	chr2:136721603	A/G	cg15123519	chr2:136567270	LCT	-0.3	-5.16	-0.3	4.95e-7	Mosquito bite size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14105000	chr17:55193516	AKAP1	-0.54	-6.59	-0.38	2.37e-10	Gut microbiome composition (summer);
CESC	cis	rs7772486	0.875	rs2207785	chr6:146332784	T/G	cg23711669	chr6:146136114	FBXO30	0.81	11.57	0.58	2.49e-25	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7666738	0.830	rs13124689	chr4:98961182	A/T	cg03676636	chr4:99064102	C4orf37	0.33	5.14	0.3	5.39e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6460942	0.915	rs1595802	chr7:12439672	C/T	cg10578991	chr7:12443926	VWDE	-0.45	-5.11	-0.3	6.15e-7	Coronary artery disease;
CESC	cis	rs902774	0.597	rs7299694	chr12:53352572	A/C	cg25025879	chr12:53359317	NA	-0.48	-6.35	-0.36	9.47e-10	Prostate cancer;
CESC	trans	rs208520	0.661	rs1100950	chr6:66827285	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.0	-12.85	-0.62	1.09e-29	Exhaled nitric oxide output;
CESC	cis	rs5760092	0.618	rs4461358	chr22:24260106	T/C	cg09033563	chr22:24373618	LOC391322	0.48	5.8	0.34	1.89e-8	Urinary 1,3-butadiene metabolite levels in smokers;
CESC	cis	rs113835537	0.529	rs2279865	chr11:66203025	A/C	cg24851651	chr11:66362959	CCS	0.46	5.99	0.35	6.96e-9	Airway imaging phenotypes;
CESC	cis	rs9443645	0.901	rs7767100	chr6:79810533	A/C	cg05283184	chr6:79620031	NA	-0.43	-6.66	-0.38	1.56e-10	Intelligence (multi-trait analysis);
CESC	cis	rs10540	0.908	rs71487293	chr11:486414	G/A	cg03352830	chr11:487213	PTDSS2	0.7	6.71	0.38	1.16e-10	Body mass index;
CESC	cis	rs10504229	0.593	rs77607045	chr8:58010464	T/C	cg24829409	chr8:58192753	C8orf71	-0.67	-7.32	-0.41	3e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs9733	0.596	rs12403255	chr1:150660412	C/T	cg22823121	chr1:150693482	HORMAD1	0.49	7.19	0.4	6.7e-12	Tonsillectomy;
CESC	cis	rs7618915	0.547	rs11709448	chr3:52647449	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	6.89	0.39	4.08e-11	Bipolar disorder;
CESC	cis	rs4566357	0.615	rs2272200	chr2:227912331	G/A	cg05526886	chr2:227700861	RHBDD1	-0.46	-6.15	-0.35	2.81e-9	Coronary artery disease;
CESC	cis	rs9527	0.571	rs10786715	chr10:104620735	G/C	cg04362960	chr10:104952993	NT5C2	0.47	6.01	0.35	6e-9	Arsenic metabolism;
CESC	cis	rs9649213	0.593	rs13307593	chr7:97986146	A/G	cg00277769	chr7:97922759	BAIAP2L1	-0.33	-5.41	-0.32	1.41e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs4253772	0.591	rs7286155	chr22:46714735	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.66	6.3	0.36	1.2e-9	LDL cholesterol;Cholesterol, total;
CESC	cis	rs9303401	0.659	rs72828726	chr17:56951217	C/G	cg02118635	chr17:56770003	RAD51C;TEX14	1.01	12.79	0.62	1.74e-29	Cognitive test performance;
CESC	cis	rs10751667	0.666	rs6597958	chr11:978087	C/T	cg06064525	chr11:970664	AP2A2	-0.47	-9.12	-0.49	1.9e-17	Alzheimer's disease (late onset);
CESC	cis	rs36051895	0.632	rs12115301	chr9:5180548	A/G	cg02405213	chr9:5042618	JAK2	0.5	6.08	0.35	4.27e-9	Pediatric autoimmune diseases;
CESC	cis	rs365132	0.967	rs11740768	chr5:176339499	G/A	cg16309518	chr5:176445507	NA	-0.41	-6.03	-0.35	5.49e-9	Menarche and menopause (age at onset);Menopause (age at onset);
CESC	cis	rs17253792	0.545	rs35294669	chr14:56017438	T/A	cg01858014	chr14:56050164	KTN1	-0.87	-6.37	-0.36	8.34e-10	Putamen volume;
CESC	cis	rs3752962	0.569	rs12451788	chr17:1941048	C/T	cg24156229	chr17:1948635	NA	0.62	9.57	0.51	7.82e-19	Itch intensity from mosquito bite;
CESC	cis	rs11674184	0.714	rs9789525	chr2:11724580	G/T	cg07314298	chr2:11723111	GREB1	-0.66	-10.06	-0.53	2.28e-20	Endometriosis;
CESC	cis	rs4727027	0.866	rs35599790	chr7:148806012	C/T	cg23583168	chr7:148888333	NA	-0.79	-12.1	-0.6	4.02e-27	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs9611565	0.592	rs4822038	chr22:41958495	G/A	cg06634786	chr22:41940651	POLR3H	-0.69	-6.9	-0.39	3.9e-11	Vitiligo;
CESC	cis	rs1218582	0.772	rs7528532	chr1:154874440	C/T	cg03351412	chr1:154909251	PMVK	0.69	9.39	0.5	2.91e-18	Prostate cancer;
CESC	cis	rs7481584	0.926	rs12806061	chr11:3008404	G/A	cg25174290	chr11:3078921	CARS	-0.49	-6.08	-0.35	4.07e-9	Calcium levels;
CESC	cis	rs875971	0.545	rs11766183	chr7:65839160	G/C	cg25405998	chr7:65216604	CCT6P1	0.51	5.52	0.32	8.13e-8	Aortic root size;
CESC	cis	rs2230307	0.536	rs506044	chr1:100611931	A/G	cg24955406	chr1:100503596	HIAT1	-0.49	-5.18	-0.3	4.29e-7	Carotid intima media thickness;
CESC	cis	rs1178968	0.818	rs2108235	chr7:72783383	A/G	cg25889504	chr7:72793014	NA	0.44	5.07	0.3	7.38e-7	Triglyceride levels;
CESC	cis	rs6912958	0.559	rs242267	chr6:88061837	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.35	-5.64	-0.33	4.43e-8	Monocyte percentage of white cells;
CESC	cis	rs3820068	0.580	rs7556473	chr1:15996858	C/T	cg18133145	chr1:16060689	PLEKHM2	0.47	5.9	0.34	1.12e-8	Systolic blood pressure;
CESC	cis	rs13256369	0.802	rs12541520	chr8:8564146	G/T	cg17143192	chr8:8559678	CLDN23	0.76	9.02	0.48	3.85e-17	Obesity-related traits;
CESC	cis	rs7949030	0.591	rs35156678	chr11:62369881	G/A	cg11742103	chr11:62369870	EML3;MTA2	0.65	9.46	0.5	1.69e-18	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs2115536	1.000	rs11072871	chr15:80197931	T/C	cg00225070	chr15:80189496	MTHFS	0.54	7.26	0.41	4.41e-12	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CESC	cis	rs9911578	1.000	rs2333332	chr17:56631054	A/G	cg05425664	chr17:57184151	TRIM37	0.5	6.93	0.39	3.29e-11	Intelligence (multi-trait analysis);
CESC	cis	rs1005277	0.505	rs13503	chr10:38239843	C/A	cg25427524	chr10:38739819	LOC399744	0.71	10.68	0.55	2.25e-22	Extrinsic epigenetic age acceleration;
CESC	cis	rs6446731	0.734	rs9996868	chr4:3275484	C/T	cg08886695	chr4:3369023	RGS12	-0.36	-5.16	-0.3	4.83e-7	Mean platelet volume;
CESC	cis	rs8050907	0.744	rs77430528	chr16:4523389	T/C	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.89	5.66	0.33	3.84e-8	Obesity-related traits;
CESC	cis	rs11148252	0.532	rs9536190	chr13:53181044	T/C	cg00495681	chr13:53174319	NA	0.67	9.12	0.49	1.99e-17	Lewy body disease;
CESC	cis	rs8062405	1.000	rs3088215	chr16:28853996	A/C	cg08761264	chr16:28874980	SH2B1	-0.47	-5.85	-0.34	1.42e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs6973256	0.543	rs13243553	chr7:133506955	A/G	cg10665199	chr7:133106180	EXOC4	-0.44	-5.95	-0.34	8.63e-9	Intelligence (multi-trait analysis);
CESC	cis	rs4664304	1.000	rs6735923	chr2:160769588	A/G	cg03641300	chr2:160917029	PLA2R1	-0.48	-6.78	-0.38	7.98e-11	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs3126085	0.544	rs3126074	chr1:152279841	G/C	cg03465714	chr1:152285911	FLG	0.43	5.2	0.3	3.91e-7	Atopic dermatitis;
CESC	cis	rs425277	0.583	rs4648807	chr1:2040898	A/G	cg19257562	chr1:2043853	PRKCZ	0.34	5.66	0.33	3.9e-8	Height;
CESC	cis	rs78132593	0.796	rs72992015	chr1:150842696	C/T	cg04414720	chr1:150670196	GOLPH3L	-0.53	-5.28	-0.31	2.72e-7	High light scatter reticulocyte count;
CESC	cis	rs858239	0.600	rs59073109	chr7:23133226	C/A	cg23682824	chr7:23144976	KLHL7	0.54	7.34	0.41	2.63e-12	Cerebrospinal fluid biomarker levels;
CESC	cis	rs1862618	0.671	rs173763	chr5:56225418	G/A	cg24531977	chr5:56204891	C5orf35	-0.67	-9.25	-0.49	7.78e-18	Initial pursuit acceleration;
CESC	cis	rs4822044	0.560	rs7284839	chr22:42010902	C/T	cg17376030	chr22:41985996	PMM1	-0.8	-8.91	-0.48	8.57e-17	Cannabis dependence symptom count;
CESC	cis	rs10504229	1.000	rs111915672	chr8:58191665	T/C	cg24829409	chr8:58192753	C8orf71	-0.77	-10.02	-0.52	2.95e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs367943	0.712	rs26968	chr5:112742429	A/G	cg12552261	chr5:112820674	MCC	0.4	5.35	0.31	1.89e-7	Type 2 diabetes;
CESC	cis	rs11122272	0.735	rs2066140	chr1:231504311	C/G	cg06096015	chr1:231504339	EGLN1	0.42	6.26	0.36	1.56e-9	Hemoglobin concentration;
CESC	cis	rs9287719	0.967	rs2110778	chr2:10748970	A/T	cg02196655	chr2:10830764	NOL10	-0.38	-5.79	-0.34	1.96e-8	Prostate cancer;
CESC	cis	rs6691722	0.583	rs35671964	chr1:24695749	C/G	cg02336364	chr1:24764700	NIPAL3	0.29	5.79	0.34	1.95e-8	Response to interferon beta in multiple sclerosis;
CESC	cis	rs6964587	0.839	rs6952459	chr7:91435820	T/A	cg17063962	chr7:91808500	NA	0.49	6.21	0.36	1.99e-9	Breast cancer;
CESC	cis	rs35160687	0.623	rs7569654	chr2:86478022	C/T	cg01119172	chr2:86362222	SNORD94;PTCD3	-0.39	-5.18	-0.3	4.5e-7	Night sleep phenotypes;
CESC	cis	rs116095464	0.558	rs9687898	chr5:253952	A/G	cg22496380	chr5:211416	CCDC127	-0.73	-8.39	-0.46	2.99e-15	Breast cancer;
CESC	cis	rs17376456	0.877	rs9314099	chr5:93447375	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.62	5.44	0.32	1.23e-7	Diabetic retinopathy;
CESC	cis	rs10463316	0.894	rs7707964	chr5:150765475	C/T	cg03212797	chr5:150827313	SLC36A1	-0.49	-6.4	-0.37	6.94e-10	Metabolite levels (Pyroglutamine);
CESC	cis	rs2734839	0.537	rs10891549	chr11:113278447	T/C	cg14159747	chr11:113255604	NA	0.36	6.48	0.37	4.52e-10	Information processing speed;
CESC	cis	rs748404	0.697	rs579651	chr15:43558376	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	7.84	0.43	1.08e-13	Lung cancer;
CESC	cis	rs8141529	0.509	rs5762863	chr22:29253335	A/C	cg15103426	chr22:29168792	CCDC117	0.63	8.51	0.46	1.29e-15	Lymphocyte counts;
CESC	cis	rs2841277	0.708	rs9671643	chr14:105408030	A/G	cg17340268	chr14:105411764	AHNAK2	-0.51	-6.84	-0.39	5.32e-11	Rheumatoid arthritis;
CESC	cis	rs5769765	0.955	rs5769761	chr22:50263641	G/T	cg02269571	chr22:50332266	NA	0.46	6.28	0.36	1.39e-9	Schizophrenia;
CESC	cis	rs854765	0.583	rs12452219	chr17:17829423	C/T	cg04398451	chr17:18023971	MYO15A	-0.65	-9.11	-0.49	2.07e-17	Total body bone mineral density;
CESC	cis	rs734999	0.524	rs4648448	chr1:2695687	C/T	cg20673091	chr1:2541236	MMEL1	0.48	7.76	0.43	1.89e-13	Ulcerative colitis;
CESC	cis	rs7412746	0.611	rs7532045	chr1:150821847	G/A	cg22823121	chr1:150693482	HORMAD1	0.39	5.55	0.32	6.99e-8	Melanoma;
CESC	cis	rs523522	1.000	rs523522	chr12:121020250	A/T	cg27279351	chr12:120934652	DYNLL1	0.72	9.32	0.5	4.74e-18	High light scatter reticulocyte count;
CESC	trans	rs875971	0.660	rs801217	chr7:66010577	C/T	cg26939375	chr7:64535504	NA	-0.63	-8.63	-0.47	5.82e-16	Aortic root size;
CESC	cis	rs9612	0.664	rs164069	chr19:44260199	T/C	cg08581076	chr19:44259116	C19orf61	0.45	5.54	0.32	7.16e-8	Exhaled nitric oxide output;
CESC	cis	rs9311474	0.539	rs12489828	chr3:52567014	G/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.42	8.27	0.45	6.75e-15	Electroencephalogram traits;
CESC	cis	rs4660261	0.526	rs2906458	chr1:44336389	A/G	cg13606994	chr1:44402422	ARTN	0.38	5.75	0.33	2.41e-8	Intelligence (multi-trait analysis);
CESC	cis	rs9649213	0.593	rs7796611	chr7:97908223	A/G	cg08684580	chr7:98029266	BAIAP2L1	-0.33	-5.27	-0.31	2.82e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs10504229	0.871	rs10504227	chr8:58162005	G/A	cg22535103	chr8:58192502	C8orf71	-0.93	-11.66	-0.58	1.19e-25	Developmental language disorder (linguistic errors);
CESC	cis	rs8028182	0.636	rs62027209	chr15:75871626	A/G	cg20655648	chr15:75932815	IMP3	0.55	7.01	0.4	1.95e-11	Sudden cardiac arrest;
CESC	cis	rs365132	1.000	rs2292255	chr5:176334195	C/T	cg16309518	chr5:176445507	NA	-0.41	-6.02	-0.35	5.77e-9	Menarche and menopause (age at onset);Menopause (age at onset);
CESC	cis	rs7666738	0.830	rs36047842	chr4:99004902	C/A	cg18180107	chr4:99064573	C4orf37	0.4	5.23	0.31	3.41e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7429990	0.930	rs11130152	chr3:48056409	T/C	cg11946769	chr3:48343235	NME6	-0.43	-5.17	-0.3	4.63e-7	Educational attainment (years of education);
CESC	cis	rs6582630	0.555	rs10880607	chr12:38508184	A/G	cg26384229	chr12:38710491	ALG10B	0.72	10.68	0.55	2.17e-22	Drug-induced liver injury (flucloxacillin);
CESC	trans	rs2099077	0.737	rs12515712	chr5:102781210	G/T	cg07434438	chr16:72961899	ZFHX3	0.44	6.09	0.35	3.87e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs2795502	0.554	rs1620395	chr10:43341185	G/A	cg20628663	chr10:43360327	NA	-0.42	-5.76	-0.33	2.36e-8	Blood protein levels;
CESC	cis	rs2933343	1.000	rs2630252	chr3:128624772	T/C	cg25356066	chr3:128598488	ACAD9	0.59	7.16	0.4	7.76e-12	IgG glycosylation;
CESC	cis	rs9796	0.624	rs9920619	chr15:41318845	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.44	-6.17	-0.35	2.48e-9	Menopause (age at onset);
CESC	cis	rs75477785	1.000	rs10779514	chr1:209987624	C/T	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.92	6.04	0.35	5.06e-9	Cleft lip with or without cleft palate;
CESC	cis	rs4665809	0.590	rs1049987	chr2:26413817	C/T	cg25036284	chr2:26402008	FAM59B	0.84	9.47	0.5	1.61e-18	Gut microbiome composition (summer);
CESC	cis	rs4704187	0.687	rs10051572	chr5:74502797	G/A	cg03227963	chr5:74354835	NA	0.28	5.18	0.3	4.33e-7	Response to amphetamines;
CESC	cis	rs9457247	0.967	rs447042	chr6:167405435	C/T	cg07741184	chr6:167504864	NA	0.29	5.31	0.31	2.32e-7	Crohn's disease;
CESC	cis	rs9733	0.744	rs2089081	chr1:150800117	T/C	cg18016565	chr1:150552671	MCL1	-0.34	-5.62	-0.33	4.84e-8	Tonsillectomy;
CESC	cis	rs9916302	0.904	rs11078897	chr17:37415870	C/T	cg20243544	chr17:37824526	PNMT	0.47	5.83	0.34	1.64e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs5769765	0.954	rs5770739	chr22:50268014	C/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.46	5.32	0.31	2.21e-7	Schizophrenia;
CESC	cis	rs2073300	0.609	rs6137907	chr20:23344511	C/T	cg12062639	chr20:23401060	NAPB	0.98	7.59	0.42	5.37e-13	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs7552404	0.855	rs385897	chr1:76106962	T/C	cg22875332	chr1:76189707	ACADM	-0.64	-7.57	-0.42	6.05e-13	Blood metabolite levels;Acylcarnitine levels;
CESC	trans	rs1423617	1.000	rs1423617	chr5:50801564	G/A	cg04420932	chr11:67195621	RPS6KB2	0.55	6.01	0.35	6.1e-9	Childhood ear infection;
CESC	cis	rs7666738	0.800	rs28427190	chr4:98989106	A/G	cg05340658	chr4:99064831	C4orf37	0.8	12.42	0.61	3.09e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7933455	0.502	rs1385850	chr11:12234595	C/T	cg10383724	chr11:12228521	MICAL2	0.57	6.79	0.39	7.3e-11	Cold sores;
CESC	cis	rs6964587	0.900	rs4279	chr7:91764128	C/A	cg17063962	chr7:91808500	NA	0.58	8.09	0.45	2.09e-14	Breast cancer;
CESC	cis	rs6089584	0.888	rs2146853	chr20:60617908	A/T	cg06108461	chr20:60628389	TAF4	-0.92	-14.55	-0.67	1.22e-35	Body mass index;
CESC	cis	rs1559088	0.947	rs12461297	chr19:33559245	A/G	cg17764715	chr19:33622953	WDR88	0.47	5.82	0.34	1.67e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg16282910	chr9:112296723	NA	0.48	6.68	0.38	1.41e-10	Fibrinogen levels;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg19983870	chr19:56671579	ZNF444	0.47	6.14	0.35	3e-9	Fibrinogen levels;
CESC	cis	rs9733	0.596	rs3087960	chr1:150620569	C/G	cg09365446	chr1:150670422	GOLPH3L	0.42	5.86	0.34	1.4e-8	Tonsillectomy;
CESC	cis	rs12497850	1.000	rs10865952	chr3:48744484	A/G	cg06212747	chr3:49208901	KLHDC8B	0.62	8.15	0.45	1.41e-14	Parkinson's disease;
CESC	cis	rs9649465	1.000	rs9641715	chr7:123348623	A/G	cg04330084	chr7:123175371	IQUB	-0.38	-5.18	-0.3	4.46e-7	Migraine;
CESC	cis	rs2742234	0.541	rs11238490	chr10:43747598	G/A	cg03680517	chr10:43632967	CSGALNACT2	-0.41	-5.11	-0.3	6.15e-7	Hirschsprung disease;
CESC	cis	rs7666738	0.800	rs13106995	chr4:99028790	A/T	cg03467027	chr4:99064603	C4orf37	0.49	6.18	0.35	2.44e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7116495	1.000	rs17161991	chr11:71839960	T/C	cg26138937	chr11:71823887	C11orf51	0.78	6.22	0.36	1.98e-9	Severe influenza A (H1N1) infection;
CESC	cis	rs60871478	0.947	rs62432239	chr7:794576	C/T	cg05535760	chr7:792225	HEATR2	0.85	10.54	0.54	6.53e-22	Cerebrospinal P-tau181p levels;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg01383268	chr17:71088868	SLC39A11	-0.43	-6.16	-0.35	2.63e-9	Gambling;
CESC	cis	rs1862618	0.671	rs2591968	chr5:56233541	A/G	cg12311346	chr5:56204834	C5orf35	-0.64	-8.82	-0.48	1.55e-16	Initial pursuit acceleration;
CESC	trans	rs877282	0.891	rs12357999	chr10:796468	A/C	cg22713356	chr15:30763199	NA	1.32	13.47	0.64	7.47e-32	Uric acid levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01742680	chr3:152879841	RAP2B	0.59	7.25	0.41	4.65e-12	Gut microbiome composition (summer);
CESC	cis	rs2243480	1.000	rs316326	chr7:65609453	T/C	cg13147721	chr7:65941812	NA	-0.97	-9.14	-0.49	1.7e-17	Diabetic kidney disease;
CESC	cis	rs2625529	0.824	rs12906711	chr15:72215065	A/G	cg16672083	chr15:72433130	SENP8	-0.39	-5.07	-0.3	7.49e-7	Red blood cell count;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg26347379	chr8:99956585	OSR2	-0.47	-6.38	-0.36	7.79e-10	Fibrinogen levels;
CESC	cis	rs7116495	0.609	rs2155145	chr11:71719619	G/T	cg07596299	chr11:71824057	C11orf51	-0.82	-5.33	-0.31	2.13e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs9858542	0.953	rs6446272	chr3:49463287	G/A	cg03060546	chr3:49711283	APEH	-0.55	-6.21	-0.36	2.08e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs7828089	0.582	rs3817445	chr8:22266054	G/T	cg13512537	chr8:22265999	SLC39A14	-0.41	-5.76	-0.33	2.3e-8	Verbal declarative memory;
CESC	cis	rs9457247	0.765	rs1060404	chr6:167429467	A/G	cg23791538	chr6:167370224	RNASET2	-0.54	-7.46	-0.42	1.26e-12	Crohn's disease;
CESC	cis	rs1005277	0.579	rs1985707	chr10:38434098	C/T	cg25517755	chr10:38738941	LOC399744	-0.49	-6.35	-0.36	9.09e-10	Extrinsic epigenetic age acceleration;
CESC	cis	rs7914558	0.966	rs10786725	chr10:104682357	T/C	cg08650961	chr10:104748594	CNNM2	0.32	5.12	0.3	5.86e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs853679	0.517	rs868987	chr6:28110148	A/G	cg12963246	chr6:28129442	ZNF389	-0.59	-7.87	-0.44	9.36e-14	Depression;
CESC	cis	rs4319547	0.626	rs10744210	chr12:122931793	A/G	cg23029597	chr12:123009494	RSRC2	-0.45	-5.08	-0.3	7.04e-7	Body mass index;
CESC	cis	rs1448094	0.512	rs7309500	chr12:86249647	C/T	cg02569458	chr12:86230093	RASSF9	0.48	7.18	0.4	6.9e-12	Major depressive disorder;
CESC	cis	rs1904096	0.506	rs10034781	chr4:95169682	A/C	cg11021082	chr4:95130006	SMARCAD1	0.62	9.54	0.51	9.85e-19	Type 2 diabetes;
CESC	cis	rs10504073	0.647	rs10435612	chr8:49993696	A/T	cg00325661	chr8:49890786	NA	0.55	8.17	0.45	1.29e-14	Blood metabolite ratios;
CESC	cis	rs7546094	0.875	rs1110043	chr1:113236421	G/A	cg22162597	chr1:113214053	CAPZA1	-0.35	-5.15	-0.3	5.05e-7	Platelet distribution width;
CESC	cis	rs28386778	0.700	rs11079515	chr17:62005645	C/G	cg26338869	chr17:61819248	STRADA	-0.62	-7.86	-0.43	9.7e-14	Prudent dietary pattern;
CESC	cis	rs3785574	0.962	rs2584621	chr17:61912436	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.57	7.05	0.4	1.57e-11	Height;
CESC	cis	rs67460515	0.892	rs34771618	chr3:161059795	A/C	cg03342759	chr3:160939853	NMD3	-0.54	-7.83	-0.43	1.17e-13	Parkinson's disease;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg03758392	chr3:184870408	C3orf70	0.48	6.69	0.38	1.28e-10	Systemic lupus erythematosus;
CESC	cis	rs7666738	0.830	rs28451001	chr4:98924544	T/A	cg17366294	chr4:99064904	C4orf37	0.6	8.23	0.45	8.65e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs506597	0.920	rs221803	chr7:100291200	C/T	cg10426581	chr7:100472382	SRRT	-0.72	-5.39	-0.31	1.53e-7	Pursuit maintenance gain in psychotic disorders;
CESC	cis	rs116095464	0.614	rs28736753	chr5:274081	G/A	cg20965017	chr5:231967	SDHA	-0.49	-5.39	-0.31	1.59e-7	Breast cancer;
CESC	cis	rs4253772	0.515	rs77797820	chr22:46771270	C/T	cg00784671	chr22:46762841	CELSR1	-0.71	-6.0	-0.35	6.48e-9	LDL cholesterol;Cholesterol, total;
CESC	cis	rs6461049	0.765	rs1476887	chr7:2151633	T/C	cg23048001	chr7:2026167	MAD1L1	0.45	5.8	0.34	1.85e-8	Schizophrenia;
CESC	cis	rs853679	0.517	rs55747925	chr6:28044337	T/C	cg19592336	chr6:28129416	ZNF389	0.6	7.97	0.44	4.69e-14	Depression;
CESC	cis	rs10504229	0.906	rs56130194	chr8:58197061	C/A	cg05313129	chr8:58192883	C8orf71	-0.56	-5.84	-0.34	1.56e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs9488822	0.676	rs12190737	chr6:116328128	C/A	cg15226275	chr6:116381976	FRK	0.24	6.16	0.35	2.73e-9	Cholesterol, total;LDL cholesterol;
CESC	cis	rs4819052	0.851	rs2838837	chr21:46665988	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.75	10.01	0.52	3.17e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19731367	chr10:95256484	CEP55	0.55	6.6	0.38	2.26e-10	Gut microbiome composition (summer);
CESC	cis	rs1401999	1.000	rs1401999	chr3:183678342	C/G	cg01324343	chr3:183735012	ABCC5	0.63	13.53	0.64	4.5e-32	Anterior chamber depth;
CESC	cis	rs7772486	0.806	rs4075696	chr6:146250947	T/C	cg23711669	chr6:146136114	FBXO30	-0.77	-10.89	-0.56	4.58e-23	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1552244	0.872	rs115331527	chr3:10154504	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.88	12.1	0.6	3.86e-27	Alzheimer's disease;
CESC	cis	rs11098499	0.619	rs28502463	chr4:120257023	T/C	cg09307838	chr4:120376055	NA	0.81	10.94	0.56	3.14e-23	Corneal astigmatism;
CESC	cis	rs11098499	0.954	rs2389802	chr4:120325732	C/A	cg24375607	chr4:120327624	NA	0.46	5.79	0.34	2e-8	Corneal astigmatism;
CESC	cis	rs2562152	0.706	rs216596	chr16:105320	A/G	cg02949481	chr16:131562	MPG	0.52	5.73	0.33	2.69e-8	Glioblastoma;
CESC	cis	rs7666738	0.830	rs4699595	chr4:99012827	A/G	cg17366294	chr4:99064904	C4orf37	0.6	8.62	0.47	6.37e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs561341	1.000	rs2470267	chr17:30274132	G/A	cg00745463	chr17:30367425	LRRC37B	-0.68	-6.78	-0.38	7.66e-11	Hip circumference adjusted for BMI;
CESC	cis	rs1552244	0.688	rs7645137	chr3:10020549	A/AT	cg02579736	chr3:10068473	FANCD2;CIDECP	0.89	11.62	0.58	1.68e-25	Alzheimer's disease;
CESC	cis	rs12477438	0.520	rs13030961	chr2:99799520	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.85	15.86	0.7	2.83e-40	Chronic sinus infection;
CESC	cis	rs28374715	0.617	rs16971733	chr15:41562030	C/A	cg18705301	chr15:41695430	NDUFAF1	-0.53	-7.59	-0.42	5.57e-13	Ulcerative colitis;
CESC	cis	rs2070488	0.745	rs7649153	chr3:38467753	T/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.68	8.89	0.48	9.74e-17	Electrocardiographic conduction measures;
CESC	cis	rs9815354	1.000	rs114960066	chr3:41882323	A/G	cg03022575	chr3:42003672	ULK4	0.45	5.29	0.31	2.59e-7	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs2070677	0.935	rs11101885	chr10:135417088	T/C	cg20169779	chr10:135381914	SYCE1	-0.72	-9.59	-0.51	6.83e-19	Gout;
CESC	cis	rs10461617	0.541	rs832575	chr5:56161787	C/T	cg24531977	chr5:56204891	C5orf35	-0.75	-7.53	-0.42	7.95e-13	Type 2 diabetes;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg06169648	chr16:85646832	KIAA0182	0.49	6.1	0.35	3.7e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs17376456	0.825	rs28645862	chr5:93233128	G/C	cg25358565	chr5:93447407	FAM172A	1.09	10.53	0.54	6.82e-22	Diabetic retinopathy;
CESC	cis	rs7216064	1.000	rs62085992	chr17:65923083	T/A	cg12091567	chr17:66097778	LOC651250	-0.8	-8.08	-0.44	2.31e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs929596	0.785	rs11695484	chr2:234654449	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.7	-8.81	-0.48	1.64e-16	Total bilirubin levels in HIV-1 infection;
CESC	cis	rs6582630	0.537	rs1851124	chr12:38516404	G/A	cg13010199	chr12:38710504	ALG10B	0.49	6.43	0.37	6.06e-10	Drug-induced liver injury (flucloxacillin);
CESC	trans	rs11098499	0.863	rs11723090	chr4:120490592	T/C	cg25214090	chr10:38739885	LOC399744	0.65	8.73	0.47	2.86e-16	Corneal astigmatism;
CESC	cis	rs9287719	0.934	rs10181806	chr2:10741141	A/G	cg00105475	chr2:10696890	NA	0.39	5.64	0.33	4.44e-8	Prostate cancer;
CESC	cis	rs2247341	1.000	rs3958122	chr4:1693931	C/T	cg07465881	chr4:1713556	SLBP	-0.53	-6.85	-0.39	5.23e-11	Hip circumference adjusted for BMI;Height;
CESC	cis	rs1008375	0.843	rs59112113	chr4:17685336	A/T	cg16339924	chr4:17578868	LAP3	0.5	6.47	0.37	4.69e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs116095464	0.614	rs78905930	chr5:246560	G/A	cg22496380	chr5:211416	CCDC127	-0.79	-9.2	-0.49	1.07e-17	Breast cancer;
CESC	cis	rs909674	0.818	rs5757680	chr22:39844793	C/T	cg02038168	chr22:39784481	NA	0.57	7.05	0.4	1.52e-11	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs1552244	0.882	rs13099136	chr3:10031431	G/A	cg08888203	chr3:10149979	C3orf24	0.48	6.06	0.35	4.71e-9	Alzheimer's disease;
CESC	cis	rs1059312	0.808	rs12831705	chr12:129294905	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.87	-13.01	-0.62	3.07e-30	Systemic lupus erythematosus;
CESC	cis	rs13256369	1.000	rs13256369	chr8:8577379	T/C	cg00074818	chr8:8560427	CLDN23	0.36	5.35	0.31	1.89e-7	Obesity-related traits;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg02576092	chr1:27668556	SYTL1	-0.42	-6.28	-0.36	1.39e-9	Gambling;
CESC	cis	rs6570726	0.935	rs9390329	chr6:145828026	T/C	cg23711669	chr6:146136114	FBXO30	0.78	11.62	0.58	1.64e-25	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6088580	0.634	rs62212172	chr20:32987705	G/A	cg24642439	chr20:33292090	TP53INP2	-0.52	-6.9	-0.39	3.82e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs832540	0.618	rs41106	chr5:56145057	G/T	cg24531977	chr5:56204891	C5orf35	-0.49	-6.0	-0.35	6.46e-9	Coronary artery disease;
CESC	cis	rs10504229	0.531	rs55923836	chr8:57999127	A/G	cg24829409	chr8:58192753	C8orf71	-0.42	-5.5	-0.32	8.75e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs2549003	1.000	rs7701588	chr5:131819970	T/C	cg00255919	chr5:131827918	IRF1	0.51	8.59	0.47	7.76e-16	Asthma (sex interaction);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg09656405	chr15:69745057	RPLP1	-0.44	-6.25	-0.36	1.6e-9	Gambling;
CESC	cis	rs6461049	0.800	rs3800913	chr7:2163237	A/G	cg08027265	chr7:2291960	NA	-0.41	-6.34	-0.36	9.6e-10	Schizophrenia;
CESC	cis	rs7208859	0.673	rs73277967	chr17:29184166	T/A	cg19761014	chr17:28927070	LRRC37B2	0.72	5.71	0.33	3.06e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs2455799	0.613	rs2470547	chr3:15737610	T/C	cg16303742	chr3:15540471	COLQ	-0.36	-5.63	-0.33	4.5e-8	Mean platelet volume;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg22879676	chr17:81009871	B3GNTL1	-0.46	-6.09	-0.35	3.86e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs17685	0.587	rs1623759	chr7:75724679	A/T	cg19862616	chr7:65841803	NCRNA00174	0.87	12.7	0.62	3.58e-29	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs60154123	0.772	rs845452	chr1:210417861	C/T	cg22029157	chr1:209979665	IRF6	0.52	5.89	0.34	1.15e-8	Coronary artery disease;
CESC	cis	rs796364	0.806	rs11694236	chr2:200916230	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.85	-7.93	-0.44	6.07e-14	Schizophrenia;
CESC	cis	rs9660180	0.967	rs11260623	chr1:1781456	G/T	cg13866156	chr1:1669148	SLC35E2	-0.5	-6.62	-0.38	1.97e-10	Body mass index;
CESC	cis	rs7772486	0.875	rs9403763	chr6:146357655	A/G	cg23711669	chr6:146136114	FBXO30	0.85	12.46	0.61	2.27e-28	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs977987	0.966	rs8055490	chr16:75497135	C/T	cg03315344	chr16:75512273	CHST6	0.54	7.91	0.44	6.89e-14	Dupuytren's disease;
CESC	cis	rs8020095	0.571	rs8012660	chr14:67300671	T/A	cg19548862	chr14:67692701	FAM71D	-0.48	-5.87	-0.34	1.27e-8	Depression (quantitative trait);
CESC	cis	rs10504229	1.000	rs57941207	chr8:58169821	A/G	cg22535103	chr8:58192502	C8orf71	-1.04	-12.83	-0.62	1.26e-29	Developmental language disorder (linguistic errors);
CESC	cis	rs9291683	0.645	rs11557743	chr4:10118377	C/G	cg00071950	chr4:10020882	SLC2A9	-0.52	-8.1	-0.45	1.96e-14	Bone mineral density;
CESC	cis	rs16866061	0.517	rs7580488	chr2:225473263	C/T	cg12698349	chr2:225449008	CUL3	0.47	6.16	0.35	2.69e-9	Acute graft versus host disease in bone marrow transplantation (recipient effect);
CESC	cis	rs13256369	0.851	rs11249889	chr8:8564992	G/T	cg17143192	chr8:8559678	CLDN23	0.78	8.81	0.48	1.63e-16	Obesity-related traits;
CESC	cis	rs3785574	0.621	rs1051684	chr17:62006497	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.45	-5.52	-0.32	7.99e-8	Height;
CESC	cis	rs853679	0.517	rs9393898	chr6:28130376	G/T	cg18032046	chr6:28092343	ZSCAN16	-0.56	-6.34	-0.36	9.9e-10	Depression;
CESC	cis	rs7078219	0.505	rs7085798	chr10:101288347	C/A	cg09788492	chr10:101292477	NKX2-3	0.32	6.12	0.35	3.29e-9	Dental caries;
CESC	cis	rs7666738	0.800	rs13107147	chr4:99028753	C/T	cg24818145	chr4:99064322	C4orf37	0.38	5.04	0.3	8.61e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4808199	0.739	rs2240117	chr19:19418916	C/T	cg03709012	chr19:19516395	GATAD2A	0.97	8.41	0.46	2.57e-15	Nonalcoholic fatty liver disease;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg23198998	chr6:150244323	RAET1G	-0.5	-6.87	-0.39	4.65e-11	Height;
CESC	cis	rs929354	0.772	rs1182364	chr7:157017912	T/C	cg05182265	chr7:156933206	UBE3C	0.52	7.57	0.42	6.2800000000000005e-13	Body mass index;
CESC	trans	rs4942242	0.512	rs9533552	chr13:44187194	C/T	cg19169023	chr15:41853346	TYRO3	-0.68	-8.5	-0.46	1.36e-15	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs9362426	1.000	rs1203156	chr6:88079694	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.49	6.17	0.35	2.61e-9	Depressive episodes in bipolar disorder;
CESC	cis	rs12142240	0.698	rs41294458	chr1:46810304	T/C	cg00530320	chr1:46809349	NSUN4	0.6	7.98	0.44	4.48e-14	Menopause (age at onset);
CESC	cis	rs1799949	0.965	rs799908	chr17:41278916	A/G	cg05368731	chr17:41323189	NBR1	0.6	8.36	0.46	3.63e-15	Menopause (age at onset);
CESC	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg02725872	chr8:58115012	NA	-0.42	-5.85	-0.34	1.48e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs9837602	1.000	rs9832186	chr3:99728503	G/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.54	7.51	0.42	9.05e-13	Breast cancer;
CESC	cis	rs425277	1.000	rs262670	chr1:2082458	C/T	cg24578937	chr1:2090814	PRKCZ	0.55	9.54	0.51	9.57e-19	Height;
CESC	cis	rs933688	0.938	rs1477348	chr5:90707823	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.99	11.82	0.59	3.43e-26	Smoking behavior;
CESC	cis	rs7605827	0.930	rs10929372	chr2:15662434	A/G	cg19274914	chr2:15703543	NA	0.36	6.32	0.36	1.12e-9	Educational attainment (years of education);
CESC	trans	rs9929218	1.000	rs13334326	chr16:68809207	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.61	-8.04	-0.44	2.94e-14	Colorectal cancer;
CESC	cis	rs67311347	1.000	rs951560	chr3:40463471	A/G	cg24209194	chr3:40518798	ZNF619	0.45	5.84	0.34	1.54e-8	Renal cell carcinoma;
CESC	cis	rs2242116	0.592	rs2290545	chr3:46967040	C/T	cg02527881	chr3:46936655	PTH1R	-0.41	-5.09	-0.3	6.66e-7	Birth weight;
CESC	cis	rs3820928	0.874	rs7423610	chr2:227836262	A/G	cg11843606	chr2:227700838	RHBDD1	-0.45	-5.77	-0.33	2.22e-8	Pulmonary function;
CESC	cis	rs2996428	0.709	rs6424052	chr1:3713746	A/G	cg13057898	chr1:3703894	LRRC47	0.47	6.33	0.36	1.04e-9	Red cell distribution width;
CESC	cis	rs2230307	0.536	rs834278	chr1:100510882	T/C	cg24955406	chr1:100503596	HIAT1	0.56	5.47	0.32	1.06e-7	Carotid intima media thickness;
CESC	cis	rs708547	0.578	rs781665	chr4:57831461	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.59	7.57	0.42	6.36e-13	Response to bleomycin (chromatid breaks);
CESC	cis	rs7945705	0.714	rs2653570	chr11:8987823	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.42	-6.86	-0.39	4.91e-11	Hemoglobin concentration;
CESC	cis	rs3126085	0.935	rs3120659	chr1:152293202	A/G	cg03465714	chr1:152285911	FLG	0.43	5.2	0.3	3.91e-7	Atopic dermatitis;
CESC	trans	rs9329221	0.935	rs3750310	chr8:10283426	G/A	cg17143192	chr8:8559678	CLDN23	-0.56	-6.25	-0.36	1.6e-9	Neuroticism;
CESC	cis	rs425277	0.606	rs2257182	chr1:2082566	C/T	cg04315214	chr1:2043799	PRKCZ	0.43	6.99	0.39	2.24e-11	Height;
CESC	trans	rs1814175	0.533	rs4528310	chr11:49983106	C/A	cg15704280	chr7:45808275	SEPT13	-1.01	-19.0	-0.76	2.27e-51	Height;
CESC	cis	rs8077577	0.945	rs62073604	chr17:18065888	T/C	cg16794390	chr17:18148240	FLII	0.41	5.65	0.33	4.04e-8	Obesity-related traits;
CESC	cis	rs2832191	0.633	rs2832166	chr21:30462395	G/C	cg24692254	chr21:30365293	RNF160	0.95	15.46	0.69	7.36e-39	Dental caries;
CESC	cis	rs863345	0.526	rs857718	chr1:158595142	T/A	cg12129480	chr1:158549410	OR10X1	-0.29	-5.53	-0.32	7.5e-8	Pneumococcal bacteremia;
CESC	cis	rs9308731	0.591	rs7572367	chr2:111942971	C/T	cg04202892	chr2:111875749	ACOXL	0.37	5.17	0.3	4.61e-7	Chronic lymphocytic leukemia;
CESC	cis	rs959260	0.623	rs2164244	chr17:73325244	C/T	cg12999837	chr17:73267436	MIF4GD	-0.41	-5.07	-0.3	7.61e-7	Systemic lupus erythematosus;
CESC	cis	rs78456975	1.000	rs13422995	chr2:1553554	C/A	cg01028140	chr2:1542097	TPO	-0.51	-5.3	-0.31	2.48e-7	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs9902453	0.933	rs8074028	chr17:28461687	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	7.5	0.42	9.48e-13	Coffee consumption (cups per day);
CESC	cis	rs3091242	0.867	rs602052	chr1:25722206	T/C	cg03538708	chr1:25844672	NA	-0.39	-5.86	-0.34	1.35e-8	Erythrocyte sedimentation rate;
CESC	cis	rs13191362	0.507	rs13211655	chr6:163177542	C/G	cg21926612	chr6:163149169	PACRG;PARK2	0.51	5.71	0.33	3.05e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs7412746	0.622	rs11552229	chr1:150783985	T/C	cg09365446	chr1:150670422	GOLPH3L	0.38	5.08	0.3	7e-7	Melanoma;
CESC	cis	rs2797160	0.515	rs4897149	chr6:125980018	G/T	cg05901451	chr6:126070800	HEY2	0.36	5.08	0.3	7.05e-7	Endometrial cancer;
CESC	cis	rs55823223	0.680	rs57287238	chr17:73850940	T/C	cg08125733	chr17:73851984	WBP2	0.91	11.82	0.59	3.7e-26	Psoriasis;
CESC	trans	rs2727020	0.658	rs1851992	chr11:49438110	C/T	cg15704280	chr7:45808275	SEPT13	-0.9	-15.53	-0.69	3.95e-39	Coronary artery disease;
CESC	cis	rs26868	0.740	rs26869	chr16:2248786	T/C	cg07587117	chr16:2239488	CASKIN1	0.33	5.2	0.3	4.08e-7	Height;
CESC	cis	rs6952808	0.723	rs4721295	chr7:2036669	G/T	cg05863683	chr7:1912471	MAD1L1	-0.44	-6.73	-0.38	1.04e-10	Bipolar disorder and schizophrenia;
CESC	cis	rs4665809	0.627	rs13032756	chr2:26489730	A/T	cg26119090	chr2:26468346	HADHA;HADHB	1.07	12.41	0.61	3.37e-28	Gut microbiome composition (summer);
CESC	cis	rs6582630	0.502	rs11520234	chr12:38255005	G/A	cg26384229	chr12:38710491	ALG10B	0.72	10.26	0.53	5.3e-21	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs7918232	0.627	rs10829165	chr10:27319465	A/G	cg14442939	chr10:27389572	ANKRD26	0.45	5.08	0.3	7.07e-7	Breast cancer;
CESC	cis	rs4835473	0.897	rs28825455	chr4:144628746	T/C	cg25736465	chr4:144833511	NA	0.4	6.1	0.35	3.71e-9	Immature fraction of reticulocytes;
CESC	cis	rs853679	0.517	rs17711801	chr6:28092307	C/G	cg18032046	chr6:28092343	ZSCAN16	-0.56	-6.49	-0.37	4.23e-10	Depression;
CESC	cis	rs6502050	0.835	rs9898697	chr17:80100498	A/G	cg11859384	chr17:80120422	CCDC57	-0.38	-5.15	-0.3	5.06e-7	Life satisfaction;
CESC	trans	rs17307778	1.000	rs2404050	chr11:25357269	G/A	cg22888484	chr20:37075185	SNHG11	-0.63	-6.08	-0.35	4.23e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs9913156	0.793	rs72835643	chr17:4573612	G/A	cg00122941	chr17:4613640	ARRB2	0.88	10.3	0.53	3.7e-21	Lymphocyte counts;
CESC	cis	rs7552404	0.924	rs7544117	chr1:76158246	A/G	cg10523679	chr1:76189770	ACADM	0.76	9.99	0.52	3.63e-20	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs151234	0.800	rs231974	chr16:28540322	A/T	cg01378222	chr16:28622494	SULT1A1	-0.5	-6.1	-0.35	3.8e-9	Platelet distribution width;
CESC	cis	rs74181299	0.855	rs2723066	chr2:65279321	T/G	cg05010058	chr2:65284262	CEP68	0.33	5.66	0.33	3.89e-8	Pulse pressure;
CESC	cis	rs7259376	0.694	rs75653200	chr19:22579503	G/T	cg02657401	chr19:22469223	NA	0.26	5.14	0.3	5.27e-7	Menopause (age at onset);
CESC	cis	rs909674	0.818	rs5757678	chr22:39843409	A/G	cg05872129	chr22:39784769	NA	0.82	10.77	0.55	1.17e-22	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs4843747	0.671	rs4075599	chr16:88107423	C/G	cg06374794	chr16:88002281	BANP	0.41	5.47	0.32	1.02e-7	Menopause (age at onset);
CESC	cis	rs9814567	0.929	rs1863912	chr3:134205227	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.45	-6.22	-0.36	1.92e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs736408	0.522	rs11716747	chr3:52748857	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.68	0.38	1.44e-10	Bipolar disorder;
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg11897279	chr19:13044638	FARSA	-0.41	-6.0	-0.35	6.45e-9	Vertical cup-disc ratio;
CESC	cis	rs8067545	0.512	rs34726000	chr17:19887821	G/T	cg12073167	chr17:19770448	ULK2	-0.47	-5.67	-0.33	3.79e-8	Schizophrenia;
CESC	cis	rs11166927	0.716	rs4736094	chr8:140802186	G/A	cg16909799	chr8:140841666	TRAPPC9	0.45	6.19	0.36	2.23e-9	Pediatric non-alcoholic fatty liver disease activity score;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05380008	chr22:42466865	NAGA	0.54	6.0	0.35	6.32e-9	Gut microbiome composition (summer);
CESC	cis	rs9649213	0.574	rs7802560	chr7:97903806	A/G	cg00277769	chr7:97922759	BAIAP2L1	0.33	5.47	0.32	1.06e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs11125080	0.735	rs7609080	chr2:46733783	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.54	5.15	0.3	5.06e-7	Anti-saccade response;Anti-saccade error rate in psychotic disorders;
CESC	cis	rs1218582	0.741	rs6656494	chr1:154839799	A/G	cg24250549	chr1:154909240	PMVK	0.72	10.53	0.54	6.84e-22	Prostate cancer;
CESC	cis	rs7666738	0.830	rs7662948	chr4:99020132	G/C	cg03467027	chr4:99064603	C4orf37	0.45	5.72	0.33	2.8e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7017914	0.967	rs17689955	chr8:71848864	C/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.43	-5.42	-0.32	1.33e-7	Bone mineral density;
CESC	cis	rs9902453	0.874	rs7220004	chr17:28369548	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.67	-8.69	-0.47	3.79e-16	Coffee consumption (cups per day);
CESC	trans	rs801193	0.967	rs34356500	chr7:66236607	G/T	cg14393609	chr7:65229607	NA	0.47	6.14	0.35	2.96e-9	Aortic root size;
CESC	cis	rs847577	0.677	rs951988	chr7:97762474	C/G	cg24562669	chr7:97807699	LMTK2	-0.57	-8.49	-0.46	1.46e-15	Breast cancer;
CESC	cis	rs561341	0.882	rs72825748	chr17:30367396	G/A	cg00745463	chr17:30367425	LRRC37B	-0.87	-7.84	-0.43	1.08e-13	Hip circumference adjusted for BMI;
CESC	cis	rs503341	0.756	rs612010	chr11:63591005	G/A	cg04362095	chr11:63592001	C11orf84	-0.58	-8.42	-0.46	2.4e-15	Pulse pressure;
CESC	cis	rs7224314	1.000	rs62084080	chr17:65387014	C/T	cg01507342	chr17:65387096	PITPNC1	-0.47	-5.66	-0.33	3.86e-8	Diisocyanate-induced asthma;
CESC	cis	rs2836974	0.899	rs68004583	chr21:40659587	T/C	cg11644478	chr21:40555479	PSMG1	1.06	17.5	0.73	4.14e-46	Cognitive function;
CESC	cis	rs7914558	0.966	rs2297786	chr10:104679978	C/T	cg15744005	chr10:104629667	AS3MT	-0.35	-5.49	-0.32	9.37e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs6540559	0.546	rs74991018	chr1:210033790	T/G	cg25204440	chr1:209979598	IRF6	0.67	6.11	0.35	3.54e-9	Cleft lip with or without cleft palate;
CESC	cis	rs1448094	0.512	rs61930861	chr12:86245023	G/T	cg02569458	chr12:86230093	RASSF9	0.49	7.27	0.41	3.98e-12	Major depressive disorder;
CESC	cis	rs7927771	0.524	rs7110300	chr11:47848442	T/G	cg20307385	chr11:47447363	PSMC3	0.62	8.62	0.47	6.37e-16	Subjective well-being;
CESC	cis	rs7552404	1.000	rs211718	chr1:76106675	C/T	cg03433033	chr1:76189801	ACADM	0.65	7.82	0.43	1.24e-13	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs34779708	0.931	rs12776390	chr10:35391535	T/G	cg04310649	chr10:35416472	CREM	-0.54	-6.56	-0.37	2.77e-10	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs2050392	1.000	rs2489864	chr10:30693744	C/G	cg25182066	chr10:30743637	MAP3K8	-0.38	-5.13	-0.3	5.52e-7	Inflammatory bowel disease;
CESC	cis	rs4764487	0.710	rs7964366	chr12:6346478	T/C	cg08284733	chr12:6341482	CD9	0.44	6.52	0.37	3.48e-10	Mean platelet volume;
CESC	cis	rs9039	1.000	rs9921107	chr16:9219845	G/T	cg08831531	chr16:9218945	NA	-0.44	-6.25	-0.36	1.64e-9	Menopause (age at onset);
CESC	cis	rs853679	0.517	rs9468292	chr6:28095355	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.56	-6.49	-0.37	4.23e-10	Depression;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07955105	chr10:27639156	NA	-0.51	-6.04	-0.35	5.13e-9	Gut microbiome composition (summer);
CESC	trans	rs9987353	0.840	rs329994	chr8:9123233	A/G	cg18551892	chr11:86667149	FZD4	-0.45	-6.01	-0.35	5.97e-9	Recombination measurement;
CESC	cis	rs9796	0.870	rs72737704	chr15:41323575	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.46	-6.86	-0.39	4.82e-11	Menopause (age at onset);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg12093930	chr8:82598664	IMPA1	-0.51	-6.67	-0.38	1.45e-10	Fibrinogen levels;
CESC	cis	rs10779751	0.770	rs7553827	chr1:11222393	C/T	cg08854313	chr1:11322531	MTOR	0.74	9.18	0.49	1.23e-17	Body mass index;
CESC	cis	rs6089829	0.962	rs3746749	chr20:61667333	T/C	cg03213289	chr20:61660250	NA	0.39	6.06	0.35	4.6e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs738322	0.742	rs4821767	chr22:38614129	G/T	cg25457927	chr22:38595422	NA	0.29	5.59	0.32	5.63e-8	Cutaneous nevi;
CESC	cis	rs4629180	0.727	rs10188564	chr2:102101064	C/A	cg01388757	chr2:102091195	RFX8	-0.45	-6.92	-0.39	3.44e-11	Chronic rhinosinusitis with nasal polyps;
CESC	cis	rs1728785	1.000	rs1170445	chr16:68573064	G/T	cg02972257	chr16:68554789	NA	-0.55	-6.34	-0.36	9.7e-10	Ulcerative colitis;
CESC	trans	rs4843747	0.671	rs8062855	chr16:88106941	T/C	cg26811252	chr16:29126840	RRN3P2	0.67	9.46	0.5	1.77e-18	Menopause (age at onset);
CESC	cis	rs2228479	0.541	rs62052173	chr16:89950739	T/C	cg00800038	chr16:89945340	TCF25	-0.64	-7.06	-0.4	1.47e-11	Skin colour saturation;
CESC	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.53	7.26	0.41	4.38e-12	Lymphocyte counts;
CESC	trans	rs748404	0.631	rs12905772	chr15:43648444	G/A	cg24053811	chr14:70265306	SLC10A1	0.43	6.06	0.35	4.72e-9	Lung cancer;
CESC	cis	rs7615952	0.576	rs17523380	chr3:125802874	C/T	cg04553112	chr3:125709451	NA	-0.51	-6.2	-0.36	2.2e-9	Blood pressure (smoking interaction);
CESC	cis	rs116095464	0.614	rs62344339	chr5:252995	T/G	cg12570787	chr5:219185	SDHA;CCDC127	0.51	5.28	0.31	2.76e-7	Breast cancer;
CESC	trans	rs1728785	1.000	rs4783653	chr16:68562815	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.59	7.23	0.41	5.24e-12	Ulcerative colitis;
CESC	cis	rs6912958	0.874	rs2103764	chr6:88157392	T/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.58	-7.94	-0.44	5.73e-14	Monocyte percentage of white cells;
CESC	cis	rs7089973	0.604	rs11196943	chr10:116598865	T/C	cg25233709	chr10:116636983	FAM160B1	0.38	5.97	0.34	7.44e-9	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs2130392	1.000	rs2130392	chr4:185639169	A/G	cg04058563	chr4:185651563	MLF1IP	0.33	5.15	0.3	5.13e-7	Kawasaki disease;
CESC	cis	rs6696846	0.765	rs61822619	chr1:205090885	C/G	cg00857998	chr1:205179979	DSTYK	0.56	7.27	0.41	4.02e-12	Red blood cell count;
CESC	cis	rs3091242	0.935	rs4233043	chr1:25765483	A/G	cg27572855	chr1:25598939	RHD	0.44	7.3	0.41	3.27e-12	Erythrocyte sedimentation rate;
CESC	cis	rs963731	0.649	rs2123879	chr2:39292598	A/G	cg04010122	chr2:39346883	SOS1	-0.87	-6.01	-0.35	5.99e-9	Corticobasal degeneration;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05942963	chr14:71787552	NA	0.61	7.27	0.41	3.98e-12	Gut microbiome composition (summer);
CESC	trans	rs61931739	0.500	rs6488224	chr12:34537205	T/C	cg26384229	chr12:38710491	ALG10B	0.54	7.53	0.42	8.03e-13	Morning vs. evening chronotype;
CESC	cis	rs7216064	1.000	rs4791212	chr17:65975385	C/T	cg12091567	chr17:66097778	LOC651250	-0.83	-8.76	-0.47	2.3e-16	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs858239	0.600	rs6961131	chr7:23134790	A/G	cg23682824	chr7:23144976	KLHL7	0.55	7.67	0.43	3.39e-13	Cerebrospinal fluid biomarker levels;
CESC	cis	rs477692	0.673	rs10829600	chr10:131322051	G/C	cg05714579	chr10:131428358	MGMT	0.41	5.27	0.31	2.78e-7	Response to temozolomide;
CESC	cis	rs4595586	0.545	rs12812750	chr12:39363258	C/T	cg26384229	chr12:38710491	ALG10B	0.53	7.23	0.41	5.29e-12	Morning vs. evening chronotype;
CESC	cis	rs12995491	0.933	rs13008732	chr2:88528771	G/A	cg14558114	chr2:88469736	THNSL2	-0.49	-7.1	-0.4	1.17e-11	Response to metformin (IC50);
CESC	cis	rs2074585	0.517	rs11635361	chr15:91081791	G/T	cg22089800	chr15:90895588	ZNF774	-0.43	-5.12	-0.3	5.77e-7	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
CESC	trans	rs116095464	0.558	rs2288458	chr5:231260	C/T	cg00938859	chr5:1591904	SDHAP3	0.63	6.87	0.39	4.48e-11	Breast cancer;
CESC	cis	rs17376456	0.825	rs66564678	chr5:93165894	C/T	cg25358565	chr5:93447407	FAM172A	1.12	10.9	0.56	4.36e-23	Diabetic retinopathy;
CESC	cis	rs116161686	0.500	rs55871867	chr1:210051029	A/G	cg23283495	chr1:209979779	IRF6	0.48	5.28	0.31	2.71e-7	Coronary artery disease;
CESC	cis	rs595982	0.546	rs9941490	chr19:49396737	G/A	cg21252483	chr19:49399788	TULP2	-0.39	-5.63	-0.33	4.59e-8	Red cell distribution width;
CESC	trans	rs2235573	0.551	rs139892	chr22:38388203	C/T	cg19894588	chr14:64061835	NA	0.61	8.06	0.44	2.68e-14	Glioblastoma;Glioma;
CESC	cis	rs1552244	1.000	rs57631744	chr3:10118962	T/C	cg16606324	chr3:10149918	C3orf24	0.43	5.36	0.31	1.81e-7	Alzheimer's disease;
CESC	cis	rs7666738	0.830	rs7687958	chr4:99014495	T/C	cg18180107	chr4:99064573	C4orf37	0.4	5.3	0.31	2.48e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs5769765	0.730	rs62233964	chr22:50317410	C/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.64	-6.54	-0.37	3.14e-10	Schizophrenia;
CESC	cis	rs8031584	0.872	rs11634761	chr15:31243173	A/C	cg14829155	chr15:31115871	NA	-0.69	-9.13	-0.49	1.78e-17	Huntington's disease progression;
CESC	cis	rs11792861	0.781	rs2297581	chr9:111755008	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.52	6.66	0.38	1.55e-10	Menarche (age at onset);
CESC	cis	rs7542091	0.637	rs9429826	chr1:210052146	G/A	cg09509183	chr1:209979624	IRF6	0.38	5.45	0.32	1.14e-7	Monobrow;
CESC	cis	rs3785574	0.962	rs2727324	chr17:61922102	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.63	8.35	0.46	3.94e-15	Height;
CESC	cis	rs854765	0.647	rs4426402	chr17:17977926	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.62	-8.75	-0.47	2.6e-16	Total body bone mineral density;
CESC	cis	rs2573652	0.722	rs11630930	chr15:100544145	G/T	cg09918751	chr15:100517450	ADAMTS17	-0.33	-6.14	-0.35	3.08e-9	Height;
CESC	cis	rs9309473	0.583	rs35885918	chr2:73612234	T/C	cg20560298	chr2:73613845	ALMS1	-0.47	-6.49	-0.37	4.22e-10	Metabolite levels;
CESC	cis	rs1799949	1.000	rs1060915	chr17:41234470	A/G	cg05368731	chr17:41323189	NBR1	0.77	10.64	0.55	2.93e-22	Menopause (age at onset);
CESC	cis	rs6032067	0.929	rs17424578	chr20:43806321	A/G	cg11264863	chr20:43835661	SEMG1	0.5	5.56	0.32	6.58e-8	Blood protein levels;
CESC	cis	rs12824058	0.798	rs7968728	chr12:130804696	T/A	cg24838063	chr12:130822603	PIWIL1	0.61	7.96	0.44	5.22e-14	Menopause (age at onset);
CESC	cis	rs78456975	1.000	rs13413356	chr2:1553849	G/T	cg26248373	chr2:1572462	NA	-0.59	-5.69	-0.33	3.31e-8	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs916888	0.610	rs199446	chr17:44813169	G/A	cg01570182	chr17:44337453	NA	-0.62	-8.47	-0.46	1.71e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	trans	rs1814175	0.616	rs1722001	chr11:49894427	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.43	-6.26	-0.36	1.51e-9	Height;
CESC	cis	rs6987853	0.787	rs2923402	chr8:42445400	G/A	cg09913449	chr8:42400586	C8orf40	0.46	7.87	0.44	9.25e-14	Mean corpuscular hemoglobin concentration;
CESC	cis	rs9543976	0.623	rs3783028	chr13:76165282	T/C	cg01531495	chr13:76123901	UCHL3	0.5	5.03	0.3	9.04e-7	Diabetic retinopathy;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg10452522	chr19:34663544	LSM14A	0.49	6.57	0.37	2.63e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs13382862	0.895	rs13385499	chr2:20882413	A/G	cg14780466	chr2:20870812	GDF7	-0.47	-7.65	-0.43	3.78e-13	Abdominal aortic aneurysm;
CESC	cis	rs8114671	0.662	rs3761143	chr20:33545745	C/T	cg24642439	chr20:33292090	TP53INP2	0.43	5.06	0.3	7.9e-7	Height;
CESC	cis	rs73206853	0.764	rs73194012	chr12:111100627	T/C	cg12870014	chr12:110450643	ANKRD13A	0.63	5.24	0.31	3.21e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	trans	rs57221529	0.709	rs4957056	chr5:570105	T/C	cg25482853	chr8:67687455	SGK3	1.05	10.55	0.54	6.01e-22	Lung disease severity in cystic fibrosis;
CESC	cis	rs11785400	0.793	rs4430070	chr8:143729184	G/C	cg10596483	chr8:143751796	JRK	0.42	5.25	0.31	3.11e-7	Schizophrenia;
CESC	cis	rs67460515	0.531	rs13060601	chr3:160823159	G/A	cg03342759	chr3:160939853	NMD3	-0.51	-6.44	-0.37	5.65e-10	Parkinson's disease;
CESC	cis	rs1550582	0.662	rs7812708	chr8:135500832	C/T	cg17885191	chr8:135476712	NA	0.85	11.36	0.57	1.23e-24	Educational attainment;
CESC	cis	rs12586317	0.547	rs28395170	chr14:35506988	C/T	cg05294307	chr14:35346193	BAZ1A	-0.54	-5.54	-0.32	7.14e-8	Psoriasis;
CESC	cis	rs36051895	0.659	rs10974944	chr9:5070831	C/G	cg02405213	chr9:5042618	JAK2	-0.52	-6.38	-0.36	8.06e-10	Pediatric autoimmune diseases;
CESC	cis	rs10791323	0.582	rs2851120	chr11:133708065	A/G	cg06766960	chr11:133703094	NA	-0.37	-5.42	-0.32	1.31e-7	Childhood ear infection;
CESC	cis	rs74781061	0.860	rs8033841	chr15:74763881	A/T	cg17294928	chr15:75287854	SCAMP5	-0.5	-5.51	-0.32	8.65e-8	Endometriosis;
CESC	cis	rs12477438	0.520	rs6542863	chr2:99725138	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.88	15.61	0.69	2.15e-39	Chronic sinus infection;
CESC	cis	rs3820928	1.000	rs7579961	chr2:227776976	T/A	cg05526886	chr2:227700861	RHBDD1	-0.44	-5.75	-0.33	2.45e-8	Pulmonary function;
CESC	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	10.23	0.53	6.6e-21	Prudent dietary pattern;
CESC	cis	rs4588572	0.643	rs1864172	chr5:77690945	T/C	cg11547950	chr5:77652471	NA	0.45	5.71	0.33	3.06e-8	Triglycerides;
CESC	cis	rs796364	0.625	rs13035260	chr2:201132377	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.48	-5.05	-0.3	8.19e-7	Schizophrenia;
CESC	cis	rs6582630	0.519	rs4436613	chr12:38293653	T/C	cg13010199	chr12:38710504	ALG10B	0.46	5.88	0.34	1.26e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs9916302	0.904	rs8068427	chr17:37511517	G/A	cg20243544	chr17:37824526	PNMT	-0.47	-5.74	-0.33	2.54e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs2637266	1.000	rs6480827	chr10:78356333	T/G	cg18941641	chr10:78392320	NA	0.42	7.79	0.43	1.49e-13	Pulmonary function;
CESC	cis	rs9915657	0.660	rs1558748	chr17:70066502	T/C	cg09344028	chr17:70110421	NA	0.39	7.1	0.4	1.16e-11	Thyroid hormone levels;
CESC	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg10150615	chr22:24372951	LOC391322	-0.53	-6.97	-0.39	2.44e-11	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs6088590	0.561	rs6087605	chr20:33180624	G/T	cg06115741	chr20:33292138	TP53INP2	0.51	6.53	0.37	3.37e-10	Coronary artery disease;
CESC	cis	rs6142102	0.580	rs761233	chr20:32568886	A/G	cg08999081	chr20:33150536	PIGU	0.33	5.08	0.3	6.97e-7	Skin pigmentation;
CESC	cis	rs4563143	0.675	rs112383987	chr19:29261081	C/T	cg04546413	chr19:29218101	NA	0.56	7.91	0.44	6.84e-14	Methadone dose in opioid dependence;
CESC	trans	rs57221529	0.766	rs72703042	chr5:579269	C/T	cg25482853	chr8:67687455	SGK3	1.01	10.05	0.53	2.35e-20	Lung disease severity in cystic fibrosis;
CESC	cis	rs2274273	1.000	rs57970196	chr14:55600405	C/T	cg04306507	chr14:55594613	LGALS3	0.29	5.16	0.3	4.74e-7	Protein biomarker;
CESC	cis	rs9549260	0.755	rs2297627	chr13:41233931	A/G	cg21288729	chr13:41239152	FOXO1	0.66	8.42	0.46	2.36e-15	Red blood cell count;
CESC	cis	rs523522	0.962	rs10744752	chr12:120900554	T/G	cg27279351	chr12:120934652	DYNLL1	0.68	8.42	0.46	2.45e-15	High light scatter reticulocyte count;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg16139770	chr10:63661496	ARID5B	0.48	6.1	0.35	3.73e-9	Systemic lupus erythematosus;
CESC	cis	rs8180040	0.835	rs6780013	chr3:47452118	G/A	cg27129171	chr3:47204927	SETD2	-0.63	-9.4	-0.5	2.63e-18	Colorectal cancer;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg20851245	chr2:219538212	STK36;RNF25	-0.4	-6.74	-0.38	9.72e-11	Gambling;
CESC	cis	rs116095464	0.558	rs10065239	chr5:275288	C/T	cg22496380	chr5:211416	CCDC127	-0.97	-9.97	-0.52	4.23e-20	Breast cancer;
CESC	cis	rs3733585	0.805	rs882222	chr4:9981294	G/A	cg00071950	chr4:10020882	SLC2A9	0.78	14.43	0.66	3.07e-35	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs9302635	0.513	rs7198572	chr16:72183220	G/A	cg01557791	chr16:72042693	DHODH	-0.63	-7.12	-0.4	1.04e-11	Blood protein levels;
CESC	trans	rs7726839	0.540	rs74553517	chr5:665671	C/T	cg25482853	chr8:67687455	SGK3	0.97	9.73	0.51	2.43e-19	Obesity-related traits;
CESC	cis	rs763014	0.931	rs62030903	chr16:638323	T/A	cg00802000	chr16:706648	WDR90	-0.37	-5.36	-0.31	1.82e-7	Height;
CESC	cis	rs2070488	0.775	rs9838614	chr3:38537671	A/C	cg24069376	chr3:38537580	EXOG	-0.3	-5.09	-0.3	6.76e-7	Electrocardiographic conduction measures;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg16572859	chr19:18263815	PIK3R2	-0.46	-6.67	-0.38	1.47e-10	Fibrinogen levels;
CESC	cis	rs7959452	0.530	rs12811632	chr12:69755003	G/A	cg14784868	chr12:69753453	YEATS4	0.83	12.85	0.62	1.03e-29	Blood protein levels;
CESC	cis	rs9611565	0.559	rs132765	chr22:42008068	A/G	cg06481639	chr22:41940642	POLR3H	0.62	6.24	0.36	1.7e-9	Vitiligo;
CESC	cis	rs1862618	0.853	rs1833896	chr5:56097669	C/A	cg18230493	chr5:56204884	C5orf35	-0.66	-8.28	-0.45	6.32e-15	Initial pursuit acceleration;
CESC	cis	rs12220238	1.000	rs10762582	chr10:75968316	T/G	cg19889307	chr10:75911429	ADK;AP3M1	0.6	5.44	0.32	1.24e-7	Soluble interleukin-2 receptor subunit alpha;
CESC	cis	rs10782582	0.593	rs6675212	chr1:76230829	C/A	cg10523679	chr1:76189770	ACADM	-0.47	-5.45	-0.32	1.18e-7	Daytime sleep phenotypes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19304273	chr11:49070231	NA	-0.44	-6.02	-0.35	5.75e-9	Gut microbiome composition (summer);
CESC	cis	rs6032067	0.929	rs6017513	chr20:43835232	A/C	cg10761708	chr20:43804764	PI3	0.5	5.94	0.34	8.83e-9	Blood protein levels;
CESC	cis	rs11122272	0.735	rs2486733	chr1:231531465	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.56	-7.66	-0.43	3.45e-13	Hemoglobin concentration;
CESC	cis	rs875971	0.545	rs3936065	chr7:65790564	C/T	cg18876405	chr7:65276391	NA	0.47	5.3	0.31	2.45e-7	Aortic root size;
CESC	cis	rs4822044	0.680	rs8138780	chr22:42097462	A/T	cg06481639	chr22:41940642	POLR3H	0.59	5.91	0.34	1.05e-8	Cannabis dependence symptom count;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg13964393	chr15:45003702	B2M	-0.44	-6.06	-0.35	4.65e-9	Asthma;
CESC	cis	rs8044868	0.530	rs2550868	chr16:72066072	G/A	cg16558253	chr16:72132732	DHX38	-0.4	-6.13	-0.35	3.24e-9	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CESC	cis	rs7618915	0.501	rs13060048	chr3:52598608	G/A	cg17372223	chr3:52568218	NT5DC2	0.4	5.93	0.34	9.47e-9	Bipolar disorder;
CESC	cis	rs1595825	0.786	rs77773624	chr2:198514845	G/A	cg10820045	chr2:198174542	NA	0.42	5.29	0.31	2.54e-7	Ulcerative colitis;
CESC	cis	rs9915657	0.870	rs12600458	chr17:70130545	C/T	cg06234051	chr17:70120541	SOX9	-0.44	-6.43	-0.37	6.05e-10	Thyroid hormone levels;
CESC	cis	rs854765	0.583	rs12452254	chr17:17829434	G/A	cg09796270	chr17:17721594	SREBF1	0.46	6.42	0.37	6.23e-10	Total body bone mineral density;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18502522	chr15:75165624	SCAMP2	0.55	6.4	0.37	6.88e-10	Gut microbiome composition (summer);
CESC	cis	rs36051895	0.664	rs10115518	chr9:5094559	T/C	cg02405213	chr9:5042618	JAK2	-0.51	-6.17	-0.35	2.61e-9	Pediatric autoimmune diseases;
CESC	cis	rs9457247	1.000	rs932644	chr6:167404187	A/C	cg07741184	chr6:167504864	NA	0.28	5.1	0.3	6.54e-7	Crohn's disease;
CESC	cis	rs7809950	1.000	rs28714607	chr7:107106253	T/C	cg23024343	chr7:107201750	COG5	-0.44	-6.24	-0.36	1.76e-9	Coronary artery disease;
CESC	cis	rs875971	1.000	rs778694	chr7:65871558	A/G	cg18876405	chr7:65276391	NA	0.52	6.87	0.39	4.49e-11	Aortic root size;
CESC	cis	rs9486719	1.000	rs11153064	chr6:97021959	A/G	cg06623918	chr6:96969491	KIAA0776	-0.8	-8.28	-0.45	6.29e-15	Migraine;Coronary artery disease;
CESC	cis	rs6032067	0.704	rs35009666	chr20:43786020	C/T	cg11264863	chr20:43835661	SEMG1	0.5	5.35	0.31	1.86e-7	Blood protein levels;
CESC	cis	rs12900413	0.687	rs35060998	chr15:90310294	A/G	cg24249390	chr15:90295951	MESP1	-0.4	-5.5	-0.32	9.05e-8	Coronary artery aneurysm in Kawasaki disease;
CESC	cis	rs58785573	0.504	rs62294474	chr4:38628725	C/T	cg18361445	chr4:38666374	KLF3;FLJ13197	0.46	6.29	0.36	1.3e-9	Lymphocyte percentage of white cells;
CESC	cis	rs1552244	1.000	rs17032414	chr3:10158302	C/G	cg00149659	chr3:10157352	C3orf10	0.7	8.7	0.47	3.6e-16	Alzheimer's disease;
CESC	cis	rs2075371	0.897	rs10488428	chr7:133997560	C/T	cg11752832	chr7:134001865	SLC35B4	0.52	6.66	0.38	1.6e-10	Mean platelet volume;
CESC	cis	rs2777491	0.957	rs3743038	chr15:41694743	C/T	cg20272979	chr15:41787780	ITPKA	0.43	6.38	0.36	7.81e-10	Ulcerative colitis;
CESC	cis	rs6493487	0.512	rs12913094	chr15:51219284	T/C	cg02338191	chr15:51200825	AP4E1	0.62	5.84	0.34	1.52e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs7666738	0.515	rs13118898	chr4:98792893	T/A	cg17366294	chr4:99064904	C4orf37	0.52	6.61	0.38	2.09e-10	Colonoscopy-negative controls vs population controls;
CESC	cis	rs8177253	0.965	rs8177245	chr3:133479230	A/G	cg11941060	chr3:133502564	NA	-0.46	-6.22	-0.36	1.93e-9	Iron status biomarkers;
CESC	cis	rs2439831	0.681	rs3742971	chr15:43622916	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.89	-13.8	-0.65	5.02e-33	Lung cancer in ever smokers;
CESC	cis	rs60154123	0.730	rs689248	chr1:210463122	A/G	cg21951975	chr1:209979733	IRF6	-0.48	-6.61	-0.38	2.16e-10	Coronary artery disease;
CESC	cis	rs3859192	0.599	rs2270401	chr17:38176256	A/T	cg17344932	chr17:38183730	MED24;SNORD124	0.62	9.17	0.49	1.33e-17	White blood cell count;
CESC	cis	rs1879734	0.689	rs12040081	chr1:54168609	A/G	cg23596471	chr1:54105337	GLIS1	0.35	5.58	0.32	5.97e-8	Mitral valve prolapse;
CESC	cis	rs7264396	0.690	rs2425172	chr20:34443893	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.88	-11.72	-0.58	7.57e-26	Total cholesterol levels;
CESC	cis	rs911555	0.755	rs12435516	chr14:103954404	T/C	cg12935359	chr14:103987150	CKB	0.67	9.78	0.52	1.73e-19	Intelligence (multi-trait analysis);
CESC	cis	rs7772486	0.686	rs9373473	chr6:146082282	A/G	cg05347473	chr6:146136440	FBXO30	0.46	6.12	0.35	3.38e-9	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs11997175	0.545	rs66783231	chr8:33811467	A/T	ch.8.33884649F	chr8:33765107	NA	0.47	6.04	0.35	5.27e-9	Body mass index;
CESC	cis	rs9532580	0.778	rs61963319	chr13:41244220	A/T	cg21288729	chr13:41239152	FOXO1	0.68	8.46	0.46	1.82e-15	Mean corpuscular hemoglobin;
CESC	cis	rs933688	1.000	rs2059208	chr5:90732065	A/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.12	15.6	0.69	2.34e-39	Smoking behavior;
CESC	cis	rs763014	0.931	rs1981483	chr16:630665	G/A	cg07343612	chr16:622815	PIGQ	-0.58	-8.49	-0.46	1.53e-15	Height;
CESC	cis	rs4713118	0.662	rs9380045	chr6:28025279	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.54	-6.2	-0.36	2.21e-9	Parkinson's disease;
CESC	cis	rs514406	0.793	rs12081018	chr1:53217542	C/A	cg08859206	chr1:53392774	SCP2	0.61	9.01	0.48	4.28e-17	Monocyte count;
CESC	cis	rs2228479	0.850	rs11645240	chr16:89837326	T/C	cg14709524	chr16:89940631	TCF25	0.91	6.74	0.38	1e-10	Skin colour saturation;
CESC	cis	rs9910055	0.509	rs9916444	chr17:42313512	C/G	cg19774624	chr17:42201019	HDAC5	-0.55	-7.36	-0.41	2.33e-12	Total body bone mineral density;
CESC	cis	rs3540	0.513	rs2589974	chr15:90891566	C/T	cg10434728	chr15:90938212	IQGAP1	-0.38	-6.64	-0.38	1.75e-10	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs1881797	0.872	rs12408686	chr1:247691141	C/T	cg05639522	chr1:247681581	NA	0.48	6.22	0.36	1.92e-9	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.51	-5.5	-0.32	8.78e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs208520	0.690	rs6929762	chr6:66709277	C/T	cg07460842	chr6:66804631	NA	0.97	13.04	0.63	2.3e-30	Exhaled nitric oxide output;
CESC	cis	rs11642862	1.000	rs113454775	chr16:30809534	A/G	cg02466173	chr16:30829666	NA	-0.59	-5.92	-0.34	9.76e-9	Tonsillectomy;
CESC	trans	rs11098499	0.863	rs10009626	chr4:120470005	T/C	cg25214090	chr10:38739885	LOC399744	0.67	9.21	0.49	1.05e-17	Corneal astigmatism;
CESC	cis	rs6429082	0.818	rs210037	chr1:235649501	A/G	cg26050004	chr1:235667680	B3GALNT2	0.63	7.82	0.43	1.24e-13	Adiposity;
CESC	cis	rs6736093	0.862	rs35382200	chr2:112780716	G/C	cg12686935	chr2:112915763	FBLN7	-0.41	-5.33	-0.31	2.1e-7	Coronary artery disease;
CESC	cis	rs1153858	1.000	rs12595087	chr15:45655232	A/G	cg14582100	chr15:45693742	SPATA5L1	0.42	5.96	0.34	7.92e-9	Homoarginine levels;
CESC	cis	rs3204270	0.810	rs8077959	chr17:79670122	G/A	cg18367735	chr17:79674897	NA	0.66	5.48	0.32	1.01e-7	Dental caries;
CESC	cis	rs7523050	0.643	rs36052234	chr1:109402943	C/T	cg08274380	chr1:109419600	GPSM2	0.86	5.69	0.33	3.36e-8	Fat distribution (HIV);
CESC	cis	rs35306767	0.903	rs11253462	chr10:889323	T/G	cg26597838	chr10:835615	NA	0.85	8.99	0.48	4.92e-17	Eosinophil percentage of granulocytes;
CESC	cis	rs6500602	0.964	rs2304633	chr16:4496973	T/A	cg08645402	chr16:4508243	NA	0.44	6.71	0.38	1.14e-10	Schizophrenia;
CESC	cis	rs807669	0.777	rs9605972	chr22:19253274	C/T	cg02655711	chr22:19163373	SLC25A1	0.58	8.39	0.46	2.88e-15	Metabolite levels;
CESC	cis	rs208520	0.690	rs851465	chr6:66840293	G/A	cg07460842	chr6:66804631	NA	-0.99	-13.42	-0.64	1.15e-31	Exhaled nitric oxide output;
CESC	cis	rs9291683	0.530	rs13115193	chr4:9982191	C/T	cg00071950	chr4:10020882	SLC2A9	0.78	14.43	0.66	3.07e-35	Bone mineral density;
CESC	cis	rs9549367	0.789	rs34989271	chr13:113894766	G/A	cg18105134	chr13:113819100	PROZ	-0.67	-8.13	-0.45	1.68e-14	Platelet distribution width;
CESC	cis	rs2367563	1.000	rs2367563	chr12:96057184	A/G	cg19013339	chr12:96052514	NTN4	0.37	5.4	0.31	1.47e-7	Allergic dermatitis (nickel);
CESC	cis	rs1215050	0.740	rs700740	chr4:98976003	A/C	cg05340658	chr4:99064831	C4orf37	-0.56	-7.55	-0.42	7e-13	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs3820068	0.581	rs72645874	chr1:15926238	C/G	cg16988262	chr1:15930761	NA	0.35	5.65	0.33	4.18e-8	Systolic blood pressure;
CESC	cis	rs8112211	0.598	rs4802351	chr19:38848796	A/G	cg14299480	chr19:38876666	GGN	-0.49	-5.58	-0.32	6.04e-8	Blood protein levels;
CESC	cis	rs9611565	0.592	rs4822040	chr22:41963553	C/G	cg06634786	chr22:41940651	POLR3H	-0.63	-6.9	-0.39	3.9e-11	Vitiligo;
CESC	cis	rs2576037	0.583	rs2187091	chr18:44520048	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.77	12.71	0.62	3.17e-29	Personality dimensions;
CESC	cis	rs1376303	0.558	rs41479949	chr7:32946363	A/G	cg06627557	chr7:32535165	LSM5;AVL9	-0.64	-5.09	-0.3	6.84e-7	Intelligence (multi-trait analysis);
CESC	cis	rs4819052	0.851	rs2255766	chr21:46683777	C/T	cg11663144	chr21:46675770	NA	-0.61	-9.6	-0.51	6.2e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs11098499	0.863	rs34308924	chr4:120481431	T/C	cg25214090	chr10:38739885	LOC399744	0.66	9.03	0.49	3.57e-17	Corneal astigmatism;
CESC	trans	rs875971	1.000	rs1968225	chr7:65874773	T/C	cg26939375	chr7:64535504	NA	0.47	6.06	0.35	4.77e-9	Aortic root size;
CESC	cis	rs9902453	0.838	rs9646437	chr17:28209065	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	8.08	0.44	2.31e-14	Coffee consumption (cups per day);
CESC	cis	rs7666738	0.791	rs1896156	chr4:99020882	C/G	cg05340658	chr4:99064831	C4orf37	0.82	12.99	0.62	3.34e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7561273	0.586	rs11902756	chr2:24300932	A/G	cg20701182	chr2:24300061	SF3B14	0.52	6.69	0.38	1.34e-10	Quantitative traits;
CESC	cis	rs17345786	0.906	rs11710016	chr3:101120030	A/C	cg12386194	chr3:101231763	SENP7	-0.61	-6.41	-0.37	6.48e-10	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9322193	0.923	rs9800806	chr6:150061486	G/T	cg07701084	chr6:150067640	NUP43	0.47	6.6	0.38	2.17e-10	Lung cancer;
CESC	cis	rs2243480	1.000	rs316321	chr7:65611613	G/A	cg13147721	chr7:65941812	NA	-0.97	-9.14	-0.49	1.7e-17	Diabetic kidney disease;
CESC	cis	rs2795502	0.702	rs3123750	chr10:43227824	C/A	cg20628663	chr10:43360327	NA	-0.65	-6.95	-0.39	2.76e-11	Blood protein levels;
CESC	cis	rs6500602	0.701	rs4785971	chr16:4577090	A/G	cg08645402	chr16:4508243	NA	0.4	5.63	0.33	4.56e-8	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19906608	chr1:94344521	DNTTIP2	0.67	7.86	0.43	9.47e-14	Gut microbiome composition (summer);
CESC	cis	rs4654899	0.965	rs2873424	chr1:21500701	C/A	cg05370193	chr1:21551575	ECE1	0.39	5.77	0.33	2.19e-8	Superior frontal gyrus grey matter volume;
CESC	cis	rs4844614	1.000	rs4844614	chr1:207875175	G/T	cg21110645	chr1:207815933	NA	0.35	5.44	0.32	1.24e-7	LDL cholesterol;
CESC	cis	rs67311347	0.955	rs4973999	chr3:40460383	G/A	cg24209194	chr3:40518798	ZNF619	0.5	6.62	0.38	1.97e-10	Renal cell carcinoma;
CESC	trans	rs7107217	1.000	rs1873872	chr11:129473993	A/T	cg12271800	chr19:59028764	ZBTB45	-0.49	-6.68	-0.38	1.36e-10	Breast cancer;Type 2 diabetes;
CESC	cis	rs1008375	0.872	rs6831115	chr4:17640463	A/G	cg15017067	chr4:17643749	FAM184B	0.36	5.11	0.3	6.3e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs7605827	0.930	rs1318980	chr2:15549890	G/T	cg19274914	chr2:15703543	NA	0.36	6.56	0.37	2.83e-10	Educational attainment (years of education);
CESC	cis	rs9925964	0.935	rs12597511	chr16:31145219	C/T	cg02466173	chr16:30829666	NA	0.33	5.07	0.3	7.51e-7	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs1448094	0.512	rs7303330	chr12:86255123	G/A	cg02569458	chr12:86230093	RASSF9	0.51	7.64	0.42	3.9e-13	Major depressive disorder;
CESC	cis	rs9291683	0.668	rs2241474	chr4:10086015	T/C	cg00071950	chr4:10020882	SLC2A9	0.7	10.92	0.56	3.72e-23	Bone mineral density;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06782493	chr16:1876874	HAGH;FAHD1	0.64	8.02	0.44	3.37e-14	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21449445	chr8:144546357	ZC3H3	-0.6	-7.1	-0.4	1.12e-11	Gut microbiome composition (summer);
CESC	cis	rs9486715	0.867	rs11152924	chr6:96877383	A/G	cg06623918	chr6:96969491	KIAA0776	0.91	14.05	0.65	6.83e-34	Headache;
CESC	cis	rs2836950	0.545	rs4818001	chr21:40575088	T/C	cg11890956	chr21:40555474	PSMG1	-0.67	-9.54	-0.51	1e-18	Menarche (age at onset);
CESC	cis	rs6546550	0.867	rs4852349	chr2:70076954	A/T	cg02498382	chr2:70120550	SNRNP27	-0.37	-6.28	-0.36	1.41e-9	Prevalent atrial fibrillation;
CESC	cis	rs4727027	0.933	rs12540094	chr7:148847178	A/G	cg23583168	chr7:148888333	NA	0.76	11.49	0.58	4.59e-25	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs7264396	0.635	rs2064724	chr20:34522520	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.8	-11.03	-0.56	1.57e-23	Total cholesterol levels;
CESC	cis	rs425277	0.565	rs61775448	chr1:2045376	A/G	cg16545954	chr1:2118288	C1orf86	-0.32	-5.98	-0.34	7.26e-9	Height;
CESC	cis	rs62229266	0.771	rs2835232	chr21:37393427	G/A	cg12218747	chr21:37451666	NA	-0.4	-5.71	-0.33	3.01e-8	Mitral valve prolapse;
CESC	cis	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg00777555	chr3:57583074	ARF4	0.38	5.03	0.3	9.01e-7	Systemic lupus erythematosus;
CESC	cis	rs16866061	1.000	rs72974205	chr2:225408468	C/T	cg12698349	chr2:225449008	CUL3	0.76	11.28	0.57	2.38e-24	Acute graft versus host disease in bone marrow transplantation (recipient effect);
CESC	cis	rs7274811	0.744	rs6141962	chr20:32110312	T/C	cg21523528	chr20:32077966	CBFA2T2	0.62	7.13	0.4	9.62e-12	Height;
CESC	cis	rs7264396	0.635	rs6058382	chr20:34553948	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.77	-10.29	-0.53	4.22e-21	Total cholesterol levels;
CESC	cis	rs875971	0.964	rs6978429	chr7:65959876	T/G	cg12463550	chr7:65579703	CRCP	0.56	7.07	0.4	1.39e-11	Aortic root size;
CESC	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.51	0.37	3.65e-10	Prudent dietary pattern;
CESC	cis	rs72781680	0.752	rs12616649	chr2:23890913	G/A	cg20701182	chr2:24300061	SF3B14	0.78	6.58	0.37	2.44e-10	Lymphocyte counts;
CESC	cis	rs4253772	0.550	rs738444	chr22:46721088	C/T	cg24881330	chr22:46731750	TRMU	0.91	10.0	0.52	3.44e-20	LDL cholesterol;Cholesterol, total;
CESC	cis	rs10751667	0.560	rs7924794	chr11:962745	A/T	cg06064525	chr11:970664	AP2A2	-0.48	-9.43	-0.5	2.11e-18	Alzheimer's disease (late onset);
CESC	trans	rs10448044	0.956	rs10448042	chr8:80101677	A/G	cg08211306	chr6:46097784	ENPP4	0.42	6.08	0.35	4.2e-9	Suicide in bipolar disorder;
CESC	trans	rs9951602	0.512	rs58352488	chr18:76651113	T/A	cg02800362	chr5:177631904	HNRNPAB	0.66	8.66	0.47	4.55e-16	Obesity-related traits;
CESC	cis	rs3858526	0.916	rs11039551	chr11:5930773	C/T	cg13902645	chr11:5959945	NA	-0.62	-7.34	-0.41	2.65e-12	DNA methylation (variation);
CESC	cis	rs2486288	0.656	rs11629859	chr15:45547121	T/G	cg21132104	chr15:45694354	SPATA5L1	-0.54	-6.5	-0.37	4.05e-10	Glomerular filtration rate;
CESC	cis	rs922182	0.633	rs12592702	chr15:64271882	C/T	cg24729988	chr15:64271149	DAPK2	-0.47	-6.72	-0.38	1.08e-10	Blood protein levels;
CESC	cis	rs7666738	0.606	rs6839946	chr4:99076132	A/C	cg03467027	chr4:99064603	C4orf37	0.41	5.09	0.3	6.89e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs7690543	0.505	rs1364981	chr4:67995183	G/A	cg05505961	chr17:66375071	ARSG	-0.51	-6.1	-0.35	3.79e-9	Glucose homeostasis traits;
CESC	cis	rs9512730	0.553	rs6491211	chr13:28049533	A/G	cg04070771	chr13:27998621	GTF3A	0.44	5.03	0.3	9.06e-7	Schizophrenia;
CESC	cis	rs13256369	1.000	rs4840351	chr8:8573148	A/G	cg17143192	chr8:8559678	CLDN23	0.73	8.6	0.47	7.31e-16	Obesity-related traits;
CESC	cis	rs1538970	0.781	rs713358	chr1:45988267	C/G	cg03146154	chr1:46216737	IPP	0.45	5.27	0.31	2.79e-7	Platelet count;
CESC	cis	rs7116495	1.000	rs4945426	chr11:71748146	A/C	cg10381502	chr11:71823885	C11orf51	0.62	5.39	0.31	1.55e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs514406	0.767	rs551591	chr1:53301876	A/G	cg24675658	chr1:53192096	ZYG11B	-0.7	-9.41	-0.5	2.53e-18	Monocyte count;
CESC	cis	rs8031584	0.918	rs34331396	chr15:31248736	C/G	cg14298792	chr15:30685198	CHRFAM7A	-0.47	-5.62	-0.33	4.81e-8	Huntington's disease progression;
CESC	cis	rs1865760	0.532	rs2006736	chr6:26086017	C/T	cg16482183	chr6:26056742	HIST1H1C	0.38	5.11	0.3	6.19e-7	Height;
CESC	cis	rs501120	0.810	rs622472	chr10:44749211	A/C	cg09554077	chr10:44749378	NA	0.48	6.2	0.36	2.13e-9	Coronary artery disease;Coronary heart disease;
CESC	cis	rs6570726	0.905	rs1355146	chr6:145781741	A/C	cg23711669	chr6:146136114	FBXO30	-0.73	-10.7	-0.55	1.96e-22	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2708240	0.540	rs1723438	chr7:147546659	G/A	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.37	-5.62	-0.33	4.84e-8	QT interval (drug interaction);
CESC	cis	rs12824058	0.831	rs7310433	chr12:130809289	C/T	cg26677194	chr12:130822605	PIWIL1	0.52	6.81	0.39	6.58e-11	Menopause (age at onset);
CESC	cis	rs4808199	0.901	rs12973258	chr19:19488718	T/C	cg03709012	chr19:19516395	GATAD2A	1.13	13.1	0.63	1.44e-30	Nonalcoholic fatty liver disease;
CESC	cis	rs2180341	0.960	rs7753913	chr6:127671296	A/G	cg24812749	chr6:127587940	RNF146	1.05	15.07	0.68	1.77e-37	Breast cancer;
CESC	cis	rs2857078	0.745	rs4793085	chr17:42320732	A/C	cg13607699	chr17:42295918	UBTF	-0.78	-11.22	-0.57	3.61e-24	Red cell distribution width;Reticulocyte count;
CESC	cis	rs9300255	0.602	rs1727296	chr12:123647725	G/C	cg00376283	chr12:123451042	ABCB9	0.7	8.86	0.48	1.16e-16	Neutrophil percentage of white cells;
CESC	cis	rs7615952	0.576	rs17523380	chr3:125802874	C/T	cg02772935	chr3:125709198	NA	-0.44	-5.48	-0.32	1.01e-7	Blood pressure (smoking interaction);
CESC	cis	rs2731664	0.792	rs335434	chr5:176867276	A/G	cg23176889	chr5:176863531	GRK6	-0.61	-9.79	-0.52	1.58e-19	Intelligence (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03411949	chr12:62654125	USP15	0.58	6.07	0.35	4.32e-9	Gut microbiome composition (summer);
CESC	cis	rs7447593	0.626	rs3812036	chr5:176813404	C/T	cg16006841	chr5:176797999	RGS14	0.5	5.21	0.3	3.75e-7	Urinary electrolytes (magnesium/calcium ratio);
CESC	cis	rs3820068	0.581	rs6429762	chr1:15945595	A/C	cg13390004	chr1:15929781	NA	0.34	5.61	0.33	5.1e-8	Systolic blood pressure;
CESC	cis	rs116095464	0.558	rs28635197	chr5:279071	T/C	cg12570787	chr5:219185	SDHA;CCDC127	0.52	5.41	0.32	1.38e-7	Breast cancer;
CESC	cis	rs10276381	1.000	rs10280937	chr7:28182306	T/C	cg23620719	chr7:28220237	JAZF1	0.7	7.22	0.41	5.61e-12	Crohn's disease;
CESC	cis	rs6762	0.748	rs7928935	chr11:839127	G/A	cg23754390	chr11:835074	CD151	0.32	5.51	0.32	8.52e-8	Mean platelet volume;
CESC	cis	rs920590	0.758	rs2898491	chr8:19661883	C/T	cg17834443	chr8:19674713	INTS10	0.58	6.53	0.37	3.27e-10	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs920590	0.758	rs1907799	chr8:19664668	A/G	cg03894339	chr8:19674705	INTS10	-0.6	-7.14	-0.4	9.02e-12	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs9486719	1.000	rs72931061	chr6:96880285	G/A	cg06623918	chr6:96969491	KIAA0776	-0.81	-8.29	-0.45	5.61e-15	Migraine;Coronary artery disease;
CESC	cis	rs8072100	0.745	rs7214410	chr17:45422628	A/G	cg08085267	chr17:45401833	C17orf57	-0.55	-7.4	-0.41	1.83e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs6088590	1.000	rs6087626	chr20:33347328	C/T	cg24642439	chr20:33292090	TP53INP2	0.84	11.78	0.59	4.81e-26	Coronary artery disease;
CESC	cis	rs116979167	0.630	rs56230603	chr7:105165268	A/G	cg02135003	chr7:105160482	PUS7	-0.46	-5.55	-0.32	6.92e-8	Bipolar disorder (body mass index interaction);
CESC	cis	rs992157	0.687	rs35271699	chr2:219117482	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.67	9.13	0.49	1.79e-17	Colorectal cancer;
CESC	cis	rs116095464	0.558	rs2288457	chr5:231270	C/T	cg10591111	chr5:226296	SDHA	-0.51	-6.18	-0.35	2.44e-9	Breast cancer;
CESC	cis	rs7527798	0.545	rs6696228	chr1:207846830	G/A	cg21110645	chr1:207815933	NA	-0.33	-5.67	-0.33	3.7e-8	Erythrocyte sedimentation rate;
CESC	cis	rs523522	0.962	rs4767904	chr12:120930798	T/G	cg27279351	chr12:120934652	DYNLL1	0.69	8.95	0.48	6.15e-17	High light scatter reticulocyte count;
CESC	cis	rs2836974	0.590	rs9974757	chr21:40617244	T/C	cg17971929	chr21:40555470	PSMG1	-0.86	-12.45	-0.61	2.59e-28	Cognitive function;
CESC	cis	rs3733585	0.699	rs2018643	chr4:9947121	C/T	cg00071950	chr4:10020882	SLC2A9	0.71	11.71	0.58	8.25e-26	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs10911251	0.546	rs1547715	chr1:183113952	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.84	13.22	0.63	5.53e-31	Colorectal cancer;
CESC	cis	rs9733	0.596	rs72702557	chr1:150680130	A/G	cg09365446	chr1:150670422	GOLPH3L	0.42	5.86	0.34	1.37e-8	Tonsillectomy;
CESC	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg15112475	chr7:1198522	ZFAND2A	-0.39	-6.13	-0.35	3.2e-9	Longevity;Endometriosis;
CESC	cis	rs2228479	1.000	rs2228479	chr16:89985940	G/A	cg00800038	chr16:89945340	TCF25	-0.92	-7.43	-0.42	1.48e-12	Skin colour saturation;
CESC	cis	rs10089	1.000	rs11957052	chr5:127524055	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.73	9.52	0.5	1.14e-18	Ileal carcinoids;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10972625	chr1:143745140	LOC100286793;FLJ39739	-0.58	-7.26	-0.41	4.22e-12	Gut microbiome composition (summer);
CESC	cis	rs2243480	1.000	rs1638734	chr7:66097539	A/C	cg13147721	chr7:65941812	NA	-0.91	-8.45	-0.46	1.99e-15	Diabetic kidney disease;
CESC	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg04025307	chr7:1156635	C7orf50	0.54	9.01	0.48	4.22e-17	Longevity;Endometriosis;
CESC	cis	rs7267979	0.932	rs2387891	chr20:25470328	C/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.74	13.2	0.63	6.56e-31	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs875971	0.522	rs1701760	chr7:65473688	A/G	cg06456125	chr7:65229604	NA	0.45	5.94	0.34	8.7e-9	Aortic root size;
CESC	cis	rs11696501	0.688	rs6094197	chr20:44316492	C/T	cg11783356	chr20:44313418	WFDC10B	-0.31	-5.08	-0.3	7.02e-7	Brain structure;
CESC	trans	rs2727020	0.523	rs7948958	chr11:49506749	G/A	cg03929089	chr4:120376271	NA	0.7	7.98	0.44	4.31e-14	Coronary artery disease;
CESC	cis	rs919433	0.680	rs3792160	chr2:198403519	G/A	cg03934865	chr2:198174659	NA	0.38	5.06	0.3	7.92e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs921968	0.540	rs7582329	chr2:219620909	C/T	cg02176678	chr2:219576539	TTLL4	-0.44	-7.67	-0.43	3.29e-13	Mean corpuscular hemoglobin concentration;
CESC	cis	rs10465746	0.967	rs6576956	chr1:84343885	T/G	cg10977910	chr1:84465055	TTLL7	0.48	6.52	0.37	3.64e-10	Obesity-related traits;
CESC	cis	rs7666738	0.830	rs60994860	chr4:99046753	G/A	cg03467027	chr4:99064603	C4orf37	0.47	5.98	0.34	7.19e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4665809	0.590	rs17528590	chr2:26505858	A/G	cg08470875	chr2:26401718	FAM59B	0.69	6.74	0.38	1.01e-10	Gut microbiome composition (summer);
CESC	cis	rs3741404	0.560	rs7938819	chr11:63910116	G/A	cg18225595	chr11:63971243	STIP1	-0.64	-8.95	-0.48	6.28e-17	Platelet count;
CESC	cis	rs7666738	0.830	rs6839277	chr4:99015563	C/T	cg18180107	chr4:99064573	C4orf37	0.4	5.3	0.31	2.48e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9916302	0.861	rs593480	chr17:37453780	A/C	cg20243544	chr17:37824526	PNMT	-0.45	-5.62	-0.33	4.75e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs7811142	0.830	rs3087502	chr7:99955364	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.72	6.41	0.37	6.71e-10	Platelet count;
CESC	trans	rs1005277	0.540	rs7903942	chr10:37929276	C/T	cg12057190	chr19:54976211	LENG9;CDC42EP5	-0.42	-6.1	-0.35	3.82e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs875971	0.862	rs9791712	chr7:66105163	C/G	cg12463550	chr7:65579703	CRCP	-0.48	-6.03	-0.35	5.35e-9	Aortic root size;
CESC	cis	rs10493773	0.609	rs6689168	chr1:86174232	G/T	cg17807903	chr1:86174739	ZNHIT6	-0.44	-6.53	-0.37	3.37e-10	Urate levels in overweight individuals;
CESC	trans	rs848353	1.000	rs11768295	chr7:108595963	T/C	cg03555276	chr13:113260139	NA	0.56	6.03	0.35	5.42e-9	Smoking behavior;
CESC	cis	rs7267979	1.000	rs6050547	chr20:25326012	C/T	cg08601574	chr20:25228251	PYGB	-0.38	-5.49	-0.32	9.45e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7927771	0.896	rs12794570	chr11:47658314	C/T	cg18512352	chr11:47633146	NA	-0.62	-9.74	-0.51	2.4e-19	Subjective well-being;
CESC	cis	rs9611565	0.649	rs202666	chr22:41814719	T/C	cg03806693	chr22:41940476	POLR3H	1.16	14.61	0.67	7.1e-36	Vitiligo;
CESC	cis	rs10504229	1.000	rs72650892	chr8:58179714	A/G	cg05313129	chr8:58192883	C8orf71	-0.55	-6.37	-0.36	8.42e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs780096	0.505	rs12475426	chr2:27599132	G/A	cg22903471	chr2:27725779	GCKR	-0.48	-6.79	-0.38	7.49e-11	Total body bone mineral density;
CESC	cis	rs9831754	0.526	rs6548551	chr3:78342292	C/T	cg06138941	chr3:78371609	NA	0.43	5.73	0.33	2.78e-8	Calcium levels;
CESC	cis	rs34779708	0.966	rs4934737	chr10:35512799	T/C	cg04310649	chr10:35416472	CREM	-0.54	-6.4	-0.37	6.97e-10	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs9291683	0.551	rs2276961	chr4:10022981	C/T	cg02734326	chr4:10020555	SLC2A9	0.48	6.82	0.39	6.31e-11	Bone mineral density;
CESC	cis	rs9815354	1.000	rs17063599	chr3:41861676	C/T	cg03022575	chr3:42003672	ULK4	0.48	5.38	0.31	1.68e-7	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs2014572	1.000	rs3746231	chr19:57760057	G/A	cg12963866	chr19:57752005	ZNF805	-0.47	-6.19	-0.36	2.29e-9	Hyperactive-impulsive symptoms;
CESC	cis	rs7615952	0.641	rs2365019	chr3:125808135	T/C	cg06494592	chr3:125709126	NA	-0.51	-5.51	-0.32	8.32e-8	Blood pressure (smoking interaction);
CESC	cis	rs28386778	0.704	rs1051688	chr17:62006433	G/C	cg11494091	chr17:61959527	GH2	-0.79	-13.94	-0.65	1.7e-33	Prudent dietary pattern;
CESC	cis	rs56399783	0.901	rs73049362	chr7:2826822	G/A	cg19731401	chr7:2775893	GNA12	0.66	5.9	0.34	1.08e-8	Childhood ear infection;
CESC	cis	rs1218582	0.741	rs10908444	chr1:154840287	G/A	cg16680214	chr1:154839983	KCNN3	-0.45	-6.93	-0.39	3.15e-11	Prostate cancer;
CESC	cis	rs9457247	1.000	rs393558	chr6:167397750	A/C	cg25258033	chr6:167368657	RNASET2	0.4	6.12	0.35	3.43e-9	Crohn's disease;
CESC	cis	rs9633740	1.000	rs7896832	chr10:82257570	T/C	cg00277334	chr10:82204260	NA	-0.58	-5.81	-0.34	1.8e-8	Post bronchodilator FEV1;
CESC	trans	rs61148964	0.826	rs58430765	chr22:37235632	G/A	cg05061107	chr11:64532875	SF1	0.62	6.0	0.35	6.63e-9	Scarlet fever;
CESC	cis	rs4919087	0.926	rs2861875	chr10:98990139	C/G	cg25902810	chr10:99078978	FRAT1	-0.66	-9.49	-0.5	1.37e-18	Monocyte count;
CESC	cis	rs9649213	0.614	rs9641236	chr7:97998124	T/A	cg09267113	chr7:98030324	BAIAP2L1	-0.42	-5.67	-0.33	3.65e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs12618769	0.597	rs4850879	chr2:99113082	A/G	cg10123293	chr2:99228465	UNC50	0.39	5.13	0.3	5.6e-7	Bipolar disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02447287	chr2:238707023	RBM44	-0.55	-6.07	-0.35	4.39e-9	Gut microbiome composition (summer);
CESC	cis	rs870825	0.655	rs72703561	chr4:185630890	T/C	cg04058563	chr4:185651563	MLF1IP	0.64	7.0	0.4	2.05e-11	Blood protein levels;
CESC	cis	rs62064224	0.902	rs35830939	chr17:30627564	A/C	cg24550644	chr17:30846204	MYO1D	-0.35	-5.14	-0.3	5.38e-7	Schizophrenia;
CESC	trans	rs8140097	0.566	rs5993688	chr22:19561066	T/G	cg03477303	chr10:134016713	DPYSL4	0.52	6.19	0.36	2.32e-9	Recurrent major depressive disorder;
CESC	cis	rs9291683	0.507	rs6827754	chr4:10018153	A/C	cg00071950	chr4:10020882	SLC2A9	-0.67	-9.45	-0.5	1.83e-18	Bone mineral density;
CESC	cis	rs8067354	0.645	rs2132715	chr17:57858374	A/T	cg02344993	chr17:57696989	CLTC	0.57	6.21	0.36	2.03e-9	Hemoglobin concentration;
CESC	cis	rs1448094	0.706	rs10863149	chr12:86425498	A/T	cg02569458	chr12:86230093	RASSF9	0.38	5.56	0.32	6.46e-8	Major depressive disorder;
CESC	cis	rs9733	0.596	rs6690725	chr1:150632322	T/C	cg22823121	chr1:150693482	HORMAD1	0.48	7.12	0.4	1.03e-11	Tonsillectomy;
CESC	cis	rs6752107	0.935	rs10199278	chr2:234160669	C/G	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.37	5.74	0.33	2.56e-8	Crohn's disease;Inflammatory bowel disease;
CESC	trans	rs208623	0.774	rs110368	chr16:22943837	C/T	cg20295040	chr1:192778396	RGS2	0.52	6.07	0.35	4.31e-9	CTACK levels;
CESC	cis	rs3015497	0.789	rs11621971	chr14:51124527	C/T	cg09863266	chr14:51125203	SAV1	0.35	5.51	0.32	8.5e-8	Mean platelet volume;
CESC	cis	rs9287719	0.967	rs4613248	chr2:10744051	C/T	cg00105475	chr2:10696890	NA	0.39	5.64	0.33	4.44e-8	Prostate cancer;
CESC	cis	rs4268898	0.662	rs56006260	chr2:24409903	A/G	cg06627628	chr2:24431161	ITSN2	-1.01	-10.33	-0.54	3.04e-21	Asthma;
CESC	cis	rs10208940	0.502	rs10203846	chr2:68670921	G/A	cg12452813	chr2:68675892	NA	-0.74	-9.16	-0.49	1.45e-17	Urate levels in lean individuals;
CESC	cis	rs16917546	1.000	rs10995248	chr10:64396042	A/G	cg03961010	chr10:64397487	ZNF365	0.38	6.26	0.36	1.58e-9	Basal cell carcinoma;
CESC	cis	rs2880765	0.835	rs2170736	chr15:86043398	A/G	cg10818794	chr15:86012489	AKAP13	-0.34	-5.2	-0.3	4.03e-7	Coronary artery disease;
CESC	cis	rs2050392	0.760	rs10826797	chr10:30690376	A/C	cg02070205	chr10:30722105	MAP3K8	-0.44	-5.29	-0.31	2.6e-7	Inflammatory bowel disease;
CESC	cis	rs709400	0.628	rs2273699	chr14:103923475	A/G	cg12935359	chr14:103987150	CKB	-0.51	-7.41	-0.41	1.71e-12	Body mass index;
CESC	cis	rs4803468	1.000	rs4674	chr19:41930396	A/G	cg09537434	chr19:41945824	ATP5SL	-1.11	-20.29	-0.78	7.01e-56	Height;
CESC	cis	rs2404602	0.692	rs35999717	chr15:77193367	G/C	cg22467129	chr15:76604101	ETFA	-0.35	-5.25	-0.31	3.13e-7	Blood metabolite levels;
CESC	cis	rs7824557	0.736	rs35392635	chr8:11164349	G/C	cg21775007	chr8:11205619	TDH	0.5	7.3	0.41	3.43e-12	Retinal vascular caliber;
CESC	cis	rs9914988	0.778	rs9907185	chr17:27122414	C/T	cg20469991	chr17:27169893	C17orf63	-0.48	-5.25	-0.31	3.18e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CESC	trans	rs8014252	0.667	rs55728800	chr14:70813520	C/T	cg03123320	chr1:229394665	NA	-0.49	-6.27	-0.36	1.45e-9	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
CESC	cis	rs1799949	1.000	rs12951869	chr17:41187567	T/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	8.22	0.45	8.86e-15	Menopause (age at onset);
CESC	cis	rs9513627	1.000	rs6491512	chr13:100199741	C/T	cg25919922	chr13:100150906	NA	0.65	5.1	0.3	6.62e-7	Obesity-related traits;
CESC	cis	rs4555082	0.834	rs2735822	chr14:105712734	C/T	cg13114125	chr14:105738426	BRF1	-0.86	-10.3	-0.53	3.86e-21	Mean platelet volume;Platelet distribution width;
CESC	cis	rs2456568	0.548	rs6483280	chr11:93661592	T/C	cg26875233	chr11:93583750	C11orf90	-0.33	-5.87	-0.34	1.3e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
CESC	cis	rs9905704	0.647	rs6503888	chr17:57028126	T/C	cg12560992	chr17:57184187	TRIM37	0.61	7.64	0.43	3.87e-13	Testicular germ cell tumor;
CESC	cis	rs17711722	0.565	rs4717276	chr7:65294741	G/T	cg25405998	chr7:65216604	CCT6P1	0.44	5.57	0.32	6.41e-8	Calcium levels;
CESC	cis	rs514406	0.727	rs61768342	chr1:53217028	G/A	cg25767906	chr1:53392781	SCP2	0.44	6.13	0.35	3.09e-9	Monocyte count;
CESC	cis	rs7560272	0.512	rs13015885	chr2:73920482	G/T	cg20560298	chr2:73613845	ALMS1	0.45	6.17	0.35	2.6e-9	Schizophrenia;
CESC	trans	rs3942852	0.568	rs10769312	chr11:48094769	C/T	cg15704280	chr7:45808275	SEPT13	0.72	9.16	0.49	1.49e-17	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs787274	0.543	rs10116897	chr9:115633479	C/T	cg13803584	chr9:115635662	SNX30	-0.68	-6.63	-0.38	1.86e-10	Age-related hearing impairment (SNP x SNP interaction);
CESC	trans	rs10489896	0.541	rs12760253	chr1:234577514	G/C	cg23817893	chr11:86085932	CCDC81	-0.46	-6.41	-0.37	6.57e-10	Cognitive test performance;
CESC	cis	rs12545109	0.800	rs2576602	chr8:57394495	C/T	cg09654669	chr8:57350985	NA	-0.57	-7.21	-0.41	5.73e-12	Obesity-related traits;
CESC	cis	rs6582630	0.555	rs10748382	chr12:38504529	C/T	cg13010199	chr12:38710504	ALG10B	0.45	5.8	0.34	1.91e-8	Drug-induced liver injury (flucloxacillin);
CESC	trans	rs116095464	0.764	rs10069197	chr5:230822	G/C	cg00938859	chr5:1591904	SDHAP3	0.61	6.74	0.38	9.82e-11	Breast cancer;
CESC	cis	rs1559088	1.000	rs8106453	chr19:33557412	C/T	cg27124370	chr19:33622961	WDR88	0.42	5.33	0.31	2.07e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs4819052	0.724	rs9753962	chr21:46661384	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.91	13.24	0.63	4.51e-31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs12748961	0.557	rs823127	chr1:205713139	G/A	cg23034840	chr1:205782522	SLC41A1	0.54	6.15	0.35	2.84e-9	White blood cell types;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg22018784	chr9:98079448	FANCC	-0.47	-6.44	-0.37	5.71e-10	Gambling;
CESC	cis	rs904092	0.786	rs2646011	chr4:100161381	A/G	cg12011299	chr4:100065546	ADH4	0.54	6.09	0.35	3.89e-9	Alcohol dependence;
CESC	cis	rs9658691	0.736	rs9658727	chr10:90761865	T/C	cg03111039	chr10:90751583	FAS;ACTA2	-0.64	-5.06	-0.3	7.71e-7	Mosquito bite size;
CESC	cis	rs7208859	0.673	rs11656845	chr17:29206164	G/T	cg19761014	chr17:28927070	LRRC37B2	0.7	5.48	0.32	9.75e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs1799949	1.000	rs4793194	chr17:41218333	G/A	cg25072359	chr17:41440525	NA	0.45	6.07	0.35	4.5e-9	Menopause (age at onset);
CESC	cis	rs7107174	1.000	rs4134379	chr11:77992588	A/G	cg02023728	chr11:77925099	USP35	0.37	5.43	0.32	1.27e-7	Testicular germ cell tumor;
CESC	cis	rs3785574	1.000	rs3785574	chr17:61763185	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.76	9.27	0.49	6.91e-18	Height;
CESC	cis	rs4595586	0.545	rs1349257	chr12:39397139	A/G	cg26384229	chr12:38710491	ALG10B	0.5	7.27	0.41	4.12e-12	Morning vs. evening chronotype;
CESC	cis	rs909674	0.731	rs4821897	chr22:39835587	A/G	cg02038168	chr22:39784481	NA	-0.71	-8.28	-0.45	6.14e-15	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs1218582	0.596	rs906595	chr1:154822907	C/T	cg06221963	chr1:154839813	KCNN3	-0.5	-7.43	-0.42	1.54e-12	Prostate cancer;
CESC	cis	rs2836974	0.931	rs2776307	chr21:40713833	C/G	cg11644478	chr21:40555479	PSMG1	-0.94	-14.21	-0.66	1.91e-34	Cognitive function;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg08925066	chr14:39572669	SEC23A	0.49	6.67	0.38	1.46e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs1707322	0.752	rs8179402	chr1:46142466	C/A	cg06784218	chr1:46089804	CCDC17	0.43	7.58	0.42	5.65e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs763121	0.889	rs9610971	chr22:38910810	C/T	cg06544989	chr22:39130855	UNC84B	0.44	7.25	0.41	4.66e-12	Menopause (age at onset);
CESC	cis	rs10504229	0.683	rs16921808	chr8:58106049	C/T	cg21724239	chr8:58056113	NA	0.58	5.91	0.34	1.02e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs763014	0.898	rs62030902	chr16:638264	C/G	cg00908189	chr16:619842	PIGQ	0.64	8.59	0.47	7.59e-16	Height;
CESC	cis	rs644799	0.862	rs1150361	chr11:95633805	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.46	5.61	0.33	5.06e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs9388451	0.591	rs1268792	chr6:126042124	G/A	cg05901451	chr6:126070800	HEY2	0.54	7.63	0.42	4.19e-13	Brugada syndrome;
CESC	cis	rs7116495	0.609	rs10898812	chr11:71698801	G/A	cg10381502	chr11:71823885	C11orf51	-1.19	-7.81	-0.43	1.32e-13	Severe influenza A (H1N1) infection;
CESC	cis	rs27434	0.605	rs1230366	chr5:96195280	A/G	cg16492584	chr5:96139282	ERAP1	-0.53	-5.94	-0.34	8.99e-9	Ankylosing spondylitis;
CESC	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.87	13.16	0.63	8.66e-31	Prudent dietary pattern;
CESC	cis	rs13343954	0.518	rs7252086	chr19:33534929	T/C	cg17764715	chr19:33622953	WDR88	0.55	7.29	0.41	3.62e-12	Colorectal cancer;
CESC	cis	rs80130819	0.688	rs2468945	chr12:48652414	G/A	cg05342945	chr12:48394962	COL2A1	-0.49	-5.33	-0.31	2.14e-7	Prostate cancer;
CESC	cis	rs13191362	1.000	rs34066731	chr6:163011047	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.87	8.98	0.48	5.33e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs7945705	0.967	rs34842234	chr11:8891894	G/A	cg12365402	chr11:9010492	NRIP3	0.36	5.61	0.33	5.01e-8	Hemoglobin concentration;
CESC	cis	rs7937682	0.889	rs7948236	chr11:111499933	C/A	cg09085632	chr11:111637200	PPP2R1B	-0.99	-15.84	-0.7	3.24e-40	Primary sclerosing cholangitis;
CESC	cis	rs4835473	0.614	rs4487293	chr4:144915033	C/G	cg25736465	chr4:144833511	NA	0.43	6.38	0.36	8.02e-10	Immature fraction of reticulocytes;
CESC	cis	rs763014	0.898	rs2017567	chr16:637212	T/C	cg09781414	chr16:715207	WDR90	-0.33	-5.03	-0.3	9.06e-7	Height;
CESC	cis	rs7659604	0.540	rs4075065	chr4:122683906	A/G	cg19671926	chr4:122722719	EXOSC9	0.58	7.25	0.41	4.44e-12	Type 2 diabetes;
CESC	cis	rs6547741	0.935	rs4260197	chr2:27794150	C/G	cg21248554	chr2:27665150	KRTCAP3	-0.26	-5.44	-0.32	1.23e-7	Oral cavity cancer;
CESC	cis	rs858239	0.669	rs12539467	chr7:23115859	A/G	cg23682824	chr7:23144976	KLHL7	0.5	6.43	0.37	5.85e-10	Cerebrospinal fluid biomarker levels;
CESC	cis	rs258892	0.895	rs13164198	chr5:72051641	G/T	cg21869765	chr5:72125136	TNPO1	0.4	5.36	0.31	1.83e-7	Small cell lung carcinoma;
CESC	cis	rs2243480	1.000	rs10950032	chr7:65738591	C/A	cg13147721	chr7:65941812	NA	0.98	9.24	0.49	8.25e-18	Diabetic kidney disease;
CESC	cis	rs4930103	0.602	rs170101	chr11:2008936	C/T	cg23202291	chr11:1979235	NA	0.36	5.06	0.3	7.84e-7	DNA methylation (parent-of-origin);DNA methylation (variation);
CESC	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg23978390	chr7:1156363	C7orf50	0.58	8.45	0.46	1.94e-15	Longevity;Endometriosis;
CESC	cis	rs9633740	1.000	rs6586028	chr10:82253984	C/T	cg00277334	chr10:82204260	NA	-0.57	-5.85	-0.34	1.42e-8	Post bronchodilator FEV1;
CESC	cis	rs634534	0.622	rs1192168	chr11:65730945	T/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.45	6.75	0.38	9.2e-11	Sum eosinophil basophil counts;Eosinophil counts;
CESC	cis	rs10782582	0.593	rs17848068	chr1:76190216	G/A	cg10523679	chr1:76189770	ACADM	-0.45	-5.35	-0.31	1.87e-7	Daytime sleep phenotypes;
CESC	cis	rs899997	0.862	rs8032552	chr15:78971136	T/C	cg04896959	chr15:78267971	NA	-0.36	-5.16	-0.3	4.94e-7	Coronary artery disease or large artery stroke;
CESC	cis	rs11583043	0.874	rs6577219	chr1:101415707	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.54	6.01	0.35	6.1e-9	Ulcerative colitis;Inflammatory bowel disease;
CESC	cis	rs8180040	0.900	rs4858894	chr3:47484953	C/G	cg27129171	chr3:47204927	SETD2	0.62	9.25	0.49	7.87e-18	Colorectal cancer;
CESC	cis	rs873946	0.689	rs2803993	chr10:134550606	T/C	cg27286337	chr10:134555280	INPP5A	0.72	9.02	0.48	4e-17	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs16857609	0.550	rs1351163	chr2:218267992	A/G	cg15335768	chr2:218268053	DIRC3	-0.41	-5.76	-0.33	2.28e-8	Breast cancer;Breast cancer (estrogen-receptor negative);
CESC	cis	rs7552404	1.000	rs2133134	chr1:76179587	G/A	cg10523679	chr1:76189770	ACADM	0.69	7.93	0.44	6.25e-14	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs7809950	1.000	rs2253146	chr7:107200319	A/G	cg23024343	chr7:107201750	COG5	-0.41	-5.72	-0.33	2.85e-8	Coronary artery disease;
CESC	cis	rs7666738	0.962	rs1527515	chr4:99025733	C/A	cg03676636	chr4:99064102	C4orf37	0.37	5.37	0.31	1.75e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3126085	0.935	rs7534716	chr1:152198654	A/G	cg03465714	chr1:152285911	FLG	-0.43	-5.24	-0.31	3.23e-7	Atopic dermatitis;
CESC	cis	rs12824058	0.678	rs11614163	chr12:130814621	C/G	cg23887609	chr12:130822674	PIWIL1	0.45	5.54	0.32	7.17e-8	Menopause (age at onset);
CESC	cis	rs10504229	0.683	rs66730544	chr8:58127280	A/T	cg02725872	chr8:58115012	NA	-0.45	-6.84	-0.39	5.31e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs7608623	0.644	rs2339940	chr2:24251787	G/T	cg20701182	chr2:24300061	SF3B14	-0.41	-5.41	-0.32	1.44e-7	Obesity-related traits;
CESC	cis	rs5753618	0.539	rs8135344	chr22:31671932	G/T	cg13145458	chr22:31556086	RNF185	0.48	5.4	0.31	1.51e-7	Colorectal cancer;
CESC	cis	rs40363	0.645	rs250633	chr16:3523002	C/T	cg22508957	chr16:3507546	NAT15	0.56	9.21	0.49	1.01e-17	Tuberculosis;
CESC	cis	rs6879260	1.000	rs7706951	chr5:179733407	C/T	cg13944838	chr5:179740914	GFPT2	-0.62	-8.31	-0.45	5.16e-15	Height;
CESC	cis	rs11122272	0.705	rs2486742	chr1:231507254	G/A	cg06096015	chr1:231504339	EGLN1	0.39	5.68	0.33	3.49e-8	Hemoglobin concentration;
CESC	cis	rs11190604	1.000	rs2495732	chr10:102357780	T/C	cg07080220	chr10:102295463	HIF1AN	0.61	5.47	0.32	1.03e-7	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs6500395	1.000	rs11076573	chr16:48632758	A/G	cg04672837	chr16:48644449	N4BP1	0.53	6.72	0.38	1.08e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs8016982	0.674	rs1957549	chr14:81706179	G/A	cg01989461	chr14:81687754	GTF2A1	0.74	11.64	0.58	1.44e-25	Schizophrenia;
CESC	cis	rs2404602	0.716	rs12438077	chr15:76863601	T/C	cg26408565	chr15:76604113	ETFA	-0.4	-5.72	-0.33	2.92e-8	Blood metabolite levels;
CESC	cis	rs34779708	0.931	rs67976880	chr10:35372261	G/C	cg03585969	chr10:35415529	CREM	0.77	10.07	0.53	2.06e-20	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs4722166	0.630	rs10950916	chr7:22799667	C/T	cg26061582	chr7:22766209	IL6	0.51	5.37	0.31	1.71e-7	Lung cancer;
CESC	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	13.77	0.65	6.55e-33	Prudent dietary pattern;
CESC	cis	rs12476592	0.571	rs10865341	chr2:63824050	A/T	cg17519650	chr2:63277830	OTX1	-0.46	-5.14	-0.3	5.28e-7	Childhood ear infection;
CESC	cis	rs793571	0.714	rs972801	chr15:58921198	C/T	cg05156742	chr15:59063176	FAM63B	-0.64	-8.58	-0.47	7.95e-16	Schizophrenia;
CESC	cis	rs9291683	0.595	rs3733585	chr4:10036339	A/G	cg02734326	chr4:10020555	SLC2A9	0.49	6.84	0.39	5.6e-11	Bone mineral density;
CESC	cis	rs1707322	0.721	rs11211157	chr1:46132844	T/C	cg06784218	chr1:46089804	CCDC17	0.43	7.48	0.42	1.07e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs4889855	0.556	rs4297763	chr17:78533626	G/C	cg16591659	chr17:78472290	NA	0.34	5.86	0.34	1.35e-8	Fractional excretion of uric acid;
CESC	cis	rs10463316	0.962	rs61647401	chr5:150743076	T/C	cg03212797	chr5:150827313	SLC36A1	-0.44	-5.19	-0.3	4.25e-7	Metabolite levels (Pyroglutamine);
CESC	cis	rs8067354	0.645	rs11079389	chr17:57887952	G/A	cg02344993	chr17:57696989	CLTC	0.56	6.04	0.35	5.31e-9	Hemoglobin concentration;
CESC	cis	rs9814567	0.712	rs9838467	chr3:134332222	C/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.4	-5.1	-0.3	6.38e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs7412746	0.658	rs6660845	chr1:150841066	G/A	cg17724175	chr1:150552817	MCL1	0.41	6.29	0.36	1.29e-9	Melanoma;
CESC	cis	rs2637266	0.549	rs11516640	chr10:78414532	A/G	cg18941641	chr10:78392320	NA	-0.32	-5.25	-0.31	3.12e-7	Pulmonary function;
CESC	cis	rs2836950	0.509	rs4816618	chr21:40599529	G/A	cg17971929	chr21:40555470	PSMG1	-0.55	-7.16	-0.4	8.14e-12	Menarche (age at onset);
CESC	cis	rs1008375	0.966	rs7666888	chr4:17695722	C/T	cg15017067	chr4:17643749	FAM184B	0.37	5.36	0.31	1.79e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs6964587	1.000	rs7455444	chr7:91639313	C/T	cg17063962	chr7:91808500	NA	0.57	7.92	0.44	6.39e-14	Breast cancer;
CESC	cis	rs12188164	1.000	rs56104584	chr5:437542	T/C	cg26850624	chr5:429559	AHRR	-0.48	-6.63	-0.38	1.85e-10	Cystic fibrosis severity;
CESC	cis	rs3785574	0.962	rs2665840	chr17:61873307	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	-0.58	-7.24	-0.41	4.99e-12	Height;
CESC	cis	rs6582630	0.554	rs8189625	chr12:38401177	C/T	cg26384229	chr12:38710491	ALG10B	-0.46	-6.19	-0.36	2.32e-9	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs11112613	0.713	rs11112587	chr12:105941285	G/A	cg03607813	chr12:105948248	NA	0.64	7.77	0.43	1.69e-13	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CESC	cis	rs72781680	0.752	rs72796138	chr2:23926233	C/T	cg08917208	chr2:24149416	ATAD2B	1.1	10.19	0.53	8.84e-21	Lymphocyte counts;
CESC	cis	rs9487051	0.837	rs4403290	chr6:109611583	A/T	cg12927641	chr6:109611667	NA	-0.43	-6.63	-0.38	1.91e-10	Reticulocyte fraction of red cells;
CESC	cis	rs1552244	1.000	rs7610821	chr3:10136150	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.89	12.81	0.62	1.48e-29	Alzheimer's disease;
CESC	trans	rs7615952	0.576	rs2276727	chr3:125826243	C/T	cg07211511	chr3:129823064	LOC729375	-0.56	-6.33	-0.36	1.05e-9	Blood pressure (smoking interaction);
CESC	cis	rs910316	0.763	rs175014	chr14:75456927	A/G	cg11812906	chr14:75593930	NEK9	-0.8	-12.37	-0.6	4.8e-28	Height;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg00634145	chr1:155108588	RAG1AP1	-0.51	-6.17	-0.35	2.55e-9	Ulcerative colitis;
CESC	cis	rs7412746	0.611	rs10888391	chr1:150729983	G/A	cg22823121	chr1:150693482	HORMAD1	0.46	6.33	0.36	1.07e-9	Melanoma;
CESC	trans	rs561341	0.714	rs474455	chr17:30312465	A/T	cg20587970	chr11:113659929	NA	-1.11	-14.12	-0.66	3.82e-34	Hip circumference adjusted for BMI;
CESC	cis	rs7666738	0.830	rs17027198	chr4:98991085	G/C	cg18180107	chr4:99064573	C4orf37	0.4	5.23	0.31	3.41e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs734999	0.545	rs10910105	chr1:2538209	G/A	cg20673091	chr1:2541236	MMEL1	0.46	7.59	0.42	5.5e-13	Ulcerative colitis;
CESC	cis	rs17376456	0.825	rs28534784	chr5:93063332	C/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.61	5.3	0.31	2.48e-7	Diabetic retinopathy;
CESC	cis	rs2576037	0.526	rs658756	chr18:44431832	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.56	-7.91	-0.44	7.01e-14	Personality dimensions;
CESC	cis	rs6456156	0.792	rs4710179	chr6:167513692	G/T	cg07741184	chr6:167504864	NA	0.38	6.94	0.39	2.95e-11	Primary biliary cholangitis;
CESC	cis	rs2404602	0.692	rs3816266	chr15:76993835	T/G	cg26408565	chr15:76604113	ETFA	-0.39	-5.58	-0.32	6.05e-8	Blood metabolite levels;
CESC	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg26516362	chr5:178986906	RUFY1	0.48	7.76	0.43	1.88e-13	Lung cancer;
CESC	cis	rs11098499	0.954	rs35091806	chr4:120325529	G/A	cg24375607	chr4:120327624	NA	0.47	5.89	0.34	1.14e-8	Corneal astigmatism;
CESC	cis	rs12620999	0.838	rs7589198	chr2:237967615	C/T	cg23555395	chr2:238036564	NA	0.46	6.3	0.36	1.22e-9	Systemic lupus erythematosus;
CESC	cis	rs4450798	0.793	rs28581168	chr3:13740488	A/C	cg05589046	chr3:13742034	LOC285375	0.37	5.49	0.32	9.59e-8	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs7726839	0.540	rs55929359	chr5:595956	C/G	cg16447950	chr5:562315	NA	-0.59	-5.95	-0.34	8.59e-9	Obesity-related traits;
CESC	cis	rs10899021	0.920	rs76121309	chr11:74343921	A/T	cg25880958	chr11:74394337	NA	-0.77	-7.0	-0.39	2.11e-11	Response to metformin (IC50);
CESC	cis	rs7107174	1.000	rs10899469	chr11:78018313	T/C	cg02023728	chr11:77925099	USP35	0.48	6.32	0.36	1.09e-9	Testicular germ cell tumor;
CESC	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg26338869	chr17:61819248	STRADA	0.69	9.24	0.49	8.34e-18	Prudent dietary pattern;
CESC	cis	rs6570726	1.000	rs386678	chr6:145869010	A/G	cg23711669	chr6:146136114	FBXO30	0.71	10.38	0.54	2.11e-21	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9916302	0.904	rs4795356	chr17:37535631	C/T	cg15445000	chr17:37608096	MED1	-0.4	-6.52	-0.37	3.49e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs4820539	1.000	rs916584	chr22:23469433	A/G	cg14186256	chr22:23484241	RTDR1	0.81	14.26	0.66	1.27e-34	Bone mineral density;
CESC	cis	rs1218582	0.772	rs6683557	chr1:154852307	C/G	cg06221963	chr1:154839813	KCNN3	-0.68	-11.73	-0.58	7.29e-26	Prostate cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03837292	chr11:67049397	ADRBK1	-0.59	-6.54	-0.37	3.24e-10	Gut microbiome composition (summer);
CESC	cis	rs5758659	1.000	rs5751255	chr22:42648408	C/T	cg05082376	chr22:42548792	NA	-0.39	-5.75	-0.33	2.5e-8	Cognitive function;
CESC	cis	rs67311347	1.000	rs1119179	chr3:40424929	A/C	cg24209194	chr3:40518798	ZNF619	-0.49	-6.17	-0.35	2.58e-9	Renal cell carcinoma;
CESC	cis	rs2228479	0.867	rs62052168	chr16:89947203	G/A	cg06558623	chr16:89946397	TCF25	1.15	9.14	0.49	1.65e-17	Skin colour saturation;
CESC	trans	rs9467711	0.606	rs34622023	chr6:26362119	A/T	cg06606381	chr12:133084897	FBRSL1	-0.76	-7.08	-0.4	1.28e-11	Autism spectrum disorder or schizophrenia;
CESC	cis	rs4594175	0.926	rs72688713	chr14:51598375	C/T	cg23942311	chr14:51606299	NA	0.37	5.4	0.31	1.48e-7	Cancer;
CESC	cis	rs11191270	0.554	rs77616533	chr10:104055983	A/G	cg15320455	chr10:103880129	LDB1	0.61	5.82	0.34	1.65e-8	Intelligence (multi-trait analysis);
CESC	cis	rs10465746	0.935	rs12133778	chr1:84367626	A/G	cg10977910	chr1:84465055	TTLL7	0.48	6.34	0.36	9.89e-10	Obesity-related traits;
CESC	cis	rs7666738	0.716	rs9994641	chr4:99101605	C/T	cg24818145	chr4:99064322	C4orf37	0.4	5.03	0.3	9.06e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9457247	1.000	rs386548	chr6:167385533	A/T	cg07741184	chr6:167504864	NA	-0.32	-5.78	-0.33	2.1e-8	Crohn's disease;
CESC	cis	rs950776	0.518	rs4243083	chr15:78833830	C/G	cg06917634	chr15:78832804	PSMA4	-0.79	-12.1	-0.6	4.1e-27	Sudden cardiac arrest;
CESC	cis	rs7520050	0.807	rs28844317	chr1:46209207	T/C	cg03146154	chr1:46216737	IPP	0.51	6.79	0.39	7.23e-11	Red blood cell count;Reticulocyte count;
CESC	cis	rs6831352	0.918	rs3919370	chr4:100064326	A/T	cg12011299	chr4:100065546	ADH4	-0.58	-6.31	-0.36	1.14e-9	Alcohol dependence;
CESC	cis	rs9487051	0.738	rs171272	chr6:109530094	T/C	cg01475377	chr6:109611718	NA	-0.45	-6.83	-0.39	5.94e-11	Reticulocyte fraction of red cells;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg03697509	chr11:72466028	STARD10	0.48	6.62	0.38	2.04e-10	Fibrinogen levels;
CESC	cis	rs4434138	0.594	rs7653028	chr3:52763000	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.62	8.66	0.47	4.87e-16	Intelligence (multi-trait analysis);
CESC	cis	rs6860806	0.507	rs272872	chr5:131675864	C/T	cg18758796	chr5:131593413	PDLIM4	-0.42	-5.74	-0.33	2.56e-8	Breast cancer;
CESC	cis	rs4803468	1.000	rs284652	chr19:41928652	C/T	cg14132834	chr19:41945861	ATP5SL	-0.66	-8.18	-0.45	1.22e-14	Height;
CESC	cis	rs60843830	0.928	rs62114494	chr2:211317	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.73	9.05	0.49	3.23e-17	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs1707322	1.000	rs11211223	chr1:46380605	C/T	cg06784218	chr1:46089804	CCDC17	0.33	5.63	0.33	4.51e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2243480	1.000	rs958550	chr7:65635679	C/T	cg13147721	chr7:65941812	NA	0.95	8.89	0.48	9.63e-17	Diabetic kidney disease;
CESC	cis	rs7412746	0.658	rs12090215	chr1:150893660	C/A	cg17724175	chr1:150552817	MCL1	0.38	5.9	0.34	1.11e-8	Melanoma;
CESC	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg07677032	chr17:61819896	STRADA	0.45	6.05	0.35	5.02e-9	Prudent dietary pattern;
CESC	cis	rs7216064	1.000	rs12600941	chr17:65918807	A/G	cg12091567	chr17:66097778	LOC651250	-0.8	-8.05	-0.44	2.9e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs6460942	0.630	rs1866650	chr7:12396897	C/T	cg06484146	chr7:12443880	VWDE	-0.67	-7.12	-0.4	9.88e-12	Coronary artery disease;
CESC	cis	rs9486715	0.867	rs9486444	chr6:96963619	A/G	cg06623918	chr6:96969491	KIAA0776	0.92	14.17	0.66	2.59e-34	Headache;
CESC	cis	rs7072216	0.727	rs7913541	chr10:100172479	A/G	cg26618903	chr10:100175079	PYROXD2	-0.38	-5.85	-0.34	1.41e-8	Metabolite levels;
CESC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg06925236	chr11:68039653	C11orf24	0.48	6.17	0.35	2.56e-9	Tetralogy of Fallot;
CESC	trans	rs1814175	0.645	rs1851844	chr11:50021773	T/C	cg03929089	chr4:120376271	NA	-0.91	-14.8	-0.67	1.58e-36	Height;
CESC	cis	rs1670533	1.000	rs604597	chr4:1094151	G/A	cg04106633	chr4:1044584	NA	-0.4	-5.16	-0.3	4.94e-7	Recombination rate (females);
CESC	cis	rs6963495	0.818	rs73190184	chr7:105163736	C/T	cg19920283	chr7:105172520	RINT1	0.7	6.66	0.38	1.58e-10	Bipolar disorder (body mass index interaction);
CESC	cis	rs12474201	0.775	rs7584870	chr2:46973400	A/T	cg06386533	chr2:46925753	SOCS5	0.74	10.33	0.54	3.15e-21	Height;
CESC	cis	rs7618501	1.000	rs34614773	chr3:49753003	T/G	cg24308560	chr3:49941425	MST1R	0.5	6.94	0.39	3.09e-11	Intelligence (multi-trait analysis);
CESC	cis	rs8031584	0.678	rs798086	chr15:31129211	C/G	cg08109568	chr15:31115862	NA	0.71	9.6	0.51	6.47e-19	Huntington's disease progression;
CESC	cis	rs68170813	0.523	rs12532447	chr7:106940476	C/T	cg02696742	chr7:106810147	HBP1	-0.55	-5.17	-0.3	4.54e-7	Coronary artery disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg14990712	chr19:4055085	ZBTB7A	0.46	6.1	0.35	3.74e-9	Fibrinogen levels;
CESC	cis	rs1448094	0.512	rs7313035	chr12:86250100	C/G	cg02569458	chr12:86230093	RASSF9	0.48	7.19	0.4	6.74e-12	Major depressive disorder;
CESC	cis	rs7923609	1.000	rs10761742	chr10:65085048	A/G	cg01631684	chr10:65280961	REEP3	-0.44	-5.56	-0.32	6.51e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs6952808	0.689	rs58227534	chr7:2046328	A/G	cg21782813	chr7:2030301	MAD1L1	0.51	7.37	0.41	2.14e-12	Bipolar disorder and schizophrenia;
CESC	cis	rs7551222	0.752	rs10900593	chr1:204470096	G/T	cg20240347	chr1:204465584	NA	-0.27	-5.52	-0.32	7.89e-8	Schizophrenia;
CESC	cis	rs6460942	1.000	rs6944134	chr7:12418036	T/C	cg17427002	chr7:12443146	VWDE	-0.51	-5.04	-0.3	8.48e-7	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10137990	chr8:145137203	GPAA1	0.58	6.79	0.38	7.37e-11	Gut microbiome composition (summer);
CESC	cis	rs939658	0.805	rs2177056	chr15:79441489	T/C	cg17916960	chr15:79447300	NA	-0.35	-5.98	-0.34	7.25e-9	Refractive error;
CESC	cis	rs10504229	0.906	rs113823909	chr8:58170635	A/G	cg22535103	chr8:58192502	C8orf71	-1.05	-12.93	-0.62	5.44e-30	Developmental language disorder (linguistic errors);
CESC	cis	rs2652834	0.904	rs2729827	chr15:63360564	C/T	cg05507819	chr15:63340323	TPM1	0.58	6.03	0.35	5.41e-9	HDL cholesterol;
CESC	cis	rs9467711	0.606	rs9358930	chr6:26357011	C/T	cg12826209	chr6:26865740	GUSBL1	0.61	5.17	0.3	4.52e-7	Autism spectrum disorder or schizophrenia;
CESC	trans	rs17685	0.712	rs1859794	chr7:75821544	G/A	cg19862616	chr7:65841803	NCRNA00174	0.81	11.3	0.57	1.92e-24	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs12136530	0.538	rs115773162	chr1:19763168	G/T	cg01832549	chr1:19774989	CAPZB	-0.46	-6.55	-0.37	2.9e-10	Lead levels in blood;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg01908177	chr3:113005203	BOC	0.44	6.29	0.36	1.28e-9	Fibrinogen levels;
CESC	cis	rs2439831	0.850	rs28891769	chr15:44072860	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.68	7.97	0.44	4.59e-14	Lung cancer in ever smokers;
CESC	cis	rs7607369	0.637	rs17462630	chr2:219286541	C/G	cg02176678	chr2:219576539	TTLL4	-0.43	-6.84	-0.39	5.37e-11	Red blood cell count;Amyotrophic lateral sclerosis;
CESC	cis	rs939658	0.805	rs11635757	chr15:79432737	T/C	cg17916960	chr15:79447300	NA	-0.36	-5.98	-0.34	7.3e-9	Refractive error;
CESC	cis	rs858239	0.600	rs7788821	chr7:23133645	A/T	cg23682824	chr7:23144976	KLHL7	0.54	7.34	0.41	2.63e-12	Cerebrospinal fluid biomarker levels;
CESC	cis	rs72781680	0.611	rs36052574	chr2:24306587	A/C	cg20701182	chr2:24300061	SF3B14	0.94	10.39	0.54	2.01e-21	Lymphocyte counts;
CESC	cis	rs1003719	0.788	rs2835605	chr21:38490734	T/A	cg10648535	chr21:38446584	PIGP;TTC3	0.63	8.77	0.47	2.14e-16	Eye color traits;
CESC	cis	rs11098499	0.955	rs1511018	chr4:120161580	G/T	cg24375607	chr4:120327624	NA	0.43	5.23	0.31	3.41e-7	Corneal astigmatism;
CESC	cis	rs2832191	0.632	rs1984011	chr21:30337831	T/A	cg24692254	chr21:30365293	RNF160	-0.96	-17.02	-0.72	2.03e-44	Dental caries;
CESC	cis	rs7618915	0.501	rs55678971	chr3:52717229	T/A	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.4	7.05	0.4	1.54e-11	Bipolar disorder;
CESC	cis	rs523522	0.962	rs10849753	chr12:120910813	C/T	cg27279351	chr12:120934652	DYNLL1	0.68	8.74	0.47	2.65e-16	High light scatter reticulocyte count;
CESC	cis	rs7561273	0.609	rs10200844	chr2:24293363	A/C	cg20701182	chr2:24300061	SF3B14	0.45	6.03	0.35	5.41e-9	Quantitative traits;
CESC	cis	rs2425143	0.908	rs6060632	chr20:34422601	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.66	5.4	0.31	1.52e-7	Blood protein levels;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg19371097	chr1:17735001	RCC2	-0.49	-6.35	-0.36	9.32e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	trans	rs3780486	0.846	rs6476402	chr9:33148552	G/A	cg20290983	chr6:43655470	MRPS18A	0.95	16.66	0.72	3.99e-43	IgG glycosylation;
CESC	cis	rs2180341	0.782	rs4897214	chr6:127723625	G/T	cg27446573	chr6:127587934	RNF146	0.8	11.46	0.58	5.73e-25	Breast cancer;
CESC	cis	rs11048434	0.687	rs12814670	chr12:9060025	C/T	cg04155231	chr12:9217510	LOC144571	0.33	5.47	0.32	1.06e-7	Sjögren's syndrome;
CESC	cis	rs2839186	0.609	rs2839189	chr21:47694357	C/T	cg12516959	chr21:47718080	NA	0.45	6.18	0.35	2.4e-9	Testicular germ cell tumor;
CESC	cis	rs896854	1.000	rs13255935	chr8:95965685	C/A	cg23172400	chr8:95962367	TP53INP1	-0.48	-10.11	-0.53	1.51e-20	Type 2 diabetes;
CESC	cis	rs172166	0.611	rs203882	chr6:28078502	G/A	cg23281280	chr6:28129359	ZNF389	0.43	6.41	0.37	6.55e-10	Cardiac Troponin-T levels;
CESC	cis	rs7044106	0.791	rs4837792	chr9:123483559	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.7	10.28	0.53	4.36e-21	Hip circumference adjusted for BMI;
CESC	cis	rs2832191	0.692	rs2776240	chr21:30310639	C/T	cg24692254	chr21:30365293	RNF160	0.95	17.09	0.72	1.15e-44	Dental caries;
CESC	cis	rs6142102	0.625	rs1883705	chr20:32552878	C/T	cg08999081	chr20:33150536	PIGU	0.34	5.1	0.3	6.63e-7	Skin pigmentation;
CESC	cis	rs34779708	0.931	rs12771399	chr10:35452377	C/T	cg03585969	chr10:35415529	CREM	0.78	10.33	0.54	2.95e-21	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs4665809	1.000	rs11126364	chr2:26314515	A/G	cg27170947	chr2:26402098	FAM59B	-0.6	-7.25	-0.41	4.7e-12	Gut microbiome composition (summer);
CESC	cis	rs798554	0.591	rs757791	chr7:2867296	A/G	cg13628971	chr7:2884303	GNA12	0.42	5.54	0.32	7.14e-8	Height;
CESC	cis	rs1670533	1.000	rs3816474	chr4:1050653	G/A	cg27284194	chr4:1044797	NA	0.49	5.23	0.31	3.4e-7	Recombination rate (females);
CESC	cis	rs7666738	0.791	rs6853608	chr4:99047916	A/G	cg17366294	chr4:99064904	C4orf37	0.61	8.78	0.47	2.13e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs780096	0.526	rs11682621	chr2:27749669	G/A	cg21248554	chr2:27665150	KRTCAP3	-0.33	-6.63	-0.38	1.85e-10	Total body bone mineral density;
CESC	cis	rs16866061	0.890	rs72972401	chr2:225404668	T/C	cg12698349	chr2:225449008	CUL3	0.75	11.48	0.58	5.14e-25	Acute graft versus host disease in bone marrow transplantation (recipient effect);
CESC	cis	rs9300255	0.568	rs3018098	chr12:123654812	T/C	cg00376283	chr12:123451042	ABCB9	0.7	8.86	0.48	1.19e-16	Neutrophil percentage of white cells;
CESC	cis	rs2637266	0.935	rs4353214	chr10:78393149	C/T	cg18941641	chr10:78392320	NA	-0.43	-8.28	-0.45	6.19e-15	Pulmonary function;
CESC	cis	rs1215050	0.740	rs783963	chr4:98989070	A/G	cg17366294	chr4:99064904	C4orf37	0.44	5.99	0.35	6.73e-9	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs514406	0.584	rs7548832	chr1:53193576	A/T	cg27535305	chr1:53392650	SCP2	-0.32	-5.08	-0.3	7.25e-7	Monocyte count;
CESC	trans	rs875971	1.000	rs778722	chr7:65844828	T/C	cg26939375	chr7:64535504	NA	0.47	6.06	0.35	4.69e-9	Aortic root size;
CESC	cis	rs17407555	0.862	rs11729685	chr4:10276787	G/T	cg11266682	chr4:10021025	SLC2A9	-0.41	-5.26	-0.31	2.92e-7	Schizophrenia (age at onset);
CESC	cis	rs5769765	1.000	rs8184990	chr22:50273174	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.45	5.28	0.31	2.7e-7	Schizophrenia;
CESC	cis	rs9790314	0.875	rs336580	chr3:161082982	A/T	cg03342759	chr3:160939853	NMD3	-0.41	-5.4	-0.31	1.5e-7	Morning vs. evening chronotype;
CESC	cis	rs477895	0.653	rs2875749	chr11:63903878	C/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.93	10.18	0.53	9.01e-21	Mean platelet volume;
CESC	cis	rs3820068	0.705	rs72643694	chr1:15860185	C/T	cg17385448	chr1:15911702	AGMAT	0.36	5.62	0.33	4.86e-8	Systolic blood pressure;
CESC	trans	rs367943	1.000	rs348961	chr5:112819944	A/C	cg08495027	chr22:31364830	MORC2;TUG1	-0.62	-6.05	-0.35	5.01e-9	Type 2 diabetes;
CESC	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg03067462	chr11:2422131	TSSC4	0.48	6.42	0.37	6.34e-10	Myopia (pathological);
CESC	cis	rs1552244	1.000	rs17032396	chr3:10153559	A/G	cg00149659	chr3:10157352	C3orf10	-0.7	-8.16	-0.45	1.37e-14	Alzheimer's disease;
CESC	cis	rs9522267	0.535	rs9522305	chr13:112237550	A/G	cg10483660	chr13:112241077	NA	-0.32	-5.69	-0.33	3.29e-8	Hepatitis;
CESC	cis	rs9868809	0.772	rs9809222	chr3:48714411	C/T	cg07636037	chr3:49044803	WDR6	-0.64	-5.65	-0.33	4.04e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs1878931	0.696	rs35175748	chr16:3445427	C/G	cg22508957	chr16:3507546	NAT15	-0.43	-6.4	-0.37	7.11e-10	Body mass index (adult);
CESC	cis	rs763121	0.962	rs138711	chr22:39139913	C/T	cg06544989	chr22:39130855	UNC84B	0.4	6.69	0.38	1.3100000000000001e-10	Menopause (age at onset);
CESC	cis	rs1048238	0.506	rs848209	chr1:16256007	T/C	cg21385522	chr1:16154831	NA	-0.43	-5.38	-0.31	1.63e-7	Systolic blood pressure;
CESC	cis	rs3126085	0.935	rs3126043	chr1:152256030	C/G	cg03465714	chr1:152285911	FLG	-0.44	-5.62	-0.33	4.84e-8	Atopic dermatitis;
CESC	cis	rs4727027	0.901	rs6943937	chr7:148869915	A/G	cg23583168	chr7:148888333	NA	-0.77	-11.26	-0.57	2.68e-24	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs4434138	0.683	rs13063160	chr3:52602274	T/C	cg17372223	chr3:52568218	NT5DC2	0.41	6.34	0.36	9.92e-10	Intelligence (multi-trait analysis);
CESC	cis	rs4889855	0.530	rs4889865	chr17:78568447	A/T	cg16591659	chr17:78472290	NA	0.35	5.73	0.33	2.77e-8	Fractional excretion of uric acid;
CESC	trans	rs11098499	0.691	rs9996494	chr4:120238880	C/A	cg25214090	chr10:38739885	LOC399744	0.59	8.08	0.44	2.33e-14	Corneal astigmatism;
CESC	cis	rs897984	0.568	rs4889653	chr16:30895713	C/T	cg02466173	chr16:30829666	NA	0.43	6.27	0.36	1.43e-9	Dementia with Lewy bodies;
CESC	trans	rs55704346	0.566	rs12509843	chr4:25385456	G/A	cg01822600	chr1:245751692	KIF26B	0.43	6.27	0.36	1.44e-9	Tonsillectomy;
CESC	trans	rs1728785	1.000	rs698728	chr16:68625253	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.65	7.72	0.43	2.35e-13	Ulcerative colitis;
CESC	cis	rs11822910	0.737	rs2584858	chr11:57207077	C/T	cg00522883	chr11:57194120	SLC43A3	0.55	7.04	0.4	1.68e-11	Platelet distribution width;
CESC	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg01171360	chr6:293285	DUSP22	-0.67	-8.79	-0.48	1.96e-16	Menopause (age at onset);
CESC	cis	rs595982	0.527	rs73061659	chr19:49373556	G/A	cg15549821	chr19:49342101	PLEKHA4	-0.65	-6.96	-0.39	2.63e-11	Red cell distribution width;
CESC	cis	rs1348850	0.872	rs2084233	chr2:178331206	G/A	cg23306229	chr2:178417860	TTC30B	0.66	8.16	0.45	1.32e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23379540	chr12:51611600	POU6F1	0.6	6.25	0.36	1.59e-9	Gut microbiome composition (summer);
CESC	cis	rs9894429	0.634	rs11655346	chr17:79572399	A/G	cg21984481	chr17:79567631	NPLOC4	0.35	5.45	0.32	1.14e-7	Eye color traits;
CESC	trans	rs4513299	1.000	rs4849326	chr2:115078288	T/A	cg26275355	chr4:12252318	NA	-0.36	-6.2	-0.36	2.2e-9	Inflammatory biomarkers;
CESC	cis	rs7208859	0.623	rs7220999	chr17:29149298	C/T	cg14008862	chr17:28927542	LRRC37B2	0.66	5.21	0.3	3.84e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs6952808	0.531	rs3779002	chr7:2183219	C/T	cg23048001	chr7:2026167	MAD1L1	0.41	5.24	0.31	3.36e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs6912958	0.712	rs2814712	chr6:88396322	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.5	6.49	0.37	4.31e-10	Monocyte percentage of white cells;
CESC	cis	rs9309473	1.000	rs60844734	chr2:73623205	T/A	cg20560298	chr2:73613845	ALMS1	-0.49	-6.49	-0.37	4.28e-10	Metabolite levels;
CESC	cis	rs13223928	0.572	rs16870744	chr7:3135781	G/A	cg19214707	chr7:3157722	NA	-0.39	-5.37	-0.31	1.74e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
CESC	cis	rs13191362	1.000	rs35383933	chr6:163002869	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.5	5.17	0.3	4.64e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs3092073	0.624	rs11696623	chr20:44580380	C/T	cg00125455	chr20:44574271	PCIF1	0.38	6.0	0.35	6.32e-9	Intelligence (multi-trait analysis);
CESC	cis	rs7107174	1.000	rs2512541	chr11:77981747	A/T	cg02023728	chr11:77925099	USP35	0.48	6.86	0.39	4.75e-11	Testicular germ cell tumor;
CESC	cis	rs11122272	0.766	rs2790871	chr1:231543555	G/C	cg06096015	chr1:231504339	EGLN1	0.41	5.71	0.33	3e-8	Hemoglobin concentration;
CESC	cis	rs477692	0.673	rs511361	chr10:131365052	C/T	cg24747557	chr10:131355152	MGMT	-0.39	-5.25	-0.31	3.14e-7	Response to temozolomide;
CESC	cis	rs9910055	0.530	rs11656758	chr17:42301541	A/G	cg19774624	chr17:42201019	HDAC5	-0.6	-8.66	-0.47	4.59e-16	Total body bone mineral density;
CESC	cis	rs6089829	0.851	rs6122346	chr20:61661822	C/G	cg16240275	chr20:61666158	NCRNA00029	0.5	8.95	0.48	6.42e-17	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs875971	0.545	rs12673308	chr7:65631361	C/A	cg18876405	chr7:65276391	NA	0.51	5.96	0.34	8.21e-9	Aortic root size;
CESC	trans	rs12356475	0.710	rs10822686	chr10:67733250	C/T	cg06324094	chr1:153950482	JTB	0.52	6.18	0.35	2.46e-9	Psoriatic arthritis;
CESC	cis	rs514406	0.893	rs499195	chr1:53344907	C/T	cg08736216	chr1:53307985	ZYG11A	-0.41	-6.77	-0.38	8.37e-11	Monocyte count;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg23806609	chr7:66369525	NA	0.52	7.42	0.41	1.58e-12	Fibrinogen levels;
CESC	cis	rs11718455	0.883	rs2372579	chr3:44034003	A/T	cg08738300	chr3:44038990	NA	0.48	6.41	0.37	6.74e-10	Coronary artery disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg24073613	chr1:210424721	NA	-0.53	-7.19	-0.4	6.73e-12	Fibrinogen levels;
CESC	cis	rs9902453	0.904	rs9905638	chr17:28261022	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	9.16	0.49	1.49e-17	Coffee consumption (cups per day);
CESC	cis	rs4971059	0.617	rs12127609	chr1:155133491	G/C	cg22049894	chr1:155113146	DPM3	0.48	6.07	0.35	4.32e-9	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	ch.11.41625527F	chr11:41668953	NA	-0.62	-6.62	-0.38	1.95e-10	Gut microbiome composition (summer);
CESC	trans	rs61931739	0.500	rs11524949	chr12:34435551	C/T	cg26384229	chr12:38710491	ALG10B	0.7	10.32	0.54	3.19e-21	Morning vs. evening chronotype;
CESC	cis	rs9322193	0.923	rs2151913	chr6:150130642	C/T	cg13206674	chr6:150067644	NUP43	0.42	5.83	0.34	1.65e-8	Lung cancer;
CESC	cis	rs9300255	0.602	rs1617434	chr12:123649486	A/G	cg00376283	chr12:123451042	ABCB9	0.58	6.51	0.37	3.75e-10	Neutrophil percentage of white cells;
CESC	cis	rs4835473	0.932	rs62339580	chr4:144706243	A/G	cg25736465	chr4:144833511	NA	-0.33	-5.43	-0.32	1.28e-7	Immature fraction of reticulocytes;
CESC	cis	rs7395581	1.000	rs830085	chr11:47251199	G/A	cg25783544	chr11:47291846	MADD	-0.57	-7.61	-0.42	4.96e-13	HDL cholesterol;
CESC	cis	rs832540	0.629	rs6888317	chr5:56093307	A/G	cg12311346	chr5:56204834	C5orf35	0.48	5.77	0.33	2.17e-8	Coronary artery disease;
CESC	cis	rs6061231	0.631	rs2427318	chr20:60975727	G/T	cg22541963	chr20:60982533	CABLES2	0.41	5.27	0.31	2.79e-7	Colorectal cancer;
CESC	cis	rs9900062	1.000	rs11871616	chr17:62737602	C/T	cg02598441	chr17:62777298	LOC146880	-0.67	-8.07	-0.44	2.53e-14	QT interval;
CESC	cis	rs853679	0.517	rs9393895	chr6:28127621	T/C	cg22143856	chr6:28129313	ZNF389	0.49	6.24	0.36	1.73e-9	Depression;
CESC	cis	rs1153858	0.621	rs2687512	chr15:45581495	T/C	cg21132104	chr15:45694354	SPATA5L1	-0.77	-9.37	-0.5	3.33e-18	Homoarginine levels;
CESC	cis	rs2797160	1.000	rs1739348	chr6:126014573	T/C	cg05901451	chr6:126070800	HEY2	0.46	6.55	0.37	2.89e-10	Endometrial cancer;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg00399650	chr7:141402322	KIAA1147	0.52	7.08	0.4	1.31e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs2011503	0.882	rs10401714	chr19:19363630	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.54	5.73	0.33	2.76e-8	Bipolar disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17472072	chr3:33759422	CLASP2	0.61	7.09	0.4	1.19e-11	Gut microbiome composition (summer);
CESC	cis	rs901683	1.000	rs17157887	chr10:46020348	G/C	cg16031567	chr10:46195673	NA	-0.77	-5.04	-0.3	8.57e-7	Red blood cell traits;Mean corpuscular volume;
CESC	cis	rs2836950	0.501	rs2836980	chr21:40687618	G/T	cg17971929	chr21:40555470	PSMG1	-0.59	-7.77	-0.43	1.76e-13	Menarche (age at onset);
CESC	cis	rs7666738	0.830	rs10001479	chr4:98918764	A/G	cg17366294	chr4:99064904	C4orf37	-0.55	-7.39	-0.41	1.95e-12	Colonoscopy-negative controls vs population controls;
CESC	cis	rs16973500	0.808	rs112452788	chr16:71911198	C/T	cg09427745	chr16:71932006	KIAA0174	-0.51	-5.05	-0.3	8.42e-7	Response to anti-TNF therapy in rheumatoid arthritis;Attention deficit hyperactivity disorder and conduct disorder;
CESC	cis	rs8070740	1.000	rs8066928	chr17:5328155	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.53	6.37	0.36	8.15e-10	Menopause (age at onset);
CESC	cis	rs1862618	0.525	rs832403	chr5:56265992	G/T	cg12311346	chr5:56204834	C5orf35	0.8	9.68	0.51	3.71e-19	Initial pursuit acceleration;
CESC	cis	rs769267	0.930	rs4808208	chr19:19650096	A/G	cg03709012	chr19:19516395	GATAD2A	1.01	15.55	0.69	3.38e-39	Tonsillectomy;
CESC	cis	rs344364	0.511	rs2982455	chr16:1950498	T/G	cg03013636	chr16:1946785	NA	0.48	6.62	0.38	2.02e-10	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs1552244	1.000	rs6782602	chr3:10116541	G/T	cg00149659	chr3:10157352	C3orf10	0.7	8.38	0.46	3.2e-15	Alzheimer's disease;
CESC	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	10.21	0.53	7.28e-21	Prudent dietary pattern;
CESC	cis	rs12190007	0.547	rs3006178	chr6:169823936	G/A	cg15038512	chr6:170123185	PHF10	-0.5	-6.99	-0.39	2.22e-11	Obesity-related traits;
CESC	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg11494091	chr17:61959527	GH2	0.73	12.48	0.61	2.02e-28	Prudent dietary pattern;
CESC	cis	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg05863683	chr7:1912471	MAD1L1	0.48	7.4	0.41	1.79e-12	Bipolar disorder and schizophrenia;
CESC	cis	rs11098499	0.505	rs75122014	chr4:120362426	G/C	cg09307838	chr4:120376055	NA	0.94	13.69	0.64	1.22e-32	Corneal astigmatism;
CESC	cis	rs4555082	0.957	rs10140586	chr14:105749582	A/G	cg27165867	chr14:105738592	BRF1	-0.47	-5.37	-0.31	1.69e-7	Mean platelet volume;Platelet distribution width;
CESC	cis	rs1707322	0.896	rs946528	chr1:46485562	C/T	cg06784218	chr1:46089804	CCDC17	-0.31	-5.38	-0.31	1.66e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04996668	chr22:24093433	ZNF70	0.56	6.42	0.37	6.14e-10	Gut microbiome composition (summer);
CESC	cis	rs1218582	0.710	rs7553195	chr1:154837796	T/C	cg24250549	chr1:154909240	PMVK	0.63	8.87	0.48	1.08e-16	Prostate cancer;
CESC	cis	rs10392	0.543	rs59777567	chr20:37557548	A/G	cg27552599	chr20:37590471	DHX35	0.41	6.08	0.35	4.15e-9	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg27226920	chr20:2733318	EBF4	-0.44	-6.32	-0.36	1.09e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs6446731	0.500	rs2858085	chr4:3271226	T/G	cg08886695	chr4:3369023	RGS12	0.39	5.59	0.33	5.5e-8	Mean platelet volume;
CESC	cis	rs9467711	0.539	rs34436535	chr6:26370365	G/C	cg14345882	chr6:26364793	BTN3A2	0.6	6.21	0.36	2.06e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs453301	0.606	rs7462373	chr8:8899318	G/C	cg06636001	chr8:8085503	FLJ10661	-0.42	-5.14	-0.3	5.39e-7	Joint mobility (Beighton score);
CESC	cis	rs875971	0.522	rs56028712	chr7:65466565	C/T	cg14393609	chr7:65229607	NA	0.52	7.02	0.4	1.81e-11	Aortic root size;
CESC	cis	rs593982	0.920	rs521678	chr11:65485727	T/G	cg08755490	chr11:65554678	OVOL1	1.19	10.86	0.55	5.78e-23	Atopic dermatitis;
CESC	cis	rs9322193	0.962	rs9688940	chr6:150110113	G/A	cg07701084	chr6:150067640	NUP43	0.43	5.85	0.34	1.45e-8	Lung cancer;
CESC	cis	rs11785400	0.793	rs9297969	chr8:143723237	A/G	cg24634471	chr8:143751801	JRK	0.46	5.82	0.34	1.73e-8	Schizophrenia;
CESC	cis	rs4243830	1.000	rs34757678	chr1:6583270	C/G	cg22792644	chr1:6614718	TAS1R1;NOL9	0.71	6.02	0.35	5.91e-9	Body mass index;
CESC	cis	rs6546550	0.869	rs6712827	chr2:70156540	C/G	cg02498382	chr2:70120550	SNRNP27	-0.39	-6.83	-0.39	5.64e-11	Prevalent atrial fibrillation;
CESC	cis	rs10752881	1.000	rs10752885	chr1:182982878	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.84	13.26	0.63	4.09e-31	Colorectal cancer;
CESC	cis	rs67478160	0.634	rs941473	chr14:104201869	C/G	cg08213375	chr14:104286397	PPP1R13B	0.45	8.6	0.47	7.26e-16	Schizophrenia;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg12065272	chr1:245028125	HNRNPU	0.45	6.11	0.35	3.53e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs6942756	0.774	rs2566876	chr7:128890055	A/G	cg02491457	chr7:128862824	NA	0.65	9.65	0.51	4.39e-19	White matter hyperintensity burden;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18436758	chr1:21113190	HP1BP3	0.55	6.2	0.36	2.11e-9	Gut microbiome composition (summer);
CESC	cis	rs6582630	0.555	rs10880602	chr12:38505660	T/C	cg13010199	chr12:38710504	ALG10B	0.42	5.5	0.32	9.16e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs763512	0.504	rs11652399	chr17:35869781	G/T	cg16670864	chr17:35848621	DUSP14	0.5	6.16	0.35	2.66e-9	3-hydroxypropylmercapturic acid levels in smokers;
CESC	cis	rs2721195	0.549	rs2958492	chr8:145919126	C/T	cg26752003	chr8:145688521	CYHR1	-0.42	-5.53	-0.32	7.75e-8	Age at first birth;
CESC	cis	rs2777491	0.574	rs2730056	chr15:41735785	A/G	cg20272979	chr15:41787780	ITPKA	0.42	5.14	0.3	5.47e-7	Ulcerative colitis;
CESC	cis	rs4523957	0.928	rs170045	chr17:2196905	A/G	cg16513277	chr17:2031491	SMG6	0.59	8.08	0.44	2.29e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs524281	0.861	rs10896090	chr11:65945186	A/G	cg14036092	chr11:66035641	RAB1B	-0.54	-5.03	-0.3	9.2e-7	Electroencephalogram traits;
CESC	cis	rs10779751	0.770	rs2258621	chr1:11141187	C/G	cg08854313	chr1:11322531	MTOR	0.74	8.78	0.47	2.09e-16	Body mass index;
CESC	cis	rs9311474	0.713	rs352170	chr3:52236077	A/G	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.3	5.55	0.32	6.85e-8	Electroencephalogram traits;
CESC	cis	rs12699921	0.933	rs6942635	chr7:17987865	A/G	cg03009463	chr7:17980271	SNX13	0.38	5.06	0.3	7.96e-7	Fibrinogen levels;
CESC	cis	rs73206853	0.609	rs55833146	chr12:110872335	A/G	cg12870014	chr12:110450643	ANKRD13A	0.62	5.09	0.3	6.71e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs910316	0.737	rs175084	chr14:75519175	C/T	cg08847533	chr14:75593920	NEK9	-0.91	-15.66	-0.69	1.43e-39	Height;
CESC	cis	rs875971	0.862	rs778680	chr7:65840414	G/A	cg12463550	chr7:65579703	CRCP	0.49	6.26	0.36	1.56e-9	Aortic root size;
CESC	cis	rs911555	0.723	rs12894652	chr14:103926024	A/G	cg12935359	chr14:103987150	CKB	0.66	9.58	0.51	7.28e-19	Intelligence (multi-trait analysis);
CESC	cis	rs13118159	0.767	rs2141656	chr4:1317192	C/T	cg20887711	chr4:1340912	KIAA1530	0.54	7.47	0.42	1.15e-12	Longevity;
CESC	cis	rs763121	0.853	rs5757181	chr22:39013522	G/A	cg14440974	chr22:39074834	NA	-0.39	-5.14	-0.3	5.34e-7	Menopause (age at onset);
CESC	cis	rs9911578	1.000	rs654778	chr17:56736473	A/C	cg12560992	chr17:57184187	TRIM37	0.93	15.58	0.69	2.6e-39	Intelligence (multi-trait analysis);
CESC	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg03188948	chr7:1209495	NA	0.73	7.05	0.4	1.54e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7586673	0.930	rs6432667	chr2:161905001	T/C	cg21518248	chr2:162101506	NA	0.5	6.52	0.37	3.6e-10	Intelligence (multi-trait analysis);
CESC	cis	rs16917546	1.000	rs10995250	chr10:64396921	G/A	cg03961010	chr10:64397487	ZNF365	-0.37	-6.06	-0.35	4.7e-9	Basal cell carcinoma;
CESC	cis	rs2180341	0.576	rs2057224	chr6:127624414	C/G	cg24812749	chr6:127587940	RNF146	0.6	8.1	0.45	1.97e-14	Breast cancer;
CESC	cis	rs9322193	0.962	rs6914319	chr6:150127440	G/A	cg04369109	chr6:150039330	LATS1	-0.4	-5.48	-0.32	9.71e-8	Lung cancer;
CESC	cis	rs4144743	0.938	rs35439279	chr17:45321694	C/T	cg18085866	chr17:45331354	ITGB3	-0.65	-7.15	-0.4	8.53e-12	Body mass index;
CESC	cis	rs8177179	0.967	rs6782434	chr3:133438834	C/G	cg18769074	chr3:133464867	TF	0.3	5.7	0.33	3.12e-8	Iron status biomarkers (transferrin levels);
CESC	cis	rs7762018	0.769	rs7766146	chr6:170070135	A/T	cg13891659	chr6:170190454	C6orf122;C6orf208	0.57	5.51	0.32	8.63e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs9457247	0.935	rs427824	chr6:167403918	T/G	cg25258033	chr6:167368657	RNASET2	0.38	5.77	0.33	2.23e-8	Crohn's disease;
CESC	trans	rs9467711	0.538	rs35942482	chr6:26444938	T/A	cg06606381	chr12:133084897	FBRSL1	-0.82	-6.76	-0.38	9.01e-11	Autism spectrum disorder or schizophrenia;
CESC	cis	rs7017914	0.967	rs1493198	chr8:71851957	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.16	-0.3	4.74e-7	Bone mineral density;
CESC	cis	rs950776	0.518	rs62008174	chr15:78808947	C/T	cg24631222	chr15:78858424	CHRNA5	-0.4	-5.03	-0.3	9.02e-7	Sudden cardiac arrest;
CESC	cis	rs7917772	0.536	rs11191361	chr10:104411958	C/T	cg22532475	chr10:104410764	TRIM8	-0.43	-6.68	-0.38	1.39e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg00164301	chr17:80351457	C17orf101	0.41	6.16	0.35	2.71e-9	Fibrinogen levels;
CESC	cis	rs10979	0.838	rs12208649	chr6:143893321	G/T	cg25407410	chr6:143891975	LOC285740	-0.61	-9.21	-0.49	1.01e-17	Hypospadias;
CESC	cis	rs2302190	0.882	rs12942018	chr17:56613277	C/T	cg25885038	chr17:56607967	SEPT4	-0.42	-5.69	-0.33	3.33e-8	Vitamin D levels;
CESC	trans	rs13098911	0.540	rs17330872	chr3:46035097	A/G	cg10236987	chr1:228114221	WNT9A	0.66	6.54	0.37	3.11e-10	Celiac disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg06148997	chr2:107084783	RGPD3	0.43	6.03	0.35	5.61e-9	Fibrinogen levels;
CESC	cis	rs6424115	0.708	rs11803575	chr1:24182348	A/T	cg15997130	chr1:24165203	NA	-0.4	-5.06	-0.3	7.96e-7	Immature fraction of reticulocytes;
CESC	cis	rs4975616	0.714	rs37007	chr5:1352372	G/C	cg06550200	chr5:1325588	CLPTM1L	-0.65	-9.79	-0.52	1.63e-19	Lung cancer;
CESC	trans	rs7615952	0.599	rs12485717	chr3:125707075	C/T	cg07211511	chr3:129823064	LOC729375	0.55	6.28	0.36	1.35e-9	Blood pressure (smoking interaction);
CESC	cis	rs10504229	0.861	rs114700910	chr8:58170642	C/T	cg14926445	chr8:58193284	C8orf71	-0.52	-5.59	-0.32	5.77e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs1153858	1.000	rs66939267	chr15:45676902	T/A	cg14582100	chr15:45693742	SPATA5L1	0.42	5.95	0.34	8.38e-9	Homoarginine levels;
CESC	cis	rs60871478	0.635	rs4311567	chr7:792295	T/C	cg15782153	chr7:917662	C7orf20	-0.47	-5.04	-0.3	8.47e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs6502050	0.871	rs6416857	chr17:80063004	A/G	cg01763666	chr17:80159506	CCDC57	0.37	5.14	0.3	5.38e-7	Life satisfaction;
CESC	cis	rs72945132	0.882	rs7116059	chr11:70159690	G/T	cg00319359	chr11:70116639	PPFIA1	0.78	7.71	0.43	2.52e-13	Coronary artery disease;
CESC	cis	rs832540	0.669	rs173764	chr5:56198920	C/T	cg12311346	chr5:56204834	C5orf35	-0.57	-7.57	-0.42	6.09e-13	Coronary artery disease;
CESC	cis	rs12477438	0.520	rs11890338	chr2:99767868	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.85	15.81	0.7	4.17e-40	Chronic sinus infection;
CESC	trans	rs11264799	0.765	rs66931510	chr1:157635085	C/T	cg22691776	chr3:15032403	NR2C2	0.33	6.1	0.35	3.79e-9	IgA nephropathy;
CESC	cis	rs7412746	0.658	rs2272214	chr1:150931462	C/T	cg04414720	chr1:150670196	GOLPH3L	0.52	6.86	0.39	4.74e-11	Melanoma;
CESC	cis	rs12824058	0.831	rs4759655	chr12:130815740	A/G	cg23887609	chr12:130822674	PIWIL1	-0.47	-6.09	-0.35	3.96e-9	Menopause (age at onset);
CESC	cis	rs4780401	0.567	rs34340800	chr16:11779318	G/A	cg01061890	chr16:11836724	TXNDC11	-0.45	-5.63	-0.33	4.67e-8	Rheumatoid arthritis;
CESC	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg11905131	chr22:24372483	LOC391322	-0.74	-10.92	-0.56	3.66e-23	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs4927850	1.000	rs10881563	chr3:195750225	A/G	cg01181863	chr3:195395398	SDHAP2	-0.54	-6.25	-0.36	1.63e-9	Pancreatic cancer;
CESC	cis	rs9902453	0.838	rs3110495	chr17:27978455	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.66	-8.62	-0.47	6.1e-16	Coffee consumption (cups per day);
CESC	cis	rs4434138	0.664	rs62255364	chr3:52701502	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.5	7.23	0.41	5.08e-12	Intelligence (multi-trait analysis);
CESC	trans	rs877282	0.898	rs11253346	chr10:765313	A/G	cg22713356	chr15:30763199	NA	1.16	11.35	0.57	1.37e-24	Uric acid levels;
CESC	trans	rs916888	0.773	rs199447	chr17:44812188	C/T	cg04282206	chr17:62833786	PLEKHM1P	0.55	6.36	0.36	8.57e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs933688	1.000	rs10059163	chr5:90742444	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.96	12.76	0.62	2.16e-29	Smoking behavior;
CESC	cis	rs8060686	0.841	rs56374641	chr16:67908713	G/T	cg26727032	chr16:67993705	SLC12A4	-0.6	-6.82	-0.39	6.03e-11	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs3617	0.625	rs2240917	chr3:52851137	T/C	cg07507251	chr3:52567010	NT5DC2	0.33	5.73	0.33	2.8e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
CESC	cis	rs1401999	1.000	rs939338	chr3:183704068	A/G	cg01324343	chr3:183735012	ABCC5	-0.63	-13.64	-0.64	1.94e-32	Anterior chamber depth;
CESC	cis	rs9611565	0.559	rs739136	chr22:42100275	C/T	cg06634786	chr22:41940651	POLR3H	-0.69	-6.91	-0.39	3.58e-11	Vitiligo;
CESC	cis	rs7116495	0.881	rs676721	chr11:71770638	G/A	cg26138937	chr11:71823887	C11orf51	-0.84	-6.98	-0.39	2.33e-11	Severe influenza A (H1N1) infection;
CESC	cis	rs796364	0.813	rs7565417	chr2:201057491	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.6	6.05	0.35	5.03e-9	Schizophrenia;
CESC	cis	rs7945705	0.837	rs2742474	chr11:9002089	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.48	-8.16	-0.45	1.33e-14	Hemoglobin concentration;
CESC	cis	rs2806561	0.765	rs605367	chr1:23518524	T/C	cg12483005	chr1:23474871	LUZP1	0.37	5.89	0.34	1.15e-8	Height;
CESC	cis	rs7833986	0.501	rs2719226	chr8:57044066	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.62	7.45	0.42	1.35e-12	Height;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg12366118	chr12:62860687	MON2	-0.43	-6.14	-0.35	2.97e-9	Gambling;
CESC	cis	rs17376456	0.825	rs17314825	chr5:93234937	A/G	cg21475434	chr5:93447410	FAM172A	0.74	6.68	0.38	1.42e-10	Diabetic retinopathy;
CESC	cis	rs4253772	0.591	rs11704614	chr22:46691936	A/G	cg18190219	chr22:46762943	CELSR1	-0.59	-5.45	-0.32	1.14e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs1799949	1.000	rs8176120	chr17:41261233	C/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.45	6.31	0.36	1.15e-9	Menopause (age at onset);
CESC	cis	rs6570726	0.755	rs2092297	chr6:145893765	A/G	cg23711669	chr6:146136114	FBXO30	0.97	14.77	0.67	2.05e-36	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13325346	chr17:37353483	CACNB1	-0.53	-6.41	-0.37	6.48e-10	Gut microbiome composition (summer);
CESC	cis	rs60733400	0.818	rs10909839	chr1:2708430	G/A	cg18854424	chr1:2615690	NA	0.31	5.79	0.34	1.98e-8	Multiple sclerosis;
CESC	cis	rs736408	0.812	rs6778329	chr3:52824610	G/A	cg07507251	chr3:52567010	NT5DC2	0.33	5.4	0.31	1.49e-7	Bipolar disorder;
CESC	cis	rs2290720	0.930	rs7301458	chr12:101747562	T/G	cg22051763	chr12:101673672	UTP20	-0.49	-6.04	-0.35	5.28e-9	Brain structure (hippocampal volume);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16029838	chr7:44530503	NUDCD3	0.6	7.21	0.4	5.69e-12	Gut microbiome composition (summer);
CESC	cis	rs6142102	0.602	rs2268079	chr20:32596750	A/G	cg08999081	chr20:33150536	PIGU	0.33	5.05	0.3	8.33e-7	Skin pigmentation;
CESC	cis	rs6582630	0.502	rs11522899	chr12:38270637	T/C	cg26384229	chr12:38710491	ALG10B	0.72	10.26	0.53	5.3e-21	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs412000	0.560	rs4793583	chr17:56451407	A/C	cg12560992	chr17:57184187	TRIM37	-0.82	-12.98	-0.62	3.76e-30	Primary tooth development (time to first tooth eruption);
CESC	cis	rs3862030	0.839	rs7078511	chr10:104283874	C/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.38	-5.26	-0.31	2.92e-7	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
CESC	cis	rs597539	0.652	rs604524	chr11:68629929	G/A	cg21963583	chr11:68658836	MRPL21	0.44	6.04	0.35	5.19e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs7659604	0.540	rs34445121	chr4:122710889	G/A	cg19671926	chr4:122722719	EXOSC9	0.67	8.89	0.48	9.9900000000000006e-17	Type 2 diabetes;
CESC	cis	rs11997175	0.545	rs7388496	chr8:33667898	A/G	ch.8.33884649F	chr8:33765107	NA	0.44	5.28	0.31	2.72e-7	Body mass index;
CESC	cis	rs7520050	0.771	rs4660882	chr1:46116292	C/T	cg06784218	chr1:46089804	CCDC17	0.33	6.06	0.35	4.56e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs10504229	1.000	rs77120900	chr8:58170368	C/T	cg14926445	chr8:58193284	C8orf71	-0.51	-5.49	-0.32	9.29e-8	Developmental language disorder (linguistic errors);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08030134	chr16:85813931	COX4NB	-0.5	-6.14	-0.35	3.05e-9	Gut microbiome composition (summer);
CESC	cis	rs832540	0.931	rs832534	chr5:56213672	G/A	cg12311346	chr5:56204834	C5orf35	-0.42	-5.21	-0.3	3.88e-7	Coronary artery disease;
CESC	cis	rs1005277	0.557	rs176887	chr10:38406094	T/C	cg00409905	chr10:38381863	ZNF37A	-0.48	-6.39	-0.37	7.55e-10	Extrinsic epigenetic age acceleration;
CESC	cis	rs6541297	0.645	rs648456	chr1:230311918	G/A	cg20703242	chr1:230279135	GALNT2	-0.43	-5.59	-0.32	5.66e-8	Coronary artery disease;
CESC	cis	rs644799	0.965	rs534488	chr11:95562327	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	9.15	0.49	1.57e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs66561647	0.661	rs7387614	chr8:128929353	C/T	cg05480350	chr8:128972681	MIR1205;PVT1	0.39	5.19	0.3	4.18e-7	Hemoglobin concentration;
CESC	cis	rs10206020	0.885	rs11899557	chr2:1576123	G/T	cg12573674	chr2:1569213	NA	-0.46	-5.2	-0.3	3.96e-7	IgG glycosylation;
CESC	cis	rs4523957	0.583	rs2984939	chr17:2023965	T/C	cg16513277	chr17:2031491	SMG6	-0.71	-10.1	-0.53	1.62e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs9811920	0.609	rs793460	chr3:99615733	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.59	7.22	0.41	5.61e-12	Axial length;
CESC	cis	rs9457247	0.534	rs9366078	chr6:167399512	A/G	cg23791538	chr6:167370224	RNASET2	0.67	9.68	0.51	3.65e-19	Crohn's disease;
CESC	cis	rs7666738	0.830	rs11940273	chr4:98979965	T/A	cg03467027	chr4:99064603	C4orf37	0.43	5.4	0.31	1.51e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs5167	0.504	rs3760628	chr19:45457225	G/A	cg09555818	chr19:45449301	APOC2	0.41	6.54	0.37	3.08e-10	Blood protein levels;
CESC	cis	rs911555	0.755	rs975892	chr14:103883349	A/T	cg12935359	chr14:103987150	CKB	-0.6	-8.86	-0.48	1.2e-16	Intelligence (multi-trait analysis);
CESC	cis	rs17854409	1.000	rs66956644	chr20:61484499	T/C	cg07645718	chr20:61493192	TCFL5	0.81	5.2	0.3	4.03e-7	Obesity-related traits;
CESC	cis	rs7474896	0.515	rs2738208	chr10:38306128	A/G	cg25427524	chr10:38739819	LOC399744	0.49	5.56	0.32	6.5e-8	Obesity (extreme);
CESC	cis	rs710216	0.957	rs859511	chr1:43430260	C/T	cg03128534	chr1:43423976	SLC2A1	0.54	6.3	0.36	1.21e-9	Red cell distribution width;
CESC	cis	rs12545109	0.800	rs1467125	chr8:57418638	C/T	cg09654669	chr8:57350985	NA	-0.55	-6.58	-0.37	2.56e-10	Obesity-related traits;
CESC	trans	rs877282	0.853	rs10904545	chr10:757100	G/A	cg22713356	chr15:30763199	NA	0.95	8.36	0.46	3.67e-15	Uric acid levels;
CESC	cis	rs10504229	0.683	rs55637580	chr8:58135419	C/T	cg02725872	chr8:58115012	NA	-0.45	-7.05	-0.4	1.52e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs77972916	0.561	rs10167415	chr2:43552460	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.6	-5.32	-0.31	2.19e-7	Granulocyte percentage of myeloid white cells;
CESC	cis	rs1862618	0.671	rs2591955	chr5:56244948	C/T	cg24549020	chr5:56110836	MAP3K1	-0.52	-6.46	-0.37	4.87e-10	Initial pursuit acceleration;
CESC	cis	rs6060717	0.610	rs1891151	chr20:34612726	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.45	-5.17	-0.3	4.71e-7	Hip circumference adjusted for BMI;
CESC	cis	rs7666738	0.830	rs7687315	chr4:98900613	A/G	cg03467027	chr4:99064603	C4orf37	0.43	5.32	0.31	2.23e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7084402	0.967	rs2438182	chr10:60314815	A/T	cg07615347	chr10:60278583	BICC1	0.61	9.59	0.51	7.04e-19	Refractive error;
CESC	cis	rs2576037	0.583	rs2576050	chr18:44558912	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.49	6.58	0.37	2.45e-10	Personality dimensions;
CESC	cis	rs10905065	1.000	rs10905065	chr10:5769827	C/T	cg11519256	chr10:5708881	ASB13	0.44	5.94	0.34	8.88e-9	Menopause (age at onset);
CESC	cis	rs920590	0.684	rs57462676	chr8:19670848	G/C	cg17834443	chr8:19674713	INTS10	0.55	6.09	0.35	3.85e-9	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs3857067	1.000	rs6532463	chr4:95027048	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.53	-8.12	-0.45	1.77e-14	QT interval;
CESC	cis	rs4819052	0.851	rs2236446	chr21:46678985	T/C	cg11663144	chr21:46675770	NA	-0.47	-6.99	-0.39	2.27e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03131298	chr16:31580889	CSDAP1	-0.47	-6.11	-0.35	3.59e-9	Gut microbiome composition (summer);
CESC	cis	rs9300255	0.510	rs1727323	chr12:123698790	T/C	cg05973401	chr12:123451056	ABCB9	0.49	5.63	0.33	4.63e-8	Neutrophil percentage of white cells;
CESC	cis	rs3806933	0.522	rs13153937	chr5:110434307	C/T	cg04022379	chr5:110408740	TSLP	0.48	7.95	0.44	5.23e-14	Eosinophilic esophagitis;
CESC	cis	rs2832077	0.527	rs9981922	chr21:30212718	A/G	cg08807101	chr21:30365312	RNF160	-0.64	-8.28	-0.45	5.94e-15	Cognitive test performance;
CESC	cis	rs7923452	0.507	rs612802	chr10:30756441	G/A	cg25182066	chr10:30743637	MAP3K8	-0.51	-7.16	-0.4	7.9e-12	Itch intensity from mosquito bite;
CESC	cis	rs2120019	0.608	rs8042558	chr15:75320433	G/T	cg09165964	chr15:75287851	SCAMP5	-0.8	-10.86	-0.56	5.61e-23	Blood trace element (Zn levels);
CESC	cis	rs4689592	0.619	rs3796908	chr4:7061378	G/A	cg19539972	chr4:7069911	GRPEL1	0.77	9.17	0.49	1.37e-17	Monocyte percentage of white cells;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg01840591	chr16:19179931	SYT17	-0.46	-6.33	-0.36	1.04e-9	Asthma;
CESC	cis	rs708547	0.836	rs1315005	chr4:57858237	C/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.77	10.29	0.53	4.12e-21	Response to bleomycin (chromatid breaks);
CESC	cis	rs7916697	0.593	rs7912895	chr10:70021498	A/G	cg06988349	chr10:69991859	ATOH7	0.32	5.19	0.3	4.12e-7	Optic disc area;
CESC	cis	rs9549367	0.636	rs486407	chr13:113833499	G/A	cg18105134	chr13:113819100	PROZ	0.55	7.12	0.4	1.04e-11	Platelet distribution width;
CESC	cis	rs9303401	0.614	rs62084384	chr17:57126842	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.99	12.57	0.61	9.48e-29	Cognitive test performance;
CESC	cis	rs9902453	0.834	rs9901694	chr17:28271645	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	8.8	0.48	1.79e-16	Coffee consumption (cups per day);
CESC	cis	rs2486288	0.656	rs2413768	chr15:45561984	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.54	-6.46	-0.37	4.99e-10	Glomerular filtration rate;
CESC	cis	rs1799949	1.000	rs11659028	chr17:41195025	T/A	cg25072359	chr17:41440525	NA	0.51	6.64	0.38	1.77e-10	Menopause (age at onset);
CESC	cis	rs801193	0.569	rs2659892	chr7:66200305	A/G	cg12463550	chr7:65579703	CRCP	0.49	6.35	0.36	9.51e-10	Aortic root size;
CESC	cis	rs6120849	0.573	rs3746429	chr20:33703607	A/G	cg24642439	chr20:33292090	TP53INP2	-0.72	-6.79	-0.38	7.52e-11	Protein C levels;
CESC	cis	rs1983170	1.000	rs12563578	chr1:91993702	T/C	cg21854759	chr1:92012499	NA	0.52	5.6	0.33	5.45e-8	Eosinophil percentage of white cells;
CESC	trans	rs1973993	0.745	rs7512263	chr1:96941158	C/A	cg10631902	chr5:14652156	NA	-0.47	-6.18	-0.35	2.43e-9	Weight;
CESC	cis	rs4363385	0.773	rs310122	chr1:153064288	C/T	cg22204954	chr1:153085998	SPRR2F	-0.4	-5.54	-0.32	7.43e-8	Inflammatory skin disease;
CESC	cis	rs6952808	0.531	rs3779002	chr7:2183219	C/T	cg08027265	chr7:2291960	NA	-0.49	-7.48	-0.42	1.09e-12	Bipolar disorder and schizophrenia;
CESC	cis	rs11122272	0.705	rs2486731	chr1:231532511	C/T	cg06096015	chr1:231504339	EGLN1	-0.38	-5.54	-0.32	7.3e-8	Hemoglobin concentration;
CESC	cis	rs7618915	0.501	rs7611731	chr3:52692721	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.61	8.97	0.48	5.62e-17	Bipolar disorder;
CESC	cis	rs9393777	0.513	rs1104871	chr6:26665235	T/G	cg12292205	chr6:26970375	C6orf41	-0.54	-5.98	-0.34	7.34e-9	Intelligence (multi-trait analysis);
CESC	cis	rs2242116	0.932	rs4683301	chr3:46931478	A/T	cg27129171	chr3:47204927	SETD2	-0.38	-5.39	-0.31	1.53e-7	Birth weight;
CESC	cis	rs72627123	0.749	rs10149956	chr14:74649106	A/G	cg12022184	chr14:74485813	ENTPD5;C14orf45	-0.75	-5.25	-0.31	3.11e-7	Morning vs. evening chronotype;
CESC	trans	rs61931739	0.500	rs11053197	chr12:34441949	C/T	cg13010199	chr12:38710504	ALG10B	0.48	6.28	0.36	1.38e-9	Morning vs. evening chronotype;
CESC	cis	rs892961	0.932	rs7223768	chr17:75410521	G/A	cg05865280	chr17:75406074	SEPT9	0.61	12.53	0.61	1.38e-28	Airflow obstruction;
CESC	cis	rs4970966	0.951	rs11204682	chr1:150595537	G/T	cg13175981	chr1:150552382	MCL1	0.6	6.22	0.36	1.95e-9	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs10504229	1.000	rs117231141	chr8:58185465	A/G	cg05313129	chr8:58192883	C8orf71	-0.55	-6.29	-0.36	1.34e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs11785400	0.793	rs9297969	chr8:143723237	A/G	cg10596483	chr8:143751796	JRK	0.42	5.36	0.31	1.77e-7	Schizophrenia;
CESC	cis	rs10504229	0.683	rs56741275	chr8:58136108	C/G	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs4547160	0.888	rs10877953	chr12:63488462	C/T	cg26727693	chr12:63544175	AVPR1A	0.43	6.35	0.36	9.56e-10	Morning vs. evening chronotype;
CESC	cis	rs35306767	1.000	rs35306767	chr10:989437	A/T	cg10556349	chr10:835070	NA	0.55	5.41	0.32	1.44e-7	Eosinophil percentage of granulocytes;
CESC	cis	rs7927592	0.763	rs10896327	chr11:68235275	G/C	cg01657329	chr11:68192670	LRP5	-0.47	-6.19	-0.36	2.29e-9	Total body bone mineral density;
CESC	cis	rs2439831	0.867	rs2412780	chr15:43655794	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.93	11.25	0.57	2.98e-24	Lung cancer in ever smokers;
CESC	cis	rs7312933	0.607	rs7965392	chr12:42540280	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.46	5.95	0.34	8.64e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	trans	rs12599106	0.680	rs34728702	chr16:34896584	A/G	cg01171360	chr6:293285	DUSP22	-0.67	-8.64	-0.47	5.47e-16	Menopause (age at onset);
CESC	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg22535103	chr8:58192502	C8orf71	0.9	9.48	0.5	1.54e-18	Developmental language disorder (linguistic errors);
CESC	cis	rs710216	0.843	rs844501	chr1:43440783	G/A	cg22176566	chr1:43424700	SLC2A1	0.48	5.16	0.3	4.86e-7	Red cell distribution width;
CESC	cis	rs9291683	0.526	rs12506122	chr4:10033538	C/A	cg11266682	chr4:10021025	SLC2A9	0.66	12.66	0.61	4.64e-29	Bone mineral density;
CESC	cis	rs17433780	0.857	rs12140979	chr1:89467242	C/G	cg09516651	chr1:89888402	LOC400759	0.67	8.98	0.48	5.18e-17	Carotid intima media thickness;
CESC	cis	rs754466	0.651	rs55738779	chr10:79652395	C/T	cg17075019	chr10:79541650	NA	-0.83	-11.79	-0.59	4.62e-26	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs1707322	0.752	rs4607935	chr1:46117161	C/T	cg05343316	chr1:45956843	TESK2	0.51	6.24	0.36	1.7e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9399135	0.967	rs6902438	chr6:135336587	C/T	cg24558204	chr6:135376177	HBS1L	0.52	7.18	0.4	7.05e-12	Red blood cell count;
CESC	cis	rs8028182	0.549	rs56395816	chr15:75664571	A/T	cg20655648	chr15:75932815	IMP3	-0.46	-5.72	-0.33	2.87e-8	Sudden cardiac arrest;
CESC	cis	rs2404602	0.574	rs4886795	chr15:76642218	G/C	cg00316803	chr15:76480434	C15orf27	0.44	5.86	0.34	1.37e-8	Blood metabolite levels;
CESC	cis	rs17445774	1.000	rs17445774	chr2:200859249	A/G	cg23649088	chr2:200775458	C2orf69	-0.64	-7.24	-0.41	4.97e-12	LDL cholesterol to HDL cholesterol ratio;
CESC	cis	rs12681288	0.676	rs2701914	chr8:999935	C/T	cg04851639	chr8:1020857	NA	-0.32	-6.86	-0.39	4.9e-11	Schizophrenia;
CESC	cis	rs17270561	1.000	rs17270561	chr6:25820439	A/C	cg16482183	chr6:26056742	HIST1H1C	-0.51	-5.86	-0.34	1.37e-8	Iron status biomarkers;
CESC	cis	rs977987	0.778	rs4887821	chr16:75398574	G/A	cg03315344	chr16:75512273	CHST6	0.39	5.63	0.33	4.61e-8	Dupuytren's disease;
CESC	cis	rs875971	0.929	rs778692	chr7:65872449	A/G	cg18876405	chr7:65276391	NA	0.5	6.68	0.38	1.43e-10	Aortic root size;
CESC	cis	rs13118159	0.550	rs4974614	chr4:1373489	A/G	cg19318889	chr4:1322082	MAEA	0.62	7.59	0.42	5.56e-13	Longevity;
CESC	cis	rs7223966	1.000	rs11657120	chr17:61857218	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.73	0.38	1.06e-10	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs4727027	0.754	rs11764892	chr7:148858916	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.47	5.59	0.32	5.74e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	trans	rs7819412	0.594	rs7460507	chr8:10969075	C/T	cg06636001	chr8:8085503	FLJ10661	-0.53	-6.97	-0.39	2.56e-11	Triglycerides;
CESC	cis	rs4713118	0.516	rs7739216	chr6:28079946	G/T	cg17949981	chr6:28129498	ZNF389	0.45	5.63	0.33	4.71e-8	Parkinson's disease;
CESC	cis	rs67478160	0.608	rs11160760	chr14:104248938	G/T	cg01849466	chr14:104193079	ZFYVE21	-0.52	-7.18	-0.4	7.16e-12	Schizophrenia;
CESC	cis	rs6120849	0.802	rs6087682	chr20:33752897	A/T	cg24642439	chr20:33292090	TP53INP2	0.61	6.49	0.37	4.21e-10	Protein C levels;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg15658577	chr2:179319711	DFNB59;MIR548N	0.52	6.78	0.38	7.94e-11	Fibrinogen levels;
CESC	cis	rs8031584	0.672	rs17815726	chr15:31313252	C/G	cg14829155	chr15:31115871	NA	0.67	7.34	0.41	2.58e-12	Huntington's disease progression;
CESC	cis	rs7927771	0.524	rs7943213	chr11:47715524	T/C	cg20307385	chr11:47447363	PSMC3	0.61	8.46	0.46	1.82e-15	Subjective well-being;
CESC	cis	rs7084402	0.967	rs1649015	chr10:60289031	A/G	cg07615347	chr10:60278583	BICC1	0.6	9.41	0.5	2.54e-18	Refractive error;
CESC	cis	rs7618915	0.571	rs34115864	chr3:52612178	A/G	cg18099408	chr3:52552593	STAB1	-0.33	-5.47	-0.32	1.02e-7	Bipolar disorder;
CESC	cis	rs9581857	0.685	rs9319372	chr13:28042796	C/T	cg01674679	chr13:27998804	GTF3A	0.67	5.43	0.32	1.26e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
CESC	cis	rs7542091	0.739	rs10863793	chr1:210037420	G/A	cg22029157	chr1:209979665	IRF6	0.47	7.0	0.39	2.15e-11	Monobrow;
CESC	cis	rs11577318	0.853	rs12743998	chr1:26629882	G/A	cg00813993	chr1:26644493	UBXN11;CD52	-0.4	-6.46	-0.37	5.05e-10	Granulocyte percentage of myeloid white cells;
CESC	cis	rs875971	0.825	rs801202	chr7:66023929	C/T	cg18252515	chr7:66147081	NA	0.46	5.96	0.34	8.08e-9	Aortic root size;
CESC	cis	rs4654899	0.931	rs1152998	chr1:21124290	C/T	cg05370193	chr1:21551575	ECE1	0.37	5.42	0.32	1.32e-7	Superior frontal gyrus grey matter volume;
CESC	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg06873352	chr17:61820015	STRADA	0.72	12.67	0.61	4.43e-29	Prudent dietary pattern;
CESC	cis	rs506597	0.920	rs221770	chr7:100302094	A/T	cg10426581	chr7:100472382	SRRT	0.61	5.23	0.31	3.52e-7	Pursuit maintenance gain in psychotic disorders;
CESC	cis	rs1018836	0.631	rs2205157	chr8:91472384	C/T	cg16814680	chr8:91681699	NA	-0.52	-6.92	-0.39	3.38e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs68170813	0.641	rs12532953	chr7:106865920	C/T	cg02696742	chr7:106810147	HBP1	-0.52	-5.08	-0.3	7.2e-7	Coronary artery disease;
CESC	cis	rs9733	0.519	rs7511673	chr1:150707636	A/T	cg18016565	chr1:150552671	MCL1	0.34	5.22	0.31	3.63e-7	Tonsillectomy;
CESC	cis	rs11577318	0.853	rs4526602	chr1:26648034	C/T	cg00813993	chr1:26644493	UBXN11;CD52	-0.4	-6.41	-0.37	6.69e-10	Granulocyte percentage of myeloid white cells;
CESC	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg11494091	chr17:61959527	GH2	0.76	13.48	0.64	6.83e-32	Prudent dietary pattern;
CESC	cis	rs1707322	0.752	rs10430105	chr1:46138876	G/A	cg03146154	chr1:46216737	IPP	0.82	11.53	0.58	3.39e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs3820068	0.603	rs998032	chr1:15989918	T/C	cg16988262	chr1:15930761	NA	0.34	5.59	0.32	5.64e-8	Systolic blood pressure;
CESC	cis	rs2073300	0.609	rs77673953	chr20:23398794	G/C	cg16736954	chr20:23401023	NAPB	0.77	5.7	0.33	3.12e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs372883	0.600	rs1236460	chr21:30615513	G/A	cg08807101	chr21:30365312	RNF160	-0.5	-5.87	-0.34	1.33e-8	Pancreatic cancer;
CESC	cis	rs6088619	1.000	rs6088619	chr20:33411871	A/G	cg08999081	chr20:33150536	PIGU	0.68	5.86	0.34	1.35e-8	Hip circumference adjusted for BMI;
CESC	cis	rs1348850	0.645	rs10181259	chr2:178428256	C/A	cg23306229	chr2:178417860	TTC30B	0.75	8.31	0.45	5.11e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs172166	0.611	rs203883	chr6:28078356	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.48	-6.22	-0.36	1.92e-9	Cardiac Troponin-T levels;
CESC	cis	rs9611565	0.592	rs8779	chr22:42070276	T/C	cg06634786	chr22:41940651	POLR3H	0.62	6.25	0.36	1.67e-9	Vitiligo;
CESC	cis	rs780096	0.647	rs11682083	chr2:27752296	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.32	-6.35	-0.36	9.28e-10	Total body bone mineral density;
CESC	cis	rs9399135	0.967	rs6925424	chr6:135313948	T/A	cg22676075	chr6:135203613	NA	0.51	7.23	0.41	5.22e-12	Red blood cell count;
CESC	cis	rs2243480	1.000	rs73150014	chr7:65450919	A/C	cg13147721	chr7:65941812	NA	-0.9	-8.73	-0.47	2.9e-16	Diabetic kidney disease;
CESC	cis	rs12497850	0.805	rs11130176	chr3:48844077	A/G	cg06212747	chr3:49208901	KLHDC8B	0.65	8.81	0.48	1.68e-16	Parkinson's disease;
CESC	cis	rs1046896	0.552	rs12602280	chr17:80805421	G/C	cg02711726	chr17:80685570	FN3KRP	-0.43	-5.56	-0.32	6.61e-8	Glycated hemoglobin levels;
CESC	cis	rs5750830	0.594	rs9611169	chr22:39783027	C/T	cg11247378	chr22:39784982	NA	-0.59	-8.94	-0.48	6.6e-17	Intelligence (multi-trait analysis);
CESC	cis	rs6466055	0.720	rs7800928	chr7:105007470	T/C	cg04380332	chr7:105027541	SRPK2	-0.42	-5.47	-0.32	1.02e-7	Schizophrenia;
CESC	cis	rs3793683	0.571	rs12781152	chr10:134590257	G/C	cg27297192	chr10:134578999	INPP5A	0.39	5.16	0.3	4.75e-7	Migraine;
CESC	cis	rs2295359	0.892	rs4655687	chr1:67649946	C/T	cg17031739	chr1:67600172	NA	0.4	5.2	0.3	4.05e-7	Psoriasis;
CESC	cis	rs832540	0.519	rs6895442	chr5:56260998	T/C	cg24531977	chr5:56204891	C5orf35	-0.43	-5.31	-0.31	2.34e-7	Coronary artery disease;
CESC	cis	rs514406	0.679	rs960570	chr1:53237763	A/G	cg08736216	chr1:53307985	ZYG11A	0.36	6.32	0.36	1.09e-9	Monocyte count;
CESC	trans	rs4950322	0.518	rs55697094	chr1:146592787	T/C	cg04954894	chr8:38089920	DDHD2	-0.6	-6.47	-0.37	4.75e-10	Protein quantitative trait loci;
CESC	cis	rs7824557	0.628	rs7831346	chr8:11193530	C/T	cg21775007	chr8:11205619	TDH	0.55	8.74	0.47	2.75e-16	Retinal vascular caliber;
CESC	cis	rs9322193	0.923	rs9479094	chr6:150046219	C/T	cg09699651	chr6:150184138	LRP11	0.39	5.04	0.3	8.83e-7	Lung cancer;
CESC	cis	rs8180040	0.764	rs12629262	chr3:47196580	C/T	cg27129171	chr3:47204927	SETD2	0.69	10.44	0.54	1.33e-21	Colorectal cancer;
CESC	cis	rs4132509	1.000	rs57824597	chr1:243930399	C/T	cg21452805	chr1:244014465	NA	0.52	6.37	0.36	8.35e-10	RR interval (heart rate);
CESC	cis	rs2795502	0.938	rs2744085	chr10:43341976	C/T	cg20628663	chr10:43360327	NA	0.57	6.85	0.39	5.02e-11	Blood protein levels;
CESC	cis	rs11098499	0.542	rs7677836	chr4:120310638	T/A	cg09307838	chr4:120376055	NA	0.92	12.66	0.61	4.96e-29	Corneal astigmatism;
CESC	cis	rs6866344	0.697	rs11743893	chr5:178125194	C/T	cg03877680	chr5:178157825	ZNF354A	0.67	7.87	0.44	9.2e-14	Neutrophil percentage of white cells;
CESC	cis	rs1129187	0.837	rs4714634	chr6:42901120	G/A	cg24101359	chr6:42928495	GNMT	0.61	8.82	0.48	1.55e-16	Alzheimer's disease in APOE e4+ carriers;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg24883605	chr17:79508142	C17orf70	0.45	6.1	0.35	3.65e-9	Fibrinogen levels;
CESC	cis	rs7552404	0.924	rs3818855	chr1:76198785	C/T	cg10523679	chr1:76189770	ACADM	0.79	10.91	0.56	3.81e-23	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs858239	0.965	rs156429	chr7:23306020	A/G	cg23682824	chr7:23144976	KLHL7	0.38	5.09	0.3	6.85e-7	Cerebrospinal fluid biomarker levels;
CESC	cis	rs13108904	0.967	rs4405964	chr4:1278814	A/G	cg22903657	chr4:1355424	KIAA1530	-0.38	-5.23	-0.31	3.48e-7	Obesity-related traits;
CESC	trans	rs1728785	1.000	rs11648314	chr16:68596775	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.71	8.6	0.47	7.11e-16	Ulcerative colitis;
CESC	cis	rs17711722	0.701	rs781143	chr7:65439879	G/C	cg18876405	chr7:65276391	NA	0.7	9.79	0.52	1.65e-19	Calcium levels;
CESC	cis	rs1400745	0.756	rs3783316	chr14:35337192	A/G	cg16230307	chr14:35515116	FAM177A1	0.44	5.25	0.31	3.18e-7	Monocyte count;
CESC	cis	rs2425143	1.000	rs11700256	chr20:34372941	C/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.69	5.94	0.34	9.08e-9	Blood protein levels;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg25018755	chr22:43506952	BIK	0.5	6.65	0.38	1.65e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs9300255	0.569	rs1727320	chr12:123700476	T/A	cg05973401	chr12:123451056	ABCB9	0.49	5.63	0.33	4.65e-8	Neutrophil percentage of white cells;
CESC	cis	rs12893668	0.543	rs1799796	chr14:104165927	T/C	cg08213375	chr14:104286397	PPP1R13B	0.31	5.1	0.3	6.45e-7	Reticulocyte count;
CESC	cis	rs2456568	0.803	rs10765641	chr11:93640312	T/C	cg26875233	chr11:93583750	C11orf90	-0.29	-5.07	-0.3	7.48e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
CESC	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.52	6.16	0.35	2.62e-9	Prudent dietary pattern;
CESC	cis	rs6500602	0.929	rs9926114	chr16:4478322	C/G	cg08645402	chr16:4508243	NA	0.4	6.03	0.35	5.44e-9	Schizophrenia;
CESC	cis	rs1511802	0.666	rs13106826	chr4:187125168	T/A	cg24794857	chr4:187113578	CYP4V2	0.46	6.08	0.35	4.23e-9	Blood protein levels;
CESC	cis	rs2985684	0.625	rs4900931	chr14:50022793	A/T	cg10008539	chr14:50087325	RPL36AL;MGAT2	-0.41	-5.04	-0.3	8.68e-7	Carotid intima media thickness;
CESC	cis	rs1008375	1.000	rs60178264	chr4:17685308	G/T	cg16339924	chr4:17578868	LAP3	0.51	6.55	0.37	2.98e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs7618915	0.547	rs34537256	chr3:52657472	A/G	cg05564831	chr3:52568323	NT5DC2	0.45	6.8	0.39	6.82e-11	Bipolar disorder;
CESC	cis	rs8050907	0.744	rs17137053	chr16:4524155	C/G	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.9	6.28	0.36	1.39e-9	Obesity-related traits;
CESC	cis	rs367943	1.000	rs348962	chr5:112819086	C/T	cg12552261	chr5:112820674	MCC	0.61	7.85	0.43	1.05e-13	Type 2 diabetes;
CESC	cis	rs4822044	0.680	rs8138780	chr22:42097462	A/T	cg17376030	chr22:41985996	PMM1	-0.78	-8.3	-0.45	5.4e-15	Cannabis dependence symptom count;
CESC	trans	rs11722228	0.522	rs73212880	chr4:10115692	T/A	cg26043149	chr18:55253948	FECH	0.97	11.8	0.59	4.27e-26	Gout;Urate levels;Serum uric acid levels;
CESC	cis	rs7267979	0.753	rs400357	chr20:25479058	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.76	13.71	0.64	1.05e-32	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs902774	0.597	rs7299694	chr12:53352572	A/C	cg14581129	chr12:53358946	NA	-0.45	-6.05	-0.35	5.02e-9	Prostate cancer;
CESC	cis	rs2576037	0.583	rs501062	chr18:44411135	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.35	5.62	0.33	4.87e-8	Personality dimensions;
CESC	cis	rs863345	0.967	rs12041218	chr1:158481574	A/G	cg12129480	chr1:158549410	OR10X1	-0.3	-5.9	-0.34	1.14e-8	Pneumococcal bacteremia;
CESC	cis	rs7618915	0.571	rs6778844	chr3:52596398	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.49	-6.33	-0.36	1.05e-9	Bipolar disorder;
CESC	cis	rs10851478	0.872	rs4480740	chr15:49755842	A/G	cg08060515	chr15:49448048	GALK2;COPS2	-0.43	-5.35	-0.31	1.87e-7	Oral cavity cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05973872	chr7:2293347	NA	-0.52	-6.12	-0.35	3.4e-9	Gut microbiome composition (summer);
CESC	cis	rs16975963	0.644	rs2290999	chr19:38138887	T/C	cg14970273	chr19:37794573	NA	-0.4	-5.08	-0.3	7.11e-7	Longevity;
CESC	cis	rs17376456	0.825	rs10056879	chr5:93282218	C/A	cg21475434	chr5:93447410	FAM172A	0.79	6.2	0.36	2.11e-9	Diabetic retinopathy;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg16249894	chr13:21141322	IFT88	-0.47	-6.05	-0.35	4.85e-9	Fibrinogen levels;
CESC	cis	rs7267979	1.000	rs2257985	chr20:25269743	G/T	cg08601574	chr20:25228251	PYGB	0.39	5.65	0.33	4.08e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs1862618	0.853	rs2432195	chr5:56120413	C/T	cg03609598	chr5:56110824	MAP3K1	-0.51	-5.5	-0.32	9.11e-8	Initial pursuit acceleration;
CESC	cis	rs11122272	0.735	rs2749716	chr1:231486908	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.48	-6.38	-0.36	7.94e-10	Hemoglobin concentration;
CESC	cis	rs524023	0.957	rs893007	chr11:64365668	C/A	cg07220939	chr11:64358617	SLC22A12	-0.37	-5.65	-0.33	4.19e-8	Urate levels in obese individuals;
CESC	cis	rs875971	0.638	rs10249404	chr7:66046724	G/A	cg25985355	chr7:65971099	NA	0.32	5.24	0.31	3.35e-7	Aortic root size;
CESC	cis	rs10504229	0.683	rs56408763	chr8:58137276	G/A	cg24829409	chr8:58192753	C8orf71	-0.58	-7.2	-0.4	6.31e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs7116495	0.881	rs6592449	chr11:71670222	C/T	cg26138937	chr11:71823887	C11orf51	-0.78	-6.48	-0.37	4.32e-10	Severe influenza A (H1N1) infection;
CESC	cis	rs9527	0.590	rs12415199	chr10:104895536	T/C	cg04362960	chr10:104952993	NT5C2	0.44	5.54	0.32	7.12e-8	Arsenic metabolism;
CESC	cis	rs6674176	0.932	rs12410334	chr1:44442521	A/C	cg12908607	chr1:44402522	ARTN	-0.43	-5.95	-0.34	8.45e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs8013055	0.846	rs8013827	chr14:105970176	C/T	cg23356831	chr14:105996513	TMEM121	-0.36	-5.22	-0.31	3.64e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
CESC	cis	rs10206020	0.842	rs7609325	chr2:1574718	G/A	cg26248373	chr2:1572462	NA	-0.59	-6.93	-0.39	3.22e-11	IgG glycosylation;
CESC	cis	rs1218582	0.772	rs1976559	chr1:154879788	A/T	cg24250549	chr1:154909240	PMVK	0.74	11.08	0.56	1.06e-23	Prostate cancer;
CESC	cis	rs7818345	1.000	rs6981898	chr8:19305705	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.34	6.18	0.35	2.45e-9	Language performance in older adults (adjusted for episodic memory);
CESC	cis	rs17376456	0.877	rs9314093	chr5:93333347	G/A	cg25358565	chr5:93447407	FAM172A	1.08	10.32	0.54	3.23e-21	Diabetic retinopathy;
CESC	cis	rs11583043	1.000	rs34915449	chr1:101476786	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.53	5.84	0.34	1.54e-8	Ulcerative colitis;Inflammatory bowel disease;
CESC	cis	rs1413885	0.549	rs9436726	chr1:65853196	T/C	cg14976592	chr1:65886160	LEPROT;LEPR	0.48	6.32	0.36	1.13e-9	Anticoagulant levels;
CESC	cis	rs7267979	0.932	rs2260997	chr20:25256266	A/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.81	-15.46	-0.69	7.27e-39	Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs561341	1.000	rs1557731	chr17:30321567	T/G	cg20587970	chr11:113659929	NA	-1.13	-14.25	-0.66	1.39e-34	Hip circumference adjusted for BMI;
CESC	cis	rs208520	0.874	rs208491	chr6:66928459	C/G	cg07460842	chr6:66804631	NA	-0.89	-10.73	-0.55	1.58e-22	Exhaled nitric oxide output;
CESC	cis	rs11625487	0.505	rs10145609	chr14:77957377	G/A	cg20045696	chr14:77926864	AHSA1	-0.44	-5.23	-0.31	3.42e-7	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
CESC	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg09177884	chr7:1199841	ZFAND2A	-0.54	-5.95	-0.34	8.41e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03661428	chr13:111589040	NA	-0.6	-6.35	-0.36	9.49e-10	Gut microbiome composition (summer);
CESC	cis	rs10832963	0.686	rs11024743	chr11:18653712	A/G	cg20219074	chr11:18656078	SPTY2D1	0.8	11.71	0.58	8.4e-26	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27613076	chr10:121484944	INPP5F	-0.66	-7.93	-0.44	6.23e-14	Gut microbiome composition (summer);
CESC	cis	rs4927850	0.881	rs7630489	chr3:195753401	T/C	cg12923728	chr3:195709715	SDHAP1	-0.67	-8.99	-0.48	4.91e-17	Pancreatic cancer;
CESC	cis	rs8016982	0.674	rs2288499	chr14:81660997	C/T	cg01989461	chr14:81687754	GTF2A1	0.75	11.64	0.58	1.4e-25	Schizophrenia;
CESC	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg11494091	chr17:61959527	GH2	0.72	12.34	0.6	6.02e-28	Prudent dietary pattern;
CESC	trans	rs916888	0.821	rs415430	chr17:44859144	C/T	cg01341218	chr17:43662625	NA	-0.86	-10.6	-0.55	3.99e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs9914988	0.887	rs11656272	chr17:27091153	A/G	cg20469991	chr17:27169893	C17orf63	-0.48	-5.25	-0.31	3.18e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CESC	cis	rs2066819	1.000	rs2020854	chr12:56743367	T/C	cg26714650	chr12:56694279	CS	-1.22	-14.58	-0.67	9.61e-36	Psoriasis vulgaris;
CESC	cis	rs1475911	0.671	rs12483409	chr21:43521902	G/A	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.47	-7.31	-0.41	3.1e-12	IgG glycosylation;
CESC	cis	rs6964587	1.000	rs1859037	chr7:91568272	A/G	cg17063962	chr7:91808500	NA	-0.59	-7.88	-0.44	8.67e-14	Breast cancer;
CESC	cis	rs28386778	0.965	rs2854154	chr17:61981696	C/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.55	-6.89	-0.39	4.08e-11	Prudent dietary pattern;
CESC	cis	rs10242455	0.702	rs79285548	chr7:99058396	T/C	cg25640893	chr7:99214727	ZNF498	1.17	7.11	0.4	1.09e-11	Blood metabolite levels;
CESC	trans	rs8135828	0.770	rs74395461	chr22:29933875	T/C	cg17961835	chr3:126195582	ZXDC	-0.45	-6.03	-0.35	5.35e-9	Lipid traits;
CESC	cis	rs13256369	0.802	rs12541520	chr8:8564146	G/T	cg18904891	chr8:8559673	CLDN23	0.69	8.09	0.45	2.13e-14	Obesity-related traits;
CESC	cis	rs7274811	0.711	rs293713	chr20:31942247	A/G	cg21523528	chr20:32077966	CBFA2T2	-0.47	-5.66	-0.33	3.84e-8	Height;
CESC	trans	rs607987	0.836	rs1222202	chr11:30336613	G/A	cg25993608	chr18:76621396	NA	-0.42	-6.0	-0.35	6.63e-9	Body mass index;
CESC	cis	rs11098499	0.863	rs6833334	chr4:120504227	C/T	cg24375607	chr4:120327624	NA	0.46	5.47	0.32	1.05e-7	Corneal astigmatism;
CESC	cis	rs1008375	1.000	rs4642241	chr4:17617111	T/C	cg04450456	chr4:17643702	FAM184B	0.36	5.24	0.31	3.28e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs6866344	0.697	rs62392832	chr5:178134395	T/C	cg10224037	chr5:178157518	ZNF354A	0.6	6.75	0.38	9.05e-11	Neutrophil percentage of white cells;
CESC	cis	rs7552404	0.961	rs448710	chr1:76116554	T/C	cg03433033	chr1:76189801	ACADM	-0.67	-8.01	-0.44	3.56e-14	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs11098499	0.866	rs7665125	chr4:120402079	G/T	cg09307838	chr4:120376055	NA	0.76	10.51	0.54	7.9e-22	Corneal astigmatism;
CESC	cis	rs9487051	0.676	rs6913093	chr6:109636205	T/C	cg21918786	chr6:109611834	NA	-0.4	-5.8	-0.34	1.91e-8	Reticulocyte fraction of red cells;
CESC	cis	rs36051895	0.623	rs11506668	chr9:5252789	C/T	cg02405213	chr9:5042618	JAK2	-0.54	-6.37	-0.36	8.41e-10	Pediatric autoimmune diseases;
CESC	cis	rs909674	0.524	rs5757670	chr22:39829736	G/A	cg02038168	chr22:39784481	NA	-0.58	-7.17	-0.4	7.65e-12	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs868036	1.000	rs8037262	chr15:68108572	C/T	cg08079166	chr15:68083412	MAP2K5	0.44	6.94	0.39	3e-11	Restless legs syndrome;
CESC	cis	rs4713118	0.516	rs7739216	chr6:28079946	G/T	cg20151795	chr6:28129481	ZNF389	0.45	5.87	0.34	1.29e-8	Parkinson's disease;
CESC	cis	rs240764	0.764	rs6903206	chr6:100929516	A/G	cg21058520	chr6:100914733	NA	-0.38	-5.94	-0.34	9.12e-9	Neuroticism;
CESC	cis	rs7647973	0.769	rs6446204	chr3:49034879	T/C	cg06212747	chr3:49208901	KLHDC8B	0.49	5.32	0.31	2.16e-7	Menarche (age at onset);
CESC	cis	rs13118159	0.714	rs6843025	chr4:1334418	C/G	cg02018176	chr4:1364513	KIAA1530	0.41	5.91	0.34	1.04e-8	Longevity;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg22081084	chr1:89990230	LRRC8B	0.46	6.36	0.36	8.61e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs853679	0.517	rs9380047	chr6:28037893	G/T	cg23161317	chr6:28129485	ZNF389	0.5	6.29	0.36	1.29e-9	Depression;
CESC	cis	rs9916302	0.784	rs4795361	chr17:37573446	G/A	cg00129232	chr17:37814104	STARD3	-0.59	-7.8	-0.43	1.45e-13	Glomerular filtration rate (creatinine);
CESC	cis	rs1670533	1.000	rs13134921	chr4:1054177	A/G	cg04106633	chr4:1044584	NA	0.42	5.34	0.31	2.04e-7	Recombination rate (females);
CESC	cis	rs2072732	0.706	rs12564456	chr1:2936386	C/G	cg15211996	chr1:2936768	ACTRT2	0.33	5.3	0.31	2.44e-7	Plateletcrit;
CESC	cis	rs9640161	0.871	rs56156367	chr7:150047201	A/T	cg10018233	chr7:150070692	REPIN1	0.36	5.2	0.3	3.99e-7	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs7918232	0.882	rs788211	chr10:27479070	C/T	cg14442939	chr10:27389572	ANKRD26	-0.63	-6.14	-0.35	2.95e-9	Breast cancer;
CESC	cis	rs11690935	0.589	rs62183782	chr2:172865009	T/A	cg13550731	chr2:172543902	DYNC1I2	0.5	6.81	0.39	6.42e-11	Schizophrenia;
CESC	cis	rs1862618	0.756	rs9292125	chr5:56107200	C/T	cg24549020	chr5:56110836	MAP3K1	0.64	7.46	0.42	1.26e-12	Initial pursuit acceleration;
CESC	cis	rs4595586	0.655	rs11831499	chr12:39310114	A/T	cg26384229	chr12:38710491	ALG10B	0.42	6.11	0.35	3.51e-9	Morning vs. evening chronotype;
CESC	cis	rs832540	0.801	rs7731700	chr5:56111927	C/T	cg24531977	chr5:56204891	C5orf35	-0.46	-5.67	-0.33	3.72e-8	Coronary artery disease;
CESC	cis	rs10504229	0.639	rs72650811	chr8:58115661	G/A	cg02725872	chr8:58115012	NA	-0.45	-7.05	-0.4	1.52e-11	Developmental language disorder (linguistic errors);
CESC	trans	rs1814175	0.566	rs1811673	chr11:49602134	A/G	cg15704280	chr7:45808275	SEPT13	-0.88	-10.8	-0.55	8.69e-23	Height;
CESC	cis	rs73110464	0.609	rs11170348	chr12:53355588	A/G	cg14581129	chr12:53358946	NA	-0.57	-7.69	-0.43	2.84e-13	Cancer (pleiotropy);
CESC	cis	rs11626933	0.959	rs2149649	chr14:90774974	A/G	cg14092571	chr14:90743983	NA	0.91	15.01	0.68	2.86e-37	Gut microbiota (bacterial taxa);
CESC	cis	rs941408	0.515	rs4624312	chr19:2774460	T/C	cg02580895	chr19:2754563	NA	-0.46	-6.02	-0.35	5.71e-9	Total cholesterol levels;
CESC	cis	rs3796352	1.000	rs11707780	chr3:53084326	A/G	cg07884673	chr3:53033167	SFMBT1	-0.59	-6.04	-0.35	5.05e-9	Immune reponse to smallpox (secreted IL-2);
CESC	cis	rs554111	0.560	rs592060	chr1:21050958	A/G	cg08890418	chr1:21044141	KIF17	-0.49	-6.23	-0.36	1.82e-9	Facial morphology (factor 17, height of vermillion upper lip);
CESC	cis	rs2901656	0.640	rs4916258	chr1:172413526	T/G	cg03748243	chr1:172413542	C1orf105;PIGC	0.54	8.28	0.45	5.98e-15	Red cell distribution width;Platelet distribution width;
CESC	cis	rs11822910	1.000	rs2439448	chr11:57199211	T/C	cg00522883	chr11:57194120	SLC43A3	0.57	6.65	0.38	1.63e-10	Platelet distribution width;
CESC	cis	rs36051895	0.623	rs12351715	chr9:5262349	A/G	cg02405213	chr9:5042618	JAK2	-0.49	-6.01	-0.35	6.2e-9	Pediatric autoimmune diseases;
CESC	cis	rs514406	0.861	rs1571979	chr1:53237526	G/A	cg08859206	chr1:53392774	SCP2	0.54	7.13	0.4	9.6e-12	Monocyte count;
CESC	cis	rs17711722	0.522	rs6957759	chr7:65271785	A/G	cg07424592	chr7:64974309	NA	-0.35	-5.09	-0.3	6.74e-7	Calcium levels;
CESC	cis	rs12188164	0.930	rs72717440	chr5:449701	A/T	cg15813090	chr5:442598	EXOC3;C5orf55	0.42	6.26	0.36	1.51e-9	Cystic fibrosis severity;
CESC	cis	rs6963495	0.818	rs73190181	chr7:105162907	A/C	cg02135003	chr7:105160482	PUS7	-0.46	-5.55	-0.32	6.92e-8	Bipolar disorder (body mass index interaction);
CESC	cis	rs1707322	0.963	rs6690652	chr1:46376692	G/T	cg06784218	chr1:46089804	CCDC17	0.32	5.57	0.32	6.35e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs13191362	1.000	rs35092540	chr6:163090778	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.51	5.07	0.3	7.6e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg18402987	chr7:1209562	NA	0.76	7.55	0.42	7.26e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs8114671	0.836	rs6060140	chr20:33566507	G/A	cg06115741	chr20:33292138	TP53INP2	0.46	5.54	0.32	7.42e-8	Height;
CESC	cis	rs897984	0.609	rs35468353	chr16:31056433	A/G	cg02466173	chr16:30829666	NA	-0.39	-6.77	-0.38	8.15e-11	Dementia with Lewy bodies;
CESC	cis	rs34779708	0.931	rs7079205	chr10:35324619	C/T	cg04310649	chr10:35416472	CREM	-0.49	-5.7	-0.33	3.24e-8	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs59574136	1	rs59574136	chr7:2036460	T/C	cg05863683	chr7:1912471	MAD1L1	0.44	6.67	0.38	1.5e-10	Autism spectrum disorder or schizophrenia;
CESC	trans	rs61931739	0.534	rs2389276	chr12:34097891	T/C	cg26384229	chr12:38710491	ALG10B	0.52	7.07	0.4	1.35e-11	Morning vs. evening chronotype;
CESC	cis	rs4423214	0.918	rs11233789	chr11:71181085	A/G	cg24826892	chr11:71159390	DHCR7	0.45	5.14	0.3	5.42e-7	Vitamin D levels;
CESC	cis	rs4253772	0.550	rs6007818	chr22:46703776	C/T	cg18190219	chr22:46762943	CELSR1	-0.56	-6.37	-0.36	8.5e-10	LDL cholesterol;Cholesterol, total;
CESC	cis	rs11792861	0.926	rs17729523	chr9:111773317	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.46	5.69	0.33	3.29e-8	Menarche (age at onset);
CESC	cis	rs7647973	0.677	rs11130211	chr3:49645209	C/T	cg03060546	chr3:49711283	APEH	0.64	7.34	0.41	2.55e-12	Menarche (age at onset);
CESC	cis	rs9303401	0.646	rs9892425	chr17:57241938	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.49	6.47	0.37	4.83e-10	Cognitive test performance;
CESC	cis	rs10089	0.953	rs1432614	chr5:127416919	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.76	9.86	0.52	9.37e-20	Ileal carcinoids;
CESC	cis	rs2243480	1.000	rs1873494	chr7:65649899	T/C	cg18252515	chr7:66147081	NA	1.36	13.62	0.64	2.24e-32	Diabetic kidney disease;
CESC	cis	rs6831352	0.918	rs13112176	chr4:100055825	G/A	cg12011299	chr4:100065546	ADH4	-0.6	-6.62	-0.38	2.04e-10	Alcohol dependence;
CESC	cis	rs6502050	0.835	rs7219138	chr17:80079896	C/T	cg23985595	chr17:80112537	CCDC57	0.42	6.56	0.37	2.87e-10	Life satisfaction;
CESC	cis	rs11690935	0.959	rs7562356	chr2:172626611	C/G	cg13550731	chr2:172543902	DYNC1I2	-1.01	-16.63	-0.71	5.07e-43	Schizophrenia;
CESC	cis	rs2033711	0.837	rs3764535	chr19:58929052	G/A	cg00825309	chr19:58991885	ZNF446	-0.58	-8.22	-0.45	8.94e-15	Uric acid clearance;
CESC	cis	rs4665809	1.000	rs4665821	chr2:26309949	A/C	cg22920501	chr2:26401640	FAM59B	-0.66	-7.89	-0.44	8.09e-14	Gut microbiome composition (summer);
CESC	cis	rs854765	0.647	rs6826	chr17:18011140	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.61	8.4	0.46	2.71e-15	Total body bone mineral density;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13769605	chr2:12857067	TRIB2	-0.55	-6.4	-0.37	6.97e-10	Gut microbiome composition (summer);
CESC	cis	rs10504229	1.000	rs75037501	chr8:58170136	T/G	cg14926445	chr8:58193284	C8orf71	-0.51	-5.49	-0.32	9.29e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs56235845	0.964	rs4075958	chr5:176784512	A/G	cg06060754	chr5:176797920	RGS14	-0.48	-5.14	-0.3	5.22e-7	Hemoglobin concentration;Hematocrit;
CESC	trans	rs7945404	0.548	rs4936618	chr11:121223996	G/T	cg09432902	chr12:113909932	LHX5	-0.39	-6.08	-0.35	4.07e-9	QT interval;
CESC	cis	rs2836974	0.584	rs34436313	chr21:40685246	A/G	cg11890956	chr21:40555474	PSMG1	-0.95	-15.1	-0.68	1.38e-37	Cognitive function;
CESC	cis	rs3008870	1.000	rs2985821	chr1:67403787	G/A	cg08660285	chr1:67390436	MIER1;WDR78	1.06	15.19	0.68	6.65e-38	Lymphocyte percentage of white cells;
CESC	cis	rs7666738	0.791	rs1896155	chr4:99020948	C/A	cg03676636	chr4:99064102	C4orf37	0.33	5.15	0.3	5.05e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7524258	0.903	rs4908608	chr1:7292772	T/C	cg07173049	chr1:7289937	CAMTA1	0.47	7.14	0.4	9e-12	Tourette's syndrome or obsessive-compulsive disorder;
CESC	cis	rs11792861	0.591	rs7044275	chr9:111717138	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.62	9.55	0.51	9.13e-19	Menarche (age at onset);
CESC	cis	rs1801251	0.929	rs10933409	chr2:233629386	A/G	cg25237894	chr2:233734115	C2orf82	0.45	7.9	0.44	7.6e-14	Coronary artery disease;
CESC	cis	rs6831352	1.000	rs1126670	chr4:100052733	C/A	cg21548116	chr4:100009993	ADH5	0.48	5.15	0.3	4.98e-7	Alcohol dependence;
CESC	cis	rs3106136	0.967	rs767657	chr4:95227901	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.45	-6.59	-0.38	2.41e-10	Capecitabine sensitivity;
CESC	cis	rs453301	0.538	rs7830804	chr8:8970762	G/T	cg06636001	chr8:8085503	FLJ10661	-0.45	-5.66	-0.33	3.95e-8	Joint mobility (Beighton score);
CESC	cis	rs9811920	0.516	rs793486	chr3:99493165	A/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.33	-5.44	-0.32	1.2e-7	Axial length;
CESC	cis	rs9487051	0.676	rs6913093	chr6:109636205	T/C	cg12927641	chr6:109611667	NA	-0.4	-5.84	-0.34	1.49e-8	Reticulocyte fraction of red cells;
CESC	cis	rs858239	0.539	rs2390757	chr7:23191492	A/G	cg23682824	chr7:23144976	KLHL7	0.42	5.23	0.31	3.38e-7	Cerebrospinal fluid biomarker levels;
CESC	cis	rs10949834	0.877	rs34325097	chr7:73492990	G/A	cg07137043	chr7:73588983	EIF4H	-0.64	-5.43	-0.32	1.28e-7	Verbal memory performance (residualized delayed recall change);
CESC	cis	rs2016266	0.859	rs10747668	chr12:53737461	C/T	cg26875137	chr12:53738046	NA	0.35	5.28	0.31	2.66e-7	Bone mineral density (spine);Bone mineral density;
CESC	cis	rs453301	0.624	rs6987558	chr8:8862521	C/G	cg15556689	chr8:8085844	FLJ10661	0.45	5.77	0.33	2.18e-8	Joint mobility (Beighton score);
CESC	cis	rs798554	1.000	rs798536	chr7:2766383	G/A	cg09658497	chr7:2847517	GNA12	-0.44	-6.32	-0.36	1.13e-9	Height;
CESC	cis	rs7937682	0.562	rs519850	chr11:111376888	A/T	cg22437258	chr11:111473054	SIK2	0.45	5.63	0.33	4.59e-8	Primary sclerosing cholangitis;
CESC	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.54	7.4	0.41	1.83e-12	Lymphocyte counts;
CESC	cis	rs9487051	0.714	rs13209277	chr6:109624963	T/A	cg01475377	chr6:109611718	NA	-0.45	-7.11	-0.4	1.08e-11	Reticulocyte fraction of red cells;
CESC	cis	rs11072805	1	rs11072805	chr15:79078518	T/C	cg04896959	chr15:78267971	NA	0.34	5.11	0.3	6.16e-7	Post bronchodilator FEV1/FVC ratio;
CESC	trans	rs7944735	0.671	rs1228044	chr11:48011180	A/G	cg07554734	chr6:7728676	BMP6	-0.36	-6.24	-0.36	1.76e-9	Intraocular pressure;
CESC	cis	rs4665809	0.531	rs34081866	chr2:26475940	C/T	cg22920501	chr2:26401640	FAM59B	0.93	10.89	0.56	4.54e-23	Gut microbiome composition (summer);
CESC	cis	rs12079745	0.793	rs12071224	chr1:169191945	C/T	cg09363564	chr1:169337483	NME7;BLZF1	-1.01	-6.29	-0.36	1.34e-9	QT interval;
CESC	cis	rs7582720	0.943	rs72928610	chr2:203838961	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.36	0.41	2.34e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs736408	0.609	rs2230534	chr3:52802402	A/C	cg05564831	chr3:52568323	NT5DC2	0.42	6.13	0.35	3.1e-9	Bipolar disorder;
CESC	cis	rs7811142	0.830	rs6975660	chr7:99975266	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.09	12.96	0.62	4.51e-30	Platelet count;
CESC	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg04267008	chr7:1944627	MAD1L1	0.72	9.66	0.51	4.02e-19	Bipolar disorder and schizophrenia;
CESC	cis	rs1707322	1.000	rs6671754	chr1:46433990	A/G	cg03146154	chr1:46216737	IPP	0.72	9.82	0.52	1.31e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs1801251	0.685	rs1515961	chr2:233623763	C/A	cg25237894	chr2:233734115	C2orf82	0.35	6.01	0.35	6.01e-9	Coronary artery disease;
CESC	cis	rs1707322	0.685	rs11211177	chr1:46226349	A/G	cg03146154	chr1:46216737	IPP	0.77	11.13	0.56	7.46e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs10510776	0.875	rs11710973	chr3:55217512	C/T	cg24055398	chr17:73127994	NT5C	0.58	6.17	0.35	2.59e-9	Cancer;
CESC	cis	rs7560272	0.723	rs1320374	chr2:73828310	T/C	cg20560298	chr2:73613845	ALMS1	0.5	7.06	0.4	1.5e-11	Schizophrenia;
CESC	cis	rs7524258	0.868	rs4243825	chr1:7308264	T/C	cg07173049	chr1:7289937	CAMTA1	0.42	6.29	0.36	1.3e-9	Tourette's syndrome or obsessive-compulsive disorder;
CESC	cis	rs2836950	0.545	rs2836940	chr21:40588696	T/C	cg17971929	chr21:40555470	PSMG1	-0.54	-7.04	-0.4	1.6e-11	Menarche (age at onset);
CESC	cis	rs854765	0.583	rs8073001	chr17:17831716	A/C	cg16928487	chr17:17741425	SREBF1	0.56	9.79	0.52	1.66e-19	Total body bone mineral density;
CESC	cis	rs769267	0.930	rs4808955	chr19:19552413	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.45	5.7	0.33	3.17e-8	Tonsillectomy;
CESC	cis	rs832540	0.898	rs331497	chr5:56251660	G/T	cg14703610	chr5:56206110	C5orf35	-0.44	-5.78	-0.33	2.07e-8	Coronary artery disease;
CESC	cis	rs17376456	0.877	rs10476596	chr5:93367074	C/T	cg21475434	chr5:93447410	FAM172A	-0.79	-6.72	-0.38	1.08e-10	Diabetic retinopathy;
CESC	cis	rs34779708	0.966	rs12775759	chr10:35400183	G/T	cg04310649	chr10:35416472	CREM	-0.52	-6.25	-0.36	1.62e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs9322193	0.962	rs10872653	chr6:150100043	A/C	cg04369109	chr6:150039330	LATS1	-0.39	-5.35	-0.31	1.92e-7	Lung cancer;
CESC	cis	rs950776	0.518	rs4886572	chr15:78837452	A/G	cg06917634	chr15:78832804	PSMA4	-0.76	-11.61	-0.58	1.83e-25	Sudden cardiac arrest;
CESC	cis	rs8023845	1.000	rs62019997	chr15:40443476	T/C	cg20259534	chr15:40453036	BUB1B	0.68	6.76	0.38	8.58e-11	Chronic lymphocytic leukemia;
CESC	cis	rs2228479	0.850	rs17226519	chr16:89839854	T/C	cg04013166	chr16:89971882	TCF25	0.78	6.69	0.38	1.3e-10	Skin colour saturation;
CESC	cis	rs977987	0.806	rs7202596	chr16:75491072	G/T	cg03315344	chr16:75512273	CHST6	0.44	6.31	0.36	1.15e-9	Dupuytren's disease;
CESC	cis	rs863345	1.000	rs863356	chr1:158543739	G/T	cg12129480	chr1:158549410	OR10X1	-0.32	-6.49	-0.37	4.31e-10	Pneumococcal bacteremia;
CESC	cis	rs7551222	0.752	rs10900594	chr1:204470129	C/G	cg20240347	chr1:204465584	NA	-0.25	-5.09	-0.3	6.89e-7	Schizophrenia;
CESC	cis	rs4130590	0.966	rs6478770	chr9:130112231	T/C	cg13736810	chr9:130213283	LRSAM1;RPL12	0.51	6.08	0.35	4.28e-9	Bipolar disorder;
CESC	cis	rs9921222	0.632	rs11649268	chr16:398643	A/C	cg08923669	chr16:420230	MRPL28	-0.47	-6.2	-0.36	2.1e-9	Bone mineral density (spine);Bone mineral density;
CESC	trans	rs61931739	0.500	rs7963282	chr12:34535255	A/C	cg26384229	chr12:38710491	ALG10B	0.54	7.53	0.42	8.03e-13	Morning vs. evening chronotype;
CESC	trans	rs561341	0.941	rs2428338	chr17:30299629	T/C	cg20587970	chr11:113659929	NA	-1.14	-14.35	-0.66	6.11e-35	Hip circumference adjusted for BMI;
CESC	trans	rs7173947	0.646	rs11634297	chr15:95267564	A/T	cg09233161	chr9:37079712	NA	-0.46	-6.42	-0.37	6.4e-10	Hematological and biochemical traits;
CESC	cis	rs1448094	0.527	rs59445394	chr12:86237843	C/T	cg00310523	chr12:86230176	RASSF9	0.37	5.57	0.32	6.15e-8	Major depressive disorder;
CESC	cis	rs7119	0.717	rs11636412	chr15:77767291	C/T	cg17802220	chr15:77601643	NA	-0.51	-7.18	-0.4	7.24e-12	Type 2 diabetes;
CESC	cis	rs4948102	0.767	rs4948096	chr7:56053118	C/T	cg09872392	chr7:56161020	PHKG1	-0.46	-7.25	-0.41	4.59e-12	Plasma homocysteine levels (post-methionine load test);
CESC	cis	rs2281558	0.833	rs6115202	chr20:25497538	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.55	-7.76	-0.43	1.9e-13	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;
CESC	cis	rs9858542	1.000	rs34762726	chr3:49689210	G/A	cg03060546	chr3:49711283	APEH	-0.59	-6.94	-0.39	2.96e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs7666738	0.724	rs28451676	chr4:98966990	C/T	cg05340658	chr4:99064831	C4orf37	0.79	12.27	0.6	1.02e-27	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6539267	0.748	rs1921953	chr12:106721012	C/T	cg02476566	chr12:106696527	TCP11L2	0.44	5.2	0.3	4.06e-7	Tourette syndrome;
CESC	cis	rs17376456	0.877	rs7701974	chr5:93311417	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.61	5.33	0.31	2.15e-7	Diabetic retinopathy;
CESC	cis	rs9399135	1.000	rs9399135	chr6:135368314	G/A	cg22676075	chr6:135203613	NA	0.48	6.71	0.38	1.2e-10	Red blood cell count;
CESC	cis	rs7552404	0.590	rs1565717	chr1:76320441	T/C	cg03433033	chr1:76189801	ACADM	-0.62	-6.54	-0.37	3.12e-10	Blood metabolite levels;Acylcarnitine levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14089512	chr10:102106757	SCD	0.61	7.37	0.41	2.13e-12	Gut microbiome composition (summer);
CESC	cis	rs57221529	0.766	rs12519763	chr5:559145	C/T	cg09021430	chr5:549028	NA	-0.42	-5.26	-0.31	2.92e-7	Lung disease severity in cystic fibrosis;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg00028918	chr5:159200479	NA	0.48	6.11	0.35	3.47e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs2836974	0.897	rs2836923	chr21:40524236	T/C	cg11644478	chr21:40555479	PSMG1	1.03	16.3	0.71	7.81e-42	Cognitive function;
CESC	cis	rs3091242	0.933	rs3093584	chr1:25668714	T/C	cg12412775	chr1:25698385	RHCE	0.32	5.68	0.33	3.54e-8	Erythrocyte sedimentation rate;
CESC	cis	rs13315871	0.929	rs73835170	chr3:58318448	A/G	cg20936604	chr3:58311152	NA	-0.51	-5.13	-0.3	5.57e-7	Cholesterol, total;
CESC	cis	rs155076	0.625	rs4769159	chr13:21881978	A/C	cg11317459	chr13:21872234	NA	1.2	15.33	0.69	2.11e-38	White matter hyperintensity burden;
CESC	cis	rs6493487	0.512	rs7165920	chr15:51229808	G/A	cg02338191	chr15:51200825	AP4E1	0.61	5.56	0.32	6.72e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs7818345	0.967	rs12679671	chr8:19270831	G/T	cg11303988	chr8:19266685	CSGALNACT1	0.33	5.96	0.34	7.84e-9	Language performance in older adults (adjusted for episodic memory);
CESC	cis	rs9325144	0.650	rs6582624	chr12:38733475	A/T	cg26384229	chr12:38710491	ALG10B	-0.55	-7.59	-0.42	5.47e-13	Morning vs. evening chronotype;
CESC	cis	rs57024841	0.500	rs6560652	chr9:139830940	C/T	cg00693599	chr9:139836323	FBXW5	-0.42	-6.11	-0.35	3.46e-9	Beta-trace protein levels;
CESC	cis	rs1707322	0.691	rs28495425	chr1:46187320	T/G	cg05343316	chr1:45956843	TESK2	0.51	6.2	0.36	2.19e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs763121	0.853	rs5757253	chr22:39104320	C/T	cg06022373	chr22:39101656	GTPBP1	0.95	18.07	0.74	3.97e-48	Menopause (age at onset);
CESC	cis	rs7552404	0.545	rs12748741	chr1:76351193	A/G	cg22875332	chr1:76189707	ACADM	-0.56	-5.75	-0.33	2.44e-8	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs9916302	0.904	rs11078898	chr17:37536480	A/G	cg15445000	chr17:37608096	MED1	-0.4	-6.54	-0.37	3.24e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs12042052	1.000	rs6686747	chr1:232912743	T/C	cg06935979	chr1:232941706	KIAA1383	0.64	6.16	0.35	2.69e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CESC	cis	rs7666738	0.830	rs1426665	chr4:99027764	C/T	cg03467027	chr4:99064603	C4orf37	0.48	6.15	0.35	2.83e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9733	0.569	rs11588404	chr1:150688529	C/A	cg22823121	chr1:150693482	HORMAD1	0.48	7.11	0.4	1.11e-11	Tonsillectomy;
CESC	cis	rs9916302	0.904	rs4795357	chr17:37569551	T/C	cg20243544	chr17:37824526	PNMT	0.49	5.92	0.34	9.98e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs3785574	0.582	rs62072238	chr17:61948841	A/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.61	7.58	0.42	5.93e-13	Height;
CESC	cis	rs9399135	0.933	rs4559100	chr6:135324085	T/C	cg22676075	chr6:135203613	NA	0.51	7.23	0.41	5.22e-12	Red blood cell count;
CESC	cis	rs1862618	0.853	rs2548664	chr5:56133555	G/A	cg24531977	chr5:56204891	C5orf35	-0.89	-11.26	-0.57	2.62e-24	Initial pursuit acceleration;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01124529	chr16:87743286	KLHDC4	-0.53	-6.63	-0.38	1.89e-10	Gut microbiome composition (summer);
CESC	cis	rs736408	0.609	rs1029871	chr3:52797634	G/C	cg07507251	chr3:52567010	NT5DC2	0.44	7.38	0.41	2.11e-12	Bipolar disorder;
CESC	cis	rs13108904	0.901	rs13124847	chr4:1278206	A/G	cg22903657	chr4:1355424	KIAA1530	-0.38	-5.23	-0.31	3.48e-7	Obesity-related traits;
CESC	cis	rs10924970	0.687	rs10802441	chr1:235357698	A/T	cg26050004	chr1:235667680	B3GALNT2	0.44	5.09	0.3	6.95e-7	Asthma;
CESC	cis	rs9311474	0.607	rs11711421	chr3:52561779	C/T	cg07507251	chr3:52567010	NT5DC2	0.45	8.38	0.46	3.04e-15	Electroencephalogram traits;
CESC	cis	rs1580019	0.522	rs10951340	chr7:32562408	G/A	cg06627557	chr7:32535165	LSM5;AVL9	1.07	19.04	0.76	1.57e-51	Cognitive ability;
CESC	cis	rs10779751	0.734	rs2261317	chr1:11124979	A/G	cg08854313	chr1:11322531	MTOR	0.77	10.41	0.54	1.73e-21	Body mass index;
CESC	cis	rs1045902	0.574	rs1053329	chr2:73461483	C/A	cg01422370	chr2:73384389	NA	0.39	5.31	0.31	2.36e-7	Intelligence (multi-trait analysis);
CESC	cis	rs4970988	0.640	rs7524734	chr1:150655686	C/T	cg22823121	chr1:150693482	HORMAD1	0.48	7.09	0.4	1.21e-11	Urate levels;
CESC	cis	rs6580649	0.943	rs1990029	chr12:48407987	C/T	cg24011408	chr12:48396354	COL2A1	0.44	5.44	0.32	1.18e-7	Lung cancer;
CESC	trans	rs9929218	0.551	rs7201437	chr16:68727130	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.9	14.8	0.67	1.6e-36	Colorectal cancer;
CESC	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg07414643	chr4:187882934	NA	-0.52	-7.28	-0.41	3.88e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7666738	0.830	rs11725477	chr4:98803266	G/T	cg05340658	chr4:99064831	C4orf37	0.75	11.11	0.56	8.68e-24	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10979	1.000	rs13211390	chr6:143888010	A/T	cg25407410	chr6:143891975	LOC285740	-0.63	-9.51	-0.5	1.24e-18	Hypospadias;
CESC	cis	rs6815814	0.731	rs66735315	chr4:38774180	G/T	cg02016764	chr4:38805732	TLR1	-0.44	-6.08	-0.35	4.24e-9	Breast cancer;
CESC	cis	rs11122272	0.735	rs2491407	chr1:231518928	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.57	-7.82	-0.43	1.29e-13	Hemoglobin concentration;
CESC	trans	rs3934047	0.904	rs4448893	chr15:82011355	T/C	cg07747791	chr7:27498134	NA	-0.4	-6.31	-0.36	1.19e-9	Response to paliperidone in schizophrenia (positive Marder score);
CESC	cis	rs1707322	0.752	rs11488313	chr1:46224780	G/C	cg03146154	chr1:46216737	IPP	0.8	11.44	0.57	6.8e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs12229918	0.540	rs10784460	chr12:65863584	C/T	cg09854775	chr9:137029881	RNU6ATAC	0.52	6.32	0.36	1.11e-9	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
CESC	cis	rs28386778	0.700	rs11079515	chr17:62005645	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.95	-15.11	-0.68	1.21e-37	Prudent dietary pattern;
CESC	cis	rs11048434	0.736	rs34798934	chr12:9108444	C/T	cg23795048	chr12:9217529	LOC144571	0.35	5.31	0.31	2.28e-7	Sjögren's syndrome;
CESC	cis	rs9300255	0.602	rs1716164	chr12:123663660	G/A	cg00376283	chr12:123451042	ABCB9	0.71	8.92	0.48	7.69e-17	Neutrophil percentage of white cells;
CESC	cis	rs3806843	0.933	rs2879087	chr5:140188575	G/C	cg16179182	chr5:140090404	VTRNA1-1	-0.4	-5.11	-0.3	6.12e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs477692	0.685	rs551491	chr10:131397821	G/A	cg05714579	chr10:131428358	MGMT	0.5	6.88	0.39	4.21e-11	Response to temozolomide;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg11383747	chr17:260000	C17orf97	-0.54	-7.27	-0.41	4.03e-12	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	trans	rs1814175	0.619	rs847644	chr11:49918418	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.43	-6.36	-0.36	8.98e-10	Height;
CESC	cis	rs2204008	0.777	rs8189597	chr12:38307739	G/C	cg26384229	chr12:38710491	ALG10B	-0.73	-10.64	-0.55	2.97e-22	Bladder cancer;
CESC	cis	rs10751667	0.666	rs7936830	chr11:959686	A/G	cg20946044	chr11:1010712	AP2A2	-0.38	-5.28	-0.31	2.65e-7	Alzheimer's disease (late onset);
CESC	cis	rs16854884	0.710	rs6782558	chr3:143817462	G/C	cg06585982	chr3:143692056	C3orf58	0.46	6.11	0.35	3.6e-9	Economic and political preferences (feminism/equality);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07023867	chr18:55710965	NEDD4L	0.59	6.56	0.37	2.89e-10	Gut microbiome composition (summer);
CESC	cis	rs6540559	0.673	rs11805830	chr1:209984969	C/T	cg23283495	chr1:209979779	IRF6	0.53	6.26	0.36	1.56e-9	Cleft lip with or without cleft palate;
CESC	cis	rs796364	0.806	rs112305133	chr2:201010380	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.67	-6.43	-0.37	5.87e-10	Schizophrenia;
CESC	cis	rs7618915	0.547	rs2878726	chr3:52748271	C/G	cg07507251	chr3:52567010	NT5DC2	0.43	7.4	0.41	1.84e-12	Bipolar disorder;
CESC	cis	rs6032067	0.704	rs2223901	chr20:43789924	C/G	cg11264863	chr20:43835661	SEMG1	0.5	5.35	0.31	1.86e-7	Blood protein levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19374457	chr1:44412380	IPO13	0.57	6.74	0.38	9.79e-11	Gut microbiome composition (summer);
CESC	cis	rs1728785	1.000	rs1624718	chr16:68580385	A/G	cg02972257	chr16:68554789	NA	-0.55	-6.31	-0.36	1.17e-9	Ulcerative colitis;
CESC	cis	rs3820928	0.874	rs13393894	chr2:227880543	A/G	cg05526886	chr2:227700861	RHBDD1	-0.43	-5.48	-0.32	9.75e-8	Pulmonary function;
CESC	cis	rs4919087	0.748	rs701810	chr10:98974849	C/T	cg25902810	chr10:99078978	FRAT1	-0.45	-5.2	-0.3	3.96e-7	Monocyte count;
CESC	cis	rs6912958	0.781	rs7742965	chr6:88278196	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-6.58	-0.37	2.55e-10	Monocyte percentage of white cells;
CESC	cis	rs30380	0.632	rs30186	chr5:96124447	G/C	cg16492584	chr5:96139282	ERAP1	-0.47	-6.63	-0.38	1.89e-10	Cerebrospinal fluid biomarker levels;
CESC	cis	rs7246657	0.943	rs13343502	chr19:37962292	C/T	cg23950597	chr19:37808831	NA	-0.61	-6.23	-0.36	1.85e-9	Coronary artery calcification;
CESC	cis	rs55788414	0.505	rs7190543	chr16:81189320	T/C	cg06400318	chr16:81190750	PKD1L2	-0.51	-6.68	-0.38	1.38e-10	Left ventricular obstructive tract defect (maternal effect);
CESC	cis	rs7666738	0.830	rs7657497	chr4:99044028	A/G	cg03467027	chr4:99064603	C4orf37	0.47	5.98	0.34	7.19e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9303401	0.659	rs35797125	chr17:56736547	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.03	13.13	0.63	1.12e-30	Cognitive test performance;
CESC	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg14893161	chr1:205819251	PM20D1	0.87	15.37	0.69	1.47e-38	Menarche (age at onset);
CESC	cis	rs477895	0.653	rs66648159	chr11:63899429	G/A	cg18225595	chr11:63971243	STIP1	0.52	5.13	0.3	5.55e-7	Mean platelet volume;
CESC	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-1.08	-20.03	-0.78	5.86e-55	Prudent dietary pattern;
CESC	cis	rs3780486	0.846	rs7036812	chr9:33143822	T/C	cg13443165	chr9:33130375	B4GALT1	0.48	7.09	0.4	1.21e-11	IgG glycosylation;
CESC	cis	rs853679	0.517	rs9393884	chr6:28046789	A/G	cg23281280	chr6:28129359	ZNF389	0.6	8.42	0.46	2.34e-15	Depression;
CESC	cis	rs7659604	0.540	rs10007956	chr4:122700669	A/T	cg19671926	chr4:122722719	EXOSC9	0.66	8.86	0.48	1.22e-16	Type 2 diabetes;
CESC	cis	rs6466055	0.501	rs6965384	chr7:104603112	A/G	cg04380332	chr7:105027541	SRPK2	-0.38	-5.5	-0.32	8.8e-8	Schizophrenia;
CESC	cis	rs28374715	1.000	rs28374715	chr15:41563950	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.83	-11.24	-0.57	3.04e-24	Ulcerative colitis;
CESC	cis	rs10504229	1.000	rs56255635	chr8:58178264	T/C	cg22535103	chr8:58192502	C8orf71	-1.05	-13.27	-0.63	3.63e-31	Developmental language disorder (linguistic errors);
CESC	cis	rs4843747	0.749	rs72818535	chr16:88074039	G/A	cg06915872	chr16:87998081	BANP	0.49	5.91	0.34	1.04e-8	Menopause (age at onset);
CESC	cis	rs9611519	0.602	rs8138520	chr22:41412928	A/G	cg03806693	chr22:41940476	POLR3H	-0.51	-6.04	-0.35	5.18e-9	Neuroticism;
CESC	cis	rs10733682	0.633	rs869500	chr9:129465898	G/A	cg00232160	chr9:129468157	NA	0.38	6.07	0.35	4.47e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs7635838	0.503	rs9853547	chr3:11396101	C/G	cg00170343	chr3:11313890	ATG7	0.47	6.56	0.37	2.77e-10	HDL cholesterol;
CESC	cis	rs9486719	1.000	rs4078038	chr6:96904366	A/G	cg18709589	chr6:96969512	KIAA0776	-0.53	-5.8	-0.34	1.92e-8	Migraine;Coronary artery disease;
CESC	cis	rs9911578	1.000	rs11869828	chr17:56609525	G/A	cg12560992	chr17:57184187	TRIM37	-0.93	-15.59	-0.69	2.43e-39	Intelligence (multi-trait analysis);
CESC	cis	rs9916302	0.904	rs8079303	chr17:37530755	G/C	cg20243544	chr17:37824526	PNMT	-0.49	-6.14	-0.35	3.08e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs9487051	0.714	rs6903695	chr6:109631422	C/G	cg01475377	chr6:109611718	NA	0.44	6.97	0.39	2.45e-11	Reticulocyte fraction of red cells;
CESC	cis	rs7927592	0.763	rs11822059	chr11:68300822	T/G	cg16797656	chr11:68205561	LRP5	0.47	7.1	0.4	1.15e-11	Total body bone mineral density;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12680424	chr13:19239716	NA	-0.56	-6.56	-0.37	2.87e-10	Gut microbiome composition (summer);
CESC	cis	rs2412488	0.893	rs6840530	chr4:54359726	C/T	cg22241045	chr4:54363911	LNX1	-0.39	-5.33	-0.31	2.09e-7	DNA methylation (variation);
CESC	cis	rs734999	0.588	rs60520190	chr1:2533706	G/A	cg20673091	chr1:2541236	MMEL1	0.44	7.36	0.41	2.28e-12	Ulcerative colitis;
CESC	cis	rs8017423	0.967	rs11621431	chr14:90709221	C/T	cg14092571	chr14:90743983	NA	-0.57	-8.44	-0.46	2.09e-15	Mortality in heart failure;
CESC	cis	rs826838	0.967	rs11183577	chr12:38781887	A/G	cg13010199	chr12:38710504	ALG10B	0.6	8.55	0.46	1.02e-15	Heart rate;
CESC	trans	rs1814175	0.645	rs1721995	chr11:49915488	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.42	-6.25	-0.36	1.68e-9	Height;
CESC	cis	rs782590	0.774	rs2627773	chr2:55900459	A/G	cg18811423	chr2:55921094	PNPT1	0.79	12.77	0.62	2.02e-29	Metabolic syndrome;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg13083637	chr1:169337225	BLZF1;NME7	-0.44	-6.38	-0.36	7.94e-10	Gambling;
CESC	cis	rs2836974	0.831	rs4375956	chr21:40521788	G/A	cg11890956	chr21:40555474	PSMG1	1.15	20.17	0.78	1.84e-55	Cognitive function;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg17043284	chr1:32228579	BAI2	0.47	6.06	0.35	4.68e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs861020	0.630	rs599649	chr1:210003402	T/C	cg05527609	chr1:210001259	C1orf107	0.75	9.82	0.52	1.25e-19	Orofacial clefts;
CESC	cis	rs3096299	0.967	rs2911253	chr16:89488587	T/G	cg02187348	chr16:89574699	SPG7	0.58	7.9	0.44	7.55e-14	Multiple myeloma (IgH translocation);
CESC	cis	rs17125944	0.505	rs118053951	chr14:53259829	G/A	cg13660082	chr14:53194042	PSMC6	-0.65	-5.74	-0.33	2.53e-8	Alzheimer's disease (late onset);
CESC	cis	rs11229555	1.000	rs7102510	chr11:58371283	T/G	cg15696309	chr11:58395628	NA	-0.43	-5.64	-0.33	4.3e-8	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs4722166	0.630	rs2091115	chr7:22810166	G/T	cg05265849	chr7:22767390	IL6	0.49	6.33	0.36	1.03e-9	Lung cancer;
CESC	cis	rs4727027	0.933	rs1468369	chr7:148839840	G/C	cg23583168	chr7:148888333	NA	-0.73	-10.82	-0.55	7.76e-23	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg20887711	chr4:1340912	KIAA1530	0.85	11.49	0.58	4.64e-25	Longevity;
CESC	cis	rs6460942	0.915	rs62448600	chr7:12454944	T/G	cg06484146	chr7:12443880	VWDE	-0.78	-9.14	-0.49	1.68e-17	Coronary artery disease;
CESC	cis	rs9488822	0.636	rs12201275	chr6:116314563	C/G	cg18764771	chr6:116381957	FRK	0.22	5.34	0.31	1.95e-7	Cholesterol, total;LDL cholesterol;
CESC	cis	rs4481887	0.800	rs4514268	chr1:248444600	T/G	cg00666640	chr1:248458726	OR2T12	0.36	6.19	0.36	2.27e-9	Common traits (Other);
CESC	cis	rs11976180	0.517	rs6949375	chr7:143773851	T/G	cg10157972	chr7:143270135	LOC441294	-0.39	-5.34	-0.31	1.97e-7	Obesity-related traits;
CESC	cis	rs3785574	0.962	rs2584614	chr17:61929445	C/T	cg07677032	chr17:61819896	STRADA	0.41	5.28	0.31	2.64e-7	Height;
CESC	cis	rs6570726	0.791	rs9390336	chr6:145896823	A/T	cg05347473	chr6:146136440	FBXO30	0.59	7.82	0.43	1.24e-13	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9926296	0.712	rs258330	chr16:89729574	T/G	cg04287289	chr16:89883240	FANCA	-0.44	-5.6	-0.33	5.3e-8	Vitiligo;
CESC	cis	rs7552167	0.925	rs3932664	chr1:24511663	G/T	cg01960748	chr1:24522592	NA	-0.42	-5.51	-0.32	8.54e-8	Psoriasis vulgaris;
CESC	cis	rs7618915	0.571	rs6778844	chr3:52596398	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	-0.38	-6.62	-0.38	1.94e-10	Bipolar disorder;
CESC	trans	rs2018683	0.624	rs1006521	chr7:28996220	G/A	cg19402173	chr7:128379420	CALU	-0.58	-7.01	-0.4	1.98e-11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CESC	cis	rs10392	0.543	rs56660421	chr20:37559329	G/T	cg27552599	chr20:37590471	DHX35	0.38	5.72	0.33	2.82e-8	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
CESC	cis	rs1775715	0.705	rs2778651	chr10:32106575	C/T	cg18675610	chr10:32216311	ARHGAP12	0.33	5.1	0.3	6.52e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs2859741	0.608	rs480411	chr1:37476077	T/C	cg09363841	chr1:37513479	NA	-0.51	-7.2	-0.4	6.25e-12	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
CESC	cis	rs2380220	0.606	rs7747776	chr6:96005852	C/T	cg23517279	chr6:96025343	MANEA	0.49	5.55	0.32	7e-8	Behavioural disinhibition (generation interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14950044	chr20:49457327	BCAS4	-0.66	-7.61	-0.42	4.86e-13	Gut microbiome composition (summer);
CESC	cis	rs4713118	0.527	rs4713151	chr6:28136356	G/A	cg17949981	chr6:28129498	ZNF389	0.42	5.24	0.31	3.27e-7	Parkinson's disease;
CESC	cis	rs10242455	0.867	rs2687081	chr7:99300758	G/A	cg07715041	chr7:99302981	CYP3A7	-0.44	-5.56	-0.32	6.73e-8	Blood metabolite levels;
CESC	cis	rs4253772	0.550	rs6008613	chr22:46707924	G/T	cg18190219	chr22:46762943	CELSR1	-0.58	-6.66	-0.38	1.6e-10	LDL cholesterol;Cholesterol, total;
CESC	cis	rs727563	0.635	rs2899348	chr22:42164516	C/G	cg06634786	chr22:41940651	POLR3H	0.68	6.78	0.38	7.6e-11	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs790123	1.000	rs790117	chr3:122380888	C/T	cg17380795	chr3:122379686	NA	0.35	5.3	0.31	2.47e-7	Response to angiotensin II receptor blocker therapy;
CESC	cis	rs1448094	0.512	rs12305828	chr12:86249153	C/G	cg00310523	chr12:86230176	RASSF9	0.35	5.46	0.32	1.1e-7	Major depressive disorder;
CESC	cis	rs7188697	0.883	rs4485352	chr16:58601410	A/G	cg02549819	chr16:58548995	SETD6	0.44	5.43	0.32	1.26e-7	QT interval;
CESC	cis	rs9649213	0.593	rs35983874	chr7:97916461	C/T	cg08684580	chr7:98029266	BAIAP2L1	-0.33	-5.28	-0.31	2.74e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.58	7.46	0.42	1.21e-12	Prudent dietary pattern;
CESC	cis	rs11098499	0.604	rs2389887	chr4:120570644	T/C	cg24375607	chr4:120327624	NA	0.44	5.35	0.31	1.87e-7	Corneal astigmatism;
CESC	cis	rs863345	0.967	rs4620544	chr1:158470747	C/T	cg12129480	chr1:158549410	OR10X1	-0.31	-6.14	-0.35	3.08e-9	Pneumococcal bacteremia;
CESC	cis	rs7618501	0.633	rs6772095	chr3:49978069	C/T	cg24110177	chr3:50126178	RBM5	-0.54	-7.23	-0.41	5.19e-12	Intelligence (multi-trait analysis);
CESC	cis	rs6964587	0.839	rs17731846	chr7:91440342	A/G	cg01689657	chr7:91764605	CYP51A1	0.28	5.03	0.3	8.96e-7	Breast cancer;
CESC	cis	rs60871478	1.000	rs62432242	chr7:797715	G/A	cg27478167	chr7:817139	HEATR2	-0.51	-6.0	-0.35	6.34e-9	Cerebrospinal P-tau181p levels;
CESC	cis	rs4563143	0.675	rs17498203	chr19:29279734	G/T	cg12756686	chr19:29218302	NA	0.58	7.36	0.41	2.38e-12	Methadone dose in opioid dependence;
CESC	cis	rs59901009	0.569	rs12280005	chr11:10228452	G/A	cg01453529	chr11:10209919	SBF2	-0.46	-5.67	-0.33	3.77e-8	Hematocrit;Hemoglobin concentration;
CESC	trans	rs1223629	1.000	rs55909847	chr10:95941476	A/G	cg16346422	chr11:2920819	SLC22A18;SLC22A18AS	0.67	6.04	0.35	5.08e-9	Glucose homeostasis traits;
CESC	cis	rs12926788	0.546	rs200537	chr16:24747787	G/C	cg00339695	chr16:24857497	SLC5A11	-0.5	-6.58	-0.37	2.49e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs4566357	1.000	rs2177598	chr2:227922900	T/C	cg11843606	chr2:227700838	RHBDD1	-0.42	-5.28	-0.31	2.76e-7	Coronary artery disease;
CESC	cis	rs2439831	0.850	rs3862142	chr15:44064806	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.7	6.79	0.38	7.39e-11	Lung cancer in ever smokers;
CESC	cis	rs9287719	0.839	rs12692415	chr2:10745474	A/G	cg02196655	chr2:10830764	NOL10	-0.38	-5.78	-0.33	2.05e-8	Prostate cancer;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg20306180	chr22:32340197	C22orf24;YWHAH	-0.47	-6.77	-0.38	8.07e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs9916302	0.904	rs3964723	chr17:37403979	C/T	cg00129232	chr17:37814104	STARD3	-0.53	-6.8	-0.39	7.03e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs2108622	1.000	rs55744319	chr19:15981821	G/A	cg13772218	chr19:15982569	NA	0.38	7.14	0.4	8.98e-12	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CESC	cis	rs709400	1.000	rs3783404	chr14:104118498	A/G	cg24130564	chr14:104152367	KLC1	-0.42	-5.41	-0.32	1.44e-7	Body mass index;
CESC	cis	rs62103177	0.810	rs62103187	chr18:77627633	G/C	cg12964065	chr18:77638022	KCNG2	0.58	5.46	0.32	1.07e-7	Opioid sensitivity;
CESC	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	13.67	0.64	1.44e-32	Prudent dietary pattern;
CESC	cis	rs2074585	0.517	rs11637971	chr15:91079863	A/C	cg22089800	chr15:90895588	ZNF774	-0.43	-5.15	-0.3	5e-7	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
CESC	cis	rs7618915	0.501	rs3852066	chr3:52621839	C/T	cg18337363	chr3:52569053	NT5DC2	0.29	5.27	0.31	2.85e-7	Bipolar disorder;
CESC	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.35	-5.26	-0.31	2.94e-7	Bipolar disorder;
CESC	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg07157834	chr1:205819609	PM20D1	0.69	10.26	0.53	5.29e-21	Menarche (age at onset);
CESC	cis	rs11098499	0.554	rs2175381	chr4:120265967	T/C	cg09307838	chr4:120376055	NA	0.75	9.66	0.51	4.11e-19	Corneal astigmatism;
CESC	cis	rs12216125	0.554	rs6942196	chr6:26072804	A/G	cg17691542	chr6:26056736	HIST1H1C	0.42	5.66	0.33	3.97e-8	Iron status biomarkers;
CESC	cis	rs4243830	0.850	rs12744992	chr1:6601290	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.99	-9.98	-0.52	4.03e-20	Body mass index;
CESC	cis	rs3820928	0.967	rs4675118	chr2:227773157	C/A	cg11843606	chr2:227700838	RHBDD1	-0.39	-5.22	-0.31	3.69e-7	Pulmonary function;
CESC	cis	rs9300255	0.698	rs4759416	chr12:123746357	C/G	cg00376283	chr12:123451042	ABCB9	0.72	9.0	0.48	4.56e-17	Neutrophil percentage of white cells;
CESC	cis	rs9905704	0.633	rs2018966	chr17:56477565	C/T	cg12560992	chr17:57184187	TRIM37	-0.61	-5.75	-0.33	2.49e-8	Testicular germ cell tumor;
CESC	cis	rs12497850	0.931	rs7643368	chr3:48992855	T/G	cg07636037	chr3:49044803	WDR6	1.07	19.82	0.77	3.09e-54	Parkinson's disease;
CESC	cis	rs875971	0.505	rs1723275	chr7:65504633	G/C	cg25985355	chr7:65971099	NA	0.32	5.3	0.31	2.4e-7	Aortic root size;
CESC	cis	rs1707322	0.721	rs7519900	chr1:46234947	C/T	cg06784218	chr1:46089804	CCDC17	0.41	7.2	0.4	6.12e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs1348850	0.914	rs2060929	chr2:178280031	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.86	12.77	0.62	1.97e-29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs7190458	0.522	rs72787110	chr16:75379533	T/C	cg04384234	chr16:75411784	CFDP1	0.61	5.17	0.3	4.54e-7	Pancreatic cancer;
CESC	cis	rs11203032	0.831	rs10788638	chr10:90950683	A/G	cg16672925	chr10:90967113	CH25H	0.46	5.42	0.32	1.32e-7	Heart failure;
CESC	cis	rs709400	0.604	rs7158144	chr14:103887615	A/G	cg12935359	chr14:103987150	CKB	-0.56	-8.18	-0.45	1.21e-14	Body mass index;
CESC	cis	rs10927875	1.000	rs10927875	chr1:16299312	A/G	cg21385522	chr1:16154831	NA	0.77	9.74	0.51	2.41e-19	Dilated cardiomyopathy;
CESC	cis	rs8060686	0.516	rs7184821	chr16:68270229	T/C	cg26727032	chr16:67993705	SLC12A4	-0.6	-8.67	-0.47	4.34e-16	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs12144044	0.701	rs2999159	chr1:113230758	A/G	cg22162597	chr1:113214053	CAPZA1	-0.5	-5.26	-0.31	2.91e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs57502260	0.704	rs41478448	chr11:68181621	A/G	cg20283391	chr11:68216788	NA	-0.57	-5.17	-0.3	4.71e-7	Total body bone mineral density (age 45-60);
CESC	cis	rs61776719	0.520	rs17465651	chr1:38418496	C/T	cg17077180	chr1:38461687	NA	0.47	7.15	0.4	8.21e-12	Coronary artery disease;
CESC	cis	rs116095464	1.000	rs56235400	chr5:312625	G/A	cg10591111	chr5:226296	SDHA	-0.61	-5.73	-0.33	2.73e-8	Breast cancer;
CESC	cis	rs4073582	0.595	rs801737	chr11:65928193	T/C	cg14036092	chr11:66035641	RAB1B	0.55	7.76	0.43	1.82e-13	Gout;
CESC	cis	rs2274273	0.837	rs7146748	chr14:55747086	G/A	cg04306507	chr14:55594613	LGALS3	0.3	5.84	0.34	1.54e-8	Protein biomarker;
CESC	cis	rs916888	0.610	rs199529	chr17:44837217	A/C	cg17911788	chr17:44343683	NA	-0.46	-6.74	-0.38	9.64e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs2228479	0.702	rs62053702	chr16:89860688	G/T	cg14709524	chr16:89940631	TCF25	0.93	6.97	0.39	2.5e-11	Skin colour saturation;
CESC	cis	rs4319547	0.614	rs10846764	chr12:122874297	T/C	cg05707623	chr12:122985044	ZCCHC8	0.56	6.28	0.36	1.35e-9	Body mass index;
CESC	trans	rs11098499	0.644	rs7676296	chr4:120555687	A/G	cg25214090	chr10:38739885	LOC399744	0.62	8.65	0.47	4.98e-16	Corneal astigmatism;
CESC	cis	rs6540559	0.611	rs61747285	chr1:210004332	G/A	cg23283495	chr1:209979779	IRF6	0.47	5.24	0.31	3.24e-7	Cleft lip with or without cleft palate;
CESC	cis	rs765787	0.530	rs12906537	chr15:45520061	T/C	cg24006582	chr15:45444508	DUOX1	0.54	6.48	0.37	4.44e-10	Uric acid levels;
CESC	cis	rs7618915	0.571	rs1961958	chr3:52585990	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	6.58	0.37	2.48e-10	Bipolar disorder;
CESC	cis	rs4253772	0.550	rs6007779	chr22:46678615	A/C	cg18190219	chr22:46762943	CELSR1	-0.42	-5.34	-0.31	2e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs1267303	0.716	rs942255	chr1:46989792	C/T	cg25110126	chr1:46999211	NA	0.76	8.82	0.48	1.57e-16	Monobrow;
CESC	cis	rs60843830	1.000	rs3791221	chr2:226933	A/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.79	10.35	0.54	2.56e-21	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs17095355	0.748	rs2501577	chr10:111846687	C/T	cg00817464	chr10:111662876	XPNPEP1	0.44	5.67	0.33	3.74e-8	Biliary atresia;
CESC	cis	rs801193	0.569	rs13226966	chr7:66233623	A/G	cg18876405	chr7:65276391	NA	0.45	6.17	0.35	2.49e-9	Aortic root size;
CESC	cis	rs2276314	1.000	rs9956938	chr18:33567061	A/G	cg19628046	chr18:33552617	C18orf21	0.5	5.33	0.31	2.1e-7	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs4253772	0.550	rs739164	chr22:46684558	C/T	cg07012999	chr22:46692446	CN5H6.4;GTSE1	-0.52	-5.28	-0.31	2.64e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs4423214	0.879	rs736894	chr11:71152258	A/G	cg05163923	chr11:71159392	DHCR7	0.7	8.59	0.47	7.51e-16	Vitamin D levels;
CESC	cis	rs6964587	0.810	rs408	chr7:91556284	A/G	cg17063962	chr7:91808500	NA	-0.54	-7.15	-0.4	8.24e-12	Breast cancer;
CESC	cis	rs7927771	1.000	rs34910028	chr11:47758449	T/C	cg05585544	chr11:47624801	NA	-0.52	-8.05	-0.44	2.78e-14	Subjective well-being;
CESC	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.09	19.75	0.77	5.18e-54	Prudent dietary pattern;
CESC	cis	rs713587	0.713	rs12466350	chr2:25239969	A/G	cg01884057	chr2:25150051	NA	0.4	7.62	0.42	4.48e-13	Body mass index in non-asthmatics;
CESC	cis	rs2637266	0.703	rs864677	chr10:78525525	G/A	cg18941641	chr10:78392320	NA	0.39	7.68	0.43	3.1400000000000003e-13	Pulmonary function;
CESC	cis	rs7615952	0.932	rs7629977	chr3:125649573	T/G	cg05084668	chr3:125655381	ALG1L	-0.54	-6.32	-0.36	1.09e-9	Blood pressure (smoking interaction);
CESC	trans	rs7980799	0.682	rs7311794	chr12:33635630	C/T	cg26384229	chr12:38710491	ALG10B	-0.57	-8.34	-0.46	3.99e-15	Heart rate;Heart rate variability traits (RMSSD);
CESC	cis	rs11718455	0.920	rs13084408	chr3:44008967	G/A	cg08738300	chr3:44038990	NA	0.46	6.1	0.35	3.7e-9	Coronary artery disease;
CESC	cis	rs76878669	0.561	rs10896111	chr11:66115690	T/C	cg18002602	chr11:66138449	SLC29A2	-0.42	-6.96	-0.39	2.67e-11	Educational attainment (years of education);
CESC	cis	rs1707322	1.000	rs12097761	chr1:46291162	T/C	cg03146154	chr1:46216737	IPP	0.78	10.73	0.55	1.5e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs1348850	0.526	rs2293475	chr2:178407897	C/T	cg23306229	chr2:178417860	TTC30B	-0.74	-6.73	-0.38	1.02e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs769267	0.965	rs2315281	chr19:19480099	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	-0.48	-6.18	-0.35	2.39e-9	Tonsillectomy;
CESC	cis	rs61996546	0.622	rs34661562	chr15:26849631	A/G	cg14859324	chr15:26874363	GABRB3	-0.37	-5.06	-0.3	7.97e-7	Response to methotrexate in juvenile idiopathic arthritis;
CESC	cis	rs6938	0.596	rs11630918	chr15:75155896	C/T	cg09165964	chr15:75287851	SCAMP5	0.51	7.09	0.4	1.19e-11	Breast cancer;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg01777103	chr8:145550585	DGAT1	-0.44	-6.11	-0.35	3.58e-9	Fibrinogen levels;
CESC	cis	rs763121	0.853	rs5750671	chr22:39094619	A/C	cg06544989	chr22:39130855	UNC84B	0.52	9.88	0.52	8.35e-20	Menopause (age at onset);
CESC	cis	rs7666738	0.830	rs11932942	chr4:98998939	T/C	cg17366294	chr4:99064904	C4orf37	0.6	8.61	0.47	6.47e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs832540	0.898	rs702680	chr5:56220382	T/C	cg24531977	chr5:56204891	C5orf35	-0.44	-5.45	-0.32	1.17e-7	Coronary artery disease;
CESC	cis	rs9322193	0.962	rs9393175	chr6:149998723	A/G	cg07701084	chr6:150067640	NUP43	0.41	5.41	0.32	1.41e-7	Lung cancer;
CESC	cis	rs514406	0.800	rs4926930	chr1:53217335	A/G	cg08736216	chr1:53307985	ZYG11A	0.41	6.85	0.39	5.29e-11	Monocyte count;
CESC	cis	rs7247513	0.790	rs17476839	chr19:12762783	C/T	cg01871581	chr19:12707946	ZNF490	0.73	10.72	0.55	1.68e-22	Bipolar disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21680979	chr1:204485559	MDM4	0.55	6.39	0.37	7.25e-10	Gut microbiome composition (summer);
CESC	cis	rs8092503	0.903	rs58243949	chr18:52509833	C/T	cg12377874	chr18:52495404	RAB27B	0.39	5.97	0.34	7.63e-9	Childhood body mass index;
CESC	cis	rs12725198	1.000	rs12725833	chr1:16080618	G/A	cg18133145	chr1:16060689	PLEKHM2	-0.52	-5.66	-0.33	4e-8	Cardiac Troponin-T levels;
CESC	cis	rs6087990	0.735	rs1855350	chr20:31387525	C/T	cg13636640	chr20:31349939	DNMT3B	0.8	12.85	0.62	1.09e-29	Ulcerative colitis;
CESC	cis	rs986417	0.901	rs10139995	chr14:60947177	G/T	cg00859478	chr14:60978094	SIX6	0.45	5.06	0.3	7.79e-7	Gut microbiota (bacterial taxa);
CESC	trans	rs9987353	0.840	rs329994	chr8:9123233	A/G	cg00772714	chr1:15479360	TMEM51;C1orf126	-0.46	-6.21	-0.36	2.09e-9	Recombination measurement;
CESC	cis	rs6582630	0.519	rs11514056	chr12:38284001	G/T	cg13010199	chr12:38710504	ALG10B	0.46	5.61	0.33	5.13e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs1862618	0.853	rs33322	chr5:56175226	A/G	cg24549020	chr5:56110836	MAP3K1	0.66	7.45	0.42	1.35e-12	Initial pursuit acceleration;
CESC	cis	rs477895	0.713	rs35095324	chr11:63948412	G/A	cg18225595	chr11:63971243	STIP1	0.52	5.16	0.3	4.77e-7	Mean platelet volume;
CESC	cis	rs1552244	0.744	rs6763366	chr3:10033544	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	10.84	0.55	6.79e-23	Alzheimer's disease;
CESC	trans	rs3942852	0.955	rs7117386	chr11:48125371	G/A	cg15704280	chr7:45808275	SEPT13	-0.59	-6.74	-0.38	9.73e-11	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs7666738	0.927	rs4699328	chr4:99055890	C/T	cg05340658	chr4:99064831	C4orf37	0.82	12.44	0.61	2.73e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9788682	0.747	rs2568490	chr15:78738370	T/C	cg24631222	chr15:78858424	CHRNA5	-0.6	-7.09	-0.4	1.21e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs897080	0.552	rs1085442	chr2:44635454	C/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.45	5.52	0.32	8.08e-8	Height;
CESC	cis	rs9640161	0.702	rs1962004	chr7:150020381	G/A	cg10018233	chr7:150070692	REPIN1	0.38	5.23	0.31	3.38e-7	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs6429082	0.608	rs4659838	chr1:235565315	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.53	-6.63	-0.38	1.84e-10	Adiposity;
CESC	cis	rs4268898	0.722	rs35520052	chr2:24415277	C/T	cg06627628	chr2:24431161	ITSN2	0.6	7.91	0.44	6.79e-14	Asthma;
CESC	cis	rs6060717	0.536	rs6060664	chr20:34478884	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-6.93	-0.39	3.22e-11	Hip circumference adjusted for BMI;
CESC	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	13.73	0.64	9.09e-33	Prudent dietary pattern;
CESC	cis	rs3741151	0.656	rs56884659	chr11:73252947	C/G	cg17517138	chr11:73019481	ARHGEF17	1.05	7.72	0.43	2.46e-13	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs742614	0.533	rs6059497	chr20:32446960	C/G	cg06304546	chr20:32448765	NA	-0.48	-6.15	-0.35	2.81e-9	Stearic acid (18:0) levels;
CESC	cis	rs6693567	0.565	rs832621	chr1:150392909	G/C	cg09579323	chr1:150459698	TARS2	0.46	5.97	0.34	7.68e-9	Migraine;
CESC	cis	rs780096	0.526	rs11126999	chr2:27670307	G/A	cg02592271	chr2:27665507	KRTCAP3	-0.27	-5.32	-0.31	2.21e-7	Total body bone mineral density;
CESC	cis	rs3791556	0.501	rs3791536	chr2:240101713	G/A	cg03281426	chr2:240109471	HDAC4	0.47	5.94	0.34	9.16e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs801193	1.000	rs1553610	chr7:66197233	T/C	cg18876405	chr7:65276391	NA	0.54	7.28	0.41	3.88e-12	Aortic root size;
CESC	cis	rs3125734	0.608	rs7905731	chr10:64018472	T/C	cg09941381	chr10:64027924	RTKN2	-0.32	-5.21	-0.3	3.79e-7	Rheumatoid arthritis;
CESC	cis	rs61542988	0.570	rs62448267	chr7:22822501	T/C	cg11367502	chr7:22862612	TOMM7	0.54	6.29	0.36	1.3e-9	Fibrinogen levels;
CESC	cis	rs77972916	0.611	rs11693190	chr2:43602415	A/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-6.05	-0.35	5.04e-9	Granulocyte percentage of myeloid white cells;
CESC	cis	rs7524258	0.868	rs2412152	chr1:7303213	C/T	cg07173049	chr1:7289937	CAMTA1	0.42	6.27	0.36	1.5e-9	Tourette's syndrome or obsessive-compulsive disorder;
CESC	cis	rs992157	0.687	rs10206984	chr2:219066980	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.68	9.56	0.51	8.5e-19	Colorectal cancer;
CESC	cis	rs8067545	0.611	rs2526465	chr17:20167611	T/C	cg13482628	chr17:19912719	NA	-0.42	-5.6	-0.33	5.37e-8	Schizophrenia;
CESC	cis	rs35110281	0.776	rs2838316	chr21:44990036	C/T	cg01579765	chr21:45077557	HSF2BP	-0.56	-9.31	-0.5	5.09e-18	Mean corpuscular volume;
CESC	cis	rs478222	0.866	rs11684464	chr2:25340610	A/G	cg01884057	chr2:25150051	NA	-0.3	-5.08	-0.3	7.24e-7	Type 1 diabetes;
CESC	cis	rs4129767	0.869	rs4969142	chr17:76398304	G/A	cg05887092	chr17:76393375	PGS1	0.68	11.21	0.57	4.1e-24	HDL cholesterol;
CESC	cis	rs367943	0.712	rs10042223	chr5:112712832	C/T	cg12552261	chr5:112820674	MCC	0.39	5.2	0.3	4e-7	Type 2 diabetes;
CESC	cis	rs6502050	0.835	rs12950475	chr17:80118924	T/C	cg23985595	chr17:80112537	CCDC57	-0.41	-6.57	-0.37	2.6200000000000003e-10	Life satisfaction;
CESC	trans	rs11148252	0.574	rs61958118	chr13:53170226	C/T	cg18335740	chr13:41363409	SLC25A15	0.57	7.92	0.44	6.73e-14	Lewy body disease;
CESC	cis	rs12142240	0.583	rs5013330	chr1:46815154	G/A	cg10495392	chr1:46806563	NSUN4	0.57	6.28	0.36	1.39e-9	Menopause (age at onset);
CESC	cis	rs3092073	0.624	rs11696196	chr20:44574533	C/T	cg17986701	chr20:44574422	PCIF1	0.35	5.22	0.31	3.62e-7	Intelligence (multi-trait analysis);
CESC	cis	rs6032067	0.866	rs2233901	chr20:43851094	A/G	cg10761708	chr20:43804764	PI3	-0.5	-6.28	-0.36	1.4e-9	Blood protein levels;
CESC	cis	rs4629180	0.630	rs10188189	chr2:102127926	A/G	cg04415270	chr2:102091202	RFX8	-0.34	-5.95	-0.34	8.64e-9	Chronic rhinosinusitis with nasal polyps;
CESC	cis	rs9443189	0.950	rs1280039	chr6:76514940	C/T	cg01950844	chr6:76311363	SENP6	0.64	6.54	0.37	3.09e-10	Prostate cancer;
CESC	cis	rs10851478	0.872	rs62022665	chr15:49873811	G/C	cg08060515	chr15:49448048	GALK2;COPS2	0.42	5.16	0.3	4.75e-7	Oral cavity cancer;
CESC	cis	rs826838	1.000	rs826851	chr12:39112639	A/G	cg26384229	chr12:38710491	ALG10B	-0.7	-11.43	-0.57	7.55e-25	Heart rate;
CESC	cis	rs11683229	0.704	rs12996320	chr2:63310229	C/T	cg17519650	chr2:63277830	OTX1	0.62	5.12	0.3	6.01e-7	Protein quantitative trait loci;
CESC	cis	rs896854	0.654	rs13278601	chr8:95972974	G/C	cg16049864	chr8:95962084	TP53INP1	-0.65	-11.3	-0.57	2.05e-24	Type 2 diabetes;
CESC	cis	rs3820068	0.581	rs72645874	chr1:15926238	C/G	cg17385448	chr1:15911702	AGMAT	0.41	6.69	0.38	1.33e-10	Systolic blood pressure;
CESC	cis	rs7937682	1.000	rs2186839	chr11:111534442	T/G	cg22437258	chr11:111473054	SIK2	0.7	9.23	0.49	9.06e-18	Primary sclerosing cholangitis;
CESC	cis	rs6580649	0.941	rs1859441	chr12:48423233	C/T	cg24011408	chr12:48396354	COL2A1	-0.42	-5.26	-0.31	2.93e-7	Lung cancer;
CESC	cis	rs7552404	0.690	rs2029681	chr1:76333846	G/A	cg03433033	chr1:76189801	ACADM	-0.63	-6.61	-0.38	2.14e-10	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs6938	0.534	rs1127796	chr15:75193004	C/T	cg09165964	chr15:75287851	SCAMP5	-0.45	-6.15	-0.35	2.89e-9	Breast cancer;
CESC	cis	rs9322193	0.962	rs1889473	chr6:150146621	C/G	cg04369109	chr6:150039330	LATS1	-0.44	-6.17	-0.35	2.52e-9	Lung cancer;
CESC	cis	rs7084402	0.967	rs1620186	chr10:60314275	G/A	cg07615347	chr10:60278583	BICC1	0.62	9.95	0.52	5.08e-20	Refractive error;
CESC	cis	rs2991971	0.967	rs512026	chr1:46009946	G/T	cg05343316	chr1:45956843	TESK2	-0.5	-6.45	-0.37	5.14e-10	High light scatter reticulocyte count;
CESC	trans	rs9329221	0.678	rs560638	chr8:9882767	A/G	cg06636001	chr8:8085503	FLJ10661	-0.55	-7.17	-0.4	7.55e-12	Neuroticism;
CESC	cis	rs12048904	0.512	rs932798	chr1:101249355	G/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.69	-8.64	-0.47	5.38e-16	Multiple sclerosis;
CESC	cis	rs6741892	0.536	rs11688977	chr2:38896631	C/T	cg01546378	chr2:38892901	GALM	-0.5	-6.7	-0.38	1.24e-10	5-HTT brain serotonin transporter levels;
CESC	cis	rs10927875	0.830	rs1763610	chr1:16335527	C/G	cg21385522	chr1:16154831	NA	-0.61	-7.58	-0.42	5.89e-13	Dilated cardiomyopathy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	ch.18.486455F	chr18:23949690	TAF4B	-0.53	-6.36	-0.36	8.81e-10	Gut microbiome composition (summer);
CESC	cis	rs9488822	0.676	rs12202641	chr6:116314634	A/G	cg26893134	chr6:116381904	FRK	-0.26	-6.5	-0.37	3.96e-10	Cholesterol, total;LDL cholesterol;
CESC	cis	rs11098499	0.644	rs3986377	chr4:120260270	G/A	cg09307838	chr4:120376055	NA	0.76	10.33	0.54	3.09e-21	Corneal astigmatism;
CESC	trans	rs17685	0.753	rs10245584	chr7:75745866	C/T	cg19862616	chr7:65841803	NCRNA00174	0.84	12.42	0.61	3.1e-28	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs2836974	0.897	rs13049280	chr21:40594656	C/G	cg27266027	chr21:40555129	PSMG1	0.46	5.37	0.31	1.72e-7	Cognitive function;
CESC	cis	rs7267979	1.000	rs6083804	chr20:25317060	A/G	cg08601574	chr20:25228251	PYGB	-0.39	-5.61	-0.33	4.99e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7818688	0.697	rs61591488	chr8:95984955	C/T	cg16049864	chr8:95962084	TP53INP1	0.57	5.73	0.33	2.68e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs12497850	0.931	rs9311430	chr3:48845251	C/T	cg02487422	chr3:49467188	NICN1	0.39	5.05	0.3	8.06e-7	Parkinson's disease;
CESC	cis	rs561341	1.000	rs4795669	chr17:30244701	C/T	cg23018236	chr17:30244563	NA	-0.52	-5.59	-0.32	5.57e-8	Hip circumference adjusted for BMI;
CESC	cis	rs9733	0.596	rs72702552	chr1:150677462	G/A	cg17724175	chr1:150552817	MCL1	0.44	7.21	0.41	5.76e-12	Tonsillectomy;
CESC	cis	rs758324	0.853	rs10051653	chr5:131248894	G/A	cg06307176	chr5:131281290	NA	-0.37	-5.06	-0.3	7.79e-7	Alzheimer's disease in APOE e4- carriers;
CESC	cis	rs7618915	0.547	rs13069481	chr3:52666866	C/T	cg07507251	chr3:52567010	NT5DC2	0.4	7.03	0.4	1.78e-11	Bipolar disorder;
CESC	cis	rs36051895	0.695	rs7045000	chr9:5015143	G/A	cg02405213	chr9:5042618	JAK2	-0.48	-6.0	-0.35	6.46e-9	Pediatric autoimmune diseases;
CESC	cis	rs7223966	1.000	rs9891018	chr17:61827856	A/G	cg11494091	chr17:61959527	GH2	0.39	5.22	0.31	3.59e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs3741151	1.000	rs75109191	chr11:73023532	T/C	cg17517138	chr11:73019481	ARHGEF17	1.16	8.06	0.44	2.63e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.61	7.94	0.44	5.84e-14	Prudent dietary pattern;
CESC	cis	rs875971	0.545	rs73142233	chr7:65686280	T/A	cg11764359	chr7:65958608	NA	0.8	8.97	0.48	5.55e-17	Aortic root size;
CESC	cis	rs9649213	0.593	rs6465675	chr7:97982103	C/T	cg21770322	chr7:97807741	LMTK2	-0.56	-8.61	-0.47	6.79e-16	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs2204008	0.837	rs2387317	chr12:38235319	T/C	cg13010199	chr12:38710504	ALG10B	0.49	6.1	0.35	3.78e-9	Bladder cancer;
CESC	cis	rs4833079	0.562	rs11944291	chr4:38631620	T/G	cg18361445	chr4:38666374	KLF3;FLJ13197	0.48	6.69	0.38	1.34e-10	Body mass index;
CESC	cis	rs933688	1.000	rs6867091	chr5:90734333	C/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.06	14.58	0.67	9.41e-36	Smoking behavior;
CESC	cis	rs3768617	0.510	rs2093985	chr1:183094322	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.84	13.25	0.63	4.17e-31	Fuchs's corneal dystrophy;
CESC	cis	rs9828933	1.000	rs9828933	chr3:64002897	T/C	cg16258503	chr3:63850278	ATXN7;THOC7	-0.52	-5.21	-0.3	3.74e-7	Type 2 diabetes;
CESC	cis	rs7512552	0.839	rs2647373	chr1:150320570	G/C	cg15654264	chr1:150340011	RPRD2	0.39	5.16	0.3	4.81e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs2933343	0.729	rs1680780	chr3:128612659	G/C	cg25356066	chr3:128598488	ACAD9	0.63	8.58	0.47	8.01e-16	IgG glycosylation;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg10909163	chr13:41635251	WBP4	-0.43	-6.11	-0.35	3.53e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs6545883	1.000	rs778758	chr2:61782161	T/C	cg15711740	chr2:61764176	XPO1	-0.43	-5.33	-0.31	2.14e-7	Tuberculosis;
CESC	cis	rs9910055	0.509	rs9916444	chr17:42313512	C/G	cg08499158	chr17:42289980	UBTF	-0.42	-5.18	-0.3	4.32e-7	Total body bone mineral density;
CESC	cis	rs2011503	0.941	rs11670775	chr19:19649636	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.52	5.13	0.3	5.7e-7	Bipolar disorder;
CESC	cis	rs57083693	0.556	rs6538984	chr12:101725669	T/G	cg22051763	chr12:101673672	UTP20	-0.44	-5.5	-0.32	8.98e-8	Alcohol dependence (age at onset);
CESC	cis	rs7202877	0.539	rs17764278	chr16:75374029	A/T	cg04384234	chr16:75411784	CFDP1	-0.63	-5.52	-0.32	8.2e-8	Type 2 diabetes;Type 1 diabetes;
CESC	cis	rs9910055	0.747	rs2905981	chr17:42238625	C/T	cg19774624	chr17:42201019	HDAC5	-0.69	-10.1	-0.53	1.62e-20	Total body bone mineral density;
CESC	cis	rs8067354	0.574	rs2526354	chr17:57976658	A/G	cg13753209	chr17:57696993	CLTC	0.54	6.03	0.35	5.57e-9	Hemoglobin concentration;
CESC	cis	rs7208859	0.673	rs1347360	chr17:28914532	T/C	cg19761014	chr17:28927070	LRRC37B2	0.7	5.97	0.34	7.4e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs11123610	0.520	rs7576146	chr2:3718393	A/C	cg19052272	chr2:3704530	ALLC	-0.48	-5.85	-0.34	1.41e-8	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CESC	cis	rs73206853	0.764	rs73206857	chr12:110767721	T/A	cg12870014	chr12:110450643	ANKRD13A	0.67	5.67	0.33	3.67e-8	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs9393777	0.623	rs7773938	chr6:26474044	C/T	cg12826209	chr6:26865740	GUSBL1	0.67	7.12	0.4	9.9e-12	Intelligence (multi-trait analysis);
CESC	cis	rs7953249	0.656	rs6489786	chr12:121397875	A/G	cg02403541	chr12:121454288	C12orf43	-0.53	-6.9	-0.39	3.77e-11	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
CESC	trans	rs7866350	0.604	rs1935389	chr9:100994470	A/G	cg18145393	chr4:520203	PIGG	-0.51	-6.62	-0.38	1.95e-10	Post-traumatic stress disorder;
CESC	trans	rs1340425	0.793	rs67551075	chr1:74441371	T/C	cg26500312	chr17:30821755	MYO1D	0.55	6.13	0.35	3.09e-9	Posterior cortical atrophy and Alzheimer's disease;
CESC	cis	rs1552244	0.572	rs12107622	chr3:10171898	T/A	cg00149659	chr3:10157352	C3orf10	0.97	11.51	0.58	3.85e-25	Alzheimer's disease;
CESC	cis	rs4242434	0.819	rs720745	chr8:22471147	G/T	cg03733263	chr8:22462867	KIAA1967	0.86	14.44	0.66	2.98e-35	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CESC	cis	rs8014204	0.868	rs2230237	chr14:75359670	G/A	cg08847533	chr14:75593920	NEK9	-0.46	-5.68	-0.33	3.46e-8	Caffeine consumption;
CESC	cis	rs7481584	0.624	rs511990	chr11:3052936	A/G	cg08508325	chr11:3079039	CARS	0.29	5.19	0.3	4.29e-7	Calcium levels;
CESC	cis	rs898097	0.510	rs10445242	chr17:80891666	G/T	cg19046167	chr17:80928561	B3GNTL1	0.4	5.34	0.31	2.04e-7	Breast cancer;
CESC	cis	rs7927592	0.763	rs10896326	chr11:68234571	T/C	cg01657329	chr11:68192670	LRP5	-0.47	-6.19	-0.36	2.29e-9	Total body bone mineral density;
CESC	cis	rs9916302	0.851	rs677888	chr17:37461018	T/G	cg00129232	chr17:37814104	STARD3	0.51	6.26	0.36	1.58e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs12579753	0.810	rs10862355	chr12:82162698	C/T	cg23701643	chr12:82153290	PPFIA2	-0.33	-5.07	-0.3	7.33e-7	Resting heart rate;
CESC	cis	rs1862618	0.853	rs252902	chr5:56116085	A/G	cg24531977	chr5:56204891	C5orf35	-0.84	-10.77	-0.55	1.09e-22	Initial pursuit acceleration;
CESC	cis	rs798766	0.953	rs798751	chr4:1719572	A/G	cg10756475	chr4:1757242	NA	0.44	5.97	0.34	7.54e-9	Bladder cancer;Urinary bladder cancer;
CESC	cis	rs4588572	0.644	rs10061149	chr5:77744201	G/A	cg11547950	chr5:77652471	NA	-0.4	-5.46	-0.32	1.12e-7	Triglycerides;
CESC	cis	rs6460942	0.841	rs17443848	chr7:12443688	A/G	cg13733410	chr7:12443478	VWDE	-0.48	-5.78	-0.33	2.07e-8	Coronary artery disease;
CESC	cis	rs9467711	0.606	rs12176317	chr6:26372786	A/G	cg14345882	chr6:26364793	BTN3A2	0.6	6.21	0.36	2.07e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs6088580	0.634	rs6059779	chr20:32950325	C/T	cg24642439	chr20:33292090	TP53INP2	-0.51	-6.66	-0.38	1.6e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs4944092	1.000	rs4944092	chr11:75909619	C/T	cg04588336	chr11:75916460	WNT11	-0.48	-7.7	-0.43	2.78e-13	PR interval;
CESC	cis	rs7727544	0.684	rs611084	chr5:131709739	A/C	cg07395648	chr5:131743802	NA	0.42	5.49	0.32	9.52e-8	Blood metabolite levels;
CESC	cis	rs1215050	0.791	rs13114823	chr4:98671119	G/A	cg05340658	chr4:99064831	C4orf37	-0.47	-6.09	-0.35	3.86e-9	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs853679	0.517	rs1947862	chr6:28105196	C/T	cg20151795	chr6:28129481	ZNF389	0.48	6.12	0.35	3.35e-9	Depression;
CESC	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg03647317	chr4:187891568	NA	-0.37	-5.56	-0.32	6.44e-8	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4423214	1.000	rs2282620	chr11:71183477	C/T	cg24826892	chr11:71159390	DHCR7	0.46	5.24	0.31	3.2e-7	Vitamin D levels;
CESC	cis	rs6088590	1.000	rs6119535	chr20:33442138	A/C	cg06115741	chr20:33292138	TP53INP2	0.55	6.84	0.39	5.34e-11	Coronary artery disease;
CESC	cis	rs30380	0.690	rs2216752	chr5:96185467	A/G	cg16492584	chr5:96139282	ERAP1	0.37	5.07	0.3	7.43e-7	Cerebrospinal fluid biomarker levels;
CESC	cis	rs7044106	0.791	rs4836830	chr9:123483668	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.37	5.88	0.34	1.21e-8	Hip circumference adjusted for BMI;
CESC	cis	rs7666738	0.830	rs28416660	chr4:98899525	C/G	cg03676636	chr4:99064102	C4orf37	0.34	5.15	0.3	5e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12059507	chr11:62606662	WDR74	0.55	6.11	0.35	3.58e-9	Gut microbiome composition (summer);
CESC	cis	rs10256972	0.527	rs2949170	chr7:1216438	A/G	cg17541715	chr7:1216824	NA	-0.39	-5.05	-0.3	8.42e-7	Longevity;Endometriosis;
CESC	cis	rs3785574	0.962	rs2665842	chr17:61878535	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.57	7.03	0.4	1.78e-11	Height;
CESC	cis	rs11122272	0.735	rs2491416	chr1:231547335	T/C	cg06096015	chr1:231504339	EGLN1	-0.42	-5.93	-0.34	9.56e-9	Hemoglobin concentration;
CESC	cis	rs9811920	0.809	rs35422475	chr3:99711545	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.46	-7.53	-0.42	7.76e-13	Axial length;
CESC	cis	rs9796	0.662	rs8033435	chr15:41436479	C/T	cg12426344	chr15:41135900	SPINT1	-0.25	-5.39	-0.31	1.59e-7	Menopause (age at onset);
CESC	trans	rs61931739	0.500	rs11053201	chr12:34453903	T/A	cg26384229	chr12:38710491	ALG10B	0.69	10.44	0.54	1.34e-21	Morning vs. evening chronotype;
CESC	cis	rs921968	0.540	rs646295	chr2:219408558	A/C	cg02176678	chr2:219576539	TTLL4	0.43	7.65	0.43	3.67e-13	Mean corpuscular hemoglobin concentration;
CESC	cis	rs11252926	0.537	rs4881255	chr10:453638	T/C	cg16386425	chr10:429943	DIP2C	-0.56	-7.18	-0.4	7.03e-12	Psychosis in Alzheimer's disease;
CESC	cis	rs4727027	0.933	rs12540094	chr7:148847178	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	-0.42	-5.41	-0.32	1.38e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs7537052	0.646	rs795045	chr1:36650055	T/C	cg24686825	chr1:36642396	MAP7D1	-0.71	-10.0	-0.52	3.38e-20	Schizophrenia;
CESC	cis	rs7833790	0.963	rs2400473	chr8:82703403	C/T	cg17211192	chr8:82754475	SNX16	-0.67	-8.1	-0.45	2.01e-14	Diastolic blood pressure;
CESC	cis	rs6687430	0.543	rs7512495	chr1:10631237	C/T	cg07384165	chr1:10488281	NA	-0.47	-6.54	-0.37	3.08e-10	Hand grip strength;
CESC	cis	rs4072980	0.545	rs10890285	chr1:38453576	A/C	cg12658694	chr1:38397304	INPP5B	-0.67	-8.87	-0.48	1.1e-16	Coronary artery disease;
CESC	cis	rs12497850	0.931	rs6791542	chr3:48787219	A/G	cg03060546	chr3:49711283	APEH	0.47	5.9	0.34	1.08e-8	Parkinson's disease;
CESC	cis	rs2404602	0.647	rs12904417	chr15:76964152	A/G	cg23625390	chr15:77176239	SCAPER	0.46	6.57	0.37	2.71e-10	Blood metabolite levels;
CESC	cis	rs344364	0.636	rs344363	chr16:1972548	C/T	cg26617929	chr16:1858877	NA	-0.52	-5.12	-0.3	5.8e-7	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs2294693	0.685	rs67525613	chr6:41008956	G/T	cg14769373	chr6:40998127	UNC5CL	-0.43	-5.17	-0.3	4.65e-7	Gastric cancer;Non-cardia gastric cancer;
CESC	cis	rs10242455	0.702	rs76702117	chr7:98916779	A/G	cg25640893	chr7:99214727	ZNF498	0.9	6.04	0.35	5.13e-9	Blood metabolite levels;
CESC	cis	rs9487051	0.768	rs351752	chr6:109536034	C/A	cg01475377	chr6:109611718	NA	-0.44	-6.76	-0.38	8.56e-11	Reticulocyte fraction of red cells;
CESC	cis	rs7726839	1.000	rs7726839	chr5:618586	A/G	cg16447950	chr5:562315	NA	-0.4	-5.2	-0.3	4.03e-7	Obesity-related traits;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg10318825	chr7:75611554	POR	0.43	6.2	0.36	2.12e-9	Fibrinogen levels;
CESC	cis	rs7527798	0.592	rs12025522	chr1:207854355	A/C	cg09232269	chr1:207846808	CR1L	0.28	5.07	0.3	7.41e-7	Erythrocyte sedimentation rate;
CESC	cis	rs1707322	1.000	rs34444543	chr1:46358862	G/A	cg05343316	chr1:45956843	TESK2	0.45	5.55	0.32	6.98e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs847577	0.609	rs7791463	chr7:97819047	G/A	cg21770322	chr7:97807741	LMTK2	0.84	13.94	0.65	1.67e-33	Breast cancer;
CESC	cis	rs593982	0.925	rs585272	chr11:65505289	A/G	cg08755490	chr11:65554678	OVOL1	1.32	20.05	0.78	4.7e-55	Atopic dermatitis;
CESC	cis	rs1005277	0.579	rs2008449	chr10:38414204	A/T	cg25427524	chr10:38739819	LOC399744	0.69	10.31	0.54	3.49e-21	Extrinsic epigenetic age acceleration;
CESC	cis	rs9291683	0.595	rs3733585	chr4:10036339	A/G	cg00071950	chr4:10020882	SLC2A9	0.87	15.5	0.69	5.06e-39	Bone mineral density;
CESC	cis	rs17601876	0.814	rs7181429	chr15:51559496	G/A	cg19946085	chr15:51559439	CYP19A1	-0.33	-5.39	-0.31	1.54e-7	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
CESC	trans	rs12356475	0.710	rs10822686	chr10:67733250	C/T	cg13783546	chr17:76671452	CYTH1	-0.49	-6.03	-0.35	5.6e-9	Psoriatic arthritis;
CESC	cis	rs4237845	0.844	rs4628718	chr12:58301600	A/C	cg02175503	chr12:58329896	NA	0.66	8.31	0.45	5.16e-15	Intelligence (multi-trait analysis);
CESC	cis	rs769267	0.930	rs2301784	chr19:19390749	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.42	5.38	0.31	1.66e-7	Tonsillectomy;
CESC	cis	rs5771225	0.563	rs738334	chr22:50688235	T/C	cg16473166	chr22:50639996	SELO	0.46	5.18	0.3	4.36e-7	Late-onset Alzheimer's disease;
CESC	trans	rs916888	0.773	rs199439	chr17:44793503	A/G	cg27125505	chr17:43679177	LOC644172	0.49	6.46	0.37	4.88e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs2072732	0.861	rs1890338	chr1:2949028	C/T	cg15211996	chr1:2936768	ACTRT2	0.35	6.12	0.35	3.42e-9	Plateletcrit;
CESC	cis	rs12765878	1.000	rs4918067	chr10:105644636	A/C	cg24587175	chr10:105670608	OBFC1	0.31	5.07	0.3	7.48e-7	Coronary artery disease;
CESC	trans	rs66573146	1.000	rs28729690	chr4:6962061	C/T	cg07817883	chr1:32538562	TMEM39B	1.36	8.74	0.47	2.78e-16	Granulocyte percentage of myeloid white cells;
CESC	cis	rs367615	0.513	rs11741087	chr5:108807760	G/A	cg17395555	chr5:108820864	NA	0.62	10.04	0.53	2.55e-20	Colorectal cancer (SNP x SNP interaction);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg09351035	chr11:748060	TALDO1	0.49	6.16	0.35	2.64e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs6088590	0.735	rs6060003	chr20:33294945	T/C	cg06115741	chr20:33292138	TP53INP2	0.48	5.89	0.34	1.16e-8	Coronary artery disease;
CESC	cis	rs8067354	0.645	rs2665400	chr17:57880201	G/A	cg13753209	chr17:57696993	CLTC	0.66	8.34	0.46	4.12e-15	Hemoglobin concentration;
CESC	cis	rs7552404	0.628	rs5745442	chr1:76342858	T/G	cg22875332	chr1:76189707	ACADM	0.59	5.77	0.33	2.27e-8	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs9549367	0.713	rs3024764	chr13:113824314	A/G	cg18105134	chr13:113819100	PROZ	-0.63	-7.92	-0.44	6.5e-14	Platelet distribution width;
CESC	cis	rs593982	0.777	rs72941015	chr11:65457514	A/C	cg08755490	chr11:65554678	OVOL1	-1.21	-8.91	-0.48	8.27e-17	Atopic dermatitis;
CESC	cis	rs12042052	1.000	rs72754230	chr1:232935071	A/G	cg00951395	chr1:232941775	KIAA1383	0.83	7.03	0.4	1.73e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CESC	cis	rs7100689	0.784	rs6585986	chr10:82171559	T/C	cg00277334	chr10:82204260	NA	-0.57	-7.11	-0.4	1.09e-11	Post bronchodilator FEV1;
CESC	cis	rs7618915	0.547	rs11720432	chr3:52672742	T/C	cg05564831	chr3:52568323	NT5DC2	0.45	6.87	0.39	4.46e-11	Bipolar disorder;
CESC	cis	rs4665809	1.000	rs10170359	chr2:26272219	G/T	cg26314531	chr2:26401878	FAM59B	-0.71	-7.89	-0.44	8.08e-14	Gut microbiome composition (summer);
CESC	cis	rs2777491	0.957	rs8027626	chr15:41711514	T/G	cg20272979	chr15:41787780	ITPKA	0.45	6.62	0.38	1.94e-10	Ulcerative colitis;
CESC	cis	rs7586879	0.616	rs12713422	chr2:25134497	A/C	cg01884057	chr2:25150051	NA	0.36	7.02	0.4	1.84e-11	Body mass index;
CESC	cis	rs5750830	0.649	rs5757659	chr22:39812409	A/C	cg24399712	chr22:39784796	NA	-0.78	-9.96	-0.52	4.84e-20	Intelligence (multi-trait analysis);
CESC	cis	rs769267	0.859	rs2916076	chr19:19545990	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.57	7.32	0.41	3.05e-12	Tonsillectomy;
CESC	cis	rs9911578	0.935	rs302873	chr17:56769481	C/G	cg12560992	chr17:57184187	TRIM37	0.93	15.26	0.68	3.64e-38	Intelligence (multi-trait analysis);
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg18875839	chr8:29120848	KIF13B	-0.46	-6.14	-0.35	3.04e-9	Height;
CESC	cis	rs6460942	0.630	rs1866650	chr7:12396897	C/T	cg20607287	chr7:12443886	VWDE	-0.64	-6.82	-0.39	6.18e-11	Coronary artery disease;
CESC	cis	rs9611565	0.506	rs2024567	chr22:41699206	G/C	cg06481639	chr22:41940642	POLR3H	-0.52	-5.74	-0.33	2.57e-8	Vitiligo;
CESC	cis	rs67311347	0.544	rs13098483	chr3:40342743	G/C	cg09455208	chr3:40491958	NA	0.37	6.51	0.37	3.77e-10	Renal cell carcinoma;
CESC	cis	rs6500395	0.775	rs28481630	chr16:48663664	G/C	cg04672837	chr16:48644449	N4BP1	0.49	6.27	0.36	1.46e-9	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs2072499	0.722	rs61462713	chr1:156161682	C/T	cg25208724	chr1:156163844	SLC25A44	1.01	12.84	0.62	1.13e-29	Testicular germ cell tumor;
CESC	cis	rs3741151	0.773	rs7950375	chr11:73281345	G/A	cg17517138	chr11:73019481	ARHGEF17	1.02	7.54	0.42	7.35e-13	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14253848	chr9:131038517	GOLGA2;C9orf119	0.6	6.48	0.37	4.56e-10	Gut microbiome composition (summer);
CESC	cis	rs7107174	0.901	rs2512525	chr11:77923019	T/C	cg02023728	chr11:77925099	USP35	0.45	6.01	0.35	6.06e-9	Testicular germ cell tumor;
CESC	cis	rs2836974	0.568	rs2836969	chr21:40648265	G/A	cg17971929	chr21:40555470	PSMG1	-0.87	-12.61	-0.61	6.96e-29	Cognitive function;
CESC	cis	rs9902453	0.612	rs2617868	chr17:28073247	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.76	-10.2	-0.53	8.08e-21	Coffee consumption (cups per day);
CESC	cis	rs2404602	0.647	rs12903331	chr15:77168268	C/G	cg23625390	chr15:77176239	SCAPER	-0.45	-6.34	-0.36	1.01e-9	Blood metabolite levels;
CESC	cis	rs25645	0.800	rs34003767	chr17:38194296	A/G	cg17467752	chr17:38218738	THRA	-0.52	-6.75	-0.38	9.49e-11	Myeloid white cell count;
CESC	trans	rs877282	0.583	rs112372193	chr10:826602	A/G	cg22713356	chr15:30763199	NA	1.02	9.67	0.51	3.88e-19	Uric acid levels;
CESC	cis	rs3733346	0.553	rs6813110	chr4:942660	C/T	cg20916646	chr4:852691	GAK	0.43	5.92	0.34	1e-8	Sjögren's syndrome;
CESC	cis	rs7520050	0.667	rs11211176	chr1:46223086	C/T	cg03146154	chr1:46216737	IPP	-0.61	-8.28	-0.45	6.01e-15	Red blood cell count;Reticulocyte count;
CESC	cis	rs6540559	1.000	rs742214	chr1:209960925	T/C	cg21951975	chr1:209979733	IRF6	0.61	9.44	0.5	2e-18	Cleft lip with or without cleft palate;
CESC	cis	rs6952808	0.929	rs12532128	chr7:1925454	T/C	cg05863683	chr7:1912471	MAD1L1	0.5	7.78	0.43	1.58e-13	Bipolar disorder and schizophrenia;
CESC	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg11494091	chr17:61959527	GH2	0.73	12.71	0.62	3.32e-29	Prudent dietary pattern;
CESC	cis	rs35110281	0.565	rs7278003	chr21:44966069	T/C	cg01579765	chr21:45077557	HSF2BP	-0.5	-8.26	-0.45	7.04e-15	Mean corpuscular volume;
CESC	cis	rs17376456	0.877	rs10213956	chr5:93460839	C/T	cg25358565	chr5:93447407	FAM172A	1.15	11.35	0.57	1.34e-24	Diabetic retinopathy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03195269	chr13:50510427	C13orf1	0.53	6.04	0.35	5.2e-9	Gut microbiome composition (summer);
CESC	trans	rs208520	0.690	rs12192710	chr6:66718137	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.94	12.17	0.6	2.34e-27	Exhaled nitric oxide output;
CESC	cis	rs4253772	0.530	rs9615349	chr22:46732418	T/G	cg10541313	chr22:46663664	TTC38	0.75	5.27	0.31	2.88e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs2486288	0.656	rs9921035	chr15:45546660	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.52	-6.07	-0.35	4.48e-9	Glomerular filtration rate;
CESC	cis	rs79349575	0.749	rs58838744	chr17:46998902	A/G	cg16584676	chr17:46985605	UBE2Z	0.54	6.7	0.38	1.24e-10	Type 2 diabetes;
CESC	cis	rs1950626	0.743	rs12884454	chr14:101465627	G/A	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.84	10.54	0.54	6.45e-22	Pelvic organ prolapse (moderate/severe);
CESC	trans	rs10411161	0.702	rs7256926	chr19:52391988	A/G	cg22319618	chr22:45562946	NUP50	-0.74	-7.44	-0.42	1.37e-12	Breast cancer;
CESC	cis	rs7662987	0.517	rs2602873	chr4:100039032	G/C	cg13256891	chr4:100009986	ADH5	0.75	8.03	0.44	3.29e-14	Smoking initiation;
CESC	cis	rs637571	0.522	rs606978	chr11:65711517	A/C	cg17985854	chr11:65770987	BANF1;EIF1AD	0.41	5.86	0.34	1.37e-8	Eosinophil percentage of white cells;
CESC	cis	rs4713118	0.621	rs9295756	chr6:28033396	G/T	cg22143856	chr6:28129313	ZNF389	0.45	5.62	0.33	4.71e-8	Parkinson's disease;
CESC	cis	rs12545109	0.879	rs1975285	chr8:57358682	G/C	cg09654669	chr8:57350985	NA	-0.59	-6.92	-0.39	3.32e-11	Obesity-related traits;
CESC	cis	rs7618915	0.621	rs6788993	chr3:52605136	T/C	cg18099408	chr3:52552593	STAB1	-0.34	-5.84	-0.34	1.49e-8	Bipolar disorder;
CESC	cis	rs71636778	0.596	rs2095637	chr1:27232845	A/G	cg12203394	chr1:27248618	NUDC	0.66	5.55	0.32	6.85e-8	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
CESC	cis	rs854765	0.534	rs7207461	chr17:17949789	T/G	cg09796270	chr17:17721594	SREBF1	-0.38	-5.04	-0.3	8.49e-7	Total body bone mineral density;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg21583412	chr17:27621436	NUFIP2	-0.43	-6.25	-0.36	1.61e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs79839061	0.610	rs78590562	chr4:869715	C/T	cg07828340	chr4:882639	GAK	1.07	8.26	0.45	6.86e-15	Intelligence (multi-trait analysis);
CESC	cis	rs12995491	0.698	rs34352413	chr2:88498754	T/G	cg04511125	chr2:88470314	THNSL2	-0.52	-7.66	-0.43	3.41e-13	Response to metformin (IC50);
CESC	cis	rs7927771	0.864	rs7937331	chr11:47430458	T/C	cg18512352	chr11:47633146	NA	0.44	6.35	0.36	9.06e-10	Subjective well-being;
CESC	cis	rs6087990	0.899	rs1333469	chr20:31361249	C/T	cg13636640	chr20:31349939	DNMT3B	0.92	16.43	0.71	2.65e-42	Ulcerative colitis;
CESC	cis	rs2404602	0.692	rs34181263	chr15:77065388	C/T	cg22467129	chr15:76604101	ETFA	-0.34	-5.1	-0.3	6.54e-7	Blood metabolite levels;
CESC	cis	rs4805272	0.539	rs1075733	chr19:29324460	C/T	cg12756686	chr19:29218302	NA	0.5	6.33	0.36	1.06e-9	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
CESC	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	10.3	0.53	3.87e-21	Prudent dietary pattern;
CESC	cis	rs1552244	1.000	rs61077902	chr3:10126153	T/G	cg08888203	chr3:10149979	C3orf24	0.48	6.19	0.36	2.33e-9	Alzheimer's disease;
CESC	cis	rs2836633	0.929	rs11701577	chr21:40028906	C/T	cg05519781	chr21:40033154	ERG	0.78	13.14	0.63	1.03e-30	Coronary artery disease;
CESC	cis	rs66561647	0.929	rs67423398	chr8:128972220	C/T	cg05480350	chr8:128972681	MIR1205;PVT1	0.58	8.11	0.45	1.91e-14	Hemoglobin concentration;
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg19403339	chr2:183580841	DNAJC10	0.41	6.13	0.35	3.14e-9	Vertical cup-disc ratio;
CESC	cis	rs7618915	0.547	rs34017441	chr3:52742413	T/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.36	6.43	0.37	5.92e-10	Bipolar disorder;
CESC	cis	rs9486719	0.947	rs2499801	chr6:96854594	G/A	cg18709589	chr6:96969512	KIAA0776	0.54	5.66	0.33	3.9e-8	Migraine;Coronary artery disease;
CESC	cis	rs7246865	0.531	rs8103913	chr19:17166229	G/C	cg16202187	chr19:17186497	HAUS8;MYO9B	0.51	6.7	0.38	1.21e-10	Reticulocyte fraction of red cells;
CESC	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	10.16	0.53	1.09e-20	Prudent dietary pattern;
CESC	cis	rs2742234	0.590	rs1254962	chr10:43696992	G/A	cg07801480	chr10:43725741	RASGEF1A	-0.41	-5.33	-0.31	2.14e-7	Hirschsprung disease;
CESC	cis	rs13385	0.769	rs6872766	chr5:139595614	A/C	cg26211634	chr5:139558579	C5orf32	0.46	5.13	0.3	5.68e-7	Atrial fibrillation;
CESC	cis	rs6121246	0.559	rs6060933	chr20:30351903	C/T	cg13852791	chr20:30311386	BCL2L1	0.85	11.17	0.57	5.35e-24	Mean corpuscular hemoglobin;
CESC	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.59	6.59	0.38	2.42e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs8031584	0.736	rs11635775	chr15:31160640	A/G	cg14298792	chr15:30685198	CHRFAM7A	-0.49	-5.93	-0.34	9.3e-9	Huntington's disease progression;
CESC	cis	rs28489187	0.683	rs6671599	chr1:85858857	T/C	cg16011679	chr1:85725395	C1orf52	-0.47	-5.61	-0.33	5.17e-8	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	cis	rs9611565	0.921	rs6002333	chr22:41719469	C/T	cg03806693	chr22:41940476	POLR3H	-0.93	-10.55	-0.54	5.74e-22	Vitiligo;
CESC	cis	rs17818399	0.749	rs13000560	chr2:46790997	G/T	cg26688816	chr2:46740690	ATP6V1E2	-0.52	-5.61	-0.33	5.16e-8	Height;
CESC	cis	rs7089973	0.604	rs55759483	chr10:116573423	T/C	cg23260525	chr10:116636907	FAM160B1	0.39	7.32	0.41	2.97e-12	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs9470366	0.816	rs7774130	chr6:36623756	C/T	cg08179530	chr6:36648295	CDKN1A	0.56	6.68	0.38	1.41e-10	QRS duration;
CESC	cis	rs1949733	0.523	rs4619877	chr4:8543235	G/A	cg11789530	chr4:8429930	ACOX3	-0.57	-7.18	-0.4	7.24e-12	Response to antineoplastic agents;
CESC	cis	rs2625529	0.526	rs8032222	chr15:72479178	C/G	cg16672083	chr15:72433130	SENP8	0.46	6.83	0.39	5.7e-11	Red blood cell count;
CESC	cis	rs2635047	1.000	rs2635045	chr18:44668417	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.48	6.58	0.37	2.47e-10	Educational attainment;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12467960	chr11:68201194	LRP5	-0.57	-6.1	-0.35	3.73e-9	Gut microbiome composition (summer);
CESC	trans	rs13360092	1.000	rs10076846	chr5:50534292	A/T	cg03200537	chr16:87022121	NA	-0.67	-6.24	-0.36	1.77e-9	Verbal declarative memory;
CESC	cis	rs9902453	0.765	rs8071576	chr17:28188554	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.68	8.97	0.48	5.59e-17	Coffee consumption (cups per day);
CESC	cis	rs875971	0.862	rs12698526	chr7:65969105	T/C	cg18876405	chr7:65276391	NA	0.52	6.98	0.39	2.44e-11	Aortic root size;
CESC	cis	rs4253772	0.550	rs6008598	chr22:46704243	C/T	cg24881330	chr22:46731750	TRMU	0.84	7.59	0.42	5.62e-13	LDL cholesterol;Cholesterol, total;
CESC	cis	rs1915146	0.967	rs7086481	chr10:126844523	A/T	cg23000734	chr10:126850823	CTBP2	-0.68	-11.07	-0.56	1.16e-23	Menarche (age at onset);
CESC	cis	rs8072100	0.713	rs4968257	chr17:45430534	A/G	cg08085267	chr17:45401833	C17orf57	-0.53	-6.65	-0.38	1.65e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs10208940	0.920	rs11886343	chr2:68750336	G/A	cg12452813	chr2:68675892	NA	0.51	5.1	0.3	6.39e-7	Urate levels in lean individuals;
CESC	cis	rs933688	1.000	rs6869717	chr5:90694797	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.11	12.36	0.6	5.17e-28	Smoking behavior;
CESC	trans	rs877282	0.945	rs35342920	chr10:790484	T/C	cg22713356	chr15:30763199	NA	1.32	13.44	0.64	9.25e-32	Uric acid levels;
CESC	cis	rs4900538	0.855	rs60215817	chr14:102873886	A/G	cg18135206	chr14:102964638	TECPR2	-0.73	-9.33	-0.5	4.35e-18	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23927983	chr2:179315956	PRKRA;MIR548N;DFNB59	0.57	6.3	0.36	1.24e-9	Gut microbiome composition (summer);
CESC	cis	rs7914558	0.966	rs10786745	chr10:104956827	A/G	cg04362960	chr10:104952993	NT5C2	0.48	6.41	0.37	6.53e-10	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs875971	1.000	rs2087647	chr7:65593188	C/A	cg10691866	chr7:65817282	TPST1	0.34	5.54	0.32	7.19e-8	Aortic root size;
CESC	cis	rs6831352	0.959	rs1139490	chr4:100045141	C/T	cg12011299	chr4:100065546	ADH4	0.67	8.64	0.47	5.48e-16	Alcohol dependence;
CESC	cis	rs9527	0.590	rs10786744	chr10:104945028	A/C	cg04362960	chr10:104952993	NT5C2	-0.4	-5.07	-0.3	7.58e-7	Arsenic metabolism;
CESC	trans	rs1667255	0.830	rs2034404	chr18:29156302	A/G	cg25709441	chr19:44507025	ZNF230	0.53	7.13	0.4	9.68e-12	Retinol levels;
CESC	trans	rs561341	1.000	rs8064843	chr17:30245744	A/G	cg27661571	chr11:113659931	NA	-0.57	-6.2	-0.36	2.17e-9	Hip circumference adjusted for BMI;
CESC	cis	rs6690583	0.524	rs12030837	chr1:85519383	A/G	cg22153463	chr1:85462885	MCOLN2	-0.75	-7.2	-0.4	6.19e-12	Serum sulfate level;
CESC	cis	rs3092073	0.624	rs13040315	chr20:44585793	A/G	cg27529037	chr20:44575021	PCIF1	0.56	8.71	0.47	3.28e-16	Intelligence (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27391037	chr22:18560705	PEX26	0.55	6.52	0.37	3.64e-10	Gut microbiome composition (summer);
CESC	cis	rs9910055	0.529	rs228746	chr17:42173752	T/C	cg13607699	chr17:42295918	UBTF	-0.51	-6.31	-0.36	1.14e-9	Total body bone mineral density;
CESC	cis	rs651907	0.557	rs2318090	chr3:101474933	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.51	6.77	0.38	8.14e-11	Colorectal cancer;
CESC	cis	rs2070488	1.000	rs6772046	chr3:38479660	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.91	16.04	0.7	6.47e-41	Electrocardiographic conduction measures;
CESC	cis	rs6460942	0.597	rs62449509	chr7:12515013	C/T	cg02935154	chr7:12443704	VWDE	-0.54	-5.5	-0.32	9.08e-8	Coronary artery disease;
CESC	cis	rs637571	0.546	rs10791827	chr11:65596546	C/A	cg26695010	chr11:65641043	EFEMP2	0.51	6.39	0.37	7.26e-10	Eosinophil percentage of white cells;
CESC	cis	rs26528	0.584	rs153103	chr16:28528623	A/G	cg07382826	chr16:28625726	SULT1A1	-0.33	-5.27	-0.31	2.82e-7	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
CESC	cis	rs4819052	0.851	rs8133045	chr21:46658137	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.46	5.77	0.33	2.24e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs896854	0.654	rs10429443	chr8:95971164	A/G	cg26343298	chr8:95960752	TP53INP1	0.36	5.93	0.34	9.41e-9	Type 2 diabetes;
CESC	cis	rs1008375	0.931	rs6449326	chr4:17699790	G/T	cg02297831	chr4:17616191	MED28	0.45	5.45	0.32	1.14e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs10479542	0.544	rs10056863	chr5:179005100	G/A	cg14820908	chr5:178986412	RUFY1	0.48	7.11	0.4	1.05e-11	Lung cancer;
CESC	cis	rs62229266	0.804	rs2835259	chr21:37425302	T/C	cg12218747	chr21:37451666	NA	-0.42	-5.92	-0.34	9.9e-9	Mitral valve prolapse;
CESC	cis	rs7178572	0.633	rs12907746	chr15:77843326	A/G	cg22256960	chr15:77711686	NA	-0.52	-6.35	-0.36	9.29e-10	Type 2 diabetes;
CESC	cis	rs563538	1	rs563538	chr13:37433721	A/G	cg23429638	chr13:37573626	EXOSC8;ALG5	-0.67	-5.09	-0.3	6.78e-7	Spontaneous preterm birth (preterm birth);
CESC	cis	rs16854884	0.632	rs35629416	chr3:143748424	C/T	cg06585982	chr3:143692056	C3orf58	0.49	6.14	0.35	2.96e-9	Economic and political preferences (feminism/equality);
CESC	cis	rs9291683	0.609	rs36084205	chr4:10028678	A/C	cg02734326	chr4:10020555	SLC2A9	0.47	6.52	0.37	3.47e-10	Bone mineral density;
CESC	cis	rs875971	1.000	rs35149210	chr7:65929925	T/C	cg12463550	chr7:65579703	CRCP	0.56	7.09	0.4	1.2e-11	Aortic root size;
CESC	cis	rs910316	0.737	rs175065	chr14:75494983	T/C	cg11812906	chr14:75593930	NEK9	-0.82	-13.3	-0.63	2.87e-31	Height;
CESC	cis	rs7520050	0.931	rs11211224	chr1:46384388	G/A	cg24296786	chr1:45957014	TESK2	0.44	5.48	0.32	9.94e-8	Red blood cell count;Reticulocyte count;
CESC	cis	rs6933660	0.721	rs2128945	chr6:151767907	A/G	cg02564969	chr6:151773285	C6orf211;RMND1	0.6	8.23	0.45	8.68e-15	Menarche (age at onset);
CESC	cis	rs28647808	0.748	rs28721280	chr9:136267318	C/G	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.84	5.73	0.33	2.7e-8	Blood protein levels;
CESC	cis	rs739401	0.611	rs10833048	chr11:3020040	A/G	cg08508325	chr11:3079039	CARS	-0.58	-10.72	-0.55	1.6400000000000001e-22	Longevity;
CESC	cis	rs2842992	0.662	rs2273825	chr6:160211424	A/C	cg26839252	chr6:160211577	TCP1;MRPL18	0.49	6.15	0.35	2.83e-9	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs2439831	0.850	rs28590651	chr15:44113016	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.65	7.54	0.42	7.27e-13	Lung cancer in ever smokers;
CESC	cis	rs7927592	0.731	rs643609	chr11:68241833	A/G	cg20283391	chr11:68216788	NA	-0.47	-5.98	-0.34	7.13e-9	Total body bone mineral density;
CESC	cis	rs7527798	0.592	rs2181694	chr1:207826776	G/A	cg21110645	chr1:207815933	NA	-0.34	-6.2	-0.36	2.1e-9	Erythrocyte sedimentation rate;
CESC	trans	rs10463316	0.894	rs7723379	chr5:150765025	T/C	cg24389359	chr12:111284228	CCDC63	-0.34	-6.08	-0.35	4.19e-9	Metabolite levels (Pyroglutamine);
CESC	cis	rs2072499	0.833	rs2842870	chr1:156200671	T/C	cg24450063	chr1:156163899	SLC25A44	0.87	13.93	0.65	1.74e-33	Testicular germ cell tumor;
CESC	trans	rs116988415	0.748	rs12587471	chr14:65292315	A/G	cg22747501	chr7:29233476	CHN2	0.51	6.16	0.35	2.75e-9	Daytime sleep phenotypes;
CESC	cis	rs7824557	0.564	rs2572394	chr8:11235393	A/G	cg21775007	chr8:11205619	TDH	-0.54	-8.12	-0.45	1.75e-14	Retinal vascular caliber;
CESC	cis	rs66573146	1.000	rs7686168	chr4:6986057	C/A	cg00086871	chr4:6988644	TBC1D14	1.11	6.36	0.36	8.97e-10	Granulocyte percentage of myeloid white cells;
CESC	cis	rs4704187	0.663	rs965735	chr5:74459220	A/G	cg03227963	chr5:74354835	NA	0.29	5.32	0.31	2.25e-7	Response to amphetamines;
CESC	cis	rs10504229	0.683	rs6998040	chr8:58110155	G/T	cg02725872	chr8:58115012	NA	0.44	6.68	0.38	1.36e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs2302190	0.882	rs6503859	chr17:56460852	C/G	cg25885038	chr17:56607967	SEPT4	-0.4	-5.42	-0.32	1.37e-7	Vitamin D levels;
CESC	cis	rs9303401	0.659	rs61291849	chr17:56909867	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.01	12.69	0.61	3.78e-29	Cognitive test performance;
CESC	cis	rs7818688	0.697	rs74553842	chr8:95984392	C/T	cg16049864	chr8:95962084	TP53INP1	0.55	5.56	0.32	6.66e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs1559088	0.744	rs12462426	chr19:33536683	A/C	cg22980127	chr19:33182716	NUDT19	0.47	5.32	0.31	2.18e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs6901004	0.803	rs4947107	chr6:111442505	C/T	cg15721981	chr6:111408429	SLC16A10	-0.34	-5.04	-0.3	8.59e-7	Blood metabolite levels;
CESC	cis	rs116095464	0.558	rs10058428	chr5:235608	A/G	cg22496380	chr5:211416	CCDC127	-0.75	-8.8	-0.48	1.82e-16	Breast cancer;
CESC	cis	rs6032067	0.777	rs34343273	chr20:43795293	G/A	cg11264863	chr20:43835661	SEMG1	0.5	5.35	0.31	1.86e-7	Blood protein levels;
CESC	cis	rs12142240	0.698	rs17357759	chr1:46832534	A/G	cg00530320	chr1:46809349	NSUN4	0.57	7.8	0.43	1.4e-13	Menopause (age at onset);
CESC	cis	rs3820928	0.874	rs13383070	chr2:227904939	C/T	cg05526886	chr2:227700861	RHBDD1	-0.43	-5.66	-0.33	3.89e-8	Pulmonary function;
CESC	cis	rs3858526	0.883	rs11039584	chr11:5935251	C/G	cg02574844	chr11:5959923	NA	-0.45	-5.63	-0.33	4.63e-8	DNA methylation (variation);
CESC	cis	rs977987	0.778	rs11862719	chr16:75431708	T/A	cg03315344	chr16:75512273	CHST6	0.4	5.71	0.33	3e-8	Dupuytren's disease;
CESC	trans	rs801193	1.000	rs7783924	chr7:66209057	A/C	cg26939375	chr7:64535504	NA	0.64	8.77	0.47	2.19e-16	Aortic root size;
CESC	trans	rs877282	0.898	rs12357016	chr10:765675	C/T	cg22713356	chr15:30763199	NA	1.16	11.35	0.57	1.37e-24	Uric acid levels;
CESC	cis	rs7412746	0.566	rs2864871	chr1:150766964	T/C	cg04414720	chr1:150670196	GOLPH3L	0.57	7.53	0.42	8.1e-13	Melanoma;
CESC	cis	rs1006703	0.544	rs8068362	chr17:3838757	T/C	cg06463185	chr17:3833770	ATP2A3	-0.64	-6.26	-0.36	1.58e-9	Glucose homeostasis traits;
CESC	cis	rs4665809	1.000	rs11678157	chr2:26321526	T/C	cg04944784	chr2:26401820	FAM59B	-0.63	-7.23	-0.41	5.29e-12	Gut microbiome composition (summer);
CESC	trans	rs13360092	0.764	rs10213960	chr5:50561783	T/C	cg03200537	chr16:87022121	NA	0.69	6.01	0.35	6.15e-9	Verbal declarative memory;
CESC	cis	rs7605827	0.897	rs11693457	chr2:15612683	A/C	cg19274914	chr2:15703543	NA	0.36	6.42	0.37	6.17e-10	Educational attainment (years of education);
CESC	cis	rs2832191	1.000	rs2832191	chr21:30489300	A/C	cg24692254	chr21:30365293	RNF160	-0.72	-10.88	-0.56	4.78e-23	Dental caries;
CESC	cis	rs597539	0.652	rs513359	chr11:68669496	A/T	cg04772025	chr11:68637568	NA	-0.5	-6.19	-0.36	2.23e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs3820068	0.581	rs6693694	chr1:15980135	G/T	cg17385448	chr1:15911702	AGMAT	0.42	6.89	0.39	4.17e-11	Systolic blood pressure;
CESC	cis	rs644799	0.896	rs4430471	chr11:95646774	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.59	7.55	0.42	7.19e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	trans	rs9354308	0.933	rs2814131	chr6:66562051	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.7	7.82	0.43	1.27e-13	Metabolite levels;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg26221637	chr1:1510359	SSU72	-0.49	-6.3	-0.36	1.24e-9	Fibrinogen levels;
CESC	cis	rs6540556	0.682	rs2282741	chr1:209900609	G/C	cg05527609	chr1:210001259	C1orf107	-0.44	-5.28	-0.31	2.68e-7	Red blood cell count;
CESC	cis	rs7208859	0.614	rs216412	chr17:28903394	A/G	cg19761014	chr17:28927070	LRRC37B2	-0.75	-7.46	-0.42	1.28e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs9311474	0.539	rs12489828	chr3:52567014	G/T	cg18404041	chr3:52824283	ITIH1	-0.37	-6.54	-0.37	3.16e-10	Electroencephalogram traits;
CESC	cis	rs2952156	0.959	rs907087	chr17:37828787	G/A	cg00129232	chr17:37814104	STARD3	-0.74	-9.51	-0.5	1.25e-18	Asthma;
CESC	cis	rs6502050	0.835	rs10163485	chr17:80110750	C/T	cg11859384	chr17:80120422	CCDC57	-0.39	-5.37	-0.31	1.76e-7	Life satisfaction;
CESC	cis	rs9372253	0.934	rs9320327	chr6:110715194	T/A	cg19196401	chr6:110721138	DDO	-0.39	-5.63	-0.33	4.51e-8	Platelet distribution width;
CESC	cis	rs826838	1.000	rs826888	chr12:39104719	C/G	cg13010199	chr12:38710504	ALG10B	-0.42	-5.86	-0.34	1.37e-8	Heart rate;
CESC	cis	rs597539	0.727	rs632984	chr11:68620271	C/T	cg01988459	chr11:68622903	NA	-0.4	-5.12	-0.3	5.75e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs853679	0.517	rs9380065	chr6:28144751	A/G	cg22143856	chr6:28129313	ZNF389	0.46	5.84	0.34	1.56e-8	Depression;
CESC	cis	rs9467711	0.606	rs35307327	chr6:26370474	C/T	cg14345882	chr6:26364793	BTN3A2	0.6	6.21	0.36	2.06e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs977987	0.806	rs11860284	chr16:75412907	A/G	cg03315344	chr16:75512273	CHST6	0.4	5.73	0.33	2.78e-8	Dupuytren's disease;
CESC	cis	rs7412746	0.611	rs12085336	chr1:150775780	A/T	cg22823121	chr1:150693482	HORMAD1	0.46	6.46	0.37	4.87e-10	Melanoma;
CESC	cis	rs2479724	0.846	rs2488338	chr6:41808351	A/G	cg17623882	chr6:41773611	USP49	-0.4	-5.75	-0.33	2.49e-8	Menarche (age at onset);
CESC	cis	rs6952808	0.595	rs2398705	chr7:2164995	G/A	cg04267008	chr7:1944627	MAD1L1	-0.6	-7.23	-0.41	5.11e-12	Bipolar disorder and schizophrenia;
CESC	cis	rs7267979	0.966	rs416745	chr20:25438868	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.86	17.57	0.73	2.33e-46	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs2777491	1.000	rs7167729	chr15:41721042	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.65	-9.78	-0.52	1.71e-19	Ulcerative colitis;
CESC	trans	rs877282	1.000	rs11253366	chr10:773386	C/T	cg22713356	chr15:30763199	NA	1.11	11.25	0.57	2.85e-24	Uric acid levels;
CESC	cis	rs7481584	0.924	rs4758502	chr11:2998461	C/T	cg25174290	chr11:3078921	CARS	-0.51	-6.22	-0.36	1.95e-9	Calcium levels;
CESC	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg27588902	chr6:42928151	GNMT	-0.31	-5.8	-0.34	1.85e-8	Alzheimer's disease in APOE e4+ carriers;
CESC	trans	rs2115172	0.836	rs4835799	chr5:122762229	A/G	cg25303336	chr6:33756862	LEMD2	0.46	6.0	0.35	6.49e-9	Weight;
CESC	trans	rs561341	1.000	rs548957	chr17:30302411	G/A	cg20587970	chr11:113659929	NA	-1.41	-18.23	-0.75	1.08e-48	Hip circumference adjusted for BMI;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg16809304	chr8:143784794	LY6K	0.39	6.04	0.35	5.07e-9	Fibrinogen levels;
CESC	cis	rs7551222	0.681	rs4252686	chr1:204496895	A/G	cg20240347	chr1:204465584	NA	-0.28	-5.74	-0.33	2.59e-8	Schizophrenia;
CESC	cis	rs6502050	0.835	rs8071737	chr17:80117537	T/C	cg23985595	chr17:80112537	CCDC57	-0.41	-6.47	-0.37	4.79e-10	Life satisfaction;
CESC	cis	rs35306767	0.903	rs7074642	chr10:878359	A/G	cg20503657	chr10:835505	NA	0.77	7.72	0.43	2.36e-13	Eosinophil percentage of granulocytes;
CESC	cis	rs2354432	0.556	rs12568866	chr1:146718430	A/C	cg25205988	chr1:146714368	CHD1L	-1.03	-8.98	-0.48	5.06e-17	Mitochondrial DNA levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06225581	chr5:140080094	ZMAT2	-0.56	-6.23	-0.36	1.87e-9	Gut microbiome composition (summer);
CESC	cis	rs6121246	0.559	rs6060932	chr20:30350545	A/G	cg13852791	chr20:30311386	BCL2L1	0.85	11.17	0.57	5.35e-24	Mean corpuscular hemoglobin;
CESC	cis	rs425277	0.583	rs10910046	chr1:2041155	C/T	cg23803603	chr1:2058230	PRKCZ	-0.37	-6.75	-0.38	9.46e-11	Height;
CESC	cis	rs1256061	0.603	rs3020445	chr14:64788644	A/G	cg23250157	chr14:64679961	SYNE2	0.53	7.39	0.41	1.96e-12	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs9611565	0.729	rs505533	chr22:41864216	A/C	cg06481639	chr22:41940642	POLR3H	0.44	5.32	0.31	2.22e-7	Vitiligo;
CESC	cis	rs7429990	0.965	rs184388	chr3:47939626	G/A	cg11946769	chr3:48343235	NME6	0.46	5.62	0.33	4.91e-8	Educational attainment (years of education);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03163734	chr2:65659863	SPRED2	0.56	6.02	0.35	5.64e-9	Gut microbiome composition (summer);
CESC	cis	rs9814567	0.752	rs4605591	chr3:134328361	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.39	-5.04	-0.3	8.59e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs853679	0.550	rs9295762	chr6:28155418	C/T	cg19592336	chr6:28129416	ZNF389	-0.49	-6.77	-0.38	8.47e-11	Depression;
CESC	cis	rs7598759	0.712	rs6740474	chr2:232331831	A/G	cg19187155	chr2:232395269	NMUR1	0.39	6.12	0.35	3.36e-9	Noise-induced hearing loss;
CESC	cis	rs113835537	0.627	rs11227534	chr11:66336171	C/A	cg24851651	chr11:66362959	CCS	0.5	5.95	0.34	8.35e-9	Airway imaging phenotypes;
CESC	cis	rs870825	0.616	rs7658186	chr4:185622509	T/C	cg04058563	chr4:185651563	MLF1IP	0.64	7.05	0.4	1.59e-11	Blood protein levels;
CESC	cis	rs734999	0.588	rs6689711	chr1:2531467	T/C	cg18854424	chr1:2615690	NA	-0.27	-5.14	-0.3	5.24e-7	Ulcerative colitis;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg07399312	chr1:156470683	MEF2D	0.47	6.2	0.36	2.16e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs68170813	0.559	rs3801963	chr7:106898036	C/T	cg02696742	chr7:106810147	HBP1	-0.53	-5.34	-0.31	2.01e-7	Coronary artery disease;
CESC	cis	rs3026445	0.851	rs34840178	chr12:110832027	A/G	cg12870014	chr12:110450643	ANKRD13A	0.42	5.18	0.3	4.33e-7	QT interval;
CESC	cis	rs8062405	1.000	rs12325113	chr16:28848668	T/C	cg08761264	chr16:28874980	SH2B1	-0.44	-5.45	-0.32	1.16e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs6545883	0.929	rs55806663	chr2:61740487	G/T	cg15711740	chr2:61764176	XPO1	-0.43	-5.3	-0.31	2.41e-7	Tuberculosis;
CESC	cis	rs938554	0.513	rs4529048	chr4:9997112	G/T	cg02734326	chr4:10020555	SLC2A9	0.43	5.29	0.31	2.58e-7	Blood metabolite levels;
CESC	cis	rs9660180	0.934	rs34849348	chr1:1762757	C/T	cg20999797	chr1:1681921	NA	0.26	5.11	0.3	6.15e-7	Body mass index;
CESC	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	7.79	0.43	1.5e-13	Prudent dietary pattern;
CESC	cis	rs7259376	0.871	rs2360622	chr19:22570622	T/C	cg02657401	chr19:22469223	NA	-0.25	-5.1	-0.3	6.58e-7	Menopause (age at onset);
CESC	cis	rs514406	0.861	rs6588443	chr1:53250650	G/A	cg08859206	chr1:53392774	SCP2	0.54	7.11	0.4	1.05e-11	Monocyte count;
CESC	cis	rs2072732	0.861	rs12409277	chr1:2957600	A/G	cg15211996	chr1:2936768	ACTRT2	0.34	6.25	0.36	1.64e-9	Plateletcrit;
CESC	cis	rs6087990	0.871	rs1007122	chr20:31346001	C/T	cg13636640	chr20:31349939	DNMT3B	0.79	12.8	0.62	1.58e-29	Ulcerative colitis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11488864	chr4:8379238	ACOX3	-0.56	-6.38	-0.36	7.86e-10	Gut microbiome composition (summer);
CESC	cis	rs17253792	0.598	rs35830444	chr14:56017350	T/C	cg01858014	chr14:56050164	KTN1	-0.87	-6.37	-0.36	8.34e-10	Putamen volume;
CESC	cis	rs7647973	1.000	rs9860055	chr3:49506900	C/T	cg02487422	chr3:49467188	NICN1	-0.41	-5.36	-0.31	1.81e-7	Menarche (age at onset);
CESC	cis	rs6667605	0.527	rs12046118	chr1:2540343	A/C	cg20673091	chr1:2541236	MMEL1	0.45	7.84	0.43	1.09e-13	Inflammatory bowel disease;Ulcerative colitis;
CESC	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg15112475	chr7:1198522	ZFAND2A	-0.36	-5.75	-0.33	2.45e-8	Longevity;Endometriosis;
CESC	cis	rs3020736	0.500	rs6002603	chr22:42492362	C/G	cg04733989	chr22:42467013	NAGA	-0.82	-12.02	-0.59	7.23e-27	Autism spectrum disorder or schizophrenia;
CESC	cis	rs4563143	0.675	rs34113156	chr19:29270822	G/A	cg12756686	chr19:29218302	NA	0.58	7.52	0.42	8.38e-13	Methadone dose in opioid dependence;
CESC	cis	rs6460942	0.841	rs6968277	chr7:12443795	C/A	cg17427002	chr7:12443146	VWDE	-0.55	-6.79	-0.38	7.54e-11	Coronary artery disease;
CESC	trans	rs875971	1.000	rs778710	chr7:65854834	T/C	cg26939375	chr7:64535504	NA	0.47	6.14	0.35	3.07e-9	Aortic root size;
CESC	cis	rs1451375	0.583	rs3779078	chr7:50610918	C/T	cg14593290	chr7:50529359	DDC	0.51	6.19	0.36	2.34e-9	Malaria;
CESC	cis	rs35306767	0.953	rs12259801	chr10:959306	C/G	cg10556349	chr10:835070	NA	0.57	6.07	0.35	4.29e-9	Eosinophil percentage of granulocytes;
CESC	cis	rs2361710	0.611	rs3816257	chr17:78074446	G/T	cg06718696	chr17:78121285	EIF4A3	-0.62	-7.51	-0.42	9.34e-13	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
CESC	cis	rs7712401	0.601	rs246271	chr5:122212822	A/G	cg19412675	chr5:122181750	SNX24	0.41	5.1	0.3	6.57e-7	Mean platelet volume;
CESC	cis	rs3818285	0.556	rs3758409	chr10:111669239	A/C	cg00817464	chr10:111662876	XPNPEP1	-0.54	-6.69	-0.38	1.33e-10	Superior crus of antihelix expression;
CESC	cis	rs7589728	0.563	rs2292868	chr2:88475047	A/G	cg07952391	chr2:88470173	THNSL2	-0.61	-5.79	-0.34	2e-8	Plasma clusterin levels;
CESC	cis	rs7666738	0.830	rs7662389	chr4:99019892	G/A	cg18180107	chr4:99064573	C4orf37	0.41	5.42	0.32	1.32e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10504229	1.000	rs60454728	chr8:58173781	G/A	cg22535103	chr8:58192502	C8orf71	-1.05	-13.27	-0.63	3.63e-31	Developmental language disorder (linguistic errors);
CESC	cis	rs1801251	1.000	rs2100053	chr2:233719516	G/T	cg25237894	chr2:233734115	C2orf82	-0.48	-8.29	-0.45	5.66e-15	Coronary artery disease;
CESC	cis	rs7916697	0.578	rs1900002	chr10:70004552	G/C	cg06988349	chr10:69991859	ATOH7	0.39	6.39	0.37	7.5e-10	Optic disc area;
CESC	cis	rs67311347	1.000	rs4974017	chr3:40473519	C/T	cg09455208	chr3:40491958	NA	0.46	8.04	0.44	2.96e-14	Renal cell carcinoma;
CESC	cis	rs916888	0.610	rs199536	chr17:44820425	T/C	cg15921436	chr17:44337874	NA	-0.44	-5.58	-0.32	6e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg27308231	chr10:94050819	CPEB3;MARCH5	-0.46	-6.51	-0.37	3.68e-10	Gambling;
CESC	cis	rs17209837	0.607	rs1473154	chr7:87082042	A/G	cg00919237	chr7:87102261	ABCB4	-0.51	-6.61	-0.38	2.1e-10	Gallbladder cancer;
CESC	trans	rs801193	1.000	rs17566701	chr7:66193183	T/C	cg26939375	chr7:64535504	NA	0.62	8.21	0.45	9.49e-15	Aortic root size;
CESC	cis	rs2439831	1.000	rs7173487	chr15:43750239	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.84	8.59	0.47	7.37e-16	Lung cancer in ever smokers;
CESC	cis	rs17711722	0.523	rs365896	chr7:65510697	A/G	cg25405998	chr7:65216604	CCT6P1	-0.44	-5.67	-0.33	3.7e-8	Calcium levels;
CESC	cis	rs7582720	1.000	rs6738618	chr2:203749439	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.39	0.41	1.96e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs4689592	0.619	rs2359011	chr4:7066052	T/G	cg19539972	chr4:7069911	GRPEL1	0.78	9.93	0.52	5.95e-20	Monocyte percentage of white cells;
CESC	cis	rs67614146	1	rs67614146	chr6:87821827	AC/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.66	-8.92	-0.48	7.61e-17	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs7772486	0.701	rs2244308	chr6:146213706	C/T	cg05347473	chr6:146136440	FBXO30	0.53	6.92	0.39	3.46e-11	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs7943203	1.000	rs11212638	chr11:108312080	T/C	cg24643211	chr18:11851603	GNAL;CHMP1B	-0.48	-6.04	-0.35	5.27e-9	Red blood cell count;Mean corpuscular volume;
CESC	cis	rs2880765	0.835	rs7169632	chr15:86044667	T/G	cg10818794	chr15:86012489	AKAP13	-0.34	-5.22	-0.31	3.68e-7	Coronary artery disease;
CESC	cis	rs3767633	0.748	rs6667896	chr1:161837407	G/A	cg09175582	chr1:161736000	ATF6	0.86	6.98	0.39	2.42e-11	IgG glycosylation;
CESC	cis	rs7474896	0.583	rs12776092	chr10:38015795	G/C	cg00409905	chr10:38381863	ZNF37A	-0.49	-5.6	-0.33	5.42e-8	Obesity (extreme);
CESC	cis	rs8050907	0.744	rs13330957	chr16:4525330	G/C	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.9	6.28	0.36	1.39e-9	Obesity-related traits;
CESC	cis	rs6597981	0.675	rs4963120	chr11:825777	A/G	cg21775979	chr11:780331	NA	0.41	6.19	0.36	2.23e-9	Breast cancer;
CESC	cis	rs6540556	0.678	rs12094117	chr1:209888435	G/T	cg05527609	chr1:210001259	C1orf107	-0.7	-7.5	-0.42	9.83e-13	Red blood cell count;
CESC	cis	rs9611565	0.694	rs106860	chr22:41840407	C/T	cg03806693	chr22:41940476	POLR3H	-1.19	-14.62	-0.67	6.9e-36	Vitiligo;
CESC	cis	rs9322193	0.962	rs9688940	chr6:150110113	G/A	cg04369109	chr6:150039330	LATS1	-0.4	-5.4	-0.31	1.48e-7	Lung cancer;
CESC	cis	rs617791	0.569	rs11227370	chr11:65747693	C/T	cg09783858	chr11:65769428	EIF1AD;BANF1	0.53	6.35	0.36	9.55e-10	Breast cancer;
CESC	cis	rs10779751	0.734	rs1211575	chr1:11118390	G/A	cg08854313	chr1:11322531	MTOR	0.77	10.46	0.54	1.17e-21	Body mass index;
CESC	cis	rs7799006	0.929	rs6951493	chr7:2257612	G/A	cg08027265	chr7:2291960	NA	-0.45	-6.8	-0.39	6.97e-11	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs250677	0.522	rs10040598	chr5:148365720	C/A	cg18129178	chr5:148520854	ABLIM3	0.47	5.16	0.3	4.93e-7	Breast cancer;
CESC	cis	rs7267979	1.000	rs6083805	chr20:25317356	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.86	-16.91	-0.72	5.15e-44	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg11494091	chr17:61959527	GH2	0.76	13.48	0.64	6.83e-32	Prudent dietary pattern;
CESC	cis	rs1448094	0.512	rs6539928	chr12:86244920	G/A	cg19622623	chr12:86230825	RASSF9	-0.46	-5.89	-0.34	1.14e-8	Major depressive disorder;
CESC	cis	rs3820928	1.000	rs1835158	chr2:227763993	C/A	cg11843606	chr2:227700838	RHBDD1	-0.43	-5.77	-0.33	2.2e-8	Pulmonary function;
CESC	cis	rs4665809	0.838	rs2243834	chr2:26357748	A/C	cg26119090	chr2:26468346	HADHA;HADHB	0.61	7.09	0.4	1.24e-11	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18202751	chr17:7620996	NA	0.6	6.7	0.38	1.24e-10	Gut microbiome composition (summer);
CESC	cis	rs2795502	0.873	rs1891324	chr10:43399581	A/G	cg20628663	chr10:43360327	NA	0.54	6.08	0.35	4.28e-9	Blood protein levels;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg13969496	chr9:140095465	C9orf75	-0.4	-6.65	-0.38	1.68e-10	Gambling;
CESC	trans	rs5769765	0.908	rs9616370	chr22:50306316	A/G	cg09872104	chr7:134855509	C7orf49	0.54	6.08	0.35	4.13e-9	Schizophrenia;
CESC	cis	rs250677	0.617	rs166106	chr5:148447061	T/C	cg18129178	chr5:148520854	ABLIM3	-0.6	-6.05	-0.35	4.91e-9	Breast cancer;
CESC	cis	rs10504229	0.593	rs75047131	chr8:58001320	A/G	cg24829409	chr8:58192753	C8orf71	-0.67	-7.38	-0.41	2.06e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs13191362	0.935	rs66962088	chr6:162963891	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.77	7.24	0.41	4.88e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs79976124	1.000	rs79976124	chr6:66618657	G/A	cg07460842	chr6:66804631	NA	0.75	8.54	0.46	1.06e-15	Type 2 diabetes;
CESC	cis	rs7188697	0.922	rs37034	chr16:58551360	C/G	cg02549819	chr16:58548995	SETD6	-0.41	-5.03	-0.3	9.12e-7	QT interval;
CESC	cis	rs36051895	0.623	rs3780382	chr9:5232299	G/A	cg02405213	chr9:5042618	JAK2	-0.49	-5.81	-0.34	1.8e-8	Pediatric autoimmune diseases;
CESC	cis	rs2304069	0.909	rs2544931	chr5:149367837	C/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.92	-11.14	-0.56	6.85e-24	HIV-1 control;
CESC	cis	rs1799949	1.000	rs72829113	chr17:41181835	C/T	cg23758822	chr17:41437982	NA	1.03	14.6	0.67	7.88e-36	Menopause (age at onset);
CESC	cis	rs7937682	0.924	rs10891288	chr11:111552053	G/T	cg22437258	chr11:111473054	SIK2	-0.67	-8.95	-0.48	6.43e-17	Primary sclerosing cholangitis;
CESC	cis	rs6987853	0.787	rs2974314	chr8:42457043	C/T	cg09913449	chr8:42400586	C8orf40	0.42	6.98	0.39	2.38e-11	Mean corpuscular hemoglobin concentration;
CESC	cis	rs9322193	0.884	rs9689702	chr6:150061856	G/A	cg04369109	chr6:150039330	LATS1	-0.45	-6.39	-0.37	7.48e-10	Lung cancer;
CESC	cis	rs4481887	0.927	rs7519334	chr1:248472076	C/T	cg00666640	chr1:248458726	OR2T12	0.35	5.81	0.34	1.81e-8	Common traits (Other);
CESC	cis	rs2014572	0.967	rs10421632	chr19:57764770	G/A	cg12963866	chr19:57752005	ZNF805	-0.48	-6.47	-0.37	4.61e-10	Hyperactive-impulsive symptoms;
CESC	cis	rs10751667	0.666	rs7395488	chr11:954111	T/C	cg01483505	chr11:975446	AP2A2	0.37	5.05	0.3	8.3e-7	Alzheimer's disease (late onset);
CESC	cis	rs6502050	0.805	rs7406858	chr17:80080623	G/A	cg11859384	chr17:80120422	CCDC57	0.38	5.12	0.3	6.01e-7	Life satisfaction;
CESC	trans	rs61931739	0.736	rs7314457	chr12:34454301	G/A	cg26384229	chr12:38710491	ALG10B	0.67	10.45	0.54	1.29e-21	Morning vs. evening chronotype;
CESC	trans	rs7618501	1.000	rs7374183	chr3:49785133	G/A	cg21659725	chr3:3221576	CRBN	-0.83	-13.42	-0.64	1.08e-31	Intelligence (multi-trait analysis);
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg15159625	chr1:118042759	MAN1A2	0.41	6.41	0.37	6.68e-10	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs12200560	0.505	rs211172	chr6:97070691	C/A	cg06623918	chr6:96969491	KIAA0776	0.46	5.75	0.33	2.48e-8	Coronary heart disease;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg06838422	chr1:62902269	USP1	0.52	7.19	0.4	6.49e-12	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs16867321	0.853	rs73023563	chr2:181502830	C/T	cg23363182	chr2:181467187	NA	-0.41	-5.53	-0.32	7.58e-8	Obesity;
CESC	cis	rs854765	0.583	rs4414547	chr17:17859052	G/T	cg09796270	chr17:17721594	SREBF1	0.45	6.15	0.35	2.87e-9	Total body bone mineral density;
CESC	cis	rs7666738	0.830	rs7664305	chr4:99037691	G/A	cg17366294	chr4:99064904	C4orf37	0.61	8.77	0.47	2.27e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3733585	0.673	rs4495037	chr4:9954050	C/G	cg02734326	chr4:10020555	SLC2A9	-0.39	-5.64	-0.33	4.45e-8	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs916888	0.610	rs199446	chr17:44813169	G/A	cg15921436	chr17:44337874	NA	-0.44	-5.64	-0.33	4.41e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs875971	0.862	rs11765791	chr7:65936574	A/G	cg18876405	chr7:65276391	NA	0.55	7.52	0.42	8.43e-13	Aortic root size;
CESC	cis	rs7829975	0.774	rs11775523	chr8:8679176	A/G	cg15556689	chr8:8085844	FLJ10661	0.45	5.69	0.33	3.44e-8	Mood instability;
CESC	cis	rs9787249	0.957	rs11809515	chr1:40205326	C/A	cg02773041	chr1:40204384	PPIE	0.54	7.69	0.43	2.82e-13	Blood protein levels;
CESC	cis	rs7851660	0.874	rs10818175	chr9:100633386	T/C	cg13688889	chr9:100608707	NA	-0.6	-8.55	-0.47	9.84e-16	Strep throat;
CESC	cis	rs3733585	0.638	rs17185835	chr4:9958180	T/G	cg02734326	chr4:10020555	SLC2A9	-0.43	-5.93	-0.34	9.22e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs9911578	0.967	rs12938821	chr17:56959422	T/C	cg05425664	chr17:57184151	TRIM37	-0.49	-6.74	-0.38	9.58e-11	Intelligence (multi-trait analysis);
CESC	cis	rs7828089	0.582	rs13259873	chr8:22266292	C/T	cg13512537	chr8:22265999	SLC39A14	-0.36	-5.1	-0.3	6.53e-7	Verbal declarative memory;
CESC	cis	rs2288912	0.838	rs2239375	chr19:45459851	T/C	cg09555818	chr19:45449301	APOC2	0.39	6.26	0.36	1.55e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs9910055	0.659	rs7214540	chr17:42256604	A/G	cg08499158	chr17:42289980	UBTF	-0.47	-5.74	-0.33	2.53e-8	Total body bone mineral density;
CESC	cis	rs921968	0.643	rs497983	chr2:219415189	A/G	cg02176678	chr2:219576539	TTLL4	0.4	6.94	0.39	2.93e-11	Mean corpuscular hemoglobin concentration;
CESC	cis	rs1401999	0.966	rs2313216	chr3:183637251	C/T	cg01324343	chr3:183735012	ABCC5	0.57	11.6	0.58	2e-25	Anterior chamber depth;
CESC	cis	rs12586317	0.883	rs4982254	chr14:35755737	C/T	cg16230307	chr14:35515116	FAM177A1	0.73	8.33	0.46	4.34e-15	Psoriasis;
CESC	cis	rs7617773	0.539	rs11706939	chr3:48383992	G/T	cg11946769	chr3:48343235	NME6	0.66	8.34	0.46	4.12e-15	Coronary artery disease;
CESC	cis	rs9300255	0.510	rs1790133	chr12:123698518	T/G	cg05973401	chr12:123451056	ABCB9	0.51	5.78	0.33	2.07e-8	Neutrophil percentage of white cells;
CESC	cis	rs9900062	0.586	rs35018407	chr17:62690181	A/C	cg02097616	chr17:62675921	NA	0.44	5.56	0.32	6.65e-8	QT interval;
CESC	trans	rs17685	0.697	rs2302437	chr7:75677016	G/A	cg19862616	chr7:65841803	NCRNA00174	-0.84	-12.47	-0.61	2.15e-28	Coffee consumption;Coffee consumption (cups per day);
CESC	trans	rs7395662	0.611	rs7478698	chr11:48549139	T/C	cg00717180	chr2:96193071	NA	-0.44	-6.06	-0.35	4.58e-9	HDL cholesterol;
CESC	cis	rs910316	0.737	rs175043	chr14:75471803	G/A	cg16144293	chr14:75469539	EIF2B2	0.4	5.18	0.3	4.45e-7	Height;
CESC	cis	rs2760061	0.626	rs594916	chr1:228133544	C/A	cg01973587	chr1:228161476	NA	0.38	5.84	0.34	1.55e-8	Diastolic blood pressure;
CESC	cis	rs847577	0.630	rs11764933	chr7:97825188	G/A	cg21770322	chr7:97807741	LMTK2	0.86	14.68	0.67	4.05e-36	Breast cancer;
CESC	cis	rs6748734	0.625	rs4312490	chr2:241821481	A/G	cg04034577	chr2:241836375	C2orf54	-0.31	-5.65	-0.33	4.16e-8	Urinary metabolites;
CESC	cis	rs1008375	1.000	rs4698199	chr4:17656738	G/C	cg02297831	chr4:17616191	MED28	0.53	6.71	0.38	1.2e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs7851660	0.844	rs993501	chr9:100623377	A/G	cg13688889	chr9:100608707	NA	0.64	8.95	0.48	6.59e-17	Strep throat;
CESC	cis	rs1862618	0.802	rs832547	chr5:56183941	C/G	cg22800045	chr5:56110881	MAP3K1	0.81	9.66	0.51	4.1e-19	Initial pursuit acceleration;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg06854353	chr6:109704291	CD164	0.45	6.15	0.35	2.79e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs9581857	0.556	rs1885991	chr13:28040470	G/A	cg01674679	chr13:27998804	GTF3A	-0.55	-5.89	-0.34	1.17e-8	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
CESC	cis	rs9403521	1.000	rs117303301	chr6:143999003	C/T	cg18240653	chr6:144019428	PHACTR2	-0.48	-5.36	-0.31	1.81e-7	Obesity-related traits;
CESC	cis	rs12188164	0.620	rs1043356	chr5:480948	C/T	cg15813090	chr5:442598	EXOC3;C5orf55	-0.39	-5.47	-0.32	1.02e-7	Cystic fibrosis severity;
CESC	cis	rs4843747	0.671	rs28451517	chr16:88109127	A/C	cg17633681	chr16:88106987	BANP	0.72	9.39	0.5	2.8e-18	Menopause (age at onset);
CESC	cis	rs933688	1.000	rs10058025	chr5:90689052	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.11	12.36	0.6	5.17e-28	Smoking behavior;
CESC	cis	rs9815354	0.680	rs73073288	chr3:42027637	G/C	cg03022575	chr3:42003672	ULK4	0.75	6.64	0.38	1.72e-10	Pulse pressure;Diastolic blood pressure;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08236912	chr17:37557587	FBXL20	-0.57	-6.09	-0.35	3.88e-9	Gut microbiome composition (summer);
CESC	cis	rs2235649	0.843	rs9932890	chr16:1847868	G/T	cg09540102	chr16:1822124	NME3;MRPS34;EME2	0.41	5.12	0.3	5.97e-7	Blood metabolite levels;
CESC	cis	rs2415984	0.622	rs7156466	chr14:46933384	A/G	cg14871534	chr14:47121158	RPL10L	-0.34	-5.12	-0.3	5.96e-7	Number of children ever born;
CESC	cis	rs4862750	0.914	rs11943333	chr4:187872455	A/G	cg22105103	chr4:187893119	NA	0.38	5.73	0.33	2.78e-8	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs858239	0.601	rs73272053	chr7:23155525	A/G	cg23682824	chr7:23144976	KLHL7	0.46	6.1	0.35	3.83e-9	Cerebrospinal fluid biomarker levels;
CESC	cis	rs13191362	1.000	rs13192894	chr6:163052444	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.91	9.96	0.52	4.74e-20	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.45	6.0	0.35	6.42e-9	Lymphocyte counts;
CESC	cis	rs75477785	0.590	rs1040424	chr1:210134382	A/G	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.84	6.29	0.36	1.29e-9	Cleft lip with or without cleft palate;
CESC	cis	rs7267979	0.586	rs11087505	chr20:25196520	T/A	cg08601574	chr20:25228251	PYGB	0.36	5.1	0.3	6.43e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7916697	0.626	rs3858145	chr10:70011838	A/G	cg06988349	chr10:69991859	ATOH7	0.31	5.03	0.3	9.05e-7	Optic disc area;
CESC	cis	rs9329289	0.510	rs10903785	chr10:2550063	C/T	cg15501526	chr10:2543763	NA	0.48	7.86	0.43	9.74e-14	Age-related hearing impairment;
CESC	cis	rs7811142	1.000	rs7811142	chr7:100065443	A/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.11	10.98	0.56	2.37e-23	Platelet count;
CESC	cis	rs950169	0.922	rs11633534	chr15:85124642	C/T	cg17507749	chr15:85114479	UBE2QP1	0.54	6.09	0.35	3.99e-9	Schizophrenia;
CESC	cis	rs2243480	1.000	rs2533288	chr7:66056711	C/G	cg13147721	chr7:65941812	NA	-0.93	-8.79	-0.47	1.98e-16	Diabetic kidney disease;
CESC	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg03188948	chr7:1209495	NA	0.72	6.93	0.39	3.15e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05407778	chr3:127399268	ABTB1	-0.54	-6.05	-0.35	4.98e-9	Gut microbiome composition (summer);
CESC	cis	rs6502050	0.835	rs6502069	chr17:80112599	G/T	cg23985595	chr17:80112537	CCDC57	-0.42	-6.59	-0.38	2.43e-10	Life satisfaction;
CESC	cis	rs172166	0.637	rs1225597	chr6:28162087	C/T	cg21251018	chr6:28226885	NKAPL	0.34	5.53	0.32	7.72e-8	Cardiac Troponin-T levels;
CESC	cis	rs873946	0.648	rs12771651	chr10:134554482	C/A	cg27297192	chr10:134578999	INPP5A	0.39	5.12	0.3	5.95e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs1020064	0.895	rs2250659	chr2:105889684	A/G	cg02079111	chr2:105885981	TGFBRAP1	0.5	6.52	0.37	3.61e-10	AIDS;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg25971741	chr6:15343116	JARID2	-0.48	-6.41	-0.37	6.61e-10	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs4481887	0.893	rs4512685	chr1:248446246	C/T	cg00666640	chr1:248458726	OR2T12	0.37	6.47	0.37	4.71e-10	Common traits (Other);
CESC	cis	rs1348850	0.914	rs2121430	chr2:178318375	A/G	cg23306229	chr2:178417860	TTC30B	0.54	6.82	0.39	6.02e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs7809950	0.773	rs2237668	chr7:107050209	A/G	cg23024343	chr7:107201750	COG5	-0.59	-7.45	-0.42	1.35e-12	Coronary artery disease;
CESC	cis	rs2228479	0.867	rs12930606	chr16:89946682	A/G	cg00800038	chr16:89945340	TCF25	-0.88	-7.85	-0.43	1.01e-13	Skin colour saturation;
CESC	cis	rs11958404	0.860	rs11135023	chr5:157420082	G/T	cg05962755	chr5:157440814	NA	0.54	6.71	0.38	1.18e-10	IgG glycosylation;
CESC	cis	rs1552244	0.810	rs7612908	chr3:10089148	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.8	-10.21	-0.53	7.17e-21	Alzheimer's disease;
CESC	cis	rs9549367	0.569	rs3024719	chr13:113814225	G/A	cg00898013	chr13:113819073	PROZ	-0.53	-6.62	-0.38	1.97e-10	Platelet distribution width;
CESC	trans	rs877282	0.947	rs957642	chr10:773966	C/T	cg22713356	chr15:30763199	NA	1.08	10.78	0.55	1.04e-22	Uric acid levels;
CESC	cis	rs12410462	1.000	rs12410462	chr1:227667790	A/G	cg23173402	chr1:227635558	NA	-0.6	-6.08	-0.35	4.26e-9	Major depressive disorder;
CESC	cis	rs798554	0.759	rs798495	chr7:2797267	T/C	cg18446336	chr7:2847575	GNA12	-0.4	-5.94	-0.34	8.91e-9	Height;
CESC	cis	rs2952156	0.959	rs1565922	chr17:37831035	A/G	cg00129232	chr17:37814104	STARD3	-0.71	-9.62	-0.51	5.48e-19	Asthma;
CESC	cis	rs7216064	0.906	rs78452260	chr17:65848522	G/T	cg07042672	chr17:66097459	LOC651250	-0.5	-5.13	-0.3	5.53e-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs2243480	1.000	rs4718269	chr7:65200778	C/G	cg13147721	chr7:65941812	NA	0.86	8.14	0.45	1.51e-14	Diabetic kidney disease;
CESC	cis	rs7267979	0.966	rs6083818	chr20:25346082	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.88	-18.07	-0.74	3.95e-48	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs3741151	0.656	rs10501411	chr11:73292085	A/C	cg17517138	chr11:73019481	ARHGEF17	0.77	6.25	0.36	1.65e-9	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs17253792	0.822	rs76192881	chr14:56034654	C/T	cg01858014	chr14:56050164	KTN1	-0.94	-6.82	-0.39	6.11e-11	Putamen volume;
CESC	cis	rs1355223	0.902	rs704744	chr11:34736561	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.48	-6.44	-0.37	5.45e-10	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.58	7.55	0.42	6.86e-13	Prudent dietary pattern;
CESC	cis	rs9303401	0.614	rs34058624	chr17:57118121	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.86	10.68	0.55	2.3e-22	Cognitive test performance;
CESC	cis	rs1538970	0.924	rs7528573	chr1:45913860	T/C	cg06784218	chr1:46089804	CCDC17	0.35	5.54	0.32	7.26e-8	Platelet count;
CESC	cis	rs4660261	0.561	rs11210934	chr1:44369435	G/A	cg13606994	chr1:44402422	ARTN	-0.38	-5.96	-0.34	7.9e-9	Intelligence (multi-trait analysis);
CESC	cis	rs17253792	0.822	rs75351812	chr14:56082192	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.79	5.91	0.34	1.06e-8	Putamen volume;
CESC	cis	rs4835473	0.932	rs10025527	chr4:144889544	C/G	cg25736465	chr4:144833511	NA	0.38	5.82	0.34	1.7e-8	Immature fraction of reticulocytes;
CESC	cis	rs13256369	1.000	rs873064	chr8:8572380	G/A	cg17143192	chr8:8559678	CLDN23	0.75	8.9	0.48	8.72e-17	Obesity-related traits;
CESC	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg03188948	chr7:1209495	NA	0.72	6.93	0.39	3.15e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs4889855	0.556	rs56873925	chr17:78536611	C/T	cg16591659	chr17:78472290	NA	0.39	6.42	0.37	6.35e-10	Fractional excretion of uric acid;
CESC	cis	rs7618501	0.633	rs11130234	chr3:50024758	G/T	cg24308560	chr3:49941425	MST1R	-0.63	-9.02	-0.48	3.95e-17	Intelligence (multi-trait analysis);
CESC	cis	rs6429082	0.783	rs291364	chr1:235687179	A/G	cg26050004	chr1:235667680	B3GALNT2	0.66	8.77	0.47	2.23e-16	Adiposity;
CESC	cis	rs4253772	0.678	rs1055659	chr22:46638298	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.54	5.65	0.33	4.08e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs854765	0.547	rs4072739	chr17:17884660	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.48	6.76	0.38	9.02e-11	Total body bone mineral density;
CESC	trans	rs561341	0.882	rs2521594	chr17:30302087	C/T	cg27661571	chr11:113659931	NA	-0.83	-7.76	-0.43	1.9e-13	Hip circumference adjusted for BMI;
CESC	cis	rs6502050	0.835	rs11654584	chr17:80079435	A/T	cg11859384	chr17:80120422	CCDC57	-0.4	-5.39	-0.31	1.59e-7	Life satisfaction;
CESC	cis	rs9649213	0.593	rs6465664	chr7:97921834	A/G	cg21770322	chr7:97807741	LMTK2	0.55	8.18	0.45	1.17e-14	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs9300255	0.602	rs1716167	chr12:123651162	C/T	cg00376283	chr12:123451042	ABCB9	-0.7	-8.72	-0.47	3.04e-16	Neutrophil percentage of white cells;
CESC	trans	rs709082	0.709	rs709105	chr3:191471655	C/T	cg25305879	chr2:106814630	NA	0.4	6.44	0.37	5.56e-10	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2839186	0.632	rs17176110	chr21:47706535	C/A	cg10351095	chr21:47802916	PCNT	-0.49	-6.62	-0.38	2.02e-10	Testicular germ cell tumor;
CESC	cis	rs7666738	0.830	rs1349757	chr4:99058763	C/G	cg03676636	chr4:99064102	C4orf37	0.33	5.05	0.3	8.16e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4595586	0.525	rs12818844	chr12:39423806	A/G	cg26384229	chr12:38710491	ALG10B	0.6	8.2	0.45	1.03e-14	Morning vs. evening chronotype;
CESC	cis	rs7666738	0.830	rs9994346	chr4:99037986	A/G	cg17366294	chr4:99064904	C4orf37	0.63	8.76	0.47	2.36e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs854765	0.552	rs6502624	chr17:17847936	G/A	cg04398451	chr17:18023971	MYO15A	-0.69	-9.72	-0.51	2.77e-19	Total body bone mineral density;
CESC	trans	rs853679	0.556	rs13200214	chr6:28017250	C/T	cg06606381	chr12:133084897	FBRSL1	-1.14	-8.21	-0.45	9.47e-15	Depression;
CESC	cis	rs2594989	0.887	rs2447604	chr3:11574297	G/A	cg00170343	chr3:11313890	ATG7	-0.63	-5.22	-0.31	3.66e-7	Circulating chemerin levels;
CESC	trans	rs116095464	0.558	rs10036253	chr5:238519	A/C	cg00938859	chr5:1591904	SDHAP3	0.64	6.99	0.39	2.27e-11	Breast cancer;
CESC	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg17178900	chr1:205818956	PM20D1	0.5	7.44	0.42	1.4e-12	Menarche (age at onset);
CESC	trans	rs116095464	0.558	rs6869925	chr5:264036	A/G	cg00938859	chr5:1591904	SDHAP3	0.63	6.77	0.38	8.38e-11	Breast cancer;
CESC	cis	rs258892	0.895	rs10039408	chr5:72069110	G/T	cg21869765	chr5:72125136	TNPO1	-0.43	-5.35	-0.31	1.93e-7	Small cell lung carcinoma;
CESC	cis	rs3762637	1.000	rs13321097	chr3:122162007	C/T	cg24169773	chr3:122142474	KPNA1	-0.54	-6.31	-0.36	1.2e-9	LDL cholesterol levels;
CESC	cis	rs9926296	0.744	rs164746	chr16:89709019	C/T	cg08949735	chr16:89699720	DPEP1	-0.28	-5.06	-0.3	7.68e-7	Vitiligo;
CESC	cis	rs4975616	0.869	rs465498	chr5:1325803	A/G	cg06550200	chr5:1325588	CLPTM1L	-0.69	-11.07	-0.56	1.16e-23	Lung cancer;
CESC	cis	rs875971	0.964	rs778723	chr7:65829497	T/C	cg10691866	chr7:65817282	TPST1	-0.34	-5.51	-0.32	8.45e-8	Aortic root size;
CESC	cis	rs5769765	0.955	rs8135963	chr22:50301476	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.49	-5.53	-0.32	7.82e-8	Schizophrenia;
CESC	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg07308232	chr7:1071921	C7orf50	-0.41	-5.59	-0.32	5.67e-8	Longevity;Endometriosis;
CESC	cis	rs7618915	0.570	rs2336145	chr3:52629750	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	6.43	0.37	6.01e-10	Bipolar disorder;
CESC	cis	rs8067354	0.645	rs1874548	chr17:57841357	A/G	cg02344993	chr17:57696989	CLTC	0.57	5.97	0.34	7.53e-9	Hemoglobin concentration;
CESC	cis	rs7666738	0.830	rs35939134	chr4:98980311	A/G	cg05340658	chr4:99064831	C4orf37	0.79	12.32	0.6	7.31e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6933660	0.646	rs3736176	chr6:151773320	T/A	cg14416726	chr6:151773293	C6orf211;RMND1	-0.53	-7.24	-0.41	4.87e-12	Menarche (age at onset);
CESC	cis	rs2050392	0.894	rs303430	chr10:30706235	C/A	cg18806716	chr10:30721971	MAP3K8	-0.43	-6.14	-0.35	3.01e-9	Inflammatory bowel disease;
CESC	cis	rs6570726	0.791	rs9497357	chr6:145912888	G/A	cg05347473	chr6:146136440	FBXO30	0.52	6.73	0.38	1.06e-10	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs7335046	1.000	rs9517678	chr13:99961059	T/C	cg14259717	chr11:18433732	LDHC	0.61	6.02	0.35	5.87e-9	Basal cell carcinoma;
CESC	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.56	7.42	0.41	1.55e-12	Lymphocyte counts;
CESC	cis	rs6089584	1.000	rs6142910	chr20:60562181	C/A	cg06108461	chr20:60628389	TAF4	-0.78	-11.36	-0.57	1.25e-24	Body mass index;
CESC	cis	rs9858542	1.000	rs9822268	chr3:49719729	G/A	cg03060546	chr3:49711283	APEH	-0.58	-6.87	-0.39	4.44e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs3096299	0.900	rs3114867	chr16:89428967	A/C	cg00750074	chr16:89608354	SPG7	-0.35	-5.06	-0.3	7.86e-7	Multiple myeloma (IgH translocation);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08568561	chr7:42834498	NA	-0.56	-6.11	-0.35	3.6e-9	Gut microbiome composition (summer);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04381741	chr7:108210905	THAP5;DNAJB9	-0.48	-6.84	-0.39	5.4e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs6991838	0.612	rs12335276	chr8:66531903	A/G	cg13398993	chr8:66546079	ARMC1	0.46	5.65	0.33	4.19e-8	Intelligence (multi-trait analysis);
CESC	cis	rs477692	0.792	rs12762024	chr10:131441055	G/C	cg05714579	chr10:131428358	MGMT	-0.57	-8.2	-0.45	1.08e-14	Response to temozolomide;
CESC	cis	rs7618915	0.501	rs34739010	chr3:52766122	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	8.22	0.45	9.26e-15	Bipolar disorder;
CESC	cis	rs9911578	1.000	rs8071280	chr17:57010225	T/C	cg05425664	chr17:57184151	TRIM37	-0.49	-6.81	-0.39	6.39e-11	Intelligence (multi-trait analysis);
CESC	cis	rs6137287	0.643	rs6047261	chr20:21103910	T/G	cg13880779	chr20:21376337	NKX2-4	0.33	5.31	0.31	2.33e-7	Height;
CESC	cis	rs9902453	1.000	rs6505152	chr17:28331466	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.62	-7.83	-0.43	1.15e-13	Coffee consumption (cups per day);
CESC	cis	rs3772130	0.564	rs28620947	chr3:121585631	G/A	cg20356878	chr3:121714668	ILDR1	0.44	6.31	0.36	1.18e-9	Cognitive performance;
CESC	cis	rs12497850	0.931	rs9876848	chr3:48844059	G/A	cg07636037	chr3:49044803	WDR6	1.02	18.44	0.75	2.06e-49	Parkinson's disease;
CESC	cis	rs8077577	0.708	rs3889544	chr17:18133788	C/T	cg16794390	chr17:18148240	FLII	-0.45	-6.69	-0.38	1.35e-10	Obesity-related traits;
CESC	cis	rs4803468	1.000	rs11670668	chr19:41920454	G/C	cg09537434	chr19:41945824	ATP5SL	-1.08	-18.9	-0.76	4.86e-51	Height;
CESC	cis	rs1448094	0.511	rs17279289	chr12:86162792	T/G	cg00310523	chr12:86230176	RASSF9	0.35	5.59	0.32	5.75e-8	Major depressive disorder;
CESC	cis	rs8078723	1.000	rs709592	chr17:38175553	C/T	cg17467752	chr17:38218738	THRA	0.66	9.91	0.52	6.68e-20	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CESC	cis	rs2486288	0.656	rs1706768	chr15:45569443	T/C	cg09092052	chr15:45571596	NA	0.51	6.0	0.35	6.6e-9	Glomerular filtration rate;
CESC	cis	rs7811142	0.562	rs7786844	chr7:99934008	T/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.74	7.57	0.42	6.21e-13	Platelet count;
CESC	cis	rs6991838	0.584	rs7012856	chr8:66534975	C/T	cg13398993	chr8:66546079	ARMC1	0.46	5.65	0.33	4.19e-8	Intelligence (multi-trait analysis);
CESC	cis	rs798554	0.704	rs798503	chr7:2789704	G/A	cg19717773	chr7:2847554	GNA12	-0.56	-8.8	-0.48	1.81e-16	Height;
CESC	cis	rs9309473	0.950	rs6705977	chr2:73849170	C/G	cg20560298	chr2:73613845	ALMS1	-0.45	-5.89	-0.34	1.17e-8	Metabolite levels;
CESC	cis	rs2228479	0.717	rs1061647	chr16:89806063	G/C	cg00800038	chr16:89945340	TCF25	-0.83	-6.65	-0.38	1.71e-10	Skin colour saturation;
CESC	cis	rs2985684	0.894	rs4900932	chr14:50022928	A/G	cg04989706	chr14:50066350	PPIL5	-0.45	-5.17	-0.3	4.58e-7	Carotid intima media thickness;
CESC	cis	rs7605827	0.930	rs2287635	chr2:15704410	C/G	cg19274914	chr2:15703543	NA	0.3	5.44	0.32	1.21e-7	Educational attainment (years of education);
CESC	cis	rs8114671	0.836	rs2425006	chr20:33571228	T/G	cg07148914	chr20:33460835	GGT7	-0.43	-5.51	-0.32	8.28e-8	Height;
CESC	cis	rs17376456	0.825	rs17314762	chr5:93231200	C/T	cg25358565	chr5:93447407	FAM172A	1.13	10.46	0.54	1.15e-21	Diabetic retinopathy;
CESC	cis	rs12410462	0.681	rs4486420	chr1:227572321	T/A	cg23173402	chr1:227635558	NA	0.68	5.73	0.33	2.78e-8	Major depressive disorder;
CESC	cis	rs17376456	0.877	rs7736620	chr5:93305762	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.64	5.63	0.33	4.56e-8	Diabetic retinopathy;
CESC	cis	rs4566357	0.615	rs10174591	chr2:227913140	G/A	cg05526886	chr2:227700861	RHBDD1	-0.47	-6.27	-0.36	1.45e-9	Coronary artery disease;
CESC	cis	rs6088590	0.930	rs6120723	chr20:33364655	C/T	cg08999081	chr20:33150536	PIGU	0.59	9.06	0.49	2.93e-17	Coronary artery disease;
CESC	cis	rs9790314	0.605	rs2593812	chr3:160703069	T/G	cg04691961	chr3:161091175	C3orf57	0.38	5.04	0.3	8.69e-7	Morning vs. evening chronotype;
CESC	cis	rs10129255	0.500	rs10142931	chr14:107190525	A/C	cg07958169	chr14:107095056	NA	-0.58	-9.32	-0.5	4.62e-18	Kawasaki disease;
CESC	cis	rs9467711	0.790	rs13195402	chr6:26463575	G/T	cg14345882	chr6:26364793	BTN3A2	0.63	5.15	0.3	4.99e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs1707322	0.964	rs785508	chr1:46527159	G/A	cg03146154	chr1:46216737	IPP	-0.7	-9.16	-0.49	1.46e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7208859	0.623	rs28627615	chr17:29145817	G/C	cg14008862	chr17:28927542	LRRC37B2	0.65	5.14	0.3	5.34e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs6752107	0.837	rs3792108	chr2:234184952	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.49	6.69	0.38	1.3e-10	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs6676180	0.514	rs868675	chr1:119773596	A/G	cg05756136	chr1:119680316	WARS2	-0.41	-5.42	-0.32	1.32e-7	Monobrow;
CESC	cis	rs4704187	0.687	rs1345705	chr5:74507007	C/A	cg03227963	chr5:74354835	NA	0.28	5.19	0.3	4.21e-7	Response to amphetamines;
CESC	cis	rs1018836	0.923	rs6986001	chr8:91650205	T/C	cg16814680	chr8:91681699	NA	-0.74	-11.4	-0.57	8.9e-25	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs28386778	0.863	rs3760252	chr17:61852186	G/C	cg26338869	chr17:61819248	STRADA	0.68	8.88	0.48	1.06e-16	Prudent dietary pattern;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg27452651	chr22:50312357	ALG12;CRELD2	-0.45	-6.18	-0.35	2.44e-9	Fibrinogen levels;
CESC	cis	rs13108904	0.604	rs11946375	chr4:1313488	T/C	cg00684032	chr4:1343700	KIAA1530	0.43	6.25	0.36	1.67e-9	Obesity-related traits;
CESC	cis	rs1799949	1.000	rs8176297	chr17:41203325	T/A	cg25072359	chr17:41440525	NA	0.45	5.96	0.34	7.83e-9	Menopause (age at onset);
CESC	trans	rs9467711	0.790	rs72843784	chr6:26498758	G/T	cg01620082	chr3:125678407	NA	-0.91	-6.59	-0.38	2.31e-10	Autism spectrum disorder or schizophrenia;
CESC	cis	rs79387448	0.592	rs6728945	chr2:102986471	T/C	cg09003973	chr2:102972529	NA	1.22	10.27	0.53	4.91e-21	Gut microbiota (bacterial taxa);
CESC	cis	rs8058578	0.943	rs7197770	chr16:30715908	T/C	cg00531865	chr16:30841666	NA	-0.44	-5.77	-0.33	2.15e-8	Multiple myeloma;
CESC	cis	rs736408	0.562	rs2072390	chr3:52780509	A/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.39	6.94	0.39	2.94e-11	Bipolar disorder;
CESC	cis	rs12155623	0.834	rs6472110	chr8:49784810	T/C	cg22283653	chr8:49824208	NA	-0.38	-5.37	-0.31	1.75e-7	Sudden cardiac arrest;
CESC	cis	rs9488822	0.636	rs7745074	chr6:116347432	G/A	cg26893134	chr6:116381904	FRK	0.25	6.14	0.35	3.03e-9	Cholesterol, total;LDL cholesterol;
CESC	cis	rs4665809	0.652	rs2384360	chr2:26405016	C/G	cg26314531	chr2:26401878	FAM59B	-0.82	-9.03	-0.48	3.69e-17	Gut microbiome composition (summer);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg03456755	chr17:75084957	SCARNA16;C17orf86	-0.42	-6.13	-0.35	3.11e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs514406	0.929	rs483073	chr1:53314084	T/C	cg24675658	chr1:53192096	ZYG11B	-0.57	-7.0	-0.39	2.13e-11	Monocyte count;
CESC	cis	rs72945132	0.882	rs72947078	chr11:70197542	G/T	cg00319359	chr11:70116639	PPFIA1	0.81	7.2	0.4	6.16e-12	Coronary artery disease;
CESC	cis	rs6688613	0.649	rs11584352	chr1:166850372	T/C	ch.1.3259774R	chr1:166827647	TADA1	0.55	5.32	0.31	2.23e-7	Refractive astigmatism;
CESC	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg07414643	chr4:187882934	NA	-0.5	-7.03	-0.4	1.77e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6461049	0.734	rs1558465	chr7:2151398	G/C	cg21782813	chr7:2030301	MAD1L1	0.42	5.83	0.34	1.59e-8	Schizophrenia;
CESC	cis	rs67311347	0.784	rs13326389	chr3:40459724	A/G	cg24209194	chr3:40518798	ZNF619	0.5	6.28	0.36	1.42e-9	Renal cell carcinoma;
CESC	cis	rs9362426	0.943	rs242291	chr6:88077083	A/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.5	-5.7	-0.33	3.21e-8	Depressive episodes in bipolar disorder;
CESC	trans	rs7246760	0.867	rs66943818	chr19:9746367	G/A	cg02900749	chr2:68251473	NA	-0.85	-7.53	-0.42	8.04e-13	Pursuit maintenance gain;
CESC	cis	rs4665809	1.000	rs1560868	chr2:26281459	A/T	cg26314531	chr2:26401878	FAM59B	0.7	7.86	0.43	9.71e-14	Gut microbiome composition (summer);
CESC	cis	rs6540559	1.000	rs12070337	chr1:209992127	G/A	cg22442454	chr1:209979470	IRF6	0.53	6.31	0.36	1.14e-9	Cleft lip with or without cleft palate;
CESC	trans	rs6759922	1.000	rs4321395	chr2:22444221	G/A	cg21162304	chr4:80247171	NAA11	0.38	6.24	0.36	1.72e-9	Subjective well-being (multi-trait analysis);
CESC	cis	rs477895	0.713	rs11601024	chr11:63943074	A/G	cg18225595	chr11:63971243	STIP1	0.52	5.13	0.3	5.56e-7	Mean platelet volume;
CESC	cis	rs2735413	0.875	rs11649082	chr16:78082256	C/T	cg04733911	chr16:78082701	NA	-0.53	-8.93	-0.48	7.29e-17	Systolic blood pressure (alcohol consumption interaction);
CESC	trans	rs11088226	1.000	rs11701627	chr21:33927794	T/A	cg09050820	chr6:167586206	TCP10L2	0.6	6.09	0.35	3.97e-9	Gastritis;
CESC	cis	rs798554	0.797	rs1182184	chr7:2872446	G/A	cg19717773	chr7:2847554	GNA12	-0.57	-8.38	-0.46	3.07e-15	Height;
CESC	cis	rs769267	0.896	rs11882123	chr19:19386339	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.42	5.38	0.31	1.66e-7	Tonsillectomy;
CESC	trans	rs4927850	1.000	rs4927850	chr3:195751630	C/T	cg16724585	chr3:197361211	NA	0.54	7.02	0.4	1.89e-11	Pancreatic cancer;
CESC	cis	rs6912958	0.535	rs448580	chr6:88040399	A/C	cg04972856	chr6:88032051	C6orf162;GJB7	0.36	5.65	0.33	4.19e-8	Monocyte percentage of white cells;
CESC	cis	rs9649213	0.593	rs6465683	chr7:98026092	C/A	cg08684580	chr7:98029266	BAIAP2L1	-0.36	-5.73	-0.33	2.66e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs12995491	0.731	rs17435439	chr2:88511391	A/G	cg14558114	chr2:88469736	THNSL2	-0.49	-7.16	-0.4	8.01e-12	Response to metformin (IC50);
CESC	cis	rs7219021	0.926	rs7209437	chr17:46855267	A/G	cg16584676	chr17:46985605	UBE2Z	-0.56	-6.32	-0.36	1.08e-9	Schizophrenia or bipolar disorder;
CESC	cis	rs561341	1.000	rs555629	chr17:30294136	T/C	cg00745463	chr17:30367425	LRRC37B	-0.81	-7.35	-0.41	2.5e-12	Hip circumference adjusted for BMI;
CESC	cis	rs10242455	0.702	rs3823813	chr7:99049389	G/A	cg25640893	chr7:99214727	ZNF498	0.81	5.34	0.31	1.98e-7	Blood metabolite levels;
CESC	cis	rs7845219	0.525	rs10956931	chr8:95930301	A/G	cg09323728	chr8:95962352	TP53INP1	-0.29	-5.56	-0.32	6.67e-8	Type 2 diabetes;
CESC	cis	rs9322193	0.884	rs62439836	chr6:149990309	A/G	cg04369109	chr6:150039330	LATS1	-0.38	-5.26	-0.31	3.04e-7	Lung cancer;
CESC	cis	rs9303401	0.614	rs35245220	chr17:56510305	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.92	10.45	0.54	1.27e-21	Cognitive test performance;
CESC	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg14159672	chr1:205819179	PM20D1	0.96	16.98	0.72	2.86e-44	Menarche (age at onset);
CESC	cis	rs9359856	0.662	rs1179904	chr6:90322573	A/G	cg13799429	chr6:90582589	CASP8AP2	0.54	6.09	0.35	3.98e-9	Bipolar disorder;
CESC	cis	rs9308731	0.505	rs10169613	chr2:111934977	C/T	cg04202892	chr2:111875749	ACOXL	0.43	5.84	0.34	1.52e-8	Chronic lymphocytic leukemia;
CESC	trans	rs7666738	0.830	rs4292341	chr4:98959724	C/T	cg11514184	chr1:161015941	USF1	0.43	6.13	0.35	3.25e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2839186	0.632	rs2839184	chr21:47689013	G/A	cg12516959	chr21:47718080	NA	-0.47	-6.45	-0.37	5.37e-10	Testicular germ cell tumor;
CESC	cis	rs8070128	0.534	rs2955350	chr17:17953548	G/A	cg09796270	chr17:17721594	SREBF1	-0.38	-5.07	-0.3	7.66e-7	Total body bone mineral density;
CESC	cis	rs116095464	0.558	rs13356367	chr5:242395	C/T	cg22496380	chr5:211416	CCDC127	-0.74	-8.63	-0.47	5.66e-16	Breast cancer;
CESC	cis	rs67311347	0.544	rs12054197	chr3:40337562	C/T	cg09455208	chr3:40491958	NA	0.36	6.35	0.36	9.37e-10	Renal cell carcinoma;
CESC	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg24642844	chr7:1081250	C7orf50	-0.71	-8.62	-0.47	6.13e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs514406	0.825	rs1242328	chr1:53396869	A/G	cg08859206	chr1:53392774	SCP2	-0.58	-7.44	-0.42	1.45e-12	Monocyte count;
CESC	cis	rs2839186	0.749	rs62226488	chr21:47710517	C/T	cg10351095	chr21:47802916	PCNT	-0.5	-6.75	-0.38	9.55e-11	Testicular germ cell tumor;
CESC	cis	rs4689592	0.546	rs10937784	chr4:7060935	G/C	cg06697600	chr4:7070879	GRPEL1	-0.47	-7.22	-0.41	5.6e-12	Monocyte percentage of white cells;
CESC	cis	rs10504229	1.000	rs66477954	chr8:58187810	C/T	cg05313129	chr8:58192883	C8orf71	-0.55	-6.29	-0.36	1.34e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs6570726	0.791	rs11155435	chr6:145938545	T/C	cg05347473	chr6:146136440	FBXO30	0.58	7.43	0.42	1.48e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs921968	0.643	rs492400	chr2:219349752	C/T	cg02176678	chr2:219576539	TTLL4	0.4	7.13	0.4	9.47e-12	Mean corpuscular hemoglobin concentration;
CESC	cis	rs7666738	0.830	rs17027198	chr4:98991085	G/C	cg03467027	chr4:99064603	C4orf37	0.44	5.51	0.32	8.65e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7542091	0.704	rs2142907	chr1:210039505	T/C	cg23283495	chr1:209979779	IRF6	0.33	5.23	0.31	3.38e-7	Monobrow;
CESC	cis	rs10504073	0.626	rs9298106	chr8:50007508	T/G	cg00325661	chr8:49890786	NA	0.51	7.78	0.43	1.65e-13	Blood metabolite ratios;
CESC	cis	rs12824058	0.831	rs7299065	chr12:130809661	A/T	cg26677194	chr12:130822605	PIWIL1	0.52	6.81	0.39	6.58e-11	Menopause (age at onset);
CESC	cis	rs11608355	0.545	rs12818120	chr12:109901916	C/T	cg05360138	chr12:110035743	NA	0.84	9.16	0.49	1.46e-17	Neuroticism;
CESC	cis	rs2115536	0.692	rs6495450	chr15:80162499	C/A	cg11839771	chr15:80205821	ST20	-0.36	-5.29	-0.31	2.59e-7	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CESC	cis	rs116095464	0.558	rs6878061	chr5:223072	A/G	cg22857025	chr5:266934	NA	-1.27	-18.89	-0.76	5.51e-51	Breast cancer;
CESC	cis	rs1691799	0.867	rs1168297	chr12:66735644	T/C	cg16791601	chr12:66731901	HELB	-0.75	-12.95	-0.62	4.83e-30	White blood cell count (basophil);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08132980	chr7:2632320	IQCE	-0.57	-7.05	-0.4	1.51e-11	Gut microbiome composition (summer);
CESC	cis	rs9611519	1.000	rs9611510	chr22:41569124	T/C	cg03806693	chr22:41940476	POLR3H	-0.57	-5.85	-0.34	1.42e-8	Neuroticism;
CESC	cis	rs60871478	0.636	rs7792072	chr7:886239	C/T	cg00475322	chr7:917719	C7orf20	0.46	5.1	0.3	6.53e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs826838	0.967	rs826855	chr12:39114888	T/C	cg26384229	chr12:38710491	ALG10B	-0.67	-11.02	-0.56	1.72e-23	Heart rate;
CESC	cis	rs7772486	0.686	rs1415744	chr6:146022531	C/T	cg05347473	chr6:146136440	FBXO30	0.53	6.76	0.38	8.75e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1801251	0.727	rs283482	chr2:233646920	A/T	cg08000102	chr2:233561755	GIGYF2	0.67	10.02	0.52	2.92e-20	Coronary artery disease;
CESC	cis	rs10504229	0.654	rs903705	chr8:58128185	T/A	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs11608355	0.557	rs759971	chr12:109826046	A/T	cg19025524	chr12:109796872	NA	-0.54	-7.73	-0.43	2.27e-13	Neuroticism;
CESC	cis	rs7618915	0.501	rs2336146	chr3:52626646	A/G	cg17372223	chr3:52568218	NT5DC2	0.42	6.42	0.37	6.33e-10	Bipolar disorder;
CESC	cis	rs7666738	0.830	rs10021709	chr4:99030587	G/A	cg03467027	chr4:99064603	C4orf37	0.49	6.18	0.35	2.44e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2011503	1.000	rs7252453	chr19:19654117	G/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.54	5.83	0.34	1.61e-8	Bipolar disorder;
CESC	cis	rs959260	1.000	rs9902966	chr17:73362147	C/T	cg20590849	chr17:73267439	MIF4GD	-0.56	-6.44	-0.37	5.52e-10	Systemic lupus erythematosus;
CESC	cis	rs13108904	0.967	rs900028	chr4:1279162	A/T	cg00684032	chr4:1343700	KIAA1530	0.4	5.59	0.32	5.54e-8	Obesity-related traits;
CESC	cis	rs7618915	0.508	rs11717043	chr3:52656092	A/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.29	5.18	0.3	4.42e-7	Bipolar disorder;
CESC	cis	rs863345	0.604	rs11265021	chr1:158511810	A/T	cg12129480	chr1:158549410	OR10X1	0.34	6.98	0.39	2.37e-11	Pneumococcal bacteremia;
CESC	cis	rs6967414	0.579	rs6968879	chr7:6757886	T/G	cg09896999	chr7:6746977	ZNF12	-0.52	-6.19	-0.36	2.31e-9	Hematocrit;Hemoglobin concentration;
CESC	cis	rs11203032	0.831	rs7076185	chr10:90923524	G/A	cg16672925	chr10:90967113	CH25H	0.7	6.65	0.38	1.62e-10	Heart failure;
CESC	cis	rs2235544	0.565	rs650134	chr1:54467342	T/C	cg25741118	chr1:54482237	LDLRAD1	0.24	5.77	0.33	2.2e-8	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
CESC	cis	rs1707322	0.821	rs11211182	chr1:46240170	G/A	cg03146154	chr1:46216737	IPP	0.8	10.82	0.55	7.95e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs4076764	1.000	rs6683181	chr1:163417077	C/T	cg24596788	chr1:163392923	NA	-0.49	-7.17	-0.4	7.57e-12	Motion sickness;
CESC	cis	rs300703	0.542	rs300691	chr2:180171	C/A	cg21211680	chr2:198530	NA	-0.86	-9.51	-0.5	1.21e-18	Blood protein levels;
CESC	cis	rs2228479	0.541	rs12918575	chr16:89811151	A/G	cg04287289	chr16:89883240	FANCA	0.71	6.53	0.37	3.42e-10	Skin colour saturation;
CESC	cis	rs1832871	0.672	rs11751553	chr6:158774750	C/T	cg07165851	chr6:158734300	TULP4	-0.59	-6.12	-0.35	3.27e-9	Height;
CESC	cis	rs13191362	1.000	rs13210756	chr6:163009030	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.82	8.75	0.47	2.56e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs10861342	0.892	rs7488014	chr12:105657527	C/T	cg23923672	chr12:105501055	KIAA1033	0.68	5.88	0.34	1.25e-8	IgG glycosylation;
CESC	cis	rs4423214	0.840	rs1792229	chr11:71179395	A/G	cg05163923	chr11:71159392	DHCR7	-0.64	-7.61	-0.42	4.66e-13	Vitamin D levels;
CESC	trans	rs7824557	0.547	rs2409745	chr8:11076635	G/T	cg06636001	chr8:8085503	FLJ10661	0.49	6.27	0.36	1.46e-9	Retinal vascular caliber;
CESC	cis	rs963731	0.649	rs1869513	chr2:39205315	A/G	cg04010122	chr2:39346883	SOS1	-0.68	-5.09	-0.3	6.82e-7	Corticobasal degeneration;
CESC	cis	rs1801251	0.964	rs10933411	chr2:233706847	A/G	cg25237894	chr2:233734115	C2orf82	-0.46	-8.06	-0.44	2.65e-14	Coronary artery disease;
CESC	cis	rs3740713	0.920	rs73438656	chr11:18455935	C/A	cg23797887	chr11:18477753	LDHAL6A	-0.53	-5.27	-0.31	2.89e-7	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs4853012	0.838	rs72911122	chr2:74344119	C/G	cg19729930	chr2:74357872	NA	0.86	12.94	0.62	5.25e-30	Gestational age at birth (maternal effect);
CESC	trans	rs62103177	0.810	rs62096746	chr18:77619556	T/A	cg05926928	chr17:57297772	GDPD1	1.2	10.71	0.55	1.82e-22	Opioid sensitivity;
CESC	cis	rs4594175	0.926	rs4901084	chr14:51634131	G/A	cg23942311	chr14:51606299	NA	0.39	6.03	0.35	5.6e-9	Cancer;
CESC	cis	rs4523957	0.552	rs923862	chr17:2031382	A/C	cg16513277	chr17:2031491	SMG6	-0.79	-11.73	-0.58	6.95e-26	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs7829975	0.511	rs2976902	chr8:8341105	T/G	cg06636001	chr8:8085503	FLJ10661	0.42	5.09	0.3	6.68e-7	Mood instability;
CESC	cis	rs9486719	0.948	rs2499817	chr6:96878321	C/T	cg18709589	chr6:96969512	KIAA0776	0.53	5.81	0.34	1.75e-8	Migraine;Coronary artery disease;
CESC	cis	rs367943	0.712	rs26959	chr5:112736615	A/G	cg12552261	chr5:112820674	MCC	0.4	5.32	0.31	2.21e-7	Type 2 diabetes;
CESC	cis	rs9733	0.596	rs6690725	chr1:150632322	T/C	cg09365446	chr1:150670422	GOLPH3L	0.42	5.98	0.34	7.35e-9	Tonsillectomy;
CESC	cis	rs362272	0.524	rs2857982	chr4:3358665	G/A	cg08886695	chr4:3369023	RGS12	-0.43	-5.95	-0.34	8.67e-9	Serum sulfate level;
CESC	cis	rs7312774	0.748	rs1861746	chr12:107301518	G/A	cg16260113	chr12:107380972	MTERFD3	0.65	6.12	0.35	3.43e-9	Severe influenza A (H1N1) infection;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10514235	chr4:15003844	NA	0.53	6.4	0.37	6.97e-10	Gut microbiome composition (summer);
CESC	cis	rs9649213	0.593	rs6963210	chr7:97944986	G/A	cg24562669	chr7:97807699	LMTK2	0.48	7.0	0.4	2.09e-11	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs11190604	1.000	rs2489050	chr10:102350898	T/A	cg07080220	chr10:102295463	HIF1AN	0.6	5.3	0.31	2.43e-7	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs514406	0.825	rs6693210	chr1:53223398	A/G	cg16325326	chr1:53192061	ZYG11B	-0.87	-14.76	-0.67	2.25e-36	Monocyte count;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg19523618	chr12:125438446	DHX37	0.49	6.35	0.36	9.29e-10	Fibrinogen levels;
CESC	cis	rs7618501	0.699	rs6446187	chr3:49907111	C/A	cg24308560	chr3:49941425	MST1R	-0.68	-10.12	-0.53	1.45e-20	Intelligence (multi-trait analysis);
CESC	cis	rs11098499	0.820	rs28578366	chr4:120536905	A/G	cg24375607	chr4:120327624	NA	-0.46	-5.67	-0.33	3.82e-8	Corneal astigmatism;
CESC	trans	rs2823962	0.759	rs8134854	chr21:18016042	C/T	cg06419850	chr17:4688683	VMO1	-0.43	-6.1	-0.35	3.83e-9	Amyotrophic lateral sclerosis;
CESC	cis	rs1707322	0.662	rs11211160	chr1:46146229	T/A	cg06784218	chr1:46089804	CCDC17	0.4	7.04	0.4	1.63e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs56235845	0.694	rs36102285	chr5:176774018	C/T	cg17509989	chr5:176798049	RGS14	0.48	5.78	0.33	2.12e-8	Hemoglobin concentration;Hematocrit;
CESC	cis	rs7592578	0.679	rs59929070	chr2:191327852	A/G	cg27211696	chr2:191398769	TMEM194B	-0.59	-5.88	-0.34	1.25e-8	Diastolic blood pressure;
CESC	cis	rs2635047	0.519	rs2668771	chr18:44775897	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.34	5.35	0.31	1.88e-7	Educational attainment;
CESC	cis	rs1712517	0.524	rs1712509	chr10:105013870	G/T	cg04362960	chr10:104952993	NT5C2	-0.48	-5.71	-0.33	2.96e-8	Migraine;
CESC	cis	rs4629710	0.545	rs2077490	chr6:131554184	C/T	cg12606694	chr6:131520996	AKAP7	0.46	5.86	0.34	1.36e-8	Multiple myeloma (IgH translocation);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11891330	chr4:2010714	WHSC2	-0.58	-6.33	-0.36	1.02e-9	Gut microbiome composition (summer);
CESC	cis	rs9788682	0.747	rs16969894	chr15:78776456	C/T	cg24631222	chr15:78858424	CHRNA5	0.64	7.6	0.42	5.15e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00045532	chr12:38493714	NA	-0.61	-7.63	-0.42	4.21e-13	Gut microbiome composition (summer);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg02931907	chr8:94753245	RBM12B	0.44	6.2	0.36	2.15e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs155076	0.711	rs9550724	chr13:21885030	G/T	cg11317459	chr13:21872234	NA	1.18	15.36	0.69	1.57e-38	White matter hyperintensity burden;
CESC	cis	rs7666738	0.830	rs880470	chr4:98922522	A/T	cg05340658	chr4:99064831	C4orf37	0.82	12.2	0.6	1.81e-27	Colonoscopy-negative controls vs population controls;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg17584085	chr17:46688329	HOXB7	-0.45	-6.24	-0.36	1.69e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs6580649	0.941	rs4760615	chr12:48428150	A/G	cg05342945	chr12:48394962	COL2A1	-0.52	-6.06	-0.35	4.61e-9	Lung cancer;
CESC	cis	rs801193	1.000	rs7782320	chr7:66177098	C/T	cg18876405	chr7:65276391	NA	0.53	7.06	0.4	1.47e-11	Aortic root size;
CESC	cis	rs9911578	0.900	rs717828	chr17:56535932	A/G	cg05425664	chr17:57184151	TRIM37	-0.5	-6.94	-0.39	2.97e-11	Intelligence (multi-trait analysis);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg15342139	chr6:170124938	PHF10	-0.46	-6.38	-0.36	7.85e-10	Fibrinogen levels;
CESC	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg14893161	chr1:205819251	PM20D1	0.86	14.4	0.66	4.17e-35	Menarche (age at onset);
CESC	cis	rs7520050	0.966	rs785471	chr1:46518677	T/C	cg24296786	chr1:45957014	TESK2	0.41	5.12	0.3	5.92e-7	Red blood cell count;Reticulocyte count;
CESC	trans	rs208520	0.690	rs12213581	chr6:66735818	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.95	12.22	0.6	1.51e-27	Exhaled nitric oxide output;
CESC	cis	rs910316	0.763	rs2080201	chr14:75629972	C/T	cg16144293	chr14:75469539	EIF2B2	0.39	5.04	0.3	8.77e-7	Height;
CESC	cis	rs6088580	0.634	rs6058051	chr20:33044862	G/A	cg24642439	chr20:33292090	TP53INP2	0.52	6.9	0.39	3.77e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs853679	1.000	rs13200462	chr6:28218199	A/C	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.74	7.3	0.41	3.39e-12	Depression;
CESC	cis	rs10751667	0.666	rs7395182	chr11:927553	A/C	cg20946044	chr11:1010712	AP2A2	-0.39	-5.26	-0.31	2.96e-7	Alzheimer's disease (late onset);
CESC	cis	rs7647973	0.516	rs4308307	chr3:49193216	C/T	cg03060546	chr3:49711283	APEH	0.54	7.09	0.4	1.2e-11	Menarche (age at onset);
CESC	cis	rs116095464	0.867	rs10074958	chr5:230828	C/T	cg12570787	chr5:219185	SDHA;CCDC127	0.5	5.23	0.31	3.47e-7	Breast cancer;
CESC	cis	rs2243480	1.000	rs1618893	chr7:66096119	C/T	cg12463550	chr7:65579703	CRCP	0.63	5.63	0.33	4.64e-8	Diabetic kidney disease;
CESC	cis	rs9611565	0.649	rs202666	chr22:41814719	T/C	cg06634786	chr22:41940651	POLR3H	0.72	7.58	0.42	5.66e-13	Vitiligo;
CESC	cis	rs875971	0.545	rs316306	chr7:65618674	G/A	cg25405998	chr7:65216604	CCT6P1	-0.45	-5.06	-0.3	7.71e-7	Aortic root size;
CESC	cis	rs7945705	0.935	rs2568062	chr11:8887945	A/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.38	-6.63	-0.38	1.92e-10	Hemoglobin concentration;
CESC	cis	rs660498	0.507	rs4018734	chr10:27741269	G/A	cg25705717	chr10:27608719	NA	0.47	5.73	0.33	2.73e-8	Asthma (childhood onset);
CESC	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg07677032	chr17:61819896	STRADA	0.45	5.9	0.34	1.12e-8	Prudent dietary pattern;
CESC	cis	rs11203032	0.831	rs2902445	chr10:90934154	A/G	cg16672925	chr10:90967113	CH25H	0.69	6.54	0.37	3.17e-10	Heart failure;
CESC	cis	rs9486719	0.843	rs2472875	chr6:96844691	G/A	cg06623918	chr6:96969491	KIAA0776	0.78	7.39	0.41	1.89e-12	Migraine;Coronary artery disease;
CESC	trans	rs17685	0.725	rs7807647	chr7:75628669	G/A	cg19862616	chr7:65841803	NCRNA00174	-0.81	-11.87	-0.59	2.41e-26	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs3785574	0.962	rs2584630	chr17:61887561	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.57	7.1	0.4	1.11e-11	Height;
CESC	cis	rs4805272	0.512	rs4805278	chr19:29336664	C/T	cg12756686	chr19:29218302	NA	0.4	5.2	0.3	3.94e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
CESC	cis	rs11997175	0.574	rs4538830	chr8:33653741	C/G	ch.8.33884649F	chr8:33765107	NA	0.66	8.38	0.46	3.14e-15	Body mass index;
CESC	cis	rs9834373	0.853	rs6797869	chr3:78495322	C/T	cg06138941	chr3:78371609	NA	-0.42	-5.18	-0.3	4.45e-7	Protein quantitative trait loci;
CESC	cis	rs2180341	0.618	rs11154398	chr6:127654281	C/A	cg27446573	chr6:127587934	RNF146	0.63	8.54	0.46	1.09e-15	Breast cancer;
CESC	cis	rs7927771	0.524	rs7939420	chr11:47723938	A/G	cg18512352	chr11:47633146	NA	-0.35	-5.46	-0.32	1.1e-7	Subjective well-being;
CESC	cis	rs4664308	0.875	rs60908067	chr2:161004983	T/G	cg03641300	chr2:160917029	PLA2R1	-0.65	-9.48	-0.5	1.49e-18	Idiopathic membranous nephropathy;
CESC	cis	rs60871478	0.545	rs35400476	chr7:795686	A/G	cg05535760	chr7:792225	HEATR2	0.85	10.38	0.54	2.06e-21	Cerebrospinal P-tau181p levels;
CESC	cis	rs7666738	0.830	rs9307218	chr4:99024885	T/C	cg03676636	chr4:99064102	C4orf37	0.34	5.18	0.3	4.4e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs5757673	1	rs5757673	chr22:39837920	T/C	cg11247378	chr22:39784982	NA	-0.66	-8.9	-0.48	9.27e-17	Post bronchodilator FEV1;
CESC	cis	rs7618915	0.547	rs2878726	chr3:52748271	C/G	cg18404041	chr3:52824283	ITIH1	-0.41	-6.82	-0.39	5.97e-11	Bipolar disorder;
CESC	cis	rs4969178	0.930	rs7208596	chr17:76396528	C/G	cg05887092	chr17:76393375	PGS1	0.58	9.22	0.49	9.9e-18	HDL cholesterol levels;
CESC	cis	rs4969178	0.930	rs12452576	chr17:76386037	A/C	cg20026190	chr17:76395443	PGS1	0.42	6.55	0.37	2.98e-10	HDL cholesterol levels;
CESC	cis	rs1046896	0.731	rs9906115	chr17:80791469	G/A	cg02711726	chr17:80685570	FN3KRP	-0.4	-5.24	-0.31	3.29e-7	Glycated hemoglobin levels;
CESC	cis	rs7772486	0.846	rs7755440	chr6:146375906	T/C	cg23711669	chr6:146136114	FBXO30	0.89	13.12	0.63	1.2e-30	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6460942	0.915	rs7809263	chr7:12450589	C/G	cg02935154	chr7:12443704	VWDE	-0.59	-6.9	-0.39	3.79e-11	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09555217	chr11:16759900	C11orf58	-0.7	-8.48	-0.46	1.58e-15	Gut microbiome composition (summer);
CESC	cis	rs3741151	0.773	rs73544716	chr11:73170061	C/T	cg17517138	chr11:73019481	ARHGEF17	1.0	7.41	0.41	1.74e-12	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs4665809	0.652	rs10779956	chr2:26405985	A/G	cg27170947	chr2:26402098	FAM59B	-0.84	-9.95	-0.52	4.91e-20	Gut microbiome composition (summer);
CESC	cis	rs7520050	0.966	rs11211230	chr1:46406767	G/T	cg03146154	chr1:46216737	IPP	-0.47	-6.1	-0.35	3.66e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs801193	1.000	rs4717319	chr7:66242593	A/G	cg10691866	chr7:65817282	TPST1	-0.32	-5.09	-0.3	6.81e-7	Aortic root size;
CESC	cis	rs6570726	0.764	rs1912023	chr6:145824278	C/A	cg05347473	chr6:146136440	FBXO30	0.59	7.59	0.42	5.36e-13	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs858239	0.600	rs10256361	chr7:23123885	C/T	cg23682824	chr7:23144976	KLHL7	0.55	7.63	0.42	4.21e-13	Cerebrospinal fluid biomarker levels;
CESC	cis	rs1552244	0.808	rs17032306	chr3:10091399	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	11.93	0.59	1.49e-26	Alzheimer's disease;
CESC	cis	rs4132509	0.649	rs12140040	chr1:243871922	G/A	cg21452805	chr1:244014465	NA	0.63	6.85	0.39	5.02e-11	RR interval (heart rate);
CESC	cis	rs4481887	1.000	rs4244174	chr1:248467956	A/G	cg00666640	chr1:248458726	OR2T12	0.39	6.36	0.36	8.71e-10	Common traits (Other);
CESC	cis	rs9300255	0.544	rs2049114	chr12:123657338	T/C	cg05973401	chr12:123451056	ABCB9	0.49	5.45	0.32	1.18e-7	Neutrophil percentage of white cells;
CESC	cis	rs7084402	0.967	rs1658436	chr10:60326910	G/A	cg07615347	chr10:60278583	BICC1	0.58	8.91	0.48	8.41e-17	Refractive error;
CESC	trans	rs11098499	0.955	rs7684942	chr4:120162201	C/T	cg25214090	chr10:38739885	LOC399744	0.64	8.53	0.46	1.16e-15	Corneal astigmatism;
CESC	cis	rs208520	0.690	rs12209753	chr6:66703951	A/G	cg07460842	chr6:66804631	NA	0.97	13.24	0.63	4.76e-31	Exhaled nitric oxide output;
CESC	cis	rs2797160	1.000	rs2747717	chr6:126008435	A/G	cg05901451	chr6:126070800	HEY2	0.45	6.51	0.37	3.77e-10	Endometrial cancer;
CESC	cis	rs870825	0.616	rs6833858	chr4:185639961	C/T	cg04058563	chr4:185651563	MLF1IP	0.64	7.15	0.4	8.53e-12	Blood protein levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01182386	chr15:75182373	MPI	0.65	7.87	0.44	8.87e-14	Gut microbiome composition (summer);
CESC	cis	rs11098499	0.954	rs28429722	chr4:120300093	G/A	cg24375607	chr4:120327624	NA	0.46	5.55	0.32	6.98e-8	Corneal astigmatism;
CESC	cis	rs763014	0.865	rs8909	chr16:633851	T/C	cg00802000	chr16:706648	WDR90	-0.39	-5.81	-0.34	1.81e-8	Height;
CESC	cis	rs2932538	0.922	rs12048528	chr1:113210534	A/C	cg22162597	chr1:113214053	CAPZA1	-0.56	-7.11	-0.4	1.1e-11	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CESC	cis	rs561341	0.783	rs512698	chr17:30292507	G/T	cg12193833	chr17:30244370	NA	-0.71	-6.56	-0.37	2.86e-10	Hip circumference adjusted for BMI;
CESC	cis	rs12134245	0.776	rs12125947	chr1:91990487	T/C	cg07090678	chr1:91966139	CDC7	0.4	5.54	0.32	7.19e-8	Breast cancer;
CESC	trans	rs12479064	0.724	rs6748200	chr2:100080895	G/A	cg20598333	chr11:3663511	ART5	0.52	6.18	0.35	2.41e-9	Chronic sinus infection;
CESC	cis	rs3820928	0.845	rs13384342	chr2:227805010	G/A	cg05526886	chr2:227700861	RHBDD1	-0.44	-5.68	-0.33	3.52e-8	Pulmonary function;
CESC	cis	rs10911251	0.546	rs2274984	chr1:183107446	A/C	ch.1.3577855R	chr1:183094577	LAMC1	-0.82	-12.53	-0.61	1.38e-28	Colorectal cancer;
CESC	trans	rs6600671	0.902	rs2222371	chr1:121289118	T/C	cg17023122	chr1:144479586	NA	-0.5	-6.57	-0.37	2.67e-10	Hip geometry;
CESC	cis	rs13191362	1.000	rs73008453	chr6:163013384	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.5	5.17	0.3	4.63e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs66573146	0.572	rs67922134	chr4:6955772	G/A	cg00086871	chr4:6988644	TBC1D14	1.05	6.88	0.39	4.25e-11	Granulocyte percentage of myeloid white cells;
CESC	cis	rs7772486	0.875	rs864390	chr6:146315035	G/T	cg05347473	chr6:146136440	FBXO30	0.52	6.98	0.39	2.32e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7481584	0.624	rs1077335	chr11:3030524	A/G	cg25174290	chr11:3078921	CARS	-0.48	-6.51	-0.37	3.85e-10	Calcium levels;
CESC	cis	rs2425143	1.000	rs13038622	chr20:34319343	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.6	5.31	0.31	2.37e-7	Blood protein levels;
CESC	cis	rs9596863	0.950	rs9568935	chr13:54397928	C/T	ch.13.53330881F	chr13:54432880	NA	0.66	5.36	0.31	1.84e-7	Epilepsy and lamotrigine-induced maculopapular eruptions;
CESC	cis	rs561341	0.882	rs2521594	chr17:30302087	C/T	cg12193833	chr17:30244370	NA	-0.7	-6.49	-0.37	4.19e-10	Hip circumference adjusted for BMI;
CESC	cis	rs3858526	0.959	rs1840179	chr11:5949148	A/G	cg05234568	chr11:5960015	NA	-0.62	-7.41	-0.41	1.74e-12	DNA methylation (variation);
CESC	cis	rs644799	0.965	rs11021305	chr11:95498269	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.66	8.67	0.47	4.33e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs8070740	0.898	rs4790770	chr17:5324893	A/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.51	6.35	0.36	9.3e-10	Menopause (age at onset);
CESC	cis	rs79839061	0.518	rs3755960	chr4:895060	G/T	cg07828340	chr4:882639	GAK	1.07	8.27	0.45	6.45e-15	Intelligence (multi-trait analysis);
CESC	cis	rs1355223	0.583	rs2956074	chr11:34864880	T/C	cg11058730	chr11:34937778	PDHX;APIP	0.83	12.66	0.61	4.91e-29	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg04025307	chr7:1156635	C7orf50	0.45	7.06	0.4	1.44e-11	Longevity;Endometriosis;
CESC	cis	rs34172651	0.517	rs12920774	chr16:24830750	T/C	cg06505273	chr16:24850292	NA	0.49	5.46	0.32	1.07e-7	Intelligence (multi-trait analysis);
CESC	cis	rs1799949	1.000	rs1135214	chr17:41292323	T/C	cg23758822	chr17:41437982	NA	1.01	15.21	0.68	5.44e-38	Menopause (age at onset);
CESC	cis	rs2243480	1.000	rs35283677	chr7:65359233	C/T	cg25894440	chr7:65020034	NA	-0.63	-5.42	-0.32	1.33e-7	Diabetic kidney disease;
CESC	cis	rs8031584	0.958	rs61997079	chr15:31238271	G/C	cg14829155	chr15:31115871	NA	-0.72	-9.72	-0.51	2.73e-19	Huntington's disease progression;
CESC	cis	rs514406	0.861	rs7524476	chr1:53240212	C/T	cg16325326	chr1:53192061	ZYG11B	-0.88	-15.06	-0.68	1.8e-37	Monocyte count;
CESC	cis	rs7666738	0.830	rs7698771	chr4:98986479	T/G	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.67e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs17362650	0.921	rs35848871	chr2:9657827	A/G	cg12832956	chr2:9616023	IAH1	-0.52	-5.09	-0.3	6.69e-7	Alcohol dependence (age at onset);
CESC	trans	rs7618501	1.000	rs6446295	chr3:49809063	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.58	8.4	0.46	2.71e-15	Intelligence (multi-trait analysis);
CESC	trans	rs17789174	0.700	rs3794679	chr16:85104588	A/C	cg23141902	chr22:39712694	RPL3;SNORD83A	-0.42	-6.36	-0.36	8.61e-10	Dysphagia;
CESC	cis	rs2985684	0.779	rs12160	chr14:50091932	T/A	cg02151108	chr14:50098012	C14orf104	-0.45	-5.85	-0.34	1.43e-8	Carotid intima media thickness;
CESC	cis	rs501120	0.810	rs474281	chr10:44749120	T/C	cg09554077	chr10:44749378	NA	0.54	6.97	0.39	2.44e-11	Coronary artery disease;Coronary heart disease;
CESC	cis	rs9911578	1.000	rs302848	chr17:56686454	C/T	cg12560992	chr17:57184187	TRIM37	0.93	15.59	0.69	2.48e-39	Intelligence (multi-trait analysis);
CESC	cis	rs748404	0.578	rs507178	chr15:43610135	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.6	8.0	0.44	3.9e-14	Lung cancer;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg13820145	chr20:26062310	FAM182A	0.39	6.36	0.36	8.89e-10	Fibrinogen levels;
CESC	cis	rs8013055	0.846	rs8003942	chr14:105971670	A/G	cg23356831	chr14:105996513	TMEM121	0.37	5.14	0.3	5.23e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
CESC	cis	rs34734847	0.898	rs696339	chr12:121169436	A/T	cg26008908	chr12:120799332	MSI1	0.34	5.23	0.31	3.53e-7	Mean corpuscular volume;
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg15441325	chr3:106959341	LOC344595;LOC100302640	-0.4	-6.24	-0.36	1.74e-9	Vertical cup-disc ratio;
CESC	cis	rs6598955	0.670	rs12733645	chr1:26540356	G/T	cg04990556	chr1:26633338	UBXN11	-0.75	-10.6	-0.55	4.14e-22	Obesity-related traits;
CESC	cis	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg03354898	chr7:1950403	MAD1L1	-0.31	-5.15	-0.3	5.11e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs9911578	1.000	rs2531732	chr17:56548420	T/A	cg05425664	chr17:57184151	TRIM37	0.5	6.94	0.39	2.97e-11	Intelligence (multi-trait analysis);
CESC	cis	rs9611565	0.659	rs4822034	chr22:41931010	T/C	cg17376030	chr22:41985996	PMM1	0.68	7.35	0.41	2.5e-12	Vitiligo;
CESC	cis	rs1788820	0.843	rs1788821	chr18:21120869	A/G	cg14672496	chr18:21087552	C18orf8	0.49	6.75	0.38	9.35e-11	Body mass index;
CESC	cis	rs9303280	0.806	rs11078927	chr17:38064405	C/T	cg20243544	chr17:37824526	PNMT	0.54	6.91	0.39	3.53e-11	Self-reported allergy;
CESC	cis	rs4595586	0.525	rs35046524	chr12:39414535	A/G	cg26384229	chr12:38710491	ALG10B	0.61	8.37	0.46	3.29e-15	Morning vs. evening chronotype;
CESC	cis	rs9291683	0.530	rs998675	chr4:9948829	A/G	cg00071950	chr4:10020882	SLC2A9	0.76	14.09	0.65	4.8e-34	Bone mineral density;
CESC	cis	rs7662987	0.517	rs1133485	chr4:100023811	T/A	cg12011299	chr4:100065546	ADH4	0.6	6.6	0.38	2.23e-10	Smoking initiation;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08837462	chr7:90893760	FZD1	0.56	6.46	0.37	4.9e-10	Gut microbiome composition (summer);
CESC	trans	rs5417	0.662	rs8067500	chr17:7172631	A/G	cg15655154	chr3:113604241	GRAMD1C	0.69	8.69	0.47	3.7e-16	Diastolic blood pressure;
CESC	cis	rs7666738	0.830	rs4699593	chr4:98980628	A/G	cg03676636	chr4:99064102	C4orf37	0.33	5.18	0.3	4.43e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11264213	0.686	rs72661655	chr1:36475401	G/T	cg27506609	chr1:36549197	TEKT2	0.69	5.65	0.33	4.09e-8	Schizophrenia;
CESC	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg02071572	chr4:1403502	NA	-0.36	-5.46	-0.32	1.1e-7	Longevity;
CESC	cis	rs6570726	0.935	rs454614	chr6:145832633	C/T	cg23711669	chr6:146136114	FBXO30	0.8	12.02	0.59	7.3e-27	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4975709	0.589	rs1466606	chr5:1865055	C/T	cg17650747	chr5:1873721	NA	0.45	6.24	0.36	1.74e-9	Cardiovascular disease risk factors;
CESC	cis	rs113835537	0.529	rs11821155	chr11:66246337	C/T	cg24851651	chr11:66362959	CCS	-0.44	-5.58	-0.32	5.98e-8	Airway imaging phenotypes;
CESC	cis	rs8180040	1.000	rs807810	chr3:47403892	G/A	cg27129171	chr3:47204927	SETD2	-0.66	-10.01	-0.52	3.3e-20	Colorectal cancer;
CESC	cis	rs13191362	0.507	rs2849525	chr6:163126652	A/C	cg06582575	chr6:163149167	PACRG;PARK2	-0.51	-5.97	-0.34	7.61e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs11098499	0.863	rs7664986	chr4:120429952	A/C	cg09307838	chr4:120376055	NA	0.93	12.74	0.62	2.6e-29	Corneal astigmatism;
CESC	cis	rs4665809	0.556	rs1560869	chr2:26417095	T/C	cg04944784	chr2:26401820	FAM59B	-0.93	-10.75	-0.55	1.28e-22	Gut microbiome composition (summer);
CESC	cis	rs703842	1.000	rs11172343	chr12:58188157	T/C	cg18357645	chr12:58087776	OS9	-0.43	-5.98	-0.34	7.09e-9	Multiple sclerosis;
CESC	cis	rs7818688	1.000	rs10111300	chr8:96025631	C/G	cg16049864	chr8:95962084	TP53INP1	0.6	5.77	0.33	2.25e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs6933660	0.666	rs9371516	chr6:151739642	G/A	cg14416726	chr6:151773293	C6orf211;RMND1	-0.55	-7.35	-0.41	2.44e-12	Menarche (age at onset);
CESC	cis	rs7605827	0.930	rs12692265	chr2:15544998	T/C	cg19274914	chr2:15703543	NA	0.37	6.65	0.38	1.72e-10	Educational attainment (years of education);
CESC	cis	rs1008375	0.966	rs3733581	chr4:17695206	C/G	cg02297831	chr4:17616191	MED28	-0.53	-6.34	-0.36	9.65e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs1707322	1.000	rs4524994	chr1:46370263	A/G	cg03146154	chr1:46216737	IPP	0.71	9.86	0.52	9.69e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs6088580	0.524	rs7269596	chr20:33229063	T/C	cg24642439	chr20:33292090	TP53INP2	-0.45	-5.24	-0.31	3.3e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs4132509	0.793	rs9428579	chr1:243690034	C/T	cg21452805	chr1:244014465	NA	0.45	5.08	0.3	7.23e-7	RR interval (heart rate);
CESC	cis	rs9467773	0.620	rs2504567	chr6:26662920	C/G	cg26531700	chr6:26746687	NA	-0.39	-5.97	-0.34	7.57e-9	Intelligence (multi-trait analysis);
CESC	cis	rs1552244	1.000	rs17032283	chr3:10081545	C/G	cg08888203	chr3:10149979	C3orf24	0.51	6.88	0.39	4.33e-11	Alzheimer's disease;
CESC	cis	rs4835473	0.897	rs55635947	chr4:144657371	G/A	cg25736465	chr4:144833511	NA	-0.32	-5.07	-0.3	7.49e-7	Immature fraction of reticulocytes;
CESC	cis	rs11098499	0.866	rs9995136	chr4:120286845	A/G	cg24375607	chr4:120327624	NA	0.42	5.19	0.3	4.19e-7	Corneal astigmatism;
CESC	trans	rs7922314	0.571	rs61865722	chr10:64755548	G/A	cg06935979	chr1:232941706	KIAA1383	-0.64	-6.12	-0.35	3.3e-9	Cutaneous psoriasis;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg03484267	chr2:207988651	KLF7	0.46	6.23	0.36	1.82e-9	Fibrinogen levels;
CESC	cis	rs62064224	0.614	rs4794923	chr17:30763009	G/A	cg18200150	chr17:30822561	MYO1D	0.42	5.45	0.32	1.15e-7	Schizophrenia;
CESC	cis	rs6547741	0.967	rs4665995	chr2:27813827	T/G	cg21248554	chr2:27665150	KRTCAP3	0.25	5.08	0.3	7.23e-7	Oral cavity cancer;
CESC	cis	rs4588572	0.643	rs10068686	chr5:77795220	C/T	cg11547950	chr5:77652471	NA	-0.44	-5.66	-0.33	3.96e-8	Triglycerides;
CESC	cis	rs6500395	1.000	rs1362636	chr16:48712779	T/C	cg04672837	chr16:48644449	N4BP1	-0.51	-6.53	-0.37	3.33e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs9300255	0.544	rs1716175	chr12:123658388	A/T	cg00376283	chr12:123451042	ABCB9	0.7	8.46	0.46	1.87e-15	Neutrophil percentage of white cells;
CESC	cis	rs8180040	0.966	rs12632132	chr3:47477019	C/T	cg27129171	chr3:47204927	SETD2	0.62	9.25	0.49	7.87e-18	Colorectal cancer;
CESC	cis	rs9611519	0.732	rs1883826	chr22:41703428	G/A	cg06634786	chr22:41940651	POLR3H	-0.5	-5.35	-0.31	1.91e-7	Neuroticism;
CESC	cis	rs709400	0.663	rs7152202	chr14:103886757	A/G	cg12935359	chr14:103987150	CKB	-0.5	-7.45	-0.42	1.28e-12	Body mass index;
CESC	cis	rs12048904	0.595	rs2295280	chr1:101342497	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.69	9.96	0.52	4.76e-20	Multiple sclerosis;
CESC	cis	rs4835473	0.831	rs4125544	chr4:144883695	G/T	cg25736465	chr4:144833511	NA	0.38	5.57	0.32	6.4e-8	Immature fraction of reticulocytes;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg07751222	chr4:102268245	PPP3CA	-0.61	-8.12	-0.45	1.77e-14	Thyroid stimulating hormone;
CESC	cis	rs6952808	0.743	rs4721097	chr7:1877503	G/T	cg04267008	chr7:1944627	MAD1L1	-0.5	-5.86	-0.34	1.34e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs9399137	0.507	rs11753673	chr6:135316476	T/C	cg22676075	chr6:135203613	NA	0.53	7.09	0.4	1.22e-11	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	cis	rs12579753	0.917	rs7132465	chr12:82205840	C/T	cg24719984	chr12:82153464	PPFIA2	-0.33	-5.04	-0.3	8.55e-7	Resting heart rate;
CESC	cis	rs7615952	0.599	rs16834938	chr3:125706046	C/T	cg02807482	chr3:125708958	NA	-0.38	-5.34	-0.31	1.98e-7	Blood pressure (smoking interaction);
CESC	cis	rs6964587	0.869	rs10276682	chr7:91486070	G/A	cg17063962	chr7:91808500	NA	-0.53	-7.23	-0.41	5.28e-12	Breast cancer;
CESC	cis	rs9522267	0.535	rs9522286	chr13:112230909	A/G	cg10483660	chr13:112241077	NA	-0.33	-5.83	-0.34	1.65e-8	Hepatitis;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg18485729	chr3:113774958	QTRTD1;KIAA1407	-0.45	-6.2	-0.36	2.18e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs7098414	0.511	rs10887828	chr10:82151470	T/C	cg00277334	chr10:82204260	NA	-0.5	-7.37	-0.41	2.23e-12	Post bronchodilator FEV1;
CESC	cis	rs12142240	0.628	rs56126529	chr1:46808860	C/T	cg00530320	chr1:46809349	NSUN4	0.6	7.98	0.44	4.48e-14	Menopause (age at onset);
CESC	cis	rs5167	0.504	rs7248162	chr19:45454686	T/C	cg09555818	chr19:45449301	APOC2	0.41	6.54	0.37	3.08e-10	Blood protein levels;
CESC	cis	rs3771570	0.901	rs56129392	chr2:242242439	C/T	cg21155796	chr2:242212141	HDLBP	0.61	5.16	0.3	4.88e-7	Prostate cancer;
CESC	cis	rs3096299	0.692	rs4785565	chr16:89515759	T/C	cg02187348	chr16:89574699	SPG7	0.64	8.83	0.48	1.42e-16	Multiple myeloma (IgH translocation);
CESC	cis	rs7635838	0.819	rs4684072	chr3:11514860	A/G	cg00170343	chr3:11313890	ATG7	0.43	5.8	0.34	1.93e-8	HDL cholesterol;
CESC	cis	rs6690583	0.623	rs1371143	chr1:85455532	C/T	cg22153463	chr1:85462885	MCOLN2	0.72	7.37	0.41	2.15e-12	Serum sulfate level;
CESC	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg02353165	chr6:42928485	GNMT	0.94	17.36	0.73	1.35e-45	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs1005277	0.563	rs2505215	chr10:38481273	A/G	cg25427524	chr10:38739819	LOC399744	-0.7	-10.24	-0.53	6.01e-21	Extrinsic epigenetic age acceleration;
CESC	cis	rs9815354	0.638	rs56008529	chr3:42026755	A/T	cg03022575	chr3:42003672	ULK4	0.75	6.64	0.38	1.72e-10	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs9875589	0.509	rs2731332	chr3:14110083	G/C	cg19554555	chr3:13937349	NA	-0.45	-5.84	-0.34	1.54e-8	Ovarian reserve;
CESC	cis	rs7000551	0.505	rs4872499	chr8:22293306	A/G	cg12081754	chr8:22256438	SLC39A14	-0.81	-9.79	-0.52	1.61e-19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CESC	cis	rs1218582	0.741	rs7544528	chr1:154844585	C/T	cg06221963	chr1:154839813	KCNN3	-0.73	-12.88	-0.62	8.02e-30	Prostate cancer;
CESC	cis	rs1348850	0.526	rs4243389	chr2:178379783	G/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.68	6.17	0.35	2.52e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs3780486	0.505	rs1411609	chr9:33137303	C/T	cg13443165	chr9:33130375	B4GALT1	0.47	7.15	0.4	8.29e-12	IgG glycosylation;
CESC	cis	rs875971	0.520	rs12666485	chr7:65625122	T/C	cg11764359	chr7:65958608	NA	0.79	9.51	0.5	1.18e-18	Aortic root size;
CESC	cis	rs7945705	0.935	rs2653567	chr11:8889630	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.49	-8.42	-0.46	2.39e-15	Hemoglobin concentration;
CESC	cis	rs1799949	0.965	rs8067269	chr17:41235799	C/T	cg23758822	chr17:41437982	NA	0.96	16.32	0.71	6.62e-42	Menopause (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02951695	chr10:134400351	INPP5A	-0.58	-6.08	-0.35	4.14e-9	Gut microbiome composition (summer);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg25844211	chr1:229761456	URB2;TAF5L	-0.51	-6.17	-0.35	2.56e-9	Ulcerative colitis;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg18539546	chr1:174992693	MRPS14	-0.49	-6.45	-0.37	5.33e-10	Fibrinogen levels;
CESC	cis	rs7756236	0.521	rs9394368	chr6:36630525	C/G	cg08179530	chr6:36648295	CDKN1A	-0.63	-9.27	-0.49	6.86e-18	QRS duration;
CESC	trans	rs9325144	0.671	rs7485963	chr12:38768254	C/G	cg23762105	chr12:34175262	ALG10	0.48	6.27	0.36	1.49e-9	Morning vs. evening chronotype;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15674175	chr20:278095	ZCCHC3	0.55	6.21	0.36	2.08e-9	Gut microbiome composition (summer);
CESC	cis	rs711245	0.572	rs3821150	chr2:36795233	G/A	cg09467607	chr2:36825704	FEZ2	0.56	9.1	0.49	2.3e-17	Height;
CESC	cis	rs9291683	0.609	rs13141233	chr4:10028729	T/C	cg11266682	chr4:10021025	SLC2A9	0.7	14.15	0.66	2.99e-34	Bone mineral density;
CESC	cis	rs7552404	0.924	rs1146588	chr1:76229787	C/G	cg10523679	chr1:76189770	ACADM	0.76	10.18	0.53	9.1e-21	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs7666738	0.830	rs35560671	chr4:99069095	G/A	cg05340658	chr4:99064831	C4orf37	0.83	12.82	0.62	1.36e-29	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4862750	0.874	rs6822062	chr4:187895553	T/C	cg06074448	chr4:187884817	NA	-0.38	-5.49	-0.32	9.35e-8	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1552244	1.000	rs34179822	chr3:10140017	A/G	cg08888203	chr3:10149979	C3orf24	0.46	6.01	0.35	6.24e-9	Alzheimer's disease;
CESC	cis	rs9611519	0.780	rs9611546	chr22:41698542	C/G	cg06481639	chr22:41940642	POLR3H	-0.53	-5.85	-0.34	1.41e-8	Neuroticism;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00120998	chr16:67881473	CENPT;NUTF2	0.72	8.63	0.47	5.88e-16	Gut microbiome composition (summer);
CESC	cis	rs7940866	0.903	rs7942900	chr11:130839244	G/A	cg12179176	chr11:130786555	SNX19	0.62	8.78	0.47	2.05e-16	Schizophrenia;
CESC	cis	rs11077998	0.901	rs4789798	chr17:80531643	C/G	cg10255544	chr17:80519551	FOXK2	0.55	8.71	0.47	3.34e-16	Reticulocyte fraction of red cells;
CESC	cis	rs2576037	0.526	rs2571026	chr18:44561795	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.42	-6.95	-0.39	2.78e-11	Personality dimensions;
CESC	cis	rs8077577	0.747	rs57697650	chr17:18224695	G/A	cg16794390	chr17:18148240	FLII	0.4	6.34	0.36	9.98e-10	Obesity-related traits;
CESC	cis	rs801193	0.844	rs732465	chr7:65998450	T/C	cg06456125	chr7:65229604	NA	0.39	5.37	0.31	1.75e-7	Aortic root size;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg02607779	chr2:208030673	KLF7	-0.48	-6.99	-0.39	2.26e-11	Fibrinogen levels;
CESC	cis	rs116988415	0.584	rs78748209	chr14:65255676	C/T	cg25083366	chr14:65239357	SPTB	0.71	5.36	0.31	1.8e-7	Daytime sleep phenotypes;
CESC	cis	rs4713675	0.584	rs3227	chr6:33662295	G/C	cg15676125	chr6:33679581	C6orf125	0.34	5.2	0.3	3.95e-7	Plateletcrit;
CESC	cis	rs10504229	0.679	rs12375285	chr8:58040084	G/A	cg24829409	chr8:58192753	C8orf71	-0.49	-5.99	-0.35	6.9e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs11971779	0.941	rs4732368	chr7:139034207	A/C	cg07862535	chr7:139043722	LUC7L2	0.54	5.56	0.32	6.42e-8	Diisocyanate-induced asthma;
CESC	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg05457628	chr5:178986728	RUFY1	-0.53	-8.08	-0.44	2.23e-14	Lung cancer;
CESC	cis	rs11650494	0.710	rs77653195	chr17:47468868	A/T	cg08112188	chr17:47440006	ZNF652	1.19	8.04	0.44	3.04e-14	Prostate cancer;
CESC	cis	rs1499614	1.000	rs1638731	chr7:66144679	C/T	cg13147721	chr7:65941812	NA	-0.96	-9.03	-0.49	3.58e-17	Gout;
CESC	cis	rs4268898	0.662	rs17789375	chr2:24502554	G/T	cg20701182	chr2:24300061	SF3B14	0.6	6.75	0.38	9.29e-11	Asthma;
CESC	cis	rs11155671	0.530	rs2342770	chr6:150216685	C/T	cg09699651	chr6:150184138	LRP11	0.54	7.43	0.42	1.48e-12	Testicular germ cell tumor;
CESC	cis	rs7605378	0.567	rs717915	chr2:200714766	C/T	cg23649088	chr2:200775458	C2orf69	0.71	8.87	0.48	1.1e-16	Osteoporosis;
CESC	cis	rs9905704	0.647	rs11650809	chr17:56972741	A/G	cg12560992	chr17:57184187	TRIM37	0.62	7.63	0.42	4.12e-13	Testicular germ cell tumor;
CESC	cis	rs17666538	0.539	rs1703925	chr8:608279	A/G	cg02524346	chr8:600233	NA	0.85	6.05	0.35	4.93e-9	IgG glycosylation;
CESC	cis	rs4689388	0.610	rs4328980	chr4:6281756	A/G	cg25554036	chr4:6271136	WFS1	0.5	6.95	0.39	2.88e-11	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs6860806	0.507	rs582490	chr5:131710095	G/A	cg07395648	chr5:131743802	NA	0.41	5.35	0.31	1.86e-7	Breast cancer;
CESC	cis	rs8014204	0.570	rs7147721	chr14:75186010	A/G	cg08847533	chr14:75593920	NEK9	0.49	6.18	0.36	2.38e-9	Caffeine consumption;
CESC	cis	rs9790314	0.905	rs1154701	chr3:161008025	T/A	cg04691961	chr3:161091175	C3orf57	-0.41	-5.37	-0.31	1.7e-7	Morning vs. evening chronotype;
CESC	cis	rs12618769	0.520	rs4851135	chr2:99050705	T/A	cg10123293	chr2:99228465	UNC50	0.41	5.51	0.32	8.4e-8	Bipolar disorder;
CESC	cis	rs2576037	0.526	rs2576051	chr18:44557884	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.55	7.45	0.42	1.29e-12	Personality dimensions;
CESC	cis	rs4253772	0.592	rs1807600	chr22:46644640	A/G	cg09491104	chr22:46646882	C22orf40	-0.56	-8.7	-0.47	3.55e-16	LDL cholesterol;Cholesterol, total;
CESC	cis	rs2050392	0.792	rs9338188	chr10:30721963	G/C	cg25182066	chr10:30743637	MAP3K8	-0.44	-5.96	-0.34	7.81e-9	Inflammatory bowel disease;
CESC	cis	rs372883	0.648	rs15092	chr21:30718201	G/A	cg24692254	chr21:30365293	RNF160	-0.54	-6.71	-0.38	1.2e-10	Pancreatic cancer;
CESC	cis	rs4789693	0.938	rs8078595	chr17:80426988	G/T	cg04308225	chr17:80449738	NA	0.45	5.26	0.31	3.02e-7	Glucocorticoid-induced osteonecrosis;
CESC	cis	rs6831352	0.918	rs28987097	chr4:100049579	C/T	cg12011299	chr4:100065546	ADH4	-0.59	-6.52	-0.37	3.62e-10	Alcohol dependence;
CESC	cis	rs11098499	0.863	rs11947234	chr4:120474859	A/G	cg24375607	chr4:120327624	NA	0.45	5.54	0.32	7.33e-8	Corneal astigmatism;
CESC	cis	rs17641971	0.619	rs6983929	chr8:49984896	T/C	cg00325661	chr8:49890786	NA	0.36	5.13	0.3	5.72e-7	Blood metabolite levels;
CESC	cis	rs1348850	0.567	rs3821006	chr2:178537694	G/A	cg22681709	chr2:178499509	PDE11A	-0.48	-7.68	-0.43	3e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs6741892	0.536	rs7590835	chr2:38893950	A/G	cg05275752	chr2:38892887	GALM	0.47	6.67	0.38	1.5e-10	5-HTT brain serotonin transporter levels;
CESC	cis	rs2836974	0.568	rs2836969	chr21:40648265	G/A	cg11644478	chr21:40555479	PSMG1	-0.84	-12.62	-0.61	6.4e-29	Cognitive function;
CESC	cis	rs35110281	0.600	rs914198	chr21:45117456	A/C	cg01579765	chr21:45077557	HSF2BP	-0.51	-8.35	-0.46	3.74e-15	Mean corpuscular volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13099829	chr1:2237991	SKI	-0.57	-6.49	-0.37	4.12e-10	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09985698	chr21:45759020	C21orf2	0.61	6.76	0.38	9.01e-11	Gut microbiome composition (summer);
CESC	cis	rs2637266	0.807	rs2256413	chr10:78315334	C/T	cg18941641	chr10:78392320	NA	-0.31	-5.2	-0.3	3.93e-7	Pulmonary function;
CESC	cis	rs807669	0.835	rs698423	chr22:19197896	T/C	cg02655711	chr22:19163373	SLC25A1	0.96	14.09	0.65	5.02e-34	Metabolite levels;
CESC	cis	rs3857536	0.813	rs2040591	chr6:66945915	A/G	cg07460842	chr6:66804631	NA	-0.42	-5.29	-0.31	2.55e-7	Blood trace element (Cu levels);
CESC	cis	rs4665809	0.938	rs6742226	chr2:26342537	A/G	cg08470875	chr2:26401718	FAM59B	-0.46	-5.05	-0.3	8.16e-7	Gut microbiome composition (summer);
CESC	cis	rs7618501	1.000	rs6785549	chr3:49736565	G/A	cg24308560	chr3:49941425	MST1R	0.5	6.86	0.39	4.8e-11	Intelligence (multi-trait analysis);
CESC	cis	rs6800768	0.633	rs59715267	chr3:24100414	C/A	cg10674438	chr3:24145617	LOC152024	-0.4	-5.32	-0.31	2.23e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs9788333	0.888	rs35880230	chr13:21885972	A/G	cg21970626	chr13:21893289	NA	-0.42	-6.09	-0.35	3.85e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg07157506	chr18:12883603	PTPN2	-0.49	-7.45	-0.42	1.32e-12	Vertical cup-disc ratio;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg21755440	chr3:20227801	SGOL1	-0.48	-6.41	-0.37	6.47e-10	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs35123781	0.696	rs904612	chr5:139070952	G/A	cg10513866	chr5:139070639	NA	0.43	6.12	0.35	3.33e-9	Schizophrenia;
CESC	cis	rs561341	0.882	rs28649357	chr17:30367190	A/G	cg00745463	chr17:30367425	LRRC37B	-0.59	-5.96	-0.34	7.98e-9	Hip circumference adjusted for BMI;
CESC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg04590956	chr2:70057467	GMCL1	0.55	7.02	0.4	1.84e-11	Tetralogy of Fallot;
CESC	cis	rs9457247	1.000	rs408918	chr6:167399282	G/T	cg23791538	chr6:167370224	RNASET2	-0.57	-7.91	-0.44	7.09e-14	Crohn's disease;
CESC	cis	rs2380220	0.872	rs4546494	chr6:95990626	A/C	cg04719120	chr6:96025338	MANEA	0.55	5.52	0.32	7.89e-8	Behavioural disinhibition (generation interaction);
CESC	cis	rs9916302	0.904	rs4239222	chr17:37696235	A/C	cg07936489	chr17:37558343	FBXL20	0.77	10.56	0.54	5.54e-22	Glomerular filtration rate (creatinine);
CESC	cis	rs116095464	0.558	rs10462754	chr5:246669	T/C	cg22496380	chr5:211416	CCDC127	-0.75	-8.7	-0.47	3.49e-16	Breast cancer;
CESC	cis	rs9733	0.569	rs11588404	chr1:150688529	C/A	cg18016565	chr1:150552671	MCL1	0.35	5.36	0.31	1.86e-7	Tonsillectomy;
CESC	cis	rs6500602	0.648	rs7702	chr16:4560929	G/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.41	5.82	0.34	1.69e-8	Schizophrenia;
CESC	trans	rs12599106	0.680	rs34728702	chr16:34896584	A/G	cg18110333	chr6:292329	DUSP22	-0.74	-9.66	-0.51	4.11e-19	Menopause (age at onset);
CESC	cis	rs10911232	0.507	rs4652766	chr1:182994336	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.84	13.19	0.63	6.74e-31	Hypertriglyceridemia;
CESC	cis	rs9902453	0.817	rs1038089	chr17:28178724	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	8.3	0.45	5.54e-15	Coffee consumption (cups per day);
CESC	cis	rs35110281	0.633	rs4818860	chr21:45119617	C/T	cg01579765	chr21:45077557	HSF2BP	-0.54	-9.0	-0.48	4.6e-17	Mean corpuscular volume;
CESC	cis	rs684232	0.543	rs4968095	chr17:507539	A/G	cg15660573	chr17:549704	VPS53	-0.78	-11.44	-0.58	6.66e-25	Prostate cancer;
CESC	cis	rs2839186	0.814	rs2839167	chr21:47661587	A/G	cg13126279	chr21:47581558	C21orf56	-0.47	-6.46	-0.37	4.99e-10	Testicular germ cell tumor;
CESC	cis	rs7851660	0.839	rs2417575	chr9:100628642	G/A	cg13688889	chr9:100608707	NA	-0.63	-8.87	-0.48	1.09e-16	Strep throat;
CESC	cis	rs11785400	1.000	rs3802232	chr8:143746701	A/G	cg24634471	chr8:143751801	JRK	0.47	6.21	0.36	2e-9	Schizophrenia;
CESC	cis	rs2836950	0.545	rs11701805	chr21:40618683	T/C	cg11890956	chr21:40555474	PSMG1	-0.64	-8.71	-0.47	3.25e-16	Menarche (age at onset);
CESC	cis	rs7845219	0.539	rs13271644	chr8:95853948	A/G	cg16049864	chr8:95962084	TP53INP1	-0.49	-7.56	-0.42	6.76e-13	Type 2 diabetes;
CESC	cis	rs35306767	0.716	rs34487581	chr10:897201	G/A	cg26597838	chr10:835615	NA	1.18	11.34	0.57	1.52e-24	Eosinophil percentage of granulocytes;
CESC	cis	rs9815354	1.000	rs9854833	chr3:41775577	C/T	cg03022575	chr3:42003672	ULK4	0.53	5.21	0.3	3.81e-7	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs12950390	0.853	rs11079790	chr17:45853626	G/A	cg00777063	chr17:45855553	NA	-0.39	-5.78	-0.33	2.05e-8	IgG glycosylation;
CESC	cis	rs801193	0.967	rs1110414	chr7:66205582	A/G	cg11764359	chr7:65958608	NA	0.69	9.1	0.49	2.27e-17	Aortic root size;
CESC	cis	rs9733	0.596	rs72702570	chr1:150688196	C/T	cg04414720	chr1:150670196	GOLPH3L	0.62	8.86	0.48	1.21e-16	Tonsillectomy;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg22728534	chr2:87034800	CD8A	-0.45	-6.01	-0.35	6.2e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs9399135	0.967	rs10872427	chr6:135353452	T/C	cg22676075	chr6:135203613	NA	0.52	7.38	0.41	1.99e-12	Red blood cell count;
CESC	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.52	-6.57	-0.37	2.71e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs9916302	0.904	rs7501488	chr17:37576417	T/G	cg07936489	chr17:37558343	FBXL20	-0.8	-11.36	-0.57	1.21e-24	Glomerular filtration rate (creatinine);
CESC	cis	rs7818688	0.697	rs77055525	chr8:95980583	G/A	cg16049864	chr8:95962084	TP53INP1	0.55	5.55	0.32	6.92e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs9487051	0.714	rs9386797	chr6:109632520	C/A	cg12927641	chr6:109611667	NA	-0.37	-5.51	-0.32	8.68e-8	Reticulocyte fraction of red cells;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg17487170	chr5:133451259	TCF7	0.44	6.42	0.37	6.37e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs8180040	0.726	rs10461018	chr3:46995242	C/T	cg27129171	chr3:47204927	SETD2	-0.62	-8.78	-0.47	2.12e-16	Colorectal cancer;
CESC	cis	rs1670533	1.000	rs7679432	chr4:1050521	G/A	cg04106633	chr4:1044584	NA	0.4	5.09	0.3	6.77e-7	Recombination rate (females);
CESC	trans	rs9987353	0.840	rs329994	chr8:9123233	A/G	cg07461501	chr17:79650226	HGS;ARL16	-0.42	-6.22	-0.36	1.88e-9	Recombination measurement;
CESC	cis	rs7615952	0.576	rs2276726	chr3:125826287	C/G	cg15145296	chr3:125709740	NA	-0.55	-6.33	-0.36	1.05e-9	Blood pressure (smoking interaction);
CESC	cis	rs1577917	0.958	rs11755864	chr6:86691791	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.45	-5.95	-0.34	8.33e-9	Response to antipsychotic treatment;
CESC	cis	rs2070729	0.523	rs743562	chr5:131872383	C/T	cg21138405	chr5:131827807	IRF1	-0.32	-5.4	-0.31	1.49e-7	Platelet count;
CESC	cis	rs902774	0.554	rs4919749	chr12:53358034	C/T	cg14581129	chr12:53358946	NA	-0.5	-6.78	-0.38	7.91e-11	Prostate cancer;
CESC	trans	rs61931739	0.500	rs11519398	chr12:34473553	C/T	cg26384229	chr12:38710491	ALG10B	0.71	10.5	0.54	8.77e-22	Morning vs. evening chronotype;
CESC	cis	rs1862618	0.671	rs2591958	chr5:56239369	C/G	cg22800045	chr5:56110881	MAP3K1	-0.6	-7.71	-0.43	2.48e-13	Initial pursuit acceleration;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg19046697	chr5:92915581	FLJ42709	-0.5	-7.24	-0.41	4.93e-12	Gut microbiota (bacterial taxa);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05985655	chr5:16616805	FAM134B	0.63	7.58	0.42	6e-13	Gut microbiome composition (summer);
CESC	cis	rs2576037	0.526	rs1539878	chr18:44523004	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.69	10.92	0.56	3.64e-23	Personality dimensions;
CESC	cis	rs56104184	0.775	rs117016425	chr19:49400216	C/T	cg21252483	chr19:49399788	TULP2	-0.52	-5.69	-0.33	3.36e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	cis	rs36051895	0.659	rs10283730	chr9:5073289	G/A	cg02405213	chr9:5042618	JAK2	-0.5	-6.07	-0.35	4.51e-9	Pediatric autoimmune diseases;
CESC	cis	rs4950322	0.570	rs72692904	chr1:146773136	T/A	cg22381352	chr1:146742008	CHD1L	-0.46	-5.05	-0.3	8.32e-7	Protein quantitative trait loci;
CESC	cis	rs6732160	0.613	rs6546804	chr2:73385919	G/A	cg01422370	chr2:73384389	NA	0.56	8.74	0.47	2.67e-16	Intelligence (multi-trait analysis);
CESC	cis	rs3862435	0.518	rs2444061	chr15:90909439	T/G	cg22089800	chr15:90895588	ZNF774	0.53	5.8	0.34	1.88e-8	Response to exercise (triglyceride level interaction);
CESC	cis	rs523522	0.962	rs3213565	chr12:120992401	C/T	cg27279351	chr12:120934652	DYNLL1	0.68	8.7	0.47	3.47e-16	High light scatter reticulocyte count;
CESC	trans	rs61931739	0.534	rs10844732	chr12:34037104	A/C	cg26384229	chr12:38710491	ALG10B	0.6	8.41	0.46	2.5e-15	Morning vs. evening chronotype;
CESC	cis	rs6912958	0.559	rs499373	chr6:88042062	A/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.34	5.53	0.32	7.5e-8	Monocyte percentage of white cells;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg11832990	chr15:78832690	PSMA4	-0.54	-6.45	-0.37	5.38e-10	Ulcerative colitis;
CESC	trans	rs7615952	0.641	rs2365019	chr3:125808135	T/C	cg07211511	chr3:129823064	LOC729375	-0.56	-6.22	-0.36	1.92e-9	Blood pressure (smoking interaction);
CESC	cis	rs367943	0.712	rs10035686	chr5:112683357	C/T	cg12552261	chr5:112820674	MCC	0.41	5.3	0.31	2.49e-7	Type 2 diabetes;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg14095983	chr9:71737204	TJP2	-0.48	-6.25	-0.36	1.65e-9	Ulcerative colitis;
CESC	cis	rs72781680	0.898	rs113027486	chr2:24098371	G/A	cg08917208	chr2:24149416	ATAD2B	0.91	8.38	0.46	3.17e-15	Lymphocyte counts;
CESC	cis	rs7927592	0.763	rs624003	chr11:68231240	C/T	cg01657329	chr11:68192670	LRP5	-0.47	-6.09	-0.35	3.93e-9	Total body bone mineral density;
CESC	cis	rs801193	0.844	rs732465	chr7:65998450	T/C	cg19163074	chr7:65112434	INTS4L2	-0.43	-5.51	-0.32	8.54e-8	Aortic root size;
CESC	cis	rs3733585	0.673	rs4312757	chr4:9956145	T/A	cg11266682	chr4:10021025	SLC2A9	-0.59	-11.16	-0.57	5.9e-24	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs9987353	0.566	rs34389718	chr8:9065525	A/G	cg06636001	chr8:8085503	FLJ10661	-0.59	-7.16	-0.4	7.73e-12	Recombination measurement;
CESC	cis	rs2576037	0.583	rs1465722	chr18:44564499	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.47	6.35	0.36	9.1e-10	Personality dimensions;
CESC	cis	rs13064411	0.696	rs2399479	chr3:113227050	G/A	cg18753928	chr3:113234510	CCDC52	-0.47	-5.44	-0.32	1.21e-7	Response to simvastatin treatment (PCSK9 protein level change);
CESC	trans	rs12542260	0.871	rs7836802	chr8:125473730	C/T	cg09438698	chr12:133365205	GOLGA3	-0.49	-6.44	-0.37	5.5e-10	Colonoscopy-negative controls vs population controls;
CESC	cis	rs651907	0.557	rs13099674	chr3:101489629	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.5	6.73	0.38	1.05e-10	Colorectal cancer;
CESC	trans	rs35110281	0.748	rs9981460	chr21:45030965	T/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.54	7.11	0.4	1.1e-11	Mean corpuscular volume;
CESC	cis	rs4481887	0.927	rs4558008	chr1:248477641	C/T	cg00666640	chr1:248458726	OR2T12	0.35	5.79	0.34	1.95e-8	Common traits (Other);
CESC	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg02725872	chr8:58115012	NA	-0.42	-5.85	-0.34	1.48e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs10504229	0.638	rs7826839	chr8:58132075	G/T	cg21724239	chr8:58056113	NA	0.58	5.95	0.34	8.29e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs12042938	0.507	rs1655301	chr1:231731730	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.59	-8.53	-0.46	1.16e-15	Neuranatomic and neurocognitive phenotypes;
CESC	cis	rs9916302	0.610	rs11078902	chr17:37631883	C/G	cg20243544	chr17:37824526	PNMT	0.51	6.44	0.37	5.65e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs9494145	0.680	rs9376092	chr6:135427144	A/C	cg22676075	chr6:135203613	NA	-0.41	-5.12	-0.3	5.97e-7	Mean platelet volume;Platelet count;Fetal hemoglobin levels in sickle cell anemia;Red blood cell traits;
CESC	cis	rs7811142	1.000	rs11763414	chr7:100016844	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.11	11.0	0.56	1.99e-23	Platelet count;
CESC	cis	rs66573146	0.831	rs56300156	chr4:6990813	G/C	cg00086871	chr4:6988644	TBC1D14	1.18	7.59	0.42	5.45e-13	Granulocyte percentage of myeloid white cells;
CESC	cis	rs868036	0.681	rs28688285	chr15:68110297	T/C	cg24579218	chr15:68104479	NA	-0.36	-5.07	-0.3	7.39e-7	Restless legs syndrome;
CESC	cis	rs7618915	0.547	rs62253703	chr3:52632357	T/C	cg18099408	chr3:52552593	STAB1	-0.31	-5.16	-0.3	4.75e-7	Bipolar disorder;
CESC	cis	rs2294693	0.947	rs736795	chr6:40998141	G/A	cg14769373	chr6:40998127	UNC5CL	-0.47	-6.6	-0.38	2.28e-10	Gastric cancer;Non-cardia gastric cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05290695	chr8:119634602	SAMD12	-0.58	-7.0	-0.4	2.15e-11	Gut microbiome composition (summer);
CESC	cis	rs9905704	0.671	rs28709536	chr17:57008912	C/A	cg12560992	chr17:57184187	TRIM37	0.62	7.8	0.43	1.47e-13	Testicular germ cell tumor;
CESC	cis	rs11696501	0.688	rs6104247	chr20:44244938	C/T	cg11783356	chr20:44313418	WFDC10B	-0.35	-5.45	-0.32	1.15e-7	Brain structure;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03474219	chr11:64072691	ESRRA	0.59	7.21	0.4	5.83e-12	Gut microbiome composition (summer);
CESC	trans	rs7618501	0.633	rs9814664	chr3:50078541	C/T	cg21659725	chr3:3221576	CRBN	-0.49	-6.92	-0.39	3.38e-11	Intelligence (multi-trait analysis);
CESC	cis	rs10492096	0.947	rs10849482	chr12:6635274	G/A	cg13857086	chr12:6580257	VAMP1	0.56	5.44	0.32	1.23e-7	Hip geometry;
CESC	cis	rs10129255	0.500	rs8011115	chr14:107194530	T/C	cg07958169	chr14:107095056	NA	-0.49	-7.38	-0.41	2.01e-12	Kawasaki disease;
CESC	cis	rs6570726	0.935	rs409121	chr6:145839793	G/A	cg05347473	chr6:146136440	FBXO30	0.49	6.74	0.38	1e-10	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25765325	chr7:25164994	CYCS	0.53	6.08	0.35	4.25e-9	Gut microbiome composition (summer);
CESC	cis	rs7927771	0.524	rs2170815	chr11:47875910	T/C	cg18512352	chr11:47633146	NA	0.35	5.38	0.31	1.66e-7	Subjective well-being;
CESC	cis	rs11792861	0.781	rs72607159	chr9:111764270	C/T	cg13535736	chr9:111863775	C9orf5	-0.46	-6.06	-0.35	4.65e-9	Menarche (age at onset);
CESC	cis	rs1568889	1.000	rs34667360	chr11:28055650	T/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.7	8.15	0.45	1.44e-14	Bipolar disorder;
CESC	cis	rs11098499	0.738	rs72918577	chr4:120326701	G/A	cg09307838	chr4:120376055	NA	0.95	13.83	0.65	4.08e-33	Corneal astigmatism;
CESC	cis	rs6089584	0.816	rs4134440	chr20:60624296	A/G	cg24733560	chr20:60626293	TAF4	0.46	6.57	0.37	2.67e-10	Body mass index;
CESC	cis	rs6724607	1.000	rs11680758	chr2:191446268	T/G	cg10560079	chr2:191398806	TMEM194B	0.47	6.77	0.38	8.47e-11	Pulse pressure;
CESC	trans	rs629535	0.821	rs650267	chr8:70029160	C/T	cg21567404	chr3:27674614	NA	0.93	11.25	0.57	2.83e-24	Dupuytren's disease;
CESC	cis	rs12497850	0.931	rs4974080	chr3:49030828	A/C	cg02487422	chr3:49467188	NICN1	0.44	5.56	0.32	6.42e-8	Parkinson's disease;
CESC	cis	rs28386778	0.701	rs2727337	chr17:61991966	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.67	-9.19	-0.49	1.22e-17	Prudent dietary pattern;
CESC	cis	rs7772486	0.790	rs9403755	chr6:146231470	C/A	cg23711669	chr6:146136114	FBXO30	-0.92	-13.36	-0.63	1.78e-31	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs453301	0.571	rs2929305	chr8:9085217	G/A	cg17143192	chr8:8559678	CLDN23	-0.47	-5.8	-0.34	1.88e-8	Joint mobility (Beighton score);
CESC	cis	rs854765	0.505	rs2955358	chr17:17946623	A/G	cg04398451	chr17:18023971	MYO15A	0.7	10.16	0.53	1.07e-20	Total body bone mineral density;
CESC	cis	rs4835473	0.618	rs12499907	chr4:144920901	A/C	cg25736465	chr4:144833511	NA	-0.45	-6.79	-0.38	7.53e-11	Immature fraction of reticulocytes;
CESC	cis	rs763014	0.931	rs7191939	chr16:630089	C/T	cg00802000	chr16:706648	WDR90	-0.42	-6.37	-0.36	8.38e-10	Height;
CESC	cis	rs733592	0.507	rs7299704	chr12:48444488	A/G	cg24011408	chr12:48396354	COL2A1	0.49	8.09	0.45	2.13e-14	Plateletcrit;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg16025584	chr9:139887217	C9orf142	-0.47	-6.33	-0.36	1.05e-9	Height;
CESC	cis	rs11048434	0.698	rs1805784	chr12:9065172	G/T	cg04155231	chr12:9217510	LOC144571	0.33	5.34	0.31	2.03e-7	Sjögren's syndrome;
CESC	cis	rs35306767	0.807	rs34527494	chr10:935192	T/C	cg20503657	chr10:835505	NA	1.07	9.91	0.52	6.79e-20	Eosinophil percentage of granulocytes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12598048	chr15:22892705	CYFIP1	0.52	6.09	0.35	3.92e-9	Gut microbiome composition (summer);
CESC	cis	rs5758511	0.508	rs58099562	chr22:42453772	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.55	7.48	0.42	1.11e-12	Birth weight;
CESC	cis	rs921968	0.643	rs611203	chr2:219472325	G/A	cg02176678	chr2:219576539	TTLL4	0.39	6.66	0.38	1.56e-10	Mean corpuscular hemoglobin concentration;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg24342864	chr17:17184608	COPS3	-0.45	-6.52	-0.37	3.59e-10	Asthma;
CESC	cis	rs7312933	0.531	rs1796380	chr12:42791543	T/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.5	-6.76	-0.38	8.51e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs2075371	1.000	rs2598288	chr7:133977304	A/T	cg11752832	chr7:134001865	SLC35B4	0.54	7.09	0.4	1.19e-11	Mean platelet volume;
CESC	cis	rs8044868	0.586	rs7188962	chr16:72098962	A/G	cg16558253	chr16:72132732	DHX38	-0.41	-6.44	-0.37	5.61e-10	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CESC	cis	rs6502050	0.871	rs8066137	chr17:80074316	T/C	cg23985595	chr17:80112537	CCDC57	0.41	6.42	0.37	6.41e-10	Life satisfaction;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18091465	chr15:82551086	EFTUD1	-0.57	-6.62	-0.38	2e-10	Gut microbiome composition (summer);
CESC	cis	rs6752107	0.967	rs56227616	chr2:234157741	T/C	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.38	5.75	0.33	2.4e-8	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs9399135	0.636	rs4646871	chr6:135265617	A/G	cg22676075	chr6:135203613	NA	-0.49	-6.94	-0.39	2.92e-11	Red blood cell count;
CESC	cis	rs854765	0.583	rs7222480	chr17:17818817	G/T	cg04398451	chr17:18023971	MYO15A	-0.65	-9.11	-0.49	2.08e-17	Total body bone mineral density;
CESC	cis	rs3785574	0.962	rs4480868	chr17:61788859	C/T	cg06420487	chr17:61919686	SMARCD2	0.44	5.3	0.31	2.48e-7	Height;
CESC	cis	rs2230307	0.656	rs1395332	chr1:100503993	A/C	cg24955406	chr1:100503596	HIAT1	0.55	5.42	0.32	1.31e-7	Carotid intima media thickness;
CESC	cis	rs2303759	0.918	rs7251704	chr19:49890873	T/G	cg24324837	chr19:49891574	CCDC155	0.52	6.07	0.35	4.32e-9	Multiple sclerosis;
CESC	cis	rs11958404	0.860	rs6885815	chr5:157437253	C/T	cg05962755	chr5:157440814	NA	0.62	6.66	0.38	1.57e-10	IgG glycosylation;
CESC	cis	rs16854884	0.632	rs1910691	chr3:143656905	G/A	cg06585982	chr3:143692056	C3orf58	0.56	7.59	0.42	5.61e-13	Economic and political preferences (feminism/equality);
CESC	cis	rs801193	0.935	rs2659899	chr7:66186721	A/G	cg18876405	chr7:65276391	NA	0.53	7.06	0.4	1.42e-11	Aortic root size;
CESC	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.09	21.48	0.8	5.66e-60	Prudent dietary pattern;
CESC	cis	rs752010	0.967	rs6703597	chr1:42097904	C/T	cg06885757	chr1:42089581	HIVEP3	0.5	8.06	0.44	2.57e-14	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs9486719	0.857	rs3798293	chr6:97033370	A/G	cg06623918	chr6:96969491	KIAA0776	-0.83	-8.97	-0.48	5.38e-17	Migraine;Coronary artery disease;
CESC	cis	rs3806843	0.966	rs11953833	chr5:140155123	T/A	cg16179182	chr5:140090404	VTRNA1-1	-0.38	-5.03	-0.3	9.03e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs965469	0.779	rs6515810	chr20:3370861	T/C	cg25506879	chr20:3388711	C20orf194	-0.49	-5.28	-0.31	2.63e-7	IFN-related cytopenia;
CESC	cis	rs1152591	0.811	rs1255984	chr14:64654431	C/T	cg23250157	chr14:64679961	SYNE2	-0.54	-7.78	-0.43	1.67e-13	Atrial fibrillation;
CESC	cis	rs12142240	0.698	rs66575205	chr1:46814092	T/G	cg10495392	chr1:46806563	NSUN4	0.57	6.28	0.36	1.39e-9	Menopause (age at onset);
CESC	cis	rs28386778	0.830	rs7209321	chr17:61855668	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	22.15	0.81	2.97e-62	Prudent dietary pattern;
CESC	cis	rs72627123	0.867	rs77321049	chr14:74455219	G/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.79	5.35	0.31	1.9e-7	Morning vs. evening chronotype;
CESC	cis	rs6674176	0.597	rs2352990	chr1:44393276	T/A	cg23954153	chr1:44402353	ARTN	-0.36	-5.44	-0.32	1.24e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs2836950	0.565	rs3171465	chr21:40552307	A/G	cg11644478	chr21:40555479	PSMG1	-0.53	-7.23	-0.41	5.11e-12	Menarche (age at onset);
CESC	trans	rs62158800	0.852	rs60010278	chr2:108270056	T/C	cg20498414	chr20:43439400	RIMS4	-0.68	-6.02	-0.35	5.81e-9	Facial morphology (factor 22);
CESC	cis	rs10751667	0.643	rs10902257	chr11:973577	T/C	cg20946044	chr11:1010712	AP2A2	-0.39	-5.32	-0.31	2.24e-7	Alzheimer's disease (late onset);
CESC	cis	rs11711311	1.000	rs7622515	chr3:113472538	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.59	7.78	0.43	1.6e-13	IgG glycosylation;
CESC	cis	rs875971	0.964	rs778723	chr7:65829497	T/C	cg18876405	chr7:65276391	NA	0.51	6.84	0.39	5.45e-11	Aortic root size;
CESC	cis	rs10504229	0.683	rs11781690	chr8:58132931	C/G	cg21724239	chr8:58056113	NA	0.58	5.95	0.34	8.29e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs6502050	0.835	rs4459614	chr17:80086597	C/T	cg23985595	chr17:80112537	CCDC57	0.4	6.23	0.36	1.85e-9	Life satisfaction;
CESC	cis	rs35851103	0.600	rs4841662	chr8:11843758	A/G	cg14752069	chr8:11977206	FAM66D	-0.31	-5.12	-0.3	5.94e-7	Neuroticism;
CESC	cis	rs4780401	0.609	rs55934118	chr16:11820003	G/C	cg01061890	chr16:11836724	TXNDC11	-0.55	-7.56	-0.42	6.67e-13	Rheumatoid arthritis;
CESC	cis	rs7078219	0.543	rs10786556	chr10:101278324	C/T	cg09788492	chr10:101292477	NKX2-3	0.33	6.23	0.36	1.81e-9	Dental caries;
CESC	cis	rs17711722	0.523	rs313812	chr7:65505043	T/C	cg02869306	chr7:64672164	INTS4L1	0.32	5.11	0.3	6.08e-7	Calcium levels;
CESC	cis	rs11792861	0.781	rs874864	chr9:111728718	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.58	7.99	0.44	4.18e-14	Menarche (age at onset);
CESC	cis	rs4665809	0.759	rs62128394	chr2:26364026	T/G	cg26314531	chr2:26401878	FAM59B	0.72	7.78	0.43	1.63e-13	Gut microbiome composition (summer);
CESC	cis	rs11696501	0.738	rs6104294	chr20:44326850	T/C	cg11783356	chr20:44313418	WFDC10B	-0.31	-5.08	-0.3	7.02e-7	Brain structure;
CESC	cis	rs748404	0.578	rs2278856	chr15:43631356	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.6	7.81	0.43	1.33e-13	Lung cancer;
CESC	cis	rs9457247	0.756	rs1811123	chr6:167403443	T/C	cg23791538	chr6:167370224	RNASET2	-0.58	-8.29	-0.45	5.65e-15	Crohn's disease;
CESC	cis	rs3749237	0.595	rs35701831	chr3:49515000	A/C	cg07636037	chr3:49044803	WDR6	0.6	8.71	0.47	3.31e-16	Resting heart rate;
CESC	cis	rs13082711	0.595	rs17317435	chr3:27339326	A/G	cg02860705	chr3:27208620	NA	0.78	9.37	0.5	3.35e-18	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg08240571	chr16:87970654	CA5A	0.36	6.53	0.37	3.35e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs34375054	0.624	rs73233307	chr12:125675873	G/C	cg25124228	chr12:125621409	AACS	-0.46	-5.24	-0.31	3.23e-7	Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs728616	0.867	rs117139504	chr10:81734207	C/A	cg05935833	chr10:81318306	SFTPA2	-0.51	-5.04	-0.3	8.51e-7	Chronic obstructive pulmonary disease-related biomarkers;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04297258	chr16:88772664	RNF166;CTU2	0.52	6.68	0.38	1.4e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs10256972	0.758	rs9801444	chr7:1080444	A/C	cg16145915	chr7:1198662	ZFAND2A	0.46	6.3	0.36	1.22e-9	Longevity;Endometriosis;
CESC	cis	rs2652822	0.662	rs34367270	chr15:63410912	G/A	cg02713581	chr15:63449717	RPS27L	0.43	5.49	0.32	9.22e-8	Metabolic traits;
CESC	cis	rs13118159	0.550	rs4974617	chr4:1373658	T/C	cg02071572	chr4:1403502	NA	0.38	5.74	0.33	2.64e-8	Longevity;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg13790199	chr7:100209986	MOSPD3	-0.49	-6.21	-0.36	2.02e-9	Ulcerative colitis;
CESC	cis	rs208520	0.690	rs4386800	chr6:66755242	A/G	cg07460842	chr6:66804631	NA	0.96	12.59	0.61	8.05e-29	Exhaled nitric oxide output;
CESC	cis	rs6952808	0.595	rs3800916	chr7:2166072	C/T	cg21782813	chr7:2030301	MAD1L1	0.51	7.29	0.41	3.59e-12	Bipolar disorder and schizophrenia;
CESC	cis	rs2268241	0.938	rs7283827	chr21:34769904	A/G	cg14850771	chr21:34775459	IFNGR2	0.94	11.49	0.58	4.44e-25	Obesity-related traits;
CESC	cis	rs2228479	0.850	rs62054638	chr16:89821131	G/C	cg14709524	chr16:89940631	TCF25	0.93	6.94	0.39	3.03e-11	Skin colour saturation;
CESC	cis	rs2836974	0.897	rs2836973	chr21:40654928	A/G	cg11890956	chr21:40555474	PSMG1	1.22	24.05	0.83	1.4e-68	Cognitive function;
CESC	cis	rs61841072	1.000	rs10803106	chr1:243129841	G/T	cg02356786	chr1:243265016	LOC731275	0.41	5.26	0.31	2.97e-7	Schizophrenia;
CESC	cis	rs1801251	1.000	rs13008942	chr2:233594875	G/A	cg25237894	chr2:233734115	C2orf82	0.45	7.78	0.43	1.68e-13	Coronary artery disease;
CESC	cis	rs1538970	0.962	rs9429075	chr1:45818421	G/A	cg06784218	chr1:46089804	CCDC17	0.31	5.15	0.3	5.19e-7	Platelet count;
CESC	cis	rs875971	0.862	rs6964437	chr7:65686444	A/G	cg18252515	chr7:66147081	NA	0.46	6.03	0.35	5.53e-9	Aortic root size;
CESC	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.55	-7.03	-0.4	1.72e-11	Longevity;Endometriosis;
CESC	cis	rs3820068	0.603	rs6660234	chr1:15962590	T/C	cg17385448	chr1:15911702	AGMAT	0.41	6.69	0.38	1.3100000000000001e-10	Systolic blood pressure;
CESC	cis	rs11155671	0.517	rs9397058	chr6:150207249	C/T	cg09699651	chr6:150184138	LRP11	0.56	7.75	0.43	2.01e-13	Testicular germ cell tumor;
CESC	cis	rs6570726	0.935	rs110289	chr6:145865176	C/G	cg23711669	chr6:146136114	FBXO30	0.8	11.78	0.59	4.84e-26	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs477895	0.568	rs34838337	chr11:63870892	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.88	9.62	0.51	5.45e-19	Mean platelet volume;
CESC	cis	rs6089584	0.816	rs6061410	chr20:60625329	A/G	cg13770153	chr20:60521292	NA	-0.5	-6.53	-0.37	3.31e-10	Body mass index;
CESC	cis	rs2456568	0.802	rs1395387	chr11:93639307	A/T	cg26875233	chr11:93583750	C11orf90	-0.31	-5.42	-0.32	1.37e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
CESC	cis	rs2197308	0.813	rs11504316	chr12:38219320	G/A	cg26384229	chr12:38710491	ALG10B	-0.47	-6.34	-0.36	1.01e-9	Morning vs. evening chronotype;
CESC	cis	rs9355610	0.727	rs2247315	chr6:167370211	A/C	cg23791538	chr6:167370224	RNASET2	0.7	9.97	0.52	4.28e-20	Graves' disease;
CESC	trans	rs7615952	0.688	rs12485622	chr3:125710739	T/C	cg07211511	chr3:129823064	LOC729375	-0.57	-6.53	-0.37	3.29e-10	Blood pressure (smoking interaction);
CESC	cis	rs12497850	0.931	rs13064911	chr3:48952385	A/G	cg07636037	chr3:49044803	WDR6	1.04	19.28	0.76	2.27e-52	Parkinson's disease;
CESC	cis	rs739401	0.595	rs6578305	chr11:3001120	C/T	cg25174290	chr11:3078921	CARS	0.51	7.05	0.4	1.51e-11	Longevity;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17492855	chr11:65585364	NA	-0.6	-6.93	-0.39	3.22e-11	Gut microbiome composition (summer);
CESC	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg03647317	chr4:187891568	NA	-0.39	-5.54	-0.32	7.26e-8	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2832191	0.597	rs8127842	chr21:30516461	G/A	cg24692254	chr21:30365293	RNF160	-0.63	-7.77	-0.43	1.74e-13	Dental caries;
CESC	cis	rs1552244	0.554	rs2272121	chr3:10047680	A/G	cg00149659	chr3:10157352	C3orf10	0.54	6.55	0.37	2.98e-10	Alzheimer's disease;
CESC	cis	rs12136530	0.774	rs12092284	chr1:19778323	C/T	cg01832549	chr1:19774989	CAPZB	-0.48	-6.78	-0.38	7.83e-11	Lead levels in blood;
CESC	cis	rs55871839	0.598	rs4737525	chr8:59799781	G/A	cg07426533	chr8:59803705	TOX	-0.5	-7.16	-0.4	8.11e-12	Pneumonia;
CESC	cis	rs10504229	0.954	rs114134184	chr8:58181969	G/A	cg24829409	chr8:58192753	C8orf71	-0.76	-9.93	-0.52	5.87e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs6952808	0.931	rs12537479	chr7:1868995	A/G	cg23102388	chr7:1867652	MAD1L1	0.36	5.54	0.32	7.34e-8	Bipolar disorder and schizophrenia;
CESC	trans	rs7246657	0.943	rs4803347	chr19:37848017	G/A	cg24637308	chr11:6592297	DNHD1	0.52	6.02	0.35	5.89e-9	Coronary artery calcification;
CESC	cis	rs7192750	0.562	rs152838	chr16:72105702	C/T	cg14768367	chr16:72042858	DHODH	0.74	6.17	0.35	2.57e-9	LDL cholesterol levels;Total cholesterol levels;
CESC	cis	rs2576037	0.623	rs2576042	chr18:44577461	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.76	-12.3	-0.6	8.23e-28	Personality dimensions;
CESC	cis	rs6456156	0.742	rs2022000	chr6:167529611	A/G	cg07741184	chr6:167504864	NA	-0.31	-5.12	-0.3	5.75e-7	Primary biliary cholangitis;
CESC	cis	rs6952808	0.595	rs3778982	chr7:2166233	T/C	cg05863683	chr7:1912471	MAD1L1	0.38	5.57	0.32	6.26e-8	Bipolar disorder and schizophrenia;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg10640168	chr8:141360745	TRAPPC9	0.51	7.2	0.4	6.39e-12	Fibrinogen levels;
CESC	cis	rs72781680	0.716	rs2551325	chr2:23979729	C/T	cg08917208	chr2:24149416	ATAD2B	0.61	5.95	0.34	8.4e-9	Lymphocyte counts;
CESC	cis	rs1552244	1.000	rs6764068	chr3:10153842	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.86	-11.97	-0.59	1.09e-26	Alzheimer's disease;
CESC	cis	rs2932538	0.961	rs10745332	chr1:113189053	G/A	cg22162597	chr1:113214053	CAPZA1	-0.52	-6.84	-0.39	5.56e-11	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CESC	cis	rs3762637	1.000	rs7642869	chr3:122190786	T/C	cg24169773	chr3:122142474	KPNA1	-0.54	-6.33	-0.36	1.04e-9	LDL cholesterol levels;
CESC	cis	rs11030122	0.702	rs7102215	chr11:3943970	C/T	cg18678763	chr11:4115507	RRM1	-0.45	-6.05	-0.35	4.94e-9	Mean platelet volume;Platelet distribution width;
CESC	cis	rs7131987	0.845	rs7299861	chr12:29409667	G/A	cg09582351	chr12:29534625	ERGIC2	-0.35	-5.72	-0.33	2.9e-8	QT interval;
CESC	cis	rs9649465	1.000	rs7805759	chr7:123318696	C/A	cg04330084	chr7:123175371	IQUB	-0.38	-5.16	-0.3	4.75e-7	Migraine;
CESC	cis	rs12458462	0.892	rs2242175	chr18:77464406	G/A	cg11879182	chr18:77439856	CTDP1	0.88	13.95	0.65	1.54e-33	Monocyte count;
CESC	trans	rs6084875	0.641	rs2025117	chr20:4723701	A/G	cg10192164	chr16:30419175	ZNF771	-0.51	-6.18	-0.35	2.44e-9	Systemic lupus erythematosus;
CESC	cis	rs1927790	0.727	rs9556550	chr13:96947034	A/C	cg02571835	chr13:96230311	CLDN10	-0.36	-5.35	-0.31	1.88e-7	Body mass index;
CESC	cis	rs7552404	0.727	rs12122939	chr1:76276353	T/C	cg10523679	chr1:76189770	ACADM	0.65	6.45	0.37	5.37e-10	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs4906332	0.811	rs2756138	chr14:103996733	C/G	cg19000871	chr14:103996768	TRMT61A	0.37	5.51	0.32	8.69e-8	Coronary artery disease;
CESC	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.4	5.08	0.3	7.01e-7	Lymphocyte counts;
CESC	cis	rs7412746	0.611	rs9661876	chr1:150910911	C/T	cg17724175	chr1:150552817	MCL1	0.33	5.08	0.3	7.16e-7	Melanoma;
CESC	cis	rs780094	0.544	rs780108	chr2:27684957	T/C	cg12648201	chr2:27665141	KRTCAP3	-0.28	-5.41	-0.32	1.4e-7	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
CESC	cis	rs3857536	0.813	rs7771716	chr6:66946769	C/T	cg07460842	chr6:66804631	NA	-0.42	-5.29	-0.31	2.55e-7	Blood trace element (Cu levels);
CESC	cis	rs2120019	0.938	rs8030089	chr15:75290377	C/T	cg11632617	chr15:75315747	PPCDC	-0.47	-5.23	-0.31	3.47e-7	Blood trace element (Zn levels);
CESC	cis	rs2795502	1.000	rs2795508	chr10:43353555	G/T	cg20628663	chr10:43360327	NA	0.54	6.64	0.38	1.74e-10	Blood protein levels;
CESC	cis	rs57502260	0.704	rs2186937	chr11:68256847	G/A	cg20283391	chr11:68216788	NA	-0.68	-5.69	-0.33	3.39e-8	Total body bone mineral density (age 45-60);
CESC	cis	rs10838687	0.736	rs2633083	chr11:47249420	T/C	cg25783544	chr11:47291846	MADD	-0.56	-6.56	-0.37	2.78e-10	Proinsulin levels;
CESC	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg14893161	chr1:205819251	PM20D1	0.87	14.6	0.67	7.96e-36	Menarche (age at onset);
CESC	cis	rs11030122	0.702	rs10835402	chr11:3990914	T/C	cg18678763	chr11:4115507	RRM1	-0.46	-6.12	-0.35	3.31e-9	Mean platelet volume;Platelet distribution width;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg03558408	chr5:134181967	C5orf24	-0.42	-6.08	-0.35	4.19e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs3733585	0.579	rs4235356	chr4:10123106	G/C	cg00071950	chr4:10020882	SLC2A9	-0.65	-10.19	-0.53	8.59e-21	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs853679	0.517	rs12332979	chr6:28141548	T/G	cg26335602	chr6:28129616	ZNF389	0.52	6.85	0.39	5.22e-11	Depression;
CESC	cis	rs9937943	0.615	rs12925346	chr16:74492495	G/C	cg01733217	chr16:74700730	RFWD3	0.63	5.48	0.32	1.01e-7	Neutrophil percentage of white cells;
CESC	cis	rs13191362	0.935	rs34009353	chr6:163007668	T/G	cg14584255	chr6:163149320	PACRG;PARK2	0.49	5.36	0.31	1.82e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg18955698	chr17:43025023	KIF18B	-0.49	-6.83	-0.39	5.92e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs3749237	0.595	rs6797765	chr3:49423976	A/G	cg07636037	chr3:49044803	WDR6	0.59	8.45	0.46	1.98e-15	Resting heart rate;
CESC	cis	rs929354	0.742	rs3808316	chr7:156944787	C/G	cg05182265	chr7:156933206	UBE3C	-0.5	-7.28	-0.41	3.7e-12	Body mass index;
CESC	cis	rs7808935	0.628	rs72598551	chr7:27939885	C/T	cg05786569	chr7:27702416	HIBADH	0.52	5.84	0.34	1.56e-8	Prostate cancer;
CESC	cis	rs2370759	0.891	rs76164690	chr10:32590362	T/G	cg01819863	chr10:32635814	EPC1	1.12	10.5	0.54	8.76e-22	Sexual dysfunction (female);
CESC	cis	rs7618915	0.501	rs2159644	chr3:52774530	C/T	cg05564831	chr3:52568323	NT5DC2	0.45	7.06	0.4	1.5e-11	Bipolar disorder;
CESC	cis	rs10883723	0.810	rs6584504	chr10:104253507	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.54	7.44	0.42	1.43e-12	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs1691799	0.899	rs1168306	chr12:66738900	A/G	cg16791601	chr12:66731901	HELB	-0.75	-12.98	-0.62	3.8e-30	White blood cell count (basophil);
CESC	cis	rs425277	0.606	rs16824792	chr1:2039521	G/T	cg19257562	chr1:2043853	PRKCZ	0.34	5.71	0.33	3.02e-8	Height;
CESC	cis	rs9309473	0.555	rs2901437	chr2:73597024	T/G	cg20560298	chr2:73613845	ALMS1	-0.46	-6.55	-0.37	3.03e-10	Metabolite levels;
CESC	cis	rs1707322	0.752	rs61784798	chr1:46173481	C/T	cg06784218	chr1:46089804	CCDC17	0.41	7.21	0.41	5.75e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs4716602	0.550	rs12672151	chr7:156159053	A/G	cg07175507	chr18:77160758	NFATC1	-0.44	-6.09	-0.35	3.91e-9	Anti-saccade response;
CESC	cis	rs10771431	0.817	rs17202253	chr12:9361850	A/G	cg08997352	chr12:9597637	DDX12	-0.75	-10.14	-0.53	1.24e-20	Breast size;
CESC	cis	rs7252981	0.632	rs880090	chr19:19740729	C/G	cg03709012	chr19:19516395	GATAD2A	0.45	5.21	0.3	3.79e-7	Perceived unattractiveness to mosquitoes;
CESC	cis	rs523522	0.962	rs11065149	chr12:120956963	G/A	cg12219531	chr12:120966889	COQ5	0.75	9.99	0.52	3.7e-20	High light scatter reticulocyte count;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg03934443	chr10:134639821	NA	-0.48	-6.58	-0.37	2.45e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs2576037	0.583	rs11660085	chr18:44529603	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.35	-5.53	-0.32	7.62e-8	Personality dimensions;
CESC	cis	rs8141529	0.764	rs5752809	chr22:29225500	G/A	cg15103426	chr22:29168792	CCDC117	0.68	9.65	0.51	4.52e-19	Lymphocyte counts;
CESC	cis	rs6724607	1.000	rs6724607	chr2:191466532	C/T	cg10560079	chr2:191398806	TMEM194B	0.49	7.03	0.4	1.8e-11	Pulse pressure;
CESC	cis	rs694739	0.541	rs61886926	chr11:64133552	C/T	cg23796481	chr11:64053134	BAD;GPR137	0.56	6.87	0.39	4.63e-11	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CESC	cis	rs769267	0.965	rs12460764	chr19:19431963	G/T	cg03709012	chr19:19516395	GATAD2A	-0.96	-14.2	-0.66	2.12e-34	Tonsillectomy;
CESC	cis	rs926938	0.563	rs360652	chr1:115445478	C/T	cg12756093	chr1:115239321	AMPD1	0.48	6.94	0.39	3e-11	Autism;
CESC	cis	rs8077577	0.836	rs58441148	chr17:18106498	T/A	cg16794390	chr17:18148240	FLII	0.41	5.59	0.32	5.53e-8	Obesity-related traits;
CESC	cis	rs2072732	0.861	rs1890338	chr1:2949028	C/T	cg03976712	chr1:2946727	NA	0.34	5.63	0.33	4.53e-8	Plateletcrit;
CESC	cis	rs4727027	0.866	rs1358062	chr7:148783743	T/C	cg23158103	chr7:148848205	ZNF398	-0.4	-6.36	-0.36	8.78e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs4523957	0.559	rs216174	chr17:2164898	A/G	cg16513277	chr17:2031491	SMG6	0.52	5.64	0.33	4.43e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs9815354	1.000	rs2683695	chr3:41914928	C/T	cg03022575	chr3:42003672	ULK4	0.44	5.13	0.3	5.55e-7	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs858239	0.600	rs2072369	chr7:23146189	A/G	cg23682824	chr7:23144976	KLHL7	0.55	7.79	0.43	1.49e-13	Cerebrospinal fluid biomarker levels;
CESC	cis	rs875971	0.617	rs810400	chr7:66022889	G/C	cg06456125	chr7:65229604	NA	-0.39	-5.1	-0.3	6.54e-7	Aortic root size;
CESC	cis	rs644799	0.965	rs10831430	chr11:95509638	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.71	9.37	0.5	3.25e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs1707322	1.000	rs3922887	chr1:46473802	A/G	cg06784218	chr1:46089804	CCDC17	0.34	5.75	0.33	2.49e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs7837860	0.588	rs28986511	chr8:89295258	G/A	cg04391754	chr17:18022714	MYO15A	0.52	6.07	0.35	4.4e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs2625529	0.617	rs2306576	chr15:72170686	C/T	cg16672083	chr15:72433130	SENP8	0.47	7.19	0.4	6.81e-12	Red blood cell count;
CESC	cis	rs9549260	0.664	rs1360719	chr13:41225874	G/C	cg21288729	chr13:41239152	FOXO1	0.66	8.55	0.47	9.85e-16	Red blood cell count;
CESC	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg02353165	chr6:42928485	GNMT	0.86	14.33	0.66	7.06e-35	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs78456975	0.527	rs10203194	chr2:1558021	A/G	cg26248373	chr2:1572462	NA	-0.57	-6.79	-0.39	7.14e-11	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs3820068	0.532	rs74057713	chr1:15944620	G/C	cg17385448	chr1:15911702	AGMAT	0.41	6.82	0.39	5.97e-11	Systolic blood pressure;
CESC	cis	rs116095464	0.558	rs73024831	chr5:257192	A/G	cg20965017	chr5:231967	SDHA	-0.47	-5.22	-0.31	3.61e-7	Breast cancer;
CESC	trans	rs12681287	0.517	rs34367154	chr8:87508749	A/T	cg27317242	chr8:23145699	R3HCC1	-0.53	-6.35	-0.36	9.05e-10	Caudate activity during reward;
CESC	cis	rs3768617	0.510	rs10911247	chr1:183076993	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.82	12.37	0.6	4.91e-28	Fuchs's corneal dystrophy;
CESC	cis	rs6840258	0.800	rs6839933	chr4:87964363	A/C	cg08197287	chr4:87952173	AFF1	-0.35	-5.18	-0.3	4.45e-7	Mean corpuscular volume;Basophil percentage of granulocytes;
CESC	cis	rs7662987	0.517	rs2602876	chr4:100039535	A/T	cg13256891	chr4:100009986	ADH5	0.7	7.59	0.42	5.63e-13	Smoking initiation;
CESC	trans	rs2823962	0.759	rs2211990	chr21:18016965	G/A	cg06419850	chr17:4688683	VMO1	-0.42	-6.13	-0.35	3.23e-9	Amyotrophic lateral sclerosis;
CESC	cis	rs9902453	0.904	rs12952179	chr17:28412687	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.71	-9.11	-0.49	2.13e-17	Coffee consumption (cups per day);
CESC	cis	rs4332037	0.530	rs62434669	chr7:1866946	G/A	cg13880726	chr7:1868755	MAD1L1	-0.52	-5.17	-0.3	4.52e-7	Bipolar disorder;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg05062148	chr1:25757186	TMEM57	-0.47	-6.2	-0.36	2.15e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	trans	rs561341	1.000	rs72825712	chr17:30316119	A/T	cg20587970	chr11:113659929	NA	-1.48	-19.48	-0.77	4.55e-53	Hip circumference adjusted for BMI;
CESC	cis	rs9611565	0.694	rs9607816	chr22:41950897	G/A	cg17376030	chr22:41985996	PMM1	0.67	7.27	0.41	3.96e-12	Vitiligo;
CESC	cis	rs67311347	1.000	rs9835219	chr3:40424093	C/T	cg24209194	chr3:40518798	ZNF619	0.51	6.64	0.38	1.74e-10	Renal cell carcinoma;
CESC	cis	rs2249694	1.000	rs1952467	chr10:135353499	T/G	cg20169779	chr10:135381914	SYCE1	0.39	5.2	0.3	3.9e-7	Obesity-related traits;
CESC	cis	rs10504229	0.679	rs72649119	chr8:58040301	T/C	cg24829409	chr8:58192753	C8orf71	-0.5	-6.25	-0.36	1.61e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs4964805	0.632	rs11111782	chr12:104188476	A/G	cg02344784	chr12:104178138	NT5DC3	-0.48	-6.91	-0.39	3.64e-11	Attention deficit hyperactivity disorder;
CESC	cis	rs929596	0.755	rs4148325	chr2:234673309	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.69	-9.23	-0.49	8.92e-18	Total bilirubin levels in HIV-1 infection;
CESC	cis	rs7914558	1.000	rs7094843	chr10:104806654	A/C	cg08650961	chr10:104748594	CNNM2	0.31	5.19	0.3	4.18e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs2760061	0.598	rs658238	chr1:228121291	A/G	cg01973587	chr1:228161476	NA	0.37	5.73	0.33	2.77e-8	Diastolic blood pressure;
CESC	cis	rs16854884	0.632	rs1466941	chr3:143670131	A/G	cg06585982	chr3:143692056	C3orf58	0.56	7.53	0.42	8.21e-13	Economic and political preferences (feminism/equality);
CESC	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg05313129	chr8:58192883	C8orf71	-0.49	-5.32	-0.31	2.23e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs73206853	0.841	rs7967246	chr12:110756569	G/A	cg12870014	chr12:110450643	ANKRD13A	0.64	5.06	0.3	7.92e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs7618915	0.501	rs11130308	chr3:52639257	G/C	cg18337363	chr3:52569053	NT5DC2	0.29	5.27	0.31	2.85e-7	Bipolar disorder;
CESC	cis	rs3785574	0.962	rs2584632	chr17:61880641	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.57	7.03	0.4	1.78e-11	Height;
CESC	cis	rs2841277	0.741	rs9672139	chr14:105408182	T/G	cg19901468	chr14:105411992	AHNAK2	-0.65	-9.71	-0.51	2.88e-19	Rheumatoid arthritis;
CESC	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg16145915	chr7:1198662	ZFAND2A	-0.51	-6.35	-0.36	9.13e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02079963	chr6:160512064	IGF2R	-0.6	-7.05	-0.4	1.58e-11	Gut microbiome composition (summer);
CESC	cis	rs2050392	0.517	rs2489847	chr10:30743673	G/A	cg18806716	chr10:30721971	MAP3K8	-0.5	-7.64	-0.42	3.9e-13	Inflammatory bowel disease;
CESC	cis	rs4268898	0.662	rs2303297	chr2:24432937	C/T	cg06627628	chr2:24431161	ITSN2	-1.02	-11.2	-0.57	4.2e-24	Asthma;
CESC	cis	rs2797685	0.773	rs2301489	chr1:7837676	G/C	cg04725166	chr1:7887271	PER3	-0.39	-5.37	-0.31	1.71e-7	Crohn's disease;
CESC	cis	rs2651899	0.934	rs1627080	chr1:3081309	T/C	cg22674798	chr1:3096360	PRDM16	0.42	8.31	0.45	5.02e-15	Migraine;
CESC	cis	rs7100689	0.784	rs10887838	chr10:82161380	G/A	cg00277334	chr10:82204260	NA	-0.59	-7.32	-0.41	3.05e-12	Post bronchodilator FEV1;
CESC	cis	rs35160687	0.623	rs4832263	chr2:86485157	G/T	cg01119172	chr2:86362222	SNORD94;PTCD3	-0.37	-5.07	-0.3	7.54e-7	Night sleep phenotypes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07565404	chr2:107084911	RGPD3	-0.56	-6.66	-0.38	1.56e-10	Gut microbiome composition (summer);
CESC	cis	rs9916302	0.904	rs12452509	chr17:37574722	G/A	cg07936489	chr17:37558343	FBXL20	-0.8	-11.5	-0.58	4.2e-25	Glomerular filtration rate (creatinine);
CESC	cis	rs6088580	0.634	rs6059880	chr20:33088669	G/A	cg08999081	chr20:33150536	PIGU	0.65	11.4	0.57	9e-25	Glomerular filtration rate (creatinine);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17621259	chr3:37035168	MLH1;EPM2AIP1	0.59	6.35	0.36	9.39e-10	Gut microbiome composition (summer);
CESC	cis	rs863345	0.604	rs10908657	chr1:158465243	T/C	cg12129480	chr1:158549410	OR10X1	-0.35	-6.9	-0.39	3.93e-11	Pneumococcal bacteremia;
CESC	cis	rs8180040	0.593	rs4018905	chr3:47138170	A/G	cg27129171	chr3:47204927	SETD2	0.66	9.84	0.52	1.1e-19	Colorectal cancer;
CESC	cis	rs4604732	0.631	rs80319072	chr1:247626835	G/A	cg12758973	chr1:247694275	LOC148824;OR2C3	0.51	6.36	0.36	8.65e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs7520050	0.931	rs6698247	chr1:46371486	C/T	cg03146154	chr1:46216737	IPP	-0.48	-6.34	-0.36	1e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs11098499	0.954	rs12506546	chr4:120301618	T/C	cg24375607	chr4:120327624	NA	0.46	5.58	0.32	5.79e-8	Corneal astigmatism;
CESC	cis	rs7917772	0.503	rs10883732	chr10:104293461	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.54	7.41	0.41	1.67e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs2066819	1.000	rs76430365	chr12:56699993	A/C	cg26734620	chr12:56694298	CS	1.03	6.25	0.36	1.65e-9	Psoriasis vulgaris;
CESC	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.48	-5.08	-0.3	7.1e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs9916302	0.904	rs8065963	chr17:37681332	C/T	cg00129232	chr17:37814104	STARD3	-0.56	-7.37	-0.41	2.15e-12	Glomerular filtration rate (creatinine);
CESC	cis	rs6701037	0.555	rs10912899	chr1:175120715	C/T	cg08873628	chr1:175162347	KIAA0040	0.43	5.54	0.32	7.28e-8	Alcohol dependence;
CESC	cis	rs2370759	1.000	rs75984055	chr10:32591276	T/C	cg05361325	chr10:32636312	EPC1	-0.55	-5.18	-0.3	4.39e-7	Sexual dysfunction (female);
CESC	cis	rs3106136	0.967	rs8026	chr4:95212185	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.45	-6.73	-0.38	1.02e-10	Capecitabine sensitivity;
CESC	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg22535103	chr8:58192502	C8orf71	-0.9	-9.52	-0.5	1.13e-18	Developmental language disorder (linguistic errors);
CESC	cis	rs9297145	0.565	rs12705030	chr7:98765041	A/G	cg05967295	chr7:98741636	SMURF1	-0.61	-8.22	-0.45	9.3e-15	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
CESC	cis	rs7811142	1.000	rs1000215	chr7:100004543	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.98	12.04	0.59	6.29e-27	Platelet count;
CESC	cis	rs4648845	0.777	rs2477686	chr1:2392648	C/G	cg11214544	chr1:2391121	NA	-0.4	-6.52	-0.37	3.5e-10	Schizophrenia;
CESC	trans	rs864643	0.773	rs11129837	chr3:39589963	A/G	cg10221240	chr4:1004669	FGFRL1	0.5	6.25	0.36	1.67e-9	Attention deficit hyperactivity disorder;
CESC	cis	rs2180341	0.960	rs1964130	chr6:127677391	C/G	cg27446573	chr6:127587934	RNF146	0.97	13.1	0.63	1.47e-30	Breast cancer;
CESC	cis	rs8017423	0.935	rs3742668	chr14:90767759	G/A	cg14092571	chr14:90743983	NA	0.53	7.94	0.44	5.81e-14	Mortality in heart failure;
CESC	cis	rs1005277	0.522	rs200943	chr10:38148730	A/G	cg25427524	chr10:38739819	LOC399744	-0.68	-10.16	-0.53	1.05e-20	Extrinsic epigenetic age acceleration;
CESC	cis	rs1045714	0.895	rs4721866	chr7:2643341	G/A	cg20813462	chr7:2646259	IQCE	0.63	5.55	0.32	6.94e-8	Urate levels in lean individuals;
CESC	cis	rs8072100	0.676	rs7221345	chr17:45405144	G/A	cg25173405	chr17:45401733	C17orf57	-0.49	-6.41	-0.37	6.71e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs9911578	0.967	rs405684	chr17:56777148	T/C	cg05425664	chr17:57184151	TRIM37	-0.51	-7.15	-0.4	8.36e-12	Intelligence (multi-trait analysis);
CESC	cis	rs9300255	0.602	rs1051431	chr12:123645803	G/A	cg05973401	chr12:123451056	ABCB9	0.5	5.81	0.34	1.79e-8	Neutrophil percentage of white cells;
CESC	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.48	-5.04	-0.3	8.58e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg18076651	chr12:53625605	RARG	-0.5	-6.66	-0.38	1.56e-10	Lung cancer in ever smokers;
CESC	cis	rs7949030	0.626	rs11231145	chr11:62328854	G/A	cg11742103	chr11:62369870	EML3;MTA2	0.65	10.01	0.52	3.3e-20	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	trans	rs9329221	0.741	rs534523	chr8:9884999	C/G	cg06636001	chr8:8085503	FLJ10661	-0.56	-7.33	-0.41	2.73e-12	Neuroticism;
CESC	trans	rs526821	0.532	rs578067	chr11:55313690	T/G	cg15704280	chr7:45808275	SEPT13	-0.52	-6.37	-0.36	8.32e-10	Pediatric bone mineral density (spine);
CESC	cis	rs2074585	0.806	rs8033813	chr15:90999715	A/T	cg22089800	chr15:90895588	ZNF774	0.65	8.76	0.47	2.32e-16	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
CESC	cis	rs1005277	0.579	rs1740735	chr10:38497777	A/C	cg25517755	chr10:38738941	LOC399744	-0.45	-5.88	-0.34	1.25e-8	Extrinsic epigenetic age acceleration;
CESC	cis	rs13191362	0.507	rs2023037	chr6:163120385	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.57	7.01	0.4	1.98e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs35110281	0.805	rs4818843	chr21:45006607	C/T	cg21573476	chr21:45109991	RRP1B	-0.42	-5.62	-0.33	4.84e-8	Mean corpuscular volume;
CESC	cis	rs1152591	0.543	rs1152592	chr14:64676098	A/G	cg23250157	chr14:64679961	SYNE2	0.47	6.65	0.38	1.65e-10	Atrial fibrillation;
CESC	cis	rs6964587	0.743	rs33993294	chr7:91998655	A/C	cg17063962	chr7:91808500	NA	0.57	7.39	0.41	1.91e-12	Breast cancer;
CESC	cis	rs10504229	0.683	rs10504225	chr8:58145121	A/T	cg21724239	chr8:58056113	NA	0.56	5.96	0.34	8.22e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs7084402	0.902	rs1582826	chr10:60297175	C/T	cg07615347	chr10:60278583	BICC1	0.6	9.42	0.5	2.35e-18	Refractive error;
CESC	cis	rs6502050	0.842	rs6502053	chr17:80066714	C/T	cg11859384	chr17:80120422	CCDC57	0.4	5.51	0.32	8.47e-8	Life satisfaction;
CESC	cis	rs4835473	0.618	rs7666297	chr4:144920158	G/A	cg25736465	chr4:144833511	NA	-0.45	-6.63	-0.38	1.91e-10	Immature fraction of reticulocytes;
CESC	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg07677032	chr17:61819896	STRADA	0.45	5.92	0.34	1.01e-8	Prudent dietary pattern;
CESC	cis	rs916888	0.610	rs199529	chr17:44837217	A/C	cg01570182	chr17:44337453	NA	0.76	9.84	0.52	1.11e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs12476592	0.602	rs6546007	chr2:63724795	C/T	cg17519650	chr2:63277830	OTX1	-0.47	-5.4	-0.31	1.46e-7	Childhood ear infection;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26074535	chr5:134094528	DDX46	-0.57	-6.29	-0.36	1.32e-9	Gut microbiome composition (summer);
CESC	cis	rs6963495	0.818	rs55794529	chr7:105165747	T/C	cg19920283	chr7:105172520	RINT1	0.7	6.66	0.38	1.58e-10	Bipolar disorder (body mass index interaction);
CESC	trans	rs7980799	0.711	rs1482993	chr12:33594515	G/A	cg26384229	chr12:38710491	ALG10B	-0.56	-8.09	-0.45	2.22e-14	Heart rate;Heart rate variability traits (RMSSD);
CESC	cis	rs7829975	0.514	rs2920991	chr8:8259117	T/A	cg08975724	chr8:8085496	FLJ10661	0.41	5.25	0.31	3.19e-7	Mood instability;
CESC	cis	rs9828933	0.938	rs3816157	chr3:63999322	G/A	cg16258503	chr3:63850278	ATXN7;THOC7	-0.66	-6.4	-0.37	7.22e-10	Type 2 diabetes;
CESC	cis	rs1008375	0.966	rs2159582	chr4:17695655	T/C	cg16339924	chr4:17578868	LAP3	0.6	7.47	0.42	1.16e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs8064299	1.000	rs8064299	chr17:72762646	C/A	cg25054828	chr17:72772726	NAT9;TMEM104	0.61	8.6	0.47	6.99e-16	Monocyte count;
CESC	trans	rs57221529	0.608	rs11749927	chr5:668842	C/T	cg25482853	chr8:67687455	SGK3	0.92	9.88	0.52	8.33e-20	Lung disease severity in cystic fibrosis;
CESC	cis	rs736408	0.509	rs13083798	chr3:52649748	A/G	cg18099408	chr3:52552593	STAB1	-0.34	-6.18	-0.35	2.39e-9	Bipolar disorder;
CESC	cis	rs854765	0.583	rs11650890	chr17:17790882	C/T	cg16928487	chr17:17741425	SREBF1	0.61	10.65	0.55	2.82e-22	Total body bone mineral density;
CESC	cis	rs736408	0.505	rs2083180	chr3:52668119	G/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.36	6.54	0.37	3.2e-10	Bipolar disorder;
CESC	cis	rs2050392	0.517	rs602966	chr10:30755853	C/T	cg18806716	chr10:30721971	MAP3K8	-0.51	-7.76	-0.43	1.9e-13	Inflammatory bowel disease;
CESC	cis	rs2839186	0.508	rs6518278	chr21:47640571	A/G	cg12379764	chr21:47803548	PCNT	0.48	5.64	0.33	4.36e-8	Testicular germ cell tumor;
CESC	cis	rs8177253	1.000	rs6439439	chr3:133481498	G/T	cg01448562	chr3:133502909	NA	-0.42	-5.87	-0.34	1.27e-8	Iron status biomarkers;
CESC	cis	rs7116495	1.000	rs10751190	chr11:71680757	C/T	cg10381502	chr11:71823885	C11orf51	-0.68	-5.67	-0.33	3.64e-8	Severe influenza A (H1N1) infection;
CESC	cis	rs35110281	0.782	rs1454651	chr21:45012476	A/G	cg01579765	chr21:45077557	HSF2BP	-0.57	-9.85	-0.52	1.05e-19	Mean corpuscular volume;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg09529150	chr10:22615839	BMI1	0.38	6.07	0.35	4.29e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs1178968	0.901	rs9784947	chr7:72748888	C/G	cg25889504	chr7:72793014	NA	0.47	5.03	0.3	8.91e-7	Triglyceride levels;
CESC	cis	rs8114671	0.562	rs3818273	chr20:33509275	G/A	cg24642439	chr20:33292090	TP53INP2	0.43	5.19	0.3	4.19e-7	Height;
CESC	trans	rs916888	0.821	rs70602	chr17:44859715	T/C	cg10053473	chr17:62856997	LRRC37A3	0.67	7.42	0.41	1.61e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs780096	0.506	rs1647285	chr2:27714511	A/C	cg17158414	chr2:27665306	KRTCAP3	-0.32	-5.98	-0.34	7.07e-9	Total body bone mineral density;
CESC	cis	rs62432291	0.681	rs385438	chr6:159656213	A/G	cg14500486	chr6:159655392	FNDC1	-0.62	-6.72	-0.38	1.08e-10	Joint mobility (Beighton score);
CESC	cis	rs6728642	1.000	rs11890407	chr2:97621647	G/C	cg26665480	chr2:98280029	ACTR1B	-0.72	-6.69	-0.38	1.29e-10	Bipolar disorder lithium response (continuous) or schizophrenia;
CESC	cis	rs7296418	0.885	rs1051434	chr12:123641200	C/T	cg00376283	chr12:123451042	ABCB9	0.68	9.47	0.5	1.67e-18	Platelet count;
CESC	cis	rs17253792	0.822	rs28681420	chr14:56088403	G/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.79	5.91	0.34	1.06e-8	Putamen volume;
CESC	cis	rs6952808	0.792	rs2056478	chr7:1953897	C/T	cg02951883	chr7:2050386	MAD1L1	-0.5	-6.71	-0.38	1.19e-10	Bipolar disorder and schizophrenia;
CESC	cis	rs17826219	0.500	rs61685770	chr17:29085713	G/A	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.91e-10	Body mass index;
CESC	cis	rs2880765	0.835	rs12708553	chr15:86046833	C/G	cg19183879	chr15:85880815	NA	0.26	5.27	0.31	2.82e-7	Coronary artery disease;
CESC	cis	rs7818688	0.697	rs74633235	chr8:95981476	A/G	cg16049864	chr8:95962084	TP53INP1	0.55	5.55	0.32	6.92e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs2072732	0.904	rs2993480	chr1:2973322	A/G	cg15211996	chr1:2936768	ACTRT2	-0.34	-6.12	-0.35	3.33e-9	Plateletcrit;
CESC	cis	rs3011225	0.691	rs3791102	chr1:44366617	C/T	cg12908607	chr1:44402522	ARTN	-0.47	-6.94	-0.39	3e-11	Amyotrophic lateral sclerosis (age of onset);
CESC	cis	rs2882667	0.929	rs17207828	chr5:138299835	A/G	cg04439458	chr5:138467593	SIL1	-0.39	-6.18	-0.36	2.34e-9	Age-related hearing impairment (SNP x SNP interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05384275	chr12:56122970	CD63	0.55	6.29	0.36	1.3e-9	Gut microbiome composition (summer);
CESC	cis	rs12477438	0.798	rs6740035	chr2:99576578	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.7	-10.22	-0.53	6.79e-21	Chronic sinus infection;
CESC	cis	rs896854	0.684	rs10098778	chr8:95992020	C/T	cg23172400	chr8:95962367	TP53INP1	-0.42	-8.94	-0.48	6.87e-17	Type 2 diabetes;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg27571405	chr3:100211424	TMEM45A	0.48	6.2	0.36	2.13e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs8017423	0.967	rs59980414	chr14:90687738	G/C	cg14092571	chr14:90743983	NA	-0.57	-8.29	-0.45	5.91e-15	Mortality in heart failure;
CESC	cis	rs9914988	0.778	rs4794837	chr17:27110024	T/C	cg20469991	chr17:27169893	C17orf63	-0.48	-5.25	-0.31	3.18e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg04101267	chr1:95538294	ALG14	-0.49	-6.04	-0.35	5.21e-9	Ulcerative colitis;
CESC	cis	rs2243480	1.000	rs437889	chr7:65509234	G/A	cg13147721	chr7:65941812	NA	-0.95	-9.01	-0.48	4.17e-17	Diabetic kidney disease;
CESC	trans	rs9929218	1.000	rs12599517	chr16:68814590	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.62	-8.22	-0.45	9.14e-15	Colorectal cancer;
CESC	cis	rs7552404	1.000	rs7524467	chr1:76194054	C/G	cg22875332	chr1:76189707	ACADM	0.63	7.38	0.41	2.06e-12	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs10493773	0.862	rs12075929	chr1:86248138	A/C	cg17807903	chr1:86174739	ZNHIT6	0.4	5.35	0.31	1.88e-7	Urate levels in overweight individuals;
CESC	cis	rs3820928	0.692	rs17416354	chr2:227770844	A/G	cg11843606	chr2:227700838	RHBDD1	-0.58	-8.05	-0.44	2.81e-14	Pulmonary function;
CESC	cis	rs2576037	0.796	rs2576041	chr18:44580919	C/T	cg19077165	chr18:44547161	KATNAL2	0.51	7.11	0.4	1.05e-11	Personality dimensions;
CESC	cis	rs6545883	0.811	rs778753	chr2:61780200	T/A	cg15711740	chr2:61764176	XPO1	-0.39	-5.06	-0.3	7.81e-7	Tuberculosis;
CESC	trans	rs11098499	0.863	rs7664986	chr4:120429952	A/C	cg25214090	chr10:38739885	LOC399744	0.71	9.72	0.51	2.69e-19	Corneal astigmatism;
CESC	cis	rs8031584	0.541	rs2955797	chr15:31210981	A/G	cg08109568	chr15:31115862	NA	0.66	9.3	0.5	5.39e-18	Huntington's disease progression;
CESC	cis	rs9322193	0.923	rs10872644	chr6:150062955	T/C	cg07701084	chr6:150067640	NUP43	0.47	6.55	0.37	3.03e-10	Lung cancer;
CESC	cis	rs6700559	0.740	rs6663322	chr1:200649869	G/A	cg07804481	chr1:200639085	DDX59	0.39	5.06	0.3	7.88e-7	Coronary artery disease;
CESC	cis	rs7208859	0.524	rs73263982	chr17:28920624	T/C	cg14008862	chr17:28927542	LRRC37B2	0.69	6.16	0.35	2.63e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs6540559	0.673	rs17015218	chr1:209967915	A/G	cg22029157	chr1:209979665	IRF6	0.75	8.93	0.48	7.38e-17	Cleft lip with or without cleft palate;
CESC	cis	rs7208859	0.623	rs1061342	chr17:29114463	G/A	cg19761014	chr17:28927070	LRRC37B2	0.78	6.41	0.37	6.74e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs2320614	0.648	rs1382661	chr4:164104090	C/T	cg15586945	chr4:164088095	NAF1	-0.6	-7.87	-0.44	9.17e-14	Lung adenocarcinoma;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15600365	chr17:1420230	LOC100306951;INPP5K	0.57	6.25	0.36	1.67e-9	Gut microbiome composition (summer);
CESC	cis	rs6964587	1.000	rs2301559	chr7:91746727	T/C	cg17063962	chr7:91808500	NA	0.58	8.02	0.44	3.33e-14	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23226134	chr1:11866389	CLCN6;MTHFR	-0.57	-6.72	-0.38	1.12e-10	Gut microbiome composition (summer);
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg13765646	chr4:47708509	CORIN	-0.47	-6.15	-0.35	2.8e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs4466137	0.953	rs1585153	chr5:83000385	A/T	cg16102102	chr5:83017553	HAPLN1	-0.47	-6.74	-0.38	9.88e-11	Prostate cancer;
CESC	cis	rs514406	0.679	rs960570	chr1:53237763	A/G	cg27535305	chr1:53392650	SCP2	0.35	6.23	0.36	1.78e-9	Monocyte count;
CESC	cis	rs9303401	0.614	rs34683543	chr17:56520036	C/A	cg12560992	chr17:57184187	TRIM37	0.5	5.07	0.3	7.47e-7	Cognitive test performance;
CESC	cis	rs4555082	0.834	rs2816624	chr14:105733909	A/G	cg13114125	chr14:105738426	BRF1	-0.9	-11.3	-0.57	1.99e-24	Mean platelet volume;Platelet distribution width;
CESC	cis	rs2012796	0.743	rs61986598	chr14:81856865	G/A	cg02996355	chr14:81879375	NA	0.64	7.93	0.44	6.28e-14	Night sleep phenotypes;
CESC	cis	rs1008375	0.897	rs3733577	chr4:17649233	T/G	cg15017067	chr4:17643749	FAM184B	0.36	5.16	0.3	4.78e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00716675	chr1:38478417	UTP11L	0.61	6.56	0.37	2.88e-10	Gut microbiome composition (summer);
CESC	cis	rs9611565	0.592	rs5758427	chr22:42099688	A/G	cg17376030	chr22:41985996	PMM1	-0.72	-7.68	-0.43	3.15e-13	Vitiligo;
CESC	cis	rs9788682	1.000	rs12438181	chr15:78812098	G/A	cg24631222	chr15:78858424	CHRNA5	0.71	8.74	0.47	2.69e-16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs875971	0.862	rs6971059	chr7:66067032	A/G	cg19163074	chr7:65112434	INTS4L2	0.42	5.28	0.31	2.63e-7	Aortic root size;
CESC	cis	rs6598955	0.543	rs4585968	chr1:26535146	G/A	cg04990556	chr1:26633338	UBXN11	0.81	9.12	0.49	1.92e-17	Obesity-related traits;
CESC	cis	rs2836974	0.796	rs77153312	chr21:40695499	G/A	cg11644478	chr21:40555479	PSMG1	0.99	15.3	0.68	2.73e-38	Cognitive function;
CESC	cis	rs9291683	0.530	rs4235346	chr4:9945296	C/T	cg02734326	chr4:10020555	SLC2A9	-0.47	-6.88	-0.39	4.28e-11	Bone mineral density;
CESC	cis	rs7210086	0.606	rs72849437	chr17:70631124	T/C	cg04206342	chr17:70636940	NA	-0.39	-6.18	-0.35	2.45e-9	Ulcerative colitis;
CESC	cis	rs6860806	0.507	rs183898	chr5:131716902	C/G	cg07395648	chr5:131743802	NA	0.42	5.56	0.32	6.71e-8	Breast cancer;
CESC	cis	rs9815354	0.627	rs115971784	chr3:42016146	T/C	cg03022575	chr3:42003672	ULK4	0.74	6.64	0.38	1.79e-10	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs9916302	0.904	rs10432031	chr17:37397852	G/A	cg20243544	chr17:37824526	PNMT	0.48	5.99	0.35	6.77e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs2197308	0.667	rs61920838	chr12:37856814	T/C	cg26384229	chr12:38710491	ALG10B	-0.54	-7.84	-0.43	1.12e-13	Morning vs. evening chronotype;
CESC	cis	rs68170813	0.559	rs75313693	chr7:106863170	T/C	cg02696742	chr7:106810147	HBP1	-0.52	-5.09	-0.3	6.89e-7	Coronary artery disease;
CESC	cis	rs7336332	0.628	rs9581854	chr13:28017782	C/T	cg22138327	chr13:27999177	GTF3A	0.62	5.66	0.33	3.95e-8	Weight;
CESC	cis	rs2204008	0.902	rs11520218	chr12:38223227	G/A	cg26384229	chr12:38710491	ALG10B	0.74	10.63	0.55	3.35e-22	Bladder cancer;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg24485466	chr1:200589999	KIF14	0.47	6.48	0.37	4.46e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs9611565	0.659	rs4822037	chr22:41945113	G/T	cg06634786	chr22:41940651	POLR3H	-0.69	-7.19	-0.4	6.63e-12	Vitiligo;
CESC	cis	rs113835537	0.529	rs11227515	chr11:66287383	C/T	cg22134325	chr11:66188745	NPAS4	0.34	5.42	0.32	1.36e-7	Airway imaging phenotypes;
CESC	cis	rs4268898	0.636	rs72787385	chr2:24585820	G/A	cg20701182	chr2:24300061	SF3B14	0.66	6.97	0.39	2.47e-11	Asthma;
CESC	cis	rs3806843	0.735	rs801189	chr5:140063091	A/G	cg16179182	chr5:140090404	VTRNA1-1	0.39	5.11	0.3	6.21e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs11098499	0.657	rs71614442	chr4:120379346	C/T	cg09307838	chr4:120376055	NA	0.95	13.8	0.65	5e-33	Corneal astigmatism;
CESC	cis	rs9818758	0.505	rs11716159	chr3:49631585	G/A	cg00383909	chr3:49044727	WDR6	0.81	5.35	0.31	1.9e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CESC	trans	rs17685	0.725	rs2302436	chr7:75676988	A/T	cg19862616	chr7:65841803	NCRNA00174	-0.86	-12.65	-0.61	4.99e-29	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs1691799	0.899	rs1168305	chr12:66738714	A/G	cg16791601	chr12:66731901	HELB	-0.75	-13.03	-0.62	2.51e-30	White blood cell count (basophil);
CESC	cis	rs9527	0.590	rs12415388	chr10:104796345	T/C	cg04362960	chr10:104952993	NT5C2	0.42	5.45	0.32	1.17e-7	Arsenic metabolism;
CESC	cis	rs17376456	0.877	rs9314099	chr5:93447375	T/C	cg21475434	chr5:93447410	FAM172A	0.82	7.56	0.42	6.81e-13	Diabetic retinopathy;
CESC	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	22.66	0.81	5.75e-64	Prudent dietary pattern;
CESC	cis	rs6460942	0.597	rs10273045	chr7:12519371	T/C	cg20607287	chr7:12443886	VWDE	-0.63	-7.11	-0.4	1.1e-11	Coronary artery disease;
CESC	cis	rs8018808	0.935	rs4223	chr14:77893276	A/G	cg20045696	chr14:77926864	AHSA1	-0.41	-5.69	-0.33	3.28e-8	Myeloid white cell count;
CESC	cis	rs2243480	0.908	rs1532573	chr7:65798802	A/G	cg13147721	chr7:65941812	NA	0.95	8.98	0.48	5.3e-17	Diabetic kidney disease;
CESC	cis	rs2439831	0.681	rs7175434	chr15:43628542	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	13.22	0.63	5.55e-31	Lung cancer in ever smokers;
CESC	cis	rs6460942	0.818	rs116613169	chr7:12234669	T/C	cg06484146	chr7:12443880	VWDE	-0.64	-6.3	-0.36	1.22e-9	Coronary artery disease;
CESC	cis	rs875971	0.895	rs1833495	chr7:65921595	T/C	cg12463550	chr7:65579703	CRCP	0.56	7.09	0.4	1.2e-11	Aortic root size;
CESC	cis	rs344364	0.511	rs2982455	chr16:1950498	T/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.55	-6.2	-0.36	2.15e-9	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs1729951	0.575	rs361243	chr3:136697786	C/T	cg03617693	chr3:136751559	NA	0.39	5.43	0.32	1.28e-7	Neuroticism;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg14558639	chr19:35760677	USF2	-0.46	-6.22	-0.36	1.93e-9	Fibrinogen levels;
CESC	cis	rs7618915	0.501	rs34739010	chr3:52766122	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.61	8.62	0.47	6.27e-16	Bipolar disorder;
CESC	cis	rs7927592	0.956	rs12274114	chr11:68255577	A/C	cg20283391	chr11:68216788	NA	-0.53	-6.41	-0.37	6.5e-10	Total body bone mineral density;
CESC	trans	rs354225	0.539	rs13428703	chr2:54960680	G/A	cg26336731	chr22:42016984	XRCC6;PPPDE2	-0.64	-6.0	-0.35	6.34e-9	Schizophrenia;
CESC	cis	rs7553864	0.667	rs6576866	chr1:87601471	T/C	cg17420885	chr1:87600446	LOC339524	-0.42	-5.68	-0.33	3.47e-8	Smoking behavior;
CESC	trans	rs208520	0.661	rs150263	chr6:66777620	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-12.48	-0.61	2.03e-28	Exhaled nitric oxide output;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25418777	chr20:44035099	DBNDD2;SYS1-DBNDD2	0.52	6.21	0.36	2.07e-9	Gut microbiome composition (summer);
CESC	cis	rs7824557	0.806	rs6601573	chr8:11094751	A/G	cg21775007	chr8:11205619	TDH	-0.36	-5.24	-0.31	3.22e-7	Retinal vascular caliber;
CESC	cis	rs12476592	0.602	rs174485	chr2:63857402	G/A	cg17519650	chr2:63277830	OTX1	-0.45	-5.1	-0.3	6.61e-7	Childhood ear infection;
CESC	cis	rs5753618	0.583	rs2899164	chr22:31790289	G/A	cg13145458	chr22:31556086	RNF185	-0.5	-5.91	-0.34	1.02e-8	Colorectal cancer;
CESC	cis	rs2832191	0.692	rs2245517	chr21:30357968	C/T	cg24692254	chr21:30365293	RNF160	0.97	17.47	0.73	5.36e-46	Dental caries;
CESC	cis	rs1577917	0.958	rs2225754	chr6:86449698	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.52	-6.76	-0.38	8.98e-11	Response to antipsychotic treatment;
CESC	cis	rs9326248	0.530	rs2000616	chr11:116916529	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.56	5.18	0.3	4.38e-7	Blood protein levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00919016	chr7:139168487	KLRG2	0.48	6.06	0.35	4.58e-9	Gut microbiome composition (summer);
CESC	cis	rs763014	0.898	rs4984897	chr16:632180	G/C	cg00802000	chr16:706648	WDR90	-0.41	-6.12	-0.35	3.33e-9	Height;
CESC	cis	rs478304	0.580	rs11606947	chr11:65508237	A/C	cg10518572	chr11:65560635	OVOL1	-0.32	-6.19	-0.36	2.31e-9	Acne (severe);
CESC	cis	rs4665809	0.590	rs6730310	chr2:26419470	C/G	cg22920501	chr2:26401640	FAM59B	-0.86	-10.21	-0.53	7.23e-21	Gut microbiome composition (summer);
CESC	trans	rs2235573	0.517	rs4821727	chr22:38393423	C/A	cg19894588	chr14:64061835	NA	0.55	7.03	0.4	1.77e-11	Glioblastoma;Glioma;
CESC	cis	rs3793683	0.520	rs12769959	chr10:134579026	A/C	cg26818010	chr10:134567672	INPP5A	-0.86	-10.62	-0.55	3.5e-22	Migraine;
CESC	cis	rs12478296	0.591	rs7573042	chr2:242996589	A/G	cg06360820	chr2:242988706	NA	-0.57	-7.78	-0.43	1.66e-13	Obesity-related traits;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg24780086	chr5:14713043	ANKH	0.47	6.76	0.38	8.71e-11	Fibrinogen levels;
CESC	cis	rs4780401	0.567	rs12920377	chr16:11781582	A/C	cg01061890	chr16:11836724	TXNDC11	-0.43	-5.57	-0.32	6.29e-8	Rheumatoid arthritis;
CESC	cis	rs5757676	0.858	rs6001585	chr22:39812986	G/T	cg02038168	chr22:39784481	NA	-0.63	-6.78	-0.38	7.83e-11	IgG glycosylation;
CESC	cis	rs3091242	0.934	rs686631	chr1:25719599	A/T	cg12412775	chr1:25698385	RHCE	-0.33	-6.03	-0.35	5.42e-9	Erythrocyte sedimentation rate;
CESC	cis	rs4253772	0.550	rs6007779	chr22:46678615	A/C	cg07012999	chr22:46692446	CN5H6.4;GTSE1	0.5	5.21	0.3	3.88e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs6502050	0.731	rs9891378	chr17:80116035	T/C	cg11859384	chr17:80120422	CCDC57	-0.38	-5.17	-0.3	4.51e-7	Life satisfaction;
CESC	cis	rs35306767	0.903	rs12761424	chr10:967295	C/T	cg10556349	chr10:835070	NA	0.54	5.77	0.33	2.17e-8	Eosinophil percentage of granulocytes;
CESC	cis	rs72781680	0.846	rs72782114	chr2:24025740	G/A	cg08917208	chr2:24149416	ATAD2B	0.96	8.71	0.47	3.37e-16	Lymphocyte counts;
CESC	cis	rs11098499	0.562	rs13101722	chr4:120555975	C/A	cg09307838	chr4:120376055	NA	-0.61	-8.05	-0.44	2.8e-14	Corneal astigmatism;
CESC	cis	rs7312774	0.618	rs4964501	chr12:107330079	C/T	cg16260113	chr12:107380972	MTERFD3	-0.77	-6.99	-0.39	2.23e-11	Severe influenza A (H1N1) infection;
CESC	cis	rs17376456	0.825	rs56108532	chr5:93276342	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.61	5.15	0.3	4.98e-7	Diabetic retinopathy;
CESC	cis	rs1552244	1.000	rs4260416	chr3:10125283	C/T	cg13047869	chr3:10149882	C3orf24	0.39	5.05	0.3	8.22e-7	Alzheimer's disease;
CESC	cis	rs6570726	0.846	rs9376954	chr6:145943737	T/A	cg05347473	chr6:146136440	FBXO30	0.53	6.89	0.39	4.01e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs651907	0.557	rs7651721	chr3:101393583	C/A	cg12386194	chr3:101231763	SENP7	0.46	5.61	0.33	5.16e-8	Colorectal cancer;
CESC	cis	rs4900538	0.821	rs8016191	chr14:102825340	G/A	cg18135206	chr14:102964638	TECPR2	-0.68	-8.13	-0.45	1.67e-14	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	cis	rs10751667	0.666	rs10902235	chr11:938892	T/C	cg01483505	chr11:975446	AP2A2	0.38	5.18	0.3	4.33e-7	Alzheimer's disease (late onset);
CESC	cis	rs6540559	0.611	rs11810817	chr1:210011747	C/G	cg21951975	chr1:209979733	IRF6	0.55	6.57	0.37	2.71e-10	Cleft lip with or without cleft palate;
CESC	cis	rs6933660	0.720	rs6913515	chr6:151753470	G/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.65	9.33	0.5	4.4e-18	Menarche (age at onset);
CESC	cis	rs4253772	0.591	rs6007795	chr22:46686792	C/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.76	8.8	0.48	1.8e-16	LDL cholesterol;Cholesterol, total;
CESC	cis	rs9858542	0.953	rs11706370	chr3:49441091	G/A	cg07274523	chr3:49395745	GPX1	0.66	8.22	0.45	8.84e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs2455799	0.573	rs924753	chr3:15706124	C/T	cg16303742	chr3:15540471	COLQ	-0.35	-5.57	-0.32	6.24e-8	Mean platelet volume;
CESC	cis	rs853679	0.517	rs9468292	chr6:28095355	G/A	cg23281280	chr6:28129359	ZNF389	0.58	8.05	0.44	2.72e-14	Depression;
CESC	cis	rs6584283	0.846	rs10883370	chr10:101291472	T/C	cg09788492	chr10:101292477	NKX2-3	0.33	6.18	0.35	2.45e-9	Ulcerative colitis;
CESC	cis	rs9399135	0.622	rs3817776	chr6:135256756	C/T	cg12549451	chr6:135224345	NA	-0.36	-5.43	-0.32	1.28e-7	Red blood cell count;
CESC	cis	rs4665809	0.878	rs4143538	chr2:26290178	A/C	cg26314531	chr2:26401878	FAM59B	-0.76	-8.42	-0.46	2.48e-15	Gut microbiome composition (summer);
CESC	cis	rs854765	0.547	rs7212167	chr17:17913504	G/A	cg09796270	chr17:17721594	SREBF1	0.4	5.52	0.32	7.97e-8	Total body bone mineral density;
CESC	cis	rs2227631	0.505	rs4729662	chr7:100765559	C/T	cg08053846	chr7:100769605	SERPINE1	-0.45	-5.26	-0.31	2.92e-7	Plasminogen activator inhibitor type 1 levels (PAI-1);
CESC	cis	rs10979	0.597	rs9390118	chr6:143907610	A/G	cg25407410	chr6:143891975	LOC285740	-0.49	-6.31	-0.36	1.16e-9	Hypospadias;
CESC	cis	rs1008375	1.000	rs1974624	chr4:17650281	A/G	cg16339924	chr4:17578868	LAP3	0.64	7.91	0.44	6.79e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs798554	0.959	rs798558	chr7:2758935	T/G	cg04166393	chr7:2884313	GNA12	0.53	6.63	0.38	1.84e-10	Height;
CESC	cis	rs7666738	0.800	rs2839836	chr4:98970512	A/G	cg03676636	chr4:99064102	C4orf37	0.34	5.2	0.3	4.04e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9457247	1.000	rs422780	chr6:167406209	A/G	cg23791538	chr6:167370224	RNASET2	-0.59	-8.54	-0.46	1.09e-15	Crohn's disease;
CESC	cis	rs12681288	0.862	rs2004701	chr8:1022287	A/G	cg04851639	chr8:1020857	NA	-0.38	-8.56	-0.47	9.08e-16	Schizophrenia;
CESC	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	10.32	0.54	3.32e-21	Prudent dietary pattern;
CESC	cis	rs1728785	1.000	rs1182968	chr16:68573945	C/T	cg02972257	chr16:68554789	NA	-0.55	-6.32	-0.36	1.08e-9	Ulcerative colitis;
CESC	cis	rs28647808	1.000	rs28709650	chr9:136276699	G/C	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.9	5.73	0.33	2.75e-8	Blood protein levels;
CESC	cis	rs4253772	0.550	rs6008598	chr22:46704243	C/T	cg00784671	chr22:46762841	CELSR1	-0.48	-5.55	-0.32	7.04e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs9287719	0.901	rs6432109	chr2:10736821	A/G	cg02196655	chr2:10830764	NOL10	-0.37	-5.72	-0.33	2.87e-8	Prostate cancer;
CESC	trans	rs208520	0.742	rs208454	chr6:66907783	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.84	-9.54	-0.51	9.64e-19	Exhaled nitric oxide output;
CESC	cis	rs2439831	0.850	rs7169988	chr15:44060435	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.71	6.71	0.38	1.18e-10	Lung cancer in ever smokers;
CESC	cis	rs5769765	0.773	rs58375955	chr22:50312630	A/G	cg02269571	chr22:50332266	NA	-0.57	-6.99	-0.39	2.29e-11	Schizophrenia;
CESC	cis	rs9287719	0.967	rs12995602	chr2:10753542	C/A	cg00105475	chr2:10696890	NA	0.38	5.42	0.32	1.34e-7	Prostate cancer;
CESC	cis	rs7116495	0.609	rs60054591	chr11:71825687	G/A	cg26138937	chr11:71823887	C11orf51	1.22	7.75	0.43	2.02e-13	Severe influenza A (H1N1) infection;
CESC	cis	rs7659604	0.502	rs4075066	chr4:122684283	T/C	cg19671926	chr4:122722719	EXOSC9	0.6	7.65	0.43	3.84e-13	Type 2 diabetes;
CESC	cis	rs881375	0.933	rs7028641	chr9:123691141	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.38	5.08	0.3	7.23e-7	Rheumatoid arthritis;
CESC	cis	rs11676348	0.846	rs3890158	chr2:218990292	G/A	cg00012203	chr2:219082015	ARPC2	-0.57	-7.46	-0.42	1.27e-12	Ulcerative colitis;
CESC	trans	rs2727020	0.553	rs7479975	chr11:49581964	C/G	cg15704280	chr7:45808275	SEPT13	-0.91	-15.17	-0.68	7.93e-38	Coronary artery disease;
CESC	cis	rs72781680	0.611	rs55983206	chr2:24333995	A/C	cg20701182	chr2:24300061	SF3B14	0.93	10.4	0.54	1.79e-21	Lymphocyte counts;
CESC	cis	rs2952156	0.883	rs1495100	chr17:37832279	C/T	cg07936489	chr17:37558343	FBXL20	-0.6	-7.57	-0.42	6.06e-13	Asthma;
CESC	cis	rs2108622	0.711	rs113059233	chr19:15977368	G/A	cg13772218	chr19:15982569	NA	0.29	5.71	0.33	2.98e-8	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CESC	cis	rs4819052	0.851	rs1056101	chr21:46678702	C/G	cg11663144	chr21:46675770	NA	-0.52	-7.66	-0.43	3.51e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs6456156	0.846	rs7749827	chr6:167515624	C/T	cg07741184	chr6:167504864	NA	-0.35	-6.04	-0.35	5.2e-9	Primary biliary cholangitis;
CESC	cis	rs6987853	0.736	rs6991995	chr8:42436219	A/C	cg09913449	chr8:42400586	C8orf40	0.45	7.54	0.42	7.31e-13	Mean corpuscular hemoglobin concentration;
CESC	cis	rs1499614	0.803	rs1922723	chr7:66175063	C/T	cg13147721	chr7:65941812	NA	-0.94	-8.9	-0.48	9.08e-17	Gout;
CESC	cis	rs7666738	0.791	rs2903151	chr4:99027218	T/C	cg18180107	chr4:99064573	C4orf37	0.42	5.43	0.32	1.29e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9486719	0.843	rs2499797	chr6:96848669	C/T	cg06623918	chr6:96969491	KIAA0776	0.79	7.21	0.4	6.01e-12	Migraine;Coronary artery disease;
CESC	cis	rs10504229	1.000	rs3814486	chr8:58191226	A/T	cg05313129	chr8:58192883	C8orf71	-0.55	-6.29	-0.36	1.34e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs3096299	0.685	rs8050512	chr16:89552320	C/G	cg08392591	chr16:89556376	ANKRD11	0.59	8.1	0.45	1.99e-14	Multiple myeloma (IgH translocation);
CESC	cis	rs2235544	0.565	rs72664114	chr1:54471747	C/T	cg25741118	chr1:54482237	LDLRAD1	-0.24	-5.76	-0.33	2.29e-8	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
CESC	cis	rs9487051	0.700	rs9400266	chr6:109596193	T/A	cg21918786	chr6:109611834	NA	-0.38	-5.52	-0.32	8.19e-8	Reticulocyte fraction of red cells;
CESC	cis	rs875971	0.545	rs73376394	chr7:65637681	C/T	cg25405998	chr7:65216604	CCT6P1	0.44	5.07	0.3	7.49e-7	Aortic root size;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg07503662	chr16:87761121	KLHDC4	0.47	6.14	0.35	3.02e-9	Fibrinogen levels;
CESC	cis	rs11722228	0.522	rs7681250	chr4:10133013	G/T	cg14348967	chr4:10160060	NA	-0.39	-5.06	-0.3	7.9e-7	Gout;Urate levels;Serum uric acid levels;
CESC	cis	rs4472734	0.965	rs61271474	chr1:214621877	G/A	cg00063699	chr1:214624242	PTPN14	-0.33	-5.28	-0.31	2.76e-7	Height;
CESC	cis	rs6964587	1.000	rs6961928	chr7:91669808	C/T	cg17063962	chr7:91808500	NA	0.57	7.92	0.44	6.51e-14	Breast cancer;
CESC	cis	rs1879734	0.731	rs7544346	chr1:54158475	C/T	cg23596471	chr1:54105337	GLIS1	0.35	5.57	0.32	6.32e-8	Mitral valve prolapse;
CESC	cis	rs6860806	0.695	rs11952099	chr5:131576772	A/G	cg09877947	chr5:131593287	PDLIM4	0.45	5.98	0.34	7.23e-9	Breast cancer;
CESC	cis	rs344364	0.511	rs2982446	chr16:1947153	C/T	cg03013636	chr16:1946785	NA	0.48	6.62	0.38	2.02e-10	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs2637266	0.714	rs6480835	chr10:78446863	T/C	cg18941641	chr10:78392320	NA	0.43	7.8	0.43	1.43e-13	Pulmonary function;
CESC	cis	rs8070624	0.543	rs57728924	chr17:17875342	A/G	cg16928487	chr17:17741425	SREBF1	-0.62	-10.37	-0.54	2.2e-21	Total body bone mineral density;
CESC	cis	rs644799	1.000	rs557079	chr11:95530125	C/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.92	13.84	0.65	3.87e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	trans	rs42714	0.688	rs73073997	chr7:28478668	G/A	cg08140114	chr6:139482238	HECA	-0.83	-6.02	-0.35	5.68e-9	Amyotrophic lateral sclerosis in C9orf72 mutation negative individuals;
CESC	trans	rs1493916	0.905	rs12455290	chr18:31398778	A/G	cg27147174	chr7:100797783	AP1S1	-0.52	-6.93	-0.39	3.22e-11	Life satisfaction;
CESC	cis	rs12477438	0.520	rs4340581	chr2:99725025	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.87	16.09	0.7	4.08e-41	Chronic sinus infection;
CESC	cis	rs875971	0.522	rs1617484	chr7:65463095	G/A	cg14393609	chr7:65229607	NA	0.48	6.24	0.36	1.74e-9	Aortic root size;
CESC	cis	rs6495122	0.699	rs2168518	chr15:75081078	G/A	cg14664628	chr15:75095509	CSK	-0.68	-9.37	-0.5	3.23e-18	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
CESC	trans	rs7246760	0.867	rs56377135	chr19:9820116	C/T	cg02900749	chr2:68251473	NA	-0.81	-7.26	-0.41	4.4e-12	Pursuit maintenance gain;
CESC	cis	rs79387448	0.638	rs13405222	chr2:102981891	T/C	cg09003973	chr2:102972529	NA	1.2	9.22	0.49	9.89e-18	Gut microbiota (bacterial taxa);
CESC	cis	rs250677	0.522	rs4562031	chr5:148368451	A/G	cg18129178	chr5:148520854	ABLIM3	0.45	5.04	0.3	8.58e-7	Breast cancer;
CESC	cis	rs13108904	0.934	rs13125338	chr4:1278435	A/C	cg22903657	chr4:1355424	KIAA1530	-0.38	-5.23	-0.31	3.48e-7	Obesity-related traits;
CESC	cis	rs501120	0.810	rs535176	chr10:44747059	C/T	cg09554077	chr10:44749378	NA	0.52	6.92	0.39	3.41e-11	Coronary artery disease;Coronary heart disease;
CESC	cis	rs12479064	0.724	rs2309618	chr2:99974473	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.6	-7.2	-0.4	6.39e-12	Chronic sinus infection;
CESC	trans	rs561341	1.000	rs4795670	chr17:30244839	T/C	cg20587970	chr11:113659929	NA	-0.89	-10.75	-0.55	1.33e-22	Hip circumference adjusted for BMI;
CESC	cis	rs2635047	0.811	rs17723754	chr18:44771481	C/T	cg24371990	chr18:44770781	NA	0.43	6.87	0.39	4.53e-11	Educational attainment;
CESC	cis	rs9322193	0.962	rs1413655	chr6:150142951	A/G	cg07701084	chr6:150067640	NUP43	0.42	5.77	0.33	2.25e-8	Lung cancer;
CESC	cis	rs854765	0.647	rs6826	chr17:18011140	C/T	cg09796270	chr17:17721594	SREBF1	0.42	5.7	0.33	3.22e-8	Total body bone mineral density;
CESC	cis	rs951366	0.903	rs708723	chr1:205739266	C/T	cg26354017	chr1:205819088	PM20D1	0.54	7.74	0.43	2.16e-13	Menarche (age at onset);
CESC	cis	rs7044106	0.762	rs966396	chr9:123453281	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.77	11.25	0.57	2.87e-24	Hip circumference adjusted for BMI;
CESC	cis	rs6724607	1.000	rs4853513	chr2:191479455	C/T	cg21644426	chr2:191273491	MFSD6	-0.49	-6.69	-0.38	1.35e-10	Pulse pressure;
CESC	cis	rs9815354	0.556	rs60966614	chr3:42005166	A/G	cg03022575	chr3:42003672	ULK4	0.65	5.73	0.33	2.75e-8	Pulse pressure;Diastolic blood pressure;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21912093	chr14:73704842	PAPLN	0.59	7.09	0.4	1.24e-11	Gut microbiome composition (summer);
CESC	cis	rs412050	0.696	rs79103791	chr22:22244897	A/G	cg17089214	chr22:22089827	YPEL1	0.72	6.21	0.36	2.09e-9	Attention deficit hyperactivity disorder;
CESC	cis	rs9467773	0.620	rs3800303	chr6:26598188	A/G	cg20266910	chr6:26577678	NA	0.36	5.86	0.34	1.34e-8	Intelligence (multi-trait analysis);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg22496665	chr3:46887449	NA	-0.43	-6.08	-0.35	4.21e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs5753618	0.583	rs2899164	chr22:31790289	G/A	cg00478049	chr22:31556069	RNF185	-0.44	-5.19	-0.3	4.24e-7	Colorectal cancer;
CESC	cis	rs3733585	0.699	rs62294331	chr4:9959889	A/G	cg11266682	chr4:10021025	SLC2A9	-0.6	-11.2	-0.57	4.42e-24	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs12477438	0.520	rs11695751	chr2:99708247	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	15.18	0.68	6.85e-38	Chronic sinus infection;
CESC	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg11301795	chr4:187892539	NA	-0.81	-14.49	-0.66	1.92e-35	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs597539	0.690	rs578791	chr11:68625809	C/T	cg21963583	chr11:68658836	MRPL21	0.42	5.68	0.33	3.45e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs5758511	0.680	rs5751243	chr22:42617177	T/C	cg12850546	chr22:42539477	CYP2D7P1	-0.48	-5.12	-0.3	5.79e-7	Birth weight;
CESC	cis	rs9291683	0.546	rs12504565	chr4:10045145	G/A	cg02734326	chr4:10020555	SLC2A9	0.45	6.19	0.36	2.29e-9	Bone mineral density;
CESC	cis	rs8114671	0.647	rs1415771	chr20:33734493	G/A	cg24642439	chr20:33292090	TP53INP2	0.51	6.5	0.37	3.86e-10	Height;
CESC	cis	rs2836974	1.000	rs2836974	chr21:40663181	A/G	cg11644478	chr21:40555479	PSMG1	-1.01	-15.87	-0.7	2.52e-40	Cognitive function;
CESC	cis	rs6951245	0.507	rs11976805	chr7:1138716	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.42	-5.59	-0.32	5.59e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs10256972	0.869	rs4720158	chr7:1040325	A/G	cg00431813	chr7:1051703	C7orf50	-0.39	-6.09	-0.35	3.97e-9	Longevity;Endometriosis;
CESC	cis	rs830124	0.516	rs1177588	chr12:122389167	A/G	cg22168489	chr12:122356033	WDR66	-0.38	-5.05	-0.3	8.27e-7	Urinary metabolites;
CESC	cis	rs853679	0.607	rs201002	chr6:27808192	A/G	cg26587870	chr6:27730563	NA	-0.55	-5.4	-0.31	1.47e-7	Depression;
CESC	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg05552183	chr6:42928497	GNMT	0.87	15.8	0.7	4.47e-40	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs6121246	0.697	rs6060446	chr20:30231637	T/C	cg13852791	chr20:30311386	BCL2L1	0.8	8.21	0.45	9.79e-15	Mean corpuscular hemoglobin;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07897837	chr1:231377046	C1orf131;GNPAT	-0.58	-6.62	-0.38	1.95e-10	Gut microbiome composition (summer);
CESC	cis	rs7107217	1.000	rs1873872	chr11:129473993	A/T	cg24592846	chr11:129873229	NCRNA00167;PRDM10	0.42	5.36	0.31	1.84e-7	Breast cancer;Type 2 diabetes;
CESC	cis	rs7216064	0.655	rs8078543	chr17:66037251	G/T	cg07042672	chr17:66097459	LOC651250	0.66	8.74	0.47	2.69e-16	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs344364	0.511	rs2917519	chr16:1950479	C/A	cg26617929	chr16:1858877	NA	-0.49	-5.15	-0.3	5.09e-7	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs12142240	0.698	rs17357711	chr1:46829013	A/G	cg00530320	chr1:46809349	NSUN4	0.6	8.04	0.44	3.02e-14	Menopause (age at onset);
CESC	cis	rs950776	0.518	rs12594391	chr15:78816240	A/G	cg06917634	chr15:78832804	PSMA4	0.79	11.88	0.59	2.16e-26	Sudden cardiac arrest;
CESC	cis	rs1443512	0.812	rs1561987	chr12:54335268	C/T	cg12374095	chr12:54320830	NA	-0.42	-5.79	-0.34	1.96e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
CESC	cis	rs2070488	0.695	rs6599201	chr3:38476614	A/G	cg24069376	chr3:38537580	EXOG	0.33	5.5	0.32	9e-8	Electrocardiographic conduction measures;
CESC	trans	rs1814175	0.754	rs28593359	chr11:50042357	C/T	cg15704280	chr7:45808275	SEPT13	-1.05	-20.97	-0.79	3.22e-58	Height;
CESC	cis	rs7937682	0.889	rs541198	chr11:111475340	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.95	-14.72	-0.67	3.09e-36	Primary sclerosing cholangitis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05137146	chr16:30103511	TBX6	0.55	6.37	0.36	8.36e-10	Gut microbiome composition (summer);
CESC	cis	rs3768617	0.510	rs2296292	chr1:183086757	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.89	14.36	0.66	5.49e-35	Fuchs's corneal dystrophy;
CESC	cis	rs10504229	0.593	rs116916898	chr8:57984958	G/A	cg24829409	chr8:58192753	C8orf71	-0.68	-6.38	-0.37	7.67e-10	Developmental language disorder (linguistic errors);
CESC	trans	rs853679	0.766	rs9368561	chr6:28168343	C/T	cg06606381	chr12:133084897	FBRSL1	-0.64	-6.06	-0.35	4.68e-9	Depression;
CESC	cis	rs644799	0.544	rs687559	chr11:95598629	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	-0.45	-5.86	-0.34	1.36e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs9488822	0.676	rs873879	chr6:116391259	A/G	cg15226275	chr6:116381976	FRK	0.26	6.69	0.38	1.3e-10	Cholesterol, total;LDL cholesterol;
CESC	cis	rs1355223	0.506	rs7130774	chr11:34869267	A/G	cg11622362	chr11:34938112	PDHX;APIP	0.46	5.45	0.32	1.14e-7	Systemic lupus erythematosus and Systemic sclerosis;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg07161888	chr16:53537348	AKTIP	-0.45	-6.13	-0.35	3.19e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs7666738	0.830	rs13137859	chr4:99050319	A/G	cg18180107	chr4:99064573	C4orf37	0.41	5.29	0.31	2.51e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7631605	0.905	rs12629462	chr3:37226969	A/C	cg22985146	chr3:37219077	LRRFIP2	-0.32	-5.24	-0.31	3.21e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs9858542	0.953	rs11713474	chr3:49611457	A/G	cg03060546	chr3:49711283	APEH	-0.53	-6.17	-0.35	2.52e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs9300255	0.739	rs4759417	chr12:123746510	C/T	cg19016782	chr12:123741754	C12orf65	-0.5	-7.23	-0.41	5.16e-12	Neutrophil percentage of white cells;
CESC	cis	rs9649213	0.593	rs6949214	chr7:97960233	G/A	cg08684580	chr7:98029266	BAIAP2L1	-0.34	-5.63	-0.33	4.6e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs11723261	0.546	rs57839456	chr4:148289	C/G	cg12746427	chr4:53362	ZNF718;ZNF595	0.46	5.96	0.34	8.05e-9	Immune response to smallpox vaccine (IL-6);
CESC	cis	rs6963495	0.872	rs1569134	chr7:105158228	T/C	cg02135003	chr7:105160482	PUS7	-0.46	-5.55	-0.32	6.92e-8	Bipolar disorder (body mass index interaction);
CESC	cis	rs3092073	0.624	rs7275164	chr20:44604822	G/A	cg23303369	chr20:44641161	MMP9	0.33	5.14	0.3	5.29e-7	Intelligence (multi-trait analysis);
CESC	cis	rs2050392	0.590	rs2065723	chr10:30720462	A/T	cg18806716	chr10:30721971	MAP3K8	-0.63	-9.25	-0.49	7.67e-18	Inflammatory bowel disease;
CESC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg15399923	chr2:209130889	PIKFYVE	0.6	6.13	0.35	3.13e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs4523957	0.818	rs4790887	chr17:2130592	C/A	cg16513277	chr17:2031491	SMG6	0.63	8.77	0.47	2.19e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs4253772	0.591	rs6008546	chr22:46686377	T/G	cg09491104	chr22:46646882	C22orf40	-0.56	-7.09	-0.4	1.24e-11	LDL cholesterol;Cholesterol, total;
CESC	cis	rs13191362	0.507	rs2849511	chr6:163139050	C/G	cg21926612	chr6:163149169	PACRG;PARK2	-0.63	-7.46	-0.42	1.24e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs4919044	0.756	rs2486686	chr10:94778511	G/T	cg00487187	chr10:94451625	HHEX	-0.45	-5.05	-0.3	8.21e-7	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11468462	chr12:57610686	NXPH4	0.53	6.05	0.35	5e-9	Gut microbiome composition (summer);
CESC	cis	rs2073300	0.609	rs6137938	chr20:23389127	C/G	cg12062639	chr20:23401060	NAPB	0.99	8.13	0.45	1.62e-14	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs7772486	0.846	rs9403767	chr6:146402386	G/T	cg05347473	chr6:146136440	FBXO30	0.5	6.37	0.36	8.55e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1008375	1.000	rs17507481	chr4:17620066	A/G	cg16339924	chr4:17578868	LAP3	0.66	8.42	0.46	2.35e-15	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs1577917	1.000	rs10455158	chr6:86672825	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.45	-5.92	-0.34	9.76e-9	Response to antipsychotic treatment;
CESC	cis	rs12142240	0.698	rs13374893	chr1:46843800	A/G	cg00530320	chr1:46809349	NSUN4	0.59	7.97	0.44	4.81e-14	Menopause (age at onset);
CESC	cis	rs7666738	0.830	rs1876192	chr4:98727555	T/C	cg03676636	chr4:99064102	C4orf37	0.33	5.03	0.3	8.96e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6933660	0.536	rs3800274	chr6:151759192	T/G	cg02564969	chr6:151773285	C6orf211;RMND1	0.51	6.09	0.35	3.98e-9	Menarche (age at onset);
CESC	cis	rs5769765	0.913	rs4824111	chr22:50284305	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.51	5.61	0.33	5.08e-8	Schizophrenia;
CESC	cis	rs1799949	0.965	rs12947782	chr17:41279882	A/G	cg23758822	chr17:41437982	NA	1.02	15.6	0.69	2.35e-39	Menopause (age at onset);
CESC	cis	rs2204008	0.591	rs11495396	chr12:38380182	C/T	cg13010199	chr12:38710504	ALG10B	0.48	6.23	0.36	1.87e-9	Bladder cancer;
CESC	cis	rs11750568	0.933	rs7719616	chr5:178536584	A/G	cg10208897	chr5:178548229	ADAMTS2	0.38	5.32	0.31	2.2e-7	Height;
CESC	cis	rs36051895	0.658	rs10974910	chr9:5010091	G/A	cg02405213	chr9:5042618	JAK2	-0.48	-5.53	-0.32	7.83e-8	Pediatric autoimmune diseases;
CESC	trans	rs11098499	0.954	rs59866101	chr4:120296591	T/G	cg25214090	chr10:38739885	LOC399744	0.68	9.2	0.49	1.14e-17	Corneal astigmatism;
CESC	cis	rs3091242	0.967	rs665372	chr1:25719235	A/C	cg03538708	chr1:25844672	NA	-0.38	-5.63	-0.33	4.66e-8	Erythrocyte sedimentation rate;
CESC	cis	rs6679073	1.000	rs6679073	chr1:205756484	A/C	cg26354017	chr1:205819088	PM20D1	0.39	5.21	0.3	3.76e-7	Prostate-specific antigen levels;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg13846960	chr9:2718456	KCNV2	0.48	6.25	0.36	1.6e-9	Fibrinogen levels;
CESC	cis	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg27589368	chr17:43923255	LOC100128977;IMP5	-0.39	-5.24	-0.31	3.28e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs910316	0.967	rs4899550	chr14:75647666	C/T	cg08847533	chr14:75593920	NEK9	-0.94	-16.62	-0.71	5.67e-43	Height;
CESC	cis	rs10927875	0.632	rs2862162	chr1:16142960	A/C	cg04889800	chr1:16163555	FLJ37453	-0.37	-5.2	-0.3	4.08e-7	Dilated cardiomyopathy;
CESC	cis	rs7605827	0.930	rs6749063	chr2:15565278	T/G	cg19274914	chr2:15703543	NA	0.35	6.29	0.36	1.3e-9	Educational attainment (years of education);
CESC	cis	rs344364	0.511	rs2982447	chr16:1947413	C/T	cg03013636	chr16:1946785	NA	-0.49	-6.61	-0.38	2.09e-10	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs11920090	0.720	rs58284370	chr3:170738849	G/A	cg09710316	chr3:170744871	SLC2A2	0.56	6.31	0.36	1.17e-9	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
CESC	cis	rs2075371	1.000	rs2058976	chr7:133981379	G/T	cg00033643	chr7:134001901	SLC35B4	0.44	5.76	0.33	2.33e-8	Mean platelet volume;
CESC	cis	rs4253772	0.872	rs41362646	chr22:46633505	G/A	cg18190219	chr22:46762943	CELSR1	-0.61	-5.86	-0.34	1.39e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs807669	0.548	rs885979	chr22:19198375	T/C	cg02655711	chr22:19163373	SLC25A1	0.79	11.96	0.59	1.24e-26	Metabolite levels;
CESC	cis	rs2249694	0.960	rs4133041	chr10:135408387	G/A	cg20169779	chr10:135381914	SYCE1	-0.39	-5.52	-0.32	7.97e-8	Obesity-related traits;
CESC	cis	rs4665809	0.590	rs1056389	chr2:26502875	T/C	cg25036284	chr2:26402008	FAM59B	0.85	8.95	0.48	6.29e-17	Gut microbiome composition (summer);
CESC	cis	rs55692411	0.517	rs62262106	chr3:49991427	A/G	cg24308560	chr3:49941425	MST1R	-0.53	-6.39	-0.37	7.37e-10	Intelligence (multi-trait analysis);
CESC	cis	rs12912251	1.000	rs7163869	chr15:38988391	G/C	cg01338139	chr15:38987640	C15orf53	-0.47	-5.43	-0.32	1.26e-7	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
CESC	cis	rs1862618	0.853	rs252887	chr5:56166188	A/G	cg22800045	chr5:56110881	MAP3K1	0.81	9.67	0.51	3.84e-19	Initial pursuit acceleration;
CESC	cis	rs1799949	0.930	rs33968979	chr17:41297992	G/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.45	6.31	0.36	1.17e-9	Menopause (age at onset);
CESC	cis	rs863345	0.604	rs6670343	chr1:158497258	A/T	cg12129480	chr1:158549410	OR10X1	-0.35	-6.86	-0.39	4.78e-11	Pneumococcal bacteremia;
CESC	cis	rs4835473	0.897	rs7681914	chr4:144629991	A/G	cg25736465	chr4:144833511	NA	0.4	6.17	0.35	2.59e-9	Immature fraction of reticulocytes;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg06925625	chr13:113887609	CUL4A	0.55	7.18	0.4	7.24e-12	Fibrinogen levels;
CESC	cis	rs7831492	0.564	rs11787479	chr8:41613496	A/G	cg17182837	chr8:41585554	ANK1	-0.41	-6.25	-0.36	1.65e-9	Colorectal cancer;
CESC	cis	rs6460942	0.597	rs6944517	chr7:12515283	C/T	cg06484146	chr7:12443880	VWDE	-0.64	-7.13	-0.4	9.4e-12	Coronary artery disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg20877507	chr13:50464614	LOC220429	0.43	6.12	0.35	3.41e-9	Fibrinogen levels;
CESC	cis	rs7959452	0.590	rs11177619	chr12:69758871	G/A	cg14784868	chr12:69753453	YEATS4	0.83	12.94	0.62	5.29e-30	Blood protein levels;
CESC	cis	rs17826219	0.500	rs28452421	chr17:29083980	G/A	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.17e-10	Body mass index;
CESC	cis	rs6860806	0.507	rs200837	chr5:131699958	G/A	cg18758796	chr5:131593413	PDLIM4	0.41	5.41	0.32	1.43e-7	Breast cancer;
CESC	cis	rs739401	0.572	rs410820	chr11:3080102	G/A	cg25174290	chr11:3078921	CARS	0.63	8.57	0.47	8.78e-16	Longevity;
CESC	cis	rs3126085	0.935	rs7531094	chr1:152176850	A/G	cg26876637	chr1:152193138	HRNR	0.46	5.33	0.31	2.14e-7	Atopic dermatitis;
CESC	cis	rs2066819	1.000	rs111885088	chr12:56657216	A/C	cg26734620	chr12:56694298	CS	1.03	6.76	0.38	8.6e-11	Psoriasis vulgaris;
CESC	cis	rs2637266	1.000	rs7897015	chr10:78366566	G/C	cg18941641	chr10:78392320	NA	0.43	8.26	0.45	6.94e-15	Pulmonary function;
CESC	cis	rs6540559	1.000	rs7522250	chr1:209962539	T/C	cg22442454	chr1:209979470	IRF6	0.43	5.15	0.3	5.13e-7	Cleft lip with or without cleft palate;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg10685559	chr22:18633123	USP18	-0.43	-6.01	-0.35	6.05e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs875971	0.862	rs801206	chr7:66021966	C/G	cg10691866	chr7:65817282	TPST1	0.33	5.51	0.32	8.51e-8	Aortic root size;
CESC	cis	rs6500395	0.890	rs3843724	chr16:48618573	C/G	cg04672837	chr16:48644449	N4BP1	0.47	5.82	0.34	1.72e-8	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs4969178	0.965	rs3817294	chr17:76396963	A/G	cg20026190	chr17:76395443	PGS1	0.49	7.81	0.43	1.34e-13	HDL cholesterol levels;
CESC	cis	rs6061231	0.761	rs2427312	chr20:60970591	C/T	cg22601191	chr20:60968625	CABLES2	0.58	5.61	0.33	5.15e-8	Colorectal cancer;
CESC	cis	rs10927875	0.632	rs4661666	chr1:16162471	C/A	cg21385522	chr1:16154831	NA	-1.02	-17.0	-0.72	2.47e-44	Dilated cardiomyopathy;
CESC	cis	rs3820068	0.603	rs59558854	chr1:15971399	T/G	cg18133145	chr1:16060689	PLEKHM2	-0.39	-5.04	-0.3	8.81e-7	Systolic blood pressure;
CESC	cis	rs12541635	0.934	rs62527361	chr8:107021574	T/A	cg10147462	chr8:107024639	NA	0.4	5.65	0.33	4.1e-8	Age of smoking initiation;
CESC	cis	rs6933660	0.745	rs9397405	chr6:151736084	G/T	cg14416726	chr6:151773293	C6orf211;RMND1	-0.55	-7.31	-0.41	3.22e-12	Menarche (age at onset);
CESC	cis	rs2011503	1.000	rs55927782	chr19:19642032	T/C	cg11584989	chr19:19387371	SF4	0.63	7.15	0.4	8.47e-12	Bipolar disorder;
CESC	cis	rs72781680	0.848	rs6754694	chr2:24155448	T/C	cg20701182	chr2:24300061	SF3B14	0.65	5.77	0.33	2.22e-8	Lymphocyte counts;
CESC	cis	rs17376456	1.000	rs13185608	chr5:93509688	T/G	cg25358565	chr5:93447407	FAM172A	1.17	10.96	0.56	2.63e-23	Diabetic retinopathy;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg15472170	chr1:12012720	PLOD1	-0.44	-6.11	-0.35	3.51e-9	Asthma;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00564598	chr19:10216860	SNORD105;PPAN-P2RY11;PPAN	0.66	7.73	0.43	2.21e-13	Gut microbiome composition (summer);
CESC	cis	rs3796352	0.892	rs11718388	chr3:53076415	G/A	cg12962167	chr3:53033115	SFMBT1	0.61	5.04	0.3	8.66e-7	Immune reponse to smallpox (secreted IL-2);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg13155599	chr4:120221765	C4orf3	-0.49	-6.38	-0.36	7.83e-10	Fibrinogen levels;
CESC	cis	rs11190604	1.000	rs11190558	chr10:102209397	C/A	cg07080220	chr10:102295463	HIF1AN	0.55	5.51	0.32	8.5e-8	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs6500602	0.627	rs9934267	chr16:4534366	G/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.41	5.81	0.34	1.83e-8	Schizophrenia;
CESC	cis	rs853679	0.517	rs9283884	chr6:28135660	C/G	cg18032046	chr6:28092343	ZSCAN16	0.55	6.22	0.36	1.92e-9	Depression;
CESC	cis	rs7666738	0.830	rs10001702	chr4:99065160	T/G	cg03467027	chr4:99064603	C4orf37	0.48	5.95	0.34	8.67e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2737618	0.674	rs2737683	chr1:200092448	G/A	cg21825944	chr1:200113062	NR5A2	-0.45	-6.72	-0.38	1.08e-10	Uric acid levels;
CESC	cis	rs295140	0.605	rs10931893	chr2:201114652	A/G	cg23649088	chr2:200775458	C2orf69	-0.42	-5.71	-0.33	3.02e-8	QT interval;
CESC	cis	rs2011503	1.000	rs77616520	chr19:19652776	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.52	5.09	0.3	6.68e-7	Bipolar disorder;
CESC	cis	rs763121	0.752	rs6001190	chr22:39073811	T/C	cg06544989	chr22:39130855	UNC84B	0.5	8.61	0.47	6.51e-16	Menopause (age at onset);
CESC	cis	rs9322193	0.923	rs12529698	chr6:149972087	G/A	cg13206674	chr6:150067644	NUP43	0.45	6.72	0.38	1.12e-10	Lung cancer;
CESC	cis	rs61931739	0.500	rs7307583	chr12:34521711	T/C	cg06521331	chr12:34319734	NA	-0.37	-5.09	-0.3	6.85e-7	Morning vs. evening chronotype;
CESC	cis	rs3015497	0.586	rs12587842	chr14:51092562	A/G	cg09863266	chr14:51125203	SAV1	-0.32	-5.07	-0.3	7.62e-7	Mean platelet volume;
CESC	cis	rs8067545	0.532	rs12936794	chr17:19912570	C/T	cg12073167	chr17:19770448	ULK2	-0.48	-5.39	-0.31	1.54e-7	Schizophrenia;
CESC	cis	rs4819052	0.851	rs8130285	chr21:46671701	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.92	13.67	0.64	1.52e-32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs3741489	1.000	rs4758915	chr12:133477147	A/G	cg01499426	chr12:133417423	CHFR	0.89	5.57	0.32	6.38e-8	Cognitive function;
CESC	cis	rs11608355	0.508	rs11066394	chr12:109799212	C/A	cg19025524	chr12:109796872	NA	-0.42	-5.28	-0.31	2.63e-7	Neuroticism;
CESC	trans	rs4671386	0.747	rs907573	chr2:60523559	C/T	cg24386296	chr4:1723849	TMEM129;TACC3	-0.48	-6.07	-0.35	4.5e-9	Acne (severe);
CESC	trans	rs2115172	0.836	rs4835799	chr5:122762229	A/G	cg24451074	chr3:129035583	H1FX;C3orf47	0.47	6.17	0.35	2.61e-9	Weight;
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg20591167	chr15:99602178	NA	-0.49	-7.48	-0.42	1.09e-12	Vertical cup-disc ratio;
CESC	cis	rs897984	0.645	rs58726213	chr16:31044683	A/G	cg00531865	chr16:30841666	NA	-0.39	-5.49	-0.32	9.18e-8	Dementia with Lewy bodies;
CESC	cis	rs708547	0.647	rs1718839	chr4:57827206	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.6	7.98	0.44	4.41e-14	Response to bleomycin (chromatid breaks);
CESC	cis	rs78456975	0.550	rs10197874	chr2:1545310	A/G	cg01028140	chr2:1542097	TPO	-0.5	-6.27	-0.36	1.45e-9	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs2836974	0.899	rs2836957	chr21:40623134	T/C	cg17971929	chr21:40555470	PSMG1	1.06	16.27	0.71	9.3e-42	Cognitive function;
CESC	cis	rs35955747	0.869	rs131213	chr22:31753849	C/T	cg25791279	chr22:32026902	PISD	0.49	6.07	0.35	4.51e-9	Neutrophil count;Sum basophil neutrophil counts;
CESC	trans	rs11039798	0.588	rs7479642	chr11:48553808	G/T	cg15704280	chr7:45808275	SEPT13	0.66	6.62	0.38	1.97e-10	Axial length;
CESC	cis	rs1858740	0.509	rs196375	chr3:38422919	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.63	8.7	0.47	3.53e-16	Schizophrenia;
CESC	cis	rs7107174	1.000	rs9651768	chr11:77996020	C/T	cg02023728	chr11:77925099	USP35	0.38	5.6	0.33	5.35e-8	Testicular germ cell tumor;
CESC	cis	rs7851660	0.527	rs7870540	chr9:100573925	T/C	cg13688889	chr9:100608707	NA	-0.9	-14.95	-0.68	4.69e-37	Strep throat;
CESC	cis	rs863345	0.967	rs1592256	chr1:158470596	C/T	cg12129480	chr1:158549410	OR10X1	-0.31	-6.19	-0.36	2.34e-9	Pneumococcal bacteremia;
CESC	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.52	0.37	3.63e-10	Prudent dietary pattern;
CESC	cis	rs9858542	0.953	rs1873625	chr3:49666964	C/A	cg03060546	chr3:49711283	APEH	-0.56	-6.6	-0.38	2.23e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs460214	0.576	rs28446127	chr21:40029568	C/A	cg05519781	chr21:40033154	ERG	-0.45	-5.46	-0.32	1.09e-7	Response to cognitive-behavioural therapy in anxiety disorder;
CESC	cis	rs6831352	0.918	rs29001199	chr4:100053891	A/G	cg12011299	chr4:100065546	ADH4	-0.61	-6.62	-0.38	1.94e-10	Alcohol dependence;
CESC	cis	rs7666738	0.830	rs2167892	chr4:99048503	G/C	cg03676636	chr4:99064102	C4orf37	0.33	5.12	0.3	5.93e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1799949	1.000	rs11659028	chr17:41195025	T/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.62	8.03	0.44	3.18e-14	Menopause (age at onset);
CESC	cis	rs10927875	0.864	rs1976402	chr1:16143779	G/A	cg21385522	chr1:16154831	NA	-0.93	-11.77	-0.59	5.17e-26	Dilated cardiomyopathy;
CESC	cis	rs3956705	0.762	rs13311608	chr7:32999601	C/T	cg06627557	chr7:32535165	LSM5;AVL9	-0.47	-5.64	-0.33	4.31e-8	Red cell distribution width;
CESC	cis	rs7084402	0.967	rs1620404	chr10:60327830	G/A	cg07615347	chr10:60278583	BICC1	0.59	9.18	0.49	1.26e-17	Refractive error;
CESC	cis	rs854765	0.583	rs4244602	chr17:17841456	A/G	cg09796270	chr17:17721594	SREBF1	0.46	6.41	0.37	6.66e-10	Total body bone mineral density;
CESC	cis	rs10479542	0.583	rs4131080	chr5:179044292	G/A	cg14820908	chr5:178986412	RUFY1	0.44	6.42	0.37	6.11e-10	Lung cancer;
CESC	trans	rs2623325	0.874	rs73138305	chr3:99139531	G/A	cg19595760	chr1:25948511	MAN1C1	-0.48	-6.28	-0.36	1.4e-9	Optic cup area;Vertical cup-disc ratio;
CESC	cis	rs4889855	0.614	rs9892081	chr17:78484484	A/C	cg16591659	chr17:78472290	NA	0.45	6.83	0.39	5.65e-11	Fractional excretion of uric acid;
CESC	cis	rs2033711	0.840	rs3764533	chr19:58929194	A/G	cg26874164	chr19:58962979	ZNF324B	0.58	7.92	0.44	6.46e-14	Uric acid clearance;
CESC	cis	rs9527	0.571	rs12219246	chr10:104613355	A/G	cg04362960	chr10:104952993	NT5C2	0.47	6.0	0.35	6.31e-9	Arsenic metabolism;
CESC	cis	rs9457247	1.000	rs389956	chr6:167407254	T/G	cg25258033	chr6:167368657	RNASET2	0.39	5.89	0.34	1.15e-8	Crohn's disease;
CESC	cis	rs7917772	0.502	rs10748827	chr10:104368336	G/T	cg22532475	chr10:104410764	TRIM8	-0.38	-6.52	-0.37	3.55e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg18652453	chr5:68665041	TAF9;RAD17	-0.44	-6.2	-0.36	2.19e-9	Gambling;
CESC	cis	rs858239	0.600	rs10256359	chr7:23123877	C/T	cg23682824	chr7:23144976	KLHL7	0.54	7.58	0.42	5.85e-13	Cerebrospinal fluid biomarker levels;
CESC	cis	rs938554	0.501	rs7671266	chr4:10056376	C/T	cg02734326	chr4:10020555	SLC2A9	-0.45	-5.07	-0.3	7.62e-7	Blood metabolite levels;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg01471259	chr16:2645846	PDPK1	-0.5	-6.74	-0.38	1.01e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs2180341	0.960	rs9398839	chr6:127665863	G/A	cg27446573	chr6:127587934	RNF146	1.08	15.6	0.69	2.29e-39	Breast cancer;
CESC	trans	rs561341	0.941	rs2428341	chr17:30317295	C/T	cg20587970	chr11:113659929	NA	-0.84	-10.91	-0.56	3.98e-23	Hip circumference adjusted for BMI;
CESC	cis	rs7772486	0.558	rs2142978	chr6:146012061	T/C	cg05347473	chr6:146136440	FBXO30	-0.71	-8.51	-0.46	1.29e-15	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs992157	0.661	rs10171839	chr2:219051314	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.65	9.47	0.5	1.68e-18	Colorectal cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23298564	chr19:41256395	C19orf54;SNRPA	-0.55	-6.47	-0.37	4.7e-10	Gut microbiome composition (summer);
CESC	cis	rs117623576	0.680	rs740859	chr10:32361839	G/A	cg03047570	chr10:32398778	NA	-0.64	-6.36	-0.36	9.02e-10	Anti-saccade response;
CESC	cis	rs7666738	0.791	rs6828752	chr4:99063382	C/T	cg03676636	chr4:99064102	C4orf37	0.33	5.04	0.3	8.47e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26289049	chr3:134080517	AMOTL2	-0.54	-6.38	-0.36	7.7e-10	Gut microbiome composition (summer);
CESC	cis	rs73206853	0.563	rs7301769	chr12:111171026	T/C	cg12870014	chr12:110450643	ANKRD13A	0.65	5.7	0.33	3.23e-8	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs763121	0.853	rs2294296	chr22:39053049	T/C	cg06022373	chr22:39101656	GTPBP1	0.88	13.87	0.65	3.04e-33	Menopause (age at onset);
CESC	cis	rs853679	0.542	rs2295594	chr6:28053097	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.53	-6.09	-0.35	3.91e-9	Depression;
CESC	cis	rs7666738	0.687	rs6839454	chr4:99073914	T/C	cg03467027	chr4:99064603	C4orf37	0.44	5.29	0.31	2.51e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9916302	0.904	rs7223438	chr17:37521355	T/C	cg15445000	chr17:37608096	MED1	-0.41	-6.54	-0.37	3.23e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs7613875	0.537	rs6446195	chr3:50070853	A/G	cg24110177	chr3:50126178	RBM5	0.54	7.47	0.42	1.17e-12	Body mass index;
CESC	cis	rs7940866	0.774	rs10894292	chr11:130820757	C/T	cg12179176	chr11:130786555	SNX19	0.6	8.12	0.45	1.79e-14	Schizophrenia;
CESC	cis	rs2836950	0.502	rs12627205	chr21:40630027	C/T	cg17971929	chr21:40555470	PSMG1	-0.55	-6.94	-0.39	3.03e-11	Menarche (age at onset);
CESC	cis	rs9596863	0.861	rs4088520	chr13:54441906	C/T	ch.13.53330881F	chr13:54432880	NA	-0.59	-5.18	-0.3	4.3e-7	Epilepsy and lamotrigine-induced maculopapular eruptions;
CESC	cis	rs7605827	0.897	rs6431698	chr2:15540156	G/C	cg19274914	chr2:15703543	NA	0.35	6.27	0.36	1.45e-9	Educational attainment (years of education);
CESC	cis	rs863345	0.933	rs10797015	chr1:158468265	T/G	cg12129480	chr1:158549410	OR10X1	-0.31	-6.23	-0.36	1.78e-9	Pneumococcal bacteremia;
CESC	cis	rs898097	0.812	rs55794221	chr17:80849003	G/A	cg15369054	chr17:80825471	TBCD	0.53	7.17	0.4	7.36e-12	Breast cancer;
CESC	cis	rs7618915	0.570	rs2336145	chr3:52629750	A/C	cg18404041	chr3:52824283	ITIH1	-0.4	-6.71	-0.38	1.19e-10	Bipolar disorder;
CESC	cis	rs6665290	0.566	rs1513617	chr1:227447213	C/T	cg10327440	chr1:227177885	CDC42BPA	0.89	12.42	0.61	3.28e-28	Myeloid white cell count;
CESC	cis	rs6952808	0.595	rs3800917	chr7:2167939	A/G	cg21782813	chr7:2030301	MAD1L1	-0.52	-7.44	-0.42	1.43e-12	Bipolar disorder and schizophrenia;
CESC	cis	rs9435341	0.930	rs61798463	chr1:107565934	G/A	cg09367891	chr1:107599246	PRMT6	0.71	8.35	0.46	3.94e-15	Facial morphology (factor 21, depth of nasal alae);
CESC	cis	rs875971	0.862	rs1860469	chr7:66106875	A/G	cg10691866	chr7:65817282	TPST1	0.3	5.05	0.3	8.38e-7	Aortic root size;
CESC	cis	rs1552244	0.938	rs7652951	chr3:10063763	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.89	11.97	0.59	1.14e-26	Alzheimer's disease;
CESC	cis	rs11792861	0.926	rs59904140	chr9:111910051	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.42	5.24	0.31	3.36e-7	Menarche (age at onset);
CESC	cis	rs3806843	0.735	rs2563314	chr5:140047289	A/G	cg26395211	chr5:140044315	WDR55	0.47	6.03	0.35	5.51e-9	Depressive symptoms (multi-trait analysis);
CESC	cis	rs7267979	1.000	rs6037105	chr20:25374199	C/A	cg08601574	chr20:25228251	PYGB	-0.38	-5.55	-0.32	6.85e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7223966	0.961	rs17631394	chr17:61646000	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.47	-5.22	-0.31	3.65e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs7945705	0.967	rs1569408	chr11:8909732	G/A	cg12365402	chr11:9010492	NRIP3	0.38	5.81	0.34	1.78e-8	Hemoglobin concentration;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07192240	chr11:3829780	PGAP2	0.53	6.22	0.36	1.91e-9	Gut microbiome composition (summer);
CESC	cis	rs4699052	0.625	rs2138592	chr4:104255718	A/G	cg16532752	chr4:104119610	CENPE	-0.39	-5.52	-0.32	8.23e-8	Testicular germ cell tumor;
CESC	cis	rs853679	0.550	rs1237875	chr6:28173010	A/G	cg19592336	chr6:28129416	ZNF389	-0.5	-6.51	-0.37	3.74e-10	Depression;
CESC	cis	rs2832191	0.791	rs2832202	chr21:30501342	G/A	cg08807101	chr21:30365312	RNF160	-0.73	-10.05	-0.53	2.35e-20	Dental caries;
CESC	cis	rs6121246	0.542	rs2376990	chr20:30238744	G/A	cg13852791	chr20:30311386	BCL2L1	0.77	7.96	0.44	5e-14	Mean corpuscular hemoglobin;
CESC	cis	rs6493487	0.546	rs12904155	chr15:51356728	C/T	cg02338191	chr15:51200825	AP4E1	-0.56	-5.39	-0.31	1.59e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs9303280	0.837	rs907092	chr17:37922259	A/G	cg19468946	chr17:37922297	IKZF3	0.47	6.5	0.37	4.01e-10	Self-reported allergy;
CESC	cis	rs13082711	0.519	rs13091109	chr3:27229125	G/A	cg02860705	chr3:27208620	NA	0.59	7.39	0.41	1.89e-12	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CESC	cis	rs1941023	0.606	rs7946122	chr11:60172770	G/A	cg08716584	chr11:60157161	MS4A7	-0.55	-9.03	-0.48	3.7e-17	Congenital heart disease (maternal effect);
CESC	cis	rs10779751	0.734	rs2039840	chr1:11125866	G/A	cg08854313	chr1:11322531	MTOR	0.77	10.41	0.54	1.73e-21	Body mass index;
CESC	cis	rs2742234	0.541	rs4648313	chr10:43716739	G/A	cg15436174	chr10:43711423	RASGEF1A	0.47	5.58	0.32	5.81e-8	Hirschsprung disease;
CESC	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg03188948	chr7:1209495	NA	0.66	6.79	0.38	7.53e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs11871801	0.958	rs8081779	chr17:40571395	G/A	cg21433558	chr17:40837037	CNTNAP1	0.45	5.04	0.3	8.46e-7	Crohn's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09315918	chr1:206137767	FAM72A	0.57	6.3	0.36	1.23e-9	Gut microbiome composition (summer);
CESC	cis	rs1336900	0.637	rs35967040	chr1:150555588	A/C	cg17724175	chr1:150552817	MCL1	-0.5	-7.92	-0.44	6.36e-14	Blood protein levels;
CESC	trans	rs11098499	0.779	rs28495013	chr4:120375831	A/C	cg25214090	chr10:38739885	LOC399744	0.7	9.92	0.52	6.5e-20	Corneal astigmatism;
CESC	cis	rs4665809	0.590	rs1368902	chr2:26440576	T/C	cg25036284	chr2:26402008	FAM59B	-0.86	-9.4	-0.5	2.74e-18	Gut microbiome composition (summer);
CESC	cis	rs6089584	0.927	rs2296083	chr20:60574216	C/T	cg13770153	chr20:60521292	NA	-0.46	-6.05	-0.35	4.84e-9	Body mass index;
CESC	cis	rs703842	0.616	rs870392	chr12:58219173	C/A	cg02175503	chr12:58329896	NA	0.48	5.88	0.34	1.25e-8	Multiple sclerosis;
CESC	cis	rs2228479	0.850	rs62056061	chr16:89901767	G/A	cg06558623	chr16:89946397	TCF25	1.12	8.22	0.45	9.28e-15	Skin colour saturation;
CESC	cis	rs9788682	1.000	rs2036534	chr15:78826948	T/C	cg06917634	chr15:78832804	PSMA4	-0.56	-6.69	-0.38	1.3100000000000001e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs9287719	0.967	rs6712304	chr2:10754375	A/C	cg02196655	chr2:10830764	NOL10	-0.37	-5.69	-0.33	3.39e-8	Prostate cancer;
CESC	cis	rs769267	0.792	rs4808961	chr19:19577215	C/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.44	5.51	0.32	8.47e-8	Tonsillectomy;
CESC	cis	rs4820294	1.000	rs7291867	chr22:38062112	C/G	cg21798802	chr22:38057573	PDXP	0.47	8.12	0.45	1.81e-14	Fat distribution (HIV);
CESC	cis	rs1799949	1.000	rs1135214	chr17:41292323	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.64	8.64	0.47	5.23e-16	Menopause (age at onset);
CESC	trans	rs9858542	0.953	rs6803222	chr3:49665976	T/G	cg21659725	chr3:3221576	CRBN	-0.52	-6.32	-0.36	1.13e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs28647808	0.867	rs28534766	chr9:136273381	T/C	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.9	5.73	0.33	2.75e-8	Blood protein levels;
CESC	cis	rs34779708	0.931	rs1926554	chr10:35344969	C/T	cg03585969	chr10:35415529	CREM	0.75	9.67	0.51	3.92e-19	Inflammatory bowel disease;Crohn's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26663063	chr12:49239477	DDX23	-0.56	-6.3	-0.36	1.23e-9	Gut microbiome composition (summer);
CESC	cis	rs1005277	0.579	rs2021649	chr10:38392122	C/T	cg00409905	chr10:38381863	ZNF37A	-0.47	-6.3	-0.36	1.24e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs116095464	0.558	rs7736600	chr5:231337	A/C	cg12570787	chr5:219185	SDHA;CCDC127	0.5	5.22	0.31	3.68e-7	Breast cancer;
CESC	cis	rs9788682	0.748	rs2456020	chr15:78868398	C/T	cg24631222	chr15:78858424	CHRNA5	0.78	9.72	0.51	2.6e-19	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs6502050	0.835	rs3088177	chr17:80111724	A/G	cg23985595	chr17:80112537	CCDC57	-0.4	-6.32	-0.36	1.12e-9	Life satisfaction;
CESC	cis	rs6456156	0.586	rs7746628	chr6:167483235	A/G	cg07741184	chr6:167504864	NA	0.37	6.36	0.36	8.83e-10	Primary biliary cholangitis;
CESC	cis	rs9611565	0.512	rs715498	chr22:42148467	G/A	cg06481639	chr22:41940642	POLR3H	0.6	5.98	0.34	7.25e-9	Vitiligo;
CESC	cis	rs1008375	0.686	rs34338142	chr4:17626174	T/A	cg15017067	chr4:17643749	FAM184B	0.38	5.41	0.32	1.41e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs11719291	0.833	rs11715835	chr3:48770732	C/T	cg00383909	chr3:49044727	WDR6	0.87	6.49	0.37	4.18e-10	Cognitive function;
CESC	cis	rs847577	0.748	rs13221897	chr7:97719699	G/A	cg24562669	chr7:97807699	LMTK2	0.63	10.23	0.53	6.29e-21	Breast cancer;
CESC	cis	rs4594175	0.926	rs11157804	chr14:51630340	A/G	cg23942311	chr14:51606299	NA	-0.35	-5.48	-0.32	9.86e-8	Cancer;
CESC	cis	rs2075371	0.863	rs9641966	chr7:133961205	G/A	cg11752832	chr7:134001865	SLC35B4	0.53	6.88	0.39	4.35e-11	Mean platelet volume;
CESC	cis	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg05863683	chr7:1912471	MAD1L1	-0.43	-6.36	-0.36	8.96e-10	Bipolar disorder and schizophrenia;
CESC	cis	rs1552244	0.816	rs56387520	chr3:10042782	C/T	cg00166722	chr3:10149974	C3orf24	0.48	5.92	0.34	1.01e-8	Alzheimer's disease;
CESC	cis	rs1008375	0.902	rs6844984	chr4:17651304	C/G	cg16339924	chr4:17578868	LAP3	0.64	7.91	0.44	6.79e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs7829975	0.623	rs10092965	chr8:8373485	A/G	cg06636001	chr8:8085503	FLJ10661	0.53	6.78	0.38	7.72e-11	Mood instability;
CESC	cis	rs854765	0.547	rs2955353	chr17:17948979	T/C	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.5	-6.33	-0.36	1.03e-9	Total body bone mineral density;
CESC	cis	rs9549260	0.564	rs4943808	chr13:41293950	C/T	cg21288729	chr13:41239152	FOXO1	0.59	7.61	0.42	4.7e-13	Red blood cell count;
CESC	cis	rs6089829	0.926	rs6062395	chr20:61667904	A/G	cg03213289	chr20:61660250	NA	0.39	6.06	0.35	4.6e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs10791323	0.604	rs2853116	chr11:133707063	A/G	cg06766960	chr11:133703094	NA	-0.37	-5.19	-0.3	4.25e-7	Childhood ear infection;
CESC	cis	rs9611565	0.592	rs12484254	chr22:41962003	T/A	cg03806693	chr22:41940476	POLR3H	-0.97	-12.07	-0.6	4.96e-27	Vitiligo;
CESC	cis	rs6426558	0.537	rs6685823	chr1:227270835	A/G	cg10327440	chr1:227177885	CDC42BPA	0.47	5.79	0.34	1.96e-8	Neutrophil percentage of white cells;
CESC	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	22.53	0.81	1.67e-63	Prudent dietary pattern;
CESC	cis	rs9911578	0.967	rs686425	chr17:56776730	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.17	0.3	4.67e-7	Intelligence (multi-trait analysis);
CESC	trans	rs853679	0.546	rs200954	chr6:27838764	C/G	cg06606381	chr12:133084897	FBRSL1	-0.78	-7.49	-0.42	1.05e-12	Depression;
CESC	cis	rs4253772	0.591	rs6007726	chr22:46650858	A/C	cg24881330	chr22:46731750	TRMU	0.89	10.09	0.53	1.86e-20	LDL cholesterol;Cholesterol, total;
CESC	cis	rs12042107	1.000	rs10922907	chr1:91193049	A/T	cg13456504	chr1:91191583	NA	0.37	6.66	0.38	1.53e-10	Educational attainment;
CESC	cis	rs9457247	1.000	rs397713	chr6:167386714	G/A	cg07741184	chr6:167504864	NA	0.31	5.53	0.32	7.87e-8	Crohn's disease;
CESC	cis	rs3806843	0.966	rs12659129	chr5:140147248	T/C	cg26395211	chr5:140044315	WDR55	-0.39	-5.12	-0.3	5.97e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs12765878	1.000	rs10883942	chr10:105651386	A/G	cg11005552	chr10:105648138	OBFC1	0.36	5.4	0.31	1.52e-7	Coronary artery disease;
CESC	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg05457628	chr5:178986728	RUFY1	0.57	8.81	0.48	1.7e-16	Lung cancer;
CESC	cis	rs2625529	0.618	rs6494992	chr15:72420750	G/C	cg16672083	chr15:72433130	SENP8	0.42	6.38	0.36	7.92e-10	Red blood cell count;
CESC	cis	rs34390795	1	rs34390795	chr12:133112394	CGT/C	cg06183872	chr12:133049993	NA	0.5	5.85	0.34	1.47e-8	Red blood cell count;
CESC	cis	rs4948102	0.655	rs4947533	chr7:56071282	T/C	cg09872392	chr7:56161020	PHKG1	-0.44	-6.73	-0.38	1.02e-10	Plasma homocysteine levels (post-methionine load test);
CESC	cis	rs2997447	0.761	rs79778025	chr1:26449337	A/G	cg24596570	chr1:26146463	FAM54B;LOC646471	0.58	5.08	0.3	7.24e-7	QRS complex (12-leadsum);
CESC	cis	rs8005677	1.000	rs10148215	chr14:23382345	C/T	cg01529538	chr14:23388837	RBM23	0.51	6.89	0.39	4.01e-11	Cognitive ability (multi-trait analysis);
CESC	cis	rs3091242	0.933	rs9438904	chr1:25756860	T/C	cg12412775	chr1:25698385	RHCE	-0.28	-5.07	-0.3	7.51e-7	Erythrocyte sedimentation rate;
CESC	cis	rs6032067	0.777	rs56191952	chr20:43802487	A/G	cg11264863	chr20:43835661	SEMG1	0.5	5.38	0.31	1.62e-7	Blood protein levels;
CESC	cis	rs7666738	0.515	rs28615369	chr4:98896858	C/T	cg17366294	chr4:99064904	C4orf37	0.51	6.53	0.37	3.27e-10	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7772486	0.714	rs1883365	chr6:146076749	C/T	cg23711669	chr6:146136114	FBXO30	-0.88	-13.21	-0.63	5.93e-31	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1008375	0.797	rs6843530	chr4:17593605	G/T	cg27347728	chr4:17578864	LAP3	0.43	5.3	0.31	2.49e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg15441629	chr19:16582551	EPS15L1	0.49	6.43	0.37	6.06e-10	Myopia (pathological);
CESC	cis	rs9911578	1.000	rs3744108	chr17:56585872	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	-0.38	-5.04	-0.3	8.8e-7	Intelligence (multi-trait analysis);
CESC	cis	rs921968	0.541	rs523305	chr2:219402691	T/C	cg02176678	chr2:219576539	TTLL4	0.5	9.0	0.48	4.36e-17	Mean corpuscular hemoglobin concentration;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03227570	chr1:17766306	RCC2	0.56	6.34	0.36	9.76e-10	Gut microbiome composition (summer);
CESC	cis	rs7264396	0.563	rs2425121	chr20:34326186	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.88	-10.7	-0.55	1.88e-22	Total cholesterol levels;
CESC	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg05313129	chr8:58192883	C8orf71	-0.49	-5.36	-0.31	1.8e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs8177179	0.967	rs9869311	chr3:133451613	C/T	cg17775713	chr3:133465469	TF	0.35	6.22	0.36	1.88e-9	Iron status biomarkers (transferrin levels);
CESC	cis	rs453301	0.653	rs7853	chr8:8890814	A/G	cg15556689	chr8:8085844	FLJ10661	0.5	6.18	0.35	2.4e-9	Joint mobility (Beighton score);
CESC	cis	rs7618915	0.547	rs13069481	chr3:52666866	C/T	cg18404041	chr3:52824283	ITIH1	-0.39	-6.58	-0.37	2.45e-10	Bipolar disorder;
CESC	cis	rs6141600	0.760	rs2746097	chr20:34672923	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.41	5.39	0.31	1.58e-7	Height;Hip circumference;
CESC	trans	rs60380162	0.963	rs11577298	chr1:87730319	G/A	cg20163645	chr8:1900353	ARHGEF10	-0.43	-6.03	-0.35	5.48e-9	Loneliness (linear analysis);
CESC	cis	rs9311474	0.508	rs17052259	chr3:52593138	A/G	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.31	5.48	0.32	9.87e-8	Electroencephalogram traits;
CESC	cis	rs7806994	1	rs7806994	chr7:56139505	A/T	cg14187409	chr7:56174376	CHCHD2	0.7	6.75	0.38	9.19e-11	PR interval in Tripanosoma cruzi seropositivity;
CESC	cis	rs6952808	0.689	rs1107591	chr7:2041638	G/A	cg04267008	chr7:1944627	MAD1L1	-0.61	-7.6	-0.42	5.21e-13	Bipolar disorder and schizophrenia;
CESC	cis	rs568617	0.768	rs12225345	chr11:65647105	A/G	cg04055107	chr11:65626734	MUS81;CFL1	0.94	9.55	0.51	9.22e-19	Crohn's disease;
CESC	cis	rs938554	0.612	rs9991278	chr4:10002665	A/G	cg11266682	chr4:10021025	SLC2A9	0.37	5.13	0.3	5.49e-7	Blood metabolite levels;
CESC	cis	rs7843479	1.000	rs67385415	chr8:21853733	T/C	cg17168535	chr8:21777572	XPO7	0.52	7.13	0.4	9.55e-12	Mean corpuscular volume;
CESC	cis	rs2197308	0.610	rs10880837	chr12:37864924	C/T	cg13010199	chr12:38710504	ALG10B	0.49	6.3	0.36	1.2e-9	Morning vs. evening chronotype;
CESC	cis	rs4555082	0.874	rs1008628	chr14:105722726	T/C	cg10792982	chr14:105748885	BRF1	0.42	5.59	0.32	5.74e-8	Mean platelet volume;Platelet distribution width;
CESC	cis	rs12291225	0.679	rs7934671	chr11:14305101	C/T	cg19336497	chr11:14380999	RRAS2	-0.37	-5.29	-0.31	2.58e-7	Sense of smell;
CESC	cis	rs7551222	0.752	rs4951398	chr1:204531876	T/C	cg20240347	chr1:204465584	NA	-0.29	-5.8	-0.34	1.89e-8	Schizophrenia;
CESC	cis	rs9303401	0.573	rs34097494	chr17:57171917	C/T	cg12560992	chr17:57184187	TRIM37	0.5	5.21	0.3	3.78e-7	Cognitive test performance;
CESC	cis	rs597539	0.617	rs686348	chr11:68636996	A/G	cg06028808	chr11:68637592	NA	0.43	5.12	0.3	5.87e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs5769765	0.954	rs5770707	chr22:50244533	G/A	cg02269571	chr22:50332266	NA	0.46	6.07	0.35	4.43e-9	Schizophrenia;
CESC	cis	rs1552244	1.000	rs7611218	chr3:10063960	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-10.79	-0.55	9.74e-23	Alzheimer's disease;
CESC	cis	rs2836974	0.897	rs35123057	chr21:40711689	C/T	cg11890956	chr21:40555474	PSMG1	1.04	16.54	0.71	1.1e-42	Cognitive function;
CESC	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg24101359	chr6:42928495	GNMT	0.63	9.67	0.51	3.77e-19	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs1707322	1.000	rs6677777	chr1:46475836	A/G	cg06784218	chr1:46089804	CCDC17	0.39	6.56	0.37	2.87e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs3741404	1.000	rs3741404	chr11:63999240	G/C	cg18225595	chr11:63971243	STIP1	0.67	8.96	0.48	5.85e-17	Platelet count;
CESC	cis	rs4654899	0.802	rs12123910	chr1:21233316	C/T	cg05370193	chr1:21551575	ECE1	0.4	5.61	0.33	5.04e-8	Superior frontal gyrus grey matter volume;
CESC	trans	rs1506636	0.854	rs6466879	chr7:123276197	G/A	cg12383159	chr11:1262597	MUC5B	0.36	6.02	0.35	5.66e-9	Plateletcrit;Platelet count;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg06749514	chr10:114206969	VTI1A;ZDHHC6	-0.54	-7.2	-0.4	6.05e-12	Fibrinogen levels;
CESC	cis	rs7000551	0.606	rs7844699	chr8:22248920	G/T	cg12081754	chr8:22256438	SLC39A14	-0.78	-10.36	-0.54	2.41e-21	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CESC	cis	rs11676855	0.927	rs4341884	chr2:235918504	G/T	cg14917874	chr2:235941519	SH3BP4	0.42	5.44	0.32	1.2e-7	Dialysis-related mortality;
CESC	cis	rs6456156	0.586	rs6456154	chr6:167472256	C/T	cg23791538	chr6:167370224	RNASET2	-0.5	-6.44	-0.37	5.46e-10	Primary biliary cholangitis;
CESC	cis	rs10949834	0.730	rs2237503	chr7:73509326	G/C	cg07137043	chr7:73588983	EIF4H	-0.69	-7.57	-0.42	6.12e-13	Verbal memory performance (residualized delayed recall change);
CESC	cis	rs11785400	0.731	rs4736363	chr8:143742112	C/A	cg24634471	chr8:143751801	JRK	0.45	5.78	0.33	2.13e-8	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04184877	chr16:22386315	CDR2	0.6	6.52	0.37	3.55e-10	Gut microbiome composition (summer);
CESC	cis	rs79839061	0.520	rs2279187	chr4:875529	C/T	cg07828340	chr4:882639	GAK	1.04	7.65	0.43	3.68e-13	Intelligence (multi-trait analysis);
CESC	cis	rs7216064	1.000	rs58122682	chr17:65876915	T/C	cg07042672	chr17:66097459	LOC651250	-0.52	-5.4	-0.31	1.5e-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs7264396	0.528	rs6058370	chr20:34518592	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.63	6.78	0.38	7.81e-11	Total cholesterol levels;
CESC	cis	rs12497850	0.897	rs9884022	chr3:48956862	G/C	cg07636037	chr3:49044803	WDR6	1.03	19.61	0.77	1.59e-53	Parkinson's disease;
CESC	cis	rs736801	0.808	rs2522057	chr5:131801947	C/G	cg21138405	chr5:131827807	IRF1	-0.38	-5.71	-0.33	3.08e-8	Breast cancer;Mosquito bite size;
CESC	cis	rs7560272	0.529	rs2421672	chr2:73955540	G/A	cg20560298	chr2:73613845	ALMS1	0.43	5.82	0.34	1.71e-8	Schizophrenia;
CESC	cis	rs6667605	0.527	rs6673993	chr1:2552071	T/C	cg20673091	chr1:2541236	MMEL1	0.47	8.28	0.45	6.16e-15	Inflammatory bowel disease;Ulcerative colitis;
CESC	cis	rs9911578	0.967	rs12944948	chr17:56951474	A/G	cg12560992	chr17:57184187	TRIM37	0.93	15.55	0.69	3.5e-39	Intelligence (multi-trait analysis);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg05265988	chr5:180688748	TRIM52	-0.45	-6.22	-0.36	1.91e-9	Fibrinogen levels;
CESC	cis	rs9300255	0.679	rs4759409	chr12:123719585	G/C	cg05973401	chr12:123451056	ABCB9	0.5	5.61	0.33	5.11e-8	Neutrophil percentage of white cells;
CESC	trans	rs1814175	0.615	rs10839378	chr11:49806943	C/T	cg03929089	chr4:120376271	NA	-0.86	-13.45	-0.64	9.04e-32	Height;
CESC	cis	rs921968	0.541	rs17572485	chr2:219296545	C/T	cg02176678	chr2:219576539	TTLL4	-0.45	-7.78	-0.43	1.66e-13	Mean corpuscular hemoglobin concentration;
CESC	cis	rs6754311	0.731	rs2164210	chr2:136580287	T/C	cg15123519	chr2:136567270	LCT	0.33	5.62	0.33	4.81e-8	Mosquito bite size;
CESC	cis	rs9457247	0.905	rs453184	chr6:167387404	A/C	cg25258033	chr6:167368657	RNASET2	0.39	5.87	0.34	1.31e-8	Crohn's disease;
CESC	cis	rs769267	0.965	rs2074296	chr19:19373689	A/G	cg11584989	chr19:19387371	SF4	0.38	5.12	0.3	5.98e-7	Tonsillectomy;
CESC	cis	rs1799949	1.000	rs12951869	chr17:41187567	T/G	cg05368731	chr17:41323189	NBR1	0.8	10.6	0.55	3.93e-22	Menopause (age at onset);
CESC	cis	rs9457247	0.555	rs2247325	chr6:167369992	A/G	cg25258033	chr6:167368657	RNASET2	-0.36	-5.21	-0.3	3.8e-7	Crohn's disease;
CESC	trans	rs7089973	0.549	rs34434610	chr10:116739745	A/G	cg17463145	chr7:79084011	MAGI2	0.32	6.36	0.36	8.92e-10	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs601339	1.000	rs601339	chr12:123174743	A/G	cg11919336	chr12:123188078	GPR109A	0.48	6.44	0.37	5.44e-10	Adiponectin levels;
CESC	cis	rs763014	0.931	rs11643039	chr16:634260	G/A	cg00908189	chr16:619842	PIGQ	0.64	8.89	0.48	9.75e-17	Height;
CESC	cis	rs7903847	0.642	rs11189178	chr10:99143272	T/G	cg20016023	chr10:99160130	RRP12	-0.29	-5.03	-0.3	9.15e-7	Granulocyte percentage of myeloid white cells;
CESC	cis	rs2228479	0.541	rs9806913	chr16:89953773	A/G	cg04013166	chr16:89971882	TCF25	0.72	8.84	0.48	1.33e-16	Skin colour saturation;
CESC	cis	rs9910055	0.659	rs721769	chr17:42261588	T/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.68	9.07	0.49	2.78e-17	Total body bone mineral density;
CESC	cis	rs10504229	1.000	rs67913746	chr8:58177825	A/G	cg14926445	chr8:58193284	C8orf71	-0.51	-5.47	-0.32	1.03e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs2075371	0.796	rs7780583	chr7:133960716	C/G	cg20476274	chr7:133979776	SLC35B4	0.62	8.86	0.48	1.15e-16	Mean platelet volume;
CESC	cis	rs7666738	0.753	rs10004827	chr4:99037953	A/C	cg03467027	chr4:99064603	C4orf37	0.47	5.97	0.34	7.51e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9300255	0.543	rs1617156	chr12:123590165	T/C	cg00376283	chr12:123451042	ABCB9	0.76	9.09	0.49	2.44e-17	Neutrophil percentage of white cells;
CESC	cis	rs694739	0.734	rs663743	chr11:64107735	G/A	cg02228329	chr11:64053129	BAD;GPR137	0.78	9.66	0.51	4.13e-19	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CESC	cis	rs6772849	0.901	rs9289330	chr3:128311067	C/G	cg16766828	chr3:128327626	NA	-0.31	-5.22	-0.31	3.64e-7	Monocyte percentage of white cells;Monocyte count;
CESC	cis	rs9467711	0.659	rs36033628	chr6:26456074	T/G	cg14345882	chr6:26364793	BTN3A2	0.66	5.26	0.31	2.98e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs763121	0.719	rs9610995	chr22:39057763	C/T	cg06022373	chr22:39101656	GTPBP1	0.88	13.88	0.65	2.66e-33	Menopause (age at onset);
CESC	cis	rs116988415	0.584	rs4902314	chr14:65254415	T/C	cg25083366	chr14:65239357	SPTB	0.7	5.29	0.31	2.6e-7	Daytime sleep phenotypes;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg19902697	chr11:76494208	TSKU	-0.46	-7.13	-0.4	9.33e-12	Gambling;
CESC	cis	rs1552244	0.882	rs13089863	chr3:10032259	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.8	-9.12	-0.49	1.98e-17	Alzheimer's disease;
CESC	trans	rs11098499	0.691	rs28396837	chr4:120271541	G/A	cg25214090	chr10:38739885	LOC399744	0.6	8.3	0.45	5.33e-15	Corneal astigmatism;
CESC	trans	rs12229918	0.540	rs10784460	chr12:65863584	C/T	cg10754697	chr17:1504809	SLC43A2	0.48	6.04	0.35	5.3e-9	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
CESC	cis	rs832540	0.519	rs10039338	chr5:56260363	C/T	cg14703610	chr5:56206110	C5orf35	-0.42	-5.59	-0.32	5.75e-8	Coronary artery disease;
CESC	cis	rs875971	0.862	rs6460306	chr7:66060793	T/C	cg12463550	chr7:65579703	CRCP	-0.52	-6.62	-0.38	1.94e-10	Aortic root size;
CESC	cis	rs2279817	0.863	rs11203439	chr1:18026328	T/C	cg21791023	chr1:18019539	ARHGEF10L	0.6	8.57	0.47	8.54e-16	Neuroticism;
CESC	cis	rs11030122	0.702	rs10767715	chr11:3951409	G/T	cg18678763	chr11:4115507	RRM1	-0.45	-6.05	-0.35	4.94e-9	Mean platelet volume;Platelet distribution width;
CESC	cis	rs10924309	0.737	rs1538957	chr1:245855639	A/G	cg00036263	chr1:245852353	KIF26B	-0.53	-7.07	-0.4	1.39e-11	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
CESC	cis	rs10504229	0.639	rs56066782	chr8:58105857	A/G	cg02725872	chr8:58115012	NA	-0.43	-6.81	-0.39	6.53e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs17376456	0.877	rs10070390	chr5:93452345	G/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.62	5.44	0.32	1.23e-7	Diabetic retinopathy;
CESC	cis	rs875971	0.660	rs79009421	chr7:66068509	G/C	cg25985355	chr7:65971099	NA	0.32	5.15	0.3	5.12e-7	Aortic root size;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg01343991	chr7:23338897	C7orf30	-0.51	-6.19	-0.36	2.28e-9	Ulcerative colitis;
CESC	cis	rs4243830	1.000	rs12027598	chr1:6600804	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	0.69	5.1	0.3	6.58e-7	Body mass index;
CESC	cis	rs9486719	1.000	rs2472890	chr6:96867646	C/T	cg06623918	chr6:96969491	KIAA0776	0.81	8.29	0.45	5.61e-15	Migraine;Coronary artery disease;
CESC	cis	rs589448	0.902	rs2603089	chr12:69776800	C/T	cg14784868	chr12:69753453	YEATS4	-0.88	-13.87	-0.65	3.01e-33	Cerebrospinal fluid biomarker levels;
CESC	cis	rs3741404	0.620	rs2236648	chr11:63964657	C/T	cg18225595	chr11:63971243	STIP1	0.62	8.75	0.47	2.62e-16	Platelet count;
CESC	cis	rs9815354	0.812	rs4547673	chr3:41952303	A/C	cg03022575	chr3:42003672	ULK4	0.68	5.92	0.34	9.9e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs7945705	0.692	rs2742470	chr11:9004002	C/T	cg12365402	chr11:9010492	NRIP3	-0.42	-7.18	-0.4	7.05e-12	Hemoglobin concentration;
CESC	cis	rs10927875	0.597	rs61782184	chr1:16150976	G/A	cg05821634	chr1:16164109	FLJ37453	0.35	5.06	0.3	7.74e-7	Dilated cardiomyopathy;
CESC	trans	rs4942242	1.000	rs1105856	chr13:44227067	G/T	cg19169023	chr15:41853346	TYRO3	0.44	6.39	0.37	7.49e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	trans	rs7090925	1.000	rs10905373	chr10:8481266	A/G	cg22997768	chr12:11092816	TAS2R14;PRR4;PRH1	0.47	6.0	0.35	6.55e-9	Systemic lupus erythematosus;
CESC	cis	rs875971	1.000	rs7792762	chr7:66004138	T/C	cg10691866	chr7:65817282	TPST1	-0.36	-5.9	-0.34	1.1e-8	Aortic root size;
CESC	cis	rs66782572	1	rs66782572	chr3:52567617	A/G	cg25934064	chr3:52569026	NT5DC2	0.25	5.08	0.3	7.15e-7	Hemoglobin concentration;
CESC	cis	rs13191362	1.000	rs2156257	chr6:163100710	G/T	cg21926612	chr6:163149169	PACRG;PARK2	1.07	10.98	0.56	2.38e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs6500602	0.653	rs4786487	chr16:4440397	C/G	cg08645402	chr16:4508243	NA	-0.41	-5.89	-0.34	1.17e-8	Schizophrenia;
CESC	cis	rs6952808	0.630	rs10239050	chr7:2158390	A/G	cg21782813	chr7:2030301	MAD1L1	0.47	6.61	0.38	2.06e-10	Bipolar disorder and schizophrenia;
CESC	cis	rs1799949	1.000	rs35668327	chr17:41273095	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.67	9.25	0.49	7.88e-18	Menopause (age at onset);
CESC	cis	rs7666738	0.830	rs6848404	chr4:98946750	A/G	cg05340658	chr4:99064831	C4orf37	0.82	12.66	0.61	4.8e-29	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9790314	1.000	rs6765269	chr3:160948542	T/C	cg04691961	chr3:161091175	C3orf57	-0.4	-5.08	-0.3	7.27e-7	Morning vs. evening chronotype;
CESC	cis	rs7714584	1.000	rs77698001	chr5:150250367	C/T	cg22134413	chr5:150180641	NA	0.5	5.59	0.32	5.78e-8	Crohn's disease;
CESC	cis	rs34779708	0.931	rs4934693	chr10:35271844	G/A	cg04310649	chr10:35416472	CREM	-0.5	-5.97	-0.34	7.5e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs4704187	0.687	rs6862754	chr5:74427193	T/C	cg03227963	chr5:74354835	NA	0.31	5.68	0.33	3.52e-8	Response to amphetamines;
CESC	cis	rs9359856	0.517	rs112527288	chr6:90509141	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.66	-6.74	-0.38	9.61e-11	Bipolar disorder;
CESC	cis	rs1878931	0.580	rs7194596	chr16:3404408	T/A	cg22508957	chr16:3507546	NAT15	-0.41	-6.04	-0.35	5.08e-9	Body mass index (adult);
CESC	cis	rs4481887	1.000	rs4409693	chr1:248479061	C/T	cg00666640	chr1:248458726	OR2T12	0.41	6.56	0.37	2.84e-10	Common traits (Other);
CESC	trans	rs673604	0.505	rs676614	chr1:36107510	G/T	cg22809411	chr8:74884737	TCEB1	0.56	6.56	0.37	2.77e-10	Endometrial cancer;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg02737830	chr12:64616354	C12orf66	-0.45	-6.1	-0.35	3.76e-9	Height;
CESC	cis	rs6842047	0.706	rs4862667	chr4:187136416	A/G	cg02012338	chr4:187126139	CYP4V2	0.68	5.78	0.33	2.13e-8	Blood protein levels;
CESC	cis	rs2836950	0.565	rs2836926	chr21:40536790	G/A	cg11644478	chr21:40555479	PSMG1	-0.53	-7.28	-0.41	3.78e-12	Menarche (age at onset);
CESC	cis	rs9303280	0.901	rs9901146	chr17:38043343	G/A	cg20243544	chr17:37824526	PNMT	0.52	6.82	0.39	6.16e-11	Self-reported allergy;
CESC	cis	rs10463316	0.894	rs4099171	chr5:150766623	C/T	cg03212797	chr5:150827313	SLC36A1	-0.47	-6.2	-0.36	2.17e-9	Metabolite levels (Pyroglutamine);
CESC	cis	rs6060717	0.610	rs2590964	chr20:34613376	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.5	6.32	0.36	1.13e-9	Hip circumference adjusted for BMI;
CESC	cis	rs9303401	0.573	rs34717648	chr17:56886624	T/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.0	12.54	0.61	1.28e-28	Cognitive test performance;
CESC	cis	rs7772486	0.875	rs1412081	chr6:146409733	A/G	cg23711669	chr6:146136114	FBXO30	0.81	12.17	0.6	2.27e-27	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7829975	0.806	rs2428	chr8:8641145	C/T	cg17143192	chr8:8559678	CLDN23	0.45	5.56	0.32	6.52e-8	Mood instability;
CESC	cis	rs2119480	0.701	rs1193458	chr13:111302922	T/C	cg16216153	chr13:111290848	CARKD	-0.36	-5.43	-0.32	1.26e-7	Diastolic blood pressure;
CESC	cis	rs1008375	1.000	rs3933453	chr4:17636319	A/C	cg15017067	chr4:17643749	FAM184B	0.39	5.57	0.32	6.24e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs2806561	0.704	rs663942	chr1:23522476	G/A	cg12483005	chr1:23474871	LUZP1	0.43	6.55	0.37	2.93e-10	Height;
CESC	trans	rs875971	1.000	rs7789768	chr7:65938980	A/C	cg26939375	chr7:64535504	NA	0.46	6.0	0.35	6.4e-9	Aortic root size;
CESC	cis	rs798554	0.797	rs798486	chr7:2803037	A/G	cg19346786	chr7:2764209	NA	-0.5	-7.17	-0.4	7.34e-12	Height;
CESC	cis	rs1348850	0.958	rs12471741	chr2:178448196	A/G	cg23306229	chr2:178417860	TTC30B	0.54	7.07	0.4	1.38e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs6669008	1.000	rs6669008	chr1:114166561	A/G	cg26035817	chr1:114414802	PTPN22	0.44	6.32	0.36	1.12e-9	Bacteremia;
CESC	cis	rs9916302	0.904	rs9944411	chr17:37483599	T/C	cg20243544	chr17:37824526	PNMT	-0.46	-5.63	-0.33	4.6e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs4665809	0.589	rs4665841	chr2:26448950	G/A	cg04944784	chr2:26401820	FAM59B	-0.98	-11.51	-0.58	3.85e-25	Gut microbiome composition (summer);
CESC	cis	rs703842	0.585	rs10877022	chr12:58223937	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.58	6.64	0.38	1.8e-10	Multiple sclerosis;
CESC	cis	rs11971779	0.688	rs1862880	chr7:139020100	T/C	cg07862535	chr7:139043722	LUC7L2	0.49	5.64	0.33	4.31e-8	Diisocyanate-induced asthma;
CESC	cis	rs1552244	0.882	rs13099136	chr3:10031431	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	10.84	0.55	6.79e-23	Alzheimer's disease;
CESC	cis	rs2997447	0.846	rs61775425	chr1:26405634	A/T	cg24596570	chr1:26146463	FAM54B;LOC646471	0.57	5.1	0.3	6.49e-7	QRS complex (12-leadsum);
CESC	cis	rs12220238	1.000	rs11000902	chr10:75920483	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.63	5.79	0.34	2.01e-8	Soluble interleukin-2 receptor subunit alpha;
CESC	cis	rs2228479	0.850	rs11076619	chr16:89831243	C/A	cg00800038	chr16:89945340	TCF25	-0.92	-7.64	-0.42	4.02e-13	Skin colour saturation;
CESC	cis	rs4925386	0.759	rs2427293	chr20:60925859	A/G	cg12382846	chr20:60892121	LAMA5	-0.32	-5.06	-0.3	7.8e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs950776	0.518	rs952215	chr15:78819153	C/T	cg06917634	chr15:78832804	PSMA4	-0.8	-12.2	-0.6	1.77e-27	Sudden cardiac arrest;
CESC	cis	rs763121	0.853	rs5757234	chr22:39072686	C/T	cg21395723	chr22:39101663	GTPBP1	0.49	6.73	0.38	1.07e-10	Menopause (age at onset);
CESC	cis	rs35306767	0.903	rs35567307	chr10:915804	G/C	cg10556349	chr10:835070	NA	0.58	5.59	0.32	5.56e-8	Eosinophil percentage of granulocytes;
CESC	trans	rs9388451	0.657	rs4895799	chr6:126052729	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.49	-6.41	-0.37	6.82e-10	Brugada syndrome;
CESC	cis	rs963731	0.579	rs4643520	chr2:39229464	T/C	cg04010122	chr2:39346883	SOS1	-0.69	-5.14	-0.3	5.41e-7	Corticobasal degeneration;
CESC	cis	rs2415984	0.644	rs1669808	chr14:46930473	A/G	cg14871534	chr14:47121158	RPL10L	0.36	5.5	0.32	8.86e-8	Number of children ever born;
CESC	cis	rs17095355	0.818	rs11194981	chr10:111861054	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.49	-6.21	-0.36	2.03e-9	Biliary atresia;
CESC	cis	rs2882667	0.858	rs11750382	chr5:138456994	A/G	cg04439458	chr5:138467593	SIL1	0.35	5.58	0.32	6.01e-8	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs4975616	0.773	rs414965	chr5:1324121	G/A	cg07493874	chr5:1342172	CLPTM1L	-0.42	-7.93	-0.44	6.1e-14	Lung cancer;
CESC	cis	rs4665809	1.000	rs4665299	chr2:26256840	A/C	cg22920501	chr2:26401640	FAM59B	-0.78	-9.08	-0.49	2.58e-17	Gut microbiome composition (summer);
CESC	cis	rs875971	0.862	rs13226170	chr7:65999298	G/A	cg11764359	chr7:65958608	NA	0.79	11.32	0.57	1.67e-24	Aortic root size;
CESC	cis	rs736408	0.812	rs2270197	chr3:52824095	T/G	cg07507251	chr3:52567010	NT5DC2	0.39	6.31	0.36	1.16e-9	Bipolar disorder;
CESC	cis	rs892961	0.932	rs9646396	chr17:75416755	G/A	cg05865280	chr17:75406074	SEPT9	0.55	10.53	0.54	7.12e-22	Airflow obstruction;
CESC	cis	rs10504229	0.683	rs16921808	chr8:58106049	C/T	cg02725872	chr8:58115012	NA	-0.46	-7.23	-0.41	5.05e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs9311474	0.607	rs4475032	chr3:52560021	C/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.29	5.2	0.3	4.08e-7	Electroencephalogram traits;
CESC	cis	rs6662572	0.737	rs56047133	chr1:46517228	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.48	5.36	0.31	1.77e-7	Blood protein levels;
CESC	cis	rs3762637	1.000	rs28434553	chr3:122229515	C/A	cg24169773	chr3:122142474	KPNA1	-0.59	-7.1	-0.4	1.16e-11	LDL cholesterol levels;
CESC	cis	rs7264396	0.635	rs6060682	chr20:34506331	G/A	cg17201900	chr20:34330562	RBM39	0.49	5.17	0.3	4.63e-7	Total cholesterol levels;
CESC	cis	rs9311474	0.508	rs4687546	chr3:52605943	T/A	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.67	0.38	1.47e-10	Electroencephalogram traits;
CESC	cis	rs769267	0.895	rs2916069	chr19:19520358	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.49	6.26	0.36	1.5e-9	Tonsillectomy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08779779	chr2:200322566	SATB2	0.59	6.73	0.38	1.02e-10	Gut microbiome composition (summer);
CESC	trans	rs7866350	0.604	rs1935389	chr9:100994470	A/G	cg10687823	chr19:36103576	HAUS5	0.46	6.13	0.35	3.16e-9	Post-traumatic stress disorder;
CESC	cis	rs7617480	0.648	rs6766238	chr3:48801929	G/A	cg07636037	chr3:49044803	WDR6	0.8	10.94	0.56	3.04e-23	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25402685	chr13:52980264	THSD1	0.47	6.11	0.35	3.58e-9	Gut microbiome composition (summer);
CESC	cis	rs4523957	0.928	rs403553	chr17:2191260	C/T	cg16513277	chr17:2031491	SMG6	0.54	7.45	0.42	1.31e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs826838	0.838	rs11183646	chr12:38799846	A/T	cg13010199	chr12:38710504	ALG10B	0.6	8.53	0.46	1.1e-15	Heart rate;
CESC	cis	rs922182	0.633	rs16947621	chr15:64271660	C/G	cg24729988	chr15:64271149	DAPK2	0.47	6.68	0.38	1.41e-10	Blood protein levels;
CESC	cis	rs919433	0.648	rs6434933	chr2:198426960	G/A	cg03934865	chr2:198174659	NA	0.38	5.16	0.3	4.82e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs72781680	1.000	rs75046532	chr2:24167267	A/G	cg08917208	chr2:24149416	ATAD2B	0.94	8.58	0.47	7.87e-16	Lymphocyte counts;
CESC	cis	rs9291683	0.585	rs12648479	chr4:10104571	G/A	cg11266682	chr4:10021025	SLC2A9	-0.5	-9.32	-0.5	4.75e-18	Bone mineral density;
CESC	trans	rs6460942	0.915	rs7803056	chr7:12306913	A/C	cg16269144	chr1:2003326	PRKCZ	0.51	6.11	0.35	3.54e-9	Coronary artery disease;
CESC	cis	rs2933343	0.729	rs789230	chr3:128602558	G/A	cg24203234	chr3:128598194	ACAD9	0.43	5.79	0.34	1.97e-8	IgG glycosylation;
CESC	cis	rs9916302	0.904	rs8066704	chr17:37477218	C/T	cg20243544	chr17:37824526	PNMT	-0.47	-5.8	-0.34	1.84e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs7618915	0.501	rs2336149	chr3:52692124	G/A	cg07507251	chr3:52567010	NT5DC2	0.32	5.56	0.32	6.75e-8	Bipolar disorder;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg11224334	chr19:53030489	ZNF808	0.45	6.63	0.38	1.89e-10	Asthma;
CESC	cis	rs853679	0.517	rs9393901	chr6:28136797	A/G	cg17949981	chr6:28129498	ZNF389	0.42	5.24	0.31	3.27e-7	Depression;
CESC	cis	rs4665809	1.000	rs2384323	chr2:26306473	C/T	cg26314531	chr2:26401878	FAM59B	-0.61	-6.97	-0.39	2.52e-11	Gut microbiome composition (summer);
CESC	cis	rs7429990	0.965	rs62260764	chr3:47990500	G/C	cg11946769	chr3:48343235	NME6	0.61	6.75	0.38	9.33e-11	Educational attainment (years of education);
CESC	cis	rs7666738	0.830	rs2865990	chr4:99067399	C/A	cg17366294	chr4:99064904	C4orf37	0.62	8.77	0.47	2.18e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7666738	0.791	rs28858828	chr4:98950442	C/G	cg03676636	chr4:99064102	C4orf37	0.33	5.09	0.3	6.71e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6500395	1.000	rs9936467	chr16:48677983	T/C	cg04672837	chr16:48644449	N4BP1	0.51	6.31	0.36	1.16e-9	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs757110	0.834	rs1002226	chr11:17405617	C/T	cg15432903	chr11:17409602	KCNJ11	0.65	9.4	0.5	2.69e-18	Type 2 diabetes;
CESC	cis	rs4662945	0.603	rs13002385	chr2:130276865	T/C	cg05903289	chr2:130345205	NA	-0.45	-6.67	-0.38	1.5e-10	Response to cytidine analogues (gemcitabine);
CESC	cis	rs2652822	1.000	rs1126309	chr15:63429062	A/G	cg02713581	chr15:63449717	RPS27L	0.56	7.23	0.41	5.07e-12	Metabolic traits;
CESC	cis	rs7927771	0.507	rs7119517	chr11:47675316	T/C	cg18512352	chr11:47633146	NA	0.34	5.34	0.31	2.03e-7	Subjective well-being;
CESC	cis	rs9290065	0.538	rs9840600	chr3:160769101	G/A	cg03342759	chr3:160939853	NMD3	-0.4	-5.22	-0.31	3.61e-7	Kawasaki disease;
CESC	cis	rs10129255	0.719	rs7156660	chr14:107129187	T/C	cg23076370	chr14:107095027	NA	-0.49	-6.73	-0.38	1.06e-10	Kawasaki disease;
CESC	cis	rs4888262	0.526	rs8055803	chr16:74615190	A/G	cg01733217	chr16:74700730	RFWD3	0.83	11.46	0.58	5.96e-25	Testicular germ cell tumor;
CESC	cis	rs12497850	0.864	rs7431857	chr3:48900347	G/A	cg07636037	chr3:49044803	WDR6	1.02	18.99	0.76	2.3e-51	Parkinson's disease;
CESC	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.55	-6.17	-0.35	2.48e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs10089	1.000	rs4835944	chr5:127490870	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.72	-9.25	-0.49	7.6e-18	Ileal carcinoids;
CESC	cis	rs6952808	0.729	rs35797753	chr7:1954914	G/A	cg04267008	chr7:1944627	MAD1L1	-0.74	-9.69	-0.51	3.28e-19	Bipolar disorder and schizophrenia;
CESC	cis	rs4819052	1.000	rs2297285	chr21:46705621	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	-0.65	-7.57	-0.42	6.27e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs10751667	0.600	rs1128419	chr11:1010750	G/A	cg20946044	chr11:1010712	AP2A2	-0.47	-6.16	-0.35	2.62e-9	Alzheimer's disease (late onset);
CESC	cis	rs727563	0.608	rs2076200	chr22:41985956	G/T	cg06481639	chr22:41940642	POLR3H	-0.65	-6.38	-0.37	7.65e-10	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs10461617	0.531	rs2662033	chr5:56213410	T/G	cg18230493	chr5:56204884	C5orf35	-0.71	-8.8	-0.48	1.77e-16	Type 2 diabetes;
CESC	cis	rs7044106	0.791	rs4836830	chr9:123483668	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.81	12.64	0.61	5.76e-29	Hip circumference adjusted for BMI;
CESC	cis	rs11822910	0.871	rs2581928	chr11:57202790	A/G	cg00522883	chr11:57194120	SLC43A3	-0.61	-6.91	-0.39	3.6e-11	Platelet distribution width;
CESC	cis	rs780096	0.526	rs3845686	chr2:27655447	T/G	cg02592271	chr2:27665507	KRTCAP3	-0.28	-5.42	-0.32	1.34e-7	Total body bone mineral density;
CESC	cis	rs4909189	0.915	rs11773551	chr7:158136146	C/T	cg24154853	chr7:158122151	PTPRN2	0.51	6.44	0.37	5.73e-10	Response to amphetamines;
CESC	cis	rs72634258	0.945	rs441597	chr1:8080895	A/G	cg00042356	chr1:8021962	PARK7	0.57	6.04	0.35	5.25e-9	Inflammatory bowel disease;
CESC	cis	rs13108904	0.934	rs13125842	chr4:1280947	G/A	cg22903657	chr4:1355424	KIAA1530	-0.38	-5.18	-0.3	4.5e-7	Obesity-related traits;
CESC	cis	rs7927771	1.000	rs12361031	chr11:47783076	G/A	cg20307385	chr11:47447363	PSMC3	-0.51	-6.23	-0.36	1.79e-9	Subjective well-being;
CESC	cis	rs7107174	0.892	rs1007837	chr11:77941076	A/G	cg02023728	chr11:77925099	USP35	0.38	5.53	0.32	7.66e-8	Testicular germ cell tumor;
CESC	cis	rs9911578	1.000	rs9907499	chr17:56949044	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.16	0.3	4.87e-7	Intelligence (multi-trait analysis);
CESC	cis	rs875971	0.862	rs10282433	chr7:65721439	G/A	cg18876405	chr7:65276391	NA	-0.51	-7.23	-0.41	5.17e-12	Aortic root size;
CESC	cis	rs7666738	0.830	rs7663661	chr4:99014761	A/G	cg03467027	chr4:99064603	C4orf37	0.44	5.63	0.33	4.57e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2249694	1.000	rs2515644	chr10:135353079	A/C	cg20169779	chr10:135381914	SYCE1	0.39	5.2	0.3	3.9e-7	Obesity-related traits;
CESC	cis	rs12893668	0.603	rs12896171	chr14:104135966	A/G	cg08213375	chr14:104286397	PPP1R13B	0.33	5.41	0.32	1.4e-7	Reticulocyte count;
CESC	cis	rs5753037	0.702	rs9614055	chr22:30187702	C/T	cg01021169	chr22:30184971	ASCC2	-0.46	-6.57	-0.37	2.65e-10	Type 1 diabetes;
CESC	cis	rs9487051	0.646	rs11153166	chr6:109622494	C/T	cg01475377	chr6:109611718	NA	0.41	5.72	0.33	2.89e-8	Reticulocyte fraction of red cells;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg05311119	chr4:1805090	FGFR3	0.45	6.23	0.36	1.82e-9	Fibrinogen levels;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg01490821	chr2:170684022	UBR3	-0.44	-6.21	-0.36	2.06e-9	Gambling;
CESC	cis	rs300703	0.935	rs300755	chr2:228505	C/T	cg21211680	chr2:198530	NA	0.97	7.77	0.43	1.68e-13	Blood protein levels;
CESC	cis	rs514406	0.861	rs72637996	chr1:53249618	A/T	cg25767906	chr1:53392781	SCP2	0.43	6.05	0.35	4.94e-9	Monocyte count;
CESC	cis	rs7520050	0.966	rs785494	chr1:46586626	C/A	cg03146154	chr1:46216737	IPP	-0.42	-5.42	-0.32	1.34e-7	Red blood cell count;Reticulocyte count;
CESC	cis	rs1448094	0.511	rs10863080	chr12:86153149	C/T	cg00310523	chr12:86230176	RASSF9	-0.31	-5.04	-0.3	8.55e-7	Major depressive disorder;
CESC	cis	rs60154123	0.730	rs689248	chr1:210463122	A/G	cg02304930	chr1:210405566	SERTAD4;C1orf133	-0.46	-5.13	-0.3	5.47e-7	Coronary artery disease;
CESC	cis	rs7666738	0.927	rs6832373	chr4:99051967	A/G	cg05340658	chr4:99064831	C4orf37	0.83	12.9	0.62	7.07e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6502050	0.769	rs9916231	chr17:80119645	A/G	cg11859384	chr17:80120422	CCDC57	-0.41	-5.67	-0.33	3.65e-8	Life satisfaction;
CESC	cis	rs1348850	0.632	rs1405718	chr2:178499809	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.57	7.47	0.42	1.17e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs365132	1.000	rs1700490	chr5:176402401	G/A	cg16309518	chr5:176445507	NA	-0.36	-5.31	-0.31	2.33e-7	Menarche and menopause (age at onset);Menopause (age at onset);
CESC	trans	rs9929218	0.859	rs9936682	chr16:68748223	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.77	-9.56	-0.51	8.63e-19	Colorectal cancer;
CESC	cis	rs4665809	0.652	rs11685594	chr2:26402846	A/G	cg26314531	chr2:26401878	FAM59B	-0.82	-9.04	-0.49	3.33e-17	Gut microbiome composition (summer);
CESC	cis	rs425277	0.606	rs2459984	chr1:2086312	A/G	cg16545954	chr1:2118288	C1orf86	0.36	7.09	0.4	1.19e-11	Height;
CESC	cis	rs748404	0.631	rs8042688	chr15:43638525	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.6	7.81	0.43	1.33e-13	Lung cancer;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg06852250	chr1:171750693	METTL13	-0.43	-6.0	-0.35	6.4e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs2486288	0.656	rs1706768	chr15:45569443	T/C	cg21132104	chr15:45694354	SPATA5L1	-0.62	-7.22	-0.41	5.34e-12	Glomerular filtration rate;
CESC	cis	rs7814319	1.000	rs7814319	chr8:97263418	C/T	cg20787634	chr8:97240163	UQCRB	-0.53	-6.91	-0.39	3.66e-11	Lung function (FVC);
CESC	cis	rs17376456	0.825	rs10064368	chr5:93266396	C/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.65	5.32	0.31	2.26e-7	Diabetic retinopathy;
CESC	cis	rs7666738	0.830	rs10021044	chr4:99002488	A/T	cg17366294	chr4:99064904	C4orf37	0.6	8.61	0.47	6.47e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs17376456	0.877	rs13170509	chr5:93378564	T/C	cg25358565	chr5:93447407	FAM172A	1.14	10.54	0.54	6.24e-22	Diabetic retinopathy;
CESC	cis	rs13256369	1.000	rs1109619	chr8:8571616	G/T	cg17143192	chr8:8559678	CLDN23	0.73	8.62	0.47	6.39e-16	Obesity-related traits;
CESC	cis	rs7208859	0.573	rs60724269	chr17:29113273	G/T	cg14008862	chr17:28927542	LRRC37B2	0.65	5.14	0.3	5.34e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs78456975	1.000	rs28742145	chr2:1562671	T/C	cg26248373	chr2:1572462	NA	-0.59	-5.66	-0.33	3.87e-8	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs60843830	1.000	rs59937473	chr2:271797	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.78	10.22	0.53	6.97e-21	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs1577917	0.771	rs2842609	chr6:86296788	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.56	-7.8	-0.43	1.46e-13	Response to antipsychotic treatment;
CESC	cis	rs1552244	0.882	rs61429272	chr3:10037320	G/C	cg08888203	chr3:10149979	C3orf24	0.48	6.1	0.35	3.84e-9	Alzheimer's disease;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg22897130	chr10:89419623	PAPSS2	0.47	6.62	0.38	2.01e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs738322	0.775	rs4375	chr22:38539041	T/C	cg17652424	chr22:38574118	PLA2G6	-0.29	-5.19	-0.3	4.14e-7	Cutaneous nevi;
CESC	cis	rs453301	0.624	rs2979265	chr8:8858717	G/C	cg15556689	chr8:8085844	FLJ10661	0.49	6.35	0.36	9.2e-10	Joint mobility (Beighton score);
CESC	cis	rs7618915	0.570	rs4687633	chr3:52630548	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	6.69	0.38	1.29e-10	Bipolar disorder;
CESC	trans	rs28549925	0.590	rs28676827	chr7:16994780	T/C	cg12639933	chr12:57626296	SHMT2	0.95	6.1	0.35	3.74e-9	Congenital heart disease (maternal effect);Conotruncal heart defects (maternal effects);
CESC	cis	rs12188164	1.000	rs56104584	chr5:437542	T/C	cg21144161	chr5:423903	AHRR	0.37	6.09	0.35	3.9e-9	Cystic fibrosis severity;
CESC	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg24829409	chr8:58192753	C8orf71	-0.67	-7.99	-0.44	4.08e-14	Developmental language disorder (linguistic errors);
CESC	cis	rs7551222	0.752	rs6681905	chr1:204535789	T/G	cg20240347	chr1:204465584	NA	-0.29	-5.78	-0.33	2.15e-8	Schizophrenia;
CESC	cis	rs6582630	0.599	rs7967598	chr12:38540760	C/T	cg26384229	chr12:38710491	ALG10B	-0.43	-5.67	-0.33	3.8e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs752010	0.714	rs2148635	chr1:42082452	C/T	cg06885757	chr1:42089581	HIVEP3	-0.52	-9.07	-0.49	2.85e-17	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs1448094	0.817	rs7972773	chr12:86340774	A/C	cg02569458	chr12:86230093	RASSF9	0.42	6.06	0.35	4.64e-9	Major depressive disorder;
CESC	cis	rs15676	0.947	rs2997922	chr9:131580744	C/T	cg00228799	chr9:131580591	ENDOG	0.45	5.67	0.33	3.76e-8	Blood metabolite levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14479329	chr6:167370587	RNASET2	0.54	7.12	0.4	1.04e-11	Gut microbiome composition (summer);
CESC	cis	rs16866061	1.000	rs72974222	chr2:225424143	C/T	cg12698349	chr2:225449008	CUL3	0.75	11.51	0.58	4.07e-25	Acute graft versus host disease in bone marrow transplantation (recipient effect);
CESC	cis	rs7811142	0.720	rs7795656	chr7:99950297	A/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.14	12.03	0.59	6.95e-27	Platelet count;
CESC	cis	rs3820928	0.874	rs10182307	chr2:227875360	C/T	cg05526886	chr2:227700861	RHBDD1	-0.44	-5.33	-0.31	2.12e-7	Pulmonary function;
CESC	cis	rs7412746	0.658	rs6677420	chr1:150946490	G/A	cg04414720	chr1:150670196	GOLPH3L	0.48	6.29	0.36	1.33e-9	Melanoma;
CESC	trans	rs629535	0.814	rs62513373	chr8:70080753	C/T	cg21567404	chr3:27674614	NA	-0.89	-10.53	-0.54	6.98e-22	Dupuytren's disease;
CESC	cis	rs4713118	0.513	rs183244	chr6:28031838	C/A	cg18032046	chr6:28092343	ZSCAN16	-0.46	-5.99	-0.35	6.88e-9	Parkinson's disease;
CESC	cis	rs13385	0.769	rs13178142	chr5:139596552	C/T	cg26211634	chr5:139558579	C5orf32	0.47	5.31	0.31	2.35e-7	Atrial fibrillation;
CESC	cis	rs9457247	1.000	rs365189	chr6:167384545	G/A	cg23791538	chr6:167370224	RNASET2	-0.6	-8.65	-0.47	5.12e-16	Crohn's disease;
CESC	cis	rs3818285	0.504	rs7100154	chr10:111650150	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.51	-7.08	-0.4	1.26e-11	Superior crus of antihelix expression;
CESC	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg01516881	chr6:292596	DUSP22	-0.84	-11.6	-0.58	1.89e-25	Menopause (age at onset);
CESC	cis	rs116095464	0.558	rs6874745	chr5:264527	A/G	cg22496380	chr5:211416	CCDC127	-0.74	-8.46	-0.46	1.86e-15	Breast cancer;
CESC	cis	rs11997175	0.646	rs6468195	chr8:33724817	A/G	ch.8.33884649F	chr8:33765107	NA	0.56	7.36	0.41	2.25e-12	Body mass index;
CESC	trans	rs62103177	0.608	rs59300126	chr18:77694439	C/A	cg05926928	chr17:57297772	GDPD1	0.87	8.21	0.45	9.47e-15	Opioid sensitivity;
CESC	trans	rs17685	0.753	rs1637051	chr7:75730659	G/A	cg19862616	chr7:65841803	NCRNA00174	0.87	12.7	0.62	3.58e-29	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs78889164	0.830	rs8111027	chr19:33877523	C/G	cg02272751	chr19:33882848	PEPD	-0.55	-7.64	-0.42	4.08e-13	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs12348691	0.503	rs10983975	chr9:100614188	A/C	cg13688889	chr9:100608707	NA	-0.9	-13.65	-0.64	1.78e-32	Alopecia areata;
CESC	cis	rs875971	0.862	rs3893216	chr7:65790707	G/C	cg11764359	chr7:65958608	NA	-0.8	-11.71	-0.58	8.38e-26	Aortic root size;
CESC	cis	rs6570726	0.791	rs405206	chr6:145836873	C/A	cg05347473	chr6:146136440	FBXO30	0.59	7.56	0.42	6.43e-13	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9818941	1.000	rs9818941	chr3:157686457	G/A	cg08654915	chr3:157813417	NA	-0.44	-7.54	-0.42	7.3e-13	Height;
CESC	cis	rs896854	0.812	rs4582532	chr8:95969257	G/A	cg13393036	chr8:95962371	TP53INP1	-0.51	-11.09	-0.56	9.71e-24	Type 2 diabetes;
CESC	cis	rs963731	0.649	rs74258982	chr2:39344474	T/C	cg04010122	chr2:39346883	SOS1	0.72	5.04	0.3	8.77e-7	Corticobasal degeneration;
CESC	cis	rs875971	0.965	rs10267430	chr7:65743023	G/T	cg12463550	chr7:65579703	CRCP	-0.54	-6.98	-0.39	2.4e-11	Aortic root size;
CESC	cis	rs7666738	0.924	rs13124368	chr4:99039615	T/C	cg18180107	chr4:99064573	C4orf37	0.41	5.29	0.31	2.51e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2929278	0.562	rs8033846	chr15:44035363	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	-0.54	-7.18	-0.4	7.19e-12	Schizophrenia;
CESC	cis	rs2455799	0.634	rs11128765	chr3:15903331	G/T	cg16303742	chr3:15540471	COLQ	-0.38	-5.91	-0.34	1.03e-8	Mean platelet volume;
CESC	cis	rs6599388	0.803	rs11248057	chr4:906131	C/G	cg23939001	chr4:940644	TMEM175	-0.48	-6.41	-0.37	6.58e-10	Parkinson's disease;
CESC	cis	rs4566357	1.000	rs2141829	chr2:227922454	G/A	cg11843606	chr2:227700838	RHBDD1	-0.42	-5.37	-0.31	1.68e-7	Coronary artery disease;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg08585351	chr13:22178326	EFHA1	-0.46	-6.05	-0.35	4.94e-9	Ulcerative colitis;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg24394020	chr22:50354019	PIM3	0.49	6.24	0.36	1.75e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs6952808	0.656	rs12699646	chr7:2093162	T/G	cg23048001	chr7:2026167	MAD1L1	-0.47	-6.07	-0.35	4.36e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs113835537	0.529	rs11227512	chr11:66281291	T/C	cg22134325	chr11:66188745	NPAS4	0.37	5.81	0.34	1.77e-8	Airway imaging phenotypes;
CESC	cis	rs11690935	0.632	rs35854151	chr2:172657439	G/A	cg13550731	chr2:172543902	DYNC1I2	0.55	7.6	0.42	4.99e-13	Schizophrenia;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg18654971	chr5:54469363	MIR449C;CDC20B	-0.43	-6.14	-0.35	3.03e-9	Gambling;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00414561	chr15:23034473	NIPA2	0.6	7.12	0.4	1.04e-11	Gut microbiome composition (summer);
CESC	cis	rs8017423	0.866	rs10184	chr14:90744672	G/A	cg14092571	chr14:90743983	NA	0.56	8.3	0.45	5.43e-15	Mortality in heart failure;
CESC	cis	rs10089	1.000	rs13357268	chr5:127423051	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.75	10.16	0.53	1.05e-20	Ileal carcinoids;
CESC	trans	rs7246760	1.000	rs12460571	chr19:9881746	C/A	cg02900749	chr2:68251473	NA	-0.74	-6.78	-0.38	7.89e-11	Pursuit maintenance gain;
CESC	cis	rs7666738	0.830	rs6832568	chr4:98994061	G/A	cg18180107	chr4:99064573	C4orf37	0.4	5.23	0.31	3.41e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9398803	0.965	rs2326387	chr6:126680489	G/A	cg19875578	chr6:126661172	C6orf173	0.48	6.73	0.38	1.06e-10	Male-pattern baldness;
CESC	cis	rs2836950	0.520	rs8133927	chr21:40689961	G/T	cg17971929	chr21:40555470	PSMG1	-0.6	-7.91	-0.44	7.15e-14	Menarche (age at onset);
CESC	cis	rs9910055	0.683	rs7220138	chr17:42254011	C/G	cg13607699	chr17:42295918	UBTF	0.56	7.08	0.4	1.31e-11	Total body bone mineral density;
CESC	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg23708337	chr7:1209742	NA	0.55	5.41	0.32	1.41e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs1153858	1.000	rs12437887	chr15:45669094	G/A	cg21132104	chr15:45694354	SPATA5L1	0.86	11.62	0.58	1.67e-25	Homoarginine levels;
CESC	cis	rs988913	0.723	rs75537920	chr6:54999717	T/C	cg03513858	chr6:54763001	FAM83B	0.34	5.2	0.3	4.05e-7	Menarche (age at onset);
CESC	cis	rs7618915	0.547	rs13069481	chr3:52666866	C/T	cg18099408	chr3:52552593	STAB1	-0.31	-5.07	-0.3	7.43e-7	Bipolar disorder;
CESC	cis	rs9818941	0.748	rs12634315	chr3:157728016	T/C	cg08654915	chr3:157813417	NA	-0.45	-7.54	-0.42	7.43e-13	Height;
CESC	cis	rs9300255	0.568	rs1047158	chr12:123644056	C/A	cg19016782	chr12:123741754	C12orf65	-0.4	-5.77	-0.33	2.27e-8	Neutrophil percentage of white cells;
CESC	cis	rs1881797	0.932	rs4551631	chr1:247667663	C/T	cg18198730	chr1:247681584	NA	-0.66	-8.59	-0.47	7.7e-16	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs7833790	0.724	rs6473310	chr8:82707981	A/G	cg17211192	chr8:82754475	SNX16	-0.59	-7.69	-0.43	2.94e-13	Diastolic blood pressure;
CESC	cis	rs6741892	0.536	rs11688977	chr2:38896631	C/T	cg19391498	chr2:38892846	GALM	-0.52	-6.74	-0.38	1.01e-10	5-HTT brain serotonin transporter levels;
CESC	cis	rs7107174	1.000	rs2510051	chr11:77981171	A/C	cg02023728	chr11:77925099	USP35	0.48	6.86	0.39	4.75e-11	Testicular germ cell tumor;
CESC	cis	rs7666738	0.830	rs9998803	chr4:99002519	C/T	cg03467027	chr4:99064603	C4orf37	0.44	5.51	0.32	8.65e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9399137	0.507	rs7761964	chr6:135314265	T/C	cg24558204	chr6:135376177	HBS1L	0.72	10.08	0.53	1.92e-20	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	cis	rs875971	0.825	rs10281499	chr7:66048966	A/G	cg18252515	chr7:66147081	NA	0.46	5.96	0.34	8.03e-9	Aortic root size;
CESC	trans	rs1728785	0.818	rs1170430	chr16:68604954	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.65	7.93	0.44	6e-14	Ulcerative colitis;
CESC	cis	rs7412746	0.658	rs6657388	chr1:150748786	A/G	cg17724175	chr1:150552817	MCL1	0.43	6.47	0.37	4.66e-10	Melanoma;
CESC	cis	rs7520050	0.778	rs2934857	chr1:46039612	A/G	cg24296786	chr1:45957014	TESK2	-0.46	-5.93	-0.34	9.54e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs6964587	1.000	rs57816416	chr7:91736078	A/C	cg17063962	chr7:91808500	NA	0.56	7.69	0.43	2.96e-13	Breast cancer;
CESC	cis	rs9858542	0.953	rs7648841	chr3:49416825	G/A	cg03060546	chr3:49711283	APEH	-0.53	-6.04	-0.35	5.23e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs10465746	0.967	rs11163879	chr1:84444051	T/C	cg10977910	chr1:84465055	TTLL7	0.47	6.43	0.37	6.02e-10	Obesity-related traits;
CESC	trans	rs208520	0.690	rs4618506	chr6:66756889	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.9	-11.53	-0.58	3.38e-25	Exhaled nitric oxide output;
CESC	cis	rs6762	0.719	rs1130698	chr11:838542	C/T	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.69	-8.78	-0.47	2.11e-16	Mean platelet volume;
CESC	cis	rs6088590	0.603	rs6579186	chr20:33282198	G/C	cg08999081	chr20:33150536	PIGU	0.65	10.66	0.55	2.54e-22	Coronary artery disease;
CESC	cis	rs9303401	0.632	rs7222087	chr17:57221619	A/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.56	7.31	0.41	3.2e-12	Cognitive test performance;
CESC	cis	rs57221529	0.766	rs72706606	chr5:558609	T/C	cg16447950	chr5:562315	NA	-0.7	-7.76	-0.43	1.9e-13	Lung disease severity in cystic fibrosis;
CESC	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg07308232	chr7:1071921	C7orf50	-0.38	-5.05	-0.3	8.19e-7	Longevity;Endometriosis;
CESC	cis	rs2228479	0.618	rs62052174	chr16:89950901	G/A	cg04013166	chr16:89971882	TCF25	0.77	7.14	0.4	8.86e-12	Skin colour saturation;
CESC	cis	rs3892630	0.824	rs2287884	chr19:33321447	A/G	cg13157960	chr19:33183277	NUDT19	0.54	5.13	0.3	5.73e-7	Red blood cell traits;
CESC	cis	rs7130144	0.541	rs1950119	chr11:130462002	A/T	cg26307797	chr11:130446613	NA	0.65	6.04	0.35	5.26e-9	Urate levels in lean individuals;
CESC	cis	rs4699052	1.000	rs6533060	chr4:104139996	T/C	cg16532752	chr4:104119610	CENPE	-0.39	-5.42	-0.32	1.35e-7	Testicular germ cell tumor;
CESC	cis	rs713587	0.521	rs35177510	chr2:25089594	C/A	cg01884057	chr2:25150051	NA	0.35	6.67	0.38	1.46e-10	Body mass index in non-asthmatics;
CESC	cis	rs4930103	0.591	rs11042048	chr11:1986240	C/G	cg23202291	chr11:1979235	NA	0.41	5.83	0.34	1.62e-8	DNA methylation (parent-of-origin);DNA methylation (variation);
CESC	cis	rs2637266	0.703	rs846641	chr10:78524136	C/T	cg18941641	chr10:78392320	NA	0.39	7.5	0.42	9.46e-13	Pulmonary function;
CESC	cis	rs736408	0.522	rs6445535	chr3:52771468	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.62	8.73	0.47	2.84e-16	Bipolar disorder;
CESC	cis	rs854765	0.583	rs4077198	chr17:17834563	T/C	cg04398451	chr17:18023971	MYO15A	-0.67	-9.61	-0.51	6.01e-19	Total body bone mineral density;
CESC	cis	rs2979489	0.891	rs2979498	chr8:30375251	T/A	cg26383811	chr8:30366931	RBPMS	-0.8	-9.88	-0.52	8.22e-20	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CESC	cis	rs7833790	0.724	rs12676336	chr8:82771008	C/T	cg07697082	chr8:82753677	SNX16	-0.39	-5.98	-0.35	7.01e-9	Diastolic blood pressure;
CESC	cis	rs6088580	0.634	rs6059878	chr20:33087166	A/T	cg24642439	chr20:33292090	TP53INP2	0.51	6.62	0.38	1.99e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs8141529	0.748	rs9620841	chr22:29290981	C/T	cg02153584	chr22:29168773	CCDC117	0.59	7.84	0.43	1.09e-13	Lymphocyte counts;
CESC	cis	rs861020	0.771	rs674804	chr1:210014603	C/G	cg05527609	chr1:210001259	C1orf107	1.09	15.51	0.69	4.93e-39	Orofacial clefts;
CESC	trans	rs66573146	0.572	rs67922134	chr4:6955772	G/A	cg07817883	chr1:32538562	TMEM39B	1.25	8.67	0.47	4.33e-16	Granulocyte percentage of myeloid white cells;
CESC	cis	rs2425143	1.000	rs56116518	chr20:34286251	G/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.6	5.11	0.3	6.03e-7	Blood protein levels;
CESC	cis	rs3785574	0.962	rs56295011	chr17:61850359	A/G	cg06873352	chr17:61820015	STRADA	0.48	7.02	0.4	1.81e-11	Height;
CESC	cis	rs992157	0.661	rs17653757	chr2:219109364	G/C	cg00012203	chr2:219082015	ARPC2	0.85	12.31	0.6	7.75e-28	Colorectal cancer;
CESC	cis	rs7264396	0.635	rs6060681	chr20:34506147	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.58	7.14	0.4	8.92e-12	Total cholesterol levels;
CESC	cis	rs7927771	0.524	rs6485763	chr11:47627302	C/T	cg20307385	chr11:47447363	PSMC3	0.65	8.97	0.48	5.58e-17	Subjective well-being;
CESC	cis	rs28386778	0.700	rs12449555	chr17:62003982	T/A	cg06873352	chr17:61820015	STRADA	-0.63	-10.1	-0.53	1.69e-20	Prudent dietary pattern;
CESC	cis	rs2836974	0.899	rs2836938	chr21:40574191	C/T	cg17971929	chr21:40555470	PSMG1	1.07	16.33	0.71	5.97e-42	Cognitive function;
CESC	cis	rs72781680	0.898	rs72782137	chr2:24047805	C/T	cg20701182	chr2:24300061	SF3B14	0.63	5.65	0.33	4.21e-8	Lymphocyte counts;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15342139	chr6:170124938	PHF10	0.62	7.18	0.4	6.93e-12	Gut microbiome composition (summer);
CESC	cis	rs12824058	0.831	rs4759657	chr12:130815818	G/A	cg26677194	chr12:130822605	PIWIL1	0.52	6.82	0.39	6.23e-11	Menopause (age at onset);
CESC	cis	rs7617773	0.780	rs11714176	chr3:48360862	C/T	cg11946769	chr3:48343235	NME6	0.89	12.34	0.6	5.98e-28	Coronary artery disease;
CESC	cis	rs2228479	0.702	rs17233441	chr16:89817998	C/G	cg14709524	chr16:89940631	TCF25	0.93	6.94	0.39	3.03e-11	Skin colour saturation;
CESC	cis	rs3741404	0.560	rs17699798	chr11:63898806	C/G	cg05555928	chr11:63887634	MACROD1	0.37	5.48	0.32	9.98e-8	Platelet count;
CESC	cis	rs933688	0.818	rs10052492	chr5:90759930	T/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.02	13.7	0.64	1.12e-32	Smoking behavior;
CESC	cis	rs1862618	0.671	rs906631	chr5:56245803	C/G	cg12311346	chr5:56204834	C5orf35	0.64	8.49	0.46	1.47e-15	Initial pursuit acceleration;
CESC	trans	rs561341	1.000	rs527256	chr17:30321293	C/G	cg20587970	chr11:113659929	NA	-1.44	-18.71	-0.75	2.25e-50	Hip circumference adjusted for BMI;
CESC	cis	rs853679	0.517	rs55747925	chr6:28044337	T/C	cg22143856	chr6:28129313	ZNF389	0.49	6.3	0.36	1.2e-9	Depression;
CESC	cis	rs6429082	0.783	rs291365	chr1:235688043	A/G	cg26050004	chr1:235667680	B3GALNT2	0.66	8.81	0.48	1.67e-16	Adiposity;
CESC	cis	rs1006703	0.544	rs35299172	chr17:3834598	C/T	cg06463185	chr17:3833770	ATP2A3	0.56	6.06	0.35	4.59e-9	Glucose homeostasis traits;
CESC	cis	rs933688	1.000	rs1035476	chr5:90745976	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.1	12.5	0.61	1.76e-28	Smoking behavior;
CESC	cis	rs11785400	1.000	rs4327844	chr8:143733540	C/T	cg24634471	chr8:143751801	JRK	-0.46	-6.11	-0.35	3.49e-9	Schizophrenia;
CESC	cis	rs7098414	0.531	rs4120852	chr10:82018594	G/T	cg00277334	chr10:82204260	NA	-0.47	-6.11	-0.35	3.5e-9	Post bronchodilator FEV1;
CESC	cis	rs1881797	0.872	rs12404733	chr1:247690417	A/C	cg11166453	chr1:247681781	NA	0.48	6.82	0.39	6.26e-11	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs3733585	0.699	rs1122142	chr4:9947548	G/C	cg02734326	chr4:10020555	SLC2A9	-0.42	-5.84	-0.34	1.49e-8	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs1707322	0.721	rs12069121	chr1:46231984	G/A	cg03146154	chr1:46216737	IPP	0.81	11.48	0.58	4.89e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs4722166	0.630	rs7808457	chr7:22798265	A/T	cg05472934	chr7:22766657	IL6	-0.87	-10.38	-0.54	2.11e-21	Lung cancer;
CESC	cis	rs8060686	0.858	rs20549	chr16:67969930	A/G	cg26727032	chr16:67993705	SLC12A4	-0.64	-9.33	-0.5	4.45e-18	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs12325245	0.536	rs34737210	chr16:58549262	T/C	cg02549819	chr16:58548995	SETD6	0.97	6.12	0.35	3.44e-9	Schizophrenia;
CESC	cis	rs7474896	0.583	rs10764144	chr10:37975732	G/C	cg00409905	chr10:38381863	ZNF37A	-0.45	-5.28	-0.31	2.75e-7	Obesity (extreme);
CESC	trans	rs2963826	0.589	rs298091	chr5:58996603	A/T	cg13789711	chr9:139743225	PHPT1	0.48	6.41	0.37	6.66e-10	Obesity-related traits;
CESC	cis	rs7923609	0.756	rs7080386	chr10:65048306	C/A	cg01631684	chr10:65280961	REEP3	-0.45	-5.64	-0.33	4.38e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7542091	0.704	rs7537294	chr1:210043777	A/G	cg22029157	chr1:209979665	IRF6	0.5	7.98	0.44	4.32e-14	Monobrow;
CESC	cis	rs4665809	1.000	rs7588802	chr2:26277789	A/G	cg22920501	chr2:26401640	FAM59B	-0.79	-9.59	-0.51	6.87e-19	Gut microbiome composition (summer);
CESC	cis	rs7615952	0.576	rs66671308	chr3:125793526	T/G	cg15145296	chr3:125709740	NA	-0.54	-5.73	-0.33	2.67e-8	Blood pressure (smoking interaction);
CESC	cis	rs561341	0.769	rs12941700	chr17:30185022	A/G	cg12193833	chr17:30244370	NA	0.55	5.31	0.31	2.35e-7	Hip circumference adjusted for BMI;
CESC	cis	rs7582720	1.000	rs72936304	chr2:204036357	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	6.87	0.39	4.55e-11	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs7560272	0.723	rs4346412	chr2:73843571	A/G	cg20560298	chr2:73613845	ALMS1	-0.51	-7.19	-0.4	6.42e-12	Schizophrenia;
CESC	cis	rs901683	1.000	rs34897497	chr10:46024677	A/G	cg16031567	chr10:46195673	NA	-0.77	-5.04	-0.3	8.57e-7	Red blood cell traits;Mean corpuscular volume;
CESC	cis	rs2576037	0.583	rs9304336	chr18:44461687	T/C	cg19077165	chr18:44547161	KATNAL2	-0.62	-9.37	-0.5	3.23e-18	Personality dimensions;
CESC	cis	rs2797160	1.000	rs1777222	chr6:126021030	C/T	cg05901451	chr6:126070800	HEY2	0.44	6.4	0.37	7.13e-10	Endometrial cancer;
CESC	cis	rs916888	0.773	rs199533	chr17:44828931	G/A	cg17911788	chr17:44343683	NA	-0.59	-7.77	-0.43	1.75e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs863345	0.967	rs7534319	chr1:158532295	G/C	cg12129480	chr1:158549410	OR10X1	-0.33	-6.66	-0.38	1.57e-10	Pneumococcal bacteremia;
CESC	cis	rs17401966	0.931	rs12130563	chr1:10428452	G/A	cg15208524	chr1:10270712	KIF1B	0.4	5.12	0.3	6e-7	Hepatocellular carcinoma;
CESC	cis	rs3768617	0.565	rs10752898	chr1:183077896	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.84	13.25	0.63	4.34e-31	Fuchs's corneal dystrophy;
CESC	cis	rs9926296	0.508	rs1558184	chr16:89842374	T/G	cg21285383	chr16:89894308	SPIRE2	0.32	5.8	0.34	1.86e-8	Vitiligo;
CESC	cis	rs1953600	0.668	rs7091565	chr10:81913561	A/G	cg04850286	chr10:81895943	PLAC9	-0.29	-5.1	-0.3	6.32e-7	Sarcoidosis;
CESC	cis	rs72949976	0.864	rs13389834	chr2:214025112	G/A	cg08319019	chr2:214017104	IKZF2	-0.45	-5.5	-0.32	9e-8	Lung cancer;Squamous cell lung carcinoma;
CESC	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg22535103	chr8:58192502	C8orf71	-0.96	-9.82	-0.52	1.3e-19	Developmental language disorder (linguistic errors);
CESC	cis	rs11098499	0.908	rs7695996	chr4:120322033	C/T	cg09307838	chr4:120376055	NA	0.91	12.48	0.61	2.07e-28	Corneal astigmatism;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg14967814	chr3:179041370	ZNF639	-0.43	-6.1	-0.35	3.72e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg24324755	chr1:44115813	KDM4A	-0.44	-6.29	-0.36	1.29e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs13256369	0.802	rs13256404	chr8:8562974	T/C	cg00074818	chr8:8560427	CLDN23	0.38	5.46	0.32	1.1e-7	Obesity-related traits;
CESC	cis	rs9733	0.596	rs72702573	chr1:150689050	C/T	cg09365446	chr1:150670422	GOLPH3L	0.42	5.86	0.34	1.37e-8	Tonsillectomy;
CESC	cis	rs10504229	0.906	rs7006539	chr8:58178799	A/T	cg24829409	chr8:58192753	C8orf71	-0.78	-10.28	-0.53	4.36e-21	Developmental language disorder (linguistic errors);
CESC	cis	rs853679	0.517	rs9393895	chr6:28127621	T/C	cg17949981	chr6:28129498	ZNF389	0.45	5.57	0.32	6.26e-8	Depression;
CESC	cis	rs30380	1.000	rs27529	chr5:96126308	A/G	cg16492584	chr5:96139282	ERAP1	-0.35	-5.13	-0.3	5.6e-7	Cerebrospinal fluid biomarker levels;
CESC	cis	rs9325144	0.600	rs6582630	chr12:38743508	A/G	cg26384229	chr12:38710491	ALG10B	-0.57	-8.08	-0.44	2.26e-14	Morning vs. evening chronotype;
CESC	cis	rs7552404	0.765	rs1251078	chr1:76189488	C/G	cg22875332	chr1:76189707	ACADM	-0.76	-11.73	-0.58	6.93e-26	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs477895	0.838	rs35090903	chr11:64000598	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.88	10.19	0.53	8.59e-21	Mean platelet volume;
CESC	cis	rs8072100	0.713	rs11079776	chr17:45546893	C/T	cg08085267	chr17:45401833	C17orf57	-0.54	-6.83	-0.39	5.68e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00784703	chr21:45139229	PDXK	0.69	7.84	0.43	1.1e-13	Gut microbiome composition (summer);
CESC	cis	rs778371	0.834	rs778364	chr2:233777859	A/G	cg08000102	chr2:233561755	GIGYF2	0.64	8.25	0.45	7.54e-15	Schizophrenia;
CESC	cis	rs7116495	0.609	rs949323	chr11:71714528	T/G	cg26138937	chr11:71823887	C11orf51	-1.16	-7.82	-0.43	1.29e-13	Severe influenza A (H1N1) infection;
CESC	trans	rs7607369	0.680	rs533760	chr2:219381405	T/C	cg15547669	chr20:2781122	CPXM1	0.36	6.03	0.35	5.54e-9	Red blood cell count;Amyotrophic lateral sclerosis;
CESC	cis	rs1153858	1.000	rs11852800	chr15:45639131	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.43	-6.08	-0.35	4.2e-9	Homoarginine levels;
CESC	cis	rs4722166	0.695	rs7808122	chr7:22798080	A/G	cg05265849	chr7:22767390	IL6	0.45	6.22	0.36	1.93e-9	Lung cancer;
CESC	cis	rs4664308	0.905	rs62175518	chr2:160915149	C/T	cg03641300	chr2:160917029	PLA2R1	-0.63	-9.44	-0.5	1.98e-18	Idiopathic membranous nephropathy;
CESC	cis	rs10256972	0.527	rs28671326	chr7:1174973	G/A	cg09177884	chr7:1199841	ZFAND2A	-0.59	-7.72	-0.43	2.38e-13	Longevity;Endometriosis;
CESC	cis	rs1790761	0.692	rs611663	chr11:67312221	C/T	cg00290607	chr11:67383545	NA	0.4	5.72	0.33	2.9e-8	Mean corpuscular volume;
CESC	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.64	7.2	0.4	6.15e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs4664304	0.781	rs6432570	chr2:160808314	A/G	cg03641300	chr2:160917029	PLA2R1	-0.41	-5.47	-0.32	1.06e-7	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs7618915	0.547	rs4130905	chr3:52709831	A/T	cg18099408	chr3:52552593	STAB1	-0.31	-5.16	-0.3	4.81e-7	Bipolar disorder;
CESC	cis	rs10504229	0.683	rs61364624	chr8:58134339	T/A	cg24829409	chr8:58192753	C8orf71	-0.58	-7.2	-0.4	6.31e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs763121	0.853	rs6001184	chr22:39052116	C/T	cg21395723	chr22:39101663	GTPBP1	0.43	5.39	0.31	1.54e-7	Menopause (age at onset);
CESC	cis	rs75887402	1.000	rs1428387	chr5:122705244	A/G	cg27033705	chr5:122759302	CEP120	-0.89	-5.95	-0.34	8.67e-9	Breast cancer;
CESC	cis	rs4906332	1.000	rs1951389	chr14:103898525	G/C	cg09975044	chr14:104007538	NA	0.47	6.4	0.37	6.89e-10	Coronary artery disease;
CESC	cis	rs6952808	0.756	rs4719311	chr7:1881813	C/T	cg13880726	chr7:1868755	MAD1L1	0.53	7.0	0.4	2.07e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs9470366	0.816	rs7742159	chr6:36619452	A/C	cg08179530	chr6:36648295	CDKN1A	0.54	6.3	0.36	1.21e-9	QRS duration;
CESC	trans	rs9650657	0.513	rs4841459	chr8:10782442	A/C	cg06636001	chr8:8085503	FLJ10661	-0.51	-6.35	-0.36	9.17e-10	Neuroticism;
CESC	cis	rs4835473	0.932	rs6826862	chr4:144899333	A/G	cg25736465	chr4:144833511	NA	0.39	6.05	0.35	4.91e-9	Immature fraction of reticulocytes;
CESC	cis	rs6546550	0.901	rs11893500	chr2:70154187	T/C	cg02498382	chr2:70120550	SNRNP27	-0.4	-6.95	-0.39	2.78e-11	Prevalent atrial fibrillation;
CESC	cis	rs782590	0.683	rs782633	chr2:55898203	A/G	cg18811423	chr2:55921094	PNPT1	0.78	12.9	0.62	7e-30	Metabolic syndrome;
CESC	cis	rs412000	0.554	rs2680700	chr17:56440542	G/T	cg25039879	chr17:56429692	SUPT4H1	0.58	7.27	0.41	4.04e-12	Primary tooth development (time to first tooth eruption);
CESC	cis	rs9311474	0.652	rs411457	chr3:52228150	A/T	cg05564831	chr3:52568323	NT5DC2	-0.39	-5.99	-0.35	6.88e-9	Electroencephalogram traits;
CESC	cis	rs7584330	0.910	rs72620830	chr2:238396985	C/T	cg11271282	chr2:238384023	NA	0.48	5.6	0.33	5.34e-8	Prostate cancer;
CESC	trans	rs9467711	0.659	rs34605993	chr6:26454363	C/T	cg06606381	chr12:133084897	FBRSL1	-0.97	-7.05	-0.4	1.58e-11	Autism spectrum disorder or schizophrenia;
CESC	trans	rs9929218	0.953	rs17772411	chr16:68810923	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.6	-7.78	-0.43	1.6e-13	Colorectal cancer;
CESC	cis	rs2273669	0.667	rs9688496	chr6:109364825	G/T	cg05315195	chr6:109294784	ARMC2	-0.67	-6.32	-0.36	1.13e-9	Prostate cancer;
CESC	cis	rs9322193	0.962	rs17673294	chr6:150134993	G/A	cg04369109	chr6:150039330	LATS1	-0.41	-5.64	-0.33	4.35e-8	Lung cancer;
CESC	cis	rs8013055	0.796	rs11628497	chr14:105970789	C/T	cg23356831	chr14:105996513	TMEM121	0.37	5.11	0.3	6.19e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
CESC	cis	rs868036	0.718	rs2241420	chr15:68082816	G/A	cg08079166	chr15:68083412	MAP2K5	0.35	5.1	0.3	6.47e-7	Restless legs syndrome;
CESC	cis	rs9486715	1.000	rs9386670	chr6:97060688	C/A	cg06623918	chr6:96969491	KIAA0776	-0.86	-11.98	-0.59	9.94e-27	Headache;
CESC	cis	rs7618915	0.571	rs33964154	chr3:52596914	A/G	cg05564831	chr3:52568323	NT5DC2	0.45	6.9	0.39	3.86e-11	Bipolar disorder;
CESC	trans	rs17685	0.753	rs1637044	chr7:75703744	T/C	cg19862616	chr7:65841803	NCRNA00174	0.85	12.47	0.61	2.13e-28	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs2933343	1.000	rs789213	chr3:128616359	C/G	cg25356066	chr3:128598488	ACAD9	-0.58	-7.34	-0.41	2.7e-12	IgG glycosylation;
CESC	cis	rs6495122	0.699	rs12905199	chr15:75070196	A/G	cg09165964	chr15:75287851	SCAMP5	0.4	5.22	0.31	3.65e-7	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
CESC	cis	rs17376456	0.877	rs13170509	chr5:93378564	T/C	cg21475434	chr5:93447410	FAM172A	0.84	7.15	0.4	8.34e-12	Diabetic retinopathy;
CESC	trans	rs3934047	0.904	rs28403489	chr15:82010502	A/G	cg17156767	chr19:30364462	NA	0.38	6.04	0.35	5.15e-9	Response to paliperidone in schizophrenia (positive Marder score);
CESC	cis	rs7618915	0.547	rs13085331	chr3:52627486	G/C	cg05564831	chr3:52568323	NT5DC2	0.45	6.97	0.39	2.55e-11	Bipolar disorder;
CESC	cis	rs4481887	0.927	rs4347240	chr1:248475403	C/G	cg00666640	chr1:248458726	OR2T12	0.36	6.12	0.35	3.33e-9	Common traits (Other);
CESC	cis	rs12497850	0.931	rs11920534	chr3:48937761	G/T	cg06212747	chr3:49208901	KLHDC8B	0.68	9.38	0.5	3.06e-18	Parkinson's disease;
CESC	cis	rs7666738	0.830	rs9995370	chr4:98732145	T/G	cg24818145	chr4:99064322	C4orf37	0.39	5.08	0.3	7.29e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10779751	0.632	rs2748876	chr1:11134157	T/G	cg08854313	chr1:11322531	MTOR	0.74	8.83	0.48	1.43e-16	Body mass index;
CESC	cis	rs9611565	0.546	rs739129	chr22:42118249	G/A	cg17376030	chr22:41985996	PMM1	-0.78	-8.45	-0.46	1.98e-15	Vitiligo;
CESC	cis	rs6439153	0.967	rs12695513	chr3:128722312	T/C	cg24203234	chr3:128598194	ACAD9	0.4	5.29	0.31	2.56e-7	Pneumococcal bacteremia;
CESC	cis	rs7044106	0.762	rs3903886	chr9:123383646	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.66	-9.71	-0.51	2.85e-19	Hip circumference adjusted for BMI;
CESC	cis	rs10203711	1.000	rs907102	chr2:239564503	G/A	cg14580085	chr2:239553406	NA	0.34	5.1	0.3	6.6e-7	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4665809	0.838	rs7565843	chr2:26292912	G/C	cg04944784	chr2:26401820	FAM59B	-0.66	-7.66	-0.43	3.61e-13	Gut microbiome composition (summer);
CESC	cis	rs12291225	0.639	rs61883858	chr11:14294708	C/T	cg19336497	chr11:14380999	RRAS2	-0.37	-5.37	-0.31	1.68e-7	Sense of smell;
CESC	cis	rs13191362	1.000	rs13220181	chr6:163004401	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.79	8.26	0.45	6.82e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs523522	0.962	rs4767905	chr12:120930835	C/T	cg27279351	chr12:120934652	DYNLL1	0.69	9.13	0.49	1.8e-17	High light scatter reticulocyte count;
CESC	trans	rs4295623	0.585	rs34421088	chr8:11589042	A/G	cg15556689	chr8:8085844	FLJ10661	-0.54	-6.31	-0.36	1.15e-9	Morning vs. evening chronotype;
CESC	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.89	13.59	0.64	2.72e-32	Prudent dietary pattern;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg15356780	chr14:90422831	TDP1	0.47	6.3	0.36	1.23e-9	Systemic lupus erythematosus;
CESC	cis	rs1552244	1.000	rs6782602	chr3:10116541	G/T	cg00166722	chr3:10149974	C3orf24	0.54	6.89	0.39	4.08e-11	Alzheimer's disease;
CESC	cis	rs2985684	0.895	rs4900940	chr14:50075310	A/C	cg10008539	chr14:50087325	RPL36AL;MGAT2	-0.48	-5.66	-0.33	3.92e-8	Carotid intima media thickness;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg09929564	chr1:153643582	ILF2	-0.47	-6.55	-0.37	2.93e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	trans	rs35146811	0.625	rs858514	chr7:99825748	A/G	cg13215871	chr17:75784724	NA	-0.34	-6.23	-0.36	1.8e-9	Coronary artery disease;
CESC	cis	rs10771431	0.597	rs3759275	chr12:9353828	A/T	cg08997352	chr12:9597637	DDX12	-0.7	-8.86	-0.48	1.17e-16	Breast size;
CESC	cis	rs477692	0.604	rs1008982	chr10:131445731	T/C	cg24747557	chr10:131355152	MGMT	0.37	5.1	0.3	6.41e-7	Response to temozolomide;
CESC	cis	rs7811142	0.667	rs3873746	chr7:99935097	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.08	13.21	0.63	5.99e-31	Platelet count;
CESC	cis	rs7666738	0.791	rs34790496	chr4:98930516	C/T	cg03467027	chr4:99064603	C4orf37	0.44	5.33	0.31	2.13e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg17446216	chr1:32480239	KHDRBS1	0.38	6.02	0.35	5.83e-9	Gambling;
CESC	cis	rs708547	0.957	rs2458552	chr4:57773442	G/A	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.53	-5.35	-0.31	1.88e-7	Response to bleomycin (chromatid breaks);
CESC	trans	rs875971	0.895	rs10755833	chr7:65913917	A/G	cg26939375	chr7:64535504	NA	0.46	6.0	0.35	6.4e-9	Aortic root size;
CESC	trans	rs35110281	0.744	rs230644	chr21:44917183	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.46	-6.08	-0.35	4.23e-9	Mean corpuscular volume;
CESC	cis	rs13191362	1.000	rs35424047	chr6:163029715	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.86	9.12	0.49	1.91e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs112790992	1	rs112790992	chr14:105758217	A/C	cg27165867	chr14:105738592	BRF1	-0.47	-5.55	-0.32	6.92e-8	Platelet count;
CESC	cis	rs9457247	0.902	rs34560498	chr6:167395862	A/G	cg23791538	chr6:167370224	RNASET2	-0.6	-8.51	-0.46	1.35e-15	Crohn's disease;
CESC	cis	rs6952808	0.656	rs73048919	chr7:2103637	C/A	cg08027265	chr7:2291960	NA	-0.45	-6.92	-0.39	3.42e-11	Bipolar disorder and schizophrenia;
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg19875216	chr3:133524841	SRPRB	-0.42	-6.08	-0.35	4.22e-9	Vertical cup-disc ratio;
CESC	cis	rs853679	0.517	rs67878650	chr6:28142587	G/C	cg20151795	chr6:28129481	ZNF389	0.41	5.28	0.31	2.69e-7	Depression;
CESC	cis	rs4713118	0.527	rs4713151	chr6:28136356	G/A	cg19592336	chr6:28129416	ZNF389	0.58	7.71	0.43	2.54e-13	Parkinson's disease;
CESC	cis	rs758324	0.947	rs2404778	chr5:131172886	T/C	cg06307176	chr5:131281290	NA	0.42	5.08	0.3	7.13e-7	Alzheimer's disease in APOE e4- carriers;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg01716223	chr13:53023979	VPS36	0.47	6.21	0.36	2.07e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs2735413	0.837	rs12920830	chr16:78083149	A/C	cg04733911	chr16:78082701	NA	-0.53	-8.89	-0.48	9.44e-17	Systolic blood pressure (alcohol consumption interaction);
CESC	cis	rs3540	0.554	rs4244879	chr15:91066915	C/T	cg22089800	chr15:90895588	ZNF774	-0.64	-8.42	-0.46	2.39e-15	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs13191362	1.000	rs67042566	chr6:163006541	A/T	cg21926612	chr6:163149169	PACRG;PARK2	0.87	9.04	0.49	3.35e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	trans	rs9467711	0.606	rs9348726	chr6:26605206	G/A	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.71	6.05	0.35	5.04e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs2011503	0.941	rs998732	chr19:19378671	A/G	cg11584989	chr19:19387371	SF4	0.63	7.58	0.42	5.75e-13	Bipolar disorder;
CESC	cis	rs898097	0.841	rs4986122	chr17:80825500	C/T	cg19046167	chr17:80928561	B3GNTL1	-0.41	-5.04	-0.3	8.77e-7	Breast cancer;
CESC	cis	rs7666738	0.830	rs1896154	chr4:99021161	T/C	cg03467027	chr4:99064603	C4orf37	0.46	5.77	0.33	2.21e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6088590	0.561	rs6088527	chr20:33155841	C/T	cg06115741	chr20:33292138	TP53INP2	0.51	6.51	0.37	3.74e-10	Coronary artery disease;
CESC	cis	rs2836974	0.932	rs2150415	chr21:40615367	A/G	cg11644478	chr21:40555479	PSMG1	0.92	13.73	0.64	8.83e-33	Cognitive function;
CESC	cis	rs897984	0.806	rs11150600	chr16:30940331	C/T	cg02466173	chr16:30829666	NA	0.49	8.33	0.46	4.26e-15	Dementia with Lewy bodies;
CESC	cis	rs3771570	0.892	rs62186433	chr2:242257835	A/G	cg21155796	chr2:242212141	HDLBP	0.6	5.12	0.3	5.96e-7	Prostate cancer;
CESC	cis	rs9311474	0.508	rs11714565	chr3:52606292	C/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	5.86	0.34	1.4e-8	Electroencephalogram traits;
CESC	cis	rs4727027	0.769	rs10952797	chr7:148816722	A/T	cg23158103	chr7:148848205	ZNF398	-0.41	-6.83	-0.39	5.9e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs5750830	0.649	rs5750808	chr22:39790987	G/A	cg02038168	chr22:39784481	NA	-0.62	-7.88	-0.44	8.34e-14	Intelligence (multi-trait analysis);
CESC	cis	rs754466	0.914	rs4595491	chr10:79685833	G/A	cg17075019	chr10:79541650	NA	-0.77	-9.42	-0.5	2.33e-18	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs939658	0.875	rs2177057	chr15:79441441	G/C	cg17916960	chr15:79447300	NA	-0.35	-5.98	-0.34	7.25e-9	Refractive error;
CESC	cis	rs6690583	0.562	rs6688354	chr1:85520854	A/G	cg22488158	chr1:85528044	WDR63	0.57	5.53	0.32	7.72e-8	Serum sulfate level;
CESC	cis	rs6565681	1.000	rs4889848	chr17:78354661	C/T	cg15383979	chr17:78362278	RNF213;LOC100294362	-0.77	-8.8	-0.48	1.75e-16	Moyamoya disease;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg15260365	chr11:67771606	UNC93B1	0.43	6.04	0.35	5.06e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs3126085	0.935	rs3126048	chr1:152260165	T/C	cg03465714	chr1:152285911	FLG	0.46	5.74	0.33	2.61e-8	Atopic dermatitis;
CESC	cis	rs9309473	0.607	rs6740173	chr2:73602266	C/G	cg20560298	chr2:73613845	ALMS1	-0.52	-7.34	-0.41	2.65e-12	Metabolite levels;
CESC	cis	rs9486715	0.867	rs926277	chr6:96868837	T/A	cg18709589	chr6:96969512	KIAA0776	0.45	6.46	0.37	5.05e-10	Headache;
CESC	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg14893161	chr1:205819251	PM20D1	-0.79	-11.4	-0.57	9.31e-25	Menarche (age at onset);
CESC	cis	rs12422267	0.536	rs11246933	chr12:132610314	G/A	cg09764611	chr12:132620959	NA	-0.58	-6.86	-0.39	4.85e-11	Plasma amyloid beta peptide concentrations (ABx-40);
CESC	cis	rs2795502	0.935	rs2744060	chr10:43262616	C/G	cg20628663	chr10:43360327	NA	-0.7	-7.58	-0.42	5.97e-13	Blood protein levels;
CESC	cis	rs12887734	0.524	rs12888002	chr14:104238647	T/C	cg08213375	chr14:104286397	PPP1R13B	0.43	7.39	0.41	1.9e-12	Schizophrenia;Autism spectrum disorder or schizophrenia;
CESC	cis	rs472402	0.623	rs8192135	chr5:6636757	T/A	cg10789808	chr5:6633262	NSUN2;SRD5A1	-0.46	-6.13	-0.35	3.2e-9	Response to amphetamines;
CESC	cis	rs425277	0.958	rs262652	chr1:2090816	T/C	cg04315214	chr1:2043799	PRKCZ	-0.38	-5.31	-0.31	2.35e-7	Height;
CESC	cis	rs10489525	0.599	rs2335724	chr1:115608444	T/C	cg01522456	chr1:115632236	TSPAN2	0.45	5.45	0.32	1.14e-7	Autism;
CESC	cis	rs4253772	0.513	rs9615345	chr22:46713631	C/T	cg09491104	chr22:46646882	C22orf40	-0.58	-8.3	-0.45	5.42e-15	LDL cholesterol;Cholesterol, total;
CESC	cis	rs8114671	0.562	rs6088636	chr20:33469746	C/T	cg07148914	chr20:33460835	GGT7	0.44	5.89	0.34	1.17e-8	Height;
CESC	cis	rs2303759	0.918	rs4802597	chr19:49872085	C/T	cg22307029	chr19:49891270	CCDC155	0.51	5.97	0.34	7.52e-9	Multiple sclerosis;
CESC	cis	rs2180341	0.960	rs6900074	chr6:127685893	A/G	cg24812749	chr6:127587940	RNF146	1.05	15.12	0.68	1.2e-37	Breast cancer;
CESC	cis	rs4970988	0.787	rs1532770	chr1:150725335	G/T	cg17724175	chr1:150552817	MCL1	0.42	6.36	0.36	8.76e-10	Urate levels;
CESC	cis	rs3015497	0.554	rs8011039	chr14:51091267	C/T	cg09863266	chr14:51125203	SAV1	-0.32	-5.03	-0.3	9.1e-7	Mean platelet volume;
CESC	cis	rs2072499	0.932	rs2736613	chr1:156196016	T/C	cg24450063	chr1:156163899	SLC25A44	0.96	15.65	0.69	1.58e-39	Testicular germ cell tumor;
CESC	cis	rs2688608	0.592	rs7909802	chr10:75484186	G/C	cg23231163	chr10:75533350	FUT11	-0.34	-5.28	-0.31	2.75e-7	Inflammatory bowel disease;
CESC	cis	rs9486719	1.000	rs2092096	chr6:96870919	A/G	cg06623918	chr6:96969491	KIAA0776	0.82	8.35	0.46	3.89e-15	Migraine;Coronary artery disease;
CESC	cis	rs7666738	0.830	rs2865989	chr4:99067532	G/A	cg03467027	chr4:99064603	C4orf37	0.48	5.96	0.34	7.81e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9457247	0.765	rs2237276	chr6:167442115	C/T	cg07741184	chr6:167504864	NA	0.36	6.49	0.37	4.31e-10	Crohn's disease;
CESC	cis	rs9291683	0.595	rs35250962	chr4:10048271	C/T	cg11266682	chr4:10021025	SLC2A9	0.68	13.29	0.63	3.1e-31	Bone mineral density;
CESC	cis	rs9733	0.596	rs1136808	chr1:150702717	G/C	cg22823121	chr1:150693482	HORMAD1	0.47	6.96	0.39	2.6e-11	Tonsillectomy;
CESC	cis	rs7635838	0.819	rs904474	chr3:11524648	C/G	cg00170343	chr3:11313890	ATG7	0.42	5.65	0.33	4.2e-8	HDL cholesterol;
CESC	cis	rs1862618	0.853	rs33322	chr5:56175226	A/G	cg24531977	chr5:56204891	C5orf35	-0.88	-10.98	-0.56	2.21e-23	Initial pursuit acceleration;
CESC	cis	rs2742234	0.590	rs2505553	chr10:43681251	G/T	cg15436174	chr10:43711423	RASGEF1A	-0.49	-5.76	-0.33	2.3e-8	Hirschsprung disease;
CESC	trans	rs7618501	0.699	rs9821675	chr3:49902544	A/G	cg21659725	chr3:3221576	CRBN	0.59	8.21	0.45	9.53e-15	Intelligence (multi-trait analysis);
CESC	cis	rs55823223	0.648	rs936394	chr17:73852008	C/A	cg02397686	chr17:73851076	WBP2	0.59	7.47	0.42	1.16e-12	Psoriasis;
CESC	cis	rs9300255	0.602	rs2682434	chr12:123694724	C/T	cg19016782	chr12:123741754	C12orf65	-0.45	-6.51	-0.37	3.65e-10	Neutrophil percentage of white cells;
CESC	cis	rs826838	1.000	rs1684416	chr12:39130301	G/A	cg26384229	chr12:38710491	ALG10B	-0.67	-11.01	-0.56	1.82e-23	Heart rate;
CESC	cis	rs1448094	0.511	rs17345975	chr12:86202318	T/A	cg02569458	chr12:86230093	RASSF9	0.52	7.79	0.43	1.55e-13	Major depressive disorder;
CESC	cis	rs5758659	0.569	rs133294	chr22:42382805	C/T	cg04733989	chr22:42467013	NAGA	0.47	6.14	0.35	2.93e-9	Cognitive function;
CESC	cis	rs7937682	0.924	rs10891283	chr11:111527672	A/G	cg22437258	chr11:111473054	SIK2	0.69	9.29	0.5	5.71e-18	Primary sclerosing cholangitis;
CESC	cis	rs898097	0.812	rs55794221	chr17:80849003	G/A	cg05255149	chr17:80675120	FN3KRP	-0.46	-5.2	-0.3	3.93e-7	Breast cancer;
CESC	cis	rs6860806	0.531	rs270607	chr5:131649186	A/G	cg18758796	chr5:131593413	PDLIM4	0.41	5.65	0.33	4.12e-8	Breast cancer;
CESC	cis	rs1568889	0.838	rs7933991	chr11:28059761	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.8	13.53	0.64	4.71e-32	Bipolar disorder;
CESC	cis	rs2742234	0.590	rs2503848	chr10:43672785	G/A	cg07801480	chr10:43725741	RASGEF1A	0.42	5.37	0.31	1.72e-7	Hirschsprung disease;
CESC	cis	rs9894429	1.000	rs4074916	chr17:79579248	G/A	cg18240062	chr17:79603768	NPLOC4	-0.72	-10.28	-0.53	4.56e-21	Eye color traits;
CESC	trans	rs57221529	0.664	rs72704802	chr5:554211	C/T	cg25482853	chr8:67687455	SGK3	1.21	10.79	0.55	9.75e-23	Lung disease severity in cystic fibrosis;
CESC	cis	rs1062177	1.000	rs2347596	chr5:151179199	T/C	cg00977110	chr5:151150581	G3BP1	0.66	7.11	0.4	1.06e-11	Preschool internalizing problems;
CESC	cis	rs3793683	1.000	rs3793683	chr10:134568387	G/T	cg27286337	chr10:134555280	INPP5A	-0.91	-14.24	-0.66	1.5e-34	Migraine;
CESC	cis	rs7408868	1.000	rs4809029	chr19:15273248	A/C	cg14696996	chr19:15285081	NOTCH3	1.11	11.32	0.57	1.67e-24	Pulse pressure;
CESC	cis	rs2076222	1.000	rs2076350	chr1:209800341	C/T	cg00257659	chr1:209800214	LAMB3	-0.87	-8.14	-0.45	1.6e-14	Fentanyl consumption in laparoscopic-assisted colectomy (first 24 hours);
CESC	cis	rs1950626	0.833	rs2400963	chr14:101395706	A/G	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.79	10.83	0.55	7.22e-23	Pelvic organ prolapse (moderate/severe);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg01764079	chr8:144718741	ZNF623	-0.45	-6.12	-0.35	3.34e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs2404602	0.583	rs12592501	chr15:76554790	C/A	cg22467129	chr15:76604101	ETFA	-0.39	-6.0	-0.35	6.37e-9	Blood metabolite levels;
CESC	trans	rs7178375	1.000	rs35162264	chr15:31200683	T/A	cg04373760	chr16:53404718	NA	0.57	7.49	0.42	1e-12	Hypertriglyceridemia;
CESC	cis	rs1371867	0.875	rs28595052	chr8:101327553	G/A	cg11906718	chr8:101322791	RNF19A	0.54	6.89	0.39	4.05e-11	Atrioventricular conduction;
CESC	cis	rs6963495	0.818	rs73192120	chr7:105171156	C/T	cg02135003	chr7:105160482	PUS7	-0.46	-5.5	-0.32	9.1e-8	Bipolar disorder (body mass index interaction);
CESC	cis	rs644799	0.965	rs2508713	chr11:95547927	T/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.54	6.61	0.38	2.07e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs727505	0.754	rs56012154	chr7:124781250	A/G	cg23710748	chr7:124431027	NA	-0.38	-6.2	-0.36	2.14e-9	Lewy body disease;
CESC	cis	rs17039065	1.000	rs11736209	chr4:109394658	A/T	cg16022748	chr4:109541635	LOC285456;RPL34	0.65	5.52	0.32	8.2e-8	Gut microbiome composition (summer);
CESC	cis	rs250677	0.652	rs1422582	chr5:148436925	T/C	cg18129178	chr5:148520854	ABLIM3	-0.54	-5.38	-0.31	1.6e-7	Breast cancer;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg07087156	chr2:228190257	NA	-0.44	-6.34	-0.36	1.01e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs877282	0.945	rs877280	chr10:771599	C/T	cg22713356	chr15:30763199	NA	1.26	12.69	0.61	3.79e-29	Uric acid levels;
CESC	cis	rs9322193	0.847	rs56103941	chr6:150137231	A/G	cg09699651	chr6:150184138	LRP11	0.41	5.14	0.3	5.32e-7	Lung cancer;
CESC	cis	rs2072732	0.687	rs10489588	chr1:2951834	C/T	cg15211996	chr1:2936768	ACTRT2	0.33	5.94	0.34	8.91e-9	Plateletcrit;
CESC	cis	rs9596863	1.000	rs9568940	chr13:54419251	C/A	ch.13.53330881F	chr13:54432880	NA	0.65	5.26	0.31	2.99e-7	Epilepsy and lamotrigine-induced maculopapular eruptions;
CESC	cis	rs9300255	0.722	rs12304248	chr12:123810425	C/T	cg19016782	chr12:123741754	C12orf65	0.44	6.02	0.35	5.91e-9	Neutrophil percentage of white cells;
CESC	trans	rs17685	0.753	rs9691174	chr7:75790405	T/C	cg19862616	chr7:65841803	NCRNA00174	0.84	12.03	0.59	6.77e-27	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs9916302	0.731	rs11868030	chr17:37650332	A/G	cg20243544	chr17:37824526	PNMT	0.51	6.5	0.37	3.97e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs17253792	0.659	rs34330219	chr14:56017375	G/A	cg01858014	chr14:56050164	KTN1	-0.87	-6.37	-0.36	8.34e-10	Putamen volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04775315	chr10:71168737	TACR2	0.61	6.95	0.39	2.82e-11	Gut microbiome composition (summer);
CESC	cis	rs17102423	0.661	rs45604339	chr14:65543102	C/T	cg11161011	chr14:65562177	MAX	-0.49	-5.45	-0.32	1.14e-7	Obesity-related traits;
CESC	cis	rs17345786	1.000	rs17345786	chr3:101318318	A/C	cg12386194	chr3:101231763	SENP7	-0.57	-6.47	-0.37	4.8e-10	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4660261	0.526	rs2485997	chr1:44345841	G/C	cg13606994	chr1:44402422	ARTN	-0.37	-5.6	-0.33	5.47e-8	Intelligence (multi-trait analysis);
CESC	cis	rs7044106	0.718	rs1960421	chr9:123394894	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.63	8.52	0.46	1.18e-15	Hip circumference adjusted for BMI;
CESC	cis	rs4466137	0.953	rs7735476	chr5:83015140	G/C	cg16102102	chr5:83017553	HAPLN1	-0.51	-7.16	-0.4	8.14e-12	Prostate cancer;
CESC	trans	rs5417	0.636	rs222851	chr17:7139238	G/A	cg15655154	chr3:113604241	GRAMD1C	0.53	7.15	0.4	8.49e-12	Diastolic blood pressure;
CESC	cis	rs780096	0.525	rs13388159	chr2:27648284	A/T	cg21248554	chr2:27665150	KRTCAP3	-0.36	-7.43	-0.42	1.46e-12	Total body bone mineral density;
CESC	cis	rs1538970	0.816	rs4633317	chr1:45985157	T/C	cg03146154	chr1:46216737	IPP	0.48	5.47	0.32	1.03e-7	Platelet count;
CESC	cis	rs9649213	0.593	rs7795176	chr7:97978287	A/C	cg00277769	chr7:97922759	BAIAP2L1	-0.33	-5.41	-0.32	1.41e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7692995	1.000	rs11930366	chr4:17960168	G/A	cg08925142	chr4:18023851	LCORL	-0.45	-5.13	-0.3	5.66e-7	Height;
CESC	cis	rs7665939	0.932	rs10022377	chr4:190108803	C/T	cg09826759	chr4:190284978	NA	-0.65	-6.9	-0.39	3.72e-11	Amyotrophic lateral sclerosis;
CESC	cis	rs72945132	0.882	rs57810426	chr11:70230030	G/A	cg00319359	chr11:70116639	PPFIA1	0.73	7.1	0.4	1.11e-11	Coronary artery disease;
CESC	cis	rs6775745	0.689	rs1406778	chr3:131750466	T/C	cg12213930	chr3:131751605	CPNE4	0.47	5.17	0.3	4.61e-7	Neutrophil count;
CESC	cis	rs2742234	0.590	rs2293020	chr10:43692887	A/G	cg07801480	chr10:43725741	RASGEF1A	-0.43	-5.6	-0.33	5.36e-8	Hirschsprung disease;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14047321	chr14:62523576	SYT16	-0.45	-6.17	-0.35	2.54e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg06066128	chr3:47018377	CCDC12	-0.53	-6.74	-0.38	9.59e-11	Asthma;
CESC	cis	rs40363	0.523	rs757270	chr16:3534451	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	0.46	5.88	0.34	1.26e-8	Tuberculosis;
CESC	trans	rs1005277	0.579	rs176838	chr10:38371899	A/T	cg17830980	chr10:43048298	ZNF37B	0.47	6.24	0.36	1.72e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs763121	0.962	rs909564	chr22:39126508	A/G	cg06544989	chr22:39130855	UNC84B	0.46	8.65	0.47	5.06e-16	Menopause (age at onset);
CESC	cis	rs4689388	0.926	rs28420833	chr4:6279504	G/A	cg25554036	chr4:6271136	WFS1	0.57	9.67	0.51	3.93e-19	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs3824867	0.920	rs7101772	chr11:47449378	A/G	cg20307385	chr11:47447363	PSMC3	-0.47	-5.54	-0.32	7.3900000000000007e-08	Mean corpuscular hemoglobin;
CESC	trans	rs7937682	0.961	rs4936682	chr11:111629743	T/G	cg18187862	chr3:45730750	SACM1L	-0.55	-6.08	-0.35	4.12e-9	Primary sclerosing cholangitis;
CESC	cis	rs911555	0.723	rs4906324	chr14:103923099	A/G	cg24130564	chr14:104152367	KLC1	0.5	6.6	0.38	2.27e-10	Intelligence (multi-trait analysis);
CESC	cis	rs9486719	1.000	rs34236778	chr6:96884556	C/A	cg06623918	chr6:96969491	KIAA0776	-0.81	-8.29	-0.45	5.61e-15	Migraine;Coronary artery disease;
CESC	cis	rs2658782	0.547	rs3133454	chr11:93059019	A/C	cg15737290	chr11:93063684	CCDC67	0.55	7.61	0.42	4.71e-13	Pulmonary function decline;
CESC	cis	rs1018836	0.892	rs1476428	chr8:91555603	G/T	cg16814680	chr8:91681699	NA	-0.61	-8.71	-0.47	3.26e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs9929218	0.551	rs2296409	chr16:68713730	G/A	cg02972257	chr16:68554789	NA	-0.43	-5.26	-0.31	2.96e-7	Colorectal cancer;
CESC	cis	rs7809950	1.000	rs17154104	chr7:107090698	C/T	cg23024343	chr7:107201750	COG5	-0.38	-5.41	-0.32	1.41e-7	Coronary artery disease;
CESC	cis	rs4665809	0.590	rs35727620	chr2:26458364	G/A	cg04944784	chr2:26401820	FAM59B	0.96	10.55	0.54	5.79e-22	Gut microbiome composition (summer);
CESC	cis	rs12497850	0.931	rs9755490	chr3:48871664	A/C	cg07636037	chr3:49044803	WDR6	1.03	18.76	0.76	1.49e-50	Parkinson's disease;
CESC	cis	rs896854	0.967	rs896853	chr8:95960855	G/C	cg16049864	chr8:95962084	TP53INP1	-0.71	-13.23	-0.63	5.18e-31	Type 2 diabetes;
CESC	cis	rs13191362	0.872	rs13206549	chr6:162978032	T/G	cg06582575	chr6:163149167	PACRG;PARK2	0.7	6.61	0.38	2.08e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs769267	0.929	rs2965180	chr19:19491973	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.45	-5.92	-0.34	1.01e-8	Tonsillectomy;
CESC	cis	rs8014204	0.604	rs11625594	chr14:75389833	G/A	cg26191576	chr14:75389716	RPS6KL1	-0.4	-5.59	-0.32	5.6e-8	Caffeine consumption;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg24409649	chr12:31479318	FAM60A	-0.46	-6.4	-0.37	7.12e-10	Asthma;
CESC	cis	rs6432018	0.964	rs7565646	chr2:9728879	A/G	cg23886495	chr2:9695866	ADAM17	0.44	5.18	0.3	4.5e-7	Heart rate variability traits;
CESC	cis	rs2404602	0.684	rs1011083	chr15:77007527	C/T	cg23625390	chr15:77176239	SCAPER	-0.47	-6.52	-0.37	3.54e-10	Blood metabolite levels;
CESC	cis	rs6800768	0.633	rs826375	chr3:24163964	A/G	cg10674438	chr3:24145617	LOC152024	-0.46	-7.02	-0.4	1.83e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs599083	0.573	rs3018713	chr11:68390986	A/G	cg20283391	chr11:68216788	NA	-0.43	-5.25	-0.31	3.18e-7	Bone mineral density (spine);
CESC	cis	rs514406	0.560	rs1889033	chr1:53211887	A/G	cg08736216	chr1:53307985	ZYG11A	0.4	6.55	0.37	3.06e-10	Monocyte count;
CESC	cis	rs7772486	0.817	rs9386145	chr6:146363519	A/T	cg05347473	chr6:146136440	FBXO30	0.47	6.16	0.35	2.66e-9	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6952808	0.792	rs2056481	chr7:1955435	A/G	cg05863683	chr7:1912471	MAD1L1	0.43	6.57	0.37	2.61e-10	Bipolar disorder and schizophrenia;
CESC	cis	rs7191439	0.858	rs11076702	chr16:88774569	A/C	cg02389323	chr16:88786976	FAM38A	1.09	8.71	0.47	3.29e-16	Plateletcrit;
CESC	cis	rs5750830	0.594	rs9611169	chr22:39783027	C/T	cg02038168	chr22:39784481	NA	-0.61	-7.98	-0.44	4.55e-14	Intelligence (multi-trait analysis);
CESC	cis	rs4523957	0.928	rs9905529	chr17:2177732	T/C	cg16513277	chr17:2031491	SMG6	-0.59	-8.07	-0.44	2.41e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	trans	rs17685	0.736	rs4732594	chr7:75753273	T/C	cg19862616	chr7:65841803	NCRNA00174	0.85	12.41	0.61	3.51e-28	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs4665809	0.652	rs6728090	chr2:26524726	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.71	-7.39	-0.41	1.9e-12	Gut microbiome composition (summer);
CESC	cis	rs7847628	0.765	rs10985024	chr9:123516812	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.5	5.97	0.34	7.78e-9	Birth weight;
CESC	cis	rs2302729	0.860	rs6489375	chr12:2777768	A/G	cg19945202	chr12:2788847	CACNA1C	-0.41	-5.66	-0.33	3.92e-8	Sleep quality;
CESC	cis	rs11785400	0.731	rs9720504	chr8:143725502	T/C	cg10596483	chr8:143751796	JRK	0.42	5.36	0.31	1.77e-7	Schizophrenia;
CESC	cis	rs597539	0.654	rs7107137	chr11:68623712	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.78	9.35	0.5	3.73e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs965469	1.000	rs6051732	chr20:3294182	G/A	cg25506879	chr20:3388711	C20orf194	-0.57	-6.08	-0.35	4.19e-9	IFN-related cytopenia;
CESC	cis	rs10242455	0.702	rs79878591	chr7:99082928	C/T	cg18809830	chr7:99032528	PTCD1	-0.84	-5.59	-0.32	5.72e-8	Blood metabolite levels;
CESC	cis	rs1799949	1.000	rs8176234	chr17:41219780	T/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.45	6.21	0.36	2.01e-9	Menopause (age at onset);
CESC	cis	rs60871478	0.786	rs62432898	chr7:826102	G/A	cg15782153	chr7:917662	C7orf20	-0.49	-5.43	-0.32	1.25e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs9916302	0.861	rs9903363	chr17:37499604	C/G	cg00129232	chr17:37814104	STARD3	0.55	7.29	0.41	3.49e-12	Glomerular filtration rate (creatinine);
CESC	cis	rs5753618	0.583	rs5753631	chr22:31863022	A/C	cg00478049	chr22:31556069	RNF185	-0.43	-5.15	-0.3	5.2e-7	Colorectal cancer;
CESC	cis	rs1670533	0.746	rs688008	chr4:1082829	T/C	cg04106633	chr4:1044584	NA	0.4	5.1	0.3	6.33e-7	Recombination rate (females);
CESC	cis	rs3820068	0.705	rs927206	chr1:15893338	C/T	cg18192808	chr1:15853278	DNAJC16	0.46	5.52	0.32	7.92e-8	Systolic blood pressure;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04245873	chr15:63796130	USP3	-0.67	-8.21	-0.45	9.48e-15	Gut microbiome composition (summer);
CESC	cis	rs6866344	0.697	rs11742808	chr5:178131658	G/A	cg03877680	chr5:178157825	ZNF354A	0.75	8.5	0.46	1.38e-15	Neutrophil percentage of white cells;
CESC	trans	rs4942242	0.763	rs7326281	chr13:44233186	G/A	cg19169023	chr15:41853346	TYRO3	-0.65	-8.88	-0.48	1.06e-16	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs3820928	0.874	rs13413235	chr2:227893863	C/T	cg11843606	chr2:227700838	RHBDD1	-0.48	-6.37	-0.36	8.53e-10	Pulmonary function;
CESC	cis	rs798554	0.797	rs35957220	chr7:2812632	C/G	cg19717773	chr7:2847554	GNA12	-0.56	-7.8	-0.43	1.42e-13	Height;
CESC	cis	rs3820928	1.000	rs12615988	chr2:227769000	A/G	cg05526886	chr2:227700861	RHBDD1	-0.42	-5.54	-0.32	7.26e-8	Pulmonary function;
CESC	cis	rs6952808	0.531	rs3778998	chr7:2180753	C/A	cg04267008	chr7:1944627	MAD1L1	-0.53	-6.51	-0.37	3.7e-10	Bipolar disorder and schizophrenia;
CESC	cis	rs9811920	0.599	rs61148087	chr3:99539891	C/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.48	-5.76	-0.33	2.3e-8	Axial length;
CESC	cis	rs8177253	1.000	rs1358023	chr3:133484393	T/C	cg01448562	chr3:133502909	NA	-0.42	-5.95	-0.34	8.32e-9	Iron status biomarkers;
CESC	cis	rs2303745	0.544	rs6512181	chr19:17399213	T/G	cg04248312	chr19:17393744	ANKLE1	-0.92	-14.85	-0.67	1.01e-36	Systemic lupus erythematosus;
CESC	cis	rs2273669	0.667	rs76267985	chr6:109326183	A/T	cg05315195	chr6:109294784	ARMC2	-0.54	-5.31	-0.31	2.36e-7	Prostate cancer;
CESC	cis	rs9287719	0.934	rs4629131	chr2:10744159	C/T	cg00105475	chr2:10696890	NA	0.39	5.64	0.33	4.44e-8	Prostate cancer;
CESC	cis	rs1642645	0.872	rs4660586	chr1:42407229	C/T	cg16685388	chr1:42384056	HIVEP3	0.37	5.04	0.3	8.77e-7	Left ventricular obstructive tract defect (maternal effect);
CESC	cis	rs9549367	0.789	rs12584813	chr13:113895443	C/G	cg00898013	chr13:113819073	PROZ	-0.5	-6.91	-0.39	3.69e-11	Platelet distribution width;
CESC	trans	rs11098499	0.562	rs13101722	chr4:120555975	C/A	cg25214090	chr10:38739885	LOC399744	-0.52	-7.39	-0.41	1.88e-12	Corneal astigmatism;
CESC	cis	rs6460942	1.000	rs62448568	chr7:12407445	A/G	cg02935154	chr7:12443704	VWDE	-0.57	-5.89	-0.34	1.16e-8	Coronary artery disease;
CESC	cis	rs72781680	0.898	rs56315094	chr2:23941952	T/C	cg20701182	chr2:24300061	SF3B14	0.69	6.2	0.36	2.18e-9	Lymphocyte counts;
CESC	cis	rs8092503	1.000	rs12968302	chr18:52478970	A/G	cg12377874	chr18:52495404	RAB27B	0.38	6.27	0.36	1.46e-9	Childhood body mass index;
CESC	cis	rs1451375	0.617	rs896307	chr7:50569060	T/C	cg14593290	chr7:50529359	DDC	-0.52	-6.56	-0.37	2.82e-10	Malaria;
CESC	cis	rs9863	0.828	rs71458830	chr12:124476561	C/T	cg17562584	chr12:124393655	DNAH10	0.3	5.21	0.3	3.88e-7	White blood cell count;
CESC	cis	rs6460942	0.591	rs4721082	chr7:12341804	A/G	cg20607287	chr7:12443886	VWDE	-0.58	-6.29	-0.36	1.28e-9	Coronary artery disease;
CESC	trans	rs1945213	0.694	rs7131381	chr11:55858158	T/G	cg15704280	chr7:45808275	SEPT13	0.76	7.34	0.41	2.57e-12	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs870825	0.616	rs6825561	chr4:185615532	A/T	cg04058563	chr4:185651563	MLF1IP	0.64	7.05	0.4	1.59e-11	Blood protein levels;
CESC	cis	rs9796	0.689	rs8032195	chr15:41448790	G/A	cg12426344	chr15:41135900	SPINT1	-0.24	-5.36	-0.31	1.79e-7	Menopause (age at onset);
CESC	cis	rs9287719	0.967	rs4613248	chr2:10744051	C/T	cg02196655	chr2:10830764	NOL10	-0.38	-5.83	-0.34	1.61e-8	Prostate cancer;
CESC	cis	rs2075371	1.000	rs1421484	chr7:133979795	T/C	cg00033643	chr7:134001901	SLC35B4	0.44	5.71	0.33	2.97e-8	Mean platelet volume;
CESC	cis	rs7666738	0.830	rs7672901	chr4:98938781	C/T	cg17366294	chr4:99064904	C4orf37	0.6	8.4	0.46	2.75e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6460942	1.000	rs118083671	chr7:12466036	C/T	cg06484146	chr7:12443880	VWDE	-0.78	-9.14	-0.49	1.68e-17	Coronary artery disease;
CESC	cis	rs7618501	0.521	rs11709573	chr3:49956628	C/T	cg24308560	chr3:49941425	MST1R	-0.58	-8.38	-0.46	3.15e-15	Intelligence (multi-trait analysis);
CESC	cis	rs8070624	0.574	rs9914127	chr17:17875836	A/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.53	6.69	0.38	1.3100000000000001e-10	Total body bone mineral density;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg27576415	chr15:41709087	RTF1	-0.53	-7.83	-0.43	1.14e-13	Gambling;
CESC	cis	rs7116495	1.000	rs7937582	chr11:71744613	C/T	cg26138937	chr11:71823887	C11orf51	-0.83	-6.72	-0.38	1.14e-10	Severe influenza A (H1N1) infection;
CESC	cis	rs79057730	0.599	rs34411410	chr7:811721	G/A	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.91	7.84	0.43	1.1e-13	Initial pursuit acceleration;
CESC	cis	rs1595825	0.891	rs74965164	chr2:198499162	C/T	cg10820045	chr2:198174542	NA	0.41	5.14	0.3	5.33e-7	Ulcerative colitis;
CESC	cis	rs9311474	0.632	rs6445528	chr3:52572447	C/T	cg18099408	chr3:52552593	STAB1	0.34	6.08	0.35	4.06e-9	Electroencephalogram traits;
CESC	cis	rs933688	1.000	rs1363839	chr5:90671274	A/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.92	12.55	0.61	1.16e-28	Smoking behavior;
CESC	cis	rs9649213	0.555	rs12667634	chr7:97965442	A/G	cg08684580	chr7:98029266	BAIAP2L1	-0.35	-5.77	-0.33	2.2e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs10504229	1.000	rs66672857	chr8:58179817	G/C	cg22535103	chr8:58192502	C8orf71	-1.05	-13.27	-0.63	3.63e-31	Developmental language disorder (linguistic errors);
CESC	cis	rs875971	0.830	rs427575	chr7:65519219	A/G	cg11764359	chr7:65958608	NA	0.89	13.18	0.63	7.3e-31	Aortic root size;
CESC	cis	rs4969178	0.965	rs3744217	chr17:76400258	G/A	cg05887092	chr17:76393375	PGS1	0.58	9.26	0.49	7e-18	HDL cholesterol levels;
CESC	cis	rs6089584	0.566	rs11699442	chr20:60623268	A/G	cg06108461	chr20:60628389	TAF4	-0.61	-8.04	-0.44	2.95e-14	Body mass index;
CESC	cis	rs116095464	0.558	rs9688136	chr5:229348	T/C	cg10591111	chr5:226296	SDHA	-0.54	-6.65	-0.38	1.72e-10	Breast cancer;
CESC	cis	rs35110281	0.807	rs2838325	chr21:45014284	A/T	cg21573476	chr21:45109991	RRP1B	0.41	6.02	0.35	5.92e-9	Mean corpuscular volume;
CESC	cis	rs9303401	0.646	rs7342863	chr17:57227010	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.55	7.28	0.41	3.78e-12	Cognitive test performance;
CESC	cis	rs7089973	0.525	rs11196945	chr10:116600424	G/A	cg03647239	chr10:116582469	FAM160B1	0.43	5.35	0.31	1.94e-7	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs67478160	0.595	rs1475007	chr14:104297147	A/G	cg08213375	chr14:104286397	PPP1R13B	0.53	10.35	0.54	2.54e-21	Schizophrenia;
CESC	cis	rs4835473	0.897	rs35598237	chr4:144657114	C/T	cg25736465	chr4:144833511	NA	-0.33	-5.16	-0.3	4.78e-7	Immature fraction of reticulocytes;
CESC	cis	rs9611519	0.567	rs8141730	chr22:41473061	A/G	cg03806693	chr22:41940476	POLR3H	-0.43	-5.22	-0.31	3.67e-7	Neuroticism;
CESC	cis	rs514406	0.708	rs546334	chr1:53326210	T/C	cg24675658	chr1:53192096	ZYG11B	-0.66	-9.3	-0.5	5.42e-18	Monocyte count;
CESC	cis	rs9733	0.650	rs2048558	chr1:150571730	A/G	cg18016565	chr1:150552671	MCL1	-0.42	-6.98	-0.39	2.33e-11	Tonsillectomy;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg11844697	chr17:80935769	B3GNTL1	0.41	6.3	0.36	1.27e-9	Gambling;
CESC	cis	rs2836974	0.965	rs8130984	chr21:40639966	A/C	cg27266027	chr21:40555129	PSMG1	0.44	5.2	0.3	4.04e-7	Cognitive function;
CESC	cis	rs7615952	0.641	rs2365019	chr3:125808135	T/C	cg04553112	chr3:125709451	NA	-0.55	-5.82	-0.34	1.71e-8	Blood pressure (smoking interaction);
CESC	cis	rs9815354	0.812	rs17215498	chr3:41829679	G/C	cg03022575	chr3:42003672	ULK4	0.7	6.04	0.35	5.26e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs72781680	1.000	rs12616899	chr2:24165235	A/G	cg20701182	chr2:24300061	SF3B14	0.64	5.74	0.33	2.63e-8	Lymphocyte counts;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg14492347	chr15:85292323	ZNF592	-0.47	-6.73	-0.38	1.05e-10	Gambling;
CESC	cis	rs7582720	1.000	rs72932588	chr2:203883193	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.36	0.41	2.34e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs898097	0.812	rs72859941	chr17:80837459	G/A	cg20271620	chr17:80763330	TBCD	0.45	5.28	0.31	2.71e-7	Breast cancer;
CESC	cis	rs6499255	0.951	rs3743673	chr16:69711311	A/T	cg15192750	chr16:69999425	NA	0.49	5.65	0.33	4.18e-8	IgE levels;
CESC	cis	rs1355223	0.583	rs2915179	chr11:34871943	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.83	12.62	0.61	6.47e-29	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs2735413	0.881	rs12927515	chr16:78080141	T/G	cg04733911	chr16:78082701	NA	-0.53	-9.01	-0.48	4.13e-17	Systolic blood pressure (alcohol consumption interaction);
CESC	cis	rs6952808	0.692	rs60755037	chr7:2030104	G/A	cg08027265	chr7:2291960	NA	-0.37	-5.53	-0.32	7.61e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs7666738	0.761	rs1456210	chr4:98645932	T/G	cg03467027	chr4:99064603	C4orf37	0.42	5.26	0.31	2.92e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg11494091	chr17:61959527	GH2	0.72	12.39	0.61	4.12e-28	Prudent dietary pattern;
CESC	cis	rs2072732	0.861	rs6661908	chr1:2950334	C/T	cg03976712	chr1:2946727	NA	0.34	5.77	0.33	2.22e-8	Plateletcrit;
CESC	cis	rs7937682	1.000	rs11608122	chr11:111535105	C/T	cg22437258	chr11:111473054	SIK2	-0.68	-7.96	-0.44	5.09e-14	Primary sclerosing cholangitis;
CESC	cis	rs7666738	0.791	rs28858828	chr4:98950442	C/G	cg05340658	chr4:99064831	C4orf37	0.8	12.48	0.61	2e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2576037	0.583	rs892586	chr18:44560429	C/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.77	-12.33	-0.6	6.78e-28	Personality dimensions;
CESC	cis	rs6752107	0.967	rs3792111	chr2:234179690	C/T	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.39	5.81	0.34	1.82e-8	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs2274273	0.870	rs10147434	chr14:55674847	C/T	cg04306507	chr14:55594613	LGALS3	0.3	5.95	0.34	8.35e-9	Protein biomarker;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00837838	chr15:45003774	B2M	0.57	6.17	0.35	2.56e-9	Gut microbiome composition (summer);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg02724903	chr13:114260339	TFDP1	0.48	6.7	0.38	1.24e-10	Fibrinogen levels;
CESC	cis	rs868036	0.522	rs3784711	chr15:68072527	C/T	cg08079166	chr15:68083412	MAP2K5	-0.43	-6.87	-0.39	4.69e-11	Restless legs syndrome;
CESC	cis	rs10883723	0.773	rs7917402	chr10:104246690	C/T	ch.10.2196322F	chr10:104248062	ACTR1A	0.42	5.14	0.3	5.44e-7	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs372883	0.600	rs1153276	chr21:30661694	T/C	cg08807101	chr21:30365312	RNF160	-0.51	-5.91	-0.34	1.03e-8	Pancreatic cancer;
CESC	cis	rs9399135	0.967	rs6915770	chr6:135369214	G/A	cg22676075	chr6:135203613	NA	0.52	7.3	0.41	3.39e-12	Red blood cell count;
CESC	cis	rs7917772	0.503	rs7096072	chr10:104299976	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.53	7.33	0.41	2.81e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs9905704	0.627	rs1267543	chr17:56656624	A/G	cg12560992	chr17:57184187	TRIM37	-0.61	-6.3	-0.36	1.24e-9	Testicular germ cell tumor;
CESC	cis	rs651907	0.557	rs34376498	chr3:101480156	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.43	5.52	0.32	8e-8	Colorectal cancer;
CESC	cis	rs9926296	0.682	rs467357	chr16:89717397	A/G	cg04287289	chr16:89883240	FANCA	-0.48	-5.89	-0.34	1.16e-8	Vitiligo;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg12457986	chr21:27107982	ATP5J;GABPA	-0.44	-6.02	-0.35	5.69e-9	Fibrinogen levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21364231	chr7:152161058	LOC100128822	0.59	6.34	0.36	9.66e-10	Gut microbiome composition (summer);
CESC	cis	rs116095464	0.558	rs55833259	chr5:286728	G/A	cg22496380	chr5:211416	CCDC127	-0.99	-10.19	-0.53	8.71e-21	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19575813	chr18:46476937	SMAD7	0.56	6.34	0.36	9.58e-10	Gut microbiome composition (summer);
CESC	cis	rs7296418	0.699	rs11057219	chr12:123750073	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.32	-5.12	-0.3	6.01e-7	Platelet count;
CESC	cis	rs9916302	0.904	rs2303316	chr17:37704217	A/G	cg00129232	chr17:37814104	STARD3	-0.59	-7.88	-0.44	8.59e-14	Glomerular filtration rate (creatinine);
CESC	cis	rs977987	0.806	rs4888411	chr16:75443183	T/A	cg03315344	chr16:75512273	CHST6	0.41	5.86	0.34	1.35e-8	Dupuytren's disease;
CESC	cis	rs1218582	0.774	rs11264284	chr1:154875793	C/T	cg06221963	chr1:154839813	KCNN3	-0.71	-12.45	-0.61	2.58e-28	Prostate cancer;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg24797830	chr7:99686956	COPS6	-0.48	-6.59	-0.38	2.42e-10	Asthma;
CESC	cis	rs4665809	0.590	rs17528590	chr2:26505858	A/G	cg26119090	chr2:26468346	HADHA;HADHB	1.08	11.71	0.58	8.24e-26	Gut microbiome composition (summer);
CESC	cis	rs6732160	0.564	rs2043096	chr2:73375723	T/C	cg01422370	chr2:73384389	NA	0.57	9.11	0.49	2.01e-17	Intelligence (multi-trait analysis);
CESC	cis	rs3617	0.625	rs56019197	chr3:52874753	T/C	cg11645453	chr3:52864694	ITIH4	-0.25	-5.07	-0.3	7.43e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
CESC	cis	rs4290604	0.665	rs6761002	chr2:238038873	T/C	cg23555395	chr2:238036564	NA	-0.62	-5.71	-0.33	3.06e-8	Asthma;
CESC	cis	rs1538970	0.924	rs11211108	chr1:45891152	C/T	cg06784218	chr1:46089804	CCDC17	0.33	5.46	0.32	1.11e-7	Platelet count;
CESC	trans	rs12310956	0.532	rs1589902	chr12:33989289	G/A	cg26384229	chr12:38710491	ALG10B	0.48	6.64	0.38	1.82e-10	Morning vs. evening chronotype;
CESC	cis	rs11098499	0.954	rs10024844	chr4:120311528	A/G	cg09307838	chr4:120376055	NA	0.92	12.66	0.61	4.96e-29	Corneal astigmatism;
CESC	cis	rs7223966	1.000	rs7216798	chr17:61740963	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.58	7.42	0.41	1.55e-12	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs1552244	0.882	rs9312044	chr3:10037481	T/C	cg08888203	chr3:10149979	C3orf24	0.49	6.24	0.36	1.68e-9	Alzheimer's disease;
CESC	cis	rs921968	0.643	rs524902	chr2:219433357	A/C	cg02176678	chr2:219576539	TTLL4	0.41	7.03	0.4	1.72e-11	Mean corpuscular hemoglobin concentration;
CESC	cis	rs6499255	0.951	rs10500551	chr16:69666970	C/T	cg15192750	chr16:69999425	NA	0.44	5.24	0.31	3.32e-7	IgE levels;
CESC	cis	rs2230307	0.536	rs7530361	chr1:100462860	T/C	cg24955406	chr1:100503596	HIAT1	0.53	5.39	0.31	1.56e-7	Carotid intima media thickness;
CESC	cis	rs9583531	0.689	rs2165418	chr13:111379365	G/T	cg15841412	chr13:111365552	ING1	-0.42	-5.16	-0.3	4.8e-7	Coronary artery disease;
CESC	cis	rs2836974	0.545	rs3167757	chr21:40714478	C/T	cg11890956	chr21:40555474	PSMG1	0.68	9.48	0.5	1.48e-18	Cognitive function;
CESC	cis	rs5750830	0.649	rs5750815	chr22:39798449	T/C	cg11247378	chr22:39784982	NA	-0.63	-9.17	-0.49	1.32e-17	Intelligence (multi-trait analysis);
CESC	cis	rs9649213	0.613	rs6961129	chr7:97975542	T/G	cg21770322	chr7:97807741	LMTK2	0.57	8.84	0.48	1.39e-16	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs769267	0.930	rs2288852	chr19:19605348	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.47	5.84	0.34	1.48e-8	Tonsillectomy;
CESC	cis	rs9611565	0.527	rs2234053	chr22:41777315	G/T	cg06634786	chr22:41940651	POLR3H	-0.7	-7.4	-0.41	1.85e-12	Vitiligo;
CESC	trans	rs1814175	0.692	rs1851873	chr11:49937767	A/G	cg15704280	chr7:45808275	SEPT13	-0.82	-11.35	-0.57	1.34e-24	Height;
CESC	cis	rs2262909	0.962	rs425781	chr19:22229306	A/G	cg11619707	chr19:22235551	ZNF257	-0.32	-5.26	-0.31	2.94e-7	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
CESC	cis	rs77106637	1.000	rs3862791	chr11:72501002	C/T	cg03713592	chr11:72463424	ARAP1	1.23	11.1	0.56	9.02e-24	Type 2 diabetes;
CESC	cis	rs2180341	0.618	rs12199451	chr6:127597780	C/G	cg27446573	chr6:127587934	RNF146	0.59	7.77	0.43	1.71e-13	Breast cancer;
CESC	cis	rs1707322	1.000	rs7517560	chr1:46425943	A/G	cg05343316	chr1:45956843	TESK2	0.44	5.42	0.32	1.36e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16285902	chr11:32605422	EIF3M	0.63	7.26	0.41	4.34e-12	Gut microbiome composition (summer);
CESC	cis	rs9322193	0.962	rs9689269	chr6:150112997	G/A	cg13206674	chr6:150067644	NUP43	0.41	5.78	0.33	2.05e-8	Lung cancer;
CESC	cis	rs863345	0.967	rs7527623	chr1:158469859	G/A	cg12129480	chr1:158549410	OR10X1	-0.31	-6.19	-0.36	2.34e-9	Pneumococcal bacteremia;
CESC	cis	rs13191362	0.938	rs35760705	chr6:163020637	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.79	8.08	0.44	2.27e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs11203032	0.831	rs10788635	chr10:90927063	A/G	cg16672925	chr10:90967113	CH25H	0.45	5.13	0.3	5.55e-7	Heart failure;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg25001845	chr14:75201709	FCF1	0.45	6.25	0.36	1.6e-9	Fibrinogen levels;
CESC	trans	rs61931739	0.500	rs34287388	chr12:34444626	C/A	cg13010199	chr12:38710504	ALG10B	0.48	6.28	0.36	1.38e-9	Morning vs. evening chronotype;
CESC	cis	rs11098499	0.575	rs907204	chr4:120238654	G/A	cg09307838	chr4:120376055	NA	0.79	10.77	0.55	1.17e-22	Corneal astigmatism;
CESC	cis	rs12500482	0.935	rs2239736	chr4:2438929	T/C	cg08330972	chr4:2403930	ZFYVE28	-0.35	-5.21	-0.3	3.85e-7	Cognitive function;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05508062	chr3:62110348	ID2B;PTPRG	-0.62	-7.1	-0.4	1.13e-11	Gut microbiome composition (summer);
CESC	cis	rs9470366	1.000	rs9470366	chr6:36625562	C/T	cg08179530	chr6:36648295	CDKN1A	0.47	5.69	0.33	3.33e-8	QRS duration;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg11725182	chr1:5968678	NPHP4	0.51	6.58	0.37	2.57e-10	Fibrinogen levels;
CESC	cis	rs727505	0.954	rs17327014	chr7:124709349	C/T	cg23710748	chr7:124431027	NA	-0.39	-6.1	-0.35	3.77e-9	Lewy body disease;
CESC	cis	rs6952808	1.000	rs10233560	chr7:1885415	T/C	cg04267008	chr7:1944627	MAD1L1	-0.6	-7.44	-0.42	1.37e-12	Bipolar disorder and schizophrenia;
CESC	cis	rs798554	0.959	rs798557	chr7:2758982	G/A	cg09658497	chr7:2847517	GNA12	-0.38	-5.33	-0.31	2.15e-7	Height;
CESC	cis	rs7605378	0.528	rs281780	chr2:200756331	G/C	cg17644776	chr2:200775616	C2orf69	0.56	6.82	0.39	5.99e-11	Osteoporosis;
CESC	cis	rs7945705	0.692	rs11042149	chr11:9010737	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.39	-6.53	-0.37	3.3e-10	Hemoglobin concentration;
CESC	cis	rs10504229	1.000	rs77857677	chr8:58170131	G/A	cg14926445	chr8:58193284	C8orf71	-0.51	-5.49	-0.32	9.29e-8	Developmental language disorder (linguistic errors);
CESC	trans	rs11098499	0.866	rs9991221	chr4:120292107	G/C	cg25214090	chr10:38739885	LOC399744	0.65	9.11	0.49	2.04e-17	Corneal astigmatism;
CESC	cis	rs9611565	0.694	rs202628	chr22:41849513	A/G	cg03806693	chr22:41940476	POLR3H	-1.15	-16.09	-0.7	4.08e-41	Vitiligo;
CESC	cis	rs1020064	0.945	rs1030878	chr2:105910598	T/G	cg02079111	chr2:105885981	TGFBRAP1	0.49	6.38	0.37	7.65e-10	AIDS;
CESC	cis	rs7605827	0.930	rs6431712	chr2:15691292	C/T	cg19274914	chr2:15703543	NA	0.37	6.67	0.38	1.5e-10	Educational attainment (years of education);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15798163	chr13:113933520	NA	-0.64	-7.49	-0.42	1.03e-12	Gut microbiome composition (summer);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg04667467	chr16:90089176	GAS8	-0.47	-6.13	-0.35	3.15e-9	Ulcerative colitis;
CESC	cis	rs2996428	0.667	rs61768933	chr1:3766587	G/A	cg13057898	chr1:3703894	LRRC47	0.45	6.14	0.35	2.98e-9	Red cell distribution width;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg07721005	chr5:87564621	TMEM161B	-0.45	-6.18	-0.35	2.43e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs9926296	0.528	rs4785721	chr16:89839997	G/A	cg21285383	chr16:89894308	SPIRE2	0.3	5.28	0.31	2.65e-7	Vitiligo;
CESC	cis	rs9658691	0.607	rs12411483	chr10:90780910	G/T	cg03111039	chr10:90751583	FAS;ACTA2	-0.58	-5.25	-0.31	3.08e-7	Mosquito bite size;
CESC	cis	rs9859260	0.614	rs493661	chr3:195786489	T/A	cg12923728	chr3:195709715	SDHAP1	0.53	6.86	0.39	4.83e-11	Mean corpuscular volume;
CESC	cis	rs2979489	0.699	rs62508370	chr8:30417026	G/A	cg26383811	chr8:30366931	RBPMS	-0.74	-8.84	-0.48	1.39e-16	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CESC	cis	rs798554	0.524	rs2283784	chr7:2855337	T/C	cg19717773	chr7:2847554	GNA12	-0.53	-8.32	-0.45	4.85e-15	Height;
CESC	cis	rs4819052	0.851	rs7275870	chr21:46671214	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.75	9.92	0.52	6.18e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs10949834	0.529	rs7785826	chr7:73548785	C/A	cg07137043	chr7:73588983	EIF4H	-0.65	-6.99	-0.39	2.23e-11	Verbal memory performance (residualized delayed recall change);
CESC	cis	rs2066819	1.000	rs75754909	chr12:56726349	A/G	cg26734620	chr12:56694298	CS	0.98	5.95	0.34	8.45e-9	Psoriasis vulgaris;
CESC	cis	rs1185460	0.967	rs1784461	chr11:118937985	G/A	cg23280166	chr11:118938394	VPS11	0.58	8.16	0.45	1.4e-14	Coronary artery disease;
CESC	cis	rs1949733	0.701	rs4696828	chr4:8455604	G/A	cg11789530	chr4:8429930	ACOX3	-0.76	-10.91	-0.56	3.99e-23	Response to antineoplastic agents;
CESC	cis	rs12476592	0.602	rs10865339	chr2:63811884	G/T	cg17519650	chr2:63277830	OTX1	-0.48	-5.42	-0.32	1.34e-7	Childhood ear infection;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg17461271	chr1:172717683	NA	-0.49	-6.59	-0.38	2.34e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs116095464	0.558	rs13357299	chr5:242211	T/C	cg12570787	chr5:219185	SDHA;CCDC127	0.48	5.12	0.3	5.84e-7	Breast cancer;
CESC	cis	rs6831352	0.918	rs29001231	chr4:100046680	T/C	cg12011299	chr4:100065546	ADH4	-0.59	-6.52	-0.37	3.62e-10	Alcohol dependence;
CESC	cis	rs7246657	0.882	rs13345148	chr19:37819631	A/G	cg23950597	chr19:37808831	NA	-0.55	-6.06	-0.35	4.54e-9	Coronary artery calcification;
CESC	cis	rs2243480	1.000	rs9769882	chr7:65642925	T/C	cg13147721	chr7:65941812	NA	0.97	9.16	0.49	1.47e-17	Diabetic kidney disease;
CESC	cis	rs72781680	0.611	rs2303287	chr2:24302246	A/G	cg08917208	chr2:24149416	ATAD2B	-0.56	-5.26	-0.31	2.92e-7	Lymphocyte counts;
CESC	cis	rs644799	0.544	rs1150360	chr11:95512060	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.49	6.47	0.37	4.68e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs10504229	0.679	rs11783963	chr8:58130496	T/A	cg24829409	chr8:58192753	C8orf71	-0.58	-7.2	-0.4	6.31e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs3785574	0.962	rs57553639	chr17:61848499	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.11	19.58	0.77	2.06e-53	Height;
CESC	cis	rs9733	0.566	rs11204675	chr1:150570985	A/C	cg18016565	chr1:150552671	MCL1	-0.39	-6.47	-0.37	4.78e-10	Tonsillectomy;
CESC	cis	rs8053891	0.615	rs2287997	chr16:72140553	G/A	cg16558253	chr16:72132732	DHX38	-0.52	-6.2	-0.36	2.1e-9	Coronary artery disease;
CESC	cis	rs6963495	0.818	rs73192145	chr7:105203628	A/C	cg13798780	chr7:105162888	PUS7	0.77	7.63	0.42	4.27e-13	Bipolar disorder (body mass index interaction);
CESC	cis	rs2204008	0.837	rs11180549	chr12:38236950	A/G	cg26384229	chr12:38710491	ALG10B	0.73	10.35	0.54	2.55e-21	Bladder cancer;
CESC	cis	rs9916302	0.861	rs11658219	chr17:37709782	G/A	cg00129232	chr17:37814104	STARD3	-0.59	-7.79	-0.43	1.49e-13	Glomerular filtration rate (creatinine);
CESC	cis	rs7520050	0.966	rs2275426	chr1:46487552	G/A	cg24296786	chr1:45957014	TESK2	0.44	5.5	0.32	8.98e-8	Red blood cell count;Reticulocyte count;
CESC	cis	rs2070997	0.607	rs9919036	chr9:133684844	A/G	cg11464064	chr9:133710261	ABL1	0.57	6.36	0.36	8.71e-10	Response to amphetamines;
CESC	cis	rs9527	0.590	rs11191553	chr10:104851396	G/T	cg04362960	chr10:104952993	NT5C2	0.44	5.6	0.33	5.49e-8	Arsenic metabolism;
CESC	cis	rs7618915	0.547	rs2268026	chr3:52778347	T/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.31	5.49	0.32	9.47e-8	Bipolar disorder;
CESC	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.04	10.14	0.53	1.26e-20	Platelet count;
CESC	cis	rs1799949	1.000	rs8176145	chr17:41249094	A/G	cg25072359	chr17:41440525	NA	0.44	6.04	0.35	5.21e-9	Menopause (age at onset);
CESC	cis	rs66731853	0.769	rs476582	chr1:20894450	A/G	cg04087271	chr1:20915334	CDA	-0.48	-6.91	-0.39	3.52e-11	Mean corpuscular volume;
CESC	cis	rs17655565	0.581	rs73093302	chr12:52763203	A/G	cg00777198	chr12:52828273	KRT75	0.35	5.07	0.3	7.59e-7	Plasma amyloid beta peptide concentrations (ABx-42);
CESC	cis	rs3008870	1.000	rs3008870	chr1:67418027	C/T	cg08660285	chr1:67390436	MIER1;WDR78	1.06	15.19	0.68	6.65e-38	Lymphocyte percentage of white cells;
CESC	cis	rs1005277	0.579	rs2749616	chr10:38510993	A/T	cg00409905	chr10:38381863	ZNF37A	-0.51	-6.8	-0.39	6.98e-11	Extrinsic epigenetic age acceleration;
CESC	cis	rs11864453	0.762	rs6416742	chr16:72149061	C/T	cg01557791	chr16:72042693	DHODH	-0.53	-7.1	-0.4	1.17e-11	Fibrinogen levels;
CESC	cis	rs1218582	0.710	rs9794000	chr1:154878876	T/A	cg16680214	chr1:154839983	KCNN3	-0.44	-6.69	-0.38	1.28e-10	Prostate cancer;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg15929228	chr2:240323491	HDAC4	-0.47	-6.2	-0.36	2.19e-9	Ulcerative colitis;
CESC	cis	rs10504229	0.683	rs10504221	chr8:58140256	A/G	cg24829409	chr8:58192753	C8orf71	-0.59	-7.31	-0.41	3.16e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs66561647	0.661	rs7835090	chr8:128940177	A/C	cg05480350	chr8:128972681	MIR1205;PVT1	0.38	5.18	0.3	4.33e-7	Hemoglobin concentration;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg01928910	chr1:31194314	MATN1	0.39	6.04	0.35	5.3e-9	Fibrinogen levels;
CESC	cis	rs17539620	0.624	rs62432746	chr6:154838986	A/G	cg17771515	chr6:154831774	CNKSR3	0.59	5.82	0.34	1.69e-8	Lipoprotein (a) levels;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg04562739	chr20:5107446	CDS2;PCNA	-0.45	-6.05	-0.35	5e-9	Asthma;
CESC	cis	rs10504229	0.683	rs10504224	chr8:58143735	A/G	cg21724239	chr8:58056113	NA	0.59	5.69	0.33	3.3e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs11828289	0.660	rs79045664	chr11:23238737	G/A	cg20040320	chr11:23191996	NA	-0.7	-5.92	-0.34	9.9e-9	Cancer;
CESC	cis	rs10504229	0.596	rs6991216	chr8:58115586	T/C	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs7116495	1.000	rs2250866	chr11:71804513	A/G	cg26138937	chr11:71823887	C11orf51	-0.65	-5.19	-0.3	4.25e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs9583531	0.657	rs7318291	chr13:111352460	C/T	cg24331049	chr13:111365604	ING1	-0.76	-10.57	-0.54	5.01e-22	Coronary artery disease;
CESC	trans	rs1667255	0.830	rs2034404	chr18:29156302	A/G	cg13517516	chr9:20684768	KIAA1797	0.48	5.99	0.35	6.71e-9	Retinol levels;
CESC	cis	rs10504229	0.679	rs72649109	chr8:58031274	A/T	cg22535103	chr8:58192502	C8orf71	-0.9	-9.01	-0.48	4.26e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs1808579	0.935	rs1140458	chr18:21119777	G/A	cg14672496	chr18:21087552	C18orf8	0.37	5.68	0.33	3.47e-8	Hip circumference;Body mass index;BMI (adjusted for smoking behaviour);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg25320668	chr1:205196970	TMCC2	-0.44	-6.08	-0.35	4.26e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs11247915	0.583	rs34058882	chr1:26659794	C/T	cg04990556	chr1:26633338	UBXN11	-0.56	-6.3	-0.36	1.2e-9	Obesity-related traits;
CESC	cis	rs17376456	0.877	rs7736620	chr5:93305762	C/T	cg21475434	chr5:93447410	FAM172A	0.75	6.78	0.38	7.96e-11	Diabetic retinopathy;
CESC	cis	rs7772486	0.754	rs702319	chr6:146006117	T/C	cg23711669	chr6:146136114	FBXO30	-1.05	-14.96	-0.68	4.26e-37	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs10883723	0.810	rs10883729	chr10:104273943	A/G	cg22532475	chr10:104410764	TRIM8	-0.35	-5.9	-0.34	1.13e-8	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs7662987	0.517	rs2602845	chr4:100023944	T/C	cg13256891	chr4:100009986	ADH5	0.75	8.03	0.44	3.21e-14	Smoking initiation;
CESC	cis	rs2235544	0.579	rs1537321	chr1:54482236	C/A	cg25741118	chr1:54482237	LDLRAD1	-0.23	-5.99	-0.35	6.92e-9	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
CESC	cis	rs6088590	0.550	rs12624640	chr20:32952125	G/A	cg06115741	chr20:33292138	TP53INP2	0.44	5.23	0.31	3.38e-7	Coronary artery disease;
CESC	cis	rs10102274	1.000	rs7823529	chr8:91661083	C/T	cg16814680	chr8:91681699	NA	-0.8	-5.4	-0.31	1.47e-7	Cerebrospinal fluid clusterin levels;
CESC	cis	rs9658691	0.607	rs9325604	chr10:90775756	A/G	cg03111039	chr10:90751583	FAS;ACTA2	-0.62	-5.41	-0.32	1.43e-7	Mosquito bite size;
CESC	cis	rs11264213	0.901	rs72661613	chr1:36364781	A/G	cg27506609	chr1:36549197	TEKT2	0.68	5.63	0.33	4.5e-8	Schizophrenia;
CESC	cis	rs4692589	0.606	rs34752946	chr4:170951738	G/T	cg19918862	chr4:170955249	NA	0.45	5.62	0.33	4.79e-8	Anxiety disorder;
CESC	cis	rs977987	0.843	rs12927562	chr16:75482860	G/A	cg03315344	chr16:75512273	CHST6	0.42	6.0	0.35	6.43e-9	Dupuytren's disease;
CESC	cis	rs9894429	0.789	rs7219915	chr17:79591813	C/T	cg18240062	chr17:79603768	NPLOC4	0.9	13.2	0.63	6.66e-31	Eye color traits;
CESC	cis	rs1670533	0.932	rs13106586	chr4:1054182	G/A	cg04106633	chr4:1044584	NA	0.42	5.34	0.31	2.04e-7	Recombination rate (females);
CESC	cis	rs1797885	0.524	rs2596823	chr3:12608345	A/G	cg26432171	chr3:12704882	RAF1	-0.46	-5.94	-0.34	8.85e-9	Immature fraction of reticulocytes;
CESC	cis	rs12995491	0.731	rs17435439	chr2:88511391	A/G	cg18490616	chr2:88469792	THNSL2	-0.5	-7.41	-0.41	1.66e-12	Response to metformin (IC50);
CESC	cis	rs2303745	0.589	rs1864115	chr19:17393327	G/C	cg22549504	chr19:17448937	GTPBP3	0.5	5.56	0.32	6.74e-8	Systemic lupus erythematosus;
CESC	cis	rs644799	1.000	rs596277	chr11:95566886	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.68	8.6	0.47	6.86e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs2070997	0.651	rs35218356	chr9:133669521	T/C	cg11464064	chr9:133710261	ABL1	0.57	6.7	0.38	1.24e-10	Response to amphetamines;
CESC	cis	rs3820068	0.581	rs111699992	chr1:15927158	G/A	cg16988262	chr1:15930761	NA	0.35	5.65	0.33	4.18e-8	Systolic blood pressure;
CESC	cis	rs7000551	0.715	rs1530874	chr8:22347777	G/C	cg12081754	chr8:22256438	SLC39A14	0.4	5.24	0.31	3.32e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CESC	cis	rs875971	0.522	rs4718285	chr7:65292005	A/G	cg05332525	chr7:65337924	VKORC1L1	0.52	6.41	0.37	6.6e-10	Aortic root size;
CESC	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg10150615	chr22:24372951	LOC391322	-0.57	-7.82	-0.43	1.28e-13	Liver enzyme levels (gamma-glutamyl transferase);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07923666	chr12:49932857	KCNH3	0.62	7.43	0.42	1.48e-12	Gut microbiome composition (summer);
CESC	cis	rs1801251	1.000	rs283484	chr2:233646505	A/G	cg25237894	chr2:233734115	C2orf82	0.46	8.08	0.44	2.3e-14	Coronary artery disease;
CESC	cis	rs2880765	0.566	rs55899824	chr15:86004091	C/T	cg10818794	chr15:86012489	AKAP13	-0.36	-5.04	-0.3	8.5e-7	Coronary artery disease;
CESC	cis	rs17539620	0.624	rs62432738	chr6:154835674	T/C	cg17771515	chr6:154831774	CNKSR3	0.58	5.81	0.34	1.83e-8	Lipoprotein (a) levels;
CESC	cis	rs10504229	1.000	rs1961778	chr8:58168756	G/A	cg22535103	chr8:58192502	C8orf71	-1.06	-13.36	-0.63	1.82e-31	Developmental language disorder (linguistic errors);
CESC	cis	rs9911578	1.000	rs368186	chr17:56736659	A/G	cg05425664	chr17:57184151	TRIM37	-0.51	-7.21	-0.4	6.03e-12	Intelligence (multi-trait analysis);
CESC	cis	rs4243830	0.850	rs4908558	chr1:6584101	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.85	-9.22	-0.49	9.6e-18	Body mass index;
CESC	cis	rs6951245	1.000	rs11764748	chr7:1094508	T/C	cg18402987	chr7:1209562	NA	0.64	6.48	0.37	4.58e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs6073597	1.000	rs6031980	chr20:43714384	C/T	cg12503243	chr14:45553114	PRPF39	0.42	6.19	0.36	2.31e-9	Positive affect;
CESC	cis	rs9399135	0.935	rs949547	chr6:135343499	C/G	cg24558204	chr6:135376177	HBS1L	0.52	7.29	0.41	3.48e-12	Red blood cell count;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg21587861	chr12:32260103	BICD1	0.49	6.18	0.35	2.34e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs7949030	0.588	rs2428548	chr11:62311462	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.57	8.63	0.47	5.87e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs12136530	0.625	rs4911992	chr1:19750486	T/A	cg01832549	chr1:19774989	CAPZB	-0.5	-6.87	-0.39	4.58e-11	Lead levels in blood;
CESC	cis	rs7044106	0.791	rs2416797	chr9:123480600	C/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.33	5.16	0.3	4.84e-7	Hip circumference adjusted for BMI;
CESC	cis	rs1620921	0.505	rs1344731	chr6:161205037	G/A	cg01280913	chr6:161186852	NA	-0.35	-5.17	-0.3	4.72e-7	Lipoprotein (a) - cholesterol levels;
CESC	cis	rs2404602	0.716	rs12441247	chr15:76812316	T/C	cg22467129	chr15:76604101	ETFA	-0.38	-5.77	-0.33	2.24e-8	Blood metabolite levels;
CESC	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg13012494	chr21:47604986	C21orf56	0.44	5.8	0.34	1.84e-8	Testicular germ cell tumor;
CESC	cis	rs514406	0.825	rs6695819	chr1:53223366	T/C	cg08859206	chr1:53392774	SCP2	0.53	7.09	0.4	1.19e-11	Monocyte count;
CESC	cis	rs2228479	0.850	rs2238527	chr16:89840708	C/A	cg14709524	chr16:89940631	TCF25	0.91	6.74	0.38	1e-10	Skin colour saturation;
CESC	cis	rs12497850	0.543	rs6446218	chr3:49075513	A/T	cg03060546	chr3:49711283	APEH	0.5	5.97	0.34	7.77e-9	Parkinson's disease;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg12994003	chr1:225616475	LBR	0.44	6.01	0.35	6.13e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs6429082	0.818	rs291391	chr1:235649955	A/G	cg26050004	chr1:235667680	B3GALNT2	0.63	7.78	0.43	1.63e-13	Adiposity;
CESC	cis	rs736408	0.716	rs2300149	chr3:52822921	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.39	5.25	0.31	3.16e-7	Bipolar disorder;
CESC	cis	rs4713675	0.565	rs4713671	chr6:33699899	A/G	cg14003231	chr6:33640908	ITPR3	0.3	5.34	0.31	1.95e-7	Plateletcrit;
CESC	cis	rs854765	0.583	rs4925125	chr17:17794444	T/C	cg09796270	chr17:17721594	SREBF1	-0.4	-5.6	-0.33	5.34e-8	Total body bone mineral density;
CESC	cis	rs16895831	0.519	rs12196856	chr6:42554187	T/A	cg10605015	chr6:42532144	UBR2	-0.5	-5.52	-0.32	7.87e-8	Granulocyte percentage of myeloid white cells;Neutrophil percentage of white cells;Eosinophil percentage of white cells;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Neutrophil count;Sum basophil neutrophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg24531794	chr11:31531233	ELP4;IMMP1L	0.47	6.28	0.36	1.41e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs1799949	0.864	rs60309406	chr17:41435665	C/T	cg25072359	chr17:41440525	NA	0.46	6.23	0.36	1.87e-9	Menopause (age at onset);
CESC	cis	rs875971	0.540	rs736270	chr7:65428822	T/C	cg26939375	chr7:64535504	NA	0.75	10.38	0.54	2.1e-21	Aortic root size;
CESC	trans	rs9329221	0.935	rs3750310	chr8:10283426	G/A	cg15556689	chr8:8085844	FLJ10661	-0.57	-6.49	-0.37	4.28e-10	Neuroticism;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06128920	chr1:1447374	ATAD3A	0.62	7.4	0.41	1.83e-12	Gut microbiome composition (summer);
CESC	cis	rs2637266	0.783	rs860165	chr10:78492807	A/G	cg18941641	chr10:78392320	NA	0.44	8.54	0.46	1.06e-15	Pulmonary function;
CESC	cis	rs896854	0.540	rs2011567	chr8:95971920	G/A	cg16049864	chr8:95962084	TP53INP1	-0.64	-10.95	-0.56	2.92e-23	Type 2 diabetes;
CESC	cis	rs10504229	1.000	rs66495524	chr8:58187365	C/T	cg05313129	chr8:58192883	C8orf71	-0.55	-6.29	-0.36	1.34e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs7399018	0.643	rs6580810	chr12:51610478	C/T	cg25754956	chr12:51612065	POU6F1	0.76	8.46	0.46	1.8e-15	Cisplatin-induced ototoxicity;
CESC	trans	rs11098499	0.754	rs66900435	chr4:120249425	C/A	cg25214090	chr10:38739885	LOC399744	0.62	8.81	0.48	1.69e-16	Corneal astigmatism;
CESC	cis	rs7084402	0.967	rs1658459	chr10:60299246	C/A	cg07615347	chr10:60278583	BICC1	0.59	9.22	0.49	9.45e-18	Refractive error;
CESC	cis	rs4700695	0.719	rs27080	chr5:65442271	A/G	cg21114390	chr5:65439923	SFRS12	-0.5	-6.1	-0.35	3.72e-9	Facial morphology (factor 19);
CESC	trans	rs3942852	0.545	rs7395231	chr11:48091689	T/C	cg15704280	chr7:45808275	SEPT13	-0.73	-9.53	-0.51	1.06e-18	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs7814319	0.933	rs13261747	chr8:97238769	A/G	cg20787634	chr8:97240163	UQCRB	-0.63	-8.3	-0.45	5.32e-15	Lung function (FVC);
CESC	cis	rs875971	0.862	rs6964437	chr7:65686444	A/G	cg18876405	chr7:65276391	NA	-0.55	-7.55	-0.42	7.19e-13	Aortic root size;
CESC	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg07677032	chr17:61819896	STRADA	0.45	5.92	0.34	1.01e-8	Prudent dietary pattern;
CESC	cis	rs9389248	0.690	rs6569982	chr6:135256495	C/G	cg22676075	chr6:135203613	NA	0.58	8.28	0.45	5.98e-15	High light scatter reticulocyte percentage of red cells;
CESC	cis	rs62005083	0.867	rs62005153	chr14:74596115	G/A	cg05179529	chr14:74551516	LIN52;ALDH6A1	0.63	5.09	0.3	6.69e-7	Mean corpuscular volume;
CESC	cis	rs1483121	0.808	rs11039482	chr11:48009074	C/T	cg20307385	chr11:47447363	PSMC3	0.71	6.41	0.37	6.47e-10	Fasting blood glucose (BMI interaction);Fasting blood glucose;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg04621042	chr22:50169721	BRD1	0.48	6.32	0.36	1.11e-9	Fibrinogen levels;
CESC	cis	rs2243480	1.000	rs36033484	chr7:65390558	T/G	cg18252515	chr7:66147081	NA	-1.18	-10.88	-0.56	5.02e-23	Diabetic kidney disease;
CESC	cis	rs10465746	0.935	rs35946036	chr1:84438991	A/G	cg10977910	chr1:84465055	TTLL7	0.47	6.43	0.37	6.02e-10	Obesity-related traits;
CESC	trans	rs9929218	0.731	rs72785179	chr16:68767912	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.77	-10.27	-0.53	4.68e-21	Colorectal cancer;
CESC	cis	rs909674	0.775	rs8138462	chr22:39839670	G/C	cg02038168	chr22:39784481	NA	-0.66	-8.54	-0.46	1.09e-15	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs58785573	0.570	rs4833078	chr4:38646476	C/G	cg18361445	chr4:38666374	KLF3;FLJ13197	0.51	7.09	0.4	1.19e-11	Lymphocyte percentage of white cells;
CESC	cis	rs7267979	1.000	rs12428	chr20:25433821	G/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.85	-17.58	-0.73	2.14e-46	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs2249694	0.960	rs11101890	chr10:135421321	G/A	cg20169779	chr10:135381914	SYCE1	-0.38	-5.5	-0.32	9.1e-8	Obesity-related traits;
CESC	cis	rs1552244	0.872	rs7646073	chr3:10097405	G/A	cg08888203	chr3:10149979	C3orf24	0.53	6.83	0.39	5.8200000000000003e-11	Alzheimer's disease;
CESC	cis	rs9486715	0.830	rs1475748	chr6:97034143	T/C	cg18709589	chr6:96969512	KIAA0776	-0.46	-6.47	-0.37	4.79e-10	Headache;
CESC	cis	rs10949834	0.824	rs2285025	chr7:73529976	T/C	cg07137043	chr7:73588983	EIF4H	-0.67	-5.8	-0.34	1.9e-8	Verbal memory performance (residualized delayed recall change);
CESC	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg07677032	chr17:61819896	STRADA	0.51	6.71	0.38	1.14e-10	Prudent dietary pattern;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10911619	chr10:96162162	TBC1D12	0.61	7.13	0.4	9.53e-12	Gut microbiome composition (summer);
CESC	cis	rs3008870	1.000	rs3008856	chr1:67387901	T/C	cg08660285	chr1:67390436	MIER1;WDR78	1.03	14.35	0.66	5.87e-35	Lymphocyte percentage of white cells;
CESC	cis	rs2933343	0.679	rs1091938	chr3:128637025	T/C	cg25356066	chr3:128598488	ACAD9	0.62	8.37	0.46	3.36e-15	IgG glycosylation;
CESC	cis	rs644799	1.000	rs693364	chr11:95621926	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.6	7.36	0.41	2.31e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs494003	1.000	rs11227284	chr11:65503224	C/T	cg04055107	chr11:65626734	MUS81;CFL1	0.65	5.05	0.3	8.41e-7	Systemic lupus erythematosus;
CESC	cis	rs8077889	0.917	rs72836547	chr17:41902799	G/T	cg26893861	chr17:41843967	DUSP3	0.83	9.86	0.52	9.44e-20	Triglycerides;
CESC	cis	rs3540	0.513	rs2589974	chr15:90891566	C/T	cg22089800	chr15:90895588	ZNF774	-0.73	-10.22	-0.53	6.91e-21	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs10484885	0.824	rs72919976	chr6:90526686	C/G	cg13799429	chr6:90582589	CASP8AP2	-0.76	-7.17	-0.4	7.34e-12	QRS interval (sulfonylurea treatment interaction);
CESC	cis	rs60871478	1.000	rs35488064	chr7:812722	G/C	cg05535760	chr7:792225	HEATR2	0.88	10.93	0.56	3.48e-23	Cerebrospinal P-tau181p levels;
CESC	cis	rs2243480	1.000	rs57057549	chr7:65405738	A/G	cg13147721	chr7:65941812	NA	-0.88	-8.09	-0.45	2.17e-14	Diabetic kidney disease;
CESC	cis	rs875971	0.789	rs7808013	chr7:66071196	A/G	cg19163074	chr7:65112434	INTS4L2	0.42	5.28	0.31	2.63e-7	Aortic root size;
CESC	cis	rs10782582	0.569	rs74090722	chr1:76197262	A/G	cg22875332	chr1:76189707	ACADM	-0.46	-5.57	-0.32	6.41e-8	Daytime sleep phenotypes;
CESC	cis	rs7945705	0.837	rs2742474	chr11:9002089	A/G	cg12365402	chr11:9010492	NRIP3	-0.44	-7.41	-0.41	1.65e-12	Hemoglobin concentration;
CESC	cis	rs2228479	0.850	rs11649510	chr16:89851004	A/G	cg00800038	chr16:89945340	TCF25	-0.91	-7.52	-0.42	8.29e-13	Skin colour saturation;
CESC	cis	rs9287719	0.901	rs13034017	chr2:10739592	C/T	cg00105475	chr2:10696890	NA	0.39	5.61	0.33	4.96e-8	Prostate cancer;
CESC	cis	rs6694270	0.913	rs11261069	chr1:19117300	C/G	cg19637330	chr1:19110922	NA	-0.4	-5.2	-0.3	3.99e-7	Drug-induced liver injury (nitrofurantoin);
CESC	cis	rs6089584	0.528	rs4925335	chr20:60627034	G/A	cg06108461	chr20:60628389	TAF4	-0.61	-8.18	-0.45	1.16e-14	Body mass index;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg17331554	chr14:105167820	INF2	0.46	6.71	0.38	1.18e-10	Fibrinogen levels;
CESC	cis	rs9325144	0.647	rs7980932	chr12:38921583	G/T	cg26384229	chr12:38710491	ALG10B	-0.51	-7.18	-0.4	6.89e-12	Morning vs. evening chronotype;
CESC	cis	rs9768139	0.935	rs7809076	chr7:158118438	C/T	cg24154853	chr7:158122151	PTPRN2	-0.4	-6.51	-0.37	3.82e-10	Calcium levels;
CESC	cis	rs911555	0.723	rs4906324	chr14:103923099	A/G	cg12935359	chr14:103987150	CKB	0.65	9.62	0.51	5.7e-19	Intelligence (multi-trait analysis);
CESC	cis	rs9733	0.525	rs11584184	chr1:150695689	A/T	cg17724175	chr1:150552817	MCL1	0.45	7.31	0.41	3.17e-12	Tonsillectomy;
CESC	cis	rs73019876	0.869	rs2666457	chr19:22126880	T/C	cg11619707	chr19:22235551	ZNF257	-0.29	-5.22	-0.31	3.61e-7	Testicular germ cell tumor;
CESC	cis	rs7264396	0.563	rs6060567	chr20:34288250	G/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.64	6.87	0.39	4.47e-11	Total cholesterol levels;
CESC	trans	rs9325144	0.600	rs6582630	chr12:38743508	A/G	cg23762105	chr12:34175262	ALG10	0.48	6.44	0.37	5.66e-10	Morning vs. evening chronotype;
CESC	cis	rs12464483	0.591	rs4952171	chr2:30886903	G/A	cg17749961	chr2:30669863	LCLAT1	0.68	6.7	0.38	1.28e-10	Pre-treatment pain in head and neck squamous cell carcinoma;
CESC	cis	rs4132509	1.000	rs7514984	chr1:243965623	C/T	cg21452805	chr1:244014465	NA	0.43	5.32	0.31	2.18e-7	RR interval (heart rate);
CESC	cis	rs7481584	1.000	rs12804412	chr11:3020782	G/A	cg25174290	chr11:3078921	CARS	-0.43	-5.36	-0.31	1.78e-7	Calcium levels;
CESC	cis	rs28374715	0.617	rs16971733	chr15:41562030	C/A	cg02330683	chr15:41787940	ITPKA	0.36	5.04	0.3	8.78e-7	Ulcerative colitis;
CESC	cis	rs7927771	0.524	rs7933184	chr11:47682402	C/T	cg18512352	chr11:47633146	NA	0.34	5.15	0.3	5.04e-7	Subjective well-being;
CESC	cis	rs9435341	0.965	rs12401598	chr1:107580533	C/A	cg09367891	chr1:107599246	PRMT6	0.71	8.35	0.46	3.78e-15	Facial morphology (factor 21, depth of nasal alae);
CESC	cis	rs9303280	0.806	rs9904624	chr17:38036586	A/G	cg19468946	chr17:37922297	IKZF3	-0.41	-5.42	-0.32	1.31e-7	Self-reported allergy;
CESC	cis	rs5758659	0.714	rs2284087	chr22:42485671	T/C	cg04733989	chr22:42467013	NAGA	-0.45	-6.36	-0.36	8.61e-10	Cognitive function;
CESC	cis	rs9549367	0.577	rs3024713	chr13:113813321	G/A	cg10067723	chr13:113807384	NA	-0.44	-5.31	-0.31	2.34e-7	Platelet distribution width;
CESC	cis	rs6662572	0.686	rs72677541	chr1:46561560	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.46	5.13	0.3	5.7e-7	Blood protein levels;
CESC	cis	rs763121	0.853	rs3788544	chr22:39064966	C/T	cg06544989	chr22:39130855	UNC84B	0.48	8.1	0.45	1.96e-14	Menopause (age at onset);
CESC	cis	rs7659604	0.605	rs1396080	chr4:122740454	T/G	cg06713675	chr4:122721982	EXOSC9	-0.43	-6.09	-0.35	4.03e-9	Type 2 diabetes;
CESC	cis	rs17253792	0.822	rs10147380	chr14:56054354	T/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.83	6.03	0.35	5.45e-9	Putamen volume;
CESC	cis	rs2576037	0.583	rs501062	chr18:44411135	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.52	-7.14	-0.4	9.21e-12	Personality dimensions;
CESC	cis	rs1020064	0.636	rs2679883	chr2:105949668	C/T	cg02079111	chr2:105885981	TGFBRAP1	0.39	5.27	0.31	2.83e-7	AIDS;
CESC	cis	rs6582630	0.555	rs10880520	chr12:38464111	C/T	cg13010199	chr12:38710504	ALG10B	0.47	6.11	0.35	3.63e-9	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs1005277	0.502	rs2800484	chr10:38542415	C/T	cg25517755	chr10:38738941	LOC399744	-0.44	-5.68	-0.33	3.45e-8	Extrinsic epigenetic age acceleration;
CESC	cis	rs10504229	0.906	rs6990615	chr8:58182956	G/A	cg14926445	chr8:58193284	C8orf71	-0.51	-5.52	-0.32	8.28e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs1775715	0.769	rs2808102	chr10:32117749	A/T	cg18675610	chr10:32216311	ARHGAP12	0.33	5.1	0.3	6.52e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26878967	chr11:66459081	SPTBN2	-0.68	-8.17	-0.45	1.27e-14	Gut microbiome composition (summer);
CESC	cis	rs425277	1.000	rs262665	chr1:2083173	A/G	cg04315214	chr1:2043799	PRKCZ	-0.38	-5.3	-0.31	2.42e-7	Height;
CESC	cis	rs12477438	0.798	rs1349779	chr2:99645055	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.73	-11.02	-0.56	1.73e-23	Chronic sinus infection;
CESC	cis	rs10779751	0.762	rs1074078	chr1:11326788	C/T	cg08854313	chr1:11322531	MTOR	-0.63	-7.92	-0.44	6.75e-14	Body mass index;
CESC	cis	rs4665809	1.000	rs750452	chr2:26324995	G/A	cg26314531	chr2:26401878	FAM59B	-0.61	-6.85	-0.39	5.26e-11	Gut microbiome composition (summer);
CESC	cis	rs3740713	1.000	rs73438674	chr11:18456889	T/C	cg23797887	chr11:18477753	LDHAL6A	-0.53	-5.27	-0.31	2.89e-7	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs12893668	0.572	rs11846404	chr14:104156108	C/G	cg24130564	chr14:104152367	KLC1	-0.49	-6.53	-0.37	3.4e-10	Reticulocyte count;
CESC	cis	rs11098499	0.789	rs1980024	chr4:120253047	C/T	cg09307838	chr4:120376055	NA	0.77	10.49	0.54	9.15e-22	Corneal astigmatism;
CESC	cis	rs2836950	0.545	rs2297256	chr21:40558421	C/T	cg17971929	chr21:40555470	PSMG1	-0.53	-6.93	-0.39	3.21e-11	Menarche (age at onset);
CESC	cis	rs1008375	1.000	rs28693609	chr4:17645233	C/T	cg16339924	chr4:17578868	LAP3	0.57	7.13	0.4	9.66e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs36051895	0.559	rs7874495	chr9:5209804	A/G	cg02405213	chr9:5042618	JAK2	-0.49	-6.03	-0.35	5.56e-9	Pediatric autoimmune diseases;
CESC	cis	rs1950626	0.750	rs34061904	chr14:101435974	A/G	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.83	11.29	0.57	2.14e-24	Pelvic organ prolapse (moderate/severe);
CESC	cis	rs7587476	0.784	rs36086595	chr2:215680293	A/G	cg04004882	chr2:215674386	BARD1	0.54	6.08	0.35	4.21e-9	Neuroblastoma;
CESC	cis	rs4253772	0.591	rs9615935	chr22:46686115	T/G	cg00784671	chr22:46762841	CELSR1	-0.57	-5.5	-0.32	8.75e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs7851660	0.805	rs7038998	chr9:100662396	C/G	cg13688889	chr9:100608707	NA	-0.63	-8.96	-0.48	5.91e-17	Strep throat;
CESC	cis	rs9929218	0.581	rs7203337	chr16:68774800	C/G	cg02972257	chr16:68554789	NA	-0.42	-5.29	-0.31	2.6e-7	Colorectal cancer;
CESC	cis	rs6456156	0.586	rs720325	chr6:167467349	G/T	cg23791538	chr6:167370224	RNASET2	-0.51	-6.52	-0.37	3.62e-10	Primary biliary cholangitis;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg06914050	chr7:56119237	PSPH;CCT6A	-0.5	-6.52	-0.37	3.5e-10	Ulcerative colitis;
CESC	trans	rs2018683	0.649	rs12536605	chr7:28970500	C/T	cg19402173	chr7:128379420	CALU	-0.5	-6.57	-0.37	2.64e-10	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CESC	cis	rs9302635	0.515	rs36033103	chr16:72142038	G/T	cg08717414	chr16:71523259	ZNF19	-0.9	-5.68	-0.33	3.63e-8	Blood protein levels;
CESC	cis	rs644799	0.710	rs10765771	chr11:95521044	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	11.8	0.59	4.17e-26	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs3105593	1.000	rs17645649	chr15:50900370	A/G	cg08437265	chr15:50716283	USP8	0.41	5.24	0.31	3.29e-7	QT interval;
CESC	cis	rs4595586	0.679	rs4768473	chr12:39326256	A/G	cg26384229	chr12:38710491	ALG10B	0.41	5.93	0.34	9.53e-9	Morning vs. evening chronotype;
CESC	cis	rs597539	0.652	rs482172	chr11:68668437	C/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.8	10.35	0.54	2.68e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs10791097	0.694	rs4264159	chr11:130755784	G/T	cg09137382	chr11:130731461	NA	0.36	5.32	0.31	2.17e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs4819052	0.851	rs2838832	chr21:46664904	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	-0.46	-5.6	-0.33	5.4e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs1552244	0.810	rs6809572	chr3:10100145	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	11.78	0.59	4.83e-26	Alzheimer's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20990694	chr7:150417431	GIMAP1	-0.52	-6.43	-0.37	5.9e-10	Gut microbiome composition (summer);
CESC	cis	rs11214589	0.651	rs11214595	chr11:113259658	G/T	cg14159747	chr11:113255604	NA	0.33	5.96	0.34	7.95e-9	Neuroticism;
CESC	cis	rs1448094	0.511	rs4897823	chr12:86161484	C/T	cg00310523	chr12:86230176	RASSF9	0.32	5.19	0.3	4.23e-7	Major depressive disorder;
CESC	cis	rs3858526	0.676	rs10838752	chr11:5887243	A/G	cg05234568	chr11:5960015	NA	-0.57	-7.15	-0.4	8.67e-12	DNA methylation (variation);
CESC	cis	rs7584330	0.554	rs13392410	chr2:238430273	G/A	cg14458575	chr2:238380390	NA	0.48	5.3	0.31	2.4e-7	Prostate cancer;
CESC	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg24503407	chr1:205819492	PM20D1	0.92	16.78	0.72	1.49e-43	Menarche (age at onset);
CESC	cis	rs1008375	1.000	rs28545485	chr4:17645376	C/T	cg15017067	chr4:17643749	FAM184B	0.35	5.07	0.3	7.59e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs9796	0.870	rs12910027	chr15:41283817	A/T	cg18705301	chr15:41695430	NDUFAF1	0.44	6.5	0.37	4.03e-10	Menopause (age at onset);
CESC	cis	rs7786808	0.741	rs11767875	chr7:158228923	A/G	cg01191920	chr7:158217561	PTPRN2	-0.45	-8.1	-0.45	2.03e-14	Obesity-related traits;
CESC	cis	rs4594175	0.926	rs12101170	chr14:51611902	T/C	cg23942311	chr14:51606299	NA	0.36	5.43	0.32	1.29e-7	Cancer;
CESC	cis	rs897984	0.609	rs12445650	chr16:31044897	G/A	cg00531865	chr16:30841666	NA	-0.39	-5.38	-0.31	1.64e-7	Dementia with Lewy bodies;
CESC	trans	rs61931739	0.517	rs1486882	chr12:34025896	A/G	cg26384229	chr12:38710491	ALG10B	0.59	8.19	0.45	1.12e-14	Morning vs. evening chronotype;
CESC	cis	rs2637266	1.000	rs2130795	chr10:78333892	C/G	cg18941641	chr10:78392320	NA	0.42	7.93	0.44	6.07e-14	Pulmonary function;
CESC	trans	rs17181170	0.574	rs9877721	chr3:87205485	G/C	ch.2.199792288R	chr2:200084043	NA	-0.46	-6.08	-0.35	4.21e-9	Prostate cancer;
CESC	cis	rs7647973	1.000	rs74471041	chr3:49542543	T/G	cg06212747	chr3:49208901	KLHDC8B	-0.59	-7.8	-0.43	1.43e-13	Menarche (age at onset);
CESC	cis	rs4834770	1.000	rs2282688	chr4:120243722	T/C	cg09307838	chr4:120376055	NA	0.45	5.37	0.31	1.74e-7	Blood protein levels;
CESC	cis	rs8180040	0.966	rs6800271	chr3:47470787	A/T	cg27129171	chr3:47204927	SETD2	-0.64	-9.95	-0.52	5.02e-20	Colorectal cancer;
CESC	cis	rs17854409	0.764	rs8114722	chr20:61478492	G/A	cg05147244	chr20:61493195	TCFL5	1.08	5.88	0.34	1.22e-8	Obesity-related traits;
CESC	cis	rs9796	0.621	rs28737302	chr15:41469943	G/A	cg12386646	chr15:41787261	ITPKA	0.33	5.08	0.3	7.11e-7	Menopause (age at onset);
CESC	cis	rs826838	1.000	rs10880914	chr12:38720543	C/T	cg13010199	chr12:38710504	ALG10B	0.62	8.83	0.48	1.5e-16	Heart rate;
CESC	cis	rs9649213	0.593	rs3801264	chr7:97950620	A/G	cg00277769	chr7:97922759	BAIAP2L1	-0.34	-5.61	-0.33	4.97e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs1580019	0.587	rs7804457	chr7:32557981	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.52	6.73	0.38	1.05e-10	Cognitive ability;
CESC	cis	rs10791097	0.739	rs11222358	chr11:130730497	G/A	cg09137382	chr11:130731461	NA	0.4	5.92	0.34	9.71e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	trans	rs9987353	0.840	rs329994	chr8:9123233	A/G	cg10487699	chr11:57480176	TMX2;MED19	-0.46	-6.02	-0.35	5.89e-9	Recombination measurement;
CESC	cis	rs7666738	0.830	rs10049985	chr4:99023517	C/T	cg05340658	chr4:99064831	C4orf37	0.82	12.99	0.62	3.34e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg24101359	chr6:42928495	GNMT	0.55	7.85	0.43	1.02e-13	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs9457247	0.534	rs933243	chr6:167403873	A/C	cg25258033	chr6:167368657	RNASET2	0.39	5.74	0.33	2.59e-8	Crohn's disease;
CESC	cis	rs34779708	0.931	rs72789609	chr10:35306206	C/T	cg03585969	chr10:35415529	CREM	0.74	9.69	0.51	3.4e-19	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs7408868	0.563	rs10423702	chr19:15300069	T/C	cg14696996	chr19:15285081	NOTCH3	0.97	9.8	0.52	1.47e-19	Pulse pressure;
CESC	cis	rs2842992	0.673	rs6930904	chr6:160217433	T/A	cg11366901	chr6:160182831	ACAT2	0.76	9.31	0.5	4.95e-18	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs2486288	0.656	rs11632651	chr15:45550838	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.54	-6.55	-0.37	3.03e-10	Glomerular filtration rate;
CESC	cis	rs589448	0.902	rs642786	chr12:69758462	T/C	cg22834771	chr12:69754056	YEATS4	-0.57	-7.68	-0.43	3.15e-13	Cerebrospinal fluid biomarker levels;
CESC	cis	rs9291683	0.527	rs73212848	chr4:10093299	T/C	cg11266682	chr4:10021025	SLC2A9	-0.56	-10.6	-0.55	4.1e-22	Bone mineral density;
CESC	cis	rs858239	0.699	rs1881201	chr7:23194013	C/T	cg23682824	chr7:23144976	KLHL7	-0.38	-5.17	-0.3	4.71e-7	Cerebrospinal fluid biomarker levels;
CESC	cis	rs7615952	0.576	rs17523380	chr3:125802874	C/T	cg18479299	chr3:125709523	NA	-0.45	-5.5	-0.32	8.73e-8	Blood pressure (smoking interaction);
CESC	cis	rs7746199	0.668	rs34864796	chr6:27459923	G/A	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.88	6.3	0.36	1.21e-9	Gait speed in old age;Autism spectrum disorder or schizophrenia;
CESC	cis	rs42648	0.837	rs10262472	chr7:89900383	T/C	cg23697855	chr7:89950296	NA	0.27	5.14	0.3	5.24e-7	Homocysteine levels;
CESC	cis	rs9393777	0.588	rs4518487	chr6:26467531	A/G	cg12826209	chr6:26865740	GUSBL1	0.59	7.13	0.4	9.69e-12	Intelligence (multi-trait analysis);
CESC	cis	rs1707322	0.752	rs6678444	chr1:46229847	A/G	cg03146154	chr1:46216737	IPP	0.8	11.41	0.57	8.33e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9300255	0.739	rs11057210	chr12:123733799	A/G	cg19016782	chr12:123741754	C12orf65	-0.49	-7.03	-0.4	1.75e-11	Neutrophil percentage of white cells;
CESC	trans	rs11098499	0.863	rs3775848	chr4:120447724	C/T	cg25214090	chr10:38739885	LOC399744	0.7	9.68	0.51	3.69e-19	Corneal astigmatism;
CESC	cis	rs1005277	0.540	rs1814077	chr10:37992018	G/C	cg25427524	chr10:38739819	LOC399744	-0.66	-9.58	-0.51	7.33e-19	Extrinsic epigenetic age acceleration;
CESC	cis	rs7481584	0.669	rs12793371	chr11:3034709	A/G	cg25174290	chr11:3078921	CARS	-0.45	-6.07	-0.35	4.48e-9	Calcium levels;
CESC	cis	rs6964587	0.647	rs38801	chr7:92046327	G/T	cg17063962	chr7:91808500	NA	-0.5	-6.55	-0.37	2.91e-10	Breast cancer;
CESC	cis	rs1267303	0.637	rs1745371	chr1:46985192	C/T	cg25110126	chr1:46999211	NA	0.71	8.78	0.47	2.11e-16	Monobrow;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03762820	chr2:43823654	THADA	-0.45	-6.15	-0.35	2.88e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs7259376	0.905	rs114170435	chr19:22562522	C/A	cg02657401	chr19:22469223	NA	-0.26	-5.18	-0.3	4.47e-7	Menopause (age at onset);
CESC	cis	rs80282103	0.867	rs3793781	chr10:1081293	G/T	cg08668510	chr10:1095578	IDI1	0.65	5.03	0.3	8.89e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs950776	0.518	rs1504545	chr15:78818471	C/G	cg06917634	chr15:78832804	PSMA4	-0.76	-11.0	-0.56	1.9e-23	Sudden cardiac arrest;
CESC	cis	rs1552244	0.882	rs13075842	chr3:10055813	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.85	11.05	0.56	1.38e-23	Alzheimer's disease;
CESC	cis	rs11146838	1	rs11146838	chr10:39149977	A/T	cg00409905	chr10:38381863	ZNF37A	-0.44	-5.86	-0.34	1.36e-8	Breast cancer;
CESC	cis	rs11623869	0.614	rs11627052	chr14:103863476	A/G	cg12935359	chr14:103987150	CKB	0.59	6.68	0.38	1.39e-10	Bone mineral density;
CESC	cis	rs5750830	0.594	rs1010170	chr22:39778327	C/T	cg24399712	chr22:39784796	NA	0.75	9.79	0.52	1.66e-19	Intelligence (multi-trait analysis);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg19322864	chr10:51572718	NCOA4	0.42	6.03	0.35	5.42e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs11638352	1.000	rs2733204	chr15:44417012	A/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.61	-5.62	-0.33	4.75e-8	Lipoprotein phospholipase A2 activity in cardiovascular disease;
CESC	cis	rs9911578	0.967	rs2333410	chr17:57137129	G/A	cg12560992	chr17:57184187	TRIM37	-0.97	-16.6	-0.71	6.75e-43	Intelligence (multi-trait analysis);
CESC	cis	rs11645898	0.745	rs55824906	chr16:72064905	A/G	cg14768367	chr16:72042858	DHODH	-0.84	-6.92	-0.39	3.43e-11	Blood protein levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01307007	chr19:3522587	FZR1	-0.59	-6.64	-0.38	1.79e-10	Gut microbiome composition (summer);
CESC	cis	rs7084402	0.935	rs10826202	chr10:60359091	C/T	cg07615347	chr10:60278583	BICC1	0.54	8.25	0.45	7.48e-15	Refractive error;
CESC	cis	rs7188697	0.922	rs7186997	chr16:58603348	A/G	cg21335942	chr16:58549945	SETD6	-0.45	-5.2	-0.3	4.06e-7	QT interval;
CESC	cis	rs36051895	0.587	rs7036761	chr9:5198781	A/C	cg02405213	chr9:5042618	JAK2	0.51	6.03	0.35	5.43e-9	Pediatric autoimmune diseases;
CESC	cis	rs10242455	0.867	rs2740558	chr7:99324743	T/C	cg07715041	chr7:99302981	CYP3A7	-0.43	-5.42	-0.32	1.36e-7	Blood metabolite levels;
CESC	cis	rs67311347	0.955	rs73078170	chr3:40483947	C/T	cg24209194	chr3:40518798	ZNF619	0.53	6.41	0.37	6.66e-10	Renal cell carcinoma;
CESC	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg23708337	chr7:1209742	NA	0.55	5.41	0.32	1.44e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs344364	0.511	rs337286	chr16:1965719	C/T	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.6	-6.41	-0.37	6.63e-10	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs6963495	0.745	rs73190179	chr7:105162812	C/A	cg19920283	chr7:105172520	RINT1	0.69	6.56	0.37	2.85e-10	Bipolar disorder (body mass index interaction);
CESC	cis	rs875971	0.522	rs1701760	chr7:65473688	A/G	cg26939375	chr7:64535504	NA	0.76	10.99	0.56	2.15e-23	Aortic root size;
CESC	cis	rs10504229	1.000	rs77823122	chr8:58170161	A/G	cg05313129	chr8:58192883	C8orf71	-0.55	-6.29	-0.36	1.31e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs9457247	1.000	rs1819333	chr6:167373547	G/T	cg07741184	chr6:167504864	NA	0.29	5.17	0.3	4.71e-7	Crohn's disease;
CESC	cis	rs847577	0.609	rs6465657	chr7:97816327	C/T	cg21770322	chr7:97807741	LMTK2	0.85	14.37	0.66	5.23e-35	Breast cancer;
CESC	cis	rs6933660	0.760	rs1825368	chr6:151775259	C/A	cg10883421	chr6:151773342	RMND1;C6orf211	0.83	13.29	0.63	3.11e-31	Menarche (age at onset);
CESC	cis	rs6831352	0.744	rs2602847	chr4:100025963	T/C	cg13256891	chr4:100009986	ADH5	0.75	8.03	0.44	3.21e-14	Alcohol dependence;
CESC	trans	rs11098499	0.697	rs10020027	chr4:120381879	G/C	cg25214090	chr10:38739885	LOC399744	0.7	9.91	0.52	6.89e-20	Corneal astigmatism;
CESC	cis	rs7178572	0.568	rs4886866	chr15:77696166	A/T	cg22256960	chr15:77711686	NA	-0.55	-6.96	-0.39	2.61e-11	Type 2 diabetes;
CESC	cis	rs9733	0.596	rs2867304	chr1:150630995	G/A	cg18016565	chr1:150552671	MCL1	0.33	5.13	0.3	5.67e-7	Tonsillectomy;
CESC	cis	rs9733	0.596	rs11586422	chr1:150679358	C/T	cg22823121	chr1:150693482	HORMAD1	0.48	7.11	0.4	1.11e-11	Tonsillectomy;
CESC	cis	rs13256369	0.802	rs1060107	chr8:8561399	G/T	cg17143192	chr8:8559678	CLDN23	0.74	8.41	0.46	2.57e-15	Obesity-related traits;
CESC	cis	rs4474465	0.703	rs10899547	chr11:78254720	C/T	cg27205649	chr11:78285834	NARS2	0.43	5.39	0.31	1.52e-7	Alzheimer's disease (survival time);
CESC	cis	rs896854	0.552	rs2515236	chr8:95934907	A/G	cg23172400	chr8:95962367	TP53INP1	0.42	7.09	0.4	1.22e-11	Type 2 diabetes;
CESC	cis	rs1847202	0.592	rs13073005	chr3:72951007	C/T	cg10804678	chr3:72788309	NA	-0.41	-5.38	-0.31	1.63e-7	Motion sickness;
CESC	cis	rs3785574	0.962	rs2665799	chr17:61919723	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.1	19.18	0.76	5.16e-52	Height;
CESC	trans	rs6084875	0.641	rs6037946	chr20:4724693	A/G	cg10192164	chr16:30419175	ZNF771	-0.51	-6.18	-0.35	2.44e-9	Systemic lupus erythematosus;
CESC	cis	rs11190604	1.000	rs2495750	chr10:102327708	A/G	cg07080220	chr10:102295463	HIF1AN	0.55	5.09	0.3	6.72e-7	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs3749237	0.595	rs11720264	chr3:49580347	C/T	cg02487422	chr3:49467188	NICN1	0.55	8.04	0.44	2.95e-14	Resting heart rate;
CESC	cis	rs7100689	0.784	rs7078075	chr10:82162768	A/G	cg00277334	chr10:82204260	NA	-0.59	-7.32	-0.41	3.05e-12	Post bronchodilator FEV1;
CESC	cis	rs7666738	0.830	rs13149346	chr4:99009933	C/T	cg03467027	chr4:99064603	C4orf37	0.44	5.63	0.33	4.57e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs644799	1.000	rs563653	chr11:95561488	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	9.15	0.49	1.57e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs113835537	0.935	rs1127145	chr11:66373305	G/A	cg24851651	chr11:66362959	CCS	0.62	5.6	0.33	5.26e-8	Airway imaging phenotypes;
CESC	cis	rs1443512	0.812	rs1561987	chr12:54335268	C/T	cg17410650	chr12:54324560	NA	-0.39	-6.53	-0.37	3.39e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
CESC	cis	rs113835537	0.529	rs17495838	chr11:66196265	T/C	cg24851651	chr11:66362959	CCS	0.56	6.51	0.37	3.65e-10	Airway imaging phenotypes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11855615	chr17:33817136	SLFN12L	-0.51	-6.08	-0.35	4.28e-9	Gut microbiome composition (summer);
CESC	cis	rs3008870	1.000	rs12041926	chr1:67434602	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.04	14.47	0.66	2.27e-35	Lymphocyte percentage of white cells;
CESC	cis	rs919433	1.000	rs919433	chr2:198166565	G/A	cg10820045	chr2:198174542	NA	-0.41	-6.27	-0.36	1.45e-9	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs9311474	0.607	rs28661185	chr3:52567188	G/T	cg17372223	chr3:52568218	NT5DC2	0.51	8.0	0.44	3.82e-14	Electroencephalogram traits;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	ch.5.409282R	chr5:15780558	FBXL7	-0.47	-6.49	-0.37	4.21e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs1348850	0.914	rs4893944	chr2:178289357	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.75	10.4	0.54	1.82e-21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs929354	0.772	rs1182442	chr7:157026633	G/A	cg05182265	chr7:156933206	UBE3C	0.5	7.33	0.41	2.87e-12	Body mass index;
CESC	cis	rs963731	0.579	rs4670902	chr2:39220904	A/T	cg04010122	chr2:39346883	SOS1	-0.57	-5.07	-0.3	7.42e-7	Corticobasal degeneration;
CESC	cis	rs4919694	0.611	rs77328741	chr10:105066314	T/C	cg04362960	chr10:104952993	NT5C2	0.68	5.59	0.32	5.56e-8	Arsenic metabolism;
CESC	cis	rs2197308	0.765	rs12230545	chr12:37927114	C/T	cg26384229	chr12:38710491	ALG10B	-0.56	-8.08	-0.44	2.34e-14	Morning vs. evening chronotype;
CESC	cis	rs832540	0.519	rs1445998	chr5:56268205	A/G	cg12311346	chr5:56204834	C5orf35	-0.41	-5.16	-0.3	4.75e-7	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01990225	chr2:97406019	LMAN2L	-0.66	-7.3	-0.41	3.41e-12	Gut microbiome composition (summer);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg23236025	chr1:109826094	PSRC1	-0.52	-6.3	-0.36	1.25e-9	Ulcerative colitis;
CESC	cis	rs9303401	0.538	rs12603174	chr17:56489279	T/C	cg12560992	chr17:57184187	TRIM37	0.5	5.03	0.3	8.86e-7	Cognitive test performance;
CESC	cis	rs6951245	0.706	rs28522260	chr7:1183964	C/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.46	5.52	0.32	7.91e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg04578304	chr7:75796096	NA	-0.42	-6.19	-0.36	2.23e-9	Vertical cup-disc ratio;
CESC	cis	rs7592578	0.882	rs58568707	chr2:191468987	G/A	cg10560079	chr2:191398806	TMEM194B	-0.68	-6.16	-0.35	2.74e-9	Diastolic blood pressure;
CESC	cis	rs593982	0.843	rs680948	chr11:65472394	C/G	cg08755490	chr11:65554678	OVOL1	1.13	10.31	0.54	3.48e-21	Atopic dermatitis;
CESC	cis	rs9393777	0.588	rs6933213	chr6:26493909	T/C	cg12826209	chr6:26865740	GUSBL1	0.6	7.02	0.4	1.89e-11	Intelligence (multi-trait analysis);
CESC	trans	rs3942852	0.774	rs10838812	chr11:48186924	T/C	cg15704280	chr7:45808275	SEPT13	-0.73	-8.25	-0.45	7.61e-15	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs6456156	0.792	rs10946215	chr6:167516181	A/G	cg23791538	chr6:167370224	RNASET2	0.42	5.2	0.3	3.99e-7	Primary biliary cholangitis;
CESC	cis	rs734999	0.549	rs2764840	chr1:2529437	C/T	cg20673091	chr1:2541236	MMEL1	-0.44	-7.49	-0.42	1.01e-12	Ulcerative colitis;
CESC	cis	rs6840360	0.517	rs4399967	chr4:152729312	T/A	cg22705602	chr4:152727874	NA	0.37	5.07	0.3	7.31e-7	Intelligence (multi-trait analysis);
CESC	cis	rs9443645	0.810	rs9361482	chr6:79750385	T/C	cg05283184	chr6:79620031	NA	-0.4	-6.07	-0.35	4.46e-9	Intelligence (multi-trait analysis);
CESC	cis	rs929354	0.566	rs6979947	chr7:157005863	C/T	cg05182265	chr7:156933206	UBE3C	0.43	6.05	0.35	4.87e-9	Body mass index;
CESC	cis	rs6543140	0.964	rs10169192	chr2:103072211	A/G	cg04239558	chr2:103089729	SLC9A4	0.47	6.16	0.35	2.64e-9	Blood protein levels;
CESC	cis	rs752010	0.695	rs10890156	chr1:42108090	T/C	cg06885757	chr1:42089581	HIVEP3	0.49	7.86	0.43	9.43e-14	Lupus nephritis in systemic lupus erythematosus;
CESC	trans	rs11098499	0.954	rs7436506	chr4:120393769	T/C	cg25214090	chr10:38739885	LOC399744	0.7	10.29	0.53	4.26e-21	Corneal astigmatism;
CESC	cis	rs3762637	0.941	rs77599736	chr3:122179509	A/T	cg24169773	chr3:122142474	KPNA1	-0.53	-6.17	-0.35	2.56e-9	LDL cholesterol levels;
CESC	trans	rs7618501	1.000	rs11130218	chr3:49752372	C/T	cg21659725	chr3:3221576	CRBN	-0.82	-13.5	-0.64	5.74e-32	Intelligence (multi-trait analysis);
CESC	cis	rs116095464	0.558	rs13356367	chr5:242395	C/T	cg12570787	chr5:219185	SDHA;CCDC127	0.5	5.27	0.31	2.9e-7	Breast cancer;
CESC	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-6.07	-0.35	4.4e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs13191362	1.000	rs34591938	chr6:163087003	C/G	cg06582575	chr6:163149167	PACRG;PARK2	0.99	10.09	0.53	1.82e-20	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs72781680	0.898	rs17763224	chr2:24213776	T/C	cg08917208	chr2:24149416	ATAD2B	0.92	8.28	0.45	6.31e-15	Lymphocyte counts;
CESC	cis	rs6430585	0.528	rs75667274	chr2:136682486	C/T	cg07169764	chr2:136633963	MCM6	1.22	14.89	0.67	7.4e-37	Corneal structure;
CESC	cis	rs9291683	0.655	rs35750364	chr4:10049049	T/C	cg02734326	chr4:10020555	SLC2A9	0.47	6.53	0.37	3.3e-10	Bone mineral density;
CESC	cis	rs12971120	0.947	rs4891559	chr18:72170397	C/T	cg25817165	chr18:72167213	CNDP2	-0.58	-8.46	-0.46	1.84e-15	Refractive error;
CESC	cis	rs7618915	0.501	rs34157897	chr3:52716937	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.53	8.02	0.44	3.41e-14	Bipolar disorder;
CESC	cis	rs67478160	0.643	rs6575999	chr14:104250609	C/G	cg01849466	chr14:104193079	ZFYVE21	-0.51	-7.11	-0.4	1.09e-11	Schizophrenia;
CESC	trans	rs1945213	0.694	rs67394518	chr11:55855303	G/A	cg15704280	chr7:45808275	SEPT13	0.75	6.95	0.39	2.83e-11	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs10779751	1.000	rs7544489	chr1:11299511	A/G	cg08854313	chr1:11322531	MTOR	-0.91	-14.27	-0.66	1.13e-34	Body mass index;
CESC	cis	rs7833790	1.000	rs7834808	chr8:82704996	A/G	cg07697082	chr8:82753677	SNX16	0.38	5.25	0.31	3.07e-7	Diastolic blood pressure;
CESC	trans	rs1814175	0.645	rs7928714	chr11:49887622	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.41	-6.15	-0.35	2.81e-9	Height;
CESC	cis	rs3749237	0.595	rs1568661	chr3:49520958	A/G	cg06212747	chr3:49208901	KLHDC8B	0.52	6.87	0.39	4.47e-11	Resting heart rate;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg17140673	chr4:111117400	ELOVL6	-0.44	-6.79	-0.38	7.47e-11	Gambling;
CESC	cis	rs4237845	0.537	rs11172369	chr12:58280592	T/C	cg00677455	chr12:58241039	CTDSP2	0.79	10.54	0.54	6.21e-22	Intelligence (multi-trait analysis);
CESC	cis	rs17666538	0.591	rs2878547	chr8:603416	G/A	cg07234876	chr8:600039	NA	0.8	6.57	0.37	2.7e-10	IgG glycosylation;
CESC	cis	rs9733	0.650	rs6698495	chr1:150564476	T/C	cg22823121	chr1:150693482	HORMAD1	-0.37	-5.38	-0.31	1.61e-7	Tonsillectomy;
CESC	cis	rs13034020	0.522	rs13005116	chr2:61241567	G/C	cg18625361	chr2:61244694	PEX13;PUS10	0.66	5.9	0.34	1.13e-8	Hodgkin's lymphoma;
CESC	cis	rs7692995	1.000	rs16896128	chr4:17953590	A/G	cg08925142	chr4:18023851	LCORL	-0.45	-5.39	-0.31	1.58e-7	Height;
CESC	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.64	0.38	1.79e-10	Prudent dietary pattern;
CESC	cis	rs2011503	0.882	rs113841472	chr19:19565482	T/G	cg11584989	chr19:19387371	SF4	0.62	7.24	0.41	4.98e-12	Bipolar disorder;
CESC	cis	rs9549367	0.789	rs9549711	chr13:113900557	C/T	cg00898013	chr13:113819073	PROZ	-0.53	-7.21	-0.41	5.74e-12	Platelet distribution width;
CESC	cis	rs6964587	1.000	rs28927678	chr7:91715662	C/T	cg17063962	chr7:91808500	NA	0.53	7.03	0.4	1.78e-11	Breast cancer;
CESC	trans	rs1667255	0.830	rs2034404	chr18:29156302	A/G	cg12952568	chr14:21924005	NA	0.51	6.26	0.36	1.56e-9	Retinol levels;
CESC	cis	rs3862260	0.509	rs3862262	chr1:120161841	G/T	cg16322792	chr1:120165303	ZNF697	0.6	11.5	0.58	4.43e-25	Systemic lupus erythematosus;
CESC	cis	rs4973397	0.509	rs10191571	chr2:232279975	C/A	cg09339159	chr2:232260559	B3GNT7	0.5	6.18	0.36	2.37e-9	Anti-saccade response;
CESC	cis	rs2243480	1.000	rs6958420	chr7:65751171	A/G	cg13147721	chr7:65941812	NA	0.98	9.24	0.49	8.25e-18	Diabetic kidney disease;
CESC	cis	rs2836974	0.583	rs9636957	chr21:40705847	G/A	cg17971929	chr21:40555470	PSMG1	-0.86	-12.5	-0.61	1.77e-28	Cognitive function;
CESC	cis	rs7208859	0.623	rs73271842	chr17:29137155	T/C	cg14008862	chr17:28927542	LRRC37B2	0.65	5.14	0.3	5.34e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs12142240	0.698	rs58162700	chr1:46816659	T/A	cg00530320	chr1:46809349	NSUN4	0.58	7.89	0.44	8.17e-14	Menopause (age at onset);
CESC	cis	rs7208859	0.573	rs55661352	chr17:29045628	A/G	cg19761014	chr17:28927070	LRRC37B2	0.79	6.32	0.36	1.1e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs801193	0.569	rs3846973	chr7:66120035	T/C	cg11764359	chr7:65958608	NA	-0.73	-10.44	-0.54	1.38e-21	Aortic root size;
CESC	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg25934064	chr3:52569026	NT5DC2	0.26	5.4	0.32	1.45e-7	Bipolar disorder;
CESC	cis	rs12530845	1.000	rs6975251	chr7:135328689	C/G	cg23117316	chr7:135346802	PL-5283	-0.41	-5.29	-0.31	2.52e-7	Red blood cell traits;
CESC	cis	rs2625529	0.938	rs2742323	chr15:72116778	A/T	cg16672083	chr15:72433130	SENP8	0.42	5.38	0.31	1.66e-7	Red blood cell count;
CESC	cis	rs1799949	0.965	rs8176140	chr17:41251646	T/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.67	9.44	0.5	1.97e-18	Menopause (age at onset);
CESC	trans	rs6572548	0.504	rs1956082	chr14:49665496	A/C	cg07520141	chr5:10564205	ANKRD33B	-0.56	-6.4	-0.37	7.2e-10	Subjective well-being;
CESC	cis	rs2832077	0.506	rs2832081	chr21:30152992	A/C	cg08807101	chr21:30365312	RNF160	0.46	5.3	0.31	2.38e-7	Cognitive test performance;
CESC	trans	rs28549925	0.590	rs1403803	chr7:16989678	A/G	cg12639933	chr12:57626296	SHMT2	0.95	6.1	0.35	3.83e-9	Congenital heart disease (maternal effect);Conotruncal heart defects (maternal effects);
CESC	cis	rs60843830	0.661	rs7561648	chr2:105171	G/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.51	6.08	0.35	4.11e-9	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs853679	0.517	rs4713148	chr6:28115921	G/A	cg20151795	chr6:28129481	ZNF389	0.46	5.83	0.34	1.65e-8	Depression;
CESC	cis	rs950169	0.840	rs62019457	chr15:85102142	T/C	cg17507749	chr15:85114479	UBE2QP1	0.56	6.24	0.36	1.7e-9	Schizophrenia;
CESC	cis	rs3096299	0.658	rs3934737	chr16:89560209	G/A	cg02034447	chr16:89574710	SPG7	0.54	6.99	0.39	2.22e-11	Multiple myeloma (IgH translocation);
CESC	cis	rs6665290	0.904	rs6426559	chr1:227195876	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.22	-32.88	-0.9	1.62e-95	Myeloid white cell count;
CESC	cis	rs763014	0.931	rs11648728	chr16:635525	C/T	cg07343612	chr16:622815	PIGQ	-0.55	-7.99	-0.44	4.25e-14	Height;
CESC	cis	rs9611565	0.659	rs202653	chr22:41840158	C/T	cg06634786	chr22:41940651	POLR3H	0.58	6.31	0.36	1.14e-9	Vitiligo;
CESC	cis	rs17253792	0.822	rs8006705	chr14:56171283	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.64	5.08	0.3	7.04e-7	Putamen volume;
CESC	cis	rs1691799	0.867	rs1168344	chr12:66758213	G/A	cg16791601	chr12:66731901	HELB	-0.79	-14.13	-0.66	3.73e-34	White blood cell count (basophil);
CESC	cis	rs10504229	0.679	rs6474100	chr8:58031161	G/A	cg24829409	chr8:58192753	C8orf71	-0.46	-5.93	-0.34	9.43e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs1552244	0.572	rs68121641	chr3:10165845	T/A	cg00149659	chr3:10157352	C3orf10	1.01	12.47	0.61	2.12e-28	Alzheimer's disease;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg06666157	chr19:4791552	FEM1A	0.55	7.2	0.4	6.3e-12	Gut microbiota (bacterial taxa);
CESC	cis	rs4925386	0.840	rs6143024	chr20:60914229	A/G	cg24112000	chr20:60950667	NA	-0.51	-6.15	-0.35	2.86e-9	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs977987	0.843	rs11860231	chr16:75385159	A/G	cg03315344	chr16:75512273	CHST6	0.4	5.82	0.34	1.72e-8	Dupuytren's disease;
CESC	cis	rs769267	0.965	rs4808200	chr19:19554803	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.45	5.51	0.32	8.43e-8	Tonsillectomy;
CESC	cis	rs9905704	0.918	rs11650343	chr17:56919549	G/A	cg12560992	chr17:57184187	TRIM37	0.6	7.02	0.4	1.81e-11	Testicular germ cell tumor;
CESC	cis	rs662064	0.928	rs685746	chr1:10537437	C/G	cg20482658	chr1:10539492	PEX14	-0.36	-7.11	-0.4	1.11e-11	Asthma;
CESC	cis	rs7552404	0.731	rs10732723	chr1:76392437	C/T	cg10523679	chr1:76189770	ACADM	-0.53	-5.54	-0.32	7.22e-8	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs2242116	0.796	rs4683297	chr3:46973673	T/C	cg02527881	chr3:46936655	PTH1R	0.52	7.28	0.41	3.69e-12	Birth weight;
CESC	cis	rs1801251	1.000	rs11679079	chr2:233612656	C/T	cg25237894	chr2:233734115	C2orf82	0.45	7.84	0.43	1.1e-13	Coronary artery disease;
CESC	trans	rs74054849	0.850	rs72878889	chr1:16014128	C/T	cg06826283	chr7:600452	PRKAR1B	0.63	6.0	0.35	6.35e-9	Alcoholic chronic pancreatitis;
CESC	cis	rs16854884	1.000	rs13067695	chr3:143781054	C/T	cg06585982	chr3:143692056	C3orf58	0.46	5.69	0.33	3.34e-8	Economic and political preferences (feminism/equality);
CESC	cis	rs9611565	0.649	rs5751108	chr22:41858035	T/C	cg17376030	chr22:41985996	PMM1	-0.74	-7.87	-0.44	9.15e-14	Vitiligo;
CESC	cis	rs875971	0.545	rs6969224	chr7:65834998	T/G	cg25405998	chr7:65216604	CCT6P1	0.5	5.39	0.31	1.53e-7	Aortic root size;
CESC	cis	rs7666738	0.830	rs13129479	chr4:98987860	T/C	cg18180107	chr4:99064573	C4orf37	0.4	5.19	0.3	4.29e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11098499	0.954	rs35091806	chr4:120325529	G/A	cg25214090	chr10:38739885	LOC399744	0.7	9.92	0.52	6.5e-20	Corneal astigmatism;
CESC	cis	rs2479724	0.868	rs2249703	chr6:41814760	A/G	cg17623882	chr6:41773611	USP49	-0.4	-5.79	-0.34	1.95e-8	Menarche (age at onset);
CESC	cis	rs11676348	0.783	rs4674252	chr2:218984478	G/A	cg00012203	chr2:219082015	ARPC2	-0.56	-7.31	-0.41	3.18e-12	Ulcerative colitis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24854085	chr5:95158523	GLRX	-0.68	-7.28	-0.41	3.74e-12	Gut microbiome composition (summer);
CESC	cis	rs4132509	1.000	rs10927059	chr1:243852079	T/C	cg21452805	chr1:244014465	NA	0.42	5.03	0.3	8.87e-7	RR interval (heart rate);
CESC	cis	rs7824557	0.707	rs3808519	chr8:11142970	C/G	cg21775007	chr8:11205619	TDH	0.47	6.94	0.39	3.05e-11	Retinal vascular caliber;
CESC	cis	rs4927850	0.709	rs6765762	chr3:195652851	G/A	cg00031303	chr3:195681400	NA	0.76	9.54	0.51	9.8e-19	Pancreatic cancer;
CESC	cis	rs11971779	0.941	rs7800795	chr7:139080348	A/G	cg07862535	chr7:139043722	LUC7L2	0.56	5.81	0.34	1.82e-8	Diisocyanate-induced asthma;
CESC	cis	rs7552404	0.883	rs7513363	chr1:76143443	A/G	cg03433033	chr1:76189801	ACADM	0.7	9.34	0.5	4.14e-18	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs10883723	0.775	rs2296579	chr10:104241375	A/G	cg22532475	chr10:104410764	TRIM8	-0.32	-5.43	-0.32	1.27e-7	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg07677032	chr17:61819896	STRADA	0.44	5.81	0.34	1.78e-8	Prudent dietary pattern;
CESC	cis	rs950169	1.000	rs35297609	chr15:84772896	A/G	cg17507749	chr15:85114479	UBE2QP1	0.6	6.5	0.37	3.92e-10	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05309454	chr17:79791505	FAM195B;DYSFIP1	0.52	6.32	0.36	1.09e-9	Gut microbiome composition (summer);
CESC	cis	rs780096	0.565	rs780104	chr2:27677691	G/A	cg17158414	chr2:27665306	KRTCAP3	-0.32	-5.97	-0.34	7.45e-9	Total body bone mineral density;
CESC	cis	rs589448	0.902	rs528974	chr12:69765918	A/T	cg14784868	chr12:69753453	YEATS4	0.89	14.22	0.66	1.68e-34	Cerebrospinal fluid biomarker levels;
CESC	cis	rs7219014	1	rs7219014	chr17:37624790	A/G	cg20243544	chr17:37824526	PNMT	0.48	5.93	0.34	9.26e-9	Urinary metabolites;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg14971544	chr1:54955149	NA	0.55	6.98	0.39	2.36e-11	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs9611565	0.513	rs739135	chr22:42090069	A/C	cg17376030	chr22:41985996	PMM1	-0.78	-8.3	-0.45	5.4e-15	Vitiligo;
CESC	cis	rs8078723	0.933	rs4794822	chr17:38156712	C/T	cg17467752	chr17:38218738	THRA	0.7	10.65	0.55	2.78e-22	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CESC	cis	rs4862750	0.914	rs11945845	chr4:187874136	T/C	cg11301795	chr4:187892539	NA	-0.72	-10.9	-0.56	4.33e-23	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg05863683	chr7:1912471	MAD1L1	-0.43	-6.64	-0.38	1.76e-10	Bipolar disorder and schizophrenia;
CESC	trans	rs62103177	0.564	rs2115996	chr18:77701007	C/G	cg05926928	chr17:57297772	GDPD1	0.83	7.77	0.43	1.76e-13	Opioid sensitivity;
CESC	cis	rs710216	1.000	rs710216	chr1:43428757	A/G	cg07803811	chr1:43423981	SLC2A1	0.47	5.03	0.3	9.03e-7	Red cell distribution width;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07005173	chr17:7977057	ALOX12B	-0.54	-6.35	-0.36	9.12e-10	Gut microbiome composition (summer);
CESC	cis	rs3780486	0.757	rs10121987	chr9:33119818	A/G	cg13443165	chr9:33130375	B4GALT1	0.44	6.37	0.36	8.22e-10	IgG glycosylation;
CESC	cis	rs9393777	0.513	rs13195210	chr6:26646521	C/T	cg12826209	chr6:26865740	GUSBL1	0.75	8.23	0.45	8.34e-15	Intelligence (multi-trait analysis);
CESC	cis	rs4660306	0.961	rs12082256	chr1:45951380	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.61	-7.67	-0.43	3.26e-13	Homocysteine levels;
CESC	cis	rs116095464	0.558	rs6555052	chr5:224268	G/A	cg22496380	chr5:211416	CCDC127	-0.74	-8.72	-0.47	3.15e-16	Breast cancer;
CESC	cis	rs710216	0.917	rs4660691	chr1:43417150	T/G	cg07803811	chr1:43423981	SLC2A1	-0.48	-5.17	-0.3	4.61e-7	Red cell distribution width;
CESC	cis	rs3857067	1.000	rs12502725	chr4:94999873	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.51	-7.64	-0.42	3.98e-13	QT interval;
CESC	cis	rs561341	0.830	rs7218801	chr17:30217778	A/G	cg13647721	chr17:30228624	UTP6	-0.63	-5.87	-0.34	1.31e-8	Hip circumference adjusted for BMI;
CESC	cis	rs9462846	0.725	rs6927188	chr6:42912589	C/T	cg02353165	chr6:42928485	GNMT	-0.62	-7.09	-0.4	1.24e-11	Blood protein levels;
CESC	cis	rs4665809	1.000	rs7599132	chr2:26279810	A/T	cg08470875	chr2:26401718	FAM59B	0.55	6.06	0.35	4.56e-9	Gut microbiome composition (summer);
CESC	cis	rs7208859	0.623	rs1054400	chr17:29109954	A/G	cg13385521	chr17:29058706	SUZ12P	0.81	6.55	0.37	3.04e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs6942756	0.747	rs692432	chr7:129113287	G/A	cg02491457	chr7:128862824	NA	-0.57	-7.83	-0.43	1.18e-13	White matter hyperintensity burden;
CESC	cis	rs643506	0.715	rs11214031	chr11:111766039	C/A	cg17089665	chr11:111648010	NA	-0.39	-5.68	-0.33	3.46e-8	Breast cancer;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg20420867	chr1:160175396	PEA15	-0.44	-6.28	-0.36	1.37e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs6500602	0.674	rs8051695	chr16:4536621	T/C	cg08645402	chr16:4508243	NA	0.43	6.69	0.38	1.35e-10	Schizophrenia;
CESC	cis	rs2228479	0.850	rs62052714	chr16:89857180	T/C	cg04013166	chr16:89971882	TCF25	0.78	6.67	0.38	1.44e-10	Skin colour saturation;
CESC	cis	rs3785574	0.962	rs2584633	chr17:61879501	T/C	cg06873352	chr17:61820015	STRADA	0.47	6.85	0.39	5.3e-11	Height;
CESC	cis	rs6460942	0.908	rs6948654	chr7:12418546	T/A	cg16278512	chr7:12443529	VWDE	-0.5	-5.21	-0.31	3.71e-7	Coronary artery disease;
CESC	cis	rs748404	0.631	rs11070399	chr15:43646347	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.6	7.71	0.43	2.5e-13	Lung cancer;
CESC	cis	rs7267979	0.844	rs6050477	chr20:25221547	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.66	-11.43	-0.57	7.25e-25	Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs650950	0.528	rs646660	chr11:35528452	C/T	cg07496882	chr10:112631570	LOC282997;PDCD4	0.48	6.54	0.37	3.22e-10	Bronchopulmonary dysplasia;
CESC	cis	rs873946	0.557	rs4880427	chr10:134591389	T/C	cg26818010	chr10:134567672	INPP5A	-0.95	-11.6	-0.58	2.03e-25	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs6754311	0.731	rs745500	chr2:136583192	G/A	cg07169764	chr2:136633963	MCM6	-0.69	-8.44	-0.46	2.16e-15	Mosquito bite size;
CESC	cis	rs10504229	0.636	rs117439064	chr8:58055279	A/G	cg02725872	chr8:58115012	NA	-0.44	-6.1	-0.35	3.84e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs7845219	0.525	rs10956931	chr8:95930301	A/G	cg16049864	chr8:95962084	TP53INP1	-0.44	-6.25	-0.36	1.59e-9	Type 2 diabetes;
CESC	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg07677032	chr17:61819896	STRADA	0.45	6.06	0.35	4.7e-9	Prudent dietary pattern;
CESC	cis	rs736408	0.609	rs13082208	chr3:52781539	T/G	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.43	0.37	6.06e-10	Bipolar disorder;
CESC	cis	rs3762637	1.000	rs9879508	chr3:122136480	A/G	cg24169773	chr3:122142474	KPNA1	-0.51	-6.03	-0.35	5.56e-9	LDL cholesterol levels;
CESC	cis	rs4342066	0.522	rs4680746	chr3:28278165	C/G	cg15038811	chr3:28283857	CMC1	0.39	5.1	0.3	6.38e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9910055	0.659	rs227580	chr17:42223068	C/T	cg19774624	chr17:42201019	HDAC5	0.83	12.85	0.62	1.02e-29	Total body bone mineral density;
CESC	cis	rs13242816	1.000	rs7796429	chr7:116144369	T/C	cg04696780	chr7:116139425	CAV2	-0.61	-5.55	-0.32	7.01e-8	P wave duration;
CESC	cis	rs7605827	0.836	rs9287662	chr2:15595994	A/G	cg19274914	chr2:15703543	NA	0.32	5.69	0.33	3.38e-8	Educational attainment (years of education);
CESC	cis	rs12971120	0.891	rs11151960	chr18:72177232	G/A	cg25817165	chr18:72167213	CNDP2	-0.62	-7.54	-0.42	7.61e-13	Refractive error;
CESC	cis	rs7762018	1.000	rs6912959	chr6:170126224	G/A	cg05834625	chr6:170176447	C6orf70	0.66	7.77	0.43	1.75e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs801193	0.569	rs11772819	chr7:66217970	T/C	cg10691866	chr7:65817282	TPST1	-0.33	-5.63	-0.33	4.48e-8	Aortic root size;
CESC	cis	rs4268898	0.662	rs2303291	chr2:24431184	C/T	cg08917208	chr2:24149416	ATAD2B	0.54	5.18	0.3	4.48e-7	Asthma;
CESC	cis	rs17253792	0.822	rs74053651	chr14:56125366	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.71	5.78	0.33	2.08e-8	Putamen volume;
CESC	cis	rs4727027	0.870	rs1105261	chr7:148794442	T/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.43	5.41	0.32	1.39e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	trans	rs7213347	0.780	rs1555568	chr17:2149505	T/C	cg16127145	chr16:1842146	IGFALS	-0.43	-6.05	-0.35	4.91e-9	Total body bone mineral density;
CESC	cis	rs367943	0.712	rs7714734	chr5:112691261	G/A	cg12552261	chr5:112820674	MCC	0.43	5.55	0.32	6.89e-8	Type 2 diabetes;
CESC	cis	rs709400	0.663	rs3783402	chr14:103967929	C/G	cg12935359	chr14:103987150	CKB	-0.52	-7.53	-0.42	8.19e-13	Body mass index;
CESC	cis	rs12477438	0.520	rs1133978	chr2:99741964	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.77	12.85	0.62	1.02e-29	Chronic sinus infection;
CESC	cis	rs6499129	0.558	rs7191281	chr16:67655133	T/C	cg26727032	chr16:67993705	SLC12A4	-0.56	-5.98	-0.34	7.22e-9	Waist-to-hip ratio adjusted for body mass index;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04381043	chr16:89341467	ANKRD11	-0.57	-6.42	-0.37	6.21e-10	Gut microbiome composition (summer);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg07417990	chr1:224051868	NA	0.42	6.09	0.35	3.87e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs35146811	0.659	rs863450	chr7:99821685	C/T	cg13215871	chr17:75784724	NA	-0.34	-6.39	-0.37	7.46e-10	Coronary artery disease;
CESC	cis	rs77861329	0.748	rs9851576	chr3:52091254	C/T	cg08692210	chr3:52188851	WDR51A	-0.44	-5.14	-0.3	5.29e-7	Macrophage inflammatory protein 1b levels;
CESC	cis	rs5758511	0.680	rs58654759	chr22:42642576	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.57	8.33	0.46	4.29e-15	Birth weight;
CESC	cis	rs4654899	0.733	rs10916907	chr1:21261088	A/C	cg05370193	chr1:21551575	ECE1	0.38	5.72	0.33	2.83e-8	Superior frontal gyrus grey matter volume;
CESC	cis	rs3785574	0.962	rs2597632	chr17:61894739	A/T	cg06420487	chr17:61919686	SMARCD2	0.44	5.28	0.31	2.68e-7	Height;
CESC	cis	rs4076764	0.958	rs10917748	chr1:163400377	T/C	cg06092702	chr1:163392909	NA	-0.41	-5.9	-0.34	1.13e-8	Motion sickness;
CESC	cis	rs17376456	0.825	rs12188163	chr5:93250608	A/G	cg21475434	chr5:93447410	FAM172A	-0.76	-6.58	-0.37	2.51e-10	Diabetic retinopathy;
CESC	cis	rs1008375	0.966	rs4235392	chr4:17696422	A/G	cg15017067	chr4:17643749	FAM184B	0.36	5.18	0.3	4.44e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs9611565	0.512	rs964898	chr22:42142306	C/T	cg17376030	chr22:41985996	PMM1	0.78	8.18	0.45	1.17e-14	Vitiligo;
CESC	cis	rs9435341	0.762	rs72697623	chr1:107554269	G/A	cg09367891	chr1:107599246	PRMT6	0.66	7.1	0.4	1.16e-11	Facial morphology (factor 21, depth of nasal alae);
CESC	cis	rs9916302	0.610	rs11078902	chr17:37631883	C/G	cg07936489	chr17:37558343	FBXL20	-0.8	-11.68	-0.58	1.06e-25	Glomerular filtration rate (creatinine);
CESC	cis	rs8060686	0.641	rs9938553	chr16:68183064	T/A	cg26727032	chr16:67993705	SLC12A4	-0.5	-6.15	-0.35	2.84e-9	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs6964587	0.692	rs10236483	chr7:91797296	A/C	cg17063962	chr7:91808500	NA	0.44	6.38	0.36	7.97e-10	Breast cancer;
CESC	cis	rs40363	0.857	rs55989968	chr16:3530658	C/G	cg00484396	chr16:3507460	NAT15	0.61	7.64	0.42	3.99e-13	Tuberculosis;
CESC	cis	rs1552244	1.000	rs7631678	chr3:10078816	T/G	cg00166722	chr3:10149974	C3orf24	0.46	5.88	0.34	1.21e-8	Alzheimer's disease;
CESC	trans	rs11098499	0.954	rs6820115	chr4:120398182	T/C	cg25214090	chr10:38739885	LOC399744	0.67	9.69	0.51	3.43e-19	Corneal astigmatism;
CESC	trans	rs1945213	0.694	rs17149976	chr11:55839746	T/C	cg03929089	chr4:120376271	NA	0.76	7.26	0.41	4.31e-12	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs9287719	0.967	rs10191883	chr2:10744136	A/G	cg00105475	chr2:10696890	NA	0.39	5.64	0.33	4.44e-8	Prostate cancer;
CESC	cis	rs9291683	0.595	rs11722930	chr4:10035454	G/A	cg11266682	chr4:10021025	SLC2A9	0.7	13.85	0.65	3.49e-33	Bone mineral density;
CESC	cis	rs9300255	0.568	rs3018098	chr12:123654812	T/C	cg19016782	chr12:123741754	C12orf65	-0.43	-6.15	-0.35	2.78e-9	Neutrophil percentage of white cells;
CESC	cis	rs7692995	1.000	rs16896068	chr4:17944840	C/T	cg08925142	chr4:18023851	LCORL	-0.45	-5.3	-0.31	2.41e-7	Height;
CESC	cis	rs9486719	0.947	rs9386648	chr6:97035656	T/C	cg06623918	chr6:96969491	KIAA0776	-0.8	-8.21	-0.45	9.56e-15	Migraine;Coronary artery disease;
CESC	cis	rs798554	0.836	rs798526	chr7:2775542	G/C	cg19717773	chr7:2847554	GNA12	-0.58	-8.34	-0.46	4.07e-15	Height;
CESC	cis	rs11098499	0.865	rs2389809	chr4:120377399	T/C	cg09307838	chr4:120376055	NA	0.96	13.95	0.65	1.6e-33	Corneal astigmatism;
CESC	cis	rs9788682	0.747	rs7174190	chr15:78763617	C/T	cg24631222	chr15:78858424	CHRNA5	0.61	7.16	0.4	8.13e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs853679	0.517	rs9357066	chr6:28129831	T/C	cg26335602	chr6:28129616	ZNF389	0.52	6.81	0.39	6.59e-11	Depression;
CESC	cis	rs875971	0.619	rs10278371	chr7:66051540	C/A	cg11764359	chr7:65958608	NA	-0.72	-9.26	-0.49	7.15e-18	Aortic root size;
CESC	cis	rs2836974	0.897	rs8132568	chr21:40527916	C/T	cg17971929	chr21:40555470	PSMG1	1.04	16.4	0.71	3.34e-42	Cognitive function;
CESC	cis	rs7666738	0.830	rs9992639	chr4:98940400	G/T	cg17366294	chr4:99064904	C4orf37	0.61	8.59	0.47	7.44e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9811920	0.535	rs792837	chr3:99477182	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.33	-5.42	-0.32	1.37e-7	Axial length;
CESC	cis	rs2243480	1.000	rs73142121	chr7:65311206	C/T	cg18252515	chr7:66147081	NA	-1.07	-10.29	-0.53	4.14e-21	Diabetic kidney disease;
CESC	cis	rs7772486	0.713	rs1986729	chr6:146194831	G/A	cg23711669	chr6:146136114	FBXO30	1.02	15.62	0.69	1.98e-39	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7618915	0.547	rs13085331	chr3:52627486	G/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	6.77	0.38	8.38e-11	Bipolar disorder;
CESC	cis	rs3026101	0.671	rs56018748	chr17:5316939	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.4	5.22	0.31	3.62e-7	Body mass index;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg09061759	chr1:65431709	JAK1	-0.49	-6.18	-0.35	2.4e-9	Ulcerative colitis;
CESC	cis	rs61931739	0.517	rs11053067	chr12:34191391	T/C	cg19457237	chr12:34500585	NA	-0.39	-5.39	-0.31	1.53e-7	Morning vs. evening chronotype;
CESC	cis	rs1707322	0.821	rs10749857	chr1:46248143	C/T	cg06784218	chr1:46089804	CCDC17	0.34	5.82	0.34	1.67e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs35146811	0.844	rs10281368	chr7:99655897	A/G	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.48	5.99	0.35	6.84e-9	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08328324	chr8:33370759	C8orf41	-0.55	-6.28	-0.36	1.38e-9	Gut microbiome composition (summer);
CESC	trans	rs11764590	0.694	rs55860148	chr7:2105594	G/A	cg11693508	chr17:37793320	STARD3	0.68	7.39	0.41	1.92e-12	Neuroticism;
CESC	trans	rs7191820	0.539	rs9927057	chr16:79360803	A/G	cg02396914	chr8:120743868	TAF2	-0.49	-6.37	-0.36	8.5e-10	Obesity-related traits;
CESC	cis	rs7208859	0.623	rs609063	chr17:28951513	A/G	cg14008862	chr17:28927542	LRRC37B2	0.75	5.53	0.32	7.72e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs796364	0.806	rs74724807	chr2:201005109	A/C	cg23649088	chr2:200775458	C2orf69	-0.55	-5.04	-0.3	8.69e-7	Schizophrenia;
CESC	cis	rs79057730	0.599	rs4721086	chr7:821123	G/A	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.72	6.55	0.37	2.98e-10	Initial pursuit acceleration;
CESC	cis	rs7811142	1.000	rs6962151	chr7:100028484	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.92	9.76	0.51	2.07e-19	Platelet count;
CESC	cis	rs7829975	0.742	rs1533059	chr8:8684953	A/G	cg15556689	chr8:8085844	FLJ10661	-0.51	-6.28	-0.36	1.37e-9	Mood instability;
CESC	cis	rs1832871	0.683	rs56197409	chr6:158684338	A/G	cg07165851	chr6:158734300	TULP4	0.6	6.34	0.36	9.88e-10	Height;
CESC	cis	rs7666738	0.830	rs35560671	chr4:99069095	G/A	cg03467027	chr4:99064603	C4orf37	0.48	5.96	0.34	7.81e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs561341	1.000	rs497479	chr17:30328605	C/T	cg12193833	chr17:30244370	NA	-0.67	-6.35	-0.36	9.44e-10	Hip circumference adjusted for BMI;
CESC	cis	rs10504229	0.906	rs73607868	chr8:58172482	T/C	cg14926445	chr8:58193284	C8orf71	-0.51	-5.47	-0.32	1.03e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs514406	0.929	rs1672909	chr1:53340824	A/G	cg24675658	chr1:53192096	ZYG11B	-0.59	-7.33	-0.41	2.83e-12	Monocyte count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00076056	chr16:85061228	KIAA0513	0.57	6.58	0.37	2.53e-10	Gut microbiome composition (summer);
CESC	cis	rs1878931	0.507	rs4429296	chr16:3408277	T/G	cg02880119	chr16:3481970	NA	0.4	5.2	0.3	3.91e-7	Body mass index (adult);
CESC	cis	rs2315504	0.692	rs12602410	chr17:39017343	A/G	cg05063374	chr17:38953512	KRT28	-0.38	-5.11	-0.3	6.06e-7	Height;
CESC	cis	rs2290159	0.800	rs5746187	chr3:12659419	A/G	cg23032965	chr3:12705835	RAF1	0.53	5.69	0.33	3.41e-8	Cholesterol, total;
CESC	cis	rs9640161	0.711	rs55881542	chr7:150025734	G/A	cg17279839	chr7:150038598	RARRES2	0.43	5.34	0.31	2.03e-7	Blood protein levels;Circulating chemerin levels;
CESC	trans	rs78049276	0.568	rs10305839	chr4:148400413	C/T	cg13149281	chr14:23389818	RBM23;PRMT5	-0.64	-6.72	-0.38	1.11e-10	Pulse pressure;
CESC	cis	rs4646450	0.636	rs2003499	chr7:99014984	A/G	cg24650262	chr7:98904301	NA	0.43	5.05	0.3	8.34e-7	Blood metabolite levels;
CESC	cis	rs113835537	0.529	rs11227502	chr11:66274148	T/G	cg22134325	chr11:66188745	NPAS4	0.36	5.65	0.33	4.17e-8	Airway imaging phenotypes;
CESC	cis	rs11048434	0.736	rs4309200	chr12:9121856	A/C	cg23795048	chr12:9217529	LOC144571	0.33	5.05	0.3	8.2e-7	Sjögren's syndrome;
CESC	cis	rs9840812	0.728	rs6439646	chr3:136273563	T/C	cg15507776	chr3:136538369	TMEM22	0.42	5.07	0.3	7.46e-7	Fibrinogen levels;
CESC	cis	rs9303401	0.703	rs9910629	chr17:57210301	C/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.59	7.67	0.43	3.29e-13	Cognitive test performance;
CESC	cis	rs6964587	0.869	rs6964050	chr7:91482418	C/T	cg17063962	chr7:91808500	NA	-0.52	-6.98	-0.39	2.31e-11	Breast cancer;
CESC	cis	rs7959452	0.640	rs4761154	chr12:69705362	A/G	cg14784868	chr12:69753453	YEATS4	-0.75	-10.95	-0.56	2.88e-23	Blood protein levels;
CESC	cis	rs2836974	0.563	rs6517522	chr21:40553845	T/C	cg11890956	chr21:40555474	PSMG1	0.81	12.36	0.6	5.15e-28	Cognitive function;
CESC	cis	rs4727027	0.754	rs917124	chr7:148851213	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.45	5.47	0.32	1.04e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs1832871	0.655	rs4273715	chr6:158722847	T/C	cg07165851	chr6:158734300	TULP4	0.61	6.77	0.38	8.06e-11	Height;
CESC	cis	rs2637266	1.000	rs10219021	chr10:78364516	C/T	cg18941641	chr10:78392320	NA	0.43	8.16	0.45	1.34e-14	Pulmonary function;
CESC	cis	rs2836974	0.644	rs4818017	chr21:40690561	G/T	cg17971929	chr21:40555470	PSMG1	-0.85	-12.14	-0.6	2.84e-27	Cognitive function;
CESC	cis	rs8058578	0.945	rs885107	chr16:30672719	T/C	cg02466173	chr16:30829666	NA	-0.4	-6.37	-0.36	8.16e-10	Multiple myeloma;
CESC	cis	rs79839061	0.610	rs2306252	chr4:892116	T/C	cg07828340	chr4:882639	GAK	0.83	7.07	0.4	1.41e-11	Intelligence (multi-trait analysis);
CESC	cis	rs3780486	0.846	rs7864705	chr9:33140352	A/C	cg13443165	chr9:33130375	B4GALT1	0.45	6.65	0.38	1.71e-10	IgG glycosylation;
CESC	cis	rs4862750	0.872	rs6830426	chr4:187897270	T/A	cg06074448	chr4:187884817	NA	-0.37	-5.44	-0.32	1.21e-7	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2066819	1.000	rs77768890	chr12:56725121	A/G	cg26734620	chr12:56694298	CS	1.02	6.17	0.35	2.52e-9	Psoriasis vulgaris;
CESC	trans	rs2727020	0.701	rs7949044	chr11:49597334	C/T	cg15704280	chr7:45808275	SEPT13	-0.86	-11.62	-0.58	1.63e-25	Coronary artery disease;
CESC	cis	rs5753037	0.564	rs131298	chr22:30180001	C/T	cg01021169	chr22:30184971	ASCC2	0.56	8.47	0.46	1.69e-15	Type 1 diabetes;
CESC	cis	rs12701220	0.655	rs10241018	chr7:1144774	G/C	cg23978390	chr7:1156363	C7orf50	0.59	6.04	0.35	5.26e-9	Bronchopulmonary dysplasia;
CESC	cis	rs12369179	0.737	rs116896792	chr12:122948907	T/C	cg18578876	chr12:123200353	GPR109B	-0.93	-7.09	-0.4	1.19e-11	Age-related diseases, mortality and associated endophenotypes;Age-related disease endophenotypes;
CESC	cis	rs6835098	1.000	rs9990666	chr4:174083150	G/T	cg08422745	chr4:174089978	GALNT7	-0.82	-11.83	-0.59	3.26e-26	Dementia and core Alzheimer's disease neuropathologic changes;
CESC	cis	rs6732160	0.588	rs2043099	chr2:73374156	G/A	cg01422370	chr2:73384389	NA	0.57	9.1	0.49	2.21e-17	Intelligence (multi-trait analysis);
CESC	cis	rs10504229	0.953	rs57131327	chr8:58171895	T/C	cg05313129	chr8:58192883	C8orf71	-0.55	-6.37	-0.36	8.42e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs7937682	1.000	rs7121011	chr11:111568681	C/T	cg22437258	chr11:111473054	SIK2	-0.68	-7.83	-0.43	1.19e-13	Primary sclerosing cholangitis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07907564	chr7:73589340	EIF4H	-0.57	-6.6	-0.38	2.28e-10	Gut microbiome composition (summer);
CESC	cis	rs6460942	1.000	rs62448563	chr7:12400040	G/A	cg17427002	chr7:12443146	VWDE	-0.51	-5.05	-0.3	8.11e-7	Coronary artery disease;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg21755457	chr12:54020320	ATF7	-0.4	-6.01	-0.35	6.18e-9	Gambling;
CESC	cis	rs8060686	0.668	rs9932414	chr16:68219969	A/G	cg26727032	chr16:67993705	SLC12A4	-0.6	-8.91	-0.48	8.26e-17	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs1003719	0.688	rs2000413	chr21:38539718	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.59	-7.77	-0.43	1.71e-13	Eye color traits;
CESC	cis	rs2180341	0.814	rs6905553	chr6:127727407	A/G	cg27446573	chr6:127587934	RNF146	0.83	12.03	0.59	6.99e-27	Breast cancer;
CESC	cis	rs17711722	0.522	rs4642526	chr7:65216742	G/T	cg25405998	chr7:65216604	CCT6P1	0.43	5.53	0.32	7.54e-8	Calcium levels;
CESC	cis	rs9311474	0.508	rs6786043	chr3:52604861	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.5	7.4	0.41	1.83e-12	Electroencephalogram traits;
CESC	cis	rs1552244	0.572	rs68013239	chr3:10165711	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.68	-7.55	-0.42	6.87e-13	Alzheimer's disease;
CESC	cis	rs7927771	0.524	rs754434	chr11:47814280	A/G	cg20307385	chr11:47447363	PSMC3	0.62	8.62	0.47	6.37e-16	Subjective well-being;
CESC	cis	rs4975616	0.804	rs457130	chr5:1336178	A/T	cg07493874	chr5:1342172	CLPTM1L	-0.42	-7.83	-0.43	1.21e-13	Lung cancer;
CESC	trans	rs6600671	0.934	rs11249348	chr1:121188302	T/C	cg17023122	chr1:144479586	NA	0.44	6.13	0.35	3.24e-9	Hip geometry;
CESC	cis	rs6076065	0.748	rs4815198	chr20:23343491	T/C	cg11657817	chr20:23433608	CST11	0.39	5.95	0.34	8.62e-9	Facial morphology (factor 15, philtrum width);
CESC	cis	rs2519796	0.531	rs2519108	chr9:136807640	C/T	cg13751417	chr9:136814406	VAV2	0.41	5.45	0.32	1.18e-7	Hematocrit;Hemoglobin concentration;
CESC	cis	rs40363	0.523	rs757270	chr16:3534451	C/T	cg00484396	chr16:3507460	NAT15	-0.42	-6.91	-0.39	3.51e-11	Tuberculosis;
CESC	cis	rs853679	0.517	rs9468292	chr6:28095355	G/A	cg23161317	chr6:28129485	ZNF389	0.51	6.5	0.37	3.98e-10	Depression;
CESC	cis	rs6456156	0.586	rs12529876	chr6:167461501	G/A	cg23791538	chr6:167370224	RNASET2	-0.49	-6.37	-0.36	8.13e-10	Primary biliary cholangitis;
CESC	cis	rs12134245	0.747	rs35654098	chr1:92001452	T/A	cg25838465	chr1:92012736	NA	-0.61	-8.91	-0.48	8.65e-17	Breast cancer;
CESC	cis	rs4911253	0.527	rs853859	chr20:31402269	A/G	cg13636640	chr20:31349939	DNMT3B	0.7	9.98	0.52	4.17e-20	Lymphocyte counts;
CESC	cis	rs6586111	0.647	rs2880655	chr10:82369816	G/T	cg03086067	chr10:82368399	SH2D4B	-0.36	-5.94	-0.34	8.82e-9	Capecitabine sensitivity;
CESC	cis	rs13256369	0.851	rs11786125	chr8:8564570	T/G	cg17143192	chr8:8559678	CLDN23	0.77	8.87	0.48	1.09e-16	Obesity-related traits;
CESC	cis	rs9487051	0.768	rs427960	chr6:109524939	C/T	cg01475377	chr6:109611718	NA	-0.44	-6.62	-0.38	1.93e-10	Reticulocyte fraction of red cells;
CESC	cis	rs57506017	0.540	rs7808568	chr7:12271252	T/C	cg23422036	chr7:12250390	TMEM106B	0.39	5.24	0.31	3.21e-7	Neuroticism;
CESC	cis	rs929354	0.742	rs7801905	chr7:156940111	T/C	cg05182265	chr7:156933206	UBE3C	-0.49	-7.03	-0.4	1.76e-11	Body mass index;
CESC	cis	rs9467711	0.606	rs12174631	chr6:26373150	C/T	cg14345882	chr6:26364793	BTN3A2	0.61	6.49	0.37	4.12e-10	Autism spectrum disorder or schizophrenia;
CESC	cis	rs875971	0.964	rs778723	chr7:65829497	T/C	cg11764359	chr7:65958608	NA	0.96	15.21	0.68	5.32e-38	Aortic root size;
CESC	cis	rs7927771	0.931	rs4752801	chr11:47907641	A/G	cg18512352	chr11:47633146	NA	-0.56	-9.14	-0.49	1.72e-17	Subjective well-being;
CESC	cis	rs12477438	0.834	rs10179043	chr2:99687490	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-10.4	-0.54	1.79e-21	Chronic sinus infection;
CESC	trans	rs6987853	0.830	rs2272685	chr8:42354102	C/T	cg27650678	chr11:66636318	PC	-0.46	-6.08	-0.35	4.13e-9	Mean corpuscular hemoglobin concentration;
CESC	cis	rs2180341	0.889	rs2000909	chr6:127711173	G/A	cg27446573	chr6:127587934	RNF146	0.81	11.43	0.57	7.46e-25	Breast cancer;
CESC	cis	rs115056730	0.520	rs114113305	chr2:98189209	A/T	cg26665480	chr2:98280029	ACTR1B	-0.96	-6.66	-0.38	1.62e-10	Monocyte chemoattractant protein-3 levels;
CESC	cis	rs7089973	0.604	rs35319791	chr10:116602296	C/A	cg25233709	chr10:116636983	FAM160B1	0.38	6.08	0.35	4.13e-9	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs4595586	0.566	rs7307174	chr12:39368862	A/G	cg26384229	chr12:38710491	ALG10B	0.43	6.1	0.35	3.82e-9	Morning vs. evening chronotype;
CESC	cis	rs4308124	0.708	rs10178095	chr2:111972516	C/T	cg04571233	chr2:111982156	NA	-0.62	-6.8	-0.39	6.82e-11	Vitiligo;
CESC	cis	rs2243480	1.000	rs383402	chr7:65586653	A/C	cg13147721	chr7:65941812	NA	0.85	8.7	0.47	3.69e-16	Diabetic kidney disease;
CESC	cis	rs875971	1.000	rs4717300	chr7:65947380	T/C	cg11764359	chr7:65958608	NA	0.96	15.17	0.68	7.94e-38	Aortic root size;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg06136617	chr16:4027502	ADCY9	0.42	6.07	0.35	4.38e-9	Fibrinogen levels;
CESC	cis	rs2404602	0.692	rs4383105	chr15:77055510	T/C	cg22467129	chr15:76604101	ETFA	-0.34	-5.16	-0.3	4.84e-7	Blood metabolite levels;
CESC	cis	rs78456975	1.000	rs13431491	chr2:1553808	T/A	cg01028140	chr2:1542097	TPO	-0.5	-5.26	-0.31	3.03e-7	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs5758511	0.633	rs5758690	chr22:42668295	C/G	cg00645731	chr22:42541494	CYP2D7P1	0.57	8.5	0.46	1.37e-15	Birth weight;
CESC	cis	rs10256972	0.758	rs4723649	chr7:1071905	T/C	cg23978390	chr7:1156363	C7orf50	0.54	7.14	0.4	9.19e-12	Longevity;Endometriosis;
CESC	cis	rs7927592	0.830	rs7120635	chr11:68261293	A/G	cg16797656	chr11:68205561	LRP5	0.41	6.2	0.36	2.16e-9	Total body bone mineral density;
CESC	trans	rs5756813	0.635	rs12160750	chr22:38199054	A/G	cg19894588	chr14:64061835	NA	-0.68	-8.42	-0.46	2.36e-15	Optic cup area;Vertical cup-disc ratio;
CESC	cis	rs7945705	0.902	rs2016942	chr11:8938787	A/G	cg12365402	chr11:9010492	NRIP3	0.37	5.68	0.33	3.49e-8	Hemoglobin concentration;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg08240007	chr2:220407822	CHPF;TMEM198	-0.39	-6.07	-0.35	4.48e-9	Gambling;
CESC	cis	rs2576037	0.583	rs487386	chr18:44377004	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.33	5.21	0.3	3.79e-7	Personality dimensions;
CESC	cis	rs72781680	0.898	rs12623316	chr2:24087857	A/G	cg08917208	chr2:24149416	ATAD2B	0.91	8.36	0.46	3.7e-15	Lymphocyte counts;
CESC	cis	rs2637266	0.626	rs2583066	chr10:78555839	T/C	cg18941641	chr10:78392320	NA	0.41	7.79	0.43	1.51e-13	Pulmonary function;
CESC	cis	rs3096299	0.967	rs2911253	chr16:89488587	T/G	cg08822215	chr16:89438651	ANKRD11	-0.37	-5.72	-0.33	2.81e-8	Multiple myeloma (IgH translocation);
CESC	cis	rs137699	0.687	rs4821887	chr22:39756985	C/T	cg11247378	chr22:39784982	NA	-0.5	-6.59	-0.38	2.4e-10	IgG glycosylation;
CESC	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg24642844	chr7:1081250	C7orf50	-0.75	-8.99	-0.48	4.94e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs10782582	0.593	rs6704444	chr1:76205108	T/C	cg22875332	chr1:76189707	ACADM	-0.47	-5.66	-0.33	3.93e-8	Daytime sleep phenotypes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14146092	chr11:129873378	NCRNA00167;PRDM10	-0.55	-6.4	-0.37	7.08e-10	Gut microbiome composition (summer);
CESC	cis	rs9303280	0.836	rs11557467	chr17:38028634	G/T	cg19468946	chr17:37922297	IKZF3	-0.41	-5.54	-0.32	7.15e-8	Self-reported allergy;
CESC	cis	rs4664293	0.967	rs12999124	chr2:160531328	A/G	cg08347373	chr2:160653686	CD302	-0.33	-5.29	-0.31	2.5e-7	Monocyte percentage of white cells;
CESC	cis	rs7809950	0.635	rs62483629	chr7:106866178	T/C	cg23024343	chr7:107201750	COG5	-0.58	-6.95	-0.39	2.79e-11	Coronary artery disease;
CESC	cis	rs8050907	0.590	rs11860985	chr16:4555965	G/C	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.8	5.38	0.31	1.61e-7	Obesity-related traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00502533	chr1:113498761	SLC16A1	-0.54	-6.36	-0.36	8.75e-10	Gut microbiome composition (summer);
CESC	cis	rs9322193	0.923	rs9800806	chr6:150061486	G/T	cg13206674	chr6:150067644	NUP43	0.45	6.43	0.37	5.82e-10	Lung cancer;
CESC	cis	rs9815354	1.000	rs1716644	chr3:41968028	A/G	cg03022575	chr3:42003672	ULK4	-0.46	-5.37	-0.31	1.76e-7	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs17818399	0.962	rs7565274	chr2:46841861	G/T	cg02822958	chr2:46747628	ATP6V1E2	0.46	5.74	0.33	2.55e-8	Height;
CESC	cis	rs6502050	0.805	rs11077970	chr17:80085916	C/T	cg11859384	chr17:80120422	CCDC57	0.38	5.12	0.3	6.01e-7	Life satisfaction;
CESC	cis	rs10504073	0.584	rs17642664	chr8:49942945	A/G	cg00325661	chr8:49890786	NA	0.58	8.67	0.47	4.37e-16	Blood metabolite ratios;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13820145	chr20:26062310	FAM182A	-0.47	-6.19	-0.36	2.28e-9	Gut microbiome composition (summer);
CESC	cis	rs2204008	0.580	rs36118148	chr12:38411812	G/A	cg26384229	chr12:38710491	ALG10B	-0.41	-5.49	-0.32	9.35e-8	Bladder cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14981573	chr1:70671146	SFRS11;LRRC40	0.57	6.36	0.36	8.8e-10	Gut microbiome composition (summer);
CESC	trans	rs7615952	0.512	rs11921452	chr3:125359750	A/G	cg07211511	chr3:129823064	LOC729375	-0.59	-7.28	-0.41	3.84e-12	Blood pressure (smoking interaction);
CESC	cis	rs644799	0.544	rs1527450	chr11:95467777	G/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.41	5.21	0.3	3.83e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs938554	0.513	rs4529048	chr4:9997112	G/T	cg00071950	chr4:10020882	SLC2A9	0.64	8.57	0.47	8.41e-16	Blood metabolite levels;
CESC	cis	rs853679	0.517	rs35512245	chr6:28079953	T/C	cg26335602	chr6:28129616	ZNF389	0.53	7.06	0.4	1.48e-11	Depression;
CESC	cis	rs60154123	0.730	rs587203	chr1:210463786	C/T	cg22029157	chr1:209979665	IRF6	0.47	5.87	0.34	1.3e-8	Coronary artery disease;
CESC	cis	rs7917772	0.503	rs11191326	chr10:104302959	C/T	ch.10.2196322F	chr10:104248062	ACTR1A	0.42	5.19	0.3	4.1e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs6060717	0.536	rs3787173	chr20:34472105	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-6.93	-0.39	3.22e-11	Hip circumference adjusted for BMI;
CESC	trans	rs7937682	0.889	rs2850247	chr11:111637202	C/A	cg18187862	chr3:45730750	SACM1L	-0.63	-7.83	-0.43	1.14e-13	Primary sclerosing cholangitis;
CESC	cis	rs9322193	0.923	rs10782314	chr6:150056663	C/T	cg04369109	chr6:150039330	LATS1	-0.46	-6.46	-0.37	4.96e-10	Lung cancer;
CESC	cis	rs9640161	0.830	rs13307276	chr7:150061525	T/C	cg21361702	chr7:150065534	REPIN1	0.69	8.45	0.46	1.94e-15	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs514406	0.823	rs501006	chr1:53368292	T/A	cg08859206	chr1:53392774	SCP2	-0.63	-8.33	-0.46	4.29e-15	Monocyte count;
CESC	cis	rs13191362	1.000	rs13191362	chr6:163033350	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.59	6.66	0.38	1.56e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.89	13.64	0.64	1.86e-32	Prudent dietary pattern;
CESC	cis	rs3820928	0.874	rs59630650	chr2:227786514	T/C	cg11843606	chr2:227700838	RHBDD1	-0.44	-5.84	-0.34	1.5e-8	Pulmonary function;
CESC	cis	rs1215050	0.791	rs260902	chr4:98764694	G/A	cg05340658	chr4:99064831	C4orf37	0.51	6.65	0.38	1.63e-10	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs1577917	1.000	rs12216203	chr6:86675301	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.47	-6.05	-0.35	4.79e-9	Response to antipsychotic treatment;
CESC	cis	rs66887589	0.592	rs2175383	chr4:120215836	C/A	cg09307838	chr4:120376055	NA	0.67	9.37	0.5	3.4e-18	Diastolic blood pressure;
CESC	cis	rs11583043	0.874	rs72734253	chr1:101380718	A/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.57	6.69	0.38	1.29e-10	Ulcerative colitis;Inflammatory bowel disease;
CESC	cis	rs703842	1.000	rs10877014	chr12:58167661	A/G	cg18357645	chr12:58087776	OS9	-0.38	-5.33	-0.31	2.06e-7	Multiple sclerosis;
CESC	cis	rs36051895	0.632	rs7040922	chr9:5174829	A/G	cg02405213	chr9:5042618	JAK2	0.53	6.88	0.39	4.37e-11	Pediatric autoimmune diseases;
CESC	cis	rs7223966	1.000	rs7209435	chr17:61712964	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.46	-5.66	-0.33	3.84e-8	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs9486715	0.867	rs4438964	chr6:96917563	T/G	cg06623918	chr6:96969491	KIAA0776	0.93	14.33	0.66	6.89e-35	Headache;
CESC	cis	rs7552404	0.655	rs5745336	chr1:76273519	G/A	cg10523679	chr1:76189770	ACADM	0.66	6.65	0.38	1.71e-10	Blood metabolite levels;Acylcarnitine levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15470736	chr7:157056012	UBE3C	-0.65	-7.63	-0.42	4.26e-13	Gut microbiome composition (summer);
CESC	cis	rs1799949	1.000	rs3950989	chr17:41237953	G/A	cg23758822	chr17:41437982	NA	0.99	15.38	0.69	1.36e-38	Menopause (age at onset);
CESC	cis	rs1046896	0.552	rs12602280	chr17:80805421	G/C	cg19046167	chr17:80928561	B3GNTL1	0.48	5.71	0.33	3.09e-8	Glycated hemoglobin levels;
CESC	cis	rs6540559	1.000	rs742214	chr1:209960925	T/C	cg09509183	chr1:209979624	IRF6	0.48	5.92	0.34	1.02e-8	Cleft lip with or without cleft palate;
CESC	cis	rs2996428	0.667	rs16824230	chr1:3766240	A/G	cg17848003	chr1:3704513	LRRC47	0.36	5.06	0.3	7.97e-7	Red cell distribution width;
CESC	cis	rs7819412	0.745	rs2898260	chr8:10939490	G/T	cg21775007	chr8:11205619	TDH	-0.42	-6.18	-0.35	2.45e-9	Triglycerides;
CESC	cis	rs7666738	0.830	rs6532720	chr4:99043781	C/T	cg18180107	chr4:99064573	C4orf37	0.41	5.29	0.31	2.51e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2297440	0.527	rs4809318	chr20:62264760	G/A	cg06363034	chr20:62225388	GMEB2	-0.5	-6.3	-0.36	1.26e-9	Glioma;Non-glioblastoma glioma;Glioblastoma;
CESC	cis	rs36051895	0.587	rs7848872	chr9:5197027	T/A	cg02405213	chr9:5042618	JAK2	-0.51	-5.73	-0.33	2.77e-8	Pediatric autoimmune diseases;
CESC	cis	rs832540	0.931	rs832399	chr5:56222358	A/T	cg14703610	chr5:56206110	C5orf35	0.53	7.01	0.4	1.95e-11	Coronary artery disease;
CESC	cis	rs4665809	0.590	rs1368902	chr2:26440576	T/C	cg22920501	chr2:26401640	FAM59B	-0.91	-10.33	-0.54	3.07e-21	Gut microbiome composition (summer);
CESC	cis	rs4604732	0.631	rs34330532	chr1:247626844	G/C	cg12758973	chr1:247694275	LOC148824;OR2C3	0.51	6.36	0.36	8.65e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs9300255	0.739	rs1402275	chr12:123750895	A/G	cg05973401	chr12:123451056	ABCB9	0.52	6.02	0.35	5.73e-9	Neutrophil percentage of white cells;
CESC	cis	rs10911251	0.508	rs6424890	chr1:183112764	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.84	13.22	0.63	5.53e-31	Colorectal cancer;
CESC	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg07677032	chr17:61819896	STRADA	0.44	5.9	0.34	1.1e-8	Prudent dietary pattern;
CESC	cis	rs425277	1.000	rs427811	chr1:2075560	T/G	cg16545954	chr1:2118288	C1orf86	0.33	5.54	0.32	7.23e-8	Height;
CESC	cis	rs7618915	0.524	rs35249778	chr3:52661640	G/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.36	6.44	0.37	5.62e-10	Bipolar disorder;
CESC	cis	rs1843834	0.539	rs1494109	chr2:225441833	G/A	cg22455342	chr2:225449267	CUL3	0.7	9.61	0.51	6.05e-19	IgE levels in asthmatics (D.p. specific);
CESC	cis	rs72634258	0.554	rs34305100	chr1:7913029	A/G	cg26816564	chr1:7831052	VAMP3	0.5	5.12	0.3	5.86e-7	Inflammatory bowel disease;
CESC	cis	rs4423214	0.879	rs1792264	chr11:71150247	C/T	cg05163923	chr11:71159392	DHCR7	-0.6	-7.02	-0.4	1.83e-11	Vitamin D levels;
CESC	cis	rs7647973	1.000	rs10865956	chr3:49581559	C/A	cg06212747	chr3:49208901	KLHDC8B	0.59	7.9	0.44	7.38e-14	Menarche (age at onset);
CESC	cis	rs875971	0.545	rs1638735	chr7:66095738	C/T	cg25405998	chr7:65216604	CCT6P1	0.45	5.19	0.3	4.22e-7	Aortic root size;
CESC	cis	rs4975616	0.804	rs457130	chr5:1336178	A/T	cg06550200	chr5:1325588	CLPTM1L	-0.66	-9.89	-0.52	7.55e-20	Lung cancer;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg21055707	chr12:110486280	C12orf76	-0.44	-6.11	-0.35	3.6e-9	Gambling;
CESC	cis	rs4700695	0.511	rs29443	chr5:65504927	G/A	cg21114390	chr5:65439923	SFRS12	-0.47	-5.62	-0.33	4.75e-8	Facial morphology (factor 19);
CESC	cis	rs3768617	0.510	rs2027075	chr1:183073266	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.89	14.36	0.66	5.5e-35	Fuchs's corneal dystrophy;
CESC	cis	rs8031584	0.678	rs4779790	chr15:31164595	T/C	cg08704250	chr15:31115839	NA	-0.68	-9.07	-0.49	2.76e-17	Huntington's disease progression;
CESC	cis	rs2033711	0.870	rs1465789	chr19:58946056	C/T	cg00825309	chr19:58991885	ZNF446	-0.53	-7.45	-0.42	1.29e-12	Uric acid clearance;
CESC	cis	rs4843747	0.671	rs4075998	chr16:88106776	G/A	cg06915872	chr16:87998081	BANP	0.44	5.24	0.31	3.36e-7	Menopause (age at onset);
CESC	cis	rs1008375	1.000	rs1558378	chr4:17650351	T/C	cg15017067	chr4:17643749	FAM184B	0.38	5.35	0.31	1.86e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	trans	rs7088969	0.587	rs9888017	chr10:119553728	A/G	cg11827998	chr14:105995685	TMEM121	-0.42	-6.13	-0.35	3.19e-9	Homeostasis model assessment of beta-cell function (dietary factor interaction);
CESC	cis	rs290268	1.000	rs290271	chr9:93551619	G/A	cg02608019	chr9:93564028	SYK	0.64	9.39	0.5	2.82e-18	Platelet count;
CESC	cis	rs826838	1.000	rs1719830	chr12:39096992	T/G	cg13010199	chr12:38710504	ALG10B	-0.4	-5.54	-0.32	7.33e-8	Heart rate;
CESC	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg24829409	chr8:58192753	C8orf71	-0.69	-7.77	-0.43	1.77e-13	Developmental language disorder (linguistic errors);
CESC	cis	rs644799	0.648	rs1255182	chr11:95472391	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.41	5.76	0.33	2.28e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs8114671	0.551	rs4911162	chr20:33411425	G/C	cg24642439	chr20:33292090	TP53INP2	0.46	5.51	0.32	8.4e-8	Height;
CESC	cis	rs780096	0.526	rs1647276	chr2:27688601	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.32	-5.97	-0.34	7.45e-9	Total body bone mineral density;
CESC	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg14893161	chr1:205819251	PM20D1	-0.74	-12.71	-0.62	3.27e-29	Monocyte percentage of white cells;
CESC	cis	rs1707322	0.717	rs3014245	chr1:46086913	C/T	cg05343316	chr1:45956843	TESK2	-0.53	-6.5	-0.37	3.98e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs4268898	1.000	rs6707781	chr2:24441883	T/G	cg20701182	chr2:24300061	SF3B14	-0.43	-5.28	-0.31	2.67e-7	Asthma;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg24043861	chr14:73396628	DCAF4	-0.45	-6.13	-0.35	3.18e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs7296418	0.699	rs11057254	chr12:123794581	A/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.32	-5.11	-0.3	6.27e-7	Platelet count;
CESC	cis	rs6541297	1.000	rs1997947	chr1:230283764	A/G	cg20703242	chr1:230279135	GALNT2	-0.68	-10.97	-0.56	2.42e-23	Coronary artery disease;
CESC	trans	rs526821	0.553	rs519637	chr11:55295935	A/T	cg15704280	chr7:45808275	SEPT13	-0.52	-6.37	-0.36	8.1e-10	Pediatric bone mineral density (spine);
CESC	trans	rs61931739	0.817	rs304313	chr12:34216898	C/T	cg26384229	chr12:38710491	ALG10B	0.5	6.83	0.39	5.7e-11	Morning vs. evening chronotype;
CESC	cis	rs6860806	0.507	rs274572	chr5:131710917	T/G	cg07395648	chr5:131743802	NA	0.41	5.35	0.31	1.86e-7	Breast cancer;
CESC	cis	rs7264396	0.563	rs2425138	chr20:34345710	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.68	7.26	0.41	4.32e-12	Total cholesterol levels;
CESC	trans	rs10411161	0.690	rs7252336	chr19:52389514	C/T	cg22319618	chr22:45562946	NUP50	-0.76	-7.71	-0.43	2.6e-13	Breast cancer;
CESC	cis	rs7412746	0.611	rs10788794	chr1:150728676	T/C	cg04414720	chr1:150670196	GOLPH3L	0.56	7.34	0.41	2.56e-12	Melanoma;
CESC	cis	rs9322193	0.923	rs4421206	chr6:150004027	A/C	cg13206674	chr6:150067644	NUP43	0.45	6.47	0.37	4.82e-10	Lung cancer;
CESC	cis	rs1538970	1.000	rs61791368	chr1:45867944	T/C	cg24296786	chr1:45957014	TESK2	-0.44	-5.04	-0.3	8.63e-7	Platelet count;
CESC	cis	rs1797885	0.564	rs2633443	chr3:12600837	G/A	cg26432171	chr3:12704882	RAF1	-0.5	-6.61	-0.38	2.15e-10	Immature fraction of reticulocytes;
CESC	cis	rs796364	0.755	rs6739563	chr2:201134216	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	0.57	5.2	0.3	3.92e-7	Schizophrenia;
CESC	cis	rs61931739	0.500	rs10844845	chr12:34381117	C/T	cg23762105	chr12:34175262	ALG10	-0.39	-5.05	-0.3	8.29e-7	Morning vs. evening chronotype;
CESC	cis	rs9399135	0.935	rs11754504	chr6:135321509	C/T	cg22676075	chr6:135203613	NA	0.51	7.23	0.41	5.22e-12	Red blood cell count;
CESC	cis	rs7044106	0.762	rs966397	chr9:123453312	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.69	10.09	0.53	1.84e-20	Hip circumference adjusted for BMI;
CESC	cis	rs2839186	0.605	rs2839173	chr21:47676711	G/A	cg00815214	chr21:47717953	NA	-0.36	-5.35	-0.31	1.91e-7	Testicular germ cell tumor;
CESC	cis	rs4523957	0.786	rs216213	chr17:2134225	G/A	cg16513277	chr17:2031491	SMG6	0.63	8.71	0.47	3.27e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs9443189	0.615	rs6453829	chr6:76268509	C/T	cg01950844	chr6:76311363	SENP6	0.87	9.17	0.49	1.36e-17	Prostate cancer;
CESC	cis	rs6461049	0.519	rs3778992	chr7:2175313	C/G	cg04267008	chr7:1944627	MAD1L1	-0.49	-5.89	-0.34	1.19e-8	Schizophrenia;
CESC	trans	rs61931739	0.500	rs7977194	chr12:34408459	G/A	cg13010199	chr12:38710504	ALG10B	0.49	6.3	0.36	1.26e-9	Morning vs. evening chronotype;
CESC	cis	rs1005277	0.505	rs200937	chr10:38135772	T/C	cg00409905	chr10:38381863	ZNF37A	-0.55	-7.6	-0.42	5.03e-13	Extrinsic epigenetic age acceleration;
CESC	cis	rs875971	0.545	rs4441996	chr7:65588220	T/C	cg19163074	chr7:65112434	INTS4L2	0.46	5.04	0.3	8.72e-7	Aortic root size;
CESC	cis	rs7582720	1.000	rs72934737	chr2:203740798	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.32	0.41	3.04e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs897080	0.515	rs698763	chr2:44573624	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.47	5.66	0.33	3.83e-8	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04095345	chr6:34857663	ANKS1A	-0.57	-6.89	-0.39	4.07e-11	Gut microbiome composition (summer);
CESC	cis	rs3096299	0.632	rs8051537	chr16:89544384	T/A	cg08392591	chr16:89556376	ANKRD11	0.56	7.59	0.42	5.32e-13	Multiple myeloma (IgH translocation);
CESC	cis	rs10848704	0.637	rs11062351	chr12:2881763	C/T	cg19995117	chr12:2880862	NA	0.57	9.66	0.51	4.08e-19	Quantitative traits;
CESC	cis	rs7666738	0.830	rs10470894	chr4:99039107	G/A	cg03467027	chr4:99064603	C4orf37	0.47	5.96	0.34	8.08e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs736408	0.609	rs2268025	chr3:52795224	A/T	cg18099408	chr3:52552593	STAB1	-0.33	-5.19	-0.3	4.21e-7	Bipolar disorder;
CESC	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg10150615	chr22:24372951	LOC391322	0.6	8.0	0.44	3.97e-14	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs17711722	0.740	rs7809991	chr7:65406218	A/G	cg26939375	chr7:64535504	NA	0.77	11.14	0.56	6.68e-24	Calcium levels;
CESC	cis	rs4604732	0.642	rs4472786	chr1:247636518	G/A	cg12758973	chr1:247694275	LOC148824;OR2C3	0.38	5.43	0.32	1.26e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs12479064	0.724	rs4851203	chr2:99986932	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.55	-6.64	-0.38	1.79e-10	Chronic sinus infection;
CESC	trans	rs7985867	0.840	rs675945	chr13:26032877	G/A	cg26929337	chr19:52511726	ZNF615	0.45	6.26	0.36	1.58e-9	Common carotid intima-media thickness;
CESC	cis	rs34375054	0.738	rs10773145	chr12:125625603	C/T	cg06287003	chr12:125626642	AACS	0.33	5.28	0.31	2.74e-7	Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs10924970	0.649	rs12753233	chr1:235487094	C/T	cg26050004	chr1:235667680	B3GALNT2	0.44	5.1	0.3	6.38e-7	Asthma;
CESC	cis	rs858239	0.712	rs200717	chr7:23392271	A/G	cg23682824	chr7:23144976	KLHL7	0.39	5.22	0.31	3.55e-7	Cerebrospinal fluid biomarker levels;
CESC	cis	rs2985684	1.000	rs2985696	chr14:50094913	C/A	cg10008539	chr14:50087325	RPL36AL;MGAT2	-0.48	-5.56	-0.32	6.45e-8	Carotid intima media thickness;
CESC	cis	rs76878669	0.561	rs2279861	chr11:66133336	A/G	cg18002602	chr11:66138449	SLC29A2	0.4	6.62	0.38	1.93e-10	Educational attainment (years of education);
CESC	cis	rs780096	0.526	rs780112	chr2:27665361	C/G	cg12648201	chr2:27665141	KRTCAP3	-0.35	-6.56	-0.37	2.79e-10	Total body bone mineral density;
CESC	cis	rs3820928	0.874	rs6718057	chr2:227834349	T/G	cg11843606	chr2:227700838	RHBDD1	-0.45	-5.77	-0.33	2.22e-8	Pulmonary function;
CESC	cis	rs4888262	0.604	rs12935075	chr16:74676033	A/T	cg01733217	chr16:74700730	RFWD3	0.94	12.4	0.61	3.68e-28	Testicular germ cell tumor;
CESC	cis	rs933688	1.000	rs12651840	chr5:90729592	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.17	16.18	0.7	2e-41	Smoking behavior;
CESC	cis	rs897080	0.515	rs786403	chr2:44710788	G/A	cg04920474	chr2:44395004	PPM1B	0.41	5.16	0.3	4.83e-7	Height;
CESC	cis	rs11792861	0.926	rs1333344	chr9:111776224	C/T	cg13535736	chr9:111863775	C9orf5	-0.44	-5.85	-0.34	1.48e-8	Menarche (age at onset);
CESC	cis	rs2841277	0.676	rs4264326	chr14:105411700	A/G	cg17340268	chr14:105411764	AHNAK2	-0.5	-6.7	-0.38	1.24e-10	Rheumatoid arthritis;
CESC	cis	rs7666738	0.752	rs62318905	chr4:99036103	T/G	cg18180107	chr4:99064573	C4orf37	0.41	5.29	0.31	2.52e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs8017423	0.900	rs7141887	chr14:90705364	G/T	cg14092571	chr14:90743983	NA	-0.58	-8.54	-0.46	1.04e-15	Mortality in heart failure;
CESC	cis	rs710216	0.957	rs841563	chr1:43429520	C/T	cg07803811	chr1:43423981	SLC2A1	0.47	5.04	0.3	8.75e-7	Red cell distribution width;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg22467232	chr5:1816093	NDUFS6	-0.5	-6.84	-0.39	5.59e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs8114671	0.967	rs3746427	chr20:33730464	A/G	cg24642439	chr20:33292090	TP53INP2	0.46	5.71	0.33	2.98e-8	Height;
CESC	cis	rs2012796	0.956	rs10450940	chr14:81825326	C/A	cg02996355	chr14:81879375	NA	0.5	5.86	0.34	1.34e-8	Night sleep phenotypes;
CESC	cis	rs9916302	0.706	rs9893735	chr17:37469858	A/C	cg07936489	chr17:37558343	FBXL20	0.92	10.37	0.54	2.23e-21	Glomerular filtration rate (creatinine);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04838709	chr14:21151782	ANG;RNASE4	-0.59	-6.98	-0.39	2.43e-11	Gut microbiome composition (summer);
CESC	cis	rs478304	0.654	rs12289836	chr11:65436888	C/T	cg27068330	chr11:65405492	SIPA1	0.43	5.33	0.31	2.12e-7	Acne (severe);
CESC	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg23131131	chr22:24373011	LOC391322	-0.63	-8.54	-0.46	1.06e-15	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs826838	1.000	rs11183196	chr12:38685915	G/T	cg13010199	chr12:38710504	ALG10B	0.62	8.78	0.47	2.05e-16	Heart rate;
CESC	cis	rs1577917	1.000	rs10944163	chr6:86658693	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.49	-6.29	-0.36	1.32e-9	Response to antipsychotic treatment;
CESC	cis	rs950027	0.620	rs1145076	chr15:45684508	G/T	cg21132104	chr15:45694354	SPATA5L1	0.65	8.35	0.46	3.84e-15	Response to fenofibrate (adiponectin levels);
CESC	cis	rs798766	1.000	rs798762	chr4:1731150	T/C	cg05874882	chr4:1763078	NA	-0.61	-8.54	-0.46	1.07e-15	Bladder cancer;Urinary bladder cancer;
CESC	cis	rs2576037	0.526	rs2571026	chr18:44561795	C/T	cg19077165	chr18:44547161	KATNAL2	0.54	8.01	0.44	3.56e-14	Personality dimensions;
CESC	cis	rs7582720	1.000	rs72934763	chr2:203758396	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.39	0.41	1.96e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs61931739	0.500	rs7137392	chr12:34447074	T/C	cg23762105	chr12:34175262	ALG10	-0.4	-5.22	-0.31	3.7e-7	Morning vs. evening chronotype;
CESC	cis	rs4523957	0.579	rs903160	chr17:2091765	C/T	cg16513277	chr17:2031491	SMG6	-0.64	-8.92	-0.48	7.58e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg00348771	chr1:165599927	MGST3	-0.46	-6.24	-0.36	1.68e-9	Asthma;
CESC	cis	rs477895	0.653	rs11606544	chr11:63896901	C/T	cg04317338	chr11:64019027	PLCB3	0.86	8.93	0.48	7.13e-17	Mean platelet volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24771206	chr2:203735709	ICA1L	0.6	6.93	0.39	3.24e-11	Gut microbiome composition (summer);
CESC	cis	rs4076764	0.958	rs11584957	chr1:163392937	C/T	cg06092702	chr1:163392909	NA	-0.42	-6.09	-0.35	4e-9	Motion sickness;
CESC	cis	rs10504229	0.724	rs73603871	chr8:58107612	A/G	cg21724239	chr8:58056113	NA	0.57	5.9	0.34	1.08e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs12249377	0.519	rs12259401	chr10:92594121	T/G	cg14313238	chr10:92632228	RPP30	0.42	5.08	0.3	7.22e-7	White matter microstructure (global fractional anisotropy);
CESC	cis	rs4853012	0.838	rs61521879	chr2:74346208	T/C	cg20891558	chr2:74357851	NA	0.82	12.12	0.6	3.38e-27	Gestational age at birth (maternal effect);
CESC	cis	rs1499614	0.831	rs3800822	chr7:66147149	A/G	cg12463550	chr7:65579703	CRCP	-0.77	-6.0	-0.35	6.47e-9	Gout;
CESC	cis	rs56161922	0.749	rs3738469	chr1:207818422	G/A	cg09557387	chr1:207818395	CR1L	0.68	5.14	0.3	5.47e-7	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
CESC	trans	rs11098499	0.955	rs7685268	chr4:120162188	G/A	cg25214090	chr10:38739885	LOC399744	0.64	8.53	0.46	1.16e-15	Corneal astigmatism;
CESC	cis	rs6540559	0.673	rs1073150	chr1:210017083	G/A	cg23283495	chr1:209979779	IRF6	0.48	5.61	0.33	5.1e-8	Cleft lip with or without cleft palate;
CESC	cis	rs7618501	0.699	rs2681780	chr3:49897830	C/T	cg24110177	chr3:50126178	RBM5	-0.45	-6.05	-0.35	5.01e-9	Intelligence (multi-trait analysis);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg13789711	chr9:139743225	PHPT1	0.49	6.43	0.37	5.89e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs763014	0.833	rs3743902	chr16:632728	T/C	cg07343612	chr16:622815	PIGQ	-0.57	-8.23	-0.45	8.47e-15	Height;
CESC	cis	rs10751667	0.643	rs7942693	chr11:957832	G/A	cg06064525	chr11:970664	AP2A2	-0.48	-9.52	-0.5	1.15e-18	Alzheimer's disease (late onset);
CESC	cis	rs79349575	0.749	rs12601672	chr17:47006493	T/C	cg26022315	chr17:47021804	SNF8	0.38	5.11	0.3	6.3e-7	Type 2 diabetes;
CESC	cis	rs55794721	0.509	rs909834	chr1:25757996	A/G	cg03538708	chr1:25844672	NA	-0.42	-6.21	-0.36	2.09e-9	Plateletcrit;Mean corpuscular volume;
CESC	trans	rs4650994	0.525	rs2224811	chr1:178544323	C/T	cg05059571	chr16:84539110	KIAA1609	0.39	6.01	0.35	5.99e-9	HDL cholesterol levels;HDL cholesterol;
CESC	cis	rs1506636	0.646	rs805776	chr7:123212561	T/C	cg03229431	chr7:123269106	ASB15	-0.42	-5.51	-0.32	8.34e-8	Plateletcrit;Platelet count;
CESC	cis	rs4319547	0.737	rs7964138	chr12:122950375	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.56	-6.87	-0.39	4.45e-11	Body mass index;
CESC	cis	rs10463316	0.894	rs6875014	chr5:150754345	C/T	cg03212797	chr5:150827313	SLC36A1	-0.44	-5.64	-0.33	4.26e-8	Metabolite levels (Pyroglutamine);
CESC	cis	rs6687430	0.532	rs2150038	chr1:10609973	G/T	cg20482658	chr1:10539492	PEX14	0.42	8.9	0.48	9.19e-17	Hand grip strength;
CESC	cis	rs8017423	0.838	rs11845950	chr14:90723962	T/A	cg14092571	chr14:90743983	NA	-0.55	-8.33	-0.46	4.53e-15	Mortality in heart failure;
CESC	cis	rs1874326	0.545	rs4620232	chr7:138110210	A/G	cg18008034	chr7:138118925	NA	-0.41	-5.14	-0.3	5.34e-7	Quantitative traits;
CESC	cis	rs9399137	0.561	rs11753985	chr6:135280438	C/T	cg22676075	chr6:135203613	NA	0.54	7.01	0.4	2.04e-11	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	cis	rs10870270	1.000	rs4880263	chr10:133787629	C/T	cg26149184	chr10:133730230	NA	0.4	5.42	0.32	1.35e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs561341	1.000	rs4795667	chr17:30244443	T/C	cg00745463	chr17:30367425	LRRC37B	-0.61	-5.86	-0.34	1.35e-8	Hip circumference adjusted for BMI;
CESC	cis	rs7503807	1.000	rs901064	chr17:78596040	C/T	cg09596252	chr17:78655493	RPTOR	-0.52	-7.65	-0.43	3.84e-13	Obesity;
CESC	cis	rs929354	0.772	rs10228145	chr7:157007337	A/G	cg05182265	chr7:156933206	UBE3C	-0.51	-7.45	-0.42	1.3e-12	Body mass index;
CESC	cis	rs2777491	0.540	rs7164684	chr15:41705008	G/T	cg02330683	chr15:41787940	ITPKA	0.42	5.03	0.3	9.14e-7	Ulcerative colitis;
CESC	cis	rs5769707	0.967	rs739248	chr22:50025205	T/C	cg20744362	chr22:50050164	C22orf34	0.46	8.05	0.44	2.79e-14	Monocyte count;Monocyte percentage of white cells;
CESC	trans	rs2115172	0.836	rs4835799	chr5:122762229	A/G	cg08555112	chr17:48942811	TOB1	0.45	6.05	0.35	5.02e-9	Weight;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24696268	chr4:49526636	NA	-0.55	-6.84	-0.39	5.51e-11	Gut microbiome composition (summer);
CESC	cis	rs875971	0.545	rs316323	chr7:65610989	C/T	cg11764359	chr7:65958608	NA	-0.79	-9.51	-0.5	1.18e-18	Aortic root size;
CESC	cis	rs4835473	0.932	rs2323190	chr4:144665435	C/T	cg25736465	chr4:144833511	NA	-0.35	-5.57	-0.32	6.16e-8	Immature fraction of reticulocytes;
CESC	cis	rs1062177	0.855	rs1346489	chr5:151266534	C/T	cg12924095	chr5:151150029	G3BP1	0.39	5.53	0.32	7.7e-8	Preschool internalizing problems;
CESC	cis	rs7580658	0.963	rs4233583	chr2:128060068	C/A	cg10021288	chr2:128175891	PROC	-0.42	-6.62	-0.38	1.93e-10	Protein C levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26401633	chr14:73925225	NUMB	-0.57	-6.71	-0.38	1.16e-10	Gut microbiome composition (summer);
CESC	cis	rs5753618	0.561	rs4603880	chr22:31744721	T/C	cg13145458	chr22:31556086	RNF185	-0.49	-5.52	-0.32	8.27e-8	Colorectal cancer;
CESC	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg24642844	chr7:1081250	C7orf50	-0.66	-8.28	-0.45	6.24e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7246657	0.943	rs9676967	chr19:37928089	G/C	cg23950597	chr19:37808831	NA	-0.55	-5.99	-0.35	6.69e-9	Coronary artery calcification;
CESC	cis	rs9612	1.000	rs61002661	chr19:44269032	T/A	cg08581076	chr19:44259116	C19orf61	0.48	5.69	0.33	3.4e-8	Exhaled nitric oxide output;
CESC	cis	rs7666738	0.791	rs1830231	chr4:99026185	A/C	cg03467027	chr4:99064603	C4orf37	0.49	6.18	0.35	2.44e-9	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12343791	chr22:39240109	NPTXR	0.59	6.57	0.37	2.58e-10	Gut microbiome composition (summer);
CESC	cis	rs6500395	1.000	rs3743779	chr16:48574040	T/G	cg04672837	chr16:48644449	N4BP1	0.49	6.08	0.35	4.18e-9	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs2842992	0.789	rs6908680	chr6:160218209	G/T	cg26839252	chr6:160211577	TCP1;MRPL18	0.44	5.03	0.3	9.06e-7	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs13108904	0.557	rs1250098	chr4:1238256	A/T	cg16405210	chr4:1374714	KIAA1530	0.75	10.47	0.54	1.09e-21	Obesity-related traits;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg12598048	chr15:22892705	CYFIP1	-0.47	-6.77	-0.38	8.41e-11	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs7584330	0.704	rs7598954	chr2:238364776	C/T	cg14458575	chr2:238380390	NA	0.89	11.72	0.58	7.74e-26	Prostate cancer;
CESC	cis	rs13191362	1.000	rs13191362	chr6:163033350	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.96	11.05	0.56	1.32e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs4555082	0.718	rs2816619	chr14:105732551	G/C	cg13114125	chr14:105738426	BRF1	-0.9	-10.96	-0.56	2.66e-23	Mean platelet volume;Platelet distribution width;
CESC	cis	rs3749237	0.615	rs55957735	chr3:49438158	G/A	cg03060546	chr3:49711283	APEH	0.75	11.31	0.57	1.91e-24	Resting heart rate;
CESC	cis	rs6089829	1.000	rs6089829	chr20:61669036	C/T	cg08564027	chr20:61660810	NA	-0.81	-12.9	-0.62	7.11e-30	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs67311347	0.869	rs7646899	chr3:40366982	A/G	cg09455208	chr3:40491958	NA	0.48	7.97	0.44	4.61e-14	Renal cell carcinoma;
CESC	cis	rs9486719	1.000	rs2179126	chr6:96871350	A/G	cg06623918	chr6:96969491	KIAA0776	0.81	8.29	0.45	5.61e-15	Migraine;Coronary artery disease;
CESC	cis	rs10751667	0.961	rs6597971	chr11:928598	T/A	cg20946044	chr11:1010712	AP2A2	-0.42	-5.56	-0.32	6.59e-8	Alzheimer's disease (late onset);
CESC	cis	rs7727544	0.571	rs12521097	chr5:131575338	G/A	cg18758796	chr5:131593413	PDLIM4	0.38	5.05	0.3	8.06e-7	Blood metabolite levels;
CESC	cis	rs1707322	0.964	rs1707339	chr1:46513179	A/G	cg06784218	chr1:46089804	CCDC17	-0.33	-5.65	-0.33	4.08e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs12497850	0.931	rs6414613	chr3:49035885	C/T	cg07636037	chr3:49044803	WDR6	1.07	19.9	0.77	1.59e-54	Parkinson's disease;
CESC	cis	rs10089	1.000	rs10061367	chr5:127449021	T/C	cg19767477	chr5:127420684	SLC12A2	-0.41	-5.59	-0.32	5.76e-8	Ileal carcinoids;
CESC	cis	rs2095921	1	rs2095921	chr1:11033322	C/G	cg02454025	chr1:11042201	C1orf127	0.99	16.1	0.7	3.84e-41	Male-pattern baldness;
CESC	cis	rs3796352	0.892	rs2581807	chr3:53088844	G/A	cg07884673	chr3:53033167	SFMBT1	-0.64	-6.12	-0.35	3.42e-9	Immune reponse to smallpox (secreted IL-2);
CESC	cis	rs7618915	0.571	rs11130307	chr3:52607682	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	6.78	0.38	7.94e-11	Bipolar disorder;
CESC	cis	rs10779751	0.666	rs77270747	chr1:11214584	A/C	cg08854313	chr1:11322531	MTOR	-0.8	-10.59	-0.55	4.35e-22	Body mass index;
CESC	cis	rs2540647	0.908	rs2540653	chr22:18973549	G/A	cg12798833	chr22:18958832	DGCR5	0.61	6.45	0.37	5.38e-10	Blood metabolite ratios;
CESC	cis	rs2204008	0.774	rs11520237	chr12:38266978	G/A	cg26384229	chr12:38710491	ALG10B	0.68	9.7	0.51	3.2e-19	Bladder cancer;
CESC	cis	rs832540	0.552	rs702681	chr5:56218029	C/T	cg12311346	chr5:56204834	C5orf35	-0.46	-5.61	-0.33	5e-8	Coronary artery disease;
CESC	cis	rs4862750	0.872	rs6852907	chr4:187897094	A/C	cg03647317	chr4:187891568	NA	-0.39	-5.8	-0.34	1.88e-8	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4629180	1.000	rs13031791	chr2:102108790	T/C	cg04415270	chr2:102091202	RFX8	0.46	7.46	0.42	1.25e-12	Chronic rhinosinusitis with nasal polyps;
CESC	cis	rs10754283	0.967	rs1953821	chr1:90107098	C/G	cg21401794	chr1:90099060	LRRC8C	0.63	8.14	0.45	1.52e-14	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs72781680	0.611	rs7602797	chr2:24318148	C/T	cg08917208	chr2:24149416	ATAD2B	0.55	5.3	0.31	2.47e-7	Lymphocyte counts;
CESC	trans	rs73191547	0.730	rs6601420	chr8:10045721	T/C	cg11410023	chr3:96533511	EPHA6	-0.35	-6.0	-0.35	6.54e-9	Schizophrenia;
CESC	cis	rs17711722	0.510	rs11767457	chr7:65290615	C/T	cg12143784	chr7:64541923	NA	0.41	5.43	0.32	1.3e-7	Calcium levels;
CESC	cis	rs1215050	0.791	rs1506438	chr4:98789542	C/T	cg05340658	chr4:99064831	C4orf37	0.52	6.86	0.39	4.98e-11	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs12478296	1.000	rs12474070	chr2:243039738	C/T	cg06360820	chr2:242988706	NA	-0.66	-7.52	-0.42	8.51e-13	Obesity-related traits;
CESC	cis	rs8049040	0.564	rs310335	chr16:71573918	T/A	cg08717414	chr16:71523259	ZNF19	-0.59	-6.49	-0.37	4.11e-10	Blood protein levels;
CESC	cis	rs6460942	0.915	rs17444141	chr7:12460971	T/G	cg06484146	chr7:12443880	VWDE	-0.78	-9.14	-0.49	1.68e-17	Coronary artery disease;
CESC	cis	rs853679	0.517	rs6932109	chr6:28078303	A/G	cg23281280	chr6:28129359	ZNF389	-0.6	-8.58	-0.47	8.27e-16	Depression;
CESC	cis	rs1670533	1.000	rs629260	chr4:1086764	A/G	cg27284194	chr4:1044797	NA	0.48	6.17	0.35	2.6e-9	Recombination rate (females);
CESC	cis	rs963731	0.649	rs297152	chr2:39326734	G/T	cg04010122	chr2:39346883	SOS1	-0.61	-5.12	-0.3	6.01e-7	Corticobasal degeneration;
CESC	cis	rs11122272	0.732	rs2808605	chr1:231540187	A/C	cg06096015	chr1:231504339	EGLN1	0.42	6.05	0.35	4.97e-9	Hemoglobin concentration;
CESC	trans	rs7746199	0.736	rs58616630	chr6:27474715	A/G	cg06606381	chr12:133084897	FBRSL1	-1.1	-8.8	-0.48	1.75e-16	Gait speed in old age;Autism spectrum disorder or schizophrenia;
CESC	cis	rs1218582	0.772	rs906593	chr1:154885255	G/A	cg03351412	chr1:154909251	PMVK	0.7	9.54	0.51	9.98e-19	Prostate cancer;
CESC	cis	rs2290720	0.930	rs7298507	chr12:101715728	G/T	cg22051763	chr12:101673672	UTP20	-0.49	-6.06	-0.35	4.55e-9	Brain structure (hippocampal volume);
CESC	cis	rs6502050	0.667	rs9892469	chr17:80093657	T/C	cg01763666	chr17:80159506	CCDC57	-0.37	-5.1	-0.3	6.61e-7	Life satisfaction;
CESC	cis	rs2439831	0.867	rs2242068	chr15:43699304	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.92	10.28	0.53	4.31e-21	Lung cancer in ever smokers;
CESC	cis	rs72634258	0.503	rs697675	chr1:7838113	A/C	cg26816564	chr1:7831052	VAMP3	0.64	6.67	0.38	1.49e-10	Inflammatory bowel disease;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05989775	chr11:2906934	CDKN1C	0.45	6.34	0.36	1e-9	Gut microbiota (bacterial taxa);
CESC	trans	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg13565492	chr6:43139072	SRF	-0.74	-8.88	-0.48	1.02e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs11864453	1.000	rs11864453	chr16:72050480	C/T	cg01557791	chr16:72042693	DHODH	-0.67	-9.02	-0.48	3.92e-17	Fibrinogen levels;
CESC	cis	rs6121246	0.821	rs3181073	chr20:30307199	A/C	cg13852791	chr20:30311386	BCL2L1	-0.72	-7.79	-0.43	1.52e-13	Mean corpuscular hemoglobin;
CESC	cis	rs7267979	1.000	rs6050561	chr20:25334855	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.88	-18.13	-0.74	2.42e-48	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs8072100	0.934	rs6504872	chr17:45438952	C/T	cg08085267	chr17:45401833	C17orf57	-0.54	-7.43	-0.42	1.46e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs1801251	0.893	rs11687128	chr2:233608901	T/C	cg25237894	chr2:233734115	C2orf82	0.45	7.84	0.43	1.1e-13	Coronary artery disease;
CESC	cis	rs1355223	1.000	rs11601205	chr11:34768479	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.43	-5.54	-0.32	7.34e-8	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs1862618	0.627	rs744023	chr5:56197078	C/T	cg24531977	chr5:56204891	C5orf35	-0.98	-12.02	-0.59	7.7e-27	Initial pursuit acceleration;
CESC	trans	rs8014252	0.667	rs10133282	chr14:70827899	C/A	cg03123320	chr1:229394665	NA	-0.49	-6.27	-0.36	1.45e-9	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
CESC	cis	rs7243790	0.967	rs62091589	chr18:51951697	G/C	cg04730925	chr18:51795821	POLI	-0.41	-5.36	-0.31	1.78e-7	Diastolic blood pressure;
CESC	cis	rs4819052	0.851	rs9977178	chr21:46664531	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.75	9.97	0.52	4.38e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs9850225	0.719	rs4856616	chr3:80466481	A/C	cg21058987	chr14:50778937	L2HGDH;ATP5S	0.38	6.12	0.35	3.42e-9	Erectile dysfunction in type 1 diabetes;
CESC	cis	rs10791323	0.572	rs10750551	chr11:133737462	G/A	cg15485101	chr11:133734466	NA	0.37	6.19	0.36	2.32e-9	Childhood ear infection;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg24558718	chr10:853215	NA	-0.48	-6.47	-0.37	4.75e-10	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs3820928	0.874	rs10188770	chr2:227877037	G/A	cg11843606	chr2:227700838	RHBDD1	-0.48	-6.13	-0.35	3.13e-9	Pulmonary function;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04025889	chr20:32891089	AHCY	0.47	6.09	0.35	3.89e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs826838	0.904	rs1554550	chr12:39208889	G/A	cg13010199	chr12:38710504	ALG10B	0.57	7.94	0.44	5.86e-14	Heart rate;
CESC	cis	rs11630290	0.592	rs12232336	chr15:64153357	T/C	cg12036633	chr15:63758958	NA	0.46	5.67	0.33	3.82e-8	Iris characteristics;
CESC	trans	rs17783634	0.509	rs11775489	chr8:11036843	T/C	cg06636001	chr8:8085503	FLJ10661	-0.54	-6.19	-0.36	2.22e-9	Subjective well-being;
CESC	cis	rs875971	0.522	rs1968127	chr7:66056803	C/T	cg14393609	chr7:65229607	NA	-0.46	-6.16	-0.35	2.62e-9	Aortic root size;
CESC	cis	rs9467711	0.606	rs9366653	chr6:26354247	G/A	cg14345882	chr6:26364793	BTN3A2	0.6	6.29	0.36	1.33e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs11098499	0.687	rs71610270	chr4:120287436	A/G	cg24375607	chr4:120327624	NA	0.42	5.19	0.3	4.19e-7	Corneal astigmatism;
CESC	cis	rs7385804	0.796	rs221799	chr7:100288545	G/A	cg16850897	chr7:100343110	ZAN	0.52	7.17	0.4	7.5e-12	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
CESC	cis	rs9858542	1.000	rs2172252	chr3:49678307	A/T	cg07274523	chr3:49395745	GPX1	0.65	8.2	0.45	1.03e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs3733585	0.683	rs13112015	chr4:9933796	C/T	cg00071950	chr4:10020882	SLC2A9	-0.72	-12.57	-0.61	1e-28	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs698813	0.763	rs1067335	chr2:44625958	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.52	6.09	0.35	3.94e-9	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
CESC	cis	rs8103278	1.000	rs1548029	chr19:46309203	A/C	cg14061069	chr19:46274453	DMPK	-0.41	-5.56	-0.32	6.67e-8	Coronary artery disease;
CESC	trans	rs1814175	0.645	rs10444311	chr11:49986906	A/G	cg15704280	chr7:45808275	SEPT13	-1.01	-19.02	-0.76	1.83e-51	Height;
CESC	cis	rs425277	0.628	rs3107145	chr1:2047547	G/A	cg23803603	chr1:2058230	PRKCZ	-0.35	-5.85	-0.34	1.42e-8	Height;
CESC	cis	rs60843830	1.000	rs3791224	chr2:221981	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.89	11.71	0.58	8.48e-26	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg07677032	chr17:61819896	STRADA	-0.45	-6.1	-0.35	3.8e-9	Prudent dietary pattern;
CESC	cis	rs7216064	1.000	rs11870068	chr17:65944515	A/C	cg12091567	chr17:66097778	LOC651250	-0.67	-6.79	-0.38	7.39e-11	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs10504073	0.584	rs4873300	chr8:49902201	C/G	cg00325661	chr8:49890786	NA	0.55	8.31	0.45	5.1e-15	Blood metabolite ratios;
CESC	cis	rs7247513	0.897	rs12979146	chr19:12717904	C/T	cg01871581	chr19:12707946	ZNF490	-0.89	-15.22	-0.68	5.25e-38	Bipolar disorder;
CESC	cis	rs2479106	0.591	rs16926721	chr9:126403335	G/C	cg16191174	chr9:126692580	DENND1A	0.4	5.58	0.32	5.94e-8	Polycystic ovary syndrome;
CESC	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	-0.92	-13.38	-0.64	1.5e-31	Prudent dietary pattern;
CESC	cis	rs9549367	0.713	rs3024756	chr13:113822950	G/C	cg18105134	chr13:113819100	PROZ	-0.65	-8.24	-0.45	8.15e-15	Platelet distribution width;
CESC	cis	rs3733585	0.699	rs7699609	chr4:9961059	A/G	cg02734326	chr4:10020555	SLC2A9	-0.43	-6.01	-0.35	6.1e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg16394138	chr1:180601363	XPR1	-0.49	-6.46	-0.37	4.97e-10	Height;
CESC	cis	rs873946	0.586	rs3793682	chr10:134564563	C/T	cg18305652	chr10:134549665	INPP5A	0.45	6.26	0.36	1.53e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	trans	rs6934970	0.696	rs4945908	chr6:112996839	A/G	cg05146922	chr2:10634174	NA	-0.38	-6.03	-0.35	5.61e-9	Bipolar disorder (body mass index interaction);
CESC	cis	rs11764590	0.950	rs55683212	chr7:2078855	G/C	cg23422044	chr7:1970798	MAD1L1	-0.48	-5.22	-0.31	3.61e-7	Neuroticism;
CESC	cis	rs4141404	0.640	rs9606854	chr22:31930567	C/T	cg13145458	chr22:31556086	RNF185	-0.58	-6.26	-0.36	1.58e-9	Paclitaxel-induced neuropathy;
CESC	cis	rs6901004	0.716	rs35312643	chr6:111574536	C/A	cg15721981	chr6:111408429	SLC16A10	0.38	5.43	0.32	1.26e-7	Blood metabolite levels;
CESC	cis	rs8070624	0.574	rs11078408	chr17:17876011	A/G	cg16928487	chr17:17741425	SREBF1	-0.54	-8.64	-0.47	5.35e-16	Total body bone mineral density;
CESC	cis	rs9875589	0.509	rs1601868	chr3:14065450	T/C	cg19554555	chr3:13937349	NA	-0.44	-5.6	-0.33	5.43e-8	Ovarian reserve;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06185204	chr15:80351985	ZFAND6	-0.67	-7.89	-0.44	8.09e-14	Gut microbiome composition (summer);
CESC	cis	rs10504073	0.647	rs12549138	chr8:50007203	C/T	cg00325661	chr8:49890786	NA	0.57	8.45	0.46	1.97e-15	Blood metabolite ratios;
CESC	cis	rs7647973	0.600	rs12631989	chr3:49273996	C/T	cg07636037	chr3:49044803	WDR6	0.8	13.11	0.63	1.37e-30	Menarche (age at onset);
CESC	cis	rs910316	0.737	rs175499	chr14:75535927	G/A	cg08847533	chr14:75593920	NEK9	-0.91	-15.78	-0.7	5.15e-40	Height;
CESC	cis	rs6952808	0.656	rs73048919	chr7:2103637	C/A	cg04267008	chr7:1944627	MAD1L1	-0.61	-7.41	-0.41	1.71e-12	Bipolar disorder and schizophrenia;
CESC	cis	rs2228479	0.681	rs4287569	chr16:89957815	A/G	cg06558623	chr16:89946397	TCF25	0.57	5.7	0.33	3.26e-8	Skin colour saturation;
CESC	cis	rs10504229	0.906	rs7846666	chr8:58172302	T/C	cg05313129	chr8:58192883	C8orf71	-0.45	-5.6	-0.33	5.3e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs801193	0.548	rs7805152	chr7:66209253	C/T	cg11764359	chr7:65958608	NA	0.73	10.6	0.55	4.14e-22	Aortic root size;
CESC	trans	rs7672847	0.547	rs61651883	chr4:170460665	T/C	cg19308436	chr1:237949471	RYR2	0.63	6.82	0.39	6.26e-11	Subjective well-being;
CESC	cis	rs4819052	0.679	rs2838860	chr21:46684904	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.86	12.94	0.62	5.1e-30	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs8067545	0.611	rs2526482	chr17:20119133	C/T	cg13482628	chr17:19912719	NA	-0.43	-5.82	-0.34	1.66e-8	Schizophrenia;
CESC	cis	rs7586879	1.000	rs7608185	chr2:25115432	G/C	cg01884057	chr2:25150051	NA	0.28	5.12	0.3	5.86e-7	Body mass index;
CESC	cis	rs12142240	0.667	rs12062	chr1:46830447	G/T	cg10495392	chr1:46806563	NSUN4	-0.57	-6.18	-0.35	2.44e-9	Menopause (age at onset);
CESC	cis	rs2797160	0.967	rs1578793	chr6:126015057	A/G	cg05901451	chr6:126070800	HEY2	0.46	6.55	0.37	2.89e-10	Endometrial cancer;
CESC	cis	rs9911578	0.967	rs72628392	chr17:56506160	A/G	cg05425664	chr17:57184151	TRIM37	0.48	6.73	0.38	1.06e-10	Intelligence (multi-trait analysis);
CESC	cis	rs950173	1.000	rs6716901	chr2:172673453	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.66	-5.12	-0.3	5.83e-7	Hippocampal volume;
CESC	cis	rs6460942	1.000	rs7808819	chr7:12297440	C/T	cg10578991	chr7:12443926	VWDE	-0.56	-5.78	-0.33	2.08e-8	Coronary artery disease;
CESC	cis	rs7220401	0.515	rs8080772	chr17:28413129	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.64	-6.77	-0.38	8.1e-11	Coronary artery disease;
CESC	cis	rs875971	0.893	rs62465470	chr7:65601218	T/C	cg12463550	chr7:65579703	CRCP	-0.5	-6.29	-0.36	1.3e-9	Aortic root size;
CESC	cis	rs6032067	0.777	rs55767422	chr20:43802497	A/G	cg10761708	chr20:43804764	PI3	0.56	6.65	0.38	1.7e-10	Blood protein levels;
CESC	cis	rs1799949	1.000	rs11657053	chr17:41191129	G/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.64	8.29	0.45	5.55e-15	Menopause (age at onset);
CESC	cis	rs911555	0.713	rs10162425	chr14:103931621	C/T	cg24130564	chr14:104152367	KLC1	-0.5	-6.66	-0.38	1.55e-10	Intelligence (multi-trait analysis);
CESC	cis	rs9915657	0.595	rs10438697	chr17:70055734	A/G	cg09344028	chr17:70110421	NA	-0.38	-6.84	-0.39	5.5e-11	Thyroid hormone levels;
CESC	cis	rs763014	0.931	rs710925	chr16:633354	G/A	cg07343612	chr16:622815	PIGQ	-0.57	-8.23	-0.45	8.47e-15	Height;
CESC	cis	rs2032447	0.714	rs199725	chr6:25953684	A/G	cg12310025	chr6:25882481	NA	-0.43	-6.22	-0.36	1.95e-9	Intelligence (multi-trait analysis);
CESC	cis	rs7818345	1.000	rs4618712	chr8:19302621	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.33	6.0	0.35	6.57e-9	Language performance in older adults (adjusted for episodic memory);
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg11461836	chr5:176739316	MXD3	-0.47	-6.1	-0.35	3.68e-9	Asthma;
CESC	cis	rs7829975	0.593	rs2979241	chr8:8303353	G/C	cg15556689	chr8:8085844	FLJ10661	0.61	8.1	0.45	2.05e-14	Mood instability;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg08017189	chr16:85680248	KIAA0182	0.44	6.46	0.37	4.93e-10	Fibrinogen levels;
CESC	cis	rs9322193	0.923	rs2297930	chr6:150039496	T/C	cg13206674	chr6:150067644	NUP43	0.46	6.59	0.38	2.43e-10	Lung cancer;
CESC	cis	rs60843830	1.000	rs36216559	chr2:262335	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.89	12.23	0.6	1.41e-27	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs7818688	1.000	rs10092003	chr8:96036422	A/G	cg16049864	chr8:95962084	TP53INP1	0.61	5.77	0.33	2.24e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00320159	chr20:48429251	SLC9A8	0.56	6.0	0.35	6.35e-9	Gut microbiome composition (summer);
CESC	cis	rs4718428	0.705	rs28648401	chr7:66367132	T/C	cg25985355	chr7:65971099	NA	-0.34	-5.12	-0.3	5.99e-7	Corneal structure;
CESC	cis	rs9322193	0.923	rs4870509	chr6:150023348	C/G	cg13206674	chr6:150067644	NUP43	0.41	5.76	0.33	2.36e-8	Lung cancer;
CESC	cis	rs35110281	0.667	rs2250773	chr21:45087786	T/C	cg04455712	chr21:45112962	RRP1B	0.47	7.73	0.43	2.3e-13	Mean corpuscular volume;
CESC	cis	rs7914558	0.966	rs7085598	chr10:104650128	T/C	cg04362960	chr10:104952993	NT5C2	0.46	5.99	0.35	6.65e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs1552244	0.938	rs67667957	chr3:10167264	G/C	cg00166722	chr3:10149974	C3orf24	0.45	5.84	0.34	1.54e-8	Alzheimer's disease;
CESC	cis	rs3741404	0.825	rs7111753	chr11:63942189	A/G	cg18225595	chr11:63971243	STIP1	0.74	10.32	0.54	3.36e-21	Platelet count;
CESC	cis	rs4727027	0.865	rs13236754	chr7:148845773	G/A	cg23583168	chr7:148888333	NA	-0.81	-12.65	-0.61	5.11e-29	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs2046867	0.774	rs9820293	chr3:72876237	T/A	cg25664220	chr3:72788482	NA	-0.4	-5.68	-0.33	3.52e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CESC	cis	rs7584330	0.737	rs6431539	chr2:238360708	G/T	cg14458575	chr2:238380390	NA	0.55	7.52	0.42	8.53e-13	Prostate cancer;
CESC	cis	rs12579753	0.879	rs11115010	chr12:82165895	G/T	cg24719984	chr12:82153464	PPFIA2	-0.37	-5.35	-0.31	1.9e-7	Resting heart rate;
CESC	cis	rs2439831	0.867	rs2614811	chr15:43913487	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.8	8.31	0.45	5.16e-15	Lung cancer in ever smokers;
CESC	cis	rs561341	1.000	rs8073186	chr17:30244956	T/C	cg12193833	chr17:30244370	NA	-0.6	-6.36	-0.36	8.68e-10	Hip circumference adjusted for BMI;
CESC	cis	rs7208859	0.623	rs8075341	chr17:29136565	A/G	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.1e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs763121	0.853	rs5750664	chr22:39072769	C/T	cg06544989	chr22:39130855	UNC84B	0.5	8.88	0.48	1.05e-16	Menopause (age at onset);
CESC	cis	rs1707322	1.000	rs9793167	chr1:46446800	G/A	cg05343316	chr1:45956843	TESK2	0.44	5.42	0.32	1.36e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7909791	0.632	rs3752949	chr10:105670503	A/G	cg24587175	chr10:105670608	OBFC1	0.43	6.03	0.35	5.44e-9	White matter hyperintensity burden;
CESC	cis	rs7178572	1.000	rs8034133	chr15:77763712	C/G	cg22256960	chr15:77711686	NA	-0.59	-7.96	-0.44	5e-14	Type 2 diabetes;
CESC	trans	rs1814175	0.645	rs1963215	chr11:49931486	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.43	-6.36	-0.36	8.98e-10	Height;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg22541143	chr4:84377292	HELQ;MRPS18C	0.45	6.29	0.36	1.3e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs77741769	0.529	rs2047568	chr12:121243790	A/G	cg02419362	chr12:121203948	SPPL3	-0.33	-5.35	-0.31	1.89e-7	Mean corpuscular volume;
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg03209809	chr3:126422892	CHCHD6	-0.44	-6.5	-0.37	3.93e-10	Vertical cup-disc ratio;
CESC	cis	rs10779751	0.734	rs2748877	chr1:11129437	T/C	cg08854313	chr1:11322531	MTOR	0.76	10.26	0.53	4.97e-21	Body mass index;
CESC	cis	rs4704187	0.617	rs2035192	chr5:74407231	T/A	cg03227963	chr5:74354835	NA	0.32	5.94	0.34	8.7e-9	Response to amphetamines;
CESC	cis	rs7107174	1.000	rs11237462	chr11:78058812	C/A	cg02023728	chr11:77925099	USP35	0.47	6.25	0.36	1.63e-9	Testicular germ cell tumor;
CESC	cis	rs708547	0.874	rs1718869	chr4:57880232	A/C	cg16868167	chr4:57843880	C4orf14;POLR2B	0.69	7.8	0.43	1.45e-13	Response to bleomycin (chromatid breaks);
CESC	cis	rs7786808	0.707	rs11770299	chr7:158228822	G/A	cg09998033	chr7:158218633	PTPRN2	-0.43	-6.48	-0.37	4.46e-10	Obesity-related traits;
CESC	cis	rs35306767	0.953	rs11253509	chr10:964306	C/T	cg25019033	chr10:957182	NA	-0.66	-8.22	-0.45	8.89e-15	Eosinophil percentage of granulocytes;
CESC	cis	rs593982	0.858	rs663797	chr11:65552740	A/G	cg08755490	chr11:65554678	OVOL1	1.35	19.68	0.77	9.23e-54	Atopic dermatitis;
CESC	cis	rs3733585	0.673	rs6836706	chr4:9964251	T/A	cg02734326	chr4:10020555	SLC2A9	-0.43	-6.01	-0.35	6.1e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs72781680	0.611	rs72783605	chr2:24287864	A/G	cg06627628	chr2:24431161	ITSN2	-0.67	-6.42	-0.37	6.35e-10	Lymphocyte counts;
CESC	cis	rs896854	0.654	rs13274945	chr8:95986626	C/T	cg23172400	chr8:95962367	TP53INP1	-0.44	-9.11	-0.49	2.05e-17	Type 2 diabetes;
CESC	cis	rs2066819	1.000	rs116849218	chr12:56683975	C/T	cg26734620	chr12:56694298	CS	1.07	6.58	0.37	2.56e-10	Psoriasis vulgaris;
CESC	cis	rs6582630	0.555	rs7965311	chr12:38513307	G/A	cg13010199	chr12:38710504	ALG10B	-0.43	-5.56	-0.32	6.5e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs116095464	0.614	rs10067482	chr5:219328	T/G	cg22857025	chr5:266934	NA	-1.27	-18.89	-0.76	5.51e-51	Breast cancer;
CESC	cis	rs796364	0.951	rs12620298	chr2:201047184	C/T	cg23649088	chr2:200775458	C2orf69	-0.55	-5.41	-0.32	1.39e-7	Schizophrenia;
CESC	cis	rs2243480	1.000	rs458291	chr7:65520479	C/A	cg12463550	chr7:65579703	CRCP	0.67	5.38	0.31	1.67e-7	Diabetic kidney disease;
CESC	cis	rs4713118	0.629	rs203887	chr6:28021269	C/T	cg23161317	chr6:28129485	ZNF389	0.46	5.41	0.32	1.42e-7	Parkinson's disease;
CESC	cis	rs7520050	0.966	rs1707340	chr1:46514942	T/C	cg03146154	chr1:46216737	IPP	-0.44	-5.72	-0.33	2.88e-8	Red blood cell count;Reticulocyte count;
CESC	trans	rs79976124	0.837	rs12201218	chr6:66653619	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.71	-8.49	-0.46	1.47e-15	Type 2 diabetes;
CESC	cis	rs868036	0.645	rs4776987	chr15:68123915	A/T	cg08079166	chr15:68083412	MAP2K5	-0.4	-5.23	-0.31	3.39e-7	Restless legs syndrome;
CESC	cis	rs798554	0.660	rs2527687	chr7:2838485	G/A	cg13628971	chr7:2884303	GNA12	0.4	5.06	0.3	8.02e-7	Height;
CESC	trans	rs61931739	0.500	rs10844862	chr12:34531965	A/T	cg26384229	chr12:38710491	ALG10B	0.54	7.53	0.42	8.03e-13	Morning vs. evening chronotype;
CESC	cis	rs7726839	0.540	rs58599998	chr5:596087	A/G	cg16447950	chr5:562315	NA	-0.59	-6.01	-0.35	6.18e-9	Obesity-related traits;
CESC	cis	rs597539	0.652	rs660614	chr11:68659488	G/A	cg21963583	chr11:68658836	MRPL21	0.38	5.39	0.31	1.55e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs11098499	0.954	rs7437420	chr4:120312903	A/G	cg09307838	chr4:120376055	NA	0.92	12.66	0.61	4.96e-29	Corneal astigmatism;
CESC	cis	rs13108904	0.557	rs1680041	chr4:1238521	C/T	cg05025164	chr4:1340916	KIAA1530	-0.65	-8.89	-0.48	9.35e-17	Obesity-related traits;
CESC	cis	rs3760982	0.565	rs3786956	chr19:44286829	C/T	cg11993925	chr19:44307056	LYPD5	0.44	7.46	0.42	1.26e-12	Breast cancer (estrogen-receptor negative);Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08493338	chr16:354269	AXIN1	-0.63	-7.08	-0.4	1.32e-11	Gut microbiome composition (summer);
CESC	cis	rs3741404	0.609	rs687581	chr11:63871533	G/T	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.71	-9.97	-0.52	4.4e-20	Platelet count;
CESC	cis	rs35955747	0.838	rs5997887	chr22:31543197	G/A	cg25791279	chr22:32026902	PISD	-0.43	-5.17	-0.3	4.66e-7	Neutrophil count;Sum basophil neutrophil counts;
CESC	trans	rs961253	0.899	rs654433	chr20:6380022	A/G	cg14636113	chr2:240742128	NA	-0.46	-6.08	-0.35	4.28e-9	Colorectal cancer;
CESC	cis	rs1153858	1.000	rs1365610	chr15:45694610	C/T	cg14582100	chr15:45693742	SPATA5L1	0.42	5.88	0.34	1.22e-8	Homoarginine levels;
CESC	trans	rs7618501	1.000	rs7618501	chr3:49772647	A/G	cg21582582	chr3:182698605	DCUN1D1	-0.44	-6.01	-0.35	6.2e-9	Intelligence (multi-trait analysis);
CESC	cis	rs7811142	0.830	rs73401443	chr7:99977582	T/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.74	7.36	0.41	2.29e-12	Platelet count;
CESC	cis	rs60871478	1.000	rs62432252	chr7:802886	C/G	cg05535760	chr7:792225	HEATR2	0.91	10.41	0.54	1.64e-21	Cerebrospinal P-tau181p levels;
CESC	trans	rs12310956	0.532	rs11052920	chr12:33955891	T/G	cg26384229	chr12:38710491	ALG10B	0.45	6.39	0.37	7.33e-10	Morning vs. evening chronotype;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg07832761	chr16:15188255	RRN3	-0.44	-6.47	-0.37	4.61e-10	Gambling;
CESC	cis	rs11785693	0.862	rs6994323	chr8:4996786	T/A	cg26367366	chr8:4980734	NA	0.83	7.83	0.43	1.16e-13	Neuroticism (multi-trait analysis);Neuroticism;
CESC	cis	rs2997447	0.688	rs3008431	chr1:26371281	A/G	cg19633962	chr1:26362018	EXTL1	-0.54	-5.49	-0.32	9.45e-8	QRS complex (12-leadsum);
CESC	cis	rs9987353	0.544	rs2929469	chr8:9062656	T/G	cg15556689	chr8:8085844	FLJ10661	0.47	5.52	0.32	8.21e-8	Recombination measurement;
CESC	cis	rs10129255	0.500	rs9324092	chr14:107139823	A/G	cg07470598	chr14:107239068	NA	-0.36	-5.06	-0.3	7.74e-7	Kawasaki disease;
CESC	cis	rs734999	0.545	rs4648356	chr1:2709164	C/A	cg18854424	chr1:2615690	NA	0.3	5.78	0.33	2.12e-8	Ulcerative colitis;
CESC	cis	rs6120849	0.950	rs6088732	chr20:33744134	A/G	cg24642439	chr20:33292090	TP53INP2	-0.63	-6.89	-0.39	4.16e-11	Protein C levels;
CESC	cis	rs6964587	1.000	rs55745934	chr7:91670998	T/C	cg17063962	chr7:91808500	NA	0.55	7.47	0.42	1.19e-12	Breast cancer;
CESC	cis	rs10242455	0.717	rs2687134	chr7:99331042	T/G	cg07715041	chr7:99302981	CYP3A7	-0.49	-5.86	-0.34	1.34e-8	Blood metabolite levels;
CESC	cis	rs10870270	0.957	rs3753008	chr10:133785129	A/C	cg08754478	chr10:133766260	PPP2R2D	-0.58	-7.62	-0.42	4.62e-13	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs12822507	0.732	rs7132530	chr12:12753950	T/C	cg11838227	chr12:12764436	CREBL2	0.42	5.61	0.33	5.15e-8	Systemic lupus erythematosus;
CESC	cis	rs9287719	0.967	rs6733416	chr2:10738684	C/T	cg02196655	chr2:10830764	NOL10	-0.37	-5.72	-0.33	2.87e-8	Prostate cancer;
CESC	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg11494091	chr17:61959527	GH2	0.74	12.76	0.62	2.2e-29	Prudent dietary pattern;
CESC	cis	rs1552244	0.882	rs13100734	chr3:10022878	A/G	cg08888203	chr3:10149979	C3orf24	0.5	6.18	0.35	2.44e-9	Alzheimer's disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg02277511	chr5:174905420	SFXN1	-0.48	-6.56	-0.37	2.82e-10	Fibrinogen levels;
CESC	cis	rs1707322	0.752	rs11211146	chr1:46109794	T/C	cg05343316	chr1:45956843	TESK2	0.5	6.18	0.35	2.46e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs11190604	1.000	rs11190570	chr10:102227702	G/C	cg07080220	chr10:102295463	HIF1AN	0.55	5.56	0.32	6.43e-8	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs7394190	0.748	rs11000780	chr10:75559077	G/A	cg07699608	chr10:75541558	CHCHD1	0.65	5.31	0.31	2.31e-7	Incident atrial fibrillation;
CESC	cis	rs9291683	0.632	rs7679916	chr4:10042160	C/T	cg02734326	chr4:10020555	SLC2A9	0.47	6.53	0.37	3.29e-10	Bone mineral density;
CESC	cis	rs6860806	0.507	rs270606	chr5:131650867	A/G	cg04518342	chr5:131593106	PDLIM4	0.36	5.22	0.31	3.57e-7	Breast cancer;
CESC	cis	rs4663969	0.733	rs6741669	chr2:234653192	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.49	-6.37	-0.36	8.39e-10	Total bilirubin levels in HIV-1 infection;
CESC	cis	rs11785400	0.793	rs13248524	chr8:143739343	T/C	cg10596483	chr8:143751796	JRK	0.42	5.31	0.31	2.32e-7	Schizophrenia;
CESC	cis	rs7223966	1.000	rs8075521	chr17:61804954	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.68	0.38	1.4e-10	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs769267	0.930	rs7254748	chr19:19397479	A/C	cg03709012	chr19:19516395	GATAD2A	0.95	13.92	0.65	1.91e-33	Tonsillectomy;
CESC	cis	rs1008375	1.000	rs55939327	chr4:17642937	T/A	cg15017067	chr4:17643749	FAM184B	0.35	5.07	0.3	7.59e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs7927592	0.871	rs55953412	chr11:68328283	C/T	cg20283391	chr11:68216788	NA	-0.61	-7.36	-0.41	2.26e-12	Total body bone mineral density;
CESC	cis	rs7575873	1	rs7575873	chr2:23962647	A/G	cg20701182	chr2:24300061	SF3B14	0.78	6.7	0.38	1.22e-10	Birth weight;
CESC	cis	rs62064224	0.560	rs12162135	chr17:30805795	A/C	cg25809561	chr17:30822961	MYO1D	0.54	8.4	0.46	2.83e-15	Schizophrenia;
CESC	cis	rs6754311	0.773	rs1435576	chr2:136641882	A/T	cg07169764	chr2:136633963	MCM6	0.7	8.66	0.47	4.59e-16	Mosquito bite size;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg25461793	chr19:17212553	MYO9B	0.52	6.73	0.38	1.06e-10	Fibrinogen levels;
CESC	cis	rs7927771	0.894	rs12798346	chr11:47583121	C/T	cg05585544	chr11:47624801	NA	-0.52	-8.03	-0.44	3.23e-14	Subjective well-being;
CESC	cis	rs7811142	1.000	rs6972167	chr7:100080013	G/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.84	8.38	0.46	3.05e-15	Platelet count;
CESC	cis	rs1707322	1.000	rs6657720	chr1:46386269	G/A	cg06784218	chr1:46089804	CCDC17	0.33	5.63	0.33	4.7e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7146395	1	rs7146395	chr14:75228647	A/C	cg08847533	chr14:75593920	NEK9	0.48	5.88	0.34	1.25e-8	Platelet count;
CESC	cis	rs7772486	0.686	rs4896828	chr6:145953339	A/C	cg05347473	chr6:146136440	FBXO30	0.56	7.24	0.41	4.97e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7814319	0.674	rs2643339	chr8:97246978	C/A	cg20787634	chr8:97240163	UQCRB	-0.5	-5.86	-0.34	1.36e-8	Lung function (FVC);
CESC	cis	rs6598955	0.543	rs881578	chr1:26536141	G/A	cg04990556	chr1:26633338	UBXN11	0.81	9.3	0.5	5.64e-18	Obesity-related traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09998632	chr17:46688433	HOXB7	0.55	6.05	0.35	4.99e-9	Gut microbiome composition (summer);
CESC	cis	rs589448	0.902	rs528974	chr12:69765918	A/T	cg22834771	chr12:69754056	YEATS4	-0.57	-7.68	-0.43	3.15e-13	Cerebrospinal fluid biomarker levels;
CESC	cis	rs2425143	0.915	rs74355238	chr20:34441541	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.78	-7.46	-0.42	1.25e-12	Blood protein levels;
CESC	cis	rs2842992	0.724	rs15982	chr6:160199687	T/C	cg26839252	chr6:160211577	TCP1;MRPL18	0.48	6.01	0.35	6.04e-9	Age-related macular degeneration (geographic atrophy);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg02196458	chr15:90809250	NGRN	-0.45	-6.47	-0.37	4.68e-10	Gambling;
CESC	trans	rs916888	0.821	rs415430	chr17:44859144	C/T	cg27125505	chr17:43679177	LOC644172	-0.48	-6.69	-0.38	1.34e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs9393777	0.513	rs3999471	chr6:26650306	T/C	cg12826209	chr6:26865740	GUSBL1	0.73	8.13	0.45	1.7e-14	Intelligence (multi-trait analysis);
CESC	cis	rs7811142	0.943	rs73403312	chr7:100024153	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.16	11.71	0.58	8.43e-26	Platelet count;
CESC	cis	rs2559856	1.000	rs2559855	chr12:102090080	A/G	cg00136105	chr12:102224911	GNPTAB	0.37	5.04	0.3	8.7e-7	Blood protein levels;
CESC	cis	rs1879734	0.731	rs4927028	chr1:54161545	T/C	cg23596471	chr1:54105337	GLIS1	0.35	5.56	0.32	6.52e-8	Mitral valve prolapse;
CESC	cis	rs60871478	0.636	rs6976929	chr7:901382	C/T	cg00475322	chr7:917719	C7orf20	0.46	5.1	0.3	6.53e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs7089973	0.668	rs7898347	chr10:116644324	G/A	cg23260525	chr10:116636907	FAM160B1	0.37	6.65	0.38	1.68e-10	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs1499972	0.938	rs817500	chr3:117713444	G/T	cg07612923	chr3:117604196	NA	0.75	5.15	0.3	5.13e-7	Schizophrenia;
CESC	cis	rs17376456	0.597	rs7708175	chr5:93381182	A/G	cg25358565	chr5:93447407	FAM172A	-0.47	-5.47	-0.32	1.03e-7	Diabetic retinopathy;
CESC	cis	rs12477438	0.798	rs13412764	chr2:99583733	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-10.51	-0.54	7.92e-22	Chronic sinus infection;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01688026	chr15:83735344	BTBD1	0.57	6.47	0.37	4.72e-10	Gut microbiome composition (summer);
CESC	cis	rs796364	1.000	rs35594306	chr2:200775125	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.95	-7.49	-0.42	1.06e-12	Schizophrenia;
CESC	trans	rs4950322	0.518	rs4950306	chr1:146589420	C/G	cg04954894	chr8:38089920	DDHD2	-0.59	-6.34	-0.36	9.74e-10	Protein quantitative trait loci;
CESC	cis	rs3771570	1.000	rs55645375	chr2:242269024	A/G	cg21155796	chr2:242212141	HDLBP	0.6	5.11	0.3	6.17e-7	Prostate cancer;
CESC	cis	rs6545883	0.929	rs2694625	chr2:61616055	G/A	cg15711740	chr2:61764176	XPO1	0.4	5.15	0.3	5.02e-7	Tuberculosis;
CESC	cis	rs1552244	0.882	rs2130813	chr3:10038706	A/C	cg00149659	chr3:10157352	C3orf10	0.69	8.2	0.45	1.02e-14	Alzheimer's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14557232	chr4:1368966	KIAA1530	-0.61	-6.96	-0.39	2.75e-11	Gut microbiome composition (summer);
CESC	cis	rs6570726	1.000	rs450076	chr6:145847655	G/T	cg05347473	chr6:146136440	FBXO30	0.42	5.68	0.33	3.58e-8	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs561341	0.941	rs4525554	chr17:30312819	T/C	cg12193833	chr17:30244370	NA	-0.7	-6.49	-0.37	4.19e-10	Hip circumference adjusted for BMI;
CESC	cis	rs2243480	1.000	rs1499614	chr7:65730798	A/T	cg18252515	chr7:66147081	NA	-1.36	-13.88	-0.65	2.66e-33	Diabetic kidney disease;
CESC	cis	rs909002	0.772	rs10798876	chr1:32074514	C/G	cg13919466	chr1:32135498	COL16A1	-0.47	-8.52	-0.46	1.24e-15	Intelligence (multi-trait analysis);
CESC	trans	rs9987353	0.840	rs329994	chr8:9123233	A/G	cg17598323	chr1:44440401	ATP6V0B	-0.47	-6.39	-0.37	7.44e-10	Recombination measurement;
CESC	cis	rs7618915	0.501	rs12635140	chr3:52738165	C/T	cg18337363	chr3:52569053	NT5DC2	-0.29	-5.37	-0.31	1.68e-7	Bipolar disorder;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg20382160	chr11:75526115	UVRAG	-0.49	-6.06	-0.35	4.62e-9	Asthma;
CESC	cis	rs950776	0.507	rs12912673	chr15:78810216	T/C	cg06917634	chr15:78832804	PSMA4	0.78	11.39	0.57	9.64e-25	Sudden cardiac arrest;
CESC	cis	rs12995491	0.843	rs1878809	chr2:88518315	C/T	cg18490616	chr2:88469792	THNSL2	-0.53	-7.53	-0.42	7.76e-13	Response to metformin (IC50);
CESC	cis	rs2011503	1.000	rs56280531	chr19:19585788	A/C	cg11584989	chr19:19387371	SF4	0.62	7.22	0.41	5.54e-12	Bipolar disorder;
CESC	cis	rs61931739	0.517	rs10844830	chr12:34308133	C/T	cg19457237	chr12:34500585	NA	-0.38	-5.4	-0.31	1.52e-7	Morning vs. evening chronotype;
CESC	cis	rs1953600	0.870	rs2573353	chr10:81940917	A/C	cg00277334	chr10:82204260	NA	-0.43	-5.93	-0.34	9.33e-9	Sarcoidosis;
CESC	cis	rs597539	0.652	rs686877	chr11:68637169	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.77	9.59	0.51	6.99e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs1577917	1.000	rs12663690	chr6:86640162	C/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.47	6.0	0.35	6.46e-9	Response to antipsychotic treatment;
CESC	trans	rs116095464	0.558	rs6866632	chr5:264429	C/G	cg00938859	chr5:1591904	SDHAP3	0.64	6.48	0.37	4.47e-10	Breast cancer;
CESC	cis	rs17818399	0.749	rs4142759	chr2:46783890	A/G	cg26688816	chr2:46740690	ATP6V1E2	-0.49	-5.37	-0.31	1.76e-7	Height;
CESC	cis	rs7666738	0.830	rs10028505	chr4:98962310	C/A	cg03467027	chr4:99064603	C4orf37	0.44	5.57	0.32	6.41e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6502050	0.835	rs67634087	chr17:80118168	C/T	cg23985595	chr17:80112537	CCDC57	-0.41	-6.42	-0.37	6.33e-10	Life satisfaction;
CESC	cis	rs7613875	0.620	rs17657688	chr3:50033228	C/T	cg24110177	chr3:50126178	RBM5	0.59	8.17	0.45	1.31e-14	Body mass index;
CESC	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg24054508	chr1:38273761	C1orf122;YRDC	0.45	6.17	0.35	2.53e-9	Myopia (pathological);
CESC	cis	rs2295499	0.773	rs2298961	chr4:2644961	T/A	cg27239842	chr4:2403781	ZFYVE28	-0.31	-5.19	-0.3	4.18e-7	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
CESC	cis	rs2576037	0.544	rs629097	chr18:44378097	T/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.34	5.5	0.32	8.89e-8	Personality dimensions;
CESC	cis	rs4727027	0.933	rs9718383	chr7:148857624	A/T	cg23583168	chr7:148888333	NA	0.82	12.74	0.62	2.48e-29	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs875971	0.862	rs7803416	chr7:65954199	A/G	cg18876405	chr7:65276391	NA	0.5	6.48	0.37	4.33e-10	Aortic root size;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg25235326	chr18:77243457	NFATC1	0.44	7.55	0.42	7.22e-13	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs2180341	0.751	rs9388553	chr6:127574044	A/G	cg24812749	chr6:127587940	RNF146	0.86	11.86	0.59	2.62e-26	Breast cancer;
CESC	cis	rs6460942	0.597	rs13245635	chr7:12526454	T/A	cg02935154	chr7:12443704	VWDE	-0.55	-5.53	-0.32	7.71e-8	Coronary artery disease;
CESC	cis	rs2404602	0.735	rs62028423	chr15:76754514	G/A	cg23625390	chr15:77176239	SCAPER	-0.42	-5.83	-0.34	1.58e-8	Blood metabolite levels;
CESC	cis	rs6912958	0.630	rs4707377	chr6:88280332	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-6.58	-0.37	2.55e-10	Monocyte percentage of white cells;
CESC	trans	rs10924245	0.867	rs77520445	chr1:245734275	T/C	cg05754179	chr11:125985044	NA	0.55	6.14	0.35	2.95e-9	Schizophrenia;
CESC	cis	rs59918340	0.509	rs11784862	chr8:142203452	T/C	cg23750338	chr8:142222470	SLC45A4	0.46	6.36	0.36	8.6e-10	Immature fraction of reticulocytes;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg13038030	chr17:73267041	MIF4GD	0.46	6.28	0.36	1.34e-9	Gut microbiota (bacterial taxa);
CESC	trans	rs7819412	0.521	rs10100660	chr8:11038885	T/A	cg06636001	chr8:8085503	FLJ10661	-0.53	-6.12	-0.35	3.27e-9	Triglycerides;
CESC	cis	rs9399135	0.967	rs1023179	chr6:135343829	T/A	cg22676075	chr6:135203613	NA	0.51	7.36	0.41	2.34e-12	Red blood cell count;
CESC	cis	rs12765878	1.000	rs10883943	chr10:105651416	G/T	cg24587175	chr10:105670608	OBFC1	0.32	5.36	0.31	1.81e-7	Coronary artery disease;
CESC	cis	rs151234	0.800	rs231972	chr16:28538336	A/C	cg01378222	chr16:28622494	SULT1A1	-0.5	-6.1	-0.35	3.8e-9	Platelet distribution width;
CESC	cis	rs2576037	0.526	rs6507714	chr18:44519574	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.53	7.46	0.42	1.24e-12	Personality dimensions;
CESC	cis	rs7811142	1.000	rs11761784	chr7:100039970	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.82	8.2	0.45	1.06e-14	Platelet count;
CESC	cis	rs2797160	0.967	rs1777224	chr6:126019527	T/C	cg05901451	chr6:126070800	HEY2	0.46	6.71	0.38	1.21e-10	Endometrial cancer;
CESC	trans	rs61931739	0.500	rs12371415	chr12:34521362	C/T	cg13010199	chr12:38710504	ALG10B	0.5	6.41	0.37	6.56e-10	Morning vs. evening chronotype;
CESC	cis	rs4835473	0.722	rs7666296	chr4:144920157	G/C	cg25736465	chr4:144833511	NA	-0.46	-6.85	-0.39	5.22e-11	Immature fraction of reticulocytes;
CESC	cis	rs3780486	0.846	rs7849148	chr9:33138352	A/T	cg13443165	chr9:33130375	B4GALT1	0.45	6.49	0.37	4.1e-10	IgG glycosylation;
CESC	cis	rs2280018	0.526	rs2966129	chr16:15152927	A/C	cg27102117	chr16:15229624	NA	-0.52	-7.8	-0.43	1.46e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs9611565	0.694	rs202616	chr22:41822221	C/G	cg06634786	chr22:41940651	POLR3H	0.71	7.17	0.4	7.6e-12	Vitiligo;
CESC	cis	rs3008870	0.701	rs2815358	chr1:67493778	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.61	7.91	0.44	7.21e-14	Lymphocyte percentage of white cells;
CESC	cis	rs2836950	0.502	rs2150411	chr21:40574552	G/T	cg11644478	chr21:40555479	PSMG1	-0.55	-7.63	-0.42	4.34e-13	Menarche (age at onset);
CESC	cis	rs34779708	0.931	rs58159560	chr10:35351249	C/T	cg04310649	chr10:35416472	CREM	-0.51	-6.0	-0.35	6.31e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs6502050	0.787	rs11653012	chr17:80058857	C/T	cg23985595	chr17:80112537	CCDC57	0.41	6.2	0.36	2.1e-9	Life satisfaction;
CESC	cis	rs35110281	0.776	rs2838338	chr21:45075582	T/C	cg04455712	chr21:45112962	RRP1B	0.38	5.69	0.33	3.43e-8	Mean corpuscular volume;
CESC	cis	rs5753618	0.583	rs5753601	chr22:31798259	G/T	cg00478049	chr22:31556069	RNF185	-0.43	-5.11	-0.3	6.22e-7	Colorectal cancer;
CESC	cis	rs4595586	0.545	rs1156705	chr12:39372672	C/T	cg26384229	chr12:38710491	ALG10B	0.54	7.53	0.42	7.85e-13	Morning vs. evening chronotype;
CESC	cis	rs11264213	0.591	rs274755	chr1:36544237	T/C	cg27506609	chr1:36549197	TEKT2	-0.75	-7.19	-0.4	6.77e-12	Schizophrenia;
CESC	trans	rs208520	0.874	rs208491	chr6:66928459	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.86	-9.96	-0.52	4.65e-20	Exhaled nitric oxide output;
CESC	cis	rs2303759	0.918	rs7251704	chr19:49890873	T/G	cg22133161	chr19:49891603	CCDC155	0.46	5.2	0.3	4.06e-7	Multiple sclerosis;
CESC	cis	rs11871801	0.541	rs4793090	chr17:40686342	G/A	cg21433558	chr17:40837037	CNTNAP1	-0.46	-5.92	-0.34	1.01e-8	Crohn's disease;
CESC	cis	rs780096	0.526	rs780107	chr2:27684734	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.35	-6.56	-0.37	2.79e-10	Total body bone mineral density;
CESC	cis	rs7618915	0.547	rs33967311	chr3:52683864	G/T	cg18099408	chr3:52552593	STAB1	-0.3	-5.2	-0.3	4.06e-7	Bipolar disorder;
CESC	cis	rs907612	0.638	rs11041476	chr11:1875067	C/T	cg05305434	chr11:1874049	LSP1	0.36	6.21	0.36	2.05e-9	Monocyte percentage of white cells;Monocyte count;Granulocyte percentage of myeloid white cells;
CESC	cis	rs7666738	0.546	rs10461174	chr4:98698293	G/A	cg17366294	chr4:99064904	C4orf37	0.49	6.11	0.35	3.59e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs763121	0.819	rs5750629	chr22:38985065	T/C	cg06022373	chr22:39101656	GTPBP1	0.94	17.17	0.73	5.98e-45	Menopause (age at onset);
CESC	cis	rs2243480	1.000	rs10807701	chr7:65724686	C/A	cg18252515	chr7:66147081	NA	1.41	14.3	0.66	9.43e-35	Diabetic kidney disease;
CESC	cis	rs7618915	0.570	rs2336145	chr3:52629750	A/C	cg07507251	chr3:52567010	NT5DC2	0.42	7.31	0.41	3.07e-12	Bipolar disorder;
CESC	cis	rs1595825	0.891	rs73061068	chr2:198908439	A/G	cg10820045	chr2:198174542	NA	0.39	5.03	0.3	8.84e-7	Ulcerative colitis;
CESC	cis	rs11792861	0.926	rs1044905	chr9:111781495	G/A	cg13535736	chr9:111863775	C9orf5	-0.51	-6.69	-0.38	1.35e-10	Menarche (age at onset);
CESC	cis	rs9486715	1.000	rs7752277	chr6:97065131	C/T	cg06623918	chr6:96969491	KIAA0776	-0.88	-13.19	-0.63	7.15e-31	Headache;
CESC	cis	rs6964587	0.967	rs4729015	chr7:91561592	T/G	cg17063962	chr7:91808500	NA	-0.59	-7.88	-0.44	8.67e-14	Breast cancer;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg27665823	chr16:460516	DECR2	0.56	7.81	0.43	1.36e-13	Fibrinogen levels;
CESC	cis	rs1552244	0.882	rs55840655	chr3:10042690	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.74	-9.42	-0.5	2.37e-18	Alzheimer's disease;
CESC	cis	rs225245	0.791	rs8067294	chr17:34027964	T/C	cg05299278	chr17:33885742	SLFN14	0.39	5.51	0.32	8.5e-8	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
CESC	cis	rs5769765	0.632	rs13056783	chr22:50259152	A/T	cg22709217	chr22:50311962	ALG12;CRELD2	0.47	5.51	0.32	8.55e-8	Schizophrenia;
CESC	cis	rs400736	0.860	rs371452	chr1:8084051	C/T	cg25007680	chr1:8021821	PARK7	0.71	10.25	0.53	5.59e-21	Response to antidepressants and depression;
CESC	cis	rs17711722	0.523	rs313812	chr7:65505043	T/C	cg06456125	chr7:65229604	NA	-0.4	-5.29	-0.31	2.53e-7	Calcium levels;
CESC	cis	rs11048434	0.673	rs1124402	chr12:9062606	C/T	cg04155231	chr12:9217510	LOC144571	0.33	5.33	0.31	2.09e-7	Sjögren's syndrome;
CESC	cis	rs965513	1.000	rs10983700	chr9:100537455	T/C	cg13688889	chr9:100608707	NA	-0.61	-8.64	-0.47	5.56e-16	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
CESC	cis	rs8180040	0.739	rs4683320	chr3:47152992	C/T	cg27129171	chr3:47204927	SETD2	0.73	11.32	0.57	1.71e-24	Colorectal cancer;
CESC	cis	rs9611565	0.512	rs9607842	chr22:42192722	G/A	cg06634786	chr22:41940651	POLR3H	-0.68	-6.84	-0.39	5.6e-11	Vitiligo;
CESC	cis	rs9287719	0.967	rs10929688	chr2:10756650	T/C	cg02196655	chr2:10830764	NOL10	-0.36	-5.52	-0.32	8.15e-8	Prostate cancer;
CESC	cis	rs854765	0.547	rs4459604	chr17:17888549	A/G	cg09796270	chr17:17721594	SREBF1	0.38	5.11	0.3	6.08e-7	Total body bone mineral density;
CESC	trans	rs10500991	0.587	rs11605315	chr11:24889365	T/C	cg07129253	chr8:30890560	PURG;WRN	-0.5	-6.6	-0.38	2.23e-10	Iron status biomarkers;
CESC	cis	rs4466137	0.903	rs3734092	chr5:83016743	C/T	cg16102102	chr5:83017553	HAPLN1	-0.51	-7.2	-0.4	6.22e-12	Prostate cancer;
CESC	cis	rs2576037	0.583	rs501882	chr18:44411066	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.77	12.94	0.62	5.09e-30	Personality dimensions;
CESC	cis	rs9300255	0.568	rs1790108	chr12:123636841	A/G	cg05973401	chr12:123451056	ABCB9	0.5	5.77	0.33	2.18e-8	Neutrophil percentage of white cells;
CESC	cis	rs6540559	0.673	rs11803382	chr1:209986426	G/A	cg21951975	chr1:209979733	IRF6	0.61	7.53	0.42	8.13e-13	Cleft lip with or without cleft palate;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg08916340	chr10:112631462	LOC282997;PDCD4	-0.48	-6.21	-0.36	2.05e-9	Ulcerative colitis;
CESC	cis	rs4665809	0.680	rs3955310	chr2:26290828	T/G	cg22920501	chr2:26401640	FAM59B	-0.69	-8.44	-0.46	2.06e-15	Gut microbiome composition (summer);
CESC	cis	rs75804782	0.641	rs11904390	chr2:239344663	T/A	cg18131467	chr2:239335373	ASB1	-0.68	-5.96	-0.34	8.16e-9	Morning vs. evening chronotype;Chronotype;
CESC	cis	rs847577	0.677	rs10242903	chr7:97741795	C/T	cg21770322	chr7:97807741	LMTK2	-0.5	-7.17	-0.4	7.68e-12	Breast cancer;
CESC	trans	rs3780486	0.874	rs10813955	chr9:33141791	C/T	cg04842962	chr6:43655489	MRPS18A	1.0	18.63	0.75	4.36e-50	IgG glycosylation;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg14422660	chr6:105628044	POPDC3	0.4	6.33	0.36	1.06e-9	Gambling;
CESC	cis	rs769267	0.895	rs1858999	chr19:19497669	C/G	cg17414380	chr19:19431394	KIAA0892;SF4	-0.5	-6.29	-0.36	1.34e-9	Tonsillectomy;
CESC	cis	rs2286503	0.839	rs2240726	chr7:22853135	C/T	cg13679077	chr7:22862647	TOMM7	0.45	5.77	0.33	2.2e-8	Fibrinogen;
CESC	cis	rs1348850	0.914	rs1348849	chr2:178358072	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.89	12.98	0.62	3.87e-30	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs2204008	0.570	rs1315664	chr12:38138274	A/G	cg26384229	chr12:38710491	ALG10B	-0.44	-5.99	-0.35	6.87e-9	Bladder cancer;
CESC	cis	rs1008375	1.000	rs6854733	chr4:17640526	C/T	cg15017067	chr4:17643749	FAM184B	0.35	5.07	0.3	7.59e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs2262909	1.000	rs2017962	chr19:22208751	T/C	cg11619707	chr19:22235551	ZNF257	-0.35	-5.7	-0.33	3.19e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
CESC	cis	rs9584850	0.834	rs12463	chr13:99105302	G/A	cg20750642	chr13:99100586	FARP1	-0.38	-5.78	-0.33	2.05e-8	Neuroticism;
CESC	cis	rs2836974	0.602	rs8130854	chr21:40707041	G/A	cg11644478	chr21:40555479	PSMG1	-0.8	-11.95	-0.59	1.27e-26	Cognitive function;
CESC	cis	rs62103177	0.810	rs62096745	chr18:77619135	A/G	cg12964065	chr18:77638022	KCNG2	0.59	5.71	0.33	2.97e-8	Opioid sensitivity;
CESC	cis	rs4689388	0.926	rs4416547	chr4:6293967	G/A	cg14416269	chr4:6271139	WFS1	0.46	7.76	0.43	1.79e-13	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs864537	0.618	rs2988277	chr1:167431352	A/G	cg22356347	chr1:167427500	CD247	0.42	8.53	0.46	1.15e-15	Celiac disease or Rheumatoid arthritis;Celiac disease;
CESC	cis	rs2108622	0.727	rs12611242	chr19:15978564	G/A	cg13772218	chr19:15982569	NA	0.29	5.69	0.33	3.28e-8	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16008945	chr10:14996031	DCLRE1C	0.55	6.49	0.37	4.25e-10	Gut microbiome composition (summer);
CESC	cis	rs11122272	0.735	rs2749717	chr1:231489353	G/T	cg06096015	chr1:231504339	EGLN1	0.41	5.9	0.34	1.1e-8	Hemoglobin concentration;
CESC	cis	rs4555082	0.874	rs56263609	chr14:105756944	C/T	cg13114125	chr14:105738426	BRF1	-0.89	-10.53	-0.54	7.09e-22	Mean platelet volume;Platelet distribution width;
CESC	cis	rs6502050	0.835	rs34673303	chr17:80085144	G/C	cg11859384	chr17:80120422	CCDC57	0.38	5.12	0.3	6.01e-7	Life satisfaction;
CESC	cis	rs713587	0.713	rs11125884	chr2:25239264	C/T	cg01884057	chr2:25150051	NA	0.38	7.33	0.41	2.87e-12	Body mass index in non-asthmatics;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg21454386	chr13:114292018	TFDP1	0.45	6.08	0.35	4.25e-9	Fibrinogen levels;
CESC	cis	rs561341	1.000	rs55962687	chr17:30260369	C/T	cg19193384	chr17:30244184	NA	-0.63	-5.95	-0.34	8.64e-9	Hip circumference adjusted for BMI;
CESC	cis	rs710216	0.917	rs900837	chr1:43412793	A/G	cg22176566	chr1:43424700	SLC2A1	-0.5	-5.54	-0.32	7.23e-8	Red cell distribution width;
CESC	cis	rs11098499	0.954	rs13145352	chr4:120409963	C/T	cg24375607	chr4:120327624	NA	-0.43	-5.12	-0.3	5.89e-7	Corneal astigmatism;
CESC	cis	rs7829975	0.658	rs907181	chr8:8702875	T/C	cg17143192	chr8:8559678	CLDN23	0.4	5.05	0.3	8.22e-7	Mood instability;
CESC	cis	rs963731	0.649	rs7577088	chr2:39233500	G/A	cg04010122	chr2:39346883	SOS1	-0.72	-5.46	-0.32	1.09e-7	Corticobasal degeneration;
CESC	cis	rs3741151	0.773	rs73542990	chr11:73134398	C/T	cg17517138	chr11:73019481	ARHGEF17	0.94	6.86	0.39	4.87e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	trans	rs12659622	0.703	rs17523908	chr5:15696499	G/T	cg22457238	chr19:58570995	ZNF135	-0.55	-6.17	-0.35	2.48e-9	Obesity-related traits;
CESC	cis	rs2806561	0.929	rs2903545	chr1:23541108	C/T	cg12483005	chr1:23474871	LUZP1	-0.33	-5.33	-0.31	2.07e-7	Height;
CESC	cis	rs7216064	1.000	rs7224923	chr17:65842265	T/G	cg07042672	chr17:66097459	LOC651250	-0.54	-5.67	-0.33	3.73e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs2836974	0.897	rs2836932	chr21:40546717	G/A	cg27266027	chr21:40555129	PSMG1	0.47	5.67	0.33	3.69e-8	Cognitive function;
CESC	cis	rs9611565	0.500	rs2011053	chr22:42121278	G/A	cg06481639	chr22:41940642	POLR3H	0.48	5.56	0.32	6.63e-8	Vitiligo;
CESC	cis	rs67311347	1.000	rs1119179	chr3:40424929	A/C	cg09455208	chr3:40491958	NA	-0.41	-6.53	-0.37	3.31e-10	Renal cell carcinoma;
CESC	cis	rs6933660	0.760	rs3806982	chr6:151774916	G/A	cg14262678	chr6:151773367	RMND1;C6orf211	0.63	8.86	0.48	1.23e-16	Menarche (age at onset);
CESC	cis	rs801193	0.569	rs881285	chr7:66119420	A/G	cg12463550	chr7:65579703	CRCP	-0.5	-6.43	-0.37	5.9e-10	Aortic root size;
CESC	cis	rs9487051	0.676	rs2884013	chr6:109599952	C/T	cg21918786	chr6:109611834	NA	-0.37	-5.5	-0.32	9.15e-8	Reticulocyte fraction of red cells;
CESC	cis	rs72634258	0.554	rs68024107	chr1:7914066	G/C	cg00042356	chr1:8021962	PARK7	0.57	5.49	0.32	9.24e-8	Inflammatory bowel disease;
CESC	cis	rs12079745	0.793	rs57776592	chr1:169268023	A/G	cg09363564	chr1:169337483	NME7;BLZF1	-1.0	-6.04	-0.35	5.12e-9	QT interval;
CESC	cis	rs6088590	0.735	rs6088618	chr20:33409350	G/A	cg06115741	chr20:33292138	TP53INP2	0.61	7.67	0.43	3.19e-13	Coronary artery disease;
CESC	cis	rs11858210	1	rs11858210	chr15:79078358	G/A	cg04896959	chr15:78267971	NA	0.34	5.09	0.3	6.64e-7	Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs763121	0.962	rs6001193	chr22:39074737	A/G	cg14440974	chr22:39074834	NA	-0.36	-5.23	-0.31	3.4e-7	Menopause (age at onset);
CESC	cis	rs4665809	1.000	rs750451	chr2:26324241	G/A	cg27170947	chr2:26402098	FAM59B	-0.58	-6.93	-0.39	3.18e-11	Gut microbiome composition (summer);
CESC	cis	rs4555082	0.830	rs2735812	chr14:105727575	A/G	cg27165867	chr14:105738592	BRF1	-0.52	-5.77	-0.33	2.22e-8	Mean platelet volume;Platelet distribution width;
CESC	cis	rs1552244	1.000	rs7628448	chr3:10146828	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	11.48	0.58	5.13e-25	Alzheimer's disease;
CESC	trans	rs7191820	0.605	rs1876764	chr16:79364932	T/C	cg02396914	chr8:120743868	TAF2	-0.52	-6.74	-0.38	9.67e-11	Obesity-related traits;
CESC	cis	rs1400745	0.756	rs3783314	chr14:35337384	T/C	cg16230307	chr14:35515116	FAM177A1	0.44	5.25	0.31	3.18e-7	Monocyte count;
CESC	cis	rs6963495	0.818	rs6977748	chr7:105167462	T/G	cg02135003	chr7:105160482	PUS7	-0.46	-5.25	-0.31	3.19e-7	Bipolar disorder (body mass index interaction);
CESC	cis	rs2404602	0.716	rs2404737	chr15:76872217	T/G	cg26408565	chr15:76604113	ETFA	-0.39	-5.66	-0.33	4.02e-8	Blood metabolite levels;
CESC	cis	rs7178572	0.524	rs12914128	chr15:77493875	T/C	cg22256960	chr15:77711686	NA	-0.53	-6.69	-0.38	1.33e-10	Type 2 diabetes;
CESC	cis	rs714031	1.000	rs4821909	chr22:40066418	T/C	cg21377881	chr22:40064566	CACNA1I	-0.34	-5.47	-0.32	1.06e-7	Schizophrenia;
CESC	cis	rs2841277	0.708	rs10083490	chr14:105402418	A/G	cg15352829	chr14:105391018	PLD4	0.61	10.68	0.55	2.23e-22	Rheumatoid arthritis;
CESC	cis	rs6582630	0.532	rs1589394	chr12:38419700	A/C	cg26384229	chr12:38710491	ALG10B	0.46	6.73	0.38	1.05e-10	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs11098499	0.754	rs12506487	chr4:120271361	T/G	cg09307838	chr4:120376055	NA	0.77	10.19	0.53	8.72e-21	Corneal astigmatism;
CESC	cis	rs6879260	1.000	rs6874653	chr5:179730843	A/G	cg02891314	chr5:179741120	GFPT2	-0.7	-9.34	-0.5	3.96e-18	Height;
CESC	cis	rs6460942	0.915	rs75158182	chr7:12456059	C/T	cg02935154	chr7:12443704	VWDE	-0.58	-6.16	-0.35	2.73e-9	Coronary artery disease;
CESC	cis	rs35146811	0.844	rs13232115	chr7:99670932	T/C	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.45	5.74	0.33	2.65e-8	Coronary artery disease;
CESC	cis	rs9611565	0.694	rs19573	chr22:41865809	C/A	cg03806693	chr22:41940476	POLR3H	1.13	15.51	0.69	4.94e-39	Vitiligo;
CESC	trans	rs61931739	0.500	rs11053203	chr12:34456593	C/T	cg26384229	chr12:38710491	ALG10B	0.69	10.44	0.54	1.34e-21	Morning vs. evening chronotype;
CESC	trans	rs60843830	0.508	rs300750	chr2:208794	T/G	cg06230206	chr11:126456119	KIRREL3	0.37	6.63	0.38	1.91e-10	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs9300255	0.602	rs1716160	chr12:123700225	C/T	cg19016782	chr12:123741754	C12orf65	-0.45	-6.5	-0.37	3.89e-10	Neutrophil percentage of white cells;
CESC	cis	rs3892630	0.824	rs34748593	chr19:33240447	T/C	cg13157960	chr19:33183277	NUDT19	0.55	5.12	0.3	5.91e-7	Red blood cell traits;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg09849967	chr3:49138870	QARS	-0.42	-6.06	-0.35	4.54e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs875971	0.929	rs34406470	chr7:65929956	A/G	cg10691866	chr7:65817282	TPST1	-0.34	-5.42	-0.32	1.31e-7	Aortic root size;
CESC	cis	rs798554	0.796	rs2158694	chr7:2863443	T/G	cg19346786	chr7:2764209	NA	-0.49	-7.02	-0.4	1.86e-11	Height;
CESC	cis	rs34779708	0.931	rs13377158	chr10:35370465	A/C	cg03585969	chr10:35415529	CREM	-0.74	-10.07	-0.53	2.12e-20	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs7818688	1.000	rs7002940	chr8:96027392	G/A	cg16049864	chr8:95962084	TP53INP1	0.58	5.63	0.33	4.56e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs1256061	0.646	rs1152588	chr14:64688175	G/C	cg23250157	chr14:64679961	SYNE2	0.53	7.35	0.41	2.5e-12	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs873946	0.648	rs12767126	chr10:134556992	C/T	cg18305652	chr10:134549665	INPP5A	0.48	6.75	0.38	9.22e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs1448094	0.512	rs2405632	chr12:86252456	A/G	cg02569458	chr12:86230093	RASSF9	0.5	7.43	0.42	1.49e-12	Major depressive disorder;
CESC	cis	rs3008870	0.727	rs11208971	chr1:67383901	G/A	cg02640540	chr1:67518911	SLC35D1	0.44	5.26	0.31	2.94e-7	Lymphocyte percentage of white cells;
CESC	cis	rs910316	1.000	rs2300601	chr14:75639571	A/G	cg08847533	chr14:75593920	NEK9	0.96	16.63	0.71	5.16e-43	Height;
CESC	cis	rs4662945	0.504	rs35568023	chr2:130251812	A/T	cg05903289	chr2:130345205	NA	-0.4	-6.23	-0.36	1.83e-9	Response to cytidine analogues (gemcitabine);
CESC	cis	rs13242816	1.000	rs35184471	chr7:116133246	G/A	cg04696780	chr7:116139425	CAV2	-0.61	-5.51	-0.32	8.44e-8	P wave duration;
CESC	cis	rs950027	0.787	rs1547487	chr15:45723983	A/G	cg21132104	chr15:45694354	SPATA5L1	0.47	5.55	0.32	6.87e-8	Response to fenofibrate (adiponectin levels);
CESC	cis	rs11098499	0.863	rs6835635	chr4:120458867	A/G	cg24375607	chr4:120327624	NA	0.44	5.33	0.31	2.13e-7	Corneal astigmatism;
CESC	cis	rs1421811	0.509	rs7733428	chr5:32689850	G/A	cg16267343	chr5:32710456	NPR3	0.58	6.53	0.37	3.3e-10	Blood pressure;
CESC	cis	rs1950626	0.623	rs34448411	chr14:101429287	G/A	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.68	9.19	0.49	1.18e-17	Pelvic organ prolapse (moderate/severe);
CESC	cis	rs875971	0.830	rs6950137	chr7:65976610	G/A	cg18876405	chr7:65276391	NA	0.49	6.55	0.37	3e-10	Aortic root size;
CESC	cis	rs2836950	0.520	rs59916147	chr21:40634702	T/G	cg17971929	chr21:40555470	PSMG1	-0.58	-7.57	-0.42	6.25e-13	Menarche (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13398782	chr1:23857288	E2F2	0.56	6.52	0.37	3.48e-10	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.830	rs10010223	chr4:99021758	G/A	cg18180107	chr4:99064573	C4orf37	0.41	5.39	0.31	1.57e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs832540	0.669	rs173764	chr5:56198920	C/T	cg18230493	chr5:56204884	C5orf35	-0.58	-7.69	-0.43	2.89e-13	Coronary artery disease;
CESC	cis	rs897984	0.721	rs2305884	chr16:30970741	G/A	cg00531865	chr16:30841666	NA	0.51	7.02	0.4	1.83e-11	Dementia with Lewy bodies;
CESC	trans	rs9354308	0.868	rs1938063	chr6:66559098	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.54	-6.52	-0.37	3.6e-10	Metabolite levels;
CESC	cis	rs10883723	0.737	rs11191312	chr10:104278601	T/C	cg22532475	chr10:104410764	TRIM8	-0.41	-6.32	-0.36	1.08e-9	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs7130144	0.541	rs7949571	chr11:130462430	A/G	cg26307797	chr11:130446613	NA	-0.76	-6.78	-0.38	7.92e-11	Urate levels in lean individuals;
CESC	cis	rs73110464	0.562	rs2363634	chr12:53354683	A/G	cg25025879	chr12:53359317	NA	-0.6	-7.9	-0.44	7.28e-14	Cancer (pleiotropy);
CESC	cis	rs7654585	0.645	rs1123943	chr4:25924426	A/G	cg10409131	chr4:25915609	C4orf52	-0.66	-8.7	-0.47	3.65e-16	Obesity-related traits;
CESC	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	21.97	0.8	1.29e-61	Prudent dietary pattern;
CESC	cis	rs1003719	1.000	rs2835607	chr21:38491973	T/G	cg10648535	chr21:38446584	PIGP;TTC3	0.64	8.63	0.47	5.67e-16	Eye color traits;
CESC	cis	rs6831352	0.734	rs2602856	chr4:100029145	C/A	cg13256891	chr4:100009986	ADH5	0.67	8.04	0.44	2.92e-14	Alcohol dependence;
CESC	cis	rs6141600	0.540	rs761312	chr20:34687809	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.43	-5.99	-0.35	6.69e-9	Height;Hip circumference;
CESC	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.55	-6.1	-0.35	3.69e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs501120	0.636	rs3123689	chr10:44773121	G/A	cg09554077	chr10:44749378	NA	0.52	6.94	0.39	3.05e-11	Coronary artery disease;Coronary heart disease;
CESC	cis	rs7666738	0.830	rs9992639	chr4:98940400	G/T	cg03467027	chr4:99064603	C4orf37	0.48	5.92	0.34	9.97e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7647973	0.580	rs12629759	chr3:49237394	T/C	cg07636037	chr3:49044803	WDR6	0.79	12.9	0.62	6.92e-30	Menarche (age at onset);
CESC	cis	rs16922576	0.623	rs2104166	chr9:5230447	T/C	cg02405213	chr9:5042618	JAK2	-0.51	-6.34	-0.36	1.01e-9	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs6754311	0.731	rs309164	chr2:136691825	T/C	cg07169764	chr2:136633963	MCM6	0.71	9.13	0.49	1.8e-17	Mosquito bite size;
CESC	cis	rs863345	0.604	rs11264991	chr1:158472861	T/G	cg12129480	chr1:158549410	OR10X1	-0.35	-7.04	-0.4	1.66e-11	Pneumococcal bacteremia;
CESC	cis	rs829883	0.659	rs11109510	chr12:98911382	A/G	cg25150519	chr12:98850993	NA	-0.65	-7.95	-0.44	5.42e-14	Colorectal adenoma (advanced);
CESC	cis	rs2273669	0.667	rs11153154	chr6:109357324	G/T	cg05315195	chr6:109294784	ARMC2	-0.67	-6.33	-0.36	1.02e-9	Prostate cancer;
CESC	cis	rs2072499	0.898	rs2758609	chr1:156202868	G/A	cg25208724	chr1:156163844	SLC25A44	0.84	13.27	0.63	3.75e-31	Testicular germ cell tumor;
CESC	cis	rs9308433	0.529	rs4655243	chr1:214497291	A/G	cg06198575	chr1:214491504	SMYD2	0.49	5.98	0.34	7.22e-9	IgG glycosylation;
CESC	cis	rs8077577	0.945	rs62073649	chr17:18080522	T/C	cg16794390	chr17:18148240	FLII	0.44	5.74	0.33	2.54e-8	Obesity-related traits;
CESC	trans	rs877282	0.945	rs10904550	chr10:774177	C/T	cg22713356	chr15:30763199	NA	1.12	11.29	0.57	2.14e-24	Uric acid levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11042866	chr11:65626132	CFL1	-0.54	-6.32	-0.36	1.08e-9	Gut microbiome composition (summer);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg02963556	chr12:132588637	EP400NL	0.47	6.26	0.36	1.54e-9	Fibrinogen levels;
CESC	cis	rs9399135	0.967	rs4142299	chr6:135377186	G/T	cg24558204	chr6:135376177	HBS1L	0.52	7.19	0.4	6.52e-12	Red blood cell count;
CESC	cis	rs698833	0.886	rs786613	chr2:44590066	C/G	cg18685995	chr2:44588913	PREPL;C2orf34	-0.54	-7.04	-0.4	1.68e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs10871290	1.000	rs11149710	chr16:74472546	G/T	cg01733217	chr16:74700730	RFWD3	-0.64	-8.56	-0.47	9.44e-16	Breast cancer;
CESC	cis	rs1065852	0.526	rs9611700	chr22:42401514	C/T	cg22189786	chr22:42395067	WBP2NL	0.43	5.34	0.31	2e-7	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
CESC	cis	rs7044106	0.708	rs1324472	chr9:123375110	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.33	5.09	0.3	6.82e-7	Hip circumference adjusted for BMI;
CESC	cis	rs6121246	0.567	rs6060297	chr20:30198560	A/G	cg13852791	chr20:30311386	BCL2L1	0.58	5.47	0.32	1.03e-7	Mean corpuscular hemoglobin;
CESC	cis	rs875971	0.862	rs2420611	chr7:65999320	A/G	cg11764359	chr7:65958608	NA	0.79	11.32	0.57	1.67e-24	Aortic root size;
CESC	cis	rs7680126	0.633	rs4697743	chr4:10294833	A/G	cg11266682	chr4:10021025	SLC2A9	-0.43	-5.6	-0.33	5.38e-8	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	cis	rs4665809	0.590	rs7260	chr2:26413917	C/T	cg27170947	chr2:26402098	FAM59B	-0.83	-10.36	-0.54	2.42e-21	Gut microbiome composition (summer);
CESC	cis	rs17401966	1.000	rs35766535	chr1:10284659	T/C	cg15208524	chr1:10270712	KIF1B	0.51	6.64	0.38	1.78e-10	Hepatocellular carcinoma;
CESC	cis	rs1552244	0.882	rs2130813	chr3:10038706	A/C	cg00166722	chr3:10149974	C3orf24	0.48	5.95	0.34	8.39e-9	Alzheimer's disease;
CESC	cis	rs6963495	0.818	rs6973263	chr7:105170293	A/G	cg02135003	chr7:105160482	PUS7	-0.46	-5.5	-0.32	9.1e-8	Bipolar disorder (body mass index interaction);
CESC	cis	rs8031584	0.541	rs2959037	chr15:31218164	T/C	cg19680485	chr15:31195859	MTMR15	0.5	6.02	0.35	5.9e-9	Huntington's disease progression;
CESC	cis	rs1707322	1.000	rs11211205	chr1:46321874	C/T	cg05343316	chr1:45956843	TESK2	0.44	5.55	0.32	7.05e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2011503	1.000	rs754256	chr19:19578591	A/G	cg11584989	chr19:19387371	SF4	-0.57	-6.45	-0.37	5.19e-10	Bipolar disorder;
CESC	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg10819733	chr22:24237672	NA	-0.48	-6.92	-0.39	3.43e-11	Liver enzyme levels (gamma-glutamyl transferase);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg10727759	chr12:50017361	PRPF40B	-0.45	-6.0	-0.35	6.46e-9	Ulcerative colitis;
CESC	cis	rs820218	0.717	rs9910627	chr17:73655529	C/T	cg01592526	chr17:73663357	RECQL5;SAP30BP	-0.4	-5.4	-0.31	1.47e-7	Rotator cuff tears;
CESC	cis	rs9908102	0.740	rs4792311	chr17:12915009	A/G	cg26162695	chr17:12921313	ELAC2	-0.54	-5.96	-0.34	8.1e-9	Schizophrenia;
CESC	cis	rs12325245	0.536	rs17821549	chr16:58554780	C/T	cg01152986	chr16:58549298	SETD6	0.85	5.17	0.3	4.54e-7	Schizophrenia;
CESC	cis	rs2996428	0.667	rs2368534	chr1:3740640	C/T	cg13057898	chr1:3703894	LRRC47	0.45	6.1	0.35	3.65e-9	Red cell distribution width;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05144345	chr4:1686368	FAM53A	0.58	7.09	0.4	1.19e-11	Gut microbiome composition (summer);
CESC	cis	rs6547741	0.935	rs6761095	chr2:27778010	G/T	cg27432699	chr2:27873401	GPN1	0.44	6.1	0.35	3.8e-9	Oral cavity cancer;
CESC	cis	rs4253772	0.591	rs12167567	chr22:46659942	G/C	cg24881330	chr22:46731750	TRMU	0.86	9.62	0.51	5.71e-19	LDL cholesterol;Cholesterol, total;
CESC	cis	rs1538970	0.884	rs781226	chr1:45872662	T/C	cg05343316	chr1:45956843	TESK2	-0.78	-11.06	-0.56	1.3e-23	Platelet count;
CESC	cis	rs3796352	1.000	rs7622420	chr3:53111069	A/G	cg12962167	chr3:53033115	SFMBT1	0.53	5.76	0.33	2.28e-8	Immune reponse to smallpox (secreted IL-2);
CESC	cis	rs514406	0.679	rs960570	chr1:53237763	A/G	cg25767906	chr1:53392781	SCP2	0.53	7.72	0.43	2.46e-13	Monocyte count;
CESC	cis	rs16854884	0.609	rs2885197	chr3:143636616	A/T	cg06585982	chr3:143692056	C3orf58	-0.44	-5.52	-0.32	8.23e-8	Economic and political preferences (feminism/equality);
CESC	cis	rs7918232	0.830	rs10764672	chr10:27392541	A/C	cg14240646	chr10:27532245	ACBD5	0.51	5.27	0.31	2.79e-7	Breast cancer;
CESC	cis	rs9902453	0.765	rs2447935	chr17:28057524	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.76	-10.3	-0.53	3.95e-21	Coffee consumption (cups per day);
CESC	cis	rs6904897	0.538	rs4639353	chr6:135224328	A/G	cg22676075	chr6:135203613	NA	-0.66	-9.75	-0.51	2.13e-19	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	cis	rs3806843	0.966	rs10036519	chr5:140151701	C/T	cg26395211	chr5:140044315	WDR55	0.41	5.38	0.31	1.61e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs738322	1.000	rs738322	chr22:38569006	A/G	cg17652424	chr22:38574118	PLA2G6	-0.34	-6.03	-0.35	5.39e-9	Cutaneous nevi;
CESC	trans	rs7943203	1.000	rs10431061	chr11:108288808	G/T	cg01416241	chr5:148737479	PCYOX1L	-0.48	-6.25	-0.36	1.61e-9	Red blood cell count;Mean corpuscular volume;
CESC	cis	rs57244997	0.685	rs2226770	chr6:162447251	C/T	cg17173639	chr6:162384350	PARK2	0.59	6.19	0.36	2.29e-9	Mosquito bite size;
CESC	cis	rs853679	0.599	rs149990	chr6:27998258	G/A	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.8	6.55	0.37	2.92e-10	Depression;
CESC	cis	rs853679	0.556	rs45509595	chr6:27840926	T/C	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.9	6.23	0.36	1.82e-9	Depression;
CESC	cis	rs10791323	0.546	rs55801927	chr11:133713094	A/C	cg15485101	chr11:133734466	NA	0.4	6.59	0.38	2.34e-10	Childhood ear infection;
CESC	cis	rs2404602	0.647	rs118129828	chr15:77015200	T/C	cg23625390	chr15:77176239	SCAPER	-0.47	-6.52	-0.37	3.54e-10	Blood metabolite levels;
CESC	cis	rs7193541	0.684	rs9931225	chr16:74699293	T/C	cg05580060	chr16:74700937	RFWD3	-0.45	-5.77	-0.33	2.2e-8	Multiple myeloma;
CESC	cis	rs853679	0.517	rs9348796	chr6:28126202	A/G	cg17949981	chr6:28129498	ZNF389	0.45	5.57	0.32	6.26e-8	Depression;
CESC	cis	rs9527	0.637	rs7085104	chr10:104628873	A/G	cg04362960	chr10:104952993	NT5C2	0.52	6.23	0.36	1.79e-9	Arsenic metabolism;
CESC	cis	rs10504229	0.817	rs55949560	chr8:58167603	T/C	cg22535103	chr8:58192502	C8orf71	-0.84	-11.02	-0.56	1.76e-23	Developmental language disorder (linguistic errors);
CESC	cis	rs3015497	0.624	rs3015486	chr14:51135330	A/G	cg26011998	chr14:51135199	SAV1	-0.62	-7.02	-0.4	1.82e-11	Mean platelet volume;
CESC	cis	rs4268898	0.662	rs2303296	chr2:24432839	A/G	cg06627628	chr2:24431161	ITSN2	-1.02	-11.2	-0.57	4.2e-24	Asthma;
CESC	cis	rs7615952	0.599	rs2270986	chr3:125701099	T/C	cg04553112	chr3:125709451	NA	-0.5	-5.48	-0.32	9.86e-8	Blood pressure (smoking interaction);
CESC	cis	rs4595586	0.545	rs12827823	chr12:39392144	G/T	cg26384229	chr12:38710491	ALG10B	0.54	7.64	0.42	3.96e-13	Morning vs. evening chronotype;
CESC	cis	rs8002861	0.875	rs12428432	chr13:44464043	A/G	cg14210620	chr13:44453864	C13orf31;CCDC122	-0.44	-5.58	-0.32	5.88e-8	Leprosy;
CESC	cis	rs12541335	0.639	rs4871994	chr8:22206038	G/A	cg18135555	chr8:22132992	PIWIL2	0.25	5.31	0.31	2.37e-7	Hypertriglyceridemia;
CESC	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg07308232	chr7:1071921	C7orf50	-0.6	-8.51	-0.46	1.29e-15	Longevity;Endometriosis;
CESC	cis	rs10504229	0.639	rs56825757	chr8:58106469	A/G	cg22535103	chr8:58192502	C8orf71	-0.77	-8.76	-0.47	2.37e-16	Developmental language disorder (linguistic errors);
CESC	cis	rs6831352	1.000	rs6532798	chr4:100054827	C/T	cg13256891	chr4:100009986	ADH5	0.73	8.48	0.46	1.62e-15	Alcohol dependence;
CESC	cis	rs1005277	0.579	rs176838	chr10:38371899	A/T	cg25427524	chr10:38739819	LOC399744	0.65	9.07	0.49	2.71e-17	Extrinsic epigenetic age acceleration;
CESC	cis	rs3096299	0.685	rs12446145	chr16:89542695	C/T	cg00750074	chr16:89608354	SPG7	-0.44	-6.44	-0.37	5.61e-10	Multiple myeloma (IgH translocation);
CESC	cis	rs67311347	0.869	rs6790495	chr3:40366770	C/T	cg09455208	chr3:40491958	NA	0.48	7.97	0.44	4.61e-14	Renal cell carcinoma;
CESC	cis	rs796364	1.000	rs35594306	chr2:200775125	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.83	-6.41	-0.37	6.49e-10	Schizophrenia;
CESC	cis	rs7847628	0.551	rs10818476	chr9:123572038	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.82	13.23	0.63	5.01e-31	Birth weight;
CESC	cis	rs4925386	0.681	rs2427296	chr20:60927475	G/A	cg22307297	chr20:60903441	LAMA5	0.37	5.28	0.31	2.65e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg05265985	chr11:20412000	PRMT3	0.43	6.37	0.36	8.51e-10	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs6541297	0.941	rs6541294	chr1:230278826	A/G	cg20703242	chr1:230279135	GALNT2	0.68	10.87	0.56	5.47e-23	Coronary artery disease;
CESC	cis	rs6546550	0.901	rs6725425	chr2:70150674	T/C	cg02498382	chr2:70120550	SNRNP27	-0.41	-7.26	-0.41	4.34e-12	Prevalent atrial fibrillation;
CESC	cis	rs7927592	0.717	rs7126451	chr11:68257386	A/G	cg16797656	chr11:68205561	LRP5	-0.5	-7.84	-0.43	1.1e-13	Total body bone mineral density;
CESC	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg24503407	chr1:205819492	PM20D1	0.48	7.23	0.41	5.18e-12	Menarche (age at onset);
CESC	cis	rs7615952	0.534	rs1503072	chr3:125754691	C/T	cg04553112	chr3:125709451	NA	-0.51	-5.37	-0.31	1.7e-7	Blood pressure (smoking interaction);
CESC	cis	rs3820928	0.874	rs13385711	chr2:227830414	G/T	cg11843606	chr2:227700838	RHBDD1	-0.44	-5.74	-0.33	2.6e-8	Pulmonary function;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17205877	chr22:41842716	TOB2	0.56	6.38	0.36	7.68e-10	Gut microbiome composition (summer);
CESC	cis	rs9733	0.596	rs17658705	chr1:150678071	A/C	cg04414720	chr1:150670196	GOLPH3L	-0.63	-8.94	-0.48	6.83e-17	Tonsillectomy;
CESC	cis	rs4906332	1.000	rs28711288	chr14:103906126	T/C	cg09975044	chr14:104007538	NA	0.48	6.67	0.38	1.46e-10	Coronary artery disease;
CESC	cis	rs748404	0.660	rs694725	chr15:43756210	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	8.19	0.45	1.12e-14	Lung cancer;
CESC	cis	rs3820068	0.734	rs72645830	chr1:15889910	A/G	cg18192808	chr1:15853278	DNAJC16	0.46	5.52	0.32	7.92e-8	Systolic blood pressure;
CESC	cis	rs3733585	0.699	rs4473653	chr4:9971058	A/G	cg02734326	chr4:10020555	SLC2A9	-0.41	-5.81	-0.34	1.79e-8	Cleft plate (environmental tobacco smoke interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06584028	chr2:69614451	GFPT1	0.59	6.29	0.36	1.28e-9	Gut microbiome composition (summer);
CESC	cis	rs11209002	0.567	rs983111	chr1:67539356	T/C	cg02640540	chr1:67518911	SLC35D1	0.47	5.39	0.31	1.52e-7	Crohn's disease;
CESC	cis	rs17539620	0.506	rs62432749	chr6:154839219	G/A	cg20019720	chr6:154832845	CNKSR3	0.46	6.04	0.35	5.07e-9	Lipoprotein (a) levels;
CESC	cis	rs1355223	0.552	rs2421743	chr11:34882840	C/T	cg24088639	chr11:34937564	PDHX;APIP	-0.4	-5.12	-0.3	5.76e-7	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs7084402	0.967	rs1649072	chr10:60298112	G/A	cg07615347	chr10:60278583	BICC1	0.6	9.46	0.5	1.77e-18	Refractive error;
CESC	cis	rs8077577	0.895	rs62072500	chr17:18126918	A/C	cg16794390	chr17:18148240	FLII	0.43	5.8	0.34	1.92e-8	Obesity-related traits;
CESC	cis	rs7659604	0.539	rs2221628	chr4:122795361	G/A	cg06713675	chr4:122721982	EXOSC9	-0.5	-6.81	-0.39	6.6e-11	Type 2 diabetes;
CESC	cis	rs4604732	0.631	rs11490201	chr1:247626262	A/G	cg12754571	chr1:247694271	LOC148824;OR2C3	0.44	5.44	0.32	1.21e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs7666738	0.800	rs11941885	chr4:99072921	A/C	cg17366294	chr4:99064904	C4orf37	0.63	8.7	0.47	3.53e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6831352	0.837	rs2924583	chr4:100044640	T/C	cg12011299	chr4:100065546	ADH4	0.59	6.66	0.38	1.56e-10	Alcohol dependence;
CESC	cis	rs875971	1.000	rs1540651	chr7:65650121	C/T	cg12463550	chr7:65579703	CRCP	-0.55	-7.0	-0.39	2.15e-11	Aortic root size;
CESC	cis	rs910316	1.000	rs10138183	chr14:75615227	T/C	cg11812906	chr14:75593930	NEK9	0.91	15.77	0.7	5.67e-40	Height;
CESC	cis	rs7666738	0.830	rs13125930	chr4:98654695	G/A	cg05340658	chr4:99064831	C4orf37	0.76	10.99	0.56	2.11e-23	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7945705	0.520	rs1984791	chr11:9035027	C/T	cg09997546	chr11:8931473	C11orf17;ST5	0.35	5.56	0.32	6.66e-8	Hemoglobin concentration;
CESC	cis	rs60871478	0.636	rs4276575	chr7:900035	C/T	cg00475322	chr7:917719	C7orf20	0.46	5.19	0.3	4.28e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs34172651	0.517	rs2547040	chr16:24736408	G/C	cg06028605	chr16:24865363	SLC5A11	-0.56	-8.24	-0.45	7.9e-15	Intelligence (multi-trait analysis);
CESC	cis	rs9788682	1.000	rs12441426	chr15:78812329	T/C	cg06917634	chr15:78832804	PSMA4	-0.53	-6.09	-0.35	3.92e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	trans	rs11098499	0.954	rs7437420	chr4:120312903	A/G	cg25214090	chr10:38739885	LOC399744	0.68	9.2	0.49	1.14e-17	Corneal astigmatism;
CESC	cis	rs1448094	0.512	rs7134732	chr12:86241908	T/C	cg00310523	chr12:86230176	RASSF9	0.35	5.46	0.32	1.11e-7	Major depressive disorder;
CESC	cis	rs2734839	1.000	rs2734839	chr11:113286490	C/T	cg14159747	chr11:113255604	NA	0.3	5.4	0.31	1.52e-7	Information processing speed;
CESC	cis	rs9649213	0.593	rs6967457	chr7:97912221	T/G	cg08684580	chr7:98029266	BAIAP2L1	-0.33	-5.11	-0.3	6.06e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs3741404	0.620	rs11231722	chr11:63967770	C/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.71	10.22	0.53	7.11e-21	Platelet count;
CESC	cis	rs6690583	0.573	rs61768854	chr1:85460021	T/C	cg22488158	chr1:85528044	WDR63	0.55	5.18	0.3	4.45e-7	Serum sulfate level;
CESC	cis	rs4604732	0.642	rs10925048	chr1:247640736	T/C	cg12758973	chr1:247694275	LOC148824;OR2C3	0.36	5.26	0.31	3.01e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs2228479	0.764	rs11641201	chr16:89983276	T/C	cg00800038	chr16:89945340	TCF25	-0.69	-7.09	-0.4	1.19e-11	Skin colour saturation;
CESC	trans	rs4332037	0.539	rs56305291	chr7:2048706	A/G	cg11693508	chr17:37793320	STARD3	0.67	6.77	0.38	8.32e-11	Bipolar disorder;
CESC	trans	rs916888	0.773	rs538628	chr17:44787313	G/C	cg22433210	chr17:43662623	NA	0.99	11.32	0.57	1.75e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg03647317	chr4:187891568	NA	-0.37	-5.56	-0.32	6.44e-8	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2072499	0.966	rs2984615	chr1:156165317	G/C	cg25208724	chr1:156163844	SLC25A44	1.01	19.18	0.76	4.95e-52	Testicular germ cell tumor;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04768184	chr8:37963284	ASH2L	0.57	6.67	0.38	1.52e-10	Gut microbiome composition (summer);
CESC	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.44	-6.22	-0.36	1.89e-9	Longevity;Endometriosis;
CESC	cis	rs9894429	0.789	rs8074989	chr17:79598728	G/C	cg21984481	chr17:79567631	NPLOC4	-0.56	-8.99	-0.48	4.98e-17	Eye color traits;
CESC	cis	rs7044106	0.762	rs10818471	chr9:123394045	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.63	8.52	0.46	1.18e-15	Hip circumference adjusted for BMI;
CESC	cis	rs4654899	0.865	rs9426730	chr1:21452255	A/T	cg05370193	chr1:21551575	ECE1	0.39	5.83	0.34	1.59e-8	Superior frontal gyrus grey matter volume;
CESC	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg27094323	chr7:1216898	NA	-0.37	-5.05	-0.3	8.32e-7	Longevity;Endometriosis;
CESC	cis	rs55794721	0.509	rs909834	chr1:25757996	A/G	cg02931644	chr1:25747376	RHCE	0.43	7.07	0.4	1.38e-11	Plateletcrit;Mean corpuscular volume;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg11286060	chr17:27182016	ERAL1	0.46	6.11	0.35	3.45e-9	Systemic lupus erythematosus;
CESC	cis	rs1799949	1.000	rs8176265	chr17:41213996	C/T	cg25072359	chr17:41440525	NA	0.48	6.36	0.36	8.96e-10	Menopause (age at onset);
CESC	cis	rs7017914	0.967	rs6991329	chr8:71593425	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.09	-0.3	6.93e-7	Bone mineral density;
CESC	cis	rs28386778	0.734	rs12946669	chr17:62006007	A/G	cg06873352	chr17:61820015	STRADA	0.59	9.28	0.5	6.17e-18	Prudent dietary pattern;
CESC	cis	rs853679	0.517	rs9380052	chr6:28064623	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.58	-6.7	-0.38	1.25e-10	Depression;
CESC	cis	rs17376456	0.877	rs12109629	chr5:93359702	A/G	cg21475434	chr5:93447410	FAM172A	0.77	6.93	0.39	3.17e-11	Diabetic retinopathy;
CESC	cis	rs780096	0.526	rs704795	chr2:27716494	G/A	cg24768116	chr2:27665128	KRTCAP3	-0.31	-5.69	-0.33	3.43e-8	Total body bone mineral density;
CESC	cis	rs4665809	0.590	rs1122972	chr2:26418788	A/C	cg04944784	chr2:26401820	FAM59B	-0.93	-10.69	-0.55	2.11e-22	Gut microbiome composition (summer);
CESC	cis	rs1878931	0.615	rs6501171	chr16:3402610	T/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.93	13.47	0.64	7.47e-32	Body mass index (adult);
CESC	cis	rs6582630	0.502	rs7312212	chr12:38274760	T/G	cg13010199	chr12:38710504	ALG10B	0.46	5.61	0.33	5.13e-8	Drug-induced liver injury (flucloxacillin);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04338281	chr16:54962385	NA	0.55	6.2	0.36	2.17e-9	Gut microbiome composition (summer);
CESC	cis	rs751837	0.591	rs10135776	chr14:103411295	G/C	cg10087771	chr14:103399429	CDC42BPB	0.59	5.43	0.32	1.29e-7	Large B-cell lymphoma;
CESC	cis	rs7520050	0.966	rs785485	chr1:46574424	C/T	cg03146154	chr1:46216737	IPP	-0.43	-5.56	-0.32	6.67e-8	Red blood cell count;Reticulocyte count;
CESC	cis	rs34311866	0.752	rs11725653	chr4:963397	C/T	cg07828340	chr4:882639	GAK	0.86	6.67	0.38	1.49e-10	Parkinson's disease;
CESC	cis	rs11785400	1.000	rs6988393	chr8:143740596	A/G	cg24634471	chr8:143751801	JRK	0.47	6.21	0.36	2e-9	Schizophrenia;
CESC	cis	rs9649213	0.613	rs7777415	chr7:97959214	A/T	cg00277769	chr7:97922759	BAIAP2L1	-0.34	-5.54	-0.32	7.46e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs8141529	1.000	rs8141529	chr22:29269692	A/G	cg15103426	chr22:29168792	CCDC117	0.46	5.58	0.32	5.81e-8	Lymphocyte counts;
CESC	cis	rs6089829	0.855	rs6062781	chr20:61667128	G/A	cg16240275	chr20:61666158	NCRNA00029	0.5	8.96	0.48	6.1e-17	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10475689	chr16:12142335	RUNDC2A	-0.53	-7.01	-0.4	1.98e-11	Gut microbiome composition (summer);
CESC	cis	rs6088590	1.000	rs12626122	chr20:33425800	A/G	cg06115741	chr20:33292138	TP53INP2	0.6	7.14	0.4	8.98e-12	Coronary artery disease;
CESC	cis	rs7267979	1.000	rs6050559	chr20:25329915	A/G	cg08601574	chr20:25228251	PYGB	0.37	5.37	0.31	1.73e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7829975	0.902	rs485107	chr8:8581408	C/G	cg15556689	chr8:8085844	FLJ10661	-0.46	-5.81	-0.34	1.81e-8	Mood instability;
CESC	cis	rs1153858	1.000	rs4271549	chr15:45652730	G/A	cg21132104	chr15:45694354	SPATA5L1	0.85	11.64	0.58	1.47e-25	Homoarginine levels;
CESC	cis	rs514406	0.505	rs436363	chr1:53172163	T/C	cg16325326	chr1:53192061	ZYG11B	0.9	15.56	0.69	3.23e-39	Monocyte count;
CESC	cis	rs34172651	0.517	rs1465423	chr16:24772680	C/G	cg06505273	chr16:24850292	NA	-0.52	-6.43	-0.37	5.95e-10	Intelligence (multi-trait analysis);
CESC	cis	rs4835473	0.549	rs11940719	chr4:144892008	C/T	cg25736465	chr4:144833511	NA	0.39	5.99	0.35	6.96e-9	Immature fraction of reticulocytes;
CESC	cis	rs28374715	0.532	rs28703570	chr15:41679492	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.07	-17.74	-0.74	6.07e-47	Ulcerative colitis;
CESC	cis	rs875971	0.862	rs11763189	chr7:65983529	G/A	cg10691866	chr7:65817282	TPST1	-0.31	-5.16	-0.3	4.74e-7	Aortic root size;
CESC	cis	rs12476592	0.602	rs262536	chr2:63906926	T/C	cg17519650	chr2:63277830	OTX1	-0.48	-5.26	-0.31	3.01e-7	Childhood ear infection;
CESC	cis	rs8062405	0.824	rs62034326	chr16:28539293	A/G	cg07382826	chr16:28625726	SULT1A1	0.31	5.05	0.3	8.32e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs9911578	1.000	rs7207693	chr17:57016525	C/T	cg12560992	chr17:57184187	TRIM37	0.93	15.28	0.68	3.05e-38	Intelligence (multi-trait analysis);
CESC	cis	rs4450131	0.522	rs34336231	chr10:126355662	C/T	cg20435097	chr10:126320824	FAM53B	0.3	5.37	0.31	1.69e-7	White blood cell count (basophil);
CESC	cis	rs6964587	0.904	rs6465339	chr7:91570790	T/A	cg17063962	chr7:91808500	NA	-0.57	-7.69	-0.43	2.84e-13	Breast cancer;
CESC	cis	rs9894429	0.572	rs112417725	chr17:79578219	A/G	cg13777783	chr17:79615861	NA	0.36	6.15	0.35	2.83e-9	Eye color traits;
CESC	cis	rs2506889	0.553	rs11580264	chr1:10605796	C/A	cg20482658	chr1:10539492	PEX14	-0.28	-5.61	-0.33	4.97e-8	Breast cancer;
CESC	cis	rs3096299	0.838	rs3102384	chr16:89411661	T/G	cg00750074	chr16:89608354	SPG7	-0.43	-5.8	-0.34	1.91e-8	Multiple myeloma (IgH translocation);
CESC	cis	rs7818688	1.000	rs10086541	chr8:96033950	A/G	cg16049864	chr8:95962084	TP53INP1	0.55	5.85	0.34	1.42e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs4819052	1.000	rs2297286	chr21:46707897	C/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.63	7.73	0.43	2.2e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs10927875	0.722	rs6660685	chr1:16346988	A/G	cg21385522	chr1:16154831	NA	0.6	7.16	0.4	8.13e-12	Dilated cardiomyopathy;
CESC	cis	rs9359856	0.564	rs72915904	chr6:90421412	C/A	cg13799429	chr6:90582589	CASP8AP2	-0.67	-6.77	-0.38	8.26e-11	Bipolar disorder;
CESC	cis	rs35306767	0.903	rs10904577	chr10:922077	A/G	cg10556349	chr10:835070	NA	0.56	5.34	0.31	2e-7	Eosinophil percentage of granulocytes;
CESC	cis	rs3785574	0.962	rs2584621	chr17:61912436	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.57	6.96	0.39	2.69e-11	Height;
CESC	cis	rs7301826	0.651	rs10734979	chr12:131288954	T/C	cg11011512	chr12:131303247	STX2	0.47	5.82	0.34	1.71e-8	Plasma plasminogen activator levels;
CESC	cis	rs9457247	0.967	rs385460	chr6:167403888	A/T	cg25258033	chr6:167368657	RNASET2	0.39	5.88	0.34	1.26e-8	Crohn's disease;
CESC	cis	rs11252926	0.527	rs11252754	chr10:538637	G/A	cg03684893	chr10:554711	DIP2C	-0.47	-7.39	-0.41	1.91e-12	Psychosis in Alzheimer's disease;
CESC	cis	rs7799006	0.755	rs12534131	chr7:2294123	C/T	cg08027265	chr7:2291960	NA	-0.58	-10.02	-0.52	2.97e-20	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs8060686	0.858	rs2008173	chr16:67856240	A/G	cg26727032	chr16:67993705	SLC12A4	-0.67	-9.45	-0.5	1.89e-18	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs7412746	0.658	rs59024312	chr1:150909005	T/G	cg17724175	chr1:150552817	MCL1	0.38	5.9	0.34	1.13e-8	Melanoma;
CESC	cis	rs875971	0.862	rs1968126	chr7:66057004	A/G	cg18876405	chr7:65276391	NA	-0.53	-7.37	-0.41	2.19e-12	Aortic root size;
CESC	cis	rs4919087	0.923	rs11189038	chr10:98974765	A/T	cg25902810	chr10:99078978	FRAT1	0.67	9.67	0.51	3.88e-19	Monocyte count;
CESC	cis	rs8045833	0.714	rs749681	chr16:88570675	A/G	cg05152867	chr16:88568237	ZFPM1	0.32	5.23	0.31	3.48e-7	Vascular endothelial growth factor levels;
CESC	cis	rs28829049	0.895	rs2313061	chr1:19360293	G/A	cg13387374	chr1:19411106	UBR4	0.42	5.24	0.31	3.25e-7	QRS duration in Tripanosoma cruzi seropositivity;
CESC	cis	rs597539	0.690	rs647661	chr11:68625875	T/C	cg21963583	chr11:68658836	MRPL21	0.42	5.71	0.33	3.1e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs2880765	0.835	rs56406982	chr15:86036379	G/A	cg10818794	chr15:86012489	AKAP13	-0.34	-5.31	-0.31	2.3e-7	Coronary artery disease;
CESC	cis	rs4819052	0.851	rs2838833	chr21:46665160	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.45	5.58	0.32	5.89e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs2228479	0.557	rs11648881	chr16:89862434	T/C	cg04013166	chr16:89971882	TCF25	0.76	6.45	0.37	5.36e-10	Skin colour saturation;
CESC	cis	rs3820928	0.874	rs4675138	chr2:227884118	G/A	cg05526886	chr2:227700861	RHBDD1	-0.43	-5.49	-0.32	9.36e-8	Pulmonary function;
CESC	cis	rs72781680	0.821	rs17045981	chr2:24109316	A/G	cg08917208	chr2:24149416	ATAD2B	0.66	6.55	0.37	2.91e-10	Lymphocyte counts;
CESC	cis	rs896854	0.684	rs10099059	chr8:95986972	G/C	cg26343298	chr8:95960752	TP53INP1	0.36	6.05	0.35	4.98e-9	Type 2 diabetes;
CESC	cis	rs3820928	0.967	rs16822905	chr2:227770727	G/C	cg11843606	chr2:227700838	RHBDD1	-0.4	-5.22	-0.31	3.58e-7	Pulmonary function;
CESC	cis	rs4805272	0.512	rs66830923	chr19:29321277	C/T	cg14983838	chr19:29218262	NA	0.45	5.38	0.31	1.66e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
CESC	cis	rs4925386	0.840	rs8124907	chr20:60913127	A/G	cg06026331	chr20:60912101	LAMA5	0.46	5.09	0.3	6.77e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs807669	0.868	rs2800973	chr22:19168616	A/G	cg02655711	chr22:19163373	SLC25A1	0.95	14.93	0.68	5.37e-37	Metabolite levels;
CESC	cis	rs1881797	1.000	rs12063141	chr1:247688343	G/A	cg11166453	chr1:247681781	NA	0.45	5.59	0.32	5.53e-8	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs10744422	0.748	rs2292138	chr12:123339712	A/G	cg25930673	chr12:123319894	HIP1R	-0.76	-5.88	-0.34	1.26e-8	Schizophrenia;
CESC	cis	rs7772486	0.727	rs10447449	chr6:146138707	A/G	cg05347473	chr6:146136440	FBXO30	0.55	7.21	0.4	5.99e-12	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs12356475	0.710	rs10822686	chr10:67733250	C/T	cg16561543	chr14:105714843	BRF1;BTBD6	0.48	6.03	0.35	5.51e-9	Psoriatic arthritis;
CESC	cis	rs9660992	0.710	rs1768586	chr1:205238275	A/G	cg21643547	chr1:205240462	TMCC2	-0.49	-6.84	-0.39	5.31e-11	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs9910055	0.762	rs1135215	chr17:42253519	T/C	cg19774624	chr17:42201019	HDAC5	-0.7	-10.12	-0.53	1.49e-20	Total body bone mineral density;
CESC	cis	rs2354432	0.607	rs59689207	chr1:146722484	G/A	cg25205988	chr1:146714368	CHD1L	-1.01	-8.47	-0.46	1.68e-15	Mitochondrial DNA levels;
CESC	cis	rs5750830	0.621	rs743838	chr22:39824707	T/G	cg05872129	chr22:39784769	NA	-0.8	-10.34	-0.54	2.79e-21	Intelligence (multi-trait analysis);
CESC	cis	rs4237845	0.837	rs7954957	chr12:58299250	C/T	cg02175503	chr12:58329896	NA	0.65	9.29	0.5	5.97e-18	Intelligence (multi-trait analysis);
CESC	cis	rs35849525	0.776	rs7615318	chr3:49987475	C/T	cg24308560	chr3:49941425	MST1R	-0.53	-6.43	-0.37	6.09e-10	Intelligence (multi-trait analysis);
CESC	cis	rs6032067	0.929	rs6017504	chr20:43818920	G/A	cg11264863	chr20:43835661	SEMG1	0.49	5.29	0.31	2.5e-7	Blood protein levels;
CESC	cis	rs858239	0.669	rs1006709	chr7:23140099	C/T	cg27449745	chr7:23145252	KLHL7	-0.48	-6.37	-0.36	8.44e-10	Cerebrospinal fluid biomarker levels;
CESC	cis	rs460214	0.564	rs9979888	chr21:40022099	A/G	cg05519781	chr21:40033154	ERG	0.45	5.53	0.32	7.65e-8	Response to cognitive-behavioural therapy in anxiety disorder;
CESC	cis	rs7845219	0.544	rs9643351	chr8:95917290	C/T	cg13393036	chr8:95962371	TP53INP1	-0.42	-7.84	-0.43	1.13e-13	Type 2 diabetes;
CESC	cis	rs1862618	0.853	rs6885541	chr5:56110857	G/C	cg03609598	chr5:56110824	MAP3K1	-0.5	-5.35	-0.31	1.9e-7	Initial pursuit acceleration;
CESC	cis	rs7666738	0.830	rs7662596	chr4:99019962	G/T	cg05340658	chr4:99064831	C4orf37	0.82	12.99	0.62	3.34e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs5760092	0.572	rs738806	chr22:24234172	A/G	cg24846343	chr22:24311635	DDTL	0.42	5.61	0.33	5.11e-8	Urinary 1,3-butadiene metabolite levels in smokers;
CESC	cis	rs2228479	0.702	rs11649501	chr16:89850957	A/T	cg06558623	chr16:89946397	TCF25	1.18	9.42	0.5	2.3e-18	Skin colour saturation;
CESC	cis	rs765787	0.530	rs3759893	chr15:45542950	G/T	cg24006582	chr15:45444508	DUOX1	-0.6	-7.38	-0.41	2.07e-12	Uric acid levels;
CESC	cis	rs9311474	0.508	rs7625743	chr3:52606366	C/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.5	7.39	0.41	1.97e-12	Electroencephalogram traits;
CESC	cis	rs80130819	0.688	rs10783233	chr12:48590899	C/G	cg05342945	chr12:48394962	COL2A1	-0.51	-5.81	-0.34	1.75e-8	Prostate cancer;
CESC	cis	rs7582720	1.000	rs72934749	chr2:203746816	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.39	0.41	1.96e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs701145	0.617	rs9820619	chr3:154028294	G/T	cg16511985	chr3:153974050	SGEF	0.4	5.33	0.31	2.06e-7	Coronary artery disease;
CESC	cis	rs10838687	0.673	rs77532017	chr11:47284317	C/T	cg25783544	chr11:47291846	MADD	0.58	6.58	0.37	2.5e-10	Proinsulin levels;
CESC	cis	rs7551222	0.752	rs11240758	chr1:204528651	C/T	cg20240347	chr1:204465584	NA	-0.28	-5.61	-0.33	5.06e-8	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09368168	chr16:15744041	NDE1	0.54	6.14	0.35	2.97e-9	Gut microbiome composition (summer);
CESC	cis	rs6693567	0.565	rs1260458	chr1:150347454	C/T	cg09579323	chr1:150459698	TARS2	0.46	6.05	0.35	4.93e-9	Migraine;
CESC	cis	rs7809950	0.637	rs3801964	chr7:106836242	T/C	cg23024343	chr7:107201750	COG5	-0.57	-6.94	-0.39	2.95e-11	Coronary artery disease;
CESC	cis	rs2760061	0.626	rs2313118	chr1:228118084	T/C	cg02753203	chr1:228287806	NA	-0.5	-7.24	-0.41	4.91e-12	Diastolic blood pressure;
CESC	cis	rs4722166	0.630	rs12700391	chr7:22777327	C/A	cg05265849	chr7:22767390	IL6	0.57	7.11	0.4	1.06e-11	Lung cancer;
CESC	cis	rs61996546	0.622	rs11637029	chr15:26836107	T/A	cg14859324	chr15:26874363	GABRB3	-0.38	-5.12	-0.3	6e-7	Response to methotrexate in juvenile idiopathic arthritis;
CESC	cis	rs9911578	1.000	rs304296	chr17:56834229	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.16	0.3	4.76e-7	Intelligence (multi-trait analysis);
CESC	cis	rs875971	1.000	rs6460295	chr7:65882728	T/C	cg12463550	chr7:65579703	CRCP	0.58	7.41	0.41	1.67e-12	Aortic root size;
CESC	cis	rs11997175	0.550	rs7459565	chr8:33836717	C/T	ch.8.33884649F	chr8:33765107	NA	0.58	6.66	0.38	1.58e-10	Body mass index;
CESC	cis	rs7772486	0.875	rs9390372	chr6:146363638	G/C	cg05347473	chr6:146136440	FBXO30	0.47	6.16	0.35	2.66e-9	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7618915	0.547	rs34017441	chr3:52742413	T/C	cg05564831	chr3:52568323	NT5DC2	0.43	6.59	0.38	2.3e-10	Bipolar disorder;
CESC	cis	rs6424115	0.830	rs2503002	chr1:24196957	C/G	cg10978503	chr1:24200527	CNR2	0.3	6.11	0.35	3.57e-9	Immature fraction of reticulocytes;
CESC	cis	rs6665290	0.904	rs3768425	chr1:227178127	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.23	-34.55	-0.9	3.8e-100	Myeloid white cell count;
CESC	cis	rs6570726	0.620	rs367693	chr6:145815949	G/A	cg05347473	chr6:146136440	FBXO30	0.72	9.07	0.49	2.79e-17	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs763121	0.853	rs6519124	chr22:39045099	T/C	cg06022373	chr22:39101656	GTPBP1	0.95	17.36	0.73	1.37e-45	Menopause (age at onset);
CESC	cis	rs7772486	0.641	rs67882056	chr6:146416301	T/C	cg05347473	chr6:146136440	FBXO30	0.64	8.16	0.45	1.37e-14	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs10911363	0.573	rs2702181	chr1:183516985	T/A	cg09173681	chr1:183549694	NCF2	0.53	7.72	0.43	2.39e-13	Systemic lupus erythematosus;
CESC	cis	rs17376456	0.877	rs10044139	chr5:93407803	T/C	cg21475434	chr5:93447410	FAM172A	0.83	7.31	0.41	3.14e-12	Diabetic retinopathy;
CESC	cis	rs875971	1.000	rs3735148	chr7:65971009	T/G	cg18876405	chr7:65276391	NA	0.48	6.32	0.36	1.08e-9	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01953119	chr2:20425340	SDC1	-0.59	-6.59	-0.38	2.32e-10	Gut microbiome composition (summer);
CESC	cis	rs4704187	0.617	rs1477936	chr5:74448502	T/A	cg03227963	chr5:74354835	NA	0.3	5.5	0.32	8.75e-8	Response to amphetamines;
CESC	cis	rs6598955	0.543	rs17163720	chr1:26549399	A/G	cg04990556	chr1:26633338	UBXN11	-0.74	-8.25	-0.45	7.73e-15	Obesity-related traits;
CESC	cis	rs10504229	0.954	rs903717	chr8:58167856	A/G	cg05313129	chr8:58192883	C8orf71	-0.4	-5.11	-0.3	6.17e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs11249608	0.789	rs903989	chr5:178434434	C/T	cg21905437	chr5:178450457	ZNF879	0.55	7.85	0.43	1.05e-13	Pubertal anthropometrics;
CESC	cis	rs11785400	0.928	rs2280878	chr8:143722366	G/A	cg10596483	chr8:143751796	JRK	0.41	5.36	0.31	1.82e-7	Schizophrenia;
CESC	cis	rs7914558	0.966	rs2297786	chr10:104679978	C/T	cg08650961	chr10:104748594	CNNM2	0.32	5.12	0.3	5.79e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs9322193	0.962	rs2342764	chr6:150156204	G/A	cg07701084	chr6:150067640	NUP43	0.44	5.94	0.34	8.85e-9	Lung cancer;
CESC	cis	rs8177253	0.829	rs9882812	chr3:133506127	A/G	cg01448562	chr3:133502909	NA	-0.57	-7.84	-0.43	1.12e-13	Iron status biomarkers;
CESC	cis	rs4665809	1.000	rs2289022	chr2:26350136	G/T	cg22920501	chr2:26401640	FAM59B	-0.67	-8.09	-0.44	2.22e-14	Gut microbiome composition (summer);
CESC	cis	rs9611565	0.506	rs1984839	chr22:41685937	G/C	cg06634786	chr22:41940651	POLR3H	-0.51	-5.48	-0.32	1.01e-7	Vitiligo;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg18076651	chr12:53625605	RARG	0.41	6.45	0.37	5.26e-10	Systemic lupus erythematosus;
CESC	cis	rs7116495	1.000	rs2508858	chr11:71805405	C/G	cg26138937	chr11:71823887	C11orf51	0.85	6.82	0.39	6e-11	Severe influenza A (H1N1) infection;
CESC	cis	rs875971	0.862	rs2901152	chr7:65765004	G/A	cg18252515	chr7:66147081	NA	0.43	5.73	0.33	2.67e-8	Aortic root size;
CESC	trans	rs10776614	0.799	rs7087729	chr10:49767103	C/T	cg19218067	chr2:181235115	NA	0.49	6.0	0.35	6.35e-9	Self-employment;
CESC	cis	rs2576037	0.526	rs2187092	chr18:44526798	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.69	10.92	0.56	3.56e-23	Personality dimensions;
CESC	cis	rs703842	1.000	rs10877012	chr12:58162085	G/T	cg18357645	chr12:58087776	OS9	-0.42	-5.84	-0.34	1.49e-8	Multiple sclerosis;
CESC	cis	rs8114671	0.836	rs734308	chr20:33572096	A/G	cg24642439	chr20:33292090	TP53INP2	-0.46	-5.48	-0.32	1.01e-7	Height;
CESC	trans	rs11989744	0.843	rs10481331	chr8:23559257	T/C	cg03492747	chr16:86543808	FOXF1	0.64	7.29	0.41	3.59e-12	Waist-hip ratio;
CESC	cis	rs7098414	0.511	rs7899545	chr10:82150635	G/C	cg00277334	chr10:82204260	NA	-0.5	-7.5	-0.42	9.84e-13	Post bronchodilator FEV1;
CESC	cis	rs4803468	1.000	rs8105833	chr19:41896145	G/A	cg14132834	chr19:41945861	ATP5SL	-0.56	-6.89	-0.39	4.02e-11	Height;
CESC	cis	rs7098414	0.511	rs7071752	chr10:82159539	C/A	cg00277334	chr10:82204260	NA	-0.52	-7.71	-0.43	2.58e-13	Post bronchodilator FEV1;
CESC	cis	rs35306767	0.953	rs11253521	chr10:976416	G/C	cg20503657	chr10:835505	NA	0.63	7.11	0.4	1.06e-11	Eosinophil percentage of granulocytes;
CESC	cis	rs6546550	0.933	rs1454498	chr2:70149225	C/A	cg02498382	chr2:70120550	SNRNP27	-0.41	-7.26	-0.41	4.34e-12	Prevalent atrial fibrillation;
CESC	trans	rs11098499	0.697	rs4560394	chr4:120313435	T/G	cg25214090	chr10:38739885	LOC399744	0.68	9.21	0.49	1.05e-17	Corneal astigmatism;
CESC	cis	rs7520050	0.807	rs28844317	chr1:46209207	T/C	cg06784218	chr1:46089804	CCDC17	0.33	5.94	0.34	9.01e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs2836974	0.965	rs9941894	chr21:40634058	C/T	cg11890956	chr21:40555474	PSMG1	1.09	18.21	0.75	1.28e-48	Cognitive function;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05354989	chr17:56429503	SUPT4H1	0.45	6.03	0.35	5.37e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs10256972	0.758	rs4723649	chr7:1071905	T/C	cg04025307	chr7:1156635	C7orf50	0.48	7.69	0.43	2.81e-13	Longevity;Endometriosis;
CESC	cis	rs12477438	0.501	rs11692336	chr2:99740606	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.8	12.74	0.62	2.5e-29	Chronic sinus infection;
CESC	cis	rs13191362	1.000	rs13204013	chr6:163002480	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.83	8.39	0.46	3.02e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs13064411	0.735	rs7636128	chr3:113133701	A/T	cg18753928	chr3:113234510	CCDC52	-0.48	-5.75	-0.33	2.39e-8	Response to simvastatin treatment (PCSK9 protein level change);
CESC	cis	rs914615	0.529	rs11264338	chr1:155138557	A/G	cg02153340	chr1:155202674	NA	-0.38	-5.48	-0.32	9.97e-8	Urinary albumin-to-creatinine ratio;
CESC	cis	rs4975616	0.804	rs31489	chr5:1342714	C/A	cg26373071	chr5:1325741	CLPTM1L	0.46	7.16	0.4	8.04e-12	Lung cancer;
CESC	cis	rs7264396	0.563	rs3827029	chr20:34332784	G/T	cg23207816	chr20:34252616	CPNE1;RBM12	-0.64	-7.19	-0.4	6.64e-12	Total cholesterol levels;
CESC	cis	rs853679	0.517	rs4713137	chr6:28083521	C/G	cg23281280	chr6:28129359	ZNF389	0.58	7.93	0.44	6.31e-14	Depression;
CESC	cis	rs1707322	1.000	rs1622208	chr1:46498375	A/G	cg03146154	chr1:46216737	IPP	-0.77	-10.51	-0.54	7.99e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs4819052	0.851	rs2236446	chr21:46678985	T/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.47	6.01	0.35	6.19e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg24642844	chr7:1081250	C7orf50	-0.76	-9.46	-0.5	1.79e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7680126	0.633	rs887732	chr4:10183117	G/C	cg00071950	chr4:10020882	SLC2A9	-0.51	-5.55	-0.32	6.79e-8	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	cis	rs854765	0.693	rs4924823	chr17:17764502	A/G	cg09796270	chr17:17721594	SREBF1	-0.4	-5.6	-0.33	5.27e-8	Total body bone mineral density;
CESC	cis	rs1879734	0.773	rs1554750	chr1:54135334	T/C	cg23596471	chr1:54105337	GLIS1	0.35	5.44	0.32	1.19e-7	Mitral valve prolapse;
CESC	trans	rs877282	0.898	rs12359731	chr10:759497	A/G	cg22713356	chr15:30763199	NA	1.12	11.1	0.56	8.99e-24	Uric acid levels;
CESC	cis	rs367943	0.966	rs364738	chr5:112808329	A/G	cg12552261	chr5:112820674	MCC	-0.62	-7.85	-0.43	1.05e-13	Type 2 diabetes;
CESC	cis	rs2228479	0.541	rs9922515	chr16:89954138	G/C	cg06558623	chr16:89946397	TCF25	0.58	5.86	0.34	1.34e-8	Skin colour saturation;
CESC	cis	rs3785574	0.924	rs2727292	chr17:61893747	A/G	cg06420487	chr17:61919686	SMARCD2	0.44	5.28	0.31	2.68e-7	Height;
CESC	cis	rs6430585	0.528	rs2278682	chr2:136743143	G/C	cg07169764	chr2:136633963	MCM6	1.09	15.1	0.68	1.35e-37	Corneal structure;
CESC	cis	rs826838	0.967	rs1719856	chr12:39127201	C/T	cg26384229	chr12:38710491	ALG10B	-0.67	-10.95	-0.56	2.81e-23	Heart rate;
CESC	cis	rs2404602	0.716	rs8025134	chr15:76781729	C/T	cg22467129	chr15:76604101	ETFA	-0.39	-5.79	-0.33	2.02e-8	Blood metabolite levels;
CESC	cis	rs3809566	1.000	rs4775612	chr15:63332157	T/C	cg05507819	chr15:63340323	TPM1	0.51	6.28	0.36	1.37e-9	Platelet count;
CESC	cis	rs8060686	0.565	rs4359427	chr16:68202747	C/T	cg26727032	chr16:67993705	SLC12A4	-0.49	-5.98	-0.34	7.1e-9	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs546131	1.000	rs546131	chr11:34851760	G/C	cg06937548	chr11:34938143	PDHX;APIP	0.5	6.22	0.36	1.93e-9	Lung disease severity in cystic fibrosis;
CESC	cis	rs6570726	0.935	rs409121	chr6:145839793	G/A	cg23711669	chr6:146136114	FBXO30	0.8	12.02	0.59	7.36e-27	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1801251	1.000	rs13013142	chr2:233600606	A/G	cg08000102	chr2:233561755	GIGYF2	0.67	9.36	0.5	3.68e-18	Coronary artery disease;
CESC	cis	rs7666738	0.962	rs17550217	chr4:98999699	T/A	cg18180107	chr4:99064573	C4orf37	0.42	5.23	0.31	3.45e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs8133932	0.608	rs373267	chr21:47343320	G/T	cg14185626	chr21:47401492	COL6A1	-0.46	-5.17	-0.3	4.62e-7	Schizophrenia;
CESC	cis	rs1005277	0.579	rs2474580	chr10:38398713	G/A	cg25427524	chr10:38739819	LOC399744	-0.66	-9.5	-0.5	1.29e-18	Extrinsic epigenetic age acceleration;
CESC	cis	rs7937682	0.562	rs955744	chr11:111374334	C/T	cg09085632	chr11:111637200	PPP2R1B	0.66	8.39	0.46	2.87e-15	Primary sclerosing cholangitis;
CESC	trans	rs801193	1.000	rs1553609	chr7:66197139	T/C	cg26939375	chr7:64535504	NA	0.64	8.67	0.47	4.39e-16	Aortic root size;
CESC	cis	rs9291683	0.609	rs12500810	chr4:10031068	G/A	cg00071950	chr4:10020882	SLC2A9	0.88	16.3	0.71	7.52e-42	Bone mineral density;
CESC	cis	rs875971	1.000	rs1544549	chr7:66090663	T/A	cg10691866	chr7:65817282	TPST1	0.34	5.58	0.32	6.03e-8	Aortic root size;
CESC	cis	rs4253772	0.637	rs8139035	chr22:46651367	A/G	cg24881330	chr22:46731750	TRMU	0.89	10.09	0.53	1.86e-20	LDL cholesterol;Cholesterol, total;
CESC	cis	rs898097	0.841	rs8074284	chr17:80909967	G/A	cg19046167	chr17:80928561	B3GNTL1	0.43	5.25	0.31	3.13e-7	Breast cancer;
CESC	cis	rs9926296	0.533	rs12102297	chr16:89812762	C/A	cg04287289	chr16:89883240	FANCA	0.92	16.38	0.71	3.91e-42	Vitiligo;
CESC	cis	rs3126085	0.935	rs11588174	chr1:152175970	C/T	cg26876637	chr1:152193138	HRNR	-0.45	-5.21	-0.31	3.73e-7	Atopic dermatitis;
CESC	cis	rs60154123	0.505	rs115881613	chr1:210040369	C/T	cg25204440	chr1:209979598	IRF6	0.67	6.11	0.35	3.54e-9	Coronary artery disease;
CESC	cis	rs1707322	0.963	rs9787412	chr1:46371596	C/T	cg06784218	chr1:46089804	CCDC17	0.32	5.57	0.32	6.35e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs5769765	0.862	rs9616380	chr22:50312225	T/C	cg02269571	chr22:50332266	NA	-0.57	-6.99	-0.39	2.29e-11	Schizophrenia;
CESC	cis	rs1348850	0.757	rs4893969	chr2:178478476	T/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.53	6.82	0.39	5.99e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs2635047	0.648	rs4986203	chr18:44597092	A/G	cg19077165	chr18:44547161	KATNAL2	-0.52	-7.51	-0.42	8.81e-13	Educational attainment;
CESC	cis	rs4474465	0.688	rs7929656	chr11:78276416	T/C	cg27205649	chr11:78285834	NARS2	0.47	6.35	0.36	9.35e-10	Alzheimer's disease (survival time);
CESC	cis	rs400736	0.562	rs12129505	chr1:8171734	T/C	cg25007680	chr1:8021821	PARK7	-0.6	-7.81	-0.43	1.32e-13	Response to antidepressants and depression;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04407228	chr1:1710158	NADK	0.6	6.36	0.36	8.77e-10	Gut microbiome composition (summer);
CESC	cis	rs6952808	0.965	rs4719318	chr7:1887930	G/A	cg13880726	chr7:1868755	MAD1L1	0.51	6.98	0.39	2.4e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs9911578	1.000	rs7342903	chr17:56914588	C/G	cg05425664	chr17:57184151	TRIM37	-0.5	-6.92	-0.39	3.44e-11	Intelligence (multi-trait analysis);
CESC	cis	rs6963495	0.818	rs73192120	chr7:105171156	C/T	cg19920283	chr7:105172520	RINT1	0.69	6.54	0.37	3.15e-10	Bipolar disorder (body mass index interaction);
CESC	trans	rs526821	0.595	rs629948	chr11:55356448	G/A	cg15704280	chr7:45808275	SEPT13	-0.52	-6.55	-0.37	2.99e-10	Pediatric bone mineral density (spine);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11957880	chr12:93835939	UBE2N	-0.6	-6.89	-0.39	4.14e-11	Gut microbiome composition (summer);
CESC	cis	rs1862618	0.853	rs6450408	chr5:56098146	T/C	cg03609598	chr5:56110824	MAP3K1	-0.5	-5.32	-0.31	2.26e-7	Initial pursuit acceleration;
CESC	cis	rs6933660	0.646	rs9397410	chr6:151770503	C/T	cg14262678	chr6:151773367	RMND1;C6orf211	0.69	10.17	0.53	9.75e-21	Menarche (age at onset);
CESC	cis	rs13191362	1.000	rs67646369	chr6:163003233	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.83	8.39	0.46	3.02e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg00746083	chr14:21905454	CHD8	0.48	6.4	0.37	7.2e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg02073954	chr6:28193080	ZNF193	-0.54	-6.87	-0.39	4.52e-11	Ulcerative colitis;
CESC	cis	rs1348850	0.914	rs10170546	chr2:178248790	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.9	13.34	0.63	2.15e-31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs11098499	0.821	rs3775852	chr4:120454556	A/G	cg24375607	chr4:120327624	NA	0.43	5.21	0.3	3.82e-7	Corneal astigmatism;
CESC	cis	rs896854	0.608	rs7004862	chr8:95876963	T/G	cg16049864	chr8:95962084	TP53INP1	-0.61	-10.57	-0.54	5.24e-22	Type 2 diabetes;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg24117723	chr11:77185398	PAK1	-0.46	-6.0	-0.35	6.56e-9	Fibrinogen levels;
CESC	cis	rs10504229	0.609	rs66477547	chr8:58105763	A/C	cg24829409	chr8:58192753	C8orf71	-0.56	-7.04	-0.4	1.61e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs2991971	0.967	rs12133294	chr1:45988764	C/T	cg24296786	chr1:45957014	TESK2	0.64	8.63	0.47	5.88e-16	High light scatter reticulocyte count;
CESC	cis	rs4713118	0.513	rs149954	chr6:28035246	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.47	-6.05	-0.35	4.86e-9	Parkinson's disease;
CESC	cis	rs2073300	1.000	rs114718317	chr20:23442620	T/C	cg12062639	chr20:23401060	NAPB	0.9	6.28	0.36	1.4e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs7811142	1.000	rs11764818	chr7:100043055	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.78	6.71	0.38	1.17e-10	Platelet count;
CESC	cis	rs66782572	1	rs66782572	chr3:52567617	A/G	cg18099408	chr3:52552593	STAB1	-0.38	-6.87	-0.39	4.69e-11	Hemoglobin concentration;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg07855967	chr6:13486425	C6orf114;GFOD1	-0.44	-6.91	-0.39	3.68e-11	Gambling;
CESC	cis	rs9467711	0.606	rs9393708	chr6:26362643	C/T	cg14345882	chr6:26364793	BTN3A2	-0.61	-6.72	-0.38	1.11e-10	Autism spectrum disorder or schizophrenia;
CESC	cis	rs2066819	1.000	rs57279772	chr12:56698960	G/A	cg26804944	chr12:56660921	COQ10A	-0.85	-5.19	-0.3	4.22e-7	Psoriasis vulgaris;
CESC	cis	rs7412746	0.611	rs2864873	chr1:150814174	A/G	cg09365446	chr1:150670422	GOLPH3L	0.41	5.58	0.32	5.85e-8	Melanoma;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25934700	chr22:50644755	SELO	-0.56	-6.43	-0.37	5.93e-10	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15983200	chr12:110562122	IFT81	0.56	6.37	0.36	8.35e-10	Gut microbiome composition (summer);
CESC	cis	rs7829975	0.688	rs6601703	chr8:8380224	A/G	cg15556689	chr8:8085844	FLJ10661	0.53	6.45	0.37	5.4e-10	Mood instability;
CESC	cis	rs9311474	0.607	rs28661185	chr3:52567188	G/T	cg18337363	chr3:52569053	NT5DC2	0.29	5.2	0.3	4e-7	Electroencephalogram traits;
CESC	cis	rs10504229	1.000	rs67188507	chr8:58187492	A/T	cg14926445	chr8:58193284	C8orf71	-0.51	-5.49	-0.32	9.4e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs3733585	0.699	rs7676733	chr4:9966956	G/A	cg11266682	chr4:10021025	SLC2A9	-0.58	-10.94	-0.56	3.03e-23	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs10779751	0.770	rs11581010	chr1:11212458	A/G	cg08854313	chr1:11322531	MTOR	-0.73	-8.44	-0.46	2.06e-15	Body mass index;
CESC	trans	rs9325144	0.647	rs7487395	chr12:38865660	C/A	cg23762105	chr12:34175262	ALG10	0.46	6.04	0.35	5.3e-9	Morning vs. evening chronotype;
CESC	cis	rs3796352	1.000	rs10510761	chr3:52965255	A/G	cg12962167	chr3:53033115	SFMBT1	-0.59	-5.1	-0.3	6.53e-7	Immune reponse to smallpox (secreted IL-2);
CESC	cis	rs12478296	0.901	rs67951957	chr2:243004901	A/G	cg06360820	chr2:242988706	NA	-0.74	-9.12	-0.49	1.92e-17	Obesity-related traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18849300	chr3:48723061	NCKIPSD	0.5	6.3	0.36	1.27e-9	Gut microbiome composition (summer);
CESC	cis	rs4319547	0.620	rs12372756	chr12:122815130	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.48	-5.6	-0.33	5.34e-8	Body mass index;
CESC	cis	rs7666738	0.830	rs11727653	chr4:99001774	T/C	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.62e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs12911832	0.958	rs12912003	chr15:58986001	A/T	cg05156742	chr15:59063176	FAM63B	0.57	7.14	0.4	8.75e-12	Schizophrenia;
CESC	cis	rs3806843	0.966	rs11953833	chr5:140155123	T/A	cg26395211	chr5:140044315	WDR55	-0.4	-5.15	-0.3	5.05e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs9911578	1.000	rs2270097	chr17:56572070	G/A	cg05425664	chr17:57184151	TRIM37	0.49	6.83	0.39	5.65e-11	Intelligence (multi-trait analysis);
CESC	trans	rs2727020	0.553	rs3862350	chr11:49595912	A/C	cg15704280	chr7:45808275	SEPT13	-0.95	-16.23	-0.71	1.34e-41	Coronary artery disease;
CESC	cis	rs6460942	1.000	rs6460935	chr7:12401317	A/T	cg17427002	chr7:12443146	VWDE	-0.51	-5.04	-0.3	8.8e-7	Coronary artery disease;
CESC	cis	rs60871478	1.000	rs62432899	chr7:826542	G/C	cg05535760	chr7:792225	HEATR2	0.97	11.19	0.57	4.78e-24	Cerebrospinal P-tau181p levels;
CESC	cis	rs801193	1.000	rs6958520	chr7:66151453	T/C	cg25985355	chr7:65971099	NA	-0.31	-5.04	-0.3	8.47e-7	Aortic root size;
CESC	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg07677032	chr17:61819896	STRADA	0.45	5.96	0.34	8.12e-9	Prudent dietary pattern;
CESC	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg18538332	chr22:24372958	LOC391322	0.72	10.22	0.53	6.92e-21	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs7680126	0.644	rs4697703	chr4:10107431	A/G	cg11266682	chr4:10021025	SLC2A9	-0.53	-7.28	-0.41	3.77e-12	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	cis	rs10242455	0.764	rs4646465	chr7:99304524	A/G	cg07715041	chr7:99302981	CYP3A7	-0.42	-5.37	-0.31	1.71e-7	Blood metabolite levels;
CESC	cis	rs2180341	0.960	rs9398839	chr6:127665863	G/A	cg24812749	chr6:127587940	RNF146	1.07	15.17	0.68	7.85e-38	Breast cancer;
CESC	cis	rs17401966	0.838	rs11580854	chr1:10293565	G/A	cg15208524	chr1:10270712	KIF1B	0.41	5.36	0.31	1.84e-7	Hepatocellular carcinoma;
CESC	cis	rs1799949	1.000	rs72829113	chr17:41181835	C/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.39	5.13	0.3	5.51e-7	Menopause (age at onset);
CESC	cis	rs1144333	1.000	rs12078893	chr1:76370862	T/C	cg10523679	chr1:76189770	ACADM	0.56	5.19	0.3	4.09e-7	Attention function in attention deficit hyperactive disorder;
CESC	trans	rs7937682	0.961	rs7106104	chr11:111635655	T/C	cg18187862	chr3:45730750	SACM1L	-0.55	-6.2	-0.36	2.1e-9	Primary sclerosing cholangitis;
CESC	cis	rs60154123	0.686	rs227222	chr1:210191272	T/C	cg22029157	chr1:209979665	IRF6	-0.62	-5.24	-0.31	3.26e-7	Coronary artery disease;
CESC	cis	rs6728642	1.000	rs60608738	chr2:97608085	G/A	cg26665480	chr2:98280029	ACTR1B	-0.65	-6.44	-0.37	5.72e-10	Bipolar disorder lithium response (continuous) or schizophrenia;
CESC	cis	rs17209837	0.920	rs17149652	chr7:87087187	G/T	cg00919237	chr7:87102261	ABCB4	-0.5	-5.83	-0.34	1.6e-8	Gallbladder cancer;
CESC	cis	rs1670533	0.932	rs13140571	chr4:1054358	T/C	cg27284194	chr4:1044797	NA	0.46	5.83	0.34	1.61e-8	Recombination rate (females);
CESC	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg23978390	chr7:1156363	C7orf50	-0.62	-8.9	-0.48	8.83e-17	Longevity;Endometriosis;
CESC	cis	rs7044106	0.718	rs1981021	chr9:123388393	T/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.36	5.84	0.34	1.54e-8	Hip circumference adjusted for BMI;
CESC	trans	rs3780486	0.629	rs10971439	chr9:33180813	C/T	cg20290983	chr6:43655470	MRPS18A	-0.57	-6.46	-0.37	4.93e-10	IgG glycosylation;
CESC	cis	rs10744422	1.000	rs7294991	chr12:123286780	C/T	cg22842854	chr12:123319900	HIP1R	-0.61	-5.09	-0.3	6.95e-7	Schizophrenia;
CESC	cis	rs4654899	1.000	rs10916921	chr1:21334542	C/T	cg05370193	chr1:21551575	ECE1	0.41	6.25	0.36	1.63e-9	Superior frontal gyrus grey matter volume;
CESC	cis	rs798554	0.679	rs2644300	chr7:2883071	G/A	cg18446336	chr7:2847575	GNA12	-0.35	-5.52	-0.32	8.23e-8	Height;
CESC	cis	rs854765	0.693	rs35451946	chr17:17764061	C/G	cg04398451	chr17:18023971	MYO15A	0.64	9.36	0.5	3.58e-18	Total body bone mineral density;
CESC	cis	rs798554	0.797	rs798488	chr7:2802522	T/C	cg04166393	chr7:2884313	GNA12	0.6	7.63	0.42	4.2e-13	Height;
CESC	cis	rs59698941	0.765	rs67045943	chr5:132219956	C/T	cg02081065	chr5:132209139	LEAP2	-0.52	-5.11	-0.3	6.08e-7	Apolipoprotein A-IV levels;
CESC	cis	rs4713118	0.527	rs35949862	chr6:28115367	A/G	cg26335602	chr6:28129616	ZNF389	0.53	6.75	0.38	9.35e-11	Parkinson's disease;
CESC	cis	rs2797160	0.967	rs926854	chr6:126021780	A/G	cg05901451	chr6:126070800	HEY2	0.45	6.51	0.37	3.77e-10	Endometrial cancer;
CESC	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg26338869	chr17:61819248	STRADA	0.69	9.2	0.49	1.12e-17	Prudent dietary pattern;
CESC	cis	rs8058578	1.000	rs56656810	chr16:30788759	C/A	cg00531865	chr16:30841666	NA	-0.43	-5.5	-0.32	8.79e-8	Multiple myeloma;
CESC	cis	rs10779751	0.770	rs10864490	chr1:11236410	A/C	cg08854313	chr1:11322531	MTOR	0.78	9.97	0.52	4.23e-20	Body mass index;
CESC	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	22.75	0.81	2.95e-64	Prudent dietary pattern;
CESC	trans	rs8073060	0.586	rs72829922	chr17:34044809	G/A	cg19694781	chr19:47549865	TMEM160	0.72	6.47	0.37	4.78e-10	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	cis	rs4555082	1.000	rs4277291	chr14:105759009	A/G	cg06808227	chr14:105710500	BRF1	-0.52	-6.31	-0.36	1.16e-9	Mean platelet volume;Platelet distribution width;
CESC	cis	rs9926296	0.605	rs8047486	chr16:89854025	A/T	cg21285383	chr16:89894308	SPIRE2	0.31	5.4	0.32	1.46e-7	Vitiligo;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11604142	chr10:101989359	CHUK	0.64	6.89	0.39	3.96e-11	Gut microbiome composition (summer);
CESC	cis	rs6752107	1.000	rs2241879	chr2:234183468	G/A	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.37	5.56	0.32	6.49e-8	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs17539620	0.534	rs7768635	chr6:154827861	C/T	cg17771515	chr6:154831774	CNKSR3	0.47	5.12	0.3	5.9e-7	Lipoprotein (a) levels;
CESC	cis	rs921968	0.565	rs7580147	chr2:219643036	A/G	cg02176678	chr2:219576539	TTLL4	-0.43	-7.73	-0.43	2.26e-13	Mean corpuscular hemoglobin concentration;
CESC	cis	rs4727027	0.704	rs12704070	chr7:148902789	G/A	cg23583168	chr7:148888333	NA	-0.94	-17.36	-0.73	1.28e-45	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs2777491	1.000	rs66538814	chr15:41685917	G/T	cg20272979	chr15:41787780	ITPKA	0.35	5.12	0.3	5.88e-7	Ulcerative colitis;
CESC	cis	rs8078723	1.000	rs4795415	chr17:38157995	C/T	cg17467752	chr17:38218738	THRA	0.69	10.55	0.54	5.78e-22	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CESC	cis	rs7659604	0.502	rs28522256	chr4:122709266	C/T	cg19671926	chr4:122722719	EXOSC9	0.67	8.89	0.48	9.9900000000000006e-17	Type 2 diabetes;
CESC	cis	rs11098499	0.866	rs12501602	chr4:120287935	A/T	cg09307838	chr4:120376055	NA	0.87	12.1	0.6	3.92e-27	Corneal astigmatism;
CESC	cis	rs4604732	0.536	rs10925056	chr1:247650472	T/C	cg12758973	chr1:247694275	LOC148824;OR2C3	0.44	5.56	0.32	6.43e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs644148	0.785	rs118112019	chr19:44965091	T/G	cg15540054	chr19:45004280	ZNF180	0.53	5.82	0.34	1.73e-8	Personality dimensions;
CESC	cis	rs6087990	0.735	rs2424913	chr20:31374259	C/T	cg13636640	chr20:31349939	DNMT3B	0.75	11.72	0.58	7.79e-26	Ulcerative colitis;
CESC	cis	rs10788264	0.621	rs7907952	chr10:124056774	C/T	cg09507567	chr10:124027408	NA	-0.37	-5.5	-0.32	8.88e-8	Total body bone mineral density;
CESC	cis	rs514406	0.825	rs6588441	chr1:53223494	G/A	cg24675658	chr1:53192096	ZYG11B	0.53	6.78	0.38	7.96e-11	Monocyte count;
CESC	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg03452623	chr4:187889614	NA	0.9	16.64	0.71	4.64e-43	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs11785400	0.793	rs750530	chr8:143744931	G/A	cg24634471	chr8:143751801	JRK	0.46	5.83	0.34	1.61e-8	Schizophrenia;
CESC	cis	rs2576037	0.796	rs2571032	chr18:44578250	T/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.43	5.66	0.33	3.98e-8	Personality dimensions;
CESC	cis	rs137603	0.562	rs137644	chr22:39728139	A/G	cg01093212	chr22:39715156	SNORD43;RPL3	-0.4	-5.16	-0.3	4.9e-7	Primary biliary cholangitis;
CESC	cis	rs8072100	1.000	rs11870935	chr17:45732605	G/A	cg08085267	chr17:45401833	C17orf57	0.42	5.63	0.33	4.55e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs9291683	0.632	rs13137074	chr4:10042842	C/T	cg02734326	chr4:10020555	SLC2A9	0.47	6.53	0.37	3.29e-10	Bone mineral density;
CESC	cis	rs769267	0.965	rs2017964	chr19:19387149	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.43	5.33	0.31	2.11e-7	Tonsillectomy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19791277	chr8:136469780	KHDRBS3	-0.55	-6.31	-0.36	1.19e-9	Gut microbiome composition (summer);
CESC	cis	rs6570726	0.791	rs7765687	chr6:145915100	A/C	cg05347473	chr6:146136440	FBXO30	0.52	6.83	0.39	5.79e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7666738	0.830	rs7664169	chr4:99037859	C/T	cg05340658	chr4:99064831	C4orf37	-0.82	-12.78	-0.62	1.89e-29	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7208859	0.623	rs9890558	chr17:29110355	T/C	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.17e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs16957304	1.000	rs9924145	chr16:67329762	T/C	cg26727032	chr16:67993705	SLC12A4	-0.52	-5.18	-0.3	4.42e-7	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
CESC	cis	rs4965006	0.915	rs4965004	chr12:132424700	A/G	cg00588090	chr12:132412438	PUS1	0.52	7.12	0.4	1.01e-11	Posterior cortical atrophy and Alzheimer's disease;
CESC	cis	rs8180040	0.653	rs6808742	chr3:47051512	G/A	cg27129171	chr3:47204927	SETD2	0.68	9.98	0.52	4.14e-20	Colorectal cancer;
CESC	cis	rs3106136	0.967	rs2664892	chr4:95154186	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.47	-7.25	-0.41	4.57e-12	Capecitabine sensitivity;
CESC	cis	rs2777491	0.957	rs919961	chr15:41651721	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.62	-9.39	-0.5	2.92e-18	Ulcerative colitis;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg00307073	chr7:116502428	CAPZA2	0.52	6.9	0.39	3.78e-11	Systemic lupus erythematosus;
CESC	cis	rs10864907	0.614	rs10199311	chr2:113697961	C/T	cg12858261	chr2:113808755	IL1F8	0.45	5.48	0.32	9.88e-8	Pulmonary function;
CESC	cis	rs4843747	0.749	rs13333619	chr16:88072076	C/T	cg09044154	chr16:88155775	NA	-0.45	-5.05	-0.3	8.33e-7	Menopause (age at onset);
CESC	cis	rs944722	0.511	rs2297520	chr17:26108040	T/C	cg07704981	chr17:26127537	NOS2	-0.35	-5.36	-0.31	1.78e-7	Fractional exhaled nitric oxide (childhood);
CESC	cis	rs9733	0.818	rs12403609	chr1:150676485	T/C	cg13175981	chr1:150552382	MCL1	0.62	9.22	0.49	9.37e-18	Tonsillectomy;
CESC	cis	rs1707322	1.000	rs4660895	chr1:46329739	C/T	cg03146154	chr1:46216737	IPP	0.71	9.86	0.52	9.69e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2836974	0.897	rs2026267	chr21:40711477	C/A	cg11644478	chr21:40555479	PSMG1	0.95	14.26	0.66	1.25e-34	Cognitive function;
CESC	cis	rs875971	0.830	rs778711	chr7:65851657	G/A	cg19163074	chr7:65112434	INTS4L2	-0.41	-5.11	-0.3	6.29e-7	Aortic root size;
CESC	cis	rs4835473	0.832	rs35763177	chr4:144658870	A/T	cg25736465	chr4:144833511	NA	-0.33	-5.2	-0.3	4.08e-7	Immature fraction of reticulocytes;
CESC	cis	rs561341	1.000	rs473356	chr17:30321762	G/C	cg23018236	chr17:30244563	NA	-0.52	-5.11	-0.3	6.12e-7	Hip circumference adjusted for BMI;
CESC	cis	rs5758659	0.652	rs133300	chr22:42389839	A/G	cg04733989	chr22:42467013	NAGA	0.46	6.13	0.35	3.12e-9	Cognitive function;
CESC	cis	rs11112613	0.713	rs60865625	chr12:105940256	A/C	cg03607813	chr12:105948248	NA	0.66	7.95	0.44	5.32e-14	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CESC	cis	rs847577	0.569	rs12674083	chr7:97696334	C/T	cg24562669	chr7:97807699	LMTK2	0.78	13.15	0.63	9.73e-31	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09149896	chr17:48624438	SPATA20	0.56	6.59	0.38	2.32e-10	Gut microbiome composition (summer);
CESC	cis	rs11638352	1.000	rs2059628	chr15:44415271	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.61	-5.62	-0.33	4.75e-8	Lipoprotein phospholipase A2 activity in cardiovascular disease;
CESC	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.58	7.51	0.42	8.95e-13	Prudent dietary pattern;
CESC	cis	rs7568498	0.517	rs11678856	chr2:161925443	C/T	cg08807892	chr2:162101083	NA	-0.52	-5.74	-0.33	2.53e-8	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);
CESC	cis	rs727505	0.551	rs2293346	chr7:124783849	C/T	cg23710748	chr7:124431027	NA	-0.34	-5.54	-0.32	7.18e-8	Lewy body disease;
CESC	cis	rs9911578	0.835	rs3744093	chr17:56492800	T/C	cg12560992	chr17:57184187	TRIM37	-0.88	-14.33	-0.66	7.21e-35	Intelligence (multi-trait analysis);
CESC	cis	rs3820928	0.874	rs2396452	chr2:227838040	T/G	cg11843606	chr2:227700838	RHBDD1	-0.51	-6.65	-0.38	1.64e-10	Pulmonary function;
CESC	cis	rs6963495	0.818	rs73190202	chr7:105166510	A/G	cg02135003	chr7:105160482	PUS7	-0.46	-5.51	-0.32	8.38e-8	Bipolar disorder (body mass index interaction);
CESC	cis	rs2243480	1.000	rs6460261	chr7:65215580	T/C	cg25894440	chr7:65020034	NA	0.65	5.42	0.32	1.36e-7	Diabetic kidney disease;
CESC	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg16405210	chr4:1374714	KIAA1530	-0.71	-9.36	-0.5	3.61e-18	Longevity;
CESC	cis	rs593982	0.777	rs534414	chr11:65475515	A/G	cg08755490	chr11:65554678	OVOL1	1.17	10.74	0.55	1.45e-22	Atopic dermatitis;
CESC	cis	rs7267979	0.868	rs6107019	chr20:25233985	C/T	cg08601574	chr20:25228251	PYGB	0.42	5.91	0.34	1.08e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs6460942	0.643	rs80264734	chr7:12233800	T/A	cg06484146	chr7:12443880	VWDE	-0.47	-5.22	-0.31	3.54e-7	Coronary artery disease;
CESC	cis	rs9875589	0.509	rs4047237	chr3:14012861	T/C	cg19554555	chr3:13937349	NA	-0.44	-5.61	-0.33	5.2e-8	Ovarian reserve;
CESC	cis	rs875971	0.862	rs6460307	chr7:66060871	A/G	cg18252515	chr7:66147081	NA	-0.43	-5.73	-0.33	2.67e-8	Aortic root size;
CESC	cis	rs7777484	0.534	rs2533886	chr7:2834869	C/T	cg19717773	chr7:2847554	GNA12	-0.68	-11.72	-0.58	7.98e-26	Height;
CESC	cis	rs12410462	0.579	rs115037090	chr1:227666191	A/G	cg23173402	chr1:227635558	NA	0.71	6.11	0.35	3.57e-9	Major depressive disorder;
CESC	cis	rs72634258	0.945	rs3766606	chr1:8022197	G/T	cg00042356	chr1:8021962	PARK7	0.71	6.91	0.39	3.59e-11	Inflammatory bowel disease;
CESC	cis	rs6502050	0.835	rs11658335	chr17:80084821	C/T	cg23985595	chr17:80112537	CCDC57	0.42	6.55	0.37	2.99e-10	Life satisfaction;
CESC	cis	rs6582630	0.537	rs11611326	chr12:38547958	C/A	cg26384229	chr12:38710491	ALG10B	0.72	10.77	0.55	1.13e-22	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs3767633	0.925	rs924777	chr1:161848904	G/A	cg09175582	chr1:161736000	ATF6	0.86	6.95	0.39	2.83e-11	IgG glycosylation;
CESC	cis	rs116095464	0.558	rs11959126	chr5:283880	T/G	cg20965017	chr5:231967	SDHA	-0.46	-5.2	-0.3	4.02e-7	Breast cancer;
CESC	cis	rs8058578	1.000	rs8051050	chr16:30687909	A/G	cg00531865	chr16:30841666	NA	-0.43	-5.58	-0.32	6.02e-8	Multiple myeloma;
CESC	cis	rs10207060	0.771	rs4852124	chr2:240680022	C/T	cg07506560	chr2:240697449	NA	0.41	5.78	0.33	2.13e-8	Obesity-related traits;
CESC	cis	rs7809950	1.000	rs10234355	chr7:107086517	T/G	cg23024343	chr7:107201750	COG5	-0.41	-5.89	-0.34	1.2e-8	Coronary artery disease;
CESC	cis	rs4699052	0.625	rs11734572	chr4:104288620	G/A	cg16532752	chr4:104119610	CENPE	-0.37	-5.28	-0.31	2.72e-7	Testicular germ cell tumor;
CESC	cis	rs4629180	0.959	rs11896771	chr2:102098328	T/C	cg04415270	chr2:102091202	RFX8	-0.42	-7.07	-0.4	1.39e-11	Chronic rhinosinusitis with nasal polyps;
CESC	cis	rs9910055	0.664	rs433610	chr17:42197281	A/G	cg08499158	chr17:42289980	UBTF	0.58	7.63	0.42	4.33e-13	Total body bone mineral density;
CESC	cis	rs9311474	0.597	rs13303	chr3:52558008	T/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.42	8.24	0.45	8.2e-15	Electroencephalogram traits;
CESC	cis	rs9916302	0.904	rs9892055	chr17:37510402	C/T	cg20243544	chr17:37824526	PNMT	-0.48	-6.07	-0.35	4.42e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs854765	0.575	rs2955357	chr17:17946401	T/C	cg16928487	chr17:17741425	SREBF1	0.56	9.38	0.5	3e-18	Total body bone mineral density;
CESC	cis	rs2011503	0.943	rs8100927	chr19:19643636	C/G	cg11584989	chr19:19387371	SF4	0.58	6.67	0.38	1.52e-10	Bipolar disorder;
CESC	cis	rs453301	0.624	rs2288671	chr8:8860894	T/C	cg15556689	chr8:8085844	FLJ10661	0.46	5.8	0.34	1.88e-8	Joint mobility (Beighton score);
CESC	cis	rs4906332	0.782	rs2236281	chr14:104000518	G/T	cg19000871	chr14:103996768	TRMT61A	-0.35	-5.09	-0.3	6.83e-7	Coronary artery disease;
CESC	cis	rs4604732	0.588	rs7549955	chr1:247628321	G/A	cg12754571	chr1:247694271	LOC148824;OR2C3	0.41	5.09	0.3	6.91e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs12188164	0.620	rs56070387	chr5:482531	A/T	cg15813090	chr5:442598	EXOC3;C5orf55	0.42	5.97	0.34	7.67e-9	Cystic fibrosis severity;
CESC	cis	rs116095464	0.558	rs6881920	chr5:222411	T/C	cg12570787	chr5:219185	SDHA;CCDC127	0.53	5.74	0.33	2.63e-8	Breast cancer;
CESC	cis	rs13191362	0.935	rs13205279	chr6:162945030	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.73	6.37	0.36	8.54e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs6499255	1.000	rs11641521	chr16:69823081	C/G	cg15192750	chr16:69999425	NA	0.45	5.51	0.32	8.31e-8	IgE levels;
CESC	cis	rs9303401	0.659	rs12602808	chr17:56698420	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	1.03	13.13	0.63	1.12e-30	Cognitive test performance;
CESC	cis	rs1729951	0.575	rs1682356	chr3:136692037	T/C	cg15507776	chr3:136538369	TMEM22	0.41	5.11	0.3	6.29e-7	Neuroticism;
CESC	cis	rs10504229	1.000	rs67237174	chr8:58175776	T/C	cg05313129	chr8:58192883	C8orf71	-0.56	-6.51	-0.37	3.67e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs1577917	1.000	rs1857965	chr6:86630776	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.44	-5.78	-0.33	2.14e-8	Response to antipsychotic treatment;
CESC	cis	rs7772486	0.754	rs6921073	chr6:146144377	G/A	cg05347473	chr6:146136440	FBXO30	0.54	6.96	0.39	2.63e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs62229266	0.771	rs7280136	chr21:37432910	C/G	cg08632701	chr21:37451849	NA	0.37	5.1	0.3	6.36e-7	Mitral valve prolapse;
CESC	cis	rs8031584	0.697	rs798080	chr15:31122169	T/C	cg14298792	chr15:30685198	CHRFAM7A	0.46	5.59	0.33	5.51e-8	Huntington's disease progression;
CESC	cis	rs4737010	0.570	rs6474364	chr8:41646997	T/G	cg08923054	chr8:41654455	ANK1	0.55	6.85	0.39	5.18e-11	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
CESC	cis	rs7560272	0.723	rs6743576	chr2:73814333	G/A	cg20560298	chr2:73613845	ALMS1	-0.51	-7.26	-0.41	4.35e-12	Schizophrenia;
CESC	cis	rs12410462	0.901	rs1120000	chr1:227659615	T/C	cg23173402	chr1:227635558	NA	0.56	5.67	0.33	3.72e-8	Major depressive disorder;
CESC	cis	rs258892	0.947	rs266443	chr5:72180377	C/T	cg21869765	chr5:72125136	TNPO1	0.45	5.65	0.33	4.2e-8	Small cell lung carcinoma;
CESC	cis	rs6570726	0.755	rs2092296	chr6:145893684	A/C	cg05347473	chr6:146136440	FBXO30	0.59	7.63	0.42	4.24e-13	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7647973	1.000	rs12583	chr3:49571462	G/T	cg07636037	chr3:49044803	WDR6	-0.69	-9.6	-0.51	6.34e-19	Menarche (age at onset);
CESC	cis	rs17039065	0.920	rs73838436	chr4:109446477	G/T	cg16022748	chr4:109541635	LOC285456;RPL34	0.62	5.61	0.33	5.08e-8	Gut microbiome composition (summer);
CESC	cis	rs853679	0.517	rs9368556	chr6:28131153	T/C	cg17949981	chr6:28129498	ZNF389	0.45	5.57	0.32	6.26e-8	Depression;
CESC	cis	rs875971	0.862	rs6958294	chr7:65794796	C/A	cg12463550	chr7:65579703	CRCP	-0.47	-6.01	-0.35	6.04e-9	Aortic root size;
CESC	cis	rs13382862	0.895	rs13385499	chr2:20882413	A/G	cg09074113	chr2:20870087	GDF7	-0.43	-7.04	-0.4	1.66e-11	Abdominal aortic aneurysm;
CESC	cis	rs6570726	0.967	rs9403707	chr6:145800010	A/G	cg23711669	chr6:146136114	FBXO30	0.76	10.99	0.56	2.11e-23	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9549367	0.789	rs9549711	chr13:113900557	C/T	cg18105134	chr13:113819100	PROZ	-0.68	-8.25	-0.45	7.53e-15	Platelet distribution width;
CESC	cis	rs6062302	0.522	rs3787107	chr20:62230576	G/A	cg09650180	chr20:62225654	GMEB2	-0.82	-9.28	-0.5	6.08e-18	Glioblastoma;
CESC	cis	rs10504073	0.669	rs4493917	chr8:50015846	C/T	cg00325661	chr8:49890786	NA	0.57	8.6	0.47	7.15e-16	Blood metabolite ratios;
CESC	cis	rs2455799	0.613	rs2470542	chr3:15724133	A/C	cg16303742	chr3:15540471	COLQ	-0.38	-5.83	-0.34	1.57e-8	Mean platelet volume;
CESC	cis	rs10479542	1.000	rs10479542	chr5:178981241	T/A	cg00080972	chr5:178986291	RUFY1	0.44	6.98	0.39	2.35e-11	Lung cancer;
CESC	cis	rs7811142	1.000	rs2406253	chr7:100077273	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.97	10.21	0.53	7.3e-21	Platelet count;
CESC	cis	rs896854	1.000	rs896854	chr8:95960511	T/C	cg13393036	chr8:95962371	TP53INP1	-0.55	-12.25	-0.6	1.25e-27	Type 2 diabetes;
CESC	cis	rs2011503	0.941	rs11670775	chr19:19649636	A/G	cg11584989	chr19:19387371	SF4	0.59	6.82	0.39	6.12e-11	Bipolar disorder;
CESC	cis	rs13126513	0.519	rs7659550	chr4:100554402	G/T	cg05468953	chr4:100565104	NA	0.34	5.24	0.31	3.34e-7	Metabolite levels (MHPG);
CESC	cis	rs11792861	0.962	rs3829084	chr9:111801724	C/G	cg05043794	chr9:111880884	C9orf5	0.41	6.84	0.39	5.37e-11	Menarche (age at onset);
CESC	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	10.25	0.53	5.71e-21	Prudent dietary pattern;
CESC	cis	rs9322193	0.962	rs9689269	chr6:150112997	G/A	cg07701084	chr6:150067640	NUP43	0.42	5.78	0.33	2.07e-8	Lung cancer;
CESC	trans	rs9393777	0.841	rs13191474	chr6:27413345	C/T	cg06606381	chr12:133084897	FBRSL1	-0.96	-7.42	-0.41	1.54e-12	Intelligence (multi-trait analysis);
CESC	cis	rs4253311	0.520	rs7687818	chr4:187122060	A/G	cg24794857	chr4:187113578	CYP4V2	0.43	5.67	0.33	3.82e-8	Plasma renin activity levels;Circulating chromogranin peptide levels;Blood metabolite levels;
CESC	cis	rs12325245	0.536	rs35432891	chr16:58561966	G/A	cg05725404	chr16:58534157	NDRG4	-0.61	-5.24	-0.31	3.21e-7	Schizophrenia;
CESC	cis	rs4819052	0.851	rs28616694	chr21:46674786	G/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.48	5.9	0.34	1.11e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs1878931	0.858	rs3760083	chr16:3450052	C/T	cg22508957	chr16:3507546	NAT15	0.38	5.5	0.32	8.88e-8	Body mass index (adult);
CESC	cis	rs17039065	0.920	rs72891053	chr4:109460871	C/T	cg16022748	chr4:109541635	LOC285456;RPL34	0.66	6.19	0.36	2.27e-9	Gut microbiome composition (summer);
CESC	cis	rs9611565	0.918	rs2281333	chr22:41749630	T/C	cg17376030	chr22:41985996	PMM1	0.43	5.03	0.3	9.05e-7	Vitiligo;
CESC	cis	rs1552244	1.000	rs55882090	chr3:10139082	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.85	-12.15	-0.6	2.74e-27	Alzheimer's disease;
CESC	cis	rs4665809	1.000	rs7599132	chr2:26279810	A/T	cg25036284	chr2:26402008	FAM59B	0.71	8.3	0.45	5.3e-15	Gut microbiome composition (summer);
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg17951368	chr11:17298273	NUCB2	0.46	6.13	0.35	3.22e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs1008375	0.932	rs4698628	chr4:17608620	A/G	cg27347728	chr4:17578864	LAP3	0.44	5.32	0.31	2.17e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs763121	0.853	rs3761454	chr22:39066820	C/T	cg14440974	chr22:39074834	NA	-0.42	-5.81	-0.34	1.75e-8	Menopause (age at onset);
CESC	cis	rs2836974	0.897	rs2836928	chr21:40543320	C/T	cg11644478	chr21:40555479	PSMG1	0.96	14.03	0.65	8.35e-34	Cognitive function;
CESC	cis	rs798554	0.757	rs1183085	chr7:2875570	G/A	cg18446336	chr7:2847575	GNA12	-0.38	-5.8	-0.34	1.93e-8	Height;
CESC	cis	rs2839186	0.560	rs9975345	chr21:47843004	T/C	cg12379764	chr21:47803548	PCNT	0.56	7.89	0.44	7.8500000000000006e-14	Testicular germ cell tumor;
CESC	cis	rs4720575	1.000	rs7791050	chr7:47086452	T/C	cg00036614	chr7:47093842	NA	-0.43	-6.62	-0.38	2e-10	Angiotensin-converting enzyme inhibitor intolerance;
CESC	cis	rs1552244	1.000	rs6786638	chr3:10118075	G/C	cg00166722	chr3:10149974	C3orf24	0.52	6.61	0.38	2.15e-10	Alzheimer's disease;
CESC	trans	rs12356475	0.710	rs10822686	chr10:67733250	C/T	cg23461432	chr11:56457812	OR8U8	-0.59	-6.81	-0.39	6.44e-11	Psoriatic arthritis;
CESC	cis	rs780096	0.546	rs6547626	chr2:27646770	C/T	cg12648201	chr2:27665141	KRTCAP3	-0.34	-6.28	-0.36	1.34e-9	Total body bone mineral density;
CESC	cis	rs4595586	0.545	rs11615638	chr12:39364766	A/C	cg26384229	chr12:38710491	ALG10B	0.54	7.57	0.42	6.23e-13	Morning vs. evening chronotype;
CESC	cis	rs780096	0.546	rs715325	chr2:27725572	C/A	cg17158414	chr2:27665306	KRTCAP3	-0.35	-6.4	-0.37	7.17e-10	Total body bone mineral density;
CESC	cis	rs62458065	0.513	rs7788809	chr7:32552622	T/A	cg20159608	chr7:32802032	NA	-0.56	-6.26	-0.36	1.54e-9	Metabolite levels (HVA/MHPG ratio);
CESC	cis	rs10416265	0.527	rs7246814	chr19:33538414	G/T	cg27124370	chr19:33622961	WDR88	0.54	7.41	0.41	1.68e-12	Bone properties (heel);
CESC	cis	rs7945705	0.747	rs2653605	chr11:8993309	C/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.41	-6.68	-0.38	1.42e-10	Hemoglobin concentration;
CESC	cis	rs7474896	0.616	rs2505239	chr10:38440765	A/G	cg25427524	chr10:38739819	LOC399744	-0.51	-5.06	-0.3	7.89e-7	Obesity (extreme);
CESC	cis	rs6942756	0.806	rs7788327	chr7:128986519	C/T	cg02491457	chr7:128862824	NA	-0.64	-9.09	-0.49	2.32e-17	White matter hyperintensity burden;
CESC	cis	rs11645898	0.687	rs56129242	chr16:72098260	C/G	cg14768367	chr16:72042858	DHODH	-0.62	-5.33	-0.31	2.11e-7	Blood protein levels;
CESC	cis	rs7116495	0.786	rs678193	chr11:71770273	A/C	cg10381502	chr11:71823885	C11orf51	-0.67	-5.66	-0.33	3.92e-8	Severe influenza A (H1N1) infection;
CESC	cis	rs4713118	0.513	rs149955	chr6:28036225	G/C	cg12963246	chr6:28129442	ZNF389	0.39	5.57	0.32	6.24e-8	Parkinson's disease;
CESC	cis	rs735396	0.770	rs2264782	chr12:121432603	C/T	cg25281562	chr12:121454272	C12orf43	0.39	5.07	0.3	7.36e-7	N-glycan levels;
CESC	cis	rs6460942	1.000	rs111761262	chr7:12415916	T/C	cg06484146	chr7:12443880	VWDE	-0.81	-9.25	-0.49	7.78e-18	Coronary artery disease;
CESC	cis	rs7599312	0.534	rs10182996	chr2:213404834	T/C	cg16329650	chr2:213403929	ERBB4	0.58	8.43	0.46	2.31e-15	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs7811142	0.943	rs67196635	chr7:100025564	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.82	8.2	0.45	1.06e-14	Platelet count;
CESC	cis	rs34172651	0.517	rs200528	chr16:24759131	A/G	cg06505273	chr16:24850292	NA	-0.53	-6.49	-0.37	4.27e-10	Intelligence (multi-trait analysis);
CESC	cis	rs2243480	0.901	rs778732	chr7:65822360	C/T	cg13147721	chr7:65941812	NA	-0.93	-8.5	-0.46	1.44e-15	Diabetic kidney disease;
CESC	cis	rs8070128	0.568	rs3935505	chr17:17882020	T/G	cg16928487	chr17:17741425	SREBF1	-0.56	-8.8	-0.48	1.84e-16	Total body bone mineral density;
CESC	cis	rs2243480	1.000	rs34970380	chr7:65431493	C/T	cg25894440	chr7:65020034	NA	-0.66	-5.72	-0.33	2.81e-8	Diabetic kidney disease;
CESC	cis	rs4665809	0.556	rs6730311	chr2:26419474	C/T	cg04944784	chr2:26401820	FAM59B	-0.95	-11.61	-0.58	1.86e-25	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.830	rs28444709	chr4:99028496	A/T	cg05340658	chr4:99064831	C4orf37	0.83	13.1	0.63	1.43e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6952808	0.601	rs3778978	chr7:2159817	A/G	cg02951883	chr7:2050386	MAD1L1	-0.46	-5.92	-0.34	9.71e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs4595586	0.545	rs12828001	chr12:39392208	G/A	cg26384229	chr12:38710491	ALG10B	0.54	7.64	0.42	3.96e-13	Morning vs. evening chronotype;
CESC	cis	rs9649213	0.574	rs9648908	chr7:97945236	C/T	cg24562669	chr7:97807699	LMTK2	0.48	7.0	0.4	2.09e-11	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25689539	chr7:149130015	ZNF777	-0.54	-6.19	-0.36	2.28e-9	Gut microbiome composition (summer);
CESC	cis	rs2124969	0.562	rs6750639	chr2:161066862	T/C	cg03641300	chr2:160917029	PLA2R1	-0.41	-5.84	-0.34	1.53e-8	Waist circumference adjusted for body mass index;
CESC	cis	rs10504229	0.639	rs16921812	chr8:58106737	C/T	cg22535103	chr8:58192502	C8orf71	-0.77	-8.76	-0.47	2.37e-16	Developmental language disorder (linguistic errors);
CESC	cis	rs9916302	0.851	rs2338795	chr17:37399364	T/G	cg00129232	chr17:37814104	STARD3	-0.55	-7.12	-0.4	1.04e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs4604732	0.631	rs74154675	chr1:247625836	G/A	cg12758973	chr1:247694275	LOC148824;OR2C3	0.51	6.36	0.36	8.65e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs7000551	0.700	rs2461480	chr8:22381839	C/T	cg12081754	chr8:22256438	SLC39A14	0.45	5.99	0.35	6.93e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CESC	cis	rs561341	0.883	rs2074102	chr17:30228884	G/A	cg12193833	chr17:30244370	NA	-0.6	-6.05	-0.35	4.88e-9	Hip circumference adjusted for BMI;
CESC	cis	rs854765	0.583	rs9912895	chr17:17826020	C/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.53	-6.98	-0.39	2.38e-11	Total body bone mineral density;
CESC	cis	rs116095464	0.558	rs10057299	chr5:242135	C/T	cg20965017	chr5:231967	SDHA	-0.47	-5.38	-0.31	1.65e-7	Breast cancer;
CESC	cis	rs4132509	0.739	rs10927033	chr1:243695539	C/A	cg21452805	chr1:244014465	NA	0.58	6.23	0.36	1.8e-9	RR interval (heart rate);
CESC	cis	rs651907	0.535	rs12633089	chr3:101528763	C/T	cg12386194	chr3:101231763	SENP7	0.41	5.14	0.3	5.44e-7	Colorectal cancer;
CESC	cis	rs7666738	0.830	rs17550630	chr4:99008332	G/T	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.62e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4843747	0.619	rs66508972	chr16:88086385	C/G	cg17633681	chr16:88106987	BANP	0.69	8.8	0.48	1.82e-16	Menopause (age at onset);
CESC	cis	rs561341	1.000	rs693116	chr17:30246124	C/T	cg00745463	chr17:30367425	LRRC37B	-0.85	-7.62	-0.42	4.38e-13	Hip circumference adjusted for BMI;
CESC	cis	rs875971	1.000	rs1565531	chr7:65663113	T/A	cg12463550	chr7:65579703	CRCP	-0.57	-7.35	-0.41	2.54e-12	Aortic root size;
CESC	cis	rs35306767	0.953	rs11253521	chr10:976416	G/C	cg10556349	chr10:835070	NA	0.47	5.2	0.3	4.05e-7	Eosinophil percentage of granulocytes;
CESC	cis	rs2070488	0.965	rs1984312	chr3:38538466	G/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.89	-16.1	-0.7	3.86e-41	Electrocardiographic conduction measures;
CESC	cis	rs7666738	0.830	rs13149779	chr4:99010145	G/T	cg03676636	chr4:99064102	C4orf37	0.33	5.08	0.3	7e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7772486	0.817	rs2748491	chr6:146327759	T/C	cg05347473	chr6:146136440	FBXO30	0.54	7.08	0.4	1.28e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs3785574	0.962	rs4480868	chr17:61788859	C/T	cg11494091	chr17:61959527	GH2	0.38	5.2	0.3	3.91e-7	Height;
CESC	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.58	7.49	0.42	1.01e-12	Prudent dietary pattern;
CESC	trans	rs8057939	0.528	rs9929573	chr16:49410565	A/G	cg15532236	chr6:170188124	NA	0.5	6.1	0.35	3.75e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs1065852	0.526	rs8138080	chr22:42396371	A/G	cg00645731	chr22:42541494	CYP2D7P1	-0.33	-5.2	-0.3	4.09e-7	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
CESC	cis	rs9457247	0.715	rs6923582	chr6:167437162	T/A	cg23791538	chr6:167370224	RNASET2	-0.54	-7.31	-0.41	3.23e-12	Crohn's disease;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg24419099	chr11:47270565	NR1H3;ACP2	-0.43	-6.23	-0.36	1.87e-9	Gambling;
CESC	cis	rs9322193	0.962	rs9322218	chr6:150103319	A/G	cg13206674	chr6:150067644	NUP43	0.39	5.58	0.32	5.93e-8	Lung cancer;
CESC	cis	rs17641971	0.684	rs6984804	chr8:49987910	G/A	cg00325661	chr8:49890786	NA	0.36	5.13	0.3	5.72e-7	Blood metabolite levels;
CESC	cis	rs9916302	0.904	rs8068427	chr17:37511517	G/A	cg07936489	chr17:37558343	FBXL20	0.78	10.7	0.55	1.93e-22	Glomerular filtration rate (creatinine);
CESC	cis	rs6860806	0.507	rs270608	chr5:131648406	C/T	cg07395648	chr5:131743802	NA	-0.46	-6.14	-0.35	2.92e-9	Breast cancer;
CESC	cis	rs79976124	0.879	rs12213669	chr6:66627704	G/A	cg07460842	chr6:66804631	NA	0.74	8.58	0.47	7.85e-16	Type 2 diabetes;
CESC	cis	rs12348691	0.503	rs7847259	chr9:100600712	A/G	cg13688889	chr9:100608707	NA	-0.91	-13.49	-0.64	6.17e-32	Alopecia areata;
CESC	cis	rs2576037	0.796	rs2571018	chr18:44585344	T/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.46	5.94	0.34	8.88e-9	Personality dimensions;
CESC	cis	rs66530629	0.874	rs7535819	chr1:25173037	C/T	cg22509179	chr1:25234806	RUNX3	0.43	5.63	0.33	4.66e-8	Plateletcrit;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05778415	chr2:75185968	POLE4	0.61	7.43	0.42	1.53e-12	Gut microbiome composition (summer);
CESC	cis	rs1707322	0.964	rs785499	chr1:46592420	G/A	cg06784218	chr1:46089804	CCDC17	-0.36	-5.93	-0.34	9.35e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2180341	1.000	rs4897207	chr6:127605898	C/T	cg24812749	chr6:127587940	RNF146	1.06	15.35	0.69	1.74e-38	Breast cancer;
CESC	cis	rs10752881	1.000	rs4233192	chr1:182970837	A/C	ch.1.3577855R	chr1:183094577	LAMC1	-0.86	-13.93	-0.65	1.86e-33	Colorectal cancer;
CESC	cis	rs9768139	0.935	rs7800718	chr7:158121878	G/A	cg25566285	chr7:158114605	PTPRN2	-0.5	-8.54	-0.46	1.03e-15	Calcium levels;
CESC	cis	rs9322193	0.962	rs62439843	chr6:149997657	T/C	cg13206674	chr6:150067644	NUP43	0.4	5.52	0.32	8.03e-8	Lung cancer;
CESC	cis	rs9457247	1.000	rs422780	chr6:167406209	A/G	cg25258033	chr6:167368657	RNASET2	0.39	5.89	0.34	1.15e-8	Crohn's disease;
CESC	cis	rs4665809	0.941	rs2289021	chr2:26362515	A/C	cg04944784	chr2:26401820	FAM59B	0.6	7.31	0.41	3.1e-12	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20777920	chr6:10404848	TFAP2A	0.56	6.64	0.38	1.79e-10	Gut microbiome composition (summer);
CESC	cis	rs7107174	1.000	rs2511155	chr11:77969223	G/A	cg02023728	chr11:77925099	USP35	0.46	6.39	0.37	7.41e-10	Testicular germ cell tumor;
CESC	cis	rs3931020	0.530	rs6668736	chr1:75234550	C/T	cg26855724	chr1:75198818	TYW3;CRYZ	0.48	6.19	0.36	2.28e-9	Resistin levels;
CESC	cis	rs9309711	0.623	rs7569694	chr2:3483390	T/G	cg10845886	chr2:3471009	TTC15	-0.67	-9.29	-0.5	5.87e-18	Neurofibrillary tangles;
CESC	trans	rs2235573	0.551	rs139898	chr22:38399979	A/G	cg19894588	chr14:64061835	NA	0.56	7.11	0.4	1.05e-11	Glioblastoma;Glioma;
CESC	cis	rs10504229	0.906	rs72650894	chr8:58179734	C/T	cg14926445	chr8:58193284	C8orf71	-0.51	-5.46	-0.32	1.12e-7	Developmental language disorder (linguistic errors);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14165241	chr9:131315156	SPTAN1	0.55	6.18	0.35	2.36e-9	Gut microbiome composition (summer);
CESC	cis	rs7216064	0.953	rs62086043	chr17:65968003	A/G	cg12091567	chr17:66097778	LOC651250	-0.78	-8.35	-0.46	3.75e-15	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs796364	0.568	rs11890894	chr2:201072055	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.48	5.38	0.31	1.62e-7	Schizophrenia;
CESC	cis	rs12900413	0.603	rs12909833	chr15:90301518	G/A	cg24249390	chr15:90295951	MESP1	-0.4	-5.36	-0.31	1.79e-7	Coronary artery aneurysm in Kawasaki disease;
CESC	cis	rs950776	0.714	rs514743	chr15:78884227	A/T	cg06917634	chr15:78832804	PSMA4	-0.54	-6.6	-0.38	2.19e-10	Sudden cardiac arrest;
CESC	cis	rs4604732	0.631	rs12039642	chr1:247624898	A/G	cg12754571	chr1:247694271	LOC148824;OR2C3	0.44	5.44	0.32	1.21e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs12477438	0.501	rs6727749	chr2:99793590	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.77	12.84	0.62	1.16e-29	Chronic sinus infection;
CESC	cis	rs9831754	0.704	rs7647185	chr3:78468807	T/C	cg06138941	chr3:78371609	NA	-0.51	-6.44	-0.37	5.69e-10	Calcium levels;
CESC	trans	rs9650657	0.562	rs10090444	chr8:10745469	C/G	cg06636001	chr8:8085503	FLJ10661	0.52	6.48	0.37	4.43e-10	Neuroticism;
CESC	cis	rs7084402	0.967	rs1649077	chr10:60293906	A/G	cg07615347	chr10:60278583	BICC1	0.6	9.42	0.5	2.35e-18	Refractive error;
CESC	cis	rs1059312	1.000	rs7136092	chr12:129280164	G/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.74	-10.51	-0.54	8.05e-22	Systemic lupus erythematosus;
CESC	cis	rs8060686	0.516	rs73612297	chr16:68284754	T/G	cg26727032	chr16:67993705	SLC12A4	-0.55	-7.23	-0.41	5.23e-12	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs8014204	0.604	rs11159109	chr14:75389074	G/A	cg08847533	chr14:75593920	NEK9	0.6	7.62	0.42	4.64e-13	Caffeine consumption;
CESC	cis	rs10851478	0.872	rs8032688	chr15:49929664	A/G	cg08060515	chr15:49448048	GALK2;COPS2	0.42	5.11	0.3	6.15e-7	Oral cavity cancer;
CESC	cis	rs208520	0.837	rs208471	chr6:66916749	A/C	cg07460842	chr6:66804631	NA	-0.89	-10.85	-0.55	6.35e-23	Exhaled nitric oxide output;
CESC	cis	rs9611565	0.659	rs1810461	chr22:41927820	G/A	cg06634786	chr22:41940651	POLR3H	-0.68	-7.15	-0.4	8.28e-12	Vitiligo;
CESC	cis	rs6032067	0.929	rs2664581	chr20:43804522	A/C	cg10761708	chr20:43804764	PI3	0.44	5.52	0.32	7.91e-8	Blood protein levels;
CESC	cis	rs6502050	0.764	rs35416122	chr17:80119006	A/G	cg11859384	chr17:80120422	CCDC57	-0.38	-5.24	-0.31	3.26e-7	Life satisfaction;
CESC	cis	rs2032447	0.714	rs199725	chr6:25953684	A/G	cg18357526	chr6:26021779	HIST1H4A	0.52	6.95	0.39	2.81e-11	Intelligence (multi-trait analysis);
CESC	cis	rs4853012	0.887	rs2280644	chr2:74358411	G/A	cg01017244	chr2:74357527	NA	0.68	9.44	0.5	1.95e-18	Gestational age at birth (maternal effect);
CESC	cis	rs7666738	0.753	rs13137152	chr4:98938044	A/T	cg05340658	chr4:99064831	C4orf37	0.82	12.32	0.6	6.98e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9393777	0.623	rs3757150	chr6:26476782	T/A	cg12826209	chr6:26865740	GUSBL1	0.65	6.85	0.39	5.16e-11	Intelligence (multi-trait analysis);
CESC	trans	rs12356475	0.710	rs10822686	chr10:67733250	C/T	cg13823003	chr17:72856049	GRIN2C	0.46	6.59	0.38	2.3e-10	Psoriatic arthritis;
CESC	cis	rs62064224	0.658	rs62065460	chr17:30715007	A/G	cg09324608	chr17:30823087	MYO1D	0.5	7.56	0.42	6.7e-13	Schizophrenia;
CESC	cis	rs8133932	0.521	rs1625244	chr21:47364499	C/T	cg14185626	chr21:47401492	COL6A1	-0.49	-5.5	-0.32	9.03e-8	Schizophrenia;
CESC	cis	rs6952808	1.000	rs10233560	chr7:1885415	T/C	cg22963979	chr7:1858916	MAD1L1	-0.38	-5.15	-0.3	5e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs10504229	0.683	rs35840293	chr8:58117634	C/T	cg02725872	chr8:58115012	NA	-0.45	-7.05	-0.4	1.52e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs9649213	0.593	rs10808107	chr7:97951671	T/C	cg00277769	chr7:97922759	BAIAP2L1	-0.34	-5.61	-0.33	4.97e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs2742417	0.603	rs2742457	chr3:45767487	G/A	cg04837898	chr3:45731254	SACM1L	-0.5	-6.55	-0.37	2.92e-10	Response to anti-depressant treatment in major depressive disorder;
CESC	cis	rs6964587	0.773	rs12740	chr7:92029302	A/G	cg17063962	chr7:91808500	NA	0.55	7.07	0.4	1.36e-11	Breast cancer;
CESC	cis	rs1707322	0.964	rs10890358	chr1:46319025	T/A	cg03146154	chr1:46216737	IPP	0.74	10.13	0.53	1.32e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7666738	0.791	rs10013680	chr4:99023030	G/C	cg05340658	chr4:99064831	C4orf37	0.75	10.97	0.56	2.55e-23	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07919162	chr19:19431259	SF4;KIAA0892	-0.67	-7.53	-0.42	7.91e-13	Gut microbiome composition (summer);
CESC	cis	rs875971	0.862	rs11760844	chr7:65739883	C/G	cg10691866	chr7:65817282	TPST1	0.31	5.37	0.31	1.75e-7	Aortic root size;
CESC	cis	rs2839186	0.900	rs2839196	chr21:47708037	G/A	cg13126279	chr21:47581558	C21orf56	-0.45	-6.1	-0.35	3.79e-9	Testicular germ cell tumor;
CESC	cis	rs6987853	0.933	rs2923434	chr8:42422307	A/G	cg09913449	chr8:42400586	C8orf40	0.4	6.38	0.36	7.85e-10	Mean corpuscular hemoglobin concentration;
CESC	cis	rs9486719	1.000	rs12197411	chr6:97039621	G/A	cg06623918	chr6:96969491	KIAA0776	-0.79	-8.13	-0.45	1.64e-14	Migraine;Coronary artery disease;
CESC	trans	rs2749592	0.550	rs7917262	chr10:37874602	A/C	cg12057190	chr19:54976211	LENG9;CDC42EP5	-0.43	-6.17	-0.35	2.56e-9	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs1348850	0.837	rs12619074	chr2:178472336	G/A	cg23306229	chr2:178417860	TTC30B	0.56	7.11	0.4	1.08e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs11677416	1.000	rs3783520	chr2:113544339	C/T	cg27083787	chr2:113543245	IL1A	0.62	7.55	0.42	6.97e-13	Response to antipsychotic treatment in schizophrenia (working memory);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08602689	chr13:103452535	BIVM;KDELC1	-0.61	-6.8	-0.39	6.8e-11	Gut microbiome composition (summer);
CESC	cis	rs36051895	0.664	rs1034072	chr9:5088903	T/A	cg02405213	chr9:5042618	JAK2	-0.54	-6.52	-0.37	3.6e-10	Pediatric autoimmune diseases;
CESC	cis	rs9815354	0.638	rs73073258	chr3:42017894	G/A	cg03022575	chr3:42003672	ULK4	0.74	6.64	0.38	1.79e-10	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs4689388	0.926	rs4458523	chr4:6289986	G/T	cg25554036	chr4:6271136	WFS1	-0.5	-8.06	-0.44	2.62e-14	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs801193	1.000	rs6975195	chr7:66124774	T/A	cg06456125	chr7:65229604	NA	-0.39	-5.09	-0.3	6.82e-7	Aortic root size;
CESC	cis	rs6963495	0.818	rs73192107	chr7:105168095	G/A	cg13798780	chr7:105162888	PUS7	0.77	7.88	0.44	8.3e-14	Bipolar disorder (body mass index interaction);
CESC	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.46	6.11	0.35	3.49e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs3820068	0.705	rs16851727	chr1:15857918	C/T	cg17385448	chr1:15911702	AGMAT	0.39	6.03	0.35	5.62e-9	Systolic blood pressure;
CESC	cis	rs57221529	0.766	rs12519763	chr5:559145	C/T	cg16447950	chr5:562315	NA	-0.7	-7.76	-0.43	1.9e-13	Lung disease severity in cystic fibrosis;
CESC	cis	rs1448094	0.512	rs4362214	chr12:86245145	C/T	cg02569458	chr12:86230093	RASSF9	0.49	7.27	0.41	3.98e-12	Major depressive disorder;
CESC	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.38	-5.6	-0.33	5.38e-8	Electroencephalogram traits;
CESC	cis	rs910316	0.967	rs10246	chr14:75544470	T/A	cg08847533	chr14:75593920	NEK9	1.0	19.06	0.76	1.34e-51	Height;
CESC	cis	rs225245	0.610	rs321607	chr17:33880584	A/G	cg05299278	chr17:33885742	SLFN14	0.38	5.2	0.3	3.9e-7	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
CESC	trans	rs3008870	0.583	rs11208985	chr1:67464666	G/A	cg19754094	chr2:74055942	STAMBP	-0.62	-6.0	-0.35	6.49e-9	Lymphocyte percentage of white cells;
CESC	cis	rs7666738	0.830	rs13125537	chr4:98978428	A/G	cg03676636	chr4:99064102	C4orf37	0.34	5.2	0.3	3.93e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs514406	0.929	rs555741	chr1:53318851	T/G	cg24675658	chr1:53192096	ZYG11B	-0.6	-7.68	-0.43	3.1e-13	Monocyte count;
CESC	cis	rs3785574	0.962	rs2584614	chr17:61929445	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.57	7.13	0.4	9.75e-12	Height;
CESC	cis	rs1707322	0.686	rs1250	chr1:46094027	A/G	cg06784218	chr1:46089804	CCDC17	0.41	7.26	0.41	4.37e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7659604	0.502	rs13108419	chr4:122687238	A/G	cg19748678	chr4:122722346	EXOSC9	-0.45	-5.56	-0.32	6.48e-8	Type 2 diabetes;
CESC	cis	rs7077164	0.846	rs1227773	chr10:71579347	C/A	cg07630274	chr10:71583235	COL13A1	-0.41	-7.77	-0.43	1.7e-13	Non-alcoholic fatty liver disease histology (lobular);
CESC	cis	rs8014204	0.836	rs11159099	chr14:75235397	A/G	cg08847533	chr14:75593920	NEK9	0.49	6.26	0.36	1.51e-9	Caffeine consumption;
CESC	cis	rs1499614	1.000	rs2659911	chr7:66158420	G/A	cg13147721	chr7:65941812	NA	-0.94	-8.9	-0.48	9.08e-17	Gout;
CESC	cis	rs2228479	0.764	rs7191836	chr16:89961597	T/C	cg00800038	chr16:89945340	TCF25	-0.69	-6.6	-0.38	2.24e-10	Skin colour saturation;
CESC	cis	rs17376456	0.825	rs72786702	chr5:93254656	A/C	cg21475434	chr5:93447410	FAM172A	0.74	6.22	0.36	1.9e-9	Diabetic retinopathy;
CESC	cis	rs7607369	0.559	rs13002060	chr2:219660394	G/T	cg02176678	chr2:219576539	TTLL4	-0.4	-7.02	-0.4	1.87e-11	Red blood cell count;Amyotrophic lateral sclerosis;
CESC	cis	rs12701220	0.690	rs10243973	chr7:1064983	T/C	cg26769984	chr7:1090371	C7orf50	0.62	7.28	0.41	3.85e-12	Bronchopulmonary dysplasia;
CESC	cis	rs35306767	0.903	rs35968821	chr10:910225	A/G	cg10556349	chr10:835070	NA	0.57	5.44	0.32	1.23e-7	Eosinophil percentage of granulocytes;
CESC	cis	rs4699052	0.662	rs1516732	chr4:104251154	A/T	cg16532752	chr4:104119610	CENPE	-0.43	-6.32	-0.36	1.08e-9	Testicular germ cell tumor;
CESC	cis	rs888194	0.544	rs7316486	chr12:109849540	A/G	cg19025524	chr12:109796872	NA	-0.46	-6.68	-0.38	1.4e-10	Neuroticism;
CESC	cis	rs2742234	0.590	rs2435383	chr10:43675671	T/C	cg15436174	chr10:43711423	RASGEF1A	-0.5	-5.84	-0.34	1.5e-8	Hirschsprung disease;
CESC	cis	rs832540	0.931	rs832535	chr5:56213334	C/T	cg12311346	chr5:56204834	C5orf35	-0.43	-5.43	-0.32	1.25e-7	Coronary artery disease;
CESC	cis	rs4555082	1.000	rs4334224	chr14:105759198	C/T	cg06808227	chr14:105710500	BRF1	-0.52	-6.34	-0.36	9.7e-10	Mean platelet volume;Platelet distribution width;
CESC	trans	rs208520	0.690	rs176289	chr6:66766522	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.95	-12.45	-0.61	2.48e-28	Exhaled nitric oxide output;
CESC	cis	rs4713118	0.662	rs149969	chr6:27977737	A/G	cg17949981	chr6:28129498	ZNF389	0.41	5.38	0.31	1.66e-7	Parkinson's disease;
CESC	trans	rs1814175	0.502	rs12365889	chr11:49623034	G/A	cg03929089	chr4:120376271	NA	-0.75	-8.98	-0.48	5.35e-17	Height;
CESC	cis	rs7666738	0.830	rs11944107	chr4:98931638	G/C	cg17366294	chr4:99064904	C4orf37	0.6	8.22	0.45	9.04e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2228479	0.850	rs12598276	chr16:89829196	G/C	cg06558623	chr16:89946397	TCF25	1.13	8.87	0.48	1.08e-16	Skin colour saturation;
CESC	cis	rs5769765	0.773	rs7410291	chr22:50300078	A/G	cg26441486	chr22:50317300	CRELD2	0.39	5.33	0.31	2.11e-7	Schizophrenia;
CESC	cis	rs2730245	0.505	rs1188956	chr7:158690576	G/A	cg01943577	chr7:158741284	NA	-0.46	-6.08	-0.35	4.23e-9	Height;
CESC	cis	rs72781680	0.848	rs2339926	chr2:24045734	C/G	cg08917208	chr2:24149416	ATAD2B	0.95	8.71	0.47	3.45e-16	Lymphocyte counts;
CESC	cis	rs1465370	0.720	rs1558917	chr7:130028723	C/T	cg04743876	chr7:130013617	NA	0.27	5.08	0.3	7.18e-7	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
CESC	cis	rs453301	0.653	rs1562211	chr8:8902424	A/G	cg06636001	chr8:8085503	FLJ10661	-0.5	-6.66	-0.38	1.54e-10	Joint mobility (Beighton score);
CESC	cis	rs2710642	0.576	rs1386399	chr2:62871303	G/A	cg17519650	chr2:63277830	OTX1	0.47	5.61	0.33	5.11e-8	LDL cholesterol levels;LDL cholesterol;
CESC	cis	rs459571	0.876	rs2520095	chr9:136919568	A/G	cg13789015	chr9:136890014	NCRNA00094	0.57	8.09	0.45	2.11e-14	Platelet distribution width;
CESC	cis	rs4819052	0.808	rs11909411	chr21:46676556	A/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.76	10.1	0.53	1.62e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08265551	chr1:151032119	CDC42SE1;MLLT11	0.57	6.89	0.39	4.14e-11	Gut microbiome composition (summer);
CESC	cis	rs11191419	1	rs11191419	chr10:104612335	T/A	cg04362960	chr10:104952993	NT5C2	0.5	6.13	0.35	3.18e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs514406	0.644	rs6662414	chr1:53198893	A/G	cg24675658	chr1:53192096	ZYG11B	0.7	9.91	0.52	6.87e-20	Monocyte count;
CESC	cis	rs9311474	0.659	rs7638808	chr3:52572056	C/T	cg17372223	chr3:52568218	NT5DC2	-0.47	-7.75	-0.43	1.97e-13	Electroencephalogram traits;
CESC	cis	rs2072499	0.750	rs55910626	chr1:156159909	C/G	cg24450063	chr1:156163899	SLC25A44	0.98	12.05	0.59	5.99e-27	Testicular germ cell tumor;
CESC	cis	rs34172651	0.917	rs12930481	chr16:24775438	A/G	cg06028605	chr16:24865363	SLC5A11	0.39	5.75	0.33	2.5e-8	Intelligence (multi-trait analysis);
CESC	trans	rs650950	0.528	rs646660	chr11:35528452	C/T	cg27127099	chr5:150158597	C5orf62	0.47	6.27	0.36	1.48e-9	Bronchopulmonary dysplasia;
CESC	cis	rs9399135	0.967	rs2150681	chr6:135375232	A/G	cg24558204	chr6:135376177	HBS1L	-0.51	-6.87	-0.39	4.48e-11	Red blood cell count;
CESC	cis	rs12893668	0.645	rs12889403	chr14:104034746	C/T	cg24130564	chr14:104152367	KLC1	-0.48	-5.87	-0.34	1.31e-8	Reticulocyte count;
CESC	cis	rs6952808	0.689	rs11771625	chr7:2050401	C/T	cg02951883	chr7:2050386	MAD1L1	-0.6	-7.97	-0.44	4.83e-14	Bipolar disorder and schizophrenia;
CESC	cis	rs7772486	0.790	rs2254257	chr6:146203724	C/T	cg05347473	chr6:146136440	FBXO30	0.58	7.51	0.42	9.28e-13	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs7944735	0.671	rs1228044	chr11:48011180	A/G	cg03929089	chr4:120376271	NA	0.55	6.17	0.35	2.53e-9	Intraocular pressure;
CESC	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg23978390	chr7:1156363	C7orf50	0.59	8.12	0.45	1.77e-14	Longevity;Endometriosis;
CESC	trans	rs74054849	0.850	rs55976422	chr1:16008379	T/C	cg06826283	chr7:600452	PRKAR1B	0.7	6.25	0.36	1.66e-9	Alcoholic chronic pancreatitis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01403123	chr2:240287795	HDAC4	-0.57	-6.69	-0.38	1.34e-10	Gut microbiome composition (summer);
CESC	cis	rs12479064	0.724	rs62153852	chr2:99934713	C/T	cg09787394	chr2:99771194	LIPT1;TSGA10	0.48	5.07	0.3	7.54e-7	Chronic sinus infection;
CESC	cis	rs2455799	0.573	rs2470546	chr3:15733897	T/C	cg09340198	chr3:15902540	ANKRD28	-0.32	-5.1	-0.3	6.53e-7	Mean platelet volume;
CESC	cis	rs853679	0.517	rs9393893	chr6:28109262	T/C	cg23161317	chr6:28129485	ZNF389	0.5	6.4	0.37	7.04e-10	Depression;
CESC	cis	rs6537837	1.000	rs6682956	chr1:110130264	G/A	cg05049280	chr1:110155535	GNAT2	0.38	5.26	0.31	3e-7	Major depressive disorder;
CESC	cis	rs9443645	0.527	rs4706743	chr6:79615793	G/T	cg05283184	chr6:79620031	NA	-0.37	-5.23	-0.31	3.45e-7	Intelligence (multi-trait analysis);
CESC	cis	rs875971	0.545	rs73136346	chr7:65566082	A/G	cg25405998	chr7:65216604	CCT6P1	-0.51	-5.35	-0.31	1.94e-7	Aortic root size;
CESC	cis	rs7084402	0.967	rs1303968	chr10:60298941	G/A	cg07615347	chr10:60278583	BICC1	0.6	9.46	0.5	1.77e-18	Refractive error;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg15465092	chr8:128747754	MYC	-0.46	-6.51	-0.37	3.8e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs1799949	0.773	rs2137990	chr17:41317896	T/A	cg23758822	chr17:41437982	NA	-1.0	-17.54	-0.73	3.02e-46	Menopause (age at onset);
CESC	cis	rs1707322	1.000	rs10890365	chr1:46359348	C/T	cg05343316	chr1:45956843	TESK2	0.42	5.24	0.31	3.26e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs5769765	0.862	rs9616386	chr22:50313179	G/A	cg09872104	chr7:134855509	C7orf49	-0.55	-6.31	-0.36	1.19e-9	Schizophrenia;
CESC	cis	rs10743315	0.547	rs7310796	chr12:19362390	C/T	cg02471346	chr12:19282374	PLEKHA5	-0.47	-5.19	-0.3	4.11e-7	Gut microbiota (bacterial taxa);
CESC	cis	rs8060686	0.516	rs11075670	chr16:68288393	C/G	cg26727032	chr16:67993705	SLC12A4	-0.55	-7.3	-0.41	3.29e-12	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs8020095	0.528	rs1950689	chr14:67338678	C/T	cg19548862	chr14:67692701	FAM71D	-0.49	-5.94	-0.34	8.74e-9	Depression (quantitative trait);
CESC	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg11494091	chr17:61959527	GH2	0.72	12.38	0.61	4.46e-28	Prudent dietary pattern;
CESC	cis	rs8070624	0.543	rs57728924	chr17:17875342	A/G	cg04398451	chr17:18023971	MYO15A	-0.69	-9.51	-0.5	1.19e-18	Total body bone mineral density;
CESC	cis	rs727563	0.593	rs5758461	chr22:42162189	G/C	cg17376030	chr22:41985996	PMM1	-0.77	-8.15	-0.45	1.45e-14	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs9302635	0.688	rs763665	chr16:72078043	C/T	cg01557791	chr16:72042693	DHODH	-0.62	-5.11	-0.3	6.11e-7	Blood protein levels;
CESC	cis	rs11150038	0.826	rs9926583	chr16:78087730	C/T	cg04733911	chr16:78082701	NA	-0.43	-5.34	-0.31	2.02e-7	Colorectal or endometrial cancer;
CESC	cis	rs6570726	0.791	rs447992	chr6:145817184	C/T	cg05347473	chr6:146136440	FBXO30	0.59	7.59	0.42	5.36e-13	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7666738	0.753	rs11097594	chr4:98944486	A/G	cg05340658	chr4:99064831	C4orf37	0.82	12.52	0.61	1.45e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs875971	0.867	rs1002053	chr7:65798545	G/A	cg12463550	chr7:65579703	CRCP	-0.55	-7.02	-0.4	1.82e-11	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20818191	chr4:866154	GAK	-0.61	-6.75	-0.38	9.36e-11	Gut microbiome composition (summer);
CESC	cis	rs6570726	0.818	rs398812	chr6:145817271	T/C	cg23711669	chr6:146136114	FBXO30	0.81	12.04	0.59	6.44e-27	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs116988415	0.584	rs17767466	chr14:65252095	G/T	cg25083366	chr14:65239357	SPTB	0.7	5.29	0.31	2.6e-7	Daytime sleep phenotypes;
CESC	cis	rs4819052	1.000	rs4819052	chr21:46699777	A/G	cg11663144	chr21:46675770	NA	-0.45	-6.02	-0.35	5.74e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg19419993	chr17:65374049	PITPNC1	-0.5	-7.2	-0.4	6.22e-12	Gut microbiota (bacterial taxa);
CESC	cis	rs4665809	0.941	rs2289021	chr2:26362515	A/C	cg27170947	chr2:26402098	FAM59B	0.53	6.74	0.38	9.89e-11	Gut microbiome composition (summer);
CESC	cis	rs4819052	0.851	rs2236445	chr21:46678453	T/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.46	5.75	0.33	2.41e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs9443189	0.570	rs7770824	chr6:76408189	G/A	cg01950844	chr6:76311363	SENP6	0.88	9.29	0.5	6.05e-18	Prostate cancer;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg04700215	chr12:46320110	SFRS2IP	0.38	6.16	0.35	2.7e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs9323205	0.577	rs9672038	chr14:51724856	A/G	cg23942311	chr14:51606299	NA	-0.44	-6.5	-0.37	4.01e-10	Cancer;
CESC	cis	rs9902453	0.845	rs12602426	chr17:28158815	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	8.38	0.46	3.08e-15	Coffee consumption (cups per day);
CESC	cis	rs11971779	0.941	rs74299967	chr7:139043769	G/T	cg07862535	chr7:139043722	LUC7L2	0.56	5.74	0.33	2.55e-8	Diisocyanate-induced asthma;
CESC	cis	rs7208859	0.623	rs9916727	chr17:29107472	A/G	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.91e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs4374383	1.000	rs4374383	chr2:112770770	A/G	cg07905836	chr2:113190072	RGPD8;RGPD5	-0.45	-5.17	-0.3	4.66e-7	Hepatitis C induced liver fibrosis;
CESC	cis	rs6088590	1.000	rs11698977	chr20:33449691	C/T	cg24642439	chr20:33292090	TP53INP2	0.85	11.94	0.59	1.39e-26	Coronary artery disease;
CESC	cis	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg16694489	chr4:22509445	GPR125	0.4	5.55	0.32	6.77e-8	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs651907	0.535	rs13065944	chr3:101473088	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.45	5.88	0.34	1.22e-8	Colorectal cancer;
CESC	trans	rs694739	0.628	rs11606081	chr11:64137875	T/C	cg01888411	chr11:34378293	ABTB2	0.4	6.01	0.35	6e-9	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CESC	cis	rs2249625	0.564	rs2463734	chr6:72882558	C/T	cg18830697	chr6:72922368	RIMS1	-0.46	-6.81	-0.39	6.53e-11	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CESC	cis	rs854765	0.583	rs950966	chr17:17783748	A/G	cg16928487	chr17:17741425	SREBF1	0.6	10.48	0.54	9.88e-22	Total body bone mineral density;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08949011	chr10:99400449	PI4K2A	0.69	7.66	0.43	3.49e-13	Gut microbiome composition (summer);
CESC	cis	rs2635047	0.811	rs17785419	chr18:44765469	A/G	cg19077165	chr18:44547161	KATNAL2	0.38	5.12	0.3	5.77e-7	Educational attainment;
CESC	cis	rs8020095	0.571	rs8012063	chr14:67434470	G/A	cg19548862	chr14:67692701	FAM71D	-0.49	-5.89	-0.34	1.15e-8	Depression (quantitative trait);
CESC	cis	rs2235544	0.664	rs12036530	chr1:54476323	T/C	cg25741118	chr1:54482237	LDLRAD1	-0.24	-6.21	-0.36	2.01e-9	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
CESC	cis	rs9303401	0.659	rs62083368	chr17:56878062	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.01	12.5	0.61	1.71e-28	Cognitive test performance;
CESC	trans	rs10435719	0.899	rs7815595	chr8:11792351	C/A	cg15556689	chr8:8085844	FLJ10661	0.52	6.39	0.37	7.33e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
CESC	cis	rs4950322	0.570	rs72691098	chr1:146771840	G/A	cg22381352	chr1:146742008	CHD1L	-0.46	-5.05	-0.3	8.32e-7	Protein quantitative trait loci;
CESC	cis	rs7847628	0.587	rs10760117	chr9:123586737	T/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.94	17.46	0.73	5.92e-46	Birth weight;
CESC	cis	rs11122272	0.766	rs2790867	chr1:231548059	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.58	7.93	0.44	5.95e-14	Hemoglobin concentration;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg21146272	chr6:42858716	C6orf226	-0.46	-6.15	-0.35	2.83e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs11608355	0.545	rs4766473	chr12:109900596	C/T	cg05360138	chr12:110035743	NA	0.82	8.92	0.48	7.93e-17	Neuroticism;
CESC	cis	rs7618915	0.547	rs4687548	chr3:52666650	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	6.98	0.39	2.38e-11	Bipolar disorder;
CESC	cis	rs559928	0.549	rs57831436	chr11:64007297	C/T	cg18225595	chr11:63971243	STIP1	0.66	5.46	0.32	1.08e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CESC	cis	rs6582630	0.519	rs4405392	chr12:38293661	A/C	cg13010199	chr12:38710504	ALG10B	0.46	5.88	0.34	1.26e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs12134245	0.755	rs11164928	chr1:92012678	G/A	cg07090678	chr1:91966139	CDC7	0.37	5.3	0.31	2.39e-7	Breast cancer;
CESC	cis	rs514406	0.679	rs61768344	chr1:53229274	G/A	cg08859206	chr1:53392774	SCP2	0.71	11.13	0.56	7.51e-24	Monocyte count;
CESC	cis	rs6089829	0.851	rs6122346	chr20:61661822	C/G	cg08564027	chr20:61660810	NA	0.9	15.36	0.69	1.69e-38	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg22535103	chr8:58192502	C8orf71	-0.92	-10.19	-0.53	8.81e-21	Developmental language disorder (linguistic errors);
CESC	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg18765753	chr7:1198926	ZFAND2A	-0.38	-5.44	-0.32	1.23e-7	Longevity;Endometriosis;
CESC	cis	rs80130819	0.636	rs4760623	chr12:48619256	A/C	cg05342945	chr12:48394962	COL2A1	-0.48	-5.2	-0.3	4.07e-7	Prostate cancer;
CESC	cis	rs72627123	0.500	rs7359018	chr14:74521008	T/C	cg05179529	chr14:74551516	LIN52;ALDH6A1	0.53	5.94	0.34	9.08e-9	Morning vs. evening chronotype;
CESC	cis	rs7772486	0.790	rs2247666	chr6:146220409	C/A	cg05347473	chr6:146136440	FBXO30	0.57	7.31	0.41	3.07e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6540556	0.654	rs6540549	chr1:209922668	G/T	cg05527609	chr1:210001259	C1orf107	0.41	5.08	0.3	7.27e-7	Red blood cell count;
CESC	cis	rs4665809	0.838	rs7565843	chr2:26292912	G/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.67	-7.6	-0.42	4.99e-13	Gut microbiome composition (summer);
CESC	cis	rs7264396	0.676	rs6060729	chr20:34557004	G/C	cg17201900	chr20:34330562	RBM39	0.51	5.31	0.31	2.37e-7	Total cholesterol levels;
CESC	cis	rs4835473	0.932	rs12512652	chr4:144657940	A/T	cg25736465	chr4:144833511	NA	-0.33	-5.05	-0.3	8.38e-7	Immature fraction of reticulocytes;
CESC	cis	rs12711979	0.509	rs10178286	chr2:3823821	A/G	cg17052675	chr2:3827356	NA	0.66	10.56	0.54	5.58e-22	Itch intensity from mosquito bite adjusted by bite size;
CESC	cis	rs7659604	0.628	rs6838153	chr4:122720999	A/G	cg06713675	chr4:122721982	EXOSC9	-0.51	-7.04	-0.4	1.65e-11	Type 2 diabetes;
CESC	cis	rs10755723	1	rs10755723	chr6:42593718	T/A	cg10605015	chr6:42532144	UBR2	0.52	5.89	0.34	1.18e-8	Lung cancer in never smokers;
CESC	cis	rs2651899	0.867	rs207200	chr1:3073555	T/C	cg22674798	chr1:3096360	PRDM16	0.41	8.06	0.44	2.65e-14	Migraine;
CESC	cis	rs2228479	0.867	rs62056110	chr16:89946388	A/C	cg04013166	chr16:89971882	TCF25	0.77	7.14	0.4	8.86e-12	Skin colour saturation;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14405528	chr22:47372700	TBC1D22A	-0.52	-6.81	-0.39	6.57e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs1707322	0.717	rs28396194	chr1:46213227	C/T	cg06784218	chr1:46089804	CCDC17	0.41	7.21	0.41	5.75e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7927592	0.731	rs2840367	chr11:68302101	G/A	cg20283391	chr11:68216788	NA	0.43	5.45	0.32	1.16e-7	Total body bone mineral density;
CESC	cis	rs965513	1.000	rs10983761	chr9:100553957	A/C	cg13688889	chr9:100608707	NA	-0.58	-8.26	-0.45	6.88e-15	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
CESC	cis	rs7551222	0.634	rs12139477	chr1:204553104	A/C	cg20240347	chr1:204465584	NA	-0.3	-6.02	-0.35	5.95e-9	Schizophrenia;
CESC	cis	rs2075371	0.933	rs1833475	chr7:133958263	C/T	cg11752832	chr7:134001865	SLC35B4	0.51	6.52	0.37	3.54e-10	Mean platelet volume;
CESC	trans	rs718857	0.524	rs1443841	chr9:106721632	A/G	cg24317979	chr2:87302855	LOC285074	0.48	6.0	0.35	6.37e-9	Breast cancer;
CESC	cis	rs1552244	1.000	rs9820598	chr3:10117912	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	12.72	0.62	2.99e-29	Alzheimer's disease;
CESC	cis	rs10504229	0.683	rs6999984	chr8:58115079	G/A	cg24829409	chr8:58192753	C8orf71	-0.58	-7.2	-0.4	6.31e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs4737010	0.501	rs1579274	chr8:41658923	T/G	cg08923054	chr8:41654455	ANK1	0.59	7.24	0.41	4.99e-12	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
CESC	cis	rs28489187	0.683	rs233050	chr1:85837793	T/C	cg16011679	chr1:85725395	C1orf52	0.54	6.3	0.36	1.25e-9	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg00271154	chr2:113033418	ZC3H6	-0.43	-6.78	-0.38	7.97e-11	Vertical cup-disc ratio;
CESC	cis	rs9291683	0.527	rs73212848	chr4:10093299	T/C	cg05927159	chr4:10118984	WDR1	0.34	5.05	0.3	8.15e-7	Bone mineral density;
CESC	cis	rs780096	0.565	rs13022659	chr2:27743630	C/T	cg24768116	chr2:27665128	KRTCAP3	-0.31	-5.63	-0.33	4.62e-8	Total body bone mineral density;
CESC	cis	rs7824557	0.564	rs1435275	chr8:11235735	T/C	cg21775007	chr8:11205619	TDH	-0.54	-8.07	-0.44	2.52e-14	Retinal vascular caliber;
CESC	cis	rs1707322	0.721	rs12043945	chr1:46106922	T/A	cg06784218	chr1:46089804	CCDC17	0.42	7.35	0.41	2.41e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs854765	0.647	rs2056842	chr17:18009028	C/T	cg09796270	chr17:17721594	SREBF1	0.42	5.56	0.32	6.44e-8	Total body bone mineral density;
CESC	cis	rs9462846	0.841	rs66541797	chr6:42825942	C/T	cg05552183	chr6:42928497	GNMT	0.44	5.28	0.31	2.69e-7	Blood protein levels;
CESC	trans	rs877282	0.898	rs12357995	chr10:765739	T/C	cg22713356	chr15:30763199	NA	1.16	11.35	0.57	1.37e-24	Uric acid levels;
CESC	cis	rs847577	0.588	rs12666406	chr7:97790991	G/A	cg21770322	chr7:97807741	LMTK2	0.83	13.92	0.65	1.95e-33	Breast cancer;
CESC	cis	rs80130819	0.892	rs7966139	chr12:48628757	T/A	cg05342945	chr12:48394962	COL2A1	-0.68	-5.38	-0.31	1.64e-7	Prostate cancer;
CESC	cis	rs7680126	0.596	rs17418533	chr4:10316941	T/C	cg11266682	chr4:10021025	SLC2A9	-0.4	-5.18	-0.3	4.42e-7	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	cis	rs17376456	0.877	rs12374463	chr5:93483569	C/G	cg21475434	chr5:93447410	FAM172A	0.88	7.64	0.42	3.98e-13	Diabetic retinopathy;
CESC	cis	rs9300255	0.507	rs1727302	chr12:123632930	G/A	cg00376283	chr12:123451042	ABCB9	0.68	9.08	0.49	2.6e-17	Neutrophil percentage of white cells;
CESC	cis	rs8114671	0.562	rs4911447	chr20:33479445	T/A	cg06115741	chr20:33292138	TP53INP2	0.47	5.66	0.33	4e-8	Height;
CESC	cis	rs3096299	0.563	rs4600467	chr16:89562516	C/T	cg02034447	chr16:89574710	SPG7	0.53	6.83	0.39	5.85e-11	Multiple myeloma (IgH translocation);
CESC	cis	rs10504229	0.683	rs7463453	chr8:58112053	A/G	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs7332672	0.532	rs9284183	chr13:99946371	G/A	cg21788972	chr13:99853209	UBAC2	-0.4	-5.13	-0.3	5.56e-7	Eosinophil counts;
CESC	trans	rs10054504	0.722	rs57193891	chr5:32001061	C/T	cg16516980	chr11:1535048	HCCA2	-0.76	-6.42	-0.37	6.4e-10	Renal cell carcinoma;
CESC	cis	rs2440129	0.611	rs1042356	chr17:6902743	G/A	cg03404566	chr17:6899310	ALOX12	0.37	6.18	0.35	2.47e-9	Tonsillectomy;
CESC	cis	rs2404602	0.716	rs7164060	chr15:76707694	T/C	cg22467129	chr15:76604101	ETFA	-0.38	-5.68	-0.33	3.56e-8	Blood metabolite levels;
CESC	cis	rs16867321	0.588	rs2368175	chr2:181493763	G/C	cg23363182	chr2:181467187	NA	-0.52	-7.96	-0.44	5.11e-14	Obesity;
CESC	cis	rs6570726	0.791	rs379040	chr6:145889035	T/C	cg23711669	chr6:146136114	FBXO30	0.91	13.76	0.65	7.31e-33	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9470366	0.883	rs7756236	chr6:36627053	A/G	cg08179530	chr6:36648295	CDKN1A	0.51	6.24	0.36	1.76e-9	QRS duration;
CESC	cis	rs7618915	0.547	rs3755806	chr3:52643685	C/T	cg07507251	chr3:52567010	NT5DC2	-0.41	-7.05	-0.4	1.55e-11	Bipolar disorder;
CESC	cis	rs1801251	1.000	rs1801251	chr2:233633460	G/A	cg08000102	chr2:233561755	GIGYF2	0.67	9.48	0.5	1.53e-18	Coronary artery disease;
CESC	trans	rs10776614	0.799	rs1473323	chr10:49764820	A/G	cg19218067	chr2:181235115	NA	0.49	6.0	0.35	6.35e-9	Self-employment;
CESC	cis	rs703842	1.000	rs11172333	chr12:58170335	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.72	9.23	0.49	8.74e-18	Multiple sclerosis;
CESC	cis	rs4665809	0.590	rs10495756	chr2:26485586	A/G	cg27170947	chr2:26402098	FAM59B	0.87	9.82	0.52	1.27e-19	Gut microbiome composition (summer);
CESC	cis	rs35306767	0.903	rs11253495	chr10:937064	C/T	cg25019033	chr10:957182	NA	-0.53	-5.67	-0.33	3.77e-8	Eosinophil percentage of granulocytes;
CESC	cis	rs244293	0.665	rs6504947	chr17:53004144	T/A	cg19360675	chr17:53046073	COX11;STXBP4	-0.42	-5.33	-0.31	2.12e-7	Menarche (age at onset);
CESC	cis	rs7666738	0.830	rs10014284	chr4:98681951	G/C	cg05340658	chr4:99064831	C4orf37	0.76	10.99	0.56	2.11e-23	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2046867	0.818	rs62249863	chr3:72868666	G/C	cg25664220	chr3:72788482	NA	-0.45	-6.52	-0.37	3.55e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CESC	cis	rs2273669	0.588	rs75995854	chr6:109325624	C/A	cg05315195	chr6:109294784	ARMC2	-0.66	-6.28	-0.36	1.36e-9	Prostate cancer;
CESC	cis	rs7927771	0.524	rs4752796	chr11:47841862	A/G	cg18512352	chr11:47633146	NA	-0.36	-5.55	-0.32	6.84e-8	Subjective well-being;
CESC	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg18402987	chr7:1209562	NA	0.46	6.1	0.35	3.76e-9	Longevity;Endometriosis;
CESC	trans	rs7246760	0.737	rs73501268	chr19:9803081	G/A	cg02900749	chr2:68251473	NA	-0.82	-7.19	-0.4	6.67e-12	Pursuit maintenance gain;
CESC	cis	rs12188164	0.931	rs115554641	chr5:443236	C/G	cg21144161	chr5:423903	AHRR	0.38	6.08	0.35	4.1e-9	Cystic fibrosis severity;
CESC	trans	rs2764766	0.721	rs245180	chr5:127204314	G/A	cg15764593	chr10:829463	NA	-0.4	-6.29	-0.36	1.33e-9	Schizophrenia;
CESC	trans	rs987724	0.542	rs4680304	chr3:156531273	G/A	cg04543008	chr11:71955332	PHOX2A	0.36	6.0	0.35	6.61e-9	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
CESC	cis	rs78456975	1.000	rs6708604	chr2:1556887	C/T	cg01028140	chr2:1542097	TPO	-0.58	-5.93	-0.34	9.51e-9	Placebo response in major depressive disorder (% change in symptom score);
CESC	trans	rs58106596	0.660	rs62197212	chr2:232562727	G/A	cg01370599	chr3:116745421	NA	0.5	6.14	0.35	3.02e-9	White blood cell count;Lymphocyte counts;
CESC	trans	rs2207136	0.835	rs532847	chr6:50910439	T/C	cg06522515	chr3:184090630	THPO	-0.36	-6.19	-0.36	2.26e-9	Myopia;
CESC	cis	rs734999	0.549	rs6670198	chr1:2520527	T/C	cg20673091	chr1:2541236	MMEL1	0.43	7.14	0.4	9.15e-12	Ulcerative colitis;
CESC	cis	rs910316	0.763	rs175490	chr14:75545685	A/G	cg11812906	chr14:75593930	NEK9	0.83	13.63	0.64	2.12e-32	Height;
CESC	cis	rs12479064	0.724	rs6748200	chr2:100080895	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.56	-6.69	-0.38	1.34e-10	Chronic sinus infection;
CESC	cis	rs561341	1.000	rs7216102	chr17:30259450	A/G	cg19193384	chr17:30244184	NA	-0.47	-5.6	-0.33	5.4e-8	Hip circumference adjusted for BMI;
CESC	cis	rs933688	1.000	rs12651840	chr5:90729592	T/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.13	14.43	0.66	3.18e-35	Smoking behavior;
CESC	trans	rs7943203	0.962	rs611646	chr11:108177097	T/A	cg24155668	chr6:36098398	MAPK13	-0.49	-6.14	-0.35	3.01e-9	Red blood cell count;Mean corpuscular volume;
CESC	cis	rs13108904	0.967	rs62293658	chr4:1276416	T/C	cg16405210	chr4:1374714	KIAA1530	0.47	6.04	0.35	5.3e-9	Obesity-related traits;
CESC	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	10.19	0.53	8.59e-21	Prudent dietary pattern;
CESC	cis	rs1862618	0.802	rs4389648	chr5:56103602	A/G	cg18230493	chr5:56204884	C5orf35	-0.71	-8.42	-0.46	2.36e-15	Initial pursuit acceleration;
CESC	cis	rs12586317	0.620	rs10145433	chr14:35583333	G/A	cg16230307	chr14:35515116	FAM177A1	0.92	10.08	0.53	1.98e-20	Psoriasis;
CESC	cis	rs7107174	0.892	rs11601866	chr11:78011153	G/A	cg02023728	chr11:77925099	USP35	0.51	6.71	0.38	1.14e-10	Testicular germ cell tumor;
CESC	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg12419862	chr22:24373484	LOC391322	-0.69	-9.86	-0.52	9.48e-20	Liver enzyme levels (gamma-glutamyl transferase);
CESC	trans	rs9929218	0.954	rs17715799	chr16:68830511	A/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.64	-8.24	-0.45	7.98e-15	Colorectal cancer;
CESC	cis	rs11864453	0.826	rs2240243	chr16:72137561	A/G	cg01557791	chr16:72042693	DHODH	0.51	6.66	0.38	1.57e-10	Fibrinogen levels;
CESC	cis	rs12142240	0.698	rs6690075	chr1:46819848	G/A	cg00530320	chr1:46809349	NSUN4	0.58	7.89	0.44	8.15e-14	Menopause (age at onset);
CESC	trans	rs877282	0.945	rs11253391	chr10:788752	G/A	cg22713356	chr15:30763199	NA	1.32	13.44	0.64	9.25e-32	Uric acid levels;
CESC	cis	rs1215050	0.791	rs1215055	chr4:98865454	C/T	cg05340658	chr4:99064831	C4orf37	-0.5	-6.61	-0.38	2.14e-10	Waist-to-hip ratio adjusted for body mass index;
CESC	trans	rs7944735	0.671	rs1228044	chr11:48011180	A/G	cg15704280	chr7:45808275	SEPT13	0.65	7.61	0.42	4.93e-13	Intraocular pressure;
CESC	cis	rs4700695	0.719	rs36922	chr5:65464856	C/T	cg21114390	chr5:65439923	SFRS12	-0.48	-5.85	-0.34	1.46e-8	Facial morphology (factor 19);
CESC	cis	rs8072100	0.817	rs11869940	chr17:45578435	T/A	cg08085267	chr17:45401833	C17orf57	0.44	5.77	0.33	2.18e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs3011225	0.683	rs4660753	chr1:44321044	G/A	cg13606994	chr1:44402422	ARTN	-0.35	-5.14	-0.3	5.31e-7	Amyotrophic lateral sclerosis (age of onset);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg06662685	chr11:2907073	CDKN1C	-0.45	-6.14	-0.35	3.06e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs672059	0.934	rs641057	chr1:183156859	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.54	6.99	0.39	2.28e-11	Hypertriglyceridemia;
CESC	cis	rs10751667	0.666	rs7396473	chr11:966181	T/C	cg06064525	chr11:970664	AP2A2	-0.48	-9.29	-0.5	5.99e-18	Alzheimer's disease (late onset);
CESC	cis	rs4835473	0.897	rs7687156	chr4:144630115	T/C	cg25736465	chr4:144833511	NA	0.4	6.17	0.35	2.59e-9	Immature fraction of reticulocytes;
CESC	cis	rs4423214	0.610	rs12793607	chr11:71129316	C/T	cg05163923	chr11:71159392	DHCR7	-0.59	-8.0	-0.44	3.86e-14	Vitamin D levels;
CESC	cis	rs752010	0.806	rs1109255	chr1:42091708	C/T	cg06885757	chr1:42089581	HIVEP3	0.5	8.31	0.45	5.03e-15	Lupus nephritis in systemic lupus erythematosus;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg19742965	chr7:42006083	GLI3	0.47	6.12	0.35	3.42e-9	Fibrinogen levels;
CESC	cis	rs6951245	1.000	rs884977	chr7:1066410	T/C	cg24642844	chr7:1081250	C7orf50	-0.62	-8.19	-0.45	1.15e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs35306767	0.903	rs7067865	chr10:908387	C/T	cg25019033	chr10:957182	NA	-0.6	-6.51	-0.37	3.72e-10	Eosinophil percentage of granulocytes;
CESC	cis	rs763014	0.931	rs3752568	chr16:628302	A/G	cg00908189	chr16:619842	PIGQ	0.67	9.39	0.5	2.81e-18	Height;
CESC	trans	rs7944735	0.832	rs7130876	chr11:48050995	A/G	cg15704280	chr7:45808275	SEPT13	0.64	6.53	0.37	3.26e-10	Intraocular pressure;
CESC	cis	rs7107174	1.000	rs2292572	chr11:78052864	G/T	cg02023728	chr11:77925099	USP35	0.38	5.39	0.31	1.57e-7	Testicular germ cell tumor;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17260383	chr8:22298246	PPP3CC	0.64	6.94	0.39	3.08e-11	Gut microbiome composition (summer);
CESC	cis	rs7116495	0.609	rs1894004	chr11:71759817	G/A	cg26138937	chr11:71823887	C11orf51	-1.33	-8.44	-0.46	2.03e-15	Severe influenza A (H1N1) infection;
CESC	cis	rs11723261	0.664	rs4627799	chr4:132389	C/T	cg12746427	chr4:53362	ZNF718;ZNF595	0.48	5.81	0.34	1.78e-8	Immune response to smallpox vaccine (IL-6);
CESC	cis	rs6087990	0.836	rs2424909	chr20:31361861	T/C	cg13636640	chr20:31349939	DNMT3B	0.91	16.01	0.7	8.02e-41	Ulcerative colitis;
CESC	cis	rs10256972	0.528	rs7784607	chr7:1178694	A/G	cg22907277	chr7:1156413	C7orf50	0.42	6.05	0.35	4.95e-9	Longevity;Endometriosis;
CESC	cis	rs2718058	0.501	rs2717938	chr7:37702545	C/T	cg15028436	chr7:37888078	TXNDC3	-0.36	-5.73	-0.33	2.69e-8	Alzheimer's disease (late onset);
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg13959152	chr12:100535986	UHRF1BP1L	-0.45	-6.08	-0.35	4.11e-9	Height;
CESC	cis	rs1129187	0.837	rs3763236	chr6:42902508	C/T	cg05552183	chr6:42928497	GNMT	-0.59	-9.09	-0.49	2.38e-17	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs2012796	0.743	rs12435764	chr14:81836866	A/C	cg02996355	chr14:81879375	NA	0.65	8.05	0.44	2.88e-14	Night sleep phenotypes;
CESC	cis	rs9399135	0.967	rs9402676	chr6:135355507	C/T	cg24558204	chr6:135376177	HBS1L	0.52	7.14	0.4	9.16e-12	Red blood cell count;
CESC	cis	rs7264396	0.790	rs12480622	chr20:34234620	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.85	-10.48	-0.54	1.01e-21	Total cholesterol levels;
CESC	cis	rs790123	1.000	rs790125	chr3:122388464	A/G	cg17380795	chr3:122379686	NA	0.38	5.65	0.33	4.19e-8	Response to angiotensin II receptor blocker therapy;
CESC	cis	rs8062405	0.824	rs4788083	chr16:28545449	A/G	cg07382826	chr16:28625726	SULT1A1	0.3	5.03	0.3	8.87e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs11764590	0.694	rs10276536	chr7:2086960	C/T	cg21782813	chr7:2030301	MAD1L1	-0.4	-5.34	-0.31	2.04e-7	Neuroticism;
CESC	cis	rs6938	0.618	rs11633472	chr15:75184084	T/G	cg13906792	chr15:75199810	C15orf17	-0.34	-5.03	-0.3	9.02e-7	Breast cancer;
CESC	cis	rs9486719	1.000	rs6921291	chr6:97066242	C/T	cg18709589	chr6:96969512	KIAA0776	-0.55	-6.01	-0.35	6.27e-9	Migraine;Coronary artery disease;
CESC	cis	rs1005277	0.579	rs2474567	chr10:38382492	C/T	cg25517755	chr10:38738941	LOC399744	-0.48	-6.22	-0.36	1.95e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs911555	0.723	rs11160751	chr14:103925740	T/C	cg24130564	chr14:104152367	KLC1	-0.52	-6.88	-0.39	4.27e-11	Intelligence (multi-trait analysis);
CESC	cis	rs6088590	0.965	rs6119534	chr20:33441257	C/T	cg06115741	chr20:33292138	TP53INP2	0.6	7.48	0.42	1.06e-12	Coronary artery disease;
CESC	cis	rs2354432	0.607	rs6694347	chr1:146751140	T/C	cg25205988	chr1:146714368	CHD1L	-0.9	-7.78	-0.43	1.64e-13	Mitochondrial DNA levels;
CESC	cis	rs909674	0.662	rs2899318	chr22:39837625	A/G	cg24399712	chr22:39784796	NA	-0.82	-10.89	-0.56	4.46e-23	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs7267979	1.000	rs2482931	chr20:25334445	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.84	-15.92	-0.7	1.72e-40	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs13031619	0.660	rs35668314	chr2:3702673	C/T	cg10645314	chr2:3704589	ALLC	-0.62	-6.02	-0.35	5.68e-9	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CESC	cis	rs589448	0.933	rs523398	chr12:69752775	C/T	cg22834771	chr12:69754056	YEATS4	-0.54	-7.24	-0.41	4.92e-12	Cerebrospinal fluid biomarker levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04822973	chr14:68086311	ARG2	0.57	6.31	0.36	1.15e-9	Gut microbiome composition (summer);
CESC	cis	rs1670533	1.000	rs11725984	chr4:1087338	C/T	cg27284194	chr4:1044797	NA	0.48	6.17	0.35	2.6e-9	Recombination rate (females);
CESC	cis	rs12348691	0.503	rs907576	chr9:100615359	C/T	cg13688889	chr9:100608707	NA	-0.9	-13.65	-0.64	1.78e-32	Alopecia areata;
CESC	trans	rs304172	0.793	rs478412	chr3:62779627	G/A	cg14089474	chr19:45280184	CBLC	0.55	6.21	0.36	2.06e-9	IgG glycosylation;
CESC	cis	rs2933343	0.729	rs1680781	chr3:128612830	C/A	cg11901034	chr3:128598214	ACAD9	-0.36	-5.17	-0.3	4.68e-7	IgG glycosylation;
CESC	cis	rs8112211	0.953	rs61160177	chr19:38819463	C/G	cg14299480	chr19:38876666	GGN	-0.43	-5.81	-0.34	1.82e-8	Blood protein levels;
CESC	cis	rs6543140	0.964	rs10193485	chr2:103089573	T/C	cg04239558	chr2:103089729	SLC9A4	0.48	6.27	0.36	1.49e-9	Blood protein levels;
CESC	cis	rs10493773	0.609	rs12058974	chr1:86192235	T/A	cg17807903	chr1:86174739	ZNHIT6	-0.44	-6.53	-0.37	3.43e-10	Urate levels in overweight individuals;
CESC	cis	rs853679	0.517	rs9368554	chr6:28082711	T/C	cg17949981	chr6:28129498	ZNF389	0.45	5.63	0.33	4.71e-8	Depression;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg22806557	chr3:178865281	PIK3CA	0.55	7.53	0.42	7.92e-13	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs7824557	0.564	rs11782430	chr8:11226071	A/G	cg27411982	chr8:10470053	RP1L1	-0.45	-5.59	-0.32	5.79e-8	Retinal vascular caliber;
CESC	cis	rs4604732	0.631	rs10925044	chr1:247627071	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.57	7.15	0.4	8.36e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01594514	chr11:67374213	NDUFV1	0.61	6.85	0.39	5.16e-11	Gut microbiome composition (summer);
CESC	cis	rs9916302	0.851	rs4390625	chr17:37620347	A/G	cg20243544	chr17:37824526	PNMT	0.51	6.5	0.37	3.97e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs2637266	0.703	rs846637	chr10:78534627	G/A	cg18941641	chr10:78392320	NA	0.4	7.71	0.43	2.61e-13	Pulmonary function;
CESC	cis	rs11871801	1.000	rs12937756	chr17:40576813	C/A	cg21433558	chr17:40837037	CNTNAP1	0.45	5.04	0.3	8.46e-7	Crohn's disease;
CESC	cis	rs2370759	1.000	rs11594459	chr10:32561858	A/C	cg18270830	chr10:32634957	EPC1	0.72	6.74	0.38	1.01e-10	Sexual dysfunction (female);
CESC	cis	rs10206020	0.921	rs10177509	chr2:1568536	T/C	cg12573674	chr2:1569213	NA	-0.45	-5.18	-0.3	4.31e-7	IgG glycosylation;
CESC	cis	rs9311474	0.632	rs6445528	chr3:52572447	C/T	cg18404041	chr3:52824283	ITIH1	0.35	6.09	0.35	3.85e-9	Electroencephalogram traits;
CESC	cis	rs1552244	0.554	rs3732965	chr3:10048760	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.56	-7.17	-0.4	7.49e-12	Alzheimer's disease;
CESC	cis	rs736801	0.740	rs12515180	chr5:131785684	C/T	cg00255919	chr5:131827918	IRF1	-0.35	-5.05	-0.3	8.15e-7	Breast cancer;Mosquito bite size;
CESC	cis	rs10870270	0.956	rs6557	chr10:133781449	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.86	-12.54	-0.61	1.24e-28	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs2415984	0.562	rs34386313	chr14:46908479	C/T	cg14871534	chr14:47121158	RPL10L	0.43	6.0	0.35	6.49e-9	Number of children ever born;
CESC	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg06873352	chr17:61820015	STRADA	0.73	13.0	0.62	3.22e-30	Prudent dietary pattern;
CESC	cis	rs3820928	0.874	rs13423714	chr2:227896652	C/G	cg11843606	chr2:227700838	RHBDD1	0.46	6.01	0.35	6.23e-9	Pulmonary function;
CESC	cis	rs2742234	0.518	rs1254967	chr10:43690391	G/A	cg07801480	chr10:43725741	RASGEF1A	-0.41	-5.3	-0.31	2.46e-7	Hirschsprung disease;
CESC	cis	rs875971	0.862	rs6945775	chr7:65968974	G/A	cg18252515	chr7:66147081	NA	-0.43	-5.62	-0.33	4.9e-8	Aortic root size;
CESC	cis	rs2303745	0.589	rs6512182	chr19:17399476	G/T	cg22549504	chr19:17448937	GTPBP3	0.52	5.88	0.34	1.24e-8	Systemic lupus erythematosus;
CESC	cis	rs4563143	0.502	rs73029061	chr19:29283980	T/A	cg04546413	chr19:29218101	NA	0.52	6.75	0.38	9.46e-11	Methadone dose in opioid dependence;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05947391	chr16:2918414	NA	0.61	6.52	0.37	3.56e-10	Gut microbiome composition (summer);
CESC	cis	rs6964587	1.000	rs6969536	chr7:91689351	C/G	cg17063962	chr7:91808500	NA	0.59	8.09	0.45	2.1e-14	Breast cancer;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg08135815	chr12:94533765	NA	0.4	6.13	0.35	3.21e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs10129255	0.701	rs2005643	chr14:107132304	C/T	cg07958169	chr14:107095056	NA	-0.43	-6.37	-0.36	8.53e-10	Kawasaki disease;
CESC	cis	rs7107174	1.000	rs12277648	chr11:78054336	C/T	cg02023728	chr11:77925099	USP35	0.39	5.55	0.32	7.03e-8	Testicular germ cell tumor;
CESC	cis	rs897080	0.552	rs1067374	chr2:44650250	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	-0.5	-6.06	-0.35	4.57e-9	Height;
CESC	cis	rs13256369	0.802	rs13255789	chr8:8562791	T/C	cg00074818	chr8:8560427	CLDN23	0.38	5.41	0.32	1.39e-7	Obesity-related traits;
CESC	cis	rs6032067	1.000	rs6032065	chr20:43855649	C/T	cg10761708	chr20:43804764	PI3	0.52	6.29	0.36	1.34e-9	Blood protein levels;
CESC	trans	rs208520	0.690	rs6929762	chr6:66709277	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.95	12.41	0.61	3.59e-28	Exhaled nitric oxide output;
CESC	cis	rs138880	0.542	rs9616215	chr22:50318834	C/T	cg02269571	chr22:50332266	NA	-0.65	-6.15	-0.35	2.82e-9	Schizophrenia;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg11004508	chr12:74686423	NA	0.47	6.57	0.37	2.6200000000000003e-10	Fibrinogen levels;
CESC	cis	rs637571	0.522	rs556643	chr11:65733289	C/T	cg02202077	chr11:65769826	EIF1AD;BANF1	0.39	5.13	0.3	5.53e-7	Eosinophil percentage of white cells;
CESC	cis	rs7833790	1.000	rs7833790	chr8:82731157	T/C	cg02079420	chr8:82753780	SNX16	0.56	7.65	0.43	3.64e-13	Diastolic blood pressure;
CESC	cis	rs6089584	0.850	rs881993	chr20:60623862	A/G	cg06108461	chr20:60628389	TAF4	-0.91	-13.97	-0.65	1.32e-33	Body mass index;
CESC	cis	rs10465746	0.935	rs11807807	chr1:84424071	C/T	cg10977910	chr1:84465055	TTLL7	0.47	6.26	0.36	1.58e-9	Obesity-related traits;
CESC	cis	rs6460942	0.915	rs75158182	chr7:12456059	C/T	cg20607287	chr7:12443886	VWDE	-0.78	-9.15	-0.49	1.61e-17	Coronary artery disease;
CESC	cis	rs854765	0.547	rs4459604	chr17:17888549	A/G	cg16928487	chr17:17741425	SREBF1	-0.6	-10.06	-0.53	2.31e-20	Total body bone mineral density;
CESC	cis	rs7666738	0.830	rs11726604	chr4:99000969	T/C	cg17366294	chr4:99064904	C4orf37	0.6	8.61	0.47	6.47e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9300255	0.663	rs7953929	chr12:123758235	C/G	cg19016782	chr12:123741754	C12orf65	-0.41	-5.18	-0.3	4.29e-7	Neutrophil percentage of white cells;
CESC	cis	rs3845702	0.736	rs3845701	chr2:180826781	A/G	cg01881094	chr2:180872142	CWC22	-0.98	-9.07	-0.49	2.78e-17	Schizophrenia;
CESC	cis	rs6460942	1.000	rs77494477	chr7:12315302	A/T	cg10578991	chr7:12443926	VWDE	-0.61	-6.41	-0.37	6.66e-10	Coronary artery disease;
CESC	cis	rs12497850	0.805	rs11130176	chr3:48844077	A/G	cg07636037	chr3:49044803	WDR6	1.01	18.68	0.75	2.81e-50	Parkinson's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05112967	chr7:63353492	NA	-0.66	-8.12	-0.45	1.8e-14	Gut microbiome composition (summer);
CESC	cis	rs3008870	0.709	rs62883160	chr1:67392889	G/A	cg02640540	chr1:67518911	SLC35D1	0.45	5.41	0.32	1.39e-7	Lymphocyte percentage of white cells;
CESC	cis	rs2836950	0.520	rs8130240	chr21:40538108	G/A	cg17971929	chr21:40555470	PSMG1	-0.6	-8.01	-0.44	3.65e-14	Menarche (age at onset);
CESC	cis	rs7909074	1.000	rs4948927	chr10:45397071	G/A	cg05187965	chr10:45406764	TMEM72	-0.33	-5.1	-0.3	6.34e-7	Mean corpuscular volume;
CESC	cis	rs10883723	0.703	rs7898410	chr10:104245858	T/C	cg22532475	chr10:104410764	TRIM8	-0.33	-5.63	-0.33	4.68e-8	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs1707322	0.963	rs6429581	chr1:46319096	G/A	cg06784218	chr1:46089804	CCDC17	0.35	5.87	0.34	1.33e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs7902708	0.920	rs7898709	chr10:54423398	T/G	cg26219051	chr22:43739629	SCUBE1	-0.48	-6.08	-0.35	4.13e-9	Bone properties (heel);
CESC	cis	rs10089	1.000	rs59484271	chr5:127503781	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.73	9.09	0.49	2.47e-17	Ileal carcinoids;
CESC	cis	rs634534	0.622	rs593525	chr11:65727799	T/C	cg17985854	chr11:65770987	BANF1;EIF1AD	0.45	6.75	0.38	9.36e-11	Sum eosinophil basophil counts;Eosinophil counts;
CESC	cis	rs916888	0.773	rs199457	chr17:44795469	C/T	cg17911788	chr17:44343683	NA	-0.63	-8.15	-0.45	1.45e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs61931739	0.534	rs11053075	chr12:34207009	A/G	cg19457237	chr12:34500585	NA	0.39	5.47	0.32	1.06e-7	Morning vs. evening chronotype;
CESC	cis	rs9814567	1.000	rs9827987	chr3:134272621	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.47	-6.37	-0.36	8.41e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs3820928	0.934	rs1366756	chr2:227772038	G/A	cg11843606	chr2:227700838	RHBDD1	-0.43	-5.74	-0.33	2.55e-8	Pulmonary function;
CESC	cis	rs897080	0.515	rs1067332	chr2:44626972	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.49	5.82	0.34	1.67e-8	Height;
CESC	cis	rs12142240	0.698	rs966907	chr1:46817125	C/G	cg10495392	chr1:46806563	NSUN4	0.57	6.28	0.36	1.39e-9	Menopause (age at onset);
CESC	cis	rs4950928	0.823	rs4950882	chr1:203164848	A/G	cg14085262	chr1:203155938	CHI3L1	-0.53	-5.76	-0.33	2.36e-8	YKL-40 levels;
CESC	cis	rs57221529	0.655	rs11948381	chr5:568413	A/T	cg09021430	chr5:549028	NA	-0.47	-6.43	-0.37	6.07e-10	Lung disease severity in cystic fibrosis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02005709	chr14:92492924	TRIP11	-0.55	-6.92	-0.39	3.36e-11	Gut microbiome composition (summer);
CESC	cis	rs2243480	0.522	rs431168	chr7:65511604	G/T	cg18252515	chr7:66147081	NA	-1.25	-9.3	-0.5	5.42e-18	Diabetic kidney disease;
CESC	cis	rs12136530	0.593	rs4911990	chr1:19731873	A/C	cg01832549	chr1:19774989	CAPZB	-0.4	-5.82	-0.34	1.67e-8	Lead levels in blood;
CESC	cis	rs902774	0.554	rs4503623	chr12:53353759	T/C	cg14581129	chr12:53358946	NA	-0.46	-6.14	-0.35	2.99e-9	Prostate cancer;
CESC	cis	rs10504229	0.639	rs66667899	chr8:58117065	C/T	cg24829409	chr8:58192753	C8orf71	-0.58	-7.2	-0.4	6.31e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs7666738	0.822	rs979946	chr4:98921235	C/A	cg03467027	chr4:99064603	C4orf37	0.43	5.35	0.31	1.91e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7618915	0.547	rs6762813	chr3:52726695	C/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	5.62	0.33	4.81e-8	Bipolar disorder;
CESC	cis	rs4478858	0.698	rs10914370	chr1:31854955	T/C	cg00250761	chr1:31883323	NA	-0.26	-5.04	-0.3	8.56e-7	Alcohol dependence;
CESC	cis	rs595982	0.527	rs17272673	chr19:49362992	C/A	cg15549821	chr19:49342101	PLEKHA4	-0.69	-7.74	-0.43	2.11e-13	Red cell distribution width;
CESC	cis	rs11792861	0.816	rs17792434	chr9:111667319	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.52	6.69	0.38	1.34e-10	Menarche (age at onset);
CESC	cis	rs10504229	0.593	rs78459635	chr8:58004995	G/T	cg05313129	chr8:58192883	C8orf71	-0.5	-5.05	-0.3	8.06e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs17376456	1.000	rs17376207	chr5:93545524	C/T	cg25358565	chr5:93447407	FAM172A	-1.13	-11.09	-0.56	1e-23	Diabetic retinopathy;
CESC	cis	rs4604732	0.631	rs74154676	chr1:247625894	T/C	cg12758973	chr1:247694275	LOC148824;OR2C3	0.51	6.36	0.36	8.65e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs2228479	0.850	rs62056061	chr16:89901767	G/A	cg04013166	chr16:89971882	TCF25	0.72	5.75	0.33	2.41e-8	Skin colour saturation;
CESC	cis	rs4835473	0.897	rs13114071	chr4:144656881	C/T	cg25736465	chr4:144833511	NA	-0.36	-5.52	-0.32	7.97e-8	Immature fraction of reticulocytes;
CESC	cis	rs9796	0.611	rs691672	chr15:41444438	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.43	-6.34	-0.36	9.71e-10	Menopause (age at onset);
CESC	cis	rs11764590	0.694	rs10276536	chr7:2086960	C/T	cg16393715	chr7:1948819	MAD1L1	-0.36	-5.06	-0.3	8e-7	Neuroticism;
CESC	cis	rs1552244	1.000	rs12152515	chr3:10143976	C/T	cg00166722	chr3:10149974	C3orf24	0.45	5.72	0.33	2.8e-8	Alzheimer's disease;
CESC	cis	rs947211	1.000	rs1775151	chr1:205745684	C/T	cg26354017	chr1:205819088	PM20D1	0.4	5.04	0.3	8.8e-7	Parkinson's disease;
CESC	cis	rs10489202	0.632	rs203779	chr1:167877647	T/G	cg24449463	chr1:168025552	DCAF6	-0.43	-5.51	-0.32	8.36e-8	Schizophrenia;
CESC	cis	rs7296418	0.885	rs1727305	chr12:123633382	T/C	cg05973401	chr12:123451056	ABCB9	0.53	6.84	0.39	5.33e-11	Platelet count;
CESC	cis	rs6500395	1.000	rs904819	chr16:48622583	C/A	cg04672837	chr16:48644449	N4BP1	0.52	6.51	0.37	3.83e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs10479542	0.892	rs7723230	chr5:178980474	T/C	cg05457628	chr5:178986728	RUFY1	0.51	7.68	0.43	3.09e-13	Lung cancer;
CESC	cis	rs1707322	1.000	rs12097799	chr1:46459886	C/A	cg06784218	chr1:46089804	CCDC17	0.33	5.67	0.33	3.8e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs4253772	0.591	rs9627324	chr22:46656511	A/G	cg09491104	chr22:46646882	C22orf40	-0.6	-9.2	-0.49	1.09e-17	LDL cholesterol;Cholesterol, total;
CESC	cis	rs6860806	0.531	rs272888	chr5:131665423	T/C	cg07395648	chr5:131743802	NA	-0.43	-5.66	-0.33	3.93e-8	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02066925	chr22:35936722	RASD2	-0.57	-6.49	-0.37	4.3e-10	Gut microbiome composition (summer);
CESC	cis	rs1800795	0.652	rs7802307	chr7:22766433	T/A	cg05265849	chr7:22767390	IL6	0.45	5.82	0.34	1.65e-8	Cerebrospinal fluid clusterin levels in APOEe4- carriers;
CESC	cis	rs9916302	0.904	rs10432031	chr17:37397852	G/A	cg15445000	chr17:37608096	MED1	0.4	6.47	0.37	4.81e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs7267979	0.932	rs449703	chr20:25458559	C/T	cg08601574	chr20:25228251	PYGB	0.37	5.36	0.31	1.77e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.5	-6.29	-0.36	1.3e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs11098499	0.644	rs28787668	chr4:120554687	G/A	cg09307838	chr4:120376055	NA	0.77	10.24	0.53	5.82e-21	Corneal astigmatism;
CESC	cis	rs10489525	0.599	rs910622	chr1:115600424	A/G	cg01522456	chr1:115632236	TSPAN2	-0.48	-5.71	-0.33	2.96e-8	Autism;
CESC	cis	rs8062405	0.756	rs151182	chr16:28495752	C/T	cg08761264	chr16:28874980	SH2B1	-0.45	-5.34	-0.31	1.99e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs3780486	0.846	rs10813960	chr9:33180362	C/T	cg13443165	chr9:33130375	B4GALT1	0.41	5.42	0.32	1.33e-7	IgG glycosylation;
CESC	cis	rs6570726	0.935	rs446242	chr6:145843866	A/G	cg23711669	chr6:146136114	FBXO30	0.78	11.38	0.57	1.07e-24	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs8177253	0.634	rs6798547	chr3:133448499	G/A	cg16262614	chr3:133464971	TF	0.3	5.33	0.31	2.14e-7	Iron status biomarkers;
CESC	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg24642844	chr7:1081250	C7orf50	-0.76	-9.16	-0.49	1.51e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs4819052	0.851	rs2838840	chr21:46668494	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.47	5.79	0.33	2.03e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs2836974	0.897	rs2026265	chr21:40595517	G/A	cg17971929	chr21:40555470	PSMG1	1.04	15.59	0.69	2.46e-39	Cognitive function;
CESC	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.56	0.37	2.89e-10	Prudent dietary pattern;
CESC	cis	rs473651	0.935	rs35080527	chr2:239351387	T/C	cg21699342	chr2:239360505	ASB1	0.54	9.21	0.49	1.05e-17	Multiple system atrophy;
CESC	cis	rs4713118	0.662	rs469228	chr6:27970704	A/G	cg17221315	chr6:27791827	HIST1H4J	0.43	5.15	0.3	4.98e-7	Parkinson's disease;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg12557418	chr8:110552613	EBAG9	-0.44	-6.24	-0.36	1.75e-9	Gambling;
CESC	cis	rs6693567	0.565	rs698917	chr1:150319884	G/A	cg09579323	chr1:150459698	TARS2	0.48	6.1	0.35	3.74e-9	Migraine;
CESC	cis	rs9814567	1.000	rs9819532	chr3:134288644	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.45	-6.05	-0.35	4.79e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs4780401	0.728	rs8057398	chr16:11780629	G/T	cg01061890	chr16:11836724	TXNDC11	-0.47	-6.19	-0.36	2.28e-9	Rheumatoid arthritis;
CESC	cis	rs2836974	0.897	rs2836924	chr21:40525639	C/T	cg11890956	chr21:40555474	PSMG1	1.18	23.84	0.83	6.88e-68	Cognitive function;
CESC	cis	rs950169	0.881	rs4842852	chr15:84941961	A/G	cg17507749	chr15:85114479	UBE2QP1	0.59	6.52	0.37	3.46e-10	Schizophrenia;
CESC	cis	rs7618915	0.501	rs7624716	chr3:52751534	T/C	cg18404041	chr3:52824283	ITIH1	-0.4	-6.73	-0.38	1.04e-10	Bipolar disorder;
CESC	cis	rs9486715	0.929	rs7775721	chr6:97056979	C/T	cg06623918	chr6:96969491	KIAA0776	-0.95	-14.69	-0.67	3.77e-36	Headache;
CESC	cis	rs7666738	0.830	rs13138438	chr4:99050545	C/A	cg05340658	chr4:99064831	C4orf37	0.82	12.88	0.62	8.44e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2635047	0.967	rs1119005	chr18:44725605	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.48	6.48	0.37	4.57e-10	Educational attainment;
CESC	cis	rs16895831	0.519	rs16895843	chr6:42541802	G/C	cg10605015	chr6:42532144	UBR2	-0.52	-5.7	-0.33	3.23e-8	Granulocyte percentage of myeloid white cells;Neutrophil percentage of white cells;Eosinophil percentage of white cells;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Neutrophil count;Sum basophil neutrophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
CESC	cis	rs875971	0.862	rs6964437	chr7:65686444	A/G	cg12463550	chr7:65579703	CRCP	-0.52	-6.63	-0.38	1.84e-10	Aortic root size;
CESC	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	7.83	0.43	1.17e-13	Prudent dietary pattern;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg14516552	chr9:96213518	FAM120AOS;FAM120A	-0.45	-6.38	-0.36	7.99e-10	Fibrinogen levels;
CESC	cis	rs722599	0.715	rs2300598	chr14:75359229	T/C	cg11812906	chr14:75593930	NEK9	-0.47	-5.58	-0.32	6.07e-8	IgG glycosylation;
CESC	cis	rs6088590	1.000	rs55753039	chr20:33394940	C/T	cg06115741	chr20:33292138	TP53INP2	0.62	7.42	0.41	1.59e-12	Coronary artery disease;
CESC	cis	rs2836974	0.568	rs11910906	chr21:40685662	T/C	cg17971929	chr21:40555470	PSMG1	-0.87	-12.28	-0.6	9.54e-28	Cognitive function;
CESC	cis	rs798554	0.836	rs798502	chr7:2789880	G/T	cg09658497	chr7:2847517	GNA12	0.43	6.12	0.35	3.33e-9	Height;
CESC	cis	rs769267	0.930	rs7256149	chr19:19566255	T/C	cg03709012	chr19:19516395	GATAD2A	1.01	15.7	0.69	1.02e-39	Tonsillectomy;
CESC	cis	rs4423214	0.592	rs11233977	chr11:71221605	C/T	cg05163923	chr11:71159392	DHCR7	-0.55	-6.0	-0.35	6.31e-9	Vitamin D levels;
CESC	cis	rs514406	0.929	rs12145105	chr1:53340564	T/C	cg25767906	chr1:53392781	SCP2	-0.41	-5.07	-0.3	7.47e-7	Monocyte count;
CESC	cis	rs9549260	0.591	rs9577108	chr13:41271764	G/A	cg21288729	chr13:41239152	FOXO1	0.59	7.68	0.43	2.99e-13	Red blood cell count;
CESC	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.56	-8.69	-0.47	3.73e-16	Longevity;Endometriosis;
CESC	cis	rs10504229	0.511	rs75967910	chr8:58024231	C/G	cg24829409	chr8:58192753	C8orf71	-0.67	-7.32	-0.41	3e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs2011503	1.000	rs11670761	chr19:19649327	G/C	cg11584989	chr19:19387371	SF4	0.58	6.67	0.38	1.52e-10	Bipolar disorder;
CESC	cis	rs6912958	0.781	rs2325064	chr6:88224467	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.51	-6.83	-0.39	5.94e-11	Monocyte percentage of white cells;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07960067	chr2:9144629	MBOAT2	0.56	6.28	0.36	1.36e-9	Gut microbiome composition (summer);
CESC	cis	rs887829	0.569	rs871514	chr2:234628529	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.52	-6.88	-0.39	4.26e-11	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CESC	cis	rs2832191	0.935	rs11910316	chr21:30519729	G/A	cg08807101	chr21:30365312	RNF160	-0.68	-9.36	-0.5	3.57e-18	Dental caries;
CESC	cis	rs4434138	0.664	rs62255364	chr3:52701502	C/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	5.7	0.33	3.27e-8	Intelligence (multi-trait analysis);
CESC	cis	rs6545883	0.965	rs6734830	chr2:61731112	G/A	cg15711740	chr2:61764176	XPO1	-0.42	-5.3	-0.31	2.48e-7	Tuberculosis;
CESC	cis	rs2710642	0.888	rs2539985	chr2:63134507	T/A	cg17519650	chr2:63277830	OTX1	0.56	7.17	0.4	7.62e-12	LDL cholesterol levels;LDL cholesterol;
CESC	cis	rs9837602	1.000	rs13323143	chr3:99811553	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.49	6.81	0.39	6.48e-11	Breast cancer;
CESC	cis	rs4076764	1.000	rs12740984	chr1:163422151	A/G	cg06092702	chr1:163392909	NA	0.39	5.68	0.33	3.5e-8	Motion sickness;
CESC	cis	rs4819052	0.851	rs2838837	chr21:46665988	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.48	5.96	0.34	7.97e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs1707322	0.721	rs10890337	chr1:46124527	C/T	cg03146154	chr1:46216737	IPP	0.82	11.52	0.58	3.64e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg05552183	chr6:42928497	GNMT	0.79	12.72	0.62	3.08e-29	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs4803468	0.904	rs60781668	chr19:41944842	A/T	cg14132834	chr19:41945861	ATP5SL	0.6	7.54	0.42	7.52e-13	Height;
CESC	cis	rs4819052	0.851	rs9974628	chr21:46672647	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.93	13.68	0.64	1.34e-32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs2033711	0.870	rs1051500	chr19:58944402	A/G	cg26874164	chr19:58962979	ZNF324B	0.54	7.46	0.42	1.23e-12	Uric acid clearance;
CESC	cis	rs2033711	0.840	rs10423138	chr19:58928302	T/C	cg00825309	chr19:58991885	ZNF446	-0.54	-7.71	-0.43	2.62e-13	Uric acid clearance;
CESC	cis	rs2439831	0.850	rs12441127	chr15:44021175	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.7	7.98	0.44	4.48e-14	Lung cancer in ever smokers;
CESC	cis	rs116095464	0.558	rs7736600	chr5:231337	A/C	cg22496380	chr5:211416	CCDC127	-0.74	-8.5	-0.46	1.44e-15	Breast cancer;
CESC	trans	rs2727020	0.729	rs1917325	chr11:49370004	G/A	cg03929089	chr4:120376271	NA	-0.79	-11.97	-0.59	1.09e-26	Coronary artery disease;
CESC	cis	rs6502050	0.761	rs9908277	chr17:80060829	T/C	cg11859384	chr17:80120422	CCDC57	0.38	5.1	0.3	6.35e-7	Life satisfaction;
CESC	cis	rs9916302	0.821	rs412430	chr17:37737094	C/G	cg20243544	chr17:37824526	PNMT	0.55	6.8	0.39	6.87e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	22.16	0.81	2.84e-62	Prudent dietary pattern;
CESC	cis	rs6500395	0.802	rs13330784	chr16:48661530	A/C	cg04672837	chr16:48644449	N4BP1	0.49	6.25	0.36	1.59e-9	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs8002861	0.875	rs12867890	chr13:44423088	A/G	cg19180546	chr13:44453867	C13orf31;CCDC122	-0.44	-5.51	-0.32	8.5e-8	Leprosy;
CESC	trans	rs1973993	1.000	rs1973993	chr1:96943994	A/G	cg10631902	chr5:14652156	NA	0.51	7.01	0.4	1.99e-11	Weight;
CESC	trans	rs1814175	0.817	rs7947526	chr11:49983654	T/C	cg03929089	chr4:120376271	NA	-0.93	-15.75	-0.7	6.58e-40	Height;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg25166340	chr7:39605883	C7orf36	-0.45	-6.41	-0.37	6.5e-10	Fibrinogen levels;
CESC	cis	rs763014	0.898	rs35666389	chr16:629458	A/G	cg00802000	chr16:706648	WDR90	-0.42	-6.36	-0.36	9.01e-10	Height;
CESC	cis	rs703842	1.000	rs703842	chr12:58162739	C/T	cg18357645	chr12:58087776	OS9	0.36	5.17	0.3	4.71e-7	Multiple sclerosis;
CESC	cis	rs8092503	1.000	rs6566870	chr18:52475860	C/G	cg12377874	chr18:52495404	RAB27B	-0.35	-5.99	-0.35	6.86e-9	Childhood body mass index;
CESC	cis	rs4704187	0.687	rs1422699	chr5:74442410	G/A	cg03227963	chr5:74354835	NA	0.3	5.58	0.32	5.99e-8	Response to amphetamines;
CESC	cis	rs7811142	0.830	rs73401451	chr7:99981895	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.01	10.07	0.53	2.07e-20	Platelet count;
CESC	cis	rs35955747	0.838	rs28716	chr22:31730189	A/C	cg25791279	chr22:32026902	PISD	0.48	5.86	0.34	1.39e-8	Neutrophil count;Sum basophil neutrophil counts;
CESC	cis	rs962856	0.619	rs6546301	chr2:67604239	G/A	cg09028215	chr2:67624308	ETAA1	-0.43	-5.25	-0.31	3.17e-7	Pancreatic cancer;
CESC	cis	rs4819052	0.851	rs35064782	chr21:46674360	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.77	10.11	0.53	1.58e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs8058578	0.943	rs3747486	chr16:30786927	C/T	cg00531865	chr16:30841666	NA	-0.46	-6.23	-0.36	1.85e-9	Multiple myeloma;
CESC	cis	rs8177253	0.930	rs12595	chr3:133496553	T/C	cg01448562	chr3:133502909	NA	-0.42	-5.81	-0.34	1.81e-8	Iron status biomarkers;
CESC	cis	rs7829975	0.846	rs6601724	chr8:8544872	C/T	cg06636001	chr8:8085503	FLJ10661	-0.49	-6.59	-0.38	2.35e-10	Mood instability;
CESC	cis	rs2404602	0.669	rs12916324	chr15:77179603	G/A	cg22467129	chr15:76604101	ETFA	-0.35	-5.3	-0.31	2.45e-7	Blood metabolite levels;
CESC	cis	rs2295359	0.892	rs72676058	chr1:67627681	C/A	cg17031739	chr1:67600172	NA	0.4	5.22	0.31	3.68e-7	Psoriasis;
CESC	cis	rs59698941	0.943	rs10491278	chr5:132220436	A/C	cg02081065	chr5:132209139	LEAP2	-0.52	-5.11	-0.3	6.08e-7	Apolipoprotein A-IV levels;
CESC	cis	rs6460942	0.915	rs17541242	chr7:12459068	A/G	cg10578991	chr7:12443926	VWDE	-0.51	-5.61	-0.33	5.17e-8	Coronary artery disease;
CESC	cis	rs274567	0.501	rs272856	chr5:131687081	G/C	cg24060327	chr5:131705240	SLC22A5	-0.75	-10.38	-0.54	2.11e-21	Blood metabolite levels;
CESC	cis	rs6912958	0.781	rs9450723	chr6:88226641	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.31	5.07	0.3	7.58e-7	Monocyte percentage of white cells;
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg24528447	chr5:92918517	NR2F1	-0.4	-6.09	-0.35	3.9e-9	Vertical cup-disc ratio;
CESC	cis	rs8018808	0.935	rs6574372	chr14:77906295	T/G	cg20045696	chr14:77926864	AHSA1	0.42	5.79	0.33	2.03e-8	Myeloid white cell count;
CESC	cis	rs523522	0.962	rs10849753	chr12:120910813	C/T	cg12219531	chr12:120966889	COQ5	0.73	9.48	0.5	1.51e-18	High light scatter reticulocyte count;
CESC	cis	rs2832191	1.000	rs9984793	chr21:30486471	T/C	cg08807101	chr21:30365312	RNF160	-0.66	-9.01	-0.48	4.11e-17	Dental caries;
CESC	cis	rs11098499	0.818	rs12498599	chr4:120468503	C/T	cg24375607	chr4:120327624	NA	0.44	5.36	0.31	1.84e-7	Corneal astigmatism;
CESC	cis	rs796364	0.806	rs112486506	chr2:201073947	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.77	-6.48	-0.37	4.42e-10	Schizophrenia;
CESC	cis	rs4689388	0.926	rs9998835	chr4:6293237	C/G	cg00701064	chr4:6280414	WFS1	0.69	11.97	0.59	1.14e-26	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02918483	chr4:84406202	FAM175A	0.56	6.17	0.35	2.6e-9	Gut microbiome composition (summer);
CESC	cis	rs16858210	0.874	rs10937153	chr3:183562925	A/G	cg25686905	chr3:183603175	PARL	0.35	6.51	0.37	3.81e-10	Menopause (age at onset);
CESC	trans	rs59827721	0.607	rs112865679	chr9:13855014	C/T	cg27555582	chr12:22094009	NA	-0.51	-6.01	-0.35	6.06e-9	Inflammatory skin disease;
CESC	cis	rs5750830	0.620	rs1007337	chr22:39781585	C/T	cg01416388	chr22:39784598	NA	-0.53	-6.96	-0.39	2.66e-11	Intelligence (multi-trait analysis);
CESC	cis	rs2295499	0.673	rs12506536	chr4:2712403	T/C	cg27239842	chr4:2403781	ZFYVE28	-0.34	-5.66	-0.33	3.98e-8	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
CESC	trans	rs801193	1.000	rs10274773	chr7:66133578	G/A	cg26939375	chr7:64535504	NA	-0.64	-8.57	-0.47	8.53e-16	Aortic root size;
CESC	cis	rs17641971	0.684	rs10957363	chr8:49999175	T/A	cg00325661	chr8:49890786	NA	0.4	5.56	0.32	6.64e-8	Blood metabolite levels;
CESC	cis	rs8031584	0.697	rs8036176	chr15:31175269	A/G	cg08109568	chr15:31115862	NA	-0.75	-9.74	-0.51	2.26e-19	Huntington's disease progression;
CESC	cis	rs16854884	0.584	rs59768870	chr3:143738366	G/A	cg06585982	chr3:143692056	C3orf58	0.5	6.46	0.37	4.94e-10	Economic and political preferences (feminism/equality);
CESC	cis	rs1008375	0.931	rs10008337	chr4:17593849	G/C	cg02297831	chr4:17616191	MED28	0.51	6.27	0.36	1.43e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs6963495	0.818	rs73192144	chr7:105203535	C/T	cg02135003	chr7:105160482	PUS7	-0.47	-5.61	-0.33	5.06e-8	Bipolar disorder (body mass index interaction);
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg03148428	chr7:156433416	C7orf13;RNF32	0.42	6.02	0.35	5.88e-9	Asthma;
CESC	cis	rs10838687	0.800	rs58023804	chr11:47312374	A/G	cg25783544	chr11:47291846	MADD	0.59	5.95	0.34	8.57e-9	Proinsulin levels;
CESC	cis	rs6942756	0.737	rs61570833	chr7:128933492	C/A	cg02491457	chr7:128862824	NA	-0.69	-9.25	-0.49	7.66e-18	White matter hyperintensity burden;
CESC	cis	rs7914558	0.966	rs12569617	chr10:104729996	T/C	cg08650961	chr10:104748594	CNNM2	0.31	5.05	0.3	8.15e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs8017423	1.000	rs1959001	chr14:90667739	G/A	cg14092571	chr14:90743983	NA	-0.58	-8.7	-0.47	3.56e-16	Mortality in heart failure;
CESC	cis	rs4819052	0.851	rs914214	chr21:46697820	G/T	cg11663144	chr21:46675770	NA	-0.62	-9.68	-0.51	3.55e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs4853012	0.838	rs60964317	chr2:74343423	A/T	cg05890377	chr2:74357713	NA	0.75	10.07	0.53	2.15e-20	Gestational age at birth (maternal effect);
CESC	cis	rs6598955	0.671	rs12145403	chr1:26597189	C/T	cg19743891	chr1:26644573	UBXN11;CD52	0.36	5.28	0.31	2.74e-7	Obesity-related traits;
CESC	cis	rs7647973	0.587	rs10452032	chr3:49680973	G/A	cg03060546	chr3:49711283	APEH	0.69	8.34	0.46	4.18e-15	Menarche (age at onset);
CESC	cis	rs2075371	1.000	rs2075371	chr7:133984127	A/G	cg00033643	chr7:134001901	SLC35B4	0.44	5.6	0.33	5.35e-8	Mean platelet volume;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg03952484	chr1:149899818	SF3B4	0.45	6.24	0.36	1.77e-9	Systemic lupus erythematosus;
CESC	cis	rs3862030	0.810	rs5870	chr10:104239100	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.38	-5.24	-0.31	3.36e-7	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
CESC	cis	rs1799949	1.000	rs8176109	chr17:41265776	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.46	6.39	0.37	7.27e-10	Menopause (age at onset);
CESC	cis	rs9457247	1.000	rs416131	chr6:167406544	A/C	cg25258033	chr6:167368657	RNASET2	-0.4	-6.07	-0.35	4.46e-9	Crohn's disease;
CESC	cis	rs6087990	0.806	rs4911254	chr20:31357579	C/A	cg13636640	chr20:31349939	DNMT3B	0.92	16.3	0.71	7.35e-42	Ulcerative colitis;
CESC	cis	rs9894429	1.000	rs9894429	chr17:79596811	C/T	cg21984481	chr17:79567631	NPLOC4	-0.49	-7.86	-0.43	9.77e-14	Eye color traits;
CESC	trans	rs324780	0.544	rs324805	chr12:83931559	C/T	cg22140261	chr22:42466895	NAGA	-0.49	-6.24	-0.36	1.68e-9	Vertical cup-disc ratio;
CESC	cis	rs4654899	1.000	rs12126133	chr1:21456537	T/C	cg05370193	chr1:21551575	ECE1	0.41	6.2	0.36	2.2e-9	Superior frontal gyrus grey matter volume;
CESC	cis	rs2549003	1.000	rs7701588	chr5:131819970	T/C	cg02551604	chr5:131831745	NA	-0.37	-5.22	-0.31	3.53e-7	Asthma (sex interaction);
CESC	cis	rs9733	0.519	rs7529194	chr1:150622620	A/T	cg04414720	chr1:150670196	GOLPH3L	0.62	9.16	0.49	1.47e-17	Tonsillectomy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20058270	chr6:43149950	CUL9	0.59	7.02	0.4	1.88e-11	Gut microbiome composition (summer);
CESC	cis	rs60787346	0.883	rs2838334	chr21:45064961	A/G	cg01579765	chr21:45077557	HSF2BP	-0.35	-5.19	-0.3	4.12e-7	Coronary artery disease;
CESC	cis	rs4665809	1.000	rs7573118	chr2:26308086	A/G	cg25036284	chr2:26402008	FAM59B	-0.61	-7.08	-0.4	1.31e-11	Gut microbiome composition (summer);
CESC	cis	rs6088580	0.634	rs4911152	chr20:32955024	T/C	cg08999081	chr20:33150536	PIGU	-0.65	-11.59	-0.58	2.17e-25	Glomerular filtration rate (creatinine);
CESC	cis	rs9911578	1.000	rs9911578	chr17:56953147	C/T	cg05425664	chr17:57184151	TRIM37	-0.5	-6.96	-0.39	2.6e-11	Intelligence (multi-trait analysis);
CESC	cis	rs6502050	0.835	rs8067875	chr17:80092778	C/T	cg11859384	chr17:80120422	CCDC57	-0.38	-5.13	-0.3	5.62e-7	Life satisfaction;
CESC	cis	rs8177253	0.965	rs7638018	chr3:133495461	C/T	cg12373951	chr3:133503437	NA	-0.35	-5.14	-0.3	5.46e-7	Iron status biomarkers;
CESC	cis	rs7577696	0.539	rs2280972	chr2:32377961	C/T	cg02381751	chr2:32503542	YIPF4	-0.46	-5.04	-0.3	8.51e-7	Inflammatory biomarkers;
CESC	cis	rs9487051	1.000	rs9487048	chr6:109615603	G/T	cg21918786	chr6:109611834	NA	-0.35	-5.03	-0.3	8.9e-7	Reticulocyte fraction of red cells;
CESC	cis	rs28374715	0.578	rs8036026	chr15:41630499	C/G	cg18705301	chr15:41695430	NDUFAF1	-1.06	-15.7	-0.69	1.03e-39	Ulcerative colitis;
CESC	cis	rs881375	0.678	rs7031752	chr9:123663482	G/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.45	6.62	0.38	1.99e-10	Rheumatoid arthritis;
CESC	cis	rs12476592	0.602	rs6546018	chr2:63817422	G/T	cg17519650	chr2:63277830	OTX1	-0.45	-5.12	-0.3	5.75e-7	Childhood ear infection;
CESC	cis	rs28386778	0.769	rs6504179	chr17:61812995	T/G	cg11494091	chr17:61959527	GH2	0.63	10.06	0.53	2.26e-20	Prudent dietary pattern;
CESC	cis	rs6963495	0.745	rs73190179	chr7:105162812	C/A	cg13798780	chr7:105162888	PUS7	0.78	8.04	0.44	2.99e-14	Bipolar disorder (body mass index interaction);
CESC	cis	rs4588572	0.643	rs6453391	chr5:77755035	T/C	cg11547950	chr5:77652471	NA	-0.44	-5.48	-0.32	9.67e-8	Triglycerides;
CESC	cis	rs2230307	0.536	rs834164	chr1:100603948	A/C	cg24955406	chr1:100503596	HIAT1	-0.51	-5.43	-0.32	1.26e-7	Carotid intima media thickness;
CESC	cis	rs1023500	0.573	rs2269524	chr22:42475703	T/G	cg04733989	chr22:42467013	NAGA	-0.83	-12.7	-0.62	3.37e-29	Schizophrenia;
CESC	cis	rs6430585	0.528	rs16832440	chr2:136754183	G/A	cg07169764	chr2:136633963	MCM6	1.27	17.1	0.72	1.1e-44	Corneal structure;
CESC	cis	rs651907	0.557	rs1031710	chr3:101463895	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.45	5.88	0.34	1.22e-8	Colorectal cancer;
CESC	cis	rs6912958	0.781	rs9450738	chr6:88267314	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-6.57	-0.37	2.58e-10	Monocyte percentage of white cells;
CESC	cis	rs3087591	0.960	rs11080146	chr17:29578724	C/T	cg24425628	chr17:29625626	OMG;NF1	-0.41	-5.04	-0.3	8.56e-7	Hip circumference;
CESC	cis	rs7829975	0.902	rs485107	chr8:8581408	C/G	cg06636001	chr8:8085503	FLJ10661	-0.45	-5.86	-0.34	1.34e-8	Mood instability;
CESC	cis	rs9660180	0.967	rs6687065	chr1:1778469	A/G	cg05132306	chr1:1846340	CALML6	-0.3	-6.27	-0.36	1.44e-9	Body mass index;
CESC	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg10150615	chr22:24372951	LOC391322	-0.54	-7.24	-0.41	4.97e-12	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs56313388	0.521	rs62039274	chr16:56328813	G/T	cg02433656	chr16:56322654	GNAO1	0.45	5.55	0.32	6.79e-8	Pulse pressure;
CESC	cis	rs4704187	0.687	rs10462513	chr5:74422607	C/T	cg03227963	chr5:74354835	NA	0.31	5.67	0.33	3.69e-8	Response to amphetamines;
CESC	cis	rs73019876	0.869	rs2522095	chr19:22124067	T/G	cg11619707	chr19:22235551	ZNF257	-0.31	-5.78	-0.33	2.11e-8	Testicular germ cell tumor;
CESC	cis	rs3091242	0.933	rs35530120	chr1:25785451	A/G	cg03538708	chr1:25844672	NA	0.38	5.79	0.34	1.98e-8	Erythrocyte sedimentation rate;
CESC	trans	rs9467711	0.606	rs12173854	chr6:26371679	A/G	cg06606381	chr12:133084897	FBRSL1	-0.76	-6.89	-0.39	4.1e-11	Autism spectrum disorder or schizophrenia;
CESC	cis	rs4713118	0.662	rs149948	chr6:27974817	C/G	cg17949981	chr6:28129498	ZNF389	0.39	5.08	0.3	7.23e-7	Parkinson's disease;
CESC	cis	rs2228479	0.867	rs57940434	chr16:89975496	G/A	cg00800038	chr16:89945340	TCF25	-0.75	-7.05	-0.4	1.54e-11	Skin colour saturation;
CESC	cis	rs9291683	0.588	rs3733586	chr4:9997534	C/T	cg11266682	chr4:10021025	SLC2A9	0.67	13.52	0.64	4.92e-32	Bone mineral density;
CESC	cis	rs2075371	0.796	rs1646644	chr7:134011817	A/T	cg20476274	chr7:133979776	SLC35B4	0.55	7.51	0.42	9e-13	Mean platelet volume;
CESC	cis	rs10504229	0.906	rs903718	chr8:58167726	A/G	cg02725872	chr8:58115012	NA	-0.34	-5.32	-0.31	2.18e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs933688	1.000	rs6452953	chr5:90723034	T/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.11	14.8	0.67	1.56e-36	Smoking behavior;
CESC	cis	rs523522	0.926	rs10774555	chr12:120971978	G/A	cg12219531	chr12:120966889	COQ5	0.75	9.99	0.52	3.7e-20	High light scatter reticulocyte count;
CESC	cis	rs10504229	0.645	rs35142596	chr8:58128151	C/T	cg02725872	chr8:58115012	NA	-0.44	-6.88	-0.39	4.33e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs7116495	0.609	rs2503	chr11:71719403	C/T	cg10381502	chr11:71823885	C11orf51	1.11	7.91	0.44	7.18e-14	Severe influenza A (H1N1) infection;
CESC	cis	rs763121	0.853	rs1056610	chr22:39080078	C/T	cg06544989	chr22:39130855	UNC84B	-0.52	-9.7	-0.51	3.19e-19	Menopause (age at onset);
CESC	cis	rs9329289	0.603	rs2458698	chr10:2548452	C/T	cg05625103	chr10:2543513	NA	0.51	7.11	0.4	1.09e-11	Age-related hearing impairment;
CESC	cis	rs3820068	0.603	rs3766163	chr1:15986547	T/C	cg16988262	chr1:15930761	NA	0.35	5.81	0.34	1.83e-8	Systolic blood pressure;
CESC	cis	rs523522	0.962	rs10774549	chr12:120891172	C/T	cg12219531	chr12:120966889	COQ5	0.72	9.05	0.49	3.08e-17	High light scatter reticulocyte count;
CESC	trans	rs1814175	0.869	rs10769600	chr11:49681832	C/T	cg15704280	chr7:45808275	SEPT13	-1.0	-17.79	-0.74	4.04e-47	Height;
CESC	cis	rs7666738	0.822	rs11097599	chr4:98959562	T/A	cg03467027	chr4:99064603	C4orf37	0.44	5.56	0.32	6.75e-8	Colonoscopy-negative controls vs population controls;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg13751213	chr7:148581913	EZH2	-0.47	-6.11	-0.35	3.57e-9	Ulcerative colitis;
CESC	cis	rs2645694	0.533	rs2703125	chr4:77819900	T/C	cg10057126	chr4:77819792	ANKRD56	0.59	8.66	0.47	4.84e-16	Emphysema distribution in smoking;
CESC	cis	rs4819052	0.788	rs13049700	chr21:46701909	G/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.6	7.58	0.42	5.8e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19886613	chr18:61089605	VPS4B	0.58	6.82	0.39	6.27e-11	Gut microbiome composition (summer);
CESC	cis	rs12765878	0.967	rs10883940	chr10:105650598	G/A	cg11005552	chr10:105648138	OBFC1	0.36	5.24	0.31	3.32e-7	Coronary artery disease;
CESC	cis	rs3106136	0.527	rs2865345	chr4:95156565	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.65	-10.45	-0.54	1.22e-21	Capecitabine sensitivity;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg00127214	chr14:36295713	BRMS1L	0.5	6.65	0.38	1.67e-10	Gut microbiota (bacterial taxa);
CESC	trans	rs7107217	1.000	rs1873872	chr11:129473993	A/T	cg05865202	chr20:36156789	BLCAP	0.46	6.01	0.35	6.24e-9	Breast cancer;Type 2 diabetes;
CESC	cis	rs10465746	0.780	rs7550413	chr1:84423891	T/A	cg10977910	chr1:84465055	TTLL7	0.52	7.01	0.4	2.02e-11	Obesity-related traits;
CESC	cis	rs2625529	0.689	rs12898728	chr15:72112853	C/T	cg16672083	chr15:72433130	SENP8	-0.52	-7.9	-0.44	7.36e-14	Red blood cell count;
CESC	cis	rs7818345	0.967	rs4617172	chr8:19273362	G/A	cg11303988	chr8:19266685	CSGALNACT1	0.31	5.43	0.32	1.28e-7	Language performance in older adults (adjusted for episodic memory);
CESC	cis	rs17711722	0.522	rs6957759	chr7:65271785	A/G	cg26939375	chr7:64535504	NA	0.67	9.74	0.51	2.4e-19	Calcium levels;
CESC	cis	rs6570726	0.764	rs448258	chr6:145869145	C/A	cg05347473	chr6:146136440	FBXO30	0.58	7.33	0.41	2.84e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs17253792	0.822	rs75399477	chr14:56174413	T/C	cg01858014	chr14:56050164	KTN1	-0.96	-7.37	-0.41	2.12e-12	Putamen volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27123106	chr10:855660	LARP4B	-0.72	-7.86	-0.43	9.84e-14	Gut microbiome composition (summer);
CESC	cis	rs9908102	0.740	rs58809197	chr17:12920260	A/G	cg26162695	chr17:12921313	ELAC2	0.58	6.18	0.35	2.47e-9	Schizophrenia;
CESC	trans	rs7824557	0.564	rs2572389	chr8:11236392	T/C	cg06636001	chr8:8085503	FLJ10661	-0.49	-6.15	-0.35	2.9e-9	Retinal vascular caliber;
CESC	cis	rs4474465	0.790	rs4944206	chr11:78263127	T/C	cg27205649	chr11:78285834	NARS2	0.41	5.27	0.31	2.81e-7	Alzheimer's disease (survival time);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27130364	chr5:36151796	LMBRD2;SKP2	0.54	6.16	0.35	2.7e-9	Gut microbiome composition (summer);
CESC	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg04234412	chr22:24373322	LOC391322	-0.65	-9.72	-0.51	2.72e-19	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs1348850	0.793	rs13020788	chr2:178480714	C/A	cg23306229	chr2:178417860	TTC30B	0.53	6.78	0.38	7.89e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	trans	rs4904167	0.841	rs1462340	chr14:84676912	T/C	cg06870609	chr15:89787223	FANCI	0.46	6.04	0.35	5.27e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs9926296	0.546	rs7187436	chr16:89845110	A/T	cg21285383	chr16:89894308	SPIRE2	0.3	5.35	0.31	1.87e-7	Vitiligo;
CESC	cis	rs3820068	0.581	rs16851876	chr1:15950628	A/T	cg18133145	chr1:16060689	PLEKHM2	0.4	5.09	0.3	6.88e-7	Systolic blood pressure;
CESC	cis	rs67311347	1.000	rs9849992	chr3:40402140	C/T	cg24209194	chr3:40518798	ZNF619	0.42	5.33	0.31	2.12e-7	Renal cell carcinoma;
CESC	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg23708337	chr7:1209742	NA	0.52	5.19	0.3	4.12e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs12492269	0.702	rs41381644	chr3:178161614	A/G	cg13389611	chr3:179370465	USP13	-0.73	-6.01	-0.35	6.06e-9	Plasma clusterin levels;
CESC	cis	rs7605827	0.930	rs12692260	chr2:15511809	A/G	cg19274914	chr2:15703543	NA	0.32	5.58	0.32	5.95e-8	Educational attainment (years of education);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg09854653	chr6:163834903	QKI	-0.5	-6.03	-0.35	5.63e-9	Ulcerative colitis;
CESC	cis	rs2404602	0.716	rs12441550	chr15:76863682	A/T	cg22467129	chr15:76604101	ETFA	-0.35	-5.24	-0.31	3.24e-7	Blood metabolite levels;
CESC	cis	rs9814567	1.000	rs934093	chr3:134195885	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.47	-6.41	-0.37	6.66e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	trans	rs4596713	0.538	rs10781456	chr9:71782869	G/A	cg16512924	chr15:28394682	HERC2	0.48	6.1	0.35	3.71e-9	Headache;
CESC	cis	rs367943	0.965	rs644154	chr5:112799080	G/T	cg12552261	chr5:112820674	MCC	-0.62	-7.68	-0.43	3.04e-13	Type 2 diabetes;
CESC	cis	rs11608355	0.515	rs35691047	chr12:109932585	C/T	cg05360138	chr12:110035743	NA	0.82	8.85	0.48	1.27e-16	Neuroticism;
CESC	cis	rs34375054	0.526	rs4412800	chr12:125674742	C/T	cg25124228	chr12:125621409	AACS	0.49	5.83	0.34	1.58e-8	Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs3096299	0.503	rs9940093	chr16:89558705	G/A	cg08392591	chr16:89556376	ANKRD11	0.67	9.05	0.49	3.17e-17	Multiple myeloma (IgH translocation);
CESC	cis	rs1878931	0.668	rs2074366	chr16:3439676	G/A	cg21433313	chr16:3507492	NAT15	-0.36	-5.35	-0.31	1.94e-7	Body mass index (adult);
CESC	cis	rs425277	0.606	rs16824792	chr1:2039521	G/T	cg12718519	chr1:2058417	PRKCZ	-0.25	-5.48	-0.32	9.73e-8	Height;
CESC	cis	rs977987	0.931	rs7195161	chr16:75495572	T/C	cg03315344	chr16:75512273	CHST6	0.55	8.01	0.44	3.67e-14	Dupuytren's disease;
CESC	cis	rs644799	0.965	rs10831425	chr11:95500628	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.72	9.85	0.52	1.06e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs10743315	0.557	rs78983750	chr12:19284967	C/T	cg02471346	chr12:19282374	PLEKHA5	0.71	5.34	0.31	1.96e-7	Gut microbiota (bacterial taxa);
CESC	cis	rs8103278	0.507	rs7246377	chr19:46292259	G/A	cg11657440	chr19:46296263	DMWD	0.86	12.95	0.62	4.58e-30	Coronary artery disease;
CESC	cis	rs8114671	0.527	rs6088650	chr20:33514465	C/T	cg06115741	chr20:33292138	TP53INP2	-0.48	-5.9	-0.34	1.13e-8	Height;
CESC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg01931797	chr11:77899910	KCTD21;USP35	0.46	6.37	0.36	8.39e-10	Intelligence (multi-trait analysis);
CESC	cis	rs9311474	0.508	rs4687546	chr3:52605943	T/A	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	5.86	0.34	1.4e-8	Electroencephalogram traits;
CESC	cis	rs2354432	0.556	rs7516165	chr1:146866418	G/T	cg25205988	chr1:146714368	CHD1L	1.01	8.88	0.48	1.06e-16	Mitochondrial DNA levels;
CESC	cis	rs4665809	0.549	rs17527979	chr2:26428132	A/G	cg26314531	chr2:26401878	FAM59B	-0.75	-7.66	-0.43	3.48e-13	Gut microbiome composition (summer);
CESC	cis	rs7824557	0.547	rs2409745	chr8:11076635	G/T	cg21775007	chr8:11205619	TDH	0.39	5.58	0.32	6.04e-8	Retinal vascular caliber;
CESC	cis	rs10504229	0.906	rs67389108	chr8:58193718	G/A	cg22535103	chr8:58192502	C8orf71	-1.07	-13.57	-0.64	3.2e-32	Developmental language disorder (linguistic errors);
CESC	cis	rs9733	0.596	rs11204687	chr1:150629880	C/A	cg09365446	chr1:150670422	GOLPH3L	0.42	5.98	0.34	7.35e-9	Tonsillectomy;
CESC	cis	rs6460942	0.915	rs10267801	chr7:12451931	G/A	cg16278512	chr7:12443529	VWDE	-0.5	-5.84	-0.34	1.53e-8	Coronary artery disease;
CESC	cis	rs1775715	0.835	rs11008701	chr10:32241096	A/G	cg18675610	chr10:32216311	ARHGAP12	0.33	5.18	0.3	4.45e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs6952808	1.000	rs4721122	chr7:1893311	C/G	cg02951883	chr7:2050386	MAD1L1	-0.4	-5.12	-0.3	5.76e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs7945705	0.902	rs1560569	chr11:8939887	C/T	cg12365402	chr11:9010492	NRIP3	-0.33	-5.31	-0.31	2.27e-7	Hemoglobin concentration;
CESC	cis	rs6980507	0.523	rs2974293	chr8:42369455	C/T	cg09913449	chr8:42400586	C8orf40	-0.34	-5.4	-0.31	1.48e-7	Glycated hemoglobin levels;
CESC	cis	rs736408	0.609	rs13082960	chr3:52785168	A/C	cg07507251	chr3:52567010	NT5DC2	0.41	7.19	0.4	6.62e-12	Bipolar disorder;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg11296937	chr11:64084966	PRDX5;TRMT112	-0.46	-6.7	-0.38	1.28e-10	Fibrinogen levels;
CESC	cis	rs238295	0.766	rs6038204	chr20:5549071	T/A	cg24001556	chr20:5591874	RP5-1022P6.2	-0.46	-5.11	-0.3	6.12e-7	Occipital cortical area (total cortical area interaction);
CESC	cis	rs34172651	0.517	rs35560136	chr16:24788915	T/A	cg06505273	chr16:24850292	NA	0.51	5.84	0.34	1.56e-8	Intelligence (multi-trait analysis);
CESC	cis	rs6540559	0.673	rs7511996	chr1:210018473	C/A	cg23283495	chr1:209979779	IRF6	0.48	5.61	0.33	5.1e-8	Cleft lip with or without cleft palate;
CESC	cis	rs3820928	0.874	rs10169717	chr2:227796911	T/G	cg11843606	chr2:227700838	RHBDD1	-0.43	-5.75	-0.33	2.45e-8	Pulmonary function;
CESC	cis	rs9858542	0.953	rs9824092	chr3:49674147	C/G	cg07274523	chr3:49395745	GPX1	0.68	8.72	0.47	3.23e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg03217679	chr4:73935524	COX18	-0.48	-6.12	-0.35	3.29e-9	Fibrinogen levels;
CESC	cis	rs10504229	0.906	rs111838497	chr8:58185620	A/C	cg24829409	chr8:58192753	C8orf71	-0.76	-9.93	-0.52	5.87e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs2243480	0.711	rs2460426	chr7:65623129	A/G	cg13147721	chr7:65941812	NA	0.97	9.19	0.49	1.2e-17	Diabetic kidney disease;
CESC	cis	rs2295359	0.892	rs2064689	chr1:67653010	G/A	cg17031739	chr1:67600172	NA	0.41	5.43	0.32	1.28e-7	Psoriasis;
CESC	cis	rs10504229	0.683	rs16921817	chr8:58107563	A/T	cg24829409	chr8:58192753	C8orf71	-0.56	-7.01	-0.4	1.97e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs7666738	0.830	rs4443295	chr4:99044935	G/A	cg17366294	chr4:99064904	C4orf37	0.6	8.51	0.46	1.33e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs73206853	0.698	rs1018134	chr12:111121119	G/A	cg12870014	chr12:110450643	ANKRD13A	0.68	5.79	0.33	2.02e-8	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs7662987	0.517	rs1154406	chr4:100008494	T/C	cg13256891	chr4:100009986	ADH5	0.75	8.06	0.44	2.55e-14	Smoking initiation;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01539269	chr19:18746992	KLHL26	-0.56	-6.51	-0.37	3.68e-10	Gut microbiome composition (summer);
CESC	cis	rs922182	0.633	rs4776700	chr15:64270861	A/T	cg24729988	chr15:64271149	DAPK2	-0.47	-6.63	-0.38	1.84e-10	Blood protein levels;
CESC	cis	rs10484885	0.878	rs111664889	chr6:90566427	G/T	cg13799429	chr6:90582589	CASP8AP2	-0.76	-7.22	-0.41	5.66e-12	QRS interval (sulfonylurea treatment interaction);
CESC	cis	rs514406	0.861	rs35517489	chr1:53304062	G/C	cg25767906	chr1:53392781	SCP2	-0.4	-5.16	-0.3	4.92e-7	Monocyte count;
CESC	trans	rs10958369	0.541	rs1477955	chr8:54435226	T/C	cg05787952	chr16:734667	JMJD8	0.44	6.22	0.36	1.93e-9	Response to antineoplastic agents;
CESC	cis	rs1728785	0.901	rs1183956	chr16:68606726	G/A	cg02972257	chr16:68554789	NA	-0.59	-6.71	-0.38	1.2e-10	Ulcerative colitis;
CESC	cis	rs9649213	0.593	rs6465673	chr7:97968887	C/T	cg21770322	chr7:97807741	LMTK2	0.55	8.31	0.45	4.96e-15	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs6502050	0.777	rs11077969	chr17:80085633	A/G	cg11859384	chr17:80120422	CCDC57	0.38	5.12	0.3	6.01e-7	Life satisfaction;
CESC	cis	rs6582630	0.573	rs12319414	chr12:38267440	T/C	cg26384229	chr12:38710491	ALG10B	-0.46	-6.06	-0.35	4.62e-9	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs1448094	0.512	rs6539933	chr12:86247611	T/C	cg19622623	chr12:86230825	RASSF9	-0.47	-5.96	-0.34	7.92e-9	Major depressive disorder;
CESC	cis	rs7845219	0.525	rs7820818	chr8:95919231	G/A	cg09323728	chr8:95962352	TP53INP1	-0.34	-6.56	-0.37	2.83e-10	Type 2 diabetes;
CESC	trans	rs7726839	0.540	rs11739847	chr5:609661	G/A	cg25482853	chr8:67687455	SGK3	1.02	9.93	0.52	5.72e-20	Obesity-related traits;
CESC	cis	rs4901869	0.902	rs10149194	chr14:59308198	A/G	cg02291164	chr14:59296302	NA	-0.43	-7.5	-0.42	9.57e-13	Panic disorder;
CESC	cis	rs79387448	0.626	rs80277428	chr2:103080056	G/A	cg09003973	chr2:102972529	NA	1.09	8.16	0.45	1.39e-14	Gut microbiota (bacterial taxa);
CESC	cis	rs9527	0.637	rs11191424	chr10:104625886	G/A	cg04362960	chr10:104952993	NT5C2	0.52	6.38	0.36	7.96e-10	Arsenic metabolism;
CESC	cis	rs35110281	0.811	rs1122873	chr21:45044672	G/C	cg01579765	chr21:45077557	HSF2BP	-0.57	-9.52	-0.5	1.15e-18	Mean corpuscular volume;
CESC	trans	rs1994135	0.617	rs10844644	chr12:33735871	A/G	cg26384229	chr12:38710491	ALG10B	0.45	6.5	0.37	3.96e-10	Resting heart rate;
CESC	cis	rs7618915	0.501	rs3733041	chr3:52731598	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.53	8.0	0.44	3.86e-14	Bipolar disorder;
CESC	cis	rs3617	0.573	rs6795646	chr3:52922621	C/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	-0.3	-5.22	-0.31	3.6e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
CESC	cis	rs477692	0.673	rs1970197	chr10:131359588	C/T	cg05714579	chr10:131428358	MGMT	0.41	5.38	0.31	1.63e-7	Response to temozolomide;
CESC	trans	rs650950	0.528	rs646660	chr11:35528452	C/T	cg14195823	chr19:39926698	RPS16	0.48	6.19	0.36	2.32e-9	Bronchopulmonary dysplasia;
CESC	cis	rs4604732	0.588	rs7552461	chr1:247628644	G/A	cg12754571	chr1:247694271	LOC148824;OR2C3	0.41	5.09	0.3	6.91e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02820613	chr16:30538074	ZNF768	0.61	6.87	0.39	4.44e-11	Gut microbiome composition (summer);
CESC	cis	rs2228479	0.850	rs62054257	chr16:89900195	G/A	cg00800038	chr16:89945340	TCF25	-0.89	-6.89	-0.39	4.13e-11	Skin colour saturation;
CESC	cis	rs4665809	1.000	rs6546728	chr2:26276531	G/C	cg26314531	chr2:26401878	FAM59B	-0.77	-8.56	-0.47	9.38e-16	Gut microbiome composition (summer);
CESC	cis	rs4563143	0.502	rs73029061	chr19:29283980	T/A	cg12756686	chr19:29218302	NA	0.55	6.67	0.38	1.51e-10	Methadone dose in opioid dependence;
CESC	cis	rs17376456	0.825	rs28645862	chr5:93233128	G/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.62	5.24	0.31	3.31e-7	Diabetic retinopathy;
CESC	cis	rs11997175	0.819	rs6415400	chr8:33783714	C/T	ch.8.33884649F	chr8:33765107	NA	0.73	10.48	0.54	1.03e-21	Body mass index;
CESC	cis	rs172166	0.611	rs203883	chr6:28078356	A/G	cg22143856	chr6:28129313	ZNF389	0.38	5.38	0.31	1.6e-7	Cardiac Troponin-T levels;
CESC	cis	rs977987	0.806	rs11642572	chr16:75452782	C/T	cg03315344	chr16:75512273	CHST6	0.41	5.84	0.34	1.56e-8	Dupuytren's disease;
CESC	cis	rs2075371	0.829	rs9641970	chr7:134004887	C/A	cg20476274	chr7:133979776	SLC35B4	0.59	8.11	0.45	1.89e-14	Mean platelet volume;
CESC	cis	rs561341	1.000	rs530209	chr17:30315287	A/G	cg19193384	chr17:30244184	NA	-0.67	-6.36	-0.36	8.74e-10	Hip circumference adjusted for BMI;
CESC	cis	rs7044106	0.537	rs10739573	chr9:123489818	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.64	7.99	0.44	4.25e-14	Hip circumference adjusted for BMI;
CESC	cis	rs870825	0.655	rs67380800	chr4:185623788	T/C	cg04058563	chr4:185651563	MLF1IP	0.64	7.05	0.4	1.59e-11	Blood protein levels;
CESC	cis	rs875971	0.862	rs6944374	chr7:65686929	C/G	cg12463550	chr7:65579703	CRCP	-0.48	-5.91	-0.34	1.05e-8	Aortic root size;
CESC	cis	rs736408	0.562	rs12497998	chr3:52793602	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.36	6.38	0.36	7.82e-10	Bipolar disorder;
CESC	cis	rs2073300	1.000	rs6132621	chr20:23442180	C/T	cg12062639	chr20:23401060	NAPB	0.91	6.41	0.37	6.71e-10	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	trans	rs9929218	0.539	rs1125557	chr16:68809599	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.86	13.93	0.65	1.77e-33	Colorectal cancer;
CESC	cis	rs739401	0.572	rs384490	chr11:3078885	A/C	cg08508325	chr11:3079039	CARS	-0.58	-11.24	-0.57	3.11e-24	Longevity;
CESC	cis	rs736408	0.522	rs11130310	chr3:52674667	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.61	8.78	0.47	2.06e-16	Bipolar disorder;
CESC	cis	rs9311474	0.597	rs6778735	chr3:52565100	T/C	cg05564831	chr3:52568323	NT5DC2	0.51	8.61	0.47	6.6e-16	Electroencephalogram traits;
CESC	cis	rs7100689	0.622	rs1417221	chr10:82100428	G/A	cg00277334	chr10:82204260	NA	-0.61	-8.03	-0.44	3.17e-14	Post bronchodilator FEV1;
CESC	cis	rs10504229	0.683	rs16921807	chr8:58105967	C/T	cg21724239	chr8:58056113	NA	0.57	5.9	0.34	1.08e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs35110281	0.743	rs2329443	chr21:45059431	C/T	cg04455712	chr21:45112962	RRP1B	0.4	5.76	0.33	2.38e-8	Mean corpuscular volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00053086	chr1:233119296	NA	-0.52	-6.22	-0.36	1.95e-9	Gut microbiome composition (summer);
CESC	cis	rs9322193	0.886	rs2065663	chr6:150081467	A/G	cg13206674	chr6:150067644	NUP43	0.42	5.81	0.34	1.75e-8	Lung cancer;
CESC	cis	rs1045714	1.000	rs1045714	chr7:2653582	A/G	cg20813462	chr7:2646259	IQCE	0.71	5.79	0.34	1.98e-8	Urate levels in lean individuals;
CESC	cis	rs10927875	0.662	rs848309	chr1:16308447	T/C	cg22431228	chr1:16359049	CLCNKA	-0.45	-8.45	-0.46	1.99e-15	Dilated cardiomyopathy;
CESC	cis	rs3096299	0.685	rs4329923	chr16:89560178	C/T	cg02187348	chr16:89574699	SPG7	0.7	10.19	0.53	8.74e-21	Multiple myeloma (IgH translocation);
CESC	cis	rs7103648	0.966	rs10838702	chr11:47410888	G/T	cg20307385	chr11:47447363	PSMC3	0.89	14.12	0.66	3.98e-34	Diastolic blood pressure;Systolic blood pressure;
CESC	cis	rs5997397	1.000	rs5997397	chr22:29154455	A/G	cg15103426	chr22:29168792	CCDC117	0.45	6.0	0.35	6.59e-9	Red cell distribution width;
CESC	cis	rs9611565	0.506	rs2024566	chr22:41697338	A/G	cg06634786	chr22:41940651	POLR3H	-0.5	-5.35	-0.31	1.91e-7	Vitiligo;
CESC	cis	rs9297145	0.916	rs4236540	chr7:98769025	A/C	cg05967295	chr7:98741636	SMURF1	0.91	12.21	0.6	1.68e-27	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
CESC	cis	rs2228479	0.717	rs12917681	chr16:89810941	C/A	cg04013166	chr16:89971882	TCF25	0.71	7.73	0.43	2.28e-13	Skin colour saturation;
CESC	cis	rs4925386	0.840	rs6142738	chr20:60919960	C/T	cg24112000	chr20:60950667	NA	0.45	5.69	0.33	3.33e-8	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs6540559	1.000	rs6659367	chr1:209982408	G/T	cg22029157	chr1:209979665	IRF6	0.69	10.11	0.53	1.57e-20	Cleft lip with or without cleft palate;
CESC	cis	rs6860806	0.603	rs112300250	chr5:131583292	G/A	cg14196790	chr5:131705035	SLC22A5	0.32	5.2	0.3	4.03e-7	Breast cancer;
CESC	cis	rs7943191	0.810	rs7942154	chr11:62337163	G/A	cg02375832	chr11:62437615	C11orf48	-0.38	-5.48	-0.32	9.85e-8	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
CESC	cis	rs13095912	1.000	rs9714158	chr3:185328780	C/T	cg11274856	chr3:185301563	NA	0.35	5.5	0.32	8.96e-8	Systolic blood pressure;
CESC	cis	rs12586317	0.534	rs2273157	chr14:35438836	A/G	cg05294307	chr14:35346193	BAZ1A	-0.5	-6.39	-0.37	7.53e-10	Psoriasis;
CESC	cis	rs12048904	0.619	rs10875347	chr1:101333737	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.88	12.02	0.59	7.32e-27	Multiple sclerosis;
CESC	cis	rs4237845	1.000	rs4237845	chr12:58302436	A/G	cg02175503	chr12:58329896	NA	-0.66	-8.84	-0.48	1.4e-16	Intelligence (multi-trait analysis);
CESC	cis	rs10979	0.894	rs6924940	chr6:143906183	C/T	cg25407410	chr6:143891975	LOC285740	-0.59	-8.51	-0.46	1.29e-15	Hypospadias;
CESC	cis	rs2629540	0.847	rs11245342	chr10:126414084	C/T	cg08799069	chr10:126477246	METTL10	0.58	7.33	0.41	2.73e-12	Cocaine dependence;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg02675260	chr11:64135691	MIR1237;RPS6KA4	0.54	7.44	0.42	1.4e-12	Fibrinogen levels;
CESC	cis	rs8031584	0.678	rs8028173	chr15:31155749	A/G	cg08704250	chr15:31115839	NA	-0.68	-9.12	-0.49	1.97e-17	Huntington's disease progression;
CESC	cis	rs10129255	0.500	rs2027902	chr14:107215393	T/C	cg23076370	chr14:107095027	NA	-0.63	-8.89	-0.48	9.53e-17	Kawasaki disease;
CESC	cis	rs896854	0.654	rs4735340	chr8:95976251	A/T	cg16049864	chr8:95962084	TP53INP1	-0.65	-11.4	-0.57	9.17e-25	Type 2 diabetes;
CESC	cis	rs7255436	0.965	rs7351098	chr19:8451671	G/C	cg10174797	chr19:8464628	RAB11B	0.39	5.57	0.32	6.11e-8	HDL cholesterol;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16010370	chr3:53290200	TKT	-0.65	-7.9	-0.44	7.36e-14	Gut microbiome composition (summer);
CESC	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg23034840	chr1:205782522	SLC41A1	0.68	8.43	0.46	2.21e-15	Menarche (age at onset);
CESC	cis	rs2073300	0.609	rs3827086	chr20:23357331	C/T	cg16736954	chr20:23401023	NAPB	0.8	6.09	0.35	3.89e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs4665809	1.000	rs4665304	chr2:26313406	C/T	cg26314531	chr2:26401878	FAM59B	-0.61	-6.93	-0.39	3.12e-11	Gut microbiome composition (summer);
CESC	cis	rs11166927	0.967	rs12680346	chr8:140814379	C/T	cg16909799	chr8:140841666	TRAPPC9	0.47	6.9	0.39	3.74e-11	Pediatric non-alcoholic fatty liver disease activity score;
CESC	cis	rs9388451	0.874	rs7739566	chr6:126094757	A/T	cg05901451	chr6:126070800	HEY2	-0.63	-9.26	-0.49	7.05e-18	Brugada syndrome;
CESC	cis	rs7267979	1.000	rs6115168	chr20:25372891	C/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.88	-18.14	-0.74	2.35e-48	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs2404602	0.655	rs4886824	chr15:76969256	A/G	cg26408565	chr15:76604113	ETFA	-0.39	-5.71	-0.33	2.98e-8	Blood metabolite levels;
CESC	cis	rs5769765	0.954	rs1569954	chr22:50244071	C/T	cg02269571	chr22:50332266	NA	0.46	6.07	0.35	4.43e-9	Schizophrenia;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg15420520	chr20:55043481	C20orf43	-0.41	-6.2	-0.36	2.11e-9	Gambling;
CESC	cis	rs9325144	0.560	rs7314632	chr12:38636979	C/T	cg26384229	chr12:38710491	ALG10B	-0.59	-9.2	-0.49	1.07e-17	Morning vs. evening chronotype;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07434447	chr7:74489725	WBSCR16	0.64	7.37	0.41	2.24e-12	Gut microbiome composition (summer);
CESC	cis	rs3824344	0.531	rs7870336	chr9:37007769	C/G	cg14294708	chr9:37120828	ZCCHC7	-0.4	-5.13	-0.3	5.54e-7	Intelligence;
CESC	cis	rs12762955	0.561	rs7075141	chr10:1091195	C/T	cg10556349	chr10:835070	NA	-0.42	-5.16	-0.3	4.83e-7	Response to angiotensin II receptor blocker therapy;
CESC	cis	rs2439831	0.850	rs12442129	chr15:44055856	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.71	6.76	0.38	8.72e-11	Lung cancer in ever smokers;
CESC	cis	rs2415984	0.622	rs73245837	chr14:46947914	A/G	cg14871534	chr14:47121158	RPL10L	-0.37	-5.64	-0.33	4.47e-8	Number of children ever born;
CESC	cis	rs7799006	0.723	rs2270052	chr7:2291399	C/T	cg12823233	chr7:2316876	SNX8	-0.3	-5.1	-0.3	6.6e-7	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs12477438	0.765	rs17708262	chr2:99696313	T/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.64	-8.57	-0.47	8.65e-16	Chronic sinus infection;
CESC	cis	rs10504229	1.000	rs78953746	chr8:58170608	A/G	cg22535103	chr8:58192502	C8orf71	-1.04	-12.84	-0.62	1.16e-29	Developmental language disorder (linguistic errors);
CESC	cis	rs1862618	0.853	rs6885541	chr5:56110857	G/C	cg12311346	chr5:56204834	C5orf35	-0.71	-8.43	-0.46	2.24e-15	Initial pursuit acceleration;
CESC	cis	rs2228479	0.681	rs8044906	chr16:89969603	T/C	cg00800038	chr16:89945340	TCF25	-0.57	-6.03	-0.35	5.45e-9	Skin colour saturation;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00026974	chr17:42298151	UBTF	0.54	6.28	0.36	1.36e-9	Gut microbiome composition (summer);
CESC	cis	rs1124376	1.000	rs9819628	chr3:20140837	A/G	cg05072819	chr3:20081367	KAT2B	-0.48	-5.4	-0.31	1.5e-7	Bipolar disorder and schizophrenia;
CESC	trans	rs10074525	0.885	rs17633498	chr5:90276385	A/G	cg22855255	chr17:50237267	CA10	-0.34	-6.05	-0.35	5.03e-9	Obesity-related traits;
CESC	cis	rs9322193	0.884	rs62439836	chr6:149990309	A/G	cg13206674	chr6:150067644	NUP43	0.43	6.17	0.35	2.58e-9	Lung cancer;
CESC	cis	rs2404602	0.583	rs12438741	chr15:76542114	C/A	cg05617483	chr15:76483344	C15orf27	0.41	5.57	0.32	6.17e-8	Blood metabolite levels;
CESC	cis	rs4629180	1.000	rs11123889	chr2:102107180	G/A	cg01388757	chr2:102091195	RFX8	0.45	6.67	0.38	1.45e-10	Chronic rhinosinusitis with nasal polyps;
CESC	cis	rs35306767	0.951	rs11253530	chr10:993729	T/C	cg10556349	chr10:835070	NA	0.55	5.39	0.31	1.54e-7	Eosinophil percentage of granulocytes;
CESC	cis	rs703842	1.000	rs2069502	chr12:58144665	A/G	cg18357645	chr12:58087776	OS9	0.43	6.1	0.35	3.79e-9	Multiple sclerosis;
CESC	cis	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04799588	chr10:6263484	PFKFB3	-0.38	-5.11	-0.3	6.28e-7	Gut microbiota (bacterial taxa);
CESC	cis	rs1881797	1.000	rs1881797	chr1:247689532	A/G	cg11166453	chr1:247681781	NA	0.4	5.96	0.34	8.17e-9	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs7937682	0.921	rs4616071	chr11:111440865	C/G	cg22437258	chr11:111473054	SIK2	-0.65	-7.0	-0.39	2.15e-11	Primary sclerosing cholangitis;
CESC	cis	rs3768617	0.510	rs10797837	chr1:183075121	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.88	14.2	0.66	2.05e-34	Fuchs's corneal dystrophy;
CESC	cis	rs2073300	0.609	rs6137929	chr20:23376357	G/A	cg12062639	chr20:23401060	NAPB	1.07	8.85	0.48	1.29e-16	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs801193	0.844	rs732465	chr7:65998450	T/C	cg18252515	chr7:66147081	NA	-0.39	-5.18	-0.3	4.4e-7	Aortic root size;
CESC	cis	rs10870270	0.913	rs4880326	chr10:133745547	C/A	cg08754478	chr10:133766260	PPP2R2D	-0.61	-7.93	-0.44	6.3e-14	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs4819052	0.590	rs414743	chr21:46512075	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.59	6.43	0.37	5.99e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs4664308	0.935	rs4292050	chr2:160940899	G/T	cg03641300	chr2:160917029	PLA2R1	-0.67	-9.84	-0.52	1.11e-19	Idiopathic membranous nephropathy;
CESC	cis	rs10504229	1.000	rs72650900	chr8:58185675	T/A	cg22535103	chr8:58192502	C8orf71	-1.05	-13.08	-0.63	1.71e-30	Developmental language disorder (linguistic errors);
CESC	cis	rs10504229	1.000	rs56255635	chr8:58178264	T/C	cg24829409	chr8:58192753	C8orf71	-0.76	-10.0	-0.52	3.53e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs765787	0.530	rs2899378	chr15:45537584	C/T	cg24006582	chr15:45444508	DUOX1	0.57	6.91	0.39	3.55e-11	Uric acid levels;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg25195100	chr20:61903949	ARFGAP1	-0.48	-6.28	-0.36	1.37e-9	Ulcerative colitis;
CESC	cis	rs4803468	1.000	rs878082	chr19:41897674	G/A	cg09537434	chr19:41945824	ATP5SL	-1.02	-18.17	-0.74	1.81e-48	Height;
CESC	cis	rs7615952	0.673	rs35001498	chr3:125628644	A/G	cg05084668	chr3:125655381	ALG1L	-0.77	-8.05	-0.44	2.74e-14	Blood pressure (smoking interaction);
CESC	cis	rs40363	0.645	rs250633	chr16:3523002	C/T	cg21433313	chr16:3507492	NAT15	0.51	8.48	0.46	1.56e-15	Tuberculosis;
CESC	cis	rs4953076	0.573	rs920519	chr2:44452344	T/C	cg04920474	chr2:44395004	PPM1B	0.51	6.65	0.38	1.72e-10	Height;
CESC	cis	rs4819052	0.679	rs2255761	chr21:46683622	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.44	5.71	0.33	3.04e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs9611565	0.840	rs2234052	chr22:41777241	A/G	cg06481639	chr22:41940642	POLR3H	-0.6	-6.44	-0.37	5.59e-10	Vitiligo;
CESC	cis	rs921968	0.565	rs7603709	chr2:219642601	C/T	cg02176678	chr2:219576539	TTLL4	-0.41	-7.51	-0.42	9.29e-13	Mean corpuscular hemoglobin concentration;
CESC	cis	rs10870270	1.000	rs3935905	chr10:133758262	A/C	cg08754478	chr10:133766260	PPP2R2D	-0.59	-7.69	-0.43	2.86e-13	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs1062746	0.777	rs34400756	chr16:87372078	A/G	cg02258303	chr16:87377426	FBXO31	-0.51	-6.5	-0.37	3.96e-10	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
CESC	trans	rs3780486	0.846	rs7865745	chr9:33140976	A/G	cg20290983	chr6:43655470	MRPS18A	-0.98	-18.27	-0.75	8.33e-49	IgG glycosylation;
CESC	cis	rs782590	0.643	rs5012561	chr2:55742032	G/C	cg18811423	chr2:55921094	PNPT1	-0.55	-7.3	-0.41	3.27e-12	Metabolic syndrome;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg12975709	chr7:47317262	TNS3	-0.45	-6.13	-0.35	3.24e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs11711311	0.747	rs7638378	chr3:113343630	T/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.56	7.46	0.42	1.26e-12	IgG glycosylation;
CESC	cis	rs3820928	0.904	rs2894623	chr2:227766112	T/C	cg11843606	chr2:227700838	RHBDD1	-0.45	-5.87	-0.34	1.27e-8	Pulmonary function;
CESC	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg11235426	chr6:292522	DUSP22	-0.74	-9.99	-0.52	3.72e-20	Menopause (age at onset);
CESC	cis	rs1005277	0.579	rs2749612	chr10:38488610	G/A	cg25517755	chr10:38738941	LOC399744	-0.49	-6.3	-0.36	1.25e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs477895	0.653	rs7939784	chr11:63910153	C/T	cg18225595	chr11:63971243	STIP1	0.52	5.13	0.3	5.55e-7	Mean platelet volume;
CESC	cis	rs4889855	0.556	rs4890040	chr17:78518408	G/A	cg16591659	chr17:78472290	NA	0.36	5.86	0.34	1.38e-8	Fractional excretion of uric acid;
CESC	cis	rs12586317	0.547	rs10134907	chr14:35499211	A/C	cg05294307	chr14:35346193	BAZ1A	-0.51	-5.4	-0.31	1.49e-7	Psoriasis;
CESC	cis	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.45	-5.1	-0.3	6.56e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs6540559	0.673	rs114467813	chr1:210017785	G/A	cg25204440	chr1:209979598	IRF6	0.68	6.35	0.36	9.09e-10	Cleft lip with or without cleft palate;
CESC	cis	rs34891900	0.507	rs12167771	chr22:18124332	G/A	cg19898043	chr22:18121309	BCL2L13	0.62	7.38	0.41	2.02e-12	Sum neutrophil eosinophil counts;
CESC	cis	rs8072100	1.000	rs4794048	chr17:45763073	A/C	cg08085267	chr17:45401833	C17orf57	-0.43	-5.82	-0.34	1.67e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs7615952	0.599	rs67575510	chr3:125742355	C/G	cg15145296	chr3:125709740	NA	-0.5	-5.26	-0.31	3.01e-7	Blood pressure (smoking interaction);
CESC	cis	rs977987	0.843	rs12443904	chr16:75438770	C/T	cg03315344	chr16:75512273	CHST6	0.4	5.83	0.34	1.57e-8	Dupuytren's disease;
CESC	cis	rs6120849	0.754	rs6088667	chr20:33566722	A/C	cg06115741	chr20:33292138	TP53INP2	0.51	5.13	0.3	5.5e-7	Protein C levels;
CESC	cis	rs9399135	0.967	rs11756988	chr6:135347595	A/G	cg22676075	chr6:135203613	NA	0.51	7.36	0.41	2.34e-12	Red blood cell count;
CESC	cis	rs9649213	0.614	rs9640655	chr7:98017099	G/A	cg09267113	chr7:98030324	BAIAP2L1	-0.45	-6.11	-0.35	3.54e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs959260	1.000	rs4789193	chr17:73404796	A/T	cg20590849	chr17:73267439	MIF4GD	0.55	6.18	0.35	2.43e-9	Systemic lupus erythematosus;
CESC	cis	rs9457247	0.967	rs428805	chr6:167403132	C/A	cg25258033	chr6:167368657	RNASET2	0.4	5.98	0.34	7.15e-9	Crohn's disease;
CESC	cis	rs9584850	0.789	rs7988345	chr13:99117685	A/G	cg20750642	chr13:99100586	FARP1	-0.39	-5.87	-0.34	1.3e-8	Neuroticism;
CESC	cis	rs568617	1.000	rs693824	chr11:65654783	A/G	cg19792802	chr11:65647270	CTSW	0.36	5.44	0.32	1.24e-7	Crohn's disease;
CESC	cis	rs7267979	1.000	rs2424712	chr20:25416942	T/C	cg08601574	chr20:25228251	PYGB	0.38	5.64	0.33	4.4e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7937682	0.883	rs486038	chr11:111465963	A/C	cg22437258	chr11:111473054	SIK2	0.71	9.19	0.49	1.16e-17	Primary sclerosing cholangitis;
CESC	cis	rs9660180	0.839	rs12040826	chr1:1705287	A/C	cg23982607	chr1:1823379	GNB1	-0.73	-11.44	-0.57	6.94e-25	Body mass index;
CESC	cis	rs7851660	0.839	rs7027221	chr9:100662379	T/C	cg13688889	chr9:100608707	NA	-0.62	-8.87	-0.48	1.11e-16	Strep throat;
CESC	cis	rs13343954	0.518	rs2216594	chr19:33533258	G/A	cg27124370	chr19:33622961	WDR88	0.5	6.63	0.38	1.88e-10	Colorectal cancer;
CESC	cis	rs853679	0.517	rs9380062	chr6:28137569	G/A	cg20151795	chr6:28129481	ZNF389	0.41	5.3	0.31	2.46e-7	Depression;
CESC	cis	rs5758659	0.714	rs5751220	chr22:42516205	A/C	cg19513890	chr22:42538836	CYP2D7P1	0.38	5.48	0.32	9.98e-8	Cognitive function;
CESC	cis	rs798766	0.909	rs28521716	chr4:1745751	A/G	cg10756475	chr4:1757242	NA	0.47	6.08	0.35	4.15e-9	Bladder cancer;Urinary bladder cancer;
CESC	cis	rs56104184	0.615	rs73061693	chr19:49399941	C/A	cg21252483	chr19:49399788	TULP2	-0.52	-5.69	-0.33	3.36e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	cis	rs916888	0.738	rs199515	chr17:44856641	C/G	cg15921436	chr17:44337874	NA	-0.71	-8.29	-0.45	5.63e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs9303280	0.806	rs12936409	chr17:38043649	C/T	cg19468946	chr17:37922297	IKZF3	-0.41	-5.41	-0.32	1.43e-7	Self-reported allergy;
CESC	cis	rs1847202	0.826	rs13063441	chr3:72952400	A/G	cg10804678	chr3:72788309	NA	-0.39	-5.04	-0.3	8.66e-7	Motion sickness;
CESC	cis	rs644799	1.000	rs10831431	chr11:95510089	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.72	9.58	0.51	7.32e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs6460942	0.591	rs62451465	chr7:12364585	A/G	cg20607287	chr7:12443886	VWDE	-0.59	-6.48	-0.37	4.4e-10	Coronary artery disease;
CESC	cis	rs3008870	1.000	rs12132068	chr1:67451924	G/T	cg08660285	chr1:67390436	MIER1;WDR78	-1.04	-14.57	-0.67	9.76e-36	Lymphocyte percentage of white cells;
CESC	cis	rs11997175	0.626	rs12155927	chr8:33789851	A/G	ch.8.33884649F	chr8:33765107	NA	0.49	5.78	0.33	2.07e-8	Body mass index;
CESC	cis	rs7044106	0.791	rs12554440	chr9:123485333	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.76	11.24	0.57	3.25e-24	Hip circumference adjusted for BMI;
CESC	cis	rs614226	0.935	rs7956998	chr12:120994932	G/A	cg01236616	chr12:121019343	POP5	1.5	18.76	0.76	1.47e-50	Type 1 diabetes nephropathy;
CESC	cis	rs9457247	1.000	rs408080	chr6:167392522	T/C	cg23791538	chr6:167370224	RNASET2	-0.59	-8.5	-0.46	1.43e-15	Crohn's disease;
CESC	cis	rs9911578	1.000	rs2009948	chr17:56611920	A/C	cg12560992	chr17:57184187	TRIM37	-0.93	-15.59	-0.69	2.43e-39	Intelligence (multi-trait analysis);
CESC	cis	rs12142240	0.698	rs72677585	chr1:46812374	T/C	cg00530320	chr1:46809349	NSUN4	0.58	7.85	0.43	1.05e-13	Menopause (age at onset);
CESC	cis	rs911555	0.673	rs7144271	chr14:103890674	A/G	cg24130564	chr14:104152367	KLC1	-0.52	-7.1	-0.4	1.16e-11	Intelligence (multi-trait analysis);
CESC	cis	rs4450798	0.793	rs9855726	chr3:13741475	T/A	cg05589046	chr3:13742034	LOC285375	0.38	5.64	0.33	4.42e-8	Bipolar disorder with mood-incongruent psychosis;
CESC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg03758392	chr3:184870408	C3orf70	0.46	6.15	0.35	2.87e-9	Tetralogy of Fallot;
CESC	cis	rs17039065	1.000	rs59671813	chr4:109393618	A/C	cg16022748	chr4:109541635	LOC285456;RPL34	0.63	5.32	0.31	2.18e-7	Gut microbiome composition (summer);
CESC	cis	rs9899728	0.539	rs77948815	chr17:73128192	C/T	cg20590849	chr17:73267439	MIF4GD	0.96	5.81	0.34	1.78e-8	Alzheimer's disease or small vessel stroke;
CESC	cis	rs7208859	0.623	rs3752021	chr17:29111043	G/C	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.91e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg03046325	chr10:93558661	TNKS2	-0.45	-6.08	-0.35	4.1e-9	Ulcerative colitis;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg22792938	chr2:228337242	AGFG1	-0.5	-6.92	-0.39	3.33e-11	Ulcerative colitis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12410370	chr1:43296526	ERMAP	-0.58	-7.03	-0.4	1.75e-11	Gut microbiome composition (summer);
CESC	cis	rs6032067	0.777	rs2868235	chr20:43794069	T/C	cg11264863	chr20:43835661	SEMG1	0.5	5.35	0.31	1.86e-7	Blood protein levels;
CESC	cis	rs796364	0.806	rs203765	chr2:200903020	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.83	-7.71	-0.43	2.49e-13	Schizophrenia;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg09067715	chr16:702600	WDR90	0.54	6.56	0.37	2.85e-10	Ulcerative colitis;
CESC	cis	rs1983891	0.954	rs1886816	chr6:41544494	A/G	cg20194872	chr6:41519635	FOXP4	0.55	7.76	0.43	1.88e-13	Prostate cancer;
CESC	cis	rs875971	0.545	rs1909508	chr7:65766353	G/T	cg18876405	chr7:65276391	NA	0.45	5.47	0.32	1.06e-7	Aortic root size;
CESC	cis	rs2228479	0.718	rs11645376	chr16:89912281	G/C	cg06558623	chr16:89946397	TCF25	1.12	8.22	0.45	9.28e-15	Skin colour saturation;
CESC	cis	rs929354	0.772	rs3802126	chr7:156970281	G/A	cg05182265	chr7:156933206	UBE3C	-0.5	-7.3	-0.41	3.28e-12	Body mass index;
CESC	cis	rs801193	1.000	rs2659909	chr7:66160279	G/A	cg11764359	chr7:65958608	NA	0.71	9.12	0.49	1.89e-17	Aortic root size;
CESC	cis	rs13191362	0.507	rs2023037	chr6:163120385	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.4	5.25	0.31	3.18e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs258892	0.841	rs266426	chr5:72131255	A/G	cg21869765	chr5:72125136	TNPO1	0.44	5.62	0.33	4.78e-8	Small cell lung carcinoma;
CESC	cis	rs4243830	0.850	rs10864612	chr1:6593830	C/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.97	-9.95	-0.52	4.99e-20	Body mass index;
CESC	cis	rs7945705	0.747	rs2568020	chr11:8994715	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.42	-6.86	-0.39	4.91e-11	Hemoglobin concentration;
CESC	cis	rs9926296	0.605	rs8046243	chr16:89852133	A/G	cg07648498	chr16:89883185	FANCA	0.5	6.1	0.35	3.78e-9	Vitiligo;
CESC	cis	rs1707322	0.721	rs10430124	chr1:46221617	C/T	cg03146154	chr1:46216737	IPP	0.79	11.09	0.56	9.79e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs832540	0.931	rs1466008	chr5:56213406	G/C	cg14703610	chr5:56206110	C5orf35	0.53	7.03	0.4	1.78e-11	Coronary artery disease;
CESC	cis	rs853679	0.517	rs35512245	chr6:28079953	T/C	cg19592336	chr6:28129416	ZNF389	0.6	7.98	0.44	4.4e-14	Depression;
CESC	cis	rs7811142	0.720	rs7795656	chr7:99950297	A/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.9	8.78	0.47	2.09e-16	Platelet count;
CESC	cis	rs10504073	0.647	rs4348510	chr8:50016027	C/A	cg00325661	chr8:49890786	NA	0.52	7.96	0.44	4.91e-14	Blood metabolite ratios;
CESC	cis	rs1799949	1.000	rs915945	chr17:41179864	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.61	7.77	0.43	1.7e-13	Menopause (age at onset);
CESC	cis	rs7631605	0.905	rs9836891	chr3:37148882	C/G	cg22985146	chr3:37219077	LRRFIP2	-0.32	-5.06	-0.3	7.85e-7	Cerebrospinal P-tau181p levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08841910	chr3:52321932	GLYCTK	0.57	6.03	0.35	5.38e-9	Gut microbiome composition (summer);
CESC	cis	rs4808199	0.793	rs12459676	chr19:19425141	A/T	cg03709012	chr19:19516395	GATAD2A	1.08	11.33	0.57	1.58e-24	Nonalcoholic fatty liver disease;
CESC	cis	rs2204008	0.743	rs2132212	chr12:38039405	G/A	cg26384229	chr12:38710491	ALG10B	0.52	7.31	0.41	3.2e-12	Bladder cancer;
CESC	cis	rs4718428	0.705	rs12698547	chr7:66278258	T/C	cg18252515	chr7:66147081	NA	-0.49	-5.4	-0.31	1.49e-7	Corneal structure;
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg27306913	chr1:231115237	TTC13;ARV1	-0.38	-6.07	-0.35	4.5e-9	Vertical cup-disc ratio;
CESC	cis	rs3796352	1.000	rs11713290	chr3:52971579	G/A	cg12962167	chr3:53033115	SFMBT1	0.6	5.09	0.3	6.95e-7	Immune reponse to smallpox (secreted IL-2);
CESC	cis	rs2180341	0.782	rs4487601	chr6:127723521	A/G	cg27446573	chr6:127587934	RNF146	0.8	11.46	0.58	5.73e-25	Breast cancer;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg15776560	chr3:25916362	NA	-0.45	-6.28	-0.36	1.39e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs1003719	0.762	rs2835598	chr21:38466669	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.62	8.5	0.46	1.44e-15	Eye color traits;
CESC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg14832358	chr2:45837811	SRBD1	0.5	6.37	0.36	8.17e-10	Tetralogy of Fallot;
CESC	cis	rs796364	0.806	rs76568708	chr2:200929531	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.83	-7.6	-0.42	5.11e-13	Schizophrenia;
CESC	cis	rs34779708	0.931	rs12242882	chr10:35347860	G/C	cg04310649	chr10:35416472	CREM	-0.53	-6.42	-0.37	6.1e-10	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs703842	1.000	rs11172344	chr12:58193448	T/C	cg00599273	chr12:58146742	CDK4	0.33	5.06	0.3	7.92e-7	Multiple sclerosis;
CESC	cis	rs7552404	0.731	rs6699682	chr1:76340123	A/G	cg10523679	chr1:76189770	ACADM	-0.63	-6.43	-0.37	6e-10	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs1218582	0.744	rs6674853	chr1:154892753	G/C	cg03351412	chr1:154909251	PMVK	0.57	7.08	0.4	1.27e-11	Prostate cancer;
CESC	cis	rs68092024	0.704	rs793487	chr3:99495422	A/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.43	-6.8	-0.39	6.87e-11	Cleft lip with or without cleft palate;
CESC	cis	rs35306767	0.909	rs12264390	chr10:959111	T/C	cg20503657	chr10:835505	NA	0.67	7.46	0.42	1.25e-12	Eosinophil percentage of granulocytes;
CESC	trans	rs239339	0.959	rs349388	chr1:4425712	C/T	cg06451177	chr17:79412583	BAHCC1	0.52	6.11	0.35	3.63e-9	Obesity-related traits;
CESC	cis	rs2880765	0.835	rs11638498	chr15:86023018	T/C	cg19183879	chr15:85880815	NA	-0.24	-5.13	-0.3	5.61e-7	Coronary artery disease;
CESC	cis	rs561341	0.769	rs8074383	chr17:30178793	C/T	cg12193833	chr17:30244370	NA	0.62	5.74	0.33	2.58e-8	Hip circumference adjusted for BMI;
CESC	cis	rs17253792	0.822	rs17685102	chr14:56129214	A/G	cg01858014	chr14:56050164	KTN1	-0.97	-7.54	-0.42	7.36e-13	Putamen volume;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg02384530	chr12:6961868	USP5;CDCA3	0.46	6.31	0.36	1.18e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs5750830	0.649	rs7949	chr22:39827553	G/A	cg24399712	chr22:39784796	NA	-0.81	-11.14	-0.56	6.95e-24	Intelligence (multi-trait analysis);
CESC	cis	rs35110281	0.776	rs229357	chr21:44982717	T/C	cg01579765	chr21:45077557	HSF2BP	-0.56	-9.3	-0.5	5.47e-18	Mean corpuscular volume;
CESC	cis	rs597539	0.616	rs513476	chr11:68698996	C/T	cg01988459	chr11:68622903	NA	-0.42	-5.9	-0.34	1.12e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs10504229	0.683	rs61306359	chr8:58134646	G/A	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23806609	chr7:66369525	NA	-0.61	-7.18	-0.4	7.08e-12	Gut microbiome composition (summer);
CESC	cis	rs2380220	0.872	rs2613528	chr6:95939437	C/G	cg04719120	chr6:96025338	MANEA	-0.55	-5.05	-0.3	8.27e-7	Behavioural disinhibition (generation interaction);
CESC	cis	rs6938	0.534	rs11072512	chr15:75204026	C/T	cg14664628	chr15:75095509	CSK	-0.54	-7.22	-0.41	5.37e-12	Breast cancer;
CESC	cis	rs4927850	0.958	rs1975582	chr3:195751439	G/T	cg12923728	chr3:195709715	SDHAP1	-0.66	-8.66	-0.47	4.59e-16	Pancreatic cancer;
CESC	cis	rs2251381	0.778	rs2245021	chr21:30546841	C/T	cg24692254	chr21:30365293	RNF160	0.78	10.72	0.55	1.6400000000000001e-22	Selective IgA deficiency;
CESC	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg16132339	chr22:24313637	DDTL;DDT	-0.37	-5.5	-0.32	9.06e-8	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs6952808	0.578	rs6949478	chr7:1841342	A/G	cg22963979	chr7:1858916	MAD1L1	0.41	5.45	0.32	1.16e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs9303029	0.866	rs72857495	chr17:80412867	A/C	cg04942655	chr17:80303572	NA	-0.47	-5.07	-0.3	7.35e-7	Protein quantitative trait loci;
CESC	cis	rs7246865	0.510	rs8103578	chr19:17171227	C/T	cg16202187	chr19:17186497	HAUS8;MYO9B	0.48	6.26	0.36	1.56e-9	Reticulocyte fraction of red cells;
CESC	cis	rs7851660	0.933	rs12341377	chr9:100610382	C/G	cg13688889	chr9:100608707	NA	-0.68	-10.64	-0.55	3.08e-22	Strep throat;
CESC	trans	rs9929218	0.954	rs9923925	chr16:68819444	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.64	-8.6	-0.47	6.95e-16	Colorectal cancer;
CESC	cis	rs798554	0.757	rs1182178	chr7:2873763	G/A	cg19346786	chr7:2764209	NA	-0.45	-6.44	-0.37	5.64e-10	Height;
CESC	cis	rs4704187	0.687	rs2059159	chr5:74451178	G/C	cg03227963	chr5:74354835	NA	0.3	5.5	0.32	8.75e-8	Response to amphetamines;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg08688335	chr8:144635260	GSDMD	-0.44	-6.38	-0.36	7.72e-10	Gambling;
CESC	cis	rs7647973	0.580	rs11130184	chr3:49229930	C/T	cg07636037	chr3:49044803	WDR6	0.8	13.39	0.64	1.45e-31	Menarche (age at onset);
CESC	cis	rs1215050	0.740	rs1214997	chr4:99041533	A/T	cg17366294	chr4:99064904	C4orf37	0.41	5.34	0.31	1.95e-7	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs10504229	0.679	rs11783444	chr8:58131267	A/G	cg21724239	chr8:58056113	NA	0.58	5.95	0.34	8.29e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs7927592	0.956	rs11228277	chr11:68308324	G/A	cg16797656	chr11:68205561	LRP5	0.43	6.33	0.36	1.03e-9	Total body bone mineral density;
CESC	cis	rs2573652	0.722	rs12908133	chr15:100544405	G/A	cg09918751	chr15:100517450	ADAMTS17	-0.29	-5.38	-0.31	1.63e-7	Height;
CESC	cis	rs10754283	0.967	rs10801757	chr1:90103080	A/G	cg21401794	chr1:90099060	LRRC8C	0.69	9.2	0.49	1.08e-17	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs6142102	0.602	rs6141433	chr20:32548862	T/C	cg08999081	chr20:33150536	PIGU	0.34	5.11	0.3	6.04e-7	Skin pigmentation;
CESC	cis	rs854765	0.647	rs9303144	chr17:17977355	T/C	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.49	6.13	0.35	3.24e-9	Total body bone mineral density;
CESC	cis	rs13118159	0.771	rs13117476	chr4:1334721	A/G	cg05025164	chr4:1340916	KIAA1530	0.52	7.28	0.41	3.88e-12	Longevity;
CESC	cis	rs1023500	0.573	rs8135801	chr22:42475568	A/G	cg15557168	chr22:42548783	NA	0.44	6.29	0.36	1.34e-9	Schizophrenia;
CESC	cis	rs7589342	0.501	rs13429800	chr2:106441002	C/T	cg16077055	chr2:106428750	NCK2	0.4	6.28	0.36	1.4e-9	Addiction;
CESC	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg04025307	chr7:1156635	C7orf50	0.5	8.53	0.46	1.15e-15	Longevity;Endometriosis;
CESC	cis	rs12893597	0.715	rs4624098	chr14:76826256	G/A	cg20290672	chr14:76816747	NA	-0.4	-5.6	-0.33	5.34e-8	Maximal oxygen uptake response;
CESC	trans	rs1814175	0.616	rs4881723	chr11:49788566	G/T	cg15704280	chr7:45808275	SEPT13	-0.99	-17.45	-0.73	6.41e-46	Height;
CESC	cis	rs12135062	0.851	rs2651926	chr1:3101820	C/T	cg00254258	chr1:3105189	PRDM16	-0.35	-5.19	-0.3	4.21e-7	Migraine;
CESC	cis	rs7223966	1.000	rs8075521	chr17:61804954	C/T	cg11494091	chr17:61959527	GH2	0.38	5.19	0.3	4.28e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs2576037	0.526	rs9962523	chr18:44486414	A/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.45	7.41	0.41	1.67e-12	Personality dimensions;
CESC	cis	rs514406	0.505	rs269289	chr1:53167151	A/C	cg24675658	chr1:53192096	ZYG11B	-0.57	-7.54	-0.42	7.73e-13	Monocyte count;
CESC	trans	rs1814175	0.562	rs1794130	chr11:49903764	T/A	cg15704280	chr7:45808275	SEPT13	-1.01	-18.94	-0.76	3.64e-51	Height;
CESC	cis	rs16866061	0.855	rs11687736	chr2:225405122	A/T	cg12698349	chr2:225449008	CUL3	0.75	11.48	0.58	5.14e-25	Acute graft versus host disease in bone marrow transplantation (recipient effect);
CESC	cis	rs10411936	0.962	rs10404046	chr19:16477255	G/C	cg10248733	chr19:16607483	C19orf44;CALR3	0.54	6.38	0.37	7.69e-10	White blood cell count;Multiple sclerosis;
CESC	cis	rs863345	0.604	rs1342948	chr1:158463294	A/G	cg12129480	chr1:158549410	OR10X1	-0.35	-6.95	-0.39	2.86e-11	Pneumococcal bacteremia;
CESC	cis	rs34172651	0.517	rs12927710	chr16:24790282	A/C	cg06028605	chr16:24865363	SLC5A11	0.57	8.01	0.44	3.63e-14	Intelligence (multi-trait analysis);
CESC	cis	rs9902453	0.578	rs8073217	chr17:28164263	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.78	10.3	0.53	3.82e-21	Coffee consumption (cups per day);
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg02677328	chr6:52267982	PAQR8	0.45	6.26	0.36	1.51e-9	Thyroid stimulating hormone;
CESC	cis	rs3824867	0.920	rs7111873	chr11:47469439	A/G	cg20307385	chr11:47447363	PSMC3	0.5	6.06	0.35	4.73e-9	Mean corpuscular hemoglobin;
CESC	cis	rs4713118	0.516	rs4713142	chr6:28106347	T/G	cg23281280	chr6:28129359	ZNF389	0.59	8.16	0.45	1.34e-14	Parkinson's disease;
CESC	cis	rs75804782	0.521	rs1123472	chr2:239414355	C/T	cg18131467	chr2:239335373	ASB1	0.69	5.68	0.33	3.63e-8	Morning vs. evening chronotype;Chronotype;
CESC	cis	rs7666738	0.830	rs4292342	chr4:98959870	A/T	cg05340658	chr4:99064831	C4orf37	0.8	12.01	0.59	8.24e-27	Colonoscopy-negative controls vs population controls;
CESC	cis	rs561341	0.505	rs548298	chr17:30297494	C/A	cg00745463	chr17:30367425	LRRC37B	-0.7	-7.02	-0.4	1.85e-11	Hip circumference adjusted for BMI;
CESC	cis	rs7772486	0.688	rs1884364	chr6:146337817	C/G	cg23711669	chr6:146136114	FBXO30	0.8	10.47	0.54	1.05e-21	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs748404	0.697	rs567357	chr15:43571390	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.6	7.99	0.44	4.21e-14	Lung cancer;
CESC	cis	rs959260	0.588	rs2385263	chr17:73321117	T/C	cg20590849	chr17:73267439	MIF4GD	-0.44	-5.2	-0.3	3.9e-7	Systemic lupus erythematosus;
CESC	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg26338869	chr17:61819248	STRADA	0.69	9.23	0.49	8.85e-18	Prudent dietary pattern;
CESC	cis	rs6693567	0.586	rs875514	chr1:150484555	C/G	cg09579323	chr1:150459698	TARS2	0.43	5.38	0.31	1.64e-7	Migraine;
CESC	cis	rs208520	0.690	rs74707865	chr6:66717352	A/G	cg07460842	chr6:66804631	NA	0.96	12.77	0.62	2e-29	Exhaled nitric oxide output;
CESC	cis	rs3806843	0.868	rs2531342	chr5:140130612	C/T	cg26395211	chr5:140044315	WDR55	0.4	5.16	0.3	4.86e-7	Depressive symptoms (multi-trait analysis);
CESC	trans	rs60843830	1.000	rs7605824	chr2:280819	A/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	-0.67	-8.37	-0.46	3.32e-15	Spherical equivalent (joint analysis main effects and education interaction);
CESC	trans	rs3780486	0.846	rs73484568	chr9:33132492	G/A	cg20290983	chr6:43655470	MRPS18A	0.99	18.31	0.75	5.73e-49	IgG glycosylation;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14482902	chr17:36714803	SRCIN1	0.54	6.0	0.35	6.44e-9	Gut microbiome composition (summer);
CESC	cis	rs7772486	0.790	rs9386141	chr6:146268623	T/A	cg23711669	chr6:146136114	FBXO30	-0.81	-11.61	-0.58	1.87e-25	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs35110281	0.811	rs2838337	chr21:45072621	A/C	cg04455712	chr21:45112962	RRP1B	0.39	5.71	0.33	3.1e-8	Mean corpuscular volume;
CESC	cis	rs7267979	0.816	rs376742	chr20:25487417	A/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.77	14.48	0.66	2.17e-35	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs4746818	1.000	rs9299502	chr10:70876934	C/T	cg11621586	chr10:70884670	VPS26A	0.96	12.58	0.61	8.98e-29	Left atrial antero-posterior diameter;
CESC	cis	rs2066819	1.000	rs117779516	chr12:56750872	G/C	cg26714650	chr12:56694279	CS	-1.4	-8.78	-0.47	2.1e-16	Psoriasis vulgaris;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg12469361	chr1:982189	AGRN	0.51	6.72	0.38	1.11e-10	Fibrinogen levels;
CESC	cis	rs3008870	1.000	rs3008855	chr1:67386204	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-0.94	-11.58	-0.58	2.28e-25	Lymphocyte percentage of white cells;
CESC	cis	rs13064411	0.696	rs2087129	chr3:113142769	T/A	cg18753928	chr3:113234510	CCDC52	-0.48	-5.75	-0.33	2.39e-8	Response to simvastatin treatment (PCSK9 protein level change);
CESC	cis	rs7208859	0.623	rs11657777	chr17:29091785	T/C	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.17e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs4665809	1.000	rs750452	chr2:26324995	G/A	cg27170947	chr2:26402098	FAM59B	-0.58	-6.92	-0.39	3.46e-11	Gut microbiome composition (summer);
CESC	cis	rs1799949	0.965	rs4793204	chr17:41279298	A/G	cg05368731	chr17:41323189	NBR1	0.8	11.32	0.57	1.66e-24	Menopause (age at onset);
CESC	cis	rs4642101	0.793	rs13320486	chr3:12822069	C/A	cg24848339	chr3:12840334	CAND2	0.39	5.96	0.34	8.16e-9	QRS complex (12-leadsum);
CESC	cis	rs7208859	0.623	rs56163556	chr17:29101868	G/C	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.91e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs9911578	0.867	rs72628394	chr17:57121313	C/T	cg12560992	chr17:57184187	TRIM37	-0.94	-15.74	-0.7	7.41e-40	Intelligence (multi-trait analysis);
CESC	cis	rs921968	0.643	rs563268	chr2:219372912	T/G	cg02176678	chr2:219576539	TTLL4	0.39	6.75	0.38	9.18e-11	Mean corpuscular hemoglobin concentration;
CESC	cis	rs798766	0.723	rs3134865	chr4:1723279	T/C	cg10756475	chr4:1757242	NA	0.45	6.2	0.36	2.15e-9	Bladder cancer;Urinary bladder cancer;
CESC	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg12419862	chr22:24373484	LOC391322	-0.84	-11.92	-0.59	1.62e-26	Liver enzyme levels (gamma-glutamyl transferase);
CESC	trans	rs4843747	0.671	rs72818576	chr16:88111019	C/G	cg26811252	chr16:29126840	RRN3P2	0.69	9.65	0.51	4.31e-19	Menopause (age at onset);
CESC	cis	rs524281	0.773	rs11227448	chr11:66048491	G/A	cg14036092	chr11:66035641	RAB1B	-0.54	-5.32	-0.31	2.23e-7	Electroencephalogram traits;
CESC	trans	rs12599106	0.792	rs12597352	chr16:34638507	A/T	cg01171360	chr6:293285	DUSP22	-0.47	-6.28	-0.36	1.4e-9	Menopause (age at onset);
CESC	cis	rs9649213	0.593	rs3801255	chr7:98000929	C/T	cg21770322	chr7:97807741	LMTK2	0.57	8.84	0.48	1.39e-16	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs736408	0.562	rs12497998	chr3:52793602	C/T	cg18099408	chr3:52552593	STAB1	-0.31	-5.14	-0.3	5.26e-7	Bipolar disorder;
CESC	cis	rs1018836	0.608	rs6992512	chr8:91477936	C/A	cg16814680	chr8:91681699	NA	-0.55	-7.57	-0.42	6.13e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs12618769	0.625	rs3769736	chr2:99089119	C/T	cg10123293	chr2:99228465	UNC50	0.39	5.13	0.3	5.6e-7	Bipolar disorder;
CESC	cis	rs7666738	0.830	rs9995370	chr4:98732145	T/G	cg03467027	chr4:99064603	C4orf37	0.44	5.42	0.32	1.36e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4566357	1.000	rs7567796	chr2:227922109	T/A	cg11843606	chr2:227700838	RHBDD1	-0.4	-5.16	-0.3	4.78e-7	Coronary artery disease;
CESC	cis	rs2019216	0.502	rs1842113	chr17:21872137	G/A	cg22648282	chr17:21454238	C17orf51	-0.41	-5.46	-0.32	1.09e-7	Pelvic organ prolapse;
CESC	cis	rs10447248	0.674	rs6594320	chr5:107896326	C/T	cg25075504	chr5:107899390	NA	0.36	5.5	0.32	9.09e-8	Adiponectin levels;
CESC	cis	rs6912958	0.781	rs4334949	chr6:88290150	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-6.58	-0.37	2.55e-10	Monocyte percentage of white cells;
CESC	cis	rs1552244	1.000	rs61077902	chr3:10126153	T/G	cg00149659	chr3:10157352	C3orf10	0.72	8.87	0.48	1.09e-16	Alzheimer's disease;
CESC	cis	rs6500395	1.000	rs7190106	chr16:48705542	C/T	cg04672837	chr16:48644449	N4BP1	0.52	6.68	0.38	1.39e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs9287719	0.967	rs1541574	chr2:10773508	A/T	cg02196655	chr2:10830764	NOL10	-0.36	-5.36	-0.31	1.79e-7	Prostate cancer;
CESC	cis	rs936229	0.654	rs762551	chr15:75041917	C/A	cg14664628	chr15:75095509	CSK	-0.79	-10.82	-0.55	7.49e-23	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CESC	cis	rs1005224	0.654	rs8005753	chr14:76136086	A/T	cg25116370	chr14:76127843	TTLL5;C14orf1	-0.44	-6.01	-0.35	6.18e-9	Large artery stroke;
CESC	cis	rs2228479	0.850	rs74251570	chr16:89910068	C/A	cg06558623	chr16:89946397	TCF25	1.12	8.22	0.45	9.28e-15	Skin colour saturation;
CESC	cis	rs3785574	0.962	rs62077512	chr17:61851435	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.58	7.24	0.41	4.89e-12	Height;
CESC	cis	rs7818688	1.000	rs34700722	chr8:96021876	A/G	cg16049864	chr8:95962084	TP53INP1	0.6	5.77	0.33	2.19e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs7666738	0.830	rs10000573	chr4:99048785	G/C	cg18180107	chr4:99064573	C4orf37	0.41	5.29	0.31	2.51e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs593982	1.000	rs650619	chr11:65506483	G/A	cg08755490	chr11:65554678	OVOL1	1.32	19.72	0.77	6.73e-54	Atopic dermatitis;
CESC	cis	rs1799949	0.965	rs34633610	chr17:41419385	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.61	8.06	0.44	2.6e-14	Menopause (age at onset);
CESC	cis	rs7762018	1.000	rs7747645	chr6:170070291	G/C	cg13891659	chr6:170190454	C6orf122;C6orf208	0.53	5.41	0.32	1.43e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs6860806	0.507	rs272883	chr5:131668698	A/G	cg24060327	chr5:131705240	SLC22A5	-0.77	-10.88	-0.56	4.91e-23	Breast cancer;
CESC	cis	rs4253772	0.637	rs8135997	chr22:46651366	G/A	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.69	8.18	0.45	1.16e-14	LDL cholesterol;Cholesterol, total;
CESC	cis	rs6964587	1.000	rs6960867	chr7:91712698	A/G	cg01689657	chr7:91764605	CYP51A1	0.29	5.16	0.3	4.88e-7	Breast cancer;
CESC	cis	rs7618915	0.501	rs2289247	chr3:52727257	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.62	8.65	0.47	4.93e-16	Bipolar disorder;
CESC	cis	rs11122272	0.735	rs2749708	chr1:231529610	G/A	cg06096015	chr1:231504339	EGLN1	0.43	6.15	0.35	2.9e-9	Hemoglobin concentration;
CESC	cis	rs3733585	0.579	rs4235356	chr4:10123106	G/C	cg02734326	chr4:10020555	SLC2A9	-0.37	-5.15	-0.3	5.14e-7	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs7666738	0.830	rs6532715	chr4:99016792	G/A	cg18180107	chr4:99064573	C4orf37	0.41	5.4	0.31	1.48e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10870270	0.784	rs10430614	chr10:133748640	C/T	cg17892150	chr10:133769511	PPP2R2D	0.78	11.4	0.57	9.42e-25	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs854765	0.587	rs4077828	chr17:17833644	A/T	cg16928487	chr17:17741425	SREBF1	-0.57	-9.74	-0.51	2.33e-19	Total body bone mineral density;
CESC	cis	rs7246865	0.859	rs7252102	chr19:17197012	A/G	cg19418318	chr19:17219073	MYO9B	0.35	5.87	0.34	1.33e-8	Reticulocyte fraction of red cells;
CESC	cis	rs6496667	0.558	rs10459677	chr15:91042399	A/C	cg10434728	chr15:90938212	IQGAP1	-0.34	-5.76	-0.33	2.29e-8	Rheumatoid arthritis;
CESC	cis	rs9926296	0.533	rs12102290	chr16:89812617	C/T	cg03388025	chr16:89894329	SPIRE2	0.39	7.42	0.41	1.63e-12	Vitiligo;
CESC	cis	rs2929278	0.617	rs663214	chr15:44113782	T/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.47	-7.27	-0.41	4.03e-12	Schizophrenia;
CESC	cis	rs1003719	0.715	rs2835647	chr21:38546773	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.59	-8.06	-0.44	2.72e-14	Eye color traits;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg11662638	chr2:45878864	PRKCE	-0.51	-6.8	-0.39	6.78e-11	Ulcerative colitis;
CESC	cis	rs12995491	0.731	rs55705009	chr2:88500718	T/G	cg07952391	chr2:88470173	THNSL2	-0.54	-8.14	-0.45	1.59e-14	Response to metformin (IC50);
CESC	cis	rs7666738	0.606	rs10006414	chr4:99101401	T/C	cg17366294	chr4:99064904	C4orf37	0.46	5.94	0.34	8.85e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7191439	0.790	rs2306046	chr16:88781419	A/G	cg27087555	chr16:88793112	FAM38A	-1.17	-10.08	-0.53	1.98e-20	Plateletcrit;
CESC	cis	rs7586879	0.521	rs1865689	chr2:25108197	C/T	cg01884057	chr2:25150051	NA	-0.33	-6.19	-0.36	2.3e-9	Body mass index;
CESC	cis	rs7129220	0.512	rs12279871	chr11:10228196	G/A	cg01453529	chr11:10209919	SBF2	-0.46	-5.67	-0.33	3.77e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CESC	cis	rs13108904	0.557	rs1250086	chr4:1248051	G/A	cg02475777	chr4:1388615	CRIPAK	-0.47	-5.98	-0.34	7.11e-9	Obesity-related traits;
CESC	cis	rs698833	0.741	rs2340808	chr2:44511861	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.56	6.91	0.39	3.68e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg04234412	chr22:24373322	LOC391322	0.65	9.54	0.51	1e-18	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs926938	0.527	rs2335954	chr1:115534151	C/T	cg12756093	chr1:115239321	AMPD1	-0.47	-6.45	-0.37	5.14e-10	Autism;
CESC	cis	rs4268898	0.636	rs72787383	chr2:24583861	G/A	cg20701182	chr2:24300061	SF3B14	0.66	6.97	0.39	2.47e-11	Asthma;
CESC	cis	rs7917772	0.560	rs729023	chr10:104341887	A/G	ch.10.2196322F	chr10:104248062	ACTR1A	-0.4	-5.03	-0.3	8.96e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs3020736	0.500	rs11090076	chr22:42514190	T/C	cg04733989	chr22:42467013	NAGA	-0.78	-11.9	-0.59	1.87e-26	Autism spectrum disorder or schizophrenia;
CESC	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg03407747	chr17:6899364	ALOX12	0.49	8.6	0.47	6.86e-16	Tonsillectomy;
CESC	trans	rs2571521	0.887	rs9298879	chr9:26097224	A/C	ch.15.23688912F	chr15:26137819	NA	0.78	6.1	0.35	3.75e-9	Pursuit maintenance gain in psychotic disorders;
CESC	cis	rs2439831	1.000	rs689754	chr15:43775895	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.83	11.48	0.58	5.16e-25	Lung cancer in ever smokers;
CESC	cis	rs10200159	1.000	rs9309267	chr2:55850333	A/G	cg13617705	chr2:55845095	SMEK2	-0.72	-5.18	-0.3	4.41e-7	Vitiligo;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03051979	chr16:58283909	CCDC113	0.58	6.84	0.39	5.37e-11	Gut microbiome composition (summer);
CESC	trans	rs12356475	0.710	rs10822686	chr10:67733250	C/T	cg23743186	chr22:39152048	UNC84B	0.55	6.57	0.37	2.58e-10	Psoriatic arthritis;
CESC	cis	rs6547741	1.000	rs4665381	chr2:27757150	A/C	cg21248554	chr2:27665150	KRTCAP3	0.25	5.15	0.3	5.01e-7	Oral cavity cancer;
CESC	cis	rs116095464	0.558	rs9688136	chr5:229348	T/C	cg22496380	chr5:211416	CCDC127	-0.74	-8.65	-0.47	5.2e-16	Breast cancer;
CESC	cis	rs10870270	0.917	rs9971362	chr10:133790150	T/C	cg17892150	chr10:133769511	PPP2R2D	-0.84	-12.03	-0.59	6.71e-27	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs35306767	0.953	rs11253520	chr10:975961	C/G	cg25019033	chr10:957182	NA	0.55	7.98	0.44	4.5e-14	Eosinophil percentage of granulocytes;
CESC	cis	rs425277	0.606	rs424079	chr1:2071340	C/A	cg16545954	chr1:2118288	C1orf86	-0.37	-7.04	-0.4	1.65e-11	Height;
CESC	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg04025307	chr7:1156635	C7orf50	-0.56	-9.95	-0.52	5.16e-20	Longevity;Endometriosis;
CESC	cis	rs10078	0.571	rs890977	chr5:476910	T/C	cg16584290	chr5:462447	EXOC3	0.47	5.1	0.3	6.39e-7	Fat distribution (HIV);
CESC	cis	rs7216064	0.953	rs11079705	chr17:65835452	A/T	cg12091567	chr17:66097778	LOC651250	-0.86	-8.83	-0.48	1.49e-16	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg10102242	chr16:4422216	VASN;CORO7	0.5	6.26	0.36	1.5e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs9488822	0.676	rs868943	chr6:116337503	G/A	cg05304507	chr6:116381966	FRK	0.25	6.58	0.37	2.49e-10	Cholesterol, total;LDL cholesterol;
CESC	cis	rs7811142	0.830	rs78256546	chr7:99952970	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.04	10.52	0.54	7.52e-22	Platelet count;
CESC	cis	rs1322639	0.614	rs4708414	chr6:169574144	C/G	cg04662567	chr6:169592167	NA	-0.38	-5.46	-0.32	1.08e-7	Pulse pressure;
CESC	cis	rs5750830	0.649	rs5750815	chr22:39798449	T/C	cg01416388	chr22:39784598	NA	-0.59	-7.23	-0.41	5.21e-12	Intelligence (multi-trait analysis);
CESC	cis	rs12893668	0.697	rs67899457	chr14:104060066	A/T	cg24130564	chr14:104152367	KLC1	-0.48	-6.09	-0.35	4.01e-9	Reticulocyte count;
CESC	cis	rs265548	0.538	rs36688	chr19:17911212	A/C	cg16024904	chr19:17905718	B3GNT3	0.43	5.72	0.33	2.8e-8	Tumor biomarkers;
CESC	cis	rs1552244	1.000	rs17032268	chr3:10067972	C/T	cg08888203	chr3:10149979	C3orf24	0.49	6.33	0.36	1.05e-9	Alzheimer's disease;
CESC	cis	rs7666738	0.830	rs35939134	chr4:98980311	A/G	cg03467027	chr4:99064603	C4orf37	0.43	5.44	0.32	1.18e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.55	0.37	2.91e-10	Prudent dietary pattern;
CESC	cis	rs11252926	0.800	rs2209625	chr10:747115	A/C	cg08603382	chr10:743973	NA	-0.61	-8.12	-0.45	1.74e-14	Psychosis in Alzheimer's disease;
CESC	cis	rs7647973	1.000	rs7647973	chr3:49510931	G/A	cg07636037	chr3:49044803	WDR6	-0.7	-9.53	-0.51	1.06e-18	Menarche (age at onset);
CESC	cis	rs3820928	0.874	rs7576081	chr2:227843634	C/G	cg11843606	chr2:227700838	RHBDD1	-0.44	-5.76	-0.33	2.35e-8	Pulmonary function;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22031650	chr11:111957494	SDHD;TIMM8B	0.58	6.67	0.38	1.51e-10	Gut microbiome composition (summer);
CESC	cis	rs634534	0.563	rs470192	chr11:65724291	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.74	10.78	0.55	1.01e-22	Sum eosinophil basophil counts;Eosinophil counts;
CESC	cis	rs17407555	0.821	rs4473652	chr4:10141617	G/C	cg00071950	chr4:10020882	SLC2A9	-0.58	-5.29	-0.31	2.53e-7	Schizophrenia (age at onset);
CESC	cis	rs2228479	0.541	rs12918575	chr16:89811151	A/G	cg27121462	chr16:89883253	FANCA	0.63	5.51	0.32	8.36e-8	Skin colour saturation;
CESC	cis	rs1707322	0.752	rs12027622	chr1:46130252	A/C	cg05343316	chr1:45956843	TESK2	0.51	6.24	0.36	1.7e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2832191	0.740	rs2832177	chr21:30478353	G/A	cg08807101	chr21:30365312	RNF160	-0.92	-13.86	-0.65	3.09e-33	Dental caries;
CESC	cis	rs7246657	0.943	rs1015849	chr19:37946180	G/A	cg23950597	chr19:37808831	NA	-0.61	-6.23	-0.36	1.85e-9	Coronary artery calcification;
CESC	cis	rs804280	0.662	rs11784764	chr8:11610874	C/T	cg26752888	chr8:11627280	NEIL2	0.68	6.18	0.36	2.38e-9	Myopia (pathological);
CESC	cis	rs698833	0.532	rs2616444	chr2:44605518	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.45	5.44	0.32	1.18e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs853679	0.517	rs4711165	chr6:28115184	T/G	cg23161317	chr6:28129485	ZNF389	0.52	6.48	0.37	4.48e-10	Depression;
CESC	cis	rs644799	0.965	rs2950522	chr11:95524719	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.71	9.3	0.5	5.52e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs6429082	0.715	rs2131924	chr1:235580928	G/A	cg26050004	chr1:235667680	B3GALNT2	-0.54	-6.75	-0.38	9.44e-11	Adiposity;
CESC	cis	rs6952808	0.630	rs1860832	chr7:2161849	G/A	cg21782813	chr7:2030301	MAD1L1	0.51	7.28	0.41	3.86e-12	Bipolar disorder and schizophrenia;
CESC	cis	rs4664304	0.629	rs1606117	chr2:160850716	C/T	cg03641300	chr2:160917029	PLA2R1	-0.43	-5.8	-0.34	1.86e-8	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs853679	0.517	rs9393886	chr6:28050039	T/G	cg17949981	chr6:28129498	ZNF389	0.45	5.62	0.33	4.9e-8	Depression;
CESC	cis	rs4953318	0.619	rs13406901	chr2:46363066	T/G	cg12428440	chr2:46370979	PRKCE	0.49	6.48	0.37	4.56e-10	Red blood cell count;Hematocrit;Red blood cell traits;
CESC	trans	rs17307778	0.908	rs10742085	chr11:25358050	A/T	cg22888484	chr20:37075185	SNHG11	-0.63	-6.07	-0.35	4.42e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg11494091	chr17:61959527	GH2	0.72	12.44	0.61	2.76e-28	Prudent dietary pattern;
CESC	cis	rs13102973	0.965	rs4535381	chr4:135861313	A/T	cg14419869	chr4:135874104	NA	0.34	5.24	0.31	3.3e-7	Subjective well-being;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg05602987	chr16:28834702	ATXN2L	-0.47	-6.36	-0.36	8.59e-10	Ulcerative colitis;
CESC	cis	rs4955124	0.730	rs12639105	chr3:32047336	C/T	cg05935571	chr3:32023257	ZNF860;OSBPL10	0.8	5.88	0.34	1.2e-8	Schizophrenia;
CESC	cis	rs6087990	0.806	rs910084	chr20:31379665	C/T	cg13636640	chr20:31349939	DNMT3B	0.76	11.63	0.58	1.55e-25	Ulcerative colitis;
CESC	trans	rs62103177	0.564	rs11874805	chr18:77697110	T/C	cg05926928	chr17:57297772	GDPD1	0.79	7.47	0.42	1.14e-12	Opioid sensitivity;
CESC	cis	rs12701220	0.847	rs10272002	chr7:1047615	A/G	cg26769984	chr7:1090371	C7orf50	0.67	7.58	0.42	5.87e-13	Bronchopulmonary dysplasia;
CESC	cis	rs7512552	0.839	rs1694362	chr1:150366963	T/A	cg15654264	chr1:150340011	RPRD2	0.39	5.17	0.3	4.68e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs2294693	0.947	rs4714417	chr6:40987782	A/G	cg14418226	chr6:40996092	UNC5CL	0.53	6.51	0.37	3.83e-10	Gastric cancer;Non-cardia gastric cancer;
CESC	cis	rs6582630	0.555	rs7133706	chr12:38475465	G/A	cg26384229	chr12:38710491	ALG10B	-0.65	-9.74	-0.51	2.31e-19	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg18538332	chr22:24372958	LOC391322	-0.75	-11.24	-0.57	3.27e-24	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs763121	0.853	rs6001182	chr22:39047443	A/G	cg06544989	chr22:39130855	UNC84B	0.5	8.66	0.47	4.63e-16	Menopause (age at onset);
CESC	cis	rs7618915	0.547	rs11130313	chr3:52676190	A/C	cg07507251	chr3:52567010	NT5DC2	0.4	7.06	0.4	1.49e-11	Bipolar disorder;
CESC	cis	rs7618915	0.501	rs34157897	chr3:52716937	T/C	cg18404041	chr3:52824283	ITIH1	-0.38	-6.53	-0.37	3.29e-10	Bipolar disorder;
CESC	cis	rs793571	0.523	rs12439457	chr15:58982390	T/C	cg05156742	chr15:59063176	FAM63B	0.58	7.79	0.43	1.53e-13	Schizophrenia;
CESC	cis	rs6502050	0.805	rs62078303	chr17:80085210	A/G	cg23985595	chr17:80112537	CCDC57	0.42	6.55	0.37	2.99e-10	Life satisfaction;
CESC	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg06873352	chr17:61820015	STRADA	0.73	13.12	0.63	1.2e-30	Prudent dietary pattern;
CESC	cis	rs7647973	0.667	rs11721148	chr3:49646669	G/A	cg13072238	chr3:49761600	GMPPB	-0.51	-6.14	-0.35	3.03e-9	Menarche (age at onset);
CESC	cis	rs9486715	1.000	rs9398148	chr6:97063555	A/G	cg18709589	chr6:96969512	KIAA0776	-0.44	-6.2	-0.36	2.17e-9	Headache;
CESC	cis	rs10504229	0.683	rs7820559	chr8:58142662	C/T	cg21724239	chr8:58056113	NA	0.56	5.97	0.34	7.66e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs920590	0.684	rs59259846	chr8:19669468	C/G	cg03894339	chr8:19674705	INTS10	0.68	7.77	0.43	1.73e-13	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs1468333	0.514	rs10515498	chr5:137586330	C/T	cg27119451	chr5:137514611	BRD8;KIF20A	0.48	5.1	0.3	6.58e-7	Resting heart rate;
CESC	cis	rs1005277	0.579	rs1621040	chr10:38497232	T/C	cg25517755	chr10:38738941	LOC399744	-0.45	-5.84	-0.34	1.55e-8	Extrinsic epigenetic age acceleration;
CESC	cis	rs30380	0.632	rs26491	chr5:96134113	A/G	cg16492584	chr5:96139282	ERAP1	-0.49	-6.65	-0.38	1.7e-10	Cerebrospinal fluid biomarker levels;
CESC	cis	rs634534	0.532	rs12794370	chr11:65770413	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.73	10.62	0.55	3.4e-22	Sum eosinophil basophil counts;Eosinophil counts;
CESC	cis	rs9733	0.519	rs1134067	chr1:150721175	G/T	cg09365446	chr1:150670422	GOLPH3L	0.4	5.29	0.31	2.54e-7	Tonsillectomy;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg20832448	chr3:36418645	NA	-0.42	-6.24	-0.36	1.76e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs7044106	0.708	rs10984992	chr9:123473416	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.37	6.07	0.35	4.38e-9	Hip circumference adjusted for BMI;
CESC	cis	rs12410462	0.581	rs77430808	chr1:227540880	C/T	cg04117972	chr1:227635322	NA	0.64	5.38	0.31	1.66e-7	Major depressive disorder;
CESC	cis	rs6938	0.618	rs11072514	chr15:75221865	T/A	cg09165964	chr15:75287851	SCAMP5	0.47	6.32	0.36	1.12e-9	Breast cancer;
CESC	cis	rs9303401	0.614	rs3087762	chr17:56568680	C/T	cg25039879	chr17:56429692	SUPT4H1	0.51	5.13	0.3	5.51e-7	Cognitive test performance;
CESC	cis	rs753778	0.602	rs9792	chr8:142205237	C/T	cg23750338	chr8:142222470	SLC45A4	-0.35	-5.05	-0.3	8.05e-7	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	cis	rs9549367	1.000	rs9549367	chr13:113911532	C/G	cg00898013	chr13:113819073	PROZ	-0.5	-7.15	-0.4	8.55e-12	Platelet distribution width;
CESC	cis	rs11792861	0.926	rs72607173	chr9:111879398	T/G	cg13535736	chr9:111863775	C9orf5	-0.49	-6.6	-0.38	2.27e-10	Menarche (age at onset);
CESC	trans	rs2877832	0.778	rs73603734	chr14:27822362	A/G	cg13449535	chr1:1101348	MIR200B	0.55	6.65	0.38	1.67e-10	Diabetes related insulin traits;
CESC	cis	rs1707322	0.686	rs2991979	chr1:46055858	A/G	cg05343316	chr1:45956843	TESK2	-0.53	-6.5	-0.37	3.87e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs72781680	0.800	rs72780112	chr2:23991182	C/T	cg20701182	chr2:24300061	SF3B14	0.63	5.65	0.33	4.21e-8	Lymphocyte counts;
CESC	cis	rs9487051	0.898	rs882072	chr6:109611806	A/G	cg21918786	chr6:109611834	NA	-0.42	-6.34	-0.36	9.81e-10	Reticulocyte fraction of red cells;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg13876163	chr1:45140495	C1orf228;TMEM53	-0.44	-6.3	-0.36	1.23e-9	Gambling;
CESC	cis	rs763121	0.889	rs4820335	chr22:38935927	C/G	cg06022373	chr22:39101656	GTPBP1	-0.74	-11.12	-0.56	7.88e-24	Menopause (age at onset);
CESC	cis	rs4664308	1.000	rs4665147	chr2:160917062	A/G	cg03641300	chr2:160917029	PLA2R1	-0.67	-10.08	-0.53	1.88e-20	Idiopathic membranous nephropathy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15264303	chr12:7013902	LRRC23	-0.68	-8.13	-0.45	1.66e-14	Gut microbiome composition (summer);
CESC	cis	rs9611565	0.694	rs202616	chr22:41822221	C/G	cg03806693	chr22:41940476	POLR3H	1.2	14.5	0.67	1.86e-35	Vitiligo;
CESC	cis	rs61931739	0.817	rs10772143	chr12:34230651	T/G	cg19457237	chr12:34500585	NA	-0.4	-5.53	-0.32	7.72e-8	Morning vs. evening chronotype;
CESC	cis	rs3733585	0.605	rs56178126	chr4:10123581	C/T	cg00071950	chr4:10020882	SLC2A9	-0.65	-9.75	-0.51	2.23e-19	Cleft plate (environmental tobacco smoke interaction);
CESC	trans	rs10242455	0.702	rs112475236	chr7:99044679	A/G	cg09045935	chr12:6379348	NA	0.92	7.57	0.42	6.02e-13	Blood metabolite levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05611199	chr16:88637223	ZC3H18	0.66	8.03	0.44	3.19e-14	Gut microbiome composition (summer);
CESC	trans	rs4927850	0.881	rs7630489	chr3:195753401	T/C	cg16724585	chr3:197361211	NA	-0.56	-7.2	-0.4	6.32e-12	Pancreatic cancer;
CESC	cis	rs1218582	0.600	rs72702224	chr1:154911689	G/A	cg03351412	chr1:154909251	PMVK	0.52	6.36	0.36	8.93e-10	Prostate cancer;
CESC	cis	rs6570726	0.935	rs380433	chr6:145859601	A/T	cg05347473	chr6:146136440	FBXO30	0.48	6.44	0.37	5.7e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6088590	1.000	rs55753039	chr20:33394940	C/T	cg08999081	chr20:33150536	PIGU	0.6	8.81	0.48	1.63e-16	Coronary artery disease;
CESC	cis	rs3785574	0.962	rs2665799	chr17:61919723	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.79	10.29	0.53	4.01e-21	Height;
CESC	cis	rs4730250	0.707	rs10253291	chr7:106786550	C/A	cg02696742	chr7:106810147	HBP1	0.54	5.18	0.3	4.44e-7	Osteoarthritis;
CESC	cis	rs1707322	1.000	rs34694458	chr1:46332696	G/A	cg05343316	chr1:45956843	TESK2	0.42	5.18	0.3	4.36e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs875971	0.789	rs28815324	chr7:65565776	A/T	cg25405998	chr7:65216604	CCT6P1	-0.5	-5.28	-0.31	2.64e-7	Aortic root size;
CESC	cis	rs9457247	1.000	rs393727	chr6:167398632	T/A	cg25258033	chr6:167368657	RNASET2	0.4	6.1	0.35	3.81e-9	Crohn's disease;
CESC	cis	rs9790314	0.818	rs6797066	chr3:161008725	T/A	cg03342759	chr3:160939853	NMD3	-0.51	-7.26	-0.41	4.27e-12	Morning vs. evening chronotype;
CESC	cis	rs2839186	1.000	rs2839186	chr21:47690068	C/T	cg10351095	chr21:47802916	PCNT	-0.53	-7.32	-0.41	3.06e-12	Testicular germ cell tumor;
CESC	cis	rs7216064	1.000	rs12451721	chr17:65939075	G/A	cg12091567	chr17:66097778	LOC651250	-0.8	-8.08	-0.44	2.31e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs290268	0.585	rs290992	chr9:93561309	C/T	cg02608019	chr9:93564028	SYK	-0.45	-6.05	-0.35	5.01e-9	Platelet count;
CESC	cis	rs28386778	0.769	rs6504179	chr17:61812995	T/G	cg26338869	chr17:61819248	STRADA	0.65	8.37	0.46	3.42e-15	Prudent dietary pattern;
CESC	cis	rs1568889	1.000	rs7937117	chr11:28370038	C/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.78	10.86	0.55	5.8e-23	Bipolar disorder;
CESC	cis	rs6502050	0.698	rs6502076	chr17:80121978	A/G	cg11859384	chr17:80120422	CCDC57	-0.39	-5.34	-0.31	1.98e-7	Life satisfaction;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02336323	chr4:54931210	CHIC2	-0.53	-6.37	-0.36	8.29e-10	Gut microbiome composition (summer);
CESC	cis	rs1552244	1.000	rs7652935	chr3:10151138	T/C	cg16606324	chr3:10149918	C3orf24	0.41	5.03	0.3	8.88e-7	Alzheimer's disease;
CESC	trans	rs7131987	0.903	rs2194518	chr12:29419460	C/T	cg13198235	chr1:193028919	TROVE2;UCHL5	0.51	6.04	0.35	5.08e-9	QT interval;
CESC	cis	rs12701220	0.901	rs12701713	chr7:1090505	G/A	cg26769984	chr7:1090371	C7orf50	0.66	7.74	0.43	2.16e-13	Bronchopulmonary dysplasia;
CESC	cis	rs4862750	0.872	rs9998173	chr4:187898778	T/A	cg22105103	chr4:187893119	NA	0.51	7.61	0.42	4.66e-13	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7940866	0.903	rs2324316	chr11:130872353	G/T	cg12179176	chr11:130786555	SNX19	0.67	9.62	0.51	5.64e-19	Schizophrenia;
CESC	cis	rs1799949	1.000	rs11653460	chr17:41331306	C/T	cg25072359	chr17:41440525	NA	0.5	6.77	0.38	8.41e-11	Menopause (age at onset);
CESC	cis	rs5769765	1.000	rs1033665	chr22:50252127	A/G	cg02269571	chr22:50332266	NA	-0.45	-6.04	-0.35	5.22e-9	Schizophrenia;
CESC	cis	rs854765	0.647	rs6826	chr17:18011140	C/T	cg04398451	chr17:18023971	MYO15A	-0.8	-11.92	-0.59	1.64e-26	Total body bone mineral density;
CESC	cis	rs76533333	0.646	rs71446623	chr13:113374732	C/T	cg08557188	chr13:113420371	ATP11A	-0.72	-5.04	-0.3	8.54e-7	Red cell distribution width;
CESC	cis	rs10979	0.931	rs12191837	chr6:143898200	T/G	cg25407410	chr6:143891975	LOC285740	-0.61	-9.19	-0.49	1.17e-17	Hypospadias;
CESC	cis	rs763014	0.593	rs28455838	chr16:681966	T/C	cg00908189	chr16:619842	PIGQ	0.61	8.5	0.46	1.37e-15	Height;
CESC	cis	rs72829446	0.556	rs10048219	chr17:7403792	C/T	cg02795151	chr17:7402630	POLR2A	0.6	5.86	0.34	1.39e-8	Androgen levels;
CESC	cis	rs5743618	0.537	rs10019951	chr4:38765584	A/G	cg02016764	chr4:38805732	TLR1	-0.34	-5.21	-0.3	3.84e-7	Asthma;Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs9486719	1.000	rs11153058	chr6:97012746	C/T	cg18709589	chr6:96969512	KIAA0776	-0.52	-5.69	-0.33	3.43e-8	Migraine;Coronary artery disease;
CESC	cis	rs10504229	0.679	rs11781858	chr8:58038406	C/T	cg24829409	chr8:58192753	C8orf71	-0.68	-7.41	-0.41	1.67e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs739401	0.611	rs391188	chr11:3047634	G/A	cg25174290	chr11:3078921	CARS	0.55	7.9	0.44	7.59e-14	Longevity;
CESC	cis	rs4689592	0.554	rs66925245	chr4:7071999	C/T	cg06697600	chr4:7070879	GRPEL1	0.51	6.49	0.37	4.15e-10	Monocyte percentage of white cells;
CESC	cis	rs863345	0.604	rs6663277	chr1:158495001	A/T	cg12129480	chr1:158549410	OR10X1	-0.35	-6.86	-0.39	4.75e-11	Pneumococcal bacteremia;
CESC	cis	rs1642645	0.831	rs7541929	chr1:42479393	G/A	cg16685388	chr1:42384056	HIVEP3	0.38	5.68	0.33	3.57e-8	Left ventricular obstructive tract defect (maternal effect);
CESC	cis	rs2243480	1.000	rs2460422	chr7:65601505	C/T	cg12463550	chr7:65579703	CRCP	0.74	5.75	0.33	2.4e-8	Diabetic kidney disease;
CESC	cis	rs12477438	0.520	rs2632283	chr2:99776000	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.77	12.84	0.62	1.16e-29	Chronic sinus infection;
CESC	cis	rs35306767	0.951	rs11253530	chr10:993729	T/C	cg25019033	chr10:957182	NA	-0.61	-6.8	-0.39	6.93e-11	Eosinophil percentage of granulocytes;
CESC	cis	rs4665809	0.590	rs36064164	chr2:26502768	C/T	cg04944784	chr2:26401820	FAM59B	0.95	9.94	0.52	5.28e-20	Gut microbiome composition (summer);
CESC	cis	rs11250464	0.755	rs11250468	chr10:1410060	A/G	cg26394196	chr10:1453818	ADARB2	-0.42	-5.66	-0.33	3.91e-8	Radiation response;
CESC	cis	rs9399135	0.967	rs7763836	chr6:135362378	T/C	cg24558204	chr6:135376177	HBS1L	0.5	6.88	0.39	4.35e-11	Red blood cell count;
CESC	trans	rs9858542	0.953	rs11922013	chr3:49458355	G/C	cg21659725	chr3:3221576	CRBN	-0.55	-6.52	-0.37	3.63e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs6598955	0.724	rs6656716	chr1:26563105	G/A	cg00852783	chr1:26633632	UBXN11	0.44	6.48	0.37	4.56e-10	Obesity-related traits;
CESC	cis	rs11078597	0.767	rs874424	chr17:1640034	G/A	cg18436246	chr17:1640651	WDR81	0.62	7.54	0.42	7.44e-13	Serum albumin level;
CESC	cis	rs7659604	0.518	rs17452156	chr4:122733623	T/C	cg06713675	chr4:122721982	EXOSC9	-0.51	-6.9	-0.39	3.9e-11	Type 2 diabetes;
CESC	cis	rs12887734	0.546	rs12885509	chr14:104273325	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.45	-5.69	-0.33	3.3e-8	Schizophrenia;Autism spectrum disorder or schizophrenia;
CESC	cis	rs1122900	1.000	rs1122900	chr5:36689181	A/C	cg24186104	chr5:36689192	NA	-0.45	-6.88	-0.39	4.29e-11	Aggressive periodontitis;
CESC	cis	rs977987	0.806	rs2161684	chr16:75479153	T/C	cg03315344	chr16:75512273	CHST6	0.43	6.15	0.35	2.85e-9	Dupuytren's disease;
CESC	cis	rs1005277	0.579	rs2474574	chr10:38387295	C/T	cg00409905	chr10:38381863	ZNF37A	-0.47	-6.3	-0.36	1.23e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs1799949	1.000	rs16941	chr17:41244435	T/C	cg23758822	chr17:41437982	NA	1.01	15.28	0.68	3.1e-38	Menopause (age at onset);
CESC	cis	rs798554	0.679	rs2644300	chr7:2883071	G/A	cg13628971	chr7:2884303	GNA12	0.64	9.03	0.49	3.6e-17	Height;
CESC	cis	rs72945132	0.882	rs66989619	chr11:70202127	G/C	cg14191688	chr11:70257035	CTTN	0.41	5.12	0.3	6.02e-7	Coronary artery disease;
CESC	cis	rs2070677	1.000	rs1410897	chr10:135349537	G/A	cg20169779	chr10:135381914	SYCE1	0.7	8.34	0.46	4.08e-15	Gout;
CESC	cis	rs4925386	0.959	rs4925385	chr20:60920624	A/G	cg24112000	chr20:60950667	NA	0.48	7.14	0.4	8.98e-12	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs909674	0.690	rs5750825	chr22:39831278	A/G	cg01416388	chr22:39784598	NA	-0.58	-7.35	-0.41	2.51e-12	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs1862618	0.715	rs6866779	chr5:56090000	G/A	cg03609598	chr5:56110824	MAP3K1	-0.51	-5.31	-0.31	2.33e-7	Initial pursuit acceleration;
CESC	cis	rs698833	0.926	rs1067339	chr2:44624448	T/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	6.51	0.37	3.71e-10	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03047724	chr7:139477895	TBXAS1;HIPK2	0.58	6.56	0.37	2.81e-10	Gut microbiome composition (summer);
CESC	trans	rs78579285	0.545	rs79311053	chr16:88785206	C/T	cg15076811	chr1:11001038	NA	0.72	6.2	0.36	2.13e-9	Joint mobility (Beighton score);
CESC	cis	rs12765878	0.967	rs10883948	chr10:105667552	G/T	cg24587175	chr10:105670608	OBFC1	0.33	5.36	0.31	1.84e-7	Coronary artery disease;
CESC	cis	rs870825	0.616	rs745656	chr4:185637523	C/T	cg04058563	chr4:185651563	MLF1IP	0.62	6.86	0.39	4.91e-11	Blood protein levels;
CESC	cis	rs2479106	0.963	rs1778900	chr9:126549420	T/G	cg16191174	chr9:126692580	DENND1A	0.51	6.95	0.39	2.83e-11	Polycystic ovary syndrome;
CESC	cis	rs1969363	0.509	rs8189633	chr12:38065155	C/G	cg26384229	chr12:38710491	ALG10B	0.74	10.7	0.55	1.96e-22	Morning vs. evening chronotype;
CESC	cis	rs2836974	0.965	rs2836965	chr21:40633631	C/G	cg11890956	chr21:40555474	PSMG1	-1.16	-20.43	-0.78	2.39e-56	Cognitive function;
CESC	trans	rs3780486	0.846	rs7036812	chr9:33143822	T/C	cg20290983	chr6:43655470	MRPS18A	0.97	17.46	0.73	5.92e-46	IgG glycosylation;
CESC	cis	rs11190604	1.000	rs1080698	chr10:102295114	G/T	cg07080220	chr10:102295463	HIF1AN	0.67	6.18	0.36	2.38e-9	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs9443645	0.901	rs2050663	chr6:79753394	T/C	cg05283184	chr6:79620031	NA	-0.42	-6.48	-0.37	4.35e-10	Intelligence (multi-trait analysis);
CESC	cis	rs2836974	0.897	rs13339986	chr21:40605982	T/C	cg27266027	chr21:40555129	PSMG1	0.47	5.42	0.32	1.32e-7	Cognitive function;
CESC	cis	rs8114671	0.836	rs6058154	chr20:33585834	C/T	cg06115741	chr20:33292138	TP53INP2	-0.48	-5.8	-0.34	1.93e-8	Height;
CESC	cis	rs9287719	0.935	rs10803723	chr2:10722877	C/T	cg00105475	chr2:10696890	NA	0.39	5.69	0.33	3.35e-8	Prostate cancer;
CESC	cis	rs35146811	0.844	rs4424195	chr7:99642745	A/G	cg22906224	chr7:99728672	NA	0.48	5.72	0.33	2.82e-8	Coronary artery disease;
CESC	cis	rs2839186	0.872	rs13052233	chr21:47707284	G/T	cg10351095	chr21:47802916	PCNT	-0.51	-6.9	-0.39	3.72e-11	Testicular germ cell tumor;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg17282910	chr5:89825494	LYSMD3	0.53	7.34	0.41	2.57e-12	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs7727544	0.735	rs274559	chr5:131720070	A/G	cg07395648	chr5:131743802	NA	0.47	6.27	0.36	1.42e-9	Blood metabolite levels;
CESC	cis	rs798554	0.644	rs7783400	chr7:2894434	A/C	cg13628971	chr7:2884303	GNA12	-0.6	-7.48	-0.42	1.11e-12	Height;
CESC	cis	rs7666738	0.830	rs1593572	chr4:98979322	A/G	cg03467027	chr4:99064603	C4orf37	-0.43	-5.32	-0.31	2.23e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1008375	0.618	rs13129002	chr4:17567513	A/G	cg27347728	chr4:17578864	LAP3	0.49	5.88	0.34	1.23e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs4665809	1.000	rs6720314	chr2:26334852	G/A	cg08470875	chr2:26401718	FAM59B	-0.62	-6.69	-0.38	1.35e-10	Gut microbiome composition (summer);
CESC	cis	rs7520050	0.966	rs12405451	chr1:46384326	T/A	cg03146154	chr1:46216737	IPP	-0.47	-6.1	-0.35	3.67e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs8044995	0.563	rs56220628	chr16:68384837	G/A	cg26727032	chr16:67993705	SLC12A4	-0.5	-5.2	-0.3	4.07e-7	Schizophrenia;
CESC	cis	rs9300255	0.722	rs34997336	chr12:123829116	G/A	cg00376283	chr12:123451042	ABCB9	-0.58	-6.75	-0.38	9.12e-11	Neutrophil percentage of white cells;
CESC	cis	rs11958404	0.932	rs72816581	chr5:157432591	T/A	cg05962755	chr5:157440814	NA	0.62	6.56	0.37	2.74e-10	IgG glycosylation;
CESC	cis	rs6541297	0.703	rs2748115	chr1:230314291	A/G	cg20703242	chr1:230279135	GALNT2	-0.43	-5.6	-0.33	5.46e-8	Coronary artery disease;
CESC	cis	rs6088590	1.000	rs6087623	chr20:33317662	C/G	cg06115741	chr20:33292138	TP53INP2	0.58	7.24	0.41	4.8e-12	Coronary artery disease;
CESC	cis	rs35146811	0.807	rs10228764	chr7:99608029	A/G	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.46	5.71	0.33	3.04e-8	Coronary artery disease;
CESC	cis	rs7208859	0.623	rs76633166	chr17:29113365	C/T	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.79e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	trans	rs11098499	0.779	rs72918579	chr4:120333222	G/C	cg25214090	chr10:38739885	LOC399744	0.71	9.83	0.52	1.2e-19	Corneal astigmatism;
CESC	cis	rs7833790	0.676	rs7834555	chr8:82697625	A/G	cg17211192	chr8:82754475	SNX16	-0.58	-7.62	-0.42	4.64e-13	Diastolic blood pressure;
CESC	cis	rs9894429	0.634	rs9709130	chr17:79583948	C/T	cg21984481	chr17:79567631	NPLOC4	-0.35	-5.52	-0.32	8.26e-8	Eye color traits;
CESC	cis	rs2295499	1.000	rs2295499	chr4:2717690	A/G	cg08330972	chr4:2403930	ZFYVE28	0.34	5.66	0.33	4e-8	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
CESC	trans	rs116095464	0.558	rs55776650	chr5:273826	G/A	cg00938859	chr5:1591904	SDHAP3	0.64	6.95	0.39	2.88e-11	Breast cancer;
CESC	cis	rs4722166	0.630	rs1581497	chr7:22779503	C/A	cg13104385	chr7:22767384	IL6	0.48	6.43	0.37	5.96e-10	Lung cancer;
CESC	cis	rs7618501	0.633	rs2353579	chr3:50027774	C/T	cg24110177	chr3:50126178	RBM5	-0.53	-7.36	-0.41	2.33e-12	Intelligence (multi-trait analysis);
CESC	cis	rs11997175	0.625	rs11991490	chr8:33595407	T/C	ch.8.33884649F	chr8:33765107	NA	0.54	6.91	0.39	3.67e-11	Body mass index;
CESC	cis	rs1862618	0.802	rs832547	chr5:56183941	C/G	cg24531977	chr5:56204891	C5orf35	-0.87	-10.87	-0.56	5.43e-23	Initial pursuit acceleration;
CESC	cis	rs4523957	0.651	rs9895342	chr17:2081647	T/C	cg16513277	chr17:2031491	SMG6	-0.71	-10.17	-0.53	1.04e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs709400	1.000	rs861539	chr14:104165753	G/A	cg24130564	chr14:104152367	KLC1	-0.43	-5.41	-0.32	1.42e-7	Body mass index;
CESC	cis	rs3096299	0.591	rs748940	chr16:89440757	T/A	cg02187348	chr16:89574699	SPG7	0.54	7.03	0.4	1.72e-11	Multiple myeloma (IgH translocation);
CESC	cis	rs11078597	0.650	rs62090056	chr17:1645410	C/T	cg18436246	chr17:1640651	WDR81	0.62	7.53	0.42	7.83e-13	Serum albumin level;
CESC	cis	rs17253792	0.822	rs12100753	chr14:56042870	G/A	cg01858014	chr14:56050164	KTN1	-0.94	-7.69	-0.43	2.87e-13	Putamen volume;
CESC	cis	rs2304069	0.545	rs1864998	chr5:149389465	C/T	cg12661370	chr5:149340060	SLC26A2	0.47	6.27	0.36	1.49e-9	HIV-1 control;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14223017	chr19:2151266	AP3D1	0.57	6.75	0.38	9.08e-11	Gut microbiome composition (summer);
CESC	cis	rs7592578	1.000	rs7592578	chr2:191439591	T/G	cg10560079	chr2:191398806	TMEM194B	0.65	5.84	0.34	1.55e-8	Diastolic blood pressure;
CESC	cis	rs35306767	0.761	rs12771539	chr10:1050653	A/G	cg25019033	chr10:957182	NA	-0.56	-5.57	-0.32	6.34e-8	Eosinophil percentage of granulocytes;
CESC	cis	rs875971	0.755	rs76288834	chr7:66069802	G/A	cg18876405	chr7:65276391	NA	-0.54	-7.48	-0.42	1.09e-12	Aortic root size;
CESC	cis	rs62458065	0.568	rs62463963	chr7:32486691	C/T	cg20159608	chr7:32802032	NA	-0.53	-5.08	-0.3	7.29e-7	Metabolite levels (HVA/MHPG ratio);
CESC	cis	rs7617773	0.744	rs2125482	chr3:48323133	T/G	cg11946769	chr3:48343235	NME6	0.82	10.95	0.56	2.9e-23	Coronary artery disease;
CESC	cis	rs4974559	0.947	rs10000797	chr4:1345647	G/A	cg02980000	chr4:1222292	CTBP1	0.7	6.48	0.37	4.4e-10	Systolic blood pressure;
CESC	cis	rs854765	0.547	rs9913277	chr17:17919749	G/T	cg04398451	chr17:18023971	MYO15A	-0.71	-10.55	-0.54	5.77e-22	Total body bone mineral density;
CESC	cis	rs16854884	0.683	rs2053211	chr3:143774592	C/T	cg06585982	chr3:143692056	C3orf58	-0.51	-6.49	-0.37	4.21e-10	Economic and political preferences (feminism/equality);
CESC	cis	rs208520	0.954	rs1468153	chr6:67009054	A/C	cg07460842	chr6:66804631	NA	0.75	8.0	0.44	3.85e-14	Exhaled nitric oxide output;
CESC	cis	rs858239	0.669	rs6461687	chr7:23116580	A/G	cg27449745	chr7:23145252	KLHL7	-0.45	-5.82	-0.34	1.73e-8	Cerebrospinal fluid biomarker levels;
CESC	cis	rs2742234	0.541	rs7096500	chr10:43712095	C/T	cg15436174	chr10:43711423	RASGEF1A	0.47	5.51	0.32	8.67e-8	Hirschsprung disease;
CESC	trans	rs4904167	0.805	rs11159637	chr14:84682116	G/C	cg06870609	chr15:89787223	FANCI	0.46	6.06	0.35	4.73e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs863345	0.967	rs10489834	chr1:158521034	G/A	cg12129480	chr1:158549410	OR10X1	-0.33	-6.51	-0.37	3.66e-10	Pneumococcal bacteremia;
CESC	cis	rs6831352	0.918	rs29001214	chr4:100051733	A/G	cg12011299	chr4:100065546	ADH4	-0.59	-6.52	-0.37	3.62e-10	Alcohol dependence;
CESC	cis	rs2235544	0.579	rs11804837	chr1:54482915	G/A	cg25741118	chr1:54482237	LDLRAD1	-0.23	-5.83	-0.34	1.58e-8	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
CESC	cis	rs2795502	0.766	rs947549	chr10:43265880	G/C	cg20628663	chr10:43360327	NA	-0.7	-7.56	-0.42	6.52e-13	Blood protein levels;
CESC	trans	rs7839040	0.698	rs13268071	chr8:82930251	G/A	cg14472086	chr9:107730925	NA	-0.48	-6.41	-0.37	6.53e-10	Response to methotrexate in juvenile idiopathic arthritis;
CESC	cis	rs881375	0.678	rs7031752	chr9:123663482	G/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.51	7.56	0.42	6.71e-13	Rheumatoid arthritis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24046888	chr2:46526785	EPAS1	-0.54	-6.62	-0.38	2e-10	Gut microbiome composition (summer);
CESC	cis	rs597539	0.652	rs646586	chr11:68681653	C/T	cg18350739	chr11:68623251	NA	0.44	6.94	0.39	3.07e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg02066925	chr22:35936722	RASD2	-0.45	-6.05	-0.35	4.94e-9	Gut microbiota (bacterial taxa);
CESC	trans	rs2975734	0.709	rs4841298	chr8:10111637	G/A	cg15556689	chr8:8085844	FLJ10661	-0.6	-6.82	-0.39	6.15e-11	Morning vs. evening chronotype;Chronotype;
CESC	cis	rs116095464	0.558	rs112343653	chr5:257174	G/A	cg22857025	chr5:266934	NA	-1.29	-18.21	-0.75	1.29e-48	Breast cancer;
CESC	cis	rs4820539	0.966	rs2157709	chr22:23457420	T/C	cg14186256	chr22:23484241	RTDR1	0.82	14.81	0.67	1.47e-36	Bone mineral density;
CESC	cis	rs9910055	1.000	rs2071167	chr17:42287519	A/G	cg19774624	chr17:42201019	HDAC5	0.65	8.44	0.46	2.04e-15	Total body bone mineral density;
CESC	cis	rs2477686	0.526	rs1998759	chr1:2397174	C/T	cg02275930	chr1:2372054	NA	-0.5	-8.04	-0.44	3.06e-14	Non-obstructive azoospermia;
CESC	trans	rs875971	0.965	rs6971509	chr7:65714970	G/T	cg26939375	chr7:64535504	NA	-0.46	-6.18	-0.35	2.39e-9	Aortic root size;
CESC	cis	rs6089829	0.962	rs9680064	chr20:61666168	G/A	cg03213289	chr20:61660250	NA	0.39	6.16	0.35	2.7e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs736408	0.609	rs2336545	chr3:52787603	C/T	cg05564831	chr3:52568323	NT5DC2	-0.45	-7.02	-0.4	1.88e-11	Bipolar disorder;
CESC	trans	rs11098499	0.863	rs36040693	chr4:120477616	A/G	cg25214090	chr10:38739885	LOC399744	0.66	8.96	0.48	5.92e-17	Corneal astigmatism;
CESC	cis	rs9733	0.596	rs12086630	chr1:150650955	T/C	cg09365446	chr1:150670422	GOLPH3L	0.42	5.9	0.34	1.09e-8	Tonsillectomy;
CESC	cis	rs6570726	0.755	rs2092296	chr6:145893684	A/C	cg23711669	chr6:146136114	FBXO30	0.97	14.77	0.67	2.05e-36	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9287719	0.781	rs6714413	chr2:10758859	C/T	cg02196655	chr2:10830764	NOL10	-0.36	-5.59	-0.32	5.58e-8	Prostate cancer;
CESC	cis	rs11098499	0.863	rs3775847	chr4:120447642	A/C	cg24375607	chr4:120327624	NA	0.43	5.22	0.31	3.68e-7	Corneal astigmatism;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg23117447	chr6:34394069	RPS10	-0.52	-6.67	-0.38	1.48e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs7216064	0.953	rs62086043	chr17:65968003	A/G	cg07042672	chr17:66097459	LOC651250	-0.59	-6.53	-0.37	3.31e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs7917772	0.503	rs11191325	chr10:104302933	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.53	7.33	0.41	2.81e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg03634887	chr16:66730948	CMTM4	-0.43	-6.26	-0.36	1.5e-9	Gambling;
CESC	cis	rs1023500	0.505	rs134888	chr22:42674281	C/T	cg05082376	chr22:42548792	NA	-0.38	-5.59	-0.32	5.66e-8	Schizophrenia;
CESC	cis	rs7542091	0.635	rs985431	chr1:210043948	A/T	cg22029157	chr1:209979665	IRF6	0.5	7.98	0.44	4.32e-14	Monobrow;
CESC	cis	rs9325144	0.647	rs7487395	chr12:38865660	C/A	cg26384229	chr12:38710491	ALG10B	-0.56	-7.89	-0.44	8.02e-14	Morning vs. evening chronotype;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg07254608	chr8:41997973	NA	-0.41	-6.0	-0.35	6.4e-9	Gambling;
CESC	cis	rs3785574	0.962	rs2665835	chr17:61903258	C/T	cg07677032	chr17:61819896	STRADA	0.42	5.33	0.31	2.08e-7	Height;
CESC	cis	rs887829	0.569	rs4124874	chr2:234665659	T/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.48	-6.19	-0.36	2.27e-9	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CESC	cis	rs287982	1.000	rs56154233	chr2:9969227	C/T	cg10881225	chr2:9984929	TAF1B	0.39	5.06	0.3	7.7e-7	Nonsyndromic cleft lip with cleft palate;
CESC	cis	rs6456156	0.586	rs1407315	chr6:167468659	A/G	cg07741184	chr6:167504864	NA	0.36	6.17	0.35	2.48e-9	Primary biliary cholangitis;
CESC	cis	rs7811142	0.830	rs76798830	chr7:99952828	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.09	10.22	0.53	6.88e-21	Platelet count;
CESC	cis	rs11969893	0.850	rs9386260	chr6:101329428	G/A	cg12253828	chr6:101329408	ASCC3	1.11	9.31	0.5	5.04e-18	Economic and political preferences (immigration/crime);
CESC	cis	rs709400	0.930	rs28513222	chr14:104028069	A/T	cg12935359	chr14:103987150	CKB	-0.51	-6.56	-0.37	2.78e-10	Body mass index;
CESC	cis	rs1322639	1.000	rs1322639	chr6:169587103	G/A	cg04662567	chr6:169592167	NA	0.52	6.9	0.39	3.85e-11	Pulse pressure;
CESC	cis	rs7666738	0.830	rs28769113	chr4:98950371	T/G	cg03676636	chr4:99064102	C4orf37	0.33	5.09	0.3	6.71e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg13941441	chr2:190649374	PMS1;ORMDL1	0.44	6.06	0.35	4.54e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs916888	0.610	rs199453	chr17:44800946	C/T	cg22968622	chr17:43663579	NA	0.77	10.56	0.54	5.65e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs4523957	0.583	rs2760737	chr17:2024647	C/T	cg16513277	chr17:2031491	SMG6	-0.71	-10.08	-0.53	1.96e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs1799949	1.000	rs12944597	chr17:41187684	A/C	cg05368731	chr17:41323189	NBR1	0.77	10.06	0.53	2.31e-20	Menopause (age at onset);
CESC	cis	rs875971	0.929	rs6970860	chr7:65976634	A/G	cg12463550	chr7:65579703	CRCP	0.56	7.07	0.4	1.39e-11	Aortic root size;
CESC	cis	rs116095464	0.614	rs62344339	chr5:252995	T/G	cg20965017	chr5:231967	SDHA	-0.47	-5.22	-0.31	3.61e-7	Breast cancer;
CESC	cis	rs561341	0.830	rs7218801	chr17:30217778	A/G	cg12193833	chr17:30244370	NA	0.53	5.42	0.32	1.32e-7	Hip circumference adjusted for BMI;
CESC	cis	rs796364	0.901	rs35572201	chr2:201035093	T/C	cg23649088	chr2:200775458	C2orf69	-0.57	-5.62	-0.33	4.88e-8	Schizophrenia;
CESC	cis	rs2836950	0.565	rs2836945	chr21:40596757	C/T	cg11890956	chr21:40555474	PSMG1	-0.62	-8.42	-0.46	2.33e-15	Menarche (age at onset);
CESC	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg26516362	chr5:178986906	RUFY1	-0.48	-7.91	-0.44	6.8e-14	Lung cancer;
CESC	cis	rs2304069	0.954	rs1469691	chr5:149386716	G/A	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.91	11.66	0.58	1.21e-25	HIV-1 control;
CESC	cis	rs2708240	0.905	rs2080154	chr7:147571529	T/C	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.34	-5.54	-0.32	7.3900000000000007e-08	QT interval (drug interaction);
CESC	cis	rs7811142	1.000	rs67239991	chr7:100046504	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.04	11.76	0.59	5.58e-26	Platelet count;
CESC	cis	rs1865721	1.000	rs8096298	chr18:73187608	C/T	cg26385618	chr18:73139727	C18orf62	-0.51	-7.6	-0.42	5.14e-13	Intelligence;
CESC	cis	rs447	1.000	rs10261415	chr7:83760881	G/T	cg22846510	chr7:83753280	SEMA3A	-0.47	-5.87	-0.34	1.32e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	trans	rs747782	0.528	rs10838881	chr11:48387275	T/C	cg15704280	chr7:45808275	SEPT13	0.68	6.21	0.36	2.09e-9	Intraocular pressure;
CESC	cis	rs17376456	0.877	rs17083455	chr5:93446380	A/C	cg25358565	chr5:93447407	FAM172A	1.12	11.84	0.59	3.05e-26	Diabetic retinopathy;
CESC	cis	rs7937682	0.814	rs1784788	chr11:111486136	T/G	cg09085632	chr11:111637200	PPP2R1B	-0.94	-14.43	-0.66	3.27e-35	Primary sclerosing cholangitis;
CESC	cis	rs875971	1.000	rs2420591	chr7:65912381	T/C	cg12463550	chr7:65579703	CRCP	0.56	7.06	0.4	1.44e-11	Aortic root size;
CESC	cis	rs9910055	0.593	rs58392387	chr17:42297889	A/G	cg19774624	chr17:42201019	HDAC5	-0.46	-5.9	-0.34	1.08e-8	Total body bone mineral density;
CESC	cis	rs8031584	0.918	rs3817498	chr15:31268781	T/C	cg14829155	chr15:31115871	NA	-0.65	-8.53	-0.46	1.12e-15	Huntington's disease progression;
CESC	cis	rs875971	0.789	rs7808013	chr7:66071196	A/G	cg18252515	chr7:66147081	NA	0.47	6.17	0.35	2.57e-9	Aortic root size;
CESC	cis	rs12048904	0.619	rs12239082	chr1:101330077	G/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.89	-12.1	-0.6	3.95e-27	Multiple sclerosis;
CESC	cis	rs7267979	0.738	rs2892409	chr20:25638138	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.71	11.83	0.59	3.42e-26	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7412746	0.611	rs6660084	chr1:150748803	T/C	cg04414720	chr1:150670196	GOLPH3L	0.58	7.54	0.42	7.34e-13	Melanoma;
CESC	cis	rs4970988	0.556	rs2280078	chr1:150600181	C/T	cg18016565	chr1:150552671	MCL1	-0.34	-5.07	-0.3	7.65e-7	Urate levels;
CESC	trans	rs561341	0.660	rs7406043	chr17:30220152	C/G	cg27661571	chr11:113659931	NA	-0.6	-6.15	-0.35	2.83e-9	Hip circumference adjusted for BMI;
CESC	cis	rs847577	0.609	rs17435590	chr7:97784061	T/C	cg24562669	chr7:97807699	LMTK2	0.82	13.45	0.64	8.74e-32	Breast cancer;
CESC	cis	rs7833790	1.000	rs7834808	chr8:82704996	A/G	cg17211192	chr8:82754475	SNX16	-0.7	-8.35	-0.46	3.95e-15	Diastolic blood pressure;
CESC	cis	rs7714584	1.000	rs10051804	chr5:150226424	T/C	cg22134413	chr5:150180641	NA	0.52	5.64	0.33	4.31e-8	Crohn's disease;
CESC	cis	rs2070488	0.804	rs13092539	chr3:38458725	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.81	12.98	0.62	3.7e-30	Electrocardiographic conduction measures;
CESC	cis	rs1552244	0.744	rs6763366	chr3:10033544	T/C	cg08888203	chr3:10149979	C3orf24	0.48	6.06	0.35	4.71e-9	Alzheimer's disease;
CESC	cis	rs34779708	0.897	rs9665538	chr10:35461038	T/C	cg04310649	chr10:35416472	CREM	-0.53	-6.67	-0.38	1.48e-10	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs963731	0.649	rs6756184	chr2:39256877	G/A	cg04010122	chr2:39346883	SOS1	-0.75	-5.48	-0.32	9.69e-8	Corticobasal degeneration;
CESC	cis	rs11203032	0.831	rs11203011	chr10:90931178	A/C	cg16672925	chr10:90967113	CH25H	0.69	6.61	0.38	2.1e-10	Heart failure;
CESC	cis	rs4665809	1.000	rs11678157	chr2:26321526	T/C	cg27170947	chr2:26402098	FAM59B	-0.57	-6.76	-0.38	8.73e-11	Gut microbiome composition (summer);
CESC	cis	rs4664308	1.000	rs925410	chr2:160912652	C/T	cg03641300	chr2:160917029	PLA2R1	0.67	10.37	0.54	2.35e-21	Idiopathic membranous nephropathy;
CESC	cis	rs7786808	0.504	rs10949725	chr7:158196003	C/T	cg09998033	chr7:158218633	PTPRN2	0.36	5.62	0.33	4.93e-8	Obesity-related traits;
CESC	cis	rs2228479	0.717	rs17226274	chr16:89850170	C/T	cg00800038	chr16:89945340	TCF25	-0.89	-7.9	-0.44	7.67e-14	Skin colour saturation;
CESC	cis	rs1003719	0.680	rs2835621	chr21:38510616	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-8.46	-0.46	1.79e-15	Eye color traits;
CESC	cis	rs9583531	0.527	rs3818496	chr13:111358488	G/A	cg24331049	chr13:111365604	ING1	0.71	10.88	0.56	4.81e-23	Coronary artery disease;
CESC	cis	rs9486719	0.843	rs2472875	chr6:96844691	G/A	cg18709589	chr6:96969512	KIAA0776	0.55	5.64	0.33	4.26e-8	Migraine;Coronary artery disease;
CESC	cis	rs3824867	0.879	rs10769267	chr11:47460098	C/T	cg20307385	chr11:47447363	PSMC3	0.5	6.06	0.35	4.73e-9	Mean corpuscular hemoglobin;
CESC	cis	rs17401966	0.838	rs55676616	chr1:10290126	T/C	cg15208524	chr1:10270712	KIF1B	0.42	5.4	0.32	1.46e-7	Hepatocellular carcinoma;
CESC	cis	rs909674	0.818	rs5757678	chr22:39843409	A/G	cg02038168	chr22:39784481	NA	0.65	8.16	0.45	1.38e-14	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs7020830	0.571	rs3780335	chr9:37376587	A/G	cg14294708	chr9:37120828	ZCCHC7	-0.91	-10.3	-0.53	3.86e-21	Schizophrenia;
CESC	cis	rs787274	0.718	rs1711745	chr9:115452909	C/A	cg13803584	chr9:115635662	SNX30	0.54	5.17	0.3	4.67e-7	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs4665809	0.590	rs11897162	chr2:26503654	T/C	cg08470875	chr2:26401718	FAM59B	0.63	6.48	0.37	4.45e-10	Gut microbiome composition (summer);
CESC	cis	rs10540	1.000	rs61876342	chr11:496193	T/G	cg03576123	chr11:487126	PTDSS2	-1.12	-11.23	-0.57	3.5e-24	Body mass index;
CESC	trans	rs61931739	0.534	rs10844800	chr12:34230734	A/G	cg26384229	chr12:38710491	ALG10B	0.63	9.17	0.49	1.41e-17	Morning vs. evening chronotype;
CESC	cis	rs5753618	0.583	rs7293171	chr22:31802324	T/C	cg13145458	chr22:31556086	RNF185	-0.49	-5.56	-0.32	6.44e-8	Colorectal cancer;
CESC	cis	rs2637266	0.703	rs4376842	chr10:78456250	C/T	cg18941641	chr10:78392320	NA	0.41	7.42	0.41	1.55e-12	Pulmonary function;
CESC	trans	rs1814175	0.817	rs10769618	chr11:49822336	A/G	cg15704280	chr7:45808275	SEPT13	-1.03	-20.12	-0.78	2.71e-55	Height;
CESC	cis	rs11997175	0.603	rs716584	chr8:33779748	C/G	ch.8.33884649F	chr8:33765107	NA	0.5	6.09	0.35	4.02e-9	Body mass index;
CESC	cis	rs853679	0.517	rs1947862	chr6:28105196	C/T	cg22143856	chr6:28129313	ZNF389	0.51	6.49	0.37	4.19e-10	Depression;
CESC	cis	rs9388451	0.874	rs9398787	chr6:126090608	A/G	cg05901451	chr6:126070800	HEY2	-0.65	-9.31	-0.5	5.17e-18	Brugada syndrome;
CESC	cis	rs11587400	0.656	rs12738051	chr1:115096964	A/G	cg12756093	chr1:115239321	AMPD1	0.43	5.82	0.34	1.7e-8	Autism;
CESC	cis	rs11190604	1.000	rs2003284	chr10:102202338	A/G	cg07080220	chr10:102295463	HIF1AN	0.55	5.56	0.32	6.43e-8	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs6964587	0.934	rs7793861	chr7:91742728	C/G	cg17063962	chr7:91808500	NA	0.57	7.92	0.44	6.64e-14	Breast cancer;
CESC	cis	rs514406	0.763	rs6685599	chr1:53213172	G/A	cg08736216	chr1:53307985	ZYG11A	0.41	6.85	0.39	5.29e-11	Monocyte count;
CESC	trans	rs10500991	0.587	rs7934559	chr11:24884066	A/G	cg07129253	chr8:30890560	PURG;WRN	-0.49	-6.54	-0.37	3.2e-10	Iron status biomarkers;
CESC	cis	rs3916	0.955	rs34030695	chr12:121156496	G/A	cg21892295	chr12:121157589	UNC119B	-0.36	-5.26	-0.31	3.04e-7	Urinary metabolites (H-NMR features);
CESC	cis	rs3736485	0.844	rs12593979	chr15:51741579	A/G	cg08986416	chr15:51914746	DMXL2	0.4	5.1	0.3	6.45e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs7927592	0.956	rs11228256	chr11:68251460	G/A	cg20283391	chr11:68216788	NA	-0.51	-6.17	-0.35	2.55e-9	Total body bone mineral density;
CESC	cis	rs941873	0.868	rs7332	chr10:81114060	G/A	cg11057378	chr10:81107060	PPIF	0.36	5.84	0.34	1.55e-8	Height;
CESC	cis	rs10791097	0.967	rs4366492	chr11:130717256	T/C	cg12179176	chr11:130786555	SNX19	0.58	8.19	0.45	1.14e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs6754311	0.551	rs9287442	chr2:136522710	A/G	cg15123519	chr2:136567270	LCT	0.33	5.64	0.33	4.29e-8	Mosquito bite size;
CESC	cis	rs4889855	0.530	rs12603265	chr17:78618637	A/G	cg16591659	chr17:78472290	NA	-0.32	-5.16	-0.3	4.85e-7	Fractional excretion of uric acid;
CESC	cis	rs4253772	0.591	rs11703435	chr22:46685563	C/T	cg24881330	chr22:46731750	TRMU	0.75	5.43	0.32	1.25e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg18538332	chr22:24372958	LOC391322	-0.72	-10.75	-0.55	1.32e-22	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs10504229	1.000	rs115548028	chr8:58170672	T/C	cg05313129	chr8:58192883	C8orf71	-0.56	-6.43	-0.37	5.99e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs868036	0.958	rs11635424	chr15:68037578	C/T	cg08079166	chr15:68083412	MAP2K5	0.4	6.4	0.37	6.93e-10	Restless legs syndrome;
CESC	cis	rs7095944	0.644	rs965484	chr10:126453481	T/C	cg08799069	chr10:126477246	METTL10	-0.37	-5.28	-0.31	2.66e-7	Asthma;
CESC	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	21.45	0.8	7.14e-60	Prudent dietary pattern;
CESC	cis	rs17253792	0.822	rs76555508	chr14:56071868	A/G	cg01858014	chr14:56050164	KTN1	-0.85	-6.99	-0.39	2.22e-11	Putamen volume;
CESC	cis	rs7959452	0.562	rs10878975	chr12:69782044	G/C	cg14784868	chr12:69753453	YEATS4	0.84	13.21	0.63	6.15e-31	Blood protein levels;
CESC	cis	rs7017914	0.967	rs1348535	chr8:71662741	A/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.43	-5.41	-0.32	1.4e-7	Bone mineral density;
CESC	cis	rs911555	0.755	rs4143998	chr14:103955247	T/C	cg12935359	chr14:103987150	CKB	-0.57	-8.24	-0.45	7.75e-15	Intelligence (multi-trait analysis);
CESC	cis	rs875971	0.895	rs778700	chr7:65866450	C/T	cg11764359	chr7:65958608	NA	0.98	15.79	0.7	4.71e-40	Aortic root size;
CESC	cis	rs897984	0.572	rs4889526	chr16:31030344	C/A	cg00531865	chr16:30841666	NA	-0.4	-5.58	-0.32	5.95e-8	Dementia with Lewy bodies;
CESC	trans	rs208520	0.565	rs1385222	chr6:66753013	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.98	18.55	0.75	8.14e-50	Exhaled nitric oxide output;
CESC	cis	rs17362650	0.653	rs13001298	chr2:9550446	G/C	cg12832956	chr2:9616023	IAH1	-0.55	-6.33	-0.36	1.05e-9	Alcohol dependence (age at onset);
CESC	cis	rs1707322	0.506	rs2991983	chr1:46079391	T/C	cg03146154	chr1:46216737	IPP	-0.81	-11.23	-0.57	3.35e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs72781680	1.000	rs72796326	chr2:24137047	G/A	cg08917208	chr2:24149416	ATAD2B	0.93	8.42	0.46	2.35e-15	Lymphocyte counts;
CESC	trans	rs7943203	1.000	rs7952492	chr11:108296680	C/T	cg01416241	chr5:148737479	PCYOX1L	-0.48	-6.21	-0.36	2.08e-9	Red blood cell count;Mean corpuscular volume;
CESC	cis	rs4481887	0.790	rs4526648	chr1:248422503	A/T	cg00666640	chr1:248458726	OR2T12	-0.33	-5.54	-0.32	7.29e-8	Common traits (Other);
CESC	cis	rs9611565	0.527	rs2234053	chr22:41777315	G/T	cg06481639	chr22:41940642	POLR3H	-0.61	-6.49	-0.37	4.09e-10	Vitiligo;
CESC	cis	rs7000551	0.751	rs2449338	chr8:22369232	A/G	cg12081754	chr8:22256438	SLC39A14	0.42	5.51	0.32	8.44e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CESC	cis	rs1799949	0.965	rs35954893	chr17:41333786	A/G	cg23758822	chr17:41437982	NA	1.04	16.01	0.7	7.99e-41	Menopause (age at onset);
CESC	cis	rs2882667	0.858	rs11242444	chr5:138406379	T/A	cg04439458	chr5:138467593	SIL1	-0.37	-5.78	-0.33	2.13e-8	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs3857067	0.806	rs7678054	chr4:95093855	A/G	cg11021082	chr4:95130006	SMARCAD1	0.58	8.51	0.46	1.3e-15	QT interval;
CESC	cis	rs10206020	0.921	rs72776300	chr2:1571152	A/G	cg26248373	chr2:1572462	NA	-0.6	-6.98	-0.39	2.43e-11	IgG glycosylation;
CESC	cis	rs4253772	0.591	rs11705624	chr22:46685380	C/T	cg18190219	chr22:46762943	CELSR1	-0.59	-5.46	-0.32	1.09e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs6539267	0.741	rs10861572	chr12:106688576	A/G	cg02476566	chr12:106696527	TCP11L2	-0.57	-6.5	-0.37	4.06e-10	Tourette syndrome;
CESC	cis	rs2425143	0.908	rs58448091	chr20:34325470	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.6	5.3	0.31	2.46e-7	Blood protein levels;
CESC	cis	rs17253792	0.822	rs58589065	chr14:56152478	T/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.72	5.5	0.32	9.03e-8	Putamen volume;
CESC	cis	rs6089829	0.855	rs6090203	chr20:61663632	G/A	cg16240275	chr20:61666158	NCRNA00029	0.5	8.97	0.48	5.67e-17	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs2228479	0.867	rs11646448	chr16:89966357	A/T	cg14709524	chr16:89940631	TCF25	0.68	5.67	0.33	3.72e-8	Skin colour saturation;
CESC	cis	rs12681366	0.762	rs7824722	chr8:95350851	A/T	cg13257157	chr8:95487014	RAD54B	0.41	5.55	0.32	6.83e-8	Nonsyndromic cleft lip with cleft palate;
CESC	cis	rs12497850	0.864	rs4521268	chr3:49137904	G/T	cg02487422	chr3:49467188	NICN1	0.45	5.69	0.33	3.33e-8	Parkinson's disease;
CESC	cis	rs7412746	0.658	rs57818453	chr1:150763139	G/A	cg22823121	chr1:150693482	HORMAD1	0.46	6.4	0.37	7.08e-10	Melanoma;
CESC	cis	rs7255436	0.931	rs7249520	chr19:8446056	G/A	cg16745616	chr19:8428856	ANGPTL4	-0.37	-5.67	-0.33	3.75e-8	HDL cholesterol;
CESC	cis	rs7577696	0.512	rs9789593	chr2:32381110	T/G	cg02381751	chr2:32503542	YIPF4	-0.44	-5.12	-0.3	5.83e-7	Inflammatory biomarkers;
CESC	trans	rs7615952	0.512	rs2979334	chr3:125358824	G/A	cg07211511	chr3:129823064	LOC729375	-0.59	-7.28	-0.41	3.84e-12	Blood pressure (smoking interaction);
CESC	cis	rs959260	1.000	rs7221050	chr17:73393949	A/T	cg20590849	chr17:73267439	MIF4GD	-0.56	-6.59	-0.38	2.39e-10	Systemic lupus erythematosus;
CESC	cis	rs1580019	0.563	rs2392071	chr7:32572536	G/A	cg07520158	chr7:32535189	LSM5;AVL9	0.52	6.38	0.36	8.07e-10	Cognitive ability;
CESC	cis	rs55692411	0.537	rs35012435	chr3:50031840	C/T	cg24308560	chr3:49941425	MST1R	-0.53	-6.39	-0.37	7.35e-10	Intelligence (multi-trait analysis);
CESC	cis	rs7044106	0.762	rs7849566	chr9:123460769	A/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.65	8.79	0.47	1.99e-16	Hip circumference adjusted for BMI;
CESC	cis	rs1005277	0.522	rs7090858	chr10:38003670	A/C	cg00409905	chr10:38381863	ZNF37A	0.52	7.16	0.4	8.05e-12	Extrinsic epigenetic age acceleration;
CESC	cis	rs1003719	0.715	rs2835653	chr21:38558636	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.6	-8.13	-0.45	1.62e-14	Eye color traits;
CESC	cis	rs7666738	0.830	rs28867087	chr4:98880349	T/A	cg17366294	chr4:99064904	C4orf37	0.56	7.87	0.44	9.05e-14	Colonoscopy-negative controls vs population controls;
CESC	cis	rs8028182	0.501	rs7166281	chr15:75928192	G/T	cg20655648	chr15:75932815	IMP3	-0.53	-6.63	-0.38	1.88e-10	Sudden cardiac arrest;
CESC	cis	rs2576037	0.623	rs2576042	chr18:44577461	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.45	6.04	0.35	5.28e-9	Personality dimensions;
CESC	cis	rs13256369	0.802	rs1060106	chr8:8561452	A/G	cg18904891	chr8:8559673	CLDN23	0.7	7.82	0.43	1.26e-13	Obesity-related traits;
CESC	cis	rs7666738	0.830	rs13110903	chr4:98946373	A/G	cg03676636	chr4:99064102	C4orf37	0.34	5.11	0.3	6.15e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1801251	1.000	rs2675971	chr2:233726154	A/G	cg25237894	chr2:233734115	C2orf82	-0.48	-8.13	-0.45	1.61e-14	Coronary artery disease;
CESC	cis	rs7647973	1.000	rs9862534	chr3:49598064	A/G	cg06212747	chr3:49208901	KLHDC8B	0.61	7.98	0.44	4.36e-14	Menarche (age at onset);
CESC	cis	rs67311347	0.544	rs35112505	chr3:40337075	A/G	cg09455208	chr3:40491958	NA	0.37	6.51	0.37	3.82e-10	Renal cell carcinoma;
CESC	cis	rs25645	0.800	rs34003767	chr17:38194296	A/G	cg17344932	chr17:38183730	MED24;SNORD124	0.54	7.42	0.41	1.61e-12	Myeloid white cell count;
CESC	cis	rs7587476	0.862	rs13001462	chr2:215678346	G/A	cg04004882	chr2:215674386	BARD1	0.54	6.05	0.35	4.81e-9	Neuroblastoma;
CESC	cis	rs344364	0.511	rs1657134	chr16:1953127	A/G	cg26617929	chr16:1858877	NA	-0.5	-5.24	-0.31	3.25e-7	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs2032447	0.530	rs9356996	chr6:26008487	C/A	cg18357526	chr6:26021779	HIST1H4A	0.44	6.23	0.36	1.78e-9	Intelligence (multi-trait analysis);
CESC	cis	rs1801251	0.963	rs35395584	chr2:233573698	G/C	cg08000102	chr2:233561755	GIGYF2	0.68	9.19	0.49	1.17e-17	Coronary artery disease;
CESC	cis	rs10979	0.644	rs12527367	chr6:143918718	C/T	cg25407410	chr6:143891975	LOC285740	-0.43	-5.82	-0.34	1.67e-8	Hypospadias;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg18190534	chr8:142225894	SLC45A4	0.47	6.63	0.38	1.84e-10	Fibrinogen levels;
CESC	cis	rs1707322	0.506	rs2991983	chr1:46079391	T/C	cg05343316	chr1:45956843	TESK2	-0.53	-6.53	-0.37	3.25e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs3768617	0.754	rs6673768	chr1:182983396	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.65	8.95	0.48	6.53e-17	Fuchs's corneal dystrophy;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg22982014	chr19:39322497	ECH1	-0.41	-6.17	-0.35	2.48e-9	Gambling;
CESC	cis	rs2652822	0.933	rs7170846	chr15:63449543	A/C	cg02713581	chr15:63449717	RPS27L	0.58	7.59	0.42	5.62e-13	Metabolic traits;
CESC	cis	rs7666738	0.791	rs13127542	chr4:98949159	C/T	cg03467027	chr4:99064603	C4orf37	0.46	5.83	0.34	1.58e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs17376456	0.569	rs7701114	chr5:93096028	T/C	cg21475434	chr5:93447410	FAM172A	0.49	5.04	0.3	8.6e-7	Diabetic retinopathy;
CESC	cis	rs8103278	0.826	rs11669442	chr19:46374557	A/G	cg11657440	chr19:46296263	DMWD	-0.46	-5.74	-0.33	2.59e-8	Coronary artery disease;
CESC	cis	rs9911578	0.967	rs6416932	chr17:57148991	G/A	cg12560992	chr17:57184187	TRIM37	1.0	17.39	0.73	9.99e-46	Intelligence (multi-trait analysis);
CESC	cis	rs483180	0.855	rs562038	chr1:120254545	G/C	cg19096424	chr1:120255104	PHGDH	0.71	8.69	0.47	3.78e-16	Macular telangiectasia type 2;
CESC	cis	rs7666738	0.830	rs13144564	chr4:98939276	A/G	cg17366294	chr4:99064904	C4orf37	0.61	8.56	0.47	9.36e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2273669	0.667	rs11752532	chr6:109335969	C/G	cg05315195	chr6:109294784	ARMC2	-0.67	-6.32	-0.36	1.13e-9	Prostate cancer;
CESC	cis	rs1355223	0.902	rs61881050	chr11:34719749	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.46	-5.9	-0.34	1.09e-8	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs62005083	1.000	rs45538635	chr14:74485592	G/A	cg05179529	chr14:74551516	LIN52;ALDH6A1	0.69	5.12	0.3	6.01e-7	Mean corpuscular volume;
CESC	cis	rs9311474	0.607	rs34005367	chr3:52558904	A/T	cg18404041	chr3:52824283	ITIH1	-0.38	-6.43	-0.37	5.77e-10	Electroencephalogram traits;
CESC	cis	rs344364	0.511	rs1742467	chr16:1950187	G/T	cg26617929	chr16:1858877	NA	-0.49	-5.15	-0.3	5.09e-7	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs10751667	0.666	rs7103585	chr11:971166	T/C	cg20946044	chr11:1010712	AP2A2	-0.39	-5.4	-0.31	1.49e-7	Alzheimer's disease (late onset);
CESC	cis	rs1005277	0.579	rs176886	chr10:38403974	C/T	cg25517755	chr10:38738941	LOC399744	-0.46	-5.98	-0.34	7.15e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs6460942	0.597	rs17277369	chr7:12536192	A/G	cg06484146	chr7:12443880	VWDE	-0.73	-7.77	-0.43	1.68e-13	Coronary artery disease;
CESC	cis	rs14403	0.519	rs2994339	chr1:243641420	A/G	cg21452805	chr1:244014465	NA	0.5	5.44	0.32	1.24e-7	Schizophrenia;
CESC	cis	rs4665809	1.000	rs13030858	chr2:26315451	G/A	cg25036284	chr2:26402008	FAM59B	-0.61	-7.08	-0.4	1.31e-11	Gut microbiome composition (summer);
CESC	cis	rs2243480	1.000	rs55895244	chr7:65387678	C/G	cg18252515	chr7:66147081	NA	-1.0	-9.22	-0.49	9.27e-18	Diabetic kidney disease;
CESC	cis	rs2836950	0.565	rs2836931	chr21:40546569	T/G	cg11890956	chr21:40555474	PSMG1	-0.69	-9.97	-0.52	4.48e-20	Menarche (age at onset);
CESC	cis	rs6460942	0.545	rs17448114	chr7:12524458	G/C	cg02935154	chr7:12443704	VWDE	-0.55	-5.53	-0.32	7.71e-8	Coronary artery disease;
CESC	cis	rs6545883	0.929	rs12612982	chr2:61747355	G/A	cg15711740	chr2:61764176	XPO1	-0.41	-5.07	-0.3	7.32e-7	Tuberculosis;
CESC	cis	rs13191362	1.000	rs71567659	chr6:163001736	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.83	8.39	0.46	3.02e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg24704015	chr2:230931896	SLC16A14	-0.5	-6.59	-0.38	2.31e-10	Ulcerative colitis;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg04127825	chr1:167503222	NA	-0.44	-6.02	-0.35	5.77e-9	Height;
CESC	cis	rs6089584	0.853	rs1740367	chr20:60574834	C/T	cg06108461	chr20:60628389	TAF4	-0.79	-10.49	-0.54	9.03e-22	Body mass index;
CESC	cis	rs992157	0.798	rs2382819	chr2:219155909	G/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.66	-8.74	-0.47	2.72e-16	Colorectal cancer;
CESC	cis	rs793571	0.744	rs4775097	chr15:59140801	C/T	cg05156742	chr15:59063176	FAM63B	-0.56	-6.88	-0.39	4.2e-11	Schizophrenia;
CESC	cis	rs7589728	1.000	rs75309929	chr2:88524377	T/C	cg04511125	chr2:88470314	THNSL2	0.58	5.62	0.33	4.78e-8	Plasma clusterin levels;
CESC	cis	rs2274273	1.000	rs2147972	chr14:55598030	T/C	cg04306507	chr14:55594613	LGALS3	0.29	5.16	0.3	4.74e-7	Protein biomarker;
CESC	trans	rs11098499	0.955	rs13114751	chr4:120156617	G/A	cg25214090	chr10:38739885	LOC399744	0.64	8.57	0.47	8.82e-16	Corneal astigmatism;
CESC	cis	rs9611565	0.918	rs73176685	chr22:41781094	C/G	cg06634786	chr22:41940651	POLR3H	-0.62	-6.61	-0.38	2.15e-10	Vitiligo;
CESC	cis	rs7017914	0.967	rs1596566	chr8:71698576	A/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.42	-5.3	-0.31	2.38e-7	Bone mineral density;
CESC	cis	rs2243480	0.901	rs778730	chr7:65823325	T/A	cg12463550	chr7:65579703	CRCP	0.68	5.26	0.31	2.94e-7	Diabetic kidney disease;
CESC	cis	rs7640424	0.652	rs12152307	chr3:107861766	T/C	cg09227934	chr3:107805635	CD47	-0.47	-6.13	-0.35	3.24e-9	Body mass index;
CESC	cis	rs9916302	0.904	rs12452880	chr17:37591149	G/C	cg07936489	chr17:37558343	FBXL20	-0.81	-11.75	-0.59	6.21e-26	Glomerular filtration rate (creatinine);
CESC	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.51	6.31	0.36	1.19e-9	Prudent dietary pattern;
CESC	cis	rs12699921	0.526	rs12699916	chr7:17908546	C/T	cg00911873	chr7:18067463	PRPS1L1	0.39	5.71	0.33	3.01e-8	Fibrinogen levels;
CESC	trans	rs7582180	0.700	rs1437971	chr2:100986964	A/C	cg22900798	chr8:23315430	ENTPD4	0.63	6.33	0.36	1.02e-9	Intelligence (multi-trait analysis);
CESC	cis	rs12142240	0.698	rs55971480	chr1:46823206	G/T	cg10495392	chr1:46806563	NSUN4	0.58	6.32	0.36	1.09e-9	Menopause (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20589815	chr10:47656205	NA	0.53	6.03	0.35	5.51e-9	Gut microbiome composition (summer);
CESC	cis	rs9611565	0.592	rs9611612	chr22:41961189	T/C	cg03806693	chr22:41940476	POLR3H	-0.98	-12.2	-0.6	1.83e-27	Vitiligo;
CESC	cis	rs9300255	0.543	rs520088	chr12:123522150	C/G	cg05973401	chr12:123451056	ABCB9	0.58	6.59	0.38	2.36e-10	Neutrophil percentage of white cells;
CESC	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg26338869	chr17:61819248	STRADA	0.68	8.87	0.48	1.08e-16	Prudent dietary pattern;
CESC	cis	rs12142240	0.698	rs17357621	chr1:46807697	C/T	cg00530320	chr1:46809349	NSUN4	0.6	7.98	0.44	4.48e-14	Menopause (age at onset);
CESC	trans	rs4129059	0.765	rs72759626	chr1:214689619	T/C	cg08821431	chr12:34491090	NA	0.54	6.33	0.36	1.04e-9	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs9311474	1.000	rs7614727	chr3:52295895	C/T	cg18337363	chr3:52569053	NT5DC2	0.3	5.79	0.34	1.99e-8	Electroencephalogram traits;
CESC	cis	rs933688	1.000	rs10073935	chr5:90742188	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.11	14.08	0.65	5.45e-34	Smoking behavior;
CESC	cis	rs7336332	0.598	rs76249173	chr13:28010445	A/G	cg01674679	chr13:27998804	GTF3A	-0.58	-5.34	-0.31	2.04e-7	Weight;
CESC	cis	rs9908102	0.740	rs59763012	chr17:12904636	C/T	cg26162695	chr17:12921313	ELAC2	0.5	5.54	0.32	7.32e-8	Schizophrenia;
CESC	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg11494091	chr17:61959527	GH2	0.73	12.52	0.61	1.41e-28	Prudent dietary pattern;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg12446722	chr1:226374380	ACBD3	-0.46	-6.03	-0.35	5.37e-9	Fibrinogen levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14134153	chr5:172386668	RPL26L1;LOC100268168	-0.55	-6.29	-0.36	1.33e-9	Gut microbiome composition (summer);
CESC	cis	rs11785693	0.862	rs62491196	chr8:4995690	C/T	cg26367366	chr8:4980734	NA	0.83	7.83	0.43	1.16e-13	Neuroticism (multi-trait analysis);Neuroticism;
CESC	cis	rs2839186	0.588	rs7280110	chr21:47619039	G/A	cg10351095	chr21:47802916	PCNT	0.43	5.55	0.32	7.02e-8	Testicular germ cell tumor;
CESC	cis	rs113835537	0.935	rs57043177	chr11:66423147	A/G	cg24851651	chr11:66362959	CCS	0.63	5.68	0.33	3.48e-8	Airway imaging phenotypes;
CESC	cis	rs7520050	0.807	rs72688483	chr1:46149209	A/G	cg06784218	chr1:46089804	CCDC17	0.32	5.8	0.34	1.88e-8	Red blood cell count;Reticulocyte count;
CESC	cis	rs36096196	0.891	rs12081179	chr1:2251119	A/G	cg17974515	chr1:2252516	NA	0.45	7.49	0.42	1.04e-12	Coronary artery disease;
CESC	cis	rs2952156	1.000	rs1565923	chr17:37858678	A/G	cg00129232	chr17:37814104	STARD3	-0.68	-8.56	-0.47	9.14e-16	Asthma;
CESC	cis	rs941873	0.803	rs5015119	chr10:81101609	G/C	cg09469691	chr10:81107165	PPIF	0.57	7.75	0.43	1.96e-13	Height;
CESC	cis	rs9354308	0.899	rs2802057	chr6:66548093	A/C	cg07460842	chr6:66804631	NA	0.58	6.53	0.37	3.29e-10	Metabolite levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25833238	chr6:153304325	FBXO5	0.63	7.69	0.43	2.98e-13	Gut microbiome composition (summer);
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg08060248	chr16:84213494	TAF1C	0.41	6.02	0.35	5.79e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs453301	0.658	rs6983877	chr8:8904639	T/C	cg06636001	chr8:8085503	FLJ10661	-0.43	-5.3	-0.31	2.49e-7	Joint mobility (Beighton score);
CESC	cis	rs798554	0.757	rs2644312	chr7:2841164	G/A	cg19717773	chr7:2847554	GNA12	-0.57	-8.1	-0.45	2.06e-14	Height;
CESC	cis	rs9549367	0.713	rs56002882	chr13:113830694	T/C	cg00898013	chr13:113819073	PROZ	-0.53	-7.25	-0.41	4.68e-12	Platelet distribution width;
CESC	cis	rs61935443	1.000	rs4761691	chr12:95248171	C/G	cg21533806	chr12:95267307	NA	0.51	6.46	0.37	4.89e-10	Schizophrenia;
CESC	cis	rs7246865	0.510	rs6512161	chr19:17171582	A/G	cg16202187	chr19:17186497	HAUS8;MYO9B	0.48	6.28	0.36	1.38e-9	Reticulocyte fraction of red cells;
CESC	cis	rs524281	0.637	rs7126075	chr11:65940563	T/G	cg14036092	chr11:66035641	RAB1B	-0.56	-5.49	-0.32	9.43e-8	Electroencephalogram traits;
CESC	cis	rs713587	0.520	rs1530016	chr2:25305756	C/T	cg01884057	chr2:25150051	NA	-0.3	-5.15	-0.3	5.08e-7	Body mass index in non-asthmatics;
CESC	cis	rs1568889	0.667	rs7123947	chr11:28399908	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.66	8.14	0.45	1.59e-14	Bipolar disorder;
CESC	cis	rs7666738	0.678	rs7670805	chr4:99008763	A/G	cg17366294	chr4:99064904	C4orf37	0.6	8.61	0.47	6.47e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10504229	1.000	rs56344560	chr8:58180626	C/G	cg24829409	chr8:58192753	C8orf71	-0.7	-9.11	-0.49	2.02e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs7833986	0.501	rs2719259	chr8:56941630	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.59	7.4	0.41	1.78e-12	Height;
CESC	cis	rs2197308	0.740	rs11182251	chr12:37919611	C/T	cg26384229	chr12:38710491	ALG10B	-0.51	-7.23	-0.41	5.25e-12	Morning vs. evening chronotype;
CESC	cis	rs6088580	0.634	rs945673	chr20:32964265	C/A	cg06115741	chr20:33292138	TP53INP2	-0.46	-5.84	-0.34	1.49e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs6540556	0.723	rs1999826	chr1:209919275	C/T	cg05527609	chr1:210001259	C1orf107	-0.48	-5.79	-0.33	2.04e-8	Red blood cell count;
CESC	cis	rs1005277	0.541	rs2505193	chr10:38394638	G/C	cg25517755	chr10:38738941	LOC399744	-0.47	-6.04	-0.35	5.12e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs9911578	1.000	rs6503866	chr17:56619581	C/T	cg05425664	chr17:57184151	TRIM37	0.5	7.06	0.4	1.5e-11	Intelligence (multi-trait analysis);
CESC	cis	rs7647973	0.621	rs3774800	chr3:49334768	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.73	-10.22	-0.53	6.79e-21	Menarche (age at onset);
CESC	cis	rs11785400	0.793	rs4457308	chr8:143733922	G/A	cg24634471	chr8:143751801	JRK	0.47	6.03	0.35	5.44e-9	Schizophrenia;
CESC	cis	rs1879734	0.636	rs11206202	chr1:54174607	A/G	cg23596471	chr1:54105337	GLIS1	0.32	5.17	0.3	4.7e-7	Mitral valve prolapse;
CESC	cis	rs7666738	0.800	rs13107147	chr4:99028753	C/T	cg05340658	chr4:99064831	C4orf37	0.81	12.59	0.61	8.13e-29	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1670533	1.000	rs10026482	chr4:1051128	C/G	cg04106633	chr4:1044584	NA	0.4	5.09	0.3	6.77e-7	Recombination rate (females);
CESC	trans	rs35110281	0.805	rs2838317	chr21:44991791	A/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.51	6.89	0.39	4.12e-11	Mean corpuscular volume;
CESC	cis	rs16895831	0.531	rs12195803	chr6:42527571	G/A	cg10605015	chr6:42532144	UBR2	-0.52	-5.63	-0.33	4.51e-8	Granulocyte percentage of myeloid white cells;Neutrophil percentage of white cells;Eosinophil percentage of white cells;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Neutrophil count;Sum basophil neutrophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
CESC	cis	rs7847628	0.765	rs10985024	chr9:123516812	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.62	7.75	0.43	2.01e-13	Birth weight;
CESC	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.6	0.38	2.17e-10	Prudent dietary pattern;
CESC	trans	rs208520	0.526	rs4710310	chr6:66802808	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.11	-24.8	-0.84	4.86e-71	Exhaled nitric oxide output;
CESC	cis	rs1042058	0.565	rs2480297	chr10:30754512	A/G	cg18806716	chr10:30721971	MAP3K8	-0.53	-8.02	-0.44	3.51e-14	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg06812651	chr1:234746099	IRF2BP2	-0.53	-6.45	-0.37	5.23e-10	Ulcerative colitis;
CESC	cis	rs9790314	1.000	rs6794601	chr3:160946769	C/T	cg03342759	chr3:160939853	NMD3	-0.55	-7.52	-0.42	8.47e-13	Morning vs. evening chronotype;
CESC	cis	rs7666738	0.819	rs62318904	chr4:99036101	A/T	cg03467027	chr4:99064603	C4orf37	0.48	5.92	0.34	9.73e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9297145	0.678	rs62473048	chr7:98775511	T/C	cg05967295	chr7:98741636	SMURF1	0.85	8.9	0.48	8.82e-17	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
CESC	trans	rs877282	0.945	rs11253396	chr10:789754	C/T	cg22713356	chr15:30763199	NA	1.32	13.44	0.64	9.25e-32	Uric acid levels;
CESC	cis	rs7927771	0.524	rs10769299	chr11:47865160	G/T	cg18512352	chr11:47633146	NA	0.35	5.44	0.32	1.23e-7	Subjective well-being;
CESC	cis	rs7666738	0.830	rs11944035	chr4:98931618	C/T	cg03467027	chr4:99064603	C4orf37	0.46	5.6	0.33	5.39e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3087591	0.922	rs12950506	chr17:29598392	A/G	cg24425628	chr17:29625626	OMG;NF1	0.43	5.35	0.31	1.87e-7	Hip circumference;
CESC	cis	rs2235642	0.750	rs2755185	chr16:1645827	A/G	cg03715980	chr16:1756201	MAPK8IP3	0.4	5.24	0.31	3.33e-7	Coronary artery disease;
CESC	trans	rs7839040	0.698	rs13249724	chr8:82931502	A/G	cg14472086	chr9:107730925	NA	-0.48	-6.45	-0.37	5.18e-10	Response to methotrexate in juvenile idiopathic arthritis;
CESC	cis	rs11864453	0.647	rs3764311	chr16:72125617	C/G	cg16558253	chr16:72132732	DHX38	-0.55	-8.54	-0.46	1.08e-15	Fibrinogen levels;
CESC	cis	rs916888	0.531	rs183211	chr17:44788310	G/A	cg15921436	chr17:44337874	NA	0.43	5.3	0.31	2.38e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs4727027	0.933	rs4725800	chr7:148862516	C/G	cg23158103	chr7:148848205	ZNF398	-0.4	-6.32	-0.36	1.08e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs6032067	0.929	rs6017511	chr20:43833132	C/T	cg10761708	chr20:43804764	PI3	0.52	6.32	0.36	1.07e-9	Blood protein levels;
CESC	cis	rs10540	0.818	rs12806089	chr11:501468	G/A	cg03576123	chr11:487126	PTDSS2	-1.12	-11.21	-0.57	3.93e-24	Body mass index;
CESC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg23543263	chr13:22245177	FGF9	0.51	6.4	0.37	7.16e-10	Intelligence (multi-trait analysis);
CESC	cis	rs2836974	0.644	rs2836986	chr21:40702136	A/C	cg17971929	chr21:40555470	PSMG1	-0.86	-12.5	-0.61	1.7e-28	Cognitive function;
CESC	cis	rs9916302	0.653	rs11654954	chr17:37745979	C/T	cg00129232	chr17:37814104	STARD3	0.59	5.55	0.32	6.82e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs909002	1.000	rs909002	chr1:32139635	C/T	cg13919466	chr1:32135498	COL16A1	-0.51	-9.57	-0.51	7.94e-19	Intelligence (multi-trait analysis);
CESC	cis	rs36051895	0.664	rs10115172	chr9:5098549	C/T	cg02405213	chr9:5042618	JAK2	-0.51	-6.17	-0.35	2.61e-9	Pediatric autoimmune diseases;
CESC	cis	rs2637266	0.745	rs241	chr10:78444456	G/T	cg18941641	chr10:78392320	NA	0.44	7.95	0.44	5.38e-14	Pulmonary function;
CESC	cis	rs6430585	0.583	rs3769001	chr2:136626078	A/G	cg07169764	chr2:136633963	MCM6	1.29	19.86	0.77	2.13e-54	Corneal structure;
CESC	cis	rs7208859	0.673	rs216440	chr17:28928309	A/T	cg14008862	chr17:28927542	LRRC37B2	0.61	5.87	0.34	1.27e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs708547	0.836	rs1625691	chr4:57845740	T/C	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.58	-6.87	-0.39	4.63e-11	Response to bleomycin (chromatid breaks);
CESC	cis	rs9611565	0.559	rs5751160	chr22:42175695	A/G	cg17376030	chr22:41985996	PMM1	-0.79	-8.37	-0.46	3.44e-15	Vitiligo;
CESC	cis	rs9911578	0.933	rs74370218	chr17:57095212	C/T	cg12560992	chr17:57184187	TRIM37	-1.0	-17.63	-0.73	1.4300000000000001e-46	Intelligence (multi-trait analysis);
CESC	cis	rs1801251	0.711	rs2592117	chr2:233735693	C/T	cg08000102	chr2:233561755	GIGYF2	-0.58	-7.82	-0.43	1.22e-13	Coronary artery disease;
CESC	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg07677032	chr17:61819896	STRADA	0.45	6.01	0.35	6.14e-9	Prudent dietary pattern;
CESC	cis	rs854765	0.587	rs4077828	chr17:17833644	A/T	cg04398451	chr17:18023971	MYO15A	-0.67	-9.61	-0.51	6.01e-19	Total body bone mineral density;
CESC	cis	rs2228479	0.850	rs62052212	chr16:89981960	G/A	cg00800038	chr16:89945340	TCF25	-0.91	-7.41	-0.41	1.67e-12	Skin colour saturation;
CESC	cis	rs7259376	0.905	rs2082479	chr19:22539847	T/C	cg02657401	chr19:22469223	NA	-0.25	-5.08	-0.3	7.12e-7	Menopause (age at onset);
CESC	cis	rs3747547	0.892	rs11789441	chr9:37993303	G/T	cg13774184	chr9:37916125	SHB	-0.73	-6.3	-0.36	1.22e-9	Metabolite levels (Dihydroxy docosatrienoic acid);
CESC	cis	rs1799949	1.000	rs8176234	chr17:41219780	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.66	9.08	0.49	2.51e-17	Menopause (age at onset);
CESC	cis	rs7605827	0.930	rs6732252	chr2:15595473	T/C	cg19274914	chr2:15703543	NA	0.31	5.45	0.32	1.13e-7	Educational attainment (years of education);
CESC	cis	rs17253792	0.822	rs77182097	chr14:56136695	G/A	cg01858014	chr14:56050164	KTN1	-0.97	-7.54	-0.42	7.36e-13	Putamen volume;
CESC	cis	rs3947	1.000	rs1736085	chr8:11703659	T/C	cg00262122	chr8:11665843	FDFT1	-0.51	-5.04	-0.3	8.69e-7	Blood protein levels;
CESC	cis	rs11719291	0.584	rs13080725	chr3:49076092	G/A	cg00383909	chr3:49044727	WDR6	0.92	6.59	0.38	2.35e-10	Cognitive function;
CESC	cis	rs1355223	0.902	rs1597962	chr11:34727172	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.48	-6.24	-0.36	1.68e-9	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs7071206	0.947	rs4979905	chr10:79416367	C/T	cg00983440	chr10:79422392	NA	-0.67	-8.2	-0.45	1.02e-14	Bone mineral density;
CESC	cis	rs11190604	1.000	rs2495755	chr10:102324649	A/C	cg07080220	chr10:102295463	HIF1AN	0.62	5.57	0.32	6.31e-8	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs7714584	1.000	rs11167515	chr5:150239471	G/T	cg22134413	chr5:150180641	NA	0.57	5.4	0.32	1.45e-7	Crohn's disease;
CESC	cis	rs17376456	0.825	rs13171131	chr5:93223028	C/T	cg21475434	chr5:93447410	FAM172A	0.83	7.21	0.41	5.8e-12	Diabetic retinopathy;
CESC	cis	rs711830	1.000	rs2249131	chr2:177032095	C/T	cg13092806	chr2:177043255	NA	0.87	11.79	0.59	4.66e-26	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
CESC	cis	rs7927771	1.000	rs11039412	chr11:47841581	G/A	cg18512352	chr11:47633146	NA	-0.6	-9.57	-0.51	8.16e-19	Subjective well-being;
CESC	cis	rs6502050	0.723	rs11650633	chr17:80083807	T/C	cg23985595	chr17:80112537	CCDC57	0.42	6.47	0.37	4.65e-10	Life satisfaction;
CESC	cis	rs9649213	0.531	rs35216698	chr7:97896175	C/T	cg21770322	chr7:97807741	LMTK2	0.58	8.49	0.46	1.53e-15	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs9611565	0.649	rs5758434	chr22:42116163	G/A	cg03806693	chr22:41940476	POLR3H	0.76	9.27	0.49	6.64e-18	Vitiligo;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17170446	chr11:16759907	C11orf58	-0.63	-7.36	-0.41	2.34e-12	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04266179	chr19:42746555	GSK3A	0.55	6.09	0.35	3.99e-9	Gut microbiome composition (summer);
CESC	cis	rs11645898	0.935	rs11640722	chr16:72172300	C/T	cg14768367	chr16:72042858	DHODH	-0.76	-6.49	-0.37	4.28e-10	Blood protein levels;
CESC	cis	rs2051211	0.947	rs73065216	chr3:38524194	G/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.66	-7.41	-0.41	1.65e-12	QRS duration;
CESC	cis	rs9831754	0.704	rs1512491	chr3:78470954	T/C	cg06138941	chr3:78371609	NA	0.4	5.17	0.3	4.63e-7	Calcium levels;
CESC	cis	rs2832077	0.527	rs1048546	chr21:30244877	G/T	cg08807101	chr21:30365312	RNF160	-0.51	-6.21	-0.36	2.04e-9	Cognitive test performance;
CESC	cis	rs503341	0.756	rs480874	chr11:63591965	A/T	cg04362095	chr11:63592001	C11orf84	-0.58	-8.42	-0.46	2.4e-15	Pulse pressure;
CESC	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.53	-7.07	-0.4	1.37e-11	Longevity;Endometriosis;
CESC	cis	rs2204008	0.529	rs1315350	chr12:38164282	C/A	cg26384229	chr12:38710491	ALG10B	-0.41	-5.66	-0.33	3.98e-8	Bladder cancer;
CESC	cis	rs11123694	1.000	rs11123694	chr2:109064563	C/T	cg20520273	chr2:109403139	CCDC138	-0.4	-5.09	-0.3	6.75e-7	Mean platelet volume;
CESC	cis	rs9814567	0.752	rs13075253	chr3:134329600	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.43	5.6	0.33	5.39e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs7301826	0.651	rs34749116	chr12:131280752	G/A	cg11011512	chr12:131303247	STX2	-0.44	-5.36	-0.31	1.81e-7	Plasma plasminogen activator levels;
CESC	cis	rs11078597	0.731	rs2070863	chr17:1648502	C/T	cg18436246	chr17:1640651	WDR81	0.62	7.5	0.42	9.49e-13	Serum albumin level;
CESC	cis	rs35110281	0.720	rs162400	chr21:44950305	A/C	cg01579765	chr21:45077557	HSF2BP	-0.54	-9.23	-0.49	8.75e-18	Mean corpuscular volume;
CESC	cis	rs6942756	0.712	rs6467241	chr7:128997838	A/G	cg02491457	chr7:128862824	NA	-0.61	-8.52	-0.46	1.22e-15	White matter hyperintensity burden;
CESC	cis	rs17601876	0.778	rs11632926	chr15:51564226	G/A	cg19946085	chr15:51559439	CYP19A1	-0.32	-5.04	-0.3	8.53e-7	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
CESC	cis	rs798554	1.000	rs798550	chr7:2760609	A/G	cg09658497	chr7:2847517	GNA12	-0.37	-5.45	-0.32	1.16e-7	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11095632	chr20:56063618	HMGB1L1	-0.52	-6.19	-0.36	2.34e-9	Gut microbiome composition (summer);
CESC	cis	rs7615952	0.673	rs35955861	chr3:125626201	T/C	cg05084668	chr3:125655381	ALG1L	-0.77	-7.99	-0.44	4.09e-14	Blood pressure (smoking interaction);
CESC	cis	rs854765	0.583	rs8065416	chr17:17851162	C/T	cg04398451	chr17:18023971	MYO15A	-0.69	-9.72	-0.51	2.77e-19	Total body bone mineral density;
CESC	cis	rs7937682	0.847	rs500163	chr11:111462649	T/G	cg22437258	chr11:111473054	SIK2	0.71	9.19	0.49	1.16e-17	Primary sclerosing cholangitis;
CESC	cis	rs3540	0.576	rs12907587	chr15:91045851	G/C	cg10434728	chr15:90938212	IQGAP1	-0.42	-7.65	-0.43	3.62e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs5750830	0.649	rs5750813	chr22:39795228	G/C	cg20735954	chr22:39777886	SYNGR1	-0.41	-5.07	-0.3	7.62e-7	Intelligence (multi-trait analysis);
CESC	cis	rs7412746	0.658	rs11204739	chr1:150865760	A/G	cg04414720	chr1:150670196	GOLPH3L	0.49	6.47	0.37	4.81e-10	Melanoma;
CESC	cis	rs4718428	0.705	rs68168107	chr7:66255238	G/A	cg18252515	chr7:66147081	NA	-0.45	-5.04	-0.3	8.7e-7	Corneal structure;
CESC	cis	rs9796	0.870	rs8023345	chr15:41338348	T/G	cg18705301	chr15:41695430	NDUFAF1	-0.46	-6.86	-0.39	4.82e-11	Menopause (age at onset);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg16629158	chr2:122042988	TFCP2L1	-0.47	-6.7	-0.38	1.23e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs9400271	0.632	rs9487020	chr6:109587672	A/G	cg01475377	chr6:109611718	NA	-0.46	-7.18	-0.4	7.24e-12	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
CESC	cis	rs2380220	0.606	rs9488080	chr6:96006973	A/G	cg04719120	chr6:96025338	MANEA	0.51	5.91	0.34	1.02e-8	Behavioural disinhibition (generation interaction);
CESC	cis	rs3806843	1.000	rs7710794	chr5:140209467	T/G	cg16179182	chr5:140090404	VTRNA1-1	-0.41	-5.25	-0.31	3.08e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs9467711	0.606	rs12174639	chr6:26373121	G/A	cg14345882	chr6:26364793	BTN3A2	0.61	6.43	0.37	5.97e-10	Autism spectrum disorder or schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13518988	chr17:73401817	GRB2	0.55	6.02	0.35	5.85e-9	Gut microbiome composition (summer);
CESC	cis	rs2228479	0.850	rs2239358	chr16:89827330	C/G	cg04013166	chr16:89971882	TCF25	0.78	6.69	0.38	1.33e-10	Skin colour saturation;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg22175779	chr15:57998734	GRINL1A;GCOM1	0.41	6.31	0.36	1.15e-9	Gambling;
CESC	cis	rs7044106	0.791	rs7043969	chr9:123493989	A/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.84	13.46	0.64	7.82e-32	Hip circumference adjusted for BMI;
CESC	cis	rs875971	0.862	rs9791713	chr7:66105198	C/A	cg12463550	chr7:65579703	CRCP	-0.48	-6.03	-0.35	5.35e-9	Aortic root size;
CESC	cis	rs7666738	0.830	rs34212748	chr4:99068708	G/A	cg17366294	chr4:99064904	C4orf37	0.61	8.5	0.46	1.41e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3008870	1.000	rs7511948	chr1:67430427	A/G	cg02640540	chr1:67518911	SLC35D1	0.51	5.58	0.32	5.89e-8	Lymphocyte percentage of white cells;
CESC	cis	rs4689388	0.890	rs4688991	chr4:6302220	C/G	cg25554036	chr4:6271136	WFS1	0.55	9.09	0.49	2.42e-17	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs1878931	0.559	rs2106863	chr16:3391330	T/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.69	8.49	0.46	1.49e-15	Body mass index (adult);
CESC	trans	rs983392	0.805	rs11230184	chr11:59965789	G/A	cg02363969	chr19:56048075	SBK2	0.41	6.12	0.35	3.39e-9	Alzheimer's disease (late onset);
CESC	trans	rs11098499	0.863	rs3775844	chr4:120428033	G/A	cg25214090	chr10:38739885	LOC399744	0.71	9.77	0.51	1.88e-19	Corneal astigmatism;
CESC	trans	rs9858542	0.903	rs11921590	chr3:49644193	T/C	cg21659725	chr3:3221576	CRBN	-0.52	-6.34	-0.36	9.97e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs6459804	0.967	rs10233396	chr7:157512290	C/T	cg05731713	chr7:157510257	PTPRN2	0.38	6.18	0.35	2.44e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs780096	0.546	rs4665976	chr2:27640325	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.29	-5.75	-0.33	2.42e-8	Total body bone mineral density;
CESC	cis	rs1348850	0.574	rs4893835	chr2:178442592	T/C	cg22681709	chr2:178499509	PDE11A	-0.44	-5.18	-0.3	4.4e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg16780939	chr12:56753945	STAT2	-0.47	-6.46	-0.37	4.99e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs9457247	0.624	rs2239826	chr6:167504880	T/C	cg23791538	chr6:167370224	RNASET2	-0.53	-6.78	-0.38	7.7e-11	Crohn's disease;
CESC	cis	rs4561483	0.582	rs3850997	chr16:12043512	G/T	cg08843971	chr16:11963173	GSPT1	-0.41	-5.47	-0.32	1.04e-7	Testicular germ cell tumor;
CESC	cis	rs7809950	0.954	rs62482543	chr7:107080656	G/A	cg23024343	chr7:107201750	COG5	-0.41	-5.89	-0.34	1.19e-8	Coronary artery disease;
CESC	cis	rs858239	0.601	rs12539331	chr7:23151330	A/G	cg23682824	chr7:23144976	KLHL7	0.46	6.0	0.35	6.55e-9	Cerebrospinal fluid biomarker levels;
CESC	cis	rs2408955	0.521	rs10875753	chr12:48557141	C/T	cg04545296	chr12:48745243	ZNF641	0.32	5.57	0.32	6.26e-8	Glycated hemoglobin levels;
CESC	cis	rs992157	0.798	rs4996257	chr2:219162836	C/T	cg00012203	chr2:219082015	ARPC2	0.76	10.05	0.53	2.51e-20	Colorectal cancer;
CESC	cis	rs875971	0.798	rs12698522	chr7:65967341	T/C	cg11764359	chr7:65958608	NA	0.79	11.17	0.57	5.2e-24	Aortic root size;
CESC	cis	rs4713118	0.662	rs149961	chr6:28015569	A/C	cg12963246	chr6:28129442	ZNF389	0.49	6.32	0.36	1.09e-9	Parkinson's disease;
CESC	cis	rs7772486	0.875	rs2777476	chr6:146345024	A/G	cg05347473	chr6:146136440	FBXO30	0.52	6.71	0.38	1.17e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7555523	0.887	rs2251768	chr1:165738311	A/T	cg24409356	chr1:165738333	TMCO1	0.94	8.44	0.46	2.08e-15	Intraocular pressure;Glaucoma (high intraocular pressure);
CESC	cis	rs7208859	0.573	rs73267873	chr17:29068457	C/T	cg14008862	chr17:28927542	LRRC37B2	0.63	5.27	0.31	2.89e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	trans	rs561341	0.739	rs4795663	chr17:30214542	T/C	cg20587970	chr11:113659929	NA	0.57	7.55	0.42	7.15e-13	Hip circumference adjusted for BMI;
CESC	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg23978390	chr7:1156363	C7orf50	0.65	9.33	0.5	4.39e-18	Longevity;Endometriosis;
CESC	cis	rs9733	0.596	rs7549795	chr1:150656873	G/A	cg17724175	chr1:150552817	MCL1	0.44	7.21	0.41	5.8e-12	Tonsillectomy;
CESC	cis	rs9300255	0.739	rs4759417	chr12:123746510	C/T	cg05973401	chr12:123451056	ABCB9	0.5	5.69	0.33	3.43e-8	Neutrophil percentage of white cells;
CESC	cis	rs2455799	0.613	rs2470538	chr3:15717124	G/C	cg16303742	chr3:15540471	COLQ	-0.39	-6.04	-0.35	5.27e-9	Mean platelet volume;
CESC	cis	rs7264396	0.563	rs78084033	chr20:34219990	A/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.58	5.65	0.33	4.22e-8	Total cholesterol levels;
CESC	trans	rs916888	0.738	rs199515	chr17:44856641	C/G	cg07870213	chr5:140052090	DND1	-0.62	-7.2	-0.4	6.04e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	trans	rs1814175	0.626	rs1722008	chr11:49897676	A/T	cg15704280	chr7:45808275	SEPT13	-1.02	-19.89	-0.77	1.79e-54	Height;
CESC	cis	rs9916302	0.904	rs8079303	chr17:37530755	G/C	cg07936489	chr17:37558343	FBXL20	0.82	11.97	0.59	1.11e-26	Glomerular filtration rate (creatinine);
CESC	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg03188948	chr7:1209495	NA	0.71	6.85	0.39	5.21e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs10089	1.000	rs4835941	chr5:127430905	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.75	10.19	0.53	8.58e-21	Ileal carcinoids;
CESC	cis	rs1050631	0.592	rs1785900	chr18:33710170	C/T	cg25426722	chr18:33708991	SLC39A6;ELP2	0.56	7.87	0.44	9.26e-14	Esophageal squamous cell cancer (length of survival);
CESC	cis	rs1355223	0.837	rs11600402	chr11:34691751	C/G	cg11058730	chr11:34937778	PDHX;APIP	-0.52	-6.67	-0.38	1.47e-10	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs9467711	0.606	rs34878490	chr6:26370572	C/T	cg14345882	chr6:26364793	BTN3A2	0.6	6.21	0.36	2.06e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs6598955	0.543	rs12125620	chr1:26552238	G/A	cg04990556	chr1:26633338	UBXN11	0.83	9.29	0.5	5.95e-18	Obesity-related traits;
CESC	cis	rs2997447	0.723	rs61776623	chr1:26474490	A/G	cg24596570	chr1:26146463	FAM54B;LOC646471	0.63	5.44	0.32	1.2e-7	QRS complex (12-leadsum);
CESC	cis	rs10791097	0.967	rs6590512	chr11:130717916	A/G	cg12179176	chr11:130786555	SNX19	-0.51	-7.53	-0.42	7.87e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs2204008	0.754	rs11181643	chr12:38380553	G/A	cg26384229	chr12:38710491	ALG10B	0.72	10.91	0.56	3.86e-23	Bladder cancer;
CESC	cis	rs10883723	0.668	rs12414479	chr10:104420902	C/T	ch.10.2196322F	chr10:104248062	ACTR1A	0.52	5.6	0.33	5.26e-8	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs873946	0.648	rs12767126	chr10:134556992	C/T	cg27286337	chr10:134555280	INPP5A	0.68	7.64	0.42	4.05e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs2486288	0.656	rs1060896	chr15:45554267	C/A	cg21132104	chr15:45694354	SPATA5L1	-0.54	-6.56	-0.37	2.75e-10	Glomerular filtration rate;
CESC	cis	rs9469578	0.636	rs16869463	chr6:33714983	A/G	cg18708504	chr6:33715942	IP6K3	-0.61	-7.22	-0.41	5.49e-12	Phosphorus levels;
CESC	cis	rs9926296	0.528	rs4785721	chr16:89839997	G/A	cg27121462	chr16:89883253	FANCA	0.75	10.62	0.55	3.59e-22	Vitiligo;
CESC	cis	rs6546550	0.869	rs6720498	chr2:70124805	T/C	cg02498382	chr2:70120550	SNRNP27	-0.4	-6.69	-0.38	1.34e-10	Prevalent atrial fibrillation;
CESC	cis	rs1005277	0.579	rs2472181	chr10:38386764	T/C	cg00409905	chr10:38381863	ZNF37A	-0.47	-6.3	-0.36	1.23e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs1552244	1.000	rs7615764	chr3:10082592	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.79	-10.53	-0.54	6.99e-22	Alzheimer's disease;
CESC	cis	rs548181	0.604	rs11608103	chr11:125627917	G/A	cg03464685	chr11:125439445	EI24	-0.61	-5.45	-0.32	1.14e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs17401966	0.838	rs946502	chr1:10309279	G/C	cg15208524	chr1:10270712	KIF1B	0.4	5.21	0.31	3.73e-7	Hepatocellular carcinoma;
CESC	cis	rs6981523	0.553	rs11989369	chr8:11055385	A/G	cg21775007	chr8:11205619	TDH	0.41	5.22	0.31	3.69e-7	Neuroticism;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg16889839	chr12:132547279	EP400	0.43	6.06	0.35	4.58e-9	Fibrinogen levels;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg00482248	chr7:73589137	EIF4H	0.47	6.43	0.37	6.07e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs17039065	0.920	rs61327329	chr4:109447407	T/C	cg16022748	chr4:109541635	LOC285456;RPL34	0.62	5.61	0.33	5.08e-8	Gut microbiome composition (summer);
CESC	cis	rs11098499	0.645	rs72676059	chr4:120290828	C/G	cg09307838	chr4:120376055	NA	0.87	12.16	0.6	2.41e-27	Corneal astigmatism;
CESC	cis	rs9488822	0.676	rs873879	chr6:116391259	A/G	cg05304507	chr6:116381966	FRK	0.26	6.84	0.39	5.58e-11	Cholesterol, total;LDL cholesterol;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg10883266	chr13:100741297	PCCA	-0.51	-6.66	-0.38	1.54e-10	Ulcerative colitis;
CESC	cis	rs826838	0.935	rs1601579	chr12:39178606	G/C	cg26384229	chr12:38710491	ALG10B	0.78	13.22	0.63	5.37e-31	Heart rate;
CESC	cis	rs10911251	0.508	rs2245784	chr1:183107665	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.84	13.2	0.63	6.6e-31	Colorectal cancer;
CESC	cis	rs3733585	0.578	rs4466042	chr4:9955367	T/C	cg11266682	chr4:10021025	SLC2A9	-0.57	-10.92	-0.56	3.75e-23	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs6424115	0.830	rs1105	chr1:24200800	T/C	cg10978503	chr1:24200527	CNR2	0.33	6.64	0.38	1.73e-10	Immature fraction of reticulocytes;
CESC	cis	rs6582630	0.502	rs11614397	chr12:38328163	C/T	cg13010199	chr12:38710504	ALG10B	0.47	6.0	0.35	6.62e-9	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs7666738	0.753	rs2903143	chr4:99040480	C/T	cg18180107	chr4:99064573	C4orf37	0.4	5.2	0.3	4.08e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7188697	0.922	rs8047769	chr16:58591987	G/A	cg02549819	chr16:58548995	SETD6	0.43	5.38	0.31	1.61e-7	QT interval;
CESC	cis	rs4819052	0.851	rs1999333	chr21:46670401	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.94	14.0	0.65	1.07e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs6736093	0.931	rs7578435	chr2:112714751	G/A	cg12686935	chr2:112915763	FBLN7	-0.42	-5.46	-0.32	1.1e-7	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11586124	chr12:58259160	NA	0.56	6.35	0.36	9.56e-10	Gut microbiome composition (summer);
CESC	cis	rs7851660	0.809	rs7032114	chr9:100656459	T/G	cg13688889	chr9:100608707	NA	-0.62	-8.87	-0.48	1.11e-16	Strep throat;
CESC	cis	rs1707322	0.686	rs1547924	chr1:46085112	C/T	cg05343316	chr1:45956843	TESK2	0.52	6.34	0.36	9.89e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs6141600	0.760	rs6060794	chr20:34682864	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.39	5.18	0.3	4.36e-7	Height;Hip circumference;
CESC	trans	rs9388451	0.626	rs1739384	chr6:126099246	C/A	cg05039488	chr6:79577232	IRAK1BP1	-0.6	-8.17	-0.45	1.28e-14	Brugada syndrome;
CESC	cis	rs8060686	0.668	rs2418739	chr16:68092850	G/C	cg26727032	chr16:67993705	SLC12A4	-0.59	-8.17	-0.45	1.24e-14	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs7945705	0.934	rs1988709	chr11:8882890	A/T	cg09997546	chr11:8931473	C11orf17;ST5	0.35	5.64	0.33	4.29e-8	Hemoglobin concentration;
CESC	cis	rs55692411	0.537	rs35012435	chr3:50031840	C/T	cg24110177	chr3:50126178	RBM5	-0.44	-5.15	-0.3	5.03e-7	Intelligence (multi-trait analysis);
CESC	cis	rs3741404	0.791	rs11603192	chr11:63927695	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.89	13.31	0.63	2.64e-31	Platelet count;
CESC	cis	rs5769765	0.818	rs8140681	chr22:50292081	C/A	cg02269571	chr22:50332266	NA	-0.45	-6.05	-0.35	4.98e-9	Schizophrenia;
CESC	cis	rs1799949	1.000	rs2175957	chr17:41286822	T/G	cg25072359	chr17:41440525	NA	0.43	5.75	0.33	2.45e-8	Menopause (age at onset);
CESC	trans	rs459571	1.000	rs456207	chr9:136911140	G/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.57	-7.48	-0.42	1.12e-12	Platelet distribution width;
CESC	cis	rs711245	0.518	rs11886145	chr2:36825716	C/G	cg10546459	chr2:36825355	FEZ2	0.5	6.03	0.35	5.58e-9	Height;
CESC	cis	rs1348850	0.651	rs4893935	chr2:178240601	C/G	cg23306229	chr2:178417860	TTC30B	0.5	6.48	0.37	4.4e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs875971	0.660	rs28698552	chr7:66005018	A/G	cg18876405	chr7:65276391	NA	0.58	7.86	0.44	9.39e-14	Aortic root size;
CESC	cis	rs6460942	0.597	rs7798779	chr7:12543490	A/G	cg06484146	chr7:12443880	VWDE	-0.71	-7.34	-0.41	2.66e-12	Coronary artery disease;
CESC	cis	rs2070488	0.965	rs4679053	chr3:38523495	G/T	cg24069376	chr3:38537580	EXOG	0.49	8.96	0.48	6.1e-17	Electrocardiographic conduction measures;
CESC	cis	rs13191362	0.935	rs67889271	chr6:163045753	T/G	cg21926612	chr6:163149169	PACRG;PARK2	0.89	9.93	0.52	5.96e-20	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs17641971	0.662	rs1858312	chr8:49996521	G/A	cg00325661	chr8:49890786	NA	0.39	5.51	0.32	8.67e-8	Blood metabolite levels;
CESC	cis	rs4253772	0.515	rs6008591	chr22:46703664	T/C	cg10541313	chr22:46663664	TTC38	0.67	5.9	0.34	1.1e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs7618915	0.547	rs2286800	chr3:52778051	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.54	0.37	3.13e-10	Bipolar disorder;
CESC	trans	rs11720469	0.934	rs11714025	chr3:166500304	C/T	cg03163944	chr19:37663716	ZNF585A	-0.41	-6.05	-0.35	5.02e-9	Fast beta electroencephalogram;
CESC	cis	rs727505	0.821	rs67167896	chr7:124614127	T/C	cg23710748	chr7:124431027	NA	-0.45	-7.08	-0.4	1.27e-11	Lewy body disease;
CESC	trans	rs12339966	0.689	rs2252358	chr9:11677252	T/C	cg03904639	chr13:37677730	CSNK1A1L	0.39	6.06	0.35	4.67e-9	Systolic blood pressure;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26602477	chr1:1476845	C1orf70	-0.59	-6.77	-0.38	8.37e-11	Gut microbiome composition (summer);
CESC	cis	rs4474465	0.850	rs10899538	chr11:78237749	C/T	cg27205649	chr11:78285834	NARS2	0.45	5.62	0.33	4.71e-8	Alzheimer's disease (survival time);
CESC	cis	rs1552244	0.935	rs11926481	chr3:10142102	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.85	-11.92	-0.59	1.68e-26	Alzheimer's disease;
CESC	cis	rs5769765	0.865	rs10854860	chr22:50320029	G/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.62	-6.38	-0.37	7.75e-10	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19936194	chr3:141595256	ATP1B3	0.67	7.86	0.43	9.73e-14	Gut microbiome composition (summer);
CESC	cis	rs873946	0.586	rs12251911	chr10:134570595	A/G	cg27297192	chr10:134578999	INPP5A	0.4	5.37	0.31	1.7e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs896854	0.517	rs10112447	chr8:95955701	C/T	cg09323728	chr8:95962352	TP53INP1	-0.35	-6.62	-0.38	1.93e-10	Type 2 diabetes;
CESC	cis	rs58688157	0.705	rs36060383	chr11:598723	A/C	cg02461776	chr11:598696	PHRF1	0.51	5.92	0.34	1.01e-8	Systemic lupus erythematosus;
CESC	cis	rs7772486	0.790	rs2254283	chr6:146204289	T/C	cg23711669	chr6:146136114	FBXO30	0.92	13.65	0.64	1.71e-32	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4803455	0.565	rs2241713	chr19:41869468	C/G	cg08477640	chr19:41863820	B9D2	-0.51	-7.44	-0.42	1.42e-12	Migraine;Coronary artery disease;
CESC	cis	rs74181299	0.890	rs2723062	chr2:65280220	G/A	cg05010058	chr2:65284262	CEP68	0.33	5.66	0.33	3.89e-8	Pulse pressure;
CESC	cis	rs12893668	0.663	rs12889731	chr14:104087482	C/T	cg08213375	chr14:104286397	PPP1R13B	0.33	5.28	0.31	2.69e-7	Reticulocyte count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02217955	chr22:50941799	LMF2	-0.49	-6.24	-0.36	1.68e-9	Gut microbiome composition (summer);
CESC	cis	rs477895	0.713	rs882146	chr11:63976699	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.94	10.33	0.54	3.08e-21	Mean platelet volume;
CESC	cis	rs2882667	1.000	rs2060222	chr5:138308466	C/T	cg04439458	chr5:138467593	SIL1	-0.36	-5.68	-0.33	3.5e-8	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs5753618	0.583	rs7285619	chr22:31842554	C/T	cg13145458	chr22:31556086	RNF185	-0.5	-5.9	-0.34	1.11e-8	Colorectal cancer;
CESC	cis	rs9322193	0.923	rs9688350	chr6:150052113	A/T	cg04369109	chr6:150039330	LATS1	-0.46	-6.46	-0.37	4.96e-10	Lung cancer;
CESC	cis	rs2180341	0.824	rs9321076	chr6:127655614	G/A	cg27446573	chr6:127587934	RNF146	1.09	16.35	0.71	5.12e-42	Breast cancer;
CESC	cis	rs3015497	0.789	rs3015500	chr14:51108877	C/T	cg09863266	chr14:51125203	SAV1	-0.35	-5.4	-0.31	1.46e-7	Mean platelet volume;
CESC	cis	rs6445967	0.569	rs7622497	chr3:58282673	A/C	cg23715586	chr3:58305044	RPP14	0.43	6.51	0.37	3.73e-10	Platelet count;
CESC	cis	rs858239	0.632	rs13438452	chr7:23174182	A/G	cg23682824	chr7:23144976	KLHL7	0.54	7.69	0.43	2.96e-13	Cerebrospinal fluid biomarker levels;
CESC	cis	rs9926296	0.565	rs8055825	chr16:89832848	C/T	cg04287289	chr16:89883240	FANCA	0.91	15.37	0.69	1.51e-38	Vitiligo;
CESC	trans	rs4332037	0.851	rs10268609	chr7:1962163	A/C	cg11693508	chr17:37793320	STARD3	0.68	6.65	0.38	1.62e-10	Bipolar disorder;
CESC	cis	rs1538970	0.739	rs4660863	chr1:45955868	T/C	cg06784218	chr1:46089804	CCDC17	0.37	5.9	0.34	1.11e-8	Platelet count;
CESC	cis	rs2251381	0.750	rs2776250	chr21:30528094	T/G	cg08807101	chr21:30365312	RNF160	0.7	8.59	0.47	7.75e-16	Selective IgA deficiency;
CESC	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.78	-13.36	-0.63	1.82e-31	Longevity;Endometriosis;
CESC	cis	rs898097	0.510	rs10445242	chr17:80891666	G/T	cg15664640	chr17:80829946	TBCD	0.4	5.75	0.33	2.44e-8	Breast cancer;
CESC	cis	rs4566357	1.000	rs2251223	chr2:227914975	T/G	cg11843606	chr2:227700838	RHBDD1	-0.42	-5.28	-0.31	2.66e-7	Coronary artery disease;
CESC	cis	rs2243480	1.000	rs4718315	chr7:65648541	T/C	cg12463550	chr7:65579703	CRCP	-0.73	-5.66	-0.33	4.03e-8	Diabetic kidney disease;
CESC	cis	rs7666738	0.830	rs28516388	chr4:98987449	A/G	cg18180107	chr4:99064573	C4orf37	0.4	5.19	0.3	4.29e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4665809	1.000	rs6546726	chr2:26275116	A/G	cg25036284	chr2:26402008	FAM59B	-0.61	-6.94	-0.39	3.08e-11	Gut microbiome composition (summer);
CESC	cis	rs17253792	0.915	rs79894275	chr14:56180285	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.74	5.1	0.3	6.53e-7	Putamen volume;
CESC	cis	rs3015497	0.603	rs2983420	chr14:51036950	T/C	cg26011998	chr14:51135199	SAV1	0.49	5.45	0.32	1.16e-7	Mean platelet volume;
CESC	cis	rs17253792	0.915	rs78498383	chr14:56177585	C/T	cg01858014	chr14:56050164	KTN1	-0.91	-7.03	-0.4	1.8e-11	Putamen volume;
CESC	cis	rs875971	1.000	rs12698523	chr7:65968113	C/G	cg18876405	chr7:65276391	NA	0.48	6.31	0.36	1.16e-9	Aortic root size;
CESC	cis	rs9487051	0.700	rs7773815	chr6:109602343	A/C	cg12927641	chr6:109611667	NA	-0.37	-5.62	-0.33	4.82e-8	Reticulocyte fraction of red cells;
CESC	cis	rs6540559	0.673	rs11805830	chr1:209984969	C/T	cg25204440	chr1:209979598	IRF6	0.66	6.78	0.38	7.96e-11	Cleft lip with or without cleft palate;
CESC	cis	rs798554	0.757	rs1182171	chr7:2878510	A/G	cg19717773	chr7:2847554	GNA12	-0.53	-7.53	-0.42	7.94e-13	Height;
CESC	cis	rs11098499	0.739	rs7441137	chr4:120133221	G/T	cg09307838	chr4:120376055	NA	-0.67	-8.37	-0.46	3.41e-15	Corneal astigmatism;
CESC	trans	rs116095464	0.558	rs56298907	chr5:283280	C/A	cg00938859	chr5:1591904	SDHAP3	0.72	6.62	0.38	2.04e-10	Breast cancer;
CESC	cis	rs9888739	0.841	rs11864503	chr16:31331137	T/C	cg15817542	chr16:31343056	ITGAM	-0.42	-5.06	-0.3	7.71e-7	Systemic lupus erythematosus;
CESC	cis	rs9660992	0.736	rs1180734	chr1:205255438	A/G	cg19090574	chr1:205240910	TMCC2	-0.4	-5.47	-0.32	1.05e-7	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs763121	0.853	rs2072796	chr22:39064230	A/G	cg06544989	chr22:39130855	UNC84B	0.48	8.4	0.46	2.69e-15	Menopause (age at onset);
CESC	cis	rs780096	0.587	rs4665969	chr2:27574953	C/T	cg21248554	chr2:27665150	KRTCAP3	0.29	5.83	0.34	1.61e-8	Total body bone mineral density;
CESC	cis	rs7208859	0.573	rs79505916	chr17:29062326	C/T	cg14008862	chr17:28927542	LRRC37B2	0.66	5.21	0.3	3.75e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs7666738	0.830	rs10028692	chr4:98962585	C/T	cg18180107	chr4:99064573	C4orf37	0.4	5.14	0.3	5.26e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs117623576	0.941	rs211409	chr10:32393213	T/C	cg03047570	chr10:32398778	NA	0.8	8.36	0.46	3.67e-15	Anti-saccade response;
CESC	trans	rs10448044	0.750	rs9298326	chr8:80103395	G/A	cg08211306	chr6:46097784	ENPP4	0.44	6.3	0.36	1.21e-9	Suicide in bipolar disorder;
CESC	cis	rs7949030	0.588	rs2512563	chr11:62311249	C/G	cg22862634	chr11:62369728	EML3;MTA2	0.49	6.83	0.39	5.97e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs2859741	0.967	rs534131	chr1:37484237	T/C	cg09363841	chr1:37513479	NA	-0.64	-10.12	-0.53	1.46e-20	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
CESC	cis	rs698833	0.538	rs1067396	chr2:44637738	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.45	5.38	0.31	1.62e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs875971	0.929	rs778712	chr7:65849978	C/T	cg10691866	chr7:65817282	TPST1	-0.34	-5.5	-0.32	8.73e-8	Aortic root size;
CESC	cis	rs77861329	1.000	rs876782	chr3:52107909	C/T	cg08692210	chr3:52188851	WDR51A	-0.86	-8.23	-0.45	8.33e-15	Macrophage inflammatory protein 1b levels;
CESC	cis	rs2839186	1.000	rs2839181	chr21:47685939	A/G	cg05896524	chr21:47604654	C21orf56	0.42	5.44	0.32	1.21e-7	Testicular germ cell tumor;
CESC	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	21.97	0.8	1.29e-61	Prudent dietary pattern;
CESC	cis	rs4722166	0.695	rs7787893	chr7:22774437	A/G	cg13104385	chr7:22767384	IL6	0.4	5.96	0.34	8.18e-9	Lung cancer;
CESC	cis	rs12824058	0.831	rs12831363	chr12:130814013	C/T	cg24838063	chr12:130822603	PIWIL1	-0.62	-8.54	-0.46	1.09e-15	Menopause (age at onset);
CESC	cis	rs2795502	0.882	rs2744093	chr10:43339243	A/G	cg27426351	chr10:43362370	NA	-0.45	-5.5	-0.32	8.91e-8	Blood protein levels;
CESC	cis	rs7617480	0.610	rs4955420	chr3:49208865	A/G	cg07636037	chr3:49044803	WDR6	0.72	11.51	0.58	3.92e-25	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CESC	cis	rs754466	0.651	rs10824583	chr10:79619402	C/T	cg17075019	chr10:79541650	NA	0.87	13.53	0.64	4.62e-32	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs798554	1.000	rs798548	chr7:2760935	A/G	cg19717773	chr7:2847554	GNA12	-0.52	-7.77	-0.43	1.72e-13	Height;
CESC	cis	rs34779708	0.931	rs72789690	chr10:35382817	T/C	cg03585969	chr10:35415529	CREM	0.77	10.07	0.53	2.06e-20	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs10791097	0.765	rs7943757	chr11:130716157	C/T	cg12179176	chr11:130786555	SNX19	0.54	7.78	0.43	1.65e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs1048238	0.506	rs698890	chr1:16267371	C/G	cg22431228	chr1:16359049	CLCNKA	0.38	6.64	0.38	1.81e-10	Systolic blood pressure;
CESC	cis	rs7666738	0.830	rs6831925	chr4:98947401	T/C	cg03676636	chr4:99064102	C4orf37	0.34	5.11	0.3	6.15e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs67478160	0.643	rs12434686	chr14:104316033	C/T	cg01849466	chr14:104193079	ZFYVE21	0.5	6.92	0.39	3.46e-11	Schizophrenia;
CESC	cis	rs6088590	0.561	rs6059918	chr20:33150503	C/T	cg06115741	chr20:33292138	TP53INP2	0.51	6.4	0.37	7.09e-10	Coronary artery disease;
CESC	cis	rs2404618	0.587	rs6994849	chr8:1492839	G/T	cg02903104	chr8:1507517	DLGAP2	-0.32	-6.07	-0.35	4.53e-9	Lung cancer;
CESC	cis	rs1950626	0.833	rs34463495	chr14:101411186	A/C	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.79	10.67	0.55	2.42e-22	Pelvic organ prolapse (moderate/severe);
CESC	cis	rs9430161	0.645	rs6675082	chr1:11033797	T/C	cg02454025	chr1:11042201	C1orf127	0.96	15.32	0.69	2.28e-38	Ewing sarcoma;
CESC	cis	rs34779708	0.966	rs998658	chr10:35408654	A/G	cg04310649	chr10:35416472	CREM	-0.54	-6.47	-0.37	4.62e-10	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs8040855	0.627	rs11631548	chr15:85619248	C/T	cg08123816	chr15:85640762	PDE8A	-0.4	-5.97	-0.34	7.56e-9	Bulimia nervosa;
CESC	cis	rs933688	1.000	rs332529	chr5:90789470	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.89	9.93	0.52	5.99e-20	Smoking behavior;
CESC	cis	rs73110464	0.609	rs6580923	chr12:53358352	A/G	cg16329197	chr12:53359506	NA	-0.7	-10.4	-0.54	1.84e-21	Cancer (pleiotropy);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg16678024	chr22:41996951	PPPDE2	-0.39	-6.53	-0.37	3.39e-10	Gambling;
CESC	trans	rs61931739	0.534	rs10844840	chr12:34364517	C/T	cg13010199	chr12:38710504	ALG10B	0.48	6.2	0.36	2.16e-9	Morning vs. evening chronotype;
CESC	cis	rs7843479	0.601	rs6557712	chr8:21826421	C/T	cg17168535	chr8:21777572	XPO7	0.75	12.24	0.6	1.31e-27	Mean corpuscular volume;
CESC	cis	rs2243480	1.000	rs958550	chr7:65635679	C/T	cg12463550	chr7:65579703	CRCP	-0.7	-5.39	-0.31	1.54e-7	Diabetic kidney disease;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03678139	chr1:41832388	NA	0.47	6.04	0.35	5.12e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs589448	0.934	rs554591	chr12:69753847	T/C	cg22834771	chr12:69754056	YEATS4	-0.55	-7.21	-0.41	5.72e-12	Cerebrospinal fluid biomarker levels;
CESC	cis	rs1552244	0.882	rs13084194	chr3:10031492	T/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.7	-8.29	-0.45	5.67e-15	Alzheimer's disease;
CESC	cis	rs7267979	1.000	rs2258135	chr20:25272323	C/A	cg08601574	chr20:25228251	PYGB	0.39	5.65	0.33	4.13e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs79349575	0.783	rs62075838	chr17:46996432	C/T	cg16584676	chr17:46985605	UBE2Z	0.53	6.6	0.38	2.25e-10	Type 2 diabetes;
CESC	cis	rs4481887	0.962	rs6663952	chr1:248465682	A/G	cg00666640	chr1:248458726	OR2T12	0.39	6.31	0.36	1.19e-9	Common traits (Other);
CESC	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	22.13	0.81	3.58e-62	Prudent dietary pattern;
CESC	cis	rs4911259	0.552	rs6058925	chr20:31465374	G/A	cg13636640	chr20:31349939	DNMT3B	-0.54	-7.47	-0.42	1.16e-12	Inflammatory bowel disease;
CESC	cis	rs9399135	0.967	rs11754783	chr6:135347661	T/A	cg22676075	chr6:135203613	NA	0.51	7.36	0.41	2.34e-12	Red blood cell count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27452651	chr22:50312357	ALG12;CRELD2	0.67	7.8	0.43	1.42e-13	Gut microbiome composition (summer);
CESC	cis	rs2932538	0.961	rs3795820	chr1:113163042	C/A	cg22162597	chr1:113214053	CAPZA1	-0.6	-7.53	-0.42	7.76e-13	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg03929816	chr8:141231575	TRAPPC9	0.49	6.6	0.38	2.25e-10	Fibrinogen levels;
CESC	cis	rs933688	1.000	rs10058025	chr5:90689052	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.99	11.87	0.59	2.36e-26	Smoking behavior;
CESC	cis	rs938554	0.612	rs4385059	chr4:9989233	A/G	cg00071950	chr4:10020882	SLC2A9	-0.58	-6.59	-0.38	2.4e-10	Blood metabolite levels;
CESC	cis	rs13191362	1.000	rs34066731	chr6:163011047	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.5	5.17	0.3	4.63e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs7829975	0.511	rs1543238	chr8:8134809	A/G	cg06636001	chr8:8085503	FLJ10661	0.63	7.76	0.43	1.83e-13	Mood instability;
CESC	cis	rs2180341	1.000	rs2144742	chr6:127595786	C/A	cg27446573	chr6:127587934	RNF146	1.07	15.98	0.7	1e-40	Breast cancer;
CESC	cis	rs4919694	0.572	rs72846714	chr10:104878454	G/A	cg04362960	chr10:104952993	NT5C2	0.63	6.25	0.36	1.66e-9	Arsenic metabolism;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg23943013	chr5:79551904	SERINC5	-0.46	-6.03	-0.35	5.58e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs7949030	0.504	rs2516633	chr11:62371773	A/C	cg13298116	chr11:62369859	EML3;MTA2	-0.5	-6.98	-0.39	2.37e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	trans	rs10506458	0.834	rs73127067	chr12:63390333	G/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.33	-17.85	-0.74	2.4e-47	Hemostatic factors and hematological phenotypes;
CESC	cis	rs4889855	0.556	rs4890039	chr17:78517883	C/T	cg16591659	chr17:78472290	NA	0.36	5.75	0.33	2.49e-8	Fractional excretion of uric acid;
CESC	cis	rs7894051	1.000	rs7899476	chr10:135197214	A/G	cg20534287	chr10:135191450	PAOX	0.66	5.33	0.31	2.12e-7	Lifespan;
CESC	cis	rs1552244	0.882	rs7636817	chr3:10014876	G/T	cg08888203	chr3:10149979	C3orf24	0.49	6.14	0.35	3.07e-9	Alzheimer's disease;
CESC	cis	rs7666738	0.830	rs7686456	chr4:99019695	T/C	cg03467027	chr4:99064603	C4orf37	0.46	5.81	0.34	1.8e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4076764	1.000	rs6683181	chr1:163417077	C/T	cg06092702	chr1:163392909	NA	-0.39	-5.66	-0.33	3.88e-8	Motion sickness;
CESC	cis	rs7296418	0.517	rs73231928	chr12:123724325	T/C	cg05973401	chr12:123451056	ABCB9	0.49	6.36	0.36	8.72e-10	Platelet count;
CESC	cis	rs6674176	0.696	rs4448553	chr1:44411589	A/G	cg13606994	chr1:44402422	ARTN	-0.38	-5.81	-0.34	1.82e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs7666738	0.800	rs7683737	chr4:99070880	A/T	cg03467027	chr4:99064603	C4orf37	0.48	5.93	0.34	9.5e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg16405210	chr4:1374714	KIAA1530	-0.96	-12.77	-0.62	2.05e-29	Longevity;
CESC	cis	rs4803468	1.000	rs3213861	chr19:41919944	A/C	cg09537434	chr19:41945824	ATP5SL	-1.08	-18.9	-0.76	4.86e-51	Height;
CESC	cis	rs8031584	0.723	rs11632229	chr15:31179534	A/G	cg14829155	chr15:31115871	NA	0.72	9.99	0.52	3.77e-20	Huntington's disease progression;
CESC	cis	rs3820928	0.845	rs1917126	chr2:227840923	G/T	cg11843606	chr2:227700838	RHBDD1	-0.44	-5.77	-0.33	2.22e-8	Pulmonary function;
CESC	cis	rs151234	0.612	rs11641853	chr16:28589719	A/G	cg01378222	chr16:28622494	SULT1A1	-0.57	-7.19	-0.4	6.43e-12	Platelet distribution width;
CESC	trans	rs1908814	0.516	rs4841641	chr8:11798227	G/A	cg15556689	chr8:8085844	FLJ10661	0.54	6.79	0.38	7.43e-11	Neuroticism;
CESC	cis	rs7615952	0.688	rs7624806	chr3:125599074	G/A	cg05084668	chr3:125655381	ALG1L	-0.43	-5.05	-0.3	8.31e-7	Blood pressure (smoking interaction);
CESC	cis	rs6938	0.534	rs1130741	chr15:75189930	A/G	cg10253484	chr15:75165896	SCAMP2	-0.52	-6.9	-0.39	3.71e-11	Breast cancer;
CESC	cis	rs7618915	0.571	rs34954168	chr3:52612159	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.47	6.67	0.38	1.48e-10	Bipolar disorder;
CESC	cis	rs875971	0.522	rs2008188	chr7:65429013	G/C	cg05332525	chr7:65337924	VKORC1L1	0.5	6.18	0.35	2.42e-9	Aortic root size;
CESC	cis	rs6693567	0.545	rs6699093	chr1:150440451	A/G	cg09579323	chr1:150459698	TARS2	-0.45	-5.77	-0.33	2.21e-8	Migraine;
CESC	cis	rs1670533	1.000	rs6850784	chr4:1059809	G/A	cg27284194	chr4:1044797	NA	0.47	6.07	0.35	4.4e-9	Recombination rate (females);
CESC	cis	rs644799	0.930	rs2186782	chr11:95649543	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.42	5.13	0.3	5.57e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs853679	0.517	rs9393901	chr6:28136797	A/G	cg20151795	chr6:28129481	ZNF389	0.41	5.3	0.31	2.46e-7	Depression;
CESC	cis	rs4242434	0.757	rs7005025	chr8:22519815	G/T	cg03733263	chr8:22462867	KIAA1967	0.73	10.67	0.55	2.4e-22	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CESC	cis	rs8072100	0.651	rs1912484	chr17:45443664	C/G	cg08085267	chr17:45401833	C17orf57	-0.53	-6.65	-0.38	1.65e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs72781680	1.000	rs72798411	chr2:24184343	A/G	cg20701182	chr2:24300061	SF3B14	0.79	6.83	0.39	5.75e-11	Lymphocyte counts;
CESC	cis	rs6912958	0.781	rs9444524	chr6:88311260	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-6.68	-0.38	1.43e-10	Monocyte percentage of white cells;
CESC	cis	rs2243480	1.000	rs1553174	chr7:65731194	T/C	cg18252515	chr7:66147081	NA	1.41	14.3	0.66	9.43e-35	Diabetic kidney disease;
CESC	cis	rs10504229	1.000	rs72652906	chr8:58188360	C/A	cg24829409	chr8:58192753	C8orf71	-0.78	-10.18	-0.53	9.38e-21	Developmental language disorder (linguistic errors);
CESC	cis	rs8014204	0.935	rs3742786	chr14:75373011	A/G	cg08847533	chr14:75593920	NEK9	-0.46	-5.79	-0.34	1.96e-8	Caffeine consumption;
CESC	cis	rs9311474	0.508	rs7652191	chr3:52610415	T/C	cg05564831	chr3:52568323	NT5DC2	0.48	7.57	0.42	6.08e-13	Electroencephalogram traits;
CESC	cis	rs28830936	1.000	rs11070343	chr15:41940146	T/A	cg11010575	chr15:42129464	JMJD7-PLA2G4B;JMJD7	-0.38	-5.48	-0.32	9.74e-8	Diastolic blood pressure;
CESC	cis	rs10504229	1.000	rs17217047	chr8:58180296	G/A	cg14926445	chr8:58193284	C8orf71	-0.51	-5.47	-0.32	1.03e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs34779708	0.931	rs7923172	chr10:35309367	G/A	cg04310649	chr10:35416472	CREM	-0.51	-6.27	-0.36	1.5e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs3733585	0.673	rs7434391	chr4:9967682	C/G	cg02734326	chr4:10020555	SLC2A9	-0.39	-5.58	-0.32	5.96e-8	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs10256972	0.521	rs7457418	chr7:1110255	C/T	cg07308232	chr7:1071921	C7orf50	-0.53	-7.42	-0.41	1.56e-12	Longevity;Endometriosis;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg25018755	chr22:43506952	BIK	0.54	7.42	0.41	1.59e-12	Systemic lupus erythematosus;
CESC	cis	rs6121246	0.909	rs4518038	chr20:30419051	A/G	cg13852791	chr20:30311386	BCL2L1	0.82	7.39	0.41	1.97e-12	Mean corpuscular hemoglobin;
CESC	cis	rs7917772	0.582	rs7907417	chr10:104370662	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.42	-5.73	-0.33	2.7e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs9549260	0.753	rs1986649	chr13:41178824	C/T	cg21288729	chr13:41239152	FOXO1	0.53	5.05	0.3	8.14e-7	Red blood cell count;
CESC	cis	rs875971	1.000	rs6957199	chr7:65978519	T/C	cg10691866	chr7:65817282	TPST1	-0.34	-5.59	-0.32	5.57e-8	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07870854	chr16:791252	NARFL	0.55	6.13	0.35	3.11e-9	Gut microbiome composition (summer);
CESC	cis	rs1862618	0.620	rs189695	chr5:56225769	T/C	cg24531977	chr5:56204891	C5orf35	-0.67	-9.25	-0.49	7.78e-18	Initial pursuit acceleration;
CESC	cis	rs79349575	0.749	rs46521	chr17:46988529	A/G	cg16584676	chr17:46985605	UBE2Z	0.53	6.6	0.38	2.25e-10	Type 2 diabetes;
CESC	cis	rs10504073	0.669	rs818559	chr8:50035806	C/T	cg00325661	chr8:49890786	NA	0.51	7.5	0.42	9.61e-13	Blood metabolite ratios;
CESC	cis	rs67460515	0.892	rs73026974	chr3:160963231	A/C	cg03342759	chr3:160939853	NMD3	-0.55	-7.79	-0.43	1.5e-13	Parkinson's disease;
CESC	cis	rs6547741	1.000	rs6547741	chr2:27855924	G/A	cg21248554	chr2:27665150	KRTCAP3	0.25	5.3	0.31	2.42e-7	Oral cavity cancer;
CESC	cis	rs6540559	0.673	rs11805830	chr1:209984969	C/T	cg09509183	chr1:209979624	IRF6	0.56	5.81	0.34	1.82e-8	Cleft lip with or without cleft palate;
CESC	cis	rs4253772	0.591	rs6008595	chr22:46703860	A/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.66	6.5	0.37	4.07e-10	LDL cholesterol;Cholesterol, total;
CESC	cis	rs9611565	0.512	rs139571	chr22:42214238	G/A	cg06634786	chr22:41940651	POLR3H	-0.64	-6.23	-0.36	1.83e-9	Vitiligo;
CESC	cis	rs10461617	0.617	rs79742142	chr5:56104377	A/G	cg12311346	chr5:56204834	C5orf35	-0.73	-8.67	-0.47	4.4e-16	Type 2 diabetes;
CESC	cis	rs7904368	0.568	rs10752061	chr10:16853900	A/G	cg23933602	chr10:16859644	RSU1	0.85	12.6	0.61	7.81e-29	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
CESC	cis	rs78456975	1.000	rs4073861	chr2:1563611	G/A	cg26248373	chr2:1572462	NA	-0.53	-5.16	-0.3	4.89e-7	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg18402987	chr7:1209562	NA	0.76	7.56	0.42	6.59e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg10504545	chr14:74769802	ABCD4	-0.49	-6.21	-0.36	2.03e-9	Ulcerative colitis;
CESC	cis	rs9649213	0.593	rs7781916	chr7:97929738	A/G	cg24562669	chr7:97807699	LMTK2	0.48	6.92	0.39	3.3e-11	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs344364	0.511	rs911392	chr16:1947259	A/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.53	-6.19	-0.36	2.29e-9	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs769267	0.899	rs67720221	chr19:19440864	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.6	-7.69	-0.43	2.89e-13	Tonsillectomy;
CESC	cis	rs2742417	1.000	rs2742406	chr3:45760600	C/T	cg10512202	chr3:45649293	LIMD1	0.35	5.03	0.3	9.01e-7	Response to anti-depressant treatment in major depressive disorder;
CESC	cis	rs12973672	0.812	rs10421504	chr19:35764701	C/G	cg12095397	chr19:35769544	USF2	0.49	5.81	0.34	1.77e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs8141529	0.702	rs8137262	chr22:29292135	C/T	cg02153584	chr22:29168773	CCDC117	0.59	7.62	0.42	4.46e-13	Lymphocyte counts;
CESC	cis	rs1707322	0.752	rs11211169	chr1:46166709	A/G	cg03146154	chr1:46216737	IPP	0.82	11.53	0.58	3.39e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs17826219	0.706	rs609472	chr17:28951427	T/C	cg04154034	chr17:28927549	LRRC37B2	0.67	5.98	0.34	7.21e-9	Body mass index;
CESC	trans	rs561341	1.000	rs550923	chr17:30327013	G/C	cg20587970	chr11:113659929	NA	-1.44	-18.71	-0.75	2.25e-50	Hip circumference adjusted for BMI;
CESC	cis	rs7188697	0.922	rs40188	chr16:58567761	T/A	cg21335942	chr16:58549945	SETD6	0.45	5.32	0.31	2.17e-7	QT interval;
CESC	cis	rs9549367	0.789	rs12869947	chr13:113896156	A/G	cg18105134	chr13:113819100	PROZ	-0.67	-8.05	-0.44	2.82e-14	Platelet distribution width;
CESC	cis	rs78366141	0.649	rs78114325	chr4:89682189	T/C	cg01026744	chr4:89619053	NAP1L5;HERC3	0.79	5.63	0.33	4.5e-8	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
CESC	cis	rs4073582	0.595	rs801731	chr11:65938446	G/C	cg14036092	chr11:66035641	RAB1B	0.54	7.52	0.42	8.55e-13	Gout;
CESC	cis	rs11122272	0.766	rs2808614	chr1:231550168	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.58	7.93	0.44	5.95e-14	Hemoglobin concentration;
CESC	cis	rs9640161	0.830	rs3757425	chr7:150067640	A/C	cg10018233	chr7:150070692	REPIN1	0.49	8.94	0.48	6.79e-17	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs7809950	0.678	rs2237661	chr7:106863123	T/C	cg23024343	chr7:107201750	COG5	-0.59	-7.11	-0.4	1.07e-11	Coronary artery disease;
CESC	cis	rs2576037	0.583	rs2164104	chr18:44567743	G/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.35	-5.52	-0.32	8.01e-8	Personality dimensions;
CESC	cis	rs736801	0.607	rs11746555	chr5:131727033	G/A	cg07395648	chr5:131743802	NA	-0.42	-5.41	-0.32	1.41e-7	Breast cancer;Mosquito bite size;
CESC	cis	rs7107174	0.892	rs1567891	chr11:78101985	A/G	cg02023728	chr11:77925099	USP35	0.47	6.3	0.36	1.24e-9	Testicular germ cell tumor;
CESC	trans	rs66573146	0.831	rs1048009	chr4:6988677	G/A	cg07817883	chr1:32538562	TMEM39B	1.04	7.45	0.42	1.34e-12	Granulocyte percentage of myeloid white cells;
CESC	cis	rs6582630	0.502	rs11520276	chr12:38359216	C/T	cg13010199	chr12:38710504	ALG10B	0.47	6.02	0.35	5.87e-9	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs10927875	1.000	rs4307563	chr1:16313788	C/T	cg21385522	chr1:16154831	NA	-0.77	-9.68	-0.51	3.51e-19	Dilated cardiomyopathy;
CESC	cis	rs4812048	0.649	rs3761258	chr20:57618596	C/G	cg14073986	chr20:57617431	SLMO2	-0.76	-6.38	-0.36	7.85e-10	Mean platelet volume;
CESC	cis	rs7965445	0.892	rs115080397	chr12:131877059	A/G	cg08164151	chr12:131118432	NA	0.62	5.38	0.31	1.6e-7	Mortality in heart failure;
CESC	cis	rs727505	0.826	rs11532793	chr7:124747952	A/G	cg23710748	chr7:124431027	NA	-0.4	-6.36	-0.36	8.79e-10	Lewy body disease;
CESC	cis	rs6951245	0.542	rs28460147	chr7:1217192	G/A	cg24642844	chr7:1081250	C7orf50	-0.56	-6.81	-0.39	6.51e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2304069	0.954	rs216125	chr5:149428395	C/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.92	11.68	0.58	1.06e-25	HIV-1 control;
CESC	cis	rs3617	0.573	rs3821873	chr3:52913006	C/T	cg07507251	chr3:52567010	NT5DC2	-0.32	-5.39	-0.31	1.57e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
CESC	cis	rs2243480	0.708	rs35310401	chr7:65390359	A/G	cg13147721	chr7:65941812	NA	-0.85	-8.1	-0.45	2e-14	Diabetic kidney disease;
CESC	cis	rs909674	0.818	rs7364148	chr22:39842165	T/C	cg24399712	chr22:39784796	NA	-0.83	-10.31	-0.53	3.67e-21	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs6502050	0.769	rs11658272	chr17:80084596	C/T	cg11859384	chr17:80120422	CCDC57	0.38	5.12	0.3	6.01e-7	Life satisfaction;
CESC	cis	rs80130819	0.688	rs2732475	chr12:48700754	G/C	cg05342945	chr12:48394962	COL2A1	-0.51	-5.6	-0.33	5.35e-8	Prostate cancer;
CESC	cis	rs6933660	0.800	rs963193	chr6:151789355	G/T	cg10883421	chr6:151773342	RMND1;C6orf211	-0.82	-13.34	-0.63	2.15e-31	Menarche (age at onset);
CESC	cis	rs2075371	0.897	rs10488428	chr7:133997560	C/T	cg20476274	chr7:133979776	SLC35B4	0.64	9.1	0.49	2.26e-17	Mean platelet volume;
CESC	cis	rs6831352	0.693	rs2602875	chr4:100039495	C/G	cg13256891	chr4:100009986	ADH5	0.69	8.13	0.45	1.61e-14	Alcohol dependence;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12975330	chr19:53228974	ZNF611	-0.51	-5.99	-0.35	6.65e-9	Gut microbiome composition (summer);
CESC	cis	rs561341	1.000	rs576985	chr17:30323323	C/T	cg23018236	chr17:30244563	NA	-0.52	-5.11	-0.3	6.12e-7	Hip circumference adjusted for BMI;
CESC	cis	rs1153858	1.000	rs2056493	chr15:45648272	A/G	cg21132104	chr15:45694354	SPATA5L1	0.79	10.96	0.56	2.66e-23	Homoarginine levels;
CESC	trans	rs1814175	0.645	rs1851869	chr11:49960552	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.43	-6.24	-0.36	1.75e-9	Height;
CESC	cis	rs117623576	0.941	rs111379000	chr10:32427247	A/G	cg03047570	chr10:32398778	NA	-0.57	-5.57	-0.32	6.11e-8	Anti-saccade response;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13921204	chr10:12171454	SEC61A2	0.58	6.75	0.38	9.51e-11	Gut microbiome composition (summer);
CESC	trans	rs1814175	0.607	rs11493324	chr11:50011304	T/C	cg03929089	chr4:120376271	NA	-0.73	-9.4	-0.5	2.77e-18	Height;
CESC	cis	rs7590368	0.640	rs12472302	chr2:10941301	G/A	cg15705551	chr2:10952987	PDIA6	0.54	5.2	0.3	4.09e-7	Educational attainment (years of education);
CESC	cis	rs507506	0.771	rs929229	chr17:7105399	C/T	cg13729891	chr17:7108468	DLG4	-0.43	-5.35	-0.31	1.91e-7	Adiponectin levels;
CESC	cis	rs7914558	0.966	rs1591915	chr10:104646849	C/T	cg15744005	chr10:104629667	AS3MT	-0.34	-5.49	-0.32	9.27e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs9322193	0.923	rs1984111	chr6:150152856	G/A	cg04369109	chr6:150039330	LATS1	-0.44	-6.24	-0.36	1.7e-9	Lung cancer;
CESC	cis	rs7666738	0.800	rs11941885	chr4:99072921	A/C	cg24818145	chr4:99064322	C4orf37	0.4	5.04	0.3	8.69e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7666738	0.830	rs7664340	chr4:99037820	C/T	cg05340658	chr4:99064831	C4orf37	0.8	12.38	0.61	4.34e-28	Colonoscopy-negative controls vs population controls;
CESC	trans	rs4129059	0.834	rs72759620	chr1:214684150	G/A	cg08821431	chr12:34491090	NA	0.62	6.73	0.38	1.03e-10	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs6430585	0.583	rs60253740	chr2:136571852	G/T	cg07169764	chr2:136633963	MCM6	1.3	19.5	0.77	4.07e-53	Corneal structure;
CESC	cis	rs11098499	0.863	rs7699064	chr4:120428309	A/G	cg24375607	chr4:120327624	NA	-0.43	-5.22	-0.31	3.68e-7	Corneal astigmatism;
CESC	cis	rs116095464	0.558	rs9312957	chr5:202194	C/T	cg16372103	chr5:203701	NA	0.49	5.49	0.32	9.48e-8	Breast cancer;
CESC	cis	rs7605827	0.930	rs10189403	chr2:15635664	T/A	cg19274914	chr2:15703543	NA	0.36	6.32	0.36	1.09e-9	Educational attainment (years of education);
CESC	cis	rs4975616	0.804	rs457130	chr5:1336178	A/T	cg26373071	chr5:1325741	CLPTM1L	0.44	6.94	0.39	2.94e-11	Lung cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23323388	chr11:6502596	FXC1;ARFIP2	0.55	6.06	0.35	4.58e-9	Gut microbiome composition (summer);
CESC	cis	rs7927771	1.000	rs12418852	chr11:47868853	C/G	cg18512352	chr11:47633146	NA	-0.6	-9.47	-0.5	1.62e-18	Subjective well-being;
CESC	cis	rs1395	0.710	rs72817533	chr2:27482612	A/G	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.42	5.48	0.32	9.82e-8	Blood metabolite levels;
CESC	cis	rs9303280	0.806	rs10852935	chr17:38031674	C/T	cg19468946	chr17:37922297	IKZF3	-0.41	-5.42	-0.32	1.34e-7	Self-reported allergy;
CESC	cis	rs10504229	0.516	rs11781671	chr8:57992733	T/C	cg22535103	chr8:58192502	C8orf71	-0.48	-5.89	-0.34	1.16e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs727505	1.000	rs10240673	chr7:124513050	A/G	cg23710748	chr7:124431027	NA	-0.47	-7.43	-0.42	1.46e-12	Lewy body disease;
CESC	cis	rs12410462	0.582	rs12408978	chr1:227596235	A/T	cg04117972	chr1:227635322	NA	-0.73	-6.88	-0.39	4.18e-11	Major depressive disorder;
CESC	cis	rs4588572	0.686	rs10078289	chr5:77670793	T/G	cg11547950	chr5:77652471	NA	0.45	5.76	0.33	2.37e-8	Triglycerides;
CESC	cis	rs863345	0.604	rs7549581	chr1:158489704	T/C	cg12129480	chr1:158549410	OR10X1	-0.34	-6.85	-0.39	5.17e-11	Pneumococcal bacteremia;
CESC	cis	rs6032067	0.929	rs2233883	chr20:43835822	T/C	cg11264863	chr20:43835661	SEMG1	0.48	5.26	0.31	2.99e-7	Blood protein levels;
CESC	cis	rs875971	0.660	rs1860470	chr7:66103694	G/C	cg25985355	chr7:65971099	NA	0.32	5.29	0.31	2.51e-7	Aortic root size;
CESC	cis	rs2735413	0.918	rs36068555	chr16:78077082	G/A	cg04733911	chr16:78082701	NA	-0.53	-9.01	-0.48	4.08e-17	Systolic blood pressure (alcohol consumption interaction);
CESC	cis	rs9611519	1.000	rs9611520	chr22:41613303	C/T	cg03806693	chr22:41940476	POLR3H	-0.62	-6.45	-0.37	5.16e-10	Neuroticism;
CESC	cis	rs6831352	0.918	rs28987097	chr4:100049579	C/T	cg13256891	chr4:100009986	ADH5	-0.77	-8.43	-0.46	2.27e-15	Alcohol dependence;
CESC	cis	rs10870270	1.000	rs7077744	chr10:133770201	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.86	-12.56	-0.61	1.08e-28	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs6964587	1.000	rs1063243	chr7:91726927	A/C	cg17063962	chr7:91808500	NA	0.55	7.6	0.42	5e-13	Breast cancer;
CESC	cis	rs7208859	0.573	rs11656278	chr17:29075188	C/T	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.1e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs1707322	0.721	rs4415615	chr1:46132109	C/T	cg05343316	chr1:45956843	TESK2	0.51	6.24	0.36	1.7e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs4803468	1.000	rs284651	chr19:41928336	T/C	cg14132834	chr19:41945861	ATP5SL	-0.66	-8.15	-0.45	1.46e-14	Height;
CESC	cis	rs55788414	0.860	rs28697180	chr16:81185079	C/T	cg06400318	chr16:81190750	PKD1L2	-0.6	-6.82	-0.39	6.19e-11	Left ventricular obstructive tract defect (maternal effect);
CESC	cis	rs2243480	1.000	rs781142	chr7:65438778	C/T	cg18252515	chr7:66147081	NA	-1.08	-10.48	-0.54	9.71e-22	Diabetic kidney disease;
CESC	cis	rs10242455	0.557	rs2404487	chr7:99038057	G/A	cg18809830	chr7:99032528	PTCD1	-0.63	-5.13	-0.3	5.68e-7	Blood metabolite levels;
CESC	cis	rs1799949	0.965	rs4793204	chr17:41279298	A/G	cg06001716	chr17:41278141	BRCA1;NBR2	0.39	5.28	0.31	2.75e-7	Menopause (age at onset);
CESC	cis	rs1514687	0.534	rs73911839	chr2:1475088	C/T	cg13703866	chr2:1479523	TPO	-0.79	-5.36	-0.31	1.81e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);
CESC	cis	rs7520050	0.743	rs61789988	chr1:46085242	G/C	cg24296786	chr1:45957014	TESK2	0.44	5.58	0.32	5.88e-8	Red blood cell count;Reticulocyte count;
CESC	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	22.27	0.81	1.17e-62	Prudent dietary pattern;
CESC	cis	rs2549003	1.000	rs6873426	chr5:131818631	G/T	cg02551604	chr5:131831745	NA	-0.37	-5.23	-0.31	3.45e-7	Asthma (sex interaction);
CESC	cis	rs6060717	0.610	rs2794383	chr20:34615152	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-7.86	-0.43	9.46e-14	Hip circumference adjusted for BMI;
CESC	cis	rs28374715	0.532	rs316606	chr15:41772202	A/C	cg18705301	chr15:41695430	NDUFAF1	-1.08	-17.26	-0.73	2.91e-45	Ulcerative colitis;
CESC	cis	rs2735413	0.875	rs4888736	chr16:78083784	T/C	cg04733911	chr16:78082701	NA	-0.53	-8.89	-0.48	9.44e-17	Systolic blood pressure (alcohol consumption interaction);
CESC	cis	rs1552244	1.000	rs113771705	chr3:10075983	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.78	-10.37	-0.54	2.25e-21	Alzheimer's disease;
CESC	cis	rs9549367	0.713	rs9549356	chr13:113851633	A/G	cg18105134	chr13:113819100	PROZ	-0.7	-8.26	-0.45	6.89e-15	Platelet distribution width;
CESC	cis	rs514406	0.607	rs6696940	chr1:53203427	C/T	cg08859206	chr1:53392774	SCP2	0.54	6.88	0.39	4.29e-11	Monocyte count;
CESC	cis	rs2204008	0.818	rs1589389	chr12:38416041	G/A	cg26384229	chr12:38710491	ALG10B	-0.62	-9.34	-0.5	4.08e-18	Bladder cancer;
CESC	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg06873352	chr17:61820015	STRADA	0.72	12.91	0.62	6.56e-30	Prudent dietary pattern;
CESC	cis	rs7618915	0.547	rs12486847	chr3:52691112	T/C	cg18404041	chr3:52824283	ITIH1	-0.4	-6.69	-0.38	1.36e-10	Bipolar disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11855759	chr17:9548802	USP43	0.59	6.85	0.39	5.05e-11	Gut microbiome composition (summer);
CESC	trans	rs7618501	1.000	rs3749241	chr3:49744392	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.58	-8.35	-0.46	3.8e-15	Intelligence (multi-trait analysis);
CESC	cis	rs4665809	0.549	rs62130460	chr2:26472718	T/C	cg26119090	chr2:26468346	HADHA;HADHB	1.05	11.23	0.57	3.43e-24	Gut microbiome composition (summer);
CESC	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg26338869	chr17:61819248	STRADA	0.67	8.77	0.47	2.24e-16	Prudent dietary pattern;
CESC	cis	rs12410462	1.000	rs75360545	chr1:227625419	T/C	cg23173402	chr1:227635558	NA	0.57	5.92	0.34	9.9e-9	Major depressive disorder;
CESC	trans	rs11098499	0.909	rs79026312	chr4:120440677	C/A	cg25214090	chr10:38739885	LOC399744	0.71	9.72	0.51	2.74e-19	Corneal astigmatism;
CESC	cis	rs12541335	0.639	rs13257108	chr8:22165043	T/C	cg02788857	chr8:22132959	PIWIL2	0.32	5.59	0.32	5.6e-8	Hypertriglyceridemia;
CESC	cis	rs2439831	0.867	rs11856184	chr15:43919162	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.71	8.69	0.47	3.81e-16	Lung cancer in ever smokers;
CESC	cis	rs6032067	0.929	rs13039213	chr20:43805712	A/C	cg10761708	chr20:43804764	PI3	0.53	6.33	0.36	1.04e-9	Blood protein levels;
CESC	cis	rs668210	0.894	rs1786171	chr11:65769809	G/C	cg02202077	chr11:65769826	EIF1AD;BANF1	0.74	9.4	0.5	2.64e-18	Cerebrospinal fluid biomarker levels;
CESC	cis	rs7680126	0.530	rs2903827	chr4:10175872	C/G	cg11266682	chr4:10021025	SLC2A9	-0.46	-6.18	-0.36	2.38e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	cis	rs875971	1.000	rs9986696	chr7:65704576	C/A	cg18876405	chr7:65276391	NA	-0.5	-6.9	-0.39	3.87e-11	Aortic root size;
CESC	cis	rs561341	0.941	rs112569713	chr17:30271738	C/T	cg12193833	chr17:30244370	NA	-0.62	-6.33	-0.36	1.06e-9	Hip circumference adjusted for BMI;
CESC	cis	rs4665809	0.590	rs13016807	chr2:26496186	G/C	cg25036284	chr2:26402008	FAM59B	0.82	8.69	0.47	3.88e-16	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01971940	chr16:1259322	CACNA1H	-0.44	-6.02	-0.35	5.89e-9	Gut microbiome composition (summer);
CESC	cis	rs2836974	0.897	rs8132295	chr21:40527774	A/G	cg11890956	chr21:40555474	PSMG1	-1.16	-23.2	-0.82	9.1e-66	Cognitive function;
CESC	cis	rs7618915	0.547	rs10780035	chr3:52764624	C/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.31	5.48	0.32	9.89e-8	Bipolar disorder;
CESC	cis	rs6502050	0.787	rs7222326	chr17:80057272	T/C	cg23985595	chr17:80112537	CCDC57	0.4	6.05	0.35	4.99e-9	Life satisfaction;
CESC	cis	rs13191362	0.935	rs34035978	chr6:163165336	G/C	cg06582575	chr6:163149167	PACRG;PARK2	0.67	7.11	0.4	1.05e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs3106136	0.934	rs35995707	chr4:95167150	C/G	cg11021082	chr4:95130006	SMARCAD1	-0.46	-6.94	-0.39	3.02e-11	Capecitabine sensitivity;
CESC	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg26354017	chr1:205819088	PM20D1	0.49	6.99	0.39	2.27e-11	Menarche (age at onset);
CESC	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.58	-8.93	-0.48	7.28e-17	Longevity;Endometriosis;
CESC	cis	rs6963495	0.818	rs6973974	chr7:105170629	C/T	cg13798780	chr7:105162888	PUS7	0.77	7.88	0.44	8.3e-14	Bipolar disorder (body mass index interaction);
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg24004055	chr6:25279718	LRRC16A	-0.45	-6.11	-0.35	3.49e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs11098499	1.000	rs13116504	chr4:120209412	A/C	cg24375607	chr4:120327624	NA	0.42	5.04	0.3	8.8e-7	Corneal astigmatism;
CESC	cis	rs9814567	0.806	rs7626557	chr3:134318213	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.38	-5.05	-0.3	8.34e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs4563143	0.675	rs55849754	chr19:29279665	G/A	cg04546413	chr19:29218101	NA	0.54	7.17	0.4	7.28e-12	Methadone dose in opioid dependence;
CESC	trans	rs916888	0.779	rs199528	chr17:44843136	C/T	cg23590916	chr17:43697445	MGC57346	0.65	6.58	0.37	2.51e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs79976124	0.797	rs74995761	chr6:66640216	G/A	cg07460842	chr6:66804631	NA	0.72	8.37	0.46	3.35e-15	Type 2 diabetes;
CESC	cis	rs7666738	0.830	rs6853266	chr4:99047528	G/T	cg03676636	chr4:99064102	C4orf37	0.36	5.42	0.32	1.35e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2479724	0.935	rs2025951	chr6:41827193	C/T	cg08135965	chr6:41755394	TOMM6	-0.39	-5.37	-0.31	1.7e-7	Menarche (age at onset);
CESC	cis	rs941408	0.515	rs759067	chr19:2775668	C/T	cg06609049	chr19:2785107	THOP1	0.96	14.63	0.67	6.13e-36	Total cholesterol levels;
CESC	cis	rs2777491	1.000	rs7177641	chr15:41743426	C/T	cg20272979	chr15:41787780	ITPKA	0.46	6.87	0.39	4.62e-11	Ulcerative colitis;
CESC	cis	rs9908102	0.740	rs58854608	chr17:12904540	C/T	cg26162695	chr17:12921313	ELAC2	0.5	5.49	0.32	9.61e-8	Schizophrenia;
CESC	cis	rs34638657	0.702	rs11866709	chr16:82201017	A/G	cg09439754	chr16:82129088	HSD17B2	-0.36	-6.24	-0.36	1.71e-9	Lung adenocarcinoma;
CESC	cis	rs853679	0.517	rs6941992	chr6:28106141	T/C	cg17949981	chr6:28129498	ZNF389	0.45	5.71	0.33	3.07e-8	Depression;
CESC	cis	rs870825	0.616	rs10006828	chr4:185651416	C/T	cg04058563	chr4:185651563	MLF1IP	0.63	6.96	0.39	2.74e-11	Blood protein levels;
CESC	cis	rs722599	0.683	rs2058918	chr14:75288518	A/G	cg08847533	chr14:75593920	NEK9	0.5	5.97	0.34	7.71e-9	IgG glycosylation;
CESC	cis	rs863345	0.604	rs1894038	chr1:158455947	T/C	cg12129480	chr1:158549410	OR10X1	-0.36	-7.14	-0.4	8.77e-12	Pneumococcal bacteremia;
CESC	cis	rs2576037	0.796	rs2571032	chr18:44578250	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.6	-8.71	-0.47	3.35e-16	Personality dimensions;
CESC	trans	rs7980799	0.711	rs12319055	chr12:33626509	C/T	cg26384229	chr12:38710491	ALG10B	-0.55	-7.81	-0.43	1.32e-13	Heart rate;Heart rate variability traits (RMSSD);
CESC	cis	rs17711722	0.701	rs4467826	chr7:65368708	A/G	cg11764359	chr7:65958608	NA	0.66	8.46	0.46	1.78e-15	Calcium levels;
CESC	cis	rs11750568	0.967	rs6864279	chr5:178515060	G/T	cg10208897	chr5:178548229	ADAMTS2	-0.38	-5.44	-0.32	1.24e-7	Height;
CESC	cis	rs9911578	0.967	rs1588322	chr17:56990099	T/C	cg05425664	chr17:57184151	TRIM37	-0.5	-6.81	-0.39	6.5500000000000006e-11	Intelligence (multi-trait analysis);
CESC	cis	rs8099014	0.814	rs7227488	chr18:56113233	A/G	cg19312305	chr18:56117016	MIR122	-0.26	-5.17	-0.3	4.51e-7	Platelet count;
CESC	cis	rs7818345	0.967	rs17479099	chr8:19277144	T/C	cg11303988	chr8:19266685	CSGALNACT1	0.32	5.84	0.34	1.56e-8	Language performance in older adults (adjusted for episodic memory);
CESC	cis	rs1538970	0.924	rs7531253	chr1:45890183	T/C	cg05343316	chr1:45956843	TESK2	0.89	12.41	0.61	3.59e-28	Platelet count;
CESC	cis	rs853679	0.517	rs4711164	chr6:28115156	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.6	-6.84	-0.39	5.51e-11	Depression;
CESC	cis	rs28374715	0.528	rs7181982	chr15:41623020	C/G	cg20272979	chr15:41787780	ITPKA	0.47	5.58	0.32	5.94e-8	Ulcerative colitis;
CESC	cis	rs853679	0.517	rs4713144	chr6:28106790	C/G	cg26335602	chr6:28129616	ZNF389	0.54	7.3	0.41	3.37e-12	Depression;
CESC	cis	rs57506017	0.561	rs3800847	chr7:12262242	G/A	cg23422036	chr7:12250390	TMEM106B	0.39	5.23	0.31	3.51e-7	Neuroticism;
CESC	cis	rs617791	0.508	rs747526	chr11:65776071	C/A	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.44	-5.12	-0.3	6.02e-7	Breast cancer;
CESC	cis	rs711245	0.574	rs1179494	chr2:36809496	C/G	cg01206211	chr2:36825736	FEZ2	-0.33	-5.75	-0.33	2.39e-8	Height;
CESC	cis	rs9488822	0.676	rs11153594	chr6:116354591	A/G	cg05304507	chr6:116381966	FRK	-0.26	-6.75	-0.38	9.16e-11	Cholesterol, total;LDL cholesterol;
CESC	cis	rs250677	0.522	rs62378210	chr5:148384885	G/A	cg18129178	chr5:148520854	ABLIM3	-0.46	-5.14	-0.3	5.32e-7	Breast cancer;
CESC	cis	rs1448094	0.511	rs17345272	chr12:86165334	A/C	cg02569458	chr12:86230093	RASSF9	0.5	7.71	0.43	2.53e-13	Major depressive disorder;
CESC	cis	rs514406	0.547	rs377808	chr1:53190359	T/G	cg24675658	chr1:53192096	ZYG11B	-0.63	-7.68	-0.43	3.03e-13	Monocyte count;
CESC	cis	rs6964587	1.000	rs2961020	chr7:91573308	G/A	cg17063962	chr7:91808500	NA	-0.54	-7.12	-0.4	9.86e-12	Breast cancer;
CESC	cis	rs8060686	0.641	rs7190079	chr16:68073834	G/A	cg26727032	chr16:67993705	SLC12A4	-0.54	-6.21	-0.36	2.01e-9	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs9291683	0.620	rs4383618	chr4:10125151	T/C	cg11266682	chr4:10021025	SLC2A9	-0.48	-8.68	-0.47	4.01e-16	Bone mineral density;
CESC	cis	rs35306767	0.761	rs12771539	chr10:1050653	A/G	cg20503657	chr10:835505	NA	0.69	6.31	0.36	1.19e-9	Eosinophil percentage of granulocytes;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg09920427	chr19:12777674	MORG1;MAN2B1	0.52	6.82	0.39	6.05e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs8077889	0.703	rs231531	chr17:41946180	A/C	cg26893861	chr17:41843967	DUSP3	0.66	6.92	0.39	3.43e-11	Triglycerides;
CESC	cis	rs9811920	0.695	rs1287284	chr3:99516962	C/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.43	-7.03	-0.4	1.72e-11	Axial length;
CESC	cis	rs875971	0.619	rs2302918	chr7:66000932	A/G	cg06456125	chr7:65229604	NA	0.41	5.26	0.31	2.99e-7	Aortic root size;
CESC	cis	rs734999	0.588	rs4648652	chr1:2535758	A/G	cg18854424	chr1:2615690	NA	0.28	5.64	0.33	4.44e-8	Ulcerative colitis;
CESC	cis	rs1552244	1.000	rs3895942	chr3:10108745	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-11.04	-0.56	1.41e-23	Alzheimer's disease;
CESC	cis	rs6964587	1.000	rs6956596	chr7:91750107	T/G	cg17063962	chr7:91808500	NA	0.53	7.14	0.4	9.24e-12	Breast cancer;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg27426340	chr1:11589839	PTCHD2	-0.37	-6.39	-0.37	7.33e-10	Systemic lupus erythematosus;
CESC	cis	rs2742234	0.541	rs7098236	chr10:43740508	T/C	cg15436174	chr10:43711423	RASGEF1A	0.46	5.3	0.31	2.44e-7	Hirschsprung disease;
CESC	cis	rs2576037	0.796	rs2576038	chr18:44582200	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.61	-8.73	-0.47	2.87e-16	Personality dimensions;
CESC	cis	rs11792861	0.781	rs2297581	chr9:111755008	C/T	cg05043794	chr9:111880884	C9orf5	-0.38	-6.26	-0.36	1.54e-9	Menarche (age at onset);
CESC	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg24846343	chr22:24311635	DDTL	0.63	10.51	0.54	7.74e-22	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs208520	0.661	rs851466	chr6:66840476	A/G	cg07460842	chr6:66804631	NA	-0.99	-13.42	-0.64	1.15e-31	Exhaled nitric oxide output;
CESC	cis	rs35306767	0.904	rs10904584	chr10:983747	A/T	cg26597838	chr10:835615	NA	0.71	8.15	0.45	1.43e-14	Eosinophil percentage of granulocytes;
CESC	cis	rs6121246	0.567	rs6060260	chr20:30192907	C/T	cg13852791	chr20:30311386	BCL2L1	0.58	5.56	0.32	6.65e-8	Mean corpuscular hemoglobin;
CESC	cis	rs12780046	0.536	rs12268360	chr10:101013466	C/G	cg27143070	chr10:101087766	CNNM1	0.38	5.62	0.33	4.74e-8	Non-glioblastoma glioma;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18048544	chr8:38033938	LSM1;BAG4	0.75	8.15	0.45	1.48e-14	Gut microbiome composition (summer);
CESC	cis	rs3540	0.597	rs1978150	chr15:91037041	A/G	cg22089800	chr15:90895588	ZNF774	-0.65	-8.92	-0.48	7.99e-17	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs75804782	0.521	rs72994973	chr2:239428315	C/T	cg18131467	chr2:239335373	ASB1	-0.68	-5.18	-0.3	4.38e-7	Morning vs. evening chronotype;Chronotype;
CESC	cis	rs10751667	0.714	rs7396700	chr11:963863	A/C	cg01483505	chr11:975446	AP2A2	0.36	5.05	0.3	8.13e-7	Alzheimer's disease (late onset);
CESC	cis	rs830124	0.602	rs686220	chr12:122386515	A/G	cg22168489	chr12:122356033	WDR66	-0.38	-5.05	-0.3	8.27e-7	Urinary metabolites;
CESC	cis	rs61931739	0.534	rs7965503	chr12:34199349	A/G	cg19457237	chr12:34500585	NA	-0.4	-5.42	-0.32	1.32e-7	Morning vs. evening chronotype;
CESC	cis	rs6089829	0.962	rs7267951	chr20:61665979	A/G	cg08564027	chr20:61660810	NA	0.9	15.37	0.69	1.54e-38	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7666738	0.546	rs9993299	chr4:98815976	G/A	cg05340658	chr4:99064831	C4orf37	0.54	6.35	0.36	9.22e-10	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9325144	0.647	rs34311455	chr12:39060889	C/T	cg26384229	chr12:38710491	ALG10B	-0.52	-7.23	-0.41	5.23e-12	Morning vs. evening chronotype;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg09311052	chr1:154531418	UBE2Q1	-0.42	-6.17	-0.35	2.58e-9	Gambling;
CESC	cis	rs3820068	0.603	rs1122387	chr1:15947282	T/C	cg17385448	chr1:15911702	AGMAT	0.42	6.83	0.39	5.64e-11	Systolic blood pressure;
CESC	cis	rs10979	1.000	rs13198159	chr6:143891953	C/T	cg25407410	chr6:143891975	LOC285740	-0.62	-9.3	-0.5	5.3e-18	Hypospadias;
CESC	cis	rs1862618	0.671	rs906631	chr5:56245803	C/G	cg22800045	chr5:56110881	MAP3K1	-0.61	-7.83	-0.43	1.21e-13	Initial pursuit acceleration;
CESC	cis	rs1008375	0.931	rs2315558	chr4:17674558	C/A	cg16339924	chr4:17578868	LAP3	0.54	6.64	0.38	1.76e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.64	7.2	0.4	6.15e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs10504073	0.584	rs62507210	chr8:49946601	C/T	cg00325661	chr8:49890786	NA	0.58	8.75	0.47	2.59e-16	Blood metabolite ratios;
CESC	cis	rs1577917	1.000	rs2324843	chr6:86617501	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-6.22	-0.36	1.9e-9	Response to antipsychotic treatment;
CESC	cis	rs12497850	0.931	rs13064784	chr3:49135961	C/G	cg03060546	chr3:49711283	APEH	0.52	6.31	0.36	1.17e-9	Parkinson's disease;
CESC	cis	rs7100689	0.622	rs1340383	chr10:82095968	T/G	cg00277334	chr10:82204260	NA	-0.6	-7.96	-0.44	5.06e-14	Post bronchodilator FEV1;
CESC	cis	rs561341	1.000	rs560132	chr17:30320019	C/T	cg19193384	chr17:30244184	NA	-0.71	-6.63	-0.38	1.85e-10	Hip circumference adjusted for BMI;
CESC	trans	rs709082	0.771	rs796627	chr3:191455386	T/G	cg25305879	chr2:106814630	NA	0.4	6.33	0.36	1.03e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4862750	0.872	rs7671914	chr4:187878165	A/G	cg03647317	chr4:187891568	NA	-0.39	-5.76	-0.33	2.37e-8	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7560272	0.501	rs7210	chr2:73957124	A/G	cg20560298	chr2:73613845	ALMS1	0.43	5.86	0.34	1.4e-8	Schizophrenia;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg14751398	chr6:20402153	E2F3	0.51	6.59	0.38	2.37e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs910316	0.673	rs2012627	chr14:75443103	C/T	cg11812906	chr14:75593930	NEK9	0.73	11.2	0.57	4.15e-24	Height;
CESC	cis	rs10540	1.000	rs61876340	chr11:495699	A/C	cg03934478	chr11:495069	RNH1	0.56	5.36	0.31	1.77e-7	Body mass index;
CESC	cis	rs9649213	0.593	rs2394854	chr7:98027306	A/G	cg24562669	chr7:97807699	LMTK2	0.52	7.75	0.43	1.91e-13	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7927771	0.756	rs10742803	chr11:47439938	A/G	cg20307385	chr11:47447363	PSMC3	0.69	8.91	0.48	8.43e-17	Subjective well-being;
CESC	cis	rs12410462	0.579	rs77529417	chr1:227547895	T/C	cg10327440	chr1:227177885	CDC42BPA	-0.68	-5.74	-0.33	2.56e-8	Major depressive disorder;
CESC	cis	rs1799949	0.550	rs2343818	chr17:41409774	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.61	8.0	0.44	3.91e-14	Menopause (age at onset);
CESC	cis	rs6570726	0.935	rs422540	chr6:145837815	G/T	cg05347473	chr6:146136440	FBXO30	0.49	6.69	0.38	1.3100000000000001e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs614226	0.938	rs7972244	chr12:120994872	A/G	cg01236616	chr12:121019343	POP5	1.5	18.76	0.76	1.47e-50	Type 1 diabetes nephropathy;
CESC	cis	rs2204008	0.582	rs11179135	chr12:38204689	A/C	cg26384229	chr12:38710491	ALG10B	0.73	10.16	0.53	1.08e-20	Bladder cancer;
CESC	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg04622731	chr7:157956161	PTPRN2	-0.5	-7.42	-0.41	1.63e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CESC	cis	rs8141529	0.764	rs8137969	chr22:29228484	G/C	cg02153584	chr22:29168773	CCDC117	0.64	9.16	0.49	1.46e-17	Lymphocyte counts;
CESC	cis	rs1270639	0.778	rs2530404	chr7:157445995	C/T	cg13357408	chr7:157437802	PTPRN2	-0.61	-7.15	-0.4	8.33e-12	Colorectal cancer;
CESC	cis	rs4253772	0.550	rs9615913	chr22:46668515	A/T	cg10231785	chr22:46692440	CN5H6.4;GTSE1	-0.56	-6.02	-0.35	5.77e-9	LDL cholesterol;Cholesterol, total;
CESC	cis	rs3820928	0.874	rs13403281	chr2:227880769	G/A	cg11843606	chr2:227700838	RHBDD1	-0.44	-5.71	-0.33	2.95e-8	Pulmonary function;
CESC	cis	rs11098499	0.863	rs10013305	chr4:120450424	G/A	cg24375607	chr4:120327624	NA	0.43	5.21	0.3	3.82e-7	Corneal astigmatism;
CESC	cis	rs2408955	0.522	rs3997	chr12:48481587	T/C	cg24011408	chr12:48396354	COL2A1	-0.5	-7.48	-0.42	1.11e-12	Glycated hemoglobin levels;
CESC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg08163220	chr3:31574309	STT3B	0.48	6.87	0.39	4.61e-11	Intelligence (multi-trait analysis);
CESC	cis	rs7666738	0.830	rs6846229	chr4:99016546	C/T	cg18180107	chr4:99064573	C4orf37	0.41	5.4	0.31	1.48e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6461049	0.608	rs3800923	chr7:2184673	A/G	cg08027265	chr7:2291960	NA	-0.39	-6.18	-0.35	2.46e-9	Schizophrenia;
CESC	cis	rs9287719	0.837	rs4233883	chr2:10755596	A/G	cg02196655	chr2:10830764	NOL10	-0.36	-5.44	-0.32	1.24e-7	Prostate cancer;
CESC	cis	rs17021463	0.673	rs35898424	chr4:95289278	A/G	cg11021082	chr4:95130006	SMARCAD1	0.51	6.98	0.39	2.32e-11	Testicular germ cell tumor;
CESC	cis	rs7666738	0.830	rs10007872	chr4:99001904	T/C	cg03467027	chr4:99064603	C4orf37	0.43	5.4	0.31	1.49e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs514406	0.895	rs1925673	chr1:53326984	T/G	cg25767906	chr1:53392781	SCP2	-0.44	-5.61	-0.33	4.98e-8	Monocyte count;
CESC	cis	rs933688	0.877	rs10474352	chr5:90732225	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.99	11.86	0.59	2.7e-26	Smoking behavior;
CESC	cis	rs644799	1.000	rs494829	chr11:95571750	C/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.55	6.53	0.37	3.39e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs2836974	0.897	rs2836929	chr21:40543811	T/C	cg17971929	chr21:40555470	PSMG1	1.03	15.85	0.7	2.92e-40	Cognitive function;
CESC	cis	rs10129255	0.833	rs61997797	chr14:107223423	G/A	cg23076370	chr14:107095027	NA	-0.44	-5.18	-0.3	4.3e-7	Kawasaki disease;
CESC	cis	rs13256369	1.000	rs873063	chr8:8572447	A/G	cg17143192	chr8:8559678	CLDN23	0.75	8.97	0.48	5.42e-17	Obesity-related traits;
CESC	cis	rs9549367	0.713	rs9577211	chr13:113830718	G/C	cg18105134	chr13:113819100	PROZ	-0.65	-8.26	-0.45	7.1e-15	Platelet distribution width;
CESC	cis	rs854765	0.964	rs12943202	chr17:17994332	T/A	cg09796270	chr17:17721594	SREBF1	-0.37	-5.08	-0.3	7.17e-7	Total body bone mineral density;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06875660	chr1:85040134	CTBS	0.64	7.18	0.4	6.9e-12	Gut microbiome composition (summer);
CESC	cis	rs425277	1.000	rs385039	chr1:2077409	C/T	cg24578937	chr1:2090814	PRKCZ	-0.54	-9.49	-0.5	1.36e-18	Height;
CESC	cis	rs11098499	0.738	rs34965784	chr4:120361586	G/C	cg09307838	chr4:120376055	NA	0.94	13.7	0.64	1.18e-32	Corneal astigmatism;
CESC	cis	rs9322193	0.736	rs3828701	chr6:150112199	C/T	cg07701084	chr6:150067640	NUP43	0.44	5.95	0.34	8.4e-9	Lung cancer;
CESC	cis	rs4919687	0.679	rs12762176	chr10:104499232	A/T	cg04362960	chr10:104952993	NT5C2	0.45	5.21	0.3	3.88e-7	Colorectal cancer;
CESC	cis	rs12410462	0.581	rs113827839	chr1:227547180	C/T	cg10327440	chr1:227177885	CDC42BPA	-0.68	-5.74	-0.33	2.56e-8	Major depressive disorder;
CESC	cis	rs1065852	0.526	rs7290655	chr22:42390225	C/G	cg22189786	chr22:42395067	WBP2NL	0.44	5.5	0.32	8.77e-8	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg26804944	chr12:56660921	COQ10A	-0.48	-6.51	-0.37	3.65e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs10504229	0.636	rs117439064	chr8:58055279	A/G	cg24829409	chr8:58192753	C8orf71	-0.61	-6.7	-0.38	1.24e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs9549367	0.713	rs576463	chr13:113846614	C/T	cg00898013	chr13:113819073	PROZ	0.46	6.8	0.39	7.09e-11	Platelet distribution width;
CESC	trans	rs1545843	0.564	rs2468287	chr12:84888498	G/A	cg03015433	chr16:56623111	MT3	0.34	6.13	0.35	3.18e-9	Major depressive disorder;
CESC	cis	rs1670533	1.000	rs676561	chr4:1083112	C/T	cg04106633	chr4:1044584	NA	0.4	5.1	0.3	6.33e-7	Recombination rate (females);
CESC	cis	rs977987	0.806	rs11644306	chr16:75490053	T/C	cg03315344	chr16:75512273	CHST6	0.46	6.72	0.38	1.09e-10	Dupuytren's disease;
CESC	cis	rs7618915	1.000	rs34569561	chr3:52287293	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.39	5.14	0.3	5.23e-7	Bipolar disorder;
CESC	cis	rs1728785	0.901	rs6499186	chr16:68660565	C/T	cg02972257	chr16:68554789	NA	-0.66	-6.89	-0.39	4.06e-11	Ulcerative colitis;
CESC	cis	rs17539620	0.624	rs62432736	chr6:154834401	A/G	cg17771515	chr6:154831774	CNKSR3	0.6	6.0	0.35	6.52e-9	Lipoprotein (a) levels;
CESC	cis	rs2075371	0.933	rs2544191	chr7:133954248	A/G	cg11752832	chr7:134001865	SLC35B4	0.51	6.52	0.37	3.54e-10	Mean platelet volume;
CESC	cis	rs769267	0.930	rs3794993	chr19:19611550	G/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.46	5.86	0.34	1.35e-8	Tonsillectomy;
CESC	cis	rs854765	0.583	rs4925123	chr17:17784374	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.48	-6.65	-0.38	1.71e-10	Total body bone mineral density;
CESC	cis	rs7772486	0.688	rs1884364	chr6:146337817	C/G	cg05347473	chr6:146136440	FBXO30	0.63	8.02	0.44	3.46e-14	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2066819	1.000	rs79718165	chr12:56644251	C/T	cg26734620	chr12:56694298	CS	1.04	6.73	0.38	1.06e-10	Psoriasis vulgaris;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19246266	chr1:68697366	GPR177	-0.6	-7.21	-0.4	6.02e-12	Gut microbiome composition (summer);
CESC	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg22963979	chr7:1858916	MAD1L1	-0.43	-5.88	-0.34	1.25e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs17376456	0.877	rs10060160	chr5:93387879	G/A	cg21475434	chr5:93447410	FAM172A	0.84	7.13	0.4	9.45e-12	Diabetic retinopathy;
CESC	cis	rs6062302	0.522	rs3761126	chr20:62252044	C/T	cg09650180	chr20:62225654	GMEB2	-0.82	-9.36	-0.5	3.43e-18	Glioblastoma;
CESC	cis	rs9486719	0.948	rs2092095	chr6:96870864	T/G	cg06623918	chr6:96969491	KIAA0776	0.81	8.29	0.45	5.61e-15	Migraine;Coronary artery disease;
CESC	cis	rs7914558	0.966	rs10748839	chr10:104953547	A/G	cg04362960	chr10:104952993	NT5C2	0.47	6.26	0.36	1.56e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs1008375	0.931	rs2315558	chr4:17674558	C/A	cg02297831	chr4:17616191	MED28	0.49	6.15	0.35	2.81e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs2243480	1.000	rs2707844	chr7:66059509	G/A	cg12463550	chr7:65579703	CRCP	0.74	5.83	0.34	1.61e-8	Diabetic kidney disease;
CESC	cis	rs10779751	0.770	rs2486922	chr1:11124885	T/C	cg08854313	chr1:11322531	MTOR	0.77	10.41	0.54	1.73e-21	Body mass index;
CESC	cis	rs6500395	0.962	rs9937623	chr16:48571590	A/T	cg04672837	chr16:48644449	N4BP1	-0.47	-5.61	-0.33	5.17e-8	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs6701037	1.000	rs6659824	chr1:175125378	C/A	cg00321850	chr1:175162397	KIAA0040	-0.42	-5.88	-0.34	1.22e-8	Alcohol dependence;
CESC	cis	rs8114671	0.562	rs34837802	chr20:33424908	C/G	cg07148914	chr20:33460835	GGT7	0.43	5.7	0.33	3.27e-8	Height;
CESC	cis	rs6011002	1.000	rs79391682	chr20:62297768	A/G	cg15212369	chr20:62274085	STMN3	-0.57	-5.16	-0.3	4.82e-7	Dental caries;
CESC	cis	rs360798	0.512	rs2710640	chr2:63144305	A/G	cg17519650	chr2:63277830	OTX1	0.54	7.04	0.4	1.66e-11	Coronary artery disease;
CESC	cis	rs9905704	0.633	rs2680712	chr17:56509865	C/T	cg12560992	chr17:57184187	TRIM37	0.53	5.27	0.31	2.83e-7	Testicular germ cell tumor;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg21211866	chr9:35111727	KIAA1539	-0.47	-6.39	-0.37	7.59e-10	Height;
CESC	cis	rs2576037	0.796	rs2576041	chr18:44580919	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.45	5.72	0.33	2.8e-8	Personality dimensions;
CESC	cis	rs2075371	0.933	rs1421482	chr7:133964383	A/G	cg00033643	chr7:134001901	SLC35B4	0.41	5.28	0.31	2.67e-7	Mean platelet volume;
CESC	cis	rs9733	0.744	rs12568757	chr1:150729793	C/T	cg13175981	chr1:150552382	MCL1	0.55	7.67	0.43	3.35e-13	Tonsillectomy;
CESC	cis	rs17376456	0.741	rs12374432	chr5:93481348	C/A	cg21475434	chr5:93447410	FAM172A	0.86	7.66	0.43	3.53e-13	Diabetic retinopathy;
CESC	cis	rs2072732	0.756	rs7514166	chr1:2949607	G/C	cg03976712	chr1:2946727	NA	0.34	5.63	0.33	4.53e-8	Plateletcrit;
CESC	cis	rs7191439	0.522	rs745326	chr16:88755245	C/G	cg27087555	chr16:88793112	FAM38A	-0.83	-5.89	-0.34	1.19e-8	Plateletcrit;
CESC	cis	rs853679	0.517	rs9368558	chr6:28133306	A/G	cg22143856	chr6:28129313	ZNF389	0.49	6.24	0.36	1.73e-9	Depression;
CESC	cis	rs875971	1.000	rs6958484	chr7:65599446	G/A	cg10691866	chr7:65817282	TPST1	0.34	5.54	0.32	7.19e-8	Aortic root size;
CESC	cis	rs2806561	0.894	rs629107	chr1:23537971	C/T	cg12483005	chr1:23474871	LUZP1	0.32	5.12	0.3	5.77e-7	Height;
CESC	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg04025307	chr7:1156635	C7orf50	0.4	5.48	0.32	9.88e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7618915	0.501	rs12635140	chr3:52738165	C/T	cg07507251	chr3:52567010	NT5DC2	-0.31	-5.29	-0.31	2.54e-7	Bipolar disorder;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg08306513	chr11:120040083	NA	0.48	6.92	0.39	3.3e-11	Systemic lupus erythematosus;
CESC	cis	rs9814567	0.963	rs36006513	chr3:134291913	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.45	6.1	0.35	3.71e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs3126085	0.935	rs12063165	chr1:152176357	C/T	cg03465714	chr1:152285911	FLG	-0.45	-5.45	-0.32	1.17e-7	Atopic dermatitis;
CESC	cis	rs9916302	0.706	rs11078894	chr17:37396805	C/G	cg07936489	chr17:37558343	FBXL20	-0.92	-10.72	-0.55	1.6e-22	Glomerular filtration rate (creatinine);
CESC	cis	rs769267	0.930	rs10419912	chr19:19597055	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	-0.47	-5.9	-0.34	1.11e-8	Tonsillectomy;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg24483304	chr1:43855122	MED8;C1orf84	0.49	6.29	0.36	1.32e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs6542838	0.641	rs13005124	chr2:99527680	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.4	-5.1	-0.3	6.46e-7	Fear of minor pain;
CESC	cis	rs1862618	0.671	rs2591966	chr5:56233688	T/G	cg24531977	chr5:56204891	C5orf35	0.62	8.47	0.46	1.69e-15	Initial pursuit acceleration;
CESC	cis	rs7949030	0.688	rs11231155	chr11:62365619	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.63	9.6	0.51	6.49e-19	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs7618915	0.570	rs11130319	chr3:52755592	A/T	cg17372223	chr3:52568218	NT5DC2	0.45	6.59	0.38	2.39e-10	Bipolar disorder;
CESC	cis	rs9611519	0.929	rs73174657	chr22:41434158	G/A	cg03806693	chr22:41940476	POLR3H	-0.57	-5.92	-0.34	1.01e-8	Neuroticism;
CESC	trans	rs1728785	1.000	rs1094282	chr16:68577260	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.61	7.49	0.42	1.04e-12	Ulcerative colitis;
CESC	cis	rs7998202	0.614	rs420431	chr13:113346317	C/G	cg02820901	chr13:113351484	ATP11A	-0.63	-5.74	-0.33	2.59e-8	Glycated hemoglobin levels;
CESC	cis	rs412050	0.948	rs34239349	chr22:22325624	G/A	cg17089214	chr22:22089827	YPEL1	0.7	5.99	0.35	6.84e-9	Attention deficit hyperactivity disorder;
CESC	cis	rs7666738	0.791	rs10033994	chr4:98969582	C/T	cg03467027	chr4:99064603	C4orf37	0.43	5.42	0.32	1.34e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1030268	0.577	rs13244007	chr7:133260825	A/G	cg10665199	chr7:133106180	EXOC4	0.5	5.32	0.31	2.25e-7	Intelligence (multi-trait analysis);
CESC	cis	rs9815354	1.000	rs9867627	chr3:41795841	G/T	cg03022575	chr3:42003672	ULK4	-0.54	-5.58	-0.32	6.05e-8	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs1401999	1.000	rs869417	chr3:183689138	T/C	cg01324343	chr3:183735012	ABCC5	0.62	13.05	0.63	2.19e-30	Anterior chamber depth;
CESC	cis	rs7560272	0.501	rs13003035	chr2:73957227	T/A	cg20560298	chr2:73613845	ALMS1	0.44	6.03	0.35	5.61e-9	Schizophrenia;
CESC	cis	rs8060686	0.516	rs1971546	chr16:68280893	T/C	cg26727032	chr16:67993705	SLC12A4	-0.57	-7.72	-0.43	2.32e-13	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs6061231	1.000	rs67941642	chr20:60958108	C/T	cg06197360	chr20:60970103	CABLES2	-0.42	-5.42	-0.32	1.33e-7	Colorectal cancer;
CESC	cis	rs7264396	0.676	rs58372200	chr20:34555445	C/A	cg17201900	chr20:34330562	RBM39	0.51	5.31	0.31	2.37e-7	Total cholesterol levels;
CESC	cis	rs9916302	0.904	rs2061342	chr17:37405657	T/G	cg20243544	chr17:37824526	PNMT	0.48	5.96	0.34	8.16e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs425277	0.583	rs1467217	chr1:2045165	G/A	cg04315214	chr1:2043799	PRKCZ	0.54	9.35	0.5	3.89e-18	Height;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg11015017	chr19:18390607	JUND	-0.48	-6.31	-0.36	1.17e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs12477438	0.501	rs7349217	chr2:99815146	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.91	15.67	0.69	1.24e-39	Chronic sinus infection;
CESC	cis	rs1062177	0.826	rs2915822	chr5:151130901	G/T	cg00977110	chr5:151150581	G3BP1	-0.58	-6.24	-0.36	1.72e-9	Preschool internalizing problems;
CESC	cis	rs7659604	0.676	rs6855269	chr4:122697418	T/G	cg19748678	chr4:122722346	EXOSC9	0.73	9.5	0.5	1.29e-18	Type 2 diabetes;
CESC	cis	rs17094448	0.557	rs117276277	chr14:74497463	G/A	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.8	5.37	0.31	1.71e-7	Blood protein levels;
CESC	cis	rs9902453	1.000	rs12600993	chr17:28291222	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	8.49	0.46	1.53e-15	Coffee consumption (cups per day);
CESC	cis	rs1018836	0.632	rs6995399	chr8:91481629	T/C	cg16814680	chr8:91681699	NA	-0.59	-8.07	-0.44	2.51e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs9457247	0.935	rs1187530	chr6:167376812	C/T	cg23791538	chr6:167370224	RNASET2	0.6	8.57	0.47	8.75e-16	Crohn's disease;
CESC	cis	rs10479542	0.892	rs7736163	chr5:178980316	G/C	cg19723775	chr5:179050963	HNRNPH1	0.41	5.46	0.32	1.08e-7	Lung cancer;
CESC	cis	rs5769765	0.874	rs4624	chr22:50281917	A/G	cg02269571	chr22:50332266	NA	0.46	6.28	0.36	1.39e-9	Schizophrenia;
CESC	cis	rs7017914	0.902	rs10504481	chr8:71699517	T/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.42	-5.3	-0.31	2.38e-7	Bone mineral density;
CESC	cis	rs2180341	1.000	rs9385419	chr6:127597591	A/G	cg24812749	chr6:127587940	RNF146	1.06	15.23	0.68	4.52e-38	Breast cancer;
CESC	cis	rs7216064	0.953	rs75231441	chr17:65885485	A/G	cg12091567	chr17:66097778	LOC651250	-0.86	-8.82	-0.48	1.55e-16	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs7580658	0.817	rs6761447	chr2:128074573	A/T	cg10021288	chr2:128175891	PROC	-0.41	-6.5	-0.37	4.02e-10	Protein C levels;
CESC	cis	rs7829975	0.871	rs572307	chr8:8578811	T/C	cg06636001	chr8:8085503	FLJ10661	-0.42	-5.43	-0.32	1.25e-7	Mood instability;
CESC	cis	rs1005277	0.579	rs2505240	chr10:38442419	G/T	cg00409905	chr10:38381863	ZNF37A	-0.45	-6.01	-0.35	6.11e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs6500602	0.767	rs8060219	chr16:4480158	T/A	cg08645402	chr16:4508243	NA	0.41	6.25	0.36	1.59e-9	Schizophrenia;
CESC	cis	rs11581903	0.568	rs11205977	chr1:53068093	G/T	cg19751897	chr1:52520827	TXNDC12;BTF3L4	0.73	5.47	0.32	1.06e-7	Joint mobility (Beighton score);
CESC	cis	rs9399135	0.967	rs6910530	chr6:135332770	C/T	cg22676075	chr6:135203613	NA	0.51	7.16	0.4	7.86e-12	Red blood cell count;
CESC	cis	rs2242194	0.816	rs2242193	chr1:154995503	A/G	cg24250549	chr1:154909240	PMVK	-0.41	-5.28	-0.31	2.69e-7	Schizophrenia;
CESC	trans	rs13398848	1.000	rs10168676	chr2:84201254	A/G	cg23262351	chr6:79576851	IRAK1BP1	-0.69	-6.08	-0.35	4.1e-9	Conduct disorder (symptom count);Conduct disorder;
CESC	cis	rs9815354	1.000	rs7624372	chr3:41881107	T/A	cg03022575	chr3:42003672	ULK4	0.45	5.29	0.31	2.59e-7	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs4665809	1.000	rs4665820	chr2:26309150	T/C	cg04944784	chr2:26401820	FAM59B	-0.67	-7.75	-0.43	2e-13	Gut microbiome composition (summer);
CESC	cis	rs35146811	0.844	rs13232115	chr7:99670932	T/C	cg13334819	chr7:99746414	C7orf59	-0.43	-5.27	-0.31	2.79e-7	Coronary artery disease;
CESC	cis	rs911555	0.755	rs8014800	chr14:103946302	T/C	cg12935359	chr14:103987150	CKB	0.67	9.78	0.52	1.73e-19	Intelligence (multi-trait analysis);
CESC	cis	rs11252926	0.501	rs2050971	chr10:525530	T/G	cg18196295	chr10:418757	DIP2C	-0.5	-6.72	-0.38	1.1e-10	Psychosis in Alzheimer's disease;
CESC	cis	rs2204008	0.701	rs3898237	chr12:38219714	A/G	cg26384229	chr12:38710491	ALG10B	0.74	10.65	0.55	2.74e-22	Bladder cancer;
CESC	cis	rs4132509	0.779	rs1538773	chr1:243674682	T/G	cg21452805	chr1:244014465	NA	0.41	5.03	0.3	9.21e-7	RR interval (heart rate);
CESC	cis	rs208520	0.690	rs10455595	chr6:66738034	T/C	cg07460842	chr6:66804631	NA	0.96	12.87	0.62	8.96e-30	Exhaled nitric oxide output;
CESC	cis	rs6460942	0.544	rs34644264	chr7:12536090	C/A	cg06484146	chr7:12443880	VWDE	-0.73	-7.77	-0.43	1.68e-13	Coronary artery disease;
CESC	trans	rs208515	0.525	rs10944859	chr6:66665197	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.87	10.74	0.55	1.42e-22	Exhaled nitric oxide levels;
CESC	cis	rs662064	0.962	rs2781232	chr1:10544388	T/C	cg20482658	chr1:10539492	PEX14	-0.41	-8.23	-0.45	8.65e-15	Asthma;
CESC	cis	rs2777491	0.915	rs8032838	chr15:41605632	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.6	-8.84	-0.48	1.39e-16	Ulcerative colitis;
CESC	cis	rs10504229	0.683	rs58883273	chr8:58138275	A/G	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs80130819	0.688	rs7313023	chr12:48584179	T/C	cg05342945	chr12:48394962	COL2A1	-0.52	-5.88	-0.34	1.26e-8	Prostate cancer;
CESC	cis	rs1018836	0.923	rs6986689	chr8:91626709	A/C	cg16814680	chr8:91681699	NA	-0.72	-10.07	-0.53	2.16e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs1577917	0.771	rs9353318	chr6:86231721	T/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.57	7.88	0.44	8.64e-14	Response to antipsychotic treatment;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06212498	chr3:49045151	WDR6	0.64	7.14	0.4	8.77e-12	Gut microbiome composition (summer);
CESC	cis	rs400736	0.655	rs55634431	chr1:8149549	G/A	cg25007680	chr1:8021821	PARK7	-0.64	-8.79	-0.48	1.86e-16	Response to antidepressants and depression;
CESC	cis	rs4523957	0.560	rs1994884	chr17:2084008	G/A	cg16513277	chr17:2031491	SMG6	-0.71	-10.17	-0.53	1.04e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs11583043	0.708	rs36023027	chr1:101575205	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.51	5.56	0.32	6.53e-8	Ulcerative colitis;Inflammatory bowel disease;
CESC	cis	rs4979906	1.000	rs4325263	chr10:79444236	A/G	cg00983440	chr10:79422392	NA	-0.48	-5.1	-0.3	6.57e-7	Mortality in heart failure;
CESC	cis	rs1552244	0.872	rs6771931	chr3:10113408	C/G	cg08888203	chr3:10149979	C3orf24	0.53	6.83	0.39	5.8200000000000003e-11	Alzheimer's disease;
CESC	cis	rs875971	0.662	rs448725	chr7:65514628	A/G	cg18876405	chr7:65276391	NA	0.56	7.47	0.42	1.15e-12	Aortic root size;
CESC	cis	rs7208859	0.623	rs55961983	chr17:29119286	G/A	cg14008862	chr17:28927542	LRRC37B2	0.65	5.14	0.3	5.34e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs7587476	0.736	rs62202002	chr2:215690600	T/C	cg04004882	chr2:215674386	BARD1	0.53	5.91	0.34	1.05e-8	Neuroblastoma;
CESC	cis	rs4924935	0.851	rs12936834	chr17:18807078	A/G	cg26378065	chr17:18585709	ZNF286B	0.47	5.4	0.31	1.47e-7	Pancreatic cancer;
CESC	cis	rs763121	0.849	rs12004	chr22:38877461	T/G	cg06544989	chr22:39130855	UNC84B	0.46	7.51	0.42	9.02e-13	Menopause (age at onset);
CESC	cis	rs1707322	1.000	rs6676982	chr1:46275401	A/T	cg06784218	chr1:46089804	CCDC17	0.33	5.75	0.33	2.42e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2243480	1.000	rs1553174	chr7:65731194	T/C	cg12463550	chr7:65579703	CRCP	-0.74	-5.73	-0.33	2.74e-8	Diabetic kidney disease;
CESC	cis	rs34779708	0.733	rs12249814	chr10:35542757	T/C	cg03585969	chr10:35415529	CREM	0.56	6.42	0.37	6.15e-10	Inflammatory bowel disease;Crohn's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18673246	chr17:7217969	GPS2	-0.6	-7.14	-0.4	9.03e-12	Gut microbiome composition (summer);
CESC	cis	rs617791	0.508	rs747526	chr11:65776071	C/A	cg09783858	chr11:65769428	EIF1AD;BANF1	0.51	6.04	0.35	5.07e-9	Breast cancer;
CESC	cis	rs7666738	0.830	rs34313689	chr4:99013689	T/C	cg03676636	chr4:99064102	C4orf37	0.33	5.04	0.3	8.62e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6430585	0.583	rs3087343	chr2:136622543	T/G	cg07169764	chr2:136633963	MCM6	1.29	19.97	0.78	9.47e-55	Corneal structure;
CESC	cis	rs7843479	0.562	rs2127206	chr8:21786989	C/T	cg17168535	chr8:21777572	XPO7	0.7	11.38	0.57	1.12e-24	Mean corpuscular volume;
CESC	cis	rs9868809	0.772	rs9841602	chr3:48713570	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.57	-5.06	-0.3	7.97e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs425277	0.585	rs2222217	chr1:2063164	G/A	cg23803603	chr1:2058230	PRKCZ	-0.34	-5.74	-0.33	2.54e-8	Height;
CESC	cis	rs7666738	0.546	rs34621463	chr4:98793357	G/C	cg05340658	chr4:99064831	C4orf37	0.58	7.25	0.41	4.5e-12	Colonoscopy-negative controls vs population controls;
CESC	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg02018176	chr4:1364513	KIAA1530	0.61	8.08	0.44	2.33e-14	Longevity;
CESC	cis	rs4713118	0.662	rs149900	chr6:28014597	C/T	cg23281280	chr6:28129359	ZNF389	0.5	6.27	0.36	1.46e-9	Parkinson's disease;
CESC	cis	rs8092503	1.000	rs8093506	chr18:52474170	A/G	cg12377874	chr18:52495404	RAB27B	0.37	5.83	0.34	1.64e-8	Childhood body mass index;
CESC	cis	rs7247513	0.964	rs8100964	chr19:12720631	C/T	cg01871581	chr19:12707946	ZNF490	-0.86	-13.76	-0.65	7.13e-33	Bipolar disorder;
CESC	cis	rs3785574	0.962	rs2727280	chr17:61918082	A/G	cg06873352	chr17:61820015	STRADA	0.47	6.63	0.38	1.92e-10	Height;
CESC	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg07157834	chr1:205819609	PM20D1	0.71	11.02	0.56	1.73e-23	Menarche (age at onset);
CESC	cis	rs6460942	1.000	rs117657017	chr7:12318891	T/C	cg02935154	chr7:12443704	VWDE	-0.59	-5.84	-0.34	1.5e-8	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06916931	chr13:49106753	RCBTB2	0.55	6.54	0.37	3.22e-10	Gut microbiome composition (summer);
CESC	cis	rs2404602	0.692	rs55676827	chr15:76961716	C/T	cg26408565	chr15:76604113	ETFA	-0.39	-5.58	-0.32	5.8e-8	Blood metabolite levels;
CESC	cis	rs7918232	0.941	rs1085782	chr10:27440517	G/A	cg14240646	chr10:27532245	ACBD5	0.68	6.49	0.37	4.18e-10	Breast cancer;
CESC	cis	rs1003719	0.654	rs764175	chr21:38517058	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.6	-8.14	-0.45	1.51e-14	Eye color traits;
CESC	cis	rs10851478	0.872	rs11854671	chr15:49765426	C/T	cg08060515	chr15:49448048	GALK2;COPS2	0.42	5.16	0.3	4.79e-7	Oral cavity cancer;
CESC	cis	rs9640161	0.750	rs3735169	chr7:150034378	A/G	cg17279839	chr7:150038598	RARRES2	0.45	5.44	0.32	1.2e-7	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs13082711	0.871	rs7624790	chr3:27468601	C/A	cg02860705	chr3:27208620	NA	0.53	6.8	0.39	7.04e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CESC	cis	rs10504229	0.679	rs60869047	chr8:58053221	G/A	cg24829409	chr8:58192753	C8orf71	-0.5	-6.27	-0.36	1.43e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs13191362	1.000	rs36113695	chr6:163004733	T/A	cg14584255	chr6:163149320	PACRG;PARK2	0.5	5.19	0.3	4.18e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs1799949	1.000	rs9646412	chr17:41425893	A/T	cg23758822	chr17:41437982	NA	1.03	15.53	0.69	4.02e-39	Menopause (age at onset);
CESC	cis	rs2790457	0.874	rs1265840	chr10:28919641	C/T	cg04045419	chr10:28823091	WAC	-0.42	-5.04	-0.3	8.49e-7	Multiple myeloma;
CESC	cis	rs1348850	0.914	rs11893448	chr2:178280013	T/C	cg22681709	chr2:178499509	PDE11A	-0.42	-6.23	-0.36	1.79e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs1065656	0.571	rs12149777	chr16:1834724	A/G	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.4	-5.54	-0.32	7.41e-8	Insulin-like growth factors;
CESC	cis	rs9611565	0.546	rs739129	chr22:42118249	G/A	cg03806693	chr22:41940476	POLR3H	1.15	13.67	0.64	1.42e-32	Vitiligo;
CESC	cis	rs7666738	0.830	rs11097598	chr4:98946057	T/C	cg17366294	chr4:99064904	C4orf37	0.6	8.54	0.46	1.08e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9309473	1.000	rs13431267	chr2:73782200	A/G	cg20560298	chr2:73613845	ALMS1	-0.54	-7.08	-0.4	1.31e-11	Metabolite levels;
CESC	cis	rs3096299	0.935	rs3102387	chr16:89432276	A/C	cg08822215	chr16:89438651	ANKRD11	-0.41	-6.19	-0.36	2.22e-9	Multiple myeloma (IgH translocation);
CESC	trans	rs7079041	1	rs7079041	chr10:32993268	G/A	cg01456440	chr13:21714647	SAP18	-0.5	-6.41	-0.37	6.77e-10	Suicide in bipolar disorder;
CESC	cis	rs9910055	0.639	rs227583	chr17:42231698	C/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.65	8.64	0.47	5.22e-16	Total body bone mineral density;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26645063	chr2:65454766	ACTR2	0.56	6.12	0.35	3.42e-9	Gut microbiome composition (summer);
CESC	trans	rs61931739	0.500	rs11053140	chr12:34316122	T/C	cg26384229	chr12:38710491	ALG10B	0.65	9.19	0.49	1.16e-17	Morning vs. evening chronotype;
CESC	cis	rs79839061	0.656	rs3775126	chr4:886345	C/T	cg07828340	chr4:882639	GAK	1.07	8.55	0.47	9.76e-16	Intelligence (multi-trait analysis);
CESC	cis	rs7165102	1.000	rs429657	chr15:65813764	G/A	cg11441148	chr15:65824328	PTPLAD1	-0.32	-5.38	-0.31	1.61e-7	Mean corpuscular hemoglobin;
CESC	trans	rs12599106	0.680	rs34728702	chr16:34896584	A/G	cg16103275	chr6:290800	DUSP22	0.44	6.02	0.35	5.78e-9	Menopause (age at onset);
CESC	cis	rs9309711	0.666	rs4321399	chr2:3481659	G/A	cg15506890	chr2:3487001	NA	-0.42	-5.24	-0.31	3.22e-7	Neurofibrillary tangles;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15891076	chr10:65930618	NA	-0.55	-6.15	-0.35	2.89e-9	Gut microbiome composition (summer);
CESC	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.42	-5.39	-0.31	1.59e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs6570726	0.875	rs368744	chr6:145812622	A/G	cg23711669	chr6:146136114	FBXO30	0.78	11.22	0.57	3.67e-24	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09133562	chr1:20126395	TMCO4	0.6	6.62	0.38	2e-10	Gut microbiome composition (summer);
CESC	cis	rs3785574	0.924	rs2727292	chr17:61893747	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.57	7.08	0.4	1.32e-11	Height;
CESC	cis	rs4713118	0.621	rs4713133	chr6:28034041	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.53	-6.06	-0.35	4.65e-9	Parkinson's disease;
CESC	cis	rs4919694	1.000	rs58317752	chr10:104799267	T/A	cg04362960	chr10:104952993	NT5C2	0.79	6.94	0.39	2.92e-11	Arsenic metabolism;
CESC	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.47	6.24	0.36	1.71e-9	Lymphocyte counts;
CESC	cis	rs9916302	0.851	rs4390625	chr17:37620347	A/G	cg19468946	chr17:37922297	IKZF3	-0.39	-5.08	-0.3	7.08e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs5750830	0.645	rs756640	chr22:39779300	G/A	cg05872129	chr22:39784769	NA	-0.74	-10.84	-0.55	6.72e-23	Intelligence (multi-trait analysis);
CESC	cis	rs644799	1.000	rs474442	chr11:95583995	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.71	9.36	0.5	3.46e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs9399135	0.660	rs4440481	chr6:135276696	A/G	cg24558204	chr6:135376177	HBS1L	0.53	7.34	0.41	2.55e-12	Red blood cell count;
CESC	cis	rs67478160	0.619	rs1040813	chr14:104306696	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.51	-7.18	-0.4	7.24e-12	Schizophrenia;
CESC	cis	rs12618769	0.597	rs3769738	chr2:99078367	T/C	cg10123293	chr2:99228465	UNC50	0.41	5.42	0.32	1.36e-7	Bipolar disorder;
CESC	cis	rs11148252	0.553	rs7999849	chr13:53249414	A/G	cg00495681	chr13:53174319	NA	0.6	8.21	0.45	9.62e-15	Lewy body disease;
CESC	cis	rs2486288	0.656	rs11637364	chr15:45579238	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.6	-7.19	-0.4	6.71e-12	Glomerular filtration rate;
CESC	cis	rs1570884	0.516	rs9316463	chr13:50176844	G/A	cg03651054	chr13:50194643	NA	0.31	5.1	0.3	6.4e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
CESC	cis	rs4925114	0.568	rs4925109	chr17:17661802	A/G	cg16928487	chr17:17741425	SREBF1	0.41	6.01	0.35	5.97e-9	Body mass index;
CESC	cis	rs3812762	0.833	rs10500707	chr11:8817580	C/T	cg03980550	chr11:8754370	ST5	0.39	5.22	0.31	3.62e-7	Hypospadias;
CESC	cis	rs7512552	0.839	rs1694369	chr1:150351101	A/G	cg15654264	chr1:150340011	RPRD2	0.39	5.13	0.3	5.73e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs875971	0.965	rs7794930	chr7:65778546	A/C	cg10691866	chr7:65817282	TPST1	0.33	5.52	0.32	8.11e-8	Aortic root size;
CESC	cis	rs11864453	0.713	rs6680	chr16:72146570	T/C	cg01557791	chr16:72042693	DHODH	-0.48	-6.35	-0.36	9.29e-10	Fibrinogen levels;
CESC	cis	rs1499614	1.000	rs2659913	chr7:66157336	T/A	cg18252515	chr7:66147081	NA	-1.42	-14.62	-0.67	6.69e-36	Gout;
CESC	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg03188948	chr7:1209495	NA	0.71	7.06	0.4	1.5e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2228479	0.850	rs11649510	chr16:89851004	A/G	cg06558623	chr16:89946397	TCF25	1.18	9.42	0.5	2.3e-18	Skin colour saturation;
CESC	cis	rs875971	0.862	rs10250544	chr7:65766561	A/G	cg19163074	chr7:65112434	INTS4L2	0.4	5.16	0.3	4.86e-7	Aortic root size;
CESC	cis	rs6952808	0.756	rs4719311	chr7:1881813	C/T	cg04267008	chr7:1944627	MAD1L1	-0.5	-5.81	-0.34	1.75e-8	Bipolar disorder and schizophrenia;
CESC	trans	rs1120787	0.793	rs478765	chr18:55013866	C/T	cg03862225	chr10:126850454	CTBP2	-0.54	-6.11	-0.35	3.53e-9	HIV-1 control;
CESC	cis	rs3820068	0.603	rs41270279	chr1:15988878	A/G	cg13390004	chr1:15929781	NA	0.34	5.49	0.32	9.33e-8	Systolic blood pressure;
CESC	cis	rs9916302	0.904	rs755500	chr17:37409865	C/T	cg20243544	chr17:37824526	PNMT	0.48	5.81	0.34	1.81e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.41	0.37	6.57e-10	Prudent dietary pattern;
CESC	cis	rs9611565	0.729	rs12165508	chr22:41819960	T/C	cg03806693	chr22:41940476	POLR3H	0.77	9.87	0.52	9.21e-20	Vitiligo;
CESC	cis	rs9303401	0.659	rs34818467	chr17:56643109	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.8	-10.1	-0.53	1.73e-20	Cognitive test performance;
CESC	cis	rs875971	1.000	rs6958271	chr7:65979331	A/C	cg10691866	chr7:65817282	TPST1	-0.36	-5.92	-0.34	9.82e-9	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11028091	chr15:72522207	PKM2	-0.6	-7.03	-0.4	1.78e-11	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07853743	chr16:2802190	SRRM2;LOC100128788	0.64	7.03	0.4	1.71e-11	Gut microbiome composition (summer);
CESC	cis	rs6736093	0.862	rs11684321	chr2:112775750	C/T	cg12686935	chr2:112915763	FBLN7	-0.41	-5.21	-0.3	3.87e-7	Coronary artery disease;
CESC	cis	rs57502260	0.704	rs60538784	chr11:68386735	G/A	cg20283391	chr11:68216788	NA	-0.6	-5.04	-0.3	8.8e-7	Total body bone mineral density (age 45-60);
CESC	cis	rs1799949	0.965	rs799910	chr17:41279561	G/C	cg25072359	chr17:41440525	NA	0.48	7.22	0.41	5.37e-12	Menopause (age at onset);
CESC	cis	rs6088580	0.634	rs6142153	chr20:32968747	C/G	cg24642439	chr20:33292090	TP53INP2	-0.53	-7.01	-0.4	2.01e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs6964587	0.967	rs6465340	chr7:91588664	G/A	cg17063962	chr7:91808500	NA	0.57	7.74	0.43	2.17e-13	Breast cancer;
CESC	cis	rs9322193	0.884	rs11155669	chr6:149954637	T/C	cg13206674	chr6:150067644	NUP43	0.43	6.18	0.35	2.39e-9	Lung cancer;
CESC	trans	rs11722228	0.508	rs2241472	chr4:10085902	C/G	cg26043149	chr18:55253948	FECH	0.94	11.05	0.56	1.31e-23	Gout;Urate levels;Serum uric acid levels;
CESC	cis	rs8058578	1.000	rs6565201	chr16:30747191	C/T	cg02466173	chr16:30829666	NA	-0.41	-6.69	-0.38	1.3100000000000001e-10	Multiple myeloma;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02751639	chr2:112641883	ANAPC1	0.54	6.03	0.35	5.61e-9	Gut microbiome composition (summer);
CESC	cis	rs13118159	1.000	rs13118159	chr4:1365127	A/G	cg20887711	chr4:1340912	KIAA1530	0.42	5.65	0.33	4.13e-8	Longevity;
CESC	cis	rs9457247	1.000	rs393558	chr6:167397750	A/C	cg23791538	chr6:167370224	RNASET2	-0.59	-8.41	-0.46	2.56e-15	Crohn's disease;
CESC	trans	rs1814175	0.712	rs9665784	chr11:50030617	C/T	cg15704280	chr7:45808275	SEPT13	-1.05	-21.42	-0.8	9.36e-60	Height;
CESC	cis	rs67257959	0.708	rs10405158	chr19:17195997	A/G	cg16202187	chr19:17186497	HAUS8;MYO9B	0.45	5.41	0.32	1.42e-7	Selective IgA deficiency;
CESC	cis	rs9926296	0.527	rs1800335	chr16:89846195	A/G	cg03388025	chr16:89894329	SPIRE2	0.39	7.4	0.41	1.76e-12	Vitiligo;
CESC	cis	rs796364	0.760	rs56285751	chr2:200919836	C/T	cg23649088	chr2:200775458	C2orf69	-0.55	-5.05	-0.3	8.29e-7	Schizophrenia;
CESC	cis	rs7216064	0.911	rs6504551	chr17:65903326	T/G	cg07042672	chr17:66097459	LOC651250	-0.55	-7.4	-0.41	1.8e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs1862618	0.853	rs832578	chr5:56164223	C/T	cg24531977	chr5:56204891	C5orf35	-0.88	-11.37	-0.57	1.16e-24	Initial pursuit acceleration;
CESC	cis	rs11098499	0.820	rs28394116	chr4:120524283	T/G	cg24375607	chr4:120327624	NA	0.43	5.28	0.31	2.66e-7	Corneal astigmatism;
CESC	cis	rs7580658	0.550	rs62160290	chr2:128200695	C/T	cg10021288	chr2:128175891	PROC	-0.4	-5.92	-0.34	1e-8	Protein C levels;
CESC	cis	rs2274273	0.662	rs2094436	chr14:55661495	C/G	cg04306507	chr14:55594613	LGALS3	0.31	5.27	0.31	2.78e-7	Protein biomarker;
CESC	trans	rs7178375	1.000	rs28693590	chr15:31195021	A/G	cg04373760	chr16:53404718	NA	0.55	7.21	0.4	5.95e-12	Hypertriglyceridemia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25233569	chr10:62703741	RHOBTB1	0.66	7.27	0.41	4.08e-12	Gut microbiome composition (summer);
CESC	cis	rs3106136	0.967	rs13135934	chr4:95207688	G/C	cg11021082	chr4:95130006	SMARCAD1	-0.46	-6.75	-0.38	9.27e-11	Capecitabine sensitivity;
CESC	cis	rs6736093	0.700	rs4848958	chr2:112785775	T/C	cg07905836	chr2:113190072	RGPD8;RGPD5	-0.48	-5.54	-0.32	7.35e-8	Coronary artery disease;
CESC	cis	rs9858542	0.953	rs35261698	chr3:49537839	C/G	cg03060546	chr3:49711283	APEH	-0.55	-6.28	-0.36	1.34e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs4948102	0.551	rs4275190	chr7:56104388	C/T	cg09872392	chr7:56161020	PHKG1	-0.48	-7.82	-0.43	1.26e-13	Plasma homocysteine levels (post-methionine load test);
CESC	trans	rs916888	0.821	rs199507	chr17:44858855	A/G	cg07870213	chr5:140052090	DND1	-0.61	-6.87	-0.39	4.47e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs2635047	0.638	rs2635054	chr18:44653028	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.39	-5.39	-0.31	1.55e-7	Educational attainment;
CESC	cis	rs12541335	0.590	rs11136002	chr8:22217082	C/T	cg27266060	chr8:22091797	NA	0.42	8.42	0.46	2.39e-15	Hypertriglyceridemia;
CESC	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.62	6.9	0.39	3.91e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs8062405	0.691	rs11646653	chr16:28922149	C/T	cg05966235	chr16:28915196	ATP2A1	-0.34	-5.06	-0.3	7.84e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs6714710	0.603	rs1875699	chr2:98580724	G/T	cg26665480	chr2:98280029	ACTR1B	0.56	7.9	0.44	7.59e-14	Posterior cortical atrophy and Alzheimer's disease;
CESC	cis	rs2486288	0.656	rs12908818	chr15:45571668	A/G	cg09092052	chr15:45571596	NA	0.44	5.23	0.31	3.44e-7	Glomerular filtration rate;
CESC	cis	rs9910055	0.762	rs2240226	chr17:42266218	C/T	cg19774624	chr17:42201019	HDAC5	-0.68	-9.97	-0.52	4.48e-20	Total body bone mineral density;
CESC	cis	rs897984	0.609	rs57576577	chr16:31036367	G/A	cg02466173	chr16:30829666	NA	-0.4	-6.95	-0.39	2.84e-11	Dementia with Lewy bodies;
CESC	cis	rs7542091	0.637	rs9429826	chr1:210052146	G/A	cg22029157	chr1:209979665	IRF6	0.49	7.73	0.43	2.23e-13	Monobrow;
CESC	cis	rs924607	1.000	rs11746907	chr5:598224	G/A	cg07001201	chr5:642380	CEP72	0.39	5.1	0.3	6.55e-7	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs9859260	0.710	rs34906439	chr3:195779706	A/G	cg12923728	chr3:195709715	SDHAP1	0.54	6.95	0.39	2.78e-11	Mean corpuscular volume;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg06569419	chr2:182827064	NA	0.37	6.56	0.37	2.75e-10	Gambling;
CESC	cis	rs28647808	1.000	rs6597630	chr9:136279935	C/T	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.9	5.73	0.33	2.75e-8	Blood protein levels;
CESC	cis	rs7312774	0.618	rs10861680	chr12:107323730	T/C	cg16260113	chr12:107380972	MTERFD3	0.78	7.11	0.4	1.05e-11	Severe influenza A (H1N1) infection;
CESC	cis	rs2109514	1.000	rs2270188	chr7:116140524	G/T	cg12739419	chr7:116140593	CAV2	-0.37	-6.71	-0.38	1.17e-10	Prevalent atrial fibrillation;
CESC	cis	rs2180341	0.538	rs11556354	chr6:127664661	G/A	cg24812749	chr6:127587940	RNF146	0.51	6.82	0.39	6.2e-11	Breast cancer;
CESC	cis	rs75804782	0.641	rs72985397	chr2:239341354	A/G	cg18131467	chr2:239335373	ASB1	-0.67	-5.7	-0.33	3.14e-8	Morning vs. evening chronotype;Chronotype;
CESC	cis	rs7264396	0.563	rs6060567	chr20:34288250	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.9	-10.87	-0.56	5.11e-23	Total cholesterol levels;
CESC	cis	rs12144309	0.554	rs2476602	chr1:114396955	C/T	cg13572289	chr1:114447746	DCLRE1B;AP4B1	0.44	5.2	0.3	4.07e-7	Coronary artery disease;
CESC	cis	rs2576037	0.583	rs9954336	chr18:44465945	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.52	-7.12	-0.4	1.02e-11	Personality dimensions;
CESC	cis	rs765787	0.556	rs12915965	chr15:45512647	T/C	cg24006582	chr15:45444508	DUOX1	0.52	6.32	0.36	1.13e-9	Uric acid levels;
CESC	cis	rs1568889	0.712	rs4567438	chr11:28380051	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.69	8.53	0.46	1.12e-15	Bipolar disorder;
CESC	cis	rs2243480	1.000	rs4718270	chr7:65202407	A/G	cg12463550	chr7:65579703	CRCP	0.68	5.29	0.31	2.55e-7	Diabetic kidney disease;
CESC	cis	rs925228	0.504	rs6755030	chr2:24318343	C/T	cg01493198	chr2:24299560	SF3B14	0.66	5.79	0.34	1.97e-8	Reticulocyte fraction of red cells;Reticulocyte count;
CESC	cis	rs77861329	1.000	rs9857878	chr3:52109668	A/G	cg08692210	chr3:52188851	WDR51A	-0.83	-7.03	-0.4	1.73e-11	Macrophage inflammatory protein 1b levels;
CESC	cis	rs75920871	0.589	rs2075547	chr11:117068534	G/T	cg01368799	chr11:117014884	PAFAH1B2	-0.71	-5.35	-0.31	1.87e-7	Subjective well-being;
CESC	cis	rs6474412	1.000	rs4950	chr8:42552633	C/T	cg25026480	chr8:42547641	NA	0.32	5.29	0.31	2.54e-7	Smoking behavior;
CESC	cis	rs35110281	0.633	rs2329593	chr21:45121987	T/C	cg04455712	chr21:45112962	RRP1B	0.51	7.91	0.44	7.22e-14	Mean corpuscular volume;
CESC	trans	rs17433710	0.543	rs10753585	chr1:162669006	C/T	cg13392022	chr1:154600693	ADAR	-0.45	-6.04	-0.35	5.09e-9	Dupuytren's disease;
CESC	cis	rs9470366	0.816	rs4331968	chr6:36623243	A/T	cg08179530	chr6:36648295	CDKN1A	0.56	6.66	0.38	1.61e-10	QRS duration;
CESC	trans	rs7607369	0.782	rs514799	chr2:219411203	A/G	cg15547669	chr20:2781122	CPXM1	0.35	6.0	0.35	6.31e-9	Red blood cell count;Amyotrophic lateral sclerosis;
CESC	cis	rs7666738	0.606	rs4577589	chr4:99087858	A/G	cg24818145	chr4:99064322	C4orf37	0.4	5.14	0.3	5.32e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11711311	1.000	rs9830978	chr3:113455940	A/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.72	10.27	0.53	4.81e-21	IgG glycosylation;
CESC	cis	rs9612	1.000	rs346523	chr19:44260681	A/C	cg08581076	chr19:44259116	C19orf61	0.52	6.19	0.36	2.33e-9	Exhaled nitric oxide output;
CESC	cis	rs2737618	0.722	rs2258675	chr1:200091548	G/C	cg21825944	chr1:200113062	NR5A2	-0.38	-5.43	-0.32	1.28e-7	Uric acid levels;
CESC	cis	rs7107174	1.000	rs4945270	chr11:78068216	A/G	cg02023728	chr11:77925099	USP35	0.48	6.3	0.36	1.23e-9	Testicular germ cell tumor;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17634588	chr8:141646421	EIF2C2	0.61	6.89	0.39	3.99e-11	Gut microbiome composition (summer);
CESC	trans	rs5756813	0.727	rs4821703	chr22:38136676	C/T	cg19894588	chr14:64061835	NA	-0.67	-7.81	-0.43	1.32e-13	Optic cup area;Vertical cup-disc ratio;
CESC	trans	rs6987853	0.830	rs4737048	chr8:42359035	G/T	cg27650678	chr11:66636318	PC	-0.46	-6.11	-0.35	3.45e-9	Mean corpuscular hemoglobin concentration;
CESC	cis	rs7666738	0.830	rs28867087	chr4:98880349	T/A	cg03467027	chr4:99064603	C4orf37	0.42	5.25	0.31	3.05e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs875971	1.000	rs2420591	chr7:65912381	T/C	cg26939375	chr7:64535504	NA	0.46	6.0	0.35	6.6e-9	Aortic root size;
CESC	cis	rs1341267	0.529	rs6492721	chr13:95258944	A/G	cg18412871	chr13:95254051	GPR180	-0.56	-7.54	-0.42	7.58e-13	Triglyceride levels;
CESC	cis	rs7666738	0.830	rs2114426	chr4:98933130	C/T	cg17366294	chr4:99064904	C4orf37	0.6	8.22	0.45	9.04e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs116095464	0.558	rs56043030	chr5:220917	A/G	cg10591111	chr5:226296	SDHA	-0.51	-6.35	-0.36	9.22e-10	Breast cancer;
CESC	cis	rs4975709	0.589	rs1684967	chr5:1863055	G/C	cg19770292	chr5:1868693	NA	0.31	5.28	0.31	2.73e-7	Cardiovascular disease risk factors;
CESC	cis	rs1005277	0.579	rs2505240	chr10:38442419	G/T	cg25517755	chr10:38738941	LOC399744	-0.49	-6.41	-0.37	6.52e-10	Extrinsic epigenetic age acceleration;
CESC	cis	rs4654899	0.965	rs7525620	chr1:21458392	G/A	cg05370193	chr1:21551575	ECE1	0.41	6.2	0.36	2.2e-9	Superior frontal gyrus grey matter volume;
CESC	cis	rs67478160	0.643	rs8005594	chr14:104279889	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.51	-7.04	-0.4	1.62e-11	Schizophrenia;
CESC	cis	rs12190007	0.547	rs3006182	chr6:169808323	C/T	cg15038512	chr6:170123185	PHF10	-0.48	-6.81	-0.39	6.6e-11	Obesity-related traits;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg00291661	chr16:30581198	ZNF688	0.49	6.53	0.37	3.3e-10	Fibrinogen levels;
CESC	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg06074448	chr4:187884817	NA	-0.46	-7.14	-0.4	8.73e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs796364	0.806	rs79156935	chr2:200913822	T/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.85	-7.93	-0.44	6.07e-14	Schizophrenia;
CESC	cis	rs10392	0.602	rs4810240	chr20:37532033	G/A	cg27552599	chr20:37590471	DHX35	0.38	5.13	0.3	5.5e-7	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
CESC	cis	rs4835473	0.800	rs2175451	chr4:144914117	T/C	cg25736465	chr4:144833511	NA	0.43	6.44	0.37	5.61e-10	Immature fraction of reticulocytes;
CESC	cis	rs7116495	0.609	rs12275171	chr11:71835373	C/T	cg26138937	chr11:71823887	C11orf51	1.23	7.77	0.43	1.75e-13	Severe influenza A (H1N1) infection;
CESC	cis	rs6456156	0.846	rs204293	chr6:167514481	T/C	cg07741184	chr6:167504864	NA	0.35	6.18	0.36	2.37e-9	Primary biliary cholangitis;
CESC	cis	rs9640161	0.830	rs3735165	chr7:150068371	T/C	cg27494647	chr7:150038898	RARRES2	0.36	5.4	0.31	1.48e-7	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs244293	0.730	rs3213757	chr17:53041857	A/G	cg19360675	chr17:53046073	COX11;STXBP4	-0.45	-6.14	-0.35	3.02e-9	Menarche (age at onset);
CESC	cis	rs16854884	0.837	rs989665	chr3:143792854	C/T	cg06585982	chr3:143692056	C3orf58	0.44	5.49	0.32	9.61e-8	Economic and political preferences (feminism/equality);
CESC	cis	rs6540556	0.723	rs6752	chr1:209908100	G/A	cg05527609	chr1:210001259	C1orf107	-0.63	-7.21	-0.41	5.81e-12	Red blood cell count;
CESC	cis	rs113835537	0.529	rs61561111	chr11:66275923	T/C	cg24851651	chr11:66362959	CCS	0.44	5.49	0.32	9.2e-8	Airway imaging phenotypes;
CESC	cis	rs1538970	1.000	rs1417578	chr1:45850590	A/G	cg06784218	chr1:46089804	CCDC17	0.3	5.19	0.3	4.14e-7	Platelet count;
CESC	cis	rs8177253	0.965	rs8177245	chr3:133479230	A/G	cg01448562	chr3:133502909	NA	-0.44	-6.1	-0.35	3.8e-9	Iron status biomarkers;
CESC	cis	rs6570726	0.755	rs451699	chr6:145830594	C/G	cg05347473	chr6:146136440	FBXO30	0.59	7.56	0.42	6.43e-13	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs117623576	0.941	rs211424	chr10:32398895	A/G	cg03047570	chr10:32398778	NA	0.62	6.65	0.38	1.68e-10	Anti-saccade response;
CESC	cis	rs801193	0.967	rs1110414	chr7:66205582	A/G	cg18876405	chr7:65276391	NA	0.54	7.28	0.41	3.88e-12	Aortic root size;
CESC	cis	rs7216064	1.000	rs62084248	chr17:65874541	C/T	cg07042672	chr17:66097459	LOC651250	-0.52	-5.4	-0.31	1.5e-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs72781680	0.611	rs72781695	chr2:24266744	T/C	cg06627628	chr2:24431161	ITSN2	-0.65	-6.21	-0.36	2.08e-9	Lymphocyte counts;
CESC	trans	rs60843830	1.000	rs58461606	chr2:267367	G/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.67	8.47	0.46	1.72e-15	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs9611565	0.694	rs79011	chr22:41866938	A/G	cg03806693	chr22:41940476	POLR3H	1.13	15.47	0.69	6.47e-39	Vitiligo;
CESC	cis	rs2506889	0.553	rs7548453	chr1:10589836	A/G	cg07384165	chr1:10488281	NA	-0.55	-7.92	-0.44	6.54e-14	Breast cancer;
CESC	cis	rs3785574	0.962	rs2584614	chr17:61929445	C/T	cg06873352	chr17:61820015	STRADA	0.45	6.62	0.38	1.96e-10	Height;
CESC	cis	rs11608355	0.521	rs1119271	chr12:109819727	A/T	cg19025524	chr12:109796872	NA	-0.55	-7.9	-0.44	7.54e-14	Neuroticism;
CESC	cis	rs5750830	0.649	rs4821894	chr22:39809820	G/C	cg05872129	chr22:39784769	NA	-0.81	-10.78	-0.55	1.07e-22	Intelligence (multi-trait analysis);
CESC	cis	rs66887589	0.592	rs11731571	chr4:120221185	G/A	cg09307838	chr4:120376055	NA	0.65	8.97	0.48	5.51e-17	Diastolic blood pressure;
CESC	cis	rs3767633	0.925	rs2134696	chr1:161781200	A/T	cg09175582	chr1:161736000	ATF6	-0.78	-7.23	-0.41	5.24e-12	IgG glycosylation;
CESC	cis	rs9633740	1.000	rs9633740	chr10:82265271	A/G	cg00277334	chr10:82204260	NA	-0.57	-5.71	-0.33	3e-8	Post bronchodilator FEV1;
CESC	cis	rs854765	0.547	rs4072739	chr17:17884660	G/A	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.5	6.69	0.38	1.3100000000000001e-10	Total body bone mineral density;
CESC	cis	rs1552244	0.882	rs112621205	chr3:10017916	G/A	cg08888203	chr3:10149979	C3orf24	0.49	6.14	0.35	3.07e-9	Alzheimer's disease;
CESC	trans	rs7628583	0.696	rs12488626	chr3:64071952	C/A	cg08189171	chr12:6420023	PLEKHG6	-0.57	-6.2	-0.36	2.15e-9	Parental extreme longevity (95 years and older);
CESC	cis	rs13064411	0.735	rs9875025	chr3:113147552	T/C	cg18753928	chr3:113234510	CCDC52	-0.46	-5.45	-0.32	1.13e-7	Response to simvastatin treatment (PCSK9 protein level change);
CESC	cis	rs3825932	0.744	rs11072818	chr15:79236933	A/G	cg25744700	chr15:79237217	CTSH	0.49	6.47	0.37	4.79e-10	Type 1 diabetes;
CESC	cis	rs79349575	0.811	rs1057897	chr17:47005509	T/G	cg16584676	chr17:46985605	UBE2Z	0.52	6.38	0.37	7.67e-10	Type 2 diabetes;
CESC	cis	rs7103648	0.630	rs7120548	chr11:47662932	A/G	cg20307385	chr11:47447363	PSMC3	0.81	12.49	0.61	1.92e-28	Diastolic blood pressure;Systolic blood pressure;
CESC	cis	rs965469	1.000	rs2281500	chr20:3262824	C/T	cg25506879	chr20:3388711	C20orf194	-0.55	-6.05	-0.35	4.82e-9	IFN-related cytopenia;
CESC	cis	rs2243480	1.000	rs60683927	chr7:65394768	T/C	cg18252515	chr7:66147081	NA	-1.0	-9.22	-0.49	9.27e-18	Diabetic kidney disease;
CESC	cis	rs6547741	0.844	rs9678851	chr2:27887034	C/A	cg27432699	chr2:27873401	GPN1	-0.59	-8.6	-0.47	6.89e-16	Oral cavity cancer;
CESC	cis	rs7618915	0.570	rs13068293	chr3:52672167	C/A	cg18099408	chr3:52552593	STAB1	-0.3	-5.05	-0.3	8.14e-7	Bipolar disorder;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg03115081	chr17:74722049	C17orf95;JMJD6	-0.49	-6.86	-0.39	4.96e-11	Height;
CESC	cis	rs17401966	0.838	rs12125535	chr1:10350849	T/A	cg15208524	chr1:10270712	KIF1B	0.41	5.32	0.31	2.16e-7	Hepatocellular carcinoma;
CESC	cis	rs2637266	0.935	rs2637265	chr10:78326104	A/G	cg18941641	chr10:78392320	NA	0.38	6.83	0.39	5.66e-11	Pulmonary function;
CESC	cis	rs4268898	0.552	rs12621083	chr2:24367540	C/T	cg20701182	chr2:24300061	SF3B14	-0.39	-5.47	-0.32	1.03e-7	Asthma;
CESC	cis	rs7301826	0.651	rs2277336	chr12:131286119	A/G	cg11011512	chr12:131303247	STX2	-0.47	-5.59	-0.32	5.74e-8	Plasma plasminogen activator levels;
CESC	cis	rs9649213	0.574	rs34830366	chr7:97899535	G/T	cg08684580	chr7:98029266	BAIAP2L1	-0.33	-5.1	-0.3	6.36e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs10489202	0.583	rs201539	chr1:167995407	A/G	cg24449463	chr1:168025552	DCAF6	-0.4	-5.14	-0.3	5.43e-7	Schizophrenia;
CESC	cis	rs11785693	0.866	rs11782170	chr8:4976942	A/G	cg26367366	chr8:4980734	NA	-0.85	-7.58	-0.42	5.67e-13	Neuroticism (multi-trait analysis);Neuroticism;
CESC	cis	rs916888	0.610	rs199438	chr17:44791643	G/A	cg17911788	chr17:44343683	NA	-0.43	-6.7	-0.38	1.22e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs514406	0.861	rs7417821	chr1:53295117	A/G	cg16325326	chr1:53192061	ZYG11B	0.72	11.92	0.59	1.6e-26	Monocyte count;
CESC	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg22535103	chr8:58192502	C8orf71	-0.93	-10.39	-0.54	1.89e-21	Developmental language disorder (linguistic errors);
CESC	cis	rs7809950	1.000	rs10274041	chr7:107261556	C/T	cg23024343	chr7:107201750	COG5	0.43	5.91	0.34	1.02e-8	Coronary artery disease;
CESC	cis	rs6691722	0.503	rs3765425	chr1:24699872	G/C	cg02336364	chr1:24764700	NIPAL3	0.34	6.94	0.39	2.96e-11	Response to interferon beta in multiple sclerosis;
CESC	cis	rs7107174	0.901	rs2450133	chr11:77925759	A/C	cg02023728	chr11:77925099	USP35	0.47	6.43	0.37	5.9e-10	Testicular germ cell tumor;
CESC	cis	rs7809950	1.000	rs10276604	chr7:107216738	C/T	cg23024343	chr7:107201750	COG5	0.43	5.56	0.32	6.71e-8	Coronary artery disease;
CESC	cis	rs6446731	0.614	rs7661630	chr4:3280106	G/A	cg08886695	chr4:3369023	RGS12	-0.37	-5.38	-0.31	1.65e-7	Mean platelet volume;
CESC	cis	rs9311474	0.652	rs614288	chr3:52220203	T/C	cg07507251	chr3:52567010	NT5DC2	0.36	6.15	0.35	2.88e-9	Electroencephalogram traits;
CESC	cis	rs7917772	0.582	rs4919663	chr10:104363293	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.42	5.66	0.33	4.02e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs854765	0.583	rs2350977	chr17:17802779	A/G	cg16928487	chr17:17741425	SREBF1	-0.56	-9.44	-0.5	1.99e-18	Total body bone mineral density;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15888741	chr10:15139207	RPP38;C10orf111	0.6	6.8	0.39	7.05e-11	Gut microbiome composition (summer);
CESC	cis	rs2637266	0.783	rs58247832	chr10:78471383	C/A	cg18941641	chr10:78392320	NA	0.43	8.19	0.45	1.08e-14	Pulmonary function;
CESC	cis	rs898097	0.812	rs7406011	chr17:80829980	C/T	cg15369054	chr17:80825471	TBCD	0.53	7.29	0.41	3.57e-12	Breast cancer;
CESC	cis	rs735396	1.000	rs1169309	chr12:121439192	G/T	cg02403541	chr12:121454288	C12orf43	0.64	9.18	0.49	1.23e-17	N-glycan levels;
CESC	cis	rs1552244	1.000	rs7615646	chr3:10089773	A/C	cg08888203	chr3:10149979	C3orf24	0.51	6.39	0.37	7.29e-10	Alzheimer's disease;
CESC	trans	rs916888	0.821	rs415430	chr17:44859144	C/T	cg22433210	chr17:43662623	NA	-0.91	-10.77	-0.55	1.15e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs3096299	0.967	rs2911257	chr16:89484134	C/G	cg00750074	chr16:89608354	SPG7	-0.37	-5.41	-0.32	1.41e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs826838	0.678	rs11182781	chr12:38610178	C/T	cg26384229	chr12:38710491	ALG10B	0.74	11.15	0.57	6.39e-24	Heart rate;
CESC	cis	rs4664304	0.629	rs955388	chr2:160837921	A/G	cg03641300	chr2:160917029	PLA2R1	-0.44	-6.02	-0.35	5.73e-9	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs6912958	0.559	rs107689	chr6:88069333	G/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.48	8.61	0.47	6.58e-16	Monocyte percentage of white cells;
CESC	cis	rs28374715	0.578	rs72739630	chr15:41631064	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.07	-15.8	-0.7	4.43e-40	Ulcerative colitis;
CESC	cis	rs8177253	0.634	rs6798547	chr3:133448499	G/A	cg18769074	chr3:133464867	TF	0.32	5.93	0.34	9.22e-9	Iron status biomarkers;
CESC	cis	rs61776719	0.520	rs12569027	chr1:38449163	C/T	cg26398791	chr1:38455867	SF3A3	-0.43	-5.46	-0.32	1.12e-7	Coronary artery disease;
CESC	cis	rs35110281	0.508	rs2838351	chr21:45110784	A/G	cg21573476	chr21:45109991	RRP1B	-0.55	-7.78	-0.43	1.67e-13	Mean corpuscular volume;
CESC	cis	rs80282103	0.764	rs12247818	chr10:1110464	G/A	cg08668510	chr10:1095578	IDI1	0.65	5.53	0.32	7.75e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs12618769	0.571	rs72821939	chr2:99138872	T/C	cg10123293	chr2:99228465	UNC50	0.39	5.13	0.3	5.6e-7	Bipolar disorder;
CESC	cis	rs2576037	0.583	rs2571028	chr18:44561100	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.49	6.54	0.37	3.08e-10	Personality dimensions;
CESC	cis	rs4460629	0.742	rs7368345	chr1:155080090	C/T	cg01019262	chr1:155095195	NA	0.29	5.15	0.3	5.14e-7	Serum magnesium levels;
CESC	cis	rs2235544	0.554	rs7540270	chr1:54484682	A/G	cg25741118	chr1:54482237	LDLRAD1	-0.23	-5.77	-0.33	2.16e-8	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
CESC	cis	rs1799949	0.965	rs4793234	chr17:41436183	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.64	8.83	0.48	1.48e-16	Menopause (age at onset);
CESC	cis	rs897984	0.806	rs8050588	chr16:30937799	G/A	cg02466173	chr16:30829666	NA	-0.48	-8.23	-0.45	8.48e-15	Dementia with Lewy bodies;
CESC	cis	rs8072100	0.713	rs1912486	chr17:45515167	A/G	cg08085267	chr17:45401833	C17orf57	-0.52	-6.6	-0.38	2.28e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs9815354	1.000	rs9856088	chr3:41860482	G/T	cg03022575	chr3:42003672	ULK4	0.45	5.06	0.3	7.71e-7	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs7582720	0.943	rs72932556	chr2:203845996	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.36	0.41	2.34e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs7727544	0.606	rs17622208	chr5:131717050	G/A	cg14196790	chr5:131705035	SLC22A5	0.37	5.63	0.33	4.49e-8	Blood metabolite levels;
CESC	cis	rs6762	0.550	rs8672	chr11:838634	C/G	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.67	-8.65	-0.47	5.21e-16	Mean platelet volume;
CESC	cis	rs977987	0.806	rs35263058	chr16:75391937	T/C	cg03315344	chr16:75512273	CHST6	0.39	5.64	0.33	4.36e-8	Dupuytren's disease;
CESC	cis	rs7662987	1.000	rs13125919	chr4:99999848	C/T	cg13256891	chr4:100009986	ADH5	-0.83	-5.87	-0.34	1.29e-8	Smoking initiation;
CESC	cis	rs9308731	1.000	rs1980045	chr2:111904541	A/G	cg04202892	chr2:111875749	ACOXL	0.37	5.34	0.31	1.97e-7	Chronic lymphocytic leukemia;
CESC	cis	rs4595586	0.545	rs969468	chr12:39367278	A/C	cg26384229	chr12:38710491	ALG10B	0.54	7.53	0.42	7.85e-13	Morning vs. evening chronotype;
CESC	cis	rs12477438	0.798	rs13409996	chr2:99575497	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-10.59	-0.55	4.26e-22	Chronic sinus infection;
CESC	cis	rs826838	0.967	rs826856	chr12:39115434	G/A	cg26384229	chr12:38710491	ALG10B	-0.67	-11.02	-0.56	1.72e-23	Heart rate;
CESC	cis	rs8077889	0.917	rs72836559	chr17:41913529	C/T	cg26893861	chr17:41843967	DUSP3	0.83	9.9	0.52	7.45e-20	Triglycerides;
CESC	cis	rs9914988	0.887	rs12451790	chr17:27112000	C/G	cg20469991	chr17:27169893	C17orf63	-0.48	-5.25	-0.31	3.18e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CESC	trans	rs916888	0.610	rs199529	chr17:44837217	A/C	cg07870213	chr5:140052090	DND1	0.53	6.43	0.37	5.85e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs7412746	0.611	rs3768018	chr1:150723747	T/C	cg04414720	chr1:150670196	GOLPH3L	0.57	7.47	0.42	1.14e-12	Melanoma;
CESC	cis	rs8067354	0.645	rs28516945	chr17:57816578	T/C	cg13753209	chr17:57696993	CLTC	0.65	7.77	0.43	1.71e-13	Hemoglobin concentration;
CESC	cis	rs9311474	0.508	rs12629701	chr3:52619836	T/C	cg17372223	chr3:52568218	NT5DC2	0.4	6.01	0.35	6.27e-9	Electroencephalogram traits;
CESC	cis	rs7539624	0.588	rs12070364	chr1:223916059	A/T	cg10100437	chr1:223903862	CAPN2	0.38	5.09	0.3	6.88e-7	Schizophrenia;
CESC	cis	rs2180341	1.000	rs9321073	chr6:127609691	C/T	cg27446573	chr6:127587934	RNF146	1.08	16.13	0.7	3.14e-41	Breast cancer;
CESC	cis	rs11920090	0.860	rs55641619	chr3:170740599	A/G	cg09710316	chr3:170744871	SLC2A2	0.45	5.41	0.32	1.42e-7	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
CESC	cis	rs28647808	1.000	rs28556828	chr9:136273106	C/T	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.9	5.74	0.33	2.53e-8	Blood protein levels;
CESC	cis	rs2070488	1.000	rs2268758	chr3:38514049	C/T	cg24069376	chr3:38537580	EXOG	0.48	8.77	0.47	2.26e-16	Electrocardiographic conduction measures;
CESC	trans	rs2727020	0.553	rs61904166	chr11:49581461	T/C	cg03929089	chr4:120376271	NA	-0.81	-12.18	-0.6	2.06e-27	Coronary artery disease;
CESC	cis	rs12410462	0.681	rs58496521	chr1:227582375	T/C	cg23173402	chr1:227635558	NA	0.65	5.73	0.33	2.74e-8	Major depressive disorder;
CESC	cis	rs1729951	0.575	rs10935213	chr3:136693459	A/G	cg04103450	chr3:136751342	NA	0.41	5.48	0.32	9.82e-8	Neuroticism;
CESC	cis	rs9611565	0.512	rs4512	chr22:42206084	G/C	cg17376030	chr22:41985996	PMM1	0.79	8.09	0.44	2.22e-14	Vitiligo;
CESC	cis	rs7592578	0.882	rs2192010	chr2:191462133	C/T	cg27211696	chr2:191398769	TMEM194B	-0.62	-5.47	-0.32	1.06e-7	Diastolic blood pressure;
CESC	cis	rs9611565	0.592	rs12484254	chr22:41962003	T/A	cg17376030	chr22:41985996	PMM1	0.53	5.88	0.34	1.25e-8	Vitiligo;
CESC	cis	rs736408	0.634	rs11717836	chr3:52807736	A/G	cg18404041	chr3:52824283	ITIH1	-0.45	-7.34	-0.41	2.64e-12	Bipolar disorder;
CESC	cis	rs1008375	0.863	rs2058336	chr4:17608299	T/C	cg16339924	chr4:17578868	LAP3	0.64	8.22	0.45	9.39e-15	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs66573146	0.831	rs67315413	chr4:6987910	T/C	cg00086871	chr4:6988644	TBC1D14	1.18	8.17	0.45	1.25e-14	Granulocyte percentage of myeloid white cells;
CESC	cis	rs611744	0.560	rs58605513	chr8:109279122	A/C	cg21045802	chr8:109455806	TTC35	0.45	5.56	0.32	6.42e-8	Dupuytren's disease;
CESC	cis	rs10479542	0.929	rs10078796	chr5:178978883	T/A	cg21226059	chr5:178986404	RUFY1	0.5	7.62	0.42	4.49e-13	Lung cancer;
CESC	cis	rs5167	0.504	rs7257476	chr19:45453165	C/T	cg13119609	chr19:45449297	APOC2	0.49	8.03	0.44	3.21e-14	Blood protein levels;
CESC	cis	rs9486719	0.843	rs2499796	chr6:96848364	A/G	cg06623918	chr6:96969491	KIAA0776	0.75	7.16	0.4	8.08e-12	Migraine;Coronary artery disease;
CESC	cis	rs7044106	0.791	rs10985001	chr9:123484232	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.34	5.55	0.32	6.77e-8	Hip circumference adjusted for BMI;
CESC	cis	rs1552244	0.872	rs6792951	chr3:10119603	C/A	cg13047869	chr3:10149882	C3orf24	0.4	5.03	0.3	8.89e-7	Alzheimer's disease;
CESC	cis	rs9457247	0.508	rs9459874	chr6:167504127	A/G	cg23791538	chr6:167370224	RNASET2	0.43	5.71	0.33	3.06e-8	Crohn's disease;
CESC	cis	rs2236918	0.710	rs2526698	chr1:242029101	T/C	cg17736920	chr1:242011382	EXO1	0.55	6.97	0.39	2.51e-11	Menopause (age at onset);
CESC	cis	rs7726839	0.561	rs11955068	chr5:582324	C/T	cg09021430	chr5:549028	NA	-0.43	-5.76	-0.33	2.29e-8	Obesity-related traits;
CESC	cis	rs561341	0.882	rs563539	chr17:30307958	A/G	cg12193833	chr17:30244370	NA	-0.57	-5.73	-0.33	2.69e-8	Hip circumference adjusted for BMI;
CESC	cis	rs2228479	0.850	rs62054611	chr16:89817017	T/C	cg06558623	chr16:89946397	TCF25	1.16	9.28	0.5	6.08e-18	Skin colour saturation;
CESC	cis	rs7762018	0.514	rs60671539	chr6:170165981	A/G	cg13891659	chr6:170190454	C6orf122;C6orf208	0.67	8.75	0.47	2.62e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs977987	0.806	rs4887818	chr16:75361995	T/C	cg03315344	chr16:75512273	CHST6	0.39	5.58	0.32	5.89e-8	Dupuytren's disease;
CESC	cis	rs6860806	0.661	rs1588263	chr5:131577158	T/C	cg09877947	chr5:131593287	PDLIM4	0.46	5.98	0.35	7.05e-9	Breast cancer;
CESC	cis	rs35306767	0.714	rs66797613	chr10:1090469	C/T	cg26597838	chr10:835615	NA	0.63	6.0	0.35	6.62e-9	Eosinophil percentage of granulocytes;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg25237692	chr15:64752785	NA	-0.47	-6.15	-0.35	2.9e-9	Ulcerative colitis;
CESC	cis	rs7712401	0.601	rs154496	chr5:122221731	A/G	cg19412675	chr5:122181750	SNX24	0.41	5.15	0.3	5.03e-7	Mean platelet volume;
CESC	cis	rs4970988	0.556	rs6695123	chr1:150563483	T/C	cg22823121	chr1:150693482	HORMAD1	-0.42	-5.69	-0.33	3.38e-8	Urate levels;
CESC	cis	rs1865721	0.771	rs6566093	chr18:73136682	T/C	cg26385618	chr18:73139727	C18orf62	-0.51	-8.36	-0.46	3.47e-15	Intelligence;
CESC	cis	rs763121	0.853	rs2267395	chr22:39113903	C/T	cg06022373	chr22:39101656	GTPBP1	0.94	18.18	0.75	1.61e-48	Menopause (age at onset);
CESC	cis	rs9916302	0.904	rs801420	chr17:37466103	C/G	cg07936489	chr17:37558343	FBXL20	0.76	10.71	0.55	1.83e-22	Glomerular filtration rate (creatinine);
CESC	cis	rs9916302	0.904	rs587343	chr17:37440603	C/T	cg07936489	chr17:37558343	FBXL20	0.75	10.23	0.53	6.6e-21	Glomerular filtration rate (creatinine);
CESC	cis	rs7512552	0.582	rs834233	chr1:150354276	G/A	cg15654264	chr1:150340011	RPRD2	0.4	5.21	0.3	3.83e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CESC	trans	rs13063635	0.915	rs75928798	chr3:45962603	A/G	cg10236987	chr1:228114221	WNT9A	0.56	6.05	0.35	4.83e-9	Eosinophil percentage of granulocytes;
CESC	cis	rs17345786	1.000	rs3804775	chr3:101306507	C/T	cg12386194	chr3:101231763	SENP7	0.58	6.6	0.38	2.25e-10	Colonoscopy-negative controls vs population controls;
CESC	cis	rs763121	0.853	rs2267393	chr22:39101619	G/C	cg06022373	chr22:39101656	GTPBP1	0.94	17.57	0.73	2.32e-46	Menopause (age at onset);
CESC	cis	rs7520050	0.966	rs7539932	chr1:46292354	C/T	cg24296786	chr1:45957014	TESK2	0.42	5.39	0.31	1.6e-7	Red blood cell count;Reticulocyte count;
CESC	cis	rs7618915	0.532	rs13060675	chr3:52674300	T/G	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.3	5.39	0.31	1.54e-7	Bipolar disorder;
CESC	cis	rs35110281	0.693	rs2251253	chr21:45092257	T/A	cg21573476	chr21:45109991	RRP1B	-0.53	-8.0	-0.44	3.92e-14	Mean corpuscular volume;
CESC	cis	rs7107174	1.000	rs2510049	chr11:77985459	G/T	cg02023728	chr11:77925099	USP35	0.48	6.63	0.38	1.82e-10	Testicular germ cell tumor;
CESC	cis	rs7811142	1.000	rs112317829	chr7:100043173	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.12	12.95	0.62	4.82e-30	Platelet count;
CESC	cis	rs10242455	0.702	rs73711293	chr7:99081595	C/T	cg25640893	chr7:99214727	ZNF498	0.76	5.39	0.31	1.58e-7	Blood metabolite levels;
CESC	cis	rs2439831	0.850	rs28718261	chr15:44043793	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.7	8.06	0.44	2.56e-14	Lung cancer in ever smokers;
CESC	trans	rs7618501	0.933	rs1128535	chr3:49866392	C/T	cg21659725	chr3:3221576	CRBN	0.84	13.68	0.64	1.39e-32	Intelligence (multi-trait analysis);
CESC	trans	rs916888	0.773	rs199447	chr17:44812188	C/T	cg01341218	chr17:43662625	NA	0.92	10.78	0.55	1.06e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs62408225	1.000	rs62408225	chr6:90956409	A/G	cg06866423	chr6:90926672	BACH2	0.46	5.67	0.33	3.74e-8	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs4927850	1.000	rs7614767	chr3:195753451	C/T	cg00031303	chr3:195681400	NA	0.47	6.26	0.36	1.52e-9	Pancreatic cancer;
CESC	cis	rs1395	0.778	rs72810794	chr2:27401260	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.42	5.5	0.32	8.91e-8	Blood metabolite levels;
CESC	cis	rs7927771	0.524	rs10838746	chr11:47706291	A/G	cg18512352	chr11:47633146	NA	0.35	5.39	0.31	1.53e-7	Subjective well-being;
CESC	cis	rs4835473	0.838	rs6832094	chr4:144716541	A/C	cg25736465	chr4:144833511	NA	-0.35	-5.83	-0.34	1.59e-8	Immature fraction of reticulocytes;
CESC	cis	rs6542838	0.611	rs17758170	chr2:99531842	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.47	-5.84	-0.34	1.55e-8	Fear of minor pain;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg00046018	chr1:202318086	PPP1R12B	-0.52	-6.21	-0.36	2.03e-9	Ulcerative colitis;
CESC	cis	rs1670533	1.000	rs629261	chr4:1086763	A/C	cg04106633	chr4:1044584	NA	0.4	5.08	0.3	6.98e-7	Recombination rate (females);
CESC	cis	rs708547	0.836	rs1718882	chr4:57859533	C/G	cg14719990	chr4:57843890	C4orf14;POLR2B	0.47	5.63	0.33	4.58e-8	Response to bleomycin (chromatid breaks);
CESC	cis	rs6570726	0.935	rs425731	chr6:145834151	A/G	cg05347473	chr6:146136440	FBXO30	0.49	6.69	0.38	1.3100000000000001e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6570726	0.934	rs430003	chr6:145819506	C/T	cg23711669	chr6:146136114	FBXO30	0.81	12.04	0.59	6.44e-27	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9649213	0.574	rs9648908	chr7:97945236	C/T	cg00277769	chr7:97922759	BAIAP2L1	-0.35	-5.71	-0.33	2.98e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7771547	0.573	rs522179	chr6:36391605	G/A	cg07856975	chr6:36356162	ETV7	0.37	5.5	0.32	8.73e-8	Platelet distribution width;
CESC	cis	rs7772486	0.875	rs2474353	chr6:146323883	G/A	cg05347473	chr6:146136440	FBXO30	0.53	6.87	0.39	4.54e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs13256369	0.802	rs4840350	chr8:8561442	A/G	cg17143192	chr8:8559678	CLDN23	0.75	8.46	0.46	1.78e-15	Obesity-related traits;
CESC	cis	rs13191362	0.935	rs35942036	chr6:163163297	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.05	10.71	0.55	1.78e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg19452060	chr12:57914632	DDIT3	-0.42	-6.71	-0.38	1.19e-10	Gambling;
CESC	cis	rs3126085	0.935	rs1858478	chr1:152257457	C/T	cg03465714	chr1:152285911	FLG	0.45	5.54	0.32	7.12e-8	Atopic dermatitis;
CESC	cis	rs11969893	0.737	rs1856131	chr6:101407104	C/G	cg12253828	chr6:101329408	ASCC3	0.89	7.23	0.41	5.04e-12	Economic and political preferences (immigration/crime);
CESC	cis	rs7666738	0.791	rs6853608	chr4:99047916	A/G	cg03676636	chr4:99064102	C4orf37	0.33	5.12	0.3	5.93e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs12956009	0.518	rs1347343	chr18:44818996	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.47	6.24	0.36	1.73e-9	Educational attainment (years of education);
CESC	trans	rs10242455	0.557	rs45492501	chr7:99047030	T/A	cg09045935	chr12:6379348	NA	0.91	7.33	0.41	2.87e-12	Blood metabolite levels;
CESC	cis	rs763121	0.853	rs4821808	chr22:39065739	A/G	cg06022373	chr22:39101656	GTPBP1	0.88	13.81	0.65	4.88e-33	Menopause (age at onset);
CESC	cis	rs2708240	1.000	rs2538990	chr7:147580041	A/G	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	0.36	5.92	0.34	1.01e-8	QT interval (drug interaction);
CESC	cis	rs3741798	1.000	rs61922023	chr12:12485555	G/A	cg08615371	chr12:12503544	MANSC1	0.87	6.35	0.36	9.19e-10	Cerebrospinal fluid biomarker levels;
CESC	cis	rs9309473	0.500	rs12472502	chr2:73859184	C/T	cg20560298	chr2:73613845	ALMS1	0.51	7.14	0.4	8.9e-12	Metabolite levels;
CESC	cis	rs4819052	0.851	rs4819049	chr21:46673086	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.76	10.07	0.53	2.08e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg23709988	chr14:23772096	PPP1R3E	-0.46	-6.42	-0.37	6.15e-10	Fibrinogen levels;
CESC	cis	rs1707322	0.656	rs3014210	chr1:46066608	A/G	cg06784218	chr1:46089804	CCDC17	-0.43	-7.66	-0.43	3.41e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7726839	0.540	rs3762951	chr5:662613	C/G	cg09021430	chr5:549028	NA	-0.4	-5.04	-0.3	8.51e-7	Obesity-related traits;
CESC	cis	rs7086627	0.506	rs10749575	chr10:82136921	C/T	cg00277334	chr10:82204260	NA	-0.52	-7.67	-0.43	3.38e-13	Post bronchodilator FEV1;
CESC	trans	rs208520	0.955	rs208532	chr6:66961280	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.85	-9.42	-0.5	2.36e-18	Exhaled nitric oxide output;
CESC	cis	rs858239	0.601	rs10278700	chr7:23160529	T/C	cg23682824	chr7:23144976	KLHL7	0.54	7.38	0.41	2.09e-12	Cerebrospinal fluid biomarker levels;
CESC	cis	rs4948102	0.924	rs13240915	chr7:56090752	G/C	cg09872392	chr7:56161020	PHKG1	-0.4	-6.15	-0.35	2.9e-9	Plasma homocysteine levels (post-methionine load test);
CESC	cis	rs1008375	0.966	rs6825133	chr4:17577776	C/T	cg16339924	chr4:17578868	LAP3	0.75	9.8	0.52	1.56e-19	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs4664308	0.618	rs62175488	chr2:160892758	T/C	cg03641300	chr2:160917029	PLA2R1	-0.59	-8.54	-0.46	1.04e-15	Idiopathic membranous nephropathy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07589846	chr1:212872696	BATF3	0.53	6.36	0.36	8.95e-10	Gut microbiome composition (summer);
CESC	cis	rs78456975	1.000	rs11898988	chr2:1560336	G/A	cg26248373	chr2:1572462	NA	-0.59	-5.7	-0.33	3.11e-8	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs2625529	0.761	rs972029	chr15:72172986	C/T	cg16672083	chr15:72433130	SENP8	-0.37	-5.05	-0.3	8.12e-7	Red blood cell count;
CESC	cis	rs6952808	0.792	rs11771973	chr7:1950440	C/G	cg02951883	chr7:2050386	MAD1L1	-0.49	-6.59	-0.38	2.32e-10	Bipolar disorder and schizophrenia;
CESC	cis	rs829883	0.621	rs11109516	chr12:98921035	G/A	cg25150519	chr12:98850993	NA	-0.64	-7.93	-0.44	6.24e-14	Colorectal adenoma (advanced);
CESC	cis	rs2295499	0.782	rs4690053	chr4:2736579	G/C	cg08330972	chr4:2403930	ZFYVE28	-0.33	-5.21	-0.3	3.89e-7	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04122601	chr12:10826785	STYK1	0.46	6.13	0.35	3.17e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs6723226	0.803	rs176415	chr2:32649778	G/A	cg02381751	chr2:32503542	YIPF4	-0.81	-11.7	-0.58	8.87e-26	Intelligence (multi-trait analysis);
CESC	cis	rs34734847	0.703	rs7978125	chr12:121167039	A/G	cg21892295	chr12:121157589	UNC119B	-0.35	-5.6	-0.33	5.48e-8	Mean corpuscular volume;
CESC	cis	rs736408	0.660	rs2019065	chr3:52809525	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	-0.35	-6.13	-0.35	3.13e-9	Bipolar disorder;
CESC	cis	rs6460942	1.000	rs111761262	chr7:12415916	T/C	cg17427002	chr7:12443146	VWDE	-0.53	-5.08	-0.3	7.29e-7	Coronary artery disease;
CESC	cis	rs6540559	0.546	rs735694	chr1:210034029	T/C	cg21951975	chr1:209979733	IRF6	0.58	6.23	0.36	1.85e-9	Cleft lip with or without cleft palate;
CESC	cis	rs1784581	0.588	rs4131681	chr6:162422167	T/G	cg17173639	chr6:162384350	PARK2	0.57	8.73	0.47	2.94e-16	Itch intensity from mosquito bite;
CESC	cis	rs34172651	0.517	rs200528	chr16:24759131	A/G	cg00339695	chr16:24857497	SLC5A11	-0.5	-6.57	-0.37	2.58e-10	Intelligence (multi-trait analysis);
CESC	cis	rs4727963	0.846	rs7805573	chr7:122699114	C/T	cg03640110	chr7:122635026	TAS2R16	-0.37	-5.71	-0.33	3.07e-8	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
CESC	cis	rs9910055	0.762	rs4239142	chr17:42205876	A/G	cg19774624	chr17:42201019	HDAC5	0.68	9.64	0.51	4.82e-19	Total body bone mineral density;
CESC	cis	rs412050	0.594	rs113463481	chr22:22097230	G/A	cg17089214	chr22:22089827	YPEL1	0.65	5.63	0.33	4.49e-8	Attention deficit hyperactivity disorder;
CESC	cis	rs9796	0.653	rs28516683	chr15:41446645	A/G	cg20272979	chr15:41787780	ITPKA	0.34	5.12	0.3	6.01e-7	Menopause (age at onset);
CESC	cis	rs7666738	0.924	rs62318940	chr4:99064768	C/T	cg05340658	chr4:99064831	C4orf37	0.64	8.22	0.45	9.31e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs68170813	0.559	rs58663672	chr7:106949444	T/C	cg02696742	chr7:106810147	HBP1	-0.54	-5.12	-0.3	5.86e-7	Coronary artery disease;
CESC	cis	rs879620	1.000	rs2531995	chr16:4013467	C/T	cg09300795	chr16:4042428	ADCY9	0.38	5.14	0.3	5.39e-7	Hip circumference;Body mass index;
CESC	cis	rs2836950	0.565	rs2836926	chr21:40536790	G/A	cg11890956	chr21:40555474	PSMG1	-0.63	-8.81	-0.48	1.69e-16	Menarche (age at onset);
CESC	cis	rs9649465	0.967	rs12706546	chr7:123353414	G/A	cg04330084	chr7:123175371	IQUB	-0.39	-5.23	-0.31	3.37e-7	Migraine;
CESC	cis	rs2836974	0.897	rs8132568	chr21:40527916	C/T	cg11890956	chr21:40555474	PSMG1	1.18	23.98	0.83	2.35e-68	Cognitive function;
CESC	cis	rs12971120	0.891	rs4891557	chr18:72170299	C/T	cg25817165	chr18:72167213	CNDP2	-0.61	-7.26	-0.41	4.39e-12	Refractive error;
CESC	cis	rs7512552	0.839	rs834232	chr1:150354682	T/C	cg15654264	chr1:150340011	RPRD2	0.39	5.25	0.31	3.16e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs4604732	0.642	rs10802514	chr1:247637749	A/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.4	5.97	0.34	7.41e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs9488822	0.676	rs11153593	chr6:116335131	C/A	cg18764771	chr6:116381957	FRK	0.22	5.42	0.32	1.32e-7	Cholesterol, total;LDL cholesterol;
CESC	cis	rs4144743	1.000	rs4144743	chr17:45323125	A/G	cg18085866	chr17:45331354	ITGB3	-0.66	-7.69	-0.43	2.84e-13	Body mass index;
CESC	cis	rs2120019	1.000	rs67544533	chr15:75361539	A/G	cg09165964	chr15:75287851	SCAMP5	-0.74	-8.79	-0.48	1.9e-16	Blood trace element (Zn levels);
CESC	cis	rs300703	0.748	rs4484059	chr2:286812	G/A	cg21211680	chr2:198530	NA	0.85	7.25	0.41	4.51e-12	Blood protein levels;
CESC	cis	rs853679	0.517	rs7755442	chr6:28039015	T/C	cg22143856	chr6:28129313	ZNF389	0.49	6.3	0.36	1.2e-9	Depression;
CESC	cis	rs3806843	0.900	rs2531340	chr5:140131046	C/T	cg26395211	chr5:140044315	WDR55	0.39	5.09	0.3	6.79e-7	Depressive symptoms (multi-trait analysis);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg21367838	chr20:47805154	STAU1	-0.41	-6.23	-0.36	1.79e-9	Gambling;
CESC	cis	rs1620921	0.505	rs13196324	chr6:161201842	A/T	cg01280913	chr6:161186852	NA	-0.36	-5.27	-0.31	2.81e-7	Lipoprotein (a) - cholesterol levels;
CESC	trans	rs2273788	1.000	rs2273788	chr9:114348617	C/T	cg24992690	chr2:160472234	BAZ2B	-0.57	-6.12	-0.35	3.27e-9	Monocyte count;
CESC	cis	rs72945132	0.825	rs7950280	chr11:70213455	G/T	cg00319359	chr11:70116639	PPFIA1	0.68	6.63	0.38	1.86e-10	Coronary artery disease;
CESC	cis	rs11122272	0.668	rs2749712	chr1:231537751	T/A	cg06096015	chr1:231504339	EGLN1	0.43	6.08	0.35	4.07e-9	Hemoglobin concentration;
CESC	cis	rs4819052	0.851	rs8126930	chr21:46671715	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.8	11.71	0.58	8.2e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs875971	0.522	rs1701760	chr7:65473688	A/G	cg18876405	chr7:65276391	NA	0.69	9.69	0.51	3.26e-19	Aortic root size;
CESC	cis	rs2576037	0.542	rs4630643	chr18:44508142	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.35	5.62	0.33	4.73e-8	Personality dimensions;
CESC	cis	rs2839186	0.900	rs2839196	chr21:47708037	G/A	cg11766577	chr21:47581405	C21orf56	-0.43	-5.94	-0.34	8.84e-9	Testicular germ cell tumor;
CESC	cis	rs6963495	0.799	rs73190201	chr7:105165891	A/C	cg19920283	chr7:105172520	RINT1	0.7	6.66	0.38	1.58e-10	Bipolar disorder (body mass index interaction);
CESC	cis	rs1707322	0.964	rs785496	chr1:46588006	T/C	cg06784218	chr1:46089804	CCDC17	-0.36	-5.93	-0.34	9.35e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs8063761	0.689	rs4785763	chr16:90066936	G/T	cg08547343	chr16:90038815	CENPBD1;AFG3L1	-0.59	-7.32	-0.41	3.01e-12	Squamous cell carcinoma;
CESC	cis	rs7216064	0.953	rs1966410	chr17:65837215	T/C	cg07042672	chr17:66097459	LOC651250	-0.57	-6.69	-0.38	1.32e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs1008375	0.902	rs12503164	chr4:17656107	C/T	cg16339924	chr4:17578868	LAP3	0.56	7.01	0.4	1.96e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs2070488	0.804	rs1817364	chr3:38474513	T/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.82	13.18	0.63	7.62e-31	Electrocardiographic conduction measures;
CESC	cis	rs854765	0.583	rs10048206	chr17:17866897	A/G	cg04398451	chr17:18023971	MYO15A	-0.69	-9.72	-0.51	2.77e-19	Total body bone mineral density;
CESC	cis	rs35306767	0.903	rs61833260	chr10:975148	T/G	cg26597838	chr10:835615	NA	0.91	9.69	0.51	3.43e-19	Eosinophil percentage of granulocytes;
CESC	cis	rs4919694	1.000	rs12257941	chr10:104833161	C/T	cg04362960	chr10:104952993	NT5C2	0.79	7.0	0.4	2.07e-11	Arsenic metabolism;
CESC	cis	rs1344694	0.566	rs13029765	chr2:216894976	A/T	cg12620499	chr2:216877984	MREG	0.57	8.08	0.44	2.34e-14	Alcohol dependence;
CESC	cis	rs11264213	0.901	rs72661605	chr1:36326227	A/G	cg27506609	chr1:36549197	TEKT2	0.66	5.59	0.32	5.58e-8	Schizophrenia;
CESC	cis	rs7666738	0.830	rs6831588	chr4:98977356	T/G	cg05340658	chr4:99064831	C4orf37	0.79	12.26	0.6	1.12e-27	Colonoscopy-negative controls vs population controls;
CESC	cis	rs514406	0.621	rs881198	chr1:53196440	C/T	cg08859206	chr1:53392774	SCP2	0.6	7.75	0.43	1.96e-13	Monocyte count;
CESC	trans	rs1448094	0.692	rs7958438	chr12:86326141	A/T	cg00308659	chr16:84871952	CRISPLD2	0.46	6.15	0.35	2.87e-9	Major depressive disorder;
CESC	cis	rs1801251	1.000	rs4517962	chr2:233578337	T/C	cg25237894	chr2:233734115	C2orf82	0.48	8.11	0.45	1.86e-14	Coronary artery disease;
CESC	cis	rs3020736	0.519	rs5996116	chr22:42517492	G/A	cg04733989	chr22:42467013	NAGA	-0.78	-11.9	-0.59	1.87e-26	Autism spectrum disorder or schizophrenia;
CESC	cis	rs77956314	0.515	rs12299065	chr12:117442304	A/G	cg25972092	chr12:117363249	FBXW8	0.53	5.85	0.34	1.46e-8	Subcortical brain region volumes;Hippocampal volume;
CESC	cis	rs748404	0.631	rs8042688	chr15:43638525	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.55	8.69	0.47	3.96e-16	Lung cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07474076	chr16:2972993	FLYWCH1	-0.67	-7.51	-0.42	9.12e-13	Gut microbiome composition (summer);
CESC	cis	rs8180040	0.934	rs4858811	chr3:47480524	G/C	cg27129171	chr3:47204927	SETD2	-0.63	-9.47	-0.5	1.61e-18	Colorectal cancer;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg16259330	chr11:13299070	ARNTL	-0.47	-6.01	-0.35	6.02e-9	Fibrinogen levels;
CESC	cis	rs16854884	0.586	rs11914731	chr3:143725594	A/G	cg06585982	chr3:143692056	C3orf58	0.52	7.07	0.4	1.42e-11	Economic and political preferences (feminism/equality);
CESC	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg23978390	chr7:1156363	C7orf50	0.57	7.84	0.43	1.1e-13	Longevity;Endometriosis;
CESC	cis	rs9291683	0.546	rs6829727	chr4:10051672	A/C	cg00071950	chr4:10020882	SLC2A9	0.77	12.81	0.62	1.51e-29	Bone mineral density;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg12504415	chr17:74722752	JMJD6;C17orf95	-0.45	-6.21	-0.36	2.03e-9	Fibrinogen levels;
CESC	cis	rs17253792	0.822	rs75288952	chr14:56034010	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.83	5.5	0.32	8.98e-8	Putamen volume;
CESC	cis	rs763014	0.966	rs4984903	chr16:680695	A/G	cg09263875	chr16:632152	PIGQ	0.68	11.68	0.58	1.06e-25	Height;
CESC	trans	rs1382269	0.866	rs3856624	chr3:136997294	C/T	cg16900796	chr19:10755136	SLC44A2	-0.4	-6.09	-0.35	4.05e-9	Metabolite levels;
CESC	cis	rs9787249	0.957	rs12239844	chr1:40217258	T/C	cg24920358	chr1:40204285	PPIE	0.43	6.41	0.37	6.57e-10	Blood protein levels;
CESC	cis	rs926938	0.584	rs869990	chr1:115379614	A/G	cg12756093	chr1:115239321	AMPD1	-0.45	-6.13	-0.35	3.15e-9	Autism;
CESC	cis	rs4713118	0.621	rs10484403	chr6:28033523	A/G	cg23281280	chr6:28129359	ZNF389	0.52	7.0	0.39	2.13e-11	Parkinson's disease;
CESC	cis	rs6466055	0.720	rs4730082	chr7:105027509	A/G	cg04380332	chr7:105027541	SRPK2	-0.42	-5.6	-0.33	5.42e-8	Schizophrenia;
CESC	cis	rs7264396	0.790	rs2425160	chr20:34425968	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.82	-11.14	-0.56	6.75e-24	Total cholesterol levels;
CESC	cis	rs546131	0.928	rs499183	chr11:34836678	A/G	cg06937548	chr11:34938143	PDHX;APIP	0.51	6.3	0.36	1.24e-9	Lung disease severity in cystic fibrosis;
CESC	cis	rs4835473	0.897	rs7676614	chr4:144616366	A/G	cg25736465	chr4:144833511	NA	-0.42	-6.22	-0.36	1.95e-9	Immature fraction of reticulocytes;
CESC	cis	rs1862618	0.802	rs252900	chr5:56185281	T/A	cg22800045	chr5:56110881	MAP3K1	0.81	9.66	0.51	4.1e-19	Initial pursuit acceleration;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg01370599	chr3:116745421	NA	-0.41	-6.5	-0.37	3.86e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs4803468	0.967	rs67047091	chr19:41938684	C/T	cg08639244	chr19:41945921	ATP5SL	0.44	5.41	0.32	1.39e-7	Height;
CESC	cis	rs7684253	0.565	rs7697176	chr4:57823048	C/T	cg21154227	chr4:57904332	IGFBP7	0.37	5.36	0.31	1.85e-7	Migraine;
CESC	cis	rs2072732	0.861	rs4576609	chr1:2938265	C/T	cg03976712	chr1:2946727	NA	0.34	5.39	0.31	1.58e-7	Plateletcrit;
CESC	cis	rs921968	0.565	rs2059717	chr2:219600316	A/T	cg02176678	chr2:219576539	TTLL4	-0.4	-7.04	-0.4	1.67e-11	Mean corpuscular hemoglobin concentration;
CESC	cis	rs67460515	0.892	rs2100238	chr3:161058055	T/A	cg03342759	chr3:160939853	NMD3	-0.54	-7.82	-0.43	1.29e-13	Parkinson's disease;
CESC	cis	rs9611565	0.685	rs169363	chr22:41853117	G/T	cg03806693	chr22:41940476	POLR3H	1.16	14.45	0.66	2.63e-35	Vitiligo;
CESC	cis	rs6831352	1.000	rs1126670	chr4:100052733	C/A	cg13256891	chr4:100009986	ADH5	0.72	8.45	0.46	1.94e-15	Alcohol dependence;
CESC	cis	rs2836974	0.932	rs11910151	chr21:40560262	T/C	cg11890956	chr21:40555474	PSMG1	1.19	23.55	0.82	6.33e-67	Cognitive function;
CESC	cis	rs9790314	1.000	rs28515190	chr3:161028605	G/A	cg04691961	chr3:161091175	C3orf57	-0.45	-5.81	-0.34	1.75e-8	Morning vs. evening chronotype;
CESC	cis	rs7178909	0.902	rs8034116	chr15:90441568	A/G	cg19708238	chr15:90437601	AP3S2	0.45	6.41	0.37	6.78e-10	Common traits (Other);
CESC	cis	rs6460942	0.915	rs62448621	chr7:12459941	G/A	cg06484146	chr7:12443880	VWDE	-0.79	-9.25	-0.49	7.67e-18	Coronary artery disease;
CESC	cis	rs61931739	0.500	rs11053272	chr12:34547020	C/G	cg19457237	chr12:34500585	NA	-0.37	-5.08	-0.3	6.97e-7	Morning vs. evening chronotype;
CESC	cis	rs7937682	0.632	rs11608193	chr11:111732215	T/C	cg09085632	chr11:111637200	PPP2R1B	0.87	10.76	0.55	1.25e-22	Primary sclerosing cholangitis;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg04179819	chr10:7860513	TAF3	-0.39	-6.2	-0.36	2.1e-9	Gambling;
CESC	cis	rs4237845	0.537	rs12426201	chr12:58259752	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.5	5.57	0.32	6.28e-8	Intelligence (multi-trait analysis);
CESC	cis	rs314370	0.951	rs12667888	chr7:100474289	T/C	cg10426581	chr7:100472382	SRRT	0.86	8.37	0.46	3.32e-15	Resting heart rate;
CESC	cis	rs4665809	1.000	rs10202478	chr2:26276049	T/C	cg25036284	chr2:26402008	FAM59B	-0.71	-8.2	-0.45	1.05e-14	Gut microbiome composition (summer);
CESC	cis	rs6933660	0.683	rs6916340	chr6:151779064	T/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.55	-7.36	-0.41	2.37e-12	Menarche (age at onset);
CESC	cis	rs7208859	0.623	rs9895785	chr17:29107708	C/T	cg19761014	chr17:28927070	LRRC37B2	-0.78	-6.45	-0.37	5.34e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs8177179	0.967	rs4994582	chr3:133437566	G/C	cg16262614	chr3:133464971	TF	0.38	7.36	0.41	2.37e-12	Iron status biomarkers (transferrin levels);
CESC	cis	rs4141404	0.740	rs9609301	chr22:31895940	C/T	cg13145458	chr22:31556086	RNF185	-0.53	-6.25	-0.36	1.63e-9	Paclitaxel-induced neuropathy;
CESC	cis	rs2228479	0.850	rs62056068	chr16:89909737	C/T	cg06558623	chr16:89946397	TCF25	1.12	8.22	0.45	9.28e-15	Skin colour saturation;
CESC	cis	rs7116495	1.000	rs7127865	chr11:71747781	G/C	cg26138937	chr11:71823887	C11orf51	-0.82	-6.68	-0.38	1.39e-10	Severe influenza A (H1N1) infection;
CESC	cis	rs853679	0.550	rs1233699	chr6:28169158	A/T	cg18032046	chr6:28092343	ZSCAN16	-0.46	-5.53	-0.32	7.74e-8	Depression;
CESC	cis	rs2243480	1.000	rs402418	chr7:65509469	G/A	cg25894440	chr7:65020034	NA	-0.61	-5.12	-0.3	5.79e-7	Diabetic kidney disease;
CESC	cis	rs6032067	0.929	rs17424868	chr20:43818519	T/G	cg11264863	chr20:43835661	SEMG1	0.48	5.29	0.31	2.53e-7	Blood protein levels;
CESC	cis	rs9811920	0.609	rs9872871	chr3:99658702	C/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.64	-10.15	-0.53	1.17e-20	Axial length;
CESC	cis	rs7666738	0.753	rs2903143	chr4:99040480	C/T	cg03676636	chr4:99064102	C4orf37	0.33	5.08	0.3	7.13e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9457247	0.508	rs6902119	chr6:167505791	T/C	cg07741184	chr6:167504864	NA	0.33	5.73	0.33	2.76e-8	Crohn's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04683551	chr10:14880332	HSPA14;CDNF	0.55	6.52	0.37	3.58e-10	Gut microbiome composition (summer);
CESC	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg16132339	chr22:24313637	DDTL;DDT	0.37	5.55	0.32	7.05e-8	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs8067342	0.611	rs6587132	chr17:21175069	C/T	cg03858720	chr17:21194718	MAP2K3	0.42	5.7	0.33	3.21e-8	Immature fraction of reticulocytes;Red cell distribution width;
CESC	cis	rs2576037	0.526	rs8095373	chr18:44527895	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.44	7.24	0.41	4.8e-12	Personality dimensions;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg12994003	chr1:225616475	LBR	-0.45	-6.12	-0.35	3.27e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs71277158	0.688	rs16854812	chr3:169774383	T/C	cg04067573	chr3:169899625	PHC3	0.56	5.73	0.33	2.73e-8	Prostate cancer;
CESC	cis	rs9902453	0.934	rs11080120	chr17:28507021	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	7.84	0.43	1.09e-13	Coffee consumption (cups per day);
CESC	cis	rs1552244	1.000	rs6786638	chr3:10118075	G/C	cg16606324	chr3:10149918	C3orf24	0.42	5.16	0.3	4.9e-7	Alzheimer's disease;
CESC	cis	rs9733	0.565	rs7524620	chr1:150616699	C/T	cg04414720	chr1:150670196	GOLPH3L	-0.63	-9.01	-0.48	4.15e-17	Tonsillectomy;
CESC	cis	rs7903847	0.642	rs6584128	chr10:99171926	G/T	cg20016023	chr10:99160130	RRP12	0.3	5.04	0.3	8.75e-7	Granulocyte percentage of myeloid white cells;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg07791762	chr19:17323290	MYO9B	0.49	6.43	0.37	5.88e-10	Fibrinogen levels;
CESC	cis	rs11098499	0.908	rs1002152	chr4:120273387	C/A	cg24375607	chr4:120327624	NA	0.46	5.59	0.32	5.72e-8	Corneal astigmatism;
CESC	cis	rs2625529	0.652	rs2899776	chr15:72268365	A/T	cg16672083	chr15:72433130	SENP8	0.46	6.81	0.39	6.7e-11	Red blood cell count;
CESC	cis	rs2243480	1.000	rs160646	chr7:65556280	C/T	cg13147721	chr7:65941812	NA	-0.98	-9.09	-0.49	2.37e-17	Diabetic kidney disease;
CESC	cis	rs798554	0.797	rs798497	chr7:2795957	A/G	cg13628971	chr7:2884303	GNA12	0.63	8.14	0.45	1.53e-14	Height;
CESC	cis	rs10256972	0.616	rs7806746	chr7:1075573	A/C	cg16145915	chr7:1198662	ZFAND2A	-0.47	-6.48	-0.37	4.33e-10	Longevity;Endometriosis;
CESC	cis	rs425277	0.585	rs2222217	chr1:2063164	G/A	cg24578937	chr1:2090814	PRKCZ	-0.34	-5.75	-0.33	2.46e-8	Height;
CESC	cis	rs1008375	0.966	rs2315553	chr4:17627332	T/C	cg15017067	chr4:17643749	FAM184B	0.4	5.69	0.33	3.38e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	trans	rs7839040	0.698	rs7820074	chr8:82928598	T/C	cg14472086	chr9:107730925	NA	-0.47	-6.33	-0.36	1.02e-9	Response to methotrexate in juvenile idiopathic arthritis;
CESC	cis	rs2832077	1.000	rs9983229	chr21:30137674	A/G	cg03476357	chr21:30257390	N6AMT1	0.53	5.79	0.33	2.02e-8	Cognitive test performance;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg04005938	chr7:148334417	NA	0.49	6.42	0.37	6.15e-10	Fibrinogen levels;
CESC	trans	rs10518765	0.945	rs35334291	chr15:54648780	C/G	cg09098624	chr8:11558334	NA	-0.56	-6.04	-0.35	5.13e-9	Select biomarker traits;
CESC	cis	rs9911578	1.000	rs4482353	chr17:56896834	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.24	0.31	3.23e-7	Intelligence (multi-trait analysis);
CESC	cis	rs3858526	0.920	rs11039698	chr11:5950907	C/T	cg02574844	chr11:5959923	NA	-0.44	-5.49	-0.32	9.52e-8	DNA methylation (variation);
CESC	cis	rs12477438	0.520	rs36071868	chr2:99737120	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.87	16.09	0.7	4.08e-41	Chronic sinus infection;
CESC	cis	rs116095464	0.614	rs4371799	chr5:268192	C/A	cg20965017	chr5:231967	SDHA	-0.46	-5.24	-0.31	3.34e-7	Breast cancer;
CESC	cis	rs1538970	0.504	rs3790585	chr1:46023356	A/T	cg05343316	chr1:45956843	TESK2	0.69	7.37	0.41	2.17e-12	Platelet count;
CESC	cis	rs9902453	0.765	rs2729436	chr17:28120670	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-10.34	-0.54	2.82e-21	Coffee consumption (cups per day);
CESC	cis	rs3858526	0.834	rs10839169	chr11:6003190	C/G	cg05234568	chr11:5960015	NA	-0.45	-5.31	-0.31	2.27e-7	DNA methylation (variation);
CESC	cis	rs6696846	0.703	rs112653854	chr1:205079251	G/T	cg00857998	chr1:205179979	DSTYK	0.53	7.03	0.4	1.78e-11	Red blood cell count;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg05742564	chr16:23568708	UBFD1;EARS2	-0.42	-6.06	-0.35	4.66e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs9914988	0.943	rs67327562	chr17:27108828	G/A	cg20469991	chr17:27169893	C17orf63	-0.48	-5.25	-0.31	3.18e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CESC	trans	rs9929218	0.551	rs3785135	chr16:68728976	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.86	-14.02	-0.65	8.54e-34	Colorectal cancer;
CESC	cis	rs3858526	0.523	rs10838749	chr11:5884246	A/G	cg19445457	chr11:5799446	OR52N5	-0.4	-5.41	-0.32	1.4e-7	DNA methylation (variation);
CESC	cis	rs7666738	0.830	rs7679961	chr4:99000202	C/T	cg17366294	chr4:99064904	C4orf37	0.6	8.61	0.47	6.47e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3733585	0.699	rs1122142	chr4:9947548	G/C	cg11266682	chr4:10021025	SLC2A9	-0.59	-11.16	-0.57	5.72e-24	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs3780486	0.846	rs913214	chr9:33135085	G/A	cg13443165	chr9:33130375	B4GALT1	0.47	6.88	0.39	4.37e-11	IgG glycosylation;
CESC	cis	rs17376456	1.000	rs17376456	chr5:93557702	C/T	cg21475434	chr5:93447410	FAM172A	-0.87	-7.24	-0.41	4.98e-12	Diabetic retinopathy;
CESC	cis	rs78456975	0.550	rs11904276	chr2:1524006	T/C	cg01028140	chr2:1542097	TPO	-0.48	-6.09	-0.35	3.97e-9	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs6088580	0.634	rs2424992	chr20:33012060	C/T	cg08999081	chr20:33150536	PIGU	0.65	11.43	0.57	7.54e-25	Glomerular filtration rate (creatinine);
CESC	trans	rs853679	0.546	rs17695758	chr6:27837183	T/C	cg01620082	chr3:125678407	NA	-0.76	-6.48	-0.37	4.51e-10	Depression;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26520976	chr11:63706312	NAA40	0.55	6.03	0.35	5.57e-9	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04769218	chr7:99098020	ZNF394	0.58	7.0	0.4	2.12e-11	Gut microbiome composition (summer);
CESC	cis	rs35995292	0.534	rs13228087	chr7:38909204	A/C	cg19327137	chr7:38886074	VPS41	0.63	10.43	0.54	1.4e-21	Subjective well-being (multi-trait analysis);
CESC	cis	rs13118159	0.778	rs12650998	chr4:1338832	T/C	cg02018176	chr4:1364513	KIAA1530	0.43	6.18	0.36	2.36e-9	Longevity;
CESC	cis	rs7267979	0.586	rs6050429	chr20:25183058	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.66	10.76	0.55	1.18e-22	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7020830	0.898	rs13284651	chr9:37222681	G/T	cg14294708	chr9:37120828	ZCCHC7	-1.23	-22.06	-0.8	6.4e-62	Schizophrenia;
CESC	cis	rs4665809	0.590	rs7606351	chr2:26292545	A/C	cg04944784	chr2:26401820	FAM59B	-0.81	-8.98	-0.48	5.09e-17	Gut microbiome composition (summer);
CESC	cis	rs9611565	0.659	rs56364401	chr22:41951243	T/G	cg06634786	chr22:41940651	POLR3H	-0.63	-6.61	-0.38	2.1e-10	Vitiligo;
CESC	cis	rs2898681	0.618	rs79471207	chr4:53738524	C/T	cg00791764	chr4:53727839	RASL11B	0.55	5.36	0.31	1.79e-7	Optic nerve measurement (cup area);
CESC	cis	rs2637266	0.703	rs12252157	chr10:78449521	G/A	cg18941641	chr10:78392320	NA	0.4	7.27	0.41	4.01e-12	Pulmonary function;
CESC	trans	rs3942852	0.915	rs905477	chr11:48148606	T/C	cg15704280	chr7:45808275	SEPT13	-0.69	-7.79	-0.43	1.51e-13	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs7465272	0.500	rs7463655	chr8:143731034	G/C	cg10596483	chr8:143751796	JRK	0.42	5.33	0.31	2.06e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs2730245	0.645	rs4909282	chr7:158699797	T/C	cg01943577	chr7:158741284	NA	-0.46	-6.13	-0.35	3.16e-9	Height;
CESC	cis	rs7811142	0.830	rs7792959	chr7:99972403	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.91	9.82	0.52	1.26e-19	Platelet count;
CESC	cis	rs933688	1.000	rs1363839	chr5:90671274	A/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.12	16.02	0.7	7.64e-41	Smoking behavior;
CESC	cis	rs13108904	0.934	rs13125338	chr4:1278435	A/C	cg00684032	chr4:1343700	KIAA1530	0.4	5.56	0.32	6.51e-8	Obesity-related traits;
CESC	cis	rs2108622	0.727	rs8102532	chr19:15980060	G/A	cg13772218	chr19:15982569	NA	0.3	5.78	0.33	2.11e-8	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CESC	cis	rs9905704	0.918	rs304272	chr17:56803028	C/A	cg12560992	chr17:57184187	TRIM37	0.59	7.01	0.4	1.92e-11	Testicular germ cell tumor;
CESC	cis	rs7216064	1.000	rs62085993	chr17:65923152	T/C	cg07042672	chr17:66097459	LOC651250	-0.54	-5.87	-0.34	1.3e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs7666738	0.830	rs28619044	chr4:98789814	G/C	cg17366294	chr4:99064904	C4orf37	0.58	8.3	0.45	5.45e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs60871478	0.730	rs13222476	chr7:826630	T/C	cg00934597	chr7:893267	UNC84A	0.53	5.41	0.32	1.43e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs7666738	0.830	rs10019087	chr4:99030211	C/T	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.58e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs597539	0.690	rs647661	chr11:68625875	T/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.81	9.88	0.52	8.25e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs2836974	0.568	rs371625	chr21:40535271	A/G	cg27266027	chr21:40555129	PSMG1	-0.4	-5.13	-0.3	5.63e-7	Cognitive function;
CESC	cis	rs10791097	0.694	rs2155749	chr11:130751094	G/T	cg12179176	chr11:130786555	SNX19	0.65	10.24	0.53	6.07e-21	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs9308731	0.842	rs56173510	chr2:111928436	G/T	cg04202892	chr2:111875749	ACOXL	0.35	5.04	0.3	8.53e-7	Chronic lymphocytic leukemia;
CESC	cis	rs12188164	0.965	rs11745789	chr5:450777	T/C	cg26850624	chr5:429559	AHRR	-0.5	-6.67	-0.38	1.52e-10	Cystic fibrosis severity;
CESC	cis	rs7927771	1.000	rs11039390	chr11:47796295	C/G	cg18512352	chr11:47633146	NA	-0.61	-9.59	-0.51	6.7e-19	Subjective well-being;
CESC	cis	rs8072100	0.688	rs8079142	chr17:45442049	G/A	cg08085267	chr17:45401833	C17orf57	-0.53	-6.65	-0.38	1.65e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs875971	0.660	rs801190	chr7:66033033	C/T	cg10691866	chr7:65817282	TPST1	0.31	5.06	0.3	7.76e-7	Aortic root size;
CESC	cis	rs798554	0.660	rs2644275	chr7:2854010	G/A	cg09658497	chr7:2847517	GNA12	-0.34	-5.09	-0.3	6.75e-7	Height;
CESC	trans	rs7615952	0.558	rs17334039	chr3:125540308	A/G	cg07211511	chr3:129823064	LOC729375	-0.84	-9.55	-0.51	9.43e-19	Blood pressure (smoking interaction);
CESC	cis	rs7647973	1.000	rs9871024	chr3:49554241	T/C	cg02487422	chr3:49467188	NICN1	-0.41	-5.35	-0.31	1.86e-7	Menarche (age at onset);
CESC	cis	rs7116495	0.609	rs6592457	chr11:71738086	G/C	cg18441811	chr11:71824068	C11orf51	-0.86	-5.19	-0.3	4.21e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs9929218	1.000	rs8056538	chr16:68802282	C/T	cg02972257	chr16:68554789	NA	0.45	5.47	0.32	1.03e-7	Colorectal cancer;
CESC	cis	rs11229555	1.000	rs11229543	chr11:58370698	G/A	cg15696309	chr11:58395628	NA	-0.43	-5.64	-0.33	4.3e-8	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs2011503	0.739	rs8108659	chr19:19680738	T/A	cg11584989	chr19:19387371	SF4	-0.45	-5.03	-0.3	9.03e-7	Bipolar disorder;
CESC	cis	rs9457247	1.000	rs393727	chr6:167398632	T/A	cg23791538	chr6:167370224	RNASET2	-0.6	-8.59	-0.47	7.81e-16	Crohn's disease;
CESC	cis	rs801193	1.000	rs62466794	chr7:66191579	G/A	cg18876405	chr7:65276391	NA	0.53	7.06	0.4	1.42e-11	Aortic root size;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg15622891	chr6:163862445	QKI	0.39	6.01	0.35	5.97e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs7666738	0.830	rs35938349	chr4:98974998	T/C	cg03676636	chr4:99064102	C4orf37	0.34	5.2	0.3	3.93e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1707322	0.721	rs56255771	chr1:46224319	C/T	cg03146154	chr1:46216737	IPP	0.74	10.62	0.55	3.46e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7927771	0.524	rs7129797	chr11:47667167	G/C	cg18512352	chr11:47633146	NA	0.34	5.18	0.3	4.49e-7	Subjective well-being;
CESC	cis	rs79057730	0.599	rs9458	chr7:825494	A/G	cg11064039	chr7:766100	PRKAR1B;HEATR2	-0.88	-8.08	-0.44	2.33e-14	Initial pursuit acceleration;
CESC	cis	rs12142240	0.738	rs10489769	chr1:46806703	A/G	cg10495392	chr1:46806563	NSUN4	0.59	6.37	0.36	8.18e-10	Menopause (age at onset);
CESC	cis	rs2842992	0.715	rs2277073	chr6:160182749	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.74	9.01	0.48	4.17e-17	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs6968419	0.755	rs4730719	chr7:115895010	A/C	cg02561103	chr7:115862891	TES	0.42	5.49	0.32	9.63e-8	Intraocular pressure;
CESC	cis	rs17253792	0.822	rs2147114	chr14:56077118	C/T	cg01858014	chr14:56050164	KTN1	-0.93	-7.33	-0.41	2.71e-12	Putamen volume;
CESC	cis	rs61656020	1	rs61656020	chr16:1882221	C/G	cg26897989	chr16:1907736	C16orf73	-0.53	-6.52	-0.37	3.49e-10	Ankle injury;
CESC	cis	rs896854	0.738	rs2515226	chr8:95965743	G/A	cg23172400	chr8:95962367	TP53INP1	0.4	7.44	0.42	1.38e-12	Type 2 diabetes;
CESC	cis	rs933688	0.938	rs6866923	chr5:90669352	A/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.2	17.43	0.73	7.37e-46	Smoking behavior;
CESC	cis	rs17253792	0.822	rs80328469	chr14:56067701	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.76	5.39	0.31	1.56e-7	Putamen volume;
CESC	cis	rs6540559	1.000	rs1044516	chr1:209959614	G/T	cg22029157	chr1:209979665	IRF6	0.66	9.23	0.49	9.02e-18	Cleft lip with or without cleft palate;
CESC	cis	rs9393777	0.623	rs9358944	chr6:26469875	A/C	cg14345882	chr6:26364793	BTN3A2	0.43	5.43	0.32	1.3e-7	Intelligence (multi-trait analysis);
CESC	cis	rs9399137	0.507	rs12663810	chr6:135289782	G/C	cg24558204	chr6:135376177	HBS1L	0.7	9.52	0.5	1.13e-18	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	cis	rs10504229	0.595	rs79077737	chr8:58117520	G/A	cg02725872	chr8:58115012	NA	-0.45	-7.05	-0.4	1.51e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs9937943	0.667	rs11862508	chr16:74598688	T/C	cg01733217	chr16:74700730	RFWD3	0.58	5.13	0.3	5.6e-7	Neutrophil percentage of white cells;
CESC	cis	rs798554	0.757	rs1183085	chr7:2875570	G/A	cg04166393	chr7:2884313	GNA12	0.57	7.27	0.41	4.13e-12	Height;
CESC	cis	rs2228479	0.850	rs62054610	chr16:89816920	G/A	cg06558623	chr16:89946397	TCF25	1.16	9.28	0.5	6.08e-18	Skin colour saturation;
CESC	cis	rs10504229	1.000	rs73609762	chr8:58192695	A/G	cg24829409	chr8:58192753	C8orf71	-0.76	-9.93	-0.52	5.87e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs858239	0.539	rs6955969	chr7:23186699	C/T	cg23682824	chr7:23144976	KLHL7	0.51	6.72	0.38	1.13e-10	Cerebrospinal fluid biomarker levels;
CESC	cis	rs11677416	1.000	rs59674541	chr2:113553824	A/T	cg27083787	chr2:113543245	IL1A	0.44	5.4	0.31	1.48e-7	Response to antipsychotic treatment in schizophrenia (working memory);
CESC	cis	rs7605827	0.836	rs13019322	chr2:15511270	G/A	cg19274914	chr2:15703543	NA	0.32	5.58	0.32	5.99e-8	Educational attainment (years of education);
CESC	cis	rs4819052	0.851	rs2838842	chr21:46669217	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.93	13.59	0.64	2.77e-32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs35306767	0.903	rs11815185	chr10:923617	T/A	cg26597838	chr10:835615	NA	0.85	9.43	0.5	2.16e-18	Eosinophil percentage of granulocytes;
CESC	cis	rs7208859	0.623	rs1061346	chr17:29114229	G/A	cg14008862	chr17:28927542	LRRC37B2	0.65	5.14	0.3	5.34e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs12464559	0.579	rs6740508	chr2:152613212	T/A	cg01189475	chr2:152685088	ARL5A	0.68	5.87	0.34	1.31e-8	Response to cognitive-behavioural therapy in anxiety disorder;
CESC	cis	rs2243480	0.803	rs160649	chr7:65543199	C/T	cg12463550	chr7:65579703	CRCP	0.65	5.11	0.3	6.05e-7	Diabetic kidney disease;
CESC	cis	rs1799949	1.000	rs8176083	chr17:41275151	G/C	cg05368731	chr17:41323189	NBR1	0.8	10.98	0.56	2.35e-23	Menopause (age at onset);
CESC	cis	rs1218582	0.741	rs6656494	chr1:154839799	A/G	cg03351412	chr1:154909251	PMVK	0.65	8.6	0.47	7.02e-16	Prostate cancer;
CESC	cis	rs6831352	0.589	rs2602836	chr4:100014805	C/T	cg13256891	chr4:100009986	ADH5	-0.77	-10.5	-0.54	8.63e-22	Alcohol dependence;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg03539850	chr10:91404063	PANK1	-0.51	-6.51	-0.37	3.78e-10	Asthma;
CESC	cis	rs1005277	0.579	rs2474569	chr10:38383491	C/G	cg00409905	chr10:38381863	ZNF37A	-0.45	-6.0	-0.35	6.61e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs2842992	0.673	rs6930904	chr6:160217433	T/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.76	9.9	0.52	7.05e-20	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs9611565	0.659	rs1569516	chr22:41910244	C/T	cg17376030	chr22:41985996	PMM1	0.75	8.13	0.45	1.65e-14	Vitiligo;
CESC	cis	rs561341	0.710	rs9900031	chr17:30199537	T/C	cg13647721	chr17:30228624	UTP6	-0.62	-5.84	-0.34	1.52e-8	Hip circumference adjusted for BMI;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10384294	chr12:57636980	NA	-0.56	-6.78	-0.38	7.98e-11	Gut microbiome composition (summer);
CESC	cis	rs2749592	0.550	rs4934881	chr10:37914346	A/C	cg00409905	chr10:38381863	ZNF37A	0.42	5.55	0.32	7.09e-8	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs6952808	0.895	rs4513875	chr7:1928159	C/T	cg04267008	chr7:1944627	MAD1L1	-0.7	-8.86	-0.48	1.16e-16	Bipolar disorder and schizophrenia;
CESC	cis	rs763121	0.925	rs1056661	chr22:39080245	A/G	cg06544989	chr22:39130855	UNC84B	0.48	9.06	0.49	3.03e-17	Menopause (age at onset);
CESC	cis	rs7772486	0.686	rs9403739	chr6:146015357	A/G	cg23711669	chr6:146136114	FBXO30	-0.92	-12.9	-0.62	6.98e-30	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26907429	chr1:165667743	ALDH9A1	0.62	6.61	0.38	2.13e-10	Gut microbiome composition (summer);
CESC	cis	rs9309473	0.519	rs13009035	chr2:73845709	T/C	cg20560298	chr2:73613845	ALMS1	0.46	6.47	0.37	4.83e-10	Metabolite levels;
CESC	cis	rs2439831	0.850	rs9944216	chr15:44160773	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.69	-7.38	-0.41	2.02e-12	Lung cancer in ever smokers;
CESC	cis	rs116095464	0.558	rs2288459	chr5:231143	T/C	cg22496380	chr5:211416	CCDC127	-0.74	-8.5	-0.46	1.44e-15	Breast cancer;
CESC	cis	rs2249694	0.878	rs2480257	chr10:135352509	T/A	cg20169779	chr10:135381914	SYCE1	0.41	5.76	0.33	2.33e-8	Obesity-related traits;
CESC	cis	rs938554	0.784	rs13145758	chr4:9981997	G/A	cg00071950	chr4:10020882	SLC2A9	0.47	5.64	0.33	4.35e-8	Blood metabolite levels;
CESC	cis	rs4665809	0.590	rs35615763	chr2:26468778	C/G	cg26119090	chr2:26468346	HADHA;HADHB	1.1	12.68	0.61	4e-29	Gut microbiome composition (summer);
CESC	cis	rs7789940	0.951	rs7787526	chr7:75947553	C/T	cg10167463	chr7:75959203	YWHAG	-0.51	-6.01	-0.35	6.11e-9	Multiple sclerosis;
CESC	cis	rs2213920	0.516	rs35976675	chr9:118173444	T/C	cg13918206	chr9:118159781	DEC1	-0.66	-5.41	-0.32	1.43e-7	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
CESC	trans	rs66573146	0.656	rs66905212	chr4:6949508	G/C	cg07817883	chr1:32538562	TMEM39B	1.35	8.85	0.48	1.24e-16	Granulocyte percentage of myeloid white cells;
CESC	trans	rs1814175	0.817	rs28525029	chr11:50045815	A/G	cg03929089	chr4:120376271	NA	-0.94	-16.17	-0.7	2.25e-41	Height;
CESC	cis	rs66561647	0.719	rs7821928	chr8:128939295	G/A	cg05480350	chr8:128972681	MIR1205;PVT1	0.45	5.87	0.34	1.28e-8	Hemoglobin concentration;
CESC	cis	rs4803468	1.000	rs4803469	chr19:41922775	A/C	cg09537434	chr19:41945824	ATP5SL	-1.11	-20.39	-0.78	3.11e-56	Height;
CESC	cis	rs2109514	0.765	rs768108	chr7:116108658	A/G	cg12739419	chr7:116140593	CAV2	-0.3	-5.52	-0.32	7.94e-8	Prevalent atrial fibrillation;
CESC	cis	rs76419734	0.510	rs2193856	chr4:106742958	A/C	cg24545054	chr4:106630052	GSTCD;INTS12	-0.63	-6.36	-0.36	8.64e-10	Post bronchodilator FEV1;
CESC	cis	rs1691799	0.867	rs1168343	chr12:66758581	C/T	cg16791601	chr12:66731901	HELB	-0.79	-14.12	-0.66	3.81e-34	White blood cell count (basophil);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg25886382	chr13:26760664	NA	-0.39	-6.15	-0.35	2.76e-9	Gambling;
CESC	cis	rs4141404	0.737	rs5998058	chr22:32006408	C/T	cg02404636	chr22:31891804	SFI1	0.45	6.09	0.35	4.05e-9	Paclitaxel-induced neuropathy;
CESC	cis	rs8114671	0.836	rs6142294	chr20:33671497	A/G	cg24642439	chr20:33292090	TP53INP2	-0.49	-5.91	-0.34	1.04e-8	Height;
CESC	cis	rs1865721	0.755	rs3813081	chr18:73185096	A/G	cg26385618	chr18:73139727	C18orf62	-0.42	-6.3	-0.36	1.24e-9	Intelligence;
CESC	cis	rs868036	1.000	rs884202	chr15:68054388	G/A	cg08079166	chr15:68083412	MAP2K5	-0.42	-6.51	-0.37	3.67e-10	Restless legs syndrome;
CESC	cis	rs832540	0.902	rs194059	chr5:56197416	G/A	cg14703610	chr5:56206110	C5orf35	0.54	7.22	0.41	5.64e-12	Coronary artery disease;
CESC	cis	rs12477438	0.765	rs6737257	chr2:99683330	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.62	-8.67	-0.47	4.43e-16	Chronic sinus infection;
CESC	cis	rs4835473	0.868	rs35016507	chr4:144655770	G/A	cg25736465	chr4:144833511	NA	-0.33	-5.23	-0.31	3.44e-7	Immature fraction of reticulocytes;
CESC	cis	rs2299587	0.554	rs13253029	chr8:17749622	C/T	cg08627089	chr8:17753878	FGL1	-0.39	-5.57	-0.32	6.34e-8	Economic and political preferences;
CESC	cis	rs6912958	1.000	rs13214153	chr6:88153983	G/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.55	-7.58	-0.42	5.88e-13	Monocyte percentage of white cells;
CESC	cis	rs34779708	0.733	rs16935948	chr10:35549748	C/G	cg03585969	chr10:35415529	CREM	0.62	6.79	0.39	7.28e-11	Inflammatory bowel disease;Crohn's disease;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03443922	chr7:107384711	CBLL1	0.49	6.45	0.37	5.27e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs2645694	0.626	rs2703121	chr4:77822328	C/G	cg10057126	chr4:77819792	ANKRD56	0.58	8.5	0.46	1.43e-15	Emphysema distribution in smoking;
CESC	cis	rs1538970	0.962	rs4660301	chr1:45820149	T/A	cg05343316	chr1:45956843	TESK2	0.82	11.17	0.57	5.6e-24	Platelet count;
CESC	cis	rs12893668	0.572	rs2273175	chr14:104160141	T/C	cg24130564	chr14:104152367	KLC1	-0.5	-6.8	-0.39	6.77e-11	Reticulocyte count;
CESC	cis	rs8044868	0.521	rs7203821	chr16:72101165	T/C	cg23815491	chr16:72088622	HP	0.34	5.16	0.3	4.87e-7	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CESC	cis	rs7520050	0.966	rs12049588	chr1:46472422	G/A	cg24296786	chr1:45957014	TESK2	0.44	5.5	0.32	9.17e-8	Red blood cell count;Reticulocyte count;
CESC	trans	rs9650657	0.571	rs4240673	chr8:10787612	T/C	cg15556689	chr8:8085844	FLJ10661	-0.55	-6.84	-0.39	5.5e-11	Neuroticism;
CESC	cis	rs2204008	0.714	rs11520135	chr12:38114863	C/T	cg13010199	chr12:38710504	ALG10B	0.54	6.71	0.38	1.17e-10	Bladder cancer;
CESC	cis	rs1008375	0.966	rs3796812	chr4:17582051	G/A	cg02297831	chr4:17616191	MED28	0.44	5.43	0.32	1.29e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs1552244	0.572	rs59074548	chr3:10164347	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.79	8.79	0.47	1.98e-16	Alzheimer's disease;
CESC	trans	rs10751667	0.961	rs7396670	chr11:929269	A/G	cg00159523	chr10:114713187	TCF7L2	-0.41	-6.11	-0.35	3.52e-9	Alzheimer's disease (late onset);
CESC	trans	rs9929218	0.953	rs3114411	chr16:68734591	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.77	10.24	0.53	5.92e-21	Colorectal cancer;
CESC	cis	rs1348850	0.554	rs11679519	chr2:178432110	C/T	cg22681709	chr2:178499509	PDE11A	-0.53	-6.59	-0.38	2.3e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs9926296	0.548	rs6500439	chr16:89808275	A/C	cg21285383	chr16:89894308	SPIRE2	0.31	5.45	0.32	1.15e-7	Vitiligo;
CESC	cis	rs1595825	1.000	rs7579905	chr2:198868109	T/A	cg00982548	chr2:198649783	BOLL	-0.44	-5.05	-0.3	8.32e-7	Ulcerative colitis;
CESC	cis	rs798554	0.797	rs798497	chr7:2795957	A/G	cg09658497	chr7:2847517	GNA12	-0.43	-6.15	-0.35	2.86e-9	Height;
CESC	cis	rs965469	0.779	rs6037515	chr20:3233091	C/A	cg25506879	chr20:3388711	C20orf194	-0.51	-5.57	-0.32	6.1e-8	IFN-related cytopenia;
CESC	cis	rs10411936	1.000	rs16995422	chr19:16519045	A/G	cg10248733	chr19:16607483	C19orf44;CALR3	-0.5	-6.08	-0.35	4.18e-9	White blood cell count;Multiple sclerosis;
CESC	cis	rs1018836	0.632	rs7002775	chr8:91476765	C/T	cg16814680	chr8:91681699	NA	0.63	8.82	0.48	1.58e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs4660306	0.961	rs4660864	chr1:45966582	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.62	-7.82	-0.43	1.23e-13	Homocysteine levels;
CESC	cis	rs4862750	0.872	rs9997374	chr4:187877549	T/A	cg03452623	chr4:187889614	NA	-0.87	-14.96	-0.68	4.25e-37	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs8023845	0.954	rs1680156	chr15:40447265	T/C	cg20259534	chr15:40453036	BUB1B	0.7	7.22	0.41	5.52e-12	Chronic lymphocytic leukemia;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg20592656	chr7:5417060	TNRC18	0.46	6.2	0.36	2.14e-9	Fibrinogen levels;
CESC	cis	rs7666738	0.830	rs7662218	chr4:98983126	T/G	cg17366294	chr4:99064904	C4orf37	0.59	8.39	0.46	2.85e-15	Colonoscopy-negative controls vs population controls;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg05221349	chr4:100870488	LOC256880;H2AFZ	-0.4	-6.74	-0.38	1e-10	Gambling;
CESC	trans	rs360798	0.532	rs9636442	chr2:62806286	A/G	cg07814414	chr15:31774773	NA	-0.43	-6.26	-0.36	1.55e-9	Coronary artery disease;
CESC	cis	rs2243480	1.000	rs410128	chr7:65603173	C/T	cg12463550	chr7:65579703	CRCP	0.74	5.66	0.33	3.91e-8	Diabetic kidney disease;
CESC	cis	rs4975709	0.589	rs4975744	chr5:1860049	A/G	cg15595755	chr5:1867978	NA	0.53	8.91	0.48	8.18e-17	Cardiovascular disease risk factors;
CESC	cis	rs1707322	0.927	rs11211194	chr1:46282084	C/T	cg03146154	chr1:46216737	IPP	0.71	9.86	0.52	9.77e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2598107	0.542	rs6965395	chr7:37950115	C/T	cg10806140	chr7:37956554	SFRP4	0.32	5.13	0.3	5.54e-7	Dupuytren's disease;
CESC	cis	rs8060686	0.641	rs1125333	chr16:68227566	C/A	cg26727032	chr16:67993705	SLC12A4	-0.53	-5.95	-0.34	8.44e-9	HDL cholesterol;Metabolic syndrome;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18664336	chr17:57970265	TUBD1;RPS6KB1	-0.57	-6.65	-0.38	1.7e-10	Gut microbiome composition (summer);
CESC	cis	rs9902453	0.780	rs7210991	chr17:28190961	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.65	8.21	0.45	9.9e-15	Coffee consumption (cups per day);
CESC	cis	rs875971	0.862	rs35378740	chr7:65987712	C/A	cg11764359	chr7:65958608	NA	0.79	11.32	0.57	1.67e-24	Aortic root size;
CESC	cis	rs3892630	0.757	rs8109823	chr19:33183316	A/G	cg13157960	chr19:33183277	NUDT19	0.53	5.2	0.3	4.04e-7	Red blood cell traits;
CESC	cis	rs6500395	0.963	rs2041921	chr16:48714002	T/C	cg04672837	chr16:48644449	N4BP1	-0.49	-6.05	-0.35	4.8e-9	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs12765878	1.000	rs12765878	chr10:105669622	C/T	cg24587175	chr10:105670608	OBFC1	-0.34	-5.56	-0.32	6.67e-8	Coronary artery disease;
CESC	cis	rs6429082	0.818	rs704714	chr1:235632094	T/C	cg26050004	chr1:235667680	B3GALNT2	0.62	7.88	0.44	8.78e-14	Adiposity;
CESC	cis	rs3820928	0.874	rs4675137	chr2:227883910	G/C	cg11843606	chr2:227700838	RHBDD1	-0.46	-6.09	-0.35	3.87e-9	Pulmonary function;
CESC	cis	rs6500395	0.928	rs4785532	chr16:48695500	G/A	cg04672837	chr16:48644449	N4BP1	-0.51	-6.36	-0.36	8.64e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs7091068	0.550	rs7901909	chr10:95492508	C/T	cg20715218	chr10:95462985	C10orf4	0.51	6.42	0.37	6.42e-10	Urinary tract infection frequency;
CESC	cis	rs7959452	0.590	rs28778648	chr12:69771911	C/A	cg20891283	chr12:69753455	YEATS4	0.91	15.05	0.68	2.02e-37	Blood protein levels;
CESC	cis	rs6089584	0.627	rs35560719	chr20:60561917	A/C	cg24733560	chr20:60626293	TAF4	0.42	6.29	0.36	1.33e-9	Body mass index;
CESC	cis	rs7659604	0.502	rs11098640	chr4:122675875	G/A	cg19671926	chr4:122722719	EXOSC9	0.53	6.7	0.38	1.21e-10	Type 2 diabetes;
CESC	trans	rs877282	0.842	rs35872126	chr10:764545	G/A	cg22713356	chr15:30763199	NA	1.16	11.35	0.57	1.37e-24	Uric acid levels;
CESC	cis	rs2836950	0.520	rs8133928	chr21:40689963	G/A	cg11890956	chr21:40555474	PSMG1	-0.66	-9.11	-0.49	2.05e-17	Menarche (age at onset);
CESC	cis	rs801193	0.660	rs1962050	chr7:66240008	C/T	cg12463550	chr7:65579703	CRCP	-0.53	-6.91	-0.39	3.65e-11	Aortic root size;
CESC	cis	rs916888	0.821	rs199514	chr17:44856881	G/A	cg01570182	chr17:44337453	NA	-0.87	-10.25	-0.53	5.7e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	trans	rs7246760	0.867	rs55800282	chr19:9833530	A/G	cg02900749	chr2:68251473	NA	-0.85	-7.44	-0.42	1.38e-12	Pursuit maintenance gain;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg27600497	chr7:155091023	INSIG1	0.46	6.23	0.36	1.85e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs8020095	0.528	rs1044745	chr14:67800815	G/A	cg19548862	chr14:67692701	FAM71D	-0.45	-5.3	-0.31	2.41e-7	Depression (quantitative trait);
CESC	cis	rs7219021	0.926	rs7217983	chr17:46853345	A/G	cg16584676	chr17:46985605	UBE2Z	-0.52	-5.9	-0.34	1.12e-8	Schizophrenia or bipolar disorder;
CESC	cis	rs4237845	0.788	rs1962047	chr12:58292707	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.49	5.43	0.32	1.26e-7	Intelligence (multi-trait analysis);
CESC	cis	rs9486719	0.749	rs1009596	chr6:96843688	A/G	cg06623918	chr6:96969491	KIAA0776	0.78	7.39	0.41	1.89e-12	Migraine;Coronary artery disease;
CESC	cis	rs514406	0.644	rs7529978	chr1:53204705	G/A	cg25767906	chr1:53392781	SCP2	0.43	5.85	0.34	1.42e-8	Monocyte count;
CESC	cis	rs36051895	0.664	rs10117565	chr9:5094461	G/A	cg02405213	chr9:5042618	JAK2	-0.51	-6.17	-0.35	2.61e-9	Pediatric autoimmune diseases;
CESC	cis	rs6060717	0.553	rs2590958	chr20:34616590	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.58	-7.83	-0.43	1.17e-13	Hip circumference adjusted for BMI;
CESC	trans	rs2900976	0.739	rs13033187	chr2:71993619	C/A	cg01646268	chr11:14367071	RRAS2	0.49	6.24	0.36	1.76e-9	Protein quantitative trait loci;
CESC	cis	rs10504229	0.953	rs66509078	chr8:58174734	G/C	cg14926445	chr8:58193284	C8orf71	-0.51	-5.49	-0.32	9.5e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs10479542	0.544	rs7706275	chr5:178990305	A/G	cg21226059	chr5:178986404	RUFY1	0.51	7.6	0.42	5.26e-13	Lung cancer;
CESC	cis	rs4563143	0.514	rs112540771	chr19:29316100	C/T	cg12756686	chr19:29218302	NA	0.54	6.5	0.37	3.99e-10	Methadone dose in opioid dependence;
CESC	cis	rs672059	0.513	rs572977	chr1:183164991	C/G	cg23696949	chr1:183155644	LAMC2	-0.25	-5.82	-0.34	1.69e-8	Hypertriglyceridemia;
CESC	cis	rs597539	0.616	rs72945243	chr11:68633358	T/C	cg18350739	chr11:68623251	NA	-0.46	-7.02	-0.4	1.87e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.55	7.42	0.41	1.57e-12	Lymphocyte counts;
CESC	cis	rs2688608	0.592	rs3933085	chr10:75483331	C/T	cg23231163	chr10:75533350	FUT11	-0.36	-5.42	-0.32	1.33e-7	Inflammatory bowel disease;
CESC	cis	rs920590	0.684	rs7461774	chr8:19666645	G/A	cg17834443	chr8:19674713	INTS10	0.59	6.47	0.37	4.76e-10	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs344364	0.511	rs1742469	chr16:1950244	C/T	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.55	-6.2	-0.36	2.15e-9	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs1552244	0.935	rs6805869	chr3:10119917	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	12.72	0.62	2.99e-29	Alzheimer's disease;
CESC	cis	rs826838	1.000	rs11168367	chr12:38913397	T/G	cg13010199	chr12:38710504	ALG10B	0.6	8.42	0.46	2.34e-15	Heart rate;
CESC	cis	rs3733585	0.781	rs4292328	chr4:9970962	C/T	cg02734326	chr4:10020555	SLC2A9	-0.45	-6.74	-0.38	1e-10	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs13108904	0.870	rs4974545	chr4:1271923	C/T	cg00684032	chr4:1343700	KIAA1530	0.41	5.87	0.34	1.33e-8	Obesity-related traits;
CESC	cis	rs10927875	0.557	rs1572381	chr1:16344494	G/A	cg22431228	chr1:16359049	CLCNKA	-0.53	-10.31	-0.54	3.47e-21	Dilated cardiomyopathy;
CESC	cis	rs7552404	0.727	rs11161626	chr1:76260837	C/T	cg22875332	chr1:76189707	ACADM	0.62	6.32	0.36	1.13e-9	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs9486719	0.948	rs2472906	chr6:96875318	G/T	cg06623918	chr6:96969491	KIAA0776	0.81	8.29	0.45	5.61e-15	Migraine;Coronary artery disease;
CESC	cis	rs10905065	0.931	rs10795510	chr10:5758827	G/A	cg11519256	chr10:5708881	ASB13	0.44	5.9	0.34	1.11e-8	Menopause (age at onset);
CESC	cis	rs9649213	0.593	rs56286037	chr7:98019522	C/T	cg08684580	chr7:98029266	BAIAP2L1	-0.35	-5.72	-0.33	2.89e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs12681288	0.550	rs4637864	chr8:959761	C/T	cg15309053	chr8:964076	NA	0.48	8.23	0.45	8.5e-15	Schizophrenia;
CESC	cis	rs4950928	0.887	rs7556099	chr1:203166198	C/G	cg17014757	chr1:203156097	CHI3L1	-0.51	-5.11	-0.3	6.1e-7	YKL-40 levels;
CESC	cis	rs1355223	0.872	rs12802798	chr11:34747434	T/G	cg11058730	chr11:34937778	PDHX;APIP	-0.47	-6.12	-0.35	3.26e-9	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs897984	0.806	rs12924903	chr16:30928970	C/T	cg00531865	chr16:30841666	NA	-0.49	-6.58	-0.37	2.57e-10	Dementia with Lewy bodies;
CESC	cis	rs4253772	0.938	rs75977757	chr22:46641525	G/T	cg00784671	chr22:46762841	CELSR1	-0.57	-5.62	-0.33	4.95e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs7223966	1.000	rs8078462	chr17:61857937	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.73	0.38	1.06e-10	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs4836694	0.574	rs4837476	chr9:132937533	T/C	cg13414629	chr9:132935646	FREQ	0.42	5.29	0.31	2.5e-7	Alzheimer's disease (cognitive decline);
CESC	cis	rs4950928	0.823	rs4950882	chr1:203164848	A/G	cg17014757	chr1:203156097	CHI3L1	-0.53	-5.23	-0.31	3.39e-7	YKL-40 levels;
CESC	cis	rs9486719	1.000	rs12208011	chr6:96991105	G/A	cg18709589	chr6:96969512	KIAA0776	-0.53	-5.83	-0.34	1.64e-8	Migraine;Coronary artery disease;
CESC	cis	rs2658782	0.951	rs2608214	chr11:93148665	C/T	cg15737290	chr11:93063684	CCDC67	0.55	6.92	0.39	3.49e-11	Pulmonary function decline;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg08131204	chr22:41487073	MIR1281	-0.52	-7.01	-0.4	2.01e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs300703	0.872	rs12233077	chr2:120949	T/A	cg21211680	chr2:198530	NA	-0.86	-6.93	-0.39	3.16e-11	Blood protein levels;
CESC	cis	rs735860	0.674	rs209485	chr6:53174448	C/T	cg10236188	chr6:53219634	NA	-0.37	-5.52	-0.32	7.98e-8	Glaucoma;
CESC	cis	rs9858542	0.953	rs35169793	chr3:49423274	A/G	cg07274523	chr3:49395745	GPX1	0.68	8.44	0.46	2.17e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs3741798	1.000	rs17375328	chr12:12485292	T/C	cg08615371	chr12:12503544	MANSC1	0.9	6.53	0.37	3.39e-10	Cerebrospinal fluid biomarker levels;
CESC	cis	rs7208859	0.623	rs11652358	chr17:29205480	T/C	cg19761014	chr17:28927070	LRRC37B2	0.72	5.71	0.33	3.06e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs853679	0.550	rs1225599	chr6:28165190	C/T	cg22143856	chr6:28129313	ZNF389	0.44	5.84	0.34	1.49e-8	Depression;
CESC	cis	rs2658782	0.756	rs3019222	chr11:93079718	C/T	cg15737290	chr11:93063684	CCDC67	0.58	7.38	0.41	2e-12	Pulmonary function decline;
CESC	cis	rs7647973	0.626	rs1996663	chr3:49878264	C/G	cg06212747	chr3:49208901	KLHDC8B	-0.6	-7.36	-0.41	2.25e-12	Menarche (age at onset);
CESC	cis	rs9814567	0.762	rs13067564	chr3:134209956	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.44	5.69	0.33	3.35e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs854765	0.583	rs11650649	chr17:17790319	C/A	cg09796270	chr17:17721594	SREBF1	-0.45	-6.32	-0.36	1.12e-9	Total body bone mineral density;
CESC	cis	rs9303401	0.659	rs17222523	chr17:56620501	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	1.02	12.92	0.62	6.16e-30	Cognitive test performance;
CESC	cis	rs3126085	0.935	rs11204943	chr1:152203906	A/C	cg03465714	chr1:152285911	FLG	-0.43	-5.17	-0.3	4.7e-7	Atopic dermatitis;
CESC	cis	rs6061231	0.505	rs13037253	chr20:60928724	G/A	cg22541963	chr20:60982533	CABLES2	0.48	5.09	0.3	6.64e-7	Colorectal cancer;
CESC	cis	rs11098499	0.874	rs12509054	chr4:120115075	A/C	cg09307838	chr4:120376055	NA	0.74	9.24	0.49	8.6e-18	Corneal astigmatism;
CESC	cis	rs2439831	1.000	rs2601014	chr15:43756013	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.9	9.31	0.5	5e-18	Lung cancer in ever smokers;
CESC	cis	rs9815354	1.000	rs11928580	chr3:41885722	C/T	cg03022575	chr3:42003672	ULK4	0.45	5.29	0.31	2.59e-7	Pulse pressure;Diastolic blood pressure;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg19937698	chr13:60970319	TDRD3	-0.42	-6.13	-0.35	3.22e-9	Gambling;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27046659	chr10:75634352	CAMK2G	0.61	6.78	0.38	7.66e-11	Gut microbiome composition (summer);
CESC	cis	rs2842992	0.714	rs2495278	chr6:160123674	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.74	8.97	0.48	5.37e-17	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg21280719	chr6:42927975	GNMT	-0.3	-7.32	-0.41	3.05e-12	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs662064	0.962	rs6540933	chr1:10547263	C/T	cg20482658	chr1:10539492	PEX14	-0.4	-8.1	-0.45	2.02e-14	Asthma;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg07732421	chr5:74633253	HMGCR	-0.41	-6.14	-0.35	3e-9	Gambling;
CESC	cis	rs35110281	0.591	rs162366	chr21:44935383	C/T	cg01579765	chr21:45077557	HSF2BP	0.48	8.13	0.45	1.63e-14	Mean corpuscular volume;
CESC	cis	rs2228479	0.702	rs17233868	chr16:89803629	C/T	cg06558623	chr16:89946397	TCF25	1.06	8.28	0.45	6.12e-15	Skin colour saturation;
CESC	cis	rs2832191	0.716	rs2297252	chr21:30377104	G/A	cg08807101	chr21:30365312	RNF160	0.96	15.02	0.68	2.66e-37	Dental caries;
CESC	trans	rs7615952	0.512	rs11929125	chr3:125359443	G/A	cg07211511	chr3:129823064	LOC729375	-0.59	-7.28	-0.41	3.84e-12	Blood pressure (smoking interaction);
CESC	trans	rs3942852	0.869	rs4752806	chr11:48118199	G/C	cg15704280	chr7:45808275	SEPT13	-0.59	-6.83	-0.39	5.9e-11	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs1153858	1.000	rs12591058	chr15:45640172	T/C	cg21132104	chr15:45694354	SPATA5L1	0.82	11.02	0.56	1.72e-23	Homoarginine levels;
CESC	cis	rs12142240	0.698	rs68191463	chr1:46808695	T/C	cg10495392	chr1:46806563	NSUN4	0.59	6.34	0.36	9.65e-10	Menopause (age at onset);
CESC	cis	rs12477438	0.798	rs13393860	chr2:99590397	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-10.51	-0.54	7.92e-22	Chronic sinus infection;
CESC	cis	rs2425143	0.818	rs12481545	chr20:34407698	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.66	5.4	0.31	1.49e-7	Blood protein levels;
CESC	cis	rs941873	0.869	rs7917610	chr10:81117237	T/C	cg11057378	chr10:81107060	PPIF	0.36	5.84	0.34	1.55e-8	Height;
CESC	cis	rs36051895	0.623	rs12349113	chr9:5254224	T/A	cg02405213	chr9:5042618	JAK2	-0.51	-6.3	-0.36	1.24e-9	Pediatric autoimmune diseases;
CESC	cis	rs75804782	0.521	rs72993056	chr2:239404671	G/T	cg18131467	chr2:239335373	ASB1	-0.71	-5.56	-0.32	6.45e-8	Morning vs. evening chronotype;Chronotype;
CESC	cis	rs10197940	0.571	rs13393021	chr2:152413258	A/C	cg19508488	chr2:152266495	RIF1	0.51	5.99	0.35	6.85e-9	Lung cancer;
CESC	cis	rs2281558	1.000	rs2281558	chr20:25240189	G/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.57	7.3	0.41	3.41e-12	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg06905970	chr19:41222748	ADCK4;ITPKC	-0.46	-6.75	-0.38	9.55e-11	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg19240110	chr19:17445963	ANO8	-0.46	-6.06	-0.35	4.65e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	trans	rs687914	0.710	rs938662	chr2:45864578	A/G	cg04776990	chr17:42853002	ADAM11	0.61	6.1	0.35	3.66e-9	Diastolic blood pressure;
CESC	cis	rs4568518	0.742	rs13245422	chr7:18015975	A/G	cg03009463	chr7:17980271	SNX13	0.45	5.97	0.34	7.52e-9	Measles;
CESC	cis	rs7834588	0.503	rs1378520	chr8:63840209	C/T	cg20602954	chr8:63776762	NKAIN3	0.32	5.3	0.31	2.44e-7	Response to Vitamin E supplementation;
CESC	cis	rs910316	0.763	rs175450	chr14:75590340	G/A	cg16144293	chr14:75469539	EIF2B2	0.41	5.42	0.32	1.36e-7	Height;
CESC	cis	rs2732480	0.577	rs1489109	chr12:48738780	C/A	cg24011408	chr12:48396354	COL2A1	0.44	5.99	0.35	6.63e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	trans	rs60843830	1.000	rs60149603	chr2:285421	A/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.69	8.62	0.47	6.18e-16	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs4975709	0.569	rs1684965	chr5:1865248	A/G	cg19770292	chr5:1868693	NA	0.3	5.04	0.3	8.57e-7	Cardiovascular disease risk factors;
CESC	cis	rs10129255	0.500	rs8006888	chr14:107190456	A/C	cg23076370	chr14:107095027	NA	-0.65	-9.66	-0.51	4.15e-19	Kawasaki disease;
CESC	cis	rs1551570	0.755	rs11667630	chr19:10229297	A/C	cg16327482	chr19:10226339	EIF3G	-0.5	-8.11	-0.45	1.93e-14	Narcolepsy;
CESC	cis	rs4423214	0.802	rs4616066	chr11:71183846	G/A	cg05163923	chr11:71159392	DHCR7	-0.68	-7.76	-0.43	1.82e-13	Vitamin D levels;
CESC	cis	rs4713118	0.621	rs9295756	chr6:28033396	G/T	cg23161317	chr6:28129485	ZNF389	0.5	6.24	0.36	1.71e-9	Parkinson's disease;
CESC	cis	rs875971	0.545	rs316316	chr7:65614257	C/T	cg19163074	chr7:65112434	INTS4L2	0.47	5.14	0.3	5.23e-7	Aortic root size;
CESC	cis	rs727505	1.000	rs720614	chr7:124452790	T/C	cg23710748	chr7:124431027	NA	-0.46	-7.21	-0.41	5.71e-12	Lewy body disease;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg01025762	chr7:107531363	DLD	-0.46	-6.25	-0.36	1.6e-9	Height;
CESC	cis	rs7385804	0.796	rs221799	chr7:100288545	G/A	cg20848291	chr7:100343083	ZAN	0.55	7.54	0.42	7.56e-13	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
CESC	cis	rs2439831	0.850	rs3097773	chr15:43893072	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.75	-8.2	-0.45	1.01e-14	Lung cancer in ever smokers;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg25951811	chr14:96858416	AK7	-0.48	-6.02	-0.35	5.77e-9	Ulcerative colitis;
CESC	cis	rs9733	0.519	rs6700022	chr1:150670484	G/T	cg22823121	chr1:150693482	HORMAD1	-0.46	-6.81	-0.39	6.43e-11	Tonsillectomy;
CESC	cis	rs9815354	1.000	rs28702390	chr3:41889920	C/A	cg03022575	chr3:42003672	ULK4	0.58	5.94	0.34	9.04e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs1506636	0.646	rs805779	chr7:123214835	C/T	cg03229431	chr7:123269106	ASB15	-0.39	-5.24	-0.31	3.21e-7	Plateletcrit;Platelet count;
CESC	cis	rs2806561	0.514	rs11801120	chr1:23543307	C/T	cg19743168	chr1:23544995	NA	0.38	5.76	0.33	2.37e-8	Height;
CESC	cis	rs4835473	0.897	rs6537170	chr4:144612900	A/T	cg25736465	chr4:144833511	NA	0.35	5.16	0.3	4.8e-7	Immature fraction of reticulocytes;
CESC	cis	rs7044106	0.762	rs1158553	chr9:123400974	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.63	8.49	0.46	1.51e-15	Hip circumference adjusted for BMI;
CESC	cis	rs67257959	1.000	rs67257959	chr19:17158145	T/C	cg16202187	chr19:17186497	HAUS8;MYO9B	0.44	5.34	0.31	1.95e-7	Selective IgA deficiency;
CESC	cis	rs854765	0.618	rs8068820	chr17:17834119	A/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.55	7.29	0.41	3.65e-12	Total body bone mineral density;
CESC	cis	rs72781680	0.898	rs72782126	chr2:24039901	A/C	cg20701182	chr2:24300061	SF3B14	0.63	5.65	0.33	4.21e-8	Lymphocyte counts;
CESC	cis	rs34779708	0.966	rs12773647	chr10:35440327	A/G	cg03585969	chr10:35415529	CREM	0.73	9.58	0.51	7.16e-19	Inflammatory bowel disease;Crohn's disease;
CESC	trans	rs61931739	0.500	rs7296061	chr12:34435009	A/G	cg13010199	chr12:38710504	ALG10B	-0.49	-6.39	-0.37	7.55e-10	Morning vs. evening chronotype;
CESC	cis	rs780096	0.506	rs2288155	chr2:27714526	T/C	cg21248554	chr2:27665150	KRTCAP3	-0.33	-6.73	-0.38	1.02e-10	Total body bone mineral density;
CESC	cis	rs748404	0.697	rs574065	chr15:43550655	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.53	-8.06	-0.44	2.59e-14	Lung cancer;
CESC	cis	rs10504229	0.679	rs56040464	chr8:58131603	G/A	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	trans	rs61931739	0.929	rs10844740	chr12:34067930	C/T	cg26384229	chr12:38710491	ALG10B	-0.47	-6.66	-0.38	1.59e-10	Morning vs. evening chronotype;
CESC	cis	rs2742234	0.590	rs1254960	chr10:43699657	C/T	cg15436174	chr10:43711423	RASGEF1A	0.5	5.85	0.34	1.45e-8	Hirschsprung disease;
CESC	cis	rs9905704	0.633	rs2680707	chr17:56455641	T/C	cg12560992	chr17:57184187	TRIM37	-0.6	-5.8	-0.34	1.93e-8	Testicular germ cell tumor;
CESC	cis	rs1506636	0.924	rs2402668	chr7:123296605	T/A	cg03229431	chr7:123269106	ASB15	-0.53	-6.83	-0.39	5.87e-11	Plateletcrit;Platelet count;
CESC	cis	rs1050631	0.592	rs1539823	chr18:33736261	T/C	cg25426722	chr18:33708991	SLC39A6;ELP2	0.53	7.16	0.4	7.87e-12	Esophageal squamous cell cancer (length of survival);
CESC	cis	rs2072732	0.861	rs67025412	chr1:2951806	T/C	cg03976712	chr1:2946727	NA	0.33	5.45	0.32	1.17e-7	Plateletcrit;
CESC	cis	rs477895	0.713	rs11600867	chr11:63972052	T/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.96	10.67	0.55	2.46e-22	Mean platelet volume;
CESC	cis	rs7662987	0.517	rs1154405	chr4:100008750	G/A	cg13256891	chr4:100009986	ADH5	0.74	8.01	0.44	3.58e-14	Smoking initiation;
CESC	cis	rs6570726	0.791	rs1280276	chr6:145892350	A/C	cg05347473	chr6:146136440	FBXO30	0.58	7.41	0.41	1.68e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9399135	0.967	rs1590975	chr6:135352088	C/T	cg24558204	chr6:135376177	HBS1L	0.48	6.64	0.38	1.73e-10	Red blood cell count;
CESC	cis	rs6499255	1.000	rs11644838	chr16:69812705	G/C	cg15192750	chr16:69999425	NA	0.46	5.64	0.33	4.46e-8	IgE levels;
CESC	cis	rs7811142	0.887	rs35111986	chr7:100000274	C/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.11	11.12	0.56	8.06e-24	Platelet count;
CESC	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg14926445	chr8:58193284	C8orf71	-0.54	-5.24	-0.31	3.28e-7	Developmental language disorder (linguistic errors);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg04230901	chr1:235292294	SNORA14B;TOMM20	-0.55	-6.54	-0.37	3.07e-10	Ulcerative colitis;
CESC	cis	rs2380220	0.516	rs7748108	chr6:96008082	T/C	cg04719120	chr6:96025338	MANEA	0.52	5.9	0.34	1.12e-8	Behavioural disinhibition (generation interaction);
CESC	cis	rs9322193	0.886	rs12525871	chr6:150097018	A/G	cg05861140	chr6:150128134	PCMT1	-0.37	-5.24	-0.31	3.23e-7	Lung cancer;
CESC	cis	rs2072499	0.767	rs3001789	chr1:156197614	T/G	cg25208724	chr1:156163844	SLC25A44	0.84	13.29	0.63	3.21e-31	Testicular germ cell tumor;
CESC	cis	rs12142240	0.698	rs17357711	chr1:46829013	A/G	cg10495392	chr1:46806563	NSUN4	0.58	6.3	0.36	1.24e-9	Menopause (age at onset);
CESC	trans	rs3942852	0.806	rs10838805	chr11:48118993	A/C	cg15704280	chr7:45808275	SEPT13	-0.61	-7.18	-0.4	7.06e-12	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	13.8	0.65	5.22e-33	Prudent dietary pattern;
CESC	cis	rs1552244	0.882	rs3755783	chr3:10029289	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.7	-7.96	-0.44	5.16e-14	Alzheimer's disease;
CESC	trans	rs2963826	0.589	rs298091	chr5:58996603	A/T	cg24583131	chr6:18265189	DEK	0.47	6.05	0.35	4.8e-9	Obesity-related traits;
CESC	cis	rs763121	0.819	rs5750658	chr22:39060917	C/T	cg06022373	chr22:39101656	GTPBP1	0.88	13.88	0.65	2.66e-33	Menopause (age at onset);
CESC	cis	rs9581857	1.000	rs9581857	chr13:28027714	A/C	cg22138327	chr13:27999177	GTF3A	0.64	5.14	0.3	5.37e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
CESC	cis	rs72781680	0.898	rs72796396	chr2:24178154	G/A	cg20701182	chr2:24300061	SF3B14	0.64	5.74	0.33	2.63e-8	Lymphocyte counts;
CESC	cis	rs9929218	0.817	rs8055912	chr16:68802068	C/T	cg02972257	chr16:68554789	NA	0.44	5.27	0.31	2.78e-7	Colorectal cancer;
CESC	cis	rs754466	0.580	rs1344966	chr10:79534527	T/C	cg17075019	chr10:79541650	NA	-0.87	-13.7	-0.64	1.14e-32	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs1862618	0.802	rs2591949	chr5:56132627	T/C	cg18230493	chr5:56204884	C5orf35	-0.75	-8.9	-0.48	9.02e-17	Initial pursuit acceleration;
CESC	cis	rs2239815	0.576	rs10427628	chr22:29239766	T/C	cg15103426	chr22:29168792	CCDC117	0.52	5.84	0.34	1.52e-8	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
CESC	cis	rs116095464	0.558	rs10065584	chr5:253997	G/A	cg22496380	chr5:211416	CCDC127	-0.98	-9.98	-0.52	4.08e-20	Breast cancer;
CESC	cis	rs7267979	1.000	rs2259956	chr20:25282433	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	18.72	0.75	2.09e-50	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs72829446	0.530	rs8075007	chr17:7374507	A/T	cg02795151	chr17:7402630	POLR2A	0.58	5.99	0.35	6.89e-9	Androgen levels;
CESC	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	22.27	0.81	1.17e-62	Prudent dietary pattern;
CESC	cis	rs155076	1.000	rs12870992	chr13:21846019	A/G	cg11317459	chr13:21872234	NA	0.91	8.96	0.48	5.78e-17	White matter hyperintensity burden;
CESC	cis	rs514406	0.861	rs7513052	chr1:53241360	C/T	cg24675658	chr1:53192096	ZYG11B	0.54	7.53	0.42	7.86e-13	Monocyte count;
CESC	trans	rs11764590	0.694	rs6461115	chr7:2103668	A/G	cg11693508	chr17:37793320	STARD3	0.54	6.37	0.36	8.23e-10	Neuroticism;
CESC	cis	rs9549367	0.569	rs3024719	chr13:113814225	G/A	cg18105134	chr13:113819100	PROZ	-0.8	-9.13	-0.49	1.84e-17	Platelet distribution width;
CESC	cis	rs477692	0.563	rs7079165	chr10:131430240	G/A	cg24747557	chr10:131355152	MGMT	0.38	5.45	0.32	1.13e-7	Response to temozolomide;
CESC	cis	rs2625529	0.730	rs3759900	chr15:72451827	A/C	cg16672083	chr15:72433130	SENP8	0.47	7.0	0.4	2.06e-11	Red blood cell count;
CESC	cis	rs798554	0.679	rs1636250	chr7:2884433	T/C	cg09658497	chr7:2847517	GNA12	-0.35	-5.09	-0.3	6.67e-7	Height;
CESC	cis	rs2836974	0.666	rs2836975	chr21:40663620	A/G	cg17971929	chr21:40555470	PSMG1	-0.88	-12.82	-0.62	1.38e-29	Cognitive function;
CESC	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.52	6.58	0.37	2.57e-10	Prudent dietary pattern;
CESC	cis	rs561341	0.882	rs2428337	chr17:30299467	C/T	cg12193833	chr17:30244370	NA	-0.71	-6.53	-0.37	3.38e-10	Hip circumference adjusted for BMI;
CESC	cis	rs7945705	0.875	rs2653616	chr11:8885892	A/G	cg12365402	chr11:9010492	NRIP3	-0.32	-5.07	-0.3	7.37e-7	Hemoglobin concentration;
CESC	cis	rs7084402	0.967	rs10826198	chr10:60274182	C/T	cg07615347	chr10:60278583	BICC1	-0.57	-8.96	-0.48	6.01e-17	Refractive error;
CESC	cis	rs17125944	0.686	rs78623109	chr14:53383077	G/T	cg00686598	chr14:53173677	PSMC6	0.96	6.93	0.39	3.2e-11	Alzheimer's disease (late onset);
CESC	cis	rs9902453	0.791	rs57719820	chr17:28335088	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.62	-7.83	-0.43	1.15e-13	Coffee consumption (cups per day);
CESC	cis	rs4332037	0.530	rs62434669	chr7:1866946	G/A	cg23422044	chr7:1970798	MAD1L1	-0.51	-5.13	-0.3	5.48e-7	Bipolar disorder;
CESC	cis	rs473651	0.935	rs482775	chr2:239335403	G/C	cg18131467	chr2:239335373	ASB1	1.02	21.0	0.79	2.57e-58	Multiple system atrophy;
CESC	cis	rs1568889	1.000	rs61236373	chr11:28212720	C/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.77	10.58	0.54	4.76e-22	Bipolar disorder;
CESC	cis	rs6545883	0.929	rs2256615	chr2:61679894	C/G	cg15711740	chr2:61764176	XPO1	-0.4	-5.22	-0.31	3.61e-7	Tuberculosis;
CESC	cis	rs477692	0.669	rs12265939	chr10:131445398	A/G	cg05714579	chr10:131428358	MGMT	-0.59	-8.3	-0.45	5.33e-15	Response to temozolomide;
CESC	cis	rs10504229	0.679	rs1442125	chr8:58036258	A/C	cg24829409	chr8:58192753	C8orf71	0.45	5.75	0.33	2.49e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs951366	1.000	rs4951261	chr1:205717823	A/C	cg07167872	chr1:205819463	PM20D1	-0.38	-5.31	-0.31	2.35e-7	Menarche (age at onset);
CESC	cis	rs9549367	0.789	rs9549705	chr13:113888425	T/C	cg18105134	chr13:113819100	PROZ	-0.69	-8.37	-0.46	3.39e-15	Platelet distribution width;
CESC	cis	rs2228479	0.850	rs11645916	chr16:89835234	G/A	cg00800038	chr16:89945340	TCF25	-0.92	-7.64	-0.42	4.02e-13	Skin colour saturation;
CESC	cis	rs28374715	0.662	rs28587487	chr15:41495460	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.83	-10.66	-0.55	2.62e-22	Ulcerative colitis;
CESC	cis	rs7607369	0.680	rs533760	chr2:219381405	T/C	cg02176678	chr2:219576539	TTLL4	0.5	9.03	0.48	3.72e-17	Red blood cell count;Amyotrophic lateral sclerosis;
CESC	cis	rs9894429	0.646	rs7405870	chr17:79617284	G/A	cg13777783	chr17:79615861	NA	-0.33	-5.51	-0.32	8.56e-8	Eye color traits;
CESC	cis	rs12200560	0.505	rs211164	chr6:97068140	G/T	cg06623918	chr6:96969491	KIAA0776	0.47	5.81	0.34	1.79e-8	Coronary heart disease;
CESC	cis	rs4969178	0.965	rs8071884	chr17:76398058	C/G	cg05887092	chr17:76393375	PGS1	0.59	9.21	0.49	1.06e-17	HDL cholesterol levels;
CESC	cis	rs3845702	0.736	rs6433821	chr2:180837806	T/A	cg01881094	chr2:180872142	CWC22	-1.08	-9.69	-0.51	3.43e-19	Schizophrenia;
CESC	trans	rs9929218	1.000	rs9937664	chr16:68784603	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.72	-9.06	-0.49	2.89e-17	Colorectal cancer;
CESC	cis	rs71277158	0.688	rs80038349	chr3:169844718	G/T	cg04067573	chr3:169899625	PHC3	0.56	5.76	0.33	2.3e-8	Prostate cancer;
CESC	cis	rs6860806	0.507	rs272880	chr5:131670178	C/T	cg24060327	chr5:131705240	SLC22A5	-0.77	-10.91	-0.56	4e-23	Breast cancer;
CESC	cis	rs4595586	0.545	rs12809206	chr12:39388748	A/C	cg26384229	chr12:38710491	ALG10B	0.54	7.6	0.42	4.97e-13	Morning vs. evening chronotype;
CESC	cis	rs9649213	0.593	rs62478177	chr7:97964611	G/A	cg24562669	chr7:97807699	LMTK2	0.49	7.17	0.4	7.48e-12	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs6088580	0.601	rs6120668	chr20:33099793	A/G	cg06115741	chr20:33292138	TP53INP2	0.45	5.8	0.34	1.88e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs938554	0.910	rs10010582	chr4:9937085	C/T	cg00071950	chr4:10020882	SLC2A9	-0.42	-5.18	-0.3	4.36e-7	Blood metabolite levels;
CESC	cis	rs4891159	0.548	rs617823	chr18:74120233	A/G	cg24786174	chr18:74118243	ZNF516	0.86	16.21	0.71	1.55e-41	Longevity;
CESC	cis	rs2075671	0.903	rs4727459	chr7:100276821	T/C	cg20848291	chr7:100343083	ZAN	-0.8	-10.16	-0.53	1.09e-20	Other erythrocyte phenotypes;
CESC	cis	rs9303401	0.659	rs11495824	chr17:56918882	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.01	12.69	0.61	3.78e-29	Cognitive test performance;
CESC	cis	rs6460942	0.659	rs17192500	chr7:12545379	A/G	cg06484146	chr7:12443880	VWDE	-0.73	-7.77	-0.43	1.68e-13	Coronary artery disease;
CESC	cis	rs10788264	0.504	rs4751885	chr10:124020305	G/T	cg09507567	chr10:124027408	NA	0.41	5.62	0.33	4.71e-8	Total body bone mineral density;
CESC	cis	rs514406	0.861	rs551435	chr1:53260537	G/T	cg08859206	chr1:53392774	SCP2	0.54	7.13	0.4	9.54e-12	Monocyte count;
CESC	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.56	-6.25	-0.36	1.67e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg17178900	chr1:205818956	PM20D1	0.8	12.65	0.61	5.1e-29	Menarche (age at onset);
CESC	cis	rs3096299	0.632	rs4399533	chr16:89539382	G/C	cg16743903	chr16:89593216	SPG7	-0.45	-5.78	-0.33	2.1e-8	Multiple myeloma (IgH translocation);
CESC	cis	rs4665809	1.000	rs10202478	chr2:26276049	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.77	-8.64	-0.47	5.4e-16	Gut microbiome composition (summer);
CESC	cis	rs9486715	0.867	rs926277	chr6:96868837	T/A	cg06623918	chr6:96969491	KIAA0776	0.91	14.05	0.65	6.83e-34	Headache;
CESC	cis	rs61931739	0.500	rs6488221	chr12:34525671	A/G	cg06521331	chr12:34319734	NA	-0.37	-5.15	-0.3	5.19e-7	Morning vs. evening chronotype;
CESC	cis	rs11683229	0.778	rs72811598	chr2:63326416	T/G	cg17519650	chr2:63277830	OTX1	-0.68	-5.33	-0.31	2.12e-7	Protein quantitative trait loci;
CESC	trans	rs863345	0.967	rs1342958	chr1:158468676	A/C	cg18533943	chr14:65380954	CHURC1	-0.44	-6.25	-0.36	1.59e-9	Pneumococcal bacteremia;
CESC	cis	rs4718428	0.705	rs4718424	chr7:66376095	G/A	cg18252515	chr7:66147081	NA	-0.45	-5.14	-0.3	5.32e-7	Corneal structure;
CESC	cis	rs4718428	0.705	rs13231140	chr7:66361618	C/G	cg12165864	chr7:66369176	NA	-0.66	-7.66	-0.43	3.45e-13	Corneal structure;
CESC	cis	rs7267979	0.586	rs1007708	chr20:25190959	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.66	10.85	0.55	6.27e-23	Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg18173830	chr6:4776623	CDYL	-0.53	-7.7	-0.43	2.78e-13	Gambling;
CESC	cis	rs72945132	0.882	rs7945389	chr11:70158876	C/A	cg14191688	chr11:70257035	CTTN	0.42	5.34	0.31	1.95e-7	Coronary artery disease;
CESC	cis	rs6502050	0.835	rs9646397	chr17:80083534	G/A	cg11859384	chr17:80120422	CCDC57	0.38	5.22	0.31	3.67e-7	Life satisfaction;
CESC	cis	rs738322	0.934	rs84473	chr22:38557326	T/C	cg17652424	chr22:38574118	PLA2G6	-0.34	-6.19	-0.36	2.28e-9	Cutaneous nevi;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05904283	chr16:716021	WDR90	-0.55	-6.1	-0.35	3.66e-9	Gut microbiome composition (summer);
CESC	cis	rs3008870	1.000	rs2815371	chr1:67504313	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.99	13.22	0.63	5.4e-31	Lymphocyte percentage of white cells;
CESC	cis	rs1642645	0.831	rs3856259	chr1:42475503	T/C	cg16685388	chr1:42384056	HIVEP3	0.38	5.68	0.33	3.57e-8	Left ventricular obstructive tract defect (maternal effect);
CESC	cis	rs2239547	0.657	rs2276817	chr3:52860936	C/T	cg11645453	chr3:52864694	ITIH4	0.32	5.89	0.34	1.15e-8	Schizophrenia;
CESC	cis	rs8017423	0.935	rs3783838	chr14:90733012	A/G	cg14092571	chr14:90743983	NA	0.53	7.96	0.44	4.93e-14	Mortality in heart failure;
CESC	cis	rs6963495	0.745	rs2392749	chr7:105182605	A/G	cg02135003	chr7:105160482	PUS7	-0.43	-5.98	-0.35	7.05e-9	Bipolar disorder (body mass index interaction);
CESC	cis	rs7927592	0.956	rs6591341	chr11:68335478	C/T	cg16797656	chr11:68205561	LRP5	0.42	6.21	0.36	2e-9	Total body bone mineral density;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg13499067	chr11:10879629	ZBED5	-0.49	-6.64	-0.38	1.78e-10	Fibrinogen levels;
CESC	cis	rs6691722	0.503	rs2274167	chr1:24707296	C/T	cg02336364	chr1:24764700	NIPAL3	0.32	6.58	0.37	2.48e-10	Response to interferon beta in multiple sclerosis;
CESC	cis	rs6460942	0.915	rs17444044	chr7:12458736	A/G	cg02935154	chr7:12443704	VWDE	-0.58	-6.16	-0.35	2.73e-9	Coronary artery disease;
CESC	cis	rs6461049	0.646	rs3778970	chr7:2143208	C/A	cg08027265	chr7:2291960	NA	-0.46	-7.15	-0.4	8.3e-12	Schizophrenia;
CESC	trans	rs10411161	0.752	rs10404812	chr19:52400691	T/C	cg22319618	chr22:45562946	NUP50	-0.76	-7.49	-0.42	1.04e-12	Breast cancer;
CESC	cis	rs2243480	1.000	rs13310597	chr7:65598540	A/G	cg13147721	chr7:65941812	NA	-0.99	-9.4	-0.5	2.68e-18	Diabetic kidney disease;
CESC	cis	rs6025261	0.761	rs3848695	chr20:55513254	C/T	cg04763273	chr20:55502381	NA	0.3	5.09	0.3	6.76e-7	Verbal memory performance (delayed recall level);
CESC	cis	rs4665809	1.000	rs4665817	chr2:26305167	G/A	cg08470875	chr2:26401718	FAM59B	-0.62	-6.71	-0.38	1.2e-10	Gut microbiome composition (summer);
CESC	cis	rs12477438	0.798	rs1453561	chr2:99613924	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.78	-10.94	-0.56	3.2e-23	Chronic sinus infection;
CESC	cis	rs939574	0.790	rs114196239	chr2:220094307	G/A	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.88	7.38	0.41	2e-12	Platelet distribution width;
CESC	cis	rs74181299	0.927	rs2723064	chr2:65279805	T/C	cg05010058	chr2:65284262	CEP68	0.33	5.79	0.34	1.98e-8	Pulse pressure;
CESC	cis	rs3916	0.955	rs35771722	chr12:121154000	A/G	cg21892295	chr12:121157589	UNC119B	-0.36	-5.26	-0.31	3.04e-7	Urinary metabolites (H-NMR features);
CESC	cis	rs9322193	0.810	rs62439811	chr6:149961552	C/T	cg04369109	chr6:150039330	LATS1	-0.39	-5.45	-0.32	1.16e-7	Lung cancer;
CESC	cis	rs56046484	0.871	rs71397837	chr15:85563561	G/A	cg08123816	chr15:85640762	PDE8A	-0.49	-5.71	-0.33	3.08e-8	Testicular germ cell tumor;
CESC	cis	rs1552244	1.000	rs111392584	chr3:10075991	A/G	cg08888203	chr3:10149979	C3orf24	0.46	5.94	0.34	9.05e-9	Alzheimer's disease;
CESC	cis	rs2120019	0.935	rs34835684	chr15:75331805	T/G	cg09165964	chr15:75287851	SCAMP5	-0.78	-9.31	-0.5	5.02e-18	Blood trace element (Zn levels);
CESC	cis	rs12477438	0.765	rs9710648	chr2:99673129	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.62	-8.67	-0.47	4.43e-16	Chronic sinus infection;
CESC	cis	rs2836974	0.931	rs12151994	chr21:40690397	A/C	cg22974920	chr21:40686053	BRWD1	0.48	5.47	0.32	1.06e-7	Cognitive function;
CESC	cis	rs11608355	0.545	rs918107	chr12:109904198	C/T	cg05360138	chr12:110035743	NA	-0.8	-8.76	-0.47	2.41e-16	Neuroticism;
CESC	cis	rs7818345	0.967	rs13255946	chr8:19275354	T/C	cg11303988	chr8:19266685	CSGALNACT1	0.32	5.85	0.34	1.43e-8	Language performance in older adults (adjusted for episodic memory);
CESC	cis	rs7264396	0.623	rs761827	chr20:34207897	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.85	-9.24	-0.49	8.07e-18	Total cholesterol levels;
CESC	cis	rs12135062	1.000	rs12135062	chr1:3103312	A/C	cg00254258	chr1:3105189	PRDM16	0.4	5.64	0.33	4.29e-8	Migraine;
CESC	cis	rs9790314	0.560	rs4856701	chr3:161044106	G/T	cg03342759	chr3:160939853	NMD3	-0.45	-6.53	-0.37	3.35e-10	Morning vs. evening chronotype;
CESC	cis	rs6582630	0.638	rs12423236	chr12:38548162	G/A	cg26384229	chr12:38710491	ALG10B	-0.39	-5.19	-0.3	4.22e-7	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs8062405	0.756	rs151182	chr16:28495752	C/T	cg05966235	chr16:28915196	ATP2A1	0.36	5.18	0.3	4.41e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs7674212	0.570	rs2711898	chr4:104063071	C/T	cg16532752	chr4:104119610	CENPE	-0.41	-5.69	-0.33	3.31e-8	Type 2 diabetes;
CESC	cis	rs10992471	0.756	rs1121979	chr9:95140218	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.45	-5.68	-0.33	3.52e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CESC	cis	rs3741404	0.537	rs1123251	chr11:63917601	G/T	cg18225595	chr11:63971243	STIP1	-0.39	-5.12	-0.3	5.94e-7	Platelet count;
CESC	cis	rs7542091	0.704	rs12022221	chr1:210046178	A/C	cg25204440	chr1:209979598	IRF6	0.37	5.16	0.3	4.95e-7	Monobrow;
CESC	cis	rs728616	0.557	rs17107449	chr10:81715696	C/T	cg05935833	chr10:81318306	SFTPA2	-0.51	-5.04	-0.3	8.51e-7	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs5769765	0.862	rs9616385	chr22:50313124	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.58	-6.23	-0.36	1.86e-9	Schizophrenia;
CESC	cis	rs1546924	0.669	rs6687953	chr1:112293512	A/G	cg23955903	chr1:112298873	DDX20;C1orf183	0.42	5.42	0.32	1.33e-7	Body mass index;
CESC	cis	rs17253792	0.822	rs112308750	chr14:56080073	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.76	5.39	0.31	1.56e-7	Putamen volume;
CESC	cis	rs738322	0.870	rs2277844	chr22:38577515	G/A	cg25457927	chr22:38595422	NA	0.31	5.71	0.33	3.07e-8	Cutaneous nevi;
CESC	cis	rs6570726	0.764	rs76635693	chr6:145834070	T/C	cg23711669	chr6:146136114	FBXO30	1.02	15.96	0.7	1.2e-40	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs11098499	0.954	rs7681544	chr4:120411255	T/C	cg09307838	chr4:120376055	NA	0.92	12.96	0.62	4.27e-30	Corneal astigmatism;
CESC	cis	rs2841277	0.509	rs11850949	chr14:105408827	A/C	cg21017887	chr14:105400489	NA	0.44	7.15	0.4	8.35e-12	Rheumatoid arthritis;
CESC	trans	rs9907295	0.818	rs4796112	chr17:34158726	A/G	cg27663249	chr16:2801092	LOC100128788;SRRM2	0.61	6.2	0.36	2.18e-9	Fibroblast growth factor basic levels;
CESC	cis	rs1552244	1.000	rs35220123	chr3:10083169	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.78	-10.37	-0.54	2.24e-21	Alzheimer's disease;
CESC	cis	rs10540	1.000	rs12418639	chr11:473300	A/C	cg03576123	chr11:487126	PTDSS2	1.05	10.55	0.54	5.94e-22	Body mass index;
CESC	cis	rs9291683	0.632	rs10939669	chr4:10045827	A/G	cg00071950	chr4:10020882	SLC2A9	0.85	14.82	0.67	1.3e-36	Bone mineral density;
CESC	cis	rs6570726	0.967	rs374728	chr6:145854598	T/A	cg23711669	chr6:146136114	FBXO30	0.8	11.74	0.58	6.58e-26	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4665809	0.618	rs7579199	chr2:26266496	G/A	cg22920501	chr2:26401640	FAM59B	-0.67	-8.01	-0.44	3.54e-14	Gut microbiome composition (summer);
CESC	cis	rs67340775	0.834	rs13218875	chr6:27884012	C/T	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.87	5.97	0.34	7.6e-9	Lung cancer in ever smokers;
CESC	cis	rs6424115	0.830	rs2502999	chr1:24198321	A/G	cg15997130	chr1:24165203	NA	0.38	5.11	0.3	6.3e-7	Immature fraction of reticulocytes;
CESC	cis	rs2243480	1.000	rs1979823	chr7:65704613	G/A	cg12463550	chr7:65579703	CRCP	-0.74	-5.73	-0.33	2.74e-8	Diabetic kidney disease;
CESC	cis	rs950027	0.620	rs1153857	chr15:45659095	G/T	cg21132104	chr15:45694354	SPATA5L1	0.67	8.55	0.46	1.01e-15	Response to fenofibrate (adiponectin levels);
CESC	cis	rs6502050	0.835	rs4789732	chr17:80131382	A/G	cg23985595	chr17:80112537	CCDC57	-0.41	-6.57	-0.37	2.61e-10	Life satisfaction;
CESC	cis	rs8072100	0.738	rs3736438	chr17:45486651	T/G	cg25173405	chr17:45401733	C17orf57	-0.44	-5.48	-0.32	9.7e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs372883	0.648	rs1153292	chr21:30689195	G/T	cg24692254	chr21:30365293	RNF160	-0.51	-6.47	-0.37	4.79e-10	Pancreatic cancer;
CESC	cis	rs34779708	0.931	rs34375045	chr10:35362356	A/C	cg03585969	chr10:35415529	CREM	0.73	9.22	0.49	9.87e-18	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs1577917	0.959	rs34258068	chr6:86679449	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.45	-5.92	-0.34	9.76e-9	Response to antipsychotic treatment;
CESC	cis	rs9303401	0.573	rs35104446	chr17:57180234	A/C	cg25039879	chr17:56429692	SUPT4H1	0.51	5.4	0.31	1.48e-7	Cognitive test performance;
CESC	cis	rs7937682	0.889	rs1789359	chr11:111475995	T/A	cg22437258	chr11:111473054	SIK2	0.72	9.69	0.51	3.38e-19	Primary sclerosing cholangitis;
CESC	cis	rs7726839	0.561	rs56410216	chr5:583216	C/A	cg09021430	chr5:549028	NA	-0.43	-5.76	-0.33	2.29e-8	Obesity-related traits;
CESC	cis	rs861020	0.630	rs592694	chr1:210009533	G/T	cg05527609	chr1:210001259	C1orf107	0.75	10.05	0.53	2.48e-20	Orofacial clefts;
CESC	cis	rs9914988	0.943	rs4795457	chr17:27087929	C/T	cg20469991	chr17:27169893	C17orf63	-0.5	-5.66	-0.33	3.89e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CESC	trans	rs2727020	0.729	rs2204366	chr11:49349367	A/C	cg15704280	chr7:45808275	SEPT13	0.88	14.64	0.67	5.8e-36	Coronary artery disease;
CESC	cis	rs7818688	0.578	rs75025610	chr8:95838303	T/G	cg16049864	chr8:95962084	TP53INP1	0.5	5.19	0.3	4.11e-7	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs8044868	0.530	rs2287998	chr16:72059269	C/T	cg01557791	chr16:72042693	DHODH	0.45	6.11	0.35	3.56e-9	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CESC	cis	rs8070128	0.637	rs4925133	chr17:17884801	A/G	cg09796270	chr17:17721594	SREBF1	0.38	5.18	0.3	4.32e-7	Total body bone mineral density;
CESC	trans	rs7307889	0.793	rs55754310	chr12:5999906	T/G	cg18407955	chr7:158110685	PTPRN2	-0.67	-6.11	-0.35	3.55e-9	Obesity-related traits;
CESC	trans	rs116095464	0.558	rs56342538	chr5:225796	T/C	cg00938859	chr5:1591904	SDHAP3	0.61	6.78	0.38	7.58e-11	Breast cancer;
CESC	cis	rs1799949	1.000	rs33994002	chr17:41328818	T/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.42	5.72	0.33	2.87e-8	Menopause (age at onset);
CESC	cis	rs4727963	0.846	rs1525472	chr7:122733976	A/G	cg03640110	chr7:122635026	TAS2R16	0.37	5.76	0.33	2.32e-8	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
CESC	cis	rs12368653	0.525	rs1564374	chr12:58010163	C/T	cg00700412	chr12:58011837	NA	0.42	6.64	0.38	1.8e-10	Multiple sclerosis;
CESC	cis	rs73206853	0.925	rs28670753	chr12:110826463	C/T	cg12870014	chr12:110450643	ANKRD13A	0.61	5.62	0.33	4.8e-8	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs2109514	0.792	rs4727831	chr7:116093983	A/G	cg12739419	chr7:116140593	CAV2	-0.29	-5.26	-0.31	3.02e-7	Prevalent atrial fibrillation;
CESC	cis	rs1862618	0.573	rs832532	chr5:56221938	T/C	cg24531977	chr5:56204891	C5orf35	-1.0	-13.13	-0.63	1.09e-30	Initial pursuit acceleration;
CESC	cis	rs11650494	0.908	rs73340399	chr17:47372743	G/C	cg08112188	chr17:47440006	ZNF652	1.11	7.71	0.43	2.48e-13	Prostate cancer;
CESC	cis	rs7208859	0.673	rs3816780	chr17:29161358	C/T	cg19761014	chr17:28927070	LRRC37B2	0.58	5.09	0.3	6.95e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs2952156	0.920	rs9303274	chr17:37836353	T/C	cg00129232	chr17:37814104	STARD3	-0.78	-11.59	-0.58	2.06e-25	Asthma;
CESC	cis	rs2299587	0.689	rs12546237	chr8:17797055	A/G	cg08627089	chr8:17753878	FGL1	-0.41	-5.61	-0.33	5e-8	Economic and political preferences;
CESC	trans	rs12599106	0.680	rs34728702	chr16:34896584	A/G	cg15383120	chr6:291909	DUSP22	-0.66	-8.33	-0.46	4.42e-15	Menopause (age at onset);
CESC	cis	rs2243480	1.000	rs12698509	chr7:65418876	C/T	cg12463550	chr7:65579703	CRCP	0.64	5.31	0.31	2.38e-7	Diabetic kidney disease;
CESC	cis	rs875971	1.000	rs1363055	chr7:65943275	A/G	cg18876405	chr7:65276391	NA	0.51	6.82	0.39	6.05e-11	Aortic root size;
CESC	cis	rs735396	0.770	rs1169315	chr12:121443753	T/G	cg15155738	chr12:121454335	C12orf43	0.44	5.08	0.3	7.18e-7	N-glycan levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25845374	chr2:119981187	STEAP3	0.49	6.05	0.35	4.92e-9	Gut microbiome composition (summer);
CESC	cis	rs35110281	0.807	rs2838326	chr21:45014315	C/T	cg01579765	chr21:45077557	HSF2BP	-0.54	-9.55	-0.51	8.97e-19	Mean corpuscular volume;
CESC	trans	rs1814175	0.615	rs4545557	chr11:50027329	A/C	cg03929089	chr4:120376271	NA	-0.91	-14.8	-0.67	1.58e-36	Height;
CESC	cis	rs3096299	0.933	rs3096297	chr16:89453155	T/G	cg08392591	chr16:89556376	ANKRD11	0.41	5.25	0.31	3.13e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs2625529	0.730	rs2957725	chr15:72248205	C/A	cg16672083	chr15:72433130	SENP8	0.4	5.89	0.34	1.17e-8	Red blood cell count;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg26176469	chr17:28951361	LRRC37B2	-0.53	-7.1	-0.4	1.16e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	trans	rs2207136	0.728	rs10948577	chr6:50827126	T/G	cg06522515	chr3:184090630	THPO	-0.38	-6.62	-0.38	2.03e-10	Myopia;
CESC	cis	rs8031584	0.918	rs61997139	chr15:31273602	C/G	cg14298792	chr15:30685198	CHRFAM7A	-0.45	-5.33	-0.31	2.05e-7	Huntington's disease progression;
CESC	cis	rs2952156	0.959	rs2941504	chr17:37830900	A/G	cg20243544	chr17:37824526	PNMT	0.59	7.41	0.41	1.73e-12	Asthma;
CESC	cis	rs6060717	0.536	rs2425104	chr20:34312346	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.82	-7.58	-0.42	5.86e-13	Hip circumference adjusted for BMI;
CESC	cis	rs3806843	0.766	rs801399	chr5:140034844	C/T	cg26395211	chr5:140044315	WDR55	0.41	5.58	0.32	5.83e-8	Depressive symptoms (multi-trait analysis);
CESC	cis	rs637571	0.676	rs1151523	chr11:65665200	C/T	cg04055107	chr11:65626734	MUS81;CFL1	-0.64	-8.3	-0.45	5.35e-15	Eosinophil percentage of white cells;
CESC	cis	rs6594499	0.542	rs7722241	chr5:110460747	T/A	cg04022379	chr5:110408740	TSLP	0.42	7.59	0.42	5.39e-13	Allergic disease (asthma, hay fever or eczema);
CESC	trans	rs5756813	0.661	rs2071910	chr22:38204259	C/T	cg19894588	chr14:64061835	NA	-0.69	-8.53	-0.46	1.12e-15	Optic cup area;Vertical cup-disc ratio;
CESC	cis	rs12530134	0.590	rs760492	chr6:170743989	A/G	cg16453901	chr6:170730693	NA	-0.75	-5.76	-0.33	2.38e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs3820068	0.532	rs72645862	chr1:15920366	A/G	cg17385448	chr1:15911702	AGMAT	0.42	6.77	0.38	8.35e-11	Systolic blood pressure;
CESC	cis	rs6540559	1.000	rs2235372	chr1:209960436	A/G	cg22442454	chr1:209979470	IRF6	-0.43	-5.11	-0.3	6.05e-7	Cleft lip with or without cleft palate;
CESC	cis	rs113835537	0.559	rs11227497	chr11:66269464	T/C	cg24851651	chr11:66362959	CCS	0.42	5.14	0.3	5.46e-7	Airway imaging phenotypes;
CESC	cis	rs1799949	1.000	rs8176120	chr17:41261233	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.67	9.43	0.5	2.2e-18	Menopause (age at onset);
CESC	cis	rs1215050	0.527	rs1214998	chr4:99042878	T/G	cg05340658	chr4:99064831	C4orf37	0.62	8.35	0.46	3.82e-15	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs7937682	0.889	rs1784785	chr11:111483306	A/G	cg22437258	chr11:111473054	SIK2	0.72	9.69	0.51	3.38e-19	Primary sclerosing cholangitis;
CESC	cis	rs78456975	1.000	rs55761535	chr2:1561450	A/G	cg01028140	chr2:1542097	TPO	-0.5	-5.36	-0.31	1.78e-7	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs1881797	0.872	rs12408686	chr1:247691141	C/T	cg21399703	chr1:247681439	NA	0.62	8.24	0.45	8.01e-15	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs6032067	1.000	rs6032042	chr20:43815949	T/C	cg10761708	chr20:43804764	PI3	0.53	6.39	0.37	7.37e-10	Blood protein levels;
CESC	trans	rs1437396	0.586	rs6756777	chr2:55623734	C/T	cg07921503	chr7:2445843	CHST12	-0.24	-6.05	-0.35	4.95e-9	Alcohol dependence;
CESC	cis	rs35110281	0.720	rs162374	chr21:44927089	T/C	cg01579765	chr21:45077557	HSF2BP	0.53	8.86	0.48	1.18e-16	Mean corpuscular volume;
CESC	cis	rs863345	0.604	rs4373761	chr1:158464634	G/A	cg12129480	chr1:158549410	OR10X1	-0.35	-6.97	-0.39	2.46e-11	Pneumococcal bacteremia;
CESC	cis	rs7617773	0.925	rs6442105	chr3:48182326	A/G	cg11946769	chr3:48343235	NME6	-0.67	-8.92	-0.48	8.12e-17	Coronary artery disease;
CESC	cis	rs10751667	0.666	rs7395321	chr11:940280	C/T	cg01483505	chr11:975446	AP2A2	0.38	5.18	0.3	4.33e-7	Alzheimer's disease (late onset);
CESC	cis	rs4689388	0.926	rs10012946	chr4:6293350	C/T	cg25554036	chr4:6271136	WFS1	-0.55	-7.5	-0.42	9.83e-13	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs400736	0.535	rs4418631	chr1:8174197	A/G	cg25007680	chr1:8021821	PARK7	0.58	7.48	0.42	1.09e-12	Response to antidepressants and depression;
CESC	cis	rs11997175	0.550	rs10954943	chr8:33815972	A/G	ch.8.33884649F	chr8:33765107	NA	0.59	7.47	0.42	1.2e-12	Body mass index;
CESC	cis	rs7811142	1.000	rs67239991	chr7:100046504	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.88	9.25	0.49	7.87e-18	Platelet count;
CESC	cis	rs8016982	0.674	rs8004096	chr14:81701082	T/G	cg01989461	chr14:81687754	GTF2A1	0.68	10.12	0.53	1.49e-20	Schizophrenia;
CESC	cis	rs2440129	0.611	rs1042356	chr17:6902743	G/A	cg05215748	chr17:6898738	ALOX12	0.31	6.35	0.36	9.5e-10	Tonsillectomy;
CESC	cis	rs1448094	0.512	rs60986162	chr12:86247054	T/G	cg00310523	chr12:86230176	RASSF9	0.35	5.46	0.32	1.1e-7	Major depressive disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03051310	chr12:108954266	SART3	-0.54	-6.27	-0.36	1.43e-9	Gut microbiome composition (summer);
CESC	cis	rs11792861	0.816	rs28361111	chr9:111761012	A/C	cg13535736	chr9:111863775	C9orf5	-0.46	-6.06	-0.35	4.65e-9	Menarche (age at onset);
CESC	cis	rs1862618	0.853	rs9283717	chr5:56078659	G/A	cg18230493	chr5:56204884	C5orf35	-0.69	-8.27	-0.45	6.71e-15	Initial pursuit acceleration;
CESC	cis	rs9790314	0.690	rs6441354	chr3:160826404	A/G	cg03342759	chr3:160939853	NMD3	-0.39	-5.19	-0.3	4.21e-7	Morning vs. evening chronotype;
CESC	trans	rs17685	0.753	rs1104879	chr7:75685568	C/T	cg19862616	chr7:65841803	NCRNA00174	0.81	11.86	0.59	2.7e-26	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs2243480	1.000	rs1701750	chr7:65467145	T/C	cg12463550	chr7:65579703	CRCP	0.72	5.92	0.34	9.68e-9	Diabetic kidney disease;
CESC	cis	rs11722228	0.522	rs881641	chr4:10133747	G/A	cg14348967	chr4:10160060	NA	-0.4	-5.22	-0.31	3.63e-7	Gout;Urate levels;Serum uric acid levels;
CESC	cis	rs4665809	0.531	rs12990692	chr2:26464939	C/T	cg26314531	chr2:26401878	FAM59B	0.85	9.23	0.49	8.65e-18	Gut microbiome composition (summer);
CESC	cis	rs9467711	0.524	rs13216484	chr6:26762087	C/T	cg21479132	chr6:26055353	NA	0.71	5.25	0.31	3.1e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs9443645	0.545	rs10755377	chr6:79637925	T/C	cg05283184	chr6:79620031	NA	-0.36	-5.15	-0.3	4.97e-7	Intelligence (multi-trait analysis);
CESC	cis	rs6541297	0.594	rs6672758	chr1:230303512	C/T	cg20703242	chr1:230279135	GALNT2	0.36	5.49	0.32	9.4e-8	Coronary artery disease;
CESC	cis	rs7212590	0.655	rs8067568	chr17:57999215	A/G	cg20303301	chr17:57937339	TUBD1	-0.52	-5.47	-0.32	1.05e-7	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs12136530	0.774	rs4911995	chr1:19765004	C/G	cg01832549	chr1:19774989	CAPZB	0.46	6.34	0.36	9.85e-10	Lead levels in blood;
CESC	cis	rs7246865	0.603	rs10423719	chr19:17211568	T/C	cg19418318	chr19:17219073	MYO9B	0.35	5.96	0.34	8.02e-9	Reticulocyte fraction of red cells;
CESC	cis	rs617791	0.530	rs7952056	chr11:65744597	C/T	cg09783858	chr11:65769428	EIF1AD;BANF1	0.53	6.35	0.36	9.55e-10	Breast cancer;
CESC	cis	rs921968	0.643	rs1516086	chr2:219431535	C/T	cg02176678	chr2:219576539	TTLL4	0.39	6.68	0.38	1.4e-10	Mean corpuscular hemoglobin concentration;
CESC	cis	rs1050631	0.960	rs1789503	chr18:33696865	T/G	cg25426722	chr18:33708991	SLC39A6;ELP2	0.44	5.68	0.33	3.58e-8	Esophageal squamous cell cancer (length of survival);
CESC	cis	rs832540	0.512	rs33320	chr5:56206529	C/T	cg24531977	chr5:56204891	C5orf35	-0.52	-6.38	-0.37	7.72e-10	Coronary artery disease;
CESC	cis	rs1153858	1.000	rs4625670	chr15:45652926	C/T	cg14582100	chr15:45693742	SPATA5L1	0.42	5.97	0.34	7.62e-9	Homoarginine levels;
CESC	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	22.11	0.81	4.36e-62	Prudent dietary pattern;
CESC	cis	rs11122272	0.701	rs743120	chr1:231531232	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.56	-7.66	-0.43	3.45e-13	Hemoglobin concentration;
CESC	cis	rs60843830	1.000	rs62114497	chr2:214837	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.74	9.25	0.49	7.87e-18	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs7666738	0.515	rs28615369	chr4:98896858	C/T	cg05340658	chr4:99064831	C4orf37	0.59	7.43	0.42	1.47e-12	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7589342	0.792	rs13426321	chr2:106500280	G/A	cg16077055	chr2:106428750	NCK2	0.42	5.92	0.34	1.02e-8	Addiction;
CESC	cis	rs861020	0.959	rs641348	chr1:209992043	A/G	cg05527609	chr1:210001259	C1orf107	1.08	12.88	0.62	8.31e-30	Orofacial clefts;
CESC	cis	rs6089584	0.850	rs6142938	chr20:60627723	A/C	cg24733560	chr20:60626293	TAF4	0.47	6.72	0.38	1.09e-10	Body mass index;
CESC	cis	rs9393777	0.841	rs13191474	chr6:27413345	C/T	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.8	5.44	0.32	1.2e-7	Intelligence (multi-trait analysis);
CESC	cis	rs2014572	0.933	rs8107516	chr19:57758445	A/G	cg24459738	chr19:57751996	ZNF805	-0.53	-7.49	-0.42	1e-12	Hyperactive-impulsive symptoms;
CESC	cis	rs35110281	0.807	rs2838325	chr21:45014284	A/T	cg01579765	chr21:45077557	HSF2BP	0.49	8.64	0.47	5.58e-16	Mean corpuscular volume;
CESC	cis	rs9611565	0.625	rs9607819	chr22:41958862	C/G	cg17376030	chr22:41985996	PMM1	0.59	6.53	0.37	3.39e-10	Vitiligo;
CESC	cis	rs34779708	0.931	rs4934709	chr10:35339324	A/C	cg04310649	chr10:35416472	CREM	0.51	6.09	0.35	3.98e-9	Inflammatory bowel disease;Crohn's disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg15921436	chr17:44337874	NA	0.46	6.37	0.36	8.2e-10	Fibrinogen levels;
CESC	cis	rs3806843	0.712	rs2530244	chr5:140109155	A/G	cg16179182	chr5:140090404	VTRNA1-1	0.38	5.06	0.3	7.77e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs9581857	0.556	rs9581864	chr13:28041567	T/C	cg01674679	chr13:27998804	GTF3A	-0.55	-5.84	-0.34	1.51e-8	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
CESC	cis	rs7927771	0.524	rs6485773	chr11:47763509	A/G	cg18512352	chr11:47633146	NA	0.35	5.51	0.32	8.36e-8	Subjective well-being;
CESC	cis	rs3784262	0.967	rs12910752	chr15:58314679	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.31	-5.08	-0.3	7.25e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
CESC	trans	rs9951602	0.512	rs4799244	chr18:76649763	T/C	cg02800362	chr5:177631904	HNRNPAB	0.65	8.64	0.47	5.23e-16	Obesity-related traits;
CESC	cis	rs6912958	0.781	rs9450723	chr6:88226641	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.5	6.63	0.38	1.83e-10	Monocyte percentage of white cells;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg17834289	chr15:41878006	NA	-0.47	-6.69	-0.38	1.35e-10	Gut microbiota (bacterial taxa);
CESC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg20151045	chr17:35414114	AATF	-0.47	-6.12	-0.35	3.34e-9	Tetralogy of Fallot;
CESC	cis	rs13256369	1.000	rs10098234	chr8:8576692	G/A	cg17143192	chr8:8559678	CLDN23	0.71	8.34	0.46	4.02e-15	Obesity-related traits;
CESC	cis	rs7811142	0.775	rs1059129	chr7:99926522	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.1	13.36	0.63	1.81e-31	Platelet count;
CESC	cis	rs3749237	1.000	rs11130216	chr3:49736172	C/A	cg03060546	chr3:49711283	APEH	0.64	7.5	0.42	9.67e-13	Resting heart rate;
CESC	cis	rs7589342	0.839	rs35812588	chr2:106432201	C/T	cg16077055	chr2:106428750	NCK2	0.52	7.44	0.42	1.42e-12	Addiction;
CESC	cis	rs763014	0.931	rs2071982	chr16:630405	T/G	cg07256732	chr16:621771	PIGQ	-0.3	-5.13	-0.3	5.63e-7	Height;
CESC	cis	rs763121	0.853	rs1056610	chr22:39080078	C/T	cg21395723	chr22:39101663	GTPBP1	-0.46	-6.14	-0.35	2.93e-9	Menopause (age at onset);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg04811621	chr4:40058985	LOC344967;N4BP2	-0.47	-6.26	-0.36	1.56e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs9311474	0.607	rs11711421	chr3:52561779	C/T	cg05564831	chr3:52568323	NT5DC2	0.46	7.39	0.41	1.91e-12	Electroencephalogram traits;
CESC	cis	rs17345786	0.861	rs74768235	chr3:101142821	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.49	-5.42	-0.32	1.32e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg05313129	chr8:58192883	C8orf71	-0.49	-5.32	-0.31	2.23e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs1218582	0.740	rs1977879	chr1:154879743	G/A	cg09359103	chr1:154839909	KCNN3	-0.65	-12.31	-0.6	7.76e-28	Prostate cancer;
CESC	cis	rs35306767	0.903	rs4522091	chr10:874116	G/T	cg25019033	chr10:957182	NA	-0.59	-6.29	-0.36	1.32e-9	Eosinophil percentage of granulocytes;
CESC	cis	rs6061231	0.583	rs2427313	chr20:60970675	G/A	cg24112000	chr20:60950667	NA	-0.51	-7.14	-0.4	8.82e-12	Colorectal cancer;
CESC	cis	rs1348850	0.632	rs11682717	chr2:178499240	C/G	cg22681709	chr2:178499509	PDE11A	-0.58	-9.05	-0.49	3.1e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs2635047	0.615	rs2684833	chr18:44719428	C/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.34	-5.11	-0.3	6.16e-7	Educational attainment;
CESC	cis	rs7772486	0.875	rs2748498	chr6:146319166	C/G	cg05347473	chr6:146136440	FBXO30	0.52	6.92	0.39	3.32e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6831352	0.918	rs2602891	chr4:100043284	C/T	cg13256891	chr4:100009986	ADH5	0.75	8.31	0.45	5.11e-15	Alcohol dependence;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg04571941	chr7:5463284	TNRC18	0.47	6.27	0.36	1.45e-9	Asthma;
CESC	trans	rs2115172	0.836	rs4835799	chr5:122762229	A/G	cg05000123	chr14:20937394	PNP	0.49	6.49	0.37	4.13e-10	Weight;
CESC	cis	rs9611565	0.513	rs739135	chr22:42090069	A/C	cg03806693	chr22:41940476	POLR3H	1.13	13.07	0.63	1.86e-30	Vitiligo;
CESC	cis	rs13392177	0.660	rs62185964	chr2:219073745	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.52	-6.44	-0.37	5.71e-10	Pyoderma gangrenosum in inflammatory bowel disease;
CESC	cis	rs1451375	0.617	rs11772714	chr7:50542843	G/A	cg14593290	chr7:50529359	DDC	-0.55	-6.4	-0.37	6.95e-10	Malaria;
CESC	cis	rs2708240	0.577	rs2373270	chr7:147567042	A/G	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.4	-6.52	-0.37	3.5e-10	QT interval (drug interaction);
CESC	cis	rs10465746	0.967	rs10493744	chr1:84444752	C/T	cg10977910	chr1:84465055	TTLL7	-0.46	-6.27	-0.36	1.47e-9	Obesity-related traits;
CESC	cis	rs10504229	0.593	rs79874994	chr8:57993709	C/A	cg24829409	chr8:58192753	C8orf71	-0.69	-7.54	-0.42	7.35e-13	Developmental language disorder (linguistic errors);
CESC	cis	rs1448094	0.511	rs4278581	chr12:86151054	A/G	cg02569458	chr12:86230093	RASSF9	-0.42	-6.44	-0.37	5.67e-10	Major depressive disorder;
CESC	cis	rs910316	0.673	rs2012627	chr14:75443103	C/T	cg08847533	chr14:75593920	NEK9	0.84	13.98	0.65	1.18e-33	Height;
CESC	cis	rs6460942	0.915	rs1595800	chr7:12439816	G/A	cg16278512	chr7:12443529	VWDE	-0.56	-5.96	-0.34	8.1e-9	Coronary artery disease;
CESC	cis	rs2180341	0.960	rs7766942	chr6:127691323	G/T	cg24812749	chr6:127587940	RNF146	1.05	15.12	0.68	1.2e-37	Breast cancer;
CESC	cis	rs616402	0.527	rs10779737	chr1:10580275	C/G	cg17425144	chr1:10567563	PEX14	0.38	6.25	0.36	1.62e-9	Breast size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15803506	chr10:135125704	ZNF511	-0.64	-7.35	-0.41	2.52e-12	Gut microbiome composition (summer);
CESC	cis	rs1499614	1.000	rs1882655	chr7:66147057	T/C	cg12463550	chr7:65579703	CRCP	-0.77	-6.0	-0.35	6.47e-9	Gout;
CESC	cis	rs10242455	0.867	rs2222411	chr7:99310331	C/G	cg07715041	chr7:99302981	CYP3A7	-0.43	-5.35	-0.31	1.9e-7	Blood metabolite levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02952494	chr16:1818699	MAPK8IP3	-0.55	-6.91	-0.39	3.71e-11	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21012729	chr14:51297401	NIN	0.59	6.89	0.39	4.13e-11	Gut microbiome composition (summer);
CESC	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.64	7.45	0.42	1.33e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs9660180	0.967	rs12034740	chr1:1728969	C/A	cg05132306	chr1:1846340	CALML6	-0.32	-6.79	-0.39	7.19e-11	Body mass index;
CESC	cis	rs8077577	0.945	rs9916193	chr17:18057215	C/G	cg16794390	chr17:18148240	FLII	0.43	6.03	0.35	5.43e-9	Obesity-related traits;
CESC	cis	rs8008758	1.000	rs915379	chr14:101689392	T/C	cg26224664	chr14:101693935	NA	-0.35	-5.36	-0.31	1.82e-7	Body mass index (alcohol intake interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27113480	chr11:33757875	CD59	0.56	6.25	0.36	1.61e-9	Gut microbiome composition (summer);
CESC	cis	rs4563143	0.663	rs73025068	chr19:29238998	G/A	cg14983838	chr19:29218262	NA	0.47	5.9	0.34	1.1e-8	Methadone dose in opioid dependence;
CESC	cis	rs11577318	0.853	rs7541333	chr1:26622889	C/T	cg00852783	chr1:26633632	UBXN11	0.5	6.98	0.39	2.31e-11	Granulocyte percentage of myeloid white cells;
CESC	cis	rs72772090	0.634	rs12186366	chr5:96088850	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.61	-5.59	-0.32	5.76e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs116095464	0.558	rs10055354	chr5:243794	G/A	cg10591111	chr5:226296	SDHA	-0.52	-6.38	-0.36	7.94e-10	Breast cancer;
CESC	cis	rs1975974	0.511	rs17052375	chr17:21743877	G/A	cg18423549	chr17:21743878	NA	-0.7	-10.07	-0.53	2.12e-20	Psoriasis;
CESC	cis	rs60871478	1.000	rs62432253	chr7:802928	A/G	cg05535760	chr7:792225	HEATR2	0.95	10.74	0.55	1.44e-22	Cerebrospinal P-tau181p levels;
CESC	cis	rs12765878	1.000	rs3850671	chr10:105659387	T/C	cg11005552	chr10:105648138	OBFC1	0.35	5.04	0.3	8.51e-7	Coronary artery disease;
CESC	cis	rs7259376	0.775	rs2360621	chr19:22548669	C/T	cg02657401	chr19:22469223	NA	-0.26	-5.23	-0.31	3.48e-7	Menopause (age at onset);
CESC	cis	rs7666738	0.830	rs9995386	chr4:98907826	T/C	cg17366294	chr4:99064904	C4orf37	0.57	7.87	0.44	9.16e-14	Colonoscopy-negative controls vs population controls;
CESC	cis	rs478304	0.903	rs61895677	chr11:65549415	T/C	cg08755490	chr11:65554678	OVOL1	0.52	6.73	0.38	1.03e-10	Acne (severe);
CESC	cis	rs6460942	0.591	rs4721079	chr7:12337742	A/G	cg20607287	chr7:12443886	VWDE	-0.59	-6.52	-0.37	3.54e-10	Coronary artery disease;
CESC	cis	rs2072732	0.861	rs66693767	chr1:2955930	A/G	cg15211996	chr1:2936768	ACTRT2	0.34	6.04	0.35	5.27e-9	Plateletcrit;
CESC	cis	rs7666738	0.791	rs6532725	chr4:99061479	T/C	cg18180107	chr4:99064573	C4orf37	0.41	5.23	0.31	3.41e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs208520	0.955	rs17644076	chr6:67004973	A/G	cg07460842	chr6:66804631	NA	-0.76	-9.13	-0.49	1.82e-17	Exhaled nitric oxide output;
CESC	cis	rs3008870	1.000	rs912797	chr1:67413478	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.06	15.19	0.68	6.65e-38	Lymphocyte percentage of white cells;
CESC	cis	rs514406	0.547	rs377808	chr1:53190359	T/G	cg08859206	chr1:53392774	SCP2	-0.57	-7.24	-0.41	4.89e-12	Monocyte count;
CESC	cis	rs6964587	0.967	rs34863529	chr7:91644341	C/G	cg17063962	chr7:91808500	NA	0.54	7.28	0.41	3.78e-12	Breast cancer;
CESC	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg10295955	chr4:187884368	NA	1.09	22.64	0.81	6.97e-64	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs5758511	0.680	rs5758681	chr22:42645091	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.57	8.53	0.46	1.12e-15	Birth weight;
CESC	cis	rs910316	0.967	rs11159116	chr14:75550584	G/T	cg11812906	chr14:75593930	NEK9	0.89	15.02	0.68	2.63e-37	Height;
CESC	cis	rs829883	0.639	rs829898	chr12:98857675	A/C	cg25150519	chr12:98850993	NA	0.87	14.78	0.67	1.88e-36	Colorectal adenoma (advanced);
CESC	cis	rs1707322	0.691	rs28495425	chr1:46187320	T/G	cg06784218	chr1:46089804	CCDC17	0.43	7.58	0.42	5.65e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7618915	0.524	rs12488461	chr3:52698417	T/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.31	5.6	0.33	5.29e-8	Bipolar disorder;
CESC	cis	rs7666738	0.791	rs34437628	chr4:99029232	C/G	cg03467027	chr4:99064603	C4orf37	0.49	6.18	0.35	2.44e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10504229	0.520	rs55967509	chr8:57992448	A/G	cg24829409	chr8:58192753	C8orf71	-0.49	-5.88	-0.34	1.21e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs9815354	0.812	rs61661916	chr3:41921915	T/C	cg03022575	chr3:42003672	ULK4	0.68	5.92	0.34	9.93e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs6933660	0.646	rs3736176	chr6:151773320	T/A	cg17179660	chr6:151773299	C6orf211;RMND1	-0.42	-5.47	-0.32	1.05e-7	Menarche (age at onset);
CESC	cis	rs7772486	0.754	rs702323	chr6:146008274	A/G	cg05347473	chr6:146136440	FBXO30	-0.53	-6.73	-0.38	1.03e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1218582	0.772	rs4845400	chr1:154872523	C/T	cg06221963	chr1:154839813	KCNN3	-0.66	-11.39	-0.57	1.03e-24	Prostate cancer;
CESC	cis	rs11122272	0.614	rs78172021	chr1:231525160	A/T	cg06096015	chr1:231504339	EGLN1	0.43	6.13	0.35	3.23e-9	Hemoglobin concentration;
CESC	cis	rs2658782	0.789	rs1456238	chr11:93117370	G/C	cg15737290	chr11:93063684	CCDC67	0.5	6.19	0.36	2.26e-9	Pulmonary function decline;
CESC	cis	rs7267979	1.000	rs2297496	chr20:25295787	T/C	cg08601574	chr20:25228251	PYGB	-0.39	-5.61	-0.33	4.99e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs2836974	0.932	rs6517527	chr21:40581751	G/A	cg11644478	chr21:40555479	PSMG1	1.02	16.31	0.71	7.16e-42	Cognitive function;
CESC	cis	rs6540559	1.000	rs742214	chr1:209960925	T/C	cg12034118	chr1:209979487	IRF6	0.46	5.63	0.33	4.54e-8	Cleft lip with or without cleft palate;
CESC	cis	rs2836950	0.545	rs1888489	chr21:40533164	T/C	cg17971929	chr21:40555470	PSMG1	-0.59	-7.89	-0.44	7.83e-14	Menarche (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03115072	chr11:207155	BET1L;RIC8A	0.55	6.46	0.37	5.04e-10	Gut microbiome composition (summer);
CESC	cis	rs4689388	0.581	rs4476672	chr4:6281496	A/G	cg25554036	chr4:6271136	WFS1	0.52	6.56	0.37	2.86e-10	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs2204008	0.837	rs55962152	chr12:38234281	G/A	cg26384229	chr12:38710491	ALG10B	0.69	9.85	0.52	1.07e-19	Bladder cancer;
CESC	cis	rs1278769	0.735	rs12585036	chr13:113535741	C/T	cg00823993	chr13:113535758	ATP11A	0.59	7.68	0.43	3e-13	Interstitial lung disease;
CESC	cis	rs67311347	1.000	rs7625736	chr3:40441345	C/G	cg09455208	chr3:40491958	NA	-0.43	-7.47	-0.42	1.14e-12	Renal cell carcinoma;
CESC	cis	rs6076065	0.748	rs6048779	chr20:23374709	C/G	cg11657817	chr20:23433608	CST11	0.4	6.06	0.35	4.71e-9	Facial morphology (factor 15, philtrum width);
CESC	cis	rs6570726	1.000	rs951143	chr6:145932576	C/T	cg23711669	chr6:146136114	FBXO30	0.71	10.56	0.54	5.7e-22	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs514406	0.565	rs897732	chr1:53382816	A/C	cg08736216	chr1:53307985	ZYG11A	-0.39	-6.65	-0.38	1.65e-10	Monocyte count;
CESC	cis	rs1832871	0.672	rs9457344	chr6:158742043	C/T	cg07165851	chr6:158734300	TULP4	0.59	6.41	0.37	6.63e-10	Height;
CESC	cis	rs11190604	0.943	rs113791644	chr10:102324330	T/G	cg07080220	chr10:102295463	HIF1AN	0.59	5.64	0.33	4.42e-8	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs9611565	0.659	rs9607815	chr22:41950671	A/T	cg03806693	chr22:41940476	POLR3H	-1.23	-16.62	-0.71	5.4e-43	Vitiligo;
CESC	cis	rs7131987	0.903	rs11050162	chr12:29420054	T/G	cg09582351	chr12:29534625	ERGIC2	-0.34	-5.39	-0.31	1.57e-7	QT interval;
CESC	cis	rs829883	0.724	rs1439774	chr12:98907692	C/T	cg25150519	chr12:98850993	NA	-0.64	-7.9	-0.44	7.53e-14	Colorectal adenoma (advanced);
CESC	cis	rs875971	1.000	rs12533997	chr7:65965377	A/G	cg12463550	chr7:65579703	CRCP	0.57	7.18	0.4	6.93e-12	Aortic root size;
CESC	cis	rs2839186	0.588	rs2839140	chr21:47616080	G/A	cg12516959	chr21:47718080	NA	0.41	5.97	0.34	7.7e-9	Testicular germ cell tumor;
CESC	cis	rs9399401	0.667	rs34018047	chr6:142790873	G/C	cg03128060	chr6:142623767	GPR126	0.31	5.15	0.3	5.12e-7	Chronic obstructive pulmonary disease;
CESC	cis	rs12477438	0.520	rs4347885	chr2:99804007	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.77	12.67	0.61	4.31e-29	Chronic sinus infection;
CESC	cis	rs35306767	0.715	rs17221463	chr10:1038040	T/C	cg25019033	chr10:957182	NA	-0.59	-5.85	-0.34	1.43e-8	Eosinophil percentage of granulocytes;
CESC	cis	rs9611565	0.559	rs739136	chr22:42100275	C/T	cg17376030	chr22:41985996	PMM1	0.73	7.76	0.43	1.89e-13	Vitiligo;
CESC	cis	rs6089584	0.566	rs6061401	chr20:60607482	G/A	cg24733560	chr20:60626293	TAF4	0.49	7.28	0.41	3.82e-12	Body mass index;
CESC	cis	rs9787249	0.957	rs3738673	chr1:40204823	C/T	cg19912559	chr1:40204330	PPIE	0.43	6.59	0.38	2.3e-10	Blood protein levels;
CESC	cis	rs875971	0.965	rs7794930	chr7:65778546	A/C	cg11764359	chr7:65958608	NA	-0.94	-15.49	-0.69	5.65e-39	Aortic root size;
CESC	cis	rs6693567	0.565	rs1260407	chr1:150306125	T/C	cg09579323	chr1:150459698	TARS2	0.49	6.28	0.36	1.35e-9	Migraine;
CESC	cis	rs7666738	0.830	rs6823718	chr4:99063202	C/T	cg17366294	chr4:99064904	C4orf37	0.62	8.8	0.48	1.82e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7666738	0.830	rs11727612	chr4:99001662	T/C	cg03467027	chr4:99064603	C4orf37	0.44	5.51	0.32	8.65e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4849845	0.637	rs2028147	chr2:121058412	C/T	cg24070213	chr2:121070622	NA	-0.4	-5.71	-0.33	3.1e-8	Mean platelet volume;
CESC	cis	rs1775715	0.835	rs1419169	chr10:32257204	C/G	cg18675610	chr10:32216311	ARHGAP12	0.32	5.11	0.3	6.16e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs12458462	0.859	rs35493271	chr18:77448793	G/T	cg11879182	chr18:77439856	CTDP1	0.87	13.93	0.65	1.87e-33	Monocyte count;
CESC	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg11494091	chr17:61959527	GH2	0.72	12.33	0.6	6.57e-28	Prudent dietary pattern;
CESC	cis	rs7795096	0.806	rs10261999	chr7:151540659	G/T	cg17008978	chr7:151542804	PRKAG2	0.39	7.25	0.41	4.53e-12	Bipolar disorder (age of onset and psychotic symptoms);
CESC	cis	rs72781680	0.898	rs12619525	chr2:23999565	G/C	cg08917208	chr2:24149416	ATAD2B	0.95	8.71	0.47	3.45e-16	Lymphocyte counts;
CESC	cis	rs6499255	0.951	rs9921045	chr16:69708698	C/T	cg15192750	chr16:69999425	NA	0.47	5.4	0.31	1.5e-7	IgE levels;
CESC	cis	rs13118159	0.550	rs4974617	chr4:1373658	T/C	cg05025164	chr4:1340916	KIAA1530	0.86	11.6	0.58	1.94e-25	Longevity;
CESC	cis	rs7116495	0.609	rs501308	chr11:71581325	C/G	cg10381502	chr11:71823885	C11orf51	1.06	7.24	0.41	4.95e-12	Severe influenza A (H1N1) infection;
CESC	cis	rs2562152	0.744	rs216597	chr16:106777	G/C	cg02949481	chr16:131562	MPG	0.55	6.14	0.35	3e-9	Glioblastoma;
CESC	cis	rs9905704	0.681	rs2108911	chr17:56570500	C/T	cg12560992	chr17:57184187	TRIM37	-0.63	-5.79	-0.34	1.99e-8	Testicular germ cell tumor;
CESC	cis	rs9796	0.621	rs1659228	chr15:41471978	A/G	cg20272979	chr15:41787780	ITPKA	0.33	5.07	0.3	7.6e-7	Menopause (age at onset);
CESC	trans	rs11098499	0.954	rs11098524	chr4:120390032	A/G	cg25214090	chr10:38739885	LOC399744	0.58	7.31	0.41	3.08e-12	Corneal astigmatism;
CESC	cis	rs1801251	0.963	rs13021246	chr2:233623111	T/C	cg08000102	chr2:233561755	GIGYF2	0.67	9.48	0.5	1.53e-18	Coronary artery disease;
CESC	cis	rs2075371	0.897	rs1646743	chr7:134003451	C/A	cg11752832	chr7:134001865	SLC35B4	0.54	7.06	0.4	1.46e-11	Mean platelet volume;
CESC	cis	rs2075371	0.897	rs1643102	chr7:133999983	T/A	cg11752832	chr7:134001865	SLC35B4	0.54	7.0	0.4	2.04e-11	Mean platelet volume;
CESC	cis	rs9362426	1.000	rs242271	chr6:88082029	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.48	5.57	0.32	6.22e-8	Depressive episodes in bipolar disorder;
CESC	cis	rs4664308	0.967	rs7563607	chr2:160910215	C/G	cg03641300	chr2:160917029	PLA2R1	-0.68	-10.17	-0.53	9.82e-21	Idiopathic membranous nephropathy;
CESC	cis	rs1552244	1.000	rs9820598	chr3:10117912	C/G	cg00166722	chr3:10149974	C3orf24	0.55	7.09	0.4	1.21e-11	Alzheimer's disease;
CESC	cis	rs6546550	0.901	rs1979214	chr2:70137498	G/C	cg02498382	chr2:70120550	SNRNP27	-0.38	-6.6	-0.38	2.18e-10	Prevalent atrial fibrillation;
CESC	cis	rs7789940	0.904	rs61294900	chr7:75937212	A/T	cg10167463	chr7:75959203	YWHAG	-0.51	-6.04	-0.35	5.31e-9	Multiple sclerosis;
CESC	cis	rs2486288	0.656	rs2461705	chr15:45570241	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.6	-6.98	-0.39	2.36e-11	Glomerular filtration rate;
CESC	cis	rs12476592	0.602	rs7570031	chr2:63792265	A/G	cg17519650	chr2:63277830	OTX1	-0.49	-5.45	-0.32	1.16e-7	Childhood ear infection;
CESC	cis	rs7666738	0.830	rs13113899	chr4:99050422	T/C	cg17366294	chr4:99064904	C4orf37	0.59	8.41	0.46	2.57e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs727505	0.954	rs2170352	chr7:124605584	G/A	cg23710748	chr7:124431027	NA	-0.45	-7.08	-0.4	1.27e-11	Lewy body disease;
CESC	cis	rs963731	0.522	rs1454225	chr2:39228632	T/G	cg04010122	chr2:39346883	SOS1	-0.69	-5.14	-0.3	5.41e-7	Corticobasal degeneration;
CESC	cis	rs514406	0.929	rs1242224	chr1:53314887	G/A	cg08736216	chr1:53307985	ZYG11A	-0.41	-6.96	-0.39	2.62e-11	Monocyte count;
CESC	cis	rs523522	0.571	rs11065120	chr12:120875456	C/T	cg12219531	chr12:120966889	COQ5	0.63	7.12	0.4	1.02e-11	High light scatter reticulocyte count;
CESC	cis	rs10911251	0.546	rs1051473	chr1:183114146	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.81	12.18	0.6	2.1e-27	Colorectal cancer;
CESC	cis	rs6460942	0.597	rs4721108	chr7:12535247	C/T	cg02935154	chr7:12443704	VWDE	-0.57	-5.7	-0.33	3.23e-8	Coronary artery disease;
CESC	cis	rs10504229	0.516	rs1866994	chr8:57990092	A/C	cg24829409	chr8:58192753	C8orf71	-0.36	-5.11	-0.3	6.21e-7	Developmental language disorder (linguistic errors);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26565578	chr12:10766330	MAGOHB	-0.55	-6.74	-0.38	9.95e-11	Gut microbiome composition (summer);
CESC	cis	rs875971	0.528	rs801213	chr7:66014918	C/T	cg18876405	chr7:65276391	NA	-0.5	-5.91	-0.34	1.05e-8	Aortic root size;
CESC	cis	rs7727544	0.735	rs272881	chr5:131669264	G/A	cg07395648	chr5:131743802	NA	-0.46	-6.06	-0.35	4.78e-9	Blood metabolite levels;
CESC	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg26354017	chr1:205819088	PM20D1	0.82	12.51	0.61	1.53e-28	Menarche (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05049681	chr22:20708652	NA	-0.56	-7.1	-0.4	1.15e-11	Gut microbiome composition (summer);
CESC	cis	rs6496667	0.533	rs7173201	chr15:90991195	A/T	cg10434728	chr15:90938212	IQGAP1	0.31	5.45	0.32	1.13e-7	Rheumatoid arthritis;
CESC	cis	rs6089829	0.962	rs6062393	chr20:61663230	G/A	cg03213289	chr20:61660250	NA	0.39	6.07	0.35	4.42e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs1983891	0.955	rs2025645	chr6:41519654	A/G	cg20194872	chr6:41519635	FOXP4	0.58	8.35	0.46	3.92e-15	Prostate cancer;
CESC	cis	rs3892630	0.878	rs6510277	chr19:33183669	C/A	cg22980127	chr19:33182716	NUDT19	1.02	11.67	0.58	1.15e-25	Red blood cell traits;
CESC	cis	rs6061231	1.000	rs11696991	chr20:60959694	G/T	cg24112000	chr20:60950667	NA	-0.67	-9.74	-0.51	2.4e-19	Colorectal cancer;
CESC	trans	rs9470794	0.790	rs10947715	chr6:38147910	C/G	cg16078060	chr6:74079719	OOEP	-0.66	-6.02	-0.35	5.82e-9	Type 2 diabetes;
CESC	cis	rs1707322	0.752	rs11211173	chr1:46219376	C/T	cg03146154	chr1:46216737	IPP	0.82	11.53	0.58	3.39e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7618915	0.570	rs4687633	chr3:52630548	G/A	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	5.66	0.33	3.97e-8	Bipolar disorder;
CESC	cis	rs3540	0.533	rs12708585	chr15:91052285	C/T	cg22089800	chr15:90895588	ZNF774	-0.63	-8.44	-0.46	2.09e-15	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs826838	0.967	rs2069211	chr12:39128892	C/T	cg13010199	chr12:38710504	ALG10B	-0.45	-6.26	-0.36	1.51e-9	Heart rate;
CESC	cis	rs2249625	0.523	rs2496552	chr6:72853042	T/C	cg18830697	chr6:72922368	RIMS1	-0.42	-6.21	-0.36	2e-9	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CESC	cis	rs7811142	0.943	rs28578163	chr7:100044754	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.83	8.17	0.45	1.25e-14	Platelet count;
CESC	cis	rs12765878	1.000	rs3814220	chr10:105647300	A/G	cg11005552	chr10:105648138	OBFC1	0.35	5.18	0.3	4.5e-7	Coronary artery disease;
CESC	cis	rs924607	1.000	rs4045344	chr5:595870	G/T	cg09021430	chr5:549028	NA	0.39	6.73	0.38	1.06e-10	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs2075371	1.000	rs2241334	chr7:133979225	C/G	cg20476274	chr7:133979776	SLC35B4	0.68	10.08	0.53	1.98e-20	Mean platelet volume;
CESC	cis	rs2777491	0.574	rs11635906	chr15:41779260	A/G	cg02330683	chr15:41787940	ITPKA	0.44	5.24	0.31	3.31e-7	Ulcerative colitis;
CESC	cis	rs11785400	1.000	rs9720653	chr8:143731939	T/G	cg10596483	chr8:143751796	JRK	0.43	5.54	0.32	7.2e-8	Schizophrenia;
CESC	cis	rs9987353	0.566	rs6998368	chr8:9070288	G/C	cg15556689	chr8:8085844	FLJ10661	-0.56	-6.41	-0.37	6.66e-10	Recombination measurement;
CESC	cis	rs2228479	0.850	rs12600051	chr16:89992072	G/T	cg00800038	chr16:89945340	TCF25	-0.92	-7.39	-0.41	1.97e-12	Skin colour saturation;
CESC	cis	rs798766	0.953	rs798751	chr4:1719572	A/G	cg07041428	chr4:1763019	NA	-0.39	-5.54	-0.32	7.44e-8	Bladder cancer;Urinary bladder cancer;
CESC	cis	rs9787249	0.957	rs56064244	chr1:40213890	C/T	cg19912559	chr1:40204330	PPIE	0.42	6.48	0.37	4.37e-10	Blood protein levels;
CESC	cis	rs9929218	0.954	rs2961	chr16:68818903	T/C	cg02972257	chr16:68554789	NA	0.47	5.64	0.33	4.46e-8	Colorectal cancer;
CESC	cis	rs9322193	0.923	rs4421206	chr6:150004027	A/C	cg07701084	chr6:150067640	NUP43	0.47	6.67	0.38	1.46e-10	Lung cancer;
CESC	cis	rs4862750	0.872	rs7671914	chr4:187878165	A/G	cg06074448	chr4:187884817	NA	-0.36	-5.21	-0.3	3.82e-7	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs3785574	0.962	rs2584630	chr17:61887561	T/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.57	7.04	0.4	1.6e-11	Height;
CESC	cis	rs853679	0.517	rs9393897	chr6:28127710	G/T	cg08968635	chr6:28129556	ZNF389	0.4	5.21	0.3	3.88e-7	Depression;
CESC	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	10.38	0.54	2.06e-21	Prudent dietary pattern;
CESC	cis	rs919433	0.963	rs13033821	chr2:198173536	T/G	cg10820045	chr2:198174542	NA	-0.38	-5.16	-0.3	4.87e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs2262909	0.962	rs7255049	chr19:22213111	A/G	cg11619707	chr19:22235551	ZNF257	-0.34	-5.8	-0.34	1.86e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
CESC	cis	rs6754311	0.597	rs2278544	chr2:136546110	A/G	cg15123519	chr2:136567270	LCT	0.31	5.22	0.31	3.65e-7	Mosquito bite size;
CESC	cis	rs9300255	0.569	rs1716170	chr12:123716513	C/T	cg00376283	chr12:123451042	ABCB9	0.72	8.89	0.48	9.37e-17	Neutrophil percentage of white cells;
CESC	cis	rs2952156	0.920	rs2952152	chr17:37832735	T/C	cg00129232	chr17:37814104	STARD3	-0.76	-10.51	-0.54	7.76e-22	Asthma;
CESC	cis	rs6582630	0.555	rs7301250	chr12:38596244	G/T	cg13010199	chr12:38710504	ALG10B	0.53	6.8	0.39	6.93e-11	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs7872515	0.838	rs7860518	chr9:94826465	C/T	cg01248375	chr9:94877805	SPTLC1	0.49	5.25	0.31	3.08e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs35110281	0.807	rs2838326	chr21:45014315	C/T	cg21573476	chr21:45109991	RRP1B	-0.43	-6.19	-0.36	2.29e-9	Mean corpuscular volume;
CESC	cis	rs10781543	0.839	rs10870071	chr9:139382184	T/C	cg14019695	chr9:139328340	INPP5E	0.35	5.31	0.31	2.29e-7	Monocyte percentage of white cells;
CESC	cis	rs9649465	0.967	rs13239184	chr7:123314618	G/T	cg04330084	chr7:123175371	IQUB	-0.38	-5.18	-0.3	4.44e-7	Migraine;
CESC	cis	rs28374715	0.662	rs522063	chr15:41476209	A/G	cg18705301	chr15:41695430	NDUFAF1	0.73	9.55	0.51	8.88e-19	Ulcerative colitis;
CESC	cis	rs3126085	0.825	rs11204933	chr1:152172185	C/T	cg26876637	chr1:152193138	HRNR	0.45	5.11	0.3	6.05e-7	Atopic dermatitis;
CESC	cis	rs113835537	0.529	rs75683511	chr11:66275026	A/G	cg22134325	chr11:66188745	NPAS4	0.45	7.09	0.4	1.2e-11	Airway imaging phenotypes;
CESC	cis	rs7937682	0.924	rs501089	chr11:111502479	G/T	cg09085632	chr11:111637200	PPP2R1B	0.98	13.74	0.65	8.22e-33	Primary sclerosing cholangitis;
CESC	cis	rs6860806	0.507	rs272854	chr5:131688017	C/T	cg24060327	chr5:131705240	SLC22A5	-0.76	-10.61	-0.55	3.71e-22	Breast cancer;
CESC	cis	rs6466055	0.777	rs2299319	chr7:104877916	C/T	cg04380332	chr7:105027541	SRPK2	-0.38	-5.11	-0.3	6.3e-7	Schizophrenia;
CESC	trans	rs9858542	0.953	rs34363169	chr3:49537712	G/A	cg21659725	chr3:3221576	CRBN	-0.55	-6.49	-0.37	4.22e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg05552183	chr6:42928497	GNMT	0.74	11.61	0.58	1.86e-25	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs873946	0.648	rs12771651	chr10:134554482	C/A	cg27286337	chr10:134555280	INPP5A	0.7	8.15	0.45	1.5e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs5769765	1.000	rs5769764	chr22:50270784	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	0.46	5.32	0.31	2.21e-7	Schizophrenia;
CESC	cis	rs4563143	0.675	rs17498203	chr19:29279734	G/T	cg04546413	chr19:29218101	NA	0.54	7.17	0.4	7.28e-12	Methadone dose in opioid dependence;
CESC	cis	rs10927875	0.578	rs10927859	chr1:16141862	C/T	cg21385522	chr1:16154831	NA	-1.03	-17.12	-0.72	9.61e-45	Dilated cardiomyopathy;
CESC	cis	rs6754311	0.597	rs6760329	chr2:136544752	A/G	cg15123519	chr2:136567270	LCT	0.3	5.24	0.31	3.25e-7	Mosquito bite size;
CESC	cis	rs8060686	0.641	rs12445533	chr16:68082527	A/G	cg26727032	chr16:67993705	SLC12A4	-0.54	-6.16	-0.35	2.65e-9	HDL cholesterol;Metabolic syndrome;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg07684353	chr15:59664799	MYO1E	-0.44	-6.17	-0.35	2.54e-9	Gambling;
CESC	cis	rs6762477	0.748	rs2073726	chr3:50223593	T/A	cg24308560	chr3:49941425	MST1R	0.4	5.12	0.3	5.76e-7	Menarche (age at onset);
CESC	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg24846343	chr22:24311635	DDTL	0.64	10.93	0.56	3.44e-23	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs35110281	0.641	rs4818858	chr21:45083097	C/T	cg21573476	chr21:45109991	RRP1B	0.57	8.15	0.45	1.43e-14	Mean corpuscular volume;
CESC	cis	rs2243480	0.706	rs6460257	chr7:65196780	C/T	cg12463550	chr7:65579703	CRCP	0.57	5.36	0.31	1.78e-7	Diabetic kidney disease;
CESC	cis	rs4555082	0.834	rs2735825	chr14:105710900	G/A	cg06808227	chr14:105710500	BRF1	-0.52	-5.7	-0.33	3.11e-8	Mean platelet volume;Platelet distribution width;
CESC	cis	rs11758351	0.660	rs11753131	chr6:26219384	G/A	cg01420254	chr6:26195488	NA	0.77	8.49	0.46	1.48e-15	Gout;Renal underexcretion gout;
CESC	cis	rs9322193	0.926	rs9766562	chr6:150109845	C/G	cg07701084	chr6:150067640	NUP43	0.43	5.74	0.33	2.56e-8	Lung cancer;
CESC	cis	rs1832871	0.672	rs1342211	chr6:158759496	G/T	cg07165851	chr6:158734300	TULP4	0.6	6.58	0.37	2.57e-10	Height;
CESC	cis	rs12711979	0.509	rs10195596	chr2:3824222	T/G	cg17052675	chr2:3827356	NA	-0.66	-11.02	-0.56	1.71e-23	Itch intensity from mosquito bite adjusted by bite size;
CESC	cis	rs7546094	1.000	rs6682737	chr1:113136229	T/C	cg22162597	chr1:113214053	CAPZA1	0.38	5.73	0.33	2.69e-8	Platelet distribution width;
CESC	cis	rs3858526	0.584	rs10742809	chr11:5862532	G/T	cg13902645	chr11:5959945	NA	0.54	7.38	0.41	2.08e-12	DNA methylation (variation);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg09658438	chr12:56693554	CS	0.48	6.28	0.36	1.37e-9	Gut microbiota (bacterial taxa);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14912727	chr1:36916005	OSCP1	0.64	7.62	0.42	4.51e-13	Gut microbiome composition (summer);
CESC	cis	rs425277	0.585	rs3107156	chr1:2060630	T/C	cg19257562	chr1:2043853	PRKCZ	0.42	6.76	0.38	8.69e-11	Height;
CESC	cis	rs9362426	1.000	rs9294377	chr6:88084839	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.48	5.98	0.34	7.16e-9	Depressive episodes in bipolar disorder;
CESC	cis	rs4665809	0.590	rs13387855	chr2:26420708	T/G	cg08470875	chr2:26401718	FAM59B	-0.73	-7.99	-0.44	4.05e-14	Gut microbiome composition (summer);
CESC	cis	rs514406	0.861	rs35517489	chr1:53304062	G/C	cg08859206	chr1:53392774	SCP2	-0.57	-7.5	-0.42	9.72e-13	Monocyte count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16727585	chr12:109592662	ACACB	0.55	6.27	0.36	1.49e-9	Gut microbiome composition (summer);
CESC	cis	rs3820928	0.874	rs55743026	chr2:227802813	G/A	cg11843606	chr2:227700838	RHBDD1	-0.42	-5.61	-0.33	5.03e-8	Pulmonary function;
CESC	cis	rs941873	0.868	rs12780295	chr10:81115438	G/A	cg08514558	chr10:81106712	PPIF	0.33	5.8	0.34	1.85e-8	Height;
CESC	cis	rs10504229	0.683	rs16921808	chr8:58106049	C/T	cg22535103	chr8:58192502	C8orf71	-0.78	-8.64	-0.47	5.58e-16	Developmental language disorder (linguistic errors);
CESC	cis	rs67311347	1.000	rs11706148	chr3:40407243	A/C	cg24209194	chr3:40518798	ZNF619	0.5	6.25	0.36	1.67e-9	Renal cell carcinoma;
CESC	cis	rs1864400	0.690	rs7098237	chr10:43740513	T/A	cg07801480	chr10:43725741	RASGEF1A	-0.41	-5.21	-0.3	3.75e-7	Hirschsprung disease;
CESC	cis	rs1152591	0.811	rs1255986	chr14:64655161	A/G	cg21174375	chr14:64681225	SYNE2	-0.48	-6.51	-0.37	3.78e-10	Atrial fibrillation;
CESC	trans	rs7246657	0.943	rs2112923	chr19:37940327	C/T	cg01833234	chr11:6592585	DNHD1	0.52	6.0	0.35	6.5e-9	Coronary artery calcification;
CESC	cis	rs35123781	1.000	rs682164	chr5:139058589	A/G	cg10513866	chr5:139070639	NA	0.36	5.29	0.31	2.55e-7	Schizophrenia;
CESC	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	22.14	0.81	3.43e-62	Prudent dietary pattern;
CESC	cis	rs2718058	0.519	rs2598054	chr7:37884640	C/T	cg24998770	chr7:37888106	TXNDC3	0.35	5.39	0.31	1.58e-7	Alzheimer's disease (late onset);
CESC	trans	rs2415984	0.811	rs7159042	chr14:46854616	T/C	cg14945696	chr3:52713679	PBRM1	-0.39	-6.05	-0.35	4.98e-9	Number of children ever born;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01512265	chr20:34359908	PHF20	-0.59	-7.14	-0.4	9.04e-12	Gut microbiome composition (summer);
CESC	cis	rs1707322	0.963	rs6429581	chr1:46319096	G/A	cg05343316	chr1:45956843	TESK2	0.49	5.96	0.34	7.98e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs6732160	0.845	rs72807999	chr2:73391695	T/C	cg01422370	chr2:73384389	NA	0.44	7.58	0.42	5.72e-13	Intelligence (multi-trait analysis);
CESC	cis	rs780096	0.526	rs809058	chr2:27616790	T/C	cg21248554	chr2:27665150	KRTCAP3	-0.34	-7.0	-0.39	2.14e-11	Total body bone mineral density;
CESC	cis	rs5758659	0.682	rs133306	chr22:42396150	G/A	cg04733989	chr22:42467013	NAGA	0.44	5.81	0.34	1.78e-8	Cognitive function;
CESC	cis	rs7833790	0.553	rs9693128	chr8:82706128	A/G	cg17211192	chr8:82754475	SNX16	-0.6	-8.07	-0.44	2.51e-14	Diastolic blood pressure;
CESC	cis	rs6714710	0.603	rs11680321	chr2:98379267	C/T	cg26665480	chr2:98280029	ACTR1B	0.54	7.64	0.42	3.91e-13	Posterior cortical atrophy and Alzheimer's disease;
CESC	cis	rs11676348	0.772	rs11676275	chr2:218944808	G/A	cg00012203	chr2:219082015	ARPC2	-0.43	-5.27	-0.31	2.8e-7	Ulcerative colitis;
CESC	cis	rs3806843	0.900	rs2531341	chr5:140130894	C/T	cg26395211	chr5:140044315	WDR55	0.39	5.09	0.3	6.79e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs11931598	0.513	rs3857170	chr4:7003366	A/T	cg19539972	chr4:7069911	GRPEL1	0.39	5.35	0.31	1.93e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
CESC	cis	rs6089584	0.606	rs2144674	chr20:60576579	G/A	cg06108461	chr20:60628389	TAF4	-0.57	-7.54	-0.42	7.57e-13	Body mass index;
CESC	cis	rs6952808	0.595	rs3778984	chr7:2166514	T/C	cg05863683	chr7:1912471	MAD1L1	0.38	5.54	0.32	7.43e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs6860806	0.507	rs2631369	chr5:131705266	G/C	cg07395648	chr5:131743802	NA	0.42	5.46	0.32	1.09e-7	Breast cancer;
CESC	cis	rs2880765	0.835	rs7169429	chr15:86036648	C/T	cg19183879	chr15:85880815	NA	-0.25	-5.18	-0.3	4.31e-7	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04784263	chr16:57318624	PLLP	0.55	6.29	0.36	1.32e-9	Gut microbiome composition (summer);
CESC	cis	rs34779708	0.931	rs13376801	chr10:35370443	T/C	cg04310649	chr10:35416472	CREM	-0.52	-6.4	-0.37	7.03e-10	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs1729951	0.575	rs10935213	chr3:136693459	A/G	cg15507776	chr3:136538369	TMEM22	0.41	5.07	0.3	7.48e-7	Neuroticism;
CESC	cis	rs17253792	0.822	rs75897560	chr14:56090965	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.79	5.91	0.34	1.06e-8	Putamen volume;
CESC	cis	rs1035144	0.510	rs12432357	chr14:81299468	A/G	cg06600135	chr14:81408086	NA	-0.58	-7.75	-0.43	2.03e-13	Male sexual orientation;
CESC	cis	rs6424115	0.830	rs2502993	chr1:24201262	A/G	cg10978503	chr1:24200527	CNR2	0.33	6.64	0.38	1.73e-10	Immature fraction of reticulocytes;
CESC	cis	rs9486715	0.838	rs4839840	chr6:96941149	T/C	cg18709589	chr6:96969512	KIAA0776	0.46	6.56	0.37	2.79e-10	Headache;
CESC	cis	rs8062405	0.965	rs56040780	chr16:28861881	C/T	cg08761264	chr16:28874980	SH2B1	-0.47	-5.85	-0.34	1.42e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs7666738	0.830	rs34135615	chr4:99001325	C/T	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.62e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs875971	1.000	rs2042133	chr7:65931922	A/G	cg12463550	chr7:65579703	CRCP	0.57	7.2	0.4	6.12e-12	Aortic root size;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg03734322	chr17:1532856	SLC43A2	0.49	6.68	0.38	1.36e-10	Systemic lupus erythematosus;
CESC	cis	rs780096	0.506	rs1728922	chr2:27644464	A/C	cg02592271	chr2:27665507	KRTCAP3	-0.28	-5.7	-0.33	3.25e-8	Total body bone mineral density;
CESC	cis	rs10208940	0.764	rs34744266	chr2:68782606	G/A	cg12452813	chr2:68675892	NA	0.52	5.16	0.3	4.88e-7	Urate levels in lean individuals;
CESC	cis	rs1018836	0.923	rs7840846	chr8:91565501	T/A	cg16814680	chr8:91681699	NA	-0.72	-10.29	-0.53	4.01e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs3733585	0.673	rs7376948	chr4:9954708	G/A	cg11266682	chr4:10021025	SLC2A9	-0.58	-10.94	-0.56	3.1e-23	Cleft plate (environmental tobacco smoke interaction);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg06544376	chr20:18548101	LOC388789	-0.53	-7.18	-0.4	6.99e-12	Fibrinogen levels;
CESC	cis	rs7188697	0.922	rs37051	chr16:58558102	C/T	cg21335942	chr16:58549945	SETD6	0.46	5.46	0.32	1.11e-7	QT interval;
CESC	cis	rs274567	0.550	rs272885	chr5:131667736	A/G	cg24060327	chr5:131705240	SLC22A5	-0.78	-10.95	-0.56	2.89e-23	Blood metabolite levels;
CESC	cis	rs7666738	0.830	rs10014986	chr4:99000687	A/C	cg03467027	chr4:99064603	C4orf37	0.44	5.51	0.32	8.65e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs75477785	0.590	rs10779521	chr1:210253508	G/C	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.95	6.41	0.37	6.82e-10	Cleft lip with or without cleft palate;
CESC	cis	rs1215050	0.791	rs649866	chr4:98738826	T/C	cg05340658	chr4:99064831	C4orf37	0.53	6.93	0.39	3.26e-11	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs96067	0.711	rs4653164	chr1:36627542	A/G	cg24686825	chr1:36642396	MAP7D1	0.42	5.61	0.33	5.18e-8	Corneal structure;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg20513643	chr12:49393348	DDN	-0.47	-6.59	-0.38	2.4e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs5758343	1	rs5758343	chr22:41816652	A/T	cg17376030	chr22:41985996	PMM1	-0.74	-7.8	-0.43	1.42e-13	Allergic disease (asthma, hay fever or eczema);
CESC	trans	rs61148964	0.826	rs11913459	chr22:37228603	G/A	cg12583095	chr10:92618141	HTR7	-0.65	-6.01	-0.35	5.96e-9	Scarlet fever;
CESC	cis	rs10189230	0.546	rs6727259	chr2:222358292	C/G	cg14652038	chr2:222343519	EPHA4	-0.3	-5.53	-0.32	7.6e-8	Urate levels in lean individuals;
CESC	cis	rs36051895	0.659	rs3780367	chr9:5068755	T/G	cg02405213	chr9:5042618	JAK2	-0.51	-6.31	-0.36	1.19e-9	Pediatric autoimmune diseases;
CESC	cis	rs12431939	0.947	rs56156789	chr14:51633899	C/G	cg23942311	chr14:51606299	NA	-0.42	-5.16	-0.3	4.89e-7	Cancer;
CESC	cis	rs16910800	0.731	rs55908012	chr11:23191640	G/A	cg20040320	chr11:23191996	NA	-0.67	-6.66	-0.38	1.53e-10	Cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22238707	chr1:28833064	SNHG3-RCC1;SNHG3	-0.57	-6.27	-0.36	1.47e-9	Gut microbiome composition (summer);
CESC	cis	rs10242455	0.702	rs73711293	chr7:99081595	C/T	cg18809830	chr7:99032528	PTCD1	-0.64	-5.07	-0.3	7.31e-7	Blood metabolite levels;
CESC	trans	rs7618501	1.000	rs3811696	chr3:49761605	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.59	-8.48	-0.46	1.62e-15	Intelligence (multi-trait analysis);
CESC	cis	rs17376456	0.542	rs10476588	chr5:93208330	C/T	cg21475434	chr5:93447410	FAM172A	-0.53	-5.33	-0.31	2.15e-7	Diabetic retinopathy;
CESC	cis	rs7605827	0.930	rs3792578	chr2:15534642	G/A	cg19274914	chr2:15703543	NA	0.35	6.39	0.37	7.22e-10	Educational attainment (years of education);
CESC	cis	rs17376456	1.000	rs66978370	chr5:93553633	G/A	cg21475434	chr5:93447410	FAM172A	0.88	7.52	0.42	8.32e-13	Diabetic retinopathy;
CESC	cis	rs6570726	0.791	rs7765687	chr6:145915100	A/C	cg23711669	chr6:146136114	FBXO30	0.88	13.21	0.63	5.75e-31	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1046896	0.586	rs9897951	chr17:80810662	T/C	cg02398342	chr17:80708632	TBCD;FN3K	0.47	5.56	0.32	6.47e-8	Glycated hemoglobin levels;
CESC	cis	rs17125944	0.505	rs77137752	chr14:53230496	G/T	cg13660082	chr14:53194042	PSMC6	-0.67	-5.98	-0.34	7.29e-9	Alzheimer's disease (late onset);
CESC	trans	rs9951602	0.512	rs12455591	chr18:76656028	A/G	cg02800362	chr5:177631904	HNRNPAB	0.64	8.39	0.46	3.02e-15	Obesity-related traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02386725	chr1:162467755	UHMK1	0.57	7.07	0.4	1.39e-11	Gut microbiome composition (summer);
CESC	cis	rs9796	0.835	rs2927062	chr15:41302687	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.4	-5.92	-0.34	1e-8	Menopause (age at onset);
CESC	cis	rs228437	1.000	rs4896083	chr6:134932535	G/A	cg24504307	chr6:134963096	NA	0.55	5.93	0.34	9.31e-9	Melanoma;
CESC	cis	rs6860806	0.661	rs2136187	chr5:131577894	T/C	cg12564285	chr5:131593104	PDLIM4	0.4	6.13	0.35	3.15e-9	Breast cancer;
CESC	cis	rs6456156	0.528	rs6936261	chr6:167469676	A/C	cg07741184	chr6:167504864	NA	0.37	6.36	0.36	8.95e-10	Primary biliary cholangitis;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg07520141	chr5:10564205	ANKRD33B	-0.45	-6.1	-0.35	3.77e-9	Height;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg02569219	chr17:2266849	SGSM2	0.47	6.34	0.36	9.84e-10	Fibrinogen levels;
CESC	cis	rs425277	0.628	rs10797427	chr1:2060732	C/T	cg23803603	chr1:2058230	PRKCZ	-0.37	-6.68	-0.38	1.43e-10	Height;
CESC	cis	rs116095464	0.558	rs6874745	chr5:264527	A/G	cg12570787	chr5:219185	SDHA;CCDC127	0.53	5.49	0.32	9.44e-8	Breast cancer;
CESC	cis	rs11971779	0.938	rs11981688	chr7:139088895	A/G	cg07862535	chr7:139043722	LUC7L2	0.56	5.74	0.33	2.63e-8	Diisocyanate-induced asthma;
CESC	cis	rs6991838	0.557	rs67685675	chr8:66486606	T/C	cg13398993	chr8:66546079	ARMC1	-0.46	-5.54	-0.32	7.22e-8	Intelligence (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08689931	chr7:86781758	DMTF1	0.55	6.52	0.37	3.52e-10	Gut microbiome composition (summer);
CESC	cis	rs7208859	0.623	rs9911490	chr17:29073013	C/T	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.1e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs6831352	0.918	rs13133633	chr4:100058697	C/G	cg13256891	chr4:100009986	ADH5	-0.77	-8.45	-0.46	1.97e-15	Alcohol dependence;
CESC	cis	rs875971	0.545	rs316328	chr7:65608838	A/G	cg19163074	chr7:65112434	INTS4L2	0.45	5.18	0.3	4.32e-7	Aortic root size;
CESC	cis	rs8072100	0.967	rs4338849	chr17:45512483	A/G	cg08085267	chr17:45401833	C17orf57	-0.52	-7.09	-0.4	1.24e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs1790761	0.505	rs4320958	chr11:67310334	G/A	cg24690094	chr11:67383802	NA	-0.32	-5.44	-0.32	1.21e-7	Mean corpuscular volume;
CESC	cis	rs11122272	0.735	rs2572251	chr1:231514243	C/T	cg06096015	chr1:231504339	EGLN1	0.43	6.18	0.35	2.46e-9	Hemoglobin concentration;
CESC	cis	rs6690583	0.697	rs10782537	chr1:85484473	C/T	cg11262906	chr1:85462892	MCOLN2	-0.55	-6.76	-0.38	8.92e-11	Serum sulfate level;
CESC	cis	rs3858526	0.584	rs10742809	chr11:5862532	G/T	cg02574844	chr11:5959923	NA	0.39	5.6	0.33	5.33e-8	DNA methylation (variation);
CESC	cis	rs9611565	0.512	rs4822052	chr22:42193741	G/A	cg06481639	chr22:41940642	POLR3H	-0.63	-6.39	-0.37	7.46e-10	Vitiligo;
CESC	cis	rs12134245	0.776	rs12124682	chr1:91995542	A/G	cg02896835	chr1:92012615	NA	-0.53	-6.82	-0.39	6.14e-11	Breast cancer;
CESC	cis	rs9399135	0.967	rs1041481	chr6:135335063	G/A	cg24558204	chr6:135376177	HBS1L	0.53	7.22	0.41	5.63e-12	Red blood cell count;
CESC	cis	rs9911578	1.000	rs2055779	chr17:57030561	A/G	cg12560992	chr17:57184187	TRIM37	0.92	15.2	0.68	5.84e-38	Intelligence (multi-trait analysis);
CESC	cis	rs60154123	0.730	rs588197	chr1:210463515	A/T	cg25204440	chr1:209979598	IRF6	0.45	5.12	0.3	5.88e-7	Coronary artery disease;
CESC	cis	rs780096	0.526	rs4582	chr2:27604279	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.28	-5.68	-0.33	3.54e-8	Total body bone mineral density;
CESC	cis	rs6088580	0.634	rs4911152	chr20:32955024	T/C	cg24642439	chr20:33292090	TP53INP2	-0.51	-6.75	-0.38	9.39e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs9858542	0.953	rs11922013	chr3:49458355	G/C	cg03060546	chr3:49711283	APEH	-0.55	-6.21	-0.36	2.08e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	trans	rs875971	0.706	rs1643374	chr7:65872682	T/A	cg26939375	chr7:64535504	NA	0.63	8.24	0.45	8.21e-15	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08321272	chr4:41992621	SLC30A9	-0.63	-7.39	-0.41	1.87e-12	Gut microbiome composition (summer);
CESC	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg12419862	chr22:24373484	LOC391322	-0.82	-12.09	-0.6	4.16e-27	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs11098499	0.954	rs11729521	chr4:120416788	T/C	cg09307838	chr4:120376055	NA	0.93	13.06	0.63	2.03e-30	Corneal astigmatism;
CESC	cis	rs7666738	0.830	rs11932887	chr4:99072965	C/G	cg24818145	chr4:99064322	C4orf37	0.4	5.04	0.3	8.69e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs12545109	0.800	rs2609978	chr8:57394467	T/C	cg09654669	chr8:57350985	NA	-0.54	-6.56	-0.37	2.86e-10	Obesity-related traits;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg00551736	chr7:151573592	PRKAG2	-0.47	-6.11	-0.35	3.59e-9	Fibrinogen levels;
CESC	cis	rs1008375	1.000	rs6849704	chr4:17652031	G/C	cg02297831	chr4:17616191	MED28	0.53	6.71	0.38	1.2e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs10088262	0.629	rs7015861	chr8:124795613	C/T	cg15047889	chr8:124780837	FAM91A1	-0.51	-6.48	-0.37	4.44e-10	Pancreatic cancer;
CESC	cis	rs10905065	0.930	rs10795485	chr10:5755047	T/C	cg11519256	chr10:5708881	ASB13	0.44	5.85	0.34	1.43e-8	Menopause (age at onset);
CESC	cis	rs7666738	0.830	rs1115616	chr4:99006603	A/C	cg05340658	chr4:99064831	C4orf37	0.8	12.44	0.61	2.83e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs875971	0.862	rs2909688	chr7:65841612	C/A	cg11764359	chr7:65958608	NA	0.78	11.28	0.57	2.25e-24	Aortic root size;
CESC	cis	rs9314323	0.535	rs1055479	chr8:26240646	A/G	cg11498726	chr8:26250323	BNIP3L	-0.41	-6.15	-0.35	2.9e-9	Red cell distribution width;
CESC	cis	rs4148883	0.675	rs11724783	chr4:100099688	C/A	cg12011299	chr4:100065546	ADH4	0.66	9.72	0.51	2.67e-19	Alcohol dependence;
CESC	cis	rs7811142	0.830	rs73401450	chr7:99981859	G/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.69	6.11	0.35	3.54e-9	Platelet count;
CESC	cis	rs2439831	1.000	rs689781	chr15:43792097	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.89	10.58	0.54	4.72e-22	Lung cancer in ever smokers;
CESC	cis	rs11048434	0.698	rs1805784	chr12:9065172	G/T	cg23795048	chr12:9217529	LOC144571	0.36	5.68	0.33	3.46e-8	Sjögren's syndrome;
CESC	cis	rs10504229	0.683	rs55986917	chr8:58137210	C/T	cg24829409	chr8:58192753	C8orf71	-0.58	-7.2	-0.4	6.31e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs7662987	0.517	rs2851265	chr4:100029684	A/G	cg13256891	chr4:100009986	ADH5	0.73	7.78	0.43	1.66e-13	Smoking initiation;
CESC	cis	rs896854	0.812	rs12546365	chr8:95911477	T/C	cg26343298	chr8:95960752	TP53INP1	0.32	5.25	0.31	3.15e-7	Type 2 diabetes;
CESC	cis	rs78456975	0.527	rs7590743	chr2:1575048	A/G	cg12573674	chr2:1569213	NA	-0.46	-5.2	-0.3	3.96e-7	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs2985684	0.947	rs1952013	chr14:50087357	C/G	cg02151108	chr14:50098012	C14orf104	-0.47	-6.09	-0.35	3.92e-9	Carotid intima media thickness;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg12121965	chr21:46293563	PTTG1IP	-0.42	-6.52	-0.37	3.49e-10	Gambling;
CESC	cis	rs9911578	1.000	rs9898626	chr17:56698219	C/G	cg12560992	chr17:57184187	TRIM37	0.93	15.58	0.69	2.6e-39	Intelligence (multi-trait analysis);
CESC	cis	rs7772486	0.738	rs75288066	chr6:146319386	C/A	cg23711669	chr6:146136114	FBXO30	0.81	11.43	0.57	7.46e-25	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9815354	1.000	rs1717017	chr3:41915616	A/C	cg03022575	chr3:42003672	ULK4	0.44	5.16	0.3	4.85e-7	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs7077164	1.000	rs1227764	chr10:71583223	G/A	cg07630274	chr10:71583235	COL13A1	-0.39	-7.33	-0.41	2.8e-12	Non-alcoholic fatty liver disease histology (lobular);
CESC	cis	rs875971	1.000	rs3735148	chr7:65971009	T/G	cg11764359	chr7:65958608	NA	0.96	15.26	0.68	3.66e-38	Aortic root size;
CESC	cis	rs3815700	1.000	rs10406750	chr19:33097144	C/T	cg02997394	chr19:33096574	ANKRD27	0.71	7.25	0.41	4.59e-12	Eosinophilic esophagitis;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg15120146	chr6:42897303	CNPY3	-0.43	-6.21	-0.36	1.98e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs1729951	0.545	rs1097288	chr3:136693721	C/T	cg04103450	chr3:136751342	NA	0.4	5.31	0.31	2.32e-7	Neuroticism;
CESC	trans	rs208520	1.000	rs208521	chr6:66953625	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.85	-9.42	-0.5	2.36e-18	Exhaled nitric oxide output;
CESC	cis	rs4268898	0.697	rs10445892	chr2:24406958	T/C	cg06627628	chr2:24431161	ITSN2	0.54	7.22	0.41	5.5e-12	Asthma;
CESC	trans	rs561341	1.000	rs693116	chr17:30246124	C/T	cg20587970	chr11:113659929	NA	-1.43	-17.6	-0.73	1.89e-46	Hip circumference adjusted for BMI;
CESC	cis	rs34375054	0.735	rs34961756	chr12:125628598	C/T	cg25124228	chr12:125621409	AACS	-0.61	-8.43	-0.46	2.2e-15	Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs7772486	0.754	rs9497401	chr6:146051271	T/C	cg05347473	chr6:146136440	FBXO30	-0.56	-7.23	-0.41	5.1e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs523522	0.962	rs2235218	chr12:120888619	A/C	cg27279351	chr12:120934652	DYNLL1	0.66	8.19	0.45	1.09e-14	High light scatter reticulocyte count;
CESC	cis	rs4665809	0.887	rs4665825	chr2:26333100	A/G	cg22920501	chr2:26401640	FAM59B	-0.67	-8.09	-0.44	2.22e-14	Gut microbiome composition (summer);
CESC	cis	rs12497850	0.931	rs6446205	chr3:49035211	C/T	cg03060546	chr3:49711283	APEH	0.47	5.68	0.33	3.6e-8	Parkinson's disease;
CESC	cis	rs6835098	1.000	rs6835098	chr4:174089238	T/C	cg08422745	chr4:174089978	GALNT7	-0.82	-12.01	-0.59	7.93e-27	Dementia and core Alzheimer's disease neuropathologic changes;
CESC	cis	rs10838687	0.736	rs7933246	chr11:47262648	G/C	cg25783544	chr11:47291846	MADD	0.57	6.63	0.38	1.91e-10	Proinsulin levels;
CESC	cis	rs7312933	0.966	rs7977365	chr12:42513127	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.44	5.75	0.33	2.48e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs6690583	0.623	rs1371140	chr1:85455362	A/C	cg22153463	chr1:85462885	MCOLN2	0.71	7.12	0.4	1.01e-11	Serum sulfate level;
CESC	cis	rs2651899	0.902	rs2742673	chr1:3080019	A/C	cg22674798	chr1:3096360	PRDM16	-0.39	-7.6	-0.42	5.07e-13	Migraine;
CESC	cis	rs1670533	0.872	rs13108222	chr4:1054256	C/A	cg27284194	chr4:1044797	NA	0.46	5.85	0.34	1.42e-8	Recombination rate (females);
CESC	cis	rs8114671	0.647	rs1124511	chr20:33736697	A/C	cg24642439	chr20:33292090	TP53INP2	0.5	6.43	0.37	5.94e-10	Height;
CESC	cis	rs854765	0.604	rs12948749	chr17:17949802	G/A	cg04398451	chr17:18023971	MYO15A	0.7	10.14	0.53	1.27e-20	Total body bone mineral density;
CESC	cis	rs4077515	1.000	rs4077515	chr9:139266496	C/T	cg14169450	chr9:139327907	INPP5E	0.36	5.24	0.31	3.35e-7	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs3806843	0.966	rs10060640	chr5:140211226	G/A	cg16179182	chr5:140090404	VTRNA1-1	-0.41	-5.26	-0.31	3.03e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs7223966	1.000	rs72848797	chr17:61934664	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.47	-5.35	-0.31	1.9e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs7107174	1.000	rs10793302	chr11:78040961	C/T	cg03754400	chr11:77348600	CLNS1A	0.43	5.06	0.3	7.72e-7	Testicular germ cell tumor;
CESC	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg03188948	chr7:1209495	NA	0.72	6.93	0.39	3.15e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs9611565	0.649	rs202657	chr22:41844786	G/T	cg06481639	chr22:41940642	POLR3H	0.58	5.81	0.34	1.75e-8	Vitiligo;
CESC	cis	rs9649213	0.593	rs11766808	chr7:97915376	A/G	cg24562669	chr7:97807699	LMTK2	0.47	6.73	0.38	1.07e-10	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02632015	chr17:19551762	ALDH3A2	0.56	6.32	0.36	1.1e-9	Gut microbiome composition (summer);
CESC	cis	rs826838	1.000	rs11168505	chr12:38939057	A/T	cg13010199	chr12:38710504	ALG10B	-0.57	-8.21	-0.45	9.74e-15	Heart rate;
CESC	cis	rs68170813	0.559	rs1002935	chr7:106832361	G/A	cg02696742	chr7:106810147	HBP1	-0.55	-5.3	-0.31	2.42e-7	Coronary artery disease;
CESC	cis	rs938554	0.657	rs9994216	chr4:9984541	G/T	cg11266682	chr4:10021025	SLC2A9	0.39	5.85	0.34	1.45e-8	Blood metabolite levels;
CESC	cis	rs9581857	0.685	rs9581856	chr13:28025615	G/C	cg01674679	chr13:27998804	GTF3A	-0.67	-5.29	-0.31	2.58e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
CESC	cis	rs13191362	1.000	rs34931503	chr6:163003876	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.88	9.16	0.49	1.46e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs34779708	0.931	rs34954932	chr10:35410807	G/T	cg04310649	chr10:35416472	CREM	-0.53	-6.54	-0.37	3.07e-10	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs3820928	0.874	rs55748731	chr2:227818629	C/A	cg11843606	chr2:227700838	RHBDD1	-0.41	-5.5	-0.32	9.06e-8	Pulmonary function;
CESC	cis	rs2204008	0.694	rs1672436	chr12:38132547	G/T	cg26384229	chr12:38710491	ALG10B	-0.44	-5.99	-0.35	6.87e-9	Bladder cancer;
CESC	trans	rs11088226	0.681	rs2833912	chr21:33949822	G/A	cg09050820	chr6:167586206	TCP10L2	0.96	10.31	0.54	3.58e-21	Gastritis;
CESC	cis	rs1008375	0.932	rs13134570	chr4:17692863	C/T	cg02297831	chr4:17616191	MED28	-0.58	-6.83	-0.39	5.83e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs7219021	0.705	rs962273	chr17:46978353	T/C	cg16584676	chr17:46985605	UBE2Z	0.66	8.32	0.46	4.68e-15	Schizophrenia or bipolar disorder;
CESC	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.44	-5.99	-0.35	6.8e-9	Lymphocyte counts;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg26685501	chr1:38019921	SNIP1	-0.46	-6.7	-0.38	1.27e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs898097	0.578	rs8069697	chr17:80908110	T/C	cg19046167	chr17:80928561	B3GNTL1	0.41	5.48	0.32	9.72e-8	Breast cancer;
CESC	cis	rs17401966	0.898	rs11582123	chr1:10303942	A/T	cg15208524	chr1:10270712	KIF1B	0.41	5.34	0.31	1.95e-7	Hepatocellular carcinoma;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03274117	chr8:56686508	TMEM68;TGS1	-0.57	-6.95	-0.39	2.87e-11	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12733907	chr3:57261991	APPL1	0.54	6.45	0.37	5.4e-10	Gut microbiome composition (summer);
CESC	cis	rs1552244	0.882	rs9757159	chr3:10039166	C/T	cg00166722	chr3:10149974	C3orf24	0.48	5.98	0.34	7.06e-9	Alzheimer's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00762468	chr16:103568	POLR3K;SNRNP25	0.6	7.24	0.41	4.77e-12	Gut microbiome composition (summer);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg04653776	chr20:32399093	CHMP4B	-0.47	-6.46	-0.37	5.01e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs9733	0.596	rs6661872	chr1:150628357	C/G	cg18016565	chr1:150552671	MCL1	0.33	5.13	0.3	5.67e-7	Tonsillectomy;
CESC	cis	rs617791	0.530	rs7934543	chr11:65752508	G/T	cg04055107	chr11:65626734	MUS81;CFL1	-0.44	-5.04	-0.3	8.66e-7	Breast cancer;
CESC	cis	rs561341	1.000	rs1681718	chr17:30296445	G/A	cg19193384	chr17:30244184	NA	-0.68	-6.43	-0.37	5.9e-10	Hip circumference adjusted for BMI;
CESC	cis	rs1005277	0.540	rs4934907	chr10:38015230	A/C	cg25427524	chr10:38739819	LOC399744	-0.64	-9.43	-0.5	2.21e-18	Extrinsic epigenetic age acceleration;
CESC	cis	rs6685188	0.920	rs10751444	chr1:205662144	A/G	cg17178900	chr1:205818956	PM20D1	-0.39	-5.32	-0.31	2.2e-7	White blood cell count (basophil);Basophil percentage of white cells;
CESC	cis	rs2708240	1.000	rs2538991	chr7:147579619	A/C	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.36	-6.05	-0.35	4.82e-9	QT interval (drug interaction);
CESC	cis	rs977987	0.843	rs12443834	chr16:75438469	C/T	cg03315344	chr16:75512273	CHST6	0.41	5.86	0.34	1.35e-8	Dupuytren's disease;
CESC	cis	rs7666738	0.830	rs10050008	chr4:99025313	T/G	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.58e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7666738	0.830	rs60411337	chr4:99046617	T/C	cg24818145	chr4:99064322	C4orf37	0.38	5.04	0.3	8.49e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs67311347	0.822	rs9826847	chr3:40345312	A/T	cg24209194	chr3:40518798	ZNF619	0.42	5.23	0.31	3.41e-7	Renal cell carcinoma;
CESC	cis	rs9443645	0.527	rs10943595	chr6:79575291	C/G	cg05283184	chr6:79620031	NA	-0.36	-5.1	-0.3	6.62e-7	Intelligence (multi-trait analysis);
CESC	cis	rs10504229	0.911	rs77203035	chr8:58175458	C/A	cg05313129	chr8:58192883	C8orf71	-0.55	-6.37	-0.36	8.42e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs6460942	0.915	rs62448594	chr7:12442229	C/G	cg06484146	chr7:12443880	VWDE	-0.78	-9.1	-0.49	2.28e-17	Coronary artery disease;
CESC	cis	rs617791	0.530	rs7952056	chr11:65744597	C/T	cg04055107	chr11:65626734	MUS81;CFL1	-0.45	-5.1	-0.3	6.46e-7	Breast cancer;
CESC	cis	rs7208859	0.673	rs56146117	chr17:29153325	C/T	cg19761014	chr17:28927070	LRRC37B2	0.74	6.03	0.35	5.43e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs9815354	0.812	rs60659106	chr3:41949569	G/C	cg03022575	chr3:42003672	ULK4	0.71	6.45	0.37	5.42e-10	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs875971	1.000	rs4717300	chr7:65947380	T/C	cg12463550	chr7:65579703	CRCP	0.56	7.06	0.4	1.47e-11	Aortic root size;
CESC	cis	rs8141529	0.748	rs2064261	chr22:29287730	C/T	cg15103426	chr22:29168792	CCDC117	0.6	7.65	0.43	3.63e-13	Lymphocyte counts;
CESC	cis	rs7084402	0.967	rs2577392	chr10:60329183	A/G	cg07615347	chr10:60278583	BICC1	0.59	9.18	0.49	1.26e-17	Refractive error;
CESC	cis	rs901683	1.000	rs9422651	chr10:46047456	C/T	cg16031567	chr10:46195673	NA	-0.74	-5.03	-0.3	8.96e-7	Red blood cell traits;Mean corpuscular volume;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg00469508	chr10:112327249	SMC3	-0.49	-6.45	-0.37	5.23e-10	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04867738	chr17:42298359	UBTF	0.55	6.05	0.35	4.81e-9	Gut microbiome composition (summer);
CESC	cis	rs477895	0.653	rs2015226	chr11:63902534	C/T	cg04317338	chr11:64019027	PLCB3	0.87	9.06	0.49	3.04e-17	Mean platelet volume;
CESC	cis	rs11252926	1.000	rs11252926	chr10:566379	C/T	cg18196295	chr10:418757	DIP2C	-0.51	-6.01	-0.35	6.01e-9	Psychosis in Alzheimer's disease;
CESC	cis	rs7216064	1.000	rs6504548	chr17:65886048	T/C	cg07042672	chr17:66097459	LOC651250	-0.63	-7.44	-0.42	1.38e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs4819052	0.851	rs914218	chr21:46698445	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.92	13.65	0.64	1.68e-32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs4704187	0.687	rs9654426	chr5:74466737	C/T	cg03227963	chr5:74354835	NA	0.29	5.28	0.31	2.67e-7	Response to amphetamines;
CESC	cis	rs12926788	0.689	rs1862450	chr16:24856775	A/G	cg06505273	chr16:24850292	NA	-0.47	-5.36	-0.31	1.79e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs1538970	0.924	rs1007858	chr1:45912005	C/T	cg03146154	chr1:46216737	IPP	0.46	5.34	0.31	1.97e-7	Platelet count;
CESC	trans	rs11039798	0.687	rs11499938	chr11:48957297	G/A	cg15704280	chr7:45808275	SEPT13	0.71	6.63	0.38	1.91e-10	Axial length;
CESC	cis	rs2239547	0.522	rs6792578	chr3:53004604	G/A	cg11645453	chr3:52864694	ITIH4	0.33	5.49	0.32	9.5e-8	Schizophrenia;
CESC	trans	rs208520	0.802	rs208496	chr6:66930786	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.86	-9.98	-0.52	4.07e-20	Exhaled nitric oxide output;
CESC	cis	rs6952808	0.601	rs3778978	chr7:2159817	A/G	cg21782813	chr7:2030301	MAD1L1	0.5	7.26	0.41	4.36e-12	Bipolar disorder and schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26591221	chr16:88942335	CBFA2T3	-0.58	-6.84	-0.39	5.36e-11	Gut microbiome composition (summer);
CESC	cis	rs36051895	0.659	rs72701605	chr9:5062056	G/A	cg02405213	chr9:5042618	JAK2	-0.5	-6.13	-0.35	3.19e-9	Pediatric autoimmune diseases;
CESC	trans	rs7819412	0.806	rs6980856	chr8:10938260	A/G	cg15556689	chr8:8085844	FLJ10661	0.52	6.45	0.37	5.2400000000000005e-10	Triglycerides;
CESC	cis	rs6963495	0.818	rs6961863	chr7:105180953	C/T	cg02135003	chr7:105160482	PUS7	-0.42	-5.42	-0.32	1.34e-7	Bipolar disorder (body mass index interaction);
CESC	trans	rs9858542	1.000	rs1131095	chr3:49714225	T/C	cg21659725	chr3:3221576	CRBN	-0.55	-6.72	-0.38	1.11e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs11997175	0.625	rs7460540	chr8:33597907	A/G	ch.8.33884649F	chr8:33765107	NA	0.51	6.29	0.36	1.34e-9	Body mass index;
CESC	cis	rs34172651	0.517	rs12920774	chr16:24830750	T/C	cg04756594	chr16:24857601	SLC5A11	0.49	5.63	0.33	4.68e-8	Intelligence (multi-trait analysis);
CESC	cis	rs7481584	0.624	rs440130	chr11:3051476	A/G	cg08508325	chr11:3079039	CARS	0.29	5.17	0.3	4.6e-7	Calcium levels;
CESC	cis	rs9457247	1.000	rs397713	chr6:167386714	G/A	cg23791538	chr6:167370224	RNASET2	-0.6	-8.65	-0.47	4.96e-16	Crohn's disease;
CESC	cis	rs72781680	0.821	rs17038360	chr2:24095798	A/G	cg08917208	chr2:24149416	ATAD2B	0.58	5.81	0.34	1.82e-8	Lymphocyte counts;
CESC	cis	rs780096	0.546	rs2293571	chr2:27729480	C/T	cg22903471	chr2:27725779	GCKR	-0.47	-6.58	-0.37	2.51e-10	Total body bone mineral density;
CESC	cis	rs4330281	0.765	rs13079096	chr3:17795076	T/A	cg20981856	chr3:17787350	NA	0.36	5.21	0.3	3.79e-7	Schizophrenia;
CESC	cis	rs9393777	0.513	rs1104871	chr6:26665235	T/G	cg14345882	chr6:26364793	BTN3A2	0.41	5.25	0.31	3.16e-7	Intelligence (multi-trait analysis);
CESC	cis	rs514406	0.825	rs497535	chr1:53284677	A/G	cg08736216	chr1:53307985	ZYG11A	0.43	7.16	0.4	7.72e-12	Monocyte count;
CESC	cis	rs870825	0.549	rs7656993	chr4:185635159	T/C	cg04058563	chr4:185651563	MLF1IP	0.63	6.89	0.39	3.95e-11	Blood protein levels;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg04873026	chr21:30365177	RNF160	-0.47	-6.47	-0.37	4.76e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs861020	0.630	rs9308411	chr1:210005713	C/T	cg05527609	chr1:210001259	C1orf107	0.72	9.81	0.52	1.35e-19	Orofacial clefts;
CESC	cis	rs7191439	0.858	rs8044367	chr16:88783374	A/G	cg02389323	chr16:88786976	FAM38A	0.85	6.44	0.37	5.49e-10	Plateletcrit;
CESC	cis	rs4253772	0.591	rs6519993	chr22:46656479	A/G	cg10231785	chr22:46692440	CN5H6.4;GTSE1	0.48	5.08	0.3	7.09e-7	LDL cholesterol;Cholesterol, total;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08928321	chr10:70748447	KIAA1279	-0.61	-7.62	-0.42	4.61e-13	Gut microbiome composition (summer);
CESC	cis	rs763121	0.853	rs138705	chr22:39133803	C/T	cg14440974	chr22:39074834	NA	-0.39	-5.42	-0.32	1.36e-7	Menopause (age at onset);
CESC	trans	rs35110281	0.720	rs162400	chr21:44950305	A/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.54	7.35	0.41	2.5e-12	Mean corpuscular volume;
CESC	cis	rs6933660	0.800	rs9383893	chr6:151757327	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.85	14.3	0.66	9.42e-35	Menarche (age at onset);
CESC	cis	rs763121	0.819	rs5757237	chr22:39073835	G/C	cg06544989	chr22:39130855	UNC84B	0.51	8.92	0.48	7.61e-17	Menopause (age at onset);
CESC	cis	rs2840044	0.517	rs2124247	chr17:33885468	G/A	cg05299278	chr17:33885742	SLFN14	0.42	5.95	0.34	8.56e-9	Response to radiotherapy in cancer (late toxicity);
CESC	cis	rs2637266	1.000	rs34483246	chr10:78342790	G/A	cg18941641	chr10:78392320	NA	0.41	7.78	0.43	1.65e-13	Pulmonary function;
CESC	cis	rs6076065	0.925	rs2281430	chr20:23399314	T/C	cg12062639	chr20:23401060	NAPB	0.41	5.08	0.3	7.25e-7	Facial morphology (factor 15, philtrum width);
CESC	cis	rs888194	0.677	rs2075431	chr12:109874621	C/T	cg19025524	chr12:109796872	NA	-0.41	-6.14	-0.35	3.08e-9	Neuroticism;
CESC	cis	rs72634258	0.786	rs9434992	chr1:8179392	G/T	cg00042356	chr1:8021962	PARK7	0.5	5.43	0.32	1.29e-7	Inflammatory bowel disease;
CESC	cis	rs6691722	0.506	rs12030365	chr1:24739220	T/A	cg02336364	chr1:24764700	NIPAL3	0.31	6.14	0.35	2.99e-9	Response to interferon beta in multiple sclerosis;
CESC	cis	rs6547741	1.000	rs1080060	chr2:27768808	T/A	cg21248554	chr2:27665150	KRTCAP3	0.25	5.21	0.31	3.71e-7	Oral cavity cancer;
CESC	cis	rs9611565	0.729	rs4822027	chr22:41786227	G/A	cg06481639	chr22:41940642	POLR3H	-0.63	-6.57	-0.37	2.63e-10	Vitiligo;
CESC	cis	rs896854	0.818	rs896855	chr8:95959808	A/G	cg23172400	chr8:95962367	TP53INP1	-0.46	-9.8	-0.52	1.55e-19	Type 2 diabetes;
CESC	cis	rs5753618	0.561	rs2040533	chr22:31679110	G/C	cg13145458	chr22:31556086	RNF185	0.48	5.38	0.31	1.61e-7	Colorectal cancer;
CESC	cis	rs10504073	0.565	rs35282337	chr8:49920994	G/A	cg00325661	chr8:49890786	NA	0.53	7.95	0.44	5.42e-14	Blood metabolite ratios;
CESC	cis	rs9640161	0.789	rs4554381	chr7:150025567	G/A	cg13722127	chr7:150037890	RARRES2	0.34	5.21	0.3	3.76e-7	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs11098499	0.662	rs13108589	chr4:120268102	G/C	cg09307838	chr4:120376055	NA	0.81	10.78	0.55	1.07e-22	Corneal astigmatism;
CESC	cis	rs7619708	1	rs7619708	chr3:195810187	T/C	cg12923728	chr3:195709715	SDHAP1	0.58	5.99	0.35	6.77e-9	Red cell distribution width;
CESC	cis	rs7927771	0.507	rs10838754	chr11:47758532	A/C	cg18512352	chr11:47633146	NA	0.36	5.58	0.32	6.08e-8	Subjective well-being;
CESC	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg12419862	chr22:24373484	LOC391322	-0.66	-9.06	-0.49	3.02e-17	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs4076764	0.830	rs10917770	chr1:163442214	G/C	cg24596788	chr1:163392923	NA	-0.47	-6.94	-0.39	3.08e-11	Motion sickness;
CESC	cis	rs7809950	0.954	rs3779494	chr7:107250355	G/A	cg23024343	chr7:107201750	COG5	0.45	6.26	0.36	1.58e-9	Coronary artery disease;
CESC	trans	rs7618501	0.699	rs2681780	chr3:49897830	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.48	6.64	0.38	1.81e-10	Intelligence (multi-trait analysis);
CESC	cis	rs962856	1.000	rs962856	chr2:67593803	C/T	cg09028215	chr2:67624308	ETAA1	-0.41	-5.43	-0.32	1.3e-7	Pancreatic cancer;
CESC	cis	rs2576037	0.583	rs616900	chr18:44410849	T/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.53	-7.26	-0.41	4.25e-12	Personality dimensions;
CESC	cis	rs425277	1.000	rs12401379	chr1:2058580	G/C	cg24578937	chr1:2090814	PRKCZ	0.54	9.0	0.48	4.48e-17	Height;
CESC	cis	rs17253792	0.822	rs74051609	chr14:56171132	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.64	5.08	0.3	7.04e-7	Putamen volume;
CESC	cis	rs9513593	1.000	rs7331894	chr13:99852952	C/T	cg21788972	chr13:99853209	UBAC2	0.61	6.81	0.39	6.58e-11	Psoriasis;
CESC	cis	rs79349575	0.756	rs2643361	chr17:46977462	T/G	cg16584676	chr17:46985605	UBE2Z	0.53	6.58	0.37	2.57e-10	Type 2 diabetes;
CESC	cis	rs6860806	0.507	rs272882	chr5:131669161	G/T	cg18758796	chr5:131593413	PDLIM4	0.38	5.17	0.3	4.59e-7	Breast cancer;
CESC	cis	rs2230307	0.536	rs490669	chr1:100484430	C/T	cg24955406	chr1:100503596	HIAT1	0.54	5.44	0.32	1.19e-7	Carotid intima media thickness;
CESC	cis	rs9660180	0.967	rs6603803	chr1:1812688	A/G	cg17747265	chr1:1875780	NA	-0.58	-9.43	-0.5	2.13e-18	Body mass index;
CESC	trans	rs17685	0.712	rs6976236	chr7:75741087	G/T	cg19862616	chr7:65841803	NCRNA00174	0.83	11.95	0.59	1.29e-26	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs6693567	0.565	rs471738	chr1:150276429	G/A	cg09579323	chr1:150459698	TARS2	-0.47	-6.06	-0.35	4.7e-9	Migraine;
CESC	cis	rs1950626	0.671	rs34675695	chr14:101447913	C/T	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.81	10.41	0.54	1.64e-21	Pelvic organ prolapse (moderate/severe);
CESC	cis	rs7666738	0.830	rs13138051	chr4:99050367	C/T	cg03467027	chr4:99064603	C4orf37	0.47	5.98	0.34	7.19e-9	Colonoscopy-negative controls vs population controls;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg10436540	chr17:4047319	ZZEF1;CYB5D2	-0.43	-6.14	-0.35	3.06e-9	Gambling;
CESC	cis	rs4629180	0.675	rs10195061	chr2:102093974	T/G	cg04415270	chr2:102091202	RFX8	-0.32	-5.46	-0.32	1.09e-7	Chronic rhinosinusitis with nasal polyps;
CESC	cis	rs2262909	0.566	rs10419058	chr19:22309972	A/C	cg07498013	chr19:22123504	NA	-0.32	-5.09	-0.3	6.66e-7	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
CESC	cis	rs938554	0.577	rs7683856	chr4:10000947	A/G	cg11266682	chr4:10021025	SLC2A9	0.46	6.2	0.36	2.11e-9	Blood metabolite levels;
CESC	cis	rs258892	0.947	rs34955	chr5:72203628	T/C	cg21869765	chr5:72125136	TNPO1	0.44	5.58	0.32	6e-8	Small cell lung carcinoma;
CESC	cis	rs9486719	1.000	rs4262195	chr6:96929475	T/C	cg06623918	chr6:96969491	KIAA0776	-0.81	-8.3	-0.45	5.45e-15	Migraine;Coronary artery disease;
CESC	cis	rs4319547	0.794	rs61954972	chr12:123074167	T/G	cg23029597	chr12:123009494	RSRC2	-0.49	-5.41	-0.32	1.41e-7	Body mass index;
CESC	cis	rs6831352	0.918	rs2213035	chr4:100064233	G/A	cg13256891	chr4:100009986	ADH5	-0.73	-7.79	-0.43	1.52e-13	Alcohol dependence;
CESC	cis	rs1008375	1.000	rs10939740	chr4:17617490	T/C	cg16339924	chr4:17578868	LAP3	0.67	8.27	0.45	6.7e-15	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs765787	0.530	rs11070445	chr15:45513163	T/A	cg24006582	chr15:45444508	DUOX1	0.54	6.54	0.37	3.12e-10	Uric acid levels;
CESC	cis	rs2742234	0.541	rs7073849	chr10:43740474	G/C	cg07801480	chr10:43725741	RASGEF1A	-0.41	-5.21	-0.3	3.75e-7	Hirschsprung disease;
CESC	cis	rs4555082	0.874	rs2816612	chr14:105723103	C/T	cg10792982	chr14:105748885	BRF1	0.41	5.26	0.31	2.96e-7	Mean platelet volume;Platelet distribution width;
CESC	cis	rs4332037	0.539	rs868754	chr7:2033780	G/C	cg23422044	chr7:1970798	MAD1L1	-0.49	-5.07	-0.3	7.48e-7	Bipolar disorder;
CESC	cis	rs793571	0.502	rs411007	chr15:59078502	G/C	cg05156742	chr15:59063176	FAM63B	0.78	11.12	0.56	8e-24	Schizophrenia;
CESC	cis	rs12950390	0.853	rs56363619	chr17:45854621	T/C	cg00777063	chr17:45855553	NA	-0.39	-5.78	-0.33	2.05e-8	IgG glycosylation;
CESC	cis	rs6952808	0.609	rs12699453	chr7:1953056	C/T	cg04267008	chr7:1944627	MAD1L1	-0.63	-8.2	-0.45	1.05e-14	Bipolar disorder and schizophrenia;
CESC	cis	rs8070740	0.898	rs4578712	chr17:5324431	G/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.51	6.35	0.36	9.3e-10	Menopause (age at onset);
CESC	cis	rs7649275	0.882	rs7373113	chr3:53790054	A/C	cg21503701	chr3:53781065	CACNA1D	-0.4	-5.03	-0.3	8.95e-7	Trans fatty acid levels;
CESC	cis	rs662064	0.692	rs12129512	chr1:10572967	G/T	cg20482658	chr1:10539492	PEX14	0.33	5.61	0.33	5.13e-8	Asthma;
CESC	cis	rs10504229	0.683	rs55645894	chr8:58116145	A/G	cg24829409	chr8:58192753	C8orf71	-0.58	-7.2	-0.4	6.31e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs2354432	0.607	rs6677679	chr1:146803630	C/T	cg25205988	chr1:146714368	CHD1L	-1.03	-9.0	-0.48	4.56e-17	Mitochondrial DNA levels;
CESC	cis	rs7246657	0.882	rs6508719	chr19:37877419	A/G	cg23950597	chr19:37808831	NA	-0.55	-6.05	-0.35	4.84e-9	Coronary artery calcification;
CESC	cis	rs7618915	0.501	rs13060048	chr3:52598608	G/A	cg18099408	chr3:52552593	STAB1	-0.36	-6.09	-0.35	4.06e-9	Bipolar disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03920172	chr3:170075494	SKIL	-0.54	-6.72	-0.38	1.11e-10	Gut microbiome composition (summer);
CESC	cis	rs9494142	0.592	rs1547247	chr6:135390836	C/T	cg24558204	chr6:135376177	HBS1L	0.59	7.0	0.39	2.13e-11	Lymphocyte counts;Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs4665809	0.941	rs6735145	chr2:26270302	T/C	cg04944784	chr2:26401820	FAM59B	-0.68	-7.71	-0.43	2.47e-13	Gut microbiome composition (summer);
CESC	cis	rs4654899	0.772	rs10916892	chr1:21201325	A/G	cg05370193	chr1:21551575	ECE1	0.36	5.2	0.3	4e-7	Superior frontal gyrus grey matter volume;
CESC	cis	rs9828933	0.577	rs704374	chr3:63865947	C/T	cg16258503	chr3:63850278	ATXN7;THOC7	0.9	8.91	0.48	8.43e-17	Type 2 diabetes;
CESC	cis	rs2204008	0.805	rs11522896	chr12:38234427	T/C	cg13010199	chr12:38710504	ALG10B	0.52	6.43	0.37	5.91e-10	Bladder cancer;
CESC	cis	rs9300255	0.566	rs1716169	chr12:123716930	A/T	cg00376283	chr12:123451042	ABCB9	0.6	6.2	0.36	2.1e-9	Neutrophil percentage of white cells;
CESC	cis	rs9611565	0.694	rs202665	chr22:41814401	A/G	cg06481639	chr22:41940642	POLR3H	0.61	6.41	0.37	6.55e-10	Vitiligo;
CESC	cis	rs6866344	0.697	rs56159071	chr5:178127246	T/A	cg10224037	chr5:178157518	ZNF354A	0.67	7.37	0.41	2.13e-12	Neutrophil percentage of white cells;
CESC	cis	rs3749237	0.636	rs1568662	chr3:49521263	A/G	cg07636037	chr3:49044803	WDR6	0.6	8.72	0.47	3.04e-16	Resting heart rate;
CESC	cis	rs11077998	1.000	rs11077998	chr17:80483946	C/G	cg10255544	chr17:80519551	FOXK2	-0.55	-8.93	-0.48	7.08e-17	Reticulocyte fraction of red cells;
CESC	trans	rs10242455	0.702	rs6974831	chr7:99131605	A/G	cg09045935	chr12:6379348	NA	0.91	7.48	0.42	1.07e-12	Blood metabolite levels;
CESC	cis	rs9467711	0.524	rs13216484	chr6:26762087	C/T	cg14345882	chr6:26364793	BTN3A2	0.64	5.81	0.34	1.8e-8	Autism spectrum disorder or schizophrenia;
CESC	cis	rs9894429	0.646	rs12948797	chr17:79617384	G/A	cg21984481	chr17:79567631	NPLOC4	-0.33	-5.08	-0.3	7.26e-7	Eye color traits;
CESC	cis	rs1499972	0.618	rs62264769	chr3:117643464	A/T	cg07612923	chr3:117604196	NA	0.69	6.32	0.36	1.12e-9	Schizophrenia;
CESC	cis	rs116161686	0.500	rs76610459	chr1:210050756	T/G	cg23283495	chr1:209979779	IRF6	0.48	5.28	0.31	2.71e-7	Coronary artery disease;
CESC	cis	rs72781680	0.611	rs72781692	chr2:24263319	T/G	cg20701182	chr2:24300061	SF3B14	0.93	10.41	0.54	1.73e-21	Lymphocyte counts;
CESC	trans	rs7656342	0.808	rs10003216	chr4:9766749	A/G	cg23522832	chr1:45769727	LOC400752	-0.49	-6.03	-0.35	5.48e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs10979	0.631	rs12530338	chr6:143872563	C/T	cg25407410	chr6:143891975	LOC285740	-0.4	-5.38	-0.31	1.62e-7	Hypospadias;
CESC	cis	rs875971	0.660	rs1860468	chr7:66107252	T/C	cg25985355	chr7:65971099	NA	0.31	5.3	0.31	2.38e-7	Aortic root size;
CESC	cis	rs7523050	0.643	rs34801874	chr1:109404382	C/T	cg08274380	chr1:109419600	GPSM2	0.85	5.82	0.34	1.74e-8	Fat distribution (HIV);
CESC	cis	rs1448094	0.845	rs17354637	chr12:86347752	A/G	cg02569458	chr12:86230093	RASSF9	0.38	5.5	0.32	8.85e-8	Major depressive disorder;
CESC	cis	rs875971	1.000	rs6970030	chr7:65968679	T/C	cg12463550	chr7:65579703	CRCP	0.56	7.07	0.4	1.39e-11	Aortic root size;
CESC	cis	rs10504229	0.953	rs17805380	chr8:58171128	C/A	cg24829409	chr8:58192753	C8orf71	-0.76	-10.0	-0.52	3.53e-20	Developmental language disorder (linguistic errors);
CESC	trans	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg07870213	chr5:140052090	DND1	0.63	7.17	0.4	7.55e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs12347191	0.500	rs907579	chr9:100622723	G/T	cg13688889	chr9:100608707	NA	-0.89	-13.0	-0.62	3.11e-30	Orofacial clefts;
CESC	cis	rs7017914	0.967	rs7001162	chr8:71587470	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.09	-0.3	6.93e-7	Bone mineral density;
CESC	cis	rs6088580	0.609	rs6059845	chr20:33036500	G/A	cg06115741	chr20:33292138	TP53INP2	0.46	5.99	0.35	6.73e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs7945705	0.967	rs56316046	chr11:8876598	G/T	cg09997546	chr11:8931473	C11orf17;ST5	0.35	5.72	0.33	2.82e-8	Hemoglobin concentration;
CESC	cis	rs4665809	0.590	rs4665313	chr2:26415897	A/G	cg22920501	chr2:26401640	FAM59B	-0.84	-9.82	-0.52	1.26e-19	Gut microbiome composition (summer);
CESC	cis	rs3008870	1.000	rs11208976	chr1:67434411	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-1.06	-15.19	-0.68	6.65e-38	Lymphocyte percentage of white cells;
CESC	cis	rs6952808	0.792	rs2056478	chr7:1953897	C/T	cg21782813	chr7:2030301	MAD1L1	0.42	5.89	0.34	1.2e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs9457247	1.000	rs408087	chr6:167398952	C/T	cg23791538	chr6:167370224	RNASET2	-0.57	-8.06	-0.44	2.59e-14	Crohn's disease;
CESC	cis	rs798554	0.759	rs1636255	chr7:2892804	A/C	cg04166393	chr7:2884313	GNA12	-0.62	-8.3	-0.45	5.27e-15	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05287481	chr11:17249967	NA	-0.58	-6.75	-0.38	9.37e-11	Gut microbiome composition (summer);
CESC	cis	rs9902453	0.715	rs2628176	chr17:28139292	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.72	-9.41	-0.5	2.5e-18	Coffee consumption (cups per day);
CESC	cis	rs6502050	0.835	rs7221451	chr17:80089785	A/G	cg01763666	chr17:80159506	CCDC57	-0.37	-5.26	-0.31	2.95e-7	Life satisfaction;
CESC	cis	rs4790312	0.748	rs4790873	chr17:1994966	G/T	cg20777128	chr17:1945076	DPH1;OVCA2	-0.39	-5.13	-0.3	5.72e-7	Left atrial antero-posterior diameter;
CESC	cis	rs637571	0.544	rs56239996	chr11:65730003	A/T	cg02202077	chr11:65769826	EIF1AD;BANF1	0.48	6.28	0.36	1.39e-9	Eosinophil percentage of white cells;
CESC	cis	rs7829975	0.564	rs2976855	chr8:8301794	G/A	cg06636001	chr8:8085503	FLJ10661	0.52	6.72	0.38	1.13e-10	Mood instability;
CESC	cis	rs72627123	0.737	rs77361581	chr14:74465290	A/G	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.78	5.43	0.32	1.26e-7	Morning vs. evening chronotype;
CESC	cis	rs28386778	0.704	rs1051688	chr17:62006433	G/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.66	-8.82	-0.48	1.54e-16	Prudent dietary pattern;
CESC	cis	rs9611565	0.659	rs73178626	chr22:41928371	T/G	cg03806693	chr22:41940476	POLR3H	-1.21	-15.69	-0.69	1.07e-39	Vitiligo;
CESC	cis	rs561341	0.700	rs886223	chr17:30229877	G/T	cg13647721	chr17:30228624	UTP6	0.81	10.17	0.53	1.01e-20	Hip circumference adjusted for BMI;
CESC	cis	rs514406	0.505	rs431427	chr1:53179094	C/A	cg08736216	chr1:53307985	ZYG11A	-0.39	-6.47	-0.37	4.79e-10	Monocyte count;
CESC	cis	rs9811920	0.541	rs1016914	chr3:99640121	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.64	10.11	0.53	1.53e-20	Axial length;
CESC	cis	rs9486719	1.000	rs2472889	chr6:96866803	T/G	cg18709589	chr6:96969512	KIAA0776	0.53	5.81	0.34	1.75e-8	Migraine;Coronary artery disease;
CESC	cis	rs35146811	0.883	rs4134903	chr7:99711040	G/A	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.48	6.01	0.35	6.15e-9	Coronary artery disease;
CESC	cis	rs116095464	0.850	rs10055295	chr5:243749	G/A	cg10591111	chr5:226296	SDHA	-0.52	-6.38	-0.36	7.94e-10	Breast cancer;
CESC	cis	rs9611565	0.659	rs56364401	chr22:41951243	T/G	cg06481639	chr22:41940642	POLR3H	-0.61	-6.47	-0.37	4.81e-10	Vitiligo;
CESC	cis	rs7618915	0.571	rs11130307	chr3:52607682	G/A	cg18099408	chr3:52552593	STAB1	-0.33	-5.45	-0.32	1.17e-7	Bipolar disorder;
CESC	cis	rs10504229	0.679	rs72649120	chr8:58040308	C/T	cg22535103	chr8:58192502	C8orf71	-0.62	-6.85	-0.39	5e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs3733585	0.664	rs17185870	chr4:9958214	C/A	cg02734326	chr4:10020555	SLC2A9	-0.43	-5.97	-0.34	7.58e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs8027181	1.000	rs7164727	chr15:73093991	C/T	cg25632853	chr15:73088954	NA	0.36	6.48	0.37	4.48e-10	Triglyceride levels;
CESC	cis	rs6500602	0.701	rs4785969	chr16:4536934	A/T	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.37	5.39	0.31	1.55e-7	Schizophrenia;
CESC	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg06873352	chr17:61820015	STRADA	0.73	12.96	0.62	4.25e-30	Prudent dietary pattern;
CESC	cis	rs6456156	0.565	rs12529959	chr6:167469292	T/C	cg07741184	chr6:167504864	NA	0.36	6.17	0.35	2.48e-9	Primary biliary cholangitis;
CESC	cis	rs733175	0.855	rs10023068	chr4:10004832	C/T	cg11266682	chr4:10021025	SLC2A9	-0.4	-5.24	-0.31	3.25e-7	Psychosis and Alzheimer's disease;
CESC	cis	rs2576037	0.544	rs629097	chr18:44378097	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.76	12.54	0.61	1.26e-28	Personality dimensions;
CESC	cis	rs35110281	0.805	rs2838317	chr21:44991791	A/C	cg04455712	chr21:45112962	RRP1B	0.37	5.5	0.32	9.16e-8	Mean corpuscular volume;
CESC	cis	rs735396	0.770	rs2264782	chr12:121432603	C/T	cg02403541	chr12:121454288	C12orf43	0.63	8.91	0.48	8.13e-17	N-glycan levels;
CESC	cis	rs6430585	0.528	rs16832205	chr2:136684632	G/A	cg07169764	chr2:136633963	MCM6	1.23	16.56	0.71	8.67e-43	Corneal structure;
CESC	cis	rs10927875	0.632	rs6699394	chr1:16145143	C/A	cg18973939	chr1:16164122	FLJ37453	0.37	5.52	0.32	8.17e-8	Dilated cardiomyopathy;
CESC	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	10.16	0.53	1.09e-20	Prudent dietary pattern;
CESC	cis	rs1322639	0.574	rs9689193	chr6:169588074	A/G	cg03254818	chr6:169586852	NA	0.55	5.75	0.33	2.5e-8	Pulse pressure;
CESC	cis	rs8062405	0.929	rs11150609	chr16:28870596	A/G	cg08761264	chr16:28874980	SH2B1	-0.47	-5.85	-0.34	1.42e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs12142240	0.698	rs17361812	chr1:46814008	C/T	cg10495392	chr1:46806563	NSUN4	0.57	6.28	0.36	1.39e-9	Menopause (age at onset);
CESC	cis	rs9611565	0.649	rs2413659	chr22:42164862	A/G	cg06481639	chr22:41940642	POLR3H	0.48	5.49	0.32	9.4e-8	Vitiligo;
CESC	cis	rs7829975	0.902	rs777707	chr8:8584344	A/G	cg15556689	chr8:8085844	FLJ10661	0.45	5.78	0.33	2.11e-8	Mood instability;
CESC	cis	rs35123781	1.000	rs35123781	chr5:139065180	A/G	cg10513866	chr5:139070639	NA	0.39	5.76	0.33	2.36e-8	Schizophrenia;
CESC	cis	rs8031584	0.723	rs11632229	chr15:31179534	A/G	cg08109568	chr15:31115862	NA	0.7	9.66	0.51	4.18e-19	Huntington's disease progression;
CESC	cis	rs7771547	0.573	rs584418	chr6:36395437	G/A	cg07856975	chr6:36356162	ETV7	0.36	5.38	0.31	1.67e-7	Platelet distribution width;
CESC	cis	rs9487051	1.000	rs9374080	chr6:109616420	C/T	cg01475377	chr6:109611718	NA	0.43	6.47	0.37	4.59e-10	Reticulocyte fraction of red cells;
CESC	cis	rs2952156	0.920	rs2517957	chr17:37838716	G/A	cg00129232	chr17:37814104	STARD3	-0.82	-12.14	-0.6	2.94e-27	Asthma;
CESC	cis	rs225245	0.782	rs161183	chr17:33919475	G/C	cg05299278	chr17:33885742	SLFN14	0.38	5.46	0.32	1.08e-7	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
CESC	cis	rs4808199	1.000	rs17288409	chr19:19504167	T/C	cg03709012	chr19:19516395	GATAD2A	1.11	13.25	0.63	4.5e-31	Nonalcoholic fatty liver disease;
CESC	cis	rs3733585	0.699	rs4621431	chr4:9947590	C/T	cg02734326	chr4:10020555	SLC2A9	-0.44	-5.79	-0.33	2.03e-8	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs60871478	0.636	rs7792072	chr7:886239	C/T	cg13798912	chr7:905769	UNC84A	-0.56	-5.53	-0.32	7.82e-8	Cerebrospinal P-tau181p levels;
CESC	cis	rs8020095	0.571	rs17247792	chr14:67234457	G/A	cg19548862	chr14:67692701	FAM71D	-0.48	-5.84	-0.34	1.53e-8	Depression (quantitative trait);
CESC	trans	rs877282	1.000	rs34257857	chr10:772993	C/A	cg22713356	chr15:30763199	NA	1.12	11.31	0.57	1.87e-24	Uric acid levels;
CESC	trans	rs724568	0.659	rs1430767	chr2:67928057	A/T	cg19718508	chr5:176831858	F12	-0.45	-6.31	-0.36	1.2e-9	Major depressive disorder (broad);
CESC	cis	rs7811142	0.830	rs11761253	chr7:99939321	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.69	6.12	0.35	3.41e-9	Platelet count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13500430	chr11:2965905	NAP1L4	-0.54	-6.43	-0.37	5.83e-10	Gut microbiome composition (summer);
CESC	cis	rs10504229	0.683	rs11774585	chr8:58132685	G/A	cg21724239	chr8:58056113	NA	0.58	5.95	0.34	8.29e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs6445797	0.547	rs13094234	chr3:56582311	T/C	cg13792233	chr3:56591045	CCDC66	0.4	5.31	0.31	2.28e-7	Gastritis;
CESC	cis	rs6547741	1.000	rs4666009	chr2:27857992	T/A	cg27432699	chr2:27873401	GPN1	0.51	7.23	0.41	5.02e-12	Oral cavity cancer;
CESC	trans	rs17685	0.523	rs10246583	chr7:75746667	C/A	cg19862616	chr7:65841803	NCRNA00174	0.83	11.92	0.59	1.67e-26	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs853679	0.517	rs9380059	chr6:28132358	A/C	cg18032046	chr6:28092343	ZSCAN16	-0.57	-6.49	-0.37	4.32e-10	Depression;
CESC	cis	rs7552404	0.924	rs2173378	chr1:76201992	G/T	cg10523679	chr1:76189770	ACADM	0.77	10.46	0.54	1.13e-21	Blood metabolite levels;Acylcarnitine levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17560006	chr3:133969591	RYK	0.59	6.42	0.37	6.25e-10	Gut microbiome composition (summer);
CESC	cis	rs778371	0.723	rs6739794	chr2:233576165	G/A	cg08000102	chr2:233561755	GIGYF2	0.84	14.3	0.66	8.84e-35	Schizophrenia;
CESC	cis	rs4642101	0.765	rs6791647	chr3:12826425	C/T	cg05775895	chr3:12838266	CAND2	-0.41	-6.23	-0.36	1.84e-9	QRS complex (12-leadsum);
CESC	cis	rs1707322	0.686	rs3014242	chr1:46087577	G/A	cg06784218	chr1:46089804	CCDC17	-0.42	-7.32	-0.41	3.04e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs854765	0.583	rs10048206	chr17:17866897	A/G	cg16928487	chr17:17741425	SREBF1	-0.57	-9.57	-0.51	7.66e-19	Total body bone mineral density;
CESC	cis	rs11608355	0.515	rs1045582	chr12:109915727	G/T	cg05360138	chr12:110035743	NA	0.81	8.75	0.47	2.52e-16	Neuroticism;
CESC	cis	rs10779751	0.887	rs6686835	chr1:11305316	G/A	cg08854313	chr1:11322531	MTOR	0.84	11.96	0.59	1.16e-26	Body mass index;
CESC	cis	rs75477785	0.590	rs17015076	chr1:209912593	C/T	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.8	5.24	0.31	3.31e-7	Cleft lip with or without cleft palate;
CESC	cis	rs1707322	1.000	rs12124847	chr1:46380850	T/A	cg06784218	chr1:46089804	CCDC17	0.35	5.96	0.34	7.85e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs4253772	0.515	rs9615969	chr22:46773592	C/G	cg24881330	chr22:46731750	TRMU	0.79	5.06	0.3	7.85e-7	LDL cholesterol;Cholesterol, total;
CESC	trans	rs10772915	0.739	rs1799497	chr12:16399551	T/C	cg01612449	chr11:66410467	RBM4	-0.38	-6.18	-0.35	2.42e-9	Visceral fat;
CESC	cis	rs6089584	0.927	rs6089593	chr20:60572312	G/A	cg06108461	chr20:60628389	TAF4	-0.81	-12.09	-0.6	4.39e-27	Body mass index;
CESC	cis	rs11997175	0.766	rs4733178	chr8:33691899	A/T	ch.8.33884649F	chr8:33765107	NA	0.44	5.61	0.33	5.18e-8	Body mass index;
CESC	cis	rs2204008	0.837	rs1842599	chr12:37986081	G/A	cg26384229	chr12:38710491	ALG10B	-0.53	-7.46	-0.42	1.26e-12	Bladder cancer;
CESC	cis	rs801193	1.000	rs11773829	chr7:66141074	G/A	cg25985355	chr7:65971099	NA	0.32	5.19	0.3	4.27e-7	Aortic root size;
CESC	trans	rs12659622	0.703	rs17523929	chr5:15700585	A/G	cg22457238	chr19:58570995	ZNF135	-0.55	-6.27	-0.36	1.47e-9	Obesity-related traits;
CESC	cis	rs727505	0.821	rs73225498	chr7:124704197	C/T	cg23710748	chr7:124431027	NA	-0.38	-5.96	-0.34	8.16e-9	Lewy body disease;
CESC	cis	rs959260	0.688	rs9894206	chr17:73360154	T/C	cg20590849	chr17:73267439	MIF4GD	-0.56	-6.17	-0.35	2.61e-9	Systemic lupus erythematosus;
CESC	cis	rs4253772	0.530	rs113258957	chr22:46663678	G/C	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.6	5.27	0.31	2.83e-7	LDL cholesterol;Cholesterol, total;
CESC	trans	rs3942852	0.806	rs4752808	chr11:48141252	G/A	cg15704280	chr7:45808275	SEPT13	-0.64	-7.36	-0.41	2.32e-12	Acute lymphoblastic leukemia (childhood);
CESC	trans	rs875971	1.000	rs778694	chr7:65871558	A/G	cg26939375	chr7:64535504	NA	0.47	6.14	0.35	3.07e-9	Aortic root size;
CESC	cis	rs3806843	0.712	rs2530244	chr5:140109155	A/G	cg26395211	chr5:140044315	WDR55	0.46	6.16	0.35	2.62e-9	Depressive symptoms (multi-trait analysis);
CESC	trans	rs629535	0.814	rs614050	chr8:70065642	G/A	cg21567404	chr3:27674614	NA	0.88	10.34	0.54	2.74e-21	Dupuytren's disease;
CESC	cis	rs752010	0.714	rs7513753	chr1:42079232	A/G	cg06885757	chr1:42089581	HIVEP3	0.48	8.21	0.45	1.01e-14	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs57506017	0.565	rs10278257	chr7:12253563	C/T	cg23422036	chr7:12250390	TMEM106B	0.39	5.21	0.3	3.76e-7	Neuroticism;
CESC	cis	rs11098499	0.754	rs1849457	chr4:120254355	A/G	cg24375607	chr4:120327624	NA	0.41	5.04	0.3	8.48e-7	Corneal astigmatism;
CESC	cis	rs1559088	0.600	rs7259117	chr19:33550113	G/T	cg27124370	chr19:33622961	WDR88	0.54	7.48	0.42	1.08e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs6831352	0.879	rs29001229	chr4:100046823	A/G	cg13256891	chr4:100009986	ADH5	-0.76	-8.32	-0.46	4.63e-15	Alcohol dependence;
CESC	cis	rs2839186	0.843	rs17182671	chr21:47696238	T/C	cg10351095	chr21:47802916	PCNT	-0.51	-6.98	-0.39	2.36e-11	Testicular germ cell tumor;
CESC	cis	rs12042052	1.000	rs6696779	chr1:232920825	G/A	cg00951395	chr1:232941775	KIAA1383	0.71	6.48	0.37	4.51e-10	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CESC	cis	rs6952808	0.594	rs3778964	chr7:2138109	C/T	cg21782813	chr7:2030301	MAD1L1	0.49	7.0	0.39	2.14e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs6540559	0.546	rs74991018	chr1:210033790	T/G	cg22029157	chr1:209979665	IRF6	0.72	7.16	0.4	8.04e-12	Cleft lip with or without cleft palate;
CESC	cis	rs763121	0.925	rs17032	chr22:39130843	C/G	cg21395723	chr22:39101663	GTPBP1	0.44	5.87	0.34	1.33e-8	Menopause (age at onset);
CESC	cis	rs7666738	0.791	rs2081621	chr4:98926753	C/A	cg05340658	chr4:99064831	C4orf37	0.82	12.23	0.6	1.45e-27	Colonoscopy-negative controls vs population controls;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg17944940	chr17:73285520	SLC25A19	-0.5	-6.49	-0.37	4.1e-10	Fibrinogen levels;
CESC	trans	rs4671386	0.901	rs2110401	chr2:60521970	T/C	cg24386296	chr4:1723849	TMEM129;TACC3	0.51	6.39	0.37	7.28e-10	Acne (severe);
CESC	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg16132339	chr22:24313637	DDTL;DDT	0.37	5.64	0.33	4.37e-8	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs1559088	0.625	rs10411739	chr19:33616327	T/C	cg03563238	chr19:33554763	RHPN2	-0.29	-5.27	-0.31	2.8e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs875971	0.862	rs778680	chr7:65840414	G/A	cg18252515	chr7:66147081	NA	-0.43	-5.62	-0.33	4.86e-8	Aortic root size;
CESC	cis	rs2380220	0.510	rs9387562	chr6:96057006	G/T	cg15832292	chr6:96025679	MANEA	0.75	7.9	0.44	7.5e-14	Behavioural disinhibition (generation interaction);
CESC	cis	rs7188697	0.922	rs37055	chr16:58560775	C/T	cg21335942	chr16:58549945	SETD6	0.47	5.5	0.32	9.04e-8	QT interval;
CESC	cis	rs17384381	0.953	rs12122816	chr1:85792384	C/T	cg16011679	chr1:85725395	C1orf52	0.79	7.98	0.44	4.35e-14	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6570726	0.791	rs6912079	chr6:145894949	G/A	cg05347473	chr6:146136440	FBXO30	0.58	7.41	0.41	1.68e-12	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs3780486	1.000	rs3780486	chr9:33139453	C/T	cg04842962	chr6:43655489	MRPS18A	0.89	13.3	0.63	2.81e-31	IgG glycosylation;
CESC	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	21.72	0.8	8.88e-61	Prudent dietary pattern;
CESC	cis	rs8062405	1.000	rs62037364	chr16:28868695	G/A	cg08761264	chr16:28874980	SH2B1	-0.47	-5.89	-0.34	1.16e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03360920	chr6:159421029	RSPH3	0.69	8.62	0.47	6.13e-16	Gut microbiome composition (summer);
CESC	cis	rs6547741	0.935	rs6749426	chr2:27847606	T/C	cg21248554	chr2:27665150	KRTCAP3	0.25	5.23	0.31	3.37e-7	Oral cavity cancer;
CESC	trans	rs61931739	0.500	rs7309421	chr12:34553795	C/T	cg26384229	chr12:38710491	ALG10B	0.73	10.94	0.56	3.11e-23	Morning vs. evening chronotype;
CESC	cis	rs34375054	0.687	rs35540170	chr12:125669122	C/G	cg25124228	chr12:125621409	AACS	-0.46	-5.2	-0.3	4.03e-7	Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs9894429	0.646	rs6565609	chr17:79592267	G/A	cg13777783	chr17:79615861	NA	-0.36	-6.11	-0.35	3.47e-9	Eye color traits;
CESC	cis	rs9868809	0.505	rs11708786	chr3:48752654	C/T	cg07636037	chr3:49044803	WDR6	-0.56	-5.09	-0.3	6.68e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs6968419	0.755	rs3807981	chr7:115896716	G/A	cg02561103	chr7:115862891	TES	-0.41	-5.35	-0.31	1.92e-7	Intraocular pressure;
CESC	cis	rs6460942	0.841	rs17443848	chr7:12443688	A/G	cg06484146	chr7:12443880	VWDE	-0.65	-9.3	-0.5	5.33e-18	Coronary artery disease;
CESC	cis	rs7927771	0.524	rs10838769	chr11:47825333	A/G	cg18512352	chr11:47633146	NA	-0.36	-5.55	-0.32	6.84e-8	Subjective well-being;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg05943731	chr12:123444284	ABCB9	0.51	7.2	0.4	6.07e-12	Fibrinogen levels;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg12783346	chr2:48117099	FBXO11	0.4	6.07	0.35	4.41e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs35110281	0.774	rs2838327	chr21:45018566	A/C	cg04455712	chr21:45112962	RRP1B	0.4	6.21	0.36	2.07e-9	Mean corpuscular volume;
CESC	cis	rs2880765	0.835	rs7163958	chr15:86045215	G/A	cg19183879	chr15:85880815	NA	-0.25	-5.12	-0.3	5.84e-7	Coronary artery disease;
CESC	cis	rs1790761	0.692	rs10896179	chr11:67316928	C/A	cg08355456	chr11:67383691	NA	0.33	5.18	0.3	4.36e-7	Mean corpuscular volume;
CESC	cis	rs6867032	0.839	rs4314451	chr5:2001859	T/C	cg26168224	chr5:2018326	NA	-0.76	-11.49	-0.58	4.47e-25	Gut microbiome composition (winter);
CESC	cis	rs1348850	0.914	rs1374437	chr2:178363423	T/C	cg23306229	chr2:178417860	TTC30B	0.67	8.57	0.47	8.73e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs2637266	0.678	rs846612	chr10:78550680	T/C	cg18941641	chr10:78392320	NA	0.4	7.57	0.42	6.16e-13	Pulmonary function;
CESC	trans	rs7944735	0.517	rs7952205	chr11:48199227	A/G	cg15704280	chr7:45808275	SEPT13	0.7	6.76	0.38	8.86e-11	Intraocular pressure;
CESC	cis	rs561341	0.941	rs501773	chr17:30314435	T/G	cg00745463	chr17:30367425	LRRC37B	-0.66	-6.7	-0.38	1.25e-10	Hip circumference adjusted for BMI;
CESC	trans	rs11658311	0.850	rs11658846	chr17:17671486	G/C	cg01883427	chr16:15242839	NA	0.55	6.22	0.36	1.96e-9	Obsessive-compulsive symptoms;
CESC	cis	rs7267979	0.868	rs6138553	chr20:25239233	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.82	14.91	0.68	6.32e-37	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs30380	1.000	rs246454	chr5:96123264	C/A	cg16492584	chr5:96139282	ERAP1	-0.35	-5.36	-0.31	1.8e-7	Cerebrospinal fluid biomarker levels;
CESC	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg02353165	chr6:42928485	GNMT	0.89	15.21	0.68	5.68e-38	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs7095944	0.614	rs10901817	chr10:126443404	A/T	cg08799069	chr10:126477246	METTL10	-0.37	-5.28	-0.31	2.66e-7	Asthma;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg24571794	chr5:179564268	RASGEF1C	0.5	6.69	0.38	1.33e-10	Fibrinogen levels;
CESC	cis	rs899997	1.000	rs9888691	chr15:79010046	T/C	cg04896959	chr15:78267971	NA	0.39	5.84	0.34	1.53e-8	Coronary artery disease or large artery stroke;
CESC	cis	rs929354	0.713	rs6946947	chr7:156948787	T/C	cg05182265	chr7:156933206	UBE3C	-0.5	-7.29	-0.41	3.49e-12	Body mass index;
CESC	cis	rs34172651	0.517	rs200526	chr16:24760511	C/T	cg02428538	chr16:24856791	SLC5A11	0.47	5.03	0.3	9.12e-7	Intelligence (multi-trait analysis);
CESC	trans	rs5758511	0.773	rs62240999	chr22:42355563	C/G	cg15080870	chr19:47770746	CCDC9	0.5	6.19	0.36	2.26e-9	Birth weight;
CESC	cis	rs5769765	0.865	rs3788730	chr22:50244695	C/T	cg02269571	chr22:50332266	NA	0.46	6.07	0.35	4.43e-9	Schizophrenia;
CESC	cis	rs2599510	0.783	rs2568464	chr2:32848658	C/T	cg02381751	chr2:32503542	YIPF4	-0.45	-5.77	-0.33	2.26e-8	Interleukin-18 levels;
CESC	trans	rs916888	0.773	rs169201	chr17:44790203	A/G	cg22968622	chr17:43663579	NA	1.36	18.55	0.75	8.09e-50	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs258892	0.895	rs155429	chr5:72108080	G/A	cg21869765	chr5:72125136	TNPO1	-0.44	-5.65	-0.33	4.05e-8	Small cell lung carcinoma;
CESC	cis	rs6674176	0.561	rs12127226	chr1:44395309	C/T	cg23954153	chr1:44402353	ARTN	-0.35	-5.46	-0.32	1.08e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs7267979	1.000	rs2500446	chr20:25339664	C/T	cg08601574	chr20:25228251	PYGB	-0.36	-5.05	-0.3	8.07e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs34779708	0.733	rs11597184	chr10:35397396	G/A	cg03585969	chr10:35415529	CREM	0.76	9.99	0.52	3.71e-20	Inflammatory bowel disease;Crohn's disease;
CESC	trans	rs61931739	0.534	rs73103090	chr12:34098801	C/T	cg26384229	chr12:38710491	ALG10B	0.58	7.92	0.44	6.37e-14	Morning vs. evening chronotype;
CESC	cis	rs6502050	0.835	rs8075086	chr17:80092649	A/G	cg23985595	chr17:80112537	CCDC57	-0.42	-6.6	-0.38	2.18e-10	Life satisfaction;
CESC	cis	rs6060717	0.610	rs2590965	chr20:34613120	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	-0.49	-6.26	-0.36	1.59e-9	Hip circumference adjusted for BMI;
CESC	cis	rs6570726	0.967	rs373704	chr6:145860618	C/A	cg05347473	chr6:146136440	FBXO30	0.43	5.76	0.33	2.38e-8	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1843834	0.539	rs12694643	chr2:225446603	A/G	cg12698349	chr2:225449008	CUL3	0.66	9.79	0.52	1.59e-19	IgE levels in asthmatics (D.p. specific);
CESC	cis	rs1552244	1.000	rs56270432	chr3:10087517	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.89	11.78	0.59	4.76e-26	Alzheimer's disease;
CESC	cis	rs6088580	0.634	rs4911418	chr20:32994257	G/A	cg06115741	chr20:33292138	TP53INP2	-0.46	-5.98	-0.34	7.28e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs4242434	0.927	rs3735894	chr8:22454826	A/G	cg03733263	chr8:22462867	KIAA1967	0.91	14.58	0.67	9.68e-36	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24690404	chr4:3507205	NA	-0.59	-7.27	-0.41	4.09e-12	Gut microbiome composition (summer);
CESC	cis	rs4975709	0.589	rs4975707	chr5:1864028	C/T	cg14773178	chr5:1868261	NA	0.34	6.28	0.36	1.4e-9	Cardiovascular disease risk factors;
CESC	cis	rs8114671	0.551	rs4911162	chr20:33411425	G/C	cg08999081	chr20:33150536	PIGU	0.39	5.45	0.32	1.18e-7	Height;
CESC	cis	rs1023500	0.596	rs5758562	chr22:42448238	C/G	cg15557168	chr22:42548783	NA	-0.41	-5.32	-0.31	2.17e-7	Schizophrenia;
CESC	cis	rs4727027	0.800	rs10952796	chr7:148813138	G/C	cg23158103	chr7:148848205	ZNF398	-0.4	-6.43	-0.37	5.86e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs34172651	0.517	rs1465423	chr16:24772680	C/G	cg00339695	chr16:24857497	SLC5A11	-0.5	-6.62	-0.38	2.01e-10	Intelligence (multi-trait analysis);
CESC	cis	rs1707322	0.964	rs1768802	chr1:46547868	A/G	cg03146154	chr1:46216737	IPP	-0.69	-9.04	-0.49	3.51e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7044106	0.791	rs10818473	chr9:123484155	A/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.86	13.99	0.65	1.12e-33	Hip circumference adjusted for BMI;
CESC	cis	rs6088580	0.608	rs2105109	chr20:32971932	A/G	cg24642439	chr20:33292090	TP53INP2	-0.52	-6.9	-0.39	3.82e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs727563	0.635	rs713988	chr22:42159072	A/G	cg06634786	chr22:41940651	POLR3H	0.7	7.03	0.4	1.8e-11	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs4474465	0.790	rs4544031	chr11:78265403	G/C	cg27205649	chr11:78285834	NARS2	0.46	5.74	0.33	2.62e-8	Alzheimer's disease (survival time);
CESC	cis	rs9611565	0.659	rs169361	chr22:41877989	A/G	cg17376030	chr22:41985996	PMM1	-0.75	-7.97	-0.44	4.7e-14	Vitiligo;
CESC	cis	rs6701037	1.000	rs7514749	chr1:175122123	A/G	cg00321850	chr1:175162397	KIAA0040	-0.42	-5.86	-0.34	1.37e-8	Alcohol dependence;
CESC	cis	rs9733	0.519	rs7511673	chr1:150707636	A/T	cg09365446	chr1:150670422	GOLPH3L	0.4	5.68	0.33	3.53e-8	Tonsillectomy;
CESC	trans	rs3780486	0.846	rs7849148	chr9:33138352	A/T	cg04842962	chr6:43655489	MRPS18A	1.0	18.63	0.75	4.36e-50	IgG glycosylation;
CESC	cis	rs4665809	0.590	rs17528590	chr2:26505858	A/G	cg04944784	chr2:26401820	FAM59B	0.91	9.37	0.5	3.37e-18	Gut microbiome composition (summer);
CESC	cis	rs873946	0.557	rs34854637	chr10:134582962	A/G	cg27297192	chr10:134578999	INPP5A	0.43	5.68	0.33	3.62e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs10927875	0.632	rs2862162	chr1:16142960	A/C	cg21385522	chr1:16154831	NA	0.99	15.92	0.7	1.7e-40	Dilated cardiomyopathy;
CESC	cis	rs9649213	0.593	rs1076272	chr7:98031005	C/G	cg08684580	chr7:98029266	BAIAP2L1	-0.35	-5.64	-0.33	4.43e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7927771	0.542	rs7102205	chr11:47745374	C/T	cg20307385	chr11:47447363	PSMC3	0.6	8.55	0.46	1.01e-15	Subjective well-being;
CESC	cis	rs9682041	0.696	rs6786542	chr3:170105378	C/T	cg11886554	chr3:170076028	SKIL	0.69	6.33	0.36	1.02e-9	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CESC	cis	rs36051895	0.695	rs11794778	chr9:5023794	G/T	cg02405213	chr9:5042618	JAK2	-0.51	-5.84	-0.34	1.49e-8	Pediatric autoimmune diseases;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11447699	chr10:99052509	ARHGAP19	-0.5	-6.03	-0.35	5.38e-9	Gut microbiome composition (summer);
CESC	cis	rs1862618	0.529	rs978406	chr5:56259808	A/T	cg24549020	chr5:56110836	MAP3K1	-0.59	-6.66	-0.38	1.54e-10	Initial pursuit acceleration;
CESC	cis	rs7949030	0.626	rs61296092	chr11:62320838	T/C	cg13298116	chr11:62369859	EML3;MTA2	0.65	9.56	0.51	8.58e-19	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs9911578	0.967	rs7503190	chr17:57184162	A/C	cg05425664	chr17:57184151	TRIM37	-0.53	-7.31	-0.41	3.19e-12	Intelligence (multi-trait analysis);
CESC	cis	rs61542988	0.756	rs5013587	chr7:22882660	C/T	cg11367502	chr7:22862612	TOMM7	0.48	5.98	0.34	7.09e-9	Fibrinogen levels;
CESC	cis	rs7957197	1.000	rs7957197	chr12:121460686	T/A	cg02403541	chr12:121454288	C12orf43	-0.55	-5.04	-0.3	8.8e-7	Type 2 diabetes;
CESC	cis	rs6980507	0.524	rs62510967	chr8:42441374	C/G	cg09913449	chr8:42400586	C8orf40	0.32	5.04	0.3	8.5e-7	Glycated hemoglobin levels;
CESC	cis	rs4927850	1.000	rs10881563	chr3:195750225	A/G	cg00031303	chr3:195681400	NA	0.49	6.04	0.35	5.08e-9	Pancreatic cancer;
CESC	cis	rs4713118	0.516	rs7739216	chr6:28079946	G/T	cg19592336	chr6:28129416	ZNF389	0.6	7.98	0.44	4.4e-14	Parkinson's disease;
CESC	cis	rs3008870	1.000	rs12044278	chr1:67460977	T/C	cg02640540	chr1:67518911	SLC35D1	-0.51	-5.58	-0.32	5.89e-8	Lymphocyte percentage of white cells;
CESC	cis	rs8031584	0.918	rs35396566	chr15:31263057	T/C	cg14298792	chr15:30685198	CHRFAM7A	-0.47	-5.23	-0.31	3.46e-7	Huntington's disease progression;
CESC	cis	rs12497850	0.863	rs4974084	chr3:48939080	G/A	cg03060546	chr3:49711283	APEH	0.46	5.7	0.33	3.23e-8	Parkinson's disease;
CESC	cis	rs1348850	0.526	rs10930802	chr2:178460095	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.58	5.25	0.31	3.15e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	trans	rs17685	0.672	rs56343450	chr7:75796235	C/T	cg19862616	chr7:65841803	NCRNA00174	0.84	12.03	0.59	6.77e-27	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs3736485	0.934	rs7170330	chr15:51859313	C/T	cg08986416	chr15:51914746	DMXL2	-0.4	-5.12	-0.3	5.86e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs35110281	0.805	rs162402	chr21:44963418	G/C	cg21573476	chr21:45109991	RRP1B	-0.42	-5.7	-0.33	3.13e-8	Mean corpuscular volume;
CESC	cis	rs6952808	0.689	rs2008263	chr7:2048335	A/G	cg04267008	chr7:1944627	MAD1L1	-0.56	-6.59	-0.38	2.37e-10	Bipolar disorder and schizophrenia;
CESC	cis	rs2404602	0.608	rs12439484	chr15:76602937	A/C	cg05617483	chr15:76483344	C15orf27	0.39	5.24	0.31	3.25e-7	Blood metabolite levels;
CESC	cis	rs425277	0.606	rs2459984	chr1:2086312	A/G	cg04315214	chr1:2043799	PRKCZ	-0.42	-6.86	-0.39	4.84e-11	Height;
CESC	cis	rs1707322	1.000	rs6682683	chr1:46342337	A/G	cg06784218	chr1:46089804	CCDC17	0.32	5.57	0.32	6.35e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs10256972	0.528	rs7784607	chr7:1178694	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.58	-7.66	-0.43	3.41e-13	Longevity;Endometriosis;
CESC	cis	rs11864453	0.647	rs3764311	chr16:72125617	C/G	cg01557791	chr16:72042693	DHODH	-0.43	-5.57	-0.32	6.39e-8	Fibrinogen levels;
CESC	cis	rs1707322	0.721	rs28442079	chr1:46172001	A/G	cg05343316	chr1:45956843	TESK2	0.51	6.2	0.36	2.19e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2933343	1.000	rs789227	chr3:128600585	C/G	cg25356066	chr3:128598488	ACAD9	0.6	7.55	0.42	6.86e-13	IgG glycosylation;
CESC	trans	rs8073060	0.544	rs225246	chr17:33944773	T/C	cg19694781	chr19:47549865	TMEM160	-0.73	-7.03	-0.4	1.79e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	cis	rs1707322	0.752	rs4607935	chr1:46117161	C/T	cg03146154	chr1:46216737	IPP	0.82	11.51	0.58	3.87e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg26998693	chr6:132834590	STX7	-0.41	-6.28	-0.36	1.39e-9	Vertical cup-disc ratio;
CESC	cis	rs12497850	0.931	rs9311430	chr3:48845251	C/T	cg03060546	chr3:49711283	APEH	0.43	5.34	0.31	2.05e-7	Parkinson's disease;
CESC	cis	rs8114671	0.562	rs6088647	chr20:33505997	T/C	cg07148914	chr20:33460835	GGT7	0.52	6.8	0.39	6.88e-11	Height;
CESC	cis	rs10504229	0.906	rs58559296	chr8:58171714	T/C	cg05313129	chr8:58192883	C8orf71	-0.55	-6.37	-0.36	8.42e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs6460942	0.597	rs17545416	chr7:12525944	A/T	cg10578991	chr7:12443926	VWDE	-0.49	-5.13	-0.3	5.63e-7	Coronary artery disease;
CESC	cis	rs79349575	0.783	rs12601858	chr17:47017477	T/C	cg26022315	chr17:47021804	SNF8	0.39	5.16	0.3	4.94e-7	Type 2 diabetes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22494505	chr1:26560657	CCDC21	0.54	6.01	0.35	6.2e-9	Gut microbiome composition (summer);
CESC	trans	rs7246657	1.000	rs10426297	chr19:37798373	A/G	cg01833234	chr11:6592585	DNHD1	0.54	6.13	0.35	3.19e-9	Coronary artery calcification;
CESC	cis	rs9467711	0.606	rs34104395	chr6:26478252	C/T	cg21479132	chr6:26055353	NA	0.74	5.07	0.3	7.56e-7	Autism spectrum disorder or schizophrenia;
CESC	trans	rs11039798	0.764	rs2089208	chr11:48899860	C/T	cg15704280	chr7:45808275	SEPT13	0.69	6.44	0.37	5.66e-10	Axial length;
CESC	cis	rs11122272	0.701	rs2749702	chr1:231523808	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.57	-7.82	-0.43	1.29e-13	Hemoglobin concentration;
CESC	cis	rs7267979	0.816	rs374701	chr20:25483616	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.78	14.71	0.67	3.22e-36	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs6724607	1.000	rs13006708	chr2:191471428	G/A	cg10560079	chr2:191398806	TMEM194B	-0.5	-7.26	-0.41	4.24e-12	Pulse pressure;
CESC	cis	rs9649213	0.727	rs12113294	chr7:97910637	C/G	cg21770322	chr7:97807741	LMTK2	0.42	5.85	0.34	1.45e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs2559856	1.000	rs2695292	chr12:102087290	G/A	cg12213457	chr12:102090980	CHPT1	-0.34	-5.1	-0.3	6.45e-7	Blood protein levels;
CESC	cis	rs9287719	0.967	rs7563894	chr2:10754649	A/G	cg00105475	chr2:10696890	NA	0.38	5.42	0.32	1.34e-7	Prostate cancer;
CESC	trans	rs7577696	0.962	rs13022197	chr2:32343167	A/T	cg13463167	chr1:197523608	DENND1B	0.37	6.18	0.35	2.38e-9	Inflammatory biomarkers;
CESC	cis	rs2228479	0.681	rs11641790	chr16:89961957	A/G	cg00800038	chr16:89945340	TCF25	0.59	6.52	0.37	3.61e-10	Skin colour saturation;
CESC	cis	rs2243480	1.000	rs6949812	chr7:65387101	G/A	cg25894440	chr7:65020034	NA	-0.59	-5.03	-0.3	8.93e-7	Diabetic kidney disease;
CESC	cis	rs6062302	0.522	rs2297427	chr20:62221364	G/A	cg06363034	chr20:62225388	GMEB2	-0.52	-6.64	-0.38	1.74e-10	Glioblastoma;
CESC	cis	rs801193	1.000	rs7785213	chr7:66138978	A/C	cg14393609	chr7:65229607	NA	-0.47	-6.33	-0.36	1.05e-9	Aortic root size;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg06757187	chr22:19110190	DGCR2	-0.43	-6.33	-0.36	1.03e-9	Gambling;
CESC	cis	rs763121	0.853	rs138705	chr22:39133803	C/T	cg21395723	chr22:39101663	GTPBP1	0.43	5.49	0.32	9.57e-8	Menopause (age at onset);
CESC	cis	rs7100689	0.646	rs2994390	chr10:82074395	C/A	cg00277334	chr10:82204260	NA	-0.57	-7.5	-0.42	9.38e-13	Post bronchodilator FEV1;
CESC	cis	rs4664308	0.618	rs55668231	chr2:160882066	A/G	cg03641300	chr2:160917029	PLA2R1	-0.59	-8.37	-0.46	3.38e-15	Idiopathic membranous nephropathy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13786801	chr1:59042745	TACSTD2	0.55	6.07	0.35	4.32e-9	Gut microbiome composition (summer);
CESC	cis	rs6912958	0.525	rs59322	chr6:88020521	C/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.72	9.98	0.52	4.07e-20	Monocyte percentage of white cells;
CESC	cis	rs447	1.000	rs447	chr7:83772415	A/G	cg22846510	chr7:83753280	SEMA3A	-0.42	-5.09	-0.3	6.78e-7	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg10862848	chr6:42927986	GNMT	0.27	6.84	0.39	5.43e-11	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs2070997	0.607	rs3808821	chr9:133712801	G/T	cg14102055	chr9:133715238	ABL1	0.39	5.29	0.31	2.51e-7	Response to amphetamines;
CESC	cis	rs1322639	0.614	rs6903921	chr6:169563957	C/T	cg03254818	chr6:169586852	NA	0.48	5.22	0.31	3.57e-7	Pulse pressure;
CESC	cis	rs7666738	0.830	rs7657490	chr4:99043973	C/T	cg03467027	chr4:99064603	C4orf37	0.47	5.98	0.34	7.19e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs73206853	0.764	rs16940935	chr12:111107470	A/G	cg12870014	chr12:110450643	ANKRD13A	0.66	5.62	0.33	4.81e-8	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg01248421	chr18:32924572	ZNF24	0.44	6.19	0.36	2.31e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs17666538	0.585	rs6559065	chr8:623156	G/C	cg23958373	chr8:599963	NA	0.82	5.92	0.34	1.02e-8	IgG glycosylation;
CESC	cis	rs66573146	0.634	rs55633489	chr4:6988745	C/A	cg00086871	chr4:6988644	TBC1D14	1.18	8.17	0.45	1.25e-14	Granulocyte percentage of myeloid white cells;
CESC	cis	rs910316	1.000	rs12589815	chr14:75544101	C/T	cg08847533	chr14:75593920	NEK9	0.99	18.71	0.75	2.29e-50	Height;
CESC	cis	rs919433	0.890	rs979020	chr2:198169749	T/C	cg10820045	chr2:198174542	NA	-0.41	-6.17	-0.35	2.49e-9	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs9733	0.519	rs7521898	chr1:150707596	G/A	cg18016565	chr1:150552671	MCL1	0.34	5.22	0.31	3.63e-7	Tonsillectomy;
CESC	cis	rs12477438	1.000	rs73963398	chr2:99887025	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.61	-7.14	-0.4	8.93e-12	Chronic sinus infection;
CESC	cis	rs7249921	0.802	rs35746990	chr19:35666857	C/T	cg15419183	chr19:35660584	FXYD5	0.54	8.39	0.46	2.95e-15	Platelet count;
CESC	cis	rs7089973	0.604	rs2420066	chr10:116583897	A/G	cg25233709	chr10:116636983	FAM160B1	0.35	5.47	0.32	1.05e-7	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs1008375	1.000	rs7659718	chr4:17638020	A/C	cg04450456	chr4:17643702	FAM184B	0.37	5.18	0.3	4.46e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	trans	rs2727020	0.755	rs652655	chr11:49251293	G/A	cg03929089	chr4:120376271	NA	0.8	12.45	0.61	2.6e-28	Coronary artery disease;
CESC	cis	rs4704187	0.687	rs2112874	chr5:74525165	G/A	cg03227963	chr5:74354835	NA	0.28	5.04	0.3	8.66e-7	Response to amphetamines;
CESC	cis	rs9905704	0.624	rs8080071	chr17:57093825	C/T	cg12560992	chr17:57184187	TRIM37	-0.61	-7.51	-0.42	8.87e-13	Testicular germ cell tumor;
CESC	cis	rs7703051	0.901	rs4549504	chr5:74808237	G/T	cg03227963	chr5:74354835	NA	0.29	5.21	0.31	3.73e-7	LDL cholesterol;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
CESC	cis	rs12530845	1.000	rs12531468	chr7:135336264	T/G	cg23117316	chr7:135346802	PL-5283	-0.4	-5.15	-0.3	5.15e-7	Red blood cell traits;
CESC	trans	rs9987353	0.840	rs329994	chr8:9123233	A/G	cg16763574	chr13:111937052	ARHGEF7	0.48	6.39	0.37	7.53e-10	Recombination measurement;
CESC	trans	rs7246760	0.867	rs66880218	chr19:9774155	A/G	cg02900749	chr2:68251473	NA	-0.85	-7.53	-0.42	8.04e-13	Pursuit maintenance gain;
CESC	cis	rs9640161	0.789	rs2159234	chr7:150020422	A/T	cg21361702	chr7:150065534	REPIN1	0.54	6.23	0.36	1.84e-9	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.54	7.31	0.41	3.13e-12	Lymphocyte counts;
CESC	cis	rs72781680	0.533	rs56009471	chr2:23890084	A/C	cg08917208	chr2:24149416	ATAD2B	1.0	9.69	0.51	3.24e-19	Lymphocyte counts;
CESC	cis	rs7605827	0.897	rs6431694	chr2:15523031	T/C	cg19274914	chr2:15703543	NA	0.35	6.11	0.35	3.61e-9	Educational attainment (years of education);
CESC	cis	rs875971	0.638	rs3898855	chr7:66036398	G/C	cg25985355	chr7:65971099	NA	0.32	5.34	0.31	2e-7	Aortic root size;
CESC	cis	rs7799006	0.755	rs2256545	chr7:2291943	G/A	cg08027265	chr7:2291960	NA	-0.56	-9.82	-0.52	1.33e-19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs875971	1.000	rs1183245	chr7:65541185	C/T	cg12463550	chr7:65579703	CRCP	-0.6	-7.4	-0.41	1.78e-12	Aortic root size;
CESC	trans	rs7839040	0.698	rs10093631	chr8:82921021	A/T	cg14472086	chr9:107730925	NA	-0.46	-6.25	-0.36	1.61e-9	Response to methotrexate in juvenile idiopathic arthritis;
CESC	cis	rs6912958	0.500	rs4707352	chr6:87929705	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	-0.35	-5.56	-0.32	6.65e-8	Monocyte percentage of white cells;
CESC	cis	rs897080	0.515	rs786616	chr2:44592975	C/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.51	6.0	0.35	6.57e-9	Height;
CESC	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.97	9.66	0.51	4.13e-19	Platelet count;
CESC	cis	rs1707322	0.752	rs11211173	chr1:46219376	C/T	cg06784218	chr1:46089804	CCDC17	0.41	7.21	0.41	5.75e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs10876993	0.928	rs10877001	chr12:58083077	T/C	cg18357645	chr12:58087776	OS9	-0.66	-10.82	-0.55	7.8e-23	Celiac disease or Rheumatoid arthritis;
CESC	cis	rs11676348	0.846	rs4674260	chr2:219002376	T/C	cg00012203	chr2:219082015	ARPC2	-0.59	-7.7	-0.43	2.68e-13	Ulcerative colitis;
CESC	cis	rs684232	0.688	rs2657633	chr17:600502	C/T	cg12384639	chr17:618140	VPS53	0.4	5.24	0.31	3.26e-7	Prostate cancer;
CESC	cis	rs3796619	1.000	rs1466215	chr4:1072220	C/T	cg27284194	chr4:1044797	NA	0.36	5.5	0.32	9.08e-8	Recombination rate (males);
CESC	cis	rs3733585	0.699	rs57574512	chr4:9960182	T/C	cg02734326	chr4:10020555	SLC2A9	-0.43	-6.01	-0.35	6.1e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs7666738	0.830	rs7662389	chr4:99019892	G/A	cg03676636	chr4:99064102	C4orf37	0.33	5.18	0.3	4.3e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4563143	0.675	rs55884228	chr19:29243897	G/T	cg12756686	chr19:29218302	NA	0.58	7.52	0.42	8.38e-13	Methadone dose in opioid dependence;
CESC	cis	rs10883723	0.810	rs10786669	chr10:104256094	C/G	cg22532475	chr10:104410764	TRIM8	-0.34	-5.73	-0.33	2.77e-8	Allergic disease (asthma, hay fever or eczema);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26994227	chr5:130971071	RAPGEF6	0.67	7.92	0.44	6.51e-14	Gut microbiome composition (summer);
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg04618842	chr12:57472555	TMEM194A	-0.43	-6.06	-0.35	4.54e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs11122272	0.733	rs2749700	chr1:231522734	A/G	cg06096015	chr1:231504339	EGLN1	0.41	5.85	0.34	1.46e-8	Hemoglobin concentration;
CESC	cis	rs853679	0.517	rs9468298	chr6:28122345	A/G	cg17949981	chr6:28129498	ZNF389	0.45	5.48	0.32	9.95e-8	Depression;
CESC	cis	rs6674176	0.932	rs4660761	chr1:44440146	G/A	cg12908607	chr1:44402522	ARTN	-0.45	-6.19	-0.36	2.24e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs1153858	0.943	rs4774580	chr15:45652086	G/A	cg21132104	chr15:45694354	SPATA5L1	0.85	11.64	0.58	1.47e-25	Homoarginine levels;
CESC	cis	rs1580019	0.523	rs9791770	chr7:32582252	C/A	cg06627557	chr7:32535165	LSM5;AVL9	1.07	18.41	0.75	2.5e-49	Cognitive ability;
CESC	trans	rs7824557	0.527	rs2572448	chr8:11239352	G/A	cg06636001	chr8:8085503	FLJ10661	-0.48	-6.11	-0.35	3.59e-9	Retinal vascular caliber;
CESC	cis	rs40363	0.680	rs4010628	chr16:3529779	G/A	cg00484396	chr16:3507460	NAT15	0.59	6.47	0.37	4.8e-10	Tuberculosis;
CESC	cis	rs1005277	0.579	rs1740742	chr10:38518860	C/T	cg25427524	chr10:38739819	LOC399744	-0.73	-10.95	-0.56	2.97e-23	Extrinsic epigenetic age acceleration;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26468130	chr11:64053342	BAD;GPR137	0.54	6.05	0.35	5.02e-9	Gut microbiome composition (summer);
CESC	cis	rs6540556	0.723	rs3766619	chr1:209895298	C/G	cg05527609	chr1:210001259	C1orf107	-0.66	-7.32	-0.41	2.95e-12	Red blood cell count;
CESC	cis	rs3736485	0.934	rs17609666	chr15:51858038	G/T	cg08986416	chr15:51914746	DMXL2	-0.4	-5.12	-0.3	5.86e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs2228479	0.850	rs11639925	chr16:89908250	C/T	cg00800038	chr16:89945340	TCF25	-0.9	-6.93	-0.39	3.24e-11	Skin colour saturation;
CESC	cis	rs30380	0.666	rs26512	chr5:96128400	G/T	cg16492584	chr5:96139282	ERAP1	-0.47	-6.59	-0.38	2.33e-10	Cerebrospinal fluid biomarker levels;
CESC	cis	rs780096	0.526	rs1260342	chr2:27663416	G/T	cg02592271	chr2:27665507	KRTCAP3	-0.29	-5.79	-0.34	2e-8	Total body bone mineral density;
CESC	cis	rs7267979	0.706	rs6138542	chr20:25207773	C/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.82	14.78	0.67	1.86e-36	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs798554	0.797	rs798494	chr7:2798294	C/A	cg19346786	chr7:2764209	NA	-0.49	-7.09	-0.4	1.19e-11	Height;
CESC	cis	rs7666738	0.830	rs6825211	chr4:98807698	A/T	cg17366294	chr4:99064904	C4orf37	0.58	8.3	0.45	5.45e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs8077577	0.747	rs62072540	chr17:18225228	G/A	cg16794390	chr17:18148240	FLII	0.4	6.24	0.36	1.75e-9	Obesity-related traits;
CESC	cis	rs17125944	0.505	rs77137752	chr14:53230496	G/T	cg00686598	chr14:53173677	PSMC6	1.36	11.65	0.58	1.34e-25	Alzheimer's disease (late onset);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg13184734	chr1:178512007	C1orf220	-0.44	-6.06	-0.35	4.55e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs1371867	0.775	rs3020183	chr8:101233297	A/T	cg11906718	chr8:101322791	RNF19A	-0.49	-6.18	-0.36	2.36e-9	Atrioventricular conduction;
CESC	cis	rs116095464	1.000	rs7723693	chr5:306032	G/A	cg10591111	chr5:226296	SDHA	-0.65	-5.92	-0.34	9.71e-9	Breast cancer;
CESC	cis	rs11764590	0.694	rs7801349	chr7:2085553	T/C	cg21782813	chr7:2030301	MAD1L1	-0.4	-5.37	-0.31	1.73e-7	Neuroticism;
CESC	cis	rs7980687	0.628	rs2102949	chr12:123676763	G/A	cg05973401	chr12:123451056	ABCB9	0.46	5.75	0.33	2.41e-8	Height;Educational attainment;Head circumference (infant);
CESC	cis	rs362272	0.505	rs10155132	chr4:3369500	A/G	cg08886695	chr4:3369023	RGS12	-0.39	-5.38	-0.31	1.64e-7	Serum sulfate level;
CESC	cis	rs9649213	0.593	rs56286037	chr7:98019522	C/T	cg21770322	chr7:97807741	LMTK2	0.55	8.3	0.45	5.5e-15	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs11650494	0.808	rs61286260	chr17:47433222	T/C	cg08112188	chr17:47440006	ZNF652	0.83	6.24	0.36	1.71e-9	Prostate cancer;
CESC	cis	rs2074585	0.517	rs11638010	chr15:91079920	A/G	cg22089800	chr15:90895588	ZNF774	-0.43	-5.15	-0.3	5e-7	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
CESC	cis	rs2354432	0.556	rs2275249	chr1:146759320	C/G	cg25205988	chr1:146714368	CHD1L	0.88	7.89	0.44	8.17e-14	Mitochondrial DNA levels;
CESC	cis	rs2841277	0.708	rs11851053	chr14:105407208	T/C	cg19901468	chr14:105411992	AHNAK2	-0.6	-8.69	-0.47	3.79e-16	Rheumatoid arthritis;
CESC	cis	rs2299587	0.582	rs17515033	chr8:17898518	A/T	cg18067069	chr8:17937731	ASAH1	-0.37	-5.03	-0.3	8.86e-7	Economic and political preferences;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18103236	chr10:81060645	ZMIZ1	-0.57	-6.22	-0.36	1.95e-9	Gut microbiome composition (summer);
CESC	cis	rs10883723	0.810	rs11191304	chr10:104255284	C/T	ch.10.2196322F	chr10:104248062	ACTR1A	0.42	5.08	0.3	6.99e-7	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs2109514	0.902	rs1007751	chr7:116110055	A/T	cg12739419	chr7:116140593	CAV2	-0.38	-6.85	-0.39	5.28e-11	Prevalent atrial fibrillation;
CESC	cis	rs2463822	0.583	rs7104825	chr11:62026833	C/T	cg06239285	chr11:62104954	ASRGL1	-0.92	-7.01	-0.4	1.99e-11	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs6860806	0.603	rs112300250	chr5:131583292	G/A	cg18758796	chr5:131593413	PDLIM4	0.46	6.66	0.38	1.57e-10	Breast cancer;
CESC	cis	rs7727544	0.684	rs272889	chr5:131665378	A/G	cg24060327	chr5:131705240	SLC22A5	-0.63	-8.22	-0.45	9.15e-15	Blood metabolite levels;
CESC	cis	rs2836974	0.932	rs2234543	chr21:40572072	G/A	cg11644478	chr21:40555479	PSMG1	1.02	16.23	0.71	1.32e-41	Cognitive function;
CESC	cis	rs5753618	0.583	rs7293171	chr22:31802324	T/C	cg02404636	chr22:31891804	SFI1	0.39	5.14	0.3	5.35e-7	Colorectal cancer;
CESC	cis	rs3785574	0.962	rs62077512	chr17:61851435	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.58	7.15	0.4	8.26e-12	Height;
CESC	cis	rs853679	0.517	rs9283884	chr6:28135660	C/G	cg19592336	chr6:28129416	ZNF389	-0.59	-7.71	-0.43	2.55e-13	Depression;
CESC	cis	rs703842	0.963	rs923829	chr12:58174306	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.7	9.11	0.49	2.09e-17	Multiple sclerosis;
CESC	cis	rs7666738	0.830	rs58696666	chr4:99006913	C/T	cg17366294	chr4:99064904	C4orf37	0.6	8.61	0.47	6.47e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6976053	0.518	rs314358	chr7:100410657	A/G	cg03098644	chr7:100410630	EPHB4	-0.51	-6.76	-0.38	8.92e-11	Plasminogen activator inhibitor type 1 levels (PAI-1);
CESC	cis	rs7264396	0.635	rs6058358	chr20:34492560	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.81	-11.23	-0.57	3.44e-24	Total cholesterol levels;
CESC	cis	rs7178909	0.866	rs3784388	chr15:90437301	C/T	cg19708238	chr15:90437601	AP3S2	0.43	6.19	0.36	2.25e-9	Common traits (Other);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15277658	chr10:73421701	CDH23	0.5	6.25	0.36	1.63e-9	Gut microbiome composition (summer);
CESC	cis	rs1670533	1.000	rs10007978	chr4:1060984	A/T	cg04106633	chr4:1044584	NA	0.4	5.19	0.3	4.15e-7	Recombination rate (females);
CESC	cis	rs9733	0.628	rs72700895	chr1:150626029	C/T	cg22823121	chr1:150693482	HORMAD1	0.48	7.12	0.4	1.03e-11	Tonsillectomy;
CESC	cis	rs2882667	0.858	rs11741150	chr5:138431457	C/T	cg04439458	chr5:138467593	SIL1	-0.43	-6.58	-0.37	2.51e-10	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs1008375	0.966	rs11733730	chr4:17625209	G/C	cg02297831	chr4:17616191	MED28	0.6	7.67	0.43	3.22e-13	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs3806843	0.966	rs3806842	chr5:140212676	C/T	cg26395211	chr5:140044315	WDR55	-0.4	-5.18	-0.3	4.4e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs8177253	0.555	rs4481157	chr3:133464684	G/A	cg24879335	chr3:133465180	TF	0.36	6.55	0.37	2.97e-10	Iron status biomarkers;
CESC	cis	rs9322193	0.962	rs3805749	chr6:150093682	C/T	cg07701084	chr6:150067640	NUP43	0.43	5.78	0.33	2.13e-8	Lung cancer;
CESC	cis	rs9300255	0.539	rs1969355	chr12:123742061	G/A	cg00376283	chr12:123451042	ABCB9	0.65	8.73	0.47	2.86e-16	Neutrophil percentage of white cells;
CESC	trans	rs208520	1.000	rs72882079	chr6:66973878	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.85	9.39	0.5	2.78e-18	Exhaled nitric oxide output;
CESC	cis	rs12476592	0.602	rs6724160	chr2:63786423	G/C	cg17519650	chr2:63277830	OTX1	-0.48	-5.42	-0.32	1.34e-7	Childhood ear infection;
CESC	cis	rs9486715	0.758	rs9386528	chr6:96928514	G/A	cg06623918	chr6:96969491	KIAA0776	-0.82	-10.96	-0.56	2.73e-23	Headache;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg13411879	chr7:30068273	PLEKHA8	-0.41	-6.12	-0.35	3.3e-9	Ulcerative colitis;
CESC	cis	rs7927771	0.864	rs11604680	chr11:47457539	A/G	cg05585544	chr11:47624801	NA	-0.51	-7.32	-0.41	3.01e-12	Subjective well-being;
CESC	cis	rs2996428	0.504	rs3765780	chr1:3767696	C/T	cg13057898	chr1:3703894	LRRC47	-0.33	-5.37	-0.31	1.69e-7	Red cell distribution width;
CESC	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.48	-6.77	-0.38	8.14e-11	Longevity;Endometriosis;
CESC	cis	rs8114671	0.836	rs6142284	chr20:33641367	G/A	cg06115741	chr20:33292138	TP53INP2	-0.44	-5.29	-0.31	2.53e-7	Height;
CESC	cis	rs2243480	1.000	rs13235972	chr7:65883605	C/T	cg18252515	chr7:66147081	NA	-1.39	-14.18	-0.66	2.5e-34	Diabetic kidney disease;
CESC	trans	rs853679	0.546	rs17695758	chr6:27837183	T/C	cg06606381	chr12:133084897	FBRSL1	-1.07	-8.89	-0.48	9.48e-17	Depression;
CESC	cis	rs13242816	1.000	rs2402079	chr7:116128670	T/A	cg04696780	chr7:116139425	CAV2	-0.61	-5.56	-0.32	6.58e-8	P wave duration;
CESC	cis	rs4665809	0.941	rs41285975	chr2:26351144	T/C	cg22920501	chr2:26401640	FAM59B	-0.67	-8.09	-0.44	2.22e-14	Gut microbiome composition (summer);
CESC	cis	rs7605827	0.930	rs11684001	chr2:15513120	C/T	cg19274914	chr2:15703543	NA	0.32	5.58	0.32	5.95e-8	Educational attainment (years of education);
CESC	cis	rs6089584	0.854	rs6061407	chr20:60622048	A/C	cg24733560	chr20:60626293	TAF4	0.45	6.44	0.37	5.45e-10	Body mass index;
CESC	cis	rs7223966	1.000	rs28463311	chr17:61919643	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.5	5.73	0.33	2.66e-8	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs11997175	0.516	rs6981283	chr8:33619363	A/G	ch.8.33884649F	chr8:33765107	NA	0.57	7.35	0.41	2.5e-12	Body mass index;
CESC	cis	rs1152591	0.505	rs1152601	chr14:64667337	T/C	cg23250157	chr14:64679961	SYNE2	0.41	5.82	0.34	1.7e-8	Atrial fibrillation;
CESC	cis	rs3812831	0.662	rs407531	chr13:114929218	G/A	cg08824895	chr13:115047677	UPF3A	0.39	5.16	0.3	4.83e-7	Schizophrenia;
CESC	cis	rs3947	0.855	rs1296026	chr8:11697442	C/T	cg00262122	chr8:11665843	FDFT1	-0.51	-5.2	-0.3	4.02e-7	Blood protein levels;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg09983252	chr4:119555556	NA	-0.41	-6.02	-0.35	5.78e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs798554	0.718	rs1636247	chr7:2881917	A/G	cg04166393	chr7:2884313	GNA12	0.6	7.91	0.44	7.05e-14	Height;
CESC	cis	rs2708240	1.000	rs2538989	chr7:147580154	T/C	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.34	-5.67	-0.33	3.73e-8	QT interval (drug interaction);
CESC	cis	rs7084402	0.967	rs7091440	chr10:60271372	T/A	cg07615347	chr10:60278583	BICC1	-0.57	-8.63	-0.47	5.58e-16	Refractive error;
CESC	cis	rs7772486	0.754	rs702319	chr6:146006117	T/C	cg05347473	chr6:146136440	FBXO30	-0.59	-7.02	-0.4	1.87e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs3780486	0.718	rs7859454	chr9:33119583	T/A	cg13443165	chr9:33130375	B4GALT1	0.44	5.37	0.31	1.76e-7	IgG glycosylation;
CESC	cis	rs1552244	0.882	rs13074282	chr3:10024699	T/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.76	-9.64	-0.51	4.86e-19	Alzheimer's disease;
CESC	cis	rs8180040	0.900	rs10865946	chr3:47425060	T/G	cg27129171	chr3:47204927	SETD2	0.63	9.65	0.51	4.34e-19	Colorectal cancer;
CESC	cis	rs17102884	0.506	rs11845397	chr14:75404587	G/A	cg08847533	chr14:75593920	NEK9	-0.44	-5.49	-0.32	9.41e-8	Neuroticism;
CESC	cis	rs8060686	0.641	rs76501820	chr16:68114582	G/A	cg26727032	chr16:67993705	SLC12A4	-0.58	-6.32	-0.36	1.11e-9	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs2832191	0.755	rs55671430	chr21:30492421	G/C	cg08807101	chr21:30365312	RNF160	-0.72	-9.88	-0.52	8.63e-20	Dental caries;
CESC	cis	rs4722166	0.508	rs2069832	chr7:22767433	A/G	cg26061582	chr7:22766209	IL6	0.47	5.39	0.31	1.58e-7	Lung cancer;
CESC	cis	rs1707322	0.865	rs785501	chr1:46579611	C/T	cg06784218	chr1:46089804	CCDC17	-0.33	-5.63	-0.33	4.67e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs801193	1.000	rs10234018	chr7:66146284	A/T	cg18876405	chr7:65276391	NA	-0.5	-6.41	-0.37	6.47e-10	Aortic root size;
CESC	cis	rs10504073	0.545	rs4406405	chr8:49957261	G/C	cg00325661	chr8:49890786	NA	0.59	8.9	0.48	9.3e-17	Blood metabolite ratios;
CESC	cis	rs67311347	1.000	rs73078169	chr3:40483798	G/A	cg24209194	chr3:40518798	ZNF619	0.5	6.21	0.36	2e-9	Renal cell carcinoma;
CESC	cis	rs7208859	0.623	rs77544470	chr17:28934550	C/A	cg19761014	chr17:28927070	LRRC37B2	0.82	6.21	0.36	2.01e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs67311347	1.000	rs7641495	chr3:40494690	T/C	cg24209194	chr3:40518798	ZNF619	-0.54	-7.24	-0.41	4.73e-12	Renal cell carcinoma;
CESC	cis	rs13191362	1.000	rs34653853	chr6:163114362	C/T	cg06582575	chr6:163149167	PACRG;PARK2	1.02	10.3	0.53	3.86e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs6502050	0.835	rs12945993	chr17:80129485	T/C	cg11859384	chr17:80120422	CCDC57	-0.38	-5.17	-0.3	4.7e-7	Life satisfaction;
CESC	cis	rs4595586	0.679	rs1356264	chr12:39393754	A/T	cg26384229	chr12:38710491	ALG10B	0.43	6.28	0.36	1.35e-9	Morning vs. evening chronotype;
CESC	cis	rs3126085	0.935	rs1390485	chr1:152182168	C/T	cg03465714	chr1:152285911	FLG	0.44	5.25	0.31	3.16e-7	Atopic dermatitis;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg08466385	chr6:18368294	NA	-0.43	-6.18	-0.35	2.37e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs12477438	0.520	rs12621007	chr2:99791946	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.86	15.08	0.68	1.62e-37	Chronic sinus infection;
CESC	cis	rs854765	0.551	rs56886154	chr17:17831473	C/A	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.49	6.36	0.36	8.96e-10	Total body bone mineral density;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21138277	chr11:93276595	C11orf75	0.55	6.44	0.37	5.73e-10	Gut microbiome composition (summer);
CESC	cis	rs66887589	0.616	rs10032299	chr4:120206419	C/T	cg09307838	chr4:120376055	NA	0.67	9.24	0.49	8.04e-18	Diastolic blood pressure;
CESC	cis	rs4803455	0.565	rs1800470	chr19:41858921	G/A	cg09537434	chr19:41945824	ATP5SL	-0.71	-9.67	-0.51	3.78e-19	Migraine;Coronary artery disease;
CESC	cis	rs7772486	0.875	rs9390372	chr6:146363638	G/C	cg23711669	chr6:146136114	FBXO30	0.83	12.12	0.6	3.46e-27	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs61869271	0.799	rs35501899	chr10:116739109	T/G	cg17463145	chr7:79084011	MAGI2	0.32	6.36	0.36	8.92e-10	Tonsillectomy;
CESC	trans	rs61931739	0.500	rs7979482	chr12:34542877	C/A	cg13010199	chr12:38710504	ALG10B	0.52	6.67	0.38	1.49e-10	Morning vs. evening chronotype;
CESC	cis	rs722599	0.748	rs2300599	chr14:75359441	A/G	cg11812906	chr14:75593930	NEK9	-0.47	-5.72	-0.33	2.83e-8	IgG glycosylation;
CESC	cis	rs2882667	0.858	rs11242442	chr5:138380489	C/T	cg04439458	chr5:138467593	SIL1	-0.4	-6.15	-0.35	2.89e-9	Age-related hearing impairment (SNP x SNP interaction);
CESC	trans	rs7656342	0.808	rs10003216	chr4:9766749	A/G	cg11152298	chr5:142783383	NR3C1	-0.5	-6.18	-0.35	2.46e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs4819052	0.851	rs2838839	chr21:46667858	C/G	cg20896738	chr21:46707857	POFUT2;LOC642852	-0.48	-6.01	-0.35	6.02e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs2455799	0.634	rs13085226	chr3:15923750	C/T	cg16303742	chr3:15540471	COLQ	-0.34	-5.23	-0.31	3.47e-7	Mean platelet volume;
CESC	cis	rs911555	0.755	rs34411783	chr14:103900639	G/A	cg12935359	chr14:103987150	CKB	0.61	9.0	0.48	4.35e-17	Intelligence (multi-trait analysis);
CESC	cis	rs6723226	0.806	rs6543658	chr2:32718849	G/A	cg02381751	chr2:32503542	YIPF4	0.8	11.56	0.58	2.72e-25	Intelligence (multi-trait analysis);
CESC	cis	rs9640161	0.830	rs13307276	chr7:150061525	T/C	cg17279839	chr7:150038598	RARRES2	0.42	5.4	0.31	1.5e-7	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs10540	0.730	rs34690033	chr11:492677	G/C	cg03934478	chr11:495069	RNH1	0.52	5.04	0.3	8.51e-7	Body mass index;
CESC	cis	rs4660261	0.562	rs3011223	chr1:44318286	T/C	cg12908607	chr1:44402522	ARTN	-0.46	-6.6	-0.38	2.29e-10	Intelligence (multi-trait analysis);
CESC	cis	rs10504073	0.584	rs55795863	chr8:49898055	A/G	cg00325661	chr8:49890786	NA	0.56	8.46	0.46	1.82e-15	Blood metabolite ratios;
CESC	cis	rs2050392	0.624	rs303444	chr10:30729347	C/T	cg02070205	chr10:30722105	MAP3K8	-0.43	-5.15	-0.3	5.03e-7	Inflammatory bowel disease;
CESC	cis	rs10781543	0.817	rs1128874	chr9:139323424	T/C	cg14019695	chr9:139328340	INPP5E	0.34	5.04	0.3	8.49e-7	Monocyte percentage of white cells;
CESC	cis	rs1707322	1.000	rs10890370	chr1:46389217	C/T	cg05343316	chr1:45956843	TESK2	0.45	5.52	0.32	8e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs13191362	1.000	rs13207239	chr6:163008772	A/C	cg06582575	chr6:163149167	PACRG;PARK2	0.82	8.19	0.45	1.08e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs7772486	0.590	rs1890170	chr6:146071839	G/C	cg05347473	chr6:146136440	FBXO30	-0.71	-9.16	-0.49	1.42e-17	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1153858	1.000	rs1346266	chr15:45694516	G/T	cg21132104	chr15:45694354	SPATA5L1	0.78	10.32	0.54	3.19e-21	Homoarginine levels;
CESC	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg07677032	chr17:61819896	STRADA	0.41	5.33	0.31	2.15e-7	Prudent dietary pattern;
CESC	cis	rs11638352	1.000	rs958485	chr15:44350065	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.66	-6.28	-0.36	1.35e-9	Lipoprotein phospholipase A2 activity in cardiovascular disease;
CESC	cis	rs11098499	0.865	rs10032158	chr4:120391632	C/T	cg24375607	chr4:120327624	NA	0.45	5.59	0.32	5.56e-8	Corneal astigmatism;
CESC	cis	rs7786877	0.626	rs11767547	chr7:100221635	C/T	cg16850897	chr7:100343110	ZAN	-0.62	-6.54	-0.37	3.07e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs7618915	0.571	rs1961959	chr3:52585760	G/C	cg07507251	chr3:52567010	NT5DC2	0.43	7.47	0.42	1.19e-12	Bipolar disorder;
CESC	cis	rs9611565	0.503	rs5996062	chr22:42167464	C/G	cg06634786	chr22:41940651	POLR3H	0.68	6.78	0.38	7.6e-11	Vitiligo;
CESC	cis	rs801193	0.591	rs9986881	chr7:66173040	A/G	cg25405998	chr7:65216604	CCT6P1	0.4	5.17	0.3	4.68e-7	Aortic root size;
CESC	cis	rs4665809	0.941	rs1434079	chr2:26284670	C/G	cg27170947	chr2:26402098	FAM59B	-0.6	-7.23	-0.41	5.28e-12	Gut microbiome composition (summer);
CESC	cis	rs116095464	0.558	rs62346508	chr5:203668	T/C	cg16372103	chr5:203701	NA	0.49	5.3	0.31	2.4e-7	Breast cancer;
CESC	cis	rs9487051	0.714	rs7757347	chr6:109633815	G/A	cg01475377	chr6:109611718	NA	-0.45	-6.96	-0.39	2.6e-11	Reticulocyte fraction of red cells;
CESC	cis	rs7666738	0.830	rs1426665	chr4:99027764	C/T	cg05340658	chr4:99064831	C4orf37	0.81	12.59	0.61	8.13e-29	Colonoscopy-negative controls vs population controls;
CESC	cis	rs875971	0.660	rs10263935	chr7:66096028	A/G	cg14393609	chr7:65229607	NA	0.41	5.57	0.32	6.1e-8	Aortic root size;
CESC	cis	rs4454254	1.000	rs4440615	chr8:141057641	G/A	cg06693505	chr8:141057453	TRAPPC9	-0.35	-5.72	-0.33	2.93e-8	Pulse pressure;
CESC	cis	rs3096299	0.935	rs3114890	chr16:89449546	C/G	cg00750074	chr16:89608354	SPG7	-0.38	-5.32	-0.31	2.16e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs9611565	0.504	rs5758452	chr22:42144927	G/A	cg03806693	chr22:41940476	POLR3H	0.79	9.66	0.51	4.04e-19	Vitiligo;
CESC	cis	rs6460942	0.915	rs7802454	chr7:12454508	A/G	cg20607287	chr7:12443886	VWDE	-0.78	-9.15	-0.49	1.61e-17	Coronary artery disease;
CESC	cis	rs7824557	0.564	rs2572400	chr8:11234367	T/G	cg21775007	chr8:11205619	TDH	-0.54	-8.07	-0.44	2.47e-14	Retinal vascular caliber;
CESC	cis	rs3858526	0.584	rs10769270	chr11:5860563	T/C	cg02574844	chr11:5959923	NA	-0.46	-6.5	-0.37	3.99e-10	DNA methylation (variation);
CESC	cis	rs72781680	1.000	rs72788286	chr2:24098321	A/C	cg08917208	chr2:24149416	ATAD2B	0.91	8.38	0.46	3.17e-15	Lymphocyte counts;
CESC	cis	rs7084402	0.967	rs1658477	chr10:60289607	A/G	cg07615347	chr10:60278583	BICC1	0.6	9.41	0.5	2.54e-18	Refractive error;
CESC	cis	rs7089973	0.872	rs7909657	chr10:116629096	C/G	cg23260525	chr10:116636907	FAM160B1	0.38	6.42	0.37	6.35e-10	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg00712792	chr16:89921048	SPIRE2	0.47	6.56	0.37	2.77e-10	Fibrinogen levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10715820	chr1:17235063	NA	-0.55	-6.34	-0.36	9.68e-10	Gut microbiome composition (summer);
CESC	cis	rs897984	0.806	rs1046276	chr16:30914626	A/G	cg00531865	chr16:30841666	NA	0.53	7.07	0.4	1.36e-11	Dementia with Lewy bodies;
CESC	cis	rs875971	0.825	rs10281499	chr7:66048966	A/G	cg12463550	chr7:65579703	CRCP	-0.5	-6.34	-0.36	9.71e-10	Aortic root size;
CESC	cis	rs9814567	0.896	rs58491661	chr3:134355189	G/T	cg15484384	chr3:134203672	ANAPC13;CEP63	0.32	5.23	0.31	3.52e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs9916302	0.851	rs7220650	chr17:37487168	A/G	cg07936489	chr17:37558343	FBXL20	0.83	12.18	0.6	2.11e-27	Glomerular filtration rate (creatinine);
CESC	cis	rs6665290	0.904	rs1045286	chr1:227179037	A/C	cg10327440	chr1:227177885	CDC42BPA	1.16	31.06	0.89	2.64e-90	Myeloid white cell count;
CESC	trans	rs9987353	0.840	rs329994	chr8:9123233	A/G	cg16882830	chr7:148823965	ZNF398;ZNF425	-0.47	-6.05	-0.35	4.83e-9	Recombination measurement;
CESC	cis	rs1552244	0.882	rs35056669	chr3:10014171	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.87	11.14	0.56	6.75e-24	Alzheimer's disease;
CESC	cis	rs9583531	0.689	rs1061386	chr13:111373368	G/C	cg24331049	chr13:111365604	ING1	0.7	9.59	0.51	6.68e-19	Coronary artery disease;
CESC	cis	rs1707322	0.928	rs6681068	chr1:46398382	G/A	cg03146154	chr1:46216737	IPP	0.72	9.82	0.52	1.31e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7851660	0.809	rs35324451	chr9:100660136	A/T	cg13688889	chr9:100608707	NA	-0.59	-8.1	-0.45	2.03e-14	Strep throat;
CESC	cis	rs4853012	0.838	rs4429500	chr2:74345336	A/G	cg19729930	chr2:74357872	NA	0.79	11.51	0.58	3.95e-25	Gestational age at birth (maternal effect);
CESC	cis	rs6866344	0.697	rs11749438	chr5:178131245	C/T	cg03877680	chr5:178157825	ZNF354A	0.75	8.54	0.46	1.08e-15	Neutrophil percentage of white cells;
CESC	cis	rs3096299	0.967	rs2911255	chr16:89487137	C/T	cg02187348	chr16:89574699	SPG7	0.59	8.02	0.44	3.43e-14	Multiple myeloma (IgH translocation);
CESC	cis	rs1461503	0.932	rs11218909	chr11:122842613	C/T	cg27398637	chr11:122830231	C11orf63	-0.55	-8.32	-0.45	4.77e-15	Menarche (age at onset);
CESC	cis	rs7811142	0.830	rs11771936	chr7:99943283	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.92	8.92	0.48	8e-17	Platelet count;
CESC	cis	rs35306767	0.903	rs10904577	chr10:922077	A/G	cg26597838	chr10:835615	NA	0.86	8.98	0.48	5.16e-17	Eosinophil percentage of granulocytes;
CESC	cis	rs4713118	0.868	rs10484401	chr6:27746590	A/T	cg20933634	chr6:27740509	NA	-0.4	-5.12	-0.3	5.8e-7	Parkinson's disease;
CESC	cis	rs1348850	0.831	rs7606235	chr2:178401288	T/C	cg23306229	chr2:178417860	TTC30B	0.61	7.36	0.41	2.33e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs35110281	0.743	rs2329443	chr21:45059431	C/T	cg21573476	chr21:45109991	RRP1B	-0.55	-7.54	-0.42	7.34e-13	Mean corpuscular volume;
CESC	cis	rs4665809	0.590	rs17528590	chr2:26505858	A/G	cg25036284	chr2:26402008	FAM59B	0.84	8.75	0.47	2.61e-16	Gut microbiome composition (summer);
CESC	cis	rs10540	1.000	rs12419766	chr11:503710	C/T	cg03576123	chr11:487126	PTDSS2	-1.12	-11.21	-0.57	3.93e-24	Body mass index;
CESC	cis	rs8018808	0.905	rs7142380	chr14:77931231	T/C	cg20045696	chr14:77926864	AHSA1	0.43	5.9	0.34	1.13e-8	Myeloid white cell count;
CESC	cis	rs9894429	0.716	rs7405578	chr17:79588306	C/A	cg18240062	chr17:79603768	NPLOC4	0.89	13.31	0.63	2.64e-31	Eye color traits;
CESC	cis	rs7607369	0.536	rs13013510	chr2:219667227	A/G	cg02176678	chr2:219576539	TTLL4	-0.35	-6.13	-0.35	3.12e-9	Red blood cell count;Amyotrophic lateral sclerosis;
CESC	cis	rs6952808	0.929	rs12667688	chr7:1931030	C/T	cg23048001	chr7:2026167	MAD1L1	0.39	5.04	0.3	8.75e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs7772486	0.686	rs9497396	chr6:146014963	C/A	cg05347473	chr6:146136440	FBXO30	-0.51	-6.55	-0.37	2.92e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9486719	1.000	rs11153023	chr6:96968525	C/T	cg06623918	chr6:96969491	KIAA0776	-0.77	-7.52	-0.42	8.36e-13	Migraine;Coronary artery disease;
CESC	cis	rs6952808	0.929	rs11761270	chr7:1923695	C/T	cg02951883	chr7:2050386	MAD1L1	-0.53	-7.1	-0.4	1.16e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs2933343	0.903	rs2638846	chr3:128587163	A/T	cg25356066	chr3:128598488	ACAD9	0.55	6.93	0.39	3.13e-11	IgG glycosylation;
CESC	cis	rs4665809	1.000	rs6546768	chr2:26328800	A/G	cg27170947	chr2:26402098	FAM59B	-0.59	-7.08	-0.4	1.26e-11	Gut microbiome composition (summer);
CESC	cis	rs2637266	0.685	rs7098713	chr10:78452828	C/T	cg18941641	chr10:78392320	NA	0.43	7.82	0.43	1.23e-13	Pulmonary function;
CESC	cis	rs6693567	0.565	rs4926422	chr1:150315436	T/C	cg09579323	chr1:150459698	TARS2	0.49	6.28	0.36	1.35e-9	Migraine;
CESC	trans	rs9646096	0.558	rs9547858	chr13:38002795	A/G	cg24730915	chr19:7570267	C19orf45	0.63	6.04	0.35	5.25e-9	Age-related macular degeneration;
CESC	cis	rs911555	0.504	rs61995761	chr14:104075712	T/C	cg12935359	chr14:103987150	CKB	-0.5	-7.3	-0.41	3.29e-12	Intelligence (multi-trait analysis);
CESC	cis	rs9322193	0.923	rs10782316	chr6:150073891	A/C	cg04369109	chr6:150039330	LATS1	-0.43	-6.04	-0.35	5.1e-9	Lung cancer;
CESC	cis	rs769267	0.965	rs12460764	chr19:19431963	G/T	cg15052019	chr19:19431593	KIAA0892;SF4	-0.42	-5.39	-0.31	1.53e-7	Tonsillectomy;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg25422665	chr17:16485103	NA	0.48	6.35	0.36	9.08e-10	Thyroid stimulating hormone;
CESC	cis	rs2425143	1.000	rs11696527	chr20:34245379	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.83	-7.54	-0.42	7.65e-13	Blood protein levels;
CESC	cis	rs6121246	0.529	rs56153385	chr20:30187609	C/T	cg13852791	chr20:30311386	BCL2L1	0.67	6.71	0.38	1.2e-10	Mean corpuscular hemoglobin;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg05176433	chr10:95242154	MYOF	0.47	6.36	0.36	8.63e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs853679	0.542	rs6934769	chr6:28090931	A/G	cg23281280	chr6:28129359	ZNF389	0.58	8.05	0.44	2.72e-14	Depression;
CESC	cis	rs10870270	0.912	rs7079991	chr10:133736130	A/G	cg26149184	chr10:133730230	NA	0.38	5.15	0.3	5.07e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs2075371	1.000	rs2598297	chr7:133993001	T/G	cg20476274	chr7:133979776	SLC35B4	0.67	9.68	0.51	3.52e-19	Mean platelet volume;
CESC	cis	rs7811142	1.000	rs1000215	chr7:100004543	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.78	8.34	0.46	4.21e-15	Platelet count;
CESC	cis	rs4948102	0.731	rs4535700	chr7:56045448	T/C	cg09872392	chr7:56161020	PHKG1	-0.46	-7.13	-0.4	9.34e-12	Plasma homocysteine levels (post-methionine load test);
CESC	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	22.0	0.8	9.67e-62	Prudent dietary pattern;
CESC	cis	rs2050392	1.000	rs2265186	chr10:30691743	C/T	cg18806716	chr10:30721971	MAP3K8	0.39	5.47	0.32	1.04e-7	Inflammatory bowel disease;
CESC	cis	rs7666738	0.830	rs62321598	chr4:99014237	C/T	cg03676636	chr4:99064102	C4orf37	0.33	5.16	0.3	4.86e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs9325144	0.624	rs7312879	chr12:39150752	G/A	cg23762105	chr12:34175262	ALG10	0.46	6.0	0.35	6.45e-9	Morning vs. evening chronotype;
CESC	cis	rs9911578	0.967	rs11656413	chr17:57082013	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	-0.39	-5.08	-0.3	7.13e-7	Intelligence (multi-trait analysis);
CESC	cis	rs4821897	0.514	rs739141	chr22:39824450	A/G	cg05872129	chr22:39784769	NA	0.72	9.83	0.52	1.22e-19	IgG glycosylation;
CESC	cis	rs258892	0.895	rs13174766	chr5:72057135	C/T	cg21869765	chr5:72125136	TNPO1	-0.43	-5.36	-0.31	1.84e-7	Small cell lung carcinoma;
CESC	cis	rs3096299	0.591	rs748940	chr16:89440757	T/A	cg08822215	chr16:89438651	ANKRD11	-0.44	-6.68	-0.38	1.42e-10	Multiple myeloma (IgH translocation);
CESC	cis	rs3126085	0.935	rs72696997	chr1:152257099	A/C	cg03465714	chr1:152285911	FLG	0.49	5.43	0.32	1.24e-7	Atopic dermatitis;
CESC	cis	rs9399135	0.967	rs9389261	chr6:135371148	C/G	cg24558204	chr6:135376177	HBS1L	0.49	6.77	0.38	8.11e-11	Red blood cell count;
CESC	cis	rs11792861	0.555	rs4978767	chr9:111762925	C/T	cg05043794	chr9:111880884	C9orf5	-0.3	-5.33	-0.31	2.11e-7	Menarche (age at onset);
CESC	cis	rs2760061	0.583	rs697763	chr1:228192622	G/C	cg02753203	chr1:228287806	NA	0.79	11.5	0.58	4.28e-25	Diastolic blood pressure;
CESC	cis	rs7811142	0.830	rs118119933	chr7:99939050	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.13	10.64	0.55	2.98e-22	Platelet count;
CESC	cis	rs360798	0.532	rs13013218	chr2:63011671	C/T	cg17519650	chr2:63277830	OTX1	-0.57	-7.54	-0.42	7.37e-13	Coronary artery disease;
CESC	cis	rs568617	1.000	rs694994	chr11:65653309	A/G	cg19792802	chr11:65647270	CTSW	0.36	5.44	0.32	1.2e-7	Crohn's disease;
CESC	trans	rs9398803	0.965	rs2326387	chr6:126680489	G/A	cg03991309	chr1:68237761	GNG12	-0.39	-6.04	-0.35	5.23e-9	Male-pattern baldness;
CESC	trans	rs208520	0.874	rs208470	chr6:66916402	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.84	-9.91	-0.52	6.69e-20	Exhaled nitric oxide output;
CESC	cis	rs698813	0.604	rs1988663	chr2:44492753	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.48	5.4	0.32	1.45e-7	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
CESC	cis	rs1256061	0.624	rs1760988	chr14:64696813	A/G	cg23250157	chr14:64679961	SYNE2	0.52	7.37	0.41	2.22e-12	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg17322163	chr12:51632344	DAZAP2	-0.45	-6.04	-0.35	5.3e-9	Fibrinogen levels;
CESC	cis	rs1062177	1.000	rs2915880	chr5:151147334	G/A	cg12924095	chr5:151150029	G3BP1	0.48	6.2	0.36	2.21e-9	Preschool internalizing problems;
CESC	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg10295955	chr4:187884368	NA	-1.07	-22.28	-0.81	1.14e-62	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6987853	0.830	rs2272685	chr8:42354102	C/T	cg09913449	chr8:42400586	C8orf40	-0.34	-5.3	-0.31	2.38e-7	Mean corpuscular hemoglobin concentration;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg13787782	chr2:239161568	PER2	-0.49	-6.42	-0.37	6.19e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs11361923	1	rs11361923	chr14:77862679	GC/G	cg20045696	chr14:77926864	AHSA1	-0.44	-5.92	-0.34	1.01e-8	Sum basophil neutrophil counts;White blood cell count;Granulocyte count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10978402	chr15:90931990	IQGAP1	0.64	7.09	0.4	1.21e-11	Gut microbiome composition (summer);
CESC	cis	rs2251381	0.750	rs2776250	chr21:30528094	T/G	cg24692254	chr21:30365293	RNF160	0.78	10.6	0.55	4.11e-22	Selective IgA deficiency;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01761420	chr6:106534239	PRDM1	0.55	6.35	0.36	9.22e-10	Gut microbiome composition (summer);
CESC	cis	rs965469	0.895	rs6037595	chr20:3401128	T/G	cg25506879	chr20:3388711	C20orf194	-0.61	-6.46	-0.37	4.98e-10	IFN-related cytopenia;
CESC	cis	rs2243480	1.000	rs12698509	chr7:65418876	C/T	cg13147721	chr7:65941812	NA	-0.86	-8.63	-0.47	5.6e-16	Diabetic kidney disease;
CESC	cis	rs7635838	0.859	rs6779840	chr3:11425423	A/G	cg00170343	chr3:11313890	ATG7	0.42	5.61	0.33	5.14e-8	HDL cholesterol;
CESC	cis	rs7918232	0.830	rs7087033	chr10:27392522	A/G	cg14442939	chr10:27389572	ANKRD26	0.83	8.27	0.45	6.65e-15	Breast cancer;
CESC	cis	rs9443645	0.901	rs2152951	chr6:79762172	A/G	cg05283184	chr6:79620031	NA	0.42	6.59	0.38	2.38e-10	Intelligence (multi-trait analysis);
CESC	cis	rs7811142	1.000	rs7794485	chr7:100068936	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.12	10.61	0.55	3.66e-22	Platelet count;
CESC	cis	rs7811142	0.943	rs28660238	chr7:100023308	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.09	13.02	0.62	2.79e-30	Platelet count;
CESC	cis	rs1355223	0.545	rs7106831	chr11:34879542	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.55	-6.58	-0.37	2.5e-10	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs959260	0.557	rs4788887	chr17:73323876	C/G	cg20590849	chr17:73267439	MIF4GD	-0.44	-5.19	-0.3	4.12e-7	Systemic lupus erythematosus;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg00173170	chr1:214779122	CENPF	-0.44	-6.1	-0.35	3.73e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs2276314	0.802	rs9963714	chr18:33592056	T/C	cg05985134	chr18:33552581	C18orf21	0.61	7.12	0.4	1.01e-11	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs36051895	0.623	rs7859361	chr9:5237479	C/T	cg02405213	chr9:5042618	JAK2	-0.56	-6.62	-0.38	1.94e-10	Pediatric autoimmune diseases;
CESC	cis	rs9381040	0.674	rs3747742	chr6:41162518	C/T	cg03526776	chr6:41159608	TREML2	-0.39	-6.92	-0.39	3.32e-11	Alzheimer's disease (late onset);
CESC	cis	rs8180040	0.764	rs2132173	chr3:47247060	C/T	cg27129171	chr3:47204927	SETD2	-0.47	-6.62	-0.38	2.03e-10	Colorectal cancer;
CESC	cis	rs7666738	0.715	rs3857216	chr4:99032129	G/T	cg18180107	chr4:99064573	C4orf37	0.42	5.43	0.32	1.29e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4975709	0.959	rs9312959	chr5:1877008	G/A	cg17650747	chr5:1873721	NA	0.38	5.15	0.3	5.03e-7	Cardiovascular disease risk factors;
CESC	cis	rs2282802	0.685	rs6580515	chr5:139698110	A/C	cg26211634	chr5:139558579	C5orf32	-0.45	-6.43	-0.37	6e-10	Intelligence (multi-trait analysis);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg09920427	chr19:12777674	MORG1;MAN2B1	-0.46	-6.72	-0.38	1.12e-10	Gambling;
CESC	trans	rs1814175	0.669	rs11040455	chr11:49669829	G/C	cg03929089	chr4:120376271	NA	-0.73	-9.61	-0.51	5.76e-19	Height;
CESC	cis	rs6987853	0.761	rs2974356	chr8:42434633	C/T	cg09913449	chr8:42400586	C8orf40	0.46	7.65	0.43	3.68e-13	Mean corpuscular hemoglobin concentration;
CESC	cis	rs2276314	0.857	rs62101394	chr18:33592299	C/T	cg05985134	chr18:33552581	C18orf21	0.61	7.33	0.41	2.8e-12	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs3026445	0.926	rs28609096	chr12:110815922	A/G	cg12870014	chr12:110450643	ANKRD13A	0.42	5.2	0.3	4.07e-7	QT interval;
CESC	cis	rs2732480	0.500	rs12829841	chr12:48628739	A/G	cg24011408	chr12:48396354	COL2A1	0.43	5.9	0.34	1.11e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.08	19.95	0.77	1.03e-54	Prudent dietary pattern;
CESC	cis	rs9309473	1.000	rs13421462	chr2:73719875	A/C	cg20560298	chr2:73613845	ALMS1	-0.54	-7.05	-0.4	1.53e-11	Metabolite levels;
CESC	cis	rs1218582	0.803	rs7531728	chr1:154840516	C/A	cg03351412	chr1:154909251	PMVK	0.57	7.06	0.4	1.46e-11	Prostate cancer;
CESC	cis	rs1707322	0.686	rs2991986	chr1:46081282	A/G	cg05343316	chr1:45956843	TESK2	-0.52	-6.36	-0.36	8.62e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9858542	0.953	rs9811982	chr3:49624377	A/C	cg03060546	chr3:49711283	APEH	-0.52	-6.14	-0.35	3.03e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs9649465	1.000	rs3807640	chr7:123338713	G/C	cg04330084	chr7:123175371	IQUB	-0.39	-5.26	-0.31	2.95e-7	Migraine;
CESC	cis	rs2832191	0.671	rs2832212	chr21:30511417	G/A	cg24692254	chr21:30365293	RNF160	-0.61	-7.69	-0.43	2.86e-13	Dental caries;
CESC	cis	rs787274	0.543	rs1041086	chr9:115627744	C/G	cg13803584	chr9:115635662	SNX30	-0.66	-6.1	-0.35	3.77e-9	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs826838	1.000	rs11183214	chr12:38692938	C/T	cg26384229	chr12:38710491	ALG10B	0.83	15.17	0.68	7.62e-38	Heart rate;
CESC	cis	rs3736485	0.966	rs4775944	chr15:51775610	T/C	cg08986416	chr15:51914746	DMXL2	-0.42	-5.54	-0.32	7.22e-8	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs9649213	0.593	rs6948540	chr7:97960066	A/G	cg24562669	chr7:97807699	LMTK2	0.48	7.1	0.4	1.13e-11	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7264396	0.635	rs6060660	chr20:34476649	T/C	cg17201900	chr20:34330562	RBM39	0.5	5.09	0.3	6.68e-7	Total cholesterol levels;
CESC	cis	rs2635047	0.967	rs2571016	chr18:44639175	C/G	cg19077165	chr18:44547161	KATNAL2	0.47	6.38	0.36	7.86e-10	Educational attainment;
CESC	trans	rs7107217	1.000	rs1873872	chr11:129473993	A/T	cg13577407	chr3:57994372	FLNB	0.48	6.08	0.35	4.22e-9	Breast cancer;Type 2 diabetes;
CESC	cis	rs2836950	0.545	rs2836956	chr21:40623018	C/G	cg11890956	chr21:40555474	PSMG1	0.64	8.97	0.48	5.72e-17	Menarche (age at onset);
CESC	cis	rs4665809	0.590	rs62128455	chr2:26466530	G/A	cg04944784	chr2:26401820	FAM59B	0.96	10.55	0.54	5.79e-22	Gut microbiome composition (summer);
CESC	cis	rs950027	0.620	rs1346267	chr15:45690989	A/G	cg21132104	chr15:45694354	SPATA5L1	0.67	8.74	0.47	2.81e-16	Response to fenofibrate (adiponectin levels);
CESC	cis	rs262147	0.610	rs2657363	chr7:158684273	C/T	cg24397884	chr7:158709396	WDR60	0.68	5.16	0.3	4.85e-7	Hippocampal volume;
CESC	cis	rs2637266	0.703	rs1345043	chr10:78458824	G/T	cg18941641	chr10:78392320	NA	0.37	6.53	0.37	3.31e-10	Pulmonary function;
CESC	cis	rs597539	0.652	rs604524	chr11:68629929	G/A	cg04772025	chr11:68637568	NA	0.57	6.63	0.38	1.87e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg23979971	chr5:138677953	PAIP2	-0.47	-6.06	-0.35	4.67e-9	Ulcerative colitis;
CESC	cis	rs939574	0.790	rs72955440	chr2:220091765	A/C	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.88	7.38	0.41	2e-12	Platelet distribution width;
CESC	cis	rs7188697	0.922	rs11862156	chr16:58596753	C/T	cg21335942	chr16:58549945	SETD6	-0.45	-5.2	-0.3	4.06e-7	QT interval;
CESC	cis	rs4595586	0.545	rs12819907	chr12:39356906	A/G	cg26384229	chr12:38710491	ALG10B	0.54	7.63	0.42	4.31e-13	Morning vs. evening chronotype;
CESC	cis	rs780096	0.527	rs59644396	chr2:27646083	A/G	cg22903471	chr2:27725779	GCKR	-0.5	-7.04	-0.4	1.66e-11	Total body bone mineral density;
CESC	cis	rs11471957	1	rs11471957	chr20:57598332	C/CAA	cg14073986	chr20:57617431	SLMO2	0.62	6.07	0.35	4.49e-9	Platelet count;Mean platelet volume;
CESC	cis	rs10883723	0.773	rs715439	chr10:104257809	A/C	cg22532475	chr10:104410764	TRIM8	-0.34	-5.73	-0.33	2.77e-8	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs7580658	0.521	rs35577992	chr2:127941324	C/T	cg10021288	chr2:128175891	PROC	-0.33	-5.07	-0.3	7.32e-7	Protein C levels;
CESC	trans	rs2727020	0.894	rs1880438	chr11:49370698	A/G	cg03929089	chr4:120376271	NA	-0.65	-7.61	-0.42	4.95e-13	Coronary artery disease;
CESC	cis	rs920590	0.721	rs67989257	chr8:19660278	G/A	cg01411142	chr8:19674711	INTS10	0.53	5.89	0.34	1.14e-8	Acute lymphoblastic leukemia (childhood);
CESC	trans	rs7107217	1.000	rs1873872	chr11:129473993	A/T	cg17076397	chr5:10353763	MARCH6	0.49	6.57	0.37	2.7e-10	Breast cancer;Type 2 diabetes;
CESC	cis	rs709400	0.628	rs4906321	chr14:103878882	C/T	cg12935359	chr14:103987150	CKB	-0.49	-7.3	-0.41	3.29e-12	Body mass index;
CESC	cis	rs7560272	0.538	rs12233112	chr2:73931764	G/A	cg20560298	chr2:73613845	ALMS1	0.47	6.36	0.36	8.73e-10	Schizophrenia;
CESC	cis	rs7122539	0.646	rs594313	chr11:66608991	A/G	cg24851651	chr11:66362959	CCS	0.46	6.56	0.37	2.77e-10	HIV-1 susceptibility;
CESC	trans	rs7246760	0.867	rs57999229	chr19:9817357	C/T	cg02900749	chr2:68251473	NA	-0.86	-7.65	-0.43	3.79e-13	Pursuit maintenance gain;
CESC	cis	rs9926296	0.607	rs2079672	chr16:89884917	A/G	cg04287289	chr16:89883240	FANCA	-0.62	-8.69	-0.47	3.92e-16	Vitiligo;
CESC	cis	rs6461049	0.800	rs3800913	chr7:2163237	A/G	cg04267008	chr7:1944627	MAD1L1	-0.5	-5.89	-0.34	1.19e-8	Schizophrenia;
CESC	cis	rs9640161	0.750	rs11538922	chr7:150035183	C/T	cg17279839	chr7:150038598	RARRES2	0.45	5.34	0.31	2e-7	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs7264396	0.943	rs6060448	chr20:34112192	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.52	6.58	0.37	2.5e-10	Total cholesterol levels;
CESC	cis	rs3091242	0.933	rs926438	chr1:25753638	C/T	cg12412775	chr1:25698385	RHCE	-0.3	-5.3	-0.31	2.39e-7	Erythrocyte sedimentation rate;
CESC	cis	rs6500395	1.000	rs1224	chr16:48572817	G/A	cg04672837	chr16:48644449	N4BP1	0.5	6.21	0.36	2.04e-9	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs1577917	0.727	rs2758840	chr6:86304625	A/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.56	-7.8	-0.43	1.46e-13	Response to antipsychotic treatment;
CESC	cis	rs7828089	0.582	rs13259873	chr8:22266292	C/T	cg23129673	chr8:22266227	SLC39A14	0.37	5.47	0.32	1.03e-7	Verbal declarative memory;
CESC	cis	rs892961	0.932	rs7216155	chr17:75405155	C/G	cg05865280	chr17:75406074	SEPT9	0.59	10.95	0.56	2.82e-23	Airflow obstruction;
CESC	cis	rs7851660	0.548	rs1156850	chr9:100573164	G/A	cg13688889	chr9:100608707	NA	-0.9	-14.89	-0.67	7.55e-37	Strep throat;
CESC	cis	rs2836974	0.966	rs7283516	chr21:40690537	A/G	cg11644478	chr21:40555479	PSMG1	0.99	15.22	0.68	5.25e-38	Cognitive function;
CESC	trans	rs10435719	0.780	rs9692662	chr8:11789863	C/T	cg15556689	chr8:8085844	FLJ10661	0.52	6.48	0.37	4.4e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
CESC	cis	rs763121	0.853	rs9610993	chr22:39042818	C/A	cg06022373	chr22:39101656	GTPBP1	0.88	13.79	0.65	5.43e-33	Menopause (age at onset);
CESC	cis	rs17655565	0.581	rs1791626	chr12:52759979	T/C	cg00777198	chr12:52828273	KRT75	0.35	5.09	0.3	6.8e-7	Plasma amyloid beta peptide concentrations (ABx-42);
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg14156121	chr10:33948478	NA	-0.43	-6.34	-0.36	1.01e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs6493487	0.512	rs7170009	chr15:51323648	C/A	cg02338191	chr15:51200825	AP4E1	0.58	5.42	0.32	1.34e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs4835473	0.801	rs35839125	chr4:144713504	C/A	cg25736465	chr4:144833511	NA	-0.35	-5.83	-0.34	1.59e-8	Immature fraction of reticulocytes;
CESC	cis	rs9811920	0.809	rs6806323	chr3:99722564	C/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.47	-7.82	-0.43	1.23e-13	Axial length;
CESC	cis	rs9611565	0.802	rs73176694	chr22:41786788	C/T	cg06481639	chr22:41940642	POLR3H	-0.63	-6.6	-0.38	2.22e-10	Vitiligo;
CESC	cis	rs7811142	1.000	rs60844404	chr7:100080474	A/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.84	8.31	0.45	4.88e-15	Platelet count;
CESC	cis	rs7692995	0.841	rs6449349	chr4:17952609	C/G	cg08925142	chr4:18023851	LCORL	-0.45	-5.26	-0.31	2.97e-7	Height;
CESC	cis	rs7917772	0.503	rs11191330	chr10:104306160	G/T	cg22532475	chr10:104410764	TRIM8	-0.33	-5.74	-0.33	2.65e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs597539	0.652	rs627731	chr11:68698663	A/C	cg06028808	chr11:68637592	NA	0.43	5.18	0.3	4.36e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs13082711	0.871	rs73046194	chr3:27454558	C/T	cg02860705	chr3:27208620	NA	0.54	7.0	0.39	2.13e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CESC	cis	rs10504229	1.000	rs17816781	chr8:58186161	A/T	cg14926445	chr8:58193284	C8orf71	-0.51	-5.52	-0.32	8.28e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs7208859	0.623	rs2035494	chr17:29130393	T/G	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.79e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs10129255	0.556	rs6576224	chr14:107186236	G/A	cg07958169	chr14:107095056	NA	-0.54	-8.51	-0.46	1.3e-15	Kawasaki disease;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg20252016	chr11:64851499	CDCA5;ZFPL1	-0.4	-6.27	-0.36	1.49e-9	Gambling;
CESC	cis	rs8020095	0.528	rs8003327	chr14:67855598	C/G	cg19548862	chr14:67692701	FAM71D	-0.45	-5.26	-0.31	2.98e-7	Depression (quantitative trait);
CESC	cis	rs7178909	0.797	rs1910586	chr15:90440489	T/G	cg19708238	chr15:90437601	AP3S2	0.46	6.52	0.37	3.52e-10	Common traits (Other);
CESC	cis	rs4689388	0.889	rs4629534	chr4:6294124	G/T	cg14416269	chr4:6271139	WFS1	0.46	7.73	0.43	2.23e-13	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs1003719	0.762	rs9975361	chr21:38450025	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.62	8.64	0.47	5.56e-16	Eye color traits;
CESC	cis	rs780096	0.526	rs780117	chr2:27698343	C/G	cg21248554	chr2:27665150	KRTCAP3	-0.36	-7.4	-0.41	1.8e-12	Total body bone mineral density;
CESC	cis	rs4648845	0.777	rs2477689	chr1:2395538	G/C	cg13556452	chr1:2391241	NA	-0.34	-5.64	-0.33	4.45e-8	Schizophrenia;
CESC	cis	rs7592578	0.882	rs58568707	chr2:191468987	G/A	cg27211696	chr2:191398769	TMEM194B	-0.62	-5.67	-0.33	3.64e-8	Diastolic blood pressure;
CESC	cis	rs763121	0.853	rs11704021	chr22:39074716	G/A	cg06544989	chr22:39130855	UNC84B	0.51	8.92	0.48	7.61e-17	Menopause (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20979926	chr12:112546623	NAA25	0.66	7.33	0.41	2.74e-12	Gut microbiome composition (summer);
CESC	cis	rs2295499	0.673	rs55688738	chr4:2704628	G/C	cg08330972	chr4:2403930	ZFYVE28	-0.32	-5.13	-0.3	5.58e-7	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
CESC	trans	rs11722228	0.521	rs56403947	chr4:10112529	T/G	cg26043149	chr18:55253948	FECH	0.99	11.82	0.59	3.63e-26	Gout;Urate levels;Serum uric acid levels;
CESC	cis	rs7618915	0.547	rs11130313	chr3:52676190	A/C	cg18404041	chr3:52824283	ITIH1	-0.39	-6.55	-0.37	2.9e-10	Bipolar disorder;
CESC	cis	rs854765	0.583	rs8065970	chr17:17858771	A/G	cg04398451	chr17:18023971	MYO15A	-0.69	-9.72	-0.51	2.77e-19	Total body bone mineral density;
CESC	trans	rs3780486	0.846	rs6476402	chr9:33148552	G/A	cg04842962	chr6:43655489	MRPS18A	0.96	17.48	0.73	4.82e-46	IgG glycosylation;
CESC	cis	rs75477785	0.590	rs17015566	chr1:210244865	T/C	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.92	6.23	0.36	1.82e-9	Cleft lip with or without cleft palate;
CESC	cis	rs2050392	0.630	rs303426	chr10:30740379	A/G	cg18806716	chr10:30721971	MAP3K8	0.39	5.8	0.34	1.89e-8	Inflammatory bowel disease;
CESC	cis	rs9788721	0.592	rs28564957	chr15:78906107	C/A	cg24631222	chr15:78858424	CHRNA5	0.43	5.46	0.32	1.08e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
CESC	cis	rs2439831	0.867	rs689616	chr15:43761901	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.89	10.58	0.54	4.72e-22	Lung cancer in ever smokers;
CESC	cis	rs11122272	0.735	rs2790892	chr1:231512771	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.57	-7.8	-0.43	1.41e-13	Hemoglobin concentration;
CESC	cis	rs11122272	0.705	rs2790879	chr1:231534389	A/C	cg06096015	chr1:231504339	EGLN1	0.38	5.29	0.31	2.54e-7	Hemoglobin concentration;
CESC	cis	rs116095464	0.558	rs1971229	chr5:268187	A/G	cg22857025	chr5:266934	NA	-1.3	-18.55	-0.75	8.05e-50	Breast cancer;
CESC	cis	rs7605827	0.704	rs62120513	chr2:15537727	T/A	cg19274914	chr2:15703543	NA	0.36	6.55	0.37	2.91e-10	Educational attainment (years of education);
CESC	cis	rs17826219	0.500	rs57005940	chr17:29066329	C/G	cg14008862	chr17:28927542	LRRC37B2	0.65	5.14	0.3	5.34e-7	Body mass index;
CESC	cis	rs7937682	0.883	rs553632	chr11:111462897	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.9	-12.87	-0.62	9.33e-30	Primary sclerosing cholangitis;
CESC	cis	rs79387448	0.576	rs11902044	chr2:102972534	C/T	cg09003973	chr2:102972529	NA	1.2	9.29	0.5	6.03e-18	Gut microbiota (bacterial taxa);
CESC	cis	rs6424115	0.830	rs2502999	chr1:24198321	A/G	cg10978503	chr1:24200527	CNR2	0.34	6.72	0.38	1.11e-10	Immature fraction of reticulocytes;
CESC	cis	rs4810479	0.513	rs3746506	chr20:44586036	G/A	cg17986701	chr20:44574422	PCIF1	0.33	5.05	0.3	8.38e-7	Metabolite levels;
CESC	cis	rs853679	0.542	rs2295594	chr6:28053097	G/A	cg26335602	chr6:28129616	ZNF389	0.53	7.05	0.4	1.55e-11	Depression;
CESC	cis	rs3796619	0.924	rs11940546	chr4:1072485	C/T	cg27284194	chr4:1044797	NA	0.37	5.53	0.32	7.53e-8	Recombination rate (males);
CESC	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.55	-6.1	-0.35	3.69e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs9300255	0.568	rs3018098	chr12:123654812	T/C	cg05973401	chr12:123451056	ABCB9	0.5	5.7	0.33	3.19e-8	Neutrophil percentage of white cells;
CESC	cis	rs72781680	0.821	rs2339887	chr2:24198376	G/A	cg08917208	chr2:24149416	ATAD2B	0.66	6.5	0.37	3.98e-10	Lymphocyte counts;
CESC	cis	rs858239	0.669	rs6461688	chr7:23116615	G/A	cg23682824	chr7:23144976	KLHL7	0.46	6.12	0.35	3.35e-9	Cerebrospinal fluid biomarker levels;
CESC	trans	rs7618501	0.815	rs3819325	chr3:49843723	T/C	cg21659725	chr3:3221576	CRBN	0.83	13.22	0.63	5.57e-31	Intelligence (multi-trait analysis);
CESC	cis	rs57506017	0.540	rs12699323	chr7:12253362	T/C	cg23422036	chr7:12250390	TMEM106B	0.38	5.17	0.3	4.71e-7	Neuroticism;
CESC	cis	rs2070677	0.866	rs2492664	chr10:135387240	G/T	cg20169779	chr10:135381914	SYCE1	-0.75	-10.24	-0.53	5.91e-21	Gout;
CESC	cis	rs75477785	0.590	rs760768	chr1:210177234	A/G	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.92	6.23	0.36	1.82e-9	Cleft lip with or without cleft palate;
CESC	cis	rs4713118	0.527	rs9461433	chr6:28095172	C/T	cg26335602	chr6:28129616	ZNF389	0.53	7.09	0.4	1.19e-11	Parkinson's disease;
CESC	cis	rs644148	0.967	rs2686778	chr19:44972257	G/A	cg15540054	chr19:45004280	ZNF180	-0.72	-8.77	-0.47	2.23e-16	Personality dimensions;
CESC	cis	rs1008375	1.000	rs4698649	chr4:17692782	A/G	cg02297831	chr4:17616191	MED28	0.46	5.62	0.33	4.91e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs863345	0.504	rs2022386	chr1:158563076	G/A	cg12129480	chr1:158549410	OR10X1	-0.3	-5.58	-0.32	6.04e-8	Pneumococcal bacteremia;
CESC	cis	rs3740713	1.000	rs73440637	chr11:18474128	C/A	cg23797887	chr11:18477753	LDHAL6A	-0.56	-5.18	-0.3	4.3e-7	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs4727027	0.870	rs62507509	chr7:148795522	C/T	cg23583168	chr7:148888333	NA	-0.79	-12.1	-0.6	4.02e-27	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs10979	1.000	rs11155300	chr6:143894576	A/G	cg25407410	chr6:143891975	LOC285740	-0.61	-9.2	-0.49	1.13e-17	Hypospadias;
CESC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg04293180	chr8:144700367	TSTA3	0.49	6.62	0.38	2.03e-10	Tetralogy of Fallot;
CESC	cis	rs75804782	0.521	rs56176151	chr2:239440220	T/C	cg18131467	chr2:239335373	ASB1	-0.69	-5.5	-0.32	9.1e-8	Morning vs. evening chronotype;Chronotype;
CESC	cis	rs9811920	0.609	rs793465	chr3:99627750	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.59	7.22	0.41	5.61e-12	Axial length;
CESC	cis	rs881375	0.678	rs3761846	chr9:123689597	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.37	5.21	0.3	3.76e-7	Rheumatoid arthritis;
CESC	cis	rs7647973	0.677	rs11130211	chr3:49645209	C/T	cg13072238	chr3:49761600	GMPPB	-0.51	-6.14	-0.35	3.03e-9	Menarche (age at onset);
CESC	trans	rs2727020	0.595	rs11040416	chr11:49566429	C/T	cg03929089	chr4:120376271	NA	-0.85	-13.62	-0.64	2.23e-32	Coronary artery disease;
CESC	cis	rs3774749	0.565	rs2188151	chr3:50201924	A/C	cg24110177	chr3:50126178	RBM5	0.39	5.31	0.31	2.3e-7	Intelligence (multi-trait analysis);
CESC	cis	rs7666738	0.530	rs2865992	chr4:99067181	A/T	cg05340658	chr4:99064831	C4orf37	0.59	7.96	0.44	5.16e-14	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7659604	0.539	rs1507995	chr4:122748308	G/A	cg06713675	chr4:122721982	EXOSC9	-0.5	-6.82	-0.39	6.07e-11	Type 2 diabetes;
CESC	cis	rs250677	0.687	rs1422581	chr5:148437386	C/T	cg18129178	chr5:148520854	ABLIM3	0.48	5.53	0.32	7.54e-8	Breast cancer;
CESC	cis	rs514406	0.525	rs269291	chr1:53189297	C/T	cg24675658	chr1:53192096	ZYG11B	-0.61	-7.44	-0.42	1.42e-12	Monocyte count;
CESC	cis	rs9361491	0.657	rs9341742	chr6:79440229	C/T	cg05283184	chr6:79620031	NA	-0.34	-5.1	-0.3	6.51e-7	Intelligence (multi-trait analysis);
CESC	cis	rs2370759	1.000	rs11008865	chr10:32574842	C/T	cg05361325	chr10:32636312	EPC1	-0.54	-5.12	-0.3	6e-7	Sexual dysfunction (female);
CESC	cis	rs593982	1.000	rs1941746	chr11:65502413	A/G	cg08755490	chr11:65554678	OVOL1	1.31	20.14	0.78	2.41e-55	Atopic dermatitis;
CESC	cis	rs5758511	0.633	rs5758689	chr22:42664972	T/G	cg00645731	chr22:42541494	CYP2D7P1	0.58	8.76	0.47	2.43e-16	Birth weight;
CESC	cis	rs1568889	1.000	rs2354427	chr11:28049623	T/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.77	10.85	0.55	6.02e-23	Bipolar disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09301471	chr16:89349945	ANKRD11	-0.57	-6.84	-0.39	5.56e-11	Gut microbiome composition (summer);
CESC	cis	rs6028335	0.674	rs3752301	chr20:37654024	T/G	cg16355469	chr20:37678765	NA	0.54	5.28	0.31	2.74e-7	Alcohol and nicotine co-dependence;
CESC	cis	rs34779708	0.931	rs2384287	chr10:35340559	A/G	cg03585969	chr10:35415529	CREM	0.76	9.74	0.51	2.35e-19	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs514406	0.505	rs387436	chr1:53179376	C/T	cg16325326	chr1:53192061	ZYG11B	-0.91	-16.01	-0.7	8.25e-41	Monocyte count;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg01184520	chr16:75032509	ZNRF1	0.38	6.14	0.35	2.94e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs2228479	0.850	rs11644213	chr16:89837367	C/T	cg04013166	chr16:89971882	TCF25	-0.67	-6.01	-0.35	6.22e-9	Skin colour saturation;
CESC	cis	rs2836974	0.931	rs2836972	chr21:40652142	G/A	cg17971929	chr21:40555470	PSMG1	1.08	16.28	0.71	9.03e-42	Cognitive function;
CESC	cis	rs7811142	1.000	rs4463351	chr7:100078226	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.83	8.24	0.45	7.99e-15	Platelet count;
CESC	cis	rs7811142	1.000	rs4472444	chr7:100070758	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.87	9.14	0.49	1.7e-17	Platelet count;
CESC	cis	rs7666738	1.000	rs1426673	chr4:98924024	G/A	cg17366294	chr4:99064904	C4orf37	0.51	6.62	0.38	1.93e-10	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4481887	0.821	rs7515408	chr1:248425738	C/T	cg00666640	chr1:248458726	OR2T12	0.41	6.69	0.38	1.32e-10	Common traits (Other);
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg26612252	chr16:48643305	N4BP1	-0.47	-6.6	-0.38	2.21e-10	Asthma;
CESC	cis	rs4629710	0.592	rs9492877	chr6:131562577	C/G	cg12606694	chr6:131520996	AKAP7	0.49	6.05	0.35	4.81e-9	Multiple myeloma (IgH translocation);
CESC	cis	rs2197308	0.765	rs11182992	chr12:37935572	G/C	cg13010199	chr12:38710504	ALG10B	0.53	6.77	0.38	8.4e-11	Morning vs. evening chronotype;
CESC	cis	rs2637266	0.686	rs1660915	chr10:78525318	T/A	cg18941641	chr10:78392320	NA	0.41	7.54	0.42	7.33e-13	Pulmonary function;
CESC	cis	rs7666738	0.830	rs28594127	chr4:99001121	T/G	cg03467027	chr4:99064603	C4orf37	0.44	5.51	0.32	8.65e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4604732	0.631	rs12031721	chr1:247623773	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.55	6.86	0.39	4.77e-11	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs6088580	0.524	rs6088568	chr20:33265971	A/C	cg08999081	chr20:33150536	PIGU	-0.45	-6.29	-0.36	1.33e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs1707322	1.000	rs4524994	chr1:46370263	A/G	cg05343316	chr1:45956843	TESK2	0.44	5.55	0.32	7.05e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs863345	0.625	rs12063360	chr1:158499494	A/C	cg12129480	chr1:158549410	OR10X1	-0.34	-6.84	-0.39	5.41e-11	Pneumococcal bacteremia;
CESC	cis	rs1538970	0.962	rs7544178	chr1:45819069	C/T	cg03146154	chr1:46216737	IPP	0.45	5.38	0.31	1.62e-7	Platelet count;
CESC	cis	rs801193	1.000	rs2003301	chr7:66147656	G/C	cg18876405	chr7:65276391	NA	-0.51	-6.73	-0.38	1.05e-10	Aortic root size;
CESC	cis	rs4523957	0.559	rs170040	chr17:2165714	C/T	cg16513277	chr17:2031491	SMG6	0.59	6.78	0.38	7.62e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs9916302	0.904	rs6503506	chr17:37524653	C/A	cg20243544	chr17:37824526	PNMT	-0.47	-5.97	-0.34	7.6e-9	Glomerular filtration rate (creatinine);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23332732	chr12:26986274	ITPR2	0.58	6.19	0.36	2.27e-9	Gut microbiome composition (summer);
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg13894163	chr9:136932022	BRD3	0.42	6.06	0.35	4.72e-9	Systemic lupus erythematosus;
CESC	cis	rs7296418	0.922	rs12425009	chr12:123502044	C/T	cg05973401	chr12:123451056	ABCB9	0.58	7.62	0.42	4.54e-13	Platelet count;
CESC	trans	rs7178375	1.000	rs7176351	chr15:31208727	G/A	cg04373760	chr16:53404718	NA	0.58	7.71	0.43	2.54e-13	Hypertriglyceridemia;
CESC	cis	rs10861342	1.000	rs12320123	chr12:105492167	C/T	cg23923672	chr12:105501055	KIAA1033	0.65	5.29	0.31	2.52e-7	IgG glycosylation;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11207852	chr1:91966655	CDC7	0.62	7.27	0.41	4.08e-12	Gut microbiome composition (summer);
CESC	cis	rs11190604	1.000	rs7090431	chr10:102261753	A/G	cg07080220	chr10:102295463	HIF1AN	0.66	6.48	0.37	4.45e-10	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs853679	0.882	rs3757188	chr6:28107357	T/C	cg23372001	chr6:27791640	HIST1H4J	0.57	5.18	0.3	4.48e-7	Depression;
CESC	cis	rs68170813	0.559	rs77422419	chr7:106957932	A/G	cg02696742	chr7:106810147	HBP1	-0.53	-5.03	-0.3	8.96e-7	Coronary artery disease;
CESC	cis	rs790123	0.965	rs2133850	chr3:122381696	C/T	cg17380795	chr3:122379686	NA	0.35	5.22	0.31	3.61e-7	Response to angiotensin II receptor blocker therapy;
CESC	trans	rs116095464	0.558	rs10462755	chr5:246748	T/C	cg00938859	chr5:1591904	SDHAP3	0.63	6.92	0.39	3.29e-11	Breast cancer;
CESC	cis	rs873946	0.564	rs12263364	chr10:134555548	G/T	cg26818010	chr10:134567672	INPP5A	-0.8	-9.85	-0.52	1.04e-19	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs10242455	0.702	rs73713531	chr7:99222379	C/T	cg24650262	chr7:98904301	NA	0.57	5.07	0.3	7.38e-7	Blood metabolite levels;
CESC	cis	rs7786808	0.649	rs1377374	chr7:158215647	G/T	cg09998033	chr7:158218633	PTPRN2	0.37	5.71	0.33	2.96e-8	Obesity-related traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13987669	chr5:33440719	TARS	0.57	6.32	0.36	1.13e-9	Gut microbiome composition (summer);
CESC	cis	rs6032067	0.641	rs74174932	chr20:43756133	G/A	cg10761708	chr20:43804764	PI3	0.5	5.25	0.31	3.12e-7	Blood protein levels;
CESC	cis	rs1448094	0.512	rs6539924	chr12:86236935	T/C	cg00310523	chr12:86230176	RASSF9	0.36	5.51	0.32	8.38e-8	Major depressive disorder;
CESC	cis	rs9457247	0.663	rs9459839	chr6:167431829	T/C	cg25258033	chr6:167368657	RNASET2	0.35	5.13	0.3	5.7e-7	Crohn's disease;
CESC	cis	rs1878931	0.668	rs2074366	chr16:3439676	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	1.03	16.68	0.72	3.5e-43	Body mass index (adult);
CESC	cis	rs921968	0.541	rs636723	chr2:219373197	A/G	cg02176678	chr2:219576539	TTLL4	0.5	9.05	0.49	3.15e-17	Mean corpuscular hemoglobin concentration;
CESC	cis	rs9303401	0.580	rs34076823	chr17:57114497	C/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.89	11.06	0.56	1.21e-23	Cognitive test performance;
CESC	cis	rs9486715	0.867	rs9373887	chr6:96957004	C/T	cg06623918	chr6:96969491	KIAA0776	0.92	14.08	0.65	5.46e-34	Headache;
CESC	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg10150615	chr22:24372951	LOC391322	-0.48	-6.22	-0.36	1.94e-9	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs9811920	0.581	rs793468	chr3:99538346	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.5	-5.99	-0.35	6.71e-9	Axial length;
CESC	cis	rs10423674	0.526	rs757317	chr19:18819984	C/T	cg14292368	chr19:18793705	CRTC1	-0.46	-5.89	-0.34	1.14e-8	Menarche (age at onset);
CESC	cis	rs2011503	0.941	rs4808934	chr19:19370917	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.53	5.53	0.32	7.55e-8	Bipolar disorder;
CESC	cis	rs16854884	1.000	rs58251824	chr3:143786258	T/C	cg06585982	chr3:143692056	C3orf58	0.46	5.65	0.33	4.2e-8	Economic and political preferences (feminism/equality);
CESC	cis	rs425277	0.539	rs3128338	chr1:2046786	G/A	cg04315214	chr1:2043799	PRKCZ	0.65	11.4	0.57	9.18e-25	Height;
CESC	cis	rs977987	0.933	rs4888431	chr16:75500699	G/T	cg03315344	chr16:75512273	CHST6	0.53	7.8	0.43	1.42e-13	Dupuytren's disease;
CESC	trans	rs4906172	0.773	rs1190613	chr14:102521534	A/G	cg17920195	chr4:129149383	NA	0.32	6.28	0.36	1.39e-9	Menopause (age at onset);
CESC	cis	rs9549367	0.673	rs575453	chr13:113837871	C/A	cg00898013	chr13:113819073	PROZ	0.47	6.89	0.39	3.97e-11	Platelet distribution width;
CESC	cis	rs7618915	0.547	rs62253733	chr3:52653414	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.48	6.77	0.38	8.42e-11	Bipolar disorder;
CESC	cis	rs35306767	0.903	rs34847097	chr10:902252	A/T	cg26597838	chr10:835615	NA	0.86	8.93	0.48	7.33e-17	Eosinophil percentage of granulocytes;
CESC	cis	rs35306767	0.715	rs11253539	chr10:1011347	G/A	cg20503657	chr10:835505	NA	0.71	6.72	0.38	1.12e-10	Eosinophil percentage of granulocytes;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg14757344	chr21:45209507	RRP1	0.48	6.5	0.37	3.88e-10	Systemic lupus erythematosus;
CESC	cis	rs12422267	0.609	rs10128884	chr12:132621624	C/T	cg09764611	chr12:132620959	NA	-0.53	-7.15	-0.4	8.44e-12	Plasma amyloid beta peptide concentrations (ABx-40);
CESC	cis	rs7412746	0.611	rs10888398	chr1:150886782	A/G	cg04414720	chr1:150670196	GOLPH3L	-0.45	-5.95	-0.34	8.38e-9	Melanoma;
CESC	cis	rs7772486	0.790	rs2243665	chr6:146208120	A/C	cg05347473	chr6:146136440	FBXO30	0.5	6.03	0.35	5.47e-9	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6987853	0.661	rs6988493	chr8:42351328	C/T	cg09913449	chr8:42400586	C8orf40	-0.37	-6.01	-0.35	6.23e-9	Mean corpuscular hemoglobin concentration;
CESC	cis	rs1552244	0.882	rs6796419	chr3:10040812	G/A	cg00149659	chr3:10157352	C3orf10	0.69	8.19	0.45	1.12e-14	Alzheimer's disease;
CESC	cis	rs11098499	0.865	rs11722183	chr4:120280597	A/C	cg24375607	chr4:120327624	NA	0.45	5.51	0.32	8.29e-8	Corneal astigmatism;
CESC	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg24642844	chr7:1081250	C7orf50	-0.77	-9.63	-0.51	5.27e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7666738	0.830	rs10050008	chr4:99025313	T/G	cg05340658	chr4:99064831	C4orf37	0.83	13.1	0.63	1.43e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6540556	0.723	rs11119327	chr1:209883804	T/C	cg05527609	chr1:210001259	C1orf107	-0.69	-7.48	-0.42	1.08e-12	Red blood cell count;
CESC	cis	rs13242816	1.000	rs987790	chr7:116134633	T/A	cg04696780	chr7:116139425	CAV2	-0.61	-5.51	-0.32	8.44e-8	P wave duration;
CESC	cis	rs7408868	1.000	rs10420466	chr19:15261371	G/T	cg14696996	chr19:15285081	NOTCH3	1.12	11.29	0.57	2.08e-24	Pulse pressure;
CESC	cis	rs12313068	0.656	rs41436646	chr12:110495171	C/G	cg12870014	chr12:110450643	ANKRD13A	0.83	9.43	0.5	2.1e-18	Intelligence (multi-trait analysis);
CESC	trans	rs9693444	0.898	rs4732697	chr8:29519861	A/G	cg09115837	chr10:79541592	NA	0.43	6.03	0.35	5.35e-9	Breast cancer;
CESC	cis	rs7615952	0.512	rs4646765	chr3:125820707	G/A	cg06494592	chr3:125709126	NA	-0.51	-5.44	-0.32	1.22e-7	Blood pressure (smoking interaction);
CESC	cis	rs113835537	0.866	rs59566349	chr11:66365994	A/T	cg24851651	chr11:66362959	CCS	0.63	5.6	0.33	5.28e-8	Airway imaging phenotypes;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg08642743	chr17:74099944	EXOC7	0.48	6.39	0.37	7.25e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg05342987	chr14:59655273	DAAM1	-0.53	-6.84	-0.39	5.33e-11	Ulcerative colitis;
CESC	cis	rs2012796	0.704	rs57670850	chr14:81841577	C/T	cg02996355	chr14:81879375	NA	0.67	8.1	0.45	2.07e-14	Night sleep phenotypes;
CESC	cis	rs7267979	1.000	rs6037095	chr20:25335687	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.84	-16.48	-0.71	1.75e-42	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs6831352	0.918	rs13110176	chr4:100062430	C/T	cg13256891	chr4:100009986	ADH5	0.74	8.35	0.46	3.84e-15	Alcohol dependence;
CESC	cis	rs597539	0.654	rs7107137	chr11:68623712	A/G	cg04772025	chr11:68637568	NA	0.53	5.95	0.34	8.3e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs9457247	0.534	rs1130033	chr6:167385623	C/T	cg23791538	chr6:167370224	RNASET2	-0.72	-10.2	-0.53	7.92e-21	Crohn's disease;
CESC	cis	rs854765	0.647	rs854814	chr17:18003648	G/A	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.48	6.05	0.35	4.92e-9	Total body bone mineral density;
CESC	cis	rs5769765	0.773	rs7410291	chr22:50300078	A/G	cg02269571	chr22:50332266	NA	-0.49	-6.49	-0.37	4.14e-10	Schizophrenia;
CESC	cis	rs8067354	0.574	rs1296279	chr17:57965731	G/A	cg13753209	chr17:57696993	CLTC	0.55	5.84	0.34	1.49e-8	Hemoglobin concentration;
CESC	cis	rs1797885	0.651	rs1552485	chr3:12580283	C/T	cg26432171	chr3:12704882	RAF1	0.53	6.91	0.39	3.71e-11	Immature fraction of reticulocytes;
CESC	cis	rs9900062	0.844	rs9908143	chr17:62754586	T/C	cg02598441	chr17:62777298	LOC146880	-0.57	-5.62	-0.33	4.84e-8	QT interval;
CESC	cis	rs2243480	1.000	rs431318	chr7:65511597	G/A	cg12463550	chr7:65579703	CRCP	0.69	5.37	0.31	1.74e-7	Diabetic kidney disease;
CESC	cis	rs1005277	0.540	rs1987431	chr10:37988887	T/C	cg25517755	chr10:38738941	LOC399744	-0.42	-5.42	-0.32	1.34e-7	Extrinsic epigenetic age acceleration;
CESC	cis	rs933688	1.000	rs186717	chr5:90780467	T/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.03	13.27	0.63	3.59e-31	Smoking behavior;
CESC	trans	rs7628583	0.660	rs11718458	chr3:64076420	T/C	cg18893528	chr10:4296406	NA	0.46	6.01	0.35	5.98e-9	Parental extreme longevity (95 years and older);
CESC	cis	rs8014204	0.935	rs2853779	chr14:75368508	G/A	cg08847533	chr14:75593920	NEK9	-0.47	-5.79	-0.34	1.94e-8	Caffeine consumption;
CESC	cis	rs34779708	0.931	rs34815241	chr10:35296676	T/C	cg03585969	chr10:35415529	CREM	0.75	9.74	0.51	2.26e-19	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs6582630	0.519	rs8189561	chr12:38296178	G/A	cg13010199	chr12:38710504	ALG10B	0.45	5.65	0.33	4.06e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs7208859	0.623	rs55961983	chr17:29119286	G/A	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.1e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs1499614	1.000	rs2707838	chr7:66159201	C/T	cg18252515	chr7:66147081	NA	-1.42	-14.62	-0.67	6.69e-36	Gout;
CESC	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg07157834	chr1:205819609	PM20D1	0.45	6.56	0.37	2.88e-10	Menarche (age at onset);
CESC	cis	rs79387448	0.638	rs11465698	chr2:103054577	T/C	cg09003973	chr2:102972529	NA	0.94	7.25	0.41	4.66e-12	Gut microbiota (bacterial taxa);
CESC	cis	rs6502050	0.799	rs9911129	chr17:80087819	C/T	cg23985595	chr17:80112537	CCDC57	-0.42	-6.6	-0.38	2.18e-10	Life satisfaction;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15153026	chr7:143058944	FAM131B	0.57	6.18	0.35	2.35e-9	Gut microbiome composition (summer);
CESC	cis	rs8067545	0.750	rs4925080	chr17:19991838	T/A	cg13482628	chr17:19912719	NA	0.4	5.33	0.31	2.12e-7	Schizophrenia;
CESC	cis	rs10908458	0.743	rs7367207	chr1:155079477	C/T	cg27045062	chr1:155054711	EFNA3	0.37	5.1	0.3	6.58e-7	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs16922576	0.623	rs2093446	chr9:5230371	G/C	cg02405213	chr9:5042618	JAK2	-0.58	-6.61	-0.38	2.05e-10	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs73206853	0.841	rs56887341	chr12:110947185	T/C	cg12870014	chr12:110450643	ANKRD13A	0.65	5.59	0.32	5.78e-8	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs2286503	0.780	rs2286506	chr7:22854815	T/C	cg11367502	chr7:22862612	TOMM7	0.39	5.14	0.3	5.45e-7	Fibrinogen;
CESC	cis	rs9611565	0.729	rs4822027	chr22:41786227	G/A	cg06634786	chr22:41940651	POLR3H	-0.73	-7.69	-0.43	2.96e-13	Vitiligo;
CESC	cis	rs7587476	0.784	rs34112702	chr2:215696002	A/G	cg04004882	chr2:215674386	BARD1	0.49	5.34	0.31	2.02e-7	Neuroblastoma;
CESC	trans	rs61931739	0.517	rs10844727	chr12:34017435	C/T	cg26384229	chr12:38710491	ALG10B	0.5	6.87	0.39	4.63e-11	Morning vs. evening chronotype;
CESC	trans	rs61931739	0.517	rs10844815	chr12:34245150	G/A	cg26384229	chr12:38710491	ALG10B	0.63	9.14	0.49	1.66e-17	Morning vs. evening chronotype;
CESC	cis	rs853679	0.517	rs9468286	chr6:28079428	C/T	cg20151795	chr6:28129481	ZNF389	0.45	5.87	0.34	1.29e-8	Depression;
CESC	trans	rs7615952	0.599	rs60847438	chr3:125746005	T/C	cg07211511	chr3:129823064	LOC729375	-0.6	-6.66	-0.38	1.62e-10	Blood pressure (smoking interaction);
CESC	cis	rs875971	0.545	rs6969224	chr7:65834998	T/G	cg11764359	chr7:65958608	NA	0.82	9.29	0.5	6.03e-18	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18235443	chr1:150980829	FAM63A;PRUNE	0.59	6.64	0.38	1.82e-10	Gut microbiome composition (summer);
CESC	cis	rs6598955	0.724	rs4659420	chr1:26614333	G/A	cg00852783	chr1:26633632	UBXN11	0.42	6.23	0.36	1.79e-9	Obesity-related traits;
CESC	cis	rs9911578	1.000	rs11869828	chr17:56609525	G/A	cg05425664	chr17:57184151	TRIM37	0.5	7.06	0.4	1.5e-11	Intelligence (multi-trait analysis);
CESC	cis	rs7602441	0.521	rs74742552	chr2:14773375	G/T	cg06545361	chr2:14773388	FAM84A	0.68	6.34	0.36	1.01e-9	Visceral adipose tissue adjusted for BMI;
CESC	trans	rs561341	1.000	rs483301	chr17:30293398	G/T	cg20587970	chr11:113659929	NA	-1.48	-19.48	-0.77	4.55e-53	Hip circumference adjusted for BMI;
CESC	cis	rs61784830	0.710	rs61783196	chr1:46291790	C/T	cg03146154	chr1:46216737	IPP	0.69	5.59	0.33	5.51e-8	Iron status biomarkers (total iron binding capacity);
CESC	cis	rs7605827	0.930	rs13030859	chr2:15701038	G/A	cg19274914	chr2:15703543	NA	0.3	5.34	0.31	2.03e-7	Educational attainment (years of education);
CESC	cis	rs6912958	0.781	rs1051148	chr6:88221892	T/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.5	-6.73	-0.38	1.06e-10	Monocyte percentage of white cells;
CESC	cis	rs7089973	0.604	rs11196932	chr10:116584386	C/T	cg23260525	chr10:116636907	FAM160B1	0.38	6.86	0.39	4.82e-11	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs13191362	1.000	rs7764785	chr6:163009967	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.5	5.17	0.3	4.63e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs13191362	1.000	rs13214516	chr6:163121583	A/T	cg21926612	chr6:163149169	PACRG;PARK2	1.07	11.07	0.56	1.14e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11412256	chr1:228612818	HIST3H3	-0.67	-7.57	-0.42	6.2800000000000005e-13	Gut microbiome composition (summer);
CESC	cis	rs2425143	0.841	rs4911519	chr20:34362326	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.8	7.75	0.43	1.96e-13	Blood protein levels;
CESC	cis	rs1218582	0.772	rs2102423	chr1:154916068	A/G	cg09359103	chr1:154839909	KCNN3	-0.67	-12.43	-0.61	2.92e-28	Prostate cancer;
CESC	cis	rs9611565	0.694	rs202613	chr22:41821993	C/A	cg17376030	chr22:41985996	PMM1	-0.76	-8.01	-0.44	3.71e-14	Vitiligo;
CESC	cis	rs3820928	0.874	rs10177995	chr2:227781600	T/C	cg05526886	chr2:227700861	RHBDD1	-0.46	-5.89	-0.34	1.16e-8	Pulmonary function;
CESC	cis	rs17253792	0.822	rs28409547	chr14:56047826	C/T	cg01858014	chr14:56050164	KTN1	-0.96	-7.65	-0.43	3.84e-13	Putamen volume;
CESC	cis	rs7659604	0.521	rs13130789	chr4:122690166	G/A	cg19671926	chr4:122722719	EXOSC9	0.65	8.55	0.46	1e-15	Type 2 diabetes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09345431	chr20:47538576	ARFGEF2	0.59	6.5	0.37	4.08e-10	Gut microbiome composition (summer);
CESC	cis	rs5758659	0.714	rs6002607	chr22:42496506	C/T	cg04733989	chr22:42467013	NAGA	-0.41	-5.59	-0.32	5.62e-8	Cognitive function;
CESC	cis	rs17711722	0.503	rs453835	chr7:65511159	T/A	cg25405998	chr7:65216604	CCT6P1	-0.5	-6.4	-0.37	7.05e-10	Calcium levels;
CESC	cis	rs2996428	0.561	rs2275833	chr1:3745721	C/T	cg10555106	chr1:3691387	LOC388588	0.37	5.26	0.31	2.94e-7	Red cell distribution width;
CESC	cis	rs7666738	0.830	rs7669407	chr4:98750251	G/A	cg03676636	chr4:99064102	C4orf37	0.34	5.12	0.3	5.85e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1008375	1.000	rs7694020	chr4:17682597	C/T	cg02297831	chr4:17616191	MED28	0.43	5.44	0.32	1.23e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs1568889	0.730	rs6484350	chr11:28113658	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	-0.8	-13.53	-0.64	4.71e-32	Bipolar disorder;
CESC	cis	rs3091242	0.933	rs35403885	chr1:25784551	G/A	cg03538708	chr1:25844672	NA	0.39	5.96	0.34	7.98e-9	Erythrocyte sedimentation rate;
CESC	cis	rs4253772	0.591	rs6007732	chr22:46652303	A/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.68	8.04	0.44	3.03e-14	LDL cholesterol;Cholesterol, total;
CESC	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.51	0.37	3.72e-10	Prudent dietary pattern;
CESC	cis	rs853679	0.517	rs9393893	chr6:28109262	T/C	cg12963246	chr6:28129442	ZNF389	0.57	7.67	0.43	3.36e-13	Depression;
CESC	cis	rs2836974	0.897	rs14194	chr21:40549466	T/C	cg11890956	chr21:40555474	PSMG1	1.15	22.29	0.81	1.04e-62	Cognitive function;
CESC	cis	rs7542091	0.635	rs985431	chr1:210043948	A/T	cg23283495	chr1:209979779	IRF6	0.35	5.8	0.34	1.84e-8	Monobrow;
CESC	cis	rs9910055	0.683	rs7220138	chr17:42254011	C/G	cg08499158	chr17:42289980	UBTF	-0.47	-5.74	-0.33	2.53e-8	Total body bone mineral density;
CESC	cis	rs453301	0.606	rs7462373	chr8:8899318	G/C	cg15556689	chr8:8085844	FLJ10661	-0.5	-6.18	-0.36	2.36e-9	Joint mobility (Beighton score);
CESC	cis	rs853679	0.517	rs4711165	chr6:28115184	T/G	cg19592336	chr6:28129416	ZNF389	0.62	8.12	0.45	1.77e-14	Depression;
CESC	cis	rs1801251	1.000	rs2674839	chr2:233669040	G/C	cg25237894	chr2:233734115	C2orf82	0.47	8.27	0.45	6.45e-15	Coronary artery disease;
CESC	cis	rs10504229	0.817	rs35207430	chr8:58167614	G/A	cg22535103	chr8:58192502	C8orf71	-1.03	-13.48	-0.64	7.04e-32	Developmental language disorder (linguistic errors);
CESC	cis	rs708547	0.874	rs73242624	chr4:57847420	C/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.68	7.47	0.42	1.15e-12	Response to bleomycin (chromatid breaks);
CESC	cis	rs9911578	1.000	rs4372750	chr17:57013803	A/C	cg05425664	chr17:57184151	TRIM37	0.5	6.86	0.39	4.94e-11	Intelligence (multi-trait analysis);
CESC	cis	rs425277	0.628	rs3107145	chr1:2047547	G/A	cg24578937	chr1:2090814	PRKCZ	-0.35	-5.91	-0.34	1.06e-8	Height;
CESC	cis	rs9486719	1.000	rs6921291	chr6:97066242	C/T	cg06623918	chr6:96969491	KIAA0776	-0.79	-8.12	-0.45	1.75e-14	Migraine;Coronary artery disease;
CESC	cis	rs4589502	0.925	rs57729347	chr15:67136438	G/A	cg12317470	chr15:67143691	NA	0.8	9.37	0.5	3.23e-18	Lung cancer (smoking interaction);
CESC	cis	rs7584330	0.744	rs10929235	chr2:238380272	A/G	cg14458575	chr2:238380390	NA	0.9	12.63	0.61	5.85e-29	Prostate cancer;
CESC	cis	rs9611565	0.694	rs202656	chr22:41842203	T/A	cg06481639	chr22:41940642	POLR3H	0.62	6.22	0.36	1.88e-9	Vitiligo;
CESC	cis	rs3768617	0.510	rs2027076	chr1:183073407	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.88	14.2	0.66	2.05e-34	Fuchs's corneal dystrophy;
CESC	cis	rs10751667	0.961	rs6597971	chr11:928598	T/A	cg06064525	chr11:970664	AP2A2	-0.43	-7.7	-0.43	2.72e-13	Alzheimer's disease (late onset);
CESC	cis	rs9486719	0.895	rs11152960	chr6:96900398	A/G	cg18709589	chr6:96969512	KIAA0776	-0.54	-5.87	-0.34	1.3e-8	Migraine;Coronary artery disease;
CESC	trans	rs11039798	0.588	rs7479642	chr11:48553808	G/T	cg03929089	chr4:120376271	NA	0.62	6.09	0.35	4.05e-9	Axial length;
CESC	cis	rs1008375	0.966	rs2315645	chr4:17579678	G/C	cg02297831	chr4:17616191	MED28	0.5	6.03	0.35	5.44e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs9715521	0.557	rs13146381	chr4:59853842	T/C	cg11281224	chr4:60001000	NA	-0.4	-5.46	-0.32	1.09e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs9311474	1.000	rs1060330	chr3:52288945	T/C	cg18337363	chr3:52569053	NT5DC2	0.32	6.09	0.35	3.87e-9	Electroencephalogram traits;
CESC	cis	rs7811142	0.830	rs73401443	chr7:99977582	T/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.93	10.32	0.54	3.22e-21	Platelet count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19368966	chr1:10458856	PGD	0.58	6.5	0.37	3.98e-10	Gut microbiome composition (summer);
CESC	cis	rs6502050	0.799	rs7406257	chr17:80089340	G/A	cg11859384	chr17:80120422	CCDC57	-0.38	-5.14	-0.3	5.31e-7	Life satisfaction;
CESC	cis	rs11688816	0.569	rs7591708	chr2:63022050	T/C	cg17519650	chr2:63277830	OTX1	-0.64	-8.78	-0.47	2.04e-16	Body mass index;
CESC	cis	rs7998202	0.614	rs423117	chr13:113346107	C/T	cg02820901	chr13:113351484	ATP11A	-0.54	-5.22	-0.31	3.65e-7	Glycated hemoglobin levels;
CESC	cis	rs977987	0.806	rs12924920	chr16:75440133	G/A	cg03315344	chr16:75512273	CHST6	0.41	5.86	0.34	1.35e-8	Dupuytren's disease;
CESC	cis	rs7855088	1.000	rs7855088	chr9:100742253	C/T	cg13688889	chr9:100608707	NA	-0.37	-5.61	-0.33	4.98e-8	Serum thyroid-stimulating hormone levels;
CESC	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg26338869	chr17:61819248	STRADA	0.67	8.77	0.47	2.24e-16	Prudent dietary pattern;
CESC	cis	rs2898681	0.561	rs7699960	chr4:53735661	C/A	cg00791764	chr4:53727839	RASL11B	0.44	5.16	0.3	4.96e-7	Optic nerve measurement (cup area);
CESC	cis	rs72634258	0.554	rs17374781	chr1:7919363	A/G	cg00042356	chr1:8021962	PARK7	-0.57	-5.42	-0.32	1.31e-7	Inflammatory bowel disease;
CESC	cis	rs514406	0.755	rs11206015	chr1:53242187	T/C	cg24675658	chr1:53192096	ZYG11B	0.54	7.53	0.42	7.86e-13	Monocyte count;
CESC	cis	rs524023	0.874	rs518053	chr11:64456099	C/T	cg19131476	chr11:64387923	NRXN2	-0.33	-5.05	-0.3	8.13e-7	Urate levels in obese individuals;
CESC	trans	rs7395662	0.534	rs12418219	chr11:48988091	G/T	cg15704280	chr7:45808275	SEPT13	-0.55	-6.66	-0.38	1.62e-10	HDL cholesterol;
CESC	cis	rs6952808	0.862	rs4721135	chr7:1912222	A/G	cg21782813	chr7:2030301	MAD1L1	0.35	5.12	0.3	6.02e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs9291683	0.509	rs998676	chr4:9948564	T/C	cg00071950	chr4:10020882	SLC2A9	-0.79	-14.72	-0.67	3.02e-36	Bone mineral density;
CESC	cis	rs16867321	0.694	rs4666853	chr2:181439671	C/T	cg23363182	chr2:181467187	NA	0.49	7.2	0.4	6.07e-12	Obesity;
CESC	cis	rs854765	0.547	rs2955380	chr17:17944349	A/G	cg09796270	chr17:17721594	SREBF1	-0.38	-5.07	-0.3	7.66e-7	Total body bone mineral density;
CESC	cis	rs3096299	0.933	rs2965824	chr16:89455306	A/G	cg08822215	chr16:89438651	ANKRD11	-0.42	-6.44	-0.37	5.7e-10	Multiple myeloma (IgH translocation);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg02769252	chr17:25932535	KSR1	0.43	6.17	0.35	2.5e-9	Fibrinogen levels;
CESC	cis	rs2380220	0.810	rs877096	chr6:95937046	A/G	cg15832292	chr6:96025679	MANEA	-0.64	-5.71	-0.33	2.99e-8	Behavioural disinhibition (generation interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26256999	chr1:249200418	PGBD2	0.63	7.09	0.4	1.19e-11	Gut microbiome composition (summer);
CESC	cis	rs4523957	0.890	rs12941621	chr17:2194852	C/T	cg16513277	chr17:2031491	SMG6	0.56	7.41	0.41	1.68e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs875971	0.862	rs6964437	chr7:65686444	A/G	cg13147721	chr7:65941812	NA	0.37	5.04	0.3	8.48e-7	Aortic root size;
CESC	cis	rs9733	0.650	rs6698495	chr1:150564476	T/C	cg17724175	chr1:150552817	MCL1	-0.34	-5.44	-0.32	1.24e-7	Tonsillectomy;
CESC	cis	rs2549003	0.966	rs2706386	chr5:131832687	C/T	cg21138405	chr5:131827807	IRF1	-0.6	-10.61	-0.55	3.84e-22	Asthma (sex interaction);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg19522900	chr3:124303745	KALRN	0.45	5.99	0.35	6.63e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs1799949	1.000	rs8176234	chr17:41219780	T/C	cg23758822	chr17:41437982	NA	1.02	15.55	0.69	3.45e-39	Menopause (age at onset);
CESC	cis	rs3736485	0.966	rs11070852	chr15:51782294	G/T	cg08986416	chr15:51914746	DMXL2	-0.41	-5.21	-0.3	3.77e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13327952	chr7:90032561	CLDN12	-0.52	-6.03	-0.35	5.56e-9	Gut microbiome composition (summer);
CESC	cis	rs10504229	0.683	rs56235637	chr8:58106008	T/C	cg21724239	chr8:58056113	NA	0.52	5.36	0.31	1.78e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs963731	0.649	rs297153	chr2:39326835	C/G	cg04010122	chr2:39346883	SOS1	-0.75	-5.58	-0.32	6.05e-8	Corticobasal degeneration;
CESC	cis	rs7223966	0.515	rs2727315	chr17:61961458	C/T	cg25324976	chr17:61989376	CSHL1	0.41	5.79	0.34	1.99e-8	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs898097	0.812	rs8065641	chr17:80820259	A/G	cg15369054	chr17:80825471	TBCD	0.56	7.77	0.43	1.68e-13	Breast cancer;
CESC	cis	rs7618915	0.547	rs1561337	chr3:52659963	C/T	cg05564831	chr3:52568323	NT5DC2	0.46	7.15	0.4	8.7e-12	Bipolar disorder;
CESC	cis	rs7927771	0.524	rs12226431	chr11:47805856	G/A	cg20307385	chr11:47447363	PSMC3	0.61	8.5	0.46	1.36e-15	Subjective well-being;
CESC	cis	rs7927771	0.965	rs3817335	chr11:47643891	T/A	cg05585544	chr11:47624801	NA	-0.54	-8.5	-0.46	1.37e-15	Subjective well-being;
CESC	cis	rs4713118	0.527	rs9461433	chr6:28095172	C/T	cg20151795	chr6:28129481	ZNF389	0.44	5.74	0.33	2.6e-8	Parkinson's disease;
CESC	cis	rs433852	0.718	rs550455	chr19:49136515	A/G	cg06530960	chr19:49140787	SEC1;DBP	-0.42	-5.15	-0.3	5.1e-7	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;
CESC	cis	rs3096299	0.692	rs4785565	chr16:89515759	T/C	cg08392591	chr16:89556376	ANKRD11	0.57	7.81	0.43	1.36e-13	Multiple myeloma (IgH translocation);
CESC	cis	rs748404	0.587	rs9920879	chr15:43639770	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.6	7.81	0.43	1.33e-13	Lung cancer;
CESC	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg02018176	chr4:1364513	KIAA1530	0.6	7.52	0.42	8.35e-13	Longevity;
CESC	cis	rs9291683	0.530	rs13115193	chr4:9982191	C/T	cg11266682	chr4:10021025	SLC2A9	0.62	12.69	0.61	3.76e-29	Bone mineral density;
CESC	cis	rs2832191	0.791	rs7282843	chr21:30475226	A/G	cg24692254	chr21:30365293	RNF160	0.8	12.54	0.61	1.25e-28	Dental caries;
CESC	cis	rs2857078	0.654	rs9896789	chr17:42314567	C/T	cg13607699	chr17:42295918	UBTF	0.84	12.25	0.6	1.27e-27	Red cell distribution width;Reticulocyte count;
CESC	cis	rs9322193	0.884	rs62439837	chr6:149991516	G/T	cg13206674	chr6:150067644	NUP43	0.4	5.45	0.32	1.18e-7	Lung cancer;
CESC	cis	rs9837602	1.000	rs9833888	chr3:99723580	G/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.54	7.51	0.42	9.05e-13	Breast cancer;
CESC	cis	rs1879734	0.731	rs6658245	chr1:54159005	T/C	cg23596471	chr1:54105337	GLIS1	0.35	5.67	0.33	3.77e-8	Mitral valve prolapse;
CESC	cis	rs6714710	0.663	rs71429376	chr2:98534412	T/C	cg26665480	chr2:98280029	ACTR1B	0.53	7.31	0.41	3.07e-12	Posterior cortical atrophy and Alzheimer's disease;
CESC	cis	rs2249625	0.523	rs2496554	chr6:72855840	A/T	cg18830697	chr6:72922368	RIMS1	-0.42	-6.14	-0.35	3.01e-9	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26944263	chr12:93964231	SOCS2	0.66	7.23	0.41	5.12e-12	Gut microbiome composition (summer);
CESC	cis	rs763014	0.932	rs35067229	chr16:649638	T/C	cg00908189	chr16:619842	PIGQ	0.64	9.15	0.49	1.61e-17	Height;
CESC	cis	rs9486719	1.000	rs6923212	chr6:97061940	A/G	cg18709589	chr6:96969512	KIAA0776	-0.54	-6.0	-0.35	6.46e-9	Migraine;Coronary artery disease;
CESC	cis	rs875971	0.862	rs6460306	chr7:66060793	T/C	cg11764359	chr7:65958608	NA	-0.78	-11.24	-0.57	3.14e-24	Aortic root size;
CESC	cis	rs72634258	0.503	rs72632055	chr1:7835774	T/G	cg26816564	chr1:7831052	VAMP3	0.7	6.42	0.37	6.33e-10	Inflammatory bowel disease;
CESC	cis	rs2742417	0.603	rs7631818	chr3:45775931	A/T	cg04837898	chr3:45731254	SACM1L	-0.46	-6.11	-0.35	3.5e-9	Response to anti-depressant treatment in major depressive disorder;
CESC	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	-0.87	-12.19	-0.6	1.98e-27	Prudent dietary pattern;
CESC	cis	rs9649213	0.593	rs6963210	chr7:97944986	G/A	cg00277769	chr7:97922759	BAIAP2L1	-0.35	-5.71	-0.33	2.98e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7607369	0.714	rs2272190	chr2:219609995	G/C	cg02176678	chr2:219576539	TTLL4	-0.46	-8.23	-0.45	8.59e-15	Red blood cell count;Amyotrophic lateral sclerosis;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg04359004	chr20:61427998	C20orf20	-0.43	-6.31	-0.36	1.15e-9	Gambling;
CESC	cis	rs13223928	0.621	rs4722438	chr7:3155813	A/G	cg19214707	chr7:3157722	NA	0.42	5.8	0.34	1.85e-8	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
CESC	cis	rs614226	1.000	rs614226	chr12:120974510	C/T	cg01236616	chr12:121019343	POP5	-1.55	-19.24	-0.76	3.12e-52	Type 1 diabetes nephropathy;
CESC	cis	rs9921222	0.632	rs11649268	chr16:398643	A/C	cg26944245	chr16:421049	TMEM8A;MRPL28	0.43	6.5	0.37	3.9e-10	Bone mineral density (spine);Bone mineral density;
CESC	cis	rs8114671	0.836	rs3746432	chr20:33592763	C/T	cg06115741	chr20:33292138	TP53INP2	-0.44	-5.23	-0.31	3.37e-7	Height;
CESC	trans	rs6572548	0.504	rs1956082	chr14:49665496	A/C	cg21177064	chr12:4410167	CCND2	0.45	6.01	0.35	6.24e-9	Subjective well-being;
CESC	cis	rs769267	0.930	rs4808203	chr19:19568659	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.47	5.66	0.33	4e-8	Tonsillectomy;
CESC	cis	rs9733	0.519	rs1336900	chr1:150679033	C/T	cg09365446	chr1:150670422	GOLPH3L	0.37	5.18	0.3	4.49e-7	Tonsillectomy;
CESC	cis	rs11864453	0.578	rs2072141	chr16:72133211	G/A	cg16558253	chr16:72132732	DHX38	-0.54	-8.47	-0.46	1.7e-15	Fibrinogen levels;
CESC	cis	rs7267979	1.000	rs6083844	chr20:25386832	C/T	cg08601574	chr20:25228251	PYGB	-0.37	-5.43	-0.32	1.3e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs10504073	0.647	rs4493918	chr8:50015937	C/G	cg00325661	chr8:49890786	NA	0.57	8.6	0.47	7.15e-16	Blood metabolite ratios;
CESC	cis	rs916888	0.821	rs415430	chr17:44859144	C/T	cg17911788	chr17:44343683	NA	0.53	7.17	0.4	7.3e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs116095464	0.558	rs2162870	chr5:228129	G/A	cg10591111	chr5:226296	SDHA	-0.54	-6.65	-0.38	1.72e-10	Breast cancer;
CESC	cis	rs1799949	0.929	rs12937015	chr17:41307473	A/C	cg25072359	chr17:41440525	NA	0.44	5.88	0.34	1.23e-8	Menopause (age at onset);
CESC	cis	rs6089584	0.861	rs2180302	chr20:60576369	A/G	cg13770153	chr20:60521292	NA	-0.48	-6.23	-0.36	1.81e-9	Body mass index;
CESC	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg15147215	chr3:52552868	STAB1	-0.3	-5.47	-0.32	1.02e-7	Bipolar disorder;
CESC	cis	rs9549367	0.789	rs7338235	chr13:113888687	T/C	cg18105134	chr13:113819100	PROZ	-0.66	-7.86	-0.43	9.75e-14	Platelet distribution width;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04444761	chr8:126442446	TRIB1	-0.55	-6.46	-0.37	4.89e-10	Gut microbiome composition (summer);
CESC	cis	rs6860806	0.661	rs2171247	chr5:131580234	G/T	cg04518342	chr5:131593106	PDLIM4	0.4	6.08	0.35	4.24e-9	Breast cancer;
CESC	cis	rs9814567	0.712	rs9838621	chr3:134332319	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.4	-5.1	-0.3	6.38e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs3936840	0.565	rs8011721	chr14:102986388	C/G	cg18135206	chr14:102964638	TECPR2	-0.5	-6.38	-0.36	7.99e-10	Plateletcrit;
CESC	cis	rs2243480	0.901	rs73142137	chr7:65343442	A/T	cg18252515	chr7:66147081	NA	-1.18	-11.4	-0.57	9.2e-25	Diabetic kidney disease;
CESC	cis	rs2180341	1.000	rs2180341	chr6:127600630	C/T	cg24812749	chr6:127587940	RNF146	1.06	15.36	0.69	1.61e-38	Breast cancer;
CESC	cis	rs2404602	0.583	rs35707798	chr15:76565026	G/C	cg22467129	chr15:76604101	ETFA	-0.39	-5.96	-0.34	8.05e-9	Blood metabolite levels;
CESC	cis	rs2228479	0.850	rs11649510	chr16:89851004	A/G	cg04013166	chr16:89971882	TCF25	0.78	6.68	0.38	1.43e-10	Skin colour saturation;
CESC	cis	rs847577	0.575	rs41278842	chr7:97815999	A/G	cg24562669	chr7:97807699	LMTK2	-0.57	-8.37	-0.46	3.36e-15	Breast cancer;
CESC	cis	rs6138458	1.000	rs227632	chr20:24913729	G/A	cg06937882	chr20:24974362	C20orf3	-0.36	-5.2	-0.3	3.9e-7	Blood protein levels;
CESC	cis	rs12136530	0.593	rs9287046	chr1:19736395	C/G	cg01832549	chr1:19774989	CAPZB	-0.43	-6.38	-0.36	7.97e-10	Lead levels in blood;
CESC	cis	rs5769765	0.817	rs8142561	chr22:50291750	T/C	cg02269571	chr22:50332266	NA	-0.45	-6.05	-0.35	4.98e-9	Schizophrenia;
CESC	cis	rs10504229	0.683	rs7460059	chr8:58111561	C/T	cg24829409	chr8:58192753	C8orf71	-0.59	-7.32	-0.41	2.94e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs58785573	0.504	rs12646137	chr4:38609650	C/T	cg18361445	chr4:38666374	KLF3;FLJ13197	0.46	6.23	0.36	1.87e-9	Lymphocyte percentage of white cells;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17216600	chr6:52442344	TRAM2	0.59	6.48	0.37	4.55e-10	Gut microbiome composition (summer);
CESC	cis	rs9309473	0.687	rs7576824	chr2:73611281	C/T	cg20560298	chr2:73613845	ALMS1	0.51	6.95	0.39	2.9100000000000002e-11	Metabolite levels;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg02056921	chr1:901892	PLEKHN1	0.47	6.2	0.36	2.15e-9	Systemic lupus erythematosus;
CESC	cis	rs4689592	0.503	rs59640165	chr4:7051661	G/A	cg26116260	chr4:7069785	GRPEL1	-0.87	-8.81	-0.48	1.7e-16	Monocyte percentage of white cells;
CESC	cis	rs1552244	1.000	rs113771705	chr3:10075983	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.87	11.84	0.59	2.99e-26	Alzheimer's disease;
CESC	cis	rs7811142	0.830	rs3087502	chr7:99955364	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.04	10.52	0.54	7.52e-22	Platelet count;
CESC	cis	rs7980687	0.506	rs1611973	chr12:123622731	C/G	cg05973401	chr12:123451056	ABCB9	0.54	6.91	0.39	3.51e-11	Height;Educational attainment;Head circumference (infant);
CESC	trans	rs9467711	0.606	rs66827971	chr6:26365766	T/C	cg06606381	chr12:133084897	FBRSL1	-0.76	-6.82	-0.39	6.01e-11	Autism spectrum disorder or schizophrenia;
CESC	cis	rs7267979	0.934	rs6037085	chr20:25305202	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.88	-18.41	-0.75	2.54e-49	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs959260	0.688	rs4789176	chr17:73352868	A/T	cg20590849	chr17:73267439	MIF4GD	-0.55	-6.16	-0.35	2.62e-9	Systemic lupus erythematosus;
CESC	cis	rs11969893	0.737	rs4098482	chr6:101377808	C/T	cg12253828	chr6:101329408	ASCC3	0.96	8.17	0.45	1.26e-14	Economic and political preferences (immigration/crime);
CESC	cis	rs6540559	0.543	rs650728	chr1:210433351	C/T	cg21951975	chr1:209979733	IRF6	0.49	6.09	0.35	4.01e-9	Cleft lip with or without cleft palate;
CESC	cis	rs6088580	0.634	rs6059866	chr20:33075810	A/C	cg06115741	chr20:33292138	TP53INP2	0.4	5.2	0.3	4.08e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs2074585	0.708	rs2589939	chr15:90930875	C/T	cg10434728	chr15:90938212	IQGAP1	0.43	7.8	0.43	1.46e-13	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg18125479	chr14:51411049	PYGL	-0.5	-7.26	-0.41	4.3e-12	Gambling;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg05477027	chr19:46295590	DMWD	-0.46	-6.3	-0.36	1.21e-9	Height;
CESC	cis	rs9911578	0.967	rs7503190	chr17:57184162	A/C	cg12560992	chr17:57184187	TRIM37	1.01	17.89	0.74	1.77e-47	Intelligence (multi-trait analysis);
CESC	cis	rs593982	0.920	rs488170	chr11:65481544	T/C	cg08755490	chr11:65554678	OVOL1	1.17	10.74	0.55	1.45e-22	Atopic dermatitis;
CESC	cis	rs4704187	0.687	rs4345300	chr5:74376571	C/T	cg03227963	chr5:74354835	NA	0.32	5.95	0.34	8.68e-9	Response to amphetamines;
CESC	cis	rs4642101	0.662	rs3901664	chr3:12824660	T/C	cg24848339	chr3:12840334	CAND2	0.42	6.64	0.38	1.78e-10	QRS complex (12-leadsum);
CESC	cis	rs2742417	1.000	rs2742397	chr3:45758946	C/G	cg10512202	chr3:45649293	LIMD1	-0.36	-5.23	-0.31	3.4e-7	Response to anti-depressant treatment in major depressive disorder;
CESC	trans	rs1545843	0.593	rs4584624	chr12:84798715	G/A	cg03015433	chr16:56623111	MT3	-0.34	-6.14	-0.35	3.04e-9	Major depressive disorder;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg08043048	chr2:197036688	STK17B	-0.46	-6.71	-0.38	1.19e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs2204008	0.774	rs7305085	chr12:38263511	C/T	cg13010199	chr12:38710504	ALG10B	0.51	6.29	0.36	1.29e-9	Bladder cancer;
CESC	cis	rs1878047	0.665	rs12972826	chr19:51775531	G/A	cg14884932	chr19:51774451	NA	-0.37	-5.16	-0.3	4.87e-7	Body mass index;
CESC	cis	rs8018808	0.936	rs4903576	chr14:77844869	A/G	cg20045696	chr14:77926864	AHSA1	-0.37	-5.06	-0.3	7.85e-7	Myeloid white cell count;
CESC	cis	rs11958404	0.615	rs7724696	chr5:157450852	A/C	cg05962755	chr5:157440814	NA	0.38	5.65	0.33	4.06e-8	IgG glycosylation;
CESC	trans	rs11678036	1.000	rs11678036	chr2:186024735	A/G	cg19931206	chr6:11138650	LOC221710	-0.43	-6.38	-0.36	8.08e-10	IgG glycosylation;
CESC	cis	rs1062746	0.771	rs10514621	chr16:87369578	G/T	cg02258303	chr16:87377426	FBXO31	-0.5	-6.35	-0.36	9.21e-10	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
CESC	cis	rs1046896	0.519	rs9900369	chr17:80829807	G/A	cg05255149	chr17:80675120	FN3KRP	0.46	5.19	0.3	4.25e-7	Glycated hemoglobin levels;
CESC	cis	rs2243480	1.000	rs1715235	chr7:65488394	T/C	cg18252515	chr7:66147081	NA	-1.19	-11.57	-0.58	2.56e-25	Diabetic kidney disease;
CESC	cis	rs4730250	0.708	rs3801965	chr7:106825628	G/T	cg02696742	chr7:106810147	HBP1	-0.53	-5.06	-0.3	7.68e-7	Osteoarthritis;
CESC	cis	rs4665809	0.549	rs72809635	chr2:26411674	G/A	cg26314531	chr2:26401878	FAM59B	0.73	7.64	0.42	4.03e-13	Gut microbiome composition (summer);
CESC	cis	rs875971	0.862	rs6947339	chr7:65888470	T/C	cg19163074	chr7:65112434	INTS4L2	-0.41	-5.11	-0.3	6.29e-7	Aortic root size;
CESC	trans	rs55704346	0.566	rs11937932	chr4:25387660	A/G	cg01822600	chr1:245751692	KIF26B	0.42	6.17	0.35	2.58e-9	Tonsillectomy;
CESC	cis	rs10504229	0.815	rs72650877	chr8:58164510	T/C	cg05313129	chr8:58192883	C8orf71	-0.48	-5.18	-0.3	4.41e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs7949030	0.620	rs2428551	chr11:62329758	T/A	cg22862634	chr11:62369728	EML3;MTA2	0.53	7.5	0.42	9.64e-13	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs1008375	1.000	rs1860596	chr4:17660082	C/T	cg16339924	chr4:17578868	LAP3	0.61	7.5	0.42	9.61e-13	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs9611565	0.559	rs4822049	chr22:41993496	G/A	cg17376030	chr22:41985996	PMM1	0.81	8.45	0.46	1.98e-15	Vitiligo;
CESC	cis	rs7811142	0.775	rs1059129	chr7:99926522	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.74	7.45	0.42	1.29e-12	Platelet count;
CESC	cis	rs561341	0.714	rs111760509	chr17:30304320	A/G	cg19193384	chr17:30244184	NA	-0.64	-6.05	-0.35	4.85e-9	Hip circumference adjusted for BMI;
CESC	cis	rs11650776	1	rs11650776	chr17:37641402	G/A	cg19468946	chr17:37922297	IKZF3	-0.39	-5.08	-0.3	7.08e-7	Lung function (FEV1);
CESC	cis	rs9814567	0.731	rs34797591	chr3:134192516	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.4	5.26	0.31	2.91e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09992653	chr13:53226650	SUGT1	-0.54	-6.33	-0.36	1.07e-9	Gut microbiome composition (summer);
CESC	cis	rs798554	0.660	rs2527694	chr7:2858240	T/C	cg19717773	chr7:2847554	GNA12	-0.52	-8.18	-0.45	1.22e-14	Height;
CESC	trans	rs116095464	0.558	rs7356535	chr5:284117	G/T	cg00938859	chr5:1591904	SDHAP3	0.72	6.62	0.38	2.04e-10	Breast cancer;
CESC	cis	rs798554	1.000	rs798559	chr7:2758341	T/C	cg19717773	chr7:2847554	GNA12	-0.54	-7.75	-0.43	1.92e-13	Height;
CESC	cis	rs4604732	0.631	rs11490200	chr1:247625915	G/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.57	7.17	0.4	7.39e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs7772486	0.875	rs9322043	chr6:146352690	A/G	cg23711669	chr6:146136114	FBXO30	0.87	12.8	0.62	1.63e-29	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6828523	0.698	rs78557674	chr4:175853032	T/A	cg14561282	chr4:175839468	ADAM29	0.43	5.04	0.3	8.73e-7	Breast cancer;
CESC	cis	rs1775715	0.870	rs10827003	chr10:32266216	A/G	cg18675610	chr10:32216311	ARHGAP12	0.33	5.14	0.3	5.29e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs4132509	1.000	rs28869008	chr1:243986344	C/A	cg21452805	chr1:244014465	NA	0.5	6.21	0.36	2.08e-9	RR interval (heart rate);
CESC	cis	rs7927771	0.864	rs2293580	chr11:47440283	T/A	cg18512352	chr11:47633146	NA	0.44	6.31	0.36	1.18e-9	Subjective well-being;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg07531037	chr17:43196299	PLCD3	0.49	6.58	0.37	2.57e-10	Fibrinogen levels;
CESC	cis	rs10779751	0.690	rs2791659	chr1:11126569	C/A	cg08854313	chr1:11322531	MTOR	0.77	10.41	0.54	1.73e-21	Body mass index;
CESC	cis	rs10791323	0.569	rs329664	chr11:133754975	G/T	cg15485101	chr11:133734466	NA	0.3	5.19	0.3	4.26e-7	Childhood ear infection;
CESC	cis	rs3091242	0.933	rs10903130	chr1:25769221	A/T	cg27572855	chr1:25598939	RHD	0.43	7.22	0.41	5.47e-12	Erythrocyte sedimentation rate;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg10599693	chr2:24300242	SF3B14	-0.41	-6.13	-0.35	3.24e-9	Gambling;
CESC	cis	rs77861329	1.000	rs13319566	chr3:52095555	C/G	cg08692210	chr3:52188851	WDR51A	0.8	7.04	0.4	1.61e-11	Macrophage inflammatory protein 1b levels;
CESC	cis	rs8077889	0.871	rs9893111	chr17:41915767	G/A	cg26893861	chr17:41843967	DUSP3	0.71	8.8	0.48	1.85e-16	Triglycerides;
CESC	cis	rs11608355	0.515	rs6606727	chr12:109941450	T/A	cg05360138	chr12:110035743	NA	0.82	8.85	0.48	1.27e-16	Neuroticism;
CESC	cis	rs9611565	0.512	rs9611667	chr22:42187015	C/T	cg17376030	chr22:41985996	PMM1	0.82	8.55	0.47	9.88e-16	Vitiligo;
CESC	cis	rs7811142	0.830	rs3087502	chr7:99955364	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.87	8.33	0.46	4.25e-15	Platelet count;
CESC	trans	rs12478296	0.901	rs67423532	chr2:243004719	A/G	cg18288967	chr1:45987694	PRDX1	0.59	6.55	0.37	2.93e-10	Obesity-related traits;
CESC	cis	rs1387259	0.859	rs2054905	chr12:48687951	A/G	cg04545296	chr12:48745243	ZNF641	0.42	7.0	0.39	2.11e-11	Obstructive sleep apnea trait (apnea hypopnea index);
CESC	cis	rs916888	0.821	rs199512	chr17:44857352	T/C	cg17911788	chr17:44343683	NA	0.53	7.2	0.4	6.14e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs9911578	1.000	rs12453049	chr17:56611372	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.41	-5.53	-0.32	7.63e-8	Intelligence (multi-trait analysis);
CESC	cis	rs75804782	0.641	rs11902599	chr2:239348400	C/T	cg18131467	chr2:239335373	ASB1	-0.66	-5.83	-0.34	1.58e-8	Morning vs. evening chronotype;Chronotype;
CESC	cis	rs2839186	0.647	rs9976233	chr21:47616913	G/A	cg10351095	chr21:47802916	PCNT	0.43	5.55	0.32	7.02e-8	Testicular germ cell tumor;
CESC	cis	rs881375	0.669	rs73541868	chr9:123639264	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.45	6.41	0.37	6.75e-10	Rheumatoid arthritis;
CESC	cis	rs853679	0.517	rs35512245	chr6:28079953	T/C	cg17949981	chr6:28129498	ZNF389	0.45	5.63	0.33	4.71e-8	Depression;
CESC	cis	rs660899	0.595	rs37458	chr1:44290530	A/G	cg11704212	chr1:44303111	ST3GAL3	-0.39	-5.29	-0.31	2.51e-7	Hypertension risk in short sleep duration;
CESC	cis	rs7072216	0.727	rs942809	chr10:100168001	G/A	cg26618903	chr10:100175079	PYROXD2	-0.33	-5.11	-0.3	6.23e-7	Metabolite levels;
CESC	cis	rs4268898	0.610	rs55860688	chr2:24451534	T/C	cg08917208	chr2:24149416	ATAD2B	0.53	5.24	0.31	3.2e-7	Asthma;
CESC	cis	rs3820928	0.874	rs59630650	chr2:227786514	T/C	cg05526886	chr2:227700861	RHBDD1	-0.41	-5.23	-0.31	3.47e-7	Pulmonary function;
CESC	cis	rs16857609	0.564	rs13388148	chr2:218281500	T/G	cg15335768	chr2:218268053	DIRC3	-0.38	-5.53	-0.32	7.68e-8	Breast cancer;Breast cancer (estrogen-receptor negative);
CESC	cis	rs12579753	0.917	rs7313521	chr12:82205656	G/A	cg24719984	chr12:82153464	PPFIA2	-0.33	-5.04	-0.3	8.55e-7	Resting heart rate;
CESC	cis	rs7020830	0.931	rs3802422	chr9:37097172	G/A	cg14294708	chr9:37120828	ZCCHC7	1.26	25.17	0.84	3.15e-72	Schizophrenia;
CESC	cis	rs2228479	0.850	rs62056065	chr16:89905115	C/G	cg06558623	chr16:89946397	TCF25	1.12	8.22	0.45	9.28e-15	Skin colour saturation;
CESC	cis	rs4665809	0.590	rs4665321	chr2:26433801	A/C	cg08470875	chr2:26401718	FAM59B	-0.74	-7.65	-0.43	3.74e-13	Gut microbiome composition (summer);
CESC	cis	rs2354432	0.607	rs894471	chr1:146687913	A/G	cg25205988	chr1:146714368	CHD1L	-0.89	-6.95	-0.39	2.9e-11	Mitochondrial DNA levels;
CESC	cis	rs662064	0.962	rs2781230	chr1:10563717	G/A	cg20482658	chr1:10539492	PEX14	0.38	7.3	0.41	3.44e-12	Asthma;
CESC	cis	rs7617773	0.501	rs12185901	chr3:48382919	G/T	cg11946769	chr3:48343235	NME6	0.66	8.34	0.46	4.12e-15	Coronary artery disease;
CESC	cis	rs3733585	0.699	rs1079128	chr4:9951221	T/C	cg00071950	chr4:10020882	SLC2A9	-0.71	-11.89	-0.59	2.08e-26	Cleft plate (environmental tobacco smoke interaction);
CESC	trans	rs1814175	0.715	rs1722007	chr11:49897319	T/C	cg03929089	chr4:120376271	NA	-0.91	-15.11	-0.68	1.28e-37	Height;
CESC	cis	rs9611519	0.780	rs2284079	chr22:41658632	C/T	cg03806693	chr22:41940476	POLR3H	-0.56	-6.46	-0.37	4.91e-10	Neuroticism;
CESC	cis	rs1862618	0.525	rs2662016	chr5:56269047	A/G	cg20203395	chr5:56204925	C5orf35	0.46	5.37	0.31	1.73e-7	Initial pursuit acceleration;
CESC	cis	rs11785693	0.862	rs11784262	chr8:4996942	G/A	cg26367366	chr8:4980734	NA	0.63	6.28	0.36	1.36e-9	Neuroticism (multi-trait analysis);Neuroticism;
CESC	cis	rs5758659	0.652	rs4822084	chr22:42435868	A/G	cg15557168	chr22:42548783	NA	0.45	6.69	0.38	1.3e-10	Cognitive function;
CESC	cis	rs362272	0.524	rs7435601	chr4:3369645	A/G	cg14583973	chr4:3374767	RGS12	0.31	5.44	0.32	1.19e-7	Serum sulfate level;
CESC	cis	rs4819052	0.808	rs11909411	chr21:46676556	A/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.95	14.1	0.65	4.6e-34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs2777491	1.000	rs2730057	chr15:41736275	C/A	cg18705301	chr15:41695430	NDUFAF1	-0.67	-10.16	-0.53	1.12e-20	Ulcerative colitis;
CESC	trans	rs617791	0.669	rs4994056	chr11:65750997	G/A	cg17712092	chr4:129076599	LARP1B	0.72	9.97	0.52	4.33e-20	Breast cancer;
CESC	cis	rs2841277	0.770	rs10149193	chr14:105403474	C/T	cg19901468	chr14:105411992	AHNAK2	-0.6	-8.69	-0.47	3.74e-16	Rheumatoid arthritis;
CESC	cis	rs2115536	0.704	rs2163005	chr15:80194480	A/G	cg00225070	chr15:80189496	MTHFS	0.64	8.8	0.48	1.83e-16	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02769252	chr17:25932535	KSR1	-0.53	-6.35	-0.36	9.42e-10	Gut microbiome composition (summer);
CESC	cis	rs9733	0.621	rs12746899	chr1:150579678	A/T	cg22823121	chr1:150693482	HORMAD1	-0.36	-5.37	-0.31	1.68e-7	Tonsillectomy;
CESC	cis	rs9322193	0.923	rs9322209	chr6:150012362	A/G	cg04369109	chr6:150039330	LATS1	-0.44	-6.1	-0.35	3.82e-9	Lung cancer;
CESC	cis	rs7666738	0.830	rs2865951	chr4:99040191	C/T	cg18180107	chr4:99064573	C4orf37	0.4	5.25	0.31	3.12e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10870270	0.956	rs10781555	chr10:133745720	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.61	-7.93	-0.44	6.3e-14	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs10911251	0.528	rs2182020	chr1:183074964	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.88	14.2	0.66	2.05e-34	Colorectal cancer;
CESC	cis	rs2228479	0.867	rs75110337	chr16:89962635	C/A	cg04013166	chr16:89971882	TCF25	0.76	6.94	0.39	3.06e-11	Skin colour saturation;
CESC	trans	rs11098499	0.863	rs3822195	chr4:120471660	C/T	cg25214090	chr10:38739885	LOC399744	0.67	9.15	0.49	1.55e-17	Corneal astigmatism;
CESC	cis	rs873946	0.529	rs12258248	chr10:134573767	A/G	cg27286337	chr10:134555280	INPP5A	0.62	7.31	0.41	3.07e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs9916302	0.904	rs34363096	chr17:37594294	G/A	cg15445000	chr17:37608096	MED1	0.41	6.74	0.38	9.67e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs798554	0.757	rs1183085	chr7:2875570	G/A	cg09658497	chr7:2847517	GNA12	-0.42	-5.87	-0.34	1.27e-8	Height;
CESC	cis	rs854765	0.647	rs6502637	chr17:17986098	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.61	8.68	0.47	4.14e-16	Total body bone mineral density;
CESC	cis	rs362296	0.661	rs3095077	chr4:3265710	A/G	cg08886695	chr4:3369023	RGS12	-0.36	-5.23	-0.31	3.53e-7	Parental longevity (mother's age at death);
CESC	cis	rs425277	0.958	rs262688	chr1:2113565	T/G	cg16545954	chr1:2118288	C1orf86	0.33	5.68	0.33	3.45e-8	Height;
CESC	cis	rs4862750	0.872	rs7679956	chr4:187900229	C/T	cg10295955	chr4:187884368	NA	-1.02	-20.59	-0.78	6.65e-57	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7818345	1.000	rs13278459	chr8:19297583	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.34	6.23	0.36	1.85e-9	Language performance in older adults (adjusted for episodic memory);
CESC	cis	rs9926296	0.712	rs258330	chr16:89729574	T/G	cg27121462	chr16:89883253	FANCA	-0.47	-5.75	-0.33	2.48e-8	Vitiligo;
CESC	cis	rs2239547	0.657	rs6445538	chr3:52874288	T/C	cg11645453	chr3:52864694	ITIH4	0.35	6.4	0.37	7.09e-10	Schizophrenia;
CESC	cis	rs7618915	0.501	rs2289247	chr3:52727257	C/T	cg05564831	chr3:52568323	NT5DC2	0.45	6.94	0.39	3.06e-11	Bipolar disorder;
CESC	trans	rs1493916	0.905	rs7239283	chr18:31395397	G/A	cg27147174	chr7:100797783	AP1S1	-0.54	-7.28	-0.41	3.85e-12	Life satisfaction;
CESC	cis	rs72945132	0.882	rs1061328	chr11:70185325	C/T	cg00319359	chr11:70116639	PPFIA1	0.71	6.92	0.39	3.49e-11	Coronary artery disease;
CESC	cis	rs9837602	0.529	rs793459	chr3:99520591	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.62	-9.72	-0.51	2.66e-19	Breast cancer;
CESC	cis	rs514406	0.505	rs269289	chr1:53167151	A/C	cg27535305	chr1:53392650	SCP2	-0.32	-5.49	-0.32	9.21e-8	Monocyte count;
CESC	cis	rs2839186	0.770	rs2330353	chr21:47669648	T/A	cg10351095	chr21:47802916	PCNT	-0.48	-6.44	-0.37	5.64e-10	Testicular germ cell tumor;
CESC	cis	rs4713118	0.515	rs9368549	chr6:28050047	T/A	cg18032046	chr6:28092343	ZSCAN16	-0.53	-6.09	-0.35	3.91e-9	Parkinson's disease;
CESC	cis	rs6460942	1.000	rs6460935	chr7:12401317	A/T	cg02935154	chr7:12443704	VWDE	-0.57	-6.18	-0.35	2.42e-9	Coronary artery disease;
CESC	cis	rs9916302	0.904	rs3964723	chr17:37403979	C/T	cg07936489	chr17:37558343	FBXL20	-0.75	-10.32	-0.54	3.35e-21	Glomerular filtration rate (creatinine);
CESC	cis	rs9549367	0.673	rs575453	chr13:113837871	C/A	cg18105134	chr13:113819100	PROZ	0.56	7.11	0.4	1.05e-11	Platelet distribution width;
CESC	cis	rs763014	0.931	rs7191939	chr16:630089	C/T	cg00908189	chr16:619842	PIGQ	0.67	9.29	0.5	6.02e-18	Height;
CESC	cis	rs1035144	0.505	rs10145099	chr14:81456694	C/T	cg06600135	chr14:81408086	NA	-0.56	-7.4	-0.41	1.85e-12	Male sexual orientation;
CESC	cis	rs3858526	0.874	rs10838879	chr11:5950169	C/T	cg13902645	chr11:5959945	NA	-0.66	-7.99	-0.44	4.21e-14	DNA methylation (variation);
CESC	cis	rs2204008	0.777	rs2049130	chr12:38444837	G/A	cg13010199	chr12:38710504	ALG10B	0.42	5.43	0.32	1.28e-7	Bladder cancer;
CESC	trans	rs2814021	0.599	rs2650720	chr10:63264332	C/T	cg08188886	chr14:105633697	JAG2	-0.42	-6.09	-0.35	3.95e-9	Obesity-related traits;
CESC	cis	rs11098499	0.863	rs1480940	chr4:120457682	T/C	cg24375607	chr4:120327624	NA	0.43	5.21	0.3	3.82e-7	Corneal astigmatism;
CESC	cis	rs2412459	0.611	rs4924402	chr15:40245754	C/T	cg21830797	chr15:40226279	EIF2AK4	-0.49	-5.5	-0.32	9.01e-8	Response to haloperidol in psychosis;
CESC	cis	rs10504229	1.000	rs66672857	chr8:58179817	G/C	cg05313129	chr8:58192883	C8orf71	-0.55	-6.37	-0.36	8.42e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs4523957	0.583	rs8067895	chr17:2030234	G/A	cg16513277	chr17:2031491	SMG6	-0.79	-11.51	-0.58	3.93e-25	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs73206853	0.841	rs73206886	chr12:110851190	T/G	cg12870014	chr12:110450643	ANKRD13A	0.63	5.18	0.3	4.34e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs6088590	0.687	rs13044899	chr20:33287078	G/A	cg06115741	chr20:33292138	TP53INP2	0.49	5.88	0.34	1.21e-8	Coronary artery disease;
CESC	cis	rs12497850	0.931	rs7616815	chr3:48779715	C/T	cg06212747	chr3:49208901	KLHDC8B	0.64	8.74	0.47	2.8e-16	Parkinson's disease;
CESC	cis	rs7590368	0.640	rs56260452	chr2:10954843	C/G	cg15705551	chr2:10952987	PDIA6	0.52	5.12	0.3	5.91e-7	Educational attainment (years of education);
CESC	cis	rs6502050	0.835	rs4789672	chr17:80126603	T/C	cg11859384	chr17:80120422	CCDC57	-0.39	-5.34	-0.31	1.97e-7	Life satisfaction;
CESC	cis	rs3858526	0.917	rs9284148	chr11:5973185	G/C	cg13902645	chr11:5959945	NA	-0.58	-6.67	-0.38	1.49e-10	DNA methylation (variation);
CESC	cis	rs16858210	0.529	rs10937154	chr3:183569489	C/T	cg25686905	chr3:183603175	PARL	-0.33	-5.84	-0.34	1.48e-8	Menopause (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.59	6.37	0.36	8.35e-10	Gut microbiome composition (summer);
CESC	cis	rs2304069	0.545	rs9686746	chr5:149399968	G/A	cg12661370	chr5:149340060	SLC26A2	0.41	5.42	0.32	1.33e-7	HIV-1 control;
CESC	trans	rs274437	0.739	rs12197788	chr6:104791156	G/A	cg23629166	chr1:2345368	PEX10	0.56	6.04	0.35	5.16e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3806843	0.705	rs35614340	chr5:140043618	C/G	cg16179182	chr5:140090404	VTRNA1-1	0.4	5.16	0.3	4.88e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs2797685	0.898	rs697693	chr1:7886424	C/T	cg04725166	chr1:7887271	PER3	-0.47	-6.72	-0.38	1.1e-10	Crohn's disease;
CESC	cis	rs2842992	0.789	rs4276525	chr6:160193612	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.76	9.79	0.52	1.65e-19	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs17376456	1.000	rs13163610	chr5:93548877	A/C	cg21475434	chr5:93447410	FAM172A	0.83	7.48	0.42	1.1e-12	Diabetic retinopathy;
CESC	cis	rs12497850	0.931	rs6791542	chr3:48787219	A/G	cg06212747	chr3:49208901	KLHDC8B	0.68	9.45	0.5	1.86e-18	Parkinson's disease;
CESC	cis	rs10870270	1.000	rs11146338	chr10:133770291	C/G	cg08754478	chr10:133766260	PPP2R2D	-0.59	-7.57	-0.42	6.29e-13	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs6963495	0.745	rs55906043	chr7:105165367	T/G	cg19920283	chr7:105172520	RINT1	0.69	6.56	0.37	2.85e-10	Bipolar disorder (body mass index interaction);
CESC	cis	rs7107174	1.000	rs1942352	chr11:77970563	T/G	cg02023728	chr11:77925099	USP35	0.52	7.5	0.42	9.85e-13	Testicular germ cell tumor;
CESC	cis	rs3741151	0.773	rs11820577	chr11:73261424	C/G	cg17517138	chr11:73019481	ARHGEF17	0.86	6.82	0.39	6.26e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs1832871	0.643	rs7750656	chr6:158725907	C/T	cg07165851	chr6:158734300	TULP4	0.61	6.77	0.38	8.06e-11	Height;
CESC	trans	rs354225	0.539	rs6752720	chr2:54962352	G/A	cg08887902	chr7:77428575	PHTF2;TMEM60	-0.61	-6.18	-0.35	2.42e-9	Schizophrenia;
CESC	cis	rs8103278	0.826	rs11669442	chr19:46374557	A/G	cg14061069	chr19:46274453	DMPK	-0.39	-5.47	-0.32	1.03e-7	Coronary artery disease;
CESC	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.46	6.17	0.35	2.6e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs314370	0.951	rs12705095	chr7:100484381	T/G	cg10426581	chr7:100472382	SRRT	0.85	8.23	0.45	8.68e-15	Resting heart rate;
CESC	cis	rs8028182	0.549	rs7402844	chr15:75637396	C/G	cg20655648	chr15:75932815	IMP3	-0.42	-5.26	-0.31	3.03e-7	Sudden cardiac arrest;
CESC	cis	rs2832191	0.716	rs7509628	chr21:30454252	C/T	cg24692254	chr21:30365293	RNF160	0.99	17.57	0.73	2.33e-46	Dental caries;
CESC	cis	rs9303401	0.659	rs34556735	chr17:56694447	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.0	11.64	0.58	1.4e-25	Cognitive test performance;
CESC	cis	rs9300255	0.568	rs1621194	chr12:123651018	T/C	cg00376283	chr12:123451042	ABCB9	0.7	8.86	0.48	1.16e-16	Neutrophil percentage of white cells;
CESC	cis	rs4555082	0.789	rs2816649	chr14:105708326	A/G	cg27165867	chr14:105738592	BRF1	-0.5	-5.81	-0.34	1.8e-8	Mean platelet volume;Platelet distribution width;
CESC	cis	rs7296418	0.922	rs12425009	chr12:123502044	C/T	cg00376283	chr12:123451042	ABCB9	0.75	10.88	0.56	4.77e-23	Platelet count;
CESC	cis	rs10883723	0.810	rs10883728	chr10:104269301	A/G	ch.10.2196322F	chr10:104248062	ACTR1A	-0.44	-5.44	-0.32	1.19e-7	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs6687430	0.512	rs34575776	chr1:10621061	A/G	cg20482658	chr1:10539492	PEX14	0.39	7.93	0.44	6.24e-14	Hand grip strength;
CESC	cis	rs1448094	0.556	rs2061686	chr12:86170951	C/T	cg02569458	chr12:86230093	RASSF9	-0.52	-7.61	-0.42	4.68e-13	Major depressive disorder;
CESC	cis	rs6466055	0.720	rs13239067	chr7:105011629	T/A	cg04380332	chr7:105027541	SRPK2	-0.41	-5.33	-0.31	2.07e-7	Schizophrenia;
CESC	cis	rs3845702	0.935	rs3845695	chr2:180796989	A/G	cg01881094	chr2:180872142	CWC22	-0.71	-7.32	-0.41	2.9e-12	Schizophrenia;
CESC	cis	rs8067545	0.636	rs11204300	chr17:20195438	C/T	cg13482628	chr17:19912719	NA	-0.42	-5.61	-0.33	5.2e-8	Schizophrenia;
CESC	cis	rs9814567	1.000	rs28409322	chr3:134252385	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.45	6.08	0.35	4.21e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs11122272	0.735	rs2749709	chr1:231530476	G/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.53	-7.12	-0.4	9.89e-12	Hemoglobin concentration;
CESC	cis	rs2576037	0.583	rs4890343	chr18:44540969	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.77	12.35	0.6	5.57e-28	Personality dimensions;
CESC	cis	rs9443645	0.901	rs9361460	chr6:79589467	C/G	cg05283184	chr6:79620031	NA	-0.43	-6.56	-0.37	2.85e-10	Intelligence (multi-trait analysis);
CESC	trans	rs9951602	0.512	rs1903722	chr18:76646539	G/A	cg02800362	chr5:177631904	HNRNPAB	0.61	7.97	0.44	4.84e-14	Obesity-related traits;
CESC	cis	rs2637266	1.000	rs2395389	chr10:78357701	C/T	cg18941641	chr10:78392320	NA	0.42	7.73	0.43	2.28e-13	Pulmonary function;
CESC	trans	rs8014204	0.816	rs10083386	chr14:75347585	C/A	cg22117143	chr9:13251431	MPDZ	0.38	6.03	0.35	5.59e-9	Caffeine consumption;
CESC	trans	rs2270927	0.834	rs4496693	chr5:75576729	T/C	cg13563193	chr19:33072644	PDCD5	0.74	6.26	0.36	1.53e-9	Mean corpuscular volume;
CESC	cis	rs61996546	0.622	rs12907116	chr15:26857399	A/G	cg15066197	chr15:26874202	GABRB3	-0.35	-5.09	-0.3	6.95e-7	Response to methotrexate in juvenile idiopathic arthritis;
CESC	cis	rs9902453	1.000	rs9890205	chr17:28382704	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.62	-7.84	-0.43	1.09e-13	Coffee consumption (cups per day);
CESC	cis	rs7089973	0.604	rs2420066	chr10:116583897	A/G	cg23260525	chr10:116636907	FAM160B1	0.38	6.86	0.39	4.82e-11	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs2645694	0.626	rs2703124	chr4:77820626	G/T	cg10057126	chr4:77819792	ANKRD56	0.59	8.69	0.47	3.72e-16	Emphysema distribution in smoking;
CESC	cis	rs8038465	0.568	rs62004592	chr15:73878019	A/G	cg15420318	chr15:73925796	NPTN	0.5	6.99	0.39	2.18e-11	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs4819052	0.851	rs13050359	chr21:46672671	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.93	13.78	0.65	6.21e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs9733	0.596	rs1336898	chr1:150665050	G/A	cg09365446	chr1:150670422	GOLPH3L	0.42	5.91	0.34	1.03e-8	Tonsillectomy;
CESC	cis	rs950169	0.881	rs62029596	chr15:84955434	A/G	cg17507749	chr15:85114479	UBE2QP1	0.59	6.54	0.37	3.11e-10	Schizophrenia;
CESC	cis	rs113835537	0.597	rs7939759	chr11:66337964	C/T	cg24851651	chr11:66362959	CCS	0.5	5.96	0.34	7.95e-9	Airway imaging phenotypes;
CESC	cis	rs7618501	0.521	rs868891	chr3:49949071	A/G	cg24308560	chr3:49941425	MST1R	-0.58	-8.38	-0.46	3.15e-15	Intelligence (multi-trait analysis);
CESC	cis	rs875971	0.545	rs10950027	chr7:65634151	C/T	cg11764359	chr7:65958608	NA	0.79	9.51	0.5	1.18e-18	Aortic root size;
CESC	trans	rs3780486	0.801	rs56687083	chr9:33132134	A/G	cg20290983	chr6:43655470	MRPS18A	0.99	18.35	0.75	4.06e-49	IgG glycosylation;
CESC	cis	rs1005277	0.505	rs7917943	chr10:38195811	T/A	cg25427524	chr10:38739819	LOC399744	0.69	10.35	0.54	2.59e-21	Extrinsic epigenetic age acceleration;
CESC	cis	rs7193541	0.965	rs7199068	chr16:74698263	C/G	cg01733217	chr16:74700730	RFWD3	0.98	14.95	0.68	4.57e-37	Multiple myeloma;
CESC	cis	rs8031584	0.958	rs35256769	chr15:31237776	G/A	cg08704250	chr15:31115839	NA	-0.63	-8.17	-0.45	1.28e-14	Huntington's disease progression;
CESC	trans	rs877282	1.000	rs12763443	chr10:771941	G/A	cg22713356	chr15:30763199	NA	1.26	12.69	0.61	3.79e-29	Uric acid levels;
CESC	trans	rs5758511	0.773	rs7288749	chr22:42356430	C/T	cg15080870	chr19:47770746	CCDC9	0.49	6.11	0.35	3.49e-9	Birth weight;
CESC	cis	rs9467711	0.606	rs9379900	chr6:26603811	A/C	cg14345882	chr6:26364793	BTN3A2	0.56	5.96	0.34	7.82e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs4803468	0.967	rs284661	chr19:41932120	C/T	cg09537434	chr19:41945824	ATP5SL	-1.05	-19.17	-0.76	5.5e-52	Height;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg23415789	chr17:59445792	BCAS3	0.45	6.12	0.35	3.42e-9	Fibrinogen levels;
CESC	cis	rs7243790	1.000	rs7243790	chr18:51961763	T/G	cg04730925	chr18:51795821	POLI	-0.42	-5.54	-0.32	7.12e-8	Diastolic blood pressure;
CESC	cis	rs1322639	1.000	rs1322639	chr6:169587103	G/A	cg03254818	chr6:169586852	NA	-0.53	-7.25	-0.41	4.57e-12	Pulse pressure;
CESC	cis	rs75477785	1.000	rs75477785	chr1:209984470	T/G	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.92	6.04	0.35	5.06e-9	Cleft lip with or without cleft palate;
CESC	cis	rs1712517	0.525	rs11191667	chr10:105128898	G/A	cg04362960	chr10:104952993	NT5C2	-0.47	-5.66	-0.33	4.01e-8	Migraine;
CESC	cis	rs7833790	0.700	rs7825180	chr8:82723991	T/A	cg02079420	chr8:82753780	SNX16	0.54	8.14	0.45	1.52e-14	Diastolic blood pressure;
CESC	trans	rs853679	0.824	rs34712084	chr6:28043828	A/G	cg06606381	chr12:133084897	FBRSL1	-0.66	-6.0	-0.35	6.41e-9	Depression;
CESC	cis	rs7618915	0.547	rs6976	chr3:52728804	C/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.31	5.46	0.32	1.12e-7	Bipolar disorder;
CESC	cis	rs9914988	0.943	rs9890377	chr17:27111111	A/G	cg20469991	chr17:27169893	C17orf63	-0.48	-5.25	-0.31	3.18e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CESC	cis	rs425277	0.606	rs377283	chr1:2075570	T/C	cg24578937	chr1:2090814	PRKCZ	0.38	6.59	0.38	2.32e-10	Height;
CESC	cis	rs6543140	0.964	rs1523205	chr2:103070176	G/T	cg04239558	chr2:103089729	SLC9A4	0.47	5.99	0.35	6.67e-9	Blood protein levels;
CESC	cis	rs8180040	0.966	rs2101247	chr3:47494303	G/A	cg27129171	chr3:47204927	SETD2	-0.63	-9.44	-0.5	1.95e-18	Colorectal cancer;
CESC	cis	rs9911578	1.000	rs391370	chr17:56675050	A/C	cg05425664	chr17:57184151	TRIM37	-0.51	-7.13	-0.4	9.35e-12	Intelligence (multi-trait analysis);
CESC	cis	rs6570726	0.764	rs9386125	chr6:145911677	C/T	cg23711669	chr6:146136114	FBXO30	0.92	13.58	0.64	3.16e-32	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7208859	0.623	rs9916727	chr17:29107472	A/G	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.17e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs4789693	0.938	rs12952655	chr17:80421139	C/T	cg04308225	chr17:80449738	NA	-0.45	-5.36	-0.31	1.79e-7	Glucocorticoid-induced osteonecrosis;
CESC	cis	rs1552244	0.515	rs67626468	chr3:10161518	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.79	8.79	0.48	1.87e-16	Alzheimer's disease;
CESC	cis	rs2072732	0.808	rs56091202	chr1:2936803	A/G	cg03976712	chr1:2946727	NA	0.33	5.17	0.3	4.53e-7	Plateletcrit;
CESC	cis	rs9611565	0.694	rs5758347	chr22:41821019	G/T	cg06634786	chr22:41940651	POLR3H	0.71	7.17	0.4	7.6e-12	Vitiligo;
CESC	cis	rs9916302	0.706	rs4287601	chr17:37513852	T/C	cg07936489	chr17:37558343	FBXL20	0.89	9.69	0.51	3.45e-19	Glomerular filtration rate (creatinine);
CESC	cis	rs4642101	0.597	rs12638595	chr3:12819281	T/C	cg05775895	chr3:12838266	CAND2	0.37	5.42	0.32	1.36e-7	QRS complex (12-leadsum);
CESC	cis	rs10540	1.000	rs61876334	chr11:487201	T/C	cg03934478	chr11:495069	RNH1	0.55	5.31	0.31	2.37e-7	Body mass index;
CESC	cis	rs1879734	0.731	rs11206200	chr1:54168545	T/C	cg23596471	chr1:54105337	GLIS1	0.34	5.44	0.32	1.19e-7	Mitral valve prolapse;
CESC	cis	rs9399137	0.507	rs4896118	chr6:135276065	A/G	cg22676075	chr6:135203613	NA	-0.48	-6.25	-0.36	1.6e-9	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	cis	rs4819052	0.808	rs2838825	chr21:46655651	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.74	9.53	0.51	1.06e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13781829	chr10:93558071	TNKS2	0.58	6.33	0.36	1.07e-9	Gut microbiome composition (summer);
CESC	cis	rs72848980	0.512	rs56984020	chr10:105386275	C/A	cg00126946	chr10:105363258	SH3PXD2A	0.6	8.55	0.46	1e-15	White matter hyperintensity burden;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg17930852	chr1:45957182	TESK2	-0.57	-7.28	-0.41	3.7e-12	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg15891644	chr15:40751006	BAHD1	-0.5	-6.15	-0.35	2.78e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs9894429	0.671	rs6565616	chr17:79612161	C/T	cg13777783	chr17:79615861	NA	-0.37	-6.17	-0.35	2.61e-9	Eye color traits;
CESC	cis	rs2228479	0.618	rs34689166	chr16:89860697	C/T	cg14709524	chr16:89940631	TCF25	0.93	6.97	0.39	2.5e-11	Skin colour saturation;
CESC	cis	rs4737010	0.578	rs4466386	chr8:41679853	A/G	cg08923054	chr8:41654455	ANK1	0.51	6.73	0.38	1.03e-10	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
CESC	cis	rs7824557	0.724	rs2251473	chr8:11177126	C/A	cg21775007	chr8:11205619	TDH	0.41	5.72	0.33	2.82e-8	Retinal vascular caliber;
CESC	cis	rs3015497	0.550	rs2934666	chr14:51154703	T/G	cg26011998	chr14:51135199	SAV1	-0.55	-5.97	-0.34	7.45e-9	Mean platelet volume;
CESC	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg26354017	chr1:205819088	PM20D1	0.84	13.17	0.63	8.53e-31	Menarche (age at onset);
CESC	cis	rs11122272	0.735	rs973252	chr1:231520802	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.57	-7.82	-0.43	1.29e-13	Hemoglobin concentration;
CESC	cis	rs3741404	0.512	rs4980504	chr11:63873083	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.62	-8.18	-0.45	1.2e-14	Platelet count;
CESC	cis	rs7772486	0.686	rs857882	chr6:145969716	T/G	cg05347473	chr6:146136440	FBXO30	-0.55	-7.1	-0.4	1.12e-11	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg13789711	chr9:139743225	PHPT1	-0.52	-7.94	-0.44	5.67e-14	Gambling;
CESC	cis	rs9322193	0.923	rs9322197	chr6:149943713	C/A	cg13206674	chr6:150067644	NUP43	0.39	5.56	0.32	6.65e-8	Lung cancer;
CESC	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.88	13.16	0.63	8.67e-31	Prudent dietary pattern;
CESC	cis	rs6800768	0.556	rs73134512	chr3:24089762	G/C	cg10674438	chr3:24145617	LOC152024	-0.4	-5.45	-0.32	1.18e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs262150	0.731	rs2657388	chr7:158763428	A/G	cg19418458	chr7:158789849	NA	0.39	5.92	0.34	9.7e-9	Facial morphology (factor 20);
CESC	cis	rs2455799	0.613	rs7633542	chr3:15816326	C/T	cg16303742	chr3:15540471	COLQ	-0.39	-6.15	-0.35	2.83e-9	Mean platelet volume;
CESC	cis	rs4450798	0.649	rs9310430	chr3:13781682	A/G	cg23332027	chr3:13681764	NA	0.38	5.2	0.3	4.01e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs3825932	0.778	rs1369324	chr15:79239719	C/T	cg25744700	chr15:79237217	CTSH	-0.5	-6.72	-0.38	1.09e-10	Type 1 diabetes;
CESC	cis	rs2933343	0.700	rs2624910	chr3:128650275	G/C	cg24203234	chr3:128598194	ACAD9	0.44	5.97	0.34	7.61e-9	IgG glycosylation;
CESC	cis	rs75477785	0.590	rs4844916	chr1:210108196	A/T	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.94	6.89	0.39	4.04e-11	Cleft lip with or without cleft palate;
CESC	cis	rs643506	0.774	rs11214033	chr11:111769702	G/A	cg17089665	chr11:111648010	NA	0.39	5.72	0.33	2.85e-8	Breast cancer;
CESC	cis	rs9287719	0.967	rs7600587	chr2:10739851	A/G	cg02196655	chr2:10830764	NOL10	-0.37	-5.72	-0.33	2.87e-8	Prostate cancer;
CESC	cis	rs6540556	0.859	rs11119341	chr1:209940675	A/G	cg05527609	chr1:210001259	C1orf107	0.56	6.97	0.39	2.49e-11	Red blood cell count;
CESC	cis	rs9911578	1.000	rs1267545	chr17:56646909	A/G	cg05425664	chr17:57184151	TRIM37	-0.5	-7.02	-0.4	1.86e-11	Intelligence (multi-trait analysis);
CESC	cis	rs9788333	0.762	rs4441120	chr13:21886863	T/A	cg21970626	chr13:21893289	NA	-0.39	-5.69	-0.33	3.31e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs7666738	0.687	rs6839454	chr4:99073914	T/C	cg07917127	chr4:99064746	C4orf37	0.43	5.21	0.3	3.86e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06708562	chr6:146285465	SHPRH	0.54	6.47	0.37	4.68e-10	Gut microbiome composition (summer);
CESC	trans	rs3942852	0.868	rs11039514	chr11:48109598	A/G	cg03929089	chr4:120376271	NA	-0.55	-6.12	-0.35	3.42e-9	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs2204008	0.743	rs11495614	chr12:38156358	C/T	cg13010199	chr12:38710504	ALG10B	0.51	6.04	0.35	5.25e-9	Bladder cancer;
CESC	cis	rs208520	0.690	rs1304672	chr6:66847973	A/G	cg07460842	chr6:66804631	NA	0.86	9.16	0.49	1.47e-17	Exhaled nitric oxide output;
CESC	cis	rs9811920	0.683	rs793502	chr3:99588417	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.39	6.46	0.37	5.02e-10	Axial length;
CESC	cis	rs425277	0.958	rs626479	chr1:2110260	A/G	cg24578937	chr1:2090814	PRKCZ	-0.54	-9.22	-0.49	9.39e-18	Height;
CESC	cis	rs9457247	0.765	rs9457259	chr6:167444281	C/T	cg23791538	chr6:167370224	RNASET2	-0.55	-7.59	-0.42	5.54e-13	Crohn's disease;
CESC	cis	rs1927790	0.727	rs6491285	chr13:96944930	T/A	cg02571835	chr13:96230311	CLDN10	-0.36	-5.3	-0.31	2.41e-7	Body mass index;
CESC	cis	rs2836974	0.865	rs34778912	chr21:40667037	T/G	cg17971929	chr21:40555470	PSMG1	1.04	15.61	0.69	2.11e-39	Cognitive function;
CESC	cis	rs3733585	0.674	rs7375643	chr4:9955239	A/G	cg11266682	chr4:10021025	SLC2A9	-0.61	-12.65	-0.61	5.05e-29	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs7408868	1.000	rs10418305	chr19:15278808	C/G	cg14696996	chr19:15285081	NOTCH3	1.11	11.94	0.59	1.43e-26	Pulse pressure;
CESC	trans	rs10743315	0.557	rs77344887	chr12:19312751	C/T	cg09562322	chr12:119419143	SRRM4	-0.48	-6.11	-0.35	3.62e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs3008870	1.000	rs3008853	chr1:67385488	C/T	cg02640540	chr1:67518911	SLC35D1	0.5	5.33	0.31	2.08e-7	Lymphocyte percentage of white cells;
CESC	cis	rs2204008	0.837	rs11180549	chr12:38236950	A/G	cg13010199	chr12:38710504	ALG10B	0.52	6.43	0.37	5.91e-10	Bladder cancer;
CESC	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg07308232	chr7:1071921	C7orf50	-0.44	-5.88	-0.34	1.26e-8	Longevity;Endometriosis;
CESC	cis	rs4423214	0.840	rs1792315	chr11:71165547	C/T	cg05163923	chr11:71159392	DHCR7	-0.63	-7.34	-0.41	2.61e-12	Vitamin D levels;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg13381753	chr1:213189256	ANGEL2	0.49	6.32	0.36	1.12e-9	Systemic lupus erythematosus;
CESC	cis	rs9733	0.650	rs11204684	chr1:150608894	A/G	cg13175981	chr1:150552382	MCL1	0.75	11.23	0.57	3.32e-24	Tonsillectomy;
CESC	cis	rs9896933	0.830	rs113051447	chr17:80791806	A/G	cg20578329	chr17:80767326	TBCD	-0.62	-7.18	-0.4	6.87e-12	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
CESC	cis	rs9487051	0.714	rs6927569	chr6:109621494	T/C	cg12927641	chr6:109611667	NA	-0.36	-5.26	-0.31	3.04e-7	Reticulocyte fraction of red cells;
CESC	cis	rs1799949	0.965	rs9646413	chr17:41426157	A/G	cg25072359	chr17:41440525	NA	0.51	7.5	0.42	9.61e-13	Menopause (age at onset);
CESC	cis	rs7666738	0.830	rs6834014	chr4:98951431	G/A	cg17366294	chr4:99064904	C4orf37	0.59	8.52	0.46	1.24e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs514406	0.607	rs1930305	chr1:53195481	G/T	cg08859206	chr1:53392774	SCP2	0.57	7.13	0.4	9.66e-12	Monocyte count;
CESC	cis	rs6866344	0.697	rs62392833	chr5:178135452	T/A	cg10224037	chr5:178157518	ZNF354A	0.69	7.77	0.43	1.78e-13	Neutrophil percentage of white cells;
CESC	cis	rs7552404	0.727	rs61770533	chr1:76306490	C/G	cg03433033	chr1:76189801	ACADM	0.62	6.27	0.36	1.49e-9	Blood metabolite levels;Acylcarnitine levels;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg21173440	chr5:55008212	SLC38A9	-0.43	-6.94	-0.39	3.01e-11	Gambling;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg09508119	chr19:506588	C19orf20	-0.49	-6.68	-0.38	1.39e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs9309711	0.961	rs11692184	chr2:3480710	C/T	cg10845886	chr2:3471009	TTC15	-0.89	-13.07	-0.63	1.84e-30	Neurofibrillary tangles;
CESC	cis	rs1003719	0.762	rs1155786	chr21:38448025	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.62	8.48	0.46	1.55e-15	Eye color traits;
CESC	cis	rs7927771	1.000	rs11039255	chr11:47495746	G/T	cg05585544	chr11:47624801	NA	-0.53	-7.99	-0.44	4.29e-14	Subjective well-being;
CESC	cis	rs7267979	0.727	rs4815431	chr20:25532405	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.71	-12.48	-0.61	1.93e-28	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7937682	1.000	rs9734135	chr11:111536190	G/A	cg22437258	chr11:111473054	SIK2	0.69	9.18	0.49	1.3e-17	Primary sclerosing cholangitis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13132016	chr14:58893740	KIAA0586;TIMM9	-0.57	-6.56	-0.37	2.8e-10	Gut microbiome composition (summer);
CESC	cis	rs916888	0.697	rs199516	chr17:44856485	C/T	cg27589368	chr17:43923255	LOC100128977;IMP5	0.35	5.09	0.3	6.78e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	trans	rs4716602	0.596	rs10267031	chr7:156159649	A/G	cg07175507	chr18:77160758	NFATC1	-0.44	-6.04	-0.35	5.07e-9	Anti-saccade response;
CESC	cis	rs5769707	0.967	rs739248	chr22:50025205	T/C	cg05373962	chr22:49881684	NA	-0.39	-6.77	-0.38	8.07e-11	Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs4805272	0.539	rs1422212	chr19:29330191	T/A	cg12756686	chr19:29218302	NA	0.49	5.91	0.34	1.04e-8	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
CESC	cis	rs7829975	0.617	rs4841071	chr8:8791144	G/T	cg15556689	chr8:8085844	FLJ10661	0.41	5.19	0.3	4.26e-7	Mood instability;
CESC	cis	rs9858542	1.000	rs13085791	chr3:49721798	C/A	cg07274523	chr3:49395745	GPX1	0.67	8.65	0.47	5.08e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs6964587	0.967	rs10429103	chr7:91598443	T/A	cg17063962	chr7:91808500	NA	0.57	7.74	0.43	2.11e-13	Breast cancer;
CESC	cis	rs977987	0.806	rs4888418	chr16:75460306	C/G	cg03315344	chr16:75512273	CHST6	0.41	5.88	0.34	1.21e-8	Dupuytren's disease;
CESC	cis	rs10242455	0.702	rs1045012	chr7:98984354	G/C	cg18809830	chr7:99032528	PTCD1	-0.89	-6.09	-0.35	3.93e-9	Blood metabolite levels;
CESC	cis	rs2479106	0.549	rs10818851	chr9:126395781	C/A	cg16191174	chr9:126692580	DENND1A	0.4	5.57	0.32	6.35e-8	Polycystic ovary syndrome;
CESC	cis	rs7811142	1.000	rs60844404	chr7:100080474	A/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.02	11.36	0.57	1.23e-24	Platelet count;
CESC	cis	rs765787	0.530	rs12910270	chr15:45512086	G/A	cg24006582	chr15:45444508	DUOX1	0.52	6.34	0.36	9.88e-10	Uric acid levels;
CESC	cis	rs2845885	0.793	rs56241103	chr11:63882364	C/T	cg05555928	chr11:63887634	MACROD1	-0.54	-5.99	-0.35	6.69e-9	Body mass index;
CESC	cis	rs698833	0.886	rs2053455	chr2:44550233	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.53	6.75	0.38	9.26e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg27224392	chr10:104474430	SFXN2;ARL3	-0.5	-7.14	-0.4	8.8e-12	Gambling;
CESC	cis	rs10911232	0.507	rs10911195	chr1:182993438	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.85	13.21	0.63	5.94e-31	Hypertriglyceridemia;
CESC	trans	rs9561428	0.850	rs9561440	chr13:94423496	A/C	cg17039369	chr21:46341006	ITGB2	0.51	6.22	0.36	1.95e-9	Bipolar disorder and schizophrenia;
CESC	trans	rs263156	0.567	rs263127	chr6:142934867	A/G	cg10648252	chr7:101469088	CUX1	-0.45	-6.13	-0.35	3.24e-9	Ear morphology;Lobe size;Lobe attachment;
CESC	cis	rs7927771	0.697	rs11039307	chr11:47611152	C/T	cg05585544	chr11:47624801	NA	-0.42	-6.6	-0.38	2.29e-10	Subjective well-being;
CESC	cis	rs1153858	1.000	rs1145081	chr15:45679667	C/G	cg21132104	chr15:45694354	SPATA5L1	0.77	10.24	0.53	5.77e-21	Homoarginine levels;
CESC	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.34	6.39	0.37	7.51e-10	Electroencephalogram traits;
CESC	cis	rs6933660	0.666	rs9371516	chr6:151739642	G/A	cg02564969	chr6:151773285	C6orf211;RMND1	0.62	8.57	0.47	8.78e-16	Menarche (age at onset);
CESC	cis	rs561341	1.000	rs72825712	chr17:30316119	A/T	cg19193384	chr17:30244184	NA	-0.71	-6.6	-0.38	2.17e-10	Hip circumference adjusted for BMI;
CESC	cis	rs7914558	0.966	rs2065977	chr10:104729415	C/T	cg15744005	chr10:104629667	AS3MT	-0.34	-5.31	-0.31	2.32e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10704137	chr6:25732153	NA	-0.63	-7.44	-0.42	1.37e-12	Gut microbiome composition (summer);
CESC	cis	rs9910055	0.659	rs7214540	chr17:42256604	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.74	10.2	0.53	8.14e-21	Total body bone mineral density;
CESC	cis	rs7666738	0.830	rs17486413	chr4:99060544	G/T	cg03467027	chr4:99064603	C4orf37	0.47	5.71	0.33	2.95e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1707322	0.928	rs61785614	chr1:46446047	A/G	cg06784218	chr1:46089804	CCDC17	0.33	5.63	0.33	4.7e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2637266	1.000	rs1907305	chr10:78339512	C/G	cg18941641	chr10:78392320	NA	0.41	7.64	0.42	4.06e-13	Pulmonary function;
CESC	cis	rs7927771	0.524	rs4752865	chr11:47759841	G/A	cg05585544	chr11:47624801	NA	-0.33	-5.22	-0.31	3.66e-7	Subjective well-being;
CESC	cis	rs4819052	0.851	rs9753963	chr21:46661437	G/A	cg11663144	chr21:46675770	NA	-0.63	-10.02	-0.52	3.12e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs2032447	0.869	rs2230655	chr6:26033506	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.75	-10.78	-0.55	1.06e-22	Intelligence (multi-trait analysis);
CESC	cis	rs9796	0.621	rs691702	chr15:41474399	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.44	-6.44	-0.37	5.52e-10	Menopause (age at onset);
CESC	cis	rs9549260	0.755	rs2721066	chr13:41156188	C/T	cg21288729	chr13:41239152	FOXO1	-0.63	-8.09	-0.44	2.2e-14	Red blood cell count;
CESC	cis	rs7584330	0.868	rs67071074	chr2:238395429	T/C	cg11271282	chr2:238384023	NA	0.51	5.76	0.33	2.31e-8	Prostate cancer;
CESC	cis	rs7666738	0.830	rs10470951	chr4:99037051	G/A	cg03676636	chr4:99064102	C4orf37	0.33	5.12	0.3	6.01e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2075371	0.933	rs1833474	chr7:133958240	A/G	cg20476274	chr7:133979776	SLC35B4	0.68	9.88	0.52	8.59e-20	Mean platelet volume;
CESC	cis	rs6733011	0.508	rs4850889	chr2:99521385	T/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.41	-5.11	-0.3	6.13e-7	Bipolar disorder;
CESC	cis	rs12220238	1.000	rs10824112	chr10:75969003	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.6	5.45	0.32	1.13e-7	Soluble interleukin-2 receptor subunit alpha;
CESC	cis	rs10744422	1.000	rs4759387	chr12:123377569	C/T	cg22842854	chr12:123319900	HIP1R	-0.62	-5.15	-0.3	5.02e-7	Schizophrenia;
CESC	trans	rs6572548	0.504	rs1956082	chr14:49665496	A/C	cg23104823	chr14:45553408	PRPF39	-0.53	-6.18	-0.35	2.39e-9	Subjective well-being;
CESC	cis	rs769267	0.930	rs10419912	chr19:19597055	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.45	-5.71	-0.33	2.99e-8	Tonsillectomy;
CESC	cis	rs6690583	0.697	rs10782537	chr1:85484473	C/T	cg22153463	chr1:85462885	MCOLN2	-0.8	-10.46	-0.54	1.2e-21	Serum sulfate level;
CESC	cis	rs5771242	0.518	rs5771258	chr22:50675648	C/A	cg08875078	chr22:50639485	SELO	0.47	5.49	0.32	9.18e-8	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
CESC	cis	rs1538970	0.816	rs3790583	chr1:45956828	C/G	cg06784218	chr1:46089804	CCDC17	0.37	5.9	0.34	1.11e-8	Platelet count;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg10446143	chr21:44394730	PKNOX1	-0.48	-6.55	-0.37	2.97e-10	Height;
CESC	cis	rs7412746	0.658	rs6660845	chr1:150841066	G/A	cg09365446	chr1:150670422	GOLPH3L	0.39	5.24	0.31	3.25e-7	Melanoma;
CESC	cis	rs1707322	1.000	rs1707338	chr1:46511981	T/G	cg05343316	chr1:45956843	TESK2	-0.44	-5.44	-0.32	1.2e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9916302	0.904	rs1619021	chr17:37739274	G/A	cg20243544	chr17:37824526	PNMT	0.56	6.79	0.38	7.35e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs561341	0.714	rs547473	chr17:30297560	T/G	cg00745463	chr17:30367425	LRRC37B	-0.7	-7.02	-0.4	1.85e-11	Hip circumference adjusted for BMI;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10015802	chr19:3492440	DOHH	-0.59	-6.78	-0.38	7.97e-11	Gut microbiome composition (summer);
CESC	cis	rs11252926	0.563	rs10795103	chr10:451849	C/A	cg18196295	chr10:418757	DIP2C	0.53	7.05	0.4	1.55e-11	Psychosis in Alzheimer's disease;
CESC	cis	rs6582630	0.502	rs11181475	chr12:38348922	G/A	cg26384229	chr12:38710491	ALG10B	0.69	10.42	0.54	1.6e-21	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs4253772	0.591	rs7286155	chr22:46714735	A/G	cg00784671	chr22:46762841	CELSR1	-0.48	-5.51	-0.32	8.51e-8	LDL cholesterol;Cholesterol, total;
CESC	trans	rs9693444	0.898	rs4732697	chr8:29519861	A/G	cg09431544	chr19:14629187	DNAJB1	-0.45	-6.54	-0.37	3.17e-10	Breast cancer;
CESC	cis	rs425277	0.606	rs16824792	chr1:2039521	G/T	cg13918804	chr1:2043761	PRKCZ	0.27	5.32	0.31	2.19e-7	Height;
CESC	cis	rs7582720	1.000	rs72926794	chr2:203827432	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.36	0.41	2.34e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs10927875	0.632	rs904911	chr1:16126932	C/T	cg05821634	chr1:16164109	FLJ37453	0.35	5.04	0.3	8.77e-7	Dilated cardiomyopathy;
CESC	cis	rs2730245	0.563	rs2709857	chr7:158685257	T/C	cg24397884	chr7:158709396	WDR60	0.68	9.92	0.52	6.27e-20	Height;
CESC	cis	rs1355223	0.583	rs2941060	chr11:34879154	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.83	12.7	0.62	3.47e-29	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs6860806	0.507	rs2631362	chr5:131707293	A/G	cg12564285	chr5:131593104	PDLIM4	-0.37	-5.43	-0.32	1.3e-7	Breast cancer;
CESC	cis	rs863345	0.604	rs7555174	chr1:158487426	A/G	cg12129480	chr1:158549410	OR10X1	-0.35	-6.98	-0.39	2.34e-11	Pneumococcal bacteremia;
CESC	cis	rs8070463	0.515	rs11655943	chr17:45385640	A/G	cg08085267	chr17:45401833	C17orf57	-0.5	-6.48	-0.37	4.54e-10	Multiple sclerosis;Ankylosing spondylitis;
CESC	cis	rs7851660	0.594	rs28703314	chr9:100660145	A/T	cg13688889	chr9:100608707	NA	-0.62	-8.45	-0.46	2.02e-15	Strep throat;
CESC	cis	rs7666738	0.962	rs2865985	chr4:99068009	T/C	cg17366294	chr4:99064904	C4orf37	0.54	7.1	0.4	1.11e-11	Colonoscopy-negative controls vs population controls;
CESC	cis	rs523522	0.962	rs651627	chr12:121009198	C/T	cg12219531	chr12:120966889	COQ5	0.74	9.78	0.51	1.75e-19	High light scatter reticulocyte count;
CESC	trans	rs9467711	0.606	rs71557334	chr6:26365913	G/T	cg06606381	chr12:133084897	FBRSL1	-0.76	-6.82	-0.39	6.01e-11	Autism spectrum disorder or schizophrenia;
CESC	cis	rs769267	0.930	rs2304098	chr19:19646272	T/C	cg03709012	chr19:19516395	GATAD2A	1.0	15.34	0.69	1.87e-38	Tonsillectomy;
CESC	cis	rs873946	0.648	rs12767126	chr10:134556992	C/T	cg06453172	chr10:134556979	INPP5A	-0.42	-5.32	-0.31	2.19e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs7084402	1.000	rs12250013	chr10:60265957	C/A	cg07615347	chr10:60278583	BICC1	-0.57	-8.73	-0.47	2.84e-16	Refractive error;
CESC	cis	rs7631605	0.905	rs6764444	chr3:37173715	T/C	cg22985146	chr3:37219077	LRRFIP2	-0.32	-5.21	-0.3	3.82e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs9322193	0.962	rs9689242	chr6:150109106	T/C	cg05861140	chr6:150128134	PCMT1	-0.36	-5.14	-0.3	5.22e-7	Lung cancer;
CESC	cis	rs8017423	1.000	rs10129210	chr14:90668379	G/T	cg14092571	chr14:90743983	NA	-0.57	-8.45	-0.46	1.97e-15	Mortality in heart failure;
CESC	cis	rs9549328	0.800	rs9549620	chr13:113633421	T/A	cg22951483	chr13:113628068	MCF2L	-0.35	-5.14	-0.3	5.44e-7	Systolic blood pressure;
CESC	cis	rs9682041	0.627	rs34392658	chr3:170091584	C/T	cg11886554	chr3:170076028	SKIL	0.56	5.64	0.33	4.46e-8	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg00781875	chr1:156252398	TMEM79;SMG5	-0.46	-6.33	-0.36	1.02e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs2658782	0.756	rs3019205	chr11:93109553	A/G	cg15737290	chr11:93063684	CCDC67	0.52	6.75	0.38	9.51e-11	Pulmonary function decline;
CESC	cis	rs1448094	0.556	rs11610789	chr12:86169541	A/G	cg00310523	chr12:86230176	RASSF9	0.42	6.27	0.36	1.47e-9	Major depressive disorder;
CESC	trans	rs629535	0.767	rs72654073	chr8:70081231	G/A	cg21567404	chr3:27674614	NA	-0.88	-10.28	-0.53	4.4e-21	Dupuytren's disease;
CESC	cis	rs896854	0.936	rs10108430	chr8:95961794	C/T	cg16049864	chr8:95962084	TP53INP1	-0.67	-12.02	-0.59	7.22e-27	Type 2 diabetes;
CESC	cis	rs10242455	0.681	rs2687140	chr7:99322342	T/C	cg07715041	chr7:99302981	CYP3A7	-0.44	-5.48	-0.32	9.91e-8	Blood metabolite levels;
CESC	cis	rs524023	1.000	rs10897518	chr11:64360705	A/G	cg07220939	chr11:64358617	SLC22A12	0.35	5.35	0.31	1.89e-7	Urate levels in obese individuals;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01823416	chr1:47082372	MOBKL2C	0.61	7.86	0.43	9.4e-14	Gut microbiome composition (summer);
CESC	cis	rs5760092	0.572	rs738806	chr22:24234172	A/G	cg23131131	chr22:24373011	LOC391322	-0.55	-6.36	-0.36	8.84e-10	Urinary 1,3-butadiene metabolite levels in smokers;
CESC	cis	rs853679	0.517	rs35227624	chr6:28132726	A/G	cg23281280	chr6:28129359	ZNF389	0.59	7.9	0.44	7.47e-14	Depression;
CESC	trans	rs1728785	0.818	rs11648503	chr16:68598938	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.71	8.43	0.46	2.17e-15	Ulcerative colitis;
CESC	cis	rs4713118	0.662	rs9468271	chr6:28024570	A/G	cg23161317	chr6:28129485	ZNF389	0.49	6.2	0.36	2.14e-9	Parkinson's disease;
CESC	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg24829409	chr8:58192753	C8orf71	-0.65	-7.84	-0.43	1.13e-13	Developmental language disorder (linguistic errors);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12647895	chr7:6629806	C7orf26	0.59	6.71	0.38	1.2e-10	Gut microbiome composition (summer);
CESC	cis	rs6964587	1.000	rs12533199	chr7:91757393	C/T	cg17063962	chr7:91808500	NA	0.59	8.13	0.45	1.69e-14	Breast cancer;
CESC	cis	rs644799	0.710	rs519511	chr11:95538270	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.76	10.93	0.56	3.47e-23	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs7089973	0.624	rs11196930	chr10:116583596	C/T	cg03647239	chr10:116582469	FAM160B1	0.42	5.13	0.3	5.71e-7	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs9910055	0.762	rs6503489	chr17:42246289	G/A	cg19774624	chr17:42201019	HDAC5	-0.7	-10.17	-0.53	1.03e-20	Total body bone mineral density;
CESC	cis	rs4819052	0.851	rs35560973	chr21:46662573	T/C	cg11663144	chr21:46675770	NA	-0.55	-8.58	-0.47	8.14e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs9649213	0.593	rs736754	chr7:97931559	C/T	cg21770322	chr7:97807741	LMTK2	0.54	8.13	0.45	1.67e-14	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs4803468	0.967	rs3213860	chr19:41920211	T/C	cg14132834	chr19:41945861	ATP5SL	-0.67	-8.23	-0.45	8.57e-15	Height;
CESC	cis	rs140365914	1	rs140365914	chr7:155106570	C/T	cg04811098	chr7:155088454	INSIG1	0.4	5.91	0.34	1.04e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs7666738	0.752	rs62318905	chr4:99036103	T/G	cg05340658	chr4:99064831	C4orf37	0.82	12.87	0.62	9.38e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3749237	0.595	rs4855864	chr3:49521974	C/T	cg06212747	chr3:49208901	KLHDC8B	0.51	6.82	0.39	6.09e-11	Resting heart rate;
CESC	cis	rs7267979	0.966	rs2257705	chr20:25264664	T/C	cg08601574	chr20:25228251	PYGB	0.39	5.65	0.33	4.08e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7552404	0.731	rs5745491	chr1:76350159	T/G	cg03433033	chr1:76189801	ACADM	-0.57	-5.87	-0.34	1.28e-8	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs1559088	0.576	rs10407255	chr19:33581150	A/G	cg03563238	chr19:33554763	RHPN2	0.34	6.55	0.37	3.04e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs9287719	1.000	rs9287719	chr2:10710730	C/T	cg02196655	chr2:10830764	NOL10	-0.36	-5.42	-0.32	1.31e-7	Prostate cancer;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg25789201	chr7:72395803	POM121	0.51	6.58	0.37	2.45e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs1941023	0.503	rs4528348	chr11:60129505	C/G	cg08716584	chr11:60157161	MS4A7	-0.51	-8.14	-0.45	1.5e-14	Congenital heart disease (maternal effect);
CESC	cis	rs3858526	0.523	rs10742818	chr11:5882535	T/C	cg25319279	chr11:5960081	NA	-0.36	-5.32	-0.31	2.19e-7	DNA methylation (variation);
CESC	cis	rs1577917	0.771	rs12205013	chr6:86333029	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.54	-7.38	-0.41	2.02e-12	Response to antipsychotic treatment;
CESC	cis	rs3925075	1.000	rs9674009	chr16:31347541	C/A	cg02846316	chr16:31340340	ITGAM	0.41	6.52	0.37	3.54e-10	IgA nephropathy;
CESC	cis	rs113835537	0.529	rs2279864	chr11:66247844	G/A	cg22134325	chr11:66188745	NPAS4	0.35	5.47	0.32	1.05e-7	Airway imaging phenotypes;
CESC	cis	rs637571	0.544	rs500161	chr11:65695438	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.73	9.97	0.52	4.4e-20	Eosinophil percentage of white cells;
CESC	cis	rs3806843	1.000	rs1548700	chr5:140164889	A/T	cg26395211	chr5:140044315	WDR55	-0.42	-5.31	-0.31	2.31e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs4555082	0.874	rs4677	chr14:105717279	T/C	cg06808227	chr14:105710500	BRF1	-0.62	-7.35	-0.41	2.46e-12	Mean platelet volume;Platelet distribution width;
CESC	cis	rs4819052	0.851	rs7281263	chr21:46695606	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.92	13.78	0.65	6.16e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs9916302	0.851	rs9904919	chr17:37556431	G/C	cg00129232	chr17:37814104	STARD3	0.59	7.96	0.44	5.17e-14	Glomerular filtration rate (creatinine);
CESC	cis	rs7098414	0.511	rs10887826	chr10:82151380	C/T	cg00277334	chr10:82204260	NA	-0.5	-7.52	-0.42	8.74e-13	Post bronchodilator FEV1;
CESC	cis	rs3126085	0.935	rs11204967	chr1:152249720	A/G	cg17718321	chr1:152188247	HRNR	0.39	5.2	0.3	3.97e-7	Atopic dermatitis;
CESC	cis	rs6502050	0.799	rs9911129	chr17:80087819	C/T	cg11859384	chr17:80120422	CCDC57	-0.38	-5.14	-0.3	5.31e-7	Life satisfaction;
CESC	cis	rs9486715	0.838	rs7770889	chr6:96858453	C/T	cg06623918	chr6:96969491	KIAA0776	-0.76	-10.72	-0.55	1.62e-22	Headache;
CESC	cis	rs12142240	0.698	rs1475390	chr1:46816340	A/G	cg10495392	chr1:46806563	NSUN4	0.57	6.28	0.36	1.39e-9	Menopause (age at onset);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg13654451	chr1:235267828	NA	-0.49	-6.11	-0.35	3.47e-9	Ulcerative colitis;
CESC	cis	rs7267979	0.932	rs6037125	chr20:25463382	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.73	13.15	0.63	9.54e-31	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs11098499	0.618	rs35265692	chr4:120325135	T/C	cg09307838	chr4:120376055	NA	0.93	12.87	0.62	9.12e-30	Corneal astigmatism;
CESC	cis	rs7680126	0.500	rs4697933	chr4:10146493	G/A	cg11266682	chr4:10021025	SLC2A9	-0.48	-6.41	-0.37	6.65e-10	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	cis	rs6987853	0.787	rs2923441	chr8:42429937	G/T	cg09913449	chr8:42400586	C8orf40	-0.46	-7.64	-0.42	4.02e-13	Mean corpuscular hemoglobin concentration;
CESC	cis	rs6570726	0.967	rs418662	chr6:145848832	A/C	cg05347473	chr6:146136440	FBXO30	0.44	5.95	0.34	8.32e-9	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs10504229	1.000	rs17805549	chr8:58179653	T/C	cg05313129	chr8:58192883	C8orf71	-0.55	-6.37	-0.36	8.42e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs780096	0.526	rs4803	chr2:27667297	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.35	-6.56	-0.37	2.79e-10	Total body bone mineral density;
CESC	cis	rs2576037	0.583	rs1465722	chr18:44564499	C/G	cg19077165	chr18:44547161	KATNAL2	0.65	9.96	0.52	4.76e-20	Personality dimensions;
CESC	cis	rs11098499	0.909	rs1546504	chr4:120241179	C/T	cg24375607	chr4:120327624	NA	0.45	5.5	0.32	8.75e-8	Corneal astigmatism;
CESC	cis	rs1949733	0.701	rs940134	chr4:8454870	C/T	cg11789530	chr4:8429930	ACOX3	0.76	11.12	0.56	8.15e-24	Response to antineoplastic agents;
CESC	cis	rs4835473	0.868	rs35809032	chr4:144745950	G/A	cg25736465	chr4:144833511	NA	-0.46	-6.98	-0.39	2.36e-11	Immature fraction of reticulocytes;
CESC	cis	rs2730245	1.000	rs2527199	chr7:158737113	G/A	cg24397884	chr7:158709396	WDR60	-0.88	-13.48	-0.64	6.6e-32	Height;
CESC	cis	rs4819052	0.819	rs8134084	chr21:46693295	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.45	5.67	0.33	3.77e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs6952808	0.825	rs34922657	chr7:1938655	C/T	cg08061076	chr7:1943177	MAD1L1	-0.38	-5.06	-0.3	7.92e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs2645694	0.626	rs2703126	chr4:77819842	T/C	cg18351406	chr4:77819688	ANKRD56	0.55	6.85	0.39	5.11e-11	Emphysema distribution in smoking;
CESC	cis	rs9733	0.596	rs11204704	chr1:150671630	T/C	cg17724175	chr1:150552817	MCL1	0.44	7.21	0.4	6.02e-12	Tonsillectomy;
CESC	cis	rs4713118	0.662	rs9380045	chr6:28025279	A/G	cg22143856	chr6:28129313	ZNF389	0.42	5.26	0.31	2.91e-7	Parkinson's disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg27432331	chr16:30544242	ZNF747	0.49	6.73	0.38	1.02e-10	Fibrinogen levels;
CESC	trans	rs7246657	0.943	rs3803895	chr19:37898669	A/G	cg24637308	chr11:6592297	DNHD1	0.54	6.32	0.36	1.11e-9	Coronary artery calcification;
CESC	cis	rs7618915	0.679	rs6802320	chr3:52241835	T/C	cg07507251	chr3:52567010	NT5DC2	0.34	5.43	0.32	1.25e-7	Bipolar disorder;
CESC	cis	rs7666738	0.753	rs2903143	chr4:99040480	C/T	cg03467027	chr4:99064603	C4orf37	0.47	5.96	0.34	8.08e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9549367	0.789	rs9549718	chr13:113909822	A/G	cg00898013	chr13:113819073	PROZ	-0.54	-7.44	-0.42	1.39e-12	Platelet distribution width;
CESC	cis	rs10089	1.000	rs4836367	chr5:127482592	A/G	cg19767477	chr5:127420684	SLC12A2	-0.39	-5.18	-0.3	4.42e-7	Ileal carcinoids;
CESC	cis	rs7085104	0.591	rs4919683	chr10:104585125	G/T	cg04362960	chr10:104952993	NT5C2	0.47	6.44	0.37	5.49e-10	Immature fraction of reticulocytes;Schizophrenia;
CESC	cis	rs853679	0.550	rs1225598	chr6:28160799	T/G	cg20151795	chr6:28129481	ZNF389	0.39	5.18	0.3	4.42e-7	Depression;
CESC	cis	rs6460942	0.591	rs10262667	chr7:12385391	C/T	cg06484146	chr7:12443880	VWDE	-0.54	-7.57	-0.42	6.23e-13	Coronary artery disease;
CESC	cis	rs920590	0.758	rs1817836	chr8:19664852	T/C	cg01411142	chr8:19674711	INTS10	0.52	5.92	0.34	1.01e-8	Acute lymphoblastic leukemia (childhood);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg27131607	chr17:61851115	DDX42;CCDC47	-0.46	-6.27	-0.36	1.44e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs2228479	0.557	rs12933317	chr16:89828220	A/G	cg06558623	chr16:89946397	TCF25	1.13	8.87	0.48	1.08e-16	Skin colour saturation;
CESC	cis	rs72781680	1.000	rs17711825	chr2:24124578	A/G	cg08917208	chr2:24149416	ATAD2B	0.91	8.18	0.45	1.18e-14	Lymphocyte counts;
CESC	cis	rs4665809	1.000	rs1371553	chr2:26262948	G/A	cg04944784	chr2:26401820	FAM59B	-0.68	-7.66	-0.43	3.59e-13	Gut microbiome composition (summer);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg01565083	chr17:80042523	FASN	0.48	6.69	0.38	1.3e-10	Fibrinogen levels;
CESC	cis	rs10479542	0.784	rs7702303	chr5:178986436	G/A	cg05457628	chr5:178986728	RUFY1	0.57	8.63	0.47	5.81e-16	Lung cancer;
CESC	cis	rs6460942	0.841	rs6968277	chr7:12443795	C/A	cg13733410	chr7:12443478	VWDE	-0.5	-6.01	-0.35	6.23e-9	Coronary artery disease;
CESC	cis	rs2074585	0.806	rs2657949	chr15:90950790	G/A	cg10434728	chr15:90938212	IQGAP1	0.42	7.71	0.43	2.57e-13	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
CESC	cis	rs11645898	0.872	rs4788459	chr16:72153125	C/G	cg14768367	chr16:72042858	DHODH	-0.69	-5.92	-0.34	1.02e-8	Blood protein levels;
CESC	cis	rs870825	0.860	rs72689277	chr4:185593699	G/A	cg04058563	chr4:185651563	MLF1IP	0.57	5.29	0.31	2.54e-7	Blood protein levels;
CESC	cis	rs6879260	1.000	rs888922	chr5:179731635	C/G	cg13944838	chr5:179740914	GFPT2	-0.73	-9.73	-0.51	2.49e-19	Height;
CESC	cis	rs10883723	0.962	rs10883726	chr10:104236276	C/T	cg22532475	chr10:104410764	TRIM8	-0.34	-5.67	-0.33	3.77e-8	Allergic disease (asthma, hay fever or eczema);
CESC	trans	rs4471313	0.955	rs6427242	chr1:170288157	C/G	cg14876685	chr7:99177937	NA	0.41	6.27	0.36	1.5e-9	Waist-hip ratio;
CESC	cis	rs4919087	0.851	rs2297987	chr10:98989454	C/T	cg25902810	chr10:99078978	FRAT1	-0.58	-8.11	-0.45	1.93e-14	Monocyte count;
CESC	cis	rs8177253	0.511	rs9830001	chr3:133433470	A/G	cg24879335	chr3:133465180	TF	-0.3	-5.23	-0.31	3.37e-7	Iron status biomarkers;
CESC	cis	rs8072100	0.935	rs8070759	chr17:45638760	C/T	cg08085267	chr17:45401833	C17orf57	0.41	5.3	0.31	2.46e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs1018836	0.631	rs9987164	chr8:91470910	T/G	cg16814680	chr8:91681699	NA	-0.52	-6.92	-0.39	3.38e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs738322	0.934	rs84473	chr22:38557326	T/C	cg25457927	chr22:38595422	NA	-0.3	-5.56	-0.32	6.47e-8	Cutaneous nevi;
CESC	cis	rs9488822	0.676	rs1338667	chr6:116323910	T/A	cg15226275	chr6:116381976	FRK	0.25	6.22	0.36	1.94e-9	Cholesterol, total;LDL cholesterol;
CESC	cis	rs16917546	0.933	rs10995238	chr10:64387108	A/G	cg03961010	chr10:64397487	ZNF365	0.38	6.1	0.35	3.66e-9	Basal cell carcinoma;
CESC	cis	rs7103648	0.864	rs10769264	chr11:47423340	C/T	cg03711944	chr11:47377212	SPI1	-0.31	-5.04	-0.3	8.72e-7	Diastolic blood pressure;Systolic blood pressure;
CESC	cis	rs2072732	0.861	rs10489589	chr1:2951244	T/C	cg03976712	chr1:2946727	NA	0.33	5.45	0.32	1.17e-7	Plateletcrit;
CESC	cis	rs1862618	0.853	rs252922	chr5:56136343	G/T	cg18230493	chr5:56204884	C5orf35	-0.74	-9.11	-0.49	2.05e-17	Initial pursuit acceleration;
CESC	cis	rs9486715	1.000	rs3798297	chr6:97062835	C/T	cg06623918	chr6:96969491	KIAA0776	-0.89	-13.28	-0.63	3.27e-31	Headache;
CESC	cis	rs1799949	1.000	rs3092988	chr17:41201702	C/T	cg25072359	chr17:41440525	NA	0.47	6.25	0.36	1.66e-9	Menopause (age at onset);
CESC	cis	rs9787249	0.957	rs2274949	chr1:40221067	G/A	cg19912559	chr1:40204330	PPIE	0.39	5.85	0.34	1.42e-8	Blood protein levels;
CESC	cis	rs4819052	0.851	rs1999333	chr21:46670401	C/G	cg11663144	chr21:46675770	NA	-0.63	-10.0	-0.52	3.38e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs698833	0.926	rs786620	chr2:44595803	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.46	5.95	0.34	8.29e-9	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs763014	0.898	rs8060585	chr16:635794	C/G	cg00802000	chr16:706648	WDR90	-0.41	-6.19	-0.36	2.26e-9	Height;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg09724427	chr17:47866462	MYST2	0.47	6.09	0.35	4.05e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs9611565	0.694	rs5751107	chr22:41857812	A/G	cg06481639	chr22:41940642	POLR3H	0.64	6.5	0.37	3.86e-10	Vitiligo;
CESC	cis	rs7772486	0.774	rs6930181	chr6:146180974	A/T	cg05347473	chr6:146136440	FBXO30	-0.44	-6.1	-0.35	3.81e-9	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6088580	0.634	rs6058041	chr20:33018008	A/G	cg06115741	chr20:33292138	TP53INP2	0.47	6.03	0.35	5.34e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs9916302	0.851	rs12936646	chr17:37647450	A/T	cg15445000	chr17:37608096	MED1	0.39	6.46	0.37	4.99e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs1552244	0.688	rs7645137	chr3:10020549	A/AT	cg00149659	chr3:10157352	C3orf10	0.71	8.3	0.45	5.44e-15	Alzheimer's disease;
CESC	cis	rs4713118	0.621	rs9295755	chr6:28033174	C/T	cg23161317	chr6:28129485	ZNF389	-0.52	-6.6	-0.38	2.28e-10	Parkinson's disease;
CESC	cis	rs2635047	0.682	rs9960932	chr18:44792445	C/T	cg24371990	chr18:44770781	NA	0.39	6.26	0.36	1.5e-9	Educational attainment;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg20861091	chr8:144881744	SCRIB	-0.43	-6.22	-0.36	1.95e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs11690935	1.000	rs1554166	chr2:172541609	G/T	cg13550731	chr2:172543902	DYNC1I2	-0.96	-15.12	-0.68	1.19e-37	Schizophrenia;
CESC	cis	rs9388451	0.559	rs1777210	chr6:126098916	T/G	cg05901451	chr6:126070800	HEY2	-0.57	-8.3	-0.45	5.53e-15	Brugada syndrome;
CESC	cis	rs9611565	1.000	rs1109151	chr22:41752944	A/G	cg06481639	chr22:41940642	POLR3H	-0.46	-5.28	-0.31	2.7e-7	Vitiligo;
CESC	cis	rs2228479	0.850	rs1800331	chr16:89858417	C/A	cg06558623	chr16:89946397	TCF25	1.18	9.47	0.5	1.65e-18	Skin colour saturation;
CESC	cis	rs9303280	0.806	rs10852935	chr17:38031674	C/T	cg20243544	chr17:37824526	PNMT	0.53	6.93	0.39	3.14e-11	Self-reported allergy;
CESC	cis	rs4713118	0.587	rs9393899	chr6:28133528	G/C	cg17949981	chr6:28129498	ZNF389	0.45	5.57	0.32	6.26e-8	Parkinson's disease;
CESC	cis	rs875971	0.895	rs6460278	chr7:65662736	T/C	cg18876405	chr7:65276391	NA	-0.55	-7.48	-0.42	1.12e-12	Aortic root size;
CESC	cis	rs763014	0.932	rs35067229	chr16:649638	T/C	cg07256732	chr16:621771	PIGQ	-0.3	-5.33	-0.31	2.09e-7	Height;
CESC	cis	rs11098499	0.909	rs10020034	chr4:120294331	A/G	cg09307838	chr4:120376055	NA	0.94	12.84	0.62	1.16e-29	Corneal astigmatism;
CESC	cis	rs6933660	0.720	rs6936936	chr6:151753395	A/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.5	-6.67	-0.38	1.5e-10	Menarche (age at onset);
CESC	cis	rs875971	0.505	rs1167386	chr7:65513096	G/A	cg25985355	chr7:65971099	NA	0.32	5.26	0.31	3e-7	Aortic root size;
CESC	cis	rs4523957	0.928	rs1122645	chr17:2170858	A/G	cg16513277	chr17:2031491	SMG6	-0.59	-8.01	-0.44	3.63e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs8067545	0.611	rs11868116	chr17:20029593	T/C	cg13482628	chr17:19912719	NA	0.4	5.4	0.31	1.47e-7	Schizophrenia;
CESC	cis	rs6484504	0.576	rs58702363	chr11:31246397	C/A	cg14844989	chr11:31128820	NA	-0.38	-5.46	-0.32	1.11e-7	Red blood cell count;
CESC	cis	rs2859741	1.000	rs543121	chr1:37497098	T/C	cg09363841	chr1:37513479	NA	-0.67	-10.66	-0.55	2.62e-22	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
CESC	cis	rs7582720	1.000	rs76890136	chr2:203850011	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.36	0.41	2.34e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs8177253	0.828	rs8177259	chr3:133480388	T/C	cg01448562	chr3:133502909	NA	-0.42	-5.9	-0.34	1.09e-8	Iron status biomarkers;
CESC	cis	rs3820068	0.532	rs72647105	chr1:15935238	C/G	cg16988262	chr1:15930761	NA	0.34	5.52	0.32	7.98e-8	Systolic blood pressure;
CESC	cis	rs1941023	0.584	rs6591578	chr11:60158649	G/A	cg08716584	chr11:60157161	MS4A7	-0.53	-8.05	-0.44	2.73e-14	Congenital heart disease (maternal effect);
CESC	cis	rs1957429	0.520	rs230723	chr14:65316017	C/T	cg23373153	chr14:65346875	NA	-0.71	-5.43	-0.32	1.25e-7	Pediatric areal bone mineral density (radius);
CESC	cis	rs6835098	0.608	rs2332668	chr4:174163360	A/G	cg08422745	chr4:174089978	GALNT7	-0.72	-10.33	-0.54	3.09e-21	Dementia and core Alzheimer's disease neuropathologic changes;
CESC	cis	rs2228479	0.702	rs62056087	chr16:89920383	C/A	cg00800038	chr16:89945340	TCF25	-0.91	-6.93	-0.39	3.21e-11	Skin colour saturation;
CESC	cis	rs1348850	0.914	rs6761593	chr2:178451600	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.56	-7.53	-0.42	7.83e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs6088580	0.602	rs6058064	chr20:33086622	A/G	cg06115741	chr20:33292138	TP53INP2	0.44	5.69	0.33	3.34e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg27094323	chr7:1216898	NA	-0.43	-5.92	-0.34	1.02e-8	Longevity;Endometriosis;
CESC	trans	rs2121875	0.667	rs1823252	chr5:44233661	A/G	cg09056876	chr6:156718398	NA	-0.48	-6.0	-0.35	6.34e-9	Prostate cancer;
CESC	cis	rs9322193	0.961	rs9027	chr6:149916057	T/A	cg07701084	chr6:150067640	NUP43	0.4	5.47	0.32	1.02e-7	Lung cancer;
CESC	cis	rs1832871	0.711	rs9459887	chr6:158696479	C/T	cg07165851	chr6:158734300	TULP4	0.58	6.25	0.36	1.63e-9	Height;
CESC	cis	rs2243480	1.000	rs313809	chr7:65499983	G/A	cg18252515	chr7:66147081	NA	-1.26	-12.38	-0.61	4.54e-28	Diabetic kidney disease;
CESC	cis	rs67311347	1.000	rs12494022	chr3:40426652	A/C	cg24209194	chr3:40518798	ZNF619	0.5	6.12	0.35	3.3e-9	Renal cell carcinoma;
CESC	cis	rs875971	0.862	rs4236208	chr7:65749078	C/T	cg18876405	chr7:65276391	NA	-0.49	-6.65	-0.38	1.64e-10	Aortic root size;
CESC	trans	rs1814175	0.692	rs1851873	chr11:49937767	A/G	cg03929089	chr4:120376271	NA	-0.72	-9.28	-0.5	6.08e-18	Height;
CESC	cis	rs11577318	0.853	rs11247913	chr1:26648551	G/C	cg00852783	chr1:26633632	UBXN11	0.49	6.75	0.38	9.16e-11	Granulocyte percentage of myeloid white cells;
CESC	cis	rs4319547	0.698	rs10744217	chr12:122942070	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.53	-6.52	-0.37	3.46e-10	Body mass index;
CESC	cis	rs2607426	0.681	rs2607418	chr19:41257396	A/G	cg09128733	chr19:41633906	CYP2F1	-0.81	-5.21	-0.3	3.83e-7	Blood protein levels;
CESC	cis	rs10504229	0.679	rs4738574	chr8:58033771	T/C	cg24829409	chr8:58192753	C8orf71	-0.46	-5.93	-0.34	9.43e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs2629540	0.824	rs10901809	chr10:126410804	C/T	cg08799069	chr10:126477246	METTL10	0.49	6.66	0.38	1.59e-10	Cocaine dependence;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03565437	chr5:14488482	TRIO	-0.73	-8.42	-0.46	2.41e-15	Gut microbiome composition (summer);
CESC	cis	rs7772486	0.875	rs6570736	chr6:146388320	C/T	cg05347473	chr6:146136440	FBXO30	0.51	6.73	0.38	1.08e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6860806	0.631	rs7736284	chr5:131588151	T/C	cg18758796	chr5:131593413	PDLIM4	0.46	6.59	0.38	2.35e-10	Breast cancer;
CESC	cis	rs10851478	0.872	rs11858411	chr15:49791951	A/G	cg08060515	chr15:49448048	GALK2;COPS2	0.42	5.19	0.3	4.12e-7	Oral cavity cancer;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg16355531	chr10:126370306	FAM53B	-0.48	-6.11	-0.35	3.56e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs5753618	0.504	rs9606847	chr22:31901789	G/C	cg00478049	chr22:31556069	RNF185	-0.46	-5.53	-0.32	7.55e-8	Colorectal cancer;
CESC	cis	rs7818345	0.967	rs4921638	chr8:19274793	C/A	cg11303988	chr8:19266685	CSGALNACT1	0.34	6.25	0.36	1.64e-9	Language performance in older adults (adjusted for episodic memory);
CESC	cis	rs56235845	0.694	rs4532376	chr5:176774403	G/A	cg17509989	chr5:176798049	RGS14	0.48	5.78	0.33	2.12e-8	Hemoglobin concentration;Hematocrit;
CESC	cis	rs4664293	0.967	rs7597488	chr2:160547096	T/G	cg08347373	chr2:160653686	CD302	-0.31	-5.09	-0.3	6.83e-7	Monocyte percentage of white cells;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03115081	chr17:74722049	C17orf95;JMJD6	0.49	6.65	0.38	1.65e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs2439831	0.850	rs12101756	chr15:44053887	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.71	6.78	0.38	7.96e-11	Lung cancer in ever smokers;
CESC	cis	rs896854	0.517	rs1011796	chr8:95951273	A/G	cg13393036	chr8:95962371	TP53INP1	0.46	8.21	0.45	9.85e-15	Type 2 diabetes;
CESC	cis	rs8133932	0.654	rs375971	chr21:47338854	C/G	cg14185626	chr21:47401492	COL6A1	-0.46	-5.12	-0.3	6.01e-7	Schizophrenia;
CESC	cis	rs921968	0.565	rs6704575	chr2:219589594	C/T	cg02176678	chr2:219576539	TTLL4	0.44	7.65	0.43	3.76e-13	Mean corpuscular hemoglobin concentration;
CESC	cis	rs9287719	0.967	rs728282	chr2:10750303	A/G	cg00105475	chr2:10696890	NA	0.38	5.57	0.32	6.34e-8	Prostate cancer;
CESC	cis	rs67478160	0.619	rs12878682	chr14:104233627	G/C	cg01849466	chr14:104193079	ZFYVE21	-0.5	-6.89	-0.39	4.13e-11	Schizophrenia;
CESC	cis	rs1707322	1.000	rs4660905	chr1:46461587	C/T	cg06784218	chr1:46089804	CCDC17	-0.33	-5.63	-0.33	4.7e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13453711	chr1:212482804	PPP2R5A	-0.73	-8.6	-0.47	6.97e-16	Gut microbiome composition (summer);
CESC	cis	rs4970988	0.556	rs6681426	chr1:150586971	G/A	cg18016565	chr1:150552671	MCL1	-0.35	-5.22	-0.31	3.62e-7	Urate levels;
CESC	cis	rs7666738	0.800	rs7683737	chr4:99070880	A/T	cg24818145	chr4:99064322	C4orf37	0.4	5.08	0.3	7.27e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs8062405	1.000	rs61737565	chr16:28855522	G/C	cg08761264	chr16:28874980	SH2B1	-0.47	-5.85	-0.34	1.42e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs7945705	0.783	rs11042125	chr11:8938049	A/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.52	-8.56	-0.47	9.57e-16	Hemoglobin concentration;
CESC	cis	rs2760061	0.655	rs686533	chr1:228119604	A/G	cg01973587	chr1:228161476	NA	0.37	5.71	0.33	3.03e-8	Diastolic blood pressure;
CESC	cis	rs7223966	1.000	rs8073373	chr17:61703320	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	7.42	0.41	1.61e-12	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs270601	0.661	rs10036208	chr5:131571323	T/C	cg18301423	chr5:131593218	PDLIM4	0.38	5.23	0.31	3.38e-7	Acylcarnitine levels;
CESC	cis	rs2645694	0.626	rs2703143	chr4:77830441	A/G	cg18351406	chr4:77819688	ANKRD56	0.53	6.34	0.36	9.71e-10	Emphysema distribution in smoking;
CESC	cis	rs10504229	0.774	rs72650880	chr8:58164727	C/T	cg14926445	chr8:58193284	C8orf71	-0.51	-5.1	-0.3	6.6e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs1728785	1.000	rs1645938	chr16:68595197	G/A	cg02972257	chr16:68554789	NA	-0.59	-6.7	-0.38	1.23e-10	Ulcerative colitis;
CESC	cis	rs10781543	0.845	rs10781542	chr9:139327439	A/G	cg14169450	chr9:139327907	INPP5E	0.53	8.12	0.45	1.79e-14	Monocyte percentage of white cells;
CESC	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.81	-14.46	-0.66	2.47e-35	Longevity;Endometriosis;
CESC	cis	rs4233802	1.000	rs4362583	chr2:151149715	A/G	cg25300694	chr2:151184358	NA	0.94	6.47	0.37	4.75e-10	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
CESC	cis	rs6598955	0.640	rs1577507	chr1:26547179	C/T	cg00852783	chr1:26633632	UBXN11	0.43	6.34	0.36	9.72e-10	Obesity-related traits;
CESC	cis	rs10979	0.571	rs6909701	chr6:143922918	C/G	cg25407410	chr6:143891975	LOC285740	-0.47	-5.86	-0.34	1.4e-8	Hypospadias;
CESC	cis	rs3806843	0.735	rs809635	chr5:140081791	A/G	cg16179182	chr5:140090404	VTRNA1-1	0.4	5.14	0.3	5.34e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs9611519	0.603	rs4821999	chr22:41470001	A/G	cg03806693	chr22:41940476	POLR3H	-0.43	-5.22	-0.31	3.67e-7	Neuroticism;
CESC	cis	rs9649213	0.574	rs7802541	chr7:97933855	C/A	cg21770322	chr7:97807741	LMTK2	0.61	9.17	0.49	1.4e-17	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs11168351	0.864	rs12228750	chr12:48496997	G/A	cg04545296	chr12:48745243	ZNF641	-0.33	-5.65	-0.33	4.11e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs6938	0.618	rs11638130	chr15:75183935	G/A	cg17294928	chr15:75287854	SCAMP5	0.49	6.53	0.37	3.31e-10	Breast cancer;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg20163463	chr17:1171417	NA	0.47	6.06	0.35	4.64e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs1799949	1.000	rs4793190	chr17:41200109	T/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.41	5.6	0.33	5.36e-8	Menopause (age at onset);
CESC	cis	rs9457247	0.765	rs9295385	chr6:167448181	A/G	cg07741184	chr6:167504864	NA	0.37	5.81	0.34	1.76e-8	Crohn's disease;
CESC	cis	rs875971	0.965	rs10267430	chr7:65743023	G/T	cg18876405	chr7:65276391	NA	-0.51	-6.96	-0.39	2.71e-11	Aortic root size;
CESC	cis	rs6570726	0.846	rs6570700	chr6:145931552	A/G	cg23711669	chr6:146136114	FBXO30	0.87	12.93	0.62	5.52e-30	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4253772	0.515	rs8142080	chr22:46647429	G/T	cg18190219	chr22:46762943	CELSR1	-0.52	-5.08	-0.3	7.06e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs7089973	0.584	rs4752322	chr10:116613258	A/C	cg03647239	chr10:116582469	FAM160B1	0.47	6.04	0.35	5.08e-9	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs9300255	0.506	rs11057251	chr12:123791227	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	0.34	5.44	0.32	1.2e-7	Neutrophil percentage of white cells;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg05612325	chr17:14110411	COX10	0.47	6.08	0.35	4.2e-9	Fibrinogen levels;
CESC	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.52	-6.93	-0.39	3.29e-11	Longevity;Endometriosis;
CESC	cis	rs7833790	0.929	rs10958048	chr8:82792914	C/T	cg17211192	chr8:82754475	SNX16	0.71	8.69	0.47	3.72e-16	Diastolic blood pressure;
CESC	cis	rs7208859	0.673	rs216418	chr17:28936537	G/A	cg14008862	chr17:28927542	LRRC37B2	0.69	6.31	0.36	1.18e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs1003719	0.679	rs2835674	chr21:38581522	T/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.6	-8.07	-0.44	2.45e-14	Eye color traits;
CESC	trans	rs1945213	0.659	rs11227133	chr11:55836620	T/C	cg15704280	chr7:45808275	SEPT13	0.76	7.31	0.41	3.15e-12	Acute lymphoblastic leukemia (childhood);
CESC	trans	rs17685	0.725	rs6947068	chr7:75662056	T/C	cg19862616	chr7:65841803	NCRNA00174	-0.86	-12.7	-0.62	3.41e-29	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs72772090	0.539	rs13601	chr5:96110596	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.6	-5.03	-0.3	8.86e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs8020095	0.528	rs1950281	chr14:67401299	T/G	cg19548862	chr14:67692701	FAM71D	-0.48	-5.76	-0.33	2.34e-8	Depression (quantitative trait);
CESC	cis	rs9790314	0.846	rs4560315	chr3:160982132	G/T	cg03342759	chr3:160939853	NMD3	-0.51	-7.39	-0.41	1.96e-12	Morning vs. evening chronotype;
CESC	cis	rs6087990	0.965	rs2424903	chr20:31349315	C/T	cg13636640	chr20:31349939	DNMT3B	0.91	16.02	0.7	7.23e-41	Ulcerative colitis;
CESC	cis	rs4722166	0.630	rs4722169	chr7:22785419	C/T	cg05265849	chr7:22767390	IL6	0.57	7.08	0.4	1.31e-11	Lung cancer;
CESC	trans	rs9858542	0.953	rs6766131	chr3:49538932	T/C	cg21659725	chr3:3221576	CRBN	-0.54	-6.37	-0.36	8.2e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs501120	1.000	rs687175	chr10:44751910	C/T	cg09554077	chr10:44749378	NA	-0.54	-7.18	-0.4	7.09e-12	Coronary artery disease;Coronary heart disease;
CESC	cis	rs8016982	0.633	rs55822231	chr14:81708677	C/T	cg01989461	chr14:81687754	GTF2A1	0.74	11.73	0.58	7.18e-26	Schizophrenia;
CESC	cis	rs6460942	1.000	rs75333414	chr7:12303829	T/A	cg20607287	chr7:12443886	VWDE	-0.66	-7.5	-0.42	9.8e-13	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12121965	chr21:46293563	PTTG1IP	0.57	6.7	0.38	1.27e-10	Gut microbiome composition (summer);
CESC	trans	rs2623325	0.874	rs7631745	chr3:99115940	G/A	cg19595760	chr1:25948511	MAN1C1	-0.48	-6.34	-0.36	9.63e-10	Optic cup area;Vertical cup-disc ratio;
CESC	cis	rs1348850	0.750	rs13031008	chr2:178477114	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.54	6.88	0.39	4.23e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs13191362	0.938	rs13208970	chr6:163006368	G/T	cg21926612	chr6:163149169	PACRG;PARK2	0.82	8.75	0.47	2.56e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg04536951	chr19:9268775	ZNF317	0.53	7.07	0.4	1.36e-11	Fibrinogen levels;
CESC	cis	rs2637266	1.000	rs7477433	chr10:78358116	C/T	cg18941641	chr10:78392320	NA	0.42	7.79	0.43	1.49e-13	Pulmonary function;
CESC	cis	rs10849689	1	rs10849689	chr12:110493222	A/G	cg12870014	chr12:110450643	ANKRD13A	0.83	9.41	0.5	2.42e-18	Schizophrenia;
CESC	cis	rs7523050	0.643	rs12729998	chr1:109405505	T/C	cg08274380	chr1:109419600	GPSM2	0.91	6.2	0.36	2.16e-9	Fat distribution (HIV);
CESC	cis	rs2439831	0.850	rs7183809	chr15:44120868	T/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.66	6.03	0.35	5.4e-9	Lung cancer in ever smokers;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg01685689	chr11:126081170	FAM118B;RPUSD4	0.48	6.27	0.36	1.49e-9	Systemic lupus erythematosus;
CESC	cis	rs12946454	0.521	rs66827053	chr17:43250653	A/G	cg10701640	chr17:43249399	NA	0.46	8.05	0.44	2.77e-14	Systolic blood pressure;
CESC	cis	rs12497850	0.829	rs8926	chr3:49052785	T/A	cg03060546	chr3:49711283	APEH	0.51	6.28	0.36	1.37e-9	Parkinson's disease;
CESC	cis	rs11098499	0.863	rs13140409	chr4:120503460	A/G	cg24375607	chr4:120327624	NA	0.46	5.47	0.32	1.05e-7	Corneal astigmatism;
CESC	cis	rs6912958	0.559	rs107689	chr6:88069333	G/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.74	11.21	0.57	4.04e-24	Monocyte percentage of white cells;
CESC	cis	rs6964587	0.610	rs10953056	chr7:91466700	C/T	cg17063962	chr7:91808500	NA	0.44	5.92	0.34	9.84e-9	Breast cancer;
CESC	cis	rs853679	0.517	rs9380056	chr6:28104476	C/T	cg23161317	chr6:28129485	ZNF389	0.51	6.63	0.38	1.85e-10	Depression;
CESC	cis	rs1552244	1.000	rs17032396	chr3:10153559	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.88	-11.59	-0.58	2.19e-25	Alzheimer's disease;
CESC	cis	rs2073499	1.000	rs57319506	chr3:50285677	T/C	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.71	5.57	0.32	6.37e-8	Schizophrenia;
CESC	cis	rs1799949	0.930	rs1554063	chr17:41287145	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	7.87	0.44	8.81e-14	Menopause (age at onset);
CESC	cis	rs2109514	1.000	rs3919515	chr7:116151784	C/G	cg12739419	chr7:116140593	CAV2	0.36	6.5	0.37	3.97e-10	Prevalent atrial fibrillation;
CESC	cis	rs4820539	1.000	rs5759596	chr22:23475750	G/A	cg14186256	chr22:23484241	RTDR1	0.83	15.08	0.68	1.65e-37	Bone mineral density;
CESC	cis	rs894734	0.567	rs7138907	chr12:54324576	C/T	cg17410650	chr12:54324560	NA	-0.53	-9.85	-0.52	1.06e-19	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24663683	chr5:39721720	NA	-0.67	-7.85	-0.43	1.03e-13	Gut microbiome composition (summer);
CESC	cis	rs7957197	0.882	rs12427353	chr12:121426901	G/C	cg12635120	chr12:121345228	NA	-0.37	-5.32	-0.31	2.18e-7	Type 2 diabetes;
CESC	cis	rs13191362	1.000	rs13190742	chr6:163008758	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.87	9.04	0.49	3.35e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs1707322	0.717	rs11211161	chr1:46148138	A/C	cg05343316	chr1:45956843	TESK2	0.51	6.32	0.36	1.09e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9303280	0.806	rs12941333	chr17:38040534	C/T	cg20243544	chr17:37824526	PNMT	0.5	6.54	0.37	3.21e-10	Self-reported allergy;
CESC	cis	rs2635047	1.000	rs9304341	chr18:44670263	G/A	cg19077165	chr18:44547161	KATNAL2	-0.41	-5.64	-0.33	4.36e-8	Educational attainment;
CESC	cis	rs2836974	0.605	rs2836971	chr21:40652040	A/C	cg11644478	chr21:40555479	PSMG1	-0.82	-12.21	-0.6	1.7e-27	Cognitive function;
CESC	cis	rs6460942	0.908	rs77799203	chr7:12264432	C/G	cg20607287	chr7:12443886	VWDE	-0.58	-6.08	-0.35	4.2e-9	Coronary artery disease;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg00531924	chr6:111279890	GTF3C6	-0.43	-6.01	-0.35	6.18e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs4555082	0.957	rs2816609	chr14:105720803	A/C	cg13114125	chr14:105738426	BRF1	-0.65	-8.32	-0.46	4.71e-15	Mean platelet volume;Platelet distribution width;
CESC	cis	rs11630290	0.592	rs1017531	chr15:64158650	G/A	cg12036633	chr15:63758958	NA	0.45	5.34	0.31	2e-7	Iris characteristics;
CESC	cis	rs7267979	0.816	rs409853	chr20:25506067	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.79	14.8	0.67	1.56e-36	Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04067506	chr5:176943966	DDX41	0.53	6.3	0.36	1.23e-9	Gut microbiome composition (summer);
CESC	trans	rs10463316	0.894	rs10476769	chr5:150763970	A/G	cg24389359	chr12:111284228	CCDC63	-0.33	-6.02	-0.35	5.68e-9	Metabolite levels (Pyroglutamine);
CESC	cis	rs9926296	0.624	rs1110331	chr16:89774396	A/G	cg04287289	chr16:89883240	FANCA	-0.42	-5.7	-0.33	3.11e-8	Vitiligo;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg04949219	chr11:64863633	C11orf2	-0.49	-6.57	-0.37	2.6e-10	Height;
CESC	cis	rs11148252	0.553	rs9536219	chr13:53227301	C/T	cg00495681	chr13:53174319	NA	0.6	8.22	0.45	8.91e-15	Lewy body disease;
CESC	cis	rs780096	0.546	rs6547626	chr2:27646770	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.32	-5.96	-0.34	8.13e-9	Total body bone mineral density;
CESC	cis	rs1401999	1.000	rs9858774	chr3:183652736	G/A	cg01324343	chr3:183735012	ABCC5	0.66	14.05	0.65	7.11e-34	Anterior chamber depth;
CESC	cis	rs3762637	0.941	rs9873842	chr3:122135331	A/T	cg24169773	chr3:122142474	KPNA1	-0.51	-6.03	-0.35	5.56e-9	LDL cholesterol levels;
CESC	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg11494091	chr17:61959527	GH2	0.73	12.74	0.62	2.55e-29	Prudent dietary pattern;
CESC	cis	rs3091242	0.900	rs4649086	chr1:25778967	T/A	cg03538708	chr1:25844672	NA	-0.38	-5.8	-0.34	1.92e-8	Erythrocyte sedimentation rate;
CESC	cis	rs962856	0.964	rs11890812	chr2:67620015	A/G	cg09028215	chr2:67624308	ETAA1	-0.42	-5.68	-0.33	3.57e-8	Pancreatic cancer;
CESC	cis	rs11098499	0.954	rs2389802	chr4:120325732	C/A	cg09307838	chr4:120376055	NA	0.94	13.61	0.64	2.45e-32	Corneal astigmatism;
CESC	cis	rs9303401	0.659	rs34426768	chr17:56683385	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.0	11.58	0.58	2.27e-25	Cognitive test performance;
CESC	cis	rs1534166	0.647	rs1464937	chr3:133536655	C/G	cg27366882	chr3:133540807	NA	-0.27	-5.28	-0.31	2.65e-7	Alcohol consumption (transferrin glycosylation);
CESC	cis	rs7618915	0.533	rs35107891	chr3:52613656	G/C	cg05564831	chr3:52568323	NT5DC2	0.46	6.98	0.39	2.33e-11	Bipolar disorder;
CESC	cis	rs12042938	0.935	rs751229	chr1:231768539	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.44	6.18	0.35	2.45e-9	Neuranatomic and neurocognitive phenotypes;
CESC	cis	rs9325144	0.647	rs17518186	chr12:38883665	T/C	cg26384229	chr12:38710491	ALG10B	-0.56	-7.87	-0.44	9.32e-14	Morning vs. evening chronotype;
CESC	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg22907277	chr7:1156413	C7orf50	0.4	5.72	0.33	2.86e-8	Longevity;Endometriosis;
CESC	cis	rs7589728	0.563	rs4972044	chr2:88466196	T/C	cg04511125	chr2:88470314	THNSL2	0.7	6.79	0.38	7.52e-11	Plasma clusterin levels;
CESC	cis	rs2228479	0.850	rs62054599	chr16:89808850	C/G	cg19635926	chr16:89946313	TCF25	0.66	5.04	0.3	8.52e-7	Skin colour saturation;
CESC	cis	rs7552404	0.691	rs1770890	chr1:76401117	A/G	cg10523679	chr1:76189770	ACADM	-0.58	-6.0	-0.35	6.31e-9	Blood metabolite levels;Acylcarnitine levels;
CESC	trans	rs4942242	1.000	rs9533572	chr13:44234265	A/C	cg19169023	chr15:41853346	TYRO3	-0.48	-6.85	-0.39	5.04e-11	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg14893161	chr1:205819251	PM20D1	0.83	13.22	0.63	5.47e-31	Menarche (age at onset);
CESC	cis	rs1046896	0.731	rs8067667	chr17:80785875	A/G	cg02398342	chr17:80708632	TBCD;FN3K	0.47	5.57	0.32	6.24e-8	Glycated hemoglobin levels;
CESC	cis	rs7635838	0.892	rs9310381	chr3:11458466	A/G	cg00170343	chr3:11313890	ATG7	0.43	5.75	0.33	2.49e-8	HDL cholesterol;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06526137	chr1:16174780	SPEN;FLJ37453	0.61	6.59	0.38	2.35e-10	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01328119	chr1:228783545	DUSP5P	-0.55	-6.53	-0.37	3.33e-10	Gut microbiome composition (summer);
CESC	cis	rs15676	0.947	rs10988124	chr9:131569345	G/A	cg00228799	chr9:131580591	ENDOG	0.42	5.12	0.3	5.98e-7	Blood metabolite levels;
CESC	cis	rs2415984	0.570	rs28674745	chr14:46924415	G/C	cg14871534	chr14:47121158	RPL10L	-0.36	-5.43	-0.32	1.3e-7	Number of children ever born;
CESC	cis	rs9457247	0.902	rs34560498	chr6:167395862	A/G	cg25258033	chr6:167368657	RNASET2	0.41	6.14	0.35	3e-9	Crohn's disease;
CESC	cis	rs2191566	0.664	rs62115477	chr19:44543027	T/G	cg20607764	chr19:44506953	ZNF230	-0.43	-5.5	-0.32	8.85e-8	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs4319547	0.741	rs4758644	chr12:122943915	A/C	cg05707623	chr12:122985044	ZCCHC8	-0.47	-5.96	-0.34	8.08e-9	Body mass index;
CESC	cis	rs9916302	0.808	rs12948906	chr17:37644854	C/T	cg07936489	chr17:37558343	FBXL20	-0.82	-12.22	-0.6	1.6e-27	Glomerular filtration rate (creatinine);
CESC	cis	rs72781680	1.000	rs17712391	chr2:24245659	C/T	cg08917208	chr2:24149416	ATAD2B	1.08	9.35	0.5	3.75e-18	Lymphocyte counts;
CESC	cis	rs2832191	0.655	rs2247110	chr21:30323888	G/A	cg08807101	chr21:30365312	RNF160	-0.91	-13.6	-0.64	2.52e-32	Dental caries;
CESC	cis	rs6910061	1.000	rs5027679	chr6:11118871	A/G	cg27233058	chr6:11094804	LOC221710	-0.44	-5.06	-0.3	7.84e-7	Diabetic kidney disease;
CESC	cis	rs1577917	1.000	rs35797755	chr6:86706554	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-6.43	-0.37	5.9e-10	Response to antipsychotic treatment;
CESC	cis	rs7618915	0.570	rs13068293	chr3:52672167	C/A	cg07507251	chr3:52567010	NT5DC2	0.4	7.03	0.4	1.75e-11	Bipolar disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24578075	chr1:154193269	C1orf43;UBAP2L	0.59	6.54	0.37	3.17e-10	Gut microbiome composition (summer);
CESC	cis	rs12479064	0.724	rs2309618	chr2:99974473	G/A	cg09787394	chr2:99771194	LIPT1;TSGA10	0.48	5.06	0.3	7.78e-7	Chronic sinus infection;
CESC	cis	rs11122272	0.766	rs1435166	chr1:231502310	T/C	cg06096015	chr1:231504339	EGLN1	0.42	6.12	0.35	3.3e-9	Hemoglobin concentration;
CESC	cis	rs1448094	0.527	rs1900700	chr12:86232166	C/T	cg02569458	chr12:86230093	RASSF9	0.52	7.46	0.42	1.24e-12	Major depressive disorder;
CESC	cis	rs138229	0.506	rs9628282	chr22:50534952	G/T	cg16473166	chr22:50639996	SELO	0.45	5.09	0.3	6.68e-7	Behavioural disinhibition (generation interaction);
CESC	trans	rs1545843	0.564	rs11116374	chr12:84811788	C/G	cg03015433	chr16:56623111	MT3	-0.34	-6.21	-0.36	2.09e-9	Major depressive disorder;
CESC	cis	rs1153858	0.725	rs74572151	chr15:45647526	T/G	cg21132104	chr15:45694354	SPATA5L1	0.81	10.68	0.55	2.28e-22	Homoarginine levels;
CESC	cis	rs6912958	0.684	rs4707382	chr6:88320641	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.5	-6.83	-0.39	5.9e-11	Monocyte percentage of white cells;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26933736	chr6:83902998	RWDD2A;PGM3	0.54	6.0	0.35	6.59e-9	Gut microbiome composition (summer);
CESC	cis	rs12681288	0.823	rs2701908	chr8:1003250	T/C	cg15309053	chr8:964076	NA	0.35	5.91	0.34	1.05e-8	Schizophrenia;
CESC	trans	rs561341	0.882	rs16967101	chr17:30377162	A/G	cg27661571	chr11:113659931	NA	-0.67	-6.78	-0.38	7.81e-11	Hip circumference adjusted for BMI;
CESC	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg10150615	chr22:24372951	LOC391322	-0.56	-7.93	-0.44	6.2e-14	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs12618769	0.597	rs17032870	chr2:99132786	C/T	cg10123293	chr2:99228465	UNC50	0.4	5.38	0.31	1.64e-7	Bipolar disorder;
CESC	cis	rs4332037	0.615	rs62435127	chr7:1884937	A/G	cg23422044	chr7:1970798	MAD1L1	-0.54	-5.85	-0.34	1.42e-8	Bipolar disorder;
CESC	cis	rs910316	1.000	rs175492	chr14:75545220	A/C	cg11812906	chr14:75593930	NEK9	0.87	15.01	0.68	2.94e-37	Height;
CESC	cis	rs12477438	0.871	rs62156364	chr2:99695097	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.61	-7.64	-0.42	3.96e-13	Chronic sinus infection;
CESC	cis	rs35110281	0.774	rs2838321	chr21:44995488	A/T	cg04455712	chr21:45112962	RRP1B	0.39	5.87	0.34	1.29e-8	Mean corpuscular volume;
CESC	cis	rs5167	0.504	rs3760629	chr19:45458146	A/C	cg09555818	chr19:45449301	APOC2	0.38	6.03	0.35	5.51e-9	Blood protein levels;
CESC	cis	rs7647973	0.626	rs9824435	chr3:49674343	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.66	-7.3	-0.41	3.29e-12	Menarche (age at onset);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg24320737	chr6:170068102	WDR27	0.45	6.33	0.36	1.03e-9	Fibrinogen levels;
CESC	cis	rs875971	0.545	rs10261710	chr7:65714189	T/A	cg25405998	chr7:65216604	CCT6P1	0.5	5.31	0.31	2.28e-7	Aortic root size;
CESC	cis	rs9309473	0.607	rs6720094	chr2:73588076	A/G	cg20560298	chr2:73613845	ALMS1	-0.46	-6.48	-0.37	4.48e-10	Metabolite levels;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg14655249	chr9:86595816	HNRNPK;RMI1	-0.49	-6.5	-0.37	4.04e-10	Height;
CESC	cis	rs2425143	1.000	rs6060643	chr20:34449851	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.78	-7.03	-0.4	1.78e-11	Blood protein levels;
CESC	cis	rs769267	0.931	rs15622	chr19:19468734	G/A	cg15052019	chr19:19431593	KIAA0892;SF4	-0.42	-5.31	-0.31	2.38e-7	Tonsillectomy;
CESC	trans	rs1814175	0.817	rs6486044	chr11:49982718	C/T	cg03929089	chr4:120376271	NA	-0.93	-15.75	-0.7	6.66e-40	Height;
CESC	cis	rs2839186	0.721	rs13051200	chr21:47701693	A/T	cg10351095	chr21:47802916	PCNT	-0.5	-6.8	-0.39	6.74e-11	Testicular germ cell tumor;
CESC	cis	rs1355223	0.552	rs2421743	chr11:34882840	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.84	13.04	0.63	2.37e-30	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs3812831	0.695	rs6560935	chr13:114945867	G/A	cg08824895	chr13:115047677	UPF3A	0.39	5.13	0.3	5.52e-7	Schizophrenia;
CESC	cis	rs11124063	1	rs11124063	chr2:106458806	T/C	cg16077055	chr2:106428750	NCK2	0.42	6.31	0.36	1.18e-9	Platelet distribution width;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05976228	chr2:74329082	TET3	-0.5	-5.99	-0.35	6.71e-9	Gut microbiome composition (summer);
CESC	cis	rs738322	0.870	rs5750558	chr22:38582497	G/A	cg25457927	chr22:38595422	NA	0.32	6.13	0.35	3.14e-9	Cutaneous nevi;
CESC	cis	rs56104184	0.775	rs56149557	chr19:49401384	C/A	cg15549821	chr19:49342101	PLEKHA4	-0.6	-5.99	-0.35	6.95e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	cis	rs7666738	0.519	rs28539191	chr4:98821552	C/T	cg05340658	chr4:99064831	C4orf37	0.54	6.39	0.37	7.37e-10	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1697139	0.604	rs874550	chr5:66530945	C/T	cg11553311	chr5:66541588	NA	-0.35	-5.07	-0.3	7.45e-7	Breast cancer;
CESC	cis	rs4595586	0.525	rs34204378	chr12:39425759	C/T	cg26384229	chr12:38710491	ALG10B	0.6	8.05	0.44	2.83e-14	Morning vs. evening chronotype;
CESC	cis	rs11098499	0.955	rs13129661	chr4:120152909	C/G	cg24375607	chr4:120327624	NA	0.42	5.05	0.3	8.26e-7	Corneal astigmatism;
CESC	cis	rs9303401	0.614	rs17175663	chr17:57108437	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.99	12.61	0.61	7.2e-29	Cognitive test performance;
CESC	cis	rs7666738	0.800	rs7684523	chr4:98983175	G/T	cg03467027	chr4:99064603	C4orf37	0.44	5.54	0.32	7.12e-8	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09276982	chr10:15130648	ACBD7	0.55	6.27	0.36	1.49e-9	Gut microbiome composition (summer);
CESC	cis	rs1707322	0.691	rs11211174	chr1:46220816	C/G	cg06784218	chr1:46089804	CCDC17	0.43	7.58	0.42	5.65e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs116095464	0.558	rs7713524	chr5:276200	C/T	cg00938859	chr5:1591904	SDHAP3	-0.6	-6.61	-0.38	2.13e-10	Breast cancer;
CESC	cis	rs4924935	1.000	rs6502674	chr17:18776897	A/G	cg26378065	chr17:18585709	ZNF286B	0.43	5.5	0.32	8.97e-8	Pancreatic cancer;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg06985755	chr7:39663123	RALA	-0.51	-6.51	-0.37	3.82e-10	Ulcerative colitis;
CESC	cis	rs1008375	0.932	rs6449315	chr4:17590219	A/G	cg16339924	chr4:17578868	LAP3	0.84	10.6	0.55	4.09e-22	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg04915425	chr11:47236385	DDB2	0.48	6.38	0.36	7.67e-10	Systemic lupus erythematosus;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11455386	chr1:2458039	PANK4	-0.6	-6.82	-0.39	6.18e-11	Gut microbiome composition (summer);
CESC	cis	rs6089829	0.926	rs1060491	chr20:61665817	C/A	cg03213289	chr20:61660250	NA	-0.39	-5.97	-0.34	7.66e-9	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09909877	chr22:38203717	GCAT	-0.52	-6.1	-0.35	3.68e-9	Gut microbiome composition (summer);
CESC	cis	rs3771570	1.000	rs6752050	chr2:242228780	T/C	cg21155796	chr2:242212141	HDLBP	0.62	5.18	0.3	4.34e-7	Prostate cancer;
CESC	cis	rs4665809	0.589	rs4665841	chr2:26448950	G/A	cg22920501	chr2:26401640	FAM59B	-0.97	-12.08	-0.6	4.81e-27	Gut microbiome composition (summer);
CESC	cis	rs7116495	0.881	rs7930142	chr11:71737016	C/T	cg26138937	chr11:71823887	C11orf51	-0.77	-6.19	-0.36	2.3e-9	Severe influenza A (H1N1) infection;
CESC	cis	rs801193	1.000	rs10252765	chr7:66228732	C/G	cg18876405	chr7:65276391	NA	0.49	6.1	0.35	3.74e-9	Aortic root size;
CESC	cis	rs7618915	0.547	rs34610142	chr3:52708429	G/A	cg18404041	chr3:52824283	ITIH1	-0.4	-6.73	-0.38	1.07e-10	Bipolar disorder;
CESC	cis	rs7927771	0.832	rs4992357	chr11:47393638	C/T	cg18512352	chr11:47633146	NA	-0.46	-6.65	-0.38	1.71e-10	Subjective well-being;
CESC	cis	rs17376456	0.877	rs9885329	chr5:93380278	G/A	cg25358565	chr5:93447407	FAM172A	1.14	10.54	0.54	6.24e-22	Diabetic retinopathy;
CESC	cis	rs4713118	0.629	rs203890	chr6:28022248	T/C	cg26335602	chr6:28129616	ZNF389	0.44	5.7	0.33	3.16e-8	Parkinson's disease;
CESC	cis	rs12738007	0.544	rs4654390	chr1:29439016	T/A	cg01925633	chr1:29338769	EPB41	0.35	5.03	0.3	9.09e-7	Schizophrenia;
CESC	cis	rs7914558	0.966	rs10786721	chr10:104654383	C/A	cg15744005	chr10:104629667	AS3MT	-0.34	-5.49	-0.32	9.45e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs36051895	0.664	rs3780377	chr9:5110899	T/C	cg02405213	chr9:5042618	JAK2	-0.54	-6.33	-0.36	1.02e-9	Pediatric autoimmune diseases;
CESC	cis	rs853679	0.517	rs9393894	chr6:28112562	A/G	cg08968635	chr6:28129556	ZNF389	0.4	5.26	0.31	3e-7	Depression;
CESC	cis	rs3820068	0.603	rs932602	chr1:15986087	A/G	cg16988262	chr1:15930761	NA	0.34	5.64	0.33	4.34e-8	Systolic blood pressure;
CESC	trans	rs79976124	0.842	rs74881738	chr6:66621825	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.72	8.11	0.45	1.91e-14	Type 2 diabetes;
CESC	cis	rs7666738	0.535	rs6850010	chr4:98971601	A/T	cg03467027	chr4:99064603	C4orf37	0.47	5.93	0.34	9.46e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6461049	0.765	rs4719431	chr7:2140312	T/C	cg02951883	chr7:2050386	MAD1L1	-0.42	-5.48	-0.32	1.01e-7	Schizophrenia;
CESC	cis	rs7618915	1.000	rs59565798	chr3:52307169	G/A	cg05315796	chr3:52349193	DNAH1	0.39	6.46	0.37	4.99e-10	Bipolar disorder;
CESC	cis	rs875971	1.000	rs12698523	chr7:65968113	C/G	cg12463550	chr7:65579703	CRCP	0.56	7.07	0.4	1.39e-11	Aortic root size;
CESC	cis	rs4268898	0.931	rs2111882	chr2:24434424	A/G	cg06627628	chr2:24431161	ITSN2	0.66	7.58	0.42	5.73e-13	Asthma;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23469188	chr7:108166441	PNPLA8	0.6	6.56	0.37	2.76e-10	Gut microbiome composition (summer);
CESC	cis	rs11122272	0.735	rs910822	chr1:231498721	G/A	cg06096015	chr1:231504339	EGLN1	0.43	6.27	0.36	1.47e-9	Hemoglobin concentration;
CESC	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg09033563	chr22:24373618	LOC391322	0.47	5.69	0.33	3.42e-8	Urinary 1,3-butadiene metabolite levels in smokers;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg08688335	chr8:144635260	GSDMD	0.49	6.34	0.36	1e-9	Gut microbiota (bacterial taxa);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09623457	chr3:183735666	ABCC5	0.6	7.45	0.42	1.32e-12	Gut microbiome composition (summer);
CESC	cis	rs4975709	0.589	rs1684967	chr5:1863055	G/C	cg12288994	chr5:1860383	NA	0.41	6.88	0.39	4.39e-11	Cardiovascular disease risk factors;
CESC	cis	rs6484504	0.532	rs7117286	chr11:31283810	T/A	cg14844989	chr11:31128820	NA	-0.36	-5.14	-0.3	5.47e-7	Red blood cell count;
CESC	trans	rs17536732	0.685	rs74542350	chr4:162858977	G/A	cg12177677	chr2:158300475	CYTIP	-0.63	-6.2	-0.36	2.17e-9	Risky sexual behaviors (alcohol dependence interaction);
CESC	cis	rs938554	0.513	rs10939650	chr4:9998440	C/T	cg00071950	chr4:10020882	SLC2A9	0.66	9.08	0.49	2.51e-17	Blood metabolite levels;
CESC	cis	rs9902453	0.904	rs11080115	chr17:28408070	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.68	-8.81	-0.48	1.74e-16	Coffee consumption (cups per day);
CESC	cis	rs10504229	0.596	rs7004566	chr8:58115602	G/C	cg21724239	chr8:58056113	NA	0.58	5.95	0.34	8.29e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs34779708	0.733	rs16935945	chr10:35540320	A/C	cg04310649	chr10:35416472	CREM	-0.47	-5.39	-0.31	1.59e-7	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs1878931	0.507	rs8054222	chr16:3413477	C/T	cg02880119	chr16:3481970	NA	0.41	5.2	0.3	4.01e-7	Body mass index (adult);
CESC	cis	rs7618915	0.571	rs17264436	chr3:52610651	T/A	cg17372223	chr3:52568218	NT5DC2	0.43	6.31	0.36	1.14e-9	Bipolar disorder;
CESC	cis	rs12477438	0.501	rs11683107	chr2:99759235	T/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.79	12.89	0.62	7.96e-30	Chronic sinus infection;
CESC	cis	rs829883	0.763	rs249843	chr12:98870987	G/A	cg25150519	chr12:98850993	NA	0.86	14.72	0.67	3.04e-36	Colorectal adenoma (advanced);
CESC	cis	rs10876993	0.855	rs1689585	chr12:58080140	A/G	cg18357645	chr12:58087776	OS9	-0.64	-10.58	-0.54	4.84e-22	Celiac disease or Rheumatoid arthritis;
CESC	cis	rs116095464	0.558	rs9688136	chr5:229348	T/C	cg22857025	chr5:266934	NA	-1.28	-18.8	-0.76	1.06e-50	Breast cancer;
CESC	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg27094323	chr7:1216898	NA	-0.36	-5.05	-0.3	8.23e-7	Longevity;Endometriosis;
CESC	cis	rs12478296	1.000	rs59036157	chr2:243040228	C/A	cg06360820	chr2:242988706	NA	-0.86	-8.97	-0.48	5.46e-17	Obesity-related traits;
CESC	cis	rs9905704	0.633	rs2021733	chr17:56489168	C/T	cg12560992	chr17:57184187	TRIM37	-0.62	-5.62	-0.33	4.95e-8	Testicular germ cell tumor;
CESC	cis	rs3136441	1.000	rs57704144	chr11:46770359	C/T	cg25783544	chr11:47291846	MADD	0.56	5.19	0.3	4.21e-7	HDL cholesterol;
CESC	cis	rs6499255	0.951	rs7186002	chr16:69751065	C/G	cg15192750	chr16:69999425	NA	0.5	5.87	0.34	1.32e-8	IgE levels;
CESC	cis	rs7618915	0.571	rs12487445	chr3:52618319	A/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	5.59	0.32	5.72e-8	Bipolar disorder;
CESC	cis	rs11583043	1.000	rs2391573	chr1:101489698	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.51	5.63	0.33	4.65e-8	Ulcerative colitis;Inflammatory bowel disease;
CESC	cis	rs7666738	0.830	rs7664051	chr4:98766970	C/G	cg05340658	chr4:99064831	C4orf37	0.76	11.12	0.56	7.66e-24	Colonoscopy-negative controls vs population controls;
CESC	cis	rs921968	0.509	rs72963905	chr2:219547027	T/G	cg02176678	chr2:219576539	TTLL4	-0.57	-9.75	-0.51	2.11e-19	Mean corpuscular hemoglobin concentration;
CESC	cis	rs2576037	0.901	rs2576036	chr18:44587102	G/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.45	-5.7	-0.33	3.23e-8	Personality dimensions;
CESC	cis	rs8067545	1.000	rs4925067	chr17:19921222	C/G	cg13482628	chr17:19912719	NA	0.46	6.2	0.36	2.19e-9	Schizophrenia;
CESC	cis	rs875971	0.662	rs448725	chr7:65514628	A/G	cg11764359	chr7:65958608	NA	0.88	13.01	0.62	3.05e-30	Aortic root size;
CESC	cis	rs10751667	0.714	rs7395879	chr11:963855	G/C	cg01483505	chr11:975446	AP2A2	0.36	5.05	0.3	8.13e-7	Alzheimer's disease (late onset);
CESC	cis	rs11098499	0.863	rs11933966	chr4:120476715	G/A	cg24375607	chr4:120327624	NA	0.45	5.54	0.32	7.33e-8	Corneal astigmatism;
CESC	cis	rs863345	0.604	rs12063320	chr1:158499423	A/T	cg12129480	chr1:158549410	OR10X1	-0.34	-6.84	-0.39	5.41e-11	Pneumococcal bacteremia;
CESC	cis	rs748404	0.631	rs28702649	chr15:43648629	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.53	7.86	0.43	9.51e-14	Lung cancer;
CESC	cis	rs9649465	1.000	rs11770041	chr7:123365788	C/T	cg04330084	chr7:123175371	IQUB	-0.39	-5.23	-0.31	3.47e-7	Migraine;
CESC	cis	rs4409675	0.576	rs6679432	chr1:28227665	T/C	cg23691781	chr1:28212827	C1orf38	0.29	5.75	0.33	2.49e-8	Corneal astigmatism;
CESC	cis	rs9911578	0.805	rs12601867	chr17:56455260	C/G	cg25039879	chr17:56429692	SUPT4H1	-0.42	-5.74	-0.33	2.52e-8	Intelligence (multi-trait analysis);
CESC	cis	rs6690583	1.000	rs6690583	chr1:85466337	A/G	cg11262906	chr1:85462892	MCOLN2	-0.57	-6.65	-0.38	1.71e-10	Serum sulfate level;
CESC	cis	rs853679	0.517	rs9380055	chr6:28081629	A/G	cg12963246	chr6:28129442	ZNF389	0.56	7.63	0.42	4.26e-13	Depression;
CESC	cis	rs71636778	0.543	rs10493037	chr1:27248645	A/G	cg12203394	chr1:27248618	NUDC	0.66	5.55	0.32	6.85e-8	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
CESC	cis	rs12042052	1.000	rs6696779	chr1:232920825	G/A	cg06935979	chr1:232941706	KIAA1383	0.62	5.48	0.32	9.65e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CESC	cis	rs9611565	0.559	rs7290990	chr22:41964357	C/A	cg06481639	chr22:41940642	POLR3H	-0.57	-6.38	-0.36	7.88e-10	Vitiligo;
CESC	cis	rs4664308	0.935	rs4520994	chr2:160937750	G/A	cg03641300	chr2:160917029	PLA2R1	-0.67	-9.84	-0.52	1.11e-19	Idiopathic membranous nephropathy;
CESC	cis	rs11098499	0.731	rs9995026	chr4:120490499	T/A	cg24375607	chr4:120327624	NA	0.46	5.59	0.32	5.73e-8	Corneal astigmatism;
CESC	cis	rs6541297	0.702	rs4846904	chr1:230279410	G/A	cg20703242	chr1:230279135	GALNT2	0.68	10.78	0.55	1.05e-22	Coronary artery disease;
CESC	cis	rs7551222	0.752	rs10793765	chr1:204549375	A/G	cg20240347	chr1:204465584	NA	-0.29	-5.88	-0.34	1.2e-8	Schizophrenia;
CESC	cis	rs67311347	0.506	rs55962832	chr3:40244451	T/C	cg09455208	chr3:40491958	NA	0.35	5.49	0.32	9.28e-8	Renal cell carcinoma;
CESC	cis	rs539096	0.500	rs2906457	chr1:44338575	A/C	cg13606994	chr1:44402422	ARTN	-0.38	-6.05	-0.35	4.82e-9	Intelligence (multi-trait analysis);
CESC	cis	rs36051895	0.659	rs12343867	chr9:5074189	T/C	cg02405213	chr9:5042618	JAK2	-0.53	-6.44	-0.37	5.75e-10	Pediatric autoimmune diseases;
CESC	cis	rs4253772	0.678	rs9627281	chr22:46644168	A/G	cg24881330	chr22:46731750	TRMU	0.73	8.07	0.44	2.51e-14	LDL cholesterol;Cholesterol, total;
CESC	cis	rs4906332	1.000	rs8012623	chr14:103937086	G/A	cg09975044	chr14:104007538	NA	0.47	6.48	0.37	4.51e-10	Coronary artery disease;
CESC	cis	rs9815354	0.767	rs61283393	chr3:41854135	T/G	cg03022575	chr3:42003672	ULK4	0.7	6.34	0.36	1.01e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs4927850	1.000	rs7625570	chr3:195747398	A/G	cg00031303	chr3:195681400	NA	0.46	5.78	0.33	2.13e-8	Pancreatic cancer;
CESC	cis	rs2439831	0.867	rs2899082	chr15:43656043	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	13.11	0.63	1.34e-30	Lung cancer in ever smokers;
CESC	cis	rs3126085	0.935	rs1496045	chr1:152184704	C/T	cg03465714	chr1:152285911	FLG	-0.43	-5.16	-0.3	4.81e-7	Atopic dermatitis;
CESC	cis	rs35306767	0.855	rs56222464	chr10:867535	C/G	cg26597838	chr10:835615	NA	1.18	11.47	0.58	5.21e-25	Eosinophil percentage of granulocytes;
CESC	cis	rs5758659	0.652	rs133314	chr22:42401841	G/A	cg04733989	chr22:42467013	NAGA	0.43	5.72	0.33	2.8e-8	Cognitive function;
CESC	cis	rs6502050	0.799	rs8069827	chr17:80089168	C/T	cg23985595	chr17:80112537	CCDC57	-0.42	-6.6	-0.38	2.18e-10	Life satisfaction;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg04774194	chr6:127664674	ECHDC1	-0.51	-6.57	-0.37	2.71e-10	Ulcerative colitis;
CESC	cis	rs2963155	0.518	rs56150733	chr5:142765099	T/C	cg17617527	chr5:142782415	NR3C1	0.82	6.79	0.39	7.2e-11	Breast cancer;
CESC	cis	rs34779708	0.931	rs11597392	chr10:35288575	T/C	cg04310649	chr10:35416472	CREM	-0.48	-5.67	-0.33	3.81e-8	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs3091242	0.934	rs666686	chr1:25719511	A/G	cg02931644	chr1:25747376	RHCE	0.44	7.48	0.42	1.08e-12	Erythrocyte sedimentation rate;
CESC	cis	rs2439831	0.850	rs28413704	chr15:44148427	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.63	5.6	0.33	5.26e-8	Lung cancer in ever smokers;
CESC	cis	rs2197308	0.765	rs11182964	chr12:37935052	C/T	cg13010199	chr12:38710504	ALG10B	0.53	6.81	0.39	6.71e-11	Morning vs. evening chronotype;
CESC	cis	rs3747547	0.685	rs72726082	chr9:38119334	A/G	cg13774184	chr9:37916125	SHB	-0.6	-5.03	-0.3	9.11e-7	Metabolite levels (Dihydroxy docosatrienoic acid);
CESC	cis	rs11563648	0.553	rs6957320	chr7:126998210	C/T	cg25922125	chr7:127225783	GCC1	-0.42	-5.11	-0.3	6.29e-7	Resting heart rate;
CESC	cis	rs7771547	0.573	rs522179	chr6:36391605	G/A	cg04289385	chr6:36355825	ETV7	0.39	5.65	0.33	4.2e-8	Platelet distribution width;
CESC	cis	rs17345786	0.861	rs11707689	chr3:101086475	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.45	-5.07	-0.3	7.59e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9894429	1.000	rs7503679	chr17:79583843	G/C	cg18240062	chr17:79603768	NPLOC4	0.72	10.27	0.53	4.71e-21	Eye color traits;
CESC	cis	rs7666738	0.830	rs28516388	chr4:98987449	A/G	cg17366294	chr4:99064904	C4orf37	0.59	8.57	0.47	8.46e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs523522	0.962	rs4766969	chr12:120988238	A/G	cg12219531	chr12:120966889	COQ5	0.74	9.75	0.51	2.17e-19	High light scatter reticulocyte count;
CESC	cis	rs3096299	0.685	rs4785675	chr16:89539974	T/C	cg16743903	chr16:89593216	SPG7	-0.46	-6.0	-0.35	6.51e-9	Multiple myeloma (IgH translocation);
CESC	cis	rs7772486	0.754	rs857881	chr6:145970793	C/A	cg05347473	chr6:146136440	FBXO30	-0.58	-7.36	-0.41	2.32e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7666738	0.861	rs28821920	chr4:98962743	T/C	cg03467027	chr4:99064603	C4orf37	0.44	5.57	0.32	6.41e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4563143	0.675	rs56322221	chr19:29270349	A/T	cg12667521	chr19:29218732	NA	0.48	6.4	0.37	6.97e-10	Methadone dose in opioid dependence;
CESC	cis	rs6952808	0.929	rs11768206	chr7:1932151	T/G	cg02951883	chr7:2050386	MAD1L1	-0.51	-6.8	-0.39	6.8e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs2243480	1.000	rs316332	chr7:65604299	A/G	cg13147721	chr7:65941812	NA	-0.94	-8.91	-0.48	8.25e-17	Diabetic kidney disease;
CESC	cis	rs10129255	0.957	rs10141052	chr14:107184767	G/A	cg23076370	chr14:107095027	NA	-0.48	-6.29	-0.36	1.32e-9	Kawasaki disease;
CESC	cis	rs1448094	0.556	rs61930632	chr12:86168937	A/C	cg02569458	chr12:86230093	RASSF9	0.57	8.38	0.46	3.07e-15	Major depressive disorder;
CESC	cis	rs9457247	0.740	rs10946204	chr6:167451129	T/C	cg23791538	chr6:167370224	RNASET2	-0.55	-7.66	-0.43	3.42e-13	Crohn's disease;
CESC	cis	rs9303401	0.614	rs34941454	chr17:57102742	T/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.87	10.87	0.56	5.18e-23	Cognitive test performance;
CESC	cis	rs9649213	1.000	rs9649213	chr7:98021211	A/G	cg21770322	chr7:97807741	LMTK2	-0.41	-5.78	-0.33	2.1e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg26338869	chr17:61819248	STRADA	-0.79	-10.55	-0.54	6.11e-22	Prudent dietary pattern;
CESC	cis	rs2243480	1.000	rs316312	chr7:65596491	T/G	cg18252515	chr7:66147081	NA	-1.41	-14.36	-0.66	5.44e-35	Diabetic kidney disease;
CESC	cis	rs6831352	0.734	rs3100630	chr4:100031715	T/A	cg13256891	chr4:100009986	ADH5	0.69	8.13	0.45	1.61e-14	Alcohol dependence;
CESC	cis	rs40363	0.645	rs1690447	chr16:3519211	T/C	cg00484396	chr16:3507460	NAT15	0.43	6.91	0.39	3.52e-11	Tuberculosis;
CESC	cis	rs6584283	0.766	rs7911680	chr10:101293468	A/C	cg09788492	chr10:101292477	NKX2-3	0.33	5.96	0.34	8.16e-9	Ulcerative colitis;
CESC	cis	rs561341	0.941	rs2428338	chr17:30299629	T/C	cg19193384	chr17:30244184	NA	-0.6	-6.24	-0.36	1.72e-9	Hip circumference adjusted for BMI;
CESC	cis	rs7312933	0.585	rs7969814	chr12:42669657	C/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.45	5.88	0.34	1.2e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs1008375	0.966	rs7666888	chr4:17695722	C/T	cg16339924	chr4:17578868	LAP3	0.57	7.13	0.4	9.77e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	trans	rs35110281	0.840	rs7276633	chr21:45078800	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.52	6.89	0.39	4.06e-11	Mean corpuscular volume;
CESC	cis	rs12579753	1.000	rs17749267	chr12:82178308	A/G	cg21193143	chr12:82153300	PPFIA2	0.35	5.06	0.3	7.88e-7	Resting heart rate;
CESC	cis	rs7666738	0.830	rs1426662	chr4:98990319	C/T	cg05340658	chr4:99064831	C4orf37	0.8	12.43	0.61	3.04e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg07677032	chr17:61819896	STRADA	0.49	6.67	0.38	1.46e-10	Prudent dietary pattern;
CESC	trans	rs4596713	0.538	rs7865373	chr9:71765105	T/C	cg16512924	chr15:28394682	HERC2	0.51	6.61	0.38	2.05e-10	Headache;
CESC	cis	rs10256972	0.933	rs35696159	chr7:1047194	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.42	-5.29	-0.31	2.6e-7	Longevity;Endometriosis;
CESC	cis	rs9905704	0.525	rs2632515	chr17:56444883	A/G	cg12560992	chr17:57184187	TRIM37	0.63	5.5	0.32	8.81e-8	Testicular germ cell tumor;
CESC	cis	rs1030268	0.505	rs80305547	chr7:133259400	A/G	cg10665199	chr7:133106180	EXOC4	0.52	5.45	0.32	1.14e-7	Intelligence (multi-trait analysis);
CESC	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	13.67	0.64	1.44e-32	Prudent dietary pattern;
CESC	cis	rs711245	0.518	rs11886145	chr2:36825716	C/G	cg09467607	chr2:36825704	FEZ2	0.61	11.73	0.58	7.01e-26	Height;
CESC	cis	rs12701220	0.655	rs6955290	chr7:1151066	A/G	cg26769984	chr7:1090371	C7orf50	-0.56	-6.49	-0.37	4.23e-10	Bronchopulmonary dysplasia;
CESC	trans	rs9858542	0.953	rs9862080	chr3:49674458	A/G	cg21659725	chr3:3221576	CRBN	-0.52	-6.3	-0.36	1.21e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs11122272	0.701	rs11582413	chr1:231530098	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.56	-7.66	-0.43	3.45e-13	Hemoglobin concentration;
CESC	cis	rs1707322	0.827	rs6683274	chr1:46241638	T/G	cg06784218	chr1:46089804	CCDC17	0.38	6.29	0.36	1.33e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs977987	0.806	rs12933281	chr16:75483064	T/G	cg03315344	chr16:75512273	CHST6	0.46	6.5	0.37	4.03e-10	Dupuytren's disease;
CESC	cis	rs4964805	0.683	rs12424737	chr12:104196221	A/C	cg02344784	chr12:104178138	NT5DC3	0.45	6.29	0.36	1.32e-9	Attention deficit hyperactivity disorder;
CESC	cis	rs1799949	1.000	rs915945	chr17:41179864	C/T	cg05368731	chr17:41323189	NBR1	0.78	10.13	0.53	1.33e-20	Menopause (age at onset);
CESC	cis	rs3733585	0.699	rs10001964	chr4:9959275	C/T	cg11266682	chr4:10021025	SLC2A9	-0.6	-11.15	-0.57	6.33e-24	Cleft plate (environmental tobacco smoke interaction);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg15197458	chr19:3464765	NA	0.45	6.22	0.36	1.97e-9	Fibrinogen levels;
CESC	cis	rs910316	1.000	rs10142865	chr14:75555624	G/A	cg11812906	chr14:75593930	NEK9	0.91	15.88	0.7	2.25e-40	Height;
CESC	cis	rs10504229	1.000	rs1961778	chr8:58168756	G/A	cg14926445	chr8:58193284	C8orf71	-0.49	-5.29	-0.31	2.57e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs11958404	0.932	rs72816563	chr5:157427447	C/T	cg05962755	chr5:157440814	NA	0.62	6.61	0.38	2.14e-10	IgG glycosylation;
CESC	cis	rs116095464	0.558	rs9688045	chr5:254035	T/C	cg22857025	chr5:266934	NA	-1.29	-18.21	-0.75	1.29e-48	Breast cancer;
CESC	cis	rs3820068	0.677	rs72643691	chr1:15856251	T/C	cg18192808	chr1:15853278	DNAJC16	0.47	5.81	0.34	1.75e-8	Systolic blood pressure;
CESC	cis	rs7647973	1.000	rs3905330	chr3:49550774	A/G	cg06212747	chr3:49208901	KLHDC8B	0.59	8.03	0.44	3.22e-14	Menarche (age at onset);
CESC	cis	rs11048434	0.673	rs11611106	chr12:9060204	A/C	cg23795048	chr12:9217529	LOC144571	-0.35	-5.5	-0.32	8.92e-8	Sjögren's syndrome;
CESC	cis	rs76419734	0.510	rs2544417	chr4:106745405	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	-0.63	-6.37	-0.36	8.24e-10	Post bronchodilator FEV1;
CESC	cis	rs10540	1.000	rs61876340	chr11:495699	A/C	cg21784768	chr11:537496	LRRC56	-0.54	-5.11	-0.3	6.29e-7	Body mass index;
CESC	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg12419862	chr22:24373484	LOC391322	0.9	13.82	0.65	4.45e-33	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs1387259	0.758	rs2634670	chr12:48771877	G/A	cg04545296	chr12:48745243	ZNF641	0.36	6.01	0.35	6.28e-9	Obstructive sleep apnea trait (apnea hypopnea index);
CESC	cis	rs7666738	0.830	rs1534319	chr4:98964804	T/C	cg03467027	chr4:99064603	C4orf37	0.44	5.57	0.32	6.41e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs61332075	0.518	rs112649209	chr2:239422814	C/G	cg18131467	chr2:239335373	ASB1	-0.72	-5.81	-0.34	1.76e-8	Lung function (FEV1/FVC);
CESC	cis	rs4713118	0.662	rs9468278	chr6:28028482	C/T	cg26335602	chr6:28129616	ZNF389	0.44	5.61	0.33	5.19e-8	Parkinson's disease;
CESC	cis	rs60843830	0.596	rs17041320	chr2:112051	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.48	5.74	0.33	2.6e-8	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs796364	1.000	rs796364	chr2:200716119	C/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.87	8.56	0.47	9.55e-16	Schizophrenia;
CESC	cis	rs6952808	0.689	rs12668156	chr7:2019875	G/A	cg23048001	chr7:2026167	MAD1L1	0.5	6.35	0.36	9.34e-10	Bipolar disorder and schizophrenia;
CESC	cis	rs7666738	0.606	rs10006454	chr4:99080361	G/A	cg17366294	chr4:99064904	C4orf37	0.43	5.71	0.33	3.05e-8	Colonoscopy-negative controls vs population controls;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg25722142	chr6:139695762	CITED2	0.49	6.6	0.38	2.27e-10	Systemic lupus erythematosus;
CESC	cis	rs2991971	0.729	rs10890328	chr1:45905383	G/T	cg15605315	chr1:45957053	TESK2	-0.39	-5.39	-0.31	1.56e-7	High light scatter reticulocyte count;
CESC	cis	rs9300255	0.620	rs1716173	chr12:123660721	A/T	cg05973401	chr12:123451056	ABCB9	0.49	5.49	0.32	9.51e-8	Neutrophil percentage of white cells;
CESC	cis	rs9311474	0.967	rs11717383	chr3:52287468	G/T	cg17372223	chr3:52568218	NT5DC2	0.39	6.1	0.35	3.84e-9	Electroencephalogram traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00647403	chr16:23521932	GGA2	-0.66	-7.95	-0.44	5.29e-14	Gut microbiome composition (summer);
CESC	cis	rs597539	0.652	rs613128	chr11:68638058	G/T	cg06028808	chr11:68637592	NA	0.43	5.12	0.3	5.87e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs6088580	0.634	rs3746455	chr20:32957216	G/A	cg06115741	chr20:33292138	TP53INP2	-0.44	-5.62	-0.33	4.71e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs6991838	0.584	rs2175810	chr8:66555818	A/C	cg13398993	chr8:66546079	ARMC1	-0.47	-5.65	-0.33	4.12e-8	Intelligence (multi-trait analysis);
CESC	cis	rs780096	0.546	rs4665976	chr2:27640325	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.29	-5.47	-0.32	1.05e-7	Total body bone mineral density;
CESC	cis	rs6964587	0.626	rs1011372	chr7:91509867	T/C	cg17063962	chr7:91808500	NA	-0.45	-6.35	-0.36	9.06e-10	Breast cancer;
CESC	cis	rs7843479	0.965	rs13269198	chr8:21823025	G/A	cg17168535	chr8:21777572	XPO7	0.5	6.82	0.39	6.27e-11	Mean corpuscular volume;
CESC	cis	rs7618915	0.501	rs7622694	chr3:52663882	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.61	8.79	0.48	1.9e-16	Bipolar disorder;
CESC	cis	rs6088580	0.634	rs11700221	chr20:32940320	T/C	cg08999081	chr20:33150536	PIGU	-0.64	-11.05	-0.56	1.4e-23	Glomerular filtration rate (creatinine);
CESC	cis	rs3857067	0.967	rs1509942	chr4:95013440	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.52	-8.04	-0.44	3.04e-14	QT interval;
CESC	cis	rs7647973	0.587	rs10452032	chr3:49680973	G/A	cg06212747	chr3:49208901	KLHDC8B	0.64	7.75	0.43	1.94e-13	Menarche (age at onset);
CESC	cis	rs7666738	0.791	rs1967978	chr4:98966152	T/C	cg17366294	chr4:99064904	C4orf37	0.6	8.52	0.46	1.2e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4835473	0.864	rs28423022	chr4:144887569	A/G	cg25736465	chr4:144833511	NA	0.41	6.37	0.36	8.26e-10	Immature fraction of reticulocytes;
CESC	cis	rs896854	0.517	rs2013597	chr8:95951807	G/A	cg09323728	chr8:95962352	TP53INP1	-0.35	-6.53	-0.37	3.29e-10	Type 2 diabetes;
CESC	cis	rs847577	0.609	rs6465658	chr7:97816638	C/G	cg24562669	chr7:97807699	LMTK2	0.81	12.94	0.62	5.24e-30	Breast cancer;
CESC	cis	rs11690935	0.549	rs796839	chr2:172916214	A/C	cg13550731	chr2:172543902	DYNC1I2	0.5	6.77	0.38	8.32e-11	Schizophrenia;
CESC	cis	rs9303401	0.614	rs34550282	chr17:57092788	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.87	10.87	0.56	5.18e-23	Cognitive test performance;
CESC	cis	rs888194	0.966	rs6606725	chr12:109905368	C/A	cg19025524	chr12:109796872	NA	-0.34	-5.04	-0.3	8.68e-7	Neuroticism;
CESC	trans	rs9858542	0.953	rs7633271	chr3:49555963	T/C	cg21659725	chr3:3221576	CRBN	-0.54	-6.71	-0.38	1.19e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs7824557	0.606	rs1047950	chr8:11185096	G/C	cg21775007	chr8:11205619	TDH	0.5	7.24	0.41	4.76e-12	Retinal vascular caliber;
CESC	cis	rs9910055	0.747	rs2905981	chr17:42238625	C/T	cg08499158	chr17:42289980	UBTF	-0.53	-6.89	-0.39	3.94e-11	Total body bone mineral density;
CESC	cis	rs55788414	0.932	rs2317119	chr16:81182854	T/C	cg06400318	chr16:81190750	PKD1L2	-0.59	-6.97	-0.39	2.49e-11	Left ventricular obstructive tract defect (maternal effect);
CESC	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	21.77	0.8	6.03e-61	Prudent dietary pattern;
CESC	cis	rs769267	0.930	rs2315022	chr19:19413381	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.42	5.39	0.31	1.52e-7	Tonsillectomy;
CESC	cis	rs1348850	0.632	rs12471621	chr2:178502353	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.6	7.78	0.43	1.62e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs4713118	0.516	rs4713142	chr6:28106347	T/G	cg23161317	chr6:28129485	ZNF389	0.51	6.63	0.38	1.85e-10	Parkinson's disease;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg21395782	chr19:19626814	NDUFA13;TSSK6	-0.42	-6.29	-0.36	1.3e-9	Gambling;
CESC	cis	rs6089829	0.925	rs2277767	chr20:61666937	G/A	cg03213289	chr20:61660250	NA	0.39	6.16	0.35	2.7e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs2274273	0.837	rs7142857	chr14:55704128	C/T	cg04306507	chr14:55594613	LGALS3	0.29	5.82	0.34	1.66e-8	Protein biomarker;
CESC	cis	rs61784830	0.710	rs61783196	chr1:46291790	C/T	cg06784218	chr1:46089804	CCDC17	0.48	5.42	0.32	1.37e-7	Iron status biomarkers (total iron binding capacity);
CESC	cis	rs7772486	0.790	rs3923579	chr6:146230232	C/G	cg05347473	chr6:146136440	FBXO30	-0.57	-7.31	-0.41	3.07e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2832191	0.636	rs8131295	chr21:30516819	A/T	cg24692254	chr21:30365293	RNF160	-0.63	-7.81	-0.43	1.34e-13	Dental caries;
CESC	cis	rs1550582	0.662	rs6981748	chr8:135501309	A/C	cg17885191	chr8:135476712	NA	-0.84	-10.91	-0.56	3.91e-23	Educational attainment;
CESC	cis	rs7224314	1.000	rs8070284	chr17:65387400	A/G	cg01507342	chr17:65387096	PITPNC1	-0.48	-5.67	-0.33	3.82e-8	Diisocyanate-induced asthma;
CESC	cis	rs1153858	1.000	rs11070456	chr15:45686835	G/A	cg14582100	chr15:45693742	SPATA5L1	0.41	5.77	0.33	2.17e-8	Homoarginine levels;
CESC	cis	rs873946	0.586	rs2001426	chr10:134563871	G/A	cg26818010	chr10:134567672	INPP5A	-0.92	-11.19	-0.57	4.64e-24	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs826838	1.000	rs1719848	chr12:39085586	A/G	cg13010199	chr12:38710504	ALG10B	-0.41	-5.63	-0.33	4.66e-8	Heart rate;
CESC	cis	rs10883723	0.847	rs3808934	chr10:104264280	C/T	ch.10.2196322F	chr10:104248062	ACTR1A	0.42	5.08	0.3	6.99e-7	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs6964587	0.585	rs10266481	chr7:91554338	T/C	cg17063962	chr7:91808500	NA	-0.44	-6.22	-0.36	1.9e-9	Breast cancer;
CESC	cis	rs875971	1.000	rs1144894	chr7:65542894	A/G	cg10691866	chr7:65817282	TPST1	0.33	5.21	0.3	3.74e-7	Aortic root size;
CESC	cis	rs1364705	1.000	rs6986732	chr8:120225428	A/C	cg09273054	chr8:120220131	MAL2	0.52	5.98	0.34	7.35e-9	Hippocampal atrophy;
CESC	cis	rs7551222	0.752	rs4252694	chr1:204499056	A/G	cg20240347	chr1:204465584	NA	-0.28	-5.7	-0.33	3.12e-8	Schizophrenia;
CESC	cis	rs9322193	0.923	rs2297928	chr6:150039720	G/C	cg09699651	chr6:150184138	LRP11	0.39	5.04	0.3	8.83e-7	Lung cancer;
CESC	cis	rs4268898	0.722	rs11691212	chr2:24404733	A/G	cg06627628	chr2:24431161	ITSN2	0.54	7.28	0.41	3.72e-12	Asthma;
CESC	cis	rs17209837	0.646	rs10452935	chr7:87094247	A/T	cg00919237	chr7:87102261	ABCB4	-0.51	-6.58	-0.37	2.45e-10	Gallbladder cancer;
CESC	cis	rs17401966	1.000	rs11121533	chr1:10292888	G/C	cg15208524	chr1:10270712	KIF1B	0.47	6.14	0.35	3.07e-9	Hepatocellular carcinoma;
CESC	cis	rs2228479	0.850	rs45524643	chr16:89815824	G/A	cg06558623	chr16:89946397	TCF25	1.16	9.28	0.5	6.08e-18	Skin colour saturation;
CESC	cis	rs2880765	0.835	rs7180213	chr15:86021187	G/A	cg10818794	chr15:86012489	AKAP13	-0.34	-5.22	-0.31	3.66e-7	Coronary artery disease;
CESC	cis	rs853679	0.517	rs4713148	chr6:28115921	G/A	cg17949981	chr6:28129498	ZNF389	0.45	5.49	0.32	9.35e-8	Depression;
CESC	cis	rs1218582	0.774	rs1007170	chr1:154881461	G/A	cg16680214	chr1:154839983	KCNN3	-0.51	-7.94	-0.44	5.69e-14	Prostate cancer;
CESC	cis	rs7552404	1.000	rs6672180	chr1:76123973	C/G	cg10523679	chr1:76189770	ACADM	0.73	8.51	0.46	1.33e-15	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs193541	0.632	rs1903260	chr5:122135188	T/C	cg19412675	chr5:122181750	SNX24	0.44	5.07	0.3	7.63e-7	Glucose homeostasis traits;
CESC	cis	rs7147624	1.000	rs8021889	chr14:66214811	A/G	cg03016385	chr14:66212404	NA	-0.5	-5.25	-0.31	3.1e-7	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	10.13	0.53	1.35e-20	Prudent dietary pattern;
CESC	trans	rs1814175	0.645	rs28549248	chr11:50042740	C/T	cg15704280	chr7:45808275	SEPT13	-1.01	-18.71	-0.75	2.23e-50	Height;
CESC	cis	rs561341	1.000	rs72825712	chr17:30316119	A/T	cg00745463	chr17:30367425	LRRC37B	-0.85	-7.72	-0.43	2.36e-13	Hip circumference adjusted for BMI;
CESC	cis	rs2180341	0.538	rs3756993	chr6:127651551	A/C	cg24812749	chr6:127587940	RNF146	0.6	8.0	0.44	3.96e-14	Breast cancer;
CESC	cis	rs7824557	0.525	rs12682349	chr8:11245303	C/G	cg21775007	chr8:11205619	TDH	0.57	8.74	0.47	2.72e-16	Retinal vascular caliber;
CESC	trans	rs3942852	0.524	rs7118665	chr11:48078427	C/A	cg03929089	chr4:120376271	NA	0.68	8.11	0.45	1.93e-14	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs7666738	0.791	rs11735105	chr4:98937357	C/T	cg17366294	chr4:99064904	C4orf37	0.61	8.56	0.47	9.36e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs826838	0.967	rs11183514	chr12:38760744	A/T	cg26384229	chr12:38710491	ALG10B	0.84	14.74	0.67	2.59e-36	Heart rate;
CESC	cis	rs7959663	1	rs7959663	chr12:109884367	G/C	cg05360138	chr12:110035743	NA	0.51	5.24	0.31	3.27e-7	Bipolar disorder lithium response (categorical) or schizophrenia;
CESC	cis	rs634534	0.622	rs1192168	chr11:65730945	T/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.65	9.21	0.49	1.05e-17	Sum eosinophil basophil counts;Eosinophil counts;
CESC	cis	rs9733	0.596	rs11204697	chr1:150658971	C/T	cg22823121	chr1:150693482	HORMAD1	0.48	7.1	0.4	1.14e-11	Tonsillectomy;
CESC	cis	rs1707322	0.721	rs10789468	chr1:46124558	A/G	cg05343316	chr1:45956843	TESK2	0.48	6.05	0.35	4.85e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2996428	0.561	rs72640913	chr1:3747023	C/G	cg13057898	chr1:3703894	LRRC47	0.35	5.1	0.3	6.53e-7	Red cell distribution width;
CESC	cis	rs875971	0.862	rs778707	chr7:65857027	G/A	cg10691866	chr7:65817282	TPST1	-0.33	-5.43	-0.32	1.3e-7	Aortic root size;
CESC	cis	rs9393777	0.623	rs9348719	chr6:26470032	T/C	cg12826209	chr6:26865740	GUSBL1	0.68	7.39	0.41	1.94e-12	Intelligence (multi-trait analysis);
CESC	cis	rs71403859	0.502	rs71403849	chr16:71484365	T/C	cg08717414	chr16:71523259	ZNF19	-0.88	-8.98	-0.48	4.99e-17	Post bronchodilator FEV1;
CESC	cis	rs1568889	1.000	rs7931847	chr11:28175245	G/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.75	9.47	0.5	1.58e-18	Bipolar disorder;
CESC	cis	rs6088580	0.634	rs1205336	chr20:32926336	G/A	cg08999081	chr20:33150536	PIGU	-0.64	-11.01	-0.56	1.78e-23	Glomerular filtration rate (creatinine);
CESC	trans	rs8073060	0.586	rs225264	chr17:33961335	A/G	cg19694781	chr19:47549865	TMEM160	-0.73	-7.03	-0.4	1.79e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	cis	rs6502050	0.769	rs4789741	chr17:80119184	A/C	cg23985595	chr17:80112537	CCDC57	-0.41	-6.57	-0.37	2.6200000000000003e-10	Life satisfaction;
CESC	cis	rs12142240	0.698	rs12385695	chr1:46819021	A/G	cg10495392	chr1:46806563	NSUN4	0.57	6.27	0.36	1.47e-9	Menopause (age at onset);
CESC	cis	rs7605827	0.930	rs6735633	chr2:15706096	G/A	cg19274914	chr2:15703543	NA	0.37	6.6	0.38	2.23e-10	Educational attainment (years of education);
CESC	cis	rs7666738	0.830	rs13129503	chr4:98987892	T/C	cg18180107	chr4:99064573	C4orf37	0.4	5.19	0.3	4.29e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2841277	0.741	rs9672139	chr14:105408182	T/G	cg17340268	chr14:105411764	AHNAK2	-0.48	-6.39	-0.37	7.62e-10	Rheumatoid arthritis;
CESC	cis	rs1062177	0.951	rs2915876	chr5:151150745	C/A	cg00977110	chr5:151150581	G3BP1	0.68	7.19	0.4	6.48e-12	Preschool internalizing problems;
CESC	cis	rs7296418	0.961	rs1790106	chr12:123591596	G/T	cg00376283	chr12:123451042	ABCB9	0.74	10.81	0.55	8.47e-23	Platelet count;
CESC	cis	rs11958404	0.860	rs72816577	chr5:157431806	A/G	cg05962755	chr5:157440814	NA	0.62	6.56	0.37	2.74e-10	IgG glycosylation;
CESC	cis	rs7666738	0.830	rs10029849	chr4:99059362	T/C	cg17366294	chr4:99064904	C4orf37	0.62	8.8	0.48	1.86e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9733	0.519	rs12095002	chr1:150649249	G/A	cg09365446	chr1:150670422	GOLPH3L	0.42	5.9	0.34	1.09e-8	Tonsillectomy;
CESC	cis	rs644799	0.542	rs10831417	chr11:95467262	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	-0.63	-8.89	-0.48	9.51e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs1949733	0.816	rs2631746	chr4:8490934	C/T	cg11789530	chr4:8429930	ACOX3	-0.64	-8.58	-0.47	8.38e-16	Response to antineoplastic agents;
CESC	cis	rs3768617	0.510	rs7529465	chr1:183096880	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.89	14.39	0.66	4.39e-35	Fuchs's corneal dystrophy;
CESC	cis	rs12142240	0.698	rs56358525	chr1:46849520	C/T	cg00530320	chr1:46809349	NSUN4	0.6	8.3	0.45	5.19e-15	Menopause (age at onset);
CESC	cis	rs9488822	0.676	rs13210143	chr6:116389636	G/A	cg26893134	chr6:116381904	FRK	0.25	6.29	0.36	1.28e-9	Cholesterol, total;LDL cholesterol;
CESC	cis	rs7312774	0.609	rs2374655	chr12:107380162	T/C	cg16260113	chr12:107380972	MTERFD3	1.14	8.79	0.48	1.88e-16	Severe influenza A (H1N1) infection;
CESC	cis	rs4713118	0.513	rs149951	chr6:28033087	T/C	cg23161317	chr6:28129485	ZNF389	0.38	5.35	0.31	1.92e-7	Parkinson's disease;
CESC	cis	rs11190604	1.000	rs7085439	chr10:102210100	C/T	cg07080220	chr10:102295463	HIF1AN	0.55	5.51	0.32	8.5e-8	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs853679	0.517	rs4713146	chr6:28111536	A/T	cg19592336	chr6:28129416	ZNF389	0.62	8.14	0.45	1.55e-14	Depression;
CESC	cis	rs1018836	0.828	rs7006279	chr8:91605364	A/G	cg16814680	chr8:91681699	NA	-0.71	-10.58	-0.54	4.89e-22	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs11166629	1.000	rs3739423	chr8:135614705	A/G	cg27224718	chr8:135614730	ZFAT	0.49	6.16	0.35	2.74e-9	Smoking quantity;
CESC	trans	rs7980799	0.935	rs10772076	chr12:33553574	A/C	cg26384229	chr12:38710491	ALG10B	-0.52	-7.11	-0.4	1.06e-11	Heart rate;Heart rate variability traits (RMSSD);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22066304	chr19:55691730	SYT5	-0.66	-7.58	-0.42	5.75e-13	Gut microbiome composition (summer);
CESC	cis	rs9621305	0.702	rs5749306	chr22:31976999	T/G	cg25791279	chr22:32026902	PISD	0.59	5.94	0.34	8.73e-9	Intelligence;
CESC	cis	rs2066819	1.000	rs808919	chr12:56647911	C/G	cg26714650	chr12:56694279	CS	1.22	14.95	0.68	4.62e-37	Psoriasis vulgaris;
CESC	cis	rs2243480	1.000	rs34192067	chr7:65887657	C/A	cg18252515	chr7:66147081	NA	-1.39	-14.18	-0.66	2.5e-34	Diabetic kidney disease;
CESC	trans	rs11098499	0.820	rs6829903	chr4:120506884	C/T	cg25214090	chr10:38739885	LOC399744	0.66	8.87	0.48	1.1e-16	Corneal astigmatism;
CESC	cis	rs829883	0.616	rs249832	chr12:98832387	C/T	cg25150519	chr12:98850993	NA	0.87	14.77	0.67	1.95e-36	Colorectal adenoma (advanced);
CESC	cis	rs6500602	0.647	rs4786514	chr16:4576798	A/C	cg08645402	chr16:4508243	NA	0.4	6.1	0.35	3.65e-9	Schizophrenia;
CESC	cis	rs4253772	0.591	rs6008365	chr22:46652929	G/A	cg24881330	chr22:46731750	TRMU	0.89	10.13	0.53	1.3e-20	LDL cholesterol;Cholesterol, total;
CESC	cis	rs4665809	0.590	rs1368902	chr2:26440576	T/C	cg04944784	chr2:26401820	FAM59B	-0.96	-10.55	-0.54	5.79e-22	Gut microbiome composition (summer);
CESC	cis	rs1003719	0.715	rs2835667	chr21:38579914	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.61	-8.22	-0.45	9.27e-15	Eye color traits;
CESC	cis	rs4555082	1.000	rs7146012	chr14:105757566	G/A	cg06808227	chr14:105710500	BRF1	-0.53	-6.49	-0.37	4.15e-10	Mean platelet volume;Platelet distribution width;
CESC	cis	rs8078723	0.866	rs3935280	chr17:38189055	A/G	cg17467752	chr17:38218738	THRA	-0.68	-10.92	-0.56	3.76e-23	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CESC	cis	rs6089829	0.962	rs7273930	chr20:61666017	G/A	cg08564027	chr20:61660810	NA	0.9	15.29	0.68	2.9e-38	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs10911232	0.507	rs10797817	chr1:182999136	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.85	13.17	0.63	8.54e-31	Hypertriglyceridemia;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg21348586	chr8:141461100	TRAPPC9	0.55	8.02	0.44	3.45e-14	Fibrinogen levels;
CESC	cis	rs6674176	0.628	rs2301993	chr1:44426025	G/A	cg13606994	chr1:44402422	ARTN	-0.37	-5.58	-0.32	6.03e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs1153858	0.723	rs1719238	chr15:45594766	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.38	-5.28	-0.31	2.76e-7	Homoarginine levels;
CESC	cis	rs17854409	0.803	rs1063247	chr20:61472118	C/G	cg07645718	chr20:61493192	TCFL5	0.79	5.2	0.3	3.98e-7	Obesity-related traits;
CESC	cis	rs7399018	0.643	rs6580810	chr12:51610478	C/T	cg12163867	chr12:51592794	POU6F1	-0.5	-6.68	-0.38	1.43e-10	Cisplatin-induced ototoxicity;
CESC	cis	rs1983891	1.000	rs4714485	chr6:41536587	T/G	cg20194872	chr6:41519635	FOXP4	0.55	7.83	0.43	1.17e-13	Prostate cancer;
CESC	cis	rs7666738	0.830	rs13129479	chr4:98987860	T/C	cg17366294	chr4:99064904	C4orf37	0.59	8.57	0.47	8.46e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9733	0.596	rs72702536	chr1:150662574	C/T	cg17724175	chr1:150552817	MCL1	0.44	7.25	0.41	4.48e-12	Tonsillectomy;
CESC	cis	rs8028182	0.609	rs8038760	chr15:75742095	A/C	cg20655648	chr15:75932815	IMP3	0.49	6.09	0.35	3.97e-9	Sudden cardiac arrest;
CESC	cis	rs514406	0.861	rs35581164	chr1:53271373	C/G	cg16325326	chr1:53192061	ZYG11B	0.91	15.48	0.69	6.08e-39	Monocyte count;
CESC	cis	rs13064411	0.696	rs7631082	chr3:113208913	C/G	cg18753928	chr3:113234510	CCDC52	-0.52	-6.31	-0.36	1.17e-9	Response to simvastatin treatment (PCSK9 protein level change);
CESC	cis	rs1728785	1.000	rs7205960	chr16:68565604	G/C	cg02972257	chr16:68554789	NA	-0.55	-6.37	-0.36	8.21e-10	Ulcerative colitis;
CESC	cis	rs11155671	0.530	rs9371542	chr6:150213085	A/T	cg09699651	chr6:150184138	LRP11	0.54	7.46	0.42	1.22e-12	Testicular germ cell tumor;
CESC	cis	rs4237845	0.816	rs61935769	chr12:58294344	G/A	cg00677455	chr12:58241039	CTDSP2	0.64	7.73	0.43	2.31e-13	Intelligence (multi-trait analysis);
CESC	cis	rs7178909	0.902	rs2043882	chr15:90439753	G/A	cg19708238	chr15:90437601	AP3S2	0.44	6.28	0.36	1.38e-9	Common traits (Other);
CESC	cis	rs7216064	1.000	rs2365468	chr17:65841318	C/T	cg07042672	chr17:66097459	LOC651250	-0.63	-7.54	-0.42	7.64e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs10504229	0.683	rs35889486	chr8:58117749	T/A	cg21724239	chr8:58056113	NA	0.58	5.95	0.34	8.29e-9	Developmental language disorder (linguistic errors);
CESC	trans	rs8057939	1.000	rs8060115	chr16:49391968	A/G	cg16782675	chr3:63943755	ATXN7	-0.57	-6.04	-0.35	5.21e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs28489187	0.666	rs233132	chr1:85796545	A/G	cg16011679	chr1:85725395	C1orf52	0.47	5.6	0.33	5.46e-8	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	cis	rs7618915	0.501	rs6617	chr3:52740182	C/G	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	5.83	0.34	1.64e-8	Bipolar disorder;
CESC	cis	rs12497850	0.931	rs7627404	chr3:48819668	A/C	cg06212747	chr3:49208901	KLHDC8B	0.64	8.55	0.46	9.98e-16	Parkinson's disease;
CESC	cis	rs34330	0.562	rs11055025	chr12:12866619	A/T	cg04607235	chr12:12878440	APOLD1	-0.76	-8.36	-0.46	3.53e-15	Systemic lupus erythematosus;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg18891615	chr8:101962925	YWHAZ	-0.47	-6.13	-0.35	3.14e-9	Fibrinogen levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13898697	chr1:36641773	MAP7D1	-0.58	-6.42	-0.37	6.09e-10	Gut microbiome composition (summer);
CESC	cis	rs3741404	0.672	rs4980524	chr11:63959259	A/C	cg18225595	chr11:63971243	STIP1	0.64	9.01	0.48	4.06e-17	Platelet count;
CESC	cis	rs9916302	0.706	rs584377	chr17:37460128	G/A	cg07936489	chr17:37558343	FBXL20	0.87	9.4	0.5	2.59e-18	Glomerular filtration rate (creatinine);
CESC	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg14159672	chr1:205819179	PM20D1	0.8	12.23	0.6	1.45e-27	Menarche (age at onset);
CESC	cis	rs6696846	0.740	rs17344537	chr1:205091427	T/G	cg00857998	chr1:205179979	DSTYK	0.56	7.33	0.41	2.86e-12	Red blood cell count;
CESC	cis	rs7429990	0.965	rs6770467	chr3:48019232	A/G	cg11946769	chr3:48343235	NME6	-0.44	-5.38	-0.31	1.65e-7	Educational attainment (years of education);
CESC	cis	rs3858526	0.752	rs11040173	chr11:6009378	A/G	cg05234568	chr11:5960015	NA	0.45	5.16	0.3	4.76e-7	DNA methylation (variation);
CESC	cis	rs2637266	0.935	rs7900900	chr10:78367383	A/T	cg18941641	chr10:78392320	NA	0.43	8.26	0.45	6.94e-15	Pulmonary function;
CESC	cis	rs11122272	0.668	rs2749712	chr1:231537751	T/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.55	-7.47	-0.42	1.15e-12	Hemoglobin concentration;
CESC	cis	rs62034325	0.697	rs710410	chr16:28603342	A/G	cg07382826	chr16:28625726	SULT1A1	0.4	6.49	0.37	4.11e-10	Body mass index;
CESC	cis	rs950776	0.518	rs3813571	chr15:78832792	G/T	cg06917634	chr15:78832804	PSMA4	0.81	12.58	0.61	8.9e-29	Sudden cardiac arrest;
CESC	cis	rs597539	0.652	rs579136	chr11:68637476	C/G	cg06028808	chr11:68637592	NA	0.43	5.12	0.3	5.87e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs1843834	0.539	rs10177898	chr2:225437552	C/T	cg12698349	chr2:225449008	CUL3	0.61	8.74	0.47	2.73e-16	IgE levels in asthmatics (D.p. specific);
CESC	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg02353165	chr6:42928485	GNMT	0.83	13.12	0.63	1.26e-30	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs72627123	0.656	rs11159064	chr14:74614743	A/G	cg12022184	chr14:74485813	ENTPD5;C14orf45	-0.75	-5.15	-0.3	5.06e-7	Morning vs. evening chronotype;
CESC	cis	rs4332037	0.851	rs1403175	chr7:1964357	A/T	cg23422044	chr7:1970798	MAD1L1	0.54	5.69	0.33	3.37e-8	Bipolar disorder;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg06767762	chr16:70323488	AARS	-0.43	-6.05	-0.35	4.92e-9	Asthma;
CESC	cis	rs938554	0.513	rs1014290	chr4:10001861	G/A	cg00071950	chr4:10020882	SLC2A9	0.62	8.22	0.45	8.95e-15	Blood metabolite levels;
CESC	cis	rs8077577	0.895	rs62073602	chr17:18057907	A/G	cg16794390	chr17:18148240	FLII	0.48	6.36	0.36	8.84e-10	Obesity-related traits;
CESC	cis	rs990171	0.506	rs4141632	chr2:102757139	A/G	cg22835712	chr2:102737379	NA	0.42	6.09	0.35	3.92e-9	Lymphocyte counts;
CESC	cis	rs854765	0.547	rs2955353	chr17:17948979	T/C	cg09796270	chr17:17721594	SREBF1	-0.38	-5.07	-0.3	7.66e-7	Total body bone mineral density;
CESC	cis	rs1915146	0.546	rs2454055	chr10:126859832	T/C	cg00406319	chr10:126851303	NA	0.38	5.85	0.34	1.44e-8	Menarche (age at onset);
CESC	cis	rs4820539	0.966	rs5751587	chr22:23470090	G/A	cg14186256	chr22:23484241	RTDR1	0.83	15.0	0.68	3.12e-37	Bone mineral density;
CESC	trans	rs3942852	0.806	rs10838805	chr11:48118993	A/C	cg03929089	chr4:120376271	NA	-0.56	-6.36	-0.36	9.04e-10	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs2012796	1.000	rs8009171	chr14:81820060	G/A	cg02996355	chr14:81879375	NA	0.51	5.97	0.34	7.64e-9	Night sleep phenotypes;
CESC	cis	rs873946	0.586	rs2001426	chr10:134563871	G/A	cg27286337	chr10:134555280	INPP5A	0.67	7.62	0.42	4.43e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs5769765	0.955	rs9616204	chr22:50303530	T/C	cg26441486	chr22:50317300	CRELD2	0.42	5.28	0.31	2.66e-7	Schizophrenia;
CESC	cis	rs1008375	0.863	rs2058336	chr4:17608299	T/C	cg02297831	chr4:17616191	MED28	0.52	6.53	0.37	3.27e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs7208859	0.573	rs11656278	chr17:29075188	C/T	cg14008862	chr17:28927542	LRRC37B2	0.65	5.14	0.3	5.34e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs2836974	0.931	rs8132285	chr21:40655752	T/C	cg27266027	chr21:40555129	PSMG1	0.45	5.34	0.31	2.05e-7	Cognitive function;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25010622	chr20:32700257	EIF2S2	0.59	7.18	0.4	6.84e-12	Gut microbiome composition (summer);
CESC	cis	rs258892	0.895	rs10041942	chr5:72049964	T/C	cg21869765	chr5:72125136	TNPO1	-0.4	-5.13	-0.3	5.56e-7	Small cell lung carcinoma;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14022530	chr1:100598534	SASS6;CCDC76	0.54	6.57	0.37	2.63e-10	Gut microbiome composition (summer);
CESC	cis	rs9325144	0.647	rs61937754	chr12:39060543	T/C	cg26384229	chr12:38710491	ALG10B	-0.52	-7.23	-0.41	5.23e-12	Morning vs. evening chronotype;
CESC	cis	rs4986172	0.655	rs1044977	chr17:43227214	T/C	cg10701640	chr17:43249399	NA	0.43	6.86	0.39	4.81e-11	Height;
CESC	cis	rs6963495	0.818	rs6977748	chr7:105167462	T/G	cg13798780	chr7:105162888	PUS7	0.77	7.59	0.42	5.45e-13	Bipolar disorder (body mass index interaction);
CESC	cis	rs524281	0.861	rs9645684	chr11:65907964	G/A	cg14036092	chr11:66035641	RAB1B	-0.58	-5.91	-0.34	1.05e-8	Electroencephalogram traits;
CESC	cis	rs2243480	1.000	rs35396113	chr7:65495461	C/T	cg25894440	chr7:65020034	NA	-0.66	-5.69	-0.33	3.42e-8	Diabetic kidney disease;
CESC	cis	rs2425143	1.000	rs79035779	chr20:34343004	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.65	5.44	0.32	1.2e-7	Blood protein levels;
CESC	cis	rs9616064	0.531	rs17821649	chr22:47050387	G/A	cg25730555	chr22:47059586	GRAMD4	0.46	5.73	0.33	2.71e-8	Urate levels in obese individuals;
CESC	cis	rs7044106	0.762	rs10491783	chr9:123450155	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.69	10.09	0.53	1.84e-20	Hip circumference adjusted for BMI;
CESC	cis	rs3106136	0.967	rs12646184	chr4:95183216	A/G	cg11021082	chr4:95130006	SMARCAD1	0.45	6.62	0.38	2.01e-10	Capecitabine sensitivity;
CESC	cis	rs4819052	0.851	rs2877020	chr21:46658742	C/T	cg11663144	chr21:46675770	NA	-0.63	-10.02	-0.52	3.12e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs4713118	0.621	rs9295755	chr6:28033174	C/T	cg22143856	chr6:28129313	ZNF389	-0.46	-5.87	-0.34	1.28e-8	Parkinson's disease;
CESC	cis	rs35306767	0.903	rs17159970	chr10:935601	T/C	cg26597838	chr10:835615	NA	0.94	10.04	0.53	2.57e-20	Eosinophil percentage of granulocytes;
CESC	cis	rs9311474	0.508	rs6786919	chr3:52599789	A/G	cg18404041	chr3:52824283	ITIH1	-0.38	-6.49	-0.37	4.13e-10	Electroencephalogram traits;
CESC	cis	rs769267	0.931	rs2965197	chr19:19470910	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	-0.5	-6.23	-0.36	1.78e-9	Tonsillectomy;
CESC	cis	rs2063714	0.967	rs913971	chr6:157197802	C/T	cg23222435	chr6:157204239	ARID1B	-0.39	-5.11	-0.3	6.29e-7	Sitting height ratio;
CESC	trans	rs11098499	0.754	rs10213554	chr4:120260785	A/G	cg25214090	chr10:38739885	LOC399744	-0.63	-8.91	-0.48	8.45e-17	Corneal astigmatism;
CESC	cis	rs616402	0.527	rs604369	chr1:10567208	C/A	cg20482658	chr1:10539492	PEX14	-0.28	-5.84	-0.34	1.54e-8	Breast size;
CESC	cis	rs7727544	0.606	rs10058074	chr5:131686146	G/A	cg14196790	chr5:131705035	SLC22A5	0.37	5.47	0.32	1.04e-7	Blood metabolite levels;
CESC	cis	rs9549367	0.789	rs9549718	chr13:113909822	A/G	cg18105134	chr13:113819100	PROZ	-0.7	-8.49	-0.46	1.48e-15	Platelet distribution width;
CESC	cis	rs7927592	0.731	rs2840367	chr11:68302101	G/A	cg16797656	chr11:68205561	LRP5	-0.48	-7.41	-0.41	1.69e-12	Total body bone mineral density;
CESC	cis	rs1707322	0.686	rs1084086	chr1:46041100	A/C	cg03146154	chr1:46216737	IPP	-0.78	-10.67	-0.55	2.34e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7202877	0.706	rs37605	chr16:75506572	G/C	cg03315344	chr16:75512273	CHST6	-0.53	-5.05	-0.3	8.28e-7	Type 2 diabetes;Type 1 diabetes;
CESC	cis	rs9815354	0.638	rs17218866	chr3:42017634	T/C	cg03022575	chr3:42003672	ULK4	0.74	6.64	0.38	1.79e-10	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs72945132	0.882	rs61260732	chr11:70162145	G/A	cg14191688	chr11:70257035	CTTN	0.42	5.34	0.31	1.95e-7	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17107193	chr6:5261438	LYRM4;FARS2	0.62	7.45	0.42	1.31e-12	Gut microbiome composition (summer);
CESC	cis	rs9300255	0.722	rs28592876	chr12:123866429	G/A	cg19016782	chr12:123741754	C12orf65	0.46	6.29	0.36	1.33e-9	Neutrophil percentage of white cells;
CESC	cis	rs9389248	0.737	rs56358308	chr6:135306980	A/T	cg22676075	chr6:135203613	NA	0.54	7.06	0.4	1.46e-11	High light scatter reticulocyte percentage of red cells;
CESC	cis	rs10504229	0.683	rs16921807	chr8:58105967	C/T	cg02725872	chr8:58115012	NA	-0.43	-6.81	-0.39	6.53e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs763121	0.719	rs138699	chr22:39129708	G/A	cg06544989	chr22:39130855	UNC84B	0.48	8.04	0.44	3.06e-14	Menopause (age at onset);
CESC	cis	rs4689388	0.889	rs13128674	chr4:6294517	C/T	cg14416269	chr4:6271139	WFS1	0.46	7.76	0.43	1.79e-13	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs7191439	0.674	rs4782429	chr16:88792097	A/G	cg02389323	chr16:88786976	FAM38A	0.93	8.34	0.46	4.01e-15	Plateletcrit;
CESC	cis	rs7618915	0.547	rs2118540	chr3:52629386	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	6.5	0.37	4.03e-10	Bipolar disorder;
CESC	cis	rs703842	1.000	rs10877014	chr12:58167661	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.71	9.41	0.5	2.48e-18	Multiple sclerosis;
CESC	trans	rs7246760	0.748	rs113745845	chr19:9736226	G/A	cg02900749	chr2:68251473	NA	-0.8	-6.18	-0.35	2.43e-9	Pursuit maintenance gain;
CESC	cis	rs10751667	0.857	rs7481221	chr11:966813	G/C	cg20946044	chr11:1010712	AP2A2	-0.4	-5.46	-0.32	1.12e-7	Alzheimer's disease (late onset);
CESC	cis	rs4561483	0.832	rs33645	chr16:11985201	T/C	cg08843971	chr16:11963173	GSPT1	-0.55	-8.15	-0.45	1.5e-14	Testicular germ cell tumor;
CESC	cis	rs10504229	1.000	rs1390411	chr8:58194146	C/A	cg24829409	chr8:58192753	C8orf71	-0.74	-9.68	-0.51	3.6e-19	Developmental language disorder (linguistic errors);
CESC	cis	rs72627123	0.656	rs76479281	chr14:74564609	C/A	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.74	5.12	0.3	5.89e-7	Morning vs. evening chronotype;
CESC	cis	rs3771570	0.786	rs62186396	chr2:242221219	A/G	cg21155796	chr2:242212141	HDLBP	0.64	5.34	0.31	2.03e-7	Prostate cancer;
CESC	cis	rs672059	0.513	rs572977	chr1:183164991	C/G	cg06211724	chr1:183155437	LAMC2	-0.35	-5.64	-0.33	4.27e-8	Hypertriglyceridemia;
CESC	cis	rs7561273	0.609	rs6545285	chr2:24340029	T/C	cg20701182	chr2:24300061	SF3B14	0.46	6.02	0.35	5.92e-9	Quantitative traits;
CESC	cis	rs9905704	0.633	rs72841019	chr17:56496346	G/A	cg12560992	chr17:57184187	TRIM37	0.6	5.54	0.32	7.38e-8	Testicular germ cell tumor;
CESC	cis	rs7662987	0.793	rs12106	chr4:99993350	A/G	cg13256891	chr4:100009986	ADH5	-0.59	-5.12	-0.3	5.89e-7	Smoking initiation;
CESC	cis	rs9611565	0.694	rs79008	chr22:41850500	C/T	cg06634786	chr22:41940651	POLR3H	-0.62	-6.36	-0.36	8.89e-10	Vitiligo;
CESC	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg24642844	chr7:1081250	C7orf50	-0.77	-9.41	-0.5	2.48e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs66573146	0.572	rs73199995	chr4:6955801	G/C	cg26116260	chr4:7069785	GRPEL1	-0.79	-5.16	-0.3	4.96e-7	Granulocyte percentage of myeloid white cells;
CESC	cis	rs9549367	0.713	rs9577211	chr13:113830718	G/C	cg00898013	chr13:113819073	PROZ	-0.52	-7.48	-0.42	1.08e-12	Platelet distribution width;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08975529	chr11:70309722	NA	-0.55	-6.02	-0.35	5.72e-9	Gut microbiome composition (summer);
CESC	trans	rs1814175	0.817	rs1851858	chr11:49855638	G/A	cg15704280	chr7:45808275	SEPT13	-1.03	-21.11	-0.79	1.04e-58	Height;
CESC	cis	rs561341	1.000	rs546519	chr17:30297682	T/G	cg12193833	chr17:30244370	NA	-0.59	-6.02	-0.35	5.78e-9	Hip circumference adjusted for BMI;
CESC	cis	rs6456156	0.586	rs2001115	chr6:167486218	A/C	cg07741184	chr6:167504864	NA	0.37	6.28	0.36	1.39e-9	Primary biliary cholangitis;
CESC	cis	rs1348850	0.567	rs4893838	chr2:178531436	T/C	cg22681709	chr2:178499509	PDE11A	-0.49	-7.27	-0.41	4.12e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	trans	rs3749237	1.000	rs3749237	chr3:49770032	C/T	cg21659725	chr3:3221576	CRBN	0.49	6.1	0.35	3.66e-9	Resting heart rate;
CESC	cis	rs9487051	0.768	rs399561	chr6:109524979	G/A	cg01475377	chr6:109611718	NA	-0.46	-6.93	-0.39	3.27e-11	Reticulocyte fraction of red cells;
CESC	cis	rs3780486	0.846	rs10813948	chr9:33121570	G/A	cg13443165	chr9:33130375	B4GALT1	0.44	6.35	0.36	9.18e-10	IgG glycosylation;
CESC	cis	rs2337406	0.714	rs7150993	chr14:107226748	A/T	cg23076370	chr14:107095027	NA	-0.52	-5.28	-0.31	2.68e-7	Alzheimer's disease (late onset);
CESC	cis	rs752010	0.871	rs10890149	chr1:42092791	T/A	cg06885757	chr1:42089581	HIVEP3	0.46	7.48	0.42	1.08e-12	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs116095464	0.558	rs10057674	chr5:266813	C/T	cg10591111	chr5:226296	SDHA	-0.52	-6.35	-0.36	9.51e-10	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26860337	chr1:155178555	MTX1;THBS3	0.56	6.39	0.37	7.37e-10	Gut microbiome composition (summer);
CESC	cis	rs9488822	0.596	rs13192549	chr6:116338352	C/A	cg15226275	chr6:116381976	FRK	0.21	5.19	0.3	4.11e-7	Cholesterol, total;LDL cholesterol;
CESC	cis	rs6952808	0.595	rs3778984	chr7:2166514	T/C	cg08027265	chr7:2291960	NA	-0.46	-7.05	-0.4	1.6e-11	Bipolar disorder and schizophrenia;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg09166770	chr16:30941758	FBXL19	0.5	6.76	0.38	8.91e-11	Fibrinogen levels;
CESC	cis	rs12586317	0.620	rs28404080	chr14:35539418	G/T	cg16230307	chr14:35515116	FAM177A1	0.93	9.91	0.52	6.88e-20	Psoriasis;
CESC	cis	rs35306767	0.953	rs35174953	chr10:961191	C/A	cg25019033	chr10:957182	NA	-0.65	-7.87	-0.44	8.8e-14	Eosinophil percentage of granulocytes;
CESC	cis	rs7584330	0.826	rs72620825	chr2:238381243	G/A	cg14458575	chr2:238380390	NA	0.89	12.4	0.61	3.61e-28	Prostate cancer;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg11704435	chr12:133281175	PXMP2	0.44	6.0	0.35	6.37e-9	Fibrinogen levels;
CESC	cis	rs10479542	0.544	rs7706275	chr5:178990305	A/G	cg05457628	chr5:178986728	RUFY1	0.52	7.55	0.42	7.04e-13	Lung cancer;
CESC	cis	rs9910055	0.708	rs2631298	chr17:42219832	T/C	cg10896456	chr17:42255109	ASB16;C17orf65	0.49	7.26	0.41	4.3e-12	Total body bone mineral density;
CESC	cis	rs17039065	0.920	rs11725434	chr4:109432750	G/A	cg16022748	chr4:109541635	LOC285456;RPL34	0.61	5.16	0.3	4.75e-7	Gut microbiome composition (summer);
CESC	cis	rs17666538	0.710	rs7834337	chr8:655828	A/G	cg26554054	chr8:600488	NA	0.65	5.6	0.33	5.31e-8	IgG glycosylation;
CESC	cis	rs3092073	0.624	rs13040315	chr20:44585793	A/G	cg00981651	chr20:44574847	PCIF1	0.34	5.26	0.31	2.93e-7	Intelligence (multi-trait analysis);
CESC	cis	rs941873	0.868	rs7898	chr10:81114959	C/T	cg11057378	chr10:81107060	PPIF	0.32	5.24	0.31	3.25e-7	Height;
CESC	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg06873352	chr17:61820015	STRADA	0.71	12.11	0.6	3.8e-27	Prudent dietary pattern;
CESC	cis	rs2073300	0.609	rs6137913	chr20:23357725	C/T	cg12062639	chr20:23401060	NAPB	0.81	7.25	0.41	4.61e-12	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs2842992	0.789	rs2475566	chr6:160148741	C/T	cg11366901	chr6:160182831	ACAT2	0.78	9.9	0.52	7.06e-20	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs11731606	0.508	rs9307140	chr4:95288670	G/C	cg00507259	chr4:95128692	SMARCAD1	0.55	5.13	0.3	5.71e-7	Mean platelet volume;
CESC	cis	rs35306767	0.903	rs12249634	chr10:872744	G/A	cg20503657	chr10:835505	NA	0.83	8.06	0.44	2.62e-14	Eosinophil percentage of granulocytes;
CESC	trans	rs747782	0.582	rs11039571	chr11:48207259	G/A	cg15704280	chr7:45808275	SEPT13	0.7	6.76	0.38	8.91e-11	Intraocular pressure;
CESC	cis	rs3008870	1.000	rs2755248	chr1:67492624	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.02	13.83	0.65	4.01e-33	Lymphocyte percentage of white cells;
CESC	cis	rs4822044	0.568	rs1883370	chr22:42143740	C/A	cg06634786	chr22:41940651	POLR3H	0.72	7.16	0.4	8.16e-12	Cannabis dependence symptom count;
CESC	cis	rs28374715	0.681	rs28728213	chr15:41653602	T/A	cg18705301	chr15:41695430	NDUFAF1	-0.84	-12.55	-0.61	1.19e-28	Ulcerative colitis;
CESC	cis	rs28489187	0.706	rs423105	chr1:85796427	A/G	cg16011679	chr1:85725395	C1orf52	0.47	5.6	0.33	5.46e-8	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	cis	rs2839186	0.770	rs2839171	chr21:47673247	C/T	cg05896524	chr21:47604654	C21orf56	-0.47	-6.16	-0.35	2.67e-9	Testicular germ cell tumor;
CESC	cis	rs7666738	0.830	rs7662389	chr4:99019892	G/A	cg17366294	chr4:99064904	C4orf37	0.61	8.82	0.48	1.58e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs8180040	0.966	rs6792488	chr3:47503349	C/T	cg27129171	chr3:47204927	SETD2	-0.63	-9.45	-0.5	1.86e-18	Colorectal cancer;
CESC	cis	rs875971	0.522	rs10807697	chr7:65416170	A/G	cg11764359	chr7:65958608	NA	0.68	8.78	0.47	2.05e-16	Aortic root size;
CESC	cis	rs798554	0.759	rs2644291	chr7:2890456	T/C	cg09658497	chr7:2847517	GNA12	-0.36	-5.14	-0.3	5.38e-7	Height;
CESC	cis	rs2292864	0.764	rs2292867	chr17:45357489	C/T	cg18085866	chr17:45331354	ITGB3	-0.56	-5.2	-0.3	4e-7	Left atrial antero-posterior diameter;
CESC	cis	rs9733	0.818	rs11204695	chr1:150657011	T/G	cg13175981	chr1:150552382	MCL1	0.62	9.22	0.49	9.44e-18	Tonsillectomy;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg14428669	chr9:114659192	UGCG	-0.44	-6.31	-0.36	1.19e-9	Fibrinogen levels;
CESC	cis	rs10129255	0.789	rs61997796	chr14:107222031	C/T	cg23076370	chr14:107095027	NA	-0.45	-5.31	-0.31	2.3e-7	Kawasaki disease;
CESC	cis	rs7666738	0.830	rs13116691	chr4:98929771	A/C	cg03467027	chr4:99064603	C4orf37	0.46	5.6	0.33	5.39e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11997175	0.598	rs4599769	chr8:33601425	T/C	ch.8.33884649F	chr8:33765107	NA	0.51	6.34	0.36	9.91e-10	Body mass index;
CESC	cis	rs6860806	0.507	rs2631372	chr5:131703578	C/G	cg18758796	chr5:131593413	PDLIM4	0.48	5.98	0.34	7.36e-9	Breast cancer;
CESC	cis	rs4474465	1.000	rs7927722	chr11:78210893	T/C	cg02023728	chr11:77925099	USP35	-0.4	-5.18	-0.3	4.3e-7	Alzheimer's disease (survival time);
CESC	cis	rs897984	0.609	rs35468353	chr16:31056433	A/G	cg00531865	chr16:30841666	NA	-0.39	-5.48	-0.32	9.95e-8	Dementia with Lewy bodies;
CESC	trans	rs7107217	1.000	rs1873872	chr11:129473993	A/T	cg01720705	chr1:231175557	FAM89A	0.43	6.0	0.35	6.29e-9	Breast cancer;Type 2 diabetes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01184139	chr5:180649358	TRIM41	0.6	6.86	0.39	4.99e-11	Gut microbiome composition (summer);
CESC	cis	rs4727027	0.899	rs11771339	chr7:148854132	A/T	cg23583168	chr7:148888333	NA	-0.81	-12.68	-0.61	4.05e-29	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs2204008	0.745	rs12146863	chr12:38502346	G/A	cg26384229	chr12:38710491	ALG10B	0.7	10.46	0.54	1.15e-21	Bladder cancer;
CESC	cis	rs116095464	0.558	rs113796397	chr5:246503	A/G	cg10591111	chr5:226296	SDHA	-0.53	-6.13	-0.35	3.16e-9	Breast cancer;
CESC	cis	rs2456568	0.531	rs7105060	chr11:93661268	C/A	cg26875233	chr11:93583750	C11orf90	-0.33	-5.84	-0.34	1.52e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
CESC	cis	rs1153858	1.000	rs72623915	chr15:45647433	C/T	cg14582100	chr15:45693742	SPATA5L1	0.42	5.95	0.34	8.45e-9	Homoarginine levels;
CESC	cis	rs13095912	0.752	rs13061708	chr3:185339984	T/C	cg11274856	chr3:185301563	NA	0.37	5.51	0.32	8.61e-8	Systolic blood pressure;
CESC	cis	rs9303401	0.614	rs17175663	chr17:57108437	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.98	12.1	0.6	4.08e-27	Cognitive test performance;
CESC	cis	rs7927592	0.956	rs6591341	chr11:68335478	C/T	cg20283391	chr11:68216788	NA	-0.49	-6.13	-0.35	3.23e-9	Total body bone mineral density;
CESC	cis	rs12479064	0.724	rs737094	chr2:100089078	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.6	-6.67	-0.38	1.5e-10	Chronic sinus infection;
CESC	cis	rs1568889	0.775	rs35243076	chr11:28250618	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.8	13.85	0.65	3.36e-33	Bipolar disorder;
CESC	cis	rs11264213	0.591	rs274732	chr1:36488199	T/G	cg27506609	chr1:36549197	TEKT2	-0.76	-6.97	-0.39	2.46e-11	Schizophrenia;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg26595336	chr15:82338380	MEX3B	-0.47	-6.34	-0.36	9.67e-10	Fibrinogen levels;
CESC	cis	rs12541635	0.966	rs4416800	chr8:106996677	T/C	cg10147462	chr8:107024639	NA	0.39	5.54	0.32	7.19e-8	Age of smoking initiation;
CESC	cis	rs7927592	0.731	rs488381	chr11:68291693	G/A	cg20283391	chr11:68216788	NA	0.44	5.53	0.32	7.51e-8	Total body bone mineral density;
CESC	cis	rs748404	0.697	rs473554	chr15:43568207	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.61	7.82	0.43	1.29e-13	Lung cancer;
CESC	cis	rs1153858	1.000	rs8042786	chr15:45703539	T/C	cg21132104	chr15:45694354	SPATA5L1	0.86	11.69	0.58	9.6e-26	Homoarginine levels;
CESC	cis	rs9486719	1.000	rs11752584	chr6:96884952	C/A	cg06623918	chr6:96969491	KIAA0776	-0.81	-8.29	-0.45	5.61e-15	Migraine;Coronary artery disease;
CESC	trans	rs35883536	1.000	rs2050472	chr1:101125560	T/C	cg16931499	chr17:42786676	DBF4B	0.42	6.14	0.35	3.05e-9	Monocyte count;
CESC	cis	rs7520050	0.897	rs4440807	chr1:46470878	T/C	cg24296786	chr1:45957014	TESK2	0.44	5.5	0.32	9.17e-8	Red blood cell count;Reticulocyte count;
CESC	cis	rs2842992	0.513	rs7759086	chr6:160193853	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.83	11.56	0.58	2.7e-25	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs9911578	0.835	rs723991	chr17:56482039	G/A	cg05425664	chr17:57184151	TRIM37	0.44	6.17	0.35	2.6e-9	Intelligence (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06503831	chr17:26634225	FLJ40504	-0.51	-6.09	-0.35	3.92e-9	Gut microbiome composition (summer);
CESC	cis	rs2455799	0.573	rs2654648	chr3:15775425	T/C	cg09340198	chr3:15902540	ANKRD28	-0.33	-5.12	-0.3	5.98e-7	Mean platelet volume;
CESC	cis	rs8020095	0.571	rs10141947	chr14:67542678	A/G	cg19548862	chr14:67692701	FAM71D	-0.51	-6.26	-0.36	1.57e-9	Depression (quantitative trait);
CESC	cis	rs854765	0.964	rs854813	chr17:18003845	C/T	cg16928487	chr17:17741425	SREBF1	0.57	9.57	0.51	7.75e-19	Total body bone mineral density;
CESC	cis	rs3733585	0.631	rs4697925	chr4:10124330	G/C	cg11266682	chr4:10021025	SLC2A9	-0.56	-10.04	-0.52	2.64e-20	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs4713118	0.662	rs149961	chr6:28015569	A/C	cg26335602	chr6:28129616	ZNF389	0.44	5.66	0.33	3.97e-8	Parkinson's disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg01184139	chr5:180649358	TRIM41	-0.46	-6.23	-0.36	1.79e-9	Fibrinogen levels;
CESC	cis	rs8070624	0.543	rs7219320	chr17:17880877	A/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.59	7.69	0.43	2.97e-13	Total body bone mineral density;
CESC	cis	rs832540	0.898	rs252890	chr5:56226410	T/C	cg14703610	chr5:56206110	C5orf35	0.53	7.12	0.4	1.01e-11	Coronary artery disease;
CESC	cis	rs3785574	0.927	rs2854183	chr17:61968002	C/T	cg07677032	chr17:61819896	STRADA	0.45	5.64	0.33	4.34e-8	Height;
CESC	cis	rs1801251	1.000	rs6714245	chr2:233580505	T/C	cg25237894	chr2:233734115	C2orf82	0.49	8.11	0.45	1.84e-14	Coronary artery disease;
CESC	cis	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.47	-6.56	-0.37	2.79e-10	Longevity;Endometriosis;
CESC	cis	rs2839186	0.559	rs2277826	chr21:47639492	C/G	cg12516959	chr21:47718080	NA	0.34	5.14	0.3	5.4e-7	Testicular germ cell tumor;
CESC	cis	rs1692580	0.846	rs377599	chr1:2164699	C/T	cg04315214	chr1:2043799	PRKCZ	-0.37	-5.31	-0.31	2.37e-7	Coronary artery disease;
CESC	cis	rs9911578	0.967	rs72628392	chr17:56506160	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	-0.38	-5.1	-0.3	6.62e-7	Intelligence (multi-trait analysis);
CESC	cis	rs6502050	0.835	rs67634087	chr17:80118168	C/T	cg11859384	chr17:80120422	CCDC57	-0.41	-5.71	-0.33	3.03e-8	Life satisfaction;
CESC	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg06873352	chr17:61820015	STRADA	0.73	12.96	0.62	4.25e-30	Prudent dietary pattern;
CESC	cis	rs17376456	1.000	rs17323433	chr5:93551028	G/A	cg21475434	chr5:93447410	FAM172A	0.86	7.53	0.42	7.93e-13	Diabetic retinopathy;
CESC	cis	rs9811920	0.809	rs6806323	chr3:99722564	C/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.4	-5.19	-0.3	4.27e-7	Axial length;
CESC	cis	rs8060686	0.516	rs7193701	chr16:68185160	A/G	cg01866162	chr16:67596514	CTCF	-0.46	-5.05	-0.3	8.11e-7	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs752010	0.695	rs11210508	chr1:42106935	A/G	cg06885757	chr1:42089581	HIVEP3	0.49	7.86	0.43	9.43e-14	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs4844614	0.904	rs6686325	chr1:207833357	G/A	cg21110645	chr1:207815933	NA	0.41	6.48	0.37	4.37e-10	LDL cholesterol;
CESC	trans	rs11098499	0.863	rs10013305	chr4:120450424	G/A	cg25214090	chr10:38739885	LOC399744	0.7	9.62	0.51	5.47e-19	Corneal astigmatism;
CESC	cis	rs2011503	1.000	rs4808205	chr19:19645493	T/G	cg11584989	chr19:19387371	SF4	0.56	6.29	0.36	1.33e-9	Bipolar disorder;
CESC	cis	rs9329221	0.537	rs6983332	chr8:9977918	A/G	cg21625330	chr8:9911636	MSRA	0.42	5.49	0.32	9.5e-8	Neuroticism;
CESC	cis	rs2242116	0.796	rs4587	chr3:46963502	T/C	cg02527881	chr3:46936655	PTH1R	-0.51	-7.13	-0.4	9.47e-12	Birth weight;
CESC	cis	rs6952808	0.501	rs3778999	chr7:2180885	G/A	cg04267008	chr7:1944627	MAD1L1	-0.58	-6.91	-0.39	3.66e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs7219021	1.000	rs72831853	chr17:46842575	A/T	cg16584676	chr17:46985605	UBE2Z	-0.68	-7.51	-0.42	9.12e-13	Schizophrenia or bipolar disorder;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg26926632	chr1:150848739	ARNT	-0.45	-6.05	-0.35	4.99e-9	Fibrinogen levels;
CESC	cis	rs79839061	0.563	rs55728587	chr4:843674	G/A	cg07828340	chr4:882639	GAK	1.09	8.29	0.45	5.76e-15	Intelligence (multi-trait analysis);
CESC	cis	rs3820068	0.608	rs12760450	chr1:16037282	G/A	cg13390004	chr1:15929781	NA	0.33	5.13	0.3	5.52e-7	Systolic blood pressure;
CESC	cis	rs2415984	0.579	rs10151988	chr14:46955203	C/T	cg14871534	chr14:47121158	RPL10L	-0.34	-5.27	-0.31	2.85e-7	Number of children ever born;
CESC	cis	rs796364	0.664	rs4673660	chr2:200915395	C/T	cg23649088	chr2:200775458	C2orf69	0.66	6.94	0.39	3.05e-11	Schizophrenia;
CESC	cis	rs10733682	0.659	rs4358894	chr9:129464802	C/G	cg00232160	chr9:129468157	NA	0.39	6.22	0.36	1.9e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg23034840	chr1:205782522	SLC41A1	-0.64	-7.82	-0.43	1.29e-13	Menarche (age at onset);
CESC	cis	rs6570726	0.935	rs12663211	chr6:145818427	G/A	cg23711669	chr6:146136114	FBXO30	0.81	12.04	0.59	6.44e-27	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs116095464	0.558	rs10058428	chr5:235608	A/G	cg22857025	chr5:266934	NA	-1.29	-18.85	-0.76	7.33e-51	Breast cancer;
CESC	cis	rs9768139	0.733	rs13309363	chr7:158122179	C/A	cg25566285	chr7:158114605	PTPRN2	0.49	8.05	0.44	2.9e-14	Calcium levels;
CESC	cis	rs2730245	1.000	rs2657345	chr7:158744169	T/C	cg15303052	chr7:158526867	ESYT2	0.42	5.12	0.3	5.86e-7	Height;
CESC	cis	rs6665290	0.558	rs1319103	chr1:227219314	A/G	cg10327440	chr1:227177885	CDC42BPA	-0.76	-11.29	-0.57	2.07e-24	Myeloid white cell count;
CESC	cis	rs9640161	0.830	rs17173682	chr7:150059602	A/G	cg17279839	chr7:150038598	RARRES2	0.41	5.31	0.31	2.33e-7	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs10870270	1.000	rs11146324	chr10:133767445	A/C	cg17892150	chr10:133769511	PPP2R2D	-0.86	-12.59	-0.61	8.22e-29	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs4665809	0.590	rs35615763	chr2:26468778	C/G	cg04944784	chr2:26401820	FAM59B	0.96	10.55	0.54	5.79e-22	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15947599	chr18:9478638	RALBP1	-0.59	-6.23	-0.36	1.84e-9	Gut microbiome composition (summer);
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg16678153	chr1:82265969	LPHN2	-0.47	-6.42	-0.37	6.24e-10	Thyroid stimulating hormone;
CESC	cis	rs938554	0.784	rs13131257	chr4:9981889	T/C	cg11266682	chr4:10021025	SLC2A9	0.36	5.06	0.3	7.84e-7	Blood metabolite levels;
CESC	trans	rs1814175	0.791	rs1722023	chr11:49908136	G/C	cg03929089	chr4:120376271	NA	-0.93	-16.26	-0.71	1.03e-41	Height;
CESC	cis	rs950776	0.518	rs12900783	chr15:78815523	G/A	cg06917634	chr15:78832804	PSMA4	0.79	11.88	0.59	2.16e-26	Sudden cardiac arrest;
CESC	trans	rs7849270	0.959	rs3124509	chr9:131896999	C/T	cg05583848	chr6:35265411	DEF6	0.45	6.26	0.36	1.53e-9	Blood metabolite ratios;
CESC	cis	rs2742417	0.603	rs2742395	chr3:45758595	A/G	cg04837898	chr3:45731254	SACM1L	-0.49	-6.49	-0.37	4.14e-10	Response to anti-depressant treatment in major depressive disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27152661	chr10:99052555	ARHGAP19	-0.66	-7.86	-0.43	9.47e-14	Gut microbiome composition (summer);
CESC	trans	rs10506458	0.915	rs17687426	chr12:63397900	G/C	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.32	-18.25	-0.75	9.19e-49	Hemostatic factors and hematological phenotypes;
CESC	cis	rs2073300	1.000	rs12626013	chr20:23442215	G/A	cg12062639	chr20:23401060	NAPB	0.91	6.41	0.37	6.71e-10	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs7833790	0.963	rs28823280	chr8:82777716	G/A	cg27398817	chr8:82754497	SNX16	0.55	6.34	0.36	1.01e-9	Diastolic blood pressure;
CESC	cis	rs9640161	0.783	rs1132261	chr7:150059987	G/A	cg17279839	chr7:150038598	RARRES2	0.43	5.43	0.32	1.3e-7	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs875971	0.660	rs801217	chr7:66010577	C/T	cg18876405	chr7:65276391	NA	-0.57	-7.63	-0.42	4.14e-13	Aortic root size;
CESC	cis	rs11997175	0.597	rs4472473	chr8:33610255	A/G	ch.8.33884649F	chr8:33765107	NA	0.54	6.88	0.39	4.27e-11	Body mass index;
CESC	cis	rs5769765	0.542	rs761878	chr22:50249677	A/G	cg02269571	chr22:50332266	NA	0.48	5.6	0.33	5.36e-8	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01618530	chr8:54755981	ATP6V1H	0.65	7.16	0.4	7.89e-12	Gut microbiome composition (summer);
CESC	cis	rs2073300	0.609	rs2281434	chr20:23378101	C/A	cg16736954	chr20:23401023	NAPB	0.8	6.25	0.36	1.67e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs9311474	1.000	rs6445358	chr3:52308845	C/G	cg07507251	chr3:52567010	NT5DC2	0.31	5.39	0.31	1.57e-7	Electroencephalogram traits;
CESC	cis	rs34779708	0.966	rs11010095	chr10:35395948	A/G	cg04310649	chr10:35416472	CREM	-0.53	-6.4	-0.37	7.11e-10	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs9649213	0.593	rs62478200	chr7:97980045	A/G	cg08684580	chr7:98029266	BAIAP2L1	-0.35	-5.8	-0.34	1.85e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs17799476	0.938	rs72808770	chr2:46361322	G/A	cg12428440	chr2:46370979	PRKCE	0.55	5.42	0.32	1.34e-7	Hemoglobin concentration;Hematocrit;
CESC	cis	rs4604732	0.527	rs12031949	chr1:247624463	G/T	cg12758973	chr1:247694275	LOC148824;OR2C3	0.51	6.4	0.37	6.94e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs2617583	0.967	rs2550947	chr5:1450506	T/C	cg07151155	chr5:1473589	LPCAT1	-0.36	-5.52	-0.32	7.96e-8	Breast cancer;
CESC	cis	rs11785400	0.793	rs9297970	chr8:143723386	C/T	cg10596483	chr8:143751796	JRK	0.42	5.36	0.31	1.77e-7	Schizophrenia;
CESC	cis	rs10504229	0.863	rs75954631	chr8:58166194	C/A	cg22535103	chr8:58192502	C8orf71	-0.95	-10.54	-0.54	6.39e-22	Developmental language disorder (linguistic errors);
CESC	cis	rs9814567	0.896	rs4435682	chr3:134344182	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.43	5.74	0.33	2.6e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs7927592	0.830	rs10896339	chr11:68302846	G/C	cg20283391	chr11:68216788	NA	-0.49	-6.23	-0.36	1.82e-9	Total body bone mineral density;
CESC	cis	rs933688	0.938	rs10942634	chr5:90658392	A/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.1	15.48	0.69	6.1e-39	Smoking behavior;
CESC	cis	rs7772486	0.790	rs2814879	chr6:146201743	T/C	cg23711669	chr6:146136114	FBXO30	0.9	13.27	0.63	3.71e-31	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4253772	0.550	rs6007819	chr22:46704916	C/G	cg00784671	chr22:46762841	CELSR1	-0.49	-5.67	-0.33	3.76e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs796364	0.951	rs11675980	chr2:201051150	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.62	-5.91	-0.34	1.05e-8	Schizophrenia;
CESC	cis	rs7116495	1.000	rs10793016	chr11:71755063	A/G	cg10381502	chr11:71823885	C11orf51	0.62	5.34	0.31	2.03e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs61759167	0.774	rs61759173	chr1:3097509	C/T	cg01961086	chr1:3086487	PRDM16	-0.35	-5.15	-0.3	5.19e-7	Motion sickness;
CESC	cis	rs17253792	0.822	rs10133962	chr14:56066088	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.85	6.13	0.35	3.15e-9	Putamen volume;
CESC	cis	rs514406	0.861	rs35581164	chr1:53271373	C/G	cg08859206	chr1:53392774	SCP2	-0.56	-7.35	-0.41	2.4e-12	Monocyte count;
CESC	cis	rs35110281	0.667	rs4819287	chr21:45120147	A/G	cg21573476	chr21:45109991	RRP1B	-0.57	-8.14	-0.45	1.52e-14	Mean corpuscular volume;
CESC	cis	rs780096	0.526	rs1647276	chr2:27688601	C/T	cg24768116	chr2:27665128	KRTCAP3	-0.3	-5.57	-0.32	6.2e-8	Total body bone mineral density;
CESC	cis	rs9309711	0.772	rs9752251	chr2:3489869	C/T	cg10845886	chr2:3471009	TTC15	-0.79	-10.42	-0.54	1.62e-21	Neurofibrillary tangles;
CESC	cis	rs7107174	1.000	rs2248407	chr11:77937800	G/A	cg02023728	chr11:77925099	USP35	0.46	6.55	0.37	2.9e-10	Testicular germ cell tumor;
CESC	cis	rs2243480	1.000	rs316317	chr7:65613637	G/T	cg13147721	chr7:65941812	NA	-0.97	-9.14	-0.49	1.7e-17	Diabetic kidney disease;
CESC	cis	rs8067354	0.574	rs1295923	chr17:57960436	A/G	cg13753209	chr17:57696993	CLTC	0.55	5.84	0.34	1.49e-8	Hemoglobin concentration;
CESC	cis	rs14403	1.000	rs55655818	chr1:243661222	G/T	cg21452805	chr1:244014465	NA	0.49	5.58	0.32	5.8e-8	Schizophrenia;
CESC	cis	rs9311474	0.659	rs1133415	chr3:52575831	G/A	cg17372223	chr3:52568218	NT5DC2	0.46	7.21	0.4	5.95e-12	Electroencephalogram traits;
CESC	cis	rs12971120	0.947	rs3764509	chr18:72167124	C/G	cg26446133	chr18:72167187	CNDP2	-0.74	-11.03	-0.56	1.55e-23	Refractive error;
CESC	cis	rs1559088	1.000	rs12985438	chr19:33559368	G/A	cg17764715	chr19:33622953	WDR88	0.47	5.78	0.33	2.13e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs4434138	0.568	rs6414569	chr3:52708075	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.61	8.8	0.48	1.78e-16	Intelligence (multi-trait analysis);
CESC	cis	rs854765	0.964	rs12950562	chr17:17995166	C/T	cg16928487	chr17:17741425	SREBF1	0.55	9.18	0.49	1.24e-17	Total body bone mineral density;
CESC	cis	rs870825	0.616	rs7680835	chr4:185652992	C/G	cg04058563	chr4:185651563	MLF1IP	-0.63	-7.15	-0.4	8.3e-12	Blood protein levels;
CESC	cis	rs6088580	0.584	rs2378203	chr20:32993846	A/T	cg08999081	chr20:33150536	PIGU	-0.64	-10.99	-0.56	2.09e-23	Glomerular filtration rate (creatinine);
CESC	cis	rs2760061	0.569	rs621631	chr1:228114728	A/G	cg01973587	chr1:228161476	NA	0.35	5.32	0.31	2.17e-7	Diastolic blood pressure;
CESC	cis	rs514406	0.893	rs1242317	chr1:53414766	T/C	cg25767906	chr1:53392781	SCP2	-0.43	-5.36	-0.31	1.77e-7	Monocyte count;
CESC	cis	rs2228479	0.867	rs11645970	chr16:89958118	G/A	cg00800038	chr16:89945340	TCF25	-0.87	-7.73	-0.43	2.3e-13	Skin colour saturation;
CESC	cis	rs1044826	0.692	rs169824	chr3:139235006	G/C	cg15131784	chr3:139108705	COPB2	-0.41	-5.04	-0.3	8.83e-7	Obesity-related traits;
CESC	cis	rs6835098	0.500	rs13112928	chr4:174158132	A/G	cg08422745	chr4:174089978	GALNT7	0.55	7.04	0.4	1.66e-11	Dementia and core Alzheimer's disease neuropathologic changes;
CESC	cis	rs7552404	0.731	rs1770887	chr1:76401812	A/G	cg03433033	chr1:76189801	ACADM	-0.57	-6.26	-0.36	1.59e-9	Blood metabolite levels;Acylcarnitine levels;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg25679743	chr19:42412463	NA	0.45	7.16	0.4	7.71e-12	Fibrinogen levels;
CESC	cis	rs8077577	0.747	rs7215678	chr17:18139793	A/C	cg16794390	chr17:18148240	FLII	-0.43	-6.28	-0.36	1.36e-9	Obesity-related traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21817075	chr14:105647734	NUDT14	0.56	6.31	0.36	1.17e-9	Gut microbiome composition (summer);
CESC	cis	rs9818941	0.824	rs7427551	chr3:157725242	C/T	cg08654915	chr3:157813417	NA	-0.45	-7.57	-0.42	6.11e-13	Height;
CESC	trans	rs677673	1.000	rs677673	chr20:10481772	A/T	cg16021678	chr13:55475951	NA	0.52	6.62	0.38	2.03e-10	Body mass index (change over time) in chronic obstructive pulmonary disease;
CESC	cis	rs3736485	0.934	rs114641722	chr15:51863572	G/A	cg08986416	chr15:51914746	DMXL2	-0.4	-5.12	-0.3	5.86e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs17095355	0.818	rs6584970	chr10:111847820	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.48	-5.5	-0.32	8.92e-8	Biliary atresia;
CESC	cis	rs7824557	0.767	rs3808509	chr8:11163256	G/T	cg21775007	chr8:11205619	TDH	0.49	7.14	0.4	8.87e-12	Retinal vascular caliber;
CESC	cis	rs13191362	0.507	rs2849527	chr6:163117932	G/T	cg21926612	chr6:163149169	PACRG;PARK2	0.57	6.91	0.39	3.58e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs8018808	0.967	rs176766	chr14:77865367	G/A	cg20045696	chr14:77926864	AHSA1	0.38	5.17	0.3	4.56e-7	Myeloid white cell count;
CESC	cis	rs13256369	0.951	rs12679360	chr8:8566269	G/T	cg17143192	chr8:8559678	CLDN23	-0.68	-8.26	-0.45	7.19e-15	Obesity-related traits;
CESC	cis	rs763121	0.853	rs2413546	chr22:39107001	G/A	cg14440974	chr22:39074834	NA	-0.42	-5.73	-0.33	2.69e-8	Menopause (age at onset);
CESC	cis	rs13418410	0.539	rs35866672	chr2:33842174	G/A	cg04131969	chr2:33951647	MYADML	-0.65	-7.95	-0.44	5.34e-14	Non-response to antidepressants and depression;
CESC	trans	rs4904167	0.841	rs7145105	chr14:84677705	C/A	cg06870609	chr15:89787223	FANCI	0.46	6.06	0.35	4.73e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs4819052	0.851	rs35871601	chr21:46675214	C/T	cg11663144	chr21:46675770	NA	-0.63	-9.84	-0.52	1.12e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs7618501	0.602	rs2071207	chr3:50159844	T/C	cg24110177	chr3:50126178	RBM5	0.55	7.61	0.42	4.8e-13	Intelligence (multi-trait analysis);
CESC	cis	rs3857067	0.967	rs964843	chr4:95032367	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.5	-7.61	-0.42	4.77e-13	QT interval;
CESC	cis	rs2250402	0.510	rs2898984	chr15:40324075	G/C	cg10636054	chr15:40330586	SRP14	0.9	6.95	0.39	2.79e-11	Corneal curvature;
CESC	cis	rs7998202	0.667	rs188166	chr13:113355498	T/C	cg02820901	chr13:113351484	ATP11A	0.65	5.78	0.33	2.05e-8	Glycated hemoglobin levels;
CESC	cis	rs9787249	0.957	rs7518431	chr1:40214944	C/T	cg19912559	chr1:40204330	PPIE	-0.41	-6.33	-0.36	1.06e-9	Blood protein levels;
CESC	cis	rs7666738	0.830	rs6823718	chr4:99063202	C/T	cg05340658	chr4:99064831	C4orf37	0.84	13.04	0.63	2.35e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9916302	0.904	rs9905432	chr17:37555918	C/A	cg15445000	chr17:37608096	MED1	-0.41	-6.74	-0.38	9.67e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs10911232	0.520	rs10797831	chr1:183036816	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.87	13.77	0.65	6.86e-33	Hypertriglyceridemia;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg12868349	chr11:71639594	RNF121;LOC100133315	-0.44	-6.35	-0.36	9.29e-10	Gambling;
CESC	cis	rs854765	0.583	rs7207043	chr17:17819188	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.56	7.99	0.44	4.08e-14	Total body bone mineral density;
CESC	trans	rs7618501	0.602	rs10049087	chr3:50123417	A/G	cg21659725	chr3:3221576	CRBN	-0.53	-7.36	-0.41	2.33e-12	Intelligence (multi-trait analysis);
CESC	cis	rs7662987	0.517	rs2851260	chr4:100033574	C/T	cg13256891	chr4:100009986	ADH5	0.75	8.03	0.44	3.29e-14	Smoking initiation;
CESC	cis	rs4862750	0.914	rs1863405	chr4:187874528	G/T	cg06074448	chr4:187884817	NA	0.35	5.14	0.3	5.41e-7	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs5753618	0.504	rs5753669	chr22:31905819	T/G	cg02404636	chr22:31891804	SFI1	0.43	5.9	0.34	1.1e-8	Colorectal cancer;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg07210466	chr3:33444388	UBP1	0.46	6.21	0.36	2.1e-9	Thyroid stimulating hormone;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11227541	chr1:84972317	GNG5;SPATA1	-0.6	-7.27	-0.41	4.04e-12	Gut microbiome composition (summer);
CESC	cis	rs10838687	0.800	rs1051006	chr11:47306585	C/T	cg25783544	chr11:47291846	MADD	0.54	6.3	0.36	1.24e-9	Proinsulin levels;
CESC	cis	rs55794721	0.509	rs4649085	chr1:25778832	G/A	cg27572855	chr1:25598939	RHD	0.49	8.31	0.45	4.97e-15	Plateletcrit;Mean corpuscular volume;
CESC	cis	rs9322193	0.923	rs2342857	chr6:150130673	G/A	cg05861140	chr6:150128134	PCMT1	-0.37	-5.33	-0.31	2.07e-7	Lung cancer;
CESC	cis	rs7089973	0.604	rs17663670	chr10:116596269	A/C	cg03647239	chr10:116582469	FAM160B1	-0.45	-5.62	-0.33	4.86e-8	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	trans	rs7319075	0.657	rs9533543	chr13:44173400	A/G	cg03288419	chr19:35225464	ZNF181	0.49	6.01	0.35	6.18e-9	Photic sneeze reflex;
CESC	cis	rs11252926	0.674	rs11598550	chr10:504778	A/C	cg03684893	chr10:554711	DIP2C	0.42	6.34	0.36	9.78e-10	Psychosis in Alzheimer's disease;
CESC	cis	rs4819052	0.851	rs35871601	chr21:46675214	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.47	5.88	0.34	1.23e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs3733585	0.605	rs4697708	chr4:10121189	A/G	cg05927159	chr4:10118984	WDR1	0.34	5.09	0.3	6.76e-7	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs8072100	1.000	rs8072100	chr17:45674687	A/T	cg08085267	chr17:45401833	C17orf57	0.44	5.87	0.34	1.29e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs7017914	0.967	rs7012404	chr8:71668698	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.2	-0.3	3.94e-7	Bone mineral density;
CESC	cis	rs6456156	0.692	rs9457270	chr6:167512928	A/G	cg07741184	chr6:167504864	NA	0.42	7.37	0.41	2.11e-12	Primary biliary cholangitis;
CESC	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg07092213	chr7:1199455	ZFAND2A	-0.46	-5.31	-0.31	2.27e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs4665809	1.000	rs4665816	chr2:26305094	G/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.68	-7.8	-0.43	1.43e-13	Gut microbiome composition (summer);
CESC	cis	rs6570726	0.577	rs403345	chr6:145845171	T/C	cg23711669	chr6:146136114	FBXO30	0.93	12.45	0.61	2.59e-28	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7949030	0.596	rs71490394	chr11:62370155	G/A	cg22862634	chr11:62369728	EML3;MTA2	0.6	8.14	0.45	1.58e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs896854	0.812	rs2340586	chr8:95969261	G/A	cg09323728	chr8:95962352	TP53INP1	-0.41	-9.06	-0.49	2.87e-17	Type 2 diabetes;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg16773294	chr8:55048378	MRPL15	-0.47	-6.56	-0.37	2.89e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs801193	1.000	rs6958520	chr7:66151453	T/C	cg10691866	chr7:65817282	TPST1	-0.31	-5.04	-0.3	8.79e-7	Aortic root size;
CESC	cis	rs4713118	0.513	rs149954	chr6:28035246	G/A	cg17221315	chr6:27791827	HIST1H4J	0.43	5.42	0.32	1.32e-7	Parkinson's disease;
CESC	cis	rs2380220	0.751	rs117986000	chr6:95923454	A/C	cg15832292	chr6:96025679	MANEA	-0.63	-5.59	-0.32	5.56e-8	Behavioural disinhibition (generation interaction);
CESC	cis	rs854765	0.583	rs11078404	chr17:17820487	A/T	cg09796270	chr17:17721594	SREBF1	0.42	5.95	0.34	8.29e-9	Total body bone mineral density;
CESC	cis	rs2243480	1.000	rs7787230	chr7:65629099	G/A	cg13147721	chr7:65941812	NA	0.97	9.19	0.49	1.2e-17	Diabetic kidney disease;
CESC	cis	rs4665809	0.549	rs7577896	chr2:26524493	C/T	cg26314531	chr2:26401878	FAM59B	0.6	5.52	0.32	8.02e-8	Gut microbiome composition (summer);
CESC	cis	rs7424096	0.527	rs4670637	chr2:37164857	T/G	cg14987922	chr2:37194071	STRN	0.43	5.36	0.31	1.8e-7	High light scatter reticulocyte percentage of red cells;
CESC	cis	rs10461617	0.617	rs1423623	chr5:56065575	A/G	cg22800045	chr5:56110881	MAP3K1	-0.58	-7.4	-0.41	1.84e-12	Type 2 diabetes;
CESC	cis	rs4665809	0.878	rs35709953	chr2:26334997	G/A	cg08470875	chr2:26401718	FAM59B	0.59	6.16	0.35	2.76e-9	Gut microbiome composition (summer);
CESC	cis	rs9892942	1	rs9892942	chr17:27178761	C/T	cg20469991	chr17:27169893	C17orf63	-0.44	-5.26	-0.31	2.97e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg01860753	chr1:206730586	RASSF5	0.49	6.11	0.35	3.52e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs7267979	0.816	rs3746337	chr20:25208272	C/T	cg08601574	chr20:25228251	PYGB	0.41	5.72	0.33	2.87e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs9303401	0.659	rs34382037	chr17:56643550	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.03	12.7	0.62	3.56e-29	Cognitive test performance;
CESC	cis	rs40363	0.951	rs72778117	chr16:3531827	T/C	cg00484396	chr16:3507460	NAT15	0.6	7.58	0.42	5.84e-13	Tuberculosis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00815862	chr16:88851914	FAM38A	0.58	6.54	0.37	3.2e-10	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10992590	chr2:130940487	SMPD4;FAM128B	0.54	6.3	0.36	1.2e-9	Gut microbiome composition (summer);
CESC	cis	rs858239	0.600	rs7799422	chr7:23128413	G/A	cg23682824	chr7:23144976	KLHL7	0.55	7.61	0.42	4.84e-13	Cerebrospinal fluid biomarker levels;
CESC	cis	rs7520050	0.966	rs11211241	chr1:46452683	T/A	cg03146154	chr1:46216737	IPP	-0.47	-6.03	-0.35	5.46e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs6088580	0.634	rs6119497	chr20:33012529	T/A	cg24642439	chr20:33292090	TP53INP2	0.53	6.95	0.39	2.87e-11	Glomerular filtration rate (creatinine);
CESC	trans	rs7246760	0.867	rs2336090	chr19:9879584	A/G	cg02900749	chr2:68251473	NA	-0.72	-6.61	-0.38	2.11e-10	Pursuit maintenance gain;
CESC	cis	rs1665050	0.534	rs8031213	chr15:59239897	A/G	cg05156742	chr15:59063176	FAM63B	0.48	6.08	0.35	4.08e-9	Atopic dermatitis;
CESC	cis	rs10504229	0.679	rs72649132	chr8:58054615	G/A	cg02725872	chr8:58115012	NA	-0.41	-5.95	-0.34	8.38e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs7937682	0.632	rs11214029	chr11:111761230	C/T	cg09085632	chr11:111637200	PPP2R1B	0.84	10.18	0.53	9.16e-21	Primary sclerosing cholangitis;
CESC	cis	rs6866344	0.697	rs6873150	chr5:178125704	G/A	cg03877680	chr5:178157825	ZNF354A	0.7	8.13	0.45	1.66e-14	Neutrophil percentage of white cells;
CESC	cis	rs2380220	0.808	rs2613551	chr6:95914740	G/A	cg15832292	chr6:96025679	MANEA	-0.65	-5.95	-0.34	8.46e-9	Behavioural disinhibition (generation interaction);
CESC	cis	rs6582630	0.502	rs4309219	chr12:38293584	A/G	cg26384229	chr12:38710491	ALG10B	0.64	9.48	0.5	1.53e-18	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs9649465	1.000	rs2109723	chr7:123325339	A/G	cg04330084	chr7:123175371	IQUB	-0.38	-5.16	-0.3	4.75e-7	Migraine;
CESC	cis	rs1538970	0.962	rs7532762	chr1:45864695	C/A	cg24296786	chr1:45957014	TESK2	-0.45	-5.45	-0.32	1.13e-7	Platelet count;
CESC	cis	rs9549367	0.713	rs1323315	chr13:113859658	T/C	cg18105134	chr13:113819100	PROZ	0.55	7.33	0.41	2.81e-12	Platelet distribution width;
CESC	cis	rs365132	1.000	rs353493	chr5:176432585	T/C	cg16309518	chr5:176445507	NA	-0.37	-5.35	-0.31	1.9e-7	Menarche and menopause (age at onset);Menopause (age at onset);
CESC	cis	rs2268241	0.938	rs17879003	chr21:34778527	C/T	cg14850771	chr21:34775459	IFNGR2	0.93	11.19	0.57	4.47e-24	Obesity-related traits;
CESC	cis	rs6732160	0.650	rs7560224	chr2:73406182	A/G	cg01422370	chr2:73384389	NA	0.45	7.7	0.43	2.8e-13	Intelligence (multi-trait analysis);
CESC	cis	rs2976388	0.556	rs4736323	chr8:143830359	C/T	cg24634471	chr8:143751801	JRK	-0.44	-5.08	-0.3	7.3e-7	Urinary tract infection frequency;
CESC	cis	rs10504229	0.953	rs67677367	chr8:58175264	T/G	cg14926445	chr8:58193284	C8orf71	-0.51	-5.47	-0.32	1.03e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs7560272	0.538	rs11126414	chr2:73932044	G/A	cg20560298	chr2:73613845	ALMS1	0.47	6.47	0.37	4.84e-10	Schizophrenia;
CESC	cis	rs3857067	0.806	rs12507575	chr4:95114920	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.6	-9.12	-0.49	1.97e-17	QT interval;
CESC	cis	rs992157	0.798	rs2382818	chr2:219155907	A/T	cg00012203	chr2:219082015	ARPC2	-0.74	-9.58	-0.51	7.54e-19	Colorectal cancer;
CESC	cis	rs9457247	0.561	rs916331	chr6:167470559	T/G	cg23791538	chr6:167370224	RNASET2	-0.52	-6.9	-0.39	3.81e-11	Crohn's disease;
CESC	cis	rs10504229	0.683	rs6999351	chr8:58127227	C/T	cg24829409	chr8:58192753	C8orf71	-0.59	-7.24	-0.41	4.79e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs3096299	0.702	rs2086824	chr16:89471246	G/T	cg08822215	chr16:89438651	ANKRD11	0.37	5.37	0.31	1.73e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs1005277	0.579	rs2474568	chr10:38383147	A/T	cg25427524	chr10:38739819	LOC399744	-0.67	-9.9	-0.52	7.2e-20	Extrinsic epigenetic age acceleration;
CESC	cis	rs1008375	0.966	rs2286773	chr4:17616214	C/A	cg04450456	chr4:17643702	FAM184B	0.37	5.3	0.31	2.47e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs1005277	0.540	rs11011351	chr10:38030525	A/G	cg25517755	chr10:38738941	LOC399744	-0.4	-5.14	-0.3	5.34e-7	Extrinsic epigenetic age acceleration;
CESC	cis	rs7666738	0.830	rs4699603	chr4:99056172	T/C	cg05340658	chr4:99064831	C4orf37	0.83	12.92	0.62	6.18e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1218582	0.772	rs10908445	chr1:154849590	A/G	cg24250549	chr1:154909240	PMVK	-0.62	-8.97	-0.48	5.67e-17	Prostate cancer;
CESC	cis	rs8053891	0.615	rs3794695	chr16:72097827	C/T	cg16558253	chr16:72132732	DHX38	-0.54	-6.34	-0.36	1.01e-9	Coronary artery disease;
CESC	cis	rs77697190	1.000	rs76097782	chr14:103842702	A/G	cg09975044	chr14:104007538	NA	-0.8	-5.15	-0.3	5.09e-7	Mean corpuscular hemoglobin;
CESC	cis	rs4253772	0.938	rs14842	chr22:46639457	A/T	cg00784671	chr22:46762841	CELSR1	-0.57	-5.61	-0.33	5.1e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs4595586	0.545	rs67985200	chr12:39386891	C/T	cg26384229	chr12:38710491	ALG10B	0.62	8.69	0.47	3.89e-16	Morning vs. evening chronotype;
CESC	cis	rs1790761	0.505	rs7927657	chr11:67346988	T/C	cg00290607	chr11:67383545	NA	-0.36	-5.33	-0.31	2.14e-7	Mean corpuscular volume;
CESC	trans	rs62103177	0.789	rs7242289	chr18:77603291	C/T	cg05926928	chr17:57297772	GDPD1	1.14	11.65	0.58	1.38e-25	Opioid sensitivity;
CESC	cis	rs1580019	0.844	rs1901202	chr7:32503724	A/T	cg06627557	chr7:32535165	LSM5;AVL9	0.89	12.61	0.61	7.03e-29	Cognitive ability;
CESC	cis	rs1799949	1.000	rs8176265	chr17:41213996	C/T	cg23758822	chr17:41437982	NA	1.03	15.1	0.68	1.32e-37	Menopause (age at onset);
CESC	cis	rs7086627	0.515	rs10887895	chr10:82210011	A/G	cg00277334	chr10:82204260	NA	-0.91	-15.92	-0.7	1.67e-40	Post bronchodilator FEV1;
CESC	cis	rs1448094	0.511	rs61930585	chr12:86158461	C/A	cg02569458	chr12:86230093	RASSF9	0.51	7.79	0.43	1.5700000000000001e-13	Major depressive disorder;
CESC	cis	rs4853012	0.775	rs12465641	chr2:74337715	A/G	cg01017244	chr2:74357527	NA	-0.48	-6.52	-0.37	3.48e-10	Gestational age at birth (maternal effect);
CESC	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg22535103	chr8:58192502	C8orf71	-0.84	-8.74	-0.47	2.73e-16	Developmental language disorder (linguistic errors);
CESC	cis	rs769267	0.965	rs4808938	chr19:19401218	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.42	5.33	0.31	2.07e-7	Tonsillectomy;
CESC	cis	rs2735413	0.958	rs1922611	chr16:78053121	C/T	cg04733911	chr16:78082701	NA	-0.41	-6.12	-0.35	3.29e-9	Systolic blood pressure (alcohol consumption interaction);
CESC	cis	rs7811142	1.000	rs11761725	chr7:100039815	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.77	6.5	0.37	3.97e-10	Platelet count;
CESC	cis	rs780096	0.546	rs35073769	chr2:27731376	C/T	cg21248554	chr2:27665150	KRTCAP3	-0.36	-7.15	-0.4	8.43e-12	Total body bone mineral density;
CESC	cis	rs4711336	1.000	rs11759396	chr6:33656654	C/G	cg14003231	chr6:33640908	ITPR3	0.32	5.44	0.32	1.22e-7	Height;
CESC	cis	rs644799	0.526	rs693172	chr11:95636618	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.54	7.18	0.4	7.07e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	trans	rs9399401	1.000	rs1040525	chr6:142703669	C/T	cg15730116	chr12:76953768	OSBPL8	-0.43	-6.22	-0.36	1.89e-9	Chronic obstructive pulmonary disease;
CESC	cis	rs9527	0.590	rs1926037	chr10:104878010	A/C	cg04362960	chr10:104952993	NT5C2	0.44	5.54	0.32	7.12e-8	Arsenic metabolism;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05306024	chr7:127292158	SND1	0.6	6.59	0.38	2.31e-10	Gut microbiome composition (summer);
CESC	cis	rs6733011	0.502	rs6542847	chr2:99573471	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.43	-5.4	-0.31	1.46e-7	Bipolar disorder;
CESC	cis	rs11792861	0.781	rs838835	chr9:111758590	A/G	cg13535736	chr9:111863775	C9orf5	0.4	5.42	0.32	1.31e-7	Menarche (age at onset);
CESC	cis	rs2019216	0.521	rs12449447	chr17:21888786	C/T	cg22648282	chr17:21454238	C17orf51	-0.42	-5.44	-0.32	1.24e-7	Pelvic organ prolapse;
CESC	cis	rs1005277	0.579	rs2021649	chr10:38392122	C/T	cg25427524	chr10:38739819	LOC399744	-0.66	-9.5	-0.5	1.29e-18	Extrinsic epigenetic age acceleration;
CESC	cis	rs1799949	1.000	rs11652332	chr17:41295489	G/A	cg25072359	chr17:41440525	NA	0.45	6.04	0.35	5.14e-9	Menopause (age at onset);
CESC	cis	rs6461049	0.765	rs4719432	chr7:2140330	A/G	cg04267008	chr7:1944627	MAD1L1	-0.51	-6.12	-0.35	3.44e-9	Schizophrenia;
CESC	cis	rs72781680	0.851	rs12612830	chr2:24134599	C/T	cg20701182	chr2:24300061	SF3B14	0.63	5.67	0.33	3.79e-8	Lymphocyte counts;
CESC	cis	rs10791323	0.536	rs4937842	chr11:133734542	C/G	cg03690763	chr11:133734501	NA	0.32	5.38	0.31	1.67e-7	Childhood ear infection;
CESC	cis	rs4595586	0.545	rs7970307	chr12:39380760	A/C	cg26384229	chr12:38710491	ALG10B	0.54	7.53	0.42	7.85e-13	Morning vs. evening chronotype;
CESC	cis	rs1775715	0.737	rs1541260	chr10:32105570	C/T	cg18675610	chr10:32216311	ARHGAP12	0.34	5.27	0.31	2.85e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.41	-5.28	-0.31	2.63e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs3785574	0.962	rs7219920	chr17:61811642	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.58	7.21	0.4	5.88e-12	Height;
CESC	cis	rs9457247	0.935	rs427824	chr6:167403918	T/G	cg23791538	chr6:167370224	RNASET2	-0.58	-8.27	-0.45	6.59e-15	Crohn's disease;
CESC	cis	rs7845219	0.544	rs7001535	chr8:95921090	C/G	cg09323728	chr8:95962352	TP53INP1	-0.32	-6.23	-0.36	1.8e-9	Type 2 diabetes;
CESC	cis	rs2839186	0.619	rs2187118	chr21:47611310	C/T	cg10351095	chr21:47802916	PCNT	-0.41	-5.21	-0.3	3.87e-7	Testicular germ cell tumor;
CESC	cis	rs7959452	0.590	rs10878974	chr12:69781528	C/G	cg14784868	chr12:69753453	YEATS4	0.84	13.21	0.63	6.15e-31	Blood protein levels;
CESC	cis	rs10979	0.679	rs2275345	chr6:143872960	G/A	cg25407410	chr6:143891975	LOC285740	-0.53	-7.62	-0.42	4.6e-13	Hypospadias;
CESC	cis	rs7680126	0.596	rs10020887	chr4:10140751	C/G	cg00071950	chr4:10020882	SLC2A9	-0.55	-6.19	-0.36	2.3e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	cis	rs13191362	0.872	rs56404230	chr6:163252863	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.7	6.67	0.38	1.48e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs3820068	0.705	rs11584209	chr1:15885041	G/T	cg17385448	chr1:15911702	AGMAT	0.38	5.79	0.34	1.95e-8	Systolic blood pressure;
CESC	cis	rs9308433	0.529	rs4655333	chr1:214493549	A/G	cg06198575	chr1:214491504	SMYD2	0.45	5.45	0.32	1.15e-7	IgG glycosylation;
CESC	cis	rs6968419	0.755	rs73452247	chr7:115893897	T/C	cg02561103	chr7:115862891	TES	-0.4	-5.26	-0.31	2.92e-7	Intraocular pressure;
CESC	cis	rs2228479	0.557	rs62056064	chr16:89903843	G/A	cg00800038	chr16:89945340	TCF25	-0.89	-6.89	-0.39	4.13e-11	Skin colour saturation;
CESC	cis	rs2540647	1.000	rs2540648	chr22:18967349	A/G	cg12798833	chr22:18958832	DGCR5	0.75	7.43	0.42	1.52e-12	Blood metabolite ratios;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg03987890	chr16:69420050	TERF2	-0.48	-6.13	-0.35	3.25e-9	Asthma;
CESC	cis	rs1552244	0.882	rs17050672	chr3:10025463	G/A	cg08888203	chr3:10149979	C3orf24	0.51	5.99	0.35	6.84e-9	Alzheimer's disease;
CESC	cis	rs1577917	0.958	rs12198876	chr6:86525476	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.51	-6.68	-0.38	1.41e-10	Response to antipsychotic treatment;
CESC	cis	rs7264396	0.635	rs2425166	chr20:34439391	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.85	-11.51	-0.58	3.81e-25	Total cholesterol levels;
CESC	cis	rs12541635	0.639	rs6469030	chr8:107030321	C/T	cg10147462	chr8:107024639	NA	0.44	6.5	0.37	3.98e-10	Age of smoking initiation;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg08491733	chr2:128051434	ERCC3	-0.48	-6.35	-0.36	9.34e-10	Fibrinogen levels;
CESC	cis	rs6120849	0.615	rs11167248	chr20:33538721	G/T	cg24642439	chr20:33292090	TP53INP2	0.69	6.83	0.39	5.7e-11	Protein C levels;
CESC	cis	rs853679	0.825	rs8180562	chr6:28141460	G/A	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.79	6.91	0.39	3.68e-11	Depression;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg13411962	chr8:28243934	ZNF395	-0.42	-6.04	-0.35	5.14e-9	Fibrinogen levels;
CESC	cis	rs10484885	0.877	rs17735389	chr6:90323139	G/T	cg13799429	chr6:90582589	CASP8AP2	-0.52	-5.29	-0.31	2.57e-7	QRS interval (sulfonylurea treatment interaction);
CESC	cis	rs7666738	0.830	rs3907021	chr4:99038668	C/T	cg17366294	chr4:99064904	C4orf37	0.61	8.78	0.47	2.13e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs637571	0.607	rs574586	chr11:65697083	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.72	9.83	0.52	1.18e-19	Eosinophil percentage of white cells;
CESC	cis	rs35110281	0.667	rs4819287	chr21:45120147	A/G	cg04455712	chr21:45112962	RRP1B	0.49	7.5	0.42	9.42e-13	Mean corpuscular volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18673825	chr12:121647177	P2RX4	-0.59	-7.32	-0.41	2.92e-12	Gut microbiome composition (summer);
CESC	cis	rs921968	0.528	rs35695178	chr2:219589164	C/T	cg02176678	chr2:219576539	TTLL4	-0.43	-7.63	-0.42	4.22e-13	Mean corpuscular hemoglobin concentration;
CESC	cis	rs889312	0.500	rs1867731	chr5:56132115	C/G	cg14703610	chr5:56206110	C5orf35	0.47	6.14	0.35	3.06e-9	Breast cancer;Breast cancer (early onset);
CESC	cis	rs1005277	0.579	rs176838	chr10:38371899	A/T	cg00409905	chr10:38381863	ZNF37A	0.43	5.51	0.32	8.69e-8	Extrinsic epigenetic age acceleration;
CESC	cis	rs6912958	0.967	rs6914299	chr6:88149176	T/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.57	-7.84	-0.43	1.12e-13	Monocyte percentage of white cells;
CESC	cis	rs2839186	0.500	rs13049893	chr21:47707054	C/T	cg10351095	chr21:47802916	PCNT	-0.49	-5.97	-0.34	7.5e-9	Testicular germ cell tumor;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18110965	chr2:62423083	B3GNT2	0.61	6.76	0.38	8.65e-11	Gut microbiome composition (summer);
CESC	cis	rs2124969	0.562	rs4665164	chr2:161070078	T/G	cg03641300	chr2:160917029	PLA2R1	-0.38	-5.31	-0.31	2.34e-7	Waist circumference adjusted for body mass index;
CESC	cis	rs3741404	0.895	rs1860368	chr11:63994692	T/C	cg18225595	chr11:63971243	STIP1	-0.66	-9.05	-0.49	3.16e-17	Platelet count;
CESC	cis	rs597539	0.616	rs473997	chr11:68639481	C/T	cg18350739	chr11:68623251	NA	-0.48	-7.02	-0.4	1.91e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs13064411	0.696	rs36054418	chr3:113204762	G/T	cg18753928	chr3:113234510	CCDC52	-0.52	-6.24	-0.36	1.73e-9	Response to simvastatin treatment (PCSK9 protein level change);
CESC	cis	rs4853012	0.941	rs4852329	chr2:74354544	A/G	cg05890377	chr2:74357713	NA	0.78	8.99	0.48	4.66e-17	Gestational age at birth (maternal effect);
CESC	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg11905131	chr22:24372483	LOC391322	0.75	10.61	0.55	3.9e-22	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs57221529	0.766	rs4081847	chr5:574072	C/T	cg16447950	chr5:562315	NA	-0.65	-6.74	-0.38	9.66e-11	Lung disease severity in cystic fibrosis;
CESC	cis	rs73206853	0.841	rs11065631	chr12:110778383	A/G	cg12870014	chr12:110450643	ANKRD13A	0.65	5.1	0.3	6.59e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs7927771	0.524	rs11039431	chr11:47872012	G/T	cg18512352	chr11:47633146	NA	0.35	5.38	0.31	1.6e-7	Subjective well-being;
CESC	cis	rs9815354	0.767	rs73071238	chr3:41992243	A/G	cg03022575	chr3:42003672	ULK4	0.67	5.88	0.34	1.23e-8	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs9910055	0.659	rs7212573	chr17:42254281	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.51	7.5	0.42	9.53e-13	Total body bone mineral density;
CESC	cis	rs1799949	0.896	rs33933393	chr17:41317432	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	8.55	0.47	9.8e-16	Menopause (age at onset);
CESC	cis	rs2576037	0.526	rs571181	chr18:44376399	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.57	-8.14	-0.45	1.55e-14	Personality dimensions;
CESC	cis	rs1799949	1.000	rs11658754	chr17:41292739	G/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.45	6.31	0.36	1.17e-9	Menopause (age at onset);
CESC	cis	rs6121246	0.954	rs73241710	chr20:30424956	G/A	cg13852791	chr20:30311386	BCL2L1	0.75	7.46	0.42	1.27e-12	Mean corpuscular hemoglobin;
CESC	cis	rs2991971	0.933	rs2356553	chr1:46009313	G/C	cg03146154	chr1:46216737	IPP	-0.44	-5.61	-0.33	5.09e-8	High light scatter reticulocyte count;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg07031794	chr2:26568949	SELI;GPR113	0.5	6.34	0.36	1e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs477895	0.838	rs12798333	chr11:64012784	G/A	cg18225595	chr11:63971243	STIP1	0.53	5.44	0.32	1.23e-7	Mean platelet volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03348573	chr5:133304316	C5orf15	0.53	6.05	0.35	5.02e-9	Gut microbiome composition (summer);
CESC	cis	rs2952156	0.876	rs2313171	chr17:37833842	T/C	cg00129232	chr17:37814104	STARD3	-0.73	-10.32	-0.54	3.36e-21	Asthma;
CESC	cis	rs875971	0.558	rs4433015	chr7:65639723	A/C	cg14393609	chr7:65229607	NA	-0.4	-5.3	-0.31	2.38e-7	Aortic root size;
CESC	cis	rs11031096	0.502	rs4910875	chr11:4047855	C/G	cg18678763	chr11:4115507	RRM1	-0.46	-6.15	-0.35	2.81e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	cis	rs684232	0.666	rs423887	chr17:593600	A/G	cg15660573	chr17:549704	VPS53	-0.64	-7.98	-0.44	4.3e-14	Prostate cancer;
CESC	cis	rs75477785	0.590	rs4844940	chr1:210190104	C/T	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.91	6.36	0.36	8.83e-10	Cleft lip with or without cleft palate;
CESC	cis	rs763014	0.898	rs8050792	chr16:656033	T/C	cg00908189	chr16:619842	PIGQ	0.62	8.66	0.47	4.86e-16	Height;
CESC	cis	rs892961	0.899	rs312911	chr17:75414585	A/C	cg05865280	chr17:75406074	SEPT9	0.65	13.79	0.65	5.73e-33	Airflow obstruction;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20809690	chr4:2757764	TNIP2	0.61	7.54	0.42	7.3e-13	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.830	rs34461023	chr4:99023751	C/T	cg05340658	chr4:99064831	C4orf37	0.82	12.87	0.62	9.16e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs12410462	0.581	rs77430808	chr1:227540880	C/T	cg10327440	chr1:227177885	CDC42BPA	-0.67	-5.56	-0.32	6.69e-8	Major depressive disorder;
CESC	cis	rs4919694	0.572	rs12243903	chr10:104906992	T/C	cg04362960	chr10:104952993	NT5C2	0.63	6.25	0.36	1.66e-9	Arsenic metabolism;
CESC	cis	rs4819052	1.000	rs2297285	chr21:46705621	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.92	-11.61	-0.58	1.81e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs1059312	0.808	rs11059921	chr12:129289919	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.85	-12.98	-0.62	3.74e-30	Systemic lupus erythematosus;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg07241146	chr10:134145514	LRRC27	0.44	6.12	0.35	3.38e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs7224668	0.647	rs9898133	chr17:79249997	C/T	cg05632623	chr17:78450055	NPTX1	-0.29	-5.1	-0.3	6.46e-7	IgG glycosylation;
CESC	cis	rs10088262	0.629	rs7827665	chr8:124804190	G/A	cg15047889	chr8:124780837	FAM91A1	-0.53	-6.72	-0.38	1.12e-10	Pancreatic cancer;
CESC	cis	rs11673344	0.528	rs573294	chr19:37410162	C/T	cg27390819	chr19:37464633	NA	-0.34	-5.12	-0.3	5.92e-7	Obesity-related traits;
CESC	cis	rs1005277	0.579	rs1740737	chr10:38499365	G/T	cg25517755	chr10:38738941	LOC399744	-0.49	-6.37	-0.36	8.45e-10	Extrinsic epigenetic age acceleration;
CESC	cis	rs10504229	0.600	rs6987243	chr8:58115406	T/C	cg24829409	chr8:58192753	C8orf71	-0.59	-7.36	-0.41	2.39e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs425277	0.959	rs77665022	chr1:2065958	C/T	cg04315214	chr1:2043799	PRKCZ	-0.41	-5.84	-0.34	1.56e-8	Height;
CESC	cis	rs12765878	1.000	rs11191865	chr10:105672842	G/A	cg11005552	chr10:105648138	OBFC1	0.37	5.27	0.31	2.84e-7	Coronary artery disease;
CESC	cis	rs9300255	0.722	rs12298826	chr12:123829028	A/G	cg00376283	chr12:123451042	ABCB9	-0.58	-6.75	-0.38	9.12e-11	Neutrophil percentage of white cells;
CESC	cis	rs7254192	0.625	rs736625	chr19:41265201	C/T	cg24958765	chr19:41283667	RAB4B	-0.4	-5.05	-0.3	8.22e-7	Post bronchodilator FEV1;
CESC	cis	rs959260	1.000	rs2053157	chr17:73378595	A/T	cg20590849	chr17:73267439	MIF4GD	-0.59	-6.78	-0.38	7.58e-11	Systemic lupus erythematosus;
CESC	cis	rs6456156	0.586	rs12198816	chr6:167483546	G/A	cg23791538	chr6:167370224	RNASET2	-0.54	-6.94	-0.39	3.07e-11	Primary biliary cholangitis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22685446	chr4:142142014	ZNF330	0.62	7.37	0.41	2.12e-12	Gut microbiome composition (summer);
CESC	cis	rs10752881	1.000	rs10911185	chr1:182971747	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.84	13.37	0.63	1.69e-31	Colorectal cancer;
CESC	cis	rs7552404	0.655	rs5745336	chr1:76273519	G/A	cg03433033	chr1:76189801	ACADM	0.61	6.28	0.36	1.39e-9	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs1552244	0.872	rs6792951	chr3:10119603	C/A	cg08888203	chr3:10149979	C3orf24	0.55	7.2	0.4	6.16e-12	Alzheimer's disease;
CESC	cis	rs4819052	0.635	rs2838808	chr21:46621106	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.51	6.06	0.35	4.54e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs1552244	0.872	rs35988239	chr3:10074145	G/T	cg00166722	chr3:10149974	C3orf24	0.48	5.35	0.31	1.93e-7	Alzheimer's disease;
CESC	cis	rs1059312	0.808	rs11059921	chr12:129289919	C/T	cg09035930	chr12:129282057	SLC15A4	0.67	9.06	0.49	2.87e-17	Systemic lupus erythematosus;
CESC	cis	rs3096299	0.967	rs753852	chr16:89446419	G/A	cg02187348	chr16:89574699	SPG7	0.56	7.25	0.41	4.68e-12	Multiple myeloma (IgH translocation);
CESC	cis	rs10504229	0.953	rs57669205	chr8:58172253	T/C	cg22535103	chr8:58192502	C8orf71	-1.05	-13.16	-0.63	8.66e-31	Developmental language disorder (linguistic errors);
CESC	cis	rs2933343	0.700	rs2630257	chr3:128644015	T/C	cg25356066	chr3:128598488	ACAD9	0.6	8.44	0.46	2.09e-15	IgG glycosylation;
CESC	cis	rs75477785	0.590	rs11119373	chr1:210122652	G/A	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.94	6.76	0.38	8.97e-11	Cleft lip with or without cleft palate;
CESC	cis	rs4665809	0.556	rs4665322	chr2:26434605	C/G	cg04944784	chr2:26401820	FAM59B	-0.97	-11.29	-0.57	2.22e-24	Gut microbiome composition (summer);
CESC	trans	rs875971	0.540	rs35510581	chr7:65578777	G/A	cg26939375	chr7:64535504	NA	-0.62	-8.29	-0.45	5.85e-15	Aortic root size;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg04238871	chr10:126431886	FAM53B	-0.44	-6.68	-0.38	1.4e-10	Gambling;
CESC	cis	rs10504229	0.679	rs12375445	chr8:58040082	A/G	cg24829409	chr8:58192753	C8orf71	-0.5	-6.25	-0.36	1.61e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs9814567	0.762	rs13070654	chr3:134219348	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.44	5.68	0.33	3.53e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs6951245	1.000	rs11764748	chr7:1094508	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.5	-5.76	-0.33	2.29e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs208520	0.690	rs1563929	chr6:66702108	G/A	cg07460842	chr6:66804631	NA	0.97	12.72	0.62	2.88e-29	Exhaled nitric oxide output;
CESC	cis	rs10504229	0.953	rs116564484	chr8:58172818	T/C	cg24829409	chr8:58192753	C8orf71	-0.75	-9.9	-0.52	7.27e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs2839186	0.807	rs2032226	chr21:47680352	G/A	cg10351095	chr21:47802916	PCNT	-0.51	-6.92	-0.39	3.35e-11	Testicular germ cell tumor;
CESC	cis	rs921968	0.591	rs3731877	chr2:219602499	G/C	cg02176678	chr2:219576539	TTLL4	-0.46	-8.24	-0.45	8.18e-15	Mean corpuscular hemoglobin concentration;
CESC	cis	rs1050631	0.564	rs1785934	chr18:33718326	A/C	cg25426722	chr18:33708991	SLC39A6;ELP2	0.59	8.21	0.45	9.51e-15	Esophageal squamous cell cancer (length of survival);
CESC	cis	rs9322193	0.962	rs3763162	chr6:150140810	A/G	cg07701084	chr6:150067640	NUP43	-0.44	-5.97	-0.34	7.45e-9	Lung cancer;
CESC	cis	rs2066819	0.786	rs111580405	chr12:56739557	A/G	cg26714650	chr12:56694279	CS	-1.39	-9.17	-0.49	1.33e-17	Psoriasis vulgaris;
CESC	cis	rs9457247	0.565	rs2038580	chr6:167456490	A/T	cg23791538	chr6:167370224	RNASET2	-0.54	-7.12	-0.4	9.98e-12	Crohn's disease;
CESC	cis	rs793571	0.543	rs4775087	chr15:58974904	T/C	cg05156742	chr15:59063176	FAM63B	0.59	8.05	0.44	2.82e-14	Schizophrenia;
CESC	trans	rs6073597	1.000	rs6031980	chr20:43714384	C/T	cg02099053	chr1:110880516	RBM15	0.43	6.23	0.36	1.79e-9	Positive affect;
CESC	cis	rs684232	0.666	rs1227028	chr17:573298	G/A	cg12384639	chr17:618140	VPS53	0.4	5.15	0.3	5.02e-7	Prostate cancer;
CESC	cis	rs6088580	0.634	rs6059887	chr20:33101102	C/G	cg06115741	chr20:33292138	TP53INP2	0.45	5.8	0.34	1.88e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs10493773	0.775	rs11161662	chr1:86185040	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.39	-5.41	-0.32	1.39e-7	Urate levels in overweight individuals;
CESC	trans	rs9693444	0.898	rs4732697	chr8:29519861	A/G	cg07049977	chr2:37458536	CEBPZ;C2orf56	-0.45	-6.52	-0.37	3.49e-10	Breast cancer;
CESC	cis	rs780096	0.546	rs2911712	chr2:27626945	A/T	cg02592271	chr2:27665507	KRTCAP3	-0.28	-5.66	-0.33	3.97e-8	Total body bone mineral density;
CESC	cis	rs6541297	0.699	rs4846916	chr1:230296492	G/A	cg20703242	chr1:230279135	GALNT2	0.61	6.92	0.39	3.31e-11	Coronary artery disease;
CESC	cis	rs11122272	0.766	rs2024879	chr1:231528638	A/G	cg06096015	chr1:231504339	EGLN1	0.43	6.15	0.35	2.9e-9	Hemoglobin concentration;
CESC	cis	rs2576037	0.526	rs4890699	chr18:44541029	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.69	10.88	0.56	4.85e-23	Personality dimensions;
CESC	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.48	-5.2	-0.3	4.05e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs6540559	0.808	rs11119358	chr1:210042456	T/C	cg10074409	chr1:209979377	IRF6	0.34	5.12	0.3	5.83e-7	Cleft lip with or without cleft palate;
CESC	cis	rs3096299	0.719	rs2911265	chr16:89511328	G/A	cg08392591	chr16:89556376	ANKRD11	0.55	7.48	0.42	1.11e-12	Multiple myeloma (IgH translocation);
CESC	cis	rs7259376	0.936	rs58170323	chr19:22539115	T/C	cg02657401	chr19:22469223	NA	-0.25	-5.05	-0.3	8.16e-7	Menopause (age at onset);
CESC	cis	rs10504229	0.516	rs4060631	chr8:57990757	G/A	cg22535103	chr8:58192502	C8orf71	-0.48	-5.89	-0.34	1.16e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs9649213	0.593	rs7789380	chr7:97956180	G/A	cg08684580	chr7:98029266	BAIAP2L1	-0.35	-5.65	-0.33	4.05e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs8077577	1.000	rs2015336	chr17:18073610	A/G	cg16794390	chr17:18148240	FLII	0.42	5.58	0.32	5.98e-8	Obesity-related traits;
CESC	cis	rs6963495	0.818	rs55691539	chr7:105165774	T/C	cg02135003	chr7:105160482	PUS7	-0.47	-5.59	-0.33	5.51e-8	Bipolar disorder (body mass index interaction);
CESC	cis	rs3020736	0.500	rs5996111	chr22:42493902	C/T	cg15557168	chr22:42548783	NA	0.44	6.1	0.35	3.82e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs727505	0.954	rs1568883	chr7:124710761	G/A	cg23710748	chr7:124431027	NA	-0.38	-5.98	-0.34	7.1e-9	Lewy body disease;
CESC	cis	rs853679	0.882	rs4713139	chr6:28092685	C/T	cg23372001	chr6:27791640	HIST1H4J	0.56	5.05	0.3	8.2e-7	Depression;
CESC	cis	rs7618915	0.547	rs34537256	chr3:52657472	A/G	cg17372223	chr3:52568218	NT5DC2	0.42	6.29	0.36	1.32e-9	Bipolar disorder;
CESC	cis	rs921968	0.541	rs6710383	chr2:219359685	T/G	cg02176678	chr2:219576539	TTLL4	0.5	8.98	0.48	5.22e-17	Mean corpuscular hemoglobin concentration;
CESC	cis	rs611744	0.647	rs4735053	chr8:109260776	A/G	cg21045802	chr8:109455806	TTC35	0.46	5.67	0.33	3.65e-8	Dupuytren's disease;
CESC	cis	rs9902453	0.619	rs1038088	chr17:28074563	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-10.22	-0.53	6.81e-21	Coffee consumption (cups per day);
CESC	cis	rs7937682	0.575	rs34695265	chr11:111719128	T/C	cg09085632	chr11:111637200	PPP2R1B	0.89	11.46	0.58	5.91e-25	Primary sclerosing cholangitis;
CESC	cis	rs6952808	0.893	rs35487994	chr7:1920171	G/A	cg02951883	chr7:2050386	MAD1L1	-0.47	-6.2	-0.36	2.19e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs9916302	0.904	rs9905432	chr17:37555918	C/A	cg00129232	chr17:37814104	STARD3	0.56	7.35	0.41	2.4e-12	Glomerular filtration rate (creatinine);
CESC	cis	rs3736485	0.966	rs4775960	chr15:51891698	C/G	cg08986416	chr15:51914746	DMXL2	-0.4	-5.07	-0.3	7.33e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs2011503	0.941	rs10422893	chr19:19372185	G/C	cg11584989	chr19:19387371	SF4	0.53	6.32	0.36	1.09e-9	Bipolar disorder;
CESC	cis	rs7208859	0.573	rs8078182	chr17:29149664	C/T	cg13385521	chr17:29058706	SUZ12P	0.53	5.04	0.3	8.47e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs17799476	0.938	rs56033319	chr2:46358886	G/C	cg12428440	chr2:46370979	PRKCE	0.53	5.23	0.31	3.48e-7	Hemoglobin concentration;Hematocrit;
CESC	cis	rs9322193	0.847	rs880246	chr6:150167108	G/A	cg13206674	chr6:150067644	NUP43	0.41	5.53	0.32	7.84e-8	Lung cancer;
CESC	cis	rs7264396	0.563	rs2425146	chr20:34355268	G/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.68	7.4	0.41	1.83e-12	Total cholesterol levels;
CESC	cis	rs9875589	0.509	rs2607757	chr3:14081948	A/G	cg19554555	chr3:13937349	NA	0.46	6.2	0.36	2.15e-9	Ovarian reserve;
CESC	cis	rs875971	0.895	rs7782806	chr7:65657897	C/T	cg11764359	chr7:65958608	NA	-0.78	-11.43	-0.57	7.35e-25	Aortic root size;
CESC	cis	rs4595586	0.545	rs4768505	chr12:39380338	C/A	cg26384229	chr12:38710491	ALG10B	0.54	7.53	0.42	7.85e-13	Morning vs. evening chronotype;
CESC	cis	rs2836974	0.897	rs7280375	chr21:40552408	C/T	cg11644478	chr21:40555479	PSMG1	-0.99	-16.65	-0.72	4.27e-43	Cognitive function;
CESC	cis	rs4253772	0.550	rs6007823	chr22:46706249	C/T	cg18190219	chr22:46762943	CELSR1	-0.6	-6.73	-0.38	1.07e-10	LDL cholesterol;Cholesterol, total;
CESC	cis	rs2732480	0.577	rs2732448	chr12:48730600	T/C	cg24011408	chr12:48396354	COL2A1	0.43	5.97	0.34	7.7e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs6499255	0.951	rs7196943	chr16:69592449	T/A	cg15192750	chr16:69999425	NA	0.54	6.3	0.36	1.24e-9	IgE levels;
CESC	cis	rs4665809	0.531	rs34081866	chr2:26475940	C/T	cg25036284	chr2:26402008	FAM59B	0.88	9.99	0.52	3.79e-20	Gut microbiome composition (summer);
CESC	cis	rs7474896	0.583	rs10740950	chr10:38003496	C/T	cg25427524	chr10:38739819	LOC399744	-0.47	-5.51	-0.32	8.62e-8	Obesity (extreme);
CESC	cis	rs2652834	1.000	rs2729833	chr15:63397044	G/A	cg05507819	chr15:63340323	TPM1	0.54	5.03	0.3	8.84e-7	HDL cholesterol;
CESC	cis	rs2425143	0.512	rs11699653	chr20:34622916	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.54	6.65	0.38	1.71e-10	Blood protein levels;
CESC	cis	rs6952808	0.825	rs34922657	chr7:1938655	C/T	cg08027265	chr7:2291960	NA	-0.34	-5.18	-0.3	4.33e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs9300255	0.722	rs12304248	chr12:123810425	C/T	cg00376283	chr12:123451042	ABCB9	-0.59	-6.87	-0.39	4.61e-11	Neutrophil percentage of white cells;
CESC	trans	rs6952808	0.789	rs35729895	chr7:1885069	C/T	cg24247370	chr13:99142703	STK24	-0.41	-6.15	-0.35	2.78e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs1707322	0.682	rs28508523	chr1:46189625	G/A	cg05343316	chr1:45956843	TESK2	0.48	6.09	0.35	3.85e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7412746	0.658	rs3843843	chr1:150918084	C/T	cg04414720	chr1:150670196	GOLPH3L	0.52	6.88	0.39	4.32e-11	Melanoma;
CESC	cis	rs6088590	0.965	rs910869	chr20:33292777	C/T	cg06115741	chr20:33292138	TP53INP2	0.61	7.4	0.41	1.83e-12	Coronary artery disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg15017043	chr7:100174944	LRCH4	0.48	6.54	0.37	3.14e-10	Fibrinogen levels;
CESC	cis	rs853679	0.517	rs4713146	chr6:28111536	A/T	cg18032046	chr6:28092343	ZSCAN16	-0.58	-6.54	-0.37	3.12e-10	Depression;
CESC	cis	rs7618501	0.602	rs2624853	chr3:50128893	A/G	cg24110177	chr3:50126178	RBM5	0.52	7.23	0.41	5.15e-12	Intelligence (multi-trait analysis);
CESC	cis	rs2070488	0.965	rs2300668	chr3:38540541	A/G	cg24069376	chr3:38537580	EXOG	-0.46	-8.63	-0.47	5.78e-16	Electrocardiographic conduction measures;
CESC	cis	rs3105593	1.000	rs3109880	chr15:50837812	G/A	cg08437265	chr15:50716283	USP8	0.43	5.62	0.33	4.77e-8	QT interval;
CESC	cis	rs801193	1.000	rs2707836	chr7:66160435	A/C	cg11764359	chr7:65958608	NA	0.69	9.1	0.49	2.27e-17	Aortic root size;
CESC	cis	rs3096299	0.933	rs2965823	chr16:89454924	G/A	cg16743903	chr16:89593216	SPG7	-0.43	-5.47	-0.32	1.05e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs9916302	0.904	rs801419	chr17:37466327	A/G	cg20243544	chr17:37824526	PNMT	-0.44	-5.29	-0.31	2.51e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs7523050	0.643	rs17621851	chr1:109400835	C/T	cg08274380	chr1:109419600	GPSM2	0.85	5.61	0.33	5.08e-8	Fat distribution (HIV);
CESC	trans	rs11039798	0.588	rs7116858	chr11:48543920	C/A	cg15704280	chr7:45808275	SEPT13	0.66	6.73	0.38	1.05e-10	Axial length;
CESC	cis	rs17711722	0.727	rs1880555	chr7:65432567	T/C	cg06456125	chr7:65229604	NA	0.45	5.94	0.34	8.73e-9	Calcium levels;
CESC	cis	rs1050631	0.564	rs1789549	chr18:33722425	A/G	cg25426722	chr18:33708991	SLC39A6;ELP2	0.59	8.21	0.45	9.51e-15	Esophageal squamous cell cancer (length of survival);
CESC	cis	rs2439831	0.702	rs16977724	chr15:44151299	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.66	5.66	0.33	3.88e-8	Lung cancer in ever smokers;
CESC	cis	rs8180040	0.676	rs13098228	chr3:47138253	A/G	cg27129171	chr3:47204927	SETD2	0.73	11.38	0.57	1.09e-24	Colorectal cancer;
CESC	cis	rs17376456	0.877	rs34595581	chr5:93369422	G/A	cg25358565	chr5:93447407	FAM172A	1.11	10.67	0.55	2.44e-22	Diabetic retinopathy;
CESC	cis	rs1348850	0.626	rs1901825	chr2:178225331	A/T	cg23306229	chr2:178417860	TTC30B	0.54	6.91	0.39	3.51e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs7216064	0.953	rs11079705	chr17:65835452	A/T	cg07042672	chr17:66097459	LOC651250	-0.54	-5.67	-0.33	3.73e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs10504229	0.683	rs55645894	chr8:58116145	A/G	cg02725872	chr8:58115012	NA	-0.45	-7.05	-0.4	1.52e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs9611519	0.603	rs9607764	chr22:41411804	G/C	cg03806693	chr22:41940476	POLR3H	-0.51	-6.04	-0.35	5.18e-9	Neuroticism;
CESC	cis	rs425277	0.583	rs12059660	chr1:2041461	C/T	cg12718519	chr1:2058417	PRKCZ	-0.25	-5.36	-0.31	1.81e-7	Height;
CESC	cis	rs3796352	1.000	rs71617204	chr3:53042951	G/A	cg12962167	chr3:53033115	SFMBT1	0.65	5.17	0.3	4.52e-7	Immune reponse to smallpox (secreted IL-2);
CESC	cis	rs853679	0.517	rs9380061	chr6:28132803	T/C	cg22143856	chr6:28129313	ZNF389	0.49	6.24	0.36	1.73e-9	Depression;
CESC	cis	rs6541297	0.941	rs2180078	chr1:230280513	T/C	cg20703242	chr1:230279135	GALNT2	0.73	11.12	0.56	8.07e-24	Coronary artery disease;
CESC	cis	rs9863	0.861	rs7973683	chr12:124449223	C/A	cg17562584	chr12:124393655	DNAH10	0.32	5.55	0.32	6.96e-8	White blood cell count;
CESC	cis	rs3858526	0.959	rs61876224	chr11:5952859	G/A	cg13902645	chr11:5959945	NA	-0.67	-8.06	-0.44	2.63e-14	DNA methylation (variation);
CESC	cis	rs2576037	0.583	rs9960463	chr18:44522808	T/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.5	-6.78	-0.38	7.97e-11	Personality dimensions;
CESC	cis	rs11252926	0.523	rs816596	chr10:548004	C/T	cg18196295	chr10:418757	DIP2C	0.5	6.78	0.38	7.76e-11	Psychosis in Alzheimer's disease;
CESC	cis	rs7772486	0.790	rs9390365	chr6:146235626	A/G	cg23711669	chr6:146136114	FBXO30	-0.94	-13.73	-0.64	9.31e-33	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs13223928	0.516	rs11763949	chr7:3150279	A/C	cg19214707	chr7:3157722	NA	-0.44	-6.05	-0.35	4.79e-9	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
CESC	cis	rs56116382	0.605	rs12715435	chr3:49338992	G/A	cg00383909	chr3:49044727	WDR6	0.58	5.32	0.31	2.26e-7	Intelligence (multi-trait analysis);High light scatter reticulocyte count;
CESC	cis	rs769267	1.000	rs2074089	chr19:19449603	G/A	cg03709012	chr19:19516395	GATAD2A	-0.96	-14.11	-0.66	4.09e-34	Tonsillectomy;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg01099470	chr2:131103656	IMP4	0.46	6.0	0.35	6.33e-9	Fibrinogen levels;
CESC	cis	rs514406	0.825	rs487453	chr1:53271225	T/C	cg25767906	chr1:53392781	SCP2	0.41	5.64	0.33	4.36e-8	Monocyte count;
CESC	cis	rs7296418	0.580	rs78455769	chr12:123856443	G/A	cg05973401	chr12:123451056	ABCB9	0.43	5.49	0.32	9.54e-8	Platelet count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13179130	chr1:24070416	TCEB3	0.65	6.91	0.39	3.5e-11	Gut microbiome composition (summer);
CESC	cis	rs10504229	0.683	rs11786843	chr8:58133629	T/C	cg22535103	chr8:58192502	C8orf71	-0.81	-9.14	-0.49	1.65e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs4689388	0.890	rs11732208	chr4:6292716	G/C	cg00701064	chr4:6280414	WFS1	0.7	12.4	0.61	3.83e-28	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs561341	1.000	rs1557731	chr17:30321567	T/G	cg00745463	chr17:30367425	LRRC37B	-0.68	-6.81	-0.39	6.34e-11	Hip circumference adjusted for BMI;
CESC	cis	rs2836974	0.897	rs6517513	chr21:40526878	A/G	cg27266027	chr21:40555129	PSMG1	0.49	6.01	0.35	6.02e-9	Cognitive function;
CESC	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg03452623	chr4:187889614	NA	-0.88	-16.16	-0.7	2.39e-41	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs9929218	1.000	rs12446407	chr16:68804068	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.62	-8.21	-0.45	9.51e-15	Colorectal cancer;
CESC	cis	rs9399137	0.507	rs13214669	chr6:135299959	T/C	cg24558204	chr6:135376177	HBS1L	0.7	9.49	0.5	1.39e-18	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	cis	rs12410462	1.000	rs12410243	chr1:227669474	A/G	cg23173402	chr1:227635558	NA	0.62	6.29	0.36	1.31e-9	Major depressive disorder;
CESC	cis	rs12142240	0.698	rs56284503	chr1:46847127	C/G	cg00530320	chr1:46809349	NSUN4	0.6	8.3	0.45	5.19e-15	Menopause (age at onset);
CESC	cis	rs2625529	0.824	rs4776581	chr15:72207071	G/A	cg16672083	chr15:72433130	SENP8	-0.39	-5.1	-0.3	6.54e-7	Red blood cell count;
CESC	cis	rs875971	0.638	rs801216	chr7:66011667	T/C	cg14393609	chr7:65229607	NA	-0.47	-6.3	-0.36	1.24e-9	Aortic root size;
CESC	cis	rs6426558	0.537	rs488104	chr1:227300277	G/A	cg10327440	chr1:227177885	CDC42BPA	0.47	5.84	0.34	1.48e-8	Neutrophil percentage of white cells;
CESC	cis	rs763121	0.813	rs4821807	chr22:39065582	A/G	cg06544989	chr22:39130855	UNC84B	0.5	8.55	0.46	1.02e-15	Menopause (age at onset);
CESC	cis	rs60843830	1.000	rs7605824	chr2:280819	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	-0.89	-12.02	-0.59	7.41e-27	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs734999	0.588	rs2985859	chr1:2532416	T/C	cg18854424	chr1:2615690	NA	-0.28	-5.34	-0.31	1.99e-7	Ulcerative colitis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10345337	chr14:65569751	MAX	-0.6	-7.21	-0.4	5.82e-12	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01796143	chr1:236687575	LGALS8	0.55	6.05	0.35	4.97e-9	Gut microbiome composition (summer);
CESC	trans	rs694739	0.628	rs508168	chr11:64135435	G/A	cg01888411	chr11:34378293	ABTB2	0.4	6.01	0.35	6e-9	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CESC	trans	rs6991952	0.845	rs7822766	chr8:25742279	A/T	cg06620762	chr15:76136437	UBE2Q2	-0.49	-6.16	-0.35	2.68e-9	Inguinal hernia;
CESC	cis	rs7666738	0.830	rs34671152	chr4:98978177	C/T	cg03467027	chr4:99064603	C4orf37	0.43	5.4	0.31	1.49e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2635047	0.601	rs2635052	chr18:44650607	C/G	cg19077165	chr18:44547161	KATNAL2	-0.37	-5.04	-0.3	8.63e-7	Educational attainment;
CESC	cis	rs6088590	0.965	rs6087619	chr20:33288511	C/G	cg08999081	chr20:33150536	PIGU	0.59	9.11	0.49	2.13e-17	Coronary artery disease;
CESC	cis	rs6502050	0.835	rs12450189	chr17:80095128	A/C	cg01763666	chr17:80159506	CCDC57	-0.37	-5.1	-0.3	6.61e-7	Life satisfaction;
CESC	cis	rs6089584	0.706	rs6089625	chr20:60620622	T/C	cg24733560	chr20:60626293	TAF4	0.46	6.62	0.38	1.97e-10	Body mass index;
CESC	cis	rs28374715	0.562	rs8036686	chr15:41550333	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.52	-7.4	-0.41	1.77e-12	Ulcerative colitis;
CESC	cis	rs17401966	0.867	rs61775872	chr1:10279308	T/C	cg15208524	chr1:10270712	KIF1B	0.42	5.45	0.32	1.17e-7	Hepatocellular carcinoma;
CESC	cis	rs7811142	0.830	rs28495773	chr7:99943583	A/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.05	10.54	0.54	6.46e-22	Platelet count;
CESC	trans	rs7178375	0.678	rs34678577	chr15:31177465	A/C	cg04373760	chr16:53404718	NA	0.49	6.42	0.37	6.37e-10	Hypertriglyceridemia;
CESC	cis	rs7605827	0.897	rs4459705	chr2:15526584	C/T	cg19274914	chr2:15703543	NA	0.35	6.27	0.36	1.43e-9	Educational attainment (years of education);
CESC	cis	rs9300255	0.739	rs4759371	chr12:123742563	T/C	cg19016782	chr12:123741754	C12orf65	-0.48	-6.9	-0.39	3.71e-11	Neutrophil percentage of white cells;
CESC	cis	rs7103648	0.695	rs11039290	chr11:47572279	G/A	cg20307385	chr11:47447363	PSMC3	0.82	11.97	0.59	1.09e-26	Diastolic blood pressure;Systolic blood pressure;
CESC	cis	rs9354308	0.933	rs2802063	chr6:66564148	T/C	cg07460842	chr6:66804631	NA	0.67	7.56	0.42	6.71e-13	Metabolite levels;
CESC	cis	rs9487051	0.872	rs9372211	chr6:109609648	C/T	cg12927641	chr6:109611667	NA	-0.43	-6.7	-0.38	1.22e-10	Reticulocyte fraction of red cells;
CESC	cis	rs7618915	0.547	rs34215106	chr3:52659124	T/C	cg17372223	chr3:52568218	NT5DC2	0.42	6.35	0.36	9.4e-10	Bipolar disorder;
CESC	cis	rs17253792	0.822	rs76472022	chr14:56053660	C/T	cg01858014	chr14:56050164	KTN1	-0.97	-7.15	-0.4	8.64e-12	Putamen volume;
CESC	cis	rs875971	0.660	rs3857686	chr7:66036191	C/T	cg25985355	chr7:65971099	NA	0.33	5.52	0.32	7.94e-8	Aortic root size;
CESC	trans	rs11638815	0.954	rs11635476	chr15:83339500	A/G	cg25333056	chr10:135107159	TUBGCP2	-0.46	-6.05	-0.35	4.9e-9	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;
CESC	cis	rs1881797	0.932	rs4551631	chr1:247667663	C/T	cg11166453	chr1:247681781	NA	-0.52	-6.86	-0.39	4.86e-11	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs6502050	0.699	rs9901808	chr17:80107814	C/T	cg11859384	chr17:80120422	CCDC57	-0.38	-5.11	-0.3	6.16e-7	Life satisfaction;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg15433164	chr3:25824899	NGLY1	0.42	6.08	0.35	4.15e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg10191684	chr8:22423014	SORBS3	-0.45	-6.35	-0.36	9.12e-10	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs3126085	0.736	rs11581433	chr1:152283236	T/C	cg03465714	chr1:152285911	FLG	0.5	5.71	0.33	2.96e-8	Atopic dermatitis;
CESC	cis	rs561341	0.883	rs1034627	chr17:30219569	C/T	cg13647721	chr17:30228624	UTP6	0.54	5.29	0.31	2.53e-7	Hip circumference adjusted for BMI;
CESC	cis	rs9916302	0.904	rs8079560	chr17:37497661	C/T	cg07936489	chr17:37558343	FBXL20	0.81	11.8	0.59	4.01e-26	Glomerular filtration rate (creatinine);
CESC	cis	rs72781680	0.851	rs72796397	chr2:24178211	T/A	cg08917208	chr2:24149416	ATAD2B	0.94	8.58	0.47	7.87e-16	Lymphocyte counts;
CESC	cis	rs3768617	0.811	rs4285667	chr1:182970225	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.65	9.01	0.48	4.1e-17	Fuchs's corneal dystrophy;
CESC	cis	rs17253792	0.822	rs79921041	chr14:56090779	T/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.79	5.91	0.34	1.06e-8	Putamen volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12728516	chr1:155197152	GBAP1	-0.6	-7.38	-0.41	2e-12	Gut microbiome composition (summer);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg25533220	chr19:2328480	SPPL2B;LSM7	0.5	6.46	0.37	4.89e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs1448094	0.511	rs61930585	chr12:86158461	C/A	cg00310523	chr12:86230176	RASSF9	0.35	5.45	0.32	1.14e-7	Major depressive disorder;
CESC	cis	rs9322193	0.923	rs9480031	chr6:150080011	A/C	cg13206674	chr6:150067644	NUP43	0.46	6.52	0.37	3.5e-10	Lung cancer;
CESC	cis	rs873946	0.648	rs12783354	chr10:134557235	T/A	cg27286337	chr10:134555280	INPP5A	0.68	7.64	0.42	4.05e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg24642844	chr7:1081250	C7orf50	-0.77	-9.65	-0.51	4.31e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs9914988	0.887	rs4795464	chr17:27146497	G/C	cg20469991	chr17:27169893	C17orf63	-0.48	-5.25	-0.31	3.18e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CESC	cis	rs597539	0.652	rs559032	chr11:68710847	G/T	cg01988459	chr11:68622903	NA	-0.46	-6.57	-0.37	2.64e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs7086627	0.515	rs7078254	chr10:82212193	C/T	cg00277334	chr10:82204260	NA	-0.91	-15.67	-0.69	1.25e-39	Post bronchodilator FEV1;
CESC	cis	rs1552244	0.882	rs13062917	chr3:10017032	T/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.76	-9.64	-0.51	4.86e-19	Alzheimer's disease;
CESC	cis	rs6493487	0.512	rs17521789	chr15:51271177	G/A	cg02338191	chr15:51200825	AP4E1	0.61	5.58	0.32	6.04e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs4308124	0.708	rs67816163	chr2:111963310	A/G	cg04571233	chr2:111982156	NA	-0.64	-7.06	-0.4	1.47e-11	Vitiligo;
CESC	cis	rs425277	1.000	rs74877653	chr1:2065949	C/T	cg24578937	chr1:2090814	PRKCZ	0.53	8.95	0.48	6.35e-17	Height;
CESC	cis	rs875971	0.660	rs10950044	chr7:66042976	A/G	cg06456125	chr7:65229604	NA	-0.4	-5.15	-0.3	5.11e-7	Aortic root size;
CESC	cis	rs10504229	0.610	rs7840469	chr8:58146992	C/T	cg22535103	chr8:58192502	C8orf71	-0.71	-8.43	-0.46	2.21e-15	Developmental language disorder (linguistic errors);
CESC	trans	rs116095464	0.558	rs55833259	chr5:286728	G/A	cg00938859	chr5:1591904	SDHAP3	0.72	6.62	0.38	2.04e-10	Breast cancer;
CESC	cis	rs8018808	0.935	rs11159262	chr14:77928735	A/G	cg20045696	chr14:77926864	AHSA1	0.43	5.9	0.34	1.13e-8	Myeloid white cell count;
CESC	cis	rs9457247	0.967	rs1794696	chr6:167396174	T/C	cg25258033	chr6:167368657	RNASET2	0.38	5.79	0.33	2.01e-8	Crohn's disease;
CESC	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	22.35	0.81	6.51e-63	Prudent dietary pattern;
CESC	cis	rs7799006	0.929	rs35629140	chr7:2257171	G/C	cg08027265	chr7:2291960	NA	-0.5	-7.67	-0.43	3.19e-13	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs4700695	0.545	rs253275	chr5:65509809	A/G	cg21114390	chr5:65439923	SFRS12	-0.5	-5.89	-0.34	1.15e-8	Facial morphology (factor 19);
CESC	cis	rs4604732	0.536	rs12049066	chr1:247642655	C/T	cg12758973	chr1:247694275	LOC148824;OR2C3	0.41	5.41	0.32	1.4e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs2228479	0.850	rs57267516	chr16:89903552	G/A	cg06558623	chr16:89946397	TCF25	0.98	7.35	0.41	2.45e-12	Skin colour saturation;
CESC	cis	rs10504229	0.679	rs11786328	chr8:58039269	A/G	cg21724239	chr8:58056113	NA	0.58	5.16	0.3	4.75e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs9894429	0.646	rs9905639	chr17:79614154	A/G	cg21984481	chr17:79567631	NPLOC4	-0.36	-5.6	-0.33	5.23e-8	Eye color traits;
CESC	cis	rs2011503	0.941	rs2315023	chr19:19413393	C/T	cg11584989	chr19:19387371	SF4	0.64	7.68	0.43	3.04e-13	Bipolar disorder;
CESC	cis	rs10887741	0.646	rs1358864	chr10:89426630	A/C	cg13926569	chr10:89418898	PAPSS2	0.48	7.39	0.41	1.97e-12	Exercise (leisure time);
CESC	cis	rs1862618	0.853	rs832565	chr5:56150803	T/G	cg24531977	chr5:56204891	C5orf35	-0.88	-11.06	-0.56	1.21e-23	Initial pursuit acceleration;
CESC	cis	rs1564271	0.553	rs9334138	chr10:26978929	G/A	cg13837822	chr10:26931731	LOC731789	0.45	6.91	0.39	3.55e-11	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;
CESC	cis	rs2204008	0.775	rs11514370	chr12:38305566	G/A	cg26384229	chr12:38710491	ALG10B	0.66	9.71	0.51	2.92e-19	Bladder cancer;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg00613399	chr15:89010912	MRPL46;MRPS11	-0.43	-6.0	-0.35	6.63e-9	Gambling;
CESC	cis	rs963731	0.649	rs2123876	chr2:39255873	C/G	cg04010122	chr2:39346883	SOS1	-0.74	-5.09	-0.3	6.9e-7	Corticobasal degeneration;
CESC	cis	rs7618915	0.547	rs33967311	chr3:52683864	G/T	cg18404041	chr3:52824283	ITIH1	-0.37	-6.32	-0.36	1.12e-9	Bipolar disorder;
CESC	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	22.16	0.81	2.75e-62	Prudent dietary pattern;
CESC	cis	rs2415984	0.600	rs2084823	chr14:46966454	C/G	cg14871534	chr14:47121158	RPL10L	0.35	5.32	0.31	2.19e-7	Number of children ever born;
CESC	cis	rs9894429	0.966	rs6565601	chr17:79580173	C/T	cg21984481	chr17:79567631	NPLOC4	-0.49	-8.04	-0.44	2.97e-14	Eye color traits;
CESC	cis	rs9486715	1.000	rs11153085	chr6:97066355	A/T	cg18709589	chr6:96969512	KIAA0776	-0.46	-6.48	-0.37	4.56e-10	Headache;
CESC	cis	rs6570726	0.791	rs414600	chr6:145879606	G/A	cg23711669	chr6:146136114	FBXO30	1.03	16.03	0.7	6.76e-41	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7193541	0.682	rs28681530	chr16:74682496	C/T	cg05580060	chr16:74700937	RFWD3	-0.49	-6.3	-0.36	1.27e-9	Multiple myeloma;
CESC	cis	rs2599510	0.703	rs58852184	chr2:32729763	A/T	cg02381751	chr2:32503542	YIPF4	0.5	6.32	0.36	1.12e-9	Interleukin-18 levels;
CESC	cis	rs6547741	1.000	rs4666007	chr2:27856495	T/C	cg21248554	chr2:27665150	KRTCAP3	0.25	5.3	0.31	2.42e-7	Oral cavity cancer;
CESC	cis	rs13102973	1.000	rs13112665	chr4:135898581	C/A	cg14419869	chr4:135874104	NA	0.33	5.1	0.3	6.62e-7	Subjective well-being;
CESC	cis	rs2228479	0.850	rs11646766	chr16:89838578	A/T	cg00800038	chr16:89945340	TCF25	-0.92	-7.64	-0.42	4.02e-13	Skin colour saturation;
CESC	cis	rs2842992	0.872	rs2758315	chr6:160158640	T/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.76	9.6	0.51	6.23e-19	Age-related macular degeneration (geographic atrophy);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01832569	chr1:171711313	VAMP4	0.51	6.01	0.35	6e-9	Gut microbiome composition (summer);
CESC	cis	rs17376456	0.877	rs10072592	chr5:93405989	C/G	cg21475434	chr5:93447410	FAM172A	0.87	7.47	0.42	1.17e-12	Diabetic retinopathy;
CESC	cis	rs56046484	0.956	rs35885781	chr15:85591083	A/T	cg08123816	chr15:85640762	PDE8A	-0.5	-6.21	-0.36	2.05e-9	Testicular germ cell tumor;
CESC	cis	rs9581857	0.556	rs9579085	chr13:28041039	G/A	cg01674679	chr13:27998804	GTF3A	-0.56	-5.93	-0.34	9.2e-9	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
CESC	cis	rs637571	0.544	rs56239996	chr11:65730003	A/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.73	10.26	0.53	5.13e-21	Eosinophil percentage of white cells;
CESC	cis	rs3767633	0.925	rs4657103	chr1:161740483	G/T	cg09175582	chr1:161736000	ATF6	0.8	6.58	0.37	2.49e-10	IgG glycosylation;
CESC	cis	rs561341	0.941	rs72825736	chr17:30330286	G/A	cg19193384	chr17:30244184	NA	-0.7	-6.62	-0.38	2e-10	Hip circumference adjusted for BMI;
CESC	cis	rs2404602	0.622	rs11632365	chr15:77139080	G/A	cg00316803	chr15:76480434	C15orf27	0.43	5.76	0.33	2.34e-8	Blood metabolite levels;
CESC	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	7.66	0.43	3.49e-13	Prudent dietary pattern;
CESC	cis	rs4523957	0.757	rs216208	chr17:2195146	T/A	cg16513277	chr17:2031491	SMG6	0.57	7.49	0.42	9.97e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs7666738	0.791	rs11097601	chr4:98960103	C/T	cg03467027	chr4:99064603	C4orf37	0.44	5.57	0.32	6.41e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6748734	1.000	rs11893118	chr2:241828308	C/G	cg04034577	chr2:241836375	C2orf54	-0.52	-9.33	-0.5	4.44e-18	Urinary metabolites;
CESC	cis	rs9682041	0.696	rs16855034	chr3:170097842	C/G	cg11886554	chr3:170076028	SKIL	0.7	6.5	0.37	3.93e-10	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CESC	cis	rs7116495	0.881	rs6592451	chr11:71674937	G/A	cg10381502	chr11:71823885	C11orf51	-0.68	-5.67	-0.33	3.64e-8	Severe influenza A (H1N1) infection;
CESC	cis	rs1728785	0.901	rs1631910	chr16:68603335	G/A	cg02972257	chr16:68554789	NA	-0.59	-6.76	-0.38	8.82e-11	Ulcerative colitis;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg21989094	chr19:39421295	MRPS12;SARS2	0.52	6.66	0.38	1.56e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs9916302	0.904	rs588193	chr17:37440439	A/C	cg20243544	chr17:37824526	PNMT	-0.45	-5.53	-0.32	7.69e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs2295359	0.892	rs2064689	chr1:67653010	G/A	cg03340356	chr1:67600835	NA	0.32	5.21	0.31	3.73e-7	Psoriasis;
CESC	cis	rs12477438	0.765	rs1453564	chr2:99564428	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.65	-8.75	-0.47	2.56e-16	Chronic sinus infection;
CESC	cis	rs17711722	0.528	rs73138179	chr7:65294482	G/T	cg26939375	chr7:64535504	NA	0.66	8.83	0.48	1.42e-16	Calcium levels;
CESC	trans	rs1814175	0.616	rs1851848	chr11:49992254	G/C	cg03929089	chr4:120376271	NA	-0.91	-15.15	-0.68	9.3e-38	Height;
CESC	cis	rs7659604	0.539	rs11098648	chr4:122759872	C/T	cg06713675	chr4:122721982	EXOSC9	-0.51	-6.96	-0.39	2.71e-11	Type 2 diabetes;
CESC	cis	rs4969178	0.965	rs3817295	chr17:76394526	T/A	cg20026190	chr17:76395443	PGS1	0.49	7.91	0.44	6.98e-14	HDL cholesterol levels;
CESC	cis	rs694739	0.628	rs645078	chr11:64135298	A/C	cg23796481	chr11:64053134	BAD;GPR137	0.57	6.71	0.38	1.18e-10	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CESC	trans	rs208520	0.955	rs17644076	chr6:67004973	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.77	-8.97	-0.48	5.51e-17	Exhaled nitric oxide output;
CESC	cis	rs727563	0.555	rs5751136	chr22:42075581	T/A	cg03806693	chr22:41940476	POLR3H	0.92	10.78	0.55	1.06e-22	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs9486719	1.000	rs2142653	chr6:96871520	C/A	cg18709589	chr6:96969512	KIAA0776	0.53	5.81	0.34	1.75e-8	Migraine;Coronary artery disease;
CESC	cis	rs3818285	0.556	rs941864	chr10:111656948	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.58	-8.35	-0.46	3.79e-15	Superior crus of antihelix expression;
CESC	cis	rs4665809	0.531	rs12990692	chr2:26464939	C/T	cg22920501	chr2:26401640	FAM59B	0.93	10.89	0.56	4.54e-23	Gut microbiome composition (summer);
CESC	cis	rs561341	1.000	rs2470243	chr17:30290955	C/T	cg23018236	chr17:30244563	NA	-0.55	-5.31	-0.31	2.37e-7	Hip circumference adjusted for BMI;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25266135	chr15:77835749	NA	0.58	6.23	0.36	1.82e-9	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.830	rs4699590	chr4:98974030	A/C	cg03676636	chr4:99064102	C4orf37	0.34	5.2	0.3	3.93e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1198872	0.526	rs57282335	chr2:10928207	G/A	cg15705551	chr2:10952987	PDIA6	0.52	6.14	0.35	2.95e-9	Cardiac Troponin-T levels;
CESC	cis	rs2304069	0.695	rs6866298	chr5:149439588	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.74	9.3	0.5	5.4e-18	HIV-1 control;
CESC	cis	rs74181299	0.591	rs2422441	chr2:65370766	A/G	cg05010058	chr2:65284262	CEP68	-0.32	-5.23	-0.31	3.48e-7	Pulse pressure;
CESC	cis	rs4664304	0.764	rs2063440	chr2:160800102	A/C	cg03641300	chr2:160917029	PLA2R1	-0.41	-5.46	-0.32	1.1e-7	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs1552244	1.000	rs17032396	chr3:10153559	A/G	cg08888203	chr3:10149979	C3orf24	-0.46	-5.67	-0.33	3.68e-8	Alzheimer's disease;
CESC	cis	rs1218582	0.772	rs4240874	chr1:154885779	C/T	cg06221963	chr1:154839813	KCNN3	-0.66	-11.23	-0.57	3.52e-24	Prostate cancer;
CESC	cis	rs6963495	0.674	rs75880756	chr7:105163821	G/C	cg19920283	chr7:105172520	RINT1	0.7	6.66	0.38	1.58e-10	Bipolar disorder (body mass index interaction);
CESC	cis	rs10752881	1.000	rs6701400	chr1:182977197	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.83	13.29	0.63	3.24e-31	Colorectal cancer;
CESC	cis	rs9322193	0.607	rs3798763	chr6:150211100	T/C	cg01145232	chr6:150245071	RAET1G	0.5	6.25	0.36	1.66e-9	Lung cancer;
CESC	cis	rs11690935	0.851	rs6433319	chr2:172830953	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.72	-10.73	-0.55	1.52e-22	Schizophrenia;
CESC	cis	rs708547	0.874	rs1718868	chr4:57881215	G/T	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.56	-5.78	-0.33	2.06e-8	Response to bleomycin (chromatid breaks);
CESC	cis	rs11098499	0.955	rs1511015	chr4:120170473	A/C	cg09307838	chr4:120376055	NA	0.86	11.39	0.57	9.73e-25	Corneal astigmatism;
CESC	cis	rs13118159	0.934	rs4974553	chr4:1356911	G/A	cg05025164	chr4:1340916	KIAA1530	0.44	6.02	0.35	5.93e-9	Longevity;
CESC	cis	rs853679	0.517	rs17711801	chr6:28092307	C/G	cg23281280	chr6:28129359	ZNF389	0.58	8.05	0.44	2.72e-14	Depression;
CESC	cis	rs61776719	0.875	rs10890238	chr1:38445654	A/T	cg18451016	chr1:38461880	NA	0.52	8.13	0.45	1.62e-14	Coronary artery disease;
CESC	cis	rs7680126	0.644	rs4697703	chr4:10107431	A/G	cg00071950	chr4:10020882	SLC2A9	-0.68	-8.19	-0.45	1.1e-14	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	cis	rs9796	0.621	rs58109657	chr15:41471750	A/G	cg18705301	chr15:41695430	NDUFAF1	0.46	6.81	0.39	6.54e-11	Menopause (age at onset);
CESC	cis	rs3916	0.911	rs12829722	chr12:121155622	C/T	cg21892295	chr12:121157589	UNC119B	-0.38	-5.26	-0.31	2.94e-7	Urinary metabolites (H-NMR features);
CESC	cis	rs7615952	0.741	rs13314845	chr3:125644782	C/T	cg05084668	chr3:125655381	ALG1L	-0.51	-6.1	-0.35	3.68e-9	Blood pressure (smoking interaction);
CESC	cis	rs10504229	0.683	rs55660024	chr8:58128943	G/A	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs752010	0.523	rs10890160	chr1:42120011	A/G	cg06885757	chr1:42089581	HIVEP3	0.5	7.95	0.44	5.36e-14	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs9549260	0.816	rs964901	chr13:41248698	C/T	cg21288729	chr13:41239152	FOXO1	0.66	8.39	0.46	2.93e-15	Red blood cell count;
CESC	cis	rs7000551	0.715	rs34649162	chr8:22314730	T/C	cg12081754	chr8:22256438	SLC39A14	0.39	5.04	0.3	8.63e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CESC	cis	rs926938	0.527	rs360583	chr1:115462743	C/T	cg12756093	chr1:115239321	AMPD1	0.45	6.28	0.36	1.41e-9	Autism;
CESC	cis	rs2204008	0.543	rs2387018	chr12:38065638	C/T	cg26384229	chr12:38710491	ALG10B	0.7	10.11	0.53	1.5e-20	Bladder cancer;
CESC	cis	rs977987	0.806	rs12448947	chr16:75462954	G/A	cg03315344	chr16:75512273	CHST6	0.41	5.91	0.34	1.07e-8	Dupuytren's disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg19064601	chr11:68142605	LRP5	0.45	6.26	0.36	1.54e-9	Fibrinogen levels;
CESC	cis	rs2075371	1.000	rs2544218	chr7:133992315	C/A	cg20476274	chr7:133979776	SLC35B4	0.67	9.79	0.52	1.65e-19	Mean platelet volume;
CESC	cis	rs904251	0.797	rs1776460	chr6:37485484	A/G	cg01843034	chr6:37503916	NA	-0.28	-5.1	-0.3	6.35e-7	Cognitive performance;
CESC	cis	rs2408955	0.568	rs12099462	chr12:48503104	T/C	cg04545296	chr12:48745243	ZNF641	-0.33	-5.59	-0.32	5.62e-8	Glycated hemoglobin levels;
CESC	cis	rs9858542	0.953	rs6779524	chr3:49450449	C/T	cg07274523	chr3:49395745	GPX1	0.67	8.36	0.46	3.5e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs2531992	0.858	rs2230742	chr16:4016676	C/T	cg05927578	chr16:4029543	ADCY9	-0.45	-5.61	-0.33	5.03e-8	Waist circumference;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg27514286	chr3:183892688	AP2M1	-0.45	-6.04	-0.35	5.26e-9	Fibrinogen levels;
CESC	cis	rs17376456	0.877	rs67066109	chr5:93494101	G/C	cg21475434	chr5:93447410	FAM172A	0.88	7.77	0.43	1.71e-13	Diabetic retinopathy;
CESC	cis	rs8050907	0.744	rs11861315	chr16:4518783	C/T	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.9	5.72	0.33	2.93e-8	Obesity-related traits;
CESC	cis	rs2073300	0.609	rs56334525	chr20:23365812	A/G	cg16736954	chr20:23401023	NAPB	0.79	5.87	0.34	1.33e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs7772486	0.686	rs857875	chr6:145980033	T/G	cg05347473	chr6:146136440	FBXO30	-0.55	-7.17	-0.4	7.36e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7618501	1.000	rs7618519	chr3:49772708	A/T	cg24308560	chr3:49941425	MST1R	0.5	6.81	0.39	6.38e-11	Intelligence (multi-trait analysis);
CESC	cis	rs12477438	0.501	rs13008171	chr2:99743419	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.77	12.85	0.62	1.02e-29	Chronic sinus infection;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02500152	chr12:48357316	TMEM106C	0.62	7.48	0.42	1.08e-12	Gut microbiome composition (summer);
CESC	cis	rs9916302	0.904	rs1966916	chr17:37425238	T/G	cg00129232	chr17:37814104	STARD3	-0.53	-6.89	-0.39	4.12e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs1008375	1.000	rs4698634	chr4:17630192	A/C	cg04450456	chr4:17643702	FAM184B	-0.36	-5.24	-0.31	3.21e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs75804782	0.521	rs56087929	chr2:239455564	G/A	cg18131467	chr2:239335373	ASB1	-0.69	-5.57	-0.32	6.11e-8	Morning vs. evening chronotype;Chronotype;
CESC	cis	rs9486715	1.000	rs9486715	chr6:97059769	A/C	cg06623918	chr6:96969491	KIAA0776	-0.92	-13.79	-0.65	5.63e-33	Headache;
CESC	cis	rs826838	1.000	rs1684395	chr12:39083161	T/G	cg13010199	chr12:38710504	ALG10B	-0.41	-5.63	-0.33	4.66e-8	Heart rate;
CESC	cis	rs9311474	0.597	rs13303	chr3:52558008	T/C	cg18099408	chr3:52552593	STAB1	-0.43	-7.97	-0.44	4.77e-14	Electroencephalogram traits;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg27520502	chr17:26684562	POLDIP2;TMEM199	-0.48	-6.33	-0.36	1.06e-9	Fibrinogen levels;
CESC	cis	rs10927875	0.662	rs698893	chr1:16302982	C/T	cg22431228	chr1:16359049	CLCNKA	-0.51	-9.61	-0.51	5.89e-19	Dilated cardiomyopathy;
CESC	cis	rs1799949	0.965	rs7212284	chr17:41205941	A/G	cg25072359	chr17:41440525	NA	0.47	6.98	0.39	2.42e-11	Menopause (age at onset);
CESC	cis	rs1267303	0.710	rs1535739	chr1:46957719	A/C	cg25110126	chr1:46999211	NA	-0.53	-5.98	-0.34	7.12e-9	Monobrow;
CESC	cis	rs7666738	0.830	rs7667796	chr4:99071415	G/T	cg17366294	chr4:99064904	C4orf37	-0.62	-8.5	-0.46	1.43e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs72945132	0.825	rs2277273	chr11:70223992	T/C	cg00319359	chr11:70116639	PPFIA1	0.72	6.93	0.39	3.17e-11	Coronary artery disease;
CESC	cis	rs17666538	0.710	rs12716640	chr8:645376	A/C	cg07234876	chr8:600039	NA	0.78	6.56	0.37	2.74e-10	IgG glycosylation;
CESC	cis	rs2180341	0.618	rs11154396	chr6:127638911	C/T	cg24812749	chr6:127587940	RNF146	0.6	8.09	0.44	2.22e-14	Breast cancer;
CESC	cis	rs2243480	1.000	rs2707844	chr7:66059509	G/A	cg13147721	chr7:65941812	NA	-0.93	-8.74	-0.47	2.72e-16	Diabetic kidney disease;
CESC	cis	rs116095464	0.558	rs7708515	chr5:234989	C/G	cg10591111	chr5:226296	SDHA	-0.51	-6.26	-0.36	1.55e-9	Breast cancer;
CESC	cis	rs9311474	1.000	rs6445358	chr3:52308845	C/G	cg18337363	chr3:52569053	NT5DC2	0.29	5.46	0.32	1.08e-7	Electroencephalogram traits;
CESC	trans	rs2727020	0.724	rs4109837	chr11:49372051	A/T	cg15704280	chr7:45808275	SEPT13	-0.78	-9.68	-0.51	3.47e-19	Coronary artery disease;
CESC	cis	rs12142240	0.698	rs66483119	chr1:46838389	T/C	cg10495392	chr1:46806563	NSUN4	0.58	6.26	0.36	1.54e-9	Menopause (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24182333	chr10:73610570	PSAP	-0.63	-7.37	-0.41	2.17e-12	Gut microbiome composition (summer);
CESC	cis	rs3820928	0.605	rs6748311	chr2:227792530	T/A	cg05526886	chr2:227700861	RHBDD1	-0.54	-7.23	-0.41	5.26e-12	Pulmonary function;
CESC	cis	rs11958404	0.932	rs12517979	chr5:157428918	T/C	cg05962755	chr5:157440814	NA	0.62	6.61	0.38	2.14e-10	IgG glycosylation;
CESC	cis	rs8141529	0.588	rs10222249	chr22:29257147	A/G	cg02153584	chr22:29168773	CCDC117	0.52	6.41	0.37	6.5e-10	Lymphocyte counts;
CESC	cis	rs9649213	0.593	rs7803372	chr7:97992257	A/G	cg24562669	chr7:97807699	LMTK2	0.49	7.17	0.4	7.33e-12	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs6580649	0.941	rs1635529	chr12:48395102	T/G	cg24011408	chr12:48396354	COL2A1	0.4	5.1	0.3	6.46e-7	Lung cancer;
CESC	cis	rs597539	0.652	rs557625	chr11:68634722	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.77	9.59	0.51	6.99e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs17711722	0.510	rs73142128	chr7:65331109	A/C	cg06456125	chr7:65229604	NA	0.41	5.31	0.31	2.29e-7	Calcium levels;
CESC	cis	rs412050	0.793	rs238782	chr22:22341992	G/A	cg17089214	chr22:22089827	YPEL1	0.56	5.04	0.3	8.7e-7	Attention deficit hyperactivity disorder;
CESC	cis	rs2243480	1.000	rs2707831	chr7:66062511	G/A	cg13147721	chr7:65941812	NA	-0.93	-8.74	-0.47	2.72e-16	Diabetic kidney disease;
CESC	cis	rs7727544	0.571	rs12521097	chr5:131575338	G/A	cg09877947	chr5:131593287	PDLIM4	0.44	5.37	0.31	1.76e-7	Blood metabolite levels;
CESC	cis	rs514406	0.929	rs555741	chr1:53318851	T/G	cg01802117	chr1:53393560	SCP2	-0.4	-5.12	-0.3	5.9e-7	Monocyte count;
CESC	cis	rs6460942	1.000	rs17668923	chr7:12302873	A/T	cg20607287	chr7:12443886	VWDE	-0.57	-6.53	-0.37	3.32e-10	Coronary artery disease;
CESC	trans	rs7937682	0.855	rs539693	chr11:111477387	A/G	cg18187862	chr3:45730750	SACM1L	0.49	6.16	0.35	2.71e-9	Primary sclerosing cholangitis;
CESC	cis	rs1799949	1.000	rs35330014	chr17:41212547	C/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.43	5.82	0.34	1.67e-8	Menopause (age at onset);
CESC	cis	rs35110281	0.563	rs162371	chr21:44931489	G/T	cg21573476	chr21:45109991	RRP1B	-0.4	-5.64	-0.33	4.34e-8	Mean corpuscular volume;
CESC	cis	rs9487051	1.000	rs11757567	chr6:109614713	G/A	cg21918786	chr6:109611834	NA	-0.35	-5.03	-0.3	8.9e-7	Reticulocyte fraction of red cells;
CESC	cis	rs832540	0.931	rs33318	chr5:56208414	G/T	cg12311346	chr5:56204834	C5orf35	-0.43	-5.46	-0.32	1.08e-7	Coronary artery disease;
CESC	cis	rs6938	0.575	rs12909335	chr15:75214789	T/G	cg09165964	chr15:75287851	SCAMP5	0.47	6.45	0.37	5.19e-10	Breast cancer;
CESC	cis	rs748404	0.631	rs7167882	chr15:43678663	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.57	8.91	0.48	8.39e-17	Lung cancer;
CESC	cis	rs6788895	1.000	rs74950732	chr3:150482621	C/T	cg09723797	chr3:150481914	SIAH2	0.73	5.55	0.32	6.95e-8	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10541813	chr2:85839361	C2orf68	-0.65	-8.09	-0.45	2.11e-14	Gut microbiome composition (summer);
CESC	cis	rs6964587	0.900	rs11984136	chr7:91766953	T/C	cg17063962	chr7:91808500	NA	0.57	7.9	0.44	7.64e-14	Breast cancer;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg09681706	chr7:75703103	NA	0.53	6.94	0.39	2.92e-11	Fibrinogen levels;
CESC	cis	rs3091242	0.933	rs11249250	chr1:25767609	G/A	cg27572855	chr1:25598939	RHD	0.44	7.36	0.41	2.34e-12	Erythrocyte sedimentation rate;
CESC	cis	rs17376456	0.825	rs34592268	chr5:93232751	G/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.64	5.49	0.32	9.59e-8	Diabetic retinopathy;
CESC	cis	rs4713118	0.587	rs9393899	chr6:28133528	G/C	cg23281280	chr6:28129359	ZNF389	0.59	7.9	0.44	7.47e-14	Parkinson's disease;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg02723225	chr16:3019192	PAQR4	-0.52	-6.52	-0.37	3.56e-10	Ulcerative colitis;
CESC	cis	rs60871478	0.636	rs61441144	chr7:897784	C/T	cg05535760	chr7:792225	HEATR2	-0.74	-7.73	-0.43	2.28e-13	Cerebrospinal P-tau181p levels;
CESC	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.45	6.18	0.35	2.42e-9	Lymphocyte counts;
CESC	cis	rs9905704	0.918	rs12942969	chr17:56892872	A/T	cg12560992	chr17:57184187	TRIM37	0.61	7.21	0.4	5.9e-12	Testicular germ cell tumor;
CESC	trans	rs853679	0.556	rs13200214	chr6:28017250	C/T	cg01620082	chr3:125678407	NA	-0.83	-6.19	-0.36	2.33e-9	Depression;
CESC	cis	rs1799949	0.965	rs9646413	chr17:41426157	A/G	cg23758822	chr17:41437982	NA	1.01	16.99	0.72	2.66e-44	Menopause (age at onset);
CESC	cis	rs9318086	0.648	rs78881146	chr13:24468704	G/A	cg25267304	chr13:24462978	PCOTH;MIPEP	0.49	6.79	0.38	7.33e-11	Myopia (pathological);
CESC	cis	rs763121	0.853	rs138716	chr22:39146527	C/T	cg06544989	chr22:39130855	UNC84B	0.47	8.12	0.45	1.75e-14	Menopause (age at onset);
CESC	cis	rs853679	0.513	rs13437444	chr6:28070998	C/T	cg23281280	chr6:28129359	ZNF389	0.5	5.49	0.32	9.49e-8	Depression;
CESC	trans	rs11250098	0.574	rs7015168	chr8:10772210	G/C	cg15556689	chr8:8085844	FLJ10661	-0.56	-6.63	-0.38	1.87e-10	Morning vs. evening chronotype;
CESC	cis	rs9359856	0.564	rs55722352	chr6:90365853	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.65	-6.35	-0.36	9.29e-10	Bipolar disorder;
CESC	cis	rs10479542	0.784	rs7702303	chr5:178986436	G/A	cg21226059	chr5:178986404	RUFY1	0.51	7.84	0.43	1.12e-13	Lung cancer;
CESC	cis	rs3762637	1.000	rs7609972	chr3:122199426	T/G	cg24169773	chr3:122142474	KPNA1	-0.54	-6.4	-0.37	6.83e-10	LDL cholesterol levels;
CESC	cis	rs875971	0.862	rs6958294	chr7:65794796	C/A	cg19163074	chr7:65112434	INTS4L2	0.41	5.28	0.31	2.74e-7	Aortic root size;
CESC	cis	rs2282802	0.685	rs7717576	chr5:139623591	G/A	cg26211634	chr5:139558579	C5orf32	0.48	6.88	0.39	4.3e-11	Intelligence (multi-trait analysis);
CESC	cis	rs7312933	0.934	rs11181289	chr12:42402342	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.41	5.24	0.31	3.28e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	trans	rs991427	0.643	rs17018718	chr12:91498199	C/T	cg01859340	chr18:44775576	NA	-0.66	-6.1	-0.35	3.79e-9	Systolic blood pressure (alcohol consumption interaction);
CESC	cis	rs17711722	0.510	rs73142128	chr7:65331109	A/C	cg12143784	chr7:64541923	NA	0.41	5.45	0.32	1.18e-7	Calcium levels;
CESC	cis	rs12824058	0.831	rs7299065	chr12:130809661	A/T	cg23887609	chr12:130822674	PIWIL1	0.45	5.82	0.34	1.69e-8	Menopause (age at onset);
CESC	cis	rs9522267	0.535	rs914031	chr13:112240176	C/A	cg10483660	chr13:112241077	NA	-0.33	-5.84	-0.34	1.54e-8	Hepatitis;
CESC	cis	rs372883	0.648	rs11088117	chr21:30737816	G/C	cg24692254	chr21:30365293	RNF160	0.52	6.54	0.37	3.21e-10	Pancreatic cancer;
CESC	cis	rs10504229	0.636	rs77691549	chr8:58055126	G/T	cg24829409	chr8:58192753	C8orf71	-0.57	-6.58	-0.37	2.54e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs4722166	0.598	rs4722171	chr7:22785717	A/G	cg26061582	chr7:22766209	IL6	0.5	5.48	0.32	9.97e-8	Lung cancer;
CESC	cis	rs17789174	0.810	rs8051308	chr16:85081953	A/G	cg01766882	chr16:85496273	NA	-0.47	-5.15	-0.3	5.07e-7	Dysphagia;
CESC	cis	rs1267303	0.798	rs1267304	chr1:46990426	C/T	cg25110126	chr1:46999211	NA	-0.69	-7.98	-0.44	4.49e-14	Monobrow;
CESC	cis	rs2191566	0.691	rs8104802	chr19:44588969	G/A	cg20607764	chr19:44506953	ZNF230	-0.4	-5.31	-0.31	2.33e-7	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs1577917	1.000	rs34852683	chr6:86702330	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.43	-5.63	-0.33	4.56e-8	Response to antipsychotic treatment;
CESC	cis	rs12136530	0.593	rs4911989	chr1:19727743	C/G	cg01832549	chr1:19774989	CAPZB	0.45	6.17	0.35	2.5e-9	Lead levels in blood;
CESC	cis	rs13242816	1.000	rs35538349	chr7:116117896	C/T	cg04696780	chr7:116139425	CAV2	-0.62	-5.46	-0.32	1.09e-7	P wave duration;
CESC	cis	rs7618915	0.547	rs62255371	chr3:52747321	A/G	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.59	0.38	2.35e-10	Bipolar disorder;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg08647641	chr7:91763896	CYP51A1	-0.44	-6.42	-0.37	6.35e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24391471	chr3:44974926	ZDHHC3	-0.56	-6.06	-0.35	4.61e-9	Gut microbiome composition (summer);
CESC	cis	rs10504229	0.679	rs16921676	chr8:58052386	G/T	cg02725872	chr8:58115012	NA	-0.34	-5.15	-0.3	5.21e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs514406	0.679	rs61768344	chr1:53229274	G/A	cg27535305	chr1:53392650	SCP2	0.35	6.21	0.36	2.01e-9	Monocyte count;
CESC	cis	rs56036086	0.824	rs73187254	chr22:50642359	C/T	cg16473166	chr22:50639996	SELO	0.62	5.1	0.3	6.6e-7	Platelet count;Plateletcrit;
CESC	cis	rs2629540	0.847	rs10901811	chr10:126417914	G/A	cg08799069	chr10:126477246	METTL10	0.58	7.55	0.42	7.26e-13	Cocaine dependence;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg23831927	chr13:20989645	CRYL1	0.5	6.91	0.39	3.61e-11	Fibrinogen levels;
CESC	cis	rs10463316	0.894	rs7723016	chr5:150764828	T/C	cg03212797	chr5:150827313	SLC36A1	-0.46	-6.02	-0.35	5.83e-9	Metabolite levels (Pyroglutamine);
CESC	cis	rs17376456	0.542	rs1453003	chr5:93151611	T/C	cg25358565	chr5:93447407	FAM172A	-0.71	-7.57	-0.42	6.21e-13	Diabetic retinopathy;
CESC	cis	rs8067354	0.958	rs2777889	chr17:57848006	A/G	cg13753209	chr17:57696993	CLTC	0.5	6.75	0.38	9.33e-11	Hemoglobin concentration;
CESC	cis	rs1185460	0.967	rs1307145	chr11:118950217	C/G	cg23280166	chr11:118938394	VPS11	0.54	7.35	0.41	2.54e-12	Coronary artery disease;
CESC	cis	rs17711722	0.510	rs11767457	chr7:65290615	C/T	cg19163074	chr7:65112434	INTS4L2	-0.46	-5.52	-0.32	8.14e-8	Calcium levels;
CESC	cis	rs4253772	0.530	rs9615955	chr22:46743931	A/G	cg18190219	chr22:46762943	CELSR1	-0.68	-6.18	-0.36	2.35e-9	LDL cholesterol;Cholesterol, total;
CESC	cis	rs6598955	0.724	rs12726972	chr1:26639634	A/G	cg00852783	chr1:26633632	UBXN11	-0.38	-5.61	-0.33	5.2e-8	Obesity-related traits;
CESC	cis	rs537626	1.000	rs612611	chr11:69307463	A/G	cg08353955	chr11:69289746	NA	-0.59	-6.36	-0.36	8.9e-10	Breast cancer (early onset);
CESC	cis	rs1707322	1.000	rs11211228	chr1:46399840	G/A	cg05343316	chr1:45956843	TESK2	0.44	5.42	0.32	1.36e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7178572	0.962	rs12324627	chr15:77767539	A/G	cg22256960	chr15:77711686	NA	-0.6	-8.09	-0.44	2.19e-14	Type 2 diabetes;
CESC	cis	rs6430585	0.536	rs60397494	chr2:136470219	C/T	cg07169764	chr2:136633963	MCM6	1.25	14.03	0.65	7.82e-34	Corneal structure;
CESC	cis	rs6460942	1.000	rs7791634	chr7:12401482	A/T	cg17427002	chr7:12443146	VWDE	-0.51	-5.04	-0.3	8.8e-7	Coronary artery disease;
CESC	cis	rs501120	0.866	rs607609	chr10:44750209	T/C	cg09554077	chr10:44749378	NA	0.5	6.65	0.38	1.71e-10	Coronary artery disease;Coronary heart disease;
CESC	cis	rs7399018	0.739	rs10747608	chr12:51616582	A/G	cg25754956	chr12:51612065	POU6F1	0.69	8.77	0.47	2.18e-16	Cisplatin-induced ototoxicity;
CESC	cis	rs4727027	0.866	rs2373437	chr7:148779032	T/C	cg23583168	chr7:148888333	NA	-0.78	-11.69	-0.58	1.01e-25	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs4319547	0.774	rs7295105	chr12:123124225	G/A	cg23029597	chr12:123009494	RSRC2	-0.45	-5.18	-0.3	4.34e-7	Body mass index;
CESC	trans	rs7989524	1.000	rs9318655	chr13:19633215	C/T	cg14825340	chr8:26681894	ADRA1A	-0.59	-6.02	-0.35	5.87e-9	Schizophrenia;
CESC	cis	rs2839186	0.708	rs6518285	chr21:47644667	T/C	cg13012494	chr21:47604986	C21orf56	0.44	5.86	0.34	1.37e-8	Testicular germ cell tumor;
CESC	cis	rs1801251	0.896	rs4973561	chr2:233687337	C/G	cg08000102	chr2:233561755	GIGYF2	-0.68	-10.57	-0.54	5.21e-22	Coronary artery disease;
CESC	cis	rs61841072	1.000	rs61841071	chr1:243129358	C/A	cg02356786	chr1:243265016	LOC731275	0.41	5.26	0.31	2.97e-7	Schizophrenia;
CESC	cis	rs9309711	0.666	rs6723126	chr2:3484500	T/C	cg10845886	chr2:3471009	TTC15	-0.68	-9.33	-0.5	4.29e-18	Neurofibrillary tangles;
CESC	cis	rs1878931	0.696	rs35175748	chr16:3445427	C/G	cg21433313	chr16:3507492	NAT15	-0.39	-5.78	-0.33	2.12e-8	Body mass index (adult);
CESC	cis	rs4808199	0.948	rs968525	chr19:19459215	C/T	cg03709012	chr19:19516395	GATAD2A	1.06	12.11	0.6	3.63e-27	Nonalcoholic fatty liver disease;
CESC	cis	rs4803468	0.967	rs16975238	chr19:41944985	T/A	cg14132834	chr19:41945861	ATP5SL	0.6	7.5	0.42	9.35e-13	Height;
CESC	cis	rs1008375	0.966	rs7658240	chr4:17588950	A/G	cg16339924	chr4:17578868	LAP3	-0.79	-10.12	-0.53	1.43e-20	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs8031584	0.651	rs28664821	chr15:31172323	G/A	cg14829155	chr15:31115871	NA	0.82	12.33	0.6	6.32e-28	Huntington's disease progression;
CESC	cis	rs6460942	0.544	rs34644264	chr7:12536090	C/A	cg20607287	chr7:12443886	VWDE	-0.72	-7.71	-0.43	2.51e-13	Coronary artery disease;
CESC	cis	rs8077889	0.750	rs72836564	chr17:41935064	G/A	cg26893861	chr17:41843967	DUSP3	0.86	8.42	0.46	2.39e-15	Triglycerides;
CESC	cis	rs4474465	0.915	rs4944204	chr11:78222013	G/T	cg27205649	chr11:78285834	NARS2	0.45	5.36	0.31	1.81e-7	Alzheimer's disease (survival time);
CESC	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg23034840	chr1:205782522	SLC41A1	0.68	8.4	0.46	2.75e-15	Menarche (age at onset);
CESC	cis	rs113835537	0.529	rs11227503	chr11:66275242	G/C	cg24851651	chr11:66362959	CCS	0.44	5.46	0.32	1.11e-7	Airway imaging phenotypes;
CESC	cis	rs9326248	0.817	rs1242127	chr11:117076564	A/G	cg26566898	chr11:117069891	TAGLN	-0.32	-5.47	-0.32	1.06e-7	Blood protein levels;
CESC	cis	rs34172651	0.917	rs2059134	chr16:24816492	C/T	cg06028605	chr16:24865363	SLC5A11	-0.4	-6.1	-0.35	3.71e-9	Intelligence (multi-trait analysis);
CESC	cis	rs3126085	0.935	rs1390485	chr1:152182168	C/T	cg26876637	chr1:152193138	HRNR	-0.44	-5.03	-0.3	9.04e-7	Atopic dermatitis;
CESC	cis	rs7927771	0.524	rs10838740	chr11:47679980	A/G	cg18512352	chr11:47633146	NA	0.35	5.4	0.31	1.51e-7	Subjective well-being;
CESC	cis	rs4974559	0.501	rs730830	chr4:1240091	T/C	cg02980000	chr4:1222292	CTBP1	-0.76	-7.67	-0.43	3.31e-13	Systolic blood pressure;
CESC	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg18402987	chr7:1209562	NA	0.61	7.2	0.4	6.1e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs1008375	0.898	rs7678654	chr4:17575376	T/G	cg02297831	chr4:17616191	MED28	0.5	6.05	0.35	4.9e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs6952808	0.825	rs34922657	chr7:1938655	C/T	cg04267008	chr7:1944627	MAD1L1	-0.71	-9.06	-0.49	2.86e-17	Bipolar disorder and schizophrenia;
CESC	cis	rs1005277	0.565	rs2474565	chr10:38380828	A/G	cg25517755	chr10:38738941	LOC399744	-0.48	-6.22	-0.36	1.95e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs4242434	0.927	rs10095121	chr8:22538426	A/G	cg03733263	chr8:22462867	KIAA1967	0.93	13.14	0.63	1.04e-30	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CESC	cis	rs2243480	1.000	rs316304	chr7:65616894	T/C	cg13147721	chr7:65941812	NA	-0.98	-9.23	-0.49	9.18e-18	Diabetic kidney disease;
CESC	cis	rs941873	0.900	rs7092536	chr10:81131332	A/C	cg09469691	chr10:81107165	PPIF	0.53	7.32	0.41	2.88e-12	Height;
CESC	cis	rs854765	0.927	rs4925138	chr17:17992793	T/G	cg16928487	chr17:17741425	SREBF1	0.58	9.78	0.51	1.75e-19	Total body bone mineral density;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg18382590	chr9:131219195	ODF2	-0.49	-7.02	-0.4	1.86e-11	Gambling;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05725452	chr22:21996709	SDF2L1	-0.49	-6.89	-0.39	4.13e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs6121246	0.909	rs6060929	chr20:30345914	C/T	cg13852791	chr20:30311386	BCL2L1	0.81	8.61	0.47	6.48e-16	Mean corpuscular hemoglobin;
CESC	cis	rs9457247	1.000	rs2149091	chr6:167372786	C/T	cg07741184	chr6:167504864	NA	-0.3	-5.39	-0.31	1.6e-7	Crohn's disease;
CESC	cis	rs2991971	0.901	rs11211122	chr1:45954650	C/T	cg15605315	chr1:45957053	TESK2	0.46	6.14	0.35	2.94e-9	High light scatter reticulocyte count;
CESC	cis	rs736408	0.812	rs2240920	chr3:52831009	A/G	cg18404041	chr3:52824283	ITIH1	0.39	5.95	0.34	8.49e-9	Bipolar disorder;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg02819828	chr13:37453855	SMAD9	0.42	6.22	0.36	1.97e-9	Fibrinogen levels;
CESC	cis	rs977987	0.872	rs4887825	chr16:75472422	C/A	cg03315344	chr16:75512273	CHST6	0.42	6.12	0.35	3.38e-9	Dupuytren's disease;
CESC	cis	rs4835473	0.900	rs13101531	chr4:144903350	G/T	cg25736465	chr4:144833511	NA	-0.43	-6.49	-0.37	4.21e-10	Immature fraction of reticulocytes;
CESC	cis	rs4595586	0.525	rs10506132	chr12:39404599	C/T	cg26384229	chr12:38710491	ALG10B	0.61	8.57	0.47	8.88e-16	Morning vs. evening chronotype;
CESC	cis	rs2303759	0.874	rs10411630	chr19:49891314	C/A	cg22307029	chr19:49891270	CCDC155	0.72	8.46	0.46	1.82e-15	Multiple sclerosis;
CESC	cis	rs4547160	0.781	rs10877951	chr12:63485882	T/C	cg26727693	chr12:63544175	AVPR1A	-0.34	-5.12	-0.3	5.82e-7	Morning vs. evening chronotype;
CESC	cis	rs35740288	0.597	rs12900830	chr15:86326154	T/C	cg20737812	chr15:86336631	KLHL25	-0.47	-5.41	-0.32	1.39e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
CESC	cis	rs16866061	0.926	rs17479770	chr2:225335814	A/G	cg12698349	chr2:225449008	CUL3	0.69	9.89	0.52	7.79e-20	Acute graft versus host disease in bone marrow transplantation (recipient effect);
CESC	cis	rs863345	0.604	rs949397	chr1:158461951	G/T	cg12129480	chr1:158549410	OR10X1	-0.36	-7.29	-0.41	3.49e-12	Pneumococcal bacteremia;
CESC	trans	rs916888	0.697	rs199516	chr17:44856485	C/T	cg23590916	chr17:43697445	MGC57346	-0.62	-6.63	-0.38	1.84e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs1355223	0.833	rs11032804	chr11:34680598	C/A	cg11058730	chr11:34937778	PDHX;APIP	-0.47	-6.13	-0.35	3.2e-9	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs6800768	0.633	rs826373	chr3:24163773	C/G	cg10674438	chr3:24145617	LOC152024	-0.48	-6.92	-0.39	3.33e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs8018808	1.000	rs12435136	chr14:77856184	G/A	cg20045696	chr14:77926864	AHSA1	-0.44	-6.14	-0.35	3.05e-9	Myeloid white cell count;
CESC	cis	rs7666738	0.830	rs4699600	chr4:99019429	C/G	cg17366294	chr4:99064904	C4orf37	0.61	8.76	0.47	2.35e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10479542	0.784	rs7702303	chr5:178986436	G/A	cg19626725	chr5:178986131	RUFY1	0.4	6.4	0.37	6.99e-10	Lung cancer;
CESC	cis	rs7917772	0.636	rs2482499	chr10:104516246	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.44	5.1	0.3	6.41e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs10504229	1.000	rs60231757	chr8:58169937	T/C	cg14926445	chr8:58193284	C8orf71	-0.51	-5.47	-0.32	1.03e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs798766	1.000	rs798755	chr4:1720824	A/G	cg07041428	chr4:1763019	NA	-0.39	-5.66	-0.33	3.86e-8	Bladder cancer;Urinary bladder cancer;
CESC	cis	rs9815354	0.680	rs114478966	chr3:42007050	T/C	cg03022575	chr3:42003672	ULK4	0.67	6.27	0.36	1.43e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs116095464	0.558	rs1812843	chr5:267658	A/G	cg22857025	chr5:266934	NA	-1.3	-18.55	-0.75	8.05e-50	Breast cancer;
CESC	cis	rs1059312	0.966	rs7135968	chr12:129280066	G/A	cg09035930	chr12:129282057	SLC15A4	0.76	10.73	0.55	1.59e-22	Systemic lupus erythematosus;
CESC	cis	rs9915657	0.870	rs4140903	chr17:70133771	C/T	cg06234051	chr17:70120541	SOX9	-0.44	-6.5	-0.37	4.06e-10	Thyroid hormone levels;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg21771171	chr6:692465	EXOC2	-0.43	-6.08	-0.35	4.18e-9	Gambling;
CESC	cis	rs10870270	1.000	rs11146338	chr10:133770291	C/G	cg26149184	chr10:133730230	NA	0.38	5.14	0.3	5.22e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs35110281	0.720	rs162392	chr21:44941406	A/G	cg01579765	chr21:45077557	HSF2BP	-0.54	-9.15	-0.49	1.58e-17	Mean corpuscular volume;
CESC	cis	rs11098499	0.605	rs6833140	chr4:120266822	G/A	cg09307838	chr4:120376055	NA	0.75	9.66	0.51	4.11e-19	Corneal astigmatism;
CESC	cis	rs875971	0.862	rs10278014	chr7:66051264	C/T	cg10691866	chr7:65817282	TPST1	0.33	5.47	0.32	1.02e-7	Aortic root size;
CESC	cis	rs9287719	0.967	rs6761678	chr2:10746341	T/C	cg02196655	chr2:10830764	NOL10	-0.38	-5.78	-0.33	2.05e-8	Prostate cancer;
CESC	cis	rs7615952	0.688	rs12485622	chr3:125710739	T/C	cg02807482	chr3:125708958	NA	-0.38	-5.08	-0.3	7.16e-7	Blood pressure (smoking interaction);
CESC	cis	rs9926296	0.533	rs12102297	chr16:89812762	C/A	cg07648498	chr16:89883185	FANCA	0.49	6.21	0.36	1.99e-9	Vitiligo;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg10828910	chr2:63850056	LOC388955	-0.5	-6.71	-0.38	1.17e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs9611565	0.569	rs188057	chr22:41822305	T/G	cg17376030	chr22:41985996	PMM1	-0.76	-8.01	-0.44	3.71e-14	Vitiligo;
CESC	cis	rs60871478	1.000	rs4721124	chr7:823761	T/C	cg27478167	chr7:817139	HEATR2	-0.45	-5.27	-0.31	2.81e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs34779708	0.966	rs10827493	chr10:35454976	C/T	cg03585969	chr10:35415529	CREM	0.77	10.56	0.54	5.56e-22	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs1799949	0.965	rs8176193	chr17:41231516	C/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.45	6.32	0.36	1.11e-9	Menopause (age at onset);
CESC	cis	rs863345	0.967	rs10908683	chr1:158522770	C/G	cg12129480	chr1:158549410	OR10X1	-0.32	-6.5	-0.37	3.89e-10	Pneumococcal bacteremia;
CESC	cis	rs4604732	0.678	rs74154674	chr1:247625685	C/T	cg12754571	chr1:247694271	LOC148824;OR2C3	0.44	5.44	0.32	1.21e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs709400	0.930	rs10149249	chr14:104047757	C/T	cg24130564	chr14:104152367	KLC1	-0.43	-5.33	-0.31	2.06e-7	Body mass index;
CESC	cis	rs9926296	0.605	rs1800287	chr16:89858525	C/G	cg04287289	chr16:89883240	FANCA	0.87	14.87	0.67	8.54e-37	Vitiligo;
CESC	cis	rs7123876	0.553	rs12099027	chr11:72433920	A/G	cg03713592	chr11:72463424	ARAP1	0.44	5.21	0.31	3.71e-7	Body mass index;
CESC	cis	rs832540	0.556	rs4146565	chr5:56093825	T/C	cg12311346	chr5:56204834	C5orf35	-0.47	-5.69	-0.33	3.41e-8	Coronary artery disease;
CESC	cis	rs2576037	0.526	rs6507714	chr18:44519574	A/G	cg07643061	chr18:44555308	TCEB3C;TCEB3CL;KATNAL2	-0.38	-5.76	-0.33	2.3e-8	Personality dimensions;
CESC	cis	rs4862750	0.872	rs6836781	chr4:187899701	G/A	cg11301795	chr4:187892539	NA	-0.75	-12.33	-0.6	6.74e-28	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs9929218	0.559	rs55907909	chr16:68805805	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.86	13.93	0.65	1.77e-33	Colorectal cancer;
CESC	cis	rs763121	0.853	rs138704	chr22:39133410	A/G	cg14440974	chr22:39074834	NA	-0.36	-5.27	-0.31	2.9e-7	Menopause (age at onset);
CESC	cis	rs9837602	0.529	rs1688774	chr3:99521108	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.52	-6.21	-0.36	2.05e-9	Breast cancer;
CESC	cis	rs8058578	0.887	rs28421305	chr16:30838128	G/A	cg00531865	chr16:30841666	NA	-0.41	-5.34	-0.31	2.02e-7	Multiple myeloma;
CESC	cis	rs7618915	0.501	rs12486554	chr3:52742537	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.53	7.7	0.43	2.75e-13	Bipolar disorder;
CESC	cis	rs12545109	0.800	rs2610052	chr8:57411316	C/A	cg09654669	chr8:57350985	NA	-0.47	-6.38	-0.36	8.01e-10	Obesity-related traits;
CESC	trans	rs1728785	0.892	rs1103955	chr16:68588488	T/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.65	7.82	0.43	1.24e-13	Ulcerative colitis;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg20685139	chr19:53238254	ZNF611	0.46	6.24	0.36	1.69e-9	Asthma;
CESC	cis	rs8016982	0.963	rs7149672	chr14:81657336	A/G	cg01989461	chr14:81687754	GTF2A1	0.52	6.62	0.38	1.98e-10	Schizophrenia;
CESC	cis	rs778371	0.723	rs6704763	chr2:233592487	C/T	cg08000102	chr2:233561755	GIGYF2	0.85	15.12	0.68	1.13e-37	Schizophrenia;
CESC	cis	rs2072732	0.861	rs10909867	chr1:2961402	G/T	cg03976712	chr1:2946727	NA	0.35	5.63	0.33	4.52e-8	Plateletcrit;
CESC	trans	rs116095464	0.558	rs113796397	chr5:246503	A/G	cg00938859	chr5:1591904	SDHAP3	0.64	6.65	0.38	1.68e-10	Breast cancer;
CESC	cis	rs2742234	0.541	rs1879310	chr10:43734775	A/G	cg15436174	chr10:43711423	RASGEF1A	0.46	5.41	0.32	1.39e-7	Hirschsprung disease;
CESC	cis	rs4713118	0.662	rs9380045	chr6:28025279	A/G	cg19592336	chr6:28129416	ZNF389	0.54	6.94	0.39	3e-11	Parkinson's disease;
CESC	cis	rs561341	1.000	rs55978022	chr17:30275937	T/C	cg00745463	chr17:30367425	LRRC37B	-0.86	-7.74	-0.43	2.15e-13	Hip circumference adjusted for BMI;
CESC	cis	rs1799949	1.000	rs1135214	chr17:41292323	T/C	cg25072359	chr17:41440525	NA	0.46	6.1	0.35	3.77e-9	Menopause (age at onset);
CESC	cis	rs7264396	0.563	rs17093093	chr20:34380925	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.66	6.74	0.38	9.78e-11	Total cholesterol levels;
CESC	cis	rs916888	0.821	rs199509	chr17:44858728	G/A	cg01570182	chr17:44337453	NA	-0.87	-10.59	-0.55	4.47e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs9487051	0.766	rs351748	chr6:109532296	C/T	cg01475377	chr6:109611718	NA	0.4	5.98	0.35	7.01e-9	Reticulocyte fraction of red cells;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg10068917	chr8:63952060	GGH	-0.45	-6.45	-0.37	5.38e-10	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs116095464	0.558	rs10475136	chr5:232796	A/G	cg22496380	chr5:211416	CCDC127	-0.73	-8.37	-0.46	3.25e-15	Breast cancer;
CESC	cis	rs72781680	1.000	rs56205282	chr2:24221317	C/T	cg20701182	chr2:24300061	SF3B14	0.81	6.96	0.39	2.71e-11	Lymphocyte counts;
CESC	cis	rs9486715	0.867	rs211159	chr6:97023026	G/A	cg06623918	chr6:96969491	KIAA0776	-0.81	-11.86	-0.59	2.51e-26	Headache;
CESC	cis	rs9640161	0.750	rs59211922	chr7:150023790	T/G	cg21361702	chr7:150065534	REPIN1	0.45	5.29	0.31	2.6e-7	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs3785574	0.962	rs2665842	chr17:61878535	G/A	cg06873352	chr17:61820015	STRADA	0.47	6.85	0.39	5.3e-11	Height;
CESC	cis	rs2836974	0.644	rs2836981	chr21:40688365	C/T	cg17971929	chr21:40555470	PSMG1	-0.85	-12.29	-0.6	9.04e-28	Cognitive function;
CESC	cis	rs7918232	1.000	rs6482595	chr10:27380261	A/G	cg14240646	chr10:27532245	ACBD5	0.55	5.82	0.34	1.69e-8	Breast cancer;
CESC	cis	rs889312	0.500	rs832580	chr5:56172646	T/C	cg12311346	chr5:56204834	C5orf35	-0.4	-5.03	-0.3	8.87e-7	Breast cancer;Breast cancer (early onset);
CESC	cis	rs3096299	0.781	rs2170839	chr16:89409452	C/G	cg02187348	chr16:89574699	SPG7	0.5	6.13	0.35	3.17e-9	Multiple myeloma (IgH translocation);
CESC	cis	rs1009170	0.794	rs7158971	chr14:92586126	T/A	cg10324096	chr14:92587714	CPSF2;NDUFB1	0.53	5.03	0.3	9.1e-7	Dialysis-related mortality;
CESC	cis	rs1046896	1.000	rs28485881	chr17:80690014	G/A	cg02711726	chr17:80685570	FN3KRP	-0.57	-8.56	-0.47	9.56e-16	Glycated hemoglobin levels;
CESC	cis	rs7267979	0.932	rs449370	chr20:25451180	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.84	-16.81	-0.72	1.13e-43	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs6502050	0.805	rs7406858	chr17:80080623	G/A	cg23985595	chr17:80112537	CCDC57	0.42	6.55	0.37	2.99e-10	Life satisfaction;
CESC	cis	rs11122272	0.701	rs2491402	chr1:231494338	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.49	-6.48	-0.37	4.4e-10	Hemoglobin concentration;
CESC	cis	rs4764487	0.760	rs10849421	chr12:6327008	A/G	cg08284733	chr12:6341482	CD9	0.41	6.04	0.35	5.21e-9	Mean platelet volume;
CESC	cis	rs7618915	0.547	rs2286800	chr3:52778051	C/T	cg17372223	chr3:52568218	NT5DC2	0.44	6.57	0.37	2.6e-10	Bipolar disorder;
CESC	cis	rs7577696	0.568	rs7574000	chr2:32342888	A/C	cg02381751	chr2:32503542	YIPF4	-0.42	-5.05	-0.3	8.31e-7	Inflammatory biomarkers;
CESC	cis	rs2576037	0.583	rs501882	chr18:44411066	A/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.5	-6.81	-0.39	6.64e-11	Personality dimensions;
CESC	cis	rs77106637	1.000	rs11602858	chr11:72615069	C/G	cg04827223	chr11:72435913	ARAP1	-0.5	-5.32	-0.31	2.26e-7	Type 2 diabetes;
CESC	cis	rs7202877	0.706	rs247425	chr16:75460402	C/T	cg04384234	chr16:75411784	CFDP1	0.48	5.68	0.33	3.51e-8	Type 2 diabetes;Type 1 diabetes;
CESC	cis	rs644799	1.000	rs543530	chr11:95545170	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.53	6.41	0.37	6.77e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs4568518	0.740	rs10429191	chr7:18009097	G/A	cg03009463	chr7:17980271	SNX13	0.46	6.0	0.35	6.45e-9	Measles;
CESC	cis	rs1034435	0.755	rs5767173	chr22:48892473	T/C	cg05992904	chr22:48892994	FAM19A5	-0.56	-9.93	-0.52	6e-20	Late-onset Alzheimer's disease;
CESC	cis	rs7481584	0.624	rs693687	chr11:3052494	A/G	cg08508325	chr11:3079039	CARS	0.29	5.2	0.3	3.96e-7	Calcium levels;
CESC	cis	rs4253772	0.591	rs11703245	chr22:46684890	A/G	cg00784671	chr22:46762841	CELSR1	-0.57	-5.47	-0.32	1.03e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs6693567	0.586	rs9661040	chr1:150483236	A/C	cg09579323	chr1:150459698	TARS2	0.47	5.85	0.34	1.41e-8	Migraine;
CESC	cis	rs6964587	1.000	rs3753107	chr7:91629151	C/T	cg17063962	chr7:91808500	NA	-0.56	-7.7	-0.43	2.64e-13	Breast cancer;
CESC	cis	rs3733585	0.673	rs4447861	chr4:9953940	C/T	cg02734326	chr4:10020555	SLC2A9	-0.39	-5.64	-0.33	4.45e-8	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs61776719	0.520	rs72661887	chr1:38416310	C/T	cg12658694	chr1:38397304	INPP5B	0.64	9.15	0.49	1.55e-17	Coronary artery disease;
CESC	cis	rs7618915	0.501	rs2109634	chr3:52752075	T/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.53	7.89	0.44	7.99e-14	Bipolar disorder;
CESC	cis	rs514406	0.505	rs374662	chr1:53164549	C/A	cg27535305	chr1:53392650	SCP2	-0.33	-5.42	-0.32	1.31e-7	Monocyte count;
CESC	cis	rs12497850	0.863	rs4974084	chr3:48939080	G/A	cg07636037	chr3:49044803	WDR6	1.03	19.22	0.76	3.77e-52	Parkinson's disease;
CESC	cis	rs6088580	0.634	rs6088483	chr20:32984714	T/A	cg24642439	chr20:33292090	TP53INP2	-0.53	-6.98	-0.39	2.39e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs1448094	0.791	rs10863110	chr12:86328523	T/C	cg02569458	chr12:86230093	RASSF9	0.45	6.43	0.37	5.79e-10	Major depressive disorder;
CESC	cis	rs4478858	0.806	rs6686845	chr1:31708796	A/T	cg00250761	chr1:31883323	NA	-0.28	-5.39	-0.31	1.57e-7	Alcohol dependence;
CESC	cis	rs6964587	1.000	rs2282968	chr7:91580287	A/C	cg17063962	chr7:91808500	NA	-0.54	-7.12	-0.4	9.86e-12	Breast cancer;
CESC	cis	rs7666738	0.753	rs6826709	chr4:98714553	C/G	cg03467027	chr4:99064603	C4orf37	0.43	5.35	0.31	1.93e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3091242	0.900	rs669063	chr1:25721154	A/G	cg03538708	chr1:25844672	NA	-0.38	-5.79	-0.33	2.02e-8	Erythrocyte sedimentation rate;
CESC	cis	rs4713118	0.662	rs9380046	chr6:28030499	T/C	cg23281280	chr6:28129359	ZNF389	0.5	6.51	0.37	3.72e-10	Parkinson's disease;
CESC	cis	rs5750830	0.595	rs4821892	chr22:39795683	G/C	cg01416388	chr22:39784598	NA	-0.6	-7.47	-0.42	1.19e-12	Intelligence (multi-trait analysis);
CESC	cis	rs10540	1.000	rs71487296	chr11:500282	G/A	cg03934478	chr11:495069	RNH1	0.56	5.41	0.32	1.38e-7	Body mass index;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20413923	chr1:27022645	ARID1A	0.51	6.02	0.35	5.88e-9	Gut microbiome composition (summer);
CESC	cis	rs3015497	0.603	rs3015447	chr14:51082586	T/C	cg26011998	chr14:51135199	SAV1	-0.47	-5.38	-0.31	1.6e-7	Mean platelet volume;
CESC	cis	rs9308731	0.644	rs3789065	chr2:111915022	C/G	cg04202892	chr2:111875749	ACOXL	0.44	6.43	0.37	5.83e-10	Chronic lymphocytic leukemia;
CESC	cis	rs6732160	0.657	rs10171459	chr2:73434728	A/C	cg01422370	chr2:73384389	NA	0.44	7.38	0.41	1.99e-12	Intelligence (multi-trait analysis);
CESC	cis	rs77106637	0.929	rs74333814	chr11:72457487	C/T	cg04827223	chr11:72435913	ARAP1	-0.57	-5.49	-0.32	9.2e-8	Type 2 diabetes;
CESC	cis	rs708547	0.647	rs1626594	chr4:57878254	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.47	6.61	0.38	2.11e-10	Response to bleomycin (chromatid breaks);
CESC	cis	rs684232	0.666	rs2254134	chr17:628664	A/G	cg15660573	chr17:549704	VPS53	-0.6	-8.04	-0.44	2.94e-14	Prostate cancer;
CESC	cis	rs7659604	0.502	rs10212738	chr4:122675724	G/A	cg19671926	chr4:122722719	EXOSC9	0.53	6.7	0.38	1.21e-10	Type 2 diabetes;
CESC	cis	rs9583531	0.574	rs7319459	chr13:111352408	T/C	cg24331049	chr13:111365604	ING1	-0.71	-10.41	-0.54	1.66e-21	Coronary artery disease;
CESC	cis	rs9457247	1.000	rs394522	chr6:167398071	A/C	cg23791538	chr6:167370224	RNASET2	-0.59	-8.43	-0.46	2.21e-15	Crohn's disease;
CESC	cis	rs763121	0.853	rs5750652	chr22:39048316	A/G	cg06544989	chr22:39130855	UNC84B	0.5	9.27	0.49	6.78e-18	Menopause (age at onset);
CESC	cis	rs9733	0.596	rs2175615	chr1:150624101	A/G	cg04414720	chr1:150670196	GOLPH3L	0.63	9.04	0.49	3.47e-17	Tonsillectomy;
CESC	cis	rs2836974	0.836	rs1041440	chr21:40627325	C/T	cg11890956	chr21:40555474	PSMG1	1.16	21.18	0.79	6.14e-59	Cognitive function;
CESC	cis	rs4604732	0.631	rs10754561	chr1:247622800	A/G	cg12754571	chr1:247694271	LOC148824;OR2C3	0.37	5.19	0.3	4.17e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs7666738	0.830	rs7659006	chr4:98934529	T/C	cg05340658	chr4:99064831	C4orf37	0.82	12.54	0.61	1.29e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11997175	0.574	rs4733456	chr8:33656359	C/T	ch.8.33884649F	chr8:33765107	NA	0.66	8.69	0.47	3.79e-16	Body mass index;
CESC	cis	rs1878931	0.567	rs7196196	chr16:3411855	C/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.96	14.37	0.66	5.2e-35	Body mass index (adult);
CESC	cis	rs9815354	0.597	rs17283481	chr3:41924015	T/C	cg03022575	chr3:42003672	ULK4	0.71	6.44	0.37	5.46e-10	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs4604732	0.536	rs4925674	chr1:247636906	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.57	7.92	0.44	6.57e-14	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs6867032	0.958	rs4975797	chr5:2015573	G/A	cg26168224	chr5:2018326	NA	0.96	19.64	0.77	1.3e-53	Gut microbiome composition (winter);
CESC	cis	rs57506017	0.585	rs6460902	chr7:12255511	G/A	cg23422036	chr7:12250390	TMEM106B	0.39	5.25	0.31	3.16e-7	Neuroticism;
CESC	cis	rs6460942	0.915	rs7809263	chr7:12450589	C/G	cg20607287	chr7:12443886	VWDE	-0.67	-8.34	-0.46	4.15e-15	Coronary artery disease;
CESC	cis	rs3087591	0.887	rs1013946	chr17:29530350	A/C	cg24425628	chr17:29625626	OMG;NF1	0.43	5.28	0.31	2.71e-7	Hip circumference;
CESC	cis	rs9303401	0.614	rs3803753	chr17:56540110	G/A	cg25039879	chr17:56429692	SUPT4H1	0.53	5.39	0.31	1.55e-7	Cognitive test performance;
CESC	cis	rs6952808	0.656	rs11764212	chr7:2067593	C/A	cg23048001	chr7:2026167	MAD1L1	0.5	6.56	0.37	2.85e-10	Bipolar disorder and schizophrenia;
CESC	cis	rs6723226	0.679	rs116617324	chr2:32622709	C/T	cg02381751	chr2:32503542	YIPF4	-0.56	-7.28	-0.41	3.86e-12	Intelligence (multi-trait analysis);
CESC	cis	rs412050	0.793	rs74576380	chr22:22283280	A/G	cg17089214	chr22:22089827	YPEL1	0.68	5.8	0.34	1.91e-8	Attention deficit hyperactivity disorder;
CESC	cis	rs2072499	0.833	rs2251847	chr1:156204047	G/A	cg25208724	chr1:156163844	SLC25A44	0.83	13.26	0.63	3.87e-31	Testicular germ cell tumor;
CESC	trans	rs3942852	0.703	rs11039513	chr11:48107204	C/T	cg03929089	chr4:120376271	NA	0.59	7.16	0.4	7.95e-12	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs2236918	0.932	rs1635501	chr1:242040775	C/T	cg17736920	chr1:242011382	EXO1	0.57	7.79	0.43	1.52e-13	Menopause (age at onset);
CESC	cis	rs17854409	0.881	rs68091818	chr20:61479882	A/C	cg07645718	chr20:61493192	TCFL5	0.82	6.0	0.35	6.51e-9	Obesity-related traits;
CESC	cis	rs854765	0.964	rs854810	chr17:18006421	G/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.46	-6.09	-0.35	3.92e-9	Total body bone mineral density;
CESC	cis	rs7552404	1.000	rs12127402	chr1:76205643	C/A	cg10523679	chr1:76189770	ACADM	0.73	8.74	0.47	2.81e-16	Blood metabolite levels;Acylcarnitine levels;
CESC	trans	rs17685	0.753	rs2868203	chr7:75680026	G/A	cg19862616	chr7:65841803	NCRNA00174	-0.84	-12.47	-0.61	2.15e-28	Coffee consumption;Coffee consumption (cups per day);
CESC	trans	rs9929218	0.551	rs9888942	chr16:68727572	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.93	15.66	0.69	1.35e-39	Colorectal cancer;
CESC	cis	rs9914988	0.887	rs12948575	chr17:27130520	G/A	cg20469991	chr17:27169893	C17orf63	-0.48	-5.25	-0.31	3.18e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CESC	cis	rs12188164	1.000	rs34847072	chr5:437862	G/C	cg15813090	chr5:442598	EXOC3;C5orf55	0.41	6.22	0.36	1.89e-9	Cystic fibrosis severity;
CESC	trans	rs3942852	0.703	rs11039513	chr11:48107204	C/T	cg15704280	chr7:45808275	SEPT13	0.68	8.61	0.47	6.57e-16	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs1865760	0.566	rs9358904	chr6:26068566	C/T	cg17691542	chr6:26056736	HIST1H1C	0.44	5.86	0.34	1.4e-8	Height;
CESC	cis	rs2228479	0.850	rs11076624	chr16:89855749	T/C	cg06558623	chr16:89946397	TCF25	1.18	9.44	0.5	1.97e-18	Skin colour saturation;
CESC	cis	rs7666738	0.800	rs13106995	chr4:99028790	A/T	cg17366294	chr4:99064904	C4orf37	0.62	8.95	0.48	6.32e-17	Colonoscopy-negative controls vs population controls;
CESC	cis	rs734999	0.588	rs745367	chr1:2524457	T/C	cg20673091	chr1:2541236	MMEL1	0.43	7.25	0.41	4.49e-12	Ulcerative colitis;
CESC	cis	rs12497850	0.931	rs10780033	chr3:48891275	T/C	cg03060546	chr3:49711283	APEH	0.44	5.38	0.31	1.61e-7	Parkinson's disease;
CESC	cis	rs7618915	0.501	rs11130308	chr3:52639257	G/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.6	8.56	0.47	9.4e-16	Bipolar disorder;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg16506072	chr16:85833520	COX4NB;COX4I1	-0.41	-6.35	-0.36	9.11e-10	Gambling;
CESC	cis	rs208520	0.874	rs208518	chr6:66948501	C/G	cg07460842	chr6:66804631	NA	0.89	10.69	0.55	2.12e-22	Exhaled nitric oxide output;
CESC	cis	rs4588572	0.643	rs7700390	chr5:77789532	T/C	cg11547950	chr5:77652471	NA	-0.45	-5.74	-0.33	2.53e-8	Triglycerides;
CESC	cis	rs858239	1.000	rs199347	chr7:23293746	A/G	cg23682824	chr7:23144976	KLHL7	0.4	5.34	0.31	2.01e-7	Cerebrospinal fluid biomarker levels;
CESC	cis	rs9311474	0.659	rs7638808	chr3:52572056	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	-0.39	-7.52	-0.42	8.27e-13	Electroencephalogram traits;
CESC	trans	rs11098499	0.739	rs10013032	chr4:120149419	C/T	cg25214090	chr10:38739885	LOC399744	-0.56	-7.5	-0.42	9.44e-13	Corneal astigmatism;
CESC	cis	rs9309473	0.898	rs7587577	chr2:73832786	C/T	cg20560298	chr2:73613845	ALMS1	-0.54	-7.04	-0.4	1.6e-11	Metabolite levels;
CESC	cis	rs6598955	0.515	rs61776655	chr1:26541430	T/C	cg04990556	chr1:26633338	UBXN11	-0.71	-9.87	-0.52	8.96e-20	Obesity-related traits;
CESC	trans	rs473518	0.891	rs554133	chr18:20103754	C/T	cg20346503	chr2:128994402	NA	-0.45	-6.06	-0.35	4.69e-9	Migraine - clinic-based;
CESC	cis	rs13118159	0.801	rs13147602	chr4:1332175	A/G	cg20887711	chr4:1340912	KIAA1530	0.65	8.85	0.48	1.26e-16	Longevity;
CESC	cis	rs2124969	0.548	rs62175384	chr2:161011128	C/T	cg03641300	chr2:160917029	PLA2R1	-0.57	-5.87	-0.34	1.29e-8	Waist circumference adjusted for body mass index;
CESC	cis	rs6088590	0.930	rs6120723	chr20:33364655	C/T	cg24642439	chr20:33292090	TP53INP2	0.84	11.81	0.59	3.81e-26	Coronary artery disease;
CESC	cis	rs875971	0.545	rs7810213	chr7:65946579	G/C	cg25405998	chr7:65216604	CCT6P1	0.5	5.36	0.31	1.81e-7	Aortic root size;
CESC	cis	rs11638352	0.661	rs11857696	chr15:44366258	T/A	cg02155558	chr15:43621948	ADAL;LCMT2	-0.5	-5.46	-0.32	1.09e-7	Lipoprotein phospholipase A2 activity in cardiovascular disease;
CESC	cis	rs853679	0.550	rs1237875	chr6:28173010	A/G	cg17949981	chr6:28129498	ZNF389	-0.41	-5.2	-0.3	4.08e-7	Depression;
CESC	trans	rs561341	1.000	rs72825740	chr17:30338356	A/G	cg27661571	chr11:113659931	NA	-0.86	-7.65	-0.43	3.84e-13	Hip circumference adjusted for BMI;
CESC	cis	rs1799949	1.000	rs33946455	chr17:41321846	C/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.42	5.71	0.33	3.01e-8	Menopause (age at onset);
CESC	cis	rs9660992	0.649	rs72745216	chr1:205261016	G/A	cg21643547	chr1:205240462	TMCC2	-0.47	-6.25	-0.36	1.6e-9	Mean corpuscular volume;Mean platelet volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00298532	chr1:9790325	CLSTN1	-0.59	-6.56	-0.37	2.78e-10	Gut microbiome composition (summer);
CESC	cis	rs4555082	0.718	rs28513571	chr14:105709592	C/A	cg06808227	chr14:105710500	BRF1	-0.59	-7.1	-0.4	1.16e-11	Mean platelet volume;Platelet distribution width;
CESC	cis	rs7223966	1.000	rs78172786	chr17:61847114	A/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.45	-5.08	-0.3	7.28e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs10911232	0.507	rs4652765	chr1:182994147	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.84	13.19	0.63	6.74e-31	Hypertriglyceridemia;
CESC	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg11494091	chr17:61959527	GH2	0.72	12.38	0.61	4.46e-28	Prudent dietary pattern;
CESC	cis	rs7100689	0.646	rs6585946	chr10:82118292	G/T	cg00277334	chr10:82204260	NA	-0.58	-7.76	-0.43	1.84e-13	Post bronchodilator FEV1;
CESC	cis	rs8053891	0.615	rs3794695	chr16:72097827	C/T	cg01557791	chr16:72042693	DHODH	-0.51	-5.17	-0.3	4.73e-7	Coronary artery disease;
CESC	cis	rs4889855	0.556	rs3923514	chr17:78515210	A/G	cg16591659	chr17:78472290	NA	0.37	5.93	0.34	9.29e-9	Fractional excretion of uric acid;
CESC	cis	rs11098499	0.774	rs11098505	chr4:120284627	C/T	cg09307838	chr4:120376055	NA	0.87	12.16	0.6	2.41e-27	Corneal astigmatism;
CESC	cis	rs8077577	0.747	rs2071242	chr17:18154510	T/C	cg16794390	chr17:18148240	FLII	0.41	6.24	0.36	1.69e-9	Obesity-related traits;
CESC	cis	rs10256972	0.616	rs6463001	chr7:1108272	A/C	cg09177884	chr7:1199841	ZFAND2A	-0.52	-6.64	-0.38	1.73e-10	Longevity;Endometriosis;
CESC	cis	rs2070488	0.965	rs35553573	chr3:38441439	C/T	cg24069376	chr3:38537580	EXOG	0.46	8.43	0.46	2.31e-15	Electrocardiographic conduction measures;
CESC	cis	rs9487051	0.872	rs1111865	chr6:109610863	A/G	cg21918786	chr6:109611834	NA	0.37	5.59	0.32	5.7e-8	Reticulocyte fraction of red cells;
CESC	cis	rs4862750	0.872	rs6830828	chr4:187897472	T/G	cg22105103	chr4:187893119	NA	0.5	7.32	0.41	2.98e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4555082	0.915	rs2816632	chr14:105741355	C/T	cg13114125	chr14:105738426	BRF1	0.62	8.13	0.45	1.61e-14	Mean platelet volume;Platelet distribution width;
CESC	cis	rs8177253	0.965	rs1525889	chr3:133490033	A/C	cg12373951	chr3:133503437	NA	0.38	5.32	0.31	2.23e-7	Iron status biomarkers;
CESC	cis	rs10256972	0.900	rs7812072	chr7:1053862	A/G	cg04025307	chr7:1156635	C7orf50	0.39	6.28	0.36	1.4e-9	Longevity;Endometriosis;
CESC	cis	rs9473147	0.543	rs9473126	chr6:47481833	C/G	cg20196966	chr6:47445060	CD2AP	0.41	5.33	0.31	2.13e-7	Platelet distribution width;Mean platelet volume;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg10355708	chr8:145618298	ADCK5	-0.47	-6.21	-0.36	2.01e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs9322193	0.810	rs62439811	chr6:149961552	C/T	cg07701084	chr6:150067640	NUP43	0.41	5.57	0.32	6.14e-8	Lung cancer;
CESC	cis	rs17253792	0.822	rs79618862	chr14:56093971	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.77	5.98	0.34	7.23e-9	Putamen volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09509543	chr4:119757682	SEC24D	-0.62	-6.84	-0.39	5.44e-11	Gut microbiome composition (summer);
CESC	cis	rs10861342	0.579	rs77585712	chr12:105482251	T/C	cg23923672	chr12:105501055	KIAA1033	0.71	5.31	0.31	2.29e-7	IgG glycosylation;
CESC	trans	rs1728785	0.901	rs1728787	chr16:68593042	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.65	7.84	0.43	1.09e-13	Ulcerative colitis;
CESC	cis	rs709400	1.000	rs57218990	chr14:104128007	T/A	cg24130564	chr14:104152367	KLC1	-0.42	-5.42	-0.32	1.36e-7	Body mass index;
CESC	cis	rs992157	0.700	rs10165153	chr2:219159629	T/C	cg20019365	chr2:219134978	PNKD;AAMP	0.68	9.02	0.48	3.81e-17	Colorectal cancer;
CESC	cis	rs7666738	0.830	rs6532723	chr4:99052147	A/T	cg24818145	chr4:99064322	C4orf37	0.38	5.04	0.3	8.49e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg26163375	chr1:1209720	UBE2J2	-0.48	-6.72	-0.38	1.12e-10	Fibrinogen levels;
CESC	cis	rs13108904	0.901	rs4493484	chr4:1279944	G/A	cg22903657	chr4:1355424	KIAA1530	-0.38	-5.18	-0.3	4.5e-7	Obesity-related traits;
CESC	cis	rs977987	0.836	rs4888376	chr16:75322573	T/C	cg03315344	chr16:75512273	CHST6	0.37	5.31	0.31	2.28e-7	Dupuytren's disease;
CESC	cis	rs66530629	0.874	rs10903102	chr1:25122839	C/G	cg22509179	chr1:25234806	RUNX3	-0.43	-5.47	-0.32	1.05e-7	Plateletcrit;
CESC	trans	rs28549925	0.590	rs9690465	chr7:16987494	C/T	cg12639933	chr12:57626296	SHMT2	0.95	6.1	0.35	3.83e-9	Congenital heart disease (maternal effect);Conotruncal heart defects (maternal effects);
CESC	cis	rs6502050	0.865	rs8073679	chr17:80155343	G/A	cg11859384	chr17:80120422	CCDC57	-0.38	-5.26	-0.31	3e-7	Life satisfaction;
CESC	cis	rs55692411	0.517	rs62262106	chr3:49991427	A/G	cg03060546	chr3:49711283	APEH	-0.48	-5.53	-0.32	7.62e-8	Intelligence (multi-trait analysis);
CESC	cis	rs6963495	0.745	rs55906043	chr7:105165367	T/G	cg02135003	chr7:105160482	PUS7	-0.46	-5.55	-0.32	6.92e-8	Bipolar disorder (body mass index interaction);
CESC	cis	rs11122272	0.735	rs2486745	chr1:231505717	T/C	cg06096015	chr1:231504339	EGLN1	0.43	6.18	0.35	2.42e-9	Hemoglobin concentration;
CESC	cis	rs523522	0.962	rs11065154	chr12:120971417	T/C	cg27279351	chr12:120934652	DYNLL1	0.69	9.11	0.49	2.02e-17	High light scatter reticulocyte count;
CESC	cis	rs79349575	0.749	rs957557	chr17:47003221	G/T	cg26022315	chr17:47021804	SNF8	0.39	5.18	0.3	4.5e-7	Type 2 diabetes;
CESC	cis	rs6952808	0.582	rs10479762	chr7:2045351	T/C	cg02951883	chr7:2050386	MAD1L1	0.46	6.03	0.35	5.44e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs300703	0.678	rs423643	chr2:199648	A/C	cg21211680	chr2:198530	NA	1.02	10.81	0.55	8.46e-23	Blood protein levels;
CESC	cis	rs11864453	0.612	rs11862813	chr16:72132356	C/T	cg16558253	chr16:72132732	DHX38	-0.54	-8.48	-0.46	1.6e-15	Fibrinogen levels;
CESC	cis	rs6543140	0.865	rs6760275	chr2:103079607	C/T	cg04239558	chr2:103089729	SLC9A4	0.47	6.16	0.35	2.64e-9	Blood protein levels;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg14159963	chr7:116139849	CAV2	-0.47	-6.05	-0.35	4.87e-9	Fibrinogen levels;
CESC	cis	rs7772486	0.875	rs2474356	chr6:146296798	G/A	cg05347473	chr6:146136440	FBXO30	0.54	6.99	0.39	2.28e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs897984	0.683	rs8046001	chr16:30833321	C/T	cg00531865	chr16:30841666	NA	-0.58	-8.58	-0.47	8.14e-16	Dementia with Lewy bodies;
CESC	cis	rs2370759	1.000	rs11599522	chr10:32568434	G/C	cg01819863	chr10:32635814	EPC1	1.15	12.94	0.62	4.99e-30	Sexual dysfunction (female);
CESC	cis	rs2836974	0.897	rs2026267	chr21:40711477	C/A	cg17971929	chr21:40555470	PSMG1	0.94	12.96	0.62	4.46e-30	Cognitive function;
CESC	cis	rs10752881	1.000	rs8179282	chr1:182974598	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.83	13.12	0.63	1.19e-30	Colorectal cancer;
CESC	cis	rs78456975	0.941	rs6755875	chr2:1557109	T/C	cg26248373	chr2:1572462	NA	-0.59	-5.7	-0.33	3.26e-8	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg24846343	chr22:24311635	DDTL	-0.67	-11.22	-0.57	3.6e-24	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs72634258	0.699	rs2493214	chr1:7994420	A/G	cg00042356	chr1:8021962	PARK7	0.46	5.33	0.31	2.15e-7	Inflammatory bowel disease;
CESC	cis	rs12762955	0.507	rs7095853	chr10:1040798	T/C	cg06753689	chr10:1034030	GTPBP4	0.5	5.03	0.3	8.97e-7	Response to angiotensin II receptor blocker therapy;
CESC	cis	rs698813	0.604	rs11676798	chr2:44479982	G/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.48	5.48	0.32	9.84e-8	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
CESC	cis	rs7520050	0.778	rs2991985	chr1:46080530	T/C	cg03146154	chr1:46216737	IPP	-0.51	-6.81	-0.39	6.4e-11	Red blood cell count;Reticulocyte count;
CESC	cis	rs36051895	0.659	rs62541540	chr9:5040080	A/G	cg02405213	chr9:5042618	JAK2	-0.48	-5.69	-0.33	3.28e-8	Pediatric autoimmune diseases;
CESC	cis	rs9389248	0.737	rs12664956	chr6:135384188	T/C	cg24558204	chr6:135376177	HBS1L	0.71	9.63	0.51	5.3e-19	High light scatter reticulocyte percentage of red cells;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg27556566	chr18:29671984	RNF138	-0.47	-6.93	-0.39	3.13e-11	Gambling;
CESC	cis	rs7208859	0.573	rs8078656	chr17:29080971	A/T	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.17e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs10088262	0.629	rs7827665	chr8:124804190	G/A	cg02993010	chr8:124780839	FAM91A1	-0.67	-8.56	-0.47	9.13e-16	Pancreatic cancer;
CESC	cis	rs9488822	0.702	rs12196154	chr6:116327471	T/G	cg26893134	chr6:116381904	FRK	0.25	6.02	0.35	5.89e-9	Cholesterol, total;LDL cholesterol;
CESC	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg23034840	chr1:205782522	SLC41A1	0.67	8.26	0.45	7.02e-15	Menarche (age at onset);
CESC	cis	rs2625529	0.652	rs2957750	chr15:72332258	C/T	cg16672083	chr15:72433130	SENP8	0.46	7.22	0.41	5.65e-12	Red blood cell count;
CESC	cis	rs5758659	0.935	rs134879	chr22:42664201	A/C	cg15557168	chr22:42548783	NA	-0.5	-8.0	-0.44	3.92e-14	Cognitive function;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg06564803	chr16:70100193	PDXDC2	0.41	6.1	0.35	3.84e-9	Systemic lupus erythematosus;
CESC	cis	rs1218582	0.774	rs4845679	chr1:154861187	G/T	cg06221963	chr1:154839813	KCNN3	-0.7	-11.99	-0.59	9.73e-27	Prostate cancer;
CESC	cis	rs1862618	0.853	rs252887	chr5:56166188	A/G	cg24531977	chr5:56204891	C5orf35	-0.88	-10.96	-0.56	2.74e-23	Initial pursuit acceleration;
CESC	cis	rs6496667	0.533	rs2589949	chr15:90955015	C/T	cg22089800	chr15:90895588	ZNF774	0.43	5.57	0.32	6.25e-8	Rheumatoid arthritis;
CESC	cis	rs7829975	0.593	rs2979241	chr8:8303353	G/C	cg06636001	chr8:8085503	FLJ10661	0.53	6.99	0.39	2.22e-11	Mood instability;
CESC	cis	rs7927771	0.839	rs3817334	chr11:47650993	C/T	cg05585544	chr11:47624801	NA	-0.44	-6.99	-0.39	2.17e-11	Subjective well-being;
CESC	cis	rs4819052	0.851	rs2838858	chr21:46681093	T/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.47	5.88	0.34	1.23e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs11098499	0.754	rs1546503	chr4:120241167	T/C	cg09307838	chr4:120376055	NA	0.79	10.65	0.55	2.89e-22	Corneal astigmatism;
CESC	cis	rs4820294	1.000	rs713835	chr22:38064650	C/T	cg21798802	chr22:38057573	PDXP	0.46	7.99	0.44	4.16e-14	Fat distribution (HIV);
CESC	cis	rs6724607	0.875	rs9630991	chr2:191432139	G/A	cg27211696	chr2:191398769	TMEM194B	0.54	7.75	0.43	1.91e-13	Pulse pressure;
CESC	cis	rs9916302	0.904	rs10491128	chr17:37551988	G/A	cg15445000	chr17:37608096	MED1	-0.4	-6.35	-0.36	9.2e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs6570726	0.846	rs441575	chr6:145849205	A/C	cg05347473	chr6:146136440	FBXO30	0.49	6.62	0.38	1.96e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9584850	0.834	rs7985565	chr13:99113471	C/G	cg20750642	chr13:99100586	FARP1	-0.38	-5.92	-0.34	9.73e-9	Neuroticism;
CESC	cis	rs9287719	0.967	rs10929682	chr2:10732189	C/A	cg02196655	chr2:10830764	NOL10	-0.36	-5.57	-0.32	6.1e-8	Prostate cancer;
CESC	cis	rs3806843	0.705	rs2530230	chr5:140088131	G/A	cg26395211	chr5:140044315	WDR55	0.48	6.1	0.35	3.71e-9	Depressive symptoms (multi-trait analysis);
CESC	cis	rs7412746	0.658	rs11582281	chr1:150826831	T/C	cg17724175	chr1:150552817	MCL1	0.41	6.3	0.36	1.24e-9	Melanoma;
CESC	cis	rs2576037	0.562	rs477826	chr18:44397649	A/G	cg19077165	chr18:44547161	KATNAL2	-0.61	-9.19	-0.49	1.2e-17	Personality dimensions;
CESC	cis	rs763121	0.853	rs2235230	chr22:39124467	A/G	cg06544989	chr22:39130855	UNC84B	-0.48	-7.94	-0.44	5.83e-14	Menopause (age at onset);
CESC	cis	rs1395	0.744	rs1975384	chr2:27542041	C/T	cg22903471	chr2:27725779	GCKR	-0.47	-5.67	-0.33	3.72e-8	Blood metabolite levels;
CESC	cis	rs6061231	0.556	rs6121571	chr20:60977323	T/G	cg15674680	chr20:60982522	CABLES2	0.51	6.28	0.36	1.37e-9	Colorectal cancer;
CESC	cis	rs897984	0.513	rs17839568	chr16:31099783	T/C	cg02466173	chr16:30829666	NA	-0.4	-6.79	-0.38	7.45e-11	Dementia with Lewy bodies;
CESC	cis	rs9322193	0.847	rs9505972	chr6:150096391	A/C	cg04369109	chr6:150039330	LATS1	-0.47	-6.36	-0.36	9.04e-10	Lung cancer;
CESC	cis	rs1348850	0.567	rs1527401	chr2:178522104	C/T	cg22681709	chr2:178499509	PDE11A	-0.5	-8.12	-0.45	1.78e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs1003719	0.788	rs1155787	chr21:38448069	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.62	8.64	0.47	5.56e-16	Eye color traits;
CESC	cis	rs1707322	0.721	rs10789470	chr1:46158331	T/G	cg03146154	chr1:46216737	IPP	0.82	11.54	0.58	3.18e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs57083693	0.518	rs7315815	chr12:101747517	C/G	cg22051763	chr12:101673672	UTP20	-0.44	-5.52	-0.32	8.05e-8	Alcohol dependence (age at onset);
CESC	cis	rs4689388	0.819	rs12649341	chr4:6294759	G/A	cg00701064	chr4:6280414	WFS1	0.68	11.71	0.58	8.68e-26	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs2486288	0.656	rs12899058	chr15:45547324	G/A	cg21132104	chr15:45694354	SPATA5L1	-0.54	-6.54	-0.37	3.21e-10	Glomerular filtration rate;
CESC	cis	rs2439831	0.867	rs2412779	chr15:43655927	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.93	11.25	0.57	2.98e-24	Lung cancer in ever smokers;
CESC	cis	rs8180040	0.966	rs17476234	chr3:47326298	G/A	cg27129171	chr3:47204927	SETD2	-0.66	-10.07	-0.53	2.14e-20	Colorectal cancer;
CESC	cis	rs3096299	0.967	rs2965827	chr16:89457350	A/C	cg08822215	chr16:89438651	ANKRD11	0.41	6.5	0.37	3.94e-10	Multiple myeloma (IgH translocation);
CESC	cis	rs9614461	0.826	rs9614649	chr22:45746097	C/A	cg15911859	chr22:45810043	RIBC2;SMC1B	0.68	7.52	0.42	8.52e-13	Tonsillectomy;
CESC	cis	rs7107174	0.892	rs10431155	chr11:78121978	T/C	cg02023728	chr11:77925099	USP35	0.43	5.5	0.32	8.8e-8	Testicular germ cell tumor;
CESC	trans	rs1814175	0.645	rs1851869	chr11:49960552	T/C	cg15704280	chr7:45808275	SEPT13	-1.01	-19.0	-0.76	2.27e-51	Height;
CESC	cis	rs7552404	1.000	rs4949874	chr1:76161889	T/C	cg03433033	chr1:76189801	ACADM	0.68	8.14	0.45	1.54e-14	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg11301795	chr4:187892539	NA	-0.75	-12.33	-0.6	6.74e-28	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4253772	0.550	rs55926596	chr22:46682955	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.66	5.24	0.31	3.26e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs35306767	0.715	rs12772979	chr10:1034412	C/T	cg25019033	chr10:957182	NA	-0.65	-6.31	-0.36	1.18e-9	Eosinophil percentage of granulocytes;
CESC	trans	rs10776614	0.799	rs7071095	chr10:49763818	A/C	cg19218067	chr2:181235115	NA	0.5	6.1	0.35	3.7e-9	Self-employment;
CESC	cis	rs7605827	0.897	rs6753675	chr2:15539706	C/T	cg19274914	chr2:15703543	NA	0.36	6.55	0.37	2.91e-10	Educational attainment (years of education);
CESC	cis	rs11098499	0.954	rs12508504	chr4:120410607	A/C	cg09307838	chr4:120376055	NA	0.93	13.81	0.65	4.64e-33	Corneal astigmatism;
CESC	cis	rs10823500	0.777	rs2184335	chr10:72006891	C/T	cg02100629	chr10:71892760	AIFM2	-0.37	-5.71	-0.33	3.03e-8	Blood protein levels;
CESC	cis	rs10129255	0.957	rs12589190	chr14:107191316	C/T	cg23076370	chr14:107095027	NA	-0.47	-5.98	-0.34	7.21e-9	Kawasaki disease;
CESC	cis	rs4975709	0.610	rs4975704	chr5:1859807	C/A	cg11168104	chr5:1857477	NA	-0.36	-5.24	-0.31	3.29e-7	Cardiovascular disease risk factors;
CESC	cis	rs40363	0.645	rs250633	chr16:3523002	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.54	-6.97	-0.39	2.56e-11	Tuberculosis;
CESC	cis	rs2576037	0.796	rs2571032	chr18:44578250	T/A	cg19077165	chr18:44547161	KATNAL2	0.52	7.41	0.41	1.74e-12	Personality dimensions;
CESC	trans	rs673604	0.505	rs676614	chr1:36107510	G/T	cg15779458	chr2:233415951	TIGD1;EIF4E2	0.55	6.2	0.36	2.12e-9	Endometrial cancer;
CESC	cis	rs713587	0.646	rs2384061	chr2:25135620	C/T	cg01884057	chr2:25150051	NA	0.29	5.54	0.32	7.2e-8	Body mass index in non-asthmatics;
CESC	cis	rs17001868	0.568	rs742140	chr22:40781586	G/A	cg07138101	chr22:40742427	ADSL	0.57	5.55	0.32	7.07e-8	Mammographic density (dense area);
CESC	cis	rs5769765	1.000	rs768619	chr22:50287266	C/T	cg26441486	chr22:50317300	CRELD2	0.38	5.37	0.31	1.77e-7	Schizophrenia;
CESC	cis	rs6433857	0.594	rs34526919	chr2:181522678	T/A	cg23363182	chr2:181467187	NA	-0.46	-6.16	-0.35	2.73e-9	Body mass index;
CESC	cis	rs3741404	0.825	rs60452247	chr11:63981507	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.89	13.01	0.62	3.06e-30	Platelet count;
CESC	cis	rs4423214	0.559	rs10898203	chr11:71203436	C/T	cg05163923	chr11:71159392	DHCR7	-0.66	-6.59	-0.38	2.38e-10	Vitamin D levels;
CESC	cis	rs367615	0.704	rs72804385	chr5:108848143	T/C	cg17395555	chr5:108820864	NA	0.61	10.98	0.56	2.33e-23	Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs739401	0.611	rs450817	chr11:3056712	A/G	cg08508325	chr11:3079039	CARS	-0.56	-11.1	-0.56	9.17e-24	Longevity;
CESC	cis	rs9291683	0.610	rs993172	chr4:10324361	G/T	cg11266682	chr4:10021025	SLC2A9	0.48	8.34	0.46	4.14e-15	Bone mineral density;
CESC	cis	rs8070740	0.841	rs2189337	chr17:5326178	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.51	6.44	0.37	5.73e-10	Menopause (age at onset);
CESC	cis	rs13108904	0.539	rs13135102	chr4:1330983	A/C	cg13395646	chr4:1353034	KIAA1530	-0.49	-6.22	-0.36	1.88e-9	Obesity-related traits;
CESC	cis	rs10411936	0.712	rs3810198	chr19:16601194	C/T	cg10248733	chr19:16607483	C19orf44;CALR3	0.58	6.83	0.39	5.83e-11	White blood cell count;Multiple sclerosis;
CESC	cis	rs12956009	0.583	rs7240132	chr18:44858634	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.46	-6.07	-0.35	4.44e-9	Educational attainment (years of education);
CESC	cis	rs2440129	0.611	rs11571335	chr17:6904263	C/T	cg08946332	chr17:6899888	ALOX12	0.45	6.52	0.37	3.51e-10	Tonsillectomy;
CESC	cis	rs1003719	0.628	rs2835635	chr21:38528866	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.56	-7.33	-0.41	2.73e-12	Eye color traits;
CESC	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.43	5.27	0.31	2.76e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs9303401	0.703	rs8072182	chr17:57211213	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.59	7.64	0.42	3.96e-13	Cognitive test performance;
CESC	cis	rs2011503	0.941	rs10422893	chr19:19372185	G/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.53	5.53	0.32	7.55e-8	Bipolar disorder;
CESC	cis	rs561341	0.505	rs548298	chr17:30297494	C/A	cg12193833	chr17:30244370	NA	-0.59	-6.02	-0.35	5.78e-9	Hip circumference adjusted for BMI;
CESC	cis	rs875971	0.862	rs1167408	chr7:65556108	G/A	cg19163074	chr7:65112434	INTS4L2	0.46	5.57	0.32	6.37e-8	Aortic root size;
CESC	cis	rs7267979	1.000	rs6050632	chr20:25432601	A/G	cg08601574	chr20:25228251	PYGB	0.38	5.64	0.33	4.4e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs875971	0.862	rs7782704	chr7:65805366	G/A	cg10691866	chr7:65817282	TPST1	0.31	5.23	0.31	3.43e-7	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13270404	chr8:99129495	POP1;HRSP12	0.62	7.04	0.4	1.69e-11	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.544	rs35160902	chr4:98974690	A/T	cg03467027	chr4:99064603	C4orf37	0.42	5.27	0.31	2.86e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24343413	chr1:151735844	OAZ3;MRPL9	0.56	7.12	0.4	1.01e-11	Gut microbiome composition (summer);
CESC	cis	rs3820928	0.605	rs2228555	chr2:227872995	C/T	cg11843606	chr2:227700838	RHBDD1	0.49	6.82	0.39	6.22e-11	Pulmonary function;
CESC	cis	rs9894429	1.000	rs7222241	chr17:79574714	C/G	cg21984481	chr17:79567631	NPLOC4	-0.5	-8.18	-0.45	1.2e-14	Eye color traits;
CESC	cis	rs7666738	0.791	rs1405766	chr4:98965389	T/C	cg05340658	chr4:99064831	C4orf37	0.8	12.39	0.61	3.96e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7772486	0.902	rs2144476	chr6:146322484	G/A	cg05347473	chr6:146136440	FBXO30	0.48	6.48	0.37	4.33e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs10392	0.571	rs6015982	chr20:37534369	C/T	cg27552599	chr20:37590471	DHX35	0.39	5.65	0.33	4.24e-8	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
CESC	trans	rs35110281	0.574	rs1836856	chr21:44964638	A/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.53	7.07	0.4	1.36e-11	Mean corpuscular volume;
CESC	cis	rs12476592	0.602	rs7571325	chr2:63785914	G/A	cg17519650	chr2:63277830	OTX1	-0.48	-5.42	-0.32	1.34e-7	Childhood ear infection;
CESC	cis	rs7210086	0.948	rs72849449	chr17:70638505	C/T	cg04206342	chr17:70636940	NA	-0.35	-6.01	-0.35	6.05e-9	Ulcerative colitis;
CESC	cis	rs875971	0.540	rs35510581	chr7:65578777	G/A	cg14393609	chr7:65229607	NA	-0.41	-5.33	-0.31	2.08e-7	Aortic root size;
CESC	cis	rs2576037	0.583	rs530205	chr18:44385150	C/T	cg19077165	chr18:44547161	KATNAL2	-0.62	-9.37	-0.5	3.26e-18	Personality dimensions;
CESC	cis	rs61776719	0.500	rs11210866	chr1:38449565	T/C	cg17077180	chr1:38461687	NA	0.47	7.13	0.4	9.57e-12	Coronary artery disease;
CESC	cis	rs3733585	0.699	rs28837683	chr4:9959808	C/T	cg02734326	chr4:10020555	SLC2A9	-0.44	-6.11	-0.35	3.58e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs2836950	0.520	rs2836966	chr21:40637521	A/G	cg11890956	chr21:40555474	PSMG1	-0.62	-8.49	-0.46	1.52e-15	Menarche (age at onset);
CESC	cis	rs9549367	0.713	rs9549681	chr13:113829873	T/C	cg00898013	chr13:113819073	PROZ	-0.55	-7.51	-0.42	8.85e-13	Platelet distribution width;
CESC	cis	rs2842992	0.789	rs2146163	chr6:160224346	T/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.75	9.56	0.51	8.73e-19	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs11098499	0.954	rs3733523	chr4:120423719	C/T	cg09307838	chr4:120376055	NA	0.93	13.08	0.63	1.67e-30	Corneal astigmatism;
CESC	trans	rs4919087	1.000	rs10786329	chr10:99074621	G/A	cg09150807	chr12:131568764	GPR133	-0.37	-6.07	-0.35	4.41e-9	Monocyte count;
CESC	cis	rs2306032	0.669	rs10838622	chr11:46856536	T/C	cg25783544	chr11:47291846	MADD	-0.4	-5.2	-0.3	4.09e-7	Total body bone mineral density;
CESC	cis	rs35146811	0.586	rs1076237	chr7:99585441	A/C	cg14163444	chr7:99595348	NA	-0.39	-5.24	-0.31	3.33e-7	Coronary artery disease;
CESC	cis	rs6121246	1.000	rs6121246	chr20:30433352	C/T	cg13852791	chr20:30311386	BCL2L1	0.76	7.67	0.43	3.38e-13	Mean corpuscular hemoglobin;
CESC	trans	rs561341	1.000	rs72823785	chr17:30273784	C/T	cg27661571	chr11:113659931	NA	-0.83	-7.62	-0.42	4.42e-13	Hip circumference adjusted for BMI;
CESC	cis	rs6120849	0.754	rs6120797	chr20:33606002	G/A	cg24642439	chr20:33292090	TP53INP2	0.68	6.77	0.38	8.46e-11	Protein C levels;
CESC	cis	rs1153858	1.000	rs1153849	chr15:45695695	G/A	cg10760299	chr15:45669010	GATM	0.37	5.14	0.3	5.42e-7	Homoarginine levels;
CESC	cis	rs12540874	0.728	rs3807563	chr7:50566390	C/T	cg18232548	chr7:50535776	DDC	-0.41	-5.49	-0.32	9.25e-8	Systemic sclerosis;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg16216227	chr4:174293382	SAP30	-0.41	-6.04	-0.35	5.19e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs7089973	0.646	rs35453961	chr10:116638166	T/C	cg25233709	chr10:116636983	FAM160B1	0.4	6.3	0.36	1.23e-9	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs1144333	1.000	rs76192904	chr1:76359995	C/T	cg22875332	chr1:76189707	ACADM	0.57	5.62	0.33	4.83e-8	Attention function in attention deficit hyperactive disorder;
CESC	cis	rs1218582	0.710	rs4845685	chr1:154878300	C/A	cg16680214	chr1:154839983	KCNN3	-0.44	-6.76	-0.38	8.73e-11	Prostate cancer;
CESC	cis	rs9487051	0.844	rs9386792	chr6:109609975	G/A	cg21918786	chr6:109611834	NA	-0.4	-6.05	-0.35	5.03e-9	Reticulocyte fraction of red cells;
CESC	cis	rs7551222	0.752	rs4252685	chr1:204496856	C/A	cg20240347	chr1:204465584	NA	-0.28	-5.74	-0.33	2.59e-8	Schizophrenia;
CESC	cis	rs4722166	0.630	rs12700391	chr7:22777327	C/A	cg05472934	chr7:22766657	IL6	0.87	10.94	0.56	3.06e-23	Lung cancer;
CESC	cis	rs12476592	0.602	rs6546009	chr2:63745742	G/C	cg17519650	chr2:63277830	OTX1	-0.48	-5.42	-0.32	1.34e-7	Childhood ear infection;
CESC	cis	rs7020830	0.571	rs7031314	chr9:37376122	A/T	cg14294708	chr9:37120828	ZCCHC7	-0.99	-12.35	-0.6	5.66e-28	Schizophrenia;
CESC	cis	rs7208859	0.623	rs11657662	chr17:29076347	A/G	cg19761014	chr17:28927070	LRRC37B2	-0.83	-6.55	-0.37	2.95e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs7618915	0.571	rs11130307	chr3:52607682	G/A	cg18404041	chr3:52824283	ITIH1	-0.41	-6.78	-0.38	7.61e-11	Bipolar disorder;
CESC	cis	rs11955398	0.625	rs34395679	chr5:59954716	A/G	cg02684056	chr5:59996105	DEPDC1B	0.4	5.09	0.3	6.86e-7	Intelligence (multi-trait analysis);
CESC	cis	rs10206020	0.921	rs6605278	chr2:1547230	C/T	cg01028140	chr2:1542097	TPO	-0.47	-5.93	-0.34	9.62e-9	IgG glycosylation;
CESC	cis	rs2952156	0.652	rs11869286	chr17:37813856	C/G	cg20243544	chr17:37824526	PNMT	0.68	9.31	0.5	5.04e-18	Asthma;
CESC	cis	rs1005277	0.602	rs2504142	chr10:38383793	C/T	cg25517755	chr10:38738941	LOC399744	-0.48	-6.22	-0.36	1.95e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs7552404	0.731	rs1493367	chr1:76344011	C/A	cg03433033	chr1:76189801	ACADM	-0.58	-5.97	-0.34	7.72e-9	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs6545883	0.894	rs12997538	chr2:61564249	A/C	cg15711740	chr2:61764176	XPO1	0.44	5.46	0.32	1.07e-7	Tuberculosis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23709988	chr14:23772096	PPP1R3E	0.57	6.58	0.37	2.43e-10	Gut microbiome composition (summer);
CESC	cis	rs7772486	0.790	rs9485024	chr6:146142487	A/G	cg23711669	chr6:146136114	FBXO30	-0.87	-11.97	-0.59	1.09e-26	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs62064224	0.714	rs4795692	chr17:30636688	G/T	cg18200150	chr17:30822561	MYO1D	0.4	5.34	0.31	1.95e-7	Schizophrenia;
CESC	cis	rs8005677	1.000	rs2295683	chr14:23388382	A/C	cg25600027	chr14:23388339	RBM23	-0.43	-5.33	-0.31	2.08e-7	Cognitive ability (multi-trait analysis);
CESC	cis	rs6500602	0.647	rs1659497	chr16:4594635	G/A	cg08645402	chr16:4508243	NA	-0.46	-7.21	-0.4	5.84e-12	Schizophrenia;
CESC	cis	rs3820928	0.605	rs2228555	chr2:227872995	C/T	cg05526886	chr2:227700861	RHBDD1	0.48	6.38	0.37	7.71e-10	Pulmonary function;
CESC	cis	rs754466	0.606	rs55854323	chr10:79589904	C/T	cg17075019	chr10:79541650	NA	-0.88	-14.05	-0.65	6.89e-34	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs2404602	0.692	rs4641709	chr15:77047736	C/T	cg26408565	chr15:76604113	ETFA	0.39	5.74	0.33	2.57e-8	Blood metabolite levels;
CESC	cis	rs7666738	0.830	rs1365458	chr4:98950961	C/T	cg03467027	chr4:99064603	C4orf37	0.45	5.8	0.34	1.87e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3092073	0.669	rs11697323	chr20:44551579	C/T	cg17986701	chr20:44574422	PCIF1	0.35	5.12	0.3	5.78e-7	Intelligence (multi-trait analysis);
CESC	cis	rs754466	0.914	rs12218917	chr10:79701479	C/T	cg17075019	chr10:79541650	NA	-0.68	-8.29	-0.45	5.91e-15	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs6088590	0.965	rs6087639	chr20:33443866	G/A	cg08999081	chr20:33150536	PIGU	0.58	8.82	0.48	1.57e-16	Coronary artery disease;
CESC	cis	rs8141529	0.702	rs469992	chr22:29314899	T/C	cg02153584	chr22:29168773	CCDC117	-0.57	-7.22	-0.41	5.58e-12	Lymphocyte counts;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05342987	chr14:59655273	DAAM1	0.62	7.16	0.4	7.84e-12	Gut microbiome composition (summer);
CESC	cis	rs7301826	0.651	rs7295705	chr12:131301885	C/T	cg11011512	chr12:131303247	STX2	0.47	5.84	0.34	1.52e-8	Plasma plasminogen activator levels;
CESC	cis	rs4595586	0.525	rs1878227	chr12:39355719	A/T	cg26384229	chr12:38710491	ALG10B	0.63	8.79	0.48	1.9e-16	Morning vs. evening chronotype;
CESC	cis	rs798554	0.704	rs798531	chr7:2770067	G/C	cg13628971	chr7:2884303	GNA12	0.41	5.39	0.31	1.54e-7	Height;
CESC	trans	rs1814175	0.935	rs11040463	chr11:49685574	C/T	cg03929089	chr4:120376271	NA	-0.87	-13.35	-0.63	1.97e-31	Height;
CESC	cis	rs6032067	0.929	rs35869085	chr20:43805134	G/C	cg10761708	chr20:43804764	PI3	0.53	6.37	0.36	8.25e-10	Blood protein levels;
CESC	cis	rs1552244	0.882	rs113268531	chr3:10167069	A/G	cg08888203	chr3:10149979	C3orf24	0.45	5.91	0.34	1.06e-8	Alzheimer's disease;
CESC	cis	rs875971	0.798	rs6460304	chr7:65964728	G/A	cg18252515	chr7:66147081	NA	-0.43	-5.62	-0.33	4.9e-8	Aortic root size;
CESC	cis	rs9399137	0.507	rs11759077	chr6:135381351	A/G	cg22676075	chr6:135203613	NA	0.53	7.01	0.4	1.95e-11	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg18402987	chr7:1209562	NA	0.75	7.51	0.42	9.28e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs1707322	0.752	rs28550303	chr1:46188914	G/T	cg06784218	chr1:46089804	CCDC17	0.42	7.26	0.41	4.34e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs807669	0.903	rs756651	chr22:19179367	T/C	cg02655711	chr22:19163373	SLC25A1	0.97	14.93	0.68	5.37e-37	Metabolite levels;
CESC	cis	rs10178094	0.933	rs7423892	chr2:161329644	C/T	cg03641300	chr2:160917029	PLA2R1	0.4	5.83	0.34	1.64e-8	White blood cell count;
CESC	cis	rs4555082	0.834	rs2735816	chr14:105721603	C/G	cg27165867	chr14:105738592	BRF1	0.49	5.29	0.31	2.59e-7	Mean platelet volume;Platelet distribution width;
CESC	cis	rs11608355	0.545	rs36094325	chr12:109911542	A/T	cg05360138	chr12:110035743	NA	0.81	8.75	0.47	2.52e-16	Neuroticism;
CESC	cis	rs10129255	0.957	rs10142859	chr14:107190475	A/G	cg07958169	chr14:107095056	NA	-0.39	-5.3	-0.31	2.47e-7	Kawasaki disease;
CESC	cis	rs7044106	0.537	rs10739573	chr9:123489818	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.74	9.51	0.5	1.21e-18	Hip circumference adjusted for BMI;
CESC	cis	rs6940638	0.513	rs4424065	chr6:27036456	C/T	cg12292205	chr6:26970375	C6orf41	-0.46	-7.16	-0.4	8.09e-12	Intelligence (multi-trait analysis);
CESC	cis	rs208520	0.690	rs207096	chr6:66797287	T/C	cg07460842	chr6:66804631	NA	-1.0	-13.43	-0.64	1.05e-31	Exhaled nitric oxide output;
CESC	cis	rs9902453	0.933	rs7216487	chr17:28502642	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	7.48	0.42	1.11e-12	Coffee consumption (cups per day);
CESC	cis	rs6087990	0.806	rs4911108	chr20:31375311	A/G	cg13636640	chr20:31349939	DNMT3B	0.81	12.51	0.61	1.56e-28	Ulcerative colitis;
CESC	cis	rs55726902	0.506	rs1006476	chr12:48179347	C/T	cg14736327	chr12:48174669	SLC48A1	-0.65	-6.69	-0.38	1.32e-10	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs72829446	0.530	rs66616380	chr17:7380188	C/A	cg02795151	chr17:7402630	POLR2A	0.57	6.07	0.35	4.53e-9	Androgen levels;
CESC	cis	rs11098499	0.909	rs10002083	chr4:120311152	C/T	cg09307838	chr4:120376055	NA	0.92	12.66	0.61	4.96e-29	Corneal astigmatism;
CESC	cis	rs12477438	0.520	rs2516830	chr2:99773702	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.77	12.84	0.62	1.16e-29	Chronic sinus infection;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg20566420	chr12:122327043	PSMD9	-0.48	-6.89	-0.39	4.16e-11	Gambling;
CESC	cis	rs9303401	0.538	rs10515155	chr17:56481944	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.95	11.32	0.57	1.75e-24	Cognitive test performance;
CESC	cis	rs9322193	0.923	rs55849538	chr6:149956466	T/C	cg13206674	chr6:150067644	NUP43	0.41	5.72	0.33	2.8e-8	Lung cancer;
CESC	cis	rs208520	0.874	rs208485	chr6:66925654	T/C	cg07460842	chr6:66804631	NA	-0.89	-10.85	-0.55	6.35e-23	Exhaled nitric oxide output;
CESC	cis	rs4141404	0.851	rs9606833	chr22:31750013	T/C	cg00478049	chr22:31556069	RNF185	-0.48	-5.13	-0.3	5.71e-7	Paclitaxel-induced neuropathy;
CESC	cis	rs9649213	0.593	rs6465665	chr7:97934150	T/C	cg24562669	chr7:97807699	LMTK2	0.47	6.8	0.39	6.92e-11	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs6752107	1.000	rs35300242	chr2:234168790	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.46	6.32	0.36	1.13e-9	Crohn's disease;Inflammatory bowel disease;
CESC	trans	rs561341	0.609	rs11658984	chr17:30186612	C/T	cg20587970	chr11:113659929	NA	0.57	6.96	0.39	2.65e-11	Hip circumference adjusted for BMI;
CESC	cis	rs7412746	0.646	rs1972060	chr1:150937594	T/C	cg17724175	chr1:150552817	MCL1	0.33	5.07	0.3	7.32e-7	Melanoma;
CESC	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg26338869	chr17:61819248	STRADA	-0.69	-9.04	-0.49	3.3e-17	Prudent dietary pattern;
CESC	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg06074448	chr4:187884817	NA	-0.39	-5.52	-0.32	8.02e-8	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs8099014	0.770	rs1135519	chr18:56117145	C/T	cg19312305	chr18:56117016	MIR122	-0.26	-5.21	-0.3	3.83e-7	Platelet count;
CESC	cis	rs11190604	1.000	rs2489051	chr10:102351785	C/T	cg07080220	chr10:102295463	HIF1AN	-0.56	-5.3	-0.31	2.47e-7	Palmitoleic acid (16:1n-7) levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25757740	chr10:72647938	PCBD1	0.56	6.46	0.37	5.07e-10	Gut microbiome composition (summer);
CESC	cis	rs873946	0.648	rs12769533	chr10:134548685	C/T	cg26818010	chr10:134567672	INPP5A	0.82	10.19	0.53	8.69e-21	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs7618915	0.501	rs1468638	chr3:52748058	T/C	cg05564831	chr3:52568323	NT5DC2	0.46	7.22	0.41	5.37e-12	Bipolar disorder;
CESC	cis	rs2180341	0.814	rs7768435	chr6:127737038	A/C	cg24812749	chr6:127587940	RNF146	0.84	12.05	0.59	5.93e-27	Breast cancer;
CESC	cis	rs116095464	0.558	rs9654452	chr5:299561	C/T	cg10591111	chr5:226296	SDHA	-0.53	-6.45	-0.37	5.35e-10	Breast cancer;
CESC	cis	rs6084875	0.733	rs7354668	chr20:4741710	A/C	cg05143360	chr20:4741328	NA	0.54	7.31	0.41	3.22e-12	Systemic lupus erythematosus;
CESC	cis	rs73206853	0.764	rs7311376	chr12:110605559	C/T	cg12870014	chr12:110450643	ANKRD13A	0.65	5.62	0.33	4.79e-8	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs9325144	0.647	rs61930266	chr12:38922048	A/G	cg26384229	chr12:38710491	ALG10B	-0.54	-7.53	-0.42	8.01e-13	Morning vs. evening chronotype;
CESC	trans	rs2115172	0.836	rs4835799	chr5:122762229	A/G	cg17492891	chr22:41843204	TOB2	0.48	6.35	0.36	9.56e-10	Weight;
CESC	cis	rs4665809	0.938	rs4665822	chr2:26312555	C/G	cg26314531	chr2:26401878	FAM59B	-0.61	-6.94	-0.39	2.97e-11	Gut microbiome composition (summer);
CESC	cis	rs1862618	0.802	rs194058	chr5:56188977	G/A	cg22800045	chr5:56110881	MAP3K1	0.8	9.58	0.51	7.41e-19	Initial pursuit acceleration;
CESC	cis	rs2797160	0.967	rs2797162	chr6:126011381	G/T	cg05901451	chr6:126070800	HEY2	0.45	6.6	0.38	2.19e-10	Endometrial cancer;
CESC	cis	rs8060686	0.641	rs8047119	chr16:68047345	G/C	cg26727032	chr16:67993705	SLC12A4	-0.54	-6.15	-0.35	2.78e-9	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs644799	0.526	rs693792	chr11:95622200	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.52	6.63	0.38	1.84e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs1801251	1.000	rs2592113	chr2:233669553	C/T	cg25237894	chr2:233734115	C2orf82	0.44	7.81	0.43	1.32e-13	Coronary artery disease;
CESC	cis	rs1046896	0.514	rs67735447	chr17:80823042	G/T	cg02398342	chr17:80708632	TBCD;FN3K	0.47	5.69	0.33	3.33e-8	Glycated hemoglobin levels;
CESC	cis	rs2228479	0.850	rs11639906	chr16:89798183	T/C	cg04013166	chr16:89971882	TCF25	0.67	5.38	0.31	1.65e-7	Skin colour saturation;
CESC	cis	rs17376456	0.877	rs28637444	chr5:93495548	C/T	cg21475434	chr5:93447410	FAM172A	0.9	7.77	0.43	1.68e-13	Diabetic retinopathy;
CESC	cis	rs6893300	0.961	rs113829727	chr5:179191896	C/T	cg14593053	chr5:179126677	CANX	-0.53	-5.87	-0.34	1.27e-8	Resting heart rate;
CESC	cis	rs6502050	0.734	rs7217625	chr17:80157766	T/C	cg23985595	chr17:80112537	CCDC57	-0.39	-6.24	-0.36	1.76e-9	Life satisfaction;
CESC	cis	rs6570726	0.902	rs373321	chr6:145854150	T/A	cg05347473	chr6:146136440	FBXO30	0.48	6.44	0.37	5.7e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs920590	0.758	rs35896770	chr8:19665616	G/C	cg03894339	chr8:19674705	INTS10	0.68	7.92	0.44	6.52e-14	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs7527798	0.592	rs10863461	chr1:207840776	C/T	cg21110645	chr1:207815933	NA	-0.32	-5.72	-0.33	2.94e-8	Erythrocyte sedimentation rate;
CESC	cis	rs6502050	0.835	rs12450189	chr17:80095128	A/C	cg23985595	chr17:80112537	CCDC57	-0.42	-6.6	-0.38	2.18e-10	Life satisfaction;
CESC	cis	rs2404602	0.698	rs12909656	chr15:76664378	A/T	cg23625390	chr15:77176239	SCAPER	-0.42	-5.77	-0.33	2.26e-8	Blood metabolite levels;
CESC	cis	rs12464483	0.591	rs4952170	chr2:30885429	G/A	cg12454169	chr2:30669597	LCLAT1	0.66	6.88	0.39	4.28e-11	Pre-treatment pain in head and neck squamous cell carcinoma;
CESC	cis	rs3096299	0.503	rs4785677	chr16:89555101	A/G	cg02187348	chr16:89574699	SPG7	0.58	7.67	0.43	3.32e-13	Multiple myeloma (IgH translocation);
CESC	cis	rs3806843	1.000	rs7701755	chr5:140182101	G/T	cg26395211	chr5:140044315	WDR55	-0.42	-5.35	-0.31	1.94e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg12419862	chr22:24373484	LOC391322	0.79	10.34	0.54	2.8e-21	Urinary 1,3-butadiene metabolite levels in smokers;
CESC	cis	rs7772486	0.720	rs1890171	chr6:146072114	T/C	cg23711669	chr6:146136114	FBXO30	-1.0	-15.48	-0.69	6.3e-39	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs66573146	0.634	rs55633489	chr4:6988745	C/A	cg07817883	chr1:32538562	TMEM39B	1.14	7.98	0.44	4.51e-14	Granulocyte percentage of myeloid white cells;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17291625	chr16:236080	NA	-0.56	-6.46	-0.37	4.88e-10	Gut microbiome composition (summer);
CESC	cis	rs7697216	0.668	rs6553846	chr4:175822759	C/T	cg14561282	chr4:175839468	ADAM29	0.47	5.55	0.32	7.01e-8	Breast cancer;
CESC	cis	rs7100689	0.784	rs3120977	chr10:82075324	C/G	cg00277334	chr10:82204260	NA	-0.59	-7.48	-0.42	1.08e-12	Post bronchodilator FEV1;
CESC	cis	rs8016982	0.657	rs8021125	chr14:81704787	C/T	cg01989461	chr14:81687754	GTF2A1	-0.69	-10.66	-0.55	2.53e-22	Schizophrenia;
CESC	cis	rs1707322	0.752	rs11211145	chr1:46108491	A/C	cg03146154	chr1:46216737	IPP	0.76	9.75	0.51	2.21e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs4563143	0.675	rs56123392	chr19:29255631	A/C	cg04546413	chr19:29218101	NA	0.56	7.79	0.43	1.52e-13	Methadone dose in opioid dependence;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg16101257	chr8:146024039	ZNF517	-0.54	-7.16	-0.4	7.99e-12	Fibrinogen levels;
CESC	cis	rs9790314	0.905	rs4518145	chr3:160950030	T/C	cg03342759	chr3:160939853	NMD3	-0.47	-6.31	-0.36	1.17e-9	Morning vs. evening chronotype;
CESC	cis	rs2836974	0.583	rs2410124	chr21:40704760	C/G	cg22974920	chr21:40686053	BRWD1	-0.44	-5.29	-0.31	2.51e-7	Cognitive function;
CESC	cis	rs748404	0.588	rs2255410	chr15:43831097	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.51	7.85	0.43	1.03e-13	Lung cancer;
CESC	cis	rs57506017	0.585	rs1054169	chr7:12273496	G/A	cg23422036	chr7:12250390	TMEM106B	0.39	5.17	0.3	4.57e-7	Neuroticism;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg13369981	chr7:100027501	MEPCE;ZCWPW1	0.45	6.42	0.37	6.34e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs11864453	0.826	rs2074626	chr16:72139184	C/A	cg01557791	chr16:72042693	DHODH	-0.52	-6.77	-0.38	8.45e-11	Fibrinogen levels;
CESC	cis	rs9291683	0.530	rs4697698	chr4:9942577	C/T	cg02734326	chr4:10020555	SLC2A9	0.43	6.35	0.36	9.3e-10	Bone mineral density;
CESC	cis	rs796364	1.000	rs281788	chr2:200783705	A/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.87	8.44	0.46	2.14e-15	Schizophrenia;
CESC	cis	rs796364	0.951	rs281769	chr2:200809709	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	0.9	9.29	0.5	5.66e-18	Schizophrenia;
CESC	cis	rs35110281	0.720	rs162372	chr21:44928863	C/T	cg21573476	chr21:45109991	RRP1B	0.43	5.93	0.34	9.21e-9	Mean corpuscular volume;
CESC	cis	rs524281	0.861	rs7943911	chr11:65943054	G/A	cg14036092	chr11:66035641	RAB1B	-0.56	-5.57	-0.32	6.24e-8	Electroencephalogram traits;
CESC	cis	rs7267979	0.586	rs6050445	chr20:25195394	C/T	cg08601574	chr20:25228251	PYGB	0.36	5.13	0.3	5.54e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs554111	0.637	rs529162	chr1:21063311	T/A	cg04902671	chr1:21058625	SH2D5	-0.43	-5.19	-0.3	4.2e-7	Facial morphology (factor 17, height of vermillion upper lip);
CESC	cis	rs7666738	0.962	rs2865985	chr4:99068009	T/C	cg05340658	chr4:99064831	C4orf37	0.69	9.2	0.49	1.08e-17	Colonoscopy-negative controls vs population controls;
CESC	cis	rs763121	0.853	rs3747174	chr22:39069181	T/C	cg14440974	chr22:39074834	NA	-0.42	-5.89	-0.34	1.14e-8	Menopause (age at onset);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg20781216	chr8:144546287	ZC3H3	0.5	6.6	0.38	2.28e-10	Fibrinogen levels;
CESC	cis	rs1832871	0.643	rs112195967	chr6:158775695	C/T	cg07165851	chr6:158734300	TULP4	0.54	5.43	0.32	1.29e-7	Height;
CESC	cis	rs873946	0.586	rs12251911	chr10:134570595	A/G	cg06453172	chr10:134556979	INPP5A	-0.39	-5.03	-0.3	8.95e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs6952808	0.595	rs3800917	chr7:2167939	A/G	cg23048001	chr7:2026167	MAD1L1	-0.49	-6.29	-0.36	1.3e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs9644630	0.870	rs4244453	chr8:19359711	G/A	cg01280390	chr8:19363452	CSGALNACT1	0.33	5.18	0.3	4.42e-7	Oropharynx cancer;
CESC	cis	rs10504229	0.953	rs114853497	chr8:58176176	A/T	cg24829409	chr8:58192753	C8orf71	-0.76	-10.0	-0.52	3.53e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs4561483	0.801	rs154148	chr16:11956478	T/C	cg08843971	chr16:11963173	GSPT1	-0.54	-7.9	-0.44	7.27e-14	Testicular germ cell tumor;
CESC	cis	rs2204008	0.683	rs11519834	chr12:38053575	T/A	cg26384229	chr12:38710491	ALG10B	0.74	10.7	0.55	1.96e-22	Bladder cancer;
CESC	cis	rs7903847	0.642	rs1048442	chr10:99160152	A/G	cg20016023	chr10:99160130	RRP12	-0.3	-5.2	-0.3	3.91e-7	Granulocyte percentage of myeloid white cells;
CESC	cis	rs4727963	0.811	rs2140853	chr7:122713121	A/T	cg03640110	chr7:122635026	TAS2R16	-0.38	-5.89	-0.34	1.18e-8	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
CESC	cis	rs2658782	1.000	rs2658779	chr11:93163137	G/T	cg15737290	chr11:93063684	CCDC67	-0.53	-6.69	-0.38	1.28e-10	Pulmonary function decline;
CESC	trans	rs208520	0.690	rs12213561	chr6:66705646	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.95	12.6	0.61	7.7e-29	Exhaled nitric oxide output;
CESC	cis	rs7927592	0.871	rs113020558	chr11:68296832	G/A	cg20283391	chr11:68216788	NA	-0.62	-7.53	-0.42	8.09e-13	Total body bone mineral density;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg07116015	chr17:27046591	RAB34;SNORD42B;RPL23A	-0.46	-6.1	-0.35	3.71e-9	Fibrinogen levels;
CESC	cis	rs7917772	0.503	rs11191328	chr10:104305185	C/T	ch.10.2196322F	chr10:104248062	ACTR1A	0.43	5.31	0.31	2.36e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs6893300	0.785	rs17617710	chr5:179206107	G/A	cg14593053	chr5:179126677	CANX	-0.49	-5.86	-0.34	1.34e-8	Resting heart rate;
CESC	cis	rs1707322	0.752	rs6678444	chr1:46229847	A/G	cg05343316	chr1:45956843	TESK2	0.5	6.25	0.36	1.62e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7666738	0.830	rs17027102	chr4:98919221	A/G	cg17366294	chr4:99064904	C4orf37	-0.56	-7.83	-0.43	1.21e-13	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10504229	1.000	rs61733801	chr8:58192513	A/G	cg22535103	chr8:58192502	C8orf71	-1.05	-13.08	-0.63	1.71e-30	Developmental language disorder (linguistic errors);
CESC	trans	rs2727020	0.729	rs10839268	chr11:49380328	G/A	cg15704280	chr7:45808275	SEPT13	-0.87	-14.48	-0.66	2.03e-35	Coronary artery disease;
CESC	cis	rs523522	0.962	rs10774549	chr12:120891172	C/T	cg27279351	chr12:120934652	DYNLL1	0.67	8.42	0.46	2.35e-15	High light scatter reticulocyte count;
CESC	cis	rs9322193	0.923	rs9377230	chr6:149934743	T/C	cg07701084	chr6:150067640	NUP43	0.45	6.45	0.37	5.26e-10	Lung cancer;
CESC	cis	rs9611565	0.659	rs17367849	chr22:41923644	G/A	cg06481639	chr22:41940642	POLR3H	-0.59	-6.17	-0.35	2.56e-9	Vitiligo;
CESC	cis	rs9611565	0.877	rs3817999	chr22:41747717	A/G	cg06481639	chr22:41940642	POLR3H	0.46	5.37	0.31	1.7e-7	Vitiligo;
CESC	cis	rs9733	0.536	rs6661415	chr1:150635869	G/A	cg18016565	chr1:150552671	MCL1	0.33	5.15	0.3	5.13e-7	Tonsillectomy;
CESC	cis	rs950169	0.800	rs34302901	chr15:85110943	C/G	cg17507749	chr15:85114479	UBE2QP1	0.54	6.31	0.36	1.17e-9	Schizophrenia;
CESC	cis	rs7615952	0.641	rs4490307	chr3:125712676	T/G	cg04553112	chr3:125709451	NA	-0.5	-5.68	-0.33	3.57e-8	Blood pressure (smoking interaction);
CESC	cis	rs2455799	0.613	rs2345736	chr3:15824860	T/G	cg16303742	chr3:15540471	COLQ	-0.38	-5.82	-0.34	1.69e-8	Mean platelet volume;
CESC	cis	rs6456156	0.755	rs4710182	chr6:167514061	G/A	cg07741184	chr6:167504864	NA	0.38	6.92	0.39	3.46e-11	Primary biliary cholangitis;
CESC	cis	rs72772090	0.539	rs55773007	chr5:96124918	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.57	-5.26	-0.31	3.01e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs644799	0.509	rs580181	chr11:95643040	G/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.49	6.56	0.37	2.85e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs7666738	0.830	rs9307218	chr4:99024885	T/C	cg18180107	chr4:99064573	C4orf37	0.41	5.32	0.31	2.16e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg24642844	chr7:1081250	C7orf50	-0.72	-8.72	-0.47	3.07e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2576037	0.583	rs2164104	chr18:44567743	G/C	cg19077165	chr18:44547161	KATNAL2	0.64	9.56	0.51	8.41e-19	Personality dimensions;
CESC	cis	rs3749237	0.595	rs4855839	chr3:49507847	G/A	cg06212747	chr3:49208901	KLHDC8B	0.52	6.9	0.39	3.72e-11	Resting heart rate;
CESC	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg05552183	chr6:42928497	GNMT	0.79	12.72	0.62	3.08e-29	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs7116495	0.786	rs1894003	chr11:71750276	A/G	cg26138937	chr11:71823887	C11orf51	-0.78	-6.37	-0.36	8.34e-10	Severe influenza A (H1N1) infection;
CESC	cis	rs11958404	1.000	rs72816531	chr5:157413079	A/G	cg05962755	chr5:157440814	NA	0.52	5.95	0.34	8.38e-9	IgG glycosylation;
CESC	cis	rs4665809	0.590	rs2033317	chr2:26477650	G/A	cg27170947	chr2:26402098	FAM59B	0.87	10.16	0.53	1.05e-20	Gut microbiome composition (summer);
CESC	cis	rs9291683	0.588	rs12506364	chr4:10023448	C/T	cg11266682	chr4:10021025	SLC2A9	0.7	14.77	0.67	1.92e-36	Bone mineral density;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg23182539	chr10:121355708	TIAL1	0.47	6.36	0.36	8.9e-10	Systemic lupus erythematosus;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg13653153	chr9:130885858	PTGES2	0.56	7.93	0.44	6.26e-14	Fibrinogen levels;
CESC	cis	rs9896933	0.775	rs79299098	chr17:80830944	G/A	cg15664640	chr17:80829946	TBCD	-0.53	-5.62	-0.33	4.83e-8	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
CESC	cis	rs4665809	1.000	rs6546767	chr2:26328746	A/G	cg22920501	chr2:26401640	FAM59B	-0.68	-8.18	-0.45	1.21e-14	Gut microbiome composition (summer);
CESC	cis	rs116095464	0.558	rs10055405	chr5:265666	C/T	cg22857025	chr5:266934	NA	-1.28	-18.09	-0.74	3.47e-48	Breast cancer;
CESC	cis	rs6445797	0.632	rs2035798	chr3:56598544	G/A	cg13792233	chr3:56591045	CCDC66	0.39	5.08	0.3	7.22e-7	Gastritis;
CESC	cis	rs9916302	0.904	rs2338798	chr17:37547269	T/C	cg07936489	chr17:37558343	FBXL20	0.8	11.62	0.58	1.74e-25	Glomerular filtration rate (creatinine);
CESC	cis	rs6088580	0.634	rs6059892	chr20:33105766	A/G	cg08999081	chr20:33150536	PIGU	0.65	11.26	0.57	2.65e-24	Glomerular filtration rate (creatinine);
CESC	cis	rs8114671	0.562	rs6088646	chr20:33505937	T/C	cg06115741	chr20:33292138	TP53INP2	0.46	5.58	0.32	6.06e-8	Height;
CESC	cis	rs853679	0.517	rs9393898	chr6:28130376	G/T	cg17221315	chr6:27791827	HIST1H4J	0.45	5.07	0.3	7.46e-7	Depression;
CESC	cis	rs3126085	0.877	rs12116736	chr1:152167062	C/T	cg26876637	chr1:152193138	HRNR	0.44	5.04	0.3	8.68e-7	Atopic dermatitis;
CESC	cis	rs4819052	0.851	rs7275468	chr21:46656499	C/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.42	5.22	0.31	3.55e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs4665809	1.000	rs10182857	chr2:26344411	C/T	cg26314531	chr2:26401878	FAM59B	-0.62	-6.99	-0.39	2.29e-11	Gut microbiome composition (summer);
CESC	cis	rs9733	0.596	rs72702556	chr1:150680115	C/T	cg09365446	chr1:150670422	GOLPH3L	0.42	5.87	0.34	1.3e-8	Tonsillectomy;
CESC	cis	rs7937682	0.921	rs688354	chr11:111438762	A/G	cg22437258	chr11:111473054	SIK2	0.67	8.51	0.46	1.33e-15	Primary sclerosing cholangitis;
CESC	cis	rs7615952	0.599	rs6766327	chr3:125723677	C/G	cg15145296	chr3:125709740	NA	-0.49	-5.27	-0.31	2.78e-7	Blood pressure (smoking interaction);
CESC	cis	rs9309473	0.950	rs1052162	chr2:73829372	A/G	cg20560298	chr2:73613845	ALMS1	0.45	6.11	0.35	3.49e-9	Metabolite levels;
CESC	cis	rs7772486	0.875	rs854145	chr6:146349650	C/T	cg23711669	chr6:146136114	FBXO30	0.83	12.1	0.6	3.95e-27	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs60843830	1.000	rs62114497	chr2:214837	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.86	11.23	0.57	3.36e-24	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs875971	0.522	rs1917563	chr7:65415647	C/T	cg14393609	chr7:65229607	NA	-0.48	-6.52	-0.37	3.63e-10	Aortic root size;
CESC	trans	rs116095464	0.558	rs10065239	chr5:275288	C/T	cg00938859	chr5:1591904	SDHAP3	0.71	6.55	0.37	2.92e-10	Breast cancer;
CESC	trans	rs60843830	1.000	rs3791223	chr2:222336	T/C	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.67	8.23	0.45	8.51e-15	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs7666738	0.830	rs28587201	chr4:98991733	C/T	cg18180107	chr4:99064573	C4orf37	0.4	5.23	0.31	3.41e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs60843830	1.000	rs4497901	chr2:239969	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.78	10.2	0.53	7.83e-21	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs6565180	0.962	rs11642676	chr16:30371655	C/G	cg17640201	chr16:30407289	ZNF48	-0.93	-13.46	-0.64	8.1e-32	Tonsillectomy;
CESC	cis	rs9291683	0.655	rs35750364	chr4:10049049	T/C	cg11266682	chr4:10021025	SLC2A9	0.68	13.42	0.64	1.11e-31	Bone mineral density;
CESC	cis	rs9311474	0.508	rs17052259	chr3:52593138	A/G	cg18404041	chr3:52824283	ITIH1	-0.38	-6.45	-0.37	5.31e-10	Electroencephalogram traits;
CESC	cis	rs4629180	0.675	rs908132	chr2:102093096	A/G	cg04415270	chr2:102091202	RFX8	-0.32	-5.46	-0.32	1.09e-7	Chronic rhinosinusitis with nasal polyps;
CESC	cis	rs12410462	0.581	rs112572966	chr1:227553905	C/T	cg04117972	chr1:227635322	NA	0.65	5.65	0.33	4.14e-8	Major depressive disorder;
CESC	cis	rs7267979	1.000	rs11087520	chr20:25436827	C/T	cg08601574	chr20:25228251	PYGB	0.37	5.28	0.31	2.73e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs10479542	0.766	rs6894980	chr5:178974592	C/T	cg05457628	chr5:178986728	RUFY1	0.43	5.97	0.34	7.53e-9	Lung cancer;
CESC	trans	rs9325144	0.600	rs10748442	chr12:38732939	A/T	cg23762105	chr12:34175262	ALG10	-0.45	-6.02	-0.35	5.64e-9	Morning vs. evening chronotype;
CESC	cis	rs2415984	0.622	rs61993305	chr14:46950955	C/T	cg14871534	chr14:47121158	RPL10L	-0.38	-5.73	-0.33	2.72e-8	Number of children ever born;
CESC	cis	rs763121	0.853	rs5750672	chr22:39104168	C/T	cg06544989	chr22:39130855	UNC84B	-0.5	-8.78	-0.47	2.02e-16	Menopause (age at onset);
CESC	cis	rs34779708	0.733	rs3936502	chr10:35549218	C/T	cg03585969	chr10:35415529	CREM	0.55	6.37	0.36	8.28e-10	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs208520	0.690	rs9345764	chr6:66820597	C/T	cg07460842	chr6:66804631	NA	-1.01	-13.53	-0.64	4.61e-32	Exhaled nitric oxide output;
CESC	cis	rs2228479	0.867	rs62052189	chr16:89975555	G/C	cg04013166	chr16:89971882	TCF25	0.7	6.91	0.39	3.7e-11	Skin colour saturation;
CESC	trans	rs7615952	0.641	rs12491577	chr3:125731131	C/T	cg07211511	chr3:129823064	LOC729375	-0.54	-6.15	-0.35	2.84e-9	Blood pressure (smoking interaction);
CESC	cis	rs7542091	0.704	rs12022221	chr1:210046178	A/C	cg23283495	chr1:209979779	IRF6	0.35	5.76	0.33	2.29e-8	Monobrow;
CESC	cis	rs10782582	0.593	rs6704444	chr1:76205108	T/C	cg10523679	chr1:76189770	ACADM	-0.49	-5.78	-0.33	2.06e-8	Daytime sleep phenotypes;
CESC	cis	rs4253772	0.550	rs6008600	chr22:46704676	A/G	cg24881330	chr22:46731750	TRMU	0.86	7.93	0.44	6.15e-14	LDL cholesterol;Cholesterol, total;
CESC	cis	rs35306767	0.761	rs11253538	chr10:1011166	C/T	cg20503657	chr10:835505	NA	0.71	6.72	0.38	1.12e-10	Eosinophil percentage of granulocytes;
CESC	cis	rs4304924	0.500	rs9601109	chr13:79220114	A/G	cg07926092	chr13:79233506	RNF219	0.61	6.68	0.38	1.43e-10	Large artery stroke;
CESC	cis	rs11785400	0.963	rs9771845	chr8:143726577	C/G	cg24634471	chr8:143751801	JRK	0.45	5.95	0.34	8.62e-9	Schizophrenia;
CESC	cis	rs3096299	0.967	rs28644774	chr16:89472181	G/C	cg08392591	chr16:89556376	ANKRD11	0.39	5.1	0.3	6.52e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs514406	0.825	rs9661082	chr1:53245472	A/T	cg24675658	chr1:53192096	ZYG11B	0.53	6.73	0.38	1.04e-10	Monocyte count;
CESC	cis	rs400736	0.729	rs2493216	chr1:8008366	C/A	cg25007680	chr1:8021821	PARK7	-0.59	-8.21	-0.45	9.51e-15	Response to antidepressants and depression;
CESC	cis	rs7264396	0.561	rs6060750	chr20:34596371	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.46	5.21	0.3	3.76e-7	Total cholesterol levels;
CESC	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg02493798	chr17:6899577	ALOX12	0.42	7.48	0.42	1.07e-12	Tonsillectomy;
CESC	cis	rs2440129	0.611	rs1042356	chr17:6902743	G/A	cg09737314	chr17:6899359	ALOX12	0.45	7.71	0.43	2.6e-13	Tonsillectomy;
CESC	cis	rs4919694	1.000	rs11191473	chr10:104710710	C/G	cg04362960	chr10:104952993	NT5C2	0.78	6.79	0.38	7.53e-11	Arsenic metabolism;
CESC	cis	rs4713118	0.629	rs203889	chr6:28021775	T/G	cg19592336	chr6:28129416	ZNF389	0.52	6.77	0.38	8.17e-11	Parkinson's disease;
CESC	cis	rs736408	0.812	rs9324	chr3:52825585	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.58	7.43	0.42	1.52e-12	Bipolar disorder;
CESC	cis	rs9649213	0.574	rs3801251	chr7:98027618	T/C	cg08684580	chr7:98029266	BAIAP2L1	-0.35	-5.69	-0.33	3.28e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7542091	0.635	rs7550733	chr1:210044968	G/A	cg25204440	chr1:209979598	IRF6	0.37	5.1	0.3	6.55e-7	Monobrow;
CESC	trans	rs9951602	0.512	rs9946120	chr18:76654548	A/T	cg02800362	chr5:177631904	HNRNPAB	0.66	8.63	0.47	5.9e-16	Obesity-related traits;
CESC	cis	rs853679	0.517	rs9368553	chr6:28082265	T/C	cg23281280	chr6:28129359	ZNF389	0.58	7.93	0.44	6.31e-14	Depression;
CESC	cis	rs6032067	0.777	rs13042694	chr20:43799368	G/A	cg11264863	chr20:43835661	SEMG1	0.5	5.41	0.32	1.42e-7	Blood protein levels;
CESC	cis	rs2230307	0.536	rs581097	chr1:100515920	C/T	cg24955406	chr1:100503596	HIAT1	0.56	5.47	0.32	1.06e-7	Carotid intima media thickness;
CESC	cis	rs9309711	0.922	rs13385119	chr2:3484521	G/A	cg10845886	chr2:3471009	TTC15	-0.87	-12.1	-0.6	3.91e-27	Neurofibrillary tangles;
CESC	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg06873352	chr17:61820015	STRADA	0.73	12.98	0.62	3.9e-30	Prudent dietary pattern;
CESC	cis	rs6060717	0.536	rs6060683	chr20:34507921	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.65	5.61	0.33	4.97e-8	Hip circumference adjusted for BMI;
CESC	trans	rs10100465	0.596	rs218009	chr8:118716275	A/G	cg00607566	chr17:45726993	KPNB1	0.62	6.0	0.35	6.47e-9	Leprosy;
CESC	cis	rs2797160	1.000	rs2747725	chr6:126012397	A/C	cg05901451	chr6:126070800	HEY2	0.51	6.47	0.37	4.58e-10	Endometrial cancer;
CESC	cis	rs734999	0.545	rs41300092	chr1:2537838	C/T	cg20673091	chr1:2541236	MMEL1	0.46	7.59	0.42	5.5e-13	Ulcerative colitis;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg12427896	chr2:111880694	BCL2L11	0.51	6.7	0.38	1.25e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs854765	0.583	rs4553680	chr17:17857722	A/G	cg16928487	chr17:17741425	SREBF1	-0.6	-10.08	-0.53	1.98e-20	Total body bone mineral density;
CESC	cis	rs12497850	0.897	rs6795025	chr3:49081247	T/C	cg02487422	chr3:49467188	NICN1	0.44	5.49	0.32	9.36e-8	Parkinson's disease;
CESC	cis	rs4853012	0.775	rs12465641	chr2:74337715	A/G	cg05890377	chr2:74357713	NA	-0.56	-7.07	-0.4	1.39e-11	Gestational age at birth (maternal effect);
CESC	cis	rs13256369	1.000	rs7820159	chr8:8576215	T/C	cg18904891	chr8:8559673	CLDN23	0.69	7.99	0.44	4.17e-14	Obesity-related traits;
CESC	cis	rs6964587	1.000	rs10234434	chr7:91673308	A/T	cg17063962	chr7:91808500	NA	0.6	8.31	0.45	5.05e-15	Breast cancer;
CESC	cis	rs9309473	0.607	rs1403412	chr2:73598092	T/C	cg20560298	chr2:73613845	ALMS1	-0.46	-6.55	-0.37	3.03e-10	Metabolite levels;
CESC	cis	rs7208859	0.623	rs55638872	chr17:29149552	G/C	cg14008862	chr17:28927542	LRRC37B2	0.66	5.21	0.3	3.84e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	trans	rs11098499	0.909	rs1546504	chr4:120241179	C/T	cg25214090	chr10:38739885	LOC399744	0.7	9.76	0.51	2.07e-19	Corneal astigmatism;
CESC	cis	rs4925325	0.955	rs1776262	chr20:60516023	G/T	cg06108461	chr20:60628389	TAF4	0.48	5.89	0.34	1.16e-8	Obesity-related traits;
CESC	cis	rs6582630	0.679	rs10785514	chr12:38573689	T/C	cg26384229	chr12:38710491	ALG10B	0.48	6.84	0.39	5.33e-11	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs1005277	0.579	rs9299760	chr10:38377920	C/T	cg00409905	chr10:38381863	ZNF37A	-0.45	-6.04	-0.35	5.25e-9	Extrinsic epigenetic age acceleration;
CESC	trans	rs561341	1.000	rs72823787	chr17:30283809	A/T	cg27661571	chr11:113659931	NA	-0.86	-7.96	-0.44	5.05e-14	Hip circumference adjusted for BMI;
CESC	cis	rs798554	0.660	rs798480	chr7:2805597	G/T	cg19717773	chr7:2847554	GNA12	-0.55	-8.46	-0.46	1.84e-15	Height;
CESC	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg06873352	chr17:61820015	STRADA	0.72	12.56	0.61	1.02e-28	Prudent dietary pattern;
CESC	cis	rs9611565	0.532	rs4401299	chr22:42156517	A/G	cg03806693	chr22:41940476	POLR3H	0.79	9.68	0.51	3.55e-19	Vitiligo;
CESC	cis	rs8072100	0.713	rs57427906	chr17:45494014	G/A	cg25173405	chr17:45401733	C17orf57	-0.43	-5.43	-0.32	1.26e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs9325144	0.577	rs10876008	chr12:39126750	T/C	cg26384229	chr12:38710491	ALG10B	-0.52	-7.14	-0.4	8.72e-12	Morning vs. evening chronotype;
CESC	cis	rs1552244	0.938	rs67667957	chr3:10167264	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.87	12.51	0.61	1.61e-28	Alzheimer's disease;
CESC	cis	rs9611565	0.512	rs2050033	chr22:42159229	G/T	cg06634786	chr22:41940651	POLR3H	0.71	7.03	0.4	1.75e-11	Vitiligo;
CESC	cis	rs8060686	0.858	rs1476306	chr16:67973171	C/T	cg26727032	chr16:67993705	SLC12A4	-0.64	-9.19	-0.49	1.22e-17	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs1316952	0.831	rs74624536	chr12:124393076	T/G	cg00084347	chr12:124393913	DNAH10	0.41	5.68	0.33	3.56e-8	Visceral adipose tissue adjusted for BMI;Visceral adipose tissue/subcutaneous adipose tissue ratio;
CESC	cis	rs1801251	0.778	rs812383	chr2:233737132	C/A	cg08000102	chr2:233561755	GIGYF2	-0.59	-8.12	-0.45	1.78e-14	Coronary artery disease;
CESC	cis	rs2645694	0.626	rs2703115	chr4:77824442	C/T	cg18351406	chr4:77819688	ANKRD56	0.53	6.69	0.38	1.28e-10	Emphysema distribution in smoking;
CESC	cis	rs61776719	0.520	rs11485595	chr1:38411350	C/T	cg04673462	chr1:38461896	NA	0.38	5.88	0.34	1.24e-8	Coronary artery disease;
CESC	cis	rs5751150	1	rs5751150	chr22:42153292	T/G	cg03806693	chr22:41940476	POLR3H	1.19	14.07	0.65	6.09e-34	Cannabis dependence symptom count;
CESC	cis	rs992157	0.560	rs12992937	chr2:219087072	A/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.57	-7.45	-0.42	1.29e-12	Colorectal cancer;
CESC	trans	rs2472476	0.900	rs10991370	chr9:107518918	C/G	cg14553338	chr2:66689807	MEIS1	0.42	6.17	0.35	2.61e-9	Obesity-related traits;
CESC	cis	rs4253772	1.000	rs11705483	chr22:46630544	C/A	cg18190219	chr22:46762943	CELSR1	-0.61	-5.84	-0.34	1.52e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs6674176	0.628	rs7556565	chr1:44416090	C/T	cg12908607	chr1:44402522	ARTN	-0.46	-6.64	-0.38	1.75e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs11690935	0.731	rs10930491	chr2:172569824	A/G	cg13550731	chr2:172543902	DYNC1I2	0.58	8.06	0.44	2.69e-14	Schizophrenia;
CESC	cis	rs875971	0.867	rs13227219	chr7:65844062	T/A	cg12463550	chr7:65579703	CRCP	0.56	6.98	0.39	2.33e-11	Aortic root size;
CESC	cis	rs7223966	1.000	rs7220821	chr17:61704147	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	7.5	0.42	9.63e-13	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs4665809	0.590	rs62128457	chr2:26467347	C/A	cg26314531	chr2:26401878	FAM59B	0.85	9.04	0.49	3.44e-17	Gut microbiome composition (summer);
CESC	cis	rs644799	1.000	rs580255	chr11:95577929	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.56	6.72	0.38	1.11e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs1348850	0.874	rs2166558	chr2:178373652	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.88	12.62	0.61	6.78e-29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs62229266	0.740	rs2835233	chr21:37393582	A/G	cg12218747	chr21:37451666	NA	-0.4	-5.71	-0.33	3.01e-8	Mitral valve prolapse;
CESC	cis	rs7811142	1.000	rs11773661	chr7:100073069	G/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.78	6.81	0.39	6.56e-11	Platelet count;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg16116313	chr12:122255002	SETD1B	0.53	7.37	0.41	2.2e-12	Fibrinogen levels;
CESC	cis	rs4423214	0.650	rs4245442	chr11:71220909	T/C	cg24826892	chr11:71159390	DHCR7	0.55	6.12	0.35	3.26e-9	Vitamin D levels;
CESC	cis	rs9322193	0.962	rs2342861	chr6:150098697	C/T	cg04369109	chr6:150039330	LATS1	-0.39	-5.28	-0.31	2.71e-7	Lung cancer;
CESC	cis	rs7412746	0.611	rs10888391	chr1:150729983	G/A	cg18016565	chr1:150552671	MCL1	0.35	5.08	0.3	7.01e-7	Melanoma;
CESC	cis	rs265548	0.646	rs36689	chr19:17910639	A/G	cg21960279	chr19:17905606	B3GNT3	0.46	6.82	0.39	6.07e-11	Tumor biomarkers;
CESC	cis	rs2486288	0.656	rs11629858	chr15:45547114	T/C	cg21132104	chr15:45694354	SPATA5L1	-0.54	-6.5	-0.37	4.05e-10	Glomerular filtration rate;
CESC	trans	rs916888	0.647	rs199524	chr17:44848438	G/T	cg01341218	chr17:43662625	NA	-0.58	-7.76	-0.43	1.87e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22187094	chr15:89878452	POLG	-0.58	-6.28	-0.36	1.42e-9	Gut microbiome composition (summer);
CESC	cis	rs727563	0.565	rs132774	chr22:42031953	C/G	cg06634786	chr22:41940651	POLR3H	-0.47	-5.31	-0.31	2.33e-7	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs798554	0.704	rs798513	chr7:2782493	C/T	cg13628971	chr7:2884303	GNA12	0.42	5.5	0.32	9.03e-8	Height;
CESC	cis	rs7592578	0.825	rs12477369	chr2:191455624	G/T	cg10560079	chr2:191398806	TMEM194B	0.59	5.19	0.3	4.11e-7	Diastolic blood pressure;
CESC	cis	rs4713118	0.586	rs9468290	chr6:28087674	C/T	cg22143856	chr6:28129313	ZNF389	0.52	6.71	0.38	1.21e-10	Parkinson's disease;
CESC	cis	rs9322193	0.923	rs9478291	chr6:150050570	A/G	cg04369109	chr6:150039330	LATS1	-0.44	-6.21	-0.36	2.05e-9	Lung cancer;
CESC	cis	rs7584330	0.554	rs10208231	chr2:238433225	C/T	cg14458575	chr2:238380390	NA	0.49	5.42	0.32	1.35e-7	Prostate cancer;
CESC	cis	rs17655565	0.543	rs2298797	chr12:52755189	A/G	cg00777198	chr12:52828273	KRT75	0.36	5.04	0.3	8.69e-7	Plasma amyloid beta peptide concentrations (ABx-42);
CESC	cis	rs35110281	0.712	rs1454648	chr21:45053815	C/T	cg04455712	chr21:45112962	RRP1B	0.38	5.58	0.32	5.8e-8	Mean corpuscular volume;
CESC	trans	rs11252926	0.501	rs2050971	chr10:525530	T/G	cg00953403	chr17:74099816	EXOC7	-0.49	-6.18	-0.35	2.4e-9	Psychosis in Alzheimer's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20235337	chr6:42981612	MEA1;KLHDC3	0.58	6.21	0.36	2.06e-9	Gut microbiome composition (summer);
CESC	cis	rs4481887	0.679	rs4466692	chr1:248423174	C/G	cg00666640	chr1:248458726	OR2T12	0.35	5.94	0.34	9.16e-9	Common traits (Other);
CESC	cis	rs875971	0.825	rs1860472	chr7:66082723	T/C	cg19163074	chr7:65112434	INTS4L2	0.42	5.28	0.31	2.73e-7	Aortic root size;
CESC	cis	rs1153858	1.000	rs66528868	chr15:45668547	A/C	cg21132104	chr15:45694354	SPATA5L1	0.86	11.62	0.58	1.67e-25	Homoarginine levels;
CESC	cis	rs17253792	0.822	rs13379343	chr14:56050205	G/A	cg01858014	chr14:56050164	KTN1	-0.95	-7.37	-0.41	2.23e-12	Putamen volume;
CESC	cis	rs9399135	0.967	rs3756799	chr6:135341011	A/G	cg24558204	chr6:135376177	HBS1L	0.49	6.8	0.39	6.8e-11	Red blood cell count;
CESC	cis	rs763121	0.853	rs1013338	chr22:38974154	C/A	cg06022373	chr22:39101656	GTPBP1	0.93	16.47	0.71	1.81e-42	Menopause (age at onset);
CESC	cis	rs10791097	0.694	rs7106973	chr11:130758113	G/A	cg09137382	chr11:130731461	NA	0.36	5.27	0.31	2.78e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	trans	rs7159888	0.727	rs11847263	chr14:65775695	A/C	cg21287597	chr13:114000024	GRTP1	0.45	6.01	0.35	6.23e-9	IgG glycosylation;N-glycan levels;
CESC	cis	rs71277158	0.688	rs73879167	chr3:169776194	T/G	cg04067573	chr3:169899625	PHC3	0.55	5.7	0.33	3.25e-8	Prostate cancer;
CESC	cis	rs17641971	0.645	rs341805	chr8:50034658	T/G	cg00325661	chr8:49890786	NA	0.39	5.28	0.31	2.64e-7	Blood metabolite levels;
CESC	cis	rs9929218	0.954	rs17715799	chr16:68830511	A/T	cg02972257	chr16:68554789	NA	0.46	5.42	0.32	1.33e-7	Colorectal cancer;
CESC	cis	rs896854	0.738	rs481887	chr8:95967838	A/G	cg23172400	chr8:95962367	TP53INP1	0.4	7.41	0.41	1.68e-12	Type 2 diabetes;
CESC	cis	rs4665809	1.000	rs2384322	chr2:26291146	C/G	cg04944784	chr2:26401820	FAM59B	-0.8	-8.93	-0.48	7.17e-17	Gut microbiome composition (summer);
CESC	cis	rs7851660	0.809	rs12550872	chr9:100653128	G/A	cg13688889	chr9:100608707	NA	-0.63	-8.96	-0.48	5.96e-17	Strep throat;
CESC	cis	rs8092503	0.859	rs35509548	chr18:52472408	A/G	cg12377874	chr18:52495404	RAB27B	0.37	5.94	0.34	8.77e-9	Childhood body mass index;
CESC	cis	rs9308731	0.591	rs55878194	chr2:111940474	C/G	cg04202892	chr2:111875749	ACOXL	0.37	5.18	0.3	4.49e-7	Chronic lymphocytic leukemia;
CESC	cis	rs7618915	0.547	rs2268027	chr3:52766606	G/A	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.31	5.48	0.32	9.89e-8	Bipolar disorder;
CESC	cis	rs7618915	0.533	rs35107891	chr3:52613656	G/C	cg18337363	chr3:52569053	NT5DC2	0.29	5.08	0.3	7.02e-7	Bipolar disorder;
CESC	cis	rs2046867	0.819	rs34132129	chr3:72829100	A/G	cg25664220	chr3:72788482	NA	-0.46	-6.67	-0.38	1.51e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CESC	trans	rs11098499	0.505	rs75122014	chr4:120362426	G/C	cg25214090	chr10:38739885	LOC399744	0.7	9.9	0.52	7.24e-20	Corneal astigmatism;
CESC	cis	rs35146811	0.961	rs1880949	chr7:99722266	A/C	cg22906224	chr7:99728672	NA	-0.47	-5.55	-0.32	7.05e-8	Coronary artery disease;
CESC	trans	rs11148252	0.532	rs9536262	chr13:53303074	A/C	cg18335740	chr13:41363409	SLC25A15	-0.55	-7.5	-0.42	9.4e-13	Lewy body disease;
CESC	cis	rs3796352	1.000	rs71301814	chr3:53117663	G/A	cg07884673	chr3:53033167	SFMBT1	0.66	5.57	0.32	6.19e-8	Immune reponse to smallpox (secreted IL-2);
CESC	cis	rs113835537	0.935	rs11550057	chr11:66392880	C/T	cg22134325	chr11:66188745	NPAS4	0.5	5.76	0.33	2.27e-8	Airway imaging phenotypes;
CESC	cis	rs8016982	0.674	rs61980899	chr14:81676844	T/C	cg01989461	chr14:81687754	GTF2A1	0.75	11.76	0.59	5.62e-26	Schizophrenia;
CESC	cis	rs9814567	0.964	rs3856729	chr3:134200925	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.47	-6.37	-0.36	8.13e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs672059	0.967	rs514183	chr1:183163174	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.58	7.5	0.42	9.59e-13	Hypertriglyceridemia;
CESC	cis	rs17433780	0.504	rs1409150	chr1:89473175	A/G	cg09516651	chr1:89888402	LOC400759	0.48	6.8	0.39	6.92e-11	Carotid intima media thickness;
CESC	cis	rs4523957	0.928	rs4790072	chr17:2173497	A/G	cg16513277	chr17:2031491	SMG6	-0.59	-7.99	-0.44	4.21e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs9322193	0.962	rs9322220	chr6:150104033	G/C	cg05861140	chr6:150128134	PCMT1	-0.36	-5.14	-0.3	5.22e-7	Lung cancer;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg10484450	chr14:67982152	TMEM229B	-0.53	-7.0	-0.4	2.1e-11	Asthma;
CESC	cis	rs59918340	0.728	rs6987335	chr8:142235358	T/G	cg23750338	chr8:142222470	SLC45A4	-0.59	-9.01	-0.48	4.12e-17	Immature fraction of reticulocytes;
CESC	cis	rs1707322	1.000	rs1768807	chr1:46510570	A/G	cg05343316	chr1:45956843	TESK2	-0.44	-5.44	-0.32	1.2e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs6570726	0.935	rs386344	chr6:145855622	A/G	cg23711669	chr6:146136114	FBXO30	0.8	11.39	0.57	1e-24	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg26684574	chr20:48532295	SPATA2	-0.53	-7.28	-0.41	3.79e-12	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs7312933	0.558	rs11181422	chr12:42718552	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.48	-6.4	-0.37	7.09e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs459571	0.883	rs2520096	chr9:136919416	A/G	cg13789015	chr9:136890014	NCRNA00094	0.54	7.91	0.44	6.88e-14	Platelet distribution width;
CESC	cis	rs9303280	0.901	rs2290400	chr17:38066240	A/G	cg20243544	chr17:37824526	PNMT	0.41	5.26	0.31	2.98e-7	Self-reported allergy;
CESC	cis	rs2486288	0.656	rs6493143	chr15:45570781	G/T	cg21132104	chr15:45694354	SPATA5L1	-0.57	-6.66	-0.38	1.55e-10	Glomerular filtration rate;
CESC	cis	rs4722166	0.508	rs1474348	chr7:22767908	C/G	cg26061582	chr7:22766209	IL6	0.47	5.32	0.31	2.26e-7	Lung cancer;
CESC	cis	rs4555082	0.874	rs2816625	chr14:105734565	G/A	cg10792982	chr14:105748885	BRF1	0.42	5.38	0.31	1.63e-7	Mean platelet volume;Platelet distribution width;
CESC	cis	rs4909189	1.000	rs12698214	chr7:158136204	T/G	cg25566285	chr7:158114605	PTPRN2	0.44	5.48	0.32	9.93e-8	Response to amphetamines;
CESC	cis	rs9443645	0.869	rs10943609	chr6:79676328	A/T	cg05283184	chr6:79620031	NA	-0.42	-6.49	-0.37	4.09e-10	Intelligence (multi-trait analysis);
CESC	cis	rs916888	0.821	rs199509	chr17:44858728	G/A	cg17911788	chr17:44343683	NA	0.53	7.2	0.4	6.14e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs798554	0.757	rs1182179	chr7:2873648	A/G	cg19346786	chr7:2764209	NA	-0.45	-6.53	-0.37	3.3e-10	Height;
CESC	cis	rs7618915	0.547	rs2878726	chr3:52748271	C/G	cg17372223	chr3:52568218	NT5DC2	0.44	6.57	0.37	2.6e-10	Bipolar disorder;
CESC	cis	rs875971	0.838	rs2173570	chr7:65762963	T/A	cg10691866	chr7:65817282	TPST1	0.35	5.9	0.34	1.12e-8	Aortic root size;
CESC	cis	rs6582630	0.519	rs4406888	chr12:38293312	A/C	cg26384229	chr12:38710491	ALG10B	0.71	10.63	0.55	3.23e-22	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs6912958	0.559	rs2985039	chr6:88041757	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	0.34	5.54	0.32	7.38e-8	Monocyte percentage of white cells;
CESC	cis	rs7267979	1.000	rs2258884	chr20:25279539	C/T	cg08601574	chr20:25228251	PYGB	0.39	5.57	0.32	6.14e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs2228479	0.717	rs11649210	chr16:89807233	C/G	cg04013166	chr16:89971882	TCF25	0.72	7.86	0.43	9.59e-14	Skin colour saturation;
CESC	cis	rs8072100	0.967	rs4338849	chr17:45512483	A/G	cg25173405	chr17:45401733	C17orf57	-0.4	-5.42	-0.32	1.34e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs9549260	0.816	rs7324090	chr13:41253958	A/T	cg21288729	chr13:41239152	FOXO1	0.63	8.2	0.45	1.02e-14	Red blood cell count;
CESC	cis	rs2404602	0.692	rs36070630	chr15:76949259	T/C	cg26408565	chr15:76604113	ETFA	-0.4	-5.68	-0.33	3.58e-8	Blood metabolite levels;
CESC	cis	rs2836974	0.674	rs1011413	chr21:40638241	A/G	cg11644478	chr21:40555479	PSMG1	-0.86	-12.94	-0.62	5.36e-30	Cognitive function;
CESC	cis	rs6061231	0.793	rs2427320	chr20:60976723	A/G	cg24112000	chr20:60950667	NA	-0.57	-7.01	-0.4	1.96e-11	Colorectal cancer;
CESC	cis	rs6499129	0.867	rs4360931	chr16:67471926	C/G	cg26727032	chr16:67993705	SLC12A4	-0.58	-5.99	-0.35	6.84e-9	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs3858526	0.727	rs10769353	chr11:5954809	C/T	cg25319279	chr11:5960081	NA	0.33	5.06	0.3	8.03e-7	DNA methylation (variation);
CESC	cis	rs1729951	0.575	rs10935214	chr3:136693485	G/A	cg25687071	chr3:136751404	NA	0.39	5.19	0.3	4.27e-7	Neuroticism;
CESC	cis	rs11030122	0.569	rs11030781	chr11:4083258	T/C	cg18678763	chr11:4115507	RRM1	-0.42	-5.66	-0.33	3.85e-8	Mean platelet volume;Platelet distribution width;
CESC	cis	rs10504229	0.679	rs72649131	chr8:58054288	G/T	cg22535103	chr8:58192502	C8orf71	-0.66	-7.28	-0.41	3.76e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs2228479	0.850	rs11076623	chr16:89844120	G/T	cg04013166	chr16:89971882	TCF25	0.78	6.65	0.38	1.64e-10	Skin colour saturation;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg09015484	chr9:96929106	NA	-0.44	-6.15	-0.35	2.81e-9	Height;
CESC	cis	rs2228479	0.850	rs62056103	chr16:89942781	G/A	cg14709524	chr16:89940631	TCF25	0.88	6.44	0.37	5.5e-10	Skin colour saturation;
CESC	cis	rs6912958	1.000	rs9294379	chr6:88152535	C/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.56	-7.57	-0.42	6.2e-13	Monocyte percentage of white cells;
CESC	cis	rs7223966	0.961	rs35844156	chr17:61837568	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.54	6.31	0.36	1.16e-9	Hip circumference adjusted for BMI;Body mass index;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg08083689	chr4:8442326	ACOX3	-0.44	-6.04	-0.35	5.25e-9	Gambling;
CESC	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg02951883	chr7:2050386	MAD1L1	0.5	6.8	0.39	6.73e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs2842992	0.714	rs2475564	chr6:160123673	A/G	cg11366901	chr6:160182831	ACAT2	0.83	10.24	0.53	6.02e-21	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs1062177	1.000	rs17804178	chr5:151197729	T/G	cg00977110	chr5:151150581	G3BP1	0.63	6.65	0.38	1.66e-10	Preschool internalizing problems;
CESC	cis	rs5758659	0.622	rs6519298	chr22:42364997	C/T	cg15557168	chr22:42548783	NA	-0.42	-6.28	-0.36	1.4e-9	Cognitive function;
CESC	cis	rs742614	0.533	rs2092737	chr20:32428135	A/C	cg06304546	chr20:32448765	NA	-0.41	-5.29	-0.31	2.57e-7	Stearic acid (18:0) levels;
CESC	cis	rs35123781	0.696	rs4912756	chr5:139070780	A/T	cg10513866	chr5:139070639	NA	0.43	6.01	0.35	6.06e-9	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03803784	chr12:51157550	ATF1	0.57	6.14	0.35	3.05e-9	Gut microbiome composition (summer);
CESC	cis	rs7872515	0.536	rs7852989	chr9:94782453	G/C	cg01248375	chr9:94877805	SPTLC1	0.59	5.08	0.3	7.23e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs6783573	0.711	rs3806701	chr3:46617337	G/A	cg21489266	chr3:46619131	LRRC2;TDGF1	-0.54	-7.79	-0.43	1.48e-13	Cerebrospinal fluid biomarker levels;
CESC	cis	rs9640161	0.789	rs11767409	chr7:150058043	C/T	cg21361702	chr7:150065534	REPIN1	0.61	6.72	0.38	1.13e-10	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs6088580	0.634	rs4911423	chr20:32999386	T/A	cg24642439	chr20:33292090	TP53INP2	-0.53	-6.98	-0.39	2.39e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs6089584	0.819	rs1467593	chr20:60601432	T/G	cg24733560	chr20:60626293	TAF4	-0.42	-5.74	-0.33	2.53e-8	Body mass index;
CESC	cis	rs2839186	0.708	rs6518285	chr21:47644667	T/C	cg10351095	chr21:47802916	PCNT	-0.45	-6.19	-0.36	2.33e-9	Testicular germ cell tumor;
CESC	cis	rs11711311	1.000	rs12632983	chr3:113481913	A/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.59	7.77	0.43	1.71e-13	IgG glycosylation;
CESC	cis	rs13108904	0.557	rs1680041	chr4:1238521	C/T	cg19318889	chr4:1322082	MAEA	-0.46	-5.94	-0.34	9.14e-9	Obesity-related traits;
CESC	cis	rs6860806	0.695	rs6867282	chr5:131583120	G/C	cg12564285	chr5:131593104	PDLIM4	0.39	5.88	0.34	1.23e-8	Breast cancer;
CESC	cis	rs1862618	0.573	rs832532	chr5:56221938	T/C	cg18230493	chr5:56204884	C5orf35	-0.81	-9.69	-0.51	3.23e-19	Initial pursuit acceleration;
CESC	cis	rs12477438	0.798	rs9808541	chr2:99642179	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-10.57	-0.54	5.22e-22	Chronic sinus infection;
CESC	cis	rs3118233	1	rs3118233	chr16:68733646	G/C	cg02972257	chr16:68554789	NA	0.48	5.69	0.33	3.36e-8	Red cell distribution width;
CESC	cis	rs763121	0.819	rs5757237	chr22:39073835	G/C	cg21395723	chr22:39101663	GTPBP1	0.42	5.3	0.31	2.39e-7	Menopause (age at onset);
CESC	cis	rs9322193	0.923	rs9322200	chr6:149951214	G/A	cg13206674	chr6:150067644	NUP43	0.41	5.77	0.33	2.21e-8	Lung cancer;
CESC	cis	rs9291683	0.655	rs55941493	chr4:10100341	G/A	cg00071950	chr4:10020882	SLC2A9	-0.56	-8.65	-0.47	5.19e-16	Bone mineral density;
CESC	cis	rs9815354	1.000	rs12639255	chr3:41861738	T/C	cg03022575	chr3:42003672	ULK4	0.48	5.38	0.31	1.68e-7	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs4253772	0.550	rs6008615	chr22:46707928	G/A	cg10541313	chr22:46663664	TTC38	0.61	5.14	0.3	5.24e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs9611565	0.592	rs28750375	chr22:41990644	A/C	cg17376030	chr22:41985996	PMM1	0.49	5.49	0.32	9.5e-8	Vitiligo;
CESC	cis	rs3820068	0.655	rs11587521	chr1:15839206	T/C	cg18192808	chr1:15853278	DNAJC16	0.46	5.53	0.32	7.56e-8	Systolic blood pressure;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	ch.2.2017299F	chr2:97269742	KIAA1310	-0.55	-6.37	-0.36	8.49e-10	Gut microbiome composition (summer);
CESC	cis	rs362272	0.524	rs2749781	chr4:3346617	T/C	cg14583973	chr4:3374767	RGS12	0.33	5.6	0.33	5.34e-8	Serum sulfate level;
CESC	cis	rs4072980	0.524	rs28442147	chr1:38395410	T/A	cg12658694	chr1:38397304	INPP5B	0.7	9.78	0.51	1.79e-19	Coronary artery disease;
CESC	cis	rs1062177	0.855	rs62395861	chr5:151269270	A/G	cg00977110	chr5:151150581	G3BP1	0.62	6.49	0.37	4.31e-10	Preschool internalizing problems;
CESC	cis	rs854765	0.583	rs11078405	chr17:17824978	G/T	cg04398451	chr17:18023971	MYO15A	-0.65	-9.23	-0.49	9.1e-18	Total body bone mineral density;
CESC	cis	rs7267979	0.868	rs6107019	chr20:25233985	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.82	15.1	0.68	1.39e-37	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs60311166	1.000	rs934839	chr3:52683898	G/T	cg13174197	chr3:52720522	GNL3;PBRM1	0.62	5.15	0.3	5.03e-7	CTACK levels;
CESC	trans	rs61931739	0.534	rs4365131	chr12:34053308	T/C	cg26384229	chr12:38710491	ALG10B	0.53	7.23	0.41	5.25e-12	Morning vs. evening chronotype;
CESC	cis	rs67311347	0.869	rs7646899	chr3:40366982	A/G	cg24209194	chr3:40518798	ZNF619	0.4	5.03	0.3	9.09e-7	Renal cell carcinoma;
CESC	cis	rs9291683	0.620	rs4444830	chr4:10124819	A/G	cg00071950	chr4:10020882	SLC2A9	-0.53	-7.28	-0.41	3.86e-12	Bone mineral density;
CESC	cis	rs6860806	0.661	rs28472559	chr5:131581611	G/A	cg09877947	chr5:131593287	PDLIM4	0.48	6.27	0.36	1.43e-9	Breast cancer;
CESC	cis	rs10751667	0.643	rs7395613	chr11:933873	C/T	cg20946044	chr11:1010712	AP2A2	-0.4	-5.43	-0.32	1.26e-7	Alzheimer's disease (late onset);
CESC	cis	rs9894429	0.789	rs7502346	chr17:79603741	T/C	cg18240062	chr17:79603768	NPLOC4	0.9	13.24	0.63	4.59e-31	Eye color traits;
CESC	cis	rs11690935	0.632	rs62183783	chr2:172865775	A/G	cg13550731	chr2:172543902	DYNC1I2	0.46	6.26	0.36	1.53e-9	Schizophrenia;
CESC	cis	rs6570726	0.935	rs424263	chr6:145840073	A/C	cg23711669	chr6:146136114	FBXO30	0.8	12.02	0.59	7.36e-27	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs597539	0.690	rs7129960	chr11:68622456	A/G	cg18350739	chr11:68623251	NA	-0.46	-6.64	-0.38	1.8e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg25549747	chr13:21750870	MRP63;SKA3	-0.46	-6.36	-0.36	8.79e-10	Fibrinogen levels;
CESC	cis	rs9486719	0.843	rs2205754	chr6:96843134	T/C	cg18709589	chr6:96969512	KIAA0776	0.55	5.64	0.33	4.26e-8	Migraine;Coronary artery disease;
CESC	cis	rs12042938	0.935	rs823159	chr1:231777168	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.47	6.57	0.37	2.65e-10	Neuranatomic and neurocognitive phenotypes;
CESC	cis	rs9913156	0.793	rs4346260	chr17:4567215	A/G	cg19197139	chr17:4613644	ARRB2	-0.92	-10.59	-0.55	4.42e-22	Lymphocyte counts;
CESC	cis	rs2299587	0.689	rs2285303	chr8:17797409	A/G	cg08627089	chr8:17753878	FGL1	-0.42	-5.65	-0.33	4.24e-8	Economic and political preferences;
CESC	cis	rs1552244	1.000	rs17032278	chr3:10077955	A/G	cg08888203	chr3:10149979	C3orf24	0.46	5.9	0.34	1.11e-8	Alzheimer's disease;
CESC	cis	rs11638352	1.000	rs2706473	chr15:44417735	C/A	cg27015174	chr15:43622946	ADAL;LCMT2	-0.61	-5.62	-0.33	4.75e-8	Lipoprotein phospholipase A2 activity in cardiovascular disease;
CESC	cis	rs2249694	0.919	rs10857769	chr10:135405047	T/C	cg20169779	chr10:135381914	SYCE1	-0.4	-5.67	-0.33	3.78e-8	Obesity-related traits;
CESC	cis	rs7851660	0.844	rs13287360	chr9:100637681	A/G	cg13688889	chr9:100608707	NA	-0.64	-8.94	-0.48	6.74e-17	Strep throat;
CESC	cis	rs9322193	0.736	rs3805750	chr6:150112201	G/A	cg04369109	chr6:150039330	LATS1	-0.4	-5.47	-0.32	1.04e-7	Lung cancer;
CESC	cis	rs11711311	1.000	rs9865435	chr3:113450046	G/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.72	10.27	0.53	4.81e-21	IgG glycosylation;
CESC	cis	rs10789491	0.565	rs2897107	chr1:47206178	A/T	cg15501359	chr1:47185051	KIAA0494	0.76	7.4	0.41	1.82e-12	Response to hepatitis C treatment;
CESC	cis	rs2836974	0.865	rs7282624	chr21:40667040	C/T	cg27266027	chr21:40555129	PSMG1	0.44	5.18	0.3	4.43e-7	Cognitive function;
CESC	cis	rs7116495	1.000	rs7128317	chr11:71701367	C/T	cg26138937	chr11:71823887	C11orf51	0.79	6.9	0.39	3.88e-11	Severe influenza A (H1N1) infection;
CESC	cis	rs6963495	0.818	rs116845562	chr7:105217038	T/C	cg02135003	chr7:105160482	PUS7	-0.47	-5.47	-0.32	1.04e-7	Bipolar disorder (body mass index interaction);
CESC	cis	rs1215050	0.791	rs2123100	chr4:98803747	T/C	cg05340658	chr4:99064831	C4orf37	0.52	6.88	0.39	4.36e-11	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs2276314	0.857	rs4799408	chr18:33588982	C/T	cg05985134	chr18:33552581	C18orf21	-0.63	-7.6	-0.42	5.2e-13	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs875971	0.861	rs801215	chr7:66011938	A/T	cg19163074	chr7:65112434	INTS4L2	0.43	5.34	0.31	2e-7	Aortic root size;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg08755283	chr5:118324104	DTWD2	-0.45	-6.51	-0.37	3.74e-10	Fibrinogen levels;
CESC	cis	rs4535700	0.501	rs6943341	chr7:55975182	A/T	cg09872392	chr7:56161020	PHKG1	0.4	5.77	0.33	2.19e-8	Macular telangiectasia type 2;
CESC	cis	rs858239	0.730	rs858279	chr7:23251005	T/C	cg23682824	chr7:23144976	KLHL7	0.42	5.72	0.33	2.86e-8	Cerebrospinal fluid biomarker levels;
CESC	cis	rs2243480	1.000	rs313831	chr7:65551226	C/T	cg18252515	chr7:66147081	NA	-1.37	-13.58	-0.64	2.97e-32	Diabetic kidney disease;
CESC	cis	rs1878931	0.582	rs4785933	chr16:3419741	T/A	cg02880119	chr16:3481970	NA	-0.42	-5.42	-0.32	1.32e-7	Body mass index (adult);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24306142	chr1:17231793	NA	-0.61	-6.75	-0.38	9.23e-11	Gut microbiome composition (summer);
CESC	cis	rs3806843	0.750	rs2563285	chr5:140126137	T/C	cg26395211	chr5:140044315	WDR55	0.41	5.25	0.31	3.1e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs736801	0.808	rs2706403	chr5:131799012	A/G	cg00255919	chr5:131827918	IRF1	0.35	5.23	0.31	3.45e-7	Breast cancer;Mosquito bite size;
CESC	cis	rs950776	0.518	rs12916483	chr15:78832397	G/A	cg06917634	chr15:78832804	PSMA4	0.81	12.32	0.6	6.91e-28	Sudden cardiac arrest;
CESC	trans	rs7902708	0.920	rs12256387	chr10:54422872	C/A	cg26219051	chr22:43739629	SCUBE1	-0.48	-6.19	-0.36	2.25e-9	Bone properties (heel);
CESC	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg05025164	chr4:1340916	KIAA1530	-0.88	-12.05	-0.59	5.84e-27	Longevity;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07352001	chr10:44144445	ZNF32	0.56	6.15	0.35	2.86e-9	Gut microbiome composition (summer);
CESC	cis	rs3820928	1.000	rs59904960	chr2:227761269	T/C	cg05526886	chr2:227700861	RHBDD1	-0.42	-5.38	-0.31	1.64e-7	Pulmonary function;
CESC	cis	rs2404602	0.716	rs1874944	chr15:76863928	A/G	cg26408565	chr15:76604113	ETFA	-0.4	-5.72	-0.33	2.92e-8	Blood metabolite levels;
CESC	cis	rs9916302	0.904	rs9944411	chr17:37483599	T/C	cg07936489	chr17:37558343	FBXL20	0.77	10.62	0.55	3.6e-22	Glomerular filtration rate (creatinine);
CESC	cis	rs9916302	0.904	rs634365	chr17:37436966	C/T	cg15445000	chr17:37608096	MED1	0.42	6.91	0.39	3.71e-11	Glomerular filtration rate (creatinine);
CESC	trans	rs11098499	1.000	rs28419773	chr4:120211061	T/C	cg25214090	chr10:38739885	LOC399744	0.68	9.37	0.5	3.4e-18	Corneal astigmatism;
CESC	cis	rs7412746	0.552	rs4970980	chr1:150864992	A/C	cg17724175	chr1:150552817	MCL1	0.33	5.15	0.3	5.14e-7	Melanoma;
CESC	cis	rs8067354	0.540	rs7221472	chr17:58036737	C/T	cg02344993	chr17:57696989	CLTC	0.53	5.41	0.32	1.4e-7	Hemoglobin concentration;
CESC	cis	rs2836950	0.520	rs8133927	chr21:40689961	G/T	cg11644478	chr21:40555479	PSMG1	-0.56	-7.58	-0.42	5.83e-13	Menarche (age at onset);
CESC	cis	rs7833790	0.676	rs7834555	chr8:82697625	A/G	cg02079420	chr8:82753780	SNX16	0.5	7.56	0.42	6.82e-13	Diastolic blood pressure;
CESC	cis	rs4629180	0.586	rs1848699	chr2:102137903	C/G	cg04415270	chr2:102091202	RFX8	-0.3	-5.24	-0.31	3.24e-7	Chronic rhinosinusitis with nasal polyps;
CESC	cis	rs74054849	0.541	rs12094673	chr1:15914820	T/C	cg17385448	chr1:15911702	AGMAT	0.53	5.21	0.3	3.83e-7	Alcoholic chronic pancreatitis;
CESC	cis	rs7173419	0.607	rs1800411	chr15:28211921	A/G	cg20906524	chr15:28200668	OCA2	0.37	5.03	0.3	9.22e-7	Eye color;
CESC	cis	rs6121246	0.559	rs6058352	chr20:30269179	T/C	cg13852791	chr20:30311386	BCL2L1	0.81	10.51	0.54	8.04e-22	Mean corpuscular hemoglobin;
CESC	cis	rs7666738	0.606	rs7663216	chr4:99088385	A/C	cg17366294	chr4:99064904	C4orf37	0.42	5.67	0.33	3.76e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6542838	0.582	rs6542845	chr2:99537600	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.44	-5.66	-0.33	3.95e-8	Fear of minor pain;
CESC	cis	rs78132593	0.757	rs41305070	chr1:150666860	A/G	cg04414720	chr1:150670196	GOLPH3L	-0.54	-5.43	-0.32	1.27e-7	High light scatter reticulocyte count;
CESC	cis	rs2952156	0.959	rs1495101	chr17:37832103	C/A	cg00129232	chr17:37814104	STARD3	-0.71	-9.32	-0.5	4.68e-18	Asthma;
CESC	cis	rs7202877	0.610	rs3851735	chr16:75372092	A/G	cg04384234	chr16:75411784	CFDP1	-0.5	-5.85	-0.34	1.42e-8	Type 2 diabetes;Type 1 diabetes;
CESC	cis	rs5750830	0.594	rs1010169	chr22:39778167	C/T	cg05872129	chr22:39784769	NA	0.83	11.54	0.58	3.12e-25	Intelligence (multi-trait analysis);
CESC	cis	rs2204008	0.580	rs11174421	chr12:38105138	A/G	cg26384229	chr12:38710491	ALG10B	0.7	9.44	0.5	2.07e-18	Bladder cancer;
CESC	cis	rs514406	0.505	rs427319	chr1:53178807	T/G	cg27535305	chr1:53392650	SCP2	-0.32	-5.31	-0.31	2.34e-7	Monocyte count;
CESC	cis	rs514406	1.000	rs514406	chr1:53330458	A/G	cg24675658	chr1:53192096	ZYG11B	-0.62	-7.63	-0.42	4.16e-13	Monocyte count;
CESC	cis	rs7628338	0.525	rs13072744	chr3:72509637	C/T	cg22685502	chr3:72496851	RYBP	-0.27	-6.21	-0.36	2.08e-9	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
CESC	trans	rs11148252	0.553	rs9536219	chr13:53227301	C/T	cg18335740	chr13:41363409	SLC25A15	0.52	7.02	0.4	1.89e-11	Lewy body disease;
CESC	cis	rs10791097	0.694	rs2155751	chr11:130755240	G/A	cg12179176	chr11:130786555	SNX19	0.65	10.15	0.53	1.18e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs4862750	0.872	rs7672831	chr4:187898882	C/T	cg07414643	chr4:187882934	NA	0.52	7.65	0.43	3.84e-13	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6502050	0.835	rs8080625	chr17:80115447	G/A	cg23985595	chr17:80112537	CCDC57	-0.41	-6.46	-0.37	4.9e-10	Life satisfaction;
CESC	cis	rs514406	0.505	rs436363	chr1:53172163	T/C	cg08859206	chr1:53392774	SCP2	-0.6	-8.04	-0.44	3.07e-14	Monocyte count;
CESC	cis	rs2836974	0.623	rs34240248	chr21:40685239	A/G	cg22974920	chr21:40686053	BRWD1	-0.47	-5.72	-0.33	2.89e-8	Cognitive function;
CESC	cis	rs3862030	0.810	rs11593710	chr10:104328719	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.4	-5.4	-0.31	1.47e-7	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
CESC	cis	rs3749237	0.595	rs11720264	chr3:49580347	C/T	cg07636037	chr3:49044803	WDR6	0.6	8.78	0.47	2.1e-16	Resting heart rate;
CESC	cis	rs4253772	0.591	rs11703245	chr22:46684890	A/G	cg03036452	chr22:46663545	TTC38	0.64	5.03	0.3	9.16e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs7149337	0.836	rs35345236	chr14:51671817	T/C	cg23942311	chr14:51606299	NA	0.44	7.47	0.42	1.17e-12	Cancer;
CESC	cis	rs12545109	0.800	rs1440747	chr8:57417924	G/T	cg09654669	chr8:57350985	NA	0.53	6.09	0.35	3.89e-9	Obesity-related traits;
CESC	cis	rs9322193	0.962	rs3763162	chr6:150140810	A/G	cg05861140	chr6:150128134	PCMT1	0.36	5.17	0.3	4.59e-7	Lung cancer;
CESC	cis	rs6032067	0.777	rs13038342	chr20:43800232	C/T	cg10761708	chr20:43804764	PI3	0.55	6.64	0.38	1.82e-10	Blood protein levels;
CESC	cis	rs75229567	0.618	rs11177819	chr12:70134836	T/G	cg10114359	chr12:70132523	RAB3IP	1.2	7.96	0.44	5.07e-14	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
CESC	cis	rs4820294	0.961	rs62236664	chr22:38059427	T/C	cg21798802	chr22:38057573	PDXP	0.46	7.93	0.44	6.33e-14	Fat distribution (HIV);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27098574	chr16:75285489	BCAR1	0.53	6.23	0.36	1.84e-9	Gut microbiome composition (summer);
CESC	cis	rs28595532	0.800	rs114321375	chr4:119341663	G/A	cg21605333	chr4:119757512	SEC24D	1.01	5.69	0.33	3.4e-8	Cannabis dependence symptom count;
CESC	trans	rs7246760	1.000	rs73014068	chr19:9922783	T/C	cg02900749	chr2:68251473	NA	-0.83	-7.08	-0.4	1.3e-11	Pursuit maintenance gain;
CESC	cis	rs72945132	0.882	rs67283107	chr11:70221204	C/T	cg00319359	chr11:70116639	PPFIA1	0.71	6.71	0.38	1.18e-10	Coronary artery disease;
CESC	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg11494091	chr17:61959527	GH2	0.72	12.07	0.6	4.93e-27	Prudent dietary pattern;
CESC	cis	rs2576037	0.583	rs8094654	chr18:44527397	C/T	cg19077165	chr18:44547161	KATNAL2	-0.64	-9.69	-0.51	3.35e-19	Personality dimensions;
CESC	cis	rs763121	0.853	rs5757204	chr22:39046700	A/C	cg14440974	chr22:39074834	NA	-0.4	-5.48	-0.32	9.77e-8	Menopause (age at onset);
CESC	cis	rs6546550	0.935	rs13392884	chr2:70036711	A/G	cg02498382	chr2:70120550	SNRNP27	-0.38	-6.47	-0.37	4.83e-10	Prevalent atrial fibrillation;
CESC	trans	rs6828577	0.819	rs368669	chr4:119634275	A/G	cg05098011	chr1:151736092	OAZ3;MRPL9	0.48	6.02	0.35	5.93e-9	Perioperative myocardial infarction in coronary artery bypass surgery;
CESC	cis	rs2235642	0.893	rs2143285	chr16:1593171	A/G	cg08296037	chr16:1584118	IFT140;TMEM204	-0.32	-5.27	-0.31	2.77e-7	Coronary artery disease;
CESC	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg11494091	chr17:61959527	GH2	0.74	12.88	0.62	8.12e-30	Prudent dietary pattern;
CESC	cis	rs875971	0.638	rs10278816	chr7:66036987	T/C	cg06456125	chr7:65229604	NA	-0.4	-5.15	-0.3	5.11e-7	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10063512	chr8:37594142	ERLIN2	0.63	7.25	0.41	4.57e-12	Gut microbiome composition (summer);
CESC	cis	rs62432291	0.681	rs445957	chr6:159662064	C/T	cg14500486	chr6:159655392	FNDC1	-0.63	-6.56	-0.37	2.84e-10	Joint mobility (Beighton score);
CESC	trans	rs7615952	0.932	rs1976458	chr3:125647512	T/G	cg07211511	chr3:129823064	LOC729375	-1.14	-15.22	-0.68	5.24e-38	Blood pressure (smoking interaction);
CESC	cis	rs763014	0.898	rs4984897	chr16:632180	G/C	cg00908189	chr16:619842	PIGQ	0.67	9.34	0.5	4.24e-18	Height;
CESC	cis	rs6724607	1.000	rs7598979	chr2:191453375	A/G	cg21644426	chr2:191273491	MFSD6	0.48	6.59	0.38	2.33e-10	Pulse pressure;
CESC	cis	rs7524258	0.903	rs6577424	chr1:7292417	C/T	cg07173049	chr1:7289937	CAMTA1	-0.44	-6.61	-0.38	2.1e-10	Tourette's syndrome or obsessive-compulsive disorder;
CESC	cis	rs3820928	0.839	rs13404750	chr2:227876129	G/A	cg11843606	chr2:227700838	RHBDD1	-0.44	-5.52	-0.32	8.19e-8	Pulmonary function;
CESC	cis	rs7243790	0.774	rs62091573	chr18:51939055	G/A	cg04730925	chr18:51795821	POLI	-0.43	-5.75	-0.33	2.4e-8	Diastolic blood pressure;
CESC	cis	rs11792861	0.816	rs2275637	chr9:111696043	C/G	cg13535736	chr9:111863775	C9orf5	-0.47	-6.19	-0.36	2.22e-9	Menarche (age at onset);
CESC	cis	rs62064224	0.765	rs62065463	chr17:30732405	G/T	cg25809561	chr17:30822961	MYO1D	0.59	8.47	0.46	1.77e-15	Schizophrenia;
CESC	cis	rs6831352	0.879	rs2602879	chr4:100040652	G/A	cg13256891	chr4:100009986	ADH5	0.75	8.03	0.44	3.29e-14	Alcohol dependence;
CESC	cis	rs6032067	0.777	rs35434469	chr20:43778544	C/T	cg11264863	chr20:43835661	SEMG1	0.49	5.1	0.3	6.5e-7	Blood protein levels;
CESC	cis	rs826838	0.654	rs7977738	chr12:38722460	G/A	cg26384229	chr12:38710491	ALG10B	0.57	8.22	0.45	9.19e-15	Heart rate;
CESC	cis	rs9649213	0.593	rs11760930	chr7:97915789	G/A	cg24562669	chr7:97807699	LMTK2	0.47	6.6	0.38	2.21e-10	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs910316	0.935	rs2268620	chr14:75640403	G/A	cg11812906	chr14:75593930	NEK9	-0.88	-14.42	-0.66	3.46e-35	Height;
CESC	cis	rs523522	0.923	rs3916065	chr12:120934624	A/C	cg27279351	chr12:120934652	DYNLL1	0.69	9.11	0.49	2.02e-17	High light scatter reticulocyte count;
CESC	cis	rs1568889	0.938	rs11601602	chr11:28233768	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.71	8.25	0.45	7.7e-15	Bipolar disorder;
CESC	cis	rs7666738	0.830	rs6839203	chr4:98839814	C/G	cg05340658	chr4:99064831	C4orf37	0.72	10.19	0.53	8.89e-21	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9926296	0.581	rs6500457	chr16:89898764	C/G	cg03388025	chr16:89894329	SPIRE2	-0.32	-5.7	-0.33	3.19e-8	Vitiligo;
CESC	cis	rs34779708	0.931	rs4934524	chr10:35270921	G/C	cg04310649	chr10:35416472	CREM	-0.5	-5.97	-0.34	7.5e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs1728785	0.892	rs1617749	chr16:68580890	A/G	cg02972257	chr16:68554789	NA	-0.62	-6.88	-0.39	4.41e-11	Ulcerative colitis;
CESC	cis	rs35306767	0.855	rs61830931	chr10:932497	T/C	cg10556349	chr10:835070	NA	0.72	6.11	0.35	3.52e-9	Eosinophil percentage of granulocytes;
CESC	cis	rs28655083	0.828	rs9938028	chr16:77127830	A/C	cg01753188	chr16:77233325	SYCE1L;MON1B	0.41	5.24	0.31	3.23e-7	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2425143	1.000	rs28685274	chr20:34358527	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.8	-8.0	-0.44	3.85e-14	Blood protein levels;
CESC	cis	rs4689592	0.587	rs3822269	chr4:7069901	T/C	cg26116260	chr4:7069785	GRPEL1	0.95	12.78	0.62	1.81e-29	Monocyte percentage of white cells;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg00969680	chr1:113466087	AFARP1;SLC16A1	0.57	7.71	0.43	2.57e-13	Fibrinogen levels;
CESC	trans	rs4335177	0.642	rs10816403	chr9:109371518	T/C	cg12580783	chr12:49362475	WNT10B	-0.32	-6.27	-0.36	1.45e-9	Response to paliperidone in schizophrenia (positive Marder score);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27171280	chr4:89205853	PPM1K	0.6	7.0	0.4	2.14e-11	Gut microbiome composition (summer);
CESC	cis	rs9322193	0.923	rs12174349	chr6:150039148	G/A	cg13206674	chr6:150067644	NUP43	0.46	6.59	0.38	2.43e-10	Lung cancer;
CESC	cis	rs208520	1.000	rs72884033	chr6:66995747	T/C	cg07460842	chr6:66804631	NA	0.88	9.99	0.52	3.87e-20	Exhaled nitric oxide output;
CESC	cis	rs854765	0.647	rs7406744	chr17:17981938	C/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.47	5.88	0.34	1.24e-8	Total body bone mineral density;
CESC	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	10.16	0.53	1.09e-20	Prudent dietary pattern;
CESC	cis	rs9911578	1.000	rs12940681	chr17:56933622	T/C	cg12560992	chr17:57184187	TRIM37	0.92	15.53	0.69	3.91e-39	Intelligence (multi-trait analysis);
CESC	cis	rs854765	0.547	rs4925135	chr17:17952868	T/C	cg09796270	chr17:17721594	SREBF1	-0.38	-5.07	-0.3	7.66e-7	Total body bone mineral density;
CESC	cis	rs6963495	0.818	rs6961863	chr7:105180953	C/T	cg19920283	chr7:105172520	RINT1	0.77	8.17	0.45	1.24e-14	Bipolar disorder (body mass index interaction);
CESC	cis	rs9359856	0.564	rs72917989	chr6:90470385	A/T	cg13799429	chr6:90582589	CASP8AP2	-0.61	-5.64	-0.33	4.36e-8	Bipolar disorder;
CESC	cis	rs807669	1.000	rs807670	chr22:19154608	A/C	cg02655711	chr22:19163373	SLC25A1	0.66	10.17	0.53	9.83e-21	Metabolite levels;
CESC	cis	rs4319547	0.695	rs55834409	chr12:122862560	C/G	cg05707623	chr12:122985044	ZCCHC8	0.53	5.92	0.34	1.01e-8	Body mass index;
CESC	cis	rs2228479	0.702	rs17177891	chr16:89799950	C/T	cg14709524	chr16:89940631	TCF25	0.81	5.97	0.34	7.63e-9	Skin colour saturation;
CESC	cis	rs7666738	0.830	rs13119913	chr4:98977983	G/T	cg05340658	chr4:99064831	C4orf37	0.77	11.71	0.58	8.52e-26	Colonoscopy-negative controls vs population controls;
CESC	cis	rs16957304	1.000	rs8062484	chr16:67343932	G/T	cg26727032	chr16:67993705	SLC12A4	-0.52	-5.13	-0.3	5.74e-7	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
CESC	cis	rs897984	0.762	rs12931046	chr16:30987144	G/A	cg00531865	chr16:30841666	NA	0.5	6.8	0.39	6.84e-11	Dementia with Lewy bodies;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11281249	chr2:198570061	MARS2	0.57	6.56	0.37	2.83e-10	Gut microbiome composition (summer);
CESC	cis	rs36051895	0.623	rs28872016	chr9:5253558	T/G	cg02405213	chr9:5042618	JAK2	-0.54	-6.37	-0.36	8.34e-10	Pediatric autoimmune diseases;
CESC	cis	rs6547741	0.935	rs2384626	chr2:27773648	A/G	cg27432699	chr2:27873401	GPN1	0.44	6.05	0.35	4.98e-9	Oral cavity cancer;
CESC	cis	rs9905704	0.681	rs2531730	chr17:56545069	T/G	cg12560992	chr17:57184187	TRIM37	-0.59	-5.62	-0.33	4.89e-8	Testicular germ cell tumor;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02136628	chr17:41476456	ARL4D	0.59	6.7	0.38	1.21e-10	Gut microbiome composition (summer);
CESC	cis	rs1552244	0.882	rs6443276	chr3:10008905	C/A	cg00149659	chr3:10157352	C3orf10	0.69	8.12	0.45	1.77e-14	Alzheimer's disease;
CESC	cis	rs10504229	0.683	rs6984765	chr8:58127124	T/C	cg21724239	chr8:58056113	NA	0.57	5.76	0.33	2.29e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs1552244	0.872	rs6803517	chr3:10065426	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.89	11.97	0.59	1.14e-26	Alzheimer's disease;
CESC	cis	rs9303542	0.559	rs1042822	chr17:46620095	G/T	cg04904318	chr17:46607828	HOXB1	-0.57	-5.49	-0.32	9.47e-8	Ovarian cancer;Epithelial ovarian cancer;
CESC	cis	rs9815354	1.000	rs9869207	chr3:41878661	C/G	cg03022575	chr3:42003672	ULK4	0.45	5.29	0.31	2.59e-7	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs1008375	0.966	rs10489036	chr4:17697687	A/G	cg02297831	chr4:17616191	MED28	0.5	6.01	0.35	6.14e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs734999	0.549	rs6667564	chr1:2520302	T/C	cg18854424	chr1:2615690	NA	0.29	5.58	0.32	5.84e-8	Ulcerative colitis;
CESC	cis	rs4253772	0.513	rs6008597	chr22:46703904	A/C	cg24881330	chr22:46731750	TRMU	0.86	7.93	0.44	6.15e-14	LDL cholesterol;Cholesterol, total;
CESC	cis	rs9322193	0.923	rs10782311	chr6:149943728	A/G	cg13206674	chr6:150067644	NUP43	0.41	5.77	0.33	2.21e-8	Lung cancer;
CESC	cis	rs16866061	0.515	rs1027340	chr2:225370554	C/A	cg12698349	chr2:225449008	CUL3	0.84	14.81	0.67	1.42e-36	Acute graft versus host disease in bone marrow transplantation (recipient effect);
CESC	cis	rs6500602	0.727	rs11076837	chr16:4569440	C/T	cg08645402	chr16:4508243	NA	0.53	8.37	0.46	3.34e-15	Schizophrenia;
CESC	cis	rs10751667	0.666	rs10902247	chr11:953686	G/A	cg01483505	chr11:975446	AP2A2	0.37	5.05	0.3	8.3e-7	Alzheimer's disease (late onset);
CESC	cis	rs11168351	0.927	rs7971880	chr12:48391055	C/T	cg04545296	chr12:48745243	ZNF641	0.35	6.04	0.35	5.16e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs10131894	0.611	rs174995	chr14:75434183	T/C	cg11812906	chr14:75593930	NEK9	-0.67	-10.02	-0.52	3e-20	Coronary artery disease;
CESC	cis	rs6933660	0.800	rs6930557	chr6:151755806	G/A	cg14262678	chr6:151773367	RMND1;C6orf211	0.66	9.44	0.5	2.04e-18	Menarche (age at onset);
CESC	trans	rs2727020	0.590	rs7949936	chr11:49378902	G/A	cg15704280	chr7:45808275	SEPT13	-0.78	-8.98	-0.48	5.13e-17	Coronary artery disease;
CESC	cis	rs6448317	0.520	rs13116411	chr4:24928949	G/A	cg21108841	chr4:24914750	CCDC149	-0.58	-8.16	-0.45	1.39e-14	Heschl's gyrus morphology;
CESC	cis	rs8017423	0.647	rs12587362	chr14:90821227	G/T	cg14092571	chr14:90743983	NA	0.43	6.5	0.37	3.92e-10	Mortality in heart failure;
CESC	cis	rs7582720	1.000	rs72934745	chr2:203744454	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.39	0.41	1.96e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.65	7.48	0.42	1.09e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs9815354	0.812	rs967619	chr3:41876710	C/G	cg03022575	chr3:42003672	ULK4	0.71	6.23	0.36	1.84e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs4665809	1.000	rs750452	chr2:26324995	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.66	-7.36	-0.41	2.36e-12	Gut microbiome composition (summer);
CESC	cis	rs4481887	1.000	rs4916128	chr1:248466706	G/A	cg00666640	chr1:248458726	OR2T12	0.39	6.37	0.36	8.47e-10	Common traits (Other);
CESC	cis	rs34779708	0.931	rs12768019	chr10:35389843	T/C	cg04310649	chr10:35416472	CREM	-0.51	-6.06	-0.35	4.62e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs17376456	0.825	rs74825443	chr5:93254973	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.65	5.32	0.31	2.22e-7	Diabetic retinopathy;
CESC	cis	rs3780486	0.522	rs10217770	chr9:33146393	C/A	cg13443165	chr9:33130375	B4GALT1	0.48	7.14	0.4	9.07e-12	IgG glycosylation;
CESC	cis	rs6088580	0.634	rs6142164	chr20:33006597	C/T	cg24642439	chr20:33292090	TP53INP2	-0.53	-7.01	-0.4	2.01e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs6860806	0.631	rs6863548	chr5:131575920	G/A	cg04518342	chr5:131593106	PDLIM4	0.4	6.17	0.35	2.6e-9	Breast cancer;
CESC	cis	rs2637266	0.967	rs10400134	chr10:78365158	G/C	cg18941641	chr10:78392320	NA	0.43	8.31	0.45	4.85e-15	Pulmonary function;
CESC	cis	rs6540556	0.769	rs7521461	chr1:209926207	C/G	cg05527609	chr1:210001259	C1orf107	-0.46	-5.66	-0.33	3.89e-8	Red blood cell count;
CESC	cis	rs6456156	0.586	rs12527827	chr6:167469271	C/T	cg23791538	chr6:167370224	RNASET2	-0.5	-6.47	-0.37	4.66e-10	Primary biliary cholangitis;
CESC	cis	rs2836974	0.897	rs6517513	chr21:40526878	A/G	cg17971929	chr21:40555470	PSMG1	1.05	16.66	0.72	4.09e-43	Cognitive function;
CESC	cis	rs55728055	0.661	rs1018488	chr22:31992376	A/G	cg01338084	chr22:32026380	PISD	1.19	8.67	0.47	4.34e-16	Age-related hearing impairment;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg26476595	chr16:2284284	E4F1	0.45	6.44	0.37	5.57e-10	Fibrinogen levels;
CESC	cis	rs2033711	0.728	rs4801586	chr19:58934528	A/G	cg00825309	chr19:58991885	ZNF446	-0.54	-7.71	-0.43	2.62e-13	Uric acid clearance;
CESC	cis	rs4979906	1.000	rs11002248	chr10:79446961	A/G	cg07817648	chr10:79422355	NA	-0.47	-5.53	-0.32	7.61e-8	Mortality in heart failure;
CESC	cis	rs8062405	1.000	rs4788101	chr16:28867804	C/T	cg08761264	chr16:28874980	SH2B1	-0.47	-5.85	-0.34	1.42e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs896854	0.552	rs2515236	chr8:95934907	A/G	cg16049864	chr8:95962084	TP53INP1	0.62	8.62	0.47	6.01e-16	Type 2 diabetes;
CESC	cis	rs17209837	0.607	rs10452936	chr7:87094306	C/A	cg00919237	chr7:87102261	ABCB4	-0.51	-6.58	-0.37	2.45e-10	Gallbladder cancer;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg24701867	chr1:1189640	UBE2J2	0.45	6.17	0.35	2.58e-9	Fibrinogen levels;
CESC	cis	rs11642862	0.901	rs77604316	chr16:30921487	G/A	cg02466173	chr16:30829666	NA	-0.57	-5.22	-0.31	3.68e-7	Tonsillectomy;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg13108601	chr6:41748242	FRS3;PRICKLE4	0.57	7.53	0.42	8.1e-13	Gut microbiota (bacterial taxa);
CESC	trans	rs13098911	0.540	rs34754340	chr3:46041837	C/T	cg10236987	chr1:228114221	WNT9A	0.66	6.54	0.37	3.11e-10	Celiac disease;
CESC	cis	rs2835872	0.758	rs7278101	chr21:39035873	T/C	cg06728970	chr21:39037746	KCNJ6	-0.29	-5.18	-0.3	4.41e-7	Electroencephalographic traits in alcoholism;
CESC	cis	rs473651	0.935	rs541013	chr2:239336492	G/A	cg21699342	chr2:239360505	ASB1	0.53	8.61	0.47	6.85e-16	Multiple system atrophy;
CESC	cis	rs875971	0.862	rs6964437	chr7:65686444	A/G	cg11764359	chr7:65958608	NA	-0.77	-10.96	-0.56	2.75e-23	Aortic root size;
CESC	cis	rs2228479	0.557	rs62056064	chr16:89903843	G/A	cg04013166	chr16:89971882	TCF25	0.72	5.75	0.33	2.41e-8	Skin colour saturation;
CESC	cis	rs6005807	0.543	rs6005868	chr22:29165766	T/C	cg15103426	chr22:29168792	CCDC117	0.5	5.1	0.3	6.37e-7	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
CESC	cis	rs597539	0.652	rs569777	chr11:68706848	G/A	cg04772025	chr11:68637568	NA	0.52	6.37	0.36	8.42e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs9372253	1.000	rs9386894	chr6:110718853	A/G	cg19196401	chr6:110721138	DDO	-0.38	-5.38	-0.31	1.64e-7	Platelet distribution width;
CESC	cis	rs7107174	0.901	rs2511159	chr11:77974193	G/T	cg02023728	chr11:77925099	USP35	-0.4	-5.84	-0.34	1.55e-8	Testicular germ cell tumor;
CESC	cis	rs910316	0.737	rs91144	chr14:75449517	G/A	cg11812906	chr14:75593930	NEK9	-0.82	-13.22	-0.63	5.34e-31	Height;
CESC	cis	rs1595825	0.891	rs7584475	chr2:198577424	A/C	cg00982548	chr2:198649783	BOLL	-0.48	-5.15	-0.3	5.05e-7	Ulcerative colitis;
CESC	cis	rs12477438	0.520	rs11123765	chr2:99768064	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.86	15.04	0.68	2.28e-37	Chronic sinus infection;
CESC	cis	rs863345	0.526	rs2051666	chr1:158507160	T/G	cg12129480	chr1:158549410	OR10X1	-0.35	-7.08	-0.4	1.32e-11	Pneumococcal bacteremia;
CESC	cis	rs3096299	0.967	rs2965937	chr16:89488779	A/T	cg02187348	chr16:89574699	SPG7	0.58	7.9	0.44	7.49e-14	Multiple myeloma (IgH translocation);
CESC	cis	rs140365914	1	rs140365914	chr7:155106570	C/T	cg14927855	chr7:155151427	NA	0.49	8.0	0.44	3.96e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs3812831	0.643	rs7322339	chr13:114929726	C/A	cg08824895	chr13:115047677	UPF3A	0.39	5.16	0.3	4.83e-7	Schizophrenia;
CESC	cis	rs7772486	0.776	rs4316025	chr6:146238032	C/T	cg05347473	chr6:146136440	FBXO30	-0.49	-6.45	-0.37	5.3e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2797160	1.000	rs2211419	chr6:125995533	C/T	cg05901451	chr6:126070800	HEY2	0.43	6.37	0.36	8.39e-10	Endometrial cancer;
CESC	trans	rs16949788	1.000	rs11071894	chr15:66773733	A/C	cg10186254	chr14:80267501	NRXN3	-0.54	-6.02	-0.35	5.78e-9	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs8044868	0.586	rs7199261	chr16:72082788	A/G	cg16558253	chr16:72132732	DHX38	-0.4	-6.32	-0.36	1.12e-9	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CESC	cis	rs2011503	0.941	rs7257875	chr19:19372150	C/T	cg11584989	chr19:19387371	SF4	0.53	6.32	0.36	1.09e-9	Bipolar disorder;
CESC	cis	rs9815354	1.000	rs28755797	chr3:41774446	C/T	cg03022575	chr3:42003672	ULK4	0.53	5.22	0.31	3.61e-7	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs4665809	0.567	rs6546848	chr2:26444414	G/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.06	-12.34	-0.6	5.85e-28	Gut microbiome composition (summer);
CESC	cis	rs12464559	0.522	rs1916301	chr2:152640498	G/A	cg01189475	chr2:152685088	ARL5A	0.72	7.08	0.4	1.29e-11	Response to cognitive-behavioural therapy in anxiety disorder;
CESC	cis	rs66887589	0.777	rs10015883	chr4:120268146	A/G	cg09307838	chr4:120376055	NA	0.55	7.42	0.41	1.63e-12	Diastolic blood pressure;
CESC	cis	rs7580658	0.895	rs9636237	chr2:128076022	T/C	cg10021288	chr2:128175891	PROC	-0.4	-6.41	-0.37	6.58e-10	Protein C levels;
CESC	cis	rs1729951	0.575	rs16844326	chr3:136678385	G/C	cg03617693	chr3:136751559	NA	0.38	5.31	0.31	2.27e-7	Neuroticism;
CESC	cis	rs514406	0.679	rs960570	chr1:53237763	A/G	cg08859206	chr1:53392774	SCP2	0.72	11.25	0.57	2.95e-24	Monocyte count;
CESC	cis	rs67311347	1.000	rs7648952	chr3:40457038	C/T	cg09455208	chr3:40491958	NA	-0.45	-7.91	-0.44	6.82e-14	Renal cell carcinoma;
CESC	cis	rs4660306	1.000	rs7536557	chr1:45992114	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.5	-6.52	-0.37	3.49e-10	Homocysteine levels;
CESC	cis	rs7618915	0.547	rs13069481	chr3:52666866	C/T	cg17372223	chr3:52568218	NT5DC2	0.43	6.5	0.37	4.08e-10	Bipolar disorder;
CESC	cis	rs6570726	0.791	rs374478	chr6:145840022	C/T	cg05347473	chr6:146136440	FBXO30	0.58	7.61	0.42	4.8e-13	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7552404	1.000	rs942270	chr1:76177332	G/A	cg03433033	chr1:76189801	ACADM	0.66	7.69	0.43	2.84e-13	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs7116495	1.000	rs12272213	chr11:71816219	G/A	cg26138937	chr11:71823887	C11orf51	0.85	6.85	0.39	5.03e-11	Severe influenza A (H1N1) infection;
CESC	cis	rs875971	0.545	rs73136346	chr7:65566082	A/G	cg18876405	chr7:65276391	NA	-0.56	-6.12	-0.35	3.35e-9	Aortic root size;
CESC	cis	rs6598955	0.543	rs6699798	chr1:26556442	G/T	cg04990556	chr1:26633338	UBXN11	0.83	9.29	0.5	5.95e-18	Obesity-related traits;
CESC	cis	rs8077889	0.719	rs57227660	chr17:41858984	T/C	cg26893861	chr17:41843967	DUSP3	0.97	17.58	0.73	2.2e-46	Triglycerides;
CESC	cis	rs9926296	0.533	rs12102290	chr16:89812617	C/T	cg27121462	chr16:89883253	FANCA	0.82	12.28	0.6	9.91e-28	Vitiligo;
CESC	cis	rs1862618	0.853	rs252921	chr5:56137787	G/A	cg24549020	chr5:56110836	MAP3K1	0.65	7.56	0.42	6.72e-13	Initial pursuit acceleration;
CESC	cis	rs344364	0.529	rs186941	chr16:1930088	T/C	cg03013636	chr16:1946785	NA	-0.39	-5.27	-0.31	2.82e-7	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs12912251	1.000	rs35024396	chr15:38989770	G/A	cg01338139	chr15:38987640	C15orf53	-0.45	-5.28	-0.31	2.71e-7	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
CESC	cis	rs11030122	0.673	rs4910590	chr11:4018619	C/T	cg18678763	chr11:4115507	RRM1	-0.48	-6.45	-0.37	5.42e-10	Mean platelet volume;Platelet distribution width;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06603377	chr14:89629090	FOXN3	-0.63	-7.25	-0.41	4.45e-12	Gut microbiome composition (summer);
CESC	cis	rs10899021	0.920	rs11236172	chr11:74330888	G/A	cg25880958	chr11:74394337	NA	-0.74	-7.91	-0.44	7.23e-14	Response to metformin (IC50);
CESC	cis	rs1707322	0.964	rs785483	chr1:46559171	T/C	cg03146154	chr1:46216737	IPP	-0.69	-9.13	-0.49	1.84e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs12142240	0.698	rs72677596	chr1:46833930	C/T	cg10495392	chr1:46806563	NSUN4	0.58	6.07	0.35	4.34e-9	Menopause (age at onset);
CESC	cis	rs3892630	0.878	rs8112955	chr19:33191192	C/T	cg13157960	chr19:33183277	NUDT19	0.55	5.39	0.31	1.58e-7	Red blood cell traits;
CESC	cis	rs4843747	0.636	rs4075597	chr16:88107590	C/A	cg06374794	chr16:88002281	BANP	0.41	5.33	0.31	2.11e-7	Menopause (age at onset);
CESC	cis	rs13108904	0.518	rs4974603	chr4:1343168	C/T	cg00684032	chr4:1343700	KIAA1530	0.6	9.13	0.49	1.79e-17	Obesity-related traits;
CESC	cis	rs9487051	0.872	rs9386794	chr6:109611521	A/C	cg12927641	chr6:109611667	NA	-0.43	-6.63	-0.38	1.91e-10	Reticulocyte fraction of red cells;
CESC	cis	rs9811920	0.666	rs793456	chr3:99525631	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.44	-7.11	-0.4	1.09e-11	Axial length;
CESC	cis	rs2228479	0.850	rs17226498	chr16:89840631	T/C	cg00800038	chr16:89945340	TCF25	-0.92	-7.64	-0.42	4.02e-13	Skin colour saturation;
CESC	cis	rs6933660	0.745	rs3778608	chr6:151738131	A/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.55	-7.3	-0.41	3.27e-12	Menarche (age at onset);
CESC	cis	rs9487051	0.836	rs9400270	chr6:109607488	G/A	cg12927641	chr6:109611667	NA	-0.43	-6.7	-0.38	1.22e-10	Reticulocyte fraction of red cells;
CESC	cis	rs4268898	0.662	rs9784114	chr2:24437517	C/T	cg06627628	chr2:24431161	ITSN2	-1.02	-11.2	-0.57	4.2e-24	Asthma;
CESC	cis	rs950776	0.518	rs2869544	chr15:78839400	G/A	cg06917634	chr15:78832804	PSMA4	-0.75	-11.31	-0.57	1.91e-24	Sudden cardiac arrest;
CESC	cis	rs748404	0.631	rs7166812	chr15:43644760	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.6	7.78	0.43	1.6e-13	Lung cancer;
CESC	cis	rs11645898	0.872	rs7206422	chr16:72152652	C/T	cg14768367	chr16:72042858	DHODH	-0.71	-6.03	-0.35	5.4e-9	Blood protein levels;
CESC	cis	rs7618501	0.633	rs6446193	chr3:50059758	T/C	cg24308560	chr3:49941425	MST1R	0.63	9.36	0.5	3.46e-18	Intelligence (multi-trait analysis);
CESC	cis	rs7208859	0.623	rs7223209	chr17:29107220	C/A	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.17e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg11843948	chr7:5410861	TNRC18	0.47	6.25	0.36	1.6e-9	Fibrinogen levels;
CESC	trans	rs650950	0.528	rs646660	chr11:35528452	C/T	cg24441975	chr1:39339062	MYCBP	0.45	6.22	0.36	1.95e-9	Bronchopulmonary dysplasia;
CESC	cis	rs703842	0.642	rs10876994	chr12:58064737	A/C	cg18357645	chr12:58087776	OS9	-0.56	-7.41	-0.41	1.68e-12	Multiple sclerosis;
CESC	cis	rs7927592	0.913	rs948316	chr11:68309670	G/T	cg20283391	chr11:68216788	NA	-0.61	-7.36	-0.41	2.26e-12	Total body bone mineral density;
CESC	cis	rs79349575	0.749	rs58838744	chr17:46998902	A/G	cg26022315	chr17:47021804	SNF8	0.39	5.18	0.3	4.5e-7	Type 2 diabetes;
CESC	cis	rs12497850	0.866	rs6791234	chr3:48996137	A/G	cg07636037	chr3:49044803	WDR6	1.08	19.59	0.77	1.89e-53	Parkinson's disease;
CESC	cis	rs9911578	1.000	rs391370	chr17:56675050	A/C	cg12560992	chr17:57184187	TRIM37	0.93	15.64	0.69	1.66e-39	Intelligence (multi-trait analysis);
CESC	cis	rs1055129	0.560	rs2666003	chr17:73942976	G/A	cg08125733	chr17:73851984	WBP2	0.5	6.74	0.38	9.73e-11	White matter hyperintensity burden;
CESC	cis	rs896854	0.967	rs1320164	chr8:95960767	G/A	cg16049864	chr8:95962084	TP53INP1	-0.72	-13.04	-0.63	2.36e-30	Type 2 diabetes;
CESC	cis	rs7927771	0.507	rs10838759	chr11:47785347	T/C	cg20307385	chr11:47447363	PSMC3	0.61	8.64	0.47	5.37e-16	Subjective well-being;
CESC	cis	rs6866344	0.697	rs6873150	chr5:178125704	G/A	cg10224037	chr5:178157518	ZNF354A	0.62	6.96	0.39	2.72e-11	Neutrophil percentage of white cells;
CESC	cis	rs7617773	0.539	rs13082217	chr3:48383264	T/C	cg11946769	chr3:48343235	NME6	0.66	8.34	0.46	4.12e-15	Coronary artery disease;
CESC	cis	rs2836974	0.931	rs2776309	chr21:40715791	A/G	cg17971929	chr21:40555470	PSMG1	0.94	12.38	0.61	4.37e-28	Cognitive function;
CESC	cis	rs2243480	1.000	rs316327	chr7:65609201	G/T	cg13147721	chr7:65941812	NA	0.92	8.74	0.47	2.66e-16	Diabetic kidney disease;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg13307718	chr11:85995223	NA	-0.39	-6.63	-0.38	1.86e-10	Gambling;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg16727006	chr16:87470545	ZCCHC14	0.45	6.28	0.36	1.36e-9	Thyroid stimulating hormone;
CESC	cis	rs7845219	0.544	rs2945554	chr8:95939594	C/A	cg13393036	chr8:95962371	TP53INP1	-0.43	-8.02	-0.44	3.31e-14	Type 2 diabetes;
CESC	cis	rs875971	0.540	rs1723268	chr7:65473080	A/C	cg25985355	chr7:65971099	NA	-0.33	-5.38	-0.31	1.62e-7	Aortic root size;
CESC	cis	rs1862618	0.715	rs6866779	chr5:56090000	G/A	cg24531977	chr5:56204891	C5orf35	-0.88	-10.8	-0.55	9.11e-23	Initial pursuit acceleration;
CESC	cis	rs14403	0.954	rs9803993	chr1:243672125	G/A	cg21452805	chr1:244014465	NA	0.49	5.59	0.32	5.78e-8	Schizophrenia;
CESC	cis	rs6963495	0.818	rs75116202	chr7:105160059	C/T	cg13798780	chr7:105162888	PUS7	0.78	8.04	0.44	2.99e-14	Bipolar disorder (body mass index interaction);
CESC	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	13.6	0.64	2.58e-32	Prudent dietary pattern;
CESC	cis	rs6484504	0.553	rs2183484	chr11:31259370	G/A	cg14844989	chr11:31128820	NA	-0.41	-5.79	-0.34	1.96e-8	Red blood cell count;
CESC	cis	rs7618915	0.570	rs11714088	chr3:52758942	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	7.2	0.4	6.31e-12	Bipolar disorder;
CESC	cis	rs73206853	0.841	rs11065663	chr12:110988886	G/T	cg12870014	chr12:110450643	ANKRD13A	0.58	5.24	0.31	3.25e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs9916302	0.706	rs57933226	chr17:37412829	C/T	cg07936489	chr17:37558343	FBXL20	-0.85	-9.92	-0.52	6.21e-20	Glomerular filtration rate (creatinine);
CESC	cis	rs9916302	0.706	rs4795385	chr17:37733148	A/G	cg20243544	chr17:37824526	PNMT	-0.56	-5.47	-0.32	1.03e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs2274273	0.934	rs2341621	chr14:55726425	C/T	cg04306507	chr14:55594613	LGALS3	0.3	5.86	0.34	1.34e-8	Protein biomarker;
CESC	cis	rs11688816	0.904	rs2539984	chr2:63133584	G/C	cg17519650	chr2:63277830	OTX1	0.41	5.63	0.33	4.67e-8	Body mass index;
CESC	cis	rs10504229	0.639	rs112926738	chr8:58054939	A/G	cg21724239	chr8:58056113	NA	0.52	5.05	0.3	8.08e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs9790314	1.000	rs1382428	chr3:161032386	A/C	cg04691961	chr3:161091175	C3orf57	-0.43	-5.56	-0.32	6.47e-8	Morning vs. evening chronotype;
CESC	cis	rs6089829	0.926	rs1060489	chr20:61665921	C/T	cg03213289	chr20:61660250	NA	0.39	6.06	0.35	4.78e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs11098499	0.615	rs28551750	chr4:120264901	C/T	cg09307838	chr4:120376055	NA	0.75	9.88	0.52	8.38e-20	Corneal astigmatism;
CESC	cis	rs1707322	0.963	rs12076580	chr1:46258159	G/A	cg05343316	chr1:45956843	TESK2	0.51	6.25	0.36	1.59e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16011496	chr8:63057206	NA	-0.56	-6.35	-0.36	9.22e-10	Gut microbiome composition (summer);
CESC	cis	rs8177253	1.000	rs1525892	chr3:133484712	C/T	cg12373951	chr3:133503437	NA	0.37	5.52	0.32	8.2e-8	Iron status biomarkers;
CESC	cis	rs9322193	0.923	rs7767622	chr6:150002902	T/C	cg07701084	chr6:150067640	NUP43	0.47	6.67	0.38	1.46e-10	Lung cancer;
CESC	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg23708337	chr7:1209742	NA	0.53	5.34	0.31	1.98e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7772486	0.754	rs702323	chr6:146008274	A/G	cg23711669	chr6:146136114	FBXO30	-0.87	-12.26	-0.6	1.14e-27	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	7.6	0.42	5.08e-13	Prudent dietary pattern;
CESC	cis	rs4689388	0.679	rs1046316	chr4:6304087	A/G	cg25554036	chr4:6271136	WFS1	0.51	7.68	0.43	3.15e-13	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg07738938	chr7:5372608	TNRC18	0.51	7.02	0.4	1.81e-11	Fibrinogen levels;
CESC	cis	rs7811142	1.000	rs67471932	chr7:100009985	C/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.78	6.78	0.38	7.85e-11	Platelet count;
CESC	cis	rs2502731	0.561	rs3003606	chr9:130982416	C/T	cg13642260	chr9:130955380	CIZ1	0.45	6.58	0.37	2.46e-10	Attention deficit hyperactivity disorder;
CESC	cis	rs6582630	0.519	rs7294292	chr12:38349540	C/T	cg26384229	chr12:38710491	ALG10B	0.73	10.95	0.56	2.81e-23	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs4843747	0.518	rs4072777	chr16:88107030	G/A	cg03395651	chr16:88107091	BANP	0.46	5.36	0.31	1.85e-7	Menopause (age at onset);
CESC	cis	rs2354432	0.556	rs72710311	chr1:146698256	A/G	cg25205988	chr1:146714368	CHD1L	-1.02	-8.03	-0.44	3.16e-14	Mitochondrial DNA levels;
CESC	cis	rs6543140	0.964	rs2310301	chr2:103072935	C/T	cg04239558	chr2:103089729	SLC9A4	0.47	6.16	0.35	2.64e-9	Blood protein levels;
CESC	cis	rs9790314	0.967	rs10804790	chr3:161039300	T/A	cg03342759	chr3:160939853	NMD3	-0.48	-6.25	-0.36	1.61e-9	Morning vs. evening chronotype;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg09158336	chr17:76338205	NA	-0.45	-6.03	-0.35	5.58e-9	Ulcerative colitis;
CESC	cis	rs7666738	0.791	rs7377018	chr4:99034962	C/T	cg18180107	chr4:99064573	C4orf37	0.42	5.4	0.31	1.48e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs12541335	0.639	rs35068739	chr8:22201719	T/C	cg26039829	chr8:22132926	PIWIL2	0.39	6.05	0.35	4.84e-9	Hypertriglyceridemia;
CESC	cis	rs7130144	0.541	rs73572219	chr11:130459830	C/T	cg26307797	chr11:130446613	NA	-0.74	-6.36	-0.36	8.72e-10	Urate levels in lean individuals;
CESC	cis	rs17021463	0.966	rs7657789	chr4:95178589	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.68	-11.15	-0.57	6.32e-24	Testicular germ cell tumor;
CESC	cis	rs2295359	1.000	rs4655684	chr1:67611772	A/G	cg03340356	chr1:67600835	NA	-0.33	-5.64	-0.33	4.39e-8	Psoriasis;
CESC	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg24642844	chr7:1081250	C7orf50	-0.77	-9.3	-0.5	5.54e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs12472274	0.646	rs10929269	chr2:239097423	A/G	cg17459225	chr2:239074497	NA	0.51	5.95	0.34	8.6e-9	Phospholipid levels (plasma);
CESC	cis	rs2303759	0.543	rs7255778	chr19:49906608	G/A	cg24324837	chr19:49891574	CCDC155	0.43	5.06	0.3	7.85e-7	Multiple sclerosis;
CESC	cis	rs10870270	0.956	rs7904594	chr10:133734671	C/T	cg26149184	chr10:133730230	NA	0.38	5.15	0.3	5.07e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg06074448	chr4:187884817	NA	-0.37	-5.43	-0.32	1.27e-7	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1387259	0.931	rs1107654	chr12:48681097	T/G	cg04545296	chr12:48745243	ZNF641	0.42	7.06	0.4	1.47e-11	Obstructive sleep apnea trait (apnea hypopnea index);
CESC	cis	rs920590	0.758	rs62496731	chr8:19659543	C/G	cg03894339	chr8:19674705	INTS10	0.64	7.32	0.41	3e-12	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs4629180	0.586	rs10172555	chr2:102126837	C/T	cg04415270	chr2:102091202	RFX8	-0.3	-5.22	-0.31	3.53e-7	Chronic rhinosinusitis with nasal polyps;
CESC	cis	rs6493487	0.512	rs8024689	chr15:51129127	C/T	cg02338191	chr15:51200825	AP4E1	0.51	5.18	0.3	4.4e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs7246657	0.943	rs8106839	chr19:37958475	C/G	cg23950597	chr19:37808831	NA	-0.58	-6.3	-0.36	1.22e-9	Coronary artery calcification;
CESC	cis	rs9811920	0.609	rs4928232	chr3:99694217	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.63	-9.86	-0.52	9.59e-20	Axial length;
CESC	cis	rs651907	0.514	rs12636046	chr3:101434448	T/G	cg12386194	chr3:101231763	SENP7	0.41	5.04	0.3	8.5e-7	Colorectal cancer;
CESC	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg03188948	chr7:1209495	NA	0.53	6.08	0.35	4.28e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg26338869	chr17:61819248	STRADA	0.67	8.79	0.48	1.9e-16	Prudent dietary pattern;
CESC	cis	rs4664308	0.505	rs1037694	chr2:161028992	A/G	cg03641300	chr2:160917029	PLA2R1	-0.37	-5.38	-0.31	1.65e-7	Idiopathic membranous nephropathy;
CESC	cis	rs8008758	0.517	rs1772024	chr14:101695220	A/C	cg26224664	chr14:101693935	NA	0.41	7.55	0.42	7.15e-13	Body mass index (alcohol intake interaction);
CESC	cis	rs13108904	0.870	rs2279281	chr4:1245277	T/G	cg00684032	chr4:1343700	KIAA1530	0.37	5.54	0.32	7.28e-8	Obesity-related traits;
CESC	cis	rs854765	0.547	rs6502632	chr17:17913057	A/G	cg16928487	chr17:17741425	SREBF1	-0.55	-9.43	-0.5	2.18e-18	Total body bone mineral density;
CESC	cis	rs875971	0.862	rs1983372	chr7:65611351	C/T	cg18252515	chr7:66147081	NA	0.41	5.28	0.31	2.73e-7	Aortic root size;
CESC	cis	rs9311474	0.597	rs13303	chr3:52558008	T/C	cg18591801	chr3:52553433	STAB1	-0.29	-5.59	-0.32	5.66e-8	Electroencephalogram traits;
CESC	trans	rs561341	0.941	rs550213	chr17:30317518	C/G	cg27661571	chr11:113659931	NA	-0.71	-7.38	-0.41	1.99e-12	Hip circumference adjusted for BMI;
CESC	cis	rs113835537	0.597	rs10896129	chr11:66338300	T/C	cg24851651	chr11:66362959	CCS	0.5	5.96	0.34	7.95e-9	Airway imaging phenotypes;
CESC	cis	rs1707322	1.000	rs10890359	chr1:46336635	A/G	cg03146154	chr1:46216737	IPP	0.74	10.16	0.53	1.08e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9926296	0.572	rs2376878	chr16:89885161	G/A	cg07648498	chr16:89883185	FANCA	0.44	5.42	0.32	1.34e-7	Vitiligo;
CESC	cis	rs7927592	0.763	rs2513277	chr11:68360887	T/G	cg16797656	chr11:68205561	LRP5	0.48	7.1	0.4	1.18e-11	Total body bone mineral density;
CESC	cis	rs6088580	0.713	rs1884669	chr20:33171287	G/A	cg08999081	chr20:33150536	PIGU	0.72	12.82	0.62	1.3e-29	Glomerular filtration rate (creatinine);
CESC	cis	rs2197308	0.703	rs10880251	chr12:37903297	G/A	cg13010199	chr12:38710504	ALG10B	0.53	6.76	0.38	8.79e-11	Morning vs. evening chronotype;
CESC	cis	rs2625529	0.617	rs8025939	chr15:72460339	T/A	cg16672083	chr15:72433130	SENP8	0.49	7.33	0.41	2.81e-12	Red blood cell count;
CESC	cis	rs727505	0.954	rs68102397	chr7:124685315	C/T	cg23710748	chr7:124431027	NA	-0.41	-6.4	-0.37	6.92e-10	Lewy body disease;
CESC	cis	rs12995849	0.714	rs7580718	chr2:106471327	C/A	cg16077055	chr2:106428750	NCK2	0.4	5.93	0.34	9.52e-9	Addiction;
CESC	cis	rs7618501	1.000	rs2271960	chr3:49878078	A/G	cg24308560	chr3:49941425	MST1R	-0.49	-6.38	-0.36	7.99e-10	Intelligence (multi-trait analysis);
CESC	cis	rs642803	0.551	rs1308020	chr11:65497558	G/A	cg08755490	chr11:65554678	OVOL1	0.44	5.62	0.33	4.92e-8	Urate levels;
CESC	cis	rs10129255	0.500	rs988132	chr14:107184997	C/T	cg07958169	chr14:107095056	NA	-0.52	-8.02	-0.44	3.42e-14	Kawasaki disease;
CESC	cis	rs9916302	0.861	rs11078896	chr17:37415544	C/T	cg20243544	chr17:37824526	PNMT	0.47	5.87	0.34	1.27e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs6032067	0.929	rs6017513	chr20:43835232	A/C	cg11264863	chr20:43835661	SEMG1	0.48	5.26	0.31	2.99e-7	Blood protein levels;
CESC	cis	rs896854	0.596	rs7823059	chr8:95974961	T/C	cg26343298	chr8:95960752	TP53INP1	0.36	5.98	0.34	7.06e-9	Type 2 diabetes;
CESC	cis	rs7666738	0.830	rs6831219	chr4:98993576	C/A	cg03467027	chr4:99064603	C4orf37	0.44	5.51	0.32	8.65e-8	Colonoscopy-negative controls vs population controls;
CESC	trans	rs1557351	0.723	rs9953564	chr18:54720196	G/A	cg11433624	chr6:7146702	RREB1	0.39	6.27	0.36	1.47e-9	Multiple sclerosis (age of onset);
CESC	cis	rs909002	0.849	rs1464306	chr1:32076261	T/C	cg13919466	chr1:32135498	COL16A1	-0.48	-8.47	-0.46	1.66e-15	Intelligence (multi-trait analysis);
CESC	cis	rs1775148	1	rs1775148	chr1:205757824	C/T	cg14893161	chr1:205819251	PM20D1	0.48	6.91	0.39	3.69e-11	Prostate cancer;
CESC	cis	rs7044106	0.762	rs10984972	chr9:123409864	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.71	10.46	0.54	1.15e-21	Hip circumference adjusted for BMI;
CESC	cis	rs2180341	0.920	rs1073931	chr6:127681762	A/T	cg24812749	chr6:127587940	RNF146	1.05	15.15	0.68	9.37e-38	Breast cancer;
CESC	cis	rs11583043	1.000	rs7535068	chr1:101490329	T/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.51	5.63	0.33	4.65e-8	Ulcerative colitis;Inflammatory bowel disease;
CESC	cis	rs4975709	0.589	rs1684967	chr5:1863055	G/C	cg17650747	chr5:1873721	NA	0.43	6.09	0.35	3.94e-9	Cardiovascular disease risk factors;
CESC	cis	rs6541297	0.703	rs650808	chr1:230317820	G/A	cg20703242	chr1:230279135	GALNT2	-0.44	-5.77	-0.33	2.27e-8	Coronary artery disease;
CESC	cis	rs6693567	0.565	rs11205370	chr1:150397567	A/G	cg09579323	chr1:150459698	TARS2	0.48	6.07	0.35	4.38e-9	Migraine;
CESC	cis	rs35110281	0.508	rs2838351	chr21:45110784	A/G	cg01579765	chr21:45077557	HSF2BP	-0.5	-7.98	-0.44	4.37e-14	Mean corpuscular volume;
CESC	cis	rs3091242	0.836	rs34997029	chr1:25783823	A/G	cg02931644	chr1:25747376	RHCE	-0.43	-7.19	-0.4	6.66e-12	Erythrocyte sedimentation rate;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg13760347	chr22:42343277	CENPM	-0.43	-6.26	-0.36	1.53e-9	Gambling;
CESC	cis	rs10779751	0.734	rs2261217	chr1:11127764	C/A	cg08854313	chr1:11322531	MTOR	0.77	10.41	0.54	1.73e-21	Body mass index;
CESC	cis	rs10504229	0.679	rs16921687	chr8:58053514	T/C	cg22535103	chr8:58192502	C8orf71	-0.65	-7.25	-0.41	4.69e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs2836950	0.509	rs4816618	chr21:40599529	G/A	cg11644478	chr21:40555479	PSMG1	-0.51	-6.94	-0.39	3.01e-11	Menarche (age at onset);
CESC	cis	rs3008870	1.000	rs2755245	chr1:67487964	C/G	cg08660285	chr1:67390436	MIER1;WDR78	1.0	14.2	0.66	2.05e-34	Lymphocyte percentage of white cells;
CESC	cis	rs7762018	1.000	rs41265383	chr6:170068025	T/C	cg05834625	chr6:170176447	C6orf70	0.62	7.35	0.41	2.48e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs1005224	0.963	rs11623813	chr14:76138194	C/T	cg25116370	chr14:76127843	TTLL5;C14orf1	-0.42	-5.81	-0.34	1.81e-8	Large artery stroke;
CESC	cis	rs1559088	0.803	rs10411529	chr19:33616256	A/C	cg27124370	chr19:33622961	WDR88	0.42	5.48	0.32	1e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23214166	chr1:26606872	SH3BGRL3	0.55	6.19	0.36	2.34e-9	Gut microbiome composition (summer);
CESC	cis	rs11122272	0.615	rs1465740	chr1:231495255	T/A	cg06096015	chr1:231504339	EGLN1	0.46	6.65	0.38	1.7e-10	Hemoglobin concentration;
CESC	cis	rs4523957	0.620	rs9900587	chr17:2071097	G/A	cg16513277	chr17:2031491	SMG6	-0.77	-11.2	-0.57	4.15e-24	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs2652822	0.525	rs58789072	chr15:63497553	G/A	cg02713581	chr15:63449717	RPS27L	0.49	6.39	0.37	7.59e-10	Metabolic traits;
CESC	cis	rs4665809	0.652	rs2384360	chr2:26405016	C/G	cg08470875	chr2:26401718	FAM59B	-0.7	-7.42	-0.41	1.55e-12	Gut microbiome composition (summer);
CESC	cis	rs656900	0.647	rs668641	chr15:80118624	C/T	cg02196730	chr15:80188777	MTHFS	-0.4	-5.29	-0.31	2.52e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs2337406	0.500	rs57619050	chr14:107228305	G/A	cg07958169	chr14:107095056	NA	-0.46	-5.09	-0.3	6.91e-7	Alzheimer's disease (late onset);
CESC	cis	rs7917772	0.582	rs10883753	chr10:104372441	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.39	5.35	0.31	1.86e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs8103278	0.507	rs7260651	chr19:46260245	G/A	cg12641515	chr19:46296257	DMWD	0.74	9.95	0.52	4.96e-20	Coronary artery disease;
CESC	cis	rs4253772	0.515	rs8142080	chr22:46647429	G/T	cg24881330	chr22:46731750	TRMU	0.82	6.49	0.37	4.09e-10	LDL cholesterol;Cholesterol, total;
CESC	cis	rs3771570	1.000	rs73002147	chr2:242302934	T/C	cg21155796	chr2:242212141	HDLBP	0.6	5.27	0.31	2.89e-7	Prostate cancer;
CESC	cis	rs2115536	1.000	rs2115540	chr15:80190308	A/G	cg00225070	chr15:80189496	MTHFS	0.6	8.42	0.46	2.33e-15	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CESC	cis	rs734999	0.505	rs10797439	chr1:2540364	G/A	cg20673091	chr1:2541236	MMEL1	0.45	7.84	0.43	1.09e-13	Ulcerative colitis;
CESC	cis	rs2243480	0.901	rs3813708	chr7:65305632	C/A	cg12463550	chr7:65579703	CRCP	0.7	5.55	0.32	6.85e-8	Diabetic kidney disease;
CESC	cis	rs3096299	0.874	rs3102342	chr16:89451575	T/C	cg08822215	chr16:89438651	ANKRD11	-0.37	-5.58	-0.32	5.87e-8	Multiple myeloma (IgH translocation);
CESC	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg20887711	chr4:1340912	KIAA1530	-0.87	-11.81	-0.59	3.71e-26	Longevity;
CESC	cis	rs1005277	0.557	rs2983338	chr10:38550734	C/T	cg00409905	chr10:38381863	ZNF37A	-0.49	-6.58	-0.37	2.54e-10	Extrinsic epigenetic age acceleration;
CESC	cis	rs9457247	1.000	rs439553	chr6:167391212	A/G	cg25258033	chr6:167368657	RNASET2	0.41	6.13	0.35	3.23e-9	Crohn's disease;
CESC	cis	rs7605827	0.930	rs2003592	chr2:15552153	C/T	cg19274914	chr2:15703543	NA	0.35	6.27	0.36	1.42e-9	Educational attainment (years of education);
CESC	cis	rs12681288	0.823	rs2701909	chr8:1003057	A/G	cg15309053	chr8:964076	NA	0.35	6.09	0.35	3.99e-9	Schizophrenia;
CESC	cis	rs875971	0.522	rs6960048	chr7:65408039	A/G	cg11764359	chr7:65958608	NA	0.66	8.45	0.46	1.95e-15	Aortic root size;
CESC	trans	rs4950322	0.580	rs7514970	chr1:146592098	C/T	cg04954894	chr8:38089920	DDHD2	-0.59	-6.43	-0.37	5.98e-10	Protein quantitative trait loci;
CESC	cis	rs2370759	1.000	rs11008865	chr10:32574842	C/T	cg01819863	chr10:32635814	EPC1	1.17	13.3	0.63	2.82e-31	Sexual dysfunction (female);
CESC	cis	rs11785693	0.862	rs7007542	chr8:4996718	G/A	cg26367366	chr8:4980734	NA	0.83	7.83	0.43	1.16e-13	Neuroticism (multi-trait analysis);Neuroticism;
CESC	cis	rs9916302	0.904	rs11869109	chr17:37518205	G/T	cg19468946	chr17:37922297	IKZF3	0.4	5.17	0.3	4.69e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs863345	0.967	rs6697568	chr1:158520466	T/G	cg12129480	chr1:158549410	OR10X1	-0.33	-6.48	-0.37	4.53e-10	Pneumococcal bacteremia;
CESC	cis	rs10949834	0.817	rs6460071	chr7:73497196	G/A	cg07137043	chr7:73588983	EIF4H	-0.69	-6.89	-0.39	4.1e-11	Verbal memory performance (residualized delayed recall change);
CESC	cis	rs2841277	0.645	rs28380382	chr14:105410827	C/T	cg19901468	chr14:105411992	AHNAK2	-0.6	-8.78	-0.47	2.07e-16	Rheumatoid arthritis;
CESC	cis	rs7666738	0.719	rs35184673	chr4:99050945	T/C	cg03676636	chr4:99064102	C4orf37	0.44	5.33	0.31	2.11e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3768617	0.510	rs3768616	chr1:183103551	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.87	13.27	0.63	3.59e-31	Fuchs's corneal dystrophy;
CESC	cis	rs6460942	0.591	rs62448733	chr7:12350526	C/T	cg20607287	chr7:12443886	VWDE	-0.61	-6.7	-0.38	1.23e-10	Coronary artery disease;
CESC	cis	rs6991838	0.584	rs3812412	chr8:66547092	G/A	cg13398993	chr8:66546079	ARMC1	0.46	5.65	0.33	4.19e-8	Intelligence (multi-trait analysis);
CESC	cis	rs3808502	0.605	rs11784572	chr8:11174484	C/G	cg21775007	chr8:11205619	TDH	-0.44	-5.93	-0.34	9.39e-9	Neuroticism;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg12738349	chr22:24236284	MIF	-0.44	-6.46	-0.37	4.91e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs6088590	0.648	rs6059991	chr20:33280836	C/T	cg24642439	chr20:33292090	TP53INP2	0.73	9.68	0.51	3.57e-19	Coronary artery disease;
CESC	trans	rs4756846	1.000	rs4756846	chr11:16403511	C/T	cg05579622	chr5:10618622	ANKRD33B	-0.77	-7.03	-0.4	1.78e-11	Obesity and osteoporosis;
CESC	cis	rs4268898	0.610	rs55860688	chr2:24451534	T/C	cg20701182	chr2:24300061	SF3B14	0.65	6.96	0.39	2.59e-11	Asthma;
CESC	cis	rs1620921	0.505	rs9458031	chr6:161210119	G/A	cg01280913	chr6:161186852	NA	-0.39	-5.63	-0.33	4.7e-8	Lipoprotein (a) - cholesterol levels;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg01217204	chr2:113239325	TTL	0.51	6.55	0.37	2.98e-10	Thyroid stimulating hormone;
CESC	cis	rs9905704	0.918	rs302868	chr17:56752123	C/T	cg12560992	chr17:57184187	TRIM37	0.59	6.95	0.39	2.75e-11	Testicular germ cell tumor;
CESC	cis	rs727505	1.000	rs6952721	chr7:124480075	T/C	cg23710748	chr7:124431027	NA	-0.39	-6.4	-0.37	7e-10	Lewy body disease;
CESC	cis	rs9322193	0.923	rs9479810	chr6:150072495	C/T	cg13206674	chr6:150067644	NUP43	0.41	5.72	0.33	2.82e-8	Lung cancer;
CESC	cis	rs57502260	0.749	rs67446678	chr11:68227466	C/T	cg20283391	chr11:68216788	NA	-0.64	-5.5	-0.32	9.07e-8	Total body bone mineral density (age 45-60);
CESC	cis	rs9287719	0.967	rs4669598	chr2:10757838	T/C	cg02196655	chr2:10830764	NOL10	-0.37	-5.67	-0.33	3.73e-8	Prostate cancer;
CESC	cis	rs1355223	0.902	rs2226113	chr11:34746289	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.48	-6.46	-0.37	5.03e-10	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs2070488	1.000	rs1002675	chr3:38445226	C/T	cg24069376	chr3:38537580	EXOG	0.45	8.15	0.45	1.43e-14	Electrocardiographic conduction measures;
CESC	trans	rs62103177	0.810	rs62103195	chr18:77629693	T/C	cg05926928	chr17:57297772	GDPD1	1.23	10.47	0.54	1.11e-21	Opioid sensitivity;
CESC	cis	rs7927592	0.956	rs12274114	chr11:68255577	A/C	cg16797656	chr11:68205561	LRP5	0.41	5.75	0.33	2.51e-8	Total body bone mineral density;
CESC	cis	rs2404602	0.684	rs11854850	chr15:76844571	C/T	cg23625390	chr15:77176239	SCAPER	-0.43	-5.91	-0.34	1.06e-8	Blood metabolite levels;
CESC	cis	rs7621025	0.599	rs13063987	chr3:136445397	C/G	cg15507776	chr3:136538369	TMEM22	-0.54	-6.08	-0.35	4.18e-9	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
CESC	cis	rs1153858	1.000	rs59889118	chr15:45618730	G/A	cg21132104	chr15:45694354	SPATA5L1	0.83	11.01	0.56	1.85e-23	Homoarginine levels;
CESC	cis	rs3096299	0.933	rs2965824	chr16:89455306	A/G	cg02187348	chr16:89574699	SPG7	0.52	6.83	0.39	5.96e-11	Multiple myeloma (IgH translocation);
CESC	cis	rs73001065	0.636	rs73002960	chr19:19582992	C/T	cg03709012	chr19:19516395	GATAD2A	0.97	6.99	0.39	2.21e-11	LDL cholesterol;
CESC	cis	rs1552244	0.554	rs6443275	chr3:10008819	G/A	cg00149659	chr3:10157352	C3orf10	0.54	6.64	0.38	1.72e-10	Alzheimer's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07450219	chr17:78428858	NA	0.63	7.04	0.4	1.61e-11	Gut microbiome composition (summer);
CESC	cis	rs2354432	0.607	rs6685775	chr1:146744294	A/G	cg25205988	chr1:146714368	CHD1L	-0.9	-7.78	-0.43	1.64e-13	Mitochondrial DNA levels;
CESC	cis	rs2354432	0.607	rs6658763	chr1:146692373	C/T	cg25205988	chr1:146714368	CHD1L	-1.01	-7.32	-0.41	2.91e-12	Mitochondrial DNA levels;
CESC	cis	rs7811142	1.000	rs6975514	chr7:100056220	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.0	9.6	0.51	6.43e-19	Platelet count;
CESC	cis	rs4979906	1.000	rs4979906	chr10:79444753	A/G	cg07817648	chr10:79422355	NA	-0.47	-5.53	-0.32	7.81e-8	Mortality in heart failure;
CESC	cis	rs736408	0.522	rs11130310	chr3:52674667	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.5	7.54	0.42	7.72e-13	Bipolar disorder;
CESC	cis	rs9814567	1.000	rs62269547	chr3:134214042	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.44	-5.99	-0.35	6.9e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	trans	rs17125944	0.773	rs1952089	chr14:53339777	C/T	cg01134794	chr4:78529898	CXCL13	0.53	6.01	0.35	6.22e-9	Alzheimer's disease (late onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19111906	chr11:67816846	TCIRG1	-0.47	-6.16	-0.35	2.62e-9	Gut microbiome composition (summer);
CESC	cis	rs826838	0.834	rs2387842	chr12:38736442	T/C	cg13010199	chr12:38710504	ALG10B	0.62	8.72	0.47	3.22e-16	Heart rate;
CESC	cis	rs2370759	1.000	rs76998371	chr10:32631785	A/G	cg01819863	chr10:32635814	EPC1	1.16	12.73	0.62	2.71e-29	Sexual dysfunction (female);
CESC	cis	rs11098499	0.754	rs2036856	chr4:120249288	G/A	cg09307838	chr4:120376055	NA	0.77	10.35	0.54	2.54e-21	Corneal astigmatism;
CESC	cis	rs546131	0.928	rs552171	chr11:34830709	G/T	cg11058730	chr11:34937778	PDHX;APIP	0.47	5.84	0.34	1.52e-8	Lung disease severity in cystic fibrosis;
CESC	trans	rs877282	0.583	rs11595057	chr10:819203	A/C	cg22713356	chr15:30763199	NA	1.01	9.48	0.5	1.47e-18	Uric acid levels;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg06683288	chr20:60813424	OSBPL2	-0.38	-6.06	-0.35	4.67e-9	Gambling;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21207217	chr5:43484130	C5orf28	-0.63	-6.74	-0.38	9.89e-11	Gut microbiome composition (summer);
CESC	cis	rs3096299	0.658	rs4785679	chr16:89566113	G/T	cg02187348	chr16:89574699	SPG7	0.7	9.92	0.52	6.38e-20	Multiple myeloma (IgH translocation);
CESC	cis	rs12762955	0.608	rs7922760	chr10:1156815	G/C	cg18964960	chr10:1102726	WDR37	-0.56	-6.33	-0.36	1.02e-9	Response to angiotensin II receptor blocker therapy;
CESC	cis	rs7208859	0.623	rs73269988	chr17:29118145	G/A	cg14008862	chr17:28927542	LRRC37B2	0.65	5.14	0.3	5.34e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs1862618	0.853	rs832565	chr5:56150803	T/G	cg03609598	chr5:56110824	MAP3K1	-0.53	-5.61	-0.33	5.2100000000000003e-08	Initial pursuit acceleration;
CESC	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	13.65	0.64	1.8e-32	Prudent dietary pattern;
CESC	cis	rs7949030	0.653	rs2516634	chr11:62367186	G/A	cg11742103	chr11:62369870	EML3;MTA2	-0.6	-9.13	-0.49	1.86e-17	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs2836974	0.897	rs7280375	chr21:40552408	C/T	cg17971929	chr21:40555470	PSMG1	-0.99	-15.24	-0.68	4.33e-38	Cognitive function;
CESC	cis	rs9303401	0.659	rs1864754	chr17:56688789	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	-1.05	-13.18	-0.63	7.78e-31	Cognitive test performance;
CESC	cis	rs34779708	0.931	rs79749947	chr10:35277081	A/T	cg04310649	chr10:35416472	CREM	-0.5	-5.97	-0.34	7.61e-9	Inflammatory bowel disease;Crohn's disease;
CESC	trans	rs7246657	0.943	rs10414904	chr19:37830088	G/A	cg24637308	chr11:6592297	DNHD1	0.53	6.17	0.35	2.55e-9	Coronary artery calcification;
CESC	cis	rs6952808	0.595	rs3800916	chr7:2166072	C/T	cg05863683	chr7:1912471	MAD1L1	0.4	5.9	0.34	1.08e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs736408	0.812	rs2270197	chr3:52824095	T/G	cg18404041	chr3:52824283	ITIH1	-0.49	-7.9	-0.44	7.26e-14	Bipolar disorder;
CESC	cis	rs1008375	1.000	rs7436403	chr4:17692685	T/G	cg27347728	chr4:17578864	LAP3	-0.45	-5.26	-0.31	3e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs9322193	0.516	rs1999632	chr6:150187873	C/T	cg01145232	chr6:150245071	RAET1G	0.48	6.07	0.35	4.48e-9	Lung cancer;
CESC	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	10.52	0.54	7.61e-22	Prudent dietary pattern;
CESC	cis	rs9322193	0.923	rs56397000	chr6:150060483	C/T	cg00933542	chr6:150070202	PCMT1	0.29	5.18	0.3	4.29e-7	Lung cancer;
CESC	cis	rs9303401	0.704	rs7359501	chr17:56641200	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.54	7.24	0.41	4.92e-12	Cognitive test performance;
CESC	cis	rs9733	0.543	rs72702558	chr1:150683251	G/A	cg17724175	chr1:150552817	MCL1	0.45	7.31	0.41	3.23e-12	Tonsillectomy;
CESC	cis	rs7818688	0.654	rs75680386	chr8:95986148	A/G	cg16049864	chr8:95962084	TP53INP1	0.56	5.62	0.33	4.74e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs227584	0.663	rs3180912	chr17:42259463	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.55	7.39	0.41	1.92e-12	Bone mineral density (hip);Bone mineral density;
CESC	cis	rs7927771	0.524	rs4752796	chr11:47841862	A/G	cg20307385	chr11:47447363	PSMC3	-0.58	-8.03	-0.44	3.12e-14	Subjective well-being;
CESC	cis	rs12476592	0.543	rs12713494	chr2:63698162	G/T	cg17519650	chr2:63277830	OTX1	-0.47	-5.23	-0.31	3.41e-7	Childhood ear infection;
CESC	cis	rs7267979	0.933	rs6138571	chr20:25435388	A/G	cg08601574	chr20:25228251	PYGB	0.37	5.31	0.31	2.31e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs2299587	0.897	rs3850745	chr8:17784277	G/A	cg08627089	chr8:17753878	FGL1	-0.36	-5.04	-0.3	8.69e-7	Economic and political preferences;
CESC	cis	rs1865760	0.566	rs9366634	chr6:26072396	C/G	cg17691542	chr6:26056736	HIST1H1C	0.41	5.47	0.32	1.05e-7	Height;
CESC	trans	rs163030	0.840	rs335611	chr5:76747860	T/C	cg26150533	chr8:82396069	FABP4	-0.39	-6.0	-0.35	6.54e-9	Caudate nucleus volume;
CESC	cis	rs3096299	0.967	rs11648663	chr16:89466307	C/T	cg08822215	chr16:89438651	ANKRD11	-0.42	-6.47	-0.37	4.58e-10	Multiple myeloma (IgH translocation);
CESC	cis	rs11792861	0.816	rs11788336	chr9:111688387	T/C	cg05043794	chr9:111880884	C9orf5	-0.37	-6.11	-0.35	3.59e-9	Menarche (age at onset);
CESC	cis	rs17039065	0.920	rs73838435	chr4:109445261	A/G	cg16022748	chr4:109541635	LOC285456;RPL34	0.66	6.18	0.35	2.47e-9	Gut microbiome composition (summer);
CESC	cis	rs1577917	1.000	rs12208493	chr6:86662267	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.47	-6.08	-0.35	4.29e-9	Response to antipsychotic treatment;
CESC	cis	rs9300255	0.596	rs1568427	chr12:123738678	A/G	cg19016782	chr12:123741754	C12orf65	-0.37	-5.61	-0.33	5.17e-8	Neutrophil percentage of white cells;
CESC	cis	rs10463316	0.894	rs6579864	chr5:150762181	G/A	cg03212797	chr5:150827313	SLC36A1	-0.46	-6.02	-0.35	5.83e-9	Metabolite levels (Pyroglutamine);
CESC	cis	rs7560272	0.723	rs780395	chr2:73700853	G/A	cg20560298	chr2:73613845	ALMS1	0.49	7.1	0.4	1.14e-11	Schizophrenia;
CESC	cis	rs4727027	0.901	rs4727017	chr7:148822062	A/G	cg23158103	chr7:148848205	ZNF398	-0.41	-6.74	-0.38	9.65e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs9611565	0.659	rs56364401	chr22:41951243	T/G	cg03806693	chr22:41940476	POLR3H	-1.22	-16.24	-0.71	1.23e-41	Vitiligo;
CESC	cis	rs8070128	0.583	rs7406982	chr17:17942613	C/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.5	6.33	0.36	1.03e-9	Total body bone mineral density;
CESC	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.52	0.37	3.63e-10	Prudent dietary pattern;
CESC	cis	rs782590	0.869	rs782599	chr2:55847423	C/T	cg18811423	chr2:55921094	PNPT1	0.79	12.22	0.6	1.55e-27	Metabolic syndrome;
CESC	cis	rs1941023	0.503	rs12798266	chr11:60118851	G/A	cg08716584	chr11:60157161	MS4A7	-0.5	-8.03	-0.44	3.19e-14	Congenital heart disease (maternal effect);
CESC	cis	rs4862750	0.832	rs10007858	chr4:187877492	A/G	cg06074448	chr4:187884817	NA	-0.37	-5.3	-0.31	2.41e-7	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4665809	0.590	rs7606351	chr2:26292545	A/C	cg08470875	chr2:26401718	FAM59B	-0.63	-6.69	-0.38	1.33e-10	Gut microbiome composition (summer);
CESC	cis	rs2228479	0.850	rs3785279	chr16:89824562	G/C	cg14709524	chr16:89940631	TCF25	0.91	6.75	0.38	9.34e-11	Skin colour saturation;
CESC	cis	rs9300255	0.602	rs1716165	chr12:123648881	C/T	cg19016782	chr12:123741754	C12orf65	-0.4	-5.77	-0.33	2.27e-8	Neutrophil percentage of white cells;
CESC	trans	rs74054849	0.850	rs72878865	chr1:16009097	G/A	cg06826283	chr7:600452	PRKAR1B	0.7	6.26	0.36	1.55e-9	Alcoholic chronic pancreatitis;
CESC	cis	rs853679	0.550	rs1233699	chr6:28169158	A/T	cg12963246	chr6:28129442	ZNF389	0.51	7.16	0.4	8.11e-12	Depression;
CESC	cis	rs3820068	0.603	rs2236215	chr1:15892415	A/C	cg17385448	chr1:15911702	AGMAT	0.39	6.35	0.36	9.13e-10	Systolic blood pressure;
CESC	cis	rs6741892	0.536	rs7590835	chr2:38893950	A/G	cg05604112	chr2:38893237	GALM	0.55	7.59	0.42	5.44e-13	5-HTT brain serotonin transporter levels;
CESC	trans	rs2727020	0.617	rs1917311	chr11:49422665	C/T	cg15704280	chr7:45808275	SEPT13	-0.89	-15.13	-0.68	1.09e-37	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22395253	chr7:104941898	SRPK2	-0.57	-6.01	-0.35	6.13e-9	Gut microbiome composition (summer);
CESC	cis	rs72945132	0.882	rs72949076	chr11:70217695	T/C	cg00319359	chr11:70116639	PPFIA1	0.76	7.17	0.4	7.33e-12	Coronary artery disease;
CESC	cis	rs9916302	0.752	rs11078895	chr17:37401051	A/G	cg07936489	chr17:37558343	FBXL20	-0.98	-11.85	-0.59	2.79e-26	Glomerular filtration rate (creatinine);
CESC	cis	rs7107174	1.000	rs7939352	chr11:78003151	G/A	cg02023728	chr11:77925099	USP35	0.41	5.97	0.34	7.43e-9	Testicular germ cell tumor;
CESC	cis	rs7085104	0.684	rs7092690	chr10:104609365	T/C	cg15744005	chr10:104629667	AS3MT	-0.37	-5.8	-0.34	1.84e-8	Immature fraction of reticulocytes;Schizophrenia;
CESC	cis	rs28374715	0.532	rs11854632	chr15:41682094	A/G	cg02330683	chr15:41787940	ITPKA	-0.42	-5.21	-0.3	3.85e-7	Ulcerative colitis;
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg12857786	chr4:83934023	LIN54	-0.44	-6.15	-0.35	2.77e-9	Vertical cup-disc ratio;
CESC	cis	rs2072438	0.503	rs2146838	chr9:123876305	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.37	-5.39	-0.31	1.58e-7	Rheumatoid arthritis;
CESC	cis	rs17826219	0.636	rs8080829	chr17:29058730	C/T	cg19761014	chr17:28927070	LRRC37B2	0.76	6.25	0.36	1.66e-9	Body mass index;
CESC	cis	rs3540	0.554	rs113942266	chr15:91072990	A/G	cg10434728	chr15:90938212	IQGAP1	-0.41	-7.42	-0.41	1.57e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03951724	chr22:30723125	TBC1D10A	0.62	7.5	0.42	9.53e-13	Gut microbiome composition (summer);
CESC	cis	rs4588572	0.602	rs10059672	chr5:77673317	G/C	cg11547950	chr5:77652471	NA	0.46	5.85	0.34	1.44e-8	Triglycerides;
CESC	cis	rs9902453	0.904	rs10853136	chr17:28406018	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.69	-9.1	-0.49	2.24e-17	Coffee consumption (cups per day);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg01553063	chr11:560751	RASSF7;C11orf35	-0.47	-6.02	-0.35	5.8e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs17376456	0.809	rs13177800	chr5:93307350	T/C	cg21475434	chr5:93447410	FAM172A	0.8	6.94	0.39	2.95e-11	Diabetic retinopathy;
CESC	cis	rs10089	1.000	rs4836369	chr5:127486462	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.78	10.51	0.54	8.08e-22	Ileal carcinoids;
CESC	cis	rs769267	0.896	rs10405625	chr19:19579046	T/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	7.4	0.41	1.78e-12	Tonsillectomy;
CESC	cis	rs7727544	0.684	rs2631363	chr5:131707095	A/G	cg24060327	chr5:131705240	SLC22A5	0.63	8.33	0.46	4.43e-15	Blood metabolite levels;
CESC	cis	rs12681366	0.734	rs16916796	chr8:95402229	A/G	cg13257157	chr8:95487014	RAD54B	0.38	5.14	0.3	5.22e-7	Nonsyndromic cleft lip with cleft palate;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg03145290	chr16:32857923	NA	0.37	6.04	0.35	5.18e-9	Fibrinogen levels;
CESC	cis	rs12545109	0.837	rs4738500	chr8:57356193	G/A	cg09654669	chr8:57350985	NA	-0.6	-6.98	-0.39	2.44e-11	Obesity-related traits;
CESC	cis	rs67311347	0.955	rs4974068	chr3:40376929	T/C	cg24209194	chr3:40518798	ZNF619	0.41	5.24	0.31	3.3e-7	Renal cell carcinoma;
CESC	cis	rs75477785	1.000	rs12075674	chr1:209995470	C/T	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.86	5.44	0.32	1.2e-7	Cleft lip with or without cleft palate;
CESC	trans	rs7937682	0.824	rs11213962	chr11:111506027	G/A	cg18187862	chr3:45730750	SACM1L	0.51	6.47	0.37	4.81e-10	Primary sclerosing cholangitis;
CESC	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.09	21.15	0.79	7.85e-59	Prudent dietary pattern;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08205843	chr19:12848293	ASNA1	-0.66	-8.05	-0.44	2.87e-14	Gut microbiome composition (summer);
CESC	trans	rs7615952	0.641	rs6438951	chr3:125696999	A/G	cg07211511	chr3:129823064	LOC729375	-0.58	-6.62	-0.38	1.96e-10	Blood pressure (smoking interaction);
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg00949670	chr12:120967105	COQ5	-0.47	-6.2	-0.36	2.11e-9	Height;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg07512676	chr17:48785330	ANKRD40	0.42	6.1	0.35	3.75e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs6540556	0.723	rs6540551	chr1:209925295	C/T	cg23920097	chr1:209922102	NA	-0.39	-5.5	-0.32	9.14e-8	Red blood cell count;
CESC	cis	rs7937682	0.575	rs7127010	chr11:111770782	C/T	cg22437258	chr11:111473054	SIK2	-0.48	-5.3	-0.31	2.44e-7	Primary sclerosing cholangitis;
CESC	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg11494091	chr17:61959527	GH2	0.73	12.56	0.61	1.02e-28	Prudent dietary pattern;
CESC	cis	rs2070433	0.800	rs11702190	chr21:47877367	C/T	cg12379764	chr21:47803548	PCNT	0.66	7.47	0.42	1.13e-12	Lymphocyte counts;
CESC	cis	rs11098499	0.954	rs12502423	chr4:120424172	A/C	cg24375607	chr4:120327624	NA	0.5	6.17	0.35	2.61e-9	Corneal astigmatism;
CESC	cis	rs1799949	1.000	rs2298862	chr17:41176688	T/C	cg25072359	chr17:41440525	NA	0.49	6.41	0.37	6.64e-10	Menopause (age at onset);
CESC	cis	rs367943	1.000	rs348931	chr5:112812864	G/C	cg12552261	chr5:112820674	MCC	-0.62	-7.73	-0.43	2.27e-13	Type 2 diabetes;
CESC	cis	rs780096	0.526	rs809058	chr2:27616790	T/C	cg24768116	chr2:27665128	KRTCAP3	-0.29	-5.37	-0.31	1.71e-7	Total body bone mineral density;
CESC	cis	rs6429082	0.782	rs704705	chr1:235612320	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.61	-7.54	-0.42	7.34e-13	Adiposity;
CESC	cis	rs9400271	0.632	rs949882	chr6:109586062	A/G	cg01475377	chr6:109611718	NA	0.44	7.0	0.4	2.06e-11	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
CESC	cis	rs4853012	0.941	rs7571083	chr2:74342260	C/G	cg01017244	chr2:74357527	NA	0.54	7.13	0.4	9.44e-12	Gestational age at birth (maternal effect);
CESC	cis	rs13067593	1.000	rs11715620	chr3:188563772	T/G	cg17809494	chr3:188572244	LPP	0.35	5.13	0.3	5.74e-7	Immune reponse to smallpox (secreted IFN-alpha);
CESC	cis	rs2243480	1.000	rs7456042	chr7:65299778	T/C	cg25894440	chr7:65020034	NA	-0.61	-5.43	-0.32	1.25e-7	Diabetic kidney disease;
CESC	cis	rs13191362	1.000	rs34619021	chr6:163029767	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.86	9.12	0.49	1.91e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs854765	0.583	rs12452219	chr17:17829423	C/T	cg16928487	chr17:17741425	SREBF1	-0.59	-10.25	-0.53	5.56e-21	Total body bone mineral density;
CESC	cis	rs4132509	1.000	rs2125230	chr1:243885848	A/G	cg21452805	chr1:244014465	NA	-0.45	-5.58	-0.32	5.92e-8	RR interval (heart rate);
CESC	cis	rs9550616	0.801	rs9579787	chr13:20726921	G/T	cg27436003	chr13:20734544	GJA3	0.37	5.31	0.31	2.31e-7	Facial emotion recognition (happy faces);
CESC	cis	rs8177253	1.000	rs3811647	chr3:133484029	G/A	cg01448562	chr3:133502909	NA	-0.42	-5.84	-0.34	1.55e-8	Iron status biomarkers;
CESC	cis	rs735396	0.770	rs1169315	chr12:121443753	T/G	cg02403541	chr12:121454288	C12orf43	0.75	10.48	0.54	1e-21	N-glycan levels;
CESC	cis	rs7395581	0.918	rs11039166	chr11:47316691	A/C	cg25783544	chr11:47291846	MADD	0.61	8.01	0.44	3.65e-14	HDL cholesterol;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg11192808	chr8:101170185	SPAG1	-0.46	-6.01	-0.35	6.27e-9	Ulcerative colitis;
CESC	cis	rs3796352	1.000	rs750474	chr3:53085280	A/C	cg12962167	chr3:53033115	SFMBT1	0.55	5.56	0.32	6.66e-8	Immune reponse to smallpox (secreted IL-2);
CESC	trans	rs3780486	0.846	rs913214	chr9:33135085	G/A	cg20290983	chr6:43655470	MRPS18A	0.98	18.11	0.74	2.86e-48	IgG glycosylation;
CESC	cis	rs765787	0.530	rs28526629	chr15:45540462	C/T	cg24006582	chr15:45444508	DUOX1	-0.55	-6.81	-0.39	6.42e-11	Uric acid levels;
CESC	cis	rs4588572	0.643	rs13359053	chr5:77690224	T/C	cg11547950	chr5:77652471	NA	0.45	5.71	0.33	3.06e-8	Triglycerides;
CESC	cis	rs6121246	0.633	rs6060986	chr20:30426297	G/A	cg13852791	chr20:30311386	BCL2L1	0.84	10.62	0.55	3.45e-22	Mean corpuscular hemoglobin;
CESC	cis	rs7666738	0.719	rs4699323	chr4:98967484	G/A	cg17366294	chr4:99064904	C4orf37	0.55	6.45	0.37	5.2400000000000005e-10	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11088226	0.681	rs2833906	chr21:33945521	G/T	cg09050820	chr6:167586206	TCP10L2	0.91	9.31	0.5	5.03e-18	Gastritis;
CESC	cis	rs76878669	0.538	rs4930360	chr11:66143247	T/A	cg18002602	chr11:66138449	SLC29A2	0.4	6.62	0.38	1.96e-10	Educational attainment (years of education);
CESC	cis	rs4853012	0.838	rs4452177	chr2:74345206	A/G	cg05890377	chr2:74357713	NA	0.76	10.34	0.54	2.76e-21	Gestational age at birth (maternal effect);
CESC	cis	rs2836950	0.545	rs2297256	chr21:40558421	C/T	cg11890956	chr21:40555474	PSMG1	-0.6	-8.39	-0.46	2.99e-15	Menarche (age at onset);
CESC	cis	rs7208859	0.623	rs73269923	chr17:29102571	C/T	cg14008862	chr17:28927542	LRRC37B2	0.68	5.3	0.31	2.47e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	trans	rs2115172	0.836	rs4835799	chr5:122762229	A/G	cg01246405	chr11:3876562	STIM1	0.5	6.81	0.39	6.46e-11	Weight;
CESC	cis	rs5747327	0.874	rs5747323	chr22:18163539	G/A	cg19898043	chr22:18121309	BCL2L13	-0.41	-5.16	-0.3	4.83e-7	Myeloid white cell count;Granulocyte count;
CESC	cis	rs4665809	0.938	rs35844686	chr2:26304949	A/G	cg08470875	chr2:26401718	FAM59B	0.59	6.16	0.35	2.71e-9	Gut microbiome composition (summer);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg14490761	chr5:137878937	ETF1	0.5	6.55	0.37	2.99e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs7605827	0.930	rs12692268	chr2:15595519	A/G	cg19274914	chr2:15703543	NA	0.34	6.12	0.35	3.4e-9	Educational attainment (years of education);
CESC	cis	rs559928	0.606	rs11605856	chr11:63925528	C/T	cg18225595	chr11:63971243	STIP1	0.65	5.97	0.34	7.73e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CESC	trans	rs13063635	0.915	rs71325091	chr3:45932407	G/A	cg10236987	chr1:228114221	WNT9A	0.64	6.58	0.37	2.56e-10	Eosinophil percentage of granulocytes;
CESC	cis	rs10504229	0.906	rs72650894	chr8:58179734	C/T	cg24829409	chr8:58192753	C8orf71	-0.75	-9.89	-0.52	7.84e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs2439831	0.681	rs526450	chr15:43599325	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	12.86	0.62	1e-29	Lung cancer in ever smokers;
CESC	cis	rs477692	0.673	rs10829600	chr10:131322051	G/C	cg24747557	chr10:131355152	MGMT	-0.38	-5.22	-0.31	3.69e-7	Response to temozolomide;
CESC	cis	rs7811142	0.830	rs41280971	chr7:99954457	G/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.08	11.0	0.56	1.98e-23	Platelet count;
CESC	cis	rs9300255	0.739	rs11057210	chr12:123733799	A/G	cg05973401	chr12:123451056	ABCB9	0.49	5.51	0.32	8.7e-8	Neutrophil percentage of white cells;
CESC	cis	rs9487051	1.000	rs9480924	chr6:109617070	T/C	cg21918786	chr6:109611834	NA	-0.36	-5.22	-0.31	3.63e-7	Reticulocyte fraction of red cells;
CESC	cis	rs11166927	1.000	rs13256625	chr8:140805003	G/T	cg16909799	chr8:140841666	TRAPPC9	0.62	9.07	0.49	2.83e-17	Pediatric non-alcoholic fatty liver disease activity score;
CESC	cis	rs9322193	0.884	rs2064521	chr6:149946472	A/C	cg13206674	chr6:150067644	NUP43	-0.45	-6.39	-0.37	7.31e-10	Lung cancer;
CESC	cis	rs1448094	0.549	rs4919770	chr12:86238050	G/T	cg02569458	chr12:86230093	RASSF9	0.52	7.5	0.42	9.37e-13	Major depressive disorder;
CESC	cis	rs2439831	0.681	rs528517	chr15:43612925	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.83	12.56	0.61	1.09e-28	Lung cancer in ever smokers;
CESC	cis	rs12291225	0.679	rs34238445	chr11:14315915	C/T	cg19336497	chr11:14380999	RRAS2	-0.37	-5.27	-0.31	2.89e-7	Sense of smell;
CESC	cis	rs2033711	0.840	rs10423138	chr19:58928302	T/C	cg26874164	chr19:58962979	ZNF324B	0.54	7.41	0.41	1.73e-12	Uric acid clearance;
CESC	cis	rs7267979	0.903	rs1118963	chr20:25247449	G/A	cg08601574	chr20:25228251	PYGB	0.42	5.9	0.34	1.12e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs9815354	0.812	rs17215988	chr3:41851320	A/C	cg03022575	chr3:42003672	ULK4	0.7	6.04	0.35	5.26e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg04267008	chr7:1944627	MAD1L1	-0.57	-6.83	-0.39	5.77e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs9287719	0.745	rs4997809	chr2:10755542	G/A	cg00105475	chr2:10696890	NA	0.37	5.2	0.3	3.96e-7	Prostate cancer;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg04094107	chr15:73976560	CD276	-0.53	-7.2	-0.4	6.21e-12	Fibrinogen levels;
CESC	cis	rs2243480	1.000	rs34974928	chr7:65364006	T/C	cg18252515	chr7:66147081	NA	-1.01	-9.32	-0.5	4.6e-18	Diabetic kidney disease;
CESC	cis	rs736408	0.521	rs13074853	chr3:52779801	T/C	cg18337363	chr3:52569053	NT5DC2	0.28	5.13	0.3	5.59e-7	Bipolar disorder;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg16480132	chr7:149571111	LOC401431;ATP6V0E2	-0.44	-6.74	-0.38	1.01e-10	Gambling;
CESC	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg18538332	chr22:24372958	LOC391322	0.68	9.68	0.51	3.49e-19	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs79349575	0.783	rs62075852	chr17:47017176	T/C	cg26022315	chr17:47021804	SNF8	0.39	5.16	0.3	4.94e-7	Type 2 diabetes;
CESC	cis	rs17253792	0.822	rs10137340	chr14:56050989	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.81	6.52	0.37	3.55e-10	Putamen volume;
CESC	cis	rs2816062	0.813	rs742485	chr1:18900943	A/T	cg18795169	chr1:18902165	NA	-0.93	-18.14	-0.74	2.22e-48	Urate levels in lean individuals;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16419620	chr12:48214187	HDAC7	-0.58	-6.86	-0.39	4.75e-11	Gut microbiome composition (summer);
CESC	cis	rs1707322	1.000	rs4660331	chr1:46458783	A/C	cg03146154	chr1:46216737	IPP	0.74	10.23	0.53	6.52e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs11696501	0.688	rs6104293	chr20:44326298	T/C	cg11783356	chr20:44313418	WFDC10B	-0.31	-5.08	-0.3	7.02e-7	Brain structure;
CESC	cis	rs3096299	0.719	rs2965818	chr16:89510494	A/G	cg02187348	chr16:89574699	SPG7	0.62	8.58	0.47	8.33e-16	Multiple myeloma (IgH translocation);
CESC	cis	rs763121	0.853	rs6001188	chr22:39062194	T/C	cg06544989	chr22:39130855	UNC84B	0.51	8.91	0.48	8.21e-17	Menopause (age at onset);
CESC	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg10819733	chr22:24237672	NA	-0.47	-6.69	-0.38	1.33e-10	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs3096299	0.933	rs2965823	chr16:89454924	G/A	cg08822215	chr16:89438651	ANKRD11	-0.43	-6.59	-0.38	2.38e-10	Multiple myeloma (IgH translocation);
CESC	cis	rs9649213	0.593	rs6465673	chr7:97968887	C/T	cg00277769	chr7:97922759	BAIAP2L1	-0.34	-5.56	-0.32	6.48e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs597539	0.652	rs654071	chr11:68653432	A/C	cg18350739	chr11:68623251	NA	-0.43	-6.72	-0.38	1.09e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs708547	0.647	rs2293175	chr4:57861358	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.59	8.71	0.47	3.29e-16	Response to bleomycin (chromatid breaks);
CESC	trans	rs11770686	0.967	rs4728289	chr7:75348505	C/T	cg02552079	chr4:1220951	CTBP1	-0.39	-6.04	-0.35	5.29e-9	Essential tremor;
CESC	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg03647317	chr4:187891568	NA	-0.44	-6.76	-0.38	8.81e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs12142240	0.698	rs41294478	chr1:46818442	G/A	cg10495392	chr1:46806563	NSUN4	0.57	6.27	0.36	1.47e-9	Menopause (age at onset);
CESC	cis	rs9303401	0.646	rs7342863	chr17:57227010	G/A	cg12560992	chr17:57184187	TRIM37	0.44	5.31	0.31	2.29e-7	Cognitive test performance;
CESC	cis	rs4665809	0.652	rs4665832	chr2:26404775	A/G	cg04944784	chr2:26401820	FAM59B	-0.91	-10.38	-0.54	2.12e-21	Gut microbiome composition (summer);
CESC	cis	rs6942756	0.806	rs6467240	chr7:128984018	T/C	cg02491457	chr7:128862824	NA	-0.61	-8.63	-0.47	5.7e-16	White matter hyperintensity burden;
CESC	cis	rs11677416	0.885	rs4849119	chr2:113523463	G/C	cg27083787	chr2:113543245	IL1A	0.58	7.33	0.41	2.81e-12	Response to antipsychotic treatment in schizophrenia (working memory);
CESC	cis	rs10479542	1.000	rs10479542	chr5:178981241	T/A	cg22764044	chr5:178986830	RUFY1	0.45	6.78	0.38	7.76e-11	Lung cancer;
CESC	cis	rs703842	1.000	rs11172351	chr12:58213485	C/T	cg18357645	chr12:58087776	OS9	-0.41	-5.65	-0.33	4.08e-8	Multiple sclerosis;
CESC	cis	rs60871478	0.636	rs6976929	chr7:901382	C/T	cg05535760	chr7:792225	HEATR2	-0.78	-8.24	-0.45	8.16e-15	Cerebrospinal P-tau181p levels;
CESC	cis	rs9649213	0.593	rs6948540	chr7:97960066	A/G	cg08684580	chr7:98029266	BAIAP2L1	-0.35	-5.7	-0.33	3.23e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs12497850	0.931	rs9840050	chr3:49133310	A/G	cg07636037	chr3:49044803	WDR6	1.06	19.29	0.76	2.09e-52	Parkinson's disease;
CESC	cis	rs3015497	0.967	rs8018308	chr14:51122633	T/C	cg26011998	chr14:51135199	SAV1	-0.44	-5.53	-0.32	7.8e-8	Mean platelet volume;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg27524515	chr8:38239417	WHSC1L1	0.48	6.37	0.36	8.16e-10	Height;
CESC	cis	rs826838	0.935	rs1486357	chr12:39073675	A/G	cg26384229	chr12:38710491	ALG10B	0.8	13.4	0.64	1.26e-31	Heart rate;
CESC	cis	rs2288073	1.000	rs6708328	chr2:24412413	A/G	cg06627628	chr2:24431161	ITSN2	-0.79	-9.79	-0.52	1.6e-19	Venous thromboembolism (SNP x SNP interaction);
CESC	cis	rs916888	0.610	rs199529	chr17:44837217	A/C	cg15921436	chr17:44337874	NA	0.61	7.37	0.41	2.2e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs2204008	0.837	rs7315255	chr12:37949279	G/A	cg26384229	chr12:38710491	ALG10B	0.75	11.2	0.57	4.3e-24	Bladder cancer;
CESC	cis	rs17376456	0.877	rs17315943	chr5:93442830	T/C	cg25358565	chr5:93447407	FAM172A	1.15	11.35	0.57	1.34e-24	Diabetic retinopathy;
CESC	trans	rs11039798	0.688	rs10839007	chr11:48703442	A/C	cg15704280	chr7:45808275	SEPT13	0.69	6.29	0.36	1.33e-9	Axial length;
CESC	cis	rs2404602	0.647	rs907594	chr15:77197745	C/A	cg23625390	chr15:77176239	SCAPER	-0.46	-6.45	-0.37	5.34e-10	Blood metabolite levels;
CESC	cis	rs597539	0.652	rs579136	chr11:68637476	C/G	cg01988459	chr11:68622903	NA	-0.39	-5.21	-0.3	3.76e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs8177179	0.967	rs4443173	chr3:133439378	A/G	cg18769074	chr3:133464867	TF	0.29	5.42	0.32	1.36e-7	Iron status biomarkers (transferrin levels);
CESC	cis	rs9287719	0.781	rs6714795	chr2:10759134	C/T	cg00105475	chr2:10696890	NA	0.35	5.07	0.3	7.65e-7	Prostate cancer;
CESC	cis	rs13242816	1.000	rs67652573	chr7:116109958	T/C	cg04696780	chr7:116139425	CAV2	-0.63	-5.71	-0.33	2.98e-8	P wave duration;
CESC	cis	rs9911578	0.967	rs6503893	chr17:57149695	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.16	0.3	4.91e-7	Intelligence (multi-trait analysis);
CESC	cis	rs6732160	0.845	rs6546809	chr2:73389681	A/C	cg01422370	chr2:73384389	NA	0.45	7.77	0.43	1.73e-13	Intelligence (multi-trait analysis);
CESC	cis	rs853679	0.517	rs9380057	chr6:28104634	G/T	cg22143856	chr6:28129313	ZNF389	0.52	6.77	0.38	8.31e-11	Depression;
CESC	cis	rs858239	0.600	rs61292332	chr7:23131862	C/T	cg23682824	chr7:23144976	KLHL7	0.54	7.34	0.41	2.63e-12	Cerebrospinal fluid biomarker levels;
CESC	cis	rs4660306	1.000	rs10157597	chr1:45990278	C/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.61	-7.69	-0.43	2.92e-13	Homocysteine levels;
CESC	cis	rs9322193	0.923	rs9371199	chr6:150138662	A/T	cg07701084	chr6:150067640	NUP43	0.43	5.71	0.33	3.1e-8	Lung cancer;
CESC	cis	rs9583531	0.600	rs6492306	chr13:111361693	G/A	cg15841412	chr13:111365552	ING1	0.47	6.31	0.36	1.17e-9	Coronary artery disease;
CESC	trans	rs1814175	0.645	rs10839448	chr11:49938930	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.42	-6.25	-0.36	1.68e-9	Height;
CESC	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	22.13	0.81	3.58e-62	Prudent dietary pattern;
CESC	cis	rs6582630	0.559	rs12318620	chr12:38522340	T/C	cg26384229	chr12:38710491	ALG10B	-0.46	-6.23	-0.36	1.83e-9	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs919433	0.889	rs12472355	chr2:198205840	C/A	cg03934865	chr2:198174659	NA	-0.45	-6.53	-0.37	3.26e-10	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs2243480	1.000	rs781142	chr7:65438778	C/T	cg12463550	chr7:65579703	CRCP	0.67	5.54	0.32	7.11e-8	Diabetic kidney disease;
CESC	trans	rs2950393	0.509	rs10459247	chr12:57171516	T/C	cg26462586	chr2:11164677	NA	0.39	6.15	0.35	2.82e-9	Platelet distribution width;
CESC	trans	rs12107539	1.000	rs4680356	chr3:151051100	A/G	cg05862518	chr17:40277425	RAB5C	-0.47	-6.19	-0.36	2.34e-9	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
CESC	cis	rs748404	0.660	rs518288	chr15:43763999	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.53	8.33	0.46	4.53e-15	Lung cancer;
CESC	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg26338869	chr17:61819248	STRADA	0.67	8.82	0.48	1.6e-16	Prudent dietary pattern;
CESC	cis	rs453301	0.624	rs330056	chr8:9089695	A/T	cg17143192	chr8:8559678	CLDN23	-0.45	-5.41	-0.32	1.42e-7	Joint mobility (Beighton score);
CESC	cis	rs240764	0.764	rs11155472	chr6:100921549	A/T	cg21058520	chr6:100914733	NA	0.36	5.64	0.33	4.44e-8	Neuroticism;
CESC	cis	rs12497850	0.931	rs9311430	chr3:48845251	C/T	cg06212747	chr3:49208901	KLHDC8B	0.65	8.81	0.48	1.68e-16	Parkinson's disease;
CESC	cis	rs6952808	0.743	rs4721097	chr7:1877503	G/T	cg13880726	chr7:1868755	MAD1L1	0.53	7.14	0.4	8.82e-12	Bipolar disorder and schizophrenia;
CESC	cis	rs400736	0.655	rs11121086	chr1:8151224	C/T	cg25007680	chr1:8021821	PARK7	-0.6	-8.29	-0.45	5.83e-15	Response to antidepressants and depression;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg16389252	chr1:894601	KLHL17;NOC2L	-0.51	-6.51	-0.37	3.67e-10	Asthma;
CESC	trans	rs916888	0.773	rs199451	chr17:44801784	G/A	cg22433210	chr17:43662623	NA	1.0	11.15	0.57	6.21e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs9788682	0.668	rs2036529	chr15:78726272	A/T	cg24631222	chr15:78858424	CHRNA5	-0.62	-7.34	-0.41	2.67e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs7927592	0.913	rs6591346	chr11:68384618	T/A	cg01657329	chr11:68192670	LRP5	-0.39	-5.04	-0.3	8.72e-7	Total body bone mineral density;
CESC	cis	rs12477438	0.798	rs6759354	chr2:99632195	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.75	-10.95	-0.56	2.84e-23	Chronic sinus infection;
CESC	cis	rs72781680	0.898	rs72786277	chr2:24062818	T/G	cg08917208	chr2:24149416	ATAD2B	0.93	8.48	0.46	1.57e-15	Lymphocyte counts;
CESC	cis	rs709400	0.628	rs11621510	chr14:103869620	T/C	cg12935359	chr14:103987150	CKB	-0.5	-7.2	-0.4	6.09e-12	Body mass index;
CESC	cis	rs6952808	0.501	rs4721429	chr7:2171704	T/C	cg08027265	chr7:2291960	NA	-0.44	-6.84	-0.39	5.51e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs11098499	0.657	rs10434028	chr4:120294464	T/G	cg09307838	chr4:120376055	NA	0.85	11.38	0.57	1.1e-24	Corneal astigmatism;
CESC	cis	rs568617	1.000	rs656980	chr11:65656282	G/A	cg04055107	chr11:65626734	MUS81;CFL1	0.69	7.43	0.42	1.47e-12	Crohn's disease;
CESC	cis	rs11971779	1.000	rs11971779	chr7:139040258	A/G	cg07862535	chr7:139043722	LUC7L2	-0.54	-5.51	-0.32	8.7e-8	Diisocyanate-induced asthma;
CESC	cis	rs796364	0.951	rs35618222	chr2:201065777	C/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.64	5.89	0.34	1.16e-8	Schizophrenia;
CESC	cis	rs727505	0.954	rs989177	chr7:124412886	A/G	cg23710748	chr7:124431027	NA	-0.46	-7.26	-0.41	4.23e-12	Lewy body disease;
CESC	cis	rs3820928	0.874	rs13393894	chr2:227880543	A/G	cg11843606	chr2:227700838	RHBDD1	-0.46	-6.09	-0.35	3.87e-9	Pulmonary function;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14276772	chr2:10588646	ODC1	0.55	6.31	0.36	1.17e-9	Gut microbiome composition (summer);
CESC	cis	rs4654899	0.865	rs6665549	chr1:21475884	G/C	cg05370193	chr1:21551575	ECE1	0.46	7.08	0.4	1.28e-11	Superior frontal gyrus grey matter volume;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg19942813	chr3:187463496	BCL6	-0.48	-6.17	-0.35	2.58e-9	Ulcerative colitis;
CESC	cis	rs10242455	0.702	rs78218664	chr7:99154381	C/A	cg18809830	chr7:99032528	PTCD1	-0.64	-5.03	-0.3	9.06e-7	Blood metabolite levels;
CESC	cis	rs2657888	0.931	rs7301093	chr12:56933244	G/T	cg23002907	chr12:56915593	RBMS2	0.4	5.22	0.31	3.53e-7	Adiponectin levels;
CESC	cis	rs7666738	0.822	rs13110418	chr4:99046963	G/A	cg03676636	chr4:99064102	C4orf37	0.33	5.12	0.3	5.93e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7246657	0.941	rs7259618	chr19:37750719	G/A	cg23950597	chr19:37808831	NA	-0.63	-6.49	-0.37	4.22e-10	Coronary artery calcification;
CESC	cis	rs6688613	0.694	rs11576455	chr1:166811970	G/A	ch.1.3259774R	chr1:166827647	TADA1	0.6	6.02	0.35	5.83e-9	Refractive astigmatism;
CESC	cis	rs1949733	0.554	rs4259044	chr4:8536188	A/G	cg11789530	chr4:8429930	ACOX3	-0.57	-7.24	-0.41	4.9e-12	Response to antineoplastic agents;
CESC	cis	rs7577696	0.568	rs410469	chr2:32476992	G/T	cg02381751	chr2:32503542	YIPF4	-0.43	-5.16	-0.3	4.93e-7	Inflammatory biomarkers;
CESC	cis	rs910316	1.000	rs12589376	chr14:75561152	C/T	cg11812906	chr14:75593930	NEK9	0.89	15.08	0.68	1.6e-37	Height;
CESC	cis	rs4423214	1.000	rs12792306	chr11:71166992	T/C	cg05163923	chr11:71159392	DHCR7	0.84	11.53	0.58	3.3e-25	Vitamin D levels;
CESC	cis	rs6088580	0.524	rs7274854	chr20:33228672	A/C	cg24642439	chr20:33292090	TP53INP2	0.42	5.03	0.3	8.97e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs10504229	1.000	rs73607875	chr8:58173522	T/C	cg05313129	chr8:58192883	C8orf71	-0.55	-6.37	-0.36	8.42e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs72945132	0.882	rs11235755	chr11:70136323	A/G	cg00319359	chr11:70116639	PPFIA1	0.78	7.67	0.43	3.32e-13	Coronary artery disease;
CESC	cis	rs6087990	0.899	rs998382	chr20:31384136	C/T	cg13636640	chr20:31349939	DNMT3B	-0.84	-14.74	-0.67	2.64e-36	Ulcerative colitis;
CESC	cis	rs875971	0.571	rs78668714	chr7:65939451	G/A	cg18876405	chr7:65276391	NA	0.48	5.27	0.31	2.88e-7	Aortic root size;
CESC	cis	rs7662987	0.517	rs2602877	chr4:100039847	T/A	cg13256891	chr4:100009986	ADH5	0.75	8.03	0.44	3.29e-14	Smoking initiation;
CESC	cis	rs4812048	0.649	rs6070702	chr20:57621562	G/C	cg14073986	chr20:57617431	SLMO2	0.83	7.12	0.4	9.9e-12	Mean platelet volume;
CESC	cis	rs17376456	0.542	rs1982439	chr5:93160560	C/G	cg21475434	chr5:93447410	FAM172A	-0.51	-5.16	-0.3	4.73e-7	Diabetic retinopathy;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg26419957	chr12:122252518	SETD1B	0.55	7.36	0.41	2.35e-12	Fibrinogen levels;
CESC	cis	rs3733585	0.673	rs4455410	chr4:9953297	C/T	cg00071950	chr4:10020882	SLC2A9	0.69	10.99	0.56	2.1e-23	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs6460942	0.915	rs62447641	chr7:12488764	G/A	cg02935154	chr7:12443704	VWDE	-0.56	-5.84	-0.34	1.5e-8	Coronary artery disease;
CESC	cis	rs875971	0.862	rs6460279	chr7:65662761	T/C	cg13147721	chr7:65941812	NA	0.37	5.04	0.3	8.53e-7	Aortic root size;
CESC	cis	rs793571	0.774	rs4775096	chr15:59140329	A/G	cg05156742	chr15:59063176	FAM63B	0.5	6.1	0.35	3.79e-9	Schizophrenia;
CESC	cis	rs7264396	0.570	rs1970576	chr20:34336720	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.62	7.46	0.42	1.24e-12	Total cholesterol levels;
CESC	cis	rs9359856	0.564	rs17292425	chr6:90372128	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.62	-5.7	-0.33	3.12e-8	Bipolar disorder;
CESC	cis	rs10779751	1.000	rs11121706	chr1:11302065	C/T	cg08854313	chr1:11322531	MTOR	0.79	11.12	0.56	7.87e-24	Body mass index;
CESC	cis	rs7520050	1.000	rs785473	chr1:46516863	T/C	cg03146154	chr1:46216737	IPP	-0.44	-5.72	-0.33	2.88e-8	Red blood cell count;Reticulocyte count;
CESC	cis	rs4713118	0.629	rs203887	chr6:28021269	C/T	cg23281280	chr6:28129359	ZNF389	0.48	5.84	0.34	1.52e-8	Parkinson's disease;
CESC	cis	rs2637266	0.783	rs7898786	chr10:78481338	T/C	cg18941641	chr10:78392320	NA	0.44	8.37	0.46	3.27e-15	Pulmonary function;
CESC	cis	rs875971	0.660	rs10281080	chr7:66042441	T/C	cg11764359	chr7:65958608	NA	-0.73	-9.77	-0.51	1.93e-19	Aortic root size;
CESC	trans	rs561341	1.000	rs7210970	chr17:30262169	G/A	cg20587970	chr11:113659929	NA	-0.8	-9.97	-0.52	4.47e-20	Hip circumference adjusted for BMI;
CESC	cis	rs6952808	0.929	rs34145223	chr7:1926237	G/A	cg23048001	chr7:2026167	MAD1L1	0.4	5.14	0.3	5.34e-7	Bipolar disorder and schizophrenia;
CESC	trans	rs10411161	0.702	rs10420224	chr19:52398955	A/G	cg22319618	chr22:45562946	NUP50	-0.75	-7.3	-0.41	3.33e-12	Breast cancer;
CESC	cis	rs58235267	0.656	rs12713469	chr2:63059927	C/T	cg17519650	chr2:63277830	OTX1	-0.68	-9.84	-0.52	1.1e-19	Prostate-specific antigen levels (conditioned on lead SNPs);
CESC	cis	rs910316	0.967	rs4384542	chr14:75658013	A/C	cg16144293	chr14:75469539	EIF2B2	0.39	5.13	0.3	5.74e-7	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23521069	chr14:39583513	SIP1	-0.59	-7.06	-0.4	1.44e-11	Gut microbiome composition (summer);
CESC	cis	rs2933343	0.649	rs789214	chr3:128594995	A/G	cg24203234	chr3:128598194	ACAD9	0.44	5.9	0.34	1.09e-8	IgG glycosylation;
CESC	cis	rs4132509	1.000	rs7534117	chr1:243964902	A/C	cg21452805	chr1:244014465	NA	-0.4	-5.13	-0.3	5.53e-7	RR interval (heart rate);
CESC	cis	rs2637266	1.000	rs10824425	chr10:78340310	C/G	cg18941641	chr10:78392320	NA	0.41	7.61	0.42	4.86e-13	Pulmonary function;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg04391736	chr16:69373674	COG8;NIP7	0.47	6.77	0.38	8.38e-11	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	7.83	0.43	1.17e-13	Prudent dietary pattern;
CESC	cis	rs2404602	0.716	rs17362383	chr15:76650702	A/G	cg22467129	chr15:76604101	ETFA	-0.39	-5.89	-0.34	1.15e-8	Blood metabolite levels;
CESC	trans	rs7944735	0.507	rs10838802	chr11:48102478	A/G	cg15704280	chr7:45808275	SEPT13	0.62	7.86	0.43	9.49e-14	Intraocular pressure;
CESC	cis	rs11190604	1.000	rs2495742	chr10:102331364	C/T	cg07080220	chr10:102295463	HIF1AN	0.64	5.85	0.34	1.46e-8	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs6964587	1.000	rs6964587	chr7:91630620	G/T	cg17063962	chr7:91808500	NA	0.56	7.72	0.43	2.41e-13	Breast cancer;
CESC	trans	rs916888	0.821	rs199504	chr17:44861003	C/T	cg22968622	chr17:43663579	NA	-1.21	-16.16	-0.7	2.31e-41	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	trans	rs324780	0.544	rs439870	chr12:83928582	A/G	cg22140261	chr22:42466895	NAGA	-0.48	-6.12	-0.35	3.34e-9	Vertical cup-disc ratio;
CESC	cis	rs1538970	1.000	rs9326141	chr1:45828943	A/G	cg06784218	chr1:46089804	CCDC17	-0.31	-5.08	-0.3	7.04e-7	Platelet count;
CESC	cis	rs4722166	0.695	rs7793125	chr7:22809160	A/G	cg05472934	chr7:22766657	IL6	0.61	8.09	0.44	2.21e-14	Lung cancer;
CESC	cis	rs6502050	0.835	rs8081783	chr17:80117388	G/A	cg11859384	chr17:80120422	CCDC57	-0.38	-5.18	-0.3	4.43e-7	Life satisfaction;
CESC	cis	rs2404602	0.583	rs2456076	chr15:76557553	T/G	cg22467129	chr15:76604101	ETFA	0.38	5.94	0.34	8.99e-9	Blood metabolite levels;
CESC	cis	rs853679	0.769	rs17720293	chr6:28214698	C/T	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.72	5.79	0.34	1.95e-8	Depression;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00134212	chr18:657361	C18orf56;TYMS	-0.61	-7.07	-0.4	1.41e-11	Gut microbiome composition (summer);
CESC	cis	rs13256369	1.000	rs13256369	chr8:8577379	T/C	cg17143192	chr8:8559678	CLDN23	0.72	8.54	0.46	1.07e-15	Obesity-related traits;
CESC	cis	rs6088580	0.634	rs1890000	chr20:32968312	G/T	cg08999081	chr20:33150536	PIGU	-0.65	-11.36	-0.57	1.22e-24	Glomerular filtration rate (creatinine);
CESC	cis	rs7129220	0.588	rs61878634	chr11:10140114	A/T	cg01453529	chr11:10209919	SBF2	-0.48	-5.63	-0.33	4.67e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CESC	cis	rs4740619	0.511	rs3008731	chr9:16003441	G/A	cg14451791	chr9:16040625	NA	-0.37	-5.81	-0.34	1.8e-8	Body mass index;
CESC	cis	rs4604732	0.642	rs7549312	chr1:247640078	C/G	cg12758973	chr1:247694275	LOC148824;OR2C3	0.38	5.38	0.31	1.63e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs6088590	1.000	rs2295353	chr20:33356511	C/T	cg08999081	chr20:33150536	PIGU	0.6	9.0	0.48	4.6e-17	Coronary artery disease;
CESC	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg11965913	chr1:205819406	PM20D1	0.83	12.87	0.62	9.23e-30	Menarche (age at onset);
CESC	cis	rs9308433	0.529	rs10465696	chr1:214499883	G/A	cg06198575	chr1:214491504	SMYD2	0.5	6.0	0.35	6.37e-9	IgG glycosylation;
CESC	cis	rs10504229	1.000	rs67705655	chr8:58177688	G/A	cg05313129	chr8:58192883	C8orf71	-0.55	-6.37	-0.36	8.42e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs10832963	1.000	rs2084220	chr11:18656932	C/T	cg09201001	chr11:18656081	SPTY2D1	0.82	12.44	0.61	2.79e-28	Breast cancer;
CESC	cis	rs12995491	0.933	rs34366691	chr2:88537451	G/A	cg18490616	chr2:88469792	THNSL2	-0.54	-8.06	-0.44	2.59e-14	Response to metformin (IC50);
CESC	cis	rs1552244	1.000	rs6807846	chr3:10134491	G/T	cg08888203	chr3:10149979	C3orf24	0.48	6.17	0.35	2.6e-9	Alzheimer's disease;
CESC	cis	rs6754311	0.597	rs6760329	chr2:136544752	A/G	cg07169764	chr2:136633963	MCM6	-0.73	-9.46	-0.5	1.76e-18	Mosquito bite size;
CESC	cis	rs4835473	0.750	rs56372690	chr4:144656969	T/A	cg25736465	chr4:144833511	NA	-0.33	-5.25	-0.31	3.06e-7	Immature fraction of reticulocytes;
CESC	cis	rs11098499	0.954	rs6847248	chr4:120225955	A/G	cg24375607	chr4:120327624	NA	0.47	5.46	0.32	1.07e-7	Corneal astigmatism;
CESC	cis	rs1448094	0.511	rs6539921	chr12:86164163	G/A	cg00310523	chr12:86230176	RASSF9	0.35	5.61	0.33	5.01e-8	Major depressive disorder;
CESC	cis	rs769267	0.895	rs2916074	chr19:19530270	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.57	7.33	0.41	2.86e-12	Tonsillectomy;
CESC	cis	rs763014	0.966	rs4984677	chr16:671682	A/G	cg07343612	chr16:622815	PIGQ	-0.57	-8.37	-0.46	3.44e-15	Height;
CESC	cis	rs938554	0.501	rs7671266	chr4:10056376	C/T	cg11266682	chr4:10021025	SLC2A9	-0.54	-7.6	-0.42	5.03e-13	Blood metabolite levels;
CESC	cis	rs1784581	0.500	rs9355379	chr6:162421466	C/T	cg17173639	chr6:162384350	PARK2	0.51	5.66	0.33	3.95e-8	Itch intensity from mosquito bite;
CESC	cis	rs7084402	0.967	rs1427198	chr10:60274970	T/G	cg07615347	chr10:60278583	BICC1	-0.57	-8.96	-0.48	6.01e-17	Refractive error;
CESC	trans	rs2727020	0.729	rs2866328	chr11:49282421	A/G	cg03929089	chr4:120376271	NA	0.79	11.91	0.59	1.7e-26	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13984512	chr1:145438431	TXNIP	0.58	7.15	0.4	8.65e-12	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.830	rs10470894	chr4:99039107	G/A	cg18180107	chr4:99064573	C4orf37	0.4	5.2	0.3	4.08e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs709400	0.628	rs7154246	chr14:103876794	G/A	cg12935359	chr14:103987150	CKB	0.48	7.16	0.4	8e-12	Body mass index;
CESC	cis	rs2836974	0.644	rs61300849	chr21:40680194	G/A	cg11890956	chr21:40555474	PSMG1	-0.97	-15.84	-0.7	3.36e-40	Cognitive function;
CESC	cis	rs1878931	0.535	rs10852706	chr16:3412582	G/C	cg02880119	chr16:3481970	NA	-0.41	-5.33	-0.31	2.06e-7	Body mass index (adult);
CESC	cis	rs4925386	0.559	rs2427291	chr20:60921324	G/A	cg12382846	chr20:60892121	LAMA5	0.45	5.77	0.33	2.16e-8	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CESC	trans	rs11227306	0.934	rs7102454	chr11:65594820	C/T	cg17712092	chr4:129076599	LARP1B	-0.63	-7.06	-0.4	1.47e-11	DNA methylation (variation);
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg16319310	chr10:52390957	NA	-0.51	-7.07	-0.4	1.38e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	trans	rs637571	0.522	rs7105628	chr11:65763067	C/T	cg17712092	chr4:129076599	LARP1B	0.75	10.38	0.54	2.16e-21	Eosinophil percentage of white cells;
CESC	cis	rs12931792	0.712	rs2887799	chr16:30163833	G/A	cg17640201	chr16:30407289	ZNF48	0.6	8.0	0.44	3.8e-14	Tonsillectomy;
CESC	cis	rs7927771	0.864	rs11600581	chr11:47448497	T/C	cg18512352	chr11:47633146	NA	-0.52	-7.38	-0.41	1.99e-12	Subjective well-being;
CESC	cis	rs2014572	0.870	rs10426580	chr19:57756221	G/A	cg12963866	chr19:57752005	ZNF805	-0.49	-6.49	-0.37	4.09e-10	Hyperactive-impulsive symptoms;
CESC	cis	rs7103648	0.695	rs11039290	chr11:47572279	G/A	cg10504702	chr11:47789108	FNBP4	0.43	5.23	0.31	3.52e-7	Diastolic blood pressure;Systolic blood pressure;
CESC	cis	rs709400	0.628	rs10141120	chr14:103923008	T/C	cg12935359	chr14:103987150	CKB	-0.51	-7.46	-0.42	1.24e-12	Body mass index;
CESC	cis	rs796364	1.000	rs796364	chr2:200716119	C/A	cg23649088	chr2:200775458	C2orf69	0.55	5.22	0.31	3.54e-7	Schizophrenia;
CESC	cis	rs10461617	0.512	rs7715746	chr5:56048837	C/T	cg24531977	chr5:56204891	C5orf35	-0.64	-8.18	-0.45	1.2e-14	Type 2 diabetes;
CESC	cis	rs4862750	0.914	rs1991255	chr4:187875340	G/A	cg11301795	chr4:187892539	NA	-0.72	-11.06	-0.56	1.3e-23	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00871673	chr12:122516220	MLXIP	0.59	6.75	0.38	9.07e-11	Gut microbiome composition (summer);
CESC	cis	rs6032067	0.925	rs13042522	chr20:43829290	G/A	cg10761708	chr20:43804764	PI3	0.52	6.15	0.35	2.77e-9	Blood protein levels;
CESC	cis	rs10191773	0.535	rs11123133	chr2:112965023	G/A	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.68	-6.92	-0.39	3.36e-11	Yeast infection;
CESC	cis	rs4629180	0.651	rs9653468	chr2:102108403	A/G	cg04415270	chr2:102091202	RFX8	-0.3	-5.19	-0.3	4.25e-7	Chronic rhinosinusitis with nasal polyps;
CESC	cis	rs11203032	1.000	rs61853072	chr10:90961500	A/T	cg16672925	chr10:90967113	CH25H	0.75	7.18	0.4	7.13e-12	Heart failure;
CESC	cis	rs854765	0.520	rs9899355	chr17:17898243	C/T	cg16928487	chr17:17741425	SREBF1	-0.47	-7.6	-0.42	5.21e-13	Total body bone mineral density;
CESC	cis	rs9322193	0.607	rs9371228	chr6:150243113	G/A	cg01145232	chr6:150245071	RAET1G	-0.56	-7.2	-0.4	6.1e-12	Lung cancer;
CESC	cis	rs829661	0.947	rs829665	chr2:30724701	T/A	cg03795903	chr2:30669940	LCLAT1	0.65	5.63	0.33	4.6e-8	Midgestational circulating levels of PBDEs (fetal genetic effect);
CESC	trans	rs17143387	0.614	rs11597013	chr10:8345388	C/G	cg21762820	chr1:166135233	FAM78B	0.51	6.1	0.35	3.67e-9	Scalp hair shape;
CESC	cis	rs611744	0.647	rs585077	chr8:109245497	C/T	cg21045802	chr8:109455806	TTC35	0.45	5.53	0.32	7.53e-8	Dupuytren's disease;
CESC	cis	rs2243480	0.522	rs778717	chr7:65848151	G/C	cg13147721	chr7:65941812	NA	-0.86	-6.39	-0.37	7.4e-10	Diabetic kidney disease;
CESC	cis	rs6582630	0.555	rs11181657	chr12:38381858	T/C	cg26384229	chr12:38710491	ALG10B	-0.68	-10.43	-0.54	1.4e-21	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs3820068	0.608	rs7514858	chr1:16035246	G/A	cg17385448	chr1:15911702	AGMAT	0.38	6.08	0.35	4.28e-9	Systolic blood pressure;
CESC	cis	rs733592	0.524	rs10875741	chr12:48492922	A/C	cg04545296	chr12:48745243	ZNF641	-0.3	-5.54	-0.32	7.37e-8	Plateletcrit;
CESC	cis	rs1348850	0.914	rs2364854	chr2:178378452	T/A	cg23306229	chr2:178417860	TTC30B	0.62	7.97	0.44	4.84e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs7249142	0.562	rs1050544	chr19:19287901	A/G	cg27384695	chr19:19271486	LOC729991-MEF2B;MEF2B	0.28	5.21	0.3	3.8e-7	IgG glycosylation;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27345282	chr3:196295526	WDR53;FBXO45	0.55	6.14	0.35	3.02e-9	Gut microbiome composition (summer);
CESC	cis	rs11997175	0.603	rs7386384	chr8:33782471	C/T	ch.8.33884649F	chr8:33765107	NA	0.49	5.88	0.34	1.23e-8	Body mass index;
CESC	cis	rs2294693	0.945	rs9349175	chr6:40982401	T/C	cg14769373	chr6:40998127	UNC5CL	-0.5	-6.43	-0.37	5.95e-10	Gastric cancer;Non-cardia gastric cancer;
CESC	cis	rs2836950	0.762	rs8134638	chr21:40644170	T/C	cg17971929	chr21:40555470	PSMG1	-0.62	-7.49	-0.42	1e-12	Menarche (age at onset);
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg15882797	chr19:7615191	PNPLA6	0.52	6.96	0.39	2.72e-11	Cleft plate (environmental tobacco smoke interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11674231	chr7:5821297	RNF216	0.52	6.39	0.37	7.45e-10	Gut microbiome composition (summer);
CESC	cis	rs7618915	0.531	rs77146033	chr3:52701501	G/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.5	7.23	0.41	5.08e-12	Bipolar disorder;
CESC	cis	rs1062177	0.774	rs2964574	chr5:151155711	G/A	cg00977110	chr5:151150581	G3BP1	0.62	6.76	0.38	8.65e-11	Preschool internalizing problems;
CESC	cis	rs748404	0.631	rs2412781	chr15:43667900	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.54	-8.45	-0.46	1.99e-15	Lung cancer;
CESC	cis	rs12477438	0.765	rs6750876	chr2:99679673	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.62	-8.67	-0.47	4.43e-16	Chronic sinus infection;
CESC	cis	rs1953600	0.870	rs2573370	chr10:81951366	C/T	cg00277334	chr10:82204260	NA	0.45	6.28	0.36	1.4e-9	Sarcoidosis;
CESC	cis	rs6433857	0.657	rs6756509	chr2:181500273	T/C	cg23363182	chr2:181467187	NA	-0.45	-6.8	-0.39	6.88e-11	Body mass index;
CESC	cis	rs4819052	0.851	rs2838832	chr21:46664904	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.75	-9.82	-0.52	1.31e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs7193541	0.510	rs79473128	chr16:74589192	G/A	cg01733217	chr16:74700730	RFWD3	0.84	11.38	0.57	1.07e-24	Multiple myeloma;
CESC	cis	rs67311347	1.000	rs7631893	chr3:40440869	C/T	cg01475735	chr3:40494733	NA	-0.42	-5.54	-0.32	7.28e-8	Renal cell carcinoma;
CESC	cis	rs10899021	0.512	rs2186955	chr11:74375475	C/T	cg25880958	chr11:74394337	NA	0.53	6.81	0.39	6.48e-11	Response to metformin (IC50);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11176342	chr11:18344099	HPS5;GTF2H1	0.57	6.02	0.35	5.73e-9	Gut microbiome composition (summer);
CESC	cis	rs67460515	0.665	rs28384382	chr3:160939141	C/T	cg03342759	chr3:160939853	NMD3	-0.57	-7.74	-0.43	2.11e-13	Parkinson's disease;
CESC	cis	rs72781680	0.611	rs72797819	chr2:24351141	T/G	cg20701182	chr2:24300061	SF3B14	0.91	10.23	0.53	6.45e-21	Lymphocyte counts;
CESC	cis	rs2439831	0.867	rs3213990	chr15:43670226	C/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.91	10.98	0.56	2.32e-23	Lung cancer in ever smokers;
CESC	cis	rs9902453	0.934	rs34433787	chr17:28496780	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	7.84	0.43	1.08e-13	Coffee consumption (cups per day);
CESC	cis	rs12142240	0.698	rs9661240	chr1:46827050	G/A	cg00530320	chr1:46809349	NSUN4	0.6	8.04	0.44	2.96e-14	Menopause (age at onset);
CESC	cis	rs425277	0.606	rs3128295	chr1:2068480	C/T	cg16545954	chr1:2118288	C1orf86	-0.35	-6.45	-0.37	5.23e-10	Height;
CESC	cis	rs929354	0.772	rs6969244	chr7:157004012	A/G	cg05182265	chr7:156933206	UBE3C	-0.51	-7.47	-0.42	1.16e-12	Body mass index;
CESC	cis	rs9902453	0.904	rs6505148	chr17:28289818	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.7	9.34	0.5	4.05e-18	Coffee consumption (cups per day);
CESC	cis	rs2050392	0.965	rs2265368	chr10:30690289	G/C	cg18806716	chr10:30721971	MAP3K8	-0.39	-5.6	-0.33	5.35e-8	Inflammatory bowel disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20796294	chr1:220219430	EPRS	0.55	6.14	0.35	2.98e-9	Gut microbiome composition (summer);
CESC	cis	rs11690935	0.959	rs10174525	chr2:172635697	T/C	cg13550731	chr2:172543902	DYNC1I2	-1.02	-16.98	-0.72	2.91e-44	Schizophrenia;
CESC	cis	rs7116495	1.000	rs679926	chr11:71769936	A/G	cg10381502	chr11:71823885	C11orf51	0.68	5.81	0.34	1.81e-8	Severe influenza A (H1N1) infection;
CESC	cis	rs78456975	0.527	rs4073862	chr2:1563433	A/G	cg12573674	chr2:1569213	NA	-0.43	-5.11	-0.3	6.09e-7	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs951366	0.966	rs11240565	chr1:205722958	C/T	cg11965913	chr1:205819406	PM20D1	-0.47	-6.48	-0.37	4.5e-10	Menarche (age at onset);
CESC	cis	rs8062405	0.755	rs56272201	chr16:28580685	A/G	cg07382826	chr16:28625726	SULT1A1	0.39	6.29	0.36	1.34e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs977987	0.835	rs8057535	chr16:75347941	C/T	cg03315344	chr16:75512273	CHST6	0.39	5.59	0.32	5.55e-8	Dupuytren's disease;
CESC	cis	rs12134245	0.776	rs6688261	chr1:91987034	C/T	cg21854759	chr1:92012499	NA	-0.44	-5.65	-0.33	4.18e-8	Breast cancer;
CESC	cis	rs896854	0.631	rs10097617	chr8:95961626	T/C	cg09323728	chr8:95962352	TP53INP1	-0.44	-10.1	-0.53	1.69e-20	Type 2 diabetes;
CESC	cis	rs4713118	0.513	rs149954	chr6:28035246	G/A	cg12963246	chr6:28129442	ZNF389	0.39	5.65	0.33	4.21e-8	Parkinson's disease;
CESC	cis	rs1552244	0.882	rs36006511	chr3:10054191	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.87	11.45	0.58	6.38e-25	Alzheimer's disease;
CESC	cis	rs853679	0.546	rs175597	chr6:27810626	T/C	cg02228804	chr6:27775720	HIST1H2AI;HIST1H2BL	0.62	5.28	0.31	2.69e-7	Depression;
CESC	cis	rs1008375	0.932	rs4698628	chr4:17608620	A/G	cg02297831	chr4:17616191	MED28	0.52	6.53	0.37	3.27e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22542420	chr17:43183176	NMT1	-0.55	-6.14	-0.35	2.94e-9	Gut microbiome composition (summer);
CESC	cis	rs2191566	0.821	rs62119173	chr19:44518073	G/A	cg20607764	chr19:44506953	ZNF230	-0.58	-7.58	-0.42	5.8e-13	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs9584850	0.708	rs4411372	chr13:99130423	T/C	cg20750642	chr13:99100586	FARP1	-0.37	-5.39	-0.31	1.53e-7	Neuroticism;
CESC	cis	rs6545883	0.895	rs4430924	chr2:61703856	A/G	cg15711740	chr2:61764176	XPO1	-0.4	-5.05	-0.3	8.35e-7	Tuberculosis;
CESC	cis	rs116095464	0.558	rs6875291	chr5:264192	T/C	cg12570787	chr5:219185	SDHA;CCDC127	0.53	5.49	0.32	9.44e-8	Breast cancer;
CESC	cis	rs2279817	0.908	rs3766310	chr1:17977642	A/C	cg21791023	chr1:18019539	ARHGEF10L	-0.68	-8.09	-0.45	2.11e-14	Neuroticism;
CESC	cis	rs7714584	1.000	rs6579803	chr5:150255559	C/T	cg22134413	chr5:150180641	NA	0.51	5.92	0.34	9.88e-9	Crohn's disease;
CESC	cis	rs1050631	0.592	rs1631346	chr18:33709664	T/G	cg25426722	chr18:33708991	SLC39A6;ELP2	0.57	7.9	0.44	7.63e-14	Esophageal squamous cell cancer (length of survival);
CESC	cis	rs1707322	0.752	rs7541962	chr1:46235117	G/A	cg03146154	chr1:46216737	IPP	0.81	11.49	0.58	4.45e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2243480	1.000	rs6949812	chr7:65387101	G/A	cg18252515	chr7:66147081	NA	-1.07	-9.84	-0.52	1.12e-19	Diabetic kidney disease;
CESC	cis	rs1801251	0.711	rs778339	chr2:233739678	T/C	cg25237894	chr2:233734115	C2orf82	-0.5	-8.81	-0.48	1.67e-16	Coronary artery disease;
CESC	cis	rs2011503	1.000	rs78883953	chr19:19630002	G/A	cg11584989	chr19:19387371	SF4	0.61	7.03	0.4	1.79e-11	Bipolar disorder;
CESC	cis	rs1595825	0.891	rs16824631	chr2:198708695	T/G	cg00982548	chr2:198649783	BOLL	-0.49	-5.19	-0.3	4.16e-7	Ulcerative colitis;
CESC	cis	rs72781680	0.561	rs72783615	chr2:24296397	C/A	cg20701182	chr2:24300061	SF3B14	0.94	10.39	0.54	2.01e-21	Lymphocyte counts;
CESC	cis	rs15676	0.947	rs1572912	chr9:131565554	T/C	cg00228799	chr9:131580591	ENDOG	-0.42	-5.09	-0.3	6.81e-7	Blood metabolite levels;
CESC	cis	rs34734847	0.703	rs3794215	chr12:121168083	T/C	cg26008908	chr12:120799332	MSI1	0.34	5.32	0.31	2.17e-7	Mean corpuscular volume;
CESC	cis	rs7044106	0.762	rs7849566	chr9:123460769	A/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.77	11.25	0.57	2.87e-24	Hip circumference adjusted for BMI;
CESC	cis	rs28374715	0.681	rs8037574	chr15:41630770	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.78	-11.24	-0.57	3.19e-24	Ulcerative colitis;
CESC	cis	rs7481584	0.624	rs413368	chr11:3047646	C/G	cg25174290	chr11:3078921	CARS	-0.46	-6.4	-0.37	6.86e-10	Calcium levels;
CESC	cis	rs796364	0.951	rs11897245	chr2:201063644	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.57	5.54	0.32	7.17e-8	Schizophrenia;
CESC	cis	rs4604732	0.536	rs12074913	chr1:247631607	G/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.52	6.44	0.37	5.54e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	trans	rs916888	0.773	rs199447	chr17:44812188	C/T	cg27125505	chr17:43679177	LOC644172	0.5	6.65	0.38	1.65e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs72772090	0.539	rs17481856	chr5:96116808	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.57	-5.19	-0.3	4.24e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs1832871	0.683	rs11756200	chr6:158657736	A/G	cg07165851	chr6:158734300	TULP4	0.62	6.3	0.36	1.23e-9	Height;
CESC	trans	rs864643	0.678	rs1609647	chr3:39533071	C/T	cg21413947	chr1:165329957	NA	0.41	6.05	0.35	5.04e-9	Attention deficit hyperactivity disorder;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg02334771	chr22:38577945	PLA2G6	-0.48	-6.3	-0.36	1.21e-9	Asthma;
CESC	cis	rs6952808	0.630	rs1860832	chr7:2161849	G/A	cg04267008	chr7:1944627	MAD1L1	-0.58	-7.02	-0.4	1.84e-11	Bipolar disorder and schizophrenia;
CESC	trans	rs7618501	0.633	rs11130234	chr3:50024758	G/T	cg21659725	chr3:3221576	CRBN	0.54	7.55	0.42	7.09e-13	Intelligence (multi-trait analysis);
CESC	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.89	13.55	0.64	3.99e-32	Prudent dietary pattern;
CESC	cis	rs7618501	0.602	rs6780731	chr3:50017478	A/G	cg24110177	chr3:50126178	RBM5	-0.54	-7.36	-0.41	2.31e-12	Intelligence (multi-trait analysis);
CESC	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg17178900	chr1:205818956	PM20D1	0.8	12.7	0.62	3.44e-29	Menarche (age at onset);
CESC	cis	rs853679	0.546	rs200948	chr6:27835272	T/C	cg02228804	chr6:27775720	HIST1H2AI;HIST1H2BL	0.64	5.44	0.32	1.21e-7	Depression;
CESC	cis	rs208520	1.000	rs28773210	chr6:66993566	C/T	cg07460842	chr6:66804631	NA	0.88	9.99	0.52	3.87e-20	Exhaled nitric oxide output;
CESC	cis	rs4409675	0.549	rs72872888	chr1:28239809	G/A	cg23691781	chr1:28212827	C1orf38	0.28	5.47	0.32	1.06e-7	Corneal astigmatism;
CESC	cis	rs72634258	0.786	rs7514098	chr1:8177632	G/A	cg00042356	chr1:8021962	PARK7	0.54	5.82	0.34	1.71e-8	Inflammatory bowel disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg13710816	chr19:8478019	MARCH2	-0.42	-6.02	-0.35	5.72e-9	Fibrinogen levels;
CESC	cis	rs10979	1.000	rs9376762	chr6:143887248	G/A	cg25407410	chr6:143891975	LOC285740	-0.61	-9.14	-0.49	1.72e-17	Hypospadias;
CESC	cis	rs34779708	0.931	rs4934702	chr10:35323074	T/C	cg04310649	chr10:35416472	CREM	-0.48	-5.79	-0.34	1.96e-8	Inflammatory bowel disease;Crohn's disease;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03670158	chr17:41323431	NBR1	0.52	6.83	0.39	5.7e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs6598163	0.517	rs10902453	chr12:132297091	G/T	cg07389463	chr12:132296394	NA	-0.42	-6.01	-0.35	6.07e-9	Migraine;
CESC	cis	rs17376456	1.000	rs12188453	chr5:93560807	G/T	cg21475434	chr5:93447410	FAM172A	-0.82	-7.0	-0.4	2.08e-11	Diabetic retinopathy;
CESC	trans	rs1908814	0.516	rs58869268	chr8:11797095	G/C	cg15556689	chr8:8085844	FLJ10661	0.52	6.44	0.37	5.68e-10	Neuroticism;
CESC	cis	rs2073300	0.609	rs34648279	chr20:23402935	T/G	cg16736954	chr20:23401023	NAPB	0.78	5.69	0.33	3.37e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg11494091	chr17:61959527	GH2	0.73	12.66	0.61	4.86e-29	Prudent dietary pattern;
CESC	cis	rs7772486	0.790	rs2253764	chr6:146199881	T/A	cg23711669	chr6:146136114	FBXO30	0.89	13.21	0.63	5.9e-31	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs769267	0.930	rs751856	chr19:19602945	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.47	5.88	0.34	1.22e-8	Tonsillectomy;
CESC	cis	rs9399135	0.935	rs4273704	chr6:135297520	G/T	cg24558204	chr6:135376177	HBS1L	0.5	6.75	0.38	9.09e-11	Red blood cell count;
CESC	cis	rs858239	0.665	rs858305	chr7:23242830	C/G	cg23682824	chr7:23144976	KLHL7	-0.43	-5.58	-0.32	5.91e-8	Cerebrospinal fluid biomarker levels;
CESC	cis	rs6460942	0.591	rs6945587	chr7:12356992	G/A	cg20607287	chr7:12443886	VWDE	-0.59	-6.32	-0.36	1.12e-9	Coronary artery disease;
CESC	cis	rs4665809	1.000	rs7588802	chr2:26277789	A/G	cg26314531	chr2:26401878	FAM59B	-0.7	-7.87	-0.44	9.29e-14	Gut microbiome composition (summer);
CESC	cis	rs9300255	0.722	rs12322888	chr12:123825559	A/G	cg00376283	chr12:123451042	ABCB9	0.59	6.85	0.39	5.1e-11	Neutrophil percentage of white cells;
CESC	cis	rs9291683	0.546	rs4575994	chr4:9997979	G/A	cg02734326	chr4:10020555	SLC2A9	0.47	6.4	0.37	6.98e-10	Bone mineral density;
CESC	cis	rs7811142	1.000	rs67315960	chr7:100015124	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.78	6.81	0.39	6.5e-11	Platelet count;
CESC	cis	rs11676348	1.000	rs11676348	chr2:219010146	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.46	-6.08	-0.35	4.18e-9	Ulcerative colitis;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg12377424	chr6:10412286	TFAP2A	0.49	6.4	0.37	6.86e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg20119798	chr7:94954144	PON1	-0.33	-5.27	-0.31	2.81e-7	Paraoxonase activity;
CESC	cis	rs3092073	0.669	rs11697323	chr20:44551579	C/T	cg27529037	chr20:44575021	PCIF1	0.64	9.81	0.52	1.44e-19	Intelligence (multi-trait analysis);
CESC	cis	rs10870270	0.957	rs3753008	chr10:133785129	A/C	cg26149184	chr10:133730230	NA	0.37	5.09	0.3	6.86e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs9287719	0.967	rs6712406	chr2:10754420	A/G	cg00105475	chr2:10696890	NA	0.38	5.42	0.32	1.34e-7	Prostate cancer;
CESC	cis	rs60871478	0.636	rs12532761	chr7:905229	C/T	cg15782153	chr7:917662	C7orf20	0.52	5.47	0.32	1.02e-7	Cerebrospinal P-tau181p levels;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg20979128	chr1:16271176	ZBTB17	0.43	5.99	0.35	6.66e-9	Fibrinogen levels;
CESC	cis	rs9948	0.655	rs62156216	chr2:97405127	C/T	cg01990225	chr2:97406019	LMAN2L	-1.02	-7.77	-0.43	1.76e-13	Erectile dysfunction and prostate cancer treatment;
CESC	cis	rs6987853	0.636	rs6988165	chr8:42351176	C/G	cg09913449	chr8:42400586	C8orf40	-0.36	-5.91	-0.34	1.03e-8	Mean corpuscular hemoglobin concentration;
CESC	cis	rs6502050	0.835	rs8080423	chr17:80102279	A/G	cg23985595	chr17:80112537	CCDC57	-0.42	-6.57	-0.37	2.72e-10	Life satisfaction;
CESC	cis	rs7107174	1.000	rs4128206	chr11:78015952	A/C	cg02023728	chr11:77925099	USP35	0.37	5.46	0.32	1.07e-7	Testicular germ cell tumor;
CESC	cis	rs8078723	0.714	rs2241244	chr17:38153554	G/C	cg17467752	chr17:38218738	THRA	-0.57	-8.62	-0.47	6.23e-16	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CESC	cis	rs739401	0.527	rs423236	chr11:3065916	C/T	cg05729581	chr11:3078854	CARS	-0.39	-5.09	-0.3	6.65e-7	Longevity;
CESC	cis	rs6459788	0.693	rs11981578	chr7:157250133	C/T	cg06271696	chr7:157225062	NA	-0.37	-5.34	-0.31	1.98e-7	Epstein-Barr virus copy number in lymphoblastoid cell lines;
CESC	cis	rs11098499	0.909	rs1546502	chr4:120235898	A/G	cg24375607	chr4:120327624	NA	0.46	5.57	0.32	6.18e-8	Corneal astigmatism;
CESC	cis	rs4665809	0.887	rs6546716	chr2:26263836	A/G	cg25036284	chr2:26402008	FAM59B	-0.6	-6.91	-0.39	3.64e-11	Gut microbiome composition (summer);
CESC	cis	rs910316	0.687	rs11627442	chr14:75669649	A/G	cg11812906	chr14:75593930	NEK9	-0.76	-11.47	-0.58	5.58e-25	Height;
CESC	cis	rs863345	0.933	rs1157523	chr1:158457638	G/T	cg12129480	chr1:158549410	OR10X1	-0.3	-6.02	-0.35	5.77e-9	Pneumococcal bacteremia;
CESC	cis	rs2361718	0.521	rs2361724	chr17:78099114	G/A	cg14949292	chr17:78079608	GAA	-0.35	-5.15	-0.3	5.02e-7	Yeast infection;
CESC	cis	rs13720	0.778	rs163783	chr20:57567730	A/C	cg23907860	chr20:57583709	CTSZ	-0.46	-5.63	-0.33	4.67e-8	Platelet distribution width;
CESC	cis	rs1144333	1.000	rs5745542	chr1:76365073	C/G	cg10523679	chr1:76189770	ACADM	0.56	5.2	0.3	3.94e-7	Attention function in attention deficit hyperactive disorder;
CESC	cis	rs7618915	0.547	rs8906	chr3:52739520	T/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	5.61	0.33	5.09e-8	Bipolar disorder;
CESC	cis	rs9858542	0.953	rs9821311	chr3:49543656	C/T	cg03060546	chr3:49711283	APEH	-0.55	-6.28	-0.36	1.34e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs7296418	0.961	rs4148862	chr12:123568619	A/C	cg05973401	chr12:123451056	ABCB9	0.59	7.5	0.42	9.64e-13	Platelet count;
CESC	cis	rs1448094	0.512	rs12314318	chr12:86249238	T/C	cg00310523	chr12:86230176	RASSF9	0.35	5.46	0.32	1.1e-7	Major depressive disorder;
CESC	cis	rs2644899	0.859	rs2545757	chr19:41297302	A/G	cg24958765	chr19:41283667	RAB4B	-0.57	-6.44	-0.37	5.52e-10	Post bronchodilator FEV1/FVC ratio;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23940655	chr14:74227020	C14orf43	0.62	6.88	0.39	4.36e-11	Gut microbiome composition (summer);
CESC	cis	rs2243480	1.000	rs34815098	chr7:65292254	A/C	cg12463550	chr7:65579703	CRCP	0.68	5.74	0.33	2.59e-8	Diabetic kidney disease;
CESC	cis	rs10838687	0.736	rs16938581	chr11:47271039	G/A	cg25783544	chr11:47291846	MADD	0.55	6.28	0.36	1.38e-9	Proinsulin levels;
CESC	cis	rs950776	0.593	rs680244	chr15:78871288	T/C	cg06917634	chr15:78832804	PSMA4	-0.59	-7.85	-0.43	1.01e-13	Sudden cardiac arrest;
CESC	cis	rs9902453	0.765	rs2617883	chr17:28120488	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-10.34	-0.54	2.82e-21	Coffee consumption (cups per day);
CESC	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.64	7.2	0.4	6.15e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs3733585	0.699	rs7663079	chr4:9966771	T/C	cg00071950	chr4:10020882	SLC2A9	-0.7	-11.44	-0.57	6.82e-25	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.52	6.34	0.36	9.63e-10	Prudent dietary pattern;
CESC	cis	rs875971	0.862	rs1643375	chr7:65872677	T/C	cg18876405	chr7:65276391	NA	0.5	6.87	0.39	4.63e-11	Aortic root size;
CESC	cis	rs1218582	0.772	rs10796935	chr1:154891363	G/T	cg24250549	chr1:154909240	PMVK	0.75	11.19	0.57	4.8e-24	Prostate cancer;
CESC	cis	rs17666538	0.710	rs11987001	chr8:630755	T/C	cg02524346	chr8:600233	NA	0.8	5.62	0.33	4.76e-8	IgG glycosylation;
CESC	cis	rs25645	0.800	rs11078935	chr17:38192137	T/G	cg17344932	chr17:38183730	MED24;SNORD124	0.56	7.72	0.43	2.33e-13	Myeloid white cell count;
CESC	cis	rs3785574	0.962	rs8066463	chr17:61818390	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.59	7.18	0.4	6.93e-12	Height;
CESC	cis	rs739401	0.611	rs2239900	chr11:3030992	C/T	cg25174290	chr11:3078921	CARS	0.51	7.14	0.4	8.98e-12	Longevity;
CESC	cis	rs5769707	0.681	rs2071902	chr22:50034538	G/C	cg20744362	chr22:50050164	C22orf34	0.38	5.19	0.3	4.24e-7	Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs875971	0.929	rs6970860	chr7:65976634	A/G	cg18876405	chr7:65276391	NA	0.48	6.31	0.36	1.16e-9	Aortic root size;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg27289501	chr12:77378460	NA	0.49	6.48	0.37	4.53e-10	Fibrinogen levels;
CESC	cis	rs617219	0.853	rs1664552	chr5:78438492	A/C	cg22188827	chr5:78429774	NA	-0.43	-5.1	-0.3	6.62e-7	Betaine levels in individuals undergoing cardiac evaluation;
CESC	cis	rs4819052	0.851	rs2877018	chr21:46658306	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.91	13.24	0.63	4.51e-31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs7615952	0.576	rs12497295	chr3:125818650	G/A	cg15145296	chr3:125709740	NA	-0.56	-5.91	-0.34	1.06e-8	Blood pressure (smoking interaction);
CESC	cis	rs4523957	0.651	rs7212342	chr17:2084305	A/G	cg16513277	chr17:2031491	SMG6	-0.71	-10.17	-0.53	1.04e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs7177699	0.567	rs67745769	chr15:79124832	G/A	cg04896959	chr15:78267971	NA	0.33	5.12	0.3	5.82e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
CESC	cis	rs9457247	0.967	rs424185	chr6:167410907	C/T	cg23791538	chr6:167370224	RNASET2	-0.61	-8.81	-0.48	1.71e-16	Crohn's disease;
CESC	cis	rs6933660	0.683	rs8180642	chr6:151756612	A/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.44	-5.63	-0.33	4.51e-8	Menarche (age at onset);
CESC	cis	rs6752107	1.000	rs2241880	chr2:234183368	A/G	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.37	5.56	0.32	6.49e-8	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs7811142	1.000	rs2406253	chr7:100077273	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.83	8.12	0.45	1.74e-14	Platelet count;
CESC	cis	rs4662945	0.762	rs1453155	chr2:130226369	G/A	cg05962382	chr2:130345044	NA	-0.36	-5.2	-0.3	4.03e-7	Response to cytidine analogues (gemcitabine);
CESC	cis	rs9311474	0.508	rs17052256	chr3:52593119	A/G	cg17372223	chr3:52568218	NT5DC2	0.4	5.94	0.34	8.99e-9	Electroencephalogram traits;
CESC	cis	rs4665809	0.590	rs3806515	chr2:26466975	C/T	cg27170947	chr2:26402098	FAM59B	0.87	9.89	0.52	7.6e-20	Gut microbiome composition (summer);
CESC	cis	rs9527	0.637	rs7085104	chr10:104628873	A/G	cg15744005	chr10:104629667	AS3MT	-0.42	-6.28	-0.36	1.38e-9	Arsenic metabolism;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg13226924	chr17:2275664	SGSM2	0.49	6.44	0.37	5.6e-10	Fibrinogen levels;
CESC	cis	rs2011503	0.941	rs80146298	chr19:19426317	C/T	cg11584989	chr19:19387371	SF4	0.68	7.54	0.42	7.41e-13	Bipolar disorder;
CESC	cis	rs9733	0.596	rs72702557	chr1:150680130	A/G	cg22823121	chr1:150693482	HORMAD1	0.48	7.11	0.4	1.11e-11	Tonsillectomy;
CESC	cis	rs9902453	0.765	rs2628167	chr17:28064498	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.76	-10.16	-0.53	1.04e-20	Coffee consumption (cups per day);
CESC	cis	rs875971	0.862	rs10274883	chr7:66116091	C/T	cg18252515	chr7:66147081	NA	0.48	6.47	0.37	4.62e-10	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14162086	chr9:129279673	NA	-0.59	-7.11	-0.4	1.07e-11	Gut microbiome composition (summer);
CESC	cis	rs2797160	1.000	rs1739347	chr6:126014157	C/T	cg05901451	chr6:126070800	HEY2	0.48	6.8	0.39	6.78e-11	Endometrial cancer;
CESC	cis	rs1707322	0.717	rs12023439	chr1:46104636	C/T	cg03146154	chr1:46216737	IPP	0.81	11.48	0.58	5.05e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs6570726	0.935	rs385185	chr6:145814992	A/G	cg23711669	chr6:146136114	FBXO30	0.82	12.29	0.6	8.74e-28	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01563148	chr8:145623258	CPSF1	-0.57	-6.75	-0.38	9.16e-11	Gut microbiome composition (summer);
CESC	cis	rs1003719	0.715	rs2051398	chr21:38550258	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.55	7.37	0.41	2.15e-12	Eye color traits;
CESC	cis	rs561341	1.000	rs8064843	chr17:30245744	A/G	cg00745463	chr17:30367425	LRRC37B	-0.5	-5.23	-0.31	3.36e-7	Hip circumference adjusted for BMI;
CESC	cis	rs854765	0.547	rs28537385	chr17:17902135	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.61	8.83	0.48	1.44e-16	Total body bone mineral density;
CESC	cis	rs35110281	0.774	rs9978811	chr21:44998683	C/T	cg01579765	chr21:45077557	HSF2BP	-0.56	-9.74	-0.51	2.37e-19	Mean corpuscular volume;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg26614578	chr12:113623930	C12orf52;DDX54	-0.48	-6.36	-0.36	8.99e-10	Height;
CESC	cis	rs9818758	0.607	rs10049462	chr3:49309684	C/T	cg00383909	chr3:49044727	WDR6	0.8	6.13	0.35	3.1e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11582617	chr6:158589302	SERAC1;GTF2H5	0.61	7.25	0.41	4.58e-12	Gut microbiome composition (summer);
CESC	cis	rs7818688	0.697	rs78777150	chr8:95984411	C/G	cg16049864	chr8:95962084	TP53INP1	0.55	5.56	0.32	6.66e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs7927771	0.524	rs7107922	chr11:47669289	C/A	cg18512352	chr11:47633146	NA	0.34	5.28	0.31	2.74e-7	Subjective well-being;
CESC	cis	rs2777491	0.540	rs7164684	chr15:41705008	G/T	cg20272979	chr15:41787780	ITPKA	0.42	5.18	0.3	4.32e-7	Ulcerative colitis;
CESC	cis	rs7660520	0.524	rs4862101	chr4:183733177	T/C	cg12524338	chr4:183729343	NA	0.54	5.12	0.3	5.84e-7	Pediatric autoimmune diseases;
CESC	cis	rs28386778	0.700	rs12449555	chr17:62003982	T/A	cg07677032	chr17:61819896	STRADA	-0.51	-6.65	-0.38	1.65e-10	Prudent dietary pattern;
CESC	cis	rs2228479	0.702	rs11649501	chr16:89850957	A/T	cg04013166	chr16:89971882	TCF25	0.78	6.68	0.38	1.43e-10	Skin colour saturation;
CESC	cis	rs55788414	0.932	rs12102293	chr16:81181607	T/C	cg06400318	chr16:81190750	PKD1L2	-0.6	-7.13	-0.4	9.29e-12	Left ventricular obstructive tract defect (maternal effect);
CESC	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg18402987	chr7:1209562	NA	0.75	7.49	0.42	1.04e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs6933660	0.800	rs2046371	chr6:151754744	G/A	cg14416726	chr6:151773293	C6orf211;RMND1	-0.44	-5.62	-0.33	4.93e-8	Menarche (age at onset);
CESC	cis	rs6121246	0.909	rs6060870	chr20:30303299	C/T	cg13852791	chr20:30311386	BCL2L1	0.79	8.37	0.46	3.41e-15	Mean corpuscular hemoglobin;
CESC	cis	rs74181299	0.750	rs58342673	chr2:65347584	T/C	cg05010058	chr2:65284262	CEP68	-0.31	-5.15	-0.3	5.01e-7	Pulse pressure;
CESC	trans	rs10506458	1.000	rs73127086	chr12:63415626	G/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.31	-18.2	-0.75	1.42e-48	Hemostatic factors and hematological phenotypes;
CESC	cis	rs4604732	0.642	rs4472786	chr1:247636518	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.46	6.51	0.37	3.81e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs9611565	0.694	rs202618	chr22:41822856	A/G	cg06634786	chr22:41940651	POLR3H	0.71	7.17	0.4	7.6e-12	Vitiligo;
CESC	trans	rs10242455	0.702	rs58348977	chr7:99188014	G/A	cg09045935	chr12:6379348	NA	0.89	7.53	0.42	8.12e-13	Blood metabolite levels;
CESC	cis	rs9303401	0.614	rs35245220	chr17:56510305	G/A	cg25039879	chr17:56429692	SUPT4H1	0.53	5.19	0.3	4.16e-7	Cognitive test performance;
CESC	cis	rs1642645	0.872	rs3856258	chr1:42473397	A/G	cg16685388	chr1:42384056	HIVEP3	0.36	5.08	0.3	7.27e-7	Left ventricular obstructive tract defect (maternal effect);
CESC	cis	rs1005277	0.557	rs1854563	chr10:38434961	G/A	cg25427524	chr10:38739819	LOC399744	-0.67	-9.8	-0.52	1.46e-19	Extrinsic epigenetic age acceleration;
CESC	cis	rs1559088	0.948	rs7259333	chr19:33579128	T/C	cg17764715	chr19:33622953	WDR88	0.51	6.69	0.38	1.28e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	trans	rs11098499	0.954	rs4577559	chr4:120404043	T/G	cg25214090	chr10:38739885	LOC399744	0.72	10.18	0.53	9.16e-21	Corneal astigmatism;
CESC	cis	rs78456975	1.000	rs13413096	chr2:1553588	G/A	cg01028140	chr2:1542097	TPO	-0.51	-5.3	-0.31	2.48e-7	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs4853012	0.887	rs2280642	chr2:74358252	T/A	cg20891558	chr2:74357851	NA	0.84	11.48	0.58	4.88e-25	Gestational age at birth (maternal effect);
CESC	cis	rs1568889	1.000	rs12797155	chr11:28290866	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.79	10.67	0.55	2.45e-22	Bipolar disorder;
CESC	cis	rs7116495	0.609	rs7121080	chr11:71703935	G/A	cg10381502	chr11:71823885	C11orf51	-1.16	-7.94	-0.44	5.77e-14	Severe influenza A (H1N1) infection;
CESC	cis	rs7208859	0.623	rs9890855	chr17:29111707	G/C	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.17e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs6032067	1.000	rs13038434	chr20:43888106	G/A	cg10761708	chr20:43804764	PI3	0.48	5.48	0.32	9.91e-8	Blood protein levels;
CESC	cis	rs4563143	0.675	rs73029042	chr19:29267979	A/T	cg12667521	chr19:29218732	NA	0.48	6.4	0.37	6.97e-10	Methadone dose in opioid dependence;
CESC	cis	rs9611565	0.694	rs5758347	chr22:41821019	G/T	cg06481639	chr22:41940642	POLR3H	0.64	6.41	0.37	6.73e-10	Vitiligo;
CESC	cis	rs12681288	0.523	rs6983944	chr8:955147	A/G	cg15309053	chr8:964076	NA	0.51	8.68	0.47	4e-16	Schizophrenia;
CESC	cis	rs7089973	0.584	rs758585	chr10:116582560	C/A	cg23260525	chr10:116636907	FAM160B1	0.4	7.51	0.42	9.07e-13	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs2236918	0.710	rs2797603	chr1:242029027	T/G	cg17736920	chr1:242011382	EXO1	0.55	7.02	0.4	1.89e-11	Menopause (age at onset);
CESC	cis	rs7412746	0.658	rs57818453	chr1:150763139	G/A	cg09365446	chr1:150670422	GOLPH3L	0.38	5.03	0.3	9.22e-7	Melanoma;
CESC	cis	rs7178572	0.568	rs4886850	chr15:77404160	G/C	cg22256960	chr15:77711686	NA	-0.54	-6.76	-0.38	8.67e-11	Type 2 diabetes;
CESC	cis	rs9916302	0.861	rs8079590	chr17:37426201	T/C	cg00129232	chr17:37814104	STARD3	-0.53	-6.89	-0.39	4.12e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs7666738	0.830	rs34135615	chr4:99001325	C/T	cg05340658	chr4:99064831	C4orf37	0.8	12.44	0.61	2.83e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs853679	0.517	rs4713141	chr6:28101678	G/C	cg17949981	chr6:28129498	ZNF389	0.46	5.77	0.33	2.16e-8	Depression;
CESC	cis	rs6502955	1.000	rs6502955	chr17:6344127	C/G	cg23465990	chr17:6347153	FAM64A	-0.53	-6.29	-0.36	1.31e-9	Life satisfaction;
CESC	cis	rs7264396	0.790	rs6058283	chr20:34216276	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.87	-11.51	-0.58	4.04e-25	Total cholesterol levels;
CESC	cis	rs7208859	0.573	rs56031503	chr17:29075665	T/C	cg13385521	chr17:29058706	SUZ12P	0.82	6.69	0.38	1.3e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs10779751	0.734	rs2791648	chr1:11132638	G/T	cg08854313	chr1:11322531	MTOR	0.76	10.24	0.53	5.91e-21	Body mass index;
CESC	cis	rs2204008	0.604	rs11172718	chr12:38069819	T/C	cg26384229	chr12:38710491	ALG10B	0.66	9.39	0.5	2.96e-18	Bladder cancer;
CESC	cis	rs3126085	0.935	rs4326625	chr1:152223996	C/T	cg03465714	chr1:152285911	FLG	-0.45	-5.69	-0.33	3.29e-8	Atopic dermatitis;
CESC	cis	rs6502050	0.749	rs7406163	chr17:80086389	C/T	cg23985595	chr17:80112537	CCDC57	0.42	6.53	0.37	3.27e-10	Life satisfaction;
CESC	cis	rs9467603	0.547	rs7774567	chr6:25425526	C/T	cg21479132	chr6:26055353	NA	0.72	5.43	0.32	1.26e-7	Intelligence (multi-trait analysis);
CESC	cis	rs2120019	1.000	rs7173833	chr15:75369618	C/T	cg09165964	chr15:75287851	SCAMP5	-0.58	-6.91	-0.39	3.66e-11	Blood trace element (Zn levels);
CESC	cis	rs7833790	0.777	rs1005850	chr8:82692255	G/A	cg27398817	chr8:82754497	SNX16	-0.55	-6.74	-0.38	1e-10	Diastolic blood pressure;
CESC	cis	rs7851660	0.967	rs3021526	chr9:100617021	C/T	cg13688889	chr9:100608707	NA	-0.69	-10.57	-0.54	4.92e-22	Strep throat;
CESC	cis	rs10504229	1.000	rs113379801	chr8:58173686	C/G	cg14926445	chr8:58193284	C8orf71	-0.5	-5.44	-0.32	1.22e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs861020	0.630	rs686582	chr1:210008673	A/C	cg05527609	chr1:210001259	C1orf107	0.75	9.99	0.52	3.88e-20	Orofacial clefts;
CESC	cis	rs11146838	1	rs11146838	chr10:39149977	A/T	cg14646974	chr10:38645378	HSD17B7P2	-0.42	-5.07	-0.3	7.59e-7	Breast cancer;
CESC	cis	rs938554	0.542	rs7678287	chr4:10000501	A/G	cg11266682	chr4:10021025	SLC2A9	0.47	6.25	0.36	1.6e-9	Blood metabolite levels;
CESC	cis	rs10463316	0.862	rs7700650	chr5:150776473	C/T	cg03212797	chr5:150827313	SLC36A1	-0.45	-5.94	-0.34	9.07e-9	Metabolite levels (Pyroglutamine);
CESC	cis	rs138880	0.542	rs9616393	chr22:50314809	A/G	cg02269571	chr22:50332266	NA	0.59	6.14	0.35	3.04e-9	Schizophrenia;
CESC	cis	rs2115630	0.691	rs8040066	chr15:85176465	G/C	cg12501888	chr15:85177176	SCAND2	-0.5	-6.73	-0.38	1.07e-10	P wave terminal force;
CESC	cis	rs2425143	0.915	rs2378408	chr20:34367732	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	-0.72	-6.67	-0.38	1.52e-10	Blood protein levels;
CESC	trans	rs11098499	0.874	rs7661020	chr4:120106982	T/C	cg25214090	chr10:38739885	LOC399744	0.57	7.53	0.42	7.93e-13	Corneal astigmatism;
CESC	cis	rs7259376	0.905	rs56027264	chr19:22554354	T/C	cg02657401	chr19:22469223	NA	-0.25	-5.05	-0.3	8.34e-7	Menopause (age at onset);
CESC	trans	rs9467711	0.606	rs34104395	chr6:26478252	C/T	cg06606381	chr12:133084897	FBRSL1	-0.96	-7.02	-0.4	1.91e-11	Autism spectrum disorder or schizophrenia;
CESC	cis	rs12477438	0.834	rs1563108	chr2:99701153	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.72	-9.85	-0.52	1.06e-19	Chronic sinus infection;
CESC	cis	rs77972916	0.611	rs6709988	chr2:43601317	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.63	-6.06	-0.35	4.59e-9	Granulocyte percentage of myeloid white cells;
CESC	cis	rs2742417	0.565	rs2673031	chr3:45756986	A/G	cg04837898	chr3:45731254	SACM1L	-0.48	-6.55	-0.37	2.96e-10	Response to anti-depressant treatment in major depressive disorder;
CESC	cis	rs9616064	0.531	rs66909472	chr22:47050210	G/A	cg25730555	chr22:47059586	GRAMD4	0.46	5.73	0.33	2.71e-8	Urate levels in obese individuals;
CESC	trans	rs11989868	1.000	rs920613	chr8:14543372	C/T	cg22006392	chr17:927457	ABR	-0.43	-6.0	-0.35	6.42e-9	Obesity-related traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12445378	chr8:48741753	PRKDC	-0.57	-6.67	-0.38	1.45e-10	Gut microbiome composition (summer);
CESC	cis	rs3126085	0.935	rs1496051	chr1:152164923	G/A	cg26876637	chr1:152193138	HRNR	0.44	5.11	0.3	6.32e-7	Atopic dermatitis;
CESC	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.43	5.76	0.33	2.37e-8	Lymphocyte counts;
CESC	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg07167872	chr1:205819463	PM20D1	0.83	15.19	0.68	6.31e-38	Menarche (age at onset);
CESC	cis	rs6537837	0.838	rs12023950	chr1:110099858	T/C	cg05049280	chr1:110155535	GNAT2	0.41	5.79	0.33	2.02e-8	Major depressive disorder;
CESC	cis	rs736408	0.716	rs2300149	chr3:52822921	C/T	cg07507251	chr3:52567010	NT5DC2	0.33	5.37	0.31	1.71e-7	Bipolar disorder;
CESC	cis	rs1904096	0.506	rs11097408	chr4:95165662	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.61	-9.61	-0.51	5.84e-19	Type 2 diabetes;
CESC	cis	rs11696501	0.688	rs6073861	chr20:44325708	G/A	cg11783356	chr20:44313418	WFDC10B	-0.31	-5.08	-0.3	7.02e-7	Brain structure;
CESC	cis	rs9916302	0.851	rs7225096	chr17:37664443	T/C	cg20243544	chr17:37824526	PNMT	0.51	6.5	0.37	3.97e-10	Glomerular filtration rate (creatinine);
CESC	trans	rs11625487	0.957	rs28820314	chr14:77963272	A/C	cg20065768	chr16:29796685	NA	0.46	6.1	0.35	3.76e-9	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
CESC	cis	rs875971	0.862	rs778680	chr7:65840414	G/A	cg11764359	chr7:65958608	NA	0.81	11.87	0.59	2.48e-26	Aortic root size;
CESC	cis	rs17376456	0.877	rs10065056	chr5:93380123	G/T	cg25358565	chr5:93447407	FAM172A	1.11	11.1	0.56	9.57e-24	Diabetic retinopathy;
CESC	cis	rs6835098	0.924	rs13138282	chr4:174120906	C/T	cg08422745	chr4:174089978	GALNT7	0.72	9.25	0.49	7.78e-18	Dementia and core Alzheimer's disease neuropathologic changes;
CESC	cis	rs9611565	0.512	rs5758439	chr22:42131762	C/T	cg06634786	chr22:41940651	POLR3H	0.68	6.72	0.38	1.13e-10	Vitiligo;
CESC	cis	rs2228479	0.557	rs57071566	chr16:89889327	T/G	cg00800038	chr16:89945340	TCF25	-0.83	-6.64	-0.38	1.77e-10	Skin colour saturation;
CESC	cis	rs7618915	0.501	rs3852066	chr3:52621839	C/T	cg17372223	chr3:52568218	NT5DC2	0.42	6.42	0.37	6.33e-10	Bipolar disorder;
CESC	cis	rs3733585	0.579	rs4235356	chr4:10123106	G/C	cg11266682	chr4:10021025	SLC2A9	-0.57	-10.59	-0.55	4.26e-22	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs1707322	0.721	rs10890333	chr1:46100322	T/C	cg03146154	chr1:46216737	IPP	0.82	11.44	0.57	7.04e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs10242455	0.867	rs2740562	chr7:99319157	G/A	cg07715041	chr7:99302981	CYP3A7	-0.43	-5.42	-0.32	1.36e-7	Blood metabolite levels;
CESC	cis	rs11785400	0.731	rs4644221	chr8:143736984	C/T	cg24634471	chr8:143751801	JRK	-0.44	-5.77	-0.33	2.19e-8	Schizophrenia;
CESC	cis	rs11122272	0.735	rs2808586	chr1:231515559	C/T	cg06096015	chr1:231504339	EGLN1	0.43	6.18	0.35	2.46e-9	Hemoglobin concentration;
CESC	cis	rs7666738	0.830	rs6831219	chr4:98993576	C/A	cg17366294	chr4:99064904	C4orf37	0.6	8.61	0.47	6.47e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1062746	0.711	rs8056833	chr16:87378388	G/C	cg02258303	chr16:87377426	FBXO31	-0.49	-6.17	-0.35	2.5e-9	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26029786	chr10:65280952	REEP3	0.55	6.06	0.35	4.72e-9	Gut microbiome composition (summer);
CESC	cis	rs4975709	0.589	rs4975745	chr5:1861058	G/C	cg20790798	chr5:1857306	NA	-0.39	-5.13	-0.3	5.58e-7	Cardiovascular disease risk factors;
CESC	cis	rs10885582	0.754	rs10885574	chr10:116296487	C/T	cg17056676	chr10:116301354	ABLIM1	-0.28	-5.16	-0.3	4.84e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs977987	0.750	rs4888407	chr16:75432390	T/C	cg03315344	chr16:75512273	CHST6	0.41	5.98	0.34	7.36e-9	Dupuytren's disease;
CESC	cis	rs4665809	0.590	rs2891496	chr2:26452605	G/A	cg25036284	chr2:26402008	FAM59B	0.86	9.42	0.5	2.32e-18	Gut microbiome composition (summer);
CESC	cis	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg05863683	chr7:1912471	MAD1L1	-0.45	-6.83	-0.39	5.81e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs1008375	1.000	rs6818639	chr4:17633049	A/G	cg02297831	chr4:17616191	MED28	0.54	6.85	0.39	5.05e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs2836974	0.568	rs428602	chr21:40547004	A/G	cg11644478	chr21:40555479	PSMG1	0.82	12.28	0.6	9.99e-28	Cognitive function;
CESC	cis	rs2404602	0.716	rs7179142	chr15:76698268	G/A	cg26408565	chr15:76604113	ETFA	-0.41	-6.02	-0.35	5.86e-9	Blood metabolite levels;
CESC	cis	rs8020095	0.528	rs7152422	chr14:67392257	T/C	cg19548862	chr14:67692701	FAM71D	-0.5	-6.1	-0.35	3.83e-9	Depression (quantitative trait);
CESC	cis	rs72627123	0.867	rs117818304	chr14:74474396	T/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.76	5.04	0.3	8.56e-7	Morning vs. evening chronotype;
CESC	cis	rs9943753	0.525	rs7957928	chr12:109835975	C/G	cg19025524	chr12:109796872	NA	-0.48	-6.87	-0.39	4.51e-11	HDL cholesterol;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02408009	chr15:28422194	HERC2	-0.55	-6.51	-0.37	3.78e-10	Gut microbiome composition (summer);
CESC	cis	rs62158211	0.565	rs62158212	chr2:114106326	A/G	cg17784749	chr2:114082611	LOC440839	0.51	6.38	0.37	7.7e-10	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;
CESC	cis	rs11190604	1.000	rs2495734	chr10:102338686	G/A	cg07080220	chr10:102295463	HIF1AN	0.6	5.52	0.32	7.97e-8	Palmitoleic acid (16:1n-7) levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14132868	chr11:18343680	HPS5;GTF2H1	0.58	6.59	0.38	2.32e-10	Gut microbiome composition (summer);
CESC	cis	rs2576037	0.526	rs4258717	chr18:44456954	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.72	11.59	0.58	2.05e-25	Personality dimensions;
CESC	cis	rs644799	0.965	rs502521	chr11:95533557	T/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.54	6.61	0.38	2.07e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs10818894	0.772	rs10120705	chr9:126692600	T/G	cg16191174	chr9:126692580	DENND1A	0.62	8.0	0.44	3.99e-14	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
CESC	cis	rs9611565	0.559	rs132765	chr22:42008068	A/G	cg17376030	chr22:41985996	PMM1	-0.82	-9.02	-0.48	3.81e-17	Vitiligo;
CESC	cis	rs3096299	0.685	rs4785675	chr16:89539974	T/C	cg02187348	chr16:89574699	SPG7	0.66	9.18	0.49	1.27e-17	Multiple myeloma (IgH translocation);
CESC	cis	rs896854	0.846	rs7845219	chr8:95937502	T/C	cg26343298	chr8:95960752	TP53INP1	0.32	5.29	0.31	2.59e-7	Type 2 diabetes;
CESC	cis	rs1062177	1.000	rs973529	chr5:151188158	T/C	cg12924095	chr5:151150029	G3BP1	0.49	6.5	0.37	3.86e-10	Preschool internalizing problems;
CESC	cis	rs2777491	0.915	rs28526381	chr15:41621842	A/C	cg02330683	chr15:41787940	ITPKA	0.45	6.56	0.37	2.73e-10	Ulcerative colitis;
CESC	cis	rs208520	0.507	rs9453585	chr6:66796668	C/T	cg07460842	chr6:66804631	NA	-1.1	-26.24	-0.85	1.17e-75	Exhaled nitric oxide output;
CESC	cis	rs514406	0.830	rs533935	chr1:53308807	T/C	cg08736216	chr1:53307985	ZYG11A	-0.39	-6.55	-0.37	3.01e-10	Monocyte count;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg03045169	chr17:62503007	CCDC45;DDX5	0.45	6.07	0.35	4.45e-9	Systemic lupus erythematosus;
CESC	cis	rs7191439	0.858	rs2340973	chr16:88773396	G/A	cg27087555	chr16:88793112	FAM38A	-1.25	-9.87	-0.52	8.84e-20	Plateletcrit;
CESC	cis	rs4969178	0.965	rs12944051	chr17:76395856	C/T	cg20026190	chr17:76395443	PGS1	-0.46	-7.28	-0.41	3.83e-12	HDL cholesterol levels;
CESC	cis	rs2235544	0.554	rs605272	chr1:54467026	T/A	cg25741118	chr1:54482237	LDLRAD1	0.24	5.8	0.34	1.91e-8	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
CESC	cis	rs9322193	0.923	rs2151913	chr6:150130642	C/T	cg07701084	chr6:150067640	NUP43	0.43	5.8	0.34	1.87e-8	Lung cancer;
CESC	cis	rs17711722	0.528	rs73138179	chr7:65294482	G/T	cg14393609	chr7:65229607	NA	0.48	6.35	0.36	9.51e-10	Calcium levels;
CESC	cis	rs12142240	0.698	rs6683192	chr1:46830257	C/T	cg00530320	chr1:46809349	NSUN4	0.6	8.04	0.44	3.02e-14	Menopause (age at onset);
CESC	cis	rs1546924	0.647	rs197422	chr1:112317512	C/A	cg23955903	chr1:112298873	DDX20;C1orf183	0.43	5.45	0.32	1.16e-7	Body mass index;
CESC	cis	rs2197308	0.610	rs10880837	chr12:37864924	C/T	cg26384229	chr12:38710491	ALG10B	0.7	10.39	0.54	1.88e-21	Morning vs. evening chronotype;
CESC	cis	rs10504229	0.569	rs75466737	chr8:58055034	A/G	cg24829409	chr8:58192753	C8orf71	-0.7	-7.71	-0.43	2.5e-13	Developmental language disorder (linguistic errors);
CESC	cis	rs9322193	0.962	rs9689447	chr6:150110486	T/A	cg04369109	chr6:150039330	LATS1	-0.39	-5.35	-0.31	1.93e-7	Lung cancer;
CESC	cis	rs9905704	0.831	rs12949598	chr17:56707245	C/T	cg12560992	chr17:57184187	TRIM37	0.59	6.98	0.39	2.34e-11	Testicular germ cell tumor;
CESC	cis	rs2929278	0.617	rs12908467	chr15:44047430	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.53	-6.99	-0.39	2.19e-11	Schizophrenia;
CESC	cis	rs1927790	0.727	rs16953068	chr13:96949327	C/G	cg02571835	chr13:96230311	CLDN10	-0.39	-5.67	-0.33	3.71e-8	Body mass index;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06058891	chr20:45523134	EYA2	-0.58	-7.21	-0.4	5.76e-12	Gut microbiome composition (summer);
CESC	cis	rs1862618	0.754	rs252899	chr5:56188569	G/C	cg20203395	chr5:56204925	C5orf35	-0.43	-5.03	-0.3	9.1e-7	Initial pursuit acceleration;
CESC	cis	rs10504229	1.000	rs6989060	chr8:58178989	T/G	cg14926445	chr8:58193284	C8orf71	-0.51	-5.47	-0.32	1.03e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs920590	0.684	rs7461774	chr8:19666645	G/A	cg03894339	chr8:19674705	INTS10	0.7	7.9	0.44	7.58e-14	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs4237845	0.735	rs11172375	chr12:58291574	G/C	cg00677455	chr12:58241039	CTDSP2	0.62	7.7	0.43	2.7e-13	Intelligence (multi-trait analysis);
CESC	cis	rs7520050	0.966	rs9429183	chr1:46524582	G/A	cg03146154	chr1:46216737	IPP	-0.44	-5.73	-0.33	2.66e-8	Red blood cell count;Reticulocyte count;
CESC	cis	rs7777484	0.571	rs2527686	chr7:2834413	G/A	cg18446336	chr7:2847575	GNA12	-0.4	-6.68	-0.38	1.39e-10	Height;
CESC	cis	rs12142240	0.698	rs112089006	chr1:46812360	C/T	cg10495392	chr1:46806563	NSUN4	0.57	6.29	0.36	1.33e-9	Menopause (age at onset);
CESC	cis	rs73206853	0.841	rs56324794	chr12:111086449	T/A	cg12870014	chr12:110450643	ANKRD13A	0.63	5.23	0.31	3.5e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs470119	1.000	rs12148	chr22:50962208	T/G	cg12969734	chr22:50962224	SCO2	0.39	6.05	0.35	4.99e-9	Mean corpuscular hemoglobin;
CESC	cis	rs9488822	0.636	rs11153592	chr6:116330574	T/C	cg15226275	chr6:116381976	FRK	0.24	6.15	0.35	2.9e-9	Cholesterol, total;LDL cholesterol;
CESC	cis	rs7089973	0.604	rs11196929	chr10:116582080	G/C	cg03647239	chr10:116582469	FAM160B1	0.42	5.2	0.3	4.07e-7	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs6690583	0.623	rs2028304	chr1:85488030	G/A	cg22153463	chr1:85462885	MCOLN2	-0.77	-7.83	-0.43	1.19e-13	Serum sulfate level;
CESC	cis	rs2235544	0.613	rs651381	chr1:54450998	G/A	cg25741118	chr1:54482237	LDLRAD1	0.24	6.05	0.35	4.9e-9	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
CESC	cis	rs7188697	0.922	rs37036	chr16:58553348	T/C	cg02549819	chr16:58548995	SETD6	-0.41	-5.03	-0.3	9.12e-7	QT interval;
CESC	cis	rs992157	0.764	rs2015863	chr2:219185161	C/T	cg00012203	chr2:219082015	ARPC2	-0.59	-7.28	-0.41	3.84e-12	Colorectal cancer;
CESC	cis	rs1975974	0.590	rs113830378	chr17:21744147	G/C	cg18423549	chr17:21743878	NA	-0.68	-9.45	-0.5	1.84e-18	Psoriasis;
CESC	cis	rs12295403	1.000	rs12295403	chr11:18689653	G/T	cg09887367	chr11:18690185	NA	-0.37	-5.41	-0.32	1.42e-7	Ovarian reserve;
CESC	cis	rs7580658	0.680	rs6710535	chr2:128190960	C/G	cg10021288	chr2:128175891	PROC	0.37	5.52	0.32	8.23e-8	Protein C levels;
CESC	cis	rs3858526	0.883	rs7481882	chr11:5944221	A/G	cg05234568	chr11:5960015	NA	-0.64	-7.52	-0.42	8.7e-13	DNA methylation (variation);
CESC	trans	rs561341	1.000	rs55736640	chr17:30333848	G/A	cg20587970	chr11:113659929	NA	-1.5	-18.7	-0.75	2.41e-50	Hip circumference adjusted for BMI;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg24529269	chr15:89164510	AEN	-0.49	-6.5	-0.37	3.94e-10	Fibrinogen levels;
CESC	cis	rs9896933	0.623	rs77166830	chr17:80833525	T/C	cg15664640	chr17:80829946	TBCD	-0.53	-5.62	-0.33	4.83e-8	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
CESC	cis	rs832540	0.931	rs702679	chr5:56221328	A/G	cg12311346	chr5:56204834	C5orf35	-0.44	-5.53	-0.32	7.59e-8	Coronary artery disease;
CESC	cis	rs7208859	0.623	rs55814012	chr17:29077697	T/A	cg14008862	chr17:28927542	LRRC37B2	0.65	5.14	0.3	5.34e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs16917546	0.935	rs12766391	chr10:64441204	C/T	cg03961010	chr10:64397487	ZNF365	-0.35	-5.85	-0.34	1.47e-8	Basal cell carcinoma;
CESC	trans	rs6934970	0.860	rs4591889	chr6:112983901	T/A	cg05146922	chr2:10634174	NA	-0.37	-6.17	-0.35	2.53e-9	Bipolar disorder (body mass index interaction);
CESC	cis	rs4969178	0.895	rs2292640	chr17:76396610	G/A	cg05887092	chr17:76393375	PGS1	0.58	9.22	0.49	9.9e-18	HDL cholesterol levels;
CESC	cis	rs6502050	0.835	rs8070014	chr17:80115247	T/G	cg23985595	chr17:80112537	CCDC57	-0.41	-6.46	-0.37	4.9e-10	Life satisfaction;
CESC	cis	rs77216612	0.835	rs56692845	chr12:12887811	C/T	cg09462578	chr12:12878428	APOLD1	-0.97	-14.4	-0.66	4.1e-35	Lymphocyte counts;
CESC	cis	rs9640161	0.636	rs56190213	chr7:150025720	T/C	cg21361702	chr7:150065534	REPIN1	0.53	5.52	0.32	8.11e-8	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs66573146	0.539	rs56659624	chr4:7069377	G/C	cg26116260	chr4:7069785	GRPEL1	-0.82	-6.06	-0.35	4.63e-9	Granulocyte percentage of myeloid white cells;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02189121	chr6:79943796	HMGN3	-0.57	-6.42	-0.37	6.35e-10	Gut microbiome composition (summer);
CESC	cis	rs1801251	1.000	rs4973054	chr2:233710713	G/C	cg25237894	chr2:233734115	C2orf82	-0.47	-8.33	-0.46	4.29e-15	Coronary artery disease;
CESC	cis	rs5760092	0.755	rs4585126	chr22:24270005	T/C	cg18538332	chr22:24372958	LOC391322	0.68	8.97	0.48	5.71e-17	Urinary 1,3-butadiene metabolite levels in smokers;
CESC	cis	rs10791097	0.694	rs10160281	chr11:130742788	T/C	cg12179176	chr11:130786555	SNX19	0.65	10.05	0.53	2.42e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs8077889	0.917	rs72836553	chr17:41909851	A/G	cg26893861	chr17:41843967	DUSP3	0.83	9.9	0.52	7.45e-20	Triglycerides;
CESC	trans	rs7866350	0.604	rs1935389	chr9:100994470	A/G	cg26291698	chr6:43445274	TJAP1	0.46	6.06	0.35	4.7e-9	Post-traumatic stress disorder;
CESC	cis	rs9611565	0.512	rs139566	chr22:42199277	A/G	cg17376030	chr22:41985996	PMM1	0.78	8.4	0.46	2.79e-15	Vitiligo;
CESC	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.89	13.55	0.64	3.99e-32	Prudent dietary pattern;
CESC	cis	rs6665290	0.835	rs7549586	chr1:227214566	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.11	-21.89	-0.8	2.41e-61	Myeloid white cell count;
CESC	cis	rs9457247	0.765	rs2237276	chr6:167442115	C/T	cg23791538	chr6:167370224	RNASET2	-0.54	-7.37	-0.41	2.19e-12	Crohn's disease;
CESC	cis	rs875971	0.862	rs6460302	chr7:65960257	C/G	cg11764359	chr7:65958608	NA	0.82	11.81	0.59	3.86e-26	Aortic root size;
CESC	cis	rs1577917	1.000	rs7756203	chr6:86627707	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.44	-5.78	-0.33	2.14e-8	Response to antipsychotic treatment;
CESC	cis	rs8070128	0.637	rs4925133	chr17:17884801	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.51	7.06	0.4	1.46e-11	Total body bone mineral density;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg25631650	chr19:633157	POLRMT	0.47	6.18	0.35	2.35e-9	Systemic lupus erythematosus;
CESC	cis	rs703842	1.000	rs8181644	chr12:58173466	A/G	cg18357645	chr12:58087776	OS9	-0.39	-5.37	-0.31	1.74e-7	Multiple sclerosis;
CESC	cis	rs7818382	1.000	rs7818382	chr8:96054000	C/T	cg13393036	chr8:95962371	TP53INP1	-0.39	-7.97	-0.44	4.71e-14	Alzheimer's disease (late onset);
CESC	cis	rs11098499	0.863	rs11947234	chr4:120474859	A/G	cg09307838	chr4:120376055	NA	0.91	12.68	0.61	4e-29	Corneal astigmatism;
CESC	cis	rs12190007	0.517	rs3006210	chr6:169828915	C/T	cg15038512	chr6:170123185	PHF10	-0.51	-7.29	-0.41	3.67e-12	Obesity-related traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08944318	chr10:15139147	RPP38;C10orf111	0.61	7.36	0.41	2.27e-12	Gut microbiome composition (summer);
CESC	cis	rs7524258	0.900	rs7544004	chr1:7314529	A/C	cg07173049	chr1:7289937	CAMTA1	0.32	5.04	0.3	8.77e-7	Tourette's syndrome or obsessive-compulsive disorder;
CESC	cis	rs847577	0.630	rs6969384	chr7:97732842	C/T	cg21770322	chr7:97807741	LMTK2	0.83	14.06	0.65	6.11e-34	Breast cancer;
CESC	cis	rs2842992	0.789	rs2295901	chr6:160201295	C/A	cg11366901	chr6:160182831	ACAT2	0.81	10.03	0.52	2.85e-20	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	21.97	0.8	1.29e-61	Prudent dietary pattern;
CESC	cis	rs9916302	0.706	rs4795375	chr17:37662932	T/C	cg07936489	chr17:37558343	FBXL20	-0.91	-9.97	-0.52	4.37e-20	Glomerular filtration rate (creatinine);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01939664	chr1:33722135	ZNF362	0.63	7.87	0.44	8.99e-14	Gut microbiome composition (summer);
CESC	cis	rs2929278	0.617	rs533143	chr15:44188854	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.39	6.08	0.35	4.22e-9	Schizophrenia;
CESC	cis	rs4713118	0.662	rs9468276	chr6:28027688	A/C	cg19592336	chr6:28129416	ZNF389	0.54	6.94	0.39	3e-11	Parkinson's disease;
CESC	cis	rs875971	0.660	rs801192	chr7:66031952	C/G	cg11764359	chr7:65958608	NA	-0.71	-9.5	-0.5	1.32e-18	Aortic root size;
CESC	cis	rs11608355	0.515	rs4766609	chr12:109973297	A/G	cg05360138	chr12:110035743	NA	0.82	8.91	0.48	8.24e-17	Neuroticism;
CESC	cis	rs6089584	0.566	rs7274240	chr20:60622004	C/T	cg06108461	chr20:60628389	TAF4	-0.64	-8.61	-0.47	6.58e-16	Body mass index;
CESC	cis	rs36051895	0.659	rs7862042	chr9:5268139	G/A	cg02405213	chr9:5042618	JAK2	-0.47	-5.54	-0.32	7.13e-8	Pediatric autoimmune diseases;
CESC	cis	rs7208859	0.673	rs216435	chr17:28922737	G/T	cg14008862	chr17:28927542	LRRC37B2	0.68	6.06	0.35	4.57e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs1577917	0.771	rs4351223	chr6:86237797	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.55	7.67	0.43	3.2e-13	Response to antipsychotic treatment;
CESC	trans	rs66573146	0.808	rs73202120	chr4:7005588	A/G	cg07817883	chr1:32538562	TMEM39B	0.81	6.2	0.36	2.19e-9	Granulocyte percentage of myeloid white cells;
CESC	trans	rs9693444	0.898	rs4732697	chr8:29519861	A/G	cg27367768	chr5:171615456	STK10	-0.4	-6.12	-0.35	3.36e-9	Breast cancer;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg00437399	chr15:40886176	CASC5	-0.44	-6.25	-0.36	1.66e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs1577917	0.771	rs2783171	chr6:86382765	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.55	7.36	0.41	2.29e-12	Response to antipsychotic treatment;
CESC	cis	rs13191362	1.000	rs13210412	chr6:163019478	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.83	8.74	0.47	2.63e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs1552244	0.935	rs28815328	chr3:10062227	G/A	cg08888203	chr3:10149979	C3orf24	0.49	6.24	0.36	1.75e-9	Alzheimer's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01193506	chr22:38004378	GGA1	-0.55	-6.17	-0.35	2.6e-9	Gut microbiome composition (summer);
CESC	cis	rs853679	0.550	rs1225599	chr6:28165190	C/T	cg17949981	chr6:28129498	ZNF389	0.43	5.58	0.32	5.97e-8	Depression;
CESC	cis	rs1707322	0.964	rs796773	chr1:46564475	C/T	cg06784218	chr1:46089804	CCDC17	-0.33	-5.63	-0.33	4.67e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg23708337	chr7:1209742	NA	0.53	5.34	0.31	1.98e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06829293	chr19:11201108	LDLR	-0.58	-6.72	-0.38	1.11e-10	Gut microbiome composition (summer);
CESC	cis	rs10870270	1.000	rs6560694	chr10:133773448	G/A	cg26149184	chr10:133730230	NA	0.38	5.14	0.3	5.22e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs1559088	0.576	rs10407255	chr19:33581150	A/G	cg17764715	chr19:33622953	WDR88	-0.61	-9.26	-0.49	7.06e-18	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs7615952	0.576	rs2276729	chr3:125826214	G/A	cg04553112	chr3:125709451	NA	-0.56	-6.33	-0.36	1.07e-9	Blood pressure (smoking interaction);
CESC	cis	rs9399135	0.967	rs6902954	chr6:135313994	C/A	cg24558204	chr6:135376177	HBS1L	0.53	7.28	0.41	3.85e-12	Red blood cell count;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg24108215	chr1:39174820	NA	-0.43	-6.34	-0.36	1.01e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs3008870	0.755	rs1925409	chr1:67365089	C/T	cg02640540	chr1:67518911	SLC35D1	-0.45	-5.56	-0.32	6.61e-8	Lymphocyte percentage of white cells;
CESC	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg22907277	chr7:1156413	C7orf50	0.49	5.68	0.33	3.5e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs8177253	0.507	rs4241357	chr3:133475563	A/C	cg18769074	chr3:133464867	TF	-0.28	-5.35	-0.31	1.9e-7	Iron status biomarkers;
CESC	cis	rs7503168	0.558	rs11870472	chr17:33872649	G/A	cg20932281	chr17:33905541	PEX12	0.72	5.36	0.31	1.77e-7	Plateletcrit;
CESC	cis	rs748404	0.697	rs1814323	chr15:43563237	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	-0.6	-7.92	-0.44	6.44e-14	Lung cancer;
CESC	cis	rs4930103	0.782	rs10840167	chr11:2022023	G/T	cg23202291	chr11:1979235	NA	0.37	5.25	0.31	3.12e-7	DNA methylation (parent-of-origin);DNA methylation (variation);
CESC	cis	rs2404602	0.583	rs2469542	chr15:76557476	A/G	cg26408565	chr15:76604113	ETFA	0.39	5.98	0.34	7.3e-9	Blood metabolite levels;
CESC	cis	rs7312774	0.867	rs10492213	chr12:107295841	A/T	cg16260113	chr12:107380972	MTERFD3	-0.62	-5.82	-0.34	1.7e-8	Severe influenza A (H1N1) infection;
CESC	cis	rs3026101	0.647	rs4790263	chr17:5307084	T/C	cg24500398	chr17:5266808	RABEP1	-0.41	-5.72	-0.33	2.9e-8	Body mass index;
CESC	cis	rs3733585	0.783	rs13148371	chr4:10032561	C/T	cg02734326	chr4:10020555	SLC2A9	0.5	6.99	0.39	2.23e-11	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs7666738	0.606	rs28481322	chr4:99086638	T/C	cg24818145	chr4:99064322	C4orf37	0.39	5.13	0.3	5.73e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3820068	0.581	rs111699992	chr1:15927158	G/A	cg17385448	chr1:15911702	AGMAT	0.41	6.69	0.38	1.33e-10	Systolic blood pressure;
CESC	cis	rs7188697	0.922	rs37051	chr16:58558102	C/T	cg02549819	chr16:58548995	SETD6	-0.41	-5.2	-0.3	4.08e-7	QT interval;
CESC	cis	rs1552244	0.572	rs67439440	chr3:10169503	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.78	8.84	0.48	1.4e-16	Alzheimer's disease;
CESC	cis	rs8031584	0.918	rs11639169	chr15:31255438	C/T	cg08109568	chr15:31115862	NA	-0.65	-8.34	-0.46	4.12e-15	Huntington's disease progression;
CESC	cis	rs875971	1.000	rs55962648	chr7:65625751	C/G	cg11764359	chr7:65958608	NA	-0.92	-14.72	-0.67	2.89e-36	Aortic root size;
CESC	cis	rs853679	0.517	rs4713143	chr6:28106759	A/C	cg26335602	chr6:28129616	ZNF389	0.54	7.3	0.41	3.37e-12	Depression;
CESC	cis	rs6502050	0.835	rs4789677	chr17:80119842	A/G	cg23985595	chr17:80112537	CCDC57	-0.41	-6.57	-0.37	2.6200000000000003e-10	Life satisfaction;
CESC	cis	rs13191362	1.000	rs73035025	chr6:163000988	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.83	8.39	0.46	3.02e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs7666738	0.830	rs17483521	chr4:98974058	A/T	cg03467027	chr4:99064603	C4orf37	0.43	5.36	0.31	1.81e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1797081	0.967	rs780632	chr10:16861400	A/G	cg23933602	chr10:16859644	RSU1	-1.1	-22.74	-0.81	3.3e-64	Platelet distribution width;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg13355623	chr17:26898935	PIGS	-0.46	-6.03	-0.35	5.62e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs12995491	0.902	rs6737641	chr2:88529471	A/T	cg18490616	chr2:88469792	THNSL2	-0.53	-7.91	-0.44	6.92e-14	Response to metformin (IC50);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg14126493	chr5:176831297	F12	-0.5	-6.74	-0.38	9.89e-11	Fibrinogen levels;
CESC	cis	rs7937682	0.924	rs10891286	chr11:111532691	C/G	cg09085632	chr11:111637200	PPP2R1B	-0.99	-16.33	-0.71	5.97e-42	Primary sclerosing cholangitis;
CESC	cis	rs3733585	0.699	rs4473653	chr4:9971058	A/G	cg00071950	chr4:10020882	SLC2A9	-0.71	-11.42	-0.57	7.69e-25	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs2836950	0.565	rs2836943	chr21:40592611	C/T	cg11644478	chr21:40555479	PSMG1	-0.54	-7.27	-0.41	4.12e-12	Menarche (age at onset);
CESC	cis	rs9611565	0.512	rs139561	chr22:42195410	C/T	cg06634786	chr22:41940651	POLR3H	0.67	6.86	0.39	4.8e-11	Vitiligo;
CESC	cis	rs25645	0.502	rs9895948	chr17:38108363	T/C	cg17467752	chr17:38218738	THRA	0.41	5.11	0.3	6.17e-7	Myeloid white cell count;
CESC	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg05313129	chr8:58192883	C8orf71	-0.49	-5.32	-0.31	2.23e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs5769765	1.000	rs5770742	chr22:50270309	T/C	cg26441486	chr22:50317300	CRELD2	-0.39	-5.5	-0.32	8.72e-8	Schizophrenia;
CESC	cis	rs7408868	0.831	rs7249115	chr19:15280765	A/G	cg14696996	chr19:15285081	NOTCH3	0.84	9.55	0.51	9.3e-19	Pulse pressure;
CESC	cis	rs11638352	1.000	rs2615287	chr15:44415993	A/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.61	-5.62	-0.33	4.75e-8	Lipoprotein phospholipase A2 activity in cardiovascular disease;
CESC	cis	rs546131	0.928	rs546521	chr11:34824773	G/C	cg06937548	chr11:34938143	PDHX;APIP	0.51	6.26	0.36	1.57e-9	Lung disease severity in cystic fibrosis;
CESC	cis	rs367615	0.879	rs56689485	chr5:108879828	A/T	cg17395555	chr5:108820864	NA	0.56	8.33	0.46	4.38e-15	Colorectal cancer (SNP x SNP interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26383454	chr6:11104957	HERV-FRD;LOC221710	-0.66	-8.07	-0.44	2.46e-14	Gut microbiome composition (summer);
CESC	cis	rs2282526	0.615	rs162377	chr21:44926001	A/G	cg01579765	chr21:45077557	HSF2BP	-0.43	-6.54	-0.37	3.09e-10	Mean corpuscular hemoglobin;
CESC	cis	rs9462846	0.959	rs9471954	chr6:42880326	C/A	cg05552183	chr6:42928497	GNMT	0.48	5.74	0.33	2.62e-8	Blood protein levels;
CESC	cis	rs10089	1.000	rs6887847	chr5:127473807	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.8	10.9	0.56	4.08e-23	Ileal carcinoids;
CESC	cis	rs7666738	0.800	rs7684523	chr4:98983175	G/T	cg17366294	chr4:99064904	C4orf37	0.59	8.57	0.47	8.46e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs12912251	0.947	rs7177621	chr15:38999394	C/G	cg01338139	chr15:38987640	C15orf53	-0.51	-5.49	-0.32	9.57e-8	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
CESC	cis	rs8067354	0.645	rs9899611	chr17:57832190	A/G	cg13753209	chr17:57696993	CLTC	0.65	7.92	0.44	6.54e-14	Hemoglobin concentration;
CESC	cis	rs4566357	1.000	rs7577005	chr2:227921573	A/G	cg11843606	chr2:227700838	RHBDD1	-0.41	-5.29	-0.31	2.58e-7	Coronary artery disease;
CESC	trans	rs17508449	0.819	rs4839331	chr1:114161631	A/G	cg15464363	chr22:32149800	DEPDC5	-0.68	-6.14	-0.35	3.03e-9	Leprosy;
CESC	cis	rs875971	0.929	rs778682	chr7:65837934	A/G	cg11764359	chr7:65958608	NA	0.98	15.78	0.7	5.36e-40	Aortic root size;
CESC	cis	rs9926296	0.744	rs164748	chr16:89708292	C/G	cg01097406	chr16:89675127	NA	0.37	5.31	0.31	2.31e-7	Vitiligo;
CESC	cis	rs561341	0.609	rs11658984	chr17:30186612	C/T	cg13647721	chr17:30228624	UTP6	-0.74	-8.56	-0.47	9.61e-16	Hip circumference adjusted for BMI;
CESC	cis	rs1552244	0.872	rs6792951	chr3:10119603	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.85	-11.68	-0.58	1.06e-25	Alzheimer's disease;
CESC	cis	rs28489187	0.683	rs1554597	chr1:85877098	C/T	cg16011679	chr1:85725395	C1orf52	-0.42	-5.17	-0.3	4.65e-7	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	cis	rs2976388	0.556	rs4736321	chr8:143822194	C/T	cg24634471	chr8:143751801	JRK	-0.46	-5.06	-0.3	7.87e-7	Urinary tract infection frequency;
CESC	cis	rs6831352	1.000	rs6831352	chr4:100063525	T/C	cg12011299	chr4:100065546	ADH4	0.69	8.37	0.46	3.38e-15	Alcohol dependence;
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg08205843	chr19:12848293	ASNA1	-0.39	-6.15	-0.35	2.86e-9	Vertical cup-disc ratio;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg20645649	chr9:127624485	RPL35	0.48	6.04	0.35	5.24e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs2880765	0.835	rs7164106	chr15:86032590	T/C	cg10818794	chr15:86012489	AKAP13	-0.35	-5.39	-0.31	1.6e-7	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06636460	chr16:3722631	TRAP1	-0.58	-6.68	-0.38	1.39e-10	Gut microbiome composition (summer);
CESC	cis	rs7674212	0.570	rs6841136	chr4:104103509	A/C	cg16532752	chr4:104119610	CENPE	-0.4	-5.5	-0.32	8.72e-8	Type 2 diabetes;
CESC	cis	rs9311474	0.508	rs6788887	chr3:52605005	T/C	cg07507251	chr3:52567010	NT5DC2	0.33	5.69	0.33	3.36e-8	Electroencephalogram traits;
CESC	cis	rs17021463	0.966	rs1565062	chr4:95183000	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.61	-9.69	-0.51	3.37e-19	Testicular germ cell tumor;
CESC	cis	rs17253792	0.822	rs78615025	chr14:56168012	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.81	5.68	0.33	3.46e-8	Putamen volume;
CESC	cis	rs6933660	0.745	rs6912830	chr6:151743629	A/C	cg02564969	chr6:151773285	C6orf211;RMND1	0.62	8.45	0.46	1.91e-15	Menarche (age at onset);
CESC	cis	rs6076065	0.548	rs6048740	chr20:23325047	G/A	cg11657817	chr20:23433608	CST11	0.35	5.09	0.3	6.82e-7	Facial morphology (factor 15, philtrum width);
CESC	cis	rs2404602	1.000	rs2896954	chr15:76851692	C/A	cg22467129	chr15:76604101	ETFA	-0.35	-5.25	-0.31	3.16e-7	Blood metabolite levels;
CESC	cis	rs1059312	0.966	rs2291349	chr12:129284248	T/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.71	-9.81	-0.52	1.42e-19	Systemic lupus erythematosus;
CESC	trans	rs877282	0.898	rs11253347	chr10:765769	A/G	cg22713356	chr15:30763199	NA	1.15	11.3	0.57	2.06e-24	Uric acid levels;
CESC	cis	rs4689592	0.622	rs2276968	chr4:7070118	T/G	cg19539972	chr4:7069911	GRPEL1	0.8	8.96	0.48	5.79e-17	Monocyte percentage of white cells;
CESC	cis	rs7949030	0.588	rs2428549	chr11:62312394	A/G	cg02375832	chr11:62437615	C11orf48	-0.36	-5.31	-0.31	2.36e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs7666738	0.830	rs13328042	chr4:99055406	A/G	cg18180107	chr4:99064573	C4orf37	0.41	5.24	0.31	3.21e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7666738	1.000	rs2865983	chr4:99033352	C/T	cg03676636	chr4:99064102	C4orf37	0.34	5.09	0.3	6.91e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg19111712	chr11:1301065	TOLLIP	-0.46	-6.29	-0.36	1.29e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs2197308	0.619	rs4002730	chr12:37876400	T/C	cg13010199	chr12:38710504	ALG10B	0.52	6.64	0.38	1.8e-10	Morning vs. evening chronotype;
CESC	cis	rs6061231	0.740	rs11698650	chr20:60958374	A/T	cg15674680	chr20:60982522	CABLES2	0.46	6.03	0.35	5.63e-9	Colorectal cancer;
CESC	cis	rs2120019	0.935	rs34913788	chr15:75372617	A/C	cg17294928	chr15:75287854	SCAMP5	-0.59	-6.65	-0.38	1.64e-10	Blood trace element (Zn levels);
CESC	cis	rs7086627	0.515	rs1870147	chr10:82212541	A/T	cg00277334	chr10:82204260	NA	-0.88	-14.63	-0.67	6.14e-36	Post bronchodilator FEV1;
CESC	cis	rs2180341	0.883	rs9388568	chr6:127690694	C/A	cg24812749	chr6:127587940	RNF146	1.05	15.12	0.68	1.2e-37	Breast cancer;
CESC	cis	rs35110281	0.713	rs6518310	chr21:45098670	T/A	cg21573476	chr21:45109991	RRP1B	-0.5	-7.42	-0.41	1.56e-12	Mean corpuscular volume;
CESC	cis	rs2842992	0.692	rs1128661	chr6:160211554	T/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.77	11.06	0.56	1.26e-23	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs2732480	0.577	rs2732486	chr12:48737834	G/A	cg24011408	chr12:48396354	COL2A1	0.44	5.99	0.35	6.99e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs7937682	0.632	rs10891297	chr11:111770150	C/T	cg09085632	chr11:111637200	PPP2R1B	0.87	10.94	0.56	3.08e-23	Primary sclerosing cholangitis;
CESC	trans	rs11148252	0.574	rs73186430	chr13:53232891	T/C	cg18335740	chr13:41363409	SLC25A15	0.53	7.08	0.4	1.31e-11	Lewy body disease;
CESC	cis	rs75477785	1.000	rs75889558	chr1:209988809	G/T	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.92	6.04	0.35	5.06e-9	Cleft lip with or without cleft palate;
CESC	cis	rs28489187	0.558	rs2474123	chr1:85827452	C/T	cg16011679	chr1:85725395	C1orf52	0.43	5.12	0.3	5.93e-7	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	cis	rs921968	0.565	rs3770219	chr2:219619766	T/C	cg02176678	chr2:219576539	TTLL4	-0.44	-7.67	-0.43	3.29e-13	Mean corpuscular hemoglobin concentration;
CESC	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg03188948	chr7:1209495	NA	0.53	7.14	0.4	8.8e-12	Longevity;Endometriosis;
CESC	cis	rs2439831	0.867	rs7170489	chr15:43636651	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.89	10.37	0.54	2.27e-21	Lung cancer in ever smokers;
CESC	cis	rs34421088	0.564	rs6983129	chr8:11591136	A/C	cg13293535	chr8:11597251	GATA4	-0.29	-5.61	-0.33	4.98e-8	Neuroticism;
CESC	cis	rs6502050	0.734	rs9674631	chr17:80096525	A/G	cg23985595	chr17:80112537	CCDC57	-0.42	-6.48	-0.37	4.35e-10	Life satisfaction;
CESC	cis	rs1881797	1.000	rs10158379	chr1:247686352	C/A	cg18198730	chr1:247681584	NA	0.59	7.76	0.43	1.84e-13	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs644799	0.625	rs1255175	chr11:95471186	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.45	6.03	0.35	5.6e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs8058578	1.000	rs8048448	chr16:30692208	T/C	cg02466173	chr16:30829666	NA	-0.41	-6.7	-0.38	1.22e-10	Multiple myeloma;
CESC	cis	rs826838	0.651	rs1843892	chr12:38616965	A/G	cg26384229	chr12:38710491	ALG10B	0.57	8.25	0.45	7.66e-15	Heart rate;
CESC	cis	rs62012628	0.527	rs12438008	chr15:79084680	C/T	cg04896959	chr15:78267971	NA	-0.5	-8.56	-0.47	9.39e-16	Diastolic blood pressure;
CESC	cis	rs10504229	1.000	rs113379801	chr8:58173686	C/G	cg24829409	chr8:58192753	C8orf71	-0.75	-9.91	-0.52	6.63e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs60843830	1.000	rs3791221	chr2:226933	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.86	11.73	0.58	7.08e-26	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs4727027	0.933	rs4725800	chr7:148862516	C/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.43	5.31	0.31	2.29e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs7264396	0.635	rs2425166	chr20:34439391	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.62	7.35	0.41	2.49e-12	Total cholesterol levels;
CESC	cis	rs11264213	0.591	rs274728	chr1:36493420	T/C	cg27506609	chr1:36549197	TEKT2	-0.76	-6.97	-0.39	2.46e-11	Schizophrenia;
CESC	cis	rs116095464	0.558	rs7356696	chr5:284251	A/G	cg12570787	chr5:219185	SDHA;CCDC127	0.52	5.41	0.32	1.38e-7	Breast cancer;
CESC	cis	rs7640424	0.649	rs35595234	chr3:107922116	C/T	cg09227934	chr3:107805635	CD47	-0.45	-5.82	-0.34	1.66e-8	Body mass index;
CESC	cis	rs4253772	0.614	rs11090859	chr22:46687460	T/G	cg09491104	chr22:46646882	C22orf40	-0.6	-8.9	-0.48	9.11e-17	LDL cholesterol;Cholesterol, total;
CESC	cis	rs9322193	0.923	rs12205092	chr6:150082511	G/T	cg09699651	chr6:150184138	LRP11	0.41	5.11	0.3	6.05e-7	Lung cancer;
CESC	cis	rs6933660	0.683	rs6916340	chr6:151779064	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.88	15.11	0.68	1.29e-37	Menarche (age at onset);
CESC	cis	rs763121	0.785	rs5757199	chr22:39040617	T/G	cg06022373	chr22:39101656	GTPBP1	0.88	13.79	0.65	5.43e-33	Menopause (age at onset);
CESC	cis	rs4268898	0.662	rs58971404	chr2:24403753	G/A	cg06627628	chr2:24431161	ITSN2	-0.97	-9.76	-0.51	2.07e-19	Asthma;
CESC	cis	rs10129255	0.536	rs10142951	chr14:107190574	A/G	cg23076370	chr14:107095027	NA	-0.65	-9.64	-0.51	4.78e-19	Kawasaki disease;
CESC	cis	rs6060717	0.536	rs6060670	chr20:34481143	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-6.93	-0.39	3.22e-11	Hip circumference adjusted for BMI;
CESC	cis	rs12545109	0.879	rs2576588	chr8:57381627	G/A	cg09654669	chr8:57350985	NA	-0.52	-6.87	-0.39	4.5e-11	Obesity-related traits;
CESC	cis	rs1799949	0.930	rs66499067	chr17:41248484	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.64	8.73	0.47	2.95e-16	Menopause (age at onset);
CESC	cis	rs11785400	1.000	rs11776301	chr8:143737142	A/G	cg24634471	chr8:143751801	JRK	0.47	6.22	0.36	1.92e-9	Schizophrenia;
CESC	cis	rs12497850	0.931	rs7626445	chr3:49114544	C/T	cg02487422	chr3:49467188	NICN1	0.42	5.34	0.31	2.01e-7	Parkinson's disease;
CESC	cis	rs2191566	0.576	rs420355	chr19:44495325	C/T	cg20607764	chr19:44506953	ZNF230	0.45	5.69	0.33	3.38e-8	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs6570726	0.935	rs386823	chr6:145841365	C/T	cg05347473	chr6:146136440	FBXO30	0.49	6.74	0.38	1e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs3096299	0.685	rs4238830	chr16:89540241	C/T	cg16743903	chr16:89593216	SPG7	-0.45	-5.85	-0.34	1.43e-8	Multiple myeloma (IgH translocation);
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg12427896	chr2:111880694	BCL2L11	0.52	7.19	0.4	6.56e-12	Systemic lupus erythematosus;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22905859	chr1:149576021	LOC728855	-0.54	-6.6	-0.38	2.21e-10	Gut microbiome composition (summer);
CESC	cis	rs13072744	0.530	rs12497521	chr3:72488540	C/G	cg22685502	chr3:72496851	RYBP	0.24	5.25	0.31	3.12e-7	Height;
CESC	cis	rs8114671	0.562	rs6120739	chr20:33405227	A/G	cg08999081	chr20:33150536	PIGU	0.39	5.53	0.32	7.84e-8	Height;
CESC	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.45	-6.56	-0.37	2.78e-10	Longevity;Endometriosis;
CESC	trans	rs2963826	0.589	rs298091	chr5:58996603	A/T	cg20566420	chr12:122327043	PSMD9	0.5	6.38	0.36	7.67e-10	Obesity-related traits;
CESC	cis	rs7927771	0.864	rs7937331	chr11:47430458	T/C	cg20307385	chr11:47447363	PSMC3	0.69	8.97	0.48	5.36e-17	Subjective well-being;
CESC	cis	rs11112613	0.653	rs941101	chr12:105937098	T/G	cg03607813	chr12:105948248	NA	0.59	6.38	0.37	7.72e-10	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CESC	cis	rs1707322	1.000	rs11211190	chr1:46266255	C/T	cg03146154	chr1:46216737	IPP	0.73	10.13	0.53	1.3e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs5750830	0.649	rs4384886	chr22:39793766	C/T	cg24399712	chr22:39784796	NA	-0.84	-11.79	-0.59	4.45e-26	Intelligence (multi-trait analysis);
CESC	cis	rs2228479	0.850	rs12596934	chr16:89841605	T/G	cg06558623	chr16:89946397	TCF25	1.17	9.29	0.5	5.84e-18	Skin colour saturation;
CESC	cis	rs6952808	1.000	rs6952808	chr7:1886535	C/G	cg04267008	chr7:1944627	MAD1L1	-0.61	-7.5	-0.42	9.64e-13	Bipolar disorder and schizophrenia;
CESC	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg07414643	chr4:187882934	NA	0.54	7.39	0.41	1.87e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6570726	0.791	rs6915094	chr6:145883540	C/G	cg05347473	chr6:146136440	FBXO30	0.56	7.08	0.4	1.27e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs11997175	0.574	rs4733453	chr8:33650745	A/G	ch.8.33884649F	chr8:33765107	NA	0.64	8.25	0.45	7.24e-15	Body mass index;
CESC	cis	rs11690935	0.885	rs7602037	chr2:172817794	G/A	cg13550731	chr2:172543902	DYNC1I2	-0.82	-12.29	-0.6	8.83e-28	Schizophrenia;
CESC	cis	rs801193	1.000	rs10274773	chr7:66133578	G/A	cg11764359	chr7:65958608	NA	-0.68	-8.81	-0.48	1.68e-16	Aortic root size;
CESC	cis	rs798554	0.757	rs2533878	chr7:2878707	A/G	cg04166393	chr7:2884313	GNA12	-0.57	-7.34	-0.41	2.62e-12	Height;
CESC	cis	rs769267	0.895	rs2916073	chr19:19528324	T/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.48	6.13	0.35	3.25e-9	Tonsillectomy;
CESC	cis	rs7726839	0.540	rs72705030	chr5:645562	C/T	cg16447950	chr5:562315	NA	-0.6	-6.44	-0.37	5.45e-10	Obesity-related traits;
CESC	cis	rs736408	0.545	rs6445529	chr3:52662722	T/A	cg05564831	chr3:52568323	NT5DC2	0.47	7.43	0.42	1.46e-12	Bipolar disorder;
CESC	cis	rs425277	0.583	rs10910046	chr1:2041155	C/T	cg12718519	chr1:2058417	PRKCZ	-0.25	-5.34	-0.31	1.99e-7	Height;
CESC	cis	rs7605827	0.930	rs6431711	chr2:15683930	G/T	cg19274914	chr2:15703543	NA	0.37	6.7	0.38	1.22e-10	Educational attainment (years of education);
CESC	trans	rs11039798	0.582	rs60764175	chr11:48775856	T/G	cg15704280	chr7:45808275	SEPT13	0.66	6.63	0.38	1.89e-10	Axial length;
CESC	cis	rs2635047	1.000	rs2684826	chr18:44679147	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.48	6.42	0.37	6.4e-10	Educational attainment;
CESC	cis	rs3768617	0.510	rs10797849	chr1:183088988	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.87	13.37	0.63	1.66e-31	Fuchs's corneal dystrophy;
CESC	cis	rs1843834	1.000	rs1565072	chr2:225545245	C/T	cg22455342	chr2:225449267	CUL3	-0.51	-6.44	-0.37	5.71e-10	IgE levels in asthmatics (D.p. specific);
CESC	cis	rs9549367	0.664	rs9549689	chr13:113848387	G/A	cg18105134	chr13:113819100	PROZ	-0.69	-8.17	-0.45	1.31e-14	Platelet distribution width;
CESC	cis	rs67478160	0.634	rs941475	chr14:104240618	A/C	cg08213375	chr14:104286397	PPP1R13B	0.47	9.13	0.49	1.81e-17	Schizophrenia;
CESC	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	7.78	0.43	1.58e-13	Prudent dietary pattern;
CESC	cis	rs7412746	0.658	rs10888397	chr1:150886752	A/G	cg04414720	chr1:150670196	GOLPH3L	-0.46	-6.11	-0.35	3.54e-9	Melanoma;
CESC	cis	rs58688157	0.705	rs12419618	chr11:611531	G/A	cg02461776	chr11:598696	PHRF1	0.46	5.06	0.3	7.91e-7	Systemic lupus erythematosus;
CESC	cis	rs7666738	0.830	rs7662596	chr4:99019962	G/T	cg03467027	chr4:99064603	C4orf37	0.46	5.81	0.34	1.8e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7927771	0.524	rs6485786	chr11:47837408	G/C	cg18512352	chr11:47633146	NA	0.35	5.33	0.31	2.05e-7	Subjective well-being;
CESC	cis	rs11719291	0.833	rs13074318	chr3:48816725	C/T	cg00383909	chr3:49044727	WDR6	0.9	6.23	0.36	1.82e-9	Cognitive function;
CESC	cis	rs7945705	0.782	rs2742545	chr11:8884308	C/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.4	-6.51	-0.37	3.73e-10	Hemoglobin concentration;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg05863534	chr17:34948351	DHRS11	-0.48	-6.05	-0.35	4.94e-9	Ulcerative colitis;
CESC	cis	rs910316	1.000	rs12879542	chr14:75507525	C/T	cg11812906	chr14:75593930	NEK9	0.89	14.59	0.67	8.27e-36	Height;
CESC	cis	rs853679	0.517	rs9348796	chr6:28126202	A/G	cg23281280	chr6:28129359	ZNF389	0.59	7.9	0.44	7.47e-14	Depression;
CESC	cis	rs7809799	1.000	rs75599274	chr7:98781259	A/C	cg05967295	chr7:98741636	SMURF1	0.88	5.54	0.32	7.27e-8	Ulcerative colitis;
CESC	trans	rs853679	0.607	rs35902873	chr6:28058949	G/C	cg06606381	chr12:133084897	FBRSL1	-1.08	-7.66	-0.43	3.42e-13	Depression;
CESC	cis	rs4665809	1.000	rs4665306	chr2:26319124	C/T	cg25036284	chr2:26402008	FAM59B	-0.6	-6.93	-0.39	3.26e-11	Gut microbiome composition (summer);
CESC	cis	rs7267979	0.966	rs6050611	chr20:25414419	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.8	16.14	0.7	2.87e-41	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs8002861	0.905	rs12874590	chr13:44433363	C/T	cg14210620	chr13:44453864	C13orf31;CCDC122	-0.39	-5.17	-0.3	4.69e-7	Leprosy;
CESC	cis	rs34779708	0.733	rs16935948	chr10:35549748	C/G	cg04310649	chr10:35416472	CREM	-0.49	-5.28	-0.31	2.69e-7	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs3741404	0.895	rs2429455	chr11:63995302	C/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.89	13.91	0.65	2.12e-33	Platelet count;
CESC	cis	rs2836974	0.897	rs2776308	chr21:40715175	A/G	cg17971929	chr21:40555470	PSMG1	0.92	12.36	0.6	5.24e-28	Cognitive function;
CESC	cis	rs4664304	0.629	rs3828324	chr2:160834991	C/T	cg03641300	chr2:160917029	PLA2R1	0.44	6.06	0.35	4.56e-9	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs80282103	0.618	rs1079389	chr10:1161980	A/G	cg08668510	chr10:1095578	IDI1	0.72	5.84	0.34	1.55e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs72781680	0.898	rs718139	chr2:23975911	G/A	cg08917208	chr2:24149416	ATAD2B	1.13	10.19	0.53	8.58e-21	Lymphocyte counts;
CESC	cis	rs2197308	0.740	rs11182967	chr12:37935140	A/C	cg26384229	chr12:38710491	ALG10B	0.75	11.19	0.57	4.49e-24	Morning vs. evening chronotype;
CESC	cis	rs1577917	0.958	rs884842	chr6:86680397	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.43	-5.67	-0.33	3.66e-8	Response to antipsychotic treatment;
CESC	cis	rs10791323	0.569	rs2282601	chr11:133712594	C/G	cg06766960	chr11:133703094	NA	-0.38	-5.41	-0.32	1.42e-7	Childhood ear infection;
CESC	cis	rs2790457	0.792	rs1265830	chr10:28912223	A/G	cg04045419	chr10:28823091	WAC	0.45	5.34	0.31	1.97e-7	Multiple myeloma;
CESC	cis	rs7208859	0.623	rs426434	chr17:28925353	C/T	cg19761014	chr17:28927070	LRRC37B2	0.69	5.92	0.34	1.02e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs3540	0.553	rs12592611	chr15:91004093	C/T	cg22089800	chr15:90895588	ZNF774	0.66	8.93	0.48	7.21e-17	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs965513	1.000	rs7864322	chr9:100548934	C/T	cg13688889	chr9:100608707	NA	-0.6	-8.59	-0.47	7.47e-16	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
CESC	cis	rs9929218	0.748	rs34592833	chr16:68739125	G/A	cg02972257	chr16:68554789	NA	0.55	6.08	0.35	4.14e-9	Colorectal cancer;
CESC	cis	rs3820928	0.605	rs7560867	chr2:227780945	C/A	cg11843606	chr2:227700838	RHBDD1	-0.57	-8.02	-0.44	3.34e-14	Pulmonary function;
CESC	cis	rs2901656	0.677	rs1063412	chr1:172410967	G/A	cg03748243	chr1:172413542	C1orf105;PIGC	0.54	8.29	0.45	5.76e-15	Red cell distribution width;Platelet distribution width;
CESC	cis	rs5757676	0.858	rs6001585	chr22:39812986	G/T	cg24399712	chr22:39784796	NA	-0.82	-9.31	-0.5	5.22e-18	IgG glycosylation;
CESC	cis	rs3780486	0.846	rs10971438	chr9:33180308	A/G	cg13443165	chr9:33130375	B4GALT1	0.4	5.29	0.31	2.59e-7	IgG glycosylation;
CESC	cis	rs2742417	0.603	rs2673075	chr3:45778288	C/A	cg04837898	chr3:45731254	SACM1L	-0.46	-5.99	-0.35	6.85e-9	Response to anti-depressant treatment in major depressive disorder;
CESC	cis	rs13191362	1.000	rs35593345	chr6:163174981	G/C	cg06582575	chr6:163149167	PACRG;PARK2	1.02	9.29	0.5	5.65e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs3806843	0.648	rs702399	chr5:140024432	C/T	cg16179182	chr5:140090404	VTRNA1-1	0.41	5.24	0.31	3.21e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs523522	0.962	rs2393590	chr12:120913900	G/A	cg12219531	chr12:120966889	COQ5	0.7	9.25	0.49	7.88e-18	High light scatter reticulocyte count;
CESC	cis	rs7772486	0.875	rs863820	chr6:146347402	C/T	cg23711669	chr6:146136114	FBXO30	-0.84	-12.23	-0.6	1.41e-27	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7584330	0.955	rs7581882	chr2:238390745	T/C	cg14458575	chr2:238380390	NA	0.65	9.1	0.49	2.28e-17	Prostate cancer;
CESC	cis	rs2404602	0.692	rs55729975	chr15:76803226	G/A	cg22467129	chr15:76604101	ETFA	-0.35	-5.22	-0.31	3.65e-7	Blood metabolite levels;
CESC	cis	rs2072499	0.778	rs41265025	chr1:156163906	C/T	cg25208724	chr1:156163844	SLC25A44	0.97	12.53	0.61	1.39e-28	Testicular germ cell tumor;
CESC	cis	rs12541635	0.966	rs6469023	chr8:106989558	T/C	cg10147462	chr8:107024639	NA	0.41	5.62	0.33	4.93e-8	Age of smoking initiation;
CESC	cis	rs6089829	0.925	rs3746748	chr20:61667526	C/T	cg08564027	chr20:61660810	NA	0.9	15.44	0.69	8.75e-39	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7818688	0.653	rs11776687	chr8:95836307	T/C	cg16049864	chr8:95962084	TP53INP1	0.54	5.7	0.33	3.15e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs7116495	0.609	rs17161751	chr11:71688347	G/A	cg10381502	chr11:71823885	C11orf51	1.16	7.27	0.41	4.06e-12	Severe influenza A (H1N1) infection;
CESC	cis	rs10504229	0.679	rs7839948	chr8:58130607	A/G	cg02725872	chr8:58115012	NA	-0.45	-7.05	-0.4	1.52e-11	Developmental language disorder (linguistic errors);
CESC	trans	rs208520	0.802	rs208516	chr6:66946119	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.86	-9.92	-0.52	6.4e-20	Exhaled nitric oxide output;
CESC	cis	rs6541297	0.645	rs612577	chr1:230324364	A/G	cg20703242	chr1:230279135	GALNT2	-0.52	-5.95	-0.34	8.44e-9	Coronary artery disease;
CESC	cis	rs10779751	0.734	rs6701726	chr1:11126941	C/T	cg08854313	chr1:11322531	MTOR	0.77	10.41	0.54	1.73e-21	Body mass index;
CESC	cis	rs2075371	0.611	rs13235296	chr7:134019192	A/G	cg20476274	chr7:133979776	SLC35B4	-0.54	-7.31	-0.41	3.08e-12	Mean platelet volume;
CESC	cis	rs116095464	0.558	rs57335027	chr5:262907	A/G	cg20965017	chr5:231967	SDHA	-0.48	-5.43	-0.32	1.25e-7	Breast cancer;
CESC	cis	rs12188164	0.965	rs11745789	chr5:450777	T/C	cg21144161	chr5:423903	AHRR	0.37	5.98	0.34	7.12e-9	Cystic fibrosis severity;
CESC	cis	rs11098499	0.604	rs2389887	chr4:120570644	T/C	cg09307838	chr4:120376055	NA	0.76	9.58	0.51	7.28e-19	Corneal astigmatism;
CESC	cis	rs9443645	0.901	rs7742034	chr6:79737106	A/G	cg05283184	chr6:79620031	NA	-0.44	-6.84	-0.39	5.6e-11	Intelligence (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12061021	chr1:95699574	RWDD3	-0.69	-7.68	-0.43	3.11e-13	Gut microbiome composition (summer);
CESC	cis	rs13256369	1.000	rs12550458	chr8:8567832	G/A	cg18904891	chr8:8559673	CLDN23	0.67	7.49	0.42	1.01e-12	Obesity-related traits;
CESC	cis	rs6967414	0.786	rs7782227	chr7:6748594	T/C	cg09896999	chr7:6746977	ZNF12	-0.58	-7.08	-0.4	1.32e-11	Hematocrit;Hemoglobin concentration;
CESC	cis	rs7267979	1.000	rs2259956	chr20:25282433	A/G	cg08601574	chr20:25228251	PYGB	0.39	5.57	0.32	6.14e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs1775715	0.870	rs1775737	chr10:32256871	T/C	cg04359828	chr10:32216031	ARHGAP12	0.35	5.13	0.3	5.49e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs7903847	0.642	rs9887991	chr10:99159634	T/C	cg20016023	chr10:99160130	RRP12	-0.3	-5.24	-0.31	3.3e-7	Granulocyte percentage of myeloid white cells;
CESC	cis	rs72781680	0.898	rs72780125	chr2:24000145	T/C	cg20701182	chr2:24300061	SF3B14	0.78	6.7	0.38	1.22e-10	Lymphocyte counts;
CESC	cis	rs17407555	0.909	rs73224409	chr4:10290646	G/T	cg11266682	chr4:10021025	SLC2A9	-0.48	-5.81	-0.34	1.83e-8	Schizophrenia (age at onset);
CESC	cis	rs8067545	0.750	rs35003563	chr17:19989218	G/A	cg13482628	chr17:19912719	NA	0.39	5.39	0.31	1.58e-7	Schizophrenia;
CESC	cis	rs4141404	0.818	rs6518737	chr22:31582662	A/G	cg02404636	chr22:31891804	SFI1	-0.38	-5.49	-0.32	9.52e-8	Paclitaxel-induced neuropathy;
CESC	cis	rs344364	0.511	rs1742472	chr16:1953040	A/G	cg03013636	chr16:1946785	NA	0.49	6.83	0.39	5.92e-11	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs1218582	0.772	rs11264282	chr1:154867370	G/A	cg09359103	chr1:154839909	KCNN3	-0.66	-12.68	-0.61	4.13e-29	Prostate cancer;
CESC	cis	rs769267	0.930	rs1047361	chr19:19606634	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.47	5.84	0.34	1.51e-8	Tonsillectomy;
CESC	cis	rs12144309	0.608	rs1217417	chr1:114400904	C/G	cg13572289	chr1:114447746	DCLRE1B;AP4B1	0.45	5.09	0.3	6.69e-7	Coronary artery disease;
CESC	cis	rs7666738	0.830	rs58696666	chr4:99006913	C/T	cg18180107	chr4:99064573	C4orf37	0.4	5.23	0.31	3.41e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3806843	0.735	rs809635	chr5:140081791	A/G	cg26395211	chr5:140044315	WDR55	0.48	6.15	0.35	2.79e-9	Depressive symptoms (multi-trait analysis);
CESC	cis	rs2014572	0.967	rs10426174	chr19:57756055	G/A	cg24459738	chr19:57751996	ZNF805	-0.54	-7.78	-0.43	1.67e-13	Hyperactive-impulsive symptoms;
CESC	cis	rs6484504	0.576	rs438578	chr11:31222579	A/G	cg14844989	chr11:31128820	NA	0.4	5.58	0.32	6.07e-8	Red blood cell count;
CESC	cis	rs875971	0.862	rs778705	chr7:65861115	G/A	cg10691866	chr7:65817282	TPST1	-0.33	-5.43	-0.32	1.3e-7	Aortic root size;
CESC	cis	rs12586317	0.547	rs45531432	chr14:35484423	C/T	cg05294307	chr14:35346193	BAZ1A	-0.51	-5.48	-0.32	1.01e-7	Psoriasis;
CESC	cis	rs965469	1.000	rs6051715	chr20:3266548	C/T	cg25506879	chr20:3388711	C20orf194	-0.55	-6.0	-0.35	6.41e-9	IFN-related cytopenia;
CESC	cis	rs3820068	0.705	rs58424111	chr1:15868470	A/C	cg18192808	chr1:15853278	DNAJC16	0.46	5.63	0.33	4.49e-8	Systolic blood pressure;
CESC	cis	rs1355223	0.583	rs2915238	chr11:34884405	C/A	cg24088639	chr11:34937564	PDHX;APIP	-0.41	-5.17	-0.3	4.72e-7	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs2816062	0.786	rs2816055	chr1:18898248	A/G	cg18795169	chr1:18902165	NA	-0.94	-18.87	-0.76	6.42e-51	Urate levels in lean individuals;
CESC	cis	rs6582630	0.555	rs6582503	chr12:38557886	A/C	cg13010199	chr12:38710504	ALG10B	0.56	7.18	0.4	7.18e-12	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs736408	0.609	rs2336545	chr3:52787603	C/T	cg18099408	chr3:52552593	STAB1	0.31	5.13	0.3	5.62e-7	Bipolar disorder;
CESC	cis	rs2066819	1.000	rs1802236	chr12:56679751	A/G	cg26804944	chr12:56660921	COQ10A	-0.85	-5.19	-0.3	4.22e-7	Psoriasis vulgaris;
CESC	cis	rs1620921	0.524	rs4440440	chr6:161183424	A/C	cg01280913	chr6:161186852	NA	-0.43	-6.41	-0.37	6.63e-10	Lipoprotein (a) - cholesterol levels;
CESC	cis	rs7084402	0.967	rs1649026	chr10:60281400	A/G	cg07615347	chr10:60278583	BICC1	-0.58	-9.28	-0.5	6.09e-18	Refractive error;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17687970	chr8:22462467	KIAA1967	0.58	6.65	0.38	1.63e-10	Gut microbiome composition (summer);
CESC	trans	rs12356475	0.710	rs10822686	chr10:67733250	C/T	cg23286353	chr2:97523832	ANKRD39	0.5	6.13	0.35	3.17e-9	Psoriatic arthritis;
CESC	cis	rs11690935	1.000	rs312918	chr2:172569587	C/G	cg13550731	chr2:172543902	DYNC1I2	-1.0	-16.63	-0.71	5.26e-43	Schizophrenia;
CESC	cis	rs7937682	0.824	rs11213962	chr11:111506027	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.99	-16.01	-0.7	8.36e-41	Primary sclerosing cholangitis;
CESC	cis	rs2576037	0.526	rs658756	chr18:44431832	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.44	7.38	0.41	2.1e-12	Personality dimensions;
CESC	cis	rs2625529	0.689	rs8178	chr15:72114747	G/A	cg16672083	chr15:72433130	SENP8	-0.53	-7.9	-0.44	7.57e-14	Red blood cell count;
CESC	cis	rs7666738	0.830	rs6840766	chr4:99016260	C/G	cg18180107	chr4:99064573	C4orf37	0.4	5.3	0.31	2.48e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2933343	0.700	rs6787833	chr3:128656184	A/G	cg25356066	chr3:128598488	ACAD9	0.61	8.56	0.47	9.37e-16	IgG glycosylation;
CESC	cis	rs10411936	0.720	rs4808513	chr19:16580498	G/C	cg10248733	chr19:16607483	C19orf44;CALR3	0.53	6.62	0.38	1.96e-10	White blood cell count;Multiple sclerosis;
CESC	cis	rs2708240	0.967	rs2247043	chr7:147580236	T/G	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.36	-5.99	-0.35	6.79e-9	QT interval (drug interaction);
CESC	cis	rs763121	0.853	rs8142098	chr22:39058757	T/G	cg06022373	chr22:39101656	GTPBP1	0.88	13.88	0.65	2.66e-33	Menopause (age at onset);
CESC	cis	rs3857536	0.706	rs7749120	chr6:66889832	T/G	cg07460842	chr6:66804631	NA	-0.42	-5.39	-0.31	1.56e-7	Blood trace element (Cu levels);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg21395147	chr1:211849137	NEK2	-0.53	-6.85	-0.39	5.12e-11	Ulcerative colitis;
CESC	cis	rs7945705	0.934	rs1988709	chr11:8882890	A/T	cg12365402	chr11:9010492	NRIP3	0.36	5.54	0.32	7.27e-8	Hemoglobin concentration;
CESC	cis	rs901683	1.000	rs12762495	chr10:46013615	T/C	cg16031567	chr10:46195673	NA	-0.77	-5.04	-0.3	8.57e-7	Red blood cell traits;Mean corpuscular volume;
CESC	cis	rs3741404	0.584	rs645461	chr11:63893694	C/T	cg18225595	chr11:63971243	STIP1	-0.64	-9.02	-0.48	3.93e-17	Platelet count;
CESC	cis	rs8077577	0.689	rs16961133	chr17:18223548	C/T	cg16794390	chr17:18148240	FLII	0.4	6.34	0.36	9.98e-10	Obesity-related traits;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg23435730	chr3:127770634	SEC61A1	0.46	5.99	0.35	6.66e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs9914988	0.943	rs7215310	chr17:27088626	G/T	cg20469991	chr17:27169893	C17orf63	-0.5	-5.45	-0.32	1.13e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CESC	cis	rs4423214	0.650	rs4245442	chr11:71220909	T/C	cg05163923	chr11:71159392	DHCR7	0.78	9.81	0.52	1.41e-19	Vitamin D levels;
CESC	cis	rs514406	0.607	rs11206000	chr1:53205923	A/C	cg27535305	chr1:53392650	SCP2	0.35	6.14	0.35	3.01e-9	Monocyte count;
CESC	cis	rs12477438	0.520	rs6542870	chr2:99796638	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.84	15.36	0.69	1.63e-38	Chronic sinus infection;
CESC	cis	rs6952808	0.929	rs11761270	chr7:1923695	C/T	cg00106254	chr7:1943704	MAD1L1	-0.5	-6.27	-0.36	1.48e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs10883723	0.773	rs11191303	chr10:104255158	T/C	ch.10.2196322F	chr10:104248062	ACTR1A	0.42	5.08	0.3	6.99e-7	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs7666738	0.830	rs2865989	chr4:99067532	G/A	cg17366294	chr4:99064904	C4orf37	0.61	8.5	0.46	1.41e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2075371	0.863	rs2075370	chr7:133967812	A/G	cg11752832	chr7:134001865	SLC35B4	0.52	6.78	0.38	7.85e-11	Mean platelet volume;
CESC	cis	rs3820068	0.608	rs12091644	chr1:16044945	G/A	cg17385448	chr1:15911702	AGMAT	0.38	5.93	0.34	9.29e-9	Systolic blood pressure;
CESC	cis	rs853679	0.517	rs9393891	chr6:28079160	C/T	cg17949981	chr6:28129498	ZNF389	0.45	5.63	0.33	4.71e-8	Depression;
CESC	cis	rs11750568	0.967	rs6879775	chr5:178515196	A/G	cg10208897	chr5:178548229	ADAMTS2	-0.38	-5.19	-0.3	4.15e-7	Height;
CESC	cis	rs2204008	0.748	rs8186658	chr12:38301461	A/C	cg26384229	chr12:38710491	ALG10B	0.64	9.48	0.5	1.53e-18	Bladder cancer;
CESC	trans	rs9987353	0.840	rs329994	chr8:9123233	A/G	cg25103766	chr1:120838445	FAM72B	-0.46	-6.16	-0.35	2.73e-9	Recombination measurement;
CESC	cis	rs736408	0.609	rs62255396	chr3:52782839	C/T	cg18099408	chr3:52552593	STAB1	-0.31	-5.08	-0.3	7.13e-7	Bipolar disorder;
CESC	cis	rs644799	0.710	rs11021311	chr11:95505227	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	11.61	0.58	1.86e-25	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs3820068	0.705	rs4646085	chr1:15825411	A/T	cg17385448	chr1:15911702	AGMAT	0.38	5.99	0.35	6.96e-9	Systolic blood pressure;
CESC	cis	rs9733	0.596	rs6678013	chr1:150623285	T/G	cg18016565	chr1:150552671	MCL1	0.33	5.13	0.3	5.67e-7	Tonsillectomy;
CESC	cis	rs951366	0.677	rs1775140	chr1:205672107	C/A	cg14159672	chr1:205819179	PM20D1	0.76	10.94	0.56	3.03e-23	Menarche (age at onset);
CESC	cis	rs3820928	0.874	rs10207404	chr2:227794420	T/C	cg11843606	chr2:227700838	RHBDD1	-0.43	-5.73	-0.33	2.73e-8	Pulmonary function;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16581532	chr11:66445312	RBM4B	0.58	6.26	0.36	1.57e-9	Gut microbiome composition (summer);
CESC	trans	rs9693444	0.898	rs4732697	chr8:29519861	A/G	cg17436476	chr1:62120002	NA	0.37	6.09	0.35	4.05e-9	Breast cancer;
CESC	cis	rs477895	0.653	rs12797120	chr11:63906819	C/T	cg18225595	chr11:63971243	STIP1	0.52	5.13	0.3	5.55e-7	Mean platelet volume;
CESC	trans	rs921968	0.541	rs667251	chr2:219384384	C/G	cg15547669	chr20:2781122	CPXM1	0.36	6.01	0.35	6.14e-9	Mean corpuscular hemoglobin concentration;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg26401822	chr12:123459832	ABCB9;OGFOD2	-0.55	-7.19	-0.4	6.68e-12	Fibrinogen levels;
CESC	cis	rs6495122	0.618	rs4886413	chr15:75262310	G/C	cg09165964	chr15:75287851	SCAMP5	0.49	6.49	0.37	4.14e-10	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
CESC	cis	rs2380220	1.000	rs9632496	chr6:95976450	C/G	cg15832292	chr6:96025679	MANEA	0.66	6.14	0.35	3.01e-9	Behavioural disinhibition (generation interaction);
CESC	cis	rs7666738	0.688	rs35739409	chr4:98576934	C/T	cg17366294	chr4:99064904	C4orf37	0.5	5.25	0.31	3.08e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6502050	0.835	rs34287733	chr17:80078236	C/T	cg23985595	chr17:80112537	CCDC57	0.42	6.56	0.37	2.87e-10	Life satisfaction;
CESC	cis	rs1144333	1.000	rs5745327	chr1:76270040	A/T	cg22875332	chr1:76189707	ACADM	-0.56	-5.8	-0.34	1.93e-8	Attention function in attention deficit hyperactive disorder;
CESC	cis	rs2247341	1.000	rs13124276	chr4:1700368	C/T	cg07465881	chr4:1713556	SLBP	-0.54	-6.94	-0.39	2.99e-11	Hip circumference adjusted for BMI;Height;
CESC	cis	rs898097	0.812	rs7406011	chr17:80829980	C/T	cg15664640	chr17:80829946	TBCD	-0.63	-8.99	-0.48	4.82e-17	Breast cancer;
CESC	cis	rs6540559	0.546	rs735693	chr1:210033988	A/C	cg21951975	chr1:209979733	IRF6	0.55	6.46	0.37	5.11e-10	Cleft lip with or without cleft palate;
CESC	cis	rs801193	0.569	rs7782587	chr7:66166472	C/T	cg12463550	chr7:65579703	CRCP	0.49	6.35	0.36	9.31e-10	Aortic root size;
CESC	cis	rs5750830	0.645	rs756640	chr22:39779300	G/A	cg02038168	chr22:39784481	NA	-0.56	-7.62	-0.42	4.59e-13	Intelligence (multi-trait analysis);
CESC	cis	rs853679	0.517	rs9368557	chr6:28131537	T/C	cg17949981	chr6:28129498	ZNF389	0.45	5.57	0.32	6.26e-8	Depression;
CESC	cis	rs634534	0.561	rs655744	chr11:65776585	G/T	cg02202077	chr11:65769826	EIF1AD;BANF1	-0.46	-6.24	-0.36	1.76e-9	Sum eosinophil basophil counts;Eosinophil counts;
CESC	cis	rs6484504	0.576	rs158146	chr11:31210433	G/A	cg14844989	chr11:31128820	NA	-0.37	-5.38	-0.31	1.65e-7	Red blood cell count;
CESC	trans	rs7307889	0.793	rs12320367	chr12:6012462	G/A	cg18407955	chr7:158110685	PTPRN2	-0.77	-6.94	-0.39	2.96e-11	Obesity-related traits;
CESC	cis	rs838147	0.508	rs507766	chr19:49208543	T/C	cg21064579	chr19:49206444	FUT2	0.44	6.15	0.35	2.83e-9	Dietary macronutrient intake;
CESC	cis	rs11676348	0.846	rs7594532	chr2:219008000	T/C	cg00012203	chr2:219082015	ARPC2	-0.58	-7.46	-0.42	1.21e-12	Ulcerative colitis;
CESC	cis	rs6429082	0.608	rs903348	chr1:235571343	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.54	-6.77	-0.38	8.47e-11	Adiposity;
CESC	cis	rs67478160	0.643	rs8005594	chr14:104279889	T/C	cg08213375	chr14:104286397	PPP1R13B	0.54	10.64	0.55	2.94e-22	Schizophrenia;
CESC	cis	rs12586317	0.620	rs79832710	chr14:35547434	G/T	cg05294307	chr14:35346193	BAZ1A	-0.5	-5.32	-0.31	2.2e-7	Psoriasis;
CESC	cis	rs2637266	0.739	rs727902	chr10:78436425	A/C	cg18941641	chr10:78392320	NA	0.4	7.32	0.41	2.99e-12	Pulmonary function;
CESC	cis	rs7666738	0.830	rs10017201	chr4:98983561	G/A	cg05340658	chr4:99064831	C4orf37	0.8	12.42	0.61	3.31e-28	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08674093	chr3:182697846	DCUN1D1	-0.66	-7.57	-0.42	6.39e-13	Gut microbiome composition (summer);
CESC	cis	rs7044106	0.791	rs12554440	chr9:123485333	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.88	14.11	0.66	4.17e-34	Hip circumference adjusted for BMI;
CESC	cis	rs875971	0.638	rs10278816	chr7:66036987	T/C	cg25985355	chr7:65971099	NA	0.33	5.39	0.31	1.53e-7	Aortic root size;
CESC	cis	rs3749237	0.595	rs11720264	chr3:49580347	C/T	cg03060546	chr3:49711283	APEH	0.75	11.44	0.58	6.67e-25	Resting heart rate;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg13318091	chr8:27145541	TRIM35	0.53	7.32	0.41	2.91e-12	Fibrinogen levels;
CESC	trans	rs61931739	0.517	rs2636073	chr12:34063049	C/T	cg26384229	chr12:38710491	ALG10B	0.52	6.96	0.39	2.64e-11	Morning vs. evening chronotype;
CESC	cis	rs4588572	0.643	rs10043115	chr5:77692019	T/C	cg11547950	chr5:77652471	NA	0.46	5.98	0.34	7.29e-9	Triglycerides;
CESC	trans	rs61931739	0.782	rs451940	chr12:34196005	T/C	cg26384229	chr12:38710491	ALG10B	0.48	6.59	0.38	2.37e-10	Morning vs. evening chronotype;
CESC	cis	rs736408	0.716	rs2239550	chr3:52822509	G/C	cg17372223	chr3:52568218	NT5DC2	0.39	5.49	0.32	9.29e-8	Bipolar disorder;
CESC	cis	rs34779708	0.966	rs11599606	chr10:35406626	G/A	cg04310649	chr10:35416472	CREM	-0.54	-6.45	-0.37	5.33e-10	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs1799949	0.929	rs799905	chr17:41277187	G/C	cg23758822	chr17:41437982	NA	1.0	17.42	0.73	7.78e-46	Menopause (age at onset);
CESC	cis	rs9611565	0.694	rs202616	chr22:41822221	C/G	cg06481639	chr22:41940642	POLR3H	0.64	6.41	0.37	6.73e-10	Vitiligo;
CESC	cis	rs4835473	0.897	rs7682204	chr4:144887459	T/G	cg25736465	chr4:144833511	NA	0.41	6.43	0.37	6.01e-10	Immature fraction of reticulocytes;
CESC	cis	rs7618915	0.547	rs33967311	chr3:52683864	G/T	cg18337363	chr3:52569053	NT5DC2	0.3	5.5	0.32	8.98e-8	Bipolar disorder;
CESC	cis	rs7927771	0.832	rs4752990	chr11:47410393	G/A	cg20307385	chr11:47447363	PSMC3	-0.62	-7.65	-0.43	3.64e-13	Subjective well-being;
CESC	cis	rs6942756	0.806	rs2718093	chr7:128939582	G/A	cg02491457	chr7:128862824	NA	-0.63	-9.0	-0.48	4.48e-17	White matter hyperintensity burden;
CESC	cis	rs916888	0.610	rs199454	chr17:44800110	G/A	cg17911788	chr17:44343683	NA	0.43	6.71	0.38	1.16e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs208520	0.690	rs866452	chr6:66849936	A/T	cg07460842	chr6:66804631	NA	-0.92	-12.59	-0.61	8.53e-29	Exhaled nitric oxide output;
CESC	cis	rs561341	1.000	rs1681718	chr17:30296445	G/A	cg00745463	chr17:30367425	LRRC37B	-0.81	-7.35	-0.41	2.5e-12	Hip circumference adjusted for BMI;
CESC	cis	rs826838	0.967	rs2892410	chr12:38990282	A/G	cg26384229	chr12:38710491	ALG10B	-0.83	-14.62	-0.67	6.94e-36	Heart rate;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg19029301	chr20:30795553	POFUT1;PLAGL2	-0.53	-7.28	-0.41	3.76e-12	Asthma;
CESC	cis	rs9467711	0.606	rs9379859	chr6:26369549	C/T	cg12826209	chr6:26865740	GUSBL1	0.62	5.22	0.31	3.66e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs4237845	0.537	rs59401446	chr12:58259564	G/A	cg02175503	chr12:58329896	NA	0.43	5.03	0.3	8.94e-7	Intelligence (multi-trait analysis);
CESC	cis	rs3096299	0.967	rs2965827	chr16:89457350	A/C	cg00750074	chr16:89608354	SPG7	0.36	5.2	0.3	4.07e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs7086627	0.515	rs2125040	chr10:82208422	G/C	cg03267442	chr10:82210566	NA	-0.34	-5.6	-0.33	5.31e-8	Post bronchodilator FEV1;
CESC	cis	rs875971	0.862	rs9791712	chr7:66105163	C/G	cg18876405	chr7:65276391	NA	-0.5	-6.67	-0.38	1.46e-10	Aortic root size;
CESC	cis	rs12545109	0.837	rs1437277	chr8:57356734	T/C	cg09654669	chr8:57350985	NA	-0.6	-6.98	-0.39	2.44e-11	Obesity-related traits;
CESC	cis	rs7659604	0.540	rs28672860	chr4:122705051	G/A	cg19748678	chr4:122722346	EXOSC9	-0.42	-5.28	-0.31	2.64e-7	Type 2 diabetes;
CESC	cis	rs4242434	0.819	rs55776566	chr8:22469492	T/C	cg03733263	chr8:22462867	KIAA1967	0.87	14.78	0.67	1.87e-36	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CESC	cis	rs7552404	0.727	rs5745433	chr1:76333163	T/G	cg10523679	chr1:76189770	ACADM	0.69	6.69	0.38	1.32e-10	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs514406	0.861	rs7518390	chr1:53233374	A/G	cg08859206	chr1:53392774	SCP2	0.48	6.33	0.36	1.06e-9	Monocyte count;
CESC	cis	rs514406	0.929	rs562178	chr1:53319562	T/C	cg25767906	chr1:53392781	SCP2	-0.45	-5.76	-0.33	2.27e-8	Monocyte count;
CESC	cis	rs909674	0.818	rs5750830	chr22:39840828	C/A	cg05872129	chr22:39784769	NA	-0.81	-9.9	-0.52	7.26e-20	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs597539	0.690	rs552517	chr11:68625286	T/G	cg18350739	chr11:68623251	NA	-0.44	-6.49	-0.37	4.16e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs9640161	0.711	rs55881542	chr7:150025734	G/A	cg21361702	chr7:150065534	REPIN1	0.49	5.41	0.32	1.43e-7	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs13256369	0.802	rs1060107	chr8:8561399	G/T	cg18904891	chr8:8559673	CLDN23	0.7	7.75	0.43	1.95e-13	Obesity-related traits;
CESC	cis	rs9388451	0.505	rs9372828	chr6:126175185	A/T	cg05901451	chr6:126070800	HEY2	-0.42	-5.71	-0.33	3.01e-8	Brugada syndrome;
CESC	cis	rs3818285	0.679	rs552419	chr10:111630883	G/T	cg00817464	chr10:111662876	XPNPEP1	0.45	6.99	0.39	2.19e-11	Superior crus of antihelix expression;
CESC	cis	rs763121	0.886	rs1013339	chr22:38974680	C/T	cg06022373	chr22:39101656	GTPBP1	0.88	14.49	0.66	2.01e-35	Menopause (age at onset);
CESC	cis	rs8177179	1.000	rs8177179	chr3:133463457	G/A	cg16262614	chr3:133464971	TF	0.38	7.59	0.42	5.42e-13	Iron status biomarkers (transferrin levels);
CESC	cis	rs4727027	0.870	rs62507509	chr7:148795522	C/T	cg23158103	chr7:148848205	ZNF398	-0.42	-6.84	-0.39	5.49e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg09320337	chr8:146033038	ZNF517	0.48	6.36	0.36	8.59e-10	Fibrinogen levels;
CESC	cis	rs6061231	0.556	rs6121571	chr20:60977323	T/G	cg24112000	chr20:60950667	NA	-0.5	-7.12	-0.4	9.97e-12	Colorectal cancer;
CESC	cis	rs7666738	0.791	rs17549003	chr4:98969132	A/C	cg05340658	chr4:99064831	C4orf37	0.79	12.28	0.6	9.45e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs798554	0.757	rs2533878	chr7:2878707	A/G	cg18446336	chr7:2847575	GNA12	0.38	5.85	0.34	1.48e-8	Height;
CESC	trans	rs11098499	0.645	rs78422072	chr4:120281042	C/T	cg25214090	chr10:38739885	LOC399744	0.67	9.02	0.48	3.81e-17	Corneal astigmatism;
CESC	cis	rs7481584	0.924	rs12805661	chr11:3020740	C/T	cg25174290	chr11:3078921	CARS	-0.45	-5.5	-0.32	8.85e-8	Calcium levels;
CESC	cis	rs6952808	0.782	rs4236271	chr7:1881369	C/T	cg04267008	chr7:1944627	MAD1L1	-0.5	-6.05	-0.35	4.86e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs4523957	0.620	rs58187837	chr17:2073272	G/C	cg16513277	chr17:2031491	SMG6	-0.77	-11.18	-0.57	4.99e-24	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs7267979	1.000	rs6050609	chr20:25411751	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.87	-18.11	-0.74	3.06e-48	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.14	12.04	0.59	6.51e-27	Platelet count;
CESC	cis	rs9916302	0.851	rs11657899	chr17:37626963	G/A	cg00129232	chr17:37814104	STARD3	-0.54	-7.14	-0.4	9.08e-12	Glomerular filtration rate (creatinine);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02795432	chr2:204193336	ABI2	0.64	7.38	0.41	2.01e-12	Gut microbiome composition (summer);
CESC	cis	rs2228479	0.867	rs34604714	chr16:89948985	A/G	cg04013166	chr16:89971882	TCF25	0.77	7.14	0.4	8.86e-12	Skin colour saturation;
CESC	cis	rs7811142	1.000	rs11761725	chr7:100039815	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.03	9.53	0.51	1.04e-18	Platelet count;
CESC	cis	rs7618915	0.501	rs2336149	chr3:52692124	G/A	cg18404041	chr3:52824283	ITIH1	-0.38	-6.51	-0.37	3.7e-10	Bipolar disorder;
CESC	cis	rs1799949	0.550	rs2343818	chr17:41409774	G/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.38	5.08	0.3	7.13e-7	Menopause (age at onset);
CESC	cis	rs3858526	1.000	rs10838909	chr11:5960490	G/A	cg13902645	chr11:5959945	NA	-0.68	-7.8	-0.43	1.45e-13	DNA methylation (variation);
CESC	cis	rs7116495	0.609	rs4477459	chr11:71720616	T/C	cg10381502	chr11:71823885	C11orf51	-1.16	-7.71	-0.43	2.62e-13	Severe influenza A (H1N1) infection;
CESC	cis	rs8180040	1.000	rs11130127	chr3:47398793	C/G	cg27129171	chr3:47204927	SETD2	-0.68	-10.46	-0.54	1.12e-21	Colorectal cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00852613	chr13:50159829	RCBTB1	0.62	7.65	0.43	3.82e-13	Gut microbiome composition (summer);
CESC	cis	rs9488822	0.676	rs1338667	chr6:116323910	T/A	cg05304507	chr6:116381966	FRK	0.26	6.56	0.37	2.82e-10	Cholesterol, total;LDL cholesterol;
CESC	cis	rs2519796	0.531	rs2789850	chr9:136807655	T/C	cg13751417	chr9:136814406	VAV2	-0.4	-5.2	-0.3	4.02e-7	Hematocrit;Hemoglobin concentration;
CESC	cis	rs9905704	0.681	rs1468540	chr17:56561942	C/T	cg12560992	chr17:57184187	TRIM37	-0.62	-5.6	-0.33	5.46e-8	Testicular germ cell tumor;
CESC	cis	rs2745967	0.650	rs11576704	chr1:208117587	G/C	cg09788693	chr1:208063733	CD34	0.31	5.07	0.3	7.55e-7	Resting heart rate;
CESC	cis	rs5758511	0.689	rs17002947	chr22:42688532	C/T	cg00645731	chr22:42541494	CYP2D7P1	-0.49	-6.76	-0.38	8.76e-11	Birth weight;
CESC	cis	rs769267	0.930	rs2315022	chr19:19413381	A/G	cg03709012	chr19:19516395	GATAD2A	0.95	13.87	0.65	2.84e-33	Tonsillectomy;
CESC	cis	rs1986734	0.576	rs12503749	chr4:77418383	T/C	cg20311846	chr4:77356250	SHROOM3	-0.26	-5.28	-0.31	2.63e-7	Eosinophilic esophagitis (pediatric);Metabolite levels (small molecules and protein measures);
CESC	trans	rs11098499	0.754	rs7672778	chr4:120248585	A/G	cg25214090	chr10:38739885	LOC399744	0.62	8.71	0.47	3.41e-16	Corneal astigmatism;
CESC	cis	rs10791097	0.694	rs2155752	chr11:130755998	C/T	cg12179176	chr11:130786555	SNX19	0.66	10.36	0.54	2.45e-21	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs2952156	0.684	rs931992	chr17:37821435	G/T	cg00129232	chr17:37814104	STARD3	-0.82	-12.28	-0.6	9.5e-28	Asthma;
CESC	cis	rs9487051	0.676	rs7753705	chr6:109593302	A/C	cg01475377	chr6:109611718	NA	-0.44	-6.99	-0.39	2.19e-11	Reticulocyte fraction of red cells;
CESC	cis	rs1728785	1.000	rs3203684	chr16:68600440	C/T	cg02972257	chr16:68554789	NA	0.58	6.67	0.38	1.49e-10	Ulcerative colitis;
CESC	cis	rs6952808	0.689	rs11771625	chr7:2050401	C/T	cg23048001	chr7:2026167	MAD1L1	0.47	6.03	0.35	5.47e-9	Bipolar disorder and schizophrenia;
CESC	trans	rs61931739	0.534	rs1490109	chr12:34064077	T/C	cg26384229	chr12:38710491	ALG10B	0.53	7.25	0.41	4.71e-12	Morning vs. evening chronotype;
CESC	cis	rs1322639	0.657	rs12203887	chr6:169572252	C/T	cg03254818	chr6:169586852	NA	0.55	5.83	0.34	1.61e-8	Pulse pressure;
CESC	cis	rs798554	0.660	rs2644295	chr7:2860217	A/C	cg19717773	chr7:2847554	GNA12	-0.5	-7.94	-0.44	5.89e-14	Height;
CESC	cis	rs4481887	0.708	rs28729425	chr1:248563027	T/C	cg26353448	chr1:248524236	OR2T4	-0.37	-5.18	-0.3	4.42e-7	Common traits (Other);
CESC	cis	rs2576037	0.796	rs2571031	chr18:44577063	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.33	-5.13	-0.3	5.49e-7	Personality dimensions;
CESC	cis	rs7551222	0.721	rs4951080	chr1:204533284	A/G	cg20240347	chr1:204465584	NA	-0.28	-5.66	-0.33	4.03e-8	Schizophrenia;
CESC	cis	rs6860806	0.632	rs4330455	chr5:131586349	T/C	cg11843238	chr5:131593191	PDLIM4	0.37	5.36	0.31	1.84e-7	Breast cancer;
CESC	cis	rs80130819	0.688	rs7305418	chr12:48586112	A/G	cg07561017	chr12:48398056	COL2A1	0.39	5.19	0.3	4.22e-7	Prostate cancer;
CESC	cis	rs9611565	0.649	rs5758344	chr22:41817685	G/A	cg06481639	chr22:41940642	POLR3H	0.64	6.41	0.37	6.77e-10	Vitiligo;
CESC	cis	rs2836974	0.932	rs13048178	chr21:40561012	G/T	cg17971929	chr21:40555470	PSMG1	1.07	16.37	0.71	4.27e-42	Cognitive function;
CESC	cis	rs7084402	0.967	rs7097576	chr10:60277055	G/A	cg07615347	chr10:60278583	BICC1	-0.6	-9.67	-0.51	3.99e-19	Refractive error;
CESC	cis	rs9303401	0.659	rs12946397	chr17:56769979	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.03	12.82	0.62	1.31e-29	Cognitive test performance;
CESC	cis	rs68170813	0.605	rs2299428	chr7:107134384	A/G	cg02696742	chr7:106810147	HBP1	-0.55	-5.09	-0.3	6.65e-7	Coronary artery disease;
CESC	cis	rs6570726	0.935	rs424263	chr6:145840073	A/C	cg05347473	chr6:146136440	FBXO30	0.49	6.74	0.38	1e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2251381	0.515	rs2832299	chr21:30749237	G/C	cg24692254	chr21:30365293	RNF160	0.47	5.89	0.34	1.14e-8	Selective IgA deficiency;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg06689688	chr16:46918233	GPT2	-0.45	-6.23	-0.36	1.84e-9	Fibrinogen levels;
CESC	trans	rs2658782	0.826	rs2925355	chr11:93090887	T/C	cg03479527	chr8:145637966	SLC39A4	-0.41	-6.0	-0.35	6.35e-9	Pulmonary function decline;
CESC	cis	rs9287719	0.934	rs10181806	chr2:10741141	A/G	cg02196655	chr2:10830764	NOL10	-0.38	-5.83	-0.34	1.61e-8	Prostate cancer;
CESC	cis	rs1355223	0.902	rs865070	chr11:34742497	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.48	-6.33	-0.36	1.05e-9	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs4319547	0.956	rs7316149	chr12:123063912	G/A	cg23029597	chr12:123009494	RSRC2	-0.5	-5.55	-0.32	7.09e-8	Body mass index;
CESC	cis	rs67478160	0.643	rs8003653	chr14:104298836	A/G	cg08213375	chr14:104286397	PPP1R13B	0.53	10.48	0.54	9.85e-22	Schizophrenia;
CESC	cis	rs7210086	0.808	rs8073267	chr17:70639514	G/C	cg04206342	chr17:70636940	NA	-0.31	-5.69	-0.33	3.31e-8	Ulcerative colitis;
CESC	cis	rs60154123	0.772	rs815358	chr1:210430437	A/G	cg21951975	chr1:209979733	IRF6	0.46	5.93	0.34	9.5e-9	Coronary artery disease;
CESC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02008169	chr16:31885058	ZNF267	-0.53	-6.18	-0.35	2.41e-9	Response to antipsychotic treatment;
CESC	cis	rs1707322	0.964	rs6697830	chr1:46290477	C/A	cg06784218	chr1:46089804	CCDC17	0.32	5.47	0.32	1.04e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2066819	1.000	rs2291361	chr12:56717805	G/A	cg26804944	chr12:56660921	COQ10A	-0.85	-5.14	-0.3	5.39e-7	Psoriasis vulgaris;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16968475	chr7:2027283	MAD1L1	-0.6	-6.77	-0.38	8.39e-11	Gut microbiome composition (summer);
CESC	cis	rs875971	0.520	rs160645	chr7:65556307	A/G	cg18876405	chr7:65276391	NA	-0.55	-6.01	-0.35	6.19e-9	Aortic root size;
CESC	cis	rs4730250	0.707	rs257381	chr7:106803963	T/C	cg02696742	chr7:106810147	HBP1	-0.54	-5.16	-0.3	4.82e-7	Osteoarthritis;
CESC	cis	rs6977660	0.507	rs4721822	chr7:19771693	T/C	cg07541023	chr7:19748670	TWISTNB	0.8	7.31	0.41	3.17e-12	Thyroid stimulating hormone;
CESC	cis	rs400736	0.729	rs9434948	chr1:8004963	A/C	cg25007680	chr1:8021821	PARK7	-0.56	-7.72	-0.43	2.44e-13	Response to antidepressants and depression;
CESC	cis	rs9486719	0.947	rs11757102	chr6:96885073	G/A	cg06623918	chr6:96969491	KIAA0776	-0.81	-8.29	-0.45	5.61e-15	Migraine;Coronary artery disease;
CESC	cis	rs556990	0.760	rs3024739	chr13:113819948	G/A	cg18105134	chr13:113819100	PROZ	-0.66	-7.47	-0.42	1.19e-12	Blood protein levels;
CESC	cis	rs16895831	0.519	rs61298049	chr6:42540394	T/G	cg10605015	chr6:42532144	UBR2	-0.52	-5.8	-0.34	1.89e-8	Granulocyte percentage of myeloid white cells;Neutrophil percentage of white cells;Eosinophil percentage of white cells;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Neutrophil count;Sum basophil neutrophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
CESC	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg11494091	chr17:61959527	GH2	0.73	12.56	0.61	1.04e-28	Prudent dietary pattern;
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg22708233	chr11:47198576	ARFGAP2	0.39	6.12	0.35	3.33e-9	Vertical cup-disc ratio;
CESC	cis	rs9467711	0.606	rs1978	chr6:26377573	A/T	cg14345882	chr6:26364793	BTN3A2	0.62	6.47	0.37	4.76e-10	Autism spectrum disorder or schizophrenia;
CESC	cis	rs611744	0.870	rs635941	chr8:109235457	G/A	cg21045802	chr8:109455806	TTC35	0.48	5.86	0.34	1.36e-8	Dupuytren's disease;
CESC	cis	rs875971	0.862	rs801204	chr7:66022921	T/C	cg11764359	chr7:65958608	NA	-0.78	-11.22	-0.57	3.73e-24	Aortic root size;
CESC	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg04234412	chr22:24373322	LOC391322	-0.61	-8.98	-0.48	5.12e-17	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs941873	0.869	rs7917610	chr10:81117237	T/C	cg08514558	chr10:81106712	PPIF	0.36	6.22	0.36	1.94e-9	Height;
CESC	cis	rs897080	0.515	rs1085486	chr2:44617324	T/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.46	5.49	0.32	9.56e-8	Height;
CESC	cis	rs910316	1.000	rs3742773	chr14:75579643	A/G	cg11812906	chr14:75593930	NEK9	0.89	15.4	0.69	1.16e-38	Height;
CESC	cis	rs10208940	0.920	rs35878577	chr2:68737456	C/T	cg12452813	chr2:68675892	NA	0.51	5.08	0.3	7.01e-7	Urate levels in lean individuals;
CESC	cis	rs2279817	0.863	rs6586569	chr1:18027377	T/C	cg21791023	chr1:18019539	ARHGEF10L	0.55	8.09	0.45	2.11e-14	Neuroticism;
CESC	trans	rs6934970	0.860	rs9374354	chr6:112986614	C/T	cg05146922	chr2:10634174	NA	0.39	6.76	0.38	8.97e-11	Bipolar disorder (body mass index interaction);
CESC	cis	rs12534701	0.904	rs3817518	chr7:154672809	C/T	cg24255201	chr7:154684926	DPP6	0.46	6.12	0.35	3.35e-9	Colorectal cancer (diet interaction);
CESC	cis	rs727505	0.954	rs2239532	chr7:124405676	A/C	cg23710748	chr7:124431027	NA	-0.46	-7.31	-0.41	3.1e-12	Lewy body disease;
CESC	cis	rs5753037	0.653	rs131272	chr22:30153655	A/G	cg01021169	chr22:30184971	ASCC2	-0.44	-6.23	-0.36	1.83e-9	Type 1 diabetes;
CESC	cis	rs3096299	0.719	rs2965818	chr16:89510494	A/G	cg02034447	chr16:89574710	SPG7	0.46	5.83	0.34	1.64e-8	Multiple myeloma (IgH translocation);
CESC	cis	rs524281	0.773	rs2155198	chr11:66014300	C/T	cg14036092	chr11:66035641	RAB1B	-0.53	-5.31	-0.31	2.38e-7	Electroencephalogram traits;
CESC	cis	rs116095464	0.510	rs73016876	chr5:244475	T/C	cg20965017	chr5:231967	SDHA	-0.47	-5.27	-0.31	2.84e-7	Breast cancer;
CESC	cis	rs965469	0.779	rs6051785	chr20:3339199	C/T	cg25506879	chr20:3388711	C20orf194	-0.47	-5.07	-0.3	7.62e-7	IFN-related cytopenia;
CESC	cis	rs7811142	0.775	rs1636980	chr7:99938864	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	-1.13	-12.09	-0.6	4.19e-27	Platelet count;
CESC	cis	rs1153858	1.000	rs60476496	chr15:45713801	C/T	cg21132104	chr15:45694354	SPATA5L1	0.86	11.69	0.58	9.6e-26	Homoarginine levels;
CESC	cis	rs7666738	0.830	rs4401456	chr4:98959902	C/T	cg17366294	chr4:99064904	C4orf37	0.6	8.52	0.46	1.2e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs13108904	0.935	rs11247984	chr4:1292811	G/A	cg22903657	chr4:1355424	KIAA1530	-0.38	-5.14	-0.3	5.24e-7	Obesity-related traits;
CESC	cis	rs8028182	0.549	rs4886696	chr15:75664570	A/T	cg20655648	chr15:75932815	IMP3	-0.46	-5.79	-0.34	2.01e-8	Sudden cardiac arrest;
CESC	cis	rs12971120	0.947	rs8083001	chr18:72165058	A/G	cg25817165	chr18:72167213	CNDP2	-0.53	-7.49	-0.42	1.05e-12	Refractive error;
CESC	cis	rs3091242	0.933	rs926438	chr1:25753638	C/T	cg03538708	chr1:25844672	NA	-0.42	-6.28	-0.36	1.4e-9	Erythrocyte sedimentation rate;
CESC	cis	rs9733	0.596	rs34600506	chr1:150687808	C/G	cg22823121	chr1:150693482	HORMAD1	0.48	7.11	0.4	1.11e-11	Tonsillectomy;
CESC	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	22.61	0.81	8.52e-64	Prudent dietary pattern;
CESC	cis	rs7267979	0.753	rs404148	chr20:25447931	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.72	12.09	0.6	4.21e-27	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs12748961	0.557	rs823127	chr1:205713139	G/A	cg14893161	chr1:205819251	PM20D1	0.4	5.18	0.3	4.33e-7	White blood cell types;
CESC	cis	rs7274811	0.681	rs158676	chr20:31974395	G/A	cg21523528	chr20:32077966	CBFA2T2	-0.54	-6.39	-0.37	7.55e-10	Height;
CESC	cis	rs10479542	0.544	rs7706275	chr5:178990305	A/G	cg09060608	chr5:178986726	RUFY1	0.52	7.65	0.43	3.73e-13	Lung cancer;
CESC	cis	rs6582630	0.502	rs1915395	chr12:38420726	A/G	cg13010199	chr12:38710504	ALG10B	0.54	6.81	0.39	6.48e-11	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs8067354	0.527	rs1292039	chr17:57974913	A/T	cg13753209	chr17:57696993	CLTC	0.55	5.81	0.34	1.79e-8	Hemoglobin concentration;
CESC	cis	rs3845702	0.736	rs72960660	chr2:180832482	A/G	cg01881094	chr2:180872142	CWC22	1.05	8.97	0.48	5.61e-17	Schizophrenia;
CESC	cis	rs4243830	0.677	rs1556035	chr1:6579607	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.67	-6.4	-0.37	7.15e-10	Body mass index;
CESC	cis	rs7246657	0.882	rs10412043	chr19:37826626	A/C	cg23950597	chr19:37808831	NA	-0.55	-6.11	-0.35	3.53e-9	Coronary artery calcification;
CESC	cis	rs7216064	0.906	rs8074644	chr17:65878217	G/C	cg12091567	chr17:66097778	LOC651250	-0.81	-9.2	-0.49	1.14e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs875971	0.862	rs6460282	chr7:65691246	T/C	cg13147721	chr7:65941812	NA	0.37	5.03	0.3	9.01e-7	Aortic root size;
CESC	cis	rs7777484	0.534	rs2258709	chr7:2832365	C/T	cg18446336	chr7:2847575	GNA12	0.36	6.07	0.35	4.52e-9	Height;
CESC	cis	rs868036	1.000	rs7168156	chr15:68102933	T/C	cg08079166	chr15:68083412	MAP2K5	0.43	6.92	0.39	3.35e-11	Restless legs syndrome;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg05415408	chr7:30410993	DKFZP586I1420	-0.37	-6.38	-0.36	8.03e-10	Gambling;
CESC	cis	rs1797885	0.934	rs299646	chr3:12540455	G/C	cg26432171	chr3:12704882	RAF1	-0.46	-5.8	-0.34	1.89e-8	Immature fraction of reticulocytes;
CESC	cis	rs9467711	0.606	rs9348726	chr6:26605206	G/A	cg12826209	chr6:26865740	GUSBL1	0.66	5.84	0.34	1.54e-8	Autism spectrum disorder or schizophrenia;
CESC	cis	rs4665809	0.590	rs17528653	chr2:26507724	T/C	cg27170947	chr2:26402098	FAM59B	0.83	8.97	0.48	5.73e-17	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03144560	chr20:55043299	C20orf43	0.51	6.23	0.36	1.87e-9	Gut microbiome composition (summer);
CESC	cis	rs7208859	0.573	rs8070182	chr17:29135594	A/C	cg14008862	chr17:28927542	LRRC37B2	0.63	5.15	0.3	5.09e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs2717559	0.522	rs10956987	chr8:143886613	T/C	cg17252645	chr8:143867129	LY6D	-0.3	-5.41	-0.32	1.4e-7	Urinary tract infection frequency;
CESC	cis	rs10504073	0.647	rs59064792	chr8:50018337	A/C	cg00325661	chr8:49890786	NA	0.52	7.95	0.44	5.53e-14	Blood metabolite ratios;
CESC	cis	rs7520050	0.831	rs61783170	chr1:46256329	T/C	cg03146154	chr1:46216737	IPP	-0.47	-6.13	-0.35	3.18e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs6662572	0.737	rs72677533	chr1:46536558	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.46	5.16	0.3	4.9e-7	Blood protein levels;
CESC	cis	rs17376456	0.825	rs6877030	chr5:93201841	C/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.6	5.05	0.3	8.28e-7	Diabetic retinopathy;
CESC	cis	rs2228479	0.681	rs10153196	chr16:89967397	A/C	cg04013166	chr16:89971882	TCF25	0.71	8.29	0.45	5.65e-15	Skin colour saturation;
CESC	cis	rs763121	0.853	rs8142098	chr22:39058757	T/G	cg06544989	chr22:39130855	UNC84B	0.49	8.49	0.46	1.53e-15	Menopause (age at onset);
CESC	cis	rs6714710	0.603	rs953320	chr2:98606770	T/C	cg26665480	chr2:98280029	ACTR1B	0.67	8.97	0.48	5.48e-17	Posterior cortical atrophy and Alzheimer's disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg02709064	chr8:142264163	NA	0.5	6.85	0.39	5.01e-11	Fibrinogen levels;
CESC	cis	rs9910055	0.747	rs2905981	chr17:42238625	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.62	8.34	0.46	4.22e-15	Total body bone mineral density;
CESC	cis	rs7512552	0.839	rs11577843	chr1:150398258	A/G	cg15654264	chr1:150340011	RPRD2	0.4	5.3	0.31	2.4e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs5417	0.689	rs55868524	chr17:7170665	G/A	cg13768953	chr17:7114967	DLG4	0.36	5.29	0.31	2.52e-7	Diastolic blood pressure;
CESC	cis	rs300703	0.515	rs424292	chr2:191931	C/T	cg21211680	chr2:198530	NA	-0.92	-10.41	-0.54	1.63e-21	Blood protein levels;
CESC	cis	rs2011503	1.000	rs11669730	chr19:19648713	G/A	cg11584989	chr19:19387371	SF4	0.58	6.67	0.38	1.52e-10	Bipolar disorder;
CESC	cis	rs1692580	0.846	rs377599	chr1:2164699	C/T	cg24578937	chr1:2090814	PRKCZ	0.34	5.4	0.31	1.49e-7	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18885365	chr1:40420800	MFSD2A	0.62	7.26	0.41	4.25e-12	Gut microbiome composition (summer);
CESC	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg26668828	chr6:292823	DUSP22	-0.71	-9.53	-0.51	1.07e-18	Menopause (age at onset);
CESC	cis	rs8114671	0.562	rs2889861	chr20:33405664	C/T	cg08999081	chr20:33150536	PIGU	0.4	5.82	0.34	1.68e-8	Height;
CESC	trans	rs6934970	0.860	rs4631328	chr6:112983203	G/A	cg05146922	chr2:10634174	NA	-0.37	-6.17	-0.35	2.53e-9	Bipolar disorder (body mass index interaction);
CESC	cis	rs7095944	0.582	rs2303611	chr10:126517989	G/A	cg08799069	chr10:126477246	METTL10	-0.4	-5.7	-0.33	3.11e-8	Asthma;
CESC	cis	rs7927592	0.913	rs6591344	chr11:68360873	G/A	cg20283391	chr11:68216788	NA	-0.61	-7.29	-0.41	3.48e-12	Total body bone mineral density;
CESC	cis	rs35306767	0.715	rs17221456	chr10:1037234	T/C	cg20503657	chr10:835505	NA	0.64	5.62	0.33	4.8e-8	Eosinophil percentage of granulocytes;
CESC	cis	rs2857078	0.654	rs4793083	chr17:42312973	C/T	cg19774624	chr17:42201019	HDAC5	0.54	7.19	0.4	6.71e-12	Red cell distribution width;Reticulocyte count;
CESC	cis	rs854765	0.583	rs7222480	chr17:17818817	G/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.49	6.36	0.36	8.96e-10	Total body bone mineral density;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13451483	chr19:5720795	TMEM146;LONP1	-0.68	-8.33	-0.46	4.31e-15	Gut microbiome composition (summer);
CESC	cis	rs6912958	0.535	rs1753153	chr6:88032834	T/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.5	8.62	0.47	6.32e-16	Monocyte percentage of white cells;
CESC	cis	rs8014204	0.773	rs2241275	chr14:75251440	C/T	cg08847533	chr14:75593920	NEK9	-0.44	-5.65	-0.33	4.03e-8	Caffeine consumption;
CESC	cis	rs2115536	0.630	rs12102032	chr15:80233399	A/C	cg00225070	chr15:80189496	MTHFS	0.44	5.6	0.33	5.26e-8	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CESC	cis	rs3126085	0.877	rs12116736	chr1:152167062	C/T	cg03465714	chr1:152285911	FLG	-0.45	-5.53	-0.32	7.5e-8	Atopic dermatitis;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg05628496	chr17:17991167	DRG2	-0.42	-6.04	-0.35	5.12e-9	Gambling;
CESC	trans	rs9850225	0.666	rs4603923	chr3:80997120	C/T	cg27138204	chr12:54446100	HOXC4	0.39	6.41	0.37	6.75e-10	Erectile dysfunction in type 1 diabetes;
CESC	cis	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg22963979	chr7:1858916	MAD1L1	-0.39	-5.32	-0.31	2.18e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs4665809	1.000	rs1550381	chr2:26266946	A/G	cg26314531	chr2:26401878	FAM59B	-0.62	-6.93	-0.39	3.23e-11	Gut microbiome composition (summer);
CESC	cis	rs7216064	0.651	rs12947658	chr17:65903006	A/G	cg07042672	chr17:66097459	LOC651250	0.5	6.76	0.38	8.76e-11	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs4253772	0.513	rs11090863	chr22:46705407	C/T	cg00784671	chr22:46762841	CELSR1	-0.54	-5.55	-0.32	6.85e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs9733	0.519	rs3768005	chr1:150680988	A/T	cg09365446	chr1:150670422	GOLPH3L	0.38	5.28	0.31	2.65e-7	Tonsillectomy;
CESC	cis	rs72781680	0.898	rs72786279	chr2:24063266	C/T	cg20701182	chr2:24300061	SF3B14	0.62	5.6	0.33	5.24e-8	Lymphocyte counts;
CESC	cis	rs1215050	0.740	rs783949	chr4:99001933	A/G	cg17366294	chr4:99064904	C4orf37	-0.39	-5.18	-0.3	4.49e-7	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs7830933	0.955	rs1550280	chr8:23601830	C/T	cg04349084	chr8:23602677	NA	0.43	5.36	0.31	1.8e-7	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI in non-smokers;
CESC	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg07157834	chr1:205819609	PM20D1	0.85	13.84	0.65	3.67e-33	Menarche (age at onset);
CESC	cis	rs8077577	0.747	rs62072544	chr17:18243873	C/T	cg16794390	chr17:18148240	FLII	0.41	6.42	0.37	6.22e-10	Obesity-related traits;
CESC	cis	rs597539	0.652	rs673821	chr11:68678718	G/T	cg21963583	chr11:68658836	MRPL21	0.39	5.5	0.32	8.94e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs7216064	1.000	rs11079706	chr17:65835470	G/T	cg07042672	chr17:66097459	LOC651250	-0.54	-5.67	-0.33	3.73e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs7617480	0.585	rs7373072	chr3:48960017	T/A	cg06212747	chr3:49208901	KLHDC8B	0.52	6.28	0.36	1.41e-9	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14849479	chr5:60039648	NA	-0.55	-6.74	-0.38	9.63e-11	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15387272	chr1:36863509	LSM10	-0.54	-6.21	-0.36	2e-9	Gut microbiome composition (summer);
CESC	cis	rs2250402	0.510	rs8031319	chr15:40323692	A/G	cg16127683	chr15:40268777	EIF2AK4	-0.67	-5.82	-0.34	1.65e-8	Corneal curvature;
CESC	cis	rs1218582	0.772	rs906593	chr1:154885255	G/A	cg09359103	chr1:154839909	KCNN3	-0.65	-12.25	-0.6	1.22e-27	Prostate cancer;
CESC	cis	rs4654899	0.785	rs7531381	chr1:21403348	A/G	cg05370193	chr1:21551575	ECE1	0.36	5.47	0.32	1.06e-7	Superior frontal gyrus grey matter volume;
CESC	cis	rs453301	0.653	rs1045529	chr8:8890098	A/G	cg15556689	chr8:8085844	FLJ10661	-0.48	-5.96	-0.34	7.89e-9	Joint mobility (Beighton score);
CESC	cis	rs7772486	0.806	rs4243478	chr6:146284560	A/G	cg05347473	chr6:146136440	FBXO30	-0.49	-6.45	-0.37	5.39e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs3096299	0.679	rs3096322	chr16:89441123	A/G	cg08392591	chr16:89556376	ANKRD11	-0.41	-5.21	-0.3	3.81e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs270601	0.770	rs4361510	chr5:131599647	C/T	cg09877947	chr5:131593287	PDLIM4	0.48	6.32	0.36	1.11e-9	Acylcarnitine levels;
CESC	cis	rs6088590	0.965	rs6120727	chr20:33374102	T/C	cg06115741	chr20:33292138	TP53INP2	0.6	7.39	0.41	1.96e-12	Coronary artery disease;
CESC	cis	rs6696846	0.515	rs12739846	chr1:205096895	T/C	cg00857998	chr1:205179979	DSTYK	0.39	5.23	0.31	3.44e-7	Red blood cell count;
CESC	cis	rs921968	0.613	rs556497	chr2:219446477	G/A	cg02176678	chr2:219576539	TTLL4	0.42	7.28	0.41	3.73e-12	Mean corpuscular hemoglobin concentration;
CESC	cis	rs977987	0.806	rs11149833	chr16:75464002	G/C	cg03315344	chr16:75512273	CHST6	0.41	5.91	0.34	1.07e-8	Dupuytren's disease;
CESC	cis	rs7772486	0.686	rs1004752	chr6:146037822	G/A	cg05347473	chr6:146136440	FBXO30	-0.52	-6.93	-0.39	3.22e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs3617	0.539	rs12629687	chr3:52950659	T/C	cg07507251	chr3:52567010	NT5DC2	-0.34	-5.59	-0.32	5.55e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
CESC	cis	rs12325245	0.536	rs3169293	chr16:58552959	A/G	cg05725404	chr16:58534157	NDRG4	-0.61	-5.24	-0.31	3.27e-7	Schizophrenia;
CESC	trans	rs208515	0.525	rs12204452	chr6:66680325	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.89	11.12	0.56	7.77e-24	Exhaled nitric oxide levels;
CESC	cis	rs7223966	1.000	rs12325866	chr17:61755974	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.54	6.44	0.37	5.7e-10	Hip circumference adjusted for BMI;Body mass index;
CESC	trans	rs116095464	0.558	rs73029475	chr5:206969	T/C	cg00938859	chr5:1591904	SDHAP3	0.66	6.26	0.36	1.55e-9	Breast cancer;
CESC	cis	rs79349575	0.783	rs962272	chr17:46978283	A/G	cg16584676	chr17:46985605	UBE2Z	0.53	6.6	0.38	2.24e-10	Type 2 diabetes;
CESC	cis	rs13191362	0.935	rs34603926	chr6:163266793	A/T	cg21926612	chr6:163149169	PACRG;PARK2	0.67	6.26	0.36	1.54e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs9488822	0.676	rs11153593	chr6:116335131	C/A	cg26893134	chr6:116381904	FRK	0.25	6.13	0.35	3.14e-9	Cholesterol, total;LDL cholesterol;
CESC	cis	rs2288912	0.807	rs7251501	chr19:45455706	C/T	cg13119609	chr19:45449297	APOC2	0.49	8.03	0.44	3.23e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	trans	rs17181170	0.574	rs1386925	chr3:87208664	T/C	ch.2.199792288R	chr2:200084043	NA	-0.46	-6.02	-0.35	5.93e-9	Prostate cancer;
CESC	cis	rs16854884	0.580	rs1445422	chr3:143863909	G/A	cg06585982	chr3:143692056	C3orf58	0.41	5.22	0.31	3.64e-7	Economic and political preferences (feminism/equality);
CESC	cis	rs7927592	0.763	rs596494	chr11:68251054	T/G	cg01657329	chr11:68192670	LRP5	-0.47	-6.26	-0.36	1.56e-9	Total body bone mineral density;
CESC	cis	rs72634258	0.740	rs4489581	chr1:8174495	A/C	cg00042356	chr1:8021962	PARK7	-0.53	-5.76	-0.33	2.32e-8	Inflammatory bowel disease;
CESC	cis	rs829883	0.659	rs11109528	chr12:98951362	G/A	cg25150519	chr12:98850993	NA	-0.62	-7.43	-0.42	1.53e-12	Colorectal adenoma (advanced);
CESC	cis	rs10504229	1.000	rs115548028	chr8:58170672	T/C	cg24829409	chr8:58192753	C8orf71	-0.76	-10.01	-0.52	3.21e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs2249625	1.000	rs2496513	chr6:72903990	C/A	cg18830697	chr6:72922368	RIMS1	-0.44	-6.22	-0.36	1.88e-9	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CESC	cis	rs11122272	0.735	rs2295420	chr1:231485640	C/T	cg06096015	chr1:231504339	EGLN1	0.41	6.04	0.35	5.15e-9	Hemoglobin concentration;
CESC	cis	rs9488822	0.676	rs7774952	chr6:116380909	A/G	cg05304507	chr6:116381966	FRK	0.26	6.94	0.39	3.08e-11	Cholesterol, total;LDL cholesterol;
CESC	cis	rs2404602	0.583	rs35707798	chr15:76565026	G/C	cg05617483	chr15:76483344	C15orf27	0.4	5.35	0.31	1.9e-7	Blood metabolite levels;
CESC	cis	rs2486288	0.656	rs12911861	chr15:45566718	T/C	cg21132104	chr15:45694354	SPATA5L1	-0.57	-6.71	-0.38	1.17e-10	Glomerular filtration rate;
CESC	cis	rs9914544	0.966	rs9906795	chr17:18816740	G/A	cg26378065	chr17:18585709	ZNF286B	0.47	6.05	0.35	4.82e-9	Educational attainment (years of education);
CESC	cis	rs9393777	0.582	rs6936561	chr6:26640895	C/T	cg11502198	chr6:26597334	ABT1	0.52	5.34	0.31	1.99e-7	Intelligence (multi-trait analysis);
CESC	cis	rs11650494	0.908	rs78208413	chr17:47398282	G/A	cg08112188	chr17:47440006	ZNF652	1.31	8.51	0.46	1.31e-15	Prostate cancer;
CESC	cis	rs1451375	0.617	rs1807066	chr7:50543683	T/C	cg14593290	chr7:50529359	DDC	-0.53	-5.97	-0.34	7.74e-9	Malaria;
CESC	cis	rs6570726	0.935	rs906774	chr6:145813770	T/C	cg23711669	chr6:146136114	FBXO30	0.83	12.36	0.6	5.07e-28	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2456568	0.508	rs1607403	chr11:93660514	A/G	cg26875233	chr11:93583750	C11orf90	-0.32	-5.66	-0.33	3.88e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
CESC	cis	rs13256369	0.802	rs1060106	chr8:8561452	A/G	cg17143192	chr8:8559678	CLDN23	0.75	8.46	0.46	1.78e-15	Obesity-related traits;
CESC	cis	rs116095464	0.558	rs6962	chr5:256509	G/A	cg10591111	chr5:226296	SDHA	-0.52	-5.76	-0.33	2.38e-8	Breast cancer;
CESC	cis	rs2204008	0.806	rs11520229	chr12:38246448	C/A	cg13010199	chr12:38710504	ALG10B	0.51	6.3	0.36	1.24e-9	Bladder cancer;
CESC	cis	rs4665809	1.000	rs6546767	chr2:26328746	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.66	-7.37	-0.41	2.12e-12	Gut microbiome composition (summer);
CESC	cis	rs71277158	0.688	rs888507	chr3:169811039	G/C	cg04067573	chr3:169899625	PHC3	0.67	6.67	0.38	1.49e-10	Prostate cancer;
CESC	cis	rs1707322	0.721	rs61784800	chr1:46178112	A/G	cg03146154	chr1:46216737	IPP	-0.76	-10.9	-0.56	4.26e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7666738	0.830	rs6830124	chr4:99054872	C/T	cg05340658	chr4:99064831	C4orf37	-0.82	-12.66	-0.61	4.75e-29	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9902453	0.967	rs12450441	chr17:28495021	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	7.88	0.44	8.52e-14	Coffee consumption (cups per day);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07908229	chr1:182353640	GLUL	-0.61	-6.89	-0.39	3.98e-11	Gut microbiome composition (summer);
CESC	cis	rs4665809	1.000	rs12469163	chr2:26283587	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.66	-7.45	-0.42	1.28e-12	Gut microbiome composition (summer);
CESC	cis	rs7223966	1.000	rs11654335	chr17:61797579	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.68	0.38	1.4e-10	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs9929218	1.000	rs2113201	chr16:68815000	C/T	cg02972257	chr16:68554789	NA	0.49	5.99	0.35	6.8e-9	Colorectal cancer;
CESC	cis	rs8038465	0.550	rs11072431	chr15:73987642	T/A	cg15420318	chr15:73925796	NPTN	0.45	6.47	0.37	4.76e-10	Liver enzyme levels (gamma-glutamyl transferase);
CESC	trans	rs3808502	0.549	rs1382563	chr8:11426790	C/G	cg15556689	chr8:8085844	FLJ10661	0.52	6.59	0.38	2.42e-10	Neuroticism;
CESC	cis	rs6061231	0.740	rs11698650	chr20:60958374	A/T	cg06197360	chr20:60970103	CABLES2	-0.35	-5.06	-0.3	7.82e-7	Colorectal cancer;
CESC	cis	rs1018836	0.632	rs7017295	chr8:91482356	C/T	cg16814680	chr8:91681699	NA	0.61	8.73	0.47	2.96e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	trans	rs71327718	1	rs71327718	chr3:125592857	C/G	cg07211511	chr3:129823064	LOC729375	-0.88	-7.98	-0.44	4.31e-14	Metabolite levels (HVA/5-HIAA ratio);
CESC	cis	rs3858526	0.883	rs1453429	chr11:5933478	C/T	cg13902645	chr11:5959945	NA	-0.64	-7.71	-0.43	2.55e-13	DNA methylation (variation);
CESC	cis	rs9768139	0.611	rs12698211	chr7:158119623	G/A	cg27057461	chr7:158136379	PTPRN2	-0.33	-5.17	-0.3	4.6e-7	Calcium levels;
CESC	cis	rs57502260	0.704	rs923346	chr11:68182375	T/C	cg20283391	chr11:68216788	NA	-0.58	-5.23	-0.31	3.41e-7	Total body bone mineral density (age 45-60);
CESC	trans	rs9467711	0.539	rs34436535	chr6:26370365	G/C	cg06606381	chr12:133084897	FBRSL1	-0.76	-6.86	-0.39	4.71e-11	Autism spectrum disorder or schizophrenia;
CESC	trans	rs6089829	0.962	rs6122344	chr20:61661738	C/T	cg23505145	chr19:12996616	KLF1	0.52	6.7	0.38	1.24e-10	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09199072	chr6:116692265	DSE	0.59	6.64	0.38	1.78e-10	Gut microbiome composition (summer);
CESC	cis	rs11031096	0.617	rs12288918	chr11:4191466	G/T	cg18678763	chr11:4115507	RRM1	-0.4	-5.18	-0.3	4.46e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg16590910	chr6:42928470	GNMT	0.45	6.43	0.37	5.88e-10	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs4713118	0.662	rs9468274	chr6:28026077	G/T	cg22143856	chr6:28129313	ZNF389	0.42	5.26	0.31	2.91e-7	Parkinson's disease;
CESC	cis	rs6893300	0.785	rs58386410	chr5:179205704	T/C	cg14593053	chr5:179126677	CANX	-0.49	-5.86	-0.34	1.34e-8	Resting heart rate;
CESC	cis	rs10479542	0.892	rs7723230	chr5:178980474	T/C	cg14820908	chr5:178986412	RUFY1	0.46	7.12	0.4	1.03e-11	Lung cancer;
CESC	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.52	-7.09	-0.4	1.23e-11	Longevity;Endometriosis;
CESC	cis	rs854765	0.583	rs7207043	chr17:17819188	A/G	cg16928487	chr17:17741425	SREBF1	-0.56	-9.74	-0.51	2.34e-19	Total body bone mineral density;
CESC	cis	rs910316	0.726	rs175040	chr14:75469555	A/G	cg16144293	chr14:75469539	EIF2B2	0.42	5.66	0.33	3.94e-8	Height;
CESC	cis	rs7772486	0.790	rs2249147	chr6:146184999	T/C	cg23711669	chr6:146136114	FBXO30	0.89	13.11	0.63	1.37e-30	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4253772	0.591	rs6007732	chr22:46652303	A/T	cg24881330	chr22:46731750	TRMU	0.87	9.84	0.52	1.13e-19	LDL cholesterol;Cholesterol, total;
CESC	cis	rs17401966	0.838	rs9332414	chr1:10326963	C/T	cg15208524	chr1:10270712	KIF1B	0.42	5.54	0.32	7.36e-8	Hepatocellular carcinoma;
CESC	trans	rs9329221	0.657	rs17694485	chr8:10114458	A/T	cg15556689	chr8:8085844	FLJ10661	0.59	7.03	0.4	1.73e-11	Neuroticism;
CESC	cis	rs56399783	0.614	rs73047368	chr7:2766396	G/T	cg19731401	chr7:2775893	GNA12	0.66	5.62	0.33	4.75e-8	Childhood ear infection;
CESC	cis	rs1620921	0.505	rs4708886	chr6:161206350	G/T	cg01280913	chr6:161186852	NA	-0.41	-6.2	-0.36	2.15e-9	Lipoprotein (a) - cholesterol levels;
CESC	cis	rs2952156	0.883	rs8077172	chr17:37834977	G/T	cg19468946	chr17:37922297	IKZF3	-0.39	-5.1	-0.3	6.37e-7	Asthma;
CESC	cis	rs2576037	0.583	rs8094654	chr18:44527397	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.37	5.89	0.34	1.17e-8	Personality dimensions;
CESC	cis	rs7618915	0.501	rs13060048	chr3:52598608	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.49	7.18	0.4	6.94e-12	Bipolar disorder;
CESC	cis	rs7552404	0.731	rs17650138	chr1:76398887	C/T	cg10523679	chr1:76189770	ACADM	-0.69	-6.5	-0.37	4.03e-10	Blood metabolite levels;Acylcarnitine levels;
CESC	trans	rs7615952	1.000	rs7615952	chr3:125649403	A/C	cg07211511	chr3:129823064	LOC729375	1.09	16.22	0.71	1.47e-41	Blood pressure (smoking interaction);
CESC	cis	rs11098499	0.954	rs35063680	chr4:120387102	T/C	cg09307838	chr4:120376055	NA	0.95	13.96	0.65	1.42e-33	Corneal astigmatism;
CESC	cis	rs3820928	0.904	rs60906902	chr2:227760034	C/T	cg11843606	chr2:227700838	RHBDD1	-0.39	-5.15	-0.3	5.03e-7	Pulmonary function;
CESC	cis	rs9814567	1.000	rs2056604	chr3:134312648	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.4	-5.44	-0.32	1.21e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs4665809	0.556	rs10221814	chr2:26442759	C/T	cg22920501	chr2:26401640	FAM59B	-0.93	-10.94	-0.56	3.12e-23	Gut microbiome composition (summer);
CESC	cis	rs4975709	0.589	rs4975746	chr5:1861069	G/A	cg15595755	chr5:1867978	NA	0.5	8.01	0.44	3.67e-14	Cardiovascular disease risk factors;
CESC	cis	rs7208859	0.623	rs3752020	chr17:29111125	T/G	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.17e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs9649465	1.000	rs1073670	chr7:123345029	A/C	cg04330084	chr7:123175371	IQUB	-0.38	-5.16	-0.3	4.75e-7	Migraine;
CESC	cis	rs17125944	0.615	rs12589020	chr14:53312002	C/T	cg00686598	chr14:53173677	PSMC6	0.89	6.86	0.39	4.76e-11	Alzheimer's disease (late onset);
CESC	cis	rs13191362	1.000	rs13207239	chr6:163008772	A/C	cg14584255	chr6:163149320	PACRG;PARK2	0.5	5.15	0.3	4.98e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs2721195	0.614	rs12719778	chr8:145879883	T/C	cg17328964	chr8:145687451	CYHR1	-0.41	-5.47	-0.32	1.05e-7	Age at first birth;
CESC	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg06873352	chr17:61820015	STRADA	0.73	12.99	0.62	3.49e-30	Prudent dietary pattern;
CESC	cis	rs2228479	0.850	rs17232910	chr16:89839766	G/C	cg04013166	chr16:89971882	TCF25	0.78	6.69	0.38	1.3e-10	Skin colour saturation;
CESC	cis	rs35306767	0.855	rs35666723	chr10:867346	A/G	cg10556349	chr10:835070	NA	0.76	6.36	0.36	8.79e-10	Eosinophil percentage of granulocytes;
CESC	cis	rs9926296	0.585	rs1800337	chr16:89845194	A/G	cg27121462	chr16:89883253	FANCA	0.79	11.63	0.58	1.54e-25	Vitiligo;
CESC	cis	rs6952808	0.564	rs73038441	chr7:2139286	T/C	cg23048001	chr7:2026167	MAD1L1	0.45	5.75	0.33	2.4e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs35306767	0.715	rs17221463	chr10:1038040	T/C	cg20503657	chr10:835505	NA	0.67	6.01	0.35	6.13e-9	Eosinophil percentage of granulocytes;
CESC	cis	rs919433	1.000	rs2889363	chr2:198163699	A/G	cg10820045	chr2:198174542	NA	-0.42	-6.44	-0.37	5.57e-10	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	trans	rs748404	0.587	rs9920879	chr15:43639770	A/G	cg24053811	chr14:70265306	SLC10A1	0.43	6.11	0.35	3.52e-9	Lung cancer;
CESC	cis	rs3126085	0.877	rs1552992	chr1:152171625	C/G	cg26876637	chr1:152193138	HRNR	0.44	5.11	0.3	6.25e-7	Atopic dermatitis;
CESC	cis	rs2304069	0.565	rs13183261	chr5:149421847	T/G	cg12661370	chr5:149340060	SLC26A2	0.44	5.83	0.34	1.61e-8	HIV-1 control;
CESC	cis	rs116095464	1.000	rs7721278	chr5:310530	G/A	cg10591111	chr5:226296	SDHA	-0.61	-5.81	-0.34	1.83e-8	Breast cancer;
CESC	cis	rs1878931	0.668	rs11643983	chr16:3438865	G/A	cg21433313	chr16:3507492	NAT15	-0.35	-5.3	-0.31	2.49e-7	Body mass index (adult);
CESC	cis	rs875971	0.660	rs2013222	chr7:66035936	C/G	cg11764359	chr7:65958608	NA	-0.73	-9.66	-0.51	4.16e-19	Aortic root size;
CESC	cis	rs2637266	0.626	rs846603	chr10:78570793	A/G	cg18941641	chr10:78392320	NA	-0.4	-7.23	-0.41	5.3e-12	Pulmonary function;
CESC	cis	rs67478160	0.619	rs12886363	chr14:104273786	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.5	-6.76	-0.38	8.71e-11	Schizophrenia;
CESC	cis	rs7772486	0.754	rs6915718	chr6:146100676	A/G	cg05347473	chr6:146136440	FBXO30	-0.55	-6.97	-0.39	2.54e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs34779708	0.931	rs2148482	chr10:35348910	A/G	cg04310649	chr10:35416472	CREM	-0.53	-6.33	-0.36	1.02e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs9291683	0.597	rs11722989	chr4:10126139	A/G	cg00071950	chr4:10020882	SLC2A9	-0.54	-8.27	-0.45	6.63e-15	Bone mineral density;
CESC	cis	rs7666738	0.830	rs11932887	chr4:99072965	C/G	cg03467027	chr4:99064603	C4orf37	0.46	5.6	0.33	5.25e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1950500	0.509	rs12882558	chr14:24819233	G/A	cg16194253	chr14:24768981	DHRS1;C14orf21	0.47	5.6	0.33	5.39e-8	Height;
CESC	cis	rs35306767	0.903	rs12769002	chr10:927666	C/G	cg16135276	chr10:459697	DIP2C	-0.6	-5.64	-0.33	4.45e-8	Eosinophil percentage of granulocytes;
CESC	trans	rs7618501	0.966	rs2352974	chr3:49890613	C/T	cg21659725	chr3:3221576	CRBN	0.77	11.76	0.59	5.47e-26	Intelligence (multi-trait analysis);
CESC	cis	rs875971	0.825	rs1860472	chr7:66082723	T/C	cg10691866	chr7:65817282	TPST1	0.33	5.54	0.32	7.11e-8	Aortic root size;
CESC	cis	rs896854	0.684	rs10099941	chr8:95987008	C/T	cg09323728	chr8:95962352	TP53INP1	-0.4	-8.97	-0.48	5.42e-17	Type 2 diabetes;
CESC	cis	rs7949030	0.596	rs71490394	chr11:62370155	G/A	cg11742103	chr11:62369870	EML3;MTA2	0.65	9.61	0.51	6.04e-19	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs6866344	0.570	rs1132336	chr5:178140090	C/T	cg03877680	chr5:178157825	ZNF354A	0.83	10.2	0.53	7.8e-21	Neutrophil percentage of white cells;
CESC	cis	rs9910055	0.530	rs2269908	chr17:42294198	G/C	cg13607699	chr17:42295918	UBTF	0.81	12.59	0.61	8.66e-29	Total body bone mineral density;
CESC	cis	rs1534166	0.647	rs7355929	chr3:133514190	C/T	cg12373951	chr3:133503437	NA	-0.35	-5.3	-0.31	2.49e-7	Alcohol consumption (transferrin glycosylation);
CESC	cis	rs2836974	0.863	rs12483216	chr21:40539614	T/C	cg11644478	chr21:40555479	PSMG1	1.02	16.76	0.72	1.74e-43	Cognitive function;
CESC	cis	rs9682041	0.627	rs11924474	chr3:170091333	T/G	cg11886554	chr3:170076028	SKIL	0.56	5.64	0.33	4.46e-8	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CESC	cis	rs9486715	1.000	rs6899647	chr6:97065661	A/G	cg06623918	chr6:96969491	KIAA0776	-0.86	-12.58	-0.61	9.16e-29	Headache;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25756398	chr11:93474621	C11orf54;TAF1D	0.57	6.86	0.39	4.88e-11	Gut microbiome composition (summer);
CESC	cis	rs2072732	0.904	rs2993480	chr1:2973322	A/G	cg03976712	chr1:2946727	NA	-0.32	-5.48	-0.32	9.82e-8	Plateletcrit;
CESC	cis	rs17826219	0.706	rs9905827	chr17:29192168	C/A	cg19761014	chr17:28927070	LRRC37B2	0.73	5.72	0.33	2.92e-8	Body mass index;
CESC	cis	rs6991838	0.584	rs7814841	chr8:66541563	A/G	cg13398993	chr8:66546079	ARMC1	0.46	5.65	0.33	4.19e-8	Intelligence (multi-trait analysis);
CESC	cis	rs798554	0.757	rs1713919	chr7:2864706	C/A	cg13628971	chr7:2884303	GNA12	0.66	8.63	0.47	5.7e-16	Height;
CESC	trans	rs2727020	0.567	rs1164687	chr11:49290669	G/A	cg03929089	chr4:120376271	NA	0.71	9.26	0.49	7.34e-18	Coronary artery disease;
CESC	trans	rs1814175	0.616	rs1794139	chr11:49910855	C/T	cg03929089	chr4:120376271	NA	-0.92	-15.04	-0.68	2.26e-37	Height;
CESC	cis	rs7666738	0.830	rs10049627	chr4:99025272	A/C	cg18180107	chr4:99064573	C4orf37	0.42	5.43	0.32	1.29e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11098499	0.820	rs13122709	chr4:120555356	T/A	cg09307838	chr4:120376055	NA	0.88	12.29	0.6	9.04e-28	Corneal astigmatism;
CESC	cis	rs7666738	0.752	rs62318905	chr4:99036103	T/G	cg03467027	chr4:99064603	C4orf37	0.47	5.97	0.34	7.51e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3733585	0.762	rs6449217	chr4:10009151	T/A	cg02734326	chr4:10020555	SLC2A9	0.47	6.49	0.37	4.26e-10	Cleft plate (environmental tobacco smoke interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26343667	chr3:156391915	TIPARP;LOC100287227	0.53	6.2	0.36	2.19e-9	Gut microbiome composition (summer);
CESC	trans	rs7618501	1.000	rs6446295	chr3:49809063	G/T	cg21659725	chr3:3221576	CRBN	0.83	13.55	0.64	3.87e-32	Intelligence (multi-trait analysis);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg25202845	chr15:74753513	UBL7	-0.5	-6.06	-0.35	4.6e-9	Ulcerative colitis;
CESC	cis	rs72781680	0.898	rs72786277	chr2:24062818	T/G	cg20701182	chr2:24300061	SF3B14	0.62	5.6	0.33	5.24e-8	Lymphocyte counts;
CESC	cis	rs9916302	0.904	rs9898170	chr17:37510092	T/C	cg07936489	chr17:37558343	FBXL20	0.78	10.7	0.55	1.93e-22	Glomerular filtration rate (creatinine);
CESC	cis	rs7772486	0.846	rs2492856	chr6:146323928	A/G	cg05347473	chr6:146136440	FBXO30	0.51	6.77	0.38	8.28e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg10150615	chr22:24372951	LOC391322	-0.57	-7.66	-0.43	3.53e-13	Liver enzyme levels (gamma-glutamyl transferase);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg19839588	chr6:42419466	TRERF1	-0.43	-6.37	-0.36	8.26e-10	Gambling;
CESC	cis	rs6815814	0.898	rs5743592	chr4:38803063	A/G	cg02016764	chr4:38805732	TLR1	-0.63	-7.47	-0.42	1.15e-12	Breast cancer;
CESC	cis	rs2243480	1.000	rs13235972	chr7:65883605	C/T	cg13147721	chr7:65941812	NA	-0.95	-8.95	-0.48	6.27e-17	Diabetic kidney disease;
CESC	cis	rs9322193	0.923	rs9689084	chr6:149960784	G/A	cg07701084	chr6:150067640	NUP43	0.44	6.12	0.35	3.27e-9	Lung cancer;
CESC	cis	rs778371	0.871	rs2675954	chr2:233750627	C/G	cg08000102	chr2:233561755	GIGYF2	-0.82	-13.27	-0.63	3.72e-31	Schizophrenia;
CESC	cis	rs6460942	1.000	rs17274870	chr7:12406221	G/T	cg20607287	chr7:12443886	VWDE	-0.8	-9.05	-0.49	3.2e-17	Coronary artery disease;
CESC	trans	rs3808502	0.585	rs4549730	chr8:11239078	T/G	cg06636001	chr8:8085503	FLJ10661	-0.48	-6.23	-0.36	1.83e-9	Neuroticism;
CESC	cis	rs9584850	0.834	rs745639	chr13:99119279	C/T	cg22223119	chr13:99095684	FARP1	-0.35	-5.05	-0.3	8.23e-7	Neuroticism;
CESC	cis	rs9733	0.503	rs7556451	chr1:150913142	A/G	cg04414720	chr1:150670196	GOLPH3L	0.45	5.96	0.34	8.13e-9	Tonsillectomy;
CESC	cis	rs6748734	0.625	rs6437372	chr2:241822406	A/G	cg04034577	chr2:241836375	C2orf54	0.32	5.85	0.34	1.47e-8	Urinary metabolites;
CESC	trans	rs11098499	0.908	rs7695996	chr4:120322033	C/T	cg25214090	chr10:38739885	LOC399744	0.72	9.92	0.52	6.25e-20	Corneal astigmatism;
CESC	cis	rs4665809	0.818	rs35413760	chr2:26267137	C/A	cg27170947	chr2:26402098	FAM59B	0.66	7.3	0.41	3.32e-12	Gut microbiome composition (summer);
CESC	cis	rs6580649	0.883	rs7967762	chr12:48420214	C/T	cg05342945	chr12:48394962	COL2A1	0.52	5.89	0.34	1.2e-8	Lung cancer;
CESC	trans	rs1116547	0.531	rs957777	chr5:112848654	C/T	cg10115368	chr14:100435663	NA	0.52	6.13	0.35	3.21e-9	Cerebral amyloid angiopathy;
CESC	cis	rs637571	0.557	rs1204649	chr11:65702776	A/C	cg04055107	chr11:65626734	MUS81;CFL1	0.44	5.35	0.31	1.94e-7	Eosinophil percentage of white cells;
CESC	trans	rs61931739	0.500	rs2389269	chr12:34034179	C/T	cg26384229	chr12:38710491	ALG10B	0.59	8.24	0.45	8.06e-15	Morning vs. evening chronotype;
CESC	cis	rs3740713	1.000	rs73438666	chr11:18456511	G/A	cg23797887	chr11:18477753	LDHAL6A	-0.53	-5.27	-0.31	2.89e-7	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs6088580	0.602	rs6059840	chr20:33030405	G/A	cg08999081	chr20:33150536	PIGU	0.65	11.37	0.57	1.17e-24	Glomerular filtration rate (creatinine);
CESC	cis	rs3806843	0.766	rs2251860	chr5:140048209	T/C	cg26395211	chr5:140044315	WDR55	0.45	6.06	0.35	4.77e-9	Depressive symptoms (multi-trait analysis);
CESC	cis	rs7615952	0.576	rs66671308	chr3:125793526	T/G	cg02807482	chr3:125708958	NA	-0.4	-5.24	-0.31	3.28e-7	Blood pressure (smoking interaction);
CESC	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg06873352	chr17:61820015	STRADA	0.72	12.67	0.61	4.43e-29	Prudent dietary pattern;
CESC	cis	rs6570726	0.846	rs371186	chr6:145886971	T/C	cg05347473	chr6:146136440	FBXO30	0.49	6.59	0.38	2.33e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs17711722	0.727	rs781151	chr7:65479878	T/C	cg14393609	chr7:65229607	NA	0.46	6.04	0.35	5.09e-9	Calcium levels;
CESC	cis	rs2404602	0.716	rs2404736	chr15:76875943	T/C	cg26408565	chr15:76604113	ETFA	-0.39	-5.5	-0.32	8.82e-8	Blood metabolite levels;
CESC	cis	rs7011049	0.915	rs78887309	chr8:53860016	A/C	cg26025543	chr8:53854495	NA	0.45	5.04	0.3	8.7e-7	Systolic blood pressure;
CESC	cis	rs10256972	0.721	rs6975972	chr7:1070468	A/G	cg23978390	chr7:1156363	C7orf50	0.51	6.69	0.38	1.35e-10	Longevity;Endometriosis;
CESC	cis	rs2637266	1.000	rs12260492	chr10:78365242	C/A	cg18941641	chr10:78392320	NA	0.42	7.87	0.44	8.96e-14	Pulmonary function;
CESC	cis	rs11098499	0.863	rs6833334	chr4:120504227	C/T	cg09307838	chr4:120376055	NA	0.95	12.98	0.62	3.72e-30	Corneal astigmatism;
CESC	cis	rs6032067	0.929	rs6032044	chr20:43819416	C/A	cg10761708	chr20:43804764	PI3	0.53	6.36	0.36	8.83e-10	Blood protein levels;
CESC	cis	rs4820539	0.934	rs3788348	chr22:23467946	G/C	cg14186256	chr22:23484241	RTDR1	0.82	14.59	0.67	8.64e-36	Bone mineral density;
CESC	cis	rs11690935	0.959	rs7572215	chr2:172634228	G/A	cg13550731	chr2:172543902	DYNC1I2	-0.97	-14.95	-0.68	4.66e-37	Schizophrenia;
CESC	cis	rs3857536	0.740	rs9360191	chr6:66942454	A/T	cg07460842	chr6:66804631	NA	-0.41	-5.28	-0.31	2.71e-7	Blood trace element (Cu levels);
CESC	cis	rs722599	0.562	rs2287400	chr14:75182937	G/A	cg11812906	chr14:75593930	NEK9	0.42	5.09	0.3	6.71e-7	IgG glycosylation;
CESC	cis	rs11098499	0.913	rs68128210	chr4:120137819	T/G	cg09307838	chr4:120376055	NA	0.79	10.07	0.53	2.04e-20	Corneal astigmatism;
CESC	cis	rs6502050	0.835	rs4789677	chr17:80119842	A/G	cg11859384	chr17:80120422	CCDC57	-0.39	-5.34	-0.31	1.98e-7	Life satisfaction;
CESC	cis	rs7412746	0.611	rs6660084	chr1:150748803	T/C	cg22823121	chr1:150693482	HORMAD1	0.47	6.54	0.37	3.17e-10	Melanoma;
CESC	cis	rs7474896	0.583	rs12783272	chr10:38024885	T/G	cg25427524	chr10:38739819	LOC399744	-0.52	-5.69	-0.33	3.4e-8	Obesity (extreme);
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg08945452	chr1:10854445	CASZ1	-0.46	-6.39	-0.37	7.62e-10	Asthma;
CESC	cis	rs2732480	0.500	rs2732461	chr12:48692802	C/A	cg04545296	chr12:48745243	ZNF641	0.43	7.31	0.41	3.22e-12	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs6430585	0.583	rs4988201	chr2:136618507	A/G	cg07169764	chr2:136633963	MCM6	1.29	19.97	0.78	9.47e-55	Corneal structure;
CESC	cis	rs4979906	1.000	rs4325263	chr10:79444236	A/G	cg07817648	chr10:79422355	NA	-0.61	-6.5	-0.37	4e-10	Mortality in heart failure;
CESC	cis	rs763014	0.932	rs2384975	chr16:651115	G/T	cg07343612	chr16:622815	PIGQ	-0.55	-8.09	-0.45	2.15e-14	Height;
CESC	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	7.56	0.42	6.72e-13	Prudent dietary pattern;
CESC	cis	rs3106136	0.872	rs2016476	chr4:95229004	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.42	-5.94	-0.34	8.87e-9	Capecitabine sensitivity;
CESC	cis	rs3008870	0.755	rs12562761	chr1:67396739	C/T	cg02640540	chr1:67518911	SLC35D1	0.45	5.42	0.32	1.33e-7	Lymphocyte percentage of white cells;
CESC	cis	rs10504229	1.000	rs73609764	chr8:58192971	G/A	cg14926445	chr8:58193284	C8orf71	-0.51	-5.52	-0.32	8.28e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs1707322	1.000	rs785467	chr1:46521559	A/T	cg03146154	chr1:46216737	IPP	-0.76	-10.26	-0.53	5.18e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2841233	0.681	rs2582558	chr14:105347488	A/G	cg16576083	chr14:105354267	KIAA0284	-0.45	-6.8	-0.39	7.03e-11	IgG glycosylation;
CESC	cis	rs10504229	0.683	rs949856	chr8:58144496	G/A	cg22535103	chr8:58192502	C8orf71	-0.76	-8.74	-0.47	2.65e-16	Developmental language disorder (linguistic errors);
CESC	cis	rs1395	0.778	rs4665959	chr2:27443256	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.46	6.04	0.35	5.05e-9	Blood metabolite levels;
CESC	cis	rs4660306	1.000	rs7522705	chr1:45992300	C/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.41	5.43	0.32	1.25e-7	Homocysteine levels;
CESC	cis	rs4974559	0.847	rs28477912	chr4:1331350	C/T	cg02980000	chr4:1222292	CTBP1	0.74	6.85	0.39	5.11e-11	Systolic blood pressure;
CESC	cis	rs3857536	0.673	rs7759888	chr6:66891922	T/C	cg07460842	chr6:66804631	NA	-0.4	-5.23	-0.31	3.47e-7	Blood trace element (Cu levels);
CESC	cis	rs7017914	0.934	rs62508771	chr8:71692688	C/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.42	-5.3	-0.31	2.38e-7	Bone mineral density;
CESC	cis	rs10129255	0.500	rs2105989	chr14:107138216	C/T	cg07958169	chr14:107095056	NA	-0.55	-8.59	-0.47	7.47e-16	Kawasaki disease;
CESC	cis	rs1218582	0.661	rs4845695	chr1:154911798	A/G	cg09359103	chr1:154839909	KCNN3	-0.59	-10.27	-0.53	4.77e-21	Prostate cancer;
CESC	cis	rs7845219	0.525	rs10956931	chr8:95930301	A/G	cg23172400	chr8:95962367	TP53INP1	-0.36	-6.53	-0.37	3.25e-10	Type 2 diabetes;
CESC	cis	rs1707322	1.000	rs12077546	chr1:46431806	C/T	cg05343316	chr1:45956843	TESK2	0.44	5.42	0.32	1.36e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs5750830	0.649	rs2413590	chr22:39790191	G/C	cg02038168	chr22:39784481	NA	-0.62	-7.88	-0.44	8.34e-14	Intelligence (multi-trait analysis);
CESC	cis	rs9916302	0.904	rs8077104	chr17:37530510	A/G	cg15445000	chr17:37608096	MED1	-0.41	-6.76	-0.38	8.97e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs7786808	0.782	rs7787923	chr7:158227312	A/G	cg09998033	chr7:158218633	PTPRN2	-0.49	-7.83	-0.43	1.21e-13	Obesity-related traits;
CESC	cis	rs17433780	1.000	rs17433780	chr1:89474818	C/T	cg09516651	chr1:89888402	LOC400759	-0.59	-8.17	-0.45	1.29e-14	Carotid intima media thickness;
CESC	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg18765753	chr7:1198926	ZFAND2A	-0.59	-9.39	-0.5	2.78e-18	Longevity;Endometriosis;
CESC	cis	rs9354308	0.933	rs12194424	chr6:66574007	T/C	cg07460842	chr6:66804631	NA	0.67	7.6	0.42	5.23e-13	Metabolite levels;
CESC	cis	rs965469	0.843	rs6051842	chr20:3397434	T/C	cg25506879	chr20:3388711	C20orf194	-0.63	-6.55	-0.37	3.01e-10	IFN-related cytopenia;
CESC	cis	rs9715521	0.867	rs4860465	chr4:59832537	G/T	cg11281224	chr4:60001000	NA	-0.51	-6.66	-0.38	1.53e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs7520050	0.966	rs785479	chr1:46492144	C/T	cg03146154	chr1:46216737	IPP	-0.47	-6.06	-0.35	4.74e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs2404602	0.684	rs12437981	chr15:76842401	A/G	cg23625390	chr15:77176239	SCAPER	-0.45	-6.24	-0.36	1.74e-9	Blood metabolite levels;
CESC	cis	rs1799949	1.000	rs11653231	chr17:41331460	G/A	cg23758822	chr17:41437982	NA	1.04	16.01	0.7	7.99e-41	Menopause (age at onset);
CESC	cis	rs34779708	0.931	rs12242882	chr10:35347860	G/C	cg03585969	chr10:35415529	CREM	0.77	10.1	0.53	1.63e-20	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs9296092	0.560	rs17627049	chr6:33537802	G/T	cg13560919	chr6:33536144	NA	-0.71	-10.84	-0.55	6.86e-23	Age at smoking initiation in chronic obstructive pulmonary disease;
CESC	cis	rs12291225	0.535	rs10832248	chr11:14413087	G/A	cg19336497	chr11:14380999	RRAS2	-0.36	-5.26	-0.31	2.92e-7	Sense of smell;
CESC	cis	rs4148883	0.629	rs10009145	chr4:100047929	G/A	cg13256891	chr4:100009986	ADH5	0.57	7.44	0.42	1.4e-12	Alcohol dependence;
CESC	cis	rs4589502	1.000	rs8023363	chr15:67154654	G/A	cg09911534	chr15:67153556	NA	-0.45	-5.04	-0.3	8.76e-7	Lung cancer (smoking interaction);
CESC	cis	rs4925386	0.840	rs6143024	chr20:60914229	A/G	cg12382846	chr20:60892121	LAMA5	0.36	5.51	0.32	8.35e-8	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs59918340	0.616	rs3739222	chr8:142205904	C/G	cg23750338	chr8:142222470	SLC45A4	0.44	6.51	0.37	3.73e-10	Immature fraction of reticulocytes;
CESC	cis	rs4820539	0.966	rs2267000	chr22:23455366	A/G	cg14186256	chr22:23484241	RTDR1	0.79	14.12	0.66	4.03e-34	Bone mineral density;
CESC	cis	rs1983891	0.955	rs4714487	chr6:41547312	T/C	cg20194872	chr6:41519635	FOXP4	0.54	7.74	0.43	2.16e-13	Prostate cancer;
CESC	cis	rs9948	0.786	rs62152774	chr2:97448377	A/G	cg01990225	chr2:97406019	LMAN2L	-0.92	-7.51	-0.42	9.04e-13	Erectile dysfunction and prostate cancer treatment;
CESC	cis	rs4595586	0.870	rs1516558	chr12:39283119	A/G	cg26384229	chr12:38710491	ALG10B	-0.39	-5.48	-0.32	1.01e-7	Morning vs. evening chronotype;
CESC	cis	rs801193	0.761	rs2659888	chr7:66230171	T/G	cg18876405	chr7:65276391	NA	0.54	7.14	0.4	8.71e-12	Aortic root size;
CESC	cis	rs6540556	0.769	rs6540553	chr1:209929044	C/G	cg23920097	chr1:209922102	NA	-0.39	-5.5	-0.32	9.14e-8	Red blood cell count;
CESC	cis	rs477895	0.652	rs72920332	chr11:63947071	G/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.95	10.4	0.54	1.84e-21	Mean platelet volume;
CESC	cis	rs9467711	0.606	rs34622023	chr6:26362119	A/T	cg14345882	chr6:26364793	BTN3A2	0.61	6.49	0.37	4.31e-10	Autism spectrum disorder or schizophrenia;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg10519082	chr1:245026741	HNRNPU	-0.53	-6.36	-0.36	8.61e-10	Ulcerative colitis;
CESC	cis	rs6598955	0.670	rs4659366	chr1:26542572	G/A	cg04990556	chr1:26633338	UBXN11	-0.72	-10.08	-0.53	1.9e-20	Obesity-related traits;
CESC	cis	rs798554	0.797	rs798494	chr7:2798294	C/A	cg18446336	chr7:2847575	GNA12	-0.4	-6.0	-0.35	6.62e-9	Height;
CESC	cis	rs7095944	0.584	rs11245347	chr10:126427037	G/T	cg08799069	chr10:126477246	METTL10	-0.4	-5.73	-0.33	2.75e-8	Asthma;
CESC	cis	rs9549260	0.785	rs2253001	chr13:41145330	A/T	cg21288729	chr13:41239152	FOXO1	0.68	8.55	0.47	9.88e-16	Red blood cell count;
CESC	cis	rs875971	1.000	rs1968225	chr7:65874773	T/C	cg12463550	chr7:65579703	CRCP	0.58	7.41	0.41	1.67e-12	Aortic root size;
CESC	cis	rs9611565	0.765	rs132921	chr22:41812044	G/A	cg06634786	chr22:41940651	POLR3H	0.63	6.75	0.38	9.04e-11	Vitiligo;
CESC	cis	rs2011503	0.714	rs7250233	chr19:19630948	C/T	cg11584989	chr19:19387371	SF4	0.61	7.03	0.4	1.79e-11	Bipolar disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02081925	chr5:176931394	DOK3	-0.57	-6.62	-0.38	1.95e-10	Gut microbiome composition (summer);
CESC	cis	rs2985684	1.000	rs2985687	chr14:50100386	T/C	cg15316458	chr14:50087796	RPL36AL;MGAT2	0.45	5.15	0.3	4.99e-7	Carotid intima media thickness;
CESC	trans	rs4596713	0.507	rs1339546	chr9:71790297	G/A	cg16512924	chr15:28394682	HERC2	0.48	6.1	0.35	3.8e-9	Headache;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg01334186	chr1:151372572	PSMB4	-0.44	-6.06	-0.35	4.71e-9	Height;
CESC	cis	rs9633740	0.947	rs1878036	chr10:82280137	T/G	cg00277334	chr10:82204260	NA	-0.56	-5.62	-0.33	4.82e-8	Post bronchodilator FEV1;
CESC	cis	rs1448094	0.527	rs59445394	chr12:86237843	C/T	cg02569458	chr12:86230093	RASSF9	0.52	7.65	0.43	3.65e-13	Major depressive disorder;
CESC	cis	rs4919087	0.715	rs793520	chr10:99032375	G/A	cg25902810	chr10:99078978	FRAT1	-0.46	-5.15	-0.3	5.08e-7	Monocyte count;
CESC	cis	rs7659604	1.000	rs28532673	chr4:122664323	A/G	cg19671926	chr4:122722719	EXOSC9	0.43	5.15	0.3	4.99e-7	Type 2 diabetes;
CESC	cis	rs1506636	1.000	rs644958	chr7:123400873	C/T	cg03229431	chr7:123269106	ASB15	0.52	6.95	0.39	2.84e-11	Plateletcrit;Platelet count;
CESC	cis	rs2354432	0.607	rs4950385	chr1:146656292	A/G	cg25205988	chr1:146714368	CHD1L	1.19	9.08	0.49	2.58e-17	Mitochondrial DNA levels;
CESC	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	22.16	0.81	2.75e-62	Prudent dietary pattern;
CESC	cis	rs7914558	1.000	rs7081075	chr10:104929191	C/T	cg15744005	chr10:104629667	AS3MT	-0.31	-5.04	-0.3	8.62e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs769267	0.930	rs2099334	chr19:19578450	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.47	5.87	0.34	1.33e-8	Tonsillectomy;
CESC	trans	rs9858542	0.953	rs11706370	chr3:49441091	G/A	cg21659725	chr3:3221576	CRBN	-0.55	-6.53	-0.37	3.38e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs17253792	0.545	rs35536987	chr14:56024021	A/G	cg01858014	chr14:56050164	KTN1	-0.88	-6.38	-0.36	7.78e-10	Putamen volume;
CESC	cis	rs6582630	0.519	rs10880194	chr12:38302836	G/A	cg13010199	chr12:38710504	ALG10B	0.45	5.65	0.33	4.06e-8	Drug-induced liver injury (flucloxacillin);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg13338022	chr15:43029438	CDAN1	0.52	6.85	0.39	5.01e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs1018836	0.608	rs2142147	chr8:91468200	A/G	cg16814680	chr8:91681699	NA	-0.52	-7.17	-0.4	7.6e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs9911578	0.933	rs11868348	chr17:57179238	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.07	0.3	7.47e-7	Intelligence (multi-trait analysis);
CESC	cis	rs2652834	1.000	rs68088462	chr15:63397617	T/C	cg05507819	chr15:63340323	TPM1	0.55	5.17	0.3	4.69e-7	HDL cholesterol;
CESC	cis	rs3106136	0.843	rs901615	chr4:95228687	A/C	cg11021082	chr4:95130006	SMARCAD1	-0.42	-5.93	-0.34	9.65e-9	Capecitabine sensitivity;
CESC	cis	rs6594499	0.872	rs2112541	chr5:110449346	T/C	cg04022379	chr5:110408740	TSLP	0.32	5.63	0.33	4.49e-8	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs35955747	0.902	rs140074	chr22:31725634	C/G	cg25791279	chr22:32026902	PISD	0.46	5.62	0.33	4.9e-8	Neutrophil count;Sum basophil neutrophil counts;
CESC	cis	rs6087990	0.735	rs1040555	chr20:31380201	A/T	cg13636640	chr20:31349939	DNMT3B	-0.77	-12.59	-0.61	8.09e-29	Ulcerative colitis;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg04198824	chr13:31191332	USPL1	0.47	6.11	0.35	3.48e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs4253772	0.575	rs9615983	chr22:46793314	G/A	cg18190219	chr22:46762943	CELSR1	-0.63	-6.28	-0.36	1.36e-9	LDL cholesterol;Cholesterol, total;
CESC	cis	rs7267979	0.966	rs2145126	chr20:25263648	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	18.61	0.75	5.02e-50	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs1401999	1.000	rs4148575	chr3:183702275	A/G	cg01324343	chr3:183735012	ABCC5	0.64	13.77	0.65	6.87e-33	Anterior chamber depth;
CESC	cis	rs62432291	0.681	rs386818	chr6:159660255	T/C	cg14500486	chr6:159655392	FNDC1	-0.62	-6.35	-0.36	9.1e-10	Joint mobility (Beighton score);
CESC	cis	rs1348850	0.668	rs12618542	chr2:178494520	A/G	cg23306229	chr2:178417860	TTC30B	0.6	6.89	0.39	4.07e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs113835537	0.529	rs10896125	chr11:66288733	G/C	cg24851651	chr11:66362959	CCS	0.43	5.35	0.31	1.87e-7	Airway imaging phenotypes;
CESC	cis	rs9488822	0.676	rs13210143	chr6:116389636	G/A	cg05304507	chr6:116381966	FRK	0.27	6.99	0.39	2.26e-11	Cholesterol, total;LDL cholesterol;
CESC	cis	rs9325144	0.513	rs7977596	chr12:38649067	C/A	cg26384229	chr12:38710491	ALG10B	-0.6	-8.49	-0.46	1.45e-15	Morning vs. evening chronotype;
CESC	cis	rs2075371	0.897	rs10488428	chr7:133997560	C/T	cg00033643	chr7:134001901	SLC35B4	0.4	5.1	0.3	6.33e-7	Mean platelet volume;
CESC	cis	rs9913156	0.793	rs55884013	chr17:4579301	G/A	cg19197139	chr17:4613644	ARRB2	0.88	9.6	0.51	6.59e-19	Lymphocyte counts;
CESC	cis	rs1153858	0.668	rs63603561	chr15:45593323	T/A	cg14582100	chr15:45693742	SPATA5L1	-0.37	-5.09	-0.3	6.85e-7	Homoarginine levels;
CESC	cis	rs6496667	0.533	rs2601206	chr15:90962699	C/T	cg22089800	chr15:90895588	ZNF774	0.47	6.09	0.35	3.93e-9	Rheumatoid arthritis;
CESC	cis	rs72781680	0.716	rs2551326	chr2:23982378	T/C	cg08917208	chr2:24149416	ATAD2B	0.57	5.62	0.33	4.79e-8	Lymphocyte counts;
CESC	cis	rs10242455	0.702	rs74347626	chr7:99206021	G/T	cg25640893	chr7:99214727	ZNF498	0.82	5.55	0.32	6.81e-8	Blood metabolite levels;
CESC	cis	rs12545109	0.800	rs2670053	chr8:57421998	A/T	cg09654669	chr8:57350985	NA	-0.45	-6.27	-0.36	1.47e-9	Obesity-related traits;
CESC	cis	rs2878628	0.650	rs56098033	chr3:52758571	T/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.61	8.51	0.46	1.28e-15	Intelligence (multi-trait analysis);
CESC	trans	rs6695352	0.802	rs11120408	chr1:214970079	A/G	cg07720334	chr2:25526752	DNMT3A	0.38	6.1	0.35	3.77e-9	Migraine without aura;
CESC	cis	rs2070997	0.607	rs7027136	chr9:133668039	C/G	cg11464064	chr9:133710261	ABL1	0.5	5.75	0.33	2.48e-8	Response to amphetamines;
CESC	cis	rs1215050	0.740	rs2695464	chr4:98980929	T/C	cg17366294	chr4:99064904	C4orf37	-0.39	-5.18	-0.3	4.3e-7	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs34172651	0.517	rs12927710	chr16:24790282	A/C	cg02428538	chr16:24856791	SLC5A11	-0.6	-6.15	-0.35	2.77e-9	Intelligence (multi-trait analysis);
CESC	cis	rs79839061	0.732	rs35177456	chr4:828994	C/T	cg07828340	chr4:882639	GAK	0.88	6.18	0.36	2.37e-9	Intelligence (multi-trait analysis);
CESC	cis	rs10979	0.557	rs9390116	chr6:143907577	A/G	cg25407410	chr6:143891975	LOC285740	-0.49	-6.31	-0.36	1.16e-9	Hypospadias;
CESC	cis	rs3806843	0.766	rs801176	chr5:140087010	A/G	cg16179182	chr5:140090404	VTRNA1-1	-0.39	-5.07	-0.3	7.33e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs4604732	1.000	rs4604732	chr1:247623872	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	-0.42	-5.7	-0.33	3.23e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs4665809	0.590	rs72809668	chr2:26467653	C/T	cg22920501	chr2:26401640	FAM59B	0.91	10.33	0.54	3.07e-21	Gut microbiome composition (summer);
CESC	cis	rs7959452	0.640	rs1598543	chr12:69688757	G/T	cg14784868	chr12:69753453	YEATS4	0.73	10.57	0.54	5.06e-22	Blood protein levels;
CESC	cis	rs2985684	0.894	rs2354439	chr14:50019417	G/C	cg02151108	chr14:50098012	C14orf104	-0.4	-5.34	-0.31	1.97e-7	Carotid intima media thickness;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04350287	chr3:52326883	GLYCTK	-0.56	-6.95	-0.39	2.79e-11	Gut microbiome composition (summer);
CESC	cis	rs4665809	1.000	rs1560868	chr2:26281459	A/T	cg26119090	chr2:26468346	HADHA;HADHB	0.79	8.79	0.48	1.9e-16	Gut microbiome composition (summer);
CESC	cis	rs12142240	0.698	rs72890727	chr1:46860237	G/A	cg10495392	chr1:46806563	NSUN4	0.56	6.17	0.35	2.61e-9	Menopause (age at onset);
CESC	cis	rs7560272	0.695	rs780394	chr2:73700930	A/G	cg20560298	chr2:73613845	ALMS1	0.49	7.1	0.4	1.14e-11	Schizophrenia;
CESC	cis	rs6577655	0.517	rs2241893	chr8:135586659	C/T	cg17885191	chr8:135476712	NA	0.45	5.08	0.3	7.1e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CESC	cis	rs6460942	1.000	rs62448563	chr7:12400040	G/A	cg13733410	chr7:12443478	VWDE	-0.55	-5.4	-0.31	1.47e-7	Coronary artery disease;
CESC	cis	rs9611519	0.929	rs9611466	chr22:41426299	A/T	cg03806693	chr22:41940476	POLR3H	-0.58	-6.03	-0.35	5.58e-9	Neuroticism;
CESC	cis	rs7811142	1.000	rs7809801	chr7:100072031	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.95	10.25	0.53	5.58e-21	Platelet count;
CESC	cis	rs1055129	0.537	rs2467100	chr17:73949038	C/G	cg08125733	chr17:73851984	WBP2	0.48	6.54	0.37	3.17e-10	White matter hyperintensity burden;
CESC	cis	rs3733585	0.673	rs4697914	chr4:9952266	G/A	cg11266682	chr4:10021025	SLC2A9	-0.58	-11.0	-0.56	2.04e-23	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs9733	0.596	rs12063547	chr1:150674053	G/T	cg22823121	chr1:150693482	HORMAD1	-0.48	-7.14	-0.4	8.85e-12	Tonsillectomy;
CESC	cis	rs832540	0.519	rs1445998	chr5:56268205	A/G	cg14703610	chr5:56206110	C5orf35	0.53	7.18	0.4	7.15e-12	Coronary artery disease;
CESC	cis	rs6912958	1.000	rs6454630	chr6:88171357	C/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.55	7.89	0.44	8.18e-14	Monocyte percentage of white cells;
CESC	cis	rs7666738	0.830	rs28802909	chr4:99039410	G/A	cg05340658	chr4:99064831	C4orf37	0.82	12.88	0.62	8.44e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3820068	0.581	rs16851819	chr1:15918739	C/T	cg16988262	chr1:15930761	NA	-0.33	-5.3	-0.31	2.43e-7	Systolic blood pressure;
CESC	trans	rs12356475	0.710	rs10822686	chr10:67733250	C/T	cg01446614	chr12:114404317	RBM19	0.54	6.14	0.35	2.95e-9	Psoriatic arthritis;
CESC	cis	rs568617	0.953	rs645900	chr11:65648135	G/A	cg19792802	chr11:65647270	CTSW	-0.35	-5.31	-0.31	2.33e-7	Crohn's disease;
CESC	cis	rs7927592	0.956	rs11228256	chr11:68251460	G/A	cg16797656	chr11:68205561	LRP5	0.39	5.47	0.32	1.06e-7	Total body bone mineral density;
CESC	cis	rs10504229	0.679	rs7813252	chr8:58136389	C/G	cg24829409	chr8:58192753	C8orf71	-0.58	-7.2	-0.4	6.31e-12	Developmental language disorder (linguistic errors);
CESC	trans	rs2115172	0.836	rs4835799	chr5:122762229	A/G	cg14173624	chr17:72199366	RPL38	0.49	6.84	0.39	5.45e-11	Weight;
CESC	trans	rs7726839	0.540	rs4957080	chr5:644552	A/C	cg25482853	chr8:67687455	SGK3	-0.93	-9.66	-0.51	4.28e-19	Obesity-related traits;
CESC	cis	rs10504229	0.679	rs4737454	chr8:58033965	A/T	cg24829409	chr8:58192753	C8orf71	-0.44	-5.73	-0.33	2.75e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs4253772	0.591	rs11705624	chr22:46685380	C/T	cg00784671	chr22:46762841	CELSR1	-0.57	-5.5	-0.32	8.75e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs6456156	0.586	rs12198816	chr6:167483546	G/A	cg07741184	chr6:167504864	NA	0.36	6.22	0.36	1.9e-9	Primary biliary cholangitis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27242549	chr2:113012627	ZC3H8	0.58	7.0	0.4	2.08e-11	Gut microbiome composition (summer);
CESC	cis	rs6963495	0.818	rs6973263	chr7:105170293	A/G	cg13798780	chr7:105162888	PUS7	0.77	7.88	0.44	8.3e-14	Bipolar disorder (body mass index interaction);
CESC	cis	rs873946	0.586	rs3793684	chr10:134568645	G/A	cg27286337	chr10:134555280	INPP5A	0.68	7.69	0.43	2.81e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs6540559	0.673	rs6698154	chr1:210007777	A/G	cg23283495	chr1:209979779	IRF6	0.48	5.59	0.32	5.78e-8	Cleft lip with or without cleft palate;
CESC	cis	rs12477438	0.798	rs4622780	chr2:99631760	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.78	-10.94	-0.56	3.2e-23	Chronic sinus infection;
CESC	cis	rs2075371	1.000	rs1421485	chr7:133985181	C/T	cg11752832	chr7:134001865	SLC35B4	0.54	7.02	0.4	1.88e-11	Mean platelet volume;
CESC	cis	rs7605827	0.897	rs11901455	chr2:15623888	C/T	cg19274914	chr2:15703543	NA	0.33	5.95	0.34	8.34e-9	Educational attainment (years of education);
CESC	cis	rs1552244	0.816	rs13059144	chr3:10010197	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.75	-9.51	-0.5	1.22e-18	Alzheimer's disease;
CESC	cis	rs4253772	0.637	rs3087501	chr22:46647909	A/G	cg24881330	chr22:46731750	TRMU	0.87	9.74	0.51	2.4e-19	LDL cholesterol;Cholesterol, total;
CESC	cis	rs965469	0.779	rs1884563	chr20:3335540	T/C	cg25506879	chr20:3388711	C20orf194	-0.47	-5.07	-0.3	7.62e-7	IFN-related cytopenia;
CESC	cis	rs10885582	0.781	rs10749168	chr10:116301983	T/C	cg17056676	chr10:116301354	ABLIM1	-0.3	-5.38	-0.31	1.61e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs35110281	0.686	rs162399	chr21:44950020	G/A	cg01579765	chr21:45077557	HSF2BP	-0.55	-9.38	-0.5	3.03e-18	Mean corpuscular volume;
CESC	cis	rs11608355	0.545	rs35590455	chr12:109893514	A/G	cg05360138	chr12:110035743	NA	0.82	8.92	0.48	7.93e-17	Neuroticism;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg10137463	chr15:23085908	NIPA1	-0.43	-6.21	-0.36	2.01e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs10504229	1.000	rs66479724	chr8:58188309	T/G	cg22535103	chr8:58192502	C8orf71	-1.05	-12.84	-0.62	1.17e-29	Developmental language disorder (linguistic errors);
CESC	cis	rs7615952	0.641	rs66520539	chr3:125780374	G/A	cg04553112	chr3:125709451	NA	-0.52	-5.47	-0.32	1.05e-7	Blood pressure (smoking interaction);
CESC	cis	rs763121	0.853	rs5750664	chr22:39072769	C/T	cg06022373	chr22:39101656	GTPBP1	0.89	14.42	0.66	3.47e-35	Menopause (age at onset);
CESC	cis	rs9611565	0.559	rs8139993	chr22:41995335	T/C	cg17376030	chr22:41985996	PMM1	0.49	5.47	0.32	1.05e-7	Vitiligo;
CESC	cis	rs6429082	0.818	rs704706	chr1:235614378	G/A	cg26050004	chr1:235667680	B3GALNT2	0.61	7.5	0.42	9.4e-13	Adiposity;
CESC	cis	rs1348850	0.914	rs7604673	chr2:178392346	A/G	cg23306229	chr2:178417860	TTC30B	0.64	8.04	0.44	2.92e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs11958404	0.932	rs72816579	chr5:157431877	T/C	cg05962755	chr5:157440814	NA	0.62	6.56	0.37	2.74e-10	IgG glycosylation;
CESC	cis	rs4970966	0.904	rs12131809	chr1:150544640	C/T	cg13175981	chr1:150552382	MCL1	0.55	5.93	0.34	9.26e-9	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs7666738	0.830	rs13138063	chr4:99050438	A/C	cg18180107	chr4:99064573	C4orf37	0.4	5.15	0.3	5.15e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7917772	0.636	rs7079231	chr10:104527341	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.43	5.23	0.31	3.45e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs7943191	0.805	rs12226821	chr11:62369018	C/G	cg02375832	chr11:62437615	C11orf48	-0.39	-5.64	-0.33	4.38e-8	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
CESC	cis	rs17376456	1.000	rs67150649	chr5:93292377	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.65	5.37	0.31	1.75e-7	Diabetic retinopathy;
CESC	cis	rs40363	0.645	rs4786421	chr16:3522303	A/G	cg05754148	chr16:3507555	NAT15	-0.61	-9.47	-0.5	1.66e-18	Tuberculosis;
CESC	cis	rs6024905	0.565	rs6024991	chr20:36970167	C/G	cg07053727	chr20:36965646	BPI	-0.52	-7.86	-0.43	9.68e-14	Bipolar disorder and schizophrenia;
CESC	cis	rs11122272	0.732	rs999010	chr1:231495316	A/G	cg06096015	chr1:231504339	EGLN1	0.42	6.12	0.35	3.3e-9	Hemoglobin concentration;
CESC	cis	rs1355223	0.867	rs3818514	chr11:34680053	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.47	-6.13	-0.35	3.2e-9	Systemic lupus erythematosus and Systemic sclerosis;
CESC	trans	rs1044826	1.000	rs13085888	chr3:139164874	C/T	cg05129325	chr1:215255161	KCNK2	0.33	6.47	0.37	4.74e-10	Obesity-related traits;
CESC	cis	rs13064411	0.696	rs6768979	chr3:113204149	G/A	cg18753928	chr3:113234510	CCDC52	-0.52	-6.24	-0.36	1.73e-9	Response to simvastatin treatment (PCSK9 protein level change);
CESC	cis	rs4808199	0.948	rs7250368	chr19:19452763	G/A	cg03709012	chr19:19516395	GATAD2A	1.07	11.98	0.59	9.93e-27	Nonalcoholic fatty liver disease;
CESC	cis	rs3820928	1.000	rs10204368	chr2:227774244	G/C	cg11843606	chr2:227700838	RHBDD1	-0.43	-5.74	-0.33	2.55e-8	Pulmonary function;
CESC	cis	rs12682352	0.602	rs6988939	chr8:8666916	C/T	cg17143192	chr8:8559678	CLDN23	0.44	5.29	0.31	2.55e-7	Neuroticism;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg01798391	chr3:16306595	OXNAD1;DPH3	0.47	6.09	0.35	3.95e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs9733	0.543	rs72702558	chr1:150683251	G/A	cg04414720	chr1:150670196	GOLPH3L	0.62	8.86	0.48	1.21e-16	Tonsillectomy;
CESC	cis	rs10484885	0.824	rs28372875	chr6:90529343	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.76	-7.15	-0.4	8.35e-12	QRS interval (sulfonylurea treatment interaction);
CESC	cis	rs1728785	0.818	rs1814299	chr16:68581332	G/A	cg02972257	chr16:68554789	NA	-0.55	-6.31	-0.36	1.17e-9	Ulcerative colitis;
CESC	cis	rs9303401	0.659	rs12935851	chr17:56600244	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.02	12.92	0.62	6.16e-30	Cognitive test performance;
CESC	cis	rs863345	0.604	rs1894040	chr1:158456336	C/T	cg12129480	chr1:158549410	OR10X1	0.35	6.93	0.39	3.13e-11	Pneumococcal bacteremia;
CESC	cis	rs2836950	0.501	rs13047518	chr21:40707307	G/A	cg17971929	chr21:40555470	PSMG1	-0.57	-7.44	-0.42	1.45e-12	Menarche (age at onset);
CESC	cis	rs4880487	0.888	rs10794730	chr10:1247022	C/T	cg03183215	chr10:1252341	ADARB2	-0.34	-5.27	-0.31	2.88e-7	Migraine;
CESC	cis	rs7666738	0.830	rs28516388	chr4:98987449	A/G	cg03467027	chr4:99064603	C4orf37	0.44	5.54	0.32	7.12e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4925386	0.765	rs6142737	chr20:60919800	C/G	cg22307297	chr20:60903441	LAMA5	0.37	5.15	0.3	5.04e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs2262909	0.962	rs4932952	chr19:22246788	G/A	cg11619707	chr19:22235551	ZNF257	0.33	5.17	0.3	4.65e-7	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
CESC	cis	rs16854884	0.538	rs61359084	chr3:143738362	T/C	cg06585982	chr3:143692056	C3orf58	0.5	6.46	0.37	4.94e-10	Economic and political preferences (feminism/equality);
CESC	cis	rs6580649	0.941	rs4141065	chr12:48523499	G/A	cg05342945	chr12:48394962	COL2A1	0.54	6.21	0.36	2.04e-9	Lung cancer;
CESC	cis	rs2835872	0.733	rs1709822	chr21:39035485	A/G	cg06728970	chr21:39037746	KCNJ6	0.3	5.51	0.32	8.67e-8	Electroencephalographic traits in alcoholism;
CESC	cis	rs1218582	0.741	rs11264283	chr1:154869552	A/G	cg16680214	chr1:154839983	KCNN3	-0.43	-6.6	-0.38	2.2e-10	Prostate cancer;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg13606015	chr3:43732015	ABHD5	-0.45	-6.47	-0.37	4.83e-10	Gut microbiota (bacterial taxa);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10021668	chr1:159751259	DUSP23	0.56	6.22	0.36	1.92e-9	Gut microbiome composition (summer);
CESC	cis	rs5758659	0.714	rs5758578	chr22:42490292	A/C	cg00645731	chr22:42541494	CYP2D7P1	0.33	5.67	0.33	3.79e-8	Cognitive function;
CESC	cis	rs1483890	0.642	rs9825845	chr3:69404572	C/A	cg22125112	chr3:69402811	FRMD4B	0.38	5.13	0.3	5.52e-7	Resting heart rate;
CESC	cis	rs9796	0.561	rs7173086	chr15:41509288	A/T	cg18705301	chr15:41695430	NDUFAF1	-0.46	-6.94	-0.39	3.09e-11	Menopause (age at onset);
CESC	cis	rs4566357	1.000	rs6436650	chr2:227925097	C/T	cg11843606	chr2:227700838	RHBDD1	-0.42	-5.37	-0.31	1.72e-7	Coronary artery disease;
CESC	cis	rs782590	0.967	rs17278044	chr2:55748217	G/C	cg18811423	chr2:55921094	PNPT1	0.8	12.38	0.61	4.26e-28	Metabolic syndrome;
CESC	cis	rs6772849	0.930	rs9868579	chr3:128351054	C/T	cg16766828	chr3:128327626	NA	0.32	5.37	0.31	1.71e-7	Monocyte percentage of white cells;Monocyte count;
CESC	cis	rs7481584	0.962	rs12805426	chr11:3020580	C/T	cg25174290	chr11:3078921	CARS	-0.43	-5.36	-0.31	1.78e-7	Calcium levels;
CESC	cis	rs477692	0.597	rs574831	chr10:131379190	C/T	cg24747557	chr10:131355152	MGMT	0.37	5.23	0.31	3.4e-7	Response to temozolomide;
CESC	cis	rs5758659	0.569	rs133293	chr22:42382797	G/A	cg04733989	chr22:42467013	NAGA	0.45	5.87	0.34	1.27e-8	Cognitive function;
CESC	cis	rs6674176	0.597	rs12127737	chr1:44402565	G/A	cg12908607	chr1:44402522	ARTN	-0.51	-8.0	-0.44	3.98e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg24367984	chr17:1945160	OVCA2;DPH1	-0.47	-6.13	-0.35	3.09e-9	Ulcerative colitis;
CESC	cis	rs4689388	0.890	rs4689398	chr4:6302199	C/T	cg14416269	chr4:6271139	WFS1	0.47	7.84	0.43	1.07e-13	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs1609391	0.543	rs6761993	chr3:136625902	C/T	cg15507776	chr3:136538369	TMEM22	0.82	11.97	0.59	1.08e-26	Neuroticism;
CESC	cis	rs10197940	0.571	rs13393021	chr2:152413258	A/C	cg06191203	chr2:152266755	RIF1	-0.44	-5.56	-0.32	6.44e-8	Lung cancer;
CESC	cis	rs3892630	0.619	rs61062732	chr19:33304717	T/C	cg22980127	chr19:33182716	NUDT19	1.15	15.15	0.68	8.77e-38	Red blood cell traits;
CESC	cis	rs875971	1.000	rs7801282	chr7:65613687	C/T	cg10691866	chr7:65817282	TPST1	0.33	5.52	0.32	8.27e-8	Aortic root size;
CESC	cis	rs854765	0.583	rs66531105	chr17:17809001	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.57	8.19	0.45	1.1e-14	Total body bone mineral density;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17376960	chr17:7197987	YBX2	0.6	6.86	0.39	4.73e-11	Gut microbiome composition (summer);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg27445386	chr6:42897250	CNPY3	-0.38	-6.06	-0.35	4.78e-9	Gambling;
CESC	cis	rs2011503	1.000	rs113527843	chr19:19643343	A/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.52	5.09	0.3	6.68e-7	Bipolar disorder;
CESC	trans	rs1814175	0.935	rs11040462	chr11:49683158	G/A	cg03929089	chr4:120376271	NA	-0.86	-13.1	-0.63	1.43e-30	Height;
CESC	cis	rs9487051	0.872	rs9398197	chr6:109609988	C/A	cg01475377	chr6:109611718	NA	-0.49	-8.11	-0.45	1.85e-14	Reticulocyte fraction of red cells;
CESC	cis	rs873946	0.504	rs12254034	chr10:134571007	T/C	cg27297192	chr10:134578999	INPP5A	0.4	5.37	0.31	1.72e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs56235845	0.694	rs12055081	chr5:176757191	C/T	cg06060754	chr5:176797920	RGS14	0.44	5.42	0.32	1.37e-7	Hemoglobin concentration;Hematocrit;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg00732428	chr17:46048392	CDK5RAP3	0.49	6.16	0.35	2.69e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs4812048	0.793	rs7266693	chr20:57593158	T/C	cg14073986	chr20:57617431	SLMO2	0.7	5.79	0.34	1.98e-8	Mean platelet volume;
CESC	cis	rs6088580	0.609	rs6059844	chr20:33036482	A/G	cg06115741	chr20:33292138	TP53INP2	0.46	6.0	0.35	6.3e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs6860806	0.661	rs3763112	chr5:131586480	A/G	cg22638593	chr5:131593259	PDLIM4	0.41	5.28	0.31	2.65e-7	Breast cancer;
CESC	cis	rs7666738	0.830	rs6832209	chr4:98994120	A/G	cg03676636	chr4:99064102	C4orf37	0.33	5.13	0.3	5.51e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7412746	0.658	rs2272214	chr1:150931462	C/T	cg22823121	chr1:150693482	HORMAD1	0.4	5.58	0.32	5.89e-8	Melanoma;
CESC	cis	rs10504229	0.683	rs7820559	chr8:58142662	C/T	cg22535103	chr8:58192502	C8orf71	-0.76	-8.73	-0.47	2.81e-16	Developmental language disorder (linguistic errors);
CESC	cis	rs9868809	0.881	rs7631574	chr3:48663046	A/G	cg06212747	chr3:49208901	KLHDC8B	0.6	5.45	0.32	1.15e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs3617	0.625	rs11922961	chr3:52868610	T/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	-0.29	-5.06	-0.3	8.01e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
CESC	trans	rs877282	0.583	rs10904564	chr10:819459	C/G	cg22713356	chr15:30763199	NA	1.07	9.68	0.51	3.6e-19	Uric acid levels;
CESC	cis	rs3750965	0.959	rs4930265	chr11:68855954	A/G	cg01403660	chr11:68851641	TPCN2	0.41	5.35	0.31	1.91e-7	Hair color;
CESC	cis	rs472402	0.560	rs10037161	chr5:6624294	C/A	cg10789808	chr5:6633262	NSUN2;SRD5A1	-0.48	-6.5	-0.37	4.03e-10	Response to amphetamines;
CESC	cis	rs2243480	1.000	rs1723267	chr7:65473314	G/A	cg25894440	chr7:65020034	NA	-0.65	-5.63	-0.33	4.5e-8	Diabetic kidney disease;
CESC	cis	rs9733	0.596	rs12072339	chr1:150686099	A/G	cg22823121	chr1:150693482	HORMAD1	0.48	7.11	0.4	1.11e-11	Tonsillectomy;
CESC	cis	rs9660180	0.868	rs12567685	chr1:1806647	T/C	cg03396347	chr1:1875803	NA	-0.46	-7.21	-0.41	5.71e-12	Body mass index;
CESC	cis	rs2197308	0.765	rs10880643	chr12:37926452	C/T	cg26384229	chr12:38710491	ALG10B	-0.54	-7.66	-0.43	3.57e-13	Morning vs. evening chronotype;
CESC	cis	rs4820539	0.966	rs5751590	chr22:23486830	A/C	cg14186256	chr22:23484241	RTDR1	0.84	14.8	0.67	1.51e-36	Bone mineral density;
CESC	cis	rs9311474	0.632	rs6445528	chr3:52572447	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.46	-6.43	-0.37	5.79e-10	Electroencephalogram traits;
CESC	cis	rs919433	0.927	rs1429412	chr2:198190894	A/G	cg10820045	chr2:198174542	NA	-0.43	-6.21	-0.36	1.99e-9	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs769267	1.000	rs7247309	chr19:19439631	A/T	cg17414380	chr19:19431394	KIAA0892;SF4	-0.46	-5.69	-0.33	3.45e-8	Tonsillectomy;
CESC	cis	rs2228479	0.850	rs17226980	chr16:89825065	G/A	cg04013166	chr16:89971882	TCF25	0.79	6.75	0.38	9.14e-11	Skin colour saturation;
CESC	cis	rs172166	0.611	rs203882	chr6:28078502	G/A	cg20151795	chr6:28129481	ZNF389	0.36	5.23	0.31	3.44e-7	Cardiac Troponin-T levels;
CESC	cis	rs3820928	0.874	rs13419455	chr2:227850465	C/G	cg11843606	chr2:227700838	RHBDD1	-0.43	-5.45	-0.32	1.15e-7	Pulmonary function;
CESC	cis	rs8017423	0.967	rs8016385	chr14:90721946	G/A	cg14092571	chr14:90743983	NA	-0.55	-8.31	-0.45	5.07e-15	Mortality in heart failure;
CESC	cis	rs2952156	0.920	rs907090	chr17:37833632	T/C	cg19468946	chr17:37922297	IKZF3	-0.4	-5.11	-0.3	6.14e-7	Asthma;
CESC	cis	rs7264396	0.635	rs6119672	chr20:34479767	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.81	-11.2	-0.57	4.18e-24	Total cholesterol levels;
CESC	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.64	7.2	0.4	6.35e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg11494091	chr17:61959527	GH2	0.72	12.13	0.6	3.13e-27	Prudent dietary pattern;
CESC	cis	rs1003719	0.612	rs2835652	chr21:38557408	G/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.6	-8.13	-0.45	1.62e-14	Eye color traits;
CESC	cis	rs9894429	0.646	rs7406522	chr17:79615396	G/T	cg21984481	chr17:79567631	NPLOC4	-0.33	-5.17	-0.3	4.7e-7	Eye color traits;
CESC	cis	rs11098499	0.954	rs11734241	chr4:120416872	A/G	cg24375607	chr4:120327624	NA	0.46	5.66	0.33	3.97e-8	Corneal astigmatism;
CESC	cis	rs60154123	0.667	rs650854	chr1:210465315	G/C	cg21951975	chr1:209979733	IRF6	0.45	6.0	0.35	6.37e-9	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05236530	chr12:7362357	PEX5	-0.6	-6.67	-0.38	1.5e-10	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08958952	chr8:142262761	NA	-0.54	-6.1	-0.35	3.7e-9	Gut microbiome composition (summer);
CESC	cis	rs425277	0.606	rs262653	chr1:2090095	T/G	cg04315214	chr1:2043799	PRKCZ	-0.45	-7.32	-0.41	2.89e-12	Height;
CESC	cis	rs2859741	0.546	rs3845491	chr1:37497521	C/T	cg09363841	chr1:37513479	NA	-0.52	-7.65	-0.43	3.77e-13	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
CESC	cis	rs4969178	0.930	rs12601079	chr17:76400329	G/A	cg05887092	chr17:76393375	PGS1	0.58	9.26	0.49	7e-18	HDL cholesterol levels;
CESC	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg07677032	chr17:61819896	STRADA	0.45	6.05	0.35	5.02e-9	Prudent dietary pattern;
CESC	cis	rs858239	0.600	rs7456915	chr7:23143049	T/C	cg23682824	chr7:23144976	KLHL7	0.54	7.7	0.43	2.68e-13	Cerebrospinal fluid biomarker levels;
CESC	cis	rs1580019	0.510	rs4723162	chr7:32543804	C/A	cg07520158	chr7:32535189	LSM5;AVL9	0.51	6.39	0.37	7.42e-10	Cognitive ability;
CESC	cis	rs34172651	0.517	rs34172679	chr16:24840381	C/T	cg06505273	chr16:24850292	NA	0.51	5.85	0.34	1.43e-8	Intelligence (multi-trait analysis);
CESC	cis	rs425277	0.917	rs262656	chr1:2088754	A/C	cg04315214	chr1:2043799	PRKCZ	-0.38	-5.25	-0.31	3.19e-7	Height;
CESC	cis	rs2066819	0.892	rs77415512	chr12:56627300	A/G	cg26804944	chr12:56660921	COQ10A	-0.86	-5.22	-0.31	3.69e-7	Psoriasis vulgaris;
CESC	cis	rs2760061	0.626	rs596208	chr1:228117982	G/C	cg01973587	chr1:228161476	NA	0.36	5.44	0.32	1.22e-7	Diastolic blood pressure;
CESC	cis	rs7818688	0.697	rs11782590	chr8:95970158	G/C	cg16049864	chr8:95962084	TP53INP1	0.57	5.64	0.33	4.29e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs1775715	0.870	rs10827001	chr10:32229734	C/T	cg04359828	chr10:32216031	ARHGAP12	0.36	5.1	0.3	6.5e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs863345	0.967	rs10908682	chr1:158522760	C/T	cg12129480	chr1:158549410	OR10X1	-0.32	-6.47	-0.37	4.65e-10	Pneumococcal bacteremia;
CESC	cis	rs35306767	0.855	rs11253459	chr10:886402	C/T	cg25019033	chr10:957182	NA	-0.62	-6.71	-0.38	1.19e-10	Eosinophil percentage of granulocytes;
CESC	cis	rs798554	0.836	rs2260230	chr7:2822986	T/A	cg09658497	chr7:2847517	GNA12	-0.43	-6.11	-0.35	3.57e-9	Height;
CESC	cis	rs2991971	0.810	rs12119202	chr1:45925931	A/T	cg05343316	chr1:45956843	TESK2	0.59	8.4	0.46	2.71e-15	High light scatter reticulocyte count;
CESC	cis	rs12900413	0.687	rs28513927	chr15:90304471	T/G	cg24249390	chr15:90295951	MESP1	-0.38	-5.2	-0.3	3.92e-7	Coronary artery aneurysm in Kawasaki disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14115740	chr9:98054883	FANCC	-0.69	-7.78	-0.43	1.58e-13	Gut microbiome composition (summer);
CESC	cis	rs4835473	0.831	rs7689328	chr4:144894921	A/C	cg25736465	chr4:144833511	NA	0.39	5.97	0.34	7.43e-9	Immature fraction of reticulocytes;
CESC	cis	rs317689	0.819	rs317683	chr12:69713630	T/G	cg14784868	chr12:69753453	YEATS4	0.48	5.14	0.3	5.26e-7	Response to diuretic therapy;
CESC	cis	rs7394190	0.748	rs2292307	chr10:75549916	C/A	cg07699608	chr10:75541558	CHCHD1	0.64	5.19	0.3	4.15e-7	Incident atrial fibrillation;
CESC	cis	rs1878931	0.580	rs4785932	chr16:3410456	C/G	cg22508957	chr16:3507546	NAT15	-0.37	-5.39	-0.31	1.6e-7	Body mass index (adult);
CESC	cis	rs2204008	0.606	rs6582502	chr12:38543352	C/T	cg26384229	chr12:38710491	ALG10B	-0.41	-5.44	-0.32	1.18e-7	Bladder cancer;
CESC	cis	rs12545109	1.000	rs2217957	chr8:57313360	T/C	cg09654669	chr8:57350985	NA	-0.59	-7.68	-0.43	3.17e-13	Obesity-related traits;
CESC	cis	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg02951883	chr7:2050386	MAD1L1	-0.44	-5.62	-0.33	4.93e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs9325144	0.624	rs7979541	chr12:39129679	T/C	cg26384229	chr12:38710491	ALG10B	-0.51	-7.07	-0.4	1.34e-11	Morning vs. evening chronotype;
CESC	cis	rs911555	0.723	rs7144010	chr14:103869869	G/A	cg24130564	chr14:104152367	KLC1	0.46	5.98	0.34	7.22e-9	Intelligence (multi-trait analysis);
CESC	cis	rs66573146	0.831	rs66645969	chr4:6985614	G/A	cg00086871	chr4:6988644	TBC1D14	1.17	7.59	0.42	5.62e-13	Granulocyte percentage of myeloid white cells;
CESC	cis	rs1008375	0.966	rs10939736	chr4:17581617	T/A	cg16339924	chr4:17578868	LAP3	0.74	9.68	0.51	3.59e-19	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs4975616	0.714	rs27069	chr5:1347128	C/T	cg07493874	chr5:1342172	CLPTM1L	-0.41	-7.58	-0.42	5.65e-13	Lung cancer;
CESC	cis	rs9768139	0.733	rs10156158	chr7:158122287	G/T	cg27057461	chr7:158136379	PTPRN2	-0.37	-5.71	-0.33	3.04e-8	Calcium levels;
CESC	cis	rs611744	0.810	rs619227	chr8:109215100	C/A	cg21045802	chr8:109455806	TTC35	0.48	5.87	0.34	1.29e-8	Dupuytren's disease;
CESC	trans	rs11039798	0.925	rs12277669	chr11:48925316	A/T	cg15704280	chr7:45808275	SEPT13	0.69	6.44	0.37	5.66e-10	Axial length;
CESC	cis	rs3785574	0.962	rs7215915	chr17:61828385	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.59	7.19	0.4	6.58e-12	Height;
CESC	cis	rs9660992	1.000	rs3851296	chr1:205253839	A/C	cg21643547	chr1:205240462	TMCC2	-0.44	-6.93	-0.39	3.27e-11	Mean corpuscular volume;Mean platelet volume;
CESC	trans	rs61931739	0.500	rs3924704	chr12:34557833	C/T	cg13010199	chr12:38710504	ALG10B	0.51	6.57	0.37	2.69e-10	Morning vs. evening chronotype;
CESC	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg10819733	chr22:24237672	NA	-0.42	-6.04	-0.35	5.09e-9	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs9815354	0.767	rs17280980	chr3:41810949	A/T	cg03022575	chr3:42003672	ULK4	0.68	6.06	0.35	4.7e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs3008870	1.000	rs2985795	chr1:67426223	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.04	14.57	0.67	9.76e-36	Lymphocyte percentage of white cells;
CESC	cis	rs367943	0.966	rs348932	chr5:112812457	G/A	cg12552261	chr5:112820674	MCC	-0.62	-7.73	-0.43	2.27e-13	Type 2 diabetes;
CESC	cis	rs7202877	0.706	rs40217	chr16:75480066	C/A	cg04384234	chr16:75411784	CFDP1	0.52	5.99	0.35	6.91e-9	Type 2 diabetes;Type 1 diabetes;
CESC	cis	rs12586317	0.547	rs114371385	chr14:35503724	G/A	cg05294307	chr14:35346193	BAZ1A	-0.51	-5.4	-0.31	1.49e-7	Psoriasis;
CESC	cis	rs6942756	0.774	rs2694574	chr7:128908963	A/G	cg02491457	chr7:128862824	NA	0.65	9.61	0.51	5.83e-19	White matter hyperintensity burden;
CESC	cis	rs10489525	0.599	rs910622	chr1:115600424	A/G	cg12756093	chr1:115239321	AMPD1	0.43	5.18	0.3	4.31e-7	Autism;
CESC	cis	rs3733585	0.673	rs7376948	chr4:9954708	G/A	cg02734326	chr4:10020555	SLC2A9	-0.41	-5.77	-0.33	2.21e-8	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs2236521	0.714	rs6062210	chr20:60890375	A/G	cg09594475	chr20:60884601	LAMA5	0.49	6.73	0.38	1.06e-10	Pelvic organ prolapse;
CESC	cis	rs2303745	0.622	rs1864113	chr19:17393504	G/C	cg02221750	chr19:17393354	ANKLE1	-0.5	-6.0	-0.35	6.45e-9	Systemic lupus erythematosus;
CESC	cis	rs4899554	0.640	rs4899555	chr14:75719834	T/C	cg18117039	chr14:75741733	NA	0.44	5.89	0.34	1.14e-8	Inflammatory bowel disease;
CESC	cis	rs10504229	0.953	rs66509078	chr8:58174734	G/C	cg22535103	chr8:58192502	C8orf71	-1.05	-13.16	-0.63	8.66e-31	Developmental language disorder (linguistic errors);
CESC	cis	rs4242434	0.672	rs10110443	chr8:22484296	C/G	cg03733263	chr8:22462867	KIAA1967	0.75	11.35	0.57	1.41e-24	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CESC	cis	rs2066819	1.000	rs35526714	chr12:56634639	G/C	cg26734620	chr12:56694298	CS	1.03	5.7	0.33	3.23e-8	Psoriasis vulgaris;
CESC	cis	rs832540	0.629	rs10055224	chr5:56081201	C/T	cg24531977	chr5:56204891	C5orf35	0.47	6.0	0.35	6.42e-9	Coronary artery disease;
CESC	cis	rs59918340	0.764	rs4961256	chr8:142229946	G/A	cg23750338	chr8:142222470	SLC45A4	0.62	9.42	0.5	2.26e-18	Immature fraction of reticulocytes;
CESC	cis	rs7107174	1.000	rs901103	chr11:77931346	C/T	cg02023728	chr11:77925099	USP35	0.54	6.93	0.39	3.2e-11	Testicular germ cell tumor;
CESC	trans	rs208520	0.955	rs9345808	chr6:67008262	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.64	7.27	0.41	4.09e-12	Exhaled nitric oxide output;
CESC	trans	rs3942852	0.806	rs10769317	chr11:48150712	T/C	cg03929089	chr4:120376271	NA	-0.57	-6.27	-0.36	1.43e-9	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs7124681	0.565	rs2904127	chr11:47817290	A/G	cg20307385	chr11:47447363	PSMC3	0.62	8.62	0.47	6.37e-16	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
CESC	trans	rs7944735	0.507	rs7396592	chr11:48100837	T/C	cg03929089	chr4:120376271	NA	-0.54	-6.29	-0.36	1.32e-9	Intraocular pressure;
CESC	cis	rs36715	0.868	rs2546147	chr5:127552590	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.44	5.12	0.3	5.83e-7	Breast cancer;
CESC	cis	rs13102973	0.931	rs6822196	chr4:135855582	T/A	cg14419869	chr4:135874104	NA	0.33	5.12	0.3	5.79e-7	Subjective well-being;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21146912	chr2:172016068	TLK1	-0.56	-6.9	-0.39	3.83e-11	Gut microbiome composition (summer);
CESC	cis	rs116095464	1.000	rs56700778	chr5:313186	A/T	cg22496380	chr5:211416	CCDC127	-0.88	-5.58	-0.32	5.91e-8	Breast cancer;
CESC	cis	rs4689388	0.853	rs1079216	chr4:6282473	T/C	cg00701064	chr4:6280414	WFS1	0.72	12.0	0.59	8.66e-27	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs4423214	0.592	rs10898211	chr11:71210677	T/C	cg05163923	chr11:71159392	DHCR7	-0.57	-6.13	-0.35	3.24e-9	Vitamin D levels;
CESC	cis	rs7927771	1.000	rs1317149	chr11:47486885	C/T	cg20135002	chr11:47629003	NA	-0.41	-5.21	-0.3	3.87e-7	Subjective well-being;
CESC	cis	rs2576037	0.583	rs487386	chr18:44377004	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.5	-6.7	-0.38	1.27e-10	Personality dimensions;
CESC	cis	rs6938	0.514	rs56338926	chr15:75259335	C/A	cg14664628	chr15:75095509	CSK	-0.55	-6.87	-0.39	4.58e-11	Breast cancer;
CESC	cis	rs1448094	0.512	rs6539926	chr12:86244460	G/A	cg02569458	chr12:86230093	RASSF9	0.49	7.27	0.41	3.98e-12	Major depressive disorder;
CESC	cis	rs2294693	0.945	rs13216361	chr6:41007046	C/T	cg14769373	chr6:40998127	UNC5CL	-0.46	-5.97	-0.34	7.43e-9	Gastric cancer;Non-cardia gastric cancer;
CESC	cis	rs1570884	0.516	rs7334387	chr13:50172133	T/A	cg08779649	chr13:50194554	NA	0.38	6.47	0.37	4.64e-10	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
CESC	cis	rs2839186	0.656	rs8128380	chr21:47665693	C/T	cg10351095	chr21:47802916	PCNT	-0.48	-6.46	-0.37	5.1e-10	Testicular germ cell tumor;
CESC	cis	rs1018836	0.851	rs7007129	chr8:91629790	T/G	cg16814680	chr8:91681699	NA	-0.77	-11.9	-0.59	1.89e-26	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs9487051	0.837	rs4403290	chr6:109611583	A/T	cg21918786	chr6:109611834	NA	-0.39	-5.98	-0.34	7.14e-9	Reticulocyte fraction of red cells;
CESC	cis	rs501120	1.000	rs634963	chr10:44760033	T/C	cg09554077	chr10:44749378	NA	0.52	6.89	0.39	4.1e-11	Coronary artery disease;Coronary heart disease;
CESC	cis	rs7923609	1.000	rs2393969	chr10:65140440	A/C	cg01631684	chr10:65280961	REEP3	-0.44	-5.43	-0.32	1.29e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7520050	0.931	rs7526678	chr1:46374159	A/G	cg24296786	chr1:45957014	TESK2	0.44	5.58	0.32	5.79e-8	Red blood cell count;Reticulocyte count;
CESC	cis	rs9916302	0.821	rs1966915	chr17:37425262	A/C	cg15445000	chr17:37608096	MED1	0.4	6.45	0.37	5.35e-10	Glomerular filtration rate (creatinine);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19191357	chr22:42196520	CCDC134	0.57	6.6	0.38	2.22e-10	Gut microbiome composition (summer);
CESC	cis	rs7917772	0.629	rs1475646	chr10:104522564	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.45	-5.28	-0.31	2.64e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs2228479	0.850	rs17233567	chr16:89813821	G/A	cg04013166	chr16:89971882	TCF25	0.79	6.78	0.38	7.83e-11	Skin colour saturation;
CESC	cis	rs875971	0.508	rs10253883	chr7:66061138	T/C	cg11764359	chr7:65958608	NA	-0.54	-7.08	-0.4	1.31e-11	Aortic root size;
CESC	cis	rs6121246	0.529	rs6060144	chr20:30178624	A/G	cg13852791	chr20:30311386	BCL2L1	0.63	5.94	0.34	8.93e-9	Mean corpuscular hemoglobin;
CESC	cis	rs926938	0.584	rs360607	chr1:115392401	C/A	cg12756093	chr1:115239321	AMPD1	0.5	7.11	0.4	1.07e-11	Autism;
CESC	cis	rs1348850	0.874	rs952746	chr2:178306584	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.76	10.79	0.55	9.99e-23	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs514406	0.755	rs11206015	chr1:53242187	T/C	cg08859206	chr1:53392774	SCP2	0.6	8.96	0.48	5.76e-17	Monocyte count;
CESC	cis	rs6570726	0.791	rs448939	chr6:145808320	T/C	cg23711669	chr6:146136114	FBXO30	0.84	12.58	0.61	8.95e-29	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2486288	0.656	rs12908818	chr15:45571668	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.56	-6.7	-0.38	1.22e-10	Glomerular filtration rate;
CESC	cis	rs3091242	0.933	rs9438904	chr1:25756860	T/C	cg27572855	chr1:25598939	RHD	0.44	7.28	0.41	3.9e-12	Erythrocyte sedimentation rate;
CESC	cis	rs589448	0.902	rs315131	chr12:69761839	T/G	cg20891283	chr12:69753455	YEATS4	0.98	16.88	0.72	6.73e-44	Cerebrospinal fluid biomarker levels;
CESC	cis	rs7666738	0.830	rs7696568	chr4:99005333	A/T	cg03467027	chr4:99064603	C4orf37	0.44	5.51	0.32	8.65e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs5769765	0.955	rs8135963	chr22:50301476	T/C	cg02269571	chr22:50332266	NA	-0.49	-6.5	-0.37	4.02e-10	Schizophrenia;
CESC	cis	rs6570726	0.791	rs9373464	chr6:145907167	T/C	cg05347473	chr6:146136440	FBXO30	0.56	7.31	0.41	3.24e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs769267	1.000	rs2074089	chr19:19449603	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	-0.49	-6.06	-0.35	4.66e-9	Tonsillectomy;
CESC	cis	rs896854	0.654	rs13281625	chr8:95972738	T/C	cg26343298	chr8:95960752	TP53INP1	0.36	5.96	0.34	7.8e-9	Type 2 diabetes;
CESC	cis	rs7412746	0.658	rs72704682	chr1:150897677	A/T	cg22823121	chr1:150693482	HORMAD1	0.4	5.64	0.33	4.46e-8	Melanoma;
CESC	cis	rs7833986	0.501	rs2953909	chr8:56968200	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.61	7.55	0.42	6.89e-13	Height;
CESC	cis	rs10129255	0.500	rs7161740	chr14:107184358	G/T	cg23076370	chr14:107095027	NA	-0.64	-9.58	-0.51	7.49e-19	Kawasaki disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01802344	chr1:155232042	SCAMP3	0.65	7.07	0.4	1.41e-11	Gut microbiome composition (summer);
CESC	cis	rs898097	0.841	rs12453162	chr17:80859971	C/T	cg05255149	chr17:80675120	FN3KRP	-0.46	-5.16	-0.3	4.95e-7	Breast cancer;
CESC	cis	rs847577	0.674	rs7790479	chr7:97713101	C/G	cg24562669	chr7:97807699	LMTK2	0.63	10.27	0.53	4.67e-21	Breast cancer;
CESC	cis	rs11247915	0.540	rs11582416	chr1:26677721	A/G	cg04990556	chr1:26633338	UBXN11	0.66	7.18	0.4	7e-12	Obesity-related traits;
CESC	cis	rs4555082	0.874	rs1008628	chr14:105722726	T/C	cg13114125	chr14:105738426	BRF1	-0.82	-10.21	-0.53	7.24e-21	Mean platelet volume;Platelet distribution width;
CESC	cis	rs6714710	0.603	rs17488897	chr2:98365164	G/C	cg26665480	chr2:98280029	ACTR1B	0.61	8.26	0.45	6.9e-15	Posterior cortical atrophy and Alzheimer's disease;
CESC	trans	rs459571	0.959	rs2520100	chr9:136918137	A/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.67	-8.79	-0.48	1.98e-16	Platelet distribution width;
CESC	cis	rs1008375	0.966	rs28441502	chr4:17598384	G/A	cg02297831	chr4:17616191	MED28	0.46	5.57	0.32	6.2e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs1642645	0.831	rs6600396	chr1:42489534	G/A	cg16685388	chr1:42384056	HIVEP3	0.37	5.49	0.32	9.65e-8	Left ventricular obstructive tract defect (maternal effect);
CESC	cis	rs10461617	0.592	rs6450403	chr5:56062737	A/C	cg24531977	chr5:56204891	C5orf35	-0.71	-9.37	-0.5	3.25e-18	Type 2 diabetes;
CESC	cis	rs9300255	0.568	rs1790102	chr12:123704890	G/A	cg05973401	chr12:123451056	ABCB9	0.5	5.68	0.33	3.48e-8	Neutrophil percentage of white cells;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14799209	chr7:106809543	HBP1	0.63	7.49	0.42	1.06e-12	Gut microbiome composition (summer);
CESC	cis	rs7927771	0.524	rs2170815	chr11:47875910	T/C	cg20307385	chr11:47447363	PSMC3	0.62	8.73	0.47	2.91e-16	Subjective well-being;
CESC	cis	rs7726839	0.561	rs4957048	chr5:583442	G/A	cg09021430	chr5:549028	NA	-0.43	-5.76	-0.33	2.29e-8	Obesity-related traits;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg23713156	chr17:80606235	WDR45L	-0.42	-6.07	-0.35	4.5e-9	Fibrinogen levels;
CESC	cis	rs9902453	0.967	rs1042173	chr17:28525011	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	7.82	0.43	1.28e-13	Coffee consumption (cups per day);
CESC	cis	rs3815700	0.841	rs10410895	chr19:33093655	T/G	cg24916020	chr19:33096688	ANKRD27	0.6	5.84	0.34	1.56e-8	Eosinophilic esophagitis;
CESC	cis	rs763121	0.853	rs5750662	chr22:39072472	G/A	cg14440974	chr22:39074834	NA	-0.42	-5.89	-0.34	1.14e-8	Menopause (age at onset);
CESC	cis	rs11098499	0.908	rs11729050	chr4:120300066	T/C	cg24375607	chr4:120327624	NA	0.46	5.55	0.32	6.98e-8	Corneal astigmatism;
CESC	trans	rs1728785	1.000	rs12918861	chr16:68566508	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.61	7.42	0.41	1.57e-12	Ulcerative colitis;
CESC	cis	rs1375194	0.606	rs13393407	chr2:33818198	C/T	cg04131969	chr2:33951647	MYADML	-0.53	-6.58	-0.37	2.52e-10	Response to antidepressants in depression;
CESC	cis	rs2839186	0.508	rs6518278	chr21:47640571	A/G	cg12516959	chr21:47718080	NA	0.48	6.49	0.37	4.27e-10	Testicular germ cell tumor;
CESC	cis	rs60871478	0.636	rs61441144	chr7:897784	C/T	cg15782153	chr7:917662	C7orf20	0.47	5.13	0.3	5.65e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs11696501	0.688	rs6073855	chr20:44309670	C/T	cg11783356	chr20:44313418	WFDC10B	-0.34	-5.3	-0.31	2.4e-7	Brain structure;
CESC	cis	rs1348850	0.757	rs2166554	chr2:178455824	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.57	7.61	0.42	4.94e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs1552244	1.000	rs66797209	chr3:10078526	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.87	11.84	0.59	2.99e-26	Alzheimer's disease;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg08977639	chr16:1047820	NA	0.48	6.52	0.37	3.59e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs10751667	0.666	rs10902242	chr11:949700	G/A	cg06064525	chr11:970664	AP2A2	-0.48	-9.45	-0.5	1.86e-18	Alzheimer's disease (late onset);
CESC	cis	rs479844	1.000	rs479844	chr11:65551957	A/G	cg04055107	chr11:65626734	MUS81;CFL1	-0.51	-6.06	-0.35	4.54e-9	Allergic disease (asthma, hay fever or eczema);Atopic march;Atopic dermatitis;
CESC	trans	rs71568191	1.000	rs1125266	chr6:104563389	A/G	cg17383421	chr3:151599085	SUCNR1	-0.73	-6.06	-0.35	4.65e-9	Epilepsy and lamotrigine-induced maculopapular eruptions;
CESC	cis	rs72781680	0.821	rs1022346	chr2:24127849	T/C	cg08917208	chr2:24149416	ATAD2B	0.57	5.62	0.33	4.79e-8	Lymphocyte counts;
CESC	cis	rs7615952	0.599	rs6438953	chr3:125724951	T/C	cg04553112	chr3:125709451	NA	-0.47	-5.34	-0.31	1.97e-7	Blood pressure (smoking interaction);
CESC	cis	rs3020736	0.500	rs6002601	chr22:42489058	A/T	cg15557168	chr22:42548783	NA	0.45	6.57	0.37	2.72e-10	Autism spectrum disorder or schizophrenia;
CESC	cis	rs6499188	1.000	rs6499188	chr16:68674788	G/A	cg02972257	chr16:68554789	NA	-0.59	-6.84	-0.39	5.41e-11	Ulcerative colitis;
CESC	cis	rs3806843	0.966	rs11741994	chr5:140145949	G/A	cg16179182	chr5:140090404	VTRNA1-1	-0.43	-5.61	-0.33	5.03e-8	Depressive symptoms (multi-trait analysis);
CESC	cis	rs3857067	0.806	rs4693374	chr4:95086164	A/C	cg11021082	chr4:95130006	SMARCAD1	-0.61	-9.0	-0.48	4.43e-17	QT interval;
CESC	cis	rs15676	0.783	rs4489410	chr9:131591649	A/C	cg00228799	chr9:131580591	ENDOG	-0.54	-6.69	-0.38	1.3100000000000001e-10	Blood metabolite levels;
CESC	cis	rs854765	0.647	rs7211714	chr17:17986955	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.61	8.63	0.47	5.7e-16	Total body bone mineral density;
CESC	cis	rs9462846	0.919	rs9471966	chr6:42891022	G/A	cg02353165	chr6:42928485	GNMT	0.43	5.2	0.3	4.07e-7	Blood protein levels;
CESC	cis	rs7927771	1.000	rs4752856	chr11:47648042	C/T	cg20307385	chr11:47447363	PSMC3	-0.52	-6.33	-0.36	1.02e-9	Subjective well-being;
CESC	trans	rs61869271	0.871	rs6585308	chr10:116727532	G/A	cg17463145	chr7:79084011	MAGI2	0.3	6.14	0.35	3.01e-9	Tonsillectomy;
CESC	cis	rs2635047	0.783	rs9952447	chr18:44784700	C/T	cg24371990	chr18:44770781	NA	0.42	6.75	0.38	9.47e-11	Educational attainment;
CESC	trans	rs916888	0.647	rs199524	chr17:44848438	G/T	cg10053473	chr17:62856997	LRRC37A3	0.61	8.05	0.44	2.72e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs6088590	1.000	rs2076668	chr20:33437621	G/A	cg08999081	chr20:33150536	PIGU	0.57	8.78	0.47	2.1e-16	Coronary artery disease;
CESC	cis	rs10242455	0.867	rs2740560	chr7:99322320	T/A	cg07715041	chr7:99302981	CYP3A7	-0.44	-5.48	-0.32	9.91e-8	Blood metabolite levels;
CESC	cis	rs116095464	0.558	rs61492827	chr5:225774	A/G	cg22857025	chr5:266934	NA	-1.27	-18.88	-0.76	5.63e-51	Breast cancer;
CESC	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg22791324	chr7:157949174	PTPRN2	0.43	6.36	0.36	8.69e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CESC	cis	rs514406	0.661	rs562641	chr1:53374666	C/T	cg16325326	chr1:53192061	ZYG11B	0.53	7.5	0.42	9.67e-13	Monocyte count;
CESC	cis	rs12478296	0.892	rs60545379	chr2:243034390	A/T	cg06360820	chr2:242988706	NA	-0.67	-7.52	-0.42	8.74e-13	Obesity-related traits;
CESC	cis	rs6493487	0.512	rs12907367	chr15:51265986	A/G	cg02338191	chr15:51200825	AP4E1	0.61	5.45	0.32	1.17e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs4975709	0.589	rs4975744	chr5:1860049	A/G	cg11168104	chr5:1857477	NA	-0.37	-5.54	-0.32	7.3e-8	Cardiovascular disease risk factors;
CESC	cis	rs10479542	0.929	rs10078796	chr5:178978883	T/A	cg19723775	chr5:179050963	HNRNPH1	0.4	5.4	0.31	1.5e-7	Lung cancer;
CESC	cis	rs7949030	0.626	rs71490390	chr11:62329185	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.65	9.58	0.51	7.44e-19	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs344364	0.511	rs2917519	chr16:1950479	C/A	cg03013636	chr16:1946785	NA	0.48	6.62	0.38	2.02e-10	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs1593	0.734	rs4862670	chr4:187145423	A/T	cg02012338	chr4:187126139	CYP4V2	0.64	5.13	0.3	5.65e-7	Activated partial thromboplastin time;
CESC	cis	rs753778	0.962	rs4961341	chr8:142235154	G/T	cg23750338	chr8:142222470	SLC45A4	0.38	5.36	0.31	1.79e-7	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	cis	rs6964587	0.626	rs404	chr7:91544316	G/T	cg17063962	chr7:91808500	NA	-0.46	-6.57	-0.37	2.63e-10	Breast cancer;
CESC	cis	rs11608355	0.545	rs33997929	chr12:109912064	C/T	cg05360138	chr12:110035743	NA	0.81	8.75	0.47	2.52e-16	Neuroticism;
CESC	cis	rs2242116	0.796	rs7645278	chr3:46974100	A/C	cg27129171	chr3:47204927	SETD2	0.55	7.11	0.4	1.05e-11	Birth weight;
CESC	cis	rs3092073	0.624	rs13040315	chr20:44585793	A/G	cg00125455	chr20:44574271	PCIF1	0.34	5.62	0.33	4.82e-8	Intelligence (multi-trait analysis);
CESC	cis	rs898097	0.805	rs60233158	chr17:80896612	A/G	cg05255149	chr17:80675120	FN3KRP	0.45	5.41	0.32	1.43e-7	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04964416	chr10:105156287	PDCD11;USMG5	0.53	6.12	0.35	3.35e-9	Gut microbiome composition (summer);
CESC	cis	rs921968	0.648	rs538483	chr2:219458656	T/C	cg02176678	chr2:219576539	TTLL4	0.42	7.28	0.41	3.73e-12	Mean corpuscular hemoglobin concentration;
CESC	cis	rs8062405	0.691	rs11646653	chr16:28922149	C/T	cg08761264	chr16:28874980	SH2B1	0.43	5.31	0.31	2.35e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs7296418	0.630	rs7974099	chr12:123771475	A/G	cg05973401	chr12:123451056	ABCB9	0.45	5.62	0.33	4.75e-8	Platelet count;
CESC	cis	rs7412746	0.611	rs111842513	chr1:150712926	G/A	cg09365446	chr1:150670422	GOLPH3L	0.42	5.85	0.34	1.43e-8	Melanoma;
CESC	cis	rs2635047	0.905	rs7504798	chr18:44610879	A/G	cg19077165	chr18:44547161	KATNAL2	-0.51	-7.05	-0.4	1.54e-11	Educational attainment;
CESC	cis	rs314370	0.904	rs13244629	chr7:100509253	A/C	cg10426581	chr7:100472382	SRRT	0.83	7.93	0.44	5.97e-14	Resting heart rate;
CESC	cis	rs875971	0.545	rs73150604	chr7:65945532	T/A	cg11764359	chr7:65958608	NA	0.82	9.36	0.5	3.45e-18	Aortic root size;
CESC	cis	rs2455799	0.573	rs2455834	chr3:15753641	A/G	cg09340198	chr3:15902540	ANKRD28	-0.34	-5.31	-0.31	2.29e-7	Mean platelet volume;
CESC	cis	rs9837602	1.000	rs923470	chr3:99757792	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.53	7.51	0.42	9.03e-13	Breast cancer;
CESC	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg24739457	chr1:205821442	NA	0.5	6.45	0.37	5.18e-10	Menarche (age at onset);
CESC	cis	rs10254118	0.757	rs6467491	chr7:133138761	A/G	cg10665199	chr7:133106180	EXOC4	0.56	7.6	0.42	4.97e-13	Intelligence (multi-trait analysis);
CESC	cis	rs4862750	0.832	rs10007858	chr4:187877492	A/G	cg03647317	chr4:187891568	NA	-0.4	-5.85	-0.34	1.45e-8	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs17253792	1.000	rs28616134	chr14:56178802	G/A	cg01858014	chr14:56050164	KTN1	-0.91	-7.03	-0.4	1.8e-11	Putamen volume;
CESC	cis	rs9303401	0.538	rs2240258	chr17:56458183	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.9	9.54	0.51	9.8e-19	Cognitive test performance;
CESC	cis	rs2075371	1.000	rs2244700	chr7:133987374	A/G	cg20476274	chr7:133979776	SLC35B4	0.64	9.27	0.49	6.83e-18	Mean platelet volume;
CESC	cis	rs425277	1.000	rs381664	chr1:2088104	A/G	cg04315214	chr1:2043799	PRKCZ	-0.38	-5.41	-0.32	1.43e-7	Height;
CESC	cis	rs514406	0.929	rs12410420	chr1:53323754	T/C	cg25767906	chr1:53392781	SCP2	-0.44	-5.61	-0.33	4.98e-8	Monocyte count;
CESC	cis	rs796364	0.806	rs10931890	chr2:201102055	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.74	-6.47	-0.37	4.78e-10	Schizophrenia;
CESC	trans	rs591166	1.000	rs2331841	chr18:57828637	G/A	cg05268347	chr19:41218064	ADCK4	-0.4	-6.22	-0.36	1.96e-9	Body mass index;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg18436758	chr1:21113190	HP1BP3	-0.48	-6.67	-0.38	1.45e-10	Fibrinogen levels;
CESC	cis	rs1707322	0.721	rs6665808	chr1:46162283	C/T	cg05343316	chr1:45956843	TESK2	0.48	6.09	0.35	3.85e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs826838	1.000	rs1843881	chr12:38733706	A/G	cg26384229	chr12:38710491	ALG10B	-0.83	-14.96	-0.68	4.09e-37	Heart rate;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg10950113	chr16:69166907	CHTF8;CIRH1A	-0.49	-6.18	-0.35	2.38e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17172773	chr1:150980817	FAM63A;PRUNE	0.57	7.03	0.4	1.8e-11	Gut microbiome composition (summer);
CESC	cis	rs7959452	0.590	rs7968629	chr12:69782857	G/A	cg14784868	chr12:69753453	YEATS4	0.84	13.21	0.63	6.15e-31	Blood protein levels;
CESC	cis	rs780096	0.587	rs1049817	chr2:27550967	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.28	-5.17	-0.3	4.59e-7	Total body bone mineral density;
CESC	cis	rs4862750	0.872	rs7671914	chr4:187878165	A/G	cg11301795	chr4:187892539	NA	-0.74	-12.08	-0.6	4.74e-27	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1018836	0.527	rs13268721	chr8:91481549	G/A	cg16814680	chr8:91681699	NA	-0.57	-7.53	-0.42	7.87e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs2425143	1.000	rs56052651	chr20:34344084	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.81	-7.52	-0.42	8.4e-13	Blood protein levels;
CESC	cis	rs4819052	0.851	rs35560973	chr21:46662573	T/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.45	5.7	0.33	3.24e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs7772486	0.658	rs4895683	chr6:146113654	T/A	cg23711669	chr6:146136114	FBXO30	-0.91	-13.64	-0.64	1.86e-32	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs853679	0.599	rs13193295	chr6:28003228	C/G	cg06606381	chr12:133084897	FBRSL1	-1.1	-8.34	-0.46	4.09e-15	Depression;
CESC	cis	rs12477438	1.000	rs57846982	chr2:99921574	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-8.45	-0.46	1.98e-15	Chronic sinus infection;
CESC	cis	rs853679	0.517	rs4711164	chr6:28115156	C/T	cg12963246	chr6:28129442	ZNF389	0.59	7.68	0.43	3e-13	Depression;
CESC	cis	rs3106136	0.843	rs7438414	chr4:95265822	T/C	cg11021082	chr4:95130006	SMARCAD1	0.38	5.32	0.31	2.26e-7	Capecitabine sensitivity;
CESC	cis	rs9399137	0.507	rs7771310	chr6:135272535	G/A	cg24558204	chr6:135376177	HBS1L	0.74	9.79	0.52	1.59e-19	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	cis	rs7666738	0.716	rs13108535	chr4:99046324	A/G	cg03467027	chr4:99064603	C4orf37	0.47	5.98	0.34	7.19e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs939574	0.858	rs2891733	chr2:220135208	A/G	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.53	5.25	0.31	3.06e-7	Platelet distribution width;
CESC	cis	rs753778	0.628	rs11579	chr8:142205132	G/A	cg18755752	chr8:142205143	DENND3	-0.69	-10.33	-0.54	3.14e-21	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	cis	rs67311347	0.866	rs9826419	chr3:40352051	G/A	cg24209194	chr3:40518798	ZNF619	0.41	5.16	0.3	4.89e-7	Renal cell carcinoma;
CESC	cis	rs9611565	0.694	rs202641	chr22:41833116	C/T	cg06481639	chr22:41940642	POLR3H	0.53	5.84	0.34	1.56e-8	Vitiligo;
CESC	cis	rs897984	0.806	rs8052245	chr16:30916430	C/G	cg02466173	chr16:30829666	NA	0.48	8.27	0.45	6.45e-15	Dementia with Lewy bodies;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg14002772	chr9:2047373	SMARCA2	0.47	6.02	0.35	5.83e-9	Fibrinogen levels;
CESC	cis	rs7666738	0.753	rs28390295	chr4:99028497	C/A	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.58e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2797160	1.000	rs1739375	chr6:126012013	T/C	cg05901451	chr6:126070800	HEY2	0.46	6.55	0.37	2.91e-10	Endometrial cancer;
CESC	cis	rs7666738	0.753	rs9991512	chr4:99007205	T/C	cg17366294	chr4:99064904	C4orf37	0.6	8.61	0.47	6.47e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs798943	0.686	rs7810755	chr7:120888382	A/G	cg09857513	chr7:120969044	WNT16	-0.31	-5.14	-0.3	5.32e-7	Bone mineral density (paediatric, upper limb);
CESC	cis	rs80130819	0.515	rs917055	chr12:48385576	A/G	cg05342945	chr12:48394962	COL2A1	-0.6	-6.98	-0.39	2.39e-11	Prostate cancer;
CESC	cis	rs6460942	0.778	rs17444259	chr7:12462428	C/T	cg20607287	chr7:12443886	VWDE	-0.69	-9.66	-0.51	4.2e-19	Coronary artery disease;
CESC	cis	rs9910055	0.571	rs10208	chr17:42300278	C/T	cg08499158	chr17:42289980	UBTF	-0.45	-5.8	-0.34	1.9e-8	Total body bone mineral density;
CESC	cis	rs8114671	0.562	rs6087649	chr20:33510662	A/G	cg07148914	chr20:33460835	GGT7	0.45	5.9	0.34	1.09e-8	Height;
CESC	cis	rs4862750	0.872	rs7672831	chr4:187898882	C/T	cg10295955	chr4:187884368	NA	-1.07	-22.81	-0.81	1.92e-64	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs12497850	0.931	rs7621015	chr3:49016056	A/G	cg02487422	chr3:49467188	NICN1	0.44	5.6	0.33	5.43e-8	Parkinson's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25252777	chr19:56709056	NA	-0.57	-6.85	-0.39	5.07e-11	Gut microbiome composition (summer);
CESC	cis	rs863345	0.604	rs6697656	chr1:158520737	A/G	cg12129480	chr1:158549410	OR10X1	-0.34	-6.86	-0.39	4.78e-11	Pneumococcal bacteremia;
CESC	cis	rs11650494	0.908	rs79768864	chr17:47446968	C/A	cg08112188	chr17:47440006	ZNF652	1.2	7.97	0.44	4.66e-14	Prostate cancer;
CESC	cis	rs2832191	0.716	rs7284006	chr21:30475186	T/A	cg08807101	chr21:30365312	RNF160	0.93	14.01	0.65	9.35e-34	Dental caries;
CESC	cis	rs2832077	0.689	rs2832055	chr21:30132382	C/G	cg08807101	chr21:30365312	RNF160	0.54	6.25	0.36	1.67e-9	Cognitive test performance;
CESC	cis	rs1799949	0.931	rs9912203	chr17:41445145	A/G	cg07153921	chr17:41440717	NA	0.38	5.15	0.3	5.13e-7	Menopause (age at onset);
CESC	cis	rs4819052	0.851	rs2838849	chr21:46671027	A/G	cg11663144	chr21:46675770	NA	-0.64	-10.02	-0.52	2.95e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg00114383	chr16:28962172	NFATC2IP	-0.43	-6.04	-0.35	5.3e-9	Asthma;
CESC	cis	rs727505	1.000	rs7777947	chr7:124436063	T/G	cg23710748	chr7:124431027	NA	-0.37	-6.14	-0.35	2.99e-9	Lewy body disease;
CESC	cis	rs10540	0.730	rs34690033	chr11:492677	G/C	cg21784768	chr11:537496	LRRC56	-0.56	-5.32	-0.31	2.19e-7	Body mass index;
CESC	cis	rs992157	0.735	rs13430006	chr2:219113089	A/C	cg00012203	chr2:219082015	ARPC2	-0.82	-11.39	-0.57	9.66e-25	Colorectal cancer;
CESC	cis	rs2303745	0.589	rs1965717	chr19:17398559	C/T	cg02221750	chr19:17393354	ANKLE1	-0.54	-6.35	-0.36	9.31e-10	Systemic lupus erythematosus;
CESC	cis	rs7659604	0.628	rs3828485	chr4:122722368	G/A	cg20573242	chr4:122745356	CCNA2	0.57	6.87	0.39	4.64e-11	Type 2 diabetes;
CESC	cis	rs1862618	0.802	rs4389648	chr5:56103602	A/G	cg03609598	chr5:56110824	MAP3K1	-0.5	-5.35	-0.31	1.86e-7	Initial pursuit acceleration;
CESC	cis	rs34172651	0.517	rs7204288	chr16:24784531	A/G	cg02428538	chr16:24856791	SLC5A11	-0.48	-5.04	-0.3	8.68e-7	Intelligence (multi-trait analysis);
CESC	cis	rs116095464	0.558	rs62347683	chr5:230331	C/T	cg12570787	chr5:219185	SDHA;CCDC127	0.53	5.69	0.33	3.34e-8	Breast cancer;
CESC	trans	rs459571	0.959	rs465724	chr9:136910097	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.58	-7.57	-0.42	6.18e-13	Platelet distribution width;
CESC	cis	rs2073300	1.000	rs6106655	chr20:23441982	C/G	cg12062639	chr20:23401060	NAPB	0.77	5.68	0.33	3.48e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs798554	0.660	rs2527694	chr7:2858240	T/C	cg13628971	chr7:2884303	GNA12	0.4	5.36	0.31	1.85e-7	Height;
CESC	cis	rs2637266	0.627	rs1992396	chr10:78482228	T/C	cg18941641	chr10:78392320	NA	0.41	7.69	0.43	2.89e-13	Pulmonary function;
CESC	trans	rs6987853	0.830	rs9643888	chr8:42352007	T/C	cg27650678	chr11:66636318	PC	-0.46	-6.08	-0.35	4.13e-9	Mean corpuscular hemoglobin concentration;
CESC	cis	rs17539620	0.624	rs7770107	chr6:154836862	A/G	cg17771515	chr6:154831774	CNKSR3	0.59	5.85	0.34	1.43e-8	Lipoprotein (a) levels;
CESC	cis	rs2652834	1.000	rs2729783	chr15:63403316	C/T	cg05507819	chr15:63340323	TPM1	0.55	5.24	0.31	3.29e-7	HDL cholesterol;
CESC	cis	rs9902453	0.808	rs56088359	chr17:28173659	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.65	8.22	0.45	9.05e-15	Coffee consumption (cups per day);
CESC	cis	rs10242455	0.702	rs6977165	chr7:99269397	T/C	cg25640893	chr7:99214727	ZNF498	0.78	5.27	0.31	2.84e-7	Blood metabolite levels;
CESC	cis	rs67311347	1.000	rs7636719	chr3:40432084	C/T	cg09455208	chr3:40491958	NA	0.45	7.7	0.43	2.71e-13	Renal cell carcinoma;
CESC	trans	rs3749237	0.964	rs7431078	chr3:49808190	G/A	cg21659725	chr3:3221576	CRBN	0.53	6.33	0.36	1.06e-9	Resting heart rate;
CESC	cis	rs7618915	0.621	rs6788993	chr3:52605136	T/C	cg18404041	chr3:52824283	ITIH1	-0.39	-6.76	-0.38	8.73e-11	Bipolar disorder;
CESC	cis	rs11190604	0.945	rs7091356	chr10:102292268	G/C	cg07080220	chr10:102295463	HIF1AN	0.69	6.48	0.37	4.37e-10	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs826838	0.510	rs10876149	chr12:39228083	C/G	cg13010199	chr12:38710504	ALG10B	-0.59	-7.99	-0.44	4.04e-14	Heart rate;
CESC	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg22105103	chr4:187893119	NA	0.51	7.39	0.41	1.91e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6665290	0.904	rs11586604	chr1:227183865	G/T	cg10327440	chr1:227177885	CDC42BPA	-1.21	-32.66	-0.89	6.96e-95	Myeloid white cell count;
CESC	cis	rs1801251	1.000	rs283486	chr2:233644223	A/G	cg08000102	chr2:233561755	GIGYF2	0.66	9.34	0.5	4.08e-18	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13920768	chr9:133557644	PRDM12	0.58	7.2	0.4	6.09e-12	Gut microbiome composition (summer);
CESC	cis	rs2228479	0.850	rs79244293	chr16:89896220	T/C	cg04013166	chr16:89971882	TCF25	0.72	5.71	0.33	3.01e-8	Skin colour saturation;
CESC	cis	rs9549367	0.713	rs3024743	chr13:113821430	C/T	cg00898013	chr13:113819073	PROZ	-0.5	-7.04	-0.4	1.64e-11	Platelet distribution width;
CESC	cis	rs11608355	0.515	rs12818537	chr12:109902150	C/T	cg05360138	chr12:110035743	NA	0.82	8.92	0.48	7.93e-17	Neuroticism;
CESC	cis	rs7940866	0.903	rs1433980	chr11:130870956	A/G	cg12179176	chr11:130786555	SNX19	0.63	9.32	0.5	4.66e-18	Schizophrenia;
CESC	cis	rs6121246	0.697	rs6088857	chr20:30226764	G/C	cg13852791	chr20:30311386	BCL2L1	0.73	7.51	0.42	9.16e-13	Mean corpuscular hemoglobin;
CESC	cis	rs1475911	0.708	rs11701371	chr21:43523972	C/G	cg09849774	chr21:43526787	UMODL1;C21orf128	-0.46	-5.72	-0.33	2.89e-8	IgG glycosylation;
CESC	cis	rs11785400	0.793	rs4403386	chr8:143736770	C/G	cg24634471	chr8:143751801	JRK	0.46	5.91	0.34	1.06e-8	Schizophrenia;
CESC	cis	rs875971	1.000	rs3981131	chr7:65951677	A/G	cg18876405	chr7:65276391	NA	0.53	6.88	0.39	4.2e-11	Aortic root size;
CESC	cis	rs72781680	0.948	rs72796385	chr2:24170360	T/A	cg08917208	chr2:24149416	ATAD2B	0.94	8.58	0.47	7.87e-16	Lymphocyte counts;
CESC	cis	rs1348850	0.537	rs3770010	chr2:178537796	T/C	cg22681709	chr2:178499509	PDE11A	-0.48	-7.7	-0.43	2.77e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs13191362	0.507	rs2849520	chr6:163132038	T/C	cg21926612	chr6:163149169	PACRG;PARK2	-0.67	-7.91	-0.44	7.23e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs9815354	0.638	rs113496706	chr3:42028574	G/T	cg03022575	chr3:42003672	ULK4	0.75	6.64	0.38	1.72e-10	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs2637266	0.846	rs2637260	chr10:78320346	C/T	cg18941641	chr10:78392320	NA	-0.38	-7.32	-0.41	2.91e-12	Pulmonary function;
CESC	cis	rs870825	0.616	rs7667409	chr4:185650941	C/T	cg04058563	chr4:185651563	MLF1IP	-0.63	-6.98	-0.39	2.36e-11	Blood protein levels;
CESC	cis	rs7412746	0.621	rs72704656	chr1:150828307	A/G	cg22823121	chr1:150693482	HORMAD1	0.45	6.3	0.36	1.24e-9	Melanoma;
CESC	cis	rs4713118	0.527	rs35949862	chr6:28115367	A/G	cg23281280	chr6:28129359	ZNF389	0.6	8.0	0.44	3.86e-14	Parkinson's disease;
CESC	cis	rs7216064	0.817	rs28609796	chr17:65855104	T/A	cg12091567	chr17:66097778	LOC651250	-0.87	-8.93	-0.48	7.41e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs2204008	0.744	rs8189486	chr12:38244968	C/T	cg26384229	chr12:38710491	ALG10B	0.71	10.11	0.53	1.52e-20	Bladder cancer;
CESC	cis	rs79976124	0.879	rs77185357	chr6:66629070	G/A	cg07460842	chr6:66804631	NA	0.7	8.21	0.45	9.9e-15	Type 2 diabetes;
CESC	cis	rs660899	0.595	rs37455	chr1:44294228	A/G	cg11704212	chr1:44303111	ST3GAL3	-0.38	-5.28	-0.31	2.74e-7	Hypertension risk in short sleep duration;
CESC	cis	rs2845885	0.744	rs2701540	chr11:63869107	T/A	cg24431193	chr11:63883947	FLRT1;MACROD1	-0.85	-7.65	-0.43	3.67e-13	Body mass index;
CESC	cis	rs12477438	0.520	rs6739579	chr2:99731552	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.88	15.61	0.69	2.15e-39	Chronic sinus infection;
CESC	cis	rs12477438	0.798	rs12477754	chr2:99628073	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-10.57	-0.54	5.22e-22	Chronic sinus infection;
CESC	cis	rs9399137	0.507	rs11757723	chr6:135291293	C/T	cg22676075	chr6:135203613	NA	0.53	7.0	0.39	2.15e-11	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	cis	rs1018836	0.923	rs2187982	chr8:91556317	G/T	cg16814680	chr8:91681699	NA	-0.74	-11.15	-0.57	6.08e-24	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs9527	0.614	rs2153774	chr10:104881035	T/C	cg04362960	chr10:104952993	NT5C2	0.44	5.54	0.32	7.12e-8	Arsenic metabolism;
CESC	cis	rs10504229	1.000	rs77823122	chr8:58170161	A/G	cg14926445	chr8:58193284	C8orf71	-0.51	-5.49	-0.32	9.29e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs763014	0.966	rs7185390	chr16:666382	A/G	cg00802000	chr16:706648	WDR90	-0.41	-6.2	-0.36	2.15e-9	Height;
CESC	cis	rs780096	0.506	rs8395	chr2:27715207	T/A	cg21248554	chr2:27665150	KRTCAP3	-0.37	-7.68	-0.43	3.02e-13	Total body bone mineral density;
CESC	cis	rs736801	0.607	rs11739135	chr5:131733397	C/G	cg14196790	chr5:131705035	SLC22A5	0.36	5.37	0.31	1.7e-7	Breast cancer;Mosquito bite size;
CESC	cis	rs4654899	0.758	rs1354792	chr1:21391875	C/T	cg05370193	chr1:21551575	ECE1	-0.33	-5.15	-0.3	4.99e-7	Superior frontal gyrus grey matter volume;
CESC	cis	rs2303745	0.589	rs11882562	chr19:17395055	C/G	cg22549504	chr19:17448937	GTPBP3	-0.5	-5.56	-0.32	6.47e-8	Systemic lupus erythematosus;
CESC	cis	rs9811920	0.609	rs4244713	chr3:99679584	T/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.59	-7.14	-0.4	8.97e-12	Axial length;
CESC	cis	rs1448094	0.512	rs4488288	chr12:86245450	A/C	cg00310523	chr12:86230176	RASSF9	0.35	5.46	0.32	1.1e-7	Major depressive disorder;
CESC	cis	rs533123	0.877	rs482692	chr1:29154255	T/C	cg08366446	chr1:29138936	OPRD1	0.54	5.55	0.32	6.92e-8	Schizophrenia;
CESC	cis	rs7605827	0.930	rs7596969	chr2:15513615	C/G	cg19274914	chr2:15703543	NA	-0.31	-5.51	-0.32	8.31e-8	Educational attainment (years of education);
CESC	cis	rs6460942	1.000	rs6948314	chr7:12418363	T/A	cg20607287	chr7:12443886	VWDE	-0.68	-8.18	-0.45	1.17e-14	Coronary artery disease;
CESC	cis	rs737337	0.623	rs3810308	chr19:11333596	T/C	cg00586551	chr19:11347513	LOC55908;DOCK6	0.54	5.66	0.33	4.02e-8	HDL cholesterol;HDL cholesterol levels;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg08286599	chr2:191208694	INPP1	-0.44	-6.32	-0.36	1.12e-9	Gambling;
CESC	trans	rs1814175	0.817	rs12290508	chr11:49621037	C/T	cg15704280	chr7:45808275	SEPT13	-1.01	-19.13	-0.76	7.6900000000000007e-52	Height;
CESC	cis	rs1023500	0.573	rs133377	chr22:42466950	C/T	cg12850546	chr22:42539477	CYP2D7P1	-0.42	-5.04	-0.3	8.6e-7	Schizophrenia;
CESC	cis	rs9910055	0.530	rs8072954	chr17:42294722	G/A	cg08499158	chr17:42289980	UBTF	-0.41	-5.25	-0.31	3.19e-7	Total body bone mineral density;
CESC	cis	rs2228479	0.850	rs9282681	chr16:89805914	T/C	cg04013166	chr16:89971882	TCF25	0.76	6.56	0.37	2.75e-10	Skin colour saturation;
CESC	cis	rs1505368	0.817	rs6435701	chr2:213283512	A/G	cg16329650	chr2:213403929	ERBB4	0.4	5.64	0.33	4.34e-8	Symmetrical dimethylarginine levels;
CESC	cis	rs4862750	0.872	rs7664463	chr4:187876686	A/C	cg11301795	chr4:187892539	NA	-0.77	-12.86	-0.62	9.98e-30	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6570726	1.000	rs1935615	chr6:145921117	G/T	cg23711669	chr6:146136114	FBXO30	0.67	9.61	0.51	5.87e-19	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7618915	0.547	rs4130905	chr3:52709831	A/T	cg07507251	chr3:52567010	NT5DC2	0.42	7.27	0.41	4.17e-12	Bipolar disorder;
CESC	cis	rs4595586	0.967	rs56149694	chr12:39263771	T/C	cg26384229	chr12:38710491	ALG10B	-0.39	-5.49	-0.32	9.39e-8	Morning vs. evening chronotype;
CESC	cis	rs12928939	0.517	rs12149307	chr16:71968091	A/C	cg03805757	chr16:71968109	PKD1L3	-0.59	-6.63	-0.38	1.93e-10	Post bronchodilator FEV1;
CESC	cis	rs10911232	0.507	rs4422969	chr1:183020762	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.87	13.5	0.64	6.03e-32	Hypertriglyceridemia;
CESC	cis	rs4853012	0.887	rs6737314	chr2:74339586	A/G	cg20891558	chr2:74357851	NA	0.69	9.12	0.49	1.95e-17	Gestational age at birth (maternal effect);
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg03518469	chr16:88791646	FAM38A	0.44	6.2	0.36	2.15e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	trans	rs7395662	0.500	rs1605360	chr11:48685714	G/A	cg15704280	chr7:45808275	SEPT13	-0.56	-6.81	-0.39	6.57e-11	HDL cholesterol;
CESC	cis	rs2839186	0.709	rs2156117	chr21:47669300	C/A	cg10351095	chr21:47802916	PCNT	-0.48	-6.53	-0.37	3.31e-10	Testicular germ cell tumor;
CESC	cis	rs11190604	1.000	rs3750719	chr10:102248950	C/G	cg07080220	chr10:102295463	HIF1AN	0.62	5.58	0.32	5.82e-8	Palmitoleic acid (16:1n-7) levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15385386	chr5:133968421	SAR1B	0.55	6.21	0.36	2e-9	Gut microbiome composition (summer);
CESC	cis	rs6920364	1	rs6920364	chr6:167376466	G/C	cg25258033	chr6:167368657	RNASET2	-0.4	-6.11	-0.35	3.49e-9	Lung cancer;
CESC	trans	rs6460942	0.915	rs7803051	chr7:12306904	A/T	cg16269144	chr1:2003326	PRKCZ	0.51	6.11	0.35	3.54e-9	Coronary artery disease;
CESC	cis	rs2204008	0.624	rs2320449	chr12:38224190	T/C	cg26384229	chr12:38710491	ALG10B	0.74	10.68	0.55	2.27e-22	Bladder cancer;
CESC	cis	rs7296418	0.738	rs1568428	chr12:123738876	A/G	cg00376283	chr12:123451042	ABCB9	-0.63	-8.89	-0.48	9.96e-17	Platelet count;
CESC	cis	rs4835473	0.897	rs4835474	chr4:144903597	A/C	cg25736465	chr4:144833511	NA	0.41	6.25	0.36	1.64e-9	Immature fraction of reticulocytes;
CESC	cis	rs2274273	0.870	rs61210954	chr14:55765402	T/C	cg04306507	chr14:55594613	LGALS3	0.3	5.9	0.34	1.1e-8	Protein biomarker;
CESC	cis	rs514406	0.763	rs9988539	chr1:53213884	T/C	cg24675658	chr1:53192096	ZYG11B	0.54	6.8	0.39	6.96e-11	Monocyte count;
CESC	cis	rs34375054	0.526	rs883315	chr12:125676889	T/C	cg00522288	chr12:125625016	AACS	-0.33	-5.14	-0.3	5.44e-7	Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs12620999	1.000	rs4377286	chr2:238069686	C/T	cg23555395	chr2:238036564	NA	-0.57	-7.74	-0.43	2.08e-13	Systemic lupus erythematosus;
CESC	cis	rs1862618	0.853	rs10461617	chr5:56104308	A/G	cg24531977	chr5:56204891	C5orf35	-0.88	-11.65	-0.58	1.32e-25	Initial pursuit acceleration;
CESC	cis	rs6963495	0.818	rs73192126	chr7:105175415	T/C	cg13798780	chr7:105162888	PUS7	0.77	7.87	0.44	9.18e-14	Bipolar disorder (body mass index interaction);
CESC	cis	rs7666738	0.830	rs28417716	chr4:98864859	C/T	cg17366294	chr4:99064904	C4orf37	0.55	7.72	0.43	2.38e-13	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9611565	0.592	rs9611613	chr22:41961831	T/C	cg03806693	chr22:41940476	POLR3H	-0.97	-12.1	-0.6	4e-27	Vitiligo;
CESC	cis	rs7481584	0.624	rs693687	chr11:3052494	A/G	cg25174290	chr11:3078921	CARS	-0.45	-6.33	-0.36	1.05e-9	Calcium levels;
CESC	cis	rs1218582	0.710	rs4845685	chr1:154878300	C/A	cg03351412	chr1:154909251	PMVK	0.69	9.39	0.5	2.91e-18	Prostate cancer;
CESC	cis	rs7589728	0.620	rs76687350	chr2:88473832	G/A	cg04511125	chr2:88470314	THNSL2	0.69	6.61	0.38	2.14e-10	Plasma clusterin levels;
CESC	cis	rs9828933	0.752	rs73117082	chr3:63947565	A/G	cg16258503	chr3:63850278	ATXN7;THOC7	-0.93	-8.12	-0.45	1.8e-14	Type 2 diabetes;
CESC	cis	rs11608355	0.545	rs6606723	chr12:109905044	C/G	cg05360138	chr12:110035743	NA	0.82	8.92	0.48	7.93e-17	Neuroticism;
CESC	cis	rs13106227	0.576	rs6843293	chr4:77392092	A/G	cg20311846	chr4:77356250	SHROOM3	0.29	5.57	0.32	6.34e-8	Eosinophilic esophagitis (pediatric);
CESC	cis	rs36051895	0.559	rs6476949	chr9:5208048	G/A	cg02405213	chr9:5042618	JAK2	-0.47	-5.75	-0.33	2.42e-8	Pediatric autoimmune diseases;
CESC	trans	rs35110281	0.720	rs162372	chr21:44928863	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.54	-7.3	-0.41	3.42e-12	Mean corpuscular volume;
CESC	cis	rs10870270	0.913	rs4550	chr10:133781798	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.86	-12.54	-0.61	1.24e-28	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs7937682	0.889	rs542424	chr11:111477698	T/C	cg09085632	chr11:111637200	PPP2R1B	-0.95	-14.8	-0.67	1.55e-36	Primary sclerosing cholangitis;
CESC	cis	rs6674176	0.561	rs4660263	chr1:44421433	A/C	cg12908607	chr1:44402522	ARTN	-0.47	-6.66	-0.38	1.55e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06522697	chr10:121356224	TIAL1	0.53	6.13	0.35	3.16e-9	Gut microbiome composition (summer);
CESC	cis	rs6812193	0.518	rs28649105	chr4:77185879	A/G	cg20311846	chr4:77356250	SHROOM3	0.28	5.07	0.3	7.61e-7	Parkinson's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26675934	chr16:2009675	NDUFB10	0.6	6.76	0.38	8.77e-11	Gut microbiome composition (summer);
CESC	cis	rs12579753	0.917	rs11115058	chr12:82263427	T/C	cg23701643	chr12:82153290	PPFIA2	-0.36	-5.21	-0.3	3.89e-7	Resting heart rate;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10169971	chr6:83902988	RWDD2A;PGM3	0.63	6.94	0.39	3.04e-11	Gut microbiome composition (summer);
CESC	cis	rs17854409	0.881	rs68091818	chr20:61479882	A/C	cg05147244	chr20:61493195	TCFL5	1.0	7.45	0.42	1.33e-12	Obesity-related traits;
CESC	cis	rs4253311	0.736	rs2292423	chr4:187175722	T/A	cg24794857	chr4:187113578	CYP4V2	0.41	5.17	0.3	4.6e-7	Plasma renin activity levels;Circulating chromogranin peptide levels;Blood metabolite levels;
CESC	cis	rs524281	0.731	rs10791840	chr11:65803383	T/C	cg14036092	chr11:66035641	RAB1B	-0.61	-5.63	-0.33	4.57e-8	Electroencephalogram traits;
CESC	cis	rs7100689	0.577	rs9421464	chr10:82043426	C/T	cg09936400	chr10:82049201	MAT1A	0.39	5.97	0.34	7.79e-9	Post bronchodilator FEV1;
CESC	cis	rs3749237	0.595	rs1464568	chr3:49458266	G/A	cg07636037	chr3:49044803	WDR6	0.59	8.58	0.47	8.1e-16	Resting heart rate;
CESC	cis	rs4843747	0.671	rs72818540	chr16:88078988	C/T	cg06915872	chr16:87998081	BANP	0.48	5.74	0.33	2.63e-8	Menopause (age at onset);
CESC	cis	rs7089973	0.604	rs7895830	chr10:116625776	A/G	cg03647239	chr10:116582469	FAM160B1	0.47	6.05	0.35	4.79e-9	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs2070488	0.775	rs2268762	chr3:38516075	A/G	cg24069376	chr3:38537580	EXOG	0.36	6.09	0.35	4.04e-9	Electrocardiographic conduction measures;
CESC	cis	rs971768	0.892	rs62623403	chr22:17595175	C/T	cg24435209	chr22:17640972	CECR5;CECR4	-0.57	-5.61	-0.33	5.04e-8	Heschl's gyrus morphology;
CESC	cis	rs6991838	0.584	rs1053088	chr8:66515783	A/G	cg13398993	chr8:66546079	ARMC1	0.43	5.19	0.3	4.25e-7	Intelligence (multi-trait analysis);
CESC	cis	rs12701220	0.895	rs12534778	chr7:1065861	C/T	cg26769984	chr7:1090371	C7orf50	-0.65	-7.53	-0.42	7.91e-13	Bronchopulmonary dysplasia;
CESC	cis	rs9311474	0.508	rs7652191	chr3:52610415	T/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	5.89	0.34	1.2e-8	Electroencephalogram traits;
CESC	cis	rs6543140	0.964	rs6543142	chr2:103082006	T/C	cg04239558	chr2:103089729	SLC9A4	0.47	6.16	0.35	2.64e-9	Blood protein levels;
CESC	cis	rs3126085	0.735	rs4845744	chr1:152185095	T/A	cg03465714	chr1:152285911	FLG	-0.43	-5.16	-0.3	4.81e-7	Atopic dermatitis;
CESC	cis	rs977987	0.806	rs1549306	chr16:75415341	A/G	cg03315344	chr16:75512273	CHST6	0.41	5.89	0.34	1.19e-8	Dupuytren's disease;
CESC	trans	rs877282	0.853	rs7079299	chr10:756455	A/G	cg22713356	chr15:30763199	NA	0.93	8.39	0.46	3e-15	Uric acid levels;
CESC	cis	rs7809950	0.861	rs10264412	chr7:107183877	G/A	cg23024343	chr7:107201750	COG5	-0.57	-7.1	-0.4	1.15e-11	Coronary artery disease;
CESC	cis	rs853679	0.550	rs1237875	chr6:28173010	A/G	cg26335602	chr6:28129616	ZNF389	-0.46	-6.1	-0.35	3.8e-9	Depression;
CESC	cis	rs61931739	0.500	rs10772160	chr12:34456848	G/A	cg23762105	chr12:34175262	ALG10	-0.4	-5.22	-0.31	3.7e-7	Morning vs. evening chronotype;
CESC	cis	rs933688	0.938	rs12110065	chr5:90718474	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.15	15.23	0.68	4.62e-38	Smoking behavior;
CESC	cis	rs1552244	1.000	rs3895942	chr3:10108745	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	12.09	0.6	4.37e-27	Alzheimer's disease;
CESC	cis	rs7635838	0.892	rs9852530	chr3:11466469	C/T	cg00170343	chr3:11313890	ATG7	0.43	5.7	0.33	3.27e-8	HDL cholesterol;
CESC	cis	rs7666738	0.546	rs10440329	chr4:98903735	C/T	cg05340658	chr4:99064831	C4orf37	0.59	7.43	0.42	1.47e-12	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10504229	0.906	rs2270607	chr8:58194699	A/G	cg22535103	chr8:58192502	C8orf71	-0.86	-10.7	-0.55	1.88e-22	Developmental language disorder (linguistic errors);
CESC	trans	rs12599106	0.715	rs34006830	chr16:34878550	C/A	cg07332563	chr6:291687	DUSP22	-0.66	-8.12	-0.45	1.78e-14	Menopause (age at onset);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg11466523	chr7:148923132	ZNF282	0.52	6.8	0.39	6.84e-11	Fibrinogen levels;
CESC	trans	rs324780	0.544	rs3112090	chr12:83917047	C/T	cg22140261	chr22:42466895	NAGA	0.48	6.11	0.35	3.55e-9	Vertical cup-disc ratio;
CESC	cis	rs875971	0.755	rs76288834	chr7:66069802	G/A	cg10691866	chr7:65817282	TPST1	0.32	5.31	0.31	2.33e-7	Aortic root size;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg11342046	chr2:242641489	ING5	-0.43	-6.39	-0.37	7.36e-10	Gambling;
CESC	cis	rs2839186	0.632	rs2839184	chr21:47689013	G/A	cg12379764	chr21:47803548	PCNT	-0.51	-6.16	-0.35	2.68e-9	Testicular germ cell tumor;
CESC	cis	rs1552244	1.000	rs4269070	chr3:10126083	C/G	cg08888203	chr3:10149979	C3orf24	0.53	7.06	0.4	1.42e-11	Alzheimer's disease;
CESC	cis	rs62064224	0.554	rs9889352	chr17:30775761	T/C	cg18200150	chr17:30822561	MYO1D	0.41	5.28	0.31	2.64e-7	Schizophrenia;
CESC	cis	rs826838	1.000	rs4768328	chr12:39129315	C/T	cg26384229	chr12:38710491	ALG10B	-0.67	-11.01	-0.56	1.82e-23	Heart rate;
CESC	cis	rs9309473	0.948	rs10199224	chr2:73761446	C/G	cg20560298	chr2:73613845	ALMS1	-0.53	-6.97	-0.39	2.54e-11	Metabolite levels;
CESC	cis	rs35146811	1.000	rs35146811	chr7:99720994	A/C	cg13334819	chr7:99746414	C7orf59	-0.43	-5.09	-0.3	6.71e-7	Coronary artery disease;
CESC	cis	rs55883249	1.000	rs62119422	chr2:9726599	A/G	cg23886495	chr2:9695866	ADAM17	0.6	5.6	0.33	5.39e-8	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
CESC	cis	rs67311347	1.000	rs9834052	chr3:40399060	G/A	cg24209194	chr3:40518798	ZNF619	0.45	5.96	0.34	8.08e-9	Renal cell carcinoma;
CESC	cis	rs34375054	0.573	rs12811438	chr12:125653490	C/T	cg25124228	chr12:125621409	AACS	-0.56	-6.02	-0.35	5.74e-9	Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs7927592	0.830	rs7120635	chr11:68261293	A/G	cg20283391	chr11:68216788	NA	-0.5	-6.44	-0.37	5.47e-10	Total body bone mineral density;
CESC	cis	rs7208859	0.623	rs55938328	chr17:29117010	T/C	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.79e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs9910055	0.762	rs2526021	chr17:42213347	G/A	cg09913183	chr17:42254507	C17orf65;ASB16	0.61	8.0	0.44	3.92e-14	Total body bone mineral density;
CESC	cis	rs11690935	0.589	rs62182403	chr2:172747182	G/A	cg13550731	chr2:172543902	DYNC1I2	0.46	6.34	0.36	1e-9	Schizophrenia;
CESC	cis	rs2243480	1.000	rs11538349	chr7:65421871	C/T	cg13147721	chr7:65941812	NA	-0.8	-8.13	-0.45	1.67e-14	Diabetic kidney disease;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg13495574	chr1:173793781	CENPL;DARS2	-0.43	-6.04	-0.35	5.25e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs116095464	1.000	rs3777237	chr5:307641	C/T	cg22857025	chr5:266934	NA	-1.28	-7.56	-0.42	6.67e-13	Breast cancer;
CESC	cis	rs1008375	0.900	rs12650220	chr4:17595365	A/T	cg15017067	chr4:17643749	FAM184B	0.36	5.13	0.3	5.53e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg26338869	chr17:61819248	STRADA	0.68	8.87	0.48	1.08e-16	Prudent dietary pattern;
CESC	cis	rs425277	0.606	rs377283	chr1:2075570	T/C	cg16545954	chr1:2118288	C1orf86	0.35	6.54	0.37	3.11e-10	Height;
CESC	cis	rs3785574	0.582	rs62072238	chr17:61948841	A/T	cg11494091	chr17:61959527	GH2	0.37	5.15	0.3	5.19e-7	Height;
CESC	cis	rs4853012	0.941	rs78128123	chr2:74347525	C/T	cg05776053	chr2:74358815	NA	0.46	5.18	0.3	4.42e-7	Gestational age at birth (maternal effect);
CESC	cis	rs875971	0.545	rs6970498	chr7:65740895	A/G	cg25405998	chr7:65216604	CCT6P1	0.48	5.34	0.31	2e-7	Aortic root size;
CESC	cis	rs9858542	0.953	rs7646366	chr3:49470668	G/A	cg03060546	chr3:49711283	APEH	-0.53	-6.04	-0.35	5.26e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	trans	rs61931739	0.892	rs61931711	chr12:34045374	C/T	cg26384229	chr12:38710491	ALG10B	-0.46	-6.16	-0.35	2.75e-9	Morning vs. evening chronotype;
CESC	cis	rs7220401	0.789	rs4794859	chr17:27962393	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.5	-6.18	-0.35	2.4e-9	Coronary artery disease;
CESC	cis	rs4243830	0.850	rs10746502	chr1:6607199	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.87	-8.64	-0.47	5.53e-16	Body mass index;
CESC	cis	rs10089	0.903	rs6862701	chr5:127391249	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.78	10.15	0.53	1.14e-20	Ileal carcinoids;
CESC	cis	rs17376456	0.757	rs6859757	chr5:93206042	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.63	5.14	0.3	5.36e-7	Diabetic retinopathy;
CESC	cis	rs561341	0.941	rs2470236	chr17:30304940	G/C	cg12193833	chr17:30244370	NA	-0.57	-5.86	-0.34	1.37e-8	Hip circumference adjusted for BMI;
CESC	cis	rs796364	0.806	rs4673634	chr2:200863349	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	0.83	7.5	0.42	9.65e-13	Schizophrenia;
CESC	cis	rs2991971	0.934	rs2991974	chr1:46020654	A/G	cg06784218	chr1:46089804	CCDC17	-0.29	-5.06	-0.3	7.93e-7	High light scatter reticulocyte count;
CESC	cis	rs10078	0.571	rs2671890	chr5:456457	A/G	cg08916839	chr5:415575	AHRR	0.59	6.81	0.39	6.34e-11	Fat distribution (HIV);
CESC	cis	rs769267	0.965	rs2074299	chr19:19380646	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.42	5.32	0.31	2.16e-7	Tonsillectomy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04620334	chr12:122985487	ZCCHC8	0.58	6.42	0.37	6.2e-10	Gut microbiome composition (summer);
CESC	cis	rs1371867	0.810	rs1618528	chr8:101259134	T/C	cg06002616	chr8:101225028	SPAG1	0.31	5.05	0.3	8.3e-7	Atrioventricular conduction;
CESC	cis	rs1799949	1.000	rs4793190	chr17:41200109	T/C	cg23758822	chr17:41437982	NA	1.0	14.95	0.68	4.7e-37	Menopause (age at onset);
CESC	cis	rs8072100	0.512	rs3809863	chr17:45385012	C/T	cg25173405	chr17:45401733	C17orf57	-0.42	-5.43	-0.32	1.3e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs8067354	0.830	rs2453913	chr17:57860150	G/T	cg02344993	chr17:57696989	CLTC	0.48	6.39	0.37	7.4e-10	Hemoglobin concentration;
CESC	cis	rs2836974	0.897	rs13047678	chr21:40708853	C/T	cg11890956	chr21:40555474	PSMG1	1.0	14.58	0.67	9.62e-36	Cognitive function;
CESC	cis	rs11792861	0.890	rs2900481	chr9:111831825	G/A	cg05043794	chr9:111880884	C9orf5	-0.39	-6.39	-0.37	7.25e-10	Menarche (age at onset);
CESC	cis	rs7824557	0.627	rs7838897	chr8:11207326	C/A	cg21775007	chr8:11205619	TDH	0.57	8.64	0.47	5.23e-16	Retinal vascular caliber;
CESC	cis	rs3892630	0.878	rs2903759	chr19:33195947	A/G	cg13157960	chr19:33183277	NUDT19	0.56	5.46	0.32	1.11e-7	Red blood cell traits;
CESC	cis	rs7666738	0.680	rs34267968	chr4:99002574	A/T	cg03467027	chr4:99064603	C4orf37	0.44	5.51	0.32	8.65e-8	Colonoscopy-negative controls vs population controls;
CESC	trans	rs1814175	0.645	rs28447324	chr11:50046629	C/A	cg15704280	chr7:45808275	SEPT13	-1.01	-18.83	-0.76	8.73e-51	Height;
CESC	cis	rs7223966	1.000	rs8069687	chr17:61883023	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.54	-6.6	-0.38	2.26e-10	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs7208859	0.623	rs12006	chr17:29110652	G/A	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.17e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	trans	rs1728785	0.901	rs11642189	chr16:68583990	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.61	7.48	0.42	1.11e-12	Ulcerative colitis;
CESC	cis	rs2066819	1.000	rs41392645	chr12:56696742	A/G	cg26714650	chr12:56694279	CS	-1.42	-10.05	-0.53	2.39e-20	Psoriasis vulgaris;
CESC	cis	rs78456975	0.527	rs11885279	chr2:1560633	T/C	cg12573674	chr2:1569213	NA	-0.45	-5.3	-0.31	2.46e-7	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs637571	0.522	rs542332	chr11:65744421	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.44	6.56	0.37	2.77e-10	Eosinophil percentage of white cells;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17584085	chr17:46688329	HOXB7	-0.55	-6.43	-0.37	6.04e-10	Gut microbiome composition (summer);
CESC	cis	rs793571	0.522	rs11071398	chr15:59120077	A/G	cg05156742	chr15:59063176	FAM63B	0.75	10.56	0.54	5.66e-22	Schizophrenia;
CESC	cis	rs67311347	0.955	rs11719205	chr3:40417258	G/A	cg09455208	chr3:40491958	NA	0.46	7.93	0.44	6.12e-14	Renal cell carcinoma;
CESC	cis	rs524023	0.958	rs12802649	chr11:64359627	C/T	cg07220939	chr11:64358617	SLC22A12	-0.35	-5.39	-0.31	1.54e-7	Urate levels in obese individuals;
CESC	cis	rs6912958	0.712	rs6908386	chr6:88354746	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-6.71	-0.38	1.19e-10	Monocyte percentage of white cells;
CESC	cis	rs8114671	0.805	rs6060168	chr20:33621017	C/T	cg24642439	chr20:33292090	TP53INP2	0.48	6.07	0.35	4.36e-9	Height;
CESC	cis	rs7520050	0.801	rs6703960	chr1:46232723	C/T	cg06784218	chr1:46089804	CCDC17	-0.31	-5.59	-0.32	5.66e-8	Red blood cell count;Reticulocyte count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24488506	chr11:65667952	FOSL1	0.6	7.29	0.41	3.52e-12	Gut microbiome composition (summer);
CESC	cis	rs4862750	0.794	rs7672272	chr4:187896774	T/G	cg22105103	chr4:187893119	NA	0.5	7.32	0.41	2.93e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1559088	1.000	rs11672313	chr19:33563190	C/T	cg17764715	chr19:33622953	WDR88	0.45	5.45	0.32	1.18e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs796364	1.000	rs769949	chr2:200729558	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.85	8.19	0.45	1.12e-14	Schizophrenia;
CESC	cis	rs10504073	0.647	rs62507247	chr8:50013554	T/G	cg00325661	chr8:49890786	NA	0.57	8.56	0.47	9.52e-16	Blood metabolite ratios;
CESC	cis	rs61776719	0.520	rs12569027	chr1:38449163	C/T	cg04673462	chr1:38461896	NA	0.4	6.06	0.35	4.69e-9	Coronary artery disease;
CESC	cis	rs45535039	1.000	rs6589724	chr11:119112503	G/C	cg16724696	chr11:118992527	HINFP	0.43	5.29	0.31	2.51e-7	Plateletcrit;
CESC	cis	rs9896933	0.778	rs80243549	chr17:80821485	G/T	cg19500275	chr17:80737654	TBCD	0.61	5.74	0.33	2.63e-8	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
CESC	cis	rs12142240	0.698	rs56049453	chr1:46835468	A/G	cg00530320	chr1:46809349	NSUN4	0.6	8.11	0.45	1.85e-14	Menopause (age at onset);
CESC	cis	rs36051895	0.593	rs2094619	chr9:5167712	G/C	cg02405213	chr9:5042618	JAK2	-0.46	-5.36	-0.31	1.77e-7	Pediatric autoimmune diseases;
CESC	cis	rs7666738	0.830	rs13101766	chr4:98957696	C/A	cg03467027	chr4:99064603	C4orf37	0.45	5.61	0.33	4.97e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs35110281	0.837	rs12627667	chr21:45071396	A/C	cg04455712	chr21:45112962	RRP1B	0.39	5.84	0.34	1.55e-8	Mean corpuscular volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14481911	chr2:242438436	STK25	-0.58	-6.71	-0.38	1.2e-10	Gut microbiome composition (summer);
CESC	cis	rs2073300	0.609	rs6137936	chr20:23385232	C/T	cg16736954	chr20:23401023	NAPB	0.8	6.25	0.36	1.67e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs7336332	0.598	rs76790205	chr13:28002885	C/T	cg01674679	chr13:27998804	GTF3A	-0.59	-5.34	-0.31	1.98e-7	Weight;
CESC	cis	rs2952156	0.883	rs907088	chr17:37833567	G/C	cg07936489	chr17:37558343	FBXL20	-0.61	-8.1	-0.45	2.03e-14	Asthma;
CESC	cis	rs7666738	1.000	rs35066600	chr4:98991066	C/A	cg03676636	chr4:99064102	C4orf37	0.34	5.07	0.3	7.65e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18849799	chr19:9929547	FBXL12	0.59	6.98	0.39	2.3e-11	Gut microbiome composition (summer);
CESC	cis	rs9287719	0.839	rs12692415	chr2:10745474	A/G	cg00105475	chr2:10696890	NA	0.38	5.55	0.32	6.76e-8	Prostate cancer;
CESC	trans	rs10751667	0.961	rs6597971	chr11:928598	T/A	cg00159523	chr10:114713187	TCF7L2	-0.41	-6.11	-0.35	3.52e-9	Alzheimer's disease (late onset);
CESC	cis	rs7193541	0.684	rs4888262	chr16:74670458	C/T	cg01733217	chr16:74700730	RFWD3	1.09	21.98	0.8	1.14e-61	Multiple myeloma;
CESC	cis	rs9894429	0.608	rs7406219	chr17:79609410	G/T	cg21984481	chr17:79567631	NPLOC4	-0.35	-5.41	-0.32	1.43e-7	Eye color traits;
CESC	trans	rs875971	0.577	rs35072105	chr7:65609817	A/G	cg26939375	chr7:64535504	NA	-0.63	-8.51	-0.46	1.27e-15	Aortic root size;
CESC	cis	rs2559856	1.000	rs2695282	chr12:102089502	A/G	cg12213457	chr12:102090980	CHPT1	0.37	5.42	0.32	1.33e-7	Blood protein levels;
CESC	cis	rs7666738	0.830	rs11731478	chr4:99001686	A/G	cg18180107	chr4:99064573	C4orf37	0.4	5.23	0.31	3.41e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10905065	0.931	rs2497	chr10:5807608	A/G	cg11519256	chr10:5708881	ASB13	-0.41	-5.38	-0.31	1.66e-7	Menopause (age at onset);
CESC	trans	rs61931739	0.500	rs11053222	chr12:34481100	C/A	cg13010199	chr12:38710504	ALG10B	0.5	6.47	0.37	4.76e-10	Morning vs. evening chronotype;
CESC	cis	rs7811142	0.943	rs28578163	chr7:100044754	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.04	11.56	0.58	2.63e-25	Platelet count;
CESC	cis	rs8067545	0.562	rs2526481	chr17:20127018	T/C	cg13482628	chr17:19912719	NA	-0.43	-5.88	-0.34	1.22e-8	Schizophrenia;
CESC	cis	rs13217239	0.646	rs11756275	chr6:27007113	A/C	cg12292205	chr6:26970375	C6orf41	-0.5	-7.89	-0.44	7.8e-14	Schizophrenia;
CESC	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg06873352	chr17:61820015	STRADA	0.72	12.83	0.62	1.2e-29	Prudent dietary pattern;
CESC	cis	rs10504229	0.953	rs75253516	chr8:58171547	C/A	cg22535103	chr8:58192502	C8orf71	-1.06	-13.13	-0.63	1.17e-30	Developmental language disorder (linguistic errors);
CESC	cis	rs896854	0.516	rs12679044	chr8:95891356	C/A	cg09323728	chr8:95962352	TP53INP1	-0.29	-5.61	-0.33	5.12e-8	Type 2 diabetes;
CESC	trans	rs11098499	0.909	rs28632018	chr4:120386730	T/C	cg25214090	chr10:38739885	LOC399744	0.7	9.93	0.52	5.63e-20	Corneal astigmatism;
CESC	cis	rs3008870	0.959	rs2815359	chr1:67494374	T/C	cg08660285	chr1:67390436	MIER1;WDR78	1.03	14.0	0.65	1e-33	Lymphocyte percentage of white cells;
CESC	cis	rs9796	0.870	rs28501589	chr15:41282534	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.47	-7.09	-0.4	1.23e-11	Menopause (age at onset);
CESC	cis	rs2836950	0.527	rs2836958	chr21:40623526	T/C	cg11890956	chr21:40555474	PSMG1	-0.64	-8.99	-0.48	4.94e-17	Menarche (age at onset);
CESC	cis	rs2652834	0.904	rs2729826	chr15:63360446	C/G	cg05507819	chr15:63340323	TPM1	-0.54	-5.51	-0.32	8.55e-8	HDL cholesterol;
CESC	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg07092213	chr7:1199455	ZFAND2A	-0.43	-5.67	-0.33	3.65e-8	Longevity;Endometriosis;
CESC	cis	rs12983728	0.732	rs34003091	chr19:58662254	T/C	cg24884572	chr19:58661833	ZNF329	0.58	5.19	0.3	4.16e-7	Cholesterol, total;
CESC	cis	rs853679	0.882	rs3757188	chr6:28107357	T/C	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.77	7.15	0.4	8.61e-12	Depression;
CESC	cis	rs12477438	0.765	rs1054042	chr2:99614396	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.64	-8.91	-0.48	8.52e-17	Chronic sinus infection;
CESC	cis	rs56104184	0.775	rs73061694	chr19:49399978	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.6	-5.99	-0.35	6.95e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	cis	rs6964587	1.000	rs28735847	chr7:91592755	T/C	cg17063962	chr7:91808500	NA	0.57	7.81	0.43	1.34e-13	Breast cancer;
CESC	cis	rs2288073	0.801	rs10176347	chr2:24367994	G/A	cg20701182	chr2:24300061	SF3B14	0.48	6.06	0.35	4.69e-9	Venous thromboembolism (SNP x SNP interaction);
CESC	cis	rs9649213	0.593	rs7458551	chr7:97952167	G/C	cg24562669	chr7:97807699	LMTK2	0.48	7.1	0.4	1.13e-11	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs77106637	0.769	rs11603313	chr11:72588177	G/A	cg03713592	chr11:72463424	ARAP1	1.07	9.62	0.51	5.53e-19	Type 2 diabetes;
CESC	cis	rs12142240	0.698	rs17361805	chr1:46813967	C/T	cg00530320	chr1:46809349	NSUN4	0.57	7.73	0.43	2.19e-13	Menopause (age at onset);
CESC	cis	rs2742234	0.590	rs2742237	chr10:43621323	C/G	cg15436174	chr10:43711423	RASGEF1A	-0.47	-5.44	-0.32	1.22e-7	Hirschsprung disease;
CESC	cis	rs853679	0.517	rs4713152	chr6:28137454	G/A	cg23281280	chr6:28129359	ZNF389	0.56	7.62	0.42	4.55e-13	Depression;
CESC	cis	rs13108904	0.837	rs4591539	chr4:1279938	G/C	cg22903657	chr4:1355424	KIAA1530	-0.38	-5.18	-0.3	4.5e-7	Obesity-related traits;
CESC	cis	rs709400	1.000	rs8018979	chr14:104109087	G/A	cg12935359	chr14:103987150	CKB	-0.44	-6.01	-0.35	6.1e-9	Body mass index;
CESC	cis	rs36051895	0.632	rs10974982	chr9:5149382	G/C	cg02405213	chr9:5042618	JAK2	-0.51	-6.4	-0.37	6.99e-10	Pediatric autoimmune diseases;
CESC	cis	rs10838687	0.800	rs10769253	chr11:47362339	G/A	cg25783544	chr11:47291846	MADD	0.57	6.38	0.36	7.81e-10	Proinsulin levels;
CESC	cis	rs7188697	0.922	rs9926577	chr16:58613431	C/T	cg02549819	chr16:58548995	SETD6	0.44	5.43	0.32	1.26e-7	QT interval;
CESC	cis	rs7914558	1.000	rs4917994	chr10:104811699	C/T	cg15744005	chr10:104629667	AS3MT	-0.34	-5.49	-0.32	9.49e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs3733585	0.673	rs4312757	chr4:9956145	T/A	cg00071950	chr4:10020882	SLC2A9	-0.7	-11.52	-0.58	3.7e-25	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs11229555	1.000	rs11229555	chr11:58408687	G/T	cg15696309	chr11:58395628	NA	-0.44	-5.62	-0.33	4.88e-8	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27607639	chr17:26879503	UNC119	0.6	6.62	0.38	2.02e-10	Gut microbiome composition (summer);
CESC	cis	rs425277	1.000	rs425277	chr1:2069172	C/T	cg24578937	chr1:2090814	PRKCZ	0.54	9.07	0.49	2.73e-17	Height;
CESC	cis	rs8177253	0.931	rs8177256	chr3:133480276	G/T	cg01448562	chr3:133502909	NA	-0.42	-5.9	-0.34	1.09e-8	Iron status biomarkers;
CESC	cis	rs1005277	0.505	rs7069702	chr10:38247359	G/T	cg25427524	chr10:38739819	LOC399744	0.71	10.67	0.55	2.36e-22	Extrinsic epigenetic age acceleration;
CESC	cis	rs1552244	0.554	rs17050704	chr3:10045734	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.56	-7.17	-0.4	7.49e-12	Alzheimer's disease;
CESC	cis	rs12618769	0.652	rs3769708	chr2:99187650	T/C	cg10123293	chr2:99228465	UNC50	0.41	5.34	0.31	2e-7	Bipolar disorder;
CESC	trans	rs6089829	0.962	rs9680064	chr20:61666168	G/A	cg23505145	chr19:12996616	KLF1	0.52	6.8	0.39	6.85e-11	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs4076764	0.914	rs10753614	chr1:163365903	C/T	cg24596788	chr1:163392923	NA	0.51	7.51	0.42	8.8e-13	Motion sickness;
CESC	cis	rs6120849	0.754	rs6120819	chr20:33653038	T/C	cg24642439	chr20:33292090	TP53INP2	0.67	6.67	0.38	1.51e-10	Protein C levels;
CESC	cis	rs3105593	1.000	rs934624	chr15:50968906	A/C	cg08437265	chr15:50716283	USP8	0.47	6.16	0.35	2.7e-9	QT interval;
CESC	cis	rs9733	0.596	rs6587516	chr1:150623221	C/T	cg17724175	chr1:150552817	MCL1	0.44	7.21	0.41	5.75e-12	Tonsillectomy;
CESC	cis	rs56046484	0.956	rs35533990	chr15:85664821	G/C	cg08123816	chr15:85640762	PDE8A	-0.5	-6.19	-0.36	2.23e-9	Testicular germ cell tumor;
CESC	cis	rs10089	1.000	rs62373701	chr5:127416294	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.77	10.09	0.53	1.76e-20	Ileal carcinoids;
CESC	trans	rs877282	0.947	rs7923867	chr10:768094	G/A	cg22713356	chr15:30763199	NA	1.16	11.7	0.58	9.33e-26	Uric acid levels;
CESC	cis	rs896854	0.684	rs2340534	chr8:95992330	G/A	cg26343298	chr8:95960752	TP53INP1	0.34	5.55	0.32	6.76e-8	Type 2 diabetes;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg13479780	chr6:41909532	CCND3	-0.41	-6.0	-0.35	6.6e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs4319547	0.915	rs10773208	chr12:122970156	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.66	-7.6	-0.42	5.09e-13	Body mass index;
CESC	cis	rs17666538	0.642	rs7821983	chr8:643696	A/G	cg07685180	chr8:600429	NA	0.59	5.13	0.3	5.5e-7	IgG glycosylation;
CESC	cis	rs7078219	0.505	rs1548964	chr10:101289653	C/G	cg09788492	chr10:101292477	NKX2-3	-0.33	-6.2	-0.36	2.18e-9	Dental caries;
CESC	cis	rs2836950	0.520	rs8133928	chr21:40689963	G/A	cg11644478	chr21:40555479	PSMG1	-0.56	-7.58	-0.42	5.83e-13	Menarche (age at onset);
CESC	cis	rs6701037	1.000	rs6677097	chr1:175123897	C/G	cg00321850	chr1:175162397	KIAA0040	-0.41	-5.85	-0.34	1.42e-8	Alcohol dependence;
CESC	trans	rs1478897	0.575	rs12679960	chr8:11430990	C/T	cg15556689	chr8:8085844	FLJ10661	0.58	6.59	0.38	2.32e-10	Systemic lupus erythematosus;
CESC	cis	rs3026101	0.624	rs11869800	chr17:5307781	G/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.42	5.6	0.33	5.31e-8	Body mass index;
CESC	cis	rs6120849	0.663	rs13041792	chr20:33545055	G/A	cg24642439	chr20:33292090	TP53INP2	0.69	6.83	0.39	5.9e-11	Protein C levels;
CESC	cis	rs7208859	0.623	rs8067035	chr17:29102188	T/C	cg19761014	chr17:28927070	LRRC37B2	0.73	6.16	0.35	2.71e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs2625529	0.730	rs8182011	chr15:72389948	C/T	cg16672083	chr15:72433130	SENP8	0.44	6.25	0.36	1.67e-9	Red blood cell count;
CESC	cis	rs6582630	0.502	rs1607876	chr12:38355750	T/C	cg26384229	chr12:38710491	ALG10B	0.69	10.42	0.54	1.6e-21	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs9894429	0.646	rs9905639	chr17:79614154	A/G	cg18240062	chr17:79603768	NPLOC4	0.51	6.62	0.38	1.98e-10	Eye color traits;
CESC	cis	rs12410462	0.681	rs115959512	chr1:227599578	T/C	cg23173402	chr1:227635558	NA	0.72	5.75	0.33	2.41e-8	Major depressive disorder;
CESC	cis	rs2180341	0.960	rs9401952	chr6:127677027	A/C	cg24812749	chr6:127587940	RNF146	1.05	15.15	0.68	9.37e-38	Breast cancer;
CESC	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.48	6.34	0.36	9.77e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7520050	0.966	rs7524495	chr1:46266932	T/C	cg24296786	chr1:45957014	TESK2	0.43	5.41	0.32	1.38e-7	Red blood cell count;Reticulocyte count;
CESC	cis	rs1847202	0.517	rs13062803	chr3:72951840	T/A	cg25664220	chr3:72788482	NA	-0.38	-5.56	-0.32	6.53e-8	Motion sickness;
CESC	cis	rs7829975	0.511	rs2976906	chr8:8342415	A/T	cg15556689	chr8:8085844	FLJ10661	0.53	6.45	0.37	5.2e-10	Mood instability;
CESC	cis	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg22963979	chr7:1858916	MAD1L1	-0.43	-5.88	-0.34	1.25e-8	Bipolar disorder and schizophrenia;
CESC	trans	rs34421088	0.560	rs2248316	chr8:11397073	A/C	cg15556689	chr8:8085844	FLJ10661	-0.51	-6.0	-0.35	6.33e-9	Neuroticism;
CESC	cis	rs425277	0.628	rs3128340	chr1:2047496	C/G	cg13918804	chr1:2043761	PRKCZ	0.28	5.07	0.3	7.45e-7	Height;
CESC	trans	rs12310956	0.532	rs1589903	chr12:33943019	C/T	cg26384229	chr12:38710491	ALG10B	0.59	8.27	0.45	6.51e-15	Morning vs. evening chronotype;
CESC	cis	rs4727027	0.870	rs13237714	chr7:148884083	A/G	cg23158103	chr7:148848205	ZNF398	-0.41	-6.57	-0.37	2.71e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs7618915	0.570	rs11714088	chr3:52758942	A/C	cg07507251	chr3:52567010	NT5DC2	0.42	7.2	0.4	6.23e-12	Bipolar disorder;
CESC	cis	rs1862618	0.853	rs11739344	chr5:56111087	A/C	cg18230493	chr5:56204884	C5orf35	-0.7	-8.22	-0.45	9.11e-15	Initial pursuit acceleration;
CESC	cis	rs6570726	0.791	rs6902410	chr6:145905261	G/A	cg05347473	chr6:146136440	FBXO30	0.59	7.62	0.42	4.47e-13	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9303280	0.806	rs34189114	chr17:38032460	C/T	cg19468946	chr17:37922297	IKZF3	-0.41	-5.42	-0.32	1.34e-7	Self-reported allergy;
CESC	cis	rs17376456	1.000	rs34013242	chr5:93507947	C/T	cg21475434	chr5:93447410	FAM172A	0.87	7.69	0.43	2.86e-13	Diabetic retinopathy;
CESC	cis	rs7296418	0.636	rs11057261	chr12:123797567	T/C	cg00376283	chr12:123451042	ABCB9	0.57	7.68	0.43	3e-13	Platelet count;
CESC	cis	rs2228479	0.850	rs17227057	chr16:89816333	C/T	cg19635926	chr16:89946313	TCF25	0.67	5.09	0.3	6.82e-7	Skin colour saturation;
CESC	cis	rs9487051	0.872	rs9374079	chr6:109609619	A/G	cg12927641	chr6:109611667	NA	-0.43	-6.7	-0.38	1.22e-10	Reticulocyte fraction of red cells;
CESC	cis	rs875971	0.545	rs1638724	chr7:66040481	A/G	cg25405998	chr7:65216604	CCT6P1	-0.47	-5.25	-0.31	3.14e-7	Aortic root size;
CESC	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg06877462	chr1:205807181	PM20D1	0.44	6.74	0.38	9.9e-11	Menarche (age at onset);
CESC	cis	rs6748734	1.000	rs6751693	chr2:241837332	T/C	cg04034577	chr2:241836375	C2orf54	-0.5	-8.55	-0.47	9.66e-16	Urinary metabolites;
CESC	cis	rs6424115	0.830	rs4649124	chr1:24201357	A/G	cg10978503	chr1:24200527	CNR2	0.33	6.64	0.38	1.73e-10	Immature fraction of reticulocytes;
CESC	cis	rs10751667	0.666	rs7943140	chr11:973824	T/C	cg06064525	chr11:970664	AP2A2	-0.46	-8.92	-0.48	7.68e-17	Alzheimer's disease (late onset);
CESC	cis	rs853679	0.824	rs1321505	chr6:28052823	A/C	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.79	6.72	0.38	1.1e-10	Depression;
CESC	cis	rs10883723	0.773	rs2296578	chr10:104240974	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.56	7.66	0.43	3.52e-13	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs1499614	1.000	rs2707830	chr7:66167645	T/C	cg12463550	chr7:65579703	CRCP	0.73	5.73	0.33	2.78e-8	Gout;
CESC	cis	rs9291683	0.588	rs34501273	chr4:9996996	C/T	cg02734326	chr4:10020555	SLC2A9	0.49	7.14	0.4	8.74e-12	Bone mineral density;
CESC	cis	rs2806561	0.734	rs2143156	chr1:23374629	T/G	cg12483005	chr1:23474871	LUZP1	0.34	5.26	0.31	2.9e-7	Height;
CESC	cis	rs1045902	0.574	rs1474298	chr2:73466592	C/T	cg01422370	chr2:73384389	NA	0.39	5.42	0.32	1.35e-7	Intelligence (multi-trait analysis);
CESC	cis	rs1953600	0.870	rs2789690	chr10:81938204	G/T	cg00277334	chr10:82204260	NA	0.45	6.28	0.36	1.39e-9	Sarcoidosis;
CESC	cis	rs1153858	1.000	rs4271549	chr15:45652730	G/A	cg14582100	chr15:45693742	SPATA5L1	0.42	5.97	0.34	7.62e-9	Homoarginine levels;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg08125682	chr16:11038455	CLEC16A	0.5	6.88	0.39	4.39e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs11098499	0.820	rs13128602	chr4:120459366	C/T	cg24375607	chr4:120327624	NA	-0.43	-5.34	-0.31	1.96e-7	Corneal astigmatism;
CESC	cis	rs11428934	1	rs11428934	chr19:49144245	T/TG	cg06677660	chr19:49140777	SEC1;DBP	0.44	5.18	0.3	4.44e-7	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Granulocyte count;
CESC	cis	rs875971	1.000	rs7789768	chr7:65938980	A/C	cg10691866	chr7:65817282	TPST1	-0.34	-5.62	-0.33	4.93e-8	Aortic root size;
CESC	cis	rs17253792	0.822	rs74412558	chr14:56054311	C/T	cg01858014	chr14:56050164	KTN1	-0.97	-7.15	-0.4	8.64e-12	Putamen volume;
CESC	cis	rs801193	0.844	rs732465	chr7:65998450	T/C	cg18876405	chr7:65276391	NA	0.54	7.59	0.42	5.49e-13	Aortic root size;
CESC	cis	rs1499614	1.000	rs2659911	chr7:66158420	G/A	cg18252515	chr7:66147081	NA	-1.42	-14.62	-0.67	6.69e-36	Gout;
CESC	cis	rs6831352	0.918	rs34876213	chr4:100062216	G/A	cg12011299	chr4:100065546	ADH4	-0.59	-6.48	-0.37	4.49e-10	Alcohol dependence;
CESC	cis	rs9929218	1.000	rs2113200	chr16:68814948	A/T	cg02972257	chr16:68554789	NA	0.48	5.74	0.33	2.61e-8	Colorectal cancer;
CESC	cis	rs12530845	0.945	rs12540273	chr7:135333854	T/G	cg23117316	chr7:135346802	PL-5283	-0.4	-5.15	-0.3	5.07e-7	Red blood cell traits;
CESC	cis	rs116095464	0.614	rs56299325	chr5:220594	C/T	cg22496380	chr5:211416	CCDC127	-0.72	-8.57	-0.47	8.59e-16	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09356014	chr16:87380193	FBXO31	-0.65	-7.2	-0.4	6.18e-12	Gut microbiome composition (summer);
CESC	cis	rs6570726	0.935	rs368848	chr6:145855281	A/T	cg05347473	chr6:146136440	FBXO30	0.48	6.47	0.37	4.82e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6460942	0.915	rs17444044	chr7:12458736	A/G	cg10578991	chr7:12443926	VWDE	-0.5	-5.52	-0.32	7.93e-8	Coronary artery disease;
CESC	cis	rs736408	0.812	rs2270197	chr3:52824095	T/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.43	5.58	0.32	5.83e-8	Bipolar disorder;
CESC	cis	rs875971	0.862	rs10278014	chr7:66051264	C/T	cg19163074	chr7:65112434	INTS4L2	0.42	5.25	0.31	3.16e-7	Aortic root size;
CESC	cis	rs9911578	0.967	rs12938821	chr17:56959422	T/C	cg12560992	chr17:57184187	TRIM37	0.94	15.4	0.69	1.19e-38	Intelligence (multi-trait analysis);
CESC	cis	rs6723226	0.961	rs13010404	chr2:32848854	T/G	cg02381751	chr2:32503542	YIPF4	-0.7	-9.33	-0.5	4.32e-18	Intelligence (multi-trait analysis);
CESC	cis	rs6740322	0.948	rs6722694	chr2:43569798	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.59	-6.44	-0.37	5.65e-10	Coronary artery disease;
CESC	cis	rs9309473	1.000	rs6546838	chr2:73679280	A/G	cg20560298	chr2:73613845	ALMS1	-0.46	-6.17	-0.35	2.53e-9	Metabolite levels;
CESC	cis	rs4563143	0.663	rs10417671	chr19:29235335	T/C	cg04546413	chr19:29218101	NA	0.48	7.8	0.43	1.38e-13	Methadone dose in opioid dependence;
CESC	cis	rs1443512	0.812	rs2044210	chr12:54335533	C/G	cg17410650	chr12:54324560	NA	-0.46	-7.97	-0.44	4.81e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
CESC	cis	rs7772486	0.875	rs2777484	chr6:146334162	A/G	cg05347473	chr6:146136440	FBXO30	0.47	6.16	0.35	2.63e-9	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs11030122	0.702	rs10835406	chr11:3992954	G/T	cg18678763	chr11:4115507	RRM1	0.52	6.95	0.39	2.82e-11	Mean platelet volume;Platelet distribution width;
CESC	cis	rs965469	0.545	rs6051845	chr20:3402792	A/G	cg25506879	chr20:3388711	C20orf194	-0.49	-5.82	-0.34	1.69e-8	IFN-related cytopenia;
CESC	cis	rs644799	1.000	rs580255	chr11:95577929	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.94	13.87	0.65	3.02e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs1577917	1.000	rs12212733	chr6:86726013	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-6.15	-0.35	2.89e-9	Response to antipsychotic treatment;
CESC	cis	rs832540	0.629	rs3309	chr5:56092779	A/T	cg24531977	chr5:56204891	C5orf35	0.46	5.41	0.32	1.42e-7	Coronary artery disease;
CESC	cis	rs2576037	0.526	rs642897	chr18:44396917	T/G	cg19077165	chr18:44547161	KATNAL2	-0.54	-7.93	-0.44	6.3e-14	Personality dimensions;
CESC	cis	rs9649213	0.593	rs736753	chr7:97931489	G/T	cg08684580	chr7:98029266	BAIAP2L1	-0.35	-5.68	-0.33	3.49e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs514406	0.929	rs11206035	chr1:53323571	T/C	cg08859206	chr1:53392774	SCP2	-0.64	-8.55	-0.47	9.9e-16	Monocyte count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08262505	chr5:32174500	GOLPH3	0.63	6.93	0.39	3.12e-11	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17481046	chr3:40547578	ZNF620	0.57	6.68	0.38	1.38e-10	Gut microbiome composition (summer);
CESC	cis	rs27434	0.561	rs151910	chr5:96156956	C/A	cg16492584	chr5:96139282	ERAP1	-0.36	-5.09	-0.3	6.81e-7	Ankylosing spondylitis;
CESC	cis	rs3020736	0.500	rs4147640	chr22:42485292	T/C	cg15557168	chr22:42548783	NA	0.45	6.57	0.37	2.72e-10	Autism spectrum disorder or schizophrenia;
CESC	cis	rs2573652	1.000	rs2581346	chr15:100514178	T/G	cg00587665	chr15:100533223	ADAMTS17	-0.34	-5.44	-0.32	1.21e-7	Height;
CESC	cis	rs796364	0.806	rs12619136	chr2:200910347	C/A	cg23649088	chr2:200775458	C2orf69	-0.55	-5.05	-0.3	8.29e-7	Schizophrenia;
CESC	cis	rs698833	0.926	rs1085449	chr2:44653432	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.46	5.83	0.34	1.6e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs523522	0.962	rs10849759	chr12:120994488	T/A	cg27279351	chr12:120934652	DYNLL1	0.68	8.78	0.47	2.09e-16	High light scatter reticulocyte count;
CESC	cis	rs896854	0.517	rs9643353	chr8:95957063	A/G	cg09323728	chr8:95962352	TP53INP1	0.38	7.42	0.41	1.6e-12	Type 2 diabetes;
CESC	cis	rs7666738	0.519	rs11732209	chr4:98801643	A/G	cg05340658	chr4:99064831	C4orf37	0.54	6.58	0.37	2.49e-10	Colonoscopy-negative controls vs population controls;
CESC	cis	rs62408225	0.894	rs17585295	chr6:90944831	C/T	cg06866423	chr6:90926672	BACH2	0.43	5.32	0.31	2.23e-7	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22902478	chr11:67085251	LOC100130987	0.61	7.4	0.41	1.83e-12	Gut microbiome composition (summer);
CESC	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg06873352	chr17:61820015	STRADA	0.72	12.45	0.61	2.58e-28	Prudent dietary pattern;
CESC	cis	rs17431357	1.000	rs73225248	chr12:120971517	G/C	cg25045489	chr12:120971538	RNF10	-0.93	-5.46	-0.32	1.1e-7	Insulin resistance/response;
CESC	trans	rs61931739	0.534	rs4001713	chr12:34154195	A/C	cg13010199	chr12:38710504	ALG10B	-0.49	-6.21	-0.36	2e-9	Morning vs. evening chronotype;
CESC	cis	rs7918232	0.882	rs788211	chr10:27479070	C/T	cg14240646	chr10:27532245	ACBD5	0.67	6.59	0.38	2.41e-10	Breast cancer;
CESC	cis	rs60154123	0.772	rs845452	chr1:210417861	C/T	cg23283495	chr1:209979779	IRF6	0.45	5.45	0.32	1.14e-7	Coronary artery disease;
CESC	cis	rs6502050	0.871	rs6416857	chr17:80063004	A/G	cg23985595	chr17:80112537	CCDC57	0.41	6.44	0.37	5.45e-10	Life satisfaction;
CESC	cis	rs10979	0.597	rs9403516	chr6:143908139	A/T	cg25407410	chr6:143891975	LOC285740	0.44	5.38	0.31	1.66e-7	Hypospadias;
CESC	trans	rs12356475	0.710	rs10822686	chr10:67733250	C/T	cg08437789	chr10:135085344	ADAM8	-0.43	-6.25	-0.36	1.63e-9	Psoriatic arthritis;
CESC	cis	rs7829975	0.714	rs59046059	chr8:8670736	C/A	cg06636001	chr8:8085503	FLJ10661	0.43	5.65	0.33	4.2e-8	Mood instability;
CESC	cis	rs910316	0.934	rs8006587	chr14:75664939	A/G	cg11812906	chr14:75593930	NEK9	0.84	13.72	0.64	1.02e-32	Height;
CESC	cis	rs4665809	0.838	rs2243834	chr2:26357748	A/C	cg27170947	chr2:26402098	FAM59B	0.57	7.04	0.4	1.67e-11	Gut microbiome composition (summer);
CESC	cis	rs853679	0.517	rs9468298	chr6:28122345	A/G	cg12963246	chr6:28129442	ZNF389	0.58	7.62	0.42	4.61e-13	Depression;
CESC	cis	rs677665	0.918	rs11590326	chr1:9339205	A/G	cg25755851	chr1:9335794	NA	-0.64	-8.15	-0.45	1.43e-14	Eosinophil percentage of white cells;
CESC	cis	rs3820068	0.705	rs2042369	chr1:15843244	A/G	cg17385448	chr1:15911702	AGMAT	-0.35	-5.54	-0.32	7.19e-8	Systolic blood pressure;
CESC	trans	rs2727020	0.675	rs1684258	chr11:49340020	G/A	cg15704280	chr7:45808275	SEPT13	0.77	8.92	0.48	7.85e-17	Coronary artery disease;
CESC	cis	rs6076065	0.748	rs2253834	chr20:23387816	C/T	cg11657817	chr20:23433608	CST11	-0.38	-5.86	-0.34	1.38e-8	Facial morphology (factor 15, philtrum width);
CESC	cis	rs6831352	0.819	rs2851274	chr4:100025866	G/C	cg21548116	chr4:100009993	ADH5	0.46	5.06	0.3	7.69e-7	Alcohol dependence;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27060912	chr19:6517005	NA	0.52	6.55	0.37	2.95e-10	Gut microbiome composition (summer);
CESC	cis	rs7927771	0.524	rs7929725	chr11:47881740	A/G	cg18512352	chr11:47633146	NA	0.35	5.41	0.32	1.44e-7	Subjective well-being;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg07287463	chr1:47903450	FOXD2	-0.46	-6.05	-0.35	5.01e-9	Asthma;
CESC	cis	rs2243480	1.000	rs35542501	chr7:65431215	T/C	cg12463550	chr7:65579703	CRCP	0.68	5.63	0.33	4.55e-8	Diabetic kidney disease;
CESC	cis	rs62064224	0.589	rs2041306	chr17:30665675	T/C	cg18200150	chr17:30822561	MYO1D	0.4	5.11	0.3	6.19e-7	Schizophrenia;
CESC	cis	rs7212590	0.655	rs8070039	chr17:57973585	G/C	cg20303301	chr17:57937339	TUBD1	-0.55	-5.46	-0.32	1.08e-7	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05020822	chr8:144373356	ZNF696	0.63	7.64	0.42	4.04e-13	Gut microbiome composition (summer);
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg17157516	chr1:35332203	DLGAP3	0.47	6.58	0.37	2.55e-10	Systemic lupus erythematosus;
CESC	cis	rs4253772	0.513	rs11090863	chr22:46705407	C/T	cg24881330	chr22:46731750	TRMU	0.75	5.72	0.33	2.81e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs62064224	0.702	rs2302277	chr17:30791509	C/G	cg09324608	chr17:30823087	MYO1D	0.52	8.05	0.44	2.88e-14	Schizophrenia;
CESC	cis	rs2033711	0.783	rs11671113	chr19:58958087	C/T	cg26874164	chr19:58962979	ZNF324B	0.54	7.57	0.42	6.14e-13	Uric acid clearance;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26824326	chr1:9664366	TMEM201	-0.71	-7.87	-0.44	8.85e-14	Gut microbiome composition (summer);
CESC	trans	rs650950	0.528	rs646660	chr11:35528452	C/T	cg22622495	chr1:91966418	CDC7	0.46	6.41	0.37	6.58e-10	Bronchopulmonary dysplasia;
CESC	cis	rs8177253	0.511	rs9830001	chr3:133433470	A/G	cg16262614	chr3:133464971	TF	-0.3	-5.45	-0.32	1.16e-7	Iron status biomarkers;
CESC	cis	rs1348850	0.914	rs1453370	chr2:178327727	C/T	cg22681709	chr2:178499509	PDE11A	-0.42	-6.02	-0.35	5.67e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs7188697	0.922	rs246196	chr16:58574253	T/C	cg02549819	chr16:58548995	SETD6	-0.42	-5.3	-0.31	2.46e-7	QT interval;
CESC	cis	rs79839061	0.610	rs17781499	chr4:889384	C/A	cg07828340	chr4:882639	GAK	1.07	8.32	0.46	4.68e-15	Intelligence (multi-trait analysis);
CESC	cis	rs7666738	0.830	rs4440224	chr4:99044924	G/A	cg03467027	chr4:99064603	C4orf37	0.47	5.98	0.34	7.19e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10883723	0.810	rs7069356	chr10:104254359	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.54	7.43	0.42	1.49e-12	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs4713118	0.621	rs9368548	chr6:28034737	A/G	cg26335602	chr6:28129616	ZNF389	0.48	6.06	0.35	4.7e-9	Parkinson's disease;
CESC	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg26304593	chr6:42947056	PEX6	-0.43	-5.58	-0.32	5.92e-8	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs7084402	0.967	rs1649065	chr10:60306386	T/G	cg07615347	chr10:60278583	BICC1	0.59	9.34	0.5	4.23e-18	Refractive error;
CESC	cis	rs116095464	0.614	rs4371799	chr5:268192	C/A	cg12570787	chr5:219185	SDHA;CCDC127	0.5	5.31	0.31	2.37e-7	Breast cancer;
CESC	cis	rs7091068	0.536	rs7893369	chr10:95410147	A/G	cg20715218	chr10:95462985	C10orf4	0.46	5.66	0.33	3.85e-8	Urinary tract infection frequency;
CESC	cis	rs1153858	1.000	rs1346268	chr15:45673029	T/C	cg14582100	chr15:45693742	SPATA5L1	0.42	5.95	0.34	8.38e-9	Homoarginine levels;
CESC	cis	rs611744	0.647	rs7016198	chr8:109262752	G/A	cg21045802	chr8:109455806	TTC35	0.46	5.7	0.33	3.13e-8	Dupuytren's disease;
CESC	trans	rs3780486	0.801	rs10971424	chr9:33138775	T/C	cg20290983	chr6:43655470	MRPS18A	0.99	18.43	0.75	2.16e-49	IgG glycosylation;
CESC	cis	rs9796	0.689	rs13329537	chr15:41449211	C/G	cg18705301	chr15:41695430	NDUFAF1	0.46	6.93	0.39	3.27e-11	Menopause (age at onset);
CESC	cis	rs7223966	1.000	rs61360320	chr17:61800392	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.68	0.38	1.39e-10	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs17253792	0.822	rs74935793	chr14:56143277	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.81	5.68	0.33	3.46e-8	Putamen volume;
CESC	cis	rs2806561	0.704	rs2868573	chr1:23508253	C/G	cg12483005	chr1:23474871	LUZP1	0.39	6.06	0.35	4.58e-9	Height;
CESC	cis	rs7998202	0.667	rs914016	chr13:113355057	A/C	cg02820901	chr13:113351484	ATP11A	0.65	5.78	0.33	2.05e-8	Glycated hemoglobin levels;
CESC	cis	rs4888262	0.545	rs36097721	chr16:74648267	C/G	cg01733217	chr16:74700730	RFWD3	0.87	12.3	0.6	8.07e-28	Testicular germ cell tumor;
CESC	cis	rs8060686	0.641	rs113896227	chr16:68101480	C/T	cg26727032	chr16:67993705	SLC12A4	-0.54	-6.06	-0.35	4.73e-9	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs6460942	1.000	rs6460942	chr7:12420989	T/C	cg06484146	chr7:12443880	VWDE	-0.75	-8.83	-0.48	1.48e-16	Coronary artery disease;
CESC	trans	rs9329221	0.537	rs12678797	chr8:9978919	A/G	cg06636001	chr8:8085503	FLJ10661	-0.47	-6.14	-0.35	3.03e-9	Neuroticism;
CESC	cis	rs2637266	1.000	rs7080883	chr10:78361200	A/G	cg18941641	chr10:78392320	NA	0.41	7.89	0.44	7.84e-14	Pulmonary function;
CESC	cis	rs514406	0.679	rs541852	chr1:53256834	A/G	cg25767906	chr1:53392781	SCP2	0.53	7.63	0.42	4.32e-13	Monocyte count;
CESC	cis	rs8066384	1	rs8066384	chr17:78625756	T/C	cg09596252	chr17:78655493	RPTOR	0.42	5.09	0.3	6.68e-7	Schizophrenia;
CESC	cis	rs9611519	0.929	rs4820423	chr22:41430338	A/T	cg03806693	chr22:41940476	POLR3H	-0.57	-5.94	-0.34	9.05e-9	Neuroticism;
CESC	cis	rs6867032	0.527	rs4246752	chr5:1975575	T/A	cg26168224	chr5:2018326	NA	-0.79	-11.67	-0.58	1.13e-25	Gut microbiome composition (winter);
CESC	cis	rs3008870	0.755	rs3929738	chr1:67397865	T/C	cg02640540	chr1:67518911	SLC35D1	0.46	5.58	0.32	5.89e-8	Lymphocyte percentage of white cells;
CESC	cis	rs3741151	0.773	rs73542979	chr11:73127526	G/C	cg17517138	chr11:73019481	ARHGEF17	0.94	6.86	0.39	4.87e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs875971	0.545	rs10950036	chr7:65818228	G/T	cg25405998	chr7:65216604	CCT6P1	0.46	5.42	0.32	1.37e-7	Aortic root size;
CESC	cis	rs2576037	0.583	rs2187091	chr18:44520048	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.37	5.87	0.34	1.27e-8	Personality dimensions;
CESC	cis	rs7666738	0.830	rs13149346	chr4:99009933	C/T	cg03676636	chr4:99064102	C4orf37	0.33	5.16	0.3	4.86e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9354308	0.866	rs2802054	chr6:66544766	G/C	cg07460842	chr6:66804631	NA	0.58	6.53	0.37	3.29e-10	Metabolite levels;
CESC	cis	rs4665809	0.887	rs4665825	chr2:26333100	A/G	cg27170947	chr2:26402098	FAM59B	-0.59	-7.07	-0.4	1.36e-11	Gut microbiome composition (summer);
CESC	cis	rs9309473	1.000	rs7598419	chr2:73798223	A/G	cg20560298	chr2:73613845	ALMS1	-0.55	-6.91	-0.39	3.61e-11	Metabolite levels;
CESC	cis	rs1799949	0.965	rs4793234	chr17:41436183	A/G	cg05368731	chr17:41323189	NBR1	0.75	10.33	0.54	3.04e-21	Menopause (age at onset);
CESC	cis	rs34779708	0.966	rs4294520	chr10:35422506	C/T	cg04310649	chr10:35416472	CREM	-0.49	-5.83	-0.34	1.63e-8	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs780096	0.545	rs6716894	chr2:27583273	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.33	-6.1	-0.35	3.76e-9	Total body bone mineral density;
CESC	cis	rs9549260	0.640	rs4943796	chr13:41196016	C/T	cg21288729	chr13:41239152	FOXO1	0.62	7.9	0.44	7.34e-14	Red blood cell count;
CESC	cis	rs854765	0.547	rs8075189	chr17:17901946	C/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.54	7.72	0.43	2.32e-13	Total body bone mineral density;
CESC	cis	rs9447004	0.584	rs12215671	chr6:74435607	T/C	cg23004174	chr6:74404879	CD109	0.36	5.06	0.3	7.8e-7	Blood protein levels;Calcium levels;
CESC	cis	rs112790992	1	rs112790992	chr14:105758217	A/C	cg10792982	chr14:105748885	BRF1	0.37	5.13	0.3	5.48e-7	Platelet count;
CESC	cis	rs11048434	0.723	rs1805737	chr12:9084670	A/T	cg04155231	chr12:9217510	LOC144571	0.32	5.13	0.3	5.61e-7	Sjögren's syndrome;
CESC	trans	rs9987353	0.840	rs329994	chr8:9123233	A/G	cg12282830	chr22:29784441	AP1B1	-0.49	-6.18	-0.35	2.39e-9	Recombination measurement;
CESC	cis	rs6540559	0.673	rs41305104	chr1:209950848	G/A	cg21951975	chr1:209979733	IRF6	0.54	6.37	0.36	8.44e-10	Cleft lip with or without cleft palate;
CESC	cis	rs4713675	0.584	rs7759668	chr6:33670406	C/T	cg15676125	chr6:33679581	C6orf125	-0.34	-5.04	-0.3	8.45e-7	Plateletcrit;
CESC	cis	rs3733585	0.631	rs3822236	chr4:10119961	T/G	cg05927159	chr4:10118984	WDR1	0.34	5.08	0.3	7.04e-7	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg24829409	chr8:58192753	C8orf71	-0.67	-8.18	-0.45	1.19e-14	Developmental language disorder (linguistic errors);
CESC	trans	rs4498364	0.541	rs1206154	chr6:97548919	G/A	cg09636063	chr6:158957850	TMEM181	0.43	6.07	0.35	4.47e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
CESC	cis	rs17209837	1.000	rs45593435	chr7:87088772	A/G	cg00919237	chr7:87102261	ABCB4	-0.5	-5.83	-0.34	1.6e-8	Gallbladder cancer;
CESC	trans	rs1814175	0.645	rs1721997	chr11:49916653	T/C	cg15704280	chr7:45808275	SEPT13	-1.01	-18.94	-0.76	3.64e-51	Height;
CESC	cis	rs1568889	1.000	rs61889046	chr11:28297024	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.82	11.86	0.59	2.68e-26	Bipolar disorder;
CESC	cis	rs6977955	1.000	rs4722762	chr7:28178262	G/T	cg23620719	chr7:28220237	JAZF1	0.61	6.74	0.38	9.96e-11	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs2880765	0.805	rs11858817	chr15:86031260	C/T	cg10818794	chr15:86012489	AKAP13	-0.35	-5.42	-0.32	1.32e-7	Coronary artery disease;
CESC	cis	rs7507204	0.723	rs12982194	chr19:3411947	G/A	cg08380311	chr19:3435252	NFIC	0.62	6.61	0.38	2.13e-10	Height;
CESC	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg11301795	chr4:187892539	NA	-0.75	-12.03	-0.59	6.89e-27	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs752010	0.806	rs11210500	chr1:42089737	A/G	cg06885757	chr1:42089581	HIVEP3	0.53	9.11	0.49	2.04e-17	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs4555082	0.794	rs2735827	chr14:105710600	T/A	cg10792982	chr14:105748885	BRF1	0.39	5.04	0.3	8.62e-7	Mean platelet volume;Platelet distribution width;
CESC	cis	rs1348850	0.574	rs4893834	chr2:178442288	C/T	cg22681709	chr2:178499509	PDE11A	0.45	5.26	0.31	3.02e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs909674	0.865	rs5757682	chr22:39848259	T/G	cg11247378	chr22:39784982	NA	-0.62	-8.34	-0.46	4.13e-15	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs6690583	0.623	rs2083283	chr1:85439996	C/A	cg22153463	chr1:85462885	MCOLN2	0.75	7.31	0.41	3.25e-12	Serum sulfate level;
CESC	cis	rs4925386	1.000	rs2151512	chr20:60913495	T/C	cg24112000	chr20:60950667	NA	0.52	7.71	0.43	2.62e-13	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs10392	0.543	rs57569873	chr20:37558293	T/C	cg27552599	chr20:37590471	DHX35	0.39	5.88	0.34	1.23e-8	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
CESC	cis	rs909674	0.515	rs9611170	chr22:39784845	G/C	cg11247378	chr22:39784982	NA	-0.67	-10.28	-0.53	4.34e-21	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs6496667	0.779	rs28516870	chr15:91037754	G/A	cg13834112	chr15:90361639	NA	0.4	5.29	0.31	2.56e-7	Rheumatoid arthritis;
CESC	cis	rs12188164	0.515	rs11745246	chr5:410943	A/G	cg26850624	chr5:429559	AHRR	-0.42	-5.43	-0.32	1.26e-7	Cystic fibrosis severity;
CESC	cis	rs425277	0.628	rs10797427	chr1:2060732	C/T	cg04315214	chr1:2043799	PRKCZ	0.54	9.25	0.49	7.68e-18	Height;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg17165990	chr19:19656778	CILP2	0.47	6.51	0.37	3.8e-10	Fibrinogen levels;
CESC	cis	rs1448094	0.545	rs11117077	chr12:86277317	A/G	cg02569458	chr12:86230093	RASSF9	0.42	6.14	0.35	3.03e-9	Major depressive disorder;
CESC	cis	rs3020736	0.500	rs2839708	chr22:42500745	A/G	cg15557168	chr22:42548783	NA	0.45	6.57	0.37	2.72e-10	Autism spectrum disorder or schizophrenia;
CESC	cis	rs4975709	0.589	rs1466607	chr5:1864856	A/G	cg20790798	chr5:1857306	NA	-0.41	-5.39	-0.31	1.59e-7	Cardiovascular disease risk factors;
CESC	cis	rs12824058	0.831	rs12831363	chr12:130814013	C/T	cg23887609	chr12:130822674	PIWIL1	-0.44	-5.75	-0.33	2.39e-8	Menopause (age at onset);
CESC	cis	rs6570726	0.791	rs6570692	chr6:145904401	T/A	cg05347473	chr6:146136440	FBXO30	0.59	7.61	0.42	4.67e-13	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs4927850	0.752	rs7618864	chr3:195749561	G/A	cg16724585	chr3:197361211	NA	-0.56	-7.19	-0.4	6.66e-12	Pancreatic cancer;
CESC	cis	rs4975709	0.569	rs931509	chr5:1858821	A/T	cg14773178	chr5:1868261	NA	0.32	5.44	0.32	1.19e-7	Cardiovascular disease risk factors;
CESC	cis	rs11122272	0.735	rs2749714	chr1:231538634	G/C	cg06096015	chr1:231504339	EGLN1	0.42	6.05	0.35	4.97e-9	Hemoglobin concentration;
CESC	cis	rs3091242	0.933	rs28633797	chr1:25741629	C/A	cg03538708	chr1:25844672	NA	-0.41	-6.17	-0.35	2.6e-9	Erythrocyte sedimentation rate;
CESC	cis	rs8114671	0.562	rs1801310	chr20:33517014	A/G	cg07148914	chr20:33460835	GGT7	0.52	6.8	0.39	6.88e-11	Height;
CESC	cis	rs116095464	0.558	rs10079760	chr5:230778	A/G	cg12570787	chr5:219185	SDHA;CCDC127	0.51	5.49	0.32	9.64e-8	Breast cancer;
CESC	cis	rs2243480	1.000	rs35825738	chr7:65318027	A/G	cg18252515	chr7:66147081	NA	-1.01	-9.73	-0.51	2.51e-19	Diabetic kidney disease;
CESC	cis	rs10504229	0.817	rs58957714	chr8:58195864	G/A	cg14926445	chr8:58193284	C8orf71	-0.6	-5.73	-0.33	2.73e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs60871478	0.945	rs4719279	chr7:813618	T/C	cg27478167	chr7:817139	HEATR2	-0.45	-5.23	-0.31	3.47e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.76	10.65	0.55	2.74e-22	Prudent dietary pattern;
CESC	trans	rs3780486	0.846	rs10113903	chr9:33122645	C/G	cg04842962	chr6:43655489	MRPS18A	-1.01	-19.55	-0.77	2.63e-53	IgG glycosylation;
CESC	cis	rs3785574	0.962	rs9944483	chr17:61783553	G/T	cg01411255	chr17:61851458	DDX42;CCDC47	-1.08	-18.78	-0.76	1.28e-50	Height;
CESC	cis	rs1215050	0.740	rs2555390	chr4:98999112	A/G	cg17366294	chr4:99064904	C4orf37	-0.39	-5.17	-0.3	4.59e-7	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg01238044	chr22:24384105	GSTT1	-0.63	-8.29	-0.45	5.65e-15	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs7666738	0.830	rs6833822	chr4:98951354	G/A	cg05340658	chr4:99064831	C4orf37	0.8	12.48	0.61	2e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs8141529	0.748	rs5997412	chr22:29276747	G/A	cg02153584	chr22:29168773	CCDC117	0.59	7.61	0.42	4.72e-13	Lymphocyte counts;
CESC	cis	rs3096299	0.748	rs3102339	chr16:89442711	C/T	cg08392591	chr16:89556376	ANKRD11	0.43	5.42	0.32	1.31e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs113835537	0.529	rs4542420	chr11:66277610	G/C	cg24851651	chr11:66362959	CCS	0.44	5.46	0.32	1.11e-7	Airway imaging phenotypes;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg11948252	chr1:160771900	LY9	-0.4	-6.31	-0.36	1.18e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	trans	rs12681287	0.547	rs7461366	chr8:87511685	C/T	cg27317242	chr8:23145699	R3HCC1	-0.53	-6.34	-0.36	9.67e-10	Caudate activity during reward;
CESC	cis	rs11122272	0.735	rs2808600	chr1:231534723	T/C	cg06096015	chr1:231504339	EGLN1	0.43	6.15	0.35	2.9e-9	Hemoglobin concentration;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13216351	chr20:49575105	MOCS3;DPM1	0.58	6.96	0.39	2.7e-11	Gut microbiome composition (summer);
CESC	cis	rs425277	0.527	rs3107144	chr1:2045380	C/A	cg23803603	chr1:2058230	PRKCZ	-0.35	-6.12	-0.35	3.38e-9	Height;
CESC	cis	rs6060717	0.536	rs17432470	chr20:34547763	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.63	5.24	0.31	3.33e-7	Hip circumference adjusted for BMI;
CESC	cis	rs4722166	0.532	rs6461662	chr7:22757089	C/T	cg05472934	chr7:22766657	IL6	0.51	6.87	0.39	4.7e-11	Lung cancer;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg19262334	chr18:74631861	ZNF236	0.48	6.3	0.36	1.2e-9	Fibrinogen levels;
CESC	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.48	6.37	0.36	8.55e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7811142	0.666	rs28401739	chr7:99905684	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.83	8.32	0.46	4.57e-15	Platelet count;
CESC	cis	rs4665809	0.590	rs4665315	chr2:26416036	T/G	cg08470875	chr2:26401718	FAM59B	-0.73	-7.98	-0.44	4.43e-14	Gut microbiome composition (summer);
CESC	trans	rs10506458	1.000	rs12425932	chr12:63410497	C/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.36	-18.93	-0.76	3.88e-51	Hemostatic factors and hematological phenotypes;
CESC	cis	rs7666738	0.791	rs7665273	chr4:98997413	C/A	cg17366294	chr4:99064904	C4orf37	0.6	8.61	0.47	6.47e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs854765	0.547	rs12150369	chr17:17911014	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.54	7.72	0.43	2.32e-13	Total body bone mineral density;
CESC	cis	rs7937682	0.883	rs1613778	chr11:111456105	G/C	cg22437258	chr11:111473054	SIK2	0.71	9.1	0.49	2.27e-17	Primary sclerosing cholangitis;
CESC	cis	rs9393777	0.623	rs3757150	chr6:26476782	T/A	cg14345882	chr6:26364793	BTN3A2	0.43	5.34	0.31	2.01e-7	Intelligence (multi-trait analysis);
CESC	cis	rs2625529	0.824	rs12439900	chr15:72373640	A/G	cg16672083	chr15:72433130	SENP8	-0.37	-5.06	-0.3	7.75e-7	Red blood cell count;
CESC	cis	rs10504229	0.683	rs11774585	chr8:58132685	G/A	cg02725872	chr8:58115012	NA	-0.45	-7.05	-0.4	1.52e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs2228479	0.702	rs11076620	chr16:89831520	A/T	cg04013166	chr16:89971882	TCF25	0.78	6.69	0.38	1.3e-10	Skin colour saturation;
CESC	trans	rs9325144	0.513	rs7977596	chr12:38649067	C/A	cg23762105	chr12:34175262	ALG10	0.48	6.31	0.36	1.15e-9	Morning vs. evening chronotype;
CESC	cis	rs13108904	0.967	rs900027	chr4:1279360	G/A	cg22903657	chr4:1355424	KIAA1530	-0.38	-5.23	-0.31	3.48e-7	Obesity-related traits;
CESC	cis	rs7178572	0.568	rs1823100	chr15:77402744	C/T	cg22256960	chr15:77711686	NA	-0.54	-6.79	-0.38	7.49e-11	Type 2 diabetes;
CESC	cis	rs9937943	0.616	rs12923487	chr16:74644112	G/T	cg01733217	chr16:74700730	RFWD3	0.59	5.27	0.31	2.89e-7	Neutrophil percentage of white cells;
CESC	cis	rs12497850	0.897	rs6781790	chr3:49044767	C/T	cg06212747	chr3:49208901	KLHDC8B	0.71	9.52	0.5	1.16e-18	Parkinson's disease;
CESC	cis	rs1218582	0.772	rs2102423	chr1:154916068	A/G	cg16680214	chr1:154839983	KCNN3	-0.47	-7.13	-0.4	9.41e-12	Prostate cancer;
CESC	cis	rs11122272	0.735	rs2808580	chr1:231509259	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.57	-7.82	-0.43	1.29e-13	Hemoglobin concentration;
CESC	cis	rs7523050	0.643	rs35885176	chr1:109401868	G/A	cg08274380	chr1:109419600	GPSM2	0.86	5.69	0.33	3.36e-8	Fat distribution (HIV);
CESC	cis	rs7833790	0.963	rs1451997	chr8:82774053	A/T	cg17211192	chr8:82754475	SNX16	0.68	8.12	0.45	1.77e-14	Diastolic blood pressure;
CESC	cis	rs7264396	0.747	rs2425112	chr20:34319775	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.85	-11.75	-0.59	5.91e-26	Total cholesterol levels;
CESC	cis	rs12477438	0.798	rs6542848	chr2:99573732	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-10.48	-0.54	1.03e-21	Chronic sinus infection;
CESC	cis	rs6032067	0.925	rs6032061	chr20:43853276	C/T	cg10761708	chr20:43804764	PI3	0.52	6.26	0.36	1.57e-9	Blood protein levels;
CESC	cis	rs36051895	0.555	rs6476953	chr9:5248742	C/T	cg02405213	chr9:5042618	JAK2	-0.54	-6.51	-0.37	3.76e-10	Pediatric autoimmune diseases;
CESC	cis	rs10870270	1.000	rs10159943	chr10:133744744	T/C	cg26149184	chr10:133730230	NA	0.37	5.09	0.3	6.85e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs1552244	0.882	rs6443279	chr3:10053599	C/A	cg08888203	chr3:10149979	C3orf24	0.49	6.17	0.35	2.51e-9	Alzheimer's disease;
CESC	cis	rs3749237	0.595	rs7643845	chr3:49530711	A/G	cg02487422	chr3:49467188	NICN1	0.56	8.19	0.45	1.09e-14	Resting heart rate;
CESC	cis	rs72781680	1.000	rs72796328	chr2:24141343	A/G	cg20701182	chr2:24300061	SF3B14	0.78	6.73	0.38	1.07e-10	Lymphocyte counts;
CESC	cis	rs9611565	0.500	rs10775759	chr22:42088158	T/C	cg17376030	chr22:41985996	PMM1	-0.67	-7.37	-0.41	2.18e-12	Vitiligo;
CESC	cis	rs6543140	0.964	rs13390895	chr2:103075499	G/A	cg04239558	chr2:103089729	SLC9A4	0.47	6.16	0.35	2.64e-9	Blood protein levels;
CESC	cis	rs1005277	0.579	rs2474572	chr10:38385316	A/G	cg25427524	chr10:38739819	LOC399744	-0.69	-10.26	-0.53	5.12e-21	Extrinsic epigenetic age acceleration;
CESC	cis	rs9457247	0.663	rs2301436	chr6:167437988	C/T	cg23791538	chr6:167370224	RNASET2	-0.55	-7.5	-0.42	9.65e-13	Crohn's disease;
CESC	cis	rs7666738	0.830	rs1025204	chr4:99023441	G/A	cg03467027	chr4:99064603	C4orf37	0.47	5.88	0.34	1.26e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs62045849	0.557	rs6500533	chr16:89190065	G/A	cg26950739	chr16:89183275	ACSF3	0.58	5.25	0.31	3.13e-7	Red blood cell count;
CESC	cis	rs9614461	0.702	rs2294202	chr22:45738327	A/T	cg01808030	chr22:45809952	RIBC2;SMC1B	0.72	7.66	0.43	3.57e-13	Tonsillectomy;
CESC	cis	rs778371	1.000	rs11535	chr2:233743532	G/C	cg08000102	chr2:233561755	GIGYF2	-0.82	-13.13	-0.63	1.11e-30	Schizophrenia;
CESC	cis	rs4704187	0.687	rs1903839	chr5:74421397	A/G	cg03227963	chr5:74354835	NA	0.31	5.7	0.33	3.22e-8	Response to amphetamines;
CESC	cis	rs2576037	0.583	rs10070	chr18:44388899	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.36	5.78	0.33	2.06e-8	Personality dimensions;
CESC	cis	rs7243790	0.805	rs12458280	chr18:51913142	C/T	cg04730925	chr18:51795821	POLI	-0.43	-5.78	-0.33	2.04e-8	Diastolic blood pressure;
CESC	cis	rs367943	0.712	rs4331889	chr5:112679795	C/T	cg12552261	chr5:112820674	MCC	0.4	5.2	0.3	4.03e-7	Type 2 diabetes;
CESC	cis	rs6541297	0.645	rs638112	chr1:230310736	C/A	cg20703242	chr1:230279135	GALNT2	-0.43	-5.56	-0.32	6.46e-8	Coronary artery disease;
CESC	cis	rs7267979	1.000	rs2259837	chr20:25280205	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	18.72	0.75	2.09e-50	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs9811920	0.638	rs7629426	chr3:99652577	C/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.61	-9.74	-0.51	2.34e-19	Axial length;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg11969144	chr1:87797684	LMO4	-0.5	-6.69	-0.38	1.34e-10	Fibrinogen levels;
CESC	cis	rs36051895	0.530	rs6476951	chr9:5221614	A/G	cg02405213	chr9:5042618	JAK2	-0.53	-6.54	-0.37	3.19e-10	Pediatric autoimmune diseases;
CESC	cis	rs10504229	0.906	rs114810777	chr8:58185298	A/G	cg24829409	chr8:58192753	C8orf71	-0.75	-9.84	-0.52	1.15e-19	Developmental language disorder (linguistic errors);
CESC	cis	rs6963495	0.592	rs114793754	chr7:105152162	G/C	cg02135003	chr7:105160482	PUS7	-0.46	-5.46	-0.32	1.08e-7	Bipolar disorder (body mass index interaction);
CESC	cis	rs6570726	0.818	rs952405	chr6:145925952	T/C	cg05347473	chr6:146136440	FBXO30	0.48	6.39	0.37	7.61e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7904368	0.754	rs66491181	chr10:16849430	T/C	cg23933602	chr10:16859644	RSU1	0.72	7.2	0.4	6.08e-12	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
CESC	cis	rs1595825	0.891	rs60129872	chr2:198653192	A/G	cg00982548	chr2:198649783	BOLL	-0.47	-5.08	-0.3	7.12e-7	Ulcerative colitis;
CESC	cis	rs7552404	0.627	rs12127049	chr1:76353248	G/A	cg10523679	chr1:76189770	ACADM	0.65	6.22	0.36	1.93e-9	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs7178572	0.568	rs12900433	chr15:77495028	T/C	cg22256960	chr15:77711686	NA	-0.53	-6.69	-0.38	1.33e-10	Type 2 diabetes;
CESC	cis	rs9287719	0.870	rs10167676	chr2:10753140	G/A	cg00105475	chr2:10696890	NA	0.38	5.42	0.32	1.34e-7	Prostate cancer;
CESC	cis	rs735396	1.000	rs1169311	chr12:121440731	C/T	cg02403541	chr12:121454288	C12orf43	0.64	9.22	0.49	9.65e-18	N-glycan levels;
CESC	cis	rs2735413	0.918	rs11646244	chr16:78082453	T/C	cg04733911	chr16:78082701	NA	-0.53	-8.89	-0.48	9.44e-17	Systolic blood pressure (alcohol consumption interaction);
CESC	cis	rs9303401	0.527	rs2116450	chr17:56745561	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.04	12.96	0.62	4.32e-30	Cognitive test performance;
CESC	cis	rs798554	0.607	rs1182151	chr7:2909225	C/G	cg09658497	chr7:2847517	GNA12	-0.4	-5.12	-0.3	5.88e-7	Height;
CESC	cis	rs933688	1.000	rs12655973	chr5:90736537	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.96	12.6	0.61	7.43e-29	Smoking behavior;
CESC	trans	rs4843747	0.671	rs72818577	chr16:88111181	G/A	cg26811252	chr16:29126840	RRN3P2	0.69	9.82	0.52	1.32e-19	Menopause (age at onset);
CESC	cis	rs7236492	0.748	rs11664153	chr18:77195813	G/A	cg15644404	chr18:77186268	NFATC1	-0.69	-5.32	-0.31	2.16e-7	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs10751667	0.643	rs7942693	chr11:957832	G/A	cg01483505	chr11:975446	AP2A2	0.37	5.05	0.3	8.3e-7	Alzheimer's disease (late onset);
CESC	cis	rs2880765	0.835	rs2170735	chr15:86043485	G/A	cg10818794	chr15:86012489	AKAP13	-0.34	-5.16	-0.3	4.93e-7	Coronary artery disease;
CESC	cis	rs2120019	0.938	rs8036573	chr15:75308690	C/T	cg09165964	chr15:75287851	SCAMP5	-0.77	-9.55	-0.51	9.13e-19	Blood trace element (Zn levels);
CESC	cis	rs718433	0.584	rs2874142	chr14:22218320	T/A	cg02257791	chr14:22217085	NA	-0.32	-5.08	-0.3	7.19e-7	Intraocular pressure;
CESC	cis	rs9818758	0.607	rs4855860	chr3:49526044	A/T	cg00383909	chr3:49044727	WDR6	-0.86	-5.67	-0.33	3.81e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CESC	cis	rs1552244	1.000	rs66838678	chr3:10150350	G/A	cg00166722	chr3:10149974	C3orf24	0.46	5.78	0.33	2.08e-8	Alzheimer's disease;
CESC	cis	rs5769765	0.908	rs9616396	chr22:50317825	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.63	-6.44	-0.37	5.53e-10	Schizophrenia;
CESC	cis	rs2991971	0.967	rs12743512	chr1:45954033	A/G	cg05343316	chr1:45956843	TESK2	0.5	6.54	0.37	3.11e-10	High light scatter reticulocyte count;
CESC	trans	rs1814175	0.817	rs10839397	chr11:49857074	C/T	cg15704280	chr7:45808275	SEPT13	-1.02	-19.98	-0.78	8.73e-55	Height;
CESC	cis	rs9976767	0.637	rs9984108	chr21:43825628	T/G	cg23042151	chr21:43824109	UBASH3A	-0.33	-6.17	-0.35	2.55e-9	Type 1 diabetes;
CESC	cis	rs3768617	0.510	rs10737245	chr1:183100884	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.89	14.39	0.66	4.39e-35	Fuchs's corneal dystrophy;
CESC	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg07414643	chr4:187882934	NA	0.56	8.14	0.45	1.53e-14	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs36051895	0.695	rs62541532	chr9:5017384	C/A	cg02405213	chr9:5042618	JAK2	-0.48	-5.31	-0.31	2.33e-7	Pediatric autoimmune diseases;
CESC	cis	rs7833790	0.685	rs13255262	chr8:82728024	T/G	cg06027949	chr8:82754900	SNX16	-0.44	-5.23	-0.31	3.48e-7	Diastolic blood pressure;
CESC	cis	rs9926296	0.632	rs1800286	chr16:89869761	T/C	cg04287289	chr16:89883240	FANCA	0.64	8.13	0.45	1.63e-14	Vitiligo;
CESC	cis	rs7811142	1.000	rs67239991	chr7:100046504	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.95	10.23	0.53	6.21e-21	Platelet count;
CESC	cis	rs12971120	1.000	rs2278162	chr18:72175814	A/G	cg25817165	chr18:72167213	CNDP2	-0.64	-8.2	-0.45	1.06e-14	Refractive error;
CESC	cis	rs7523050	0.730	rs12079547	chr1:109469314	A/C	cg08274380	chr1:109419600	GPSM2	0.79	5.92	0.34	9.72e-9	Fat distribution (HIV);
CESC	cis	rs9549367	0.713	rs553316	chr13:113838015	A/G	cg00898013	chr13:113819073	PROZ	0.46	6.88	0.39	4.4e-11	Platelet distribution width;
CESC	cis	rs1881797	1.000	rs12063141	chr1:247688343	G/A	cg21399703	chr1:247681439	NA	0.6	7.76	0.43	1.87e-13	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs17345786	0.861	rs11711808	chr3:101235101	T/C	cg12386194	chr3:101231763	SENP7	0.59	6.48	0.37	4.48e-10	Colonoscopy-negative controls vs population controls;
CESC	cis	rs919433	0.680	rs8539	chr2:198362018	A/G	cg03934865	chr2:198174659	NA	0.43	5.81	0.34	1.82e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs4713118	0.515	rs9368549	chr6:28050047	T/A	cg12963246	chr6:28129442	ZNF389	0.55	7.35	0.41	2.46e-12	Parkinson's disease;
CESC	trans	rs66573146	1.000	rs67067921	chr4:6984341	A/T	cg07817883	chr1:32538562	TMEM39B	1.47	9.22	0.49	9.35e-18	Granulocyte percentage of myeloid white cells;
CESC	cis	rs10927875	0.631	rs945418	chr1:16344730	T/C	cg21385522	chr1:16154831	NA	0.6	7.24	0.41	4.95e-12	Dilated cardiomyopathy;
CESC	cis	rs9486719	0.843	rs3860230	chr6:97036560	T/A	cg06623918	chr6:96969491	KIAA0776	-0.88	-10.5	-0.54	8.92e-22	Migraine;Coronary artery disease;
CESC	cis	rs7542091	0.704	rs7537294	chr1:210043777	A/G	cg23283495	chr1:209979779	IRF6	0.35	5.8	0.34	1.84e-8	Monobrow;
CESC	cis	rs9399137	0.529	rs7739722	chr6:135282225	T/C	cg24558204	chr6:135376177	HBS1L	0.71	9.6	0.51	6.54e-19	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	cis	rs826838	0.616	rs4619214	chr12:38614704	C/A	cg26384229	chr12:38710491	ALG10B	0.46	6.62	0.38	1.96e-10	Heart rate;
CESC	cis	rs2074585	0.517	rs11635361	chr15:91081791	G/T	cg10434728	chr15:90938212	IQGAP1	-0.32	-5.32	-0.31	2.16e-7	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
CESC	cis	rs926392	0.640	rs62202616	chr20:37692775	G/C	cg16355469	chr20:37678765	NA	0.57	6.48	0.37	4.58e-10	Dialysis-related mortality;
CESC	cis	rs854765	0.647	rs4365346	chr17:17989373	G/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.47	5.96	0.34	8.22e-9	Total body bone mineral density;
CESC	cis	rs8114671	0.836	rs6120778	chr20:33565169	T/C	cg07148914	chr20:33460835	GGT7	0.43	5.46	0.32	1.09e-7	Height;
CESC	cis	rs372883	0.506	rs2832301	chr21:30749712	G/A	cg24692254	chr21:30365293	RNF160	0.47	5.89	0.34	1.14e-8	Pancreatic cancer;
CESC	cis	rs3096299	0.967	rs2965937	chr16:89488779	A/T	cg16743903	chr16:89593216	SPG7	-0.42	-5.51	-0.32	8.3e-8	Multiple myeloma (IgH translocation);
CESC	cis	rs4148883	0.651	rs10020052	chr4:100086331	C/G	cg13256891	chr4:100009986	ADH5	0.53	6.93	0.39	3.22e-11	Alcohol dependence;
CESC	cis	rs2839186	0.619	rs55689527	chr21:47622727	A/G	cg00815214	chr21:47717953	NA	-0.42	-6.09	-0.35	3.9e-9	Testicular germ cell tumor;
CESC	cis	rs654950	1.000	rs621680	chr1:41984584	C/T	cg06885757	chr1:42089581	HIVEP3	-0.47	-7.24	-0.41	4.9e-12	Airway imaging phenotypes;
CESC	cis	rs8114671	0.562	rs34837802	chr20:33424908	C/G	cg08999081	chr20:33150536	PIGU	0.38	5.49	0.32	9.61e-8	Height;
CESC	cis	rs10876993	0.928	rs813854	chr12:58071347	A/G	cg18357645	chr12:58087776	OS9	0.63	10.45	0.54	1.28e-21	Celiac disease or Rheumatoid arthritis;
CESC	cis	rs7552404	0.691	rs5745449	chr1:76344711	A/T	cg22875332	chr1:76189707	ACADM	-0.58	-6.06	-0.35	4.53e-9	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs1983170	0.736	rs12127718	chr1:91997490	A/T	cg02896835	chr1:92012615	NA	0.57	6.32	0.36	1.13e-9	Eosinophil percentage of white cells;
CESC	trans	rs7615952	0.673	rs9289270	chr3:125636979	A/T	cg07211511	chr3:129823064	LOC729375	-0.87	-7.64	-0.42	3.97e-13	Blood pressure (smoking interaction);
CESC	cis	rs2276314	0.748	rs4799839	chr18:33597531	T/C	cg19628046	chr18:33552617	C18orf21	0.51	5.58	0.32	5.92e-8	Endometriosis;Drug-induced torsades de pointes;
CESC	trans	rs3942852	0.774	rs10838811	chr11:48186795	A/G	cg15704280	chr7:45808275	SEPT13	-0.73	-8.31	-0.45	5.08e-15	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs932287	0.666	rs10840161	chr11:9053824	G/A	cg21881798	chr11:8931708	C11orf17;ST5	0.34	5.61	0.33	5.11e-8	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05349356	chr20:3451609	ATRN	0.56	6.21	0.36	2.03e-9	Gut microbiome composition (summer);
CESC	cis	rs11792861	0.546	rs7873569	chr9:111796753	A/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.37	5.03	0.3	9.03e-7	Menarche (age at onset);
CESC	cis	rs3008870	0.755	rs2815381	chr1:67514591	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.55	6.81	0.39	6.64e-11	Lymphocyte percentage of white cells;
CESC	cis	rs28595532	1.000	rs11938970	chr4:119660152	A/G	cg21605333	chr4:119757512	SEC24D	1.07	6.5	0.37	4.08e-10	Cannabis dependence symptom count;
CESC	cis	rs72792276	1.000	rs17839658	chr5:127423013	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.67	5.42	0.32	1.36e-7	Red cell distribution width;
CESC	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	22.1	0.81	4.4e-62	Prudent dietary pattern;
CESC	trans	rs1223629	1.000	rs1223632	chr10:95905614	T/C	cg21019522	chr11:2920789	SLC22A18;SLC22A18AS	-0.72	-6.02	-0.35	5.71e-9	Glucose homeostasis traits;
CESC	cis	rs36051895	0.659	rs16922576	chr9:5064193	T/C	cg02405213	chr9:5042618	JAK2	-0.48	-5.87	-0.34	1.29e-8	Pediatric autoimmune diseases;
CESC	cis	rs9916302	0.904	rs10432031	chr17:37397852	G/A	cg00129232	chr17:37814104	STARD3	-0.57	-7.49	-0.42	1.02e-12	Glomerular filtration rate (creatinine);
CESC	cis	rs6967414	0.579	rs6968879	chr7:6757886	T/G	cg00387323	chr7:6746715	ZNF12	0.61	5.77	0.33	2.21e-8	Hematocrit;Hemoglobin concentration;
CESC	cis	rs1050631	0.592	rs1789508	chr18:33736845	G/A	cg25426722	chr18:33708991	SLC39A6;ELP2	0.52	7.16	0.4	7.96e-12	Esophageal squamous cell cancer (length of survival);
CESC	cis	rs6831352	0.879	rs36034266	chr4:100061388	T/C	cg13256891	chr4:100009986	ADH5	-0.75	-8.21	-0.45	9.89e-15	Alcohol dependence;
CESC	cis	rs17095355	1.000	rs17126890	chr10:111699169	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.43	-5.23	-0.31	3.37e-7	Biliary atresia;
CESC	cis	rs57083693	0.518	rs1009090	chr12:101703251	C/T	cg22051763	chr12:101673672	UTP20	-0.45	-5.68	-0.33	3.61e-8	Alcohol dependence (age at onset);
CESC	cis	rs8072100	0.934	rs6504872	chr17:45438952	C/T	cg25173405	chr17:45401733	C17orf57	-0.43	-5.71	-0.33	3.07e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs853679	0.517	rs9393893	chr6:28109262	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.55	-6.36	-0.36	8.66e-10	Depression;
CESC	cis	rs17253792	0.822	rs74720318	chr14:56099828	G/T	cg01858014	chr14:56050164	KTN1	-0.85	-6.99	-0.39	2.22e-11	Putamen volume;
CESC	cis	rs7824557	0.628	rs3174048	chr8:11184937	G/A	cg21775007	chr8:11205619	TDH	0.55	8.7	0.47	3.67e-16	Retinal vascular caliber;
CESC	cis	rs7552404	0.889	rs380075	chr1:76106961	T/A	cg10523679	chr1:76189770	ACADM	-0.7	-8.07	-0.44	2.39e-14	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs34172651	0.571	rs9922156	chr16:24704329	C/A	cg00339695	chr16:24857497	SLC5A11	-0.45	-6.0	-0.35	6.55e-9	Intelligence (multi-trait analysis);
CESC	cis	rs61935443	0.666	rs73218073	chr12:95314346	A/G	cg21533806	chr12:95267307	NA	0.5	5.44	0.32	1.24e-7	Schizophrenia;
CESC	cis	rs7208859	0.562	rs216408	chr17:28907757	C/G	cg14008862	chr17:28927542	LRRC37B2	-0.7	-6.51	-0.37	3.65e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs11723261	0.621	rs11721745	chr4:114934	T/G	cg12746427	chr4:53362	ZNF718;ZNF595	0.43	5.16	0.3	4.74e-7	Immune response to smallpox vaccine (IL-6);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23661578	chr6:42981936	MEA1;KLHDC3	0.56	6.48	0.37	4.47e-10	Gut microbiome composition (summer);
CESC	cis	rs9611565	0.918	rs7290404	chr22:41749796	C/T	cg06481639	chr22:41940642	POLR3H	-0.71	-7.63	-0.42	4.11e-13	Vitiligo;
CESC	cis	rs736408	0.570	rs11130327	chr3:52793239	A/G	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.35	6.01	0.35	6.05e-9	Bipolar disorder;
CESC	cis	rs7666738	0.830	rs6532721	chr4:99048015	G/A	cg03676636	chr4:99064102	C4orf37	0.33	5.12	0.3	5.93e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4689388	0.890	rs4688991	chr4:6302220	C/G	cg00701064	chr4:6280414	WFS1	0.73	12.87	0.62	9e-30	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	trans	rs9929218	0.954	rs7199991	chr16:68818245	T/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.65	-8.59	-0.47	7.34e-16	Colorectal cancer;
CESC	cis	rs9527	0.545	rs7915816	chr10:104881750	A/G	cg04362960	chr10:104952993	NT5C2	0.44	5.54	0.32	7.12e-8	Arsenic metabolism;
CESC	cis	rs4555082	0.718	rs28513571	chr14:105709592	C/A	cg27165867	chr14:105738592	BRF1	-0.54	-6.04	-0.35	5.27e-9	Mean platelet volume;Platelet distribution width;
CESC	cis	rs367943	1.000	rs348957	chr5:112821178	C/T	cg12552261	chr5:112820674	MCC	0.64	8.05	0.44	2.83e-14	Type 2 diabetes;
CESC	trans	rs1945213	0.694	rs34390414	chr11:55863367	T/G	cg15704280	chr7:45808275	SEPT13	0.7	6.72	0.38	1.1e-10	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs60843830	1.000	rs17714252	chr2:285471	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.89	12.24	0.6	1.37e-27	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs4704187	0.687	rs9763362	chr5:74406316	T/C	cg03227963	chr5:74354835	NA	0.32	5.94	0.34	8.7e-9	Response to amphetamines;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02011054	chr11:2950754	PHLDA2	0.65	7.46	0.42	1.27e-12	Gut microbiome composition (summer);
CESC	cis	rs13191362	0.938	rs13192618	chr6:163132822	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.89	9.28	0.5	6.15e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs1050631	1.000	rs11081934	chr18:33705304	G/A	cg25426722	chr18:33708991	SLC39A6;ELP2	0.45	5.83	0.34	1.6e-8	Esophageal squamous cell cancer (length of survival);
CESC	cis	rs4474465	1.000	rs7121283	chr11:78149340	T/A	cg27205649	chr11:78285834	NARS2	-0.42	-5.19	-0.3	4.22e-7	Alzheimer's disease (survival time);
CESC	cis	rs875971	0.825	rs28480509	chr7:66099224	A/G	cg18252515	chr7:66147081	NA	0.5	6.62	0.38	1.96e-10	Aortic root size;
CESC	cis	rs7264396	0.790	rs761826	chr20:34194243	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.45	5.48	0.32	9.78e-8	Total cholesterol levels;
CESC	cis	rs4073221	0.520	rs13067391	chr3:18191929	C/T	cg07694806	chr3:18168406	NA	-0.71	-5.59	-0.32	5.74e-8	Parkinson's disease;
CESC	cis	rs9311474	0.607	rs13076398	chr3:52573096	G/A	cg05564831	chr3:52568323	NT5DC2	0.44	7.02	0.4	1.89e-11	Electroencephalogram traits;
CESC	cis	rs965513	1.000	rs925489	chr9:100546600	C/T	cg13688889	chr9:100608707	NA	-0.6	-8.5	-0.46	1.38e-15	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
CESC	cis	rs2239547	0.522	rs2581797	chr3:52972468	C/T	cg11645453	chr3:52864694	ITIH4	-0.32	-5.42	-0.32	1.33e-7	Schizophrenia;
CESC	cis	rs7301826	0.651	rs10848209	chr12:131311272	A/G	cg11011512	chr12:131303247	STX2	0.46	5.56	0.32	6.57e-8	Plasma plasminogen activator levels;
CESC	cis	rs17376456	0.877	rs10514380	chr5:93409370	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.6	5.23	0.31	3.49e-7	Diabetic retinopathy;
CESC	cis	rs9828933	0.752	rs13434089	chr3:63948566	C/T	cg16258503	chr3:63850278	ATXN7;THOC7	0.9	8.04	0.44	2.94e-14	Type 2 diabetes;
CESC	cis	rs1218582	0.774	rs11264284	chr1:154875793	C/T	cg09359103	chr1:154839909	KCNN3	-0.68	-13.05	-0.63	2.11e-30	Prostate cancer;
CESC	cis	rs34779708	0.706	rs36027395	chr10:35550323	T/A	cg04310649	chr10:35416472	CREM	-0.46	-5.21	-0.3	3.75e-7	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs901683	1.000	rs71496608	chr10:46017132	G/A	cg16031567	chr10:46195673	NA	-0.77	-5.04	-0.3	8.57e-7	Red blood cell traits;Mean corpuscular volume;
CESC	cis	rs75804782	0.641	rs57080728	chr2:239350487	T/C	cg18131467	chr2:239335373	ASB1	-0.67	-5.91	-0.34	1.06e-8	Morning vs. evening chronotype;Chronotype;
CESC	cis	rs4566357	0.930	rs6436647	chr2:227922958	G/C	cg11843606	chr2:227700838	RHBDD1	-0.42	-5.28	-0.31	2.76e-7	Coronary artery disease;
CESC	cis	rs7208859	0.623	rs55938328	chr17:29117010	T/C	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.1e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs1879734	0.731	rs7555908	chr1:54158462	A/G	cg23596471	chr1:54105337	GLIS1	0.35	5.67	0.33	3.77e-8	Mitral valve prolapse;
CESC	cis	rs425277	0.527	rs3107144	chr1:2045380	C/A	cg16545954	chr1:2118288	C1orf86	-0.32	-5.98	-0.34	7.26e-9	Height;
CESC	cis	rs12602901	0.519	rs238238	chr17:4856376	A/G	cg24768135	chr17:4805392	CHRNE;C17orf107	0.35	5.42	0.32	1.33e-7	Blood metabolite levels;
CESC	cis	rs7586879	0.639	rs3903070	chr2:25123463	C/G	cg01884057	chr2:25150051	NA	0.36	7.01	0.4	2.02e-11	Body mass index;
CESC	cis	rs7659604	0.582	rs3217780	chr4:122737278	T/C	cg19748678	chr4:122722346	EXOSC9	0.79	9.99	0.52	3.82e-20	Type 2 diabetes;
CESC	cis	rs4727027	0.704	rs13229244	chr7:148898219	A/C	cg23583168	chr7:148888333	NA	0.95	17.1	0.72	1.13e-44	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	trans	rs916888	0.697	rs199516	chr17:44856485	C/T	cg22433210	chr17:43662623	NA	-0.91	-10.79	-0.55	9.74e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs9399137	0.507	rs4520025	chr6:135278619	G/T	cg22676075	chr6:135203613	NA	0.54	7.12	0.4	1.04e-11	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	cis	rs9393777	0.513	rs9368450	chr6:26652489	A/C	cg12826209	chr6:26865740	GUSBL1	0.73	7.83	0.43	1.17e-13	Intelligence (multi-trait analysis);
CESC	cis	rs36051895	0.695	rs7043489	chr9:5023604	A/C	cg02405213	chr9:5042618	JAK2	-0.48	-5.95	-0.34	8.24e-9	Pediatric autoimmune diseases;
CESC	trans	rs10743315	0.557	rs16915323	chr12:19437529	A/G	cg09562322	chr12:119419143	SRRM4	-0.43	-6.36	-0.36	8.83e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs6142102	0.538	rs6142058	chr20:32542801	A/G	cg08999081	chr20:33150536	PIGU	0.34	5.12	0.3	5.81e-7	Skin pigmentation;
CESC	cis	rs16910800	0.731	rs59333536	chr11:23191649	G/A	cg20040320	chr11:23191996	NA	-0.67	-6.66	-0.38	1.53e-10	Cancer;
CESC	cis	rs6460942	0.730	rs73053536	chr7:12323131	C/G	cg06484146	chr7:12443880	VWDE	-0.8	-8.19	-0.45	1.08e-14	Coronary artery disease;
CESC	cis	rs703842	1.000	rs11172333	chr12:58170335	A/G	cg00677455	chr12:58241039	CTDSP2	0.51	6.6	0.38	2.17e-10	Multiple sclerosis;
CESC	cis	rs2404602	0.692	rs12595586	chr15:77172210	A/G	cg22467129	chr15:76604101	ETFA	-0.35	-5.23	-0.31	3.42e-7	Blood metabolite levels;
CESC	cis	rs6831352	0.918	rs34805407	chr4:100050786	C/A	cg12011299	chr4:100065546	ADH4	-0.59	-6.52	-0.37	3.62e-10	Alcohol dependence;
CESC	cis	rs2836974	0.674	rs1011413	chr21:40638241	A/G	cg17971929	chr21:40555470	PSMG1	-0.88	-12.76	-0.62	2.2e-29	Cognitive function;
CESC	cis	rs7772486	0.625	rs9390355	chr6:146112942	C/T	cg23711669	chr6:146136114	FBXO30	-0.91	-13.64	-0.64	1.86e-32	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs922182	0.569	rs72752984	chr15:64264082	G/T	cg24729988	chr15:64271149	DAPK2	0.4	5.32	0.31	2.21e-7	Blood protein levels;
CESC	cis	rs3126085	0.935	rs4845751	chr1:152208997	T/C	cg03465714	chr1:152285911	FLG	-0.43	-5.17	-0.3	4.53e-7	Atopic dermatitis;
CESC	cis	rs4727027	0.901	rs10952792	chr7:148760501	C/T	cg23158103	chr7:148848205	ZNF398	-0.41	-6.56	-0.37	2.74e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs7267979	0.844	rs6107017	chr20:25232300	A/G	cg08601574	chr20:25228251	PYGB	0.42	5.81	0.34	1.82e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs9309473	0.687	rs12465867	chr2:73612102	C/T	cg20560298	chr2:73613845	ALMS1	-0.47	-6.49	-0.37	4.22e-10	Metabolite levels;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg09529537	chr5:78531947	JMY	0.48	6.64	0.38	1.74e-10	Systemic lupus erythematosus;
CESC	cis	rs6912958	0.703	rs9353483	chr6:88097180	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	0.33	5.34	0.31	2.05e-7	Monocyte percentage of white cells;
CESC	cis	rs9733	0.565	rs7524620	chr1:150616699	C/T	cg17724175	chr1:150552817	MCL1	-0.45	-7.33	-0.41	2.71e-12	Tonsillectomy;
CESC	cis	rs3785574	0.962	rs58131426	chr17:61854375	T/C	cg07677032	chr17:61819896	STRADA	0.41	5.22	0.31	3.57e-7	Height;
CESC	cis	rs875971	0.825	rs801202	chr7:66023929	C/T	cg11764359	chr7:65958608	NA	-0.78	-11.22	-0.57	3.73e-24	Aortic root size;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg05208423	chr11:13689596	FAR1	0.5	6.55	0.37	2.91e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs7914558	1.000	rs1926030	chr10:104855656	T/C	cg04362960	chr10:104952993	NT5C2	0.46	5.9	0.34	1.09e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs7077164	1.000	rs1227775	chr10:71580862	C/G	cg20696214	chr10:71583771	COL13A1	-0.46	-6.56	-0.37	2.74e-10	Non-alcoholic fatty liver disease histology (lobular);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg20272604	chr1:231004631	C1orf198	-0.48	-6.01	-0.35	5.99e-9	Ulcerative colitis;
CESC	cis	rs9916302	0.561	rs12453198	chr17:37741879	T/C	cg00129232	chr17:37814104	STARD3	-0.55	-5.22	-0.31	3.64e-7	Glomerular filtration rate (creatinine);
CESC	trans	rs9693444	0.898	rs4732697	chr8:29519861	A/G	cg14684675	chr11:66139712	SLC29A2	-0.4	-6.55	-0.37	3.02e-10	Breast cancer;
CESC	cis	rs35306767	0.903	rs12249828	chr10:894838	C/T	cg10556349	chr10:835070	NA	0.51	5.04	0.3	8.56e-7	Eosinophil percentage of granulocytes;
CESC	cis	rs4242434	0.536	rs1871900	chr8:22481449	A/G	cg03733263	chr8:22462867	KIAA1967	0.63	8.97	0.48	5.6e-17	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CESC	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg05313129	chr8:58192883	C8orf71	-0.48	-5.27	-0.31	2.89e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs1862618	0.715	rs6866779	chr5:56090000	G/A	cg12311346	chr5:56204834	C5orf35	-0.73	-8.56	-0.47	9.08e-16	Initial pursuit acceleration;
CESC	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg09060608	chr5:178986726	RUFY1	-0.53	-8.23	-0.45	8.57e-15	Lung cancer;
CESC	cis	rs4523957	0.820	rs7212249	chr17:2135980	A/T	cg16513277	chr17:2031491	SMG6	-0.64	-9.0	-0.48	4.46e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	trans	rs7656342	0.808	rs10003216	chr4:9766749	A/G	cg03138854	chr1:159895315	TAGLN2	-0.52	-6.29	-0.36	1.28e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs910316	1.000	rs1043674	chr14:75549370	T/C	cg08847533	chr14:75593920	NEK9	1.01	19.32	0.76	1.63e-52	Height;
CESC	cis	rs2290159	0.800	rs5746191	chr3:12658774	G/A	cg23032965	chr3:12705835	RAF1	0.53	5.71	0.33	3.04e-8	Cholesterol, total;
CESC	cis	rs10791097	0.739	rs12279359	chr11:130730544	G/A	cg12179176	chr11:130786555	SNX19	0.56	8.14	0.45	1.57e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06561044	chr16:67969622	PSMB10	0.6	6.92	0.39	3.46e-11	Gut microbiome composition (summer);
CESC	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg21226059	chr5:178986404	RUFY1	0.51	7.96	0.44	5.11e-14	Lung cancer;
CESC	cis	rs3091242	0.781	rs71652378	chr1:25721457	G/C	cg03538708	chr1:25844672	NA	-0.41	-6.03	-0.35	5.49e-9	Erythrocyte sedimentation rate;
CESC	cis	rs12681288	0.823	rs2701905	chr8:1003482	T/C	cg15309053	chr8:964076	NA	0.36	6.22	0.36	1.95e-9	Schizophrenia;
CESC	trans	rs7395662	0.517	rs11039885	chr11:48647107	A/G	cg15704280	chr7:45808275	SEPT13	-0.56	-6.73	-0.38	1.07e-10	HDL cholesterol;
CESC	cis	rs2361718	0.568	rs1042397	chr17:78092063	G/A	cg06718696	chr17:78121285	EIF4A3	0.4	5.07	0.3	7.53e-7	Yeast infection;
CESC	cis	rs28829049	0.861	rs10492996	chr1:19365552	C/T	cg13387374	chr1:19411106	UBR4	0.44	5.71	0.33	2.98e-8	QRS duration in Tripanosoma cruzi seropositivity;
CESC	cis	rs9611565	0.659	rs12484228	chr22:41939739	A/G	cg06481639	chr22:41940642	POLR3H	-0.61	-6.46	-0.37	4.88e-10	Vitiligo;
CESC	cis	rs1707322	0.686	rs61784833	chr1:46233772	T/C	cg05343316	chr1:45956843	TESK2	0.5	6.16	0.35	2.72e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7119	0.717	rs34981488	chr15:77723403	T/G	cg17802220	chr15:77601643	NA	-0.54	-7.5	-0.42	9.44e-13	Type 2 diabetes;
CESC	cis	rs6963495	0.818	rs1721498	chr7:105178819	A/C	cg02135003	chr7:105160482	PUS7	0.44	6.17	0.35	2.6e-9	Bipolar disorder (body mass index interaction);
CESC	cis	rs853679	0.550	rs1233704	chr6:28166923	A/G	cg23161317	chr6:28129485	ZNF389	-0.43	-5.62	-0.33	4.74e-8	Depression;
CESC	cis	rs1475911	1.000	rs34421316	chr21:43513989	C/T	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.43	-6.16	-0.35	2.73e-9	IgG glycosylation;
CESC	cis	rs739401	0.611	rs450817	chr11:3056712	A/G	cg25174290	chr11:3078921	CARS	0.55	7.65	0.43	3.75e-13	Longevity;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg25974723	chr19:50119415	PRR12	-0.44	-6.01	-0.35	6.22e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs4660261	0.545	rs803682	chr1:44362623	G/A	cg23954153	chr1:44402353	ARTN	-0.35	-5.59	-0.32	5.69e-8	Intelligence (multi-trait analysis);
CESC	cis	rs853679	0.517	rs9393895	chr6:28127621	T/C	cg19592336	chr6:28129416	ZNF389	0.61	8.03	0.44	3.13e-14	Depression;
CESC	cis	rs67311347	0.911	rs6775936	chr3:40377399	T/G	cg09455208	chr3:40491958	NA	0.48	8.3	0.45	5.47e-15	Renal cell carcinoma;
CESC	cis	rs1801251	1.000	rs6717841	chr2:233590255	C/T	cg25237894	chr2:233734115	C2orf82	0.48	8.19	0.45	1.08e-14	Coronary artery disease;
CESC	cis	rs6089584	0.889	rs6142923	chr20:60596617	C/T	cg06108461	chr20:60628389	TAF4	0.83	11.48	0.58	4.88e-25	Body mass index;
CESC	cis	rs67311347	1.000	rs2371186	chr3:40488713	G/C	cg24209194	chr3:40518798	ZNF619	0.5	6.26	0.36	1.54e-9	Renal cell carcinoma;
CESC	cis	rs3733585	0.699	rs6449171	chr4:9965998	C/T	cg02734326	chr4:10020555	SLC2A9	0.44	5.99	0.35	6.77e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs9527	0.590	rs11191547	chr10:104843148	C/T	cg04362960	chr10:104952993	NT5C2	0.45	5.66	0.33	3.87e-8	Arsenic metabolism;
CESC	cis	rs597539	0.615	rs583182	chr11:68678634	C/T	cg01988459	chr11:68622903	NA	-0.46	-6.62	-0.38	2.03e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg11905131	chr22:24372483	LOC391322	-0.73	-10.65	-0.55	2.71e-22	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs7666738	0.830	rs35491210	chr4:99003364	T/C	cg17366294	chr4:99064904	C4orf37	0.59	8.43	0.46	2.2e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2032447	0.507	rs199748	chr6:25909045	C/G	cg18357526	chr6:26021779	HIST1H4A	0.47	5.77	0.33	2.18e-8	Intelligence (multi-trait analysis);
CESC	cis	rs10504229	1.000	rs74546828	chr8:58171678	A/G	cg05313129	chr8:58192883	C8orf71	-0.55	-6.37	-0.36	8.42e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs796364	0.806	rs11684942	chr2:201009136	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.75	-6.83	-0.39	5.71e-11	Schizophrenia;
CESC	cis	rs2576037	0.501	rs7245049	chr18:44528213	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.7	10.93	0.56	3.27e-23	Personality dimensions;
CESC	cis	rs1003719	0.715	rs2212742	chr21:38578685	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.59	-8.14	-0.45	1.58e-14	Eye color traits;
CESC	cis	rs7618915	0.547	rs6768697	chr3:52703615	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.66	0.38	1.54e-10	Bipolar disorder;
CESC	trans	rs2823962	0.759	rs8134854	chr21:18016042	C/T	cg01437917	chr17:4688569	NA	-0.44	-6.21	-0.36	2.02e-9	Amyotrophic lateral sclerosis;
CESC	cis	rs593982	1.000	rs593982	chr11:65513107	T/C	cg08755490	chr11:65554678	OVOL1	1.31	19.94	0.77	1.14e-54	Atopic dermatitis;
CESC	cis	rs6951245	0.507	rs10227709	chr7:1180515	T/G	cg04025307	chr7:1156635	C7orf50	0.36	5.06	0.3	8.02e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs12410462	1.000	rs6672162	chr1:227632335	G/A	cg23173402	chr1:227635558	NA	0.59	6.06	0.35	4.66e-9	Major depressive disorder;
CESC	cis	rs1707322	0.721	rs4660314	chr1:46229885	T/C	cg05343316	chr1:45956843	TESK2	0.5	6.13	0.35	3.23e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg14214745	chr3:9975533	CRELD1	0.47	6.64	0.38	1.78e-10	Intelligence (multi-trait analysis);
CESC	cis	rs425277	0.606	rs16824792	chr1:2039521	G/T	cg16545954	chr1:2118288	C1orf86	-0.31	-6.02	-0.35	5.77e-9	Height;
CESC	cis	rs8067545	1.000	rs8071730	chr17:19932731	C/T	cg13482628	chr17:19912719	NA	0.46	6.2	0.36	2.19e-9	Schizophrenia;
CESC	cis	rs763121	0.853	rs138713	chr22:39142615	T/C	cg21395723	chr22:39101663	GTPBP1	0.47	6.26	0.36	1.55e-9	Menopause (age at onset);
CESC	cis	rs3857536	0.813	rs9453639	chr6:66933538	C/T	cg07460842	chr6:66804631	NA	-0.42	-5.36	-0.31	1.8e-7	Blood trace element (Cu levels);
CESC	cis	rs734999	0.545	rs7364820	chr1:2556709	G/A	cg18854424	chr1:2615690	NA	0.31	5.91	0.34	1.08e-8	Ulcerative colitis;
CESC	cis	rs1862618	0.853	rs2432195	chr5:56120413	C/T	cg18230493	chr5:56204884	C5orf35	-0.72	-8.78	-0.47	2.09e-16	Initial pursuit acceleration;
CESC	cis	rs6089584	0.888	rs6142927	chr20:60605848	A/G	cg13770153	chr20:60521292	NA	-0.51	-6.47	-0.37	4.81e-10	Body mass index;
CESC	cis	rs17253792	0.555	rs17683626	chr14:56041112	G/T	cg01858014	chr14:56050164	KTN1	-0.99	-7.46	-0.42	1.21e-12	Putamen volume;
CESC	cis	rs7647973	0.593	rs4855885	chr3:49690199	G/A	cg03060546	chr3:49711283	APEH	0.64	7.19	0.4	6.47e-12	Menarche (age at onset);
CESC	cis	rs7552404	1.000	rs441109	chr1:76120430	T/G	cg22875332	chr1:76189707	ACADM	-0.62	-7.26	-0.41	4.27e-12	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs897080	0.515	rs1067359	chr2:44661997	G/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.45	5.44	0.32	1.2e-7	Height;
CESC	cis	rs1862618	0.853	rs2548665	chr5:56131805	T/A	cg12311346	chr5:56204834	C5orf35	-0.74	-8.81	-0.48	1.63e-16	Initial pursuit acceleration;
CESC	cis	rs3736485	0.934	rs8036904	chr15:51861438	G/A	cg08986416	chr15:51914746	DMXL2	-0.4	-5.12	-0.3	5.86e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs1508086	0.749	rs6987876	chr8:57807943	A/G	cg10342016	chr8:57802622	NA	-0.31	-5.1	-0.3	6.46e-7	Hand grip strength;
CESC	cis	rs863345	0.967	rs863360	chr1:158549264	G/A	cg12129480	chr1:158549410	OR10X1	-0.32	-6.46	-0.37	5.08e-10	Pneumococcal bacteremia;
CESC	cis	rs1790761	0.520	rs1551884	chr11:67399601	C/G	cg24690094	chr11:67383802	NA	-0.37	-6.18	-0.35	2.44e-9	Mean corpuscular volume;
CESC	cis	rs9532580	0.553	rs9549250	chr13:41225229	T/G	cg21288729	chr13:41239152	FOXO1	0.65	8.35	0.46	3.76e-15	Mean corpuscular hemoglobin;
CESC	cis	rs853679	0.517	rs12174753	chr6:28042465	C/G	cg23281280	chr6:28129359	ZNF389	0.57	7.78	0.43	1.61e-13	Depression;
CESC	cis	rs1862618	0.620	rs2591967	chr5:56233551	C/G	cg24531977	chr5:56204891	C5orf35	0.68	9.37	0.5	3.26e-18	Initial pursuit acceleration;
CESC	cis	rs36051895	0.589	rs16922779	chr9:5200127	G/A	cg02405213	chr9:5042618	JAK2	-0.5	-5.96	-0.34	8.08e-9	Pediatric autoimmune diseases;
CESC	cis	rs6952808	0.582	rs871925	chr7:2047875	G/A	cg02951883	chr7:2050386	MAD1L1	0.49	6.4	0.37	7.12e-10	Bipolar disorder and schizophrenia;
CESC	cis	rs67460515	0.500	rs1562464	chr3:160681614	G/A	cg03342759	chr3:160939853	NMD3	-0.47	-5.87	-0.34	1.31e-8	Parkinson's disease;
CESC	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg07677032	chr17:61819896	STRADA	0.44	5.88	0.34	1.22e-8	Prudent dietary pattern;
CESC	cis	rs7666738	0.830	rs28852677	chr4:99039509	T/G	cg18180107	chr4:99064573	C4orf37	0.41	5.29	0.31	2.51e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs25645	0.502	rs7223318	chr17:38108553	G/C	cg17467752	chr17:38218738	THRA	0.41	5.07	0.3	7.47e-7	Myeloid white cell count;
CESC	cis	rs9303280	0.806	rs12232497	chr17:38040119	T/C	cg20243544	chr17:37824526	PNMT	0.53	6.96	0.39	2.6e-11	Self-reported allergy;
CESC	cis	rs12142240	0.920	rs6697623	chr1:46757542	G/A	cg00530320	chr1:46809349	NSUN4	0.55	6.89	0.39	3.99e-11	Menopause (age at onset);
CESC	cis	rs4604732	0.642	rs6426252	chr1:247639887	G/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.38	5.66	0.33	3.84e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs73195822	0.506	rs55948838	chr12:111142793	C/T	cg12870014	chr12:110450643	ANKRD13A	0.64	5.51	0.32	8.64e-8	Itch intensity from mosquito bite;
CESC	cis	rs12134245	0.776	rs12124682	chr1:91995542	A/G	cg25838465	chr1:92012736	NA	-0.61	-8.89	-0.48	9.45e-17	Breast cancer;
CESC	cis	rs1448094	0.845	rs7966131	chr12:86350633	T/G	cg02569458	chr12:86230093	RASSF9	0.39	5.7	0.33	3.18e-8	Major depressive disorder;
CESC	cis	rs9399135	0.967	rs1014020	chr6:135334426	C/A	cg22676075	chr6:135203613	NA	0.51	7.21	0.4	5.91e-12	Red blood cell count;
CESC	cis	rs9660180	0.967	rs6687065	chr1:1778469	A/G	cg03396347	chr1:1875803	NA	-0.44	-6.85	-0.39	5.19e-11	Body mass index;
CESC	cis	rs4654899	0.802	rs10493004	chr1:21442736	T/C	cg05370193	chr1:21551575	ECE1	0.44	6.81	0.39	6.46e-11	Superior frontal gyrus grey matter volume;
CESC	cis	rs9522267	0.535	rs6492373	chr13:112238627	T/C	cg10483660	chr13:112241077	NA	0.32	5.63	0.33	4.64e-8	Hepatitis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00962125	chr14:24616485	PSME2;RNF31	0.57	6.61	0.38	2.05e-10	Gut microbiome composition (summer);
CESC	cis	rs3785574	0.962	rs2584632	chr17:61880641	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.8	10.57	0.54	4.93e-22	Height;
CESC	cis	rs7824557	0.527	rs2572446	chr8:11239565	C/T	cg21775007	chr8:11205619	TDH	-0.52	-7.79	-0.43	1.53e-13	Retinal vascular caliber;
CESC	cis	rs72634258	0.554	rs17374292	chr1:7881234	C/T	cg26816564	chr1:7831052	VAMP3	0.65	6.09	0.35	3.85e-9	Inflammatory bowel disease;
CESC	cis	rs7618915	0.547	rs34017441	chr3:52742413	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.5	7.18	0.4	6.91e-12	Bipolar disorder;
CESC	cis	rs3126085	0.877	rs1552996	chr1:152171104	C/A	cg03465714	chr1:152285911	FLG	-0.46	-5.62	-0.33	4.83e-8	Atopic dermatitis;
CESC	cis	rs2836950	0.545	rs11701805	chr21:40618683	T/C	cg11644478	chr21:40555479	PSMG1	-0.53	-7.04	-0.4	1.69e-11	Menarche (age at onset);
CESC	cis	rs561341	1.000	rs8064843	chr17:30245744	A/G	cg19193384	chr17:30244184	NA	-0.53	-5.98	-0.34	7.27e-9	Hip circumference adjusted for BMI;
CESC	cis	rs853679	0.517	rs9368556	chr6:28131153	T/C	cg12963246	chr6:28129442	ZNF389	0.56	7.38	0.41	1.99e-12	Depression;
CESC	cis	rs3785574	0.962	rs2665799	chr17:61919723	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.58	7.07	0.4	1.37e-11	Height;
CESC	cis	rs651907	0.557	rs13077925	chr3:101488181	T/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.44	5.85	0.34	1.45e-8	Colorectal cancer;
CESC	cis	rs7044106	0.708	rs959558	chr9:123368911	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.69	9.97	0.52	4.5e-20	Hip circumference adjusted for BMI;
CESC	cis	rs13102973	0.965	rs13103954	chr4:135844189	A/G	cg14419869	chr4:135874104	NA	0.33	5.18	0.3	4.35e-7	Subjective well-being;
CESC	cis	rs7605827	0.930	rs10172344	chr2:15521591	A/G	cg19274914	chr2:15703543	NA	0.35	6.26	0.36	1.53e-9	Educational attainment (years of education);
CESC	cis	rs4665809	0.887	rs2384324	chr2:26354239	A/G	cg26314531	chr2:26401878	FAM59B	-0.76	-8.5	-0.46	1.38e-15	Gut microbiome composition (summer);
CESC	cis	rs7727544	0.735	rs272881	chr5:131669264	G/A	cg24060327	chr5:131705240	SLC22A5	-0.67	-8.93	-0.48	7.2e-17	Blood metabolite levels;
CESC	cis	rs2236918	0.710	rs1776130	chr1:242023362	A/G	cg17736920	chr1:242011382	EXO1	0.57	7.13	0.4	9.8e-12	Menopause (age at onset);
CESC	cis	rs6752107	0.967	rs55835501	chr2:234157733	C/T	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.35	5.44	0.32	1.23e-7	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs3020736	0.500	rs6002616	chr22:42504679	A/G	cg12850546	chr22:42539477	CYP2D7P1	0.43	5.16	0.3	4.86e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs6032067	0.777	rs62208386	chr20:43790872	G/A	cg11264863	chr20:43835661	SEMG1	0.5	5.35	0.31	1.86e-7	Blood protein levels;
CESC	cis	rs1448094	0.556	rs61930626	chr12:86167445	A/G	cg02569458	chr12:86230093	RASSF9	0.57	8.34	0.46	4.13e-15	Major depressive disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18780217	chr12:112204756	ALDH2	0.55	6.15	0.35	2.89e-9	Gut microbiome composition (summer);
CESC	cis	rs5750830	0.649	rs2413590	chr22:39790191	G/C	cg01416388	chr22:39784598	NA	-0.62	-7.88	-0.44	8.63e-14	Intelligence (multi-trait analysis);
CESC	cis	rs6879260	1.000	rs6879260	chr5:179731014	A/G	cg13944838	chr5:179740914	GFPT2	-0.67	-8.59	-0.47	7.56e-16	Height;
CESC	cis	rs1005277	0.541	rs1740741	chr10:38515334	C/T	cg25427524	chr10:38739819	LOC399744	-0.73	-10.93	-0.56	3.43e-23	Extrinsic epigenetic age acceleration;
CESC	cis	rs7927771	0.524	rs1563821	chr11:47756568	C/T	cg20307385	chr11:47447363	PSMC3	0.61	8.6	0.47	7.26e-16	Subjective well-being;
CESC	cis	rs769267	1.000	rs3764567	chr19:19440066	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.43	-5.54	-0.32	7.29e-8	Tonsillectomy;
CESC	cis	rs17711722	0.503	rs453835	chr7:65511159	T/A	cg14393609	chr7:65229607	NA	-0.46	-6.13	-0.35	3.17e-9	Calcium levels;
CESC	cis	rs6963495	0.818	rs73192141	chr7:105201129	T/G	cg19920283	chr7:105172520	RINT1	0.7	6.37	0.36	8.43e-10	Bipolar disorder (body mass index interaction);
CESC	cis	rs2637266	0.626	rs2583069	chr10:78546775	T/C	cg18941641	chr10:78392320	NA	0.4	7.52	0.42	8.34e-13	Pulmonary function;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg25107978	chr12:57916571	MBD6	0.49	6.01	0.35	6.06e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs853679	0.769	rs17720293	chr6:28214698	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.75	-6.01	-0.35	6.03e-9	Depression;
CESC	cis	rs514406	0.861	rs12141260	chr1:53300127	C/T	cg25767906	chr1:53392781	SCP2	-0.4	-5.08	-0.3	7.1e-7	Monocyte count;
CESC	cis	rs1801251	1.000	rs283477	chr2:233649427	A/G	cg08000102	chr2:233561755	GIGYF2	0.68	9.35	0.5	3.74e-18	Coronary artery disease;
CESC	cis	rs8050907	0.744	rs8058798	chr16:4531659	C/G	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.89	6.22	0.36	1.94e-9	Obesity-related traits;
CESC	cis	rs8038465	0.615	rs4075802	chr15:73963239	A/G	cg15420318	chr15:73925796	NPTN	0.56	8.54	0.46	1.04e-15	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs9858542	0.953	rs6779524	chr3:49450449	C/T	cg03060546	chr3:49711283	APEH	-0.54	-6.21	-0.36	2.07e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs9311474	0.597	rs6778735	chr3:52565100	T/C	cg18099408	chr3:52552593	STAB1	-0.46	-8.78	-0.47	2e-16	Electroencephalogram traits;
CESC	cis	rs1552244	0.572	rs58862481	chr3:10164308	G/A	cg00149659	chr3:10157352	C3orf10	1.02	12.06	0.6	5.29e-27	Alzheimer's disease;
CESC	cis	rs9300255	0.679	rs10772998	chr12:123721177	T/G	cg19016782	chr12:123741754	C12orf65	-0.48	-6.7	-0.38	1.22e-10	Neutrophil percentage of white cells;
CESC	cis	rs763121	0.626	rs5750643	chr22:39009017	A/G	cg06022373	chr22:39101656	GTPBP1	0.94	16.88	0.72	6.58e-44	Menopause (age at onset);
CESC	cis	rs2625529	0.824	rs4777480	chr15:72328997	A/C	cg16672083	chr15:72433130	SENP8	-0.38	-5.25	-0.31	3.05e-7	Red blood cell count;
CESC	cis	rs847577	0.515	rs10953238	chr7:97676259	C/T	cg24562669	chr7:97807699	LMTK2	0.76	12.76	0.62	2.23e-29	Breast cancer;
CESC	cis	rs9640161	0.673	rs34489187	chr7:150044379	G/A	cg27494647	chr7:150038898	RARRES2	0.44	5.24	0.31	3.36e-7	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs3096299	0.503	rs9940093	chr16:89558705	G/A	cg02187348	chr16:89574699	SPG7	0.62	8.2	0.45	1.04e-14	Multiple myeloma (IgH translocation);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg04631728	chr17:4607671	PELP1	0.45	6.09	0.35	3.9e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs9549260	0.755	rs12585277	chr13:41224813	C/T	cg21288729	chr13:41239152	FOXO1	0.65	8.5	0.46	1.4e-15	Red blood cell count;
CESC	cis	rs763121	0.853	rs5750668	chr22:39079964	T/C	cg06544989	chr22:39130855	UNC84B	0.52	9.06	0.49	2.96e-17	Menopause (age at onset);
CESC	cis	rs3540	0.533	rs7495080	chr15:91056681	G/A	cg10434728	chr15:90938212	IQGAP1	-0.39	-7.23	-0.41	5.28e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs9549367	0.789	rs57747440	chr13:113894750	C/A	cg00898013	chr13:113819073	PROZ	-0.51	-6.94	-0.39	3.06e-11	Platelet distribution width;
CESC	cis	rs12048904	0.619	rs12239082	chr1:101330077	G/T	cg15686842	chr1:101360669	SLC30A7;EXTL2	-0.65	-7.56	-0.42	6.55e-13	Multiple sclerosis;
CESC	cis	rs875971	0.660	rs801217	chr7:66010577	C/T	cg11764359	chr7:65958608	NA	-0.72	-9.68	-0.51	3.48e-19	Aortic root size;
CESC	cis	rs13191362	1.000	rs28360546	chr6:163210973	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.61	5.68	0.33	3.55e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17326317	chr2:69240950	ANTXR1	0.49	6.11	0.35	3.51e-9	Gut microbiome composition (summer);
CESC	cis	rs7116495	1.000	rs7101701	chr11:71762155	A/G	cg26138937	chr11:71823887	C11orf51	-0.81	-6.46	-0.37	4.87e-10	Severe influenza A (H1N1) infection;
CESC	cis	rs9926296	0.605	rs7205053	chr16:89856763	G/C	cg03388025	chr16:89894329	SPIRE2	0.41	7.95	0.44	5.32e-14	Vitiligo;
CESC	cis	rs1949733	1.000	rs2631758	chr4:8495304	G/A	cg11789530	chr4:8429930	ACOX3	-0.78	-11.05	-0.56	1.37e-23	Response to antineoplastic agents;
CESC	cis	rs8092503	1.000	rs2015502	chr18:52489982	A/G	cg12377874	chr18:52495404	RAB27B	-0.35	-6.01	-0.35	6.1e-9	Childhood body mass index;
CESC	trans	rs9467711	0.584	rs34244947	chr6:26761745	T/C	cg06606381	chr12:133084897	FBRSL1	-0.94	-7.65	-0.43	3.72e-13	Autism spectrum disorder or schizophrenia;
CESC	cis	rs3733585	0.781	rs57250714	chr4:9984529	C/T	cg11266682	chr4:10021025	SLC2A9	0.58	10.76	0.55	1.2e-22	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs7727544	0.684	rs270602	chr5:131656700	T/C	cg07395648	chr5:131743802	NA	-0.44	-5.71	-0.33	3.04e-8	Blood metabolite levels;
CESC	cis	rs10782582	0.593	rs17647178	chr1:76210524	A/G	cg10523679	chr1:76189770	ACADM	-0.48	-5.58	-0.32	5.93e-8	Daytime sleep phenotypes;
CESC	cis	rs9287719	0.967	rs7593496	chr2:10738176	A/C	cg00105475	chr2:10696890	NA	0.39	5.61	0.33	4.96e-8	Prostate cancer;
CESC	cis	rs3820928	0.904	rs10188570	chr2:227792540	G/A	cg11843606	chr2:227700838	RHBDD1	-0.47	-5.85	-0.34	1.42e-8	Pulmonary function;
CESC	cis	rs514406	1.000	rs514406	chr1:53330458	A/G	cg08859206	chr1:53392774	SCP2	-0.53	-6.68	-0.38	1.38e-10	Monocyte count;
CESC	cis	rs10504229	1.000	rs66886949	chr8:58187613	A/G	cg14926445	chr8:58193284	C8orf71	-0.51	-5.52	-0.32	8.28e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs2425143	0.598	rs2425118	chr20:34324098	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.63	6.86	0.39	4.77e-11	Blood protein levels;
CESC	cis	rs6964587	0.755	rs13229505	chr7:91444679	G/T	cg17063962	chr7:91808500	NA	0.49	6.29	0.36	1.29e-9	Breast cancer;
CESC	trans	rs17645023	0.689	rs7220428	chr17:64933218	C/G	cg13810570	chr9:35079651	FANCG	0.59	6.03	0.35	5.48e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs1799949	1.000	rs4792981	chr17:41308274	A/G	cg05368731	chr17:41323189	NBR1	0.79	11.14	0.56	6.92e-24	Menopause (age at onset);
CESC	cis	rs35110281	0.774	rs141521	chr21:44963686	G/A	cg04455712	chr21:45112962	RRP1B	0.37	5.46	0.32	1.12e-7	Mean corpuscular volume;
CESC	cis	rs6662572	0.737	rs72677518	chr1:46511118	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.46	5.2	0.3	4.03e-7	Blood protein levels;
CESC	cis	rs4812048	1.000	rs6070697	chr20:57599402	G/A	cg14073986	chr20:57617431	SLMO2	0.64	5.77	0.33	2.18e-8	Mean platelet volume;
CESC	cis	rs4955124	0.558	rs76673738	chr3:32016935	A/G	cg05935571	chr3:32023257	ZNF860;OSBPL10	1.0	8.4	0.46	2.67e-15	Schizophrenia;
CESC	cis	rs7666738	0.830	rs13137859	chr4:99050319	A/G	cg03467027	chr4:99064603	C4orf37	0.47	5.98	0.34	7.19e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2749592	0.531	rs10764134	chr10:37856660	T/C	cg25427524	chr10:38739819	LOC399744	0.54	7.42	0.41	1.56e-12	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs1153858	1.000	rs1980288	chr15:45620612	T/C	cg21132104	chr15:45694354	SPATA5L1	0.83	11.01	0.56	1.8e-23	Homoarginine levels;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03700121	chr11:60610004	CCDC86	0.46	6.45	0.37	5.33e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs7772486	0.686	rs1337839	chr6:146010239	A/G	cg05347473	chr6:146136440	FBXO30	-0.53	-6.79	-0.38	7.46e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4812048	0.689	rs151360	chr20:57613373	T/C	cg14073986	chr20:57617431	SLMO2	0.55	5.4	0.32	1.46e-7	Mean platelet volume;
CESC	cis	rs1775715	0.737	rs2799018	chr10:32202069	C/T	cg26784012	chr10:32216390	ARHGAP12	0.39	5.18	0.3	4.29e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs79387448	0.638	rs7600961	chr2:103035455	G/A	cg09003973	chr2:102972529	NA	0.94	7.74	0.43	2.11e-13	Gut microbiota (bacterial taxa);
CESC	cis	rs1552244	0.882	rs13063929	chr3:10010308	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.76	-9.73	-0.51	2.53e-19	Alzheimer's disease;
CESC	cis	rs7998202	0.667	rs914017	chr13:113355037	G/A	cg02820901	chr13:113351484	ATP11A	0.65	5.78	0.33	2.05e-8	Glycated hemoglobin levels;
CESC	cis	rs2197308	0.740	rs10880619	chr12:37922720	T/C	cg13010199	chr12:38710504	ALG10B	0.53	6.76	0.38	8.79e-11	Morning vs. evening chronotype;
CESC	cis	rs2440129	0.611	rs11571335	chr17:6904263	C/T	cg05657792	chr17:6899758	ALOX12	0.4	6.91	0.39	3.5e-11	Tonsillectomy;
CESC	cis	rs17376456	1.000	rs34068652	chr5:93563319	G/A	cg21475434	chr5:93447410	FAM172A	0.84	7.3	0.41	3.39e-12	Diabetic retinopathy;
CESC	cis	rs7772486	0.875	rs2224120	chr6:146343280	A/C	cg05347473	chr6:146136440	FBXO30	0.52	6.71	0.38	1.19e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs10504229	0.683	rs35840293	chr8:58117634	C/T	cg24829409	chr8:58192753	C8orf71	-0.58	-7.2	-0.4	6.31e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs769267	0.930	rs4808203	chr19:19568659	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.59	7.31	0.41	3.1e-12	Tonsillectomy;
CESC	cis	rs9768139	0.903	rs10262701	chr7:158114591	G/A	cg25566285	chr7:158114605	PTPRN2	-0.59	-10.39	-0.54	1.97e-21	Calcium levels;
CESC	trans	rs2623325	0.874	rs9874386	chr3:99095322	A/C	cg19595760	chr1:25948511	MAN1C1	-0.46	-6.23	-0.36	1.82e-9	Optic cup area;Vertical cup-disc ratio;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07312366	chr2:74710011	TTC31;CCDC142	0.62	7.0	0.4	2.07e-11	Gut microbiome composition (summer);
CESC	cis	rs13191362	0.507	rs2849520	chr6:163132038	T/C	cg14584255	chr6:163149320	PACRG;PARK2	-0.43	-5.29	-0.31	2.58e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs4474465	0.790	rs4945292	chr11:78254424	T/A	cg27205649	chr11:78285834	NARS2	0.43	5.34	0.31	2.05e-7	Alzheimer's disease (survival time);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg06212607	chr1:235491708	GGPS1;ARID4B	0.43	6.15	0.35	2.91e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs2011503	0.882	rs8108777	chr19:19359058	C/A	cg11584989	chr19:19387371	SF4	0.54	6.58	0.37	2.46e-10	Bipolar disorder;
CESC	cis	rs763121	0.962	rs138703	chr22:39132748	C/T	cg06022373	chr22:39101656	GTPBP1	0.72	11.26	0.57	2.69e-24	Menopause (age at onset);
CESC	cis	rs2262909	1.000	rs2175366	chr19:22128279	C/T	cg11619707	chr19:22235551	ZNF257	-0.33	-5.52	-0.32	7.97e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
CESC	cis	rs17376456	0.569	rs11948511	chr5:93286601	A/C	cg25358565	chr5:93447407	FAM172A	-0.47	-5.43	-0.32	1.25e-7	Diabetic retinopathy;
CESC	cis	rs3824867	0.920	rs10742805	chr11:47454701	A/G	cg20307385	chr11:47447363	PSMC3	0.5	6.09	0.35	3.87e-9	Mean corpuscular hemoglobin;
CESC	cis	rs244293	1.000	rs244316	chr17:53215223	G/A	cg19360675	chr17:53046073	COX11;STXBP4	-0.41	-5.25	-0.31	3.19e-7	Menarche (age at onset);
CESC	cis	rs1728785	1.000	rs1728784	chr16:68591156	T/A	cg02972257	chr16:68554789	NA	-0.68	-7.65	-0.43	3.84e-13	Ulcerative colitis;
CESC	cis	rs5747327	0.839	rs2024230	chr22:18132930	C/T	cg19898043	chr22:18121309	BCL2L13	-0.4	-5.11	-0.3	6.13e-7	Myeloid white cell count;Granulocyte count;
CESC	cis	rs9457247	0.935	rs2149093	chr6:167373045	T/C	cg07741184	chr6:167504864	NA	-0.3	-5.38	-0.31	1.66e-7	Crohn's disease;
CESC	cis	rs6088580	0.634	rs6142159	chr20:32993035	G/A	cg24642439	chr20:33292090	TP53INP2	-0.53	-6.97	-0.39	2.55e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs17095355	1.000	rs12570230	chr10:111691614	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.43	-5.06	-0.3	7.86e-7	Biliary atresia;
CESC	cis	rs3806933	0.500	rs10491423	chr5:110453977	C/A	cg04022379	chr5:110408740	TSLP	0.45	7.3	0.41	3.37e-12	Eosinophilic esophagitis;
CESC	cis	rs7762018	1.000	rs1127489	chr6:170107702	C/T	cg05834625	chr6:170176447	C6orf70	0.63	7.58	0.42	5.82e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs672059	1.000	rs660602	chr1:183162774	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.56	7.17	0.4	7.56e-12	Hypertriglyceridemia;
CESC	cis	rs10751667	0.666	rs10902243	chr11:949900	T/C	cg06064525	chr11:970664	AP2A2	-0.48	-9.45	-0.5	1.86e-18	Alzheimer's disease (late onset);
CESC	cis	rs920590	0.876	rs3907478	chr8:19657753	G/T	cg03894339	chr8:19674705	INTS10	0.54	6.42	0.37	6.28e-10	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs5769765	0.773	rs9616391	chr22:50314573	C/T	cg02269571	chr22:50332266	NA	-0.63	-6.82	-0.39	6.18e-11	Schizophrenia;
CESC	cis	rs9300255	0.602	rs941305	chr12:123715266	T/C	cg05973401	chr12:123451056	ABCB9	0.5	5.58	0.32	5.95e-8	Neutrophil percentage of white cells;
CESC	cis	rs2594989	1.000	rs2606761	chr3:11344427	G/A	cg00170343	chr3:11313890	ATG7	0.59	5.25	0.31	3.1e-7	Circulating chemerin levels;
CESC	cis	rs9287719	0.967	rs6432122	chr2:10753844	A/G	cg00105475	chr2:10696890	NA	0.38	5.42	0.32	1.34e-7	Prostate cancer;
CESC	cis	rs3733585	0.624	rs58130873	chr4:9972081	T/C	cg00071950	chr4:10020882	SLC2A9	-0.69	-11.32	-0.57	1.7e-24	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs9457247	0.765	rs6900701	chr6:167434112	A/G	cg07741184	chr6:167504864	NA	0.35	6.27	0.36	1.43e-9	Crohn's disease;
CESC	cis	rs8014204	0.762	rs12889665	chr14:75234830	T/G	cg08847533	chr14:75593920	NEK9	0.42	5.56	0.32	6.62e-8	Caffeine consumption;
CESC	trans	rs61931739	0.857	rs999715	chr12:34143253	G/C	cg26384229	chr12:38710491	ALG10B	0.48	6.64	0.38	1.8e-10	Morning vs. evening chronotype;
CESC	cis	rs3617	0.598	rs56214994	chr3:52878600	G/C	cg07507251	chr3:52567010	NT5DC2	-0.32	-5.5	-0.32	8.9e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
CESC	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg23034840	chr1:205782522	SLC41A1	0.59	6.61	0.38	2.06e-10	Menarche (age at onset);
CESC	cis	rs9322193	0.923	rs10872644	chr6:150062955	T/C	cg13206674	chr6:150067644	NUP43	0.45	6.39	0.37	7.26e-10	Lung cancer;
CESC	cis	rs372883	0.507	rs8132992	chr21:30750561	T/C	cg24692254	chr21:30365293	RNF160	0.47	5.89	0.34	1.14e-8	Pancreatic cancer;
CESC	cis	rs9660992	0.573	rs1172139	chr1:205213962	G/A	cg21643547	chr1:205240462	TMCC2	-0.39	-5.45	-0.32	1.18e-7	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs12142240	0.698	rs72885198	chr1:46812888	C/T	cg00530320	chr1:46809349	NSUN4	0.58	7.85	0.43	1.05e-13	Menopause (age at onset);
CESC	cis	rs3820928	0.804	rs4675125	chr2:227802499	T/C	cg11843606	chr2:227700838	RHBDD1	-0.42	-5.61	-0.33	5.03e-8	Pulmonary function;
CESC	cis	rs7666738	0.830	rs3857217	chr4:99034347	T/C	cg03467027	chr4:99064603	C4orf37	0.48	6.05	0.35	4.87e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6460942	0.915	rs6968695	chr7:12443878	G/C	cg06484146	chr7:12443880	VWDE	-0.73	-8.75	-0.47	2.6e-16	Coronary artery disease;
CESC	cis	rs7833790	1.000	rs7834808	chr8:82704996	A/G	cg27398817	chr8:82754497	SNX16	-0.56	-6.53	-0.37	3.27e-10	Diastolic blood pressure;
CESC	cis	rs8067545	0.750	rs4924804	chr17:19991839	C/T	cg13482628	chr17:19912719	NA	0.4	5.46	0.32	1.11e-7	Schizophrenia;
CESC	cis	rs9611565	0.659	rs17367716	chr22:41913844	A/G	cg17376030	chr22:41985996	PMM1	0.77	8.31	0.45	4.94e-15	Vitiligo;
CESC	cis	rs7512552	0.839	rs2867894	chr1:150452912	T/A	cg15654264	chr1:150340011	RPRD2	0.39	5.2	0.3	3.98e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs10883723	0.810	rs7917525	chr10:104246755	C/G	cg22532475	chr10:104410764	TRIM8	-0.33	-5.68	-0.33	3.59e-8	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs7659604	0.539	rs11098645	chr4:122729251	G/A	cg19748678	chr4:122722346	EXOSC9	0.77	9.62	0.51	5.51e-19	Type 2 diabetes;
CESC	cis	rs1915146	0.546	rs1715862	chr10:126856255	C/T	cg23000734	chr10:126850823	CTBP2	-0.53	-8.14	-0.45	1.59e-14	Menarche (age at onset);
CESC	cis	rs9814567	1.000	rs6439487	chr3:134260860	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.45	-6.15	-0.35	2.87e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs2836974	0.897	rs3945	chr21:40566067	A/G	cg17971929	chr21:40555470	PSMG1	1.0	13.76	0.65	7.15e-33	Cognitive function;
CESC	cis	rs13385	0.769	rs4913073	chr5:139612854	A/G	cg26211634	chr5:139558579	C5orf32	0.48	5.24	0.31	3.28e-7	Atrial fibrillation;
CESC	cis	rs9948	0.521	rs61750875	chr2:97359364	A/G	cg01990225	chr2:97406019	LMAN2L	-0.74	-6.99	-0.39	2.19e-11	Erectile dysfunction and prostate cancer treatment;
CESC	cis	rs59918340	0.764	rs753779	chr8:142228809	T/C	cg16341495	chr8:142228727	SLC45A4	-0.44	-5.25	-0.31	3.17e-7	Immature fraction of reticulocytes;
CESC	cis	rs2404602	0.692	rs8037005	chr15:76951109	C/T	cg22467129	chr15:76604101	ETFA	-0.35	-5.22	-0.31	3.63e-7	Blood metabolite levels;
CESC	cis	rs901683	1.000	rs12779198	chr10:46013547	G/A	cg16031567	chr10:46195673	NA	-0.77	-5.04	-0.3	8.57e-7	Red blood cell traits;Mean corpuscular volume;
CESC	cis	rs9303401	0.580	rs12603808	chr17:56578508	T/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.96	10.8	0.55	9.33e-23	Cognitive test performance;
CESC	cis	rs3741151	1.000	rs61037777	chr11:73046663	A/G	cg17517138	chr11:73019481	ARHGEF17	0.61	5.04	0.3	8.58e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs5758659	0.714	rs5758578	chr22:42490292	A/C	cg15557168	chr22:42548783	NA	0.44	6.79	0.38	7.38e-11	Cognitive function;
CESC	cis	rs13191362	1.000	rs35818596	chr6:163001874	C/G	cg21926612	chr6:163149169	PACRG;PARK2	0.88	9.16	0.49	1.46e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg04025307	chr7:1156635	C7orf50	0.44	7.13	0.4	9.6e-12	Longevity;Endometriosis;
CESC	cis	rs7586879	0.593	rs11689543	chr2:25130440	A/T	cg01884057	chr2:25150051	NA	0.37	7.08	0.4	1.26e-11	Body mass index;
CESC	cis	rs4819052	0.851	rs2838850	chr21:46671445	G/C	cg11663144	chr21:46675770	NA	-0.63	-9.96	-0.52	4.67e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs10781543	0.839	rs6560632	chr9:139371786	A/C	cg14169450	chr9:139327907	INPP5E	0.52	8.08	0.44	2.24e-14	Monocyte percentage of white cells;
CESC	cis	rs1862618	0.641	rs2591954	chr5:56245044	G/C	cg12311346	chr5:56204834	C5orf35	0.64	8.49	0.46	1.47e-15	Initial pursuit acceleration;
CESC	cis	rs11718455	0.960	rs1852037	chr3:44003720	G/T	cg08738300	chr3:44038990	NA	-0.44	-5.84	-0.34	1.52e-8	Coronary artery disease;
CESC	cis	rs10504229	1.000	rs1390411	chr8:58194146	C/A	cg05313129	chr8:58192883	C8orf71	-0.52	-6.03	-0.35	5.41e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs9486719	1.000	rs11756315	chr6:97008678	A/G	cg06623918	chr6:96969491	KIAA0776	0.78	8.3	0.45	5.3e-15	Migraine;Coronary artery disease;
CESC	cis	rs4474465	0.646	rs7927503	chr11:78280606	G/T	cg01578073	chr11:78285783	NARS2	-0.44	-5.1	-0.3	6.33e-7	Alzheimer's disease (survival time);
CESC	cis	rs4629180	0.959	rs11896771	chr2:102098328	T/C	cg01388757	chr2:102091195	RFX8	-0.4	-6.22	-0.36	1.98e-9	Chronic rhinosinusitis with nasal polyps;
CESC	cis	rs3743266	0.507	rs62003261	chr15:60761489	T/C	cg22293140	chr15:60689852	ANXA2	-0.7	-7.37	-0.41	2.12e-12	Menarche (age at onset);
CESC	cis	rs763121	0.853	rs5750621	chr22:38956166	C/T	cg06022373	chr22:39101656	GTPBP1	0.83	11.89	0.59	2.05e-26	Menopause (age at onset);
CESC	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg22535103	chr8:58192502	C8orf71	-0.92	-10.16	-0.53	1.04e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs2710642	0.611	rs1527959	chr2:62867413	T/C	cg17519650	chr2:63277830	OTX1	0.47	5.54	0.32	7.36e-8	LDL cholesterol levels;LDL cholesterol;
CESC	cis	rs4722166	0.598	rs35658589	chr7:22800435	C/A	cg05472934	chr7:22766657	IL6	0.4	5.53	0.32	7.51e-8	Lung cancer;
CESC	cis	rs57786342	0.569	rs10139199	chr14:69277800	G/T	cg03189333	chr14:69283534	NA	-0.43	-5.11	-0.3	6.22e-7	Macrophage inflammatory protein 1a levels;
CESC	cis	rs1847202	0.859	rs13090900	chr3:72946560	C/A	cg10804678	chr3:72788309	NA	-0.41	-5.42	-0.32	1.31e-7	Motion sickness;
CESC	cis	rs11650494	0.908	rs111834333	chr17:47411814	C/T	cg08112188	chr17:47440006	ZNF652	0.99	7.0	0.39	2.13e-11	Prostate cancer;
CESC	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg15147215	chr3:52552868	STAB1	-0.38	-6.86	-0.39	4.86e-11	Electroencephalogram traits;
CESC	cis	rs3740713	1.000	rs114330751	chr11:18462475	A/G	cg23797887	chr11:18477753	LDHAL6A	-0.52	-5.05	-0.3	8.21e-7	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs12497850	0.931	rs7431710	chr3:48935583	G/A	cg03060546	chr3:49711283	APEH	0.44	5.57	0.32	6.1e-8	Parkinson's disease;
CESC	cis	rs1669338	0.588	rs3864050	chr3:3186769	T/C	cg16797762	chr3:3221439	CRBN	-0.61	-6.42	-0.37	6.21e-10	White matter integrity;
CESC	cis	rs2370759	0.891	rs11592754	chr10:32619572	A/C	cg18270830	chr10:32634957	EPC1	0.65	5.44	0.32	1.19e-7	Sexual dysfunction (female);
CESC	cis	rs3106136	0.967	rs2306802	chr4:95186055	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.37	-5.31	-0.31	2.32e-7	Capecitabine sensitivity;
CESC	cis	rs7927592	0.763	rs2513277	chr11:68360887	T/G	cg01657329	chr11:68192670	LRP5	-0.47	-6.12	-0.35	3.27e-9	Total body bone mineral density;
CESC	cis	rs74781061	0.722	rs4073149	chr15:74898419	A/G	cg17294928	chr15:75287854	SCAMP5	0.52	5.18	0.3	4.39e-7	Endometriosis;
CESC	cis	rs748404	0.660	rs509306	chr15:43715171	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	8.13	0.45	1.66e-14	Lung cancer;
CESC	cis	rs6545883	0.899	rs12473030	chr2:61720497	T/A	cg15711740	chr2:61764176	XPO1	-0.43	-5.39	-0.31	1.54e-7	Tuberculosis;
CESC	cis	rs798554	0.724	rs798498	chr7:2795882	T/G	cg19346786	chr7:2764209	NA	-0.47	-6.84	-0.39	5.5e-11	Height;
CESC	cis	rs561341	0.714	rs474455	chr17:30312465	A/T	cg19193384	chr17:30244184	NA	-0.6	-6.4	-0.37	7.11e-10	Hip circumference adjusted for BMI;
CESC	cis	rs2797160	1.000	rs984040	chr6:126021277	A/G	cg05901451	chr6:126070800	HEY2	0.43	6.29	0.36	1.3e-9	Endometrial cancer;
CESC	cis	rs1808579	0.935	rs6507720	chr18:21119291	A/G	cg14672496	chr18:21087552	C18orf8	0.44	6.7	0.38	1.24e-10	Hip circumference;Body mass index;BMI (adjusted for smoking behaviour);
CESC	cis	rs4141404	0.673	rs1968023	chr22:31942770	A/G	cg00478049	chr22:31556069	RNF185	0.5	5.53	0.32	7.86e-8	Paclitaxel-induced neuropathy;
CESC	cis	rs9287719	0.967	rs10929686	chr2:10743705	A/C	cg02196655	chr2:10830764	NOL10	-0.36	-5.61	-0.33	5.2100000000000003e-08	Prostate cancer;
CESC	cis	rs12912251	0.591	rs3102118	chr15:39003475	A/C	cg10631289	chr15:39006617	NA	-0.49	-5.46	-0.32	1.11e-7	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
CESC	cis	rs832540	0.864	rs252908	chr5:56120686	T/C	cg14703610	chr5:56206110	C5orf35	0.5	6.64	0.38	1.79e-10	Coronary artery disease;
CESC	cis	rs2479724	0.901	rs2185798	chr6:41773576	G/C	cg08135965	chr6:41755394	TOMM6	-0.42	-5.63	-0.33	4.64e-8	Menarche (age at onset);
CESC	cis	rs6835098	0.962	rs6851632	chr4:174109611	A/G	cg08422745	chr4:174089978	GALNT7	-0.72	-9.42	-0.5	2.4e-18	Dementia and core Alzheimer's disease neuropathologic changes;
CESC	cis	rs2836974	0.966	rs7283420	chr21:40666865	T/C	cg11644478	chr21:40555479	PSMG1	0.96	13.79	0.65	5.62e-33	Cognitive function;
CESC	cis	rs72781680	0.846	rs72780108	chr2:23986780	G/A	cg08917208	chr2:24149416	ATAD2B	0.95	8.71	0.47	3.45e-16	Lymphocyte counts;
CESC	cis	rs9457247	0.935	rs2757050	chr6:167377165	G/T	cg07741184	chr6:167504864	NA	-0.3	-5.38	-0.31	1.62e-7	Crohn's disease;
CESC	cis	rs59918340	0.764	rs4961339	chr8:142231504	A/G	cg16341495	chr8:142228727	SLC45A4	-0.44	-5.39	-0.31	1.55e-7	Immature fraction of reticulocytes;
CESC	cis	rs72945132	0.882	rs7950916	chr11:70210001	T/C	cg00319359	chr11:70116639	PPFIA1	0.73	6.96	0.39	2.63e-11	Coronary artery disease;
CESC	cis	rs10129255	0.536	rs10139058	chr14:107141916	C/T	cg23076370	chr14:107095027	NA	-0.53	-7.54	-0.42	7.43e-13	Kawasaki disease;
CESC	cis	rs853679	0.517	rs55747925	chr6:28044337	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.53	-6.09	-0.35	3.91e-9	Depression;
CESC	cis	rs8067545	0.516	rs4925086	chr17:20013459	A/T	cg13482628	chr17:19912719	NA	0.41	5.43	0.32	1.3e-7	Schizophrenia;
CESC	cis	rs731174	0.921	rs6686264	chr1:38192337	A/T	cg06917450	chr1:38156652	C1orf109	-0.4	-5.29	-0.31	2.56e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs561341	0.769	rs9899093	chr17:30191954	C/G	cg19193384	chr17:30244184	NA	-0.53	-5.24	-0.31	3.23e-7	Hip circumference adjusted for BMI;
CESC	cis	rs10256972	0.616	rs7806746	chr7:1075573	A/C	cg23978390	chr7:1156363	C7orf50	0.44	5.54	0.32	7.44e-8	Longevity;Endometriosis;
CESC	cis	rs11696501	0.694	rs6073823	chr20:44256910	G/C	cg11783356	chr20:44313418	WFDC10B	-0.35	-5.4	-0.31	1.49e-7	Brain structure;
CESC	cis	rs9611565	0.512	rs132784	chr22:42052363	G/A	cg03806693	chr22:41940476	POLR3H	1.04	12.04	0.59	6.41e-27	Vitiligo;
CESC	cis	rs1832871	0.711	rs9459877	chr6:158692331	G/A	cg07165851	chr6:158734300	TULP4	0.58	6.08	0.35	4.11e-9	Height;
CESC	cis	rs514406	0.792	rs481440	chr1:53344976	C/T	cg24675658	chr1:53192096	ZYG11B	-0.6	-8.14	-0.45	1.52e-14	Monocyte count;
CESC	cis	rs4822044	0.680	rs8138780	chr22:42097462	A/T	cg03806693	chr22:41940476	POLR3H	1.13	13.07	0.63	1.86e-30	Cannabis dependence symptom count;
CESC	cis	rs4700695	0.719	rs153390	chr5:65431087	G/C	cg21114390	chr5:65439923	SFRS12	-0.48	-5.82	-0.34	1.69e-8	Facial morphology (factor 19);
CESC	cis	rs7666738	0.830	rs35822567	chr4:98654138	G/A	cg17366294	chr4:99064904	C4orf37	0.56	7.61	0.42	4.87e-13	Colonoscopy-negative controls vs population controls;
CESC	cis	rs870825	0.616	rs7700216	chr4:185648510	G/T	cg04058563	chr4:185651563	MLF1IP	0.63	6.96	0.39	2.59e-11	Blood protein levels;
CESC	cis	rs8053891	0.585	rs12926804	chr16:71994932	A/G	cg04254540	chr16:71951199	KIAA0174	-0.88	-8.04	-0.44	2.94e-14	Coronary artery disease;
CESC	trans	rs916888	0.610	rs199529	chr17:44837217	A/C	cg10053473	chr17:62856997	LRRC37A3	-0.62	-7.71	-0.43	2.49e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs7412746	0.611	rs10888394	chr1:150749913	C/T	cg22823121	chr1:150693482	HORMAD1	0.47	6.57	0.37	2.6e-10	Melanoma;
CESC	cis	rs9549367	0.577	rs3024711	chr13:113813268	A/G	cg10067723	chr13:113807384	NA	-0.43	-5.23	-0.31	3.41e-7	Platelet distribution width;
CESC	cis	rs9811920	0.609	rs9817005	chr3:99682692	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.59	-7.14	-0.4	8.97e-12	Axial length;
CESC	cis	rs6674176	0.628	rs3791116	chr1:44414156	T/A	cg13606994	chr1:44402422	ARTN	-0.37	-5.51	-0.32	8.35e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs9682041	0.696	rs9872796	chr3:170099393	T/G	cg11886554	chr3:170076028	SKIL	1.05	8.52	0.46	1.25e-15	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CESC	cis	rs1008375	0.966	rs2159582	chr4:17695655	T/C	cg02297831	chr4:17616191	MED28	0.45	5.47	0.32	1.04e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs561341	1.000	rs117979353	chr17:30272866	A/G	cg00745463	chr17:30367425	LRRC37B	-0.86	-7.76	-0.43	1.85e-13	Hip circumference adjusted for BMI;
CESC	cis	rs7116495	0.867	rs612255	chr11:71778664	A/G	cg26138937	chr11:71823887	C11orf51	-1.35	-8.41	-0.46	2.63e-15	Severe influenza A (H1N1) infection;
CESC	trans	rs116095464	0.558	rs59113266	chr5:279965	T/C	cg00938859	chr5:1591904	SDHAP3	0.65	7.03	0.4	1.73e-11	Breast cancer;
CESC	cis	rs36051895	0.587	rs11999802	chr9:5189773	T/G	cg02405213	chr9:5042618	JAK2	-0.48	-5.55	-0.32	6.94e-8	Pediatric autoimmune diseases;
CESC	cis	rs3617	0.625	rs2071042	chr3:52864584	A/G	cg07507251	chr3:52567010	NT5DC2	0.32	5.46	0.32	1.1e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
CESC	cis	rs2832191	0.791	rs7282843	chr21:30475226	A/G	cg08807101	chr21:30365312	RNF160	0.76	11.01	0.56	1.88e-23	Dental caries;
CESC	cis	rs6089584	0.924	rs6142906	chr20:60552554	G/C	cg06108461	chr20:60628389	TAF4	-0.81	-11.84	-0.59	3.09e-26	Body mass index;
CESC	cis	rs9796	0.621	rs1659228	chr15:41471978	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.44	-6.44	-0.37	5.52e-10	Menopause (age at onset);
CESC	cis	rs4975709	0.569	rs1684965	chr5:1865248	A/G	cg17650747	chr5:1873721	NA	0.46	6.37	0.36	8.11e-10	Cardiovascular disease risk factors;
CESC	cis	rs2836974	0.644	rs2836981	chr21:40688365	C/T	cg11890956	chr21:40555474	PSMG1	-0.91	-14.42	-0.66	3.48e-35	Cognitive function;
CESC	cis	rs12291225	0.585	rs34171876	chr11:14353957	G/C	cg19336497	chr11:14380999	RRAS2	-0.44	-6.61	-0.38	2.13e-10	Sense of smell;
CESC	cis	rs926938	0.527	rs58658580	chr1:115539726	A/G	cg12756093	chr1:115239321	AMPD1	0.46	6.32	0.36	1.12e-9	Autism;
CESC	cis	rs7552404	0.924	rs1146580	chr1:76209935	T/C	cg03433033	chr1:76189801	ACADM	0.73	10.22	0.53	6.96e-21	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs4819052	0.765	rs2838827	chr21:46656146	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.74	9.43	0.5	2.17e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs7246865	0.859	rs11086052	chr19:17169081	G/A	cg19418318	chr19:17219073	MYO9B	0.33	5.43	0.32	1.26e-7	Reticulocyte fraction of red cells;
CESC	cis	rs2073300	0.609	rs6132605	chr20:23354839	A/C	cg12062639	chr20:23401060	NAPB	1.03	7.98	0.44	4.32e-14	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05849319	chr11:65172370	FRMD8	-0.55	-6.27	-0.36	1.45e-9	Gut microbiome composition (summer);
CESC	cis	rs7917772	0.582	rs4285804	chr10:104386309	T/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.37	-5.05	-0.3	8.25e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg13883366	chr10:29747149	SVIL	0.41	6.15	0.35	2.88e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs4665809	0.556	rs4665314	chr2:26415912	T/C	cg22920501	chr2:26401640	FAM59B	-0.86	-10.09	-0.53	1.75e-20	Gut microbiome composition (summer);
CESC	cis	rs1267303	0.642	rs61783087	chr1:46999955	T/C	cg25110126	chr1:46999211	NA	1.07	12.0	0.59	8.98e-27	Monobrow;
CESC	cis	rs6089584	0.606	rs6089599	chr20:60576992	A/G	cg06108461	chr20:60628389	TAF4	0.56	7.52	0.42	8.71e-13	Body mass index;
CESC	cis	rs9322193	0.884	rs2342858	chr6:150127103	C/T	cg04369109	chr6:150039330	LATS1	-0.41	-5.54	-0.32	7.16e-8	Lung cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09234025	chr7:6145309	USP42	0.57	6.54	0.37	3.19e-10	Gut microbiome composition (summer);
CESC	cis	rs35110281	0.805	rs2838330	chr21:45023876	T/A	cg04455712	chr21:45112962	RRP1B	0.4	5.97	0.34	7.72e-9	Mean corpuscular volume;
CESC	cis	rs7267979	1.000	rs6107045	chr20:25441936	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.83	16.25	0.71	1.14e-41	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs72792276	1.000	rs72794386	chr5:127479278	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.65	5.03	0.3	8.92e-7	Red cell distribution width;
CESC	cis	rs362296	0.671	rs1006798	chr4:3258373	A/G	cg08886695	chr4:3369023	RGS12	0.4	5.41	0.32	1.41e-7	Parental longevity (mother's age at death);
CESC	cis	rs4950322	0.857	rs72694703	chr1:146830138	C/A	cg22381352	chr1:146742008	CHD1L	-0.44	-5.08	-0.3	7.24e-7	Protein quantitative trait loci;
CESC	cis	rs8180040	0.603	rs9854790	chr3:47101306	T/G	cg27129171	chr3:47204927	SETD2	0.67	9.83	0.52	1.18e-19	Colorectal cancer;
CESC	cis	rs75804782	0.641	rs3769125	chr2:239349562	A/G	cg18131467	chr2:239335373	ASB1	-0.66	-5.83	-0.34	1.58e-8	Morning vs. evening chronotype;Chronotype;
CESC	cis	rs2594989	0.895	rs439738	chr3:11322577	G/C	cg00170343	chr3:11313890	ATG7	0.58	5.13	0.3	5.53e-7	Circulating chemerin levels;
CESC	cis	rs8068544	0.818	rs78333491	chr17:40163138	A/G	cg18442075	chr17:40169520	DNAJC7;NKIRAS2	-0.94	-8.43	-0.46	2.27e-15	Reticulocyte fraction of red cells;Reticulocyte count;
CESC	cis	rs6665290	0.901	rs68087483	chr1:227202668	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.19	-29.95	-0.88	4.9e-87	Myeloid white cell count;
CESC	cis	rs863345	0.604	rs12133794	chr1:158506697	C/G	cg12129480	chr1:158549410	OR10X1	-0.34	-6.78	-0.38	7.87e-11	Pneumococcal bacteremia;
CESC	cis	rs6458375	1.000	rs6458375	chr6:44202352	C/T	cg02172915	chr6:44211962	NA	0.46	5.23	0.31	3.38e-7	Interleukin-10 levels;
CESC	cis	rs2303745	0.544	rs12710308	chr19:17395879	T/A	cg02221750	chr19:17393354	ANKLE1	-0.51	-6.2	-0.36	2.19e-9	Systemic lupus erythematosus;
CESC	cis	rs10504229	0.906	rs66480865	chr8:58187100	C/T	cg24829409	chr8:58192753	C8orf71	-0.76	-9.93	-0.52	5.87e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs7618915	0.547	rs11130314	chr3:52697082	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.5	7.23	0.41	5.08e-12	Bipolar disorder;
CESC	cis	rs9611565	0.504	rs5758452	chr22:42144927	G/A	cg06481639	chr22:41940642	POLR3H	0.5	5.82	0.34	1.71e-8	Vitiligo;
CESC	trans	rs7395662	0.500	rs7951327	chr11:48925359	C/T	cg15704280	chr7:45808275	SEPT13	-0.55	-6.69	-0.38	1.32e-10	HDL cholesterol;
CESC	cis	rs9682041	0.696	rs13101192	chr3:170080752	C/G	cg11886554	chr3:170076028	SKIL	0.66	6.21	0.36	1.99e-9	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CESC	cis	rs2933343	0.729	rs6767104	chr3:128648117	G/T	cg25356066	chr3:128598488	ACAD9	-0.64	-8.8	-0.48	1.78e-16	IgG glycosylation;
CESC	cis	rs938554	0.513	rs11943372	chr4:9999346	T/A	cg11266682	chr4:10021025	SLC2A9	0.45	6.83	0.39	5.72e-11	Blood metabolite levels;
CESC	cis	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg07518170	chr20:30865285	KIF3B	-0.43	-5.49	-0.32	9.45e-8	Ulcerative colitis;
CESC	cis	rs8027181	0.682	rs11637168	chr15:73100694	C/A	cg25632853	chr15:73088954	NA	0.31	5.69	0.33	3.44e-8	Triglyceride levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16677885	chr7:150778122	FASTK	-0.54	-6.21	-0.36	1.99e-9	Gut microbiome composition (summer);
CESC	cis	rs7727544	0.735	rs270605	chr5:131651811	C/T	cg07395648	chr5:131743802	NA	-0.48	-6.58	-0.37	2.52e-10	Blood metabolite levels;
CESC	trans	rs9364687	0.966	rs4709713	chr6:163800837	G/A	cg08378220	chr11:102678779	NA	-0.4	-6.27	-0.36	1.46e-9	Body mass index;
CESC	trans	rs877282	0.891	rs11599917	chr10:762288	G/A	cg22713356	chr15:30763199	NA	1.16	11.42	0.57	7.89e-25	Uric acid levels;
CESC	cis	rs728616	0.867	rs723193	chr10:81708155	G/T	cg05935833	chr10:81318306	SFTPA2	-0.51	-5.04	-0.3	8.51e-7	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs4332037	0.707	rs62435132	chr7:1891315	C/T	cg23422044	chr7:1970798	MAD1L1	-0.5	-5.41	-0.32	1.43e-7	Bipolar disorder;
CESC	cis	rs559928	0.606	rs11600628	chr11:63976027	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.64	5.74	0.33	2.56e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CESC	cis	rs4835473	0.897	rs7678190	chr4:144643574	G/A	cg25736465	chr4:144833511	NA	0.39	6.01	0.35	6.07e-9	Immature fraction of reticulocytes;
CESC	cis	rs9611565	0.607	rs132792	chr22:42062822	C/T	cg03806693	chr22:41940476	POLR3H	0.73	8.84	0.48	1.38e-16	Vitiligo;
CESC	cis	rs9300255	0.679	rs10772998	chr12:123721177	T/G	cg05973401	chr12:123451056	ABCB9	0.5	5.61	0.33	5.11e-8	Neutrophil percentage of white cells;
CESC	cis	rs2273669	0.667	rs9688896	chr6:109364698	T/C	cg05315195	chr6:109294784	ARMC2	-0.67	-6.32	-0.36	1.13e-9	Prostate cancer;
CESC	cis	rs2011503	1.000	rs77254326	chr19:19626781	T/G	cg11584989	chr19:19387371	SF4	0.61	7.08	0.4	1.25e-11	Bipolar disorder;
CESC	cis	rs3892630	0.500	rs6510301	chr19:33359791	A/T	cg22980127	chr19:33182716	NUDT19	0.79	8.86	0.48	1.15e-16	Red blood cell traits;
CESC	cis	rs875971	0.862	rs10263690	chr7:65766453	G/C	cg10691866	chr7:65817282	TPST1	0.33	5.55	0.32	6.96e-8	Aortic root size;
CESC	cis	rs559928	0.692	rs876064	chr11:64037033	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.61	5.08	0.3	7.07e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CESC	cis	rs7809950	1.000	rs2808	chr7:107260856	A/G	cg23024343	chr7:107201750	COG5	0.43	5.91	0.34	1.02e-8	Coronary artery disease;
CESC	trans	rs61931739	0.500	rs7133447	chr12:34041901	A/G	cg26384229	chr12:38710491	ALG10B	0.5	6.75	0.38	9.3e-11	Morning vs. evening chronotype;
CESC	cis	rs796364	0.906	rs281766	chr2:200820505	T/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.85	8.43	0.46	2.18e-15	Schizophrenia;
CESC	cis	rs6570726	0.846	rs6570698	chr6:145918635	C/G	cg05347473	chr6:146136440	FBXO30	0.47	6.22	0.36	1.97e-9	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6460942	0.591	rs62448729	chr7:12333720	G/C	cg06484146	chr7:12443880	VWDE	-0.66	-7.27	-0.41	4.01e-12	Coronary artery disease;
CESC	cis	rs5750830	0.649	rs4821895	chr22:39823015	A/G	cg11247378	chr22:39784982	NA	-0.64	-9.5	-0.5	1.28e-18	Intelligence (multi-trait analysis);
CESC	cis	rs6460942	0.778	rs74993124	chr7:12462917	A/G	cg02935154	chr7:12443704	VWDE	-0.57	-7.08	-0.4	1.29e-11	Coronary artery disease;
CESC	cis	rs6496667	0.533	rs886491	chr15:90993215	G/A	cg22089800	chr15:90895588	ZNF774	0.45	5.81	0.34	1.75e-8	Rheumatoid arthritis;
CESC	cis	rs736801	0.808	rs2706403	chr5:131799012	A/G	cg21138405	chr5:131827807	IRF1	0.38	5.62	0.33	4.76e-8	Breast cancer;Mosquito bite size;
CESC	cis	rs13191362	0.507	rs2510207	chr6:163086592	T/C	cg06582575	chr6:163149167	PACRG;PARK2	-0.65	-7.55	-0.42	6.82e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs3806843	0.931	rs13168670	chr5:140146899	T/C	cg16179182	chr5:140090404	VTRNA1-1	-0.41	-5.38	-0.31	1.65e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs6685188	0.920	rs6593964	chr1:205662337	G/T	cg14893161	chr1:205819251	PM20D1	0.45	6.14	0.35	3.06e-9	White blood cell count (basophil);Basophil percentage of white cells;
CESC	cis	rs4665809	0.887	rs6546716	chr2:26263836	A/G	cg08470875	chr2:26401718	FAM59B	-0.48	-5.2	-0.3	3.97e-7	Gut microbiome composition (summer);
CESC	cis	rs4629180	0.675	rs10184144	chr2:102104978	C/T	cg04415270	chr2:102091202	RFX8	-0.3	-5.35	-0.31	1.86e-7	Chronic rhinosinusitis with nasal polyps;
CESC	cis	rs3026101	0.671	rs2871210	chr17:5305027	G/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.43	5.59	0.32	5.53e-8	Body mass index;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg03956680	chr2:64067521	UGP2	0.52	6.88	0.39	4.4e-11	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs57083693	0.518	rs6538981	chr12:101702505	T/C	cg22051763	chr12:101673672	UTP20	-0.44	-5.5	-0.32	8.8e-8	Alcohol dependence (age at onset);
CESC	cis	rs8180040	0.620	rs2278963	chr3:47054869	G/T	cg27129171	chr3:47204927	SETD2	-0.7	-9.55	-0.51	8.87e-19	Colorectal cancer;
CESC	cis	rs7666738	0.830	rs6854703	chr4:98977586	A/T	cg17366294	chr4:99064904	C4orf37	0.58	8.25	0.45	7.41e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11638352	1.000	rs8035212	chr15:44304636	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	-0.66	-5.93	-0.34	9.41e-9	Lipoprotein phospholipase A2 activity in cardiovascular disease;
CESC	cis	rs7100689	0.784	rs7082102	chr10:82104890	A/C	cg00277334	chr10:82204260	NA	-0.59	-7.75	-0.43	1.95e-13	Post bronchodilator FEV1;
CESC	cis	rs7937682	0.924	rs10891286	chr11:111532691	C/G	cg22437258	chr11:111473054	SIK2	0.68	9.21	0.49	1e-17	Primary sclerosing cholangitis;
CESC	cis	rs11123694	1.000	rs11123694	chr2:109064563	C/T	cg02082929	chr2:109068933	GCC2	0.51	7.76	0.43	1.91e-13	Mean platelet volume;
CESC	cis	rs3858526	0.834	rs10839160	chr11:6002113	T/C	cg05234568	chr11:5960015	NA	-0.47	-5.53	-0.32	7.54e-8	DNA methylation (variation);
CESC	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg26338869	chr17:61819248	STRADA	0.69	8.87	0.48	1.09e-16	Prudent dietary pattern;
CESC	cis	rs116095464	0.510	rs7723883	chr5:270798	T/C	cg10591111	chr5:226296	SDHA	-0.51	-6.27	-0.36	1.45e-9	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15446238	chr11:64037516	BAD	0.6	6.37	0.36	8.09e-10	Gut microbiome composition (summer);
CESC	cis	rs10979	0.679	rs35914889	chr6:143886392	A/T	cg25407410	chr6:143891975	LOC285740	-0.54	-7.42	-0.41	1.62e-12	Hypospadias;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg01953429	chr4:1367848	KIAA1530	0.45	6.21	0.36	2.05e-9	Fibrinogen levels;
CESC	cis	rs17253792	0.555	rs17683626	chr14:56041112	G/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.84	5.73	0.33	2.76e-8	Putamen volume;
CESC	cis	rs9443645	0.509	rs9361459	chr6:79572922	A/G	cg05283184	chr6:79620031	NA	0.37	5.58	0.32	6.03e-8	Intelligence (multi-trait analysis);
CESC	cis	rs7772486	0.790	rs1854900	chr6:146331382	G/A	cg05347473	chr6:146136440	FBXO30	0.5	6.51	0.37	3.72e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs10781543	0.845	rs10781542	chr9:139327439	A/G	cg14019695	chr9:139328340	INPP5E	0.35	5.27	0.31	2.82e-7	Monocyte percentage of white cells;
CESC	cis	rs6060717	0.536	rs6060669	chr20:34480557	G/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.64	5.64	0.33	4.31e-8	Hip circumference adjusted for BMI;
CESC	cis	rs9486715	0.758	rs9386528	chr6:96928514	G/A	cg18709589	chr6:96969512	KIAA0776	-0.52	-7.01	-0.4	1.92e-11	Headache;
CESC	cis	rs4819052	0.766	rs4819035	chr21:46645715	A/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.79	9.73	0.51	2.44e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs7267979	0.966	rs6037103	chr20:25369095	A/G	cg08601574	chr20:25228251	PYGB	-0.38	-5.49	-0.32	9.43e-8	Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg15730116	chr12:76953768	OSBPL8	-0.43	-6.13	-0.35	3.11e-9	Fibrinogen levels;
CESC	cis	rs4568518	0.740	rs12699925	chr7:18010662	G/A	cg03009463	chr7:17980271	SNX13	0.46	6.24	0.36	1.69e-9	Measles;
CESC	cis	rs2599510	0.783	rs62136349	chr2:32827504	G/A	cg02381751	chr2:32503542	YIPF4	0.45	5.5	0.32	8.74e-8	Interleukin-18 levels;
CESC	cis	rs2836974	0.899	rs6517514	chr21:40527095	G/T	cg11890956	chr21:40555474	PSMG1	1.18	23.93	0.83	3.5e-68	Cognitive function;
CESC	trans	rs853679	0.769	rs17720293	chr6:28214698	C/T	cg21479132	chr6:26055353	NA	0.75	6.37	0.36	8.19e-10	Depression;
CESC	cis	rs875971	0.862	rs9791713	chr7:66105198	C/A	cg10691866	chr7:65817282	TPST1	0.31	5.07	0.3	7.31e-7	Aortic root size;
CESC	cis	rs3026101	0.671	rs3026134	chr17:5309690	G/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.42	5.6	0.33	5.31e-8	Body mass index;
CESC	cis	rs1577917	0.771	rs9362233	chr6:86358247	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.52	-7.02	-0.4	1.9e-11	Response to antipsychotic treatment;
CESC	cis	rs34779708	0.931	rs11010130	chr10:35513307	T/C	cg04310649	chr10:35416472	CREM	-0.55	-6.38	-0.36	7.93e-10	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs68170813	0.559	rs10953534	chr7:106913718	A/G	cg02696742	chr7:106810147	HBP1	0.55	5.68	0.33	3.52e-8	Coronary artery disease;
CESC	cis	rs11155671	0.530	rs9397420	chr6:150206781	C/T	cg09699651	chr6:150184138	LRP11	-0.51	-7.05	-0.4	1.51e-11	Testicular germ cell tumor;
CESC	cis	rs1665050	0.534	rs4465553	chr15:59246820	C/T	cg05156742	chr15:59063176	FAM63B	0.47	6.0	0.35	6.49e-9	Atopic dermatitis;
CESC	cis	rs7618915	0.501	rs13079063	chr3:52744460	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	8.08	0.44	2.26e-14	Bipolar disorder;
CESC	trans	rs877282	0.945	rs11599043	chr10:777972	C/T	cg22713356	chr15:30763199	NA	1.24	12.93	0.62	5.55e-30	Uric acid levels;
CESC	cis	rs71277158	0.688	rs16854875	chr3:169899667	T/G	cg04067573	chr3:169899625	PHC3	0.72	6.92	0.39	3.34e-11	Prostate cancer;
CESC	cis	rs55879323	1	rs55879323	chr1:152168740	C/T	cg25272121	chr1:152190972	HRNR	-0.41	-5.99	-0.35	6.78e-9	Inflammatory skin disease;
CESC	cis	rs12050794	0.671	rs8192362	chr15:72519858	G/A	cg16672083	chr15:72433130	SENP8	0.46	6.84	0.39	5.41e-11	Metabolite levels (HVA/MHPG ratio);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg17446216	chr1:32480239	KHDRBS1	-0.44	-6.28	-0.36	1.42e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs1624802	0.966	rs1707933	chr12:130497813	T/G	cg15444478	chr12:130494697	NA	-0.27	-5.4	-0.32	1.45e-7	Obesity-related traits;
CESC	cis	rs9311474	1.000	rs2276834	chr3:52325759	A/G	cg25934064	chr3:52569026	NT5DC2	0.29	5.85	0.34	1.48e-8	Electroencephalogram traits;
CESC	cis	rs8016982	0.633	rs8015423	chr14:81719357	C/T	cg01989461	chr14:81687754	GTF2A1	0.71	11.1	0.56	9.2e-24	Schizophrenia;
CESC	cis	rs2276314	0.857	rs62101393	chr18:33592168	T/C	cg05985134	chr18:33552581	C18orf21	0.61	7.33	0.41	2.8e-12	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs2380220	0.720	rs9400397	chr6:95980623	C/A	cg15832292	chr6:96025679	MANEA	0.62	6.87	0.39	4.62e-11	Behavioural disinhibition (generation interaction);
CESC	cis	rs4319547	0.728	rs61954974	chr12:123074169	T/C	cg23029597	chr12:123009494	RSRC2	-0.49	-5.41	-0.32	1.41e-7	Body mass index;
CESC	cis	rs2070488	0.965	rs7433277	chr3:38529818	C/T	cg24069376	chr3:38537580	EXOG	0.49	8.96	0.48	5.98e-17	Electrocardiographic conduction measures;
CESC	cis	rs9467711	0.606	rs68112369	chr6:26365759	T/C	cg14345882	chr6:26364793	BTN3A2	0.6	6.14	0.35	3.01e-9	Autism spectrum disorder or schizophrenia;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg00529053	chr6:158589440	GTF2H5;SERAC1	0.44	6.06	0.35	4.72e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs7267979	0.932	rs417110	chr20:25458297	T/C	cg08601574	chr20:25228251	PYGB	0.37	5.36	0.31	1.77e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs9322193	0.923	rs62441284	chr6:150072678	C/A	cg09699651	chr6:150184138	LRP11	0.4	5.08	0.3	7.22e-7	Lung cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23236025	chr1:109826094	PSRC1	0.62	6.84	0.39	5.48e-11	Gut microbiome composition (summer);
CESC	cis	rs7216064	1.000	rs8081517	chr17:65845697	A/T	cg12091567	chr17:66097778	LOC651250	-0.81	-9.14	-0.49	1.72e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	trans	rs853679	0.546	rs200995	chr6:27813694	C/T	cg06606381	chr12:133084897	FBRSL1	0.77	7.61	0.42	4.87e-13	Depression;
CESC	cis	rs798554	0.797	rs1182174	chr7:2875420	G/A	cg18446336	chr7:2847575	GNA12	-0.39	-5.93	-0.34	9.49e-9	Height;
CESC	cis	rs71277158	0.688	rs17471922	chr3:169779394	A/G	cg04067573	chr3:169899625	PHC3	0.65	6.57	0.37	2.59e-10	Prostate cancer;
CESC	cis	rs9467773	0.620	rs2451738	chr6:26618459	A/T	cg11502198	chr6:26597334	ABT1	-0.48	-6.88	-0.39	4.26e-11	Intelligence (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09972077	chr17:57232291	SKA2;PRR11	0.63	7.0	0.4	2.14e-11	Gut microbiome composition (summer);
CESC	cis	rs7552404	0.727	rs12093623	chr1:76256232	T/G	cg03433033	chr1:76189801	ACADM	0.62	6.34	0.36	9.58e-10	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs6502050	0.835	rs11654584	chr17:80079435	A/T	cg23985595	chr17:80112537	CCDC57	-0.4	-6.14	-0.35	3.01e-9	Life satisfaction;
CESC	cis	rs4969178	0.896	rs12602206	chr17:76397133	A/G	cg05887092	chr17:76393375	PGS1	0.58	9.2	0.49	1.13e-17	HDL cholesterol levels;
CESC	cis	rs244293	0.730	rs12951898	chr17:53035602	C/T	cg19360675	chr17:53046073	COX11;STXBP4	-0.48	-6.63	-0.38	1.83e-10	Menarche (age at onset);
CESC	cis	rs4727963	0.869	rs10262500	chr7:122799737	C/T	cg03640110	chr7:122635026	TAS2R16	0.34	5.16	0.3	4.86e-7	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
CESC	trans	rs2963826	0.589	rs298091	chr5:58996603	A/T	cg14797243	chr11:68671428	IGHMBP2;MRPL21	0.47	6.02	0.35	5.93e-9	Obesity-related traits;
CESC	cis	rs6762	0.748	rs7929032	chr11:839078	G/A	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.67	-8.57	-0.47	8.66e-16	Mean platelet volume;
CESC	cis	rs11690935	0.838	rs10432423	chr2:172753295	G/A	cg13550731	chr2:172543902	DYNC1I2	-0.85	-12.52	-0.61	1.46e-28	Schizophrenia;
CESC	cis	rs3733585	0.806	rs7375599	chr4:9954918	C/T	cg02734326	chr4:10020555	SLC2A9	0.44	6.61	0.38	2.11e-10	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs2625529	0.824	rs7170754	chr15:72218594	G/A	cg16672083	chr15:72433130	SENP8	-0.39	-5.06	-0.3	7.68e-7	Red blood cell count;
CESC	trans	rs4349753	0.640	rs28509278	chr5:144088800	C/T	cg22407458	chr6:35109121	TCP11	0.51	6.4	0.37	7e-10	Photic sneeze reflex;
CESC	cis	rs7264396	0.635	rs6060673	chr20:34482396	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.77	10.38	0.54	2.04e-21	Total cholesterol levels;
CESC	cis	rs9649213	0.593	rs6944262	chr7:97985415	T/G	cg00277769	chr7:97922759	BAIAP2L1	-0.31	-5.11	-0.3	6.27e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs56313388	0.793	rs9937815	chr16:56330832	C/T	cg02433656	chr16:56322654	GNAO1	-0.44	-5.59	-0.32	5.6e-8	Pulse pressure;
CESC	cis	rs990171	0.607	rs2192752	chr2:102769373	A/C	cg22835712	chr2:102737379	NA	-0.44	-5.96	-0.34	7.99e-9	Lymphocyte counts;
CESC	cis	rs863345	0.604	rs7514968	chr1:158493852	A/T	cg12129480	chr1:158549410	OR10X1	-0.35	-6.86	-0.39	4.75e-11	Pneumococcal bacteremia;
CESC	cis	rs1799949	1.000	rs8176234	chr17:41219780	T/C	cg25072359	chr17:41440525	NA	0.45	6.07	0.35	4.5e-9	Menopause (age at onset);
CESC	cis	rs875971	0.545	rs73150604	chr7:65945532	T/A	cg25405998	chr7:65216604	CCT6P1	0.49	5.22	0.31	3.57e-7	Aortic root size;
CESC	cis	rs290268	1.000	rs290274	chr9:93546913	C/T	cg02608019	chr9:93564028	SYK	0.63	9.36	0.5	3.47e-18	Platelet count;
CESC	cis	rs7917772	0.582	rs10786685	chr10:104323103	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.42	5.59	0.32	5.57e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs7786808	0.653	rs7810861	chr7:158212633	G/A	cg01191920	chr7:158217561	PTPRN2	-0.31	-5.17	-0.3	4.67e-7	Obesity-related traits;
CESC	cis	rs3857536	0.813	rs7743965	chr6:66941346	C/G	cg07460842	chr6:66804631	NA	-0.41	-5.28	-0.31	2.71e-7	Blood trace element (Cu levels);
CESC	cis	rs703842	0.575	rs701006	chr12:58106836	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.41	5.27	0.31	2.89e-7	Multiple sclerosis;
CESC	cis	rs875971	0.522	rs2008188	chr7:65429013	G/C	cg14393609	chr7:65229607	NA	0.52	7.08	0.4	1.28e-11	Aortic root size;
CESC	cis	rs12474201	0.894	rs34401107	chr2:46972768	A/C	cg06386533	chr2:46925753	SOCS5	0.89	12.27	0.6	1.07e-27	Height;
CESC	cis	rs1364705	0.955	rs12677274	chr8:120222541	C/T	cg09273054	chr8:120220131	MAL2	-0.63	-7.23	-0.41	5.13e-12	Hippocampal atrophy;
CESC	cis	rs7044106	0.762	rs4837790	chr9:123446325	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.81	12.82	0.62	1.3e-29	Hip circumference adjusted for BMI;
CESC	cis	rs8060686	0.545	rs55897859	chr16:68286748	G/C	cg26727032	chr16:67993705	SLC12A4	-0.51	-5.35	-0.31	1.94e-7	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs10752881	1.000	rs10752886	chr1:182987248	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.84	13.3	0.63	2.79e-31	Colorectal cancer;
CESC	cis	rs72781680	0.611	rs56326157	chr2:24312407	T/C	cg08917208	chr2:24149416	ATAD2B	0.6	5.66	0.33	3.99e-8	Lymphocyte counts;
CESC	cis	rs1467026	0.606	rs9814180	chr3:12818386	A/G	cg24848339	chr3:12840334	CAND2	0.43	6.79	0.38	7.49e-11	P wave duration;
CESC	cis	rs1348850	0.846	rs4893962	chr2:178421106	A/G	cg22681709	chr2:178499509	PDE11A	-0.38	-5.73	-0.33	2.76e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs6546537	0.824	rs3771543	chr2:69784255	C/T	cg10773587	chr2:69614142	GFPT1	-0.63	-7.77	-0.43	1.78e-13	Serum thyroid-stimulating hormone levels;
CESC	cis	rs4642101	0.793	rs6799179	chr3:12829095	A/C	cg05775895	chr3:12838266	CAND2	0.35	5.28	0.31	2.72e-7	QRS complex (12-leadsum);
CESC	cis	rs75477785	1.000	rs11119359	chr1:210054435	T/C	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.81	5.37	0.31	1.69e-7	Cleft lip with or without cleft palate;
CESC	cis	rs61931739	0.500	rs10844845	chr12:34381117	C/T	cg06521331	chr12:34319734	NA	-0.36	-5.06	-0.3	8.03e-7	Morning vs. evening chronotype;
CESC	cis	rs4819052	1.000	rs9984901	chr21:46663952	C/T	cg11663144	chr21:46675770	NA	-0.53	-7.18	-0.4	6.99e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs875971	0.862	rs4718330	chr7:65715243	G/A	cg12463550	chr7:65579703	CRCP	-0.47	-6.11	-0.35	3.6e-9	Aortic root size;
CESC	cis	rs7149337	1.000	rs35567150	chr14:51725944	A/G	cg23942311	chr14:51606299	NA	0.44	7.32	0.41	2.92e-12	Cancer;
CESC	cis	rs863345	0.604	rs2051451	chr1:158464265	A/C	cg12129480	chr1:158549410	OR10X1	-0.35	-6.97	-0.39	2.46e-11	Pneumococcal bacteremia;
CESC	cis	rs854765	0.693	rs9907287	chr17:17774118	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.61	-9.02	-0.48	3.99e-17	Total body bone mineral density;
CESC	cis	rs3820068	0.581	rs16849152	chr1:15921774	A/C	cg16988262	chr1:15930761	NA	0.35	5.58	0.32	5.86e-8	Systolic blood pressure;
CESC	cis	rs1862618	0.671	rs2591964	chr5:56236900	T/G	cg22800045	chr5:56110881	MAP3K1	-0.6	-7.76	-0.43	1.79e-13	Initial pursuit acceleration;
CESC	cis	rs13056815	1	rs13056815	chr22:31668250	G/A	cg25791279	chr22:32026902	PISD	-0.46	-5.46	-0.32	1.08e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs1775715	0.870	rs1419168	chr10:32257332	A/C	cg04359828	chr10:32216031	ARHGAP12	0.36	5.31	0.31	2.29e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs2204008	0.774	rs11495520	chr12:38060605	T/G	cg13010199	chr12:38710504	ALG10B	0.54	6.69	0.38	1.28e-10	Bladder cancer;
CESC	cis	rs1167827	1.000	rs1167827	chr7:75163169	A/G	cg16384552	chr7:74938386	SPDYE8P	-0.43	-5.47	-0.32	1.03e-7	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs710216	0.957	rs3806401	chr1:43426212	G/T	cg03128534	chr1:43423976	SLC2A1	-0.53	-5.61	-0.33	5.07e-8	Red cell distribution width;
CESC	cis	rs72781680	0.665	rs2953028	chr2:24068126	T/C	cg08917208	chr2:24149416	ATAD2B	0.63	6.28	0.36	1.41e-9	Lymphocyte counts;
CESC	cis	rs2243480	0.803	rs34004500	chr7:65312178	A/T	cg13147721	chr7:65941812	NA	-0.85	-8.51	-0.46	1.26e-15	Diabetic kidney disease;
CESC	cis	rs35740288	0.571	rs11633790	chr15:86326370	G/A	cg20737812	chr15:86336631	KLHL25	-0.42	-5.2	-0.3	3.9e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
CESC	cis	rs12477438	0.798	rs9679602	chr2:99577827	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.74	10.52	0.54	7.26e-22	Chronic sinus infection;
CESC	cis	rs8141529	0.748	rs1318025	chr22:29283757	C/T	cg15103426	chr22:29168792	CCDC117	0.61	7.81	0.43	1.31e-13	Lymphocyte counts;
CESC	cis	rs5769765	0.955	rs2319465	chr22:50265784	A/C	cg26441486	chr22:50317300	CRELD2	-0.39	-5.5	-0.32	8.72e-8	Schizophrenia;
CESC	cis	rs4319547	1.000	rs6489157	chr12:123101673	C/G	cg05707623	chr12:122985044	ZCCHC8	0.59	7.1	0.4	1.15e-11	Body mass index;
CESC	cis	rs7959452	0.536	rs4761237	chr12:69776461	C/G	cg14784868	chr12:69753453	YEATS4	0.83	12.99	0.62	3.36e-30	Blood protein levels;
CESC	cis	rs11122272	0.735	rs2572251	chr1:231514243	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.57	-7.82	-0.43	1.29e-13	Hemoglobin concentration;
CESC	cis	rs875971	0.545	rs6979636	chr7:65741625	A/G	cg25405998	chr7:65216604	CCT6P1	0.48	5.32	0.31	2.16e-7	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07472772	chr20:31071948	C20orf112	0.55	6.44	0.37	5.44e-10	Gut microbiome composition (summer);
CESC	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg23708337	chr7:1209742	NA	0.55	5.41	0.32	1.44e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7605827	0.930	rs12995776	chr2:15717131	T/A	cg19274914	chr2:15703543	NA	0.34	6.0	0.35	6.52e-9	Educational attainment (years of education);
CESC	cis	rs17253792	0.822	rs78429067	chr14:56092551	G/A	cg01858014	chr14:56050164	KTN1	-0.93	-7.33	-0.41	2.71e-12	Putamen volume;
CESC	cis	rs4969178	0.965	rs3744217	chr17:76400258	G/A	cg20026190	chr17:76395443	PGS1	0.46	7.35	0.41	2.41e-12	HDL cholesterol levels;
CESC	cis	rs796364	1.000	rs281785	chr2:200749566	A/G	cg23649088	chr2:200775458	C2orf69	0.55	5.07	0.3	7.6e-7	Schizophrenia;
CESC	cis	rs7666738	0.830	rs17484966	chr4:99014432	T/C	cg03467027	chr4:99064603	C4orf37	0.44	5.63	0.33	4.57e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs34779708	0.931	rs2505631	chr10:35368385	A/T	cg03585969	chr10:35415529	CREM	-0.74	-9.75	-0.51	2.16e-19	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs561341	1.000	rs2470243	chr17:30290955	C/T	cg12193833	chr17:30244370	NA	-0.76	-6.94	-0.39	2.92e-11	Hip circumference adjusted for BMI;
CESC	cis	rs5750830	0.594	rs5757648	chr22:39775156	G/A	cg02038168	chr22:39784481	NA	-0.56	-7.35	-0.41	2.5e-12	Intelligence (multi-trait analysis);
CESC	cis	rs9399135	0.838	rs4896126	chr6:135342786	C/A	cg24558204	chr6:135376177	HBS1L	0.52	7.29	0.41	3.48e-12	Red blood cell count;
CESC	cis	rs4819052	1.000	rs28628220	chr21:46663741	G/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.57	6.8	0.39	6.84e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs854765	0.663	rs12941550	chr17:17753828	C/A	cg09796270	chr17:17721594	SREBF1	-0.45	-6.5	-0.37	3.89e-10	Total body bone mineral density;
CESC	cis	rs1862618	0.802	rs2591949	chr5:56132627	T/C	cg12311346	chr5:56204834	C5orf35	-0.74	-8.81	-0.48	1.63e-16	Initial pursuit acceleration;
CESC	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg10295955	chr4:187884368	NA	-1.03	-20.74	-0.79	1.94e-57	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs10979	1.000	rs9285500	chr6:143897614	G/C	cg25407410	chr6:143891975	LOC285740	-0.61	-9.2	-0.49	1.13e-17	Hypospadias;
CESC	cis	rs17666538	0.585	rs336437	chr8:636251	A/C	cg07234876	chr8:600039	NA	0.78	5.78	0.33	2.11e-8	IgG glycosylation;
CESC	cis	rs7219021	0.674	rs11656939	chr17:46964406	G/C	cg16584676	chr17:46985605	UBE2Z	-0.65	-7.82	-0.43	1.24e-13	Schizophrenia or bipolar disorder;
CESC	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	13.6	0.64	2.58e-32	Prudent dietary pattern;
CESC	cis	rs846111	1.000	rs846111	chr1:6279370	G/C	cg02892189	chr1:6321676	GPR153	-0.55	-7.16	-0.4	8.18e-12	QT interval;
CESC	cis	rs3857536	0.776	rs4710583	chr6:66940101	A/C	cg07460842	chr6:66804631	NA	-0.42	-5.34	-0.31	1.96e-7	Blood trace element (Cu levels);
CESC	cis	rs9814567	1.000	rs9289476	chr3:134237103	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.43	-5.82	-0.34	1.68e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs854765	0.551	rs56886154	chr17:17831473	C/A	cg16928487	chr17:17741425	SREBF1	-0.59	-10.25	-0.53	5.56e-21	Total body bone mineral density;
CESC	cis	rs7953508	0.506	rs2053196	chr12:93962959	T/C	cg18151635	chr12:93972918	NA	-0.44	-5.85	-0.34	1.41e-8	Pubertal anthropometrics;
CESC	cis	rs1355223	1.000	rs1355222	chr11:34758716	C/G	cg11058730	chr11:34937778	PDHX;APIP	-0.46	-5.97	-0.34	7.75e-9	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs9902453	0.716	rs3098949	chr17:27978694	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	9.76	0.51	1.98e-19	Coffee consumption (cups per day);
CESC	cis	rs7208859	0.573	rs73267829	chr17:29003939	G/A	cg19761014	chr17:28927070	LRRC37B2	0.82	6.73	0.38	1.02e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs7296418	0.922	rs1790134	chr12:123697898	T/C	cg05973401	chr12:123451056	ABCB9	0.51	6.52	0.37	3.49e-10	Platelet count;
CESC	cis	rs1355223	0.506	rs11032894	chr11:34865544	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.54	-6.72	-0.38	1.12e-10	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs2304069	1.000	rs10072275	chr5:149401596	T/C	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.91	11.52	0.58	3.72e-25	HIV-1 control;
CESC	cis	rs2797160	1.000	rs1739363	chr6:126020980	G/A	cg05901451	chr6:126070800	HEY2	0.44	6.32	0.36	1.13e-9	Endometrial cancer;
CESC	cis	rs7833986	0.501	rs2953897	chr8:56980569	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.61	7.55	0.42	6.89e-13	Height;
CESC	cis	rs4819052	0.765	rs2838854	chr21:46680364	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.75	10.11	0.53	1.56e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs7772486	0.790	rs2250387	chr6:146205233	C/T	cg23711669	chr6:146136114	FBXO30	0.92	13.5	0.64	5.99e-32	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7617773	0.780	rs3731550	chr3:48206583	A/C	cg11946769	chr3:48343235	NME6	0.88	11.47	0.58	5.58e-25	Coronary artery disease;
CESC	cis	rs34375054	0.624	rs7295689	chr12:125680922	T/G	cg25124228	chr12:125621409	AACS	-0.5	-5.76	-0.33	2.28e-8	Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs3096299	0.685	rs3803681	chr16:89544756	C/T	cg00750074	chr16:89608354	SPG7	-0.41	-6.02	-0.35	5.83e-9	Multiple myeloma (IgH translocation);
CESC	cis	rs5753618	0.583	rs2899164	chr22:31790289	G/A	cg02404636	chr22:31891804	SFI1	0.4	5.41	0.32	1.42e-7	Colorectal cancer;
CESC	cis	rs6740322	1.000	rs4128209	chr2:43554729	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.59	-6.47	-0.37	4.64e-10	Coronary artery disease;
CESC	cis	rs4665809	0.878	rs4143538	chr2:26290178	A/C	cg08470875	chr2:26401718	FAM59B	-0.62	-6.6	-0.38	2.28e-10	Gut microbiome composition (summer);
CESC	cis	rs524281	0.773	rs2155201	chr11:65992344	T/C	cg14036092	chr11:66035641	RAB1B	-0.53	-5.31	-0.31	2.38e-7	Electroencephalogram traits;
CESC	cis	rs7107174	0.892	rs2510042	chr11:77923665	C/T	cg02023728	chr11:77925099	USP35	0.49	6.56	0.37	2.89e-10	Testicular germ cell tumor;
CESC	cis	rs7851660	0.809	rs10739526	chr9:100662671	T/C	cg13688889	chr9:100608707	NA	-0.62	-8.87	-0.48	1.11e-16	Strep throat;
CESC	cis	rs258892	0.895	rs13181437	chr5:72051657	G/A	cg21869765	chr5:72125136	TNPO1	-0.4	-5.26	-0.31	2.97e-7	Small cell lung carcinoma;
CESC	cis	rs67311347	0.544	rs7644643	chr3:40350209	C/T	cg09455208	chr3:40491958	NA	-0.35	-6.15	-0.35	2.77e-9	Renal cell carcinoma;
CESC	cis	rs1267303	0.636	rs1267310	chr1:46987307	A/T	cg25110126	chr1:46999211	NA	-0.72	-8.88	-0.48	1.04e-16	Monobrow;
CESC	cis	rs6546550	0.901	rs3732266	chr2:70057448	T/G	cg02498382	chr2:70120550	SNRNP27	-0.38	-6.4	-0.37	7.17e-10	Prevalent atrial fibrillation;
CESC	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg23978390	chr7:1156363	C7orf50	0.65	9.08	0.49	2.53e-17	Longevity;Endometriosis;
CESC	trans	rs9329221	0.905	rs17765901	chr8:10249480	G/T	cg15556689	chr8:8085844	FLJ10661	-0.52	-6.0	-0.35	6.6e-9	Neuroticism;
CESC	cis	rs453301	0.686	rs1045527	chr8:8890041	A/G	cg15556689	chr8:8085844	FLJ10661	-0.49	-6.0	-0.35	6.44e-9	Joint mobility (Beighton score);
CESC	cis	rs8062405	0.723	rs12445744	chr16:28588395	A/C	cg07382826	chr16:28625726	SULT1A1	0.4	6.58	0.37	2.54e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs2439831	0.850	rs12441984	chr15:44126285	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.69	7.6	0.42	4.99e-13	Lung cancer in ever smokers;
CESC	cis	rs7829975	0.517	rs12542733	chr8:8824858	G/T	cg15556689	chr8:8085844	FLJ10661	-0.44	-5.51	-0.32	8.58e-8	Mood instability;
CESC	cis	rs1152591	0.967	rs1152589	chr14:64683926	A/T	cg21174375	chr14:64681225	SYNE2	-0.47	-6.32	-0.36	1.1e-9	Atrial fibrillation;
CESC	cis	rs7017914	0.934	rs13274062	chr8:71737087	G/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.44	-5.68	-0.33	3.58e-8	Bone mineral density;
CESC	cis	rs2519796	0.564	rs2519799	chr9:136810857	A/G	cg13751417	chr9:136814406	VAV2	0.41	5.35	0.31	1.88e-7	Hematocrit;Hemoglobin concentration;
CESC	cis	rs1348850	0.645	rs10164417	chr2:178444130	A/G	cg23306229	chr2:178417860	TTC30B	0.66	7.1	0.4	1.14e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs477895	0.652	rs72920332	chr11:63947071	G/T	cg04317338	chr11:64019027	PLCB3	0.9	9.36	0.5	3.64e-18	Mean platelet volume;
CESC	cis	rs12188164	0.965	rs56146525	chr5:442571	A/C	cg15813090	chr5:442598	EXOC3;C5orf55	0.43	6.43	0.37	6.03e-10	Cystic fibrosis severity;
CESC	cis	rs4665809	0.878	rs6748745	chr2:26364190	C/T	cg26314531	chr2:26401878	FAM59B	-0.66	-7.68	-0.43	3.17e-13	Gut microbiome composition (summer);
CESC	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.54	-6.12	-0.35	3.4e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs728616	0.681	rs55855057	chr10:82034729	G/A	cg05935833	chr10:81318306	SFTPA2	-0.45	-5.78	-0.33	2.1e-8	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs6952808	0.756	rs12537348	chr7:1948172	C/G	cg05863683	chr7:1912471	MAD1L1	0.43	6.62	0.38	2e-10	Bipolar disorder and schizophrenia;
CESC	cis	rs41308713	0.681	rs8116426	chr20:37034643	A/C	cg09132763	chr20:37064059	LOC388796;SNORA71D	1.13	6.51	0.37	3.77e-10	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
CESC	cis	rs7818688	0.697	rs11782818	chr8:95978221	A/G	cg16049864	chr8:95962084	TP53INP1	0.57	5.74	0.33	2.65e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs17253792	0.822	rs75437558	chr14:56066798	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.83	6.18	0.36	2.36e-9	Putamen volume;
CESC	cis	rs6540559	1.000	rs12070337	chr1:209992127	G/A	cg09509183	chr1:209979624	IRF6	0.52	6.24	0.36	1.72e-9	Cleft lip with or without cleft palate;
CESC	cis	rs769267	1.000	rs7247309	chr19:19439631	A/T	cg15052019	chr19:19431593	KIAA0892;SF4	-0.42	-5.39	-0.31	1.53e-7	Tonsillectomy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19942813	chr3:187463496	BCL6	0.57	6.55	0.37	2.98e-10	Gut microbiome composition (summer);
CESC	cis	rs7772486	0.875	rs13204280	chr6:146415368	T/C	cg05347473	chr6:146136440	FBXO30	0.5	6.72	0.38	1.14e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2730245	0.661	rs842696	chr7:158662698	T/C	cg01943577	chr7:158741284	NA	-0.46	-6.07	-0.35	4.5e-9	Height;
CESC	cis	rs9916302	0.555	rs12940193	chr17:37652178	T/G	cg19468946	chr17:37922297	IKZF3	-0.39	-5.09	-0.3	6.9e-7	Glomerular filtration rate (creatinine);
CESC	trans	rs10242455	0.702	rs73713521	chr7:99188649	G/A	cg09045935	chr12:6379348	NA	0.93	6.94	0.39	3.02e-11	Blood metabolite levels;
CESC	cis	rs9513593	0.901	rs7997943	chr13:99810343	T/C	cg21788972	chr13:99853209	UBAC2	0.47	5.62	0.33	4.73e-8	Psoriasis;
CESC	cis	rs2708240	0.936	rs2538981	chr7:147582251	A/C	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.35	-6.02	-0.35	5.89e-9	QT interval (drug interaction);
CESC	cis	rs67311347	1.000	rs9841335	chr3:40475858	G/A	cg24209194	chr3:40518798	ZNF619	0.46	5.99	0.35	6.9e-9	Renal cell carcinoma;
CESC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg01043383	chr19:57630742	USP29	-0.46	-6.08	-0.35	4.26e-9	Intelligence (multi-trait analysis);
CESC	cis	rs7223966	0.960	rs2854222	chr17:61939015	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.54	6.9	0.39	3.94e-11	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs7208859	0.623	rs73263788	chr17:29216490	T/C	cg19761014	chr17:28927070	LRRC37B2	0.63	5.32	0.31	2.26e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs1499614	1.000	rs2707840	chr7:66158015	C/T	cg12463550	chr7:65579703	CRCP	0.74	5.75	0.33	2.47e-8	Gout;
CESC	cis	rs7586879	0.639	rs2033656	chr2:25100902	C/G	cg01884057	chr2:25150051	NA	0.36	6.89	0.39	3.95e-11	Body mass index;
CESC	cis	rs13191362	1.000	rs35092540	chr6:163090778	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.03	10.9	0.56	4.11e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs7267979	1.000	rs1888997	chr20:25298988	G/A	cg08601574	chr20:25228251	PYGB	-0.37	-5.24	-0.31	3.3e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs847577	0.609	rs34320230	chr7:97785500	C/T	cg21770322	chr7:97807741	LMTK2	0.83	13.85	0.65	3.33e-33	Breast cancer;
CESC	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg07677032	chr17:61819896	STRADA	0.45	5.95	0.34	8.6e-9	Prudent dietary pattern;
CESC	cis	rs7666738	0.830	rs1426662	chr4:98990319	C/T	cg17366294	chr4:99064904	C4orf37	0.6	8.6	0.47	7.1e-16	Colonoscopy-negative controls vs population controls;
CESC	trans	rs17685	0.712	rs10275521	chr7:75770972	T/C	cg19862616	chr7:65841803	NCRNA00174	0.85	12.41	0.61	3.51e-28	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs9733	0.596	rs34140753	chr1:150642583	T/C	cg04414720	chr1:150670196	GOLPH3L	0.63	9.02	0.48	3.87e-17	Tonsillectomy;
CESC	cis	rs10089	1.000	rs4836370	chr5:127499224	A/G	cg19767477	chr5:127420684	SLC12A2	-0.39	-5.26	-0.31	2.96e-7	Ileal carcinoids;
CESC	cis	rs9457247	0.646	rs4710160	chr6:167409241	T/A	cg23791538	chr6:167370224	RNASET2	-0.61	-8.81	-0.48	1.71e-16	Crohn's disease;
CESC	cis	rs10242455	0.681	rs1851425	chr7:99300231	G/A	cg07715041	chr7:99302981	CYP3A7	-0.44	-5.56	-0.32	6.73e-8	Blood metabolite levels;
CESC	cis	rs7267979	1.000	rs6050631	chr20:25431749	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.83	16.43	0.71	2.68e-42	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs9291683	0.561	rs3733584	chr4:10036506	T/C	cg02734326	chr4:10020555	SLC2A9	0.49	6.84	0.39	5.6e-11	Bone mineral density;
CESC	cis	rs3096299	0.617	rs2353030	chr16:89405827	C/T	cg02187348	chr16:89574699	SPG7	-0.48	-6.18	-0.35	2.44e-9	Multiple myeloma (IgH translocation);
CESC	cis	rs8092503	1.000	rs12454336	chr18:52497204	C/T	cg12377874	chr18:52495404	RAB27B	-0.36	-6.08	-0.35	4.29e-9	Childhood body mass index;
CESC	cis	rs11574514	1.000	rs1107767	chr16:68020063	C/G	cg01866162	chr16:67596514	CTCF	0.97	5.6	0.33	5.22e-8	Crohn's disease;
CESC	cis	rs780096	0.526	rs72819536	chr2:27682850	G/T	cg24768116	chr2:27665128	KRTCAP3	-0.28	-5.07	-0.3	7.42e-7	Total body bone mineral density;
CESC	trans	rs9987353	0.840	rs329994	chr8:9123233	A/G	cg13986503	chr11:126152983	TIRAP	-0.44	-6.16	-0.35	2.63e-9	Recombination measurement;
CESC	cis	rs514406	0.861	rs1412706	chr1:53237721	G/A	cg16325326	chr1:53192061	ZYG11B	-0.88	-15.0	-0.68	3.14e-37	Monocyte count;
CESC	cis	rs6665290	0.901	rs61834004	chr1:227202782	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.18	-28.43	-0.87	1.81e-82	Myeloid white cell count;
CESC	cis	rs8071756	1.000	rs62089969	chr17:1575196	T/C	ch.17.72133F	chr17:1577994	PRPF8	0.49	5.23	0.31	3.4e-7	Blood protein levels;
CESC	cis	rs1862618	0.853	rs832569	chr5:56154584	T/A	cg18230493	chr5:56204884	C5orf35	-0.73	-8.61	-0.47	6.69e-16	Initial pursuit acceleration;
CESC	cis	rs651907	0.557	rs11712748	chr3:101383562	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	7.0	0.39	2.15e-11	Colorectal cancer;
CESC	cis	rs6487679	0.526	rs972111	chr12:9374373	A/G	cg08997352	chr12:9597637	DDX12	-0.5	-5.48	-0.32	1.01e-7	Non-alcoholic fatty liver disease histology (AST);
CESC	cis	rs2933343	0.729	rs813732	chr3:128619357	C/T	cg11901034	chr3:128598214	ACAD9	-0.37	-5.35	-0.31	1.94e-7	IgG glycosylation;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg25464034	chr11:450264	PTDSS2	0.5	7.06	0.4	1.47e-11	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs10751667	1.000	rs6597972	chr11:928402	C/T	cg01483505	chr11:975446	AP2A2	0.41	5.45	0.32	1.13e-7	Alzheimer's disease (late onset);
CESC	cis	rs3820928	0.934	rs60141402	chr2:227761445	A/C	cg05526886	chr2:227700861	RHBDD1	-0.42	-5.5	-0.32	8.95e-8	Pulmonary function;
CESC	cis	rs2303759	0.709	rs3760667	chr19:49814832	C/T	cg22307029	chr19:49891270	CCDC155	0.54	5.9	0.34	1.1e-8	Multiple sclerosis;
CESC	cis	rs1267303	0.675	rs1267313	chr1:46986322	G/T	cg25110126	chr1:46999211	NA	-0.72	-8.95	-0.48	6.36e-17	Monobrow;
CESC	cis	rs7666738	0.830	rs2865977	chr4:99017916	C/T	cg18180107	chr4:99064573	C4orf37	0.41	5.39	0.31	1.57e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19473056	chr3:41996898	ULK4	-0.58	-6.36	-0.36	9.03e-10	Gut microbiome composition (summer);
CESC	cis	rs2635047	0.682	rs7242976	chr18:44797159	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.39	5.07	0.3	7.62e-7	Educational attainment;
CESC	cis	rs7903847	0.642	rs10882922	chr10:99158537	C/T	cg20016023	chr10:99160130	RRP12	-0.3	-5.19	-0.3	4.18e-7	Granulocyte percentage of myeloid white cells;
CESC	cis	rs4665809	1.000	rs6709595	chr2:26259885	A/G	cg08470875	chr2:26401718	FAM59B	-0.48	-5.26	-0.31	2.94e-7	Gut microbiome composition (summer);
CESC	cis	rs9815354	0.680	rs73073296	chr3:42028074	G/A	cg03022575	chr3:42003672	ULK4	0.75	6.64	0.38	1.72e-10	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs9902453	0.753	rs3097118	chr17:27978466	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.76	10.19	0.53	8.39e-21	Coffee consumption (cups per day);
CESC	cis	rs4604732	0.631	rs4436425	chr1:247632323	T/C	cg12758973	chr1:247694275	LOC148824;OR2C3	0.42	5.4	0.31	1.47e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs12497850	0.931	rs7628719	chr3:48995487	C/T	cg07636037	chr3:49044803	WDR6	1.02	18.48	0.75	1.47e-49	Parkinson's disease;
CESC	cis	rs17039065	1.000	rs72889396	chr4:109400426	T/A	cg16022748	chr4:109541635	LOC285456;RPL34	0.66	5.49	0.32	9.29e-8	Gut microbiome composition (summer);
CESC	cis	rs514406	0.823	rs501006	chr1:53368292	T/A	cg08736216	chr1:53307985	ZYG11A	-0.38	-6.16	-0.35	2.68e-9	Monocyte count;
CESC	cis	rs317689	0.918	rs610192	chr12:69739941	T/C	cg14784868	chr12:69753453	YEATS4	0.61	6.8	0.39	7.01e-11	Response to diuretic therapy;
CESC	cis	rs7147624	1.000	rs7150233	chr14:66200816	A/G	cg03016385	chr14:66212404	NA	-0.52	-5.09	-0.3	6.81e-7	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs637571	0.522	rs12792888	chr11:65761446	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.73	10.3	0.53	3.89e-21	Eosinophil percentage of white cells;
CESC	cis	rs7107174	1.000	rs6592772	chr11:78015563	A/C	cg02023728	chr11:77925099	USP35	0.48	6.26	0.36	1.51e-9	Testicular germ cell tumor;
CESC	cis	rs2115630	0.645	rs2292463	chr15:85175750	A/G	cg12501888	chr15:85177176	SCAND2	-0.45	-5.99	-0.35	6.69e-9	P wave terminal force;
CESC	cis	rs6598955	0.724	rs869683	chr1:26570993	T/A	cg04990556	chr1:26633338	UBXN11	-0.75	-10.61	-0.55	3.68e-22	Obesity-related traits;
CESC	cis	rs17376456	0.825	rs17372725	chr5:93135588	C/A	cg21475434	chr5:93447410	FAM172A	0.8	7.22	0.41	5.48e-12	Diabetic retinopathy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18970754	chr14:74079533	NA	0.52	6.15	0.35	2.81e-9	Gut microbiome composition (summer);
CESC	cis	rs875971	0.767	rs1643394	chr7:65836094	A/G	cg12463550	chr7:65579703	CRCP	0.49	6.27	0.36	1.48e-9	Aortic root size;
CESC	cis	rs4665809	0.887	rs4665825	chr2:26333100	A/G	cg26314531	chr2:26401878	FAM59B	-0.62	-6.99	-0.39	2.29e-11	Gut microbiome composition (summer);
CESC	cis	rs4803468	1.000	rs2231940	chr19:41944237	T/C	cg14132834	chr19:41945861	ATP5SL	0.66	8.19	0.45	1.09e-14	Height;
CESC	cis	rs3126085	0.778	rs10788828	chr1:152191879	G/A	cg26876637	chr1:152193138	HRNR	0.48	5.5	0.32	8.93e-8	Atopic dermatitis;
CESC	cis	rs875971	0.660	rs12698534	chr7:65986845	C/T	cg11764359	chr7:65958608	NA	0.71	9.46	0.5	1.77e-18	Aortic root size;
CESC	cis	rs9487051	0.676	rs9374077	chr6:109600194	C/T	cg21918786	chr6:109611834	NA	-0.37	-5.5	-0.32	9.15e-8	Reticulocyte fraction of red cells;
CESC	cis	rs11229555	0.609	rs12575080	chr11:58224917	A/G	cg15696309	chr11:58395628	NA	-0.45	-5.22	-0.31	3.63e-7	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs4243830	0.850	rs3761927	chr1:6601773	T/C	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.99	-10.01	-0.52	3.22e-20	Body mass index;
CESC	trans	rs1728785	1.000	rs1749793	chr16:68569312	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.63	7.39	0.41	1.91e-12	Ulcerative colitis;
CESC	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg23708337	chr7:1209742	NA	0.5	5.42	0.32	1.32e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7618915	0.547	rs2118540	chr3:52629386	T/C	cg18099408	chr3:52552593	STAB1	-0.33	-5.34	-0.31	2.02e-7	Bipolar disorder;
CESC	cis	rs7188697	0.922	rs37039	chr16:58578091	C/T	cg02549819	chr16:58548995	SETD6	-0.42	-5.29	-0.31	2.55e-7	QT interval;
CESC	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg17372223	chr3:52568218	NT5DC2	0.52	8.76	0.47	2.32e-16	Electroencephalogram traits;
CESC	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg18402987	chr7:1209562	NA	0.59	7.0	0.4	2.04e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2294693	0.891	rs1072119	chr6:40993072	G/A	cg14769373	chr6:40998127	UNC5CL	-0.47	-6.37	-0.36	8.3e-10	Gastric cancer;Non-cardia gastric cancer;
CESC	cis	rs4665809	1.000	rs4665816	chr2:26305094	G/C	cg08470875	chr2:26401718	FAM59B	-0.48	-5.32	-0.31	2.21e-7	Gut microbiome composition (summer);
CESC	cis	rs71007656	1	rs71007656	chr10:37970845	CGGCTG/C	cg00409905	chr10:38381863	ZNF37A	-0.45	-6.21	-0.36	2.04e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs7666738	0.515	rs10015315	chr4:98700137	A/G	cg17366294	chr4:99064904	C4orf37	0.53	6.7	0.38	1.27e-10	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9393777	0.513	rs6924727	chr6:26491234	A/G	cg12826209	chr6:26865740	GUSBL1	0.59	6.91	0.39	3.52e-11	Intelligence (multi-trait analysis);
CESC	cis	rs9325144	0.647	rs3759139	chr12:39087609	G/A	cg26384229	chr12:38710491	ALG10B	-0.51	-7.09	-0.4	1.22e-11	Morning vs. evening chronotype;
CESC	cis	rs13095912	0.597	rs112800013	chr3:185313807	A/G	cg11274856	chr3:185301563	NA	0.41	6.36	0.36	8.6e-10	Systolic blood pressure;
CESC	cis	rs9649213	0.593	rs7795176	chr7:97978287	A/C	cg08684580	chr7:98029266	BAIAP2L1	-0.35	-5.8	-0.34	1.85e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs1153858	0.621	rs12913645	chr15:45555066	G/A	cg14582100	chr15:45693742	SPATA5L1	-0.41	-5.45	-0.32	1.16e-7	Homoarginine levels;
CESC	cis	rs4555082	0.874	rs113291192	chr14:105738181	C/T	cg06808227	chr14:105710500	BRF1	-0.61	-6.98	-0.39	2.42e-11	Mean platelet volume;Platelet distribution width;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13680954	chr1:1850738	TMEM52	-0.59	-7.05	-0.4	1.54e-11	Gut microbiome composition (summer);
CESC	cis	rs9910055	0.762	rs11080007	chr17:42265442	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.6	-8.01	-0.44	3.74e-14	Total body bone mineral density;
CESC	cis	rs7914558	1.000	rs7914558	chr10:104775908	G/A	cg08650961	chr10:104748594	CNNM2	0.33	5.52	0.32	7.94e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs8062405	1.000	rs12446589	chr16:28870962	G/A	cg08761264	chr16:28874980	SH2B1	-0.44	-5.37	-0.31	1.7e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs9611565	0.649	rs202657	chr22:41844786	G/T	cg17376030	chr22:41985996	PMM1	-0.77	-8.24	-0.45	8.27e-15	Vitiligo;
CESC	cis	rs425277	0.561	rs925906	chr1:2044054	A/C	cg24578937	chr1:2090814	PRKCZ	-0.32	-5.5	-0.32	9.1e-8	Height;
CESC	cis	rs6748734	1.000	rs11898716	chr2:241828311	A/G	cg04034577	chr2:241836375	C2orf54	-0.48	-7.98	-0.44	4.39e-14	Urinary metabolites;
CESC	cis	rs7647973	0.626	rs4855846	chr3:49683526	G/A	cg13072238	chr3:49761600	GMPPB	-0.45	-5.46	-0.32	1.12e-7	Menarche (age at onset);
CESC	cis	rs9649213	0.593	rs12704983	chr7:97927045	G/A	cg08684580	chr7:98029266	BAIAP2L1	-0.35	-5.68	-0.33	3.49e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs2204008	0.678	rs7299686	chr12:38212307	G/A	cg26384229	chr12:38710491	ALG10B	-0.43	-5.73	-0.33	2.66e-8	Bladder cancer;
CESC	cis	rs10206020	0.885	rs11885392	chr2:1578182	C/A	cg26248373	chr2:1572462	NA	-0.61	-7.12	-0.4	9.87e-12	IgG glycosylation;
CESC	cis	rs9303401	0.659	rs17222691	chr17:56771096	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.01	11.58	0.58	2.38e-25	Cognitive test performance;
CESC	cis	rs7726839	0.574	rs12522955	chr5:639231	C/A	cg16447950	chr5:562315	NA	-0.58	-6.0	-0.35	6.45e-9	Obesity-related traits;
CESC	cis	rs4566357	1.000	rs6705989	chr2:227923320	G/A	cg11843606	chr2:227700838	RHBDD1	-0.42	-5.28	-0.31	2.76e-7	Coronary artery disease;
CESC	cis	rs9486715	0.825	rs211158	chr6:97022938	C/G	cg18709589	chr6:96969512	KIAA0776	-0.46	-6.62	-0.38	1.98e-10	Headache;
CESC	cis	rs2274273	0.837	rs7148171	chr14:55770744	G/C	cg04306507	chr14:55594613	LGALS3	0.31	6.09	0.35	4.01e-9	Protein biomarker;
CESC	cis	rs801193	0.591	rs721717	chr7:66130292	G/T	cg12463550	chr7:65579703	CRCP	-0.49	-6.42	-0.37	6.41e-10	Aortic root size;
CESC	cis	rs7927771	1.000	rs34910028	chr11:47758449	T/C	cg20307385	chr11:47447363	PSMC3	-0.52	-6.37	-0.36	8.3e-10	Subjective well-being;
CESC	cis	rs4689592	0.513	rs3857178	chr4:7066516	G/A	cg26116260	chr4:7069785	GRPEL1	0.99	14.54	0.67	1.24e-35	Monocyte percentage of white cells;
CESC	cis	rs11785693	0.862	rs11781233	chr8:4993653	C/G	cg26367366	chr8:4980734	NA	-0.9	-8.97	-0.48	5.49e-17	Neuroticism (multi-trait analysis);Neuroticism;
CESC	cis	rs9549260	0.755	rs2755216	chr13:41156938	G/A	cg21288729	chr13:41239152	FOXO1	0.63	7.91	0.44	6.83e-14	Red blood cell count;
CESC	cis	rs2549003	1.000	rs2070725	chr5:131821788	C/T	cg21138405	chr5:131827807	IRF1	0.54	9.32	0.5	4.74e-18	Asthma (sex interaction);
CESC	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg02071572	chr4:1403502	NA	0.39	5.76	0.33	2.29e-8	Longevity;
CESC	cis	rs6662572	1.000	rs72688469	chr1:46118393	T/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.52	5.65	0.33	4.18e-8	Blood protein levels;
CESC	cis	rs644799	0.965	rs3016295	chr11:95554311	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	13.94	0.65	1.61e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs73206853	0.764	rs9737665	chr12:111031847	A/C	cg12870014	chr12:110450643	ANKRD13A	0.64	5.7	0.33	3.22e-8	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs3916	0.911	rs7313271	chr12:121152667	C/T	cg21892295	chr12:121157589	UNC119B	-0.36	-5.23	-0.31	3.47e-7	Urinary metabolites (H-NMR features);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19160353	chr10:3827878	KLF6	0.57	6.41	0.37	6.73e-10	Gut microbiome composition (summer);
CESC	cis	rs2486288	0.656	rs7166580	chr15:45571209	C/G	cg21132104	chr15:45694354	SPATA5L1	-0.57	-6.66	-0.38	1.55e-10	Glomerular filtration rate;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg16703126	chr22:38598924	MAFF	-0.48	-6.72	-0.38	1.08e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs10504229	0.775	rs17805074	chr8:58161048	C/T	cg24829409	chr8:58192753	C8orf71	0.67	7.92	0.44	6.49e-14	Developmental language disorder (linguistic errors);
CESC	cis	rs514406	0.584	rs11205997	chr1:53195271	G/C	cg08736216	chr1:53307985	ZYG11A	0.4	6.35	0.36	9.55e-10	Monocyte count;
CESC	cis	rs501120	1.000	rs1746048	chr10:44775824	A/G	cg09554077	chr10:44749378	NA	-0.54	-7.09	-0.4	1.25e-11	Coronary artery disease;Coronary heart disease;
CESC	cis	rs9308433	0.529	rs867444	chr1:214502160	T/C	cg06198575	chr1:214491504	SMYD2	0.5	6.01	0.35	6.23e-9	IgG glycosylation;
CESC	cis	rs5750830	0.649	rs5757664	chr22:39821536	A/G	cg01416388	chr22:39784598	NA	-0.6	-7.51	-0.42	9.01e-13	Intelligence (multi-trait analysis);
CESC	cis	rs2486288	0.656	rs11639420	chr15:45559268	A/C	cg21132104	chr15:45694354	SPATA5L1	-0.56	-6.72	-0.38	1.09e-10	Glomerular filtration rate;
CESC	cis	rs13108904	0.517	rs13134568	chr4:1334289	G/A	cg00684032	chr4:1343700	KIAA1530	0.56	8.59	0.47	7.56e-16	Obesity-related traits;
CESC	cis	rs506597	0.704	rs4729598	chr7:100221867	T/C	cg10426581	chr7:100472382	SRRT	-0.69	-5.34	-0.31	2e-7	Pursuit maintenance gain in psychotic disorders;
CESC	cis	rs10779751	0.770	rs2015818	chr1:11170743	G/A	cg08854313	chr1:11322531	MTOR	0.79	11.29	0.57	2.1e-24	Body mass index;
CESC	cis	rs116095464	0.558	rs6869925	chr5:264036	A/G	cg12570787	chr5:219185	SDHA;CCDC127	0.53	5.49	0.32	9.44e-8	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12391232	chr1:155247117	HCN3	0.61	6.6	0.38	2.27e-10	Gut microbiome composition (summer);
CESC	cis	rs250677	0.687	rs185155	chr5:148455893	T/C	cg18129178	chr5:148520854	ABLIM3	-0.52	-5.85	-0.34	1.45e-8	Breast cancer;
CESC	cis	rs6973256	0.605	rs7808879	chr7:133345471	A/T	cg10665199	chr7:133106180	EXOC4	0.46	6.19	0.36	2.31e-9	Intelligence (multi-trait analysis);
CESC	cis	rs16867321	0.950	rs16867322	chr2:181369403	A/G	cg23363182	chr2:181467187	NA	-0.41	-5.13	-0.3	5.65e-7	Obesity;
CESC	cis	rs2549003	1.000	rs3846732	chr5:131816087	T/C	cg02551604	chr5:131831745	NA	-0.37	-5.24	-0.31	3.21e-7	Asthma (sex interaction);
CESC	cis	rs11758351	1.000	rs17598927	chr6:26184640	C/G	cg23601095	chr6:26197514	HIST1H3D	-0.89	-8.25	-0.45	7.46e-15	Gout;Renal underexcretion gout;
CESC	cis	rs7520050	0.966	rs6662641	chr1:46571509	T/A	cg24296786	chr1:45957014	TESK2	0.41	5.17	0.3	4.63e-7	Red blood cell count;Reticulocyte count;
CESC	cis	rs863345	0.967	rs2873588	chr1:158467615	T/A	cg12129480	chr1:158549410	OR10X1	-0.32	-6.27	-0.36	1.42e-9	Pneumococcal bacteremia;
CESC	cis	rs798554	0.757	rs1182172	chr7:2878103	G/A	cg09658497	chr7:2847517	GNA12	-0.44	-5.87	-0.34	1.28e-8	Height;
CESC	trans	rs11039798	0.544	rs114343057	chr11:48558172	C/T	cg03929089	chr4:120376271	NA	0.62	6.07	0.35	4.44e-9	Axial length;
CESC	cis	rs9916302	0.904	rs4794814	chr17:37696852	G/A	cg20243544	chr17:37824526	PNMT	0.52	6.61	0.38	2.14e-10	Glomerular filtration rate (creatinine);
CESC	trans	rs1557351	0.723	rs6566851	chr18:54723408	T/A	cg11433624	chr6:7146702	RREB1	0.37	6.06	0.35	4.6e-9	Multiple sclerosis (age of onset);
CESC	cis	rs1799949	0.965	rs7223952	chr17:41194885	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.48	6.55	0.37	3.03e-10	Menopause (age at onset);
CESC	cis	rs6088580	0.634	rs6141465	chr20:32967314	T/C	cg24642439	chr20:33292090	TP53INP2	-0.53	-6.97	-0.39	2.55e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs2032447	0.869	rs199752	chr6:26012875	C/T	cg03264133	chr6:25882463	NA	-0.51	-7.11	-0.4	1.05e-11	Intelligence (multi-trait analysis);
CESC	cis	rs6582630	0.519	rs7294292	chr12:38349540	C/T	cg13010199	chr12:38710504	ALG10B	0.48	6.06	0.35	4.62e-9	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs910316	1.000	rs175492	chr14:75545220	A/C	cg16144293	chr14:75469539	EIF2B2	-0.38	-5.1	-0.3	6.44e-7	Height;
CESC	cis	rs875971	1.000	rs7789768	chr7:65938980	A/C	cg18876405	chr7:65276391	NA	0.51	6.82	0.39	6.05e-11	Aortic root size;
CESC	cis	rs1799949	1.000	rs72829113	chr17:41181835	C/T	cg05368731	chr17:41323189	NBR1	0.8	10.6	0.55	4.09e-22	Menopause (age at onset);
CESC	cis	rs1050631	0.592	rs1632169	chr18:33709762	G/C	cg25426722	chr18:33708991	SLC39A6;ELP2	0.52	7.04	0.4	1.63e-11	Esophageal squamous cell cancer (length of survival);
CESC	cis	rs684232	0.563	rs12939528	chr17:524391	C/T	cg15660573	chr17:549704	VPS53	-0.81	-11.99	-0.59	9.07e-27	Prostate cancer;
CESC	cis	rs4654899	0.525	rs12035087	chr1:21471606	T/A	cg05370193	chr1:21551575	ECE1	-0.38	-5.7	-0.33	3.13e-8	Superior frontal gyrus grey matter volume;
CESC	cis	rs7044106	0.762	rs1324473	chr9:123404610	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.68	-9.88	-0.52	8.36e-20	Hip circumference adjusted for BMI;
CESC	cis	rs1538970	0.851	rs2055145	chr1:45926495	C/G	cg05343316	chr1:45956843	TESK2	0.9	12.56	0.61	1.08e-28	Platelet count;
CESC	cis	rs858239	0.508	rs2390754	chr7:23190494	A/G	cg23682824	chr7:23144976	KLHL7	0.45	5.65	0.33	4.12e-8	Cerebrospinal fluid biomarker levels;
CESC	cis	rs7618915	0.571	rs6778844	chr3:52596398	C/T	cg17372223	chr3:52568218	NT5DC2	-0.43	-6.2	-0.36	2.12e-9	Bipolar disorder;
CESC	cis	rs11785400	0.731	rs4644221	chr8:143736984	C/T	cg10596483	chr8:143751796	JRK	-0.41	-5.33	-0.31	2.1e-7	Schizophrenia;
CESC	cis	rs314370	0.951	rs12666989	chr7:100486754	G/C	cg10426581	chr7:100472382	SRRT	0.85	8.23	0.45	8.68e-15	Resting heart rate;
CESC	cis	rs12200560	0.505	rs11153095	chr6:97078592	T/C	cg06623918	chr6:96969491	KIAA0776	-0.44	-5.63	-0.33	4.7e-8	Coronary heart disease;
CESC	cis	rs4819143	0.504	rs6518259	chr21:47317886	C/G	cg14185626	chr21:47401492	COL6A1	0.46	5.12	0.3	5.91e-7	Insulin resistance/response;
CESC	cis	rs853679	0.599	rs149949	chr6:28011516	T/C	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.81	6.45	0.37	5.34e-10	Depression;
CESC	cis	rs2439831	1.000	rs2467743	chr15:43750346	T/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.83	12.14	0.6	2.88e-27	Lung cancer in ever smokers;
CESC	cis	rs6009527	1.000	rs6009188	chr22:49572751	G/A	cg12746016	chr22:49560550	NA	0.34	5.33	0.31	2.09e-7	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);
CESC	cis	rs1499972	0.648	rs62264767	chr3:117642005	A/C	cg07612923	chr3:117604196	NA	0.66	5.98	0.34	7.1e-9	Schizophrenia;
CESC	cis	rs478304	0.718	rs1151490	chr11:65390485	A/C	cg27068330	chr11:65405492	SIPA1	0.46	5.47	0.32	1.03e-7	Acne (severe);
CESC	cis	rs66573146	0.831	rs73088564	chr4:6984553	G/C	cg00086871	chr4:6988644	TBC1D14	1.17	7.59	0.42	5.62e-13	Granulocyte percentage of myeloid white cells;
CESC	cis	rs1799949	1.000	rs12936816	chr17:41301709	C/T	cg23758822	chr17:41437982	NA	1.02	15.64	0.69	1.65e-39	Menopause (age at onset);
CESC	cis	rs12142240	0.738	rs10489769	chr1:46806703	A/G	cg00530320	chr1:46809349	NSUN4	0.59	7.87	0.44	9.26e-14	Menopause (age at onset);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg26029250	chr17:40695519	NAGLU	0.5	6.79	0.38	7.48e-11	Fibrinogen levels;
CESC	cis	rs13385	0.769	rs17286613	chr5:139581205	T/G	cg26211634	chr5:139558579	C5orf32	0.49	5.47	0.32	1.02e-7	Atrial fibrillation;
CESC	cis	rs10737909	0.510	rs12025158	chr1:15539259	A/G	cg21012057	chr1:15538911	TMEM51	0.61	9.07	0.49	2.67e-17	Migraine;
CESC	cis	rs1552244	1.000	rs2272123	chr3:10140115	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.8	-10.93	-0.56	3.47e-23	Alzheimer's disease;
CESC	cis	rs3749237	0.595	rs3870337	chr3:49557095	G/T	cg07636037	chr3:49044803	WDR6	0.63	9.29	0.5	6.03e-18	Resting heart rate;
CESC	cis	rs921968	0.565	rs11896209	chr2:219599268	C/T	cg02176678	chr2:219576539	TTLL4	-0.44	-7.82	-0.43	1.23e-13	Mean corpuscular hemoglobin concentration;
CESC	cis	rs3126085	0.800	rs55650366	chr1:152279920	A/G	cg03465714	chr1:152285911	FLG	0.5	5.71	0.33	2.96e-8	Atopic dermatitis;
CESC	cis	rs11828289	0.660	rs77575887	chr11:23174504	T/A	cg20040320	chr11:23191996	NA	-0.68	-5.88	-0.34	1.25e-8	Cancer;
CESC	cis	rs2952156	1.000	rs2934971	chr17:37854507	G/T	cg00129232	chr17:37814104	STARD3	-0.69	-8.96	-0.48	6.07e-17	Asthma;
CESC	cis	rs2180341	0.889	rs9321074	chr6:127618019	G/A	cg24812749	chr6:127587940	RNF146	1.06	15.35	0.69	1.74e-38	Breast cancer;
CESC	cis	rs8038465	0.615	rs6495075	chr15:73981005	A/G	cg15420318	chr15:73925796	NPTN	0.48	6.98	0.39	2.41e-11	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs1387259	0.931	rs11168474	chr12:48621384	A/C	cg24011408	chr12:48396354	COL2A1	0.44	6.18	0.36	2.36e-9	Obstructive sleep apnea trait (apnea hypopnea index);
CESC	cis	rs9549260	0.753	rs9532563	chr13:41160270	T/C	cg21288729	chr13:41239152	FOXO1	0.53	5.22	0.31	3.57e-7	Red blood cell count;
CESC	cis	rs12956009	0.583	rs11662486	chr18:44868325	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.5	6.45	0.37	5.28e-10	Educational attainment (years of education);
CESC	cis	rs10489202	0.657	rs201540	chr1:167992883	G/A	cg24449463	chr1:168025552	DCAF6	-0.4	-5.13	-0.3	5.62e-7	Schizophrenia;
CESC	cis	rs863345	0.604	rs6699473	chr1:158495209	C/T	cg12129480	chr1:158549410	OR10X1	-0.35	-6.86	-0.39	4.75e-11	Pneumococcal bacteremia;
CESC	cis	rs1062177	1.000	rs2915877	chr5:151150601	C/G	cg12924095	chr5:151150029	G3BP1	0.48	6.19	0.36	2.3e-9	Preschool internalizing problems;
CESC	cis	rs7308134	0.766	rs79208794	chr12:1990170	C/G	cg19708984	chr12:1973340	CACNA2D4	0.53	5.07	0.3	7.4e-7	QRS duration in Tripanosoma cruzi seropositivity;
CESC	cis	rs7772486	0.624	rs6930154	chr6:146025662	C/T	cg05347473	chr6:146136440	FBXO30	-0.54	-7.06	-0.4	1.5e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9457247	1.000	rs422562	chr6:167406318	A/G	cg23791538	chr6:167370224	RNASET2	-0.64	-9.16	-0.49	1.47e-17	Crohn's disease;
CESC	cis	rs4975616	0.804	rs456366	chr5:1337070	T/C	cg06550200	chr5:1325588	CLPTM1L	-0.67	-9.94	-0.52	5.33e-20	Lung cancer;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg18313694	chr15:45480185	SHF	0.47	6.05	0.35	4.8e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	trans	rs7107217	1.000	rs1873872	chr11:129473993	A/T	cg27400923	chr3:185826929	ETV5	0.48	6.11	0.35	3.48e-9	Breast cancer;Type 2 diabetes;
CESC	cis	rs40363	0.645	rs250627	chr16:3527050	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.52	-6.6	-0.38	2.18e-10	Tuberculosis;
CESC	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg16405210	chr4:1374714	KIAA1530	-0.91	-12.03	-0.59	6.78e-27	Longevity;
CESC	cis	rs7659604	0.676	rs7691955	chr4:122700462	A/T	cg19748678	chr4:122722346	EXOSC9	0.72	9.4	0.5	2.74e-18	Type 2 diabetes;
CESC	cis	rs2249694	0.960	rs4351776	chr10:135415572	G/T	cg19469447	chr10:135341870	CYP2E1	0.37	5.22	0.31	3.55e-7	Obesity-related traits;
CESC	cis	rs4566357	0.615	rs2272204	chr2:227915601	G/T	cg05526886	chr2:227700861	RHBDD1	-0.5	-6.54	-0.37	3.14e-10	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08974656	chr2:96931567	CIAO1;TMEM127	0.55	6.26	0.36	1.58e-9	Gut microbiome composition (summer);
CESC	cis	rs735539	1.000	rs6490604	chr13:21284828	A/G	cg04906043	chr13:21280425	IL17D	-0.36	-5.15	-0.3	5.02e-7	Dental caries;
CESC	cis	rs713587	0.967	rs6749422	chr2:25150011	C/G	cg01884057	chr2:25150051	NA	0.42	7.78	0.43	1.6e-13	Body mass index in non-asthmatics;
CESC	cis	rs12597458	0.789	rs7186207	chr16:72035359	C/T	cg01557791	chr16:72042693	DHODH	-0.83	-12.7	-0.62	3.56e-29	Prostate cancer;
CESC	cis	rs8031584	0.723	rs711224	chr15:31127921	G/C	cg08109568	chr15:31115862	NA	0.74	10.28	0.53	4.44e-21	Huntington's disease progression;
CESC	cis	rs425277	0.628	rs3128340	chr1:2047496	C/G	cg04315214	chr1:2043799	PRKCZ	0.64	10.88	0.56	5.03e-23	Height;
CESC	cis	rs9910055	0.659	rs227580	chr17:42223068	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	-0.74	-10.18	-0.53	9.41e-21	Total body bone mineral density;
CESC	cis	rs9916302	0.851	rs612209	chr17:37442713	G/C	cg15445000	chr17:37608096	MED1	-0.4	-6.55	-0.37	3.05e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs938554	0.737	rs10939637	chr4:9977577	A/G	cg00071950	chr4:10020882	SLC2A9	0.48	5.68	0.33	3.49e-8	Blood metabolite levels;
CESC	cis	rs60843830	1.000	rs62114548	chr2:274672	C/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.8	10.3	0.53	3.86e-21	Spherical equivalent (joint analysis main effects and education interaction);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg16620766	chr12:122268197	SETD1B	0.45	6.14	0.35	3.06e-9	Fibrinogen levels;
CESC	cis	rs698833	0.828	rs6705951	chr2:44534012	A/C	cg04920474	chr2:44395004	PPM1B	0.39	5.55	0.32	6.77e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs17666538	0.535	rs1669658	chr8:607380	A/G	cg02524346	chr8:600233	NA	0.85	6.42	0.37	6.4e-10	IgG glycosylation;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg25713684	chr10:105127687	TAF5	0.47	6.3	0.36	1.22e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs7811142	0.830	rs6965458	chr7:99973402	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.07	10.34	0.54	2.91e-21	Platelet count;
CESC	cis	rs599083	0.530	rs583545	chr11:68178635	T/C	cg16797656	chr11:68205561	LRP5	-0.38	-5.09	-0.3	6.79e-7	Bone mineral density (spine);
CESC	cis	rs780096	0.587	rs6743819	chr2:27567407	G/T	cg21248554	chr2:27665150	KRTCAP3	-0.35	-7.43	-0.42	1.45e-12	Total body bone mineral density;
CESC	trans	rs61931739	0.500	rs9669027	chr12:34583528	C/T	cg26384229	chr12:38710491	ALG10B	-0.53	-7.43	-0.42	1.46e-12	Morning vs. evening chronotype;
CESC	cis	rs10426930	0.700	rs7246791	chr19:5013776	T/C	cg18115693	chr19:4968519	KDM4B	-0.42	-5.29	-0.31	2.62e-7	Monocyte percentage of white cells;
CESC	cis	rs4523957	0.583	rs8068508	chr17:2047624	A/G	cg16513277	chr17:2031491	SMG6	-0.77	-11.43	-0.57	7.26e-25	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs2380220	0.678	rs4308568	chr6:96009525	A/C	cg15832292	chr6:96025679	MANEA	-0.6	-6.51	-0.37	3.77e-10	Behavioural disinhibition (generation interaction);
CESC	cis	rs727505	1.000	rs77718560	chr7:124514544	T/A	cg23710748	chr7:124431027	NA	-0.48	-7.52	-0.42	8.73e-13	Lewy body disease;
CESC	cis	rs11122272	0.525	rs61835222	chr1:231537917	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-6.98	-0.39	2.38e-11	Hemoglobin concentration;
CESC	cis	rs9787249	1.000	rs9787249	chr1:40212878	G/A	cg19912559	chr1:40204330	PPIE	0.42	6.5	0.37	3.87e-10	Blood protein levels;
CESC	cis	rs1862618	0.853	rs190414	chr5:56116772	C/A	cg22800045	chr5:56110881	MAP3K1	0.83	10.29	0.53	4.05e-21	Initial pursuit acceleration;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg26251429	chr2:28113398	BRE;RBKS;LOC100302650	-0.44	-6.36	-0.36	8.64e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs1799949	0.965	rs11654051	chr17:41419656	C/T	cg25072359	chr17:41440525	NA	0.49	6.51	0.37	3.85e-10	Menopause (age at onset);
CESC	cis	rs1050631	0.574	rs1789507	chr18:33732354	A/C	cg25426722	chr18:33708991	SLC39A6;ELP2	0.59	8.21	0.45	9.72e-15	Esophageal squamous cell cancer (length of survival);
CESC	cis	rs7949030	0.591	rs12049914	chr11:62369436	C/G	cg13298116	chr11:62369859	EML3;MTA2	0.64	9.31	0.5	5.15e-18	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs875971	0.545	rs73146609	chr7:65767464	A/G	cg25405998	chr7:65216604	CCT6P1	0.51	5.71	0.33	2.95e-8	Aortic root size;
CESC	cis	rs7772486	0.641	rs960385	chr6:146371074	G/A	cg23711669	chr6:146136114	FBXO30	0.84	11.08	0.56	1.1e-23	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9311474	0.508	rs11720159	chr3:52617802	T/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.5	7.35	0.41	2.52e-12	Electroencephalogram traits;
CESC	cis	rs3981351	0.528	rs12768908	chr10:115443894	C/T	cg24846397	chr10:115438155	CASP7	-0.34	-5.27	-0.31	2.76e-7	Obesity-related traits;
CESC	cis	rs8031584	0.918	rs34693097	chr15:31253984	A/G	cg08109568	chr15:31115862	NA	-0.71	-9.5	-0.5	1.29e-18	Huntington's disease progression;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg17347471	chr5:52405518	MOCS2	-0.46	-6.32	-0.36	1.08e-9	Asthma;
CESC	cis	rs4819052	0.851	rs1999335	chr21:46670613	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.45	5.6	0.33	5.33e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs7208859	0.623	rs73267858	chr17:29059737	A/G	cg13385521	chr17:29058706	SUZ12P	0.81	6.53	0.37	3.28e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs1538970	1.000	rs4520450	chr1:45834773	A/G	cg06784218	chr1:46089804	CCDC17	0.34	5.66	0.33	4e-8	Platelet count;
CESC	cis	rs2243480	1.000	rs6460261	chr7:65215580	T/C	cg18252515	chr7:66147081	NA	1.26	11.9	0.59	1.98e-26	Diabetic kidney disease;
CESC	trans	rs921968	0.541	rs588770	chr2:219494638	T/C	cg15547669	chr20:2781122	CPXM1	0.37	6.16	0.35	2.7e-9	Mean corpuscular hemoglobin concentration;
CESC	cis	rs11122272	0.764	rs4486439	chr1:231477470	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.51	-7.13	-0.4	9.56e-12	Hemoglobin concentration;
CESC	cis	rs11077998	0.933	rs7215465	chr17:80532532	C/T	cg10255544	chr17:80519551	FOXK2	0.55	8.73	0.47	2.83e-16	Reticulocyte fraction of red cells;
CESC	cis	rs1707322	0.963	rs10789478	chr1:46350506	C/T	cg03146154	chr1:46216737	IPP	0.78	10.67	0.55	2.45e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs4665809	1.000	rs1470097	chr2:26312840	A/G	cg08470875	chr2:26401718	FAM59B	-0.48	-5.34	-0.31	2e-7	Gut microbiome composition (summer);
CESC	cis	rs3733585	0.699	rs7663097	chr4:9966791	T/C	cg02734326	chr4:10020555	SLC2A9	-0.39	-5.58	-0.32	5.91e-8	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs3733585	0.699	rs6449172	chr4:9966036	A/T	cg02734326	chr4:10020555	SLC2A9	-0.42	-5.87	-0.34	1.32e-8	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs7833986	0.501	rs2953910	chr8:56968761	C/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.61	7.55	0.42	6.89e-13	Height;
CESC	cis	rs9926296	0.572	rs8047581	chr16:89884502	C/T	cg04287289	chr16:89883240	FANCA	0.64	9.02	0.48	3.83e-17	Vitiligo;
CESC	cis	rs1691799	0.899	rs1168325	chr12:66728234	C/G	cg16791601	chr12:66731901	HELB	-0.73	-12.46	-0.61	2.25e-28	White blood cell count (basophil);
CESC	cis	rs4746818	0.892	rs10823298	chr10:70867083	T/C	cg04149295	chr10:70884716	VPS26A	0.56	5.13	0.3	5.63e-7	Left atrial antero-posterior diameter;
CESC	trans	rs7618501	0.735	rs9876508	chr3:49780844	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.58	-8.4	-0.46	2.71e-15	Intelligence (multi-trait analysis);
CESC	cis	rs7811142	1.000	rs67163493	chr7:100023838	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.11	11.1	0.56	9.54e-24	Platelet count;
CESC	cis	rs2243480	0.666	rs1880311	chr7:65276752	G/C	cg18252515	chr7:66147081	NA	1.21	11.42	0.57	7.99e-25	Diabetic kidney disease;
CESC	cis	rs644799	0.648	rs1016031	chr11:95473365	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	-0.44	-5.89	-0.34	1.14e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs11122272	0.735	rs2066140	chr1:231504311	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.53	-7.37	-0.41	2.22e-12	Hemoglobin concentration;
CESC	cis	rs9309473	0.583	rs6718864	chr2:73574591	A/G	cg20560298	chr2:73613845	ALMS1	-0.46	-6.49	-0.37	4.21e-10	Metabolite levels;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg02585102	chr12:49525240	TUBA1B	-0.4	-6.06	-0.35	4.54e-9	Gambling;
CESC	cis	rs5769707	0.609	rs2071890	chr22:50001291	G/A	cg20744362	chr22:50050164	C22orf34	0.36	5.27	0.31	2.82e-7	Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs3820068	0.581	rs6693694	chr1:15980135	G/T	cg13390004	chr1:15929781	NA	0.36	5.69	0.33	3.37e-8	Systolic blood pressure;
CESC	cis	rs854765	0.655	rs4470201	chr17:17844870	G/A	cg04398451	chr17:18023971	MYO15A	-0.67	-9.61	-0.51	5.88e-19	Total body bone mineral density;
CESC	cis	rs9611565	0.568	rs5751159	chr22:42175365	G/A	cg06481639	chr22:41940642	POLR3H	0.47	5.28	0.31	2.75e-7	Vitiligo;
CESC	cis	rs7845219	0.539	rs13271644	chr8:95853948	A/G	cg09323728	chr8:95962352	TP53INP1	-0.26	-5.12	-0.3	5.82e-7	Type 2 diabetes;
CESC	cis	rs7219014	1	rs7219014	chr17:37624790	A/G	cg15445000	chr17:37608096	MED1	0.4	6.37	0.36	8.09e-10	Urinary metabolites;
CESC	cis	rs28489187	0.617	rs233109	chr1:85783101	T/C	cg16011679	chr1:85725395	C1orf52	0.46	5.55	0.32	6.97e-8	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	cis	rs6964587	1.000	rs6968870	chr7:91661111	G/C	cg17063962	chr7:91808500	NA	0.58	8.07	0.44	2.53e-14	Breast cancer;
CESC	cis	rs9913156	0.696	rs72835620	chr17:4558128	G/A	cg00122941	chr17:4613640	ARRB2	0.85	9.92	0.52	6.24e-20	Lymphocyte counts;
CESC	cis	rs3858526	0.628	rs1840177	chr11:5944627	T/G	cg05234568	chr11:5960015	NA	0.65	8.67	0.47	4.54e-16	DNA methylation (variation);
CESC	cis	rs9486715	0.830	rs4425602	chr6:96893906	G/A	cg06623918	chr6:96969491	KIAA0776	0.92	14.36	0.66	5.75e-35	Headache;
CESC	cis	rs10504229	1.000	rs67546820	chr8:58168567	G/A	cg05313129	chr8:58192883	C8orf71	-0.53	-6.16	-0.35	2.69e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs9911578	1.000	rs368186	chr17:56736659	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.27	0.31	2.87e-7	Intelligence (multi-trait analysis);
CESC	cis	rs3733585	0.699	rs6449157	chr4:9960442	G/A	cg02734326	chr4:10020555	SLC2A9	-0.44	-6.11	-0.35	3.58e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs6952808	0.500	rs3778996	chr7:2177190	G/A	cg08027265	chr7:2291960	NA	-0.47	-7.2	-0.4	6.11e-12	Bipolar disorder and schizophrenia;
CESC	cis	rs62064224	0.791	rs2344977	chr17:30720573	C/G	cg12855166	chr17:30846586	MYO1D	0.4	5.05	0.3	8.34e-7	Schizophrenia;
CESC	cis	rs10504229	1.000	rs67630725	chr8:58185580	G/A	cg14926445	chr8:58193284	C8orf71	-0.51	-5.52	-0.32	8.28e-8	Developmental language disorder (linguistic errors);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02753233	chr17:18218331	TOP3A;SMCR8	0.63	6.82	0.39	6.32e-11	Gut microbiome composition (summer);
CESC	cis	rs801193	0.569	rs2707847	chr7:66202871	C/G	cg10691866	chr7:65817282	TPST1	-0.32	-5.44	-0.32	1.19e-7	Aortic root size;
CESC	cis	rs2797160	1.000	rs2747724	chr6:126004935	G/A	cg05901451	chr6:126070800	HEY2	-0.45	-6.53	-0.37	3.43e-10	Endometrial cancer;
CESC	cis	rs7586879	0.598	rs6545806	chr2:25124348	G/A	cg01884057	chr2:25150051	NA	0.38	7.37	0.41	2.19e-12	Body mass index;
CESC	cis	rs9858542	0.903	rs9875617	chr3:49634696	G/A	cg07274523	chr3:49395745	GPX1	0.65	8.23	0.45	8.58e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	trans	rs7173947	0.646	rs11634297	chr15:95267564	A/T	cg05226323	chr17:71228757	FAM104A;C17orf80	-0.46	-6.11	-0.35	3.48e-9	Hematological and biochemical traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09163998	chr19:48103707	NA	-0.63	-6.78	-0.38	7.85e-11	Gut microbiome composition (summer);
CESC	cis	rs9322193	0.923	rs9285524	chr6:150015258	G/A	cg05861140	chr6:150128134	PCMT1	-0.36	-5.25	-0.31	3.16e-7	Lung cancer;
CESC	cis	rs2243480	1.000	rs34136756	chr7:65381256	A/G	cg25894440	chr7:65020034	NA	-0.59	-5.07	-0.3	7.57e-7	Diabetic kidney disease;
CESC	cis	rs10883723	0.810	rs7074343	chr10:104283165	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.55	7.59	0.42	5.46e-13	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs1059312	0.808	rs4482069	chr12:129294252	G/C	cg09035930	chr12:129282057	SLC15A4	0.69	9.2	0.49	1.1e-17	Systemic lupus erythematosus;
CESC	cis	rs2439831	0.867	rs28415933	chr15:43635800	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.89	10.73	0.55	1.57e-22	Lung cancer in ever smokers;
CESC	cis	rs17253792	0.822	rs77033617	chr14:56129746	T/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.81	5.68	0.33	3.46e-8	Putamen volume;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg02464656	chr6:44214659	HSP90AB1	-0.44	-6.09	-0.35	3.9e-9	Asthma;
CESC	cis	rs11958404	0.932	rs60504573	chr5:157436786	T/A	cg05962755	chr5:157440814	NA	0.59	6.43	0.37	5.93e-10	IgG glycosylation;
CESC	cis	rs6982240	1.000	rs6982240	chr8:142257378	A/T	cg00131261	chr8:142287264	NA	-0.43	-6.47	-0.37	4.59e-10	Tonsillectomy;
CESC	cis	rs2075371	0.863	rs1421479	chr7:133949345	T/G	cg11752832	chr7:134001865	SLC35B4	0.52	6.77	0.38	8.12e-11	Mean platelet volume;
CESC	cis	rs7267979	0.833	rs6138556	chr20:25243310	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.81	14.68	0.67	4.28e-36	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs6502050	0.835	rs4789744	chr17:80101506	A/C	cg11859384	chr17:80120422	CCDC57	-0.38	-5.11	-0.3	6.21e-7	Life satisfaction;
CESC	cis	rs7927771	0.524	rs6485773	chr11:47763509	A/G	cg20307385	chr11:47447363	PSMC3	0.61	8.6	0.47	7.26e-16	Subjective well-being;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg26290114	chr13:52159332	WDFY2	0.47	6.32	0.36	1.11e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs1003719	0.646	rs9985082	chr21:38501021	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-8.47	-0.46	1.69e-15	Eye color traits;
CESC	cis	rs9399401	0.677	rs11155241	chr6:142664439	T/A	cg04461802	chr6:142623433	GPR126	0.35	5.09	0.3	6.91e-7	Chronic obstructive pulmonary disease;
CESC	cis	rs798502	0.522	rs7790322	chr7:2830498	C/T	cg09658497	chr7:2847517	GNA12	-0.46	-7.03	-0.4	1.78e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Inflammatory bowel disease;Waist circumference adjusted for BMI in non-smokers;Ulcerative colitis;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
CESC	cis	rs2204008	0.811	rs11525004	chr12:38333807	T/A	cg13010199	chr12:38710504	ALG10B	0.48	6.11	0.35	3.53e-9	Bladder cancer;
CESC	cis	rs7666738	0.830	rs4699589	chr4:98973889	A/G	cg17366294	chr4:99064904	C4orf37	0.59	8.43	0.46	2.31e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs763121	0.853	rs4821811	chr22:39075145	C/T	cg06544989	chr22:39130855	UNC84B	0.52	9.07	0.49	2.76e-17	Menopause (age at onset);
CESC	cis	rs1552244	1.000	rs17032276	chr3:10076975	A/C	cg08888203	chr3:10149979	C3orf24	0.46	5.94	0.34	9.05e-9	Alzheimer's disease;
CESC	cis	rs1448094	0.556	rs11611968	chr12:86168022	G/A	cg00310523	chr12:86230176	RASSF9	0.41	6.23	0.36	1.85e-9	Major depressive disorder;
CESC	cis	rs9733	0.596	rs11204687	chr1:150629880	C/A	cg17724175	chr1:150552817	MCL1	0.44	7.21	0.41	5.75e-12	Tonsillectomy;
CESC	cis	rs13191362	1.000	rs73035012	chr6:162997279	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.83	8.39	0.46	3.02e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs3733585	0.699	rs6449177	chr4:9968050	T/C	cg02734326	chr4:10020555	SLC2A9	-0.39	-5.42	-0.32	1.32e-7	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs929354	0.772	rs1182438	chr7:157027438	G/A	cg05182265	chr7:156933206	UBE3C	0.48	7.11	0.4	1.05e-11	Body mass index;
CESC	cis	rs6088580	0.634	rs6120666	chr20:33090718	A/G	cg08999081	chr20:33150536	PIGU	0.66	11.69	0.58	9.97e-26	Glomerular filtration rate (creatinine);
CESC	cis	rs4727027	0.933	rs6464940	chr7:148826309	G/T	cg23583168	chr7:148888333	NA	-0.74	-10.89	-0.56	4.6e-23	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs4076764	0.914	rs7536270	chr1:163377379	T/C	cg06092702	chr1:163392909	NA	-0.4	-5.94	-0.34	8.76e-9	Motion sickness;
CESC	trans	rs35110281	0.714	rs7277539	chr21:45053011	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.52	6.85	0.39	5.05e-11	Mean corpuscular volume;
CESC	trans	rs61931739	0.534	rs1586410	chr12:33999142	C/T	cg26384229	chr12:38710491	ALG10B	0.58	8.06	0.44	2.57e-14	Morning vs. evening chronotype;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19795592	chr19:40932176	SERTAD1	-0.65	-7.77	-0.43	1.7e-13	Gut microbiome composition (summer);
CESC	trans	rs10242455	0.702	rs78218664	chr7:99154381	C/A	cg09045935	chr12:6379348	NA	0.91	7.03	0.4	1.73e-11	Blood metabolite levels;
CESC	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg23978390	chr7:1156363	C7orf50	0.61	8.77	0.47	2.21e-16	Longevity;Endometriosis;
CESC	cis	rs10887741	0.624	rs6586092	chr10:89428994	A/T	cg13926569	chr10:89418898	PAPSS2	0.46	7.37	0.41	2.23e-12	Exercise (leisure time);
CESC	cis	rs9911578	1.000	rs8076121	chr17:57041699	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.38	5.08	0.3	7.21e-7	Intelligence (multi-trait analysis);
CESC	cis	rs7659604	0.539	rs3217771	chr4:122739483	G/A	cg20573242	chr4:122745356	CCNA2	0.62	7.64	0.42	3.94e-13	Type 2 diabetes;
CESC	cis	rs6998277	0.830	rs7017839	chr8:103610769	G/C	cg10187029	chr8:103597600	NA	0.74	9.55	0.51	9.29e-19	Migraine;
CESC	cis	rs8062405	0.723	rs4788077	chr16:28569764	G/C	cg07382826	chr16:28625726	SULT1A1	0.39	6.34	0.36	9.83e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs6088590	1.000	rs2378256	chr20:33292127	G/C	cg08999081	chr20:33150536	PIGU	0.59	8.82	0.48	1.54e-16	Coronary artery disease;
CESC	cis	rs1559088	0.947	rs12461297	chr19:33559245	A/G	cg27124370	chr19:33622961	WDR88	0.44	5.46	0.32	1.1e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs9611565	0.649	rs5758344	chr22:41817685	G/A	cg17376030	chr22:41985996	PMM1	-0.74	-7.8	-0.43	1.42e-13	Vitiligo;
CESC	cis	rs782590	0.967	rs782592	chr2:55843875	T/A	cg18811423	chr2:55921094	PNPT1	0.64	9.21	0.49	1.06e-17	Metabolic syndrome;
CESC	cis	rs3892630	0.824	rs12327732	chr19:33221767	C/T	cg22980127	chr19:33182716	NUDT19	1.03	11.32	0.57	1.67e-24	Red blood cell traits;
CESC	cis	rs9549260	0.755	rs1923249	chr13:41143881	C/A	cg21288729	chr13:41239152	FOXO1	0.66	8.4	0.46	2.69e-15	Red blood cell count;
CESC	cis	rs12142240	0.738	rs41293275	chr1:46806429	A/T	cg10495392	chr1:46806563	NSUN4	0.59	6.36	0.36	8.9e-10	Menopause (age at onset);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg19418648	chr5:176789979	RGS14	-0.38	-6.4	-0.37	7.03e-10	Gambling;
CESC	cis	rs2549003	1.000	rs9282762	chr5:131822055	T/C	cg21138405	chr5:131827807	IRF1	0.54	9.32	0.5	4.74e-18	Asthma (sex interaction);
CESC	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg07092213	chr7:1199455	ZFAND2A	-0.43	-5.81	-0.34	1.79e-8	Longevity;Endometriosis;
CESC	cis	rs2929278	0.617	rs3087657	chr15:44063859	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.45	6.95	0.39	2.8e-11	Schizophrenia;
CESC	cis	rs2425143	1.000	rs2425142	chr20:34350346	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.8	-7.71	-0.43	2.53e-13	Blood protein levels;
CESC	cis	rs2072732	0.861	rs12048975	chr1:2962225	T/C	cg15211996	chr1:2936768	ACTRT2	0.34	5.44	0.32	1.19e-7	Plateletcrit;
CESC	cis	rs941873	0.803	rs2105461	chr10:81101679	A/G	cg11057378	chr10:81107060	PPIF	-0.36	-5.86	-0.34	1.38e-8	Height;
CESC	cis	rs8177253	1.000	rs3811647	chr3:133484029	G/A	cg12373951	chr3:133503437	NA	0.41	6.09	0.35	3.96e-9	Iron status biomarkers;
CESC	cis	rs1975974	1.000	rs1985718	chr17:21731656	C/T	cg18423549	chr17:21743878	NA	-0.54	-7.26	-0.41	4.38e-12	Psoriasis;
CESC	cis	rs9325144	0.555	rs6582607	chr12:38717678	T/C	cg26384229	chr12:38710491	ALG10B	-0.58	-7.99	-0.44	4.15e-14	Morning vs. evening chronotype;
CESC	cis	rs936229	0.813	rs1378938	chr15:75096443	T/C	cg14664628	chr15:75095509	CSK	-0.93	-13.72	-0.64	9.83e-33	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CESC	cis	rs9649213	0.574	rs9648908	chr7:97945236	C/T	cg21770322	chr7:97807741	LMTK2	0.54	8.17	0.45	1.31e-14	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs1153858	0.621	rs1706824	chr15:45579948	C/T	cg14582100	chr15:45693742	SPATA5L1	0.4	5.29	0.31	2.52e-7	Homoarginine levels;
CESC	trans	rs116095464	0.558	rs62347677	chr5:227453	A/G	cg00938859	chr5:1591904	SDHAP3	0.61	6.7	0.38	1.23e-10	Breast cancer;
CESC	cis	rs3096299	0.563	rs4600467	chr16:89562516	C/T	cg00750074	chr16:89608354	SPG7	-0.43	-6.23	-0.36	1.82e-9	Multiple myeloma (IgH translocation);
CESC	cis	rs11098499	0.909	rs7659501	chr4:120371552	G/T	cg24375607	chr4:120327624	NA	0.47	5.89	0.34	1.14e-8	Corneal astigmatism;
CESC	cis	rs643506	0.845	rs7114594	chr11:111768113	A/G	cg09085632	chr11:111637200	PPP2R1B	0.4	5.14	0.3	5.26e-7	Breast cancer;
CESC	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg03461704	chr1:205818484	PM20D1	0.42	5.08	0.3	7.13e-7	Menarche (age at onset);
CESC	cis	rs9640161	0.663	rs1916932	chr7:150021644	T/C	cg21361702	chr7:150065534	REPIN1	0.46	5.42	0.32	1.37e-7	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs853679	0.517	rs4713146	chr6:28111536	A/T	cg26335602	chr6:28129616	ZNF389	0.53	6.86	0.39	4.94e-11	Depression;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg27326469	chr22:47133964	CERK	-0.49	-6.56	-0.37	2.78e-10	Ulcerative colitis;
CESC	cis	rs1881797	1.000	rs10925062	chr1:247658978	G/C	cg18198730	chr1:247681584	NA	0.63	7.82	0.43	1.27e-13	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs2645694	0.626	rs2645704	chr4:77830805	T/C	cg18351406	chr4:77819688	ANKRD56	0.52	6.31	0.36	1.14e-9	Emphysema distribution in smoking;
CESC	cis	rs6952808	0.689	rs2008263	chr7:2048335	A/G	cg02951883	chr7:2050386	MAD1L1	-0.56	-7.4	-0.41	1.75e-12	Bipolar disorder and schizophrenia;
CESC	cis	rs7845219	0.544	rs6987400	chr8:95921295	T/C	cg16049864	chr8:95962084	TP53INP1	-0.49	-7.22	-0.41	5.48e-12	Type 2 diabetes;
CESC	cis	rs1008375	0.872	rs2315552	chr4:17627294	A/G	cg04450456	chr4:17643702	FAM184B	0.38	5.47	0.32	1.05e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs3096299	0.606	rs4785573	chr16:89565403	A/G	cg08392591	chr16:89556376	ANKRD11	0.42	5.06	0.3	7.68e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs8141529	0.748	rs715531	chr22:29282679	A/G	cg15103426	chr22:29168792	CCDC117	0.61	8.08	0.44	2.34e-14	Lymphocyte counts;
CESC	cis	rs7301826	0.627	rs34103763	chr12:131290149	G/A	cg11011512	chr12:131303247	STX2	-0.45	-5.46	-0.32	1.1e-7	Plasma plasminogen activator levels;
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg01596986	chr13:48611463	NUDT15	-0.41	-6.26	-0.36	1.54e-9	Vertical cup-disc ratio;
CESC	cis	rs5758659	0.653	rs133383	chr22:42473603	C/T	cg04733989	chr22:42467013	NAGA	0.41	5.53	0.32	7.61e-8	Cognitive function;
CESC	cis	rs17401966	0.898	rs11587495	chr1:10448999	T/C	cg15208524	chr1:10270712	KIF1B	0.41	5.19	0.3	4.15e-7	Hepatocellular carcinoma;
CESC	cis	rs11676348	0.846	rs6723449	chr2:218997580	C/T	cg00012203	chr2:219082015	ARPC2	0.56	7.38	0.41	2e-12	Ulcerative colitis;
CESC	cis	rs10089	1.000	rs2898096	chr5:127433214	C/T	cg19767477	chr5:127420684	SLC12A2	-0.42	-5.7	-0.33	3.26e-8	Ileal carcinoids;
CESC	cis	rs12681366	0.537	rs10956913	chr8:95483687	G/A	cg13257157	chr8:95487014	RAD54B	0.46	5.64	0.33	4.39e-8	Nonsyndromic cleft lip with cleft palate;
CESC	cis	rs815815	0.583	rs11125126	chr2:47395379	C/T	cg27223769	chr2:47403360	CALM2	-0.44	-5.13	-0.3	5.48e-7	Dialysis-related mortality;
CESC	cis	rs2637266	0.599	rs846574	chr10:78503082	G/A	cg18941641	chr10:78392320	NA	0.42	7.82	0.43	1.26e-13	Pulmonary function;
CESC	cis	rs7666738	0.830	rs4619898	chr4:98959646	G/A	cg17366294	chr4:99064904	C4orf37	0.59	8.45	0.46	1.9e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4665809	0.590	rs7260	chr2:26413917	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.96	-11.59	-0.58	2.11e-25	Gut microbiome composition (summer);
CESC	cis	rs6446731	0.614	rs6446727	chr4:3274488	T/A	cg08886695	chr4:3369023	RGS12	-0.37	-5.44	-0.32	1.2e-7	Mean platelet volume;
CESC	cis	rs9914988	0.778	rs35398767	chr17:27122960	A/T	cg20469991	chr17:27169893	C17orf63	-0.48	-5.25	-0.31	3.18e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CESC	cis	rs7267979	1.000	rs4813563	chr20:25365340	T/C	cg08601574	chr20:25228251	PYGB	-0.38	-5.49	-0.32	9.43e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs4665809	0.838	rs2243834	chr2:26357748	A/C	cg22920501	chr2:26401640	FAM59B	0.66	8.25	0.45	7.35e-15	Gut microbiome composition (summer);
CESC	cis	rs1707322	1.000	rs1622208	chr1:46498375	A/G	cg06784218	chr1:46089804	CCDC17	-0.37	-6.36	-0.36	8.8e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs3820068	0.603	rs35509554	chr1:15993514	C/T	cg17385448	chr1:15911702	AGMAT	0.45	7.27	0.41	4.1e-12	Systolic blood pressure;
CESC	cis	rs16854884	1.000	rs35887108	chr3:143780632	C/T	cg06585982	chr3:143692056	C3orf58	0.46	5.05	0.3	8.3e-7	Economic and political preferences (feminism/equality);
CESC	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg26338869	chr17:61819248	STRADA	0.7	9.28	0.5	6.1e-18	Prudent dietary pattern;
CESC	cis	rs57502260	0.704	rs72936599	chr11:68320405	G/A	cg20283391	chr11:68216788	NA	-0.66	-5.47	-0.32	1.03e-7	Total body bone mineral density (age 45-60);
CESC	cis	rs2933343	0.679	rs789221	chr3:128591625	A/G	cg11901034	chr3:128598214	ACAD9	-0.36	-5.39	-0.31	1.55e-7	IgG glycosylation;
CESC	trans	rs629535	0.590	rs56200825	chr8:70123450	G/A	cg21567404	chr3:27674614	NA	-0.85	-9.18	-0.49	1.31e-17	Dupuytren's disease;
CESC	cis	rs12410462	0.581	rs75219436	chr1:227546617	C/T	cg10327440	chr1:227177885	CDC42BPA	-0.67	-5.69	-0.33	3.43e-8	Major depressive disorder;
CESC	cis	rs911555	0.723	rs6575986	chr14:103886671	G/A	cg12935359	chr14:103987150	CKB	-0.56	-8.0	-0.44	3.82e-14	Intelligence (multi-trait analysis);
CESC	cis	rs10911232	0.507	rs6672306	chr1:183058898	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.85	13.87	0.65	2.95e-33	Hypertriglyceridemia;
CESC	cis	rs11997175	0.624	rs7819074	chr8:33682472	C/T	ch.8.33884649F	chr8:33765107	NA	0.57	7.29	0.41	3.65e-12	Body mass index;
CESC	cis	rs875971	0.895	rs10755833	chr7:65913917	A/G	cg12463550	chr7:65579703	CRCP	0.56	7.09	0.4	1.2e-11	Aortic root size;
CESC	cis	rs7772486	0.790	rs4075694	chr6:146251108	G/C	cg23711669	chr6:146136114	FBXO30	-0.94	-13.66	-0.64	1.66e-32	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1008375	0.966	rs758483	chr4:17703614	G/T	cg16339924	chr4:17578868	LAP3	-0.68	-8.28	-0.45	6.19e-15	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs4664308	1.000	rs62175517	chr2:160911575	C/T	cg03641300	chr2:160917029	PLA2R1	-0.68	-10.17	-0.53	9.82e-21	Idiopathic membranous nephropathy;
CESC	cis	rs9322193	0.884	rs7743823	chr6:150170880	A/G	cg04369109	chr6:150039330	LATS1	-0.38	-5.04	-0.3	8.83e-7	Lung cancer;
CESC	cis	rs13394619	0.775	rs10165819	chr2:11722102	A/T	cg07314298	chr2:11723111	GREB1	-0.38	-5.3	-0.31	2.47e-7	Endometriosis;
CESC	cis	rs9457247	0.637	rs9459846	chr6:167441023	T/G	cg25258033	chr6:167368657	RNASET2	0.36	5.16	0.3	4.88e-7	Crohn's disease;
CESC	cis	rs780096	0.526	rs809058	chr2:27616790	T/C	cg02592271	chr2:27665507	KRTCAP3	-0.28	-5.66	-0.33	3.97e-8	Total body bone mineral density;
CESC	cis	rs7527798	0.592	rs11118337	chr1:207852693	G/C	cg09232269	chr1:207846808	CR1L	-0.28	-5.14	-0.3	5.27e-7	Erythrocyte sedimentation rate;
CESC	cis	rs9611565	0.659	rs4822037	chr22:41945113	G/T	cg06481639	chr22:41940642	POLR3H	-0.64	-6.61	-0.38	2.13e-10	Vitiligo;
CESC	cis	rs2635047	0.530	rs4986228	chr18:44595259	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.34	5.14	0.3	5.46e-7	Educational attainment;
CESC	cis	rs2839186	0.967	rs9637172	chr21:47685787	T/C	cg10351095	chr21:47802916	PCNT	-0.56	-7.65	-0.43	3.82e-13	Testicular germ cell tumor;
CESC	cis	rs514406	0.644	rs6661196	chr1:53203664	A/G	cg16325326	chr1:53192061	ZYG11B	-0.69	-10.99	-0.56	2.09e-23	Monocyte count;
CESC	cis	rs1008375	0.966	rs2286773	chr4:17616214	C/A	cg15017067	chr4:17643749	FAM184B	0.39	5.6	0.33	5.4e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs2295499	0.673	rs55641756	chr4:2704621	C/T	cg27239842	chr4:2403781	ZFYVE28	-0.33	-5.6	-0.33	5.29e-8	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
CESC	cis	rs10733682	0.659	rs3861879	chr9:129464856	A/G	cg00232160	chr9:129468157	NA	0.4	6.28	0.36	1.4e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg01348570	chr4:68566604	UBA6;LOC550112	-0.42	-6.06	-0.35	4.74e-9	Gambling;
CESC	cis	rs736408	0.609	rs62255396	chr3:52782839	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	6.9	0.39	3.71e-11	Bipolar disorder;
CESC	cis	rs7824557	0.606	rs2736270	chr8:11192593	G/A	cg21775007	chr8:11205619	TDH	0.52	7.55	0.42	6.87e-13	Retinal vascular caliber;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01447966	chr1:234744778	IRF2BP2	0.6	6.95	0.39	2.82e-11	Gut microbiome composition (summer);
CESC	cis	rs34779708	0.931	rs4934719	chr10:35376769	T/C	cg04310649	chr10:35416472	CREM	-0.51	-6.06	-0.35	4.62e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs801193	0.569	rs2659892	chr7:66200305	A/G	cg10691866	chr7:65817282	TPST1	-0.32	-5.44	-0.32	1.19e-7	Aortic root size;
CESC	cis	rs7666738	0.830	rs6832568	chr4:98994061	G/A	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.62e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9916302	0.706	rs667239	chr17:37442241	A/G	cg07936489	chr17:37558343	FBXL20	0.9	11.28	0.57	2.24e-24	Glomerular filtration rate (creatinine);
CESC	trans	rs1814175	0.646	rs61904497	chr11:49883449	A/T	cg03929089	chr4:120376271	NA	-0.9	-14.51	-0.67	1.62e-35	Height;
CESC	cis	rs7666738	0.830	rs13140676	chr4:98804978	C/T	cg17366294	chr4:99064904	C4orf37	0.58	8.3	0.45	5.45e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs875971	0.545	rs17138156	chr7:65714695	C/T	cg18876405	chr7:65276391	NA	0.46	5.55	0.32	7.03e-8	Aortic root size;
CESC	cis	rs769267	0.896	rs10410664	chr19:19556651	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.47	5.87	0.34	1.33e-8	Tonsillectomy;
CESC	cis	rs875971	0.862	rs6978028	chr7:65886300	G/C	cg19163074	chr7:65112434	INTS4L2	-0.41	-5.11	-0.3	6.29e-7	Aortic root size;
CESC	cis	rs734999	0.588	rs6668149	chr1:2558308	A/C	cg18854424	chr1:2615690	NA	-0.31	-5.91	-0.34	1.08e-8	Ulcerative colitis;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg26462404	chr19:2270807	OAZ1	0.51	6.69	0.38	1.29e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs7937682	0.824	rs510866	chr11:111484113	A/C	cg22437258	chr11:111473054	SIK2	0.72	9.71	0.51	2.86e-19	Primary sclerosing cholangitis;
CESC	cis	rs2658782	0.951	rs2608215	chr11:93148817	G/A	cg15737290	chr11:93063684	CCDC67	0.52	6.33	0.36	1.04e-9	Pulmonary function decline;
CESC	cis	rs9790314	0.779	rs12493960	chr3:160899772	T/C	cg03342759	chr3:160939853	NMD3	-0.41	-5.08	-0.3	7.1e-7	Morning vs. evening chronotype;
CESC	cis	rs992157	0.835	rs2045434	chr2:219144498	A/G	cg00012203	chr2:219082015	ARPC2	-0.76	-9.55	-0.51	9.45e-19	Colorectal cancer;
CESC	cis	rs1062177	1.000	rs2964584	chr5:151142878	T/C	cg00977110	chr5:151150581	G3BP1	0.66	7.15	0.4	8.34e-12	Preschool internalizing problems;
CESC	trans	rs7819412	0.668	rs2409721	chr8:11038244	A/T	cg15556689	chr8:8085844	FLJ10661	-0.54	-6.68	-0.38	1.41e-10	Triglycerides;
CESC	cis	rs2506889	0.553	rs7548453	chr1:10589836	A/G	cg17425144	chr1:10567563	PEX14	0.36	5.73	0.33	2.68e-8	Breast cancer;
CESC	cis	rs4862750	0.872	rs6811837	chr4:187898162	G/A	cg06074448	chr4:187884817	NA	-0.37	-5.45	-0.32	1.16e-7	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs10754283	0.967	rs1934044	chr1:90107501	C/T	cg21401794	chr1:90099060	LRRC8C	-0.68	-9.16	-0.49	1.44e-17	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs9910055	0.639	rs7217858	chr17:42254527	T/G	cg19774624	chr17:42201019	HDAC5	-0.82	-12.61	-0.61	7.15e-29	Total body bone mineral density;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24641901	chr11:93212232	C11orf75	-0.58	-6.35	-0.36	9.34e-10	Gut microbiome composition (summer);
CESC	cis	rs4713118	0.586	rs6905516	chr6:28086478	A/G	cg12963246	chr6:28129442	ZNF389	0.56	7.63	0.42	4.26e-13	Parkinson's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21395147	chr1:211849137	NEK2	0.65	7.62	0.42	4.49e-13	Gut microbiome composition (summer);
CESC	cis	rs7809799	0.850	rs6962075	chr7:98757940	A/G	cg05967295	chr7:98741636	SMURF1	-0.75	-5.19	-0.3	4.14e-7	Ulcerative colitis;
CESC	cis	rs651907	0.557	rs3094295	chr3:101401995	T/C	cg12386194	chr3:101231763	SENP7	0.46	5.68	0.33	3.57e-8	Colorectal cancer;
CESC	cis	rs10911232	0.507	rs10797819	chr1:183006911	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.87	13.67	0.64	1.52e-32	Hypertriglyceridemia;
CESC	cis	rs10779751	0.922	rs2746637	chr1:11275588	A/G	cg08854313	chr1:11322531	MTOR	0.8	10.76	0.55	1.21e-22	Body mass index;
CESC	cis	rs9325144	0.625	rs12227353	chr12:38734542	C/T	cg26384229	chr12:38710491	ALG10B	-0.56	-7.82	-0.43	1.27e-13	Morning vs. evening chronotype;
CESC	trans	rs8073060	0.586	rs2523116	chr17:34025460	T/C	cg19694781	chr19:47549865	TMEM160	-0.68	-6.25	-0.36	1.63e-9	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	cis	rs7412746	0.634	rs12409208	chr1:150860055	A/G	cg17724175	chr1:150552817	MCL1	0.39	5.95	0.34	8.56e-9	Melanoma;
CESC	trans	rs2727020	0.675	rs7929401	chr11:49350832	C/A	cg03929089	chr4:120376271	NA	-0.62	-6.72	-0.38	1.08e-10	Coronary artery disease;
CESC	cis	rs4555082	0.957	rs2816627	chr14:105736109	A/G	cg27165867	chr14:105738592	BRF1	-0.51	-6.09	-0.35	3.89e-9	Mean platelet volume;Platelet distribution width;
CESC	cis	rs6724607	1.000	rs6724607	chr2:191466532	C/T	cg27211696	chr2:191398769	TMEM194B	0.51	7.61	0.42	4.87e-13	Pulse pressure;
CESC	cis	rs4975709	0.801	rs3797063	chr5:1881549	A/T	cg17650747	chr5:1873721	NA	0.4	5.31	0.31	2.33e-7	Cardiovascular disease risk factors;
CESC	cis	rs6582630	0.537	rs1851124	chr12:38516404	G/A	cg26384229	chr12:38710491	ALG10B	0.73	11.35	0.57	1.32e-24	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	7.64	0.43	3.85e-13	Prudent dietary pattern;
CESC	cis	rs10256972	0.933	rs35696159	chr7:1047194	A/G	cg07930192	chr7:1003750	NA	0.42	5.65	0.33	4.05e-8	Longevity;Endometriosis;
CESC	cis	rs4268898	0.932	rs7577964	chr2:24598279	A/G	cg20701182	chr2:24300061	SF3B14	-0.46	-5.48	-0.32	9.7e-8	Asthma;
CESC	cis	rs2249625	0.874	rs2463733	chr6:72882996	T/C	cg18830697	chr6:72922368	RIMS1	-0.39	-5.5	-0.32	8.88e-8	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CESC	cis	rs2486288	0.656	rs11639349	chr15:45568260	C/T	cg09092052	chr15:45571596	NA	0.51	5.92	0.34	9.94e-9	Glomerular filtration rate;
CESC	cis	rs12478296	1.000	rs7420157	chr2:243005204	G/A	cg06360820	chr2:242988706	NA	-0.73	-9.03	-0.48	3.74e-17	Obesity-related traits;
CESC	cis	rs6445967	0.530	rs12633937	chr3:58333637	C/T	cg23715586	chr3:58305044	RPP14	-0.36	-5.08	-0.3	7.3e-7	Platelet count;
CESC	cis	rs4474465	0.736	rs11237541	chr11:78261703	T/C	cg27205649	chr11:78285834	NARS2	0.42	5.23	0.31	3.39e-7	Alzheimer's disease (survival time);
CESC	cis	rs1005224	0.853	rs9323616	chr14:76151697	T/C	cg25116370	chr14:76127843	TTLL5;C14orf1	-0.43	-5.88	-0.34	1.21e-8	Large artery stroke;
CESC	cis	rs2721195	0.719	rs4925811	chr8:145802447	G/T	cg26752003	chr8:145688521	CYHR1	0.45	6.1	0.35	3.8e-9	Age at first birth;
CESC	cis	rs7726839	0.540	rs72703087	chr5:598029	C/T	cg16447950	chr5:562315	NA	-0.6	-6.05	-0.35	4.91e-9	Obesity-related traits;
CESC	cis	rs11696501	0.688	rs6065851	chr20:44279034	C/T	cg11783356	chr20:44313418	WFDC10B	-0.34	-5.19	-0.3	4.2e-7	Brain structure;
CESC	cis	rs7666738	0.962	rs17550217	chr4:98999699	T/A	cg17366294	chr4:99064904	C4orf37	0.56	7.55	0.42	6.87e-13	Colonoscopy-negative controls vs population controls;
CESC	cis	rs780096	0.506	rs780100	chr2:27652153	G/T	cg02592271	chr2:27665507	KRTCAP3	-0.29	-5.79	-0.34	1.97e-8	Total body bone mineral density;
CESC	cis	rs5758659	0.714	rs133373	chr22:42465788	G/A	cg00645731	chr22:42541494	CYP2D7P1	-0.34	-5.82	-0.34	1.7e-8	Cognitive function;
CESC	trans	rs561341	0.941	rs4795664	chr17:30233467	C/T	cg27661571	chr11:113659931	NA	-0.65	-6.49	-0.37	4.23e-10	Hip circumference adjusted for BMI;
CESC	cis	rs4665809	0.590	rs66477033	chr2:26472497	T/C	cg26314531	chr2:26401878	FAM59B	0.85	9.04	0.49	3.46e-17	Gut microbiome composition (summer);
CESC	cis	rs4555082	0.834	rs2735826	chr14:105710866	G/A	cg27165867	chr14:105738592	BRF1	-0.49	-5.3	-0.31	2.41e-7	Mean platelet volume;Platelet distribution width;
CESC	cis	rs1862618	0.853	rs1559282	chr5:56099375	T/A	cg22800045	chr5:56110881	MAP3K1	0.73	9.21	0.49	1e-17	Initial pursuit acceleration;
CESC	cis	rs8031584	0.958	rs7168641	chr15:31235452	G/A	cg08109568	chr15:31115862	NA	-0.7	-9.34	-0.5	4.04e-18	Huntington's disease progression;
CESC	cis	rs651907	0.557	rs34457525	chr3:101435225	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.45	5.88	0.34	1.22e-8	Colorectal cancer;
CESC	trans	rs2727020	0.553	rs4980447	chr11:49591662	T/C	cg15704280	chr7:45808275	SEPT13	-0.84	-10.3	-0.53	3.95e-21	Coronary artery disease;
CESC	cis	rs9322193	0.847	rs9383844	chr6:150037404	T/C	cg09699651	chr6:150184138	LRP11	0.42	5.48	0.32	1.01e-7	Lung cancer;
CESC	cis	rs853679	0.517	rs6941992	chr6:28106141	T/C	cg19592336	chr6:28129416	ZNF389	0.61	8.24	0.45	8.13e-15	Depression;
CESC	cis	rs1790761	0.658	rs684928	chr11:67329742	G/A	cg00290607	chr11:67383545	NA	0.41	5.7	0.33	3.17e-8	Mean corpuscular volume;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg09632163	chr16:2339292	ABCA3	0.45	6.13	0.35	3.14e-9	Fibrinogen levels;
CESC	cis	rs270601	0.770	rs1007602	chr5:131602166	T/C	cg04518342	chr5:131593106	PDLIM4	0.4	5.96	0.34	7.99e-9	Acylcarnitine levels;
CESC	cis	rs2073300	0.609	rs6132615	chr20:23413200	T/C	cg16736954	chr20:23401023	NAPB	0.78	5.68	0.33	3.45e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs6432018	0.964	rs13415136	chr2:9729708	A/G	cg23886495	chr2:9695866	ADAM17	0.44	5.14	0.3	5.32e-7	Heart rate variability traits;
CESC	cis	rs7680126	0.633	rs74469609	chr4:10294424	G/A	cg11266682	chr4:10021025	SLC2A9	-0.43	-5.58	-0.32	5.89e-8	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	cis	rs7264396	0.635	rs6060685	chr20:34512023	G/A	cg17201900	chr20:34330562	RBM39	0.49	5.13	0.3	5.54e-7	Total cholesterol levels;
CESC	cis	rs8114671	0.527	rs2253484	chr20:33405263	A/T	cg06115741	chr20:33292138	TP53INP2	-0.45	-5.35	-0.31	1.87e-7	Height;
CESC	cis	rs3820928	0.692	rs2396434	chr2:227775223	G/T	cg05526886	chr2:227700861	RHBDD1	-0.54	-7.32	-0.41	3e-12	Pulmonary function;
CESC	cis	rs6582630	0.519	rs11182457	chr12:38538331	G/A	cg26384229	chr12:38710491	ALG10B	0.74	11.17	0.57	5.31e-24	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs10504229	0.683	rs73605816	chr8:58117167	T/C	cg02725872	chr8:58115012	NA	-0.45	-7.05	-0.4	1.52e-11	Developmental language disorder (linguistic errors);
CESC	trans	rs997295	0.529	rs12592315	chr15:68040266	A/G	cg05642446	chr12:117316716	HRK	0.47	6.34	0.36	9.82e-10	Motion sickness;
CESC	cis	rs9611565	0.659	rs73178641	chr22:41952075	A/T	cg03806693	chr22:41940476	POLR3H	-1.19	-15.09	-0.68	1.46e-37	Vitiligo;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg17447877	chr11:65554407	OVOL1	-0.46	-6.04	-0.35	5.19e-9	Height;
CESC	cis	rs921968	0.643	rs545779	chr2:219336108	A/G	cg02176678	chr2:219576539	TTLL4	0.43	7.65	0.43	3.63e-13	Mean corpuscular hemoglobin concentration;
CESC	cis	rs9911578	1.000	rs302848	chr17:56686454	C/T	cg05425664	chr17:57184151	TRIM37	-0.53	-7.42	-0.41	1.58e-12	Intelligence (multi-trait analysis);
CESC	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg24642844	chr7:1081250	C7orf50	-0.77	-9.41	-0.5	2.48e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs12220238	0.558	rs76330316	chr10:76002291	G/C	cg19889307	chr10:75911429	ADK;AP3M1	0.62	6.08	0.35	4.12e-9	Soluble interleukin-2 receptor subunit alpha;
CESC	cis	rs73058052	1.000	rs12462756	chr19:50098423	G/A	cg09250473	chr19:50168907	IRF3;BCL2L12	0.59	5.65	0.33	4.22e-8	Fibrinogen levels;
CESC	cis	rs6541297	0.703	rs619899	chr1:230310069	A/G	cg20703242	chr1:230279135	GALNT2	-0.43	-5.59	-0.33	5.51e-8	Coronary artery disease;
CESC	cis	rs4853012	0.838	rs60705299	chr2:74345370	C/G	cg19729930	chr2:74357872	NA	0.86	13.07	0.63	1.83e-30	Gestational age at birth (maternal effect);
CESC	cis	rs801193	0.569	rs4717315	chr7:66178325	C/T	cg10691866	chr7:65817282	TPST1	-0.32	-5.45	-0.32	1.15e-7	Aortic root size;
CESC	cis	rs2228479	0.867	rs73276534	chr16:89950557	A/G	cg00800038	chr16:89945340	TCF25	-0.64	-7.05	-0.4	1.52e-11	Skin colour saturation;
CESC	cis	rs3015497	1.000	rs3015497	chr14:51113398	T/C	cg26011998	chr14:51135199	SAV1	-0.41	-5.2	-0.3	3.97e-7	Mean platelet volume;
CESC	cis	rs9443645	0.808	rs9361484	chr6:79758218	C/A	cg05283184	chr6:79620031	NA	-0.45	-6.87	-0.39	4.53e-11	Intelligence (multi-trait analysis);
CESC	trans	rs916888	0.773	rs538628	chr17:44787313	G/C	cg04282206	chr17:62833786	PLEKHM1P	0.56	6.48	0.37	4.45e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs13082711	0.522	rs569960	chr3:27329540	C/T	cg02860705	chr3:27208620	NA	0.4	5.43	0.32	1.27e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CESC	cis	rs1799949	0.965	rs2236762	chr17:41226675	A/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.52	7.26	0.41	4.33e-12	Menopause (age at onset);
CESC	cis	rs9733	0.715	rs12402006	chr1:150869829	G/A	cg22823121	chr1:150693482	HORMAD1	-0.36	-5.17	-0.3	4.66e-7	Tonsillectomy;
CESC	cis	rs4242434	0.927	rs2291234	chr8:22464390	T/C	cg03733263	chr8:22462867	KIAA1967	0.95	16.01	0.7	7.75e-41	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CESC	cis	rs11098499	0.657	rs7664458	chr4:120371967	A/G	cg09307838	chr4:120376055	NA	0.94	13.7	0.64	1.18e-32	Corneal astigmatism;
CESC	cis	rs4588572	0.643	rs7701154	chr5:77716621	G/A	cg11547950	chr5:77652471	NA	-0.44	-5.61	-0.33	5.15e-8	Triglycerides;
CESC	cis	rs2710642	0.861	rs2710644	chr2:63248968	A/C	cg17519650	chr2:63277830	OTX1	0.61	7.33	0.41	2.73e-12	LDL cholesterol levels;LDL cholesterol;
CESC	cis	rs4803468	1.000	rs10417997	chr19:41902361	G/A	cg09537434	chr19:41945824	ATP5SL	-1.01	-17.92	-0.74	1.36e-47	Height;
CESC	cis	rs17401966	1.000	rs60743860	chr1:10442926	G/C	cg15208524	chr1:10270712	KIF1B	0.46	5.84	0.34	1.52e-8	Hepatocellular carcinoma;
CESC	cis	rs1559088	0.901	rs7249983	chr19:33598851	C/A	cg27124370	chr19:33622961	WDR88	0.46	6.08	0.35	4.11e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs1005277	0.541	rs2472177	chr10:38384015	T/G	cg25427524	chr10:38739819	LOC399744	-0.69	-10.3	-0.53	3.72e-21	Extrinsic epigenetic age acceleration;
CESC	cis	rs7937682	0.889	rs559482	chr11:111497902	G/A	cg09085632	chr11:111637200	PPP2R1B	-1.0	-15.55	-0.69	3.45e-39	Primary sclerosing cholangitis;
CESC	cis	rs8027181	0.839	rs9460	chr15:73044575	C/T	cg25632853	chr15:73088954	NA	0.31	5.51	0.32	8.53e-8	Triglyceride levels;
CESC	cis	rs9322193	0.923	rs10872650	chr6:150082095	A/G	cg13206674	chr6:150067644	NUP43	0.46	6.49	0.37	4.15e-10	Lung cancer;
CESC	cis	rs4654899	0.865	rs6671056	chr1:21488610	G/A	cg05370193	chr1:21551575	ECE1	0.46	7.08	0.4	1.28e-11	Superior frontal gyrus grey matter volume;
CESC	cis	rs7216064	1.000	rs12602912	chr17:65870073	C/T	cg07042672	chr17:66097459	LOC651250	-0.54	-5.59	-0.32	5.61e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs17433780	0.964	rs12146148	chr1:89471892	C/T	cg09516651	chr1:89888402	LOC400759	0.67	9.03	0.49	3.54e-17	Carotid intima media thickness;
CESC	cis	rs523522	0.962	rs12814055	chr12:120987391	G/A	cg27279351	chr12:120934652	DYNLL1	0.68	8.94	0.48	6.97e-17	High light scatter reticulocyte count;
CESC	cis	rs6088580	0.524	rs6088552	chr20:33226491	A/G	cg24642439	chr20:33292090	TP53INP2	-0.47	-5.39	-0.31	1.57e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs11608355	0.545	rs12819142	chr12:109896316	G/T	cg05360138	chr12:110035743	NA	0.79	8.25	0.45	7.43e-15	Neuroticism;
CESC	cis	rs9457247	1.000	rs364451	chr6:167384756	G/A	cg07741184	chr6:167504864	NA	0.3	5.52	0.32	7.99e-8	Crohn's disease;
CESC	cis	rs2635047	0.601	rs2576057	chr18:44644127	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.41	5.56	0.32	6.6e-8	Educational attainment;
CESC	cis	rs17001868	0.568	rs9611328	chr22:40791972	C/T	cg07138101	chr22:40742427	ADSL	0.56	5.36	0.31	1.81e-7	Mammographic density (dense area);
CESC	trans	rs208520	1.000	rs12212063	chr6:66985148	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.76	8.47	0.46	1.71e-15	Exhaled nitric oxide output;
CESC	cis	rs79349575	0.687	rs12602179	chr17:47010034	G/T	cg26022315	chr17:47021804	SNF8	0.39	5.16	0.3	4.94e-7	Type 2 diabetes;
CESC	trans	rs801193	0.613	rs2016325	chr7:66323500	T/C	cg26939375	chr7:64535504	NA	-0.52	-6.31	-0.36	1.14e-9	Aortic root size;
CESC	cis	rs9649213	0.574	rs13238610	chr7:97909277	T/C	cg21770322	chr7:97807741	LMTK2	0.55	8.18	0.45	1.16e-14	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs4819052	0.851	rs35064782	chr21:46674360	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.94	13.81	0.65	4.88e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs599083	0.590	rs661988	chr11:68189251	T/G	cg01657329	chr11:68192670	LRP5	-0.5	-5.06	-0.3	7.75e-7	Bone mineral density (spine);
CESC	cis	rs739401	1.000	rs739401	chr11:3036324	C/T	cg08508325	chr11:3079039	CARS	0.43	7.92	0.44	6.69e-14	Longevity;
CESC	cis	rs7267979	1.000	rs1888998	chr20:25291826	A/G	cg08601574	chr20:25228251	PYGB	-0.36	-5.13	-0.3	5.74e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs2070488	0.775	rs6599207	chr3:38554901	T/C	cg24069376	chr3:38537580	EXOG	-0.34	-5.92	-0.34	1e-8	Electrocardiographic conduction measures;
CESC	cis	rs77972916	0.505	rs3851318	chr2:43532808	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.61	-5.97	-0.34	7.4e-9	Granulocyte percentage of myeloid white cells;
CESC	cis	rs1035144	0.524	rs8009260	chr14:81408591	G/T	cg06600135	chr14:81408086	NA	0.51	6.8	0.39	6.73e-11	Male sexual orientation;
CESC	cis	rs561341	1.000	rs510264	chr17:30323414	A/G	cg19193384	chr17:30244184	NA	-0.71	-6.61	-0.38	2.14e-10	Hip circumference adjusted for BMI;
CESC	cis	rs9911578	0.967	rs2643124	chr17:56741672	T/C	cg12560992	chr17:57184187	TRIM37	0.93	15.58	0.69	2.66e-39	Intelligence (multi-trait analysis);
CESC	trans	rs804280	0.509	rs9886639	chr8:11784529	G/T	cg15556689	chr8:8085844	FLJ10661	0.53	6.43	0.37	5.88e-10	Myopia (pathological);
CESC	cis	rs10851478	0.872	rs12912703	chr15:49869141	C/G	cg08060515	chr15:49448048	GALK2;COPS2	0.43	5.25	0.31	3.07e-7	Oral cavity cancer;
CESC	cis	rs2839186	0.786	rs7409792	chr21:47691729	C/A	cg10351095	chr21:47802916	PCNT	-0.51	-6.94	-0.39	3e-11	Testicular germ cell tumor;
CESC	cis	rs4481887	0.893	rs4423045	chr1:248479495	T/C	cg00666640	chr1:248458726	OR2T12	0.33	5.45	0.32	1.17e-7	Common traits (Other);
CESC	cis	rs11126435	0.591	rs6546909	chr2:74746322	A/T	cg11955373	chr2:74710513	TTC31;CCDC142	0.51	5.14	0.3	5.35e-7	Age-related hearing impairment (SNP x SNP interaction);
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg17430032	chr12:64317120	SRGAP1	0.47	6.95	0.39	2.84e-11	Thyroid stimulating hormone;
CESC	cis	rs2294693	0.853	rs9296350	chr6:40977623	G/A	cg14418226	chr6:40996092	UNC5CL	0.47	5.87	0.34	1.27e-8	Gastric cancer;Non-cardia gastric cancer;
CESC	cis	rs933688	1.000	rs35712350	chr5:90679519	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.19	17.21	0.73	4.47e-45	Smoking behavior;
CESC	cis	rs9815354	0.767	rs11917248	chr3:41885723	T/C	cg03022575	chr3:42003672	ULK4	0.45	5.29	0.31	2.59e-7	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs12410462	0.681	rs114950580	chr1:227673334	G/C	cg04117972	chr1:227635322	NA	0.82	6.26	0.36	1.51e-9	Major depressive disorder;
CESC	trans	rs722599	0.683	rs7160852	chr14:75239424	T/C	cg00095594	chr1:236228625	NID1	0.4	6.14	0.35	3e-9	IgG glycosylation;
CESC	cis	rs12142240	0.698	rs112068407	chr1:46822291	T/C	cg00530320	chr1:46809349	NSUN4	0.6	8.04	0.44	2.96e-14	Menopause (age at onset);
CESC	cis	rs6120849	0.901	rs6088739	chr20:33748724	G/A	cg24642439	chr20:33292090	TP53INP2	0.61	6.53	0.37	3.26e-10	Protein C levels;
CESC	cis	rs4665809	0.627	rs7562192	chr2:26469457	C/G	cg27170947	chr2:26402098	FAM59B	0.87	10.16	0.53	1.05e-20	Gut microbiome composition (summer);
CESC	cis	rs4568518	0.530	rs10269921	chr7:17997940	G/A	cg03009463	chr7:17980271	SNX13	0.44	5.77	0.33	2.18e-8	Measles;
CESC	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.97	9.35	0.5	3.75e-18	Platelet count;
CESC	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg23708337	chr7:1209742	NA	0.54	5.38	0.31	1.61e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs853679	0.517	rs4713144	chr6:28106790	C/G	cg23161317	chr6:28129485	ZNF389	0.51	6.63	0.38	1.85e-10	Depression;
CESC	cis	rs13191362	0.935	rs13215748	chr6:163010710	A/C	cg21926612	chr6:163149169	PACRG;PARK2	0.87	8.98	0.48	5.33e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs1862618	0.853	rs1423620	chr5:56100996	G/T	cg18230493	chr5:56204884	C5orf35	-0.66	-8.38	-0.46	3.04e-15	Initial pursuit acceleration;
CESC	trans	rs9650657	0.513	rs7005884	chr8:10796472	A/G	cg15556689	chr8:8085844	FLJ10661	-0.56	-6.85	-0.39	5.05e-11	Neuroticism;
CESC	cis	rs7165102	1.000	rs7165102	chr15:65888359	G/T	cg11441148	chr15:65824328	PTPLAD1	0.32	5.43	0.32	1.29e-7	Mean corpuscular hemoglobin;
CESC	cis	rs10089	0.951	rs56066100	chr5:127460571	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.76	10.07	0.53	2.04e-20	Ileal carcinoids;
CESC	trans	rs916888	0.821	rs199509	chr17:44858728	G/A	cg27125505	chr17:43679177	LOC644172	-0.48	-6.74	-0.38	1.01e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs9399401	0.710	rs12190271	chr6:142681409	A/G	cg04461802	chr6:142623433	GPR126	-0.39	-5.76	-0.33	2.38e-8	Chronic obstructive pulmonary disease;
CESC	cis	rs7618915	0.501	rs6617	chr3:52740182	C/G	cg18099408	chr3:52552593	STAB1	-0.3	-5.05	-0.3	8.2e-7	Bipolar disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21918026	chr16:68344902	SLC7A6OS;PRMT7	-0.6	-6.34	-0.36	9.81e-10	Gut microbiome composition (summer);
CESC	cis	rs763121	0.853	rs5750669	chr22:39080638	T/A	cg14440974	chr22:39074834	NA	-0.43	-5.76	-0.33	2.3e-8	Menopause (age at onset);
CESC	cis	rs6088580	0.660	rs6087592	chr20:33114503	A/G	cg08999081	chr20:33150536	PIGU	0.64	11.0	0.56	1.94e-23	Glomerular filtration rate (creatinine);
CESC	cis	rs3096299	0.967	rs753852	chr16:89446419	G/A	cg08392591	chr16:89556376	ANKRD11	0.42	5.31	0.31	2.34e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs1218582	0.772	rs6686873	chr1:154913404	C/G	cg03351412	chr1:154909251	PMVK	0.68	9.09	0.49	2.38e-17	Prostate cancer;
CESC	cis	rs7851660	0.874	rs7037175	chr9:100631662	G/C	cg13688889	chr9:100608707	NA	-0.6	-8.55	-0.47	9.84e-16	Strep throat;
CESC	cis	rs4713118	0.662	rs149948	chr6:27974817	C/G	cg23161317	chr6:28129485	ZNF389	0.46	6.18	0.35	2.4e-9	Parkinson's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00661620	chr1:93298059	RPL5	0.59	6.53	0.37	3.25e-10	Gut microbiome composition (summer);
CESC	trans	rs896655	0.567	rs10811625	chr9:21826840	G/A	cg04880063	chr10:102790718	SFXN3;PDZD7	0.41	6.0	0.35	6.34e-9	Coronary artery disease;
CESC	cis	rs7927771	0.931	rs4752801	chr11:47907641	A/G	cg20307385	chr11:47447363	PSMC3	-0.44	-5.55	-0.32	6.93e-8	Subjective well-being;
CESC	cis	rs8051149	0.688	rs16943320	chr16:87870379	A/G	cg03408354	chr16:87871219	SLC7A5	-0.45	-5.68	-0.33	3.61e-8	Blood metabolite levels;
CESC	cis	rs7618915	0.508	rs7628578	chr3:52628321	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.49	7.37	0.41	2.17e-12	Bipolar disorder;
CESC	cis	rs2439831	0.717	rs2470132	chr15:43835481	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.69	8.9	0.48	8.94e-17	Lung cancer in ever smokers;
CESC	trans	rs1814175	0.619	rs847644	chr11:49918418	G/A	cg15704280	chr7:45808275	SEPT13	-1.01	-18.94	-0.76	3.64e-51	Height;
CESC	cis	rs9905704	0.718	rs62083411	chr17:56980188	A/G	cg12560992	chr17:57184187	TRIM37	0.63	5.53	0.32	7.65e-8	Testicular germ cell tumor;
CESC	cis	rs798554	0.679	rs798499	chr7:2792013	G/A	cg13628971	chr7:2884303	GNA12	0.39	5.12	0.3	5.76e-7	Height;
CESC	cis	rs7264396	0.790	rs6060562	chr20:34282053	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.86	-10.37	-0.54	2.22e-21	Total cholesterol levels;
CESC	cis	rs9943753	0.508	rs11066422	chr12:109807153	A/G	cg19025524	chr12:109796872	NA	-0.47	-6.7	-0.38	1.23e-10	HDL cholesterol;
CESC	cis	rs9788333	0.962	rs61951450	chr13:21886354	G/A	cg23743428	chr13:21893420	NA	-0.38	-6.1	-0.35	3.69e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs1348850	0.608	rs2364845	chr2:178226240	T/C	cg23306229	chr2:178417860	TTC30B	0.54	6.91	0.39	3.51e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs116095464	0.558	rs10057492	chr5:239503	T/C	cg12570787	chr5:219185	SDHA;CCDC127	0.5	5.31	0.31	2.3e-7	Breast cancer;
CESC	cis	rs4481887	0.888	rs12042602	chr1:248482053	C/T	cg00666640	chr1:248458726	OR2T12	0.36	6.07	0.35	4.47e-9	Common traits (Other);
CESC	cis	rs4819052	1.000	rs13053002	chr21:46677854	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.59	7.12	0.4	1.01e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs4423214	0.650	rs7940244	chr11:71221574	C/T	cg24826892	chr11:71159390	DHCR7	-0.52	-5.84	-0.34	1.54e-8	Vitamin D levels;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg01630199	chr7:66369076	NA	0.53	7.06	0.4	1.45e-11	Fibrinogen levels;
CESC	cis	rs1046896	0.553	rs56775875	chr17:80831291	G/T	cg19046167	chr17:80928561	B3GNTL1	0.47	5.61	0.33	5.16e-8	Glycated hemoglobin levels;
CESC	cis	rs66573146	0.572	rs55740475	chr4:6954092	C/G	cg26116260	chr4:7069785	GRPEL1	-0.8	-5.31	-0.31	2.3e-7	Granulocyte percentage of myeloid white cells;
CESC	cis	rs11677416	0.601	rs12469600	chr2:113572357	T/C	cg27083787	chr2:113543245	IL1A	0.59	7.01	0.4	2e-11	Response to antipsychotic treatment in schizophrenia (working memory);
CESC	cis	rs10950821	0.505	rs6949755	chr7:20688042	C/G	cg02470904	chr7:20686108	ABCB5	0.33	5.44	0.32	1.22e-7	Response to statin therapy;
CESC	cis	rs2842992	0.662	rs2273826	chr6:160211421	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.85	12.01	0.59	8.38e-27	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs7927592	0.731	rs11228275	chr11:68303980	G/A	cg16797656	chr11:68205561	LRP5	-0.49	-7.79	-0.43	1.56e-13	Total body bone mineral density;
CESC	cis	rs11031096	0.678	rs61899666	chr11:4178711	C/A	cg18678763	chr11:4115507	RRM1	-0.42	-5.75	-0.33	2.5e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	cis	rs7927592	0.956	rs11228269	chr11:68289796	A/G	cg20283391	chr11:68216788	NA	-0.49	-5.84	-0.34	1.56e-8	Total body bone mineral density;
CESC	cis	rs116095464	0.614	rs10067482	chr5:219328	T/G	cg22496380	chr5:211416	CCDC127	-0.72	-8.57	-0.47	8.59e-16	Breast cancer;
CESC	cis	rs9311474	0.597	rs13303	chr3:52558008	T/C	cg17372223	chr3:52568218	NT5DC2	0.55	9.32	0.5	4.7e-18	Electroencephalogram traits;
CESC	cis	rs9314323	0.964	rs3808576	chr8:26266834	G/A	cg13160058	chr8:26243215	BNIP3L	-0.32	-5.16	-0.3	4.9e-7	Red cell distribution width;
CESC	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg26354017	chr1:205819088	PM20D1	-0.71	-11.51	-0.58	3.87e-25	Monocyte percentage of white cells;
CESC	cis	rs7666738	0.753	rs6826709	chr4:98714553	C/G	cg05340658	chr4:99064831	C4orf37	0.75	11.02	0.56	1.71e-23	Colonoscopy-negative controls vs population controls;
CESC	cis	rs910316	1.000	rs3742780	chr14:75505008	G/C	cg11812906	chr14:75593930	NEK9	0.88	14.5	0.67	1.74e-35	Height;
CESC	cis	rs7843479	0.582	rs13439690	chr8:21778082	T/C	cg17168535	chr8:21777572	XPO7	0.74	12.06	0.6	5.5e-27	Mean corpuscular volume;
CESC	cis	rs13256369	0.755	rs11776987	chr8:8559401	C/G	cg00074818	chr8:8560427	CLDN23	0.38	5.37	0.31	1.71e-7	Obesity-related traits;
CESC	cis	rs9733	0.526	rs11204698	chr1:150659545	G/A	cg22823121	chr1:150693482	HORMAD1	0.47	7.03	0.4	1.79e-11	Tonsillectomy;
CESC	cis	rs17125944	0.686	rs4450307	chr14:53334783	G/A	cg00686598	chr14:53173677	PSMC6	-0.63	-5.26	-0.31	2.99e-7	Alzheimer's disease (late onset);
CESC	cis	rs34779708	0.733	rs3853672	chr10:35549606	A/C	cg04310649	chr10:35416472	CREM	-0.46	-5.25	-0.31	3.17e-7	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg24846343	chr22:24311635	DDTL	0.64	10.82	0.55	7.67e-23	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs4727027	0.933	rs1058059	chr7:148879134	A/T	cg23158103	chr7:148848205	ZNF398	-0.4	-6.45	-0.37	5.26e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25318278	chr11:50257830	LOC441601	-0.57	-7.68	-0.43	3.11e-13	Gut microbiome composition (summer);
CESC	cis	rs739401	0.572	rs7111857	chr11:3068106	A/G	cg25174290	chr11:3078921	CARS	-0.56	-7.98	-0.44	4.51e-14	Longevity;
CESC	cis	rs9549367	0.789	rs34448227	chr13:113884754	A/C	cg18105134	chr13:113819100	PROZ	-0.63	-7.52	-0.42	8.31e-13	Platelet distribution width;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg06632829	chr19:45394476	TOMM40	-0.55	-7.63	-0.42	4.22e-13	Height;
CESC	cis	rs4450131	0.522	rs17152232	chr10:126398927	A/G	cg20435097	chr10:126320824	FAM53B	0.28	5.13	0.3	5.62e-7	White blood cell count (basophil);
CESC	cis	rs7824557	0.527	rs2409756	chr8:11242025	A/C	cg21775007	chr8:11205619	TDH	-0.54	-7.27	-0.41	4.17e-12	Retinal vascular caliber;
CESC	cis	rs4234284	0.556	rs9968173	chr3:126965437	G/A	cg27326032	chr3:127006922	NA	-0.41	-5.62	-0.33	4.83e-8	Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel);
CESC	cis	rs561341	0.882	rs2521594	chr17:30302087	C/T	cg00745463	chr17:30367425	LRRC37B	-0.78	-7.09	-0.4	1.2e-11	Hip circumference adjusted for BMI;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13633529	chr15:101141955	ASB7;LINS1	-0.54	-6.34	-0.36	1.01e-9	Gut microbiome composition (summer);
CESC	cis	rs12618769	0.597	rs11888595	chr2:99084708	T/G	cg10123293	chr2:99228465	UNC50	0.39	5.13	0.3	5.6e-7	Bipolar disorder;
CESC	cis	rs644799	1.000	rs494829	chr11:95571750	C/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.94	13.73	0.64	9.26e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs1371867	0.839	rs1660313	chr8:101332712	G/A	cg11906718	chr8:101322791	RNF19A	0.53	6.86	0.39	4.86e-11	Atrioventricular conduction;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg26011156	chr1:156183096	PMF1	-0.45	-6.41	-0.37	6.64e-10	Gambling;
CESC	cis	rs914615	0.552	rs11264337	chr1:155138450	C/T	cg02153340	chr1:155202674	NA	-0.37	-5.48	-0.32	1.01e-7	Urinary albumin-to-creatinine ratio;
CESC	cis	rs9322193	0.923	rs1112729	chr6:150087627	C/A	cg07701084	chr6:150067640	NUP43	0.44	5.95	0.34	8.59e-9	Lung cancer;
CESC	cis	rs27434	0.583	rs151908	chr5:96156494	A/G	cg16492584	chr5:96139282	ERAP1	-0.36	-5.09	-0.3	6.81e-7	Ankylosing spondylitis;
CESC	trans	rs2351088	0.706	rs11704989	chr22:46205231	A/G	cg07046818	chr8:97166291	GDF6	-0.48	-6.06	-0.35	4.68e-9	Tonsillectomy;
CESC	cis	rs11031096	0.678	rs2044135	chr11:4187233	G/A	cg18678763	chr11:4115507	RRM1	-0.47	-6.31	-0.36	1.19e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	cis	rs17001868	0.614	rs61467436	chr22:40736713	T/C	cg07138101	chr22:40742427	ADSL	0.57	5.38	0.31	1.66e-7	Mammographic density (dense area);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg02068989	chr1:10458939	PGD	-0.54	-6.72	-0.38	1.09e-10	Ulcerative colitis;
CESC	cis	rs9611565	0.921	rs5751077	chr22:41720728	G/C	cg06481639	chr22:41940642	POLR3H	-0.45	-5.36	-0.31	1.83e-7	Vitiligo;
CESC	trans	rs13398848	1.000	rs10192434	chr2:84201256	C/T	cg23262351	chr6:79576851	IRAK1BP1	-0.69	-6.08	-0.35	4.1e-9	Conduct disorder (symptom count);Conduct disorder;
CESC	cis	rs832540	1.000	rs192249	chr5:56197514	C/G	cg14703610	chr5:56206110	C5orf35	0.53	7.03	0.4	1.73e-11	Coronary artery disease;
CESC	cis	rs6952808	0.895	rs4513875	chr7:1928159	C/T	cg02951883	chr7:2050386	MAD1L1	-0.53	-7.02	-0.4	1.91e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs1878931	0.501	rs9302871	chr16:3415512	T/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.77	10.22	0.53	6.84e-21	Body mass index (adult);
CESC	cis	rs8077889	0.703	rs231532	chr17:41945769	C/T	cg26893861	chr17:41843967	DUSP3	-0.65	-6.7	-0.38	1.28e-10	Triglycerides;
CESC	cis	rs780096	0.526	rs1647267	chr2:27651054	A/T	cg17158414	chr2:27665306	KRTCAP3	-0.32	-5.97	-0.34	7.45e-9	Total body bone mineral density;
CESC	trans	rs2898290	0.622	rs978803	chr8:11343475	C/T	cg15556689	chr8:8085844	FLJ10661	0.5	6.02	0.35	5.89e-9	Systolic blood pressure;
CESC	cis	rs6831352	0.918	rs4699712	chr4:100060490	A/T	cg12011299	chr4:100065546	ADH4	-0.59	-6.59	-0.38	2.35e-10	Alcohol dependence;
CESC	trans	rs9467711	0.606	rs2076030	chr6:26426856	G/A	cg06606381	chr12:133084897	FBRSL1	-0.82	-6.98	-0.39	2.4e-11	Autism spectrum disorder or schizophrenia;
CESC	cis	rs4568518	0.501	rs6966247	chr7:17989247	A/G	cg03009463	chr7:17980271	SNX13	0.4	5.27	0.31	2.79e-7	Measles;
CESC	cis	rs6580649	0.941	rs1793933	chr12:48396450	G/T	cg05342945	chr12:48394962	COL2A1	-0.54	-6.44	-0.37	5.55e-10	Lung cancer;
CESC	cis	rs7412746	0.634	rs12409208	chr1:150860055	A/G	cg22823121	chr1:150693482	HORMAD1	0.42	5.86	0.34	1.35e-8	Melanoma;
CESC	cis	rs7659604	0.605	rs1507994	chr4:122749541	C/T	cg20573242	chr4:122745356	CCNA2	0.76	10.31	0.54	3.5e-21	Type 2 diabetes;
CESC	trans	rs7142881	0.508	rs1954441	chr14:32118713	A/G	cg07757386	chr14:102771445	RAGE	-0.46	-6.37	-0.36	8.28e-10	Response to iloperidone treatment (QT prolongation);
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg22335246	chr12:120763591	PLA2G1B	-0.39	-6.03	-0.35	5.61e-9	Vertical cup-disc ratio;
CESC	cis	rs7666738	0.830	rs13144771	chr4:99026935	G/C	cg24818145	chr4:99064322	C4orf37	0.39	5.09	0.3	6.95e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs656319	0.638	rs670044	chr8:9892529	G/T	cg15556689	chr8:8085844	FLJ10661	0.48	6.15	0.35	2.88e-9	Myopia (pathological);
CESC	cis	rs10876993	0.821	rs1678522	chr12:58049923	G/A	cg18357645	chr12:58087776	OS9	0.6	9.2	0.49	1.1e-17	Celiac disease or Rheumatoid arthritis;
CESC	cis	rs9291683	0.552	rs10939655	chr4:10014642	A/T	cg02734326	chr4:10020555	SLC2A9	0.52	7.43	0.42	1.5e-12	Bone mineral density;
CESC	cis	rs7243790	1.000	rs17473264	chr18:51962904	T/C	cg04730925	chr18:51795821	POLI	-0.42	-5.54	-0.32	7.12e-8	Diastolic blood pressure;
CESC	cis	rs7560272	0.564	rs4852939	chr2:73856769	C/G	cg20560298	chr2:73613845	ALMS1	-0.51	-7.2	-0.4	6.12e-12	Schizophrenia;
CESC	cis	rs7552404	0.883	rs7513363	chr1:76143443	A/G	cg10523679	chr1:76189770	ACADM	0.76	9.96	0.52	4.53e-20	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs7772486	0.743	rs1292339	chr6:145967086	C/T	cg05347473	chr6:146136440	FBXO30	-0.48	-6.34	-0.36	9.8e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg18538332	chr22:24372958	LOC391322	-0.72	-10.45	-0.54	1.26e-21	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs769267	0.895	rs2315279	chr19:19479936	C/A	cg17414380	chr19:19431394	KIAA0892;SF4	-0.48	-6.18	-0.35	2.39e-9	Tonsillectomy;
CESC	cis	rs2228479	0.850	rs62052660	chr16:89847420	T/A	cg19635926	chr16:89946313	TCF25	0.67	5.09	0.3	6.8e-7	Skin colour saturation;
CESC	cis	rs9300255	0.602	rs2851450	chr12:123703501	C/T	cg05973401	chr12:123451056	ABCB9	0.5	5.68	0.33	3.48e-8	Neutrophil percentage of white cells;
CESC	cis	rs1620921	0.505	rs9458025	chr6:161203435	T/C	cg01280913	chr6:161186852	NA	-0.36	-5.27	-0.31	2.81e-7	Lipoprotein (a) - cholesterol levels;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg14347670	chr6:41908995	CCND3	-0.48	-6.43	-0.37	5.93e-10	Height;
CESC	cis	rs8014204	0.901	rs4899536	chr14:75316614	A/G	cg08847533	chr14:75593920	NEK9	-0.5	-6.34	-0.36	9.88e-10	Caffeine consumption;
CESC	cis	rs896854	0.967	rs10808671	chr8:95967372	A/G	cg16049864	chr8:95962084	TP53INP1	-0.68	-12.35	-0.6	5.62e-28	Type 2 diabetes;
CESC	cis	rs17125944	0.505	rs118053951	chr14:53259829	G/A	cg00686598	chr14:53173677	PSMC6	1.36	11.53	0.58	3.33e-25	Alzheimer's disease (late onset);
CESC	cis	rs8017423	0.967	rs11628812	chr14:90713720	G/T	cg14092571	chr14:90743983	NA	0.59	8.8	0.48	1.75e-16	Mortality in heart failure;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg16278828	chr15:75648574	MAN2C1	0.41	6.21	0.36	2.01e-9	Fibrinogen levels;
CESC	cis	rs6461049	0.800	rs3778977	chr7:2159746	C/T	cg23048001	chr7:2026167	MAD1L1	0.45	5.85	0.34	1.48e-8	Schizophrenia;
CESC	cis	rs6951245	0.882	rs11764817	chr7:1064610	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.45	-5.34	-0.31	2.04e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs12291225	0.679	rs4757245	chr11:14297872	A/C	cg19336497	chr11:14380999	RRAS2	-0.37	-5.27	-0.31	2.79e-7	Sense of smell;
CESC	cis	rs2777491	0.957	rs2015781	chr15:41648967	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.62	-9.57	-0.51	8.12e-19	Ulcerative colitis;
CESC	cis	rs72945132	0.882	rs7129843	chr11:70180381	G/A	cg00319359	chr11:70116639	PPFIA1	0.74	7.16	0.4	7.98e-12	Coronary artery disease;
CESC	cis	rs6540559	1.000	rs2235373	chr1:209963803	G/A	cg23283495	chr1:209979779	IRF6	0.52	7.39	0.41	1.9e-12	Cleft lip with or without cleft palate;
CESC	cis	rs11098499	0.743	rs11098501	chr4:120252017	T/G	cg09307838	chr4:120376055	NA	0.77	10.49	0.54	9.15e-22	Corneal astigmatism;
CESC	cis	rs425277	0.585	rs364677	chr1:2071765	A/G	cg24578937	chr1:2090814	PRKCZ	-0.35	-6.2	-0.36	2.12e-9	Height;
CESC	cis	rs7666738	0.791	rs7665273	chr4:98997413	C/A	cg05340658	chr4:99064831	C4orf37	0.8	12.44	0.61	2.83e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7527798	0.592	rs2025372	chr1:207829653	T/G	cg21110645	chr1:207815933	NA	-0.33	-5.81	-0.34	1.81e-8	Erythrocyte sedimentation rate;
CESC	trans	rs561341	0.609	rs2051810	chr17:30195841	C/T	cg20587970	chr11:113659929	NA	0.57	6.94	0.39	2.95e-11	Hip circumference adjusted for BMI;
CESC	cis	rs4332037	0.539	rs3823624	chr7:2110346	T/C	cg02743256	chr7:2109353	MAD1L1	-0.49	-5.22	-0.31	3.54e-7	Bipolar disorder;
CESC	cis	rs6546550	0.935	rs3771541	chr2:70031797	C/G	cg02498382	chr2:70120550	SNRNP27	-0.38	-6.5	-0.37	4.04e-10	Prevalent atrial fibrillation;
CESC	cis	rs4835473	0.864	rs13117932	chr4:144657026	G/T	cg25736465	chr4:144833511	NA	-0.33	-5.2	-0.3	3.99e-7	Immature fraction of reticulocytes;
CESC	cis	rs16854884	0.837	rs4362712	chr3:143801076	G/A	cg06585982	chr3:143692056	C3orf58	0.43	5.31	0.31	2.37e-7	Economic and political preferences (feminism/equality);
CESC	cis	rs6952808	0.594	rs3778965	chr7:2138296	G/A	cg23048001	chr7:2026167	MAD1L1	0.45	5.74	0.33	2.61e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs7586673	0.930	rs2884364	chr2:161977647	G/A	cg22496339	chr2:162101262	NA	0.49	6.51	0.37	3.64e-10	Intelligence (multi-trait analysis);
CESC	cis	rs9467711	0.606	rs34550936	chr6:26361985	A/G	cg14345882	chr6:26364793	BTN3A2	0.61	6.49	0.37	4.31e-10	Autism spectrum disorder or schizophrenia;
CESC	cis	rs9916302	0.821	rs1966915	chr17:37425262	A/C	cg20243544	chr17:37824526	PNMT	0.46	5.76	0.33	2.31e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs1559088	0.576	rs10407255	chr19:33581150	A/G	cg27124370	chr19:33622961	WDR88	-0.57	-8.58	-0.47	8.26e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs853679	0.517	rs9368553	chr6:28082265	T/C	cg17949981	chr6:28129498	ZNF389	0.45	5.63	0.33	4.71e-8	Depression;
CESC	cis	rs1372520	0.684	rs356191	chr4:90688120	G/A	cg15133208	chr4:90757351	SNCA	0.42	5.4	0.31	1.5e-7	Neuroticism;
CESC	cis	rs3796352	1.000	rs11714876	chr3:53101640	C/G	cg15956490	chr3:53032818	SFMBT1	-0.61	-5.33	-0.31	2.11e-7	Immune reponse to smallpox (secreted IL-2);
CESC	cis	rs7927771	0.965	rs4752845	chr11:47539697	T/C	cg18512352	chr11:47633146	NA	-0.6	-9.23	-0.49	8.67e-18	Subjective well-being;
CESC	cis	rs911555	0.755	rs11620897	chr14:103944861	T/G	cg12935359	chr14:103987150	CKB	-0.57	-8.24	-0.45	7.75e-15	Intelligence (multi-trait analysis);
CESC	cis	rs4595586	0.545	rs7973338	chr12:39380704	T/C	cg26384229	chr12:38710491	ALG10B	0.54	7.53	0.42	7.85e-13	Morning vs. evening chronotype;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg01351177	chr2:88991149	RPIA	0.5	6.99	0.39	2.17e-11	Systemic lupus erythematosus;
CESC	cis	rs7727544	0.606	rs200838	chr5:131710399	A/C	cg24060327	chr5:131705240	SLC22A5	0.43	5.26	0.31	2.99e-7	Blood metabolite levels;
CESC	cis	rs67072384	0.818	rs7926287	chr11:72464525	A/G	cg04827223	chr11:72435913	ARAP1	-0.61	-6.22	-0.36	1.97e-9	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
CESC	cis	rs7084402	1.000	rs1427204	chr10:60267640	A/C	cg07615347	chr10:60278583	BICC1	-0.61	-9.58	-0.51	7.18e-19	Refractive error;
CESC	cis	rs2439831	0.867	rs12443102	chr15:43932103	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.83	8.45	0.46	1.91e-15	Lung cancer in ever smokers;
CESC	cis	rs8020095	0.571	rs7141519	chr14:67524525	A/G	cg19548862	chr14:67692701	FAM71D	-0.5	-6.05	-0.35	4.95e-9	Depression (quantitative trait);
CESC	cis	rs1799949	1.000	rs34534709	chr17:41302940	C/G	cg23758822	chr17:41437982	NA	1.01	15.21	0.68	5.44e-38	Menopause (age at onset);
CESC	cis	rs4308124	0.708	rs6716091	chr2:111991133	C/T	cg04571233	chr2:111982156	NA	-0.6	-6.58	-0.37	2.54e-10	Vitiligo;
CESC	cis	rs4604732	0.588	rs7549955	chr1:247628321	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.53	6.57	0.37	2.7e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg11494091	chr17:61959527	GH2	0.77	13.38	0.63	1.54e-31	Prudent dietary pattern;
CESC	cis	rs2243480	1.000	rs316318	chr7:65612904	A/G	cg12463550	chr7:65579703	CRCP	0.75	5.84	0.34	1.56e-8	Diabetic kidney disease;
CESC	cis	rs929354	0.772	rs1182441	chr7:157026650	A/G	cg05182265	chr7:156933206	UBE3C	0.5	7.33	0.41	2.87e-12	Body mass index;
CESC	cis	rs1862618	0.756	rs13356762	chr5:56110992	G/T	cg18230493	chr5:56204884	C5orf35	-0.7	-8.48	-0.46	1.56e-15	Initial pursuit acceleration;
CESC	cis	rs7666738	0.606	rs28481322	chr4:99086638	T/C	cg05340658	chr4:99064831	C4orf37	0.65	9.03	0.49	3.66e-17	Colonoscopy-negative controls vs population controls;
CESC	cis	rs804280	0.662	rs810738	chr8:11611206	A/G	cg26752888	chr8:11627280	NEIL2	-0.67	-6.07	-0.35	4.38e-9	Myopia (pathological);
CESC	cis	rs910316	0.967	rs2010678	chr14:75567178	C/T	cg11812906	chr14:75593930	NEK9	0.91	15.5	0.69	5.27e-39	Height;
CESC	cis	rs7084783	0.500	rs10883892	chr10:105397102	C/T	cg00126946	chr10:105363258	SH3PXD2A	0.32	5.1	0.3	6.41e-7	Fear of pain;
CESC	cis	rs10256972	0.521	rs7457418	chr7:1110255	C/T	cg23978390	chr7:1156363	C7orf50	0.48	6.38	0.36	8.01e-10	Longevity;Endometriosis;
CESC	cis	rs7666738	0.822	rs9992360	chr4:98937123	T/C	cg03467027	chr4:99064603	C4orf37	0.48	5.91	0.34	1.03e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7301826	0.580	rs61938969	chr12:131316070	A/G	cg11011512	chr12:131303247	STX2	-0.44	-5.26	-0.31	3.02e-7	Plasma plasminogen activator levels;
CESC	cis	rs7937682	1.000	rs10502147	chr11:111569931	G/A	cg09085632	chr11:111637200	PPP2R1B	1.03	14.07	0.65	5.86e-34	Primary sclerosing cholangitis;
CESC	cis	rs637571	0.512	rs660118	chr11:65735174	G/C	cg02202077	chr11:65769826	EIF1AD;BANF1	0.45	5.92	0.34	9.86e-9	Eosinophil percentage of white cells;
CESC	trans	rs60843830	1.000	rs10193373	chr2:281886	T/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.68	8.44	0.46	2.1e-15	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs3771570	1.000	rs60209440	chr2:242260340	G/C	cg21155796	chr2:242212141	HDLBP	0.6	5.05	0.3	8.15e-7	Prostate cancer;
CESC	cis	rs2439831	1.000	rs689754	chr15:43775895	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.9	10.2	0.53	8.18e-21	Lung cancer in ever smokers;
CESC	cis	rs6076065	0.748	rs999068	chr20:23376483	G/A	cg11657817	chr20:23433608	CST11	0.4	6.1	0.35	3.7e-9	Facial morphology (factor 15, philtrum width);
CESC	cis	rs7927592	0.956	rs11228277	chr11:68308324	G/A	cg20283391	chr11:68216788	NA	-0.5	-6.35	-0.36	9.36e-10	Total body bone mineral density;
CESC	trans	rs17613427	1.000	rs111624850	chr2:142246560	T/G	cg16810031	chr17:38024146	ZPBP2	-0.9	-6.25	-0.36	1.65e-9	Left  ventricle systolic dysfunction;
CESC	cis	rs2014572	0.967	rs10413671	chr19:57763489	G/A	cg24459738	chr19:57751996	ZNF805	-0.53	-7.57	-0.42	6.02e-13	Hyperactive-impulsive symptoms;
CESC	cis	rs11098499	0.954	rs7687843	chr4:120421211	C/T	cg09307838	chr4:120376055	NA	0.92	12.98	0.62	3.83e-30	Corneal astigmatism;
CESC	cis	rs6964587	1.000	rs7781066	chr7:91691946	G/T	cg17063962	chr7:91808500	NA	0.59	8.2	0.45	1.03e-14	Breast cancer;
CESC	cis	rs1129187	0.837	rs3763236	chr6:42902508	C/T	cg02353165	chr6:42928485	GNMT	-0.61	-9.25	-0.49	8.01e-18	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg16132339	chr22:24313637	DDTL;DDT	0.42	6.41	0.37	6.65e-10	Liver enzyme levels (gamma-glutamyl transferase);
CESC	trans	rs208520	1.000	rs12190773	chr6:66968194	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.85	9.42	0.5	2.36e-18	Exhaled nitric oxide output;
CESC	cis	rs1816752	1.000	rs7988810	chr13:25019096	T/C	cg02811702	chr13:24901961	NA	0.39	5.63	0.33	4.52e-8	Obesity-related traits;
CESC	cis	rs763121	0.853	rs5995610	chr22:39064681	C/T	cg14440974	chr22:39074834	NA	-0.42	-5.82	-0.34	1.69e-8	Menopause (age at onset);
CESC	cis	rs769267	1.000	rs12985655	chr19:19442434	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.42	-5.35	-0.31	1.9e-7	Tonsillectomy;
CESC	cis	rs8058578	1.000	rs7187359	chr16:30703155	G/A	cg02466173	chr16:30829666	NA	-0.4	-6.38	-0.36	8.06e-10	Multiple myeloma;
CESC	cis	rs4481887	1.000	rs11204636	chr1:248492409	A/C	cg00666640	chr1:248458726	OR2T12	-0.39	-6.85	-0.39	5.1e-11	Common traits (Other);
CESC	cis	rs6912958	0.712	rs7746465	chr6:88348996	T/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.32	-5.24	-0.31	3.32e-7	Monocyte percentage of white cells;
CESC	cis	rs473651	0.904	rs62196716	chr2:239356977	C/G	cg21699342	chr2:239360505	ASB1	0.58	10.22	0.53	7.17e-21	Multiple system atrophy;
CESC	cis	rs7666738	0.830	rs6532723	chr4:99052147	A/T	cg05340658	chr4:99064831	C4orf37	0.82	12.88	0.62	8.44e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6500602	0.623	rs9929311	chr16:4510426	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.38	5.34	0.31	1.97e-7	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05590616	chr11:59522917	STX3	0.55	6.1	0.35	3.69e-9	Gut microbiome composition (summer);
CESC	cis	rs7814319	0.674	rs7836698	chr8:97242849	C/T	cg20787634	chr8:97240163	UQCRB	-0.55	-6.47	-0.37	4.6e-10	Lung function (FVC);
CESC	cis	rs61774743	0.557	rs4359027	chr1:41848296	G/A	cg08462924	chr1:41848221	NA	0.45	6.24	0.36	1.69e-9	Intelligence (multi-trait analysis);
CESC	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg12419862	chr22:24373484	LOC391322	-0.59	-8.07	-0.44	2.41e-14	Liver enzyme levels (gamma-glutamyl transferase);
CESC	trans	rs10435719	0.899	rs11250177	chr8:11799099	G/A	cg15556689	chr8:8085844	FLJ10661	0.54	6.73	0.38	1.03e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
CESC	trans	rs13035304	0.773	rs7586873	chr2:130507396	A/G	cg18827756	chr15:42130735	JMJD7-PLA2G4B;PLA2G4B	-0.41	-6.7	-0.38	1.28e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
CESC	cis	rs9640161	0.750	rs3735167	chr7:150039555	C/T	cg27494647	chr7:150038898	RARRES2	0.43	5.16	0.3	4.84e-7	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs4665809	0.589	rs4665842	chr2:26448954	A/G	cg26314531	chr2:26401878	FAM59B	-0.85	-8.91	-0.48	8.54e-17	Gut microbiome composition (summer);
CESC	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.56	-8.7	-0.47	3.69e-16	Longevity;Endometriosis;
CESC	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg26354017	chr1:205819088	PM20D1	1.01	18.11	0.74	3.04e-48	Menarche (age at onset);
CESC	cis	rs1799949	1.000	rs11652332	chr17:41295489	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.64	8.64	0.47	5.5e-16	Menopause (age at onset);
CESC	cis	rs4555082	0.957	rs2816628	chr14:105736134	T/G	cg06808227	chr14:105710500	BRF1	-0.54	-6.86	-0.39	4.88e-11	Mean platelet volume;Platelet distribution width;
CESC	cis	rs4713118	0.586	rs6905522	chr6:28086479	A/C	cg08968635	chr6:28129556	ZNF389	0.4	5.36	0.31	1.84e-7	Parkinson's disease;
CESC	cis	rs7618501	0.516	rs2856236	chr3:50161717	A/C	cg24308560	chr3:49941425	MST1R	0.57	8.04	0.44	3.06e-14	Intelligence (multi-trait analysis);
CESC	cis	rs8114671	0.528	rs6119542	chr20:33484545	G/T	cg24642439	chr20:33292090	TP53INP2	0.43	5.19	0.3	4.19e-7	Height;
CESC	trans	rs62103177	0.759	rs7227794	chr18:77610925	C/T	cg05926928	chr17:57297772	GDPD1	1.16	11.61	0.58	1.88e-25	Opioid sensitivity;
CESC	cis	rs4665809	0.816	rs2384359	chr2:26371364	T/C	cg22920501	chr2:26401640	FAM59B	-0.84	-10.1	-0.53	1.72e-20	Gut microbiome composition (summer);
CESC	cis	rs6736093	0.932	rs77096506	chr2:112657554	T/G	cg12686935	chr2:112915763	FBLN7	-0.42	-5.17	-0.3	4.56e-7	Coronary artery disease;
CESC	cis	rs8114671	0.562	rs4911161	chr20:33402231	C/T	cg07148914	chr20:33460835	GGT7	0.45	5.9	0.34	1.1e-8	Height;
CESC	cis	rs4971059	0.629	rs4246529	chr1:155115260	T/C	cg22049894	chr1:155113146	DPM3	0.46	5.91	0.34	1.06e-8	Breast cancer;
CESC	cis	rs4665809	0.938	rs6742226	chr2:26342537	A/G	cg22920501	chr2:26401640	FAM59B	-0.63	-7.49	-0.42	1e-12	Gut microbiome composition (summer);
CESC	cis	rs9858542	0.953	rs9853683	chr3:49512588	A/G	cg03060546	chr3:49711283	APEH	-0.54	-6.12	-0.35	3.44e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	trans	rs12356475	0.710	rs10822686	chr10:67733250	C/T	cg19726959	chr15:75094782	CSK	-0.49	-6.09	-0.35	3.99e-9	Psoriatic arthritis;
CESC	cis	rs6121246	0.559	rs6119650	chr20:30258480	C/A	cg13852791	chr20:30311386	BCL2L1	0.79	10.1	0.53	1.74e-20	Mean corpuscular hemoglobin;
CESC	cis	rs9300255	0.537	rs1727334	chr12:123714236	A/G	cg00376283	chr12:123451042	ABCB9	0.72	8.84	0.48	1.34e-16	Neutrophil percentage of white cells;
CESC	cis	rs6500395	0.775	rs4277341	chr16:48664387	T/G	cg04672837	chr16:48644449	N4BP1	0.49	6.27	0.36	1.46e-9	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs4665809	1.000	rs3910272	chr2:26287842	T/A	cg22920501	chr2:26401640	FAM59B	-0.79	-9.3	-0.5	5.61e-18	Gut microbiome composition (summer);
CESC	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg23708337	chr7:1209742	NA	0.55	5.42	0.32	1.33e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2408955	0.522	rs4760679	chr12:48461635	G/T	cg24011408	chr12:48396354	COL2A1	-0.49	-7.41	-0.41	1.74e-12	Glycated hemoglobin levels;
CESC	cis	rs7666738	0.830	rs13106434	chr4:98991651	T/A	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.62e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs875971	0.505	rs2462573	chr7:65507392	C/T	cg26939375	chr7:64535504	NA	-0.74	-10.63	-0.55	3.13e-22	Aortic root size;
CESC	cis	rs11252926	0.770	rs2124585	chr10:680428	G/A	cg08603382	chr10:743973	NA	0.4	5.56	0.32	6.62e-8	Psychosis in Alzheimer's disease;
CESC	cis	rs933688	0.877	rs10474352	chr5:90732225	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.12	12.71	0.62	3.1e-29	Smoking behavior;
CESC	cis	rs9910055	0.615	rs189049	chr17:42197213	A/C	cg08499158	chr17:42289980	UBTF	0.51	6.47	0.37	4.62e-10	Total body bone mineral density;
CESC	cis	rs40363	0.645	rs250627	chr16:3527050	G/A	cg00484396	chr16:3507460	NAT15	0.42	6.79	0.38	7.34e-11	Tuberculosis;
CESC	cis	rs769267	0.864	rs7245983	chr19:19657632	A/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.45	5.61	0.33	4.99e-8	Tonsillectomy;
CESC	cis	rs7274811	0.688	rs6141400	chr20:32056087	C/T	cg21523528	chr20:32077966	CBFA2T2	0.58	6.93	0.39	3.19e-11	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15947099	chr10:70481448	CCAR1	0.52	6.04	0.35	5.18e-9	Gut microbiome composition (summer);
CESC	cis	rs12824058	0.549	rs4759453	chr12:130824565	C/G	cg24838063	chr12:130822603	PIWIL1	0.73	9.31	0.5	5.11e-18	Menopause (age at onset);
CESC	cis	rs9322193	0.962	rs2151912	chr6:150152908	A/G	cg13206674	chr6:150067644	NUP43	0.41	5.66	0.33	3.88e-8	Lung cancer;
CESC	cis	rs4819052	0.851	rs7276591	chr21:46680156	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.93	14.04	0.65	7.76e-34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs6952808	0.862	rs4721167	chr7:1933224	C/T	cg02951883	chr7:2050386	MAD1L1	-0.51	-6.88	-0.39	4.26e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs3785574	0.962	rs2665840	chr17:61873307	C/T	cg07677032	chr17:61819896	STRADA	-0.41	-5.25	-0.31	3.11e-7	Height;
CESC	cis	rs72781680	0.611	rs72797810	chr2:24336469	G/A	cg20701182	chr2:24300061	SF3B14	0.91	10.51	0.54	7.88e-22	Lymphocyte counts;
CESC	cis	rs6540559	0.546	rs57315825	chr1:210030197	C/T	cg21951975	chr1:209979733	IRF6	0.54	6.35	0.36	9.15e-10	Cleft lip with or without cleft palate;
CESC	cis	rs11122272	0.701	rs2011383	chr1:231479788	T/A	cg06096015	chr1:231504339	EGLN1	0.43	6.41	0.37	6.78e-10	Hemoglobin concentration;
CESC	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.64	7.2	0.4	6.15e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs9323205	0.953	rs61144314	chr14:51620556	G/A	cg23942311	chr14:51606299	NA	-0.44	-5.7	-0.33	3.21e-8	Cancer;
CESC	cis	rs1062177	0.855	rs919262	chr5:151266084	C/T	cg12924095	chr5:151150029	G3BP1	-0.45	-6.16	-0.35	2.71e-9	Preschool internalizing problems;
CESC	cis	rs17253792	0.822	rs9972180	chr14:56073732	G/T	cg01858014	chr14:56050164	KTN1	-0.85	-6.99	-0.39	2.22e-11	Putamen volume;
CESC	cis	rs1552244	1.000	rs7622966	chr3:10139833	C/T	cg08888203	chr3:10149979	C3orf24	0.44	5.6	0.33	5.31e-8	Alzheimer's disease;
CESC	cis	rs5750830	0.649	rs4821895	chr22:39823015	A/G	cg01416388	chr22:39784598	NA	-0.58	-7.21	-0.4	6.02e-12	Intelligence (multi-trait analysis);
CESC	trans	rs637571	0.565	rs633800	chr11:65638719	G/A	cg17712092	chr4:129076599	LARP1B	-0.7	-8.88	-0.48	1.02e-16	Eosinophil percentage of white cells;
CESC	cis	rs4243830	0.850	rs4908910	chr1:6599362	T/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.86	-7.53	-0.42	7.77e-13	Body mass index;
CESC	cis	rs7605827	0.897	rs7567750	chr2:15690412	C/T	cg19274914	chr2:15703543	NA	0.37	6.7	0.38	1.22e-10	Educational attainment (years of education);
CESC	cis	rs7582720	0.943	rs72926798	chr2:203827675	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.36	0.41	2.34e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs2066819	1.000	rs41423244	chr12:56693520	A/C	cg26804944	chr12:56660921	COQ10A	0.87	5.3	0.31	2.45e-7	Psoriasis vulgaris;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg06995624	chr17:73043174	ATP5H;KCTD2	-0.5	-6.63	-0.38	1.88e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs11785400	0.701	rs9721143	chr8:143727511	A/T	cg24634471	chr8:143751801	JRK	0.46	5.82	0.34	1.73e-8	Schizophrenia;
CESC	cis	rs10865397	0.539	rs13414338	chr2:73383375	C/T	cg01422370	chr2:73384389	NA	0.47	7.47	0.42	1.15e-12	Intelligence (multi-trait analysis);
CESC	cis	rs7927592	0.763	rs7129248	chr11:68263276	A/T	cg20283391	chr11:68216788	NA	-0.44	-5.47	-0.32	1.06e-7	Total body bone mineral density;
CESC	cis	rs2760061	0.819	rs708112	chr1:228192452	G/A	cg18477163	chr1:228402036	OBSCN	0.31	5.5	0.32	9.1e-8	Diastolic blood pressure;
CESC	cis	rs4319547	0.586	rs7956480	chr12:122817507	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.48	-5.52	-0.32	8.2e-8	Body mass index;
CESC	cis	rs116095464	0.558	rs62347678	chr5:227496	A/G	cg10591111	chr5:226296	SDHA	-0.53	-6.65	-0.38	1.64e-10	Breast cancer;
CESC	cis	rs1552244	0.808	rs7615088	chr3:10035896	A/T	cg00149659	chr3:10157352	C3orf10	0.7	8.31	0.45	5.08e-15	Alzheimer's disease;
CESC	cis	rs13082711	0.911	rs17682751	chr3:27497027	C/T	cg02860705	chr3:27208620	NA	-0.54	-6.75	-0.38	9.43e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CESC	trans	rs6572548	0.504	rs1956082	chr14:49665496	A/C	cg26035463	chr12:117627651	FBXO21	-0.56	-6.09	-0.35	3.92e-9	Subjective well-being;
CESC	cis	rs853679	0.546	rs35353359	chr6:28324378	C/T	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.84	5.51	0.32	8.48e-8	Depression;
CESC	cis	rs74781061	0.929	rs12442097	chr15:74847133	A/C	cg17294928	chr15:75287854	SCAMP5	-0.49	-5.24	-0.31	3.28e-7	Endometriosis;
CESC	cis	rs875971	1.000	rs7789554	chr7:65946038	A/G	cg18876405	chr7:65276391	NA	0.51	6.82	0.39	6.05e-11	Aortic root size;
CESC	cis	rs7772486	0.686	rs4896827	chr6:145953338	T/A	cg23711669	chr6:146136114	FBXO30	0.92	13.65	0.64	1.81e-32	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs17376456	0.877	rs9314099	chr5:93447375	T/C	cg25358565	chr5:93447407	FAM172A	1.15	11.8	0.59	4.11e-26	Diabetic retinopathy;
CESC	cis	rs7267979	1.000	rs8125868	chr20:25324410	A/G	cg08601574	chr20:25228251	PYGB	-0.37	-5.36	-0.31	1.81e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs1008375	0.900	rs1003413	chr4:17582442	C/T	cg16339924	chr4:17578868	LAP3	-0.82	-10.32	-0.54	3.28e-21	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs4523957	0.928	rs170044	chr17:2197502	C/G	cg16513277	chr17:2031491	SMG6	-0.57	-7.7	-0.43	2.79e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs769267	0.965	rs4808938	chr19:19401218	G/A	cg03709012	chr19:19516395	GATAD2A	0.95	13.98	0.65	1.22e-33	Tonsillectomy;
CESC	cis	rs6952808	0.723	rs11766575	chr7:2005747	T/C	cg08027265	chr7:2291960	NA	-0.41	-6.08	-0.35	4.22e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs959260	0.688	rs9899687	chr17:73358259	C/T	cg20590849	chr17:73267439	MIF4GD	-0.56	-6.11	-0.35	3.55e-9	Systemic lupus erythematosus;
CESC	cis	rs71403859	0.614	rs12935422	chr16:71664225	T/A	cg08717414	chr16:71523259	ZNF19	-0.69	-5.94	-0.34	9.1e-9	Post bronchodilator FEV1;
CESC	cis	rs736408	0.608	rs6445534	chr3:52743384	G/A	cg18404041	chr3:52824283	ITIH1	-0.39	-6.64	-0.38	1.81e-10	Bipolar disorder;
CESC	cis	rs3096299	0.632	rs8051537	chr16:89544384	T/A	cg00750074	chr16:89608354	SPG7	-0.41	-6.05	-0.35	4.84e-9	Multiple myeloma (IgH translocation);
CESC	cis	rs7647973	0.771	rs9865051	chr3:49166069	C/T	cg07636037	chr3:49044803	WDR6	0.9	11.4	0.57	8.91e-25	Menarche (age at onset);
CESC	cis	rs35995292	0.534	rs917322	chr7:38943165	A/T	cg19327137	chr7:38886074	VPS41	-0.65	-10.64	-0.55	2.96e-22	Subjective well-being (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26726542	chr13:20702031	NA	0.54	6.62	0.38	2e-10	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06528150	chr2:61293470	KIAA1841	0.54	6.2	0.36	2.17e-9	Gut microbiome composition (summer);
CESC	cis	rs4253772	0.744	rs9627278	chr22:46643432	C/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.49	5.12	0.3	5.79e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs17601876	0.807	rs12910259	chr15:51555049	G/A	cg19946085	chr15:51559439	CYP19A1	-0.34	-5.29	-0.31	2.52e-7	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
CESC	cis	rs3820928	1.000	rs4675120	chr2:227774888	C/T	cg05526886	chr2:227700861	RHBDD1	-0.44	-5.75	-0.33	2.45e-8	Pulmonary function;
CESC	cis	rs3087591	1.000	rs2905795	chr17:29547601	A/G	cg24425628	chr17:29625626	OMG;NF1	0.42	5.11	0.3	6.32e-7	Hip circumference;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03582286	chr4:71571171	RUFY3	0.57	6.79	0.38	7.25e-11	Gut microbiome composition (summer);
CESC	cis	rs3793683	0.597	rs12783367	chr10:134587334	T/C	cg18305652	chr10:134549665	INPP5A	0.48	6.82	0.39	6.13e-11	Migraine;
CESC	cis	rs1348850	0.958	rs4893941	chr2:178269531	A/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.88	12.78	0.62	1.88e-29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs2839186	0.558	rs2968	chr21:47608580	C/T	cg00612595	chr21:47717864	NA	0.41	5.57	0.32	6.27e-8	Testicular germ cell tumor;
CESC	cis	rs10504229	0.639	rs66667899	chr8:58117065	C/T	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs7829975	0.714	rs12544992	chr8:8661681	C/G	cg17143192	chr8:8559678	CLDN23	0.44	5.37	0.31	1.74e-7	Mood instability;
CESC	cis	rs1577917	0.958	rs1335442	chr6:86466692	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.52	-6.84	-0.39	5.52e-11	Response to antipsychotic treatment;
CESC	cis	rs6752107	0.791	rs3792106	chr2:234190740	A/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.44	5.91	0.34	1.04e-8	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs2070488	0.775	rs6780349	chr3:38555178	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.76	-12.23	-0.6	1.43e-27	Electrocardiographic conduction measures;
CESC	cis	rs9393777	0.513	rs6936555	chr6:26640886	C/T	cg11502198	chr6:26597334	ABT1	0.52	5.34	0.31	1.99e-7	Intelligence (multi-trait analysis);
CESC	cis	rs72781680	0.665	rs2675356	chr2:24074734	C/T	cg08917208	chr2:24149416	ATAD2B	0.63	6.28	0.36	1.41e-9	Lymphocyte counts;
CESC	cis	rs10540	1.000	rs61876341	chr11:495892	C/G	cg21784768	chr11:537496	LRRC56	-0.55	-5.13	-0.3	5.71e-7	Body mass index;
CESC	cis	rs3785574	0.638	rs2854182	chr17:61969062	G/A	cg06873352	chr17:61820015	STRADA	0.48	6.88	0.39	4.26e-11	Height;
CESC	cis	rs2842992	0.789	rs4276525	chr6:160193612	G/A	cg27503950	chr6:160024002	NA	0.35	5.08	0.3	7.22e-7	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs2732480	0.577	rs2634691	chr12:48708259	G/T	cg24011408	chr12:48396354	COL2A1	0.43	5.97	0.34	7.7e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs514406	0.861	rs1412706	chr1:53237721	G/A	cg24675658	chr1:53192096	ZYG11B	0.53	6.69	0.38	1.29e-10	Monocyte count;
CESC	cis	rs1983891	1.000	rs9381082	chr6:41542214	T/C	cg20194872	chr6:41519635	FOXP4	0.55	7.76	0.43	1.88e-13	Prostate cancer;
CESC	cis	rs2074409	0.571	rs67499664	chr17:35893645	T/A	cg16670864	chr17:35848621	DUSP14	0.43	5.16	0.3	4.87e-7	Response to angiotensin II receptor blocker therapy;
CESC	cis	rs4727963	0.792	rs1525469	chr7:122718038	A/G	cg03640110	chr7:122635026	TAS2R16	0.41	6.65	0.38	1.67e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
CESC	cis	rs9303280	0.806	rs35569035	chr17:38035624	C/T	cg20243544	chr17:37824526	PNMT	0.53	6.96	0.39	2.6e-11	Self-reported allergy;
CESC	cis	rs67311347	0.824	rs73073561	chr3:40357298	G/T	cg24209194	chr3:40518798	ZNF619	0.4	5.04	0.3	8.46e-7	Renal cell carcinoma;
CESC	cis	rs8114671	0.869	rs1407202	chr20:33651967	C/T	cg06115741	chr20:33292138	TP53INP2	-0.45	-5.44	-0.32	1.23e-7	Height;
CESC	cis	rs6032067	0.714	rs35770435	chr20:43788804	C/T	cg11264863	chr20:43835661	SEMG1	0.51	5.46	0.32	1.11e-7	Blood protein levels;
CESC	cis	rs6121246	0.529	rs7261354	chr20:30202414	T/C	cg13852791	chr20:30311386	BCL2L1	0.66	6.6	0.38	2.23e-10	Mean corpuscular hemoglobin;
CESC	cis	rs7772486	0.622	rs1292333	chr6:145982344	C/T	cg05347473	chr6:146136440	FBXO30	-0.55	-7.23	-0.41	5.17e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6938	0.534	rs12904897	chr15:75217686	A/G	cg14664628	chr15:75095509	CSK	-0.59	-8.12	-0.45	1.77e-14	Breast cancer;
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg11922607	chr18:21083993	C18orf8	-0.41	-6.12	-0.35	3.41e-9	Vertical cup-disc ratio;
CESC	cis	rs7312933	0.558	rs3747560	chr12:42719890	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.48	-6.4	-0.37	7.09e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs896854	0.714	rs6471503	chr8:95990283	G/A	cg23172400	chr8:95962367	TP53INP1	-0.44	-9.21	-0.49	1e-17	Type 2 diabetes;
CESC	cis	rs28386778	0.704	rs1051688	chr17:62006433	G/C	cg06601766	chr17:61851465	DDX42;CCDC47	-0.54	-6.65	-0.38	1.63e-10	Prudent dietary pattern;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg06713297	chr1:242011104	EXO1	0.53	7.19	0.4	6.48e-12	Systemic lupus erythematosus;
CESC	cis	rs6860806	0.507	rs272880	chr5:131670178	C/T	cg07395648	chr5:131743802	NA	-0.43	-5.64	-0.33	4.38e-8	Breast cancer;
CESC	cis	rs7618915	0.547	rs10780035	chr3:52764624	C/T	cg18404041	chr3:52824283	ITIH1	-0.41	-6.88	-0.39	4.39e-11	Bipolar disorder;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg20029123	chr22:30783486	RNF215	-0.47	-6.14	-0.35	2.99e-9	Ulcerative colitis;
CESC	cis	rs713587	0.563	rs1529897	chr2:25086827	T/G	cg01884057	chr2:25150051	NA	0.34	6.36	0.36	8.88e-10	Body mass index in non-asthmatics;
CESC	cis	rs2479724	0.811	rs8393	chr6:41757836	C/A	cg17623882	chr6:41773611	USP49	0.41	5.57	0.32	6.41e-8	Menarche (age at onset);
CESC	cis	rs12220238	1.000	rs1908331	chr10:75885817	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.64	6.52	0.37	3.45e-10	Soluble interleukin-2 receptor subunit alpha;
CESC	cis	rs941408	0.515	rs1640265	chr19:2784405	C/T	cg02580895	chr19:2754563	NA	-0.48	-6.56	-0.37	2.73e-10	Total cholesterol levels;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg24274347	chr12:132497611	EP400	0.51	7.0	0.4	2.07e-11	Fibrinogen levels;
CESC	cis	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg05863683	chr7:1912471	MAD1L1	0.42	6.2	0.36	2.2e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs6912958	0.712	rs4498321	chr6:88339251	G/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-6.72	-0.38	1.09e-10	Monocyte percentage of white cells;
CESC	cis	rs4563143	0.675	rs73029050	chr19:29276554	G/T	cg12667521	chr19:29218732	NA	0.49	6.35	0.36	9.47e-10	Methadone dose in opioid dependence;
CESC	cis	rs4820539	1.000	rs885965	chr22:23461425	A/G	cg14186256	chr22:23484241	RTDR1	0.83	14.44	0.66	2.92e-35	Bone mineral density;
CESC	cis	rs736408	0.609	rs2230534	chr3:52802402	A/C	cg18404041	chr3:52824283	ITIH1	-0.44	-7.28	-0.41	3.87e-12	Bipolar disorder;
CESC	cis	rs3857536	0.740	rs9342532	chr6:66886297	T/C	cg07460842	chr6:66804631	NA	-0.42	-5.39	-0.31	1.53e-7	Blood trace element (Cu levels);
CESC	cis	rs67311347	1.000	rs1466236	chr3:40462162	C/T	cg09455208	chr3:40491958	NA	0.45	7.93	0.44	6.31e-14	Renal cell carcinoma;
CESC	cis	rs916888	0.773	rs199451	chr17:44801784	G/A	cg27589368	chr17:43923255	LOC100128977;IMP5	-0.39	-5.28	-0.31	2.72e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs708547	0.647	rs1713982	chr4:57881715	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.47	6.61	0.38	2.11e-10	Response to bleomycin (chromatid breaks);
CESC	cis	rs1799949	1.000	rs8176273	chr17:41211653	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.4	5.38	0.31	1.68e-7	Menopause (age at onset);
CESC	cis	rs7100689	0.646	rs2039757	chr10:82078868	C/A	cg00277334	chr10:82204260	NA	-0.6	-7.96	-0.44	4.91e-14	Post bronchodilator FEV1;
CESC	cis	rs8141529	0.778	rs5762795	chr22:29182500	C/A	cg15103426	chr22:29168792	CCDC117	0.68	9.79	0.52	1.59e-19	Lymphocyte counts;
CESC	cis	rs9314323	0.798	rs12682345	chr8:26218332	A/G	cg13160058	chr8:26243215	BNIP3L	0.32	5.13	0.3	5.53e-7	Red cell distribution width;
CESC	cis	rs7607369	0.718	rs6727147	chr2:219639024	G/A	cg02176678	chr2:219576539	TTLL4	-0.43	-7.65	-0.43	3.62e-13	Red blood cell count;Amyotrophic lateral sclerosis;
CESC	cis	rs769267	0.965	rs2074299	chr19:19380646	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.44	5.42	0.32	1.37e-7	Tonsillectomy;
CESC	cis	rs36051895	0.623	rs76960049	chr9:5064548	G/A	cg02405213	chr9:5042618	JAK2	-0.47	-5.89	-0.34	1.14e-8	Pediatric autoimmune diseases;
CESC	cis	rs1799949	0.965	rs12947782	chr17:41279882	A/G	cg25072359	chr17:41440525	NA	0.43	5.78	0.33	2.04e-8	Menopause (age at onset);
CESC	cis	rs7520050	0.966	rs10749860	chr1:46328210	C/G	cg24296786	chr1:45957014	TESK2	0.42	5.37	0.31	1.69e-7	Red blood cell count;Reticulocyte count;
CESC	cis	rs1538970	0.924	rs12097497	chr1:45880669	C/T	cg24296786	chr1:45957014	TESK2	-0.45	-5.28	-0.31	2.65e-7	Platelet count;
CESC	trans	rs11039798	0.588	rs113800184	chr11:48756855	G/A	cg15704280	chr7:45808275	SEPT13	0.65	6.5	0.37	4.05e-10	Axial length;
CESC	cis	rs7267979	1.000	rs2258719	chr20:25275843	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.84	16.05	0.7	5.98e-41	Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs1814175	0.616	rs10769644	chr11:49987676	C/A	cg15704280	chr7:45808275	SEPT13	-1.01	-19.02	-0.76	1.83e-51	Height;
CESC	cis	rs77106637	0.932	rs74439784	chr11:72649396	A/T	cg03713592	chr11:72463424	ARAP1	1.07	9.88	0.52	8.17e-20	Type 2 diabetes;
CESC	trans	rs9929218	0.748	rs34592833	chr16:68739125	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.73	-8.79	-0.48	1.92e-16	Colorectal cancer;
CESC	cis	rs1568889	0.838	rs4572130	chr11:28371794	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.82	13.76	0.65	6.99e-33	Bipolar disorder;
CESC	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg11965913	chr1:205819406	PM20D1	0.82	13.45	0.64	8.74e-32	Menarche (age at onset);
CESC	cis	rs6537837	1.000	rs7355157	chr1:110129835	T/C	cg05049280	chr1:110155535	GNAT2	0.38	5.32	0.31	2.17e-7	Major depressive disorder;
CESC	cis	rs2180341	0.538	rs3756993	chr6:127651551	A/C	cg27446573	chr6:127587934	RNF146	0.63	8.57	0.47	8.45e-16	Breast cancer;
CESC	cis	rs2932538	0.922	rs12750621	chr1:113206502	G/C	cg22162597	chr1:113214053	CAPZA1	0.61	7.42	0.41	1.55e-12	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CESC	cis	rs1348850	0.574	rs2365617	chr2:178421934	C/A	cg23306229	chr2:178417860	TTC30B	0.79	6.97	0.39	2.45e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs6582630	0.502	rs1589390	chr12:38416139	C/T	cg26384229	chr12:38710491	ALG10B	-0.4	-5.32	-0.31	2.24e-7	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs9467773	0.620	rs2504567	chr6:26662920	C/G	cg20266910	chr6:26577678	NA	0.35	5.67	0.33	3.79e-8	Intelligence (multi-trait analysis);
CESC	cis	rs2637266	0.783	rs720249	chr10:78476143	T/C	cg18941641	chr10:78392320	NA	0.44	8.37	0.46	3.29e-15	Pulmonary function;
CESC	cis	rs910316	1.000	rs4903289	chr14:75623988	C/T	cg11812906	chr14:75593930	NEK9	-0.91	-16.2	-0.71	1.69e-41	Height;
CESC	cis	rs7937682	0.881	rs4936678	chr11:111625085	C/T	cg22437258	chr11:111473054	SIK2	-0.56	-5.28	-0.31	2.76e-7	Primary sclerosing cholangitis;
CESC	cis	rs116095464	0.558	rs2288458	chr5:231260	C/T	cg22496380	chr5:211416	CCDC127	-0.74	-8.5	-0.46	1.44e-15	Breast cancer;
CESC	cis	rs2573652	1.000	rs12441080	chr15:100516968	A/G	cg00587665	chr15:100533223	ADAMTS17	0.36	5.84	0.34	1.54e-8	Height;
CESC	trans	rs17428076	0.836	rs12053046	chr2:172673399	A/G	cg14287618	chr9:37440492	ZBTB5	0.47	6.01	0.35	6.13e-9	Myopia;
CESC	trans	rs10242455	0.702	rs73711293	chr7:99081595	C/T	cg09045935	chr12:6379348	NA	0.88	6.81	0.39	6.62e-11	Blood metabolite levels;
CESC	cis	rs2481665	0.777	rs17379217	chr1:62545085	C/T	cg18591186	chr1:62594603	INADL	-0.43	-5.08	-0.3	7.16e-7	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs477692	0.905	rs524545	chr10:131411840	A/C	cg05714579	chr10:131428358	MGMT	-0.53	-7.36	-0.41	2.3e-12	Response to temozolomide;
CESC	cis	rs10779751	0.922	rs2295080	chr1:11322628	G/T	cg08854313	chr1:11322531	MTOR	0.93	14.76	0.67	2.21e-36	Body mass index;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg24936468	chr1:25663368	TMEM50A	0.48	6.52	0.37	3.61e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs708547	0.624	rs1718886	chr4:57849251	C/T	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.55	-7.52	-0.42	8.66e-13	Response to bleomycin (chromatid breaks);
CESC	cis	rs4319547	0.956	rs10744275	chr12:123048618	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.58	-6.41	-0.37	6.77e-10	Body mass index;
CESC	cis	rs4665809	1.000	rs1470097	chr2:26312840	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.7	-7.98	-0.44	4.48e-14	Gut microbiome composition (summer);
CESC	cis	rs10504229	0.683	rs61201557	chr8:58138370	T/C	cg02725872	chr8:58115012	NA	-0.45	-7.05	-0.4	1.52e-11	Developmental language disorder (linguistic errors);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07419830	chr16:3332899	ZNF263	0.62	7.2	0.4	6.22e-12	Gut microbiome composition (summer);
CESC	cis	rs6163	0.588	rs10786706	chr10:104500659	C/T	cg04362960	chr10:104952993	NT5C2	0.4	5.45	0.32	1.15e-7	Waist circumference;Hip circumference;
CESC	cis	rs9916302	0.851	rs4794810	chr17:37603774	T/C	cg20243544	chr17:37824526	PNMT	0.49	6.23	0.36	1.85e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs7666738	0.830	rs2903150	chr4:99027184	T/C	cg03467027	chr4:99064603	C4orf37	0.49	6.18	0.35	2.44e-9	Colonoscopy-negative controls vs population controls;
CESC	trans	rs1373453	0.808	rs117805570	chr12:70069098	C/T	cg19702771	chr4:82058885	PRKG2	0.74	6.04	0.35	5.28e-9	Orofacial clefts;
CESC	cis	rs2072732	0.706	rs112690788	chr1:2954055	A/G	cg15211996	chr1:2936768	ACTRT2	0.34	5.78	0.33	2.08e-8	Plateletcrit;
CESC	cis	rs17376456	0.877	rs28575883	chr5:93346035	T/C	cg21475434	chr5:93447410	FAM172A	0.77	6.74	0.38	9.6e-11	Diabetic retinopathy;
CESC	cis	rs763121	0.889	rs9610971	chr22:38910810	C/T	cg06022373	chr22:39101656	GTPBP1	0.78	11.1	0.56	9.56e-24	Menopause (age at onset);
CESC	cis	rs7666738	0.830	rs6532715	chr4:99016792	G/A	cg05340658	chr4:99064831	C4orf37	0.82	13.05	0.63	2.08e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs35146811	0.555	rs2525539	chr7:99545309	A/G	cg14163444	chr7:99595348	NA	0.4	5.13	0.3	5.67e-7	Coronary artery disease;
CESC	cis	rs5750830	0.649	rs2413590	chr22:39790191	G/C	cg05872129	chr22:39784769	NA	-0.85	-11.73	-0.58	7.18e-26	Intelligence (multi-trait analysis);
CESC	cis	rs17711722	0.528	rs73138179	chr7:65294482	G/T	cg19163074	chr7:65112434	INTS4L2	-0.44	-5.3	-0.31	2.41e-7	Calcium levels;
CESC	cis	rs2228479	0.850	rs1108063	chr16:89893983	A/G	cg00800038	chr16:89945340	TCF25	-0.86	-6.89	-0.39	3.98e-11	Skin colour saturation;
CESC	cis	rs7247513	0.897	rs12979146	chr19:12717904	C/T	cg11738485	chr19:12877000	HOOK2	0.41	5.07	0.3	7.56e-7	Bipolar disorder;
CESC	cis	rs3096299	0.967	rs2911255	chr16:89487137	C/T	cg00750074	chr16:89608354	SPG7	-0.38	-5.51	-0.32	8.31e-8	Multiple myeloma (IgH translocation);
CESC	cis	rs7662987	1.000	rs1061187	chr4:99992853	G/A	cg13256891	chr4:100009986	ADH5	-0.83	-5.91	-0.34	1.04e-8	Smoking initiation;
CESC	cis	rs1707322	0.717	rs3014246	chr1:46086077	C/T	cg06784218	chr1:46089804	CCDC17	-0.4	-6.93	-0.39	3.29e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7582720	1.000	rs72926787	chr2:203818299	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.36	0.41	2.34e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	trans	rs11098499	0.909	rs28793658	chr4:120307214	A/C	cg25214090	chr10:38739885	LOC399744	0.68	9.2	0.49	1.14e-17	Corneal astigmatism;
CESC	cis	rs1218582	0.772	rs4845400	chr1:154872523	C/T	cg03351412	chr1:154909251	PMVK	0.69	9.39	0.5	2.91e-18	Prostate cancer;
CESC	cis	rs1707322	1.000	rs7532204	chr1:46485075	C/G	cg06784218	chr1:46089804	CCDC17	-0.33	-5.6	-0.33	5.27e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs34779708	0.966	rs1545757	chr10:35445588	A/T	cg04310649	chr10:35416472	CREM	-0.51	-6.18	-0.35	2.39e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs875971	0.867	rs1002053	chr7:65798545	G/A	cg18876405	chr7:65276391	NA	-0.53	-7.19	-0.4	6.46e-12	Aortic root size;
CESC	cis	rs4862750	0.872	rs6830426	chr4:187897270	T/A	cg03647317	chr4:187891568	NA	-0.39	-5.8	-0.34	1.88e-8	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs96067	0.607	rs274761	chr1:36574023	C/T	cg27506609	chr1:36549197	TEKT2	-0.44	-5.34	-0.31	1.97e-7	Corneal structure;
CESC	trans	rs802075	0.905	rs2396918	chr6:49636027	A/T	cg06254729	chr2:28550422	BRE	-0.37	-6.32	-0.36	1.08e-9	Bone mineral density (hip) and age at menarche;
CESC	cis	rs11649653	0.502	rs62057232	chr16:30820866	T/C	cg00531865	chr16:30841666	NA	0.44	5.64	0.33	4.44e-8	Triglycerides;
CESC	trans	rs9467711	0.606	rs9393705	chr6:26361011	G/A	cg06606381	chr12:133084897	FBRSL1	-0.76	-6.87	-0.39	4.66e-11	Autism spectrum disorder or schizophrenia;
CESC	cis	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg08668662	chr20:30539908	PDRG1	-0.44	-5.84	-0.34	1.52e-8	Ulcerative colitis;
CESC	cis	rs7666738	0.830	rs11731478	chr4:99001686	A/G	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.62e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4665809	0.549	rs7577896	chr2:26524493	C/T	cg04944784	chr2:26401820	FAM59B	0.78	7.46	0.42	1.23e-12	Gut microbiome composition (summer);
CESC	cis	rs561341	0.883	rs886224	chr17:30229902	T/C	cg19193384	chr17:30244184	NA	-0.56	-5.77	-0.33	2.16e-8	Hip circumference adjusted for BMI;
CESC	cis	rs7243790	0.805	rs3809947	chr18:51906766	A/T	cg04730925	chr18:51795821	POLI	-0.42	-5.58	-0.32	6.04e-8	Diastolic blood pressure;
CESC	cis	rs2050392	0.861	rs1042058	chr10:30728101	T/C	cg18806716	chr10:30721971	MAP3K8	-0.4	-5.8	-0.34	1.86e-8	Inflammatory bowel disease;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg24763869	chr17:3572311	TMEM93;TAX1BP3	-0.45	-6.15	-0.35	2.77e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg06873352	chr17:61820015	STRADA	0.73	13.07	0.63	1.78e-30	Prudent dietary pattern;
CESC	cis	rs12701220	0.948	rs10275712	chr7:1082918	G/A	cg26769984	chr7:1090371	C7orf50	0.7	8.06	0.44	2.64e-14	Bronchopulmonary dysplasia;
CESC	cis	rs55728055	0.661	rs16989379	chr22:32058269	G/A	cg01338084	chr22:32026380	PISD	1.26	8.24	0.45	8.13e-15	Age-related hearing impairment;
CESC	cis	rs17601876	0.786	rs2414100	chr15:51562420	T/A	cg19946085	chr15:51559439	CYP19A1	-0.33	-5.42	-0.32	1.33e-7	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
CESC	cis	rs2072732	0.904	rs717795	chr1:2970464	T/C	cg03976712	chr1:2946727	NA	0.33	5.64	0.33	4.25e-8	Plateletcrit;
CESC	cis	rs889312	0.500	rs702688	chr5:56190986	A/G	cg12311346	chr5:56204834	C5orf35	-0.44	-5.44	-0.32	1.22e-7	Breast cancer;Breast cancer (early onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27587223	chr3:113822217	NA	-0.58	-6.72	-0.38	1.11e-10	Gut microbiome composition (summer);
CESC	cis	rs7772486	0.840	rs11155451	chr6:146422524	A/G	cg23711669	chr6:146136114	FBXO30	0.88	12.95	0.62	4.95e-30	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs12824058	0.831	rs12297939	chr12:130811923	G/C	cg23887609	chr12:130822674	PIWIL1	0.45	5.82	0.34	1.69e-8	Menopause (age at onset);
CESC	cis	rs3749237	0.595	rs7637999	chr3:49535115	C/T	cg07636037	chr3:49044803	WDR6	0.61	8.81	0.48	1.66e-16	Resting heart rate;
CESC	cis	rs6933660	0.760	rs3806982	chr6:151774916	G/A	cg14416726	chr6:151773293	C6orf211;RMND1	-0.53	-7.02	-0.4	1.88e-11	Menarche (age at onset);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg09019002	chr7:102715232	ARMC10;FBXL13	-0.45	-6.62	-0.38	2.04e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs7129220	0.588	rs16907462	chr11:10137404	T/C	cg01453529	chr11:10209919	SBF2	-0.47	-5.5	-0.32	8.95e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CESC	cis	rs6540556	0.954	rs6540555	chr1:209936571	A/G	cg05527609	chr1:210001259	C1orf107	-0.47	-5.88	-0.34	1.25e-8	Red blood cell count;
CESC	cis	rs12477438	0.520	rs34252185	chr2:99737646	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.87	16.09	0.7	4.08e-41	Chronic sinus infection;
CESC	cis	rs10504229	0.683	rs11774585	chr8:58132685	G/A	cg24829409	chr8:58192753	C8orf71	-0.58	-7.2	-0.4	6.31e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs7666738	0.791	rs28858828	chr4:98950442	C/G	cg17366294	chr4:99064904	C4orf37	0.59	8.52	0.46	1.24e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2721195	0.874	rs2721173	chr8:145744429	C/T	cg15320075	chr8:145703422	NA	0.56	7.88	0.44	8.48e-14	Age at first birth;
CESC	cis	rs15676	0.783	rs2997917	chr9:131586918	G/A	cg00228799	chr9:131580591	ENDOG	0.55	7.13	0.4	9.74e-12	Blood metabolite levels;
CESC	cis	rs10504229	0.724	rs16922734	chr8:58111192	C/T	cg24829409	chr8:58192753	C8orf71	-0.59	-7.32	-0.41	2.94e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs7000551	0.581	rs11136030	chr8:22254235	C/T	cg12081754	chr8:22256438	SLC39A14	0.92	13.24	0.63	4.74e-31	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CESC	cis	rs7605827	0.930	rs7598196	chr2:15596662	A/G	cg19274914	chr2:15703543	NA	0.33	5.97	0.34	7.72e-9	Educational attainment (years of education);
CESC	cis	rs6502050	0.799	rs12940433	chr17:80120826	C/T	cg23985595	chr17:80112537	CCDC57	-0.41	-6.57	-0.37	2.6200000000000003e-10	Life satisfaction;
CESC	cis	rs7851660	0.809	rs12006522	chr9:100652711	G/C	cg13688889	chr9:100608707	NA	-0.63	-8.96	-0.48	5.96e-17	Strep throat;
CESC	cis	rs10751667	0.666	rs7105477	chr11:964271	C/G	cg06064525	chr11:970664	AP2A2	-0.47	-9.27	-0.49	6.7e-18	Alzheimer's disease (late onset);
CESC	cis	rs7605827	0.930	rs12692273	chr2:15688834	G/C	cg19274914	chr2:15703543	NA	0.37	6.7	0.38	1.22e-10	Educational attainment (years of education);
CESC	cis	rs11997175	0.655	rs4380889	chr8:33663381	C/T	ch.8.33884649F	chr8:33765107	NA	0.48	6.21	0.36	2.06e-9	Body mass index;
CESC	cis	rs916888	0.821	rs199506	chr17:44859031	A/G	cg15921436	chr17:44337874	NA	-0.71	-7.96	-0.44	5.06e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs1953600	0.870	rs2788296	chr10:81937889	G/A	cg00277334	chr10:82204260	NA	0.47	6.54	0.37	3.2e-10	Sarcoidosis;
CESC	cis	rs13385	0.769	rs3822739	chr5:139625743	A/G	cg26211634	chr5:139558579	C5orf32	0.47	5.2	0.3	3.94e-7	Atrial fibrillation;
CESC	cis	rs9611565	0.659	rs73178632	chr22:41934573	C/T	cg06634786	chr22:41940651	POLR3H	-0.69	-7.12	-0.4	1.01e-11	Vitiligo;
CESC	cis	rs9311474	0.607	rs34005367	chr3:52558904	A/T	cg17372223	chr3:52568218	NT5DC2	0.51	7.92	0.44	6.62e-14	Electroencephalogram traits;
CESC	cis	rs6991838	0.530	rs6472217	chr8:66547731	A/G	cg13398993	chr8:66546079	ARMC1	0.46	5.65	0.33	4.19e-8	Intelligence (multi-trait analysis);
CESC	cis	rs57502260	0.764	rs3867143	chr11:68223074	A/G	cg20283391	chr11:68216788	NA	-0.66	-5.76	-0.33	2.35e-8	Total body bone mineral density (age 45-60);
CESC	cis	rs7618915	0.547	rs12486847	chr3:52691112	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.48	6.9	0.39	3.88e-11	Bipolar disorder;
CESC	cis	rs9905704	0.836	rs170024	chr17:56831887	T/C	cg12560992	chr17:57184187	TRIM37	0.63	7.76	0.43	1.87e-13	Testicular germ cell tumor;
CESC	cis	rs8180040	0.966	rs11130137	chr3:47578838	C/T	cg27129171	chr3:47204927	SETD2	0.63	9.36	0.5	3.65e-18	Colorectal cancer;
CESC	cis	rs7208859	0.623	rs73271872	chr17:29152228	C/G	cg13385521	chr17:29058706	SUZ12P	0.75	6.0	0.35	6.29e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs2014572	0.967	rs8112572	chr19:57759612	T/C	cg24459738	chr19:57751996	ZNF805	-0.54	-7.57	-0.42	6.06e-13	Hyperactive-impulsive symptoms;
CESC	cis	rs3796352	1.000	rs34340609	chr3:53077276	A/G	cg12962167	chr3:53033115	SFMBT1	0.55	5.48	0.32	1e-7	Immune reponse to smallpox (secreted IL-2);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07589143	chr5:54603461	DHX29;SKIV2L2	0.52	6.03	0.35	5.4e-9	Gut microbiome composition (summer);
CESC	cis	rs1008375	0.932	rs13134570	chr4:17692863	C/T	cg27347728	chr4:17578864	LAP3	-0.49	-5.64	-0.33	4.42e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs6982240	0.514	rs10481391	chr8:142277149	A/G	cg27411547	chr8:142287226	NA	-0.54	-7.59	-0.42	5.55e-13	Tonsillectomy;
CESC	cis	rs962856	1.000	rs6739392	chr2:67601971	A/T	cg09028215	chr2:67624308	ETAA1	-0.41	-5.42	-0.32	1.33e-7	Pancreatic cancer;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg08849330	chr6:166797222	BRP44L	-0.47	-6.33	-0.36	1.07e-9	Ulcerative colitis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24183484	chr19:38878553	GGN	-0.58	-6.18	-0.35	2.38e-9	Gut microbiome composition (summer);
CESC	cis	rs73206853	0.841	rs57821814	chr12:110829254	A/C	cg12870014	chr12:110450643	ANKRD13A	0.65	5.14	0.3	5.33e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs9818758	0.607	rs34343820	chr3:49309534	C/G	cg00383909	chr3:49044727	WDR6	0.8	6.13	0.35	3.1e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CESC	trans	rs1545843	0.565	rs7966752	chr12:84792097	G/T	cg03015433	chr16:56623111	MT3	-0.34	-6.12	-0.35	3.37e-9	Major depressive disorder;
CESC	cis	rs1552244	0.572	rs7645667	chr3:10157337	C/A	cg00149659	chr3:10157352	C3orf10	1.04	11.93	0.59	1.47e-26	Alzheimer's disease;
CESC	cis	rs963731	0.649	rs78421201	chr2:39339424	C/A	cg04010122	chr2:39346883	SOS1	0.76	5.65	0.33	4.06e-8	Corticobasal degeneration;
CESC	cis	rs4555082	0.874	rs2245329	chr14:105719181	T/C	cg06808227	chr14:105710500	BRF1	-0.63	-7.51	-0.42	9.08e-13	Mean platelet volume;Platelet distribution width;
CESC	cis	rs7188697	0.922	rs9923491	chr16:58603176	T/G	cg21335942	chr16:58549945	SETD6	-0.45	-5.2	-0.3	4.06e-7	QT interval;
CESC	cis	rs853679	0.517	rs4711164	chr6:28115156	C/T	cg23281280	chr6:28129359	ZNF389	0.6	8.0	0.44	3.86e-14	Depression;
CESC	cis	rs1355223	0.506	rs7130774	chr11:34869267	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.56	-6.86	-0.39	4.97e-11	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs2075371	0.796	rs7780583	chr7:133960716	C/G	cg00033643	chr7:134001901	SLC35B4	0.4	5.19	0.3	4.14e-7	Mean platelet volume;
CESC	cis	rs2191566	0.576	rs382255	chr19:44494156	T/C	cg20607764	chr19:44506953	ZNF230	0.45	5.75	0.33	2.39e-8	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs2425143	1.000	rs45595739	chr20:34320759	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.8	-7.51	-0.42	9.02e-13	Blood protein levels;
CESC	cis	rs13191362	0.872	rs36069443	chr6:163248701	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.5	5.1	0.3	6.34e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs875971	0.522	rs7784623	chr7:65395034	T/G	cg14393609	chr7:65229607	NA	0.52	7.12	0.4	1.04e-11	Aortic root size;
CESC	cis	rs9611565	0.592	rs4822046	chr22:41987543	G/A	cg03806693	chr22:41940476	POLR3H	-1.14	-13.16	-0.63	8.62e-31	Vitiligo;
CESC	trans	rs3780486	0.846	rs7850878	chr9:33126570	A/G	cg20290983	chr6:43655470	MRPS18A	0.98	18.09	0.74	3.45e-48	IgG glycosylation;
CESC	cis	rs35110281	0.681	rs162343	chr21:44957072	A/G	cg04455712	chr21:45112962	RRP1B	0.37	5.56	0.32	6.69e-8	Mean corpuscular volume;
CESC	cis	rs1957429	0.614	rs66883381	chr14:65334773	C/T	cg23373153	chr14:65346875	NA	-0.76	-5.81	-0.34	1.77e-8	Pediatric areal bone mineral density (radius);
CESC	cis	rs919433	0.927	rs13032495	chr2:198189346	C/T	cg10820045	chr2:198174542	NA	-0.44	-6.42	-0.37	6.16e-10	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs3820928	1.000	rs7579961	chr2:227776976	T/A	cg11843606	chr2:227700838	RHBDD1	-0.43	-5.81	-0.34	1.74e-8	Pulmonary function;
CESC	cis	rs11645898	0.935	rs4788614	chr16:72188828	C/T	cg14768367	chr16:72042858	DHODH	0.58	5.25	0.31	3.15e-7	Blood protein levels;
CESC	cis	rs820218	0.886	rs2165635	chr17:73663296	C/A	cg01592526	chr17:73663357	RECQL5;SAP30BP	0.43	5.52	0.32	7.91e-8	Rotator cuff tears;
CESC	cis	rs2836974	0.965	rs9941894	chr21:40634058	C/T	cg17971929	chr21:40555470	PSMG1	1.01	14.68	0.67	4.01e-36	Cognitive function;
CESC	cis	rs17345786	0.628	rs11718446	chr3:101552553	C/T	cg12386194	chr3:101231763	SENP7	0.49	5.87	0.34	1.27e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9815354	0.812	rs73079360	chr3:41888372	T/A	cg03022575	chr3:42003672	ULK4	0.71	6.23	0.36	1.84e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs12541635	0.677	rs7003520	chr8:107061724	G/A	cg10147462	chr8:107024639	NA	0.39	5.79	0.34	2e-8	Age of smoking initiation;
CESC	cis	rs7666738	0.830	rs115279324	chr4:99042114	T/C	cg05340658	chr4:99064831	C4orf37	0.8	12.39	0.61	3.91e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs8028182	0.636	rs4886715	chr15:75831449	C/T	cg20655648	chr15:75932815	IMP3	0.48	5.9	0.34	1.08e-8	Sudden cardiac arrest;
CESC	cis	rs2880765	0.835	rs4281668	chr15:86047286	C/T	cg19183879	chr15:85880815	NA	-0.26	-5.21	-0.3	3.89e-7	Coronary artery disease;
CESC	cis	rs6502050	0.835	rs3935128	chr17:80113414	T/C	cg23985595	chr17:80112537	CCDC57	-0.42	-6.59	-0.38	2.43e-10	Life satisfaction;
CESC	cis	rs853679	0.517	rs9348793	chr6:28084189	G/A	cg20151795	chr6:28129481	ZNF389	0.45	5.87	0.34	1.29e-8	Depression;
CESC	cis	rs61759167	1.000	rs7518255	chr1:3086464	G/A	cg01961086	chr1:3086487	PRDM16	-0.34	-5.08	-0.3	7.16e-7	Motion sickness;
CESC	cis	rs861020	1.000	rs630984	chr1:209982293	C/T	cg05527609	chr1:210001259	C1orf107	0.96	12.16	0.6	2.57e-27	Orofacial clefts;
CESC	cis	rs801193	0.569	rs13242290	chr7:66121885	G/A	cg11764359	chr7:65958608	NA	-0.72	-10.43	-0.54	1.46e-21	Aortic root size;
CESC	cis	rs921968	0.643	rs523396	chr2:219338789	T/G	cg02176678	chr2:219576539	TTLL4	0.42	7.54	0.42	7.49e-13	Mean corpuscular hemoglobin concentration;
CESC	cis	rs73019876	0.901	rs2666448	chr19:22132508	G/A	cg11619707	chr19:22235551	ZNF257	-0.27	-5.13	-0.3	5.5e-7	Testicular germ cell tumor;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg09324016	chr16:31085582	ZNF668;ZNF646	-0.48	-7.07	-0.4	1.36e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs3806843	1.000	rs2098058	chr5:140157427	A/C	cg26395211	chr5:140044315	WDR55	0.44	5.53	0.32	7.82e-8	Depressive symptoms (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27400923	chr3:185826929	ETV5	0.67	7.39	0.41	1.92e-12	Gut microbiome composition (summer);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg14906687	chr6:157099894	ARID1B	0.47	6.0	0.35	6.46e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs6121246	0.609	rs1009453	chr20:30404840	C/G	cg13852791	chr20:30311386	BCL2L1	0.83	10.68	0.55	2.22e-22	Mean corpuscular hemoglobin;
CESC	cis	rs10206020	0.921	rs2280127	chr2:1546531	C/T	cg26248373	chr2:1572462	NA	-0.59	-6.84	-0.39	5.44e-11	IgG glycosylation;
CESC	cis	rs10504229	0.683	rs55645894	chr8:58116145	A/G	cg21724239	chr8:58056113	NA	0.58	5.95	0.34	8.29e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs4481887	0.861	rs4497248	chr1:248450525	T/C	cg00666640	chr1:248458726	OR2T12	0.38	6.29	0.36	1.27e-9	Common traits (Other);
CESC	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg26338869	chr17:61819248	STRADA	0.7	9.28	0.5	6.1e-18	Prudent dietary pattern;
CESC	cis	rs11190604	1.000	rs10786598	chr10:102291579	G/A	cg07080220	chr10:102295463	HIF1AN	0.7	6.48	0.37	4.34e-10	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs754466	0.606	rs11002308	chr10:79594796	A/T	cg17075019	chr10:79541650	NA	-0.87	-13.7	-0.64	1.2e-32	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs2204008	0.837	rs11169157	chr12:37980047	T/C	cg13010199	chr12:38710504	ALG10B	0.46	5.75	0.33	2.48e-8	Bladder cancer;
CESC	cis	rs9389248	0.708	rs7750574	chr6:135350932	G/C	cg22676075	chr6:135203613	NA	0.53	7.15	0.4	8.36e-12	High light scatter reticulocyte percentage of red cells;
CESC	cis	rs11025559	0.812	rs10833338	chr11:20514709	A/G	cg19653624	chr11:20408972	PRMT3	-0.45	-5.2	-0.3	4.02e-7	Pursuit maintenance gain;
CESC	cis	rs722599	0.748	rs2300599	chr14:75359441	A/G	cg08847533	chr14:75593920	NEK9	-0.46	-5.54	-0.32	7.45e-8	IgG glycosylation;
CESC	cis	rs9381040	0.701	rs6933231	chr6:41163700	T/C	cg03526776	chr6:41159608	TREML2	0.32	5.94	0.34	9.15e-9	Alzheimer's disease (late onset);
CESC	cis	rs1707322	0.721	rs10890344	chr1:46166090	C/T	cg06784218	chr1:46089804	CCDC17	0.43	7.58	0.42	5.65e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs709400	0.628	rs3783394	chr14:103858673	G/A	cg12935359	chr14:103987150	CKB	-0.52	-7.62	-0.42	4.4e-13	Body mass index;
CESC	cis	rs9311474	0.508	rs11718420	chr3:52611413	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.57	7.91	0.44	6.82e-14	Electroencephalogram traits;
CESC	cis	rs4975709	0.589	rs1684967	chr5:1863055	G/C	cg14773178	chr5:1868261	NA	0.32	5.77	0.33	2.18e-8	Cardiovascular disease risk factors;
CESC	cis	rs4900538	0.928	rs1190551	chr14:102911508	A/G	cg18135206	chr14:102964638	TECPR2	-0.8	-10.78	-0.55	1.03e-22	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	trans	rs123509	0.913	rs339685	chr3:42782952	C/G	cg22035501	chr5:112073398	APC	0.56	6.0	0.35	6.42e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs2777491	0.915	rs7178634	chr15:41634587	A/G	cg20272979	chr15:41787780	ITPKA	0.36	5.33	0.31	2.09e-7	Ulcerative colitis;
CESC	cis	rs11642862	1.000	rs75500538	chr16:30782449	G/A	cg02466173	chr16:30829666	NA	-0.6	-6.08	-0.35	4.15e-9	Tonsillectomy;
CESC	cis	rs6687430	0.562	rs6676491	chr1:10633421	A/C	cg07384165	chr1:10488281	NA	-0.45	-6.27	-0.36	1.49e-9	Hand grip strength;
CESC	cis	rs6088590	1.000	rs6120747	chr20:33449769	T/C	cg08999081	chr20:33150536	PIGU	0.6	9.03	0.48	3.75e-17	Coronary artery disease;
CESC	cis	rs7267979	0.966	rs2261720	chr20:25260641	T/G	cg08601574	chr20:25228251	PYGB	0.39	5.65	0.33	4.14e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs6665290	0.669	rs3795446	chr1:227180981	C/T	cg10327440	chr1:227177885	CDC42BPA	1.11	24.6	0.83	2.18e-70	Myeloid white cell count;
CESC	cis	rs25645	0.792	rs8077456	chr17:38128765	C/G	cg17344932	chr17:38183730	MED24;SNORD124	0.5	7.09	0.4	1.24e-11	Myeloid white cell count;
CESC	cis	rs763014	0.931	rs2071981	chr16:630025	C/G	cg09263875	chr16:632152	PIGQ	0.67	11.14	0.56	6.6e-24	Height;
CESC	cis	rs77106637	0.860	rs11603334	chr11:72432985	G/A	cg04827223	chr11:72435913	ARAP1	-0.62	-6.53	-0.37	3.25e-10	Type 2 diabetes;
CESC	cis	rs6977660	0.507	rs72591448	chr7:19775298	C/T	cg07541023	chr7:19748670	TWISTNB	0.81	7.44	0.42	1.42e-12	Thyroid stimulating hormone;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg13671121	chr17:36908172	PSMB3	-0.44	-6.19	-0.36	2.29e-9	Gambling;
CESC	cis	rs6933660	0.676	rs3757316	chr6:151774339	A/G	cg02564969	chr6:151773285	C6orf211;RMND1	-0.67	-8.97	-0.48	5.59e-17	Menarche (age at onset);
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg02551244	chr2:23608357	KLHL29	0.5	6.9	0.39	3.84e-11	Systemic lupus erythematosus;
CESC	cis	rs4665809	0.590	rs10197494	chr2:26445550	A/G	cg08470875	chr2:26401718	FAM59B	-0.75	-7.79	-0.43	1.49e-13	Gut microbiome composition (summer);
CESC	cis	rs514406	0.668	rs1672911	chr1:53340320	T/C	cg25767906	chr1:53392781	SCP2	-0.54	-7.5	-0.42	9.4e-13	Monocyte count;
CESC	cis	rs2576037	0.526	rs509647	chr18:44383675	G/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.57	-7.68	-0.43	3.12e-13	Personality dimensions;
CESC	cis	rs6570726	0.967	rs9403706	chr6:145795187	C/T	cg05347473	chr6:146136440	FBXO30	-0.42	-5.63	-0.33	4.68e-8	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs738322	0.870	rs2277844	chr22:38577515	G/A	cg17652424	chr22:38574118	PLA2G6	0.31	5.34	0.31	2.01e-7	Cutaneous nevi;
CESC	cis	rs6061231	0.631	rs2427317	chr20:60975725	C/T	cg23531748	chr20:60969906	CABLES2	0.39	5.41	0.32	1.41e-7	Colorectal cancer;
CESC	cis	rs9837602	1.000	rs10049383	chr3:99748548	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.53	7.45	0.42	1.36e-12	Breast cancer;
CESC	cis	rs727505	1.000	rs28392553	chr7:124442944	C/T	cg23710748	chr7:124431027	NA	-0.38	-6.06	-0.35	4.77e-9	Lewy body disease;
CESC	cis	rs7666738	0.830	rs7662389	chr4:99019892	G/A	cg03467027	chr4:99064603	C4orf37	0.46	5.82	0.34	1.73e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4665809	1.000	rs1550381	chr2:26266946	A/G	cg04944784	chr2:26401820	FAM59B	-0.66	-7.5	-0.42	9.54e-13	Gut microbiome composition (summer);
CESC	cis	rs2075371	0.966	rs2544224	chr7:133995832	A/G	cg11752832	chr7:134001865	SLC35B4	0.53	6.86	0.39	4.93e-11	Mean platelet volume;
CESC	cis	rs17826219	0.706	rs8071236	chr17:29100002	T/C	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.91e-10	Body mass index;
CESC	cis	rs4728302	0.869	rs7792905	chr7:133595602	G/T	cg10665199	chr7:133106180	EXOC4	0.39	5.51	0.32	8.43e-8	Intelligence;Intelligence (multi-trait analysis);
CESC	cis	rs7296418	0.636	rs11057261	chr12:123797567	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.33	-5.29	-0.31	2.57e-7	Platelet count;
CESC	cis	rs4481887	1.000	rs11204626	chr1:248458974	T/A	cg00666640	chr1:248458726	OR2T12	0.39	6.5	0.37	3.86e-10	Common traits (Other);
CESC	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.11	11.68	0.58	1.07e-25	Platelet count;
CESC	cis	rs9322193	0.923	rs2297930	chr6:150039496	T/C	cg00933542	chr6:150070202	PCMT1	0.29	5.11	0.3	6.09e-7	Lung cancer;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg00171436	chr12:122985592	ZCCHC8	-0.44	-6.32	-0.36	1.09e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs11853189	0.882	rs78827644	chr15:78556250	G/A	cg22935921	chr15:78556834	DNAJA4	0.61	5.1	0.3	6.35e-7	Red cell distribution width;
CESC	cis	rs55871839	0.684	rs13271523	chr8:59806664	T/C	cg07426533	chr8:59803705	TOX	-0.49	-7.08	-0.4	1.32e-11	Pneumonia;
CESC	trans	rs9792269	0.735	rs12541389	chr8:129243389	C/T	cg07707498	chr16:46865555	C16orf87	-0.57	-6.04	-0.35	5.08e-9	Celiac disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15824864	chr17:77812175	CBX4	-0.53	-6.18	-0.35	2.38e-9	Gut microbiome composition (summer);
CESC	cis	rs6088580	0.634	rs6059896	chr20:33111783	T/C	cg08999081	chr20:33150536	PIGU	0.65	11.45	0.58	6.19e-25	Glomerular filtration rate (creatinine);
CESC	cis	rs2072732	0.861	rs67919793	chr1:2954230	T/C	cg15211996	chr1:2936768	ACTRT2	0.34	6.04	0.35	5.27e-9	Plateletcrit;
CESC	cis	rs1862618	0.802	rs7733041	chr5:56107377	A/C	cg20203395	chr5:56204925	C5orf35	-0.42	-5.08	-0.3	7.06e-7	Initial pursuit acceleration;
CESC	cis	rs36051895	0.553	rs16922773	chr9:5197436	T/G	cg02405213	chr9:5042618	JAK2	-0.57	-6.37	-0.36	8.28e-10	Pediatric autoimmune diseases;
CESC	cis	rs1577917	0.958	rs34765423	chr6:86484448	C/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.5	-6.7	-0.38	1.28e-10	Response to antipsychotic treatment;
CESC	cis	rs11711311	0.736	rs13320940	chr3:113400954	G/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.52	6.56	0.37	2.87e-10	IgG glycosylation;
CESC	cis	rs1008375	1.000	rs1006722	chr4:17618713	A/G	cg16339924	chr4:17578868	LAP3	-0.54	-6.8	-0.39	6.74e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs55871839	0.559	rs66954327	chr8:59825133	A/G	cg07426533	chr8:59803705	TOX	0.39	5.23	0.31	3.43e-7	Pneumonia;
CESC	cis	rs7589728	0.563	rs75606549	chr2:88466069	T/C	cg14558114	chr2:88469736	THNSL2	0.59	5.56	0.32	6.52e-8	Plasma clusterin levels;
CESC	cis	rs67478160	0.655	rs4900598	chr14:104281541	T/C	cg08213375	chr14:104286397	PPP1R13B	0.54	10.69	0.55	2.07e-22	Schizophrenia;
CESC	cis	rs3096299	0.838	rs4785561	chr16:89429052	C/T	cg08822215	chr16:89438651	ANKRD11	-0.35	-5.09	-0.3	6.72e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs13256369	1.000	rs873063	chr8:8572447	A/G	cg18904891	chr8:8559673	CLDN23	0.7	8.35	0.46	3.92e-15	Obesity-related traits;
CESC	cis	rs4975709	1.000	rs4975709	chr5:1877280	A/C	cg17650747	chr5:1873721	NA	0.38	5.17	0.3	4.56e-7	Cardiovascular disease risk factors;
CESC	cis	rs17655565	1.000	rs17126647	chr12:52706194	C/T	cg08257133	chr12:52711352	KRT83	0.51	6.28	0.36	1.37e-9	Plasma amyloid beta peptide concentrations (ABx-42);
CESC	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg11494091	chr17:61959527	GH2	0.75	12.76	0.62	2.11e-29	Prudent dietary pattern;
CESC	cis	rs1670533	1.000	rs11735663	chr4:1051845	C/T	cg04106633	chr4:1044584	NA	0.41	5.14	0.3	5.46e-7	Recombination rate (females);
CESC	trans	rs498872	0.507	rs10892247	chr11:118490076	G/A	cg24645679	chr7:2611236	IQCE	-0.51	-6.07	-0.35	4.31e-9	Glioma;
CESC	trans	rs9987353	0.840	rs329994	chr8:9123233	A/G	cg03321319	chr22:22222323	MAPK1	-0.46	-6.05	-0.35	5.04e-9	Recombination measurement;
CESC	cis	rs853679	0.628	rs9368560	chr6:28159960	T/C	cg22143856	chr6:28129313	ZNF389	0.45	5.66	0.33	3.95e-8	Depression;
CESC	cis	rs708547	0.874	rs7674167	chr4:57721477	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.53	-5.91	-0.34	1.05e-8	Response to bleomycin (chromatid breaks);
CESC	cis	rs1799949	1.000	rs4793212	chr17:41302750	T/C	cg05368731	chr17:41323189	NBR1	0.78	10.79	0.55	9.37e-23	Menopause (age at onset);
CESC	cis	rs6087990	1.000	rs2018002	chr20:31351623	A/T	cg13636640	chr20:31349939	DNMT3B	0.94	16.99	0.72	2.74e-44	Ulcerative colitis;
CESC	cis	rs7772486	0.790	rs2253768	chr6:146199922	A/G	cg23711669	chr6:146136114	FBXO30	1.02	15.48	0.69	5.93e-39	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1728785	1.000	rs1170431	chr16:68605639	T/C	cg02972257	chr16:68554789	NA	-0.59	-6.71	-0.38	1.2e-10	Ulcerative colitis;
CESC	trans	rs1814175	0.616	rs847641	chr11:49919261	T/C	cg15704280	chr7:45808275	SEPT13	-1.01	-18.94	-0.76	3.64e-51	Height;
CESC	cis	rs1348850	0.914	rs6761593	chr2:178451600	A/G	cg23306229	chr2:178417860	TTC30B	-0.47	-5.95	-0.34	8.32e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs6061231	0.624	rs8668	chr20:60964064	C/T	cg22541963	chr20:60982533	CABLES2	-0.52	-6.55	-0.37	2.9e-10	Colorectal cancer;
CESC	cis	rs7927592	0.871	rs871212	chr11:68348695	T/A	cg20283391	chr11:68216788	NA	-0.5	-6.01	-0.35	6.01e-9	Total body bone mineral density;
CESC	trans	rs2415984	0.846	rs7156814	chr14:46854097	C/A	cg14945696	chr3:52713679	PBRM1	-0.39	-6.05	-0.35	4.98e-9	Number of children ever born;
CESC	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg07677032	chr17:61819896	STRADA	0.45	6.05	0.35	5.02e-9	Prudent dietary pattern;
CESC	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.75	10.28	0.53	4.53e-21	Prudent dietary pattern;
CESC	trans	rs60380162	0.928	rs60507195	chr1:87727014	G/A	cg20163645	chr8:1900353	ARHGEF10	-0.43	-6.03	-0.35	5.48e-9	Loneliness (linear analysis);
CESC	cis	rs7078219	0.505	rs4129133	chr10:101284570	T/C	cg09788492	chr10:101292477	NKX2-3	0.33	6.35	0.36	9.54e-10	Dental caries;
CESC	trans	rs7618501	0.633	rs9853222	chr3:50022926	T/C	cg21659725	chr3:3221576	CRBN	0.53	7.37	0.41	2.19e-12	Intelligence (multi-trait analysis);
CESC	cis	rs7772486	0.875	rs2474353	chr6:146323883	G/A	cg23711669	chr6:146136114	FBXO30	0.85	12.2	0.6	1.88e-27	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs9325144	0.555	rs11183215	chr12:38693127	G/A	cg23762105	chr12:34175262	ALG10	0.49	6.45	0.37	5.43e-10	Morning vs. evening chronotype;
CESC	cis	rs3096299	0.685	rs4785676	chr16:89553624	T/C	cg02187348	chr16:89574699	SPG7	0.66	9.15	0.49	1.56e-17	Multiple myeloma (IgH translocation);
CESC	cis	rs17407555	0.821	rs4533775	chr4:10141404	G/C	cg00071950	chr4:10020882	SLC2A9	-0.58	-5.29	-0.31	2.53e-7	Schizophrenia (age at onset);
CESC	cis	rs1976403	0.510	rs1697421	chr1:21823292	C/T	cg21906605	chr1:21766650	NBPF3	0.41	5.38	0.31	1.61e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs13108904	0.934	rs13134106	chr4:1302902	A/G	cg00684032	chr4:1343700	KIAA1530	0.41	5.72	0.33	2.95e-8	Obesity-related traits;
CESC	cis	rs2228479	0.850	rs17233455	chr16:89816407	A/G	cg04013166	chr16:89971882	TCF25	0.77	6.66	0.38	1.58e-10	Skin colour saturation;
CESC	trans	rs561341	0.769	rs7217004	chr17:30178092	A/G	cg27661571	chr11:113659931	NA	0.66	6.04	0.35	5.3300000000000004e-09	Hip circumference adjusted for BMI;
CESC	cis	rs2816062	0.747	rs2816049	chr1:18893768	A/G	cg18795169	chr1:18902165	NA	-0.95	-19.06	-0.76	1.32e-51	Urate levels in lean individuals;
CESC	cis	rs6662572	1.000	rs41310432	chr1:46083706	C/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.51	5.63	0.33	4.52e-8	Blood protein levels;
CESC	cis	rs1185460	1.000	rs15818	chr11:118952173	A/G	cg23280166	chr11:118938394	VPS11	0.42	5.48	0.32	9.76e-8	Coronary artery disease;
CESC	cis	rs6582630	0.519	rs4405392	chr12:38293661	A/C	cg26384229	chr12:38710491	ALG10B	0.71	10.63	0.55	3.23e-22	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs7917772	0.503	rs7093285	chr10:104374815	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.55	7.33	0.41	2.77e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs250677	0.652	rs36042	chr5:148439782	G/T	cg18129178	chr5:148520854	ABLIM3	-0.6	-6.13	-0.35	3.23e-9	Breast cancer;
CESC	cis	rs2124969	0.527	rs72982044	chr2:161049395	G/A	cg03641300	chr2:160917029	PLA2R1	-0.58	-5.98	-0.35	7.01e-9	Waist circumference adjusted for body mass index;
CESC	cis	rs896854	0.818	rs13262110	chr8:95926890	C/T	cg09323728	chr8:95962352	TP53INP1	-0.4	-8.78	-0.47	2.13e-16	Type 2 diabetes;
CESC	cis	rs2180341	0.960	rs6913424	chr6:127707010	A/C	cg24812749	chr6:127587940	RNF146	1.03	14.68	0.67	4.05e-36	Breast cancer;
CESC	cis	rs7208859	0.623	rs1054397	chr17:29110196	T/C	cg13385521	chr17:29058706	SUZ12P	0.8	6.45	0.37	5.29e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs854765	0.693	rs12941039	chr17:17765655	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.48	-6.71	-0.38	1.18e-10	Total body bone mineral density;
CESC	cis	rs7116495	0.609	rs6592457	chr11:71738086	G/C	cg26138937	chr11:71823887	C11orf51	-1.33	-7.85	-0.43	1.06e-13	Severe influenza A (H1N1) infection;
CESC	cis	rs561341	1.000	rs483301	chr17:30293398	G/T	cg12193833	chr17:30244370	NA	-0.76	-6.94	-0.39	2.92e-11	Hip circumference adjusted for BMI;
CESC	trans	rs35851103	0.600	rs4841662	chr8:11843758	A/G	cg06636001	chr8:8085503	FLJ10661	-0.48	-6.01	-0.35	6.16e-9	Neuroticism;
CESC	cis	rs1218582	0.772	rs4845688	chr1:154884142	T/C	cg24250549	chr1:154909240	PMVK	0.75	11.2	0.57	4.32e-24	Prostate cancer;
CESC	trans	rs1814175	0.817	rs2866863	chr11:49953242	C/T	cg15704280	chr7:45808275	SEPT13	-1.03	-20.41	-0.78	2.75e-56	Height;
CESC	cis	rs2836950	0.520	rs8130240	chr21:40538108	G/A	cg11644478	chr21:40555479	PSMG1	-0.57	-7.88	-0.44	8.72e-14	Menarche (age at onset);
CESC	cis	rs703842	0.560	rs11533604	chr12:58047713	G/A	cg18357645	chr12:58087776	OS9	-0.54	-7.04	-0.4	1.65e-11	Multiple sclerosis;
CESC	cis	rs13385	0.813	rs6859064	chr5:139663301	A/T	cg26211634	chr5:139558579	C5orf32	0.47	5.09	0.3	6.77e-7	Atrial fibrillation;
CESC	cis	rs4889855	0.505	rs8076974	chr17:78621817	G/A	cg16591659	chr17:78472290	NA	-0.32	-5.22	-0.31	3.68e-7	Fractional excretion of uric acid;
CESC	trans	rs9296661	1.000	rs1326589	chr6:51674161	A/G	cg18455653	chr20:17662865	RRBP1	0.46	6.11	0.35	3.47e-9	Weight loss (gastric bypass surgery);
CESC	trans	rs11098499	0.909	rs2127821	chr4:120394535	T/C	cg25214090	chr10:38739885	LOC399744	0.71	10.36	0.54	2.41e-21	Corneal astigmatism;
CESC	cis	rs3857067	0.509	rs61069704	chr4:95091856	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.47	-6.28	-0.36	1.39e-9	QT interval;
CESC	cis	rs712039	0.652	rs853227	chr17:35797529	C/T	cg16670864	chr17:35848621	DUSP14	0.41	5.07	0.3	7.41e-7	Tuberculosis;
CESC	cis	rs11864453	0.611	rs9926927	chr16:72130556	G/T	cg16558253	chr16:72132732	DHX38	-0.54	-8.44	-0.46	2.03e-15	Fibrinogen levels;
CESC	cis	rs9811920	0.809	rs4928150	chr3:99685991	A/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.46	7.66	0.43	3.51e-13	Axial length;
CESC	cis	rs10504229	0.871	rs60342323	chr8:58154899	T/C	cg02725872	chr8:58115012	NA	-0.37	-5.86	-0.34	1.39e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs7296418	0.699	rs11608297	chr12:123826642	T/C	cg00376283	chr12:123451042	ABCB9	0.56	7.64	0.42	3.92e-13	Platelet count;
CESC	cis	rs2742234	0.541	rs11528481	chr10:43737767	C/A	cg07801480	chr10:43725741	RASGEF1A	-0.4	-5.13	-0.3	5.71e-7	Hirschsprung disease;
CESC	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg10150615	chr22:24372951	LOC391322	-0.55	-7.14	-0.4	8.73e-12	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs6502050	0.835	rs4789724	chr17:80150546	G/A	cg11859384	chr17:80120422	CCDC57	-0.38	-5.25	-0.31	3.18e-7	Life satisfaction;
CESC	cis	rs4253772	0.550	rs9615913	chr22:46668515	A/T	cg24881330	chr22:46731750	TRMU	-0.86	-9.8	-0.52	1.46e-19	LDL cholesterol;Cholesterol, total;
CESC	cis	rs2439831	0.867	rs935901	chr15:43651256	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.73	5.75	0.33	2.39e-8	Lung cancer in ever smokers;
CESC	cis	rs60871478	0.730	rs13222476	chr7:826630	T/C	cg27478167	chr7:817139	HEATR2	-0.47	-5.05	-0.3	8.35e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs7267979	0.744	rs6050464	chr20:25209299	C/A	cg08601574	chr20:25228251	PYGB	0.44	6.33	0.36	1.05e-9	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs2180341	1.000	rs2180341	chr6:127600630	C/T	cg27446573	chr6:127587934	RNF146	1.07	15.79	0.7	4.78e-40	Breast cancer;
CESC	cis	rs12368653	0.651	rs2277326	chr12:58202419	A/C	cg00677455	chr12:58241039	CTDSP2	0.48	6.02	0.35	5.8e-9	Multiple sclerosis;
CESC	cis	rs3008870	1.000	rs3008856	chr1:67387901	T/C	cg02640540	chr1:67518911	SLC35D1	0.48	5.2	0.3	3.97e-7	Lymphocyte percentage of white cells;
CESC	cis	rs897080	0.552	rs698799	chr2:44690618	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.48	5.55	0.32	7.09e-8	Height;
CESC	cis	rs870825	0.616	rs1401361	chr4:185643742	G/C	cg04058563	chr4:185651563	MLF1IP	0.64	7.13	0.4	9.4e-12	Blood protein levels;
CESC	cis	rs13082711	0.554	rs13087873	chr3:27392326	C/T	cg02860705	chr3:27208620	NA	0.73	8.23	0.45	8.65e-15	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CESC	cis	rs6088590	1.000	rs55753039	chr20:33394940	C/T	cg24642439	chr20:33292090	TP53INP2	0.84	11.3	0.57	2e-24	Coronary artery disease;
CESC	cis	rs7590720	1.000	rs934156	chr2:216901482	C/T	cg12620499	chr2:216877984	MREG	-0.84	-11.47	-0.58	5.37e-25	Alcohol dependence;
CESC	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg18402987	chr7:1209562	NA	0.76	7.61	0.42	4.74e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg04267008	chr7:1944627	MAD1L1	-0.57	-6.83	-0.39	5.77e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs3749237	0.964	rs2352967	chr3:49871641	C/T	cg02487422	chr3:49467188	NICN1	0.43	5.05	0.3	8.09e-7	Resting heart rate;
CESC	cis	rs6815814	0.731	rs10776482	chr4:38774785	A/G	cg02016764	chr4:38805732	TLR1	-0.44	-6.08	-0.35	4.24e-9	Breast cancer;
CESC	cis	rs514406	0.830	rs533935	chr1:53308807	T/C	cg16325326	chr1:53192061	ZYG11B	0.81	12.89	0.62	7.72e-30	Monocyte count;
CESC	cis	rs6991838	0.550	rs7817112	chr8:66537120	C/A	cg13398993	chr8:66546079	ARMC1	0.46	5.65	0.33	4.19e-8	Intelligence (multi-trait analysis);
CESC	cis	rs1003719	0.715	rs1981432	chr21:38541356	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.59	-8.02	-0.44	3.39e-14	Eye color traits;
CESC	cis	rs11249608	0.548	rs2132672	chr5:178457742	A/C	cg01312482	chr5:178451176	ZNF879	-0.44	-5.88	-0.34	1.22e-8	Pubertal anthropometrics;
CESC	cis	rs854765	0.619	rs1101727	chr17:18016148	T/C	cg16928487	chr17:17741425	SREBF1	-0.51	-8.07	-0.44	2.42e-14	Total body bone mineral density;
CESC	cis	rs4919087	0.590	rs61569149	chr10:99073879	A/G	cg25902810	chr10:99078978	FRAT1	-0.5	-5.65	-0.33	4.22e-8	Monocyte count;
CESC	cis	rs477692	1.000	rs577227	chr10:131404528	C/T	cg05714579	chr10:131428358	MGMT	0.49	6.7	0.38	1.24e-10	Response to temozolomide;
CESC	cis	rs854765	0.551	rs6502626	chr17:17849450	C/T	cg04398451	chr17:18023971	MYO15A	-0.73	-10.65	-0.55	2.87e-22	Total body bone mineral density;
CESC	cis	rs6460942	0.597	rs6968664	chr7:12515493	T/C	cg06484146	chr7:12443880	VWDE	-0.64	-7.13	-0.4	9.4e-12	Coronary artery disease;
CESC	cis	rs7927771	0.832	rs11601173	chr11:47401058	A/G	cg20307385	chr11:47447363	PSMC3	-0.6	-7.31	-0.41	3.23e-12	Subjective well-being;
CESC	cis	rs12188164	1.000	rs34453673	chr5:434722	G/C	cg15813090	chr5:442598	EXOC3;C5orf55	0.41	6.2	0.36	2.17e-9	Cystic fibrosis severity;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg15479073	chr15:59499039	LDHAL6B;MYO1E	0.46	6.19	0.36	2.24e-9	Fibrinogen levels;
CESC	cis	rs801193	0.839	rs6968619	chr7:66068867	T/C	cg11764359	chr7:65958608	NA	-0.54	-7.05	-0.4	1.59e-11	Aortic root size;
CESC	cis	rs4253772	0.530	rs79354880	chr22:46746419	C/A	cg10541313	chr22:46663664	TTC38	0.74	5.15	0.3	4.99e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs6964587	0.626	rs4729011	chr7:91515419	G/A	cg17063962	chr7:91808500	NA	-0.46	-6.54	-0.37	3.22e-10	Breast cancer;
CESC	trans	rs1728785	1.000	rs7205960	chr16:68565604	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.61	7.42	0.41	1.57e-12	Ulcerative colitis;
CESC	cis	rs1801251	0.778	rs778340	chr2:233734083	C/T	cg08000102	chr2:233561755	GIGYF2	-0.59	-7.94	-0.44	5.66e-14	Coronary artery disease;
CESC	trans	rs9467711	0.606	rs9379899	chr6:26603015	T/A	cg06606381	chr12:133084897	FBRSL1	-0.78	-7.41	-0.41	1.7e-12	Autism spectrum disorder or schizophrenia;
CESC	cis	rs9847710	0.566	rs2564951	chr3:53060449	C/T	cg18337363	chr3:52569053	NT5DC2	-0.31	-5.09	-0.3	6.94e-7	Ulcerative colitis;
CESC	cis	rs7656342	0.686	rs1464258	chr4:9834107	A/C	cg00071950	chr4:10020882	SLC2A9	-0.37	-5.18	-0.3	4.36e-7	Gut microbiota (bacterial taxa);
CESC	cis	rs3820928	0.904	rs2396432	chr2:227765891	C/T	cg05526886	chr2:227700861	RHBDD1	-0.44	-5.65	-0.33	4.24e-8	Pulmonary function;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg10283690	chr1:245027135	HNRNPU	-0.48	-6.32	-0.36	1.09e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs2576037	0.583	rs646128	chr18:44397691	A/C	cg19077165	chr18:44547161	KATNAL2	-0.58	-8.68	-0.47	4e-16	Personality dimensions;
CESC	cis	rs2576037	0.526	rs9304340	chr18:44526582	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.55	-7.41	-0.41	1.71e-12	Personality dimensions;
CESC	cis	rs9291683	0.585	rs12648479	chr4:10104571	G/A	cg00071950	chr4:10020882	SLC2A9	-0.59	-9.38	-0.5	3.1e-18	Bone mineral density;
CESC	cis	rs644799	1.000	rs12786522	chr11:95522858	G/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	14.69	0.67	3.96e-36	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs2439831	0.681	rs7175434	chr15:43628542	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.91	10.99	0.56	2.1e-23	Lung cancer in ever smokers;
CESC	cis	rs4906332	1.000	rs4900574	chr14:103879024	G/A	cg09975044	chr14:104007538	NA	-0.38	-5.28	-0.31	2.68e-7	Coronary artery disease;
CESC	cis	rs10479542	0.549	rs4376229	chr5:179042971	A/G	cg22764044	chr5:178986830	RUFY1	0.38	5.33	0.31	2.13e-7	Lung cancer;
CESC	cis	rs11785693	0.862	rs17435835	chr8:5000713	C/T	cg26367366	chr8:4980734	NA	-0.78	-7.36	-0.41	2.27e-12	Neuroticism (multi-trait analysis);Neuroticism;
CESC	cis	rs79349575	0.811	rs12601072	chr17:46997998	T/C	cg26022315	chr17:47021804	SNF8	0.39	5.18	0.3	4.5e-7	Type 2 diabetes;
CESC	cis	rs7762018	1.000	rs7746598	chr6:170084933	T/A	cg13891659	chr6:170190454	C6orf122;C6orf208	0.53	5.52	0.32	8.28e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs10905065	0.965	rs12571639	chr10:5748052	G/A	cg11519256	chr10:5708881	ASB13	0.44	5.89	0.34	1.17e-8	Menopause (age at onset);
CESC	cis	rs7659604	0.539	rs7660548	chr4:122730821	G/C	cg20573242	chr4:122745356	CCNA2	0.62	7.44	0.42	1.41e-12	Type 2 diabetes;
CESC	cis	rs8180040	0.726	rs2385867	chr3:47059323	C/T	cg27129171	chr3:47204927	SETD2	0.72	11.05	0.56	1.38e-23	Colorectal cancer;
CESC	cis	rs7605827	0.897	rs1468912	chr2:15662922	A/G	cg19274914	chr2:15703543	NA	0.36	6.38	0.36	8.02e-10	Educational attainment (years of education);
CESC	cis	rs7524258	0.867	rs916392	chr1:7271930	T/C	cg07173049	chr1:7289937	CAMTA1	0.44	6.52	0.37	3.46e-10	Tourette's syndrome or obsessive-compulsive disorder;
CESC	cis	rs2573652	0.722	rs12914180	chr15:100544416	T/C	cg09918751	chr15:100517450	ADAMTS17	-0.31	-5.76	-0.33	2.39e-8	Height;
CESC	cis	rs12368653	0.666	rs1050045	chr12:58115271	A/G	cg18357645	chr12:58087776	OS9	0.43	6.6	0.38	2.21e-10	Multiple sclerosis;
CESC	cis	rs1862618	0.853	rs252887	chr5:56166188	A/G	cg24549020	chr5:56110836	MAP3K1	0.66	7.4	0.41	1.77e-12	Initial pursuit acceleration;
CESC	cis	rs2228479	0.702	rs12600047	chr16:89831630	G/A	cg06558623	chr16:89946397	TCF25	1.15	8.92	0.48	8.06e-17	Skin colour saturation;
CESC	cis	rs6964587	1.000	rs11772102	chr7:91558326	A/T	cg17063962	chr7:91808500	NA	-0.58	-7.81	-0.43	1.34e-13	Breast cancer;
CESC	cis	rs9926296	0.533	rs9938865	chr16:89867797	A/G	cg04287289	chr16:89883240	FANCA	0.93	16.69	0.72	3.23e-43	Vitiligo;
CESC	cis	rs4665809	0.567	rs6711402	chr2:26430983	A/G	cg25036284	chr2:26402008	FAM59B	-0.8	-8.57	-0.47	8.7e-16	Gut microbiome composition (summer);
CESC	cis	rs875971	0.505	rs1167385	chr7:65513308	G/A	cg25985355	chr7:65971099	NA	0.32	5.26	0.31	2.95e-7	Aortic root size;
CESC	cis	rs1707322	1.000	rs785510	chr1:46528618	T/C	cg06784218	chr1:46089804	CCDC17	-0.36	-5.86	-0.34	1.35e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg11234017	chr17:42767172	CCDC43	0.45	6.04	0.35	5.17e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs3540	0.618	rs11609	chr15:91043765	C/G	cg10434728	chr15:90938212	IQGAP1	-0.41	-7.27	-0.41	3.94e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10999410	chr5:14487610	TRIO	-0.6	-6.98	-0.39	2.31e-11	Gut microbiome composition (summer);
CESC	cis	rs4927850	1.000	rs7627706	chr3:195753353	A/C	cg01181863	chr3:195395398	SDHAP2	-0.48	-5.71	-0.33	3.03e-8	Pancreatic cancer;
CESC	cis	rs7555523	0.830	rs12691500	chr1:165687761	A/G	cg24409356	chr1:165738333	TMCO1	0.73	6.67	0.38	1.5e-10	Intraocular pressure;Glaucoma (high intraocular pressure);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01084379	chr5:179160712	MAML1	0.64	7.69	0.43	2.96e-13	Gut microbiome composition (summer);
CESC	cis	rs2842992	0.789	rs10945635	chr6:160214487	C/A	cg11366901	chr6:160182831	ACAT2	0.76	9.37	0.5	3.35e-18	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs7833986	0.501	rs2719245	chr8:56894359	G/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.58	7.16	0.4	8.04e-12	Height;
CESC	cis	rs1801251	0.963	rs35395584	chr2:233573698	G/C	cg25237894	chr2:233734115	C2orf82	0.5	8.43	0.46	2.24e-15	Coronary artery disease;
CESC	cis	rs10751667	0.643	rs11246362	chr11:969818	C/T	cg20946044	chr11:1010712	AP2A2	-0.39	-5.29	-0.31	2.51e-7	Alzheimer's disease (late onset);
CESC	cis	rs1775715	0.835	rs12266771	chr10:32231380	G/A	cg18675610	chr10:32216311	ARHGAP12	0.35	5.35	0.31	1.87e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs4595586	0.545	rs7310463	chr12:39368927	T/C	cg26384229	chr12:38710491	ALG10B	0.54	7.53	0.42	7.85e-13	Morning vs. evening chronotype;
CESC	cis	rs6951245	0.542	rs28460147	chr7:1217192	G/A	cg23708337	chr7:1209742	NA	0.52	5.52	0.32	8.27e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7618915	0.547	rs12487591	chr3:52642936	A/T	cg18099408	chr3:52552593	STAB1	-0.34	-5.44	-0.32	1.2e-7	Bipolar disorder;
CESC	cis	rs11997175	0.846	rs11776207	chr8:33765126	G/T	ch.8.33884649F	chr8:33765107	NA	-0.67	-8.37	-0.46	3.4e-15	Body mass index;
CESC	cis	rs193541	0.632	rs154512	chr5:122195040	T/C	cg19412675	chr5:122181750	SNX24	0.47	5.58	0.32	5.95e-8	Glucose homeostasis traits;
CESC	cis	rs3741404	0.560	rs7938819	chr11:63910116	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.75	-10.83	-0.55	7.34e-23	Platelet count;
CESC	cis	rs1008375	0.966	rs1476836	chr4:17585014	G/C	cg16339924	chr4:17578868	LAP3	0.73	9.53	0.51	1.03e-18	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs11098499	0.863	rs3736115	chr4:120488703	A/G	cg09307838	chr4:120376055	NA	-0.85	-10.87	-0.56	5.46e-23	Corneal astigmatism;
CESC	cis	rs765787	0.530	rs2668751	chr15:45517293	T/C	cg24006582	chr15:45444508	DUOX1	-0.58	-7.07	-0.4	1.4e-11	Uric acid levels;
CESC	cis	rs1348850	0.651	rs4893936	chr2:178240676	C/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.65	8.92	0.48	7.66e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs7618915	0.501	rs2289247	chr3:52727257	C/T	cg07507251	chr3:52567010	NT5DC2	0.32	5.41	0.32	1.42e-7	Bipolar disorder;
CESC	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	7.75	0.43	1.94e-13	Prudent dietary pattern;
CESC	trans	rs11098499	0.954	rs9685777	chr4:120365965	C/A	cg25214090	chr10:38739885	LOC399744	0.7	9.92	0.52	6.5e-20	Corneal astigmatism;
CESC	cis	rs6691722	0.506	rs11587667	chr1:24715435	C/G	cg18323236	chr1:24743029	NIPAL3	0.5	7.62	0.42	4.41e-13	Response to interferon beta in multiple sclerosis;
CESC	cis	rs72945132	0.522	rs4367974	chr11:70248900	C/T	cg00319359	chr11:70116639	PPFIA1	0.61	6.64	0.38	1.77e-10	Coronary artery disease;
CESC	cis	rs9303280	0.743	rs12946510	chr17:37912377	C/T	cg20243544	chr17:37824526	PNMT	0.52	6.95	0.39	2.83e-11	Self-reported allergy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15192242	chr7:102279588	UPLP;POLR2J2	-0.68	-8.15	-0.45	1.47e-14	Gut microbiome composition (summer);
CESC	trans	rs877282	0.735	rs111609055	chr10:826539	A/G	cg22713356	chr15:30763199	NA	0.95	9.12	0.49	1.99e-17	Uric acid levels;
CESC	cis	rs4820294	1.000	rs739139	chr22:38067011	C/G	cg21798802	chr22:38057573	PDXP	0.46	7.99	0.44	4.16e-14	Fat distribution (HIV);
CESC	cis	rs12681366	0.734	rs2046664	chr8:95387941	G/A	cg13257157	chr8:95487014	RAD54B	0.39	5.24	0.31	3.34e-7	Nonsyndromic cleft lip with cleft palate;
CESC	cis	rs2425143	1.000	rs2425141	chr20:34350123	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.72	6.81	0.39	6.58e-11	Blood protein levels;
CESC	cis	rs1062177	0.826	rs2915879	chr5:151147442	A/G	cg00977110	chr5:151150581	G3BP1	0.61	6.71	0.38	1.17e-10	Preschool internalizing problems;
CESC	cis	rs2976388	0.566	rs6998746	chr8:143802456	A/C	cg10596483	chr8:143751796	JRK	0.44	5.36	0.31	1.8e-7	Urinary tract infection frequency;
CESC	cis	rs9322193	0.923	rs9800686	chr6:149955600	A/C	cg13206674	chr6:150067644	NUP43	0.39	5.53	0.32	7.66e-8	Lung cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25350635	chr12:49182847	ADCY6	0.53	6.0	0.35	6.56e-9	Gut microbiome composition (summer);
CESC	cis	rs7772486	0.754	rs6922507	chr6:146250155	A/T	cg23711669	chr6:146136114	FBXO30	-0.94	-13.66	-0.64	1.66e-32	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs425277	0.565	rs2480711	chr1:2111376	A/G	cg04315214	chr1:2043799	PRKCZ	-0.41	-6.69	-0.38	1.34e-10	Height;
CESC	cis	rs1483890	0.723	rs34184121	chr3:69411426	A/T	cg22125112	chr3:69402811	FRMD4B	0.39	5.24	0.31	3.3e-7	Resting heart rate;
CESC	cis	rs11792861	0.962	rs3750452	chr9:111801353	T/C	cg05043794	chr9:111880884	C9orf5	-0.41	-6.87	-0.39	4.47e-11	Menarche (age at onset);
CESC	cis	rs6424115	0.830	rs6663474	chr1:24199642	G/A	cg10978503	chr1:24200527	CNR2	0.33	6.63	0.38	1.85e-10	Immature fraction of reticulocytes;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03469472	chr1:173991446	NA	0.47	6.21	0.36	2.07e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs2730245	1.000	rs2730241	chr7:158723014	T/C	cg15303052	chr7:158526867	ESYT2	0.43	5.16	0.3	4.93e-7	Height;
CESC	cis	rs4253772	0.591	rs9627324	chr22:46656511	A/G	cg24881330	chr22:46731750	TRMU	0.89	9.99	0.52	3.68e-20	LDL cholesterol;Cholesterol, total;
CESC	cis	rs9309711	0.643	rs10188449	chr2:3480366	T/C	cg15541040	chr2:3486749	NA	-0.45	-5.6	-0.33	5.33e-8	Neurofibrillary tangles;
CESC	cis	rs6088580	0.524	rs6088568	chr20:33265971	A/C	cg24642439	chr20:33292090	TP53INP2	-0.47	-5.48	-0.32	9.79e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs9303280	0.773	rs4795397	chr17:38023745	A/G	cg20243544	chr17:37824526	PNMT	0.52	6.91	0.39	3.61e-11	Self-reported allergy;
CESC	cis	rs2731664	0.740	rs2731670	chr5:176848019	G/T	cg23176889	chr5:176863531	GRK6	0.56	9.52	0.5	1.12e-18	Intelligence (multi-trait analysis);
CESC	trans	rs4942242	0.663	rs34978818	chr13:44214096	T/C	cg19169023	chr15:41853346	TYRO3	-0.59	-7.71	-0.43	2.52e-13	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg07677032	chr17:61819896	STRADA	0.45	5.97	0.34	7.8e-9	Prudent dietary pattern;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg08448040	chr3:13521693	HDAC11	-0.45	-6.39	-0.37	7.57e-10	Gambling;
CESC	cis	rs4660261	0.526	rs2485997	chr1:44345841	G/C	cg12908607	chr1:44402522	ARTN	-0.43	-6.2	-0.36	2.12e-9	Intelligence (multi-trait analysis);
CESC	trans	rs2997457	0.527	rs2997451	chr1:26369297	T/C	cg08109345	chr1:204226218	PLEKHA6	-0.59	-6.09	-0.35	3.91e-9	Facial morphology (factor 16);
CESC	cis	rs3126085	0.935	rs6666382	chr1:152217226	C/G	cg26876637	chr1:152193138	HRNR	-0.45	-5.11	-0.3	6.14e-7	Atopic dermatitis;
CESC	cis	rs6754311	0.731	rs7579771	chr2:136580260	T/A	cg15123519	chr2:136567270	LCT	-0.33	-5.63	-0.33	4.57e-8	Mosquito bite size;
CESC	cis	rs77741769	0.529	rs909053	chr12:121237668	G/A	cg02419362	chr12:121203948	SPPL3	0.34	5.51	0.32	8.52e-8	Mean corpuscular volume;
CESC	cis	rs559928	0.606	rs55970968	chr11:63961433	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.66	5.82	0.34	1.7e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CESC	cis	rs712039	0.687	rs11656455	chr17:35771885	G/A	cg16670864	chr17:35848621	DUSP14	0.44	5.5	0.32	8.74e-8	Tuberculosis;
CESC	cis	rs3858526	0.606	rs10838883	chr11:5952147	G/A	cg05234568	chr11:5960015	NA	0.73	10.56	0.54	5.64e-22	DNA methylation (variation);
CESC	cis	rs72945132	0.678	rs35733235	chr11:70235595	C/T	cg00319359	chr11:70116639	PPFIA1	0.71	6.66	0.38	1.6e-10	Coronary artery disease;
CESC	cis	rs4594175	0.926	rs11157803	chr14:51627700	C/T	cg23942311	chr14:51606299	NA	0.39	5.93	0.34	9.29e-9	Cancer;
CESC	cis	rs853679	0.517	rs4713148	chr6:28115921	G/A	cg22143856	chr6:28129313	ZNF389	0.53	6.71	0.38	1.2e-10	Depression;
CESC	cis	rs2040771	0.740	rs9605960	chr22:19214636	G/C	cg02655711	chr22:19163373	SLC25A1	0.41	5.97	0.34	7.41e-9	Metabolite levels (small molecules and protein measures);
CESC	cis	rs13064411	0.696	rs6783965	chr3:113198722	C/T	cg18753928	chr3:113234510	CCDC52	-0.48	-5.62	-0.33	4.78e-8	Response to simvastatin treatment (PCSK9 protein level change);
CESC	cis	rs7943191	0.768	rs34065644	chr11:62371938	C/T	cg22862634	chr11:62369728	EML3;MTA2	0.5	6.58	0.37	2.44e-10	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
CESC	cis	rs963731	0.579	rs1531021	chr2:39199955	C/G	cg04010122	chr2:39346883	SOS1	-0.58	-5.13	-0.3	5.48e-7	Corticobasal degeneration;
CESC	cis	rs7824557	0.564	rs7839307	chr8:11198792	A/G	cg21775007	chr8:11205619	TDH	0.54	7.89	0.44	7.8500000000000006e-14	Retinal vascular caliber;
CESC	cis	rs13191362	0.872	rs35443919	chr6:163055804	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.52	5.39	0.31	1.54e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs35306767	0.622	rs66462130	chr10:1022108	C/T	cg25019033	chr10:957182	NA	-0.65	-6.53	-0.37	3.33e-10	Eosinophil percentage of granulocytes;
CESC	cis	rs11122272	0.735	rs2790873	chr1:231539685	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-6.93	-0.39	3.24e-11	Hemoglobin concentration;
CESC	cis	rs798766	1.000	rs7682402	chr4:1743343	G/A	cg10756475	chr4:1757242	NA	0.47	6.12	0.35	3.31e-9	Bladder cancer;Urinary bladder cancer;
CESC	cis	rs10504229	1.000	rs61212428	chr8:58173963	G/A	cg05313129	chr8:58192883	C8orf71	-0.55	-6.37	-0.36	8.42e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs35306767	0.761	rs11253557	chr10:1043667	C/T	cg26597838	chr10:835615	NA	0.7	6.45	0.37	5.29e-10	Eosinophil percentage of granulocytes;
CESC	cis	rs7572733	0.555	rs7590828	chr2:198940251	A/G	cg03934865	chr2:198174659	NA	-0.37	-5.2	-0.3	3.9e-7	Dermatomyositis;
CESC	cis	rs1003719	0.699	rs1015549	chr21:38448880	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.62	8.64	0.47	5.56e-16	Eye color traits;
CESC	cis	rs1797885	0.844	rs1699351	chr3:12560317	A/G	cg26432171	chr3:12704882	RAF1	-0.47	-5.83	-0.34	1.61e-8	Immature fraction of reticulocytes;
CESC	cis	rs7613875	0.600	rs2624826	chr3:50155468	T/G	cg24110177	chr3:50126178	RBM5	0.56	7.68	0.43	2.99e-13	Body mass index;
CESC	cis	rs7552404	0.924	rs1303169	chr1:76195041	T/C	cg10523679	chr1:76189770	ACADM	0.74	9.84	0.52	1.11e-19	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs11792861	0.781	rs11789252	chr9:111762010	A/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.52	6.7	0.38	1.23e-10	Menarche (age at onset);
CESC	trans	rs3087243	0.755	rs863603	chr2:204694974	C/T	cg01841312	chr10:38069945	NA	0.38	6.33	0.36	1.03e-9	Rheumatoid arthritis;Hypothyroidism;Type 1 diabetes;
CESC	cis	rs72772090	0.539	rs72773942	chr5:96123366	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.57	-5.26	-0.31	3.01e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs10504229	0.906	rs72650894	chr8:58179734	C/T	cg05313129	chr8:58192883	C8orf71	-0.55	-6.31	-0.36	1.15e-9	Developmental language disorder (linguistic errors);
CESC	trans	rs801193	0.844	rs732465	chr7:65998450	T/C	cg26939375	chr7:64535504	NA	0.53	7.31	0.41	3.22e-12	Aortic root size;
CESC	cis	rs6032067	0.929	rs6017512	chr20:43835038	G/A	cg11264863	chr20:43835661	SEMG1	0.48	5.26	0.31	2.98e-7	Blood protein levels;
CESC	cis	rs2625529	0.652	rs8030815	chr15:72403001	T/C	cg16672083	chr15:72433130	SENP8	0.42	6.57	0.37	2.6200000000000003e-10	Red blood cell count;
CESC	trans	rs12429889	0.831	rs9600245	chr13:74746219	G/A	cg03455107	chr17:54509207	ANKFN1	-0.35	-6.0	-0.35	6.62e-9	Sudden cardiac arrest;
CESC	cis	rs11722228	0.539	rs62287552	chr4:10153197	C/T	cg14348967	chr4:10160060	NA	-0.39	-5.05	-0.3	8.22e-7	Gout;Urate levels;Serum uric acid levels;
CESC	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	7.84	0.43	1.14e-13	Prudent dietary pattern;
CESC	cis	rs6460942	0.915	rs62447641	chr7:12488764	G/A	cg10578991	chr7:12443926	VWDE	-0.48	-5.15	-0.3	5.04e-7	Coronary artery disease;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg23739036	chr1:2343736	PEX10	-0.49	-6.26	-0.36	1.56e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg11494091	chr17:61959527	GH2	0.75	12.85	0.62	1.09e-29	Prudent dietary pattern;
CESC	cis	rs4561483	0.583	rs12149833	chr16:12003723	C/T	cg08843971	chr16:11963173	GSPT1	0.46	6.46	0.37	5.02e-10	Testicular germ cell tumor;
CESC	cis	rs4727027	0.704	rs12704070	chr7:148902789	G/A	cg23158103	chr7:148848205	ZNF398	-0.32	-5.13	-0.3	5.65e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs561341	1.000	rs546748	chr17:30324293	A/C	cg19193384	chr17:30244184	NA	-0.53	-6.22	-0.36	1.89e-9	Hip circumference adjusted for BMI;
CESC	cis	rs9611565	0.918	rs12484074	chr22:41752747	G/A	cg06481639	chr22:41940642	POLR3H	-0.69	-7.12	-0.4	9.86e-12	Vitiligo;
CESC	cis	rs7662987	0.517	rs2602866	chr4:100034997	A/G	cg13256891	chr4:100009986	ADH5	0.75	8.03	0.44	3.29e-14	Smoking initiation;
CESC	cis	rs6545883	0.931	rs778765	chr2:61786385	A/T	cg15711740	chr2:61764176	XPO1	-0.43	-5.2	-0.3	3.98e-7	Tuberculosis;
CESC	trans	rs10242455	0.702	rs59240302	chr7:99072991	C/G	cg09045935	chr12:6379348	NA	0.89	7.38	0.41	2.01e-12	Blood metabolite levels;
CESC	cis	rs2075371	0.932	rs2241332	chr7:133969439	A/G	cg11752832	chr7:134001865	SLC35B4	0.53	6.65	0.38	1.65e-10	Mean platelet volume;
CESC	cis	rs1256061	0.603	rs1256045	chr14:64729760	A/C	cg21174375	chr14:64681225	SYNE2	0.51	6.82	0.39	6.15e-11	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs2842992	0.789	rs7758895	chr6:160193465	T/C	cg11366901	chr6:160182831	ACAT2	0.83	10.38	0.54	2.06e-21	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs62408225	1.000	rs1604831	chr6:90967197	G/A	cg06866423	chr6:90926672	BACH2	0.46	5.55	0.32	6.84e-8	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs2708240	0.504	rs851704	chr7:147538431	G/C	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.34	-5.06	-0.3	7.99e-7	QT interval (drug interaction);
CESC	cis	rs11785400	0.793	rs4736366	chr8:143742413	C/T	cg24634471	chr8:143751801	JRK	0.49	6.06	0.35	4.78e-9	Schizophrenia;
CESC	cis	rs7666738	0.830	rs1426669	chr4:98945534	C/T	cg03676636	chr4:99064102	C4orf37	0.34	5.11	0.3	6.15e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10751667	0.643	rs11246344	chr11:933783	A/C	cg06064525	chr11:970664	AP2A2	-0.52	-10.37	-0.54	2.34e-21	Alzheimer's disease (late onset);
CESC	cis	rs2228479	1.000	rs2228479	chr16:89985940	G/A	cg04013166	chr16:89971882	TCF25	0.77	6.44	0.37	5.6e-10	Skin colour saturation;
CESC	cis	rs35306767	0.903	rs7074642	chr10:878359	A/G	cg26597838	chr10:835615	NA	0.85	9.06	0.49	2.95e-17	Eosinophil percentage of granulocytes;
CESC	cis	rs769267	0.930	rs2099334	chr19:19578450	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.46	5.94	0.34	8.86e-9	Tonsillectomy;
CESC	cis	rs3096299	0.658	rs34590044	chr16:89543157	A/C	cg16743903	chr16:89593216	SPG7	-0.42	-5.5	-0.32	9.16e-8	Multiple myeloma (IgH translocation);
CESC	cis	rs9828933	0.766	rs864975	chr3:63885615	T/C	cg16258503	chr3:63850278	ATXN7;THOC7	0.94	8.55	0.46	1.02e-15	Type 2 diabetes;
CESC	cis	rs12497850	1.000	rs12497850	chr3:48748989	G/T	cg07636037	chr3:49044803	WDR6	0.94	16.03	0.7	6.6e-41	Parkinson's disease;
CESC	cis	rs9902453	0.845	rs2617875	chr17:28090024	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	8.23	0.45	8.59e-15	Coffee consumption (cups per day);
CESC	cis	rs6952808	0.689	rs871924	chr7:2047845	A/G	cg08027265	chr7:2291960	NA	-0.34	-5.08	-0.3	7.23e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs6912958	0.712	rs2754262	chr6:88405585	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.5	-6.28	-0.36	1.37e-9	Monocyte percentage of white cells;
CESC	cis	rs9549260	0.753	rs9549238	chr13:41179321	G/A	cg21288729	chr13:41239152	FOXO1	0.53	5.05	0.3	8.14e-7	Red blood cell count;
CESC	cis	rs2404602	0.716	rs56216512	chr15:76686936	T/C	cg26408565	chr15:76604113	ETFA	-0.42	-6.07	-0.35	4.47e-9	Blood metabolite levels;
CESC	cis	rs875971	0.862	rs6964437	chr7:65686444	A/G	cg10691866	chr7:65817282	TPST1	0.32	5.3	0.31	2.49e-7	Aortic root size;
CESC	cis	rs250677	0.522	rs3763022	chr5:148381078	A/G	cg18129178	chr5:148520854	ABLIM3	-0.39	-5.04	-0.3	8.59e-7	Breast cancer;
CESC	cis	rs10791097	0.694	rs12361892	chr11:130744490	T/G	cg12179176	chr11:130786555	SNX19	0.64	9.93	0.52	5.73e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs801193	1.000	rs7782320	chr7:66177098	C/T	cg06456125	chr7:65229604	NA	0.39	5.13	0.3	5.57e-7	Aortic root size;
CESC	cis	rs6840258	0.941	rs7665282	chr4:87900850	C/T	cg08197287	chr4:87952173	AFF1	-0.39	-5.11	-0.3	6.15e-7	Mean corpuscular volume;Basophil percentage of granulocytes;
CESC	cis	rs11112613	0.609	rs11112585	chr12:105933442	A/G	cg03607813	chr12:105948248	NA	-0.54	-5.75	-0.33	2.47e-8	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CESC	cis	rs7084402	0.935	rs4948523	chr10:60339098	A/C	cg07615347	chr10:60278583	BICC1	0.57	8.6	0.47	6.98e-16	Refractive error;
CESC	cis	rs8114671	0.562	rs6119545	chr20:33522869	T/C	cg06115741	chr20:33292138	TP53INP2	0.48	5.79	0.34	1.97e-8	Height;
CESC	cis	rs12220238	1.000	rs11000890	chr10:75904073	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.64	6.52	0.37	3.45e-10	Soluble interleukin-2 receptor subunit alpha;
CESC	cis	rs736408	0.648	rs3774355	chr3:52817778	G/A	cg18404041	chr3:52824283	ITIH1	-0.47	-7.71	-0.43	2.56e-13	Bipolar disorder;
CESC	cis	rs9733	0.596	rs11586422	chr1:150679358	C/T	cg17724175	chr1:150552817	MCL1	0.45	7.31	0.41	3.23e-12	Tonsillectomy;
CESC	cis	rs10197940	0.662	rs4592848	chr2:152337822	G/A	cg19508488	chr2:152266495	RIF1	0.49	5.36	0.31	1.85e-7	Lung cancer;
CESC	cis	rs4561483	0.801	rs33643	chr16:11986149	A/G	cg08843971	chr16:11963173	GSPT1	-0.56	-8.39	-0.46	2.97e-15	Testicular germ cell tumor;
CESC	cis	rs72781680	0.898	rs17762651	chr2:24115922	A/G	cg08917208	chr2:24149416	ATAD2B	0.93	8.42	0.46	2.35e-15	Lymphocyte counts;
CESC	cis	rs7772486	0.790	rs11760	chr6:146205973	G/T	cg23711669	chr6:146136114	FBXO30	0.92	13.35	0.63	1.96e-31	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4722585	0.605	rs10268883	chr7:26200417	C/T	cg07876897	chr7:26191696	NFE2L3	0.47	5.96	0.34	8.1e-9	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
CESC	cis	rs7666738	0.753	rs13120995	chr4:98972762	A/G	cg03467027	chr4:99064603	C4orf37	0.43	5.4	0.31	1.49e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3806843	0.868	rs2262573	chr5:140123627	T/A	cg26395211	chr5:140044315	WDR55	0.4	5.2	0.3	3.99e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs7122539	0.646	rs627330	chr11:66602099	C/T	cg24851651	chr11:66362959	CCS	0.49	7.11	0.4	1.08e-11	HIV-1 susceptibility;
CESC	cis	rs9291683	0.546	rs13139055	chr4:10038924	G/T	cg02734326	chr4:10020555	SLC2A9	0.45	6.19	0.36	2.3e-9	Bone mineral density;
CESC	trans	rs9467711	0.659	rs13220261	chr6:26499185	C/T	cg06606381	chr12:133084897	FBRSL1	-0.96	-7.07	-0.4	1.39e-11	Autism spectrum disorder or schizophrenia;
CESC	cis	rs80130819	0.748	rs2732446	chr12:48690177	T/C	cg05342945	chr12:48394962	COL2A1	-0.48	-5.16	-0.3	4.82e-7	Prostate cancer;
CESC	cis	rs1506636	1.000	rs7357252	chr7:123369856	C/T	cg03229431	chr7:123269106	ASB15	-0.52	-6.91	-0.39	3.58e-11	Plateletcrit;Platelet count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18101314	chr11:72504857	STARD10	0.6	6.84	0.39	5.38e-11	Gut microbiome composition (summer);
CESC	cis	rs6582630	0.555	rs2004152	chr12:38478951	C/T	cg13010199	chr12:38710504	ALG10B	0.53	6.74	0.38	9.64e-11	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs9926296	0.529	rs7195906	chr16:89806347	A/T	cg07648498	chr16:89883185	FANCA	0.48	6.01	0.35	5.98e-9	Vitiligo;
CESC	cis	rs35520189	0.591	rs12995439	chr2:113703646	T/C	cg06156847	chr2:113672199	IL1F7	0.37	5.17	0.3	4.63e-7	Obstructive sleep apnea trait (apnea hypopnea index);
CESC	cis	rs1843834	0.539	rs10177898	chr2:225437552	C/T	cg22455342	chr2:225449267	CUL3	0.7	9.62	0.51	5.41e-19	IgE levels in asthmatics (D.p. specific);
CESC	cis	rs10256972	0.967	rs4723338	chr7:1036241	A/G	cg00431813	chr7:1051703	C7orf50	-0.35	-5.4	-0.31	1.49e-7	Longevity;Endometriosis;
CESC	cis	rs79349575	0.783	rs4794003	chr17:47029904	C/T	cg16584676	chr17:46985605	UBE2Z	0.54	6.67	0.38	1.46e-10	Type 2 diabetes;
CESC	cis	rs7107174	0.892	rs1893449	chr11:77968977	G/C	cg02023728	chr11:77925099	USP35	0.48	6.34	0.36	9.87e-10	Testicular germ cell tumor;
CESC	cis	rs5758659	0.714	rs6002626	chr22:42517989	C/G	cg15557168	chr22:42548783	NA	0.48	7.42	0.41	1.62e-12	Cognitive function;
CESC	cis	rs6815814	0.950	rs11722889	chr4:38810975	C/T	cg02016764	chr4:38805732	TLR1	-0.62	-7.43	-0.42	1.5e-12	Breast cancer;
CESC	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	22.27	0.81	1.17e-62	Prudent dietary pattern;
CESC	cis	rs10905065	0.930	rs9423726	chr10:5737979	A/G	cg11519256	chr10:5708881	ASB13	-0.42	-5.43	-0.32	1.29e-7	Menopause (age at onset);
CESC	cis	rs12190007	0.573	rs13202383	chr6:169826544	A/G	cg15038512	chr6:170123185	PHF10	-0.51	-7.29	-0.41	3.68e-12	Obesity-related traits;
CESC	cis	rs7586879	0.598	rs6724772	chr2:25128730	T/C	cg01884057	chr2:25150051	NA	0.36	7.01	0.4	2.04e-11	Body mass index;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23125901	chr10:504452	DIP2C	-0.52	-6.2	-0.36	2.18e-9	Gut microbiome composition (summer);
CESC	cis	rs2996428	0.643	rs6424056	chr1:3722486	G/A	cg13057898	chr1:3703894	LRRC47	0.47	6.46	0.37	4.98e-10	Red cell distribution width;
CESC	cis	rs12681288	0.676	rs935820	chr8:1022168	A/G	cg15309053	chr8:964076	NA	0.37	6.47	0.37	4.79e-10	Schizophrenia;
CESC	cis	rs8078723	0.714	rs2241244	chr17:38153554	G/C	cg17344932	chr17:38183730	MED24;SNORD124	0.38	5.52	0.32	8.15e-8	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CESC	cis	rs72781680	0.611	rs6720131	chr2:24364736	C/T	cg08917208	chr2:24149416	ATAD2B	0.63	6.04	0.35	5.28e-9	Lymphocyte counts;
CESC	cis	rs6732160	0.845	rs6752507	chr2:73385158	C/G	cg01422370	chr2:73384389	NA	0.42	7.15	0.4	8.29e-12	Intelligence (multi-trait analysis);
CESC	cis	rs2251381	0.750	rs2251087	chr21:30527999	C/T	cg08807101	chr21:30365312	RNF160	0.7	8.59	0.47	7.75e-16	Selective IgA deficiency;
CESC	cis	rs6540559	1.000	rs742214	chr1:209960925	T/C	cg10074409	chr1:209979377	IRF6	0.37	6.02	0.35	5.89e-9	Cleft lip with or without cleft palate;
CESC	cis	rs9611565	0.592	rs80477	chr22:42001183	C/T	cg06481639	chr22:41940642	POLR3H	0.57	6.31	0.36	1.17e-9	Vitiligo;
CESC	cis	rs6088580	0.634	rs6579165	chr20:32994715	A/G	cg06115741	chr20:33292138	TP53INP2	-0.46	-5.98	-0.34	7.28e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs2228479	0.618	rs17233623	chr16:89811209	C/T	cg04287289	chr16:89883240	FANCA	0.67	5.53	0.32	7.48e-8	Skin colour saturation;
CESC	cis	rs853679	0.517	rs9468286	chr6:28079428	C/T	cg23161317	chr6:28129485	ZNF389	0.51	6.53	0.37	3.44e-10	Depression;
CESC	cis	rs798554	0.757	rs1182185	chr7:2872233	A/G	cg19717773	chr7:2847554	GNA12	-0.53	-7.83	-0.43	1.15e-13	Height;
CESC	cis	rs10504229	1.000	rs58053450	chr8:58173348	T/C	cg24829409	chr8:58192753	C8orf71	-0.76	-10.0	-0.52	3.53e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs34779708	0.931	rs34087268	chr10:35346724	T/G	cg03585969	chr10:35415529	CREM	0.77	10.01	0.52	3.32e-20	Inflammatory bowel disease;Crohn's disease;
CESC	trans	rs7839040	0.698	rs11774876	chr8:82929277	G/A	cg14472086	chr9:107730925	NA	-0.47	-6.33	-0.36	1.02e-9	Response to methotrexate in juvenile idiopathic arthritis;
CESC	cis	rs875971	0.508	rs10950045	chr7:66066373	T/C	cg18252515	chr7:66147081	NA	0.39	5.2	0.3	4.01e-7	Aortic root size;
CESC	cis	rs2180341	0.920	rs7756880	chr6:127683999	A/T	cg27446573	chr6:127587934	RNF146	1.06	15.51	0.69	4.62e-39	Breast cancer;
CESC	cis	rs2243480	1.000	rs160648	chr7:65543384	C/A	cg18252515	chr7:66147081	NA	-1.34	-13.59	-0.64	2.89e-32	Diabetic kidney disease;
CESC	cis	rs7160336	0.641	rs10136002	chr14:74681775	T/C	cg08255017	chr14:74727001	VSX2	-0.38	-5.53	-0.32	7.71e-8	Blood protein levels;
CESC	cis	rs79057730	0.599	rs9458	chr7:825494	A/G	cg05729249	chr7:766119	PRKAR1B;HEATR2	-0.87	-8.01	-0.44	3.67e-14	Initial pursuit acceleration;
CESC	cis	rs561341	0.883	rs2074102	chr17:30228884	G/A	cg13647721	chr17:30228624	UTP6	0.59	5.42	0.32	1.33e-7	Hip circumference adjusted for BMI;
CESC	cis	rs7959452	0.605	rs12819406	chr12:69696400	G/T	cg14784868	chr12:69753453	YEATS4	0.73	10.59	0.55	4.42e-22	Blood protein levels;
CESC	cis	rs6952808	0.689	rs1107591	chr7:2041638	G/A	cg02951883	chr7:2050386	MAD1L1	-0.57	-7.76	-0.43	1.81e-13	Bipolar disorder and schizophrenia;
CESC	cis	rs1949733	0.656	rs2688224	chr4:8404700	C/G	cg11789530	chr4:8429930	ACOX3	0.69	9.69	0.51	3.36e-19	Response to antineoplastic agents;
CESC	trans	rs916888	0.821	rs70600	chr17:44860021	C/T	cg10053473	chr17:62856997	LRRC37A3	-0.66	-6.94	-0.39	2.96e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs7666738	0.830	rs6855393	chr4:99056534	T/C	cg03467027	chr4:99064603	C4orf37	0.48	6.04	0.35	5.29e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2404602	0.692	rs4360890	chr15:77173295	G/A	cg22467129	chr15:76604101	ETFA	-0.35	-5.23	-0.31	3.42e-7	Blood metabolite levels;
CESC	cis	rs11098499	0.954	rs6849171	chr4:120409549	G/A	cg09307838	chr4:120376055	NA	0.96	13.98	0.65	1.21e-33	Corneal astigmatism;
CESC	trans	rs1557351	0.723	rs1942345	chr18:54721169	G/C	cg11433624	chr6:7146702	RREB1	0.38	6.14	0.35	2.94e-9	Multiple sclerosis (age of onset);
CESC	cis	rs9311474	0.508	rs4687546	chr3:52605943	T/A	cg18337363	chr3:52569053	NT5DC2	0.29	5.26	0.31	3.02e-7	Electroencephalogram traits;
CESC	cis	rs7927592	0.956	rs55816191	chr11:68262979	G/T	cg20283391	chr11:68216788	NA	-0.49	-6.29	-0.36	1.34e-9	Total body bone mineral density;
CESC	cis	rs2797160	0.967	rs1739358	chr6:126019736	G/A	cg05901451	chr6:126070800	HEY2	0.46	6.54	0.37	3.08e-10	Endometrial cancer;
CESC	cis	rs2932538	0.922	rs4838961	chr1:113163967	T/C	cg22162597	chr1:113214053	CAPZA1	-0.58	-7.44	-0.42	1.45e-12	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CESC	cis	rs11792861	0.591	rs10979632	chr9:111732140	G/C	cg13535736	chr9:111863775	C9orf5	-0.4	-5.89	-0.34	1.18e-8	Menarche (age at onset);
CESC	cis	rs7671266	0.668	rs10002562	chr4:10159736	C/G	cg00071950	chr4:10020882	SLC2A9	-0.56	-6.0	-0.35	6.43e-9	Cardiovascular disease risk factors;
CESC	cis	rs6952808	0.656	rs11764212	chr7:2067593	C/A	cg05863683	chr7:1912471	MAD1L1	0.43	6.29	0.36	1.33e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs644148	0.738	rs2686768	chr19:44995990	C/T	cg15540054	chr19:45004280	ZNF180	-0.43	-5.35	-0.31	1.94e-7	Personality dimensions;
CESC	cis	rs6502050	0.736	rs11658040	chr17:80059891	C/T	cg23985595	chr17:80112537	CCDC57	0.4	6.14	0.35	2.98e-9	Life satisfaction;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24418621	chr11:129993688	APLP2	0.51	6.06	0.35	4.69e-9	Gut microbiome composition (summer);
CESC	cis	rs1008375	1.000	rs4235388	chr4:17682030	G/A	cg16339924	chr4:17578868	LAP3	0.48	6.13	0.35	3.11e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs1775715	0.870	rs1755072	chr10:32266642	A/G	cg18675610	chr10:32216311	ARHGAP12	-0.33	-5.04	-0.3	8.46e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs854765	0.547	rs2955384	chr17:17939573	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.58	8.42	0.46	2.42e-15	Total body bone mineral density;
CESC	cis	rs9300255	0.739	rs12824957	chr12:123750228	T/C	cg00376283	chr12:123451042	ABCB9	-0.68	-6.99	-0.39	2.22e-11	Neutrophil percentage of white cells;
CESC	cis	rs13118159	0.550	rs4974614	chr4:1373489	A/G	cg02475777	chr4:1388615	CRIPAK	0.7	8.78	0.47	2e-16	Longevity;
CESC	cis	rs10540	0.908	rs71487293	chr11:486414	G/A	cg03934478	chr11:495069	RNH1	0.55	5.31	0.31	2.37e-7	Body mass index;
CESC	cis	rs4555082	0.834	rs28846738	chr14:105745781	A/G	cg13114125	chr14:105738426	BRF1	-0.81	-10.2	-0.53	8.28e-21	Mean platelet volume;Platelet distribution width;
CESC	cis	rs4253772	0.591	rs6008545	chr22:46686375	C/T	cg10231785	chr22:46692440	CN5H6.4;GTSE1	0.53	5.26	0.31	3.02e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs7586879	0.521	rs7597332	chr2:25075675	A/G	cg01884057	chr2:25150051	NA	0.37	7.18	0.4	7.06e-12	Body mass index;
CESC	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.48	-5.08	-0.3	7.1e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs4253772	0.591	rs7291444	chr22:46656246	T/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.67	7.99	0.44	4.2e-14	LDL cholesterol;Cholesterol, total;
CESC	trans	rs11098499	0.754	rs11732087	chr4:120239831	A/G	cg25214090	chr10:38739885	LOC399744	0.61	8.4	0.46	2.69e-15	Corneal astigmatism;
CESC	cis	rs1942	0.837	rs12440045	chr15:41782684	A/C	cg20272979	chr15:41787780	ITPKA	0.37	5.4	0.32	1.45e-7	Eosinophil percentage of granulocytes;
CESC	cis	rs3796619	1.000	rs55741287	chr4:1094670	T/C	cg27284194	chr4:1044797	NA	0.37	5.56	0.32	6.46e-8	Recombination rate (males);
CESC	cis	rs6088590	0.561	rs6059926	chr20:33164804	C/T	cg24642439	chr20:33292090	TP53INP2	0.63	8.5	0.46	1.36e-15	Coronary artery disease;
CESC	cis	rs12701220	0.655	rs34696066	chr7:1140919	C/T	cg26769984	chr7:1090371	C7orf50	0.6	6.77	0.38	8.2e-11	Bronchopulmonary dysplasia;
CESC	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg14893161	chr1:205819251	PM20D1	0.86	14.44	0.66	2.81e-35	Menarche (age at onset);
CESC	cis	rs611744	0.647	rs12675265	chr8:109268805	C/T	cg21045802	chr8:109455806	TTC35	0.5	6.25	0.36	1.62e-9	Dupuytren's disease;
CESC	cis	rs3806843	1.000	rs6885319	chr5:140200611	A/C	cg16179182	chr5:140090404	VTRNA1-1	-0.4	-5.13	-0.3	5.71e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs1552244	0.882	rs113268531	chr3:10167069	A/G	cg00166722	chr3:10149974	C3orf24	0.45	5.84	0.34	1.54e-8	Alzheimer's disease;
CESC	cis	rs4906332	1.000	rs2065018	chr14:103879187	C/T	cg09975044	chr14:104007538	NA	-0.45	-6.27	-0.36	1.45e-9	Coronary artery disease;
CESC	cis	rs7412746	0.611	rs9661876	chr1:150910911	C/T	cg22823121	chr1:150693482	HORMAD1	0.36	5.12	0.3	5.88e-7	Melanoma;
CESC	cis	rs733592	0.507	rs7304428	chr12:48494275	T/G	cg24011408	chr12:48396354	COL2A1	-0.51	-8.57	-0.47	8.97e-16	Plateletcrit;
CESC	cis	rs2075371	0.966	rs1646676	chr7:133999267	G/A	cg00033643	chr7:134001901	SLC35B4	0.44	5.59	0.32	5.71e-8	Mean platelet volume;
CESC	cis	rs6547741	0.935	rs4666005	chr2:27855239	A/G	cg27432699	chr2:27873401	GPN1	0.46	6.4	0.37	7.11e-10	Oral cavity cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07335843	chr2:133030691	NA	-0.54	-7.19	-0.4	6.55e-12	Gut microbiome composition (summer);
CESC	cis	rs1144333	1.000	rs1021464	chr1:76375415	G/A	cg10523679	chr1:76189770	ACADM	0.56	5.15	0.3	5e-7	Attention function in attention deficit hyperactive disorder;
CESC	cis	rs10189230	0.935	rs6731133	chr2:222359155	C/T	cg14652038	chr2:222343519	EPHA4	0.34	6.8	0.39	6.79e-11	Urate levels in lean individuals;
CESC	cis	rs9473147	0.543	rs9473119	chr6:47450618	G/A	cg20196966	chr6:47445060	CD2AP	0.4	5.1	0.3	6.36e-7	Platelet distribution width;Mean platelet volume;
CESC	cis	rs1499614	0.831	rs3800822	chr7:66147149	A/G	cg18252515	chr7:66147081	NA	1.42	14.47	0.66	2.33e-35	Gout;
CESC	cis	rs6502050	0.835	rs8075086	chr17:80092649	A/G	cg11859384	chr17:80120422	CCDC57	-0.38	-5.14	-0.3	5.31e-7	Life satisfaction;
CESC	cis	rs901683	1.000	rs35349326	chr10:45973624	A/G	cg16031567	chr10:46195673	NA	-0.75	-5.04	-0.3	8.78e-7	Red blood cell traits;Mean corpuscular volume;
CESC	cis	rs9287719	0.934	rs6706763	chr2:10751407	C/T	cg00105475	chr2:10696890	NA	0.38	5.57	0.32	6.34e-8	Prostate cancer;
CESC	cis	rs853679	0.550	rs6901017	chr6:28152583	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.47	-5.56	-0.32	6.59e-8	Depression;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24536114	chr1:89448405	RBMXL1;CCBL2	-0.54	-6.75	-0.38	9.54e-11	Gut microbiome composition (summer);
CESC	trans	rs983392	0.679	rs7121656	chr11:60024008	C/T	cg13921652	chr1:144931966	PDE4DIP	0.48	6.06	0.35	4.63e-9	Alzheimer's disease (late onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17816495	chr19:19030203	DDX49;COPE	0.65	7.44	0.42	1.39e-12	Gut microbiome composition (summer);
CESC	trans	rs61931739	0.534	rs11053005	chr12:34091626	A/C	cg26384229	chr12:38710491	ALG10B	0.59	8.25	0.45	7.65e-15	Morning vs. evening chronotype;
CESC	cis	rs6032067	0.777	rs62208416	chr20:43803226	G/A	cg11264863	chr20:43835661	SEMG1	0.51	5.43	0.32	1.25e-7	Blood protein levels;
CESC	cis	rs10927875	0.501	rs9660676	chr1:16279041	C/T	cg21385522	chr1:16154831	NA	-0.89	-9.91	-0.52	6.55e-20	Dilated cardiomyopathy;
CESC	cis	rs8020095	0.528	rs10147362	chr14:67820372	A/T	cg19548862	chr14:67692701	FAM71D	-0.45	-5.39	-0.31	1.52e-7	Depression (quantitative trait);
CESC	cis	rs637571	0.654	rs1058068	chr11:65667796	G/A	cg02202077	chr11:65769826	EIF1AD;BANF1	0.44	5.42	0.32	1.33e-7	Eosinophil percentage of white cells;
CESC	cis	rs7659604	0.539	rs3217773	chr4:122739121	A/G	cg19748678	chr4:122722346	EXOSC9	0.79	9.99	0.52	3.82e-20	Type 2 diabetes;
CESC	cis	rs10504229	1.000	rs17217033	chr8:58180061	G/T	cg05313129	chr8:58192883	C8orf71	-0.55	-6.37	-0.36	8.42e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs9611565	0.570	rs12159188	chr22:42121125	A/T	cg17376030	chr22:41985996	PMM1	-0.56	-6.11	-0.35	3.48e-9	Vitiligo;
CESC	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg14893161	chr1:205819251	PM20D1	0.71	11.88	0.59	2.18e-26	Monocyte percentage of white cells;
CESC	cis	rs12477438	0.798	rs12468419	chr2:99579680	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.64	-8.91	-0.48	8.52e-17	Chronic sinus infection;
CESC	cis	rs853679	0.517	rs9393897	chr6:28127710	G/T	cg19592336	chr6:28129416	ZNF389	0.61	7.98	0.44	4.44e-14	Depression;
CESC	cis	rs6582630	0.519	rs8189623	chr12:38351436	G/A	cg26384229	chr12:38710491	ALG10B	0.73	10.95	0.56	2.81e-23	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs6460942	0.597	rs4719315	chr7:12528634	A/G	cg06484146	chr7:12443880	VWDE	-0.71	-7.7	-0.43	2.7e-13	Coronary artery disease;
CESC	cis	rs7640424	0.819	rs34937412	chr3:107829484	G/C	cg09227934	chr3:107805635	CD47	-0.48	-6.05	-0.35	4.81e-9	Body mass index;
CESC	cis	rs704795	0.902	rs11887784	chr2:27679919	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.31	-5.65	-0.33	4.22e-8	Menopause (age at onset);
CESC	cis	rs9303401	0.659	rs7216648	chr17:56790858	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.03	12.82	0.62	1.31e-29	Cognitive test performance;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26396086	chr1:247494708	ZNF496	0.56	6.37	0.36	8.53e-10	Gut microbiome composition (summer);
CESC	cis	rs17601876	0.814	rs28520437	chr15:51553277	C/T	cg19946085	chr15:51559439	CYP19A1	-0.34	-5.41	-0.32	1.44e-7	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
CESC	cis	rs7845219	0.539	rs713113	chr8:95877787	C/T	cg09323728	chr8:95962352	TP53INP1	0.27	5.31	0.31	2.28e-7	Type 2 diabetes;
CESC	cis	rs11030122	0.702	rs10835311	chr11:3949027	G/T	cg18678763	chr11:4115507	RRM1	-0.46	-6.08	-0.35	4.1e-9	Mean platelet volume;Platelet distribution width;
CESC	cis	rs514406	0.505	rs6688064	chr1:53165609	C/T	cg27535305	chr1:53392650	SCP2	-0.34	-5.57	-0.32	6.16e-8	Monocyte count;
CESC	cis	rs12464559	0.522	rs6715027	chr2:152626657	T/C	cg01189475	chr2:152685088	ARL5A	0.72	6.98	0.39	2.38e-11	Response to cognitive-behavioural therapy in anxiety disorder;
CESC	cis	rs2735413	0.957	rs2735414	chr16:78053658	C/A	cg04733911	chr16:78082701	NA	-0.42	-6.24	-0.36	1.74e-9	Systolic blood pressure (alcohol consumption interaction);
CESC	cis	rs910316	0.737	rs175065	chr14:75494983	T/C	cg08847533	chr14:75593920	NEK9	-0.89	-15.46	-0.69	6.99e-39	Height;
CESC	cis	rs13191362	0.507	rs6907151	chr6:163200701	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.5	5.93	0.34	9.18e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs2228479	0.850	rs11649510	chr16:89851004	A/G	cg19635926	chr16:89946313	TCF25	0.67	5.08	0.3	7.08e-7	Skin colour saturation;
CESC	cis	rs921968	0.643	rs485765	chr2:219480804	C/G	cg02176678	chr2:219576539	TTLL4	0.32	5.19	0.3	4.14e-7	Mean corpuscular hemoglobin concentration;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg16424519	chr16:21531031	SLC7A5P2	-0.44	-6.25	-0.36	1.62e-9	Gambling;
CESC	cis	rs7666738	0.830	rs4699580	chr4:98930673	T/C	cg05340658	chr4:99064831	C4orf37	0.82	12.17	0.6	2.24e-27	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9733	0.593	rs10888384	chr1:150574256	C/T	cg13175981	chr1:150552382	MCL1	0.71	10.45	0.54	1.22e-21	Tonsillectomy;
CESC	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg18538332	chr22:24372958	LOC391322	-0.71	-10.69	-0.55	2.13e-22	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs4665809	0.627	rs1465720	chr2:26412638	G/T	cg25036284	chr2:26402008	FAM59B	-0.83	-9.37	-0.5	3.23e-18	Gut microbiome composition (summer);
CESC	cis	rs2354432	1.000	rs2120003	chr1:146690635	A/G	cg25205988	chr1:146714368	CHD1L	0.7	6.45	0.37	5.42e-10	Mitochondrial DNA levels;
CESC	cis	rs6754311	0.731	rs309160	chr2:136685228	C/T	cg07169764	chr2:136633963	MCM6	0.68	8.49	0.46	1.51e-15	Mosquito bite size;
CESC	trans	rs12681287	0.517	rs13249753	chr8:87513216	A/G	cg27317242	chr8:23145699	R3HCC1	-0.51	-6.12	-0.35	3.28e-9	Caudate activity during reward;
CESC	cis	rs9581857	0.685	rs9319371	chr13:28042564	A/G	cg01674679	chr13:27998804	GTF3A	-0.69	-5.52	-0.32	8.1e-8	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
CESC	cis	rs921968	0.541	rs496674	chr2:219432569	G/A	cg02176678	chr2:219576539	TTLL4	0.5	8.91	0.48	8.15e-17	Mean corpuscular hemoglobin concentration;
CESC	cis	rs2108225	0.872	rs2051954	chr7:107441097	G/C	cg18560240	chr7:107437656	SLC26A3	-0.43	-5.95	-0.34	8.65e-9	Ulcerative colitis;
CESC	cis	rs1707322	1.000	rs4460583	chr1:46449918	C/G	cg06784218	chr1:46089804	CCDC17	0.33	5.63	0.33	4.7e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs4727027	0.754	rs11764892	chr7:148858916	G/A	cg23158103	chr7:148848205	ZNF398	-0.36	-5.2	-0.3	4.05e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs7615952	0.599	rs66532274	chr3:125731845	G/A	cg04553112	chr3:125709451	NA	-0.48	-5.41	-0.32	1.44e-7	Blood pressure (smoking interaction);
CESC	cis	rs7208859	0.623	rs11657369	chr17:29136468	G/A	cg14008862	chr17:28927542	LRRC37B2	0.65	5.14	0.3	5.34e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs9457247	1.000	rs409356	chr6:167405226	T/A	cg23791538	chr6:167370224	RNASET2	-0.59	-8.42	-0.46	2.44e-15	Crohn's disease;
CESC	cis	rs4665809	1.000	rs6709595	chr2:26259885	A/G	cg25036284	chr2:26402008	FAM59B	-0.57	-6.54	-0.37	3.12e-10	Gut microbiome composition (summer);
CESC	cis	rs7542091	0.704	rs7550330	chr1:210044587	G/A	cg25204440	chr1:209979598	IRF6	0.37	5.1	0.3	6.55e-7	Monobrow;
CESC	cis	rs881375	0.678	rs9886724	chr9:123665019	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.47	6.83	0.39	5.66e-11	Rheumatoid arthritis;
CESC	cis	rs6665290	0.901	rs12410103	chr1:227197408	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.22	-33.0	-0.9	7.42e-96	Myeloid white cell count;
CESC	cis	rs425277	0.606	rs3128339	chr1:2046938	G/T	cg16545954	chr1:2118288	C1orf86	-0.31	-5.7	-0.33	3.13e-8	Height;
CESC	cis	rs10752881	0.775	rs2147585	chr1:183074875	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.88	14.2	0.66	2.05e-34	Colorectal cancer;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg20032723	chr11:126174041	DCPS	0.46	6.3	0.36	1.25e-9	Systemic lupus erythematosus;
CESC	cis	rs6500395	0.928	rs12934788	chr16:48706343	C/A	cg04672837	chr16:48644449	N4BP1	-0.52	-6.64	-0.38	1.75e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs4919694	0.808	rs77521106	chr10:104980726	G/T	cg04362960	chr10:104952993	NT5C2	0.79	5.91	0.34	1.03e-8	Arsenic metabolism;
CESC	cis	rs9303280	0.776	rs9910826	chr17:38035648	A/G	cg19468946	chr17:37922297	IKZF3	-0.41	-5.42	-0.32	1.31e-7	Self-reported allergy;
CESC	trans	rs4957048	0.541	rs12519390	chr5:676546	A/G	cg25482853	chr8:67687455	SGK3	0.99	9.0	0.48	4.53e-17	Ulcerative colitis;
CESC	cis	rs1478897	0.898	rs2248932	chr8:11391650	A/G	cg09528494	chr8:11338675	NA	-0.28	-5.12	-0.3	5.99e-7	Systemic lupus erythematosus;
CESC	cis	rs736801	0.569	rs11748193	chr5:131725329	A/T	cg14196790	chr5:131705035	SLC22A5	0.34	5.21	0.3	3.82e-7	Breast cancer;Mosquito bite size;
CESC	cis	rs11690935	0.959	rs12692973	chr2:172642057	A/G	cg13550731	chr2:172543902	DYNC1I2	0.96	14.96	0.68	4.09e-37	Schizophrenia;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg11141692	chr4:111866916	NA	-0.45	-6.21	-0.36	2.04e-9	Gut microbiota (bacterial taxa);
CESC	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg18106800	chr5:94890715	ARSK;TTC37	0.44	6.08	0.35	4.29e-9	Myopia;
CESC	cis	rs35306767	0.761	rs12359796	chr10:1021479	G/C	cg26597838	chr10:835615	NA	0.76	7.15	0.4	8.67e-12	Eosinophil percentage of granulocytes;
CESC	cis	rs9818758	0.607	rs34823813	chr3:49749976	G/A	cg00383909	chr3:49044727	WDR6	0.84	5.53	0.32	7.76e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CESC	cis	rs4925325	0.955	rs1776262	chr20:60516023	G/T	cg23262073	chr20:60523788	NA	0.54	7.63	0.42	4.31e-13	Obesity-related traits;
CESC	cis	rs9733	0.596	rs17658705	chr1:150678071	A/C	cg17724175	chr1:150552817	MCL1	-0.45	-7.33	-0.41	2.74e-12	Tonsillectomy;
CESC	cis	rs9640161	0.742	rs2108853	chr7:150017589	A/C	cg21361702	chr7:150065534	REPIN1	0.55	6.45	0.37	5.33e-10	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs1355223	0.583	rs2941058	chr11:34880245	C/G	cg18508148	chr11:34937573	PDHX;APIP	0.41	5.31	0.31	2.33e-7	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs67311347	1.000	rs7628247	chr3:40512682	G/T	cg24209194	chr3:40518798	ZNF619	-0.53	-6.88	-0.39	4.25e-11	Renal cell carcinoma;
CESC	cis	rs7582720	1.000	rs72936830	chr2:203769803	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.39	0.41	1.96e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs3020736	0.500	rs5996111	chr22:42493902	C/T	cg12850546	chr22:42539477	CYP2D7P1	0.45	5.3	0.31	2.4e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg11494091	chr17:61959527	GH2	0.74	12.63	0.61	6.3e-29	Prudent dietary pattern;
CESC	cis	rs10461617	0.541	rs7715822	chr5:56043600	G/T	cg12311346	chr5:56204834	C5orf35	-0.62	-5.77	-0.33	2.24e-8	Type 2 diabetes;
CESC	cis	rs11920090	0.858	rs10513688	chr3:170727218	G/A	cg09710316	chr3:170744871	SLC2A2	0.51	5.84	0.34	1.53e-8	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg09366641	chr1:153643528	ILF2	-0.39	-6.2	-0.36	2.17e-9	Vertical cup-disc ratio;
CESC	cis	rs3096299	0.685	rs4785676	chr16:89553624	T/C	cg08392591	chr16:89556376	ANKRD11	0.61	8.31	0.45	5.13e-15	Multiple myeloma (IgH translocation);
CESC	cis	rs10463316	0.894	rs3846712	chr5:150759813	C/A	cg03212797	chr5:150827313	SLC36A1	-0.44	-5.74	-0.33	2.54e-8	Metabolite levels (Pyroglutamine);
CESC	cis	rs3820068	0.581	rs1547033	chr1:15918988	T/C	cg17385448	chr1:15911702	AGMAT	0.44	7.11	0.4	1.08e-11	Systolic blood pressure;
CESC	cis	rs4713118	0.512	rs2622319	chr6:28120401	G/C	cg20151795	chr6:28129481	ZNF389	0.37	5.23	0.31	3.51e-7	Parkinson's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12805764	chr1:153631263	SNAPIN	0.58	6.2	0.36	2.2e-9	Gut microbiome composition (summer);
CESC	cis	rs60154123	0.772	rs614167	chr1:210425895	T/C	cg23283495	chr1:209979779	IRF6	0.44	5.3	0.31	2.4e-7	Coronary artery disease;
CESC	cis	rs11098499	1.000	rs11726229	chr4:120211580	C/T	cg09307838	chr4:120376055	NA	0.88	11.91	0.59	1.75e-26	Corneal astigmatism;
CESC	cis	rs4237845	0.551	rs116263297	chr12:58273445	A/C	cg00677455	chr12:58241039	CTDSP2	0.8	10.71	0.55	1.82e-22	Intelligence (multi-trait analysis);
CESC	cis	rs901683	1.000	rs71499565	chr10:45977715	T/C	cg16031567	chr10:46195673	NA	-0.75	-5.04	-0.3	8.78e-7	Red blood cell traits;Mean corpuscular volume;
CESC	cis	rs748404	0.631	rs6493086	chr15:43655394	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.6	7.69	0.43	2.83e-13	Lung cancer;
CESC	cis	rs7089973	0.604	rs3758603	chr10:116605368	T/C	cg25233709	chr10:116636983	FAM160B1	0.38	6.08	0.35	4.13e-9	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs9916302	0.904	rs8065879	chr17:37515978	G/A	cg20243544	chr17:37824526	PNMT	-0.49	-6.09	-0.35	3.9e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs6952808	0.789	rs35729895	chr7:1885069	C/T	cg23102388	chr7:1867652	MAD1L1	-0.33	-5.05	-0.3	8.16e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs919433	0.783	rs2565158	chr2:198236103	T/A	cg10820045	chr2:198174542	NA	0.41	5.93	0.34	9.34e-9	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs7678296	0.764	rs1426408	chr4:37183131	G/C	cg06805348	chr4:37245195	KIAA1239	0.44	5.15	0.3	5.09e-7	3-hydroxypropylmercapturic acid levels in smokers;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg23210049	chr8:143695893	ARC	-0.46	-6.37	-0.36	8.36e-10	Fibrinogen levels;
CESC	cis	rs2599510	0.783	rs2038534	chr2:32659489	G/A	cg02381751	chr2:32503542	YIPF4	0.41	5.06	0.3	7.83e-7	Interleukin-18 levels;
CESC	cis	rs1348850	0.793	rs13020788	chr2:178480714	C/A	cg22681709	chr2:178499509	PDE11A	-0.42	-6.39	-0.37	7.48e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs17052344	0.543	rs2342183	chr17:21738349	G/T	cg18423549	chr17:21743878	NA	-0.62	-9.14	-0.49	1.65e-17	Cutaneous psoriasis;
CESC	cis	rs3806843	0.648	rs2530233	chr5:140082876	A/G	cg16179182	chr5:140090404	VTRNA1-1	0.4	5.14	0.3	5.34e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs7618915	0.501	rs34754793	chr3:52629177	A/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	5.83	0.34	1.59e-8	Bipolar disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14975961	chr20:2821322	VPS16;FAM113A	0.51	6.35	0.36	9.22e-10	Gut microbiome composition (summer);
CESC	cis	rs10463316	0.817	rs13355052	chr5:150802003	A/G	cg03212797	chr5:150827313	SLC36A1	-0.48	-6.2	-0.36	2.1e-9	Metabolite levels (Pyroglutamine);
CESC	cis	rs9733	0.596	rs72700897	chr1:150626038	C/G	cg22823121	chr1:150693482	HORMAD1	0.48	7.12	0.4	1.03e-11	Tonsillectomy;
CESC	cis	rs7605827	0.930	rs11685629	chr2:15662271	A/T	cg19274914	chr2:15703543	NA	0.37	6.67	0.38	1.51e-10	Educational attainment (years of education);
CESC	cis	rs1005277	0.540	rs2474598	chr10:38430296	C/T	cg00409905	chr10:38381863	ZNF37A	0.43	5.6	0.33	5.49e-8	Extrinsic epigenetic age acceleration;
CESC	cis	rs7949030	0.590	rs12225213	chr11:62350248	T/A	cg23462726	chr11:62437636	C11orf83;C11orf48	-0.4	-5.17	-0.3	4.67e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs5769765	0.954	rs5769762	chr22:50264042	G/A	cg02269571	chr22:50332266	NA	0.46	6.28	0.36	1.39e-9	Schizophrenia;
CESC	cis	rs2243480	1.000	rs67536397	chr7:65947917	G/A	cg18252515	chr7:66147081	NA	-1.41	-14.24	-0.66	1.46e-34	Diabetic kidney disease;
CESC	cis	rs5769765	0.955	rs9616367	chr22:50303515	A/C	cg03033257	chr22:50311977	ALG12;CRELD2	0.52	5.22	0.31	3.59e-7	Schizophrenia;
CESC	cis	rs3749237	0.595	rs3924462	chr3:49524236	T/G	cg06212747	chr3:49208901	KLHDC8B	0.49	6.55	0.37	3.02e-10	Resting heart rate;
CESC	cis	rs8031584	0.697	rs798080	chr15:31122169	T/C	cg08109568	chr15:31115862	NA	0.73	10.07	0.53	2.13e-20	Huntington's disease progression;
CESC	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg04234412	chr22:24373322	LOC391322	-0.53	-7.55	-0.42	7.15e-13	Liver enzyme levels (gamma-glutamyl transferase);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04499690	chr3:93781964	NSUN3;DHFRL1	-0.53	-6.12	-0.35	3.38e-9	Gut microbiome composition (summer);
CESC	cis	rs6460942	1.000	rs75564554	chr7:12319362	A/C	cg10578991	chr7:12443926	VWDE	-0.61	-6.41	-0.37	6.66e-10	Coronary artery disease;
CESC	cis	rs875971	0.767	rs12668005	chr7:65909021	T/C	cg12463550	chr7:65579703	CRCP	0.5	6.23	0.36	1.85e-9	Aortic root size;
CESC	cis	rs3741404	0.825	rs11603384	chr11:63949095	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.98	15.33	0.69	2.11e-38	Platelet count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16267304	chr21:44985357	HSF2BP	-0.62	-7.32	-0.41	3.03e-12	Gut microbiome composition (summer);
CESC	cis	rs34779708	0.931	rs11010077	chr10:35328088	C/T	cg04310649	chr10:35416472	CREM	0.52	6.43	0.37	6.04e-10	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs1799949	0.930	rs3092987	chr17:41222723	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.64	8.39	0.46	2.96e-15	Menopause (age at onset);
CESC	cis	rs6460942	0.591	rs80311633	chr7:12339690	G/C	cg06484146	chr7:12443880	VWDE	-0.65	-7.16	-0.4	7.88e-12	Coronary artery disease;
CESC	cis	rs523522	0.847	rs11065132	chr12:120908459	C/T	cg12219531	chr12:120966889	COQ5	0.73	9.48	0.5	1.51e-18	High light scatter reticulocyte count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07032256	chr7:57712753	NA	-0.44	-6.12	-0.35	3.28e-9	Gut microbiome composition (summer);
CESC	trans	rs9929218	0.551	rs2296405	chr16:68721470	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.98	-17.2	-0.73	4.82e-45	Colorectal cancer;
CESC	cis	rs863345	0.584	rs6427438	chr1:158454730	C/T	cg12129480	chr1:158549410	OR10X1	-0.36	-7.14	-0.4	8.83e-12	Pneumococcal bacteremia;
CESC	cis	rs6429082	0.818	rs291381	chr1:235641924	A/G	cg26050004	chr1:235667680	B3GALNT2	0.62	7.83	0.43	1.19e-13	Adiposity;
CESC	trans	rs9369898	1.000	rs6915187	chr6:49423547	G/C	cg15934674	chr1:150266645	MRPS21	-0.38	-6.15	-0.35	2.89e-9	Homocysteine levels;
CESC	cis	rs6500395	1.000	rs1039340	chr16:48574637	A/C	cg04672837	chr16:48644449	N4BP1	0.49	6.08	0.35	4.18e-9	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs9911578	0.835	rs9889419	chr17:56473259	C/T	cg12560992	chr17:57184187	TRIM37	0.86	14.32	0.66	7.55e-35	Intelligence (multi-trait analysis);
CESC	cis	rs1062177	0.855	rs6892117	chr5:151264985	C/T	cg00977110	chr5:151150581	G3BP1	-0.53	-6.2	-0.36	2.2e-9	Preschool internalizing problems;
CESC	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg18402987	chr7:1209562	NA	0.74	7.18	0.4	7.11e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2276314	0.857	rs62101393	chr18:33592168	T/C	cg19628046	chr18:33552617	C18orf21	0.51	5.76	0.33	2.3e-8	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs7089973	0.604	rs7903663	chr10:116609904	G/A	cg23260525	chr10:116636907	FAM160B1	0.39	7.2	0.4	6.12e-12	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs300703	0.515	rs300693	chr2:181748	C/A	cg21211680	chr2:198530	NA	-0.91	-10.69	-0.55	2.11e-22	Blood protein levels;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg21679509	chr7:28219613	JAZF1	-0.41	-6.25	-0.36	1.65e-9	Fibrinogen levels;
CESC	cis	rs1552244	0.554	rs4488814	chr3:10002400	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	0.61	8.48	0.46	1.65e-15	Alzheimer's disease;
CESC	cis	rs8177253	0.665	rs11921527	chr3:133441167	G/A	cg12373951	chr3:133503437	NA	0.35	5.11	0.3	6.29e-7	Iron status biomarkers;
CESC	cis	rs727505	0.954	rs1009450	chr7:124628723	C/G	cg23710748	chr7:124431027	NA	-0.45	-6.97	-0.39	2.58e-11	Lewy body disease;
CESC	cis	rs2732480	0.577	rs2634693	chr12:48706498	C/T	cg04545296	chr12:48745243	ZNF641	0.44	7.34	0.41	2.57e-12	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs10504229	0.683	rs73603877	chr8:58108428	C/T	cg24829409	chr8:58192753	C8orf71	-0.56	-7.01	-0.4	1.97e-11	Developmental language disorder (linguistic errors);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg26464185	chr16:1838079	NUBP2	0.47	6.77	0.38	8.43e-11	Fibrinogen levels;
CESC	cis	rs7666738	0.830	rs4443295	chr4:99044935	G/A	cg03676636	chr4:99064102	C4orf37	0.33	5.08	0.3	7.13e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1801251	1.000	rs2674839	chr2:233669040	G/C	cg08000102	chr2:233561755	GIGYF2	0.68	9.91	0.52	6.72e-20	Coronary artery disease;
CESC	cis	rs875971	0.830	rs778711	chr7:65851657	G/A	cg18252515	chr7:66147081	NA	-0.46	-6.05	-0.35	5e-9	Aortic root size;
CESC	cis	rs10751667	0.643	rs10751671	chr11:944479	T/G	cg01483505	chr11:975446	AP2A2	0.38	5.18	0.3	4.44e-7	Alzheimer's disease (late onset);
CESC	cis	rs2742234	0.590	rs2503864	chr10:43666767	G/T	cg15436174	chr10:43711423	RASGEF1A	-0.5	-5.89	-0.34	1.16e-8	Hirschsprung disease;
CESC	cis	rs1670533	0.818	rs643484	chr4:1085826	A/G	cg04106633	chr4:1044584	NA	0.4	5.08	0.3	6.98e-7	Recombination rate (females);
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg22081084	chr1:89990230	LRRC8B	0.45	6.3	0.36	1.26e-9	Systemic lupus erythematosus;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05993854	chr4:90032464	NA	0.53	6.12	0.35	3.34e-9	Gut microbiome composition (summer);
CESC	cis	rs9322193	0.962	rs2151912	chr6:150152908	A/G	cg04369109	chr6:150039330	LATS1	-0.4	-5.43	-0.32	1.28e-7	Lung cancer;
CESC	cis	rs4930561	0.714	rs7950451	chr11:67962406	C/A	cg16338278	chr11:67432957	ALDH3B2	0.42	5.27	0.31	2.77e-7	Breast cancer in childhood cancer survivors;IgG glycosylation;
CESC	cis	rs559928	0.692	rs12146487	chr11:64026639	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.61	5.08	0.3	7.07e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CESC	cis	rs1670533	1.000	rs6852850	chr4:1052857	C/G	cg04106633	chr4:1044584	NA	0.4	5.13	0.3	5.58e-7	Recombination rate (females);
CESC	cis	rs1005277	0.579	rs2472174	chr10:38375382	A/G	cg25427524	chr10:38739819	LOC399744	-0.66	-9.52	-0.5	1.15e-18	Extrinsic epigenetic age acceleration;
CESC	cis	rs2235642	0.601	rs2235647	chr16:1601331	C/A	cg09080909	chr16:1797204	MAPK8IP3	-0.42	-5.82	-0.34	1.69e-8	Coronary artery disease;
CESC	cis	rs7618915	0.571	rs12487445	chr3:52618319	A/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.38	6.65	0.38	1.66e-10	Bipolar disorder;
CESC	cis	rs933688	1.000	rs10073935	chr5:90742188	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.15	15.71	0.69	9.34e-40	Smoking behavior;
CESC	cis	rs9911578	0.805	rs1811202	chr17:56454435	T/G	cg25039879	chr17:56429692	SUPT4H1	-0.44	-6.0	-0.35	6.39e-9	Intelligence (multi-trait analysis);
CESC	cis	rs727505	0.954	rs7789055	chr7:124677543	G/T	cg23710748	chr7:124431027	NA	-0.41	-6.39	-0.37	7.48e-10	Lewy body disease;
CESC	cis	rs858239	0.899	rs858271	chr7:23278283	G/T	cg23682824	chr7:23144976	KLHL7	0.42	5.49	0.32	9.35e-8	Cerebrospinal fluid biomarker levels;
CESC	cis	rs6977660	0.598	rs72591445	chr7:19773035	G/A	cg05791153	chr7:19748676	TWISTNB	0.76	6.82	0.39	6.28e-11	Thyroid stimulating hormone;
CESC	cis	rs36051895	0.625	rs12340344	chr9:5176281	C/A	cg02405213	chr9:5042618	JAK2	-0.55	-6.83	-0.39	5.68e-11	Pediatric autoimmune diseases;
CESC	cis	rs7937682	0.889	rs11213971	chr11:111529829	A/G	cg22437258	chr11:111473054	SIK2	0.69	9.25	0.49	7.9e-18	Primary sclerosing cholangitis;
CESC	cis	rs2011503	1.000	rs4808968	chr19:19644402	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.52	5.09	0.3	6.68e-7	Bipolar disorder;
CESC	cis	rs7647973	0.506	rs11920251	chr3:49356671	C/T	cg02487422	chr3:49467188	NICN1	0.38	5.3	0.31	2.42e-7	Menarche (age at onset);
CESC	cis	rs10256972	0.521	rs871019	chr7:1105230	A/G	cg07308232	chr7:1071921	C7orf50	-0.51	-7.16	-0.4	7.72e-12	Longevity;Endometriosis;
CESC	cis	rs35306767	0.909	rs12264390	chr10:959111	T/C	cg10556349	chr10:835070	NA	0.49	5.24	0.31	3.33e-7	Eosinophil percentage of granulocytes;
CESC	cis	rs950169	1.000	rs34751999	chr15:84758419	T/C	cg17507749	chr15:85114479	UBE2QP1	0.64	7.11	0.4	1.11e-11	Schizophrenia;
CESC	cis	rs4819052	0.885	rs28576202	chr21:46674684	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.94	14.0	0.65	1.02e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs1552244	0.882	rs67631672	chr3:10004768	G/A	cg00149659	chr3:10157352	C3orf10	0.67	7.8	0.43	1.45e-13	Alzheimer's disease;
CESC	cis	rs67478160	0.619	rs3742365	chr14:104198251	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.51	-7.39	-0.41	1.94e-12	Schizophrenia;
CESC	cis	rs12325245	0.536	rs12931051	chr16:58626534	C/T	cg01152986	chr16:58549298	SETD6	0.86	5.07	0.3	7.48e-7	Schizophrenia;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg06320606	chr5:60139941	ELOVL7	-0.46	-6.04	-0.35	5.28e-9	Ulcerative colitis;
CESC	cis	rs7095944	0.644	rs4962694	chr10:126436717	G/T	cg08799069	chr10:126477246	METTL10	-0.37	-5.29	-0.31	2.58e-7	Asthma;
CESC	cis	rs6997458	0.742	rs6988475	chr8:86383268	A/G	cg21346043	chr8:86351067	CA3	-0.34	-5.11	-0.3	6.28e-7	Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	cis	rs7089973	0.604	rs11196943	chr10:116598865	T/C	cg23260525	chr10:116636907	FAM160B1	0.4	7.38	0.41	2.03e-12	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs704795	0.902	rs11887784	chr2:27679919	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.33	-6.7	-0.38	1.27e-10	Menopause (age at onset);
CESC	cis	rs6088590	1.000	rs6120750	chr20:33465289	A/C	cg08999081	chr20:33150536	PIGU	0.57	8.42	0.46	2.34e-15	Coronary artery disease;
CESC	trans	rs2115172	0.836	rs4835799	chr5:122762229	A/G	cg02233558	chr5:127418922	SLC12A2;FLJ33630	0.48	6.29	0.36	1.28e-9	Weight;
CESC	cis	rs9311474	0.607	rs4687625	chr3:52563718	C/T	cg15147215	chr3:52552868	STAB1	-0.31	-5.26	-0.31	2.96e-7	Electroencephalogram traits;
CESC	cis	rs7188697	0.922	rs8047769	chr16:58591987	G/A	cg21335942	chr16:58549945	SETD6	-0.45	-5.28	-0.31	2.69e-7	QT interval;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11645754	chr17:21188174	MAP2K3	0.53	6.32	0.36	1.11e-9	Gut microbiome composition (summer);
CESC	cis	rs28386778	0.965	rs2854154	chr17:61981696	C/A	cg26338869	chr17:61819248	STRADA	-0.64	-8.12	-0.45	1.72e-14	Prudent dietary pattern;
CESC	cis	rs896854	0.625	rs4735335	chr8:95973327	G/C	cg16049864	chr8:95962084	TP53INP1	-0.65	-11.35	-0.57	1.31e-24	Type 2 diabetes;
CESC	cis	rs13034020	0.522	rs4564760	chr2:61248575	T/C	cg18625361	chr2:61244694	PEX13;PUS10	0.65	6.33	0.36	1.04e-9	Hodgkin's lymphoma;
CESC	cis	rs1707322	0.650	rs4660879	chr1:46105401	C/A	cg05343316	chr1:45956843	TESK2	0.5	6.34	0.36	9.93e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg01592312	chr17:79658424	HGS	0.51	7.1	0.4	1.17e-11	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs35955747	0.869	rs131219	chr22:31760250	T/C	cg25791279	chr22:32026902	PISD	0.46	5.66	0.33	3.95e-8	Neutrophil count;Sum basophil neutrophil counts;
CESC	cis	rs7833986	0.501	rs2719255	chr8:57036658	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.61	7.55	0.42	7e-13	Height;
CESC	cis	rs2204008	0.715	rs12815986	chr12:38343869	G/A	cg13010199	chr12:38710504	ALG10B	0.53	6.64	0.38	1.78e-10	Bladder cancer;
CESC	cis	rs11030122	0.673	rs10835474	chr11:4020819	G/T	cg18678763	chr11:4115507	RRM1	-0.49	-6.59	-0.38	2.37e-10	Mean platelet volume;Platelet distribution width;
CESC	cis	rs6032067	1.000	rs2233896	chr20:43850400	C/A	cg10761708	chr20:43804764	PI3	0.52	6.22	0.36	1.92e-9	Blood protein levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19491415	chr10:32217948	ARHGAP12	0.54	6.65	0.38	1.62e-10	Gut microbiome composition (summer);
CESC	trans	rs8073060	0.586	rs4796101	chr17:33998593	C/T	cg19694781	chr19:47549865	TMEM160	-0.74	-7.25	-0.41	4.47e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	cis	rs4604732	0.589	rs78689516	chr1:247626274	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.57	7.17	0.4	7.39e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs2549003	0.966	rs10065633	chr5:131816716	T/C	cg00255919	chr5:131827918	IRF1	0.51	8.59	0.47	7.76e-16	Asthma (sex interaction);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg26635474	chr16:1706710	CRAMP1L	0.43	6.51	0.37	3.82e-10	Fibrinogen levels;
CESC	cis	rs9287719	0.967	rs7582775	chr2:10738449	C/T	cg02196655	chr2:10830764	NOL10	-0.37	-5.72	-0.33	2.87e-8	Prostate cancer;
CESC	cis	rs9814567	0.752	rs13075117	chr3:134329535	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.43	5.6	0.33	5.39e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs9549367	0.865	rs3861721	chr13:113906308	C/T	cg00898013	chr13:113819073	PROZ	-0.53	-7.21	-0.41	5.74e-12	Platelet distribution width;
CESC	cis	rs7582720	0.945	rs114604411	chr2:203811912	A/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.36	0.41	2.34e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs11958404	0.860	rs72818116	chr5:157440616	G/T	cg05962755	chr5:157440814	NA	0.59	6.52	0.37	3.45e-10	IgG glycosylation;
CESC	cis	rs1707322	1.000	rs785469	chr1:46521091	C/T	cg05343316	chr1:45956843	TESK2	-0.44	-5.44	-0.32	1.2e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs599083	0.573	rs3018713	chr11:68390986	A/G	cg01657329	chr11:68192670	LRP5	-0.47	-6.12	-0.35	3.39e-9	Bone mineral density (spine);
CESC	cis	rs6547741	1.000	rs6737921	chr2:27839107	T/C	cg27432699	chr2:27873401	GPN1	0.49	6.91	0.39	3.56e-11	Oral cavity cancer;
CESC	cis	rs9399137	0.561	rs11753985	chr6:135280438	C/T	cg24558204	chr6:135376177	HBS1L	0.71	9.63	0.51	5.17e-19	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22777309	chr6:35182216	SCUBE3	0.62	7.12	0.4	9.89e-12	Gut microbiome composition (summer);
CESC	cis	rs12545109	0.571	rs7002482	chr8:57295200	C/T	cg09654669	chr8:57350985	NA	-0.49	-5.95	-0.34	8.29e-9	Obesity-related traits;
CESC	cis	rs73206853	0.841	rs111612251	chr12:111017607	T/C	cg12870014	chr12:110450643	ANKRD13A	0.7	6.18	0.36	2.38e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs10838687	0.736	rs4647725	chr11:47245389	T/C	cg25783544	chr11:47291846	MADD	0.57	6.54	0.37	3.15e-10	Proinsulin levels;
CESC	cis	rs7116495	0.609	rs10501408	chr11:71680590	C/T	cg07596299	chr11:71824057	C11orf51	-0.88	-5.07	-0.3	7.53e-7	Severe influenza A (H1N1) infection;
CESC	trans	rs2727020	0.615	rs4980435	chr11:49591576	G/A	cg03929089	chr4:120376271	NA	-0.85	-13.48	-0.64	6.81e-32	Coronary artery disease;
CESC	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg24642844	chr7:1081250	C7orf50	-0.75	-8.99	-0.48	4.94e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7336332	0.598	rs74563672	chr13:28010660	A/G	cg22138327	chr13:27999177	GTF3A	0.62	5.82	0.34	1.71e-8	Weight;
CESC	cis	rs769267	0.895	rs2965182	chr19:19548246	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.57	7.33	0.41	2.84e-12	Tonsillectomy;
CESC	cis	rs1552244	0.554	rs4488814	chr3:10002400	C/T	cg00149659	chr3:10157352	C3orf10	-0.52	-6.75	-0.38	9.49e-11	Alzheimer's disease;
CESC	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.44	-5.51	-0.32	8.46e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2235544	0.542	rs679801	chr1:54470757	T/C	cg25741118	chr1:54482237	LDLRAD1	0.24	5.76	0.33	2.29e-8	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
CESC	cis	rs9311474	0.508	rs17052256	chr3:52593119	A/G	cg07507251	chr3:52567010	NT5DC2	0.34	5.8	0.34	1.85e-8	Electroencephalogram traits;
CESC	cis	rs6762	0.748	rs1130719	chr11:838760	T/A	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.68	-9.11	-0.49	2.14e-17	Mean platelet volume;
CESC	cis	rs4819052	0.851	rs2838845	chr21:46670812	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.91	13.41	0.64	1.22e-31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg23978390	chr7:1156363	C7orf50	0.57	8.29	0.45	5.56e-15	Longevity;Endometriosis;
CESC	cis	rs151234	0.741	rs10521145	chr16:28596884	A/G	cg01378222	chr16:28622494	SULT1A1	0.57	7.55	0.42	6.92e-13	Platelet distribution width;
CESC	cis	rs362296	0.661	rs3095079	chr4:3265414	A/G	cg08886695	chr4:3369023	RGS12	-0.4	-5.45	-0.32	1.16e-7	Parental longevity (mother's age at death);
CESC	trans	rs1285495	0.627	rs10912059	chr1:187354887	C/T	cg24669728	chr1:41445888	CTPS	-0.5	-6.12	-0.35	3.37e-9	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
CESC	trans	rs61931739	0.577	rs7313428	chr12:33672325	T/C	cg26384229	chr12:38710491	ALG10B	-0.46	-6.54	-0.37	3.07e-10	Morning vs. evening chronotype;
CESC	cis	rs561341	0.602	rs114562703	chr17:30233899	G/T	cg13647721	chr17:30228624	UTP6	0.8	9.63	0.51	5.09e-19	Hip circumference adjusted for BMI;
CESC	cis	rs7786808	0.741	rs62479982	chr7:158227546	A/G	cg09998033	chr7:158218633	PTPRN2	-0.44	-6.59	-0.38	2.33e-10	Obesity-related traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10207181	chr1:147801090	NA	-0.44	-6.1	-0.35	3.67e-9	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00577569	chr7:66093764	KCTD7	0.54	6.22	0.36	1.91e-9	Gut microbiome composition (summer);
CESC	cis	rs2228479	0.850	rs17232630	chr16:89851179	C/T	cg00800038	chr16:89945340	TCF25	-0.91	-7.52	-0.42	8.29e-13	Skin colour saturation;
CESC	cis	rs7818345	0.967	rs4433156	chr8:19284247	A/C	cg11303988	chr8:19266685	CSGALNACT1	0.33	5.96	0.34	8.14e-9	Language performance in older adults (adjusted for episodic memory);
CESC	cis	rs875971	0.505	rs1723275	chr7:65504633	G/C	cg11764359	chr7:65958608	NA	-0.7	-9.2	-0.49	1.14e-17	Aortic root size;
CESC	cis	rs7618501	0.633	rs6771546	chr3:49968572	T/C	cg24308560	chr3:49941425	MST1R	-0.64	-9.34	-0.5	3.96e-18	Intelligence (multi-trait analysis);
CESC	cis	rs9916302	0.904	rs2338797	chr17:37548241	G/A	cg07936489	chr17:37558343	FBXL20	0.8	11.64	0.58	1.44e-25	Glomerular filtration rate (creatinine);
CESC	cis	rs2072732	0.861	rs12567620	chr1:2956999	T/G	cg03976712	chr1:2946727	NA	0.33	5.52	0.32	8.2e-8	Plateletcrit;
CESC	cis	rs3892630	0.588	rs2287881	chr19:33333155	A/G	cg22980127	chr19:33182716	NUDT19	-1.03	-13.41	-0.64	1.21e-31	Red blood cell traits;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg02446366	chr6:41514112	FOXP4	-0.51	-6.46	-0.37	4.95e-10	Ulcerative colitis;
CESC	cis	rs3785574	0.962	rs2955235	chr17:61966950	A/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.59	7.22	0.41	5.62e-12	Height;
CESC	cis	rs4919087	0.810	rs10786321	chr10:99026112	T/C	cg25902810	chr10:99078978	FRAT1	0.65	9.18	0.49	1.3e-17	Monocyte count;
CESC	trans	rs79976124	0.879	rs78012385	chr6:66618091	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.76	8.59	0.47	7.54e-16	Type 2 diabetes;
CESC	cis	rs6493487	0.512	rs1904432	chr15:51249851	G/T	cg02338191	chr15:51200825	AP4E1	0.63	5.86	0.34	1.39e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs4713118	0.629	rs203890	chr6:28022248	T/C	cg23281280	chr6:28129359	ZNF389	0.49	6.52	0.37	3.55e-10	Parkinson's disease;
CESC	cis	rs36051895	0.659	rs10815150	chr9:5067301	C/A	cg02405213	chr9:5042618	JAK2	-0.48	-5.93	-0.34	9.18e-9	Pediatric autoimmune diseases;
CESC	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg27532560	chr4:187881888	NA	-0.38	-5.91	-0.34	1.03e-8	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs514406	0.505	rs387436	chr1:53179376	C/T	cg08859206	chr1:53392774	SCP2	0.55	7.23	0.41	5.1e-12	Monocyte count;
CESC	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	10.58	0.55	4.6e-22	Prudent dietary pattern;
CESC	cis	rs703842	0.616	rs4760332	chr12:58222672	A/C	cg04478727	chr12:58166393	METTL1;FAM119B	-0.56	-6.54	-0.37	3.22e-10	Multiple sclerosis;
CESC	trans	rs11039798	0.512	rs3974936	chr11:49005012	C/T	cg15704280	chr7:45808275	SEPT13	0.66	6.91	0.39	3.58e-11	Axial length;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg11062677	chr19:13976917	NA	-0.46	-6.06	-0.35	4.62e-9	Height;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg14086791	chr11:69489770	ORAOV1	-0.44	-6.57	-0.37	2.72e-10	Gambling;
CESC	cis	rs6460942	0.545	rs17448114	chr7:12524458	G/C	cg10578991	chr7:12443926	VWDE	-0.49	-5.13	-0.3	5.63e-7	Coronary artery disease;
CESC	trans	rs17307778	0.808	rs10767361	chr11:25357543	C/T	cg22888484	chr20:37075185	SNHG11	-0.63	-6.06	-0.35	4.53e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs2439831	0.702	rs9989313	chr15:44152817	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.68	7.43	0.42	1.45e-12	Lung cancer in ever smokers;
CESC	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg01238044	chr22:24384105	GSTT1	0.5	6.45	0.37	5.2400000000000005e-10	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs7219021	0.926	rs9912856	chr17:46861667	C/T	cg16584676	chr17:46985605	UBE2Z	-0.56	-6.44	-0.37	5.45e-10	Schizophrenia or bipolar disorder;
CESC	cis	rs12618769	0.652	rs72821965	chr2:99188783	T/C	cg10123293	chr2:99228465	UNC50	0.41	5.34	0.31	2e-7	Bipolar disorder;
CESC	cis	rs5758659	0.714	rs7245	chr22:42481849	G/A	cg00645731	chr22:42541494	CYP2D7P1	0.33	5.52	0.32	7.9e-8	Cognitive function;
CESC	cis	rs7412746	0.658	rs11204739	chr1:150865760	A/G	cg22823121	chr1:150693482	HORMAD1	0.39	5.43	0.32	1.26e-7	Melanoma;
CESC	cis	rs4713118	0.662	rs149900	chr6:28014597	C/T	cg12963246	chr6:28129442	ZNF389	0.49	6.09	0.35	3.94e-9	Parkinson's disease;
CESC	cis	rs1799949	0.930	rs3765640	chr17:41276247	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.45	6.3	0.36	1.21e-9	Menopause (age at onset);
CESC	cis	rs5758659	1.000	rs5758660	chr22:42623718	C/A	cg05082376	chr22:42548792	NA	-0.37	-5.43	-0.32	1.28e-7	Cognitive function;
CESC	cis	rs826838	0.967	rs11169387	chr12:39145737	C/T	cg13010199	chr12:38710504	ALG10B	0.57	7.99	0.44	4.1e-14	Heart rate;
CESC	cis	rs7666738	0.791	rs6532725	chr4:99061479	T/C	cg17366294	chr4:99064904	C4orf37	0.62	8.89	0.48	9.9e-17	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg07092213	chr7:1199455	ZFAND2A	-0.44	-5.91	-0.34	1.03e-8	Longevity;Endometriosis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07516076	chr7:64197245	NA	-0.62	-7.31	-0.41	3.25e-12	Gut microbiome composition (summer);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg21695485	chr11:66824219	RHOD	-0.51	-6.92	-0.39	3.32e-11	Fibrinogen levels;
CESC	trans	rs61931739	0.517	rs11611190	chr12:34015697	G/A	cg26384229	chr12:38710491	ALG10B	0.59	8.24	0.45	8.19e-15	Morning vs. evening chronotype;
CESC	cis	rs9372253	0.678	rs9487392	chr6:110708626	C/T	cg19196401	chr6:110721138	DDO	0.41	5.81	0.34	1.78e-8	Platelet distribution width;
CESC	cis	rs807669	0.835	rs1780639	chr22:19174603	T/C	cg02655711	chr22:19163373	SLC25A1	0.96	14.54	0.67	1.32e-35	Metabolite levels;
CESC	trans	rs11250098	0.547	rs2409764	chr8:11281273	C/T	cg15556689	chr8:8085844	FLJ10661	0.53	6.3	0.36	1.23e-9	Morning vs. evening chronotype;
CESC	cis	rs7084402	0.967	rs1427222	chr10:60290970	A/G	cg07615347	chr10:60278583	BICC1	0.6	9.42	0.5	2.31e-18	Refractive error;
CESC	trans	rs2623325	0.874	rs1481543	chr3:99113531	G/A	cg19595760	chr1:25948511	MAN1C1	-0.48	-6.41	-0.37	6.61e-10	Optic cup area;Vertical cup-disc ratio;
CESC	cis	rs6577655	0.517	rs11998030	chr8:135585325	C/T	cg17885191	chr8:135476712	NA	0.45	5.08	0.3	7.18e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CESC	cis	rs61931739	0.500	rs11053268	chr12:34545121	T/C	cg06521331	chr12:34319734	NA	-0.36	-5.03	-0.3	9.01e-7	Morning vs. evening chronotype;
CESC	cis	rs35110281	0.782	rs1454650	chr21:45012353	C/T	cg21573476	chr21:45109991	RRP1B	-0.51	-7.18	-0.4	7.23e-12	Mean corpuscular volume;
CESC	cis	rs7666738	0.830	rs3846444	chr4:99032888	T/C	cg03467027	chr4:99064603	C4orf37	0.49	6.18	0.35	2.44e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg06873352	chr17:61820015	STRADA	0.72	12.8	0.62	1.61e-29	Prudent dietary pattern;
CESC	cis	rs9311474	0.597	rs6778735	chr3:52565100	T/C	cg18404041	chr3:52824283	ITIH1	-0.36	-6.38	-0.36	7.86e-10	Electroencephalogram traits;
CESC	cis	rs9733	0.596	rs6690725	chr1:150632322	T/C	cg04414720	chr1:150670196	GOLPH3L	0.63	9.04	0.49	3.47e-17	Tonsillectomy;
CESC	trans	rs2415984	0.846	rs10146746	chr14:46853609	C/G	cg14945696	chr3:52713679	PBRM1	-0.4	-6.03	-0.35	5.55e-9	Number of children ever born;
CESC	cis	rs4665809	1.000	rs2891490	chr2:26325927	T/C	cg22920501	chr2:26401640	FAM59B	-0.65	-7.85	-0.43	1.06e-13	Gut microbiome composition (summer);
CESC	cis	rs5753618	0.561	rs737887	chr22:31696615	A/G	cg00478049	chr22:31556069	RNF185	0.45	5.09	0.3	6.87e-7	Colorectal cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04521409	chr20:34287082	ROMO1;NFS1	0.56	6.46	0.37	5.05e-10	Gut microbiome composition (summer);
CESC	cis	rs9611565	0.592	rs4822040	chr22:41963553	C/G	cg17376030	chr22:41985996	PMM1	0.52	5.83	0.34	1.61e-8	Vitiligo;
CESC	cis	rs7208859	0.623	rs216439	chr17:28927884	T/C	cg19761014	chr17:28927070	LRRC37B2	0.85	6.59	0.38	2.33e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs7086627	0.515	rs10887905	chr10:82210855	A/T	cg00277334	chr10:82204260	NA	-0.91	-16.25	-0.71	1.13e-41	Post bronchodilator FEV1;
CESC	cis	rs1799949	1.000	rs33920795	chr17:41329010	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.42	5.72	0.33	2.87e-8	Menopause (age at onset);
CESC	cis	rs17292804	0.527	rs12887734	chr14:104046834	G/T	cg24130564	chr14:104152367	KLC1	-0.47	-5.86	-0.34	1.39e-8	Autism spectrum disorder or schizophrenia;
CESC	cis	rs7834588	0.523	rs4645553	chr8:63835295	A/G	cg20602954	chr8:63776762	NKAIN3	0.3	5.08	0.3	7.18e-7	Response to Vitamin E supplementation;
CESC	cis	rs9303280	0.773	rs11078925	chr17:38025208	T/C	cg19468946	chr17:37922297	IKZF3	-0.41	-5.42	-0.32	1.34e-7	Self-reported allergy;
CESC	cis	rs4746818	1.000	rs7091695	chr10:70964997	A/G	cg11621586	chr10:70884670	VPS26A	-0.86	-8.54	-0.46	1.04e-15	Left atrial antero-posterior diameter;
CESC	cis	rs6952808	0.893	rs35487994	chr7:1920171	G/A	cg04267008	chr7:1944627	MAD1L1	-0.67	-8.45	-0.46	1.93e-15	Bipolar disorder and schizophrenia;
CESC	cis	rs9399135	0.967	rs4895439	chr6:135318854	A/T	cg22676075	chr6:135203613	NA	0.51	7.23	0.41	5.22e-12	Red blood cell count;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg08928321	chr10:70748447	KIAA1279	0.46	6.81	0.39	6.61e-11	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs244293	0.701	rs4793784	chr17:53038430	A/G	cg19360675	chr17:53046073	COX11;STXBP4	-0.45	-6.14	-0.35	3.02e-9	Menarche (age at onset);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg11248668	chr11:45826493	SLC35C1	-0.47	-6.56	-0.37	2.88e-10	Gambling;
CESC	cis	rs7589342	0.862	rs10469862	chr2:106509907	C/T	cg16077055	chr2:106428750	NCK2	0.41	5.72	0.33	2.86e-8	Addiction;
CESC	cis	rs1790761	0.520	rs12805884	chr11:67387977	G/A	cg24690094	chr11:67383802	NA	-0.38	-6.26	-0.36	1.56e-9	Mean corpuscular volume;
CESC	cis	rs7680126	0.500	rs4640669	chr4:10145733	A/G	cg11266682	chr4:10021025	SLC2A9	0.48	6.48	0.37	4.55e-10	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	cis	rs56399783	0.901	rs73049341	chr7:2812255	G/C	cg19731401	chr7:2775893	GNA12	0.65	5.87	0.34	1.32e-8	Childhood ear infection;
CESC	cis	rs1801251	1.000	rs11679079	chr2:233612656	C/T	cg08000102	chr2:233561755	GIGYF2	0.66	9.34	0.5	4.05e-18	Coronary artery disease;
CESC	cis	rs7208859	0.673	rs9899525	chr17:29120296	T/A	cg14008862	chr17:28927542	LRRC37B2	0.65	5.14	0.3	5.34e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs854765	0.583	rs4925130	chr17:17807858	G/A	cg04398451	chr17:18023971	MYO15A	-0.64	-8.85	-0.48	1.23e-16	Total body bone mineral density;
CESC	cis	rs1215050	0.765	rs6852699	chr4:98767505	T/C	cg05340658	chr4:99064831	C4orf37	0.53	6.85	0.39	5.29e-11	Waist-to-hip ratio adjusted for body mass index;
CESC	trans	rs9399401	1.000	rs1040525	chr6:142703669	C/T	cg23543539	chr11:125461746	STT3A	-0.43	-6.06	-0.35	4.66e-9	Chronic obstructive pulmonary disease;
CESC	cis	rs7208859	0.623	rs9911997	chr17:29124648	A/G	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.79e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs9457247	1.000	rs430477	chr6:167389851	T/C	cg07741184	chr6:167504864	NA	0.31	5.53	0.32	7.87e-8	Crohn's disease;
CESC	cis	rs589448	0.902	rs2603090	chr12:69777188	G/A	cg22834771	chr12:69754056	YEATS4	-0.56	-7.63	-0.42	4.19e-13	Cerebrospinal fluid biomarker levels;
CESC	cis	rs2109514	0.765	rs28494601	chr7:116101261	A/C	cg12739419	chr7:116140593	CAV2	-0.32	-5.7	-0.33	3.11e-8	Prevalent atrial fibrillation;
CESC	cis	rs6570726	0.935	rs382910	chr6:145865941	G/A	cg23711669	chr6:146136114	FBXO30	0.79	11.47	0.58	5.24e-25	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2933343	0.700	rs789233	chr3:128603150	G/T	cg25356066	chr3:128598488	ACAD9	0.64	9.08	0.49	2.52e-17	IgG glycosylation;
CESC	cis	rs1552244	0.935	rs41520445	chr3:10153141	A/C	cg00166722	chr3:10149974	C3orf24	-0.47	-6.15	-0.35	2.81e-9	Alzheimer's disease;
CESC	cis	rs2404602	0.692	rs59088060	chr15:76859974	T/C	cg22467129	chr15:76604101	ETFA	-0.35	-5.24	-0.31	3.24e-7	Blood metabolite levels;
CESC	trans	rs79976124	0.879	rs17511467	chr6:66627293	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.74	8.48	0.46	1.58e-15	Type 2 diabetes;
CESC	cis	rs1008375	0.863	rs7680984	chr4:17600884	A/G	cg16339924	chr4:17578868	LAP3	0.68	8.78	0.47	2.03e-16	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs5769707	0.935	rs1109320	chr22:49989106	G/A	cg05373962	chr22:49881684	NA	-0.36	-6.24	-0.36	1.69e-9	Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs6089829	0.962	rs4809456	chr20:61660849	C/A	cg08564027	chr20:61660810	NA	0.9	15.26	0.68	3.54e-38	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs9916302	0.653	rs4239223	chr17:37717004	T/C	cg20243544	chr17:37824526	PNMT	0.53	5.26	0.31	3.03e-7	Glomerular filtration rate (creatinine);
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg19354750	chr17:61554413	ACE	0.4	6.01	0.35	6.21e-9	Vertical cup-disc ratio;
CESC	cis	rs9649213	0.555	rs6968193	chr7:97915902	C/T	cg00277769	chr7:97922759	BAIAP2L1	-0.35	-5.75	-0.33	2.49e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs72781680	0.611	rs72781695	chr2:24266744	T/C	cg08917208	chr2:24149416	ATAD2B	0.63	6.09	0.35	3.87e-9	Lymphocyte counts;
CESC	cis	rs763014	1.000	rs2269558	chr16:682250	C/T	cg00908189	chr16:619842	PIGQ	0.64	8.99	0.48	4.69e-17	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20831041	chr11:464554	PTDSS2	-0.58	-6.48	-0.37	4.35e-10	Gut microbiome composition (summer);
CESC	cis	rs1005277	0.579	rs2474608	chr10:38457109	C/T	cg25427524	chr10:38739819	LOC399744	-0.68	-9.8	-0.52	1.54e-19	Extrinsic epigenetic age acceleration;
CESC	cis	rs6723226	0.521	rs1991626	chr2:32602450	G/A	cg02381751	chr2:32503542	YIPF4	-0.5	-6.55	-0.37	3.01e-10	Intelligence (multi-trait analysis);
CESC	cis	rs1879734	0.636	rs12025857	chr1:54175360	C/T	cg23596471	chr1:54105337	GLIS1	0.32	5.17	0.3	4.7e-7	Mitral valve prolapse;
CESC	cis	rs6088580	0.634	rs6059829	chr20:33017074	G/A	cg24642439	chr20:33292090	TP53INP2	0.52	6.79	0.39	7.18e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs722599	0.683	rs10139016	chr14:75274288	T/C	cg11812906	chr14:75593930	NEK9	0.44	5.26	0.31	2.91e-7	IgG glycosylation;
CESC	cis	rs35306767	0.903	rs11253462	chr10:889323	T/G	cg25019033	chr10:957182	NA	-0.62	-6.76	-0.38	8.97e-11	Eosinophil percentage of granulocytes;
CESC	cis	rs9611565	0.729	rs73176689	chr22:41782633	T/C	cg06634786	chr22:41940651	POLR3H	-0.72	-7.52	-0.42	8.35e-13	Vitiligo;
CESC	cis	rs10129255	0.957	rs8009638	chr14:107185809	G/A	cg07958169	chr14:107095056	NA	-0.44	-6.01	-0.35	6.17e-9	Kawasaki disease;
CESC	cis	rs7666738	0.800	rs12163918	chr4:98835794	T/C	cg05340658	chr4:99064831	C4orf37	0.7	9.83	0.52	1.17e-19	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1865721	0.804	rs59187673	chr18:73143964	A/G	cg26385618	chr18:73139727	C18orf62	-0.52	-8.31	-0.45	5.15e-15	Intelligence;
CESC	cis	rs2180341	1.000	rs9401950	chr6:127655485	C/T	cg27446573	chr6:127587934	RNF146	1.09	16.35	0.71	5.12e-42	Breast cancer;
CESC	cis	rs11920090	0.720	rs60354090	chr3:170740217	C/T	cg09710316	chr3:170744871	SLC2A2	0.51	5.99	0.35	6.67e-9	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
CESC	cis	rs897984	0.646	rs9938088	chr16:30830004	G/A	cg02466173	chr16:30829666	NA	-0.6	-11.58	-0.58	2.23e-25	Dementia with Lewy bodies;
CESC	cis	rs1862618	0.671	rs2591955	chr5:56244948	C/T	cg24531977	chr5:56204891	C5orf35	0.7	9.44	0.5	2.05e-18	Initial pursuit acceleration;
CESC	cis	rs2880765	0.743	rs7168345	chr15:86013601	A/G	cg10818794	chr15:86012489	AKAP13	0.33	5.12	0.3	5.8e-7	Coronary artery disease;
CESC	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg11494091	chr17:61959527	GH2	0.71	12.02	0.59	7.32e-27	Prudent dietary pattern;
CESC	cis	rs10089	0.953	rs758179	chr5:127354424	C/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.78	9.94	0.52	5.36e-20	Ileal carcinoids;
CESC	cis	rs208520	0.690	rs864314	chr6:66814830	G/A	cg07460842	chr6:66804631	NA	-1.11	-27.03	-0.86	3.9e-78	Exhaled nitric oxide output;
CESC	cis	rs7617773	0.817	rs6794644	chr3:48330037	T/C	cg11946769	chr3:48343235	NME6	0.81	10.91	0.56	3.86e-23	Coronary artery disease;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg03399598	chr4:174091002	GALNT7	0.46	6.34	0.36	9.93e-10	Systemic lupus erythematosus;
CESC	cis	rs2637266	0.703	rs846589	chr10:78491742	A/G	cg18941641	chr10:78392320	NA	0.37	7.19	0.4	6.47e-12	Pulmonary function;
CESC	cis	rs9911578	0.967	rs4132925	chr17:56938016	C/G	cg02118635	chr17:56770003	RAD51C;TEX14	-0.39	-5.26	-0.31	2.94e-7	Intelligence (multi-trait analysis);
CESC	cis	rs4665809	1.000	rs2384322	chr2:26291146	C/G	cg22920501	chr2:26401640	FAM59B	-0.79	-9.3	-0.5	5.61e-18	Gut microbiome composition (summer);
CESC	cis	rs898097	0.841	rs11656358	chr17:80853956	G/A	cg19046167	chr17:80928561	B3GNTL1	-0.41	-5.03	-0.3	8.9e-7	Breast cancer;
CESC	cis	rs4722166	0.604	rs2390715	chr7:22783878	A/C	cg05265849	chr7:22767390	IL6	0.57	7.07	0.4	1.4e-11	Lung cancer;
CESC	cis	rs2573652	0.722	rs11636047	chr15:100543341	A/G	cg09918751	chr15:100517450	ADAMTS17	-0.31	-5.82	-0.34	1.69e-8	Height;
CESC	cis	rs9649213	0.574	rs34717219	chr7:97962271	A/C	cg21770322	chr7:97807741	LMTK2	0.55	8.25	0.45	7.24e-15	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs4423214	0.840	rs1540127	chr11:71179038	G/A	cg05163923	chr11:71159392	DHCR7	-0.65	-7.55	-0.42	6.91e-13	Vitamin D levels;
CESC	cis	rs1862618	0.853	rs832583	chr5:56178217	A/C	cg22800045	chr5:56110881	MAP3K1	0.81	9.74	0.51	2.35e-19	Initial pursuit acceleration;
CESC	cis	rs3820068	0.603	rs56032936	chr1:15970953	T/C	cg17385448	chr1:15911702	AGMAT	0.42	6.75	0.38	9.26e-11	Systolic blood pressure;
CESC	trans	rs11264799	0.765	rs12128597	chr1:157623603	C/T	cg22691776	chr3:15032403	NR2C2	0.33	6.1	0.35	3.7e-9	IgA nephropathy;
CESC	trans	rs916888	0.610	rs199452	chr17:44801340	C/T	cg22433210	chr17:43662623	NA	0.58	7.49	0.42	1.01e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs6963495	0.818	rs6973974	chr7:105170629	C/T	cg02135003	chr7:105160482	PUS7	-0.46	-5.5	-0.32	9.1e-8	Bipolar disorder (body mass index interaction);
CESC	cis	rs7772486	0.875	rs6934467	chr6:146410529	G/T	cg23711669	chr6:146136114	FBXO30	0.88	12.95	0.62	4.95e-30	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs875971	0.867	rs13227219	chr7:65844062	T/A	cg18876405	chr7:65276391	NA	0.48	6.23	0.36	1.79e-9	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00355673	chr14:92573075	ATXN3	0.52	6.52	0.37	3.56e-10	Gut microbiome composition (summer);
CESC	cis	rs3126085	0.877	rs6662450	chr1:152191709	C/G	cg26876637	chr1:152193138	HRNR	0.47	5.43	0.32	1.28e-7	Atopic dermatitis;
CESC	trans	rs61931739	0.500	rs34107854	chr12:34482333	C/A	cg26384229	chr12:38710491	ALG10B	0.7	10.6	0.55	4.1e-22	Morning vs. evening chronotype;
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg03637622	chr5:179334771	TBC1D9B	-0.42	-6.3	-0.36	1.21e-9	Vertical cup-disc ratio;
CESC	cis	rs853679	0.517	rs9380057	chr6:28104634	G/T	cg20151795	chr6:28129481	ZNF389	0.45	5.92	0.34	9.77e-9	Depression;
CESC	cis	rs5167	0.504	rs8100120	chr19:45466058	T/C	cg20090143	chr19:45452003	APOC2	0.35	6.01	0.35	6.06e-9	Blood protein levels;
CESC	cis	rs916888	0.610	rs199453	chr17:44800946	C/T	cg15921436	chr17:44337874	NA	0.42	5.36	0.31	1.85e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs4595586	1.000	rs1403521	chr12:39232007	A/G	cg26384229	chr12:38710491	ALG10B	0.38	5.28	0.31	2.69e-7	Morning vs. evening chronotype;
CESC	cis	rs2842992	0.672	rs7738253	chr6:160193917	G/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.79	9.31	0.5	5.04e-18	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs7104764	0.507	rs6598054	chr11:254010	C/T	cg19998151	chr11:267613	NA	0.42	5.17	0.3	4.52e-7	Menarche (age at onset);
CESC	cis	rs1499972	0.529	rs1499982	chr3:117820386	C/T	cg07612923	chr3:117604196	NA	-0.66	-5.59	-0.33	5.51e-8	Schizophrenia;
CESC	trans	rs8073060	0.586	rs225286	chr17:33930458	G/A	cg19694781	chr19:47549865	TMEM160	-0.73	-7.05	-0.4	1.52e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	cis	rs8077577	0.895	rs16960986	chr17:18108562	A/G	cg16794390	chr17:18148240	FLII	-0.43	-5.65	-0.33	4.11e-8	Obesity-related traits;
CESC	cis	rs7635838	0.963	rs7627171	chr3:11413429	G/C	cg00170343	chr3:11313890	ATG7	0.41	5.47	0.32	1.05e-7	HDL cholesterol;
CESC	cis	rs1215050	0.791	rs9993992	chr4:98810851	C/G	cg05340658	chr4:99064831	C4orf37	0.52	6.83	0.39	5.72e-11	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs9715521	0.935	rs6818912	chr4:59834738	A/G	cg11281224	chr4:60001000	NA	-0.52	-6.9	-0.39	3.76e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs3540	0.557	rs11634314	chr15:91042066	A/C	cg10434728	chr15:90938212	IQGAP1	-0.41	-7.27	-0.41	3.94e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs10504229	0.610	rs7840469	chr8:58146992	C/T	cg24829409	chr8:58192753	C8orf71	-0.51	-6.64	-0.38	1.72e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs4819052	0.851	rs7279011	chr21:46655995	G/A	cg11663144	chr21:46675770	NA	-0.62	-9.45	-0.5	1.88e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs704795	0.867	rs7566052	chr2:27628635	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.34	-6.99	-0.39	2.2e-11	Menopause (age at onset);
CESC	cis	rs12579753	0.789	rs35448307	chr12:82165817	A/G	cg24719984	chr12:82153464	PPFIA2	-0.37	-5.35	-0.31	1.9e-7	Resting heart rate;
CESC	cis	rs10751667	0.961	rs7480178	chr11:927108	T/C	cg20946044	chr11:1010712	AP2A2	-0.43	-5.63	-0.33	4.57e-8	Alzheimer's disease (late onset);
CESC	cis	rs67311347	1.000	rs11914297	chr3:40410070	T/C	cg24209194	chr3:40518798	ZNF619	0.43	5.36	0.31	1.78e-7	Renal cell carcinoma;
CESC	cis	rs9522267	0.535	rs9515447	chr13:112222303	C/T	cg10483660	chr13:112241077	NA	-0.33	-5.79	-0.34	1.98e-8	Hepatitis;
CESC	cis	rs3859192	0.599	rs12451897	chr17:38179275	G/T	cg17344932	chr17:38183730	MED24;SNORD124	0.63	9.61	0.51	6.04e-19	White blood cell count;
CESC	cis	rs1801251	1.000	rs12478564	chr2:233598340	C/T	cg08000102	chr2:233561755	GIGYF2	0.67	9.4	0.5	2.59e-18	Coronary artery disease;
CESC	cis	rs8002861	0.905	rs12875768	chr13:44428305	C/T	cg14210620	chr13:44453864	C13orf31;CCDC122	-0.42	-5.21	-0.3	3.75e-7	Leprosy;
CESC	cis	rs17376456	0.877	rs7736620	chr5:93305762	C/T	cg25358565	chr5:93447407	FAM172A	1.07	10.7	0.55	1.86e-22	Diabetic retinopathy;
CESC	cis	rs7927771	0.770	rs11039203	chr11:47384597	A/G	cg20307385	chr11:47447363	PSMC3	-0.59	-7.05	-0.4	1.56e-11	Subjective well-being;
CESC	cis	rs1448094	0.527	rs1900700	chr12:86232166	C/T	cg19622623	chr12:86230825	RASSF9	-0.44	-5.36	-0.31	1.81e-7	Major depressive disorder;
CESC	trans	rs3942852	0.955	rs1503190	chr11:48117873	A/G	cg15704280	chr7:45808275	SEPT13	-0.59	-6.83	-0.39	5.9e-11	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs10129255	0.912	rs67410411	chr14:107136341	G/A	cg23076370	chr14:107095027	NA	-0.41	-5.15	-0.3	5.19e-7	Kawasaki disease;
CESC	cis	rs4132509	0.793	rs12037013	chr1:243784207	G/A	cg21452805	chr1:244014465	NA	0.64	6.69	0.38	1.3e-10	RR interval (heart rate);
CESC	cis	rs10504229	0.953	rs78089850	chr8:58171557	A/G	cg24829409	chr8:58192753	C8orf71	-0.75	-9.78	-0.51	1.74e-19	Developmental language disorder (linguistic errors);
CESC	cis	rs3617	0.625	rs3774364	chr3:52863605	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.36	5.16	0.3	4.89e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
CESC	cis	rs4704187	0.574	rs4704184	chr5:74471677	A/G	cg03227963	chr5:74354835	NA	0.28	5.15	0.3	5e-7	Response to amphetamines;
CESC	trans	rs2018683	0.899	rs10269454	chr7:28978400	C/T	cg19402173	chr7:128379420	CALU	-0.58	-7.79	-0.43	1.56e-13	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05707844	chr2:37383994	EIF2AK2	0.64	7.37	0.41	2.24e-12	Gut microbiome composition (summer);
CESC	cis	rs17253792	0.822	rs8013831	chr14:56172898	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.69	5.94	0.34	8.99e-9	Putamen volume;
CESC	trans	rs35110281	0.517	rs11089020	chr21:44939991	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.51	7.03	0.4	1.72e-11	Mean corpuscular volume;
CESC	cis	rs2880765	0.631	rs55767890	chr15:86004142	C/G	cg19183879	chr15:85880815	NA	-0.31	-5.93	-0.34	9.57e-9	Coronary artery disease;
CESC	cis	rs7618915	0.547	rs13085895	chr3:52678270	G/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	7.01	0.4	2e-11	Bipolar disorder;
CESC	cis	rs7666738	0.830	rs28867388	chr4:98962794	A/T	cg17366294	chr4:99064904	C4orf37	0.6	8.52	0.46	1.2e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs17818399	0.547	rs4952833	chr2:46762034	T/C	cg02822958	chr2:46747628	ATP6V1E2	0.44	5.11	0.3	6.1e-7	Height;
CESC	cis	rs2933343	0.700	rs883602	chr3:128653952	A/G	cg24203234	chr3:128598194	ACAD9	0.44	6.01	0.35	5.99e-9	IgG glycosylation;
CESC	cis	rs4822044	0.568	rs1883370	chr22:42143740	C/A	cg17376030	chr22:41985996	PMM1	-0.75	-7.85	-0.43	1.06e-13	Cannabis dependence symptom count;
CESC	cis	rs769267	0.930	rs2315022	chr19:19413381	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.44	5.44	0.32	1.23e-7	Tonsillectomy;
CESC	cis	rs2276314	1.000	rs9304154	chr18:33562227	C/T	cg05985134	chr18:33552581	C18orf21	0.63	7.17	0.4	7.56e-12	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs1950626	0.662	rs72700538	chr14:101441911	C/G	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.83	11.29	0.57	2.14e-24	Pelvic organ prolapse (moderate/severe);
CESC	cis	rs9896933	0.887	rs78483419	chr17:80870884	T/C	cg19500275	chr17:80737654	TBCD	0.67	6.29	0.36	1.28e-9	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
CESC	cis	rs16910800	0.731	rs16910759	chr11:23192131	C/G	cg20040320	chr11:23191996	NA	-0.67	-6.56	-0.37	2.77e-10	Cancer;
CESC	cis	rs11098499	0.575	rs9996586	chr4:120326942	A/G	cg09307838	chr4:120376055	NA	0.52	7.01	0.4	1.95e-11	Corneal astigmatism;
CESC	cis	rs67478160	0.619	rs10083370	chr14:104314182	G/A	cg08213375	chr14:104286397	PPP1R13B	-0.54	-10.67	-0.55	2.33e-22	Schizophrenia;
CESC	cis	rs2839186	0.647	rs9976233	chr21:47616913	G/A	cg12516959	chr21:47718080	NA	0.41	5.97	0.34	7.7e-9	Testicular germ cell tumor;
CESC	cis	rs7833790	0.636	rs12544174	chr8:82731477	G/A	cg02079420	chr8:82753780	SNX16	0.54	8.28	0.45	6.23e-15	Diastolic blood pressure;
CESC	cis	rs258892	0.895	rs9293442	chr5:72055595	T/C	cg21869765	chr5:72125136	TNPO1	-0.42	-5.32	-0.31	2.2e-7	Small cell lung carcinoma;
CESC	trans	rs61931739	0.534	rs10506120	chr12:34235603	G/A	cg26384229	chr12:38710491	ALG10B	0.63	9.17	0.49	1.41e-17	Morning vs. evening chronotype;
CESC	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg00945038	chr17:61921165	SMARCD2	-0.36	-5.13	-0.3	5.71e-7	Prudent dietary pattern;
CESC	cis	rs1538970	0.816	rs3790583	chr1:45956828	C/G	cg05343316	chr1:45956843	TESK2	0.93	12.78	0.62	1.91e-29	Platelet count;
CESC	trans	rs6794880	0.778	rs80331882	chr3:84420289	C/G	cg03554283	chr8:76319451	NA	0.57	6.07	0.35	4.44e-9	Body mass index (joint analysis main effects and smoking interaction);BMI in non-smokers;BMI (adjusted for smoking behaviour);
CESC	cis	rs9372253	1.000	rs2235989	chr6:110714584	A/T	cg19196401	chr6:110721138	DDO	-0.37	-5.38	-0.31	1.68e-7	Platelet distribution width;
CESC	cis	rs360798	0.512	rs9973612	chr2:63019815	G/C	cg17519650	chr2:63277830	OTX1	-0.58	-7.62	-0.42	4.62e-13	Coronary artery disease;
CESC	cis	rs617791	0.508	rs10896074	chr11:65776304	C/T	cg09783858	chr11:65769428	EIF1AD;BANF1	0.51	5.95	0.34	8.47e-9	Breast cancer;
CESC	cis	rs2299587	0.554	rs3913558	chr8:17747909	T/G	cg08627089	chr8:17753878	FGL1	-0.41	-5.87	-0.34	1.33e-8	Economic and political preferences;
CESC	cis	rs559928	0.606	rs57021319	chr11:63956102	G/A	cg18225595	chr11:63971243	STIP1	0.69	6.2	0.36	2.17e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CESC	cis	rs10276381	1.000	rs10263857	chr7:28187284	C/G	cg23620719	chr7:28220237	JAZF1	0.74	7.91	0.44	6.86e-14	Crohn's disease;
CESC	cis	rs3768617	0.528	rs4652778	chr1:183097420	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.89	14.27	0.66	1.13e-34	Fuchs's corneal dystrophy;
CESC	cis	rs12701220	0.503	rs12702024	chr7:1129820	G/C	cg23978390	chr7:1156363	C7orf50	0.58	5.24	0.31	3.26e-7	Bronchopulmonary dysplasia;
CESC	cis	rs10504229	0.593	rs1442127	chr8:57992136	T/C	cg22535103	chr8:58192502	C8orf71	-0.66	-7.06	-0.4	1.45e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs10905065	0.861	rs10752069	chr10:5752403	A/G	cg11519256	chr10:5708881	ASB13	0.48	6.43	0.37	5.95e-10	Menopause (age at onset);
CESC	cis	rs10504229	0.636	rs72649133	chr8:58054681	G/A	cg14926445	chr8:58193284	C8orf71	-0.54	-5.14	-0.3	5.39e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs2281845	0.507	rs1536127	chr1:201086894	C/A	cg06714761	chr1:201096289	NA	0.43	6.47	0.37	4.79e-10	Permanent tooth development;
CESC	cis	rs8062405	1.000	rs62036617	chr16:28827498	T/C	cg08761264	chr16:28874980	SH2B1	-0.46	-5.73	-0.33	2.73e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs9790314	1.000	rs336548	chr3:161058412	T/C	cg03342759	chr3:160939853	NMD3	-0.47	-6.07	-0.35	4.48e-9	Morning vs. evening chronotype;
CESC	cis	rs6570726	0.738	rs6917199	chr6:145918320	G/A	cg05347473	chr6:146136440	FBXO30	0.57	7.24	0.41	4.72e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs782590	0.934	rs62165184	chr2:55788253	G/C	cg18811423	chr2:55921094	PNPT1	0.77	12.37	0.6	4.82e-28	Metabolic syndrome;
CESC	cis	rs3820068	0.506	rs17448966	chr1:15990983	T/G	cg13390004	chr1:15929781	NA	0.31	5.12	0.3	5.81e-7	Systolic blood pressure;
CESC	cis	rs62005083	0.867	rs55785954	chr14:74633609	G/A	cg05179529	chr14:74551516	LIN52;ALDH6A1	0.71	5.53	0.32	7.52e-8	Mean corpuscular volume;
CESC	cis	rs6088580	0.634	rs4911418	chr20:32994257	G/A	cg08999081	chr20:33150536	PIGU	-0.65	-11.29	-0.57	2.22e-24	Glomerular filtration rate (creatinine);
CESC	cis	rs3091242	0.933	rs10903130	chr1:25769221	A/T	cg12412775	chr1:25698385	RHCE	-0.28	-5.13	-0.3	5.65e-7	Erythrocyte sedimentation rate;
CESC	cis	rs367615	0.659	rs13435970	chr5:108884660	C/T	cg17395555	chr5:108820864	NA	0.55	8.19	0.45	1.14e-14	Colorectal cancer (SNP x SNP interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14087051	chr9:34126687	DCAF12	0.58	6.67	0.38	1.46e-10	Gut microbiome composition (summer);
CESC	cis	rs8027181	1.000	rs7166595	chr15:73094204	A/G	cg25632853	chr15:73088954	NA	0.35	6.34	0.36	9.6e-10	Triglyceride levels;
CESC	cis	rs7666738	0.830	rs2865990	chr4:99067399	C/A	cg03467027	chr4:99064603	C4orf37	0.48	5.93	0.34	9.28e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3540	0.533	rs2601197	chr15:90940059	C/A	cg10434728	chr15:90938212	IQGAP1	0.43	7.83	0.43	1.21e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg11370512	chr12:113796654	PLBD2	-0.42	-6.75	-0.38	9.09e-11	Gambling;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg14060719	chr14:96797241	ATG2B	0.38	6.31	0.36	1.16e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs7605827	0.893	rs1024871	chr2:15626162	C/T	cg19274914	chr2:15703543	NA	0.36	6.42	0.37	6.36e-10	Educational attainment (years of education);
CESC	cis	rs735860	0.726	rs209510	chr6:53202035	T/C	cg10236188	chr6:53219634	NA	0.34	5.08	0.3	7.21e-7	Glaucoma;
CESC	cis	rs7267979	1.000	rs422844	chr20:25445591	T/C	cg08601574	chr20:25228251	PYGB	0.37	5.31	0.31	2.31e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs34172651	0.517	rs1465423	chr16:24772680	C/G	cg04756594	chr16:24857601	SLC5A11	-0.45	-5.48	-0.32	9.67e-8	Intelligence (multi-trait analysis);
CESC	cis	rs5753618	0.504	rs9606847	chr22:31901789	G/C	cg13145458	chr22:31556086	RNF185	-0.48	-5.69	-0.33	3.28e-8	Colorectal cancer;
CESC	cis	rs1371867	0.846	rs1613453	chr8:101244215	G/T	cg11906718	chr8:101322791	RNF19A	-0.47	-5.97	-0.34	7.5e-9	Atrioventricular conduction;
CESC	cis	rs9649213	0.574	rs34830366	chr7:97899535	G/T	cg24562669	chr7:97807699	LMTK2	0.52	7.41	0.41	1.66e-12	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs11871801	0.517	rs35635959	chr17:40772288	T/C	cg21433558	chr17:40837037	CNTNAP1	0.48	5.84	0.34	1.56e-8	Crohn's disease;
CESC	cis	rs644148	0.770	rs2571113	chr19:44999814	A/G	cg15540054	chr19:45004280	ZNF180	-0.71	-8.42	-0.46	2.38e-15	Personality dimensions;
CESC	trans	rs208520	0.661	rs7766144	chr6:66827795	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.0	-12.85	-0.62	1.09e-29	Exhaled nitric oxide output;
CESC	cis	rs11155671	0.530	rs2342770	chr6:150216685	C/T	cg11878867	chr6:150167359	LRP11	-0.35	-5.15	-0.3	5.02e-7	Testicular germ cell tumor;
CESC	cis	rs6982240	0.514	rs10088801	chr8:142275801	T/C	cg27411547	chr8:142287226	NA	-0.53	-7.28	-0.41	3.69e-12	Tonsillectomy;
CESC	cis	rs5769765	1.000	rs8184990	chr22:50273174	A/G	cg26441486	chr22:50317300	CRELD2	-0.39	-5.44	-0.32	1.23e-7	Schizophrenia;
CESC	cis	rs7833986	0.501	rs2719255	chr8:57036658	A/G	cg26371346	chr8:56986568	SNORD54;RPS20	0.56	5.04	0.3	8.57e-7	Height;
CESC	cis	rs28374715	0.510	rs8034073	chr15:41545613	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.52	-7.21	-0.4	5.89e-12	Ulcerative colitis;
CESC	cis	rs4665809	0.652	rs2241739	chr2:26411894	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.94	-11.28	-0.57	2.3e-24	Gut microbiome composition (summer);
CESC	cis	rs9611565	0.659	rs116959331	chr22:41932774	A/G	cg17376030	chr22:41985996	PMM1	0.68	7.35	0.41	2.5e-12	Vitiligo;
CESC	cis	rs8072100	0.790	rs11656856	chr17:45714671	C/T	cg08085267	chr17:45401833	C17orf57	0.45	5.61	0.33	5.11e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	trans	rs9929218	0.551	rs6499193	chr16:68727069	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.86	14.01	0.65	9.65e-34	Colorectal cancer;
CESC	cis	rs1801251	1.000	rs283479	chr2:233648754	A/G	cg25237894	chr2:233734115	C2orf82	0.46	7.81	0.43	1.33e-13	Coronary artery disease;
CESC	cis	rs7044106	0.734	rs1981020	chr9:123388464	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.68	9.89	0.52	7.73e-20	Hip circumference adjusted for BMI;
CESC	cis	rs4718428	0.705	rs4718424	chr7:66376095	G/A	cg25985355	chr7:65971099	NA	-0.34	-5.09	-0.3	6.81e-7	Corneal structure;
CESC	cis	rs10129255	0.957	rs10142859	chr14:107190475	A/G	cg23076370	chr14:107095027	NA	-0.46	-5.79	-0.34	1.96e-8	Kawasaki disease;
CESC	cis	rs798554	1.000	rs798548	chr7:2760935	A/G	cg04166393	chr7:2884313	GNA12	0.56	7.46	0.42	1.24e-12	Height;
CESC	cis	rs9318086	0.712	rs9318100	chr13:24442482	A/G	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.44	-6.11	-0.35	3.61e-9	Myopia (pathological);
CESC	cis	rs17407555	0.738	rs73212870	chr4:10111798	C/G	cg11266682	chr4:10021025	SLC2A9	-0.49	-5.88	-0.34	1.24e-8	Schizophrenia (age at onset);
CESC	cis	rs2180341	0.618	rs12199451	chr6:127597780	C/G	cg24812749	chr6:127587940	RNF146	0.56	7.35	0.41	2.45e-12	Breast cancer;
CESC	cis	rs1008375	0.898	rs4698623	chr4:17594702	T/C	cg15017067	chr4:17643749	FAM184B	0.36	5.11	0.3	6.09e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg11494091	chr17:61959527	GH2	0.73	12.66	0.61	4.86e-29	Prudent dietary pattern;
CESC	cis	rs17253792	0.822	rs77315200	chr14:56072643	C/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.79	5.91	0.34	1.06e-8	Putamen volume;
CESC	cis	rs6938	0.618	rs62029167	chr15:75228350	G/A	cg17294928	chr15:75287854	SCAMP5	0.48	6.24	0.36	1.76e-9	Breast cancer;
CESC	cis	rs6952808	0.789	rs35729895	chr7:1885069	C/T	cg22963979	chr7:1858916	MAD1L1	-0.38	-5.19	-0.3	4.18e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg22907277	chr7:1156413	C7orf50	0.41	5.97	0.34	7.76e-9	Longevity;Endometriosis;
CESC	cis	rs7772486	0.790	rs6926657	chr6:146255794	G/A	cg23711669	chr6:146136114	FBXO30	-0.92	-13.3	-0.63	2.94e-31	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1865721	0.804	rs1319789	chr18:73161157	C/A	cg26385618	chr18:73139727	C18orf62	-0.45	-6.94	-0.39	3.02e-11	Intelligence;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg10020083	chr5:176873646	PRR7	-0.52	-6.42	-0.37	6.19e-10	Asthma;
CESC	cis	rs11030122	0.632	rs11030599	chr11:4031677	A/G	cg18678763	chr11:4115507	RRM1	-0.42	-5.65	-0.33	4.19e-8	Mean platelet volume;Platelet distribution width;
CESC	cis	rs921968	0.643	rs520095	chr2:219329485	C/T	cg02176678	chr2:219576539	TTLL4	0.38	6.74	0.38	1.01e-10	Mean corpuscular hemoglobin concentration;
CESC	cis	rs938554	0.513	rs11943372	chr4:9999346	T/A	cg00071950	chr4:10020882	SLC2A9	0.62	8.36	0.46	3.61e-15	Blood metabolite levels;
CESC	cis	rs2878628	0.650	rs56098033	chr3:52758571	T/A	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.68	0.38	1.41e-10	Intelligence (multi-trait analysis);
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg05014452	chr15:79603196	TMED3	-0.4	-6.29	-0.36	1.27e-9	Vertical cup-disc ratio;
CESC	cis	rs2243480	1.000	rs1701758	chr7:65470201	T/A	cg12463550	chr7:65579703	CRCP	0.72	5.92	0.34	9.68e-9	Diabetic kidney disease;
CESC	cis	rs10504229	0.639	rs67996345	chr8:58117127	A/G	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs12701220	0.894	rs2141274	chr7:1034717	G/A	cg26769984	chr7:1090371	C7orf50	0.52	6.19	0.36	2.3e-9	Bronchopulmonary dysplasia;
CESC	cis	rs2901656	0.875	rs7516301	chr1:172372260	T/C	cg03748243	chr1:172413542	C1orf105;PIGC	0.41	5.99	0.35	6.87e-9	Red cell distribution width;Platelet distribution width;
CESC	cis	rs7193541	0.684	rs7201320	chr16:74694058	T/G	cg05580060	chr16:74700937	RFWD3	-0.5	-6.49	-0.37	4.27e-10	Multiple myeloma;
CESC	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg23708337	chr7:1209742	NA	0.55	5.41	0.32	1.44e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs10489202	0.632	rs202265	chr1:167990231	G/C	cg24449463	chr1:168025552	DCAF6	-0.41	-5.24	-0.31	3.33e-7	Schizophrenia;
CESC	cis	rs6540559	0.673	rs926346	chr1:209962204	A/T	cg10074409	chr1:209979377	IRF6	0.4	5.32	0.31	2.16e-7	Cleft lip with or without cleft palate;
CESC	cis	rs916888	0.821	rs199513	chr17:44856932	A/G	cg15921436	chr17:44337874	NA	-0.65	-7.14	-0.4	9.23e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs9640161	0.659	rs7806429	chr7:150013393	A/G	cg10018233	chr7:150070692	REPIN1	0.45	7.16	0.4	8.07e-12	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs9311474	0.508	rs4687546	chr3:52605943	T/A	cg05564831	chr3:52568323	NT5DC2	0.47	7.46	0.42	1.24e-12	Electroencephalogram traits;
CESC	cis	rs10479542	0.642	rs6879665	chr5:178974581	T/A	cg21226059	chr5:178986404	RUFY1	0.45	6.32	0.36	1.09e-9	Lung cancer;
CESC	cis	rs3892630	0.878	rs11878394	chr19:33205844	G/C	cg22980127	chr19:33182716	NUDT19	1.02	10.92	0.56	3.55e-23	Red blood cell traits;
CESC	trans	rs5763662	1.000	rs5763769	chr22:30495745	G/A	cg23513814	chr17:72857430	GRIN2C	-0.53	-6.04	-0.35	5.1e-9	LDL cholesterol levels;LDL cholesterol;
CESC	cis	rs854765	0.547	rs7209003	chr17:17907393	T/A	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.54	7.23	0.41	5.11e-12	Total body bone mineral density;
CESC	cis	rs875971	0.545	rs6969224	chr7:65834998	T/G	cg18876405	chr7:65276391	NA	0.49	5.33	0.31	2.1e-7	Aortic root size;
CESC	trans	rs2235573	0.625	rs139901	chr22:38406147	T/C	cg19894588	chr14:64061835	NA	0.49	6.27	0.36	1.43e-9	Glioblastoma;Glioma;
CESC	cis	rs473651	0.935	rs474478	chr2:239335473	C/T	cg21699342	chr2:239360505	ASB1	0.53	8.62	0.47	6.17e-16	Multiple system atrophy;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg00767560	chr19:19887256	LOC284440	0.47	6.41	0.37	6.74e-10	Systemic lupus erythematosus;
CESC	cis	rs8067545	0.578	rs9901336	chr17:20064190	G/A	cg13482628	chr17:19912719	NA	0.42	5.5	0.32	8.74e-8	Schizophrenia;
CESC	cis	rs7208859	0.725	rs9915802	chr17:29173058	T/C	cg19761014	chr17:28927070	LRRC37B2	0.57	5.71	0.33	2.96e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs4722166	0.532	rs1404008	chr7:22756000	A/T	cg05472934	chr7:22766657	IL6	0.5	6.56	0.37	2.73e-10	Lung cancer;
CESC	cis	rs1218582	0.710	rs9794000	chr1:154878876	T/A	cg24250549	chr1:154909240	PMVK	0.74	11.08	0.56	1.06e-23	Prostate cancer;
CESC	cis	rs7937682	0.855	rs490897	chr11:111487914	A/G	cg22437258	chr11:111473054	SIK2	0.71	9.48	0.5	1.47e-18	Primary sclerosing cholangitis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23586394	chr17:8286572	RPL26	0.55	6.51	0.37	3.71e-10	Gut microbiome composition (summer);
CESC	trans	rs875971	1.000	rs55962648	chr7:65625751	C/G	cg26939375	chr7:64535504	NA	-0.46	-6.09	-0.35	4e-9	Aortic root size;
CESC	cis	rs780096	0.565	rs813592	chr2:27721971	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.34	-6.34	-0.36	9.82e-10	Total body bone mineral density;
CESC	cis	rs9611565	0.649	rs202657	chr22:41844786	G/T	cg03806693	chr22:41940476	POLR3H	1.19	14.51	0.67	1.64e-35	Vitiligo;
CESC	trans	rs801193	1.000	rs7789184	chr7:66210195	A/T	cg26939375	chr7:64535504	NA	0.64	8.77	0.47	2.19e-16	Aortic root size;
CESC	cis	rs1728785	1.000	rs1170429	chr16:68604126	A/G	cg02972257	chr16:68554789	NA	-0.59	-6.71	-0.38	1.2e-10	Ulcerative colitis;
CESC	cis	rs2573652	1.000	rs2581341	chr15:100514494	T/C	cg09918751	chr15:100517450	ADAMTS17	-0.41	-7.8	-0.43	1.47e-13	Height;
CESC	cis	rs77106637	1.000	rs11602858	chr11:72615069	C/G	cg03713592	chr11:72463424	ARAP1	1.11	10.14	0.53	1.25e-20	Type 2 diabetes;
CESC	cis	rs10504229	0.679	rs72649107	chr8:58030453	C/A	cg22535103	chr8:58192502	C8orf71	-0.57	-6.56	-0.37	2.78e-10	Developmental language disorder (linguistic errors);
CESC	trans	rs8073060	0.586	rs6505486	chr17:33996776	G/A	cg19694781	chr19:47549865	TMEM160	-0.75	-7.09	-0.4	1.2e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	cis	rs3091242	0.933	rs932372	chr1:25755014	G/A	cg27572855	chr1:25598939	RHD	0.46	7.61	0.42	4.83e-13	Erythrocyte sedimentation rate;
CESC	cis	rs9399135	0.816	rs4134030	chr6:135354094	G/T	cg24558204	chr6:135376177	HBS1L	0.51	7.09	0.4	1.25e-11	Red blood cell count;
CESC	cis	rs1797885	1.000	rs1797885	chr3:12517103	G/A	cg26432171	chr3:12704882	RAF1	-0.5	-6.42	-0.37	6.13e-10	Immature fraction of reticulocytes;
CESC	cis	rs11864453	0.713	rs12708927	chr16:72126165	C/T	cg01557791	chr16:72042693	DHODH	-0.46	-5.92	-0.34	9.98e-9	Fibrinogen levels;
CESC	cis	rs9814567	0.896	rs2177602	chr3:134245866	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.45	-6.15	-0.35	2.87e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs1448094	0.512	rs6539929	chr12:86244932	T/C	cg02569458	chr12:86230093	RASSF9	0.49	7.27	0.41	3.98e-12	Major depressive disorder;
CESC	cis	rs10129255	0.518	rs10150460	chr14:107133196	C/G	cg07958169	chr14:107095056	NA	0.56	9.29	0.5	5.64e-18	Kawasaki disease;
CESC	cis	rs7772486	0.754	rs6910790	chr6:146255330	G/A	cg05347473	chr6:146136440	FBXO30	-0.55	-7.0	-0.39	2.12e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9303401	0.614	rs2240719	chr17:56582477	G/C	cg25039879	chr17:56429692	SUPT4H1	0.51	5.11	0.3	6.24e-7	Cognitive test performance;
CESC	cis	rs10504229	0.683	rs62621195	chr8:58133964	G/A	cg24829409	chr8:58192753	C8orf71	-0.58	-7.2	-0.4	6.31e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs4665809	0.938	rs6742226	chr2:26342537	A/G	cg04944784	chr2:26401820	FAM59B	-0.65	-7.42	-0.41	1.56e-12	Gut microbiome composition (summer);
CESC	cis	rs875971	0.862	rs801204	chr7:66022921	T/C	cg12463550	chr7:65579703	CRCP	-0.5	-6.32	-0.36	1.08e-9	Aortic root size;
CESC	trans	rs7726839	0.540	rs61580655	chr5:597564	A/G	cg25482853	chr8:67687455	SGK3	1.04	10.08	0.53	1.87e-20	Obesity-related traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10546579	chr7:44646217	OGDH	0.57	6.56	0.37	2.88e-10	Gut microbiome composition (summer);
CESC	cis	rs208520	0.507	rs7755710	chr6:66783355	G/A	cg07460842	chr6:66804631	NA	-1.09	-25.19	-0.84	2.82e-72	Exhaled nitric oxide output;
CESC	cis	rs6688613	0.694	rs1476347	chr1:166815587	G/T	cg07049167	chr1:166818506	POGK	0.55	6.76	0.38	8.62e-11	Refractive astigmatism;
CESC	cis	rs13191362	0.507	rs2849540	chr6:163094522	G/A	cg14584255	chr6:163149320	PACRG;PARK2	-0.43	-5.36	-0.31	1.81e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs2425143	1.000	rs6060642	chr20:34449840	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.78	-7.03	-0.4	1.78e-11	Blood protein levels;
CESC	cis	rs2836974	0.965	rs6517538	chr21:40656242	C/T	cg17971929	chr21:40555470	PSMG1	1.07	16.32	0.71	6.47e-42	Cognitive function;
CESC	cis	rs17407555	0.821	rs80278615	chr4:10143666	G/A	cg11266682	chr4:10021025	SLC2A9	-0.51	-5.73	-0.33	2.79e-8	Schizophrenia (age at onset);
CESC	cis	rs1005277	0.579	rs2474563	chr10:38375938	T/C	cg25427524	chr10:38739819	LOC399744	-0.66	-9.52	-0.5	1.15e-18	Extrinsic epigenetic age acceleration;
CESC	cis	rs4713118	0.662	rs464312	chr6:27967591	T/A	cg12963246	chr6:28129442	ZNF389	0.42	5.78	0.33	2.1e-8	Parkinson's disease;
CESC	cis	rs2625529	0.529	rs1552133	chr15:72232897	T/A	cg16672083	chr15:72433130	SENP8	0.43	6.2	0.36	2.1e-9	Red blood cell count;
CESC	cis	rs3096299	0.748	rs2965822	chr16:89444677	A/T	cg02187348	chr16:89574699	SPG7	0.52	6.82	0.39	6.32e-11	Multiple myeloma (IgH translocation);
CESC	cis	rs17253792	0.822	rs13379342	chr14:56050452	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.82	5.8	0.34	1.89e-8	Putamen volume;
CESC	cis	rs4889855	0.585	rs72855201	chr17:78530597	A/G	cg16591659	chr17:78472290	NA	0.38	6.27	0.36	1.47e-9	Fractional excretion of uric acid;
CESC	cis	rs11122272	0.735	rs1416916	chr1:231533027	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.56	-7.66	-0.43	3.45e-13	Hemoglobin concentration;
CESC	cis	rs4891159	0.790	rs7234653	chr18:74111988	C/T	cg24786174	chr18:74118243	ZNF516	-0.75	-11.88	-0.59	2.16e-26	Longevity;
CESC	cis	rs2197308	0.585	rs10878014	chr12:38114496	A/G	cg26384229	chr12:38710491	ALG10B	0.42	5.67	0.33	3.8e-8	Morning vs. evening chronotype;
CESC	cis	rs7116495	1.000	rs2298456	chr11:71730715	A/T	cg10381502	chr11:71823885	C11orf51	0.62	5.35	0.31	1.94e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs7086627	0.515	rs11202960	chr10:82209807	G/A	cg03267442	chr10:82210566	NA	-0.34	-5.6	-0.33	5.45e-8	Post bronchodilator FEV1;
CESC	cis	rs2236918	0.932	rs1635517	chr1:242012033	A/G	cg17736920	chr1:242011382	EXO1	-0.74	-9.93	-0.52	5.65e-20	Menopause (age at onset);
CESC	cis	rs472402	0.560	rs10065299	chr5:6654489	T/C	cg10789808	chr5:6633262	NSUN2;SRD5A1	-0.55	-7.06	-0.4	1.43e-11	Response to amphetamines;
CESC	cis	rs9322193	0.923	rs9767652	chr6:150055638	A/T	cg13206674	chr6:150067644	NUP43	0.43	6.05	0.35	4.94e-9	Lung cancer;
CESC	cis	rs116095464	0.558	rs28418643	chr5:240859	A/G	cg20965017	chr5:231967	SDHA	-0.47	-5.3	-0.31	2.49e-7	Breast cancer;
CESC	cis	rs7618915	0.501	rs6617	chr3:52740182	C/G	cg05564831	chr3:52568323	NT5DC2	0.46	7.26	0.41	4.25e-12	Bipolar disorder;
CESC	cis	rs116095464	0.558	rs73029475	chr5:206969	T/C	cg22857025	chr5:266934	NA	-1.28	-14.21	-0.66	1.88e-34	Breast cancer;
CESC	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg22105103	chr4:187893119	NA	0.47	7.09	0.4	1.22e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1006703	0.544	rs8067516	chr17:3838248	T/C	cg06463185	chr17:3833770	ATP2A3	-0.63	-6.08	-0.35	4.1e-9	Glucose homeostasis traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20969242	chr1:155827044	GON4L	-0.53	-6.51	-0.37	3.78e-10	Gut microbiome composition (summer);
CESC	trans	rs12339966	0.643	rs2586342	chr9:11677445	A/G	cg03904639	chr13:37677730	CSNK1A1L	0.39	6.06	0.35	4.67e-9	Systolic blood pressure;
CESC	cis	rs17376456	0.877	rs13153245	chr5:93374891	G/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.6	5.18	0.3	4.41e-7	Diabetic retinopathy;
CESC	trans	rs11250098	0.567	rs4326350	chr8:10763655	C/G	cg15556689	chr8:8085844	FLJ10661	0.56	6.81	0.39	6.67e-11	Morning vs. evening chronotype;
CESC	cis	rs10992471	0.756	rs3758229	chr9:95078852	G/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.43	-5.41	-0.32	1.39e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CESC	cis	rs9916302	0.851	rs11078906	chr17:37662767	C/T	cg19468946	chr17:37922297	IKZF3	-0.39	-5.13	-0.3	5.47e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs6912958	0.781	rs9444512	chr6:88223397	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.37	-6.01	-0.35	6.1e-9	Monocyte percentage of white cells;
CESC	cis	rs8038465	0.622	rs60696711	chr15:73873005	C/A	cg15420318	chr15:73925796	NPTN	0.49	6.87	0.39	4.6e-11	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs4919694	1.000	rs7083328	chr10:104769268	G/A	cg04362960	chr10:104952993	NT5C2	0.75	6.44	0.37	5.54e-10	Arsenic metabolism;
CESC	cis	rs1451375	0.617	rs10271341	chr7:50591583	A/C	cg14593290	chr7:50529359	DDC	0.49	5.92	0.34	9.95e-9	Malaria;
CESC	cis	rs2842992	0.830	rs2842974	chr6:160159034	C/T	cg26839252	chr6:160211577	TCP1;MRPL18	0.45	5.35	0.31	1.92e-7	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs763121	0.776	rs4820346	chr22:39125074	C/G	cg21395723	chr22:39101663	GTPBP1	-0.45	-5.69	-0.33	3.36e-8	Menopause (age at onset);
CESC	cis	rs12618769	0.570	rs116051325	chr2:99056836	G/A	cg10123293	chr2:99228465	UNC50	0.39	5.18	0.3	4.49e-7	Bipolar disorder;
CESC	cis	rs16867321	0.627	rs1950028	chr2:181587222	A/G	cg23363182	chr2:181467187	NA	-0.43	-5.67	-0.33	3.7e-8	Obesity;
CESC	trans	rs2797160	0.651	rs6939969	chr6:126034563	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.47	6.36	0.36	8.95e-10	Endometrial cancer;
CESC	cis	rs597539	0.652	rs516425	chr11:68715675	G/A	cg04772025	chr11:68637568	NA	0.53	6.38	0.37	7.7e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs8177253	0.763	rs8177224	chr3:133474003	C/G	cg01448562	chr3:133502909	NA	0.42	5.66	0.33	3.93e-8	Iron status biomarkers;
CESC	cis	rs3741404	0.825	rs60452247	chr11:63981507	G/A	cg04317338	chr11:64019027	PLCB3	0.49	5.78	0.33	2.06e-8	Platelet count;
CESC	cis	rs644799	1.000	rs693364	chr11:95621926	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.83	11.71	0.58	8.53e-26	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs7666738	0.830	rs9999200	chr4:99030690	A/C	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.58e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7178572	1.000	rs965480	chr15:77781926	A/G	cg22256960	chr15:77711686	NA	-0.6	-8.09	-0.44	2.19e-14	Type 2 diabetes;
CESC	cis	rs4665809	0.590	rs7582341	chr2:26416301	A/G	cg22920501	chr2:26401640	FAM59B	-0.85	-10.05	-0.53	2.5e-20	Gut microbiome composition (summer);
CESC	cis	rs8077577	0.895	rs13284	chr17:18112130	C/T	cg16794390	chr17:18148240	FLII	0.41	5.64	0.33	4.37e-8	Obesity-related traits;
CESC	cis	rs6860806	0.661	rs4705927	chr5:131578608	C/G	cg18758796	chr5:131593413	PDLIM4	0.45	6.31	0.36	1.19e-9	Breast cancer;
CESC	trans	rs3087243	0.755	rs6714925	chr2:204694235	T/A	cg01841312	chr10:38069945	NA	-0.4	-6.67	-0.38	1.52e-10	Rheumatoid arthritis;Hypothyroidism;Type 1 diabetes;
CESC	cis	rs7605827	0.930	rs6737962	chr2:15526998	T/G	cg19274914	chr2:15703543	NA	0.35	6.11	0.35	3.61e-9	Educational attainment (years of education);
CESC	cis	rs2274273	1.000	rs72718804	chr14:55630610	G/A	cg04306507	chr14:55594613	LGALS3	0.29	5.32	0.31	2.21e-7	Protein biomarker;
CESC	cis	rs2236521	0.659	rs72487383	chr20:60889313	A/C	cg09594475	chr20:60884601	LAMA5	0.49	6.63	0.38	1.91e-10	Pelvic organ prolapse;
CESC	cis	rs7811142	1.000	rs11764818	chr7:100043055	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.15	11.42	0.57	7.76e-25	Platelet count;
CESC	cis	rs1879734	0.689	rs6673378	chr1:54160812	G/T	cg23596471	chr1:54105337	GLIS1	0.35	5.56	0.32	6.52e-8	Mitral valve prolapse;
CESC	cis	rs2576037	0.583	rs8096263	chr18:44515216	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.77	12.82	0.62	1.32e-29	Personality dimensions;
CESC	cis	rs9914988	0.887	rs34644886	chr17:27168327	T/C	cg20469991	chr17:27169893	C17orf63	-0.46	-5.11	-0.3	6.27e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CESC	cis	rs4535700	0.501	rs28678267	chr7:56009490	A/G	cg09872392	chr7:56161020	PHKG1	0.41	5.9	0.34	1.08e-8	Macular telangiectasia type 2;
CESC	cis	rs7618915	0.547	rs12487591	chr3:52642936	A/T	cg07507251	chr3:52567010	NT5DC2	0.43	7.13	0.4	9.6e-12	Bipolar disorder;
CESC	cis	rs7666738	0.830	rs3907021	chr4:99038668	C/T	cg05340658	chr4:99064831	C4orf37	0.82	12.88	0.62	8.44e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2337406	0.714	rs2337463	chr14:107224299	A/G	cg23076370	chr14:107095027	NA	-0.48	-5.26	-0.31	2.93e-7	Alzheimer's disease (late onset);
CESC	trans	rs12356475	0.710	rs10822686	chr10:67733250	C/T	cg12512039	chr7:65958832	NA	0.57	6.4	0.37	7.19e-10	Psoriatic arthritis;
CESC	trans	rs1814175	0.817	rs4405313	chr11:50013636	G/A	cg03929089	chr4:120376271	NA	-0.94	-16.01	-0.7	7.75e-41	Height;
CESC	cis	rs4835473	0.932	rs1839449	chr4:144651375	A/G	cg25736465	chr4:144833511	NA	0.36	5.42	0.32	1.31e-7	Immature fraction of reticulocytes;
CESC	cis	rs780096	0.506	rs780100	chr2:27652153	G/T	cg17158414	chr2:27665306	KRTCAP3	-0.32	-5.97	-0.34	7.59e-9	Total body bone mineral density;
CESC	cis	rs2197308	0.765	rs12824529	chr12:37931656	T/C	cg13010199	chr12:38710504	ALG10B	0.53	6.81	0.39	6.71e-11	Morning vs. evening chronotype;
CESC	cis	rs2836974	0.897	rs1541102	chr21:40628765	C/T	cg11644478	chr21:40555479	PSMG1	1.04	16.65	0.71	4.41e-43	Cognitive function;
CESC	cis	rs6546550	0.900	rs2054047	chr2:70117421	A/C	cg02498382	chr2:70120550	SNRNP27	-0.41	-7.0	-0.39	2.11e-11	Prevalent atrial fibrillation;
CESC	cis	rs10504073	0.584	rs56074306	chr8:49940282	C/T	cg00325661	chr8:49890786	NA	0.58	8.62	0.47	6.09e-16	Blood metabolite ratios;
CESC	trans	rs7902708	0.920	rs11002989	chr10:54425167	C/T	cg26219051	chr22:43739629	SCUBE1	-0.48	-6.19	-0.36	2.25e-9	Bone properties (heel);
CESC	cis	rs2708240	0.666	rs2710118	chr7:147603362	A/C	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.34	-5.58	-0.32	6.03e-8	QT interval (drug interaction);
CESC	cis	rs11640734	0.609	rs11647746	chr16:89806343	C/A	cg14709524	chr16:89940631	TCF25	0.59	5.03	0.3	9.18e-7	Interleukin-17 levels;
CESC	cis	rs7296418	0.738	rs10846489	chr12:123743927	A/G	cg05973401	chr12:123451056	ABCB9	-0.47	-6.05	-0.35	5.01e-9	Platelet count;
CESC	cis	rs1799949	1.000	rs2070834	chr17:41242285	T/G	cg05368731	chr17:41323189	NBR1	0.77	11.01	0.56	1.79e-23	Menopause (age at onset);
CESC	cis	rs1799949	1.000	rs3092994	chr17:41215825	C/T	cg06001716	chr17:41278141	BRCA1;NBR2	0.38	5.16	0.3	4.96e-7	Menopause (age at onset);
CESC	cis	rs7760535	0.597	rs9320368	chr6:111904737	T/C	cg22127309	chr6:111907043	TRAF3IP2	-0.44	-6.68	-0.38	1.36e-10	Metabolic traits;
CESC	cis	rs77861329	0.748	rs747343	chr3:52109407	T/C	cg08692210	chr3:52188851	WDR51A	0.46	5.43	0.32	1.25e-7	Macrophage inflammatory protein 1b levels;
CESC	cis	rs12822507	0.899	rs4763859	chr12:12787005	G/A	cg11838227	chr12:12764436	CREBL2	-0.41	-5.33	-0.31	2.1e-7	Systemic lupus erythematosus;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg03409120	chr17:58754402	BCAS3	0.45	6.74	0.38	9.87e-11	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs4450798	0.793	rs4640541	chr3:13758997	C/G	cg05589046	chr3:13742034	LOC285375	-0.38	-5.8	-0.34	1.88e-8	Bipolar disorder with mood-incongruent psychosis;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg14304014	chr19:1625356	TCF3	0.43	6.27	0.36	1.44e-9	Fibrinogen levels;
CESC	cis	rs6912958	0.702	rs2300909	chr6:88212100	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-6.62	-0.38	1.95e-10	Monocyte percentage of white cells;
CESC	cis	rs362272	0.505	rs13104157	chr4:3366950	T/C	cg14583973	chr4:3374767	RGS12	0.31	5.48	0.32	9.88e-8	Serum sulfate level;
CESC	cis	rs4668356	0.892	rs1863679	chr2:172017906	C/T	cg13882835	chr2:172017928	TLK1	0.52	5.13	0.3	5.61e-7	Cognitive performance;
CESC	cis	rs9640161	0.789	rs4554381	chr7:150025567	G/A	cg21361702	chr7:150065534	REPIN1	0.47	5.58	0.32	5.88e-8	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs17401966	1.000	rs3753037	chr1:10355834	C/T	cg15208524	chr1:10270712	KIF1B	0.48	6.13	0.35	3.2e-9	Hepatocellular carcinoma;
CESC	cis	rs6032067	0.777	rs2868236	chr20:43794070	G/A	cg10761708	chr20:43804764	PI3	0.56	6.55	0.37	3.01e-10	Blood protein levels;
CESC	cis	rs896854	0.517	rs1011795	chr8:95951073	G/A	cg16049864	chr8:95962084	TP53INP1	-0.53	-7.59	-0.42	5.61e-13	Type 2 diabetes;
CESC	cis	rs2204008	0.715	rs11514282	chr12:38169056	G/T	cg26384229	chr12:38710491	ALG10B	0.75	10.86	0.55	5.81e-23	Bladder cancer;
CESC	cis	rs1552244	1.000	rs9827740	chr3:10120531	T/C	cg16606324	chr3:10149918	C3orf24	0.43	5.36	0.31	1.81e-7	Alzheimer's disease;
CESC	cis	rs10206020	0.921	rs4072986	chr2:1547734	C/G	cg01028140	chr2:1542097	TPO	-0.47	-5.93	-0.34	9.62e-9	IgG glycosylation;
CESC	cis	rs1348850	0.750	rs12997716	chr2:178494629	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.51	6.59	0.38	2.42e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs5769765	0.954	rs5770707	chr22:50244533	G/A	cg26441486	chr22:50317300	CRELD2	-0.4	-5.52	-0.32	8.04e-8	Schizophrenia;
CESC	cis	rs763121	0.853	rs5757187	chr22:39021522	A/G	cg06022373	chr22:39101656	GTPBP1	-0.88	-13.54	-0.64	4.17e-32	Menopause (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00067814	chr7:134896357	WDR91	0.54	6.05	0.35	5.04e-9	Gut microbiome composition (summer);
CESC	cis	rs611744	0.647	rs633901	chr8:109242981	G/T	cg21045802	chr8:109455806	TTC35	0.46	5.67	0.33	3.65e-8	Dupuytren's disease;
CESC	cis	rs2282802	0.685	rs13177186	chr5:139640476	A/G	cg26211634	chr5:139558579	C5orf32	0.53	7.66	0.43	3.55e-13	Intelligence (multi-trait analysis);
CESC	cis	rs2760061	0.598	rs2796056	chr1:228122901	G/A	cg02753203	chr1:228287806	NA	-0.51	-7.36	-0.41	2.3e-12	Diastolic blood pressure;
CESC	cis	rs2842992	0.789	rs4276525	chr6:160193612	G/A	cg11366901	chr6:160182831	ACAT2	0.83	10.38	0.54	2.06e-21	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs7546094	0.935	rs6700673	chr1:113157054	C/T	cg22162597	chr1:113214053	CAPZA1	0.4	6.13	0.35	3.09e-9	Platelet distribution width;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg27559595	chr15:79237381	CTSH	-0.44	-6.1	-0.35	3.73e-9	Fibrinogen levels;
CESC	cis	rs7666738	1.000	rs880473	chr4:98922596	C/T	cg05340658	chr4:99064831	C4orf37	0.59	7.45	0.42	1.32e-12	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1707322	0.963	rs34907901	chr1:46405214	T/G	cg05343316	chr1:45956843	TESK2	0.43	5.2	0.3	3.9e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg18110333	chr6:292329	DUSP22	-0.74	-9.98	-0.52	4.17e-20	Menopause (age at onset);
CESC	cis	rs36051895	0.632	rs1581927	chr9:5177462	C/T	cg02405213	chr9:5042618	JAK2	-0.51	-6.62	-0.38	2.03e-10	Pediatric autoimmune diseases;
CESC	cis	rs4594175	0.886	rs11157802	chr14:51622984	C/T	cg23942311	chr14:51606299	NA	0.39	5.95	0.34	8.67e-9	Cancer;
CESC	cis	rs28647808	0.881	rs71483208	chr9:136258824	T/C	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.85	5.74	0.33	2.59e-8	Blood protein levels;
CESC	trans	rs473518	0.891	rs554856	chr18:20103788	A/C	cg20346503	chr2:128994402	NA	0.47	6.32	0.36	1.11e-9	Migraine - clinic-based;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg24424381	chr15:90233857	WDR93;PEX11A	-0.53	-6.57	-0.37	2.72e-10	Asthma;
CESC	cis	rs847577	0.748	rs940430	chr7:97716540	A/G	cg24562669	chr7:97807699	LMTK2	0.63	10.15	0.53	1.13e-20	Breast cancer;
CESC	cis	rs1552244	1.000	rs35220123	chr3:10083169	C/T	cg00166722	chr3:10149974	C3orf24	0.47	5.91	0.34	1.05e-8	Alzheimer's disease;
CESC	cis	rs2070488	0.775	rs2268762	chr3:38516075	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.82	13.35	0.63	2.01e-31	Electrocardiographic conduction measures;
CESC	cis	rs1499972	0.529	rs58533135	chr3:117655311	T/C	cg07612923	chr3:117604196	NA	0.69	6.3	0.36	1.22e-9	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05994294	chr4:1374658	KIAA1530	-0.58	-6.9	-0.39	3.93e-11	Gut microbiome composition (summer);
CESC	cis	rs858239	0.632	rs7811903	chr7:23119056	A/G	cg23682824	chr7:23144976	KLHL7	0.55	7.61	0.42	4.7e-13	Cerebrospinal fluid biomarker levels;
CESC	cis	rs6429082	0.783	rs291385	chr1:235646613	T/C	cg26050004	chr1:235667680	B3GALNT2	0.62	7.88	0.44	8.78e-14	Adiposity;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg09571097	chr17:899782	TIMM22	-0.45	-6.29	-0.36	1.31e-9	Asthma;
CESC	cis	rs11166927	1.000	rs13260415	chr8:140805137	A/C	cg16909799	chr8:140841666	TRAPPC9	0.61	8.99	0.48	4.89e-17	Pediatric non-alcoholic fatty liver disease activity score;
CESC	cis	rs477692	1.000	rs479478	chr10:131428959	G/A	cg05714579	chr10:131428358	MGMT	0.52	7.09	0.4	1.21e-11	Response to temozolomide;
CESC	trans	rs916888	0.773	rs538628	chr17:44787313	G/C	cg01341218	chr17:43662625	NA	0.92	10.84	0.55	6.44e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs7243790	0.805	rs7243441	chr18:51917733	C/T	cg04730925	chr18:51795821	POLI	-0.43	-5.68	-0.33	3.47e-8	Diastolic blood pressure;
CESC	cis	rs6582630	0.502	rs11610978	chr12:38356957	C/G	cg13010199	chr12:38710504	ALG10B	0.44	5.58	0.32	5.9e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs2019216	0.500	rs6565385	chr17:21897646	C/A	cg22648282	chr17:21454238	C17orf51	-0.42	-5.55	-0.32	6.94e-8	Pelvic organ prolapse;
CESC	cis	rs7949030	0.591	rs12049914	chr11:62369436	C/G	cg23462726	chr11:62437636	C11orf83;C11orf48	-0.41	-5.3	-0.31	2.5e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs1881797	1.000	rs1881797	chr1:247689532	A/G	cg05639522	chr1:247681581	NA	0.44	6.69	0.38	1.33e-10	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs875971	0.522	rs1880556	chr7:65432544	T/C	cg26939375	chr7:64535504	NA	0.78	10.85	0.55	6.36e-23	Aortic root size;
CESC	cis	rs4474465	1.000	rs7950865	chr11:78157401	A/G	cg27205649	chr11:78285834	NARS2	-0.41	-5.13	-0.3	5.53e-7	Alzheimer's disease (survival time);
CESC	cis	rs72945132	0.714	rs57320340	chr11:70160010	G/C	cg00319359	chr11:70116639	PPFIA1	0.78	7.71	0.43	2.52e-13	Coronary artery disease;
CESC	cis	rs757110	0.648	rs12146443	chr11:17384498	T/C	cg15432903	chr11:17409602	KCNJ11	0.6	8.51	0.46	1.3e-15	Type 2 diabetes;
CESC	cis	rs796364	1.000	rs281783	chr2:200751582	G/A	cg23649088	chr2:200775458	C2orf69	0.56	5.25	0.31	3.09e-7	Schizophrenia;
CESC	trans	rs1814175	0.645	rs28478790	chr11:50054322	C/A	cg03929089	chr4:120376271	NA	-0.91	-14.82	-0.67	1.29e-36	Height;
CESC	cis	rs9291683	0.546	rs13146686	chr4:10034933	A/G	cg02734326	chr4:10020555	SLC2A9	0.43	5.97	0.34	7.52e-9	Bone mineral density;
CESC	cis	rs921968	0.510	rs591573	chr2:219478193	C/T	cg02176678	chr2:219576539	TTLL4	0.44	7.54	0.42	7.44e-13	Mean corpuscular hemoglobin concentration;
CESC	cis	rs2976388	0.566	rs2585146	chr8:143798641	A/C	cg10596483	chr8:143751796	JRK	0.43	5.19	0.3	4.28e-7	Urinary tract infection frequency;
CESC	cis	rs4819052	0.851	rs2838843	chr21:46669284	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.92	13.3	0.63	2.84e-31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs3793683	0.545	rs12784407	chr10:134589631	A/G	cg18305652	chr10:134549665	INPP5A	0.48	6.79	0.39	7.14e-11	Migraine;
CESC	cis	rs7666738	0.822	rs13110418	chr4:99046963	G/A	cg24818145	chr4:99064322	C4orf37	0.38	5.04	0.3	8.49e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7937682	0.632	rs3944619	chr11:111774743	A/G	cg09085632	chr11:111637200	PPP2R1B	0.88	11.26	0.57	2.77e-24	Primary sclerosing cholangitis;
CESC	cis	rs7762018	0.769	rs4716339	chr6:170063210	C/T	cg05834625	chr6:170176447	C6orf70	0.51	5.22	0.31	3.6e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs8031584	1.000	rs1474380	chr15:31269235	T/C	cg08704250	chr15:31115839	NA	-0.63	-8.15	-0.45	1.44e-14	Huntington's disease progression;
CESC	cis	rs7607369	0.559	rs4674339	chr2:219659787	C/G	cg02176678	chr2:219576539	TTLL4	-0.4	-7.23	-0.41	5.21e-12	Red blood cell count;Amyotrophic lateral sclerosis;
CESC	cis	rs561341	1.000	rs484175	chr17:30309041	G/A	cg19193384	chr17:30244184	NA	-0.67	-6.36	-0.36	8.74e-10	Hip circumference adjusted for BMI;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23539780	chr8:10696689	PINX1	-0.58	-6.61	-0.38	2.08e-10	Gut microbiome composition (summer);
CESC	cis	rs17376456	0.825	rs10054903	chr5:93281491	C/A	cg21475434	chr5:93447410	FAM172A	0.75	6.27	0.36	1.5e-9	Diabetic retinopathy;
CESC	cis	rs4704187	0.595	rs6859176	chr5:74379425	T/C	cg03227963	chr5:74354835	NA	0.32	5.95	0.34	8.68e-9	Response to amphetamines;
CESC	cis	rs2857078	0.720	rs9906669	chr17:42305706	A/G	cg19774624	chr17:42201019	HDAC5	-0.55	-7.41	-0.41	1.75e-12	Red cell distribution width;Reticulocyte count;
CESC	trans	rs9354308	0.933	rs55672811	chr6:66571730	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.71	7.93	0.44	6.11e-14	Metabolite levels;
CESC	cis	rs9457247	1.000	rs385113	chr6:167403971	A/G	cg07741184	chr6:167504864	NA	0.28	5.1	0.3	6.54e-7	Crohn's disease;
CESC	cis	rs7267979	1.000	rs2424700	chr20:25266513	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	18.61	0.75	5.3e-50	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs853679	0.517	rs56310871	chr6:28044482	A/G	cg23161317	chr6:28129485	ZNF389	0.5	6.31	0.36	1.19e-9	Depression;
CESC	cis	rs9840812	0.567	rs2655008	chr3:136123775	A/T	cg15507776	chr3:136538369	TMEM22	0.42	5.11	0.3	6.2e-7	Fibrinogen levels;
CESC	trans	rs11098499	0.863	rs2306456	chr4:120472422	C/G	cg25214090	chr10:38739885	LOC399744	0.66	8.96	0.48	5.92e-17	Corneal astigmatism;
CESC	trans	rs11165623	0.765	rs11807955	chr1:96891623	C/T	cg10631902	chr5:14652156	NA	-0.57	-8.51	-0.46	1.31e-15	Hip circumference;Waist circumference;
CESC	cis	rs7914558	0.966	rs11191518	chr10:104782853	C/G	cg08650961	chr10:104748594	CNNM2	0.33	5.43	0.32	1.29e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs447	0.848	rs9969195	chr7:83753142	T/C	cg22846510	chr7:83753280	SEMA3A	-0.45	-5.61	-0.33	5e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg07058132	chr16:1755945	MAPK8IP3	-0.46	-6.21	-0.36	1.98e-9	Ulcerative colitis;
CESC	cis	rs728616	0.681	rs55899456	chr10:82050646	G/A	cg05935833	chr10:81318306	SFTPA2	-0.44	-5.53	-0.32	7.71e-8	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs4819052	0.807	rs7283915	chr21:46671288	T/C	cg11663144	chr21:46675770	NA	-0.63	-9.96	-0.52	4.67e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs8114671	0.562	rs6088642	chr20:33483186	G/T	cg24642439	chr20:33292090	TP53INP2	0.44	5.32	0.31	2.18e-7	Height;
CESC	cis	rs7727544	0.631	rs13357280	chr5:131600187	A/G	cg14196790	chr5:131705035	SLC22A5	0.38	5.67	0.33	3.81e-8	Blood metabolite levels;
CESC	cis	rs28680850	1.000	rs28680850	chr8:1373720	G/A	cg02490460	chr8:1365502	NA	-0.42	-5.19	-0.3	4.11e-7	Triglycerides;
CESC	cis	rs2486288	0.586	rs12909883	chr15:45572054	G/C	cg09092052	chr15:45571596	NA	0.44	5.23	0.31	3.44e-7	Glomerular filtration rate;
CESC	trans	rs3741578	0.702	rs1813812	chr12:57333395	A/G	cg27208169	chr17:17603584	RAI1	0.44	6.07	0.35	4.31e-9	Asthma;
CESC	cis	rs654950	0.934	rs662999	chr1:42001160	A/C	cg06885757	chr1:42089581	HIVEP3	0.65	9.93	0.52	5.8e-20	Airway imaging phenotypes;
CESC	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg07677032	chr17:61819896	STRADA	0.5	6.66	0.38	1.55e-10	Prudent dietary pattern;
CESC	cis	rs11864453	0.826	rs12448315	chr16:72147242	G/T	cg01557791	chr16:72042693	DHODH	-0.52	-6.82	-0.39	6.06e-11	Fibrinogen levels;
CESC	cis	rs4555082	0.834	rs2816623	chr14:105733295	G/A	cg10792982	chr14:105748885	BRF1	0.4	5.04	0.3	8.82e-7	Mean platelet volume;Platelet distribution width;
CESC	cis	rs4132509	1.000	rs9782958	chr1:243892972	C/G	cg21452805	chr1:244014465	NA	0.45	5.68	0.33	3.5e-8	RR interval (heart rate);
CESC	cis	rs35110281	0.782	rs6518309	chr21:45047992	C/A	cg04455712	chr21:45112962	RRP1B	0.43	5.95	0.34	8.28e-9	Mean corpuscular volume;
CESC	cis	rs3008870	1.000	rs2985822	chr1:67404910	T/G	cg02640540	chr1:67518911	SLC35D1	0.52	5.66	0.33	3.9e-8	Lymphocyte percentage of white cells;
CESC	cis	rs11677416	1.000	rs1516790	chr2:113531291	G/A	cg27083787	chr2:113543245	IL1A	0.41	5.17	0.3	4.53e-7	Response to antipsychotic treatment in schizophrenia (working memory);
CESC	cis	rs1799949	1.000	rs8176269	chr17:41213626	G/T	cg25072359	chr17:41440525	NA	0.47	6.26	0.36	1.51e-9	Menopause (age at onset);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg11582617	chr6:158589302	SERAC1;GTF2H5	-0.43	-6.09	-0.35	3.92e-9	Fibrinogen levels;
CESC	cis	rs3785574	0.962	rs2955235	chr17:61966950	A/C	cg06420487	chr17:61919686	SMARCD2	0.47	5.55	0.32	6.89e-8	Height;
CESC	cis	rs7945705	0.840	rs10840136	chr11:8885024	C/T	cg12365402	chr11:9010492	NRIP3	-0.33	-5.25	-0.31	3.14e-7	Hemoglobin concentration;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06086071	chr1:151847151	THEM4	-0.57	-6.2	-0.36	2.17e-9	Gut microbiome composition (summer);
CESC	cis	rs9926296	0.632	rs4785717	chr16:89801133	A/G	cg27121462	chr16:89883253	FANCA	0.63	8.05	0.44	2.77e-14	Vitiligo;
CESC	cis	rs769267	0.965	rs2315281	chr19:19480099	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.59	-7.76	-0.43	1.81e-13	Tonsillectomy;
CESC	cis	rs7914558	0.933	rs12763665	chr10:104653717	G/A	cg04362960	chr10:104952993	NT5C2	0.46	5.99	0.35	6.65e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs155076	1.000	rs484365	chr13:21845944	G/T	cg11317459	chr13:21872234	NA	-1.01	-11.12	-0.56	7.88e-24	White matter hyperintensity burden;
CESC	cis	rs9888739	1.000	rs11865746	chr16:31326587	T/G	cg15817542	chr16:31343056	ITGAM	-0.46	-5.46	-0.32	1.11e-7	Systemic lupus erythematosus;
CESC	trans	rs57221529	0.713	rs56328416	chr5:591138	G/A	cg25482853	chr8:67687455	SGK3	1.02	9.96	0.52	4.61e-20	Lung disease severity in cystic fibrosis;
CESC	cis	rs12971120	0.891	rs12608037	chr18:72169395	A/G	cg25817165	chr18:72167213	CNDP2	-0.61	-7.15	-0.4	8.4e-12	Refractive error;
CESC	cis	rs77106637	0.932	rs2886599	chr11:72721271	C/A	cg04827223	chr11:72435913	ARAP1	-0.53	-5.44	-0.32	1.2e-7	Type 2 diabetes;
CESC	cis	rs10504229	0.683	rs72650849	chr8:58140323	A/G	cg24829409	chr8:58192753	C8orf71	-0.59	-7.31	-0.41	3.16e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs3126085	1.000	rs4845756	chr1:152254919	T/A	cg03465714	chr1:152285911	FLG	-0.46	-5.75	-0.33	2.42e-8	Atopic dermatitis;
CESC	cis	rs7666738	0.830	rs1813642	chr4:98852225	G/A	cg05340658	chr4:99064831	C4orf37	0.76	11.26	0.57	2.68e-24	Colonoscopy-negative controls vs population controls;
CESC	trans	rs1888221	0.580	rs7030164	chr9:117815613	C/T	cg11017500	chr13:111290755	CARKD	-0.46	-6.06	-0.35	4.61e-9	Glucose homeostasis traits;
CESC	cis	rs9715521	0.677	rs62301200	chr4:59855179	G/A	cg11281224	chr4:60001000	NA	-0.51	-7.15	-0.4	8.65e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg15154797	chr10:91174526	IFIT5	-0.45	-6.0	-0.35	6.28e-9	Fibrinogen levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09256781	chr7:23145220	KLHL7	0.6	6.58	0.37	2.44e-10	Gut microbiome composition (summer);
CESC	cis	rs12497850	1.000	rs10865952	chr3:48744484	A/G	cg07636037	chr3:49044803	WDR6	0.95	16.31	0.71	6.93e-42	Parkinson's disease;
CESC	cis	rs12136530	0.509	rs77930907	chr1:19724752	G/C	cg01832549	chr1:19774989	CAPZB	-0.46	-6.29	-0.36	1.32e-9	Lead levels in blood;
CESC	cis	rs7772486	0.846	rs1331636	chr6:146338826	T/C	cg23711669	chr6:146136114	FBXO30	0.86	12.53	0.61	1.39e-28	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs208520	0.690	rs12202401	chr6:66760544	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.94	12.07	0.6	5.01e-27	Exhaled nitric oxide output;
CESC	cis	rs1152591	0.624	rs1266927	chr14:64651663	C/A	cg21174375	chr14:64681225	SYNE2	0.49	6.96	0.39	2.67e-11	Atrial fibrillation;
CESC	cis	rs798554	0.655	rs798492	chr7:2799184	C/T	cg09658497	chr7:2847517	GNA12	0.33	5.11	0.3	6.3e-7	Height;
CESC	cis	rs3126085	0.935	rs3120660	chr1:152258701	G/T	cg03465714	chr1:152285911	FLG	0.46	5.74	0.33	2.61e-8	Atopic dermatitis;
CESC	cis	rs858239	0.537	rs2286272	chr7:23224367	T/C	cg23682824	chr7:23144976	KLHL7	0.45	5.85	0.34	1.46e-8	Cerebrospinal fluid biomarker levels;
CESC	cis	rs6968419	0.755	rs3173919	chr7:115898177	G/C	cg02561103	chr7:115862891	TES	-0.41	-5.4	-0.31	1.51e-7	Intraocular pressure;
CESC	cis	rs62064224	0.703	rs62065493	chr17:30822620	C/G	cg09324608	chr17:30823087	MYO1D	0.5	7.61	0.42	4.96e-13	Schizophrenia;
CESC	cis	rs28374715	0.662	rs28493087	chr15:41486504	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.81	-10.64	-0.55	3.12e-22	Ulcerative colitis;
CESC	cis	rs67311347	0.544	rs1902073	chr3:40333497	C/T	cg24209194	chr3:40518798	ZNF619	0.38	5.2	0.3	3.91e-7	Renal cell carcinoma;
CESC	cis	rs7666738	0.546	rs10010088	chr4:98655945	C/T	cg05340658	chr4:99064831	C4orf37	0.54	6.55	0.37	2.96e-10	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4523957	0.583	rs2760741	chr17:2020443	C/T	cg16513277	chr17:2031491	SMG6	-0.71	-10.1	-0.53	1.62e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs6461049	0.800	rs1860831	chr7:2160931	T/C	cg23048001	chr7:2026167	MAD1L1	0.46	6.04	0.35	5.3e-9	Schizophrenia;
CESC	cis	rs3540	0.553	rs12592611	chr15:91004093	C/T	cg10434728	chr15:90938212	IQGAP1	0.42	7.58	0.42	5.96e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs2455799	0.613	rs4684259	chr3:15791279	G/A	cg09340198	chr3:15902540	ANKRD28	-0.33	-5.16	-0.3	4.94e-7	Mean platelet volume;
CESC	cis	rs2933343	0.700	rs883602	chr3:128653952	A/G	cg25356066	chr3:128598488	ACAD9	0.61	8.59	0.47	7.6e-16	IgG glycosylation;
CESC	cis	rs9467711	0.606	rs9379899	chr6:26603015	T/A	cg14345882	chr6:26364793	BTN3A2	0.56	5.96	0.34	7.82e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs1003719	1.000	rs2835608	chr21:38493455	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.63	8.54	0.46	1.1e-15	Eye color traits;
CESC	cis	rs10256972	0.900	rs7812072	chr7:1053862	A/G	cg00431813	chr7:1051703	C7orf50	-0.35	-5.43	-0.32	1.26e-7	Longevity;Endometriosis;
CESC	cis	rs2073300	1.000	rs6106656	chr20:23444301	A/G	cg12062639	chr20:23401060	NAPB	0.77	5.68	0.33	3.48e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs2273669	0.667	rs28504359	chr6:109330417	C/T	cg05315195	chr6:109294784	ARMC2	-0.67	-6.32	-0.36	1.13e-9	Prostate cancer;
CESC	cis	rs7789940	0.904	rs6953281	chr7:75946943	C/T	cg10167463	chr7:75959203	YWHAG	-0.51	-6.01	-0.35	6.11e-9	Multiple sclerosis;
CESC	cis	rs4072980	0.524	rs16824514	chr1:38395947	A/T	cg17077180	chr1:38461687	NA	0.42	6.04	0.35	5.16e-9	Coronary artery disease;
CESC	cis	rs820218	0.926	rs820200	chr17:73632030	C/A	cg01592526	chr17:73663357	RECQL5;SAP30BP	0.42	5.56	0.32	6.57e-8	Rotator cuff tears;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg13669089	chr11:31391497	DNAJC24;DCDC1	-0.45	-5.99	-0.35	6.63e-9	Height;
CESC	cis	rs1707322	0.963	rs4630155	chr1:46257110	G/C	cg06784218	chr1:46089804	CCDC17	0.37	6.37	0.36	8.49e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs6582630	0.574	rs12146797	chr12:38436499	T/C	cg13010199	chr12:38710504	ALG10B	0.46	6.0	0.35	6.56e-9	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs4835473	0.932	rs34917094	chr4:144753156	T/A	cg25736465	chr4:144833511	NA	-0.45	-6.75	-0.38	9.22e-11	Immature fraction of reticulocytes;
CESC	trans	rs2727020	0.553	rs10839295	chr11:49527345	A/C	cg03929089	chr4:120376271	NA	-0.81	-12.21	-0.6	1.64e-27	Coronary artery disease;
CESC	cis	rs7666738	0.716	rs13108535	chr4:99046324	A/G	cg03676636	chr4:99064102	C4orf37	0.33	5.12	0.3	5.93e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3820068	0.506	rs17448966	chr1:15990983	T/G	cg16988262	chr1:15930761	NA	0.3	5.03	0.3	8.91e-7	Systolic blood pressure;
CESC	cis	rs11583043	1.000	rs6700743	chr1:101447384	A/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.5	5.54	0.32	7.41e-8	Ulcerative colitis;Inflammatory bowel disease;
CESC	cis	rs7666738	0.830	rs72882693	chr4:98960804	T/A	cg03467027	chr4:99064603	C4orf37	0.44	5.57	0.32	6.41e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4665809	0.589	rs4665841	chr2:26448950	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.98	-11.2	-0.57	4.24e-24	Gut microbiome composition (summer);
CESC	cis	rs12682352	0.715	rs332039	chr8:8723651	C/G	cg15556689	chr8:8085844	FLJ10661	0.46	5.81	0.34	1.78e-8	Neuroticism;
CESC	cis	rs3925075	1.000	rs3925074	chr16:31347807	G/A	cg02846316	chr16:31340340	ITGAM	0.41	6.52	0.37	3.54e-10	IgA nephropathy;
CESC	cis	rs71277158	0.688	rs76146702	chr3:169868720	G/T	cg04067573	chr3:169899625	PHC3	0.71	7.11	0.4	1.08e-11	Prostate cancer;
CESC	cis	rs7829975	0.514	rs2976926	chr8:8261624	T/C	cg08975724	chr8:8085496	FLJ10661	0.4	5.1	0.3	6.54e-7	Mood instability;
CESC	cis	rs7666738	0.830	rs7662948	chr4:99020132	G/C	cg17366294	chr4:99064904	C4orf37	0.6	8.73	0.47	2.97e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9311474	0.508	rs2878628	chr3:52584715	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	-0.36	-6.49	-0.37	4.29e-10	Electroencephalogram traits;
CESC	cis	rs2880765	0.743	rs6416598	chr15:86011848	G/A	cg10818794	chr15:86012489	AKAP13	-0.35	-5.41	-0.32	1.42e-7	Coronary artery disease;
CESC	cis	rs2050392	0.861	rs1042058	chr10:30728101	T/C	cg25182066	chr10:30743637	MAP3K8	-0.43	-5.79	-0.33	2.04e-8	Inflammatory bowel disease;
CESC	cis	rs7412746	0.658	rs6660845	chr1:150841066	G/A	cg22823121	chr1:150693482	HORMAD1	0.44	6.21	0.36	2.09e-9	Melanoma;
CESC	cis	rs10170846	0.800	rs10180462	chr2:223526385	C/T	cg25565276	chr2:223520875	FARSB	0.5	6.98	0.39	2.39e-11	Schizophrenia (inflammation and infection response interaction);
CESC	cis	rs742614	0.533	rs13041078	chr20:32435497	G/T	cg06304546	chr20:32448765	NA	-0.41	-5.16	-0.3	4.85e-7	Stearic acid (18:0) levels;
CESC	cis	rs7659604	0.967	rs34949254	chr4:122664344	G/A	cg19671926	chr4:122722719	EXOSC9	-0.44	-5.22	-0.31	3.56e-7	Type 2 diabetes;
CESC	cis	rs9611565	0.838	rs4239894	chr22:41745548	C/G	cg17376030	chr22:41985996	PMM1	0.6	6.45	0.37	5.18e-10	Vitiligo;
CESC	cis	rs853679	0.517	rs4713150	chr6:28136212	G/A	cg19592336	chr6:28129416	ZNF389	0.58	7.71	0.43	2.54e-13	Depression;
CESC	cis	rs12995491	0.731	rs56188884	chr2:88508657	G/A	cg18490616	chr2:88469792	THNSL2	-0.52	-7.76	-0.43	1.87e-13	Response to metformin (IC50);
CESC	cis	rs2842992	0.872	rs9456440	chr6:160074463	G/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.63	7.29	0.41	3.5e-12	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs7084402	0.967	rs7921207	chr10:60270235	G/T	cg07615347	chr10:60278583	BICC1	-0.57	-8.71	-0.47	3.43e-16	Refractive error;
CESC	cis	rs2836950	0.501	rs2836985	chr21:40701169	A/G	cg11890956	chr21:40555474	PSMG1	-0.67	-9.42	-0.5	2.35e-18	Menarche (age at onset);
CESC	cis	rs2066819	1.000	rs77853814	chr12:56687572	G/T	cg26734620	chr12:56694298	CS	0.97	5.99	0.35	6.91e-9	Psoriasis vulgaris;
CESC	cis	rs10918270	1.000	rs10737521	chr1:161932193	C/T	cg19735514	chr1:161762739	ATF6	-0.35	-5.24	-0.31	3.32e-7	Parkinson's disease (age of onset);
CESC	cis	rs2576037	0.526	rs4890699	chr18:44541029	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.55	-7.65	-0.43	3.81e-13	Personality dimensions;
CESC	cis	rs6570726	0.791	rs7755253	chr6:145858893	C/G	cg23711669	chr6:146136114	FBXO30	1.01	15.52	0.69	4.59e-39	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4700695	0.719	rs27082	chr5:65436152	A/C	cg21114390	chr5:65439923	SFRS12	-0.52	-6.07	-0.35	4.47e-9	Facial morphology (factor 19);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg12726807	chr15:41056075	GCHFR	-0.53	-6.7	-0.38	1.27e-10	Ulcerative colitis;
CESC	cis	rs1023500	0.573	rs133381	chr22:42470608	C/G	cg12850546	chr22:42539477	CYP2D7P1	-0.45	-5.29	-0.31	2.59e-7	Schizophrenia;
CESC	cis	rs2439831	0.681	rs3742969	chr15:43621947	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.91	10.94	0.56	3.23e-23	Lung cancer in ever smokers;
CESC	cis	rs1348850	0.651	rs4893931	chr2:178228212	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.62	8.84	0.48	1.33e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs7666738	0.830	rs10028505	chr4:98962310	C/A	cg17366294	chr4:99064904	C4orf37	0.6	8.52	0.46	1.2e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1552244	0.882	rs34779351	chr3:10021801	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.75	-9.49	-0.5	1.38e-18	Alzheimer's disease;
CESC	cis	rs72634258	0.891	rs404381	chr1:8080745	C/T	cg25007680	chr1:8021821	PARK7	0.47	5.51	0.32	8.29e-8	Inflammatory bowel disease;
CESC	cis	rs3096299	0.617	rs2353030	chr16:89405827	C/T	cg08822215	chr16:89438651	ANKRD11	0.39	5.9	0.34	1.11e-8	Multiple myeloma (IgH translocation);
CESC	cis	rs11997175	0.603	rs4291230	chr8:33674570	A/C	ch.8.33884649F	chr8:33765107	NA	-0.5	-6.12	-0.35	3.39e-9	Body mass index;
CESC	cis	rs344364	0.511	rs1657133	chr16:1950300	A/G	cg26617929	chr16:1858877	NA	-0.49	-5.15	-0.3	5.09e-7	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs9287719	0.810	rs7601748	chr2:10785446	A/G	cg00105475	chr2:10696890	NA	0.36	5.15	0.3	5.01e-7	Prostate cancer;
CESC	trans	rs11039798	0.502	rs961863	chr11:48417021	T/C	cg15704280	chr7:45808275	SEPT13	-0.69	-6.81	-0.39	6.49e-11	Axial length;
CESC	cis	rs7666738	0.830	rs7678567	chr4:99057346	A/G	cg05340658	chr4:99064831	C4orf37	0.82	12.55	0.61	1.13e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9910055	0.659	rs2246287	chr17:42232442	C/G	cg08499158	chr17:42289980	UBTF	-0.53	-6.66	-0.38	1.59e-10	Total body bone mineral density;
CESC	cis	rs7618915	0.547	rs35211965	chr3:52685305	C/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.49	7.02	0.4	1.85e-11	Bipolar disorder;
CESC	cis	rs6032067	0.929	rs36032462	chr20:43873088	T/C	cg10761708	chr20:43804764	PI3	0.52	6.17	0.35	2.53e-9	Blood protein levels;
CESC	cis	rs921968	0.541	rs12619347	chr2:219419935	T/C	cg02176678	chr2:219576539	TTLL4	-0.53	-9.38	-0.5	3.15e-18	Mean corpuscular hemoglobin concentration;
CESC	cis	rs10883723	0.810	rs61873733	chr10:104251458	G/A	cg22532475	chr10:104410764	TRIM8	-0.34	-5.71	-0.33	2.98e-8	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs4722166	0.695	rs35779989	chr7:22800314	A/C	cg05265849	chr7:22767390	IL6	0.46	6.3	0.36	1.21e-9	Lung cancer;
CESC	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg01171360	chr6:293285	DUSP22	-0.67	-8.92	-0.48	8.07e-17	Menopause (age at onset);
CESC	cis	rs7539409	0.651	rs6696140	chr1:84317468	C/T	cg10977910	chr1:84465055	TTLL7	-0.75	-7.33	-0.41	2.8e-12	Alzheimer's disease;
CESC	cis	rs1215050	0.704	rs783915	chr4:99023151	C/G	cg17366294	chr4:99064904	C4orf37	0.42	5.51	0.32	8.51e-8	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs11098499	0.954	rs10017371	chr4:120293776	A/G	cg24375607	chr4:120327624	NA	0.46	5.62	0.33	4.77e-8	Corneal astigmatism;
CESC	cis	rs9894429	0.789	rs7213849	chr17:79567610	C/T	cg13777783	chr17:79615861	NA	0.34	5.36	0.31	1.82e-7	Eye color traits;
CESC	cis	rs7312774	0.618	rs4964195	chr12:107392778	T/C	cg16260113	chr12:107380972	MTERFD3	1.01	8.78	0.47	2.02e-16	Severe influenza A (H1N1) infection;
CESC	cis	rs1558375	0.679	rs31676	chr7:87069880	T/C	cg00919237	chr7:87102261	ABCB4	0.39	5.39	0.31	1.54e-7	Gallbladder cancer;
CESC	cis	rs1005277	0.522	rs289643	chr10:37941494	T/G	cg00409905	chr10:38381863	ZNF37A	-0.48	-6.49	-0.37	4.26e-10	Extrinsic epigenetic age acceleration;
CESC	cis	rs765787	0.530	rs1706832	chr15:45517173	C/T	cg24006582	chr15:45444508	DUOX1	-0.6	-7.36	-0.41	2.35e-12	Uric acid levels;
CESC	cis	rs7772486	0.875	rs9322044	chr6:146369608	T/C	cg23711669	chr6:146136114	FBXO30	0.85	12.56	0.61	1.02e-28	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs3780486	0.846	rs10738905	chr9:33123627	A/G	cg20290983	chr6:43655470	MRPS18A	0.98	18.2	0.75	1.44e-48	IgG glycosylation;
CESC	cis	rs910316	1.000	rs12897094	chr14:75579416	C/T	cg11812906	chr14:75593930	NEK9	0.89	15.42	0.69	9.8e-39	Height;
CESC	cis	rs1552244	1.000	rs17032278	chr3:10077955	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.87	11.84	0.59	2.99e-26	Alzheimer's disease;
CESC	cis	rs672059	1.000	rs1760621	chr1:183156006	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.52	6.75	0.38	9.41e-11	Hypertriglyceridemia;
CESC	cis	rs10883723	0.810	rs12162	chr10:104240498	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.49	5.04	0.3	8.74e-7	Allergic disease (asthma, hay fever or eczema);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg14242958	chr11:101785693	KIAA1377;ANGPTL5	-0.43	-6.09	-0.35	3.97e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs2075371	0.829	rs35897242	chr7:134004041	G/A	cg20476274	chr7:133979776	SLC35B4	0.6	8.32	0.45	4.79e-15	Mean platelet volume;
CESC	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg03647317	chr4:187891568	NA	-0.38	-5.7	-0.33	3.21e-8	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs17253792	0.732	rs79014965	chr14:56117551	T/G	cg01858014	chr14:56050164	KTN1	-0.96	-7.52	-0.42	8.3e-13	Putamen volume;
CESC	cis	rs11958404	1.000	rs72816527	chr5:157409633	C/T	cg05962755	chr5:157440814	NA	0.56	6.1	0.35	3.82e-9	IgG glycosylation;
CESC	cis	rs12136530	0.774	rs10799812	chr1:19770256	C/T	cg01832549	chr1:19774989	CAPZB	-0.48	-6.86	-0.39	4.71e-11	Lead levels in blood;
CESC	cis	rs11583043	0.708	rs17123647	chr1:101529018	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.52	5.52	0.32	8.24e-8	Ulcerative colitis;Inflammatory bowel disease;
CESC	cis	rs9900062	0.586	rs12600679	chr17:62687327	T/G	cg02598441	chr17:62777298	LOC146880	-0.52	-5.56	-0.32	6.66e-8	QT interval;
CESC	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg26354017	chr1:205819088	PM20D1	0.93	16.67	0.72	3.8e-43	Menarche (age at onset);
CESC	cis	rs798554	0.680	rs2533889	chr7:2900309	G/C	cg09658497	chr7:2847517	GNA12	-0.37	-5.2	-0.3	4.04e-7	Height;
CESC	cis	rs34779708	0.966	rs11010129	chr10:35510822	T/C	cg04310649	chr10:35416472	CREM	-0.54	-6.4	-0.37	6.97e-10	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg04234412	chr22:24373322	LOC391322	0.53	7.63	0.42	4.11e-13	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs3820068	0.656	rs72645829	chr1:15889748	A/G	cg17385448	chr1:15911702	AGMAT	0.37	5.81	0.34	1.8e-8	Systolic blood pressure;
CESC	cis	rs67311347	0.866	rs1454491	chr3:40352647	C/G	cg24209194	chr3:40518798	ZNF619	0.42	5.36	0.31	1.79e-7	Renal cell carcinoma;
CESC	cis	rs13118159	0.651	rs4974599	chr4:1314430	A/C	cg20887711	chr4:1340912	KIAA1530	0.59	8.21	0.45	1e-14	Longevity;
CESC	cis	rs9581857	0.556	rs1885990	chr13:28040502	C/T	cg01674679	chr13:27998804	GTF3A	-0.54	-5.77	-0.33	2.2e-8	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
CESC	cis	rs4843747	0.671	rs9933794	chr16:88116981	T/C	cg17633681	chr16:88106987	BANP	0.78	10.56	0.54	5.46e-22	Menopause (age at onset);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg19138325	chr12:129429698	GLT1D1	-0.47	-6.97	-0.39	2.56e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs3820068	0.603	rs72647138	chr1:15980929	C/T	cg16988262	chr1:15930761	NA	0.33	5.4	0.31	1.47e-7	Systolic blood pressure;
CESC	cis	rs7843479	0.965	rs17581910	chr8:21799626	A/G	cg17168535	chr8:21777572	XPO7	0.51	7.03	0.4	1.8e-11	Mean corpuscular volume;
CESC	cis	rs5769707	0.632	rs135872	chr22:50009300	T/C	cg20744362	chr22:50050164	C22orf34	0.38	5.44	0.32	1.24e-7	Monocyte count;Monocyte percentage of white cells;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14559409	chr10:65930703	NA	-0.61	-7.29	-0.41	3.53e-12	Gut microbiome composition (summer);
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg04391736	chr16:69373674	COG8;NIP7	-0.41	-6.35	-0.36	9.14e-10	Vertical cup-disc ratio;
CESC	cis	rs1059312	1.000	rs1059312	chr12:129278864	A/G	cg09035930	chr12:129282057	SLC15A4	-0.68	-9.25	-0.49	7.79e-18	Systemic lupus erythematosus;
CESC	cis	rs6598955	0.627	rs6684875	chr1:26567044	A/G	cg19743891	chr1:26644573	UBXN11;CD52	0.38	5.44	0.32	1.21e-7	Obesity-related traits;
CESC	cis	rs4819052	0.851	rs2838856	chr21:46680766	T/G	cg11663144	chr21:46675770	NA	-0.48	-7.25	-0.41	4.6e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs7552404	1.000	rs4646961	chr1:76217169	G/A	cg03433033	chr1:76189801	ACADM	0.68	8.23	0.45	8.33e-15	Blood metabolite levels;Acylcarnitine levels;
CESC	trans	rs800888	0.772	rs10808475	chr8:116601071	A/G	cg19047077	chr12:105044897	CHST11	0.46	6.01	0.35	6.11e-9	Monocyte percentage of white cells;
CESC	cis	rs8077577	0.895	rs735960	chr17:18057301	G/A	cg16794390	chr17:18148240	FLII	0.48	6.0	0.35	6.62e-9	Obesity-related traits;
CESC	cis	rs28386778	0.701	rs2727337	chr17:61991966	G/A	cg06873352	chr17:61820015	STRADA	-0.65	-11.01	-0.56	1.79e-23	Prudent dietary pattern;
CESC	cis	rs6728642	1.000	rs7593754	chr2:97607544	C/T	cg26665480	chr2:98280029	ACTR1B	-0.64	-6.4	-0.37	7.14e-10	Bipolar disorder lithium response (continuous) or schizophrenia;
CESC	cis	rs2637266	1.000	rs2130799	chr10:78322922	C/T	cg18941641	chr10:78392320	NA	0.4	7.21	0.41	5.78e-12	Pulmonary function;
CESC	cis	rs2836974	0.899	rs114399588	chr21:40653958	G/A	cg17971929	chr21:40555470	PSMG1	1.0	13.77	0.65	6.38e-33	Cognitive function;
CESC	cis	rs10242455	0.681	rs2740559	chr7:99324515	G/C	cg07715041	chr7:99302981	CYP3A7	-0.43	-5.42	-0.32	1.36e-7	Blood metabolite levels;
CESC	cis	rs950776	0.518	rs952216	chr15:78819202	C/T	cg24631222	chr15:78858424	CHRNA5	-0.4	-5.2	-0.3	4.05e-7	Sudden cardiac arrest;
CESC	cis	rs875971	0.830	rs778711	chr7:65851657	G/A	cg10691866	chr7:65817282	TPST1	-0.33	-5.43	-0.32	1.3e-7	Aortic root size;
CESC	cis	rs7089973	0.624	rs10885614	chr10:116609098	C/T	cg23260525	chr10:116636907	FAM160B1	0.4	7.2	0.4	6.31e-12	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs698833	0.892	rs698801	chr2:44691662	G/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.48	6.18	0.35	2.4e-9	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs911555	0.706	rs10129426	chr14:104018455	C/T	cg12935359	chr14:103987150	CKB	-0.44	-6.43	-0.37	6.02e-10	Intelligence (multi-trait analysis);
CESC	cis	rs17666538	0.642	rs7821983	chr8:643696	A/G	cg07234876	chr8:600039	NA	0.77	6.34	0.36	9.6e-10	IgG glycosylation;
CESC	cis	rs2439831	1.000	rs2584726	chr15:43715382	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.86	10.51	0.54	7.92e-22	Lung cancer in ever smokers;
CESC	cis	rs1799949	1.000	rs16940	chr17:41245237	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.42	5.78	0.33	2.1e-8	Menopause (age at onset);
CESC	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg23978390	chr7:1156363	C7orf50	0.57	7.82	0.43	1.28e-13	Longevity;Endometriosis;
CESC	cis	rs2243480	0.901	rs12530490	chr7:65691647	G/A	cg18252515	chr7:66147081	NA	1.41	14.3	0.66	9.43e-35	Diabetic kidney disease;
CESC	cis	rs1008375	1.000	rs6854733	chr4:17640526	C/T	cg16339924	chr4:17578868	LAP3	0.56	7.02	0.4	1.9e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs3008870	1.000	rs2182143	chr1:67378936	T/C	cg08660285	chr1:67390436	MIER1;WDR78	1.05	14.57	0.67	9.8e-36	Lymphocyte percentage of white cells;
CESC	cis	rs9300255	0.602	rs1727314	chr12:123640664	C/A	cg05973401	chr12:123451056	ABCB9	0.5	5.81	0.34	1.79e-8	Neutrophil percentage of white cells;
CESC	cis	rs12497850	0.931	rs13315711	chr3:48986399	A/T	cg07636037	chr3:49044803	WDR6	1.07	19.81	0.77	3.34e-54	Parkinson's disease;
CESC	cis	rs8072100	0.582	rs3826536	chr17:45501967	T/A	cg08085267	chr17:45401833	C17orf57	-0.52	-6.6	-0.38	2.28e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs763121	0.853	rs2413547	chr22:39107338	A/G	cg21395723	chr22:39101663	GTPBP1	0.43	5.45	0.32	1.13e-7	Menopause (age at onset);
CESC	cis	rs6963495	0.872	rs73190193	chr7:105164852	A/G	cg19920283	chr7:105172520	RINT1	0.7	6.66	0.38	1.58e-10	Bipolar disorder (body mass index interaction);
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg07194495	chr7:148958859	ZNF783	0.45	6.05	0.35	4.84e-9	Systemic lupus erythematosus;
CESC	cis	rs3806843	1.000	rs6891995	chr5:140172008	A/G	cg26395211	chr5:140044315	WDR55	-0.41	-5.26	-0.31	2.97e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs7000551	0.751	rs1116084	chr8:22395309	C/T	cg12081754	chr8:22256438	SLC39A14	0.4	5.05	0.3	8.1e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CESC	cis	rs9911578	0.967	rs57869245	chr17:57106630	A/G	cg12560992	chr17:57184187	TRIM37	-0.94	-15.76	-0.7	6.18e-40	Intelligence (multi-trait analysis);
CESC	cis	rs4975709	0.589	rs931508	chr5:1861224	C/G	cg12288994	chr5:1860383	NA	0.41	6.9	0.39	3.75e-11	Cardiovascular disease risk factors;
CESC	cis	rs919433	0.963	rs1429417	chr2:198158171	T/G	cg10820045	chr2:198174542	NA	-0.43	-6.58	-0.37	2.5e-10	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs7827545	1.000	rs1372660	chr8:135566788	C/G	cg17885191	chr8:135476712	NA	0.48	6.28	0.36	1.35e-9	Hypertension (SNP x SNP interaction);
CESC	cis	rs13108904	0.517	rs4974551	chr4:1336410	C/A	cg13395646	chr4:1353034	KIAA1530	-0.49	-6.25	-0.36	1.64e-9	Obesity-related traits;
CESC	cis	rs6088580	0.524	rs6087616	chr20:33263033	T/C	cg24642439	chr20:33292090	TP53INP2	-0.45	-5.33	-0.31	2.08e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs1008375	0.872	rs6831115	chr4:17640463	A/G	cg02297831	chr4:17616191	MED28	0.57	7.34	0.41	2.67e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs9733	0.596	rs7538493	chr1:150655421	T/C	cg09365446	chr1:150670422	GOLPH3L	0.42	5.9	0.34	1.09e-8	Tonsillectomy;
CESC	cis	rs801193	0.839	rs12534943	chr7:66070520	A/G	cg19163074	chr7:65112434	INTS4L2	0.43	5.49	0.32	9.54e-8	Aortic root size;
CESC	cis	rs6963495	0.769	rs73192134	chr7:105189338	T/C	cg19920283	chr7:105172520	RINT1	0.67	6.32	0.36	1.11e-9	Bipolar disorder (body mass index interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22170962	chr19:57765336	ZNF805	-0.5	-6.09	-0.35	3.95e-9	Gut microbiome composition (summer);
CESC	cis	rs6964587	0.869	rs55811257	chr7:91484799	T/A	cg17063962	chr7:91808500	NA	-0.52	-6.98	-0.39	2.42e-11	Breast cancer;
CESC	cis	rs7584330	0.518	rs11888077	chr2:238424763	G/A	cg14458575	chr2:238380390	NA	0.7	6.67	0.38	1.52e-10	Prostate cancer;
CESC	cis	rs2742234	0.541	rs12416428	chr10:43708998	G/A	cg07801480	chr10:43725741	RASGEF1A	-0.41	-5.25	-0.31	3.08e-7	Hirschsprung disease;
CESC	cis	rs17376456	1.000	rs9968691	chr5:93509756	C/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.61	5.04	0.3	8.6e-7	Diabetic retinopathy;
CESC	cis	rs698833	0.886	rs1056865	chr2:44546741	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.45	5.73	0.33	2.72e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs10392	0.516	rs3752293	chr20:37570725	A/G	cg27552599	chr20:37590471	DHX35	-0.37	-5.49	-0.32	9.55e-8	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
CESC	cis	rs78456975	0.527	rs7590742	chr2:1575049	A/T	cg26248373	chr2:1572462	NA	-0.59	-6.93	-0.39	3.22e-11	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs12956009	0.583	rs35970525	chr18:44882625	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.51	6.59	0.38	2.42e-10	Educational attainment (years of education);
CESC	cis	rs2070488	0.775	rs7644530	chr3:38558316	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.78	-12.57	-0.61	1.01e-28	Electrocardiographic conduction measures;
CESC	trans	rs61931739	0.500	rs11053260	chr12:34530215	T/G	cg26384229	chr12:38710491	ALG10B	0.54	7.53	0.42	8.03e-13	Morning vs. evening chronotype;
CESC	cis	rs4728302	0.869	rs6955279	chr7:133612113	C/T	cg10665199	chr7:133106180	EXOC4	0.42	5.73	0.33	2.74e-8	Intelligence;Intelligence (multi-trait analysis);
CESC	cis	rs2228479	0.867	rs62052187	chr16:89973071	G/A	cg06558623	chr16:89946397	TCF25	0.9	7.95	0.44	5.37e-14	Skin colour saturation;
CESC	cis	rs875971	1.000	rs1144895	chr7:65541307	C/G	cg18876405	chr7:65276391	NA	-0.55	-7.1	-0.4	1.11e-11	Aortic root size;
CESC	cis	rs6831352	0.734	rs12502237	chr4:100015675	G/A	cg13256891	chr4:100009986	ADH5	0.69	8.17	0.45	1.29e-14	Alcohol dependence;
CESC	cis	rs7916697	0.947	rs1900004	chr10:70000881	C/T	cg06988349	chr10:69991859	ATOH7	0.37	6.34	0.36	9.66e-10	Optic disc area;
CESC	cis	rs9549260	0.816	rs9532582	chr13:41251207	A/G	cg21288729	chr13:41239152	FOXO1	0.64	8.18	0.45	1.19e-14	Red blood cell count;
CESC	trans	rs8073060	0.559	rs17550632	chr17:33890883	G/C	cg19694781	chr19:47549865	TMEM160	0.75	7.01	0.4	2.01e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	cis	rs7100689	0.646	rs12253992	chr10:82158710	G/A	cg00277334	chr10:82204260	NA	-0.46	-6.31	-0.36	1.19e-9	Post bronchodilator FEV1;
CESC	cis	rs36051895	0.658	rs10975029	chr9:5251068	T/C	cg02405213	chr9:5042618	JAK2	-0.48	-5.8	-0.34	1.86e-8	Pediatric autoimmune diseases;
CESC	cis	rs1008375	0.966	rs10489036	chr4:17697687	A/G	cg16339924	chr4:17578868	LAP3	0.64	7.83	0.43	1.21e-13	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs9287719	0.967	rs6751398	chr2:10738972	T/C	cg00105475	chr2:10696890	NA	0.39	5.61	0.33	4.96e-8	Prostate cancer;
CESC	trans	rs1557351	0.723	rs9949903	chr18:54722522	A/G	cg11433624	chr6:7146702	RREB1	0.38	6.14	0.35	2.94e-9	Multiple sclerosis (age of onset);
CESC	cis	rs6502050	0.805	rs62080003	chr17:80078957	C/T	cg23985595	chr17:80112537	CCDC57	0.41	6.54	0.37	3.19e-10	Life satisfaction;
CESC	cis	rs10504229	0.645	rs56670121	chr8:58138872	C/T	cg02725872	chr8:58115012	NA	-0.45	-7.12	-0.4	1.02e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs2991971	0.934	rs7903	chr1:45976472	G/C	cg24296786	chr1:45957014	TESK2	0.68	9.37	0.5	3.33e-18	High light scatter reticulocyte count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26316544	chr3:52188418	WDR51A	0.59	6.78	0.38	7.88e-11	Gut microbiome composition (summer);
CESC	cis	rs6540556	0.723	rs6540550	chr1:209925251	A/G	cg05527609	chr1:210001259	C1orf107	-0.46	-5.66	-0.33	3.89e-8	Red blood cell count;
CESC	cis	rs8114671	0.662	rs6058146	chr20:33540529	A/G	cg24642439	chr20:33292090	TP53INP2	0.43	5.07	0.3	7.34e-7	Height;
CESC	cis	rs769267	0.930	rs4808964	chr19:19603692	A/C	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.45	-5.89	-0.34	1.19e-8	Tonsillectomy;
CESC	cis	rs7618915	0.501	rs3755798	chr3:52741160	G/A	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.31	5.67	0.33	3.69e-8	Bipolar disorder;
CESC	cis	rs4713118	0.512	rs2622319	chr6:28120401	G/C	cg17221315	chr6:27791827	HIST1H4J	0.45	5.74	0.33	2.53e-8	Parkinson's disease;
CESC	cis	rs7561273	0.609	rs2339945	chr2:24348096	G/A	cg20701182	chr2:24300061	SF3B14	0.46	6.01	0.35	6.27e-9	Quantitative traits;
CESC	cis	rs864537	0.622	rs1214598	chr1:167426424	C/T	cg09179987	chr1:167433047	CD247	0.52	7.89	0.44	8.24e-14	Celiac disease or Rheumatoid arthritis;Celiac disease;
CESC	cis	rs4819052	1.000	rs9306123	chr21:46709922	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.63	7.73	0.43	2.2e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs7107174	1.000	rs2450128	chr11:77940075	G/A	cg02023728	chr11:77925099	USP35	0.46	6.7	0.38	1.22e-10	Testicular germ cell tumor;
CESC	cis	rs3733585	0.699	rs7686538	chr4:9948077	C/T	cg02734326	chr4:10020555	SLC2A9	-0.42	-5.84	-0.34	1.51e-8	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs654950	0.934	rs653369	chr1:42002376	A/T	cg06885757	chr1:42089581	HIVEP3	-0.68	-10.85	-0.55	6.07e-23	Airway imaging phenotypes;
CESC	cis	rs1153858	1.000	rs12440038	chr15:45706739	A/G	cg14582100	chr15:45693742	SPATA5L1	0.41	5.79	0.33	2.03e-8	Homoarginine levels;
CESC	cis	rs736801	0.521	rs2070729	chr5:131819921	G/T	cg00255919	chr5:131827918	IRF1	0.37	6.35	0.36	9.43e-10	Breast cancer;Mosquito bite size;
CESC	trans	rs11638815	0.639	rs783542	chr15:83236014	G/C	cg25333056	chr10:135107159	TUBGCP2	0.5	6.02	0.35	5.92e-9	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;
CESC	cis	rs933688	0.941	rs2887007	chr5:90740531	A/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.06	13.34	0.63	2.14e-31	Smoking behavior;
CESC	cis	rs56104184	0.775	rs73061692	chr19:49399676	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.6	-5.99	-0.35	6.95e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	trans	rs2797160	0.651	rs1268093	chr6:126029235	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.48	6.54	0.37	3.22e-10	Endometrial cancer;
CESC	trans	rs7307889	0.793	rs55783865	chr12:6013681	G/A	cg18407955	chr7:158110685	PTPRN2	-0.72	-6.68	-0.38	1.41e-10	Obesity-related traits;
CESC	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.56	7.21	0.41	5.75e-12	Prudent dietary pattern;
CESC	cis	rs9443189	0.570	rs504323	chr6:76294965	A/G	cg01950844	chr6:76311363	SENP6	-0.86	-8.27	-0.45	6.58e-15	Prostate cancer;
CESC	cis	rs9359856	0.510	rs3736984	chr6:90408589	C/T	cg13799429	chr6:90582589	CASP8AP2	0.73	8.3	0.45	5.19e-15	Bipolar disorder;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg14630947	chr20:47894888	C20orf199;ZNFX1;SNORD12C	-0.52	-6.44	-0.37	5.52e-10	Ulcerative colitis;
CESC	cis	rs888194	0.649	rs10774697	chr12:109875981	A/G	cg19025524	chr12:109796872	NA	-0.41	-6.24	-0.36	1.75e-9	Neuroticism;
CESC	cis	rs11864453	0.647	rs8043606	chr16:72135319	T/C	cg16558253	chr16:72132732	DHX38	-0.54	-8.44	-0.46	2.04e-15	Fibrinogen levels;
CESC	cis	rs3749237	0.576	rs3877784	chr3:49539417	C/T	cg03060546	chr3:49711283	APEH	0.77	11.82	0.59	3.5e-26	Resting heart rate;
CESC	cis	rs7586879	1.000	rs7603153	chr2:25116966	T/C	cg01884057	chr2:25150051	NA	0.28	5.12	0.3	5.86e-7	Body mass index;
CESC	cis	rs9457247	0.565	rs55873403	chr6:167511800	C/T	cg23791538	chr6:167370224	RNASET2	-0.53	-6.98	-0.39	2.32e-11	Crohn's disease;
CESC	cis	rs2243480	1.000	rs6966322	chr7:65646754	A/G	cg12463550	chr7:65579703	CRCP	-0.73	-5.66	-0.33	4.03e-8	Diabetic kidney disease;
CESC	cis	rs2952156	0.920	rs2941506	chr17:37833035	A/G	cg00129232	chr17:37814104	STARD3	-0.74	-10.19	-0.53	8.45e-21	Asthma;
CESC	cis	rs1348850	0.539	rs1453371	chr2:178227862	T/G	cg23306229	chr2:178417860	TTC30B	0.48	5.96	0.34	8.03e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12968172	chr2:239112248	ILKAP	0.57	6.51	0.37	3.71e-10	Gut microbiome composition (summer);
CESC	cis	rs735860	0.712	rs9395855	chr6:53176765	G/T	cg10236188	chr6:53219634	NA	-0.35	-5.14	-0.3	5.28e-7	Glaucoma;
CESC	cis	rs9916302	0.645	rs1053651	chr17:37822311	A/C	cg07936489	chr17:37558343	FBXL20	-0.54	-6.58	-0.37	2.52e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs2832191	0.626	rs2254796	chr21:30341891	A/G	cg24692254	chr21:30365293	RNF160	-0.93	-15.77	-0.7	5.57e-40	Dental caries;
CESC	cis	rs4711336	1.000	rs4711337	chr6:33659987	T/C	cg14003231	chr6:33640908	ITPR3	0.32	5.42	0.32	1.34e-7	Height;
CESC	cis	rs4604732	0.642	rs4266925	chr1:247639165	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.46	6.57	0.37	2.64e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs36051895	0.623	rs72703608	chr9:5258127	A/G	cg02405213	chr9:5042618	JAK2	-0.55	-6.12	-0.35	3.44e-9	Pediatric autoimmune diseases;
CESC	cis	rs2115630	0.645	rs3825877	chr15:85174631	G/A	cg12501888	chr15:85177176	SCAND2	-0.48	-6.34	-0.36	9.89e-10	P wave terminal force;
CESC	cis	rs6540559	0.605	rs3753518	chr1:209977964	G/C	cg21951975	chr1:209979733	IRF6	0.63	7.76	0.43	1.86e-13	Cleft lip with or without cleft palate;
CESC	trans	rs634534	0.561	rs14157	chr11:65769780	T/G	cg17712092	chr4:129076599	LARP1B	0.73	10.25	0.53	5.63e-21	Sum eosinophil basophil counts;Eosinophil counts;
CESC	cis	rs763121	0.853	rs2413547	chr22:39107338	A/G	cg06544989	chr22:39130855	UNC84B	0.51	8.87	0.48	1.07e-16	Menopause (age at onset);
CESC	cis	rs2228479	0.850	rs17226966	chr16:89825338	A/G	cg00800038	chr16:89945340	TCF25	-0.92	-7.67	-0.43	3.37e-13	Skin colour saturation;
CESC	cis	rs425277	0.583	rs3128334	chr1:2038662	G/A	cg16545954	chr1:2118288	C1orf86	-0.35	-6.69	-0.38	1.33e-10	Height;
CESC	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.12	11.36	0.57	1.25e-24	Platelet count;
CESC	cis	rs4665809	1.000	rs12469163	chr2:26283587	T/C	cg25036284	chr2:26402008	FAM59B	-0.58	-6.77	-0.38	8.35e-11	Gut microbiome composition (summer);
CESC	cis	rs9926296	0.643	rs2159114	chr16:89831841	A/G	cg04287289	chr16:89883240	FANCA	0.59	7.67	0.43	3.2e-13	Vitiligo;
CESC	cis	rs1008375	0.900	rs6851783	chr4:17578469	A/G	cg27347728	chr4:17578864	LAP3	0.49	5.56	0.32	6.68e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs2463822	1.000	rs2463821	chr11:62111662	T/C	cg06239285	chr11:62104954	ASRGL1	0.98	8.74	0.47	2.74e-16	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs2073300	0.609	rs6137948	chr20:23416845	G/A	cg12062639	chr20:23401060	NAPB	1.05	8.13	0.45	1.7e-14	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs9291683	0.552	rs11736410	chr4:10017241	G/A	cg02734326	chr4:10020555	SLC2A9	0.52	7.43	0.42	1.5e-12	Bone mineral density;
CESC	cis	rs514406	0.793	rs4500255	chr1:53213279	A/G	cg24675658	chr1:53192096	ZYG11B	0.58	7.97	0.44	4.88e-14	Monocyte count;
CESC	cis	rs3857067	1.000	rs1904094	chr4:95012459	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.52	-8.04	-0.44	3.04e-14	QT interval;
CESC	cis	rs4665809	0.590	rs10179959	chr2:26426403	G/A	cg26314531	chr2:26401878	FAM59B	-0.84	-9.15	-0.49	1.62e-17	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.830	rs17484890	chr4:99013778	T/C	cg05340658	chr4:99064831	C4orf37	0.78	11.94	0.59	1.39e-26	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7937682	0.883	rs510388	chr11:111451869	G/T	cg09085632	chr11:111637200	PPP2R1B	0.86	12.9	0.62	6.92e-30	Primary sclerosing cholangitis;
CESC	cis	rs12134245	0.776	rs61548854	chr1:92001536	C/T	cg07090678	chr1:91966139	CDC7	0.41	5.63	0.33	4.52e-8	Breast cancer;
CESC	cis	rs34172651	0.517	rs36113933	chr16:24838862	A/G	cg04756594	chr16:24857601	SLC5A11	0.49	5.99	0.35	6.68e-9	Intelligence (multi-trait analysis);
CESC	cis	rs1799949	1.000	rs1824889	chr17:41421876	C/G	cg25072359	chr17:41440525	NA	0.46	6.21	0.36	2.04e-9	Menopause (age at onset);
CESC	cis	rs6952808	0.825	rs11761818	chr7:1935273	C/T	cg00106254	chr7:1943704	MAD1L1	-0.5	-6.25	-0.36	1.67e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs477895	0.653	rs2015226	chr11:63902534	C/T	cg18225595	chr11:63971243	STIP1	0.52	5.13	0.3	5.55e-7	Mean platelet volume;
CESC	cis	rs921968	0.643	rs586374	chr2:219383003	A/C	cg02176678	chr2:219576539	TTLL4	0.43	7.69	0.43	2.95e-13	Mean corpuscular hemoglobin concentration;
CESC	cis	rs11997175	0.524	rs12164218	chr8:33669658	G/C	ch.8.33884649F	chr8:33765107	NA	0.51	6.22	0.36	1.97e-9	Body mass index;
CESC	cis	rs941408	0.515	rs7253128	chr19:2776982	C/T	cg06609049	chr19:2785107	THOP1	0.88	13.46	0.64	7.89e-32	Total cholesterol levels;
CESC	cis	rs10197940	0.624	rs6731486	chr2:152410732	C/T	cg19508488	chr2:152266495	RIF1	-0.5	-5.98	-0.34	7.14e-9	Lung cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	ch.4.2917740F	chr4:159758027	FNIP2	-0.54	-6.04	-0.35	5.1e-9	Gut microbiome composition (summer);
CESC	trans	rs11098499	0.863	rs6534141	chr4:120485223	A/T	cg25214090	chr10:38739885	LOC399744	0.67	9.14	0.49	1.7e-17	Corneal astigmatism;
CESC	cis	rs1062753	0.922	rs9611712	chr22:42410993	T/C	cg22189786	chr22:42395067	WBP2NL	0.42	5.24	0.31	3.29e-7	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
CESC	cis	rs397969	0.570	rs62066349	chr17:19899940	C/G	cg12073167	chr17:19770448	ULK2	-0.47	-5.34	-0.31	2.04e-7	Platelet count;
CESC	cis	rs3857536	0.740	rs4710572	chr6:66890361	C/A	cg07460842	chr6:66804631	NA	-0.41	-5.36	-0.31	1.82e-7	Blood trace element (Cu levels);
CESC	cis	rs4919087	0.715	rs8181326	chr10:98998195	G/A	cg25902810	chr10:99078978	FRAT1	0.58	7.81	0.43	1.31e-13	Monocyte count;
CESC	cis	rs796364	0.806	rs10445792	chr2:201078821	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.75	-6.26	-0.36	1.54e-9	Schizophrenia;
CESC	trans	rs61931739	0.500	rs10772160	chr12:34456848	G/A	cg26384229	chr12:38710491	ALG10B	0.54	7.5	0.42	9.79e-13	Morning vs. evening chronotype;
CESC	cis	rs3749237	0.595	rs11130192	chr3:49467206	C/G	cg06212747	chr3:49208901	KLHDC8B	0.49	6.53	0.37	3.25e-10	Resting heart rate;
CESC	cis	rs2425143	1.000	rs2295356	chr20:34252856	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.83	-7.54	-0.42	7.65e-13	Blood protein levels;
CESC	cis	rs7044106	0.762	rs12003646	chr9:123470621	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.34	5.16	0.3	4.83e-7	Hip circumference adjusted for BMI;
CESC	trans	rs2867695	0.590	rs11727456	chr4:81181908	C/T	cg01943478	chr2:176032600	ATF2;MIR933	-0.73	-6.24	-0.36	1.71e-9	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CESC	cis	rs2732480	0.577	rs2732466	chr12:48732459	A/G	cg04545296	chr12:48745243	ZNF641	0.44	7.24	0.41	4.8e-12	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs7078219	0.543	rs7092009	chr10:101277239	A/G	cg09788492	chr10:101292477	NKX2-3	0.32	6.0	0.35	6.52e-9	Dental caries;
CESC	cis	rs763121	0.853	rs6001182	chr22:39047443	A/G	cg14440974	chr22:39074834	NA	-0.4	-5.48	-0.32	9.77e-8	Menopause (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23086892	chr6:38670856	GLO1	0.56	6.17	0.35	2.55e-9	Gut microbiome composition (summer);
CESC	cis	rs11864453	0.963	rs7185215	chr16:72034864	T/C	cg01557791	chr16:72042693	DHODH	-0.66	-9.0	-0.48	4.38e-17	Fibrinogen levels;
CESC	cis	rs5769765	0.862	rs9616392	chr22:50314705	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.58	-5.93	-0.34	9.49e-9	Schizophrenia;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg15193461	chr17:42977049	CCDC103;EFTUD2	-0.46	-6.28	-0.36	1.42e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs853679	0.517	rs4713152	chr6:28137454	G/A	cg17949981	chr6:28129498	ZNF389	0.42	5.24	0.31	3.27e-7	Depression;
CESC	cis	rs6701037	0.625	rs67332874	chr1:175128537	G/A	cg00321850	chr1:175162397	KIAA0040	-0.43	-6.2	-0.36	2.1e-9	Alcohol dependence;
CESC	trans	rs1814175	0.727	rs2140597	chr11:49873946	G/A	cg03929089	chr4:120376271	NA	-0.91	-15.11	-0.68	1.3e-37	Height;
CESC	cis	rs3862030	0.503	rs10786673	chr10:104280537	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.55	7.59	0.42	5.46e-13	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
CESC	cis	rs9916302	0.808	rs12948906	chr17:37644854	C/T	cg15445000	chr17:37608096	MED1	0.41	6.83	0.39	5.8200000000000003e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs6540559	0.611	rs11810817	chr1:210011747	C/G	cg25204440	chr1:209979598	IRF6	0.53	5.23	0.31	3.44e-7	Cleft lip with or without cleft palate;
CESC	trans	rs60380162	0.963	rs58458824	chr1:87726966	G/C	cg20163645	chr8:1900353	ARHGEF10	-0.43	-6.0	-0.35	6.5e-9	Loneliness (linear analysis);
CESC	cis	rs2762353	0.595	rs10498728	chr6:25751320	A/T	cg12310025	chr6:25882481	NA	-0.6	-9.19	-0.49	1.22e-17	Blood metabolite levels;
CESC	cis	rs12497850	0.864	rs4521268	chr3:49137904	G/T	cg03060546	chr3:49711283	APEH	0.52	6.34	0.36	1e-9	Parkinson's disease;
CESC	cis	rs1023500	0.573	rs6002592	chr22:42476754	A/C	cg12850546	chr22:42539477	CYP2D7P1	0.43	5.12	0.3	5.88e-7	Schizophrenia;
CESC	cis	rs11122272	0.701	rs11582413	chr1:231530098	C/G	cg06096015	chr1:231504339	EGLN1	0.43	6.15	0.35	2.9e-9	Hemoglobin concentration;
CESC	cis	rs258892	0.894	rs155435	chr5:72200093	G/A	cg21869765	chr5:72125136	TNPO1	0.45	5.62	0.33	4.9e-8	Small cell lung carcinoma;
CESC	cis	rs34779708	0.931	rs66887762	chr10:35330577	C/T	cg04310649	chr10:35416472	CREM	-0.5	-5.96	-0.34	7.83e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg11494091	chr17:61959527	GH2	0.71	12.56	0.61	1.05e-28	Prudent dietary pattern;
CESC	cis	rs2549003	1.000	rs2070723	chr5:131823187	A/G	cg00255919	chr5:131827918	IRF1	0.51	8.51	0.46	1.26e-15	Asthma (sex interaction);
CESC	cis	rs7824557	0.628	rs6601580	chr8:11193736	T/G	cg21775007	chr8:11205619	TDH	0.55	8.74	0.47	2.75e-16	Retinal vascular caliber;
CESC	cis	rs2742234	1.000	rs1864399	chr10:43610455	T/C	cg15436174	chr10:43711423	RASGEF1A	-0.41	-5.08	-0.3	7.03e-7	Hirschsprung disease;
CESC	cis	rs2033711	0.840	rs10423138	chr19:58928302	T/C	cg13877915	chr19:58951672	ZNF132	0.39	5.81	0.34	1.83e-8	Uric acid clearance;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg21014120	chr2:203736523	ICA1L	-0.45	-6.49	-0.37	4.28e-10	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs9650657	0.537	rs4841457	chr8:10773511	T/G	cg06636001	chr8:8085503	FLJ10661	-0.57	-7.31	-0.41	3.1e-12	Neuroticism;
CESC	cis	rs4665809	1.000	rs6709595	chr2:26259885	A/G	cg27170947	chr2:26402098	FAM59B	-0.57	-6.75	-0.38	9.46e-11	Gut microbiome composition (summer);
CESC	cis	rs2635047	1.000	rs2635043	chr18:44679769	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.5	6.8	0.39	7.02e-11	Educational attainment;
CESC	cis	rs66573146	0.561	rs67245546	chr4:6947164	T/C	cg26116260	chr4:7069785	GRPEL1	-0.83	-5.11	-0.3	6.23e-7	Granulocyte percentage of myeloid white cells;
CESC	cis	rs10129255	0.912	rs6576227	chr14:107186441	A/G	cg07958169	chr14:107095056	NA	-0.42	-5.87	-0.34	1.28e-8	Kawasaki disease;
CESC	cis	rs258892	0.895	rs6871969	chr5:72085036	C/T	cg21869765	chr5:72125136	TNPO1	-0.42	-5.42	-0.32	1.36e-7	Small cell lung carcinoma;
CESC	cis	rs1552244	0.882	rs13063929	chr3:10010308	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.87	11.36	0.57	1.3e-24	Alzheimer's disease;
CESC	cis	rs2549003	0.934	rs2549006	chr5:131827065	A/G	cg00255919	chr5:131827918	IRF1	-0.6	-10.0	-0.52	3.52e-20	Asthma (sex interaction);
CESC	cis	rs8067354	0.574	rs2526358	chr17:57942585	A/G	cg13753209	chr17:57696993	CLTC	0.54	5.67	0.33	3.75e-8	Hemoglobin concentration;
CESC	cis	rs703842	1.000	rs10877012	chr12:58162085	G/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.73	9.4	0.5	2.63e-18	Multiple sclerosis;
CESC	cis	rs116095464	0.558	rs10060089	chr5:205565	G/A	cg16372103	chr5:203701	NA	0.49	5.29	0.31	2.6e-7	Breast cancer;
CESC	cis	rs10504229	1.000	rs76944716	chr8:58191643	T/C	cg24829409	chr8:58192753	C8orf71	-0.78	-10.21	-0.53	7.21e-21	Developmental language disorder (linguistic errors);
CESC	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg24503407	chr1:205819492	PM20D1	0.81	12.58	0.61	9.28e-29	Menarche (age at onset);
CESC	cis	rs1595825	0.891	rs6733834	chr2:198518709	C/G	cg10820045	chr2:198174542	NA	-0.43	-5.44	-0.32	1.24e-7	Ulcerative colitis;
CESC	cis	rs2011503	1.000	rs80200208	chr19:19554725	C/T	cg11584989	chr19:19387371	SF4	0.62	7.22	0.41	5.54e-12	Bipolar disorder;
CESC	trans	rs11098499	0.863	rs17050695	chr4:120489527	G/T	cg25214090	chr10:38739885	LOC399744	0.64	8.52	0.46	1.23e-15	Corneal astigmatism;
CESC	cis	rs2979489	0.773	rs10954993	chr8:30303388	C/T	cg26383811	chr8:30366931	RBPMS	0.82	9.85	0.52	1.02e-19	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CESC	cis	rs2286503	0.780	rs1304431	chr7:22865412	T/C	cg13679077	chr7:22862647	TOMM7	0.52	6.78	0.38	7.96e-11	Fibrinogen;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06883736	chr1:182992627	LAMC1	0.55	6.18	0.35	2.41e-9	Gut microbiome composition (summer);
CESC	cis	rs798766	1.000	rs4865463	chr4:1742400	T/C	cg07041428	chr4:1763019	NA	-0.4	-5.67	-0.33	3.75e-8	Bladder cancer;Urinary bladder cancer;
CESC	cis	rs13108904	0.870	rs4974542	chr4:1250908	A/G	cg00684032	chr4:1343700	KIAA1530	0.41	5.77	0.33	2.22e-8	Obesity-related traits;
CESC	cis	rs7000551	0.532	rs4872486	chr8:22256359	G/T	cg12081754	chr8:22256438	SLC39A14	0.84	12.46	0.61	2.34e-28	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CESC	cis	rs7149337	0.805	rs4350491	chr14:51675798	A/G	cg23942311	chr14:51606299	NA	0.45	7.55	0.42	6.84e-13	Cancer;
CESC	cis	rs8114671	0.562	rs34837802	chr20:33424908	C/G	cg06115741	chr20:33292138	TP53INP2	0.43	5.26	0.31	2.94e-7	Height;
CESC	cis	rs10883723	0.810	rs13287	chr10:104240438	A/G	ch.10.2196322F	chr10:104248062	ACTR1A	0.43	5.25	0.31	3.18e-7	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs72781680	0.611	rs72797810	chr2:24336469	G/A	cg08917208	chr2:24149416	ATAD2B	0.56	5.49	0.32	9.59e-8	Lymphocyte counts;
CESC	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg18404041	chr3:52824283	ITIH1	-0.36	-6.52	-0.37	3.61e-10	Electroencephalogram traits;
CESC	cis	rs36051895	0.632	rs72701654	chr9:5161453	T/C	cg02405213	chr9:5042618	JAK2	-0.49	-5.53	-0.32	7.59e-8	Pediatric autoimmune diseases;
CESC	cis	rs2836974	0.604	rs2854727	chr21:40713787	A/G	cg11644478	chr21:40555479	PSMG1	0.59	8.09	0.44	2.2e-14	Cognitive function;
CESC	cis	rs8099014	0.559	rs9319928	chr18:56099996	T/G	cg12827950	chr18:55968429	NEDD4L	-0.53	-5.66	-0.33	3.92e-8	Platelet count;
CESC	cis	rs6736093	0.897	rs4848874	chr2:112681500	A/G	cg12686935	chr2:112915763	FBLN7	-0.44	-5.72	-0.33	2.86e-8	Coronary artery disease;
CESC	cis	rs2204008	0.715	rs11514342	chr12:38236710	T/A	cg26384229	chr12:38710491	ALG10B	0.69	9.8	0.52	1.51e-19	Bladder cancer;
CESC	cis	rs1707322	1.000	rs7527079	chr1:46413450	C/G	cg05343316	chr1:45956843	TESK2	0.44	5.42	0.32	1.36e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04928513	chr20:60717545	PSMA7;SS18L1	-0.57	-6.62	-0.38	2e-10	Gut microbiome composition (summer);
CESC	cis	rs929354	0.713	rs10085650	chr7:156993413	T/C	cg05182265	chr7:156933206	UBE3C	-0.51	-7.42	-0.41	1.57e-12	Body mass index;
CESC	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg03647317	chr4:187891568	NA	-0.38	-5.33	-0.31	2.09e-7	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1355223	0.506	rs1828299	chr11:34870418	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.55	-6.64	-0.38	1.81e-10	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs8017423	0.647	rs4904680	chr14:90822075	C/T	cg14092571	chr14:90743983	NA	0.44	6.82	0.39	6.11e-11	Mortality in heart failure;
CESC	cis	rs7208859	0.614	rs216412	chr17:28903394	A/G	cg14008862	chr17:28927542	LRRC37B2	-0.67	-6.44	-0.37	5.67e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs6681460	0.966	rs10789214	chr1:67146817	C/T	cg02459107	chr1:67143332	SGIP1	0.38	5.25	0.31	3.1e-7	Presence of antiphospholipid antibodies;
CESC	cis	rs2479106	0.549	rs1928482	chr9:126432448	T/C	cg16191174	chr9:126692580	DENND1A	0.4	5.7	0.33	3.21e-8	Polycystic ovary syndrome;
CESC	cis	rs1552244	0.554	rs6762397	chr3:10007840	C/T	cg00149659	chr3:10157352	C3orf10	0.57	7.1	0.4	1.17e-11	Alzheimer's disease;
CESC	cis	rs597539	0.652	rs10792001	chr11:68637737	G/C	cg06028808	chr11:68637592	NA	0.43	5.12	0.3	5.87e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs9910055	0.718	rs7212854	chr17:42254417	A/G	cg08499158	chr17:42289980	UBTF	-0.51	-6.52	-0.37	3.47e-10	Total body bone mineral density;
CESC	cis	rs6942756	0.876	rs822039	chr7:129065774	A/G	cg02491457	chr7:128862824	NA	-0.52	-7.07	-0.4	1.4e-11	White matter hyperintensity burden;
CESC	cis	rs6952808	0.501	rs3778999	chr7:2180885	G/A	cg23048001	chr7:2026167	MAD1L1	0.41	5.27	0.31	2.89e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg11494091	chr17:61959527	GH2	0.73	12.57	0.61	1e-28	Prudent dietary pattern;
CESC	cis	rs7811142	1.000	rs67163493	chr7:100023838	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.01	9.85	0.52	1.05e-19	Platelet count;
CESC	cis	rs13191362	1.000	rs13195226	chr6:163006421	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.49	5.36	0.31	1.82e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	trans	rs7726839	0.507	rs111707179	chr5:593308	T/A	cg25482853	chr8:67687455	SGK3	1.03	9.89	0.52	7.86e-20	Obesity-related traits;
CESC	cis	rs4563143	0.647	rs73029014	chr19:29257655	G/C	cg12667521	chr19:29218732	NA	0.47	6.25	0.36	1.64e-9	Methadone dose in opioid dependence;
CESC	cis	rs35146811	0.844	rs4729576	chr7:99692594	G/A	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.48	5.88	0.34	1.2e-8	Coronary artery disease;
CESC	cis	rs3008870	0.920	rs1925413	chr1:67417101	T/C	cg08660285	chr1:67390436	MIER1;WDR78	1.04	14.53	0.67	1.38e-35	Lymphocyte percentage of white cells;
CESC	cis	rs6089584	0.927	rs2296083	chr20:60574216	C/T	cg06108461	chr20:60628389	TAF4	-0.8	-11.58	-0.58	2.38e-25	Body mass index;
CESC	cis	rs10992471	0.756	rs11792342	chr9:95143668	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.45	-5.68	-0.33	3.52e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CESC	trans	rs561341	1.000	rs550264	chr17:30317540	G/T	cg27661571	chr11:113659931	NA	-0.83	-7.7	-0.43	2.79e-13	Hip circumference adjusted for BMI;
CESC	cis	rs12410462	0.681	rs115956039	chr1:227661978	G/A	cg23173402	chr1:227635558	NA	0.71	6.11	0.35	3.57e-9	Major depressive disorder;
CESC	cis	rs8005677	1.000	rs7155857	chr14:23400059	C/A	cg25600027	chr14:23388339	RBM23	-0.43	-5.24	-0.31	3.22e-7	Cognitive ability (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23663318	chr1:89448407	RBMXL1;CCBL2	-0.5	-6.22	-0.36	1.88e-9	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17823076	chr12:53574937	ZNF740;CSAD	0.6	7.1	0.4	1.13e-11	Gut microbiome composition (summer);
CESC	cis	rs7613875	0.600	rs1138536	chr3:50153356	C/T	cg24110177	chr3:50126178	RBM5	-0.5	-6.95	-0.39	2.83e-11	Body mass index;
CESC	cis	rs875971	0.862	rs801203	chr7:66023012	A/G	cg12463550	chr7:65579703	CRCP	-0.5	-6.32	-0.36	1.08e-9	Aortic root size;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg20273774	chr5:180671298	GNB2L1;SNORD95	-0.45	-6.06	-0.35	4.67e-9	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08648346	chr2:95825642	ZNF514	0.61	6.73	0.38	1.04e-10	Gut microbiome composition (summer);
CESC	cis	rs2952156	0.959	rs2517956	chr17:37843859	G/A	cg00129232	chr17:37814104	STARD3	-0.72	-9.44	-0.5	2e-18	Asthma;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg24583131	chr6:18265189	DEK	0.5	6.6	0.38	2.2e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs6952808	0.689	rs871924	chr7:2047845	A/G	cg02951883	chr7:2050386	MAD1L1	-0.56	-7.4	-0.41	1.75e-12	Bipolar disorder and schizophrenia;
CESC	cis	rs9926296	0.744	rs154657	chr16:89708096	A/G	cg27121462	chr16:89883253	FANCA	0.45	5.37	0.31	1.74e-7	Vitiligo;
CESC	trans	rs561341	1.000	rs497479	chr17:30328605	C/T	cg27661571	chr11:113659931	NA	-0.8	-7.58	-0.42	5.95e-13	Hip circumference adjusted for BMI;
CESC	cis	rs7678296	1.000	rs73142714	chr4:37179884	G/A	cg06805348	chr4:37245195	KIAA1239	0.44	5.12	0.3	5.78e-7	3-hydroxypropylmercapturic acid levels in smokers;
CESC	cis	rs6456156	0.586	rs6456150	chr6:167468922	A/G	cg23791538	chr6:167370224	RNASET2	-0.5	-6.46	-0.37	4.9e-10	Primary biliary cholangitis;
CESC	cis	rs7647973	0.626	rs1996663	chr3:49878264	C/G	cg03060546	chr3:49711283	APEH	-0.62	-7.59	-0.42	5.49e-13	Menarche (age at onset);
CESC	cis	rs4450798	0.649	rs9845991	chr3:13778031	C/A	cg23332027	chr3:13681764	NA	0.38	5.2	0.3	4.01e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs564309	0.681	rs2230656	chr1:228612838	G/T	cg13771378	chr1:228613100	HIST3H3	0.54	5.22	0.31	3.57e-7	Hip circumference (psychosocial stress interaction);
CESC	cis	rs1799949	1.000	rs3092994	chr17:41215825	C/T	cg23758822	chr17:41437982	NA	1.02	15.37	0.69	1.45e-38	Menopause (age at onset);
CESC	cis	rs921968	0.541	rs12987171	chr2:219327030	G/C	cg02176678	chr2:219576539	TTLL4	0.5	8.91	0.48	8.53e-17	Mean corpuscular hemoglobin concentration;
CESC	cis	rs6831352	0.703	rs2602854	chr4:100028651	C/T	cg13256891	chr4:100009986	ADH5	0.7	8.18	0.45	1.19e-14	Alcohol dependence;
CESC	trans	rs11098499	0.954	rs10518328	chr4:120401779	G/A	cg25214090	chr10:38739885	LOC399744	0.72	10.09	0.53	1.79e-20	Corneal astigmatism;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg04048796	chr4:57301372	PAICS;PPAT	-0.45	-6.23	-0.36	1.87e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs11971779	0.816	rs11979272	chr7:139074069	C/T	cg07862535	chr7:139043722	LUC7L2	0.56	5.65	0.33	4.1e-8	Diisocyanate-induced asthma;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg05296608	chr10:134537282	INPP5A	0.47	6.43	0.37	5.87e-10	Fibrinogen levels;
CESC	cis	rs909674	0.775	rs4821896	chr22:39833437	T/C	cg11247378	chr22:39784982	NA	-0.58	-8.49	-0.46	1.53e-15	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs875971	0.862	rs6952182	chr7:65683317	T/G	cg18876405	chr7:65276391	NA	-0.55	-7.55	-0.42	7.19e-13	Aortic root size;
CESC	cis	rs9649213	0.593	rs3801263	chr7:97965016	A/G	cg08684580	chr7:98029266	BAIAP2L1	-0.35	-5.77	-0.33	2.2e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs116095464	0.558	rs62347677	chr5:227453	A/G	cg22857025	chr5:266934	NA	-1.27	-18.49	-0.75	1.32e-49	Breast cancer;
CESC	cis	rs2066819	1.000	rs58852079	chr12:56706922	A/C	cg26714650	chr12:56694279	CS	-1.48	-9.9	-0.52	7.03e-20	Psoriasis vulgaris;
CESC	cis	rs6539267	0.741	rs35816179	chr12:106693710	T/C	cg02476566	chr12:106696527	TCP11L2	0.58	6.84	0.39	5.59e-11	Tourette syndrome;
CESC	trans	rs8073060	0.544	rs7210966	chr17:33986334	G/C	cg19694781	chr19:47549865	TMEM160	-0.75	-7.42	-0.41	1.55e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	cis	rs7824557	0.872	rs2572431	chr8:11105077	C/T	cg21775007	chr8:11205619	TDH	-0.39	-5.72	-0.33	2.82e-8	Retinal vascular caliber;
CESC	cis	rs16854884	0.632	rs35716467	chr3:143684993	C/A	cg06585982	chr3:143692056	C3orf58	0.53	7.02	0.4	1.83e-11	Economic and political preferences (feminism/equality);
CESC	cis	rs6009527	0.963	rs6009532	chr22:49572757	C/G	cg12746016	chr22:49560550	NA	0.34	5.32	0.31	2.25e-7	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);
CESC	cis	rs2635047	0.935	rs2461247	chr18:44698537	T/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.47	6.36	0.36	8.56e-10	Educational attainment;
CESC	cis	rs35306767	0.953	rs35174953	chr10:961191	C/A	cg10556349	chr10:835070	NA	0.57	6.07	0.35	4.29e-9	Eosinophil percentage of granulocytes;
CESC	cis	rs12824058	0.831	rs4759657	chr12:130815818	G/A	cg24838063	chr12:130822603	PIWIL1	0.63	8.58	0.47	7.91e-16	Menopause (age at onset);
CESC	cis	rs7714584	1.000	rs10058943	chr5:150226586	A/G	cg22134413	chr5:150180641	NA	0.52	5.64	0.33	4.31e-8	Crohn's disease;
CESC	cis	rs9467711	0.516	rs548987	chr6:25869371	C/G	cg21479132	chr6:26055353	NA	0.57	6.17	0.35	2.51e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs9581857	0.615	rs9581848	chr13:28003997	C/T	cg22138327	chr13:27999177	GTF3A	0.66	5.35	0.31	1.9e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
CESC	cis	rs59918340	0.764	rs4961339	chr8:142231504	A/G	cg23750338	chr8:142222470	SLC45A4	0.63	9.64	0.51	4.88e-19	Immature fraction of reticulocytes;
CESC	cis	rs11785400	1.000	rs6997670	chr8:143737915	G/A	cg10596483	chr8:143751796	JRK	0.43	5.65	0.33	4.1e-8	Schizophrenia;
CESC	cis	rs7635838	0.684	rs346079	chr3:11328139	G/A	cg00170343	chr3:11313890	ATG7	0.56	8.18	0.45	1.16e-14	HDL cholesterol;
CESC	cis	rs896854	0.654	rs16893776	chr8:95973604	C/T	cg23172400	chr8:95962367	TP53INP1	-0.41	-8.29	-0.45	5.85e-15	Type 2 diabetes;
CESC	cis	rs4711336	0.935	rs3818529	chr6:33661106	T/C	cg15676125	chr6:33679581	C6orf125	0.36	5.35	0.31	1.89e-7	Height;
CESC	cis	rs11167764	1.000	rs11167764	chr5:141479065	A/C	cg08523384	chr5:141488047	NDFIP1	-0.34	-5.09	-0.3	6.87e-7	Crohn's disease;
CESC	trans	rs561341	0.700	rs2074101	chr17:30228656	G/A	cg20587970	chr11:113659929	NA	-0.61	-7.94	-0.44	5.68e-14	Hip circumference adjusted for BMI;
CESC	cis	rs780096	0.546	rs715325	chr2:27725572	C/A	cg02592271	chr2:27665507	KRTCAP3	-0.35	-7.02	-0.4	1.84e-11	Total body bone mineral density;
CESC	cis	rs2898681	0.519	rs7670068	chr4:53733984	T/G	cg00791764	chr4:53727839	RASL11B	0.43	5.12	0.3	5.82e-7	Optic nerve measurement (cup area);
CESC	cis	rs9916302	0.861	rs644173	chr17:37430519	T/C	cg07936489	chr17:37558343	FBXL20	-0.79	-11.47	-0.58	5.27e-25	Glomerular filtration rate (creatinine);
CESC	cis	rs7605827	0.836	rs2052436	chr2:15697518	T/C	cg19274914	chr2:15703543	NA	0.3	5.39	0.31	1.59e-7	Educational attainment (years of education);
CESC	cis	rs6582630	0.555	rs11610015	chr12:38508856	A/G	cg13010199	chr12:38710504	ALG10B	0.42	5.47	0.32	1.05e-7	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs4835473	0.897	rs6537172	chr4:144631765	C/T	cg25736465	chr4:144833511	NA	0.4	6.24	0.36	1.74e-9	Immature fraction of reticulocytes;
CESC	cis	rs2204008	0.658	rs11495742	chr12:38395688	C/A	cg26384229	chr12:38710491	ALG10B	0.73	10.43	0.54	1.42e-21	Bladder cancer;
CESC	cis	rs9611565	0.512	rs139561	chr22:42195410	C/T	cg17376030	chr22:41985996	PMM1	-0.74	-8.03	-0.44	3.24e-14	Vitiligo;
CESC	cis	rs5750830	0.649	rs5750811	chr22:39793066	G/T	cg11247378	chr22:39784982	NA	0.6	8.68	0.47	4.06e-16	Intelligence (multi-trait analysis);
CESC	cis	rs9640161	0.702	rs11765692	chr7:150026567	C/T	cg21361702	chr7:150065534	REPIN1	0.49	5.77	0.33	2.24e-8	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs9611565	0.512	rs5758436	chr22:42124265	C/T	cg17376030	chr22:41985996	PMM1	-0.79	-8.55	-0.46	1e-15	Vitiligo;
CESC	cis	rs10791323	0.546	rs55801927	chr11:133713094	A/C	cg06766960	chr11:133703094	NA	-0.4	-5.67	-0.33	3.7e-8	Childhood ear infection;
CESC	trans	rs10506458	1.000	rs12580997	chr12:63433420	G/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.32	-17.48	-0.73	4.95e-46	Hemostatic factors and hematological phenotypes;
CESC	cis	rs5769707	0.967	rs763127	chr22:50006078	C/T	cg20744362	chr22:50050164	C22orf34	0.48	8.45	0.46	1.95e-15	Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs7481584	1.000	rs7481584	chr11:3029089	G/A	cg25174290	chr11:3078921	CARS	-0.43	-5.41	-0.32	1.43e-7	Calcium levels;
CESC	cis	rs9486719	1.000	rs11152959	chr6:96900272	C/T	cg18709589	chr6:96969512	KIAA0776	-0.54	-5.87	-0.34	1.3e-8	Migraine;Coronary artery disease;
CESC	cis	rs9549367	0.789	rs6577031	chr13:113878182	T/C	cg00898013	chr13:113819073	PROZ	0.5	7.52	0.42	8.49e-13	Platelet distribution width;
CESC	cis	rs7264396	0.666	rs1536147	chr20:34173046	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.49	6.47	0.37	4.64e-10	Total cholesterol levels;
CESC	cis	rs4423214	0.879	rs4945008	chr11:71221248	A/G	cg24826892	chr11:71159390	DHCR7	0.45	5.31	0.31	2.37e-7	Vitamin D levels;
CESC	cis	rs5167	0.504	rs4803779	chr19:45456497	T/C	cg13119609	chr19:45449297	APOC2	0.49	8.03	0.44	3.23e-14	Blood protein levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02222103	chr17:5389592	DERL2;MIS12	-0.66	-8.14	-0.45	1.58e-14	Gut microbiome composition (summer);
CESC	cis	rs367615	0.512	rs246104	chr5:108700982	A/C	cg17395555	chr5:108820864	NA	-0.54	-8.71	-0.47	3.45e-16	Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs6933660	0.760	rs6904364	chr6:151754273	T/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.44	-5.62	-0.33	4.93e-8	Menarche (age at onset);
CESC	cis	rs4664308	1.000	rs6707458	chr2:160914540	G/T	cg03641300	chr2:160917029	PLA2R1	-0.67	-10.07	-0.53	2.06e-20	Idiopathic membranous nephropathy;
CESC	cis	rs713587	0.806	rs6737082	chr2:25138040	A/C	cg01884057	chr2:25150051	NA	0.39	7.29	0.41	3.65e-12	Body mass index in non-asthmatics;
CESC	cis	rs2732480	0.500	rs2450986	chr12:48661688	G/A	cg04545296	chr12:48745243	ZNF641	0.42	7.06	0.4	1.47e-11	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs6089584	0.888	rs2386555	chr20:60612373	C/T	cg06108461	chr20:60628389	TAF4	-0.93	-14.4	-0.66	4.08e-35	Body mass index;
CESC	cis	rs5750830	0.649	rs7949	chr22:39827553	G/A	cg05872129	chr22:39784769	NA	-0.82	-11.17	-0.57	5.22e-24	Intelligence (multi-trait analysis);
CESC	cis	rs11025559	0.796	rs10833317	chr11:20412277	A/T	cg19653624	chr11:20408972	PRMT3	-0.47	-5.43	-0.32	1.3e-7	Pursuit maintenance gain;
CESC	cis	rs769267	0.930	rs747050	chr19:19584987	C/G	cg03709012	chr19:19516395	GATAD2A	1.01	15.7	0.69	1.02e-39	Tonsillectomy;
CESC	cis	rs9532580	0.620	rs2755210	chr13:41141282	C/G	cg21288729	chr13:41239152	FOXO1	0.69	8.04	0.44	2.92e-14	Mean corpuscular hemoglobin;
CESC	cis	rs1950626	0.833	rs72700524	chr14:101417309	G/A	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.79	10.67	0.55	2.42e-22	Pelvic organ prolapse (moderate/severe);
CESC	trans	rs208520	0.874	rs208512	chr6:66943869	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.81	-9.39	-0.5	2.82e-18	Exhaled nitric oxide output;
CESC	cis	rs9768139	0.733	rs71545585	chr7:158118672	G/A	cg24154853	chr7:158122151	PTPRN2	0.43	6.61	0.38	2.07e-10	Calcium levels;
CESC	cis	rs3105593	1.000	rs62017206	chr15:50955626	A/G	cg08437265	chr15:50716283	USP8	0.44	5.66	0.33	3.95e-8	QT interval;
CESC	cis	rs4243830	0.850	rs4434862	chr1:6602241	C/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.99	-10.01	-0.52	3.22e-20	Body mass index;
CESC	cis	rs2087017	0.744	rs9816914	chr3:113816942	T/A	cg11311190	chr3:113822454	NA	-0.33	-5.91	-0.34	1.08e-8	Personality dimensions;
CESC	cis	rs2953174	0.744	rs2975748	chr2:241518989	A/G	cg07929629	chr2:241523174	NA	0.56	6.09	0.35	3.97e-9	Bipolar disorder;
CESC	cis	rs910316	0.967	rs175432	chr14:75615246	C/G	cg08847533	chr14:75593920	NEK9	-0.96	-17.56	-0.73	2.63e-46	Height;
CESC	cis	rs2075371	1.000	rs7486	chr7:133975183	A/G	cg00033643	chr7:134001901	SLC35B4	0.42	5.47	0.32	1.04e-7	Mean platelet volume;
CESC	cis	rs703842	0.616	rs10877024	chr12:58226709	C/T	cg00677455	chr12:58241039	CTDSP2	0.72	9.86	0.52	1.01e-19	Multiple sclerosis;
CESC	cis	rs875971	0.522	rs709604	chr7:65497434	A/G	cg14393609	chr7:65229607	NA	-0.54	-7.27	-0.41	4.06e-12	Aortic root size;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg26551688	chr8:103822898	NA	-0.45	-6.14	-0.35	2.95e-9	Fibrinogen levels;
CESC	cis	rs2637266	0.714	rs7895605	chr10:78454207	G/A	cg18941641	chr10:78392320	NA	0.43	7.82	0.43	1.23e-13	Pulmonary function;
CESC	cis	rs7811142	1.000	rs113738841	chr7:100081306	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.98	10.55	0.54	5.96e-22	Platelet count;
CESC	cis	rs56161922	0.908	rs113826410	chr1:207849815	C/T	cg09557387	chr1:207818395	CR1L	0.68	5.07	0.3	7.54e-7	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
CESC	cis	rs1799949	0.965	rs7212284	chr17:41205941	A/G	cg23758822	chr17:41437982	NA	0.94	15.65	0.69	1.46e-39	Menopause (age at onset);
CESC	cis	rs42648	0.869	rs2027965	chr7:89912513	C/T	cg23697855	chr7:89950296	NA	0.27	5.19	0.3	4.26e-7	Homocysteine levels;
CESC	cis	rs6977955	0.838	rs917116	chr7:28172739	T/G	cg23620719	chr7:28220237	JAZF1	0.53	5.99	0.35	6.74e-9	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs853679	0.517	rs4713148	chr6:28115921	G/A	cg23161317	chr6:28129485	ZNF389	0.52	6.48	0.37	4.48e-10	Depression;
CESC	cis	rs10465746	0.747	rs34155960	chr1:84447539	T/G	cg10977910	chr1:84465055	TTLL7	0.52	7.13	0.4	9.46e-12	Obesity-related traits;
CESC	cis	rs9325144	0.534	rs4882283	chr12:38710249	C/T	cg26384229	chr12:38710491	ALG10B	0.64	9.86	0.52	9.6e-20	Morning vs. evening chronotype;
CESC	cis	rs35306767	0.807	rs34885925	chr10:919032	G/C	cg20503657	chr10:835505	NA	1.07	9.49	0.5	1.43e-18	Eosinophil percentage of granulocytes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11258043	chr6:73972820	KHDC1	0.58	6.38	0.36	7.8e-10	Gut microbiome composition (summer);
CESC	cis	rs1448094	0.512	rs10863086	chr12:86244225	G/A	cg19622623	chr12:86230825	RASSF9	-0.46	-5.88	-0.34	1.22e-8	Major depressive disorder;
CESC	cis	rs9300255	0.602	rs1106240	chr12:123626982	C/T	cg00376283	chr12:123451042	ABCB9	0.62	6.76	0.38	8.89e-11	Neutrophil percentage of white cells;
CESC	trans	rs208520	1.000	rs208520	chr6:66952828	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.78	-8.69	-0.47	3.76e-16	Exhaled nitric oxide output;
CESC	cis	rs9902453	1.000	rs7222308	chr17:28277041	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.64	8.28	0.45	6.2e-15	Coffee consumption (cups per day);
CESC	cis	rs939574	1.000	rs1109866	chr2:220083279	C/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-0.55	-5.26	-0.31	2.94e-7	Platelet distribution width;
CESC	cis	rs10751667	0.857	rs6597952	chr11:991109	C/G	cg20946044	chr11:1010712	AP2A2	-0.46	-5.89	-0.34	1.17e-8	Alzheimer's disease (late onset);
CESC	cis	rs7824557	0.583	rs2263511	chr8:11233318	A/C	cg21775007	chr8:11205619	TDH	-0.53	-8.02	-0.44	3.51e-14	Retinal vascular caliber;
CESC	cis	rs7937682	0.575	rs7124696	chr11:111747297	A/G	cg09085632	chr11:111637200	PPP2R1B	0.91	12.08	0.6	4.6e-27	Primary sclerosing cholangitis;
CESC	trans	rs1728785	0.901	rs1645974	chr16:68564774	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.61	7.42	0.41	1.57e-12	Ulcerative colitis;
CESC	trans	rs9329221	0.683	rs814359	chr8:9883132	T/G	cg15556689	chr8:8085844	FLJ10661	-0.53	-6.78	-0.38	7.71e-11	Neuroticism;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02396143	chr1:29063512	YTHDF2	0.64	7.59	0.42	5.51e-13	Gut microbiome composition (summer);
CESC	cis	rs344364	0.518	rs1657129	chr16:1945826	G/A	cg26617929	chr16:1858877	NA	-0.49	-5.15	-0.3	5.09e-7	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs3740713	1.000	rs73438699	chr11:18462684	C/T	cg23797887	chr11:18477753	LDHAL6A	-0.53	-5.13	-0.3	5.58e-7	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs644799	0.932	rs480079	chr11:95643777	A/T	cg25622487	chr11:95524042	FAM76B;CEP57	-0.6	-8.13	-0.45	1.69e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs6496667	0.533	rs2601206	chr15:90962699	C/T	cg10434728	chr15:90938212	IQGAP1	0.32	5.65	0.33	4.24e-8	Rheumatoid arthritis;
CESC	cis	rs2952156	0.959	rs1495102	chr17:37832093	T/C	cg07936489	chr17:37558343	FBXL20	-0.55	-6.65	-0.38	1.68e-10	Asthma;
CESC	cis	rs4927850	0.723	rs7630825	chr3:195753740	T/C	cg00031303	chr3:195681400	NA	0.41	5.1	0.3	6.59e-7	Pancreatic cancer;
CESC	cis	rs6121246	0.909	rs6119720	chr20:30347568	T/G	cg13852791	chr20:30311386	BCL2L1	0.81	8.61	0.47	6.48e-16	Mean corpuscular hemoglobin;
CESC	cis	rs9487051	0.676	rs9386788	chr6:109600523	C/T	cg01475377	chr6:109611718	NA	0.43	6.84	0.39	5.33e-11	Reticulocyte fraction of red cells;
CESC	cis	rs453301	0.597	rs7001187	chr8:8792782	G/A	cg15556689	chr8:8085844	FLJ10661	-0.45	-5.03	-0.3	8.91e-7	Joint mobility (Beighton score);
CESC	cis	rs12765878	1.000	rs11191865	chr10:105672842	G/A	cg24587175	chr10:105670608	OBFC1	0.34	5.45	0.32	1.15e-7	Coronary artery disease;
CESC	cis	rs4665809	0.590	rs3792007	chr2:26497541	C/T	cg04944784	chr2:26401820	FAM59B	0.92	9.76	0.51	2.02e-19	Gut microbiome composition (summer);
CESC	cis	rs11098499	0.954	rs11098524	chr4:120390032	A/G	cg09307838	chr4:120376055	NA	0.94	12.47	0.61	2.1e-28	Corneal astigmatism;
CESC	cis	rs10242455	0.702	rs73711294	chr7:99088714	G/A	cg18809830	chr7:99032528	PTCD1	-0.64	-5.07	-0.3	7.31e-7	Blood metabolite levels;
CESC	cis	rs7412746	0.611	rs2280627	chr1:150935872	A/G	cg04414720	chr1:150670196	GOLPH3L	0.45	5.96	0.34	7.83e-9	Melanoma;
CESC	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg08914378	chr7:98923334	ARPC1A	0.45	6.03	0.35	5.46e-9	Myopia (pathological);
CESC	trans	rs561341	1.000	rs555629	chr17:30294136	T/C	cg27661571	chr11:113659931	NA	-0.83	-7.69	-0.43	2.82e-13	Hip circumference adjusted for BMI;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04429285	chr6:28048973	ZNF165	0.61	6.47	0.37	4.76e-10	Gut microbiome composition (summer);
CESC	trans	rs11098499	0.863	rs13140409	chr4:120503460	A/G	cg25214090	chr10:38739885	LOC399744	0.66	8.85	0.48	1.28e-16	Corneal astigmatism;
CESC	cis	rs6964587	0.869	rs4729010	chr7:91486751	G/A	cg17063962	chr7:91808500	NA	-0.53	-7.23	-0.41	5.28e-12	Breast cancer;
CESC	cis	rs780096	0.526	rs13391837	chr2:27649375	A/G	cg22903471	chr2:27725779	GCKR	-0.58	-8.48	-0.46	1.6e-15	Total body bone mineral density;
CESC	cis	rs425277	1.000	rs436045	chr1:2071556	A/G	cg24578937	chr1:2090814	PRKCZ	-0.54	-9.38	-0.5	3.12e-18	Height;
CESC	cis	rs1401999	1.000	rs7632670	chr3:183713877	A/G	cg01324343	chr3:183735012	ABCC5	0.64	13.68	0.64	1.32e-32	Anterior chamber depth;
CESC	cis	rs4975709	0.610	rs4975706	chr5:1860365	G/T	cg15595755	chr5:1867978	NA	0.51	8.38	0.46	3.17e-15	Cardiovascular disease risk factors;
CESC	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg04025307	chr7:1156635	C7orf50	0.54	9.09	0.49	2.42e-17	Longevity;Endometriosis;
CESC	cis	rs72781680	1.000	rs72796351	chr2:24158425	T/C	cg20701182	chr2:24300061	SF3B14	0.65	5.81	0.34	1.79e-8	Lymphocyte counts;
CESC	trans	rs916888	0.773	rs199535	chr17:44822662	A/G	cg04282206	chr17:62833786	PLEKHM1P	0.54	6.41	0.37	6.67e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs13095912	0.785	rs35637544	chr3:185329958	A/G	cg11274856	chr3:185301563	NA	0.39	5.73	0.33	2.71e-8	Systolic blood pressure;
CESC	cis	rs736408	0.511	rs12637632	chr3:52708073	A/T	cg17372223	chr3:52568218	NT5DC2	0.44	6.69	0.38	1.32e-10	Bipolar disorder;
CESC	cis	rs8044868	0.566	rs3812984	chr16:72207797	C/T	cg16558253	chr16:72132732	DHX38	-0.4	-6.16	-0.35	2.64e-9	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CESC	cis	rs875971	0.660	rs13224319	chr7:66007363	A/G	cg14393609	chr7:65229607	NA	0.47	6.29	0.36	1.28e-9	Aortic root size;
CESC	cis	rs9926296	0.527	rs1800335	chr16:89846195	A/G	cg21285383	chr16:89894308	SPIRE2	0.3	5.35	0.31	1.89e-7	Vitiligo;
CESC	cis	rs7605827	0.930	rs13384921	chr2:15602840	C/T	cg19274914	chr2:15703543	NA	0.37	6.59	0.38	2.38e-10	Educational attainment (years of education);
CESC	cis	rs61332075	0.500	rs55917008	chr2:239380244	C/A	cg18131467	chr2:239335373	ASB1	-0.73	-5.88	-0.34	1.23e-8	Lung function (FEV1/FVC);
CESC	cis	rs2191566	0.664	rs6509138	chr19:44570393	C/A	cg20607764	chr19:44506953	ZNF230	-0.44	-5.58	-0.32	5.88e-8	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs2425143	1.000	rs1890470	chr20:34357008	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.8	-8.0	-0.44	3.85e-14	Blood protein levels;
CESC	cis	rs10242455	0.571	rs79694709	chr7:99214711	C/G	cg25640893	chr7:99214727	ZNF498	1.15	7.65	0.43	3.65e-13	Blood metabolite levels;
CESC	cis	rs4242434	0.819	rs1059592	chr8:22477778	G/A	cg03733263	chr8:22462867	KIAA1967	0.87	14.09	0.65	5.05e-34	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CESC	cis	rs59918340	0.728	rs4961340	chr8:142232002	G/A	cg16341495	chr8:142228727	SLC45A4	-0.44	-5.29	-0.31	2.56e-7	Immature fraction of reticulocytes;
CESC	cis	rs10129255	0.518	rs8010020	chr14:107186255	A/G	cg23076370	chr14:107095027	NA	-0.65	-9.62	-0.51	5.59e-19	Kawasaki disease;
CESC	cis	rs2276314	0.762	rs3826600	chr18:33609053	A/G	cg05985134	chr18:33552581	C18orf21	0.61	7.33	0.41	2.8e-12	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs1215050	0.791	rs165250	chr4:98696259	G/A	cg05340658	chr4:99064831	C4orf37	0.49	6.3	0.36	1.26e-9	Waist-to-hip ratio adjusted for body mass index;
CESC	trans	rs62210650	0.881	rs41442149	chr21:20990343	A/C	cg17270013	chr15:79236839	CTSH	0.39	6.41	0.37	6.47e-10	Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;
CESC	cis	rs17253792	0.822	rs79921041	chr14:56090779	T/C	cg01858014	chr14:56050164	KTN1	-0.85	-6.99	-0.39	2.22e-11	Putamen volume;
CESC	cis	rs1153858	1.000	rs1145091	chr15:45649996	A/G	cg21132104	chr15:45694354	SPATA5L1	0.77	10.48	0.54	9.92e-22	Homoarginine levels;
CESC	cis	rs9929218	0.953	rs16260	chr16:68771034	C/A	cg02972257	chr16:68554789	NA	0.55	6.51	0.37	3.77e-10	Colorectal cancer;
CESC	cis	rs10504229	1.000	rs116995796	chr8:58181960	G/A	cg22535103	chr8:58192502	C8orf71	-1.05	-13.08	-0.63	1.71e-30	Developmental language disorder (linguistic errors);
CESC	cis	rs240110	0.539	rs6919745	chr6:101338978	T/C	cg09795085	chr6:101329169	ASCC3	0.46	6.0	0.35	6.5e-9	Neuroticism;
CESC	cis	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg11644478	chr21:40555479	PSMG1	-0.48	-6.22	-0.36	1.89e-9	Cognitive function;
CESC	cis	rs2839186	0.588	rs7280110	chr21:47619039	G/A	cg12516959	chr21:47718080	NA	0.41	5.97	0.34	7.7e-9	Testicular germ cell tumor;
CESC	cis	rs2243480	1.000	rs6460261	chr7:65215580	T/C	cg13147721	chr7:65941812	NA	0.88	8.1	0.45	1.96e-14	Diabetic kidney disease;
CESC	cis	rs8002861	0.905	rs12429722	chr13:44412466	T/A	cg14210620	chr13:44453864	C13orf31;CCDC122	-0.43	-5.41	-0.32	1.39e-7	Leprosy;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg22695372	chr1:94354654	GCLM	0.38	6.09	0.35	3.9e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs8114671	0.562	rs6060064	chr20:33406339	C/G	cg07148914	chr20:33460835	GGT7	-0.44	-5.85	-0.34	1.41e-8	Height;
CESC	cis	rs7216064	0.953	rs12601759	chr17:65955284	A/G	cg07042672	chr17:66097459	LOC651250	-0.54	-5.8	-0.34	1.84e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs4737010	0.501	rs990174	chr8:41632230	A/G	cg08923054	chr8:41654455	ANK1	0.47	5.81	0.34	1.74e-8	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03672602	chr19:19754555	GMIP	0.49	6.41	0.37	6.71e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs11252926	0.502	rs7072510	chr10:455596	C/T	cg03684893	chr10:554711	DIP2C	-0.36	-5.36	-0.31	1.84e-7	Psychosis in Alzheimer's disease;
CESC	cis	rs6942756	0.806	rs68184415	chr7:128988862	C/T	cg02491457	chr7:128862824	NA	-0.59	-8.37	-0.46	3.34e-15	White matter hyperintensity burden;
CESC	cis	rs7949030	0.591	rs35156678	chr11:62369881	G/A	cg22862634	chr11:62369728	EML3;MTA2	0.6	8.16	0.45	1.37e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs6938	0.596	rs11072511	chr15:75159433	A/G	cg14664628	chr15:75095509	CSK	-0.58	-8.21	-0.45	9.96e-15	Breast cancer;
CESC	cis	rs2070488	0.965	rs7372386	chr3:38484175	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.91	15.98	0.7	1.07e-40	Electrocardiographic conduction measures;
CESC	cis	rs2694528	0.544	rs6449481	chr5:59911179	G/C	cg11474532	chr5:59995715	DEPDC1B	0.87	5.78	0.33	2.05e-8	Parkinson's disease;
CESC	cis	rs9309473	0.950	rs10206899	chr2:73900900	T/C	cg20560298	chr2:73613845	ALMS1	-0.56	-7.06	-0.4	1.46e-11	Metabolite levels;
CESC	cis	rs854765	0.547	rs2955377	chr17:17932818	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.6	8.66	0.47	4.83e-16	Total body bone mineral density;
CESC	cis	rs9926296	0.585	rs4785595	chr16:89835521	C/T	cg27121462	chr16:89883253	FANCA	-0.66	-8.66	-0.47	4.8e-16	Vitiligo;
CESC	cis	rs7917772	0.503	rs7093285	chr10:104374815	G/C	cg22532475	chr10:104410764	TRIM8	-0.39	-6.43	-0.37	5.85e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs9660180	0.934	rs12729990	chr1:1812035	T/A	cg13866156	chr1:1669148	SLC35E2	-0.5	-6.5	-0.37	3.99e-10	Body mass index;
CESC	trans	rs1667255	0.830	rs2034404	chr18:29156302	A/G	cg23171099	chr19:49217468	MAMSTR	0.52	6.43	0.37	5.91e-10	Retinol levels;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg10832476	chr1:28476863	PTAFR	0.45	6.5	0.37	4.01e-10	Fibrinogen levels;
CESC	cis	rs4862750	0.832	rs6836426	chr4:187897837	T/G	cg22105103	chr4:187893119	NA	0.48	6.79	0.38	7.4e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7223966	0.729	rs9902761	chr17:62010627	A/G	cg11494091	chr17:61959527	GH2	0.41	5.24	0.31	3.31e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs4253772	0.550	rs6007823	chr22:46706249	C/T	cg09491104	chr22:46646882	C22orf40	-0.48	-5.78	-0.33	2.14e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs1862618	0.853	rs866222	chr5:56184444	T/C	cg24549020	chr5:56110836	MAP3K1	0.66	7.45	0.42	1.29e-12	Initial pursuit acceleration;
CESC	cis	rs8070624	0.543	rs4299203	chr17:17878159	T/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.6	7.71	0.43	2.59e-13	Total body bone mineral density;
CESC	cis	rs2354432	0.607	rs68080346	chr1:146708484	T/C	cg25205988	chr1:146714368	CHD1L	-1.04	-8.53	-0.46	1.14e-15	Mitochondrial DNA levels;
CESC	cis	rs9549367	0.789	rs71446679	chr13:113894821	C/T	cg18105134	chr13:113819100	PROZ	-0.66	-7.97	-0.44	4.85e-14	Platelet distribution width;
CESC	cis	rs10791097	1.000	rs10791098	chr11:130718711	T/G	cg14779329	chr11:130786720	SNX19	0.4	6.24	0.36	1.73e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs61776719	0.738	rs7555461	chr1:38444749	T/C	cg04673462	chr1:38461896	NA	-0.41	-6.05	-0.35	5.01e-9	Coronary artery disease;
CESC	trans	rs7726839	0.574	rs72707007	chr5:661856	T/C	cg25482853	chr8:67687455	SGK3	1.02	10.32	0.54	3.29e-21	Obesity-related traits;
CESC	cis	rs1218582	0.772	rs4845689	chr1:154885524	A/G	cg06221963	chr1:154839813	KCNN3	-0.66	-11.2	-0.57	4.29e-24	Prostate cancer;
CESC	cis	rs4803468	1.000	rs10422783	chr19:41906436	T/C	cg08477640	chr19:41863820	B9D2	0.38	5.07	0.3	7.53e-7	Height;
CESC	cis	rs7072216	0.763	rs6584201	chr10:100170209	T/C	cg26618903	chr10:100175079	PYROXD2	-0.37	-5.76	-0.33	2.33e-8	Metabolite levels;
CESC	cis	rs644799	0.687	rs11021318	chr11:95522996	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.74	10.86	0.56	5.58e-23	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs853679	0.517	rs9380058	chr6:28127444	T/C	cg23281280	chr6:28129359	ZNF389	0.61	8.26	0.45	6.87e-15	Depression;
CESC	cis	rs2836950	0.509	rs11088466	chr21:40580017	T/A	cg11644478	chr21:40555479	PSMG1	-0.52	-7.14	-0.4	8.98e-12	Menarche (age at onset);
CESC	cis	rs1862618	0.853	rs252915	chr5:56121754	C/T	cg24549020	chr5:56110836	MAP3K1	-0.65	-7.5	-0.42	9.62e-13	Initial pursuit acceleration;
CESC	cis	rs34779708	0.931	rs4934723	chr10:35381763	A/G	cg03585969	chr10:35415529	CREM	0.77	10.07	0.53	2.06e-20	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs9614461	0.702	rs16993867	chr22:45733199	A/G	cg22884516	chr22:45809543	SMC1B;RIBC2	0.5	5.08	0.3	7.06e-7	Tonsillectomy;
CESC	cis	rs13191362	0.938	rs35395472	chr6:163008493	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.87	9.04	0.49	3.35e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs796364	0.951	rs11680258	chr2:200996976	T/C	cg23649088	chr2:200775458	C2orf69	-0.56	-5.7	-0.33	3.16e-8	Schizophrenia;
CESC	cis	rs13095912	0.785	rs6783023	chr3:185330189	A/G	cg11274856	chr3:185301563	NA	0.37	5.51	0.32	8.45e-8	Systolic blood pressure;
CESC	trans	rs78049276	0.512	rs6820938	chr4:148395903	A/G	cg13149281	chr14:23389818	RBM23;PRMT5	-0.71	-9.27	-0.49	6.75e-18	Pulse pressure;
CESC	cis	rs1559088	0.749	rs10405757	chr19:33616526	C/A	cg27124370	chr19:33622961	WDR88	0.43	5.59	0.32	5.74e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs7264396	0.635	rs6060692	chr20:34517925	A/T	cg23207816	chr20:34252616	CPNE1;RBM12	-0.55	-6.92	-0.39	3.49e-11	Total cholesterol levels;
CESC	trans	rs6089829	0.962	rs4997812	chr20:61663153	T/G	cg23505145	chr19:12996616	KLF1	0.54	6.95	0.39	2.81e-11	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs9733	0.536	rs10888385	chr1:150574302	T/C	cg17724175	chr1:150552817	MCL1	-0.34	-5.46	-0.32	1.12e-7	Tonsillectomy;
CESC	cis	rs6598955	0.670	rs6676619	chr1:26539035	T/G	cg00852783	chr1:26633632	UBXN11	0.4	5.81	0.34	1.79e-8	Obesity-related traits;
CESC	cis	rs10823500	0.748	rs7072230	chr10:71978144	A/G	cg02100629	chr10:71892760	AIFM2	-0.32	-5.13	-0.3	5.6e-7	Blood protein levels;
CESC	cis	rs6088590	1.000	rs6088590	chr20:33313566	T/C	cg08999081	chr20:33150536	PIGU	0.57	8.82	0.48	1.56e-16	Coronary artery disease;
CESC	cis	rs6681460	0.932	rs2044399	chr1:67054080	T/C	cg02459107	chr1:67143332	SGIP1	0.36	5.08	0.3	7.08e-7	Presence of antiphospholipid antibodies;
CESC	cis	rs9902453	0.817	rs2321333	chr17:28140857	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.77	10.34	0.54	2.82e-21	Coffee consumption (cups per day);
CESC	cis	rs2658782	0.547	rs4344448	chr11:93047047	T/C	cg15737290	chr11:93063684	CCDC67	0.52	7.23	0.41	5.13e-12	Pulmonary function decline;
CESC	cis	rs3785574	0.962	rs2727329	chr17:61924566	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.43	5.09	0.3	6.66e-7	Height;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg03742932	chr7:90338067	CDK14	-0.48	-6.69	-0.38	1.33e-10	Thyroid stimulating hormone;
CESC	cis	rs1008375	1.000	rs4698641	chr4:17642630	C/T	cg04450456	chr4:17643702	FAM184B	0.37	5.23	0.31	3.4e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20383078	chr12:93965728	SOCS2	0.58	6.97	0.39	2.47e-11	Gut microbiome composition (summer);
CESC	cis	rs7103648	1.000	rs10838709	chr11:47447346	C/T	cg03711944	chr11:47377212	SPI1	-0.32	-5.05	-0.3	8.21e-7	Diastolic blood pressure;Systolic blood pressure;
CESC	cis	rs10751667	0.666	rs4074234	chr11:977715	C/G	cg20946044	chr11:1010712	AP2A2	-0.39	-5.4	-0.31	1.48e-7	Alzheimer's disease (late onset);
CESC	cis	rs4713675	0.584	rs7759668	chr6:33670406	C/T	cg14003231	chr6:33640908	ITPR3	-0.36	-6.21	-0.36	2e-9	Plateletcrit;
CESC	cis	rs1059312	0.808	rs12816551	chr12:129295616	T/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.82	-12.1	-0.6	3.83e-27	Systemic lupus erythematosus;
CESC	cis	rs4660306	1.000	rs4660306	chr1:45978675	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.59	7.44	0.42	1.4e-12	Homocysteine levels;
CESC	cis	rs34172651	0.517	rs35560136	chr16:24788915	T/A	cg00339695	chr16:24857497	SLC5A11	0.54	6.72	0.38	1.12e-10	Intelligence (multi-trait analysis);
CESC	cis	rs7666738	0.830	rs4472144	chr4:98956494	G/A	cg17366294	chr4:99064904	C4orf37	0.59	8.29	0.45	5.64e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9649213	0.593	rs35535338	chr7:97962319	C/T	cg21770322	chr7:97807741	LMTK2	0.58	8.8	0.48	1.82e-16	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs8177253	0.965	rs3811658	chr3:133476852	C/T	cg01448562	chr3:133502909	NA	-0.44	-6.03	-0.35	5.42e-9	Iron status biomarkers;
CESC	cis	rs6762	0.748	rs7936838	chr11:839093	G/C	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.74	-9.68	-0.51	3.62e-19	Mean platelet volume;
CESC	cis	rs6076065	0.748	rs2295239	chr20:23387550	C/T	cg11657817	chr20:23433608	CST11	0.4	6.1	0.35	3.7e-9	Facial morphology (factor 15, philtrum width);
CESC	cis	rs8060686	0.545	rs12600062	chr16:68287544	C/A	cg26727032	chr16:67993705	SLC12A4	-0.51	-5.35	-0.31	1.94e-7	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs6500395	1.000	rs12933948	chr16:48705825	C/G	cg04672837	chr16:48644449	N4BP1	-0.49	-6.06	-0.35	4.66e-9	Response to tocilizumab in rheumatoid arthritis;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg19468962	chr19:33622911	WDR88	-0.43	-6.17	-0.35	2.54e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs3806843	0.741	rs4912597	chr5:140106857	C/G	cg26395211	chr5:140044315	WDR55	0.47	5.95	0.34	8.5e-9	Depressive symptoms (multi-trait analysis);
CESC	cis	rs7666738	0.830	rs28810677	chr4:99043193	C/T	cg03467027	chr4:99064603	C4orf37	0.47	5.98	0.34	7.19e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7945705	0.837	rs10769981	chr11:9024460	T/C	cg12365402	chr11:9010492	NRIP3	0.43	7.06	0.4	1.42e-11	Hemoglobin concentration;
CESC	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.46	6.05	0.35	5.01e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2576037	0.899	rs2246877	chr18:44577005	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.39	-6.06	-0.35	4.63e-9	Personality dimensions;
CESC	cis	rs4242434	0.757	rs2280104	chr8:22525980	C/T	cg03733263	chr8:22462867	KIAA1967	0.8	11.65	0.58	1.33e-25	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CESC	cis	rs9322193	0.923	rs57938011	chr6:149964105	T/A	cg13206674	chr6:150067644	NUP43	0.39	5.53	0.32	7.66e-8	Lung cancer;
CESC	cis	rs7666738	0.535	rs6850010	chr4:98971601	A/T	cg05340658	chr4:99064831	C4orf37	0.78	11.71	0.58	8.33e-26	Colonoscopy-negative controls vs population controls;
CESC	cis	rs17125944	0.505	rs77949716	chr14:53204234	G/A	cg13660082	chr14:53194042	PSMC6	-0.67	-5.83	-0.34	1.58e-8	Alzheimer's disease (late onset);
CESC	cis	rs9948	0.786	rs62156231	chr2:97425603	G/A	cg01990225	chr2:97406019	LMAN2L	-0.93	-7.49	-0.42	1.04e-12	Erectile dysfunction and prostate cancer treatment;
CESC	cis	rs4665809	1.000	rs1550381	chr2:26266946	A/G	cg25036284	chr2:26402008	FAM59B	-0.59	-6.71	-0.38	1.2e-10	Gut microbiome composition (summer);
CESC	cis	rs4132509	0.793	rs4478795	chr1:243844576	C/T	cg21452805	chr1:244014465	NA	0.57	6.4	0.37	6.85e-10	RR interval (heart rate);
CESC	cis	rs9858542	0.953	rs7646366	chr3:49470668	G/A	cg07274523	chr3:49395745	GPX1	0.67	8.24	0.45	8.23e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs962856	0.719	rs12713597	chr2:67621067	T/C	cg09028215	chr2:67624308	ETAA1	-0.44	-5.64	-0.33	4.26e-8	Pancreatic cancer;
CESC	cis	rs710216	0.536	rs710221	chr1:43414200	G/A	cg07803811	chr1:43423981	SLC2A1	0.6	7.98	0.44	4.31e-14	Red cell distribution width;
CESC	cis	rs853679	0.517	rs17711344	chr6:28077602	A/G	cg26335602	chr6:28129616	ZNF389	-0.49	-6.39	-0.37	7.58e-10	Depression;
CESC	cis	rs4074961	0.527	rs6704190	chr1:38010751	C/T	cg13401533	chr1:37979913	MEAF6	0.44	5.48	0.32	9.98e-8	Axial length;
CESC	cis	rs3091242	0.933	rs28633797	chr1:25741629	C/A	cg02931644	chr1:25747376	RHCE	0.39	6.4	0.37	7e-10	Erythrocyte sedimentation rate;
CESC	cis	rs6502050	0.871	rs8072702	chr17:80074280	C/T	cg11859384	chr17:80120422	CCDC57	0.4	5.52	0.32	8.22e-8	Life satisfaction;
CESC	cis	rs12142240	0.698	rs68012736	chr1:46839510	A/G	cg10495392	chr1:46806563	NSUN4	0.58	6.26	0.36	1.54e-9	Menopause (age at onset);
CESC	cis	rs1499614	1.000	rs2141924	chr7:66186246	C/T	cg13147721	chr7:65941812	NA	-0.94	-8.9	-0.48	9.08e-17	Gout;
CESC	cis	rs1552244	1.000	rs17032268	chr3:10067972	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.89	12.17	0.6	2.39e-27	Alzheimer's disease;
CESC	cis	rs7429990	0.965	rs1137524	chr3:47956424	C/T	cg11946769	chr3:48343235	NME6	0.42	5.07	0.3	7.49e-7	Educational attainment (years of education);
CESC	cis	rs8062405	0.755	rs1074631	chr16:28554108	A/G	cg07382826	chr16:28625726	SULT1A1	-0.4	-6.51	-0.37	3.65e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs6951245	0.744	rs1133122	chr7:1192572	C/A	cg03188948	chr7:1209495	NA	0.73	7.81	0.43	1.31e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs1371867	0.846	rs1660348	chr8:101315248	A/G	cg11906718	chr8:101322791	RNF19A	0.46	5.92	0.34	1.02e-8	Atrioventricular conduction;
CESC	trans	rs6981523	0.553	rs2409730	chr8:11060638	C/A	cg06636001	chr8:8085503	FLJ10661	-0.53	-6.25	-0.36	1.67e-9	Neuroticism;
CESC	cis	rs10504229	0.871	rs56048296	chr8:58163781	C/T	cg24829409	chr8:58192753	C8orf71	-0.62	-8.78	-0.47	2.03e-16	Developmental language disorder (linguistic errors);
CESC	cis	rs854765	0.724	rs2955371	chr17:17967397	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.5	-6.89	-0.39	4e-11	Total body bone mineral density;
CESC	cis	rs6089584	0.816	rs4925336	chr20:60627180	A/G	cg06108461	chr20:60628389	TAF4	-0.95	-15.02	-0.68	2.56e-37	Body mass index;
CESC	cis	rs6460942	0.915	rs62448593	chr7:12436845	G/C	cg16278512	chr7:12443529	VWDE	-0.5	-5.08	-0.3	7.3e-7	Coronary artery disease;
CESC	cis	rs12477438	0.798	rs1349778	chr2:99645011	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.78	-10.94	-0.56	3.2e-23	Chronic sinus infection;
CESC	trans	rs11098499	0.866	rs10518329	chr4:120401835	A/G	cg25214090	chr10:38739885	LOC399744	0.61	8.92	0.48	8.03e-17	Corneal astigmatism;
CESC	cis	rs4242434	0.927	rs13271626	chr8:22467760	C/G	cg03733263	chr8:22462867	KIAA1967	0.92	13.69	0.64	1.26e-32	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CESC	cis	rs2742234	0.541	rs61268333	chr10:43721370	G/A	cg15436174	chr10:43711423	RASGEF1A	0.47	5.58	0.32	5.81e-8	Hirschsprung disease;
CESC	cis	rs8005677	1.000	rs10148215	chr14:23382345	C/T	cg25600027	chr14:23388339	RBM23	-0.45	-5.49	-0.32	9.62e-8	Cognitive ability (multi-trait analysis);
CESC	cis	rs6860806	0.695	rs11952099	chr5:131576772	A/G	cg18758796	chr5:131593413	PDLIM4	0.47	6.82	0.39	6.01e-11	Breast cancer;
CESC	cis	rs2549003	0.870	rs10053046	chr5:131821558	A/G	cg02551604	chr5:131831745	NA	-0.37	-5.27	-0.31	2.81e-7	Asthma (sex interaction);
CESC	cis	rs9443645	0.901	rs6454092	chr6:79701972	G/A	cg05283184	chr6:79620031	NA	-0.43	-6.56	-0.37	2.83e-10	Intelligence (multi-trait analysis);
CESC	cis	rs9611565	0.614	rs4822053	chr22:42212936	C/A	cg06481639	chr22:41940642	POLR3H	-0.46	-5.37	-0.31	1.73e-7	Vitiligo;
CESC	trans	rs7824557	0.527	rs2572449	chr8:11239137	A/G	cg06636001	chr8:8085503	FLJ10661	0.49	6.46	0.37	4.98e-10	Retinal vascular caliber;
CESC	cis	rs11190604	0.673	rs10883498	chr10:102228709	T/A	cg07080220	chr10:102295463	HIF1AN	0.55	5.56	0.32	6.43e-8	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs9443645	0.901	rs9361480	chr6:79724429	C/T	cg05283184	chr6:79620031	NA	-0.36	-5.46	-0.32	1.11e-7	Intelligence (multi-trait analysis);
CESC	cis	rs2836974	0.897	rs35064900	chr21:40555492	A/G	cg27266027	chr21:40555129	PSMG1	0.47	5.63	0.33	4.62e-8	Cognitive function;
CESC	cis	rs12477438	0.520	rs6741772	chr2:99738961	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.85	15.4	0.69	1.17e-38	Chronic sinus infection;
CESC	cis	rs3815700	0.614	rs259255	chr19:33151765	T/C	cg25945090	chr19:33463020	C19orf40;CCDC123	0.75	5.2	0.3	3.95e-7	Eosinophilic esophagitis;
CESC	cis	rs17253792	0.822	rs17832371	chr14:56162302	C/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.81	5.68	0.33	3.46e-8	Putamen volume;
CESC	cis	rs7833790	0.929	rs28464834	chr8:82797356	A/T	cg02079420	chr8:82753780	SNX16	-0.55	-7.45	-0.42	1.34e-12	Diastolic blood pressure;
CESC	cis	rs798766	0.903	rs798726	chr4:1685211	C/T	cg05874882	chr4:1763078	NA	0.54	7.18	0.4	6.89e-12	Bladder cancer;Urinary bladder cancer;
CESC	cis	rs2276314	0.857	rs28431958	chr18:33578401	T/G	cg05985134	chr18:33552581	C18orf21	0.61	7.03	0.4	1.72e-11	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs12995491	0.763	rs1914735	chr2:88511953	A/T	cg18302933	chr2:88491318	NA	-0.32	-5.07	-0.3	7.32e-7	Response to metformin (IC50);
CESC	cis	rs7917772	0.565	rs61869210	chr10:104437175	A/C	cg22532475	chr10:104410764	TRIM8	-0.38	-5.52	-0.32	7.94e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs561341	0.941	rs17780080	chr17:30343146	G/A	cg12193833	chr17:30244370	NA	-0.75	-6.57	-0.37	2.6e-10	Hip circumference adjusted for BMI;
CESC	cis	rs4665809	0.590	rs4665313	chr2:26415897	A/G	cg27170947	chr2:26402098	FAM59B	-0.83	-9.92	-0.52	6.4e-20	Gut microbiome composition (summer);
CESC	cis	rs2440129	0.611	rs11571335	chr17:6904263	C/T	cg02493798	chr17:6899577	ALOX12	0.42	7.35	0.41	2.47e-12	Tonsillectomy;
CESC	cis	rs34779708	0.750	rs35032841	chr10:35312687	G/A	cg04310649	chr10:35416472	CREM	-0.5	-5.95	-0.34	8.64e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs6696846	0.765	rs11240360	chr1:205083865	T/C	cg00857998	chr1:205179979	DSTYK	0.54	7.13	0.4	9.57e-12	Red blood cell count;
CESC	cis	rs7089973	0.604	rs17095662	chr10:116596071	A/C	cg23260525	chr10:116636907	FAM160B1	0.41	7.39	0.41	1.87e-12	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs769267	0.896	rs7250893	chr19:19625547	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	7.56	0.42	6.58e-13	Tonsillectomy;
CESC	cis	rs10870270	0.956	rs11146325	chr10:133767529	A/G	cg08754478	chr10:133766260	PPP2R2D	-0.59	-7.62	-0.42	4.57e-13	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs11677416	1.000	rs4848303	chr2:113552698	A/G	cg27083787	chr2:113543245	IL1A	0.62	7.72	0.43	2.32e-13	Response to antipsychotic treatment in schizophrenia (working memory);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18001435	chr13:111291955	CARKD	-0.55	-6.4	-0.37	7.1e-10	Gut microbiome composition (summer);
CESC	cis	rs4148883	0.504	rs28720150	chr4:100132790	T/G	cg12011299	chr4:100065546	ADH4	-0.51	-7.19	-0.4	6.6e-12	Alcohol dependence;
CESC	cis	rs11758351	0.660	rs11753131	chr6:26219384	G/A	cg23601095	chr6:26197514	HIST1H3D	0.91	9.96	0.52	4.64e-20	Gout;Renal underexcretion gout;
CESC	cis	rs9910055	0.530	rs2269907	chr17:42294215	G/A	cg13607699	chr17:42295918	UBTF	0.81	12.59	0.61	8.66e-29	Total body bone mineral density;
CESC	cis	rs11098499	0.874	rs12502503	chr4:120116255	C/T	cg09307838	chr4:120376055	NA	0.75	9.35	0.5	3.76e-18	Corneal astigmatism;
CESC	cis	rs2839186	0.721	rs3788252	chr21:47661235	C/T	cg10351095	chr21:47802916	PCNT	-0.5	-7.01	-0.4	1.99e-11	Testicular germ cell tumor;
CESC	cis	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg02951883	chr7:2050386	MAD1L1	-0.44	-5.69	-0.33	3.4e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs208520	1.000	rs208521	chr6:66953625	C/T	cg07460842	chr6:66804631	NA	-0.9	-10.34	-0.54	2.79e-21	Exhaled nitric oxide output;
CESC	cis	rs74181299	0.806	rs2723063	chr2:65280185	A/G	cg05010058	chr2:65284262	CEP68	0.3	5.16	0.3	4.93e-7	Pulse pressure;
CESC	cis	rs4713118	0.527	rs4713151	chr6:28136356	G/A	cg26335602	chr6:28129616	ZNF389	0.52	6.84	0.39	5.58e-11	Parkinson's disease;
CESC	cis	rs6028335	0.674	rs57993460	chr20:37662068	C/A	cg16355469	chr20:37678765	NA	0.54	5.27	0.31	2.89e-7	Alcohol and nicotine co-dependence;
CESC	cis	rs4654899	1.000	rs6681064	chr1:21339644	A/G	cg05370193	chr1:21551575	ECE1	0.38	5.75	0.33	2.48e-8	Superior frontal gyrus grey matter volume;
CESC	cis	rs17854409	0.764	rs8116995	chr20:61475824	A/G	cg05147244	chr20:61493195	TCFL5	0.92	6.73	0.38	1.07e-10	Obesity-related traits;
CESC	cis	rs1395	0.778	rs6709602	chr2:27405497	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.44	5.75	0.33	2.45e-8	Blood metabolite levels;
CESC	cis	rs8114671	0.836	rs17404569	chr20:33674077	A/C	cg24642439	chr20:33292090	TP53INP2	-0.47	-5.7	-0.33	3.19e-8	Height;
CESC	cis	rs763121	0.962	rs138703	chr22:39132748	C/T	cg06544989	chr22:39130855	UNC84B	0.46	8.56	0.47	9.32e-16	Menopause (age at onset);
CESC	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg07308232	chr7:1071921	C7orf50	-0.63	-9.11	-0.49	2.15e-17	Longevity;Endometriosis;
CESC	cis	rs17384381	1.000	rs35193119	chr1:85859265	T/C	cg16011679	chr1:85725395	C1orf52	0.8	8.15	0.45	1.47e-14	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs27434	0.529	rs42443	chr5:96156224	G/A	cg16492584	chr5:96139282	ERAP1	-0.36	-5.09	-0.3	6.81e-7	Ankylosing spondylitis;
CESC	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg18402987	chr7:1209562	NA	0.75	7.39	0.41	1.9e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7412746	0.634	rs12096831	chr1:150864113	T/G	cg17724175	chr1:150552817	MCL1	0.39	5.93	0.34	9.43e-9	Melanoma;
CESC	cis	rs5753618	0.583	rs7285619	chr22:31842554	C/T	cg02404636	chr22:31891804	SFI1	0.39	5.25	0.31	3.1e-7	Colorectal cancer;
CESC	cis	rs4253772	0.550	rs738444	chr22:46721088	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.78	9.23	0.49	8.88e-18	LDL cholesterol;Cholesterol, total;
CESC	cis	rs7918232	0.825	rs4749233	chr10:27467967	G/A	cg14442939	chr10:27389572	ANKRD26	0.7	6.99	0.39	2.29e-11	Breast cancer;
CESC	trans	rs11098499	0.863	rs11947234	chr4:120474859	A/G	cg25214090	chr10:38739885	LOC399744	0.66	8.96	0.48	5.92e-17	Corneal astigmatism;
CESC	cis	rs875971	0.545	rs6970498	chr7:65740895	A/G	cg11764359	chr7:65958608	NA	0.81	9.55	0.51	9.32e-19	Aortic root size;
CESC	cis	rs7666738	0.753	rs2865957	chr4:99040725	G/A	cg05340658	chr4:99064831	C4orf37	0.8	12.39	0.61	3.91e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11153306	1.000	rs11153306	chr6:111950649	G/A	cg22127309	chr6:111907043	TRAF3IP2	-0.35	-5.21	-0.3	3.82e-7	Tonsillectomy;
CESC	cis	rs611744	0.631	rs627392	chr8:109254677	C/T	cg21045802	chr8:109455806	TTC35	0.49	6.06	0.35	4.71e-9	Dupuytren's disease;
CESC	cis	rs72945132	0.882	rs72949081	chr11:70219070	A/G	cg00319359	chr11:70116639	PPFIA1	0.78	7.12	0.4	9.86e-12	Coronary artery disease;
CESC	cis	rs2991971	0.967	rs12133294	chr1:45988764	C/T	cg15605315	chr1:45957053	TESK2	0.49	6.42	0.37	6.28e-10	High light scatter reticulocyte count;
CESC	cis	rs8180040	1.000	rs295428	chr3:47359262	G/T	cg27129171	chr3:47204927	SETD2	0.66	10.1	0.53	1.7e-20	Colorectal cancer;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg23857200	chr19:39882127	MED29;PAF1	-0.42	-6.11	-0.35	3.47e-9	Gambling;
CESC	trans	rs17039065	0.920	rs7674961	chr4:109440528	G/A	cg27151770	chr16:49620536	ZNF423	-0.51	-6.21	-0.36	2.09e-9	Gut microbiome composition (summer);
CESC	cis	rs10504229	0.683	rs903706	chr8:58128134	T/G	cg24829409	chr8:58192753	C8orf71	-0.58	-7.2	-0.4	6.31e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs6502050	0.835	rs10163496	chr17:80110867	G/A	cg23985595	chr17:80112537	CCDC57	-0.41	-6.41	-0.37	6.76e-10	Life satisfaction;
CESC	cis	rs6598955	0.585	rs12138111	chr1:26590432	G/A	cg19743891	chr1:26644573	UBXN11;CD52	0.37	5.19	0.3	4.16e-7	Obesity-related traits;
CESC	cis	rs8114671	0.967	rs1415773	chr20:33765585	G/A	cg24642439	chr20:33292090	TP53INP2	0.44	5.26	0.31	2.95e-7	Height;
CESC	cis	rs9309711	0.643	rs4535074	chr2:3481637	A/G	cg15506890	chr2:3487001	NA	-0.5	-6.45	-0.37	5.28e-10	Neurofibrillary tangles;
CESC	cis	rs4481887	0.927	rs4244173	chr1:248466899	G/C	cg00666640	chr1:248458726	OR2T12	0.4	6.58	0.37	2.52e-10	Common traits (Other);
CESC	cis	rs6142102	0.502	rs58393429	chr20:32545802	C/G	cg08999081	chr20:33150536	PIGU	0.35	5.32	0.31	2.18e-7	Skin pigmentation;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18538297	chr19:58892579	ZNF837	0.58	7.11	0.4	1.07e-11	Gut microbiome composition (summer);
CESC	cis	rs2180341	0.596	rs12215298	chr6:127676833	C/T	cg24812749	chr6:127587940	RNF146	0.73	9.35	0.5	3.75e-18	Breast cancer;
CESC	trans	rs57221529	0.709	rs72706612	chr5:561198	C/T	cg25482853	chr8:67687455	SGK3	1.12	11.92	0.59	1.58e-26	Lung disease severity in cystic fibrosis;
CESC	cis	rs3785574	0.927	rs2727313	chr17:61961914	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.05	17.19	0.73	5.42e-45	Height;
CESC	cis	rs3785574	0.745	rs2854162	chr17:61975610	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.61	-7.6	-0.42	5.02e-13	Height;
CESC	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.65	0.38	1.71e-10	Prudent dietary pattern;
CESC	cis	rs3091242	1.000	rs9689	chr1:25688276	A/G	cg27572855	chr1:25598939	RHD	0.45	7.59	0.42	5.61e-13	Erythrocyte sedimentation rate;
CESC	cis	rs1862618	0.853	rs2432195	chr5:56120413	C/T	cg24549020	chr5:56110836	MAP3K1	0.65	7.54	0.42	7.42e-13	Initial pursuit acceleration;
CESC	cis	rs2011503	1.000	rs2965181	chr19:19512317	C/T	cg11584989	chr19:19387371	SF4	0.63	7.42	0.41	1.63e-12	Bipolar disorder;
CESC	trans	rs6991952	0.845	rs7822766	chr8:25742279	A/T	cg06665941	chr21:34602869	IFNAR2	-0.48	-6.09	-0.35	3.97e-9	Inguinal hernia;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg12121965	chr21:46293563	PTTG1IP	-0.5	-6.49	-0.37	4.11e-10	Ulcerative colitis;
CESC	cis	rs7621025	0.691	rs4678438	chr3:136344920	A/C	cg15507776	chr3:136538369	TMEM22	0.41	5.08	0.3	7.18e-7	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12197656	chr2:85108351	C2orf89	0.54	6.43	0.37	6.08e-10	Gut microbiome composition (summer);
CESC	cis	rs4836694	0.517	rs1017112	chr9:132936804	A/G	cg13414629	chr9:132935646	FREQ	0.44	5.56	0.32	6.66e-8	Alzheimer's disease (cognitive decline);
CESC	cis	rs8177253	0.761	rs1830084	chr3:133508464	A/T	cg12373951	chr3:133503437	NA	-0.52	-7.66	-0.43	3.4e-13	Iron status biomarkers;
CESC	cis	rs765787	0.556	rs2413778	chr15:45539397	C/A	cg24006582	chr15:45444508	DUOX1	-0.59	-7.32	-0.41	3.04e-12	Uric acid levels;
CESC	cis	rs60154123	0.505	rs76101197	chr1:210044089	T/C	cg22029157	chr1:209979665	IRF6	0.73	7.51	0.42	8.78e-13	Coronary artery disease;
CESC	cis	rs7666738	0.830	rs28795113	chr4:98951331	A/G	cg03467027	chr4:99064603	C4orf37	0.45	5.67	0.33	3.69e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs28374715	0.681	rs59000092	chr15:41626148	A/G	cg02330683	chr15:41787940	ITPKA	0.47	6.28	0.36	1.35e-9	Ulcerative colitis;
CESC	cis	rs2832191	0.671	rs68101501	chr21:30513229	G/T	cg08807101	chr21:30365312	RNF160	-0.54	-6.29	-0.36	1.3e-9	Dental caries;
CESC	cis	rs11051970	0.559	rs11051986	chr12:32555273	A/G	cg24626660	chr12:32551988	NA	0.36	5.27	0.31	2.77e-7	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs765787	0.530	rs1648289	chr15:45516494	A/G	cg24006582	chr15:45444508	DUOX1	-0.53	-6.64	-0.38	1.75e-10	Uric acid levels;
CESC	trans	rs9929218	0.529	rs35854485	chr16:68730855	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.88	14.37	0.66	5.19e-35	Colorectal cancer;
CESC	cis	rs1218582	0.772	rs4845682	chr1:154877105	T/C	cg16680214	chr1:154839983	KCNN3	-0.44	-6.76	-0.38	8.73e-11	Prostate cancer;
CESC	cis	rs2304069	0.954	rs1962603	chr5:149393006	G/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.91	11.66	0.58	1.21e-25	HIV-1 control;
CESC	cis	rs6088580	0.634	rs6059887	chr20:33101102	C/G	cg08999081	chr20:33150536	PIGU	0.65	11.26	0.57	2.65e-24	Glomerular filtration rate (creatinine);
CESC	cis	rs34779708	0.931	rs17583009	chr10:35320915	T/C	cg03585969	chr10:35415529	CREM	0.75	9.82	0.52	1.31e-19	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs6665290	0.594	rs17592479	chr1:227173892	T/A	cg10327440	chr1:227177885	CDC42BPA	-1.12	-24.29	-0.83	2.31e-69	Myeloid white cell count;
CESC	cis	rs7829975	0.514	rs2979151	chr8:8258019	A/G	cg06636001	chr8:8085503	FLJ10661	-0.43	-5.5	-0.32	8.89e-8	Mood instability;
CESC	cis	rs1707322	1.000	rs12097761	chr1:46291162	T/C	cg05343316	chr1:45956843	TESK2	0.49	5.88	0.34	1.22e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs798554	0.679	rs2533868	chr7:2886559	G/A	cg04166393	chr7:2884313	GNA12	0.6	8.23	0.45	8.69e-15	Height;
CESC	cis	rs7633857	0.532	rs9858335	chr3:160760146	A/G	cg03342759	chr3:160939853	NMD3	-0.44	-6.05	-0.35	4.89e-9	Educational attainment (years of education);
CESC	cis	rs79839061	0.666	rs62297063	chr4:869708	G/A	cg07828340	chr4:882639	GAK	1.07	8.26	0.45	6.86e-15	Intelligence (multi-trait analysis);
CESC	trans	rs208520	0.690	rs207082	chr6:66773796	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.97	-12.37	-0.61	4.83e-28	Exhaled nitric oxide output;
CESC	cis	rs7267979	0.714	rs1555329	chr20:25231858	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.71	11.38	0.57	1.04e-24	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs910316	0.737	rs175055	chr14:75488946	T/G	cg11812906	chr14:75593930	NEK9	-0.81	-13.25	-0.63	4.31e-31	Height;
CESC	cis	rs9916302	0.904	rs2024073	chr17:37471330	T/G	cg20243544	chr17:37824526	PNMT	-0.45	-5.64	-0.33	4.3e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs7044106	0.512	rs7873848	chr9:123354222	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.67	9.7	0.51	3.2e-19	Hip circumference adjusted for BMI;
CESC	trans	rs7246760	1.000	rs67507476	chr19:9852948	G/A	cg02900749	chr2:68251473	NA	-0.84	-7.32	-0.41	2.99e-12	Pursuit maintenance gain;
CESC	cis	rs10479542	0.784	rs7703730	chr5:178986632	C/A	cg05457628	chr5:178986728	RUFY1	-0.51	-7.46	-0.42	1.26e-12	Lung cancer;
CESC	cis	rs6088580	0.634	rs6141471	chr20:33006730	A/G	cg08999081	chr20:33150536	PIGU	-0.65	-11.34	-0.57	1.5e-24	Glomerular filtration rate (creatinine);
CESC	cis	rs9733	0.519	rs10788792	chr1:150638572	T/G	cg18016565	chr1:150552671	MCL1	0.33	5.09	0.3	6.9e-7	Tonsillectomy;
CESC	trans	rs61931739	0.500	rs34061369	chr12:34519283	C/T	cg13010199	chr12:38710504	ALG10B	0.5	6.42	0.37	6.3e-10	Morning vs. evening chronotype;
CESC	trans	rs208520	0.674	rs207103	chr6:66795568	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.0	-12.83	-0.62	1.2e-29	Exhaled nitric oxide output;
CESC	cis	rs8067354	0.872	rs2645483	chr17:57848184	T/G	cg13753209	chr17:57696993	CLTC	0.5	6.75	0.38	9.33e-11	Hemoglobin concentration;
CESC	cis	rs12497850	0.931	rs13316620	chr3:49045355	T/C	cg03060546	chr3:49711283	APEH	0.49	5.89	0.34	1.16e-8	Parkinson's disease;
CESC	cis	rs1580019	0.844	rs1584615	chr7:32503258	G/C	cg06627557	chr7:32535165	LSM5;AVL9	0.89	12.64	0.61	5.67e-29	Cognitive ability;
CESC	cis	rs2749592	0.550	rs12255038	chr10:37869332	T/C	cg25427524	chr10:38739819	LOC399744	0.57	7.93	0.44	5.98e-14	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs6429082	0.714	rs704719	chr1:235667170	G/A	cg26050004	chr1:235667680	B3GALNT2	0.68	8.26	0.45	7.1e-15	Adiposity;
CESC	cis	rs3806843	0.966	rs2337516	chr5:140140853	A/G	cg16179182	chr5:140090404	VTRNA1-1	0.43	5.64	0.33	4.31e-8	Depressive symptoms (multi-trait analysis);
CESC	cis	rs11630290	0.592	rs1912048	chr15:64155974	G/A	cg12036633	chr15:63758958	NA	0.45	5.46	0.32	1.12e-7	Iris characteristics;
CESC	cis	rs4819052	0.851	rs9974891	chr21:46680767	T/A	cg11663144	chr21:46675770	NA	-0.48	-7.28	-0.41	3.76e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs6987853	0.787	rs10958722	chr8:42425487	T/C	cg09913449	chr8:42400586	C8orf40	0.45	7.62	0.42	4.61e-13	Mean corpuscular hemoglobin concentration;
CESC	cis	rs3768617	0.610	rs10911228	chr1:183049792	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.66	9.11	0.49	2.07e-17	Fuchs's corneal dystrophy;
CESC	cis	rs4595586	0.525	rs17464772	chr12:39247777	G/A	cg13010199	chr12:38710504	ALG10B	0.56	7.57	0.42	6.21e-13	Morning vs. evening chronotype;
CESC	cis	rs7555523	0.887	rs2790053	chr1:165737704	C/G	cg24409356	chr1:165738333	TMCO1	0.98	8.91	0.48	8.52e-17	Intraocular pressure;Glaucoma (high intraocular pressure);
CESC	cis	rs1153858	1.000	rs12441971	chr15:45671957	A/T	cg21132104	chr15:45694354	SPATA5L1	0.86	11.62	0.58	1.67e-25	Homoarginine levels;
CESC	cis	rs6582630	0.519	rs1851130	chr12:38507819	C/T	cg13010199	chr12:38710504	ALG10B	0.46	5.9	0.34	1.13e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs9911578	1.000	rs999431	chr17:56854441	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.24	0.31	3.22e-7	Intelligence (multi-trait analysis);
CESC	cis	rs1775715	0.678	rs2105360	chr10:32210198	C/T	cg18675610	chr10:32216311	ARHGAP12	0.35	5.43	0.32	1.27e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs67478160	0.619	rs11623546	chr14:104269098	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.51	-7.09	-0.4	1.2e-11	Schizophrenia;
CESC	cis	rs16854884	0.683	rs6766544	chr3:143736659	G/T	cg06585982	chr3:143692056	C3orf58	0.5	6.7	0.38	1.26e-10	Economic and political preferences (feminism/equality);
CESC	cis	rs748404	0.697	rs498227	chr15:43573052	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.61	7.98	0.44	4.54e-14	Lung cancer;
CESC	cis	rs9467711	0.606	rs9366653	chr6:26354247	G/A	cg12826209	chr6:26865740	GUSBL1	0.62	5.31	0.31	2.36e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs300703	0.576	rs3791216	chr2:237142	C/A	cg21211680	chr2:198530	NA	0.92	7.6	0.42	5.03e-13	Blood protein levels;
CESC	cis	rs11247915	0.561	rs12750420	chr1:26608649	G/A	cg04990556	chr1:26633338	UBXN11	-0.62	-6.88	-0.39	4.24e-11	Obesity-related traits;
CESC	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg14159672	chr1:205819179	PM20D1	0.95	16.72	0.72	2.48e-43	Menarche (age at onset);
CESC	trans	rs9929218	0.559	rs11642362	chr16:68811307	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.86	13.68	0.64	1.32e-32	Colorectal cancer;
CESC	trans	rs561341	1.000	rs55978022	chr17:30275937	T/C	cg20587970	chr11:113659929	NA	-1.49	-19.52	-0.77	3.46e-53	Hip circumference adjusted for BMI;
CESC	cis	rs853679	0.517	rs9368555	chr6:28108967	T/C	cg17949981	chr6:28129498	ZNF389	0.44	5.53	0.32	7.84e-8	Depression;
CESC	cis	rs7267979	1.000	rs2482930	chr20:25334115	G/C	cg08601574	chr20:25228251	PYGB	-0.36	-5.05	-0.3	8.07e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs919433	0.963	rs12617117	chr2:198155170	T/A	cg03934865	chr2:198174659	NA	-0.4	-5.32	-0.31	2.17e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs2075371	1.000	rs2598288	chr7:133977304	A/T	cg00033643	chr7:134001901	SLC35B4	0.42	5.47	0.32	1.04e-7	Mean platelet volume;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg03553080	chr16:88697695	ZC3H18	0.47	6.71	0.38	1.18e-10	Fibrinogen levels;
CESC	trans	rs7246760	1.000	rs56357664	chr19:9903399	C/T	cg02900749	chr2:68251473	NA	-0.78	-6.84	-0.39	5.48e-11	Pursuit maintenance gain;
CESC	cis	rs12410462	0.892	rs75757169	chr1:227629855	A/G	cg23173402	chr1:227635558	NA	0.59	6.06	0.35	4.66e-9	Major depressive disorder;
CESC	cis	rs11122272	0.735	rs2355873	chr1:231477442	A/G	cg06096015	chr1:231504339	EGLN1	0.43	6.24	0.36	1.74e-9	Hemoglobin concentration;
CESC	cis	rs1799949	0.965	rs11656945	chr17:41330265	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.59	7.73	0.43	2.2e-13	Menopause (age at onset);
CESC	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.97	9.35	0.5	3.75e-18	Platelet count;
CESC	trans	rs4332037	0.901	rs11767040	chr7:1945468	C/T	cg11693508	chr17:37793320	STARD3	0.7	6.63	0.38	1.89e-10	Bipolar disorder;
CESC	cis	rs2921036	0.529	rs2979192	chr8:8338147	C/T	cg15556689	chr8:8085844	FLJ10661	0.53	6.61	0.38	2.12e-10	Neuroticism;
CESC	cis	rs8177253	0.965	rs7638018	chr3:133495461	C/T	cg11941060	chr3:133502564	NA	0.44	6.09	0.35	3.91e-9	Iron status biomarkers;
CESC	cis	rs16854884	0.837	rs6804060	chr3:143804040	C/T	cg06585982	chr3:143692056	C3orf58	0.42	5.12	0.3	5.99e-7	Economic and political preferences (feminism/equality);
CESC	cis	rs738322	1.000	rs4382	chr22:38570842	T/C	cg25457927	chr22:38595422	NA	-0.3	-5.46	-0.32	1.1e-7	Cutaneous nevi;
CESC	trans	rs1493916	0.905	rs34910379	chr18:31400047	A/G	cg27147174	chr7:100797783	AP1S1	-0.55	-7.47	-0.42	1.19e-12	Life satisfaction;
CESC	cis	rs17253792	0.822	rs112739186	chr14:56065167	A/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.84	5.62	0.33	4.81e-8	Putamen volume;
CESC	cis	rs12971120	0.838	rs2241510	chr18:72180739	G/A	cg26446133	chr18:72167187	CNDP2	-0.73	-8.98	-0.48	5.09e-17	Refractive error;
CESC	cis	rs4919087	1.000	rs4919087	chr10:99072507	C/T	cg25902810	chr10:99078978	FRAT1	-0.7	-10.41	-0.54	1.66e-21	Monocyte count;
CESC	cis	rs2204008	0.743	rs2127952	chr12:37995364	G/T	cg13010199	chr12:38710504	ALG10B	0.46	5.68	0.33	3.46e-8	Bladder cancer;
CESC	cis	rs3858526	0.834	rs7129481	chr11:5991114	G/T	cg05234568	chr11:5960015	NA	-0.45	-5.17	-0.3	4.7e-7	DNA methylation (variation);
CESC	cis	rs9309473	0.687	rs11693531	chr2:73608614	C/G	cg20560298	chr2:73613845	ALMS1	-0.49	-6.75	-0.38	9.22e-11	Metabolite levels;
CESC	cis	rs736408	0.924	rs2535629	chr3:52833219	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.42	5.26	0.31	2.96e-7	Bipolar disorder;
CESC	cis	rs796364	0.806	rs74724807	chr2:201005109	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.72	-6.48	-0.37	4.47e-10	Schizophrenia;
CESC	cis	rs250677	0.522	rs10040798	chr5:148367324	A/G	cg18129178	chr5:148520854	ABLIM3	0.46	5.12	0.3	5.9e-7	Breast cancer;
CESC	cis	rs7847628	0.551	rs10818476	chr9:123572038	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.94	17.29	0.73	2.29e-45	Birth weight;
CESC	cis	rs8064299	0.655	rs12797	chr17:72766993	G/A	cg25054828	chr17:72772726	NAT9;TMEM104	0.54	7.34	0.41	2.54e-12	Monocyte count;
CESC	cis	rs13034020	0.522	rs62150970	chr2:61244410	C/G	cg18625361	chr2:61244694	PEX13;PUS10	0.64	6.18	0.35	2.39e-9	Hodgkin's lymphoma;
CESC	trans	rs2216164	0.966	rs7956817	chr12:68573934	T/A	cg27495728	chr7:99067116	NA	-0.34	-6.02	-0.35	5.75e-9	Alopecia areata;
CESC	cis	rs4718428	0.672	rs4718412	chr7:66286867	C/T	cg12165864	chr7:66369176	NA	0.58	6.15	0.35	2.92e-9	Corneal structure;
CESC	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg17178900	chr1:205818956	PM20D1	0.63	10.13	0.53	1.32e-20	Monocyte percentage of white cells;
CESC	cis	rs12497850	0.931	rs10780033	chr3:48891275	T/C	cg02487422	chr3:49467188	NICN1	0.4	5.11	0.3	6.09e-7	Parkinson's disease;
CESC	cis	rs13191362	0.935	rs67368176	chr6:162968436	A/T	cg06582575	chr6:163149167	PACRG;PARK2	0.78	7.01	0.4	1.93e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs796364	0.951	rs6722092	chr2:201059371	G/T	cg23649088	chr2:200775458	C2orf69	0.5	5.26	0.31	2.98e-7	Schizophrenia;
CESC	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg11494091	chr17:61959527	GH2	-0.72	-12.38	-0.61	4.26e-28	Prudent dietary pattern;
CESC	cis	rs6831256	0.550	rs9993109	chr4:3473659	A/G	cg04102620	chr4:3473595	DOK7	0.34	5.45	0.32	1.15e-7	LDL cholesterol;Triglyceride levels;Triglycerides;Cholesterol, total;
CESC	cis	rs1570884	0.536	rs1359541	chr13:50158939	A/G	cg08779649	chr13:50194554	NA	0.37	6.37	0.36	8.27e-10	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
CESC	cis	rs9916302	0.904	rs9894500	chr17:37515735	G/C	cg15445000	chr17:37608096	MED1	-0.41	-6.6	-0.38	2.18e-10	Glomerular filtration rate (creatinine);
CESC	trans	rs7246760	0.867	rs58461110	chr19:9833390	G/A	cg02900749	chr2:68251473	NA	-0.85	-7.44	-0.42	1.38e-12	Pursuit maintenance gain;
CESC	cis	rs9815354	0.669	rs113059632	chr3:41932858	G/A	cg03022575	chr3:42003672	ULK4	0.71	6.44	0.37	5.46e-10	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs992157	0.835	rs4674283	chr2:219144254	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.67	-8.69	-0.47	3.72e-16	Colorectal cancer;
CESC	cis	rs1799949	1.000	rs4792981	chr17:41308274	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.65	8.99	0.48	4.96e-17	Menopause (age at onset);
CESC	cis	rs875971	0.545	rs1547529	chr7:65723846	T/C	cg25405998	chr7:65216604	CCT6P1	0.45	5.3	0.31	2.43e-7	Aortic root size;
CESC	cis	rs2303745	0.589	rs7246262	chr19:17392483	C/G	cg02221750	chr19:17393354	ANKLE1	-0.5	-6.08	-0.35	4.11e-9	Systemic lupus erythematosus;
CESC	cis	rs28386778	0.769	rs6504179	chr17:61812995	T/G	cg06873352	chr17:61820015	STRADA	0.7	12.06	0.6	5.25e-27	Prudent dietary pattern;
CESC	cis	rs11048434	0.736	rs2377672	chr12:9112414	A/G	cg23795048	chr12:9217529	LOC144571	0.36	5.53	0.32	7.76e-8	Sjögren's syndrome;
CESC	cis	rs4237845	0.537	rs1599931	chr12:58258850	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.49	5.48	0.32	9.9e-8	Intelligence (multi-trait analysis);
CESC	cis	rs6087990	0.748	rs4911255	chr20:31357580	A/T	cg13636640	chr20:31349939	DNMT3B	0.92	16.3	0.71	7.35e-42	Ulcerative colitis;
CESC	cis	rs992157	0.731	rs1399132	chr2:219159770	G/A	cg00012203	chr2:219082015	ARPC2	0.75	9.97	0.52	4.31e-20	Colorectal cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04774374	chr7:128379134	CALU	0.58	6.91	0.39	3.63e-11	Gut microbiome composition (summer);
CESC	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg26354017	chr1:205819088	PM20D1	0.97	17.12	0.72	9.23e-45	Menarche (age at onset);
CESC	cis	rs2304069	0.826	rs245076	chr5:149350648	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.66	9.0	0.48	4.47e-17	HIV-1 control;
CESC	cis	rs8017423	0.967	rs2277514	chr14:90723059	T/C	cg14092571	chr14:90743983	NA	-0.55	-8.31	-0.45	5.06e-15	Mortality in heart failure;
CESC	cis	rs853679	0.517	rs1340004	chr6:28103691	C/T	cg19592336	chr6:28129416	ZNF389	0.49	5.83	0.34	1.6e-8	Depression;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg26216002	chr1:10093067	UBE4B	-0.45	-6.2	-0.36	2.15e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg03452623	chr4:187889614	NA	-0.89	-14.8	-0.67	1.53e-36	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs11148252	0.553	rs7999849	chr13:53249414	A/G	cg18335740	chr13:41363409	SLC25A15	0.51	6.99	0.39	2.17e-11	Lewy body disease;
CESC	cis	rs875971	0.862	rs7786892	chr7:65628876	G/A	cg18876405	chr7:65276391	NA	-0.53	-7.38	-0.41	2.05e-12	Aortic root size;
CESC	cis	rs7762018	1.000	rs1127489	chr6:170107702	C/T	cg13891659	chr6:170190454	C6orf122;C6orf208	0.53	5.49	0.32	9.38e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs9486715	0.964	rs6921480	chr6:97066329	C/G	cg06623918	chr6:96969491	KIAA0776	-0.86	-12.58	-0.61	9.16e-29	Headache;
CESC	cis	rs79349575	0.783	rs15563	chr17:47005193	A/G	cg16584676	chr17:46985605	UBE2Z	0.53	6.68	0.38	1.4e-10	Type 2 diabetes;
CESC	cis	rs2637266	1.000	rs7474960	chr10:78359021	C/T	cg18941641	chr10:78392320	NA	0.41	7.89	0.44	7.87e-14	Pulmonary function;
CESC	cis	rs7618915	0.501	rs12635140	chr3:52738165	C/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	-0.33	-5.94	-0.34	9.12e-9	Bipolar disorder;
CESC	trans	rs11992162	1.000	rs11994417	chr8:11833262	G/A	cg15556689	chr8:8085844	FLJ10661	0.55	6.28	0.36	1.37e-9	Monocyte count;
CESC	cis	rs1355223	0.902	rs836466	chr11:34737366	G/T	cg11058730	chr11:34937778	PDHX;APIP	-0.48	-6.44	-0.37	5.45e-10	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs6138458	1.000	rs6707	chr20:24944166	C/T	cg06937882	chr20:24974362	C20orf3	-0.35	-5.06	-0.3	7.72e-7	Blood protein levels;
CESC	cis	rs4072980	0.545	rs11210870	chr1:38449910	T/C	cg17077180	chr1:38461687	NA	-0.43	-5.9	-0.34	1.14e-8	Coronary artery disease;
CESC	cis	rs919433	0.929	rs7592511	chr2:198177974	A/G	cg03934865	chr2:198174659	NA	-0.48	-7.53	-0.42	7.95e-13	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	trans	rs916888	0.821	rs199513	chr17:44856932	A/G	cg10053473	chr17:62856997	LRRC37A3	0.61	6.68	0.38	1.43e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs910316	0.836	rs6574212	chr14:75671659	G/A	cg08847533	chr14:75593920	NEK9	-0.94	-16.15	-0.7	2.56e-41	Height;
CESC	cis	rs12497850	0.931	rs12493289	chr3:48905161	G/A	cg02487422	chr3:49467188	NICN1	0.4	5.11	0.3	6.09e-7	Parkinson's disease;
CESC	cis	rs3741404	0.825	rs2515241	chr11:63975331	C/T	cg18225595	chr11:63971243	STIP1	0.73	10.09	0.53	1.74e-20	Platelet count;
CESC	cis	rs796364	0.760	rs1569178	chr2:201024512	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.74	-6.24	-0.36	1.76e-9	Schizophrenia;
CESC	cis	rs12042107	0.841	rs1008078	chr1:91189731	C/T	cg13456504	chr1:91191583	NA	-0.33	-5.7	-0.33	3.14e-8	Educational attainment;
CESC	cis	rs17711722	0.653	rs2460421	chr7:65491123	A/T	cg19163074	chr7:65112434	INTS4L2	0.5	6.44	0.37	5.52e-10	Calcium levels;
CESC	cis	rs4722166	0.630	rs4722169	chr7:22785419	C/T	cg13104385	chr7:22767384	IL6	0.48	6.36	0.36	8.7e-10	Lung cancer;
CESC	cis	rs798554	0.679	rs2266922	chr7:2824707	G/A	cg09658497	chr7:2847517	GNA12	-0.38	-5.79	-0.34	1.96e-8	Height;
CESC	cis	rs4253772	0.637	rs56017104	chr22:46651982	A/G	cg10541313	chr22:46663664	TTC38	0.74	5.91	0.34	1.02e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs769267	1.000	rs1009136	chr19:19440428	A/G	cg15052019	chr19:19431593	KIAA0892;SF4	-0.4	-5.07	-0.3	7.59e-7	Tonsillectomy;
CESC	cis	rs11098499	0.954	rs1546505	chr4:120241224	A/G	cg09307838	chr4:120376055	NA	0.89	12.09	0.6	4.26e-27	Corneal astigmatism;
CESC	cis	rs11642862	1.000	rs11642466	chr16:30781942	A/G	cg02466173	chr16:30829666	NA	-0.6	-6.08	-0.35	4.15e-9	Tonsillectomy;
CESC	cis	rs13064411	0.696	rs869342	chr3:113226330	C/T	cg18753928	chr3:113234510	CCDC52	-0.5	-6.13	-0.35	3.23e-9	Response to simvastatin treatment (PCSK9 protein level change);
CESC	cis	rs4974559	0.739	rs28429103	chr4:1320023	G/A	cg02980000	chr4:1222292	CTBP1	0.78	7.02	0.4	1.86e-11	Systolic blood pressure;
CESC	cis	rs11190604	1.000	rs10883506	chr10:102289743	C/G	cg07080220	chr10:102295463	HIF1AN	0.7	6.48	0.37	4.34e-10	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs7551222	0.749	rs10900600	chr1:204559707	G/T	cg20240347	chr1:204465584	NA	-0.28	-5.78	-0.33	2.09e-8	Schizophrenia;
CESC	cis	rs2228479	0.717	rs17233678	chr16:89809962	T/C	cg06558623	chr16:89946397	TCF25	1.17	9.44	0.5	1.96e-18	Skin colour saturation;
CESC	cis	rs12995491	0.843	rs1878809	chr2:88518315	C/T	cg14558114	chr2:88469736	THNSL2	-0.53	-7.35	-0.41	2.51e-12	Response to metformin (IC50);
CESC	cis	rs1799949	1.000	rs34942571	chr17:41273379	G/C	cg23758822	chr17:41437982	NA	1.03	15.32	0.69	2.32e-38	Menopause (age at onset);
CESC	cis	rs6582630	0.519	rs8189609	chr12:38281408	A/G	cg13010199	chr12:38710504	ALG10B	0.52	6.38	0.36	8.04e-10	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs60871478	1.000	rs4720930	chr7:808073	G/A	cg05535760	chr7:792225	HEATR2	0.94	10.83	0.55	7.19e-23	Cerebrospinal P-tau181p levels;
CESC	cis	rs763121	0.853	rs3747172	chr22:39067524	A/G	cg06544989	chr22:39130855	UNC84B	0.5	8.88	0.48	1.05e-16	Menopause (age at onset);
CESC	cis	rs7943191	0.805	rs12226821	chr11:62369018	C/G	cg13298116	chr11:62369859	EML3;MTA2	0.53	7.38	0.41	2.06e-12	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
CESC	cis	rs1799949	0.965	rs799912	chr17:41257134	T/C	cg23758822	chr17:41437982	NA	0.99	17.68	0.74	1.01e-46	Menopause (age at onset);
CESC	cis	rs4555082	0.834	rs2735819	chr14:105713449	C/T	cg13114125	chr14:105738426	BRF1	-0.8	-9.77	-0.51	1.83e-19	Mean platelet volume;Platelet distribution width;
CESC	cis	rs888194	0.651	rs6606734	chr12:110013639	T/G	cg19025524	chr12:109796872	NA	-0.34	-5.08	-0.3	7.25e-7	Neuroticism;
CESC	cis	rs60871478	0.636	rs12534606	chr7:895928	A/G	cg15782153	chr7:917662	C7orf20	0.52	5.72	0.33	2.91e-8	Cerebrospinal P-tau181p levels;
CESC	cis	rs2046867	0.818	rs62249874	chr3:72911202	G/C	cg25664220	chr3:72788482	NA	-0.45	-6.48	-0.37	4.56e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CESC	cis	rs13191362	1.000	rs73008453	chr6:163013384	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.87	8.98	0.48	5.33e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs1256061	0.624	rs1152586	chr14:64690784	T/C	cg23250157	chr14:64679961	SYNE2	0.53	7.51	0.42	9.13e-13	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs2302190	0.882	rs7213415	chr17:56672433	C/G	cg25885038	chr17:56607967	SEPT4	-0.4	-5.43	-0.32	1.27e-7	Vitamin D levels;
CESC	cis	rs644799	1.000	rs527899	chr11:95529242	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.92	13.87	0.65	2.93e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs868036	0.681	rs2241423	chr15:68086838	G/A	cg08079166	chr15:68083412	MAP2K5	0.35	5.1	0.3	6.47e-7	Restless legs syndrome;
CESC	cis	rs4699052	0.625	rs7695593	chr4:104263783	A/T	cg16532752	chr4:104119610	CENPE	-0.38	-5.32	-0.31	2.19e-7	Testicular germ cell tumor;
CESC	cis	rs2228479	0.850	rs62056068	chr16:89909737	C/T	cg04013166	chr16:89971882	TCF25	0.72	5.75	0.33	2.41e-8	Skin colour saturation;
CESC	cis	rs4853012	1.000	rs4853012	chr2:74361290	G/A	cg01017244	chr2:74357527	NA	0.72	8.74	0.47	2.8e-16	Gestational age at birth (maternal effect);
CESC	cis	rs78456975	0.941	rs13412229	chr2:1520381	C/T	cg01028140	chr2:1542097	TPO	-0.57	-5.49	-0.32	9.47e-8	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs9488822	0.636	rs11153592	chr6:116330574	T/C	cg05304507	chr6:116381966	FRK	0.25	6.49	0.37	4.22e-10	Cholesterol, total;LDL cholesterol;
CESC	cis	rs7100689	0.622	rs2342816	chr10:82086546	G/A	cg00277334	chr10:82204260	NA	-0.6	-7.96	-0.44	4.91e-14	Post bronchodilator FEV1;
CESC	cis	rs858239	0.570	rs10235467	chr7:23148808	C/T	cg23682824	chr7:23144976	KLHL7	0.54	7.45	0.42	1.32e-12	Cerebrospinal fluid biomarker levels;
CESC	cis	rs13034020	0.522	rs13017457	chr2:61248645	G/A	cg18625361	chr2:61244694	PEX13;PUS10	0.66	5.9	0.34	1.13e-8	Hodgkin's lymphoma;
CESC	cis	rs12681288	0.862	rs7814231	chr8:1021103	A/G	cg15309053	chr8:964076	NA	0.33	5.58	0.32	5.82e-8	Schizophrenia;
CESC	cis	rs1670533	1.000	rs10031302	chr4:1059664	G/A	cg27284194	chr4:1044797	NA	0.48	6.12	0.35	3.43e-9	Recombination rate (females);
CESC	cis	rs7945705	0.967	rs10769968	chr11:8907583	G/C	cg21881798	chr11:8931708	C11orf17;ST5	0.5	7.97	0.44	4.84e-14	Hemoglobin concentration;
CESC	cis	rs4803468	1.000	rs284656	chr19:41929251	T/C	cg08639244	chr19:41945921	ATP5SL	-0.42	-5.11	-0.3	6.12e-7	Height;
CESC	cis	rs113835537	0.866	rs59566349	chr11:66365994	A/T	cg22134325	chr11:66188745	NPAS4	0.52	5.9	0.34	1.13e-8	Airway imaging phenotypes;
CESC	cis	rs2274273	0.967	rs2094102	chr14:55591098	T/C	cg04306507	chr14:55594613	LGALS3	0.31	6.15	0.35	2.91e-9	Protein biomarker;
CESC	cis	rs7264396	0.790	rs6060518	chr20:34217309	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.87	-11.9	-0.59	1.96e-26	Total cholesterol levels;
CESC	cis	rs2637266	0.714	rs7082421	chr10:78446313	G/A	cg18941641	chr10:78392320	NA	0.4	7.28	0.41	3.76e-12	Pulmonary function;
CESC	cis	rs6752107	0.936	rs6431660	chr2:234167234	A/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.46	6.34	0.36	1.01e-9	Crohn's disease;Inflammatory bowel disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09026481	chr5:74633022	HMGCR	0.59	6.37	0.36	8.55e-10	Gut microbiome composition (summer);
CESC	cis	rs9733	0.596	rs1415148	chr1:150705755	G/A	cg04414720	chr1:150670196	GOLPH3L	0.62	8.8	0.48	1.76e-16	Tonsillectomy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17150465	chr8:144897558	SCRIB	0.55	6.71	0.38	1.18e-10	Gut microbiome composition (summer);
CESC	cis	rs56399783	0.901	rs11764225	chr7:2775607	G/A	cg19731401	chr7:2775893	GNA12	0.67	6.12	0.35	3.39e-9	Childhood ear infection;
CESC	cis	rs9733	0.596	rs6669369	chr1:150695892	C/T	cg09365446	chr1:150670422	GOLPH3L	0.42	5.84	0.34	1.55e-8	Tonsillectomy;
CESC	cis	rs1865721	0.804	rs7229401	chr18:73148127	T/G	cg26385618	chr18:73139727	C18orf62	-0.51	-7.88	-0.44	8.26e-14	Intelligence;
CESC	cis	rs9926296	0.605	rs3743859	chr16:89846050	A/G	cg04287289	chr16:89883240	FANCA	-0.87	-14.96	-0.68	4.15e-37	Vitiligo;
CESC	cis	rs7680126	0.596	rs4697714	chr4:10143786	A/T	cg11266682	chr4:10021025	SLC2A9	-0.42	-5.94	-0.34	9.04e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	cis	rs1552244	1.000	rs4269070	chr3:10126083	C/G	cg00166722	chr3:10149974	C3orf24	0.54	7.12	0.4	1.02e-11	Alzheimer's disease;
CESC	cis	rs7772486	0.790	rs4314514	chr6:146260010	A/G	cg23711669	chr6:146136114	FBXO30	-0.92	-13.3	-0.63	2.94e-31	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7666738	0.830	rs4699584	chr4:98952019	A/G	cg05340658	chr4:99064831	C4orf37	0.8	12.4	0.61	3.71e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.07	10.54	0.54	6.37e-22	Platelet count;
CESC	cis	rs17253792	0.822	rs10136155	chr14:56049129	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.86	6.26	0.36	1.58e-9	Putamen volume;
CESC	cis	rs9318086	0.648	rs9510927	chr13:24467641	T/C	cg25267304	chr13:24462978	PCOTH;MIPEP	0.49	6.93	0.39	3.23e-11	Myopia (pathological);
CESC	cis	rs8031584	0.678	rs8035703	chr15:31168472	T/C	cg08704250	chr15:31115839	NA	-0.68	-9.17	-0.49	1.35e-17	Huntington's disease progression;
CESC	cis	rs708547	0.581	rs10020462	chr4:57825593	C/T	cg25525207	chr4:57843836	C4orf14;POLR2B	0.46	5.49	0.32	9.65e-8	Response to bleomycin (chromatid breaks);
CESC	cis	rs7980687	0.662	rs585522	chr12:123550813	A/G	cg05973401	chr12:123451056	ABCB9	0.62	6.99	0.39	2.27e-11	Height;Educational attainment;Head circumference (infant);
CESC	cis	rs4911259	0.552	rs6058926	chr20:31465450	T/C	cg13636640	chr20:31349939	DNMT3B	-0.54	-7.47	-0.42	1.16e-12	Inflammatory bowel disease;
CESC	cis	rs17826219	0.706	rs2322197	chr17:29105805	T/C	cg19761014	chr17:28927070	LRRC37B2	0.71	5.97	0.34	7.65e-9	Body mass index;
CESC	cis	rs7937682	0.632	rs11214037	chr11:111773296	C/T	cg09085632	chr11:111637200	PPP2R1B	0.88	11.23	0.57	3.37e-24	Primary sclerosing cholangitis;
CESC	cis	rs7851660	0.874	rs925487	chr9:100636398	C/T	cg13688889	chr9:100608707	NA	-0.62	-8.62	-0.47	6.13e-16	Strep throat;
CESC	cis	rs763121	0.853	rs2179142	chr22:39037954	G/A	cg21395723	chr22:39101663	GTPBP1	0.45	5.66	0.33	3.97e-8	Menopause (age at onset);
CESC	cis	rs1448094	0.817	rs10863112	chr12:86330844	C/T	cg02569458	chr12:86230093	RASSF9	0.45	6.43	0.37	5.79e-10	Major depressive disorder;
CESC	cis	rs1152591	0.643	rs3020449	chr14:64773392	C/T	cg21174375	chr14:64681225	SYNE2	-0.53	-6.95	-0.39	2.88e-11	Atrial fibrillation;
CESC	trans	rs28549925	0.590	rs17136950	chr7:16994248	G/T	cg12639933	chr12:57626296	SHMT2	0.95	6.1	0.35	3.74e-9	Congenital heart disease (maternal effect);Conotruncal heart defects (maternal effects);
CESC	cis	rs12477438	0.871	rs62156364	chr2:99695097	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.65	-7.95	-0.44	5.45e-14	Chronic sinus infection;
CESC	cis	rs1448094	0.512	rs7957170	chr12:86243282	A/G	cg00310523	chr12:86230176	RASSF9	0.35	5.44	0.32	1.21e-7	Major depressive disorder;
CESC	cis	rs965469	1.000	rs6051807	chr20:3350485	A/G	cg25506879	chr20:3388711	C20orf194	-0.58	-5.97	-0.34	7.49e-9	IFN-related cytopenia;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg09090048	chr11:134093731	VPS26B;NCAPD3	-0.39	-6.19	-0.36	2.27e-9	Gambling;
CESC	cis	rs875971	0.862	rs10950043	chr7:65988610	T/C	cg10691866	chr7:65817282	TPST1	-0.33	-5.39	-0.31	1.58e-7	Aortic root size;
CESC	cis	rs780096	0.506	rs1647286	chr2:27714517	A/T	cg21248554	chr2:27665150	KRTCAP3	-0.36	-7.42	-0.41	1.59e-12	Total body bone mineral density;
CESC	cis	rs8044995	0.706	rs111948678	chr16:68255959	G/A	cg26727032	chr16:67993705	SLC12A4	-0.48	-5.18	-0.3	4.5e-7	Schizophrenia;
CESC	cis	rs7726839	0.561	rs3915384	chr5:573395	G/T	cg16447950	chr5:562315	NA	-0.54	-5.98	-0.34	7.29e-9	Obesity-related traits;
CESC	cis	rs6964587	1.000	rs4727267	chr7:91570290	G/C	cg17063962	chr7:91808500	NA	-0.57	-7.62	-0.42	4.53e-13	Breast cancer;
CESC	cis	rs6540559	0.543	rs672819	chr1:210436404	T/A	cg23283495	chr1:209979779	IRF6	0.43	5.19	0.3	4.16e-7	Cleft lip with or without cleft palate;
CESC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg14751398	chr6:20402153	E2F3	0.47	6.03	0.35	5.57e-9	Tetralogy of Fallot;
CESC	cis	rs4144743	0.759	rs16969966	chr17:45318452	G/T	cg18085866	chr17:45331354	ITGB3	-0.57	-5.66	-0.33	3.88e-8	Body mass index;
CESC	cis	rs6912958	0.781	rs6454631	chr6:88225863	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.5	-6.55	-0.37	3.01e-10	Monocyte percentage of white cells;
CESC	cis	rs7917772	0.503	rs2031602	chr10:104307955	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.56	7.87	0.44	9.28e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs79839061	0.656	rs11726508	chr4:888937	C/T	cg04824913	chr4:887549	GAK	0.6	5.16	0.3	4.96e-7	Intelligence (multi-trait analysis);
CESC	cis	rs868036	1.000	rs3784719	chr15:68098180	C/T	cg08079166	chr15:68083412	MAP2K5	0.44	6.94	0.39	2.94e-11	Restless legs syndrome;
CESC	cis	rs1799949	1.000	rs12944597	chr17:41187684	A/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.61	7.83	0.43	1.21e-13	Menopause (age at onset);
CESC	cis	rs61931739	0.746	rs1687003	chr12:34170099	T/A	cg19457237	chr12:34500585	NA	-0.41	-5.63	-0.33	4.55e-8	Morning vs. evening chronotype;
CESC	cis	rs17001868	0.568	rs2280790	chr22:40745181	T/C	cg07138101	chr22:40742427	ADSL	0.55	5.2	0.3	3.96e-7	Mammographic density (dense area);
CESC	cis	rs2832191	0.967	rs2832216	chr21:30521921	C/T	cg24692254	chr21:30365293	RNF160	0.73	10.88	0.56	4.79e-23	Dental caries;
CESC	cis	rs5498	0.809	rs1056538	chr19:10402938	G/A	cg08845333	chr19:10403403	ICAM5	0.4	5.49	0.32	9.2e-8	Lymphocyte counts;Soluble ICAM-1;Blood protein levels;
CESC	cis	rs7116495	1.000	rs949325	chr11:71729656	A/G	cg26138937	chr11:71823887	C11orf51	-0.77	-6.35	-0.36	9.29e-10	Severe influenza A (H1N1) infection;
CESC	cis	rs1799949	1.000	rs11658754	chr17:41292739	G/A	cg06001716	chr17:41278141	BRCA1;NBR2	0.39	5.26	0.31	3e-7	Menopause (age at onset);
CESC	cis	rs4604732	0.631	rs4411161	chr1:247632374	G/A	cg12758973	chr1:247694275	LOC148824;OR2C3	0.43	5.42	0.32	1.37e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs8017423	0.569	rs10141476	chr14:90823351	C/T	cg14092571	chr14:90743983	NA	0.44	6.77	0.38	8.12e-11	Mortality in heart failure;
CESC	cis	rs9457247	0.905	rs444210	chr6:167390242	A/G	cg23791538	chr6:167370224	RNASET2	-0.62	-8.79	-0.47	1.99e-16	Crohn's disease;
CESC	trans	rs61931739	0.500	rs28692887	chr12:34457075	G/A	cg13010199	chr12:38710504	ALG10B	0.48	6.28	0.36	1.38e-9	Morning vs. evening chronotype;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17903999	chr18:56338584	MALT1	0.58	6.65	0.38	1.72e-10	Gut microbiome composition (summer);
CESC	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.89	13.48	0.64	7.06e-32	Prudent dietary pattern;
CESC	cis	rs35306767	0.714	rs28512382	chr10:1092195	G/C	cg26597838	chr10:835615	NA	0.61	5.91	0.34	1.07e-8	Eosinophil percentage of granulocytes;
CESC	cis	rs9916302	0.861	rs11078913	chr17:37671714	G/T	cg15445000	chr17:37608096	MED1	0.4	6.63	0.38	1.89e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs6541297	1.000	rs4846838	chr1:230281618	G/A	cg05784532	chr1:230284198	GALNT2	0.5	5.61	0.33	5.13e-8	Coronary artery disease;
CESC	cis	rs10078	0.515	rs1053299	chr5:470760	G/A	cg08916839	chr5:415575	AHRR	0.58	6.76	0.38	8.54e-11	Fat distribution (HIV);
CESC	cis	rs13191362	1.000	rs34228197	chr6:163008232	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.49	5.36	0.31	1.82e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs2836974	0.549	rs34160989	chr21:40554118	C/G	cg11890956	chr21:40555474	PSMG1	0.93	9.99	0.52	3.81e-20	Cognitive function;
CESC	cis	rs4819052	0.788	rs4819051	chr21:46693128	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.45	5.67	0.33	3.77e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs72945132	0.882	rs7122057	chr11:70201430	T/C	cg14191688	chr11:70257035	CTTN	0.43	5.41	0.32	1.42e-7	Coronary artery disease;
CESC	cis	rs10754283	0.840	rs6428560	chr1:90102462	A/T	cg21401794	chr1:90099060	LRRC8C	0.71	9.51	0.5	1.24e-18	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs801193	1.000	rs4279493	chr7:66226620	C/T	cg10691866	chr7:65817282	TPST1	-0.32	-5.04	-0.3	8.78e-7	Aortic root size;
CESC	cis	rs4665809	0.590	rs62128457	chr2:26467347	C/A	cg04944784	chr2:26401820	FAM59B	0.96	10.55	0.54	5.79e-22	Gut microbiome composition (summer);
CESC	cis	rs7129220	0.588	rs61878625	chr11:10123136	T/C	cg01453529	chr11:10209919	SBF2	-0.49	-5.67	-0.33	3.71e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CESC	cis	rs7937682	1.000	rs11213980	chr11:111562692	A/T	cg22437258	chr11:111473054	SIK2	-0.55	-6.47	-0.37	4.72e-10	Primary sclerosing cholangitis;
CESC	cis	rs875971	0.522	rs56028712	chr7:65466565	C/T	cg11764359	chr7:65958608	NA	0.68	8.78	0.47	2.08e-16	Aortic root size;
CESC	cis	rs11098499	0.722	rs10025925	chr4:120271744	A/T	cg09307838	chr4:120376055	NA	0.77	10.19	0.53	8.72e-21	Corneal astigmatism;
CESC	cis	rs11112613	0.775	rs12371537	chr12:105971425	T/C	cg03607813	chr12:105948248	NA	0.56	6.26	0.36	1.58e-9	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CESC	cis	rs116095464	0.764	rs10069197	chr5:230822	G/C	cg12570787	chr5:219185	SDHA;CCDC127	0.53	5.69	0.33	3.34e-8	Breast cancer;
CESC	cis	rs1729951	0.575	rs1682333	chr3:136688618	G/A	cg03617693	chr3:136751559	NA	0.38	5.32	0.31	2.21e-7	Neuroticism;
CESC	cis	rs1124376	1.000	rs10084714	chr3:20183332	T/C	cg05072819	chr3:20081367	KAT2B	0.51	5.56	0.32	6.54e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs1355223	0.872	rs1258466	chr11:34730066	T/A	cg11058730	chr11:34937778	PDHX;APIP	-0.48	-6.41	-0.37	6.58e-10	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.71	9.9	0.52	7.25e-20	Prudent dietary pattern;
CESC	cis	rs4950928	0.823	rs2153101	chr1:203168474	A/T	cg14085262	chr1:203155938	CHI3L1	-0.49	-5.55	-0.32	6.96e-8	YKL-40 levels;
CESC	cis	rs9300255	0.510	rs1727323	chr12:123698790	T/C	cg19016782	chr12:123741754	C12orf65	-0.45	-6.51	-0.37	3.65e-10	Neutrophil percentage of white cells;
CESC	cis	rs9811920	0.535	rs792831	chr3:99473720	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.34	-5.45	-0.32	1.14e-7	Axial length;
CESC	cis	rs3820928	0.839	rs12151848	chr2:227859326	G/A	cg11843606	chr2:227700838	RHBDD1	-0.42	-5.45	-0.32	1.12e-7	Pulmonary function;
CESC	cis	rs9815354	0.812	rs73077358	chr3:41850005	C/T	cg03022575	chr3:42003672	ULK4	0.7	6.04	0.35	5.26e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs5747327	0.804	rs2401165	chr22:18147071	C/T	cg19898043	chr22:18121309	BCL2L13	-0.41	-5.18	-0.3	4.41e-7	Myeloid white cell count;Granulocyte count;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg03885022	chr7:92158293	C7orf64;PEX1	-0.46	-6.44	-0.37	5.48e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs9303280	0.776	rs11078926	chr17:38062976	G/A	cg20243544	chr17:37824526	PNMT	0.53	6.87	0.39	4.54e-11	Self-reported allergy;
CESC	cis	rs4722166	0.695	rs7787893	chr7:22774437	A/G	cg05265849	chr7:22767390	IL6	0.44	6.16	0.35	2.68e-9	Lung cancer;
CESC	cis	rs858239	0.669	rs6461688	chr7:23116615	G/A	cg27449745	chr7:23145252	KLHL7	-0.46	-5.83	-0.34	1.58e-8	Cerebrospinal fluid biomarker levels;
CESC	cis	rs7210086	0.768	rs4485409	chr17:70640381	C/T	cg04206342	chr17:70636940	NA	-0.28	-5.15	-0.3	5.13e-7	Ulcerative colitis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09645772	chr5:180688272	TRIM52	0.6	6.65	0.38	1.63e-10	Gut microbiome composition (summer);
CESC	cis	rs864537	0.676	rs2056625	chr1:167420299	G/A	cg22356347	chr1:167427500	CD247	-0.39	-8.01	-0.44	3.69e-14	Celiac disease or Rheumatoid arthritis;Celiac disease;
CESC	cis	rs7618915	0.571	rs11130307	chr3:52607682	G/A	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.38	6.72	0.38	1.13e-10	Bipolar disorder;
CESC	cis	rs4253772	0.550	rs12165597	chr22:46705584	A/G	cg18190219	chr22:46762943	CELSR1	-0.59	-6.7	-0.38	1.23e-10	LDL cholesterol;Cholesterol, total;
CESC	cis	rs910316	0.967	rs8013444	chr14:75661981	A/G	cg11812906	chr14:75593930	NEK9	-0.85	-13.99	-0.65	1.13e-33	Height;
CESC	cis	rs2576037	0.583	rs501882	chr18:44411066	A/T	cg19077165	chr18:44547161	KATNAL2	-0.58	-8.68	-0.47	4e-16	Personality dimensions;
CESC	cis	rs2836974	0.897	rs11911112	chr21:40528346	A/C	cg11890956	chr21:40555474	PSMG1	1.18	24.03	0.83	1.59e-68	Cognitive function;
CESC	cis	rs7949030	0.626	rs35587183	chr11:62318656	C/T	cg13298116	chr11:62369859	EML3;MTA2	0.53	7.41	0.41	1.67e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs2637266	0.600	rs11591359	chr10:78339907	G/A	cg18941641	chr10:78392320	NA	-0.35	-5.42	-0.32	1.31e-7	Pulmonary function;
CESC	cis	rs9393777	0.513	rs13190754	chr6:26587406	G/A	cg12292205	chr6:26970375	C6orf41	-0.49	-5.63	-0.33	4.53e-8	Intelligence (multi-trait analysis);
CESC	cis	rs9640161	0.830	rs36069544	chr7:150061538	G/A	cg21361702	chr7:150065534	REPIN1	0.69	8.27	0.45	6.42e-15	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs748404	0.660	rs2467738	chr15:43739936	T/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.53	8.38	0.46	3.14e-15	Lung cancer;
CESC	cis	rs9287719	0.967	rs6432122	chr2:10753844	A/G	cg02196655	chr2:10830764	NOL10	-0.37	-5.69	-0.33	3.39e-8	Prostate cancer;
CESC	cis	rs12479064	0.724	rs3087403	chr2:100058870	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.65	-7.95	-0.44	5.33e-14	Chronic sinus infection;
CESC	cis	rs926938	0.608	rs360612	chr1:115394747	G/A	cg12756093	chr1:115239321	AMPD1	0.46	6.21	0.36	2.03e-9	Autism;
CESC	cis	rs7267979	0.966	rs2257705	chr20:25264664	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	18.61	0.75	5.02e-50	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs3026445	0.925	rs73206861	chr12:110798562	A/T	cg12870014	chr12:110450643	ANKRD13A	0.42	5.2	0.3	4.06e-7	QT interval;
CESC	cis	rs10744422	1.000	rs7138398	chr12:123341833	G/C	cg25930673	chr12:123319894	HIP1R	-0.81	-6.32	-0.36	1.09e-9	Schizophrenia;
CESC	trans	rs61931739	0.517	rs12816423	chr12:34067736	G/A	cg26384229	chr12:38710491	ALG10B	0.6	8.38	0.46	3.12e-15	Morning vs. evening chronotype;
CESC	cis	rs35306767	0.903	rs11815185	chr10:923617	T/A	cg20503657	chr10:835505	NA	0.76	8.01	0.44	3.56e-14	Eosinophil percentage of granulocytes;
CESC	cis	rs965469	0.779	rs6037581	chr20:3351595	C/T	cg17110299	chr20:3385021	C20orf194	0.39	5.12	0.3	5.87e-7	IFN-related cytopenia;
CESC	cis	rs3015469	0.550	rs2236316	chr14:51224417	C/G	cg26011998	chr14:51135199	SAV1	0.47	5.21	0.31	3.72e-7	Plasma amyloid beta peptide concentrations (ABx-40);
CESC	cis	rs12999616	0.948	rs35958372	chr2:98330858	T/C	cg26665480	chr2:98280029	ACTR1B	0.58	5.71	0.33	2.97e-8	Colorectal cancer;
CESC	cis	rs962856	0.575	rs598108	chr2:67656232	G/A	cg09028215	chr2:67624308	ETAA1	-0.43	-5.23	-0.31	3.45e-7	Pancreatic cancer;
CESC	cis	rs6460942	0.730	rs73053536	chr7:12323131	C/G	cg20607287	chr7:12443886	VWDE	-0.78	-8.01	-0.44	3.61e-14	Coronary artery disease;
CESC	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.89	13.67	0.64	1.49e-32	Prudent dietary pattern;
CESC	cis	rs11650494	0.908	rs75904857	chr17:47370449	T/G	cg08112188	chr17:47440006	ZNF652	1.22	8.11	0.45	1.93e-14	Prostate cancer;
CESC	cis	rs8180040	1.000	rs7613282	chr3:47389409	C/T	cg27129171	chr3:47204927	SETD2	-0.66	-10.19	-0.53	8.43e-21	Colorectal cancer;
CESC	cis	rs6495122	0.644	rs11630087	chr15:75261673	G/T	cg17294928	chr15:75287854	SCAMP5	0.49	6.17	0.35	2.54e-9	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
CESC	cis	rs4237845	0.586	rs4760174	chr12:58320436	G/A	cg02175503	chr12:58329896	NA	0.93	15.08	0.68	1.59e-37	Intelligence (multi-trait analysis);
CESC	cis	rs367615	0.552	rs7720036	chr5:108710699	A/G	cg17395555	chr5:108820864	NA	-0.52	-8.52	-0.46	1.24e-15	Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs8077889	1.000	rs2880329	chr17:41866168	T/A	cg26893861	chr17:41843967	DUSP3	0.85	9.86	0.52	1e-19	Triglycerides;
CESC	cis	rs798554	0.679	rs2527677	chr7:2882621	A/G	cg18446336	chr7:2847575	GNA12	-0.36	-5.64	-0.33	4.32e-8	Height;
CESC	cis	rs258892	0.947	rs250517	chr5:72200626	G/C	cg21869765	chr5:72125136	TNPO1	0.45	5.62	0.33	4.9e-8	Small cell lung carcinoma;
CESC	cis	rs72781680	1.000	rs11553491	chr2:24225901	G/C	cg20701182	chr2:24300061	SF3B14	0.74	6.38	0.36	7.9e-10	Lymphocyte counts;
CESC	cis	rs7811142	1.000	rs2406255	chr7:100053690	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.04	9.6	0.51	6.59e-19	Platelet count;
CESC	cis	rs17433780	0.892	rs72726528	chr1:89455980	C/A	cg09516651	chr1:89888402	LOC400759	0.67	9.06	0.49	2.92e-17	Carotid intima media thickness;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22818988	chr3:3168509	TRNT1	0.58	6.93	0.39	3.17e-11	Gut microbiome composition (summer);
CESC	cis	rs888194	0.690	rs888192	chr12:109995097	C/T	cg19025524	chr12:109796872	NA	0.34	5.17	0.3	4.56e-7	Neuroticism;
CESC	cis	rs4689388	0.890	rs9993624	chr4:6286528	C/T	cg25554036	chr4:6271136	WFS1	0.53	8.62	0.47	6.35e-16	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs7635838	0.686	rs347589	chr3:11288419	A/G	cg00170343	chr3:11313890	ATG7	0.52	7.21	0.41	5.79e-12	HDL cholesterol;
CESC	cis	rs644799	1.000	rs593665	chr11:95574302	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.55	6.52	0.37	3.44e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs514406	0.505	rs405208	chr1:53176674	C/T	cg08736216	chr1:53307985	ZYG11A	-0.4	-6.53	-0.37	3.32e-10	Monocyte count;
CESC	cis	rs9888739	0.800	rs1143683	chr16:31336888	A/G	cg15817542	chr16:31343056	ITGAM	0.49	7.29	0.41	3.57e-12	Systemic lupus erythematosus;
CESC	cis	rs7408868	1.000	rs10416389	chr19:15278674	G/C	cg14696996	chr19:15285081	NOTCH3	1.11	11.94	0.59	1.43e-26	Pulse pressure;
CESC	cis	rs10851478	0.872	rs12907944	chr15:49906971	G/A	cg08060515	chr15:49448048	GALK2;COPS2	0.43	5.26	0.31	3e-7	Oral cavity cancer;
CESC	trans	rs7095944	0.614	rs10901816	chr10:126440395	G/A	cg27222157	chr11:66382978	RBM14	0.38	6.13	0.35	3.17e-9	Asthma;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00009214	chr12:16064569	DERA	0.66	7.3	0.41	3.42e-12	Gut microbiome composition (summer);
CESC	cis	rs2295499	0.673	rs55993221	chr4:2704910	G/T	cg08330972	chr4:2403930	ZFYVE28	-0.32	-5.24	-0.31	3.34e-7	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
CESC	cis	rs2247341	0.965	rs2854913	chr4:1723137	A/T	cg07465881	chr4:1713556	SLBP	-0.51	-6.21	-0.36	2.04e-9	Hip circumference adjusted for BMI;Height;
CESC	cis	rs6500602	0.598	rs3859155	chr16:4593741	A/C	cg08645402	chr16:4508243	NA	-0.45	-7.2	-0.4	6.32e-12	Schizophrenia;
CESC	cis	rs8177179	0.967	rs6782434	chr3:133438834	C/G	cg17775713	chr3:133465469	TF	0.33	6.0	0.35	6.57e-9	Iron status biomarkers (transferrin levels);
CESC	cis	rs9788682	0.747	rs2568499	chr15:78722359	T/C	cg24631222	chr15:78858424	CHRNA5	-0.6	-6.99	-0.39	2.2e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs7301826	0.627	rs73162873	chr12:131296013	A/G	cg11011512	chr12:131303247	STX2	0.47	5.84	0.34	1.52e-8	Plasma plasminogen activator levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14584159	chr10:134351371	INPP5A	0.65	7.81	0.43	1.34e-13	Gut microbiome composition (summer);
CESC	cis	rs9325144	0.560	rs2013804	chr12:38631079	C/T	cg26384229	chr12:38710491	ALG10B	-0.61	-9.62	-0.51	5.7e-19	Morning vs. evening chronotype;
CESC	cis	rs3091242	0.900	rs1883427	chr1:25744468	C/T	cg02931644	chr1:25747376	RHCE	0.42	6.98	0.39	2.36e-11	Erythrocyte sedimentation rate;
CESC	trans	rs1814175	0.645	rs866427	chr11:49923853	G/A	cg15704280	chr7:45808275	SEPT13	-1.01	-18.94	-0.76	3.64e-51	Height;
CESC	cis	rs4319547	0.915	rs10734924	chr12:123018894	T/G	cg05707623	chr12:122985044	ZCCHC8	-0.59	-6.72	-0.38	1.11e-10	Body mass index;
CESC	cis	rs11650776	1	rs11650776	chr17:37641402	G/A	cg07936489	chr17:37558343	FBXL20	-0.81	-11.96	-0.59	1.17e-26	Lung function (FEV1);
CESC	cis	rs412050	0.547	rs61757982	chr22:22113740	A/G	cg17089214	chr22:22089827	YPEL1	0.71	6.1	0.35	3.78e-9	Attention deficit hyperactivity disorder;
CESC	cis	rs6545883	0.929	rs6545873	chr2:61733012	T/C	cg15711740	chr2:61764176	XPO1	-0.43	-5.4	-0.31	1.47e-7	Tuberculosis;
CESC	cis	rs709400	0.663	rs7158822	chr14:103887868	C/T	cg12935359	chr14:103987150	CKB	-0.5	-7.3	-0.41	3.28e-12	Body mass index;
CESC	cis	rs7605827	0.930	rs11676115	chr2:15602962	G/A	cg19274914	chr2:15703543	NA	0.34	6.09	0.35	3.92e-9	Educational attainment (years of education);
CESC	cis	rs1552244	1.000	rs6781811	chr3:10121922	A/G	cg08888203	chr3:10149979	C3orf24	-0.52	-6.96	-0.39	2.65e-11	Alzheimer's disease;
CESC	cis	rs1448094	0.511	rs10506920	chr12:86165212	A/T	cg00310523	chr12:86230176	RASSF9	0.35	5.56	0.32	6.53e-8	Major depressive disorder;
CESC	cis	rs9911578	0.867	rs72628394	chr17:57121313	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.38	-5.09	-0.3	6.92e-7	Intelligence (multi-trait analysis);
CESC	cis	rs9649213	0.593	rs7458551	chr7:97952167	G/C	cg00277769	chr7:97922759	BAIAP2L1	-0.34	-5.63	-0.33	4.68e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs853679	0.517	rs4713152	chr6:28137454	G/A	cg22143856	chr6:28129313	ZNF389	0.46	5.83	0.34	1.58e-8	Depression;
CESC	cis	rs501120	0.733	rs587375	chr10:44745808	T/C	cg09554077	chr10:44749378	NA	0.52	6.89	0.39	4.17e-11	Coronary artery disease;Coronary heart disease;
CESC	cis	rs9611565	0.545	rs5758432	chr22:42111693	T/C	cg06634786	chr22:41940651	POLR3H	0.67	6.57	0.37	2.64e-10	Vitiligo;
CESC	cis	rs62064224	0.714	rs8074594	chr17:30632998	G/A	cg18200150	chr17:30822561	MYO1D	0.38	5.14	0.3	5.46e-7	Schizophrenia;
CESC	cis	rs8114671	0.836	rs62213676	chr20:33612676	T/A	cg24642439	chr20:33292090	TP53INP2	-0.45	-5.44	-0.32	1.19e-7	Height;
CESC	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg10862848	chr6:42927986	GNMT	-0.25	-6.39	-0.37	7.35e-10	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs3845702	0.736	rs1904850	chr2:180852767	A/G	cg01881094	chr2:180872142	CWC22	-1.12	-10.13	-0.53	1.31e-20	Schizophrenia;
CESC	trans	rs1814175	0.647	rs1404157	chr11:49917301	G/C	cg03929089	chr4:120376271	NA	-0.72	-9.28	-0.5	6.08e-18	Height;
CESC	cis	rs9815354	0.951	rs1716679	chr3:41905339	T/C	cg03022575	chr3:42003672	ULK4	0.44	5.16	0.3	4.85e-7	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs4975709	0.569	rs1684965	chr5:1865248	A/G	cg12288994	chr5:1860383	NA	0.4	6.71	0.38	1.21e-10	Cardiovascular disease risk factors;
CESC	trans	rs9693444	0.898	rs4732697	chr8:29519861	A/G	cg20725035	chr3:148709344	GYG1	-0.45	-6.79	-0.38	7.22e-11	Breast cancer;
CESC	cis	rs597539	0.652	rs557625	chr11:68634722	G/A	cg04772025	chr11:68637568	NA	0.55	6.49	0.37	4.17e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	trans	rs11039798	0.588	rs61932767	chr11:48704806	C/T	cg15704280	chr7:45808275	SEPT13	0.62	6.6	0.38	2.24e-10	Axial length;
CESC	cis	rs67311347	1.000	rs1454497	chr3:40496326	C/T	cg01475735	chr3:40494733	NA	0.46	5.85	0.34	1.45e-8	Renal cell carcinoma;
CESC	cis	rs7618915	0.570	rs13068293	chr3:52672167	C/A	cg05564831	chr3:52568323	NT5DC2	0.45	6.88	0.39	4.31e-11	Bipolar disorder;
CESC	cis	rs910316	0.967	rs11159121	chr14:75666029	A/T	cg08847533	chr14:75593920	NEK9	-0.91	-15.97	-0.7	1.08e-40	Height;
CESC	trans	rs875971	0.965	rs28682868	chr7:65689809	C/T	cg26939375	chr7:64535504	NA	-0.47	-6.15	-0.35	2.89e-9	Aortic root size;
CESC	cis	rs854765	0.547	rs4368210	chr17:17896090	A/G	cg04398451	chr17:18023971	MYO15A	0.68	9.89	0.52	7.75e-20	Total body bone mineral density;
CESC	cis	rs1538970	0.924	rs12037201	chr1:45941349	G/T	cg24296786	chr1:45957014	TESK2	-0.46	-5.21	-0.31	3.71e-7	Platelet count;
CESC	cis	rs9487051	0.676	rs9386788	chr6:109600523	C/T	cg12927641	chr6:109611667	NA	0.37	5.6	0.33	5.3e-8	Reticulocyte fraction of red cells;
CESC	cis	rs8099014	0.731	rs9966665	chr18:56099407	A/C	cg12827950	chr18:55968429	NEDD4L	0.5	5.55	0.32	6.84e-8	Platelet count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16284168	chr7:99698217	MCM7;AP4M1	-0.54	-6.05	-0.35	4.9e-9	Gut microbiome composition (summer);
CESC	cis	rs9660992	0.686	rs1668870	chr1:205239031	C/G	cg00857998	chr1:205179979	DSTYK	0.47	5.35	0.31	1.87e-7	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs698813	0.604	rs4953077	chr2:44481207	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.51	5.69	0.33	3.44e-8	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
CESC	cis	rs7945705	0.935	rs11042103	chr11:8888700	C/T	cg09997546	chr11:8931473	C11orf17;ST5	0.36	5.76	0.33	2.38e-8	Hemoglobin concentration;
CESC	cis	rs2576037	0.796	rs2571033	chr18:44578552	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.43	5.66	0.33	3.98e-8	Personality dimensions;
CESC	cis	rs6539267	0.741	rs7314289	chr12:106686260	A/C	cg00173435	chr12:106696525	TCP11L2	0.69	8.06	0.44	2.58e-14	Tourette syndrome;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg21302562	chr1:44497012	SLC6A9	-0.52	-6.33	-0.36	1.04e-9	Ulcerative colitis;
CESC	cis	rs2836974	1.000	rs28360661	chr21:40681972	G/C	cg11890956	chr21:40555474	PSMG1	1.09	16.66	0.72	4.13e-43	Cognitive function;
CESC	cis	rs17376456	0.597	rs7728825	chr5:93384594	T/C	cg25358565	chr5:93447407	FAM172A	-0.47	-5.49	-0.32	9.61e-8	Diabetic retinopathy;
CESC	cis	rs12541635	0.966	rs11782609	chr8:106967919	G/A	cg10147462	chr8:107024639	NA	0.39	5.34	0.31	2.02e-7	Age of smoking initiation;
CESC	cis	rs4713118	0.629	rs203890	chr6:28022248	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.52	-6.03	-0.35	5.44e-9	Parkinson's disease;
CESC	cis	rs3793683	0.571	rs12781152	chr10:134590257	G/C	cg27286337	chr10:134555280	INPP5A	0.7	8.14	0.45	1.6e-14	Migraine;
CESC	cis	rs2235544	0.565	rs635509	chr1:54469227	A/G	cg25741118	chr1:54482237	LDLRAD1	0.24	5.92	0.34	9.71e-9	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26352439	chr17:157043	RPH3AL	-0.54	-6.84	-0.39	5.37e-11	Gut microbiome composition (summer);
CESC	cis	rs9916302	0.718	rs10445306	chr17:37591422	A/G	cg15445000	chr17:37608096	MED1	0.41	6.72	0.38	1.1e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs736408	0.522	rs11130310	chr3:52674667	C/T	cg07507251	chr3:52567010	NT5DC2	0.31	5.43	0.32	1.27e-7	Bipolar disorder;
CESC	cis	rs6460942	0.908	rs78682952	chr7:12284886	C/A	cg06484146	chr7:12443880	VWDE	-0.57	-6.01	-0.35	6.03e-9	Coronary artery disease;
CESC	cis	rs870825	0.616	rs7692367	chr4:185651056	T/C	cg04058563	chr4:185651563	MLF1IP	0.63	6.96	0.39	2.74e-11	Blood protein levels;
CESC	cis	rs3617	0.539	rs4687689	chr3:52948674	A/C	cg07507251	chr3:52567010	NT5DC2	-0.35	-5.79	-0.34	1.97e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23815043	chr16:88729854	MGC23284;MVD	-0.56	-6.21	-0.36	2.08e-9	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.927	rs11736876	chr4:98987206	A/G	cg18180107	chr4:99064573	C4orf37	0.41	5.2	0.3	3.93e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs62408225	1.000	rs17513531	chr6:90951239	C/T	cg06866423	chr6:90926672	BACH2	0.48	5.73	0.33	2.73e-8	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs1348850	0.540	rs6737342	chr2:178419117	G/A	cg22681709	chr2:178499509	PDE11A	-0.53	-5.97	-0.34	7.5e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs896854	0.654	rs13281625	chr8:95972738	T/C	cg13393036	chr8:95962371	TP53INP1	-0.48	-10.36	-0.54	2.51e-21	Type 2 diabetes;
CESC	cis	rs6088580	0.524	rs6088569	chr20:33268199	G/A	cg24642439	chr20:33292090	TP53INP2	-0.47	-5.48	-0.32	9.79e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs34779708	0.897	rs16935880	chr10:35415468	C/G	cg03585969	chr10:35415529	CREM	0.76	10.01	0.52	3.26e-20	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs17039065	0.920	rs17039099	chr4:109434574	C/T	cg16022748	chr4:109541635	LOC285456;RPL34	0.67	6.15	0.35	2.81e-9	Gut microbiome composition (summer);
CESC	cis	rs7254114	0.578	rs12980863	chr19:11309871	C/T	cg02815516	chr19:11306319	KANK2	-0.44	-7.24	-0.41	4.81e-12	Immature fraction of reticulocytes;
CESC	cis	rs16973500	0.808	rs57807129	chr16:71948043	T/C	cg09427745	chr16:71932006	KIAA0174	-0.52	-5.3	-0.31	2.39e-7	Response to anti-TNF therapy in rheumatoid arthritis;Attention deficit hyperactivity disorder and conduct disorder;
CESC	cis	rs6539267	0.885	rs34762209	chr12:106722466	T/C	cg02476566	chr12:106696527	TCP11L2	0.5	5.45	0.32	1.15e-7	Tourette syndrome;
CESC	cis	rs4805272	0.539	rs1422212	chr19:29330191	T/A	cg04546413	chr19:29218101	NA	0.4	5.09	0.3	6.68e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08889949	chr3:49044473	P4HTM;WDR6	-0.56	-6.39	-0.37	7.53e-10	Gut microbiome composition (summer);
CESC	cis	rs13191362	1.000	rs34052221	chr6:163160803	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.09	10.99	0.56	2.16e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs9858542	0.953	rs67216675	chr3:49493151	G/T	cg03060546	chr3:49711283	APEH	-0.54	-6.08	-0.35	4.07e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	trans	rs1973993	0.967	rs10489741	chr1:96942406	G/A	cg10631902	chr5:14652156	NA	0.55	7.58	0.42	5.89e-13	Weight;
CESC	cis	rs6089829	0.816	rs6062397	chr20:61668268	A/G	cg16240275	chr20:61666158	NCRNA00029	0.5	8.91	0.48	8.46e-17	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs11098499	0.754	rs9991959	chr4:120253773	C/T	cg09307838	chr4:120376055	NA	-0.78	-10.68	-0.55	2.29e-22	Corneal astigmatism;
CESC	cis	rs7811142	1.000	rs73161762	chr7:100014846	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.99	8.64	0.47	5.56e-16	Platelet count;
CESC	cis	rs6083	0.549	rs11858020	chr15:58852422	A/T	cg05156742	chr15:59063176	FAM63B	0.66	9.25	0.49	8.01e-18	Schizophrenia;
CESC	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	13.76	0.65	7.11e-33	Prudent dietary pattern;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg10950113	chr16:69166907	CHTF8;CIRH1A	-0.46	-5.99	-0.35	6.63e-9	Height;
CESC	trans	rs916888	0.773	rs199448	chr17:44809001	A/G	cg04282206	chr17:62833786	PLEKHM1P	0.55	6.62	0.38	1.98e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs9322193	0.847	rs4870054	chr6:150169538	C/T	cg09699651	chr6:150184138	LRP11	0.43	5.53	0.32	7.59e-8	Lung cancer;
CESC	cis	rs4664304	0.629	rs3792168	chr2:160846472	T/C	cg03641300	chr2:160917029	PLA2R1	-0.43	-5.82	-0.34	1.68e-8	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs116095464	0.558	rs10036253	chr5:238519	A/C	cg12570787	chr5:219185	SDHA;CCDC127	0.5	5.31	0.31	2.3e-7	Breast cancer;
CESC	cis	rs12220238	1.000	rs2279648	chr10:75867193	G/T	cg19889307	chr10:75911429	ADK;AP3M1	0.69	6.33	0.36	1.06e-9	Soluble interleukin-2 receptor subunit alpha;
CESC	trans	rs561341	1.000	rs55962687	chr17:30260369	C/T	cg27661571	chr11:113659931	NA	-0.75	-6.87	-0.39	4.57e-11	Hip circumference adjusted for BMI;
CESC	cis	rs8058578	0.775	rs8046391	chr16:30836648	G/C	cg02466173	chr16:30829666	NA	-0.47	-7.63	-0.42	4.15e-13	Multiple myeloma;
CESC	trans	rs656319	0.607	rs35437983	chr8:10005053	C/T	cg15556689	chr8:8085844	FLJ10661	-0.52	-6.13	-0.35	3.19e-9	Myopia (pathological);
CESC	cis	rs8028182	0.577	rs8023268	chr15:75814672	A/T	cg20655648	chr15:75932815	IMP3	0.48	5.9	0.34	1.08e-8	Sudden cardiac arrest;
CESC	cis	rs7208859	0.623	rs1061342	chr17:29114463	G/A	cg13385521	chr17:29058706	SUZ12P	0.81	6.49	0.37	4.22e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg00624375	chr12:110841656	ANAPC7	-0.49	-6.33	-0.36	1.05e-9	Thyroid stimulating hormone;
CESC	cis	rs9649465	1.000	rs13230294	chr7:123380821	T/C	cg04330084	chr7:123175371	IQUB	-0.38	-5.17	-0.3	4.64e-7	Migraine;
CESC	cis	rs3858526	0.584	rs10769266	chr11:5858460	C/T	cg02574844	chr11:5959923	NA	-0.46	-6.44	-0.37	5.57e-10	DNA methylation (variation);
CESC	cis	rs9549367	0.789	rs912012	chr13:113886152	G/A	cg18105134	chr13:113819100	PROZ	-0.67	-8.17	-0.45	1.29e-14	Platelet distribution width;
CESC	cis	rs9399135	0.967	rs4376365	chr6:135307740	T/C	cg24558204	chr6:135376177	HBS1L	0.5	6.74	0.38	1.01e-10	Red blood cell count;
CESC	cis	rs589448	0.902	rs2603089	chr12:69776800	C/T	cg20891283	chr12:69753455	YEATS4	-0.97	-16.47	-0.71	1.87e-42	Cerebrospinal fluid biomarker levels;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg06240275	chr17:2239739	TSR1;SGSM2	-0.49	-6.2	-0.36	2.18e-9	Fibrinogen levels;
CESC	cis	rs616402	0.527	rs604369	chr1:10567208	C/A	cg17425144	chr1:10567563	PEX14	0.38	6.09	0.35	4.02e-9	Breast size;
CESC	cis	rs1670533	0.932	rs610218	chr4:1080083	C/G	cg27284194	chr4:1044797	NA	0.47	5.91	0.34	1.04e-8	Recombination rate (females);
CESC	cis	rs7131987	0.675	rs2194515	chr12:29550383	T/C	cg09582351	chr12:29534625	ERGIC2	0.35	5.54	0.32	7.23e-8	QT interval;
CESC	cis	rs2070488	0.775	rs6599207	chr3:38554901	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.78	-12.49	-0.61	1.89e-28	Electrocardiographic conduction measures;
CESC	cis	rs597539	0.652	rs668576	chr11:68668208	A/G	cg21963583	chr11:68658836	MRPL21	0.36	5.08	0.3	7.2e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg23300289	chr9:132146083	NA	0.48	6.1	0.35	3.8e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs2797160	0.935	rs60515555	chr6:126000638	T/G	cg05901451	chr6:126070800	HEY2	-0.45	-6.67	-0.38	1.44e-10	Endometrial cancer;
CESC	cis	rs2235642	0.821	rs2281236	chr16:1603576	G/A	cg03771183	chr16:1608904	IFT140	0.41	5.95	0.34	8.47e-9	Coronary artery disease;
CESC	cis	rs7264396	0.790	rs10211771	chr20:34219994	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.64	7.67	0.43	3.29e-13	Total cholesterol levels;
CESC	cis	rs7044106	0.791	rs747819	chr9:123488441	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.87	13.78	0.65	6.13e-33	Hip circumference adjusted for BMI;
CESC	cis	rs9916302	0.904	rs7503069	chr17:37697128	C/G	cg15445000	chr17:37608096	MED1	0.42	6.91	0.39	3.53e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs56235845	0.665	rs4976685	chr5:176766177	C/T	cg06060754	chr5:176797920	RGS14	-0.44	-5.83	-0.34	1.61e-8	Hemoglobin concentration;Hematocrit;
CESC	cis	rs9322193	0.923	rs10872649	chr6:150080590	T/G	cg07701084	chr6:150067640	NUP43	0.49	6.77	0.38	8.5e-11	Lung cancer;
CESC	cis	rs5747327	1.000	rs5747327	chr22:18169212	T/G	cg19898043	chr22:18121309	BCL2L13	-0.41	-5.28	-0.31	2.63e-7	Myeloid white cell count;Granulocyte count;
CESC	cis	rs17095355	0.579	rs72828224	chr10:111702047	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.42	-5.16	-0.3	4.96e-7	Biliary atresia;
CESC	cis	rs11203032	0.831	rs10887932	chr10:90966996	C/G	cg16672925	chr10:90967113	CH25H	0.73	7.12	0.4	1.01e-11	Heart failure;
CESC	cis	rs11214589	0.651	rs11214594	chr11:113259332	G/A	cg14159747	chr11:113255604	NA	0.33	5.91	0.34	1.04e-8	Neuroticism;
CESC	cis	rs270601	0.913	rs273899	chr5:131695178	G/A	cg18758796	chr5:131593413	PDLIM4	0.39	5.25	0.31	3.11e-7	Acylcarnitine levels;
CESC	cis	rs9388451	0.903	rs9388446	chr6:126064920	T/A	cg05901451	chr6:126070800	HEY2	-0.62	-8.72	-0.47	3.16e-16	Brugada syndrome;
CESC	cis	rs2011503	0.882	rs1064395	chr19:19361735	C/T	cg11584989	chr19:19387371	SF4	0.54	6.53	0.37	3.31e-10	Bipolar disorder;
CESC	trans	rs11992162	0.967	rs11250185	chr8:11833123	G/C	cg15556689	chr8:8085844	FLJ10661	0.54	6.25	0.36	1.64e-9	Monocyte count;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg01062786	chr14:20929651	TMEM55B	-0.45	-6.0	-0.35	6.62e-9	Ulcerative colitis;
CESC	cis	rs60871478	0.679	rs6962050	chr7:817201	A/G	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.62	6.03	0.35	5.53e-9	Cerebrospinal P-tau181p levels;
CESC	cis	rs933688	1.000	rs6865495	chr5:90746424	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.06	13.27	0.63	3.82e-31	Smoking behavior;
CESC	trans	rs4349753	0.663	rs10051221	chr5:144079276	A/G	cg22407458	chr6:35109121	TCP11	0.5	6.35	0.36	9.52e-10	Photic sneeze reflex;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10316662	chr8:93156389	NA	-0.56	-6.35	-0.36	9.22e-10	Gut microbiome composition (summer);
CESC	cis	rs3761218	1.000	rs3761219	chr20:3776368	T/C	cg25011176	chr20:3776985	CDC25B	-0.5	-6.4	-0.37	6.92e-10	Bipolar disorder;
CESC	cis	rs11642862	1.000	rs74483355	chr16:30836430	C/T	cg02466173	chr16:30829666	NA	-0.58	-5.75	-0.33	2.39e-8	Tonsillectomy;
CESC	cis	rs17001868	0.568	rs73167007	chr22:40734241	G/C	cg07138101	chr22:40742427	ADSL	0.54	5.18	0.3	4.49e-7	Mammographic density (dense area);
CESC	cis	rs8067354	0.540	rs1051424	chr17:58024324	A/G	cg02344993	chr17:57696989	CLTC	0.51	5.24	0.31	3.32e-7	Hemoglobin concentration;
CESC	cis	rs2204008	0.805	rs11180825	chr12:38242916	G/T	cg13010199	chr12:38710504	ALG10B	0.51	6.3	0.36	1.24e-9	Bladder cancer;
CESC	cis	rs7666738	0.723	rs35327100	chr4:98977788	C/A	cg03467027	chr4:99064603	C4orf37	0.43	5.4	0.31	1.49e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7188697	0.848	rs42947	chr16:58579158	A/C	cg21335942	chr16:58549945	SETD6	0.45	5.37	0.31	1.75e-7	QT interval;
CESC	trans	rs1681739	0.540	rs10886010	chr10:118546590	C/T	cg02989244	chr10:28657270	NA	0.39	6.02	0.35	5.66e-9	Vertical cup-disc ratio;
CESC	cis	rs2963155	0.518	rs72801080	chr5:142751990	T/C	cg17617527	chr5:142782415	NR3C1	0.74	5.78	0.33	2.12e-8	Breast cancer;
CESC	cis	rs1707322	1.000	rs10890370	chr1:46389217	C/T	cg03146154	chr1:46216737	IPP	0.74	10.22	0.53	6.86e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs6121246	0.821	rs6121209	chr20:30311258	G/C	cg13852791	chr20:30311386	BCL2L1	0.83	8.72	0.47	3.23e-16	Mean corpuscular hemoglobin;
CESC	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	10.25	0.53	5.71e-21	Prudent dietary pattern;
CESC	cis	rs478304	0.817	rs524475	chr11:65518065	T/A	cg08755490	chr11:65554678	OVOL1	0.46	6.15	0.35	2.83e-9	Acne (severe);
CESC	cis	rs965469	0.817	rs6037582	chr20:3351696	C/T	cg17110299	chr20:3385021	C20orf194	0.39	5.12	0.3	5.87e-7	IFN-related cytopenia;
CESC	cis	rs35306767	0.807	rs34885925	chr10:919032	G/C	cg26597838	chr10:835615	NA	1.16	10.98	0.56	2.22e-23	Eosinophil percentage of granulocytes;
CESC	cis	rs2721195	0.614	rs12719778	chr8:145879883	T/C	cg26752003	chr8:145688521	CYHR1	-0.4	-5.07	-0.3	7.35e-7	Age at first birth;
CESC	cis	rs3857067	0.806	rs72665608	chr4:95093501	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.61	-9.04	-0.49	3.47e-17	QT interval;
CESC	cis	rs12458462	0.892	rs58675823	chr18:77463672	G/A	cg11879182	chr18:77439856	CTDP1	0.88	13.89	0.65	2.56e-33	Monocyte count;
CESC	cis	rs854765	0.618	rs8066982	chr17:17851377	T/C	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.54	7.08	0.4	1.28e-11	Total body bone mineral density;
CESC	cis	rs7258465	0.965	rs1560118	chr19:18570035	G/A	cg25828334	chr19:18545568	ISYNA1	-0.32	-5.16	-0.3	4.8e-7	Breast cancer;
CESC	cis	rs61759167	0.954	rs28594467	chr1:3097051	C/T	cg01961086	chr1:3086487	PRDM16	-0.34	-5.08	-0.3	6.97e-7	Motion sickness;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12699044	chr12:113703999	TPCN1	-0.51	-6.08	-0.35	4.12e-9	Gut microbiome composition (summer);
CESC	cis	rs9303401	0.659	rs34913878	chr17:56897094	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	1.01	12.5	0.61	1.71e-28	Cognitive test performance;
CESC	cis	rs6860806	0.507	rs272868	chr5:131680751	C/G	cg07395648	chr5:131743802	NA	-0.42	-5.52	-0.32	7.91e-8	Breast cancer;
CESC	cis	rs11792861	0.926	rs7870597	chr9:111871864	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.41	5.15	0.3	5.08e-7	Menarche (age at onset);
CESC	cis	rs523522	0.885	rs524735	chr12:121022099	T/C	cg27279351	chr12:120934652	DYNLL1	0.7	8.92	0.48	7.88e-17	High light scatter reticulocyte count;
CESC	cis	rs2404602	0.647	rs11631394	chr15:76973209	G/T	cg23625390	chr15:77176239	SCAPER	-0.47	-6.59	-0.38	2.42e-10	Blood metabolite levels;
CESC	cis	rs853679	0.517	rs35227624	chr6:28132726	A/G	cg17949981	chr6:28129498	ZNF389	0.45	5.57	0.32	6.26e-8	Depression;
CESC	cis	rs4130590	1.000	rs4130590	chr9:130107964	C/T	cg13736810	chr9:130213283	LRSAM1;RPL12	-0.48	-5.88	-0.34	1.22e-8	Bipolar disorder;
CESC	cis	rs3785574	0.962	rs62077483	chr17:61806380	C/T	cg06873352	chr17:61820015	STRADA	0.49	7.24	0.41	4.86e-12	Height;
CESC	cis	rs9902453	0.866	rs4795529	chr17:28443549	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	8.69	0.47	3.72e-16	Coffee consumption (cups per day);
CESC	cis	rs7589728	0.514	rs78204719	chr2:88460747	G/C	cg07952391	chr2:88470173	THNSL2	0.59	5.81	0.34	1.74e-8	Plasma clusterin levels;
CESC	cis	rs7811142	1.000	rs73161762	chr7:100014846	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.01	8.88	0.48	1.05e-16	Platelet count;
CESC	cis	rs6570726	0.846	rs439035	chr6:145887990	G/C	cg23711669	chr6:146136114	FBXO30	0.84	12.72	0.62	3.06e-29	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6691722	0.503	rs6667695	chr1:24707669	G/A	cg18323236	chr1:24743029	NIPAL3	0.37	5.47	0.32	1.02e-7	Response to interferon beta in multiple sclerosis;
CESC	trans	rs7246657	0.943	rs10417844	chr19:37837587	C/T	cg24637308	chr11:6592297	DNHD1	0.53	6.17	0.35	2.55e-9	Coronary artery calcification;
CESC	cis	rs950776	0.616	rs6495307	chr15:78890321	C/T	cg06917634	chr15:78832804	PSMA4	0.56	7.31	0.41	3.14e-12	Sudden cardiac arrest;
CESC	cis	rs6831352	0.918	rs17218108	chr4:100055755	T/C	cg13256891	chr4:100009986	ADH5	-0.77	-8.45	-0.46	1.97e-15	Alcohol dependence;
CESC	cis	rs1552244	0.872	rs6792951	chr3:10119603	C/A	cg00149659	chr3:10157352	C3orf10	0.73	8.89	0.48	9.97e-17	Alzheimer's disease;
CESC	cis	rs7772486	0.875	rs7761033	chr6:146356106	C/T	cg23711669	chr6:146136114	FBXO30	0.85	12.46	0.61	2.27e-28	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2439831	1.000	rs471229	chr15:43733994	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.91	10.52	0.54	7.36e-22	Lung cancer in ever smokers;
CESC	cis	rs7666738	0.830	rs1967979	chr4:98966201	G/T	cg03467027	chr4:99064603	C4orf37	0.44	5.57	0.32	6.41e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7666738	0.680	rs34267968	chr4:99002574	A/T	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.62e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs765787	0.530	rs12442533	chr15:45529631	G/C	cg24006582	chr15:45444508	DUOX1	0.57	6.94	0.39	3.04e-11	Uric acid levels;
CESC	cis	rs6688613	0.579	rs4657609	chr1:166839174	G/A	ch.1.3259774R	chr1:166827647	TADA1	0.56	5.38	0.31	1.66e-7	Refractive astigmatism;
CESC	trans	rs877282	1.000	rs12773872	chr10:771939	T/C	cg22713356	chr15:30763199	NA	1.26	12.75	0.62	2.39e-29	Uric acid levels;
CESC	cis	rs2842992	0.830	rs2758312	chr6:160153452	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.76	9.6	0.51	6.23e-19	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs6582630	0.594	rs7308707	chr12:38450428	G/C	cg26384229	chr12:38710491	ALG10B	-0.44	-5.83	-0.34	1.62e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs2066819	1.000	rs116849218	chr12:56683975	C/T	cg26714650	chr12:56694279	CS	-1.52	-10.39	-0.54	1.95e-21	Psoriasis vulgaris;
CESC	cis	rs2281558	0.876	rs6107025	chr20:25279880	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.62	8.34	0.46	4.18e-15	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;
CESC	cis	rs10504229	0.636	rs114725691	chr8:58054292	C/T	cg02725872	chr8:58115012	NA	-0.33	-5.06	-0.3	7.77e-7	Developmental language disorder (linguistic errors);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16365729	chr1:244998894	FAM36A	0.56	6.83	0.39	5.89e-11	Gut microbiome composition (summer);
CESC	cis	rs7085104	0.700	rs7096183	chr10:104609466	T/C	cg04362960	chr10:104952993	NT5C2	0.52	6.74	0.38	1.01e-10	Immature fraction of reticulocytes;Schizophrenia;
CESC	cis	rs514406	0.861	rs72637996	chr1:53249618	A/T	cg24675658	chr1:53192096	ZYG11B	0.54	7.53	0.42	7.89e-13	Monocyte count;
CESC	cis	rs7044106	0.791	rs10760116	chr9:123494681	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.74	10.98	0.56	2.31e-23	Hip circumference adjusted for BMI;
CESC	trans	rs2727020	0.576	rs1814175	chr11:49559172	T/C	cg15704280	chr7:45808275	SEPT13	-0.94	-16.04	-0.7	6.25e-41	Coronary artery disease;
CESC	cis	rs1045714	0.943	rs56063345	chr7:2653504	C/G	cg20813462	chr7:2646259	IQCE	0.74	6.04	0.35	5.3e-9	Urate levels in lean individuals;
CESC	cis	rs7833986	0.501	rs72653921	chr8:56897157	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.58	7.16	0.4	8.04e-12	Height;
CESC	cis	rs10779751	0.960	rs4845860	chr1:11324193	A/G	cg08854313	chr1:11322531	MTOR	0.82	11.19	0.57	4.69e-24	Body mass index;
CESC	cis	rs2439831	0.850	rs7169322	chr15:44131014	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.63	5.6	0.33	5.26e-8	Lung cancer in ever smokers;
CESC	cis	rs17253792	0.822	rs17747083	chr14:56110594	T/C	cg01858014	chr14:56050164	KTN1	-0.85	-7.03	-0.4	1.73e-11	Putamen volume;
CESC	cis	rs4722585	0.533	rs12334205	chr7:26202490	G/A	cg07876897	chr7:26191696	NFE2L3	0.42	5.38	0.31	1.68e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
CESC	cis	rs7264396	1.000	rs224415	chr20:34135629	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.53	-6.86	-0.39	4.94e-11	Total cholesterol levels;
CESC	cis	rs992157	0.798	rs7557709	chr2:219167529	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.68	9.16	0.49	1.46e-17	Colorectal cancer;
CESC	cis	rs11098499	0.779	rs10016060	chr4:120298412	A/G	cg24375607	chr4:120327624	NA	0.46	5.55	0.32	6.98e-8	Corneal astigmatism;
CESC	cis	rs6752107	1.000	rs6738490	chr2:234161583	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.49	6.92	0.39	3.4e-11	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs7412746	0.611	rs4319334	chr1:150766822	G/A	cg04414720	chr1:150670196	GOLPH3L	0.48	6.49	0.37	4.12e-10	Melanoma;
CESC	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.77	10.94	0.56	3.14e-23	Prudent dietary pattern;
CESC	cis	rs10791097	0.690	rs12286234	chr11:130730528	T/C	cg12179176	chr11:130786555	SNX19	0.56	8.14	0.45	1.57e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs763014	0.966	rs7198877	chr16:661439	A/G	cg00802000	chr16:706648	WDR90	-0.41	-6.33	-0.36	1.04e-9	Height;
CESC	cis	rs7267979	1.000	rs2482943	chr20:25380593	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.85	-15.87	-0.7	2.51e-40	Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05166819	chr7:72936456	BAZ1B	0.58	6.32	0.36	1.08e-9	Gut microbiome composition (summer);
CESC	cis	rs752010	0.655	rs10890145	chr1:42086290	A/G	cg06885757	chr1:42089581	HIVEP3	0.51	8.84	0.48	1.39e-16	Lupus nephritis in systemic lupus erythematosus;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08679808	chr17:79886116	LOC92659;MAFG	0.63	7.37	0.41	2.21e-12	Gut microbiome composition (summer);
CESC	cis	rs13256369	0.760	rs7839473	chr8:8575836	C/T	cg17143192	chr8:8559678	CLDN23	0.73	8.68	0.47	4.03e-16	Obesity-related traits;
CESC	cis	rs6061231	1.000	rs11908473	chr20:60957770	C/G	cg06197360	chr20:60970103	CABLES2	-0.4	-5.03	-0.3	8.87e-7	Colorectal cancer;
CESC	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg07167872	chr1:205819463	PM20D1	0.86	15.38	0.69	1.36e-38	Menarche (age at onset);
CESC	cis	rs4595586	0.679	rs7312898	chr12:39346833	T/C	cg26384229	chr12:38710491	ALG10B	0.42	6.07	0.35	4.31e-9	Morning vs. evening chronotype;
CESC	cis	rs10479542	0.721	rs6894113	chr5:178974789	G/C	cg05457628	chr5:178986728	RUFY1	0.45	6.47	0.37	4.74e-10	Lung cancer;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg02895995	chr19:7554069	PEX11G	-0.47	-6.58	-0.37	2.49e-10	Height;
CESC	cis	rs503341	0.756	rs626333	chr11:63591861	C/T	cg04362095	chr11:63592001	C11orf84	-0.56	-8.25	-0.45	7.67e-15	Pulse pressure;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg03946899	chr15:98503444	ARRDC4	0.46	6.05	0.35	4.82e-9	Thyroid stimulating hormone;
CESC	cis	rs10838687	0.736	rs12574081	chr11:47286414	G/A	cg25783544	chr11:47291846	MADD	0.59	5.78	0.33	2.05e-8	Proinsulin levels;
CESC	cis	rs6502050	0.835	rs4789668	chr17:80161990	C/T	cg11859384	chr17:80120422	CCDC57	-0.37	-5.15	-0.3	4.98e-7	Life satisfaction;
CESC	cis	rs4713118	0.516	rs4713142	chr6:28106347	T/G	cg08968635	chr6:28129556	ZNF389	0.42	5.72	0.33	2.82e-8	Parkinson's disease;
CESC	cis	rs10504229	0.683	rs2005392	chr8:58106896	T/C	cg02725872	chr8:58115012	NA	-0.43	-6.81	-0.39	6.53e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs11711311	1.000	rs9288984	chr3:113525956	A/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.55	7.19	0.4	6.5e-12	IgG glycosylation;
CESC	cis	rs8072100	0.607	rs9894594	chr17:45461383	A/G	cg08085267	chr17:45401833	C17orf57	-0.51	-6.49	-0.37	4.12e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs6991838	0.584	rs35790435	chr8:66502523	G/A	cg13398993	chr8:66546079	ARMC1	-0.47	-5.65	-0.33	4.19e-8	Intelligence (multi-trait analysis);
CESC	cis	rs9549367	0.774	rs2287246	chr13:113889127	A/G	cg00898013	chr13:113819073	PROZ	-0.52	-7.2	-0.4	6.09e-12	Platelet distribution width;
CESC	cis	rs79976124	0.837	rs12194087	chr6:66644399	T/A	cg07460842	chr6:66804631	NA	0.69	8.07	0.44	2.5e-14	Type 2 diabetes;
CESC	cis	rs10089	1.000	rs2409109	chr5:127461471	C/T	cg19767477	chr5:127420684	SLC12A2	-0.4	-5.32	-0.31	2.18e-7	Ileal carcinoids;
CESC	cis	rs950776	0.684	rs692780	chr15:78876505	C/G	cg06917634	chr15:78832804	PSMA4	-0.54	-6.65	-0.38	1.62e-10	Sudden cardiac arrest;
CESC	cis	rs66731853	0.557	rs477190	chr1:20898514	C/A	cg04087271	chr1:20915334	CDA	-0.39	-5.47	-0.32	1.06e-7	Mean corpuscular volume;
CESC	cis	rs7647973	0.626	rs2329021	chr3:49679072	G/A	cg13072238	chr3:49761600	GMPPB	-0.45	-5.47	-0.32	1.04e-7	Menarche (age at onset);
CESC	cis	rs12618769	0.652	rs4851145	chr2:99222916	A/G	cg10123293	chr2:99228465	UNC50	-0.41	-5.47	-0.32	1.02e-7	Bipolar disorder;
CESC	cis	rs2658782	0.789	rs2658776	chr11:93147927	A/G	cg15737290	chr11:93063684	CCDC67	0.49	5.87	0.34	1.27e-8	Pulmonary function decline;
CESC	cis	rs727563	0.594	rs132807	chr22:42071584	T/C	cg03806693	chr22:41940476	POLR3H	1.09	12.68	0.61	4.09e-29	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs447	1.000	rs3801655	chr7:83753335	C/G	cg22846510	chr7:83753280	SEMA3A	-0.45	-5.73	-0.33	2.66e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	trans	rs4596713	0.538	rs11145484	chr9:71769857	G/C	cg16512924	chr15:28394682	HERC2	0.48	6.09	0.35	3.97e-9	Headache;
CESC	cis	rs2952156	0.920	rs2934956	chr17:37830447	T/A	cg07936489	chr17:37558343	FBXL20	-0.59	-7.57	-0.42	6.11e-13	Asthma;
CESC	cis	rs6540559	1.000	rs742215	chr1:209961023	A/T	cg10074409	chr1:209979377	IRF6	0.36	5.79	0.34	1.94e-8	Cleft lip with or without cleft palate;
CESC	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg06877462	chr1:205807181	PM20D1	0.4	5.88	0.34	1.21e-8	Menarche (age at onset);
CESC	cis	rs514406	0.505	rs447581	chr1:53177098	T/C	cg08736216	chr1:53307985	ZYG11A	-0.34	-5.79	-0.34	1.97e-8	Monocyte count;
CESC	cis	rs873946	0.648	rs12769533	chr10:134548685	C/T	cg18305652	chr10:134549665	INPP5A	-0.49	-7.28	-0.41	3.77e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs9399137	0.507	rs6923512	chr6:135335268	A/G	cg22676075	chr6:135203613	NA	-0.53	-6.93	-0.39	3.21e-11	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	cis	rs6088580	0.524	rs6088569	chr20:33268199	G/A	cg08999081	chr20:33150536	PIGU	-0.45	-6.29	-0.36	1.33e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs11252926	0.673	rs7096559	chr10:499188	C/T	cg16386425	chr10:429943	DIP2C	-0.45	-5.68	-0.33	3.48e-8	Psychosis in Alzheimer's disease;
CESC	cis	rs748404	0.660	rs689767	chr15:43722077	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.57	7.55	0.42	7.19e-13	Lung cancer;
CESC	cis	rs6540556	0.682	rs667681	chr1:209914449	A/G	cg23920097	chr1:209922102	NA	0.39	5.1	0.3	6.53e-7	Red blood cell count;
CESC	cis	rs1006703	0.544	rs35586043	chr17:3832981	A/G	cg06463185	chr17:3833770	ATP2A3	-0.54	-5.89	-0.34	1.18e-8	Glucose homeostasis traits;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg13369624	chr13:21714458	SAP18	-0.51	-6.4	-0.37	7e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg17108838	chr11:10327138	ADM	-0.49	-7.08	-0.4	1.29e-11	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs2727020	0.617	rs1917311	chr11:49422665	C/T	cg03929089	chr4:120376271	NA	-0.82	-12.66	-0.61	4.91e-29	Coronary artery disease;
CESC	cis	rs11792861	0.816	rs28361111	chr9:111761012	A/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.53	6.83	0.39	5.63e-11	Menarche (age at onset);
CESC	cis	rs7267979	0.932	rs6037125	chr20:25463382	G/A	cg08601574	chr20:25228251	PYGB	0.36	5.34	0.31	2.05e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7953508	0.506	rs12425869	chr12:93961353	A/G	cg18151635	chr12:93972918	NA	-0.4	-5.32	-0.31	2.18e-7	Pubertal anthropometrics;
CESC	cis	rs12477438	0.798	rs2084987	chr2:99587885	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-10.57	-0.54	5.22e-22	Chronic sinus infection;
CESC	cis	rs4722166	0.630	rs1581497	chr7:22779503	C/A	cg05472934	chr7:22766657	IL6	0.87	10.94	0.56	3.06e-23	Lung cancer;
CESC	cis	rs801193	0.569	rs2659892	chr7:66200305	A/G	cg18252515	chr7:66147081	NA	-0.47	-6.41	-0.37	6.57e-10	Aortic root size;
CESC	trans	rs9467711	0.659	rs13195509	chr6:26463660	C/T	cg06606381	chr12:133084897	FBRSL1	-1.0	-8.39	-0.46	2.9e-15	Autism spectrum disorder or schizophrenia;
CESC	cis	rs7605827	0.930	rs6760888	chr2:15537863	T/C	cg19274914	chr2:15703543	NA	0.36	6.55	0.37	2.91e-10	Educational attainment (years of education);
CESC	cis	rs4908768	0.501	rs4908760	chr1:8526142	G/A	cg00120948	chr1:8484417	RERE	-0.34	-5.28	-0.31	2.7e-7	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
CESC	cis	rs6540559	0.673	rs58637469	chr1:209971480	T/A	cg23283495	chr1:209979779	IRF6	0.53	6.34	0.36	9.65e-10	Cleft lip with or without cleft palate;
CESC	cis	rs6504663	0.558	rs7627	chr17:48552154	G/C	cg03611598	chr17:48586076	MYCBPAP	0.52	6.06	0.35	4.6e-9	Visceral fat;
CESC	cis	rs4141404	0.582	rs5753630	chr22:31861950	A/G	cg13145458	chr22:31556086	RNF185	-0.42	-5.09	-0.3	6.73e-7	Paclitaxel-induced neuropathy;
CESC	cis	rs9611565	0.694	rs4822032	chr22:41925535	T/C	cg17376030	chr22:41985996	PMM1	0.42	5.05	0.3	8.22e-7	Vitiligo;
CESC	cis	rs9926296	0.712	rs2437957	chr16:89715648	G/A	cg27121462	chr16:89883253	FANCA	-0.48	-5.66	-0.33	3.97e-8	Vitiligo;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10756274	chr17:77813223	CBX4	0.54	6.13	0.35	3.15e-9	Gut microbiome composition (summer);
CESC	cis	rs2440129	0.611	rs434473	chr17:6904934	A/G	cg05215748	chr17:6898738	ALOX12	-0.33	-6.64	-0.38	1.77e-10	Tonsillectomy;
CESC	cis	rs72949976	1.000	rs62186569	chr2:214034151	C/T	cg08319019	chr2:214017104	IKZF2	-0.44	-5.49	-0.32	9.55e-8	Lung cancer;Squamous cell lung carcinoma;
CESC	cis	rs7949030	0.588	rs2512563	chr11:62311249	C/G	cg23462726	chr11:62437636	C11orf83;C11orf48	-0.4	-5.4	-0.31	1.52e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs9362426	0.895	rs242292	chr6:88078074	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.48	5.92	0.34	9.87e-9	Depressive episodes in bipolar disorder;
CESC	cis	rs7107174	1.000	rs11237469	chr11:78072875	A/T	cg02023728	chr11:77925099	USP35	0.47	6.18	0.35	2.45e-9	Testicular germ cell tumor;
CESC	cis	rs7267979	0.649	rs2500406	chr20:25401862	A/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.71	-11.09	-0.56	9.89e-24	Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18577128	chr1:46269120	MAST2	0.62	6.99	0.39	2.2e-11	Gut microbiome composition (summer);
CESC	cis	rs9611565	0.512	rs964899	chr22:42142386	G/A	cg03806693	chr22:41940476	POLR3H	1.21	14.0	0.65	1.02e-33	Vitiligo;
CESC	cis	rs7071206	1.000	rs7071206	chr10:79401316	C/T	cg23888215	chr10:79422304	NA	0.54	6.26	0.36	1.54e-9	Bone mineral density;
CESC	cis	rs7177699	0.557	rs7403593	chr15:79111962	A/G	cg04896959	chr15:78267971	NA	0.32	5.04	0.3	8.54e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
CESC	cis	rs17253792	0.822	rs80174205	chr14:56058694	T/C	cg01858014	chr14:56050164	KTN1	-0.96	-7.13	-0.4	9.72e-12	Putamen volume;
CESC	trans	rs1945213	0.694	rs7122627	chr11:55862565	A/G	cg15704280	chr7:45808275	SEPT13	0.76	7.34	0.41	2.57e-12	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs7666738	0.830	rs991168	chr4:98928293	T/C	cg17366294	chr4:99064904	C4orf37	0.6	8.23	0.45	8.65e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg06873352	chr17:61820015	STRADA	0.72	12.67	0.61	4.43e-29	Prudent dietary pattern;
CESC	cis	rs12142240	0.698	rs55971480	chr1:46823206	G/T	cg00530320	chr1:46809349	NSUN4	0.6	8.04	0.44	2.96e-14	Menopause (age at onset);
CESC	cis	rs875971	0.862	rs6958294	chr7:65794796	C/A	cg18876405	chr7:65276391	NA	-0.52	-7.17	-0.4	7.39e-12	Aortic root size;
CESC	cis	rs71191701	1.000	rs71191701	chr9:139322257	G/C	cg14169450	chr9:139327907	INPP5E	0.43	5.32	0.31	2.17e-7	Myeloid white cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;
CESC	trans	rs35110281	0.748	rs1584918	chr21:45042419	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.53	6.9	0.39	3.75e-11	Mean corpuscular volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04179819	chr10:7860513	TAF3	0.52	6.16	0.35	2.7e-9	Gut microbiome composition (summer);
CESC	trans	rs60843830	1.000	rs55753056	chr2:243929	G/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.64	8.07	0.44	2.53e-14	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs858239	0.508	rs7805085	chr7:23190243	C/T	cg23682824	chr7:23144976	KLHL7	0.46	5.85	0.34	1.45e-8	Cerebrospinal fluid biomarker levels;
CESC	cis	rs35306767	0.714	rs17293608	chr10:1056252	C/T	cg20503657	chr10:835505	NA	0.72	6.47	0.37	4.64e-10	Eosinophil percentage of granulocytes;
CESC	cis	rs7927771	0.832	rs896816	chr11:47394338	T/C	cg20307385	chr11:47447363	PSMC3	0.59	7.02	0.4	1.88e-11	Subjective well-being;
CESC	cis	rs9902453	0.679	rs2054847	chr17:28532013	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	7.05	0.4	1.59e-11	Coffee consumption (cups per day);
CESC	cis	rs2991971	0.810	rs998199	chr1:45912898	A/C	cg05343316	chr1:45956843	TESK2	0.59	8.4	0.46	2.68e-15	High light scatter reticulocyte count;
CESC	cis	rs2731664	0.765	rs2630766	chr5:176874941	A/C	cg23176889	chr5:176863531	GRK6	-0.64	-11.24	-0.57	3.19e-24	Intelligence (multi-trait analysis);
CESC	cis	rs17826219	0.706	rs8071236	chr17:29100002	T/C	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.17e-10	Body mass index;
CESC	cis	rs6460942	0.630	rs17671056	chr7:12390961	C/G	cg20607287	chr7:12443886	VWDE	-0.62	-6.71	-0.38	1.21e-10	Coronary artery disease;
CESC	cis	rs12200560	0.505	rs172425	chr6:97075299	A/T	cg06623918	chr6:96969491	KIAA0776	0.5	6.49	0.37	4.13e-10	Coronary heart disease;
CESC	cis	rs1401999	0.510	rs17817736	chr3:183720313	A/T	cg01324343	chr3:183735012	ABCC5	-0.36	-6.13	-0.35	3.18e-9	Anterior chamber depth;
CESC	cis	rs9788682	0.747	rs2656071	chr15:78745343	A/T	cg24631222	chr15:78858424	CHRNA5	-0.62	-7.58	-0.42	5.91e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs2845885	0.744	rs3802932	chr11:63988045	G/A	cg24431193	chr11:63883947	FLRT1;MACROD1	0.63	5.83	0.34	1.59e-8	Body mass index;
CESC	cis	rs4237845	0.844	rs7306124	chr12:58303349	A/T	cg02175503	chr12:58329896	NA	0.74	10.46	0.54	1.16e-21	Intelligence (multi-trait analysis);
CESC	cis	rs6545883	0.929	rs778155	chr2:61647901	A/G	cg15711740	chr2:61764176	XPO1	0.4	5.13	0.3	5.47e-7	Tuberculosis;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg05654049	chr3:23852499	UBE2E1	0.49	6.59	0.38	2.38e-10	Height;
CESC	cis	rs6011002	0.938	rs117314802	chr20:62301849	A/G	cg15212369	chr20:62274085	STMN3	-0.57	-5.16	-0.3	4.91e-7	Dental caries;
CESC	cis	rs7811142	0.775	rs6946768	chr7:99954393	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.89	7.95	0.44	5.36e-14	Platelet count;
CESC	cis	rs72781680	1.000	rs12623496	chr2:24181583	C/T	cg08917208	chr2:24149416	ATAD2B	0.94	8.58	0.47	7.87e-16	Lymphocyte counts;
CESC	cis	rs8017423	0.934	rs2401874	chr14:90682467	C/T	cg14092571	chr14:90743983	NA	-0.57	-8.61	-0.47	6.77e-16	Mortality in heart failure;
CESC	cis	rs9443645	0.901	rs12193319	chr6:79583437	C/A	cg05283184	chr6:79620031	NA	-0.44	-6.64	-0.38	1.74e-10	Intelligence (multi-trait analysis);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg22273042	chr8:81083829	TPD52	-0.45	-6.44	-0.37	5.63e-10	Fibrinogen levels;
CESC	cis	rs2290159	0.800	rs6792773	chr3:12668726	C/T	cg23032965	chr3:12705835	RAF1	0.54	5.71	0.33	3.02e-8	Cholesterol, total;
CESC	cis	rs6540559	0.543	rs650728	chr1:210433351	C/T	cg22029157	chr1:209979665	IRF6	0.52	5.9	0.34	1.13e-8	Cleft lip with or without cleft palate;
CESC	cis	rs2072499	0.966	rs2842865	chr1:156159532	G/A	cg06970220	chr1:156163860	SLC25A44	0.39	5.18	0.3	4.32e-7	Testicular germ cell tumor;
CESC	cis	rs10851478	0.872	rs12906972	chr15:49858901	T/C	cg08060515	chr15:49448048	GALK2;COPS2	0.42	5.19	0.3	4.12e-7	Oral cavity cancer;
CESC	cis	rs12579753	0.871	rs10862363	chr12:82201254	T/A	cg24719984	chr12:82153464	PPFIA2	-0.33	-5.04	-0.3	8.55e-7	Resting heart rate;
CESC	cis	rs3096299	0.685	rs4785675	chr16:89539974	T/C	cg00750074	chr16:89608354	SPG7	-0.44	-6.41	-0.37	6.71e-10	Multiple myeloma (IgH translocation);
CESC	trans	rs11252926	0.624	rs7085214	chr10:468133	A/G	cg00953403	chr17:74099816	EXOC7	0.54	6.96	0.39	2.67e-11	Psychosis in Alzheimer's disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg16712549	chr7:39773156	LOC349114	-0.46	-6.07	-0.35	4.44e-9	Fibrinogen levels;
CESC	cis	rs965469	0.724	rs6051818	chr20:3362033	T/C	cg25506879	chr20:3388711	C20orf194	-0.49	-5.28	-0.31	2.63e-7	IFN-related cytopenia;
CESC	cis	rs2576037	0.526	rs2510444	chr18:44376849	G/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.43	7.26	0.41	4.4e-12	Personality dimensions;
CESC	cis	rs9322193	0.962	rs9322220	chr6:150104033	G/C	cg13206674	chr6:150067644	NUP43	0.42	5.89	0.34	1.19e-8	Lung cancer;
CESC	trans	rs11039798	1.000	rs10769370	chr11:48515430	A/G	cg15704280	chr7:45808275	SEPT13	0.69	6.14	0.35	3.07e-9	Axial length;
CESC	cis	rs854765	0.647	rs4426402	chr17:17977926	C/T	cg16928487	chr17:17741425	SREBF1	0.53	8.68	0.47	4.22e-16	Total body bone mineral density;
CESC	trans	rs17685	0.712	rs1859792	chr7:75789264	T/C	cg19862616	chr7:65841803	NCRNA00174	0.79	10.97	0.56	2.48e-23	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs2302190	0.882	rs12939703	chr17:56611090	G/C	cg25885038	chr17:56607967	SEPT4	-0.41	-5.61	-0.33	5.13e-8	Vitamin D levels;
CESC	cis	rs6088580	0.634	rs1205338	chr20:32925625	C/G	cg06115741	chr20:33292138	TP53INP2	-0.44	-5.54	-0.32	7.13e-8	Glomerular filtration rate (creatinine);
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg06657462	chr10:94608040	EXOC6	0.52	6.76	0.38	8.91e-11	Thyroid stimulating hormone;
CESC	cis	rs13191362	1.000	rs34725898	chr6:163127302	C/T	cg06582575	chr6:163149167	PACRG;PARK2	1.05	10.33	0.54	2.97e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs1799949	1.000	rs8176109	chr17:41265776	A/G	cg05368731	chr17:41323189	NBR1	0.8	11.27	0.57	2.6e-24	Menopause (age at onset);
CESC	cis	rs7223966	1.000	rs7222060	chr17:61868279	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.74	0.38	9.84e-11	Hip circumference adjusted for BMI;Body mass index;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07348339	chr7:2609259	IQCE	-0.55	-6.2	-0.36	2.13e-9	Gut microbiome composition (summer);
CESC	cis	rs6598955	0.671	rs7417505	chr1:26575523	A/G	cg19743891	chr1:26644573	UBXN11;CD52	0.37	5.19	0.3	4.16e-7	Obesity-related traits;
CESC	cis	rs6540559	0.673	rs17015183	chr1:209948711	A/C	cg22029157	chr1:209979665	IRF6	0.66	8.08	0.44	2.34e-14	Cleft lip with or without cleft palate;
CESC	cis	rs6952808	0.723	rs4721295	chr7:2036669	G/T	cg02951883	chr7:2050386	MAD1L1	0.56	7.77	0.43	1.73e-13	Bipolar disorder and schizophrenia;
CESC	cis	rs9987353	0.544	rs2929469	chr8:9062656	T/G	cg06636001	chr8:8085503	FLJ10661	0.52	6.29	0.36	1.34e-9	Recombination measurement;
CESC	trans	rs6054906	0.710	rs6117744	chr20:7265038	A/C	cg19245296	chr20:10015646	ANKRD5	0.45	6.3	0.36	1.23e-9	Response to amphetamines;
CESC	cis	rs35849525	0.814	rs35491931	chr3:49993462	T/A	cg03060546	chr3:49711283	APEH	-0.47	-5.43	-0.32	1.3e-7	Intelligence (multi-trait analysis);
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg27391037	chr22:18560705	PEX26	0.46	6.18	0.35	2.39e-9	Thyroid stimulating hormone;
CESC	cis	rs17431357	0.867	rs117054838	chr12:120993600	C/G	cg25045489	chr12:120971538	RNF10	-0.93	-5.46	-0.32	1.1e-7	Insulin resistance/response;
CESC	cis	rs853679	0.517	rs4711165	chr6:28115184	T/G	cg26335602	chr6:28129616	ZNF389	0.53	6.75	0.38	9.35e-11	Depression;
CESC	cis	rs7666738	0.830	rs9995370	chr4:98732145	T/G	cg05340658	chr4:99064831	C4orf37	0.76	11.15	0.57	6.22e-24	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7520050	0.966	rs7556615	chr1:46461369	G/A	cg24296786	chr1:45957014	TESK2	0.45	5.65	0.33	4.17e-8	Red blood cell count;Reticulocyte count;
CESC	cis	rs7666738	0.830	rs1593569	chr4:99017485	C/G	cg05340658	chr4:99064831	C4orf37	0.8	12.49	0.61	1.91e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs896854	0.967	rs2879813	chr8:95960947	A/G	cg26343298	chr8:95960752	TP53INP1	0.35	5.77	0.33	2.22e-8	Type 2 diabetes;
CESC	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg22907277	chr7:1156413	C7orf50	0.44	6.33	0.36	1.02e-9	Longevity;Endometriosis;
CESC	cis	rs2742234	0.541	rs10899778	chr10:43718509	G/C	cg07801480	chr10:43725741	RASGEF1A	-0.4	-5.24	-0.31	3.22e-7	Hirschsprung disease;
CESC	cis	rs72901758	0.768	rs55782477	chr17:76250703	G/C	cg23302638	chr17:76210176	BIRC5	0.48	5.22	0.31	3.6e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
CESC	cis	rs1799949	0.930	rs66499067	chr17:41248484	G/C	cg05368731	chr17:41323189	NBR1	0.76	10.6	0.55	4.15e-22	Menopause (age at onset);
CESC	cis	rs10479542	0.544	rs10056863	chr5:179005100	G/A	cg19626725	chr5:178986131	RUFY1	0.34	5.2	0.3	4.06e-7	Lung cancer;
CESC	cis	rs3857536	0.730	rs7761295	chr6:66932532	G/A	cg07460842	chr6:66804631	NA	-0.42	-5.36	-0.31	1.8e-7	Blood trace element (Cu levels);
CESC	cis	rs911555	0.539	rs4374097	chr14:104072766	A/C	cg12935359	chr14:103987150	CKB	-0.5	-7.39	-0.41	1.9e-12	Intelligence (multi-trait analysis);
CESC	trans	rs208520	0.690	rs207740	chr6:66764132	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.95	12.45	0.61	2.48e-28	Exhaled nitric oxide output;
CESC	cis	rs36096196	0.891	rs12082516	chr1:2251160	C/T	cg00093522	chr1:2252019	NA	-0.43	-6.2	-0.36	2.16e-9	Coronary artery disease;
CESC	trans	rs1814175	0.645	rs7123448	chr11:49764865	T/G	cg03929089	chr4:120376271	NA	-0.89	-13.73	-0.64	8.96e-33	Height;
CESC	cis	rs10982213	0.830	rs7861409	chr9:117181190	A/G	cg00969271	chr9:117093052	ORM2	0.4	5.61	0.33	5.12e-8	Interleukin-6 levels;
CESC	cis	rs798766	1.000	rs798741	chr4:1712413	A/G	cg10756475	chr4:1757242	NA	0.38	5.24	0.31	3.35e-7	Bladder cancer;Urinary bladder cancer;
CESC	trans	rs9388451	0.868	rs1268083	chr6:126049040	T/C	cg05039488	chr6:79577232	IRAK1BP1	0.55	7.25	0.41	4.53e-12	Brugada syndrome;
CESC	cis	rs7772486	0.720	rs991507	chr6:146023609	G/A	cg23711669	chr6:146136114	FBXO30	-1.0	-15.54	-0.69	3.89e-39	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4803455	0.565	rs11670143	chr19:41864971	A/G	cg09537434	chr19:41945824	ATP5SL	-0.71	-9.67	-0.51	3.97e-19	Migraine;Coronary artery disease;
CESC	cis	rs7618501	0.521	rs2352984	chr3:49948728	T/C	cg24110177	chr3:50126178	RBM5	-0.55	-7.72	-0.43	2.39e-13	Intelligence (multi-trait analysis);
CESC	cis	rs7264396	0.635	rs6060719	chr20:34546013	A/C	cg17201900	chr20:34330562	RBM39	0.52	5.44	0.32	1.21e-7	Total cholesterol levels;
CESC	cis	rs561341	1.000	rs484175	chr17:30309041	G/A	cg23018236	chr17:30244563	NA	-0.52	-5.1	-0.3	6.39e-7	Hip circumference adjusted for BMI;
CESC	trans	rs338389	0.934	rs338403	chr15:68251687	T/C	cg10595952	chr5:2097052	NA	-0.36	-6.03	-0.35	5.34e-9	Survival in rectal cancer;
CESC	trans	rs1249910	0.845	rs820544	chr3:112406563	A/G	cg23605328	chr1:201951606	RNPEP	-0.48	-6.27	-0.36	1.44e-9	Diabetic kidney disease;
CESC	cis	rs875971	0.862	rs6460302	chr7:65960257	C/G	cg18876405	chr7:65276391	NA	0.47	6.21	0.36	1.98e-9	Aortic root size;
CESC	cis	rs2832191	0.740	rs2832175	chr21:30475606	A/G	cg08807101	chr21:30365312	RNF160	-0.93	-14.29	-0.66	9.64e-35	Dental caries;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg01882179	chr12:93964653	SOCS2	-0.4	-6.08	-0.35	4.11e-9	Gambling;
CESC	cis	rs5769765	0.817	rs9616212	chr22:50317687	G/A	cg02269571	chr22:50332266	NA	-0.57	-6.6	-0.38	2.28e-10	Schizophrenia;
CESC	cis	rs11190604	1.000	rs10883509	chr10:102296461	C/T	cg07080220	chr10:102295463	HIF1AN	0.7	6.5	0.37	4.02e-10	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs62064224	0.748	rs72813015	chr17:30693331	T/C	cg25809561	chr17:30822961	MYO1D	0.58	8.2	0.45	1.04e-14	Schizophrenia;
CESC	cis	rs10899021	0.790	rs12288525	chr11:74332589	T/A	cg25880958	chr11:74394337	NA	-0.65	-6.92	-0.39	3.44e-11	Response to metformin (IC50);
CESC	cis	rs6963495	0.546	rs2697020	chr7:105150046	C/T	cg19920283	chr7:105172520	RINT1	0.53	6.19	0.36	2.3e-9	Bipolar disorder (body mass index interaction);
CESC	cis	rs8141529	0.719	rs9625619	chr22:29272328	T/A	cg02153584	chr22:29168773	CCDC117	0.6	7.84	0.43	1.13e-13	Lymphocyte counts;
CESC	cis	rs7811142	1.000	rs6962151	chr7:100028484	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.03	11.56	0.58	2.62e-25	Platelet count;
CESC	cis	rs4242434	0.892	rs71513892	chr8:22456517	C/G	cg03733263	chr8:22462867	KIAA1967	0.97	15.09	0.68	1.51e-37	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CESC	cis	rs7412746	0.621	rs11204749	chr1:150929563	G/A	cg22823121	chr1:150693482	HORMAD1	0.37	5.26	0.31	3.01e-7	Melanoma;
CESC	trans	rs801193	0.967	rs2707841	chr7:66157020	A/G	cg26939375	chr7:64535504	NA	0.64	8.67	0.47	4.39e-16	Aortic root size;
CESC	cis	rs11785693	0.862	rs17435605	chr8:4987302	A/G	cg26367366	chr8:4980734	NA	0.73	7.3	0.41	3.26e-12	Neuroticism (multi-trait analysis);Neuroticism;
CESC	cis	rs60843830	1.000	rs55753056	chr2:243929	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.79	10.32	0.54	3.23e-21	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs910316	1.000	rs8003506	chr14:75586288	A/C	cg08847533	chr14:75593920	NEK9	-0.99	-17.91	-0.74	1.46e-47	Height;
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg22834172	chr17:37774349	NA	-0.49	-7.2	-0.4	6.11e-12	Vertical cup-disc ratio;
CESC	cis	rs2228479	0.717	rs1007932	chr16:89838541	C/T	cg27121462	chr16:89883253	FANCA	0.63	5.11	0.3	6.21e-7	Skin colour saturation;
CESC	cis	rs2050392	1.000	rs2489864	chr10:30693744	C/G	cg18806716	chr10:30721971	MAP3K8	-0.4	-5.76	-0.33	2.29e-8	Inflammatory bowel disease;
CESC	cis	rs3008870	0.755	rs10749766	chr1:67376921	A/G	cg02640540	chr1:67518911	SLC35D1	0.44	5.26	0.31	2.94e-7	Lymphocyte percentage of white cells;
CESC	cis	rs739401	0.611	rs2239899	chr11:3024624	A/G	cg25174290	chr11:3078921	CARS	-0.56	-7.51	-0.42	9.23e-13	Longevity;
CESC	cis	rs9467711	0.606	rs72841536	chr6:26378288	T/A	cg14345882	chr6:26364793	BTN3A2	0.64	6.38	0.36	7.8e-10	Autism spectrum disorder or schizophrenia;
CESC	cis	rs7618915	0.508	rs13065851	chr3:52644836	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.48	6.81	0.39	6.37e-11	Bipolar disorder;
CESC	cis	rs270601	0.770	rs10463891	chr5:131597392	C/T	cg09877947	chr5:131593287	PDLIM4	-0.51	-6.81	-0.39	6.7e-11	Acylcarnitine levels;
CESC	trans	rs116095464	0.558	rs7731089	chr5:290422	A/C	cg00938859	chr5:1591904	SDHAP3	0.65	7.03	0.4	1.73e-11	Breast cancer;
CESC	cis	rs896854	0.530	rs10956934	chr8:95992473	C/A	cg13393036	chr8:95962371	TP53INP1	-0.45	-9.35	-0.5	3.79e-18	Type 2 diabetes;
CESC	cis	rs763121	1.000	rs763121	chr22:38879940	C/T	cg06022373	chr22:39101656	GTPBP1	-0.61	-8.53	-0.46	1.13e-15	Menopause (age at onset);
CESC	cis	rs6547741	0.935	rs6761095	chr2:27778010	G/T	cg21248554	chr2:27665150	KRTCAP3	0.26	5.38	0.31	1.62e-7	Oral cavity cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18550498	chr11:1008985	AP2A2	-0.65	-7.62	-0.42	4.41e-13	Gut microbiome composition (summer);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg08496016	chr9:99181722	ZNF367	-0.41	-6.16	-0.35	2.7e-9	Gambling;
CESC	cis	rs16937	0.662	rs12137294	chr1:205182872	A/C	cg21643547	chr1:205240462	TMCC2	-0.33	-5.4	-0.31	1.48e-7	Schizophrenia;
CESC	cis	rs2288912	0.838	rs2239375	chr19:45459851	T/C	cg20090143	chr19:45452003	APOC2	0.36	6.25	0.36	1.61e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs854765	0.583	rs11869536	chr17:17826528	T/A	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.55	7.28	0.41	3.9e-12	Total body bone mineral density;
CESC	cis	rs3806843	0.735	rs801188	chr5:140066916	G/T	cg16179182	chr5:140090404	VTRNA1-1	0.42	5.48	0.32	1e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs9303280	0.773	rs12949100	chr17:38057189	G/A	cg20243544	chr17:37824526	PNMT	0.53	6.86	0.39	4.75e-11	Self-reported allergy;
CESC	cis	rs6088580	0.634	rs6059887	chr20:33101102	C/G	cg24642439	chr20:33292090	TP53INP2	0.51	6.62	0.38	1.99e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs4665809	0.887	rs28699126	chr2:26357294	C/T	cg04944784	chr2:26401820	FAM59B	-0.61	-7.05	-0.4	1.6e-11	Gut microbiome composition (summer);
CESC	cis	rs10256972	0.524	rs6945202	chr7:1116558	T/C	cg17541715	chr7:1216824	NA	-0.38	-5.11	-0.3	6.04e-7	Longevity;Endometriosis;
CESC	cis	rs13256369	0.760	rs7816171	chr8:8575835	T/C	cg17143192	chr8:8559678	CLDN23	0.73	8.68	0.47	4.03e-16	Obesity-related traits;
CESC	cis	rs34638657	0.833	rs7200628	chr16:82200747	C/T	cg09439754	chr16:82129088	HSD17B2	-0.36	-5.74	-0.33	2.52e-8	Lung adenocarcinoma;
CESC	cis	rs1862618	1.000	rs1862618	chr5:56096315	C/G	cg24531977	chr5:56204891	C5orf35	-0.85	-10.98	-0.56	2.27e-23	Initial pursuit acceleration;
CESC	cis	rs7666738	0.830	rs4441757	chr4:98927059	T/C	cg05340658	chr4:99064831	C4orf37	0.82	12.2	0.6	1.81e-27	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9303280	0.936	rs907091	chr17:37921742	A/G	cg20243544	chr17:37824526	PNMT	0.55	7.53	0.42	7.94e-13	Self-reported allergy;
CESC	cis	rs7666738	0.830	rs13147768	chr4:98833675	A/T	cg17366294	chr4:99064904	C4orf37	0.54	7.42	0.41	1.61e-12	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7927771	1.000	rs11039255	chr11:47495746	G/T	cg20307385	chr11:47447363	PSMC3	-0.55	-6.53	-0.37	3.35e-10	Subjective well-being;
CESC	cis	rs798554	0.797	rs1182184	chr7:2872446	G/A	cg19346786	chr7:2764209	NA	-0.46	-6.75	-0.38	9.28e-11	Height;
CESC	cis	rs2011503	1.000	rs11669558	chr19:19655670	C/T	cg11584989	chr19:19387371	SF4	0.57	6.34	0.36	9.88e-10	Bipolar disorder;
CESC	cis	rs9910055	0.512	rs7209801	chr17:42323376	G/A	cg08499158	chr17:42289980	UBTF	-0.49	-6.01	-0.35	6.19e-9	Total body bone mineral density;
CESC	cis	rs10876993	1.000	rs10876993	chr12:58062667	C/T	cg18357645	chr12:58087776	OS9	0.63	10.16	0.53	1.09e-20	Celiac disease or Rheumatoid arthritis;
CESC	cis	rs3812831	0.599	rs428637	chr13:114927139	T/G	cg08824895	chr13:115047677	UPF3A	0.43	5.51	0.32	8.54e-8	Schizophrenia;
CESC	cis	rs7659604	0.676	rs4077102	chr4:122699830	A/G	cg06713675	chr4:122721982	EXOSC9	-0.45	-6.38	-0.36	7.86e-10	Type 2 diabetes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23939166	chr14:55032812	NA	-0.64	-7.64	-0.42	3.97e-13	Gut microbiome composition (summer);
CESC	cis	rs6901004	0.935	rs1150078	chr6:111560301	C/T	cg15721981	chr6:111408429	SLC16A10	0.37	5.4	0.32	1.45e-7	Blood metabolite levels;
CESC	cis	rs1862618	0.853	rs2548664	chr5:56133555	G/A	cg24549020	chr5:56110836	MAP3K1	0.68	7.76	0.43	1.85e-13	Initial pursuit acceleration;
CESC	cis	rs2075371	0.932	rs2544215	chr7:133987896	T/C	cg20476274	chr7:133979776	SLC35B4	0.67	9.8	0.52	1.53e-19	Mean platelet volume;
CESC	cis	rs4862750	0.872	rs13101380	chr4:187894744	G/A	cg06074448	chr4:187884817	NA	-0.47	-7.25	-0.41	4.57e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs898097	0.783	rs11650335	chr17:80835111	A/G	cg10494973	chr17:80897199	TBCD	0.5	5.64	0.33	4.35e-8	Breast cancer;
CESC	cis	rs1348850	0.757	rs4893969	chr2:178478476	T/A	cg23306229	chr2:178417860	TTC30B	0.53	6.66	0.38	1.59e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs11098499	0.909	rs10017335	chr4:120381523	C/G	cg09307838	chr4:120376055	NA	-0.85	-11.56	-0.58	2.63e-25	Corneal astigmatism;
CESC	cis	rs225245	0.817	rs225273	chr17:33970935	A/T	cg05299278	chr17:33885742	SLFN14	0.36	5.17	0.3	4.71e-7	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
CESC	cis	rs4268898	0.662	rs9917355	chr2:24433400	C/T	cg06627628	chr2:24431161	ITSN2	-1.02	-11.2	-0.57	4.2e-24	Asthma;
CESC	cis	rs4909189	1.000	rs4909189	chr7:158136986	A/T	cg24154853	chr7:158122151	PTPRN2	-0.39	-5.28	-0.31	2.67e-7	Response to amphetamines;
CESC	cis	rs861020	0.563	rs12046618	chr1:210043135	C/T	cg05527609	chr1:210001259	C1orf107	0.97	10.7	0.55	1.97e-22	Orofacial clefts;
CESC	cis	rs3749237	0.595	rs4855877	chr3:49448527	T/C	cg07636037	chr3:49044803	WDR6	0.62	9.04	0.49	3.35e-17	Resting heart rate;
CESC	cis	rs9926296	0.605	rs6500449	chr16:89856393	T/C	cg04287289	chr16:89883240	FANCA	0.89	15.0	0.68	2.95e-37	Vitiligo;
CESC	cis	rs9346455	0.881	rs9354993	chr6:72030526	A/G	cg27238071	chr6:71998145	OGFRL1	0.6	5.07	0.3	7.56e-7	Antipsychotic drug-induced weight gain (time interaction);Antipsychotic drug-induced weight gain;
CESC	trans	rs916888	0.647	rs199523	chr17:44848517	C/A	cg22433210	chr17:43662623	NA	-0.63	-8.1	-0.45	2e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs854765	0.583	rs9890341	chr17:17823175	G/C	cg09796270	chr17:17721594	SREBF1	0.43	6.05	0.35	4.93e-9	Total body bone mineral density;
CESC	cis	rs854765	0.693	rs9907287	chr17:17774118	C/T	cg09796270	chr17:17721594	SREBF1	-0.4	-5.58	-0.32	6.08e-8	Total body bone mineral density;
CESC	cis	rs1878931	0.543	rs17612463	chr16:3420479	G/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.71	8.83	0.48	1.51e-16	Body mass index (adult);
CESC	trans	rs916888	0.773	rs199457	chr17:44795469	C/T	cg27125505	chr17:43679177	LOC644172	0.5	6.51	0.37	3.7e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs7107174	0.711	rs66583694	chr11:78037773	C/T	cg02023728	chr11:77925099	USP35	0.4	5.88	0.34	1.24e-8	Testicular germ cell tumor;
CESC	cis	rs863345	0.604	rs1578763	chr1:158497414	C/T	cg12129480	chr1:158549410	OR10X1	-0.35	-6.86	-0.39	4.78e-11	Pneumococcal bacteremia;
CESC	cis	rs5769765	1.000	rs34774661	chr22:50267508	C/G	cg02269571	chr22:50332266	NA	0.46	6.28	0.36	1.39e-9	Schizophrenia;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg10164272	chr16:89456328	ANKRD11	0.48	6.61	0.38	2.09e-10	Fibrinogen levels;
CESC	cis	rs863345	0.604	rs1578762	chr1:158497440	G/A	cg12129480	chr1:158549410	OR10X1	-0.35	-6.86	-0.39	4.78e-11	Pneumococcal bacteremia;
CESC	cis	rs1218582	0.772	rs10908448	chr1:154882544	A/G	cg09359103	chr1:154839909	KCNN3	0.64	12.44	0.61	2.74e-28	Prostate cancer;
CESC	cis	rs10504229	0.683	rs56211106	chr8:58113497	A/G	cg24829409	chr8:58192753	C8orf71	-0.59	-7.32	-0.41	2.94e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs853679	1.000	rs853678	chr6:28297313	T/A	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.68	7.15	0.4	8.65e-12	Depression;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg07080220	chr10:102295463	HIF1AN	-0.54	-7.28	-0.41	3.78e-12	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	trans	rs677673	0.953	rs632424	chr20:10479545	T/C	cg16021678	chr13:55475951	NA	0.52	6.51	0.37	3.77e-10	Body mass index (change over time) in chronic obstructive pulmonary disease;
CESC	trans	rs9596009	0.591	rs959353	chr13:49344662	G/C	cg13176070	chr2:32503943	YIPF4	0.52	6.07	0.35	4.5e-9	Cough in response to angiotensin-converting enzyme inhibitor drugs;
CESC	cis	rs72945132	0.556	rs57172967	chr11:70160060	G/A	cg00319359	chr11:70116639	PPFIA1	0.78	7.71	0.43	2.52e-13	Coronary artery disease;
CESC	cis	rs1862618	0.853	rs33326	chr5:56142601	G/A	cg12311346	chr5:56204834	C5orf35	-0.74	-8.76	-0.47	2.43e-16	Initial pursuit acceleration;
CESC	cis	rs35110281	0.627	rs56369437	chr21:44970275	A/G	cg04455712	chr21:45112962	RRP1B	0.36	5.46	0.32	1.07e-7	Mean corpuscular volume;
CESC	cis	rs9322193	0.923	rs9800806	chr6:150061486	G/T	cg04369109	chr6:150039330	LATS1	-0.43	-5.96	-0.34	7.97e-9	Lung cancer;
CESC	cis	rs7659604	0.592	rs56077950	chr4:122721412	C/T	cg20573242	chr4:122745356	CCNA2	0.57	6.92	0.39	3.45e-11	Type 2 diabetes;
CESC	cis	rs6580649	0.783	rs7969749	chr12:48550755	C/T	cg05342945	chr12:48394962	COL2A1	-0.54	-6.06	-0.35	4.78e-9	Lung cancer;
CESC	trans	rs61931739	0.500	rs11053167	chr12:34387092	A/C	cg26384229	chr12:38710491	ALG10B	0.67	10.2	0.53	7.78e-21	Morning vs. evening chronotype;
CESC	cis	rs9788682	0.948	rs34664138	chr15:78831624	T/G	cg06917634	chr15:78832804	PSMA4	-0.55	-6.49	-0.37	4.15e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12780433	chr3:159481918	SCHIP1	0.52	6.05	0.35	4.82e-9	Gut microbiome composition (summer);
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg06128920	chr1:1447374	ATAD3A	0.4	6.19	0.36	2.27e-9	Vertical cup-disc ratio;
CESC	cis	rs644799	1.000	rs472231	chr11:95532166	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	9.15	0.49	1.61e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs62064224	0.589	rs2285428	chr17:30820176	C/T	cg18200150	chr17:30822561	MYO1D	-0.4	-5.12	-0.3	6.02e-7	Schizophrenia;
CESC	cis	rs1775715	0.870	rs1775731	chr10:32253512	A/G	cg04359828	chr10:32216031	ARHGAP12	0.35	5.17	0.3	4.72e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs10883723	0.810	rs6584507	chr10:104254623	G/A	cg22532475	chr10:104410764	TRIM8	-0.34	-5.73	-0.33	2.77e-8	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs12971120	0.504	rs11665154	chr18:72147006	A/C	cg25817165	chr18:72167213	CNDP2	-0.43	-6.08	-0.35	4.16e-9	Refractive error;
CESC	cis	rs9926296	0.605	rs886951	chr16:89836865	A/G	cg27121462	chr16:89883253	FANCA	0.75	10.84	0.55	6.6e-23	Vitiligo;
CESC	cis	rs3096299	0.967	rs28575874	chr16:89469890	C/T	cg02187348	chr16:89574699	SPG7	0.57	7.68	0.43	3.15e-13	Multiple myeloma (IgH translocation);
CESC	cis	rs708547	0.647	rs12621	chr4:57897570	G/T	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.43	-5.53	-0.32	7.67e-8	Response to bleomycin (chromatid breaks);
CESC	cis	rs7592578	0.771	rs12053190	chr2:191383348	A/G	cg27211696	chr2:191398769	TMEM194B	-0.62	-5.63	-0.33	4.7e-8	Diastolic blood pressure;
CESC	cis	rs7927771	0.832	rs7940536	chr11:47395240	G/A	cg05585544	chr11:47624801	NA	0.49	7.2	0.4	6.32e-12	Subjective well-being;
CESC	cis	rs7809950	1.000	rs2520264	chr7:107179344	T/C	cg23024343	chr7:107201750	COG5	-0.42	-5.88	-0.34	1.22e-8	Coronary artery disease;
CESC	cis	rs7666738	0.830	rs6833822	chr4:98951354	G/A	cg03676636	chr4:99064102	C4orf37	0.33	5.09	0.3	6.71e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4969178	0.965	rs8071889	chr17:76398101	A/G	cg20026190	chr17:76395443	PGS1	0.49	7.82	0.43	1.25e-13	HDL cholesterol levels;
CESC	cis	rs6933660	0.744	rs35143743	chr6:151768532	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.47	5.42	0.32	1.33e-7	Menarche (age at onset);
CESC	cis	rs12477438	0.834	rs6757019	chr2:99676936	T/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.75	-10.87	-0.56	5.17e-23	Chronic sinus infection;
CESC	cis	rs7843479	0.965	rs2291317	chr8:21827162	C/T	cg17168535	chr8:21777572	XPO7	0.57	7.79	0.43	1.48e-13	Mean corpuscular volume;
CESC	cis	rs12579753	0.833	rs12579530	chr12:82163930	A/C	cg23701643	chr12:82153290	PPFIA2	-0.35	-5.06	-0.3	7.93e-7	Resting heart rate;
CESC	trans	rs2589561	0.872	rs2440781	chr10:9051328	A/G	cg09169283	chr17:72856452	GRIN2C	0.53	6.46	0.37	4.97e-10	Asthma;
CESC	cis	rs853679	0.546	rs175597	chr6:27810626	T/C	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.86	7.35	0.41	2.53e-12	Depression;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg19947233	chr4:90032727	TIGD2	-0.47	-6.03	-0.35	5.55e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs11190604	1.000	rs6584379	chr10:102224490	G/A	cg07080220	chr10:102295463	HIF1AN	0.55	5.56	0.32	6.43e-8	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs7613875	0.580	rs11709503	chr3:49991167	G/T	cg24110177	chr3:50126178	RBM5	-0.56	-7.75	-0.43	1.95e-13	Body mass index;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15208247	chr1:244857838	PPPDE1	-0.58	-6.3	-0.36	1.25e-9	Gut microbiome composition (summer);
CESC	cis	rs12791968	0.765	rs12794846	chr11:44998943	C/T	cg11846598	chr11:44996168	LOC221122	0.49	5.89	0.34	1.18e-8	Inhibitory control;
CESC	cis	rs2304069	0.954	rs2340462	chr5:149415219	G/A	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.82	10.24	0.53	5.96e-21	HIV-1 control;
CESC	cis	rs514406	0.861	rs72637996	chr1:53249618	A/T	cg08859206	chr1:53392774	SCP2	0.6	8.96	0.48	5.95e-17	Monocyte count;
CESC	trans	rs728996	0.561	rs1326559	chr6:51652335	A/G	cg15101985	chr10:85961501	PCDH21	-0.47	-6.17	-0.35	2.53e-9	Weight loss (gastric bypass surgery);
CESC	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg06873352	chr17:61820015	STRADA	0.72	12.56	0.61	1.02e-28	Prudent dietary pattern;
CESC	cis	rs2415984	0.600	rs61993299	chr14:46944880	A/C	cg14871534	chr14:47121158	RPL10L	-0.37	-5.61	-0.33	4.98e-8	Number of children ever born;
CESC	cis	rs2404602	0.692	rs1838048	chr15:76931679	A/G	cg26408565	chr15:76604113	ETFA	-0.38	-5.44	-0.32	1.21e-7	Blood metabolite levels;
CESC	cis	rs1580019	0.547	rs56981934	chr7:32535202	C/G	cg06627557	chr7:32535165	LSM5;AVL9	1.09	20.08	0.78	3.92e-55	Cognitive ability;
CESC	cis	rs80282103	0.618	rs1079390	chr10:1161653	C/A	cg08668510	chr10:1095578	IDI1	0.72	5.84	0.34	1.55e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs9902453	0.874	rs62070271	chr17:28268358	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	9.16	0.49	1.49e-17	Coffee consumption (cups per day);
CESC	cis	rs853679	0.517	rs9380061	chr6:28132803	T/C	cg08968635	chr6:28129556	ZNF389	0.4	5.22	0.31	3.69e-7	Depression;
CESC	cis	rs6964587	0.967	rs58673519	chr7:91823887	T/G	cg17063962	chr7:91808500	NA	0.58	7.9	0.44	7.4e-14	Breast cancer;
CESC	cis	rs921968	0.541	rs2556391	chr2:219556346	T/C	cg02176678	chr2:219576539	TTLL4	-0.56	-9.86	-0.52	1.01e-19	Mean corpuscular hemoglobin concentration;
CESC	cis	rs7412746	0.611	rs11204726	chr1:150743492	T/C	cg17724175	chr1:150552817	MCL1	0.42	6.34	0.36	1e-9	Melanoma;
CESC	cis	rs9291683	0.609	rs13141233	chr4:10028729	T/C	cg00071950	chr4:10020882	SLC2A9	0.89	16.34	0.71	5.39e-42	Bone mineral density;
CESC	cis	rs60154123	0.772	rs845452	chr1:210417861	C/T	cg21951975	chr1:209979733	IRF6	0.49	6.12	0.35	3.35e-9	Coronary artery disease;
CESC	trans	rs9467711	0.606	rs9379899	chr6:26603015	T/A	cg01620082	chr3:125678407	NA	-0.64	-6.33	-0.36	1.03e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs769267	0.895	rs2916069	chr19:19520358	A/G	cg03709012	chr19:19516395	GATAD2A	0.99	15.8	0.7	4.37e-40	Tonsillectomy;
CESC	cis	rs71403859	0.502	rs17280181	chr16:71523514	C/T	cg08717414	chr16:71523259	ZNF19	-1.01	-9.55	-0.51	8.95e-19	Post bronchodilator FEV1;
CESC	cis	rs1059312	0.778	rs4760594	chr12:129296865	T/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.82	-12.1	-0.6	3.83e-27	Systemic lupus erythematosus;
CESC	cis	rs1707322	1.000	rs4390216	chr1:46266456	C/T	cg05343316	chr1:45956843	TESK2	0.44	5.53	0.32	7.85e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs853679	0.556	rs13200214	chr6:28017250	C/T	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.89	5.57	0.32	6.14e-8	Depression;
CESC	cis	rs863345	0.967	rs863347	chr1:158536008	C/G	cg12129480	chr1:158549410	OR10X1	0.33	6.82	0.39	6.07e-11	Pneumococcal bacteremia;
CESC	cis	rs698833	0.852	rs698774	chr2:44584314	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.56	7.03	0.4	1.74e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs1801251	1.000	rs2592105	chr2:233645968	C/G	cg08000102	chr2:233561755	GIGYF2	0.66	9.19	0.49	1.22e-17	Coronary artery disease;
CESC	cis	rs1448094	0.512	rs4488288	chr12:86245450	A/C	cg19622623	chr12:86230825	RASSF9	-0.46	-5.89	-0.34	1.14e-8	Major depressive disorder;
CESC	cis	rs7814319	0.933	rs13260865	chr8:97238472	A/T	cg20787634	chr8:97240163	UQCRB	-0.63	-8.18	-0.45	1.2e-14	Lung function (FVC);
CESC	cis	rs4819052	0.800	rs4819045	chr21:46660138	C/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.75	9.98	0.52	4.1e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs8114671	0.527	rs6060068	chr20:33415820	T/A	cg07148914	chr20:33460835	GGT7	0.41	5.28	0.31	2.71e-7	Height;
CESC	cis	rs3747547	0.892	rs17439509	chr9:38016419	A/C	cg13774184	chr9:37916125	SHB	-0.71	-6.07	-0.35	4.31e-9	Metabolite levels (Dihydroxy docosatrienoic acid);
CESC	cis	rs78707713	0.836	rs112843485	chr10:71211707	T/C	cg12610070	chr10:71211762	TSPAN15	-0.36	-6.48	-0.37	4.36e-10	Venous thromboembolism;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg24862861	chr10:976594	NA	0.48	6.16	0.35	2.69e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs1348850	0.519	rs1527406	chr2:178525655	C/T	cg23306229	chr2:178417860	TTC30B	0.46	5.39	0.31	1.59e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs3741151	0.773	rs7931767	chr11:73239207	A/G	cg17517138	chr11:73019481	ARHGEF17	1.05	7.72	0.43	2.46e-13	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs10883723	0.810	rs6584508	chr10:104258567	A/G	cg22532475	chr10:104410764	TRIM8	-0.34	-5.75	-0.33	2.44e-8	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs2204008	0.837	rs2127955	chr12:37969194	A/G	cg26384229	chr12:38710491	ALG10B	0.55	7.85	0.43	1.02e-13	Bladder cancer;
CESC	cis	rs1008375	0.966	rs11737844	chr4:17697421	A/C	cg04450456	chr4:17643702	FAM184B	0.36	5.15	0.3	5.16e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs7818688	1.000	rs11774085	chr8:96020877	G/A	cg16049864	chr8:95962084	TP53INP1	0.56	5.04	0.3	8.8e-7	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs7089973	0.604	rs10490909	chr10:116593532	C/T	cg23260525	chr10:116636907	FAM160B1	0.4	7.41	0.41	1.7e-12	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs10504229	1.000	rs55787104	chr8:58178519	C/T	cg22535103	chr8:58192502	C8orf71	-1.05	-13.21	-0.63	5.95e-31	Developmental language disorder (linguistic errors);
CESC	cis	rs7666738	0.830	rs62321598	chr4:99014237	C/T	cg17366294	chr4:99064904	C4orf37	0.6	8.62	0.47	6.37e-16	Colonoscopy-negative controls vs population controls;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg13028789	chr6:34856920	ANKS1A;TAF11	-0.48	-6.57	-0.37	2.68e-10	Fibrinogen levels;
CESC	cis	rs1707322	0.721	rs61784796	chr1:46163256	A/G	cg06784218	chr1:46089804	CCDC17	0.43	7.58	0.42	5.65e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs3733418	0.860	rs12647427	chr4:165929209	G/A	cg10852876	chr4:165953100	TRIM60	-0.46	-5.42	-0.32	1.32e-7	Obesity-related traits;
CESC	cis	rs9403521	0.947	rs7741424	chr6:143981662	G/A	cg18240653	chr6:144019428	PHACTR2	-0.5	-5.57	-0.32	6.28e-8	Obesity-related traits;
CESC	cis	rs7523050	0.643	rs34367763	chr1:109400805	C/T	cg08274380	chr1:109419600	GPSM2	0.85	5.61	0.33	5.08e-8	Fat distribution (HIV);
CESC	cis	rs523522	0.962	rs4767902	chr12:120910004	C/T	cg27279351	chr12:120934652	DYNLL1	0.68	8.74	0.47	2.65e-16	High light scatter reticulocyte count;
CESC	cis	rs916888	0.821	rs199514	chr17:44856881	G/A	cg17911788	chr17:44343683	NA	0.55	7.19	0.4	6.57e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs853679	0.517	rs9368554	chr6:28082711	T/C	cg26335602	chr6:28129616	ZNF389	0.53	7.06	0.4	1.48e-11	Depression;
CESC	cis	rs61931739	0.517	rs10844815	chr12:34245150	G/A	cg19457237	chr12:34500585	NA	-0.38	-5.34	-0.31	2.04e-7	Morning vs. evening chronotype;
CESC	cis	rs6088580	0.634	rs6059850	chr20:33044784	C/G	cg06115741	chr20:33292138	TP53INP2	0.46	5.98	0.34	7.26e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs2637266	0.783	rs846597	chr10:78529114	A/G	cg18941641	chr10:78392320	NA	0.42	8.11	0.45	1.91e-14	Pulmonary function;
CESC	cis	rs28386778	0.669	rs12603821	chr17:62006432	G/A	cg06873352	chr17:61820015	STRADA	-0.6	-9.63	-0.51	5.11e-19	Prudent dietary pattern;
CESC	cis	rs9611565	0.918	rs2281333	chr22:41749630	T/C	cg06481639	chr22:41940642	POLR3H	-0.47	-5.48	-0.32	9.79e-8	Vitiligo;
CESC	trans	rs1814175	0.754	rs7103235	chr11:49699191	A/G	cg15704280	chr7:45808275	SEPT13	-0.86	-12.5	-0.61	1.71e-28	Height;
CESC	cis	rs1218582	0.688	rs58629129	chr1:154910930	T/C	cg24250549	chr1:154909240	PMVK	0.57	7.59	0.42	5.54e-13	Prostate cancer;
CESC	cis	rs748404	0.697	rs504417	chr15:43554226	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.61	8.03	0.44	3.2e-14	Lung cancer;
CESC	cis	rs3736485	0.966	rs7173880	chr15:51785433	C/A	cg08986416	chr15:51914746	DMXL2	-0.41	-5.24	-0.31	3.24e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs965469	0.762	rs6515783	chr20:3245006	T/C	cg25506879	chr20:3388711	C20orf194	-0.51	-5.55	-0.32	6.97e-8	IFN-related cytopenia;
CESC	cis	rs3857536	0.642	rs7755840	chr6:66891913	A/G	cg07460842	chr6:66804631	NA	-0.4	-5.23	-0.31	3.47e-7	Blood trace element (Cu levels);
CESC	cis	rs7809950	1.000	rs7786801	chr7:107085889	C/T	cg23024343	chr7:107201750	COG5	-0.41	-5.83	-0.34	1.58e-8	Coronary artery disease;
CESC	cis	rs7666738	0.830	rs1426665	chr4:99027764	C/T	cg24818145	chr4:99064322	C4orf37	0.38	5.04	0.3	8.61e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7584330	0.868	rs67071074	chr2:238395429	T/C	cg14458575	chr2:238380390	NA	0.73	10.09	0.53	1.86e-20	Prostate cancer;
CESC	cis	rs12136530	0.774	rs883961	chr1:19781155	G/C	cg01832549	chr1:19774989	CAPZB	-0.47	-6.86	-0.39	4.91e-11	Lead levels in blood;
CESC	cis	rs2991971	0.934	rs2991974	chr1:46020654	A/G	cg15605315	chr1:45957053	TESK2	0.41	5.24	0.31	3.34e-7	High light scatter reticulocyte count;
CESC	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg04267008	chr7:1944627	MAD1L1	-0.56	-6.69	-0.38	1.32e-10	Bipolar disorder and schizophrenia;
CESC	cis	rs6502050	0.723	rs11657069	chr17:80083809	C/T	cg11859384	chr17:80120422	CCDC57	0.38	5.22	0.31	3.67e-7	Life satisfaction;
CESC	cis	rs12540874	0.663	rs1451371	chr7:50553051	T/C	cg18232548	chr7:50535776	DDC	-0.42	-6.12	-0.35	3.42e-9	Systemic sclerosis;
CESC	cis	rs2243480	1.000	rs3885839	chr7:65290403	G/T	cg18252515	chr7:66147081	NA	-1.18	-11.4	-0.57	9.41e-25	Diabetic kidney disease;
CESC	cis	rs769267	0.965	rs8103496	chr19:19386015	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.42	5.38	0.31	1.66e-7	Tonsillectomy;
CESC	trans	rs4950322	0.547	rs56864370	chr1:146583429	A/G	cg04954894	chr8:38089920	DDHD2	-0.57	-6.23	-0.36	1.84e-9	Protein quantitative trait loci;
CESC	cis	rs2282802	0.635	rs270162	chr5:139539090	A/G	cg26211634	chr5:139558579	C5orf32	-0.38	-5.11	-0.3	6.05e-7	Intelligence (multi-trait analysis);
CESC	cis	rs10045504	0.502	rs72746032	chr5:38743982	T/C	cg15396434	chr5:38725168	NA	-0.72	-6.75	-0.38	9.09e-11	Night sleep phenotypes;
CESC	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg17178900	chr1:205818956	PM20D1	0.72	10.89	0.56	4.64e-23	Menarche (age at onset);
CESC	cis	rs765787	0.530	rs4775835	chr15:45537553	T/C	cg24006582	chr15:45444508	DUOX1	-0.59	-7.32	-0.41	3.04e-12	Uric acid levels;
CESC	cis	rs7666738	0.830	rs11935078	chr4:99010476	T/A	cg03676636	chr4:99064102	C4orf37	0.33	5.16	0.3	4.86e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7089973	0.604	rs2420067	chr10:116590348	A/G	cg23260525	chr10:116636907	FAM160B1	0.4	7.19	0.4	6.76e-12	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs2228479	0.850	rs17226498	chr16:89840631	T/C	cg04013166	chr16:89971882	TCF25	0.78	6.69	0.38	1.3e-10	Skin colour saturation;
CESC	cis	rs10504229	1.000	rs67594249	chr8:58180521	T/A	cg22535103	chr8:58192502	C8orf71	-1.05	-13.27	-0.63	3.63e-31	Developmental language disorder (linguistic errors);
CESC	cis	rs6835098	0.961	rs2877748	chr4:174102397	G/A	cg08422745	chr4:174089978	GALNT7	-0.71	-9.27	-0.49	6.64e-18	Dementia and core Alzheimer's disease neuropathologic changes;
CESC	cis	rs7799006	0.757	rs2398668	chr7:2298227	A/G	cg08027265	chr7:2291960	NA	0.55	9.76	0.51	1.97e-19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs4588572	0.643	rs13155648	chr5:77755343	A/G	cg11547950	chr5:77652471	NA	-0.44	-5.48	-0.32	9.67e-8	Triglycerides;
CESC	trans	rs17039065	0.834	rs17039112	chr4:109439739	G/A	cg27151770	chr16:49620536	ZNF423	-0.5	-6.01	-0.35	6.02e-9	Gut microbiome composition (summer);
CESC	cis	rs9649213	0.574	rs36099592	chr7:98002331	T/C	cg08684580	chr7:98029266	BAIAP2L1	-0.35	-5.8	-0.34	1.85e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs400736	0.671	rs2472862	chr1:7991203	G/A	cg25007680	chr1:8021821	PARK7	-0.57	-8.16	-0.45	1.35e-14	Response to antidepressants and depression;
CESC	cis	rs2267137	0.868	rs174770	chr22:29766895	C/T	cg07256473	chr22:29710276	RASL10A	0.42	6.5	0.37	3.92e-10	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22097276	chr17:73937072	FBF1	0.64	7.25	0.41	4.54e-12	Gut microbiome composition (summer);
CESC	cis	rs6545883	0.929	rs1838978	chr2:61540923	T/C	cg15711740	chr2:61764176	XPO1	0.44	5.54	0.32	7.36e-8	Tuberculosis;
CESC	cis	rs1862618	0.802	rs832547	chr5:56183941	C/G	cg24549020	chr5:56110836	MAP3K1	0.66	7.45	0.42	1.29e-12	Initial pursuit acceleration;
CESC	cis	rs2952156	0.876	rs903504	chr17:37829570	C/G	cg00129232	chr17:37814104	STARD3	-0.81	-11.81	-0.59	3.71e-26	Asthma;
CESC	cis	rs72781680	0.898	rs72780188	chr2:24006065	G/A	cg20701182	chr2:24300061	SF3B14	0.63	5.65	0.33	4.21e-8	Lymphocyte counts;
CESC	cis	rs9399135	0.967	rs9321481	chr6:135352648	C/G	cg24558204	chr6:135376177	HBS1L	-0.53	-7.11	-0.4	1.06e-11	Red blood cell count;
CESC	cis	rs924607	1.000	rs2455331	chr5:643593	T/C	cg09021430	chr5:549028	NA	-0.38	-6.71	-0.38	1.15e-10	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs854765	0.663	rs16960744	chr17:17755259	A/G	cg09796270	chr17:17721594	SREBF1	-0.46	-6.69	-0.38	1.29e-10	Total body bone mineral density;
CESC	cis	rs933688	1.000	rs11948075	chr5:90680579	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.18	14.27	0.66	1.16e-34	Smoking behavior;
CESC	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg01238044	chr22:24384105	GSTT1	-0.74	-10.23	-0.53	6.2e-21	Liver enzyme levels (gamma-glutamyl transferase);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg13040021	chr20:5093911	C20orf30	-0.44	-6.29	-0.36	1.28e-9	Gambling;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	ch.2.10906491R	chr2:10989040	NA	0.46	6.57	0.37	2.59e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs599083	0.530	rs689179	chr11:68179166	A/G	cg01657329	chr11:68192670	LRP5	0.44	5.23	0.31	3.39e-7	Bone mineral density (spine);
CESC	cis	rs870825	0.860	rs2705899	chr4:185596219	A/G	cg04058563	chr4:185651563	MLF1IP	0.51	5.35	0.31	1.93e-7	Blood protein levels;
CESC	cis	rs11625487	0.957	rs28820314	chr14:77963272	A/C	cg20045696	chr14:77926864	AHSA1	-0.6	-6.55	-0.37	3.04e-10	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
CESC	trans	rs61931739	0.890	rs1705753	chr12:34144594	C/T	cg26384229	chr12:38710491	ALG10B	0.48	6.64	0.38	1.8e-10	Morning vs. evening chronotype;
CESC	cis	rs7916697	0.898	rs1900005	chr10:69998055	A/C	cg06988349	chr10:69991859	ATOH7	-0.38	-6.22	-0.36	1.88e-9	Optic disc area;
CESC	cis	rs6032067	0.641	rs34919068	chr20:43755830	C/A	cg10761708	chr20:43804764	PI3	0.5	5.25	0.31	3.12e-7	Blood protein levels;
CESC	cis	rs769267	0.930	rs1054284	chr19:19616953	T/G	cg03709012	chr19:19516395	GATAD2A	1.02	15.57	0.69	2.98e-39	Tonsillectomy;
CESC	cis	rs909674	0.818	rs5757681	chr22:39845547	A/G	cg05872129	chr22:39784769	NA	-0.8	-10.0	-0.52	3.43e-20	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs9815354	0.812	rs55916959	chr3:41849130	G/A	cg03022575	chr3:42003672	ULK4	0.7	6.04	0.35	5.26e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs599083	0.569	rs685095	chr11:68170376	C/T	cg16797656	chr11:68205561	LRP5	-0.42	-5.49	-0.32	9.43e-8	Bone mineral density (spine);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08687137	chr11:62389499	B3GAT3	0.55	6.03	0.35	5.63e-9	Gut microbiome composition (summer);
CESC	cis	rs17039065	0.920	rs57594448	chr4:109461514	A/T	cg16022748	chr4:109541635	LOC285456;RPL34	0.65	5.9	0.34	1.12e-8	Gut microbiome composition (summer);
CESC	cis	rs7336332	0.598	rs45622135	chr13:28011594	T/C	cg01674679	chr13:27998804	GTF3A	-0.58	-5.34	-0.31	2.04e-7	Weight;
CESC	cis	rs12325245	0.536	rs34129245	chr16:58588191	A/G	cg02549819	chr16:58548995	SETD6	0.96	6.42	0.37	6.42e-10	Schizophrenia;
CESC	cis	rs7772486	0.590	rs1890170	chr6:146071839	G/C	cg23711669	chr6:146136114	FBXO30	-0.92	-12.48	-0.61	2.03e-28	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7039377	0.541	rs7850196	chr9:38671574	G/T	cg14625731	chr9:38672608	NA	-0.4	-5.46	-0.32	1.08e-7	Obesity-related traits;
CESC	cis	rs4974559	0.501	rs2101094	chr4:1235643	A/G	cg02980000	chr4:1222292	CTBP1	-0.83	-8.54	-0.46	1.03e-15	Systolic blood pressure;
CESC	cis	rs2040771	0.770	rs2518840	chr22:19255856	A/C	cg17887427	chr22:19166691	SLC25A1	-0.39	-5.11	-0.3	6.3e-7	Metabolite levels (small molecules and protein measures);
CESC	cis	rs6424115	0.830	rs3123554	chr1:24196401	C/T	cg15997130	chr1:24165203	NA	-0.4	-5.28	-0.31	2.67e-7	Immature fraction of reticulocytes;
CESC	cis	rs6912958	0.605	rs2754247	chr6:88383571	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.37	-6.02	-0.35	5.81e-9	Monocyte percentage of white cells;
CESC	cis	rs9814567	0.964	rs9815894	chr3:134282796	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.45	-6.05	-0.35	4.79e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs10504229	0.593	rs74760806	chr8:58024785	C/T	cg22535103	chr8:58192502	C8orf71	-0.67	-7.19	-0.4	6.53e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.46	-6.04	-0.35	5.3e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs6963495	0.606	rs6969426	chr7:105147150	G/A	cg02135003	chr7:105160482	PUS7	-0.47	-5.63	-0.33	4.51e-8	Bipolar disorder (body mass index interaction);
CESC	cis	rs9486719	1.000	rs11153018	chr6:96956137	G/A	cg06623918	chr6:96969491	KIAA0776	-0.8	-8.21	-0.45	9.67e-15	Migraine;Coronary artery disease;
CESC	cis	rs8028182	0.636	rs4322627	chr15:75810659	C/T	cg20655648	chr15:75932815	IMP3	0.48	5.91	0.34	1.04e-8	Sudden cardiac arrest;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00828305	chr2:178077190	HNRNPA3	0.62	7.19	0.4	6.75e-12	Gut microbiome composition (summer);
CESC	cis	rs4566357	0.930	rs13424003	chr2:227926860	G/A	cg11843606	chr2:227700838	RHBDD1	-0.43	-5.45	-0.32	1.16e-7	Coronary artery disease;
CESC	cis	rs10089	1.000	rs4836361	chr5:127459991	T/C	cg19767477	chr5:127420684	SLC12A2	-0.4	-5.32	-0.31	2.18e-7	Ileal carcinoids;
CESC	cis	rs1707322	0.963	rs6666763	chr1:46436451	C/A	cg06784218	chr1:46089804	CCDC17	0.33	5.63	0.33	4.7e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2479724	0.840	rs6925777	chr6:41750822	C/T	cg17623882	chr6:41773611	USP49	0.42	5.93	0.34	9.52e-9	Menarche (age at onset);
CESC	cis	rs7829975	0.871	rs777709	chr8:8583872	T/C	cg17143192	chr8:8559678	CLDN23	-0.48	-5.85	-0.34	1.46e-8	Mood instability;
CESC	cis	rs929354	0.553	rs34498858	chr7:156931337	T/C	cg05182265	chr7:156933206	UBE3C	-0.49	-7.09	-0.4	1.22e-11	Body mass index;
CESC	cis	rs6842047	0.901	rs2102575	chr4:187131504	G/A	cg02012338	chr4:187126139	CYP4V2	0.74	5.88	0.34	1.21e-8	Blood protein levels;
CESC	cis	rs977987	0.762	rs1364079	chr16:75393131	C/A	cg03315344	chr16:75512273	CHST6	0.39	5.66	0.33	3.86e-8	Dupuytren's disease;
CESC	cis	rs7666738	0.546	rs10018080	chr4:98758436	C/A	cg05340658	chr4:99064831	C4orf37	0.54	6.63	0.38	1.89e-10	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10484885	0.878	rs72921955	chr6:90588789	C/G	cg13799429	chr6:90582589	CASP8AP2	-0.8	-7.63	-0.42	4.23e-13	QRS interval (sulfonylurea treatment interaction);
CESC	cis	rs853679	0.607	rs71559070	chr6:28038929	G/A	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.85	5.33	0.31	2.14e-7	Depression;
CESC	cis	rs896854	1.000	rs13255935	chr8:95965685	C/A	cg09323728	chr8:95962352	TP53INP1	-0.44	-9.67	-0.51	3.93e-19	Type 2 diabetes;
CESC	cis	rs7216064	0.734	rs11653507	chr17:65892064	A/T	cg07042672	chr17:66097459	LOC651250	-0.58	-7.1	-0.4	1.14e-11	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs1799949	0.965	rs1842147	chr17:41435192	C/T	cg25072359	chr17:41440525	NA	0.48	6.46	0.37	4.98e-10	Menopause (age at onset);
CESC	cis	rs644799	0.544	rs56298021	chr11:95545113	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.47	6.18	0.35	2.41e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs921968	0.510	rs620887	chr2:219465594	C/A	cg02176678	chr2:219576539	TTLL4	0.48	8.27	0.45	6.35e-15	Mean corpuscular hemoglobin concentration;
CESC	cis	rs7927592	0.956	rs7113287	chr11:68372186	A/T	cg16797656	chr11:68205561	LRP5	0.41	6.05	0.35	4.89e-9	Total body bone mineral density;
CESC	cis	rs514406	0.861	rs10888755	chr1:53240829	A/G	cg24675658	chr1:53192096	ZYG11B	0.54	7.08	0.4	1.28e-11	Monocyte count;
CESC	cis	rs5758659	0.714	rs5751216	chr22:42508937	G/T	cg19513890	chr22:42538836	CYP2D7P1	0.36	5.28	0.31	2.71e-7	Cognitive function;
CESC	cis	rs1815787	1	rs1815787	chr11:116921397	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.56	5.14	0.3	5.4e-7	Subjective well-being;
CESC	cis	rs72781680	0.898	rs7569424	chr2:24036222	A/G	cg08917208	chr2:24149416	ATAD2B	0.95	8.71	0.47	3.45e-16	Lymphocyte counts;
CESC	cis	rs853679	0.517	rs3757187	chr6:28107654	T/C	cg19592336	chr6:28129416	ZNF389	0.62	8.32	0.46	4.64e-15	Depression;
CESC	cis	rs7560272	0.549	rs2421554	chr2:73806202	A/T	cg20560298	chr2:73613845	ALMS1	-0.4	-5.45	-0.32	1.14e-7	Schizophrenia;
CESC	cis	rs2760061	0.626	rs596675	chr1:228117892	G/A	cg01973587	chr1:228161476	NA	0.35	5.29	0.31	2.55e-7	Diastolic blood pressure;
CESC	cis	rs7523050	0.643	rs12725689	chr1:109405151	T/C	cg08274380	chr1:109419600	GPSM2	0.9	5.85	0.34	1.44e-8	Fat distribution (HIV);
CESC	cis	rs9488822	0.676	rs4354188	chr6:116327936	T/C	cg15226275	chr6:116381976	FRK	0.25	6.18	0.35	2.39e-9	Cholesterol, total;LDL cholesterol;
CESC	cis	rs3820068	0.581	rs72645888	chr1:15929922	C/A	cg16988262	chr1:15930761	NA	0.35	5.65	0.33	4.18e-8	Systolic blood pressure;
CESC	cis	rs7586673	1.000	rs7586673	chr2:161923520	C/A	cg21518248	chr2:162101506	NA	0.47	6.4	0.37	7.14e-10	Intelligence (multi-trait analysis);
CESC	cis	rs7937682	0.575	rs1346180	chr11:111715570	G/C	cg09085632	chr11:111637200	PPP2R1B	0.89	11.62	0.58	1.66e-25	Primary sclerosing cholangitis;
CESC	cis	rs896854	0.738	rs481887	chr8:95967838	A/G	cg09323728	chr8:95962352	TP53INP1	0.36	6.98	0.39	2.35e-11	Type 2 diabetes;
CESC	cis	rs1451375	0.652	rs1470747	chr7:50627009	C/T	cg14593290	chr7:50529359	DDC	0.44	5.34	0.31	2.02e-7	Malaria;
CESC	cis	rs780096	0.587	rs6743819	chr2:27567407	G/T	cg12648201	chr2:27665141	KRTCAP3	-0.34	-6.39	-0.37	7.61e-10	Total body bone mineral density;
CESC	cis	rs4974559	0.947	rs58750335	chr4:1364764	G/A	cg02980000	chr4:1222292	CTBP1	0.74	6.56	0.37	2.85e-10	Systolic blood pressure;
CESC	cis	rs13256369	0.802	rs34762800	chr8:8559294	G/A	cg17143192	chr8:8559678	CLDN23	0.77	8.63	0.47	5.79e-16	Obesity-related traits;
CESC	cis	rs4481887	0.617	rs28719164	chr1:248543802	T/G	cg26353448	chr1:248524236	OR2T4	-0.41	-6.17	-0.35	2.53e-9	Common traits (Other);
CESC	cis	rs9649213	0.593	rs12704982	chr7:97926053	C/T	cg08684580	chr7:98029266	BAIAP2L1	-0.35	-5.68	-0.33	3.49e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs1005277	0.557	rs2983338	chr10:38550734	C/T	cg25517755	chr10:38738941	LOC399744	-0.46	-5.94	-0.34	8.7e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs2295499	0.715	rs2282766	chr4:2658327	G/A	cg27239842	chr4:2403781	ZFYVE28	-0.31	-5.16	-0.3	4.74e-7	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
CESC	cis	rs7107174	1.000	rs10899474	chr11:78043636	T/C	cg02023728	chr11:77925099	USP35	0.48	6.34	0.36	9.59e-10	Testicular germ cell tumor;
CESC	cis	rs801193	1.000	rs2659889	chr7:66217112	A/G	cg18876405	chr7:65276391	NA	0.52	6.87	0.39	4.64e-11	Aortic root size;
CESC	cis	rs597539	0.652	rs546382	chr11:68704264	C/T	cg21963583	chr11:68658836	MRPL21	0.39	5.66	0.33	3.86e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs7647973	0.626	rs2329021	chr3:49679072	G/A	cg03060546	chr3:49711283	APEH	0.69	8.34	0.46	4.18e-15	Menarche (age at onset);
CESC	cis	rs6724607	0.905	rs10173771	chr2:191439248	T/C	cg21644426	chr2:191273491	MFSD6	0.48	6.31	0.36	1.17e-9	Pulse pressure;
CESC	cis	rs73110464	0.609	rs4919752	chr12:53359229	G/C	cg25025879	chr12:53359317	NA	-0.61	-8.13	-0.45	1.7e-14	Cancer (pleiotropy);
CESC	cis	rs4843747	0.709	rs72818521	chr16:88058751	C/G	cg06915872	chr16:87998081	BANP	0.59	6.78	0.38	8e-11	Menopause (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01129751	chr2:42796040	MTA3	0.56	6.02	0.35	5.72e-9	Gut microbiome composition (summer);
CESC	cis	rs4629180	0.701	rs10202801	chr2:102106670	T/C	cg21388029	chr2:102003306	CREG2	0.31	5.06	0.3	8e-7	Chronic rhinosinusitis with nasal polyps;
CESC	cis	rs67478160	0.654	rs1535097	chr14:104216649	C/T	cg08213375	chr14:104286397	PPP1R13B	0.53	10.51	0.54	7.85e-22	Schizophrenia;
CESC	cis	rs1799949	0.931	rs34410138	chr17:41279770	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.64	8.95	0.48	6.28e-17	Menopause (age at onset);
CESC	cis	rs36051895	0.558	rs7038687	chr9:5134065	C/T	cg02405213	chr9:5042618	JAK2	0.47	5.96	0.34	8.05e-9	Pediatric autoimmune diseases;
CESC	trans	rs208520	0.955	rs28684412	chr6:66979430	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.84	9.33	0.5	4.5e-18	Exhaled nitric oxide output;
CESC	cis	rs7100689	0.622	rs4536152	chr10:82119242	C/T	cg00277334	chr10:82204260	NA	-0.58	-7.85	-0.43	1.05e-13	Post bronchodilator FEV1;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg19508191	chr12:109124361	CORO1C	0.47	6.47	0.37	4.84e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg19754536	chr21:32624274	TIAM1	0.47	6.25	0.36	1.61e-9	Fibrinogen levels;
CESC	cis	rs875971	0.862	rs6945775	chr7:65968974	G/A	cg10691866	chr7:65817282	TPST1	-0.32	-5.25	-0.31	3.16e-7	Aortic root size;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg10658516	chr2:98612531	TMEM131	-0.47	-6.3	-0.36	1.22e-9	Fibrinogen levels;
CESC	cis	rs10463316	0.928	rs4958267	chr5:150752643	A/T	cg03212797	chr5:150827313	SLC36A1	-0.52	-6.74	-0.38	9.96e-11	Metabolite levels (Pyroglutamine);
CESC	cis	rs9660180	0.967	rs10907191	chr1:1774820	A/T	cg20999797	chr1:1681921	NA	0.26	5.11	0.3	6.15e-7	Body mass index;
CESC	cis	rs12477438	0.520	rs8179690	chr2:99795300	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.84	-14.61	-0.67	7.35e-36	Chronic sinus infection;
CESC	cis	rs752010	1.000	rs6656183	chr1:42094025	A/G	cg06885757	chr1:42089581	HIVEP3	0.49	8.15	0.45	1.43e-14	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs7589342	0.929	rs12053259	chr2:106428720	G/A	cg16077055	chr2:106428750	NCK2	0.53	7.57	0.42	6.1e-13	Addiction;
CESC	cis	rs60154123	0.772	rs664072	chr1:210422160	G/A	cg23283495	chr1:209979779	IRF6	0.43	5.21	0.3	3.74e-7	Coronary artery disease;
CESC	cis	rs7605827	0.856	rs35549453	chr2:15527220	C/T	cg19274914	chr2:15703543	NA	0.36	6.45	0.37	5.37e-10	Educational attainment (years of education);
CESC	cis	rs793571	0.521	rs12594872	chr15:58912749	T/C	cg05156742	chr15:59063176	FAM63B	0.77	11.04	0.56	1.47e-23	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22307732	chr7:2559417	LFNG	0.61	7.37	0.41	2.18e-12	Gut microbiome composition (summer);
CESC	cis	rs7772486	0.641	rs9390374	chr6:146368175	A/T	cg05347473	chr6:146136440	FBXO30	0.57	6.96	0.39	2.75e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs10504229	1.000	rs72652906	chr8:58188360	C/A	cg05313129	chr8:58192883	C8orf71	-0.57	-6.47	-0.37	4.59e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs1023500	0.505	rs134891	chr22:42675882	T/C	cg04733989	chr22:42467013	NAGA	0.64	9.84	0.52	1.16e-19	Schizophrenia;
CESC	cis	rs7084402	1.000	rs1863665	chr10:60266640	T/C	cg07615347	chr10:60278583	BICC1	-0.58	-8.92	-0.48	8.11e-17	Refractive error;
CESC	cis	rs9611565	0.512	rs45500192	chr22:42177899	A/G	cg06634786	chr22:41940651	POLR3H	-0.67	-6.64	-0.38	1.8e-10	Vitiligo;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg03269368	chr19:19431604	KIAA0892;SF4	-0.45	-6.55	-0.37	2.91e-10	Fibrinogen levels;
CESC	cis	rs7811142	0.830	rs705866	chr7:99965285	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.91	8.47	0.46	1.68e-15	Platelet count;
CESC	cis	rs10504229	0.906	rs113823909	chr8:58170635	A/G	cg14926445	chr8:58193284	C8orf71	-0.52	-5.59	-0.32	5.77e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs7255436	1.000	rs7255436	chr19:8433196	C/A	cg16745616	chr19:8428856	ANGPTL4	-0.37	-5.64	-0.33	4.37e-8	HDL cholesterol;
CESC	cis	rs9325144	0.560	rs7971313	chr12:38653413	A/G	cg26384229	chr12:38710491	ALG10B	-0.62	-9.6	-0.51	6.43e-19	Morning vs. evening chronotype;
CESC	trans	rs4716602	0.596	rs28451598	chr7:156158974	G/A	cg07175507	chr18:77160758	NFATC1	-0.44	-6.09	-0.35	3.91e-9	Anti-saccade response;
CESC	cis	rs7552404	0.727	rs5745427	chr1:76332637	C/A	cg22875332	chr1:76189707	ACADM	-0.62	-6.57	-0.37	2.73e-10	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs2764980	1.000	rs2814925	chr10:3284061	A/G	cg11630169	chr10:3283847	NA	-0.35	-5.13	-0.3	5.54e-7	Attention deficit hyperactivity disorder and conduct disorder;
CESC	cis	rs7772486	0.875	rs2814874	chr6:146305895	C/T	cg23711669	chr6:146136114	FBXO30	0.9	13.1	0.63	1.45e-30	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs35110281	0.807	rs6518301	chr21:45016818	T/C	cg21573476	chr21:45109991	RRP1B	-0.45	-6.39	-0.37	7.53e-10	Mean corpuscular volume;
CESC	cis	rs12497850	0.897	rs7432989	chr3:49105136	A/G	cg03060546	chr3:49711283	APEH	0.49	5.93	0.34	9.54e-9	Parkinson's disease;
CESC	cis	rs909674	0.818	rs5757681	chr22:39845547	A/G	cg24399712	chr22:39784796	NA	-0.81	-10.34	-0.54	2.76e-21	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs4242434	0.892	rs34269854	chr8:22465160	G/C	cg03733263	chr8:22462867	KIAA1967	0.95	15.72	0.69	8.78e-40	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CESC	cis	rs28830936	1.000	rs28830936	chr15:41906408	G/A	cg11010575	chr15:42129464	JMJD7-PLA2G4B;JMJD7	-0.36	-5.1	-0.3	6.47e-7	Diastolic blood pressure;
CESC	cis	rs9911578	1.000	rs12602346	chr17:56901713	T/C	cg12560992	chr17:57184187	TRIM37	0.94	15.75	0.7	6.57e-40	Intelligence (multi-trait analysis);
CESC	cis	rs11098499	1.000	rs3749591	chr4:120214030	T/G	cg09307838	chr4:120376055	NA	0.87	11.61	0.58	1.88e-25	Corneal astigmatism;
CESC	cis	rs10489525	0.583	rs1967711	chr1:115630967	C/T	cg01522456	chr1:115632236	TSPAN2	0.68	7.83	0.43	1.18e-13	Autism;
CESC	cis	rs10465746	0.570	rs11163886	chr1:84473445	C/A	cg10977910	chr1:84465055	TTLL7	0.44	5.54	0.32	7.2e-8	Obesity-related traits;
CESC	cis	rs7520050	0.966	rs6669522	chr1:46397941	A/G	cg24296786	chr1:45957014	TESK2	0.44	5.49	0.32	9.64e-8	Red blood cell count;Reticulocyte count;
CESC	cis	rs9911578	1.000	rs12940681	chr17:56933622	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.38	5.06	0.3	7.91e-7	Intelligence (multi-trait analysis);
CESC	cis	rs4604732	0.631	rs11490201	chr1:247626262	A/G	cg12758973	chr1:247694275	LOC148824;OR2C3	0.51	6.36	0.36	8.65e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs79349575	0.715	rs62075844	chr17:47002389	G/A	cg16584676	chr17:46985605	UBE2Z	0.54	6.7	0.38	1.24e-10	Type 2 diabetes;
CESC	cis	rs7408868	0.656	rs1043997	chr19:15292437	T/C	cg14696996	chr19:15285081	NOTCH3	0.77	8.89	0.48	9.75e-17	Pulse pressure;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg03556369	chr5:172721020	NA	0.45	6.18	0.35	2.36e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs6952407	1	rs6952407	chr7:66045512	A/G	cg11764359	chr7:65958608	NA	-0.7	-8.85	-0.48	1.25e-16	Cotinine glucuronidation;
CESC	cis	rs7824557	0.767	rs4559208	chr8:11153925	C/G	cg21775007	chr8:11205619	TDH	0.46	6.93	0.39	3.28e-11	Retinal vascular caliber;
CESC	cis	rs611744	0.870	rs650925	chr8:109196725	T/C	cg21045802	chr8:109455806	TTC35	0.46	5.51	0.32	8.49e-8	Dupuytren's disease;
CESC	cis	rs6580649	0.941	rs1968071	chr12:48489357	A/G	cg05342945	chr12:48394962	COL2A1	0.49	5.59	0.32	5.65e-8	Lung cancer;
CESC	cis	rs9311474	0.508	rs12637627	chr3:52619962	G/T	cg18404041	chr3:52824283	ITIH1	-0.39	-6.61	-0.38	2.12e-10	Electroencephalogram traits;
CESC	trans	rs10500991	0.587	rs73442315	chr11:24887646	G/A	cg07129253	chr8:30890560	PURG;WRN	-0.49	-6.52	-0.37	3.52e-10	Iron status biomarkers;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg06896663	chr8:82754093	SNX16	-0.5	-6.6	-0.38	2.26e-10	Fibrinogen levels;
CESC	cis	rs4665809	1.000	rs6546766	chr2:26328680	T/C	cg04944784	chr2:26401820	FAM59B	-0.67	-7.67	-0.43	3.35e-13	Gut microbiome composition (summer);
CESC	cis	rs10504229	0.639	rs67002486	chr8:58117218	A/G	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs4555082	0.874	rs11622166	chr14:105759763	C/A	cg13114125	chr14:105738426	BRF1	-0.88	-10.43	-0.54	1.41e-21	Mean platelet volume;Platelet distribution width;
CESC	cis	rs1595825	0.891	rs4422151	chr2:198544183	A/T	cg00982548	chr2:198649783	BOLL	-0.48	-5.25	-0.31	3.07e-7	Ulcerative colitis;
CESC	cis	rs4819052	0.851	rs2838836	chr21:46665875	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.92	13.51	0.64	5.51e-32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs7618915	0.547	rs11709448	chr3:52647449	T/C	cg07507251	chr3:52567010	NT5DC2	0.42	7.29	0.41	3.61e-12	Bipolar disorder;
CESC	cis	rs7561273	0.586	rs11902756	chr2:24300932	A/G	cg01493198	chr2:24299560	SF3B14	0.41	5.04	0.3	8.6e-7	Quantitative traits;
CESC	cis	rs6430585	0.591	rs1374330	chr2:136420908	A/C	cg07169764	chr2:136633963	MCM6	1.0	11.16	0.57	5.94e-24	Corneal structure;
CESC	cis	rs10504229	1.000	rs112272435	chr8:58170371	A/G	cg14926445	chr8:58193284	C8orf71	-0.51	-5.49	-0.32	9.29e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs9905704	0.918	rs12947196	chr17:56902444	G/A	cg12560992	chr17:57184187	TRIM37	0.61	7.05	0.4	1.54e-11	Testicular germ cell tumor;
CESC	cis	rs2658782	0.789	rs56091149	chr11:93073640	A/C	cg15737290	chr11:93063684	CCDC67	-0.55	-6.86	-0.39	4.79e-11	Pulmonary function decline;
CESC	cis	rs6087990	1.000	rs1007124	chr20:31345752	G/C	cg13636640	chr20:31349939	DNMT3B	0.9	16.32	0.71	6.41e-42	Ulcerative colitis;
CESC	cis	rs2204008	0.840	rs7957966	chr12:37953629	A/G	cg26384229	chr12:38710491	ALG10B	-0.51	-7.24	-0.41	4.85e-12	Bladder cancer;
CESC	cis	rs172166	0.694	rs203884	chr6:28077374	G/T	cg17221315	chr6:27791827	HIST1H4J	0.42	5.17	0.3	4.72e-7	Cardiac Troponin-T levels;
CESC	cis	rs1799949	0.965	rs11650913	chr17:41331597	T/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.38	5.04	0.3	8.73e-7	Menopause (age at onset);
CESC	cis	rs1371867	0.875	rs1660319	chr8:101337530	A/G	cg11906718	chr8:101322791	RNF19A	0.47	6.07	0.35	4.4e-9	Atrioventricular conduction;
CESC	cis	rs7666738	0.753	rs28390295	chr4:99028497	C/A	cg05340658	chr4:99064831	C4orf37	0.83	13.1	0.63	1.43e-30	Colonoscopy-negative controls vs population controls;
CESC	trans	rs875971	0.508	rs10253883	chr7:66061138	T/C	cg26939375	chr7:64535504	NA	-0.53	-7.37	-0.41	2.22e-12	Aortic root size;
CESC	cis	rs4665809	0.590	rs9309474	chr2:26448830	T/A	cg27170947	chr2:26402098	FAM59B	-0.87	-9.89	-0.52	7.6e-20	Gut microbiome composition (summer);
CESC	cis	rs660899	0.595	rs34224911	chr1:44258341	A/T	cg11704212	chr1:44303111	ST3GAL3	-0.38	-5.17	-0.3	4.72e-7	Hypertension risk in short sleep duration;
CESC	cis	rs524281	0.861	rs7946917	chr11:65956577	A/G	cg14036092	chr11:66035641	RAB1B	-0.59	-6.13	-0.35	3.24e-9	Electroencephalogram traits;
CESC	cis	rs9549367	0.712	rs2316443	chr13:113864837	G/A	cg00898013	chr13:113819073	PROZ	-0.5	-7.27	-0.41	4.16e-12	Platelet distribution width;
CESC	cis	rs8133932	0.608	rs413246	chr21:47346066	G/A	cg14185626	chr21:47401492	COL6A1	-0.48	-5.4	-0.31	1.47e-7	Schizophrenia;
CESC	cis	rs1799949	0.501	rs35399157	chr17:41411602	G/C	cg23758822	chr17:41437982	NA	1.05	16.25	0.71	1.17e-41	Menopause (age at onset);
CESC	trans	rs1945213	0.694	rs12222077	chr11:55848116	T/A	cg15704280	chr7:45808275	SEPT13	0.76	7.31	0.41	3.15e-12	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs597539	0.652	rs482172	chr11:68668437	C/A	cg18350739	chr11:68623251	NA	-0.46	-7.1	-0.4	1.15e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs7772486	0.713	rs79248977	chr6:146319388	C/A	cg23711669	chr6:146136114	FBXO30	0.81	11.43	0.57	7.46e-25	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1046896	0.594	rs4075209	chr17:80800027	G/T	cg19046167	chr17:80928561	B3GNTL1	0.46	5.4	0.31	1.47e-7	Glycated hemoglobin levels;
CESC	cis	rs30380	1.000	rs30378	chr5:96121994	A/G	cg16492584	chr5:96139282	ERAP1	-0.36	-5.41	-0.32	1.42e-7	Cerebrospinal fluid biomarker levels;
CESC	cis	rs2243480	1.000	rs73142122	chr7:65311298	C/A	cg18252515	chr7:66147081	NA	-1.18	-11.4	-0.57	9.2e-25	Diabetic kidney disease;
CESC	cis	rs796364	0.760	rs55906940	chr2:201049386	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.77	-6.49	-0.37	4.29e-10	Schizophrenia;
CESC	cis	rs2635047	0.682	rs7242976	chr18:44797159	T/A	cg24371990	chr18:44770781	NA	0.39	6.27	0.36	1.48e-9	Educational attainment;
CESC	trans	rs1728785	1.000	rs7195979	chr16:68586801	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.69	8.13	0.45	1.71e-14	Ulcerative colitis;
CESC	cis	rs829661	0.532	rs2363073	chr2:30796008	A/C	cg17749961	chr2:30669863	LCLAT1	-0.44	-5.39	-0.31	1.59e-7	Midgestational circulating levels of PBDEs (fetal genetic effect);
CESC	cis	rs208520	1.000	rs12190187	chr6:66973207	T/G	cg07460842	chr6:66804631	NA	0.9	10.27	0.53	4.61e-21	Exhaled nitric oxide output;
CESC	cis	rs6088590	0.710	rs6059992	chr20:33282275	T/C	cg24642439	chr20:33292090	TP53INP2	0.66	8.77	0.47	2.24e-16	Coronary artery disease;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg04915425	chr11:47236385	DDB2	-0.43	-6.21	-0.36	2.04e-9	Gambling;
CESC	cis	rs1799949	1.000	rs8176212	chr17:41226601	G/C	cg23758822	chr17:41437982	NA	1.03	15.68	0.69	1.19e-39	Menopause (age at onset);
CESC	cis	rs7615952	0.673	rs9821905	chr3:125620850	A/G	cg05084668	chr3:125655381	ALG1L	0.7	7.73	0.43	2.21e-13	Blood pressure (smoking interaction);
CESC	cis	rs3015497	0.506	rs10144234	chr14:51172219	A/C	cg26011998	chr14:51135199	SAV1	0.5	5.68	0.33	3.6e-8	Mean platelet volume;
CESC	cis	rs11785400	1.000	rs4736365	chr8:143742197	A/G	cg24634471	chr8:143751801	JRK	0.47	6.2	0.36	2.21e-9	Schizophrenia;
CESC	cis	rs6952808	0.723	rs60995052	chr7:2030007	G/C	cg05863683	chr7:1912471	MAD1L1	0.43	6.35	0.36	9.24e-10	Bipolar disorder and schizophrenia;
CESC	cis	rs6570726	0.791	rs407887	chr6:145843759	C/T	cg23711669	chr6:146136114	FBXO30	1.0	15.63	0.69	1.86e-39	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs7107217	1.000	rs1873872	chr11:129473993	A/T	cg16510040	chr1:40042432	PABPC4	0.45	6.05	0.35	4.85e-9	Breast cancer;Type 2 diabetes;
CESC	trans	rs17027633	0.867	rs7543384	chr1:111948014	G/T	cg23429042	chr3:32023402	ZNF860;OSBPL10	-0.56	-6.13	-0.35	3.12e-9	Cerebrospinal fluid t-tau:AB1-42 ratio;
CESC	cis	rs6815814	0.950	rs11727978	chr4:38811051	T/A	cg02016764	chr4:38805732	TLR1	-0.62	-7.43	-0.42	1.5e-12	Breast cancer;
CESC	cis	rs11122272	0.735	rs2808586	chr1:231515559	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.57	-7.82	-0.43	1.29e-13	Hemoglobin concentration;
CESC	cis	rs5769765	0.837	rs4824110	chr22:50271631	T/A	cg26441486	chr22:50317300	CRELD2	-0.39	-5.5	-0.32	8.72e-8	Schizophrenia;
CESC	cis	rs1707322	0.964	rs10890358	chr1:46319025	T/A	cg06784218	chr1:46089804	CCDC17	0.32	5.48	0.32	1e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs897080	0.515	rs1067321	chr2:44631312	G/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	5.88	0.34	1.2e-8	Height;
CESC	trans	rs743002	0.554	rs5751014	chr22:41358092	A/T	cg21776993	chr19:1449424	APC2	-0.63	-6.25	-0.36	1.63e-9	Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;Eosinophil counts;
CESC	cis	rs1707322	0.896	rs785518	chr1:46568422	A/T	cg06784218	chr1:46089804	CCDC17	-0.33	-5.63	-0.33	4.67e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs72945132	0.882	rs72945194	chr11:70138621	A/G	cg14191688	chr11:70257035	CTTN	0.48	5.7	0.33	3.21e-8	Coronary artery disease;
CESC	cis	rs6502050	0.805	rs7406682	chr17:80084368	C/T	cg23985595	chr17:80112537	CCDC57	0.42	6.55	0.37	2.99e-10	Life satisfaction;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12703194	chr16:3086867	CCDC64B	0.57	6.7	0.38	1.25e-10	Gut microbiome composition (summer);
CESC	cis	rs690037	0.528	rs568833	chr3:16367836	C/T	cg23474789	chr3:16306055	DPH3;OXNAD1	-0.59	-8.1	-0.45	2.05e-14	Optic nerve measurement (cup-to-disc ratio);Optic nerve measurement (cup area);
CESC	cis	rs72781680	1.000	rs72781683	chr2:24247423	T/C	cg20701182	chr2:24300061	SF3B14	0.85	7.4	0.41	1.8e-12	Lymphocyte counts;
CESC	cis	rs644799	0.932	rs523934	chr11:95641775	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.43	5.2	0.3	3.99e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.37	-5.48	-0.32	9.66e-8	Electroencephalogram traits;
CESC	cis	rs9649213	0.593	rs6955647	chr7:98004562	T/C	cg00277769	chr7:97922759	BAIAP2L1	-0.34	-5.57	-0.32	6.33e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs897984	0.762	rs2054213	chr16:30971810	A/G	cg00531865	chr16:30841666	NA	0.51	7.01	0.4	2e-11	Dementia with Lewy bodies;
CESC	cis	rs514406	0.644	rs7530078	chr1:53204861	G/T	cg16325326	chr1:53192061	ZYG11B	-0.7	-11.18	-0.57	4.87e-24	Monocyte count;
CESC	cis	rs2108622	0.559	rs7252638	chr19:15981025	G/C	cg13772218	chr19:15982569	NA	0.3	5.87	0.34	1.27e-8	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CESC	cis	rs9443645	0.901	rs9448596	chr6:79629429	T/C	cg05283184	chr6:79620031	NA	-0.42	-6.43	-0.37	5.98e-10	Intelligence (multi-trait analysis);
CESC	cis	rs10129255	0.957	rs8009464	chr14:107185850	C/T	cg07958169	chr14:107095056	NA	-0.41	-5.82	-0.34	1.7e-8	Kawasaki disease;
CESC	cis	rs17253792	0.822	rs10137340	chr14:56050989	A/G	cg01858014	chr14:56050164	KTN1	-0.76	-6.56	-0.37	2.87e-10	Putamen volume;
CESC	cis	rs7552404	0.727	rs5745427	chr1:76332637	C/A	cg03433033	chr1:76189801	ACADM	-0.62	-6.52	-0.37	3.45e-10	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs9611565	0.694	rs5758368	chr22:41862288	C/T	cg06634786	chr22:41940651	POLR3H	-0.65	-7.22	-0.41	5.43e-12	Vitiligo;
CESC	cis	rs7618501	0.932	rs4855850	chr3:49761571	G/A	cg24308560	chr3:49941425	MST1R	0.51	7.06	0.4	1.48e-11	Intelligence (multi-trait analysis);
CESC	cis	rs7618915	0.571	rs17264436	chr3:52610651	T/A	cg07507251	chr3:52567010	NT5DC2	0.43	7.44	0.42	1.43e-12	Bipolar disorder;
CESC	cis	rs1003719	0.713	rs2835594	chr21:38466064	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.63	8.77	0.47	2.14e-16	Eye color traits;
CESC	cis	rs1405069	0.809	rs1063021	chr6:36932327	A/G	cg26433444	chr6:36932349	PI16	0.42	8.17	0.45	1.26e-14	Chemerin levels;
CESC	cis	rs9303401	0.659	rs34468504	chr17:56648277	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.02	12.93	0.62	5.59e-30	Cognitive test performance;
CESC	cis	rs10504229	0.593	rs17794451	chr8:58019217	C/T	cg02725872	chr8:58115012	NA	-0.38	-5.1	-0.3	6.54e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs4523957	0.620	rs898749	chr17:2085185	G/A	cg16513277	chr17:2031491	SMG6	-0.71	-10.17	-0.53	1.04e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs2228479	0.850	rs17232630	chr16:89851179	C/T	cg19635926	chr16:89946313	TCF25	0.67	5.08	0.3	7.08e-7	Skin colour saturation;
CESC	cis	rs12586317	0.547	rs4982234	chr14:35460106	T/A	cg05294307	chr14:35346193	BAZ1A	-0.51	-5.45	-0.32	1.16e-7	Psoriasis;
CESC	cis	rs853679	0.517	rs9357061	chr6:28051772	A/G	cg08968635	chr6:28129556	ZNF389	0.39	5.22	0.31	3.64e-7	Depression;
CESC	cis	rs796364	1.000	rs281785	chr2:200749566	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.83	7.81	0.43	1.36e-13	Schizophrenia;
CESC	cis	rs2718058	0.560	rs2709109	chr7:37832852	G/A	cg24998770	chr7:37888106	TXNDC3	0.38	5.37	0.31	1.7e-7	Alzheimer's disease (late onset);
CESC	cis	rs9487051	0.735	rs455839	chr6:109524221	G/A	cg01475377	chr6:109611718	NA	-0.46	-6.91	-0.39	3.52e-11	Reticulocyte fraction of red cells;
CESC	cis	rs72781680	0.950	rs72796343	chr2:24147631	G/A	cg08917208	chr2:24149416	ATAD2B	1.11	9.73	0.51	2.43e-19	Lymphocyte counts;
CESC	trans	rs1814175	0.616	rs1722020	chr11:49904189	G/A	cg03929089	chr4:120376271	NA	-0.92	-15.2	-0.68	6e-38	Height;
CESC	cis	rs10540	1.000	rs12419766	chr11:503710	C/T	cg03352830	chr11:487213	PTDSS2	0.74	7.21	0.4	5.99e-12	Body mass index;
CESC	cis	rs4727027	0.933	rs7788925	chr7:148831621	A/G	cg23583168	chr7:148888333	NA	-0.73	-10.82	-0.55	7.76e-23	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs7520050	0.778	rs3014216	chr1:46035760	A/T	cg03146154	chr1:46216737	IPP	0.48	6.17	0.35	2.55e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs4835473	0.932	rs55862664	chr4:144657464	G/A	cg25736465	chr4:144833511	NA	-0.32	-5.07	-0.3	7.49e-7	Immature fraction of reticulocytes;
CESC	cis	rs425277	0.583	rs925905	chr1:2044037	T/C	cg04315214	chr1:2043799	PRKCZ	0.6	10.44	0.54	1.32e-21	Height;
CESC	cis	rs4689592	0.503	rs59640165	chr4:7051661	G/A	cg19539972	chr4:7069911	GRPEL1	-0.72	-6.88	-0.39	4.34e-11	Monocyte percentage of white cells;
CESC	cis	rs10504229	0.775	rs56155911	chr8:58163247	C/T	cg22535103	chr8:58192502	C8orf71	-0.95	-10.54	-0.54	6.39e-22	Developmental language disorder (linguistic errors);
CESC	cis	rs6580649	0.882	rs59766465	chr12:48470169	G/A	cg05342945	chr12:48394962	COL2A1	0.5	5.74	0.33	2.59e-8	Lung cancer;
CESC	cis	rs2072732	0.861	rs10909866	chr1:2960372	C/T	cg15211996	chr1:2936768	ACTRT2	0.35	5.87	0.34	1.31e-8	Plateletcrit;
CESC	cis	rs736408	0.509	rs13083798	chr3:52649748	A/G	cg07507251	chr3:52567010	NT5DC2	0.35	6.61	0.38	2.07e-10	Bipolar disorder;
CESC	cis	rs6815814	0.699	rs11730390	chr4:38881414	T/C	cg02016764	chr4:38805732	TLR1	-0.62	-6.87	-0.39	4.61e-11	Breast cancer;
CESC	cis	rs7130144	0.541	rs57851196	chr11:130465218	T/C	cg26307797	chr11:130446613	NA	-0.79	-7.11	-0.4	1.07e-11	Urate levels in lean individuals;
CESC	cis	rs763121	0.853	rs2281019	chr22:39064378	T/A	cg21395723	chr22:39101663	GTPBP1	0.43	5.39	0.31	1.58e-7	Menopause (age at onset);
CESC	cis	rs10129255	0.957	rs7493713	chr14:107191922	T/C	cg07958169	chr14:107095056	NA	-0.4	-5.52	-0.32	8.02e-8	Kawasaki disease;
CESC	trans	rs7726839	0.561	rs56410216	chr5:583216	C/A	cg25482853	chr8:67687455	SGK3	0.88	9.24	0.49	8.24e-18	Obesity-related traits;
CESC	cis	rs79349575	0.783	rs62075820	chr17:46983171	G/C	cg16584676	chr17:46985605	UBE2Z	0.53	6.6	0.38	2.25e-10	Type 2 diabetes;
CESC	cis	rs2841277	0.708	rs9671643	chr14:105408030	A/G	cg14403583	chr14:105418241	AHNAK2	-0.58	-8.07	-0.44	2.5e-14	Rheumatoid arthritis;
CESC	cis	rs763121	0.853	rs5757211	chr22:39051705	C/T	cg06022373	chr22:39101656	GTPBP1	0.88	13.79	0.65	5.43e-33	Menopause (age at onset);
CESC	cis	rs9354308	0.868	rs9363460	chr6:66557539	C/A	cg07460842	chr6:66804631	NA	-0.42	-5.03	-0.3	8.94e-7	Metabolite levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11184091	chr9:131843633	DOLPP1	0.56	6.5	0.37	3.9e-10	Gut microbiome composition (summer);
CESC	cis	rs4835473	0.900	rs5015758	chr4:144659205	G/A	cg25736465	chr4:144833511	NA	-0.33	-5.2	-0.3	4.04e-7	Immature fraction of reticulocytes;
CESC	cis	rs9311474	1.000	rs6445358	chr3:52308845	C/G	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.78	0.38	8.01e-11	Electroencephalogram traits;
CESC	cis	rs965469	1.000	rs2236106	chr20:3278410	A/C	cg25506879	chr20:3388711	C20orf194	-0.54	-5.88	-0.34	1.24e-8	IFN-related cytopenia;
CESC	cis	rs478304	0.903	rs495961	chr11:65540886	C/T	cg08755490	chr11:65554678	OVOL1	0.47	6.14	0.35	3.06e-9	Acne (severe);
CESC	cis	rs17253792	0.822	rs2296181	chr14:56107051	G/A	cg01858014	chr14:56050164	KTN1	-0.85	-7.03	-0.4	1.73e-11	Putamen volume;
CESC	cis	rs4076764	0.522	rs4265409	chr1:163414559	C/T	cg24596788	chr1:163392923	NA	-0.35	-5.15	-0.3	5.16e-7	Motion sickness;
CESC	cis	rs79349575	0.715	rs11657238	chr17:46985634	A/G	cg16584676	chr17:46985605	UBE2Z	0.72	9.58	0.51	7.19e-19	Type 2 diabetes;
CESC	cis	rs1545257	0.537	rs2702089	chr2:24643291	A/G	cg06627628	chr2:24431161	ITSN2	0.46	5.66	0.33	3.95e-8	Sjögren's syndrome;
CESC	cis	rs3857536	0.740	rs4710571	chr6:66890250	T/C	cg07460842	chr6:66804631	NA	-0.41	-5.36	-0.31	1.82e-7	Blood trace element (Cu levels);
CESC	cis	rs7666738	0.830	rs28887893	chr4:98963006	G/A	cg03467027	chr4:99064603	C4orf37	0.44	5.57	0.32	6.41e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1799949	0.896	rs8176086	chr17:41274778	G/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.45	6.3	0.36	1.21e-9	Menopause (age at onset);
CESC	cis	rs7666738	0.830	rs1349757	chr4:99058763	C/G	cg17366294	chr4:99064904	C4orf37	0.61	8.61	0.47	6.71e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9487051	0.597	rs412754	chr6:109522057	G/C	cg01475377	chr6:109611718	NA	-0.39	-5.15	-0.3	5.18e-7	Reticulocyte fraction of red cells;
CESC	cis	rs1218582	0.628	rs12130132	chr1:154880386	C/T	cg03351412	chr1:154909251	PMVK	0.48	5.91	0.34	1.03e-8	Prostate cancer;
CESC	cis	rs727505	0.954	rs59670428	chr7:124520966	C/A	cg23710748	chr7:124431027	NA	-0.4	-6.46	-0.37	4.92e-10	Lewy body disease;
CESC	cis	rs514406	0.644	rs1855127	chr1:53199594	A/G	cg24675658	chr1:53192096	ZYG11B	0.64	9.0	0.48	4.44e-17	Monocyte count;
CESC	cis	rs2228479	0.681	rs62052184	chr16:89967217	T/C	cg00800038	chr16:89945340	TCF25	-0.59	-6.29	-0.36	1.33e-9	Skin colour saturation;
CESC	cis	rs67478160	0.643	rs2295145	chr14:104202304	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.52	-7.26	-0.41	4.37e-12	Schizophrenia;
CESC	cis	rs10870270	1.000	rs4880250	chr10:133773919	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.85	-12.48	-0.61	2.02e-28	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs6460942	0.597	rs6968664	chr7:12515493	T/C	cg02935154	chr7:12443704	VWDE	-0.48	-5.09	-0.3	6.85e-7	Coronary artery disease;
CESC	cis	rs7264396	0.887	rs224363	chr20:34062710	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.42	-5.11	-0.3	6.12e-7	Total cholesterol levels;
CESC	cis	rs7621025	0.664	rs6439657	chr3:136494639	C/T	cg15507776	chr3:136538369	TMEM22	-0.53	-6.28	-0.36	1.37e-9	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
CESC	cis	rs3816788	0.596	rs4872083	chr8:21770372	C/T	cg17168535	chr8:21777572	XPO7	0.63	9.57	0.51	8e-19	Lung cancer in ever smokers;
CESC	cis	rs2281558	0.754	rs73597824	chr20:25591477	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.51	6.91	0.39	3.68e-11	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;
CESC	cis	rs72781680	0.821	rs72796401	chr2:24180078	T/A	cg08917208	chr2:24149416	ATAD2B	0.69	6.74	0.38	1e-10	Lymphocyte counts;
CESC	cis	rs2806561	0.929	rs6694445	chr1:23540428	A/G	cg12483005	chr1:23474871	LUZP1	0.32	5.23	0.31	3.41e-7	Height;
CESC	cis	rs9899728	0.764	rs7219493	chr17:73044188	T/C	cg27626185	chr17:73056755	KCTD2	-0.61	-6.08	-0.35	4.26e-9	Alzheimer's disease or small vessel stroke;
CESC	cis	rs7149337	0.836	rs4901087	chr14:51668499	T/C	cg23942311	chr14:51606299	NA	0.44	7.41	0.41	1.67e-12	Cancer;
CESC	cis	rs7786877	0.723	rs10487157	chr7:100214487	C/G	cg20848291	chr7:100343083	ZAN	-0.63	-6.66	-0.38	1.59e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs8077889	0.619	rs1230399	chr17:41845403	C/T	cg26893861	chr17:41843967	DUSP3	-1.02	-19.07	-0.76	1.3e-51	Triglycerides;
CESC	cis	rs12541635	0.677	rs1429681	chr8:107048808	A/C	cg10147462	chr8:107024639	NA	0.47	6.97	0.39	2.46e-11	Age of smoking initiation;
CESC	cis	rs2842992	0.872	rs2758330	chr6:160104844	G/T	cg11366901	chr6:160182831	ACAT2	0.77	9.69	0.51	3.29e-19	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs4629180	1.000	rs4851457	chr2:102091220	C/T	cg01388757	chr2:102091195	RFX8	0.44	6.62	0.38	1.94e-10	Chronic rhinosinusitis with nasal polyps;
CESC	cis	rs1538970	0.924	rs1006216	chr1:45909994	A/G	cg06784218	chr1:46089804	CCDC17	0.35	5.54	0.32	7.26e-8	Platelet count;
CESC	trans	rs6759922	1.000	rs13387284	chr2:22448133	G/A	cg21162304	chr4:80247171	NAA11	0.37	6.08	0.35	4.24e-9	Subjective well-being (multi-trait analysis);
CESC	cis	rs12134245	0.776	rs12124682	chr1:91995542	A/G	cg07090678	chr1:91966139	CDC7	0.41	5.65	0.33	4.1e-8	Breast cancer;
CESC	cis	rs7089973	0.604	rs7919649	chr10:116609576	T/C	cg23260525	chr10:116636907	FAM160B1	0.37	6.71	0.38	1.21e-10	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs1046896	0.520	rs8074086	chr17:80818460	A/C	cg19046167	chr17:80928561	B3GNTL1	0.46	5.51	0.32	8.46e-8	Glycated hemoglobin levels;
CESC	cis	rs3820068	0.581	rs78175477	chr1:15948091	C/G	cg16988262	chr1:15930761	NA	0.34	5.45	0.32	1.13e-7	Systolic blood pressure;
CESC	trans	rs650950	0.528	rs646660	chr11:35528452	C/T	cg10807698	chr14:103243805	TRAF3	0.48	6.37	0.36	8.47e-10	Bronchopulmonary dysplasia;
CESC	cis	rs9916302	0.821	rs4795386	chr17:37746847	A/G	cg15445000	chr17:37608096	MED1	0.34	5.19	0.3	4.1e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs910316	1.000	rs175492	chr14:75545220	A/C	cg08847533	chr14:75593920	NEK9	0.97	18.89	0.76	5.36e-51	Height;
CESC	cis	rs919433	0.750	rs788012	chr2:198229856	A/T	cg03934865	chr2:198174659	NA	0.43	6.18	0.35	2.41e-9	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs3858526	0.920	rs11039698	chr11:5950907	C/T	cg05234568	chr11:5960015	NA	-0.63	-7.49	-0.42	1.03e-12	DNA methylation (variation);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg16341945	chr7:111846878	ZNF277;DOCK4	0.47	6.61	0.38	2.13e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs6732160	0.845	rs13413175	chr2:73389916	T/C	cg01422370	chr2:73384389	NA	0.44	7.58	0.42	5.72e-13	Intelligence (multi-trait analysis);
CESC	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg26338869	chr17:61819248	STRADA	0.68	8.87	0.48	1.08e-16	Prudent dietary pattern;
CESC	cis	rs2228479	0.618	rs62052174	chr16:89950901	G/A	cg06558623	chr16:89946397	TCF25	1.06	8.98	0.48	5.17e-17	Skin colour saturation;
CESC	cis	rs875971	0.545	rs4441996	chr7:65588220	T/C	cg18876405	chr7:65276391	NA	-0.51	-6.0	-0.35	6.32e-9	Aortic root size;
CESC	cis	rs9733	0.596	rs2867304	chr1:150630995	G/A	cg17724175	chr1:150552817	MCL1	0.44	7.21	0.41	5.75e-12	Tonsillectomy;
CESC	cis	rs7914558	0.966	rs10450373	chr10:104728616	T/C	cg15744005	chr10:104629667	AS3MT	-0.33	-5.28	-0.31	2.64e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg00629816	chr9:37784931	EXOSC3	-0.48	-6.29	-0.36	1.28e-9	Height;
CESC	cis	rs4713118	0.662	rs156744	chr6:27967274	G/A	cg23281280	chr6:28129359	ZNF389	0.53	7.13	0.4	9.73e-12	Parkinson's disease;
CESC	cis	rs344364	0.511	rs1657134	chr16:1953127	A/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.53	-5.93	-0.34	9.43e-9	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs13256369	0.901	rs12681298	chr8:8566235	A/G	cg00074818	chr8:8560427	CLDN23	-0.36	-5.47	-0.32	1.05e-7	Obesity-related traits;
CESC	cis	rs12200560	0.505	rs4240555	chr6:97076274	T/C	cg06623918	chr6:96969491	KIAA0776	0.51	6.46	0.37	5.04e-10	Coronary heart disease;
CESC	cis	rs12822507	0.899	rs4763859	chr12:12787005	G/A	cg04607235	chr12:12878440	APOLD1	-0.5	-6.45	-0.37	5.29e-10	Systemic lupus erythematosus;
CESC	cis	rs7811142	0.943	rs11769886	chr7:99998607	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.13	10.95	0.56	2.82e-23	Platelet count;
CESC	cis	rs546131	0.600	rs525202	chr11:34821948	A/C	cg11058730	chr11:34937778	PDHX;APIP	0.42	5.17	0.3	4.61e-7	Lung disease severity in cystic fibrosis;
CESC	cis	rs12497850	0.931	rs9311433	chr3:48863835	T/C	cg07636037	chr3:49044803	WDR6	1.01	18.66	0.75	3.36e-50	Parkinson's disease;
CESC	trans	rs875971	1.000	rs2420168	chr7:65630631	C/G	cg26939375	chr7:64535504	NA	-0.46	-6.09	-0.35	4e-9	Aortic root size;
CESC	cis	rs3008870	1.000	rs2985794	chr1:67425311	T/G	cg02640540	chr1:67518911	SLC35D1	0.51	5.58	0.32	5.89e-8	Lymphocyte percentage of white cells;
CESC	cis	rs6964587	0.934	rs1544377	chr7:91687351	A/G	cg17063962	chr7:91808500	NA	0.6	8.37	0.46	3.45e-15	Breast cancer;
CESC	trans	rs116095464	0.558	rs6866776	chr5:264495	C/T	cg00938859	chr5:1591904	SDHAP3	0.63	6.77	0.38	8.38e-11	Breast cancer;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg12720424	chr1:94713229	NA	-0.51	-7.24	-0.41	4.91e-12	Gut microbiota (bacterial taxa);
CESC	cis	rs10131894	0.611	rs174994	chr14:75434102	A/G	cg11812906	chr14:75593930	NEK9	-0.67	-10.02	-0.52	3e-20	Coronary artery disease;
CESC	cis	rs7851660	0.809	rs7031386	chr9:100665669	G/T	cg13688889	chr9:100608707	NA	-0.63	-8.95	-0.48	6.33e-17	Strep throat;
CESC	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg15112475	chr7:1198522	ZFAND2A	-0.4	-6.25	-0.36	1.6e-9	Longevity;Endometriosis;
CESC	cis	rs7833790	0.700	rs7825180	chr8:82723991	T/A	cg17211192	chr8:82754475	SNX16	-0.55	-7.03	-0.4	1.71e-11	Diastolic blood pressure;
CESC	cis	rs10504229	0.596	rs6991216	chr8:58115586	T/C	cg21724239	chr8:58056113	NA	0.58	5.95	0.34	8.29e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs727505	1.000	rs56313563	chr7:124507003	G/A	cg23710748	chr7:124431027	NA	-0.48	-7.52	-0.42	8.73e-13	Lewy body disease;
CESC	cis	rs561341	0.941	rs736678	chr17:30347423	G/T	cg19193384	chr17:30244184	NA	-0.71	-6.43	-0.37	6.05e-10	Hip circumference adjusted for BMI;
CESC	trans	rs2109514	0.505	rs1633714	chr7:116022538	C/T	cg18851521	chr18:268131	THOC1	0.43	6.0	0.35	6.6e-9	Prevalent atrial fibrillation;
CESC	cis	rs11785693	0.862	rs62491169	chr8:4986425	C/A	cg26367366	chr8:4980734	NA	0.92	8.42	0.46	2.35e-15	Neuroticism (multi-trait analysis);Neuroticism;
CESC	cis	rs590820	0.712	rs2144300	chr1:230294916	C/T	cg20703242	chr1:230279135	GALNT2	0.3	5.04	0.3	8.63e-7	Metabolite levels (lipoprotein measures);
CESC	cis	rs6088580	0.634	rs4911419	chr20:32995873	G/A	cg06115741	chr20:33292138	TP53INP2	-0.46	-5.98	-0.34	7.28e-9	Glomerular filtration rate (creatinine);
CESC	trans	rs561341	1.000	rs72821952	chr17:30248133	T/A	cg27661571	chr11:113659931	NA	-0.83	-7.52	-0.42	8.25e-13	Hip circumference adjusted for BMI;
CESC	cis	rs72634258	0.520	rs12078018	chr1:7857309	G/A	cg26816564	chr1:7831052	VAMP3	0.65	6.0	0.35	6.58e-9	Inflammatory bowel disease;
CESC	cis	rs6840258	0.825	rs79998318	chr4:87954166	A/G	cg08197287	chr4:87952173	AFF1	-0.4	-5.54	-0.32	7.19e-8	Mean corpuscular volume;Basophil percentage of granulocytes;
CESC	cis	rs7208859	0.623	rs11657990	chr17:29124200	C/T	cg13385521	chr17:29058706	SUZ12P	0.81	6.49	0.37	4.12e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs853679	0.517	rs9295761	chr6:28147987	A/G	cg23161317	chr6:28129485	ZNF389	0.47	5.84	0.34	1.53e-8	Depression;
CESC	cis	rs4535700	0.501	rs11765531	chr7:56010287	C/G	cg09872392	chr7:56161020	PHKG1	0.41	5.9	0.34	1.08e-8	Macular telangiectasia type 2;
CESC	cis	rs10504229	0.683	rs11786845	chr8:58133642	T/C	cg02725872	chr8:58115012	NA	-0.44	-6.89	-0.39	3.94e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs4689388	0.926	rs10937720	chr4:6295451	A/G	cg25554036	chr4:6271136	WFS1	0.51	8.37	0.46	3.31e-15	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs9309473	1.000	rs62151652	chr2:73700131	A/C	cg20560298	chr2:73613845	ALMS1	-0.55	-7.15	-0.4	8.23e-12	Metabolite levels;
CESC	trans	rs7746199	0.736	rs34573979	chr6:27480526	C/T	cg21479132	chr6:26055353	NA	0.85	6.39	0.37	7.39e-10	Gait speed in old age;Autism spectrum disorder or schizophrenia;
CESC	cis	rs2050392	0.858	rs2250569	chr10:30698914	G/C	cg18806716	chr10:30721971	MAP3K8	-0.42	-6.16	-0.35	2.71e-9	Inflammatory bowel disease;
CESC	cis	rs10028773	0.506	rs12374346	chr4:120281705	G/A	cg24375607	chr4:120327624	NA	0.42	5.19	0.3	4.19e-7	Educational attainment;
CESC	cis	rs1008375	0.932	rs13127157	chr4:17618049	A/G	cg27347728	chr4:17578864	LAP3	-0.45	-5.21	-0.3	3.78e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	22.0	0.8	9.67e-62	Prudent dietary pattern;
CESC	cis	rs2573652	0.722	rs12914189	chr15:100544429	A/T	cg00587665	chr15:100533223	ADAMTS17	0.39	6.49	0.37	4.25e-10	Height;
CESC	cis	rs7827545	1.000	rs4909481	chr8:135564555	A/G	cg17885191	chr8:135476712	NA	0.48	6.36	0.36	8.96e-10	Hypertension (SNP x SNP interaction);
CESC	cis	rs5769765	1.000	rs4824106	chr22:50267822	T/C	cg26441486	chr22:50317300	CRELD2	-0.39	-5.5	-0.32	8.72e-8	Schizophrenia;
CESC	cis	rs17376456	0.825	rs17314797	chr5:93234845	T/A	cg25358565	chr5:93447407	FAM172A	1.09	10.53	0.54	6.82e-22	Diabetic retinopathy;
CESC	cis	rs12900413	0.687	rs34484228	chr15:90304067	A/G	cg24249390	chr15:90295951	MESP1	-0.41	-5.63	-0.33	4.5e-8	Coronary artery aneurysm in Kawasaki disease;
CESC	cis	rs12477438	0.798	rs972768	chr2:99682397	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.75	-10.87	-0.56	5.17e-23	Chronic sinus infection;
CESC	trans	rs6076699	0.623	rs297757	chr20:4503605	C/T	cg03800178	chr7:109217284	NA	-0.75	-6.0	-0.35	6.48e-9	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (smoking interaction);
CESC	trans	rs1814175	0.676	rs1721999	chr11:49917372	A/G	cg03929089	chr4:120376271	NA	-0.92	-15.2	-0.68	6e-38	Height;
CESC	cis	rs9322193	0.923	rs56397000	chr6:150060483	C/T	cg07701084	chr6:150067640	NUP43	0.46	6.54	0.37	3.15e-10	Lung cancer;
CESC	cis	rs7666738	0.830	rs13145011	chr4:98993410	G/A	cg05340658	chr4:99064831	C4orf37	0.8	12.44	0.61	2.83e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7678296	1.000	rs7678296	chr4:37182646	T/C	cg06805348	chr4:37245195	KIAA1239	0.44	5.18	0.3	4.32e-7	3-hydroxypropylmercapturic acid levels in smokers;
CESC	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	7.64	0.43	3.85e-13	Prudent dietary pattern;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16756419	chr11:6704627	MRPL17	0.59	7.07	0.4	1.39e-11	Gut microbiome composition (summer);
CESC	cis	rs35306767	0.855	rs12774985	chr10:904245	C/T	cg10556349	chr10:835070	NA	0.77	6.43	0.37	5.91e-10	Eosinophil percentage of granulocytes;
CESC	cis	rs875971	0.516	rs6945322	chr7:65336056	T/C	cg18876405	chr7:65276391	NA	0.7	9.88	0.52	8.55e-20	Aortic root size;
CESC	cis	rs9399135	0.660	rs9376072	chr6:135280519	G/C	cg22676075	chr6:135203613	NA	0.48	6.75	0.38	9.45e-11	Red blood cell count;
CESC	cis	rs478304	0.651	rs12225620	chr11:65505448	T/C	cg27068330	chr11:65405492	SIPA1	-0.45	-5.46	-0.32	1.08e-7	Acne (severe);
CESC	cis	rs1348850	0.632	rs12471621	chr2:178502353	T/C	cg22681709	chr2:178499509	PDE11A	-0.57	-8.86	-0.48	1.18e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09856797	chr16:67980139	SLC12A4	-0.48	-6.03	-0.35	5.51e-9	Gut microbiome composition (summer);
CESC	cis	rs4662945	0.737	rs4662950	chr2:130238492	A/G	cg05903289	chr2:130345205	NA	-0.35	-5.45	-0.32	1.13e-7	Response to cytidine analogues (gemcitabine);
CESC	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg23978390	chr7:1156363	C7orf50	0.54	7.18	0.4	7.04e-12	Longevity;Endometriosis;
CESC	cis	rs7944584	0.611	rs10838696	chr11:47363285	A/G	cg20307385	chr11:47447363	PSMC3	-0.69	-8.69	-0.47	3.92e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CESC	cis	rs2487048	0.773	rs2472494	chr9:107695539	T/C	cg14470647	chr9:107690075	ABCA1	-0.47	-5.51	-0.32	8.54e-8	Intraocular pressure;
CESC	cis	rs798554	0.610	rs2251491	chr7:2852835	T/C	cg19717773	chr7:2847554	GNA12	-0.54	-8.47	-0.46	1.68e-15	Height;
CESC	cis	rs863345	0.526	rs863931	chr1:158612236	A/G	cg12129480	chr1:158549410	OR10X1	-0.3	-5.77	-0.33	2.16e-8	Pneumococcal bacteremia;
CESC	cis	rs910316	1.000	rs7156105	chr14:75541954	C/A	cg08847533	chr14:75593920	NEK9	1.02	19.66	0.77	1.08e-53	Height;
CESC	cis	rs834811	0.831	rs834810	chr7:135879825	T/C	cg01726295	chr7:135938950	NA	0.37	6.3	0.36	1.23e-9	Post-traumatic stress disorder;
CESC	cis	rs7937682	0.632	rs4935811	chr11:111679262	C/T	cg22437258	chr11:111473054	SIK2	-0.52	-5.67	-0.33	3.75e-8	Primary sclerosing cholangitis;
CESC	cis	rs7727544	0.836	rs10463892	chr5:131598705	T/C	cg09877947	chr5:131593287	PDLIM4	0.4	5.07	0.3	7.56e-7	Blood metabolite levels;
CESC	cis	rs916888	0.773	rs199447	chr17:44812188	C/T	cg17911788	chr17:44343683	NA	-0.61	-7.97	-0.44	4.66e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18466340	chr20:50417476	SALL4	-0.65	-7.66	-0.43	3.43e-13	Gut microbiome composition (summer);
CESC	trans	rs57221529	0.766	rs4527146	chr5:555236	A/G	cg25482853	chr8:67687455	SGK3	1.03	10.82	0.55	8.03e-23	Lung disease severity in cystic fibrosis;
CESC	cis	rs6582630	0.555	rs10880624	chr12:38526316	C/T	cg26384229	chr12:38710491	ALG10B	0.73	11.35	0.57	1.32e-24	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs7945705	0.902	rs11042152	chr11:9020987	C/T	cg09997546	chr11:8931473	C11orf17;ST5	0.36	5.91	0.34	1.04e-8	Hemoglobin concentration;
CESC	cis	rs6732160	0.809	rs13406142	chr2:73384098	A/G	cg01422370	chr2:73384389	NA	0.43	7.35	0.41	2.5e-12	Intelligence (multi-trait analysis);
CESC	trans	rs1908814	0.516	rs4367597	chr8:11793529	C/T	cg15556689	chr8:8085844	FLJ10661	0.52	6.39	0.37	7.33e-10	Neuroticism;
CESC	cis	rs8005677	0.828	rs34584578	chr14:23411690	C/T	cg01529538	chr14:23388837	RBM23	0.44	5.83	0.34	1.63e-8	Cognitive ability (multi-trait analysis);
CESC	cis	rs9660180	0.967	rs12034740	chr1:1728969	C/A	cg20999797	chr1:1681921	NA	0.26	5.12	0.3	6.01e-7	Body mass index;
CESC	cis	rs2573652	0.722	rs8034841	chr15:100541593	G/T	cg00587665	chr15:100533223	ADAMTS17	-0.39	-6.17	-0.35	2.56e-9	Height;
CESC	cis	rs1707322	1.000	rs1707317	chr1:46510642	C/T	cg03146154	chr1:46216737	IPP	-0.76	-10.26	-0.53	5.18e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs9325144	0.600	rs12424410	chr12:38758035	A/T	cg23762105	chr12:34175262	ALG10	0.48	6.23	0.36	1.84e-9	Morning vs. evening chronotype;
CESC	cis	rs10905065	1.000	rs7913067	chr10:5787305	C/T	cg11519256	chr10:5708881	ASB13	0.41	5.42	0.32	1.32e-7	Menopause (age at onset);
CESC	trans	rs459571	0.834	rs379417	chr9:136890704	G/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.6	-7.73	-0.43	2.3e-13	Platelet distribution width;
CESC	cis	rs796364	0.951	rs7608668	chr2:201000017	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.64	-6.49	-0.37	4.16e-10	Schizophrenia;
CESC	cis	rs798554	1.000	rs798544	chr7:2763102	A/G	cg13628971	chr7:2884303	GNA12	-0.61	-7.88	-0.44	8.41e-14	Height;
CESC	cis	rs4900538	0.855	rs1210074	chr14:102889098	G/A	cg18135206	chr14:102964638	TECPR2	-0.75	-9.62	-0.51	5.62e-19	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	trans	rs1814175	0.645	rs847635	chr11:49923323	G/A	cg15704280	chr7:45808275	SEPT13	-1.01	-18.94	-0.76	3.64e-51	Height;
CESC	cis	rs60154123	0.772	rs845452	chr1:210417861	C/T	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.49	5.03	0.3	8.94e-7	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04026000	chr5:79628372	NA	-0.6	-7.15	-0.4	8.22e-12	Gut microbiome composition (summer);
CESC	cis	rs9304742	0.962	rs1808106	chr19:53452944	T/G	cg09915433	chr19:53449742	NA	-0.38	-5.18	-0.3	4.45e-7	Psoriasis;
CESC	cis	rs7927771	0.793	rs12803525	chr11:47413475	G/A	cg05585544	chr11:47624801	NA	-0.47	-6.91	-0.39	3.5e-11	Subjective well-being;
CESC	cis	rs6964587	0.869	rs34791781	chr7:91532720	C/T	cg17063962	chr7:91808500	NA	-0.53	-6.95	-0.39	2.88e-11	Breast cancer;
CESC	cis	rs9640161	0.789	rs60283368	chr7:150023258	G/A	cg13722127	chr7:150037890	RARRES2	0.33	5.07	0.3	7.38e-7	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs1707322	0.752	rs28545085	chr1:46201950	G/A	cg03146154	chr1:46216737	IPP	0.82	11.53	0.58	3.39e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9837602	0.938	rs34922392	chr3:99794730	G/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.45	6.3	0.36	1.2e-9	Breast cancer;
CESC	cis	rs1018836	0.923	rs9694450	chr8:91618292	G/A	cg16814680	chr8:91681699	NA	-0.75	-10.9	-0.56	4.28e-23	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs10504229	0.815	rs75577263	chr8:58188434	A/G	cg14926445	chr8:58193284	C8orf71	-0.51	-5.52	-0.32	8.28e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs1707322	1.000	rs4606257	chr1:46307268	G/A	cg03146154	chr1:46216737	IPP	0.78	10.67	0.55	2.45e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9649213	0.533	rs1541409	chr7:98027580	C/T	cg09267113	chr7:98030324	BAIAP2L1	-0.44	-5.86	-0.34	1.37e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7833790	0.660	rs7839178	chr8:82763479	A/G	cg17211192	chr8:82754475	SNX16	0.51	6.63	0.38	1.89e-10	Diastolic blood pressure;
CESC	trans	rs73198271	0.653	rs10087742	chr8:8660474	A/G	cg23754772	chr18:12253859	CIDEA	-0.33	-6.01	-0.35	6.07e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs6952808	0.630	rs1860832	chr7:2161849	G/A	cg05863683	chr7:1912471	MAD1L1	0.4	5.91	0.34	1.07e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs35306767	0.953	rs12354639	chr10:963681	G/A	cg26597838	chr10:835615	NA	0.8	9.43	0.5	2.09e-18	Eosinophil percentage of granulocytes;
CESC	cis	rs17376456	0.877	rs10060160	chr5:93387879	G/A	cg25358565	chr5:93447407	FAM172A	1.14	10.64	0.55	2.97e-22	Diabetic retinopathy;
CESC	cis	rs2072732	0.861	rs12044848	chr1:2960790	C/T	cg15211996	chr1:2936768	ACTRT2	0.35	5.87	0.34	1.31e-8	Plateletcrit;
CESC	cis	rs7811142	1.000	rs67471932	chr7:100009985	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.15	11.52	0.58	3.59e-25	Platelet count;
CESC	cis	rs2230307	0.536	rs575971	chr1:100546591	T/C	cg24955406	chr1:100503596	HIAT1	0.53	5.25	0.31	3.18e-7	Carotid intima media thickness;
CESC	cis	rs2415984	0.622	rs1761029	chr14:46934764	T/C	cg14871534	chr14:47121158	RPL10L	0.35	5.36	0.31	1.82e-7	Number of children ever born;
CESC	cis	rs7208859	0.623	rs2035494	chr17:29130393	T/G	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.1e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg09177884	chr7:1199841	ZFAND2A	-0.56	-6.29	-0.36	1.29e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs13108904	0.967	rs4405964	chr4:1278814	A/G	cg00684032	chr4:1343700	KIAA1530	0.4	5.56	0.32	6.51e-8	Obesity-related traits;
CESC	cis	rs6693567	0.545	rs7411534	chr1:150447269	C/T	cg09579323	chr1:150459698	TARS2	0.44	5.65	0.33	4.12e-8	Migraine;
CESC	cis	rs2760061	0.583	rs708121	chr1:228208257	A/G	cg02753203	chr1:228287806	NA	0.8	11.29	0.57	2.17e-24	Diastolic blood pressure;
CESC	cis	rs3733585	0.699	rs62294332	chr4:9959989	T/C	cg02734326	chr4:10020555	SLC2A9	-0.43	-6.01	-0.35	6.1e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs6860806	0.507	rs272883	chr5:131668698	A/G	cg07395648	chr5:131743802	NA	-0.44	-5.72	-0.33	2.95e-8	Breast cancer;
CESC	cis	rs4253772	0.530	rs6008623	chr22:46710024	G/A	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.66	6.3	0.36	1.2e-9	LDL cholesterol;Cholesterol, total;
CESC	cis	rs1008375	0.966	rs4235392	chr4:17696422	A/G	cg04450456	chr4:17643702	FAM184B	0.36	5.13	0.3	5.72e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs7223966	1.000	rs8068603	chr17:61755211	T/A	cg11494091	chr17:61959527	GH2	0.38	5.35	0.31	1.93e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg26304593	chr6:42947056	PEX6	-0.43	-5.5	-0.32	8.76e-8	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs3106136	0.586	rs72663785	chr4:95069794	C/G	cg11021082	chr4:95130006	SMARCAD1	-0.4	-5.08	-0.3	7.11e-7	Capecitabine sensitivity;
CESC	cis	rs12973672	1.000	rs34832786	chr19:35769518	T/C	cg12095397	chr19:35769544	USF2	0.54	7.35	0.41	2.49e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs597539	0.616	rs10896386	chr11:68722694	C/T	cg06028808	chr11:68637592	NA	0.44	5.24	0.31	3.2e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs4718428	0.705	rs4717331	chr7:66378886	C/T	cg25985355	chr7:65971099	NA	-0.36	-5.35	-0.31	1.94e-7	Corneal structure;
CESC	cis	rs77106637	0.932	rs17244499	chr11:72629946	C/T	cg03713592	chr11:72463424	ARAP1	-1.08	-9.66	-0.51	4.03e-19	Type 2 diabetes;
CESC	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg14159672	chr1:205819179	PM20D1	-0.7	-11.41	-0.57	8.82e-25	Monocyte percentage of white cells;
CESC	cis	rs7520050	1.000	rs12143096	chr1:46469763	G/A	cg24296786	chr1:45957014	TESK2	0.44	5.5	0.32	9.17e-8	Red blood cell count;Reticulocyte count;
CESC	cis	rs12541635	0.966	rs34177605	chr8:107065105	G/A	cg10147462	chr8:107024639	NA	0.37	5.16	0.3	4.74e-7	Age of smoking initiation;
CESC	cis	rs6723226	0.882	rs13035097	chr2:32836362	A/G	cg02381751	chr2:32503542	YIPF4	-0.69	-8.88	-0.48	1.04e-16	Intelligence (multi-trait analysis);
CESC	cis	rs7412746	0.588	rs10305664	chr1:150839686	A/C	cg17724175	chr1:150552817	MCL1	0.4	6.14	0.35	2.98e-9	Melanoma;
CESC	cis	rs5750830	0.649	rs5750822	chr22:39826788	C/T	cg02038168	chr22:39784481	NA	-0.61	-7.47	-0.42	1.13e-12	Intelligence (multi-trait analysis);
CESC	cis	rs79057730	0.599	rs34411410	chr7:811721	G/A	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.91	7.83	0.43	1.19e-13	Initial pursuit acceleration;
CESC	cis	rs2290159	0.747	rs6777175	chr3:12646255	A/T	cg23032965	chr3:12705835	RAF1	0.51	5.63	0.33	4.48e-8	Cholesterol, total;
CESC	cis	rs7412746	0.658	rs11589458	chr1:150792616	A/G	cg04414720	chr1:150670196	GOLPH3L	0.55	7.19	0.4	6.44e-12	Melanoma;
CESC	cis	rs2991971	0.967	rs6661321	chr1:45954599	C/G	cg05343316	chr1:45956843	TESK2	-0.51	-6.75	-0.38	9.56e-11	High light scatter reticulocyte count;
CESC	cis	rs7666738	0.830	rs10022389	chr4:99022229	T/C	cg18180107	chr4:99064573	C4orf37	0.41	5.39	0.31	1.57e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs13191362	1.000	rs13190742	chr6:163008758	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.82	8.29	0.45	5.87e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs1538970	0.924	rs6657284	chr1:45879088	T/C	cg06784218	chr1:46089804	CCDC17	0.33	5.49	0.32	9.28e-8	Platelet count;
CESC	cis	rs763121	0.853	rs2072796	chr22:39064230	A/G	cg14440974	chr22:39074834	NA	-0.42	-5.82	-0.34	1.69e-8	Menopause (age at onset);
CESC	cis	rs769267	0.930	rs10402451	chr19:19608537	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.59	7.48	0.42	1.1e-12	Tonsillectomy;
CESC	cis	rs2760061	0.717	rs708117	chr1:228199902	G/A	cg18477163	chr1:228402036	OBSCN	0.32	5.69	0.33	3.3e-8	Diastolic blood pressure;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg16025584	chr9:139887217	C9orf142	0.5	6.61	0.38	2.07e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs2120019	1.000	rs2415253	chr15:75375699	A/G	cg09165964	chr15:75287851	SCAMP5	-0.69	-8.37	-0.46	3.42e-15	Blood trace element (Zn levels);
CESC	cis	rs4481887	1.000	rs4457616	chr1:248492198	A/G	cg00666640	chr1:248458726	OR2T12	0.41	6.68	0.38	1.42e-10	Common traits (Other);
CESC	cis	rs6952808	0.609	rs4721190	chr7:1954732	A/G	cg00106254	chr7:1943704	MAD1L1	0.43	5.31	0.31	2.37e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs7927771	0.524	rs10838782	chr11:47877800	A/G	cg18512352	chr11:47633146	NA	0.35	5.35	0.31	1.87e-7	Subjective well-being;
CESC	trans	rs11971186	0.662	rs1204529	chr7:126515801	T/C	cg10894441	chr11:111169905	C11orf92;C11orf93	-0.52	-6.67	-0.38	1.49e-10	Chemerin levels;
CESC	cis	rs9788682	1.000	rs7181447	chr15:78814567	A/G	cg06917634	chr15:78832804	PSMA4	-0.56	-6.64	-0.38	1.72e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs2836974	0.533	rs4817999	chr21:40554355	C/A	cg17971929	chr21:40555470	PSMG1	-0.87	-12.78	-0.62	1.78e-29	Cognitive function;
CESC	cis	rs2742234	1.000	rs2742234	chr10:43612609	A/G	cg07801480	chr10:43725741	RASGEF1A	-0.39	-5.55	-0.32	6.85e-8	Hirschsprung disease;
CESC	cis	rs7833790	1.000	rs1463259	chr8:82737745	A/G	cg02079420	chr8:82753780	SNX16	0.57	7.65	0.43	3.81e-13	Diastolic blood pressure;
CESC	cis	rs7560272	0.501	rs11891140	chr2:73944084	A/G	cg20560298	chr2:73613845	ALMS1	0.41	5.69	0.33	3.43e-8	Schizophrenia;
CESC	cis	rs4253772	0.938	rs41427746	chr22:46637239	T/C	cg09491104	chr22:46646882	C22orf40	-0.51	-6.54	-0.37	3.24e-10	LDL cholesterol;Cholesterol, total;
CESC	cis	rs7116495	1.000	rs642573	chr11:71780854	G/C	cg10381502	chr11:71823885	C11orf51	-0.61	-5.13	-0.3	5.6e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs2243480	1.000	rs410128	chr7:65603173	C/T	cg13147721	chr7:65941812	NA	-0.98	-9.03	-0.48	3.72e-17	Diabetic kidney disease;
CESC	cis	rs7666738	0.830	rs62318906	chr4:99037110	C/T	cg05340658	chr4:99064831	C4orf37	0.82	12.87	0.62	9.38e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2243480	0.708	rs35825036	chr7:65986502	T/C	cg18252515	chr7:66147081	NA	-1.4	-14.3	-0.66	9.38e-35	Diabetic kidney disease;
CESC	cis	rs2576037	0.583	rs1970668	chr18:44523220	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.48	-6.46	-0.37	5.03e-10	Personality dimensions;
CESC	cis	rs1256061	0.564	rs1256043	chr14:64734282	A/G	cg21174375	chr14:64681225	SYNE2	0.51	6.82	0.39	6.15e-11	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs2276314	0.857	rs28396546	chr18:33639024	T/C	cg05985134	chr18:33552581	C18orf21	0.62	7.16	0.4	8.06e-12	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs1862618	0.853	rs1423621	chr5:56101035	G/T	cg22800045	chr5:56110881	MAP3K1	0.74	9.18	0.49	1.3e-17	Initial pursuit acceleration;
CESC	cis	rs9303401	0.659	rs62083525	chr17:56658088	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	1.03	12.7	0.62	3.56e-29	Cognitive test performance;
CESC	cis	rs2797160	0.651	rs1268066	chr6:126035041	C/T	cg05901451	chr6:126070800	HEY2	0.52	7.49	0.42	1.04e-12	Endometrial cancer;
CESC	cis	rs9611565	0.559	rs12483860	chr22:41961916	C/T	cg17376030	chr22:41985996	PMM1	0.53	5.88	0.34	1.25e-8	Vitiligo;
CESC	cis	rs8014204	0.868	rs2230237	chr14:75359670	G/A	cg26191576	chr14:75389716	RPS6KL1	0.36	5.17	0.3	4.61e-7	Caffeine consumption;
CESC	cis	rs2414059	0.518	rs2289108	chr15:50782335	G/A	cg05456662	chr15:50716270	USP8	-0.4	-5.22	-0.31	3.69e-7	QT interval;
CESC	cis	rs6933660	0.800	rs13201167	chr6:151773504	T/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.52	-6.94	-0.39	2.93e-11	Menarche (age at onset);
CESC	cis	rs9486715	0.867	rs9373829	chr6:96897201	A/C	cg18709589	chr6:96969512	KIAA0776	-0.41	-5.77	-0.33	2.16e-8	Headache;
CESC	cis	rs501120	1.000	rs552794	chr10:44771666	G/A	cg09554077	chr10:44749378	NA	0.52	6.94	0.39	3.05e-11	Coronary artery disease;Coronary heart disease;
CESC	cis	rs17253792	0.822	rs76472022	chr14:56053660	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.84	5.66	0.33	3.95e-8	Putamen volume;
CESC	cis	rs12477438	0.765	rs7605734	chr2:99644068	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.64	-8.73	-0.47	2.94e-16	Chronic sinus infection;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg02631680	chr6:44094852	TMEM63B;MRPL14	-0.46	-6.38	-0.36	7.69e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs2652822	0.509	rs6494394	chr15:63440938	A/G	cg02713581	chr15:63449717	RPS27L	0.47	5.51	0.32	8.36e-8	Metabolic traits;
CESC	cis	rs6570726	0.902	rs406979	chr6:145838983	G/T	cg23711669	chr6:146136114	FBXO30	0.78	11.62	0.58	1.64e-25	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs2727020	0.554	rs2866490	chr11:49425463	A/G	cg15704280	chr7:45808275	SEPT13	-0.81	-9.53	-0.51	1.04e-18	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19643035	chr5:177022360	TMED9	-0.55	-6.28	-0.36	1.39e-9	Gut microbiome composition (summer);
CESC	cis	rs752010	0.714	rs7552928	chr1:42086664	C/T	cg06885757	chr1:42089581	HIVEP3	0.51	8.84	0.48	1.39e-16	Lupus nephritis in systemic lupus erythematosus;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18304472	chr19:45844176	KLC3	0.57	6.52	0.37	3.49e-10	Gut microbiome composition (summer);
CESC	cis	rs11583043	1.000	rs6660290	chr1:101483512	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.47	-5.22	-0.31	3.58e-7	Ulcerative colitis;Inflammatory bowel disease;
CESC	cis	rs2637266	1.000	rs10219107	chr10:78364369	T/C	cg18941641	chr10:78392320	NA	0.42	7.87	0.44	8.96e-14	Pulmonary function;
CESC	cis	rs9611565	0.649	rs4822050	chr22:42177453	C/G	cg03806693	chr22:41940476	POLR3H	-0.68	-7.85	-0.43	1.07e-13	Vitiligo;
CESC	cis	rs2425143	1.000	rs11699690	chr20:34271774	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.83	-7.53	-0.42	8.04e-13	Blood protein levels;
CESC	cis	rs7552404	0.924	rs1146579	chr1:76209792	C/T	cg10523679	chr1:76189770	ACADM	-0.77	-10.6	-0.55	4.2e-22	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs11690935	1.000	rs6757773	chr2:172549630	T/A	cg13550731	chr2:172543902	DYNC1I2	1.0	16.64	0.71	4.76e-43	Schizophrenia;
CESC	cis	rs780094	0.564	rs4665978	chr2:27648726	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.27	-5.33	-0.31	2.06e-7	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
CESC	cis	rs875971	0.545	rs73148639	chr7:65855329	A/T	cg18876405	chr7:65276391	NA	0.5	5.91	0.34	1.05e-8	Aortic root size;
CESC	cis	rs727505	1.000	rs3925331	chr7:124446137	C/G	cg23710748	chr7:124431027	NA	-0.38	-6.11	-0.35	3.48e-9	Lewy body disease;
CESC	cis	rs2637266	0.663	rs846581	chr10:78497984	C/T	cg18941641	chr10:78392320	NA	0.43	8.46	0.46	1.81e-15	Pulmonary function;
CESC	cis	rs459571	1.000	rs456207	chr9:136911140	G/A	cg13789015	chr9:136890014	NCRNA00094	0.52	7.56	0.42	6.52e-13	Platelet distribution width;
CESC	cis	rs34779708	0.733	rs60553075	chr10:35542462	T/A	cg04310649	chr10:35416472	CREM	-0.47	-5.39	-0.31	1.59e-7	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs2262909	0.962	rs436662	chr19:22232107	C/T	cg11619707	chr19:22235551	ZNF257	-0.32	-5.26	-0.31	2.94e-7	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg16828585	chr10:8051100	TAF3	0.46	6.02	0.35	5.9e-9	Fibrinogen levels;
CESC	cis	rs8018808	0.935	rs12436593	chr14:77928476	C/T	cg20045696	chr14:77926864	AHSA1	0.41	5.74	0.33	2.54e-8	Myeloid white cell count;
CESC	cis	rs7945705	0.935	rs11042103	chr11:8888700	C/T	cg12365402	chr11:9010492	NRIP3	0.35	5.45	0.32	1.16e-7	Hemoglobin concentration;
CESC	cis	rs2228479	0.557	rs57071566	chr16:89889327	T/G	cg06558623	chr16:89946397	TCF25	0.99	7.42	0.41	1.62e-12	Skin colour saturation;
CESC	cis	rs1005277	0.522	rs11011343	chr10:38002698	A/G	cg00409905	chr10:38381863	ZNF37A	-0.52	-7.13	-0.4	9.74e-12	Extrinsic epigenetic age acceleration;
CESC	cis	rs9322193	0.923	rs12205092	chr6:150082511	G/T	cg13206674	chr6:150067644	NUP43	0.43	5.89	0.34	1.18e-8	Lung cancer;
CESC	cis	rs1218582	0.741	rs883718	chr1:154846274	C/T	cg03351412	chr1:154909251	PMVK	0.59	7.8	0.43	1.46e-13	Prostate cancer;
CESC	cis	rs9322193	0.566	rs3922947	chr6:150245992	G/A	cg01145232	chr6:150245071	RAET1G	-0.51	-6.63	-0.38	1.86e-10	Lung cancer;
CESC	cis	rs9287719	0.967	rs11674433	chr2:10730839	T/C	cg00105475	chr2:10696890	NA	0.39	5.69	0.33	3.35e-8	Prostate cancer;
CESC	cis	rs1371867	0.875	rs1788176	chr8:101332112	A/G	cg11906718	chr8:101322791	RNF19A	0.53	6.86	0.39	4.86e-11	Atrioventricular conduction;
CESC	cis	rs6088590	1.000	rs2180276	chr20:33360785	T/A	cg06115741	chr20:33292138	TP53INP2	0.59	7.35	0.41	2.41e-12	Coronary artery disease;
CESC	cis	rs28489187	0.617	rs233133	chr1:85796557	G/T	cg16011679	chr1:85725395	C1orf52	0.46	5.45	0.32	1.12e-7	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	cis	rs8049040	0.500	rs7188475	chr16:71446358	C/T	cg08717414	chr16:71523259	ZNF19	-0.5	-5.75	-0.33	2.44e-8	Blood protein levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06604058	chr11:63448992	RTN3	0.55	6.61	0.38	2.15e-10	Gut microbiome composition (summer);
CESC	cis	rs1559088	0.573	rs1270591	chr19:33622942	C/T	cg17764715	chr19:33622953	WDR88	-0.6	-8.57	-0.47	8.82e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg01989157	chr22:40742702	ADSL	-0.47	-6.38	-0.36	7.82e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs11809207	0.523	rs2186232	chr1:26502676	T/A	cg00147160	chr1:26503991	CNKSR1	0.29	5.52	0.32	8.08e-8	Height;
CESC	cis	rs7577696	0.524	rs212696	chr2:32441685	A/G	cg02381751	chr2:32503542	YIPF4	0.48	5.44	0.32	1.18e-7	Inflammatory biomarkers;
CESC	cis	rs6582630	0.519	rs11519914	chr12:38287014	A/G	cg13010199	chr12:38710504	ALG10B	0.4	5.13	0.3	5.54e-7	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs4595586	0.545	rs1562728	chr12:39405740	C/T	cg26384229	chr12:38710491	ALG10B	0.54	7.64	0.42	3.96e-13	Morning vs. evening chronotype;
CESC	cis	rs7267979	1.000	rs2500432	chr20:25290512	A/C	cg08601574	chr20:25228251	PYGB	0.39	5.69	0.33	3.39e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs898097	0.841	rs12453162	chr17:80859971	C/T	cg15369054	chr17:80825471	TBCD	0.53	7.07	0.4	1.41e-11	Breast cancer;
CESC	cis	rs5753618	0.504	rs5753671	chr22:31910734	T/C	cg02404636	chr22:31891804	SFI1	0.43	5.96	0.34	7.98e-9	Colorectal cancer;
CESC	cis	rs672059	0.967	rs657901	chr1:183163411	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.56	7.2	0.4	6.39e-12	Hypertriglyceridemia;
CESC	cis	rs1799949	1.000	rs8176269	chr17:41213626	G/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.6	7.89	0.44	8.1e-14	Menopause (age at onset);
CESC	cis	rs4727963	0.846	rs1525485	chr7:122702653	G/A	cg03640110	chr7:122635026	TAS2R16	-0.37	-5.7	-0.33	3.11e-8	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
CESC	cis	rs1552244	0.882	rs3732966	chr3:10015740	C/T	cg08888203	chr3:10149979	C3orf24	0.49	6.14	0.35	3.07e-9	Alzheimer's disease;
CESC	cis	rs9649213	0.574	rs62478236	chr7:98030377	G/A	cg08684580	chr7:98029266	BAIAP2L1	-0.35	-5.64	-0.33	4.28e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs9457247	1.000	rs402749	chr6:167386104	C/T	cg25258033	chr6:167368657	RNASET2	0.39	5.87	0.34	1.31e-8	Crohn's disease;
CESC	cis	rs7267979	1.000	rs6107033	chr20:25363591	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.85	-17.13	-0.72	8.57e-45	Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs57221529	0.766	rs4245972	chr5:578572	A/G	cg25482853	chr8:67687455	SGK3	1.01	10.17	0.53	9.74e-21	Lung disease severity in cystic fibrosis;
CESC	trans	rs7246760	0.867	rs66927855	chr19:9811728	C/T	cg02900749	chr2:68251473	NA	-0.82	-7.26	-0.41	4.38e-12	Pursuit maintenance gain;
CESC	cis	rs6502050	0.799	rs6416859	chr17:80111442	G/C	cg11859384	chr17:80120422	CCDC57	-0.39	-5.37	-0.31	1.76e-7	Life satisfaction;
CESC	cis	rs1799949	1.000	rs4792981	chr17:41308274	A/G	cg06001716	chr17:41278141	BRCA1;NBR2	0.37	5.04	0.3	8.7e-7	Menopause (age at onset);
CESC	cis	rs2249694	0.960	rs7094588	chr10:135401586	A/G	cg20169779	chr10:135381914	SYCE1	-0.4	-5.81	-0.34	1.76e-8	Obesity-related traits;
CESC	cis	rs79387448	0.701	rs76943877	chr2:102970677	T/C	cg09003973	chr2:102972529	NA	1.2	9.29	0.5	6.03e-18	Gut microbiota (bacterial taxa);
CESC	cis	rs67366981	0.720	rs4447349	chr14:77685381	G/A	cg22824376	chr14:77648248	TMEM63C	0.78	7.51	0.42	9.21e-13	Obsessive-compulsive symptoms;
CESC	cis	rs10504229	0.683	rs55881798	chr8:58106406	T/C	cg21724239	chr8:58056113	NA	0.57	5.9	0.34	1.08e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs929354	0.772	rs2023977	chr7:156996022	C/G	cg05182265	chr7:156933206	UBE3C	-0.51	-7.47	-0.42	1.2e-12	Body mass index;
CESC	trans	rs7618501	1.000	rs2271960	chr3:49878078	A/G	cg21659725	chr3:3221576	CRBN	0.81	12.35	0.6	5.71e-28	Intelligence (multi-trait analysis);
CESC	cis	rs1008375	1.000	rs2315560	chr4:17677305	C/G	cg02297831	chr4:17616191	MED28	0.45	5.64	0.33	4.42e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs2617583	0.967	rs2550946	chr5:1450513	A/G	cg07151155	chr5:1473589	LPCAT1	-0.36	-5.52	-0.32	7.95e-8	Breast cancer;
CESC	cis	rs7980687	0.527	rs1727295	chr12:123616861	G/A	cg00376283	chr12:123451042	ABCB9	0.71	9.87	0.52	9.06e-20	Height;Educational attainment;Head circumference (infant);
CESC	cis	rs3768617	0.706	rs10797801	chr1:182971965	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.69	9.92	0.52	6.42e-20	Fuchs's corneal dystrophy;
CESC	cis	rs4713118	0.662	rs9468278	chr6:28028482	C/T	cg23161317	chr6:28129485	ZNF389	0.49	6.19	0.36	2.28e-9	Parkinson's disease;
CESC	cis	rs2404602	0.575	rs11633309	chr15:76962349	C/A	cg00316803	chr15:76480434	C15orf27	0.43	5.91	0.34	1.05e-8	Blood metabolite levels;
CESC	trans	rs2415984	0.811	rs7157724	chr14:46854443	G/T	cg14945696	chr3:52713679	PBRM1	-0.39	-6.05	-0.35	4.98e-9	Number of children ever born;
CESC	cis	rs7666738	0.830	rs34892904	chr4:98938097	T/C	cg03467027	chr4:99064603	C4orf37	0.48	5.91	0.34	1.03e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11098499	0.866	rs6847778	chr4:120293582	A/G	cg24375607	chr4:120327624	NA	0.42	5.15	0.3	5.21e-7	Corneal astigmatism;
CESC	cis	rs832540	0.669	rs832539	chr5:56199386	A/C	cg18230493	chr5:56204884	C5orf35	-0.58	-7.81	-0.43	1.38e-13	Coronary artery disease;
CESC	cis	rs881375	0.967	rs10733648	chr9:123700779	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.41	5.52	0.32	7.97e-8	Rheumatoid arthritis;
CESC	cis	rs10503871	0.690	rs7812836	chr8:30352258	A/G	cg26383811	chr8:30366931	RBPMS	-0.37	-5.08	-0.3	7.25e-7	Metabolite levels  (X-11787);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06296570	chr7:130792605	FLJ43663	-0.52	-6.08	-0.35	4.09e-9	Gut microbiome composition (summer);
CESC	cis	rs7264396	0.635	rs6058355	chr20:34491343	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.59	7.2	0.4	6.2e-12	Total cholesterol levels;
CESC	cis	rs1009170	0.794	rs58036446	chr14:92590192	A/C	cg10324096	chr14:92587714	CPSF2;NDUFB1	0.55	5.17	0.3	4.73e-7	Dialysis-related mortality;
CESC	cis	rs11608355	0.521	rs7976839	chr12:109830534	C/A	cg19025524	chr12:109796872	NA	-0.54	-7.7	-0.43	2.8e-13	Neuroticism;
CESC	cis	rs6460942	0.597	rs17544637	chr7:12521871	T/C	cg02935154	chr7:12443704	VWDE	-0.48	-5.09	-0.3	6.85e-7	Coronary artery disease;
CESC	cis	rs7666738	0.830	rs11727612	chr4:99001662	T/C	cg17366294	chr4:99064904	C4orf37	0.6	8.61	0.47	6.47e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs67311347	1.000	rs9833430	chr3:40459043	C/T	cg09455208	chr3:40491958	NA	0.51	8.53	0.46	1.11e-15	Renal cell carcinoma;
CESC	cis	rs1348850	0.632	rs12467363	chr2:178502512	C/T	cg22681709	chr2:178499509	PDE11A	-0.57	-8.82	-0.48	1.52e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs4664308	0.905	rs62177860	chr2:160960571	C/T	cg03641300	chr2:160917029	PLA2R1	-0.66	-9.7	-0.51	3.12e-19	Idiopathic membranous nephropathy;
CESC	cis	rs853679	0.517	rs11552219	chr6:28126834	C/T	cg23161317	chr6:28129485	ZNF389	0.52	6.48	0.37	4.37e-10	Depression;
CESC	cis	rs7927592	0.763	rs4340059	chr11:68362433	A/G	cg20283391	chr11:68216788	NA	-0.42	-5.17	-0.3	4.58e-7	Total body bone mineral density;
CESC	cis	rs9807841	0.500	rs1368459	chr19:10835338	C/G	cg17710535	chr19:10819994	QTRT1	0.42	6.01	0.35	6.16e-9	Inflammatory skin disease;
CESC	cis	rs5747327	0.839	rs7291752	chr22:18180911	T/C	cg19898043	chr22:18121309	BCL2L13	-0.4	-5.19	-0.3	4.18e-7	Myeloid white cell count;Granulocyte count;
CESC	cis	rs798554	0.655	rs798492	chr7:2799184	C/T	cg19717773	chr7:2847554	GNA12	0.51	8.11	0.45	1.95e-14	Height;
CESC	cis	rs1577917	0.916	rs12198730	chr6:86555138	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-6.18	-0.36	2.36e-9	Response to antipsychotic treatment;
CESC	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg03452623	chr4:187889614	NA	-0.89	-15.84	-0.7	3.13e-40	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs11190604	1.000	rs10786596	chr10:102282126	C/A	cg07080220	chr10:102295463	HIF1AN	0.6	5.84	0.34	1.56e-8	Palmitoleic acid (16:1n-7) levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07953307	chr16:29000920	LAT	-0.65	-7.31	-0.41	3.11e-12	Gut microbiome composition (summer);
CESC	cis	rs7590368	0.926	rs12623588	chr2:10957612	C/G	cg15705551	chr2:10952987	PDIA6	-0.52	-5.96	-0.34	7.97e-9	Educational attainment (years of education);
CESC	cis	rs67311347	1.000	rs56992941	chr3:40472434	A/T	cg24209194	chr3:40518798	ZNF619	0.5	6.63	0.38	1.85e-10	Renal cell carcinoma;
CESC	cis	rs7216064	1.000	rs3206817	chr17:65892834	A/G	cg12091567	chr17:66097778	LOC651250	-0.78	-8.09	-0.45	2.1e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs6750795	0.518	rs1434519	chr2:232433761	A/G	cg19187155	chr2:232395269	NMUR1	0.49	5.98	0.34	7.24e-9	Height;
CESC	cis	rs2072499	0.778	rs2247476	chr1:156190280	C/A	cg25208724	chr1:156163844	SLC25A44	0.91	11.42	0.57	8.02e-25	Testicular germ cell tumor;
CESC	cis	rs2304069	0.545	rs6866616	chr5:149415401	A/G	cg12661370	chr5:149340060	SLC26A2	0.46	6.11	0.35	3.46e-9	HIV-1 control;
CESC	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.89	13.67	0.64	1.49e-32	Prudent dietary pattern;
CESC	cis	rs7208859	0.623	rs1061346	chr17:29114229	G/A	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.1e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs847577	0.748	rs940432	chr7:97716483	G/A	cg24562669	chr7:97807699	LMTK2	0.63	10.15	0.53	1.13e-20	Breast cancer;
CESC	cis	rs5769707	0.904	rs7288869	chr22:50015327	C/T	cg20744362	chr22:50050164	C22orf34	0.46	8.09	0.44	2.2e-14	Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs7945705	0.902	rs1560569	chr11:8939887	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.49	-8.36	-0.46	3.59e-15	Hemoglobin concentration;
CESC	cis	rs6540559	0.546	rs634601	chr1:210421594	C/T	cg21951975	chr1:209979733	IRF6	0.46	6.2	0.36	2.16e-9	Cleft lip with or without cleft palate;
CESC	cis	rs910316	1.000	rs7142235	chr14:75559963	T/C	cg08847533	chr14:75593920	NEK9	1.01	19.43	0.77	6.73e-53	Height;
CESC	cis	rs1878931	0.615	rs6501171	chr16:3402610	T/A	cg22508957	chr16:3507546	NAT15	-0.36	-5.08	-0.3	7.05e-7	Body mass index (adult);
CESC	cis	rs853679	0.546	rs13214023	chr6:28332141	A/G	cg18032046	chr6:28092343	ZSCAN16	0.66	5.23	0.31	3.52e-7	Depression;
CESC	cis	rs12545109	0.613	rs4541914	chr8:57254555	T/G	cg09654669	chr8:57350985	NA	-0.56	-6.17	-0.35	2.48e-9	Obesity-related traits;
CESC	cis	rs3858526	0.883	rs10769320	chr11:5932831	G/C	cg05234568	chr11:5960015	NA	-0.56	-6.54	-0.37	3.15e-10	DNA methylation (variation);
CESC	cis	rs2412488	0.853	rs6818788	chr4:54356173	C/T	cg22241045	chr4:54363911	LNX1	-0.38	-5.32	-0.31	2.19e-7	DNA methylation (variation);
CESC	cis	rs2742234	0.590	rs2503848	chr10:43672785	G/A	cg15436174	chr10:43711423	RASGEF1A	-0.5	-5.76	-0.33	2.34e-8	Hirschsprung disease;
CESC	cis	rs57244997	0.685	rs1954916	chr6:162447612	A/G	cg17173639	chr6:162384350	PARK2	-0.58	-6.11	-0.35	3.53e-9	Mosquito bite size;
CESC	cis	rs6828523	0.698	rs75086254	chr4:175851520	T/G	cg14561282	chr4:175839468	ADAM29	0.44	5.05	0.3	8.12e-7	Breast cancer;
CESC	cis	rs79057730	0.639	rs6463933	chr7:793954	G/A	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.65	5.62	0.33	4.8e-8	Initial pursuit acceleration;
CESC	cis	rs6460942	1.000	rs6460938	chr7:12406808	T/G	cg10578991	chr7:12443926	VWDE	-0.53	-5.69	-0.33	3.32e-8	Coronary artery disease;
CESC	cis	rs7188697	0.743	rs11859781	chr16:58602589	T/A	cg21335942	chr16:58549945	SETD6	-0.45	-5.2	-0.3	4.06e-7	QT interval;
CESC	cis	rs2836974	0.644	rs1882779	chr21:40690938	T/C	cg22974920	chr21:40686053	BRWD1	-0.46	-5.72	-0.33	2.9e-8	Cognitive function;
CESC	cis	rs10479542	0.503	rs12719865	chr5:178993566	C/T	cg09060608	chr5:178986726	RUFY1	0.52	7.75	0.43	1.97e-13	Lung cancer;
CESC	cis	rs66887589	0.720	rs2036858	chr4:120249237	A/C	cg09307838	chr4:120376055	NA	0.56	7.54	0.42	7.59e-13	Diastolic blood pressure;
CESC	cis	rs6460942	0.505	rs73290446	chr7:12358133	T/G	cg06484146	chr7:12443880	VWDE	-0.6	-6.44	-0.37	5.7e-10	Coronary artery disease;
CESC	trans	rs12615721	0.892	rs34426147	chr2:81957166	T/C	cg13174197	chr3:52720522	GNL3;PBRM1	0.78	6.24	0.36	1.77e-9	Pulmonary function decline;
CESC	cis	rs2228479	0.681	rs10153055	chr16:89965842	C/T	cg00800038	chr16:89945340	TCF25	-0.6	-6.48	-0.37	4.56e-10	Skin colour saturation;
CESC	cis	rs7582720	1.000	rs72926767	chr2:203796814	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.38	0.41	1.99e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	trans	rs916888	0.779	rs199498	chr17:44865603	A/G	cg01341218	chr17:43662625	NA	0.55	6.62	0.38	1.94e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	trans	rs1814175	0.645	rs12364337	chr11:49942580	A/T	cg15704280	chr7:45808275	SEPT13	-1.01	-18.94	-0.76	3.64e-51	Height;
CESC	cis	rs9300255	0.739	rs1533703	chr12:123742093	T/G	cg00376283	chr12:123451042	ABCB9	0.7	8.63	0.47	5.59e-16	Neutrophil percentage of white cells;
CESC	cis	rs11098499	0.866	rs3756156	chr4:120524841	G/A	cg24375607	chr4:120327624	NA	0.43	5.28	0.31	2.66e-7	Corneal astigmatism;
CESC	cis	rs4820539	0.641	rs5759602	chr22:23489362	C/T	cg14186256	chr22:23484241	RTDR1	-0.72	-10.79	-0.55	1.01e-22	Bone mineral density;
CESC	cis	rs9488822	0.676	rs11757115	chr6:116362619	C/T	cg05304507	chr6:116381966	FRK	0.26	6.6	0.38	2.24e-10	Cholesterol, total;LDL cholesterol;
CESC	cis	rs7811142	0.830	rs75636500	chr7:99947657	C/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.03	9.61	0.51	6.02e-19	Platelet count;
CESC	cis	rs1580019	0.844	rs4723159	chr7:32512804	T/C	cg07520158	chr7:32535189	LSM5;AVL9	0.43	5.13	0.3	5.72e-7	Cognitive ability;
CESC	cis	rs36051895	0.589	rs10491651	chr9:5200060	A/G	cg02405213	chr9:5042618	JAK2	-0.5	-5.85	-0.34	1.46e-8	Pediatric autoimmune diseases;
CESC	cis	rs2832191	1.000	rs2832185	chr21:30483761	C/G	cg08807101	chr21:30365312	RNF160	-0.65	-8.88	-0.48	1.03e-16	Dental caries;
CESC	cis	rs35146811	0.961	rs35991721	chr7:99728790	G/T	cg22906224	chr7:99728672	NA	0.46	5.17	0.3	4.51e-7	Coronary artery disease;
CESC	cis	rs1847202	0.859	rs4490296	chr3:72949197	C/A	cg25664220	chr3:72788482	NA	-0.37	-5.44	-0.32	1.2e-7	Motion sickness;
CESC	cis	rs3820068	0.581	rs16851855	chr1:15930869	G/A	cg17385448	chr1:15911702	AGMAT	0.41	6.69	0.38	1.33e-10	Systolic blood pressure;
CESC	cis	rs4566357	0.615	rs10177528	chr2:227913706	G/A	cg11843606	chr2:227700838	RHBDD1	-0.5	-6.82	-0.39	6.08e-11	Coronary artery disease;
CESC	cis	rs3733585	0.673	rs7672947	chr4:9961368	G/C	cg11266682	chr4:10021025	SLC2A9	-0.6	-11.2	-0.57	4.42e-24	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs1799949	0.965	rs799910	chr17:41279561	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	7.0	0.39	2.11e-11	Menopause (age at onset);
CESC	cis	rs9457247	0.624	rs17524252	chr6:167466978	T/G	cg23791538	chr6:167370224	RNASET2	-0.52	-6.87	-0.39	4.45e-11	Crohn's disease;
CESC	cis	rs67340775	0.541	rs200973	chr6:27858421	A/G	cg17221315	chr6:27791827	HIST1H4J	0.55	5.35	0.31	1.93e-7	Lung cancer in ever smokers;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg00597055	chr15:41523239	CHP;EXD1	-0.46	-6.34	-0.36	1.01e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs2797160	0.522	rs6925158	chr6:125940188	T/G	cg05901451	chr6:126070800	HEY2	-0.39	-5.27	-0.31	2.87e-7	Endometrial cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06982628	chr22:38597918	MAFF	0.56	6.15	0.35	2.83e-9	Gut microbiome composition (summer);
CESC	cis	rs10504229	0.683	rs11786527	chr8:58131344	G/C	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg13379827	chr1:65468782	NA	-0.55	-7.1	-0.4	1.13e-11	Ulcerative colitis;
CESC	cis	rs1800469	1.000	rs1549933	chr19:41871142	A/G	cg09537434	chr19:41945824	ATP5SL	-0.67	-8.31	-0.45	5.12e-15	Colorectal cancer;
CESC	cis	rs2228479	0.702	rs11649501	chr16:89850957	A/T	cg14709524	chr16:89940631	TCF25	0.94	7.05	0.4	1.57e-11	Skin colour saturation;
CESC	cis	rs2243480	1.000	rs34577383	chr7:65385726	C/T	cg18252515	chr7:66147081	NA	-1.0	-9.22	-0.49	9.27e-18	Diabetic kidney disease;
CESC	cis	rs10504229	0.683	rs6982990	chr8:58115275	C/T	cg02725872	chr8:58115012	NA	0.45	7.12	0.4	1.02e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs4727027	0.754	rs917124	chr7:148851213	C/T	cg23583168	chr7:148888333	NA	-0.71	-9.51	-0.5	1.26e-18	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	trans	rs7726839	0.540	rs11750321	chr5:599196	C/T	cg25482853	chr8:67687455	SGK3	1.04	10.14	0.53	1.27e-20	Obesity-related traits;
CESC	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg15112475	chr7:1198522	ZFAND2A	-0.44	-7.11	-0.4	1.06e-11	Longevity;Endometriosis;
CESC	trans	rs3780486	0.846	rs3780487	chr9:33139237	T/C	cg04842962	chr6:43655489	MRPS18A	1.01	19.75	0.77	5.15e-54	IgG glycosylation;
CESC	cis	rs5758659	0.714	rs133376	chr22:42466905	C/T	cg00645731	chr22:42541494	CYP2D7P1	-0.34	-5.73	-0.33	2.71e-8	Cognitive function;
CESC	cis	rs7560272	0.538	rs17350056	chr2:73922877	G/A	cg20560298	chr2:73613845	ALMS1	0.46	6.23	0.36	1.87e-9	Schizophrenia;
CESC	cis	rs1691799	0.899	rs1185244	chr12:66725160	C/T	cg16791601	chr12:66731901	HELB	-0.73	-12.46	-0.61	2.25e-28	White blood cell count (basophil);
CESC	cis	rs12956009	0.583	rs4331415	chr18:44885048	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.51	6.78	0.38	8e-11	Educational attainment (years of education);
CESC	cis	rs78707713	0.560	rs17569412	chr10:71237536	C/A	cg12610070	chr10:71211762	TSPAN15	-0.33	-6.85	-0.39	5.18e-11	Venous thromboembolism;
CESC	cis	rs4253772	0.550	rs6007761	chr22:46670394	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	-0.65	-7.85	-0.43	1.06e-13	LDL cholesterol;Cholesterol, total;
CESC	cis	rs6543140	0.964	rs10200081	chr2:103091556	T/C	cg04239558	chr2:103089729	SLC9A4	0.48	6.28	0.36	1.35e-9	Blood protein levels;
CESC	cis	rs13191362	0.935	rs35942036	chr6:163163297	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.64	6.46	0.37	4.99e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg05313129	chr8:58192883	C8orf71	-0.48	-5.27	-0.31	2.89e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs9911578	1.000	rs1057068	chr17:56598439	T/C	cg05425664	chr17:57184151	TRIM37	0.49	6.82	0.39	6.17e-11	Intelligence (multi-trait analysis);
CESC	cis	rs6456156	0.524	rs6934043	chr6:167466449	C/T	cg23791538	chr6:167370224	RNASET2	-0.49	-6.37	-0.36	8.13e-10	Primary biliary cholangitis;
CESC	cis	rs936229	0.749	rs6495127	chr15:75194490	C/T	cg10253484	chr15:75165896	SCAMP2	-0.45	-5.12	-0.3	5.98e-7	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CESC	cis	rs12701220	0.553	rs13245507	chr7:1163694	C/T	cg26769984	chr7:1090371	C7orf50	0.48	5.09	0.3	6.85e-7	Bronchopulmonary dysplasia;
CESC	cis	rs9926296	0.605	rs7205053	chr16:89856763	G/C	cg04287289	chr16:89883240	FANCA	0.88	14.99	0.68	3.3e-37	Vitiligo;
CESC	cis	rs7818688	1.000	rs28651964	chr8:96026781	C/T	cg16049864	chr8:95962084	TP53INP1	0.61	5.74	0.33	2.62e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs13118159	0.778	rs12640984	chr4:1338834	G/A	cg16405210	chr4:1374714	KIAA1530	-0.53	-7.09	-0.4	1.25e-11	Longevity;
CESC	cis	rs7605827	0.930	rs13004154	chr2:15664325	A/G	cg19274914	chr2:15703543	NA	0.3	5.26	0.31	2.96e-7	Educational attainment (years of education);
CESC	cis	rs13720	0.915	rs163782	chr20:57565943	G/C	cg23907860	chr20:57583709	CTSZ	-0.45	-5.41	-0.32	1.44e-7	Platelet distribution width;
CESC	cis	rs10911363	0.592	rs10911354	chr1:183489278	G/A	cg09173681	chr1:183549694	NCF2	0.53	7.81	0.43	1.3e-13	Systemic lupus erythematosus;
CESC	cis	rs4819052	0.918	rs2330013	chr21:46658662	G/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.56	6.79	0.38	7.43e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs7208859	0.623	rs11658945	chr17:29122509	T/C	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.79e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs7542091	0.704	rs7550330	chr1:210044587	G/A	cg22029157	chr1:209979665	IRF6	0.5	7.98	0.44	4.32e-14	Monobrow;
CESC	cis	rs7772486	0.754	rs702306	chr6:145991029	T/C	cg05347473	chr6:146136440	FBXO30	-0.52	-6.72	-0.38	1.1e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1552244	0.882	rs3732966	chr3:10015740	C/T	cg00149659	chr3:10157352	C3orf10	0.73	8.54	0.46	1.05e-15	Alzheimer's disease;
CESC	cis	rs7917772	0.503	rs7902306	chr10:104290462	C/T	cg22532475	chr10:104410764	TRIM8	-0.31	-5.12	-0.3	5.75e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs12497850	0.864	rs7431857	chr3:48900347	G/A	cg06212747	chr3:49208901	KLHDC8B	0.67	8.99	0.48	4.66e-17	Parkinson's disease;
CESC	cis	rs875971	0.862	rs2901152	chr7:65765004	G/A	cg11764359	chr7:65958608	NA	-0.78	-11.64	-0.58	1.47e-25	Aortic root size;
CESC	cis	rs2952156	0.920	rs2517958	chr17:37838751	G/A	cg07936489	chr17:37558343	FBXL20	-0.6	-7.77	-0.43	1.77e-13	Asthma;
CESC	cis	rs6460942	1.000	rs112794590	chr7:12319426	G/A	cg10578991	chr7:12443926	VWDE	-0.61	-6.41	-0.37	6.66e-10	Coronary artery disease;
CESC	cis	rs2832191	0.967	rs1999321	chr21:30530233	A/C	cg24692254	chr21:30365293	RNF160	0.73	10.75	0.55	1.34e-22	Dental caries;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23296408	chr14:91580613	C14orf159	-0.57	-6.38	-0.36	8.04e-10	Gut microbiome composition (summer);
CESC	cis	rs8141529	0.644	rs5752795	chr22:29178820	T/C	cg15103426	chr22:29168792	CCDC117	0.7	9.85	0.52	1.06e-19	Lymphocyte counts;
CESC	cis	rs6076065	0.748	rs2180139	chr20:23405281	G/A	cg11657817	chr20:23433608	CST11	0.41	6.09	0.35	4.04e-9	Facial morphology (factor 15, philtrum width);
CESC	cis	rs7572263	0.724	rs11676550	chr2:209053775	T/C	cg23998903	chr2:209048830	C2orf80	-0.39	-5.14	-0.3	5.4e-7	Glioma;Non-glioblastoma glioma;
CESC	cis	rs12190007	1.000	rs12190007	chr6:169727601	C/T	cg16388071	chr6:169726476	NA	-0.46	-6.29	-0.36	1.33e-9	Obesity-related traits;
CESC	cis	rs977987	0.806	rs4888390	chr16:75400320	G/A	cg03315344	chr16:75512273	CHST6	0.4	5.73	0.33	2.73e-8	Dupuytren's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04048411	chr12:94541943	PLXNC1	0.5	6.6	0.38	2.26e-10	Gut microbiome composition (summer);
CESC	cis	rs9682041	0.660	rs13089074	chr3:170113481	G/A	cg11886554	chr3:170076028	SKIL	0.7	6.46	0.37	4.94e-10	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CESC	cis	rs12477438	0.798	rs6732579	chr2:99560239	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.7	-10.06	-0.53	2.22e-20	Chronic sinus infection;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23892547	chr17:29886066	MIR193A	0.54	6.35	0.36	9.13e-10	Gut microbiome composition (summer);
CESC	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.49	-6.15	-0.35	2.77e-9	Longevity;Endometriosis;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg18544450	chr19:14264896	LPHN1	0.43	6.36	0.36	9.05e-10	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs8180040	0.577	rs12493425	chr3:47176946	T/G	cg27129171	chr3:47204927	SETD2	0.66	9.89	0.52	7.98e-20	Colorectal cancer;
CESC	cis	rs5769765	0.908	rs9616213	chr22:50317851	T/G	cg02269571	chr22:50332266	NA	-0.57	-6.6	-0.38	2.28e-10	Schizophrenia;
CESC	cis	rs6087990	1.000	rs2424901	chr20:31344512	A/G	cg13636640	chr20:31349939	DNMT3B	0.91	16.04	0.7	6.22e-41	Ulcerative colitis;
CESC	cis	rs2952156	0.920	rs2517954	chr17:37843550	T/C	cg00129232	chr17:37814104	STARD3	-0.73	-9.72	-0.51	2.62e-19	Asthma;
CESC	cis	rs412000	0.553	rs2680702	chr17:56431549	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.43	5.21	0.3	3.75e-7	Primary tooth development (time to first tooth eruption);
CESC	cis	rs4268898	0.795	rs12470303	chr2:24619883	C/T	cg06627628	chr2:24431161	ITSN2	-0.48	-5.73	-0.33	2.7e-8	Asthma;
CESC	cis	rs6088590	0.561	rs6087600	chr20:33157217	T/C	cg08999081	chr20:33150536	PIGU	0.7	12.65	0.61	5.4e-29	Coronary artery disease;
CESC	cis	rs6570726	0.764	rs451108	chr6:145844309	T/C	cg23711669	chr6:146136114	FBXO30	1.01	15.7	0.69	1.05e-39	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7618915	0.571	rs2251219	chr3:52584787	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.45	-5.96	-0.34	8.06e-9	Bipolar disorder;
CESC	cis	rs13108904	0.967	rs11727167	chr4:1285521	A/G	cg22903657	chr4:1355424	KIAA1530	-0.38	-5.17	-0.3	4.72e-7	Obesity-related traits;
CESC	cis	rs7208859	0.623	rs7214570	chr17:29147164	A/G	cg13385521	chr17:29058706	SUZ12P	0.69	5.64	0.33	4.44e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs941873	0.868	rs2145998	chr10:81121696	T/A	cg11057378	chr10:81107060	PPIF	0.33	5.42	0.32	1.37e-7	Height;
CESC	cis	rs631288	0.793	rs1530337	chr1:146683319	C/A	cg25205988	chr1:146714368	CHD1L	1.05	6.69	0.38	1.28e-10	PR interval in Tripanosoma cruzi seropositivity;
CESC	cis	rs9322193	0.847	rs12210605	chr6:150138403	A/G	cg13206674	chr6:150067644	NUP43	0.41	5.61	0.33	5.2100000000000003e-08	Lung cancer;
CESC	cis	rs68170813	0.559	rs7804979	chr7:106999453	C/G	cg02696742	chr7:106810147	HBP1	-0.53	-5.16	-0.3	4.9e-7	Coronary artery disease;
CESC	cis	rs9300255	0.722	rs10846515	chr12:123801672	T/G	cg00376283	chr12:123451042	ABCB9	0.59	6.86	0.39	4.85e-11	Neutrophil percentage of white cells;
CESC	cis	rs2302729	0.545	rs10161181	chr12:2770730	A/C	cg19945202	chr12:2788847	CACNA1C	-0.47	-7.08	-0.4	1.29e-11	Sleep quality;
CESC	cis	rs910316	0.737	rs175049	chr14:75481368	C/T	cg16144293	chr14:75469539	EIF2B2	0.39	5.15	0.3	5.01e-7	Height;
CESC	cis	rs4727027	0.865	rs12154368	chr7:148862041	C/T	cg23158103	chr7:148848205	ZNF398	-0.42	-6.92	-0.39	3.45e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs7707921	0.522	rs10070637	chr5:81490608	A/G	cg15871215	chr5:81402204	ATG10	0.47	6.8	0.39	6.74e-11	Breast cancer;
CESC	cis	rs10504229	0.639	rs2318145	chr8:58114867	A/G	cg24829409	chr8:58192753	C8orf71	-0.58	-7.2	-0.4	6.31e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs1023500	0.552	rs5758566	chr22:42454354	G/A	cg04733989	chr22:42467013	NAGA	0.79	11.89	0.59	2.06e-26	Schizophrenia;
CESC	cis	rs2404602	0.692	rs55864032	chr15:77122548	A/G	cg22467129	chr15:76604101	ETFA	-0.34	-5.12	-0.3	5.97e-7	Blood metabolite levels;
CESC	cis	rs12681288	0.823	rs4735974	chr8:1000218	T/G	cg15309053	chr8:964076	NA	0.32	5.46	0.32	1.11e-7	Schizophrenia;
CESC	cis	rs7605827	0.930	rs10200346	chr2:15635728	A/C	cg19274914	chr2:15703543	NA	0.36	6.32	0.36	1.09e-9	Educational attainment (years of education);
CESC	trans	rs7726839	0.561	rs11955068	chr5:582324	C/T	cg25482853	chr8:67687455	SGK3	0.88	9.24	0.49	8.24e-18	Obesity-related traits;
CESC	cis	rs9937943	0.615	rs35495670	chr16:74610422	T/C	cg01733217	chr16:74700730	RFWD3	0.58	5.05	0.3	8.06e-7	Neutrophil percentage of white cells;
CESC	cis	rs6963495	0.745	rs68153235	chr7:105184832	A/C	cg13798780	chr7:105162888	PUS7	0.63	7.31	0.41	3.16e-12	Bipolar disorder (body mass index interaction);
CESC	cis	rs290268	0.874	rs290995	chr9:93559477	C/A	cg02608019	chr9:93564028	SYK	0.67	10.21	0.53	7.53e-21	Platelet count;
CESC	cis	rs3812762	0.833	rs10500705	chr11:8805261	A/G	cg03980550	chr11:8754370	ST5	-0.38	-5.3	-0.31	2.47e-7	Hypospadias;
CESC	cis	rs1448094	0.512	rs61930862	chr12:86246567	A/G	cg19622623	chr12:86230825	RASSF9	-0.46	-5.89	-0.34	1.14e-8	Major depressive disorder;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg26723570	chr6:170102133	WDR27;C6orf120	-0.49	-6.4	-0.37	6.86e-10	Ulcerative colitis;
CESC	cis	rs60843830	0.964	rs17713879	chr2:254215	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.79	10.42	0.54	1.61e-21	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs1878931	0.501	rs28735976	chr16:3418419	G/A	cg05754148	chr16:3507555	NAT15	-0.39	-5.19	-0.3	4.24e-7	Body mass index (adult);
CESC	cis	rs1559088	1.000	rs28840147	chr19:33561976	A/G	cg27124370	chr19:33622961	WDR88	0.44	5.46	0.32	1.1e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs8067545	0.611	rs2526466	chr17:20165251	C/T	cg13482628	chr17:19912719	NA	-0.4	-5.19	-0.3	4.14e-7	Schizophrenia;
CESC	cis	rs4835473	0.932	rs11100806	chr4:144682159	C/G	cg25736465	chr4:144833511	NA	0.34	5.29	0.31	2.59e-7	Immature fraction of reticulocytes;
CESC	cis	rs7639513	0.767	rs6784168	chr3:12702847	T/G	cg23032965	chr3:12705835	RAF1	0.76	10.67	0.55	2.34e-22	Itch intensity from mosquito bite;
CESC	cis	rs9399135	0.967	rs1854865	chr6:135360300	C/G	cg24558204	chr6:135376177	HBS1L	0.49	6.84	0.39	5.41e-11	Red blood cell count;
CESC	cis	rs9549367	0.577	rs776904	chr13:113810542	C/T	cg18105134	chr13:113819100	PROZ	-0.75	-8.35	-0.46	3.92e-15	Platelet distribution width;
CESC	cis	rs7552404	0.960	rs61797339	chr1:76189946	G/T	cg10523679	chr1:76189770	ACADM	0.72	8.4	0.46	2.82e-15	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs4665809	0.567	rs12999875	chr2:26414847	A/C	cg27170947	chr2:26402098	FAM59B	0.85	10.0	0.52	3.45e-20	Gut microbiome composition (summer);
CESC	trans	rs9975691	1	rs9975691	chr21:14928355	G/T	cg11289296	chr17:74383131	SPHK1	-0.46	-6.07	-0.35	4.36e-9	Neurofibrillary tangles;
CESC	cis	rs1691799	0.899	rs1168328	chr12:66729250	T/C	cg16791601	chr12:66731901	HELB	-0.78	-14.06	-0.65	6.2e-34	White blood cell count (basophil);
CESC	cis	rs4523957	0.651	rs9894613	chr17:2071058	C/T	cg16513277	chr17:2031491	SMG6	-0.72	-10.21	-0.53	7.63e-21	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	trans	rs4332037	0.539	rs55773130	chr7:2070554	T/C	cg11693508	chr17:37793320	STARD3	0.66	6.66	0.38	1.57e-10	Bipolar disorder;
CESC	cis	rs13242816	1.000	rs35515812	chr7:116156032	C/G	cg04696780	chr7:116139425	CAV2	-0.61	-5.55	-0.32	7.01e-8	P wave duration;
CESC	cis	rs113835537	0.529	rs3179961	chr11:66244454	A/G	cg24851651	chr11:66362959	CCS	0.47	5.76	0.33	2.31e-8	Airway imaging phenotypes;
CESC	cis	rs17253792	0.822	rs10483646	chr14:56103872	A/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.86	5.36	0.31	1.78e-7	Putamen volume;
CESC	trans	rs10776614	0.799	rs7074631	chr10:49767369	G/A	cg19218067	chr2:181235115	NA	0.49	6.0	0.35	6.35e-9	Self-employment;
CESC	cis	rs2415984	0.600	rs72672853	chr14:46932920	T/G	cg14871534	chr14:47121158	RPL10L	-0.34	-5.12	-0.3	5.96e-7	Number of children ever born;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg21205276	chr9:95056231	IARS;SNORA84	-0.44	-6.01	-0.35	6.2e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs7851660	0.967	rs4743134	chr9:100598568	C/A	cg13688889	chr9:100608707	NA	-0.68	-10.61	-0.55	3.8e-22	Strep throat;
CESC	cis	rs1552244	0.882	rs13075842	chr3:10055813	A/C	cg00166722	chr3:10149974	C3orf24	0.48	5.95	0.34	8.64e-9	Alzheimer's disease;
CESC	cis	rs9837602	1.000	rs923471	chr3:99757853	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.52	6.98	0.39	2.43e-11	Breast cancer;
CESC	cis	rs2243480	1.000	rs67728539	chr7:65378124	G/A	cg18252515	chr7:66147081	NA	-1.0	-9.22	-0.49	9.27e-18	Diabetic kidney disease;
CESC	cis	rs9287719	0.967	rs3815521	chr2:10743654	G/C	cg00105475	chr2:10696890	NA	0.39	5.64	0.33	4.44e-8	Prostate cancer;
CESC	cis	rs7666738	0.830	rs1115616	chr4:99006603	A/C	cg17366294	chr4:99064904	C4orf37	0.6	8.61	0.47	6.47e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6912958	0.712	rs6930600	chr6:88349787	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-6.72	-0.38	1.09e-10	Monocyte percentage of white cells;
CESC	cis	rs11122272	0.735	rs2486727	chr1:231539245	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-6.93	-0.39	3.24e-11	Hemoglobin concentration;
CESC	cis	rs11577318	1.000	rs11577318	chr1:26601570	A/G	cg19743891	chr1:26644573	UBXN11;CD52	0.36	5.08	0.3	7.25e-7	Granulocyte percentage of myeloid white cells;
CESC	cis	rs1372520	0.684	rs3113355	chr4:90745345	A/T	cg15133208	chr4:90757351	SNCA	-0.4	-5.4	-0.31	1.48e-7	Neuroticism;
CESC	cis	rs524281	0.814	rs10896098	chr11:65968416	G/A	cg14036092	chr11:66035641	RAB1B	-0.59	-6.08	-0.35	4.11e-9	Electroencephalogram traits;
CESC	cis	rs9768139	0.935	rs6953748	chr7:158121184	G/A	cg25566285	chr7:158114605	PTPRN2	-0.52	-8.89	-0.48	9.74e-17	Calcium levels;
CESC	cis	rs11792861	0.591	rs7044275	chr9:111717138	T/C	cg05043794	chr9:111880884	C9orf5	-0.32	-5.77	-0.33	2.18e-8	Menarche (age at onset);
CESC	cis	rs1348850	0.574	rs11691740	chr2:178445161	A/G	cg23306229	chr2:178417860	TTC30B	-0.58	-5.83	-0.34	1.58e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs1552244	1.000	rs7610821	chr3:10136150	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.84	-12.08	-0.6	4.61e-27	Alzheimer's disease;
CESC	cis	rs8031584	0.505	rs2959036	chr15:31219742	T/G	cg08704250	chr15:31115839	NA	0.63	8.61	0.47	6.65e-16	Huntington's disease progression;
CESC	cis	rs9303401	0.614	rs28687626	chr17:57191904	G/A	cg25039879	chr17:56429692	SUPT4H1	0.53	5.09	0.3	6.92e-7	Cognitive test performance;
CESC	cis	rs644799	0.672	rs61902245	chr11:95517737	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.75	11.23	0.57	3.33e-24	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs933688	0.938	rs10942634	chr5:90658392	A/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.08	14.28	0.66	1.07e-34	Smoking behavior;
CESC	trans	rs324780	0.544	rs11115900	chr12:83923359	A/G	cg22140261	chr22:42466895	NAGA	-0.48	-6.07	-0.35	4.49e-9	Vertical cup-disc ratio;
CESC	cis	rs9914544	0.966	rs1737943	chr17:18841590	A/G	cg26378065	chr17:18585709	ZNF286B	-0.42	-5.19	-0.3	4.23e-7	Educational attainment (years of education);
CESC	cis	rs3806843	1.000	rs9686540	chr5:140174622	G/A	cg26395211	chr5:140044315	WDR55	-0.41	-5.26	-0.31	2.97e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs1153858	0.943	rs12439575	chr15:45684816	T/G	cg21132104	chr15:45694354	SPATA5L1	0.86	11.62	0.58	1.67e-25	Homoarginine levels;
CESC	cis	rs9303401	0.625	rs10515159	chr17:56802693	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.05	12.77	0.62	1.94e-29	Cognitive test performance;
CESC	cis	rs7666738	0.830	rs1115616	chr4:99006603	A/C	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.62e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9322193	0.923	rs7753812	chr6:150011286	C/T	cg05861140	chr6:150128134	PCMT1	-0.36	-5.25	-0.31	3.11e-7	Lung cancer;
CESC	cis	rs2070488	0.775	rs11926767	chr3:38527913	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.78	-11.99	-0.59	9.13e-27	Electrocardiographic conduction measures;
CESC	cis	rs2576037	0.562	rs13381557	chr18:44513371	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.5	-6.74	-0.38	9.62e-11	Personality dimensions;
CESC	cis	rs9329289	0.510	rs35854428	chr10:2554280	T/C	cg15501526	chr10:2543763	NA	0.47	7.52	0.42	8.48e-13	Age-related hearing impairment;
CESC	cis	rs1371867	0.846	rs1660349	chr8:101319326	G/A	cg11906718	chr8:101322791	RNF19A	0.54	6.93	0.39	3.1e-11	Atrioventricular conduction;
CESC	cis	rs2742417	1.000	rs2742431	chr3:45737121	C/G	cg10512202	chr3:45649293	LIMD1	-0.36	-5.32	-0.31	2.18e-7	Response to anti-depressant treatment in major depressive disorder;
CESC	cis	rs992157	0.710	rs13026485	chr2:219057984	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.66	-8.82	-0.48	1.6e-16	Colorectal cancer;
CESC	cis	rs4665809	1.000	rs6546744	chr2:26302161	A/G	cg22920501	chr2:26401640	FAM59B	-0.67	-8.09	-0.45	2.16e-14	Gut microbiome composition (summer);
CESC	cis	rs35306767	0.953	rs11253509	chr10:964306	C/T	cg10556349	chr10:835070	NA	0.54	5.81	0.34	1.83e-8	Eosinophil percentage of granulocytes;
CESC	cis	rs34779708	0.931	rs4934535	chr10:35432721	G/T	cg03585969	chr10:35415529	CREM	0.75	9.84	0.52	1.09e-19	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs9303401	0.527	rs12946522	chr17:56768103	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.96	11.48	0.58	4.87e-25	Cognitive test performance;
CESC	cis	rs35955747	0.902	rs4820961	chr22:31679449	C/T	cg25791279	chr22:32026902	PISD	-0.45	-5.5	-0.32	8.92e-8	Neutrophil count;Sum basophil neutrophil counts;
CESC	cis	rs7809950	0.953	rs2253271	chr7:107201252	G/C	cg23024343	chr7:107201750	COG5	-0.42	-5.89	-0.34	1.14e-8	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09429345	chr3:138327826	FAIM	0.64	7.48	0.42	1.1e-12	Gut microbiome composition (summer);
CESC	cis	rs1008375	0.966	rs7666888	chr4:17695722	C/T	cg04450456	chr4:17643702	FAM184B	0.37	5.25	0.31	3.17e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs508618	0.666	rs480902	chr1:231531627	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.42	5.42	0.32	1.33e-7	Red blood cell count;
CESC	cis	rs2011503	1.000	rs2965178	chr19:19482911	T/G	cg11584989	chr19:19387371	SF4	-0.62	-7.53	-0.42	7.83e-13	Bipolar disorder;
CESC	cis	rs7824557	0.628	rs11782706	chr8:11186215	A/C	cg21775007	chr8:11205619	TDH	0.55	8.57	0.47	8.45e-16	Retinal vascular caliber;
CESC	cis	rs2979489	0.945	rs11993146	chr8:30319537	G/A	cg26383811	chr8:30366931	RBPMS	-0.81	-10.02	-0.52	2.96e-20	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CESC	cis	rs910316	0.967	rs35446981	chr14:75637351	A/T	cg11812906	chr14:75593930	NEK9	-0.87	-14.35	-0.66	5.82e-35	Height;
CESC	cis	rs2576037	0.526	rs571181	chr18:44376399	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.63	9.78	0.51	1.79e-19	Personality dimensions;
CESC	cis	rs12477438	0.798	rs6712338	chr2:99585457	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.75	-10.87	-0.56	5.17e-23	Chronic sinus infection;
CESC	cis	rs1355223	0.583	rs2915238	chr11:34884405	C/A	cg11058730	chr11:34937778	PDHX;APIP	0.86	13.16	0.63	9.16e-31	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs61841072	0.961	rs6672908	chr1:243126730	G/A	cg02356786	chr1:243265016	LOC731275	0.4	5.03	0.3	9.1e-7	Schizophrenia;
CESC	cis	rs30380	0.632	rs26500	chr5:96133712	A/C	cg16492584	chr5:96139282	ERAP1	-0.49	-6.84	-0.39	5.49e-11	Cerebrospinal fluid biomarker levels;
CESC	trans	rs2018683	0.707	rs4722878	chr7:28973031	C/T	cg19402173	chr7:128379420	CALU	-0.51	-6.73	-0.38	1.06e-10	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CESC	cis	rs9527	0.615	rs10883811	chr10:104727279	A/G	cg04362960	chr10:104952993	NT5C2	0.42	5.28	0.31	2.7e-7	Arsenic metabolism;
CESC	cis	rs2361718	0.564	rs2304844	chr17:78084507	G/C	cg20811857	chr17:78079795	GAA	-0.43	-6.26	-0.36	1.58e-9	Yeast infection;
CESC	cis	rs7017914	1.000	rs13252719	chr8:71734569	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.43	-5.57	-0.32	6.34e-8	Bone mineral density;
CESC	cis	rs6952808	0.595	rs3778983	chr7:2166319	T/G	cg23048001	chr7:2026167	MAD1L1	0.46	6.09	0.35	3.91e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs2710642	0.611	rs6749020	chr2:62861957	G/A	cg17519650	chr2:63277830	OTX1	0.47	5.54	0.32	7.36e-8	LDL cholesterol levels;LDL cholesterol;
CESC	trans	rs6073597	1.000	rs6031980	chr20:43714384	C/T	cg19936885	chr3:9404556	THUMPD3	0.48	6.49	0.37	4.23e-10	Positive affect;
CESC	cis	rs1552244	1.000	rs35741213	chr3:10087661	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	11.97	0.59	1.1e-26	Alzheimer's disease;
CESC	cis	rs72627123	0.867	rs75773875	chr14:74498053	C/T	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.79	5.85	0.34	1.48e-8	Morning vs. evening chronotype;
CESC	cis	rs7552404	0.656	rs11161792	chr1:76336746	C/T	cg22875332	chr1:76189707	ACADM	0.63	6.26	0.36	1.52e-9	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs7660520	0.524	rs12643521	chr4:183728242	C/G	cg12524338	chr4:183729343	NA	0.52	5.12	0.3	5.98e-7	Pediatric autoimmune diseases;
CESC	cis	rs2040771	0.804	rs1340958	chr22:19253332	A/G	cg02655711	chr22:19163373	SLC25A1	-0.41	-6.0	-0.35	6.47e-9	Metabolite levels (small molecules and protein measures);
CESC	cis	rs6460942	0.597	rs13245635	chr7:12526454	T/A	cg20607287	chr7:12443886	VWDE	-0.71	-7.67	-0.43	3.19e-13	Coronary artery disease;
CESC	cis	rs939658	0.626	rs11636901	chr15:79446292	T/C	cg17916960	chr15:79447300	NA	-0.31	-5.06	-0.3	7.79e-7	Refractive error;
CESC	cis	rs6088590	0.561	rs6088527	chr20:33155841	C/T	cg08999081	chr20:33150536	PIGU	0.69	12.25	0.6	1.2100000000000001e-27	Coronary artery disease;
CESC	cis	rs875971	1.000	rs709597	chr7:65825983	A/G	cg11764359	chr7:65958608	NA	-0.91	-14.51	-0.67	1.64e-35	Aortic root size;
CESC	cis	rs1799949	1.000	rs11657835	chr17:41291953	C/G	cg05368731	chr17:41323189	NBR1	0.78	10.79	0.55	9.37e-23	Menopause (age at onset);
CESC	cis	rs763121	0.853	rs6001185	chr22:39052155	G/A	cg14440974	chr22:39074834	NA	-0.4	-5.49	-0.32	9.53e-8	Menopause (age at onset);
CESC	cis	rs9929218	1.000	rs28660361	chr16:68800838	T/C	cg02972257	chr16:68554789	NA	0.43	5.22	0.31	3.65e-7	Colorectal cancer;
CESC	cis	rs3617	0.539	rs12629687	chr3:52950659	T/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	-0.32	-5.4	-0.31	1.5e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
CESC	cis	rs4805272	0.512	rs7260055	chr19:29341599	G/A	cg12756686	chr19:29218302	NA	0.43	5.86	0.34	1.37e-8	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
CESC	cis	rs8072100	0.666	rs6503804	chr17:45772447	G/A	cg08085267	chr17:45401833	C17orf57	-0.43	-5.43	-0.32	1.27e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs9916302	0.904	rs8081338	chr17:37406139	C/T	cg15445000	chr17:37608096	MED1	0.4	6.38	0.36	7.97e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs1062177	1.000	rs2016409	chr5:151126324	G/T	cg00977110	chr5:151150581	G3BP1	-0.68	-6.89	-0.39	4.15e-11	Preschool internalizing problems;
CESC	cis	rs2742234	0.590	rs741968	chr10:43611708	A/G	cg15436174	chr10:43711423	RASGEF1A	-0.45	-5.35	-0.31	1.94e-7	Hirschsprung disease;
CESC	cis	rs2425143	0.841	rs4911519	chr20:34362326	A/T	cg23207816	chr20:34252616	CPNE1;RBM12	-0.72	-6.67	-0.38	1.52e-10	Blood protein levels;
CESC	cis	rs2228479	0.850	rs12597299	chr16:89822364	C/A	cg19635926	chr16:89946313	TCF25	0.67	5.09	0.3	6.82e-7	Skin colour saturation;
CESC	cis	rs4555082	0.834	rs2816624	chr14:105733909	A/G	cg10792982	chr14:105748885	BRF1	0.42	5.38	0.31	1.63e-7	Mean platelet volume;Platelet distribution width;
CESC	cis	rs6580649	1.000	rs9805048	chr12:48403692	C/T	cg05342945	chr12:48394962	COL2A1	-0.54	-6.75	-0.38	9.25e-11	Lung cancer;
CESC	cis	rs4891159	0.790	rs59762437	chr18:74153146	G/A	cg24786174	chr18:74118243	ZNF516	-0.74	-10.88	-0.56	5.03e-23	Longevity;
CESC	cis	rs4819052	0.851	rs9977178	chr21:46664531	G/T	cg11663144	chr21:46675770	NA	-0.62	-9.83	-0.52	1.19e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs7246760	0.867	rs35416342	chr19:9779058	A/G	cg02900749	chr2:68251473	NA	-0.85	-7.53	-0.42	8.04e-13	Pursuit maintenance gain;
CESC	cis	rs7116495	0.609	rs2845860	chr11:71716661	C/T	cg07596299	chr11:71824057	C11orf51	-0.85	-5.7	-0.33	3.12e-8	Severe influenza A (H1N1) infection;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18961773	chr17:74222942	RNF157	-0.53	-6.72	-0.38	1.11e-10	Gut microbiome composition (summer);
CESC	cis	rs73206853	0.764	rs56123836	chr12:110999032	G/A	cg12870014	chr12:110450643	ANKRD13A	0.65	5.65	0.33	4.09e-8	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	trans	rs4824093	0.610	rs2208023	chr22:50249983	A/G	cg09872104	chr7:134855509	C7orf49	-0.94	-6.62	-0.38	1.99e-10	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs6933660	0.646	rs6915598	chr6:151778664	T/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.53	5.39	0.31	1.59e-7	Menarche (age at onset);
CESC	cis	rs2228479	0.850	rs17227064	chr16:89816314	A/G	cg04013166	chr16:89971882	TCF25	0.77	6.66	0.38	1.58e-10	Skin colour saturation;
CESC	cis	rs1006703	0.544	rs34713010	chr17:3834718	A/G	cg06463185	chr17:3833770	ATP2A3	-0.56	-6.01	-0.35	6.17e-9	Glucose homeostasis traits;
CESC	cis	rs9443189	0.570	rs775075	chr6:76380035	A/C	cg01950844	chr6:76311363	SENP6	-0.87	-9.27	-0.49	6.59e-18	Prostate cancer;
CESC	cis	rs875971	0.522	rs10807697	chr7:65416170	A/G	cg05332525	chr7:65337924	VKORC1L1	0.5	6.18	0.36	2.35e-9	Aortic root size;
CESC	cis	rs7726839	0.561	rs4957049	chr5:579080	C/A	cg16447950	chr5:562315	NA	-0.58	-6.74	-0.38	9.99e-11	Obesity-related traits;
CESC	cis	rs1915146	0.546	rs9422857	chr10:126861278	C/G	cg23000734	chr10:126850823	CTBP2	0.54	8.01	0.44	3.69e-14	Menarche (age at onset);
CESC	trans	rs9929218	1.000	rs12446575	chr16:68791644	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.71	-8.97	-0.48	5.37e-17	Colorectal cancer;
CESC	cis	rs9309473	0.898	rs6546861	chr2:73849861	C/T	cg20560298	chr2:73613845	ALMS1	-0.45	-5.89	-0.34	1.17e-8	Metabolite levels;
CESC	cis	rs6088590	0.648	rs6059991	chr20:33280836	C/T	cg06115741	chr20:33292138	TP53INP2	0.55	6.7	0.38	1.24e-10	Coronary artery disease;
CESC	cis	rs920590	0.642	rs6993525	chr8:19671104	A/G	cg03894339	chr8:19674705	INTS10	-0.6	-7.01	-0.4	1.95e-11	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs17401966	0.931	rs17034821	chr1:10414645	A/G	cg15208524	chr1:10270712	KIF1B	0.41	5.18	0.3	4.35e-7	Hepatocellular carcinoma;
CESC	cis	rs875971	0.895	rs778700	chr7:65866450	C/T	cg12463550	chr7:65579703	CRCP	0.58	7.41	0.41	1.67e-12	Aortic root size;
CESC	cis	rs1461503	0.966	rs10892939	chr11:122841959	T/C	cg27398637	chr11:122830231	C11orf63	-0.55	-8.32	-0.45	4.77e-15	Menarche (age at onset);
CESC	cis	rs9309711	0.922	rs13431788	chr2:3482912	G/A	cg10845886	chr2:3471009	TTC15	-0.87	-12.13	-0.6	3.07e-27	Neurofibrillary tangles;
CESC	cis	rs614226	1.000	rs541126	chr12:120972396	C/T	cg01236616	chr12:121019343	POP5	-1.53	-18.68	-0.75	2.86e-50	Type 1 diabetes nephropathy;
CESC	trans	rs7107217	1.000	rs1873872	chr11:129473993	A/T	cg09431544	chr19:14629187	DNAJB1	0.48	6.27	0.36	1.43e-9	Breast cancer;Type 2 diabetes;
CESC	cis	rs2576037	0.796	rs2576038	chr18:44582200	C/G	cg19077165	chr18:44547161	KATNAL2	0.51	7.15	0.4	8.58e-12	Personality dimensions;
CESC	cis	rs801193	1.000	rs2707850	chr7:66203870	G/T	cg14393609	chr7:65229607	NA	0.47	6.31	0.36	1.17e-9	Aortic root size;
CESC	cis	rs6502050	0.835	rs7221544	chr17:80087337	C/T	cg11859384	chr17:80120422	CCDC57	0.38	5.13	0.3	5.68e-7	Life satisfaction;
CESC	cis	rs2842992	0.789	rs2295901	chr6:160201295	C/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.76	9.74	0.51	2.39e-19	Age-related macular degeneration (geographic atrophy);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26859586	chr10:104953231	NT5C2	0.63	7.42	0.41	1.58e-12	Gut microbiome composition (summer);
CESC	cis	rs9309711	0.623	rs4641971	chr2:3481857	A/C	cg15541040	chr2:3486749	NA	0.44	5.48	0.32	9.91e-8	Neurofibrillary tangles;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg15884411	chr2:96932403	CIAO1;TMEM127	0.5	6.25	0.36	1.6e-9	Gut microbiota (bacterial taxa);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg02355411	chr19:49700427	TRPM4	-0.35	-6.1	-0.35	3.71e-9	Gambling;
CESC	cis	rs2288912	0.838	rs7251503	chr19:45455715	C/G	cg20090143	chr19:45452003	APOC2	0.37	6.39	0.37	7.51e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg15112475	chr7:1198522	ZFAND2A	-0.46	-7.68	-0.43	3.13e-13	Longevity;Endometriosis;
CESC	cis	rs9660180	0.934	rs12729990	chr1:1812035	T/A	cg03396347	chr1:1875803	NA	-0.46	-7.13	-0.4	9.43e-12	Body mass index;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg04522931	chr7:30324582	ZNRF2	-0.5	-7.01	-0.4	2e-11	Fibrinogen levels;
CESC	trans	rs7819412	0.740	rs7844536	chr8:11034028	A/G	cg06636001	chr8:8085503	FLJ10661	-0.65	-7.87	-0.44	9.32e-14	Triglycerides;
CESC	cis	rs12190007	0.547	rs2981945	chr6:169819839	G/A	cg15038512	chr6:170123185	PHF10	-0.51	-7.26	-0.41	4.43e-12	Obesity-related traits;
CESC	cis	rs2295499	0.754	rs4690052	chr4:2736567	C/T	cg27239842	chr4:2403781	ZFYVE28	-0.32	-5.15	-0.3	5.12e-7	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
CESC	cis	rs6502050	0.635	rs9889327	chr17:80087839	G/A	cg23985595	chr17:80112537	CCDC57	-0.42	-6.6	-0.38	2.18e-10	Life satisfaction;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg07556730	chr11:679706	DEAF1	0.47	6.63	0.38	1.84e-10	Fibrinogen levels;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg07805240	chr7:8008383	GLCCI1	-0.47	-6.26	-0.36	1.51e-9	Ulcerative colitis;
CESC	cis	rs35079168	0.923	rs11103473	chr9:137287629	A/T	cg13941235	chr9:137270186	RXRA	0.31	5.62	0.33	4.88e-8	Intelligence;
CESC	cis	rs4148883	0.713	rs3828541	chr4:100042262	A/G	cg13256891	chr4:100009986	ADH5	0.57	7.6	0.42	4.99e-13	Alcohol dependence;
CESC	cis	rs2576037	0.526	rs1789152	chr18:44433092	G/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.57	-8.07	-0.44	2.52e-14	Personality dimensions;
CESC	cis	rs4474465	1.000	rs7943815	chr11:78173160	A/G	cg27205649	chr11:78285834	NARS2	-0.41	-5.11	-0.3	6.27e-7	Alzheimer's disease (survival time);
CESC	cis	rs9297145	0.761	rs62473015	chr7:98763301	G/A	cg05967295	chr7:98741636	SMURF1	0.9	9.34	0.5	4.06e-18	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
CESC	cis	rs7267979	0.844	rs4423675	chr20:25402778	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.78	-14.59	-0.67	8.55e-36	Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs7819412	0.715	rs35223712	chr8:11043926	C/T	cg15556689	chr8:8085844	FLJ10661	-0.53	-6.47	-0.37	4.65e-10	Triglycerides;
CESC	cis	rs60843830	1.000	rs10193373	chr2:281886	T/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.78	9.95	0.52	4.96e-20	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs8050907	0.744	rs8063956	chr16:4531761	T/C	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.89	6.22	0.36	1.94e-9	Obesity-related traits;
CESC	cis	rs10504229	1.000	rs17805656	chr8:58180318	T/C	cg24829409	chr8:58192753	C8orf71	-0.76	-10.0	-0.52	3.53e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs116095464	0.558	rs10043002	chr5:226753	G/A	cg22496380	chr5:211416	CCDC127	-0.74	-8.66	-0.47	4.79e-16	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12095720	chr17:72978304	NA	0.55	6.34	0.36	9.63e-10	Gut microbiome composition (summer);
CESC	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg24642844	chr7:1081250	C7orf50	-0.77	-9.63	-0.51	5.27e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs274567	0.501	rs2631368	chr5:131705297	T/G	cg24060327	chr5:131705240	SLC22A5	0.8	11.21	0.57	3.88e-24	Blood metabolite levels;
CESC	cis	rs1707322	1.000	rs11211235	chr1:46440375	G/A	cg03146154	chr1:46216737	IPP	0.72	9.82	0.52	1.31e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2249625	0.545	rs10498880	chr6:72882183	G/T	cg18830697	chr6:72922368	RIMS1	0.42	5.94	0.34	8.7e-9	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CESC	cis	rs6594499	0.903	rs1438672	chr5:110467753	G/A	cg04022379	chr5:110408740	TSLP	0.34	5.99	0.35	6.74e-9	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs2228479	0.850	rs74251568	chr16:89903416	A/C	cg14709524	chr16:89940631	TCF25	0.88	6.1	0.35	3.82e-9	Skin colour saturation;
CESC	cis	rs4665809	0.878	rs6720312	chr2:26364934	A/G	cg04944784	chr2:26401820	FAM59B	0.74	8.77	0.47	2.15e-16	Gut microbiome composition (summer);
CESC	cis	rs7224737	1.000	rs8074708	chr17:40286354	A/G	cg20291162	chr17:40259547	DHX58	0.44	5.96	0.34	7.93e-9	Fibrinogen levels;
CESC	cis	rs6933660	0.683	rs6916340	chr6:151779064	T/C	cg02564969	chr6:151773285	C6orf211;RMND1	0.67	9.42	0.5	2.33e-18	Menarche (age at onset);
CESC	cis	rs13108904	0.967	rs12642396	chr4:1293055	C/A	cg00684032	chr4:1343700	KIAA1530	0.39	5.46	0.32	1.11e-7	Obesity-related traits;
CESC	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg18538332	chr22:24372958	LOC391322	-0.77	-11.28	-0.57	2.4e-24	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs9660992	0.573	rs12140422	chr1:205187981	G/A	cg00857998	chr1:205179979	DSTYK	0.54	6.73	0.38	1.06e-10	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs769267	0.740	rs2965185	chr19:19525792	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.57	7.1	0.4	1.14e-11	Tonsillectomy;
CESC	cis	rs7666738	0.830	rs1593569	chr4:99017485	C/G	cg18180107	chr4:99064573	C4orf37	0.41	5.34	0.31	1.98e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg20703320	chr12:111021296	PPTC7	-0.5	-6.33	-0.36	1.01e-9	Asthma;
CESC	cis	rs9649213	0.555	rs6968193	chr7:97915902	C/T	cg21770322	chr7:97807741	LMTK2	0.55	8.07	0.44	2.41e-14	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7666738	0.830	rs1834647	chr4:98882915	G/A	cg03467027	chr4:99064603	C4orf37	0.42	5.17	0.3	4.56e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs72781680	0.533	rs34668726	chr2:23895901	C/G	cg08917208	chr2:24149416	ATAD2B	1.01	9.71	0.51	2.84e-19	Lymphocyte counts;
CESC	cis	rs6835098	0.961	rs11737748	chr4:174130503	T/C	cg08422745	chr4:174089978	GALNT7	0.73	9.26	0.49	7.24e-18	Dementia and core Alzheimer's disease neuropathologic changes;
CESC	cis	rs258892	0.895	rs13181060	chr5:72071769	T/C	cg21869765	chr5:72125136	TNPO1	-0.37	-5.05	-0.3	8.41e-7	Small cell lung carcinoma;
CESC	trans	rs997295	0.529	rs12592315	chr15:68040266	A/G	cg12489069	chr17:26898961	PIGS	0.47	6.06	0.35	4.63e-9	Motion sickness;
CESC	cis	rs79349575	0.811	rs80032154	chr17:47014992	C/A	cg16584676	chr17:46985605	UBE2Z	0.49	5.87	0.34	1.31e-8	Type 2 diabetes;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg09430954	chr19:46236890	NA	0.48	6.63	0.38	1.91e-10	Fibrinogen levels;
CESC	cis	rs561341	1.000	rs72825740	chr17:30338356	A/G	cg12193833	chr17:30244370	NA	-0.72	-6.32	-0.36	1.07e-9	Hip circumference adjusted for BMI;
CESC	cis	rs11098499	0.954	rs12505469	chr4:120249585	C/T	cg09307838	chr4:120376055	NA	0.91	12.63	0.61	6.24e-29	Corneal astigmatism;
CESC	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg11301795	chr4:187892539	NA	-0.75	-11.49	-0.58	4.49e-25	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7666738	0.830	rs35685312	chr4:98858521	G/A	cg17366294	chr4:99064904	C4orf37	0.55	7.72	0.43	2.38e-13	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11078597	0.731	rs2287322	chr17:1641035	A/G	cg18436246	chr17:1640651	WDR81	0.63	7.64	0.42	4.07e-13	Serum albumin level;
CESC	cis	rs9733	0.596	rs11204697	chr1:150658971	C/T	cg18016565	chr1:150552671	MCL1	0.33	5.16	0.3	4.96e-7	Tonsillectomy;
CESC	cis	rs7542091	0.579	rs34638782	chr1:210032055	C/G	cg05527609	chr1:210001259	C1orf107	-0.45	-5.72	-0.33	2.91e-8	Monobrow;
CESC	cis	rs7116495	0.867	rs4378421	chr11:71761996	T/C	cg07596299	chr11:71824057	C11orf51	-1.01	-6.0	-0.35	6.58e-9	Severe influenza A (H1N1) infection;
CESC	cis	rs7666738	0.830	rs11725652	chr4:98878362	G/A	cg05340658	chr4:99064831	C4orf37	0.75	11.15	0.56	6.44e-24	Colonoscopy-negative controls vs population controls;
CESC	cis	rs617791	0.530	rs7952056	chr11:65744597	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.44	-5.2	-0.3	4e-7	Breast cancer;
CESC	cis	rs7799006	0.755	rs12534131	chr7:2294123	C/T	cg12745145	chr7:2261452	MAD1L1	-0.32	-5.09	-0.3	6.8e-7	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs4835473	0.801	rs76574827	chr4:144658456	G/A	cg25736465	chr4:144833511	NA	-0.33	-5.25	-0.31	3.1e-7	Immature fraction of reticulocytes;
CESC	cis	rs1862618	0.671	rs2255726	chr5:56243128	T/C	cg22800045	chr5:56110881	MAP3K1	-0.6	-7.71	-0.43	2.55e-13	Initial pursuit acceleration;
CESC	cis	rs7845219	0.539	rs13271644	chr8:95853948	A/G	cg23172400	chr8:95962367	TP53INP1	-0.31	-5.71	-0.33	3.07e-8	Type 2 diabetes;
CESC	cis	rs4862750	0.914	rs1863405	chr4:187874528	G/T	cg03452623	chr4:187889614	NA	0.84	14.53	0.67	1.35e-35	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs11997175	0.766	rs4442096	chr8:33691039	T/C	ch.8.33884649F	chr8:33765107	NA	0.44	5.56	0.32	6.56e-8	Body mass index;
CESC	cis	rs4835473	0.864	rs1597446	chr4:144629491	A/G	cg25736465	chr4:144833511	NA	0.4	6.17	0.35	2.59e-9	Immature fraction of reticulocytes;
CESC	cis	rs8038465	0.592	rs1542580	chr15:73935834	C/G	cg15420318	chr15:73925796	NPTN	0.51	7.15	0.4	8.69e-12	Liver enzyme levels (gamma-glutamyl transferase);
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg07505334	chr10:13629015	PRPF18	-0.47	-6.42	-0.37	6.26e-10	Thyroid stimulating hormone;
CESC	cis	rs854765	0.929	rs2955360	chr17:17974887	G/A	cg16928487	chr17:17741425	SREBF1	0.53	8.99	0.48	4.88e-17	Total body bone mineral density;
CESC	cis	rs7582720	0.778	rs6719001	chr2:203777903	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.38	0.41	1.99e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs12618769	0.652	rs72823801	chr2:99235055	A/G	cg10123293	chr2:99228465	UNC50	0.41	5.4	0.31	1.51e-7	Bipolar disorder;
CESC	cis	rs875971	1.000	rs6963646	chr7:65685767	T/C	cg18876405	chr7:65276391	NA	-0.52	-7.16	-0.4	7.95e-12	Aortic root size;
CESC	cis	rs8031584	0.958	rs7176569	chr15:31244495	G/T	cg08704250	chr15:31115839	NA	0.62	8.01	0.44	3.54e-14	Huntington's disease progression;
CESC	cis	rs9916302	0.851	rs7220650	chr17:37487168	A/G	cg15445000	chr17:37608096	MED1	-0.42	-6.97	-0.39	2.51e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs7811142	0.830	rs77861211	chr7:99962096	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.89	8.82	0.48	1.51e-16	Platelet count;
CESC	cis	rs4237845	0.537	rs11172369	chr12:58280592	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.52	5.75	0.33	2.5e-8	Intelligence (multi-trait analysis);
CESC	cis	rs9388451	0.903	rs9388446	chr6:126064920	T/A	cg10911889	chr6:126070802	HEY2	0.39	5.47	0.32	1.05e-7	Brugada syndrome;
CESC	cis	rs72627123	0.867	rs74492048	chr14:74439895	C/T	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.76	5.04	0.3	8.57e-7	Morning vs. evening chronotype;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg02803047	chr19:50643420	SNAR-B1;SNAR-B2	-0.36	-6.33	-0.36	1.04e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs10782582	0.545	rs12138018	chr1:76186794	T/C	cg10523679	chr1:76189770	ACADM	-0.44	-5.16	-0.3	4.95e-7	Daytime sleep phenotypes;
CESC	cis	rs7814319	0.674	rs2292835	chr8:97243720	G/A	cg20787634	chr8:97240163	UQCRB	-0.55	-6.47	-0.37	4.6e-10	Lung function (FVC);
CESC	cis	rs12701220	0.553	rs7782024	chr7:1157502	G/T	cg04025307	chr7:1156635	C7orf50	0.45	5.3	0.31	2.41e-7	Bronchopulmonary dysplasia;
CESC	cis	rs1218582	0.772	rs4845694	chr1:154911651	C/G	cg24250549	chr1:154909240	PMVK	0.71	10.45	0.54	1.29e-21	Prostate cancer;
CESC	cis	rs4604732	0.631	rs75600450	chr1:247625492	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.57	7.1	0.4	1.11e-11	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs11645898	0.687	rs72787058	chr16:72105084	C/T	cg14768367	chr16:72042858	DHODH	-0.6	-5.13	-0.3	5.47e-7	Blood protein levels;
CESC	cis	rs2839186	0.588	rs7280110	chr21:47619039	G/A	cg00612595	chr21:47717864	NA	0.42	5.69	0.33	3.43e-8	Testicular germ cell tumor;
CESC	cis	rs6032067	0.929	rs6017510	chr20:43831785	A/G	cg10761708	chr20:43804764	PI3	0.52	6.32	0.36	1.07e-9	Blood protein levels;
CESC	cis	rs9611565	0.592	rs80477	chr22:42001183	C/T	cg06634786	chr22:41940651	POLR3H	0.55	5.96	0.34	8e-9	Vitiligo;
CESC	cis	rs9660180	0.837	rs915292	chr1:1792157	A/C	cg20999797	chr1:1681921	NA	0.28	5.35	0.31	1.9e-7	Body mass index;
CESC	cis	rs9549260	0.755	rs3900833	chr13:41188292	A/G	cg21288729	chr13:41239152	FOXO1	0.61	7.66	0.43	3.49e-13	Red blood cell count;
CESC	cis	rs12220238	1.000	rs10824084	chr10:75911415	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.66	6.68	0.38	1.42e-10	Soluble interleukin-2 receptor subunit alpha;
CESC	cis	rs7666738	0.680	rs34267968	chr4:99002574	A/T	cg17366294	chr4:99064904	C4orf37	0.6	8.61	0.47	6.47e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs72901758	0.696	rs72909029	chr17:76249451	A/G	cg26068271	chr17:76253126	NA	0.43	6.16	0.35	2.71e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
CESC	cis	rs78456975	0.657	rs116217838	chr2:1569173	T/C	cg12573674	chr2:1569213	NA	-0.47	-5.37	-0.31	1.68e-7	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs7267979	0.932	rs446649	chr20:25467359	A/G	cg08601574	chr20:25228251	PYGB	0.37	5.62	0.33	4.9e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg12419862	chr22:24373484	LOC391322	-0.74	-10.49	-0.54	9.52e-22	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs7116495	0.609	rs4387373	chr11:71774908	A/G	cg07596299	chr11:71824057	C11orf51	-0.93	-5.87	-0.34	1.32e-8	Severe influenza A (H1N1) infection;
CESC	cis	rs2842992	0.709	rs1853257	chr6:160212710	C/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.76	9.53	0.51	1.09e-18	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs3733585	0.624	rs76574510	chr4:9953252	T/A	cg02734326	chr4:10020555	SLC2A9	-0.39	-5.64	-0.33	4.45e-8	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs13191362	1.000	rs13192894	chr6:163052444	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.84	9.0	0.48	4.4e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs3806933	0.522	rs13186912	chr5:110456704	A/T	cg04022379	chr5:110408740	TSLP	-0.43	-7.22	-0.41	5.48e-12	Eosinophilic esophagitis;
CESC	cis	rs9300255	0.722	rs28592876	chr12:123866429	G/A	cg00376283	chr12:123451042	ABCB9	-0.59	-6.67	-0.38	1.46e-10	Neutrophil percentage of white cells;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04262179	chr1:178482030	C1orf49	-0.62	-6.82	-0.39	6.03e-11	Gut microbiome composition (summer);
CESC	cis	rs2637266	0.626	rs2583067	chr10:78555804	A/G	cg18941641	chr10:78392320	NA	0.41	7.79	0.43	1.51e-13	Pulmonary function;
CESC	cis	rs1707322	0.691	rs61784803	chr1:46179271	C/A	cg06784218	chr1:46089804	CCDC17	-0.43	-7.58	-0.42	5.65e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg11717552	chr14:23311678	MMP14	0.48	6.85	0.39	5.14e-11	Fibrinogen levels;
CESC	cis	rs9916302	0.904	rs35285898	chr17:37555872	A/C	cg15445000	chr17:37608096	MED1	-0.41	-6.74	-0.38	9.67e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs7772486	0.743	rs9376955	chr6:145949404	T/A	cg05347473	chr6:146136440	FBXO30	0.49	6.51	0.37	3.71e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs72945132	0.882	rs3900797	chr11:70186614	C/T	cg00319359	chr11:70116639	PPFIA1	0.71	6.83	0.39	5.73e-11	Coronary artery disease;
CESC	cis	rs7618915	0.571	rs1961958	chr3:52585990	A/G	cg18099408	chr3:52552593	STAB1	-0.34	-5.61	-0.33	5.02e-8	Bipolar disorder;
CESC	cis	rs832540	0.564	rs33329	chr5:56145068	T/C	cg24531977	chr5:56204891	C5orf35	-0.49	-6.0	-0.35	6.46e-9	Coronary artery disease;
CESC	cis	rs12497850	0.931	rs7647813	chr3:48833348	G/T	cg06212747	chr3:49208901	KLHDC8B	0.65	8.81	0.48	1.68e-16	Parkinson's disease;
CESC	cis	rs965469	0.843	rs6037597	chr20:3408374	A/G	cg25506879	chr20:3388711	C20orf194	-0.47	-5.12	-0.3	5.96e-7	IFN-related cytopenia;
CESC	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg06873352	chr17:61820015	STRADA	0.73	13.07	0.63	1.78e-30	Prudent dietary pattern;
CESC	cis	rs7809950	0.784	rs7803102	chr7:107248929	T/G	cg23024343	chr7:107201750	COG5	0.43	6.06	0.35	4.74e-9	Coronary artery disease;
CESC	cis	rs400736	0.562	rs10864331	chr1:8172178	A/G	cg25007680	chr1:8021821	PARK7	-0.47	-6.06	-0.35	4.64e-9	Response to antidepressants and depression;
CESC	cis	rs2777491	1.000	rs7177641	chr15:41743426	C/T	cg02330683	chr15:41787940	ITPKA	0.49	7.24	0.41	5.01e-12	Ulcerative colitis;
CESC	cis	rs7539409	0.651	rs10747407	chr1:84314754	G/A	cg10977910	chr1:84465055	TTLL7	0.78	7.42	0.41	1.61e-12	Alzheimer's disease;
CESC	cis	rs1552244	1.000	rs111392584	chr3:10075991	A/G	cg00149659	chr3:10157352	C3orf10	0.76	9.51	0.5	1.26e-18	Alzheimer's disease;
CESC	cis	rs10504229	1.000	rs67344620	chr8:58187537	C/A	cg22535103	chr8:58192502	C8orf71	-1.05	-13.08	-0.63	1.71e-30	Developmental language disorder (linguistic errors);
CESC	cis	rs5769765	1.000	rs761879	chr22:50241210	G/A	cg26441486	chr22:50317300	CRELD2	-0.37	-5.11	-0.3	6.26e-7	Schizophrenia;
CESC	cis	rs7927592	0.913	rs7925275	chr11:68290433	T/C	cg16797656	chr11:68205561	LRP5	0.37	5.04	0.3	8.47e-7	Total body bone mineral density;
CESC	cis	rs6121246	0.609	rs6087783	chr20:30421224	T/G	cg13852791	chr20:30311386	BCL2L1	0.84	10.86	0.55	5.92e-23	Mean corpuscular hemoglobin;
CESC	cis	rs7131987	0.676	rs10843407	chr12:29550244	A/G	cg09582351	chr12:29534625	ERGIC2	0.35	5.54	0.32	7.23e-8	QT interval;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg19794706	chr14:75643232	TMED10	-0.42	-6.07	-0.35	4.4e-9	Fibrinogen levels;
CESC	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg10150615	chr22:24372951	LOC391322	-0.59	-7.99	-0.44	4.18e-14	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs7178572	0.633	rs7162637	chr15:77843365	A/G	cg22256960	chr15:77711686	NA	-0.53	-6.58	-0.37	2.47e-10	Type 2 diabetes;
CESC	cis	rs4253772	0.591	rs6007748	chr22:46657798	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.69	7.98	0.44	4.41e-14	LDL cholesterol;Cholesterol, total;
CESC	cis	rs6752107	1.000	rs2241878	chr2:234183718	T/C	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.38	5.68	0.33	3.53e-8	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs9389248	0.690	rs728030	chr6:135246294	G/T	cg22676075	chr6:135203613	NA	-0.59	-8.35	-0.46	3.96e-15	High light scatter reticulocyte percentage of red cells;
CESC	cis	rs9815354	0.855	rs73071261	chr3:42003369	C/A	cg03022575	chr3:42003672	ULK4	0.66	5.77	0.33	2.17e-8	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs7827545	1.000	rs6578234	chr8:135566363	A/G	cg17885191	chr8:135476712	NA	0.47	6.22	0.36	1.94e-9	Hypertension (SNP x SNP interaction);
CESC	cis	rs9487051	0.639	rs2884012	chr6:109598221	C/T	cg21918786	chr6:109611834	NA	-0.38	-5.52	-0.32	8.19e-8	Reticulocyte fraction of red cells;
CESC	cis	rs9308731	0.591	rs6542350	chr2:111944740	C/T	cg04202892	chr2:111875749	ACOXL	0.41	5.81	0.34	1.8e-8	Chronic lymphocytic leukemia;
CESC	cis	rs1008375	1.000	rs13119927	chr4:17691640	G/A	cg02297831	chr4:17616191	MED28	-0.55	-6.48	-0.37	4.38e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs11792861	0.962	rs72607162	chr9:111793719	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.46	5.76	0.33	2.35e-8	Menarche (age at onset);
CESC	cis	rs10504229	1.000	rs56344560	chr8:58180626	C/G	cg22535103	chr8:58192502	C8orf71	-1.04	-13.3	-0.63	2.89e-31	Developmental language disorder (linguistic errors);
CESC	cis	rs11123610	0.520	rs12711962	chr2:3717985	C/T	cg10645314	chr2:3704589	ALLC	-0.49	-5.54	-0.32	7.25e-8	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CESC	cis	rs6060717	0.536	rs11696912	chr20:34497660	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.72	6.7	0.38	1.24e-10	Hip circumference adjusted for BMI;
CESC	cis	rs314370	0.855	rs17883557	chr7:100494949	G/T	cg10426581	chr7:100472382	SRRT	0.84	8.18	0.45	1.23e-14	Resting heart rate;
CESC	trans	rs7819412	0.807	rs4840542	chr8:10944809	G/T	cg06636001	chr8:8085503	FLJ10661	-0.51	-6.16	-0.35	2.76e-9	Triglycerides;
CESC	cis	rs250677	0.687	rs250672	chr5:148446110	A/G	cg18129178	chr5:148520854	ABLIM3	-0.51	-5.83	-0.34	1.58e-8	Breast cancer;
CESC	cis	rs801193	0.636	rs2659895	chr7:66196471	C/A	cg12463550	chr7:65579703	CRCP	0.56	7.24	0.41	4.94e-12	Aortic root size;
CESC	cis	rs7216064	0.954	rs12602556	chr17:65826861	A/G	cg12091567	chr17:66097778	LOC651250	-0.86	-8.5	-0.46	1.42e-15	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs78366141	0.536	rs76806573	chr4:89682729	C/T	cg01026744	chr4:89619053	NAP1L5;HERC3	0.78	5.23	0.31	3.48e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
CESC	cis	rs546131	0.820	rs744841	chr11:34857667	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.46	5.9	0.34	1.13e-8	Lung disease severity in cystic fibrosis;
CESC	cis	rs10911232	0.507	rs35782443	chr1:183051502	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.85	13.7	0.64	1.21e-32	Hypertriglyceridemia;
CESC	cis	rs1348850	0.526	rs7607073	chr2:178375065	C/A	cg23306229	chr2:178417860	TTC30B	0.78	6.92	0.39	3.32e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs60871478	1.000	rs62432899	chr7:826542	G/C	cg15782153	chr7:917662	C7orf20	-0.49	-5.41	-0.32	1.4e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs6121246	0.609	rs2376998	chr20:30340663	T/C	cg13852791	chr20:30311386	BCL2L1	0.81	10.36	0.54	2.4e-21	Mean corpuscular hemoglobin;
CESC	cis	rs6570726	1.000	rs436066	chr6:145847127	C/T	cg23711669	chr6:146136114	FBXO30	0.77	11.53	0.58	3.48e-25	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs9951602	0.512	rs77157626	chr18:76644771	C/T	cg02800362	chr5:177631904	HNRNPAB	0.62	8.1	0.45	1.96e-14	Obesity-related traits;
CESC	cis	rs3858526	0.883	rs10769326	chr11:5934358	C/T	cg05234568	chr11:5960015	NA	-0.49	-5.77	-0.33	2.15e-8	DNA methylation (variation);
CESC	cis	rs1799949	1.000	rs4534897	chr17:41431808	A/G	cg25072359	chr17:41440525	NA	0.48	6.54	0.37	3.13e-10	Menopause (age at onset);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg21300719	chr1:201097122	NA	0.48	6.96	0.39	2.67e-11	Fibrinogen levels;
CESC	cis	rs9300255	0.537	rs1618679	chr12:123650714	A/G	cg00376283	chr12:123451042	ABCB9	0.7	8.86	0.48	1.16e-16	Neutrophil percentage of white cells;
CESC	cis	rs977987	0.806	rs11648176	chr16:75456423	C/G	cg03315344	chr16:75512273	CHST6	0.41	5.89	0.34	1.16e-8	Dupuytren's disease;
CESC	cis	rs4588572	0.643	rs10075726	chr5:77669053	T/A	cg11547950	chr5:77652471	NA	0.44	5.59	0.32	5.56e-8	Triglycerides;
CESC	cis	rs7208859	0.623	rs7220999	chr17:29149298	C/T	cg13385521	chr17:29058706	SUZ12P	0.8	6.38	0.37	7.71e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs7615952	0.641	rs12487875	chr3:125787224	C/A	cg04553112	chr3:125709451	NA	-0.54	-5.75	-0.33	2.4e-8	Blood pressure (smoking interaction);
CESC	cis	rs1800795	0.901	rs2069833	chr7:22767664	C/T	cg05265849	chr7:22767390	IL6	0.5	6.5	0.37	3.86e-10	Cerebrospinal fluid clusterin levels in APOEe4- carriers;
CESC	cis	rs9894429	1.000	rs7222241	chr17:79574714	C/G	cg18240062	chr17:79603768	NPLOC4	0.71	9.98	0.52	3.97e-20	Eye color traits;
CESC	cis	rs1801251	1.000	rs13035829	chr2:233604487	A/T	cg25237894	chr2:233734115	C2orf82	0.44	7.55	0.42	7.05e-13	Coronary artery disease;
CESC	cis	rs9322193	0.923	rs10747276	chr6:150079875	G/A	cg13206674	chr6:150067644	NUP43	0.46	6.67	0.38	1.5e-10	Lung cancer;
CESC	cis	rs5769765	0.773	rs9616383	chr22:50313014	T/C	cg02269571	chr22:50332266	NA	-0.56	-6.99	-0.39	2.26e-11	Schizophrenia;
CESC	cis	rs1797885	1.000	rs709164	chr3:12514157	A/G	cg26432171	chr3:12704882	RAF1	-0.5	-6.47	-0.37	4.75e-10	Immature fraction of reticulocytes;
CESC	cis	rs597539	0.652	rs10792001	chr11:68637737	G/C	cg18350739	chr11:68623251	NA	-0.46	-7.02	-0.4	1.88e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs5750830	0.649	rs5750815	chr22:39798449	T/C	cg02038168	chr22:39784481	NA	-0.62	-7.72	-0.43	2.38e-13	Intelligence (multi-trait analysis);
CESC	cis	rs9640161	0.789	rs28439010	chr7:150046276	C/T	cg27494647	chr7:150038898	RARRES2	0.41	5.08	0.3	7.15e-7	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs9303401	0.659	rs56162835	chr17:56687315	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	1.03	13.13	0.63	1.12e-30	Cognitive test performance;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg20560906	chr3:47459876	SCAP	0.53	7.07	0.4	1.39e-11	Fibrinogen levels;
CESC	cis	rs9311474	0.508	rs12637627	chr3:52619962	G/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	7.47	0.42	1.18e-12	Electroencephalogram traits;
CESC	cis	rs5750830	0.649	rs5757663	chr22:39821319	T/C	cg01416388	chr22:39784598	NA	-0.59	-7.18	-0.4	6.84e-12	Intelligence (multi-trait analysis);
CESC	cis	rs763014	1.000	rs2269558	chr16:682250	C/T	cg07343612	chr16:622815	PIGQ	-0.54	-7.96	-0.44	5.21e-14	Height;
CESC	cis	rs965469	1.000	rs6037567	chr20:3332160	C/A	cg25506879	chr20:3388711	C20orf194	-0.54	-5.78	-0.33	2.14e-8	IFN-related cytopenia;
CESC	cis	rs7149337	0.804	rs4131981	chr14:51667504	A/T	cg23942311	chr14:51606299	NA	-0.42	-7.04	-0.4	1.68e-11	Cancer;
CESC	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg07677032	chr17:61819896	STRADA	0.46	6.18	0.35	2.43e-9	Prudent dietary pattern;
CESC	cis	rs11098499	0.913	rs11098496	chr4:120167466	C/G	cg09307838	chr4:120376055	NA	0.86	11.46	0.58	5.96e-25	Corneal astigmatism;
CESC	cis	rs7085104	0.632	rs6162	chr10:104596981	G/A	cg15744005	chr10:104629667	AS3MT	-0.33	-5.16	-0.3	4.91e-7	Immature fraction of reticulocytes;Schizophrenia;
CESC	cis	rs4566357	0.595	rs10206912	chr2:227921095	A/T	cg05526886	chr2:227700861	RHBDD1	-0.48	-6.5	-0.37	4.04e-10	Coronary artery disease;
CESC	cis	rs936229	0.768	rs11072509	chr15:75114374	C/G	cg14664628	chr15:75095509	CSK	-1.0	-16.17	-0.7	2.21e-41	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CESC	trans	rs6499188	0.522	rs10153230	chr16:68671741	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.65	8.12	0.45	1.76e-14	Ulcerative colitis;
CESC	cis	rs1552244	1.000	rs6793396	chr3:10110927	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.8	-10.46	-0.54	1.15e-21	Alzheimer's disease;
CESC	cis	rs2050392	0.517	rs2489847	chr10:30743673	G/A	cg25182066	chr10:30743637	MAP3K8	-0.56	-8.23	-0.45	8.31e-15	Inflammatory bowel disease;
CESC	cis	rs10744422	0.925	rs2292132	chr12:123332834	T/C	cg25930673	chr12:123319894	HIP1R	-0.72	-5.73	-0.33	2.79e-8	Schizophrenia;
CESC	cis	rs8060686	0.858	rs10468274	chr16:67922342	C/T	cg26727032	chr16:67993705	SLC12A4	-0.65	-9.71	-0.51	2.86e-19	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs5753618	0.554	rs5753648	chr22:31879465	A/G	cg13145458	chr22:31556086	RNF185	-0.55	-6.3	-0.36	1.22e-9	Colorectal cancer;
CESC	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg24503407	chr1:205819492	PM20D1	0.82	13.96	0.65	1.43e-33	Menarche (age at onset);
CESC	cis	rs96067	0.805	rs12033825	chr1:36600311	C/T	cg24686825	chr1:36642396	MAP7D1	-0.52	-5.71	-0.33	2.99e-8	Corneal structure;
CESC	cis	rs4689388	0.926	rs9998835	chr4:6293237	C/G	cg14416269	chr4:6271139	WFS1	0.46	7.83	0.43	1.14e-13	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs473651	0.716	rs548179	chr2:239320505	G/A	cg18131467	chr2:239335373	ASB1	0.97	18.44	0.75	2.08e-49	Multiple system atrophy;
CESC	cis	rs965469	1.000	rs2236123	chr20:3305305	C/G	cg25506879	chr20:3388711	C20orf194	0.51	5.29	0.31	2.61e-7	IFN-related cytopenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26270066	chr15:43941407	CATSPER2	-0.65	-8.0	-0.44	3.78e-14	Gut microbiome composition (summer);
CESC	cis	rs7811142	1.000	rs11773661	chr7:100073069	G/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.05	10.31	0.54	3.54e-21	Platelet count;
CESC	trans	rs877282	0.853	rs7092805	chr10:756246	G/A	cg22713356	chr15:30763199	NA	1.01	8.95	0.48	6.15e-17	Uric acid levels;
CESC	cis	rs2576037	0.526	rs9962523	chr18:44486414	A/T	cg19077165	chr18:44547161	KATNAL2	-0.55	-7.87	-0.44	9.07e-14	Personality dimensions;
CESC	cis	rs3096299	0.658	rs4291902	chr16:89560315	G/C	cg02034447	chr16:89574710	SPG7	0.52	6.7	0.38	1.26e-10	Multiple myeloma (IgH translocation);
CESC	cis	rs17345786	0.511	rs13061565	chr3:101392270	T/C	cg12386194	chr3:101231763	SENP7	0.44	5.48	0.32	9.88e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs829883	0.902	rs1620317	chr12:98890566	T/C	cg25150519	chr12:98850993	NA	0.7	9.64	0.51	4.82e-19	Colorectal adenoma (advanced);
CESC	cis	rs12477438	0.715	rs6724476	chr2:99627316	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.64	-8.73	-0.47	2.94e-16	Chronic sinus infection;
CESC	cis	rs2820292	0.500	rs61824384	chr1:201859213	A/G	cg06775570	chr1:201857621	SHISA4	-0.34	-5.46	-0.32	1.07e-7	Waist circumference;Body mass index (joint analysis main effects and smoking interaction);Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);
CESC	cis	rs7843479	0.601	rs2306646	chr8:21846586	C/G	cg17168535	chr8:21777572	XPO7	0.75	12.27	0.6	1.04e-27	Mean corpuscular volume;
CESC	cis	rs12142240	0.698	rs56130131	chr1:46861306	A/C	cg10495392	chr1:46806563	NSUN4	0.56	6.15	0.35	2.91e-9	Menopause (age at onset);
CESC	cis	rs2625529	1.000	rs2625529	chr15:72118777	C/G	cg16672083	chr15:72433130	SENP8	0.5	6.75	0.38	9.26e-11	Red blood cell count;
CESC	cis	rs3736485	0.966	rs10851500	chr15:51783820	T/C	cg08986416	chr15:51914746	DMXL2	-0.41	-5.24	-0.31	3.24e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs7959452	0.570	rs10878964	chr12:69720691	T/G	cg20891283	chr12:69753455	YEATS4	0.76	11.16	0.57	5.65e-24	Blood protein levels;
CESC	cis	rs7635838	0.892	rs7372723	chr3:11466511	G/A	cg00170343	chr3:11313890	ATG7	0.43	5.7	0.33	3.27e-8	HDL cholesterol;
CESC	cis	rs17376456	0.877	rs10476526	chr5:93461916	G/A	cg25358565	chr5:93447407	FAM172A	1.15	11.8	0.59	4.11e-26	Diabetic retinopathy;
CESC	cis	rs875971	0.862	rs880166	chr7:65670762	T/C	cg12463550	chr7:65579703	CRCP	-0.49	-6.28	-0.36	1.4e-9	Aortic root size;
CESC	cis	rs12893668	0.572	rs11846404	chr14:104156108	C/G	cg08213375	chr14:104286397	PPP1R13B	0.31	5.22	0.31	3.53e-7	Reticulocyte count;
CESC	cis	rs7086627	0.515	rs11202963	chr10:82210392	A/G	cg03267442	chr10:82210566	NA	-0.34	-5.63	-0.33	4.55e-8	Post bronchodilator FEV1;
CESC	cis	rs12956009	0.518	rs953291	chr18:44870499	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.51	6.75	0.38	9.47e-11	Educational attainment (years of education);
CESC	cis	rs10463316	0.817	rs7709507	chr5:150783349	C/T	cg03212797	chr5:150827313	SLC36A1	-0.43	-5.38	-0.31	1.64e-7	Metabolite levels (Pyroglutamine);
CESC	cis	rs7666738	0.609	rs28833816	chr4:98868866	T/C	cg05340658	chr4:99064831	C4orf37	0.59	7.46	0.42	1.26e-12	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2860975	0.620	rs2275622	chr10:96827178	T/C	cg09036531	chr10:96991505	NA	-0.38	-5.27	-0.31	2.85e-7	Immune response to smallpox vaccine (IL-6);
CESC	cis	rs561341	1.000	rs4795667	chr17:30244443	T/C	cg13647721	chr17:30228624	UTP6	0.59	5.3	0.31	2.42e-7	Hip circumference adjusted for BMI;
CESC	cis	rs7107174	1.000	rs11237468	chr11:78072833	A/G	cg02023728	chr11:77925099	USP35	0.38	5.34	0.31	2.05e-7	Testicular germ cell tumor;
CESC	cis	rs9611565	0.659	rs9611602	chr22:41908405	T/C	cg06634786	chr22:41940651	POLR3H	-0.64	-6.57	-0.37	2.67e-10	Vitiligo;
CESC	cis	rs2841277	0.738	rs1036713	chr14:105396693	C/G	cg19901468	chr14:105411992	AHNAK2	0.44	6.01	0.35	6.12e-9	Rheumatoid arthritis;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg15747848	chr15:40074985	FSIP1	-0.43	-6.06	-0.35	4.69e-9	Gambling;
CESC	cis	rs7267979	0.933	rs2387887	chr20:25427081	G/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.87	18.11	0.74	3e-48	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs6662572	0.703	rs17855317	chr1:46500613	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.49	5.49	0.32	9.51e-8	Blood protein levels;
CESC	cis	rs899997	1.000	rs11072793	chr15:79006442	C/T	cg04896959	chr15:78267971	NA	0.37	5.58	0.32	5.91e-8	Coronary artery disease or large artery stroke;
CESC	cis	rs4665809	0.590	rs35532350	chr2:26441605	T/C	cg22920501	chr2:26401640	FAM59B	-0.91	-10.33	-0.54	3.07e-21	Gut microbiome composition (summer);
CESC	cis	rs7949030	0.591	rs11231156	chr11:62366454	G/A	cg23462726	chr11:62437636	C11orf83;C11orf48	-0.4	-5.21	-0.3	3.82e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs10779751	0.770	rs11121695	chr1:11229515	G/A	cg08854313	chr1:11322531	MTOR	-0.74	-8.96	-0.48	6.01e-17	Body mass index;
CESC	cis	rs4595586	0.870	rs2388172	chr12:39290539	A/G	cg26384229	chr12:38710491	ALG10B	0.37	5.28	0.31	2.76e-7	Morning vs. evening chronotype;
CESC	cis	rs8014204	0.967	rs1319171	chr14:75334096	G/T	cg08847533	chr14:75593920	NEK9	-0.47	-5.88	-0.34	1.25e-8	Caffeine consumption;
CESC	cis	rs637571	0.565	rs633800	chr11:65638719	G/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.69	-8.63	-0.47	5.76e-16	Eosinophil percentage of white cells;
CESC	cis	rs6582630	0.555	rs11182193	chr12:38474090	C/G	cg13010199	chr12:38710504	ALG10B	0.47	6.11	0.35	3.63e-9	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs314370	0.951	rs13226502	chr7:100506381	C/T	cg10426581	chr7:100472382	SRRT	0.85	8.22	0.45	9.23e-15	Resting heart rate;
CESC	cis	rs7762018	0.556	rs78864023	chr6:170059755	T/A	cg19338460	chr6:170058176	WDR27	-0.98	-8.17	-0.45	1.29e-14	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs950027	0.620	rs1049518	chr15:45653367	G/A	cg21132104	chr15:45694354	SPATA5L1	0.66	8.52	0.46	1.22e-15	Response to fenofibrate (adiponectin levels);
CESC	cis	rs6089584	1.000	rs6089591	chr20:60570548	A/C	cg06108461	chr20:60628389	TAF4	-0.76	-11.3	-0.57	1.95e-24	Body mass index;
CESC	cis	rs847577	0.609	rs34320230	chr7:97785500	C/T	cg24562669	chr7:97807699	LMTK2	0.82	13.45	0.64	8.74e-32	Breast cancer;
CESC	cis	rs6752107	1.000	rs3792112	chr2:234176609	C/T	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.36	5.44	0.32	1.19e-7	Crohn's disease;Inflammatory bowel disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17412974	chr12:80496965	NA	-0.61	-7.09	-0.4	1.21e-11	Gut microbiome composition (summer);
CESC	cis	rs6772849	0.830	rs7633674	chr3:128355026	G/A	cg16766828	chr3:128327626	NA	-0.31	-5.06	-0.3	7.7e-7	Monocyte percentage of white cells;Monocyte count;
CESC	cis	rs4975616	0.869	rs455433	chr5:1336243	A/G	cg06550200	chr5:1325588	CLPTM1L	-0.69	-10.71	-0.55	1.76e-22	Lung cancer;
CESC	cis	rs10540	1.000	rs61876340	chr11:495699	A/C	cg03352830	chr11:487213	PTDSS2	0.74	7.24	0.41	4.78e-12	Body mass index;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg03818826	chr16:70323689	AARS	-0.47	-6.48	-0.37	4.34e-10	Asthma;
CESC	cis	rs6088580	0.524	rs4911437	chr20:33266149	G/T	cg07148914	chr20:33460835	GGT7	-0.44	-5.44	-0.32	1.24e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs1552244	0.572	rs66514627	chr3:10166632	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.68	-7.7	-0.43	2.64e-13	Alzheimer's disease;
CESC	cis	rs6860806	0.661	rs6871350	chr5:131580220	A/G	cg12564285	chr5:131593104	PDLIM4	0.4	6.07	0.35	4.37e-9	Breast cancer;
CESC	cis	rs34779708	0.966	rs34630580	chr10:35449228	A/G	cg04310649	chr10:35416472	CREM	-0.51	-6.23	-0.36	1.78e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs7618501	0.633	rs4688689	chr3:50035542	C/T	cg24308560	chr3:49941425	MST1R	-0.56	-8.05	-0.44	2.88e-14	Intelligence (multi-trait analysis);
CESC	cis	rs9467711	0.606	rs9358936	chr6:26370657	A/G	cg12826209	chr6:26865740	GUSBL1	0.62	5.22	0.31	3.66e-7	Autism spectrum disorder or schizophrenia;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg25913147	chr15:38545284	SPRED1	-0.49	-6.49	-0.37	4.2e-10	Asthma;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg23409613	chr14:53196849	STYX	-0.38	-6.1	-0.35	3.69e-9	Gambling;
CESC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg14492347	chr15:85292323	ZNF592	0.48	6.05	0.35	4.93e-9	Tetralogy of Fallot;
CESC	cis	rs5769765	0.671	rs138832	chr22:50178082	A/G	cg02269571	chr22:50332266	NA	-0.49	-6.19	-0.36	2.27e-9	Schizophrenia;
CESC	cis	rs597539	0.652	rs553875	chr11:68695144	T/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.79	9.63	0.51	5.09e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs6741892	0.536	rs6761563	chr2:38891406	A/T	cg05275752	chr2:38892887	GALM	-0.5	-6.83	-0.39	5.66e-11	5-HTT brain serotonin transporter levels;
CESC	trans	rs526821	0.595	rs624478	chr11:55340778	C/G	cg15704280	chr7:45808275	SEPT13	-0.53	-6.55	-0.37	2.9e-10	Pediatric bone mineral density (spine);
CESC	cis	rs8070624	0.543	rs8068175	chr17:17874486	C/T	cg16928487	chr17:17741425	SREBF1	-0.62	-10.37	-0.54	2.2e-21	Total body bone mineral density;
CESC	cis	rs9443645	0.901	rs9352675	chr6:79612800	G/A	cg05283184	chr6:79620031	NA	-0.43	-6.5	-0.37	3.91e-10	Intelligence (multi-trait analysis);
CESC	cis	rs34375054	0.526	rs117431213	chr12:125675271	C/G	cg25124228	chr12:125621409	AACS	-0.53	-6.26	-0.36	1.56e-9	Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs7223966	1.000	rs6504169	chr17:61709145	A/G	cg11494091	chr17:61959527	GH2	0.38	5.16	0.3	4.92e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs7618915	0.547	rs12496476	chr3:52708737	A/G	cg18404041	chr3:52824283	ITIH1	-0.4	-6.73	-0.38	1.07e-10	Bipolar disorder;
CESC	cis	rs9303401	0.614	rs34941454	chr17:57102742	T/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.9	11.27	0.57	2.59e-24	Cognitive test performance;
CESC	cis	rs3126085	0.935	rs12729662	chr1:152185750	G/A	cg03465714	chr1:152285911	FLG	0.43	5.04	0.3	8.56e-7	Atopic dermatitis;
CESC	cis	rs875971	1.000	rs709597	chr7:65825983	A/G	cg18876405	chr7:65276391	NA	-0.44	-5.86	-0.34	1.36e-8	Aortic root size;
CESC	cis	rs7772486	0.790	rs4896852	chr6:146284621	T/C	cg23711669	chr6:146136114	FBXO30	-0.93	-13.53	-0.64	4.58e-32	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4862750	0.872	rs9998173	chr4:187898778	T/A	cg03647317	chr4:187891568	NA	-0.39	-5.83	-0.34	1.57e-8	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs5756813	0.688	rs56114444	chr22:38123364	C/T	cg19894588	chr14:64061835	NA	-0.65	-7.47	-0.42	1.13e-12	Optic cup area;Vertical cup-disc ratio;
CESC	cis	rs1003719	0.715	rs2835658	chr21:38565201	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.6	-8.08	-0.44	2.33e-14	Eye color traits;
CESC	cis	rs9311474	0.607	rs28661185	chr3:52567188	G/T	cg15147215	chr3:52552868	STAB1	-0.32	-5.39	-0.31	1.53e-7	Electroencephalogram traits;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg07146535	chr1:63782988	NA	-0.5	-6.13	-0.35	3.23e-9	Thyroid stimulating hormone;
CESC	cis	rs9916302	0.904	rs57399933	chr17:37551189	A/G	cg15445000	chr17:37608096	MED1	-0.41	-6.74	-0.38	9.67e-11	Glomerular filtration rate (creatinine);
CESC	trans	rs11098499	0.599	rs3864142	chr4:120266191	A/T	cg25214090	chr10:38739885	LOC399744	0.59	7.99	0.44	4.13e-14	Corneal astigmatism;
CESC	cis	rs9287719	0.839	rs11683335	chr2:10756665	C/G	cg02196655	chr2:10830764	NOL10	-0.36	-5.53	-0.32	7.69e-8	Prostate cancer;
CESC	cis	rs1005277	0.602	rs2504142	chr10:38383793	C/T	cg00409905	chr10:38381863	ZNF37A	-0.45	-6.0	-0.35	6.61e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs8111998	0.826	rs59427371	chr19:22766462	C/T	cg19914732	chr19:22715077	NA	-0.37	-5.18	-0.3	4.45e-7	Corneal structure;
CESC	cis	rs7824557	0.564	rs2572404	chr8:11199584	A/G	cg21775007	chr8:11205619	TDH	0.52	7.53	0.42	7.81e-13	Retinal vascular caliber;
CESC	cis	rs9811920	0.928	rs9865713	chr3:99870299	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.4	5.22	0.31	3.59e-7	Axial length;
CESC	cis	rs941873	0.868	rs7898	chr10:81114959	C/T	cg09469691	chr10:81107165	PPIF	0.55	7.6	0.42	5.14e-13	Height;
CESC	cis	rs763014	0.932	rs2384972	chr16:674424	G/A	cg07256732	chr16:621771	PIGQ	-0.32	-5.62	-0.33	4.94e-8	Height;
CESC	trans	rs9650657	0.513	rs4841459	chr8:10782442	A/C	cg15556689	chr8:8085844	FLJ10661	-0.56	-7.04	-0.4	1.65e-11	Neuroticism;
CESC	cis	rs7590720	0.819	rs6435931	chr2:216892754	C/G	cg12620499	chr2:216877984	MREG	0.91	14.08	0.65	5.37e-34	Alcohol dependence;
CESC	cis	rs3857536	0.785	rs6455089	chr6:66944733	A/C	cg07460842	chr6:66804631	NA	-0.42	-5.29	-0.31	2.55e-7	Blood trace element (Cu levels);
CESC	cis	rs7811142	1.000	rs1073	chr7:100031612	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.78	6.78	0.38	7.61e-11	Platelet count;
CESC	cis	rs7552404	1.000	rs4949674	chr1:76213715	C/A	cg10523679	chr1:76189770	ACADM	0.71	8.42	0.46	2.39e-15	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs1707322	0.721	rs12049027	chr1:46118184	A/T	cg03146154	chr1:46216737	IPP	0.82	11.52	0.58	3.64e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs4819052	0.851	rs10470247	chr21:46659018	T/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.45	5.58	0.32	5.81e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs2072732	0.904	rs72629496	chr1:2953143	G/A	cg15211996	chr1:2936768	ACTRT2	0.35	5.05	0.3	8.22e-7	Plateletcrit;
CESC	cis	rs9814567	1.000	rs9834755	chr3:134206845	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.46	-6.37	-0.36	8.36e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs6500395	1.000	rs1558816	chr16:48704868	T/A	cg04672837	chr16:48644449	N4BP1	-0.51	-6.43	-0.37	6.05e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09782746	chr12:132553998	EP400	-0.54	-6.38	-0.36	7.92e-10	Gut microbiome composition (summer);
CESC	cis	rs7131987	0.675	rs3847678	chr12:29551560	A/C	cg09582351	chr12:29534625	ERGIC2	0.32	5.2	0.3	3.93e-7	QT interval;
CESC	cis	rs35849525	0.814	rs35491931	chr3:49993462	T/A	cg24110177	chr3:50126178	RBM5	-0.43	-5.1	-0.3	6.39e-7	Intelligence (multi-trait analysis);
CESC	cis	rs72781680	0.898	rs7569424	chr2:24036222	A/G	cg20701182	chr2:24300061	SF3B14	0.63	5.65	0.33	4.21e-8	Lymphocyte counts;
CESC	cis	rs1799949	1.000	rs12516	chr17:41196408	G/A	cg25072359	chr17:41440525	NA	0.44	5.83	0.34	1.64e-8	Menopause (age at onset);
CESC	cis	rs4665809	1.000	rs13030858	chr2:26315451	G/A	cg26314531	chr2:26401878	FAM59B	-0.62	-7.07	-0.4	1.37e-11	Gut microbiome composition (summer);
CESC	cis	rs8002861	0.905	rs6561150	chr13:44460470	C/T	cg19180546	chr13:44453867	C13orf31;CCDC122	0.49	6.18	0.35	2.39e-9	Leprosy;
CESC	cis	rs60843830	0.964	rs7584915	chr2:264227	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.89	12.39	0.61	4.07e-28	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs2180341	1.000	rs7756336	chr6:127650299	T/C	cg24812749	chr6:127587940	RNF146	1.07	15.4	0.69	1.16e-38	Breast cancer;
CESC	cis	rs3008870	0.755	rs1121824	chr1:67475616	C/A	cg08660285	chr1:67390436	MIER1;WDR78	0.62	8.04	0.44	3.01e-14	Lymphocyte percentage of white cells;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25009451	chr14:65006716	HSPA2	-0.6	-6.89	-0.39	4.1e-11	Gut microbiome composition (summer);
CESC	cis	rs2197308	0.765	rs12370231	chr12:37917881	T/C	cg26384229	chr12:38710491	ALG10B	0.74	10.89	0.56	4.4e-23	Morning vs. evening chronotype;
CESC	cis	rs4835473	0.897	rs6835827	chr4:144633956	A/G	cg25736465	chr4:144833511	NA	0.39	6.03	0.35	5.47e-9	Immature fraction of reticulocytes;
CESC	cis	rs9815354	0.638	rs73075241	chr3:42058045	C/T	cg03022575	chr3:42003672	ULK4	0.76	6.84	0.39	5.6e-11	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs9611565	0.500	rs10775759	chr22:42088158	T/C	cg03806693	chr22:41940476	POLR3H	1.03	12.23	0.6	1.39e-27	Vitiligo;
CESC	cis	rs7633770	0.786	rs1402148	chr3:46678295	C/T	cg11219411	chr3:46661640	NA	0.32	5.14	0.3	5.43e-7	Coronary artery disease;
CESC	cis	rs36051895	0.658	rs10974912	chr9:5010885	A/C	cg02405213	chr9:5042618	JAK2	-0.49	-5.41	-0.32	1.42e-7	Pediatric autoimmune diseases;
CESC	cis	rs7726839	0.561	rs72703058	chr5:584519	G/A	cg09021430	chr5:549028	NA	-0.43	-5.76	-0.33	2.29e-8	Obesity-related traits;
CESC	cis	rs11792861	0.926	rs77567374	chr9:111835034	T/C	cg13535736	chr9:111863775	C9orf5	-0.52	-6.86	-0.39	4.94e-11	Menarche (age at onset);
CESC	cis	rs10479542	0.784	rs7703730	chr5:178986632	C/A	cg14820908	chr5:178986412	RUFY1	-0.46	-6.88	-0.39	4.4e-11	Lung cancer;
CESC	cis	rs887829	0.569	rs2008595	chr2:234637192	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.48	-6.23	-0.36	1.77e-9	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CESC	cis	rs1552244	1.000	rs4260416	chr3:10125283	C/T	cg08888203	chr3:10149979	C3orf24	0.54	7.15	0.4	8.57e-12	Alzheimer's disease;
CESC	cis	rs13256369	0.950	rs12548792	chr8:8568031	T/C	cg17143192	chr8:8559678	CLDN23	0.71	7.92	0.44	6.78e-14	Obesity-related traits;
CESC	cis	rs77741769	0.571	rs11611087	chr12:121267126	C/T	cg02419362	chr12:121203948	SPPL3	0.33	5.33	0.31	2.09e-7	Mean corpuscular volume;
CESC	cis	rs4665809	0.941	rs11126336	chr2:26245931	C/T	cg25036284	chr2:26402008	FAM59B	-0.58	-6.44	-0.37	5.66e-10	Gut microbiome composition (summer);
CESC	trans	rs1814175	0.645	rs1963215	chr11:49931486	G/A	cg15704280	chr7:45808275	SEPT13	-1.01	-18.94	-0.76	3.64e-51	Height;
CESC	cis	rs7666738	0.830	rs10856936	chr4:99011319	T/C	cg03676636	chr4:99064102	C4orf37	0.33	5.07	0.3	7.39e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1018836	0.812	rs10808619	chr8:91622916	A/T	cg16814680	chr8:91681699	NA	-0.71	-10.77	-0.55	1.15e-22	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs11864453	0.749	rs7192730	chr16:72124219	T/C	cg16558253	chr16:72132732	DHX38	-0.56	-8.7	-0.47	3.62e-16	Fibrinogen levels;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg02865818	chr5:167719214	WWC1	-0.48	-6.18	-0.35	2.38e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs9303401	0.659	rs17822837	chr17:56737838	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.99	11.25	0.57	2.97e-24	Cognitive test performance;
CESC	cis	rs2836974	0.897	rs2836928	chr21:40543320	C/T	cg17971929	chr21:40555470	PSMG1	0.98	13.49	0.64	6.2e-32	Cognitive function;
CESC	cis	rs3733585	0.699	rs62294332	chr4:9959989	T/C	cg00071950	chr4:10020882	SLC2A9	-0.73	-11.79	-0.59	4.58e-26	Cleft plate (environmental tobacco smoke interaction);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg03360920	chr6:159421029	RSPH3	-0.43	-6.21	-0.36	2.02e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg25834275	chr19:3359809	NFIC	-0.49	-6.31	-0.36	1.14e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs4595586	0.545	rs925827	chr12:39364307	C/T	cg26384229	chr12:38710491	ALG10B	0.53	7.42	0.41	1.6e-12	Morning vs. evening chronotype;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18336435	chr15:60884637	RORA	0.56	6.74	0.38	9.77e-11	Gut microbiome composition (summer);
CESC	cis	rs2836974	0.565	rs34304022	chr21:40579619	G/A	cg17971929	chr21:40555470	PSMG1	0.78	7.76	0.43	1.85e-13	Cognitive function;
CESC	cis	rs7605378	1.000	rs797163	chr2:200696387	G/A	cg23649088	chr2:200775458	C2orf69	0.5	6.7	0.38	1.24e-10	Osteoporosis;
CESC	cis	rs12497850	0.931	rs10780033	chr3:48891275	T/C	cg06212747	chr3:49208901	KLHDC8B	0.67	8.99	0.48	4.66e-17	Parkinson's disease;
CESC	cis	rs36051895	0.632	rs7469563	chr9:5139489	C/T	cg02405213	chr9:5042618	JAK2	-0.54	-6.88	-0.39	4.39e-11	Pediatric autoimmune diseases;
CESC	cis	rs4899260	0.711	rs194716	chr14:69294467	C/A	cg03189333	chr14:69283534	NA	0.47	5.13	0.3	5.5e-7	Celiac disease;
CESC	cis	rs3096299	0.748	rs2965822	chr16:89444677	A/T	cg08822215	chr16:89438651	ANKRD11	-0.38	-5.64	-0.33	4.37e-8	Multiple myeloma (IgH translocation);
CESC	cis	rs2806561	0.828	rs604030	chr1:23518227	T/C	cg12483005	chr1:23474871	LUZP1	0.39	6.04	0.35	5.16e-9	Height;
CESC	cis	rs3617	0.625	rs56019197	chr3:52874753	T/C	cg07507251	chr3:52567010	NT5DC2	-0.31	-5.38	-0.31	1.61e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
CESC	trans	rs853679	0.607	rs17763089	chr6:27835218	G/A	cg21479132	chr6:26055353	NA	0.81	6.09	0.35	4.04e-9	Depression;
CESC	cis	rs1799949	1.000	rs34572725	chr17:41428666	G/A	cg05368731	chr17:41323189	NBR1	0.77	10.67	0.55	2.44e-22	Menopause (age at onset);
CESC	cis	rs8062405	1.000	rs12444171	chr16:28845251	G/A	cg08761264	chr16:28874980	SH2B1	-0.46	-5.72	-0.33	2.9e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02102644	chr17:35969361	SYNRG	0.57	6.7	0.38	1.26e-10	Gut microbiome composition (summer);
CESC	cis	rs477895	0.838	rs12798333	chr11:64012784	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.91	10.21	0.53	7.64e-21	Mean platelet volume;
CESC	cis	rs13382862	0.895	rs13385499	chr2:20882413	A/G	cg12334488	chr2:20871173	GDF7	-0.38	-5.61	-0.33	5.05e-8	Abdominal aortic aneurysm;
CESC	cis	rs7811142	1.000	rs6962151	chr7:100028484	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.82	8.2	0.45	1.06e-14	Platelet count;
CESC	cis	rs12765878	0.967	rs10883941	chr10:105650782	C/T	cg24587175	chr10:105670608	OBFC1	0.32	5.36	0.31	1.81e-7	Coronary artery disease;
CESC	cis	rs113835537	0.529	rs2276406	chr11:66283257	C/T	cg24851651	chr11:66362959	CCS	0.45	5.55	0.32	6.92e-8	Airway imaging phenotypes;
CESC	cis	rs1005277	0.579	rs1780138	chr10:38501654	A/G	cg00409905	chr10:38381863	ZNF37A	-0.52	-7.04	-0.4	1.69e-11	Extrinsic epigenetic age acceleration;
CESC	cis	rs9399135	0.967	rs6908512	chr6:135367757	A/G	cg22676075	chr6:135203613	NA	0.5	7.06	0.4	1.49e-11	Red blood cell count;
CESC	cis	rs5769765	0.773	rs9616378	chr22:50311973	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.58	-6.18	-0.35	2.39e-9	Schizophrenia;
CESC	cis	rs17641971	0.645	rs10504073	chr8:50024944	C/T	cg00325661	chr8:49890786	NA	0.38	5.38	0.31	1.62e-7	Blood metabolite levels;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg03613717	chr10:121356708	TIAL1	-0.45	-6.34	-0.36	9.69e-10	Gambling;
CESC	cis	rs6598955	0.671	rs17163746	chr1:26564230	C/A	cg19743891	chr1:26644573	UBXN11;CD52	0.38	5.44	0.32	1.21e-7	Obesity-related traits;
CESC	cis	rs12449000	1	rs12449000	chr16:89872970	T/C	cg21285383	chr16:89894308	SPIRE2	0.34	6.2	0.36	2.17e-9	Schizophrenia;
CESC	cis	rs1808579	0.804	rs1652376	chr18:21109466	A/C	cg14672496	chr18:21087552	C18orf8	-0.39	-5.76	-0.33	2.3e-8	Hip circumference;Body mass index;BMI (adjusted for smoking behaviour);
CESC	cis	rs55788414	0.651	rs2317121	chr16:81182826	T/G	cg06400318	chr16:81190750	PKD1L2	-0.58	-6.67	-0.38	1.44e-10	Left ventricular obstructive tract defect (maternal effect);
CESC	cis	rs769267	0.965	rs2269873	chr19:19392401	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.42	5.38	0.31	1.66e-7	Tonsillectomy;
CESC	cis	rs561341	0.714	rs7218466	chr17:30263314	A/G	cg19193384	chr17:30244184	NA	-0.48	-5.51	-0.32	8.41e-8	Hip circumference adjusted for BMI;
CESC	cis	rs1008375	1.000	rs2159584	chr4:17620568	G/A	cg15017067	chr4:17643749	FAM184B	0.44	6.31	0.36	1.17e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs1062177	0.855	rs6896664	chr5:151265274	A/G	cg12924095	chr5:151150029	G3BP1	0.39	5.51	0.32	8.52e-8	Preschool internalizing problems;
CESC	cis	rs2635047	0.638	rs28718304	chr18:44632830	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.41	5.56	0.32	6.58e-8	Educational attainment;
CESC	cis	rs1577917	1.000	rs34622557	chr6:86630852	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.42	-5.53	-0.32	7.75e-8	Response to antipsychotic treatment;
CESC	cis	rs7680126	0.596	rs10805364	chr4:10275518	A/G	cg11266682	chr4:10021025	SLC2A9	-0.38	-5.2	-0.3	4e-7	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	cis	rs9926296	0.744	rs6860	chr16:89711120	C/T	cg04287289	chr16:89883240	FANCA	-0.49	-5.98	-0.34	7.18e-9	Vitiligo;
CESC	cis	rs939574	1.000	rs1024131	chr2:220117458	G/A	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.87	7.49	0.42	1.02e-12	Platelet distribution width;
CESC	cis	rs6540559	0.546	rs735694	chr1:210034029	T/C	cg25204440	chr1:209979598	IRF6	0.67	6.11	0.35	3.54e-9	Cleft lip with or without cleft palate;
CESC	cis	rs561341	1.000	rs113676348	chr17:30244327	A/G	cg23018236	chr17:30244563	NA	-0.51	-5.54	-0.32	7.41e-8	Hip circumference adjusted for BMI;
CESC	cis	rs2576037	0.583	rs11660085	chr18:44529603	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.47	6.15	0.35	2.88e-9	Personality dimensions;
CESC	cis	rs7937682	0.924	rs10891283	chr11:111527672	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.0	-16.56	-0.71	9.02e-43	Primary sclerosing cholangitis;
CESC	cis	rs10504229	0.636	rs114725691	chr8:58054292	C/T	cg24829409	chr8:58192753	C8orf71	-0.51	-6.4	-0.37	7.21e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs9487051	0.872	rs9487033	chr6:109605388	C/G	cg01475377	chr6:109611718	NA	0.51	8.43	0.46	2.19e-15	Reticulocyte fraction of red cells;
CESC	cis	rs1801251	1.000	rs3817311	chr2:233612557	C/T	cg25237894	chr2:233734115	C2orf82	0.45	7.84	0.43	1.1e-13	Coronary artery disease;
CESC	cis	rs17253792	0.749	rs79713967	chr14:56124186	T/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.8	5.65	0.33	4.2e-8	Putamen volume;
CESC	cis	rs853679	0.517	rs9357066	chr6:28129831	T/C	cg17949981	chr6:28129498	ZNF389	0.45	5.57	0.32	6.26e-8	Depression;
CESC	cis	rs3204270	0.639	rs7215738	chr17:79659847	C/T	cg26965718	chr17:79658957	HGS	-0.78	-5.81	-0.34	1.77e-8	Dental caries;
CESC	cis	rs6570726	0.846	rs7762536	chr6:145923145	T/C	cg05347473	chr6:146136440	FBXO30	0.5	6.61	0.38	2.11e-10	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs7726839	0.540	rs57306627	chr5:597643	T/C	cg25482853	chr8:67687455	SGK3	1.04	10.08	0.53	1.87e-20	Obesity-related traits;
CESC	cis	rs12579753	0.917	rs7138895	chr12:82203280	T/G	cg24719984	chr12:82153464	PPFIA2	-0.33	-5.04	-0.3	8.55e-7	Resting heart rate;
CESC	cis	rs2635047	0.713	rs9304344	chr18:44758665	A/C	cg24371990	chr18:44770781	NA	-0.41	-6.65	-0.38	1.68e-10	Educational attainment;
CESC	cis	rs11864453	0.647	rs3764314	chr16:72127078	T/C	cg01557791	chr16:72042693	DHODH	-0.43	-5.57	-0.32	6.39e-8	Fibrinogen levels;
CESC	cis	rs7618915	0.547	rs33967311	chr3:52683864	G/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	7.09	0.4	1.22e-11	Bipolar disorder;
CESC	cis	rs8111998	0.826	rs4932776	chr19:22766697	T/C	cg19914732	chr19:22715077	NA	-0.37	-5.18	-0.3	4.45e-7	Corneal structure;
CESC	cis	rs4595586	0.525	rs4768531	chr12:39417754	T/A	cg13010199	chr12:38710504	ALG10B	0.43	5.23	0.31	3.49e-7	Morning vs. evening chronotype;
CESC	cis	rs6701037	0.625	rs72719370	chr1:175128536	G/C	cg00321850	chr1:175162397	KIAA0040	-0.43	-6.2	-0.36	2.1e-9	Alcohol dependence;
CESC	trans	rs8073060	0.586	rs7214742	chr17:33981969	C/A	cg19694781	chr19:47549865	TMEM160	-0.73	-7.32	-0.41	3.05e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	cis	rs7520050	0.966	rs11589562	chr1:46466721	C/T	cg03146154	chr1:46216737	IPP	0.46	6.1	0.35	3.74e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs7647973	0.769	rs6772452	chr3:49040462	A/G	cg07636037	chr3:49044803	WDR6	0.91	14.38	0.66	4.69e-35	Menarche (age at onset);
CESC	cis	rs2658782	0.694	rs3019221	chr11:93079700	C/G	cg15737290	chr11:93063684	CCDC67	0.58	7.27	0.41	4.11e-12	Pulmonary function decline;
CESC	trans	rs3934047	0.904	rs4448893	chr15:82011355	T/C	cg17156767	chr19:30364462	NA	0.39	6.1	0.35	3.74e-9	Response to paliperidone in schizophrenia (positive Marder score);
CESC	cis	rs1728785	0.901	rs1170438	chr16:68608256	T/C	cg02972257	chr16:68554789	NA	-0.6	-6.82	-0.39	6.33e-11	Ulcerative colitis;
CESC	cis	rs863345	0.604	rs12044283	chr1:158463833	C/T	cg12129480	chr1:158549410	OR10X1	-0.35	-6.97	-0.39	2.57e-11	Pneumococcal bacteremia;
CESC	cis	rs9486719	0.857	rs11751075	chr6:97065751	G/A	cg06623918	chr6:96969491	KIAA0776	-0.83	-8.95	-0.48	6.52e-17	Migraine;Coronary artery disease;
CESC	cis	rs9303401	0.646	rs9892425	chr17:57241938	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.5	6.5	0.37	3.93e-10	Cognitive test performance;
CESC	cis	rs34779708	0.931	rs7897457	chr10:35386040	A/G	cg03585969	chr10:35415529	CREM	0.76	10.09	0.53	1.8e-20	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs684232	0.602	rs35206514	chr17:519859	T/C	cg15660573	chr17:549704	VPS53	-0.81	-11.88	-0.59	2.24e-26	Prostate cancer;
CESC	cis	rs60871478	0.679	rs6962050	chr7:817201	A/G	cg13798912	chr7:905769	UNC84A	0.56	5.57	0.32	6.34e-8	Cerebrospinal P-tau181p levels;
CESC	cis	rs4965006	1.000	rs11246900	chr12:132506784	G/T	cg00588090	chr12:132412438	PUS1	0.51	6.45	0.37	5.29e-10	Posterior cortical atrophy and Alzheimer's disease;
CESC	cis	rs1034435	0.547	rs743846	chr22:48900819	C/T	cg05992904	chr22:48892994	FAM19A5	-0.46	-6.64	-0.38	1.73e-10	Late-onset Alzheimer's disease;
CESC	cis	rs4925386	0.681	rs2427296	chr20:60927475	G/A	cg24112000	chr20:60950667	NA	-0.47	-5.89	-0.34	1.14e-8	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs1881797	1.000	rs7527856	chr1:247688139	C/T	cg21399703	chr1:247681439	NA	0.56	7.54	0.42	7.34e-13	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs5769765	0.955	rs6520066	chr22:50294988	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.44	-5.09	-0.3	6.7e-7	Schizophrenia;
CESC	cis	rs6679073	1.000	rs6679073	chr1:205756484	A/C	cg07167872	chr1:205819463	PM20D1	0.41	5.92	0.34	9.78e-9	Prostate-specific antigen levels;
CESC	cis	rs3008870	1.000	rs2985818	chr1:67398916	G/A	cg02640540	chr1:67518911	SLC35D1	0.51	5.58	0.32	5.89e-8	Lymphocyte percentage of white cells;
CESC	cis	rs7412746	0.658	rs6658066	chr1:150918937	T/G	cg04414720	chr1:150670196	GOLPH3L	0.44	5.83	0.34	1.61e-8	Melanoma;
CESC	cis	rs478304	0.651	rs11604451	chr11:65551710	C/T	cg27068330	chr11:65405492	SIPA1	-0.46	-5.55	-0.32	6.97e-8	Acne (severe);
CESC	cis	rs12142240	0.698	rs28578741	chr1:46825176	T/C	cg10495392	chr1:46806563	NSUN4	0.58	6.32	0.36	1.09e-9	Menopause (age at onset);
CESC	cis	rs7811142	1.000	rs7803454	chr7:99991548	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.05	10.05	0.53	2.46e-20	Platelet count;
CESC	cis	rs13191362	0.507	rs2023038	chr6:163119280	C/G	cg06582575	chr6:163149167	PACRG;PARK2	-0.48	-5.76	-0.33	2.32e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs4665809	0.618	rs7579199	chr2:26266496	G/A	cg25036284	chr2:26402008	FAM59B	-0.57	-6.51	-0.37	3.78e-10	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.830	rs4699593	chr4:98980628	A/G	cg17366294	chr4:99064904	C4orf37	0.59	8.46	0.46	1.8e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs5769765	0.778	rs4574208	chr22:50256738	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	0.46	5.41	0.32	1.38e-7	Schizophrenia;
CESC	cis	rs1568889	1.000	rs1568889	chr11:28009463	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.64	6.64	0.38	1.74e-10	Bipolar disorder;
CESC	cis	rs929596	0.785	rs6747843	chr2:234664354	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.67	-8.3	-0.45	5.21e-15	Total bilirubin levels in HIV-1 infection;
CESC	cis	rs7219014	1	rs7219014	chr17:37624790	A/G	cg07936489	chr17:37558343	FBXL20	-0.79	-11.12	-0.56	7.81e-24	Urinary metabolites;
CESC	cis	rs1799949	1.000	rs11655505	chr17:41278377	G/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.45	6.3	0.36	1.21e-9	Menopause (age at onset);
CESC	trans	rs208515	0.592	rs10944862	chr6:66674215	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.89	11.12	0.56	7.77e-24	Exhaled nitric oxide levels;
CESC	cis	rs7552404	0.883	rs2185436	chr1:76203783	A/G	cg10523679	chr1:76189770	ACADM	0.8	11.03	0.56	1.58e-23	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs9894429	0.646	rs6565609	chr17:79592267	G/A	cg18240062	chr17:79603768	NPLOC4	0.54	7.07	0.4	1.39e-11	Eye color traits;
CESC	cis	rs2573652	1.000	rs1469828	chr15:100517210	A/C	cg09918751	chr15:100517450	ADAMTS17	-0.43	-8.46	-0.46	1.78e-15	Height;
CESC	trans	rs3942852	0.726	rs1503171	chr11:48175152	T/C	cg03929089	chr4:120376271	NA	-0.66	-7.19	-0.4	6.48e-12	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs11785400	1.000	rs3802232	chr8:143746701	A/G	cg10596483	chr8:143751796	JRK	0.43	5.65	0.33	4.1e-8	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12278653	chr12:31944807	H3F3C	-0.59	-6.77	-0.38	8.07e-11	Gut microbiome composition (summer);
CESC	cis	rs3096299	0.566	rs4129126	chr16:89561475	A/C	cg16743903	chr16:89593216	SPG7	-0.52	-6.51	-0.37	3.64e-10	Multiple myeloma (IgH translocation);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23719950	chr11:63933701	MACROD1	0.53	6.1	0.35	3.75e-9	Gut microbiome composition (summer);
CESC	cis	rs798554	1.000	rs798545	chr7:2762386	C/T	cg19717773	chr7:2847554	GNA12	-0.57	-8.24	-0.45	7.9e-15	Height;
CESC	trans	rs2727020	0.521	rs7946190	chr11:49521964	T/A	cg15704280	chr7:45808275	SEPT13	0.82	9.96	0.52	4.58e-20	Coronary artery disease;
CESC	cis	rs67478160	0.643	rs12878868	chr14:104233725	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.49	-6.84	-0.39	5.57e-11	Schizophrenia;
CESC	cis	rs561341	0.941	rs72825746	chr17:30364610	G/A	cg23018236	chr17:30244563	NA	-0.53	-5.06	-0.3	7.84e-7	Hip circumference adjusted for BMI;
CESC	cis	rs3806843	0.676	rs1583005	chr5:140031537	G/A	cg16179182	chr5:140090404	VTRNA1-1	0.4	5.08	0.3	7.23e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs748404	0.578	rs512628	chr15:43618734	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.55	8.68	0.47	3.97e-16	Lung cancer;
CESC	cis	rs7927592	0.763	rs10896326	chr11:68234571	T/C	cg20283391	chr11:68216788	NA	-0.45	-5.58	-0.32	5.81e-8	Total body bone mineral density;
CESC	cis	rs9287719	0.967	rs6750891	chr2:10738563	T/C	cg00105475	chr2:10696890	NA	0.39	5.61	0.33	4.96e-8	Prostate cancer;
CESC	cis	rs3026101	0.671	rs7502643	chr17:5297009	A/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.47	6.23	0.36	1.85e-9	Body mass index;
CESC	cis	rs1552244	0.554	rs2272120	chr3:10046703	C/T	cg00149659	chr3:10157352	C3orf10	0.54	6.55	0.37	2.98e-10	Alzheimer's disease;
CESC	cis	rs1799949	0.965	rs35954893	chr17:41333786	A/G	cg05368731	chr17:41323189	NBR1	0.77	10.72	0.55	1.69e-22	Menopause (age at onset);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg26513519	chr5:623344	CEP72	0.45	6.39	0.37	7.35e-10	Fibrinogen levels;
CESC	cis	rs1005277	0.579	rs2474608	chr10:38457109	C/T	cg25517755	chr10:38738941	LOC399744	-0.48	-6.26	-0.36	1.5e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs7618915	0.571	rs2251219	chr3:52584787	C/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	-0.32	-5.33	-0.31	2.13e-7	Bipolar disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02592615	chr6:12012261	HIVEP1	0.63	6.62	0.38	2.03e-10	Gut microbiome composition (summer);
CESC	cis	rs904092	0.786	rs1497375	chr4:100161833	T/A	cg12011299	chr4:100065546	ADH4	0.54	6.09	0.35	3.89e-9	Alcohol dependence;
CESC	trans	rs11638815	0.954	rs35734713	chr15:83338505	G/C	cg25333056	chr10:135107159	TUBGCP2	-0.46	-6.03	-0.35	5.63e-9	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;
CESC	cis	rs11122272	0.701	rs2474628	chr1:231526000	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.57	-7.82	-0.43	1.29e-13	Hemoglobin concentration;
CESC	cis	rs2243480	0.901	rs2949697	chr7:65464236	A/G	cg12463550	chr7:65579703	CRCP	0.72	5.92	0.34	9.68e-9	Diabetic kidney disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13095091	chr1:17949604	ARHGEF10L	-0.48	-6.15	-0.35	2.88e-9	Gut microbiome composition (summer);
CESC	cis	rs1799949	1.000	rs8176126	chr17:41259049	A/G	cg06001716	chr17:41278141	BRCA1;NBR2	-0.38	-5.2	-0.3	3.92e-7	Menopause (age at onset);
CESC	cis	rs6714710	0.580	rs6711101	chr2:98379813	G/A	cg26665480	chr2:98280029	ACTR1B	0.54	7.64	0.42	3.91e-13	Posterior cortical atrophy and Alzheimer's disease;
CESC	cis	rs933688	1.000	rs332529	chr5:90789470	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.96	9.85	0.52	1.05e-19	Smoking behavior;
CESC	cis	rs875971	0.964	rs11765965	chr7:65842221	A/G	cg11764359	chr7:65958608	NA	0.98	15.78	0.7	5.36e-40	Aortic root size;
CESC	cis	rs9916302	0.904	rs4795384	chr17:37716771	C/G	cg00129232	chr17:37814104	STARD3	-0.56	-7.02	-0.4	1.82e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs9815354	0.857	rs7634985	chr3:42019565	C/T	cg03022575	chr3:42003672	ULK4	-0.48	-5.49	-0.32	9.53e-8	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs853679	0.517	rs9368553	chr6:28082265	T/C	cg26335602	chr6:28129616	ZNF389	0.53	7.06	0.4	1.48e-11	Depression;
CESC	cis	rs709400	0.628	rs6575984	chr14:103876454	A/G	cg12935359	chr14:103987150	CKB	0.48	7.16	0.4	8e-12	Body mass index;
CESC	cis	rs2742234	0.590	rs2503864	chr10:43666767	G/T	cg07801480	chr10:43725741	RASGEF1A	0.41	5.24	0.31	3.25e-7	Hirschsprung disease;
CESC	cis	rs7927771	0.832	rs11039212	chr11:47393303	A/T	cg18512352	chr11:47633146	NA	0.47	6.69	0.38	1.33e-10	Subjective well-being;
CESC	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg19318889	chr4:1322082	MAEA	0.57	6.92	0.39	3.48e-11	Longevity;
CESC	cis	rs1740073	0.624	rs9472179	chr6:43938931	C/T	cg14777908	chr6:43939685	NA	-0.37	-5.57	-0.32	6.25e-8	Vascular endothelial growth factor levels;
CESC	cis	rs6546550	0.935	rs2305523	chr2:70039677	G/T	cg02498382	chr2:70120550	SNRNP27	0.4	7.01	0.4	1.97e-11	Prevalent atrial fibrillation;
CESC	cis	rs9486715	0.838	rs6928442	chr6:96870118	A/G	cg18709589	chr6:96969512	KIAA0776	0.45	6.46	0.37	5.05e-10	Headache;
CESC	cis	rs6964587	0.773	rs13236026	chr7:91885873	A/G	cg17063962	chr7:91808500	NA	0.57	7.28	0.41	3.84e-12	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15452590	chr11:607997	PHRF1	-0.74	-8.62	-0.47	6.2e-16	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26996458	chr8:141636297	EIF2C2	-0.54	-6.29	-0.36	1.31e-9	Gut microbiome composition (summer);
CESC	cis	rs9837602	1.000	rs71313585	chr3:99770696	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.51	7.29	0.41	3.59e-12	Breast cancer;
CESC	cis	rs875971	0.862	rs7796162	chr7:65745758	T/C	cg18252515	chr7:66147081	NA	0.44	5.85	0.34	1.48e-8	Aortic root size;
CESC	trans	rs6445797	0.632	rs17216740	chr3:56685213	A/G	cg15444621	chr13:113611794	NA	0.34	6.0	0.35	6.36e-9	Gastritis;
CESC	cis	rs1256061	0.669	rs1256065	chr14:64698932	G/T	cg21174375	chr14:64681225	SYNE2	0.49	6.41	0.37	6.78e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs763014	0.966	rs4984904	chr16:680809	C/G	cg07343612	chr16:622815	PIGQ	-0.54	-7.97	-0.44	4.81e-14	Height;
CESC	cis	rs9329289	1.000	rs9329289	chr10:2542389	A/G	cg15501526	chr10:2543763	NA	0.64	11.59	0.58	2.2e-25	Age-related hearing impairment;
CESC	cis	rs1559088	1.000	rs7260051	chr19:33550111	C/A	cg27124370	chr19:33622961	WDR88	0.42	5.34	0.31	1.99e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs798554	1.000	rs798559	chr7:2758341	T/C	cg19346786	chr7:2764209	NA	-0.46	-6.71	-0.38	1.2e-10	Height;
CESC	cis	rs9796	0.621	rs11858678	chr15:41467932	A/G	cg20272979	chr15:41787780	ITPKA	0.34	5.14	0.3	5.35e-7	Menopause (age at onset);
CESC	cis	rs11711311	1.000	rs9827682	chr3:113450251	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.64	8.85	0.48	1.26e-16	IgG glycosylation;
CESC	cis	rs769267	1.000	rs8103197	chr19:19443466	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	-0.48	-6.02	-0.35	5.82e-9	Tonsillectomy;
CESC	cis	rs2742234	0.541	rs11238481	chr10:43719286	A/G	cg07801480	chr10:43725741	RASGEF1A	-0.4	-5.24	-0.31	3.22e-7	Hirschsprung disease;
CESC	cis	rs6728642	0.519	rs4260285	chr2:97570081	A/G	cg26665480	chr2:98280029	ACTR1B	-0.52	-5.03	-0.3	9.13e-7	Bipolar disorder lithium response (continuous) or schizophrenia;
CESC	cis	rs172166	0.694	rs1631552	chr6:28089699	C/A	cg26335602	chr6:28129616	ZNF389	0.38	5.58	0.32	6.02e-8	Cardiac Troponin-T levels;
CESC	cis	rs992157	0.560	rs10932763	chr2:219085863	G/C	cg00012203	chr2:219082015	ARPC2	-0.74	-9.9	-0.52	7.06e-20	Colorectal cancer;
CESC	cis	rs7267979	0.932	rs433352	chr20:25467992	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.78	-14.88	-0.67	8.2e-37	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs11711311	0.712	rs11718013	chr3:113341661	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.49	6.62	0.38	1.99e-10	IgG glycosylation;
CESC	cis	rs3818285	0.544	rs9787456	chr10:111711822	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.51	-6.5	-0.37	4.06e-10	Superior crus of antihelix expression;
CESC	cis	rs2282802	0.685	rs6870103	chr5:139692515	G/T	cg26211634	chr5:139558579	C5orf32	-0.45	-6.46	-0.37	5.01e-10	Intelligence (multi-trait analysis);
CESC	cis	rs9912789	0.807	rs9896850	chr17:79191726	C/T	cg09314803	chr17:79180344	AZI1	-0.47	-7.01	-0.4	1.92e-11	Frontotemporal dementia;
CESC	cis	rs12477438	0.501	rs6708878	chr2:99801564	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.78	12.45	0.61	2.6e-28	Chronic sinus infection;
CESC	trans	rs561341	0.843	rs2028067	chr17:30239698	T/C	cg20587970	chr11:113659929	NA	-0.74	-9.63	-0.51	5.18e-19	Hip circumference adjusted for BMI;
CESC	cis	rs1552244	0.935	rs35148833	chr3:10116937	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	11.65	0.58	1.34e-25	Alzheimer's disease;
CESC	cis	rs1953600	0.805	rs2819947	chr10:81947757	T/C	cg00277334	chr10:82204260	NA	0.46	6.44	0.37	5.54e-10	Sarcoidosis;
CESC	cis	rs3026101	0.671	rs56300366	chr17:5297839	T/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.44	5.82	0.34	1.74e-8	Body mass index;
CESC	cis	rs12142240	0.698	rs67200518	chr1:46835777	T/C	cg00530320	chr1:46809349	NSUN4	0.6	8.07	0.44	2.4e-14	Menopause (age at onset);
CESC	cis	rs2180341	0.694	rs2875972	chr6:127585522	T/C	cg24812749	chr6:127587940	RNF146	0.86	11.85	0.59	2.85e-26	Breast cancer;
CESC	cis	rs4810479	0.513	rs3746506	chr20:44586036	G/A	cg00125455	chr20:44574271	PCIF1	0.31	5.13	0.3	5.7e-7	Metabolite levels;
CESC	cis	rs1005277	0.579	rs2008449	chr10:38414204	A/T	cg25517755	chr10:38738941	LOC399744	0.45	5.9	0.34	1.09e-8	Extrinsic epigenetic age acceleration;
CESC	cis	rs11630290	0.736	rs6494440	chr15:64145709	C/T	cg12036633	chr15:63758958	NA	0.57	5.9	0.34	1.1e-8	Iris characteristics;
CESC	cis	rs3785574	0.962	rs62077483	chr17:61806380	C/T	cg06420487	chr17:61919686	SMARCD2	0.47	5.66	0.33	3.87e-8	Height;
CESC	cis	rs875971	0.862	rs6960446	chr7:65733259	A/G	cg10691866	chr7:65817282	TPST1	0.33	5.5	0.32	8.83e-8	Aortic root size;
CESC	cis	rs4780401	0.609	rs8047190	chr16:11807097	T/C	cg01061890	chr16:11836724	TXNDC11	-0.56	-7.59	-0.42	5.59e-13	Rheumatoid arthritis;
CESC	cis	rs853679	0.599	rs149949	chr6:28011516	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.68	-5.25	-0.31	3.14e-7	Depression;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06529459	chr11:67397595	NUDT8	0.67	7.45	0.42	1.29e-12	Gut microbiome composition (summer);
CESC	cis	rs1218582	0.745	rs1580943	chr1:154865125	G/A	cg03351412	chr1:154909251	PMVK	0.66	8.89	0.48	9.97e-17	Prostate cancer;
CESC	cis	rs801193	0.773	rs801207	chr7:66020590	T/C	cg18876405	chr7:65276391	NA	-0.54	-7.59	-0.42	5.49e-13	Aortic root size;
CESC	cis	rs9400271	0.632	rs9374071	chr6:109588681	T/C	cg01475377	chr6:109611718	NA	-0.46	-7.18	-0.4	7.24e-12	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
CESC	cis	rs7089973	0.604	rs11196932	chr10:116584386	C/T	cg03647239	chr10:116582469	FAM160B1	0.42	5.13	0.3	5.48e-7	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs3820928	0.874	rs13423046	chr2:227901805	G/T	cg11843606	chr2:227700838	RHBDD1	-0.5	-6.55	-0.37	3.03e-10	Pulmonary function;
CESC	cis	rs854765	0.505	rs4924832	chr17:17897739	A/G	cg04398451	chr17:18023971	MYO15A	-0.65	-9.26	-0.49	7.33e-18	Total body bone mineral density;
CESC	cis	rs858239	0.570	rs10271613	chr7:23162586	G/A	cg23682824	chr7:23144976	KLHL7	0.55	7.71	0.43	2.59e-13	Cerebrospinal fluid biomarker levels;
CESC	cis	rs13256369	0.802	rs13255789	chr8:8562791	T/C	cg18904891	chr8:8559673	CLDN23	0.72	8.1	0.45	2.05e-14	Obesity-related traits;
CESC	trans	rs7839040	0.698	rs10107284	chr8:82921199	C/T	cg14472086	chr9:107730925	NA	-0.46	-6.12	-0.35	3.3e-9	Response to methotrexate in juvenile idiopathic arthritis;
CESC	cis	rs6964587	1.000	rs35653487	chr7:91745441	C/G	cg17063962	chr7:91808500	NA	0.58	8.02	0.44	3.33e-14	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00360757	chr4:49526009	NA	-0.53	-6.24	-0.36	1.75e-9	Gut microbiome composition (summer);
CESC	cis	rs9660180	0.783	rs1107910	chr1:1692321	C/T	cg23982607	chr1:1823379	GNB1	-0.38	-5.41	-0.32	1.42e-7	Body mass index;
CESC	cis	rs35955747	0.902	rs5997929	chr22:31664032	C/T	cg25791279	chr22:32026902	PISD	-0.49	-5.87	-0.34	1.32e-8	Neutrophil count;Sum basophil neutrophil counts;
CESC	cis	rs8014204	1.000	rs8014374	chr14:75322914	G/A	cg26191576	chr14:75389716	RPS6KL1	0.37	5.36	0.31	1.85e-7	Caffeine consumption;
CESC	cis	rs593982	1.000	rs72922786	chr11:65562852	G/C	cg08755490	chr11:65554678	OVOL1	-1.13	-10.79	-0.55	1.01e-22	Atopic dermatitis;
CESC	cis	rs7666738	0.830	rs13119995	chr4:99026790	T/C	cg24818145	chr4:99064322	C4orf37	0.39	5.09	0.3	6.95e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.55	0.37	2.91e-10	Prudent dietary pattern;
CESC	cis	rs172166	0.694	rs1225716	chr6:28113746	A/C	cg19592336	chr6:28129416	ZNF389	0.48	7.07	0.4	1.41e-11	Cardiac Troponin-T levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27317242	chr8:23145699	R3HCC1	0.63	7.13	0.4	9.3e-12	Gut microbiome composition (summer);
CESC	cis	rs10484885	0.824	rs112817281	chr6:90555658	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.79	-7.7	-0.43	2.63e-13	QRS interval (sulfonylurea treatment interaction);
CESC	cis	rs9303401	0.921	rs34102441	chr17:56877414	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.74	9.58	0.51	7.58e-19	Cognitive test performance;
CESC	cis	rs910316	0.875	rs12588099	chr14:75594462	A/T	cg08847533	chr14:75593920	NEK9	0.98	18.89	0.76	5.34e-51	Height;
CESC	cis	rs7089973	0.934	rs12771956	chr10:116576228	C/G	cg23260525	chr10:116636907	FAM160B1	0.36	5.72	0.33	2.81e-8	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs514406	0.668	rs1672911	chr1:53340320	T/C	cg16325326	chr1:53192061	ZYG11B	0.63	9.34	0.5	4.18e-18	Monocyte count;
CESC	cis	rs17376456	1.000	rs6867042	chr5:93555761	C/T	cg21475434	chr5:93447410	FAM172A	0.89	7.33	0.41	2.76e-12	Diabetic retinopathy;
CESC	cis	rs561341	1.000	rs484175	chr17:30309041	G/A	cg12193833	chr17:30244370	NA	-0.7	-6.49	-0.37	4.19e-10	Hip circumference adjusted for BMI;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg22198823	chr11:66394098	RBM14	-0.43	-6.0	-0.35	6.39e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs2506889	0.553	rs17035189	chr1:10597024	A/G	cg07384165	chr1:10488281	NA	-0.54	-7.73	-0.43	2.19e-13	Breast cancer;
CESC	cis	rs225245	0.755	rs8078905	chr17:34009029	T/C	cg05299278	chr17:33885742	SLFN14	0.4	5.69	0.33	3.37e-8	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
CESC	cis	rs4523957	0.713	rs9906500	chr17:2129210	C/A	cg16513277	chr17:2031491	SMG6	-0.63	-8.76	-0.47	2.43e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs6952808	0.564	rs73038441	chr7:2139286	T/C	cg21782813	chr7:2030301	MAD1L1	0.49	6.93	0.39	3.13e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs8020095	0.571	rs12588821	chr14:67424500	G/C	cg19548862	chr14:67692701	FAM71D	-0.49	-5.98	-0.35	7.01e-9	Depression (quantitative trait);
CESC	cis	rs2414059	0.518	rs56398519	chr15:50773432	A/G	cg05456662	chr15:50716270	USP8	-0.4	-5.48	-0.32	1.01e-7	QT interval;
CESC	cis	rs4665809	0.549	rs34075014	chr2:26520842	T/C	cg27170947	chr2:26402098	FAM59B	0.72	7.36	0.41	2.28e-12	Gut microbiome composition (summer);
CESC	cis	rs67311347	1.000	rs2276868	chr3:40498845	C/T	cg09455208	chr3:40491958	NA	-0.47	-8.27	-0.45	6.35e-15	Renal cell carcinoma;
CESC	cis	rs911555	0.723	rs2273701	chr14:103923225	G/T	cg12935359	chr14:103987150	CKB	0.65	9.62	0.51	5.7e-19	Intelligence (multi-trait analysis);
CESC	cis	rs7481584	0.624	rs12417389	chr11:3035304	G/C	cg25174290	chr11:3078921	CARS	-0.44	-6.02	-0.35	5.88e-9	Calcium levels;
CESC	cis	rs3806843	0.733	rs801181	chr5:140092814	C/T	cg16179182	chr5:140090404	VTRNA1-1	0.39	5.22	0.31	3.57e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs6582630	0.519	rs11181294	chr12:38312787	C/T	cg26384229	chr12:38710491	ALG10B	0.7	10.34	0.54	2.92e-21	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs7551222	0.752	rs11240756	chr1:204482594	C/T	cg20240347	chr1:204465584	NA	-0.28	-5.61	-0.33	5.15e-8	Schizophrenia;
CESC	trans	rs7945705	0.935	rs2568062	chr11:8887945	A/G	cg10637292	chr12:52960529	KRT74	0.35	6.11	0.35	3.45e-9	Hemoglobin concentration;
CESC	cis	rs875971	0.545	rs4718335	chr7:65804606	C/T	cg25405998	chr7:65216604	CCT6P1	0.52	5.71	0.33	3e-8	Aortic root size;
CESC	cis	rs3845702	0.736	rs259811	chr2:180787801	C/T	cg01881094	chr2:180872142	CWC22	-1.15	-9.71	-0.51	2.8e-19	Schizophrenia;
CESC	cis	rs7103648	0.864	rs10742802	chr11:47432725	T/G	cg20307385	chr11:47447363	PSMC3	0.97	16.84	0.72	9.04e-44	Diastolic blood pressure;Systolic blood pressure;
CESC	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	7.53	0.42	8.04e-13	Prudent dietary pattern;
CESC	cis	rs2742417	0.603	rs2742455	chr3:45767116	A/G	cg04837898	chr3:45731254	SACM1L	-0.47	-6.17	-0.35	2.54e-9	Response to anti-depressant treatment in major depressive disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08744097	chr16:1550264	TELO2	-0.61	-6.92	-0.39	3.47e-11	Gut microbiome composition (summer);
CESC	cis	rs10479542	0.544	rs7706275	chr5:178990305	A/G	cg19626725	chr5:178986131	RUFY1	0.36	5.58	0.32	6.06e-8	Lung cancer;
CESC	cis	rs9322193	0.923	rs10872649	chr6:150080590	T/G	cg13206674	chr6:150067644	NUP43	0.46	6.52	0.37	3.5e-10	Lung cancer;
CESC	cis	rs6456156	0.586	rs13195158	chr6:167481392	G/A	cg23791538	chr6:167370224	RNASET2	-0.51	-6.46	-0.37	4.98e-10	Primary biliary cholangitis;
CESC	cis	rs12681366	0.537	rs2919667	chr8:95465202	C/G	cg13257157	chr8:95487014	RAD54B	0.45	5.47	0.32	1.05e-7	Nonsyndromic cleft lip with cleft palate;
CESC	cis	rs17052344	0.582	rs111876736	chr17:21747067	A/G	cg18423549	chr17:21743878	NA	-0.68	-9.74	-0.51	2.31e-19	Cutaneous psoriasis;
CESC	cis	rs2730245	0.528	rs1188954	chr7:158691417	G/A	cg24397884	chr7:158709396	WDR60	0.73	11.08	0.56	1.11e-23	Height;
CESC	cis	rs4555082	0.718	rs28513571	chr14:105709592	C/A	cg10792982	chr14:105748885	BRF1	0.4	5.35	0.31	1.86e-7	Mean platelet volume;Platelet distribution width;
CESC	cis	rs763121	0.853	rs5757234	chr22:39072686	C/T	cg06022373	chr22:39101656	GTPBP1	0.94	18.23	0.75	1.15e-48	Menopause (age at onset);
CESC	cis	rs7618915	0.547	rs13065019	chr3:52685244	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.49	7.14	0.4	9.11e-12	Bipolar disorder;
CESC	cis	rs896854	0.714	rs572547	chr8:95966286	A/G	cg16049864	chr8:95962084	TP53INP1	0.63	9.82	0.52	1.33e-19	Type 2 diabetes;
CESC	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg21724239	chr8:58056113	NA	0.58	5.47	0.32	1.06e-7	Developmental language disorder (linguistic errors);
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg27613236	chr5:138940718	UBE2D2	0.57	7.24	0.41	4.97e-12	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs2014572	0.967	rs8100154	chr19:57765432	A/G	cg24459738	chr19:57751996	ZNF805	-0.53	-7.57	-0.42	6.02e-13	Hyperactive-impulsive symptoms;
CESC	cis	rs6089829	0.925	rs6122086	chr20:61664528	T/C	cg03213289	chr20:61660250	NA	0.38	5.94	0.34	9.08e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs1475911	0.708	rs56109792	chr21:43520060	A/G	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.52	-7.99	-0.44	4.18e-14	IgG glycosylation;
CESC	cis	rs12586317	0.525	rs10144430	chr14:35433682	T/A	cg05294307	chr14:35346193	BAZ1A	-0.51	-6.38	-0.36	7.78e-10	Psoriasis;
CESC	cis	rs7511006	0.893	rs5771104	chr22:50651839	C/T	cg16473166	chr22:50639996	SELO	0.59	8.31	0.45	5.04e-15	Obesity-related traits;
CESC	cis	rs11039389	1	rs11039389	chr11:47796062	T/C	cg20307385	chr11:47447363	PSMC3	-0.51	-6.21	-0.36	2e-9	Neuroticism;
CESC	cis	rs9649213	0.593	rs7795176	chr7:97978287	A/C	cg24562669	chr7:97807699	LMTK2	0.51	7.63	0.42	4.29e-13	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10075284	chr2:85765766	MAT2A	0.6	6.24	0.36	1.76e-9	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01395650	chr1:197170599	ZBTB41	0.55	6.16	0.35	2.63e-9	Gut microbiome composition (summer);
CESC	cis	rs4665809	1.000	rs6729080	chr2:26301282	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.7	-8.01	-0.44	3.69e-14	Gut microbiome composition (summer);
CESC	cis	rs6963495	0.818	rs73190189	chr7:105164452	G/A	cg19920283	chr7:105172520	RINT1	0.71	6.71	0.38	1.17e-10	Bipolar disorder (body mass index interaction);
CESC	cis	rs2236918	0.710	rs1635507	chr1:242028358	G/T	cg17736920	chr1:242011382	EXO1	0.69	9.11	0.49	2.14e-17	Menopause (age at onset);
CESC	cis	rs35110281	0.591	rs230642	chr21:44915533	A/C	cg21573476	chr21:45109991	RRP1B	0.36	5.23	0.31	3.43e-7	Mean corpuscular volume;
CESC	cis	rs748404	0.578	rs510108	chr15:43605439	T/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.61	8.15	0.45	1.45e-14	Lung cancer;
CESC	cis	rs7520050	0.807	rs5021934	chr1:46109304	A/G	cg24296786	chr1:45957014	TESK2	0.46	5.97	0.34	7.71e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs7216064	0.911	rs12449442	chr17:65947640	G/A	cg12091567	chr17:66097778	LOC651250	-0.71	-7.12	-0.4	1.01e-11	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs2354432	0.546	rs7539416	chr1:146881586	C/T	cg25205988	chr1:146714368	CHD1L	0.83	8.93	0.48	7.56e-17	Mitochondrial DNA levels;
CESC	cis	rs80130819	0.515	rs1476608	chr12:48493731	C/T	cg24011408	chr12:48396354	COL2A1	0.42	5.36	0.31	1.79e-7	Prostate cancer;
CESC	cis	rs2439831	0.850	rs28707214	chr15:44131623	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.63	5.6	0.33	5.26e-8	Lung cancer in ever smokers;
CESC	cis	rs2204008	0.840	rs11181795	chr12:38401129	A/G	cg13010199	chr12:38710504	ALG10B	0.48	6.21	0.36	2.03e-9	Bladder cancer;
CESC	cis	rs4853012	0.838	rs72915068	chr2:74356185	G/A	cg19729930	chr2:74357872	NA	0.94	14.25	0.66	1.37e-34	Gestational age at birth (maternal effect);
CESC	cis	rs6867032	1.000	rs61177713	chr5:2017255	G/A	cg26168224	chr5:2018326	NA	0.95	19.24	0.76	3.09e-52	Gut microbiome composition (winter);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17900697	chr17:27139003	C17orf63	-0.56	-6.34	-0.36	1e-9	Gut microbiome composition (summer);
CESC	cis	rs7017914	0.935	rs6472551	chr8:71781849	C/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.44	-5.61	-0.33	5.2100000000000003e-08	Bone mineral density;
CESC	cis	rs6426558	0.572	rs2670471	chr1:227454328	T/C	cg10327440	chr1:227177885	CDC42BPA	0.5	6.15	0.35	2.87e-9	Neutrophil percentage of white cells;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg11382993	chr10:60028551	IPMK;CISD1	0.45	6.06	0.35	4.77e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs10416265	0.527	rs7246814	chr19:33538414	G/T	cg17764715	chr19:33622953	WDR88	0.59	8.11	0.45	1.94e-14	Bone properties (heel);
CESC	cis	rs524281	1.000	rs472518	chr11:65851902	A/G	cg14036092	chr11:66035641	RAB1B	0.54	6.23	0.36	1.87e-9	Electroencephalogram traits;
CESC	cis	rs116095464	0.558	rs13357299	chr5:242211	T/C	cg22857025	chr5:266934	NA	-1.26	-18.11	-0.74	2.9e-48	Breast cancer;
CESC	cis	rs10129255	0.500	rs988133	chr14:107184963	A/G	cg07958169	chr14:107095056	NA	-0.54	-8.52	-0.46	1.26e-15	Kawasaki disease;
CESC	cis	rs6540556	0.723	rs6540550	chr1:209925251	A/G	cg23920097	chr1:209922102	NA	-0.36	-5.2	-0.3	4.02e-7	Red blood cell count;
CESC	cis	rs7216064	0.861	rs73352810	chr17:65875184	G/A	cg07042672	chr17:66097459	LOC651250	-0.57	-6.54	-0.37	3.09e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs875971	0.965	rs6971509	chr7:65714970	G/T	cg18876405	chr7:65276391	NA	-0.5	-6.84	-0.39	5.39e-11	Aortic root size;
CESC	cis	rs6951245	0.542	rs28460147	chr7:1217192	G/A	cg03188948	chr7:1209495	NA	0.72	7.44	0.42	1.45e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2066819	0.892	rs112931321	chr12:56667894	C/T	cg26804944	chr12:56660921	COQ10A	-0.85	-5.19	-0.3	4.28e-7	Psoriasis vulgaris;
CESC	cis	rs9322193	0.886	rs2065663	chr6:150081467	A/G	cg07701084	chr6:150067640	NUP43	0.43	5.75	0.33	2.51e-8	Lung cancer;
CESC	cis	rs9393777	0.623	rs34313099	chr6:26489607	C/T	cg12826209	chr6:26865740	GUSBL1	0.67	7.11	0.4	1.08e-11	Intelligence (multi-trait analysis);
CESC	trans	rs637571	0.544	rs500161	chr11:65695438	C/T	cg17712092	chr4:129076599	LARP1B	0.79	10.8	0.55	8.7e-23	Eosinophil percentage of white cells;
CESC	cis	rs801193	0.569	rs35070132	chr7:66238083	C/T	cg18252515	chr7:66147081	NA	-0.47	-6.18	-0.35	2.42e-9	Aortic root size;
CESC	cis	rs2439831	0.867	rs16957627	chr15:43642657	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.84	12.1	0.6	4.05e-27	Lung cancer in ever smokers;
CESC	cis	rs6496667	0.779	rs8037260	chr15:91049960	C/T	cg13834112	chr15:90361639	NA	0.41	5.38	0.31	1.68e-7	Rheumatoid arthritis;
CESC	cis	rs4713118	0.516	rs6931858	chr6:28078411	A/T	cg18032046	chr6:28092343	ZSCAN16	-0.58	-6.53	-0.37	3.29e-10	Parkinson's disease;
CESC	cis	rs514406	0.763	rs9988539	chr1:53213884	T/C	cg08736216	chr1:53307985	ZYG11A	0.41	6.85	0.39	5.29e-11	Monocyte count;
CESC	cis	rs873946	0.590	rs12259699	chr10:134549692	A/G	cg26818010	chr10:134567672	INPP5A	-0.81	-10.03	-0.52	2.81e-20	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs9430161	0.611	rs2095920	chr1:11033457	T/A	cg27631724	chr1:11040367	C1orf127	0.38	6.21	0.36	2.02e-9	Ewing sarcoma;
CESC	cis	rs728616	0.614	rs61859210	chr10:82131468	G/C	cg05935833	chr10:81318306	SFTPA2	-0.45	-5.74	-0.33	2.59e-8	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs9359856	0.564	rs56281344	chr6:90445393	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.61	-5.81	-0.34	1.78e-8	Bipolar disorder;
CESC	cis	rs6831352	0.918	rs34071486	chr4:100051087	A/G	cg12011299	chr4:100065546	ADH4	-0.59	-6.52	-0.37	3.62e-10	Alcohol dependence;
CESC	cis	rs7772486	0.875	rs1412080	chr6:146417304	T/C	cg23711669	chr6:146136114	FBXO30	0.77	11.23	0.57	3.4e-24	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs12291225	0.585	rs10832242	chr11:14340504	C/T	cg19336497	chr11:14380999	RRAS2	0.45	6.75	0.38	9.29e-11	Sense of smell;
CESC	trans	rs7310309	0.830	rs11114200	chr12:80038849	A/C	cg02623991	chr19:54926431	TTYH1	-0.41	-6.02	-0.35	5.79e-9	Classic bladder exstrophy;
CESC	cis	rs7208859	0.623	rs8080882	chr17:29081146	G/A	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.17e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs1552244	0.810	rs4019706	chr3:10112862	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	12.09	0.6	4.37e-27	Alzheimer's disease;
CESC	cis	rs3741404	0.791	rs11603192	chr11:63927695	A/G	cg04317338	chr11:64019027	PLCB3	0.5	5.97	0.34	7.53e-9	Platelet count;
CESC	cis	rs769267	0.965	rs2074550	chr19:19387743	A/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.43	5.41	0.32	1.4e-7	Tonsillectomy;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg07376846	chr1:203765385	ZC3H11A	0.5	6.74	0.38	9.63e-11	Systemic lupus erythematosus;
CESC	cis	rs704010	0.543	rs10824713	chr10:80835868	C/T	cg11504511	chr10:80827333	ZMIZ1;LOC283050	0.47	6.16	0.35	2.68e-9	Breast cancer;
CESC	cis	rs4555082	0.957	rs2816628	chr14:105736134	T/G	cg13114125	chr14:105738426	BRF1	-0.64	-8.22	-0.45	9e-15	Mean platelet volume;Platelet distribution width;
CESC	cis	rs2842992	0.789	rs4709370	chr6:160210061	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.76	9.75	0.51	2.19e-19	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs11098499	0.754	rs1980026	chr4:120251643	C/A	cg09307838	chr4:120376055	NA	0.77	10.49	0.54	9.15e-22	Corneal astigmatism;
CESC	cis	rs11871801	0.881	rs2071046	chr17:40689613	G/C	cg21433558	chr17:40837037	CNTNAP1	-0.44	-5.1	-0.3	6.35e-7	Crohn's disease;
CESC	cis	rs4722166	0.630	rs6969258	chr7:22782528	C/T	cg13104385	chr7:22767384	IL6	0.48	6.43	0.37	5.96e-10	Lung cancer;
CESC	cis	rs1018836	0.631	rs9987133	chr8:91470730	T/C	cg16814680	chr8:91681699	NA	-0.52	-6.92	-0.39	3.38e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	trans	rs12599106	0.707	rs2163977	chr16:34916134	A/G	cg18110333	chr6:292329	DUSP22	-0.71	-9.17	-0.49	1.32e-17	Menopause (age at onset);
CESC	trans	rs7395662	0.500	rs7951327	chr11:48925359	C/T	cg00717180	chr2:96193071	NA	-0.46	-6.16	-0.35	2.75e-9	HDL cholesterol;
CESC	cis	rs7605827	0.930	rs7606850	chr2:15678250	T/C	cg19274914	chr2:15703543	NA	0.37	6.7	0.38	1.22e-10	Educational attainment (years of education);
CESC	cis	rs853679	0.546	rs200948	chr6:27835272	T/C	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.85	7.2	0.4	6.18e-12	Depression;
CESC	cis	rs4662945	0.525	rs4662951	chr2:130256272	C/T	cg05962382	chr2:130345044	NA	-0.47	-6.99	-0.39	2.22e-11	Response to cytidine analogues (gemcitabine);
CESC	cis	rs9811920	0.965	rs9849632	chr3:99867211	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.41	5.38	0.31	1.62e-7	Axial length;
CESC	cis	rs7546094	1.000	rs7513716	chr1:113089320	A/T	cg22162597	chr1:113214053	CAPZA1	0.37	5.63	0.33	4.59e-8	Platelet distribution width;
CESC	cis	rs6089829	0.962	rs4809456	chr20:61660849	C/A	cg03213289	chr20:61660250	NA	0.39	6.15	0.35	2.87e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs8170	0.603	rs4808622	chr19:17415457	C/G	cg04749549	chr19:17459798	NA	-0.35	-5.57	-0.32	6.28e-8	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23057040	chr1:211433972	RCOR3	0.57	6.16	0.35	2.69e-9	Gut microbiome composition (summer);
CESC	cis	rs7551222	0.721	rs1460036	chr1:204527379	A/G	cg20240347	chr1:204465584	NA	-0.28	-5.53	-0.32	7.6e-8	Schizophrenia;
CESC	cis	rs9649465	0.542	rs616297	chr7:123426949	A/G	cg03229431	chr7:123269106	ASB15	0.42	5.73	0.33	2.67e-8	Migraine;
CESC	cis	rs4268898	0.662	rs74470633	chr2:24438712	A/G	cg20701182	chr2:24300061	SF3B14	0.68	7.16	0.4	7.75e-12	Asthma;
CESC	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg10295955	chr4:187884368	NA	-1.07	-22.28	-0.81	1.14e-62	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs12615721	0.792	rs714984	chr2:81946577	A/T	cg13174197	chr3:52720522	GNL3;PBRM1	0.77	6.21	0.36	2.06e-9	Pulmonary function decline;
CESC	cis	rs2274273	0.935	rs8004787	chr14:55607366	C/T	cg04306507	chr14:55594613	LGALS3	0.29	5.79	0.34	2e-8	Protein biomarker;
CESC	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg06873352	chr17:61820015	STRADA	0.72	12.71	0.62	3.11e-29	Prudent dietary pattern;
CESC	cis	rs1008375	0.966	rs3775924	chr4:17585984	T/C	cg02297831	chr4:17616191	MED28	0.51	6.26	0.36	1.5e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs2243480	0.901	rs1701759	chr7:65470932	G/T	cg12463550	chr7:65579703	CRCP	0.72	5.92	0.34	9.68e-9	Diabetic kidney disease;
CESC	cis	rs875971	0.830	rs1167406	chr7:65556936	G/C	cg19163074	chr7:65112434	INTS4L2	0.46	5.57	0.32	6.37e-8	Aortic root size;
CESC	cis	rs34779708	0.868	rs2384352	chr10:35492832	A/G	cg03585969	chr10:35415529	CREM	0.74	9.44	0.5	1.94e-18	Inflammatory bowel disease;Crohn's disease;
CESC	trans	rs916888	0.610	rs199446	chr17:44813169	G/A	cg10053473	chr17:62856997	LRRC37A3	0.66	9.22	0.49	9.62e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs3749237	0.595	rs12489092	chr3:49550914	G/C	cg02487422	chr3:49467188	NICN1	0.56	8.2	0.45	1.07e-14	Resting heart rate;
CESC	cis	rs6460942	0.915	rs1595802	chr7:12439672	C/T	cg13733410	chr7:12443478	VWDE	-0.53	-5.47	-0.32	1.02e-7	Coronary artery disease;
CESC	cis	rs116095464	0.558	rs56298907	chr5:283280	C/A	cg22857025	chr5:266934	NA	-1.32	-14.16	-0.66	2.9e-34	Breast cancer;
CESC	cis	rs2797685	1.000	rs707466	chr1:7861600	C/A	cg04725166	chr1:7887271	PER3	-0.45	-6.19	-0.36	2.31e-9	Crohn's disease;
CESC	cis	rs2075371	1.000	rs2598286	chr7:133976029	G/A	cg00033643	chr7:134001901	SLC35B4	0.41	5.31	0.31	2.34e-7	Mean platelet volume;
CESC	cis	rs4409675	0.576	rs2474470	chr1:28234999	C/T	cg23691781	chr1:28212827	C1orf38	0.29	5.81	0.34	1.83e-8	Corneal astigmatism;
CESC	cis	rs28830936	0.966	rs17733613	chr15:41917585	A/G	cg11010575	chr15:42129464	JMJD7-PLA2G4B;JMJD7	-0.36	-5.13	-0.3	5.51e-7	Diastolic blood pressure;
CESC	cis	rs1050631	0.564	rs10153377	chr18:33727984	G/C	cg25426722	chr18:33708991	SLC39A6;ELP2	0.59	8.21	0.45	9.72e-15	Esophageal squamous cell cancer (length of survival);
CESC	cis	rs8177179	0.967	rs6439436	chr3:133453779	C/T	cg17775713	chr3:133465469	TF	-0.29	-5.25	-0.31	3.18e-7	Iron status biomarkers (transferrin levels);
CESC	cis	rs826838	1.000	rs6582619	chr12:38729904	A/G	cg26384229	chr12:38710491	ALG10B	0.84	14.75	0.67	2.43e-36	Heart rate;
CESC	cis	rs763121	0.706	rs3827356	chr22:39064806	G/T	cg06544989	chr22:39130855	UNC84B	-0.46	-8.28	-0.45	6.19e-15	Menopause (age at onset);
CESC	cis	rs72781680	0.821	rs72796378	chr2:24167385	G/A	cg08917208	chr2:24149416	ATAD2B	0.62	6.11	0.35	3.53e-9	Lymphocyte counts;
CESC	cis	rs1691799	0.867	rs6581677	chr12:66770379	C/G	cg16791601	chr12:66731901	HELB	-0.74	-13.04	-0.63	2.31e-30	White blood cell count (basophil);
CESC	cis	rs752010	0.746	rs10890146	chr1:42089389	G/A	cg12614395	chr1:42085415	HIVEP3	0.3	5.19	0.3	4.24e-7	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs12137294	0.866	rs1172156	chr1:205220087	C/T	cg21643547	chr1:205240462	TMCC2	-0.34	-5.49	-0.32	9.58e-8	Red cell distribution width;
CESC	cis	rs9913156	0.748	rs72835619	chr17:4557285	G/A	cg19197139	chr17:4613644	ARRB2	0.91	10.39	0.54	1.96e-21	Lymphocyte counts;
CESC	cis	rs6120849	0.617	rs12480442	chr20:33648388	C/G	cg06115741	chr20:33292138	TP53INP2	0.53	5.08	0.3	7.23e-7	Protein C levels;
CESC	cis	rs3733585	0.699	rs60045583	chr4:9971950	G/A	cg02734326	chr4:10020555	SLC2A9	-0.39	-5.53	-0.32	7.54e-8	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs11764590	0.694	rs6972969	chr7:2099331	A/G	cg21782813	chr7:2030301	MAD1L1	-0.43	-5.44	-0.32	1.24e-7	Neuroticism;
CESC	cis	rs10743315	0.557	rs1552750	chr12:19356505	A/T	cg02471346	chr12:19282374	PLEKHA5	0.68	5.15	0.3	4.98e-7	Gut microbiota (bacterial taxa);
CESC	cis	rs4819052	0.851	rs2330011	chr21:46658498	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.87	12.85	0.62	1.1e-29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs11252926	0.674	rs11598550	chr10:504778	A/C	cg16386425	chr10:429943	DIP2C	0.44	5.46	0.32	1.11e-7	Psychosis in Alzheimer's disease;
CESC	cis	rs9399135	0.967	rs7766189	chr6:135353851	A/C	cg22676075	chr6:135203613	NA	0.52	7.36	0.41	2.3e-12	Red blood cell count;
CESC	cis	rs514406	0.929	rs1242224	chr1:53314887	G/A	cg16325326	chr1:53192061	ZYG11B	0.8	12.75	0.62	2.39e-29	Monocyte count;
CESC	cis	rs447	1.000	rs10263314	chr7:83776972	C/T	cg22846510	chr7:83753280	SEMA3A	-0.42	-5.07	-0.3	7.48e-7	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs7666738	0.830	rs2903152	chr4:99067992	A/G	cg05340658	chr4:99064831	C4orf37	0.83	12.82	0.62	1.36e-29	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9660180	0.967	rs6603802	chr1:1812521	C/T	cg23982607	chr1:1823379	GNB1	-0.79	-13.12	-0.63	1.22e-30	Body mass index;
CESC	cis	rs1799949	0.965	rs4793237	chr17:41436595	A/T	cg07153921	chr17:41440717	NA	-0.41	-5.53	-0.32	7.87e-8	Menopause (age at onset);
CESC	cis	rs6920965	0.583	rs9388456	chr6:126147197	C/T	cg05901451	chr6:126070800	HEY2	-0.41	-5.64	-0.33	4.26e-8	High light scatter reticulocyte count;
CESC	cis	rs5769765	0.908	rs9616388	chr22:50313438	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.58	-6.34	-0.36	9.93e-10	Schizophrenia;
CESC	trans	rs7839040	0.672	rs9298381	chr8:82926496	T/A	cg14472086	chr9:107730925	NA	-0.47	-6.03	-0.35	5.53e-9	Response to methotrexate in juvenile idiopathic arthritis;
CESC	cis	rs11098499	0.954	rs71629403	chr4:120372567	C/T	cg24375607	chr4:120327624	NA	0.48	5.93	0.34	9.24e-9	Corneal astigmatism;
CESC	cis	rs67311347	0.544	rs6599088	chr3:40329288	T/C	cg24209194	chr3:40518798	ZNF619	0.38	5.25	0.31	3.05e-7	Renal cell carcinoma;
CESC	cis	rs593982	0.843	rs565267	chr11:65473597	T/C	cg08755490	chr11:65554678	OVOL1	1.15	10.31	0.53	3.64e-21	Atopic dermatitis;
CESC	cis	rs8114671	0.562	rs6087643	chr20:33474462	C/T	cg24642439	chr20:33292090	TP53INP2	0.43	5.17	0.3	4.52e-7	Height;
CESC	cis	rs10465746	0.747	rs10493741	chr1:84388118	G/C	cg10977910	chr1:84465055	TTLL7	0.52	7.06	0.4	1.47e-11	Obesity-related traits;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg07031794	chr2:26568949	SELI;GPR113	-0.46	-6.01	-0.35	6.08e-9	Fibrinogen levels;
CESC	cis	rs6724607	0.875	rs9630991	chr2:191432139	G/A	cg21644426	chr2:191273491	MFSD6	0.48	6.32	0.36	1.12e-9	Pulse pressure;
CESC	cis	rs34286592	1.000	rs62056375	chr16:29857901	G/A	cg27338089	chr16:29820515	MAZ	0.56	5.57	0.32	6.26e-8	Multiple sclerosis;
CESC	trans	rs673604	0.505	rs676614	chr1:36107510	G/T	cg07508260	chr11:111742291	ALG9	0.53	6.18	0.35	2.35e-9	Endometrial cancer;
CESC	cis	rs12410462	0.581	rs113827839	chr1:227547180	C/T	cg04117972	chr1:227635322	NA	0.63	5.35	0.31	1.9e-7	Major depressive disorder;
CESC	cis	rs4566357	1.000	rs2396444	chr2:227921314	T/G	cg11843606	chr2:227700838	RHBDD1	-0.41	-5.29	-0.31	2.58e-7	Coronary artery disease;
CESC	cis	rs35146811	0.844	rs10281368	chr7:99655897	A/G	cg13334819	chr7:99746414	C7orf59	-0.43	-5.13	-0.3	5.61e-7	Coronary artery disease;
CESC	cis	rs1552244	0.935	rs7621551	chr3:10114205	C/T	cg00149659	chr3:10157352	C3orf10	0.72	8.61	0.47	6.41e-16	Alzheimer's disease;
CESC	trans	rs11088226	0.681	rs2833911	chr21:33949629	C/T	cg09050820	chr6:167586206	TCP10L2	-0.93	-9.84	-0.52	1.15e-19	Gastritis;
CESC	cis	rs763121	1.000	rs1946990	chr22:38912771	C/T	cg06544989	chr22:39130855	UNC84B	-0.44	-7.83	-0.43	1.18e-13	Menopause (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03796655	chr15:89456767	MFGE8	0.56	6.11	0.35	3.51e-9	Gut microbiome composition (summer);
CESC	cis	rs3750965	0.806	rs7107680	chr11:68859894	C/T	cg01403660	chr11:68851641	TPCN2	0.41	5.51	0.32	8.44e-8	Hair color;
CESC	cis	rs6088590	0.735	rs6088618	chr20:33409350	G/A	cg08999081	chr20:33150536	PIGU	0.65	10.44	0.54	1.35e-21	Coronary artery disease;
CESC	cis	rs9815354	0.670	rs73073238	chr3:42014325	G/C	cg03022575	chr3:42003672	ULK4	0.68	6.13	0.35	3.21e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs7208859	0.623	rs9915566	chr17:29132158	G/A	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.79e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs2576037	0.526	rs10853545	chr18:44475220	A/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.6	-8.35	-0.46	3.87e-15	Personality dimensions;
CESC	cis	rs8027181	0.740	rs8038247	chr15:73096573	A/G	cg25632853	chr15:73088954	NA	0.33	5.89	0.34	1.19e-8	Triglyceride levels;
CESC	cis	rs3749237	0.964	rs1799843	chr3:49849723	G/A	cg03060546	chr3:49711283	APEH	0.65	7.65	0.43	3.69e-13	Resting heart rate;
CESC	cis	rs60871478	1.000	rs62432899	chr7:826542	G/C	cg00934597	chr7:893267	UNC84A	0.53	5.41	0.32	1.43e-7	Cerebrospinal P-tau181p levels;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg25682936	chr1:38455768	SF3A3	0.51	6.47	0.37	4.63e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs7580658	0.750	rs4497825	chr2:128061053	A/G	cg10021288	chr2:128175891	PROC	-0.37	-5.97	-0.34	7.58e-9	Protein C levels;
CESC	cis	rs7432375	0.566	rs835636	chr3:136674500	A/C	cg15507776	chr3:136538369	TMEM22	0.63	8.47	0.46	1.77e-15	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
CESC	cis	rs12618769	0.597	rs3769741	chr2:99068204	G/T	cg10123293	chr2:99228465	UNC50	0.41	5.5	0.32	8.76e-8	Bipolar disorder;
CESC	trans	rs629535	0.773	rs568159	chr8:70032908	C/G	cg21567404	chr3:27674614	NA	0.93	11.25	0.57	2.83e-24	Dupuytren's disease;
CESC	trans	rs1814175	0.527	rs10769595	chr11:49638212	A/G	cg15704280	chr7:45808275	SEPT13	-0.83	-10.51	-0.54	7.82e-22	Height;
CESC	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg26354017	chr1:205819088	PM20D1	0.85	13.43	0.64	1.06e-31	Menarche (age at onset);
CESC	cis	rs208520	0.742	rs208454	chr6:66907783	T/C	cg07460842	chr6:66804631	NA	-0.86	-10.11	-0.53	1.55e-20	Exhaled nitric oxide output;
CESC	cis	rs7615952	0.576	rs1127717	chr3:125826059	T/C	cg15145296	chr3:125709740	NA	-0.55	-5.96	-0.34	7.81e-9	Blood pressure (smoking interaction);
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg13709634	chr11:679709	DEAF1	-0.53	-7.2	-0.4	6.18e-12	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs4253772	0.530	rs8140573	chr22:46800363	G/C	cg18190219	chr22:46762943	CELSR1	-0.59	-6.12	-0.35	3.28e-9	LDL cholesterol;Cholesterol, total;
CESC	trans	rs208520	0.507	rs3903670	chr6:66812183	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.11	-25.1	-0.84	5.19e-72	Exhaled nitric oxide output;
CESC	cis	rs6570726	0.967	rs1396648	chr6:145785248	C/A	cg05347473	chr6:146136440	FBXO30	-0.4	-5.45	-0.32	1.18e-7	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6433857	0.627	rs1406259	chr2:181522879	T/G	cg23363182	chr2:181467187	NA	-0.46	-6.26	-0.36	1.58e-9	Body mass index;
CESC	cis	rs10242455	0.702	rs28377312	chr7:98984213	G/A	cg18809830	chr7:99032528	PTCD1	-0.83	-5.55	-0.32	7.04e-8	Blood metabolite levels;
CESC	cis	rs854765	0.583	rs12452219	chr17:17829423	C/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.49	6.36	0.36	8.95e-10	Total body bone mineral density;
CESC	cis	rs7208859	0.573	rs8064686	chr17:29134839	C/T	cg14008862	chr17:28927542	LRRC37B2	0.65	5.14	0.3	5.34e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs853679	0.517	rs12332979	chr6:28141548	T/G	cg22143856	chr6:28129313	ZNF389	0.46	5.84	0.34	1.56e-8	Depression;
CESC	cis	rs7659604	0.540	rs10012775	chr4:122676878	T/C	cg19671926	chr4:122722719	EXOSC9	0.53	6.7	0.38	1.21e-10	Type 2 diabetes;
CESC	trans	rs61931739	0.500	rs11053268	chr12:34545121	T/C	cg26384229	chr12:38710491	ALG10B	0.53	7.41	0.41	1.74e-12	Morning vs. evening chronotype;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20476801	chr6:131949468	MED23	0.6	6.41	0.37	6.65e-10	Gut microbiome composition (summer);
CESC	cis	rs9399135	0.660	rs4646868	chr6:135271946	A/G	cg22676075	chr6:135203613	NA	0.51	7.05	0.4	1.52e-11	Red blood cell count;
CESC	cis	rs4906332	1.000	rs12885762	chr14:103882200	C/A	cg09975044	chr14:104007538	NA	0.46	6.32	0.36	1.07e-9	Coronary artery disease;
CESC	cis	rs6732160	0.845	rs6546805	chr2:73386115	G/T	cg01422370	chr2:73384389	NA	0.42	7.15	0.4	8.33e-12	Intelligence (multi-trait analysis);
CESC	cis	rs4268898	1.000	rs4268898	chr2:24490413	C/T	cg20701182	chr2:24300061	SF3B14	-0.42	-5.1	-0.3	6.46e-7	Asthma;
CESC	cis	rs853679	0.517	rs9348794	chr6:28117757	T/A	cg19592336	chr6:28129416	ZNF389	0.62	8.12	0.45	1.77e-14	Depression;
CESC	cis	rs2243480	1.000	rs7795242	chr7:65390094	T/C	cg13147721	chr7:65941812	NA	-0.83	-7.92	-0.44	6.77e-14	Diabetic kidney disease;
CESC	cis	rs17253792	0.732	rs75796044	chr14:56034128	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.8	5.87	0.34	1.27e-8	Putamen volume;
CESC	cis	rs367615	0.537	rs1965670	chr5:108649798	A/T	cg17395555	chr5:108820864	NA	-0.48	-7.92	-0.44	6.58e-14	Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs1983891	0.742	rs755304	chr6:41552101	T/C	cg20194872	chr6:41519635	FOXP4	0.48	6.71	0.38	1.16e-10	Prostate cancer;
CESC	cis	rs2842992	0.724	rs1128670	chr6:160211636	G/A	cg11366901	chr6:160182831	ACAT2	0.64	8.17	0.45	1.24e-14	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs2730245	0.527	rs842695	chr7:158662182	G/A	cg24397884	chr7:158709396	WDR60	0.81	8.17	0.45	1.28e-14	Height;
CESC	cis	rs6546550	0.901	rs4144081	chr2:70155482	G/A	cg02498382	chr2:70120550	SNRNP27	-0.41	-7.1	-0.4	1.16e-11	Prevalent atrial fibrillation;
CESC	cis	rs9322193	0.962	rs9689269	chr6:150112997	G/A	cg05861140	chr6:150128134	PCMT1	-0.37	-5.3	-0.31	2.42e-7	Lung cancer;
CESC	cis	rs67478160	0.643	rs12891175	chr14:104274166	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.51	-7.19	-0.4	6.56e-12	Schizophrenia;
CESC	cis	rs854765	0.583	rs9635697	chr17:17870394	T/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.59	8.22	0.45	9.43e-15	Total body bone mineral density;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17617805	chr17:56595405	MTMR4	-0.73	-7.93	-0.44	5.99e-14	Gut microbiome composition (summer);
CESC	cis	rs7618915	0.547	rs11720432	chr3:52672742	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	6.9	0.39	3.9e-11	Bipolar disorder;
CESC	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg06873352	chr17:61820015	STRADA	0.73	12.89	0.62	7.87e-30	Prudent dietary pattern;
CESC	cis	rs1552244	1.000	rs9849434	chr3:10133710	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	0.85	11.76	0.59	5.89e-26	Alzheimer's disease;
CESC	trans	rs1814175	0.817	rs1615305	chr11:49895222	T/A	cg03929089	chr4:120376271	NA	-0.91	-15.66	-0.69	1.37e-39	Height;
CESC	cis	rs4523957	0.788	rs7217687	chr17:2098272	G/C	cg16513277	chr17:2031491	SMG6	-0.57	-7.75	-0.43	1.91e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs7666738	0.791	rs7665273	chr4:98997413	C/A	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.62e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs2727020	0.930	rs1164686	chr11:49291822	C/T	cg03929089	chr4:120376271	NA	0.71	9.26	0.49	7.34e-18	Coronary artery disease;
CESC	cis	rs75804782	0.641	rs60841092	chr2:239349640	G/A	cg18131467	chr2:239335373	ASB1	-0.67	-5.66	-0.33	3.93e-8	Morning vs. evening chronotype;Chronotype;
CESC	cis	rs71277158	0.688	rs76146592	chr3:169789234	C/T	cg04067573	chr3:169899625	PHC3	0.71	6.99	0.39	2.24e-11	Prostate cancer;
CESC	cis	rs3858526	0.584	rs10769271	chr11:5860572	T/C	cg02574844	chr11:5959923	NA	-0.46	-6.5	-0.37	3.99e-10	DNA methylation (variation);
CESC	cis	rs6088590	0.523	rs6088536	chr20:33189106	T/C	cg24642439	chr20:33292090	TP53INP2	0.64	8.49	0.46	1.52e-15	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10206887	chr8:22102902	POLR3D;MIR320A	0.63	7.41	0.41	1.66e-12	Gut microbiome composition (summer);
CESC	cis	rs9311474	1.000	rs1060330	chr3:52288945	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.35	5.03	0.3	9.02e-7	Electroencephalogram traits;
CESC	cis	rs11690935	0.885	rs6750058	chr2:172786909	G/T	cg13550731	chr2:172543902	DYNC1I2	-0.84	-12.29	-0.6	8.81e-28	Schizophrenia;
CESC	cis	rs477895	1.000	rs7939107	chr11:64034773	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.73	6.44	0.37	5.47e-10	Mean platelet volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18170098	chr16:71880032	ATXN1L	-0.68	-8.27	-0.45	6.76e-15	Gut microbiome composition (summer);
CESC	cis	rs1400745	0.729	rs28472856	chr14:35332157	C/T	cg16230307	chr14:35515116	FAM177A1	0.44	5.17	0.3	4.67e-7	Monocyte count;
CESC	cis	rs1881797	1.000	rs10925062	chr1:247658978	G/C	cg05639522	chr1:247681581	NA	0.51	6.43	0.37	5.89e-10	Acute lymphoblastic leukemia (childhood);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg10585161	chr5:115420544	COMMD10	0.46	6.49	0.37	4.21e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs870825	0.616	rs2310110	chr4:185647902	G/A	cg04058563	chr4:185651563	MLF1IP	0.63	6.96	0.39	2.59e-11	Blood protein levels;
CESC	cis	rs2073300	0.609	rs6137915	chr20:23358509	A/G	cg12062639	chr20:23401060	NAPB	-0.99	-7.93	-0.44	6e-14	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs7116495	0.609	rs10736780	chr11:71650241	T/C	cg10381502	chr11:71823885	C11orf51	-1.1	-7.6	-0.42	5.21e-13	Severe influenza A (H1N1) infection;
CESC	cis	rs919433	1.000	rs1346649	chr2:198166117	C/A	cg10820045	chr2:198174542	NA	-0.43	-6.53	-0.37	3.42e-10	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs295140	0.526	rs295114	chr2:201195602	C/T	cg23649088	chr2:200775458	C2orf69	0.49	6.51	0.37	3.73e-10	QT interval;
CESC	cis	rs10129255	0.500	rs988134	chr14:107184937	A/G	cg07958169	chr14:107095056	NA	-0.54	-8.52	-0.46	1.26e-15	Kawasaki disease;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg21939482	chr7:6388130	C7orf70	0.52	6.9	0.39	3.86e-11	Systemic lupus erythematosus;
CESC	cis	rs796364	0.806	rs77853713	chr2:201006880	A/T	cg23649088	chr2:200775458	C2orf69	-0.55	-5.04	-0.3	8.69e-7	Schizophrenia;
CESC	cis	rs2439831	0.850	rs68079546	chr15:44136957	G/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.66	6.03	0.35	5.4e-9	Lung cancer in ever smokers;
CESC	cis	rs6543140	0.964	rs11886793	chr2:103072220	T/G	cg04239558	chr2:103089729	SLC9A4	0.47	6.16	0.35	2.64e-9	Blood protein levels;
CESC	cis	rs554111	0.660	rs541464	chr1:21067095	C/T	cg04902671	chr1:21058625	SH2D5	-0.43	-5.23	-0.31	3.41e-7	Facial morphology (factor 17, height of vermillion upper lip);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11897034	chr16:22386000	CDR2	0.58	6.45	0.37	5.15e-10	Gut microbiome composition (summer);
CESC	cis	rs854765	0.547	rs4365348	chr17:17912548	C/T	cg09796270	chr17:17721594	SREBF1	0.39	5.42	0.32	1.34e-7	Total body bone mineral density;
CESC	cis	rs875971	0.660	rs3764903	chr7:66098482	G/A	cg06456125	chr7:65229604	NA	-0.4	-5.27	-0.31	2.86e-7	Aortic root size;
CESC	cis	rs67478160	0.634	rs2295140	chr14:104216293	C/T	cg08213375	chr14:104286397	PPP1R13B	0.46	9.07	0.49	2.69e-17	Schizophrenia;
CESC	cis	rs7216064	0.648	rs61676547	chr17:65892507	G/C	cg07042672	chr17:66097459	LOC651250	-0.59	-7.01	-0.4	1.97e-11	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs9715521	0.588	rs11731207	chr4:59852246	G/A	cg11281224	chr4:60001000	NA	-0.51	-7.11	-0.4	1.09e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs7666738	0.830	rs1967979	chr4:98966201	G/T	cg03676636	chr4:99064102	C4orf37	0.33	5.14	0.3	5.39e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs12188164	1.000	rs34453673	chr5:434722	G/C	cg26850624	chr5:429559	AHRR	-0.48	-6.58	-0.37	2.56e-10	Cystic fibrosis severity;
CESC	cis	rs9611565	0.592	rs4822044	chr22:41979668	G/C	cg06481639	chr22:41940642	POLR3H	-0.63	-6.24	-0.36	1.76e-9	Vitiligo;
CESC	cis	rs10504229	0.683	rs55714371	chr8:58131846	T/G	cg02725872	chr8:58115012	NA	-0.45	-7.05	-0.4	1.52e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs4523957	0.788	rs2169357	chr17:2096441	C/T	cg16513277	chr17:2031491	SMG6	-0.64	-8.83	-0.48	1.5e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	trans	rs116095464	0.558	rs28635197	chr5:279071	T/C	cg00938859	chr5:1591904	SDHAP3	0.65	7.03	0.4	1.73e-11	Breast cancer;
CESC	cis	rs6598955	0.640	rs1577507	chr1:26547179	C/T	cg04990556	chr1:26633338	UBXN11	-0.8	-11.48	-0.58	4.95e-25	Obesity-related traits;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg23064501	chr12:42680748	NA	0.44	6.19	0.36	2.32e-9	Fibrinogen levels;
CESC	trans	rs7937682	0.855	rs10891285	chr11:111527775	T/C	cg18187862	chr3:45730750	SACM1L	0.48	6.19	0.36	2.22e-9	Primary sclerosing cholangitis;
CESC	cis	rs13108904	0.905	rs1732108	chr4:1276550	C/T	cg22903657	chr4:1355424	KIAA1530	0.4	5.5	0.32	8.81e-8	Obesity-related traits;
CESC	cis	rs763121	0.853	rs10135	chr22:39082174	C/T	cg06544989	chr22:39130855	UNC84B	-0.51	-9.69	-0.51	3.24e-19	Menopause (age at onset);
CESC	cis	rs9311474	0.967	rs11717383	chr3:52287468	G/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.35	6.56	0.37	2.84e-10	Electroencephalogram traits;
CESC	cis	rs1801251	1.000	rs1867778	chr2:233679644	C/T	cg25237894	chr2:233734115	C2orf82	-0.44	-7.66	-0.43	3.57e-13	Coronary artery disease;
CESC	cis	rs863345	0.604	rs7518708	chr1:158504274	C/T	cg12129480	chr1:158549410	OR10X1	-0.34	-6.84	-0.39	5.41e-11	Pneumococcal bacteremia;
CESC	cis	rs4665809	0.590	rs4665313	chr2:26415897	A/G	cg04944784	chr2:26401820	FAM59B	-0.9	-10.24	-0.53	5.81e-21	Gut microbiome composition (summer);
CESC	cis	rs7772486	0.641	rs2253757	chr6:146199686	C/T	cg05347473	chr6:146136440	FBXO30	0.76	9.61	0.51	5.93e-19	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9902453	1.000	rs7221743	chr17:28407876	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.64	-8.06	-0.44	2.71e-14	Coffee consumption (cups per day);
CESC	cis	rs854765	0.663	rs16960744	chr17:17755259	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.48	-6.84	-0.39	5.41e-11	Total body bone mineral density;
CESC	cis	rs73206853	0.764	rs61117387	chr12:110867725	C/A	cg12870014	chr12:110450643	ANKRD13A	0.62	5.09	0.3	6.71e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22315683	chr3:101280662	RG9MTD1	-0.67	-7.84	-0.43	1.09e-13	Gut microbiome composition (summer);
CESC	cis	rs2228479	0.850	rs74251568	chr16:89903416	A/C	cg06558623	chr16:89946397	TCF25	1.12	8.22	0.45	9.28e-15	Skin colour saturation;
CESC	trans	rs9325144	0.647	rs61937754	chr12:39060543	T/C	cg23762105	chr12:34175262	ALG10	0.46	6.01	0.35	6.05e-9	Morning vs. evening chronotype;
CESC	cis	rs6430585	1.000	rs6732236	chr2:136501509	T/G	cg07169764	chr2:136633963	MCM6	1.02	13.21	0.63	5.99e-31	Corneal structure;
CESC	cis	rs7618915	0.547	rs2289250	chr3:52682946	A/C	cg18337363	chr3:52569053	NT5DC2	-0.28	-5.13	-0.3	5.56e-7	Bipolar disorder;
CESC	trans	rs11098499	0.954	rs1480931	chr4:120395809	G/T	cg25214090	chr10:38739885	LOC399744	0.7	10.09	0.53	1.78e-20	Corneal astigmatism;
CESC	trans	rs72766638	0.895	rs11795079	chr9:136930134	T/C	cg10765909	chr12:53715428	AAAS	-0.72	-6.48	-0.37	4.33e-10	Mosquito bite size;
CESC	cis	rs72781680	0.898	rs72790310	chr2:24116716	C/T	cg20701182	chr2:24300061	SF3B14	0.63	5.65	0.33	4.07e-8	Lymphocyte counts;
CESC	cis	rs9486719	0.895	rs3734238	chr6:96996228	A/T	cg06623918	chr6:96969491	KIAA0776	-0.8	-8.3	-0.45	5.39e-15	Migraine;Coronary artery disease;
CESC	cis	rs7605827	0.930	rs13024104	chr2:15603346	T/C	cg19274914	chr2:15703543	NA	0.35	6.11	0.35	3.48e-9	Educational attainment (years of education);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06251129	chr1:155990657	SSR2	0.61	7.29	0.41	3.61e-12	Gut microbiome composition (summer);
CESC	cis	rs4253772	0.530	rs8140573	chr22:46800363	G/C	cg09491104	chr22:46646882	C22orf40	-0.5	-5.5	-0.32	8.75e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs796364	0.760	rs56285751	chr2:200919836	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.84	-7.75	-0.43	1.94e-13	Schizophrenia;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg18767088	chr21:30670919	BACH1	0.46	6.1	0.35	3.67e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs1878931	0.501	rs42329	chr16:3425524	G/A	cg22508957	chr16:3507546	NAT15	0.39	5.6	0.33	5.26e-8	Body mass index (adult);
CESC	trans	rs11098499	0.913	rs56122576	chr4:120129336	A/G	cg25214090	chr10:38739885	LOC399744	0.63	8.33	0.46	4.44e-15	Corneal astigmatism;
CESC	cis	rs561341	1.000	rs576985	chr17:30323323	C/T	cg12193833	chr17:30244370	NA	-0.72	-6.68	-0.38	1.42e-10	Hip circumference adjusted for BMI;
CESC	cis	rs9457247	0.602	rs12208359	chr6:167458455	G/A	cg23791538	chr6:167370224	RNASET2	-0.55	-7.17	-0.4	7.51e-12	Crohn's disease;
CESC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg01931797	chr11:77899910	KCTD21;USP35	-0.5	-6.12	-0.35	3.27e-9	Lung cancer in ever smokers;
CESC	cis	rs7666738	0.830	rs4334758	chr4:98971875	A/G	cg03467027	chr4:99064603	C4orf37	0.43	5.4	0.31	1.49e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11608355	0.538	rs10850074	chr12:109800531	T/C	cg19025524	chr12:109796872	NA	-0.51	-7.14	-0.4	9.08e-12	Neuroticism;
CESC	cis	rs10791097	0.592	rs4936122	chr11:130734264	A/C	cg12179176	chr11:130786555	SNX19	0.68	10.0	0.52	3.48e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs13256369	0.851	rs11249890	chr8:8565245	G/T	cg00074818	chr8:8560427	CLDN23	0.37	5.34	0.31	2.02e-7	Obesity-related traits;
CESC	cis	rs3859192	0.599	rs2227321	chr17:38171294	G/C	cg17344932	chr17:38183730	MED24;SNORD124	0.62	9.31	0.5	5.1e-18	White blood cell count;
CESC	cis	rs780096	0.546	rs6547626	chr2:27646770	C/T	cg21248554	chr2:27665150	KRTCAP3	-0.34	-7.08	-0.4	1.27e-11	Total body bone mineral density;
CESC	cis	rs9914544	1.000	rs8066385	chr17:18761133	C/T	cg26378065	chr17:18585709	ZNF286B	0.44	5.49	0.32	9.61e-8	Educational attainment (years of education);
CESC	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg07677032	chr17:61819896	STRADA	0.44	5.88	0.34	1.21e-8	Prudent dietary pattern;
CESC	cis	rs1348850	0.513	rs6730406	chr2:178492722	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.48	5.59	0.32	5.57e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs4843747	0.671	rs74729706	chr16:88104159	C/T	cg06915872	chr16:87998081	BANP	0.44	5.2	0.3	3.99e-7	Menopause (age at onset);
CESC	cis	rs13031619	1.000	rs13031619	chr2:3698371	A/G	cg19052272	chr2:3704530	ALLC	0.53	6.87	0.39	4.56e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CESC	cis	rs9309473	0.898	rs10201159	chr2:73858965	T/C	cg20560298	chr2:73613845	ALMS1	-0.53	-6.78	-0.38	7.74e-11	Metabolite levels;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg01334186	chr1:151372572	PSMB4	0.49	6.74	0.38	9.88e-11	Systemic lupus erythematosus;
CESC	cis	rs4315565	1.000	rs4315565	chr2:69287943	A/G	cg12800200	chr2:69260302	ANTXR1	-0.41	-5.91	-0.34	1.04e-8	Height;
CESC	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg11494091	chr17:61959527	GH2	0.73	12.68	0.61	4.13e-29	Prudent dietary pattern;
CESC	cis	rs7618915	0.501	rs2159644	chr3:52774530	C/T	cg07507251	chr3:52567010	NT5DC2	0.33	5.61	0.33	5.09e-8	Bipolar disorder;
CESC	cis	rs477895	0.713	rs7952318	chr11:63961242	G/A	cg04317338	chr11:64019027	PLCB3	0.8	8.46	0.46	1.83e-15	Mean platelet volume;
CESC	cis	rs6580649	0.941	rs6580651	chr12:48429933	A/T	cg24011408	chr12:48396354	COL2A1	-0.42	-5.28	-0.31	2.68e-7	Lung cancer;
CESC	cis	rs4409675	0.576	rs2749119	chr1:28236248	G/A	cg23691781	chr1:28212827	C1orf38	0.28	5.59	0.32	5.61e-8	Corneal astigmatism;
CESC	cis	rs6964587	0.933	rs10271174	chr7:91785970	A/G	cg17063962	chr7:91808500	NA	0.59	8.24	0.45	7.92e-15	Breast cancer;
CESC	cis	rs1797885	0.934	rs709165	chr3:12514124	A/G	cg26432171	chr3:12704882	RAF1	-0.52	-6.71	-0.38	1.21e-10	Immature fraction of reticulocytes;
CESC	cis	rs7552404	1.000	rs4949674	chr1:76213715	C/A	cg03433033	chr1:76189801	ACADM	0.68	8.23	0.45	8.33e-15	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs3015497	0.934	rs2934691	chr14:51121333	C/A	cg26011998	chr14:51135199	SAV1	-0.43	-5.49	-0.32	9.62e-8	Mean platelet volume;
CESC	cis	rs11048434	0.736	rs2041624	chr12:9111855	C/G	cg23795048	chr12:9217529	LOC144571	0.35	5.35	0.31	1.9e-7	Sjögren's syndrome;
CESC	cis	rs362272	0.524	rs3129334	chr4:3368526	T/C	cg08886695	chr4:3369023	RGS12	-0.42	-5.82	-0.34	1.72e-8	Serum sulfate level;
CESC	cis	rs1005277	0.579	rs2474587	chr10:38420666	C/T	cg00409905	chr10:38381863	ZNF37A	-0.46	-6.18	-0.35	2.39e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs7084402	0.967	rs1658460	chr10:60299151	T/G	cg07615347	chr10:60278583	BICC1	0.6	9.46	0.5	1.77e-18	Refractive error;
CESC	cis	rs1552244	0.810	rs4019706	chr3:10112862	G/A	cg00166722	chr3:10149974	C3orf24	0.54	6.89	0.39	4.08e-11	Alzheimer's disease;
CESC	cis	rs1059312	0.522	rs3825181	chr12:129279264	G/A	cg09035930	chr12:129282057	SLC15A4	-0.52	-6.67	-0.38	1.5e-10	Systemic lupus erythematosus;
CESC	cis	rs6424115	0.830	rs2501425	chr1:24199339	A/C	cg10978503	chr1:24200527	CNR2	0.33	6.63	0.38	1.85e-10	Immature fraction of reticulocytes;
CESC	cis	rs11122272	0.735	rs2790882	chr1:231532783	A/G	cg06096015	chr1:231504339	EGLN1	-0.41	-5.86	-0.34	1.37e-8	Hemoglobin concentration;
CESC	cis	rs10242455	0.702	rs75156180	chr7:98964100	G/A	cg25640893	chr7:99214727	ZNF498	0.85	5.5	0.32	9.08e-8	Blood metabolite levels;
CESC	cis	rs6430585	0.583	rs4594504	chr2:136625113	A/C	cg07169764	chr2:136633963	MCM6	1.3	20.08	0.78	3.71e-55	Corneal structure;
CESC	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg23034840	chr1:205782522	SLC41A1	0.68	8.11	0.45	1.88e-14	Menarche (age at onset);
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg05609414	chr7:39873832	NA	-0.41	-6.35	-0.36	9.33e-10	Asthma;
CESC	trans	rs2115172	0.836	rs4835799	chr5:122762229	A/G	cg12427896	chr2:111880694	BCL2L11	0.47	6.37	0.36	8.2e-10	Weight;
CESC	cis	rs10870270	0.913	rs115236491	chr10:133766855	T/G	cg08754478	chr10:133766260	PPP2R2D	-0.59	-7.62	-0.42	4.57e-13	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	10.16	0.53	1.09e-20	Prudent dietary pattern;
CESC	cis	rs919433	0.783	rs55725278	chr2:198238223	C/T	cg03934865	chr2:198174659	NA	0.44	6.27	0.36	1.49e-9	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs9902453	0.933	rs9908901	chr17:28469713	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	7.6	0.42	5.23e-13	Coffee consumption (cups per day);
CESC	cis	rs4950928	0.823	rs7541061	chr1:203163367	G/T	cg14085262	chr1:203155938	CHI3L1	0.47	5.26	0.31	3e-7	YKL-40 levels;
CESC	cis	rs7666738	0.830	rs11723283	chr4:99001617	C/T	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.62e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs8177253	0.829	rs6794945	chr3:133518463	A/G	cg12373951	chr3:133503437	NA	-0.49	-7.29	-0.41	3.65e-12	Iron status biomarkers;
CESC	cis	rs826838	1.000	rs2129627	chr12:38653036	C/T	cg13010199	chr12:38710504	ALG10B	0.59	8.31	0.45	4.93e-15	Heart rate;
CESC	cis	rs7659604	0.539	rs2063165	chr4:122750005	A/G	cg06713675	chr4:122721982	EXOSC9	-0.5	-6.86	-0.39	4.93e-11	Type 2 diabetes;
CESC	cis	rs524023	1.000	rs11602903	chr11:64358241	A/T	cg07220939	chr11:64358617	SLC22A12	-0.35	-5.46	-0.32	1.09e-7	Urate levels in obese individuals;
CESC	cis	rs9910055	0.708	rs2631298	chr17:42219832	T/C	cg13607699	chr17:42295918	UBTF	0.57	7.38	0.41	2.07e-12	Total body bone mineral density;
CESC	cis	rs7666738	0.830	rs13118945	chr4:98968586	T/G	cg03467027	chr4:99064603	C4orf37	0.43	5.42	0.32	1.34e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs898097	0.627	rs3785514	chr17:80888905	A/G	cg15369054	chr17:80825471	TBCD	-0.46	-6.23	-0.36	1.84e-9	Breast cancer;
CESC	cis	rs12477438	0.501	rs17759607	chr2:99737005	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.78	13.44	0.64	9.76e-32	Chronic sinus infection;
CESC	cis	rs6942756	0.531	rs2896415	chr7:128904523	G/A	cg02491457	chr7:128862824	NA	0.46	6.6	0.38	2.2e-10	White matter hyperintensity burden;
CESC	cis	rs9818758	0.545	rs11717978	chr3:48969036	T/A	cg00383909	chr3:49044727	WDR6	0.92	6.76	0.38	8.71e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CESC	cis	rs1067327	1	rs1067327	chr2:44628529	C/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	6.51	0.37	3.65e-10	Anxiety disorder (factor score);
CESC	cis	rs514406	0.763	rs7535088	chr1:53215042	A/G	cg08736216	chr1:53307985	ZYG11A	0.41	6.85	0.39	5.29e-11	Monocyte count;
CESC	cis	rs7219021	0.926	rs10468570	chr17:46862085	G/A	cg16584676	chr17:46985605	UBE2Z	-0.56	-6.44	-0.37	5.45e-10	Schizophrenia or bipolar disorder;
CESC	cis	rs4481887	0.790	rs6587440	chr1:248415662	A/G	cg00666640	chr1:248458726	OR2T12	0.33	5.72	0.33	2.87e-8	Common traits (Other);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg07089834	chr17:79239572	SLC38A10	0.5	6.81	0.39	6.46e-11	Fibrinogen levels;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg10450178	chr12:89920041	WDR51B	-0.49	-6.69	-0.38	1.35e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs17253792	0.545	rs12879705	chr14:56017684	C/G	cg01858014	chr14:56050164	KTN1	-0.87	-6.37	-0.36	8.34e-10	Putamen volume;
CESC	cis	rs4076764	0.881	rs10917758	chr1:163430652	G/A	cg24596788	chr1:163392923	NA	-0.41	-5.79	-0.34	1.96e-8	Motion sickness;
CESC	cis	rs367615	0.879	rs4351197	chr5:108866667	A/G	cg17395555	chr5:108820864	NA	0.57	8.42	0.46	2.39e-15	Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs4665809	0.652	rs12611790	chr2:26404221	C/T	cg25036284	chr2:26402008	FAM59B	-0.83	-9.16	-0.49	1.46e-17	Gut microbiome composition (summer);
CESC	cis	rs2795502	1.000	rs3121323	chr10:43377166	A/G	cg20628663	chr10:43360327	NA	-0.56	-6.82	-0.39	6.19e-11	Blood protein levels;
CESC	cis	rs10504229	1.000	rs73609764	chr8:58192971	G/A	cg22535103	chr8:58192502	C8orf71	-1.05	-13.08	-0.63	1.71e-30	Developmental language disorder (linguistic errors);
CESC	cis	rs7259376	0.936	rs1865075	chr19:22554854	T/C	cg02657401	chr19:22469223	NA	-0.25	-5.05	-0.3	8.34e-7	Menopause (age at onset);
CESC	cis	rs1215050	0.791	rs165237	chr4:98712029	T/C	cg05340658	chr4:99064831	C4orf37	0.5	6.37	0.36	8.34e-10	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs6088590	0.687	rs73106933	chr20:33287425	T/C	cg08999081	chr20:33150536	PIGU	0.64	10.41	0.54	1.64e-21	Coronary artery disease;
CESC	cis	rs8078723	0.714	rs9915252	chr17:38145088	C/G	cg17467752	chr17:38218738	THRA	-0.57	-8.48	-0.46	1.57e-15	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CESC	cis	rs1707322	1.000	rs785465	chr1:46522577	G/T	cg06784218	chr1:46089804	CCDC17	0.34	5.85	0.34	1.41e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs1552244	0.816	rs13076197	chr3:10019773	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.76	-9.64	-0.51	4.86e-19	Alzheimer's disease;
CESC	cis	rs10751667	0.666	rs4074233	chr11:977685	G/A	cg06064525	chr11:970664	AP2A2	-0.47	-9.12	-0.49	1.9e-17	Alzheimer's disease (late onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17887793	chr1:161494110	HSPA6	0.53	6.36	0.36	8.84e-10	Gut microbiome composition (summer);
CESC	cis	rs12413816	0.784	rs35537139	chr10:13768894	G/A	cg16485048	chr10:13749193	FRMD4A	0.48	5.9	0.34	1.14e-8	Red cell distribution width;
CESC	cis	rs863345	0.967	rs2157689	chr1:158459264	T/C	cg12129480	chr1:158549410	OR10X1	-0.3	-6.01	-0.35	6.27e-9	Pneumococcal bacteremia;
CESC	cis	rs1153858	0.621	rs12913645	chr15:45555066	G/A	cg21132104	chr15:45694354	SPATA5L1	-0.74	-8.64	-0.47	5.35e-16	Homoarginine levels;
CESC	cis	rs4523957	0.820	rs9908972	chr17:2103810	A/C	cg16513277	chr17:2031491	SMG6	-0.67	-9.25	-0.49	7.79e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs175714	0.845	rs175706	chr14:75976200	G/A	cg01624173	chr14:75981868	NA	0.57	8.11	0.45	1.87e-14	Lymphocyte counts;
CESC	cis	rs2294693	0.891	rs1072119	chr6:40993072	G/A	cg14418226	chr6:40996092	UNC5CL	0.52	6.3	0.36	1.2e-9	Gastric cancer;Non-cardia gastric cancer;
CESC	cis	rs10504229	0.593	rs10504216	chr8:57981470	G/A	cg24829409	chr8:58192753	C8orf71	-0.67	-7.3	-0.41	3.45e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs10504229	0.906	rs58559296	chr8:58171714	T/C	cg24829409	chr8:58192753	C8orf71	-0.76	-10.0	-0.52	3.53e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs4819052	1.000	rs13052356	chr21:46663588	G/A	cg11663144	chr21:46675770	NA	-0.51	-7.05	-0.4	1.53e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs7927592	0.913	rs11228292	chr11:68379772	C/T	cg20283391	chr11:68216788	NA	-0.61	-7.39	-0.41	1.87e-12	Total body bone mineral density;
CESC	cis	rs11792861	0.591	rs2282206	chr9:111746267	A/G	cg05043794	chr9:111880884	C9orf5	-0.32	-5.68	-0.33	3.56e-8	Menarche (age at onset);
CESC	cis	rs2075371	0.933	rs2244548	chr7:133986234	A/G	cg20476274	chr7:133979776	SLC35B4	0.67	9.79	0.52	1.65e-19	Mean platelet volume;
CESC	cis	rs11690935	1.000	rs35549875	chr2:172532392	A/G	cg13550731	chr2:172543902	DYNC1I2	0.93	13.56	0.64	3.73e-32	Schizophrenia;
CESC	cis	rs9596863	0.808	rs9316647	chr13:54220636	G/A	ch.13.53330881F	chr13:54432880	NA	0.63	5.11	0.3	6.3e-7	Epilepsy and lamotrigine-induced maculopapular eruptions;
CESC	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.42	5.66	0.33	3.97e-8	Lymphocyte counts;
CESC	cis	rs7520050	0.778	rs12404197	chr1:46232420	G/A	cg06784218	chr1:46089804	CCDC17	-0.31	-5.59	-0.32	5.66e-8	Red blood cell count;Reticulocyte count;
CESC	cis	rs6500395	0.889	rs2080507	chr16:48688634	T/A	cg04672837	chr16:48644449	N4BP1	-0.51	-6.36	-0.36	8.64e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs736408	0.812	rs6778329	chr3:52824610	G/A	cg05564831	chr3:52568323	NT5DC2	0.41	5.95	0.34	8.52e-9	Bipolar disorder;
CESC	cis	rs7772486	0.754	rs1055212	chr6:146058315	A/T	cg23711669	chr6:146136114	FBXO30	-0.99	-15.23	-0.68	4.75e-38	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs40363	0.723	rs8060367	chr16:3537919	C/A	cg00484396	chr16:3507460	NAT15	-0.57	-6.35	-0.36	9.52e-10	Tuberculosis;
CESC	cis	rs2603127	0.768	rs959106	chr3:108479517	A/G	cg03329597	chr3:108125523	MYH15	0.6	5.35	0.31	1.91e-7	Hemostatic factors and hematological phenotypes;
CESC	cis	rs7618915	0.571	rs12487445	chr3:52618319	A/C	cg07507251	chr3:52567010	NT5DC2	0.44	7.65	0.43	3.83e-13	Bipolar disorder;
CESC	trans	rs7618501	1.000	rs57648519	chr3:49813169	C/A	cg21659725	chr3:3221576	CRBN	0.83	13.52	0.64	4.88e-32	Intelligence (multi-trait analysis);
CESC	cis	rs9379850	0.730	rs9393738	chr6:26620658	G/A	cg11502198	chr6:26597334	ABT1	0.52	5.31	0.31	2.35e-7	Intelligence (multi-trait analysis);
CESC	cis	rs7666738	0.715	rs3857216	chr4:99032129	G/T	cg24818145	chr4:99064322	C4orf37	0.39	5.09	0.3	6.95e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7116495	0.609	rs2845860	chr11:71716661	C/T	cg26138937	chr11:71823887	C11orf51	-1.22	-8.0	-0.44	3.97e-14	Severe influenza A (H1N1) infection;
CESC	cis	rs36051895	0.623	rs7027871	chr9:5236822	C/G	cg02405213	chr9:5042618	JAK2	0.61	7.29	0.41	3.56e-12	Pediatric autoimmune diseases;
CESC	trans	rs7326068	0.576	rs34880311	chr13:21329255	A/T	cg00192819	chr18:76486611	NA	0.43	6.01	0.35	6.11e-9	Schizophrenia, bipolar disorder and depression (combined);
CESC	cis	rs863345	0.584	rs10908677	chr1:158506186	C/T	cg12129480	chr1:158549410	OR10X1	0.27	5.56	0.32	6.55e-8	Pneumococcal bacteremia;
CESC	cis	rs6879260	1.000	rs729568	chr5:179732350	C/T	cg23248424	chr5:179741104	GFPT2	0.56	7.81	0.43	1.38e-13	Height;
CESC	cis	rs2576037	0.583	rs2156049	chr18:44455717	G/A	cg19077165	chr18:44547161	KATNAL2	-0.61	-9.35	-0.5	3.87e-18	Personality dimensions;
CESC	cis	rs6754311	0.731	rs2236783	chr2:136594158	G/A	cg15123519	chr2:136567270	LCT	0.34	5.55	0.32	6.92e-8	Mosquito bite size;
CESC	cis	rs2652822	0.525	rs35594365	chr15:63520154	T/C	cg02713581	chr15:63449717	RPS27L	0.48	6.22	0.36	1.95e-9	Metabolic traits;
CESC	cis	rs654950	1.000	rs646228	chr1:41986066	A/C	cg06885757	chr1:42089581	HIVEP3	0.53	8.21	0.45	1.01e-14	Airway imaging phenotypes;
CESC	cis	rs453301	0.658	rs12114954	chr8:8904862	T/G	cg15556689	chr8:8085844	FLJ10661	-0.51	-6.35	-0.36	9.38e-10	Joint mobility (Beighton score);
CESC	cis	rs35306767	0.714	rs17293608	chr10:1056252	C/T	cg26597838	chr10:835615	NA	0.74	6.87	0.39	4.52e-11	Eosinophil percentage of granulocytes;
CESC	cis	rs8114671	0.836	rs745849	chr20:33572178	G/A	cg06115741	chr20:33292138	TP53INP2	-0.44	-5.23	-0.31	3.46e-7	Height;
CESC	cis	rs13256369	0.802	rs11995449	chr8:8559898	G/A	cg17143192	chr8:8559678	CLDN23	0.77	8.61	0.47	6.8e-16	Obesity-related traits;
CESC	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg18402987	chr7:1209562	NA	0.75	7.49	0.42	1.04e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs1862618	0.853	rs1862619	chr5:56098256	T/A	cg22800045	chr5:56110881	MAP3K1	0.73	9.21	0.49	1e-17	Initial pursuit acceleration;
CESC	cis	rs2050392	0.928	rs2250077	chr10:30702929	A/G	cg25182066	chr10:30743637	MAP3K8	-0.39	-5.28	-0.31	2.71e-7	Inflammatory bowel disease;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg07423838	chr7:73062350	NA	-0.46	-6.63	-0.38	1.9e-10	Gambling;
CESC	cis	rs4629180	0.586	rs1509494	chr2:102134862	G/T	cg04415270	chr2:102091202	RFX8	-0.3	-5.11	-0.3	6.1e-7	Chronic rhinosinusitis with nasal polyps;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21662494	chr21:37502552	NA	0.64	6.85	0.39	5.12e-11	Gut microbiome composition (summer);
CESC	cis	rs17253792	0.822	rs10133962	chr14:56066088	G/A	cg01858014	chr14:56050164	KTN1	-0.87	-6.75	-0.38	9.11e-11	Putamen volume;
CESC	cis	rs733592	0.524	rs10875727	chr12:48426143	T/C	cg04545296	chr12:48745243	ZNF641	-0.29	-5.46	-0.32	1.07e-7	Plateletcrit;
CESC	cis	rs7777484	0.571	rs2527686	chr7:2834413	G/A	cg19717773	chr7:2847554	GNA12	-0.68	-11.82	-0.59	3.61e-26	Height;
CESC	cis	rs7833790	0.660	rs7839178	chr8:82763479	A/G	cg02079420	chr8:82753780	SNX16	-0.54	-8.28	-0.45	6.31e-15	Diastolic blood pressure;
CESC	cis	rs1461503	0.809	rs7121955	chr11:122845478	A/T	cg27398637	chr11:122830231	C11orf63	-0.55	-8.03	-0.44	3.2e-14	Menarche (age at onset);
CESC	cis	rs4423214	1.000	rs12807718	chr11:71171170	T/C	cg05163923	chr11:71159392	DHCR7	0.83	11.29	0.57	2.17e-24	Vitamin D levels;
CESC	cis	rs2075371	0.897	rs12667905	chr7:134000812	A/C	cg20476274	chr7:133979776	SLC35B4	0.61	8.7	0.47	3.49e-16	Mean platelet volume;
CESC	cis	rs10870270	1.000	rs7199	chr10:133769848	C/G	cg26149184	chr10:133730230	NA	0.38	5.14	0.3	5.22e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs7680126	0.633	rs4697743	chr4:10294833	A/G	cg00071950	chr4:10020882	SLC2A9	-0.51	-5.73	-0.33	2.66e-8	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg22538323	chr7:27702700	HIBADH	-0.44	-6.11	-0.35	3.63e-9	Vertical cup-disc ratio;
CESC	cis	rs853679	0.550	rs1225599	chr6:28165190	C/T	cg23281280	chr6:28129359	ZNF389	0.5	6.98	0.39	2.39e-11	Depression;
CESC	cis	rs7527798	0.592	rs6671969	chr1:207839667	C/T	cg21110645	chr1:207815933	NA	-0.3	-5.28	-0.31	2.75e-7	Erythrocyte sedimentation rate;
CESC	cis	rs9309473	0.950	rs6546859	chr2:73842055	C/A	cg20560298	chr2:73613845	ALMS1	-0.43	-5.74	-0.33	2.61e-8	Metabolite levels;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg02126464	chr7:128695174	LOC286016;TNPO3	0.46	6.25	0.36	1.61e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs6088580	0.524	rs1853056	chr20:33262058	C/T	cg08999081	chr20:33150536	PIGU	-0.43	-6.02	-0.35	5.65e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg18402987	chr7:1209562	NA	0.76	7.61	0.42	4.74e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs9611565	0.659	rs11090049	chr22:41915329	C/T	cg06634786	chr22:41940651	POLR3H	-0.7	-7.1	-0.4	1.15e-11	Vitiligo;
CESC	cis	rs42648	0.837	rs4728879	chr7:89924237	T/G	cg23697855	chr7:89950296	NA	0.28	5.25	0.31	3.08e-7	Homocysteine levels;
CESC	cis	rs3857067	0.806	rs6532472	chr4:95110113	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.6	-9.12	-0.49	1.97e-17	QT interval;
CESC	cis	rs2120019	0.938	rs2120020	chr15:75316845	T/C	cg09165964	chr15:75287851	SCAMP5	-0.8	-9.87	-0.52	9.2e-20	Blood trace element (Zn levels);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13284070	chr3:128483832	RAB7A	-0.65	-6.91	-0.39	3.5e-11	Gut microbiome composition (summer);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg09965679	chr14:75179859	FCF1;KIAA0317	-0.43	-6.0	-0.35	6.37e-9	Gut microbiota (bacterial taxa);
CESC	trans	rs7980799	0.654	rs10844618	chr12:33625010	A/G	cg26384229	chr12:38710491	ALG10B	-0.55	-7.81	-0.43	1.32e-13	Heart rate;Heart rate variability traits (RMSSD);
CESC	cis	rs6500602	0.928	rs3747581	chr16:4462619	A/G	cg08645402	chr16:4508243	NA	0.47	7.27	0.41	4e-12	Schizophrenia;
CESC	cis	rs7927592	0.913	rs3740629	chr11:68343593	C/T	cg20283391	chr11:68216788	NA	-0.61	-7.29	-0.41	3.48e-12	Total body bone mineral density;
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg07483432	chr12:72079704	TMEM19	-0.45	-7.12	-0.4	9.87e-12	Vertical cup-disc ratio;
CESC	cis	rs864537	0.584	rs7523907	chr1:167427247	A/G	cg22356347	chr1:167427500	CD247	-0.29	-5.96	-0.34	7.98e-9	Celiac disease or Rheumatoid arthritis;Celiac disease;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg03625951	chr6:149867442	PPIL4	-0.5	-7.29	-0.41	3.5e-12	Gambling;
CESC	cis	rs2295499	0.615	rs57978437	chr4:2711162	C/T	cg08330972	chr4:2403930	ZFYVE28	-0.33	-5.41	-0.32	1.41e-7	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
CESC	cis	rs9457247	0.566	rs10946207	chr6:167456036	C/T	cg23791538	chr6:167370224	RNASET2	-0.54	-6.99	-0.39	2.22e-11	Crohn's disease;
CESC	cis	rs4253772	0.550	rs739164	chr22:46684558	C/T	cg14686297	chr22:46650375	NA	0.4	5.19	0.3	4.13e-7	LDL cholesterol;Cholesterol, total;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg21751231	chr11:64490736	NRXN2	-0.37	-6.94	-0.39	2.98e-11	Gambling;
CESC	cis	rs12144309	0.608	rs1217408	chr1:114396280	T/C	cg13572289	chr1:114447746	DCLRE1B;AP4B1	0.44	5.15	0.3	5.07e-7	Coronary artery disease;
CESC	cis	rs78707713	0.560	rs35060419	chr10:71229539	A/G	cg12610070	chr10:71211762	TSPAN15	-0.32	-6.75	-0.38	9.22e-11	Venous thromboembolism;
CESC	cis	rs59724122	0.542	rs28633173	chr8:27446980	A/G	cg01579299	chr8:27450062	NA	0.45	5.46	0.32	1.11e-7	Bipolar disorder lithium response (categorical) or schizophrenia;
CESC	cis	rs13108904	0.935	rs6853002	chr4:1295991	C/T	cg16405210	chr4:1374714	KIAA1530	-0.44	-5.46	-0.32	1.11e-7	Obesity-related traits;
CESC	cis	rs8070740	0.838	rs1050390	chr17:5336058	G/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.57	6.74	0.38	9.9e-11	Menopause (age at onset);
CESC	cis	rs6088580	0.634	rs6087579	chr20:32985155	A/G	cg06115741	chr20:33292138	TP53INP2	-0.46	-5.93	-0.34	9.62e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs7107174	1.000	rs2511168	chr11:77965081	T/G	cg02023728	chr11:77925099	USP35	0.44	6.23	0.36	1.84e-9	Testicular germ cell tumor;
CESC	cis	rs2997447	0.739	rs72884784	chr1:26432246	G/A	cg24596570	chr1:26146463	FAM54B;LOC646471	0.62	5.33	0.31	2.07e-7	QRS complex (12-leadsum);
CESC	cis	rs6754311	0.731	rs1470457	chr2:136581848	A/G	cg15123519	chr2:136567270	LCT	-0.33	-5.85	-0.34	1.46e-8	Mosquito bite size;
CESC	cis	rs7666738	0.830	rs13149779	chr4:99010145	G/T	cg05340658	chr4:99064831	C4orf37	0.78	11.94	0.59	1.39e-26	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6580649	0.941	rs4760618	chr12:48434767	G/A	cg05342945	chr12:48394962	COL2A1	0.54	6.11	0.35	3.53e-9	Lung cancer;
CESC	cis	rs875971	0.862	rs7796162	chr7:65745758	T/C	cg19163074	chr7:65112434	INTS4L2	0.4	5.07	0.3	7.58e-7	Aortic root size;
CESC	cis	rs6540559	0.673	rs7550857	chr1:209956542	C/A	cg23283495	chr1:209979779	IRF6	0.52	6.16	0.35	2.65e-9	Cleft lip with or without cleft palate;
CESC	cis	rs4665809	0.567	rs12999875	chr2:26414847	A/C	cg25036284	chr2:26402008	FAM59B	0.84	9.53	0.51	1.04e-18	Gut microbiome composition (summer);
CESC	cis	rs5769765	0.825	rs7511620	chr22:50307932	T/C	cg02269571	chr22:50332266	NA	-0.55	-6.8	-0.39	7.11e-11	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25107717	chr1:94312368	MIR760	0.66	7.83	0.43	1.14e-13	Gut microbiome composition (summer);
CESC	cis	rs9311474	0.508	rs11720243	chr3:52618018	T/C	cg18337363	chr3:52569053	NT5DC2	0.3	5.5	0.32	8.87e-8	Electroencephalogram traits;
CESC	cis	rs1964356	0.967	rs17701675	chr8:8850633	A/G	cg06636001	chr8:8085503	FLJ10661	-0.42	-5.64	-0.33	4.32e-8	Mean corpuscular volume;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg26770187	chr3:14693171	C3orf19	0.48	6.34	0.36	9.72e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs2932538	0.883	rs7549547	chr1:113086717	A/T	cg22162597	chr1:113214053	CAPZA1	0.56	7.0	0.39	2.15e-11	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg18882091	chr7:99058544	ATP5J2	-0.43	-6.28	-0.36	1.36e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs11971779	0.878	rs4732378	chr7:139120395	C/T	cg07862535	chr7:139043722	LUC7L2	0.57	5.67	0.33	3.64e-8	Diisocyanate-induced asthma;
CESC	cis	rs796364	0.756	rs2949006	chr2:200715388	T/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.9	8.82	0.48	1.57e-16	Schizophrenia;
CESC	cis	rs1506636	0.924	rs4370458	chr7:123260968	G/A	cg03229431	chr7:123269106	ASB15	-0.52	-6.8	-0.39	7.05e-11	Plateletcrit;Platelet count;
CESC	trans	rs1814175	0.588	rs10466497	chr11:49864381	A/T	cg03929089	chr4:120376271	NA	-0.9	-14.58	-0.67	9.13e-36	Height;
CESC	cis	rs9902453	0.726	rs4795523	chr17:28176314	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.73	9.67	0.51	3.74e-19	Coffee consumption (cups per day);
CESC	cis	rs7523050	0.643	rs7551142	chr1:109399710	G/T	cg08274380	chr1:109419600	GPSM2	0.83	5.58	0.32	5.89e-8	Fat distribution (HIV);
CESC	cis	rs9470366	0.527	rs4711456	chr6:36632482	C/T	cg08179530	chr6:36648295	CDKN1A	-0.63	-9.28	-0.5	6.12e-18	QRS duration;
CESC	cis	rs78456975	0.506	rs13402886	chr2:1575348	G/A	cg26248373	chr2:1572462	NA	-0.57	-6.58	-0.37	2.55e-10	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs10504229	1.000	rs66886949	chr8:58187613	A/G	cg05313129	chr8:58192883	C8orf71	-0.55	-6.29	-0.36	1.34e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs9487051	0.735	rs882074	chr6:109611720	C/T	cg01475377	chr6:109611718	NA	-0.49	-8.21	-0.45	9.56e-15	Reticulocyte fraction of red cells;
CESC	cis	rs1707322	0.752	rs4660313	chr1:46110841	A/G	cg06784218	chr1:46089804	CCDC17	-0.4	-6.94	-0.39	3e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs3812565	0.506	rs4259518	chr9:139322503	T/C	cg14169450	chr9:139327907	INPP5E	0.54	8.08	0.44	2.26e-14	Granulocyte percentage of myeloid white cells;
CESC	cis	rs7267979	0.903	rs6050482	chr20:25226327	C/T	cg08601574	chr20:25228251	PYGB	0.39	5.83	0.34	1.62e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs9487051	0.872	rs9400269	chr6:109606065	C/G	cg21918786	chr6:109611834	NA	-0.41	-6.07	-0.35	4.49e-9	Reticulocyte fraction of red cells;
CESC	cis	rs1670533	1.000	rs6821725	chr4:1060360	C/G	cg27284194	chr4:1044797	NA	0.47	6.07	0.35	4.4e-9	Recombination rate (females);
CESC	cis	rs7727544	0.735	rs2631370	chr5:131703776	T/C	cg24060327	chr5:131705240	SLC22A5	0.67	8.84	0.48	1.41e-16	Blood metabolite levels;
CESC	cis	rs67478160	0.634	rs7141928	chr14:104219949	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.52	-7.62	-0.42	4.49e-13	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16319310	chr10:52390957	NA	-0.7	-8.38	-0.46	3.12e-15	Gut microbiome composition (summer);
CESC	cis	rs6502050	0.842	rs7218075	chr17:80076808	C/G	cg23985595	chr17:80112537	CCDC57	0.41	6.42	0.37	6.41e-10	Life satisfaction;
CESC	cis	rs9815354	0.812	rs73077361	chr3:41850146	G/A	cg03022575	chr3:42003672	ULK4	0.7	6.04	0.35	5.26e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs897984	0.683	rs729482	chr16:31016970	T/C	cg02466173	chr16:30829666	NA	-0.44	-7.11	-0.4	1.1e-11	Dementia with Lewy bodies;
CESC	cis	rs9297145	1.000	rs9297145	chr7:98759117	A/C	cg05967295	chr7:98741636	SMURF1	0.95	12.55	0.61	1.11e-28	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
CESC	cis	rs10979	0.597	rs9403514	chr6:143907790	T/C	cg25407410	chr6:143891975	LOC285740	-0.49	-6.31	-0.36	1.16e-9	Hypospadias;
CESC	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg14159672	chr1:205819179	PM20D1	0.79	12.7	0.62	3.4e-29	Menarche (age at onset);
CESC	cis	rs9457247	0.534	rs933243	chr6:167403873	A/C	cg23791538	chr6:167370224	RNASET2	-0.66	-9.43	-0.5	2.09e-18	Crohn's disease;
CESC	cis	rs75477785	0.590	rs12061641	chr1:210255104	A/G	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.95	6.41	0.37	6.82e-10	Cleft lip with or without cleft palate;
CESC	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.55	-6.17	-0.35	2.48e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7818345	0.845	rs11785649	chr8:19268233	G/A	cg11303988	chr8:19266685	CSGALNACT1	0.38	6.62	0.38	1.95e-10	Language performance in older adults (adjusted for episodic memory);
CESC	cis	rs58688157	0.705	rs7112149	chr11:595890	G/A	cg02461776	chr11:598696	PHRF1	0.5	5.85	0.34	1.46e-8	Systemic lupus erythematosus;
CESC	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg06877462	chr1:205807181	PM20D1	-0.34	-5.4	-0.31	1.47e-7	Monocyte percentage of white cells;
CESC	cis	rs1799949	0.628	rs4474733	chr17:41433660	G/T	cg25072359	chr17:41440525	NA	0.45	5.28	0.31	2.71e-7	Menopause (age at onset);
CESC	cis	rs1707322	1.000	rs7538978	chr1:46505054	C/T	cg05343316	chr1:45956843	TESK2	-0.44	-5.41	-0.32	1.38e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7000551	0.725	rs2449349	chr8:22383284	A/G	cg12081754	chr8:22256438	SLC39A14	0.39	5.22	0.31	3.6e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CESC	cis	rs6840258	1.000	rs75550773	chr4:87955423	G/T	cg08197287	chr4:87952173	AFF1	-0.38	-5.27	-0.31	2.85e-7	Mean corpuscular volume;Basophil percentage of granulocytes;
CESC	cis	rs4665809	0.838	rs2243834	chr2:26357748	A/C	cg04944784	chr2:26401820	FAM59B	0.63	7.39	0.41	1.94e-12	Gut microbiome composition (summer);
CESC	cis	rs6973256	0.583	rs6955530	chr7:133339511	T/C	cg10665199	chr7:133106180	EXOC4	0.46	6.21	0.36	2e-9	Intelligence (multi-trait analysis);
CESC	cis	rs2243480	1.000	rs12698509	chr7:65418876	C/T	cg18252515	chr7:66147081	NA	-1.03	-9.89	-0.52	7.88e-20	Diabetic kidney disease;
CESC	cis	rs9341835	0.511	rs1744146	chr6:64221869	A/C	cg03326410	chr6:64151739	NA	0.32	5.15	0.3	5.1e-7	Schizophrenia;
CESC	cis	rs6582630	0.539	rs35114325	chr12:38320886	G/T	cg26384229	chr12:38710491	ALG10B	-0.46	-5.96	-0.34	8.17e-9	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs2929278	0.617	rs693919	chr15:44102328	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.47	-7.2	-0.4	6.27e-12	Schizophrenia;
CESC	cis	rs7772486	0.658	rs6570706	chr6:145962922	T/C	cg23711669	chr6:146136114	FBXO30	0.86	12.69	0.61	3.91e-29	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs1814175	0.645	rs10128563	chr11:50023681	T/C	cg03929089	chr4:120376271	NA	-0.91	-14.8	-0.67	1.58e-36	Height;
CESC	cis	rs7927592	0.913	rs10896329	chr11:68250029	A/G	cg20283391	chr11:68216788	NA	-0.64	-7.81	-0.43	1.36e-13	Total body bone mineral density;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02306946	chr12:105630036	APPL2	0.55	6.79	0.38	7.28e-11	Gut microbiome composition (summer);
CESC	cis	rs6460942	1.000	rs17191008	chr7:12417690	T/G	cg10578991	chr7:12443926	VWDE	-0.53	-5.69	-0.33	3.35e-8	Coronary artery disease;
CESC	cis	rs875971	0.862	rs2420174	chr7:65645361	C/T	cg11764359	chr7:65958608	NA	-0.78	-11.43	-0.57	7.35e-25	Aortic root size;
CESC	cis	rs7617773	0.514	rs11130166	chr3:48388056	A/G	cg11946769	chr3:48343235	NME6	0.65	8.35	0.46	3.86e-15	Coronary artery disease;
CESC	cis	rs10129255	0.957	rs10141009	chr14:107184934	A/G	cg23076370	chr14:107095027	NA	-0.48	-6.29	-0.36	1.32e-9	Kawasaki disease;
CESC	cis	rs7829975	0.684	rs488904	chr8:8587571	T/G	cg06636001	chr8:8085503	FLJ10661	-0.42	-5.17	-0.3	4.64e-7	Mood instability;
CESC	cis	rs7584330	0.666	rs72620818	chr2:238354652	G/A	cg14458575	chr2:238380390	NA	0.85	10.76	0.55	1.22e-22	Prostate cancer;
CESC	cis	rs708547	0.871	rs2687238	chr4:57880474	C/T	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.52	-5.54	-0.32	7.27e-8	Response to bleomycin (chromatid breaks);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00436610	chr16:89284637	ZNF778	-0.62	-7.06	-0.4	1.43e-11	Gut microbiome composition (summer);
CESC	cis	rs7100689	0.784	rs7895042	chr10:82095276	G/A	cg00277334	chr10:82204260	NA	-0.59	-7.47	-0.42	1.14e-12	Post bronchodilator FEV1;
CESC	cis	rs9486715	0.659	rs9399930	chr6:96854444	G/T	cg18709589	chr6:96969512	KIAA0776	0.49	6.76	0.38	9e-11	Headache;
CESC	cis	rs17125944	0.505	rs77690283	chr14:53233320	C/G	cg00686598	chr14:53173677	PSMC6	1.34	11.5	0.58	4.42e-25	Alzheimer's disease (late onset);
CESC	cis	rs6963495	0.818	rs73190186	chr7:105164368	G/C	cg02135003	chr7:105160482	PUS7	-0.47	-5.59	-0.33	5.51e-8	Bipolar disorder (body mass index interaction);
CESC	cis	rs2425143	1.000	rs7267759	chr20:34257284	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.83	-7.53	-0.42	8.04e-13	Blood protein levels;
CESC	cis	rs6460942	1.000	rs62448562	chr7:12398785	T/C	cg10578991	chr7:12443926	VWDE	-0.58	-6.08	-0.35	4.26e-9	Coronary artery disease;
CESC	cis	rs12822507	0.732	rs873218	chr12:12765603	G/A	cg11838227	chr12:12764436	CREBL2	0.43	5.63	0.33	4.48e-8	Systemic lupus erythematosus;
CESC	cis	rs8060686	0.858	rs6499143	chr16:67874264	T/C	cg26727032	chr16:67993705	SLC12A4	-0.68	-9.79	-0.52	1.61e-19	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs875971	1.000	rs6961990	chr7:65888570	C/A	cg11764359	chr7:65958608	NA	0.97	15.73	0.69	7.9e-40	Aortic root size;
CESC	cis	rs7605827	0.729	rs35131126	chr2:15537730	A/G	cg19274914	chr2:15703543	NA	0.36	6.55	0.37	2.91e-10	Educational attainment (years of education);
CESC	cis	rs1538970	0.924	rs11211118	chr1:45930270	A/C	cg03146154	chr1:46216737	IPP	0.45	5.24	0.31	3.31e-7	Platelet count;
CESC	cis	rs7617773	0.963	rs12495221	chr3:48179178	C/T	cg11946769	chr3:48343235	NME6	-0.58	-7.73	-0.43	2.26e-13	Coronary artery disease;
CESC	cis	rs4664293	0.967	rs12611922	chr2:160462749	T/G	cg08347373	chr2:160653686	CD302	-0.33	-5.24	-0.31	3.33e-7	Monocyte percentage of white cells;
CESC	cis	rs7208859	0.573	rs55661352	chr17:29045628	A/G	cg13385521	chr17:29058706	SUZ12P	0.81	6.37	0.36	8.33e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs9611519	0.808	rs5751074	chr22:41665722	G/A	cg03806693	chr22:41940476	POLR3H	-0.58	-6.72	-0.38	1.08e-10	Neuroticism;
CESC	cis	rs3820068	0.705	rs41270255	chr1:15892980	G/A	cg17385448	chr1:15911702	AGMAT	0.37	5.81	0.34	1.8e-8	Systolic blood pressure;
CESC	cis	rs3738443	0.520	rs1771932	chr1:247382049	A/G	cg07706540	chr1:247373924	NA	-0.47	-5.67	-0.33	3.63e-8	Alcohol dependence;
CESC	cis	rs3806843	0.735	rs801180	chr5:140092903	G/T	cg16179182	chr5:140090404	VTRNA1-1	0.42	5.43	0.32	1.27e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs8028182	0.636	rs8036758	chr15:75817562	G/A	cg20655648	chr15:75932815	IMP3	0.47	5.81	0.34	1.75e-8	Sudden cardiac arrest;
CESC	cis	rs7772486	0.720	rs4896844	chr6:146075224	T/C	cg05347473	chr6:146136440	FBXO30	-0.57	-7.36	-0.41	2.27e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs875971	0.638	rs10278816	chr7:66036987	T/C	cg18876405	chr7:65276391	NA	-0.59	-7.9	-0.44	7.25e-14	Aortic root size;
CESC	cis	rs875971	0.543	rs801191	chr7:66032955	G/A	cg06456125	chr7:65229604	NA	-0.39	-5.37	-0.31	1.75e-7	Aortic root size;
CESC	trans	rs6587515	0.901	rs3738483	chr1:150801466	T/C	cg23436960	chr14:77239540	VASH1	0.45	5.99	0.35	6.67e-9	Pericardial adipose tissue adjusted for height and weight;
CESC	cis	rs7618915	0.547	rs2286800	chr3:52778051	C/T	cg18404041	chr3:52824283	ITIH1	-0.41	-6.82	-0.39	5.97e-11	Bipolar disorder;
CESC	cis	rs9905704	0.671	rs2531737	chr17:56554357	A/G	cg12560992	chr17:57184187	TRIM37	-0.62	-5.93	-0.34	9.6e-9	Testicular germ cell tumor;
CESC	cis	rs7618915	0.547	rs62253700	chr3:52625019	T/A	cg18099408	chr3:52552593	STAB1	-0.31	-5.16	-0.3	4.75e-7	Bipolar disorder;
CESC	cis	rs2842992	0.830	rs2025190	chr6:160138241	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.71	9.06	0.49	2.94e-17	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs1552244	0.882	rs34779351	chr3:10021801	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.86	11.09	0.56	9.7e-24	Alzheimer's disease;
CESC	cis	rs13191362	1.000	rs36113695	chr6:163004733	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.88	9.1	0.49	2.28e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs2637266	0.653	rs2583068	chr10:78553731	T/C	cg18941641	chr10:78392320	NA	0.4	7.57	0.42	6.04e-13	Pulmonary function;
CESC	cis	rs1881797	1.000	rs66845073	chr1:247688010	C/T	cg11166453	chr1:247681781	NA	0.44	5.77	0.33	2.24e-8	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs9287719	0.901	rs4555317	chr2:10744247	A/G	cg00105475	chr2:10696890	NA	0.39	5.64	0.33	4.44e-8	Prostate cancer;
CESC	cis	rs12701220	0.655	rs34344742	chr7:1149288	C/G	cg04025307	chr7:1156635	C7orf50	0.44	5.33	0.31	2.16e-7	Bronchopulmonary dysplasia;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg20919306	chr17:11924526	MAP2K4	-0.48	-6.46	-0.37	4.94e-10	Fibrinogen levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00974149	chr17:56296512	MKS1	0.55	6.32	0.36	1.09e-9	Gut microbiome composition (summer);
CESC	cis	rs11098499	0.580	rs12509234	chr4:120319434	T/C	cg24375607	chr4:120327624	NA	0.48	5.82	0.34	1.66e-8	Corneal astigmatism;
CESC	trans	rs7577696	0.962	rs13022197	chr2:32343167	A/T	cg00459447	chr7:108210006	THAP5;DNAJB9	0.38	6.06	0.35	4.68e-9	Inflammatory biomarkers;
CESC	cis	rs2204008	0.617	rs11831608	chr12:38210687	C/T	cg26384229	chr12:38710491	ALG10B	-0.46	-6.27	-0.36	1.46e-9	Bladder cancer;
CESC	cis	rs57083693	0.518	rs10860711	chr12:101723568	T/G	cg22051763	chr12:101673672	UTP20	-0.45	-5.59	-0.32	5.71e-8	Alcohol dependence (age at onset);
CESC	cis	rs8060686	0.641	rs8058690	chr16:68136622	T/G	cg26727032	chr16:67993705	SLC12A4	-0.52	-6.33	-0.36	1.05e-9	HDL cholesterol;Metabolic syndrome;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg05874913	chr2:160569340	MARCH7	-0.55	-7.36	-0.41	2.39e-12	Fibrinogen levels;
CESC	cis	rs72781680	1.000	rs55982282	chr2:24188128	G/A	cg08917208	chr2:24149416	ATAD2B	1.03	9.37	0.5	3.32e-18	Lymphocyte counts;
CESC	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg23034840	chr1:205782522	SLC41A1	0.69	8.35	0.46	3.84e-15	Menarche (age at onset);
CESC	cis	rs1670533	1.000	rs11247972	chr4:1060550	A/G	cg27284194	chr4:1044797	NA	0.47	6.07	0.35	4.4e-9	Recombination rate (females);
CESC	cis	rs7577696	0.568	rs7562653	chr2:32478629	T/C	cg02381751	chr2:32503542	YIPF4	0.46	5.51	0.32	8.49e-8	Inflammatory biomarkers;
CESC	cis	rs853679	0.517	rs9295759	chr6:28124469	C/T	cg23161317	chr6:28129485	ZNF389	0.53	6.52	0.37	3.64e-10	Depression;
CESC	cis	rs13256369	0.756	rs13282580	chr8:8562903	C/T	cg17143192	chr8:8559678	CLDN23	0.78	8.81	0.48	1.63e-16	Obesity-related traits;
CESC	cis	rs7666738	0.830	rs35938349	chr4:98974998	T/C	cg05340658	chr4:99064831	C4orf37	0.79	12.26	0.6	1.12e-27	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7659604	0.502	rs28435300	chr4:122709412	T/C	cg19671926	chr4:122722719	EXOSC9	0.67	8.89	0.48	9.9900000000000006e-17	Type 2 diabetes;
CESC	cis	rs763121	0.853	rs2413547	chr22:39107338	A/G	cg14440974	chr22:39074834	NA	-0.42	-5.73	-0.33	2.69e-8	Menopause (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07545535	chr7:76256818	POMZP3;LOC100133091	0.6	7.27	0.41	4.09e-12	Gut microbiome composition (summer);
CESC	cis	rs2576037	0.526	rs4890703	chr18:44522037	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.45	7.14	0.4	8.76e-12	Personality dimensions;
CESC	cis	rs4888262	0.508	rs4544266	chr16:74660993	C/A	cg01733217	chr16:74700730	RFWD3	0.85	10.7	0.55	1.88e-22	Testicular germ cell tumor;
CESC	cis	rs344364	0.511	rs62040571	chr16:1948514	C/G	cg26617929	chr16:1858877	NA	-0.49	-5.15	-0.3	5.09e-7	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs514406	0.861	rs12141260	chr1:53300127	C/T	cg24675658	chr1:53192096	ZYG11B	-0.61	-7.88	-0.44	8.59e-14	Monocyte count;
CESC	cis	rs11679564	0.714	rs4670638	chr2:37164911	C/G	cg14987922	chr2:37194071	STRN	0.42	5.33	0.31	2.11e-7	Immature fraction of reticulocytes;
CESC	cis	rs5758511	0.680	rs34107327	chr22:42648353	T/G	cg00645731	chr22:42541494	CYP2D7P1	0.57	8.61	0.47	6.72e-16	Birth weight;
CESC	cis	rs713587	0.520	rs519111	chr2:25333735	T/C	cg01884057	chr2:25150051	NA	-0.3	-5.21	-0.3	3.89e-7	Body mass index in non-asthmatics;
CESC	cis	rs80282103	0.764	rs7093915	chr10:1107341	A/G	cg08668510	chr10:1095578	IDI1	-0.66	-5.58	-0.32	6.07e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs3820928	1.000	rs10193316	chr2:227777650	A/G	cg11843606	chr2:227700838	RHBDD1	-0.44	-5.86	-0.34	1.4e-8	Pulmonary function;
CESC	cis	rs870825	0.616	rs72703531	chr4:185611092	C/T	cg04058563	chr4:185651563	MLF1IP	0.64	6.47	0.37	4.64e-10	Blood protein levels;
CESC	cis	rs6580649	0.941	rs72644842	chr12:48448274	A/G	cg05342945	chr12:48394962	COL2A1	0.5	5.85	0.34	1.47e-8	Lung cancer;
CESC	cis	rs769267	0.965	rs2905425	chr19:19475717	G/C	cg20644253	chr19:19431407	KIAA0892;SF4	-0.56	-7.1	-0.4	1.18e-11	Tonsillectomy;
CESC	cis	rs3087591	1.000	rs7220483	chr17:29577248	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.42	-5.08	-0.3	7.22e-7	Hip circumference;
CESC	cis	rs4722166	0.630	rs12537614	chr7:22789551	C/G	cg26061582	chr7:22766209	IL6	0.48	5.24	0.31	3.35e-7	Lung cancer;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg23466916	chr2:192543328	OBFC2A	-0.44	-6.09	-0.35	3.89e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs72627123	0.656	rs6574169	chr14:74637178	G/A	cg12022184	chr14:74485813	ENTPD5;C14orf45	-0.75	-5.25	-0.31	3.11e-7	Morning vs. evening chronotype;
CESC	trans	rs561341	1.000	rs576985	chr17:30323323	C/T	cg27661571	chr11:113659931	NA	-0.82	-7.63	-0.42	4.18e-13	Hip circumference adjusted for BMI;
CESC	cis	rs684232	0.583	rs4968094	chr17:507120	A/T	cg15660573	chr17:549704	VPS53	-0.81	-11.77	-0.59	5.08e-26	Prostate cancer;
CESC	cis	rs12900413	0.687	rs6496599	chr15:90314582	C/T	cg24249390	chr15:90295951	MESP1	-0.41	-5.73	-0.33	2.78e-8	Coronary artery aneurysm in Kawasaki disease;
CESC	trans	rs4942242	0.663	rs9525817	chr13:44225189	C/T	cg19169023	chr15:41853346	TYRO3	0.65	8.17	0.45	1.29e-14	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs801193	0.967	rs2707853	chr7:66214010	G/A	cg14393609	chr7:65229607	NA	0.48	6.47	0.37	4.72e-10	Aortic root size;
CESC	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg23708337	chr7:1209742	NA	0.55	5.38	0.31	1.67e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg24829409	chr8:58192753	C8orf71	0.61	7.03	0.4	1.74e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs10504229	0.871	rs10504227	chr8:58162005	G/A	cg05313129	chr8:58192883	C8orf71	-0.43	-5.09	-0.3	6.93e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs1005277	0.540	rs11011351	chr10:38030525	A/G	cg25427524	chr10:38739819	LOC399744	-0.64	-9.43	-0.5	2.21e-18	Extrinsic epigenetic age acceleration;
CESC	cis	rs9896052	0.625	rs11656558	chr17:73440437	T/C	cg25649188	chr17:73499917	CASKIN2	0.46	5.31	0.31	2.33e-7	Sight-threatening diabetic retinopathy in type 2 diabetes;
CESC	cis	rs734999	0.505	rs10910108	chr1:2539532	A/G	cg20673091	chr1:2541236	MMEL1	0.46	7.82	0.43	1.24e-13	Ulcerative colitis;
CESC	cis	rs6772849	0.965	rs4286447	chr3:128310589	G/T	cg16766828	chr3:128327626	NA	-0.31	-5.06	-0.3	7.77e-7	Monocyte percentage of white cells;Monocyte count;
CESC	cis	rs1008375	0.932	rs2302394	chr4:17641188	A/G	cg15017067	chr4:17643749	FAM184B	0.38	5.09	0.3	6.76e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs870825	0.616	rs61539306	chr4:185650276	C/T	cg04058563	chr4:185651563	MLF1IP	0.62	6.83	0.39	5.67e-11	Blood protein levels;
CESC	cis	rs752010	0.668	rs10890147	chr1:42089725	A/T	cg06885757	chr1:42089581	HIVEP3	0.7	11.53	0.58	3.51e-25	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs9291683	0.507	rs6827754	chr4:10018153	A/C	cg11266682	chr4:10021025	SLC2A9	-0.57	-9.46	-0.5	1.79e-18	Bone mineral density;
CESC	cis	rs3780486	0.846	rs10971420	chr9:33125000	T/C	cg13443165	chr9:33130375	B4GALT1	0.44	6.38	0.37	7.66e-10	IgG glycosylation;
CESC	cis	rs853679	0.517	rs9380059	chr6:28132358	A/C	cg20151795	chr6:28129481	ZNF389	0.44	5.55	0.32	6.85e-8	Depression;
CESC	cis	rs4727027	0.651	rs12704068	chr7:148856153	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.44	5.36	0.31	1.82e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs514406	0.792	rs1242201	chr1:53344748	G/A	cg08736216	chr1:53307985	ZYG11A	-0.41	-6.87	-0.39	4.54e-11	Monocyte count;
CESC	cis	rs6599388	0.803	rs11248057	chr4:906131	C/G	cg08222618	chr4:941054	TMEM175	-0.42	-5.47	-0.32	1.02e-7	Parkinson's disease;
CESC	cis	rs2842992	0.789	rs2475566	chr6:160148741	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.69	8.9	0.48	8.93e-17	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs6032067	0.852	rs6032046	chr20:43823679	A/G	cg11264863	chr20:43835661	SEMG1	0.48	5.29	0.31	2.53e-7	Blood protein levels;
CESC	cis	rs2625529	0.652	rs8028115	chr15:72339503	C/T	cg16672083	chr15:72433130	SENP8	0.42	6.57	0.37	2.59e-10	Red blood cell count;
CESC	cis	rs3733585	0.673	rs6843873	chr4:9958788	A/C	cg00071950	chr4:10020882	SLC2A9	-0.73	-11.79	-0.59	4.4e-26	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs72634258	0.519	rs2071984	chr1:7928656	C/T	cg00042356	chr1:8021962	PARK7	0.52	5.77	0.33	2.18e-8	Inflammatory bowel disease;
CESC	trans	rs9951602	0.512	rs7234283	chr18:76640552	T/G	cg02800362	chr5:177631904	HNRNPAB	0.62	8.13	0.45	1.7e-14	Obesity-related traits;
CESC	cis	rs6964587	1.000	rs36120033	chr7:91679298	G/A	cg17063962	chr7:91808500	NA	0.59	8.15	0.45	1.48e-14	Breast cancer;
CESC	cis	rs7412746	0.611	rs11803940	chr1:150685835	A/G	cg04414720	chr1:150670196	GOLPH3L	0.62	8.86	0.48	1.17e-16	Melanoma;
CESC	cis	rs7659604	0.539	rs2221628	chr4:122795361	G/A	cg20573242	chr4:122745356	CCNA2	0.66	8.1	0.45	1.99e-14	Type 2 diabetes;
CESC	cis	rs6748734	0.901	rs6720357	chr2:241830296	A/C	cg04034577	chr2:241836375	C2orf54	-0.49	-8.33	-0.46	4.28e-15	Urinary metabolites;
CESC	cis	rs60154123	0.730	rs608791	chr1:210464638	C/T	cg22029157	chr1:209979665	IRF6	0.47	5.75	0.33	2.42e-8	Coronary artery disease;
CESC	cis	rs7772486	0.754	rs697055	chr6:146003790	C/G	cg23711669	chr6:146136114	FBXO30	1.0	14.05	0.65	7e-34	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg16439118	chr18:54814548	NA	0.44	6.3	0.36	1.21e-9	Fibrinogen levels;
CESC	cis	rs10540	1.000	rs12788729	chr11:502371	G/A	cg21784768	chr11:537496	LRRC56	-0.54	-5.08	-0.3	7.13e-7	Body mass index;
CESC	cis	rs113835537	0.529	rs75683511	chr11:66275026	A/G	cg24851651	chr11:66362959	CCS	0.49	5.86	0.34	1.34e-8	Airway imaging phenotypes;
CESC	cis	rs12791968	0.527	rs12285862	chr11:45014326	T/G	cg11846598	chr11:44996168	LOC221122	-0.55	-6.13	-0.35	3.09e-9	Inhibitory control;
CESC	cis	rs611744	0.781	rs656406	chr8:109173843	G/A	cg21045802	chr8:109455806	TTC35	0.47	5.67	0.33	3.81e-8	Dupuytren's disease;
CESC	cis	rs10504229	0.679	rs11783557	chr8:58030644	A/G	cg24829409	chr8:58192753	C8orf71	-0.44	-5.73	-0.33	2.75e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs9630089	0.622	rs7906782	chr10:98961596	C/T	cg25902810	chr10:99078978	FRAT1	0.53	7.02	0.4	1.87e-11	Neutrophil percentage of white cells;
CESC	cis	rs2439831	0.867	rs16957627	chr15:43642657	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.9	10.46	0.54	1.12e-21	Lung cancer in ever smokers;
CESC	trans	rs9929218	1.000	rs2113200	chr16:68814948	A/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.65	-8.5	-0.46	1.39e-15	Colorectal cancer;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg07307426	chr15:89089587	DET1	0.43	6.61	0.38	2.05e-10	Gambling;
CESC	cis	rs2439831	0.867	rs2245176	chr15:43750762	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.83	12.14	0.6	2.88e-27	Lung cancer in ever smokers;
CESC	trans	rs1814175	0.645	rs10128563	chr11:50023681	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.42	-6.13	-0.35	3.1e-9	Height;
CESC	cis	rs11122272	0.735	rs11122279	chr1:231519804	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.57	-7.75	-0.43	2.03e-13	Hemoglobin concentration;
CESC	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg11494091	chr17:61959527	GH2	-0.73	-12.68	-0.61	4.17e-29	Prudent dietary pattern;
CESC	cis	rs6541297	0.703	rs636810	chr1:230317018	C/T	cg20703242	chr1:230279135	GALNT2	-0.43	-5.62	-0.33	4.84e-8	Coronary artery disease;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg26877198	chr19:9938416	UBL5	-0.45	-7.12	-0.4	1.01e-11	Gambling;
CESC	cis	rs9611565	0.765	rs132908	chr22:41801795	G/A	cg06481639	chr22:41940642	POLR3H	0.64	6.56	0.37	2.82e-10	Vitiligo;
CESC	cis	rs6938	0.597	rs11856413	chr15:75199892	A/G	cg17294928	chr15:75287854	SCAMP5	0.5	6.59	0.38	2.32e-10	Breast cancer;
CESC	cis	rs9359856	0.529	rs72919922	chr6:90492997	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.63	-6.04	-0.35	5.17e-9	Bipolar disorder;
CESC	cis	rs597539	0.652	rs604524	chr11:68629929	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.75	9.07	0.49	2.7e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs2836974	0.897	rs8132419	chr21:40527827	C/T	cg11644478	chr21:40555479	PSMG1	1.05	17.79	0.74	4.12e-47	Cognitive function;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg10139015	chr11:47448256	PSMC3	-0.44	-6.02	-0.35	5.68e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs7635838	0.573	rs73019547	chr3:11493323	A/C	cg00170343	chr3:11313890	ATG7	0.47	6.36	0.36	8.89e-10	HDL cholesterol;
CESC	cis	rs3749237	0.595	rs4855859	chr3:49526300	C/T	cg07636037	chr3:49044803	WDR6	0.61	8.81	0.48	1.66e-16	Resting heart rate;
CESC	cis	rs2836974	0.568	rs2142111	chr21:40549289	G/C	cg17971929	chr21:40555470	PSMG1	0.84	12.01	0.59	7.85e-27	Cognitive function;
CESC	cis	rs9447004	0.865	rs6924739	chr6:74445387	C/T	cg23004174	chr6:74404879	CD109	0.4	6.09	0.35	3.86e-9	Blood protein levels;Calcium levels;
CESC	cis	rs6433857	0.536	rs1971134	chr2:181351532	G/A	cg23363182	chr2:181467187	NA	-0.42	-5.92	-0.34	9.98e-9	Body mass index;
CESC	cis	rs12042107	0.740	rs2166172	chr1:91208514	A/C	cg13456504	chr1:91191583	NA	-0.31	-5.45	-0.32	1.18e-7	Educational attainment;
CESC	cis	rs933688	1.000	rs186717	chr5:90780467	T/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.98	11.76	0.59	5.82e-26	Smoking behavior;
CESC	cis	rs2997447	0.761	rs17184884	chr1:26446565	G/A	cg24596570	chr1:26146463	FAM54B;LOC646471	0.59	5.17	0.3	4.68e-7	QRS complex (12-leadsum);
CESC	cis	rs11098499	0.913	rs13126596	chr4:120140729	A/G	cg09307838	chr4:120376055	NA	0.79	10.07	0.53	2.04e-20	Corneal astigmatism;
CESC	cis	rs9733	0.519	rs1134067	chr1:150721175	G/T	cg22823121	chr1:150693482	HORMAD1	0.47	6.58	0.37	2.52e-10	Tonsillectomy;
CESC	cis	rs7666738	0.830	rs4502686	chr4:98765117	T/C	cg05340658	chr4:99064831	C4orf37	0.76	11.26	0.57	2.63e-24	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11785400	0.793	rs2280879	chr8:143722228	T/C	cg24634471	chr8:143751801	JRK	0.43	5.57	0.32	6.39e-8	Schizophrenia;
CESC	cis	rs3859192	0.577	rs2227333	chr17:38174167	C/G	cg17344932	chr17:38183730	MED24;SNORD124	0.62	9.03	0.49	3.56e-17	White blood cell count;
CESC	trans	rs3780486	0.846	rs10813950	chr9:33127640	A/G	cg04842962	chr6:43655489	MRPS18A	-0.96	-16.95	-0.72	3.81e-44	IgG glycosylation;
CESC	cis	rs68170813	0.559	rs77150993	chr7:106817100	G/T	cg02696742	chr7:106810147	HBP1	-0.53	-5.07	-0.3	7.37e-7	Coronary artery disease;
CESC	cis	rs13168506	0.538	rs12521857	chr5:135440364	G/A	cg15329133	chr5:135467951	SMAD5;SMAD5OS	-0.33	-5.1	-0.3	6.57e-7	Stroke;
CESC	cis	rs10751667	0.961	rs7480178	chr11:927108	T/C	cg06064525	chr11:970664	AP2A2	-0.43	-7.7	-0.43	2.8e-13	Alzheimer's disease (late onset);
CESC	cis	rs4481887	1.000	rs4579792	chr1:248463742	C/T	cg00666640	chr1:248458726	OR2T12	-0.38	-6.19	-0.36	2.22e-9	Common traits (Other);
CESC	cis	rs4665809	0.556	rs1560869	chr2:26417095	T/C	cg26314531	chr2:26401878	FAM59B	-0.83	-9.26	-0.49	7.29e-18	Gut microbiome composition (summer);
CESC	trans	rs1814175	0.645	rs11040671	chr11:49958776	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.43	-6.26	-0.36	1.53e-9	Height;
CESC	cis	rs9905704	0.846	rs302877	chr17:56764018	G/A	cg12560992	chr17:57184187	TRIM37	0.62	7.88	0.44	8.72e-14	Testicular germ cell tumor;
CESC	cis	rs2635047	0.638	rs2289133	chr18:44602249	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.45	6.24	0.36	1.75e-9	Educational attainment;
CESC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg06966887	chr5:443603	EXOC3;C5orf55	0.47	6.27	0.36	1.42e-9	Tetralogy of Fallot;
CESC	cis	rs1218582	0.741	rs11264283	chr1:154869552	A/G	cg03351412	chr1:154909251	PMVK	0.69	9.32	0.5	4.71e-18	Prostate cancer;
CESC	cis	rs4819052	0.851	rs13050359	chr21:46672671	T/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.46	5.72	0.33	2.89e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg26963397	chr16:50059081	TMEM188	-0.49	-6.15	-0.35	2.92e-9	Asthma;
CESC	cis	rs6662572	0.737	rs10789476	chr1:46305362	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.44	-5.04	-0.3	8.65e-7	Blood protein levels;
CESC	cis	rs11235843	0.636	rs10736793	chr11:73402576	A/C	cg18195628	chr11:73498948	MRPL48	-0.48	-5.27	-0.31	2.83e-7	Hand grip strength;
CESC	cis	rs7618915	0.547	rs11130314	chr3:52697082	T/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	5.7	0.33	3.27e-8	Bipolar disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04096435	chr6:111195733	AMD1	-0.61	-6.63	-0.38	1.89e-10	Gut microbiome composition (summer);
CESC	cis	rs11623869	0.711	rs2403173	chr14:103909289	T/C	cg12935359	chr14:103987150	CKB	-0.51	-7.49	-0.42	1.06e-12	Bone mineral density;
CESC	cis	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg21782813	chr7:2030301	MAD1L1	0.49	6.96	0.39	2.75e-11	Bipolar disorder and schizophrenia;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg23300289	chr9:132146083	NA	-0.44	-6.41	-0.37	6.8e-10	Gambling;
CESC	cis	rs853679	0.517	rs9295758	chr6:28120663	C/G	cg20151795	chr6:28129481	ZNF389	0.46	5.81	0.34	1.76e-8	Depression;
CESC	cis	rs2243480	1.000	rs778729	chr7:65824419	T/C	cg13147721	chr7:65941812	NA	-0.95	-8.95	-0.48	6.27e-17	Diabetic kidney disease;
CESC	trans	rs7246760	0.867	rs57943754	chr19:9841283	G/A	cg02900749	chr2:68251473	NA	-0.79	-7.17	-0.4	7.34e-12	Pursuit maintenance gain;
CESC	cis	rs4665809	0.878	rs4665826	chr2:26367503	A/T	cg08470875	chr2:26401718	FAM59B	0.66	7.11	0.4	1.08e-11	Gut microbiome composition (summer);
CESC	cis	rs897080	0.515	rs786403	chr2:44710788	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	5.55	0.32	6.8e-8	Height;
CESC	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg01238044	chr22:24384105	GSTT1	-0.68	-9.08	-0.49	2.5e-17	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg04025307	chr7:1156635	C7orf50	0.55	9.36	0.5	3.5e-18	Longevity;Endometriosis;
CESC	cis	rs1538970	0.962	rs3219489	chr1:45797505	C/G	cg06784218	chr1:46089804	CCDC17	0.34	5.19	0.3	4.12e-7	Platelet count;
CESC	cis	rs17376456	0.866	rs13356088	chr5:93423479	C/T	cg21475434	chr5:93447410	FAM172A	0.91	7.42	0.41	1.62e-12	Diabetic retinopathy;
CESC	cis	rs7927771	0.524	rs10458915	chr11:47864392	T/A	cg18512352	chr11:47633146	NA	0.35	5.37	0.31	1.7e-7	Subjective well-being;
CESC	cis	rs3749237	0.595	rs7643845	chr3:49530711	A/G	cg06212747	chr3:49208901	KLHDC8B	0.49	6.55	0.37	3.02e-10	Resting heart rate;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg09976282	chr15:31357238	TRPM1;MIR211	-0.41	-6.12	-0.35	3.3e-9	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06963844	chr1:11724238	FBXO6	-0.53	-6.04	-0.35	5.18e-9	Gut microbiome composition (summer);
CESC	cis	rs9359856	0.564	rs17506403	chr6:90499059	C/G	cg13799429	chr6:90582589	CASP8AP2	-0.61	-6.04	-0.35	5.32e-9	Bipolar disorder;
CESC	cis	rs4595586	0.545	rs9669705	chr12:39374459	C/T	cg26384229	chr12:38710491	ALG10B	0.54	7.53	0.42	7.85e-13	Morning vs. evening chronotype;
CESC	cis	rs873946	0.586	rs3793682	chr10:134564563	C/T	cg27286337	chr10:134555280	INPP5A	0.68	7.69	0.43	2.81e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs4660261	0.526	rs3094954	chr1:44320919	C/T	cg12908607	chr1:44402522	ARTN	-0.46	-6.6	-0.38	2.26e-10	Intelligence (multi-trait analysis);
CESC	cis	rs977987	0.843	rs4146810	chr16:75415831	A/G	cg03315344	chr16:75512273	CHST6	0.4	5.78	0.33	2.14e-8	Dupuytren's disease;
CESC	cis	rs56399783	0.901	rs79932907	chr7:2827901	C/G	cg19731401	chr7:2775893	GNA12	0.67	6.04	0.35	5.19e-9	Childhood ear infection;
CESC	cis	rs6460942	0.778	rs17444259	chr7:12462428	C/T	cg06484146	chr7:12443880	VWDE	-0.67	-9.2	-0.49	1.11e-17	Coronary artery disease;
CESC	cis	rs8141529	0.753	rs5752813	chr22:29226570	T/G	cg15103426	chr22:29168792	CCDC117	0.67	9.66	0.51	4.15e-19	Lymphocyte counts;
CESC	cis	rs8044868	0.530	rs9932951	chr16:72075341	A/G	cg16558253	chr16:72132732	DHX38	-0.39	-6.15	-0.35	2.86e-9	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CESC	cis	rs9894429	1.000	rs11652797	chr17:79574124	A/G	cg13777783	chr17:79615861	NA	-0.34	-5.68	-0.33	3.46e-8	Eye color traits;
CESC	cis	rs3540	0.512	rs11633872	chr15:91080512	G/A	cg10434728	chr15:90938212	IQGAP1	-0.41	-7.2	-0.4	6.37e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs4268898	0.636	rs9636438	chr2:24460566	C/T	cg20701182	chr2:24300061	SF3B14	-0.64	-7.07	-0.4	1.38e-11	Asthma;
CESC	cis	rs9926296	0.568	rs1230	chr16:89804855	A/G	cg27121462	chr16:89883253	FANCA	-0.81	-12.1	-0.6	3.93e-27	Vitiligo;
CESC	cis	rs4853012	0.793	rs6707619	chr2:74344656	G/A	cg19729930	chr2:74357872	NA	0.86	12.78	0.62	1.82e-29	Gestational age at birth (maternal effect);
CESC	cis	rs10504229	0.775	rs17805110	chr8:58161439	C/G	cg24829409	chr8:58192753	C8orf71	0.66	7.83	0.43	1.21e-13	Developmental language disorder (linguistic errors);
CESC	cis	rs9863	0.827	rs6488913	chr12:124445569	C/G	cg17562584	chr12:124393655	DNAH10	-0.3	-5.28	-0.31	2.66e-7	White blood cell count;
CESC	cis	rs644799	0.965	rs607039	chr11:95547086	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	9.15	0.49	1.61e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs727505	1.000	rs722560	chr7:124488035	T/C	cg23710748	chr7:124431027	NA	-0.48	-7.64	-0.42	4.06e-13	Lewy body disease;
CESC	trans	rs61931739	0.534	rs7138522	chr12:34039762	G/A	cg26384229	chr12:38710491	ALG10B	0.6	8.36	0.46	3.68e-15	Morning vs. evening chronotype;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27511265	chr7:150102280	LOC728743	0.58	6.06	0.35	4.75e-9	Gut microbiome composition (summer);
CESC	cis	rs2730245	0.527	rs2730237	chr7:158706166	A/G	cg24397884	chr7:158709396	WDR60	0.67	7.44	0.42	1.41e-12	Height;
CESC	cis	rs62158211	1.000	rs4618068	chr2:114109355	C/T	cg17784749	chr2:114082611	LOC440839	0.7	7.54	0.42	7.35e-13	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;
CESC	cis	rs7412746	0.658	rs59988025	chr1:150940358	C/T	cg22823121	chr1:150693482	HORMAD1	0.39	5.35	0.31	1.93e-7	Melanoma;
CESC	cis	rs9322193	0.962	rs1889473	chr6:150146621	C/G	cg09699651	chr6:150184138	LRP11	0.4	5.1	0.3	6.4e-7	Lung cancer;
CESC	cis	rs4653767	0.573	rs708772	chr1:226912891	A/G	cg10327440	chr1:227177885	CDC42BPA	-0.39	-5.15	-0.3	5.12e-7	Parkinson's disease;
CESC	cis	rs12477438	0.520	rs720229	chr2:99704273	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.78	13.37	0.63	1.7e-31	Chronic sinus infection;
CESC	cis	rs7301826	0.580	rs12821464	chr12:131322719	T/G	cg11011512	chr12:131303247	STX2	-0.46	-5.67	-0.33	3.76e-8	Plasma plasminogen activator levels;
CESC	cis	rs3126085	0.935	rs4845736	chr1:152175551	G/A	cg03465714	chr1:152285911	FLG	-0.45	-5.55	-0.32	7.03e-8	Atopic dermatitis;
CESC	cis	rs7666738	0.830	rs6817645	chr4:99016054	T/C	cg03467027	chr4:99064603	C4orf37	0.44	5.63	0.33	4.57e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7771547	0.573	rs517890	chr6:36397786	G/C	cg07856975	chr6:36356162	ETV7	0.36	5.38	0.31	1.67e-7	Platelet distribution width;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21149582	chr1:10532838	DFFA	-0.63	-7.68	-0.43	3.02e-13	Gut microbiome composition (summer);
CESC	cis	rs2980439	0.818	rs2948294	chr8:8094961	A/G	cg15556689	chr8:8085844	FLJ10661	0.66	8.48	0.46	1.65e-15	Neuroticism;
CESC	cis	rs7945705	0.719	rs2012680	chr11:8996059	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.42	-6.81	-0.39	6.51e-11	Hemoglobin concentration;
CESC	trans	rs8073060	0.586	rs9649	chr17:34050934	C/T	cg19694781	chr19:47549865	TMEM160	0.72	6.47	0.37	4.78e-10	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	cis	rs9916302	0.904	rs68178216	chr17:37526241	A/C	cg07936489	chr17:37558343	FBXL20	0.78	10.74	0.55	1.4e-22	Glomerular filtration rate (creatinine);
CESC	cis	rs734999	0.545	rs3890745	chr1:2553624	C/T	cg18854424	chr1:2615690	NA	-0.31	-6.09	-0.35	4.01e-9	Ulcerative colitis;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg03639964	chr10:71415564	NA	0.39	6.11	0.35	3.62e-9	Fibrinogen levels;
CESC	cis	rs9522267	0.535	rs7323829	chr13:112232308	C/G	cg10483660	chr13:112241077	NA	-0.32	-5.77	-0.33	2.19e-8	Hepatitis;
CESC	cis	rs67478160	0.643	rs7147171	chr14:104264857	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.51	-7.09	-0.4	1.2e-11	Schizophrenia;
CESC	cis	rs854765	0.663	rs12941550	chr17:17753828	C/A	cg04398451	chr17:18023971	MYO15A	0.63	9.23	0.49	8.8e-18	Total body bone mineral density;
CESC	cis	rs992157	0.965	rs13427681	chr2:219167563	G/C	cg00012203	chr2:219082015	ARPC2	0.84	11.74	0.58	6.6e-26	Colorectal cancer;
CESC	cis	rs7621025	0.500	rs16844241	chr3:136635171	A/G	cg15507776	chr3:136538369	TMEM22	-0.74	-8.58	-0.47	8.14e-16	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
CESC	cis	rs11122272	0.735	rs2250719	chr1:231486208	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.51	-6.97	-0.39	2.52e-11	Hemoglobin concentration;
CESC	cis	rs4141404	0.923	rs2413046	chr22:31665909	C/A	cg00478049	chr22:31556069	RNF185	0.45	5.16	0.3	4.89e-7	Paclitaxel-induced neuropathy;
CESC	cis	rs1799949	1.000	rs4340367	chr17:41307772	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.65	9.04	0.49	3.4e-17	Menopause (age at onset);
CESC	cis	rs2549003	1.000	rs2549007	chr5:131826875	T/C	cg21138405	chr5:131827807	IRF1	-0.6	-10.77	-0.55	1.14e-22	Asthma (sex interaction);
CESC	cis	rs10242455	0.702	rs74416635	chr7:99180569	G/A	cg25640893	chr7:99214727	ZNF498	0.7	5.13	0.3	5.53e-7	Blood metabolite levels;
CESC	cis	rs72781680	0.566	rs6714016	chr2:23899948	A/G	cg08917208	chr2:24149416	ATAD2B	0.76	7.38	0.41	2.03e-12	Lymphocyte counts;
CESC	cis	rs6502050	0.871	rs6416857	chr17:80063004	A/G	cg11859384	chr17:80120422	CCDC57	0.43	5.91	0.34	1.02e-8	Life satisfaction;
CESC	cis	rs2249694	0.920	rs1536826	chr10:135357239	A/C	cg20169779	chr10:135381914	SYCE1	0.45	6.27	0.36	1.48e-9	Obesity-related traits;
CESC	cis	rs1878931	0.615	rs4786412	chr16:3440390	C/T	cg22508957	chr16:3507546	NAT15	-0.4	-5.93	-0.34	9.63e-9	Body mass index (adult);
CESC	cis	rs1009170	0.794	rs12589375	chr14:92584380	T/C	cg10324096	chr14:92587714	CPSF2;NDUFB1	0.54	5.07	0.3	7.36e-7	Dialysis-related mortality;
CESC	cis	rs1034435	0.723	rs713946	chr22:48891376	T/C	cg05992904	chr22:48892994	FAM19A5	-0.58	-10.27	-0.53	4.66e-21	Late-onset Alzheimer's disease;
CESC	cis	rs7927771	0.524	rs9633830	chr11:47849470	T/G	cg20307385	chr11:47447363	PSMC3	0.62	8.62	0.47	6.37e-16	Subjective well-being;
CESC	cis	rs6912958	0.559	rs445434	chr6:88041849	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.5	8.67	0.47	4.51e-16	Monocyte percentage of white cells;
CESC	trans	rs1814175	0.817	rs10839358	chr11:49770972	G/A	cg15704280	chr7:45808275	SEPT13	-1.02	-19.96	-0.77	1.02e-54	Height;
CESC	cis	rs9640161	0.789	rs1464752	chr7:150021284	C/T	cg21361702	chr7:150065534	REPIN1	0.5	5.72	0.33	2.8e-8	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs4268898	0.662	rs2303291	chr2:24431184	C/T	cg06627628	chr2:24431161	ITSN2	-1.01	-10.88	-0.56	5.09e-23	Asthma;
CESC	cis	rs9611565	0.921	rs2143695	chr22:41728620	A/G	cg03806693	chr22:41940476	POLR3H	-0.71	-8.55	-0.47	9.8e-16	Vitiligo;
CESC	cis	rs3820928	0.874	rs10174073	chr2:227794944	A/G	cg05526886	chr2:227700861	RHBDD1	-0.47	-6.06	-0.35	4.56e-9	Pulmonary function;
CESC	cis	rs7618501	0.633	rs11130234	chr3:50024758	G/T	cg24110177	chr3:50126178	RBM5	-0.53	-7.23	-0.41	5.13e-12	Intelligence (multi-trait analysis);
CESC	cis	rs11638352	1.000	rs2733221	chr15:44389870	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.71	-5.15	-0.3	5.13e-7	Lipoprotein phospholipase A2 activity in cardiovascular disease;
CESC	cis	rs7959452	1.000	rs7959452	chr12:69735492	A/G	cg14784868	chr12:69753453	YEATS4	0.57	7.62	0.42	4.46e-13	Blood protein levels;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg11038604	chr10:14996337	DCLRE1C	-0.45	-6.0	-0.35	6.3e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs4654899	0.865	rs12406144	chr1:21347228	A/C	cg05370193	chr1:21551575	ECE1	0.43	6.21	0.36	2.09e-9	Superior frontal gyrus grey matter volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11059266	chr4:48782139	FRYL	0.57	6.36	0.36	8.57e-10	Gut microbiome composition (summer);
CESC	cis	rs6460942	0.597	rs13245635	chr7:12526454	T/A	cg06484146	chr7:12443880	VWDE	-0.71	-7.69	-0.43	2.88e-13	Coronary artery disease;
CESC	cis	rs5753618	0.529	rs5749298	chr22:31941032	C/T	cg13145458	chr22:31556086	RNF185	-0.5	-5.84	-0.34	1.5e-8	Colorectal cancer;
CESC	cis	rs611744	0.529	rs13282825	chr8:109263237	T/C	cg21045802	chr8:109455806	TTC35	0.46	5.7	0.33	3.13e-8	Dupuytren's disease;
CESC	cis	rs617791	0.508	rs10791837	chr11:65774596	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.38	-5.03	-0.3	8.96e-7	Breast cancer;
CESC	cis	rs2011503	1.000	rs8105642	chr19:19558468	G/A	cg11584989	chr19:19387371	SF4	0.61	7.08	0.4	1.3e-11	Bipolar disorder;
CESC	cis	rs853679	0.517	rs9295758	chr6:28120663	C/G	cg12963246	chr6:28129442	ZNF389	0.59	7.7	0.43	2.7e-13	Depression;
CESC	cis	rs12618769	0.597	rs72821920	chr2:99111591	A/G	cg10123293	chr2:99228465	UNC50	0.39	5.13	0.3	5.6e-7	Bipolar disorder;
CESC	cis	rs7044106	0.791	rs4836831	chr9:123496570	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.89	14.39	0.66	4.47e-35	Hip circumference adjusted for BMI;
CESC	cis	rs4727027	0.800	rs10952796	chr7:148813138	G/C	cg23583168	chr7:148888333	NA	-0.73	-10.69	-0.55	2.02e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs10089	1.000	rs10463838	chr5:127518305	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.72	9.48	0.5	1.53e-18	Ileal carcinoids;
CESC	trans	rs7107217	1.000	rs1873872	chr11:129473993	A/T	cg01163298	chr12:49393408	DDN	-0.45	-6.25	-0.36	1.67e-9	Breast cancer;Type 2 diabetes;
CESC	trans	rs6934970	0.860	rs6921006	chr6:112986439	G/A	cg05146922	chr2:10634174	NA	-0.37	-6.17	-0.35	2.53e-9	Bipolar disorder (body mass index interaction);
CESC	cis	rs2904967	0.526	rs171193	chr11:64982599	A/G	cg01213895	chr11:65029414	POLA2	-0.46	-5.24	-0.31	3.33e-7	Mean corpuscular volume;
CESC	cis	rs79349575	0.749	rs957557	chr17:47003221	G/T	cg16584676	chr17:46985605	UBE2Z	0.54	6.7	0.38	1.24e-10	Type 2 diabetes;
CESC	cis	rs7917772	0.503	rs11191321	chr10:104293412	C/T	cg22532475	chr10:104410764	TRIM8	-0.35	-5.97	-0.34	7.47e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs2439831	0.850	rs2957637	chr15:43951118	C/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.81	8.23	0.45	8.46e-15	Lung cancer in ever smokers;
CESC	cis	rs4474465	0.833	rs10793320	chr11:78217460	G/A	cg27205649	chr11:78285834	NARS2	0.45	5.58	0.32	5.97e-8	Alzheimer's disease (survival time);
CESC	cis	rs3785574	0.927	rs2854183	chr17:61968002	C/T	cg06420487	chr17:61919686	SMARCD2	0.43	5.12	0.3	5.8e-7	Height;
CESC	cis	rs4718428	0.672	rs13241598	chr7:66300652	A/G	cg25985355	chr7:65971099	NA	-0.34	-5.04	-0.3	8.6e-7	Corneal structure;
CESC	trans	rs1814175	0.647	rs61306292	chr11:49856040	G/C	cg03929089	chr4:120376271	NA	-0.92	-15.68	-0.69	1.2e-39	Height;
CESC	cis	rs7131987	0.903	rs11050161	chr12:29420049	A/G	cg09582351	chr12:29534625	ERGIC2	-0.34	-5.39	-0.31	1.57e-7	QT interval;
CESC	cis	rs12048904	0.505	rs11166508	chr1:101233511	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.66	-8.0	-0.44	3.9e-14	Multiple sclerosis;
CESC	cis	rs8062405	0.755	rs62034350	chr16:28562256	A/G	cg01378222	chr16:28622494	SULT1A1	0.31	5.14	0.3	5.27e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs9913156	0.707	rs11657052	chr17:4570573	C/T	cg00122941	chr17:4613640	ARRB2	-0.79	-9.64	-0.51	4.84e-19	Lymphocyte counts;
CESC	cis	rs849898	1	rs849898	chr1:228153917	A/G	cg02753203	chr1:228287806	NA	-0.71	-10.11	-0.53	1.6e-20	Parkinson's disease;
CESC	cis	rs2243480	1.000	rs34577383	chr7:65385726	C/T	cg13147721	chr7:65941812	NA	-0.83	-7.92	-0.44	6.77e-14	Diabetic kidney disease;
CESC	cis	rs6688613	0.694	rs1476347	chr1:166815587	G/T	ch.1.3259774R	chr1:166827647	TADA1	0.62	6.35	0.36	9.23e-10	Refractive astigmatism;
CESC	cis	rs3785574	0.962	rs2584623	chr17:61906679	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.79	10.49	0.54	9.34e-22	Height;
CESC	cis	rs8078723	0.966	rs2227322	chr17:38171668	C/G	cg17467752	chr17:38218738	THRA	0.66	9.82	0.52	1.25e-19	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CESC	cis	rs7580658	0.895	rs7589451	chr2:128128775	T/C	cg10021288	chr2:128175891	PROC	-0.4	-6.38	-0.36	8.05e-10	Protein C levels;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg27651003	chr16:67261081	TMEM208;LRRC29	-0.47	-6.81	-0.39	6.67e-11	Asthma;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg05214047	chr5:56112645	MAP3K1	0.49	6.55	0.37	2.98e-10	Systemic lupus erythematosus;
CESC	cis	rs8060686	0.516	rs8048364	chr16:68253324	T/G	cg26727032	chr16:67993705	SLC12A4	-0.59	-8.5	-0.46	1.38e-15	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg07157834	chr1:205819609	PM20D1	0.73	10.58	0.54	4.79e-22	Menarche (age at onset);
CESC	cis	rs8141529	0.664	rs5762862	chr22:29252732	C/T	cg02153584	chr22:29168773	CCDC117	0.53	6.51	0.37	3.78e-10	Lymphocyte counts;
CESC	cis	rs875971	0.545	rs4441996	chr7:65588220	T/C	cg25405998	chr7:65216604	CCT6P1	-0.46	-5.2	-0.3	3.9e-7	Aortic root size;
CESC	cis	rs2455799	0.573	rs2654650	chr3:15779214	C/T	cg16303742	chr3:15540471	COLQ	-0.39	-6.13	-0.35	3.12e-9	Mean platelet volume;
CESC	cis	rs4077515	0.839	rs3812563	chr9:139271106	A/G	cg14169450	chr9:139327907	INPP5E	0.41	5.87	0.34	1.31e-8	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs8060686	0.641	rs8064114	chr16:68240185	G/A	cg26727032	chr16:67993705	SLC12A4	-0.51	-6.11	-0.35	3.5e-9	HDL cholesterol;Metabolic syndrome;
CESC	trans	rs10878577	0.813	rs4913531	chr12:67584661	C/T	cg07881065	chr8:840398	NA	0.37	6.06	0.35	4.66e-9	Schizophrenia;
CESC	cis	rs6460942	0.659	rs13247187	chr7:12551851	T/C	cg06484146	chr7:12443880	VWDE	-0.7	-7.59	-0.42	5.46e-13	Coronary artery disease;
CESC	cis	rs929354	0.935	rs1182392	chr7:157036200	C/T	cg05182265	chr7:156933206	UBE3C	0.4	5.57	0.32	6.19e-8	Body mass index;
CESC	cis	rs1552244	1.000	rs7611218	chr3:10063960	T/C	cg00166722	chr3:10149974	C3orf24	0.51	6.38	0.37	7.76e-10	Alzheimer's disease;
CESC	cis	rs4930103	0.935	rs4930101	chr11:2021859	G/T	cg23202291	chr11:1979235	NA	0.37	5.38	0.31	1.62e-7	DNA methylation (parent-of-origin);DNA methylation (variation);
CESC	cis	rs1348850	0.768	rs57681892	chr2:178357645	G/C	cg22681709	chr2:178499509	PDE11A	-0.43	-6.31	-0.36	1.19e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs425277	1.000	rs55826501	chr1:2059143	G/A	cg24578937	chr1:2090814	PRKCZ	0.52	8.72	0.47	3.02e-16	Height;
CESC	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg12419862	chr22:24373484	LOC391322	-0.81	-11.98	-0.59	1.04e-26	Liver enzyme levels (gamma-glutamyl transferase);
CESC	trans	rs10776614	0.799	rs7098068	chr10:49763717	C/T	cg19218067	chr2:181235115	NA	0.5	6.29	0.36	1.27e-9	Self-employment;
CESC	cis	rs9399137	0.529	rs7739722	chr6:135282225	T/C	cg22676075	chr6:135203613	NA	0.55	7.15	0.4	8.61e-12	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	cis	rs10540	0.908	rs71487293	chr11:486414	G/A	cg03576123	chr11:487126	PTDSS2	-1.08	-10.51	-0.54	7.9e-22	Body mass index;
CESC	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg01939980	chr4:1354348	KIAA1530	0.43	5.35	0.31	1.88e-7	Longevity;
CESC	cis	rs62064224	0.614	rs4795700	chr17:30763794	A/G	cg18200150	chr17:30822561	MYO1D	0.42	5.41	0.32	1.43e-7	Schizophrenia;
CESC	cis	rs921968	0.643	rs13431399	chr2:219469498	G/C	cg02176678	chr2:219576539	TTLL4	-0.52	-8.96	-0.48	6.06e-17	Mean corpuscular hemoglobin concentration;
CESC	cis	rs763121	0.853	rs6519124	chr22:39045099	T/C	cg21395723	chr22:39101663	GTPBP1	0.5	6.66	0.38	1.6e-10	Menopause (age at onset);
CESC	cis	rs853679	0.550	rs1225599	chr6:28165190	C/T	cg23161317	chr6:28129485	ZNF389	0.44	5.72	0.33	2.8e-8	Depression;
CESC	cis	rs10504229	0.593	rs79874994	chr8:57993709	C/A	cg22535103	chr8:58192502	C8orf71	-0.92	-9.13	-0.49	1.84e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs1799949	1.000	rs1135214	chr17:41292323	T/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.42	5.76	0.33	2.3e-8	Menopause (age at onset);
CESC	cis	rs3733585	0.674	rs7375643	chr4:9955239	A/G	cg02734326	chr4:10020555	SLC2A9	-0.46	-6.94	-0.39	3.08e-11	Cleft plate (environmental tobacco smoke interaction);
CESC	trans	rs1728785	1.000	rs12925177	chr16:68569645	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.6	-7.4	-0.41	1.76e-12	Ulcerative colitis;
CESC	cis	rs3733585	0.673	rs9994937	chr4:9964799	G/T	cg00071950	chr4:10020882	SLC2A9	-0.74	-11.9	-0.59	1.84e-26	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs75477785	1.000	rs4844908	chr1:210054718	C/T	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.8	5.19	0.3	4.2e-7	Cleft lip with or without cleft palate;
CESC	cis	rs6121246	0.567	rs6120815	chr20:30184866	T/C	cg13852791	chr20:30311386	BCL2L1	0.58	5.56	0.32	6.65e-8	Mean corpuscular hemoglobin;
CESC	cis	rs11864453	0.713	rs8051882	chr16:72142072	A/G	cg01557791	chr16:72042693	DHODH	0.48	6.15	0.35	2.79e-9	Fibrinogen levels;
CESC	cis	rs832540	0.629	rs10461616	chr5:56080347	T/C	cg22800045	chr5:56110881	MAP3K1	0.44	5.38	0.31	1.6e-7	Coronary artery disease;
CESC	cis	rs977987	0.843	rs12149063	chr16:75451758	G/A	cg03315344	chr16:75512273	CHST6	0.41	5.84	0.34	1.56e-8	Dupuytren's disease;
CESC	cis	rs651907	0.535	rs34063583	chr3:101509948	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.46	6.05	0.35	4.95e-9	Colorectal cancer;
CESC	cis	rs1538970	1.000	rs4660852	chr1:45848931	A/C	cg06784218	chr1:46089804	CCDC17	-0.32	-5.47	-0.32	1.07e-7	Platelet count;
CESC	cis	rs1322639	0.697	rs12661910	chr6:169584388	A/G	cg04662567	chr6:169592167	NA	-0.5	-5.5	-0.32	8.85e-8	Pulse pressure;
CESC	cis	rs9611565	0.506	rs1883825	chr22:41703408	A/G	cg06481639	chr22:41940642	POLR3H	-0.49	-5.57	-0.32	6.21e-8	Vitiligo;
CESC	cis	rs7568458	0.660	rs6722691	chr2:85758352	C/T	cg02493740	chr2:85810744	VAMP5	-0.57	-8.4	-0.46	2.81e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CESC	cis	rs9916302	0.851	rs11078904	chr17:37650569	G/A	cg19468946	chr17:37922297	IKZF3	-0.39	-5.08	-0.3	7.08e-7	Glomerular filtration rate (creatinine);
CESC	trans	rs877282	0.853	rs12779017	chr10:763619	T/C	cg22713356	chr15:30763199	NA	1.16	11.35	0.57	1.37e-24	Uric acid levels;
CESC	cis	rs5753037	0.653	rs131265	chr22:30145591	C/T	cg01021169	chr22:30184971	ASCC2	-0.47	-6.6	-0.38	2.17e-10	Type 1 diabetes;
CESC	cis	rs477692	0.673	rs511361	chr10:131365052	C/T	cg05714579	chr10:131428358	MGMT	0.4	5.15	0.3	4.97e-7	Response to temozolomide;
CESC	cis	rs9303401	0.614	rs12948536	chr17:56580413	G/T	cg25039879	chr17:56429692	SUPT4H1	0.51	5.11	0.3	6.24e-7	Cognitive test performance;
CESC	cis	rs1552244	0.938	rs67667957	chr3:10167264	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.82	-11.61	-0.58	1.83e-25	Alzheimer's disease;
CESC	cis	rs34375054	0.526	rs34764657	chr12:125679639	A/G	cg25124228	chr12:125621409	AACS	-0.5	-5.82	-0.34	1.73e-8	Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs55986470	0.817	rs6710301	chr2:239441308	A/C	cg18131467	chr2:239335373	ASB1	0.6	5.29	0.31	2.59e-7	Chronotype;
CESC	cis	rs4654899	0.865	rs6426658	chr1:21361176	G/A	cg05370193	chr1:21551575	ECE1	0.41	6.23	0.36	1.82e-9	Superior frontal gyrus grey matter volume;
CESC	cis	rs2072499	0.966	rs2984615	chr1:156165317	G/C	cg06970220	chr1:156163860	SLC25A44	0.39	5.22	0.31	3.67e-7	Testicular germ cell tumor;
CESC	cis	rs4409675	0.597	rs1467464	chr1:28211650	T/C	cg11176159	chr1:28213800	NA	0.23	5.09	0.3	6.87e-7	Corneal astigmatism;
CESC	trans	rs13402330	1.000	rs10181783	chr2:103509684	G/A	cg14228246	chr9:132165670	NA	0.46	6.05	0.35	4.9e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs910316	0.935	rs3742771	chr14:75599647	A/G	cg11812906	chr14:75593930	NEK9	0.89	15.03	0.68	2.4e-37	Height;
CESC	cis	rs8180040	0.715	rs6772670	chr3:47191349	G/A	cg27129171	chr3:47204927	SETD2	0.69	10.44	0.54	1.33e-21	Colorectal cancer;
CESC	cis	rs3105593	1.000	rs4509958	chr15:50894175	T/C	cg08437265	chr15:50716283	USP8	0.41	5.22	0.31	3.57e-7	QT interval;
CESC	cis	rs4853012	1.000	rs4853012	chr2:74361290	G/A	cg20891558	chr2:74357851	NA	0.8	9.47	0.5	1.62e-18	Gestational age at birth (maternal effect);
CESC	trans	rs11098499	0.754	rs1511025	chr4:120240238	T/C	cg25214090	chr10:38739885	LOC399744	0.61	8.51	0.46	1.33e-15	Corneal astigmatism;
CESC	cis	rs7811142	1.000	rs6975729	chr7:100028187	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.06	10.39	0.54	1.98e-21	Platelet count;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg07130416	chr16:2052619	ZNF598	0.48	6.3	0.36	1.24e-9	Fibrinogen levels;
CESC	cis	rs12711979	0.765	rs881852	chr2:3821508	A/G	cg17052675	chr2:3827356	NA	-0.37	-5.72	-0.33	2.83e-8	Itch intensity from mosquito bite adjusted by bite size;
CESC	cis	rs9435341	0.965	rs1762482	chr1:107599002	A/C	cg09367891	chr1:107599246	PRMT6	-0.61	-7.51	-0.42	9.27e-13	Facial morphology (factor 21, depth of nasal alae);
CESC	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg26338869	chr17:61819248	STRADA	0.63	8.16	0.45	1.32e-14	Prudent dietary pattern;
CESC	cis	rs1023500	0.596	rs133369	chr22:42463814	C/T	cg15557168	chr22:42548783	NA	-0.46	-6.5	-0.37	4e-10	Schizophrenia;
CESC	trans	rs7618501	0.571	rs2240329	chr3:50107512	G/A	cg21659725	chr3:3221576	CRBN	-0.49	-6.92	-0.39	3.38e-11	Intelligence (multi-trait analysis);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg00206853	chr16:3647862	BTBD12	0.43	6.21	0.36	2.03e-9	Fibrinogen levels;
CESC	cis	rs9473147	0.543	rs4715025	chr6:47483653	C/G	cg20196966	chr6:47445060	CD2AP	0.41	5.33	0.31	2.13e-7	Platelet distribution width;Mean platelet volume;
CESC	cis	rs7089973	0.604	rs1924034	chr10:116578539	C/T	cg03647239	chr10:116582469	FAM160B1	0.44	5.67	0.33	3.78e-8	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	trans	rs208520	0.837	rs208488	chr6:66926902	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.87	-10.08	-0.53	1.88e-20	Exhaled nitric oxide output;
CESC	cis	rs4862750	0.914	rs1991256	chr4:187875330	A/G	cg06074448	chr4:187884817	NA	-0.37	-5.22	-0.31	3.6e-7	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9916302	0.904	rs55689507	chr17:37404436	G/C	cg15445000	chr17:37608096	MED1	0.4	6.45	0.37	5.28e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs3767633	0.528	rs4417044	chr1:161888955	T/C	cg27519958	chr1:161735129	ATF6	-0.48	-6.02	-0.35	5.83e-9	IgG glycosylation;
CESC	cis	rs4076764	0.958	rs6688997	chr1:163411562	G/A	cg06092702	chr1:163392909	NA	-0.41	-5.92	-0.34	9.92e-9	Motion sickness;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg14361641	chr2:70056642	GMCL1	-0.47	-6.75	-0.38	9.18e-11	Gambling;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg16629569	chr3:122513933	DIRC2;HSPBAP1	-0.47	-6.07	-0.35	4.45e-9	Asthma;
CESC	cis	rs9322193	0.736	rs10457851	chr6:150096352	T/A	cg07701084	chr6:150067640	NUP43	0.43	5.8	0.34	1.91e-8	Lung cancer;
CESC	cis	rs1023500	0.551	rs2854837	chr22:42458481	G/A	cg04733989	chr22:42467013	NAGA	0.75	10.83	0.55	7.23e-23	Schizophrenia;
CESC	cis	rs2046867	0.818	rs6786469	chr3:72873809	A/G	cg25664220	chr3:72788482	NA	-0.45	-6.09	-0.35	4e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CESC	cis	rs7572263	0.724	rs6749281	chr2:209050696	C/A	cg23998903	chr2:209048830	C2orf80	-0.39	-5.14	-0.3	5.4e-7	Glioma;Non-glioblastoma glioma;
CESC	cis	rs7647973	0.577	rs6446247	chr3:49102001	A/T	cg07636037	chr3:49044803	WDR6	0.86	11.4	0.57	9.24e-25	Menarche (age at onset);
CESC	cis	rs1348850	0.668	rs2365619	chr2:178497366	A/G	cg22681709	chr2:178499509	PDE11A	0.47	6.42	0.37	6.34e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs9858542	0.953	rs7633271	chr3:49555963	T/C	cg07274523	chr3:49395745	GPX1	0.66	8.5	0.46	1.37e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs10206020	0.885	rs11887527	chr2:1578080	A/G	cg12573674	chr2:1569213	NA	-0.45	-5.18	-0.3	4.5e-7	IgG glycosylation;
CESC	cis	rs3733585	0.664	rs17185870	chr4:9958214	C/A	cg00071950	chr4:10020882	SLC2A9	-0.72	-11.54	-0.58	3.14e-25	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs4969178	0.641	rs4969141	chr17:76391653	C/T	cg05887092	chr17:76393375	PGS1	0.68	11.55	0.58	2.99e-25	HDL cholesterol levels;
CESC	trans	rs1814175	0.587	rs7937757	chr11:49978342	G/A	cg03929089	chr4:120376271	NA	-0.92	-15.24	-0.68	4.38e-38	Height;
CESC	cis	rs9614461	0.702	rs16993867	chr22:45733199	A/G	cg15911859	chr22:45810043	RIBC2;SMC1B	0.6	7.03	0.4	1.7e-11	Tonsillectomy;
CESC	trans	rs61931739	0.500	rs7309421	chr12:34553795	C/T	cg13010199	chr12:38710504	ALG10B	0.51	6.49	0.37	4.16e-10	Morning vs. evening chronotype;
CESC	trans	rs116095464	0.558	rs28418643	chr5:240859	A/G	cg00938859	chr5:1591904	SDHAP3	0.64	6.99	0.39	2.27e-11	Breast cancer;
CESC	cis	rs9916302	0.904	rs9904334	chr17:37468336	G/A	cg15445000	chr17:37608096	MED1	-0.4	-6.61	-0.38	2.1e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs1003719	0.641	rs13046844	chr21:38517603	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.6	-8.06	-0.44	2.56e-14	Eye color traits;
CESC	cis	rs2075671	0.903	rs62483570	chr7:100300649	C/T	cg20848291	chr7:100343083	ZAN	-0.79	-9.89	-0.52	7.81e-20	Other erythrocyte phenotypes;
CESC	trans	rs5756813	0.754	rs4820307	chr22:38175955	G/A	cg19894588	chr14:64061835	NA	-0.68	-8.83	-0.48	1.45e-16	Optic cup area;Vertical cup-disc ratio;
CESC	cis	rs35110281	0.712	rs1454648	chr21:45053815	C/T	cg01579765	chr21:45077557	HSF2BP	-0.55	-9.1	-0.49	2.31e-17	Mean corpuscular volume;
CESC	cis	rs4555082	0.957	rs3000073	chr14:105729792	G/A	cg06808227	chr14:105710500	BRF1	-0.62	-7.91	-0.44	7.23e-14	Mean platelet volume;Platelet distribution width;
CESC	cis	rs1348850	0.561	rs57986285	chr2:178468663	C/T	cg22681709	chr2:178499509	PDE11A	-0.47	-5.14	-0.3	5.22e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs6736093	0.966	rs870761	chr2:112745290	A/T	cg12686935	chr2:112915763	FBLN7	-0.43	-5.61	-0.33	5.09e-8	Coronary artery disease;
CESC	cis	rs5769765	0.862	rs138856	chr22:50199378	G/T	cg02269571	chr22:50332266	NA	-0.46	-5.72	-0.33	2.9e-8	Schizophrenia;
CESC	cis	rs7617773	0.780	rs3197223	chr3:48335857	C/T	cg11946769	chr3:48343235	NME6	0.87	11.45	0.58	6.11e-25	Coronary artery disease;
CESC	cis	rs881375	0.692	rs2072438	chr9:123651301	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.53	7.85	0.43	1.01e-13	Rheumatoid arthritis;
CESC	cis	rs28647808	0.881	rs4962139	chr9:136267869	C/T	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	-0.96	-8.2	-0.45	1.02e-14	Blood protein levels;
CESC	trans	rs882300	0.758	rs10191360	chr2:136884679	A/G	cg11058932	chr7:130372167	TSGA13	0.4	6.06	0.35	4.71e-9	Multiple sclerosis;Electrocardiographic traits;
CESC	cis	rs9660180	0.935	rs2180311	chr1:1748734	T/C	cg03396347	chr1:1875803	NA	-0.43	-6.67	-0.38	1.46e-10	Body mass index;
CESC	cis	rs4481887	0.861	rs6669290	chr1:248476804	G/A	cg00666640	chr1:248458726	OR2T12	0.35	5.89	0.34	1.17e-8	Common traits (Other);
CESC	cis	rs2832191	0.791	rs9983651	chr21:30491227	T/A	cg08807101	chr21:30365312	RNF160	-0.72	-9.88	-0.52	8.63e-20	Dental caries;
CESC	cis	rs13096760	1	rs13096760	chr3:49476806	T/C	cg07636037	chr3:49044803	WDR6	0.61	8.83	0.48	1.42e-16	Intelligence (multi-trait analysis);
CESC	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg05564831	chr3:52568323	NT5DC2	0.48	8.13	0.45	1.63e-14	Bipolar disorder;
CESC	cis	rs2404618	0.593	rs7829532	chr8:1485190	C/A	cg02903104	chr8:1507517	DLGAP2	0.29	5.42	0.32	1.37e-7	Lung cancer;
CESC	cis	rs7188697	0.848	rs42947	chr16:58579158	A/C	cg02549819	chr16:58548995	SETD6	-0.43	-5.47	-0.32	1.03e-7	QT interval;
CESC	cis	rs2243480	1.000	rs34560516	chr7:65404092	A/T	cg12463550	chr7:65579703	CRCP	0.71	5.5	0.32	8.79e-8	Diabetic kidney disease;
CESC	cis	rs7584330	0.910	rs72620830	chr2:238396985	C/T	cg14458575	chr2:238380390	NA	0.69	10.02	0.52	3.03e-20	Prostate cancer;
CESC	cis	rs832540	0.629	rs6888317	chr5:56093307	A/G	cg14703610	chr5:56206110	C5orf35	-0.42	-5.13	-0.3	5.69e-7	Coronary artery disease;
CESC	cis	rs6580649	0.941	rs1793931	chr12:48396505	G/T	cg05342945	chr12:48394962	COL2A1	-0.54	-6.44	-0.37	5.55e-10	Lung cancer;
CESC	cis	rs7246657	0.943	rs7255952	chr19:37988797	A/G	cg23950597	chr19:37808831	NA	-0.58	-6.34	-0.36	1e-9	Coronary artery calcification;
CESC	cis	rs3820928	1.000	rs10210763	chr2:227776029	G/T	cg05526886	chr2:227700861	RHBDD1	-0.42	-5.54	-0.32	7.19e-8	Pulmonary function;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg00729291	chr7:38725630	FAM183B	0.5	7.24	0.41	4.73e-12	Fibrinogen levels;
CESC	cis	rs3858526	0.584	rs10769276	chr11:5868020	G/T	cg19445457	chr11:5799446	OR52N5	-0.39	-5.27	-0.31	2.8e-7	DNA methylation (variation);
CESC	trans	rs9929218	0.954	rs9646284	chr16:68791306	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.63	-8.02	-0.44	3.45e-14	Colorectal cancer;
CESC	cis	rs2070488	1.000	rs2268753	chr3:38500189	C/T	cg24069376	chr3:38537580	EXOG	0.48	8.8	0.48	1.8e-16	Electrocardiographic conduction measures;
CESC	cis	rs9322193	0.923	rs4870509	chr6:150023348	C/G	cg04369109	chr6:150039330	LATS1	-0.43	-5.88	-0.34	1.26e-8	Lung cancer;
CESC	cis	rs7582720	1.000	rs72928608	chr2:203836507	G/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.36	0.41	2.34e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs6502050	0.731	rs34796376	chr17:80116635	G/T	cg23985595	chr17:80112537	CCDC57	-0.41	-6.46	-0.37	4.88e-10	Life satisfaction;
CESC	cis	rs7412746	0.587	rs11204722	chr1:150730184	A/C	cg22823121	chr1:150693482	HORMAD1	-0.46	-6.47	-0.37	4.69e-10	Melanoma;
CESC	cis	rs896854	0.625	rs7823886	chr8:95986459	A/T	cg26343298	chr8:95960752	TP53INP1	0.32	5.27	0.31	2.78e-7	Type 2 diabetes;
CESC	cis	rs738322	0.836	rs4821741	chr22:38514745	A/G	cg17652424	chr22:38574118	PLA2G6	-0.29	-5.1	-0.3	6.59e-7	Cutaneous nevi;
CESC	cis	rs9611565	0.921	rs3927	chr22:41722864	A/G	cg17376030	chr22:41985996	PMM1	0.58	6.29	0.36	1.31e-9	Vitiligo;
CESC	cis	rs1801251	0.896	rs79793315	chr2:233690864	C/T	cg08000102	chr2:233561755	GIGYF2	-0.72	-11.48	-0.58	5.05e-25	Coronary artery disease;
CESC	cis	rs722599	1.000	rs722599	chr14:75327443	T/C	cg08847533	chr14:75593920	NEK9	-0.45	-5.68	-0.33	3.53e-8	IgG glycosylation;
CESC	cis	rs741677	0.964	rs8077122	chr17:495522	G/A	cg06217071	chr17:408420	NA	-0.31	-5.11	-0.3	6.32e-7	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
CESC	cis	rs7598759	0.548	rs1584462	chr2:232369798	A/G	cg19187155	chr2:232395269	NMUR1	0.61	10.3	0.53	3.88e-21	Noise-induced hearing loss;
CESC	cis	rs8177253	0.965	rs7638018	chr3:133495461	C/T	cg01448562	chr3:133502909	NA	0.4	5.55	0.32	6.79e-8	Iron status biomarkers;
CESC	cis	rs929596	0.785	rs17864701	chr2:234652717	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.69	-8.59	-0.47	7.64e-16	Total bilirubin levels in HIV-1 infection;
CESC	cis	rs9287719	0.967	rs4453662	chr2:10739128	G/A	cg00105475	chr2:10696890	NA	0.39	5.61	0.33	4.96e-8	Prostate cancer;
CESC	cis	rs10751667	0.643	rs10902234	chr11:935578	A/G	cg01483505	chr11:975446	AP2A2	0.38	5.27	0.31	2.8e-7	Alzheimer's disease (late onset);
CESC	cis	rs7772486	0.875	rs2814877	chr6:146299763	C/G	cg05347473	chr6:146136440	FBXO30	0.55	7.19	0.4	6.54e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4654899	0.932	rs10916943	chr1:21472429	T/C	cg05370193	chr1:21551575	ECE1	-0.38	-5.75	-0.33	2.4e-8	Superior frontal gyrus grey matter volume;
CESC	cis	rs2479724	0.875	rs2253961	chr6:41827011	A/G	cg17623882	chr6:41773611	USP49	-0.41	-5.77	-0.33	2.26e-8	Menarche (age at onset);
CESC	cis	rs13108904	0.934	rs13115173	chr4:1316824	T/C	cg00684032	chr4:1343700	KIAA1530	0.49	6.98	0.39	2.31e-11	Obesity-related traits;
CESC	cis	rs524281	0.861	rs10791856	chr11:65964650	T/C	cg14036092	chr11:66035641	RAB1B	-0.5	-5.48	-0.32	9.95e-8	Electroencephalogram traits;
CESC	cis	rs2204008	0.749	rs4579984	chr12:38166266	A/G	cg13010199	chr12:38710504	ALG10B	0.49	6.07	0.35	4.34e-9	Bladder cancer;
CESC	cis	rs9478638	0.507	rs2184406	chr6:155629678	T/C	cg07943832	chr6:155568918	TIAM2	-0.37	-5.49	-0.32	9.33e-8	Electroencephalogram traits;
CESC	cis	rs1559088	0.895	rs1974784	chr19:33551563	T/G	cg27124370	chr19:33622961	WDR88	0.42	5.33	0.31	2.14e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs61931739	0.500	rs11053261	chr12:34530810	C/T	cg19457237	chr12:34500585	NA	-0.37	-5.08	-0.3	6.97e-7	Morning vs. evening chronotype;
CESC	cis	rs754466	0.580	rs10824571	chr10:79531931	G/A	cg17075019	chr10:79541650	NA	-0.89	-13.81	-0.65	4.92e-33	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs11190604	1.000	rs3750626	chr10:102266316	C/T	cg07080220	chr10:102295463	HIF1AN	0.64	5.88	0.34	1.23e-8	Palmitoleic acid (16:1n-7) levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03616030	chr8:94766944	TMEM67	-0.5	-6.24	-0.36	1.7e-9	Gut microbiome composition (summer);
CESC	cis	rs7937682	0.924	rs499750	chr11:111513645	T/G	cg22437258	chr11:111473054	SIK2	0.69	9.23	0.49	8.64e-18	Primary sclerosing cholangitis;
CESC	cis	rs2637266	1.000	rs1873461	chr10:78338966	A/C	cg18941641	chr10:78392320	NA	-0.43	-8.02	-0.44	3.32e-14	Pulmonary function;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02399233	chr11:71201915	NADSYN1	-0.57	-6.16	-0.35	2.66e-9	Gut microbiome composition (summer);
CESC	cis	rs2836950	0.840	rs12482317	chr21:40588241	A/G	cg11644478	chr21:40555479	PSMG1	-0.56	-7.12	-0.4	9.97e-12	Menarche (age at onset);
CESC	cis	rs7666738	0.830	rs17483521	chr4:98974058	A/T	cg03676636	chr4:99064102	C4orf37	0.33	5.16	0.3	4.78e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4704187	0.687	rs10079346	chr5:74536655	G/A	cg03227963	chr5:74354835	NA	0.27	5.04	0.3	8.67e-7	Response to amphetamines;
CESC	cis	rs6580649	1.000	rs6580649	chr12:48410517	A/G	cg24011408	chr12:48396354	COL2A1	0.44	5.51	0.32	8.58e-8	Lung cancer;
CESC	cis	rs2243480	1.000	rs160637	chr7:65584318	C/T	cg18252515	chr7:66147081	NA	-1.39	-13.92	-0.65	1.93e-33	Diabetic kidney disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg12052203	chr11:66115045	B3GNT1	-0.47	-6.24	-0.36	1.7e-9	Fibrinogen levels;
CESC	trans	rs17685	0.712	rs6953342	chr7:75776753	T/C	cg19862616	chr7:65841803	NCRNA00174	0.8	11.44	0.57	6.89e-25	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs11098499	0.754	rs878372	chr4:120238780	A/C	cg09307838	chr4:120376055	NA	0.79	10.77	0.55	1.17e-22	Corneal astigmatism;
CESC	cis	rs7395581	0.798	rs10769252	chr11:47343955	A/G	cg25783544	chr11:47291846	MADD	0.61	7.88	0.44	8.49e-14	HDL cholesterol;
CESC	cis	rs4253772	0.550	rs6007823	chr22:46706249	C/T	cg24881330	chr22:46731750	TRMU	0.82	7.29	0.41	3.49e-12	LDL cholesterol;Cholesterol, total;
CESC	cis	rs708547	0.836	rs1612191	chr4:57724320	A/C	cg25525207	chr4:57843836	C4orf14;POLR2B	0.49	5.06	0.3	7.85e-7	Response to bleomycin (chromatid breaks);
CESC	cis	rs6594499	0.500	rs12514810	chr5:110455357	T/A	cg04022379	chr5:110408740	TSLP	0.41	6.94	0.39	3.02e-11	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs11608355	0.515	rs61941591	chr12:109919965	A/C	cg05360138	chr12:110035743	NA	0.81	8.75	0.47	2.52e-16	Neuroticism;
CESC	cis	rs3733585	0.699	rs7686538	chr4:9948077	C/T	cg11266682	chr4:10021025	SLC2A9	-0.59	-11.08	-0.56	1.03e-23	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs17345786	0.798	rs9817043	chr3:101281852	A/G	cg12386194	chr3:101231763	SENP7	0.49	5.96	0.34	7.84e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4665809	0.590	rs1865324	chr2:26417533	C/A	cg08470875	chr2:26401718	FAM59B	-0.73	-8.0	-0.44	3.99e-14	Gut microbiome composition (summer);
CESC	cis	rs7824557	0.583	rs2736292	chr8:11234500	A/T	cg21775007	chr8:11205619	TDH	0.53	8.24	0.45	8.16e-15	Retinal vascular caliber;
CESC	cis	rs13256369	0.853	rs13256216	chr8:8577883	C/T	cg00074818	chr8:8560427	CLDN23	0.41	5.99	0.35	6.78e-9	Obesity-related traits;
CESC	cis	rs523522	0.923	rs10774553	chr12:120954984	T/C	cg12219531	chr12:120966889	COQ5	0.75	9.99	0.52	3.7e-20	High light scatter reticulocyte count;
CESC	cis	rs514406	0.667	rs10788942	chr1:53210521	A/T	cg08736216	chr1:53307985	ZYG11A	0.29	5.04	0.3	8.51e-7	Monocyte count;
CESC	cis	rs9584850	0.794	rs72655609	chr13:99128622	C/G	cg20750642	chr13:99100586	FARP1	-0.38	-5.59	-0.32	5.57e-8	Neuroticism;
CESC	cis	rs7116495	0.609	rs10898812	chr11:71698801	G/A	cg26138937	chr11:71823887	C11orf51	-1.26	-8.07	-0.44	2.43e-14	Severe influenza A (H1N1) infection;
CESC	cis	rs7216064	1.000	rs55939964	chr17:65869297	G/A	cg07042672	chr17:66097459	LOC651250	-0.54	-5.59	-0.32	5.61e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs9322193	1.000	rs9767077	chr6:150109615	T/A	cg05861140	chr6:150128134	PCMT1	-0.36	-5.14	-0.3	5.22e-7	Lung cancer;
CESC	cis	rs5750830	0.649	rs4337572	chr22:39800704	C/G	cg01416388	chr22:39784598	NA	-0.51	-5.95	-0.34	8.5e-9	Intelligence (multi-trait analysis);
CESC	cis	rs12541635	0.966	rs7812766	chr8:107057033	G/A	cg10147462	chr8:107024639	NA	0.43	6.01	0.35	6.12e-9	Age of smoking initiation;
CESC	cis	rs12928939	0.517	rs17358402	chr16:71967927	C/T	cg03805757	chr16:71968109	PKD1L3	-0.59	-6.62	-0.38	2.01e-10	Post bronchodilator FEV1;
CESC	cis	rs9790314	1.000	rs7638668	chr3:161047283	G/A	cg03342759	chr3:160939853	NMD3	-0.47	-6.11	-0.35	3.61e-9	Morning vs. evening chronotype;
CESC	cis	rs3762637	0.943	rs10439995	chr3:122189160	C/A	cg24169773	chr3:122142474	KPNA1	-0.53	-6.17	-0.35	2.56e-9	LDL cholesterol levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26996779	chr5:69784092	NA	-0.47	-6.1	-0.35	3.71e-9	Gut microbiome composition (summer);
CESC	cis	rs12780046	0.536	rs7092010	chr10:101006228	G/A	cg27143070	chr10:101087766	CNNM1	0.38	5.63	0.33	4.7e-8	Non-glioblastoma glioma;
CESC	cis	rs4665809	1.000	rs6546767	chr2:26328746	A/G	cg27170947	chr2:26402098	FAM59B	-0.59	-7.08	-0.4	1.26e-11	Gut microbiome composition (summer);
CESC	cis	rs1957429	0.520	rs72625648	chr14:65344602	A/G	cg23373153	chr14:65346875	NA	-0.85	-6.5	-0.37	3.94e-10	Pediatric areal bone mineral density (radius);
CESC	cis	rs11098499	1.000	rs11726229	chr4:120211580	C/T	cg24375607	chr4:120327624	NA	0.42	5.03	0.3	8.94e-7	Corneal astigmatism;
CESC	cis	rs1799949	0.965	rs11650132	chr17:41326087	T/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.6	7.87	0.44	8.81e-14	Menopause (age at onset);
CESC	cis	rs2251381	0.778	rs2245021	chr21:30546841	C/T	cg08807101	chr21:30365312	RNF160	0.67	8.23	0.45	8.77e-15	Selective IgA deficiency;
CESC	trans	rs1814175	0.616	rs1794131	chr11:49904194	A/G	cg15704280	chr7:45808275	SEPT13	-1.01	-18.94	-0.76	3.64e-51	Height;
CESC	cis	rs9611565	0.918	rs4822024	chr22:41757647	G/A	cg03806693	chr22:41940476	POLR3H	-1.01	-11.77	-0.59	5.31e-26	Vitiligo;
CESC	cis	rs72781680	1.000	rs72798411	chr2:24184343	A/G	cg08917208	chr2:24149416	ATAD2B	1.11	10.02	0.52	3.07e-20	Lymphocyte counts;
CESC	cis	rs875971	0.660	rs10272357	chr7:66063074	G/A	cg06456125	chr7:65229604	NA	-0.41	-5.41	-0.32	1.4e-7	Aortic root size;
CESC	cis	rs854765	0.583	rs7214536	chr17:17852446	G/A	cg09796270	chr17:17721594	SREBF1	0.45	6.15	0.35	2.87e-9	Total body bone mineral density;
CESC	trans	rs801193	1.000	rs2707850	chr7:66203870	G/T	cg26939375	chr7:64535504	NA	0.64	8.77	0.47	2.19e-16	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05775796	chr11:67719813	NA	-0.55	-7.28	-0.41	3.89e-12	Gut microbiome composition (summer);
CESC	cis	rs17533156	0.557	rs16969683	chr17:75128195	A/G	cg18815765	chr17:75136729	SEC14L1	-0.43	-5.07	-0.3	7.52e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs736408	0.609	rs2230534	chr3:52802402	A/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.31	5.21	0.3	3.83e-7	Bipolar disorder;
CESC	cis	rs875971	0.660	rs10272357	chr7:66063074	G/A	cg25985355	chr7:65971099	NA	0.33	5.41	0.32	1.39e-7	Aortic root size;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg05730215	chr2:27435253	SLC5A6;C2orf28	-0.46	-6.34	-0.36	1.01e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs10737909	1.000	rs10737909	chr1:15548636	A/C	cg21012057	chr1:15538911	TMEM51	0.42	5.97	0.34	7.5e-9	Migraine;
CESC	cis	rs10504229	0.683	rs7464038	chr8:58111908	T/C	cg24829409	chr8:58192753	C8orf71	-0.57	-6.91	-0.39	3.67e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs1983170	0.736	rs11164909	chr1:92002506	T/C	cg02896835	chr1:92012615	NA	0.59	6.19	0.36	2.31e-9	Eosinophil percentage of white cells;
CESC	cis	rs9660180	0.839	rs12040826	chr1:1705287	A/C	cg13866156	chr1:1669148	SLC35E2	-0.51	-6.76	-0.38	8.91e-11	Body mass index;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26968203	chr17:4871318	CAMTA2;SPAG7	-0.66	-7.14	-0.4	8.71e-12	Gut microbiome composition (summer);
CESC	trans	rs9951602	0.541	rs7243702	chr18:76645637	G/A	cg02800362	chr5:177631904	HNRNPAB	0.61	7.97	0.44	4.84e-14	Obesity-related traits;
CESC	trans	rs17764205	0.777	rs10424519	chr19:3253532	C/G	cg03776506	chr16:30581384	ZNF688	0.73	6.07	0.35	4.46e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs9660180	0.967	rs61422524	chr1:1767565	C/A	cg13866156	chr1:1669148	SLC35E2	-0.51	-6.72	-0.38	1.09e-10	Body mass index;
CESC	cis	rs2576037	0.583	rs9954336	chr18:44465945	A/G	cg19077165	chr18:44547161	KATNAL2	-0.62	-9.27	-0.49	6.83e-18	Personality dimensions;
CESC	cis	rs12681288	0.676	rs2600514	chr8:994175	G/A	cg04851639	chr8:1020857	NA	-0.34	-7.32	-0.41	3.04e-12	Schizophrenia;
CESC	trans	rs11628318	0.802	rs2277471	chr14:103024387	A/C	cg08318076	chr8:62051812	NA	-0.38	-6.18	-0.35	2.42e-9	Platelet count;
CESC	cis	rs5758659	0.714	rs133373	chr22:42465788	G/A	cg19513890	chr22:42538836	CYP2D7P1	-0.39	-5.73	-0.33	2.78e-8	Cognitive function;
CESC	cis	rs7267979	0.966	rs2387885	chr20:25415224	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.83	-15.87	-0.7	2.52e-40	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs9300255	0.602	rs941305	chr12:123715266	T/C	cg19016782	chr12:123741754	C12orf65	-0.5	-7.08	-0.4	1.33e-11	Neutrophil percentage of white cells;
CESC	cis	rs4665809	1.000	rs6546767	chr2:26328746	A/G	cg25036284	chr2:26402008	FAM59B	-0.59	-6.83	-0.39	5.71e-11	Gut microbiome composition (summer);
CESC	cis	rs9325144	0.555	rs2387843	chr12:38711203	T/C	cg26384229	chr12:38710491	ALG10B	0.59	8.49	0.46	1.53e-15	Morning vs. evening chronotype;
CESC	cis	rs11098499	0.542	rs7677836	chr4:120310638	T/A	cg24375607	chr4:120327624	NA	0.46	5.55	0.32	6.98e-8	Corneal astigmatism;
CESC	cis	rs7264396	0.563	rs2425088	chr20:34303902	C/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.63	6.7	0.38	1.23e-10	Total cholesterol levels;
CESC	cis	rs1153858	1.000	rs4775895	chr15:45617957	T/A	cg14582100	chr15:45693742	SPATA5L1	0.4	5.66	0.33	3.89e-8	Homoarginine levels;
CESC	trans	rs11098499	0.865	rs10032158	chr4:120391632	C/T	cg25214090	chr10:38739885	LOC399744	0.71	10.27	0.53	4.75e-21	Corneal astigmatism;
CESC	cis	rs7615952	0.576	rs17523380	chr3:125802874	C/T	cg06494592	chr3:125709126	NA	-0.43	-5.19	-0.3	4.19e-7	Blood pressure (smoking interaction);
CESC	cis	rs909674	0.818	rs5750830	chr22:39840828	C/A	cg01416388	chr22:39784598	NA	-0.65	-7.62	-0.42	4.41e-13	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs9303401	0.614	rs3803753	chr17:56540110	G/A	cg12560992	chr17:57184187	TRIM37	0.51	5.08	0.3	7.08e-7	Cognitive test performance;
CESC	cis	rs6582630	0.502	rs2387603	chr12:38353389	A/C	cg26384229	chr12:38710491	ALG10B	0.69	10.42	0.54	1.6e-21	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs8031584	0.678	rs4779496	chr15:31151054	A/G	cg08704250	chr15:31115839	NA	-0.68	-9.12	-0.49	1.97e-17	Huntington's disease progression;
CESC	cis	rs2549003	1.000	rs6894655	chr5:131818649	T/C	cg02551604	chr5:131831745	NA	-0.37	-5.23	-0.31	3.45e-7	Asthma (sex interaction);
CESC	cis	rs9916302	0.752	rs9901219	chr17:37558369	T/G	cg20243544	chr17:37824526	PNMT	-0.52	-5.87	-0.34	1.29e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs2262909	0.924	rs4290587	chr19:22164646	A/G	cg11619707	chr19:22235551	ZNF257	-0.35	-5.82	-0.34	1.68e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
CESC	cis	rs2228479	0.717	rs2074904	chr16:89811546	A/G	cg14709524	chr16:89940631	TCF25	0.95	7.1	0.4	1.18e-11	Skin colour saturation;
CESC	cis	rs7666738	0.830	rs6846229	chr4:99016546	C/T	cg17366294	chr4:99064904	C4orf37	0.61	8.77	0.47	2.15e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs736408	0.677	rs2286798	chr3:52821177	G/T	cg18404041	chr3:52824283	ITIH1	0.43	7.13	0.4	9.52e-12	Bipolar disorder;
CESC	cis	rs9322193	0.962	rs13215691	chr6:150113802	T/C	cg05861140	chr6:150128134	PCMT1	-0.36	-5.33	-0.31	2.15e-7	Lung cancer;
CESC	cis	rs2599510	0.783	rs2710630	chr2:32765997	A/C	cg02381751	chr2:32503542	YIPF4	-0.43	-5.48	-0.32	9.76e-8	Interleukin-18 levels;
CESC	cis	rs2795502	0.873	rs2077626	chr10:43410962	A/G	cg27426351	chr10:43362370	NA	0.49	6.08	0.35	4.26e-9	Blood protein levels;
CESC	cis	rs7552404	0.924	rs1313071	chr1:76195542	C/G	cg22875332	chr1:76189707	ACADM	0.7	9.57	0.51	7.8e-19	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs2576037	0.583	rs1465722	chr18:44564499	C/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.34	-5.34	-0.31	1.97e-7	Personality dimensions;
CESC	cis	rs769267	0.965	rs2916068	chr19:19516433	A/G	cg03709012	chr19:19516395	GATAD2A	1.0	15.73	0.69	7.65e-40	Tonsillectomy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12073537	chr12:49658926	TUBA1C	-0.59	-6.09	-0.35	3.97e-9	Gut microbiome composition (summer);
CESC	cis	rs4803468	1.000	rs284650	chr19:41927129	A/G	cg14132834	chr19:41945861	ATP5SL	-0.67	-8.35	-0.46	3.74e-15	Height;
CESC	cis	rs9549260	0.755	rs9532577	chr13:41231542	A/G	cg21288729	chr13:41239152	FOXO1	0.66	8.57	0.47	8.94e-16	Red blood cell count;
CESC	cis	rs6460942	0.908	rs117451929	chr7:12265149	A/T	cg06484146	chr7:12443880	VWDE	-0.61	-6.34	-0.36	9.59e-10	Coronary artery disease;
CESC	cis	rs765787	0.530	rs7167389	chr15:45535683	A/G	cg24006582	chr15:45444508	DUOX1	-0.59	-7.11	-0.4	1.08e-11	Uric acid levels;
CESC	cis	rs34779708	0.733	rs7914468	chr10:35548071	G/A	cg04310649	chr10:35416472	CREM	-0.45	-5.14	-0.3	5.34e-7	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs710865	0.527	rs2275403	chr1:19557713	C/G	cg13387374	chr1:19411106	UBR4	-0.81	-12.36	-0.6	5.24e-28	Brain structure;
CESC	cis	rs2243480	1.000	rs1546059	chr7:65654709	C/A	cg18252515	chr7:66147081	NA	1.36	13.62	0.64	2.24e-32	Diabetic kidney disease;
CESC	cis	rs12155623	1.000	rs12155623	chr8:49812201	A/T	cg22283653	chr8:49824208	NA	-0.35	-5.5	-0.32	8.85e-8	Sudden cardiac arrest;
CESC	cis	rs588177	0.613	rs3782101	chr11:64131280	A/G	cg24431193	chr11:63883947	FLRT1;MACROD1	0.42	6.06	0.35	4.59e-9	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	trans	rs7618501	1.000	rs35261599	chr3:49773236	G/A	cg21659725	chr3:3221576	CRBN	-0.83	-13.69	-0.64	1.24e-32	Intelligence (multi-trait analysis);
CESC	cis	rs7250872	0.647	rs2304612	chr19:1817866	A/G	cg10370574	chr19:1840461	REXO1	0.45	6.32	0.36	1.09e-9	Bipolar disorder;
CESC	cis	rs3780486	0.834	rs75443249	chr9:33149207	A/G	cg13443165	chr9:33130375	B4GALT1	0.41	5.48	0.32	9.86e-8	IgG glycosylation;
CESC	cis	rs3096299	0.606	rs8052103	chr16:89541243	A/T	cg16743903	chr16:89593216	SPG7	0.55	6.9	0.39	3.76e-11	Multiple myeloma (IgH translocation);
CESC	cis	rs1062177	0.756	rs2964591	chr5:151117397	A/G	cg00977110	chr5:151150581	G3BP1	-0.58	-6.16	-0.35	2.67e-9	Preschool internalizing problems;
CESC	cis	rs1799949	0.965	rs8176193	chr17:41231516	C/T	cg23758822	chr17:41437982	NA	1.02	15.8	0.7	4.51e-40	Menopause (age at onset);
CESC	cis	rs1707322	1.000	rs785478	chr1:46491635	C/T	cg05343316	chr1:45956843	TESK2	-0.45	-5.57	-0.32	6.17e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs3796619	1.000	rs13146371	chr4:1082887	C/T	cg27284194	chr4:1044797	NA	0.37	5.51	0.32	8.48e-8	Recombination rate (males);
CESC	cis	rs10883723	0.737	rs7074444	chr10:104249922	A/G	cg22532475	chr10:104410764	TRIM8	-0.33	-5.67	-0.33	3.67e-8	Allergic disease (asthma, hay fever or eczema);
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg03115081	chr17:74722049	C17orf95;JMJD6	0.49	6.8	0.39	7.06e-11	Systemic lupus erythematosus;
CESC	cis	rs9443645	0.836	rs9352676	chr6:79629999	A/G	cg05283184	chr6:79620031	NA	-0.43	-6.5	-0.37	3.94e-10	Intelligence (multi-trait analysis);
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg21647170	chr7:56119546	CCT6A;PSPH	0.47	6.19	0.36	2.32e-9	Systemic lupus erythematosus;
CESC	cis	rs2832191	0.716	rs9983051	chr21:30371890	C/T	cg24692254	chr21:30365293	RNF160	1.02	18.47	0.75	1.56e-49	Dental caries;
CESC	cis	rs950776	0.593	rs621849	chr15:78872861	G/A	cg06917634	chr15:78832804	PSMA4	-0.6	-8.04	-0.44	2.96e-14	Sudden cardiac arrest;
CESC	cis	rs6860806	0.632	rs4330455	chr5:131586349	T/C	cg09877947	chr5:131593287	PDLIM4	0.48	6.24	0.36	1.7e-9	Breast cancer;
CESC	cis	rs10461617	0.617	rs79742142	chr5:56104377	A/G	cg03609598	chr5:56110824	MAP3K1	-0.51	-5.42	-0.32	1.36e-7	Type 2 diabetes;
CESC	cis	rs7223966	0.921	rs2727300	chr17:61965398	G/A	cg11494091	chr17:61959527	GH2	0.42	5.66	0.33	3.9e-8	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs10465746	0.967	rs11163876	chr1:84440605	T/C	cg10977910	chr1:84465055	TTLL7	0.47	6.43	0.37	6.02e-10	Obesity-related traits;
CESC	cis	rs1005277	0.589	rs2749624	chr10:38529865	A/G	cg25517755	chr10:38738941	LOC399744	-0.44	-5.68	-0.33	3.45e-8	Extrinsic epigenetic age acceleration;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg20011543	chr20:42086465	SFRS6	-0.51	-6.48	-0.37	4.5e-10	Asthma;
CESC	cis	rs780096	0.546	rs1060525	chr2:27635582	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.31	-5.83	-0.34	1.62e-8	Total body bone mineral density;
CESC	cis	rs4835473	0.932	rs13134327	chr4:144659795	A/G	cg25736465	chr4:144833511	NA	0.32	5.04	0.3	8.45e-7	Immature fraction of reticulocytes;
CESC	cis	rs2294693	0.947	rs9381025	chr6:40986623	C/T	cg14769373	chr6:40998127	UNC5CL	-0.41	-5.95	-0.34	8.64e-9	Gastric cancer;Non-cardia gastric cancer;
CESC	cis	rs7666738	0.791	rs7658177	chr4:99035192	T/C	cg03676636	chr4:99064102	C4orf37	0.34	5.14	0.3	5.47e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7617773	0.817	rs9819094	chr3:48319558	C/T	cg11946769	chr3:48343235	NME6	0.76	9.85	0.52	1.05e-19	Coronary artery disease;
CESC	cis	rs13256369	0.802	rs11249888	chr8:8564934	T/C	cg18904891	chr8:8559673	CLDN23	0.73	8.12	0.45	1.74e-14	Obesity-related traits;
CESC	cis	rs9611565	0.625	rs12483991	chr22:41935285	A/G	cg03806693	chr22:41940476	POLR3H	-0.91	-11.39	-0.57	1e-24	Vitiligo;
CESC	cis	rs7666738	0.753	rs35194639	chr4:99053819	G/C	cg24818145	chr4:99064322	C4orf37	0.38	5.04	0.3	8.49e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs921968	0.519	rs62191659	chr2:219630510	C/T	cg02176678	chr2:219576539	TTLL4	-0.44	-7.71	-0.43	2.56e-13	Mean corpuscular hemoglobin concentration;
CESC	cis	rs11098499	0.863	rs34308924	chr4:120481431	T/C	cg24375607	chr4:120327624	NA	0.45	5.51	0.32	8.55e-8	Corneal astigmatism;
CESC	cis	rs9308731	0.591	rs7588534	chr2:111945087	T/C	cg04202892	chr2:111875749	ACOXL	0.37	5.17	0.3	4.61e-7	Chronic lymphocytic leukemia;
CESC	trans	rs7937682	0.824	rs539524	chr11:111477325	A/G	cg18187862	chr3:45730750	SACM1L	0.48	6.17	0.35	2.61e-9	Primary sclerosing cholangitis;
CESC	cis	rs4660306	0.961	rs2152077	chr1:45986670	G/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.52	-6.68	-0.38	1.41e-10	Homocysteine levels;
CESC	cis	rs9926296	0.546	rs6500442	chr16:89828862	T/C	cg07648498	chr16:89883185	FANCA	0.43	5.39	0.31	1.57e-7	Vitiligo;
CESC	cis	rs922182	0.569	rs6494457	chr15:64263532	C/A	cg24729988	chr15:64271149	DAPK2	0.4	5.32	0.31	2.21e-7	Blood protein levels;
CESC	cis	rs2795502	1.000	rs1581702	chr10:43344246	G/A	cg27426351	chr10:43362370	NA	0.48	6.05	0.35	4.79e-9	Blood protein levels;
CESC	cis	rs9291683	0.527	rs3822247	chr4:10094671	G/A	cg05927159	chr4:10118984	WDR1	0.36	5.39	0.31	1.54e-7	Bone mineral density;
CESC	cis	rs7726839	0.526	rs11960158	chr5:568665	C/T	cg16447950	chr5:562315	NA	-0.67	-7.91	-0.44	6.9e-14	Obesity-related traits;
CESC	trans	rs877282	1.000	rs112522746	chr10:772288	T/C	cg22713356	chr15:30763199	NA	1.15	11.76	0.59	5.59e-26	Uric acid levels;
CESC	cis	rs34375054	0.525	rs7136220	chr12:125602684	T/C	cg25124228	chr12:125621409	AACS	-0.57	-7.12	-0.4	1.01e-11	Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs34779708	0.966	rs12762493	chr10:35471873	G/A	cg03585969	chr10:35415529	CREM	0.77	10.23	0.53	6.59e-21	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs2180341	1.000	rs3798852	chr6:127636733	A/G	cg27446573	chr6:127587934	RNF146	1.09	16.38	0.71	3.79e-42	Breast cancer;
CESC	cis	rs7666738	0.830	rs62318503	chr4:98935479	T/C	cg17366294	chr4:99064904	C4orf37	0.61	8.56	0.47	9.36e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7927592	0.731	rs11228288	chr11:68353550	A/G	cg16797656	chr11:68205561	LRP5	0.48	7.13	0.4	9.41e-12	Total body bone mineral density;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17274881	chr4:79103244	FRAS1	-0.63	-7.68	-0.43	3.09e-13	Gut microbiome composition (summer);
CESC	cis	rs2718058	0.519	rs2722233	chr7:37875982	A/T	cg15028436	chr7:37888078	TXNDC3	0.42	6.37	0.36	8.15e-10	Alzheimer's disease (late onset);
CESC	cis	rs2228479	0.850	rs76075456	chr16:89834270	T/C	cg06558623	chr16:89946397	TCF25	1.17	9.29	0.5	5.84e-18	Skin colour saturation;
CESC	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	7.86	0.43	9.54e-14	Prudent dietary pattern;
CESC	cis	rs2637266	0.783	rs846585	chr10:78494466	T/G	cg18941641	chr10:78392320	NA	0.44	8.57	0.47	8.52e-16	Pulmonary function;
CESC	cis	rs7914558	1.000	rs10748838	chr10:104943986	T/A	cg04362960	chr10:104952993	NT5C2	0.46	6.16	0.35	2.74e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs614226	1.000	rs1167725	chr12:120968559	A/T	cg01236616	chr12:121019343	POP5	1.55	19.98	0.78	8.29e-55	Type 1 diabetes nephropathy;
CESC	cis	rs4919087	0.748	rs1687369	chr10:98976923	G/A	cg25902810	chr10:99078978	FRAT1	-0.51	-5.72	-0.33	2.82e-8	Monocyte count;
CESC	cis	rs631288	0.557	rs894470	chr1:146671947	A/G	cg25205988	chr1:146714368	CHD1L	1.05	6.7	0.38	1.23e-10	PR interval in Tripanosoma cruzi seropositivity;
CESC	cis	rs8114671	0.562	rs6088621	chr20:33418740	C/T	cg08999081	chr20:33150536	PIGU	0.39	5.49	0.32	9.56e-8	Height;
CESC	cis	rs4481887	0.741	rs6674078	chr1:248543026	G/A	cg26353448	chr1:248524236	OR2T4	-0.37	-5.12	-0.3	5.85e-7	Common traits (Other);
CESC	cis	rs2070677	0.799	rs11101854	chr10:135394430	G/A	cg20169779	chr10:135381914	SYCE1	-0.76	-10.08	-0.53	1.91e-20	Gout;
CESC	cis	rs1801251	1.000	rs895430	chr2:233725483	C/A	cg25237894	chr2:233734115	C2orf82	-0.48	-8.29	-0.45	5.74e-15	Coronary artery disease;
CESC	cis	rs7980687	0.628	rs1609520	chr12:123735937	A/G	cg05973401	chr12:123451056	ABCB9	-0.44	-5.19	-0.3	4.26e-7	Height;Educational attainment;Head circumference (infant);
CESC	cis	rs12497850	0.865	rs7649458	chr3:48920127	C/T	cg07636037	chr3:49044803	WDR6	1.02	19.51	0.77	3.76e-53	Parkinson's disease;
CESC	cis	rs11190604	1.000	rs1106565	chr10:102211613	T/C	cg07080220	chr10:102295463	HIF1AN	0.55	5.51	0.32	8.5e-8	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs3747547	0.792	rs11790106	chr9:38047710	G/A	cg13774184	chr9:37916125	SHB	-0.71	-5.6	-0.33	5.44e-8	Metabolite levels (Dihydroxy docosatrienoic acid);
CESC	cis	rs7605378	0.528	rs281791	chr2:200850402	A/G	cg23649088	chr2:200775458	C2orf69	-0.77	-10.07	-0.53	2.05e-20	Osteoporosis;
CESC	cis	rs12497850	0.931	rs4974085	chr3:48924900	C/T	cg07636037	chr3:49044803	WDR6	0.99	18.75	0.76	1.69e-50	Parkinson's disease;
CESC	cis	rs2281845	0.507	rs10800760	chr1:201100439	G/A	cg06714761	chr1:201096289	NA	0.44	6.83	0.39	5.8200000000000003e-11	Permanent tooth development;
CESC	cis	rs6540559	1.000	rs742215	chr1:209961023	A/T	cg12034118	chr1:209979487	IRF6	0.44	5.4	0.32	1.46e-7	Cleft lip with or without cleft palate;
CESC	cis	rs7851660	0.874	rs10120412	chr9:100628238	T/C	cg13688889	chr9:100608707	NA	-0.63	-8.87	-0.48	1.09e-16	Strep throat;
CESC	cis	rs6598955	0.666	rs12759434	chr1:26607123	C/T	cg04990556	chr1:26633338	UBXN11	-0.79	-11.49	-0.58	4.51e-25	Obesity-related traits;
CESC	cis	rs7826238	0.535	rs2979179	chr8:8320029	C/T	cg06636001	chr8:8085503	FLJ10661	0.47	6.3	0.36	1.26e-9	Systolic blood pressure;
CESC	cis	rs208520	0.690	rs12213561	chr6:66705646	T/C	cg07460842	chr6:66804631	NA	0.97	13.24	0.63	4.76e-31	Exhaled nitric oxide output;
CESC	cis	rs6089584	0.566	rs55881457	chr20:60608424	G/A	cg24733560	chr20:60626293	TAF4	0.48	7.18	0.4	6.85e-12	Body mass index;
CESC	cis	rs875971	0.545	rs313828	chr7:65552614	T/C	cg11764359	chr7:65958608	NA	-0.8	-8.87	-0.48	1.14e-16	Aortic root size;
CESC	cis	rs35110281	0.744	rs162396	chr21:44947807	T/C	cg04455712	chr21:45112962	RRP1B	0.34	5.16	0.3	4.93e-7	Mean corpuscular volume;
CESC	trans	rs35110281	0.626	rs162388	chr21:44936032	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.44	6.07	0.35	4.34e-9	Mean corpuscular volume;
CESC	cis	rs6424115	0.830	rs2229584	chr1:24200969	T/C	cg10978503	chr1:24200527	CNR2	0.33	6.64	0.38	1.73e-10	Immature fraction of reticulocytes;
CESC	cis	rs13191362	0.507	rs2155506	chr6:163035342	G/A	cg21926612	chr6:163149169	PACRG;PARK2	-0.54	-6.89	-0.39	3.97e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs2991971	0.934	rs2991974	chr1:46020654	A/G	cg05343316	chr1:45956843	TESK2	-0.47	-5.9	-0.34	1.1e-8	High light scatter reticulocyte count;
CESC	cis	rs17711722	0.701	rs781143	chr7:65439879	G/C	cg05332525	chr7:65337924	VKORC1L1	0.51	6.21	0.36	2.01e-9	Calcium levels;
CESC	cis	rs7917772	0.503	rs1409310	chr10:104282265	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.55	7.59	0.42	5.46e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs7618915	0.547	rs34610142	chr3:52708429	G/A	cg07507251	chr3:52567010	NT5DC2	0.42	7.32	0.41	2.95e-12	Bipolar disorder;
CESC	cis	rs7568458	0.527	rs35416445	chr2:85773659	A/G	cg02493740	chr2:85810744	VAMP5	-0.57	-8.33	-0.46	4.41e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CESC	cis	rs71636778	0.543	rs11810321	chr1:27220521	T/G	cg12203394	chr1:27248618	NUDC	0.67	5.43	0.32	1.26e-7	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
CESC	cis	rs9309473	0.898	rs7580750	chr2:73788126	A/G	cg20560298	chr2:73613845	ALMS1	-0.47	-6.37	-0.36	8.47e-10	Metabolite levels;
CESC	cis	rs796364	0.806	rs12616905	chr2:201007764	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.75	-6.83	-0.39	5.71e-11	Schizophrenia;
CESC	cis	rs6732160	0.741	rs6546806	chr2:73386160	T/C	cg01422370	chr2:73384389	NA	0.43	7.36	0.41	2.38e-12	Intelligence (multi-trait analysis);
CESC	cis	rs6089829	1.000	rs6089828	chr20:61668998	C/T	cg08564027	chr20:61660810	NA	0.89	14.86	0.67	9.37e-37	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg22798821	chr11:11864085	USP47	-0.49	-7.02	-0.4	1.91e-11	Gambling;
CESC	cis	rs769267	0.930	rs2304098	chr19:19646272	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.45	5.8	0.34	1.92e-8	Tonsillectomy;
CESC	cis	rs7772486	0.790	rs2265917	chr6:146212285	A/G	cg23711669	chr6:146136114	FBXO30	0.92	13.36	0.63	1.78e-31	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7666738	0.888	rs13110683	chr4:98983368	G/C	cg18180107	chr4:99064573	C4orf37	0.41	5.2	0.3	3.93e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9488822	0.676	rs12202641	chr6:116314634	A/G	cg18764771	chr6:116381957	FRK	-0.23	-5.84	-0.34	1.51e-8	Cholesterol, total;LDL cholesterol;
CESC	cis	rs12048904	0.595	rs2295280	chr1:101342497	T/C	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.48	6.13	0.35	3.17e-9	Multiple sclerosis;
CESC	cis	rs763121	1.000	rs138464	chr22:38906432	C/T	cg06544989	chr22:39130855	UNC84B	-0.45	-8.16	-0.45	1.37e-14	Menopause (age at onset);
CESC	cis	rs9381040	0.748	rs9357348	chr6:41154232	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.4	-5.21	-0.3	3.83e-7	Alzheimer's disease (late onset);
CESC	trans	rs2207136	0.771	rs2746660	chr6:50878205	A/T	cg06522515	chr3:184090630	THPO	-0.34	-6.02	-0.35	5.64e-9	Myopia;
CESC	cis	rs1023500	0.596	rs5751204	chr22:42433801	C/T	cg15557168	chr22:42548783	NA	-0.4	-5.35	-0.31	1.93e-7	Schizophrenia;
CESC	cis	rs2549003	0.933	rs7719499	chr5:131814091	C/G	cg21138405	chr5:131827807	IRF1	0.54	8.92	0.48	7.98e-17	Asthma (sex interaction);
CESC	cis	rs13031619	0.660	rs35668314	chr2:3702673	C/T	cg25251562	chr2:3704773	ALLC	-0.59	-5.75	-0.33	2.5e-8	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CESC	cis	rs155076	0.711	rs4770129	chr13:21882059	T/G	cg06138931	chr13:21896616	NA	0.51	5.27	0.31	2.8e-7	White matter hyperintensity burden;
CESC	cis	rs796364	0.806	rs203765	chr2:200903020	G/A	cg23649088	chr2:200775458	C2orf69	-0.57	-5.24	-0.31	3.23e-7	Schizophrenia;
CESC	cis	rs11123694	1.000	rs11123694	chr2:109064563	C/T	cg23706161	chr2:109336669	RANBP2	-0.39	-5.54	-0.32	7.24e-8	Mean platelet volume;
CESC	cis	rs9910055	0.529	rs2523161	chr17:42179405	C/T	cg19774624	chr17:42201019	HDAC5	0.62	8.84	0.48	1.33e-16	Total body bone mineral density;
CESC	cis	rs9888739	0.800	rs11859300	chr16:31355895	G/T	cg15817542	chr16:31343056	ITGAM	-0.53	-7.61	-0.42	4.83e-13	Systemic lupus erythematosus;
CESC	cis	rs7560272	0.723	rs7562047	chr2:73725168	G/T	cg20560298	chr2:73613845	ALMS1	-0.48	-6.83	-0.39	5.8e-11	Schizophrenia;
CESC	cis	rs60871478	1.000	rs62432899	chr7:826542	G/C	cg13798912	chr7:905769	UNC84A	0.56	5.7	0.33	3.11e-8	Cerebrospinal P-tau181p levels;
CESC	cis	rs9291683	0.530	rs6449196	chr4:9973660	C/T	cg11266682	chr4:10021025	SLC2A9	-0.61	-12.55	-0.61	1.13e-28	Bone mineral density;
CESC	cis	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg22963979	chr7:1858916	MAD1L1	-0.43	-5.95	-0.34	8.59e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs17826219	0.706	rs9893922	chr17:29068425	T/C	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.1e-10	Body mass index;
CESC	cis	rs6430585	0.697	rs115944351	chr2:136515458	G/A	cg07169764	chr2:136633963	MCM6	1.27	16.82	0.72	1.04e-43	Corneal structure;
CESC	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	22.34	0.81	6.93e-63	Prudent dietary pattern;
CESC	cis	rs477692	0.905	rs485579	chr10:131425492	T/G	cg26102564	chr10:131424627	MGMT	0.36	5.39	0.31	1.52e-7	Response to temozolomide;
CESC	cis	rs8014204	0.967	rs2359240	chr14:75328247	T/C	cg11812906	chr14:75593930	NEK9	-0.41	-5.08	-0.3	7.16e-7	Caffeine consumption;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02480931	chr1:228270396	ARF1	0.62	6.63	0.38	1.86e-10	Gut microbiome composition (summer);
CESC	cis	rs524023	0.874	rs519090	chr11:64456240	G/C	cg07220939	chr11:64358617	SLC22A12	-0.35	-5.42	-0.32	1.36e-7	Urate levels in obese individuals;
CESC	cis	rs3785574	0.925	rs2727340	chr17:61970224	T/A	cg11494091	chr17:61959527	GH2	0.37	5.12	0.3	5.97e-7	Height;
CESC	cis	rs3812762	0.868	rs7952335	chr11:8754031	A/G	cg03980550	chr11:8754370	ST5	0.36	5.19	0.3	4.17e-7	Hypospadias;
CESC	cis	rs854765	0.693	rs8079321	chr17:17760789	C/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.44	5.87	0.34	1.28e-8	Total body bone mineral density;
CESC	cis	rs6963495	0.818	rs56177071	chr7:105165648	C/T	cg13798780	chr7:105162888	PUS7	0.78	8.06	0.44	2.68e-14	Bipolar disorder (body mass index interaction);
CESC	cis	rs5769765	1.000	rs5769765	chr22:50271176	G/A	cg26441486	chr22:50317300	CRELD2	-0.39	-5.5	-0.32	8.72e-8	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21173440	chr5:55008212	SLC38A9	0.61	7.38	0.41	2.08e-12	Gut microbiome composition (summer);
CESC	trans	rs11098499	0.754	rs1980026	chr4:120251643	C/A	cg25214090	chr10:38739885	LOC399744	0.62	8.7	0.47	3.58e-16	Corneal astigmatism;
CESC	cis	rs1355223	0.902	rs34610590	chr11:34725440	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.48	-6.24	-0.36	1.68e-9	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs4434138	0.568	rs6414569	chr3:52708075	A/T	cg18404041	chr3:52824283	ITIH1	-0.38	-6.53	-0.37	3.44e-10	Intelligence (multi-trait analysis);
CESC	cis	rs597539	0.690	rs578791	chr11:68625809	C/T	cg06028808	chr11:68637592	NA	0.49	5.74	0.33	2.6e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg23838308	chr17:57785056	PTRH2;TMEM49	0.49	6.38	0.36	7.79e-10	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs2629540	0.508	rs12217633	chr10:126533872	A/G	cg08799069	chr10:126477246	METTL10	-0.52	-6.34	-0.36	9.63e-10	Cocaine dependence;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg22141780	chr2:132233726	TUBA3D	0.45	6.0	0.35	6.33e-9	Fibrinogen levels;
CESC	cis	rs6120849	0.754	rs13433216	chr20:33616301	T/C	cg24642439	chr20:33292090	TP53INP2	0.68	6.77	0.38	8.46e-11	Protein C levels;
CESC	cis	rs1348850	0.519	rs1544002	chr2:178529534	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.58	7.06	0.4	1.5e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg23708337	chr7:1209742	NA	0.55	5.41	0.32	1.44e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs3820928	0.839	rs13398103	chr2:227859693	T/G	cg11843606	chr2:227700838	RHBDD1	-0.5	-6.03	-0.35	5.52e-9	Pulmonary function;
CESC	cis	rs7918232	0.891	rs10443987	chr10:27375377	A/T	cg14442939	chr10:27389572	ANKRD26	0.7	6.5	0.37	4.04e-10	Breast cancer;
CESC	trans	rs208515	0.525	rs9453538	chr6:66668508	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.87	10.74	0.55	1.42e-22	Exhaled nitric oxide levels;
CESC	cis	rs7666738	0.830	rs9998682	chr4:98939009	T/C	cg05340658	chr4:99064831	C4orf37	0.82	12.54	0.61	1.29e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6088580	0.505	rs6058106	chr20:33278255	T/C	cg08999081	chr20:33150536	PIGU	-0.45	-6.52	-0.37	3.51e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs7618915	0.547	rs12487591	chr3:52642936	A/T	cg05564831	chr3:52568323	NT5DC2	0.43	6.24	0.36	1.71e-9	Bipolar disorder;
CESC	cis	rs7666738	0.830	rs1593570	chr4:99017058	T/C	cg18180107	chr4:99064573	C4orf37	0.41	5.4	0.31	1.48e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6938	0.534	rs11072512	chr15:75204026	C/T	cg13906792	chr15:75199810	C15orf17	-0.34	-5.18	-0.3	4.47e-7	Breast cancer;
CESC	cis	rs9457247	0.967	rs1211447	chr6:167381979	C/T	cg25258033	chr6:167368657	RNASET2	0.39	5.87	0.34	1.27e-8	Crohn's disease;
CESC	cis	rs3749237	0.595	rs12489092	chr3:49550914	G/C	cg07636037	chr3:49044803	WDR6	0.63	9.27	0.49	6.73e-18	Resting heart rate;
CESC	cis	rs8180040	0.654	rs62246451	chr3:47211632	C/T	cg27129171	chr3:47204927	SETD2	-0.67	-9.83	-0.52	1.2e-19	Colorectal cancer;
CESC	cis	rs9914988	0.725	rs66531973	chr17:27125993	G/T	cg20469991	chr17:27169893	C17orf63	-0.48	-5.25	-0.31	3.18e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CESC	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.55	-7.31	-0.41	3.16e-12	Longevity;Endometriosis;
CESC	cis	rs875971	0.825	rs7384021	chr7:66077904	A/G	cg19163074	chr7:65112434	INTS4L2	0.42	5.28	0.31	2.63e-7	Aortic root size;
CESC	trans	rs10506458	1.000	rs73128779	chr12:63441852	T/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.32	-17.48	-0.73	4.95e-46	Hemostatic factors and hematological phenotypes;
CESC	cis	rs10504073	0.647	rs62507246	chr8:50013449	G/A	cg00325661	chr8:49890786	NA	0.57	8.6	0.47	7.15e-16	Blood metabolite ratios;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg04691540	chr1:179198414	ABL2	-0.47	-6.99	-0.39	2.23e-11	Gambling;
CESC	cis	rs13191362	0.507	rs2155506	chr6:163035342	G/A	cg06582575	chr6:163149167	PACRG;PARK2	-0.5	-6.24	-0.36	1.74e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs1005277	0.579	rs9418322	chr10:38377296	G/T	cg25427524	chr10:38739819	LOC399744	-0.66	-9.52	-0.5	1.15e-18	Extrinsic epigenetic age acceleration;
CESC	cis	rs763121	0.853	rs2413545	chr22:39092524	C/T	cg14440974	chr22:39074834	NA	-0.43	-5.63	-0.33	4.49e-8	Menopause (age at onset);
CESC	cis	rs7904368	0.901	rs7923189	chr10:16850214	C/T	cg23933602	chr10:16859644	RSU1	0.74	8.23	0.45	8.48e-15	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
CESC	cis	rs854765	0.583	rs7214536	chr17:17852446	G/A	cg04398451	chr17:18023971	MYO15A	-0.69	-9.72	-0.51	2.77e-19	Total body bone mineral density;
CESC	cis	rs2842992	0.872	rs1570318	chr6:160111473	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.64	8.08	0.44	2.36e-14	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs12325245	0.536	rs34161389	chr16:58622604	G/A	cg01152986	chr16:58549298	SETD6	0.86	5.07	0.3	7.48e-7	Schizophrenia;
CESC	cis	rs6942756	0.680	rs691555	chr7:129135770	C/T	cg02491457	chr7:128862824	NA	-0.54	-7.68	-0.43	3e-13	White matter hyperintensity burden;
CESC	cis	rs9325144	0.555	rs2387855	chr12:38687964	T/G	cg26384229	chr12:38710491	ALG10B	0.58	8.59	0.47	7.74e-16	Morning vs. evening chronotype;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg24598330	chr12:95467350	NR2C1	0.48	6.06	0.35	4.71e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs9611565	0.840	rs4822025	chr22:41776646	C/G	cg03806693	chr22:41940476	POLR3H	-1.11	-13.72	-0.64	1.03e-32	Vitiligo;
CESC	cis	rs736408	0.509	rs3774349	chr3:52722335	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.48	7.58	0.42	5.94e-13	Bipolar disorder;
CESC	cis	rs909674	0.775	rs4821896	chr22:39833437	T/C	cg24399712	chr22:39784796	NA	-0.8	-10.86	-0.55	5.8e-23	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs28386778	0.704	rs1051688	chr17:62006433	G/C	cg07677032	chr17:61819896	STRADA	-0.47	-6.25	-0.36	1.67e-9	Prudent dietary pattern;
CESC	cis	rs10504229	0.906	rs2270608	chr8:58194688	T/C	cg05313129	chr8:58192883	C8orf71	-0.53	-6.07	-0.35	4.46e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs10504229	1.000	rs59797486	chr8:58174435	T/C	cg14926445	chr8:58193284	C8orf71	-0.49	-5.54	-0.32	7.13e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs853679	0.517	rs1904840	chr6:28108232	C/T	cg19592336	chr6:28129416	ZNF389	0.61	8.17	0.45	1.28e-14	Depression;
CESC	cis	rs5769765	0.908	rs9627788	chr22:50300438	T/C	cg02269571	chr22:50332266	NA	-0.49	-6.59	-0.38	2.43e-10	Schizophrenia;
CESC	cis	rs2836974	0.568	rs371625	chr21:40535271	A/G	cg11890956	chr21:40555474	PSMG1	-0.97	-16.62	-0.71	5.65e-43	Cognitive function;
CESC	cis	rs9527	0.830	rs10883790	chr10:104640955	A/C	cg04362960	chr10:104952993	NT5C2	0.45	5.28	0.31	2.69e-7	Arsenic metabolism;
CESC	cis	rs1707322	1.000	rs10890376	chr1:46406582	C/T	cg06784218	chr1:46089804	CCDC17	0.36	6.01	0.35	5.95e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7615952	0.515	rs4441610	chr3:125681307	C/G	cg05084668	chr3:125655381	ALG1L	-0.48	-5.62	-0.33	4.93e-8	Blood pressure (smoking interaction);
CESC	cis	rs4835473	0.900	rs13105550	chr4:144655373	C/T	cg25736465	chr4:144833511	NA	-0.32	-5.04	-0.3	8.48e-7	Immature fraction of reticulocytes;
CESC	cis	rs2832191	0.755	rs2832192	chr21:30491173	G/T	cg24692254	chr21:30365293	RNF160	-0.7	-9.97	-0.52	4.44e-20	Dental caries;
CESC	cis	rs7520050	0.807	rs4274104	chr1:46217941	T/C	cg06784218	chr1:46089804	CCDC17	0.32	5.84	0.34	1.55e-8	Red blood cell count;Reticulocyte count;
CESC	cis	rs2243480	0.901	rs35256305	chr7:65306405	T/C	cg12463550	chr7:65579703	CRCP	0.68	5.73	0.33	2.72e-8	Diabetic kidney disease;
CESC	cis	rs9303401	0.614	rs3803753	chr17:56540110	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.98	11.87	0.59	2.46e-26	Cognitive test performance;
CESC	cis	rs7666738	0.830	rs7659420	chr4:98878714	G/C	cg03467027	chr4:99064603	C4orf37	0.43	5.3	0.31	2.49e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9311474	0.508	rs11720243	chr3:52618018	T/C	cg05564831	chr3:52568323	NT5DC2	0.48	7.68	0.43	3.01e-13	Electroencephalogram traits;
CESC	cis	rs6831352	1.000	rs6822348	chr4:100053894	A/T	cg12011299	chr4:100065546	ADH4	0.7	8.56	0.47	9.45e-16	Alcohol dependence;
CESC	cis	rs113835537	0.935	rs79106199	chr11:66420518	T/C	cg24851651	chr11:66362959	CCS	0.63	5.68	0.33	3.48e-8	Airway imaging phenotypes;
CESC	cis	rs477692	0.569	rs1711670	chr10:131281115	A/G	cg05714579	chr10:131428358	MGMT	0.39	5.13	0.3	5.63e-7	Response to temozolomide;
CESC	cis	rs2228479	0.850	rs17226428	chr16:89842884	T/A	cg06558623	chr16:89946397	TCF25	1.17	9.33	0.5	4.35e-18	Skin colour saturation;
CESC	cis	rs10883723	0.810	rs913025	chr10:104276043	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.54	7.41	0.41	1.65e-12	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs78456975	0.657	rs116217838	chr2:1569173	T/C	cg26248373	chr2:1572462	NA	-0.6	-6.99	-0.39	2.18e-11	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs9457247	0.588	rs35171809	chr6:167432766	A/G	cg25258033	chr6:167368657	RNASET2	0.35	5.13	0.3	5.7e-7	Crohn's disease;
CESC	cis	rs898097	0.812	rs8065641	chr17:80820259	A/G	cg05255149	chr17:80675120	FN3KRP	-0.46	-5.3	-0.31	2.43e-7	Breast cancer;
CESC	cis	rs7590368	0.673	rs17365216	chr2:10939241	A/G	cg15705551	chr2:10952987	PDIA6	0.54	5.23	0.31	3.48e-7	Educational attainment (years of education);
CESC	cis	rs453301	0.658	rs6986044	chr8:8874786	G/C	cg15556689	chr8:8085844	FLJ10661	-0.47	-5.71	-0.33	3.03e-8	Joint mobility (Beighton score);
CESC	trans	rs9929218	1.000	rs13334294	chr16:68809278	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.61	-8.03	-0.44	3.1e-14	Colorectal cancer;
CESC	cis	rs9910055	0.762	rs6503489	chr17:42246289	G/A	cg09913183	chr17:42254507	C17orf65;ASB16	0.65	8.59	0.47	7.54e-16	Total body bone mineral density;
CESC	cis	rs2455799	0.613	rs13080145	chr3:15880060	C/G	cg16303742	chr3:15540471	COLQ	-0.37	-5.74	-0.33	2.59e-8	Mean platelet volume;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg06419771	chr15:42264912	EHD4	0.49	6.29	0.36	1.32e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs57506017	0.585	rs1468801	chr7:12276045	G/C	cg23422036	chr7:12250390	TMEM106B	0.39	5.24	0.31	3.35e-7	Neuroticism;
CESC	cis	rs34375054	0.558	rs67041765	chr12:125672913	T/G	cg00522288	chr12:125625016	AACS	-0.36	-5.65	-0.33	4.05e-8	Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs2880765	0.835	rs4344688	chr15:86043007	A/C	cg19183879	chr15:85880815	NA	-0.26	-5.38	-0.31	1.67e-7	Coronary artery disease;
CESC	cis	rs6088580	0.634	rs1205345	chr20:32914699	A/G	cg06115741	chr20:33292138	TP53INP2	-0.43	-5.51	-0.32	8.33e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs7914558	1.000	rs4917994	chr10:104811699	C/T	cg04362960	chr10:104952993	NT5C2	0.47	6.32	0.36	1.11e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs10905065	0.895	rs1567706	chr10:5853767	T/C	cg11519256	chr10:5708881	ASB13	-0.4	-5.21	-0.3	3.87e-7	Menopause (age at onset);
CESC	cis	rs2228479	0.618	rs72477006	chr16:89950299	G/C	cg14709524	chr16:89940631	TCF25	0.73	5.55	0.32	6.81e-8	Skin colour saturation;
CESC	cis	rs7615952	0.512	rs1077621	chr3:125819799	A/G	cg15145296	chr3:125709740	NA	-0.56	-5.91	-0.34	1.06e-8	Blood pressure (smoking interaction);
CESC	cis	rs2290720	0.930	rs11110742	chr12:101692559	G/A	cg22051763	chr12:101673672	UTP20	-0.48	-6.0	-0.35	6.43e-9	Brain structure (hippocampal volume);
CESC	cis	rs2250402	0.510	rs2291621	chr15:40324837	C/T	cg01081584	chr15:40268610	EIF2AK4	-0.54	-5.05	-0.3	8.23e-7	Corneal curvature;
CESC	cis	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg04267008	chr7:1944627	MAD1L1	0.53	6.51	0.37	3.79e-10	Bipolar disorder and schizophrenia;
CESC	cis	rs763121	0.752	rs5757222	chr22:39060473	C/T	cg14440974	chr22:39074834	NA	-0.4	-5.5	-0.32	9.03e-8	Menopause (age at onset);
CESC	cis	rs9815354	0.680	rs73073292	chr3:42028023	C/A	cg03022575	chr3:42003672	ULK4	0.75	6.64	0.38	1.72e-10	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs7527798	0.592	rs10863437	chr1:207817612	T/C	cg21110645	chr1:207815933	NA	-0.31	-5.38	-0.31	1.64e-7	Erythrocyte sedimentation rate;
CESC	cis	rs2070677	0.501	rs2274665	chr10:135295630	T/C	cg20169779	chr10:135381914	SYCE1	0.41	5.39	0.31	1.54e-7	Gout;
CESC	cis	rs227584	0.663	rs2040810	chr17:42243771	C/T	cg08499158	chr17:42289980	UBTF	0.43	5.47	0.32	1.05e-7	Bone mineral density (hip);Bone mineral density;
CESC	cis	rs9549260	0.755	rs9532579	chr13:41243458	T/C	cg21288729	chr13:41239152	FOXO1	0.67	8.59	0.47	7.42e-16	Red blood cell count;
CESC	cis	rs7592578	0.723	rs4371384	chr2:191430741	A/G	cg10560079	chr2:191398806	TMEM194B	0.67	5.98	0.34	7.17e-9	Diastolic blood pressure;
CESC	cis	rs7772486	0.597	rs1970306	chr6:146154543	A/G	cg05347473	chr6:146136440	FBXO30	0.75	9.51	0.5	1.19e-18	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs13064411	0.696	rs9869318	chr3:113146271	T/C	cg18753928	chr3:113234510	CCDC52	-0.49	-5.34	-0.31	2.04e-7	Response to simvastatin treatment (PCSK9 protein level change);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09800975	chr10:6130861	RBM17	-0.6	-6.69	-0.38	1.32e-10	Gut microbiome composition (summer);
CESC	cis	rs12464559	0.522	rs7424335	chr2:152593741	C/T	cg01189475	chr2:152685088	ARL5A	0.65	6.32	0.36	1.09e-9	Response to cognitive-behavioural therapy in anxiety disorder;
CESC	cis	rs875971	1.000	rs778694	chr7:65871558	A/G	cg11764359	chr7:65958608	NA	0.96	15.23	0.68	4.78e-38	Aortic root size;
CESC	cis	rs17601876	0.814	rs8038715	chr15:51561120	T/A	cg19946085	chr15:51559439	CYP19A1	-0.32	-5.06	-0.3	7.7e-7	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
CESC	cis	rs12188164	0.965	rs11743639	chr5:450710	C/T	cg21144161	chr5:423903	AHRR	0.37	5.98	0.34	7.12e-9	Cystic fibrosis severity;
CESC	cis	rs4423214	0.840	rs1792231	chr11:71182681	G/A	cg05163923	chr11:71159392	DHCR7	-0.68	-7.76	-0.43	1.82e-13	Vitamin D levels;
CESC	cis	rs875971	1.000	rs11974264	chr7:65647582	C/G	cg12463550	chr7:65579703	CRCP	-0.55	-7.0	-0.39	2.15e-11	Aortic root size;
CESC	cis	rs2440129	0.611	rs1126667	chr17:6902760	C/T	cg05215748	chr17:6898738	ALOX12	-0.29	-5.95	-0.34	8.35e-9	Tonsillectomy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18950102	chr11:33397689	NA	0.57	6.78	0.38	7.95e-11	Gut microbiome composition (summer);
CESC	cis	rs7640424	0.819	rs34154497	chr3:107824222	T/C	cg09227934	chr3:107805635	CD47	-0.5	-6.23	-0.36	1.82e-9	Body mass index;
CESC	cis	rs2839186	0.721	rs3788252	chr21:47661235	C/T	cg05896524	chr21:47604654	C21orf56	0.41	5.32	0.31	2.17e-7	Testicular germ cell tumor;
CESC	trans	rs11989744	0.597	rs11135768	chr8:23573278	A/G	cg03492747	chr16:86543808	FOXF1	0.83	12.66	0.61	4.64e-29	Waist-hip ratio;
CESC	cis	rs10256972	0.967	rs7799110	chr7:1039065	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.42	-5.22	-0.31	3.7e-7	Longevity;Endometriosis;
CESC	cis	rs2075371	0.829	rs11770521	chr7:133936251	A/C	cg11752832	chr7:134001865	SLC35B4	0.53	6.85	0.39	5.07e-11	Mean platelet volume;
CESC	cis	rs7618501	1.000	rs4855867	chr3:49745822	C/T	cg24308560	chr3:49941425	MST1R	0.5	6.94	0.39	3.08e-11	Intelligence (multi-trait analysis);
CESC	trans	rs11088226	0.681	rs2833926	chr21:33975279	A/G	cg09050820	chr6:167586206	TCP10L2	0.76	8.03	0.44	3.2e-14	Gastritis;
CESC	cis	rs7107174	1.000	rs10899452	chr11:77995143	A/C	cg02023728	chr11:77925099	USP35	0.42	5.54	0.32	7.12e-8	Testicular germ cell tumor;
CESC	cis	rs10256972	0.900	rs4388364	chr7:1033045	T/G	cg04025307	chr7:1156635	C7orf50	0.39	6.19	0.36	2.32e-9	Longevity;Endometriosis;
CESC	cis	rs11792861	0.816	rs7021366	chr9:111727670	C/G	cg05043794	chr9:111880884	C9orf5	-0.4	-6.59	-0.38	2.33e-10	Menarche (age at onset);
CESC	cis	rs9399137	0.507	rs4451150	chr6:135279063	T/G	cg22676075	chr6:135203613	NA	0.56	7.24	0.41	4.99e-12	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	cis	rs4944092	0.960	rs10400322	chr11:75910913	C/T	cg04588336	chr11:75916460	WNT11	0.5	7.83	0.43	1.16e-13	PR interval;
CESC	cis	rs2797160	1.000	rs1739371	chr6:126011291	G/A	cg05901451	chr6:126070800	HEY2	0.46	6.69	0.38	1.33e-10	Endometrial cancer;
CESC	cis	rs854765	0.693	rs12941039	chr17:17765655	C/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.47	-6.17	-0.35	2.59e-9	Total body bone mineral density;
CESC	cis	rs909674	0.541	rs5757655	chr22:39797178	C/G	cg01416388	chr22:39784598	NA	0.57	7.18	0.4	7.01e-12	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs35306767	0.715	rs12777801	chr10:1036285	T/A	cg26597838	chr10:835615	NA	0.65	5.82	0.34	1.71e-8	Eosinophil percentage of granulocytes;
CESC	cis	rs8070740	0.898	rs4442872	chr17:5324236	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.51	6.28	0.36	1.35e-9	Menopause (age at onset);
CESC	cis	rs7605827	0.930	rs1990755	chr2:15616013	C/G	cg19274914	chr2:15703543	NA	0.35	6.13	0.35	3.19e-9	Educational attainment (years of education);
CESC	cis	rs2439831	0.850	rs3759790	chr15:44121030	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.67	7.46	0.42	1.21e-12	Lung cancer in ever smokers;
CESC	cis	rs7089973	0.668	rs61868024	chr10:116637939	A/G	cg23260525	chr10:116636907	FAM160B1	0.37	6.55	0.37	2.92e-10	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs2836950	0.565	rs8130320	chr21:40580258	C/T	cg11890956	chr21:40555474	PSMG1	-0.63	-8.74	-0.47	2.78e-16	Menarche (age at onset);
CESC	trans	rs1493916	1.000	rs9964702	chr18:31390427	A/C	cg27147174	chr7:100797783	AP1S1	-0.52	-7.04	-0.4	1.62e-11	Life satisfaction;
CESC	cis	rs6987853	0.933	rs2923424	chr8:42382222	A/G	cg09913449	chr8:42400586	C8orf40	-0.4	-6.36	-0.36	9.04e-10	Mean corpuscular hemoglobin concentration;
CESC	cis	rs763014	0.966	rs7198877	chr16:661439	A/G	cg07256732	chr16:621771	PIGQ	-0.32	-5.55	-0.32	6.94e-8	Height;
CESC	cis	rs10504229	0.683	rs7000349	chr8:58114569	C/A	cg24829409	chr8:58192753	C8orf71	-0.59	-7.32	-0.41	2.94e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.58	-6.41	-0.37	6.65e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06692641	chr19:40030326	EID2	0.54	6.09	0.35	3.88e-9	Gut microbiome composition (summer);
CESC	cis	rs936229	0.668	rs67411922	chr15:75187612	A/G	cg14664628	chr15:75095509	CSK	-0.72	-9.02	-0.48	3.93e-17	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CESC	cis	rs7208859	0.623	rs73269988	chr17:29118145	G/A	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.1e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	trans	rs7726839	0.507	rs56282020	chr5:596701	T/C	cg25482853	chr8:67687455	SGK3	1.04	10.08	0.53	1.87e-20	Obesity-related traits;
CESC	cis	rs116095464	0.558	rs6555056	chr5:226222	T/C	cg22496380	chr5:211416	CCDC127	-0.74	-8.78	-0.47	2.06e-16	Breast cancer;
CESC	cis	rs1800469	1.000	rs1549933	chr19:41871142	A/G	cg08477640	chr19:41863820	B9D2	0.67	9.24	0.49	8.62e-18	Colorectal cancer;
CESC	cis	rs4835473	0.771	rs2175452	chr4:144914040	C/G	cg25736465	chr4:144833511	NA	0.43	6.44	0.37	5.61e-10	Immature fraction of reticulocytes;
CESC	cis	rs4604732	0.603	rs10802513	chr1:247633919	C/T	cg12758973	chr1:247694275	LOC148824;OR2C3	0.38	5.58	0.32	6e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs12500824	0.506	rs11935098	chr4:77301687	T/C	cg20311846	chr4:77356250	SHROOM3	0.37	7.24	0.41	4.96e-12	Coronary artery disease;
CESC	cis	rs4481887	0.893	rs6587450	chr1:248480496	T/A	cg00666640	chr1:248458726	OR2T12	0.36	5.98	0.34	7.16e-9	Common traits (Other);
CESC	cis	rs1348850	0.914	rs10194648	chr2:178337031	G/A	cg22681709	chr2:178499509	PDE11A	-0.44	-6.48	-0.37	4.55e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs7512552	0.839	rs696616	chr1:150336173	G/A	cg15654264	chr1:150340011	RPRD2	0.39	5.12	0.3	5.94e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs910316	1.000	rs175425	chr14:75626131	T/C	cg11812906	chr14:75593930	NEK9	-0.87	-14.35	-0.66	5.82e-35	Height;
CESC	cis	rs10751667	0.666	rs10794347	chr11:939863	G/A	cg06064525	chr11:970664	AP2A2	-0.5	-10.04	-0.52	2.7e-20	Alzheimer's disease (late onset);
CESC	cis	rs17023223	0.537	rs12064137	chr1:119709749	G/A	cg05756136	chr1:119680316	WARS2	-0.47	-5.69	-0.33	3.34e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg26108683	chr11:67250618	AIP	-0.52	-6.33	-0.36	1.07e-9	Ulcerative colitis;
CESC	cis	rs9815354	0.638	rs111465678	chr3:41864405	C/A	cg03022575	chr3:42003672	ULK4	0.49	5.52	0.32	7.99e-8	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs8078723	1.000	rs56922390	chr17:38157021	C/G	cg17467752	chr17:38218738	THRA	0.69	10.55	0.54	5.78e-22	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CESC	cis	rs2227631	0.505	rs6955537	chr7:100759727	A/G	cg18465962	chr7:100767262	NA	-0.57	-9.5	-0.5	1.31e-18	Plasminogen activator inhibitor type 1 levels (PAI-1);
CESC	cis	rs4253772	0.530	rs11090875	chr22:46785301	C/T	cg18190219	chr22:46762943	CELSR1	-0.72	-6.66	-0.38	1.62e-10	LDL cholesterol;Cholesterol, total;
CESC	cis	rs910316	0.687	rs175059	chr14:75490667	T/C	cg11812906	chr14:75593930	NEK9	-0.82	-13.6	-0.64	2.7e-32	Height;
CESC	cis	rs13256369	0.755	rs12680167	chr8:8562467	A/G	cg18904891	chr8:8559673	CLDN23	0.73	8.41	0.46	2.59e-15	Obesity-related traits;
CESC	trans	rs8073060	0.586	rs7214250	chr17:33981704	C/G	cg19694781	chr19:47549865	TMEM160	-0.73	-7.32	-0.41	3.05e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	cis	rs9584850	0.834	rs2031239	chr13:99111560	C/T	cg20750642	chr13:99100586	FARP1	-0.38	-5.74	-0.33	2.6e-8	Neuroticism;
CESC	cis	rs78456975	0.607	rs72776258	chr2:1530732	C/G	cg01028140	chr2:1542097	TPO	-0.59	-5.65	-0.33	4.21e-8	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs11997175	0.846	rs34860600	chr8:33761566	C/A	ch.8.33884649F	chr8:33765107	NA	0.78	10.38	0.54	2.15e-21	Body mass index;
CESC	cis	rs4819052	0.851	rs7279011	chr21:46655995	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.91	12.78	0.62	1.78e-29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs7618501	1.000	rs2234391	chr3:49842625	A/G	cg21659725	chr3:3221576	CRBN	0.82	13.21	0.63	5.99e-31	Intelligence (multi-trait analysis);
CESC	cis	rs9457247	0.967	rs2015864	chr6:167381476	T/C	cg23791538	chr6:167370224	RNASET2	0.6	8.64	0.47	5.52e-16	Crohn's disease;
CESC	cis	rs2072732	0.861	rs12039132	chr1:2949355	C/T	cg03976712	chr1:2946727	NA	0.34	5.63	0.33	4.53e-8	Plateletcrit;
CESC	cis	rs3540	0.512	rs3862433	chr15:91076028	G/A	cg10434728	chr15:90938212	IQGAP1	-0.39	-7.05	-0.4	1.59e-11	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs796364	0.715	rs1106399	chr2:201003837	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.67	-6.43	-0.37	5.87e-10	Schizophrenia;
CESC	cis	rs362272	0.545	rs3129308	chr4:3309272	C/T	cg08886695	chr4:3369023	RGS12	-0.47	-6.34	-0.36	1e-9	Serum sulfate level;
CESC	cis	rs4474465	0.850	rs10899552	chr11:78262262	G/A	cg27205649	chr11:78285834	NARS2	0.4	5.09	0.3	6.82e-7	Alzheimer's disease (survival time);
CESC	cis	rs10751667	1.000	rs10794357	chr11:973374	T/C	cg20946044	chr11:1010712	AP2A2	-0.41	-5.4	-0.31	1.48e-7	Alzheimer's disease (late onset);
CESC	cis	rs2880765	0.835	rs7161880	chr15:86018746	C/T	cg19183879	chr15:85880815	NA	-0.25	-5.22	-0.31	3.69e-7	Coronary artery disease;
CESC	cis	rs1355223	0.545	rs7111695	chr11:34874906	T/G	cg11058730	chr11:34937778	PDHX;APIP	-0.55	-6.59	-0.38	2.37e-10	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg04025307	chr7:1156635	C7orf50	0.48	7.76	0.43	1.79e-13	Longevity;Endometriosis;
CESC	cis	rs11252926	0.801	rs12358553	chr10:558014	C/T	cg08603382	chr10:743973	NA	-0.55	-6.96	-0.39	2.71e-11	Psychosis in Alzheimer's disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg12565215	chr6:21602408	NA	0.54	7.09	0.4	1.19e-11	Fibrinogen levels;
CESC	cis	rs2797160	1.000	rs1832938	chr6:125988964	G/C	cg05901451	chr6:126070800	HEY2	-0.45	-6.62	-0.38	1.96e-10	Endometrial cancer;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg27050550	chr7:44613552	DDX56	-0.45	-6.04	-0.35	5.08e-9	Fibrinogen levels;
CESC	cis	rs9796	0.689	rs28497404	chr15:41449510	A/C	cg12426344	chr15:41135900	SPINT1	-0.24	-5.15	-0.3	4.97e-7	Menopause (age at onset);
CESC	cis	rs12822507	0.868	rs34051318	chr12:12798338	T/C	cg09462578	chr12:12878428	APOLD1	-0.44	-5.52	-0.32	8.08e-8	Systemic lupus erythematosus;
CESC	cis	rs6963495	0.818	rs73192115	chr7:105169605	T/A	cg13798780	chr7:105162888	PUS7	0.77	7.88	0.44	8.3e-14	Bipolar disorder (body mass index interaction);
CESC	cis	rs75477785	0.590	rs4844935	chr1:210176554	T/A	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.92	6.23	0.36	1.82e-9	Cleft lip with or without cleft palate;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg07364676	chr22:29137974	CHEK2;HSCB	-0.42	-6.1	-0.35	3.82e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs9790314	1.000	rs1382426	chr3:161045933	G/A	cg03342759	chr3:160939853	NMD3	-0.47	-6.11	-0.35	3.61e-9	Morning vs. evening chronotype;
CESC	cis	rs4237845	0.513	rs7134797	chr12:58263852	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.51	5.61	0.33	4.96e-8	Intelligence (multi-trait analysis);
CESC	cis	rs644799	0.710	rs12272061	chr11:95524067	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.77	11.31	0.57	1.88e-24	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg21214715	chr1:184838445	FAM129A	-0.42	-6.16	-0.35	2.62e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs6688613	0.694	rs2075946	chr1:166818566	A/G	cg07049167	chr1:166818506	POGK	0.54	6.68	0.38	1.37e-10	Refractive astigmatism;
CESC	cis	rs8017423	0.967	rs11159956	chr14:90715890	C/T	cg14092571	chr14:90743983	NA	0.59	8.87	0.48	1.14e-16	Mortality in heart failure;
CESC	cis	rs14403	0.521	rs3006916	chr1:243639859	A/G	cg21452805	chr1:244014465	NA	0.51	5.28	0.31	2.72e-7	Schizophrenia;
CESC	cis	rs881375	0.678	rs1930782	chr9:123687905	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.45	6.47	0.37	4.63e-10	Rheumatoid arthritis;
CESC	cis	rs10504229	0.953	rs6991035	chr8:58183374	C/T	cg22535103	chr8:58192502	C8orf71	-1.05	-13.08	-0.63	1.71e-30	Developmental language disorder (linguistic errors);
CESC	cis	rs17253792	0.749	rs79713967	chr14:56124186	T/C	cg01858014	chr14:56050164	KTN1	-0.96	-7.52	-0.42	8.3e-13	Putamen volume;
CESC	cis	rs7666738	0.830	rs17550610	chr4:99008273	T/C	cg18180107	chr4:99064573	C4orf37	0.4	5.23	0.31	3.41e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4474465	0.790	rs12363982	chr11:78229167	C/T	cg27205649	chr11:78285834	NARS2	0.45	5.48	0.32	1e-7	Alzheimer's disease (survival time);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg12357364	chr17:1557144	PRPF8	0.45	6.29	0.36	1.32e-9	Fibrinogen levels;
CESC	cis	rs2032447	0.839	rs199751	chr6:26015583	T/C	cg03264133	chr6:25882463	NA	-0.52	-7.28	-0.41	3.8e-12	Intelligence (multi-trait analysis);
CESC	cis	rs4950322	0.515	rs11239958	chr1:146719108	G/A	cg16700924	chr1:146552102	NA	-0.39	-5.1	-0.3	6.63e-7	Protein quantitative trait loci;
CESC	cis	rs11677416	1.000	rs4848304	chr2:113552737	T/C	cg27083787	chr2:113543245	IL1A	0.62	7.7	0.43	2.66e-13	Response to antipsychotic treatment in schizophrenia (working memory);
CESC	cis	rs7666738	0.830	rs10017557	chr4:98983969	G/A	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.67e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4746818	0.892	rs10823298	chr10:70867083	T/C	cg11621586	chr10:70884670	VPS26A	0.93	9.85	0.52	1.03e-19	Left atrial antero-posterior diameter;
CESC	cis	rs7267979	0.873	rs6037062	chr20:25202892	G/A	cg08601574	chr20:25228251	PYGB	0.38	5.47	0.32	1.03e-7	Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg05064044	chr6:292385	DUSP22	-0.7	-9.11	-0.49	2.11e-17	Menopause (age at onset);
CESC	cis	rs10089	0.951	rs736969	chr5:127466347	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.76	10.22	0.53	6.73e-21	Ileal carcinoids;
CESC	cis	rs4704187	0.601	rs77819698	chr5:74530658	G/T	cg03227963	chr5:74354835	NA	0.28	5.17	0.3	4.61e-7	Response to amphetamines;
CESC	cis	rs2249694	1.000	rs2480258	chr10:135352100	T/C	cg20169779	chr10:135381914	SYCE1	0.4	5.27	0.31	2.83e-7	Obesity-related traits;
CESC	trans	rs61931739	0.500	rs12832312	chr12:34031199	G/A	cg26384229	chr12:38710491	ALG10B	0.59	8.24	0.45	8.06e-15	Morning vs. evening chronotype;
CESC	cis	rs916888	0.821	rs70602	chr17:44859715	T/C	cg15921436	chr17:44337874	NA	-0.68	-7.54	-0.42	7.6e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs4862750	0.872	rs13101380	chr4:187894744	G/A	cg07414643	chr4:187882934	NA	0.46	6.55	0.37	2.95e-10	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14454397	chr2:225450036	CUL3	0.57	6.82	0.39	6.1e-11	Gut microbiome composition (summer);
CESC	cis	rs3105593	1.000	rs28494067	chr15:50908272	A/G	cg08437265	chr15:50716283	USP8	0.4	5.13	0.3	5.69e-7	QT interval;
CESC	cis	rs9640161	0.830	rs17173682	chr7:150059602	A/G	cg21361702	chr7:150065534	REPIN1	0.68	8.52	0.46	1.2e-15	Blood protein levels;Circulating chemerin levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14788660	chr1:155278430	FDPS	0.6	7.21	0.4	5.73e-12	Gut microbiome composition (summer);
CESC	cis	rs11577318	0.853	rs12728971	chr1:26626612	C/T	cg19743891	chr1:26644573	UBXN11;CD52	-0.28	-5.11	-0.3	6.05e-7	Granulocyte percentage of myeloid white cells;
CESC	cis	rs1376303	0.558	rs12533180	chr7:32944132	A/C	cg06627557	chr7:32535165	LSM5;AVL9	0.73	5.58	0.32	5.91e-8	Intelligence (multi-trait analysis);
CESC	cis	rs9322193	0.884	rs9689702	chr6:150061856	G/A	cg09699651	chr6:150184138	LRP11	0.4	5.19	0.3	4.14e-7	Lung cancer;
CESC	cis	rs6912958	0.874	rs9294381	chr6:88152681	A/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.55	-7.48	-0.42	1.08e-12	Monocyte percentage of white cells;
CESC	cis	rs4803468	1.000	rs284656	chr19:41929251	T/C	cg14132834	chr19:41945861	ATP5SL	-0.66	-8.18	-0.45	1.22e-14	Height;
CESC	cis	rs875971	0.862	rs2909688	chr7:65841612	C/A	cg18876405	chr7:65276391	NA	0.53	7.28	0.41	3.73e-12	Aortic root size;
CESC	cis	rs916888	0.610	rs199442	chr17:44820122	G/A	cg01570182	chr17:44337453	NA	0.63	8.56	0.47	9.17e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs7208859	0.623	rs56095789	chr17:29060170	A/G	cg19761014	chr17:28927070	LRRC37B2	0.76	6.25	0.36	1.66e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs7666738	0.830	rs10025174	chr4:98914172	A/G	cg17366294	chr4:99064904	C4orf37	0.56	7.68	0.43	3.1e-13	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6089584	0.546	rs4925337	chr20:60637637	T/C	cg24733560	chr20:60626293	TAF4	0.43	6.36	0.36	8.93e-10	Body mass index;
CESC	cis	rs290986	0.857	rs158509	chr9:93546449	C/G	cg02608019	chr9:93564028	SYK	0.5	5.38	0.31	1.61e-7	Multiple sclerosis;
CESC	cis	rs6582630	0.537	rs11520294	chr12:38402705	C/A	cg13010199	chr12:38710504	ALG10B	0.54	6.87	0.39	4.7e-11	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs1144333	1.000	rs5745327	chr1:76270040	A/T	cg03433033	chr1:76189801	ACADM	-0.53	-5.5	-0.32	8.83e-8	Attention function in attention deficit hyperactive disorder;
CESC	trans	rs7944735	0.507	rs10742827	chr11:48102350	C/T	cg03929089	chr4:120376271	NA	0.55	6.56	0.37	2.87e-10	Intraocular pressure;
CESC	cis	rs12545109	0.879	rs2576580	chr8:57365828	G/C	cg09654669	chr8:57350985	NA	-0.57	-6.67	-0.38	1.46e-10	Obesity-related traits;
CESC	cis	rs208520	0.690	rs207077	chr6:66769855	A/C	cg07460842	chr6:66804631	NA	-0.96	-12.78	-0.62	1.87e-29	Exhaled nitric oxide output;
CESC	cis	rs477895	0.713	rs1059440	chr11:63991801	C/T	cg04317338	chr11:64019027	PLCB3	-0.87	-9.28	-0.5	6.19e-18	Mean platelet volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00346556	chr12:15942191	EPS8	0.51	6.06	0.35	4.62e-9	Gut microbiome composition (summer);
CESC	cis	rs4862750	0.872	rs13143414	chr4:187878213	G/A	cg11301795	chr4:187892539	NA	-0.81	-14.41	-0.66	3.69e-35	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs597539	0.652	rs501799	chr11:68631240	G/T	cg21963583	chr11:68658836	MRPL21	0.39	5.6	0.33	5.26e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs6460942	0.511	rs13245890	chr7:12543134	A/C	cg02935154	chr7:12443704	VWDE	-0.56	-5.53	-0.32	7.57e-8	Coronary artery disease;
CESC	cis	rs2573652	1.000	rs2581358	chr15:100513725	C/G	cg09918751	chr15:100517450	ADAMTS17	-0.39	-7.57	-0.42	6.24e-13	Height;
CESC	cis	rs78456975	1.000	rs13431491	chr2:1553808	T/A	cg26248373	chr2:1572462	NA	-0.58	-5.48	-0.32	9.71e-8	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs7818688	1.000	rs28712702	chr8:96026980	G/A	cg16049864	chr8:95962084	TP53INP1	0.6	5.77	0.33	2.25e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs4474465	0.850	rs10793332	chr11:78270020	C/G	cg27205649	chr11:78285834	NARS2	0.45	5.9	0.34	1.11e-8	Alzheimer's disease (survival time);
CESC	cis	rs2243480	1.000	rs1267820	chr7:66050295	C/G	cg13147721	chr7:65941812	NA	-0.93	-8.79	-0.47	1.98e-16	Diabetic kidney disease;
CESC	cis	rs2749592	0.588	rs2505192	chr10:38395023	G/A	cg25427524	chr10:38739819	LOC399744	-0.62	-8.3	-0.45	5.37e-15	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs17376456	0.809	rs13177800	chr5:93307350	T/C	cg25358565	chr5:93447407	FAM172A	1.11	10.49	0.54	9.3e-22	Diabetic retinopathy;
CESC	cis	rs9393777	0.623	rs16891717	chr6:26477143	T/A	cg12826209	chr6:26865740	GUSBL1	0.65	6.85	0.39	5.16e-11	Intelligence (multi-trait analysis);
CESC	cis	rs514406	0.861	rs505444	chr1:53251860	C/T	cg24675658	chr1:53192096	ZYG11B	-0.53	-6.82	-0.39	6.32e-11	Monocyte count;
CESC	cis	rs4919694	1.000	rs12258551	chr10:104767892	C/G	cg04362960	chr10:104952993	NT5C2	0.75	6.44	0.37	5.54e-10	Arsenic metabolism;
CESC	cis	rs9790314	0.846	rs9809522	chr3:160983768	G/C	cg03342759	chr3:160939853	NMD3	-0.51	-7.39	-0.41	1.98e-12	Morning vs. evening chronotype;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25495775	chr17:46970705	ATP5G1	-0.56	-6.78	-0.38	7.68e-11	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15979344	chr10:99496871	ZFYVE27	0.55	6.69	0.38	1.3e-10	Gut microbiome composition (summer);
CESC	trans	rs12310956	0.532	rs11052952	chr12:33988048	G/A	cg26384229	chr12:38710491	ALG10B	0.59	8.14	0.45	1.56e-14	Morning vs. evening chronotype;
CESC	trans	rs1728785	1.000	rs1749791	chr16:68572347	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.61	7.44	0.42	1.41e-12	Ulcerative colitis;
CESC	cis	rs4481887	0.927	rs11204637	chr1:248492581	G/A	cg00666640	chr1:248458726	OR2T12	0.36	6.17	0.35	2.56e-9	Common traits (Other);
CESC	cis	rs12142240	0.698	rs1057535	chr1:46815898	T/C	cg00530320	chr1:46809349	NSUN4	0.58	7.89	0.44	8.17e-14	Menopause (age at onset);
CESC	cis	rs9287719	0.967	rs6432116	chr2:10748615	T/C	cg00105475	chr2:10696890	NA	0.38	5.57	0.32	6.34e-8	Prostate cancer;
CESC	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg26338869	chr17:61819248	STRADA	0.67	8.74	0.47	2.72e-16	Prudent dietary pattern;
CESC	cis	rs698833	0.886	rs4953090	chr2:44565194	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.55	6.96	0.39	2.69e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs17601876	0.814	rs8029537	chr15:51557698	A/G	cg19946085	chr15:51559439	CYP19A1	-0.35	-5.63	-0.33	4.54e-8	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg18145393	chr4:520203	PIGG	0.52	6.78	0.38	7.92e-11	Fibrinogen levels;
CESC	cis	rs425277	0.917	rs78609670	chr1:2045886	G/T	cg16545954	chr1:2118288	C1orf86	0.33	5.4	0.31	1.48e-7	Height;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg26635474	chr16:1706710	CRAMP1L	-0.41	-6.03	-0.35	5.43e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs17376456	0.569	rs2045019	chr5:93201971	C/T	cg25358565	chr5:93447407	FAM172A	-0.71	-7.62	-0.42	4.44e-13	Diabetic retinopathy;
CESC	cis	rs2180341	0.618	rs12529077	chr6:127634244	G/T	cg24812749	chr6:127587940	RNF146	0.6	8.09	0.44	2.22e-14	Breast cancer;
CESC	cis	rs35522438	1	rs35522438	chr7:91872872	A/AT	cg17063962	chr7:91808500	NA	0.59	8.09	0.45	2.1e-14	Breast cancer;
CESC	trans	rs1814175	0.654	rs1164676	chr11:49324868	T/C	cg15704280	chr7:45808275	SEPT13	0.82	12.25	0.6	1.2100000000000001e-27	Height;
CESC	cis	rs782590	0.902	rs2586947	chr2:55854009	C/G	cg18811423	chr2:55921094	PNPT1	0.76	11.74	0.58	6.83e-26	Metabolic syndrome;
CESC	cis	rs763014	0.931	rs11643039	chr16:634260	G/A	cg00802000	chr16:706648	WDR90	-0.4	-6.09	-0.35	4.02e-9	Height;
CESC	cis	rs7666738	0.830	rs9995386	chr4:98907826	T/C	cg03676636	chr4:99064102	C4orf37	0.34	5.17	0.3	4.54e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11098499	0.691	rs2136911	chr4:120265859	G/A	cg25214090	chr10:38739885	LOC399744	0.59	8.14	0.45	1.55e-14	Corneal astigmatism;
CESC	cis	rs796364	0.616	rs769956	chr2:200693720	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.53	-5.11	-0.3	6.17e-7	Schizophrenia;
CESC	cis	rs2066819	1.000	rs59811639	chr12:56695954	C/T	cg26734620	chr12:56694298	CS	1.07	6.58	0.37	2.56e-10	Psoriasis vulgaris;
CESC	cis	rs8103278	1.000	rs8108864	chr19:46301671	G/A	cg12641515	chr19:46296257	DMWD	-0.52	-5.81	-0.34	1.76e-8	Coronary artery disease;
CESC	cis	rs17711722	0.528	rs73138179	chr7:65294482	G/T	cg12143784	chr7:64541923	NA	0.43	5.63	0.33	4.64e-8	Calcium levels;
CESC	cis	rs780094	0.585	rs3739095	chr2:27556721	C/T	cg21248554	chr2:27665150	KRTCAP3	-0.29	-6.18	-0.36	2.35e-9	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
CESC	cis	rs7618915	0.524	rs2028216	chr3:52680823	C/T	cg18404041	chr3:52824283	ITIH1	-0.37	-6.17	-0.35	2.53e-9	Bipolar disorder;
CESC	cis	rs12497850	0.931	rs9682444	chr3:48852639	A/G	cg03060546	chr3:49711283	APEH	0.45	5.5	0.32	9e-8	Parkinson's disease;
CESC	cis	rs7959452	0.719	rs57954211	chr12:69748397	C/A	cg22834771	chr12:69754056	YEATS4	-0.43	-5.67	-0.33	3.67e-8	Blood protein levels;
CESC	cis	rs9549260	0.712	rs1334241	chr13:41223110	C/T	cg21288729	chr13:41239152	FOXO1	0.54	5.31	0.31	2.33e-7	Red blood cell count;
CESC	cis	rs6952808	0.656	rs12699646	chr7:2093162	T/G	cg04267008	chr7:1944627	MAD1L1	0.6	7.27	0.41	3.94e-12	Bipolar disorder and schizophrenia;
CESC	trans	rs2727020	0.566	rs10839234	chr11:49185524	C/T	cg15704280	chr7:45808275	SEPT13	-0.85	-13.78	-0.65	6.19e-33	Coronary artery disease;
CESC	cis	rs8040855	0.627	rs17541051	chr15:85649353	C/G	cg08123816	chr15:85640762	PDE8A	-0.39	-5.74	-0.33	2.6e-8	Bulimia nervosa;
CESC	cis	rs9486719	1.000	rs2499809	chr6:96870110	C/T	cg18709589	chr6:96969512	KIAA0776	0.53	5.81	0.34	1.75e-8	Migraine;Coronary artery disease;
CESC	cis	rs926392	0.572	rs6129158	chr20:37673967	A/G	cg16355469	chr20:37678765	NA	0.57	7.17	0.4	7.44e-12	Dialysis-related mortality;
CESC	cis	rs1552244	0.572	rs66514627	chr3:10166632	A/C	cg00149659	chr3:10157352	C3orf10	1.01	12.53	0.61	1.33e-28	Alzheimer's disease;
CESC	cis	rs7714584	1.000	rs4958842	chr5:150224877	G/A	cg22134413	chr5:150180641	NA	0.62	5.94	0.34	8.89e-9	Crohn's disease;
CESC	cis	rs28489187	0.706	rs233067	chr1:85804978	C/G	cg16011679	chr1:85725395	C1orf52	0.48	5.59	0.33	5.51e-8	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	cis	rs2370759	0.891	rs77706860	chr10:32628537	C/T	cg01819863	chr10:32635814	EPC1	1.12	10.39	0.54	1.99e-21	Sexual dysfunction (female);
CESC	cis	rs12048904	0.964	rs3188491	chr1:101338482	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.53	6.81	0.39	6.4e-11	Multiple sclerosis;
CESC	trans	rs7945705	0.902	rs2568059	chr11:8884161	T/C	cg10637292	chr12:52960529	KRT74	0.35	6.18	0.35	2.42e-9	Hemoglobin concentration;
CESC	cis	rs2180341	0.961	rs9375501	chr6:127652539	C/T	cg27446573	chr6:127587934	RNF146	1.09	16.35	0.71	5.12e-42	Breast cancer;
CESC	cis	rs7615952	0.800	rs35390120	chr3:125599809	G/A	cg05084668	chr3:125655381	ALG1L	-0.6	-6.48	-0.37	4.49e-10	Blood pressure (smoking interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07373003	chr10:22614444	BMI1	0.56	6.12	0.35	3.41e-9	Gut microbiome composition (summer);
CESC	trans	rs4733781	1.000	rs4733781	chr8:131296767	A/C	cg15602633	chr10:134698661	NA	0.33	6.06	0.35	4.55e-9	Tuberculosis;
CESC	cis	rs9322193	0.923	rs11155671	chr6:149972132	G/A	cg07701084	chr6:150067640	NUP43	0.46	6.49	0.37	4.3e-10	Lung cancer;
CESC	cis	rs9902453	0.904	rs4461132	chr17:28423430	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.7	9.02	0.48	3.81e-17	Coffee consumption (cups per day);
CESC	cis	rs34779708	0.966	rs11010102	chr10:35411066	T/A	cg03585969	chr10:35415529	CREM	0.77	10.38	0.54	2.06e-21	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs12900413	0.687	rs12902786	chr15:90304376	G/A	cg24249390	chr15:90295951	MESP1	-0.4	-5.57	-0.32	6.23e-8	Coronary artery aneurysm in Kawasaki disease;
CESC	cis	rs7267979	1.000	rs6050598	chr20:25397257	C/G	cg08601574	chr20:25228251	PYGB	0.37	5.37	0.31	1.7e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs2380220	0.808	rs2716072	chr6:95909773	A/G	cg15832292	chr6:96025679	MANEA	-0.65	-5.95	-0.34	8.46e-9	Behavioural disinhibition (generation interaction);
CESC	cis	rs2303745	0.544	rs6512181	chr19:17399213	T/G	cg02221750	chr19:17393354	ANKLE1	-0.51	-6.24	-0.36	1.71e-9	Systemic lupus erythematosus;
CESC	cis	rs642858	0.784	rs592755	chr6:140237606	A/G	cg27524944	chr6:140295369	NA	0.35	5.18	0.3	4.3e-7	Type 2 diabetes;
CESC	cis	rs16917546	0.967	rs10995256	chr10:64402434	G/T	cg03961010	chr10:64397487	ZNF365	-0.37	-6.11	-0.35	3.47e-9	Basal cell carcinoma;
CESC	cis	rs11098499	0.955	rs13114751	chr4:120156617	G/A	cg24375607	chr4:120327624	NA	0.43	5.15	0.3	5.05e-7	Corneal astigmatism;
CESC	cis	rs9788682	0.747	rs2656073	chr15:78742276	G/T	cg24631222	chr15:78858424	CHRNA5	0.65	7.64	0.43	3.9e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	trans	rs916888	0.821	rs199505	chr17:44859410	A/G	cg22433210	chr17:43662623	NA	-0.91	-10.51	-0.54	7.86e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs11650494	0.908	rs11656535	chr17:47425588	C/T	cg08112188	chr17:47440006	ZNF652	1.11	7.72	0.43	2.31e-13	Prostate cancer;
CESC	cis	rs7772486	0.738	rs2246334	chr6:146183635	G/A	cg05347473	chr6:146136440	FBXO30	0.59	7.54	0.42	7.31e-13	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs12356475	0.710	rs10822686	chr10:67733250	C/T	cg20430063	chr12:65672888	MSRB3	0.48	6.08	0.35	4.17e-9	Psoriatic arthritis;
CESC	cis	rs67366981	0.925	rs41438045	chr14:77692781	A/T	cg22824376	chr14:77648248	TMEM63C	0.64	5.32	0.31	2.23e-7	Obsessive-compulsive symptoms;
CESC	cis	rs7216064	1.000	rs9897982	chr17:65879592	G/T	cg07042672	chr17:66097459	LOC651250	-0.62	-7.45	-0.42	1.35e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs909674	0.818	rs5757678	chr22:39843409	A/G	cg01416388	chr22:39784598	NA	0.59	7.24	0.41	4.87e-12	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs853679	0.517	rs4713143	chr6:28106759	A/C	cg23161317	chr6:28129485	ZNF389	0.51	6.63	0.38	1.85e-10	Depression;
CESC	cis	rs4969178	0.896	rs11077361	chr17:76397128	A/G	cg05887092	chr17:76393375	PGS1	0.58	9.2	0.49	1.13e-17	HDL cholesterol levels;
CESC	cis	rs4665809	0.941	rs1434079	chr2:26284670	C/G	cg04944784	chr2:26401820	FAM59B	-0.66	-7.66	-0.43	3.61e-13	Gut microbiome composition (summer);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg02653728	chr5:132165751	NA	-0.49	-6.75	-0.38	9.32e-11	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs28489187	0.617	rs233072	chr1:85807695	A/G	cg16011679	chr1:85725395	C1orf52	0.45	5.33	0.31	2.12e-7	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	cis	rs6952808	0.789	rs35729895	chr7:1885069	C/T	cg05863683	chr7:1912471	MAD1L1	0.37	5.38	0.31	1.64e-7	Bipolar disorder and schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03032015	chr1:142618752	NA	-0.56	-6.88	-0.39	4.26e-11	Gut microbiome composition (summer);
CESC	cis	rs2286503	0.839	rs4722188	chr7:22860211	C/G	cg11367502	chr7:22862612	TOMM7	0.39	5.28	0.31	2.72e-7	Fibrinogen;
CESC	cis	rs7246657	0.943	rs6508732	chr19:38000468	C/T	cg23950597	chr19:37808831	NA	-0.49	-5.49	-0.32	9.38e-8	Coronary artery calcification;
CESC	cis	rs1008375	1.000	rs555	chr4:17625658	A/G	cg15017067	chr4:17643749	FAM184B	0.39	5.68	0.33	3.58e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	trans	rs561341	1.000	rs8069199	chr17:30281845	A/G	cg20587970	chr11:113659929	NA	-1.12	-14.24	-0.66	1.49e-34	Hip circumference adjusted for BMI;
CESC	cis	rs80282103	0.618	rs74117848	chr10:1160974	T/G	cg08668510	chr10:1095578	IDI1	0.75	6.01	0.35	5.97e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs5751150	1	rs5751150	chr22:42153292	T/G	cg06481639	chr22:41940642	POLR3H	0.6	5.95	0.34	8.27e-9	Cannabis dependence symptom count;
CESC	cis	rs7927771	0.826	rs2293578	chr11:47437403	C/T	cg05585544	chr11:47624801	NA	-0.5	-7.19	-0.4	6.51e-12	Subjective well-being;
CESC	cis	rs79349575	0.778	rs12950328	chr17:46967061	C/T	cg16584676	chr17:46985605	UBE2Z	0.55	6.62	0.38	2.03e-10	Type 2 diabetes;
CESC	trans	rs4388249	0.516	rs435494	chr5:109010578	G/C	cg00054525	chr16:88717587	CYBA	-0.61	-6.8	-0.39	7.05e-11	Schizophrenia;
CESC	cis	rs67311347	1.000	rs11539046	chr3:40503809	G/A	cg24209194	chr3:40518798	ZNF619	-0.54	-7.02	-0.4	1.9e-11	Renal cell carcinoma;
CESC	cis	rs1395	0.626	rs72817537	chr2:27497549	G/A	cg22903471	chr2:27725779	GCKR	-0.5	-5.85	-0.34	1.46e-8	Blood metabolite levels;
CESC	cis	rs3785574	0.962	rs8079161	chr17:61808561	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.56	6.9	0.39	3.81e-11	Height;
CESC	cis	rs7927771	0.864	rs3781627	chr11:47441472	T/A	cg20307385	chr11:47447363	PSMC3	0.71	8.78	0.47	2.01e-16	Subjective well-being;
CESC	cis	rs9611565	0.546	rs132793	chr22:42063681	A/G	cg06634786	chr22:41940651	POLR3H	0.61	5.97	0.34	7.66e-9	Vitiligo;
CESC	cis	rs9457247	0.967	rs433191	chr6:167409662	T/A	cg23791538	chr6:167370224	RNASET2	-0.61	-8.75	-0.47	2.59e-16	Crohn's disease;
CESC	cis	rs4253772	0.575	rs9615979	chr22:46789021	G/T	cg24881330	chr22:46731750	TRMU	0.78	5.18	0.3	4.38e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs116095464	0.558	rs10067021	chr5:221490	C/T	cg12570787	chr5:219185	SDHA;CCDC127	0.53	5.74	0.33	2.63e-8	Breast cancer;
CESC	cis	rs1448094	0.512	rs6539932	chr12:86247497	T/C	cg00310523	chr12:86230176	RASSF9	0.37	5.63	0.33	4.47e-8	Major depressive disorder;
CESC	cis	rs875971	1.000	rs4717292	chr7:65895598	G/A	cg18876405	chr7:65276391	NA	0.51	6.82	0.39	6.05e-11	Aortic root size;
CESC	cis	rs853679	0.517	rs6932109	chr6:28078303	A/G	cg20151795	chr6:28129481	ZNF389	-0.49	-6.57	-0.37	2.58e-10	Depression;
CESC	cis	rs61008539	0.586	rs6959154	chr7:856320	C/T	cg00934597	chr7:893267	UNC84A	-0.51	-6.75	-0.38	9.31e-11	Perceived unattractiveness to mosquitoes;
CESC	cis	rs7666738	0.830	rs1426663	chr4:98990092	T/G	cg03676636	chr4:99064102	C4orf37	0.34	5.21	0.31	3.73e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7666738	0.830	rs7684646	chr4:99071062	C/T	cg03467027	chr4:99064603	C4orf37	0.46	5.73	0.33	2.71e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6963495	0.818	rs115609508	chr7:105163716	C/A	cg02135003	chr7:105160482	PUS7	-0.47	-5.59	-0.33	5.51e-8	Bipolar disorder (body mass index interaction);
CESC	cis	rs4243830	0.850	rs13513	chr1:6585804	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.77	-7.91	-0.44	7.21e-14	Body mass index;
CESC	cis	rs988913	1.000	rs1393776	chr6:54763018	A/C	cg03513858	chr6:54763001	FAM83B	0.37	5.32	0.31	2.21e-7	Menarche (age at onset);
CESC	cis	rs12701220	0.739	rs2293523	chr7:1098518	G/A	cg26769984	chr7:1090371	C7orf50	0.58	5.92	0.34	1.01e-8	Bronchopulmonary dysplasia;
CESC	cis	rs11969893	0.850	rs9498409	chr6:101299966	G/A	cg12253828	chr6:101329408	ASCC3	1.14	9.68	0.51	3.71e-19	Economic and political preferences (immigration/crime);
CESC	cis	rs6752107	0.837	rs3792108	chr2:234184952	T/C	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.39	5.91	0.34	1.07e-8	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs921968	0.542	rs588182	chr2:219412335	C/A	cg02176678	chr2:219576539	TTLL4	0.5	9.06	0.49	3.06e-17	Mean corpuscular hemoglobin concentration;
CESC	cis	rs796364	0.951	rs11897245	chr2:201063644	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.55	5.36	0.31	1.86e-7	Schizophrenia;
CESC	trans	rs11098499	0.954	rs10008459	chr4:120394231	T/C	cg25214090	chr10:38739885	LOC399744	0.7	10.29	0.53	4.26e-21	Corneal astigmatism;
CESC	cis	rs644799	0.710	rs519511	chr11:95538270	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.77	10.82	0.55	8.02e-23	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs3820928	0.605	rs6748311	chr2:227792530	T/A	cg11843606	chr2:227700838	RHBDD1	-0.56	-7.76	-0.43	1.87e-13	Pulmonary function;
CESC	cis	rs10504229	1.000	rs17805326	chr8:58169533	A/C	cg14926445	chr8:58193284	C8orf71	-0.5	-5.39	-0.31	1.6e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs67311347	0.956	rs4974029	chr3:40521318	C/G	cg24209194	chr3:40518798	ZNF619	0.54	7.15	0.4	8.34e-12	Renal cell carcinoma;
CESC	cis	rs12477438	0.501	rs6753063	chr2:99801469	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.84	15.36	0.69	1.63e-38	Chronic sinus infection;
CESC	cis	rs6582630	0.516	rs8186746	chr12:38347638	G/T	cg26384229	chr12:38710491	ALG10B	-0.47	-6.06	-0.35	4.54e-9	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs9788682	0.948	rs34664138	chr15:78831624	T/G	cg24631222	chr15:78858424	CHRNA5	0.81	10.53	0.54	6.79e-22	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18102949	chr7:128116732	METTL2B	0.69	7.9	0.44	7.64e-14	Gut microbiome composition (summer);
CESC	cis	rs916888	0.687	rs199456	chr17:44797919	C/T	cg17911788	chr17:44343683	NA	-0.63	-8.15	-0.45	1.45e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs4819052	0.851	rs10470246	chr21:46659017	C/G	cg11663144	chr21:46675770	NA	-0.62	-9.74	-0.51	2.36e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs6901250	0.851	rs6938235	chr6:117147946	G/T	cg12892004	chr6:117198278	RFX6	0.27	5.07	0.3	7.65e-7	C-reactive protein levels;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg05995172	chr11:57434667	ZDHHC5	-0.47	-6.42	-0.37	6.16e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs9467711	0.659	rs13216828	chr6:26373507	G/A	cg06606381	chr12:133084897	FBRSL1	-0.76	-7.09	-0.4	1.23e-11	Autism spectrum disorder or schizophrenia;
CESC	cis	rs7666738	0.830	rs2865979	chr4:99027137	T/C	cg05340658	chr4:99064831	C4orf37	0.83	13.1	0.63	1.43e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2228479	0.702	rs17233868	chr16:89803629	C/T	cg04013166	chr16:89971882	TCF25	0.76	6.51	0.37	3.7e-10	Skin colour saturation;
CESC	trans	rs2235573	0.527	rs139879	chr22:38364552	T/C	cg19894588	chr14:64061835	NA	0.63	8.32	0.46	4.69e-15	Glioblastoma;Glioma;
CESC	cis	rs9309473	0.607	rs1851546	chr2:73591127	C/A	cg20560298	chr2:73613845	ALMS1	-0.45	-5.69	-0.33	3.44e-8	Metabolite levels;
CESC	cis	rs344364	0.511	rs337286	chr16:1965719	C/T	cg03013636	chr16:1946785	NA	0.43	5.5	0.32	8.99e-8	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs910316	1.000	rs12889472	chr14:75543979	A/G	cg11812906	chr14:75593930	NEK9	0.88	14.52	0.67	1.47e-35	Height;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg09059988	chr1:150693299	HORMAD1	-0.46	-6.46	-0.37	4.88e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs7586879	0.616	rs11900505	chr2:25131986	A/C	cg01884057	chr2:25150051	NA	0.36	6.87	0.39	4.46e-11	Body mass index;
CESC	cis	rs3008870	0.755	rs2815366	chr1:67499930	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.6	7.97	0.44	4.75e-14	Lymphocyte percentage of white cells;
CESC	cis	rs798554	0.679	rs7784066	chr7:2819727	T/A	cg04166393	chr7:2884313	GNA12	0.59	7.45	0.42	1.32e-12	Height;
CESC	cis	rs6121246	0.609	rs6089075	chr20:30392884	A/G	cg13852791	chr20:30311386	BCL2L1	0.82	10.49	0.54	9.55e-22	Mean corpuscular hemoglobin;
CESC	cis	rs9487051	0.660	rs2884036	chr6:109642916	A/G	cg01475377	chr6:109611718	NA	0.45	6.5	0.37	3.95e-10	Reticulocyte fraction of red cells;
CESC	cis	rs5769765	0.658	rs2157536	chr22:50190180	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.46	-5.16	-0.3	4.78e-7	Schizophrenia;
CESC	cis	rs1784581	0.894	rs1790001	chr6:162387504	G/T	cg17173639	chr6:162384350	PARK2	-0.8	-12.97	-0.62	4.11e-30	Itch intensity from mosquito bite;
CESC	cis	rs734999	0.588	rs11585048	chr1:2534087	C/T	cg18854424	chr1:2615690	NA	0.27	5.23	0.31	3.49e-7	Ulcerative colitis;
CESC	cis	rs9359856	0.564	rs72915918	chr6:90430792	G/C	cg13799429	chr6:90582589	CASP8AP2	-0.59	-5.58	-0.32	6.07e-8	Bipolar disorder;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg12754671	chr1:161171876	NDUFS2	-0.4	-6.18	-0.35	2.47e-9	Gambling;
CESC	cis	rs2742234	0.590	rs2257767	chr10:43657811	T/G	cg15436174	chr10:43711423	RASGEF1A	-0.51	-5.84	-0.34	1.54e-8	Hirschsprung disease;
CESC	cis	rs7267979	1.000	rs6083828	chr20:25369918	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.85	-16.93	-0.72	4.43e-44	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7605827	0.930	rs2058867	chr2:15520153	T/C	cg19274914	chr2:15703543	NA	0.36	6.45	0.37	5.37e-10	Educational attainment (years of education);
CESC	cis	rs2072732	0.861	rs2993510	chr1:2956666	C/T	cg15211996	chr1:2936768	ACTRT2	-0.33	-6.14	-0.35	2.99e-9	Plateletcrit;
CESC	cis	rs36051895	0.664	rs10117459	chr9:5094034	G/A	cg02405213	chr9:5042618	JAK2	-0.51	-6.17	-0.35	2.61e-9	Pediatric autoimmune diseases;
CESC	cis	rs9733	0.596	rs12072339	chr1:150686099	A/G	cg09365446	chr1:150670422	GOLPH3L	0.42	5.86	0.34	1.37e-8	Tonsillectomy;
CESC	cis	rs7818688	0.697	rs80217195	chr8:95986853	T/C	cg16049864	chr8:95962084	TP53INP1	0.55	5.58	0.32	5.99e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05458841	chr5:65221764	ERBB2IP	0.62	7.85	0.43	1.04e-13	Gut microbiome composition (summer);
CESC	cis	rs9811920	0.641	rs58704213	chr3:99690331	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.38	-6.29	-0.36	1.3e-9	Axial length;
CESC	cis	rs4662945	0.525	rs4662951	chr2:130256272	C/T	cg05903289	chr2:130345205	NA	-0.41	-6.35	-0.36	9.19e-10	Response to cytidine analogues (gemcitabine);
CESC	cis	rs7949030	0.620	rs2428551	chr11:62329758	T/A	cg11742103	chr11:62369870	EML3;MTA2	0.6	9.23	0.49	8.91e-18	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs7086627	0.515	rs10887901	chr10:82210581	G/A	cg03267442	chr10:82210566	NA	-0.33	-5.49	-0.32	9.45e-8	Post bronchodilator FEV1;
CESC	cis	rs7116495	1.000	rs73543633	chr11:71828844	T/C	cg10381502	chr11:71823885	C11orf51	0.72	5.91	0.34	1.05e-8	Severe influenza A (H1N1) infection;
CESC	cis	rs17376456	0.825	rs10078941	chr5:93279029	C/T	cg25358565	chr5:93447407	FAM172A	1.11	10.16	0.53	1.06e-20	Diabetic retinopathy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03956243	chr12:54059090	ATP5G2	-0.68	-8.35	-0.46	3.8e-15	Gut microbiome composition (summer);
CESC	cis	rs829883	0.659	rs12366950	chr12:98947900	T/C	cg25150519	chr12:98850993	NA	-0.61	-7.37	-0.41	2.23e-12	Colorectal adenoma (advanced);
CESC	cis	rs6460942	0.731	rs75994414	chr7:12307992	C/A	cg06484146	chr7:12443880	VWDE	-0.78	-8.3	-0.45	5.42e-15	Coronary artery disease;
CESC	cis	rs9649213	0.555	rs7785612	chr7:97933867	T/A	cg08684580	chr7:98029266	BAIAP2L1	-0.34	-5.48	-0.32	9.67e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs6728642	0.908	rs17842456	chr2:98014319	C/T	cg26665480	chr2:98280029	ACTR1B	0.76	6.99	0.39	2.28e-11	Bipolar disorder lithium response (continuous) or schizophrenia;
CESC	cis	rs9457247	0.905	rs453184	chr6:167387404	A/C	cg23791538	chr6:167370224	RNASET2	-0.6	-8.65	-0.47	4.96e-16	Crohn's disease;
CESC	cis	rs7264396	0.623	rs2425123	chr20:34329547	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.63	6.86	0.39	4.77e-11	Total cholesterol levels;
CESC	cis	rs10465746	0.905	rs1324484	chr1:84382844	T/C	cg10977910	chr1:84465055	TTLL7	0.46	6.17	0.35	2.51e-9	Obesity-related traits;
CESC	cis	rs769267	0.965	rs6511026	chr19:19391402	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	7.34	0.41	2.56e-12	Tonsillectomy;
CESC	cis	rs7618915	0.501	rs2079929	chr3:52765646	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.36	6.48	0.37	4.53e-10	Bipolar disorder;
CESC	cis	rs7216064	1.000	rs8072225	chr17:65912960	A/G	cg07042672	chr17:66097459	LOC651250	-0.61	-7.66	-0.43	3.45e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs875971	1.000	rs10257427	chr7:65743208	T/C	cg11764359	chr7:65958608	NA	-0.94	-15.49	-0.69	5.83e-39	Aortic root size;
CESC	cis	rs2836974	0.644	rs11088472	chr21:40699376	A/C	cg22974920	chr21:40686053	BRWD1	-0.42	-5.17	-0.3	4.7e-7	Cognitive function;
CESC	trans	rs9693444	0.898	rs4732697	chr8:29519861	A/G	cg13834670	chr9:129677390	RALGPS1	-0.4	-6.06	-0.35	4.6e-9	Breast cancer;
CESC	cis	rs2576037	0.583	rs2187091	chr18:44520048	T/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.32	5.11	0.3	6.08e-7	Personality dimensions;
CESC	cis	rs9917256	1.000	rs13016703	chr2:169155595	T/G	cg07857142	chr2:169103971	STK39	0.58	5.3	0.31	2.48e-7	Parkinson's disease;
CESC	cis	rs2439831	1.000	rs2245790	chr15:43744457	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.88	10.56	0.54	5.55e-22	Lung cancer in ever smokers;
CESC	cis	rs1008375	1.000	rs6811887	chr4:17640858	C/T	cg15017067	chr4:17643749	FAM184B	0.36	5.11	0.3	6.3e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs11098499	0.863	rs6534141	chr4:120485223	A/T	cg09307838	chr4:120376055	NA	0.91	12.54	0.61	1.27e-28	Corneal astigmatism;
CESC	cis	rs28386778	0.830	rs7209321	chr17:61855668	A/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	7.69	0.43	2.93e-13	Prudent dietary pattern;
CESC	cis	rs933688	1.000	rs12654787	chr5:90713259	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.99	11.82	0.59	3.43e-26	Smoking behavior;
CESC	cis	rs72781680	0.898	rs72780123	chr2:23996009	G/A	cg20701182	chr2:24300061	SF3B14	0.63	5.65	0.33	4.21e-8	Lymphocyte counts;
CESC	cis	rs858239	0.600	rs28483572	chr7:23131785	A/G	cg23682824	chr7:23144976	KLHL7	0.55	7.61	0.42	4.84e-13	Cerebrospinal fluid biomarker levels;
CESC	cis	rs1707322	1.000	rs11211235	chr1:46440375	G/A	cg06784218	chr1:46089804	CCDC17	0.33	5.63	0.33	4.7e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs6952808	0.531	rs1107351	chr7:2177093	G/A	cg23048001	chr7:2026167	MAD1L1	0.42	5.29	0.31	2.6e-7	Bipolar disorder and schizophrenia;
CESC	trans	rs2727020	0.729	rs2299650	chr11:49174007	A/C	cg15704280	chr7:45808275	SEPT13	-0.84	-13.74	-0.65	8.15e-33	Coronary artery disease;
CESC	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg10150615	chr22:24372951	LOC391322	-0.58	-7.87	-0.44	9.21e-14	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs909674	0.731	rs6001594	chr22:39837472	C/T	cg02038168	chr22:39784481	NA	-0.69	-8.63	-0.47	5.92e-16	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs1862618	0.620	rs189695	chr5:56225769	T/C	cg24549020	chr5:56110836	MAP3K1	0.47	5.82	0.34	1.66e-8	Initial pursuit acceleration;
CESC	cis	rs7512552	0.839	rs486275	chr1:150282784	G/A	cg15654264	chr1:150340011	RPRD2	-0.4	-5.25	-0.31	3.06e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs9894429	0.966	rs6565601	chr17:79580173	C/T	cg18240062	chr17:79603768	NPLOC4	0.72	10.27	0.53	4.71e-21	Eye color traits;
CESC	cis	rs9911578	0.967	rs6503883	chr17:56917543	C/T	cg12560992	chr17:57184187	TRIM37	0.94	15.75	0.7	6.57e-40	Intelligence (multi-trait analysis);
CESC	cis	rs11690935	1.000	rs312925	chr2:172563922	G/A	cg13550731	chr2:172543902	DYNC1I2	-0.95	-14.62	-0.67	6.75e-36	Schizophrenia;
CESC	cis	rs7827545	1.000	rs7008121	chr8:135565904	T/C	cg17885191	chr8:135476712	NA	0.49	6.36	0.36	8.72e-10	Hypertension (SNP x SNP interaction);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg00399650	chr7:141402322	KIAA1147	-0.44	-6.66	-0.38	1.54e-10	Gambling;
CESC	cis	rs863345	0.604	rs7512592	chr1:158489945	G/A	cg12129480	chr1:158549410	OR10X1	-0.34	-6.85	-0.39	5.17e-11	Pneumococcal bacteremia;
CESC	cis	rs7429990	0.931	rs62262084	chr3:47653822	C/T	cg11946769	chr3:48343235	NME6	0.53	5.34	0.31	2.04e-7	Educational attainment (years of education);
CESC	cis	rs3733585	0.699	rs6844316	chr4:9958977	A/G	cg00071950	chr4:10020882	SLC2A9	-0.73	-11.79	-0.59	4.58e-26	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg09177884	chr7:1199841	ZFAND2A	-0.46	-5.73	-0.33	2.66e-8	Longevity;Endometriosis;
CESC	cis	rs367943	0.634	rs6594701	chr5:112685743	C/T	cg12552261	chr5:112820674	MCC	0.42	5.42	0.32	1.36e-7	Type 2 diabetes;
CESC	cis	rs7100689	0.725	rs2185425	chr10:82139941	T/C	cg00277334	chr10:82204260	NA	-0.61	-7.65	-0.43	3.66e-13	Post bronchodilator FEV1;
CESC	cis	rs7726839	0.574	rs11134149	chr5:637277	A/G	cg16447950	chr5:562315	NA	-0.6	-6.7	-0.38	1.27e-10	Obesity-related traits;
CESC	cis	rs6860806	0.507	rs2631364	chr5:131706914	C/G	cg18758796	chr5:131593413	PDLIM4	-0.44	-6.04	-0.35	5.26e-9	Breast cancer;
CESC	cis	rs3126085	1.000	rs2011331	chr1:152286002	T/C	cg03465714	chr1:152285911	FLG	0.41	5.05	0.3	8.31e-7	Atopic dermatitis;
CESC	cis	rs6736093	0.796	rs13006228	chr2:112806738	G/A	cg12686935	chr2:112915763	FBLN7	-0.43	-5.63	-0.33	4.55e-8	Coronary artery disease;
CESC	cis	rs959260	0.925	rs4788890	chr17:73389446	A/G	cg12999837	chr17:73267436	MIF4GD	-0.51	-5.74	-0.33	2.57e-8	Systemic lupus erythematosus;
CESC	cis	rs1949733	0.958	rs2631731	chr4:8429817	A/G	cg11789530	chr4:8429930	ACOX3	0.82	11.91	0.59	1.8e-26	Response to antineoplastic agents;
CESC	cis	rs12971120	0.838	rs747176	chr18:72154931	G/A	cg25817165	chr18:72167213	CNDP2	-0.49	-6.36	-0.36	8.97e-10	Refractive error;
CESC	cis	rs7598759	0.712	rs12991636	chr2:232333666	T/C	cg19187155	chr2:232395269	NMUR1	0.41	6.37	0.36	8.46e-10	Noise-induced hearing loss;
CESC	cis	rs10504229	0.683	rs6982990	chr8:58115275	C/T	cg22535103	chr8:58192502	C8orf71	0.8	9.09	0.49	2.46e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs1577917	0.771	rs2475791	chr6:86368164	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.55	-7.36	-0.41	2.29e-12	Response to antipsychotic treatment;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03046325	chr10:93558661	TNKS2	0.53	6.33	0.36	1.06e-9	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18194353	chr1:100315666	AGL	0.61	7.41	0.41	1.65e-12	Gut microbiome composition (summer);
CESC	cis	rs7618915	0.547	rs13065019	chr3:52685244	T/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.63	0.38	1.83e-10	Bipolar disorder;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg02357637	chr15:100268975	LYSMD4	0.43	6.44	0.37	5.44e-10	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs12497850	0.864	rs12493001	chr3:49181885	A/G	cg02487422	chr3:49467188	NICN1	0.5	6.35	0.36	9.14e-10	Parkinson's disease;
CESC	cis	rs2549003	1.000	rs2070731	chr5:131819798	T/C	cg21138405	chr5:131827807	IRF1	0.57	9.05	0.49	3.24e-17	Asthma (sex interaction);
CESC	cis	rs4819052	0.885	rs9980676	chr21:46665430	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.47	5.91	0.34	1.07e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs227584	0.663	rs3180912	chr17:42259463	A/G	cg08499158	chr17:42289980	UBTF	-0.42	-5.44	-0.32	1.23e-7	Bone mineral density (hip);Bone mineral density;
CESC	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.46	-5.39	-0.31	1.53e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs6783573	0.683	rs3806702	chr3:46617502	T/C	cg27371741	chr3:46619158	LRRC2;TDGF1	-0.38	-5.95	-0.34	8.42e-9	Cerebrospinal fluid biomarker levels;
CESC	cis	rs3540	0.553	rs2158406	chr15:90994499	T/C	cg10434728	chr15:90938212	IQGAP1	0.42	7.49	0.42	1.05e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs7188697	0.775	rs8056620	chr16:58604387	T/A	cg21335942	chr16:58549945	SETD6	-0.45	-5.2	-0.3	4.06e-7	QT interval;
CESC	cis	rs801193	0.569	rs7800620	chr7:66223688	T/C	cg18876405	chr7:65276391	NA	0.45	6.18	0.35	2.39e-9	Aortic root size;
CESC	trans	rs8007846	0.569	rs4400971	chr14:66254578	A/C	cg13219509	chr22:40440322	TNRC6B	0.5	6.6	0.38	2.27e-10	Multiple sclerosis--Brain Glutamate Levels;
CESC	cis	rs870825	0.616	rs6552805	chr4:185637894	C/A	cg04058563	chr4:185651563	MLF1IP	0.62	6.86	0.39	4.91e-11	Blood protein levels;
CESC	cis	rs1448094	0.527	rs1900700	chr12:86232166	C/T	cg00310523	chr12:86230176	RASSF9	0.37	5.5	0.32	9.17e-8	Major depressive disorder;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg17181325	chr17:1613831	TLCD2	-0.44	-6.25	-0.36	1.61e-9	Fibrinogen levels;
CESC	cis	rs9916302	0.851	rs7225096	chr17:37664443	T/C	cg00129232	chr17:37814104	STARD3	-0.54	-7.14	-0.4	9.08e-12	Glomerular filtration rate (creatinine);
CESC	cis	rs9733	0.621	rs6669122	chr1:150591732	A/G	cg22823121	chr1:150693482	HORMAD1	-0.37	-5.46	-0.32	1.12e-7	Tonsillectomy;
CESC	cis	rs6938	0.662	rs12487	chr15:75136694	A/G	cg14664628	chr15:75095509	CSK	-0.65	-8.56	-0.47	9.13e-16	Breast cancer;
CESC	cis	rs7851660	0.844	rs10119853	chr9:100624981	G/A	cg13688889	chr9:100608707	NA	-0.64	-8.89	-0.48	9.61e-17	Strep throat;
CESC	cis	rs6503863	1	rs6503863	chr17:56517034	G/A	cg12560992	chr17:57184187	TRIM37	0.62	8.43	0.46	2.28e-15	Intelligence (multi-trait analysis);
CESC	cis	rs4523957	0.570	rs2126202	chr17:2095712	G/T	cg16513277	chr17:2031491	SMG6	0.41	5.54	0.32	7.31e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs9443189	0.570	rs523465	chr6:76330434	G/C	cg01950844	chr6:76311363	SENP6	0.87	9.29	0.5	6.04e-18	Prostate cancer;
CESC	cis	rs12541635	0.653	rs7014265	chr8:107026412	G/A	cg10147462	chr8:107024639	NA	0.42	6.25	0.36	1.65e-9	Age of smoking initiation;
CESC	cis	rs27434	0.583	rs34762	chr5:96153966	A/G	cg16492584	chr5:96139282	ERAP1	-0.38	-5.54	-0.32	7.47e-8	Ankylosing spondylitis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02576610	chr16:75657395	ADAT1	-0.59	-6.98	-0.39	2.34e-11	Gut microbiome composition (summer);
CESC	cis	rs7584330	0.518	rs80282956	chr2:238447929	G/A	cg14458575	chr2:238380390	NA	0.67	6.2	0.36	2.14e-9	Prostate cancer;
CESC	cis	rs1878931	0.696	rs35984213	chr16:3451030	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	1.07	17.87	0.74	2.07e-47	Body mass index (adult);
CESC	cis	rs1775715	0.678	rs2105360	chr10:32210198	C/T	cg04359828	chr10:32216031	ARHGAP12	0.35	5.04	0.3	8.57e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs6088813	1.000	rs6142379	chr20:33999267	A/G	cg14752227	chr20:34000481	UQCC	-0.39	-5.06	-0.3	7.88e-7	Height;
CESC	cis	rs7100689	0.754	rs10736339	chr10:82059970	G/C	cg00277334	chr10:82204260	NA	-0.58	-7.37	-0.41	2.2e-12	Post bronchodilator FEV1;
CESC	cis	rs9916302	0.904	rs8076546	chr17:37555403	G/A	cg07936489	chr17:37558343	FBXL20	0.79	11.49	0.58	4.71e-25	Glomerular filtration rate (creatinine);
CESC	cis	rs2204008	0.583	rs12820907	chr12:37990931	T/C	cg13010199	chr12:38710504	ALG10B	0.46	5.68	0.33	3.46e-8	Bladder cancer;
CESC	cis	rs2180341	0.711	rs4371861	chr6:127568447	G/T	cg24812749	chr6:127587940	RNF146	0.67	9.64	0.51	4.63e-19	Breast cancer;
CESC	trans	rs61931739	0.534	rs7133262	chr12:34279444	G/A	cg26384229	chr12:38710491	ALG10B	0.64	9.21	0.49	1.01e-17	Morning vs. evening chronotype;
CESC	cis	rs6938	0.534	rs11072512	chr15:75204026	C/T	cg09165964	chr15:75287851	SCAMP5	0.45	6.09	0.35	3.99e-9	Breast cancer;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg00568128	chr10:115934100	MIR2110;C10orf118	-0.42	-6.03	-0.35	5.38e-9	Gambling;
CESC	cis	rs116095464	0.558	rs1971229	chr5:268187	A/G	cg22496380	chr5:211416	CCDC127	-0.74	-8.46	-0.46	1.86e-15	Breast cancer;
CESC	cis	rs10504229	0.511	rs75967910	chr8:58024231	C/G	cg05313129	chr8:58192883	C8orf71	-0.5	-5.05	-0.3	8.06e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs68170813	0.559	rs58319984	chr7:106965794	G/A	cg02696742	chr7:106810147	HBP1	-0.54	-5.17	-0.3	4.66e-7	Coronary artery disease;
CESC	cis	rs9303280	0.806	rs10445308	chr17:37938047	C/T	cg19468946	chr17:37922297	IKZF3	-0.41	-5.66	-0.33	3.9e-8	Self-reported allergy;
CESC	cis	rs796364	0.906	rs1658810	chr2:200816382	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.85	8.35	0.46	3.96e-15	Schizophrenia;
CESC	cis	rs12042938	1.000	rs4366301	chr1:231806286	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.46	-6.39	-0.37	7.31e-10	Neuranatomic and neurocognitive phenotypes;
CESC	cis	rs4900538	0.963	rs4906205	chr14:102932447	A/G	cg18135206	chr14:102964638	TECPR2	0.78	10.53	0.54	7.1e-22	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg16143763	chr17:41116517	AARSD1	-0.5	-6.06	-0.35	4.76e-9	Ulcerative colitis;
CESC	cis	rs7208859	0.623	rs73269988	chr17:29118145	G/A	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.79e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs1552244	1.000	rs17032278	chr3:10077955	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.78	-10.37	-0.54	2.25e-21	Alzheimer's disease;
CESC	cis	rs698813	0.674	rs4952707	chr2:44500683	G/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.46	5.13	0.3	5.66e-7	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
CESC	cis	rs34779708	0.931	rs1926556	chr10:35344907	T/C	cg04310649	chr10:35416472	CREM	-0.49	-5.87	-0.34	1.31e-8	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs11997175	0.646	rs55898196	chr8:33765862	A/G	ch.8.33884649F	chr8:33765107	NA	0.55	6.93	0.39	3.17e-11	Body mass index;
CESC	cis	rs11249608	0.548	rs13156530	chr5:178475017	C/T	cg21905437	chr5:178450457	ZNF879	0.55	7.58	0.42	6e-13	Pubertal anthropometrics;
CESC	cis	rs7208859	0.673	rs11654914	chr17:29229424	C/G	cg19761014	chr17:28927070	LRRC37B2	0.64	5.32	0.31	2.2e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	trans	rs61931739	0.500	rs11053198	chr12:34444013	G/C	cg26384229	chr12:38710491	ALG10B	0.54	7.5	0.42	9.79e-13	Morning vs. evening chronotype;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16324876	chr22:36424481	RBM9	0.62	7.34	0.41	2.61e-12	Gut microbiome composition (summer);
CESC	cis	rs11608355	0.545	rs9943724	chr12:109902903	G/A	cg05360138	chr12:110035743	NA	0.82	8.92	0.48	7.83e-17	Neuroticism;
CESC	cis	rs6942756	1.000	rs12111832	chr7:128889025	G/C	cg02491457	chr7:128862824	NA	-0.69	-9.82	-0.52	1.29e-19	White matter hyperintensity burden;
CESC	cis	rs9314323	0.767	rs1865305	chr8:26233325	G/A	cg11498726	chr8:26250323	BNIP3L	-0.44	-6.36	-0.36	8.62e-10	Red cell distribution width;
CESC	cis	rs4604732	0.527	rs7539082	chr1:247627260	T/C	cg12758973	chr1:247694275	LOC148824;OR2C3	0.51	6.37	0.36	8.49e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs9549260	0.755	rs8001443	chr13:41216646	C/T	cg21288729	chr13:41239152	FOXO1	-0.69	-8.87	-0.48	1.08e-16	Red blood cell count;
CESC	cis	rs748404	0.560	rs529611	chr15:43805988	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.49	7.29	0.41	3.47e-12	Lung cancer;
CESC	cis	rs4974559	0.501	rs900013	chr4:1240450	G/A	cg02980000	chr4:1222292	CTBP1	-0.76	-7.88	-0.44	8.61e-14	Systolic blood pressure;
CESC	cis	rs6963495	0.769	rs11556986	chr7:105177041	A/T	cg19920283	chr7:105172520	RINT1	0.76	7.88	0.44	8.75e-14	Bipolar disorder (body mass index interaction);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg02955050	chr19:59070391	UBE2M;LOC100131691	-0.51	-7.27	-0.41	4.16e-12	Fibrinogen levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01933576	chr16:15083564	PDXDC1	-0.61	-6.79	-0.38	7.51e-11	Gut microbiome composition (summer);
CESC	trans	rs2018683	0.770	rs10951208	chr7:29022504	G/T	cg19402173	chr7:128379420	CALU	-0.6	-7.48	-0.42	1.13e-12	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CESC	cis	rs2576037	0.526	rs4890699	chr18:44541029	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.43	7.08	0.4	1.26e-11	Personality dimensions;
CESC	cis	rs9815354	1.000	rs1613759	chr3:41906183	G/A	cg03022575	chr3:42003672	ULK4	0.44	5.16	0.3	4.85e-7	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs7336332	0.800	rs9805452	chr13:28047908	C/T	cg01674679	chr13:27998804	GTF3A	-0.46	-5.05	-0.3	8.37e-7	Weight;
CESC	cis	rs9611565	0.512	rs1983576	chr22:42166486	G/A	cg06634786	chr22:41940651	POLR3H	0.68	6.78	0.38	7.6e-11	Vitiligo;
CESC	cis	rs875971	1.000	rs10215948	chr7:65747786	G/A	cg12463550	chr7:65579703	CRCP	-0.52	-6.76	-0.38	8.97e-11	Aortic root size;
CESC	cis	rs12142240	0.698	rs67941619	chr1:46838219	A/G	cg00530320	chr1:46809349	NSUN4	0.6	7.92	0.44	6.39e-14	Menopause (age at onset);
CESC	cis	rs853679	0.550	rs1150689	chr6:28165099	T/C	cg19592336	chr6:28129416	ZNF389	0.51	6.88	0.39	4.26e-11	Depression;
CESC	cis	rs731174	0.959	rs7546741	chr1:38191397	G/C	cg06917450	chr1:38156652	C1orf109	-0.44	-5.45	-0.32	1.17e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs55823223	0.564	rs936391	chr17:73847799	A/G	cg02397686	chr17:73851076	WBP2	-0.48	-6.44	-0.37	5.54e-10	Psoriasis;
CESC	cis	rs250677	1.000	rs36079	chr5:148430504	G/A	cg18129178	chr5:148520854	ABLIM3	-0.45	-5.31	-0.31	2.31e-7	Breast cancer;
CESC	trans	rs1814175	0.645	rs7952104	chr11:49964180	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.43	-6.26	-0.36	1.53e-9	Height;
CESC	cis	rs4862750	0.872	rs6811837	chr4:187898162	G/A	cg03452623	chr4:187889614	NA	-0.88	-16.31	-0.71	7.08e-42	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs13102973	0.640	rs4864245	chr4:135882847	G/C	cg14419869	chr4:135874104	NA	-0.35	-5.03	-0.3	8.86e-7	Subjective well-being;
CESC	cis	rs4588572	0.570	rs2362832	chr5:77795843	A/G	cg11547950	chr5:77652471	NA	-0.45	-5.72	-0.33	2.92e-8	Triglycerides;
CESC	trans	rs629535	0.783	rs538832	chr8:70033817	A/G	cg21567404	chr3:27674614	NA	0.93	11.25	0.57	2.83e-24	Dupuytren's disease;
CESC	cis	rs798554	0.796	rs2158694	chr7:2863443	T/G	cg18446336	chr7:2847575	GNA12	-0.34	-5.08	-0.3	7.23e-7	Height;
CESC	cis	rs2279817	0.820	rs924686	chr1:18027726	C/A	cg21791023	chr1:18019539	ARHGEF10L	0.55	8.03	0.44	3.12e-14	Neuroticism;
CESC	cis	rs2576037	0.523	rs1539881	chr18:44477897	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.78	13.14	0.63	1.06e-30	Personality dimensions;
CESC	cis	rs875971	0.862	rs10276077	chr7:65728411	A/G	cg11764359	chr7:65958608	NA	-0.79	-11.87	-0.59	2.42e-26	Aortic root size;
CESC	cis	rs6957923	0.655	rs13241000	chr7:23588135	A/G	cg20265043	chr7:23510089	IGF2BP3	0.41	5.12	0.3	5.83e-7	Height;
CESC	cis	rs12530845	0.623	rs73721669	chr7:135347107	C/G	cg23117316	chr7:135346802	PL-5283	-0.59	-6.4	-0.37	6.93e-10	Red blood cell traits;
CESC	cis	rs1322639	0.614	rs6925188	chr6:169563337	T/C	cg03254818	chr6:169586852	NA	0.5	5.32	0.31	2.2e-7	Pulse pressure;
CESC	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg06873352	chr17:61820015	STRADA	-0.66	-11.43	-0.57	7.58e-25	Prudent dietary pattern;
CESC	cis	rs7236492	0.683	rs79747802	chr18:77198964	C/T	cg15644404	chr18:77186268	NFATC1	-0.69	-5.4	-0.31	1.49e-7	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs4808199	1.000	rs12972397	chr19:19562349	G/A	cg03709012	chr19:19516395	GATAD2A	1.13	13.2	0.63	6.29e-31	Nonalcoholic fatty liver disease;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg13265914	chr8:21999630	REEP4	-0.46	-6.72	-0.38	1.14e-10	Gambling;
CESC	cis	rs4665809	1.000	rs10048683	chr2:26320519	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.69	-7.9	-0.44	7.36e-14	Gut microbiome composition (summer);
CESC	cis	rs9488822	0.636	rs6937104	chr6:116375302	A/G	cg26893134	chr6:116381904	FRK	0.25	6.16	0.35	2.67e-9	Cholesterol, total;LDL cholesterol;
CESC	cis	rs6912958	0.874	rs9294381	chr6:88152681	A/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.33	-5.36	-0.31	1.81e-7	Monocyte percentage of white cells;
CESC	cis	rs1538970	0.962	rs7544178	chr1:45819069	C/T	cg06784218	chr1:46089804	CCDC17	0.31	5.16	0.3	4.94e-7	Platelet count;
CESC	cis	rs10504229	1.000	rs67895971	chr8:58177994	A/G	cg24829409	chr8:58192753	C8orf71	-0.76	-10.0	-0.52	3.53e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs40363	0.672	rs1617722	chr16:3520806	C/T	cg21433313	chr16:3507492	NAT15	-0.48	-7.66	-0.43	3.51e-13	Tuberculosis;
CESC	cis	rs4555082	0.915	rs79048296	chr14:105754944	G/A	cg27165867	chr14:105738592	BRF1	-0.49	-5.22	-0.31	3.63e-7	Mean platelet volume;Platelet distribution width;
CESC	cis	rs12477438	0.765	rs10181422	chr2:99558970	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.63	-8.84	-0.48	1.33e-16	Chronic sinus infection;
CESC	cis	rs7949030	0.504	rs2516633	chr11:62371773	A/C	cg22862634	chr11:62369728	EML3;MTA2	-0.43	-5.72	-0.33	2.94e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs6121246	0.954	rs6060989	chr20:30429763	C/T	cg13852791	chr20:30311386	BCL2L1	0.75	7.48	0.42	1.09e-12	Mean corpuscular hemoglobin;
CESC	cis	rs796364	0.806	rs79333757	chr2:200915716	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.84	-7.75	-0.43	1.94e-13	Schizophrenia;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg15650240	chr1:15736530	EFHD2	-0.47	-6.14	-0.35	2.93e-9	Ulcerative colitis;
CESC	cis	rs801193	0.569	rs13242290	chr7:66121885	G/A	cg18876405	chr7:65276391	NA	-0.45	-6.2	-0.36	2.15e-9	Aortic root size;
CESC	cis	rs2735413	0.846	rs12923290	chr16:78079956	A/G	cg04733911	chr16:78082701	NA	-0.53	-9.05	-0.49	3.19e-17	Systolic blood pressure (alcohol consumption interaction);
CESC	cis	rs11792861	0.888	rs57314245	chr9:111813832	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.52	7.02	0.4	1.89e-11	Menarche (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03216991	chr17:2415620	METT10D	0.58	6.16	0.35	2.68e-9	Gut microbiome composition (summer);
CESC	cis	rs34172651	0.517	rs874484	chr16:24803242	T/C	cg02428538	chr16:24856791	SLC5A11	-0.6	-6.15	-0.35	2.78e-9	Intelligence (multi-trait analysis);
CESC	cis	rs7618915	0.547	rs6768697	chr3:52703615	C/T	cg18404041	chr3:52824283	ITIH1	-0.4	-6.73	-0.38	1.07e-10	Bipolar disorder;
CESC	cis	rs2635047	0.811	rs17723754	chr18:44771481	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.45	6.0	0.35	6.34e-9	Educational attainment;
CESC	trans	rs3812049	0.826	rs34576922	chr5:127364103	C/G	cg16011800	chr17:1958478	HIC1	0.53	6.17	0.35	2.55e-9	Lymphocyte counts;Red cell distribution width;
CESC	cis	rs1799949	1.000	rs8074136	chr17:41342313	A/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.62	8.38	0.46	3.1e-15	Menopause (age at onset);
CESC	cis	rs6582630	0.599	rs12824838	chr12:38373584	G/T	cg26384229	chr12:38710491	ALG10B	-0.49	-6.77	-0.38	8.39e-11	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs875971	0.522	rs34973832	chr7:65396204	A/G	cg11987759	chr7:65425863	GUSB	-0.47	-6.42	-0.37	6.18e-10	Aortic root size;
CESC	cis	rs8141529	0.748	rs5762882	chr22:29290680	C/A	cg15103426	chr22:29168792	CCDC117	0.6	7.75	0.43	1.97e-13	Lymphocyte counts;
CESC	cis	rs959260	0.765	rs12945469	chr17:73372243	G/A	cg12999837	chr17:73267436	MIF4GD	-0.51	-5.78	-0.33	2.1e-8	Systemic lupus erythematosus;
CESC	cis	rs7223966	1.000	rs56383601	chr17:61929968	A/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.47	-5.35	-0.31	1.9e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs763014	0.865	rs4006748	chr16:632225	T/C	cg09263875	chr16:632152	PIGQ	0.67	11.24	0.57	3.15e-24	Height;
CESC	cis	rs798554	0.660	rs2644295	chr7:2860217	A/C	cg13628971	chr7:2884303	GNA12	0.4	5.35	0.31	1.87e-7	Height;
CESC	cis	rs2880765	0.566	rs17553790	chr15:86013665	C/T	cg10818794	chr15:86012489	AKAP13	0.38	5.25	0.31	3.2e-7	Coronary artery disease;
CESC	cis	rs1215050	0.791	rs165252	chr4:98758728	A/C	cg05340658	chr4:99064831	C4orf37	0.51	6.64	0.38	1.8e-10	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs1552244	1.000	rs55822690	chr3:10128003	A/G	cg16606324	chr3:10149918	C3orf24	0.42	5.19	0.3	4.26e-7	Alzheimer's disease;
CESC	cis	rs1448094	0.512	rs60986162	chr12:86247054	T/G	cg02569458	chr12:86230093	RASSF9	0.49	7.27	0.41	3.98e-12	Major depressive disorder;
CESC	cis	rs1034435	0.547	rs6008741	chr22:48897881	G/A	cg05992904	chr22:48892994	FAM19A5	-0.46	-6.61	-0.38	2.15e-10	Late-onset Alzheimer's disease;
CESC	cis	rs12142240	0.698	rs68083747	chr1:46807416	T/G	cg10495392	chr1:46806563	NSUN4	0.59	6.34	0.36	9.65e-10	Menopause (age at onset);
CESC	cis	rs9660992	0.512	rs12142402	chr1:205128215	A/T	cg00857998	chr1:205179979	DSTYK	0.56	7.14	0.4	9.03e-12	Mean corpuscular volume;Mean platelet volume;
CESC	trans	rs9929218	0.861	rs8056206	chr16:68802072	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.63	-8.45	-0.46	1.96e-15	Colorectal cancer;
CESC	cis	rs4812048	0.793	rs62205397	chr20:57597011	C/T	cg14073986	chr20:57617431	SLMO2	0.7	5.9	0.34	1.09e-8	Mean platelet volume;
CESC	cis	rs71403859	0.554	rs12920245	chr16:72029069	C/A	cg08717414	chr16:71523259	ZNF19	-0.75	-5.11	-0.3	6.23e-7	Post bronchodilator FEV1;
CESC	cis	rs4563143	0.647	rs34218744	chr19:29256821	A/T	cg14983838	chr19:29218262	NA	0.51	6.13	0.35	3.09e-9	Methadone dose in opioid dependence;
CESC	cis	rs453301	0.507	rs2929306	chr8:9084909	C/T	cg17143192	chr8:8559678	CLDN23	-0.47	-5.78	-0.33	2.13e-8	Joint mobility (Beighton score);
CESC	cis	rs17818399	0.547	rs4953400	chr2:46777208	T/A	cg06386533	chr2:46925753	SOCS5	0.44	5.1	0.3	6.54e-7	Height;
CESC	cis	rs763121	0.853	rs35565791	chr22:39063011	C/A	cg21395723	chr22:39101663	GTPBP1	0.43	5.39	0.31	1.58e-7	Menopause (age at onset);
CESC	cis	rs9513593	1.000	rs1964898	chr13:99997181	A/G	cg21788972	chr13:99853209	UBAC2	0.63	7.12	0.4	9.89e-12	Psoriasis;
CESC	cis	rs3740540	0.507	rs2362500	chr10:126290431	T/C	cg04949429	chr10:126290192	LHPP	0.39	5.46	0.32	1.11e-7	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
CESC	cis	rs290268	0.669	rs10448310	chr9:93556174	A/G	cg02608019	chr9:93564028	SYK	0.45	6.49	0.37	4.16e-10	Platelet count;
CESC	cis	rs12900413	0.687	rs12911126	chr15:90315380	T/C	cg24249390	chr15:90295951	MESP1	-0.39	-5.34	-0.31	1.99e-7	Coronary artery aneurysm in Kawasaki disease;
CESC	cis	rs9322193	0.962	rs9688809	chr6:150109056	C/T	cg05861140	chr6:150128134	PCMT1	-0.36	-5.14	-0.3	5.22e-7	Lung cancer;
CESC	cis	rs1882538	0.538	rs7783217	chr7:133104117	C/G	cg10665199	chr7:133106180	EXOC4	-0.57	-7.67	-0.43	3.21e-13	Intelligence (multi-trait analysis);
CESC	cis	rs10479542	0.892	rs7723230	chr5:178980474	T/C	cg09060608	chr5:178986726	RUFY1	0.51	7.79	0.43	1.5700000000000001e-13	Lung cancer;
CESC	cis	rs769267	0.965	rs8101938	chr19:19390497	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.42	5.38	0.31	1.66e-7	Tonsillectomy;
CESC	cis	rs3741798	0.614	rs61922044	chr12:12490914	G/A	cg08615371	chr12:12503544	MANSC1	0.94	6.58	0.37	2.54e-10	Cerebrospinal fluid biomarker levels;
CESC	cis	rs9486719	0.901	rs760619	chr6:96857431	A/G	cg06623918	chr6:96969491	KIAA0776	0.82	8.03	0.44	3.28e-14	Migraine;Coronary artery disease;
CESC	trans	rs1667255	0.830	rs2034404	chr18:29156302	A/G	cg17850538	chr15:35280322	ZNF770	0.51	6.48	0.37	4.33e-10	Retinol levels;
CESC	cis	rs6460942	0.908	rs73677570	chr7:12280329	T/C	cg06484146	chr7:12443880	VWDE	-0.54	-5.77	-0.33	2.26e-8	Coronary artery disease;
CESC	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.5	-5.28	-0.31	2.67e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2836974	0.666	rs35182074	chr21:40685284	A/C	cg11644478	chr21:40555479	PSMG1	-0.8	-11.96	-0.59	1.23e-26	Cognitive function;
CESC	cis	rs3741151	1.000	rs3741149	chr11:73021084	A/G	cg17517138	chr11:73019481	ARHGEF17	-0.59	-5.06	-0.3	7.67e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	trans	rs9850225	0.666	rs1438565	chr3:81030149	T/C	cg27138204	chr12:54446100	HOXC4	-0.37	-6.06	-0.35	4.76e-9	Erectile dysfunction in type 1 diabetes;
CESC	cis	rs2991971	0.967	rs2356551	chr1:46009318	C/T	cg24296786	chr1:45957014	TESK2	0.63	8.48	0.46	1.62e-15	High light scatter reticulocyte count;
CESC	cis	rs6089584	0.507	rs28545731	chr20:60634102	C/T	cg24733560	chr20:60626293	TAF4	0.45	6.63	0.38	1.83e-10	Body mass index;
CESC	cis	rs4689388	0.750	rs10755148	chr4:6295064	A/G	cg25554036	chr4:6271136	WFS1	0.48	6.96	0.39	2.6e-11	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs9325144	0.647	rs35254764	chr12:39102928	T/C	cg26384229	chr12:38710491	ALG10B	-0.5	-7.06	-0.4	1.47e-11	Morning vs. evening chronotype;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg21235025	chr13:72249355	DACH1	-0.48	-6.96	-0.39	2.66e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs11122272	0.603	rs2998427	chr1:231528112	A/G	cg06096015	chr1:231504339	EGLN1	0.43	6.15	0.35	2.79e-9	Hemoglobin concentration;
CESC	cis	rs7809950	0.954	rs2520247	chr7:107143946	A/T	cg23024343	chr7:107201750	COG5	-0.43	-6.08	-0.35	4.18e-9	Coronary artery disease;
CESC	cis	rs7605827	0.897	rs10432400	chr2:15667324	T/C	cg19274914	chr2:15703543	NA	0.33	5.76	0.33	2.28e-8	Educational attainment (years of education);
CESC	cis	rs10504229	0.683	rs57866073	chr8:58139138	A/G	cg24829409	chr8:58192753	C8orf71	-0.57	-6.89	-0.39	4.16e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs9640161	0.789	rs2373751	chr7:150021599	G/C	cg21361702	chr7:150065534	REPIN1	0.52	5.34	0.31	2.05e-7	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs12545109	0.800	rs1467126	chr8:57418452	C/T	cg09654669	chr8:57350985	NA	-0.45	-6.27	-0.36	1.47e-9	Obesity-related traits;
CESC	cis	rs2073300	0.609	rs6132617	chr20:23420151	G/C	cg16736954	chr20:23401023	NAPB	0.71	5.63	0.33	4.67e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs2228479	0.850	rs2238527	chr16:89840708	C/A	cg04013166	chr16:89971882	TCF25	0.78	6.69	0.38	1.3e-10	Skin colour saturation;
CESC	cis	rs4481887	0.927	rs4916087	chr1:248493833	T/C	cg00666640	chr1:248458726	OR2T12	0.36	6.17	0.35	2.56e-9	Common traits (Other);
CESC	cis	rs9311474	0.607	rs34005367	chr3:52558904	A/T	cg15147215	chr3:52552868	STAB1	-0.31	-5.24	-0.31	3.27e-7	Electroencephalogram traits;
CESC	cis	rs2180341	1.000	rs7776136	chr6:127638348	A/T	cg24812749	chr6:127587940	RNF146	1.08	15.58	0.69	2.77e-39	Breast cancer;
CESC	trans	rs1814175	0.817	rs3974439	chr11:50022607	G/A	cg03929089	chr4:120376271	NA	-0.94	-16.01	-0.7	7.75e-41	Height;
CESC	cis	rs9309473	0.528	rs6546820	chr2:73553397	G/A	cg20560298	chr2:73613845	ALMS1	-0.46	-6.39	-0.37	7.54e-10	Metabolite levels;
CESC	cis	rs9309473	0.583	rs6713196	chr2:73576405	T/C	cg20560298	chr2:73613845	ALMS1	-0.44	-5.97	-0.34	7.66e-9	Metabolite levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10626718	chr8:67687371	SGK3	0.56	6.13	0.35	3.13e-9	Gut microbiome composition (summer);
CESC	cis	rs10504229	0.683	rs1495866	chr8:58141128	T/C	cg24829409	chr8:58192753	C8orf71	-0.59	-7.31	-0.41	3.16e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs7666738	0.753	rs28390295	chr4:99028497	C/A	cg17366294	chr4:99064904	C4orf37	0.62	8.95	0.48	6.32e-17	Colonoscopy-negative controls vs population controls;
CESC	cis	rs55788414	0.932	rs12103358	chr16:81185844	C/G	cg06400318	chr16:81190750	PKD1L2	-0.5	-6.08	-0.35	4.16e-9	Left ventricular obstructive tract defect (maternal effect);
CESC	cis	rs4319547	0.695	rs10773103	chr12:122856532	A/G	cg05707623	chr12:122985044	ZCCHC8	0.56	6.3	0.36	1.2e-9	Body mass index;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27432331	chr16:30544242	ZNF747	-0.57	-6.41	-0.37	6.62e-10	Gut microbiome composition (summer);
CESC	cis	rs8070624	0.543	rs7219320	chr17:17880877	A/G	cg16928487	chr17:17741425	SREBF1	-0.61	-10.21	-0.53	7.35e-21	Total body bone mineral density;
CESC	cis	rs8111998	0.702	rs16999400	chr19:22768608	A/G	cg19914732	chr19:22715077	NA	-0.37	-5.18	-0.3	4.45e-7	Corneal structure;
CESC	cis	rs561341	0.714	rs55925849	chr17:30253085	C/T	cg19193384	chr17:30244184	NA	-0.7	-6.41	-0.37	6.77e-10	Hip circumference adjusted for BMI;
CESC	cis	rs804280	0.565	rs1466785	chr8:11623456	C/T	cg12395012	chr8:11607386	GATA4	-0.45	-6.38	-0.36	7.96e-10	Myopia (pathological);
CESC	cis	rs4721295	0.573	rs3779000	chr7:2181628	G/A	cg08027265	chr7:2291960	NA	-0.48	-7.45	-0.42	1.31e-12	Schizophrenia, schizoaffective disorder or bipolar disorder;
CESC	cis	rs116095464	0.510	rs60844864	chr5:267000	A/G	cg22496380	chr5:211416	CCDC127	-0.74	-8.35	-0.46	3.92e-15	Breast cancer;
CESC	trans	rs11098499	0.863	rs11731756	chr4:120478696	T/G	cg25214090	chr10:38739885	LOC399744	0.66	9.03	0.49	3.57e-17	Corneal astigmatism;
CESC	cis	rs4969178	0.965	rs12450528	chr17:76395753	G/A	cg05887092	chr17:76393375	PGS1	0.58	9.22	0.49	9.9e-18	HDL cholesterol levels;
CESC	cis	rs1538970	0.924	rs1007858	chr1:45912005	C/T	cg24296786	chr1:45957014	TESK2	-0.46	-5.25	-0.31	3.14e-7	Platelet count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17727855	chr9:108007124	SLC44A1	0.61	6.56	0.37	2.82e-10	Gut microbiome composition (summer);
CESC	cis	rs11997175	0.603	rs12156112	chr8:33791598	T/C	ch.8.33884649F	chr8:33765107	NA	0.47	5.55	0.32	6.87e-8	Body mass index;
CESC	cis	rs8017423	0.967	rs2401875	chr14:90688451	A/G	cg14092571	chr14:90743983	NA	-0.56	-8.24	-0.45	7.77e-15	Mortality in heart failure;
CESC	cis	rs727505	0.954	rs67870530	chr7:124591878	A/G	cg23710748	chr7:124431027	NA	-0.46	-7.28	-0.41	3.87e-12	Lewy body disease;
CESC	cis	rs752010	0.756	rs6600380	chr1:42054814	C/T	cg06885757	chr1:42089581	HIVEP3	-0.41	-6.68	-0.38	1.44e-10	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs9649213	0.537	rs35997266	chr7:97965566	T/C	cg21770322	chr7:97807741	LMTK2	0.57	8.71	0.47	3.45e-16	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7178572	0.539	rs12594346	chr15:77671966	A/T	cg22256960	chr15:77711686	NA	0.48	5.39	0.31	1.53e-7	Type 2 diabetes;
CESC	cis	rs61931739	0.500	rs11053251	chr12:34520743	A/G	cg06521331	chr12:34319734	NA	-0.37	-5.09	-0.3	6.85e-7	Morning vs. evening chronotype;
CESC	cis	rs9926296	0.605	rs1800287	chr16:89858525	C/G	cg21285383	chr16:89894308	SPIRE2	0.31	5.6	0.33	5.34e-8	Vitiligo;
CESC	cis	rs13191362	1.000	rs67487119	chr6:163102657	A/C	cg21926612	chr6:163149169	PACRG;PARK2	1.07	10.98	0.56	2.38e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs11785400	0.793	rs4587307	chr8:143738529	G/A	cg24634471	chr8:143751801	JRK	0.46	5.91	0.34	1.06e-8	Schizophrenia;
CESC	cis	rs7618915	0.547	rs62253700	chr3:52625019	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.48	6.81	0.39	6.45e-11	Bipolar disorder;
CESC	cis	rs7084402	0.565	rs1982173	chr10:60334002	G/T	cg07615347	chr10:60278583	BICC1	0.41	6.0	0.35	6.44e-9	Refractive error;
CESC	cis	rs7084402	1.000	rs12257983	chr10:60266555	A/C	cg07615347	chr10:60278583	BICC1	-0.58	-8.92	-0.48	8.11e-17	Refractive error;
CESC	trans	rs877282	0.945	rs10904554	chr10:786768	T/C	cg22713356	chr15:30763199	NA	1.31	13.31	0.63	2.78e-31	Uric acid levels;
CESC	cis	rs6570726	0.791	rs447992	chr6:145817184	C/T	cg23711669	chr6:146136114	FBXO30	1.02	16.0	0.7	8.93e-41	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs12545109	0.879	rs7845180	chr8:57324431	C/T	cg09654669	chr8:57350985	NA	0.51	6.3	0.36	1.21e-9	Obesity-related traits;
CESC	cis	rs2072499	1.000	rs2540173	chr1:156188214	A/G	cg25208724	chr1:156163844	SLC25A44	0.99	17.59	0.73	2.02e-46	Testicular germ cell tumor;
CESC	cis	rs1799949	1.000	rs33945274	chr17:41280073	G/A	cg05368731	chr17:41323189	NBR1	0.8	11.32	0.57	1.66e-24	Menopause (age at onset);
CESC	cis	rs9487051	0.698	rs35849756	chr6:109644610	G/A	cg01475377	chr6:109611718	NA	-0.39	-5.14	-0.3	5.41e-7	Reticulocyte fraction of red cells;
CESC	cis	rs2439831	0.681	rs1095386	chr15:43609509	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.86	12.9	0.62	7.3e-30	Lung cancer in ever smokers;
CESC	cis	rs9362426	1.000	rs173334	chr6:88080223	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.48	6.04	0.35	5.08e-9	Depressive episodes in bipolar disorder;
CESC	cis	rs875971	0.861	rs801215	chr7:66011938	A/T	cg11764359	chr7:65958608	NA	-0.79	-11.32	-0.57	1.67e-24	Aortic root size;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg06231882	chr16:81040594	CENPN;C16orf61	-0.44	-6.09	-0.35	3.89e-9	Gambling;
CESC	trans	rs1814175	0.717	rs11040450	chr11:49650638	G/A	cg03929089	chr4:120376271	NA	-0.87	-13.23	-0.63	4.97e-31	Height;
CESC	cis	rs11587400	0.572	rs2268699	chr1:115227896	G/T	cg12756093	chr1:115239321	AMPD1	0.52	7.36	0.41	2.38e-12	Autism;
CESC	cis	rs514406	0.825	rs9661082	chr1:53245472	A/T	cg16325326	chr1:53192061	ZYG11B	-0.88	-15.06	-0.68	1.8e-37	Monocyte count;
CESC	cis	rs9302635	0.745	rs35909200	chr16:72156666	T/G	cg01557791	chr16:72042693	DHODH	-0.6	-5.46	-0.32	1.09e-7	Blood protein levels;
CESC	cis	rs2742234	0.955	rs2075913	chr10:43622368	T/A	cg07801480	chr10:43725741	RASGEF1A	0.38	5.49	0.32	9.27e-8	Hirschsprung disease;
CESC	cis	rs965513	0.627	rs7848973	chr9:100588839	A/G	cg13688889	chr9:100608707	NA	-0.52	-7.72	-0.43	2.46e-13	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
CESC	cis	rs798554	0.686	rs2644298	chr7:2858448	G/C	cg19717773	chr7:2847554	GNA12	-0.52	-8.18	-0.45	1.22e-14	Height;
CESC	cis	rs8013055	0.846	rs10136015	chr14:105973469	A/C	cg23356831	chr14:105996513	TMEM121	0.37	5.14	0.3	5.23e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
CESC	cis	rs477692	1.000	rs558764	chr10:131426957	G/T	cg05714579	chr10:131428358	MGMT	-0.47	-6.44	-0.37	5.63e-10	Response to temozolomide;
CESC	cis	rs10504229	0.953	rs114853497	chr8:58176176	A/T	cg05313129	chr8:58192883	C8orf71	-0.55	-6.37	-0.36	8.42e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs61931739	0.736	rs7314457	chr12:34454301	G/A	cg19457237	chr12:34500585	NA	-0.35	-5.15	-0.3	5.05e-7	Morning vs. evening chronotype;
CESC	cis	rs2228479	0.850	rs11645240	chr16:89837326	T/C	cg06558623	chr16:89946397	TCF25	1.17	9.29	0.5	5.84e-18	Skin colour saturation;
CESC	cis	rs9486715	0.867	rs4839842	chr6:96955387	A/T	cg18709589	chr6:96969512	KIAA0776	0.46	6.48	0.37	4.41e-10	Headache;
CESC	cis	rs5758659	1.000	rs134900	chr22:42683343	C/G	cg04733989	chr22:42467013	NAGA	0.42	5.98	0.34	7.15e-9	Cognitive function;
CESC	cis	rs2976388	0.578	rs3736010	chr8:143817503	T/C	cg24634471	chr8:143751801	JRK	-0.47	-5.14	-0.3	5.47e-7	Urinary tract infection frequency;
CESC	cis	rs1862618	0.853	rs252915	chr5:56121754	C/T	cg22800045	chr5:56110881	MAP3K1	-0.82	-10.17	-0.53	9.98e-21	Initial pursuit acceleration;
CESC	cis	rs372883	0.600	rs407712	chr21:30722531	G/A	cg24692254	chr21:30365293	RNF160	-0.59	-7.4	-0.41	1.75e-12	Pancreatic cancer;
CESC	cis	rs4862750	0.872	rs7664463	chr4:187876686	A/C	cg27532560	chr4:187881888	NA	-0.36	-5.46	-0.32	1.09e-7	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6912958	0.703	rs6903219	chr6:88096498	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	0.33	5.35	0.31	1.88e-7	Monocyte percentage of white cells;
CESC	cis	rs9902453	0.704	rs2617874	chr17:28085172	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.65	8.18	0.45	1.22e-14	Coffee consumption (cups per day);
CESC	cis	rs7666738	0.830	rs1559859	chr4:99024325	C/T	cg05340658	chr4:99064831	C4orf37	0.83	12.91	0.62	6.62e-30	Colonoscopy-negative controls vs population controls;
CESC	trans	rs208520	0.661	rs207111	chr6:66792513	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.0	-12.83	-0.62	1.2e-29	Exhaled nitric oxide output;
CESC	cis	rs8017423	0.967	rs7160032	chr14:90708472	A/G	cg14092571	chr14:90743983	NA	-0.56	-8.31	-0.45	4.95e-15	Mortality in heart failure;
CESC	cis	rs6860806	0.661	rs4705927	chr5:131578608	C/G	cg04518342	chr5:131593106	PDLIM4	0.4	5.96	0.34	8.2e-9	Breast cancer;
CESC	cis	rs2842992	0.789	rs2277072	chr6:160182845	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.71	8.4	0.46	2.77e-15	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs10479542	0.642	rs6879665	chr5:178974581	T/A	cg26516362	chr5:178986906	RUFY1	0.41	6.02	0.35	5.78e-9	Lung cancer;
CESC	cis	rs4805272	0.512	rs8105613	chr19:29339151	C/T	cg12756686	chr19:29218302	NA	0.41	5.36	0.31	1.78e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
CESC	cis	rs2688608	0.592	rs12253482	chr10:75496130	G/A	cg23231163	chr10:75533350	FUT11	-0.36	-5.53	-0.32	7.68e-8	Inflammatory bowel disease;
CESC	cis	rs10911251	0.528	rs4652777	chr1:183091992	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.89	14.39	0.66	4.39e-35	Colorectal cancer;
CESC	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.89	13.59	0.64	2.72e-32	Prudent dietary pattern;
CESC	cis	rs561341	0.943	rs508566	chr17:30289861	G/C	cg19193384	chr17:30244184	NA	-0.72	-6.61	-0.38	2.11e-10	Hip circumference adjusted for BMI;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg04251662	chr3:4535075	ITPR1	-0.48	-6.14	-0.35	2.92e-9	Asthma;
CESC	cis	rs2404602	0.716	rs17364076	chr15:76760891	C/T	cg22467129	chr15:76604101	ETFA	-0.39	-6.03	-0.35	5.57e-9	Blood metabolite levels;
CESC	cis	rs140364877	1	rs140364877	chr7:1885178	C/T	cg22963979	chr7:1858916	MAD1L1	-0.37	-5.06	-0.3	7.72e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs72634258	0.519	rs4908713	chr1:7946831	G/A	cg00042356	chr1:8021962	PARK7	0.57	5.27	0.31	2.84e-7	Inflammatory bowel disease;
CESC	cis	rs2455799	0.573	rs2654650	chr3:15779214	C/T	cg09340198	chr3:15902540	ANKRD28	-0.33	-5.16	-0.3	4.81e-7	Mean platelet volume;
CESC	cis	rs965469	1.000	rs2236118	chr20:3302058	C/T	cg25506879	chr20:3388711	C20orf194	-0.55	-5.9	-0.34	1.08e-8	IFN-related cytopenia;
CESC	cis	rs1799949	0.965	rs4793230	chr17:41427403	A/C	cg07153921	chr17:41440717	NA	-0.4	-5.29	-0.31	2.58e-7	Menopause (age at onset);
CESC	cis	rs12995491	0.731	rs17435433	chr2:88509616	A/G	cg18490616	chr2:88469792	THNSL2	-0.52	-7.61	-0.42	4.92e-13	Response to metformin (IC50);
CESC	cis	rs4563143	0.514	rs55727361	chr19:29300415	A/T	cg04546413	chr19:29218101	NA	0.48	5.97	0.34	7.4e-9	Methadone dose in opioid dependence;
CESC	cis	rs8050907	0.744	rs7195782	chr16:4539861	C/T	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.89	6.22	0.36	1.94e-9	Obesity-related traits;
CESC	cis	rs9915657	0.840	rs10512582	chr17:70139393	A/C	cg06234051	chr17:70120541	SOX9	-0.44	-6.65	-0.38	1.67e-10	Thyroid hormone levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06361278	chr17:25783929	NA	0.53	6.19	0.36	2.27e-9	Gut microbiome composition (summer);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg26354882	chr1:167691290	MPZL1	-0.48	-6.11	-0.35	3.51e-9	Ulcerative colitis;
CESC	cis	rs10028773	0.700	rs7690338	chr4:120256468	C/G	cg09307838	chr4:120376055	NA	0.81	10.94	0.56	3.14e-23	Educational attainment;
CESC	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg26338869	chr17:61819248	STRADA	0.71	9.63	0.51	5.01e-19	Prudent dietary pattern;
CESC	cis	rs992157	0.835	rs12987180	chr2:219144089	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.67	-8.69	-0.47	3.72e-16	Colorectal cancer;
CESC	cis	rs10870270	0.956	rs10781555	chr10:133745720	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.86	-12.61	-0.61	6.93e-29	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs67311347	1.000	rs9829800	chr3:40443927	T/C	cg09455208	chr3:40491958	NA	0.46	7.71	0.43	2.48e-13	Renal cell carcinoma;
CESC	cis	rs1707322	0.752	rs6658700	chr1:46160260	C/T	cg03146154	chr1:46216737	IPP	0.82	11.53	0.58	3.39e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs6952808	0.531	rs3779003	chr7:2184902	C/T	cg21782813	chr7:2030301	MAD1L1	0.49	6.99	0.39	2.26e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs8070128	0.583	rs7406982	chr17:17942613	C/T	cg16928487	chr17:17741425	SREBF1	-0.55	-9.13	-0.49	1.86e-17	Total body bone mineral density;
CESC	cis	rs9910055	0.762	rs2240226	chr17:42266218	C/T	cg13607699	chr17:42295918	UBTF	0.62	8.37	0.46	3.46e-15	Total body bone mineral density;
CESC	cis	rs12368653	0.840	rs3816896	chr12:58195773	C/T	cg00677455	chr12:58241039	CTDSP2	-0.47	-6.24	-0.36	1.71e-9	Multiple sclerosis;
CESC	cis	rs977987	0.800	rs12922951	chr16:75355096	C/G	cg03315344	chr16:75512273	CHST6	0.39	5.59	0.32	5.55e-8	Dupuytren's disease;
CESC	cis	rs4332037	0.624	rs73046339	chr7:1889300	G/A	cg13880726	chr7:1868755	MAD1L1	-0.48	-5.08	-0.3	7.17e-7	Bipolar disorder;
CESC	cis	rs7044106	0.762	rs10984974	chr9:123421556	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.36	5.77	0.33	2.18e-8	Hip circumference adjusted for BMI;
CESC	cis	rs4680	0.737	rs4646312	chr22:19948337	C/T	cg23601416	chr22:19950040	COMT	0.27	5.09	0.3	6.85e-7	Blood metabolite levels;
CESC	trans	rs9858542	0.953	rs9827021	chr3:49514764	C/A	cg21659725	chr3:3221576	CRBN	-0.54	-6.37	-0.36	8.2e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs9322193	0.886	rs12525871	chr6:150097018	A/G	cg04369109	chr6:150039330	LATS1	-0.4	-5.34	-0.31	2e-7	Lung cancer;
CESC	cis	rs9467711	0.659	rs35555795	chr6:26509382	C/T	cg21479132	chr6:26055353	NA	0.78	5.36	0.31	1.84e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs7786877	0.582	rs2075674	chr7:100225031	G/A	cg16850897	chr7:100343110	ZAN	-0.62	-6.63	-0.38	1.9e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg23679085	chr3:183892773	AP2M1	-0.47	-6.83	-0.39	5.91e-11	Gambling;
CESC	cis	rs1799949	0.930	rs3765640	chr17:41276247	A/G	cg23758822	chr17:41437982	NA	1.02	15.6	0.69	2.35e-39	Menopause (age at onset);
CESC	cis	rs7666738	0.546	rs7699578	chr4:98838893	T/C	cg17366294	chr4:99064904	C4orf37	0.5	5.35	0.31	1.87e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3858526	0.959	rs4758219	chr11:5951846	G/C	cg05234568	chr11:5960015	NA	-0.63	-7.53	-0.42	8.12e-13	DNA methylation (variation);
CESC	cis	rs7727544	0.660	rs272886	chr5:131665840	T/C	cg07395648	chr5:131743802	NA	-0.5	-6.56	-0.37	2.8e-10	Blood metabolite levels;
CESC	cis	rs8114671	0.562	rs1013677	chr20:33468793	C/T	cg06115741	chr20:33292138	TP53INP2	0.43	5.46	0.32	1.11e-7	Height;
CESC	cis	rs6963495	0.818	rs73192105	chr7:105167945	T/C	cg13798780	chr7:105162888	PUS7	0.77	7.87	0.44	9.18e-14	Bipolar disorder (body mass index interaction);
CESC	cis	rs4595586	0.545	rs12812762	chr12:39371141	T/C	cg26384229	chr12:38710491	ALG10B	0.53	7.51	0.42	8.86e-13	Morning vs. evening chronotype;
CESC	cis	rs4665809	0.590	rs2303892	chr2:26461733	C/G	cg25036284	chr2:26402008	FAM59B	0.86	9.36	0.5	3.44e-18	Gut microbiome composition (summer);
CESC	cis	rs2836950	0.545	rs2836952	chr21:40616651	G/C	cg11890956	chr21:40555474	PSMG1	-0.61	-8.41	-0.46	2.6e-15	Menarche (age at onset);
CESC	cis	rs2455799	0.573	rs2455831	chr3:15751583	T/A	cg16303742	chr3:15540471	COLQ	-0.35	-5.38	-0.31	1.61e-7	Mean platelet volume;
CESC	cis	rs2204008	0.806	rs1589382	chr12:38408565	T/A	cg13010199	chr12:38710504	ALG10B	0.46	5.98	0.35	7.04e-9	Bladder cancer;
CESC	cis	rs9329289	0.926	rs9329290	chr10:2542751	G/T	cg15501526	chr10:2543763	NA	0.65	11.89	0.59	2.1e-26	Age-related hearing impairment;
CESC	cis	rs7917772	0.636	rs7088981	chr10:104520423	T/C	cg04362960	chr10:104952993	NT5C2	0.46	5.27	0.31	2.86e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs8078723	1.000	rs6503530	chr17:38161823	T/C	cg17467752	chr17:38218738	THRA	0.69	10.55	0.54	5.78e-22	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CESC	cis	rs11153306	0.677	rs10872070	chr6:111921804	T/C	cg22127309	chr6:111907043	TRAF3IP2	-0.4	-5.8	-0.34	1.91e-8	Tonsillectomy;
CESC	cis	rs6121246	0.779	rs6060763	chr20:30282223	A/G	cg13852791	chr20:30311386	BCL2L1	0.76	8.37	0.46	3.36e-15	Mean corpuscular hemoglobin;
CESC	cis	rs804280	0.525	rs17153755	chr8:11611500	C/G	cg12395012	chr8:11607386	GATA4	-0.48	-7.13	-0.4	9.84e-12	Myopia (pathological);
CESC	cis	rs863345	0.604	rs12122663	chr1:158506724	A/G	cg12129480	chr1:158549410	OR10X1	-0.34	-6.82	-0.39	6.1e-11	Pneumococcal bacteremia;
CESC	cis	rs7618501	0.722	rs9853458	chr3:49783211	A/C	cg24308560	chr3:49941425	MST1R	0.49	6.74	0.38	9.66e-11	Intelligence (multi-trait analysis);
CESC	cis	rs7786808	0.712	rs2335170	chr7:158207101	G/A	cg01191920	chr7:158217561	PTPRN2	-0.36	-5.92	-0.34	9.94e-9	Obesity-related traits;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg15813570	chr14:64854563	MTHFD1	0.47	6.24	0.36	1.72e-9	Gut microbiota (bacterial taxa);
CESC	trans	rs9325144	0.555	rs10748433	chr12:38696352	C/G	cg23762105	chr12:34175262	ALG10	-0.49	-6.56	-0.37	2.76e-10	Morning vs. evening chronotype;
CESC	cis	rs7312933	1.000	rs7312933	chr12:42503467	C/T	cg01256987	chr12:42539512	GXYLT1	0.34	5.09	0.3	6.78e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs57083693	0.518	rs6538982	chr12:101708103	T/C	cg22051763	chr12:101673672	UTP20	-0.42	-5.28	-0.31	2.68e-7	Alcohol dependence (age at onset);
CESC	cis	rs6570726	0.935	rs391820	chr6:145821284	C/T	cg05347473	chr6:146136440	FBXO30	0.42	5.72	0.33	2.93e-8	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6142102	0.602	rs1054534	chr20:32605327	G/C	cg08999081	chr20:33150536	PIGU	0.33	5.05	0.3	8.33e-7	Skin pigmentation;
CESC	cis	rs4588572	0.673	rs9293745	chr5:77646075	G/A	cg11547950	chr5:77652471	NA	-0.4	-5.77	-0.33	2.19e-8	Triglycerides;
CESC	cis	rs9287719	0.967	rs2010073	chr2:10736478	C/T	cg02196655	chr2:10830764	NOL10	-0.37	-5.72	-0.33	2.87e-8	Prostate cancer;
CESC	cis	rs7474896	0.526	rs1208633	chr10:38156873	A/C	cg25427524	chr10:38739819	LOC399744	0.51	5.87	0.34	1.3e-8	Obesity (extreme);
CESC	cis	rs8077577	0.689	rs16961114	chr17:18215339	G/C	cg16794390	chr17:18148240	FLII	0.41	6.48	0.37	4.41e-10	Obesity-related traits;
CESC	cis	rs262150	0.659	rs2657340	chr7:158796968	C/T	cg19418458	chr7:158789849	NA	0.48	7.8	0.43	1.42e-13	Facial morphology (factor 20);
CESC	cis	rs854765	0.583	rs11650649	chr17:17790319	C/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.53	-7.27	-0.41	4.14e-12	Total body bone mineral density;
CESC	cis	rs2832191	0.935	rs67287920	chr21:30523519	C/A	cg08807101	chr21:30365312	RNF160	-0.68	-9.43	-0.5	2.23e-18	Dental caries;
CESC	trans	rs12356475	0.710	rs10822686	chr10:67733250	C/T	cg04917391	chr4:40859259	APBB2	0.55	6.43	0.37	5.83e-10	Psoriatic arthritis;
CESC	cis	rs9303401	0.659	rs9303399	chr17:56672309	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.04	12.9	0.62	6.96e-30	Cognitive test performance;
CESC	trans	rs208520	1.000	rs12190316	chr6:66973365	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.7	7.86	0.43	9.45e-14	Exhaled nitric oxide output;
CESC	cis	rs1448094	0.511	rs7967183	chr12:86216845	T/G	cg02569458	chr12:86230093	RASSF9	0.45	6.7	0.38	1.27e-10	Major depressive disorder;
CESC	cis	rs7666738	0.830	rs28622458	chr4:98916651	A/G	cg03676636	chr4:99064102	C4orf37	0.35	5.2	0.3	3.93e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7772486	0.790	rs2265469	chr6:146219049	T/C	cg23711669	chr6:146136114	FBXO30	0.92	13.36	0.63	1.78e-31	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs524023	1.000	rs559946	chr11:64358605	T/C	cg07220939	chr11:64358617	SLC22A12	0.36	5.54	0.32	7.2e-8	Urate levels in obese individuals;
CESC	cis	rs9787249	0.957	rs56064244	chr1:40213890	C/T	cg24920358	chr1:40204285	PPIE	0.43	6.4	0.37	7.07e-10	Blood protein levels;
CESC	cis	rs57244997	1.000	rs73026573	chr6:162405119	C/T	cg17173639	chr6:162384350	PARK2	-0.79	-7.93	-0.44	5.96e-14	Mosquito bite size;
CESC	cis	rs644799	0.623	rs17207890	chr11:95490754	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.54	6.56	0.37	2.78e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs17376456	0.877	rs9314093	chr5:93333347	G/A	cg21475434	chr5:93447410	FAM172A	0.78	6.94	0.39	3.03e-11	Diabetic retinopathy;
CESC	trans	rs1476587	0.920	rs55657695	chr7:86734709	G/T	cg09114546	chr16:70099078	PDXDC2	0.59	6.12	0.35	3.41e-9	Brachial circumference;
CESC	cis	rs924607	0.583	rs12516251	chr5:608939	C/T	cg07001201	chr5:642380	CEP72	0.55	7.75	0.43	2e-13	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs9814567	1.000	rs9989967	chr3:134238964	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.43	-5.82	-0.34	1.69e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs73206853	0.563	rs4073472	chr12:111176494	A/G	cg12870014	chr12:110450643	ANKRD13A	0.73	5.39	0.31	1.53e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs12142240	0.731	rs6658556	chr1:46844180	A/C	cg00530320	chr1:46809349	NSUN4	0.62	8.36	0.46	3.52e-15	Menopause (age at onset);
CESC	cis	rs6952808	0.792	rs11771973	chr7:1950440	C/G	cg08027265	chr7:2291960	NA	-0.34	-5.17	-0.3	4.57e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs9733	0.536	rs6661415	chr1:150635869	G/A	cg09365446	chr1:150670422	GOLPH3L	0.42	5.93	0.34	9.63e-9	Tonsillectomy;
CESC	cis	rs12893668	0.572	rs1606	chr14:104161281	G/A	cg24130564	chr14:104152367	KLC1	-0.49	-6.53	-0.37	3.28e-10	Reticulocyte count;
CESC	cis	rs4819052	0.851	rs2838840	chr21:46668494	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.93	13.67	0.64	1.5e-32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs9393777	0.513	rs9379893	chr6:26584668	A/G	cg12292205	chr6:26970375	C6orf41	0.45	5.12	0.3	5.92e-7	Intelligence (multi-trait analysis);
CESC	cis	rs3733585	0.699	rs6856127	chr4:9965443	T/C	cg00071950	chr4:10020882	SLC2A9	-0.73	-11.79	-0.59	4.66e-26	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs6952808	0.929	rs11768206	chr7:1932151	T/G	cg05863683	chr7:1912471	MAD1L1	0.5	7.71	0.43	2.62e-13	Bipolar disorder and schizophrenia;
CESC	cis	rs875971	1.000	rs1182882	chr7:65562063	C/T	cg11764359	chr7:65958608	NA	-0.94	-14.21	-0.66	1.83e-34	Aortic root size;
CESC	cis	rs11792861	0.781	rs838835	chr9:111758590	A/G	cg05043794	chr9:111880884	C9orf5	0.37	6.32	0.36	1.08e-9	Menarche (age at onset);
CESC	cis	rs6461049	0.646	rs3778970	chr7:2143208	C/A	cg21782813	chr7:2030301	MAD1L1	0.49	6.98	0.39	2.31e-11	Schizophrenia;
CESC	cis	rs7429990	0.901	rs7433678	chr3:48037078	G/A	cg11946769	chr3:48343235	NME6	-0.43	-5.22	-0.31	3.62e-7	Educational attainment (years of education);
CESC	cis	rs2439831	0.717	rs9806227	chr15:43680115	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.86	13.04	0.63	2.26e-30	Lung cancer in ever smokers;
CESC	cis	rs9291683	0.546	rs10939672	chr4:10052136	A/G	cg11266682	chr4:10021025	SLC2A9	0.65	12.92	0.62	5.96e-30	Bone mineral density;
CESC	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg26338869	chr17:61819248	STRADA	0.69	9.18	0.49	1.31e-17	Prudent dietary pattern;
CESC	cis	rs11098499	0.863	rs3775841	chr4:120425777	A/C	cg09307838	chr4:120376055	NA	0.95	13.0	0.62	3.29e-30	Corneal astigmatism;
CESC	cis	rs939658	0.805	rs34478496	chr15:79440997	C/A	cg17916960	chr15:79447300	NA	-0.35	-5.98	-0.34	7.25e-9	Refractive error;
CESC	cis	rs3820068	0.581	rs72645879	chr1:15928199	A/G	cg16988262	chr1:15930761	NA	0.35	5.65	0.33	4.18e-8	Systolic blood pressure;
CESC	cis	rs4808199	0.649	rs34755166	chr19:19665581	G/A	cg03709012	chr19:19516395	GATAD2A	0.98	8.36	0.46	3.61e-15	Nonalcoholic fatty liver disease;
CESC	cis	rs763014	0.931	rs56048717	chr16:634867	A/G	cg07343612	chr16:622815	PIGQ	-0.55	-8.06	-0.44	2.55e-14	Height;
CESC	trans	rs10506458	0.834	rs58821476	chr12:63389425	T/C	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.33	-17.85	-0.74	2.4e-47	Hemostatic factors and hematological phenotypes;
CESC	cis	rs854765	0.964	rs854762	chr17:18009102	G/A	cg16928487	chr17:17741425	SREBF1	0.58	9.6	0.51	6.17e-19	Total body bone mineral density;
CESC	cis	rs4953076	0.574	rs4953074	chr2:44464629	C/T	cg04920474	chr2:44395004	PPM1B	0.54	7.07	0.4	1.38e-11	Height;
CESC	cis	rs9287719	0.967	rs12464908	chr2:10761496	T/G	cg00105475	chr2:10696890	NA	0.38	5.37	0.31	1.7e-7	Prostate cancer;
CESC	cis	rs7666738	0.830	rs13106434	chr4:98991651	T/A	cg17366294	chr4:99064904	C4orf37	0.6	8.61	0.47	6.47e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6964587	0.869	rs10241720	chr7:91527367	G/T	cg17063962	chr7:91808500	NA	-0.54	-7.24	-0.41	4.76e-12	Breast cancer;
CESC	cis	rs4268898	0.662	rs72795824	chr2:24435837	T/C	cg08917208	chr2:24149416	ATAD2B	0.55	5.27	0.31	2.89e-7	Asthma;
CESC	cis	rs1799949	0.965	rs12947782	chr17:41279882	A/G	cg05368731	chr17:41323189	NBR1	0.8	11.32	0.57	1.66e-24	Menopause (age at onset);
CESC	cis	rs9787249	0.957	rs7547787	chr1:40220806	C/T	cg02773041	chr1:40204384	PPIE	0.52	7.3	0.41	3.29e-12	Blood protein levels;
CESC	cis	rs9790314	0.690	rs7617204	chr3:160821969	A/G	cg03342759	chr3:160939853	NMD3	-0.45	-5.9	-0.34	1.12e-8	Morning vs. evening chronotype;
CESC	cis	rs2404602	0.716	rs1946650	chr15:76848463	T/C	cg22467129	chr15:76604101	ETFA	-0.38	-5.67	-0.33	3.64e-8	Blood metabolite levels;
CESC	cis	rs863345	0.967	rs11264990	chr1:158469359	T/C	cg12129480	chr1:158549410	OR10X1	-0.31	-6.19	-0.36	2.34e-9	Pneumococcal bacteremia;
CESC	cis	rs75477785	1.000	rs77037440	chr1:209985136	C/T	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.92	6.04	0.35	5.06e-9	Cleft lip with or without cleft palate;
CESC	cis	rs561341	1.000	rs4795670	chr17:30244839	T/C	cg19193384	chr17:30244184	NA	-0.54	-5.93	-0.34	9.62e-9	Hip circumference adjusted for BMI;
CESC	cis	rs7568498	0.564	rs10490563	chr2:161914168	G/A	cg21518248	chr2:162101506	NA	-0.49	-5.34	-0.31	2.02e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg12909921	chr17:37558512	FBXL20	-0.46	-6.71	-0.38	1.17e-10	Gambling;
CESC	cis	rs3768617	0.811	rs12022720	chr1:183017223	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.65	8.79	0.48	1.91e-16	Fuchs's corneal dystrophy;
CESC	cis	rs10504229	1.000	rs59383954	chr8:58189689	G/A	cg24829409	chr8:58192753	C8orf71	-0.76	-9.93	-0.52	5.87e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs1670533	1.000	rs2045069	chr4:1052206	T/C	cg27284194	chr4:1044797	NA	0.45	5.62	0.33	4.91e-8	Recombination rate (females);
CESC	cis	rs514406	0.505	rs6703127	chr1:53180565	C/T	cg24675658	chr1:53192096	ZYG11B	-0.49	-6.16	-0.35	2.67e-9	Monocyte count;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg11814422	chr18:47018265	SNORD58A;RPL17;SNORD58B	-0.46	-6.25	-0.36	1.66e-9	Height;
CESC	cis	rs7584330	0.826	rs72620824	chr2:238381083	G/A	cg14458575	chr2:238380390	NA	0.92	13.16	0.63	8.78e-31	Prostate cancer;
CESC	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg24739457	chr1:205821442	NA	-0.45	-6.32	-0.36	1.09e-9	Monocyte percentage of white cells;
CESC	cis	rs2404602	0.692	rs12594556	chr15:77165363	G/A	cg26408565	chr15:76604113	ETFA	-0.39	-5.68	-0.33	3.63e-8	Blood metabolite levels;
CESC	cis	rs7937682	0.855	rs527078	chr11:111479713	T/C	cg09085632	chr11:111637200	PPP2R1B	-0.92	-14.19	-0.66	2.29e-34	Primary sclerosing cholangitis;
CESC	cis	rs72781680	1.000	rs56339200	chr2:24188194	C/A	cg08917208	chr2:24149416	ATAD2B	0.94	8.54	0.46	1.09e-15	Lymphocyte counts;
CESC	cis	rs7666738	0.783	rs10028584	chr4:98962404	C/T	cg18180107	chr4:99064573	C4orf37	0.39	5.04	0.3	8.7e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3106136	0.967	rs282448	chr4:95141411	T/G	cg11021082	chr4:95130006	SMARCAD1	-0.46	-7.01	-0.4	1.94e-11	Capecitabine sensitivity;
CESC	cis	rs875971	0.862	rs13226170	chr7:65999298	G/A	cg18876405	chr7:65276391	NA	0.53	7.28	0.41	3.9e-12	Aortic root size;
CESC	cis	rs853679	0.517	rs9393885	chr6:28050009	A/T	cg17949981	chr6:28129498	ZNF389	0.45	5.62	0.33	4.9e-8	Depression;
CESC	trans	rs561341	0.609	rs7214626	chr17:30190989	G/A	cg20587970	chr11:113659929	NA	0.57	6.96	0.39	2.65e-11	Hip circumference adjusted for BMI;
CESC	cis	rs453301	0.686	rs11785819	chr8:8870378	T/G	cg15556689	chr8:8085844	FLJ10661	-0.48	-5.71	-0.33	2.97e-8	Joint mobility (Beighton score);
CESC	cis	rs7084402	0.967	rs1649036	chr10:60331878	C/A	cg07615347	chr10:60278583	BICC1	0.59	9.15	0.49	1.57e-17	Refractive error;
CESC	cis	rs698813	0.851	rs786420	chr2:44719893	C/T	cg04920474	chr2:44395004	PPM1B	0.4	5.09	0.3	6.83e-7	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
CESC	cis	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg21782813	chr7:2030301	MAD1L1	-0.36	-5.26	-0.31	2.92e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs829883	0.573	rs73136486	chr12:98913727	T/A	cg25150519	chr12:98850993	NA	-0.65	-7.95	-0.44	5.42e-14	Colorectal adenoma (advanced);
CESC	cis	rs4253772	0.530	rs9615955	chr22:46743931	A/G	cg24881330	chr22:46731750	TRMU	0.8	5.61	0.33	5.02e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs9325144	0.647	rs35138700	chr12:38804474	C/T	cg26384229	chr12:38710491	ALG10B	-0.53	-7.5	-0.42	9.73e-13	Morning vs. evening chronotype;
CESC	cis	rs7666738	0.830	rs1405767	chr4:98965295	T/C	cg17366294	chr4:99064904	C4orf37	0.6	8.52	0.46	1.2e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7246657	0.525	rs997516	chr19:37474264	T/C	cg23950597	chr19:37808831	NA	-0.51	-5.05	-0.3	8.18e-7	Coronary artery calcification;
CESC	cis	rs7020830	0.861	rs13295981	chr9:37330067	C/T	cg14294708	chr9:37120828	ZCCHC7	1.25	24.44	0.83	7.55e-70	Schizophrenia;
CESC	cis	rs769267	0.930	rs1063966	chr19:19616742	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.48	6.05	0.35	4.83e-9	Tonsillectomy;
CESC	cis	rs875971	0.862	rs2024192	chr7:66041447	G/T	cg19163074	chr7:65112434	INTS4L2	0.42	5.25	0.31	3.16e-7	Aortic root size;
CESC	cis	rs9640161	0.659	rs17837498	chr7:150009679	A/G	cg21361702	chr7:150065534	REPIN1	0.54	6.29	0.36	1.3e-9	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs7312933	1.000	rs12372623	chr12:42531666	G/A	cg01256987	chr12:42539512	GXYLT1	-0.33	-5.11	-0.3	6.22e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs1451375	0.572	rs4948205	chr7:50557774	G/A	cg14593290	chr7:50529359	DDC	-0.5	-6.27	-0.36	1.47e-9	Malaria;
CESC	cis	rs7084402	0.935	rs2393449	chr10:60343030	A/G	cg07615347	chr10:60278583	BICC1	0.56	8.67	0.47	4.26e-16	Refractive error;
CESC	cis	rs1799949	1.000	rs11651341	chr17:41428061	T/C	cg06001716	chr17:41278141	BRCA1;NBR2	0.41	5.62	0.33	4.72e-8	Menopause (age at onset);
CESC	cis	rs4728302	0.869	rs10155909	chr7:133593036	A/G	cg10665199	chr7:133106180	EXOC4	0.38	5.33	0.31	2.05e-7	Intelligence;Intelligence (multi-trait analysis);
CESC	cis	rs7937	0.693	rs2279011	chr19:41269288	G/T	cg09128733	chr19:41633906	CYP2F1	-0.36	-5.15	-0.3	5.04e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Chronic obstructive pulmonary disease;Emphysema imaging phenotypes;
CESC	cis	rs854765	0.547	rs2955383	chr17:17941364	A/G	cg16928487	chr17:17741425	SREBF1	-0.57	-9.8	-0.52	1.45e-19	Total body bone mineral density;
CESC	cis	rs6952808	0.929	rs12532128	chr7:1925454	T/C	cg04267008	chr7:1944627	MAD1L1	-0.71	-9.09	-0.49	2.4e-17	Bipolar disorder and schizophrenia;
CESC	cis	rs7412746	0.658	rs12097963	chr1:150870450	T/C	cg17724175	chr1:150552817	MCL1	0.38	5.96	0.34	8.07e-9	Melanoma;
CESC	cis	rs634534	0.562	rs1151505	chr11:65734539	C/T	cg04055107	chr11:65626734	MUS81;CFL1	0.44	5.59	0.32	5.77e-8	Sum eosinophil basophil counts;Eosinophil counts;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10229899	chr1:49364797	AGBL4	-0.53	-6.39	-0.37	7.44e-10	Gut microbiome composition (summer);
CESC	cis	rs2576037	0.583	rs616900	chr18:44410849	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.78	13.13	0.63	1.09e-30	Personality dimensions;
CESC	trans	rs1814175	0.817	rs28594987	chr11:50045181	C/T	cg15704280	chr7:45808275	SEPT13	-1.05	-20.97	-0.79	3.22e-58	Height;
CESC	cis	rs6963495	0.818	rs73192143	chr7:105202415	A/G	cg02135003	chr7:105160482	PUS7	-0.48	-5.66	-0.33	3.95e-8	Bipolar disorder (body mass index interaction);
CESC	cis	rs3857067	1.000	rs1509943	chr4:95013366	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.52	-8.04	-0.44	3.04e-14	QT interval;
CESC	cis	rs4853012	0.838	rs60964317	chr2:74343423	A/T	cg20891558	chr2:74357851	NA	0.78	11.16	0.57	5.72e-24	Gestational age at birth (maternal effect);
CESC	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg07677032	chr17:61819896	STRADA	0.45	5.95	0.34	8.68e-9	Prudent dietary pattern;
CESC	cis	rs6762	0.719	rs7936806	chr11:839186	G/C	cg23754390	chr11:835074	CD151	0.32	5.56	0.32	6.52e-8	Mean platelet volume;
CESC	cis	rs2074585	0.708	rs2589939	chr15:90930875	C/T	cg22089800	chr15:90895588	ZNF774	0.69	9.63	0.51	5.17e-19	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
CESC	cis	rs3008870	0.755	rs4655662	chr1:67416432	T/C	cg02640540	chr1:67518911	SLC35D1	0.46	5.56	0.32	6.52e-8	Lymphocyte percentage of white cells;
CESC	cis	rs13256369	0.802	rs11781257	chr8:8559663	A/T	cg17143192	chr8:8559678	CLDN23	0.78	8.72	0.47	3.13e-16	Obesity-related traits;
CESC	cis	rs4803468	0.967	rs4802116	chr19:41905540	C/T	cg09537434	chr19:41945824	ATP5SL	-1.02	-18.28	-0.75	7.49e-49	Height;
CESC	cis	rs7264396	0.537	rs6119628	chr20:34170174	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	0.47	6.22	0.36	1.98e-9	Total cholesterol levels;
CESC	cis	rs9457247	0.740	rs10946204	chr6:167451129	T/C	cg07741184	chr6:167504864	NA	0.36	6.48	0.37	4.57e-10	Crohn's disease;
CESC	cis	rs1953600	0.870	rs2573356	chr10:81949363	C/T	cg00277334	chr10:82204260	NA	0.45	6.28	0.36	1.4e-9	Sarcoidosis;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg19763735	chr2:170550826	C2orf77;PHOSPHO2;KLHL23	-0.5	-7.09	-0.4	1.25e-11	Gambling;
CESC	cis	rs16854884	0.683	rs10935505	chr3:143777966	T/C	cg06585982	chr3:143692056	C3orf58	0.49	6.36	0.36	8.82e-10	Economic and political preferences (feminism/equality);
CESC	cis	rs9660992	0.710	rs1768587	chr1:205236432	C/T	cg21643547	chr1:205240462	TMCC2	-0.47	-6.34	-0.36	1.01e-9	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs7208859	0.673	rs9894876	chr17:29182020	G/A	cg19761014	chr17:28927070	LRRC37B2	0.72	5.71	0.33	3.06e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs201673768	1	rs201673768	chr12:48699606	TGTTTTGTTTTG/T	cg04545296	chr12:48745243	ZNF641	0.28	5.12	0.3	5.92e-7	Platelet count;
CESC	cis	rs12369635	1.000	rs9645723	chr12:129554501	C/T	cg01909103	chr12:129572610	TMEM132D	-0.7	-6.01	-0.35	6.1e-9	Schizophrenia (inflammation and infection response interaction);
CESC	trans	rs7839040	0.698	rs7836583	chr8:82928643	G/T	cg14472086	chr9:107730925	NA	-0.47	-6.33	-0.36	1.02e-9	Response to methotrexate in juvenile idiopathic arthritis;
CESC	cis	rs4253772	0.678	rs1055659	chr22:46638298	C/T	cg24881330	chr22:46731750	TRMU	0.66	6.45	0.37	5.22e-10	LDL cholesterol;Cholesterol, total;
CESC	cis	rs7666738	0.830	rs2015828	chr4:98984594	A/G	cg03676636	chr4:99064102	C4orf37	0.35	5.37	0.31	1.73e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs831571	0.519	rs13059603	chr3:63827381	C/T	cg16258503	chr3:63850278	ATXN7;THOC7	0.65	7.71	0.43	2.5e-13	Type 2 diabetes;
CESC	cis	rs9311474	0.508	rs2878628	chr3:52584715	C/T	cg17372223	chr3:52568218	NT5DC2	-0.4	-5.97	-0.34	7.57e-9	Electroencephalogram traits;
CESC	cis	rs1506636	0.886	rs6466878	chr7:123272278	T/C	cg03229431	chr7:123269106	ASB15	-0.52	-6.88	-0.39	4.35e-11	Plateletcrit;Platelet count;
CESC	trans	rs7618501	1.000	rs3811696	chr3:49761605	C/T	cg21659725	chr3:3221576	CRBN	-0.83	-13.7	-0.64	1.17e-32	Intelligence (multi-trait analysis);
CESC	cis	rs1538970	1.000	rs4660853	chr1:45849090	C/T	cg06784218	chr1:46089804	CCDC17	0.34	5.76	0.33	2.36e-8	Platelet count;
CESC	cis	rs832540	0.931	rs832536	chr5:56212595	C/T	cg24531977	chr5:56204891	C5orf35	-0.44	-5.49	-0.32	9.32e-8	Coronary artery disease;
CESC	cis	rs722599	0.748	rs741096	chr14:75351487	A/G	cg08847533	chr14:75593920	NEK9	-0.45	-5.51	-0.32	8.52e-8	IgG glycosylation;
CESC	cis	rs9322193	0.962	rs17673294	chr6:150134993	G/A	cg07701084	chr6:150067640	NUP43	0.44	6.0	0.35	6.45e-9	Lung cancer;
CESC	cis	rs4975616	0.773	rs414965	chr5:1324121	G/A	cg06550200	chr5:1325588	CLPTM1L	-0.68	-10.36	-0.54	2.42e-21	Lung cancer;
CESC	cis	rs7843479	1.000	rs66824050	chr8:21815425	T/G	cg17168535	chr8:21777572	XPO7	0.46	6.27	0.36	1.47e-9	Mean corpuscular volume;
CESC	cis	rs6893300	0.542	rs3797774	chr5:179193970	C/T	cg14593053	chr5:179126677	CANX	0.55	8.17	0.45	1.24e-14	Resting heart rate;
CESC	cis	rs7264396	0.570	rs6060717	chr20:34544647	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.82	-11.49	-0.58	4.75e-25	Total cholesterol levels;
CESC	cis	rs56235845	0.796	rs13153019	chr5:176782218	T/C	cg06060754	chr5:176797920	RGS14	0.51	5.14	0.3	5.42e-7	Hemoglobin concentration;Hematocrit;
CESC	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg23708337	chr7:1209742	NA	0.53	5.34	0.31	1.98e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs3096299	0.933	rs889576	chr16:89429653	A/G	cg08822215	chr16:89438651	ANKRD11	0.38	5.73	0.33	2.73e-8	Multiple myeloma (IgH translocation);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11949866	chr1:10754891	CASZ1	0.51	6.33	0.36	1.02e-9	Gut microbiome composition (summer);
CESC	cis	rs959260	1.000	rs2117563	chr17:73368985	A/G	cg12999837	chr17:73267436	MIF4GD	-0.47	-5.5	-0.32	8.8e-8	Systemic lupus erythematosus;
CESC	cis	rs826838	0.967	rs1719854	chr12:39127707	G/A	cg13010199	chr12:38710504	ALG10B	-0.45	-6.26	-0.36	1.51e-9	Heart rate;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16249798	chr1:38325439	MTF1	0.53	6.09	0.35	3.96e-9	Gut microbiome composition (summer);
CESC	cis	rs6762	0.550	rs8672	chr11:838634	C/G	cg23754390	chr11:835074	CD151	0.31	5.59	0.32	5.74e-8	Mean platelet volume;
CESC	trans	rs1814175	0.529	rs10839396	chr11:49852406	G/T	cg03929089	chr4:120376271	NA	0.76	9.94	0.52	5.31e-20	Height;
CESC	cis	rs7726839	0.561	rs72703046	chr5:580129	T/C	cg16447950	chr5:562315	NA	-0.55	-6.2	-0.36	2.1e-9	Obesity-related traits;
CESC	cis	rs7044106	0.615	rs10818470	chr9:123359204	A/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.67	9.49	0.5	1.42e-18	Hip circumference adjusted for BMI;
CESC	cis	rs2439831	1.000	rs2584725	chr15:43793135	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.89	10.58	0.54	4.72e-22	Lung cancer in ever smokers;
CESC	cis	rs12497850	0.764	rs6784111	chr3:49178846	T/C	cg03060546	chr3:49711283	APEH	0.55	6.66	0.38	1.6e-10	Parkinson's disease;
CESC	cis	rs2635047	0.783	rs9948677	chr18:44790343	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.42	5.46	0.32	1.1e-7	Educational attainment;
CESC	cis	rs798554	1.000	rs798550	chr7:2760609	A/G	cg18446336	chr7:2847575	GNA12	-0.36	-5.59	-0.32	5.53e-8	Height;
CESC	cis	rs62064224	0.614	rs2286645	chr17:30696292	C/T	cg18200150	chr17:30822561	MYO1D	0.39	5.11	0.3	6.17e-7	Schizophrenia;
CESC	cis	rs748404	0.650	rs518261	chr15:43573429	A/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.53	8.3	0.45	5.45e-15	Lung cancer;
CESC	cis	rs17253792	0.822	rs75663029	chr14:56092385	T/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.79	5.91	0.34	1.06e-8	Putamen volume;
CESC	cis	rs35306767	0.903	rs12769873	chr10:936526	G/T	cg25019033	chr10:957182	NA	-0.58	-6.32	-0.36	1.1e-9	Eosinophil percentage of granulocytes;
CESC	cis	rs4780401	0.933	rs4584833	chr16:11798758	C/T	cg01061890	chr16:11836724	TXNDC11	-0.38	-5.07	-0.3	7.33e-7	Rheumatoid arthritis;
CESC	trans	rs11098499	0.605	rs6833140	chr4:120266822	G/A	cg25214090	chr10:38739885	LOC399744	0.59	7.99	0.44	4.13e-14	Corneal astigmatism;
CESC	cis	rs10865397	0.506	rs6546810	chr2:73389716	A/G	cg01422370	chr2:73384389	NA	0.46	7.31	0.41	3.08e-12	Intelligence (multi-trait analysis);
CESC	cis	rs7078219	1.000	rs7081330	chr10:101274465	A/G	cg09788492	chr10:101292477	NKX2-3	0.29	5.29	0.31	2.62e-7	Dental caries;
CESC	cis	rs3747547	1.000	rs11788065	chr9:37925826	G/C	cg13774184	chr9:37916125	SHB	-0.71	-5.94	-0.34	9.05e-9	Metabolite levels (Dihydroxy docosatrienoic acid);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg20930618	chr1:151162157	VPS72	0.45	6.07	0.35	4.47e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg13353311	chr5:59996240	DEPDC1B	-0.49	-6.99	-0.39	2.28e-11	Asthma;
CESC	cis	rs2425143	1.000	rs11167275	chr20:34340275	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.6	5.11	0.3	6.22e-7	Blood protein levels;
CESC	cis	rs12200560	0.505	rs1334321	chr6:97079571	C/T	cg06623918	chr6:96969491	KIAA0776	-0.45	-5.83	-0.34	1.57e-8	Coronary heart disease;
CESC	trans	rs748404	0.578	rs552701	chr15:43613810	T/C	cg24053811	chr14:70265306	SLC10A1	0.41	6.0	0.35	6.61e-9	Lung cancer;
CESC	cis	rs4969178	0.931	rs6501208	chr17:76395038	A/T	cg05887092	chr17:76393375	PGS1	0.57	9.02	0.48	4.04e-17	HDL cholesterol levels;
CESC	cis	rs1707322	0.721	rs6665808	chr1:46162283	C/T	cg03146154	chr1:46216737	IPP	0.76	10.9	0.56	4.26e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs916888	0.821	rs199513	chr17:44856932	A/G	cg17911788	chr17:44343683	NA	0.48	6.4	0.37	7.19e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs262150	0.574	rs2730273	chr7:158797754	A/C	cg19418458	chr7:158789849	NA	-0.5	-8.11	-0.45	1.83e-14	Facial morphology (factor 20);
CESC	cis	rs7312933	0.526	rs1669892	chr12:42811305	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.51	-6.75	-0.38	9.47e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs875971	0.862	rs1167390	chr7:65575893	G/A	cg12463550	chr7:65579703	CRCP	-0.52	-6.49	-0.37	4.08e-10	Aortic root size;
CESC	cis	rs9311474	0.581	rs4687626	chr3:52569098	G/A	cg18099408	chr3:52552593	STAB1	-0.38	-6.53	-0.37	3.4e-10	Electroencephalogram traits;
CESC	cis	rs1552244	0.935	rs35586456	chr3:10116938	A/G	cg16606324	chr3:10149918	C3orf24	0.42	5.09	0.3	6.72e-7	Alzheimer's disease;
CESC	cis	rs7674212	0.570	rs1031804	chr4:104066049	C/T	cg16532752	chr4:104119610	CENPE	-0.45	-6.18	-0.35	2.43e-9	Type 2 diabetes;
CESC	cis	rs3741151	0.773	rs58334887	chr11:73171510	A/C	cg17517138	chr11:73019481	ARHGEF17	0.97	7.21	0.4	5.99e-12	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs425277	1.000	rs809912	chr1:2078385	C/T	cg04315214	chr1:2043799	PRKCZ	-0.38	-5.3	-0.31	2.42e-7	Height;
CESC	cis	rs8070740	0.838	rs8072363	chr17:5335752	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.57	6.75	0.38	9.56e-11	Menopause (age at onset);
CESC	cis	rs34891900	0.507	rs12167823	chr22:18124362	G/A	cg19898043	chr22:18121309	BCL2L13	0.62	7.38	0.41	2.02e-12	Sum neutrophil eosinophil counts;
CESC	trans	rs7615952	0.599	rs6438955	chr3:125730333	C/A	cg07211511	chr3:129823064	LOC729375	-0.59	-7.14	-0.4	9.16e-12	Blood pressure (smoking interaction);
CESC	cis	rs4664293	0.764	rs1425044	chr2:160474937	C/T	cg08347373	chr2:160653686	CD302	-0.3	-5.19	-0.3	4.13e-7	Monocyte percentage of white cells;
CESC	cis	rs6502050	0.835	rs34620191	chr17:80149532	G/A	cg11859384	chr17:80120422	CCDC57	-0.38	-5.17	-0.3	4.56e-7	Life satisfaction;
CESC	cis	rs8067354	0.789	rs1292068	chr17:57929319	T/C	cg13753209	chr17:57696993	CLTC	0.51	7.06	0.4	1.44e-11	Hemoglobin concentration;
CESC	cis	rs6570726	0.599	rs455001	chr6:145854450	A/T	cg05347473	chr6:146136440	FBXO30	0.71	8.98	0.48	5.2e-17	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs460214	0.576	rs2836604	chr21:40041295	A/C	cg05519781	chr21:40033154	ERG	-0.49	-6.22	-0.36	1.96e-9	Response to cognitive-behavioural therapy in anxiety disorder;
CESC	cis	rs8077889	0.917	rs72836556	chr17:41911824	G/T	cg26893861	chr17:41843967	DUSP3	0.84	10.49	0.54	9.31e-22	Triglycerides;
CESC	cis	rs17376456	0.825	rs13182631	chr5:93115701	A/G	cg25358565	chr5:93447407	FAM172A	1.1	10.84	0.55	6.88e-23	Diabetic retinopathy;
CESC	trans	rs650950	0.528	rs646660	chr11:35528452	C/T	cg09315918	chr1:206137767	FAM72A	0.5	6.45	0.37	5.2e-10	Bronchopulmonary dysplasia;
CESC	cis	rs72634258	0.503	rs2794666	chr1:7822009	A/G	cg26816564	chr1:7831052	VAMP3	0.66	6.28	0.36	1.36e-9	Inflammatory bowel disease;
CESC	cis	rs933688	1.000	rs7720132	chr5:90745105	T/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.1	12.13	0.6	3.17e-27	Smoking behavior;
CESC	cis	rs7210086	0.808	rs72849443	chr17:70637437	G/A	cg04206342	chr17:70636940	NA	-0.35	-6.5	-0.37	3.91e-10	Ulcerative colitis;
CESC	cis	rs2072438	0.503	rs1323474	chr9:123852859	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.37	5.26	0.31	2.93e-7	Rheumatoid arthritis;
CESC	cis	rs1348850	0.914	rs12104588	chr2:178253675	G/A	cg22681709	chr2:178499509	PDE11A	-0.43	-6.29	-0.36	1.33e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs9443645	0.901	rs971994	chr6:79559602	G/C	cg05283184	chr6:79620031	NA	-0.42	-6.62	-0.38	1.93e-10	Intelligence (multi-trait analysis);
CESC	trans	rs12599106	0.625	rs12923277	chr16:34896261	G/A	cg03395511	chr6:291903	DUSP22	-0.7	-8.8	-0.48	1.81e-16	Menopause (age at onset);
CESC	cis	rs62064224	0.675	rs4795693	chr17:30636727	A/G	cg18200150	chr17:30822561	MYO1D	0.39	5.21	0.3	3.89e-7	Schizophrenia;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg13599271	chr3:58291905	RPP14	-0.46	-6.04	-0.35	5.25e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs7618915	0.571	rs11130307	chr3:52607682	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.47	6.59	0.38	2.33e-10	Bipolar disorder;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg09123307	chr7:6746650	ZNF12	-0.44	-6.05	-0.35	4.85e-9	Fibrinogen levels;
CESC	cis	rs709400	1.000	rs2403205	chr14:104143385	C/T	cg12935359	chr14:103987150	CKB	-0.45	-6.04	-0.35	5.3e-9	Body mass index;
CESC	cis	rs72781680	0.898	rs112985192	chr2:24102797	G/A	cg08917208	chr2:24149416	ATAD2B	0.94	8.68	0.47	4.03e-16	Lymphocyte counts;
CESC	cis	rs7617480	0.616	rs7429596	chr3:48808531	T/C	cg07636037	chr3:49044803	WDR6	0.8	10.82	0.55	7.48e-23	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CESC	cis	rs7605827	0.930	rs1035246	chr2:15512891	G/A	cg19274914	chr2:15703543	NA	0.31	5.51	0.32	8.7e-8	Educational attainment (years of education);
CESC	cis	rs34779708	0.966	rs10827491	chr10:35427395	G/A	cg04310649	chr10:35416472	CREM	-0.52	-6.45	-0.37	5.15e-10	Inflammatory bowel disease;Crohn's disease;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg19538699	chr3:112281021	SLC35A5;ATG3	0.52	6.81	0.39	6.71e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs4423214	0.798	rs1894100	chr11:71130343	G/T	cg05163923	chr11:71159392	DHCR7	-0.63	-7.19	-0.4	6.76e-12	Vitamin D levels;
CESC	cis	rs10089	1.000	rs17164310	chr5:127493679	A/G	cg19767477	chr5:127420684	SLC12A2	-0.38	-5.05	-0.3	8.14e-7	Ileal carcinoids;
CESC	cis	rs7582720	1.000	rs4510208	chr2:203734866	C/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.32	0.41	3.04e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg19230575	chr3:179041494	ZNF639	-0.39	-6.05	-0.35	4.79e-9	Gambling;
CESC	cis	rs7618915	0.501	rs7622694	chr3:52663882	G/A	cg05564831	chr3:52568323	NT5DC2	0.47	7.51	0.42	9.1e-13	Bipolar disorder;
CESC	cis	rs12701220	0.725	rs13242971	chr7:1055515	C/T	cg26769984	chr7:1090371	C7orf50	0.67	7.6	0.42	5.05e-13	Bronchopulmonary dysplasia;
CESC	cis	rs10206020	0.885	rs6746052	chr2:1576811	T/C	cg12573674	chr2:1569213	NA	-0.46	-5.2	-0.3	3.96e-7	IgG glycosylation;
CESC	cis	rs9311474	0.713	rs352169	chr3:52236762	C/T	cg07507251	chr3:52567010	NT5DC2	0.37	6.72	0.38	1.09e-10	Electroencephalogram traits;
CESC	cis	rs727505	1.000	rs10464529	chr7:124520308	G/A	cg23710748	chr7:124431027	NA	-0.48	-7.52	-0.42	8.73e-13	Lewy body disease;
CESC	cis	rs3008870	0.959	rs2985808	chr1:67367741	T/C	cg02640540	chr1:67518911	SLC35D1	0.5	5.33	0.31	2.11e-7	Lymphocyte percentage of white cells;
CESC	cis	rs763121	0.853	rs2072798	chr22:39148483	G/A	cg14440974	chr22:39074834	NA	-0.38	-5.25	-0.31	3.06e-7	Menopause (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11913790	chr5:154136136	LARP1	-0.72	-7.72	-0.43	2.33e-13	Gut microbiome composition (summer);
CESC	cis	rs116095464	0.558	rs10462754	chr5:246669	T/C	cg12570787	chr5:219185	SDHA;CCDC127	0.51	5.37	0.31	1.73e-7	Breast cancer;
CESC	cis	rs2625529	0.652	rs3759820	chr15:72300031	A/C	cg16672083	chr15:72433130	SENP8	0.44	6.72	0.38	1.09e-10	Red blood cell count;
CESC	cis	rs667920	0.512	rs13065626	chr3:136294757	C/G	cg15507776	chr3:136538369	TMEM22	-0.77	-6.78	-0.38	7.78e-11	Coronary artery disease;
CESC	cis	rs12500824	0.564	rs62300854	chr4:77280999	T/C	cg20311846	chr4:77356250	SHROOM3	0.37	6.88	0.39	4.32e-11	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21417675	chr7:128695180	LOC286016;TNPO3	-0.55	-6.25	-0.36	1.6e-9	Gut microbiome composition (summer);
CESC	cis	rs9911578	0.835	rs9904993	chr17:56468569	G/T	cg25039879	chr17:56429692	SUPT4H1	-0.39	-5.16	-0.3	4.81e-7	Intelligence (multi-trait analysis);
CESC	cis	rs870825	0.616	rs7680639	chr4:185652915	C/T	cg04058563	chr4:185651563	MLF1IP	-0.6	-6.93	-0.39	3.28e-11	Blood protein levels;
CESC	cis	rs2439831	1.000	rs2245908	chr15:43731454	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.88	10.28	0.53	4.37e-21	Lung cancer in ever smokers;
CESC	cis	rs2370759	1.000	rs11594963	chr10:32625736	G/A	cg01819863	chr10:32635814	EPC1	1.14	12.25	0.6	1.2100000000000001e-27	Sexual dysfunction (female);
CESC	cis	rs6088580	0.634	rs2184836	chr20:32963369	A/G	cg24642439	chr20:33292090	TP53INP2	-0.52	-6.9	-0.39	3.82e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	7.64	0.42	3.91e-13	Prudent dietary pattern;
CESC	cis	rs1215050	0.791	rs783969	chr4:98906504	C/T	cg05340658	chr4:99064831	C4orf37	0.46	5.93	0.34	9.58e-9	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs780096	0.526	rs75855890	chr2:27625005	G/T	cg02592271	chr2:27665507	KRTCAP3	-0.26	-5.07	-0.3	7.35e-7	Total body bone mineral density;
CESC	cis	rs4665809	0.590	rs10495756	chr2:26485586	A/G	cg26119090	chr2:26468346	HADHA;HADHB	1.11	12.84	0.62	1.1e-29	Gut microbiome composition (summer);
CESC	cis	rs7833790	0.700	rs28390260	chr8:82769175	A/T	cg17211192	chr8:82754475	SNX16	0.49	6.32	0.36	1.09e-9	Diastolic blood pressure;
CESC	cis	rs7659604	0.521	rs10001697	chr4:122677737	G/T	cg19671926	chr4:122722719	EXOSC9	0.53	6.7	0.38	1.21e-10	Type 2 diabetes;
CESC	cis	rs804292	1.000	rs804292	chr8:11643915	C/T	cg26752888	chr8:11627280	NEIL2	-0.95	-10.95	-0.56	2.91e-23	Alcohol dependence;Nicotine use;
CESC	cis	rs7084402	0.902	rs10763557	chr10:60341515	C/T	cg07615347	chr10:60278583	BICC1	0.57	8.79	0.47	1.98e-16	Refractive error;
CESC	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.48	-5.2	-0.3	4.05e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2836974	0.602	rs2836987	chr21:40706594	C/T	cg11644478	chr21:40555479	PSMG1	-0.79	-11.77	-0.59	5.07e-26	Cognitive function;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06481699	chr7:101458740	CUX1	0.57	6.71	0.38	1.16e-10	Gut microbiome composition (summer);
CESC	cis	rs11792861	0.781	rs874864	chr9:111728718	C/T	cg13535736	chr9:111863775	C9orf5	-0.42	-5.74	-0.33	2.62e-8	Menarche (age at onset);
CESC	cis	rs2635047	0.837	rs2571009	chr18:44650279	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.49	6.86	0.39	4.72e-11	Educational attainment;
CESC	cis	rs3747547	0.539	rs11791344	chr9:38125272	C/T	cg13774184	chr9:37916125	SHB	-0.67	-5.99	-0.35	6.95e-9	Metabolite levels (Dihydroxy docosatrienoic acid);
CESC	cis	rs853679	0.517	rs9295759	chr6:28124469	C/T	cg08968635	chr6:28129556	ZNF389	0.4	5.22	0.31	3.57e-7	Depression;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08655701	chr19:10363255	MRPL4	0.59	6.45	0.37	5.22e-10	Gut microbiome composition (summer);
CESC	cis	rs854765	0.964	rs2230316	chr17:17997209	C/T	cg16928487	chr17:17741425	SREBF1	0.55	8.72	0.47	3.08e-16	Total body bone mineral density;
CESC	cis	rs896854	0.653	rs13266313	chr8:95975302	C/T	cg09323728	chr8:95962352	TP53INP1	-0.4	-8.68	-0.47	4.05e-16	Type 2 diabetes;
CESC	cis	rs9457247	0.663	rs7749278	chr6:167435325	C/T	cg23791538	chr6:167370224	RNASET2	0.55	7.43	0.42	1.46e-12	Crohn's disease;
CESC	cis	rs7568458	0.709	rs56819945	chr2:85755139	C/T	cg02493740	chr2:85810744	VAMP5	-0.56	-8.34	-0.46	4.12e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CESC	cis	rs2288073	0.965	rs6545335	chr2:24422011	G/A	cg06627628	chr2:24431161	ITSN2	-0.78	-9.39	-0.5	2.93e-18	Venous thromboembolism (SNP x SNP interaction);
CESC	cis	rs6484504	0.576	rs2150213	chr11:31244634	A/G	cg14844989	chr11:31128820	NA	-0.43	-6.01	-0.35	6.1e-9	Red blood cell count;
CESC	cis	rs2204008	0.619	rs8189576	chr12:38307275	G/A	cg26384229	chr12:38710491	ALG10B	-0.44	-5.78	-0.33	2.1e-8	Bladder cancer;
CESC	cis	rs704795	0.836	rs1083865	chr2:27620827	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.34	-7.07	-0.4	1.39e-11	Menopause (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18483322	chr2:97523826	ANKRD39	0.54	6.52	0.37	3.63e-10	Gut microbiome composition (summer);
CESC	cis	rs514406	0.760	rs475969	chr1:53292607	T/A	cg24675658	chr1:53192096	ZYG11B	-0.68	-9.7	-0.51	3.13e-19	Monocyte count;
CESC	trans	rs2898290	0.500	rs11998678	chr8:11830150	A/G	cg15556689	chr8:8085844	FLJ10661	-0.66	-7.92	-0.44	6.62e-14	Systolic blood pressure;
CESC	cis	rs3820068	0.581	rs12385690	chr1:15932932	A/T	cg13390004	chr1:15929781	NA	0.34	5.45	0.32	1.14e-7	Systolic blood pressure;
CESC	cis	rs897984	0.683	rs12926237	chr16:30837596	C/T	cg00531865	chr16:30841666	NA	0.56	8.06	0.44	2.55e-14	Dementia with Lewy bodies;
CESC	cis	rs7923452	0.938	rs34560372	chr10:30773831	G/A	cg25182066	chr10:30743637	MAP3K8	0.47	5.21	0.31	3.73e-7	Itch intensity from mosquito bite;
CESC	cis	rs514406	0.929	rs1242224	chr1:53314887	G/A	cg24675658	chr1:53192096	ZYG11B	-0.6	-7.74	-0.43	2.06e-13	Monocyte count;
CESC	cis	rs734999	0.588	rs78506337	chr1:2537095	G/A	cg18854424	chr1:2615690	NA	0.28	5.51	0.32	8.66e-8	Ulcerative colitis;
CESC	cis	rs7618915	0.501	rs2289247	chr3:52727257	C/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.29	5.14	0.3	5.43e-7	Bipolar disorder;
CESC	cis	rs703842	1.000	rs10783847	chr12:58196447	G/A	cg00677455	chr12:58241039	CTDSP2	0.53	6.96	0.39	2.71e-11	Multiple sclerosis;
CESC	cis	rs4604732	0.536	rs76191272	chr1:247628055	A/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.53	6.57	0.37	2.7e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs7656342	0.636	rs4697902	chr4:9863936	T/C	cg11266682	chr4:10021025	SLC2A9	-0.35	-5.46	-0.32	1.08e-7	Gut microbiota (bacterial taxa);
CESC	cis	rs8002861	0.905	rs6561150	chr13:44460470	C/T	cg14210620	chr13:44453864	C13orf31;CCDC122	0.48	6.01	0.35	6.16e-9	Leprosy;
CESC	cis	rs2880765	0.566	rs55899824	chr15:86004091	C/T	cg19183879	chr15:85880815	NA	-0.31	-5.88	-0.34	1.2e-8	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12267883	chr13:30424914	UBL3	-0.62	-7.16	-0.4	7.86e-12	Gut microbiome composition (summer);
CESC	trans	rs1814175	0.791	rs9787917	chr11:49937281	C/T	cg15704280	chr7:45808275	SEPT13	-1.03	-21.21	-0.79	4.77e-59	Height;
CESC	trans	rs1728785	1.000	rs1728792	chr16:68596534	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	7.95	0.44	5.4e-14	Ulcerative colitis;
CESC	trans	rs4942242	0.663	rs9525812	chr13:44200099	T/C	cg19169023	chr15:41853346	TYRO3	-0.59	-7.66	-0.43	3.51e-13	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs780096	0.546	rs1528533	chr2:27595756	G/C	cg02592271	chr2:27665507	KRTCAP3	-0.29	-6.02	-0.35	5.85e-9	Total body bone mineral density;
CESC	cis	rs798554	0.757	rs1182179	chr7:2873648	A/G	cg04166393	chr7:2884313	GNA12	0.58	7.51	0.42	8.92e-13	Height;
CESC	cis	rs9837602	0.507	rs793448	chr3:99532949	G/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.53	-6.26	-0.36	1.52e-9	Breast cancer;
CESC	cis	rs10876993	0.855	rs1678520	chr12:58049319	C/G	cg18357645	chr12:58087776	OS9	0.6	9.04	0.49	3.45e-17	Celiac disease or Rheumatoid arthritis;
CESC	cis	rs711830	0.931	rs717852	chr2:177031623	C/T	cg13092806	chr2:177043255	NA	0.87	11.79	0.59	4.66e-26	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
CESC	cis	rs4073582	0.516	rs1151539	chr11:66031660	C/T	cg14036092	chr11:66035641	RAB1B	0.56	7.87	0.44	9.14e-14	Gout;
CESC	cis	rs6460942	0.597	rs62449509	chr7:12515013	C/T	cg10578991	chr7:12443926	VWDE	-0.49	-5.07	-0.3	7.32e-7	Coronary artery disease;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg04626574	chr22:26879726	HPS4;SRRD	-0.44	-6.11	-0.35	3.47e-9	Gambling;
CESC	cis	rs6500395	0.651	rs28432694	chr16:48666310	A/T	cg04672837	chr16:48644449	N4BP1	0.43	5.19	0.3	4.09e-7	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs28489187	0.683	rs6704103	chr1:85868657	C/A	cg16011679	chr1:85725395	C1orf52	-0.48	-5.7	-0.33	3.19e-8	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	cis	rs1862618	0.573	rs2034245	chr5:56243685	T/C	cg24531977	chr5:56204891	C5orf35	1.0	12.95	0.62	4.71e-30	Initial pursuit acceleration;
CESC	trans	rs1545843	0.593	rs4761085	chr12:84794017	A/T	cg03015433	chr16:56623111	MT3	-0.34	-6.12	-0.35	3.37e-9	Major depressive disorder;
CESC	trans	rs3925158	0.510	rs12054266	chr3:38302912	A/G	cg23247845	chr10:3679085	NA	0.67	6.1	0.35	3.77e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs2439831	0.702	rs2467402	chr15:44024490	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	-0.59	-7.56	-0.42	6.67e-13	Lung cancer in ever smokers;
CESC	cis	rs9311474	0.607	rs4475032	chr3:52560021	C/T	cg17372223	chr3:52568218	NT5DC2	0.51	7.94	0.44	5.81e-14	Electroencephalogram traits;
CESC	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.64	7.2	0.4	6.35e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg14159672	chr1:205819179	PM20D1	0.76	11.29	0.57	2.11e-24	Menarche (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09475402	chr22:47158619	TBC1D22A	0.55	6.01	0.35	6.04e-9	Gut microbiome composition (summer);
CESC	cis	rs2635047	0.811	rs17785603	chr18:44769534	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.45	5.95	0.34	8.42e-9	Educational attainment;
CESC	cis	rs875971	0.862	rs1612452	chr7:65573896	T/A	cg12463550	chr7:65579703	CRCP	-0.52	-6.41	-0.37	6.69e-10	Aortic root size;
CESC	cis	rs2074585	0.583	rs28406958	chr15:91069364	C/A	cg10434728	chr15:90938212	IQGAP1	-0.32	-5.11	-0.3	6.21e-7	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
CESC	cis	rs2952156	0.920	rs2517953	chr17:37841211	G/C	cg07936489	chr17:37558343	FBXL20	-0.6	-7.71	-0.43	2.57e-13	Asthma;
CESC	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.6	0.38	2.17e-10	Prudent dietary pattern;
CESC	cis	rs896854	0.902	rs726816	chr8:95968413	T/G	cg13393036	chr8:95962371	TP53INP1	-0.51	-10.77	-0.55	1.15e-22	Type 2 diabetes;
CESC	trans	rs3741578	0.702	rs725956	chr12:57331936	A/G	cg27208169	chr17:17603584	RAI1	0.44	6.07	0.35	4.31e-9	Asthma;
CESC	cis	rs67311347	1.000	rs73078158	chr3:40472567	G/C	cg24209194	chr3:40518798	ZNF619	0.51	6.3	0.36	1.22e-9	Renal cell carcinoma;
CESC	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.55	-6.17	-0.35	2.48e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs35110281	0.837	rs2838343	chr21:45078035	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.51	6.63	0.38	1.91e-10	Mean corpuscular volume;
CESC	cis	rs12541635	0.639	rs10095827	chr8:106984403	A/G	cg10147462	chr8:107024639	NA	0.46	6.71	0.38	1.19e-10	Age of smoking initiation;
CESC	cis	rs12477438	0.520	rs6743355	chr2:99732360	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.88	15.61	0.69	2.15e-39	Chronic sinus infection;
CESC	trans	rs11039798	0.588	rs10838923	chr11:48534864	C/G	cg03929089	chr4:120376271	NA	0.6	6.21	0.36	2.06e-9	Axial length;
CESC	cis	rs3091242	0.866	rs11249249	chr1:25758134	A/G	cg02931644	chr1:25747376	RHCE	0.46	7.92	0.44	6.55e-14	Erythrocyte sedimentation rate;
CESC	cis	rs2576037	0.526	rs626217	chr18:44429182	T/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.57	-8.07	-0.44	2.4e-14	Personality dimensions;
CESC	cis	rs12136530	0.727	rs4911998	chr1:19765834	C/T	cg01832549	chr1:19774989	CAPZB	-0.47	-6.76	-0.38	8.85e-11	Lead levels in blood;
CESC	trans	rs60843830	1.000	rs56321614	chr2:268191	G/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.65	8.16	0.45	1.35e-14	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs7301826	0.651	rs10848206	chr12:131281471	G/C	cg11011512	chr12:131303247	STX2	0.47	5.71	0.33	3.07e-8	Plasma plasminogen activator levels;
CESC	cis	rs7149337	1.000	rs4901103	chr14:51746873	C/T	cg23942311	chr14:51606299	NA	0.41	6.78	0.38	7.87e-11	Cancer;
CESC	cis	rs9311474	0.652	rs411457	chr3:52228150	A/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	-0.33	-5.74	-0.33	2.58e-8	Electroencephalogram traits;
CESC	cis	rs9926296	0.585	rs6500441	chr16:89828669	C/G	cg04287289	chr16:89883240	FANCA	0.87	14.99	0.68	3.22e-37	Vitiligo;
CESC	cis	rs8114671	0.562	rs2223881	chr20:33506463	A/C	cg07148914	chr20:33460835	GGT7	0.52	6.8	0.39	6.88e-11	Height;
CESC	trans	rs1422110	0.681	rs35625401	chr5:85465408	G/A	cg01787110	chr1:109008453	NBPF6	0.42	6.23	0.36	1.81e-9	Attention function in attention deficit hyperactive disorder;
CESC	cis	rs5758511	0.689	rs55906806	chr22:42644471	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.55	6.96	0.39	2.68e-11	Birth weight;
CESC	cis	rs6426558	0.502	rs2813965	chr1:227445733	A/G	cg10327440	chr1:227177885	CDC42BPA	0.52	6.4	0.37	7.17e-10	Neutrophil percentage of white cells;
CESC	cis	rs1707322	1.000	rs9803784	chr1:46401907	T/C	cg05343316	chr1:45956843	TESK2	0.44	5.42	0.32	1.36e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs6952808	0.792	rs2056481	chr7:1955435	A/G	cg04267008	chr7:1944627	MAD1L1	-0.74	-9.88	-0.52	8.45e-20	Bipolar disorder and schizophrenia;
CESC	cis	rs7772486	0.790	rs6926076	chr6:146232804	C/T	cg23711669	chr6:146136114	FBXO30	-0.92	-13.36	-0.63	1.78e-31	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6570726	0.791	rs6912079	chr6:145894949	G/A	cg23711669	chr6:146136114	FBXO30	1.0	15.28	0.68	3.05e-38	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7666738	0.753	rs11097594	chr4:98944486	A/G	cg03467027	chr4:99064603	C4orf37	0.48	5.95	0.34	8.45e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9611565	0.512	rs1983576	chr22:42166486	G/A	cg06481639	chr22:41940642	POLR3H	0.6	5.92	0.34	9.88e-9	Vitiligo;
CESC	cis	rs7927592	0.763	rs1193699	chr11:68249480	C/G	cg20283391	chr11:68216788	NA	-0.47	-5.94	-0.34	8.94e-9	Total body bone mineral density;
CESC	cis	rs875971	0.658	rs432667	chr7:65514633	A/G	cg11764359	chr7:65958608	NA	0.88	13.01	0.62	3.05e-30	Aortic root size;
CESC	trans	rs2727020	0.729	rs6485965	chr11:49166730	C/T	cg15704280	chr7:45808275	SEPT13	0.82	12.84	0.62	1.17e-29	Coronary artery disease;
CESC	cis	rs4595586	0.525	rs7968566	chr12:39377200	C/T	cg26384229	chr12:38710491	ALG10B	0.54	7.53	0.42	7.85e-13	Morning vs. evening chronotype;
CESC	cis	rs10771431	0.810	rs10771418	chr12:9358995	A/G	cg08997352	chr12:9597637	DDX12	-0.77	-10.44	-0.54	1.34e-21	Breast size;
CESC	cis	rs1801251	1.000	rs1446308	chr2:233639309	T/C	cg25237894	chr2:233734115	C2orf82	0.46	8.06	0.44	2.6e-14	Coronary artery disease;
CESC	cis	rs12130219	0.500	rs4845737	chr1:152177539	G/A	cg25272121	chr1:152190972	HRNR	-0.39	-5.85	-0.34	1.48e-8	Inflammatory skin disease;
CESC	cis	rs7615952	0.599	rs6438953	chr3:125724951	T/C	cg06494592	chr3:125709126	NA	-0.44	-5.05	-0.3	8.41e-7	Blood pressure (smoking interaction);
CESC	cis	rs1008375	0.898	rs4698623	chr4:17594702	T/C	cg16339924	chr4:17578868	LAP3	0.69	8.85	0.48	1.24e-16	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs6964587	0.620	rs6967588	chr7:91643402	G/T	cg17063962	chr7:91808500	NA	0.46	6.55	0.37	2.91e-10	Breast cancer;
CESC	cis	rs1448094	0.533	rs10863078	chr12:86152672	C/T	cg00310523	chr12:86230176	RASSF9	-0.31	-5.04	-0.3	8.55e-7	Major depressive disorder;
CESC	cis	rs4835473	0.932	rs7668698	chr4:144907486	C/G	cg25736465	chr4:144833511	NA	0.41	6.29	0.36	1.28e-9	Immature fraction of reticulocytes;
CESC	cis	rs9916302	0.904	rs8076494	chr17:37516722	A/G	cg00129232	chr17:37814104	STARD3	0.51	6.38	0.37	7.72e-10	Glomerular filtration rate (creatinine);
CESC	trans	rs526821	0.553	rs510095	chr11:55289154	T/C	cg15704280	chr7:45808275	SEPT13	-0.52	-6.42	-0.37	6.24e-10	Pediatric bone mineral density (spine);
CESC	cis	rs4819052	0.724	rs9753987	chr21:46661389	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.75	9.98	0.52	4.1e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs9322193	0.962	rs9322223	chr6:150122645	G/A	cg04369109	chr6:150039330	LATS1	-0.42	-5.95	-0.34	8.52e-9	Lung cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13825663	chr2:96873994	STARD7	0.56	6.15	0.35	2.79e-9	Gut microbiome composition (summer);
CESC	cis	rs7945705	0.967	rs10840141	chr11:8902218	T/C	cg12365402	chr11:9010492	NRIP3	0.34	5.3	0.31	2.43e-7	Hemoglobin concentration;
CESC	cis	rs951366	1.000	rs4951261	chr1:205717823	A/C	cg17178900	chr1:205818956	PM20D1	-0.49	-6.9	-0.39	3.93e-11	Menarche (age at onset);
CESC	cis	rs9303542	0.559	rs12938390	chr17:46614722	T/C	cg04904318	chr17:46607828	HOXB1	-0.6	-5.73	-0.33	2.76e-8	Ovarian cancer;Epithelial ovarian cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20318713	chr1:45805724	MUTYH;TOE1	0.71	8.12	0.45	1.76e-14	Gut microbiome composition (summer);
CESC	cis	rs7246657	0.943	rs6508733	chr19:38000548	A/T	cg23950597	chr19:37808831	NA	-0.49	-5.57	-0.32	6.39e-8	Coronary artery calcification;
CESC	cis	rs7819412	0.715	rs2409727	chr8:11043236	C/T	cg21775007	chr8:11205619	TDH	-0.37	-5.14	-0.3	5.47e-7	Triglycerides;
CESC	cis	rs7481584	0.624	rs451060	chr11:3056389	G/A	cg25174290	chr11:3078921	CARS	-0.48	-6.7	-0.38	1.24e-10	Calcium levels;
CESC	cis	rs4819052	0.851	rs914218	chr21:46698445	G/C	cg11663144	chr21:46675770	NA	-0.63	-9.95	-0.52	5.12e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs6938	0.534	rs59945415	chr15:75228427	C/A	cg14664628	chr15:75095509	CSK	-0.55	-7.15	-0.4	8.2e-12	Breast cancer;
CESC	cis	rs763121	0.853	rs4821812	chr22:39075235	G/C	cg14440974	chr22:39074834	NA	-0.42	-5.77	-0.33	2.19e-8	Menopause (age at onset);
CESC	cis	rs9926296	0.512	rs11076626	chr16:89865103	T/A	cg04287289	chr16:89883240	FANCA	0.91	16.29	0.71	7.88e-42	Vitiligo;
CESC	cis	rs10504229	1.000	rs73607863	chr8:58170178	A/G	cg24829409	chr8:58192753	C8orf71	-0.76	-9.92	-0.52	6.14e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs950169	0.922	rs67804993	chr15:85104030	T/G	cg17507749	chr15:85114479	UBE2QP1	0.58	6.4	0.37	6.88e-10	Schizophrenia;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg21640038	chr17:65362901	PSMD12	0.5	6.72	0.38	1.1e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs7713065	1.000	rs7713065	chr5:131788334	A/C	cg09877947	chr5:131593287	PDLIM4	0.49	5.77	0.33	2.22e-8	Lung function (FEV1/FVC);
CESC	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg16590910	chr6:42928470	GNMT	0.37	5.19	0.3	4.12e-7	Alzheimer's disease in APOE e4+ carriers;
CESC	trans	rs11098499	0.863	rs11098531	chr4:120465001	G/A	cg25214090	chr10:38739885	LOC399744	0.67	9.21	0.49	1.05e-17	Corneal astigmatism;
CESC	cis	rs12497850	0.931	rs9311430	chr3:48845251	C/T	cg07636037	chr3:49044803	WDR6	1.01	18.68	0.75	2.81e-50	Parkinson's disease;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg24507739	chr2:27546399	MPV17	-0.41	-6.19	-0.36	2.26e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs2191566	0.691	rs56149185	chr19:44588067	A/T	cg20607764	chr19:44506953	ZNF230	-0.4	-5.31	-0.31	2.28e-7	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg26338869	chr17:61819248	STRADA	0.68	8.87	0.48	1.08e-16	Prudent dietary pattern;
CESC	cis	rs6500602	0.702	rs3789038	chr16:4546586	C/G	cg08645402	chr16:4508243	NA	-0.51	-7.78	-0.43	1.6e-13	Schizophrenia;
CESC	cis	rs875971	0.789	rs7808013	chr7:66071196	A/G	cg18876405	chr7:65276391	NA	-0.53	-7.2	-0.4	6.41e-12	Aortic root size;
CESC	cis	rs67478160	0.654	rs11628240	chr14:104218135	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.5	-6.93	-0.39	3.17e-11	Schizophrenia;
CESC	cis	rs769267	0.895	rs2315279	chr19:19479936	C/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.59	-7.76	-0.43	1.81e-13	Tonsillectomy;
CESC	cis	rs4077515	0.901	rs11791262	chr9:139271919	C/T	cg14169450	chr9:139327907	INPP5E	0.37	5.4	0.31	1.47e-7	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs1008375	0.932	rs964012	chr4:17619184	A/G	cg16339924	chr4:17578868	LAP3	0.71	8.94	0.48	6.8e-17	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs2075371	0.835	rs1646724	chr7:134001875	T/G	cg11752832	chr7:134001865	SLC35B4	0.56	7.31	0.41	3.19e-12	Mean platelet volume;
CESC	cis	rs4803468	1.000	rs284650	chr19:41927129	A/G	cg09537434	chr19:41945824	ATP5SL	-1.1	-20.32	-0.78	5.54e-56	Height;
CESC	cis	rs35110281	0.807	rs1598206	chr21:45058776	A/G	cg01579765	chr21:45077557	HSF2BP	-0.58	-10.03	-0.52	2.7e-20	Mean corpuscular volume;
CESC	cis	rs939658	0.776	rs4778925	chr15:79443791	C/T	cg17916960	chr15:79447300	NA	-0.37	-6.13	-0.35	3.13e-9	Refractive error;
CESC	cis	rs7107174	1.000	rs10899458	chr11:78007451	A/T	cg02023728	chr11:77925099	USP35	0.5	6.69	0.38	1.33e-10	Testicular germ cell tumor;
CESC	cis	rs73019876	0.869	rs2359812	chr19:22153495	A/T	cg11619707	chr19:22235551	ZNF257	-0.28	-5.11	-0.3	6.09e-7	Testicular germ cell tumor;
CESC	cis	rs7615952	0.576	rs6780025	chr3:125815624	A/C	cg15145296	chr3:125709740	NA	-0.56	-5.97	-0.34	7.52e-9	Blood pressure (smoking interaction);
CESC	cis	rs11098499	0.697	rs4560394	chr4:120313435	T/G	cg24375607	chr4:120327624	NA	0.46	5.52	0.32	8.27e-8	Corneal astigmatism;
CESC	cis	rs1927790	0.616	rs1925119	chr13:96939586	C/A	cg02571835	chr13:96230311	CLDN10	-0.34	-5.23	-0.31	3.53e-7	Body mass index;
CESC	cis	rs2070488	0.775	rs762318	chr3:38516369	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.82	13.27	0.63	3.79e-31	Electrocardiographic conduction measures;
CESC	cis	rs3540	0.512	rs3930162	chr15:91075129	C/T	cg22089800	chr15:90895588	ZNF774	-0.63	-8.44	-0.46	2.12e-15	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs4808199	0.947	rs754255	chr19:19578890	T/C	cg03709012	chr19:19516395	GATAD2A	1.14	13.23	0.63	4.9e-31	Nonalcoholic fatty liver disease;
CESC	cis	rs9911578	0.757	rs8081906	chr17:56631907	A/T	cg12560992	chr17:57184187	TRIM37	-0.86	-12.17	-0.6	2.26e-27	Intelligence (multi-trait analysis);
CESC	cis	rs2228479	0.850	rs17226428	chr16:89842884	T/A	cg19635926	chr16:89946313	TCF25	0.67	5.03	0.3	9.05e-7	Skin colour saturation;
CESC	cis	rs801193	0.660	rs4610622	chr7:66224497	T/C	cg12463550	chr7:65579703	CRCP	0.56	7.21	0.41	5.78e-12	Aortic root size;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg07928541	chr7:151038942	NUB1	-0.45	-6.03	-0.35	5.46e-9	Fibrinogen levels;
CESC	cis	rs2733201	1.000	rs2042741	chr15:44390286	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	-0.61	-5.47	-0.32	1.06e-7	Lipoprotein phospholipase A2 activity in cardiovascular disease;
CESC	trans	rs35110281	0.811	rs4819264	chr21:45017349	G/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.55	7.28	0.41	3.8e-12	Mean corpuscular volume;
CESC	cis	rs7091068	0.518	rs1543580	chr10:95446811	C/T	cg20715218	chr10:95462985	C10orf4	0.53	6.47	0.37	4.62e-10	Urinary tract infection frequency;
CESC	cis	rs4588572	0.601	rs10070202	chr5:77792462	A/C	cg11547950	chr5:77652471	NA	-0.43	-5.53	-0.32	7.68e-8	Triglycerides;
CESC	cis	rs2732480	0.500	rs1387257	chr12:48636666	C/A	cg24011408	chr12:48396354	COL2A1	0.42	5.83	0.34	1.59e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs12618769	0.597	rs4599165	chr2:99144483	G/A	cg10123293	chr2:99228465	UNC50	0.39	5.13	0.3	5.6e-7	Bipolar disorder;
CESC	trans	rs55704346	0.507	rs1533133	chr4:25384305	T/C	cg01822600	chr1:245751692	KIF26B	0.43	6.27	0.36	1.44e-9	Tonsillectomy;
CESC	trans	rs11252926	0.589	rs12359901	chr10:475068	A/G	cg00953403	chr17:74099816	EXOC7	-0.55	-7.01	-0.4	2.01e-11	Psychosis in Alzheimer's disease;
CESC	trans	rs916888	0.779	rs430685	chr17:44859148	T/C	cg22968622	chr17:43663579	NA	-1.19	-16.22	-0.71	1.43e-41	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs270601	0.710	rs4705852	chr5:131602807	A/G	cg12564285	chr5:131593104	PDLIM4	0.38	5.78	0.33	2.08e-8	Acylcarnitine levels;
CESC	cis	rs55871839	0.708	rs4738730	chr8:59808935	A/T	cg07426533	chr8:59803705	TOX	-0.44	-6.41	-0.37	6.5e-10	Pneumonia;
CESC	cis	rs6938	0.534	rs1130741	chr15:75189930	A/G	cg14664628	chr15:75095509	CSK	-0.59	-8.01	-0.44	3.71e-14	Breast cancer;
CESC	cis	rs736408	0.609	rs2230534	chr3:52802402	A/C	cg07507251	chr3:52567010	NT5DC2	0.42	7.17	0.4	7.35e-12	Bipolar disorder;
CESC	cis	rs7618501	0.635	rs34080578	chr3:50026029	A/C	cg24308560	chr3:49941425	MST1R	-0.63	-9.02	-0.48	3.81e-17	Intelligence (multi-trait analysis);
CESC	cis	rs10504229	1.000	rs72650899	chr8:58180525	G/T	cg24829409	chr8:58192753	C8orf71	-0.76	-10.0	-0.52	3.53e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs55882075	0.808	rs6867806	chr5:179179585	C/G	cg14593053	chr5:179126677	CANX	0.42	5.48	0.32	1.01e-7	Monocyte percentage of white cells;
CESC	cis	rs3733585	0.699	rs28613263	chr4:9964880	C/T	cg11266682	chr4:10021025	SLC2A9	-0.6	-11.2	-0.57	4.42e-24	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs881375	0.678	rs1014530	chr9:123685092	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.39	5.54	0.32	7.25e-8	Rheumatoid arthritis;
CESC	cis	rs7017914	0.967	rs13255735	chr8:71859739	C/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.43	-5.42	-0.32	1.33e-7	Bone mineral density;
CESC	cis	rs1256061	0.603	rs1256037	chr14:64743301	G/A	cg21174375	chr14:64681225	SYNE2	0.51	6.77	0.38	8.38e-11	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs2576037	0.899	rs2576035	chr18:44587654	C/T	cg19077165	chr18:44547161	KATNAL2	0.49	6.6	0.38	2.19e-10	Personality dimensions;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05193570	chr5:893022	TRIP13;BRD9	0.59	6.76	0.38	8.51e-11	Gut microbiome composition (summer);
CESC	cis	rs365132	1.000	rs7718874	chr5:176358065	A/G	cg16309518	chr5:176445507	NA	-0.39	-5.72	-0.33	2.93e-8	Menarche and menopause (age at onset);Menopause (age at onset);
CESC	cis	rs17253792	0.822	rs76164147	chr14:56140369	T/C	cg01858014	chr14:56050164	KTN1	-0.97	-7.54	-0.42	7.36e-13	Putamen volume;
CESC	cis	rs3015497	0.624	rs3015488	chr14:51135309	A/G	cg26011998	chr14:51135199	SAV1	-0.62	-7.28	-0.41	3.87e-12	Mean platelet volume;
CESC	cis	rs2243480	0.901	rs778730	chr7:65823325	T/A	cg13147721	chr7:65941812	NA	-0.95	-8.96	-0.48	6.14e-17	Diabetic kidney disease;
CESC	cis	rs3767633	0.925	rs4656339	chr1:161915387	A/T	cg09175582	chr1:161736000	ATF6	0.88	7.42	0.41	1.6e-12	IgG glycosylation;
CESC	cis	rs425277	0.606	rs262664	chr1:2083537	G/C	cg04315214	chr1:2043799	PRKCZ	-0.44	-7.05	-0.4	1.53e-11	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02070114	chr5:139555300	C5orf32	0.57	6.52	0.37	3.51e-10	Gut microbiome composition (summer);
CESC	cis	rs11098499	0.954	rs28429722	chr4:120300093	G/A	cg09307838	chr4:120376055	NA	0.92	12.66	0.61	4.96e-29	Corneal astigmatism;
CESC	cis	rs11098499	0.604	rs34278750	chr4:120571136	G/A	cg09307838	chr4:120376055	NA	0.76	9.58	0.51	7.28e-19	Corneal astigmatism;
CESC	cis	rs12282928	0.788	rs753095	chr11:48328644	C/T	cg26585981	chr11:48327164	OR4S1	0.38	5.32	0.31	2.25e-7	Migraine - clinic-based;
CESC	cis	rs854765	0.562	rs2955381	chr17:17945500	G/C	cg16928487	chr17:17741425	SREBF1	0.55	9.13	0.49	1.86e-17	Total body bone mineral density;
CESC	cis	rs7084402	0.967	rs2393448	chr10:60333260	T/G	cg07615347	chr10:60278583	BICC1	0.59	9.23	0.49	9.22e-18	Refractive error;
CESC	cis	rs4713118	0.586	rs9468290	chr6:28087674	C/T	cg26335602	chr6:28129616	ZNF389	0.53	7.06	0.4	1.48e-11	Parkinson's disease;
CESC	cis	rs9814567	1.000	rs6793487	chr3:134299426	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.41	5.52	0.32	8.13e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs2243480	1.000	rs186378	chr7:65582058	A/C	cg12463550	chr7:65579703	CRCP	0.74	5.77	0.33	2.23e-8	Diabetic kidney disease;
CESC	cis	rs8099014	0.861	rs4940705	chr18:56120155	G/A	cg19312305	chr18:56117016	MIR122	-0.27	-5.29	-0.31	2.61e-7	Platelet count;
CESC	cis	rs6484504	0.600	rs2616815	chr11:31327316	C/T	cg14844989	chr11:31128820	NA	0.39	5.51	0.32	8.53e-8	Red blood cell count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16626480	chr22:25575426	KIAA1671	-0.56	-6.01	-0.35	6.25e-9	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.830	rs11097609	chr4:99011707	C/T	cg05340658	chr4:99064831	C4orf37	0.8	12.51	0.61	1.52e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6060717	0.536	rs3829829	chr20:34537160	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.71	6.36	0.36	8.95e-10	Hip circumference adjusted for BMI;
CESC	cis	rs7586879	0.575	rs6721750	chr2:25128719	A/G	cg01884057	chr2:25150051	NA	0.36	7.01	0.4	2.02e-11	Body mass index;
CESC	cis	rs7264396	0.790	rs6121018	chr20:34249060	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.86	-11.84	-0.59	3.14e-26	Total cholesterol levels;
CESC	cis	rs4474465	1.000	rs7950813	chr11:78215082	A/T	cg27205649	chr11:78285834	NARS2	0.44	5.36	0.31	1.8e-7	Alzheimer's disease (survival time);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg04066316	chr4:189433040	NA	0.38	6.08	0.35	4.21e-9	Fibrinogen levels;
CESC	cis	rs11997175	0.692	rs6995075	chr8:33673816	G/A	ch.8.33884649F	chr8:33765107	NA	0.49	6.15	0.35	2.83e-9	Body mass index;
CESC	cis	rs910316	0.789	rs175444	chr14:75601782	G/C	cg08847533	chr14:75593920	NEK9	-0.91	-15.66	-0.69	1.38e-39	Height;
CESC	cis	rs4588572	0.644	rs891150	chr5:77761794	G/A	cg11547950	chr5:77652471	NA	-0.4	-5.37	-0.31	1.73e-7	Triglycerides;
CESC	cis	rs7412746	0.588	rs10305664	chr1:150839686	A/C	cg04414720	chr1:150670196	GOLPH3L	0.55	7.33	0.41	2.84e-12	Melanoma;
CESC	cis	rs2425143	1.000	rs6060642	chr20:34449840	G/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.66	5.69	0.33	3.4e-8	Blood protein levels;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg08209163	chr13:28024472	MTIF3	-0.45	-6.43	-0.37	6.02e-10	Fibrinogen levels;
CESC	cis	rs9926296	0.572	rs8047581	chr16:89884502	C/T	cg07648498	chr16:89883185	FANCA	0.45	5.48	0.32	9.91e-8	Vitiligo;
CESC	cis	rs9910055	0.762	rs4239142	chr17:42205876	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	-0.45	-6.55	-0.37	2.94e-10	Total body bone mineral density;
CESC	cis	rs4900538	0.750	rs12590618	chr14:102808330	C/T	cg18135206	chr14:102964638	TECPR2	-0.59	-7.01	-0.4	1.95e-11	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	cis	rs116095464	0.558	rs7730700	chr5:264713	G/A	cg22496380	chr5:211416	CCDC127	-0.74	-8.46	-0.46	1.86e-15	Breast cancer;
CESC	cis	rs2576037	0.523	rs4890705	chr18:44509758	A/G	cg19077165	chr18:44547161	KATNAL2	-0.62	-9.44	-0.5	2.05e-18	Personality dimensions;
CESC	cis	rs2637266	0.703	rs846635	chr10:78535132	G/A	cg18941641	chr10:78392320	NA	0.41	7.79	0.43	1.48e-13	Pulmonary function;
CESC	cis	rs6951245	0.882	rs56048221	chr7:1092533	A/G	cg03188948	chr7:1209495	NA	0.59	6.05	0.35	4.95e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs875971	0.862	rs4368860	chr7:65608482	C/G	cg10691866	chr7:65817282	TPST1	0.31	5.15	0.3	5.12e-7	Aortic root size;
CESC	cis	rs2839186	0.900	rs56840278	chr21:47708933	T/G	cg10351095	chr21:47802916	PCNT	-0.5	-6.69	-0.38	1.35e-10	Testicular germ cell tumor;
CESC	cis	rs4253772	0.637	rs41279831	chr22:46651623	T/C	cg10541313	chr22:46663664	TTC38	0.74	5.91	0.34	1.02e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs12822507	0.831	rs34975957	chr12:12786190	G/A	cg04607235	chr12:12878440	APOLD1	-0.51	-6.48	-0.37	4.43e-10	Systemic lupus erythematosus;
CESC	cis	rs6061231	0.631	rs2427317	chr20:60975725	C/T	cg15674680	chr20:60982522	CABLES2	0.42	5.35	0.31	1.89e-7	Colorectal cancer;
CESC	cis	rs172166	0.694	rs1150666	chr6:28123928	T/C	cg19592336	chr6:28129416	ZNF389	0.47	6.7	0.38	1.21e-10	Cardiac Troponin-T levels;
CESC	cis	rs96067	0.652	rs274137	chr1:36577945	A/G	cg27506609	chr1:36549197	TEKT2	-0.4	-5.1	-0.3	6.45e-7	Corneal structure;
CESC	cis	rs8177253	0.829	rs9882812	chr3:133506127	A/G	cg11941060	chr3:133502564	NA	-0.5	-6.47	-0.37	4.79e-10	Iron status biomarkers;
CESC	cis	rs17376456	0.877	rs28539612	chr5:93499099	C/T	cg21475434	chr5:93447410	FAM172A	0.9	7.81	0.43	1.35e-13	Diabetic retinopathy;
CESC	cis	rs473651	0.503	rs515342	chr2:239367296	A/G	cg18131467	chr2:239335373	ASB1	-0.68	-8.07	-0.44	2.4e-14	Multiple system atrophy;
CESC	cis	rs17253792	0.822	rs10083493	chr14:56045411	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.82	5.88	0.34	1.25e-8	Putamen volume;
CESC	cis	rs2952156	0.883	rs8077172	chr17:37834977	G/T	cg20243544	chr17:37824526	PNMT	0.63	8.38	0.46	3.08e-15	Asthma;
CESC	cis	rs1862618	0.853	rs6450408	chr5:56098146	T/C	cg22800045	chr5:56110881	MAP3K1	0.84	10.23	0.53	6.2e-21	Initial pursuit acceleration;
CESC	trans	rs17508449	0.865	rs80348557	chr1:114151116	C/T	cg23028848	chr11:57092561	TNKS1BP1	-0.77	-6.14	-0.35	2.98e-9	Leprosy;
CESC	cis	rs6980507	0.523	rs2974294	chr8:42369473	C/T	cg09913449	chr8:42400586	C8orf40	-0.36	-5.66	-0.33	3.84e-8	Glycated hemoglobin levels;
CESC	cis	rs9487051	0.735	rs351756	chr6:109538773	A/G	cg01475377	chr6:109611718	NA	0.39	5.82	0.34	1.68e-8	Reticulocyte fraction of red cells;
CESC	cis	rs8141529	0.748	rs5752826	chr22:29269808	A/G	cg02153584	chr22:29168773	CCDC117	0.56	7.45	0.42	1.34e-12	Lymphocyte counts;
CESC	cis	rs8031584	0.541	rs2955797	chr15:31210981	A/G	cg08704250	chr15:31115839	NA	0.64	8.93	0.48	7.57e-17	Huntington's disease progression;
CESC	cis	rs853679	0.882	rs9380069	chr6:28203300	A/G	cg19592336	chr6:28129416	ZNF389	0.54	5.5	0.32	8.89e-8	Depression;
CESC	cis	rs875971	0.790	rs10257911	chr7:65743770	A/G	cg18876405	chr7:65276391	NA	-0.51	-7.01	-0.4	1.94e-11	Aortic root size;
CESC	cis	rs4955124	0.558	rs12485651	chr3:32018536	C/T	cg05935571	chr3:32023257	ZNF860;OSBPL10	0.98	8.8	0.48	1.77e-16	Schizophrenia;
CESC	cis	rs9322193	0.926	rs3805751	chr6:150112329	G/A	cg04369109	chr6:150039330	LATS1	-0.4	-5.5	-0.32	9.07e-8	Lung cancer;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg13682598	chr10:135195405	PAOX	0.48	6.53	0.37	3.33e-10	Fibrinogen levels;
CESC	cis	rs12476592	0.602	rs9789351	chr2:63740614	A/G	cg17519650	chr2:63277830	OTX1	-0.48	-5.42	-0.32	1.34e-7	Childhood ear infection;
CESC	cis	rs12497850	0.931	rs62262517	chr3:49134914	T/G	cg07636037	chr3:49044803	WDR6	1.07	18.96	0.76	3.01e-51	Parkinson's disease;
CESC	cis	rs7617480	0.648	rs4974083	chr3:49000626	A/G	cg07636037	chr3:49044803	WDR6	0.87	11.16	0.57	5.93e-24	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CESC	cis	rs9611565	0.694	rs79008	chr22:41850500	C/T	cg06481639	chr22:41940642	POLR3H	-0.56	-5.78	-0.33	2.07e-8	Vitiligo;
CESC	cis	rs10504229	1.000	rs78953746	chr8:58170608	A/G	cg05313129	chr8:58192883	C8orf71	-0.54	-6.23	-0.36	1.83e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs1707322	1.000	rs11211232	chr1:46411146	C/T	cg03146154	chr1:46216737	IPP	0.78	10.82	0.55	7.98e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs10479542	0.583	rs4131080	chr5:179044292	G/A	cg19723775	chr5:179050963	HNRNPH1	0.51	6.8	0.39	6.92e-11	Lung cancer;
CESC	cis	rs7100689	0.577	rs9421464	chr10:82043426	C/T	cg00277334	chr10:82204260	NA	-0.53	-7.04	-0.4	1.62e-11	Post bronchodilator FEV1;
CESC	cis	rs9549260	0.727	rs4603422	chr13:41148353	T/C	cg21288729	chr13:41239152	FOXO1	0.63	7.94	0.44	5.91e-14	Red blood cell count;
CESC	cis	rs10771431	0.967	rs7137443	chr12:9372029	C/T	cg08997352	chr12:9597637	DDX12	-0.67	-8.9	-0.48	9.24e-17	Breast size;
CESC	cis	rs780096	0.526	rs72819536	chr2:27682850	G/T	cg12648201	chr2:27665141	KRTCAP3	-0.31	-5.65	-0.33	4.22e-8	Total body bone mineral density;
CESC	cis	rs55728055	0.661	rs55931230	chr22:32028028	T/A	cg01338084	chr22:32026380	PISD	1.26	8.23	0.45	8.62e-15	Age-related hearing impairment;
CESC	trans	rs9467711	0.606	rs12174602	chr6:26372827	C/T	cg06606381	chr12:133084897	FBRSL1	-0.75	-6.75	-0.38	9.06e-11	Autism spectrum disorder or schizophrenia;
CESC	cis	rs854765	0.604	rs12948749	chr17:17949802	G/A	cg16928487	chr17:17741425	SREBF1	0.59	10.2	0.53	8.07e-21	Total body bone mineral density;
CESC	trans	rs9325144	0.647	rs17518186	chr12:38883665	T/C	cg23762105	chr12:34175262	ALG10	0.46	6.05	0.35	4.84e-9	Morning vs. evening chronotype;
CESC	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	13.67	0.64	1.44e-32	Prudent dietary pattern;
CESC	cis	rs9300255	0.596	rs4460848	chr12:123677810	A/G	cg05973401	chr12:123451056	ABCB9	0.46	5.75	0.33	2.41e-8	Neutrophil percentage of white cells;
CESC	cis	rs6088590	0.523	rs6059913	chr20:33143288	G/A	cg06115741	chr20:33292138	TP53INP2	0.51	6.54	0.37	3.21e-10	Coronary artery disease;
CESC	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg11494091	chr17:61959527	GH2	0.73	12.52	0.61	1.43e-28	Prudent dietary pattern;
CESC	trans	rs2963826	0.589	rs298091	chr5:58996603	A/T	cg02737830	chr12:64616354	C12orf66	0.47	6.28	0.36	1.4e-9	Obesity-related traits;
CESC	cis	rs6500395	1.000	rs871903	chr16:48593643	A/C	cg04672837	chr16:48644449	N4BP1	0.51	6.36	0.36	8.56e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs11792861	0.816	rs113624314	chr9:111689953	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.51	6.62	0.38	1.96e-10	Menarche (age at onset);
CESC	cis	rs7143963	0.609	rs57521303	chr14:103361937	T/C	cg24154132	chr14:103367632	TRAF3	0.35	6.55	0.37	2.91e-10	Body mass index;
CESC	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg11905131	chr22:24372483	LOC391322	-0.73	-10.82	-0.55	7.99e-23	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs17608059	0.518	rs4792436	chr17:13972307	T/A	cg27005118	chr17:13972210	COX10	0.48	7.47	0.42	1.16e-12	Temperament;
CESC	cis	rs317689	0.613	rs315112	chr12:69785926	T/A	cg14784868	chr12:69753453	YEATS4	0.67	8.58	0.47	7.98e-16	Response to diuretic therapy;
CESC	cis	rs7811142	1.000	rs113738841	chr7:100081306	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.87	9.04	0.49	3.44e-17	Platelet count;
CESC	cis	rs9787249	0.957	rs3738673	chr1:40204823	C/T	cg24920358	chr1:40204285	PPIE	0.43	6.47	0.37	4.74e-10	Blood protein levels;
CESC	cis	rs11997175	0.603	rs66828270	chr8:33790155	C/G	ch.8.33884649F	chr8:33765107	NA	0.52	6.75	0.38	9.38e-11	Body mass index;
CESC	cis	rs780096	0.526	rs1647266	chr2:27693485	T/C	cg12648201	chr2:27665141	KRTCAP3	-0.35	-6.56	-0.37	2.79e-10	Total body bone mineral density;
CESC	cis	rs7236492	0.688	rs9709477	chr18:77202786	C/A	cg15644404	chr18:77186268	NFATC1	-0.67	-5.26	-0.31	2.98e-7	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs1799949	0.965	rs8176193	chr17:41231516	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.67	9.45	0.5	1.9e-18	Menopause (age at onset);
CESC	cis	rs2404602	0.716	rs1874944	chr15:76863928	A/G	cg22467129	chr15:76604101	ETFA	-0.35	-5.24	-0.31	3.24e-7	Blood metabolite levels;
CESC	cis	rs1046896	0.519	rs9900369	chr17:80829807	G/A	cg19046167	chr17:80928561	B3GNTL1	0.47	5.67	0.33	3.63e-8	Glycated hemoglobin levels;
CESC	cis	rs13266463	0.830	rs6983790	chr8:143406575	A/G	cg16886403	chr8:143471632	TSNARE1	0.43	5.28	0.31	2.66e-7	Schizophrenia;
CESC	cis	rs6570726	1.000	rs1935617	chr6:145943326	C/T	cg05347473	chr6:146136440	FBXO30	0.44	6.07	0.35	4.35e-9	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs10504229	0.683	rs72649188	chr8:58108829	A/G	cg21724239	chr8:58056113	NA	0.56	5.9	0.34	1.1e-8	Developmental language disorder (linguistic errors);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06927217	chr1:149193722	NA	-0.55	-6.88	-0.39	4.4e-11	Gut microbiome composition (summer);
CESC	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg18538332	chr22:24372958	LOC391322	0.71	10.37	0.54	2.28e-21	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs4144743	1.000	rs4144746	chr17:45323355	C/G	cg18085866	chr17:45331354	ITGB3	-0.66	-7.64	-0.43	3.87e-13	Body mass index;
CESC	cis	rs13118159	0.801	rs7664474	chr4:1329116	T/A	cg00684032	chr4:1343700	KIAA1530	0.36	5.45	0.32	1.15e-7	Longevity;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27457105	chr17:36003574	DDX52	-0.61	-6.75	-0.38	9.13e-11	Gut microbiome composition (summer);
CESC	cis	rs2430307	0.518	rs67763033	chr7:76517677	A/G	cg15770687	chr7:76625569	PMS2L11	0.6	5.7	0.33	3.22e-8	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
CESC	cis	rs9815354	1.000	rs73079316	chr3:41863859	G/A	cg03022575	chr3:42003672	ULK4	0.58	5.99	0.35	6.78e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs4665809	0.590	rs10197494	chr2:26445550	A/G	cg22920501	chr2:26401640	FAM59B	-0.91	-10.33	-0.54	3.07e-21	Gut microbiome composition (summer);
CESC	cis	rs9487051	0.836	rs9400270	chr6:109607488	G/A	cg01475377	chr6:109611718	NA	-0.51	-8.36	-0.46	3.66e-15	Reticulocyte fraction of red cells;
CESC	trans	rs12599106	0.584	rs12929704	chr16:34898258	C/A	cg07332563	chr6:291687	DUSP22	-0.66	-8.36	-0.46	3.52e-15	Menopause (age at onset);
CESC	cis	rs896854	0.684	rs10098778	chr8:95992020	C/T	cg26343298	chr8:95960752	TP53INP1	0.34	5.66	0.33	3.92e-8	Type 2 diabetes;
CESC	cis	rs4523957	0.523	rs2760746	chr17:2034806	G/C	cg16513277	chr17:2031491	SMG6	-0.78	-11.57	-0.58	2.42e-25	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs7949030	0.626	rs7124057	chr11:62334096	A/G	cg23462726	chr11:62437636	C11orf83;C11orf48	-0.4	-5.22	-0.31	3.56e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs5769707	0.967	rs17182154	chr22:49990470	A/G	cg20744362	chr22:50050164	C22orf34	0.42	7.17	0.4	7.46e-12	Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs10992471	0.729	rs7042335	chr9:95122547	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.45	-5.62	-0.33	4.71e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CESC	trans	rs208520	0.507	rs7755710	chr6:66783355	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.07	-22.35	-0.81	6.49e-63	Exhaled nitric oxide output;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03712758	chr16:48400154	SIAH1	-0.66	-7.28	-0.41	3.79e-12	Gut microbiome composition (summer);
CESC	cis	rs3105593	1.000	rs3105591	chr15:50869042	C/T	cg08437265	chr15:50716283	USP8	0.4	5.28	0.31	2.71e-7	QT interval;
CESC	cis	rs9399135	0.967	rs2150681	chr6:135375232	A/G	cg22676075	chr6:135203613	NA	-0.49	-6.77	-0.38	8.35e-11	Red blood cell count;
CESC	cis	rs477692	0.699	rs471390	chr10:131382825	A/G	cg05714579	chr10:131428358	MGMT	-0.41	-5.36	-0.31	1.84e-7	Response to temozolomide;
CESC	cis	rs1005224	1.000	rs1005224	chr14:76173860	A/T	cg25116370	chr14:76127843	TTLL5;C14orf1	-0.4	-5.45	-0.32	1.17e-7	Large artery stroke;
CESC	cis	rs1348850	0.645	rs10181259	chr2:178428256	C/A	cg22681709	chr2:178499509	PDE11A	-0.5	-6.34	-0.36	9.61e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs7100689	0.622	rs10887798	chr10:82131613	G/A	cg00277334	chr10:82204260	NA	-0.58	-7.63	-0.42	4.2e-13	Post bronchodilator FEV1;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg17014947	chr15:35529521	LOC723972	-0.48	-6.45	-0.37	5.39e-10	Gut microbiota (bacterial taxa);
CESC	trans	rs9951602	0.512	rs8098115	chr18:76653986	G/T	cg02800362	chr5:177631904	HNRNPAB	0.66	8.63	0.47	5.9e-16	Obesity-related traits;
CESC	cis	rs7927592	0.673	rs498782	chr11:68275851	A/G	cg16797656	chr11:68205561	LRP5	0.49	7.52	0.42	8.77e-13	Total body bone mineral density;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg02835036	chr3:58318399	PXK	0.47	6.4	0.37	7.16e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs78456975	0.527	rs11901028	chr2:1557972	A/G	cg26248373	chr2:1572462	NA	-0.57	-6.87	-0.39	4.63e-11	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs524023	0.874	rs7105665	chr11:64396568	T/C	cg07220939	chr11:64358617	SLC22A12	-0.36	-5.45	-0.32	1.17e-7	Urate levels in obese individuals;
CESC	cis	rs36051895	0.659	rs1576271	chr9:5039652	A/C	cg02405213	chr9:5042618	JAK2	-0.43	-5.2	-0.3	4.06e-7	Pediatric autoimmune diseases;
CESC	cis	rs875971	0.508	rs10242423	chr7:66059175	A/G	cg18876405	chr7:65276391	NA	-0.54	-7.7	-0.43	2.66e-13	Aortic root size;
CESC	cis	rs3741404	0.574	rs638227	chr11:63871549	T/C	cg18225595	chr11:63971243	STIP1	0.5	6.59	0.38	2.39e-10	Platelet count;
CESC	cis	rs7246657	0.943	rs10405325	chr19:37883477	G/C	cg23950597	chr19:37808831	NA	-0.61	-6.2	-0.36	2.21e-9	Coronary artery calcification;
CESC	cis	rs9916302	0.904	rs11078910	chr17:37671269	G/T	cg07936489	chr17:37558343	FBXL20	-0.81	-12.09	-0.6	4.18e-27	Glomerular filtration rate (creatinine);
CESC	cis	rs959260	1.000	rs2053157	chr17:73378595	A/T	cg12999837	chr17:73267436	MIF4GD	-0.51	-5.85	-0.34	1.48e-8	Systemic lupus erythematosus;
CESC	cis	rs7336332	0.547	rs9581859	chr13:28035147	A/T	cg01674679	chr13:27998804	GTF3A	-0.66	-5.25	-0.31	3.11e-7	Weight;
CESC	cis	rs4819052	0.851	rs2838834	chr21:46665208	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.45	5.54	0.32	7.11e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs2011503	0.941	rs55765017	chr19:19368264	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.5	5.06	0.3	7.87e-7	Bipolar disorder;
CESC	cis	rs7659604	1.000	rs7659604	chr4:122665514	A/G	cg19671926	chr4:122722719	EXOSC9	0.48	5.95	0.34	8.57e-9	Type 2 diabetes;
CESC	cis	rs3733585	0.578	rs4466042	chr4:9955367	T/C	cg02734326	chr4:10020555	SLC2A9	-0.4	-5.77	-0.33	2.19e-8	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs8141529	0.584	rs58004020	chr22:29257050	A/T	cg15103426	chr22:29168792	CCDC117	0.67	9.52	0.5	1.15e-18	Lymphocyte counts;
CESC	cis	rs1707322	0.963	rs6690652	chr1:46376692	G/T	cg03146154	chr1:46216737	IPP	0.71	9.86	0.52	9.69e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg02072376	chr1:153606637	C1orf77;S100A13	-0.44	-6.26	-0.36	1.52e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs9322193	0.923	rs7769101	chr6:150169904	C/A	cg13206674	chr6:150067644	NUP43	0.43	5.69	0.33	3.4e-8	Lung cancer;
CESC	cis	rs1218582	0.772	rs4845688	chr1:154884142	T/C	cg06221963	chr1:154839813	KCNN3	-0.66	-11.27	-0.57	2.55e-24	Prostate cancer;
CESC	cis	rs10899021	0.790	rs59958321	chr11:74354614	G/A	cg25880958	chr11:74394337	NA	-0.76	-7.88	-0.44	8.55e-14	Response to metformin (IC50);
CESC	cis	rs1144333	1.000	rs2202019	chr1:76299181	G/A	cg10523679	chr1:76189770	ACADM	0.56	5.28	0.31	2.65e-7	Attention function in attention deficit hyperactive disorder;
CESC	cis	rs9393777	0.623	rs16891717	chr6:26477143	T/A	cg14345882	chr6:26364793	BTN3A2	0.43	5.34	0.31	2.01e-7	Intelligence (multi-trait analysis);
CESC	trans	rs1814175	0.715	rs10839409	chr11:49884647	G/T	cg15704280	chr7:45808275	SEPT13	-1.03	-20.73	-0.79	2.07e-57	Height;
CESC	cis	rs3008870	1.000	rs2065001	chr1:67486509	C/G	cg08660285	chr1:67390436	MIER1;WDR78	1.02	13.47	0.64	7.49e-32	Lymphocyte percentage of white cells;
CESC	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.55	-6.13	-0.35	3.19e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs6674176	0.628	rs4660759	chr1:44432500	C/G	cg12908607	chr1:44402522	ARTN	-0.49	-6.92	-0.39	3.44e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs11958404	0.860	rs56090852	chr5:157431120	A/G	cg05962755	chr5:157440814	NA	0.62	6.56	0.37	2.74e-10	IgG glycosylation;
CESC	cis	rs1799949	0.965	rs11650913	chr17:41331597	T/C	cg05368731	chr17:41323189	NBR1	0.76	10.35	0.54	2.73e-21	Menopause (age at onset);
CESC	cis	rs2836974	0.931	rs8132285	chr21:40655752	T/C	cg11644478	chr21:40555479	PSMG1	1.05	16.84	0.72	9.02e-44	Cognitive function;
CESC	cis	rs17376456	0.825	rs10075217	chr5:93176774	C/G	cg21475434	chr5:93447410	FAM172A	0.75	6.68	0.38	1.38e-10	Diabetic retinopathy;
CESC	cis	rs3026101	0.671	rs8076560	chr17:5299527	G/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.42	5.6	0.33	5.31e-8	Body mass index;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg12548629	chr7:92463334	CDK6	-0.48	-6.41	-0.37	6.77e-10	Asthma;
CESC	cis	rs514406	0.858	rs574853	chr1:53310959	A/T	cg25767906	chr1:53392781	SCP2	-0.46	-6.01	-0.35	6.16e-9	Monocyte count;
CESC	cis	rs12458462	0.892	rs2007483	chr18:77476131	A/T	cg23301140	chr18:77439876	CTDP1	0.57	7.75	0.43	2.02e-13	Monocyte count;
CESC	cis	rs2576037	0.583	rs530205	chr18:44385150	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.35	5.64	0.33	4.24e-8	Personality dimensions;
CESC	cis	rs2243480	1.000	rs1392104	chr7:65759107	G/A	cg18252515	chr7:66147081	NA	1.41	14.3	0.66	9.43e-35	Diabetic kidney disease;
CESC	cis	rs8067354	0.645	rs2645492	chr17:57875554	A/G	cg02344993	chr17:57696989	CLTC	-0.55	-6.01	-0.35	6.27e-9	Hemoglobin concentration;
CESC	cis	rs6582630	0.555	rs10880611	chr12:38509316	C/G	cg26384229	chr12:38710491	ALG10B	0.7	10.5	0.54	8.9e-22	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs12618769	0.597	rs3769713	chr2:99151434	A/G	cg10123293	chr2:99228465	UNC50	0.4	5.23	0.31	3.4e-7	Bipolar disorder;
CESC	cis	rs7666738	0.830	rs1593573	chr4:98925293	T/C	cg17366294	chr4:99064904	C4orf37	0.6	8.23	0.45	8.65e-15	Colonoscopy-negative controls vs population controls;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg15894619	chr12:56993036	BAZ2A	0.52	6.05	0.35	4.87e-9	Ulcerative colitis;
CESC	cis	rs7071206	0.740	rs2048781	chr10:79422975	T/C	cg00983440	chr10:79422392	NA	-0.66	-8.01	-0.44	3.62e-14	Bone mineral density;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg18342900	chr16:46865048	C16orf87	-0.44	-6.26	-0.36	1.53e-9	Gambling;
CESC	cis	rs68170813	0.559	rs2299422	chr7:106959832	A/T	cg02696742	chr7:106810147	HBP1	-0.53	-5.04	-0.3	8.64e-7	Coronary artery disease;
CESC	cis	rs16854884	0.545	rs7650459	chr3:143658934	C/G	cg01302019	chr3:143689584	C3orf58	-0.35	-5.53	-0.32	7.68e-8	Economic and political preferences (feminism/equality);
CESC	cis	rs7089973	0.604	rs2420066	chr10:116583897	A/G	cg03647239	chr10:116582469	FAM160B1	0.42	5.13	0.3	5.48e-7	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs3768617	0.510	rs10797851	chr1:183098001	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.89	14.39	0.66	4.39e-35	Fuchs's corneal dystrophy;
CESC	cis	rs962856	0.619	rs4671795	chr2:67567068	A/G	cg09028215	chr2:67624308	ETAA1	-0.44	-5.29	-0.31	2.58e-7	Pancreatic cancer;
CESC	cis	rs2760061	0.819	rs1745417	chr1:228204279	C/T	cg18477163	chr1:228402036	OBSCN	0.33	5.77	0.33	2.23e-8	Diastolic blood pressure;
CESC	cis	rs7618915	0.501	rs7624716	chr3:52751534	T/C	cg17372223	chr3:52568218	NT5DC2	0.44	6.64	0.38	1.8e-10	Bipolar disorder;
CESC	cis	rs4660261	0.526	rs3011228	chr1:44325995	A/G	cg12908607	chr1:44402522	ARTN	-0.45	-6.39	-0.37	7.55e-10	Intelligence (multi-trait analysis);
CESC	cis	rs2251381	0.606	rs8129515	chr21:30520167	C/G	cg08807101	chr21:30365312	RNF160	0.68	8.58	0.47	8.18e-16	Selective IgA deficiency;
CESC	cis	rs514406	0.727	rs61768342	chr1:53217028	G/A	cg08736216	chr1:53307985	ZYG11A	0.32	5.53	0.32	7.58e-8	Monocyte count;
CESC	cis	rs7824557	0.767	rs11250127	chr8:11170209	G/A	cg21775007	chr8:11205619	TDH	0.47	6.95	0.39	2.85e-11	Retinal vascular caliber;
CESC	cis	rs7336332	0.569	rs7988412	chr13:28000282	C/T	cg01674679	chr13:27998804	GTF3A	-0.64	-6.18	-0.36	2.39e-9	Weight;
CESC	cis	rs9318086	0.753	rs9553094	chr13:24474613	A/G	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.43	-6.39	-0.37	7.37e-10	Myopia (pathological);
CESC	cis	rs2439831	1.000	rs2467736	chr15:43784917	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.83	11.92	0.59	1.68e-26	Lung cancer in ever smokers;
CESC	cis	rs6976053	0.564	rs314347	chr7:100399149	G/A	cg03098644	chr7:100410630	EPHB4	-0.46	-5.84	-0.34	1.54e-8	Plasminogen activator inhibitor type 1 levels (PAI-1);
CESC	cis	rs4727027	0.901	rs4727018	chr7:148822247	G/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.41	5.08	0.3	7.22e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs7615952	0.576	rs4646748	chr3:125826329	G/A	cg18479299	chr3:125709523	NA	-0.49	-5.19	-0.3	4.16e-7	Blood pressure (smoking interaction);
CESC	cis	rs4665809	1.000	rs4665308	chr2:26330514	C/A	cg27170947	chr2:26402098	FAM59B	-0.59	-7.07	-0.4	1.36e-11	Gut microbiome composition (summer);
CESC	trans	rs916888	0.687	rs199456	chr17:44797919	C/T	cg23590916	chr17:43697445	MGC57346	0.65	6.44	0.37	5.62e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs1568889	1.000	rs16917735	chr11:28119980	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	-0.72	-9.21	-0.49	1.05e-17	Bipolar disorder;
CESC	cis	rs3008870	1.000	rs35365746	chr1:67438900	G/A	cg08660285	chr1:67390436	MIER1;WDR78	-1.04	-14.53	-0.67	1.38e-35	Lymphocyte percentage of white cells;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg06111305	chr13:98086784	RAP2A	-0.46	-6.04	-0.35	5.07e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs2425143	0.822	rs6060677	chr20:34499368	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.75	6.96	0.39	2.69e-11	Blood protein levels;
CESC	cis	rs524281	0.861	rs10896094	chr11:65959206	C/T	cg14036092	chr11:66035641	RAB1B	-0.59	-6.13	-0.35	3.24e-9	Electroencephalogram traits;
CESC	cis	rs3096299	0.967	rs7205785	chr16:89458984	A/G	cg08822215	chr16:89438651	ANKRD11	-0.41	-6.28	-0.36	1.38e-9	Multiple myeloma (IgH translocation);
CESC	cis	rs12142240	0.698	rs6697123	chr1:46811310	A/C	cg00530320	chr1:46809349	NSUN4	0.58	7.85	0.43	1.05e-13	Menopause (age at onset);
CESC	cis	rs12765878	1.000	rs2067832	chr10:105643134	G/A	cg11005552	chr10:105648138	OBFC1	0.36	5.29	0.31	2.51e-7	Coronary artery disease;
CESC	cis	rs2204008	0.775	rs11182513	chr12:38560252	G/C	cg26384229	chr12:38710491	ALG10B	0.76	11.63	0.58	1.62e-25	Bladder cancer;
CESC	cis	rs9303401	0.614	rs3803752	chr17:56540267	C/T	cg25039879	chr17:56429692	SUPT4H1	0.53	5.14	0.3	5.32e-7	Cognitive test performance;
CESC	cis	rs7666738	0.830	rs7657179	chr4:98948569	G/A	cg05340658	chr4:99064831	C4orf37	0.82	12.65	0.61	5.23e-29	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7216064	0.953	rs12601759	chr17:65955284	A/G	cg12091567	chr17:66097778	LOC651250	-0.7	-7.16	-0.4	7.85e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs8060686	0.641	rs7192187	chr16:68132109	T/C	cg26727032	chr16:67993705	SLC12A4	-0.52	-6.33	-0.36	1.05e-9	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs7584330	0.740	rs11896232	chr2:238438124	T/C	cg14458575	chr2:238380390	NA	0.51	7.64	0.42	3.95e-13	Prostate cancer;
CESC	cis	rs10782582	0.593	rs4646960	chr1:76211103	C/A	cg10523679	chr1:76189770	ACADM	-0.48	-5.59	-0.32	5.59e-8	Daytime sleep phenotypes;
CESC	trans	rs17181170	0.666	rs6801665	chr3:87209149	T/C	ch.2.199792288R	chr2:200084043	NA	-0.48	-6.23	-0.36	1.82e-9	Prostate cancer;
CESC	cis	rs7914558	1.000	rs7081075	chr10:104929191	C/T	cg04362960	chr10:104952993	NT5C2	0.47	6.21	0.36	2e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs6952808	0.510	rs13227554	chr7:2048220	G/C	cg21782813	chr7:2030301	MAD1L1	-0.4	-5.57	-0.32	6.23e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs28489187	0.660	rs4949900	chr1:85861034	T/G	cg16011679	chr1:85725395	C1orf52	-0.44	-5.24	-0.31	3.36e-7	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	cis	rs28386778	0.700	rs11079515	chr17:62005645	C/G	cg07677032	chr17:61819896	STRADA	-0.48	-6.3	-0.36	1.21e-9	Prudent dietary pattern;
CESC	cis	rs2228479	0.867	rs34604714	chr16:89948985	A/G	cg14709524	chr16:89940631	TCF25	0.74	5.75	0.33	2.43e-8	Skin colour saturation;
CESC	cis	rs116095464	0.558	rs73024831	chr5:257192	A/G	cg22496380	chr5:211416	CCDC127	-0.73	-8.39	-0.46	2.99e-15	Breast cancer;
CESC	cis	rs12477438	0.798	rs6736064	chr2:99658201	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-10.57	-0.54	5.22e-22	Chronic sinus infection;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11216682	chr2:131113867	PTPN18	0.54	6.55	0.37	2.9e-10	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10480950	chr6:5067127	NA	-0.6	-7.16	-0.4	8.19e-12	Gut microbiome composition (summer);
CESC	cis	rs9487051	0.652	rs9372210	chr6:109601703	G/C	cg12927641	chr6:109611667	NA	-0.36	-5.24	-0.31	3.24e-7	Reticulocyte fraction of red cells;
CESC	cis	rs910316	0.699	rs175039	chr14:75468950	G/C	cg11812906	chr14:75593930	NEK9	-0.8	-12.67	-0.61	4.38e-29	Height;
CESC	cis	rs1707322	0.827	rs10890347	chr1:46242332	A/T	cg03146154	chr1:46216737	IPP	-0.78	-10.48	-0.54	1.02e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7811142	0.943	rs111493473	chr7:100049742	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.95	10.19	0.53	8.92e-21	Platelet count;
CESC	cis	rs7959452	0.590	rs11177644	chr12:69785748	A/G	cg22834771	chr12:69754056	YEATS4	-0.46	-6.2	-0.36	2.17e-9	Blood protein levels;
CESC	cis	rs270601	0.633	rs4535443	chr5:131572561	A/G	cg18301423	chr5:131593218	PDLIM4	0.38	5.24	0.31	3.27e-7	Acylcarnitine levels;
CESC	cis	rs875971	0.660	rs62465434	chr7:66005152	A/C	cg25985355	chr7:65971099	NA	-0.32	-5.28	-0.31	2.71e-7	Aortic root size;
CESC	cis	rs941873	0.868	rs4980063	chr10:81105844	A/T	cg11057378	chr10:81107060	PPIF	0.32	5.15	0.3	5.12e-7	Height;
CESC	cis	rs7264396	0.836	rs6058282	chr20:34212590	T/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.65	7.48	0.42	1.06e-12	Total cholesterol levels;
CESC	cis	rs2046867	0.908	rs1106310	chr3:72818902	A/T	cg25664220	chr3:72788482	NA	0.45	6.94	0.39	2.92e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CESC	cis	rs9581857	0.547	rs4612914	chr13:28049128	A/G	cg01674679	chr13:27998804	GTF3A	-0.68	-5.47	-0.32	1.04e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
CESC	cis	rs524281	0.731	rs11227433	chr11:66004693	G/A	cg14036092	chr11:66035641	RAB1B	-0.53	-5.31	-0.31	2.28e-7	Electroencephalogram traits;
CESC	cis	rs1707322	1.000	rs10890382	chr1:46469674	A/G	cg06784218	chr1:46089804	CCDC17	0.38	6.42	0.37	6.22e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs67311347	1.000	rs9882171	chr3:40518821	G/A	cg09455208	chr3:40491958	NA	0.48	8.36	0.46	3.68e-15	Renal cell carcinoma;
CESC	cis	rs6840360	0.554	rs61308159	chr4:152728941	G/A	cg22705602	chr4:152727874	NA	0.37	5.07	0.3	7.32e-7	Intelligence (multi-trait analysis);
CESC	cis	rs858239	0.669	rs10950940	chr7:23196816	C/T	cg23682824	chr7:23144976	KLHL7	-0.43	-5.78	-0.33	2.05e-8	Cerebrospinal fluid biomarker levels;
CESC	cis	rs965469	1.000	rs77763497	chr20:3250007	A/G	cg25506879	chr20:3388711	C20orf194	-0.62	-6.55	-0.37	3.01e-10	IFN-related cytopenia;
CESC	cis	rs10771431	0.782	rs10771415	chr12:9358223	C/T	cg08997352	chr12:9597637	DDX12	-0.76	-10.48	-0.54	1.01e-21	Breast size;
CESC	cis	rs6089584	0.924	rs6142906	chr20:60552554	G/C	cg24733560	chr20:60626293	TAF4	0.42	6.06	0.35	4.61e-9	Body mass index;
CESC	cis	rs12477438	0.520	rs11685759	chr2:99766217	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.86	16.02	0.7	7.14e-41	Chronic sinus infection;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01989157	chr22:40742702	ADSL	-0.63	-7.47	-0.42	1.16e-12	Gut microbiome composition (summer);
CESC	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.61	-9.12	-0.49	1.96e-17	Longevity;Endometriosis;
CESC	cis	rs9987353	0.519	rs2929465	chr8:9064002	C/G	cg15556689	chr8:8085844	FLJ10661	-0.46	-5.54	-0.32	7.43e-8	Recombination measurement;
CESC	cis	rs3733585	0.699	rs7435196	chr4:9967556	A/C	cg00071950	chr4:10020882	SLC2A9	-0.7	-11.56	-0.58	2.67e-25	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs763121	0.819	rs5750629	chr22:38985065	T/C	cg06544989	chr22:39130855	UNC84B	0.5	9.21	0.49	1e-17	Menopause (age at onset);
CESC	cis	rs1062177	1.000	rs12515762	chr5:151209922	G/T	cg12924095	chr5:151150029	G3BP1	0.5	6.48	0.37	4.55e-10	Preschool internalizing problems;
CESC	cis	rs2777491	0.522	rs7173571	chr15:41712807	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.55	-7.63	-0.42	4.24e-13	Ulcerative colitis;
CESC	cis	rs2576037	0.583	rs10070	chr18:44388899	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.78	12.92	0.62	6.19e-30	Personality dimensions;
CESC	cis	rs6963495	0.769	rs73192134	chr7:105189338	T/C	cg02135003	chr7:105160482	PUS7	-0.46	-5.48	-0.32	1.01e-7	Bipolar disorder (body mass index interaction);
CESC	cis	rs9815354	0.812	rs73083333	chr3:41927505	G/A	cg03022575	chr3:42003672	ULK4	0.71	6.39	0.37	7.39e-10	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs2929278	0.546	rs686666	chr15:44161550	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.49	7.63	0.42	4.13e-13	Schizophrenia;
CESC	cis	rs12477438	0.798	rs13414153	chr2:99624748	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.64	-8.91	-0.48	8.52e-17	Chronic sinus infection;
CESC	cis	rs763121	0.853	rs2413544	chr22:39059404	A/C	cg14440974	chr22:39074834	NA	-0.4	-5.5	-0.32	9.03e-8	Menopause (age at onset);
CESC	cis	rs72387598	1	rs72387598	chr1:45922977	CAT/C	cg03146154	chr1:46216737	IPP	0.47	5.44	0.32	1.23e-7	Platelet distribution width;
CESC	cis	rs3733585	0.604	rs73215003	chr4:10126317	C/G	cg00071950	chr4:10020882	SLC2A9	-0.66	-10.48	-0.54	9.69e-22	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs870825	0.616	rs4519834	chr4:185633865	A/G	cg04058563	chr4:185651563	MLF1IP	-0.67	-7.35	-0.41	2.41e-12	Blood protein levels;
CESC	cis	rs10504229	1.000	rs74546828	chr8:58171678	A/G	cg24829409	chr8:58192753	C8orf71	-0.76	-10.0	-0.52	3.53e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs61931739	0.500	rs34703942	chr12:34583776	T/C	cg23762105	chr12:34175262	ALG10	0.4	5.17	0.3	4.62e-7	Morning vs. evening chronotype;
CESC	cis	rs4660261	0.526	rs3094954	chr1:44320919	C/T	cg13606994	chr1:44402422	ARTN	-0.35	-5.14	-0.3	5.31e-7	Intelligence (multi-trait analysis);
CESC	cis	rs7666738	0.830	rs34671152	chr4:98978177	C/T	cg03676636	chr4:99064102	C4orf37	0.34	5.2	0.3	3.93e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs780096	0.526	rs1406295	chr2:27689700	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.35	-6.56	-0.37	2.79e-10	Total body bone mineral density;
CESC	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg01171360	chr6:293285	DUSP22	0.66	8.66	0.47	4.7e-16	Menopause (age at onset);
CESC	trans	rs116095464	0.558	rs6872854	chr5:209038	G/T	cg00938859	chr5:1591904	SDHAP3	0.6	6.68	0.38	1.41e-10	Breast cancer;
CESC	cis	rs7917772	0.636	rs4418737	chr10:104525123	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.44	-5.18	-0.3	4.3e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs7523050	0.643	rs7519293	chr1:109399543	A/G	cg08274380	chr1:109419600	GPSM2	0.83	5.58	0.32	5.89e-8	Fat distribution (HIV);
CESC	cis	rs651907	0.514	rs55654108	chr3:101425703	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.45	5.9	0.34	1.1e-8	Colorectal cancer;
CESC	cis	rs7582720	1.000	rs35212307	chr2:203765756	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.39	0.41	1.96e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs9788682	0.792	rs35031105	chr15:78772806	C/T	cg24631222	chr15:78858424	CHRNA5	0.62	7.27	0.41	3.96e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs2243480	1.000	rs313814	chr7:65503293	C/A	cg18252515	chr7:66147081	NA	-1.29	-12.65	-0.61	5.36e-29	Diabetic kidney disease;
CESC	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg07308232	chr7:1071921	C7orf50	-0.6	-8.54	-0.46	1.04e-15	Longevity;Endometriosis;
CESC	cis	rs12681288	0.823	rs2701909	chr8:1003057	A/G	cg04851639	chr8:1020857	NA	-0.34	-7.49	-0.42	1e-12	Schizophrenia;
CESC	cis	rs6963495	0.818	rs73192125	chr7:105175068	A/C	cg13798780	chr7:105162888	PUS7	0.73	7.9	0.44	7.36e-14	Bipolar disorder (body mass index interaction);
CESC	trans	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg13565492	chr6:43139072	SRF	-0.75	-9.29	-0.5	5.94e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7520050	0.933	rs6661163	chr1:46255004	A/G	cg03146154	chr1:46216737	IPP	-0.5	-6.78	-0.38	7.95e-11	Red blood cell count;Reticulocyte count;
CESC	cis	rs7618915	0.547	rs4687548	chr3:52666650	A/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.31	5.43	0.32	1.24e-7	Bipolar disorder;
CESC	cis	rs2243480	0.908	rs313822	chr7:65573939	G/A	cg13147721	chr7:65941812	NA	-0.99	-9.34	-0.5	4.25e-18	Diabetic kidney disease;
CESC	cis	rs1568889	1.000	rs12287732	chr11:28120845	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.75	10.76	0.55	1.19e-22	Bipolar disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15454818	chr7:75932933	HSPB1	0.56	6.01	0.35	6.14e-9	Gut microbiome composition (summer);
CESC	cis	rs858239	0.539	rs2141305	chr7:23191899	T/C	cg23682824	chr7:23144976	KLHL7	0.51	6.77	0.38	8.05e-11	Cerebrospinal fluid biomarker levels;
CESC	trans	rs12615721	0.786	rs60344971	chr2:81948537	C/T	cg13174197	chr3:52720522	GNL3;PBRM1	0.78	6.3	0.36	1.22e-9	Pulmonary function decline;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11789684	chr7:141251045	AGK	0.56	6.45	0.37	5.3e-10	Gut microbiome composition (summer);
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg27099511	chr16:88729703	MGC23284;MVD	-0.52	-6.59	-0.38	2.38e-10	Asthma;
CESC	cis	rs2012796	0.956	rs7146802	chr14:81820515	A/G	cg02996355	chr14:81879375	NA	0.53	6.15	0.35	2.91e-9	Night sleep phenotypes;
CESC	cis	rs7527798	0.592	rs6667118	chr1:207822724	G/T	cg21110645	chr1:207815933	NA	-0.33	-5.94	-0.34	9.12e-9	Erythrocyte sedimentation rate;
CESC	cis	rs798554	0.683	rs1182155	chr7:2902890	C/G	cg13628971	chr7:2884303	GNA12	0.63	8.33	0.46	4.4e-15	Height;
CESC	cis	rs367943	0.698	rs2900074	chr5:113000374	A/C	cg12552261	chr5:112820674	MCC	0.46	5.88	0.34	1.26e-8	Type 2 diabetes;
CESC	cis	rs2204008	0.744	rs12099650	chr12:38317140	C/G	cg26384229	chr12:38710491	ALG10B	0.66	9.82	0.52	1.26e-19	Bladder cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22914762	chr4:117220908	MIR1973	-0.6	-7.48	-0.42	1.09e-12	Gut microbiome composition (summer);
CESC	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg23131131	chr22:24373011	LOC391322	-0.63	-9.02	-0.48	3.88e-17	Liver enzyme levels (gamma-glutamyl transferase);
CESC	trans	rs1814175	0.645	rs10742953	chr11:49807491	C/G	cg11707556	chr5:10655725	ANKRD33B	0.43	6.12	0.35	3.43e-9	Height;
CESC	cis	rs7666738	0.893	rs11729640	chr4:99052699	C/T	cg24818145	chr4:99064322	C4orf37	0.38	5.04	0.3	8.49e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs933688	1.000	rs11950530	chr5:90688740	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.99	11.87	0.59	2.36e-26	Smoking behavior;
CESC	cis	rs10880689	1	rs10880689	chr12:37930102	A/G	cg26384229	chr12:38710491	ALG10B	0.67	9.69	0.51	3.43e-19	Resting heart rate;
CESC	cis	rs5769765	0.671	rs138841	chr22:50181960	C/A	cg02269571	chr22:50332266	NA	-0.46	-5.94	-0.34	9.04e-9	Schizophrenia;
CESC	cis	rs7666738	0.830	rs28769113	chr4:98950371	T/G	cg03467027	chr4:99064603	C4orf37	0.45	5.67	0.33	3.69e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10504229	1.000	rs112284078	chr8:58191640	A/G	cg14926445	chr8:58193284	C8orf71	-0.53	-5.61	-0.33	5.1e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs896854	0.902	rs726816	chr8:95968413	T/G	cg16049864	chr8:95962084	TP53INP1	-0.69	-11.99	-0.59	9.66e-27	Type 2 diabetes;
CESC	trans	rs747782	0.527	rs12289516	chr11:48234680	G/A	cg15704280	chr7:45808275	SEPT13	0.71	6.65	0.38	1.68e-10	Intraocular pressure;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16224671	chr7:23146217	KLHL7	-0.5	-6.06	-0.35	4.73e-9	Gut microbiome composition (summer);
CESC	cis	rs9583531	0.657	rs7318291	chr13:111352460	C/T	cg15841412	chr13:111365552	ING1	-0.43	-5.18	-0.3	4.32e-7	Coronary artery disease;
CESC	cis	rs12136530	0.774	rs4912095	chr1:19766236	T/C	cg01832549	chr1:19774989	CAPZB	-0.48	-6.66	-0.38	1.54e-10	Lead levels in blood;
CESC	cis	rs939574	1.000	rs11552796	chr2:220108300	T/C	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.84	7.22	0.41	5.65e-12	Platelet distribution width;
CESC	cis	rs7259376	0.936	rs1975173	chr19:22534538	C/G	cg02657401	chr19:22469223	NA	-0.27	-5.21	-0.3	3.74e-7	Menopause (age at onset);
CESC	cis	rs11792861	0.591	rs4978763	chr9:111728067	C/T	cg05043794	chr9:111880884	C9orf5	-0.31	-5.65	-0.33	4.22e-8	Menarche (age at onset);
CESC	cis	rs10771431	0.935	rs1117735	chr12:9372728	G/A	cg00504896	chr12:9437009	LOC642846	-0.41	-5.49	-0.32	9.33e-8	Breast size;
CESC	cis	rs8017423	0.904	rs11623741	chr14:90804474	C/T	cg14092571	chr14:90743983	NA	-0.57	-8.94	-0.48	7.01e-17	Mortality in heart failure;
CESC	cis	rs736408	0.562	rs12497998	chr3:52793602	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.62	8.59	0.47	7.71e-16	Bipolar disorder;
CESC	cis	rs10129255	0.509	rs756583	chr14:107136019	C/T	cg23076370	chr14:107095027	NA	-0.53	-7.45	-0.42	1.34e-12	Kawasaki disease;
CESC	cis	rs7512552	0.839	rs834229	chr1:150384665	G/C	cg15654264	chr1:150340011	RPRD2	0.4	5.2	0.3	4.06e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs9487051	0.872	rs9400271	chr6:109607556	G/A	cg21918786	chr6:109611834	NA	-0.4	-6.01	-0.35	6.17e-9	Reticulocyte fraction of red cells;
CESC	cis	rs801193	0.569	rs2707847	chr7:66202871	C/G	cg18876405	chr7:65276391	NA	0.45	6.09	0.35	3.92e-9	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17478615	chr1:185285364	IVNS1ABP	0.64	7.75	0.43	1.95e-13	Gut microbiome composition (summer);
CESC	cis	rs9359856	0.564	rs1036853	chr6:90499502	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.62	-5.94	-0.34	8.89e-9	Bipolar disorder;
CESC	cis	rs3785574	0.962	rs58131426	chr17:61854375	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.58	7.24	0.41	4.89e-12	Height;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg01390039	chr16:89315293	NA	0.49	6.32	0.36	1.1e-9	Fibrinogen levels;
CESC	cis	rs1784581	0.569	rs9364629	chr6:162416831	T/G	cg17173639	chr6:162384350	PARK2	0.56	8.43	0.46	2.21e-15	Itch intensity from mosquito bite;
CESC	cis	rs4727027	0.901	rs10952792	chr7:148760501	C/T	cg23583168	chr7:148888333	NA	-0.77	-11.6	-0.58	1.95e-25	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	trans	rs11098499	0.866	rs12374244	chr4:120281972	A/T	cg25214090	chr10:38739885	LOC399744	0.65	9.11	0.49	2.04e-17	Corneal astigmatism;
CESC	cis	rs826838	1.000	rs10880963	chr12:38748408	T/C	cg13010199	chr12:38710504	ALG10B	0.62	8.74	0.47	2.7e-16	Heart rate;
CESC	cis	rs4889855	0.530	rs75398920	chr17:78544540	C/T	cg16591659	chr17:78472290	NA	0.39	6.5	0.37	3.9e-10	Fractional excretion of uric acid;
CESC	cis	rs7618915	0.571	rs12632381	chr3:52607685	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	6.78	0.38	7.94e-11	Bipolar disorder;
CESC	cis	rs548181	0.611	rs562599	chr11:125459951	A/C	cg03464685	chr11:125439445	EI24	1.24	9.77	0.51	1.89e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs35110281	0.667	rs4819286	chr21:45120121	G/A	cg21573476	chr21:45109991	RRP1B	-0.58	-8.43	-0.46	2.18e-15	Mean corpuscular volume;
CESC	cis	rs3741151	0.773	rs57354084	chr11:73139376	A/T	cg17517138	chr11:73019481	ARHGEF17	0.94	6.86	0.39	4.87e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	trans	rs17508449	0.819	rs78394484	chr1:114282758	T/C	cg23028848	chr11:57092561	TNKS1BP1	-0.76	-6.07	-0.35	4.52e-9	Leprosy;
CESC	cis	rs4713118	0.512	rs2622319	chr6:28120401	G/C	cg23281280	chr6:28129359	ZNF389	0.44	6.46	0.37	5.1e-10	Parkinson's disease;
CESC	cis	rs2299587	0.527	rs7818801	chr8:17722867	G/C	cg08627089	chr8:17753878	FGL1	-0.39	-5.57	-0.32	6.35e-8	Economic and political preferences;
CESC	cis	rs6964587	1.000	rs10263309	chr7:91645265	A/G	cg17063962	chr7:91808500	NA	0.57	7.92	0.44	6.39e-14	Breast cancer;
CESC	cis	rs769267	0.965	rs735273	chr19:19385411	T/C	cg03709012	chr19:19516395	GATAD2A	0.96	14.18	0.66	2.35e-34	Tonsillectomy;
CESC	cis	rs7070678	0.662	rs913035	chr10:29818604	A/C	cg12329853	chr10:29834266	MIR604;SVIL	-0.38	-5.26	-0.31	3.03e-7	Platelet thrombus formation;
CESC	cis	rs6541297	0.793	rs6692319	chr1:230284375	C/T	cg20703242	chr1:230279135	GALNT2	0.74	11.07	0.56	1.18e-23	Coronary artery disease;
CESC	cis	rs72781680	1.000	rs6710426	chr2:24159288	A/G	cg08917208	chr2:24149416	ATAD2B	0.94	8.66	0.47	4.66e-16	Lymphocyte counts;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27115721	chr2:16790338	FAM49A	0.57	6.09	0.35	3.97e-9	Gut microbiome composition (summer);
CESC	cis	rs6545883	0.929	rs10190332	chr2:61619267	T/G	cg15711740	chr2:61764176	XPO1	0.39	5.03	0.3	9.02e-7	Tuberculosis;
CESC	cis	rs4812048	0.649	rs6070705	chr20:57625231	A/C	cg14073986	chr20:57617431	SLMO2	0.84	7.18	0.4	6.92e-12	Mean platelet volume;
CESC	cis	rs17407555	0.779	rs57757169	chr4:10115703	G/A	cg11266682	chr4:10021025	SLC2A9	-0.48	-5.87	-0.34	1.29e-8	Schizophrenia (age at onset);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg17086759	chr4:6303693	WFS1	0.49	6.35	0.36	9.32e-10	Fibrinogen levels;
CESC	cis	rs17376456	0.825	rs10072232	chr5:93398890	G/A	cg21475434	chr5:93447410	FAM172A	0.79	6.99	0.39	2.2e-11	Diabetic retinopathy;
CESC	cis	rs6815814	0.950	rs66979032	chr4:38814700	A/G	cg02016764	chr4:38805732	TLR1	-0.57	-6.5	-0.37	4.05e-10	Breast cancer;
CESC	cis	rs13095912	0.778	rs11914529	chr3:185296513	C/T	cg11274856	chr3:185301563	NA	0.39	5.86	0.34	1.4e-8	Systolic blood pressure;
CESC	cis	rs523516	0.645	rs520054	chr17:37321538	G/A	cg20555674	chr17:37321631	ARL5C	0.37	6.32	0.36	1.1e-9	IgG glycosylation;
CESC	cis	rs35306767	0.855	rs2050944	chr10:918910	T/C	cg10556349	chr10:835070	NA	0.59	5.6	0.33	5.25e-8	Eosinophil percentage of granulocytes;
CESC	cis	rs9583531	0.600	rs7984468	chr13:111362093	C/A	cg24331049	chr13:111365604	ING1	0.75	10.98	0.56	2.28e-23	Coronary artery disease;
CESC	cis	rs1568889	0.838	rs7121937	chr11:28359858	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.81	13.71	0.64	1.11e-32	Bipolar disorder;
CESC	cis	rs7267979	1.000	rs6050590	chr20:25384994	G/A	cg08601574	chr20:25228251	PYGB	-0.38	-5.55	-0.32	6.85e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs79976124	0.837	rs10498840	chr6:66658513	A/G	cg07460842	chr6:66804631	NA	0.78	9.08	0.49	2.57e-17	Type 2 diabetes;
CESC	cis	rs910316	0.935	rs3742771	chr14:75599647	A/G	cg08847533	chr14:75593920	NEK9	0.99	18.93	0.76	3.76e-51	Height;
CESC	cis	rs7143963	0.666	rs57613851	chr14:103319835	C/T	cg24154132	chr14:103367632	TRAF3	0.3	5.55	0.32	6.91e-8	Body mass index;
CESC	cis	rs6424115	0.830	rs2502991	chr1:24202318	A/G	cg10978503	chr1:24200527	CNR2	0.33	6.59	0.38	2.41e-10	Immature fraction of reticulocytes;
CESC	cis	rs9649213	0.593	rs13246868	chr7:97986453	T/C	cg08684580	chr7:98029266	BAIAP2L1	-0.35	-5.8	-0.34	1.85e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7789940	1.000	rs76024966	chr7:75995021	C/T	cg10167463	chr7:75959203	YWHAG	-0.55	-6.81	-0.39	6.33e-11	Multiple sclerosis;
CESC	cis	rs7103648	0.695	rs10838726	chr11:47568344	C/G	cg10504702	chr11:47789108	FNBP4	0.42	5.2	0.3	4.01e-7	Diastolic blood pressure;Systolic blood pressure;
CESC	cis	rs3820928	0.874	rs4675128	chr2:227814757	T/C	cg05526886	chr2:227700861	RHBDD1	-0.44	-5.68	-0.33	3.56e-8	Pulmonary function;
CESC	cis	rs40363	0.857	rs55989968	chr16:3530658	C/G	cg21433313	chr16:3507492	NAT15	0.68	8.36	0.46	3.49e-15	Tuberculosis;
CESC	cis	rs4728302	0.583	rs1424583	chr7:133159583	T/G	cg10665199	chr7:133106180	EXOC4	0.54	7.47	0.42	1.17e-12	Intelligence;Intelligence (multi-trait analysis);
CESC	cis	rs798554	0.679	rs2533877	chr7:2882421	G/A	cg19717773	chr7:2847554	GNA12	-0.48	-7.01	-0.4	1.97e-11	Height;
CESC	cis	rs9894429	0.646	rs9904137	chr17:79613925	C/T	cg21984481	chr17:79567631	NPLOC4	-0.33	-5.17	-0.3	4.68e-7	Eye color traits;
CESC	cis	rs9733	0.527	rs11204694	chr1:150653391	G/A	cg04414720	chr1:150670196	GOLPH3L	0.58	8.15	0.45	1.42e-14	Tonsillectomy;
CESC	cis	rs796364	1.000	rs35220450	chr2:200780737	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.83	-6.41	-0.37	6.49e-10	Schizophrenia;
CESC	cis	rs5750830	0.649	rs5757657	chr22:39798429	G/T	cg24399712	chr22:39784796	NA	-0.83	-11.67	-0.58	1.15e-25	Intelligence (multi-trait analysis);
CESC	cis	rs7666738	0.546	rs3911415	chr4:98692401	T/A	cg05340658	chr4:99064831	C4orf37	0.55	6.57	0.37	2.6e-10	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6939532	0.522	rs4712981	chr6:26361430	C/T	cg14345882	chr6:26364793	BTN3A2	0.38	6.06	0.35	4.64e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs2033711	0.783	rs8113810	chr19:58932106	A/G	cg13877915	chr19:58951672	ZNF132	0.39	5.8	0.34	1.84e-8	Uric acid clearance;
CESC	cis	rs8060686	0.565	rs8057577	chr16:68033143	C/T	cg26727032	chr16:67993705	SLC12A4	-0.52	-5.78	-0.33	2.09e-8	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs7829975	0.688	rs7826654	chr8:8379106	C/T	cg15556689	chr8:8085844	FLJ10661	0.53	6.45	0.37	5.3e-10	Mood instability;
CESC	cis	rs7586879	0.616	rs6545813	chr2:25131287	C/T	cg01884057	chr2:25150051	NA	0.36	7.02	0.4	1.82e-11	Body mass index;
CESC	cis	rs7107174	0.681	rs10899499	chr11:78124797	A/G	cg02023728	chr11:77925099	USP35	-0.42	-5.55	-0.32	6.83e-8	Testicular germ cell tumor;
CESC	cis	rs6460942	0.915	rs80345607	chr7:12442249	T/C	cg06484146	chr7:12443880	VWDE	-0.78	-9.1	-0.49	2.28e-17	Coronary artery disease;
CESC	cis	rs12122100	0.545	rs1984615	chr1:146506206	G/A	cg02487331	chr1:146550467	NA	-0.36	-5.46	-0.32	1.11e-7	HIV-1 control;
CESC	cis	rs2576037	0.526	rs538221	chr18:44375111	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.43	7.23	0.41	5.16e-12	Personality dimensions;
CESC	cis	rs4835473	0.868	rs62337291	chr4:144729056	G/A	cg25736465	chr4:144833511	NA	-0.33	-5.35	-0.31	1.92e-7	Immature fraction of reticulocytes;
CESC	cis	rs7474896	0.559	rs1735629	chr10:38178309	C/T	cg25427524	chr10:38739819	LOC399744	0.48	5.27	0.31	2.9e-7	Obesity (extreme);
CESC	cis	rs870825	0.587	rs58332461	chr4:185639742	G/A	cg04058563	chr4:185651563	MLF1IP	0.64	7.09	0.4	1.21e-11	Blood protein levels;
CESC	cis	rs7666738	0.830	rs115712871	chr4:98954535	A/T	cg03467027	chr4:99064603	C4orf37	0.45	5.61	0.33	4.97e-8	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17373321	chr8:21999250	REEP4	0.56	6.51	0.37	3.76e-10	Gut microbiome composition (summer);
CESC	cis	rs4665809	0.590	rs62128457	chr2:26467347	C/A	cg27170947	chr2:26402098	FAM59B	0.87	9.89	0.52	7.6e-20	Gut microbiome composition (summer);
CESC	cis	rs72627123	0.656	rs17096208	chr14:74555269	G/A	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.74	5.12	0.3	5.89e-7	Morning vs. evening chronotype;
CESC	cis	rs34779708	0.931	rs13376801	chr10:35370443	T/C	cg03585969	chr10:35415529	CREM	0.76	10.09	0.53	1.8e-20	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs1691799	0.836	rs1168334	chr12:66760972	A/G	cg16791601	chr12:66731901	HELB	-0.77	-13.33	-0.63	2.24e-31	White blood cell count (basophil);
CESC	cis	rs832540	0.629	rs10461616	chr5:56080347	T/C	cg14703610	chr5:56206110	C5orf35	0.4	5.1	0.3	6.49e-7	Coronary artery disease;
CESC	trans	rs2727020	0.729	rs685789	chr11:49241228	G/A	cg15704280	chr7:45808275	SEPT13	0.85	13.86	0.65	3.28e-33	Coronary artery disease;
CESC	cis	rs96067	0.711	rs11263861	chr1:36628033	G/A	cg24686825	chr1:36642396	MAP7D1	-0.43	-5.93	-0.34	9.58e-9	Corneal structure;
CESC	cis	rs9322193	0.923	rs11155683	chr6:150100477	T/C	cg07701084	chr6:150067640	NUP43	0.42	5.78	0.33	2.07e-8	Lung cancer;
CESC	cis	rs7551222	0.716	rs4245738	chr1:204506107	C/T	cg20240347	chr1:204465584	NA	-0.27	-5.53	-0.32	7.68e-8	Schizophrenia;
CESC	cis	rs425277	1.000	rs809912	chr1:2078385	C/T	cg16545954	chr1:2118288	C1orf86	0.33	5.6	0.33	5.35e-8	Height;
CESC	cis	rs2070488	0.775	rs6599204	chr3:38525734	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.78	12.02	0.59	7.73e-27	Electrocardiographic conduction measures;
CESC	cis	rs1878931	0.582	rs27231	chr16:3434966	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	0.66	8.06	0.44	2.66e-14	Body mass index (adult);
CESC	cis	rs11997175	0.784	rs36083407	chr8:33812930	G/T	ch.8.33884649F	chr8:33765107	NA	0.65	9.1	0.49	2.22e-17	Body mass index;
CESC	cis	rs7959452	0.535	rs1350166	chr12:69636314	G/T	cg14784868	chr12:69753453	YEATS4	0.74	10.76	0.55	1.23e-22	Blood protein levels;
CESC	trans	rs7839040	0.698	rs7836715	chr8:82928699	G/C	cg14472086	chr9:107730925	NA	-0.47	-6.33	-0.36	1.02e-9	Response to methotrexate in juvenile idiopathic arthritis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14582245	chr3:42632291	SS18L2	0.54	6.27	0.36	1.43e-9	Gut microbiome composition (summer);
CESC	cis	rs9311474	0.569	rs7614981	chr3:52566914	G/T	cg07507251	chr3:52567010	NT5DC2	0.54	11.16	0.57	5.94e-24	Electroencephalogram traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04460668	chr12:122984780	ZCCHC8	-0.54	-6.39	-0.37	7.61e-10	Gut microbiome composition (summer);
CESC	cis	rs11683229	0.704	rs4671454	chr2:63156832	T/G	cg17519650	chr2:63277830	OTX1	-0.66	-5.51	-0.32	8.5e-8	Protein quantitative trait loci;
CESC	cis	rs7945705	0.902	rs10769979	chr11:9010659	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.46	7.64	0.42	3.98e-13	Hemoglobin concentration;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03823722	chr10:3214957	PITRM1	0.58	6.53	0.37	3.38e-10	Gut microbiome composition (summer);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg17900697	chr17:27139003	C17orf63	0.46	6.3	0.36	1.25e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs11792861	0.926	rs75128146	chr9:111833791	G/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.43	5.31	0.31	2.29e-7	Menarche (age at onset);
CESC	cis	rs514406	0.861	rs2448792	chr1:53268313	T/C	cg08736216	chr1:53307985	ZYG11A	0.43	7.13	0.4	9.53e-12	Monocyte count;
CESC	cis	rs1552244	1.000	rs6781811	chr3:10121922	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.93	-13.38	-0.63	1.57e-31	Alzheimer's disease;
CESC	trans	rs561341	0.941	rs17780086	chr17:30343282	G/A	cg27661571	chr11:113659931	NA	-0.85	-7.51	-0.42	9.26e-13	Hip circumference adjusted for BMI;
CESC	cis	rs7582720	1.000	rs72934729	chr2:203737770	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.32	0.41	3.04e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18708365	chr7:103848079	ORC5L	-0.59	-7.14	-0.4	8.82e-12	Gut microbiome composition (summer);
CESC	trans	rs801193	0.901	rs4273746	chr7:66301111	C/T	cg18876405	chr7:65276391	NA	-0.67	-8.75	-0.47	2.48e-16	Aortic root size;
CESC	trans	rs1977584	0.725	rs61853976	chr10:45399242	T/C	cg09262100	chr14:103416268	CDC42BPB	0.61	6.14	0.35	3.02e-9	Selective IgA deficiency;
CESC	cis	rs2439831	0.867	rs28729853	chr15:43673680	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.86	13.04	0.63	2.26e-30	Lung cancer in ever smokers;
CESC	cis	rs13191362	0.938	rs59067610	chr6:163030440	C/A	cg06582575	chr6:163149167	PACRG;PARK2	0.73	7.77	0.43	1.74e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs6991838	0.550	rs4737750	chr8:66550959	G/C	cg13398993	chr8:66546079	ARMC1	0.47	5.72	0.33	2.92e-8	Intelligence (multi-trait analysis);
CESC	cis	rs7520050	0.898	rs34175029	chr1:46483871	C/T	cg24296786	chr1:45957014	TESK2	0.44	5.48	0.32	1.01e-7	Red blood cell count;Reticulocyte count;
CESC	cis	rs1448094	0.512	rs61930137	chr12:86242930	C/T	cg02569458	chr12:86230093	RASSF9	0.49	7.22	0.41	5.67e-12	Major depressive disorder;
CESC	cis	rs754466	0.561	rs72806025	chr10:79707026	C/T	cg17075019	chr10:79541650	NA	-0.68	-6.32	-0.36	1.12e-9	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs9811920	0.809	rs1387647	chr3:99826942	T/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.46	7.33	0.41	2.78e-12	Axial length;
CESC	cis	rs9443645	0.901	rs4706077	chr6:79548845	G/A	cg05283184	chr6:79620031	NA	-0.44	-6.84	-0.39	5.36e-11	Intelligence (multi-trait analysis);
CESC	cis	rs780096	0.526	rs780102	chr2:27659491	T/C	cg02592271	chr2:27665507	KRTCAP3	-0.29	-5.79	-0.34	2e-8	Total body bone mineral density;
CESC	cis	rs9311474	0.607	rs4475032	chr3:52560021	C/T	cg05564831	chr3:52568323	NT5DC2	0.46	7.08	0.4	1.31e-11	Electroencephalogram traits;
CESC	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg07414643	chr4:187882934	NA	0.56	8.14	0.45	1.53e-14	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs116095464	0.681	rs1574220	chr5:314518	T/C	cg10591111	chr5:226296	SDHA	-0.62	-5.95	-0.34	8.46e-9	Breast cancer;
CESC	cis	rs887829	0.569	rs3806597	chr2:234637569	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.48	6.46	0.37	4.89e-10	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CESC	cis	rs1451375	0.572	rs3807558	chr7:50571022	A/G	cg14593290	chr7:50529359	DDC	-0.52	-6.6	-0.38	2.18e-10	Malaria;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg00177013	chr20:62339100	ARFRP1;ZGPAT	0.5	6.61	0.38	2.07e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs6540556	0.679	rs11808690	chr1:209891450	T/G	cg05527609	chr1:210001259	C1orf107	-0.67	-7.35	-0.41	2.43e-12	Red blood cell count;
CESC	cis	rs656900	0.967	rs661478	chr15:80115100	C/T	cg02196730	chr15:80188777	MTHFS	-0.4	-5.04	-0.3	8.75e-7	Cerebrospinal P-tau181p levels;
CESC	trans	rs7824557	0.527	rs2572369	chr8:11238597	C/T	cg06636001	chr8:8085503	FLJ10661	-0.5	-6.43	-0.37	5.8e-10	Retinal vascular caliber;
CESC	cis	rs875971	1.000	rs10244498	chr7:66116056	A/G	cg12463550	chr7:65579703	CRCP	0.56	7.3	0.41	3.42e-12	Aortic root size;
CESC	cis	rs4888262	0.508	rs12598701	chr16:74539904	G/A	cg01733217	chr16:74700730	RFWD3	0.82	11.38	0.57	1.07e-24	Testicular germ cell tumor;
CESC	cis	rs208346	1.000	rs208346	chr7:2799686	G/T	cg19717773	chr7:2847554	GNA12	0.5	7.99	0.44	4.21e-14	Loneliness (linear analysis);
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg09311052	chr1:154531418	UBE2Q1	0.48	6.67	0.38	1.51e-10	Systemic lupus erythematosus;
CESC	cis	rs7615952	0.512	rs1077621	chr3:125819799	A/G	cg06494592	chr3:125709126	NA	-0.51	-5.44	-0.32	1.22e-7	Blood pressure (smoking interaction);
CESC	cis	rs9911578	0.902	rs12948746	chr17:57071892	A/G	cg05425664	chr17:57184151	TRIM37	-0.52	-7.09	-0.4	1.21e-11	Intelligence (multi-trait analysis);
CESC	cis	rs2408955	0.542	rs7975632	chr12:48443048	C/T	cg04545296	chr12:48745243	ZNF641	0.35	6.14	0.35	3.05e-9	Glycated hemoglobin levels;
CESC	cis	rs11264213	0.901	rs72661640	chr1:36447232	T/G	cg27506609	chr1:36549197	TEKT2	0.67	5.56	0.32	6.59e-8	Schizophrenia;
CESC	cis	rs10256972	0.527	rs28671326	chr7:1174973	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.63	-9.68	-0.51	3.64e-19	Longevity;Endometriosis;
CESC	cis	rs35110281	0.641	rs9978858	chr21:45085552	A/G	cg01579765	chr21:45077557	HSF2BP	-0.55	-8.79	-0.48	1.89e-16	Mean corpuscular volume;
CESC	trans	rs11098499	0.821	rs10032151	chr4:120391628	C/T	cg25214090	chr10:38739885	LOC399744	0.71	10.27	0.53	4.75e-21	Corneal astigmatism;
CESC	cis	rs7666738	0.927	rs11736876	chr4:98987206	A/G	cg17366294	chr4:99064904	C4orf37	0.56	7.52	0.42	8.37e-13	Colonoscopy-negative controls vs population controls;
CESC	cis	rs17376456	0.825	rs56108532	chr5:93276342	C/T	cg21475434	chr5:93447410	FAM172A	0.73	6.34	0.36	9.97e-10	Diabetic retinopathy;
CESC	cis	rs965469	1.000	rs6037560	chr20:3323055	T/C	cg25506879	chr20:3388711	C20orf194	-0.52	-5.66	-0.33	3.89e-8	IFN-related cytopenia;
CESC	cis	rs1801251	0.778	rs2592115	chr2:233736349	C/T	cg25237894	chr2:233734115	C2orf82	-0.48	-8.7	-0.47	3.54e-16	Coronary artery disease;
CESC	cis	rs853679	0.542	rs9380063	chr6:28137853	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.57	-6.57	-0.37	2.69e-10	Depression;
CESC	cis	rs7107174	0.688	rs11237489	chr11:78130325	G/A	cg02023728	chr11:77925099	USP35	0.43	5.45	0.32	1.17e-7	Testicular germ cell tumor;
CESC	cis	rs1005277	0.579	rs2474599	chr10:38438939	A/G	cg25427524	chr10:38739819	LOC399744	-0.67	-9.8	-0.52	1.46e-19	Extrinsic epigenetic age acceleration;
CESC	cis	rs875971	1.000	rs7783613	chr7:65805261	C/T	cg12463550	chr7:65579703	CRCP	-0.54	-6.96	-0.39	2.67e-11	Aortic root size;
CESC	cis	rs9715521	0.719	rs11936702	chr4:59849081	G/A	cg11281224	chr4:60001000	NA	-0.5	-6.56	-0.37	2.88e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs10129255	0.957	rs10137980	chr14:107183974	G/C	cg07958169	chr14:107095056	NA	-0.41	-5.72	-0.33	2.86e-8	Kawasaki disease;
CESC	cis	rs35306767	0.903	rs35567307	chr10:915804	G/C	cg20503657	chr10:835505	NA	0.79	7.89	0.44	8.13e-14	Eosinophil percentage of granulocytes;
CESC	cis	rs9910055	0.762	rs2526021	chr17:42213347	G/A	cg19774624	chr17:42201019	HDAC5	-0.69	-10.03	-0.52	2.7e-20	Total body bone mineral density;
CESC	cis	rs3785574	0.886	rs62077504	chr17:61837734	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.81	10.73	0.55	1.55e-22	Height;
CESC	trans	rs7618501	0.633	rs7628058	chr3:50039474	C/T	cg21659725	chr3:3221576	CRBN	0.52	7.13	0.4	9.35e-12	Intelligence (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19882093	chr20:23969397	GGTLC1	-0.46	-6.58	-0.37	2.56e-10	Gut microbiome composition (summer);
CESC	cis	rs10540	1.000	rs67912009	chr11:495057	G/T	cg03576123	chr11:487126	PTDSS2	-1.04	-10.83	-0.55	7.17e-23	Body mass index;
CESC	cis	rs9815354	0.638	rs73073267	chr3:42021163	A/T	cg03022575	chr3:42003672	ULK4	0.74	6.59	0.38	2.33e-10	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs514406	0.505	rs447581	chr1:53177098	T/C	cg16325326	chr1:53192061	ZYG11B	0.83	14.09	0.65	4.81e-34	Monocyte count;
CESC	cis	rs3858526	0.676	rs10838752	chr11:5887243	A/G	cg02574844	chr11:5959923	NA	-0.42	-5.6	-0.33	5.48e-8	DNA methylation (variation);
CESC	cis	rs9815354	0.812	rs59476821	chr3:41946481	A/G	cg03022575	chr3:42003672	ULK4	0.71	6.45	0.37	5.42e-10	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs1707322	0.964	rs785499	chr1:46592420	G/A	cg05343316	chr1:45956843	TESK2	-0.47	-5.52	-0.32	7.97e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs524023	0.958	rs11231825	chr11:64360274	T/C	cg07220939	chr11:64358617	SLC22A12	-0.36	-5.59	-0.32	5.57e-8	Urate levels in obese individuals;
CESC	cis	rs7615952	0.576	rs4646748	chr3:125826329	G/A	cg02772935	chr3:125709198	NA	-0.47	-5.14	-0.3	5.41e-7	Blood pressure (smoking interaction);
CESC	cis	rs10504229	0.683	rs34804288	chr8:58117570	C/A	cg24829409	chr8:58192753	C8orf71	-0.58	-7.2	-0.4	6.31e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs933688	0.532	rs868557	chr5:90550379	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	-0.45	-5.03	-0.3	9.09e-7	Smoking behavior;
CESC	cis	rs172166	0.637	rs1071893	chr6:28167635	G/C	cg26335602	chr6:28129616	ZNF389	0.38	5.49	0.32	9.51e-8	Cardiac Troponin-T levels;
CESC	cis	rs2294693	0.945	rs9394755	chr6:41006680	C/T	cg14418226	chr6:40996092	UNC5CL	-0.42	-5.28	-0.31	2.7e-7	Gastric cancer;Non-cardia gastric cancer;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg19487717	chr11:70263216	CTTN	0.46	6.19	0.36	2.25e-9	Fibrinogen levels;
CESC	cis	rs769267	0.930	rs4808208	chr19:19650096	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.57	7.18	0.4	6.99e-12	Tonsillectomy;
CESC	cis	rs4472734	0.896	rs3902966	chr1:214629277	C/T	cg00063699	chr1:214624242	PTPN14	-0.33	-5.08	-0.3	7.25e-7	Height;
CESC	cis	rs1538970	0.962	rs9429160	chr1:45827968	G/T	cg06784218	chr1:46089804	CCDC17	0.32	5.16	0.3	4.76e-7	Platelet count;
CESC	trans	rs561341	1.000	rs7214017	chr17:30332220	T/C	cg20587970	chr11:113659929	NA	-1.1	-13.84	-0.65	3.63e-33	Hip circumference adjusted for BMI;
CESC	cis	rs9818758	0.607	rs61729488	chr3:49067904	T/C	cg00383909	chr3:49044727	WDR6	0.87	5.62	0.33	4.88e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CESC	cis	rs1008375	0.898	rs9998130	chr4:17593905	A/G	cg02297831	chr4:17616191	MED28	0.55	6.3	0.36	1.24e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs875971	0.660	rs801190	chr7:66033033	C/T	cg18876405	chr7:65276391	NA	-0.59	-7.97	-0.44	4.6e-14	Aortic root size;
CESC	cis	rs875971	0.660	rs10215132	chr7:66054406	C/A	cg06456125	chr7:65229604	NA	-0.4	-5.23	-0.31	3.44e-7	Aortic root size;
CESC	cis	rs3741404	0.620	rs2236648	chr11:63964657	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.7	10.2	0.53	7.77e-21	Platelet count;
CESC	cis	rs12995491	0.731	rs34991383	chr2:88500337	T/G	cg14558114	chr2:88469736	THNSL2	-0.5	-7.28	-0.41	3.9e-12	Response to metformin (IC50);
CESC	cis	rs7582720	0.943	rs72932583	chr2:203869847	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.36	0.41	2.34e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs17711722	0.522	rs6957759	chr7:65271785	A/G	cg14393609	chr7:65229607	NA	0.45	6.2	0.36	2.11e-9	Calcium levels;
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg22645636	chr2:55496232	MTIF2	-0.42	-6.08	-0.35	4.09e-9	Vertical cup-disc ratio;
CESC	cis	rs6426558	0.537	rs4653813	chr1:227461510	G/C	cg10327440	chr1:227177885	CDC42BPA	0.49	6.09	0.35	4.02e-9	Neutrophil percentage of white cells;
CESC	cis	rs9660992	0.710	rs1768586	chr1:205238275	A/G	cg00857998	chr1:205179979	DSTYK	0.45	5.22	0.31	3.7e-7	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs1799949	0.965	rs35521261	chr17:41313612	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	8.6	0.47	7.29e-16	Menopause (age at onset);
CESC	cis	rs7618915	0.570	rs13068293	chr3:52672167	C/A	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.3	5.42	0.32	1.33e-7	Bipolar disorder;
CESC	cis	rs59072704	0.843	rs12031783	chr1:244498748	A/G	cg16908123	chr1:244486252	NA	0.44	6.82	0.39	6.1e-11	Monocyte count;
CESC	cis	rs11098499	0.954	rs9685777	chr4:120365965	C/A	cg24375607	chr4:120327624	NA	0.47	5.89	0.34	1.14e-8	Corneal astigmatism;
CESC	cis	rs10779751	0.960	rs12739368	chr1:11288247	T/C	cg08854313	chr1:11322531	MTOR	0.79	10.62	0.55	3.5e-22	Body mass index;
CESC	cis	rs9611565	0.559	rs4822048	chr22:41988225	C/T	cg03806693	chr22:41940476	POLR3H	-1.16	-13.06	-0.63	1.99e-30	Vitiligo;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11432751	chr19:40854313	C19orf47;PLD3	0.56	6.7	0.38	1.25e-10	Gut microbiome composition (summer);
CESC	cis	rs7223966	1.000	rs9901112	chr17:61730617	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.57	6.8	0.39	6.72e-11	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs3733585	0.699	rs12498956	chr4:9950705	G/T	cg11266682	chr4:10021025	SLC2A9	-0.57	-11.03	-0.56	1.61e-23	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs5750830	0.594	rs5757647	chr22:39775047	C/A	cg02038168	chr22:39784481	NA	-0.56	-7.35	-0.41	2.5e-12	Intelligence (multi-trait analysis);
CESC	cis	rs9916302	0.904	rs9894500	chr17:37515735	G/C	cg20243544	chr17:37824526	PNMT	-0.47	-5.74	-0.33	2.54e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs9911578	1.000	rs302848	chr17:56686454	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.41	5.51	0.32	8.34e-8	Intelligence (multi-trait analysis);
CESC	cis	rs17209837	0.607	rs2071645	chr7:87105276	G/C	cg00919237	chr7:87102261	ABCB4	-0.48	-6.15	-0.35	2.77e-9	Gallbladder cancer;
CESC	cis	rs9399135	0.838	rs4896126	chr6:135342786	C/A	cg22676075	chr6:135203613	NA	0.51	7.36	0.41	2.34e-12	Red blood cell count;
CESC	cis	rs901683	1.000	rs12764693	chr10:46023327	A/G	cg16031567	chr10:46195673	NA	-0.77	-5.04	-0.3	8.57e-7	Red blood cell traits;Mean corpuscular volume;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg20318713	chr1:45805724	MUTYH;TOE1	-0.46	-6.19	-0.36	2.3e-9	Fibrinogen levels;
CESC	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.64	-8.48	-0.46	1.59e-15	Longevity;Endometriosis;
CESC	cis	rs2243480	0.908	rs4718273	chr7:65216099	G/A	cg12463550	chr7:65579703	CRCP	-0.69	-5.32	-0.31	2.22e-7	Diabetic kidney disease;
CESC	cis	rs10857712	0.851	rs56153177	chr10:135216975	G/A	cg01444801	chr10:135216882	MTG1	-0.49	-5.62	-0.33	4.92e-8	Systemic lupus erythematosus;
CESC	cis	rs10504229	1.000	rs6987435	chr8:58177334	G/A	cg14926445	chr8:58193284	C8orf71	-0.47	-5.09	-0.3	6.82e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg07092213	chr7:1199455	ZFAND2A	-0.39	-5.3	-0.31	2.43e-7	Longevity;Endometriosis;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg25750404	chr12:6579648	VAMP1	-0.45	-6.46	-0.37	4.92e-10	Gambling;
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg19319069	chr7:129593010	UBE2H	-0.42	-6.58	-0.37	2.45e-10	Vertical cup-disc ratio;
CESC	cis	rs1005277	0.522	rs1208767	chr10:38042295	G/T	cg25517755	chr10:38738941	LOC399744	-0.4	-5.14	-0.3	5.37e-7	Extrinsic epigenetic age acceleration;
CESC	cis	rs1799949	1.000	rs11653253	chr17:41182662	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	8.22	0.45	8.86e-15	Menopause (age at onset);
CESC	cis	rs8067545	0.611	rs9907516	chr17:20070490	G/A	cg13482628	chr17:19912719	NA	0.43	5.74	0.33	2.65e-8	Schizophrenia;
CESC	cis	rs1448094	0.511	rs7967183	chr12:86216845	T/G	cg00310523	chr12:86230176	RASSF9	0.35	5.52	0.32	7.92e-8	Major depressive disorder;
CESC	cis	rs3617	0.591	rs2276823	chr3:52869263	C/A	cg11645453	chr3:52864694	ITIH4	-0.26	-5.21	-0.3	3.84e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
CESC	cis	rs17641971	0.645	rs341806	chr8:50034028	A/C	cg00325661	chr8:49890786	NA	0.39	5.28	0.31	2.64e-7	Blood metabolite levels;
CESC	cis	rs2247341	0.928	rs2854916	chr4:1721348	G/A	cg07465881	chr4:1713556	SLBP	-0.51	-6.21	-0.36	2.01e-9	Hip circumference adjusted for BMI;Height;
CESC	cis	rs2408955	0.522	rs11168408	chr12:48498327	G/A	cg04545296	chr12:48745243	ZNF641	-0.37	-6.24	-0.36	1.77e-9	Glycated hemoglobin levels;
CESC	cis	rs7264396	0.561	rs6058387	chr20:34568092	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-7.68	-0.43	3.12e-13	Total cholesterol levels;
CESC	cis	rs4629710	0.592	rs11759793	chr6:131546384	G/A	cg12606694	chr6:131520996	AKAP7	0.46	5.7	0.33	3.18e-8	Multiple myeloma (IgH translocation);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg15680518	chr12:132414800	PUS1	0.48	6.2	0.36	2.12e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs4423214	1.000	rs12792306	chr11:71166992	T/C	cg24826892	chr11:71159390	DHCR7	0.44	5.06	0.3	7.93e-7	Vitamin D levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25299201	chr13:22178312	EFHA1	0.55	6.54	0.37	3.08e-10	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20110633	chr19:44302906	LYPD5	0.59	6.93	0.39	3.15e-11	Gut microbiome composition (summer);
CESC	cis	rs12950390	0.853	rs4794107	chr17:45843159	T/G	cg00777063	chr17:45855553	NA	-0.41	-6.12	-0.35	3.4e-9	IgG glycosylation;
CESC	cis	rs4919087	0.748	rs701817	chr10:98977329	G/C	cg25902810	chr10:99078978	FRAT1	-0.49	-5.6	-0.33	5.38e-8	Monocyte count;
CESC	cis	rs35306767	0.903	rs12769431	chr10:922633	T/C	cg26597838	chr10:835615	NA	0.86	9.03	0.49	3.59e-17	Eosinophil percentage of granulocytes;
CESC	cis	rs3733585	0.699	rs11724510	chr4:9958583	C/T	cg11266682	chr4:10021025	SLC2A9	-0.6	-11.22	-0.57	3.77e-24	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs1879734	0.636	rs2186041	chr1:54180287	G/A	cg23596471	chr1:54105337	GLIS1	0.31	5.13	0.3	5.63e-7	Mitral valve prolapse;
CESC	cis	rs9435341	0.965	rs1730864	chr1:107607810	C/T	cg09367891	chr1:107599246	PRMT6	-0.71	-8.53	-0.46	1.13e-15	Facial morphology (factor 21, depth of nasal alae);
CESC	cis	rs7618501	0.633	rs2883057	chr3:49998282	C/T	cg24308560	chr3:49941425	MST1R	-0.64	-9.19	-0.49	1.17e-17	Intelligence (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08386450	chr20:43104574	TTPAL	0.54	6.42	0.37	6.19e-10	Gut microbiome composition (summer);
CESC	trans	rs1814175	0.645	rs2140602	chr11:50022800	G/C	cg03929089	chr4:120376271	NA	-0.91	-14.8	-0.67	1.58e-36	Height;
CESC	cis	rs12348691	0.503	rs894672	chr9:100612185	C/T	cg13688889	chr9:100608707	NA	-0.9	-13.6	-0.64	2.68e-32	Alopecia areata;
CESC	cis	rs2439831	0.717	rs28495368	chr15:43895642	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.82	8.62	0.47	6.24e-16	Lung cancer in ever smokers;
CESC	trans	rs11088226	0.681	rs2409456	chr21:33929374	G/A	cg09050820	chr6:167586206	TCP10L2	0.86	8.44	0.46	2.16e-15	Gastritis;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg26512142	chr11:2554198	KCNQ1	-0.42	-6.28	-0.36	1.35e-9	Gambling;
CESC	cis	rs2742234	0.590	rs2505506	chr10:43645854	C/T	cg15436174	chr10:43711423	RASGEF1A	-0.47	-5.43	-0.32	1.29e-7	Hirschsprung disease;
CESC	trans	rs6818288	0.778	rs4619851	chr4:30077626	T/C	cg12528397	chr3:62933670	NA	0.42	6.13	0.35	3.2e-9	Obesity-related traits;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg03277652	chr8:142011117	PTK2	-0.48	-6.58	-0.37	2.46e-10	Fibrinogen levels;
CESC	trans	rs1814175	0.653	rs10839480	chr11:50034556	C/T	cg03929089	chr4:120376271	NA	-0.94	-15.73	-0.69	7.69e-40	Height;
CESC	cis	rs4919087	0.884	rs4917762	chr10:98976471	G/T	cg25902810	chr10:99078978	FRAT1	0.71	10.11	0.53	1.53e-20	Monocyte count;
CESC	cis	rs2070997	0.607	rs4740371	chr9:133673777	G/C	cg11464064	chr9:133710261	ABL1	0.57	6.69	0.38	1.33e-10	Response to amphetamines;
CESC	cis	rs875971	0.660	rs6460308	chr7:66084740	T/C	cg06456125	chr7:65229604	NA	-0.4	-5.15	-0.3	5.12e-7	Aortic root size;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg15150274	chr8:33330294	FUT10	0.5	6.52	0.37	3.54e-10	Systemic lupus erythematosus;
CESC	cis	rs1594829	0.535	rs17055121	chr8:26170975	C/T	cg11498726	chr8:26250323	BNIP3L	-0.41	-6.3	-0.36	1.23e-9	Height;
CESC	cis	rs854765	0.647	rs854770	chr17:18019048	A/G	cg04398451	chr17:18023971	MYO15A	-0.78	-11.5	-0.58	4.15e-25	Total body bone mineral density;
CESC	cis	rs9814567	0.752	rs1880378	chr3:134330709	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.4	-5.09	-0.3	6.84e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs698813	0.763	rs698764	chr2:44573658	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.52	6.16	0.35	2.64e-9	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
CESC	cis	rs10779751	0.770	rs2791643	chr1:11207269	C/T	cg08854313	chr1:11322531	MTOR	0.74	9.41	0.5	2.46e-18	Body mass index;
CESC	cis	rs668210	0.793	rs507672	chr11:65767153	C/T	cg02202077	chr11:65769826	EIF1AD;BANF1	-0.72	-7.94	-0.44	5.7e-14	Cerebrospinal fluid biomarker levels;
CESC	cis	rs10411936	0.720	rs2885706	chr19:16582937	C/A	cg10248733	chr19:16607483	C19orf44;CALR3	0.53	6.64	0.38	1.82e-10	White blood cell count;Multiple sclerosis;
CESC	cis	rs941873	0.835	rs10762859	chr10:81103370	T/A	cg08514558	chr10:81106712	PPIF	0.33	5.63	0.33	4.55e-8	Height;
CESC	cis	rs7927592	0.956	rs12277225	chr11:68340967	T/C	cg20283391	chr11:68216788	NA	-0.49	-5.85	-0.34	1.43e-8	Total body bone mineral density;
CESC	cis	rs2637266	1.000	rs7392737	chr10:78366059	C/T	cg18941641	chr10:78392320	NA	0.43	8.26	0.45	6.94e-15	Pulmonary function;
CESC	cis	rs3617	0.573	rs2336668	chr3:52919096	G/T	cg11645453	chr3:52864694	ITIH4	-0.27	-5.17	-0.3	4.67e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
CESC	cis	rs853679	0.517	rs9368550	chr6:28051803	T/A	cg22143856	chr6:28129313	ZNF389	0.49	6.3	0.36	1.2e-9	Depression;
CESC	cis	rs7772486	0.790	rs2265472	chr6:146220758	G/C	cg23711669	chr6:146136114	FBXO30	0.92	13.36	0.63	1.78e-31	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2963155	0.518	rs33389	chr5:142700499	C/T	cg17617527	chr5:142782415	NR3C1	0.81	7.53	0.42	8.03e-13	Breast cancer;
CESC	cis	rs6460942	0.597	rs7808537	chr7:12520913	G/C	cg10578991	chr7:12443926	VWDE	-0.48	-5.06	-0.3	7.85e-7	Coronary artery disease;
CESC	cis	rs9790314	0.846	rs6768818	chr3:160951648	A/G	cg03342759	chr3:160939853	NMD3	-0.51	-7.37	-0.41	2.12e-12	Morning vs. evening chronotype;
CESC	cis	rs1059312	0.500	rs10734964	chr12:129286486	C/T	cg09035930	chr12:129282057	SLC15A4	0.53	6.8	0.39	6.98e-11	Systemic lupus erythematosus;
CESC	cis	rs2486288	0.656	rs7166580	chr15:45571209	C/G	cg09092052	chr15:45571596	NA	0.45	5.33	0.31	2.14e-7	Glomerular filtration rate;
CESC	cis	rs2070997	0.607	rs2987902	chr9:133710246	A/T	cg11464064	chr9:133710261	ABL1	0.73	8.42	0.46	2.44e-15	Response to amphetamines;
CESC	cis	rs769267	0.895	rs2916074	chr19:19530270	C/T	cg03709012	chr19:19516395	GATAD2A	1.01	15.93	0.7	1.49e-40	Tonsillectomy;
CESC	cis	rs17711722	0.701	rs4467826	chr7:65368708	A/G	cg11987759	chr7:65425863	GUSB	-0.47	-6.32	-0.36	1.09e-9	Calcium levels;
CESC	cis	rs72781680	0.948	rs113530757	chr2:24142500	G/A	cg08917208	chr2:24149416	ATAD2B	0.93	8.42	0.46	2.35e-15	Lymphocyte counts;
CESC	cis	rs80130819	0.748	rs2732474	chr12:48700817	A/T	cg05342945	chr12:48394962	COL2A1	-0.51	-5.6	-0.33	5.35e-8	Prostate cancer;
CESC	cis	rs7267979	0.966	rs2500417	chr20:25383287	A/G	cg08601574	chr20:25228251	PYGB	-0.36	-5.06	-0.3	7.97e-7	Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15227217	chr7:35734836	HERPUD2	0.56	6.71	0.38	1.14e-10	Gut microbiome composition (summer);
CESC	cis	rs10751667	0.961	rs7395928	chr11:952605	T/G	cg06064525	chr11:970664	AP2A2	-0.39	-6.99	-0.39	2.29e-11	Alzheimer's disease (late onset);
CESC	cis	rs1153858	1.000	rs7169587	chr15:45640379	A/G	cg14582100	chr15:45693742	SPATA5L1	0.42	6.08	0.35	4.2e-9	Homoarginine levels;
CESC	cis	rs13118159	0.934	rs4974608	chr4:1356780	C/T	cg19318889	chr4:1322082	MAEA	0.37	5.04	0.3	8.49e-7	Longevity;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg17142486	chr19:56089493	ZNF579	0.45	6.0	0.35	6.49e-9	Fibrinogen levels;
CESC	cis	rs4319547	0.915	rs10773208	chr12:122970156	T/C	cg23029597	chr12:123009494	RSRC2	-0.5	-5.43	-0.32	1.26e-7	Body mass index;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27549887	chr15:48623952	DUT	0.61	7.22	0.41	5.58e-12	Gut microbiome composition (summer);
CESC	trans	rs4843747	0.636	rs4075597	chr16:88107590	C/A	cg26811252	chr16:29126840	RRN3P2	0.67	9.33	0.5	4.29e-18	Menopause (age at onset);
CESC	cis	rs2228479	0.764	rs11641201	chr16:89983276	T/C	cg04287289	chr16:89883240	FANCA	0.56	5.07	0.3	7.38e-7	Skin colour saturation;
CESC	cis	rs13242816	1.000	rs17138750	chr7:116134170	A/G	cg04696780	chr7:116139425	CAV2	-0.61	-5.51	-0.32	8.44e-8	P wave duration;
CESC	cis	rs17102884	0.506	rs4899541	chr14:75403437	T/G	cg11812906	chr14:75593930	NEK9	-0.44	-5.41	-0.32	1.44e-7	Neuroticism;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg10729317	chr20:2821390	FAM113A;VPS16	-0.41	-6.0	-0.35	6.63e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs67366981	1.000	rs56357623	chr14:77697393	C/A	cg22824376	chr14:77648248	TMEM63C	0.65	5.52	0.32	8.21e-8	Obsessive-compulsive symptoms;
CESC	cis	rs6582630	0.555	rs10880625	chr12:38526612	A/C	cg13010199	chr12:38710504	ALG10B	0.53	6.84	0.39	5.44e-11	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs16867321	1.000	rs4289138	chr2:181364220	T/G	cg23363182	chr2:181467187	NA	-0.41	-5.13	-0.3	5.65e-7	Obesity;
CESC	cis	rs8062405	0.755	rs4787456	chr16:28559573	C/T	cg07382826	chr16:28625726	SULT1A1	0.4	6.69	0.38	1.3e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs8133932	0.654	rs2839041	chr21:47322616	T/C	cg14185626	chr21:47401492	COL6A1	0.46	5.04	0.3	8.81e-7	Schizophrenia;
CESC	cis	rs889312	0.500	rs252903	chr5:56117952	A/G	cg14703610	chr5:56206110	C5orf35	0.47	6.28	0.36	1.35e-9	Breast cancer;Breast cancer (early onset);
CESC	cis	rs7772486	0.686	rs2328708	chr6:146095739	G/A	cg05347473	chr6:146136440	FBXO30	-0.5	-6.57	-0.37	2.59e-10	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27442478	chr6:155635788	TFB1M	0.58	7.04	0.4	1.7e-11	Gut microbiome composition (summer);
CESC	cis	rs10504229	1.000	rs58053450	chr8:58173348	T/C	cg14926445	chr8:58193284	C8orf71	-0.51	-5.47	-0.32	1.03e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs11030122	0.673	rs10835596	chr11:4099666	C/T	cg18678763	chr11:4115507	RRM1	-0.54	-7.1	-0.4	1.14e-11	Mean platelet volume;Platelet distribution width;
CESC	cis	rs1878931	0.726	rs3843728	chr16:3448251	T/C	cg00484396	chr16:3507460	NAT15	-0.41	-6.43	-0.37	5.87e-10	Body mass index (adult);
CESC	trans	rs3942852	0.550	rs1113480	chr11:48058313	G/T	cg15704280	chr7:45808275	SEPT13	-0.71	-9.0	-0.48	4.61e-17	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs412000	0.560	rs4793583	chr17:56451407	A/C	cg25039879	chr17:56429692	SUPT4H1	-0.42	-5.56	-0.32	6.45e-8	Primary tooth development (time to first tooth eruption);
CESC	cis	rs736408	0.509	rs13083798	chr3:52649748	A/G	cg17372223	chr3:52568218	NT5DC2	0.43	7.02	0.4	1.87e-11	Bipolar disorder;
CESC	cis	rs4148883	0.615	rs2187483	chr4:100134103	G/T	cg12011299	chr4:100065546	ADH4	-0.5	-7.15	-0.4	8.48e-12	Alcohol dependence;
CESC	cis	rs2120019	1.000	rs35577967	chr15:75354621	G/A	cg09165964	chr15:75287851	SCAMP5	-0.73	-8.47	-0.46	1.7e-15	Blood trace element (Zn levels);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10971928	chr5:16902573	MYO10	-0.56	-6.77	-0.38	8.27e-11	Gut microbiome composition (summer);
CESC	cis	rs7618915	0.547	rs2268026	chr3:52778347	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	6.83	0.39	5.96e-11	Bipolar disorder;
CESC	cis	rs4727027	0.870	rs1105261	chr7:148794442	T/G	cg23158103	chr7:148848205	ZNF398	-0.38	-5.97	-0.34	7.45e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs10851478	0.872	rs34694913	chr15:49831894	G/T	cg08060515	chr15:49448048	GALK2;COPS2	0.42	5.19	0.3	4.12e-7	Oral cavity cancer;
CESC	trans	rs829883	0.902	rs829884	chr12:98879500	C/G	cg04550079	chr16:67212681	KIAA0895L	-0.37	-6.07	-0.35	4.34e-9	Colorectal adenoma (advanced);
CESC	cis	rs35146811	0.586	rs12705067	chr7:99594726	T/C	cg22531904	chr7:99595276	NA	-0.39	-5.23	-0.31	3.39e-7	Coronary artery disease;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg08321272	chr4:41992621	SLC30A9	-0.45	-6.18	-0.35	2.45e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs9611565	0.592	rs4481089	chr22:41980892	T/C	cg06634786	chr22:41940651	POLR3H	-0.57	-6.28	-0.36	1.35e-9	Vitiligo;
CESC	cis	rs7296418	0.961	rs7957096	chr12:123544878	A/G	cg05973401	chr12:123451056	ABCB9	0.62	8.09	0.44	2.23e-14	Platelet count;
CESC	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg24101359	chr6:42928495	GNMT	0.56	8.16	0.45	1.38e-14	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs2836950	0.565	rs2836926	chr21:40536790	G/A	cg17971929	chr21:40555470	PSMG1	-0.55	-7.22	-0.41	5.4e-12	Menarche (age at onset);
CESC	cis	rs13256369	0.851	rs11249889	chr8:8564992	G/T	cg18904891	chr8:8559673	CLDN23	0.73	8.12	0.45	1.74e-14	Obesity-related traits;
CESC	cis	rs2839186	0.605	rs2839174	chr21:47676934	T/C	cg00815214	chr21:47717953	NA	-0.36	-5.3	-0.31	2.44e-7	Testicular germ cell tumor;
CESC	cis	rs7666738	0.830	rs11940273	chr4:98979965	T/A	cg03676636	chr4:99064102	C4orf37	0.34	5.19	0.3	4.17e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08984023	chr10:64133896	ZNF365	0.47	6.28	0.36	1.4e-9	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24865802	chr22:42084920	NHP2L1	0.55	6.11	0.35	3.48e-9	Gut microbiome composition (summer);
CESC	cis	rs9322193	0.923	rs9322204	chr6:149957183	A/C	cg07701084	chr6:150067640	NUP43	0.43	6.0	0.35	6.51e-9	Lung cancer;
CESC	cis	rs7246657	0.525	rs10410594	chr19:37477758	C/T	cg23950597	chr19:37808831	NA	-0.51	-5.05	-0.3	8.18e-7	Coronary artery calcification;
CESC	cis	rs4906332	0.966	rs2065016	chr14:103879656	T/A	cg09975044	chr14:104007538	NA	0.46	6.34	0.36	9.68e-10	Coronary artery disease;
CESC	cis	rs929354	0.772	rs2301914	chr7:157000176	T/C	cg05182265	chr7:156933206	UBE3C	-0.5	-7.41	-0.41	1.68e-12	Body mass index;
CESC	cis	rs9457247	1.000	rs2769354	chr6:167379771	G/T	cg25258033	chr6:167368657	RNASET2	-0.42	-6.25	-0.36	1.63e-9	Crohn's disease;
CESC	cis	rs4642101	0.824	rs3889515	chr3:12844112	G/C	cg05775895	chr3:12838266	CAND2	0.39	5.78	0.33	2.1e-8	QRS complex (12-leadsum);
CESC	trans	rs11098499	0.865	rs1112817	chr4:120297800	T/C	cg25214090	chr10:38739885	LOC399744	0.68	9.2	0.49	1.14e-17	Corneal astigmatism;
CESC	cis	rs11098499	0.505	rs75122014	chr4:120362426	G/C	cg24375607	chr4:120327624	NA	0.47	5.9	0.34	1.11e-8	Corneal astigmatism;
CESC	cis	rs514406	0.798	rs576650	chr1:53327207	C/T	cg25767906	chr1:53392781	SCP2	-0.51	-6.76	-0.38	8.8e-11	Monocyte count;
CESC	cis	rs2933343	0.909	rs1683817	chr3:128651536	G/A	cg25356066	chr3:128598488	ACAD9	0.63	7.53	0.42	8.01e-13	IgG glycosylation;
CESC	cis	rs644799	1.000	rs12291986	chr11:95523030	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	9.31	0.5	5.15e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs11122272	0.735	rs2572253	chr1:231512768	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.57	-7.8	-0.43	1.41e-13	Hemoglobin concentration;
CESC	cis	rs4843747	0.671	rs8053377	chr16:88106465	A/G	cg17633681	chr16:88106987	BANP	0.76	10.43	0.54	1.41e-21	Menopause (age at onset);
CESC	cis	rs8077577	0.895	rs10048161	chr17:18082796	C/G	cg16794390	chr17:18148240	FLII	0.42	5.64	0.33	4.41e-8	Obesity-related traits;
CESC	cis	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26546685	chr4:100870642	LOC256880;H2AFZ	0.51	5.22	0.31	3.55e-7	Gut microbiome composition (summer);
CESC	cis	rs3820928	0.967	rs16822905	chr2:227770727	G/C	cg05526886	chr2:227700861	RHBDD1	-0.41	-5.29	-0.31	2.59e-7	Pulmonary function;
CESC	cis	rs9733	0.596	rs56058687	chr1:150635066	C/T	cg18016565	chr1:150552671	MCL1	0.34	5.18	0.3	4.39e-7	Tonsillectomy;
CESC	cis	rs9487051	0.836	rs9400270	chr6:109607488	G/A	cg21918786	chr6:109611834	NA	-0.4	-6.01	-0.35	6.17e-9	Reticulocyte fraction of red cells;
CESC	cis	rs1691799	0.899	rs1168357	chr12:66749879	T/C	cg16791601	chr12:66731901	HELB	-0.79	-14.19	-0.66	2.26e-34	White blood cell count (basophil);
CESC	cis	rs12681366	0.537	rs2381886	chr8:95477053	T/C	cg13257157	chr8:95487014	RAD54B	0.45	5.47	0.32	1.05e-7	Nonsyndromic cleft lip with cleft palate;
CESC	cis	rs1949733	0.656	rs2631762	chr4:8423122	A/T	cg11789530	chr4:8429930	ACOX3	0.71	10.13	0.53	1.32e-20	Response to antineoplastic agents;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg21774865	chr7:157009442	UBE3C	0.48	6.66	0.38	1.58e-10	Fibrinogen levels;
CESC	cis	rs12579753	1.000	rs11115030	chr12:82203021	A/T	cg24719984	chr12:82153464	PPFIA2	-0.36	-5.07	-0.3	7.59e-7	Resting heart rate;
CESC	cis	rs2859741	0.647	rs548661	chr1:37479392	T/G	cg09363841	chr1:37513479	NA	-0.51	-6.98	-0.39	2.43e-11	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
CESC	cis	rs501120	0.810	rs473501	chr10:44749171	G/A	cg09554077	chr10:44749378	NA	0.52	6.93	0.39	3.28e-11	Coronary artery disease;Coronary heart disease;
CESC	cis	rs6723226	0.739	rs2069213	chr2:32743084	C/T	cg02381751	chr2:32503542	YIPF4	0.85	12.52	0.61	1.4e-28	Intelligence (multi-trait analysis);
CESC	cis	rs7618915	0.571	rs6762457	chr3:52609157	G/A	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.33	5.76	0.33	2.31e-8	Bipolar disorder;
CESC	cis	rs4150161	0.656	rs2288026	chr16:84220344	C/G	cg10106505	chr16:84220380	TAF1C	0.77	5.56	0.32	6.75e-8	Systolic blood pressure response to hydrochlorothiazide in hypertension;
CESC	cis	rs72901758	0.669	rs17641275	chr17:76247796	A/C	cg26068271	chr17:76253126	NA	-0.43	-6.48	-0.37	4.5e-10	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
CESC	cis	rs3858526	0.514	rs4595572	chr11:5864045	T/G	cg02574844	chr11:5959923	NA	-0.5	-7.68	-0.43	3.13e-13	DNA methylation (variation);
CESC	cis	rs763014	0.865	rs8909	chr16:633851	T/C	cg00908189	chr16:619842	PIGQ	0.65	9.0	0.48	4.54e-17	Height;
CESC	cis	rs4654899	0.758	rs12402486	chr1:21447935	A/G	cg05370193	chr1:21551575	ECE1	-0.37	-5.58	-0.32	5.9e-8	Superior frontal gyrus grey matter volume;
CESC	cis	rs597539	0.652	rs636049	chr11:68667198	A/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.82	10.65	0.55	2.75e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg12128740	chr1:62207888	INADL	0.41	6.04	0.35	5.1e-9	Fibrinogen levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25723933	chr1:155099956	EFNA1	0.57	6.17	0.35	2.52e-9	Gut microbiome composition (summer);
CESC	cis	rs4319547	0.508	rs10846826	chr12:122894987	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.53	-6.11	-0.35	3.47e-9	Body mass index;
CESC	cis	rs59918340	0.764	rs10101692	chr8:142230823	C/T	cg16341495	chr8:142228727	SLC45A4	-0.44	-5.37	-0.31	1.72e-7	Immature fraction of reticulocytes;
CESC	cis	rs2836974	0.897	rs36113648	chr21:40555497	G/A	cg11644478	chr21:40555479	PSMG1	1.06	17.91	0.74	1.44e-47	Cognitive function;
CESC	cis	rs769267	0.930	rs1865034	chr19:19605763	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.45	5.73	0.33	2.7e-8	Tonsillectomy;
CESC	cis	rs61931739	0.817	rs304313	chr12:34216898	C/T	cg19457237	chr12:34500585	NA	-0.37	-5.1	-0.3	6.51e-7	Morning vs. evening chronotype;
CESC	cis	rs8031584	0.918	rs61997140	chr15:31277312	A/G	cg14298792	chr15:30685198	CHRFAM7A	-0.46	-5.44	-0.32	1.19e-7	Huntington's disease progression;
CESC	cis	rs9921222	0.500	rs8046256	chr16:393948	C/T	cg00101154	chr16:420108	MRPL28	-0.55	-6.08	-0.35	4.17e-9	Bone mineral density (spine);Bone mineral density;
CESC	cis	rs1552244	0.706	rs279545	chr3:9972493	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.6	-8.3	-0.45	5.42e-15	Alzheimer's disease;
CESC	cis	rs2839186	0.587	rs35679325	chr21:47640980	A/G	cg12516959	chr21:47718080	NA	0.34	5.1	0.3	6.55e-7	Testicular germ cell tumor;
CESC	cis	rs7904368	0.806	rs3858182	chr10:16855094	C/T	cg23933602	chr10:16859644	RSU1	0.76	7.09	0.4	1.19e-11	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
CESC	cis	rs6076065	0.748	rs4142246	chr20:23388975	A/G	cg11657817	chr20:23433608	CST11	0.4	6.11	0.35	3.46e-9	Facial morphology (factor 15, philtrum width);
CESC	cis	rs2836974	0.897	rs34599551	chr21:40594898	C/A	cg11890956	chr21:40555474	PSMG1	1.22	24.53	0.83	3.87e-70	Cognitive function;
CESC	cis	rs7659604	0.539	rs7699776	chr4:122753885	A/G	cg19748678	chr4:122722346	EXOSC9	0.79	10.06	0.53	2.23e-20	Type 2 diabetes;
CESC	cis	rs751837	0.591	rs34407983	chr14:103429786	T/C	cg18135206	chr14:102964638	TECPR2	0.69	5.07	0.3	7.46e-7	Large B-cell lymphoma;
CESC	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	10.31	0.54	3.43e-21	Prudent dietary pattern;
CESC	cis	rs60871478	1.000	rs6460801	chr7:810506	T/C	cg05535760	chr7:792225	HEATR2	0.94	10.83	0.55	7.19e-23	Cerebrospinal P-tau181p levels;
CESC	cis	rs6964587	0.967	rs410	chr7:91557425	C/G	cg17063962	chr7:91808500	NA	-0.59	-7.85	-0.43	1.03e-13	Breast cancer;
CESC	trans	rs9944275	0.860	rs71396871	chr15:97192085	C/G	cg26794346	chr6:16472305	ATXN1	0.75	6.06	0.35	4.65e-9	Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
CESC	cis	rs7666738	0.753	rs13120995	chr4:98972762	A/G	cg03676636	chr4:99064102	C4orf37	0.34	5.2	0.3	3.93e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4304924	0.500	rs7339081	chr13:79235501	A/G	cg05295671	chr13:79234353	RNF219	0.36	5.1	0.3	6.4e-7	Large artery stroke;
CESC	cis	rs13064411	0.696	rs9808893	chr3:113228444	G/A	cg18753928	chr3:113234510	CCDC52	-0.5	-6.13	-0.35	3.23e-9	Response to simvastatin treatment (PCSK9 protein level change);
CESC	cis	rs40363	0.645	rs250631	chr16:3523215	G/C	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.46	-5.55	-0.32	7.03e-8	Tuberculosis;
CESC	cis	rs3806843	0.568	rs2530232	chr5:140082878	A/G	cg26395211	chr5:140044315	WDR55	0.47	5.97	0.34	7.78e-9	Depressive symptoms (multi-trait analysis);
CESC	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg26338869	chr17:61819248	STRADA	0.69	9.21	0.49	1.06e-17	Prudent dietary pattern;
CESC	cis	rs7666738	0.830	rs58367603	chr4:99015350	T/C	cg18180107	chr4:99064573	C4orf37	0.4	5.3	0.31	2.48e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7173419	0.655	rs12899295	chr15:28226597	G/A	cg20906524	chr15:28200668	OCA2	-0.38	-5.21	-0.31	3.72e-7	Eye color;
CESC	cis	rs1878931	0.582	rs27227	chr16:3429778	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.66	-8.0	-0.44	3.94e-14	Body mass index (adult);
CESC	trans	rs4689592	0.546	rs10937782	chr4:7057106	G/C	cg07817883	chr1:32538562	TMEM39B	-0.52	-6.14	-0.35	2.95e-9	Monocyte percentage of white cells;
CESC	cis	rs2304069	0.545	rs13168011	chr5:149392377	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.48	6.51	0.37	3.82e-10	HIV-1 control;
CESC	cis	rs11764590	0.694	rs3996323	chr7:2079428	G/T	cg21782813	chr7:2030301	MAD1L1	-0.41	-5.36	-0.31	1.8e-7	Neuroticism;
CESC	trans	rs916888	0.773	rs199439	chr17:44793503	A/G	cg22433210	chr17:43662623	NA	1.0	11.42	0.57	7.92e-25	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs1878931	0.582	rs9921152	chr16:3421199	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.71	8.83	0.48	1.51e-16	Body mass index (adult);
CESC	cis	rs1065852	0.861	rs5758627	chr22:42572547	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.6	9.14	0.49	1.73e-17	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
CESC	cis	rs736408	0.509	rs3774349	chr3:52722335	A/C	cg25934064	chr3:52569026	NT5DC2	0.26	5.61	0.33	5e-8	Bipolar disorder;
CESC	cis	rs4268898	0.662	rs2288074	chr2:24413595	C/T	cg20701182	chr2:24300061	SF3B14	0.69	6.97	0.39	2.47e-11	Asthma;
CESC	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg20887711	chr4:1340912	KIAA1530	0.85	11.46	0.58	5.8e-25	Longevity;
CESC	cis	rs1008375	1.000	rs10012335	chr4:17628630	C/G	cg02297831	chr4:17616191	MED28	0.55	6.83	0.39	5.64e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	7.7	0.43	2.77e-13	Prudent dietary pattern;
CESC	cis	rs2439831	1.000	rs527921	chr15:43770416	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.83	-12.08	-0.6	4.75e-27	Lung cancer in ever smokers;
CESC	cis	rs9399135	0.967	rs12661423	chr6:135349570	C/T	cg22676075	chr6:135203613	NA	0.48	6.66	0.38	1.62e-10	Red blood cell count;
CESC	cis	rs9916302	0.706	rs2302073	chr17:37457342	A/G	cg07936489	chr17:37558343	FBXL20	0.92	10.37	0.54	2.23e-21	Glomerular filtration rate (creatinine);
CESC	trans	rs2727020	0.595	rs10839281	chr11:49483373	A/C	cg03929089	chr4:120376271	NA	-0.85	-13.36	-0.63	1.85e-31	Coronary artery disease;
CESC	cis	rs1790761	0.520	rs1551884	chr11:67399601	C/G	cg00290607	chr11:67383545	NA	-0.38	-5.25	-0.31	3.15e-7	Mean corpuscular volume;
CESC	cis	rs3806843	0.766	rs2530239	chr5:140062547	C/T	cg26395211	chr5:140044315	WDR55	0.44	5.8	0.34	1.85e-8	Depressive symptoms (multi-trait analysis);
CESC	cis	rs1976403	0.659	rs10799700	chr1:21820968	G/C	cg02390115	chr1:21767211	NBPF3	0.4	5.72	0.33	2.92e-8	Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs61931739	0.500	rs1601628	chr12:34047375	A/C	cg26384229	chr12:38710491	ALG10B	0.53	7.22	0.41	5.44e-12	Morning vs. evening chronotype;
CESC	cis	rs3785574	0.962	rs13030	chr17:61908556	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.57	7.0	0.39	2.11e-11	Height;
CESC	cis	rs4481887	1.000	rs6681423	chr1:248482834	C/A	cg00666640	chr1:248458726	OR2T12	0.41	6.64	0.38	1.75e-10	Common traits (Other);
CESC	cis	rs9796	0.717	rs2947494	chr15:41375741	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.43	-6.28	-0.36	1.39e-9	Menopause (age at onset);
CESC	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg04234412	chr22:24373322	LOC391322	0.46	6.48	0.37	4.57e-10	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs763014	0.932	rs2269559	chr16:682297	T/C	cg00908189	chr16:619842	PIGQ	0.64	8.88	0.48	1.02e-16	Height;
CESC	trans	rs650950	0.528	rs646660	chr11:35528452	C/T	cg17944940	chr17:73285520	SLC25A19	0.5	6.16	0.35	2.65e-9	Bronchopulmonary dysplasia;
CESC	cis	rs763121	0.853	rs2267394	chr22:39101633	T/C	cg06022373	chr22:39101656	GTPBP1	0.94	17.57	0.73	2.32e-46	Menopause (age at onset);
CESC	cis	rs9908102	0.740	rs59287437	chr17:12912727	C/G	cg26162695	chr17:12921313	ELAC2	0.52	5.71	0.33	3.04e-8	Schizophrenia;
CESC	cis	rs1712517	0.525	rs7911488	chr10:105154089	A/G	cg04362960	chr10:104952993	NT5C2	-0.49	-5.94	-0.34	8.9e-9	Migraine;
CESC	cis	rs9303401	0.703	rs8077052	chr17:57208921	T/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.68	8.89	0.48	9.48e-17	Cognitive test performance;
CESC	cis	rs3820928	0.874	rs4675131	chr2:227836742	T/G	cg11843606	chr2:227700838	RHBDD1	-0.51	-6.65	-0.38	1.64e-10	Pulmonary function;
CESC	cis	rs514406	0.800	rs4926930	chr1:53217335	A/G	cg16325326	chr1:53192061	ZYG11B	-0.89	-15.22	-0.68	5.28e-38	Monocyte count;
CESC	cis	rs4704187	0.687	rs7735937	chr5:74441700	G/A	cg03227963	chr5:74354835	NA	0.3	5.54	0.32	7.14e-8	Response to amphetamines;
CESC	cis	rs896854	0.684	rs10099059	chr8:95986972	G/C	cg16049864	chr8:95962084	TP53INP1	-0.65	-11.59	-0.58	2.1e-25	Type 2 diabetes;
CESC	cis	rs3820928	0.874	rs4675132	chr2:227841792	A/C	cg05526886	chr2:227700861	RHBDD1	-0.42	-5.26	-0.31	3.02e-7	Pulmonary function;
CESC	cis	rs35110281	0.713	rs6518310	chr21:45098670	T/A	cg04455712	chr21:45112962	RRP1B	0.48	7.68	0.43	3.17e-13	Mean corpuscular volume;
CESC	cis	rs116095464	0.558	rs6555052	chr5:224268	G/A	cg22857025	chr5:266934	NA	-1.27	-18.88	-0.76	5.63e-51	Breast cancer;
CESC	cis	rs4595586	0.525	rs3914597	chr12:39388693	G/A	cg26384229	chr12:38710491	ALG10B	0.54	7.6	0.42	4.97e-13	Morning vs. evening chronotype;
CESC	cis	rs684232	0.602	rs445268	chr17:563338	G/A	cg12384639	chr17:618140	VPS53	0.42	5.4	0.32	1.46e-7	Prostate cancer;
CESC	cis	rs2243480	1.000	rs34702770	chr7:65344823	T/C	cg18252515	chr7:66147081	NA	-1.07	-10.29	-0.53	4.14e-21	Diabetic kidney disease;
CESC	cis	rs34172651	0.917	rs2112786	chr16:24778944	C/T	cg06028605	chr16:24865363	SLC5A11	0.35	5.5	0.32	8.72e-8	Intelligence (multi-trait analysis);
CESC	cis	rs4969178	0.895	rs2292640	chr17:76396610	G/A	cg20026190	chr17:76395443	PGS1	0.49	7.81	0.43	1.34e-13	HDL cholesterol levels;
CESC	cis	rs13082711	0.911	rs2131205	chr3:27428501	A/G	cg02860705	chr3:27208620	NA	0.52	6.71	0.38	1.14e-10	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CESC	cis	rs1011108	1.000	rs1011108	chr2:26782621	A/G	cg27305303	chr2:26781231	OTOF	0.27	5.28	0.31	2.74e-7	Periodontal microbiota;
CESC	cis	rs10089	1.000	rs1864922	chr5:127420700	T/C	cg19767477	chr5:127420684	SLC12A2	-0.41	-5.52	-0.32	7.88e-8	Ileal carcinoids;
CESC	cis	rs7927592	0.956	rs7116899	chr11:68385535	G/T	cg16797656	chr11:68205561	LRP5	0.38	5.28	0.31	2.69e-7	Total body bone mineral density;
CESC	cis	rs1545257	0.537	rs3108793	chr2:24648138	A/C	cg06627628	chr2:24431161	ITSN2	-0.49	-5.97	-0.34	7.67e-9	Sjögren's syndrome;
CESC	cis	rs67311347	0.713	rs114569261	chr3:40314580	G/A	cg09455208	chr3:40491958	NA	0.42	7.05	0.4	1.56e-11	Renal cell carcinoma;
CESC	cis	rs13191362	0.935	rs13215748	chr6:163010710	A/C	cg06582575	chr6:163149167	PACRG;PARK2	0.82	8.22	0.45	9.12e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs3749237	0.595	rs6784820	chr3:49450864	C/T	cg07636037	chr3:49044803	WDR6	-0.61	-9.07	-0.49	2.74e-17	Resting heart rate;
CESC	cis	rs12681366	0.511	rs2919670	chr8:95456618	A/G	cg13257157	chr8:95487014	RAD54B	0.45	5.47	0.32	1.05e-7	Nonsyndromic cleft lip with cleft palate;
CESC	cis	rs4665809	0.652	rs6728090	chr2:26524726	C/T	cg25036284	chr2:26402008	FAM59B	-0.67	-7.18	-0.4	6.93e-12	Gut microbiome composition (summer);
CESC	cis	rs2635047	0.601	rs2635052	chr18:44650607	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.39	5.32	0.31	2.19e-7	Educational attainment;
CESC	cis	rs9311474	0.967	rs11717383	chr3:52287468	G/T	cg25934064	chr3:52569026	NT5DC2	0.29	5.9	0.34	1.11e-8	Electroencephalogram traits;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg17319894	chr3:9791448	OGG1	-0.46	-6.04	-0.35	5.25e-9	Fibrinogen levels;
CESC	cis	rs4268898	0.662	rs72795832	chr2:24441855	C/A	cg08917208	chr2:24149416	ATAD2B	0.51	5.14	0.3	5.36e-7	Asthma;
CESC	cis	rs9649213	0.593	rs736753	chr7:97931489	G/T	cg21770322	chr7:97807741	LMTK2	0.54	8.13	0.45	1.67e-14	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs116095464	0.558	rs10077076	chr5:231940	C/T	cg22496380	chr5:211416	CCDC127	-0.74	-8.57	-0.47	8.98e-16	Breast cancer;
CESC	cis	rs4925386	1.000	rs4925382	chr20:60918542	G/C	cg24112000	chr20:60950667	NA	0.51	7.53	0.42	8.17e-13	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs7584330	0.554	rs114331205	chr2:238432559	A/C	cg14458575	chr2:238380390	NA	0.48	5.3	0.31	2.4e-7	Prostate cancer;
CESC	cis	rs7772486	0.790	rs2249386	chr6:146186611	G/A	cg23711669	chr6:146136114	FBXO30	1.02	15.79	0.7	4.7e-40	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4819052	0.851	rs2838840	chr21:46668494	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.75	9.93	0.52	5.92e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs6032067	0.925	rs35875037	chr20:43859921	A/G	cg10761708	chr20:43804764	PI3	0.52	6.29	0.36	1.34e-9	Blood protein levels;
CESC	cis	rs6582630	0.502	rs11520278	chr12:38359642	T/A	cg13010199	chr12:38710504	ALG10B	0.53	6.62	0.38	2.03e-10	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg04025307	chr7:1156635	C7orf50	0.46	6.3	0.36	1.22e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs3768617	0.510	rs10752899	chr1:183081241	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.88	14.13	0.66	3.71e-34	Fuchs's corneal dystrophy;
CESC	cis	rs6460942	1.000	rs6460936	chr7:12404913	T/C	cg02935154	chr7:12443704	VWDE	-0.57	-5.8	-0.34	1.89e-8	Coronary artery disease;
CESC	cis	rs12474201	0.925	rs17822294	chr2:46960004	G/A	cg06386533	chr2:46925753	SOCS5	0.91	12.78	0.62	1.83e-29	Height;
CESC	cis	rs116095464	0.558	rs61689490	chr5:224904	T/C	cg10591111	chr5:226296	SDHA	-0.52	-6.52	-0.37	3.47e-10	Breast cancer;
CESC	trans	rs7615952	0.512	rs11929125	chr3:125359443	G/A	cg00769240	chr8:12517080	NA	-0.44	-6.02	-0.35	5.7e-9	Blood pressure (smoking interaction);
CESC	cis	rs26868	0.766	rs26867	chr16:2249410	T/C	cg07587117	chr16:2239488	CASKIN1	0.33	5.34	0.31	2.02e-7	Height;
CESC	cis	rs60843830	1.000	rs55936726	chr2:258210	T/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.89	12.07	0.6	5.23e-27	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs9318086	0.648	rs7330140	chr13:24473074	A/T	cg25267304	chr13:24462978	PCOTH;MIPEP	0.44	6.27	0.36	1.44e-9	Myopia (pathological);
CESC	cis	rs4713118	0.588	rs200994	chr6:27813813	A/C	cg17221315	chr6:27791827	HIST1H4J	-0.42	-5.04	-0.3	8.78e-7	Parkinson's disease;
CESC	cis	rs832540	0.931	rs331499	chr5:56210923	C/T	cg14703610	chr5:56206110	C5orf35	0.52	6.76	0.38	8.99e-11	Coronary artery disease;
CESC	cis	rs2228479	0.850	rs11649162	chr16:89807131	C/A	cg04013166	chr16:89971882	TCF25	0.76	6.59	0.38	2.39e-10	Skin colour saturation;
CESC	cis	rs5769765	0.542	rs738707	chr22:50250827	G/A	cg02269571	chr22:50332266	NA	0.46	5.44	0.32	1.19e-7	Schizophrenia;
CESC	cis	rs7412746	0.611	rs4970984	chr1:150887377	T/C	cg22823121	chr1:150693482	HORMAD1	0.36	5.12	0.3	5.88e-7	Melanoma;
CESC	cis	rs727505	1.000	rs68007199	chr7:124491307	T/C	cg23710748	chr7:124431027	NA	-0.48	-7.61	-0.42	4.76e-13	Lewy body disease;
CESC	cis	rs1348850	0.914	rs12616443	chr2:178315751	A/G	cg23306229	chr2:178417860	TTC30B	0.62	7.92	0.44	6.66e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs7659604	0.540	rs10007956	chr4:122700669	A/T	cg19748678	chr4:122722346	EXOSC9	-0.4	-5.1	-0.3	6.62e-7	Type 2 diabetes;
CESC	cis	rs10791097	0.694	rs10894275	chr11:130756251	C/T	cg12179176	chr11:130786555	SNX19	0.66	10.36	0.54	2.45e-21	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs6952808	0.564	rs55865401	chr7:2145720	G/C	cg05863683	chr7:1912471	MAD1L1	0.36	5.31	0.31	2.32e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs1728785	1.000	rs7196104	chr16:68579746	C/A	cg02972257	chr16:68554789	NA	-0.55	-6.31	-0.36	1.17e-9	Ulcerative colitis;
CESC	cis	rs2463822	0.669	rs72919484	chr11:62043430	T/C	cg06239285	chr11:62104954	ASRGL1	-1.13	-9.21	-0.49	1.05e-17	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs75477785	1.000	rs77249837	chr1:209988527	G/A	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.92	6.04	0.35	5.06e-9	Cleft lip with or without cleft palate;
CESC	cis	rs9302635	0.513	rs13334151	chr16:72189727	A/C	cg01557791	chr16:72042693	DHODH	-0.62	-6.91	-0.39	3.5e-11	Blood protein levels;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg09546895	chr5:32174322	GOLPH3	-0.42	-6.13	-0.35	3.12e-9	Fibrinogen levels;
CESC	cis	rs708547	0.647	rs781666	chr4:57830981	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.6	7.92	0.44	6.59e-14	Response to bleomycin (chromatid breaks);
CESC	cis	rs6964587	1.000	rs10234071	chr7:91645152	C/G	cg01689657	chr7:91764605	CYP51A1	-0.28	-5.09	-0.3	6.82e-7	Breast cancer;
CESC	trans	rs747782	0.585	rs1316604	chr11:48279796	G/A	cg15704280	chr7:45808275	SEPT13	0.68	6.39	0.37	7.34e-10	Intraocular pressure;
CESC	cis	rs72781680	0.898	rs6545127	chr2:24060670	C/T	cg20701182	chr2:24300061	SF3B14	0.62	5.6	0.33	5.24e-8	Lymphocyte counts;
CESC	cis	rs13108904	0.967	rs11730939	chr4:1285560	G/A	cg22903657	chr4:1355424	KIAA1530	-0.38	-5.17	-0.3	4.72e-7	Obesity-related traits;
CESC	cis	rs736408	0.509	rs1108842	chr3:52720080	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	7.14	0.4	8.95e-12	Bipolar disorder;
CESC	cis	rs11148252	0.904	rs7321964	chr13:53040822	A/G	cg00495681	chr13:53174319	NA	0.38	5.29	0.31	2.52e-7	Lewy body disease;
CESC	cis	rs2354432	0.607	rs7523812	chr1:146673489	A/G	cg25205988	chr1:146714368	CHD1L	-1.19	-9.08	-0.49	2.58e-17	Mitochondrial DNA levels;
CESC	cis	rs2204008	0.502	rs2387275	chr12:38142836	G/A	cg26384229	chr12:38710491	ALG10B	0.74	10.5	0.54	8.8e-22	Bladder cancer;
CESC	cis	rs514406	0.929	rs485631	chr1:53330245	A/G	cg08736216	chr1:53307985	ZYG11A	-0.45	-7.38	-0.41	2e-12	Monocyte count;
CESC	cis	rs1448094	0.872	rs10863146	chr12:86408326	C/G	cg02569458	chr12:86230093	RASSF9	0.34	5.14	0.3	5.45e-7	Major depressive disorder;
CESC	cis	rs875971	1.000	rs2036264	chr7:65799904	G/A	cg11764359	chr7:65958608	NA	-0.94	-15.34	-0.69	1.97e-38	Aortic root size;
CESC	cis	rs2637266	1.000	rs12251543	chr10:78345465	G/A	cg18941641	chr10:78392320	NA	0.43	7.93	0.44	5.97e-14	Pulmonary function;
CESC	cis	rs3796619	1.000	rs28620427	chr4:1086247	T/G	cg27284194	chr4:1044797	NA	0.37	5.69	0.33	3.38e-8	Recombination rate (males);
CESC	cis	rs1322639	0.618	rs9505942	chr6:169591793	T/C	cg03254818	chr6:169586852	NA	0.53	5.94	0.34	9.04e-9	Pulse pressure;
CESC	cis	rs763121	0.925	rs9611008	chr22:39098787	T/C	cg06022373	chr22:39101656	GTPBP1	0.88	15.22	0.68	5.14e-38	Menopause (age at onset);
CESC	cis	rs4689388	0.853	rs4293850	chr4:6292020	A/C	cg25554036	chr4:6271136	WFS1	0.48	7.6	0.42	5.21e-13	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs7927771	1.000	rs11039390	chr11:47796295	C/G	cg20307385	chr11:47447363	PSMC3	-0.51	-6.25	-0.36	1.62e-9	Subjective well-being;
CESC	cis	rs1348850	0.837	rs12619074	chr2:178472336	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.55	7.13	0.4	9.5e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs2243480	1.000	rs160642	chr7:65558373	C/T	cg18252515	chr7:66147081	NA	-1.39	-13.81	-0.65	4.83e-33	Diabetic kidney disease;
CESC	cis	rs34779708	0.897	rs12764820	chr10:35386321	G/A	cg04310649	chr10:35416472	CREM	-0.51	-6.06	-0.35	4.62e-9	Inflammatory bowel disease;Crohn's disease;
CESC	trans	rs7618501	1.000	rs4855862	chr3:49748833	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.58	-8.44	-0.46	2.11e-15	Intelligence (multi-trait analysis);
CESC	cis	rs7312933	0.533	rs11181499	chr12:42818761	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.5	6.45	0.37	5.42e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs9612	1.000	rs16976747	chr19:44238152	G/A	cg08581076	chr19:44259116	C19orf61	0.56	6.37	0.36	8.53e-10	Exhaled nitric oxide output;
CESC	cis	rs2932538	0.922	rs7522110	chr1:113072914	A/C	cg22162597	chr1:113214053	CAPZA1	0.52	6.55	0.37	2.96e-10	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CESC	cis	rs2576037	0.796	rs2247221	chr18:44580082	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.33	-5.16	-0.3	4.75e-7	Personality dimensions;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg06535952	chr19:56126775	NA	0.45	6.4	0.37	7.02e-10	Fibrinogen levels;
CESC	cis	rs8114671	0.562	rs6088622	chr20:33419977	C/A	cg08999081	chr20:33150536	PIGU	0.39	5.52	0.32	7.98e-8	Height;
CESC	cis	rs4919044	0.545	rs9420603	chr10:94777490	T/C	cg16508068	chr10:94451736	HHEX	-0.5	-5.49	-0.32	9.61e-8	Coronary artery disease;
CESC	cis	rs9611519	0.964	rs2092563	chr22:41592677	G/A	cg03806693	chr22:41940476	POLR3H	-0.58	-5.86	-0.34	1.39e-8	Neuroticism;
CESC	cis	rs752010	0.631	rs7515066	chr1:42076915	A/G	cg06885757	chr1:42089581	HIVEP3	-0.7	-11.66	-0.58	1.25e-25	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs4555082	0.645	rs2816605	chr14:105715515	C/T	cg13114125	chr14:105738426	BRF1	-0.86	-10.28	-0.53	4.36e-21	Mean platelet volume;Platelet distribution width;
CESC	cis	rs6867032	1.000	rs2129472	chr5:2016247	G/A	cg26168224	chr5:2018326	NA	0.96	19.64	0.77	1.3e-53	Gut microbiome composition (winter);
CESC	cis	rs875971	0.862	rs6460282	chr7:65691246	T/C	cg11764359	chr7:65958608	NA	-0.77	-10.8	-0.55	8.76e-23	Aortic root size;
CESC	cis	rs6570726	0.935	rs414646	chr6:145831685	T/C	cg23711669	chr6:146136114	FBXO30	0.8	12.02	0.59	7.3e-27	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs16906415	0.546	rs71530187	chr8:137802025	C/T	cg18579875	chr2:217540128	IGFBP5	-0.68	-6.01	-0.35	6.22e-9	IgG glycosylation;
CESC	cis	rs9926296	0.681	rs12923946	chr16:89821080	C/T	cg27121462	chr16:89883253	FANCA	0.57	6.9	0.39	3.71e-11	Vitiligo;
CESC	cis	rs6141600	0.760	rs2590986	chr20:34686496	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.4	-5.44	-0.32	1.2e-7	Height;Hip circumference;
CESC	cis	rs6679073	1.000	rs10494874	chr1:205754688	C/G	cg26354017	chr1:205819088	PM20D1	0.4	5.31	0.31	2.28e-7	Prostate-specific antigen levels;
CESC	cis	rs11792861	0.591	rs7027874	chr9:111717112	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.62	9.52	0.5	1.17e-18	Menarche (age at onset);
CESC	cis	rs2370759	0.898	rs113412621	chr10:32579306	C/T	cg05361325	chr10:32636312	EPC1	-0.55	-5.18	-0.3	4.39e-7	Sexual dysfunction (female);
CESC	cis	rs8020095	0.571	rs7145917	chr14:67372526	C/T	cg19548862	chr14:67692701	FAM71D	-0.49	-6.03	-0.35	5.38e-9	Depression (quantitative trait);
CESC	cis	rs2997447	0.761	rs56078964	chr1:26442600	C/A	cg24596570	chr1:26146463	FAM54B;LOC646471	0.59	5.17	0.3	4.68e-7	QRS complex (12-leadsum);
CESC	cis	rs13256369	0.802	rs11249885	chr8:8562008	C/T	cg17143192	chr8:8559678	CLDN23	0.69	8.55	0.46	1.02e-15	Obesity-related traits;
CESC	cis	rs938554	0.513	rs3733588	chr4:9997303	A/G	cg00071950	chr4:10020882	SLC2A9	-0.6	-7.86	-0.43	9.72e-14	Blood metabolite levels;
CESC	cis	rs3733585	0.577	rs5014939	chr4:9953253	T/A	cg11266682	chr4:10021025	SLC2A9	-0.58	-11.0	-0.56	2.04e-23	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs1062177	0.855	rs6884630	chr5:151268997	A/T	cg00977110	chr5:151150581	G3BP1	0.52	5.69	0.33	3.28e-8	Preschool internalizing problems;
CESC	cis	rs10752881	1.000	rs10797810	chr1:182980950	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.83	13.29	0.63	3.24e-31	Colorectal cancer;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg02457826	chr20:30310733	BCL2L1	-0.49	-6.28	-0.36	1.39e-9	Fibrinogen levels;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg20250396	chr14:65880036	FUT8;LOC645431	-0.44	-6.1	-0.35	3.75e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs1707322	0.964	rs10437063	chr1:46273666	G/A	cg05343316	chr1:45956843	TESK2	0.44	5.53	0.32	7.85e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs11122272	0.735	rs2739507	chr1:231527329	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.53	-7.18	-0.4	7.02e-12	Hemoglobin concentration;
CESC	cis	rs921968	0.541	rs3821031	chr2:219295249	C/T	cg02176678	chr2:219576539	TTLL4	-0.47	-8.27	-0.45	6.59e-15	Mean corpuscular hemoglobin concentration;
CESC	trans	rs3780486	0.846	rs10124479	chr9:33136233	T/G	cg20290983	chr6:43655470	MRPS18A	0.98	18.17	0.74	1.8e-48	IgG glycosylation;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27277367	chr15:100106179	MEF2A	0.54	6.0	0.35	6.55e-9	Gut microbiome composition (summer);
CESC	cis	rs35110281	0.776	rs62226866	chr21:45024186	T/C	cg21573476	chr21:45109991	RRP1B	-0.48	-6.69	-0.38	1.33e-10	Mean corpuscular volume;
CESC	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg23708337	chr7:1209742	NA	0.55	5.41	0.32	1.44e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs9303280	0.901	rs883770	chr17:38063381	C/T	cg20243544	chr17:37824526	PNMT	0.56	7.37	0.41	2.23e-12	Self-reported allergy;
CESC	cis	rs1008375	0.931	rs6831211	chr4:17697009	G/A	cg02297831	chr4:17616191	MED28	0.49	5.83	0.34	1.61e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs1775715	0.651	rs2808033	chr10:32194127	A/T	cg18675610	chr10:32216311	ARHGAP12	0.34	5.24	0.31	3.21e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs9487051	0.768	rs1766814	chr6:109526696	G/A	cg01475377	chr6:109611718	NA	-0.44	-6.67	-0.38	1.49e-10	Reticulocyte fraction of red cells;
CESC	cis	rs6582630	0.598	rs10880645	chr12:38556172	G/A	cg26384229	chr12:38710491	ALG10B	-0.42	-5.5	-0.32	8.81e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs1045714	0.836	rs73033691	chr7:2636522	T/G	cg20813462	chr7:2646259	IQCE	0.67	5.8	0.34	1.92e-8	Urate levels in lean individuals;
CESC	cis	rs854765	0.663	rs1108648	chr17:17750558	G/A	cg09796270	chr17:17721594	SREBF1	-0.44	-6.22	-0.36	1.97e-9	Total body bone mineral density;
CESC	trans	rs2733310	0.793	rs28468978	chr15:57153089	C/A	cg13494055	chr3:59115467	NA	-0.43	-6.01	-0.35	6.06e-9	Mean platelet volume;
CESC	trans	rs7230711	0.808	rs73960393	chr18:48755075	C/A	cg03986574	chr11:64544080	SF1	-0.78	-6.3	-0.36	1.23e-9	Immune response to anthrax vaccine;
CESC	cis	rs853679	0.517	rs9393884	chr6:28046789	A/G	cg26335602	chr6:28129616	ZNF389	0.54	7.21	0.4	5.86e-12	Depression;
CESC	cis	rs72781680	0.612	rs33913065	chr2:24344060	T/G	cg06627628	chr2:24431161	ITSN2	-0.67	-6.56	-0.37	2.87e-10	Lymphocyte counts;
CESC	cis	rs1215050	0.755	rs9991112	chr4:98651479	A/C	cg05340658	chr4:99064831	C4orf37	-0.48	-6.22	-0.36	1.89e-9	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs2032447	0.507	rs199748	chr6:25909045	C/G	cg12310025	chr6:25882481	NA	-0.63	-9.31	-0.5	5.2e-18	Intelligence (multi-trait analysis);
CESC	cis	rs11785400	0.793	rs4467920	chr8:143736846	C/T	cg10596483	chr8:143751796	JRK	0.43	5.41	0.32	1.37e-7	Schizophrenia;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg03321319	chr22:22222323	MAPK1	-0.44	-6.82	-0.39	6.27e-11	Gambling;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg23597562	chr20:54976805	CSTF1	0.46	6.75	0.38	9.27e-11	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs8031584	0.918	rs61997138	chr15:31270776	C/T	cg08704250	chr15:31115839	NA	-0.63	-8.12	-0.45	1.82e-14	Huntington's disease progression;
CESC	cis	rs35146811	0.883	rs4134903	chr7:99711040	G/A	cg13334819	chr7:99746414	C7orf59	-0.44	-5.28	-0.31	2.65e-7	Coronary artery disease;
CESC	cis	rs7666738	0.791	rs2903142	chr4:99040071	C/T	cg17366294	chr4:99064904	C4orf37	0.61	8.78	0.47	2.13e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4319547	0.695	rs10744211	chr12:122931820	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.5	-5.77	-0.33	2.19e-8	Body mass index;
CESC	cis	rs11252926	0.931	rs4881399	chr10:567325	A/G	cg16386425	chr10:429943	DIP2C	-0.46	-5.3	-0.31	2.42e-7	Psychosis in Alzheimer's disease;
CESC	trans	rs1545843	0.595	rs11116360	chr12:84791082	A/G	cg03015433	chr16:56623111	MT3	-0.33	-6.01	-0.35	6.11e-9	Major depressive disorder;
CESC	cis	rs9818758	0.607	rs13087930	chr3:48961726	A/G	cg00383909	chr3:49044727	WDR6	0.95	6.8	0.39	6.82e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CESC	cis	rs6424115	0.692	rs573361	chr1:24053674	A/T	cg15997130	chr1:24165203	NA	0.42	5.62	0.33	4.95e-8	Immature fraction of reticulocytes;
CESC	cis	rs10979	1.000	rs12203151	chr6:143884856	C/T	cg25407410	chr6:143891975	LOC285740	-0.63	-9.57	-0.51	8.08e-19	Hypospadias;
CESC	cis	rs228437	0.913	rs7763821	chr6:134939618	A/G	cg24504307	chr6:134963096	NA	-0.47	-5.52	-0.32	8.01e-8	Melanoma;
CESC	cis	rs7927771	0.524	rs10838740	chr11:47679980	A/G	cg20307385	chr11:47447363	PSMC3	0.6	8.38	0.46	3.1e-15	Subjective well-being;
CESC	cis	rs2717559	0.542	rs2585156	chr8:143879795	G/A	cg17252645	chr8:143867129	LY6D	-0.33	-5.75	-0.33	2.43e-8	Urinary tract infection frequency;
CESC	trans	rs7246760	1.000	rs10412903	chr19:9880927	C/A	cg02900749	chr2:68251473	NA	-0.71	-6.55	-0.37	3.05e-10	Pursuit maintenance gain;
CESC	cis	rs4268898	0.662	rs72795832	chr2:24441855	C/A	cg06627628	chr2:24431161	ITSN2	-0.98	-11.22	-0.57	3.77e-24	Asthma;
CESC	cis	rs8067354	0.645	rs7215180	chr17:57822354	A/G	cg13753209	chr17:57696993	CLTC	0.65	7.89	0.44	7.95e-14	Hemoglobin concentration;
CESC	cis	rs13315871	0.929	rs13094898	chr3:58290143	G/A	cg20936604	chr3:58311152	NA	-0.63	-5.04	-0.3	8.69e-7	Cholesterol, total;
CESC	cis	rs4604732	0.631	rs4436425	chr1:247632323	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.5	6.39	0.37	7.55e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs113835537	0.529	rs11227509	chr11:66281194	T/C	cg22134325	chr11:66188745	NPAS4	0.37	5.81	0.34	1.77e-8	Airway imaging phenotypes;
CESC	cis	rs6964587	1.000	rs9969198	chr7:91567492	G/T	cg17063962	chr7:91808500	NA	-0.58	-7.81	-0.43	1.34e-13	Breast cancer;
CESC	cis	rs763014	0.966	rs7185390	chr16:666382	A/G	cg09781414	chr16:715207	WDR90	-0.35	-5.33	-0.31	2.07e-7	Height;
CESC	cis	rs514406	0.698	rs522259	chr1:53365481	A/G	cg08736216	chr1:53307985	ZYG11A	-0.37	-6.43	-0.37	6.03e-10	Monocyte count;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg04526616	chr7:4757846	FOXK1	0.46	6.32	0.36	1.13e-9	Fibrinogen levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01919652	chr6:150259930	NA	0.54	6.1	0.35	3.65e-9	Gut microbiome composition (summer);
CESC	cis	rs910316	0.737	rs175045	chr14:75475275	A/C	cg08847533	chr14:75593920	NEK9	-0.86	-13.32	-0.63	2.49e-31	Height;
CESC	cis	rs11098499	0.909	rs11098530	chr4:120413154	C/T	cg09307838	chr4:120376055	NA	0.92	12.96	0.62	4.27e-30	Corneal astigmatism;
CESC	cis	rs875971	0.964	rs9691480	chr7:65944306	A/C	cg10691866	chr7:65817282	TPST1	-0.34	-5.62	-0.33	4.93e-8	Aortic root size;
CESC	cis	rs4141404	0.828	rs2413043	chr22:31648576	G/T	cg13145458	chr22:31556086	RNF185	0.46	5.26	0.31	2.98e-7	Paclitaxel-induced neuropathy;
CESC	cis	rs12887734	0.524	rs17791722	chr14:104286210	C/T	cg08213375	chr14:104286397	PPP1R13B	0.4	6.86	0.39	4.74e-11	Schizophrenia;Autism spectrum disorder or schizophrenia;
CESC	cis	rs3126085	0.597	rs12047544	chr1:152169922	C/T	cg26876637	chr1:152193138	HRNR	0.44	5.04	0.3	8.68e-7	Atopic dermatitis;
CESC	cis	rs6540559	1.000	rs2235373	chr1:209963803	G/A	cg21951975	chr1:209979733	IRF6	0.62	9.5	0.5	1.3e-18	Cleft lip with or without cleft palate;
CESC	cis	rs7917772	0.502	rs2296583	chr10:104244322	T/G	ch.10.2196322F	chr10:104248062	ACTR1A	0.43	5.25	0.31	3.06e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs208520	0.802	rs1342959	chr6:66883329	A/G	cg07460842	chr6:66804631	NA	-0.94	-12.15	-0.6	2.75e-27	Exhaled nitric oxide output;
CESC	cis	rs7811142	0.830	rs6948685	chr7:99970188	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.08	10.92	0.56	3.59e-23	Platelet count;
CESC	trans	rs1116547	0.571	rs11748794	chr5:112917278	T/G	cg10115368	chr14:100435663	NA	0.5	6.01	0.35	6.13e-9	Cerebral amyloid angiopathy;
CESC	cis	rs3820928	0.874	rs9288618	chr2:227872617	A/G	cg11843606	chr2:227700838	RHBDD1	-0.46	-6.03	-0.35	5.41e-9	Pulmonary function;
CESC	cis	rs1003719	0.646	rs2032063	chr21:38576657	A/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.61	-8.29	-0.45	5.58e-15	Eye color traits;
CESC	cis	rs10876993	0.890	rs7963927	chr12:58046272	T/G	cg18357645	chr12:58087776	OS9	0.59	9.07	0.49	2.72e-17	Celiac disease or Rheumatoid arthritis;
CESC	cis	rs72781680	0.898	rs56303870	chr2:24086944	G/A	cg08917208	chr2:24149416	ATAD2B	0.91	8.38	0.46	3.04e-15	Lymphocyte counts;
CESC	cis	rs9393777	0.513	rs9295702	chr6:26634040	T/C	cg11502198	chr6:26597334	ABT1	0.52	5.34	0.31	1.99e-7	Intelligence (multi-trait analysis);
CESC	cis	rs7165102	1.000	rs600193	chr15:65729409	A/G	cg11441148	chr15:65824328	PTPLAD1	-0.32	-5.33	-0.31	2.1e-7	Mean corpuscular hemoglobin;
CESC	cis	rs9814567	1.000	rs9968172	chr3:134231251	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.44	5.97	0.34	7.69e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	trans	rs208520	1.000	rs208536	chr6:66963440	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.85	-9.42	-0.5	2.36e-18	Exhaled nitric oxide output;
CESC	cis	rs11048434	0.736	rs1805733	chr12:9089272	A/C	cg23795048	chr12:9217529	LOC144571	0.33	5.12	0.3	5.94e-7	Sjögren's syndrome;
CESC	cis	rs17711722	0.510	rs73142128	chr7:65331109	A/C	cg14393609	chr7:65229607	NA	0.47	6.24	0.36	1.68e-9	Calcium levels;
CESC	cis	rs736408	0.609	rs13082208	chr3:52781539	T/G	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.3	5.36	0.31	1.83e-7	Bipolar disorder;
CESC	cis	rs1799949	1.000	rs4793189	chr17:41190715	G/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.4	5.21	0.3	3.86e-7	Menopause (age at onset);
CESC	trans	rs7726839	0.540	rs72703078	chr5:594987	A/C	cg25482853	chr8:67687455	SGK3	1.04	10.11	0.53	1.55e-20	Obesity-related traits;
CESC	cis	rs12220238	0.915	rs11001027	chr10:76152655	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.55	5.1	0.3	6.42e-7	Soluble interleukin-2 receptor subunit alpha;
CESC	cis	rs6674176	0.660	rs3791112	chr1:44379248	T/G	cg23954153	chr1:44402353	ARTN	-0.35	-5.47	-0.32	1.04e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg20044189	chr5:141704548	SPRY4	-0.49	-6.29	-0.36	1.33e-9	Ulcerative colitis;
CESC	cis	rs425277	0.606	rs2460001	chr1:2111030	T/C	cg04315214	chr1:2043799	PRKCZ	-0.4	-6.51	-0.37	3.71e-10	Height;
CESC	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg22535103	chr8:58192502	C8orf71	-0.96	-9.81	-0.52	1.45e-19	Developmental language disorder (linguistic errors);
CESC	cis	rs2832077	0.527	rs2705690	chr21:30239245	T/A	cg24692254	chr21:30365293	RNF160	0.53	6.89	0.39	3.98e-11	Cognitive test performance;
CESC	cis	rs7851660	0.901	rs7873389	chr9:100609230	C/T	cg13688889	chr9:100608707	NA	-0.69	-10.57	-0.54	4.92e-22	Strep throat;
CESC	cis	rs1862618	0.671	rs2034244	chr5:56242774	T/C	cg24549020	chr5:56110836	MAP3K1	-0.49	-6.0	-0.35	6.46e-9	Initial pursuit acceleration;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg14354430	chr9:136911493	BRD3	0.45	6.02	0.35	5.86e-9	Fibrinogen levels;
CESC	cis	rs7223966	1.000	rs9908044	chr17:61747032	A/C	cg11494091	chr17:61959527	GH2	0.38	5.35	0.31	1.93e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs2439831	1.000	rs689647	chr15:43762196	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.83	12.17	0.6	2.26e-27	Lung cancer in ever smokers;
CESC	cis	rs7552404	0.960	rs12134854	chr1:76137606	A/G	cg10523679	chr1:76189770	ACADM	0.72	8.42	0.46	2.33e-15	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs7107174	1.000	rs10793297	chr11:78009660	T/C	cg02023728	chr11:77925099	USP35	0.5	6.66	0.38	1.62e-10	Testicular germ cell tumor;
CESC	cis	rs10751667	0.714	rs7396700	chr11:963863	A/C	cg20946044	chr11:1010712	AP2A2	-0.38	-5.35	-0.31	1.92e-7	Alzheimer's disease (late onset);
CESC	cis	rs7666738	0.791	rs1967978	chr4:98966152	T/C	cg05340658	chr4:99064831	C4orf37	0.8	12.39	0.61	3.96e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs8177253	0.965	rs3811658	chr3:133476852	C/T	cg11941060	chr3:133502564	NA	-0.45	-6.09	-0.35	4.01e-9	Iron status biomarkers;
CESC	cis	rs7666738	0.753	rs2865957	chr4:99040725	G/A	cg03676636	chr4:99064102	C4orf37	0.33	5.08	0.3	7.13e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10504229	1.000	rs6989060	chr8:58178989	T/G	cg22535103	chr8:58192502	C8orf71	-1.05	-13.27	-0.63	3.63e-31	Developmental language disorder (linguistic errors);
CESC	cis	rs7223966	1.000	rs9901507	chr17:61765524	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.58	7.44	0.42	1.42e-12	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs4481887	0.708	rs6587463	chr1:248544452	G/C	cg26353448	chr1:248524236	OR2T4	-0.37	-5.12	-0.3	5.85e-7	Common traits (Other);
CESC	cis	rs6570726	0.791	rs374478	chr6:145840022	C/T	cg23711669	chr6:146136114	FBXO30	1.01	15.9	0.7	1.9e-40	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1799949	0.965	rs4793234	chr17:41436183	A/G	cg25072359	chr17:41440525	NA	0.44	5.9	0.34	1.13e-8	Menopause (age at onset);
CESC	cis	rs11158198	0.738	rs10134110	chr14:58573183	C/G	cg15908186	chr14:58618357	C14orf37	0.34	5.17	0.3	4.64e-7	Dementia and core Alzheimer's disease neuropathologic changes;
CESC	cis	rs7914558	0.933	rs10786729	chr10:104719378	A/G	cg04362960	chr10:104952993	NT5C2	0.43	5.51	0.32	8.58e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs6987853	0.933	rs55881007	chr8:42367290	A/G	cg09913449	chr8:42400586	C8orf40	-0.42	-6.72	-0.38	1.1e-10	Mean corpuscular hemoglobin concentration;
CESC	cis	rs17253792	0.915	rs74580958	chr14:56181511	G/A	cg01858014	chr14:56050164	KTN1	-0.94	-7.27	-0.41	4.03e-12	Putamen volume;
CESC	cis	rs4665809	1.000	rs4665305	chr2:26313524	C/T	cg22920501	chr2:26401640	FAM59B	-0.65	-7.61	-0.42	4.88e-13	Gut microbiome composition (summer);
CESC	cis	rs9649213	0.593	rs6465682	chr7:98016417	C/A	cg24562669	chr7:97807699	LMTK2	0.52	7.59	0.42	5.59e-13	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs4253772	0.637	rs41279831	chr22:46651623	T/C	cg24881330	chr22:46731750	TRMU	0.77	6.19	0.36	2.26e-9	LDL cholesterol;Cholesterol, total;
CESC	cis	rs3741151	0.686	rs17851510	chr11:73106294	A/C	cg17517138	chr11:73019481	ARHGEF17	0.82	6.55	0.37	3.06e-10	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs9649213	0.593	rs6465677	chr7:98003552	C/T	cg08684580	chr7:98029266	BAIAP2L1	-0.35	-5.78	-0.33	2.05e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs6750795	0.746	rs1667301	chr2:232423717	C/T	cg12810212	chr2:232379626	C2orf52	0.38	5.14	0.3	5.36e-7	Height;
CESC	cis	rs4595586	0.655	rs11170269	chr12:39387077	G/A	cg26384229	chr12:38710491	ALG10B	0.44	6.31	0.36	1.15e-9	Morning vs. evening chronotype;
CESC	cis	rs4555082	0.874	rs2816625	chr14:105734565	G/A	cg06808227	chr14:105710500	BRF1	-0.6	-6.87	-0.39	4.44e-11	Mean platelet volume;Platelet distribution width;
CESC	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg06873352	chr17:61820015	STRADA	0.73	12.89	0.62	7.87e-30	Prudent dietary pattern;
CESC	cis	rs2559856	1.000	rs2559858	chr12:102089300	A/G	cg12213457	chr12:102090980	CHPT1	-0.37	-5.56	-0.32	6.66e-8	Blood protein levels;
CESC	cis	rs6456156	0.792	rs10946214	chr6:167516122	G/A	cg23791538	chr6:167370224	RNASET2	-0.4	-5.21	-0.3	3.82e-7	Primary biliary cholangitis;
CESC	cis	rs7666738	0.830	rs28615340	chr4:98896922	T/C	cg03676636	chr4:99064102	C4orf37	0.34	5.17	0.3	4.59e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7666738	0.800	rs2839836	chr4:98970512	A/G	cg05340658	chr4:99064831	C4orf37	0.79	12.28	0.6	9.45e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9291683	0.620	rs4383618	chr4:10125151	T/C	cg00071950	chr4:10020882	SLC2A9	-0.56	-8.61	-0.47	6.51e-16	Bone mineral density;
CESC	cis	rs73206853	0.841	rs56379265	chr12:110956370	G/A	cg12870014	chr12:110450643	ANKRD13A	0.63	5.22	0.31	3.56e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	trans	rs11098499	0.909	rs28581362	chr4:120283548	T/A	cg25214090	chr10:38739885	LOC399744	0.65	9.11	0.49	2.04e-17	Corneal astigmatism;
CESC	cis	rs1395	0.778	rs2078616	chr2:27441904	A/G	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.45	5.99	0.35	6.99e-9	Blood metabolite levels;
CESC	cis	rs6831352	0.918	rs17217949	chr4:100054312	A/G	cg12011299	chr4:100065546	ADH4	-0.6	-6.62	-0.38	2.04e-10	Alcohol dependence;
CESC	cis	rs7178572	0.568	rs1125617	chr15:77532711	A/G	cg22256960	chr15:77711686	NA	-0.53	-6.69	-0.38	1.33e-10	Type 2 diabetes;
CESC	cis	rs14403	0.874	rs3006923	chr1:243648757	C/G	cg21452805	chr1:244014465	NA	-0.47	-5.65	-0.33	4.05e-8	Schizophrenia;
CESC	cis	rs36051895	0.623	rs7847811	chr9:5237081	T/C	cg02405213	chr9:5042618	JAK2	-0.56	-6.62	-0.38	1.95e-10	Pediatric autoimmune diseases;
CESC	cis	rs6570726	0.905	rs452770	chr6:145847162	T/C	cg23711669	chr6:146136114	FBXO30	0.8	11.89	0.59	2e-26	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg06348651	chr12:110562118	IFT81	-0.46	-6.28	-0.36	1.36e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs801193	0.569	rs7800620	chr7:66223688	T/C	cg18252515	chr7:66147081	NA	-0.44	-5.96	-0.34	8.18e-9	Aortic root size;
CESC	cis	rs10899021	1.000	rs61900635	chr11:74359010	C/G	cg25880958	chr11:74394337	NA	-0.76	-7.25	-0.41	4.55e-12	Response to metformin (IC50);
CESC	cis	rs1862618	0.671	rs2591957	chr5:56243146	A/T	cg24531977	chr5:56204891	C5orf35	0.69	9.31	0.5	5.13e-18	Initial pursuit acceleration;
CESC	cis	rs6582630	0.537	rs7299661	chr12:38527713	C/T	cg26384229	chr12:38710491	ALG10B	0.66	10.09	0.53	1.76e-20	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs11690935	0.918	rs12692978	chr2:172725981	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.97	-14.0	-0.65	1.06e-33	Schizophrenia;
CESC	cis	rs854765	0.583	rs7207395	chr17:17819335	C/T	cg09796270	chr17:17721594	SREBF1	0.47	6.52	0.37	3.49e-10	Total body bone mineral density;
CESC	cis	rs2629540	0.765	rs7097254	chr10:126512248	A/C	cg08799069	chr10:126477246	METTL10	-0.54	-7.95	-0.44	5.38e-14	Cocaine dependence;
CESC	cis	rs16917546	1.000	rs10995249	chr10:64396916	C/T	cg03961010	chr10:64397487	ZNF365	-0.37	-6.06	-0.35	4.7e-9	Basal cell carcinoma;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17554553	chr10:31321002	ZNF438	0.55	6.24	0.36	1.75e-9	Gut microbiome composition (summer);
CESC	cis	rs1552244	0.882	rs67631672	chr3:10004768	G/A	cg08888203	chr3:10149979	C3orf24	0.45	5.57	0.32	6.17e-8	Alzheimer's disease;
CESC	trans	rs875971	1.000	rs2042133	chr7:65931922	A/G	cg26939375	chr7:64535504	NA	0.47	6.09	0.35	4.06e-9	Aortic root size;
CESC	cis	rs9303401	0.659	rs7216648	chr17:56790858	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.05	12.77	0.62	1.94e-29	Cognitive test performance;
CESC	cis	rs752010	0.875	rs11210501	chr1:42091634	T/C	cg06885757	chr1:42089581	HIVEP3	0.46	7.42	0.41	1.64e-12	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs3096299	0.967	rs2911256	chr16:89485096	G/C	cg00750074	chr16:89608354	SPG7	-0.37	-5.33	-0.31	2.13e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg26354017	chr1:205819088	PM20D1	0.84	12.49	0.61	1.86e-28	Menarche (age at onset);
CESC	cis	rs1538970	0.884	rs61788261	chr1:45899114	G/A	cg24296786	chr1:45957014	TESK2	-0.46	-5.28	-0.31	2.72e-7	Platelet count;
CESC	cis	rs2404602	0.716	rs1588961	chr15:76752698	A/G	cg26408565	chr15:76604113	ETFA	-0.43	-6.25	-0.36	1.65e-9	Blood metabolite levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11563264	chr4:190862026	FRG1	0.53	6.02	0.35	5.71e-9	Gut microbiome composition (summer);
CESC	cis	rs1865760	0.532	rs2794719	chr6:26088890	T/G	cg17691542	chr6:26056736	HIST1H1C	0.45	6.0	0.35	6.36e-9	Height;
CESC	cis	rs1008375	1.000	rs1558377	chr4:17650758	A/G	cg02297831	chr4:17616191	MED28	0.61	7.82	0.43	1.23e-13	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs1218582	0.741	rs10908444	chr1:154840287	G/A	cg06221963	chr1:154839813	KCNN3	-0.68	-11.89	-0.59	2.11e-26	Prostate cancer;
CESC	cis	rs11098499	0.866	rs12374352	chr4:120281977	C/T	cg24375607	chr4:120327624	NA	0.42	5.19	0.3	4.19e-7	Corneal astigmatism;
CESC	cis	rs17209837	1.000	rs45554032	chr7:87078547	G/T	cg00919237	chr7:87102261	ABCB4	-0.5	-5.85	-0.34	1.44e-8	Gallbladder cancer;
CESC	cis	rs2070997	0.607	rs2480372	chr9:133706389	G/A	cg11464064	chr9:133710261	ABL1	0.68	7.89	0.44	8.03e-14	Response to amphetamines;
CESC	trans	rs9987353	0.840	rs329994	chr8:9123233	A/G	cg14064766	chr2:239344455	ASB1	0.5	6.32	0.36	1.11e-9	Recombination measurement;
CESC	cis	rs7017914	0.783	rs13252584	chr8:71689031	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.2	-0.3	3.94e-7	Bone mineral density;
CESC	cis	rs4253772	0.591	rs6519994	chr22:46656805	A/G	cg24881330	chr22:46731750	TRMU	-0.87	-9.79	-0.52	1.6e-19	LDL cholesterol;Cholesterol, total;
CESC	cis	rs1707322	0.963	rs34907901	chr1:46405214	T/G	cg03146154	chr1:46216737	IPP	0.72	9.69	0.51	3.34e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7772486	0.875	rs854146	chr6:146341033	A/G	cg05347473	chr6:146136440	FBXO30	0.51	6.56	0.37	2.88e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs752010	0.967	rs10890151	chr1:42101843	C/A	cg06885757	chr1:42089581	HIVEP3	0.49	7.83	0.43	1.17e-13	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs4665809	0.531	rs10199898	chr2:26445485	T/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.1	-12.68	-0.61	4e-29	Gut microbiome composition (summer);
CESC	trans	rs2727020	0.658	rs10839278	chr11:49450847	G/C	cg15704280	chr7:45808275	SEPT13	-0.91	-15.67	-0.69	1.28e-39	Coronary artery disease;
CESC	trans	rs72996113	0.702	rs79174253	chr11:100519054	A/C	cg20136100	chr11:63974860	FERMT3	-0.51	-6.49	-0.37	4.27e-10	Reticulocyte fraction of red cells;Reticulocyte count;
CESC	cis	rs2354432	0.607	rs1890039	chr1:146681951	T/C	cg25205988	chr1:146714368	CHD1L	1.15	8.65	0.47	4.98e-16	Mitochondrial DNA levels;
CESC	cis	rs6912958	0.559	rs183599	chr6:88061024	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.45	8.02	0.44	3.47e-14	Monocyte percentage of white cells;
CESC	cis	rs3796352	1.000	rs13078971	chr3:53103645	G/C	cg15956490	chr3:53032818	SFMBT1	0.63	5.18	0.3	4.44e-7	Immune reponse to smallpox (secreted IL-2);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg19006130	chr11:118478252	PHLDB1	-0.47	-6.53	-0.37	3.36e-10	Fibrinogen levels;
CESC	cis	rs6860806	0.507	rs272891	chr5:131664394	G/T	cg24060327	chr5:131705240	SLC22A5	-0.77	-10.83	-0.55	7.15e-23	Breast cancer;
CESC	cis	rs6582630	0.502	rs11610978	chr12:38356957	C/G	cg26384229	chr12:38710491	ALG10B	0.67	9.99	0.52	3.88e-20	Drug-induced liver injury (flucloxacillin);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg25061763	chr12:62860430	MON2	0.45	6.02	0.35	5.95e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs782590	0.935	rs782606	chr2:55886602	T/C	cg18811423	chr2:55921094	PNPT1	0.79	12.72	0.62	3.03e-29	Metabolic syndrome;
CESC	cis	rs2576037	0.526	rs1893427	chr18:44434987	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.32	5.16	0.3	4.85e-7	Personality dimensions;
CESC	cis	rs4589502	1.000	rs79390908	chr15:67130924	C/T	cg12317470	chr15:67143691	NA	0.68	5.26	0.31	2.92e-7	Lung cancer (smoking interaction);
CESC	cis	rs1707322	0.717	rs3014245	chr1:46086913	C/T	cg06784218	chr1:46089804	CCDC17	-0.42	-7.24	-0.41	4.76e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs4588572	0.644	rs2241566	chr5:77784738	C/T	cg11547950	chr5:77652471	NA	0.39	5.38	0.31	1.61e-7	Triglycerides;
CESC	cis	rs7666738	0.645	rs10013290	chr4:99082799	G/A	cg05340658	chr4:99064831	C4orf37	0.75	10.74	0.55	1.38e-22	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6964587	0.967	rs28594877	chr7:91644070	C/T	cg17063962	chr7:91808500	NA	0.55	7.63	0.42	4.25e-13	Breast cancer;
CESC	cis	rs4919694	0.572	rs12261294	chr10:104934952	C/T	cg04362960	chr10:104952993	NT5C2	0.64	6.44	0.37	5.66e-10	Arsenic metabolism;
CESC	cis	rs67478160	0.571	rs1155751	chr14:104286547	C/G	cg01849466	chr14:104193079	ZFYVE21	-0.49	-6.96	-0.39	2.65e-11	Schizophrenia;
CESC	cis	rs9457247	1.000	rs422094	chr6:167397033	C/G	cg23791538	chr6:167370224	RNASET2	-0.6	-8.48	-0.46	1.57e-15	Crohn's disease;
CESC	cis	rs4665809	1.000	rs4233710	chr2:26291565	G/A	cg04944784	chr2:26401820	FAM59B	-0.78	-8.86	-0.48	1.18e-16	Gut microbiome composition (summer);
CESC	cis	rs9549367	0.826	rs9549710	chr13:113898064	A/C	cg18105134	chr13:113819100	PROZ	-0.68	-8.11	-0.45	1.94e-14	Platelet distribution width;
CESC	cis	rs6685188	0.920	rs10751444	chr1:205662144	A/G	cg11965913	chr1:205819406	PM20D1	-0.46	-6.4	-0.37	6.88e-10	White blood cell count (basophil);Basophil percentage of white cells;
CESC	cis	rs2251381	0.520	rs873651	chr21:30781848	G/A	cg24692254	chr21:30365293	RNF160	0.47	6.03	0.35	5.46e-9	Selective IgA deficiency;
CESC	cis	rs10256972	0.621	rs2280725	chr7:1087426	G/T	cg09177884	chr7:1199841	ZFAND2A	-0.49	-6.42	-0.37	6.31e-10	Longevity;Endometriosis;
CESC	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg11803278	chr7:157951799	PTPRN2	0.28	5.96	0.34	7.98e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CESC	cis	rs7824557	0.591	rs2043510	chr8:11225168	G/A	cg21775007	chr8:11205619	TDH	-0.55	-8.56	-0.47	9.45e-16	Retinal vascular caliber;
CESC	cis	rs34734847	1.000	rs55730005	chr12:121157536	C/A	cg21892295	chr12:121157589	UNC119B	-0.42	-6.65	-0.38	1.66e-10	Mean corpuscular volume;
CESC	cis	rs4642101	0.793	rs6799179	chr3:12829095	A/C	cg24848339	chr3:12840334	CAND2	0.36	5.48	0.32	9.72e-8	QRS complex (12-leadsum);
CESC	cis	rs8114671	0.562	rs2076667	chr20:33506964	G/A	cg06115741	chr20:33292138	TP53INP2	0.48	5.79	0.34	1.97e-8	Height;
CESC	cis	rs514406	0.792	rs1242201	chr1:53344748	G/A	cg16325326	chr1:53192061	ZYG11B	0.75	11.27	0.57	2.57e-24	Monocyte count;
CESC	cis	rs709400	0.628	rs72708854	chr14:103864885	T/C	cg12935359	chr14:103987150	CKB	-0.53	-7.76	-0.43	1.88e-13	Body mass index;
CESC	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.55	-6.09	-0.35	3.98e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2239547	0.521	rs9682464	chr3:52888485	C/T	cg11645453	chr3:52864694	ITIH4	0.32	5.91	0.34	1.04e-8	Schizophrenia;
CESC	cis	rs68170813	0.559	rs17428126	chr7:106897037	C/T	cg02696742	chr7:106810147	HBP1	-0.52	-5.08	-0.3	7.2e-7	Coronary artery disease;
CESC	cis	rs34779708	0.931	rs4007289	chr10:35269790	G/A	cg03585969	chr10:35415529	CREM	0.76	10.14	0.53	1.27e-20	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs7937682	0.710	rs674230	chr11:111437887	A/G	cg22437258	chr11:111473054	SIK2	0.74	9.62	0.51	5.34e-19	Primary sclerosing cholangitis;
CESC	cis	rs72781680	0.898	rs56315094	chr2:23941952	T/C	cg08917208	chr2:24149416	ATAD2B	1.0	9.21	0.49	1.03e-17	Lymphocyte counts;
CESC	cis	rs9906944	0.707	rs9916472	chr17:47109998	C/T	cg09029085	chr17:47094198	IGF2BP1	0.26	5.07	0.3	7.32e-7	Intelligence (multi-trait analysis);Body fat percentage;
CESC	cis	rs11122272	0.735	rs2250704	chr1:231486647	A/G	cg06096015	chr1:231504339	EGLN1	0.43	6.24	0.36	1.69e-9	Hemoglobin concentration;
CESC	cis	rs2398668	0.570	rs4721548	chr7:2330496	A/G	cg08027265	chr7:2291960	NA	-0.44	-7.28	-0.41	3.83e-12	Bipolar disorder and schizophrenia;
CESC	cis	rs7267979	1.000	rs11100	chr20:25281184	G/C	cg08601574	chr20:25228251	PYGB	0.39	5.57	0.32	6.14e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7551222	0.716	rs12041075	chr1:204492153	C/G	cg20240347	chr1:204465584	NA	-0.28	-5.69	-0.33	3.39e-8	Schizophrenia;
CESC	cis	rs769267	1.000	rs7246748	chr19:19433105	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	-0.46	-5.69	-0.33	3.45e-8	Tonsillectomy;
CESC	trans	rs57221529	0.766	rs12521051	chr5:560440	A/G	cg25482853	chr8:67687455	SGK3	-1.07	-12.11	-0.6	3.81e-27	Lung disease severity in cystic fibrosis;
CESC	cis	rs4234284	0.556	rs34147515	chr3:126965137	G/C	cg27326032	chr3:127006922	NA	-0.4	-5.5	-0.32	8.97e-8	Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel);
CESC	cis	rs116095464	0.558	rs61492827	chr5:225774	A/G	cg10591111	chr5:226296	SDHA	-0.52	-6.52	-0.37	3.47e-10	Breast cancer;
CESC	cis	rs3785574	0.962	rs2247435	chr17:61892862	G/A	cg07677032	chr17:61819896	STRADA	0.42	5.36	0.31	1.78e-7	Height;
CESC	cis	rs2074585	0.560	rs12903058	chr15:91061121	G/T	cg10434728	chr15:90938212	IQGAP1	-0.32	-5.35	-0.31	1.94e-7	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
CESC	cis	rs3091242	0.933	rs34006994	chr1:25780668	C/T	cg03538708	chr1:25844672	NA	0.38	5.8	0.34	1.92e-8	Erythrocyte sedimentation rate;
CESC	cis	rs523522	0.962	rs687873	chr12:121019634	G/A	cg27279351	chr12:120934652	DYNLL1	0.7	9.06	0.49	2.86e-17	High light scatter reticulocyte count;
CESC	cis	rs7666738	0.649	rs28865589	chr4:98954279	C/A	cg17366294	chr4:99064904	C4orf37	0.59	8.21	0.45	1.01e-14	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2732480	0.557	rs923397	chr12:48720392	G/A	cg24011408	chr12:48396354	COL2A1	0.4	5.76	0.33	2.31e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs6696846	0.749	rs11578293	chr1:205070178	T/C	cg00857998	chr1:205179979	DSTYK	0.51	6.96	0.39	2.65e-11	Red blood cell count;
CESC	cis	rs2204008	0.807	rs8186948	chr12:38325101	C/G	cg26384229	chr12:38710491	ALG10B	0.69	10.31	0.53	3.6e-21	Bladder cancer;
CESC	cis	rs780096	0.527	rs11127044	chr2:27740404	C/G	cg22903471	chr2:27725779	GCKR	-0.53	-7.32	-0.41	2.91e-12	Total body bone mineral density;
CESC	cis	rs7465272	0.500	rs7463655	chr8:143731034	G/C	cg24634471	chr8:143751801	JRK	0.45	5.78	0.33	2.12e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs2760061	0.784	rs708116	chr1:228198196	C/A	cg02753203	chr1:228287806	NA	0.53	7.89	0.44	8.14e-14	Diastolic blood pressure;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15606388	chr17:42219409	C17orf53	0.57	6.22	0.36	1.93e-9	Gut microbiome composition (summer);
CESC	cis	rs2549003	1.000	rs2549003	chr5:131829297	A/G	cg00255919	chr5:131827918	IRF1	0.61	11.15	0.56	6.42e-24	Asthma (sex interaction);
CESC	cis	rs4253772	0.515	rs9615968	chr22:46772695	A/G	cg18190219	chr22:46762943	CELSR1	-0.77	-6.28	-0.36	1.34e-9	LDL cholesterol;Cholesterol, total;
CESC	cis	rs769267	0.965	rs1469712	chr19:19528821	C/A	cg03709012	chr19:19516395	GATAD2A	0.99	15.45	0.69	7.62e-39	Tonsillectomy;
CESC	cis	rs4919044	0.756	rs835257	chr10:94779801	T/A	cg16508068	chr10:94451736	HHEX	-0.5	-5.49	-0.32	9.61e-8	Coronary artery disease;
CESC	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg24642844	chr7:1081250	C7orf50	-0.64	-8.58	-0.47	8.21e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2070488	0.662	rs7372545	chr3:38507570	T/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.68	8.94	0.48	7.02e-17	Electrocardiographic conduction measures;
CESC	cis	rs11711311	0.955	rs7650764	chr3:113414439	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.52	6.84	0.39	5.58e-11	IgG glycosylation;
CESC	cis	rs853679	0.517	rs12174753	chr6:28042465	C/G	cg18032046	chr6:28092343	ZSCAN16	-0.53	-6.09	-0.35	3.91e-9	Depression;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24568194	chr20:36156405	BLCAP	-0.56	-6.43	-0.37	6.04e-10	Gut microbiome composition (summer);
CESC	cis	rs72627123	0.867	rs59675549	chr14:74469480	A/T	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.8	5.77	0.33	2.2e-8	Morning vs. evening chronotype;
CESC	cis	rs12042938	1.000	rs11122319	chr1:231808282	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.37	-5.16	-0.3	4.84e-7	Neuranatomic and neurocognitive phenotypes;
CESC	cis	rs7618915	0.501	rs2079929	chr3:52765646	C/T	cg18404041	chr3:52824283	ITIH1	-0.39	-6.63	-0.38	1.85e-10	Bipolar disorder;
CESC	trans	rs7395662	0.517	rs2021248	chr11:49013054	C/T	cg00717180	chr2:96193071	NA	-0.48	-6.59	-0.38	2.41e-10	HDL cholesterol;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16098923	chr2:88927231	EIF2AK3	0.64	7.58	0.42	5.97e-13	Gut microbiome composition (summer);
CESC	cis	rs4253772	0.530	rs9615362	chr22:46795141	A/C	cg09491104	chr22:46646882	C22orf40	0.48	6.48	0.37	4.45e-10	LDL cholesterol;Cholesterol, total;
CESC	cis	rs9549260	0.753	rs9532578	chr13:41236407	G/A	cg21288729	chr13:41239152	FOXO1	0.54	5.12	0.3	5.76e-7	Red blood cell count;
CESC	cis	rs7089973	0.604	rs7897937	chr10:116591318	A/G	cg03647239	chr10:116582469	FAM160B1	0.43	5.29	0.31	2.6e-7	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg15262992	chr20:61442882	OGFR	0.44	6.11	0.35	3.54e-9	Fibrinogen levels;
CESC	cis	rs2836974	0.899	rs6517514	chr21:40527095	G/T	cg17971929	chr21:40555470	PSMG1	1.05	16.66	0.72	4.09e-43	Cognitive function;
CESC	trans	rs11098499	0.663	rs28369503	chr4:120238925	G/A	cg25214090	chr10:38739885	LOC399744	0.59	8.11	0.45	1.85e-14	Corneal astigmatism;
CESC	cis	rs1801251	0.896	rs2305141	chr2:233684402	A/G	cg25237894	chr2:233734115	C2orf82	-0.36	-6.41	-0.37	6.47e-10	Coronary artery disease;
CESC	cis	rs7666738	0.830	rs7664305	chr4:99037691	G/A	cg03676636	chr4:99064102	C4orf37	0.33	5.12	0.3	6.01e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11583043	1.000	rs17123612	chr1:101476814	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.53	5.84	0.34	1.54e-8	Ulcerative colitis;Inflammatory bowel disease;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg01993411	chr20:44562842	PCIF1	0.54	6.74	0.38	1e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs7274811	0.688	rs56234419	chr20:32086447	C/T	cg21523528	chr20:32077966	CBFA2T2	0.63	7.16	0.4	8.07e-12	Height;
CESC	cis	rs875971	0.964	rs778721	chr7:65845397	C/G	cg18876405	chr7:65276391	NA	0.5	6.66	0.38	1.61e-10	Aortic root size;
CESC	cis	rs7560272	0.501	rs12615807	chr2:73947583	T/C	cg20560298	chr2:73613845	ALMS1	0.41	5.64	0.33	4.42e-8	Schizophrenia;
CESC	cis	rs9733	0.818	rs11204702	chr1:150663507	C/A	cg22823121	chr1:150693482	HORMAD1	-0.41	-6.45	-0.37	5.32e-10	Tonsillectomy;
CESC	trans	rs1973993	0.689	rs67544133	chr1:96971241	G/A	cg10631902	chr5:14652156	NA	-0.46	-6.25	-0.36	1.6e-9	Weight;
CESC	cis	rs875971	0.862	rs949930	chr7:65766822	C/G	cg18876405	chr7:65276391	NA	-0.49	-6.75	-0.38	9.38e-11	Aortic root size;
CESC	cis	rs1799949	1.000	rs8176318	chr17:41197274	G/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.56	7.4	0.41	1.77e-12	Menopause (age at onset);
CESC	cis	rs4253772	0.513	rs9615345	chr22:46713631	C/T	cg10231785	chr22:46692440	CN5H6.4;GTSE1	0.63	6.51	0.37	3.85e-10	LDL cholesterol;Cholesterol, total;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg21786873	chr4:4250096	TMEM128	-0.5	-7.17	-0.4	7.36e-12	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs2732480	0.538	rs1387260	chr12:48703091	A/C	cg04545296	chr12:48745243	ZNF641	0.43	7.15	0.4	8.3e-12	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs9457247	0.765	rs1322077	chr6:167424293	T/C	cg23791538	chr6:167370224	RNASET2	-0.53	-7.37	-0.41	2.17e-12	Crohn's disease;
CESC	cis	rs12449000	1	rs12449000	chr16:89872970	T/C	cg04287289	chr16:89883240	FANCA	0.8	12.6	0.61	7.71e-29	Schizophrenia;
CESC	trans	rs11098499	0.754	rs938056	chr4:120237453	C/T	cg25214090	chr10:38739885	LOC399744	0.63	8.77	0.47	2.16e-16	Corneal astigmatism;
CESC	trans	rs1038903	0.893	rs981103	chr4:28760835	A/G	cg15651925	chr7:156259219	NA	0.49	6.11	0.35	3.59e-9	Menarche (age at onset);
CESC	cis	rs4835473	0.932	rs9685306	chr4:144669996	G/A	cg25736465	chr4:144833511	NA	-0.43	-6.65	-0.38	1.67e-10	Immature fraction of reticulocytes;
CESC	cis	rs8014204	0.967	rs4903266	chr14:75344941	C/G	cg08847533	chr14:75593920	NEK9	-0.42	-5.1	-0.3	6.46e-7	Caffeine consumption;
CESC	cis	rs10489525	0.599	rs11102879	chr1:115603504	C/T	cg01522456	chr1:115632236	TSPAN2	0.48	5.67	0.33	3.69e-8	Autism;
CESC	cis	rs1218582	0.774	rs4845679	chr1:154861187	G/T	cg03351412	chr1:154909251	PMVK	0.59	7.56	0.42	6.42e-13	Prostate cancer;
CESC	cis	rs425277	0.539	rs3128337	chr1:2045882	A/G	cg23803603	chr1:2058230	PRKCZ	-0.34	-5.8	-0.34	1.92e-8	Height;
CESC	cis	rs6570726	0.837	rs636894	chr6:145864122	T/C	cg23711669	chr6:146136114	FBXO30	0.79	11.47	0.58	5.24e-25	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2836974	0.831	rs2836921	chr21:40516070	C/T	cg11890956	chr21:40555474	PSMG1	1.1	17.2	0.73	4.66e-45	Cognitive function;
CESC	cis	rs818427	0.593	rs67293732	chr5:112217964	G/C	cg07820702	chr5:112228657	REEP5	-0.4	-5.12	-0.3	5.75e-7	Total body bone mineral density;
CESC	trans	rs7615952	0.512	rs4679430	chr3:125357893	T/C	cg21747405	chr11:67723411	NA	-0.44	-6.69	-0.38	1.3100000000000001e-10	Blood pressure (smoking interaction);
CESC	cis	rs9303280	0.806	rs12232497	chr17:38040119	T/C	cg19468946	chr17:37922297	IKZF3	-0.41	-5.49	-0.32	9.59e-8	Self-reported allergy;
CESC	cis	rs933688	1.000	rs10045280	chr5:90717675	T/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.91	12.36	0.6	5.13e-28	Smoking behavior;
CESC	trans	rs2018683	0.707	rs1021689	chr7:28974223	G/T	cg19402173	chr7:128379420	CALU	-0.5	-6.62	-0.38	1.93e-10	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CESC	cis	rs1065852	0.906	rs9611734	chr22:42502070	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.59	9.07	0.49	2.68e-17	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
CESC	cis	rs6933660	0.721	rs2128945	chr6:151767907	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.83	13.61	0.64	2.31e-32	Menarche (age at onset);
CESC	trans	rs561341	1.000	rs530715	chr17:30320544	T/G	cg20587970	chr11:113659929	NA	-1.11	-14.12	-0.66	4e-34	Hip circumference adjusted for BMI;
CESC	cis	rs9768139	0.733	rs921617	chr7:158118198	A/G	cg24154853	chr7:158122151	PTPRN2	0.43	6.78	0.38	7.65e-11	Calcium levels;
CESC	trans	rs1373453	0.908	rs17106937	chr12:70066280	A/G	cg19702771	chr4:82058885	PRKG2	0.74	6.04	0.35	5.28e-9	Orofacial clefts;
CESC	cis	rs4727027	0.901	rs1534197	chr7:148771970	T/C	cg23158103	chr7:148848205	ZNF398	-0.41	-6.47	-0.37	4.66e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs7833790	0.777	rs1005850	chr8:82692255	G/A	cg17211192	chr8:82754475	SNX16	-0.69	-8.57	-0.47	8.92e-16	Diastolic blood pressure;
CESC	cis	rs7959452	0.590	rs11177628	chr12:69765421	G/A	cg14784868	chr12:69753453	YEATS4	0.83	12.94	0.62	5.03e-30	Blood protein levels;
CESC	cis	rs17376456	1.000	rs10514382	chr5:93566534	G/A	cg25358565	chr5:93447407	FAM172A	1.22	10.21	0.53	7.61e-21	Diabetic retinopathy;
CESC	cis	rs6500602	0.627	rs860891	chr16:4586529	C/T	cg08645402	chr16:4508243	NA	-0.37	-5.76	-0.33	2.31e-8	Schizophrenia;
CESC	cis	rs11690935	0.877	rs72890834	chr2:172835802	G/T	cg13550731	chr2:172543902	DYNC1I2	-0.92	-12.98	-0.62	3.66e-30	Schizophrenia;
CESC	cis	rs1215050	0.740	rs1214994	chr4:99035577	C/T	cg05340658	chr4:99064831	C4orf37	0.57	7.59	0.42	5.49e-13	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs722599	0.748	rs731952	chr14:75366447	A/G	cg08847533	chr14:75593920	NEK9	0.42	5.1	0.3	6.62e-7	IgG glycosylation;
CESC	trans	rs11098499	0.955	rs4145951	chr4:120155817	A/G	cg25214090	chr10:38739885	LOC399744	0.65	8.59	0.47	7.54e-16	Corneal astigmatism;
CESC	cis	rs9911578	1.000	rs10401050	chr17:56953786	A/C	cg12560992	chr17:57184187	TRIM37	0.94	15.65	0.69	1.5e-39	Intelligence (multi-trait analysis);
CESC	cis	rs6748734	0.625	rs6741220	chr2:241822432	C/T	cg04034577	chr2:241836375	C2orf54	0.33	5.97	0.34	7.67e-9	Urinary metabolites;
CESC	cis	rs9322193	0.962	rs35443312	chr6:149991761	T/C	cg13206674	chr6:150067644	NUP43	0.39	5.41	0.32	1.42e-7	Lung cancer;
CESC	cis	rs7301826	0.651	rs7132657	chr12:131285187	T/C	cg11011512	chr12:131303247	STX2	0.47	5.81	0.34	1.81e-8	Plasma plasminogen activator levels;
CESC	trans	rs2207136	0.835	rs2817351	chr6:50897613	A/G	cg06522515	chr3:184090630	THPO	-0.35	-6.04	-0.35	5.31e-9	Myopia;
CESC	cis	rs1023500	0.596	rs5758562	chr22:42448238	C/G	cg04733989	chr22:42467013	NAGA	0.81	11.08	0.56	1.09e-23	Schizophrenia;
CESC	cis	rs2766692	0.843	rs10873515	chr14:100766664	C/T	cg14866419	chr14:100704911	YY1	-0.42	-5.1	-0.3	6.63e-7	Electroencephalographic traits in alcoholism;
CESC	cis	rs7714584	1.000	rs1896707	chr5:150245129	C/T	cg22134413	chr5:150180641	NA	0.49	5.65	0.33	4.22e-8	Crohn's disease;
CESC	cis	rs3785574	0.927	rs2854160	chr17:61977248	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.57	7.06	0.4	1.5e-11	Height;
CESC	cis	rs514406	0.621	rs881198	chr1:53196440	C/T	cg16325326	chr1:53192061	ZYG11B	-0.94	-16.08	-0.7	4.45e-41	Monocyte count;
CESC	cis	rs6964587	1.000	rs6976122	chr7:91610962	T/C	cg17063962	chr7:91808500	NA	0.57	7.74	0.43	2.11e-13	Breast cancer;
CESC	cis	rs10089	0.953	rs10045113	chr5:127386631	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.78	10.53	0.54	6.98e-22	Ileal carcinoids;
CESC	cis	rs6912958	0.559	rs1201409	chr6:88055264	T/C	cg04972856	chr6:88032051	C6orf162;GJB7	0.33	5.49	0.32	9.58e-8	Monocyte percentage of white cells;
CESC	cis	rs12137294	0.866	rs1078362	chr1:205209530	A/G	cg21643547	chr1:205240462	TMCC2	-0.35	-5.66	-0.33	4e-8	Red cell distribution width;
CESC	cis	rs9649213	0.614	rs3801258	chr7:97988428	G/A	cg09267113	chr7:98030324	BAIAP2L1	-0.45	-6.1	-0.35	3.72e-9	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg23129613	chr7:150065255	REPIN1	0.48	6.39	0.37	7.42e-10	Systemic lupus erythematosus;
CESC	cis	rs12541635	0.966	rs7839239	chr8:107020406	C/T	cg10147462	chr8:107024639	NA	0.41	5.98	0.34	7.16e-9	Age of smoking initiation;
CESC	cis	rs1499614	1.000	rs1267817	chr7:66110040	G/T	cg08632164	chr7:65971372	NA	-0.49	-5.15	-0.3	5.03e-7	Gout;
CESC	cis	rs7666738	0.830	rs28728124	chr4:99001116	G/T	cg17366294	chr4:99064904	C4orf37	0.6	8.61	0.47	6.47e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs116095464	0.558	rs10067021	chr5:221490	C/T	cg22857025	chr5:266934	NA	-1.27	-18.89	-0.76	5.51e-51	Breast cancer;
CESC	cis	rs4665809	0.590	rs4665313	chr2:26415897	A/G	cg26314531	chr2:26401878	FAM59B	-0.81	-9.01	-0.48	4.3e-17	Gut microbiome composition (summer);
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg26782824	chr11:82867961	PCF11	-0.46	-6.47	-0.37	4.78e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs7811142	0.945	rs6955362	chr7:100056166	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.14	11.43	0.57	7.11e-25	Platelet count;
CESC	cis	rs875971	0.660	rs1860470	chr7:66103694	G/C	cg11764359	chr7:65958608	NA	-0.65	-8.46	-0.46	1.78e-15	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12612340	chr11:47664330	MTCH2	0.59	6.66	0.38	1.61e-10	Gut microbiome composition (summer);
CESC	cis	rs3106136	0.872	rs10030713	chr4:95238536	C/G	cg11021082	chr4:95130006	SMARCAD1	-0.41	-5.66	-0.33	3.85e-8	Capecitabine sensitivity;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg25433267	chr10:77161647	C10orf41;ZNF503	-0.53	-6.52	-0.37	3.45e-10	Ulcerative colitis;
CESC	cis	rs763014	0.833	rs3743902	chr16:632728	T/C	cg09263875	chr16:632152	PIGQ	0.67	11.24	0.57	3.15e-24	Height;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg21242327	chr4:57829539	C4orf14	-0.4	-6.09	-0.35	3.99e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg19558860	chr14:93582779	ITPK1	-0.47	-6.33	-0.36	1.02e-9	Ulcerative colitis;
CESC	cis	rs9311474	0.508	rs6786919	chr3:52599789	A/G	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.65	0.38	1.65e-10	Electroencephalogram traits;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg01579086	chr17:40719412	MLX	0.52	6.78	0.38	7.88e-11	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs514406	0.729	rs534070	chr1:53308858	T/G	cg08859206	chr1:53392774	SCP2	-0.64	-9.56	-0.51	8.45e-19	Monocyte count;
CESC	cis	rs57221529	0.709	rs72706611	chr5:561146	C/A	cg16447950	chr5:562315	NA	-0.71	-7.83	-0.43	1.2e-13	Lung disease severity in cystic fibrosis;
CESC	cis	rs13031619	0.660	rs34855424	chr2:3702780	C/A	cg25251562	chr2:3704773	ALLC	-0.59	-5.75	-0.33	2.5e-8	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CESC	cis	rs7959452	0.590	rs11177628	chr12:69765421	G/A	cg20891283	chr12:69753455	YEATS4	0.9	14.79	0.67	1.71e-36	Blood protein levels;
CESC	cis	rs9596863	1.000	rs9536564	chr13:54460395	G/A	ch.13.53330881F	chr13:54432880	NA	-0.67	-5.68	-0.33	3.5e-8	Epilepsy and lamotrigine-induced maculopapular eruptions;
CESC	trans	rs11088226	0.681	rs11702499	chr21:33938565	C/T	cg09050820	chr6:167586206	TCP10L2	0.83	7.75	0.43	2.01e-13	Gastritis;
CESC	cis	rs2279817	1.000	rs2279817	chr1:18021858	T/C	cg21791023	chr1:18019539	ARHGEF10L	-0.63	-8.42	-0.46	2.44e-15	Neuroticism;
CESC	cis	rs7786877	0.521	rs4729606	chr7:100321790	T/C	cg16850897	chr7:100343110	ZAN	-0.63	-7.75	-0.43	2.02e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs7246865	0.906	rs2278997	chr19:17166981	G/A	cg19418318	chr19:17219073	MYO9B	0.32	5.32	0.31	2.17e-7	Reticulocyte fraction of red cells;
CESC	cis	rs1005277	0.541	rs2472177	chr10:38384015	T/G	cg25517755	chr10:38738941	LOC399744	-0.44	-5.76	-0.33	2.29e-8	Extrinsic epigenetic age acceleration;
CESC	cis	rs9457247	0.967	rs443570	chr6:167389925	G/A	cg23791538	chr6:167370224	RNASET2	-0.63	-8.95	-0.48	6.25e-17	Crohn's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14163802	chr2:206547479	NRP2	0.58	6.64	0.38	1.78e-10	Gut microbiome composition (summer);
CESC	cis	rs12048904	0.541	rs6699536	chr1:101276544	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.74	9.36	0.5	3.58e-18	Multiple sclerosis;
CESC	cis	rs7662987	0.517	rs2602872	chr4:100038996	A/G	cg12011299	chr4:100065546	ADH4	0.57	6.32	0.36	1.09e-9	Smoking initiation;
CESC	cis	rs2239547	0.522	rs2581801	chr3:52972907	G/T	cg11645453	chr3:52864694	ITIH4	-0.31	-5.17	-0.3	4.6e-7	Schizophrenia;
CESC	cis	rs7631605	0.905	rs6796088	chr3:37147572	G/T	cg22985146	chr3:37219077	LRRFIP2	-0.32	-5.07	-0.3	7.57e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs17376456	0.877	rs12153788	chr5:93405437	A/G	cg25358565	chr5:93447407	FAM172A	1.13	10.9	0.56	4.33e-23	Diabetic retinopathy;
CESC	cis	rs3857067	0.776	rs6858265	chr4:95112565	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.6	-9.12	-0.49	1.97e-17	QT interval;
CESC	trans	rs9951602	0.512	rs6506872	chr18:76649695	T/C	cg02800362	chr5:177631904	HNRNPAB	0.65	8.64	0.47	5.23e-16	Obesity-related traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.62	-7.17	-0.4	7.36e-12	Gut microbiome composition (summer);
CESC	cis	rs7116495	0.609	rs2735787	chr11:71717873	T/C	cg18441811	chr11:71824068	C11orf51	-0.78	-5.19	-0.3	4.26e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs7927592	0.913	rs7118897	chr11:68360680	G/A	cg20283391	chr11:68216788	NA	-0.59	-7.4	-0.41	1.85e-12	Total body bone mineral density;
CESC	cis	rs11051970	0.559	rs56670459	chr12:32543325	G/A	cg24626660	chr12:32551988	NA	0.42	5.37	0.31	1.7e-7	Response to tocilizumab in rheumatoid arthritis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07649988	chr10:102106576	SCD	0.55	6.06	0.35	4.55e-9	Gut microbiome composition (summer);
CESC	cis	rs801193	1.000	rs3857688	chr7:66127806	G/A	cg25985355	chr7:65971099	NA	0.32	5.23	0.31	3.53e-7	Aortic root size;
CESC	cis	rs8018808	0.875	rs7250	chr14:77935520	G/A	cg20045696	chr14:77926864	AHSA1	0.43	5.9	0.34	1.13e-8	Myeloid white cell count;
CESC	cis	rs9911578	1.000	rs9897326	chr17:56902297	A/G	cg12560992	chr17:57184187	TRIM37	0.94	15.75	0.7	6.57e-40	Intelligence (multi-trait analysis);
CESC	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg26338869	chr17:61819248	STRADA	0.7	9.28	0.5	6.1e-18	Prudent dietary pattern;
CESC	cis	rs60871478	1.000	rs60871478	chr7:827325	A/G	cg05535760	chr7:792225	HEATR2	0.86	10.68	0.55	2.27e-22	Cerebrospinal P-tau181p levels;
CESC	cis	rs1577917	0.958	rs12196377	chr6:86566775	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-6.14	-0.35	2.93e-9	Response to antipsychotic treatment;
CESC	cis	rs6952808	0.601	rs3800882	chr7:2120758	G/A	cg05863683	chr7:1912471	MAD1L1	0.36	5.36	0.31	1.84e-7	Bipolar disorder and schizophrenia;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg00753739	chr10:11653489	USP6NL	0.5	6.34	0.36	9.83e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs7312933	0.531	rs2708059	chr12:42851008	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.48	-6.37	-0.36	8.42e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs2120019	0.608	rs4886414	chr15:75308650	C/T	cg00629941	chr15:75287862	SCAMP5	0.53	6.32	0.36	1.12e-9	Blood trace element (Zn levels);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg22501760	chr22:29137527	CHEK2;HSCB	0.45	6.11	0.35	3.49e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs2836950	0.501	rs2836984	chr21:40700949	A/C	cg11644478	chr21:40555479	PSMG1	-0.57	-7.68	-0.43	2.98e-13	Menarche (age at onset);
CESC	cis	rs3820928	0.874	rs11685983	chr2:227799853	A/G	cg11843606	chr2:227700838	RHBDD1	-0.42	-5.62	-0.33	4.72e-8	Pulmonary function;
CESC	cis	rs55788414	0.932	rs12103301	chr16:81181423	A/C	cg06400318	chr16:81190750	PKD1L2	-0.58	-6.86	-0.39	4.78e-11	Left ventricular obstructive tract defect (maternal effect);
CESC	cis	rs360798	0.512	rs2058566	chr2:63179076	C/T	cg17519650	chr2:63277830	OTX1	0.53	6.54	0.37	3.21e-10	Coronary artery disease;
CESC	cis	rs7147624	1.000	rs10873192	chr14:66110653	A/G	cg03016385	chr14:66212404	NA	-0.54	-5.34	-0.31	1.96e-7	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs7589342	0.831	rs13429270	chr2:106453060	C/T	cg16077055	chr2:106428750	NCK2	0.5	7.04	0.4	1.68e-11	Addiction;
CESC	cis	rs7520050	0.966	rs11211208	chr1:46334256	A/C	cg24296786	chr1:45957014	TESK2	0.42	5.35	0.31	1.89e-7	Red blood cell count;Reticulocyte count;
CESC	cis	rs910316	0.737	rs175080	chr14:75513828	G/A	cg16144293	chr14:75469539	EIF2B2	0.39	5.11	0.3	6.21e-7	Height;
CESC	cis	rs2929278	0.617	rs3087657	chr15:44063859	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.48	6.1	0.35	3.82e-9	Schizophrenia;
CESC	trans	rs877282	0.838	rs34778553	chr10:796865	T/C	cg22713356	chr15:30763199	NA	1.32	13.53	0.64	4.55e-32	Uric acid levels;
CESC	cis	rs78889164	0.876	rs78134016	chr19:33855373	C/T	cg02272751	chr19:33882848	PEPD	-0.47	-6.34	-0.36	9.92e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs3096299	0.748	rs3102339	chr16:89442711	C/T	cg08822215	chr16:89438651	ANKRD11	-0.42	-6.25	-0.36	1.59e-9	Multiple myeloma (IgH translocation);
CESC	cis	rs16854884	0.586	rs6440212	chr3:143748526	T/C	cg01302019	chr3:143689584	C3orf58	-0.32	-5.07	-0.3	7.32e-7	Economic and political preferences (feminism/equality);
CESC	cis	rs7666738	0.830	rs10470951	chr4:99037051	G/A	cg05340658	chr4:99064831	C4orf37	0.82	12.87	0.62	9.38e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9487051	0.933	rs5005289	chr6:109617673	C/G	cg01475377	chr6:109611718	NA	-0.42	-6.43	-0.37	6.01e-10	Reticulocyte fraction of red cells;
CESC	cis	rs10504229	0.683	rs72649188	chr8:58108829	A/G	cg24829409	chr8:58192753	C8orf71	-0.56	-7.11	-0.4	1.1e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs10883723	0.810	rs13287	chr10:104240438	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.56	7.7	0.43	2.73e-13	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs367943	1.000	rs460079	chr5:112800525	G/A	cg12552261	chr5:112820674	MCC	-0.6	-7.04	-0.4	1.68e-11	Type 2 diabetes;
CESC	cis	rs5750830	0.594	rs5757647	chr22:39775047	C/A	cg05872129	chr22:39784769	NA	-0.75	-10.71	-0.55	1.76e-22	Intelligence (multi-trait analysis);
CESC	cis	rs826838	1.000	rs1843881	chr12:38733706	A/G	cg13010199	chr12:38710504	ALG10B	-0.61	-8.73	-0.47	2.95e-16	Heart rate;
CESC	cis	rs5769765	0.955	rs5770750	chr22:50276828	A/G	cg26441486	chr22:50317300	CRELD2	-0.39	-5.5	-0.32	8.72e-8	Schizophrenia;
CESC	cis	rs7618915	0.547	rs34610142	chr3:52708429	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.49	7.14	0.4	9.06e-12	Bipolar disorder;
CESC	cis	rs12477438	0.798	rs9308816	chr2:99637230	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.75	-10.74	-0.55	1.39e-22	Chronic sinus infection;
CESC	cis	rs7618501	0.603	rs72942333	chr3:49986118	T/C	cg24110177	chr3:50126178	RBM5	-0.54	-7.23	-0.41	5.19e-12	Intelligence (multi-trait analysis);
CESC	cis	rs698833	0.926	rs1067399	chr2:44678648	A/G	cg04920474	chr2:44395004	PPM1B	0.37	5.29	0.31	2.6e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs11690935	0.531	rs4280428	chr2:172813219	G/A	cg13550731	chr2:172543902	DYNC1I2	0.46	6.37	0.36	8.38e-10	Schizophrenia;
CESC	cis	rs12477438	0.520	rs6542863	chr2:99725138	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.86	15.87	0.7	2.48e-40	Chronic sinus infection;
CESC	cis	rs11098499	0.644	rs3806808	chr4:120551085	A/C	cg09307838	chr4:120376055	NA	0.74	9.81	0.52	1.4e-19	Corneal astigmatism;
CESC	cis	rs9911578	1.000	rs9807057	chr17:56889952	A/C	cg12560992	chr17:57184187	TRIM37	0.92	15.58	0.69	2.71e-39	Intelligence (multi-trait analysis);
CESC	cis	rs28673728	0.868	rs28380108	chr1:38409103	G/C	cg12658694	chr1:38397304	INPP5B	0.64	9.27	0.49	6.76e-18	Red cell distribution width;
CESC	cis	rs8018808	1.000	rs35881785	chr14:77873571	C/T	cg20045696	chr14:77926864	AHSA1	0.38	5.18	0.3	4.49e-7	Myeloid white cell count;
CESC	cis	rs75477785	1.000	rs1883332	chr1:210046786	G/A	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.8	5.16	0.3	4.87e-7	Cleft lip with or without cleft palate;
CESC	cis	rs7219021	0.739	rs3760451	chr17:46969177	G/A	cg16584676	chr17:46985605	UBE2Z	-0.65	-7.82	-0.43	1.24e-13	Schizophrenia or bipolar disorder;
CESC	cis	rs2985684	1.000	rs1957977	chr14:50090603	A/G	cg10008539	chr14:50087325	RPL36AL;MGAT2	-0.48	-5.66	-0.33	3.97e-8	Carotid intima media thickness;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg09258082	chr22:41791815	TEF	-0.47	-6.15	-0.35	2.82e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs4555082	0.874	rs2015978	chr14:105720134	G/C	cg06808227	chr14:105710500	BRF1	-0.57	-6.63	-0.38	1.85e-10	Mean platelet volume;Platelet distribution width;
CESC	cis	rs1862618	0.671	rs2591956	chr5:56244604	G/A	cg24549020	chr5:56110836	MAP3K1	-0.51	-6.28	-0.36	1.4e-9	Initial pursuit acceleration;
CESC	cis	rs11722228	1.000	rs11722228	chr4:9915741	C/T	cg11266682	chr4:10021025	SLC2A9	0.46	7.76	0.43	1.81e-13	Gout;Urate levels;Serum uric acid levels;
CESC	cis	rs12497850	1.000	rs12493578	chr3:48730116	C/T	cg07636037	chr3:49044803	WDR6	-0.99	-14.57	-0.67	1.01e-35	Parkinson's disease;
CESC	cis	rs9611565	0.512	rs139566	chr22:42199277	A/G	cg03806693	chr22:41940476	POLR3H	-1.14	-13.28	-0.63	3.33e-31	Vitiligo;
CESC	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg18402987	chr7:1209562	NA	0.59	7.03	0.4	1.79e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs601339	1.000	rs630408	chr12:123172822	C/T	cg11919336	chr12:123188078	GPR109A	0.48	6.44	0.37	5.44e-10	Adiponectin levels;
CESC	cis	rs9300255	0.596	rs7304782	chr12:123719444	A/G	cg19016782	chr12:123741754	C12orf65	0.36	5.35	0.31	1.94e-7	Neutrophil percentage of white cells;
CESC	cis	rs2732480	0.538	rs1387259	chr12:48703522	C/T	cg24011408	chr12:48396354	COL2A1	-0.43	-5.91	-0.34	1.07e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	trans	rs864643	0.773	rs11129837	chr3:39589963	A/G	cg21593860	chr22:35796189	MCM5	0.48	6.05	0.35	5.05e-9	Attention deficit hyperactivity disorder;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg10328259	chr2:3321226	TSSC1	-0.5	-6.6	-0.38	2.18e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs2576037	0.583	rs11659693	chr18:44458733	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.34	5.42	0.32	1.37e-7	Personality dimensions;
CESC	cis	rs11871801	0.560	rs1905339	chr17:40582296	T/C	cg21433558	chr17:40837037	CNTNAP1	0.46	5.96	0.34	8.13e-9	Crohn's disease;
CESC	cis	rs11203032	0.831	rs4933494	chr10:90917892	T/A	cg16672925	chr10:90967113	CH25H	0.75	6.89	0.39	4.02e-11	Heart failure;
CESC	cis	rs1843834	0.755	rs11898692	chr2:225575173	T/C	cg22455342	chr2:225449267	CUL3	0.45	5.69	0.33	3.28e-8	IgE levels in asthmatics (D.p. specific);
CESC	trans	rs61931739	0.556	rs7954221	chr12:33825077	C/T	cg26384229	chr12:38710491	ALG10B	0.5	7.41	0.41	1.71e-12	Morning vs. evening chronotype;
CESC	cis	rs2836974	0.965	rs6517538	chr21:40656242	C/T	cg11644478	chr21:40555479	PSMG1	1.02	16.09	0.7	4.04e-41	Cognitive function;
CESC	cis	rs7408868	0.706	rs2238642	chr19:15282237	T/C	cg14696996	chr19:15285081	NOTCH3	0.83	9.44	0.5	1.97e-18	Pulse pressure;
CESC	cis	rs4665809	1.000	rs750452	chr2:26324995	G/A	cg22920501	chr2:26401640	FAM59B	-0.67	-8.05	-0.44	2.86e-14	Gut microbiome composition (summer);
CESC	trans	rs9369898	0.963	rs9381788	chr6:49413289	G/A	cg15934674	chr1:150266645	MRPS21	-0.37	-6.03	-0.35	5.37e-9	Homocysteine levels;
CESC	cis	rs12900413	0.645	rs28507224	chr15:90305393	T/C	cg24249390	chr15:90295951	MESP1	-0.39	-5.33	-0.31	2.11e-7	Coronary artery aneurysm in Kawasaki disease;
CESC	cis	rs7617773	0.780	rs13081169	chr3:48356797	G/A	cg11946769	chr3:48343235	NME6	0.89	12.23	0.6	1.46e-27	Coronary artery disease;
CESC	cis	rs11969893	0.649	rs9498408	chr6:101292340	C/T	cg12253828	chr6:101329408	ASCC3	0.95	8.4	0.46	2.76e-15	Economic and political preferences (immigration/crime);
CESC	cis	rs12142240	0.698	rs41293285	chr1:46808426	C/T	cg10495392	chr1:46806563	NSUN4	0.59	6.34	0.36	9.65e-10	Menopause (age at onset);
CESC	cis	rs561341	0.941	rs72825736	chr17:30330286	G/A	cg23018236	chr17:30244563	NA	-0.53	-5.14	-0.3	5.32e-7	Hip circumference adjusted for BMI;
CESC	cis	rs1799949	0.965	rs33925201	chr17:41280682	A/G	cg23758822	chr17:41437982	NA	1.02	15.6	0.69	2.35e-39	Menopause (age at onset);
CESC	cis	rs9814567	1.000	rs9832785	chr3:134213070	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.46	-6.29	-0.36	1.3e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs9660992	0.762	rs1172130	chr1:205244953	G/A	cg21643547	chr1:205240462	TMCC2	-0.46	-6.73	-0.38	1.05e-10	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs6460942	0.915	rs17541464	chr7:12462675	A/G	cg06484146	chr7:12443880	VWDE	-0.76	-10.38	-0.54	2.06e-21	Coronary artery disease;
CESC	cis	rs9891119	0.811	rs744166	chr17:40514201	A/G	cg21433558	chr17:40837037	CNTNAP1	0.37	5.19	0.3	4.25e-7	Multiple sclerosis;Crohn's disease;
CESC	cis	rs921968	0.643	rs590771	chr2:219369851	C/T	cg02176678	chr2:219576539	TTLL4	0.43	7.61	0.42	4.66e-13	Mean corpuscular hemoglobin concentration;
CESC	cis	rs2204008	0.775	rs11514370	chr12:38305566	G/A	cg13010199	chr12:38710504	ALG10B	0.42	5.42	0.32	1.37e-7	Bladder cancer;
CESC	cis	rs6685188	0.920	rs10751444	chr1:205662144	A/G	cg24503407	chr1:205819492	PM20D1	-0.45	-6.28	-0.36	1.35e-9	White blood cell count (basophil);Basophil percentage of white cells;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01139101	chr2:17492831	NA	0.49	6.27	0.36	1.42e-9	Gut microbiome composition (summer);
CESC	cis	rs7267979	1.000	rs2500404	chr20:25359758	A/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.84	-15.92	-0.7	1.72e-40	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs853679	0.517	rs3757187	chr6:28107654	T/C	cg08968635	chr6:28129556	ZNF389	0.42	5.75	0.33	2.45e-8	Depression;
CESC	cis	rs4665809	1.000	rs4665816	chr2:26305094	G/C	cg22920501	chr2:26401640	FAM59B	-0.63	-7.63	-0.42	4.24e-13	Gut microbiome composition (summer);
CESC	cis	rs735860	0.763	rs6458912	chr6:53147965	G/A	cg10236188	chr6:53219634	NA	-0.34	-5.06	-0.3	7.77e-7	Glaucoma;
CESC	cis	rs6964587	0.869	rs7793946	chr7:91520628	T/C	cg17063962	chr7:91808500	NA	-0.5	-6.62	-0.38	1.96e-10	Breast cancer;
CESC	cis	rs57506017	0.606	rs12699324	chr7:12253372	T/C	cg23422036	chr7:12250390	TMEM106B	0.39	5.21	0.3	3.76e-7	Neuroticism;
CESC	cis	rs2204008	0.521	rs7311188	chr12:38542813	C/G	cg26384229	chr12:38710491	ALG10B	-0.45	-5.99	-0.35	6.97e-9	Bladder cancer;
CESC	cis	rs11190604	0.945	rs11190553	chr10:102207959	T/C	cg07080220	chr10:102295463	HIF1AN	0.55	5.51	0.32	8.5e-8	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs7584330	0.744	rs58223447	chr2:238378644	G/C	cg14458575	chr2:238380390	NA	0.91	12.35	0.6	5.69e-28	Prostate cancer;
CESC	cis	rs801193	1.000	rs2707836	chr7:66160435	A/C	cg18876405	chr7:65276391	NA	0.54	7.28	0.41	3.88e-12	Aortic root size;
CESC	cis	rs6772849	0.930	rs6768344	chr3:128373556	G/A	cg16766828	chr3:128327626	NA	-0.31	-5.08	-0.3	7.28e-7	Monocyte percentage of white cells;Monocyte count;
CESC	cis	rs896854	0.654	rs13248607	chr8:95986637	T/G	cg16049864	chr8:95962084	TP53INP1	-0.66	-11.64	-0.58	1.46e-25	Type 2 diabetes;
CESC	cis	rs12497850	1.000	rs12493578	chr3:48730116	C/T	cg02487422	chr3:49467188	NICN1	-0.5	-5.93	-0.34	9.65e-9	Parkinson's disease;
CESC	cis	rs6952808	0.689	rs1107591	chr7:2041638	G/A	cg05863683	chr7:1912471	MAD1L1	0.46	6.96	0.39	2.67e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs735860	0.726	rs209519	chr6:53208680	G/A	cg10236188	chr6:53219634	NA	0.35	5.23	0.31	3.48e-7	Glaucoma;
CESC	cis	rs7618915	0.571	rs67539070	chr3:52711974	T/C	cg17372223	chr3:52568218	NT5DC2	0.44	6.63	0.38	1.88e-10	Bipolar disorder;
CESC	cis	rs11792861	0.591	rs10979613	chr9:111687584	A/G	cg13535736	chr9:111863775	C9orf5	-0.38	-5.58	-0.32	6.04e-8	Menarche (age at onset);
CESC	cis	rs295140	0.605	rs3769471	chr2:201195403	G/A	cg23649088	chr2:200775458	C2orf69	-0.43	-5.64	-0.33	4.41e-8	QT interval;
CESC	cis	rs1799949	1.000	rs67060599	chr17:41255102	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.64	8.72	0.47	3.02e-16	Menopause (age at onset);
CESC	cis	rs6758955	0.850	rs56261863	chr2:10480339	G/A	cg15773312	chr2:10472214	HPCAL1	-0.45	-5.04	-0.3	8.65e-7	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CESC	cis	rs6432018	0.897	rs7556678	chr2:9755366	T/C	cg23886495	chr2:9695866	ADAM17	0.44	5.12	0.3	5.91e-7	Heart rate variability traits;
CESC	cis	rs2236918	0.710	rs1776138	chr1:242027075	G/A	cg17736920	chr1:242011382	EXO1	0.56	7.18	0.4	6.97e-12	Menopause (age at onset);
CESC	trans	rs1728785	1.000	rs1645936	chr16:68563743	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.51	6.53	0.37	3.42e-10	Ulcerative colitis;
CESC	cis	rs7605827	0.930	rs9287664	chr2:15597116	A/G	cg19274914	chr2:15703543	NA	-0.32	-5.65	-0.33	4.2e-8	Educational attainment (years of education);
CESC	trans	rs561341	1.000	rs113115092	chr17:30284164	G/A	cg20587970	chr11:113659929	NA	-1.43	-18.65	-0.75	3.85e-50	Hip circumference adjusted for BMI;
CESC	cis	rs66573146	0.561	rs67245546	chr4:6947164	T/C	cg00086871	chr4:6988644	TBC1D14	0.97	5.88	0.34	1.23e-8	Granulocyte percentage of myeloid white cells;
CESC	cis	rs4665809	1.000	rs6720314	chr2:26334852	G/A	cg25036284	chr2:26402008	FAM59B	-0.73	-8.35	-0.46	3.78e-15	Gut microbiome composition (summer);
CESC	cis	rs4665809	0.590	rs6730317	chr2:26419482	C/T	cg27170947	chr2:26402098	FAM59B	-0.84	-10.24	-0.53	5.89e-21	Gut microbiome composition (summer);
CESC	cis	rs60871478	0.945	rs4719279	chr7:813618	T/C	cg05535760	chr7:792225	HEATR2	0.88	10.83	0.55	7.1e-23	Cerebrospinal P-tau181p levels;
CESC	cis	rs861020	0.630	rs655713	chr1:210006438	C/T	cg05527609	chr1:210001259	C1orf107	0.74	9.67	0.51	3.97e-19	Orofacial clefts;
CESC	cis	rs7666738	0.830	rs12233741	chr4:98950296	C/T	cg05340658	chr4:99064831	C4orf37	0.8	12.48	0.61	2e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7772486	0.790	rs6917135	chr6:146152426	T/C	cg23711669	chr6:146136114	FBXO30	0.9	13.27	0.63	3.71e-31	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9322193	0.962	rs13215691	chr6:150113802	T/C	cg13206674	chr6:150067644	NUP43	0.4	5.71	0.33	3.09e-8	Lung cancer;
CESC	cis	rs11785400	0.762	rs9694556	chr8:143727841	A/G	cg10596483	chr8:143751796	JRK	0.42	5.24	0.31	3.24e-7	Schizophrenia;
CESC	cis	rs2204008	0.569	rs11495449	chr12:37995753	C/T	cg13010199	chr12:38710504	ALG10B	0.53	6.63	0.38	1.87e-10	Bladder cancer;
CESC	cis	rs7927592	0.913	rs3758643	chr11:68367193	C/T	cg20283391	chr11:68216788	NA	-0.62	-7.43	-0.42	1.51e-12	Total body bone mineral density;
CESC	cis	rs2531992	0.620	rs2041248	chr16:4032489	T/G	cg05927578	chr16:4029543	ADCY9	0.56	6.99	0.39	2.26e-11	Waist circumference;
CESC	trans	rs116095464	0.558	rs10067021	chr5:221490	C/T	cg00938859	chr5:1591904	SDHAP3	0.6	6.66	0.38	1.55e-10	Breast cancer;
CESC	cis	rs17867775	0.793	rs17864127	chr7:126730470	C/A	cg02090654	chr7:126698344	MIR592;GRM8	0.68	5.04	0.3	8.68e-7	Anti-saccade response;
CESC	cis	rs139156536	1	rs139156536	chr17:38164432	TTTTA/T	cg17344932	chr17:38183730	MED24;SNORD124	-0.52	-7.4	-0.41	1.82e-12	Lymphocyte percentage of white cells;
CESC	cis	rs798554	0.680	rs1713912	chr7:2895784	C/A	cg19717773	chr7:2847554	GNA12	-0.48	-6.7	-0.38	1.25e-10	Height;
CESC	cis	rs909674	0.734	rs5757675	chr22:39838892	G/T	cg24399712	chr22:39784796	NA	-0.81	-11.14	-0.56	6.68e-24	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs2996428	0.667	rs61768932	chr1:3765671	G/C	cg10555106	chr1:3691387	LOC388588	0.39	5.13	0.3	5.73e-7	Red cell distribution width;
CESC	cis	rs7216064	1.000	rs7208663	chr17:65885171	T/C	cg07042672	chr17:66097459	LOC651250	-0.56	-6.52	-0.37	3.5e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs4665809	0.590	rs10495756	chr2:26485586	A/G	cg04944784	chr2:26401820	FAM59B	0.96	10.5	0.54	8.44e-22	Gut microbiome composition (summer);
CESC	cis	rs875971	0.545	rs2420456	chr7:65745606	T/G	cg18876405	chr7:65276391	NA	0.46	5.48	0.32	1.01e-7	Aortic root size;
CESC	cis	rs10129255	0.957	rs11846893	chr14:107187307	T/C	cg07958169	chr14:107095056	NA	-0.42	-5.91	-0.34	1.05e-8	Kawasaki disease;
CESC	cis	rs3733585	0.579	rs4235353	chr4:10122934	C/T	cg11266682	chr4:10021025	SLC2A9	-0.57	-10.19	-0.53	8.72e-21	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs7631605	0.905	rs7620643	chr3:37152131	T/C	cg22985146	chr3:37219077	LRRFIP2	-0.32	-5.04	-0.3	8.48e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs10129255	0.957	rs12590799	chr14:107187952	G/A	cg07958169	chr14:107095056	NA	-0.41	-5.69	-0.33	3.29e-8	Kawasaki disease;
CESC	cis	rs763121	0.752	rs6001190	chr22:39073811	T/C	cg21395723	chr22:39101663	GTPBP1	0.4	5.03	0.3	9.18e-7	Menopause (age at onset);
CESC	cis	rs4588572	0.643	rs10474554	chr5:77799158	C/T	cg11547950	chr5:77652471	NA	-0.45	-5.62	-0.33	4.9e-8	Triglycerides;
CESC	trans	rs8073060	0.544	rs17550716	chr17:33893208	A/G	cg19694781	chr19:47549865	TMEM160	0.73	7.21	0.4	5.93e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	cis	rs3820928	0.874	rs10182307	chr2:227875360	C/T	cg11843606	chr2:227700838	RHBDD1	-0.46	-5.86	-0.34	1.36e-8	Pulmonary function;
CESC	cis	rs9814567	0.964	rs9841180	chr3:134191880	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.4	-5.61	-0.33	5.09e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs17253792	0.822	rs76819679	chr14:56134672	C/G	cg01858014	chr14:56050164	KTN1	-0.97	-7.54	-0.42	7.36e-13	Putamen volume;
CESC	cis	rs73206853	0.764	rs58535454	chr12:111003457	C/T	cg12870014	chr12:110450643	ANKRD13A	0.65	5.65	0.33	4.09e-8	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs12995849	0.676	rs934306	chr2:106459654	C/A	cg16077055	chr2:106428750	NCK2	0.4	5.9	0.34	1.08e-8	Addiction;
CESC	cis	rs9914988	0.943	rs28847895	chr17:27172520	T/C	cg20469991	chr17:27169893	C17orf63	-0.43	-5.15	-0.3	5.12e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10210571	chr1:231664364	TSNAX-DISC1;TSNAX	0.64	7.08	0.4	1.33e-11	Gut microbiome composition (summer);
CESC	cis	rs9311474	0.607	rs13076398	chr3:52573096	G/A	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.36	6.58	0.37	2.57e-10	Electroencephalogram traits;
CESC	cis	rs1008375	1.000	rs11724495	chr4:17621310	G/A	cg16339924	chr4:17578868	LAP3	0.54	6.77	0.38	8.19e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs875971	0.660	rs6460308	chr7:66084740	T/C	cg11764359	chr7:65958608	NA	-0.72	-9.49	-0.5	1.36e-18	Aortic root size;
CESC	cis	rs9910055	0.593	rs2905983	chr17:42212429	T/G	cg19774624	chr17:42201019	HDAC5	0.88	14.21	0.66	1.95e-34	Total body bone mineral density;
CESC	cis	rs1707322	1.000	rs7553924	chr1:46352624	T/C	cg05343316	chr1:45956843	TESK2	0.44	5.55	0.32	7.05e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9322193	0.962	rs10872656	chr6:150120580	A/C	cg07701084	chr6:150067640	NUP43	0.44	5.99	0.35	6.96e-9	Lung cancer;
CESC	cis	rs7635838	0.718	rs2606736	chr3:11400249	C/T	cg00170343	chr3:11313890	ATG7	0.5	7.09	0.4	1.25e-11	HDL cholesterol;
CESC	cis	rs7107174	1.000	rs11601196	chr11:78043431	A/C	cg02023728	chr11:77925099	USP35	0.48	6.36	0.36	8.58e-10	Testicular germ cell tumor;
CESC	cis	rs6987853	0.933	rs2974341	chr8:42398302	T/A	cg09913449	chr8:42400586	C8orf40	0.39	6.13	0.35	3.15e-9	Mean corpuscular hemoglobin concentration;
CESC	cis	rs1218582	0.741	rs11264283	chr1:154869552	A/G	cg24250549	chr1:154909240	PMVK	0.74	11.19	0.57	4.71e-24	Prostate cancer;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg10651300	chr12:53661859	ESPL1	-0.48	-6.17	-0.35	2.6e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs593982	0.920	rs618456	chr11:65475620	C/T	cg08755490	chr11:65554678	OVOL1	1.19	11.15	0.57	6.14e-24	Atopic dermatitis;
CESC	cis	rs763121	0.853	rs8138996	chr22:39047435	G/T	cg06022373	chr22:39101656	GTPBP1	0.88	13.79	0.65	5.43e-33	Menopause (age at onset);
CESC	cis	rs12478296	0.892	rs60042638	chr2:243038707	G/A	cg06360820	chr2:242988706	NA	-0.66	-7.52	-0.42	8.51e-13	Obesity-related traits;
CESC	cis	rs875971	0.545	rs66594357	chr7:65792784	G/A	cg25405998	chr7:65216604	CCT6P1	0.48	5.59	0.32	5.67e-8	Aortic root size;
CESC	cis	rs2370759	1.000	rs79487858	chr10:32616405	T/C	cg18270830	chr10:32634957	EPC1	0.71	6.78	0.38	7.78e-11	Sexual dysfunction (female);
CESC	cis	rs8020095	0.571	rs7147690	chr14:67242337	C/G	cg19548862	chr14:67692701	FAM71D	0.5	6.13	0.35	3.14e-9	Depression (quantitative trait);
CESC	cis	rs6669008	1.000	rs1891969	chr1:114185855	C/A	cg26035817	chr1:114414802	PTPN22	0.43	6.21	0.36	2.09e-9	Bacteremia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09275602	chr7:66370330	NA	-0.56	-6.31	-0.36	1.16e-9	Gut microbiome composition (summer);
CESC	cis	rs9457247	0.663	rs2282861	chr6:167440128	C/T	cg25258033	chr6:167368657	RNASET2	0.37	5.4	0.31	1.51e-7	Crohn's disease;
CESC	cis	rs12887734	0.566	rs3742366	chr14:104198351	T/C	cg08213375	chr14:104286397	PPP1R13B	0.43	7.2	0.4	6.36e-12	Schizophrenia;Autism spectrum disorder or schizophrenia;
CESC	cis	rs8114671	0.552	rs2024635	chr20:33422614	G/A	cg24642439	chr20:33292090	TP53INP2	0.46	5.5	0.32	9.07e-8	Height;
CESC	cis	rs9911578	1.000	rs9807057	chr17:56889952	A/C	cg05425664	chr17:57184151	TRIM37	-0.49	-6.87	-0.39	4.62e-11	Intelligence (multi-trait analysis);
CESC	cis	rs1461503	0.966	rs7113725	chr11:122843511	G/T	cg27398637	chr11:122830231	C11orf63	-0.55	-8.32	-0.45	4.77e-15	Menarche (age at onset);
CESC	cis	rs7666738	0.716	rs6817529	chr4:99023213	T/C	cg03676636	chr4:99064102	C4orf37	0.33	5.15	0.3	5.05e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs514406	0.698	rs576891	chr1:53364976	A/G	cg25767906	chr1:53392781	SCP2	-0.54	-7.54	-0.42	7.6e-13	Monocyte count;
CESC	cis	rs2859741	0.546	rs3934329	chr1:37504523	C/T	cg09363841	chr1:37513479	NA	-0.54	-8.0	-0.44	3.96e-14	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
CESC	cis	rs2243480	1.000	rs1715235	chr7:65488394	T/C	cg25894440	chr7:65020034	NA	-0.65	-5.63	-0.33	4.5e-8	Diabetic kidney disease;
CESC	cis	rs61931739	0.817	rs592857	chr12:34197673	T/G	cg19457237	chr12:34500585	NA	-0.39	-5.33	-0.31	2.15e-7	Morning vs. evening chronotype;
CESC	cis	rs61776719	0.520	rs11485595	chr1:38411350	C/T	cg18451016	chr1:38461880	NA	0.4	5.94	0.34	8.96e-9	Coronary artery disease;
CESC	cis	rs4836694	0.574	rs3780712	chr9:132943082	A/G	cg05251000	chr9:132935664	FREQ	0.41	5.43	0.32	1.27e-7	Alzheimer's disease (cognitive decline);
CESC	cis	rs801193	1.000	rs2003301	chr7:66147656	G/C	cg14393609	chr7:65229607	NA	-0.47	-6.32	-0.36	1.08e-9	Aortic root size;
CESC	trans	rs9467711	0.606	rs9358937	chr6:26374274	C/G	cg06606381	chr12:133084897	FBRSL1	-0.75	-6.61	-0.38	2.1e-10	Autism spectrum disorder or schizophrenia;
CESC	cis	rs7666738	0.830	rs10010698	chr4:98981594	C/T	cg05340658	chr4:99064831	C4orf37	0.77	11.85	0.59	2.88e-26	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3105593	0.933	rs3101850	chr15:50844314	A/G	cg08437265	chr15:50716283	USP8	0.45	5.74	0.33	2.63e-8	QT interval;
CESC	cis	rs7666738	0.791	rs11730069	chr4:98945772	A/G	cg05340658	chr4:99064831	C4orf37	0.82	12.66	0.61	4.8e-29	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg18402987	chr7:1209562	NA	0.49	6.68	0.38	1.4e-10	Longevity;Endometriosis;
CESC	cis	rs40363	0.723	rs2736	chr16:3536872	G/A	cg21433313	chr16:3507492	NAT15	-0.61	-6.53	-0.37	3.24e-10	Tuberculosis;
CESC	cis	rs9354308	0.899	rs2814099	chr6:66555130	A/G	cg07460842	chr6:66804631	NA	0.61	6.93	0.39	3.29e-11	Metabolite levels;
CESC	cis	rs7264396	0.563	rs2425109	chr20:34316218	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.89	-10.74	-0.55	1.38e-22	Total cholesterol levels;
CESC	cis	rs116095464	0.558	rs10462754	chr5:246669	T/C	cg22857025	chr5:266934	NA	-1.28	-18.26	-0.75	8.94e-49	Breast cancer;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg00357671	chr12:124809516	NCOR2	0.49	6.54	0.37	3.16e-10	Fibrinogen levels;
CESC	cis	rs9790314	1.000	rs28515190	chr3:161028605	G/A	cg03342759	chr3:160939853	NMD3	-0.47	-6.09	-0.35	3.99e-9	Morning vs. evening chronotype;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg06506598	chr5:79783889	FAM151B	-0.47	-6.57	-0.37	2.59e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs9929218	1.000	rs7186084	chr16:68816260	C/G	cg02972257	chr16:68554789	NA	-0.46	-5.47	-0.32	1.03e-7	Colorectal cancer;
CESC	cis	rs6570726	0.720	rs412623	chr6:145883257	C/A	cg23711669	chr6:146136114	FBXO30	0.87	12.81	0.62	1.49e-29	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs7618501	1.000	rs34614773	chr3:49753003	T/G	cg21659725	chr3:3221576	CRBN	-0.82	-13.58	-0.64	3.15e-32	Intelligence (multi-trait analysis);
CESC	cis	rs853679	0.517	rs9357066	chr6:28129831	T/C	cg23161317	chr6:28129485	ZNF389	0.52	6.48	0.37	4.37e-10	Depression;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15109179	chr17:41323082	NBR1	0.64	7.11	0.4	1.07e-11	Gut microbiome composition (summer);
CESC	cis	rs7511006	1.000	rs5771109	chr22:50678571	T/C	cg07895657	chr22:50616420	PANX2	-0.36	-5.11	-0.3	6.05e-7	Obesity-related traits;
CESC	cis	rs36093924	0.646	rs7285557	chr22:42348790	T/C	cg15557168	chr22:42548783	NA	0.36	5.25	0.31	3.18e-7	Intelligence;
CESC	cis	rs72781680	1.000	rs75046532	chr2:24167267	A/G	cg20701182	chr2:24300061	SF3B14	0.64	5.74	0.33	2.63e-8	Lymphocyte counts;
CESC	cis	rs4253772	0.938	rs41378347	chr22:46636976	G/A	cg00784671	chr22:46762841	CELSR1	-0.51	-5.29	-0.31	2.54e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs7827545	0.545	rs16905172	chr8:135556373	A/G	cg17885191	chr8:135476712	NA	0.53	6.09	0.35	4.05e-9	Hypertension (SNP x SNP interaction);
CESC	cis	rs35110281	0.713	rs1378079	chr21:45011187	A/G	cg04455712	chr21:45112962	RRP1B	0.4	6.14	0.35	3.04e-9	Mean corpuscular volume;
CESC	cis	rs6456156	0.586	rs13208636	chr6:167461965	T/G	cg07741184	chr6:167504864	NA	0.35	6.08	0.35	4.1e-9	Primary biliary cholangitis;
CESC	cis	rs1538970	1.000	rs11211101	chr1:45849311	C/G	cg03146154	chr1:46216737	IPP	0.44	5.37	0.31	1.75e-7	Platelet count;
CESC	cis	rs7772486	0.754	rs9373475	chr6:146126419	C/T	cg23711669	chr6:146136114	FBXO30	1.01	15.9	0.7	2.05e-40	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2228479	0.850	rs62054257	chr16:89900195	G/A	cg14709524	chr16:89940631	TCF25	0.88	6.1	0.35	3.82e-9	Skin colour saturation;
CESC	cis	rs3858526	0.916	rs11039551	chr11:5930773	C/T	cg05234568	chr11:5960015	NA	-0.55	-6.43	-0.37	5.77e-10	DNA methylation (variation);
CESC	cis	rs2836974	0.932	rs6517526	chr21:40581530	T/C	cg11890956	chr21:40555474	PSMG1	1.17	21.83	0.8	3.83e-61	Cognitive function;
CESC	cis	rs3096299	0.563	rs4600467	chr16:89562516	C/T	cg08392591	chr16:89556376	ANKRD11	0.59	8.07	0.44	2.52e-14	Multiple myeloma (IgH translocation);
CESC	cis	rs875971	0.862	rs13536	chr7:66019190	G/A	cg19163074	chr7:65112434	INTS4L2	0.42	5.25	0.31	3.18e-7	Aortic root size;
CESC	trans	rs7246760	1.000	rs59867671	chr19:9933558	G/C	cg02900749	chr2:68251473	NA	-0.8	-6.75	-0.38	9.06e-11	Pursuit maintenance gain;
CESC	cis	rs668210	0.793	rs540584	chr11:65765866	C/G	cg02202077	chr11:65769826	EIF1AD;BANF1	-0.67	-6.49	-0.37	4.16e-10	Cerebrospinal fluid biomarker levels;
CESC	cis	rs853679	0.517	rs9380060	chr6:28132603	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.57	-6.49	-0.37	4.32e-10	Depression;
CESC	cis	rs7666738	0.830	rs10001701	chr4:98918871	G/C	cg03676636	chr4:99064102	C4orf37	0.35	5.22	0.31	3.66e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg21800906	chr11:32914818	QSER1	-0.46	-6.7	-0.38	1.26e-10	Gambling;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg04604752	chr16:1570881	IFT140	0.45	6.13	0.35	3.25e-9	Fibrinogen levels;
CESC	cis	rs4253772	0.530	rs9615349	chr22:46732418	T/G	cg18190219	chr22:46762943	CELSR1	-0.67	-6.16	-0.35	2.71e-9	LDL cholesterol;Cholesterol, total;
CESC	cis	rs875971	0.662	rs448725	chr7:65514628	A/G	cg12463550	chr7:65579703	CRCP	0.59	7.47	0.42	1.16e-12	Aortic root size;
CESC	trans	rs17685	0.753	rs10085567	chr7:75734206	A/C	cg19862616	chr7:65841803	NCRNA00174	0.83	11.96	0.59	1.23e-26	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs644799	0.965	rs549695	chr11:95617788	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	12.05	0.59	6.06e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs5769765	0.908	rs4074304	chr22:50309446	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.58	-6.21	-0.36	2.01e-9	Schizophrenia;
CESC	cis	rs875971	0.862	rs10250544	chr7:65766561	A/G	cg12463550	chr7:65579703	CRCP	-0.46	-5.81	-0.34	1.76e-8	Aortic root size;
CESC	cis	rs7733403	1	rs7733403	chr5:140154215	A/G	cg26395211	chr5:140044315	WDR55	-0.41	-5.16	-0.3	4.91e-7	Schizophrenia;
CESC	cis	rs2832191	1.000	rs6516891	chr21:30483070	C/T	cg24692254	chr21:30365293	RNF160	-0.74	-11.15	-0.57	6.22e-24	Dental caries;
CESC	cis	rs7666738	0.716	rs13108535	chr4:99046324	A/G	cg17366294	chr4:99064904	C4orf37	0.61	8.78	0.47	2.13e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7666738	0.791	rs4699329	chr4:99056212	G/A	cg03676636	chr4:99064102	C4orf37	0.34	5.15	0.3	5.06e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7216064	0.817	rs12603589	chr17:65825248	T/C	cg12091567	chr17:66097778	LOC651250	-0.87	-8.62	-0.47	6.33e-16	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs9911578	0.817	rs304264	chr17:56749628	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.38	5.06	0.3	8.03e-7	Intelligence (multi-trait analysis);
CESC	cis	rs6456156	0.819	rs9457273	chr6:167520749	A/T	cg23791538	chr6:167370224	RNASET2	0.45	5.87	0.34	1.33e-8	Primary biliary cholangitis;
CESC	cis	rs1692580	0.870	rs590367	chr1:2162944	C/T	cg04315214	chr1:2043799	PRKCZ	-0.39	-5.64	-0.33	4.43e-8	Coronary artery disease;
CESC	cis	rs2346177	0.519	rs2121698	chr2:46709571	C/T	cg02822958	chr2:46747628	ATP6V1E2	0.45	5.59	0.32	5.72e-8	HDL cholesterol;
CESC	cis	rs7666738	0.830	rs7686456	chr4:99019695	T/C	cg05340658	chr4:99064831	C4orf37	0.82	12.99	0.62	3.34e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7605827	0.930	rs12993042	chr2:15708218	A/T	cg19274914	chr2:15703543	NA	0.29	5.22	0.31	3.7e-7	Educational attainment (years of education);
CESC	cis	rs11792861	0.566	rs67780641	chr9:111850710	A/G	cg05043794	chr9:111880884	C9orf5	-0.29	-5.13	-0.3	5.62e-7	Menarche (age at onset);
CESC	cis	rs801193	0.548	rs6975044	chr7:66227482	C/T	cg12463550	chr7:65579703	CRCP	0.49	6.24	0.36	1.69e-9	Aortic root size;
CESC	cis	rs17384381	0.953	rs12139958	chr1:85842112	A/G	cg16011679	chr1:85725395	C1orf52	0.79	8.08	0.44	2.34e-14	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7666738	0.925	rs2865952	chr4:99040305	C/T	cg17366294	chr4:99064904	C4orf37	0.59	7.74	0.43	2.15e-13	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7824557	0.564	rs2572395	chr8:11235360	A/C	cg21775007	chr8:11205619	TDH	-0.53	-7.9	-0.44	7.62e-14	Retinal vascular caliber;
CESC	cis	rs2635047	0.519	rs2668771	chr18:44775897	G/A	cg24371990	chr18:44770781	NA	0.34	5.46	0.32	1.1e-7	Educational attainment;
CESC	cis	rs7666738	0.800	rs13107147	chr4:99028753	C/T	cg03467027	chr4:99064603	C4orf37	0.48	6.15	0.35	2.83e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs8072100	0.713	rs9899859	chr17:45513049	A/G	cg25173405	chr17:45401733	C17orf57	-0.43	-5.43	-0.32	1.26e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs9487051	0.714	rs9487058	chr6:109631060	A/C	cg12927641	chr6:109611667	NA	-0.37	-5.51	-0.32	8.68e-8	Reticulocyte fraction of red cells;
CESC	cis	rs870825	0.616	rs28558715	chr4:185627761	G/A	cg04058563	chr4:185651563	MLF1IP	0.64	7.05	0.4	1.59e-11	Blood protein levels;
CESC	cis	rs2228479	0.702	rs17233868	chr16:89803629	C/T	cg00800038	chr16:89945340	TCF25	-0.79	-6.4	-0.37	6.93e-10	Skin colour saturation;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg27612744	chr5:16465883	ZNF622	-0.47	-6.03	-0.35	5.36e-9	Ulcerative colitis;
CESC	cis	rs7144547	0.803	rs8008602	chr14:81890171	T/A	cg23690444	chr14:81902736	NA	0.73	7.67	0.43	3.27e-13	Prudent dietary pattern;
CESC	cis	rs1957429	0.731	rs1951495	chr14:65336690	T/C	cg23373153	chr14:65346875	NA	1.01	8.81	0.48	1.72e-16	Pediatric areal bone mineral density (radius);
CESC	cis	rs11190604	1.000	rs10883504	chr10:102280687	G/A	cg07080220	chr10:102295463	HIF1AN	0.67	6.17	0.35	2.58e-9	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs7412746	0.611	rs4319334	chr1:150766822	G/A	cg18016565	chr1:150552671	MCL1	0.33	5.03	0.3	8.96e-7	Melanoma;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg27380774	chr11:1000560	AP2A2	0.51	6.99	0.39	2.18e-11	Fibrinogen levels;
CESC	cis	rs1801251	0.964	rs10933411	chr2:233706847	A/G	cg08000102	chr2:233561755	GIGYF2	-0.7	-10.07	-0.53	2.08e-20	Coronary artery disease;
CESC	trans	rs7618501	1.000	rs7618519	chr3:49772708	A/T	cg21659725	chr3:3221576	CRBN	-0.83	-13.61	-0.64	2.43e-32	Intelligence (multi-trait analysis);
CESC	cis	rs7927771	0.832	rs7105851	chr11:47383275	T/C	cg05585544	chr11:47624801	NA	0.48	7.02	0.4	1.89e-11	Subjective well-being;
CESC	cis	rs10504229	0.953	rs2270610	chr8:58194669	A/G	cg14926445	chr8:58193284	C8orf71	-0.49	-5.18	-0.3	4.44e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs1448094	0.512	rs7299285	chr12:86244959	A/T	cg02569458	chr12:86230093	RASSF9	0.49	7.27	0.41	3.98e-12	Major depressive disorder;
CESC	cis	rs79387448	0.638	rs11465670	chr2:103034440	A/G	cg09003973	chr2:102972529	NA	0.88	7.51	0.42	8.92e-13	Gut microbiota (bacterial taxa);
CESC	cis	rs8062405	0.755	rs62034350	chr16:28562256	A/G	cg07382826	chr16:28625726	SULT1A1	0.41	6.71	0.38	1.15e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	trans	rs35110281	0.774	rs2838323	chr21:44999086	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.5	6.56	0.37	2.83e-10	Mean corpuscular volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25368943	chr5:93905257	MIR1974;C5orf36	-0.53	-6.3	-0.36	1.24e-9	Gut microbiome composition (summer);
CESC	cis	rs4689388	0.890	rs1801206	chr4:6302707	C/T	cg14416269	chr4:6271139	WFS1	0.45	7.27	0.41	4.07e-12	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs6088580	0.634	rs6088508	chr20:33060081	A/G	cg08999081	chr20:33150536	PIGU	0.66	11.59	0.58	2.04e-25	Glomerular filtration rate (creatinine);
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg09042752	chr12:105500971	KIAA1033	-0.47	-6.27	-0.36	1.44e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs798554	0.610	rs2248390	chr7:2855594	T/C	cg13628971	chr7:2884303	GNA12	0.43	5.74	0.33	2.58e-8	Height;
CESC	cis	rs453301	0.562	rs1038248	chr8:9040858	G/T	cg15556689	chr8:8085844	FLJ10661	-0.42	-5.16	-0.3	4.96e-7	Joint mobility (Beighton score);
CESC	cis	rs9467711	0.606	rs9379852	chr6:26357278	A/G	cg12826209	chr6:26865740	GUSBL1	0.61	5.17	0.3	4.52e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs7666738	0.830	rs13141752	chr4:98893128	G/A	cg05340658	chr4:99064831	C4orf37	0.75	11.14	0.56	6.81e-24	Colonoscopy-negative controls vs population controls;
CESC	cis	rs8060686	0.565	rs75286242	chr16:68145798	C/T	cg26727032	chr16:67993705	SLC12A4	-0.54	-6.05	-0.35	4.92e-9	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs11122272	0.735	rs2790891	chr1:231513190	G/A	cg06096015	chr1:231504339	EGLN1	0.43	6.18	0.35	2.46e-9	Hemoglobin concentration;
CESC	cis	rs3845702	0.800	rs6744281	chr2:180844382	G/A	cg01881094	chr2:180872142	CWC22	-1.02	-9.36	-0.5	3.69e-18	Schizophrenia;
CESC	trans	rs9929218	0.954	rs10163398	chr16:68823124	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.62	-8.13	-0.45	1.69e-14	Colorectal cancer;
CESC	cis	rs11195062	0.805	rs10884942	chr10:112016926	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.38	-5.26	-0.31	3.03e-7	Multiple myeloma;
CESC	cis	rs6062302	0.522	rs2872810	chr20:62241931	C/T	cg09650180	chr20:62225654	GMEB2	0.82	9.38	0.5	3.04e-18	Glioblastoma;
CESC	cis	rs4975709	0.610	rs4975705	chr5:1860359	T/C	cg10800226	chr5:1850261	NA	0.34	5.62	0.33	4.84e-8	Cardiovascular disease risk factors;
CESC	cis	rs73206853	0.841	rs3893403	chr12:111083980	G/A	cg12870014	chr12:110450643	ANKRD13A	0.64	5.24	0.31	3.23e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs4242434	0.927	rs34027561	chr8:22465385	T/C	cg03733263	chr8:22462867	KIAA1967	0.96	14.94	0.68	5.09e-37	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CESC	cis	rs2455799	0.613	rs1969095	chr3:15733552	C/T	cg16303742	chr3:15540471	COLQ	-0.38	-6.09	-0.35	3.98e-9	Mean platelet volume;
CESC	cis	rs853679	0.517	rs868987	chr6:28110148	A/G	cg26335602	chr6:28129616	ZNF389	-0.54	-7.17	-0.4	7.67e-12	Depression;
CESC	cis	rs2180341	0.781	rs7742161	chr6:127571676	T/C	cg27446573	chr6:127587934	RNF146	0.82	11.45	0.58	6.06e-25	Breast cancer;
CESC	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg04025307	chr7:1156635	C7orf50	0.43	5.98	0.34	7.37e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg14831746	chr12:49961631	MCRS1	0.48	6.84	0.39	5.34e-11	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs6073597	1.000	rs6031980	chr20:43714384	C/T	cg09338170	chr1:100436032	SLC35A3	0.44	6.48	0.37	4.41e-10	Positive affect;
CESC	cis	rs753778	0.667	rs10092439	chr8:142210881	C/T	cg23750338	chr8:142222470	SLC45A4	0.38	5.56	0.32	6.67e-8	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	cis	rs826838	0.967	rs11183514	chr12:38760744	A/T	cg13010199	chr12:38710504	ALG10B	0.62	8.74	0.47	2.7e-16	Heart rate;
CESC	cis	rs9463078	0.817	rs3799967	chr6:44798701	A/G	cg25276700	chr6:44698697	NA	-0.34	-5.03	-0.3	9.05e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CESC	cis	rs1729951	0.575	rs1654904	chr3:136681149	T/C	cg25687071	chr3:136751404	NA	0.39	5.17	0.3	4.72e-7	Neuroticism;
CESC	trans	rs1219407	0.655	rs1219392	chr11:121764234	A/G	cg05493580	chr10:23569664	NA	-0.48	-6.1	-0.35	3.66e-9	Mood disorder in prion disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10326224	chr17:60501257	METTL2A	0.62	6.5	0.37	4.04e-10	Gut microbiome composition (summer);
CESC	cis	rs4665809	1.000	rs6546766	chr2:26328680	T/C	cg25036284	chr2:26402008	FAM59B	-0.6	-6.94	-0.39	2.95e-11	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.753	rs7698541	chr4:98986351	T/A	cg17366294	chr4:99064904	C4orf37	0.59	8.57	0.47	8.46e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7811142	0.943	rs66958101	chr7:100074020	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.14	11.43	0.57	7.11e-25	Platelet count;
CESC	cis	rs4450798	0.793	rs79204004	chr3:13758473	G/C	cg05589046	chr3:13742034	LOC285375	0.38	5.8	0.34	1.86e-8	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs151234	0.741	rs151227	chr16:28549508	C/T	cg01378222	chr16:28622494	SULT1A1	-0.49	-6.55	-0.37	2.94e-10	Platelet distribution width;
CESC	cis	rs116095464	0.558	rs62344300	chr5:246336	A/G	cg12570787	chr5:219185	SDHA;CCDC127	0.5	5.27	0.31	2.9e-7	Breast cancer;
CESC	cis	rs7666738	0.830	rs9307218	chr4:99024885	T/C	cg17366294	chr4:99064904	C4orf37	0.61	8.67	0.47	4.35e-16	Colonoscopy-negative controls vs population controls;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg03205495	chr19:14640249	TECR;MIR639	-0.52	-6.9	-0.39	3.84e-11	Height;
CESC	cis	rs9300255	0.506	rs61388686	chr12:123810873	G/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.32	-5.11	-0.3	6.23e-7	Neutrophil percentage of white cells;
CESC	cis	rs7000551	0.527	rs11783730	chr8:22244897	C/T	cg12081754	chr8:22256438	SLC39A14	0.93	12.5	0.61	1.75e-28	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CESC	cis	rs4889855	0.530	rs72856551	chr17:78552267	G/T	cg16591659	chr17:78472290	NA	0.35	5.74	0.33	2.63e-8	Fractional excretion of uric acid;
CESC	cis	rs4642101	0.824	rs3889514	chr3:12844072	T/C	cg05775895	chr3:12838266	CAND2	0.39	5.78	0.33	2.1e-8	QRS complex (12-leadsum);
CESC	cis	rs28489187	0.730	rs12121675	chr1:85798484	A/G	cg16011679	chr1:85725395	C1orf52	0.56	6.58	0.37	2.49e-10	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	cis	rs6831352	0.918	rs4699713	chr4:100060513	C/T	cg12011299	chr4:100065546	ADH4	-0.59	-6.59	-0.38	2.35e-10	Alcohol dependence;
CESC	trans	rs11098499	1.000	rs12506395	chr4:120185094	C/T	cg25214090	chr10:38739885	LOC399744	0.66	8.84	0.48	1.34e-16	Corneal astigmatism;
CESC	cis	rs763014	0.966	rs12935215	chr16:670605	T/C	cg07256732	chr16:621771	PIGQ	-0.32	-5.62	-0.33	4.94e-8	Height;
CESC	trans	rs12681287	0.547	rs60982560	chr8:87515046	C/T	cg27317242	chr8:23145699	R3HCC1	-0.51	-6.05	-0.35	4.96e-9	Caudate activity during reward;
CESC	cis	rs72615157	0.561	rs113844570	chr7:99873778	A/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.61	5.71	0.33	3.02e-8	Lung function (FEV1/FVC);
CESC	cis	rs909002	0.800	rs4949454	chr1:32099041	A/G	cg13919466	chr1:32135498	COL16A1	0.45	8.06	0.44	2.55e-14	Intelligence (multi-trait analysis);
CESC	cis	rs11711311	0.955	rs3796254	chr3:113380332	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.65	8.47	0.46	1.67e-15	IgG glycosylation;
CESC	cis	rs11871801	0.517	rs668799	chr17:40716235	C/T	cg21433558	chr17:40837037	CNTNAP1	0.47	5.76	0.33	2.29e-8	Crohn's disease;
CESC	cis	rs30380	1.000	rs30187	chr5:96124330	T/C	cg16492584	chr5:96139282	ERAP1	-0.34	-5.06	-0.3	7.84e-7	Cerebrospinal fluid biomarker levels;
CESC	cis	rs2950393	0.794	rs1563897	chr12:57093100	T/C	cg05584118	chr12:57595605	LRP1	-0.38	-5.38	-0.31	1.67e-7	Platelet distribution width;
CESC	cis	rs7659604	0.521	rs13130789	chr4:122690166	G/A	cg19748678	chr4:122722346	EXOSC9	-0.48	-6.07	-0.35	4.47e-9	Type 2 diabetes;
CESC	cis	rs9549367	0.636	rs486407	chr13:113833499	G/A	cg00898013	chr13:113819073	PROZ	0.46	6.9	0.39	3.73e-11	Platelet distribution width;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25655593	chr20:48599521	SNAI1	-0.58	-6.66	-0.38	1.57e-10	Gut microbiome composition (summer);
CESC	cis	rs2721195	0.967	rs1480000	chr8:145702007	C/T	cg26752003	chr8:145688521	CYHR1	0.6	8.07	0.44	2.48e-14	Age at first birth;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10656664	chr5:853447	NA	-0.53	-6.59	-0.38	2.4e-10	Gut microbiome composition (summer);
CESC	cis	rs8078723	0.714	rs2241245	chr17:38151014	C/T	cg17467752	chr17:38218738	THRA	-0.56	-8.52	-0.46	1.22e-15	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CESC	cis	rs3820928	1.000	rs2396433	chr2:227772502	A/G	cg11843606	chr2:227700838	RHBDD1	-0.43	-5.74	-0.33	2.55e-8	Pulmonary function;
CESC	cis	rs7618915	0.501	rs767418	chr3:52767427	C/T	cg05564831	chr3:52568323	NT5DC2	0.44	6.84	0.39	5.53e-11	Bipolar disorder;
CESC	cis	rs9359856	0.564	rs72915944	chr6:90447226	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.64	-6.24	-0.36	1.77e-9	Bipolar disorder;
CESC	cis	rs270601	0.721	rs162894	chr5:131611872	T/G	cg09877947	chr5:131593287	PDLIM4	0.43	5.22	0.31	3.54e-7	Acylcarnitine levels;
CESC	cis	rs4925386	1.000	rs2151512	chr20:60913495	T/C	cg22633769	chr20:60982531	CABLES2	-0.43	-5.12	-0.3	6.02e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs7666738	0.830	rs6829567	chr4:99047340	T/C	cg03467027	chr4:99064603	C4orf37	0.47	5.98	0.34	7.19e-9	Colonoscopy-negative controls vs population controls;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg26737766	chr1:24127303	GALE	-0.44	-6.02	-0.35	5.68e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs977987	0.931	rs1834013	chr16:75496163	G/T	cg03315344	chr16:75512273	CHST6	0.53	7.82	0.43	1.23e-13	Dupuytren's disease;
CESC	cis	rs9457247	0.967	rs402191	chr6:167405553	T/C	cg07741184	chr6:167504864	NA	0.29	5.31	0.31	2.32e-7	Crohn's disease;
CESC	cis	rs57221529	0.709	rs72703090	chr5:598314	C/T	cg16447950	chr5:562315	NA	-0.59	-6.01	-0.35	6.18e-9	Lung disease severity in cystic fibrosis;
CESC	cis	rs4862750	0.914	rs1991256	chr4:187875330	A/G	cg11301795	chr4:187892539	NA	-0.72	-11.06	-0.56	1.3e-23	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg14159672	chr1:205819179	PM20D1	0.79	11.62	0.58	1.62e-25	Menarche (age at onset);
CESC	cis	rs7481584	0.624	rs412842	chr11:3047448	A/G	cg25174290	chr11:3078921	CARS	-0.46	-6.4	-0.37	6.86e-10	Calcium levels;
CESC	cis	rs7605827	0.930	rs4140713	chr2:15536128	C/T	cg19274914	chr2:15703543	NA	0.36	6.59	0.38	2.3e-10	Educational attainment (years of education);
CESC	cis	rs6688613	0.649	rs2280995	chr1:166846069	A/G	ch.1.3259774R	chr1:166827647	TADA1	0.54	5.24	0.31	3.25e-7	Refractive astigmatism;
CESC	cis	rs9811920	0.965	rs10222474	chr3:99862551	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.44	7.02	0.4	1.9e-11	Axial length;
CESC	cis	rs829880	0.789	rs1096146	chr12:98850966	A/G	cg25150519	chr12:98850993	NA	0.8	11.66	0.58	1.27e-25	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7833790	0.700	rs7825180	chr8:82723991	T/A	cg07697082	chr8:82753677	SNX16	0.39	5.94	0.34	8.74e-9	Diastolic blood pressure;
CESC	cis	rs1799949	1.000	rs12950607	chr17:41299928	G/C	cg25072359	chr17:41440525	NA	0.43	5.83	0.34	1.61e-8	Menopause (age at onset);
CESC	cis	rs8060686	0.844	rs3785100	chr16:67997920	T/C	cg26727032	chr16:67993705	SLC12A4	-0.56	-6.18	-0.36	2.36e-9	HDL cholesterol;Metabolic syndrome;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27594834	chr19:11708137	ZNF627	-0.59	-6.49	-0.37	4.2e-10	Gut microbiome composition (summer);
CESC	cis	rs2487048	0.761	rs2980083	chr9:107691362	A/C	cg14470647	chr9:107690075	ABCA1	-0.57	-7.07	-0.4	1.36e-11	Intraocular pressure;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg20809690	chr4:2757764	TNIP2	-0.45	-6.65	-0.38	1.71e-10	Fibrinogen levels;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg02432159	chr15:75661014	MAN2C1	0.42	6.08	0.35	4.07e-9	Systemic lupus erythematosus;
CESC	cis	rs875971	0.545	rs7783889	chr7:65748353	T/A	cg25405998	chr7:65216604	CCT6P1	0.46	5.37	0.31	1.72e-7	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23202316	chr17:33447048	RAD51L3	-0.7	-8.87	-0.48	1.1e-16	Gut microbiome composition (summer);
CESC	cis	rs6137287	0.668	rs6082331	chr20:21108350	A/G	cg13880779	chr20:21376337	NKX2-4	0.34	5.51	0.32	8.43e-8	Height;
CESC	cis	rs6691722	0.503	rs2274168	chr1:24707211	G/T	cg18323236	chr1:24743029	NIPAL3	0.37	5.47	0.32	1.02e-7	Response to interferon beta in multiple sclerosis;
CESC	cis	rs11958404	0.932	rs72816598	chr5:157436017	G/A	cg05962755	chr5:157440814	NA	0.59	6.43	0.37	5.8e-10	IgG glycosylation;
CESC	cis	rs2735413	0.881	rs12919818	chr16:78082862	C/T	cg04733911	chr16:78082701	NA	-0.53	-8.86	-0.48	1.17e-16	Systolic blood pressure (alcohol consumption interaction);
CESC	cis	rs2273669	0.667	rs17070136	chr6:109350550	T/C	cg05315195	chr6:109294784	ARMC2	-0.67	-6.06	-0.35	4.74e-9	Prostate cancer;
CESC	cis	rs7044106	0.664	rs7861679	chr9:123375589	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.68	-9.89	-0.52	8.01e-20	Hip circumference adjusted for BMI;
CESC	cis	rs2073300	0.609	rs77673953	chr20:23398794	G/C	cg12062639	chr20:23401060	NAPB	1.06	8.32	0.46	4.59e-15	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs9443189	0.570	rs504446	chr6:76326939	T/C	cg01950844	chr6:76311363	SENP6	0.87	9.39	0.5	2.95e-18	Prostate cancer;
CESC	cis	rs9303280	0.628	rs12939565	chr17:38038389	A/T	cg20243544	chr17:37824526	PNMT	0.54	7.15	0.4	8.36e-12	Self-reported allergy;
CESC	cis	rs2997447	0.761	rs17257113	chr1:26449595	G/A	cg24596570	chr1:26146463	FAM54B;LOC646471	0.59	5.16	0.3	4.74e-7	QRS complex (12-leadsum);
CESC	cis	rs12497850	0.931	rs13064911	chr3:48952385	A/G	cg02487422	chr3:49467188	NICN1	0.42	5.36	0.31	1.78e-7	Parkinson's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19296153	chr4:1232112	CTBP1	-0.54	-6.09	-0.35	3.92e-9	Gut microbiome composition (summer);
CESC	cis	rs7949030	0.590	rs12225213	chr11:62350248	T/A	cg13298116	chr11:62369859	EML3;MTA2	0.64	9.22	0.49	9.73e-18	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs9322193	0.884	rs12528279	chr6:150072028	A/C	cg13206674	chr6:150067644	NUP43	0.45	6.44	0.37	5.65e-10	Lung cancer;
CESC	cis	rs10504229	0.593	rs79874994	chr8:57993709	C/A	cg05313129	chr8:58192883	C8orf71	-0.51	-5.07	-0.3	7.46e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs11785400	0.793	rs7459963	chr8:143737129	C/T	cg10596483	chr8:143751796	JRK	0.43	5.45	0.32	1.14e-7	Schizophrenia;
CESC	cis	rs9467711	0.606	rs9348709	chr6:26360311	G/A	cg12826209	chr6:26865740	GUSBL1	0.61	5.17	0.3	4.52e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs7772486	0.790	rs9485024	chr6:146142487	A/G	cg05347473	chr6:146136440	FBXO30	-0.48	-5.89	-0.34	1.15e-8	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs916888	0.821	rs199504	chr17:44861003	C/T	cg23590916	chr17:43697445	MGC57346	-0.63	-6.59	-0.38	2.38e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs7216064	1.000	rs8072225	chr17:65912960	A/G	cg12091567	chr17:66097778	LOC651250	-0.7	-8.12	-0.45	1.72e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	trans	rs2085496	0.764	rs1596751	chr2:193807860	A/G	cg01640444	chr3:193311744	OPA1	0.44	6.06	0.35	4.58e-9	Neuroticism;
CESC	cis	rs2249625	0.967	rs2463725	chr6:72897212	C/T	cg18830697	chr6:72922368	RIMS1	-0.44	-6.23	-0.36	1.86e-9	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CESC	cis	rs6964587	0.692	rs12536220	chr7:91805595	T/G	cg01689657	chr7:91764605	CYP51A1	0.27	5.37	0.31	1.69e-7	Breast cancer;
CESC	cis	rs1707322	0.721	rs28641748	chr1:46212836	A/G	cg03146154	chr1:46216737	IPP	0.82	11.54	0.58	3.18e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs4713118	0.662	rs9468277	chr6:28028390	C/A	cg19592336	chr6:28129416	ZNF389	0.54	6.94	0.39	3e-11	Parkinson's disease;
CESC	cis	rs2228479	0.850	rs62054599	chr16:89808850	C/G	cg04013166	chr16:89971882	TCF25	0.77	6.69	0.38	1.32e-10	Skin colour saturation;
CESC	cis	rs6088580	0.634	rs1890002	chr20:32919219	A/G	cg08999081	chr20:33150536	PIGU	-0.65	-11.31	-0.57	1.86e-24	Glomerular filtration rate (creatinine);
CESC	cis	rs6448317	0.911	rs10939013	chr4:24903015	G/A	cg21108841	chr4:24914750	CCDC149	0.49	6.08	0.35	4.25e-9	Heschl's gyrus morphology;
CESC	cis	rs769267	0.965	rs2017964	chr19:19387149	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.42	5.38	0.31	1.66e-7	Tonsillectomy;
CESC	cis	rs17125944	0.505	rs10483618	chr14:53203590	T/C	cg13660082	chr14:53194042	PSMC6	-0.65	-5.88	-0.34	1.23e-8	Alzheimer's disease (late onset);
CESC	cis	rs7666738	0.830	rs7664305	chr4:99037691	G/A	cg03467027	chr4:99064603	C4orf37	0.47	5.97	0.34	7.51e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs425277	0.565	rs2480711	chr1:2111376	A/G	cg23803603	chr1:2058230	PRKCZ	0.33	5.76	0.33	2.37e-8	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09686635	chr1:210001418	C1orf107	-0.58	-6.78	-0.38	7.82e-11	Gut microbiome composition (summer);
CESC	cis	rs8060686	0.591	rs80346622	chr16:68074419	C/T	cg26727032	chr16:67993705	SLC12A4	-0.54	-6.18	-0.35	2.43e-9	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs2243480	1.000	rs1701758	chr7:65470201	T/A	cg13147721	chr7:65941812	NA	-0.86	-8.36	-0.46	3.7e-15	Diabetic kidney disease;
CESC	cis	rs9916302	0.904	rs55660616	chr17:37684990	C/A	cg20243544	chr17:37824526	PNMT	0.52	6.58	0.37	2.56e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs9894429	0.752	rs7502883	chr17:79588557	T/C	cg18240062	chr17:79603768	NPLOC4	0.89	13.21	0.63	6.03e-31	Eye color traits;
CESC	cis	rs8068544	0.818	rs79892925	chr17:40171819	A/G	cg26502583	chr17:39992600	KLHL10;NT5C3L	-0.77	-6.07	-0.35	4.42e-9	Reticulocyte fraction of red cells;Reticulocyte count;
CESC	cis	rs7666738	0.791	rs13149968	chr4:99070262	G/T	cg17366294	chr4:99064904	C4orf37	0.61	8.5	0.46	1.36e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11599315	0.757	rs11250392	chr10:1342543	T/C	cg09624528	chr10:1369823	ADARB2	0.43	5.94	0.34	8.79e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs2228479	0.850	rs62056066	chr16:89906563	G/A	cg14709524	chr16:89940631	TCF25	0.88	6.1	0.35	3.82e-9	Skin colour saturation;
CESC	cis	rs10779751	0.922	rs4845985	chr1:11288618	G/A	cg08854313	chr1:11322531	MTOR	0.83	11.83	0.59	3.29e-26	Body mass index;
CESC	cis	rs12474201	1.000	rs12474201	chr2:46921285	C/T	cg06386533	chr2:46925753	SOCS5	0.81	11.39	0.57	9.87e-25	Height;
CESC	cis	rs7617773	0.817	rs9853804	chr3:48327729	T/C	cg11946769	chr3:48343235	NME6	0.8	10.89	0.56	4.71e-23	Coronary artery disease;
CESC	trans	rs11098499	0.955	rs1511015	chr4:120170473	A/C	cg25214090	chr10:38739885	LOC399744	0.63	8.31	0.45	4.87e-15	Corneal astigmatism;
CESC	cis	rs7605827	0.866	rs2276664	chr2:15701002	A/T	cg19274914	chr2:15703543	NA	0.3	5.34	0.31	2.03e-7	Educational attainment (years of education);
CESC	cis	rs2228479	0.681	rs7196840	chr16:89959647	A/G	cg06558623	chr16:89946397	TCF25	0.6	5.97	0.34	7.77e-9	Skin colour saturation;
CESC	cis	rs4665809	0.652	rs2241739	chr2:26411894	C/T	cg04944784	chr2:26401820	FAM59B	-0.88	-10.55	-0.54	5.72e-22	Gut microbiome composition (summer);
CESC	cis	rs1322639	1.000	rs9689079	chr6:169587148	A/G	cg04662567	chr6:169592167	NA	0.52	6.86	0.39	4.87e-11	Pulse pressure;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg06031423	chr22:24059642	LOC91316	-0.42	-6.5	-0.37	3.91e-10	Gambling;
CESC	cis	rs35306767	0.903	rs12240651	chr10:943656	A/G	cg25019033	chr10:957182	NA	-0.57	-6.14	-0.35	3.01e-9	Eosinophil percentage of granulocytes;
CESC	cis	rs514406	0.767	rs551591	chr1:53301876	A/G	cg06600287	chr1:53387719	ECHDC2	-0.3	-5.34	-0.31	1.98e-7	Monocyte count;
CESC	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg02725872	chr8:58115012	NA	-0.41	-5.73	-0.33	2.68e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs7786808	0.615	rs1563066	chr7:158194935	A/C	cg01191920	chr7:158217561	PTPRN2	-0.33	-5.47	-0.32	1.03e-7	Obesity-related traits;
CESC	cis	rs12497850	0.897	rs6446252	chr3:48911125	C/T	cg02487422	chr3:49467188	NICN1	0.4	5.15	0.3	5.11e-7	Parkinson's disease;
CESC	cis	rs447735	0.587	rs258335	chr16:89720944	G/A	cg04240660	chr16:89714849	CHMP1A	-0.37	-5.23	-0.31	3.46e-7	Hemoglobin concentration;
CESC	cis	rs2806561	0.734	rs2235548	chr1:23394062	G/A	cg12483005	chr1:23474871	LUZP1	0.34	5.22	0.31	3.61e-7	Height;
CESC	trans	rs2727020	0.729	rs10742932	chr11:49173234	T/C	cg15704280	chr7:45808275	SEPT13	-0.82	-13.13	-0.63	1.12e-30	Coronary artery disease;
CESC	cis	rs763014	1.000	rs7205409	chr16:642610	A/G	cg09781414	chr16:715207	WDR90	-0.35	-5.29	-0.31	2.62e-7	Height;
CESC	cis	rs8050907	0.744	rs10438587	chr16:4522160	C/T	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.9	6.28	0.36	1.39e-9	Obesity-related traits;
CESC	cis	rs801193	0.660	rs1016265	chr7:66214567	C/T	cg12463550	chr7:65579703	CRCP	0.56	7.22	0.41	5.46e-12	Aortic root size;
CESC	trans	rs1994135	0.692	rs7297538	chr12:33693438	T/C	cg26384229	chr12:38710491	ALG10B	0.54	7.34	0.41	2.7e-12	Resting heart rate;
CESC	cis	rs11252926	0.603	rs11252670	chr10:529152	A/G	cg18196295	chr10:418757	DIP2C	-0.51	-6.87	-0.39	4.57e-11	Psychosis in Alzheimer's disease;
CESC	cis	rs7649275	0.655	rs898420	chr3:53783784	T/G	cg21503701	chr3:53781065	CACNA1D	-0.39	-5.19	-0.3	4.28e-7	Trans fatty acid levels;
CESC	cis	rs1670533	1.000	rs1670534	chr4:1087265	T/C	cg04106633	chr4:1044584	NA	0.4	5.08	0.3	6.98e-7	Recombination rate (females);
CESC	cis	rs11122272	0.735	rs2749711	chr1:231537543	G/A	cg06096015	chr1:231504339	EGLN1	0.42	6.07	0.35	4.33e-9	Hemoglobin concentration;
CESC	cis	rs4566357	0.557	rs2272201	chr2:227912551	T/A	cg11843606	chr2:227700838	RHBDD1	-0.5	-6.83	-0.39	5.8e-11	Coronary artery disease;
CESC	cis	rs3733585	0.699	rs7663097	chr4:9966791	T/C	cg00071950	chr4:10020882	SLC2A9	-0.7	-11.44	-0.57	6.82e-25	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs4803468	1.000	rs10422956	chr19:41901261	C/T	cg09537434	chr19:41945824	ATP5SL	-1.06	-18.97	-0.76	2.87e-51	Height;
CESC	cis	rs7666738	0.830	rs10470893	chr4:99038756	C/T	cg18180107	chr4:99064573	C4orf37	0.41	5.29	0.31	2.51e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2576037	0.583	rs646128	chr18:44397691	A/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.5	-6.81	-0.39	6.64e-11	Personality dimensions;
CESC	cis	rs113835537	0.529	rs2305532	chr11:66298594	C/T	cg24851651	chr11:66362959	CCS	0.5	5.96	0.34	8.04e-9	Airway imaging phenotypes;
CESC	cis	rs7927592	0.913	rs6591340	chr11:68297636	A/G	cg16797656	chr11:68205561	LRP5	0.38	5.08	0.3	7.27e-7	Total body bone mineral density;
CESC	cis	rs72627123	0.500	rs68148895	chr14:74529523	C/T	cg05179529	chr14:74551516	LIN52;ALDH6A1	0.53	5.94	0.34	9.08e-9	Morning vs. evening chronotype;
CESC	cis	rs72781680	0.898	rs72786288	chr2:24075416	G/T	cg20701182	chr2:24300061	SF3B14	0.62	5.6	0.33	5.24e-8	Lymphocyte counts;
CESC	cis	rs12422267	0.536	rs12303484	chr12:132609558	G/A	cg05134918	chr12:132603531	EP400NL	-0.45	-5.22	-0.31	3.69e-7	Plasma amyloid beta peptide concentrations (ABx-40);
CESC	cis	rs1799949	1.000	rs11657053	chr17:41191129	G/T	cg25072359	chr17:41440525	NA	0.5	6.5	0.37	3.94e-10	Menopause (age at onset);
CESC	cis	rs752092	1.000	rs8033360	chr15:101778710	C/A	cg19997662	chr15:101784653	CHSY1	-0.53	-7.05	-0.4	1.54e-11	Corneal structure;
CESC	cis	rs6499255	1.000	rs8045682	chr16:69786092	C/A	cg15192750	chr16:69999425	NA	0.44	5.32	0.31	2.26e-7	IgE levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15673731	chr1:156084691	LMNA	0.64	7.34	0.41	2.57e-12	Gut microbiome composition (summer);
CESC	cis	rs8072100	0.713	rs57427906	chr17:45494014	G/A	cg08085267	chr17:45401833	C17orf57	-0.52	-6.6	-0.38	2.28e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs5758659	0.967	rs5758670	chr22:42636687	T/C	cg04733989	chr22:42467013	NAGA	0.41	5.65	0.33	4.06e-8	Cognitive function;
CESC	cis	rs929354	1.000	rs1182389	chr7:157038803	C/T	cg05182265	chr7:156933206	UBE3C	-0.4	-5.49	-0.32	9.53e-8	Body mass index;
CESC	cis	rs916888	0.821	rs199504	chr17:44861003	C/T	cg15921436	chr17:44337874	NA	-0.69	-7.63	-0.42	4.11e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs875971	0.660	rs62465434	chr7:66005152	A/C	cg11764359	chr7:65958608	NA	0.72	9.69	0.51	3.24e-19	Aortic root size;
CESC	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg15112475	chr7:1198522	ZFAND2A	-0.43	-6.79	-0.38	7.32e-11	Longevity;Endometriosis;
CESC	cis	rs6952808	0.582	rs10479762	chr7:2045351	T/C	cg23048001	chr7:2026167	MAD1L1	-0.47	-6.27	-0.36	1.44e-9	Bipolar disorder and schizophrenia;
CESC	trans	rs9858542	0.953	rs7648841	chr3:49416825	G/A	cg21659725	chr3:3221576	CRBN	-0.55	-6.53	-0.37	3.34e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs12791968	0.765	rs11038250	chr11:45009114	A/G	cg11846598	chr11:44996168	LOC221122	-0.49	-6.06	-0.35	4.53e-9	Inhibitory control;
CESC	cis	rs72781680	1.000	rs72788278	chr2:24095285	A/C	cg08917208	chr2:24149416	ATAD2B	0.91	8.38	0.46	3.17e-15	Lymphocyte counts;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16262357	chr19:36266374	SNX26	0.69	8.13	0.45	1.63e-14	Gut microbiome composition (summer);
CESC	cis	rs72627123	0.867	rs3815331	chr14:74482948	A/G	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.81	5.36	0.31	1.78e-7	Morning vs. evening chronotype;
CESC	cis	rs3749237	0.595	rs3870338	chr3:49557051	A/G	cg03060546	chr3:49711283	APEH	0.75	11.67	0.58	1.15e-25	Resting heart rate;
CESC	cis	rs4727027	0.933	rs13225884	chr7:148857795	A/G	cg23158103	chr7:148848205	ZNF398	-0.44	-7.15	-0.4	8.28e-12	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg02018176	chr4:1364513	KIAA1530	0.6	7.5	0.42	9.39e-13	Longevity;
CESC	cis	rs9311474	0.508	rs3796353	chr3:52593230	C/T	cg05564831	chr3:52568323	NT5DC2	0.47	7.33	0.41	2.79e-12	Electroencephalogram traits;
CESC	cis	rs7824557	0.592	rs2572371	chr8:11223793	G/T	cg21775007	chr8:11205619	TDH	0.48	7.07	0.4	1.35e-11	Retinal vascular caliber;
CESC	cis	rs2733201	1.000	rs1426658	chr15:44338919	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.67	-5.5	-0.32	8.75e-8	Lipoprotein phospholipase A2 activity in cardiovascular disease;
CESC	cis	rs7794273	0.821	rs7810384	chr7:18844771	C/T	cg13420273	chr7:18810212	HDAC9	0.4	5.64	0.33	4.32e-8	Night sleep phenotypes;
CESC	cis	rs2011503	1.000	rs2905422	chr19:19460703	A/G	cg11584989	chr19:19387371	SF4	-0.65	-7.28	-0.41	3.9e-12	Bipolar disorder;
CESC	cis	rs8031584	0.958	rs11293	chr15:31234981	G/A	cg08109568	chr15:31115862	NA	-0.71	-9.49	-0.5	1.42e-18	Huntington's disease progression;
CESC	cis	rs7772486	0.846	rs2144478	chr6:146381445	A/G	cg05347473	chr6:146136440	FBXO30	0.49	6.66	0.38	1.55e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9322193	0.923	rs9766004	chr6:150075499	C/T	cg04369109	chr6:150039330	LATS1	-0.43	-6.08	-0.35	4.24e-9	Lung cancer;
CESC	cis	rs977987	0.835	rs11641532	chr16:75329480	T/C	cg03315344	chr16:75512273	CHST6	0.38	5.57	0.32	6.31e-8	Dupuytren's disease;
CESC	cis	rs734999	0.549	rs2764840	chr1:2529437	C/T	cg18854424	chr1:2615690	NA	-0.27	-5.46	-0.32	1.12e-7	Ulcerative colitis;
CESC	cis	rs11608355	0.521	rs6606709	chr12:109846714	A/C	cg19025524	chr12:109796872	NA	-0.52	-7.14	-0.4	9e-12	Neuroticism;
CESC	cis	rs6951245	0.832	rs79808627	chr7:1092519	C/G	cg03188948	chr7:1209495	NA	0.61	6.09	0.35	3.91e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs875971	1.000	rs7789554	chr7:65946038	A/G	cg26939375	chr7:64535504	NA	0.46	6.0	0.35	6.4e-9	Aortic root size;
CESC	cis	rs8070740	0.838	rs1050461	chr17:5336210	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.58	6.7	0.38	1.27e-10	Menopause (age at onset);
CESC	cis	rs11190604	1.000	rs11190540	chr10:102202629	A/G	cg07080220	chr10:102295463	HIF1AN	0.55	5.56	0.32	6.43e-8	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs1642645	0.793	rs7546128	chr1:42473659	C/A	cg16685388	chr1:42384056	HIVEP3	0.38	5.68	0.33	3.57e-8	Left ventricular obstructive tract defect (maternal effect);
CESC	trans	rs2115172	0.836	rs4835799	chr5:122762229	A/G	cg25458520	chr6:36099195	MAPK13	0.43	6.1	0.35	3.77e-9	Weight;
CESC	cis	rs559928	0.569	rs7103915	chr11:63944370	A/G	cg18225595	chr11:63971243	STIP1	-0.62	-5.26	-0.31	3.01e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CESC	cis	rs10504229	0.595	rs116490935	chr8:58117531	A/G	cg21724239	chr8:58056113	NA	0.58	5.97	0.34	7.54e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs10791097	0.720	rs6590515	chr11:130733365	A/G	cg12179176	chr11:130786555	SNX19	-0.65	-9.98	-0.52	3.91e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs258892	0.947	rs9885319	chr5:72179404	T/G	cg21869765	chr5:72125136	TNPO1	0.45	5.65	0.33	4.2e-8	Small cell lung carcinoma;
CESC	cis	rs7666738	0.791	rs6828752	chr4:99063382	C/T	cg03467027	chr4:99064603	C4orf37	0.48	5.95	0.34	8.67e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1005277	0.505	rs1208689	chr10:38097775	C/G	cg00409905	chr10:38381863	ZNF37A	-0.55	-7.61	-0.42	4.93e-13	Extrinsic epigenetic age acceleration;
CESC	cis	rs116095464	0.558	rs11959126	chr5:283880	T/G	cg12570787	chr5:219185	SDHA;CCDC127	0.52	5.41	0.32	1.38e-7	Breast cancer;
CESC	cis	rs9311474	0.508	rs12637627	chr3:52619962	G/T	cg18337363	chr3:52569053	NT5DC2	0.29	5.29	0.31	2.56e-7	Electroencephalogram traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13599271	chr3:58291905	RPP14	0.6	6.63	0.38	1.83e-10	Gut microbiome composition (summer);
CESC	cis	rs6060717	0.610	rs2244883	chr20:34620896	A/G	cg17201900	chr20:34330562	RBM39	0.47	5.26	0.31	2.97e-7	Hip circumference adjusted for BMI;
CESC	cis	rs1348850	0.632	rs13009207	chr2:178501632	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.56	7.49	0.42	1.06e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs1577917	0.739	rs2758846	chr6:86349570	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.53	-7.11	-0.4	1.05e-11	Response to antipsychotic treatment;
CESC	cis	rs6570726	0.935	rs408723	chr6:145838535	A/G	cg23711669	chr6:146136114	FBXO30	0.8	12.02	0.59	7.3e-27	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg01091156	chr16:87991122	BANP	0.45	6.18	0.35	2.41e-9	Fibrinogen levels;
CESC	cis	rs1799949	1.000	rs8176269	chr17:41213626	G/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.4	5.38	0.31	1.65e-7	Menopause (age at onset);
CESC	cis	rs2197308	0.565	rs4123923	chr12:37857684	T/C	cg26384229	chr12:38710491	ALG10B	0.74	10.95	0.56	2.84e-23	Morning vs. evening chronotype;
CESC	cis	rs28374715	0.662	rs691907	chr15:41474657	C/G	cg18705301	chr15:41695430	NDUFAF1	0.74	9.83	0.52	1.25e-19	Ulcerative colitis;
CESC	cis	rs5769765	1.000	rs2092982	chr22:50282204	C/A	cg22709217	chr22:50311962	ALG12;CRELD2	0.46	5.32	0.31	2.21e-7	Schizophrenia;
CESC	cis	rs2777491	1.000	rs316610	chr15:41752852	C/T	cg20272979	chr15:41787780	ITPKA	0.44	6.5	0.37	4.02e-10	Ulcerative colitis;
CESC	cis	rs9790314	0.586	rs16832279	chr3:161120483	C/T	cg03342759	chr3:160939853	NMD3	-0.44	-5.71	-0.33	2.99e-8	Morning vs. evening chronotype;
CESC	cis	rs12143943	0.934	rs1870551	chr1:204581014	A/G	cg20240347	chr1:204465584	NA	-0.26	-5.08	-0.3	7.07e-7	Cognitive performance;
CESC	cis	rs910316	0.967	rs4903292	chr14:75656245	A/G	cg11812906	chr14:75593930	NEK9	0.85	14.67	0.67	4.43e-36	Height;
CESC	cis	rs873946	0.586	rs12770021	chr10:134562021	G/A	cg26818010	chr10:134567672	INPP5A	-0.91	-11.08	-0.56	1.05e-23	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs6445797	0.890	rs13073181	chr3:56572454	C/G	cg13792233	chr3:56591045	CCDC66	0.39	5.4	0.32	1.45e-7	Gastritis;
CESC	cis	rs761746	0.960	rs738656	chr22:31935347	G/A	cg25791279	chr22:32026902	PISD	-0.52	-5.9	-0.34	1.09e-8	Intelligence;
CESC	cis	rs780096	0.526	rs4803	chr2:27667297	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.36	-7.38	-0.41	2.02e-12	Total body bone mineral density;
CESC	cis	rs1862618	0.511	rs2591952	chr5:56120769	T/A	cg12311346	chr5:56204834	C5orf35	-0.72	-8.88	-0.48	1.01e-16	Initial pursuit acceleration;
CESC	cis	rs12136530	0.625	rs10917447	chr1:19749743	T/C	cg01832549	chr1:19774989	CAPZB	-0.5	-6.92	-0.39	3.42e-11	Lead levels in blood;
CESC	cis	rs4862750	0.872	rs13101380	chr4:187894744	G/A	cg03647317	chr4:187891568	NA	-0.46	-7.03	-0.4	1.79e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1797081	0.561	rs2603795	chr10:16860256	A/G	cg23933602	chr10:16859644	RSU1	0.73	9.45	0.5	1.81e-18	Platelet distribution width;
CESC	cis	rs1799949	0.965	rs8176161	chr17:41241390	C/A	cg23758822	chr17:41437982	NA	1.0	15.66	0.69	1.44e-39	Menopause (age at onset);
CESC	cis	rs7666738	0.830	rs62318504	chr4:98935558	T/G	cg03467027	chr4:99064603	C4orf37	0.48	5.91	0.34	1.03e-8	Colonoscopy-negative controls vs population controls;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg12090654	chr8:6424636	MCPH1	0.49	6.44	0.37	5.44e-10	Fibrinogen levels;
CESC	cis	rs6752107	0.967	rs36001488	chr2:234185267	C/T	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.39	5.91	0.34	1.07e-8	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs1580019	0.562	rs4720064	chr7:32559638	G/A	cg07520158	chr7:32535189	LSM5;AVL9	0.52	6.73	0.38	1.05e-10	Cognitive ability;
CESC	cis	rs514406	0.793	rs12402415	chr1:53218539	G/T	cg08736216	chr1:53307985	ZYG11A	0.31	5.41	0.32	1.39e-7	Monocyte count;
CESC	trans	rs78049276	0.688	rs56024659	chr4:148378604	C/T	cg13149281	chr14:23389818	RBM23;PRMT5	-0.69	-8.02	-0.44	3.47e-14	Pulse pressure;
CESC	cis	rs1790761	0.692	rs611663	chr11:67312221	C/T	cg24690094	chr11:67383802	NA	0.35	5.86	0.34	1.4e-8	Mean corpuscular volume;
CESC	cis	rs11608355	0.545	rs6606724	chr12:109905179	T/C	cg05360138	chr12:110035743	NA	0.82	8.92	0.48	7.93e-17	Neuroticism;
CESC	cis	rs896854	0.654	rs2011566	chr8:95971921	G/A	cg23172400	chr8:95962367	TP53INP1	-0.43	-8.89	-0.48	9.58e-17	Type 2 diabetes;
CESC	cis	rs873946	0.586	rs12783078	chr10:134569706	C/T	cg27297192	chr10:134578999	INPP5A	0.4	5.15	0.3	5.16e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs4803468	1.000	rs2241706	chr19:41912807	A/G	cg14132834	chr19:41945861	ATP5SL	-0.67	-8.31	-0.45	5.08e-15	Height;
CESC	cis	rs6540559	0.673	rs7511996	chr1:210018473	C/A	cg25204440	chr1:209979598	IRF6	0.53	5.27	0.31	2.8e-7	Cleft lip with or without cleft palate;
CESC	cis	rs1538970	0.924	rs11211111	chr1:45908782	C/T	cg03146154	chr1:46216737	IPP	0.46	5.34	0.31	1.97e-7	Platelet count;
CESC	cis	rs7084402	0.967	rs1658458	chr10:60301382	T/C	cg07615347	chr10:60278583	BICC1	0.6	9.46	0.5	1.77e-18	Refractive error;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24100506	chr3:44903551	TMEM42	0.68	7.85	0.43	1.05e-13	Gut microbiome composition (summer);
CESC	cis	rs78889164	0.876	rs1061338	chr19:33878198	A/G	cg02272751	chr19:33882848	PEPD	-0.53	-7.75	-0.43	1.91e-13	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6912958	0.781	rs9450732	chr6:88249826	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-6.56	-0.37	2.75e-10	Monocyte percentage of white cells;
CESC	cis	rs2629540	0.737	rs10901821	chr10:126480556	T/C	cg08799069	chr10:126477246	METTL10	-0.56	-7.98	-0.44	4.55e-14	Cocaine dependence;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09134154	chr10:60094858	UBE2D1	0.6	6.89	0.39	4.05e-11	Gut microbiome composition (summer);
CESC	cis	rs5758659	1.000	rs134902	chr22:42683997	C/T	cg04733989	chr22:42467013	NAGA	0.41	5.84	0.34	1.49e-8	Cognitive function;
CESC	cis	rs1044826	0.642	rs4683464	chr3:139196961	C/T	cg15131784	chr3:139108705	COPB2	0.41	5.15	0.3	5.16e-7	Obesity-related traits;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg07738014	chr19:3627036	C19orf29	-0.43	-6.54	-0.37	3.16e-10	Gambling;
CESC	cis	rs6582630	0.555	rs11182148	chr12:38464883	A/C	cg26384229	chr12:38710491	ALG10B	0.66	10.01	0.52	3.14e-20	Drug-induced liver injury (flucloxacillin);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg16491506	chr14:61189969	SIX4	-0.53	-6.86	-0.39	4.92e-11	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs7618501	0.933	rs3811695	chr3:49761613	C/T	cg21659725	chr3:3221576	CRBN	-0.83	-13.7	-0.64	1.18e-32	Intelligence (multi-trait analysis);
CESC	cis	rs763121	0.853	rs1043441	chr22:39130964	C/T	cg06544989	chr22:39130855	UNC84B	0.46	8.07	0.44	2.39e-14	Menopause (age at onset);
CESC	cis	rs854765	0.583	rs7214536	chr17:17852446	G/A	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.54	7.08	0.4	1.28e-11	Total body bone mineral density;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg02283353	chr19:622406	POLRMT	0.45	6.02	0.35	5.66e-9	Fibrinogen levels;
CESC	cis	rs651907	0.557	rs11917682	chr3:101355427	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.46	5.84	0.34	1.56e-8	Colorectal cancer;
CESC	cis	rs73206853	0.563	rs73194040	chr12:111181106	C/T	cg12870014	chr12:110450643	ANKRD13A	0.67	5.25	0.31	3.16e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs1799949	1.000	rs34942571	chr17:41273379	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.65	8.64	0.47	5.48e-16	Menopause (age at onset);
CESC	cis	rs4969178	0.965	rs8072632	chr17:76397830	T/C	cg05887092	chr17:76393375	PGS1	0.58	9.21	0.49	1.01e-17	HDL cholesterol levels;
CESC	cis	rs9487051	0.676	rs6568567	chr6:109596993	A/G	cg01475377	chr6:109611718	NA	-0.45	-7.04	-0.4	1.6e-11	Reticulocyte fraction of red cells;
CESC	cis	rs67478160	0.619	rs28698555	chr14:104316486	C/A	cg01849466	chr14:104193079	ZFYVE21	0.5	6.92	0.39	3.35e-11	Schizophrenia;
CESC	cis	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.48	6.27	0.36	1.47e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs875971	1.000	rs2220626	chr7:65546062	C/T	cg11764359	chr7:65958608	NA	-0.94	-13.99	-0.65	1.14e-33	Aortic root size;
CESC	cis	rs9815354	1.000	rs9818169	chr3:41860599	A/G	cg03022575	chr3:42003672	ULK4	0.45	5.06	0.3	7.71e-7	Pulse pressure;Diastolic blood pressure;
CESC	trans	rs916888	0.610	rs142167	chr17:44795234	C/T	cg22968622	chr17:43663579	NA	-0.79	-10.84	-0.55	6.65e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs11718455	0.653	rs28533958	chr3:43974179	C/A	cg08738300	chr3:44038990	NA	0.47	6.25	0.36	1.66e-9	Coronary artery disease;
CESC	cis	rs4566357	0.576	rs10187255	chr2:227913442	T/A	cg11843606	chr2:227700838	RHBDD1	-0.5	-6.82	-0.39	6.08e-11	Coronary artery disease;
CESC	cis	rs2742234	0.541	rs12416428	chr10:43708998	G/A	cg15436174	chr10:43711423	RASGEF1A	0.47	5.53	0.32	7.48e-8	Hirschsprung disease;
CESC	cis	rs6460942	0.597	rs7778131	chr7:12543233	T/G	cg06484146	chr7:12443880	VWDE	-0.72	-7.45	-0.42	1.35e-12	Coronary artery disease;
CESC	cis	rs875971	0.522	rs6960048	chr7:65408039	A/G	cg18876405	chr7:65276391	NA	0.7	9.79	0.52	1.64e-19	Aortic root size;
CESC	cis	rs4805272	0.539	rs7256211	chr19:29333063	C/G	cg12756686	chr19:29218302	NA	0.4	5.3	0.31	2.45e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
CESC	cis	rs10779751	1.000	rs742824	chr1:11274022	G/A	cg08854313	chr1:11322531	MTOR	0.91	14.23	0.66	1.61e-34	Body mass index;
CESC	cis	rs9322193	0.923	rs9800736	chr6:149982417	A/G	cg13206674	chr6:150067644	NUP43	0.46	6.66	0.38	1.61e-10	Lung cancer;
CESC	trans	rs1814175	0.646	rs1722010	chr11:49897958	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.43	-6.26	-0.36	1.51e-9	Height;
CESC	trans	rs17685	0.753	rs10262501	chr7:75668172	G/A	cg19862616	chr7:65841803	NCRNA00174	-0.84	-12.36	-0.6	5.05e-28	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs7044106	0.791	rs10985004	chr9:123484937	T/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.91	15.2	0.68	6.03e-38	Hip circumference adjusted for BMI;
CESC	cis	rs9649465	0.846	rs13044	chr7:123322716	T/A	cg04330084	chr7:123175371	IQUB	-0.38	-5.15	-0.3	5.02e-7	Migraine;
CESC	cis	rs28386778	0.799	rs12450683	chr17:61984299	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.49	6.21	0.36	2.03e-9	Prudent dietary pattern;
CESC	cis	rs3820068	0.603	rs41270279	chr1:15988878	A/G	cg16988262	chr1:15930761	NA	0.34	5.64	0.33	4.34e-8	Systolic blood pressure;
CESC	cis	rs67311347	0.956	rs4974029	chr3:40521318	C/G	cg01475735	chr3:40494733	NA	-0.41	-5.23	-0.31	3.52e-7	Renal cell carcinoma;
CESC	cis	rs10504229	1.000	rs58608483	chr8:58195269	T/G	cg24829409	chr8:58192753	C8orf71	-0.63	-8.53	-0.46	1.1e-15	Developmental language disorder (linguistic errors);
CESC	cis	rs9916302	0.904	rs9892055	chr17:37510402	C/T	cg00129232	chr17:37814104	STARD3	0.59	7.82	0.43	1.22e-13	Glomerular filtration rate (creatinine);
CESC	cis	rs6987853	0.966	rs2974359	chr8:42434194	T/C	cg09913449	chr8:42400586	C8orf40	0.39	6.2	0.36	2.12e-9	Mean corpuscular hemoglobin concentration;
CESC	cis	rs1707322	0.964	rs10890358	chr1:46319025	T/A	cg05343316	chr1:45956843	TESK2	0.43	5.28	0.31	2.68e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9487051	0.837	rs6568561	chr6:109592909	A/G	cg21918786	chr6:109611834	NA	-0.39	-6.04	-0.35	5.08e-9	Reticulocyte fraction of red cells;
CESC	cis	rs10883723	0.810	rs7094366	chr10:104274730	C/G	ch.10.2196322F	chr10:104248062	ACTR1A	0.44	5.15	0.3	5.03e-7	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs688020	1.000	rs688020	chr7:4228553	C/T	cg02004499	chr7:4244250	SDK1	0.42	6.01	0.35	6.14e-9	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease;
CESC	cis	rs11997175	0.583	rs56045827	chr8:33787015	G/A	ch.8.33884649F	chr8:33765107	NA	0.45	5.73	0.33	2.78e-8	Body mass index;
CESC	cis	rs2573652	1.000	rs2581359	chr15:100513707	A/G	cg00587665	chr15:100533223	ADAMTS17	-0.37	-5.9	-0.34	1.1e-8	Height;
CESC	cis	rs7552404	0.727	rs61770533	chr1:76306490	C/G	cg10523679	chr1:76189770	ACADM	0.68	6.63	0.38	1.86e-10	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs4654899	0.606	rs13376428	chr1:21120027	T/C	cg05370193	chr1:21551575	ECE1	0.35	5.22	0.31	3.54e-7	Superior frontal gyrus grey matter volume;
CESC	trans	rs9929218	0.906	rs33965787	chr16:68828173	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.62	-8.01	-0.44	3.55e-14	Colorectal cancer;
CESC	cis	rs2576037	0.583	rs10070	chr18:44388899	G/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.34	5.47	0.32	1.06e-7	Personality dimensions;
CESC	cis	rs17253792	0.822	rs75999534	chr14:56036413	A/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.83	5.51	0.32	8.68e-8	Putamen volume;
CESC	cis	rs950169	0.887	rs12903946	chr15:84954430	T/C	cg17507749	chr15:85114479	UBE2QP1	0.59	6.54	0.37	3.11e-10	Schizophrenia;
CESC	cis	rs13108904	0.517	rs4974551	chr4:1336410	C/A	cg22903657	chr4:1355424	KIAA1530	-0.4	-5.7	-0.33	3.2e-8	Obesity-related traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25382472	chr1:47779932	STIL	0.6	7.01	0.4	1.99e-11	Gut microbiome composition (summer);
CESC	cis	rs3815700	1.000	rs8109768	chr19:33095463	A/G	cg24916020	chr19:33096688	ANKRD27	0.59	5.75	0.33	2.5e-8	Eosinophilic esophagitis;
CESC	trans	rs7335046	1.000	rs9517667	chr13:99915135	G/A	cg08418111	chr11:18433745	LDHC	0.6	6.01	0.35	6.07e-9	Basal cell carcinoma;
CESC	cis	rs9902453	0.904	rs9900112	chr17:28282910	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.7	9.34	0.5	4.06e-18	Coffee consumption (cups per day);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13909320	chr9:125026858	MRRF;RBM18	0.63	7.51	0.42	8.96e-13	Gut microbiome composition (summer);
CESC	cis	rs9303401	0.614	rs56284918	chr17:57178838	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.92	11.49	0.58	4.47e-25	Cognitive test performance;
CESC	cis	rs2073300	0.609	rs56094936	chr20:23401586	G/A	cg16736954	chr20:23401023	NAPB	0.77	5.57	0.32	6.37e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs7605827	0.857	rs9973946	chr2:15631022	C/T	cg19274914	chr2:15703543	NA	0.35	6.12	0.35	3.27e-9	Educational attainment (years of education);
CESC	cis	rs477692	1.000	rs565974	chr10:131423274	C/T	cg05714579	chr10:131428358	MGMT	0.48	6.49	0.37	4.29e-10	Response to temozolomide;
CESC	cis	rs854765	0.655	rs4470201	chr17:17844870	G/A	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.55	7.28	0.41	3.7e-12	Total body bone mineral density;
CESC	cis	rs4812048	1.000	rs4812048	chr20:57587771	C/T	cg14073986	chr20:57617431	SLMO2	0.6	5.15	0.3	5.11e-7	Mean platelet volume;
CESC	cis	rs7945705	0.967	rs10769970	chr11:8917937	A/G	cg12365402	chr11:9010492	NRIP3	0.38	5.86	0.34	1.39e-8	Hemoglobin concentration;
CESC	cis	rs7666738	0.830	rs6833312	chr4:98951356	A/T	cg05340658	chr4:99064831	C4orf37	0.8	12.48	0.61	2e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg24503407	chr1:205819492	PM20D1	0.81	13.75	0.65	7.52e-33	Menarche (age at onset);
CESC	cis	rs875971	0.660	rs3857686	chr7:66036191	C/T	cg10691866	chr7:65817282	TPST1	0.31	5.06	0.3	7.76e-7	Aortic root size;
CESC	cis	rs6568686	0.627	rs174381	chr6:111913479	C/T	cg22127309	chr6:111907043	TRAF3IP2	0.54	5.15	0.3	5.14e-7	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
CESC	cis	rs9902453	1.000	rs57411618	chr17:28273052	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.64	8.28	0.45	6.2e-15	Coffee consumption (cups per day);
CESC	cis	rs798554	0.660	rs2527687	chr7:2838485	G/A	cg09658497	chr7:2847517	GNA12	-0.37	-5.49	-0.32	9.32e-8	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21611868	chr3:135969116	PCCB	0.62	7.07	0.4	1.41e-11	Gut microbiome composition (summer);
CESC	cis	rs11997175	0.546	rs11778519	chr8:33615873	G/A	ch.8.33884649F	chr8:33765107	NA	0.57	7.35	0.41	2.5e-12	Body mass index;
CESC	cis	rs1008375	0.932	rs6844593	chr4:17659039	T/C	cg02297831	chr4:17616191	MED28	0.63	8.03	0.44	3.3e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs875971	0.862	rs12698521	chr7:65939489	T/C	cg12463550	chr7:65579703	CRCP	0.57	7.2	0.4	6.12e-12	Aortic root size;
CESC	cis	rs6011002	0.935	rs75123278	chr20:62312531	G/A	cg15212369	chr20:62274085	STMN3	-0.59	-5.11	-0.3	6.12e-7	Dental caries;
CESC	cis	rs9911578	1.000	rs9901114	chr17:56575208	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	-0.4	-5.42	-0.32	1.33e-7	Intelligence (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13555728	chr17:77071390	ENGASE	0.56	6.5	0.37	4.07e-10	Gut microbiome composition (summer);
CESC	cis	rs4555082	0.830	rs2816648	chr14:105708289	C/T	cg06808227	chr14:105710500	BRF1	-0.55	-6.16	-0.35	2.71e-9	Mean platelet volume;Platelet distribution width;
CESC	cis	rs9814567	1.000	rs1917130	chr3:134313773	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.46	6.24	0.36	1.76e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs9611565	0.512	rs4820444	chr22:42202606	A/G	cg06481639	chr22:41940642	POLR3H	0.57	5.83	0.34	1.62e-8	Vitiligo;
CESC	cis	rs7208859	0.623	rs9911997	chr17:29124648	A/G	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.1e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs9916302	0.904	rs2024073	chr17:37471330	T/G	cg00129232	chr17:37814104	STARD3	0.58	7.66	0.43	3.48e-13	Glomerular filtration rate (creatinine);
CESC	cis	rs113835537	0.529	rs17147644	chr11:66256660	C/T	cg22134325	chr11:66188745	NPAS4	0.36	5.54	0.32	7.37e-8	Airway imaging phenotypes;
CESC	cis	rs875971	0.651	rs313829	chr7:65552497	A/G	cg06263672	chr7:65235340	NA	-0.45	-5.16	-0.3	4.93e-7	Aortic root size;
CESC	cis	rs736408	0.634	rs11717836	chr3:52807736	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	6.47	0.37	4.74e-10	Bipolar disorder;
CESC	cis	rs992157	0.560	rs6738394	chr2:219110625	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.57	-7.29	-0.41	3.47e-12	Colorectal cancer;
CESC	cis	rs909002	0.886	rs10798880	chr1:32097088	G/T	cg13919466	chr1:32135498	COL16A1	-0.48	-8.3	-0.45	5.4e-15	Intelligence (multi-trait analysis);
CESC	cis	rs4888262	0.545	rs4888270	chr16:74698576	A/G	cg01733217	chr16:74700730	RFWD3	0.91	12.9	0.62	7.31e-30	Testicular germ cell tumor;
CESC	cis	rs875971	0.660	rs12698534	chr7:65986845	C/T	cg14393609	chr7:65229607	NA	0.47	6.33	0.36	1.05e-9	Aortic root size;
CESC	cis	rs7216064	1.000	rs62084210	chr17:65828710	A/G	cg12091567	chr17:66097778	LOC651250	-0.87	-8.69	-0.47	3.74e-16	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs798554	0.704	rs2527684	chr7:2825922	G/T	cg09658497	chr7:2847517	GNA12	-0.35	-5.31	-0.31	2.37e-7	Height;
CESC	cis	rs898097	0.691	rs7222773	chr17:80907283	A/G	cg10494973	chr17:80897199	TBCD	-0.5	-6.28	-0.36	1.39e-9	Breast cancer;
CESC	cis	rs36229146	1	rs36229146	chr7:22784486	TTATATATAAATATATATATATATATA/T	cg26061582	chr7:22766209	IL6	0.51	5.44	0.32	1.19e-7	Eosinophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;
CESC	cis	rs6963495	0.818	rs73190156	chr7:105153567	C/T	cg13798780	chr7:105162888	PUS7	0.78	8.04	0.44	2.99e-14	Bipolar disorder (body mass index interaction);
CESC	cis	rs2228479	0.850	rs11639906	chr16:89798183	T/C	cg06558623	chr16:89946397	TCF25	1.03	7.52	0.42	8.67e-13	Skin colour saturation;
CESC	cis	rs7216064	1.000	rs6504542	chr17:65836642	T/C	cg07042672	chr17:66097459	LOC651250	-0.57	-6.69	-0.38	1.32e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg24642844	chr7:1081250	C7orf50	-0.77	-9.63	-0.51	5.27e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg10169971	chr6:83902988	RWDD2A;PGM3	-0.55	-7.31	-0.41	3.13e-12	Fibrinogen levels;
CESC	cis	rs4253772	0.550	rs6008598	chr22:46704243	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.67	6.47	0.37	4.82e-10	LDL cholesterol;Cholesterol, total;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg24712243	chr11:61310195	SYT7	0.48	6.34	0.36	9.62e-10	Fibrinogen levels;
CESC	cis	rs735396	1.000	rs1169306	chr12:121438311	C/T	cg02403541	chr12:121454288	C12orf43	0.63	9.0	0.48	4.61e-17	N-glycan levels;
CESC	cis	rs9354308	0.901	rs12197136	chr6:66590953	T/C	cg07460842	chr6:66804631	NA	0.65	7.46	0.42	1.26e-12	Metabolite levels;
CESC	cis	rs1552244	1.000	rs35220123	chr3:10083169	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.87	11.86	0.59	2.65e-26	Alzheimer's disease;
CESC	cis	rs4594175	0.926	rs10135534	chr14:51617970	C/A	cg23942311	chr14:51606299	NA	0.39	5.95	0.34	8.44e-9	Cancer;
CESC	cis	rs763121	0.853	rs6001175	chr22:39018334	T/C	cg21395723	chr22:39101663	GTPBP1	0.5	6.75	0.38	9.48e-11	Menopause (age at onset);
CESC	cis	rs11252926	0.537	rs4554800	chr10:458477	G/T	cg16386425	chr10:429943	DIP2C	0.55	7.14	0.4	8.79e-12	Psychosis in Alzheimer's disease;
CESC	cis	rs911555	0.755	rs34411783	chr14:103900639	G/A	cg24130564	chr14:104152367	KLC1	0.5	6.68	0.38	1.4e-10	Intelligence (multi-trait analysis);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg21146272	chr6:42858716	C6orf226	0.45	6.18	0.35	2.37e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs9611565	0.592	rs4822046	chr22:41987543	G/A	cg06634786	chr22:41940651	POLR3H	-0.66	-6.56	-0.37	2.76e-10	Vitiligo;
CESC	cis	rs2991971	0.901	rs11211122	chr1:45954650	C/T	cg24296786	chr1:45957014	TESK2	0.66	9.2	0.49	1.09e-17	High light scatter reticulocyte count;
CESC	cis	rs11893307	0.507	rs1465303	chr2:191585440	A/C	cg10560079	chr2:191398806	TMEM194B	-0.45	-5.59	-0.32	5.55e-8	Mean platelet volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14967814	chr3:179041370	ZNF639	0.58	6.91	0.39	3.52e-11	Gut microbiome composition (summer);
CESC	cis	rs875971	0.862	rs6962717	chr7:65883735	G/A	cg10691866	chr7:65817282	TPST1	-0.32	-5.25	-0.31	3.06e-7	Aortic root size;
CESC	cis	rs796364	0.616	rs2030653	chr2:200677625	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.55	5.1	0.3	6.6e-7	Schizophrenia;
CESC	cis	rs977987	0.864	rs37592	chr16:75496791	G/C	cg03315344	chr16:75512273	CHST6	-0.46	-6.48	-0.37	4.48e-10	Dupuytren's disease;
CESC	cis	rs2070488	0.775	rs1073505	chr3:38566722	T/C	cg24069376	chr3:38537580	EXOG	-0.32	-5.54	-0.32	7.32e-8	Electrocardiographic conduction measures;
CESC	cis	rs7116495	0.609	rs595062	chr11:71809635	C/T	cg26138937	chr11:71823887	C11orf51	1.29	7.98	0.44	4.34e-14	Severe influenza A (H1N1) infection;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg09513169	chr5:178287767	ZNF354B	0.41	6.08	0.35	4.13e-9	Gambling;
CESC	cis	rs10493773	0.894	rs12067749	chr1:86197922	T/C	cg17807903	chr1:86174739	ZNHIT6	-0.42	-5.58	-0.32	5.98e-8	Urate levels in overweight individuals;
CESC	cis	rs916888	0.697	rs199516	chr17:44856485	C/T	cg14517863	chr17:44321492	NA	-0.4	-5.25	-0.31	3.08e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs11997175	1.000	rs6468203	chr8:33749572	T/A	ch.8.33884649F	chr8:33765107	NA	0.64	8.22	0.45	9.09e-15	Body mass index;
CESC	cis	rs9611565	0.765	rs132909	chr22:41802031	G/A	cg03806693	chr22:41940476	POLR3H	1.04	12.37	0.61	4.76e-28	Vitiligo;
CESC	cis	rs2742234	0.541	rs2742235	chr10:43616325	A/G	cg07801480	chr10:43725741	RASGEF1A	0.4	5.26	0.31	3.01e-7	Hirschsprung disease;
CESC	cis	rs6598955	0.671	rs12116908	chr1:26587918	G/A	cg19743891	chr1:26644573	UBXN11;CD52	0.37	5.19	0.3	4.16e-7	Obesity-related traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27612058	chr17:30228670	UTP6	0.59	6.56	0.37	2.82e-10	Gut microbiome composition (summer);
CESC	cis	rs9811920	0.928	rs9865713	chr3:99870299	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.43	7.02	0.4	1.81e-11	Axial length;
CESC	cis	rs13108904	0.935	rs2199956	chr4:1248919	A/G	cg16405210	chr4:1374714	KIAA1530	-0.41	-5.36	-0.31	1.85e-7	Obesity-related traits;
CESC	cis	rs9611565	0.649	rs79005	chr22:41835544	G/A	cg03806693	chr22:41940476	POLR3H	1.13	15.27	0.68	3.52e-38	Vitiligo;
CESC	cis	rs8049040	0.524	rs891125	chr16:71431621	C/T	cg08717414	chr16:71523259	ZNF19	-0.63	-6.94	-0.39	3.06e-11	Blood protein levels;
CESC	cis	rs11718455	0.767	rs6785433	chr3:43964265	A/G	cg08738300	chr3:44038990	NA	0.44	5.82	0.34	1.65e-8	Coronary artery disease;
CESC	cis	rs796364	0.806	rs1106400	chr2:201004089	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.64	-6.04	-0.35	5.26e-9	Schizophrenia;
CESC	trans	rs10156309	0.732	rs12542711	chr8:63489846	C/T	cg01805890	chr16:75271872	BCAR1	-0.65	-6.16	-0.35	2.65e-9	Allergic rhinitis;
CESC	cis	rs858239	0.699	rs955187	chr7:23194605	A/G	cg27449745	chr7:23145252	KLHL7	0.4	5.09	0.3	6.92e-7	Cerebrospinal fluid biomarker levels;
CESC	cis	rs4253772	0.637	rs56017104	chr22:46651982	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.59	5.16	0.3	4.74e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs875971	0.660	rs13224319	chr7:66007363	A/G	cg11764359	chr7:65958608	NA	0.72	9.69	0.51	3.24e-19	Aortic root size;
CESC	cis	rs875971	0.964	rs55748098	chr7:65763618	T/C	cg12463550	chr7:65579703	CRCP	-0.54	-6.93	-0.39	3.25e-11	Aortic root size;
CESC	cis	rs6024905	0.587	rs1579101	chr20:36966334	C/T	cg07053727	chr20:36965646	BPI	0.53	8.63	0.47	5.94e-16	Bipolar disorder and schizophrenia;
CESC	cis	rs3733585	0.699	rs28837683	chr4:9959808	C/T	cg00071950	chr4:10020882	SLC2A9	-0.73	-11.91	-0.59	1.82e-26	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs13108904	0.518	rs4974603	chr4:1343168	C/T	cg13395646	chr4:1353034	KIAA1530	-0.53	-6.63	-0.38	1.83e-10	Obesity-related traits;
CESC	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg16145915	chr7:1198662	ZFAND2A	-0.78	-13.36	-0.63	1.73e-31	Longevity;Endometriosis;
CESC	trans	rs2727020	0.658	rs7120136	chr11:49384358	A/C	cg15704280	chr7:45808275	SEPT13	-0.91	-15.87	-0.7	2.58e-40	Coronary artery disease;
CESC	cis	rs7811142	0.830	rs11761426	chr7:99956893	A/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.08	11.0	0.56	1.98e-23	Platelet count;
CESC	cis	rs6502050	0.835	rs10163483	chr17:80110396	C/A	cg11859384	chr17:80120422	CCDC57	-0.39	-5.31	-0.31	2.34e-7	Life satisfaction;
CESC	cis	rs9916302	0.904	rs12952384	chr17:37669536	T/C	cg00129232	chr17:37814104	STARD3	-0.54	-7.13	-0.4	9.71e-12	Glomerular filtration rate (creatinine);
CESC	cis	rs7666738	0.924	rs11097592	chr4:98927532	C/T	cg17366294	chr4:99064904	C4orf37	0.52	7.03	0.4	1.71e-11	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2243480	0.901	rs12530490	chr7:65691647	G/A	cg12463550	chr7:65579703	CRCP	-0.74	-5.73	-0.33	2.74e-8	Diabetic kidney disease;
CESC	cis	rs2070677	0.935	rs13376793	chr10:135421344	C/G	cg20169779	chr10:135381914	SYCE1	-0.74	-9.88	-0.52	8.58e-20	Gout;
CESC	cis	rs1862618	0.573	rs2591962	chr5:56237155	G/A	cg24531977	chr5:56204891	C5orf35	1.0	13.17	0.63	8.1e-31	Initial pursuit acceleration;
CESC	cis	rs1008375	0.931	rs6813374	chr4:17649494	T/C	cg02297831	chr4:17616191	MED28	0.61	7.82	0.43	1.23e-13	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs6493487	0.512	rs11070825	chr15:51249529	C/A	cg02338191	chr15:51200825	AP4E1	0.63	5.86	0.34	1.39e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs9796	0.689	rs9888710	chr15:41446153	G/C	cg20272979	chr15:41787780	ITPKA	0.34	5.11	0.3	6.31e-7	Menopause (age at onset);
CESC	cis	rs2479106	0.570	rs10986088	chr9:126443959	C/T	cg16191174	chr9:126692580	DENND1A	0.4	5.4	0.31	1.5e-7	Polycystic ovary syndrome;
CESC	cis	rs9916302	0.904	rs2338798	chr17:37547269	T/C	cg00129232	chr17:37814104	STARD3	0.6	8.02	0.44	3.47e-14	Glomerular filtration rate (creatinine);
CESC	cis	rs1862618	0.671	rs2591970	chr5:56232595	T/C	cg24549020	chr5:56110836	MAP3K1	-0.47	-5.95	-0.34	8.25e-9	Initial pursuit acceleration;
CESC	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg26304593	chr6:42947056	PEX6	-0.41	-5.16	-0.3	4.8e-7	Alzheimer's disease in APOE e4+ carriers;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19134567	chr3:128444816	RAB7A	-0.57	-5.99	-0.35	6.68e-9	Gut microbiome composition (summer);
CESC	cis	rs2439831	1.000	rs2439841	chr15:43734749	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.9	10.38	0.54	2.15e-21	Lung cancer in ever smokers;
CESC	cis	rs9486719	1.000	rs9486719	chr6:97060124	G/A	cg18709589	chr6:96969512	KIAA0776	-0.46	-5.66	-0.33	4e-8	Migraine;Coronary artery disease;
CESC	trans	rs2109514	0.505	rs1633714	chr7:116022538	C/T	cg26736154	chr15:37020592	C15orf41	0.41	6.24	0.36	1.73e-9	Prevalent atrial fibrillation;
CESC	cis	rs2985684	0.948	rs12897941	chr14:50016701	G/C	cg02151108	chr14:50098012	C14orf104	-0.38	-5.05	-0.3	8.37e-7	Carotid intima media thickness;
CESC	cis	rs4555082	0.957	rs2975216	chr14:105713134	T/C	cg27165867	chr14:105738592	BRF1	-0.51	-6.03	-0.35	5.55e-9	Mean platelet volume;Platelet distribution width;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03651852	chr6:52285170	EFHC1	0.58	6.28	0.36	1.38e-9	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03655016	chr12:49453990	NA	0.54	6.14	0.35	2.97e-9	Gut microbiome composition (summer);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg08573313	chr7:94139369	CASD1	0.5	6.19	0.36	2.28e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs4819052	0.851	rs7275870	chr21:46671214	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.45	5.62	0.33	4.81e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs13191362	1.000	rs35126854	chr6:163012443	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.82	8.69	0.47	3.96e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs9733	0.596	rs72700897	chr1:150626038	C/G	cg09365446	chr1:150670422	GOLPH3L	0.42	5.98	0.34	7.35e-9	Tonsillectomy;
CESC	trans	rs7937682	0.889	rs11213971	chr11:111529829	A/G	cg18187862	chr3:45730750	SACM1L	0.48	6.19	0.36	2.22e-9	Primary sclerosing cholangitis;
CESC	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg17178900	chr1:205818956	PM20D1	0.79	12.8	0.62	1.57e-29	Menarche (age at onset);
CESC	cis	rs12474201	0.822	rs897530	chr2:46948150	C/G	cg06386533	chr2:46925753	SOCS5	0.84	11.45	0.58	6.18e-25	Height;
CESC	cis	rs6032067	0.571	rs6017536	chr20:43907369	G/T	cg10761708	chr20:43804764	PI3	0.38	5.05	0.3	8.34e-7	Blood protein levels;
CESC	trans	rs2121875	0.667	rs10079810	chr5:44219951	A/G	cg07292773	chr6:156718177	NA	-0.47	-6.01	-0.35	6.16e-9	Prostate cancer;
CESC	cis	rs6582630	0.555	rs35186318	chr12:38295822	C/T	cg26384229	chr12:38710491	ALG10B	-0.45	-5.9	-0.34	1.13e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs798554	0.757	rs1182177	chr7:2874540	C/T	cg13628971	chr7:2884303	GNA12	0.59	7.58	0.42	5.65e-13	Height;
CESC	cis	rs8044868	0.541	rs7202268	chr16:72086746	A/G	cg01557791	chr16:72042693	DHODH	-0.43	-5.83	-0.34	1.61e-8	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CESC	cis	rs9896933	0.723	rs7224189	chr17:80782227	C/T	cg15664640	chr17:80829946	TBCD	-0.55	-6.33	-0.36	1.06e-9	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
CESC	cis	rs4450798	0.649	rs4234518	chr3:13785373	C/T	cg23332027	chr3:13681764	NA	0.4	5.58	0.32	5.95e-8	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs1005277	0.579	rs2749612	chr10:38488610	G/A	cg00409905	chr10:38381863	ZNF37A	-0.48	-6.34	-0.36	9.88e-10	Extrinsic epigenetic age acceleration;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16652648	chr2:197791396	PGAP1	0.56	6.73	0.38	1.02e-10	Gut microbiome composition (summer);
CESC	cis	rs2066819	1.000	rs59295315	chr12:56708576	G/A	cg26714650	chr12:56694279	CS	-1.48	-9.9	-0.52	7.03e-20	Psoriasis vulgaris;
CESC	cis	rs2243480	1.000	rs78803505	chr7:65382572	A/T	cg18252515	chr7:66147081	NA	-1.0	-9.22	-0.49	9.27e-18	Diabetic kidney disease;
CESC	cis	rs2637266	1.000	rs10824431	chr10:78356622	C/A	cg18941641	chr10:78392320	NA	0.42	7.79	0.43	1.49e-13	Pulmonary function;
CESC	cis	rs9916302	0.904	rs612194	chr17:37442707	T/A	cg07936489	chr17:37558343	FBXL20	0.78	11.12	0.56	7.9e-24	Glomerular filtration rate (creatinine);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06872435	chr12:43031000	NA	-0.63	-7.48	-0.42	1.08e-12	Gut microbiome composition (summer);
CESC	cis	rs6879260	1.000	rs7730585	chr5:179733440	T/C	cg23221052	chr5:179740743	GFPT2	-0.55	-7.36	-0.41	2.32e-12	Height;
CESC	cis	rs631288	0.793	rs1822312	chr1:146687250	A/T	cg25205988	chr1:146714368	CHD1L	-1.18	-6.79	-0.38	7.51e-11	PR interval in Tripanosoma cruzi seropositivity;
CESC	trans	rs7829975	0.774	rs1039915	chr8:8679614	T/C	cg21775007	chr8:11205619	TDH	0.41	6.11	0.35	3.58e-9	Mood instability;
CESC	cis	rs1862618	0.853	rs832565	chr5:56150803	T/G	cg22800045	chr5:56110881	MAP3K1	0.83	9.99	0.52	3.76e-20	Initial pursuit acceleration;
CESC	cis	rs7666738	0.861	rs13139309	chr4:99020916	A/G	cg03467027	chr4:99064603	C4orf37	0.46	5.81	0.34	1.8e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11249608	0.548	rs7733072	chr5:178456007	A/G	cg21905437	chr5:178450457	ZNF879	0.6	8.73	0.47	2.84e-16	Pubertal anthropometrics;
CESC	trans	rs57221529	0.766	rs72703070	chr5:590458	T/C	cg25482853	chr8:67687455	SGK3	1.0	10.02	0.52	2.99e-20	Lung disease severity in cystic fibrosis;
CESC	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg17178900	chr1:205818956	PM20D1	-0.78	-12.65	-0.61	5.15e-29	Menarche (age at onset);
CESC	cis	rs72615157	0.539	rs12673441	chr7:99670328	A/T	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.42	5.12	0.3	5.94e-7	Lung function (FEV1/FVC);
CESC	cis	rs17739794	0.677	rs17739674	chr8:801584	G/T	cg20652464	chr8:752313	NA	-0.29	-5.22	-0.31	3.6e-7	Clozapine-induced cytotoxicity;
CESC	cis	rs2262909	0.962	rs408687	chr19:22231123	T/C	cg11619707	chr19:22235551	ZNF257	-0.32	-5.26	-0.31	2.94e-7	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
CESC	cis	rs2933343	0.700	rs876754	chr3:128627753	T/C	cg24203234	chr3:128598194	ACAD9	0.43	5.82	0.34	1.74e-8	IgG glycosylation;
CESC	cis	rs7949030	0.626	rs7943191	chr11:62328551	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.65	10.08	0.53	1.98e-20	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs6547741	0.775	rs11692692	chr2:27861707	G/A	cg27432699	chr2:27873401	GPN1	-0.61	-8.69	-0.47	3.72e-16	Oral cavity cancer;
CESC	cis	rs4803468	1.000	rs10417311	chr19:41902038	G/A	cg09537434	chr19:41945824	ATP5SL	-1.06	-19.22	-0.76	3.86e-52	Height;
CESC	cis	rs12291225	0.585	rs4517475	chr11:14386145	A/G	cg19336497	chr11:14380999	RRAS2	-0.45	-6.62	-0.38	1.98e-10	Sense of smell;
CESC	cis	rs11583043	0.667	rs4617425	chr1:101543205	C/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.51	5.41	0.32	1.42e-7	Ulcerative colitis;Inflammatory bowel disease;
CESC	cis	rs1595825	0.945	rs1518369	chr2:198859183	C/T	cg00982548	chr2:198649783	BOLL	-0.44	-5.03	-0.3	8.89e-7	Ulcerative colitis;
CESC	trans	rs61931739	0.517	rs11053063	chr12:34181011	C/T	cg13010199	chr12:38710504	ALG10B	0.48	5.99	0.35	6.66e-9	Morning vs. evening chronotype;
CESC	cis	rs9322193	0.962	rs9689447	chr6:150110486	T/A	cg13206674	chr6:150067644	NUP43	0.41	5.78	0.33	2.05e-8	Lung cancer;
CESC	cis	rs34779708	0.931	rs17591135	chr10:35465190	T/A	cg04310649	chr10:35416472	CREM	-0.52	-6.34	-0.36	9.84e-10	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs56235845	0.694	rs11738681	chr5:176761535	A/G	cg17509989	chr5:176798049	RGS14	0.49	6.2	0.36	2.16e-9	Hemoglobin concentration;Hematocrit;
CESC	cis	rs4843747	0.671	rs72818577	chr16:88111181	G/A	cg03395651	chr16:88107091	BANP	0.45	5.21	0.3	3.84e-7	Menopause (age at onset);
CESC	cis	rs9828933	0.938	rs2578011	chr3:64004819	C/T	cg16258503	chr3:63850278	ATXN7;THOC7	-0.61	-6.2	-0.36	2.15e-9	Type 2 diabetes;
CESC	cis	rs854765	0.565	rs854768	chr17:18018806	T/C	cg04398451	chr17:18023971	MYO15A	-0.77	-11.43	-0.57	7.2e-25	Total body bone mineral density;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg16008945	chr10:14996031	DCLRE1C	-0.45	-6.48	-0.37	4.38e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs2294693	0.947	rs736793	chr6:40997919	A/T	cg14418226	chr6:40996092	UNC5CL	0.53	6.66	0.38	1.59e-10	Gastric cancer;Non-cardia gastric cancer;
CESC	cis	rs7520050	0.807	rs6429576	chr1:46216575	T/C	cg03146154	chr1:46216737	IPP	0.51	6.79	0.39	7.23e-11	Red blood cell count;Reticulocyte count;
CESC	cis	rs2180341	0.960	rs9375503	chr6:127677071	T/C	cg27446573	chr6:127587934	RNF146	1.06	15.51	0.69	4.62e-39	Breast cancer;
CESC	cis	rs875971	0.830	rs6950137	chr7:65976610	G/A	cg12463550	chr7:65579703	CRCP	0.49	6.11	0.35	3.61e-9	Aortic root size;
CESC	cis	rs10751667	0.560	rs7924794	chr11:962745	A/T	cg20946044	chr11:1010712	AP2A2	-0.38	-5.24	-0.31	3.33e-7	Alzheimer's disease (late onset);
CESC	cis	rs35306767	0.903	rs12769002	chr10:927666	C/G	cg20503657	chr10:835505	NA	-1.04	-9.71	-0.51	2.96e-19	Eosinophil percentage of granulocytes;
CESC	cis	rs4423214	1.000	rs12790558	chr11:71170905	T/C	cg05163923	chr11:71159392	DHCR7	0.78	10.34	0.54	2.91e-21	Vitamin D levels;
CESC	cis	rs1797081	1.000	rs812426	chr10:16857133	C/G	cg23933602	chr10:16859644	RSU1	1.13	23.72	0.82	1.72e-67	Platelet distribution width;
CESC	trans	rs1728785	1.000	rs1170426	chr16:68603798	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.65	7.93	0.44	6e-14	Ulcerative colitis;
CESC	cis	rs7555523	0.887	rs2814471	chr1:165739598	C/T	cg24409356	chr1:165738333	TMCO1	0.99	8.52	0.46	1.2e-15	Intraocular pressure;Glaucoma (high intraocular pressure);
CESC	cis	rs637571	0.512	rs660118	chr11:65735174	G/C	cg17985854	chr11:65770987	BANF1;EIF1AD	0.42	6.14	0.35	2.94e-9	Eosinophil percentage of white cells;
CESC	trans	rs7395662	0.500	rs1304199	chr11:48699032	A/G	cg15704280	chr7:45808275	SEPT13	-0.51	-6.12	-0.35	3.31e-9	HDL cholesterol;
CESC	cis	rs36051895	0.659	rs7045491	chr9:5045658	G/A	cg02405213	chr9:5042618	JAK2	-0.43	-5.31	-0.31	2.36e-7	Pediatric autoimmune diseases;
CESC	cis	rs10504229	0.683	rs6984765	chr8:58127124	T/C	cg02725872	chr8:58115012	NA	-0.45	-6.84	-0.39	5.31e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs1707322	1.000	rs6682683	chr1:46342337	A/G	cg03146154	chr1:46216737	IPP	0.71	9.86	0.52	9.69e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9322193	0.962	rs4552	chr6:150132319	A/T	cg13206674	chr6:150067644	NUP43	0.42	5.83	0.34	1.65e-8	Lung cancer;
CESC	cis	rs10256972	0.786	rs3735686	chr7:1062527	G/A	cg07308232	chr7:1071921	C7orf50	-0.53	-7.31	-0.41	3.11e-12	Longevity;Endometriosis;
CESC	cis	rs193541	0.632	rs7735618	chr5:122176245	C/G	cg19412675	chr5:122181750	SNX24	0.45	5.22	0.31	3.69e-7	Glucose homeostasis traits;
CESC	cis	rs7615952	0.512	rs1077621	chr3:125819799	A/G	cg04553112	chr3:125709451	NA	-0.54	-5.82	-0.34	1.71e-8	Blood pressure (smoking interaction);
CESC	cis	rs3862030	0.503	rs6584506	chr10:104254428	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.54	7.43	0.42	1.49e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
CESC	cis	rs7674212	0.539	rs7676041	chr4:104126421	T/A	cg16532752	chr4:104119610	CENPE	-0.4	-5.46	-0.32	1.09e-7	Type 2 diabetes;
CESC	cis	rs1448094	0.549	rs4919770	chr12:86238050	G/T	cg00310523	chr12:86230176	RASSF9	0.35	5.23	0.31	3.47e-7	Major depressive disorder;
CESC	cis	rs9640161	0.742	rs2108854	chr7:150017408	C/T	cg10018233	chr7:150070692	REPIN1	-0.44	-7.09	-0.4	1.21e-11	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs12477438	0.765	rs6737257	chr2:99683330	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.64	-8.73	-0.47	2.94e-16	Chronic sinus infection;
CESC	cis	rs6736093	0.799	rs13025651	chr2:112777853	A/G	cg12686935	chr2:112915763	FBLN7	-0.41	-5.32	-0.31	2.2e-7	Coronary artery disease;
CESC	cis	rs634534	0.591	rs688862	chr11:65733393	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.55	7.17	0.4	7.59e-12	Sum eosinophil basophil counts;Eosinophil counts;
CESC	cis	rs796364	0.951	rs281776	chr2:200834282	T/G	cg23649088	chr2:200775458	C2orf69	0.54	5.16	0.3	4.75e-7	Schizophrenia;
CESC	cis	rs6502050	0.765	rs6502074	chr17:80121776	T/C	cg11859384	chr17:80120422	CCDC57	-0.38	-5.24	-0.31	3.29e-7	Life satisfaction;
CESC	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg23034840	chr1:205782522	SLC41A1	0.63	7.43	0.42	1.46e-12	Menarche (age at onset);
CESC	cis	rs9902453	0.904	rs7219456	chr17:28374112	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.67	-8.69	-0.47	3.79e-16	Coffee consumption (cups per day);
CESC	cis	rs2832077	0.527	rs59730679	chr21:30226244	T/C	cg24692254	chr21:30365293	RNF160	-0.66	-9.15	-0.49	1.56e-17	Cognitive test performance;
CESC	cis	rs4253772	0.550	rs6007819	chr22:46704916	C/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.67	6.46	0.37	5.02e-10	LDL cholesterol;Cholesterol, total;
CESC	cis	rs113835537	0.529	rs7950407	chr11:66258006	A/G	cg24851651	chr11:66362959	CCS	0.45	5.77	0.33	2.24e-8	Airway imaging phenotypes;
CESC	cis	rs7100689	0.646	rs2095994	chr10:82127956	G/A	cg00277334	chr10:82204260	NA	-0.58	-7.76	-0.43	1.84e-13	Post bronchodilator FEV1;
CESC	cis	rs10911251	0.546	rs10911260	chr1:183106230	A/C	ch.1.3577855R	chr1:183094577	LAMC1	-0.79	-12.58	-0.61	9.29e-29	Colorectal cancer;
CESC	cis	rs1018836	0.923	rs4735256	chr8:91612145	C/G	cg16814680	chr8:91681699	NA	-0.71	-10.08	-0.53	1.96e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs1218582	0.710	rs4845685	chr1:154878300	C/A	cg06221963	chr1:154839813	KCNN3	-0.66	-11.39	-0.57	1.03e-24	Prostate cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23274912	chr8:67898781	NA	-0.55	-6.35	-0.36	9.32e-10	Gut microbiome composition (summer);
CESC	cis	rs80130819	0.748	rs2932095	chr12:48658212	C/T	cg05342945	chr12:48394962	COL2A1	-0.49	-5.26	-0.31	3.01e-7	Prostate cancer;
CESC	cis	rs911555	0.755	rs7148567	chr14:103882234	C/T	cg12935359	chr14:103987150	CKB	-0.56	-8.0	-0.44	3.82e-14	Intelligence (multi-trait analysis);
CESC	cis	rs9583531	0.600	rs4773241	chr13:111363021	A/G	cg24331049	chr13:111365604	ING1	0.8	11.87	0.59	2.44e-26	Coronary artery disease;
CESC	cis	rs3858526	0.883	rs7481882	chr11:5944221	A/G	cg02574844	chr11:5959923	NA	-0.45	-5.47	-0.32	1.05e-7	DNA methylation (variation);
CESC	cis	rs2290159	0.800	rs60953453	chr3:12654921	C/A	cg23032965	chr3:12705835	RAF1	0.54	5.86	0.34	1.35e-8	Cholesterol, total;
CESC	cis	rs9902453	0.689	rs56788338	chr17:28186557	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	8.8	0.48	1.86e-16	Coffee consumption (cups per day);
CESC	trans	rs877282	1.000	rs2004479	chr10:770854	G/A	cg22713356	chr15:30763199	NA	1.15	11.42	0.57	7.63e-25	Uric acid levels;
CESC	cis	rs801193	0.569	rs2659893	chr7:66199993	G/A	cg18252515	chr7:66147081	NA	-0.47	-6.41	-0.37	6.57e-10	Aortic root size;
CESC	cis	rs919433	0.927	rs13032495	chr2:198189346	C/T	cg20885578	chr2:198174922	NA	-0.4	-5.28	-0.31	2.73e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg18466340	chr20:50417476	SALL4	-0.47	-6.51	-0.37	3.81e-10	Gut microbiota (bacterial taxa);
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg00930706	chr16:88752925	MGC23284;SNAI3	-0.42	-6.26	-0.36	1.54e-9	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg21229253	chr9:134406525	UCK1	-0.45	-6.07	-0.35	4.38e-9	Fibrinogen levels;
CESC	cis	rs7618915	0.501	rs2336146	chr3:52626646	A/G	cg07507251	chr3:52567010	NT5DC2	0.32	5.5	0.32	8.74e-8	Bipolar disorder;
CESC	cis	rs11098499	0.909	rs10014719	chr4:120320715	G/A	cg09307838	chr4:120376055	NA	0.91	12.48	0.61	2.07e-28	Corneal astigmatism;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg24218925	chr19:2578938	GNG7	-0.43	-6.39	-0.37	7.41e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs896854	0.738	rs509594	chr8:95967156	C/G	cg23172400	chr8:95962367	TP53INP1	0.4	7.44	0.42	1.38e-12	Type 2 diabetes;
CESC	cis	rs7666738	0.791	rs2865953	chr4:99040319	C/T	cg17366294	chr4:99064904	C4orf37	0.61	8.76	0.47	2.3e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs78456975	0.527	rs10184112	chr2:1571112	A/G	cg26248373	chr2:1572462	NA	-0.6	-6.98	-0.39	2.43e-11	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs17826219	0.568	rs7213925	chr17:29121634	A/G	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.1e-10	Body mass index;
CESC	cis	rs9291683	0.609	rs12507050	chr4:10007305	G/T	cg02734326	chr4:10020555	SLC2A9	0.48	7.12	0.4	1.02e-11	Bone mineral density;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16731429	chr12:122268654	SETD1B	-0.64	-7.97	-0.44	4.76e-14	Gut microbiome composition (summer);
CESC	cis	rs7647973	0.626	rs4855846	chr3:49683526	G/A	cg06212747	chr3:49208901	KLHDC8B	0.64	7.76	0.43	1.84e-13	Menarche (age at onset);
CESC	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg22907277	chr7:1156413	C7orf50	0.36	5.12	0.3	5.74e-7	Longevity;Endometriosis;
CESC	cis	rs7017914	0.967	rs12679261	chr8:71844649	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.18	-0.3	4.4e-7	Bone mineral density;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02855078	chr16:188863	C16orf35	-0.7	-8.67	-0.47	4.28e-16	Gut microbiome composition (summer);
CESC	cis	rs10789491	1.000	rs4097354	chr1:47187073	T/G	cg15501359	chr1:47185051	KIAA0494	0.75	7.97	0.44	4.62e-14	Response to hepatitis C treatment;
CESC	cis	rs875971	0.651	rs313829	chr7:65552497	A/G	cg18876405	chr7:65276391	NA	-0.45	-5.35	-0.31	1.89e-7	Aortic root size;
CESC	cis	rs116095464	0.614	rs56299325	chr5:220594	C/T	cg10591111	chr5:226296	SDHA	-0.51	-6.35	-0.36	9.22e-10	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02931907	chr8:94753245	RBM12B	-0.55	-6.49	-0.37	4.19e-10	Gut microbiome composition (summer);
CESC	cis	rs752010	0.746	rs10890146	chr1:42089389	G/A	cg06885757	chr1:42089581	HIVEP3	0.53	9.1	0.49	2.23e-17	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs155076	1.000	rs2783107	chr13:21837532	C/A	cg11317459	chr13:21872234	NA	-1.01	-10.78	-0.55	1.07e-22	White matter hyperintensity burden;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg05642746	chr17:8024095	HES7	0.48	6.78	0.38	7.79e-11	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs897984	0.511	rs7196726	chr16:31092075	G/A	cg00531865	chr16:30841666	NA	-0.39	-5.47	-0.32	1.03e-7	Dementia with Lewy bodies;
CESC	cis	rs3092073	0.624	rs3848719	chr20:44596545	G/A	cg27529037	chr20:44575021	PCIF1	0.64	9.82	0.52	1.25e-19	Intelligence (multi-trait analysis);
CESC	cis	rs7949030	0.588	rs2512562	chr11:62312156	A/G	cg02375832	chr11:62437615	C11orf48	-0.36	-5.27	-0.31	2.83e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs7944584	0.511	rs10838731	chr11:47607135	C/T	cg10504702	chr11:47789108	FNBP4	0.42	5.22	0.31	3.66e-7	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CESC	trans	rs61931739	0.500	rs7979769	chr12:34509522	C/T	cg26384229	chr12:38710491	ALG10B	0.71	10.63	0.55	3.31e-22	Morning vs. evening chronotype;
CESC	cis	rs12136530	0.681	rs6426798	chr1:19719728	C/T	cg25210609	chr1:19642293	PQLC2	0.3	5.11	0.3	6.15e-7	Lead levels in blood;
CESC	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg07167872	chr1:205819463	PM20D1	0.73	11.69	0.58	1.01e-25	Menarche (age at onset);
CESC	cis	rs4683142	0.518	rs4682801	chr3:46021218	G/T	cg18004856	chr3:46029278	FYCO1	0.4	5.47	0.32	1.03e-7	Methadone dose in opioid dependence;
CESC	cis	rs40363	0.645	rs250629	chr16:3525431	C/A	cg22508957	chr16:3507546	NAT15	0.57	9.47	0.5	1.63e-18	Tuberculosis;
CESC	cis	rs611744	0.573	rs674580	chr8:109251690	C/G	cg21045802	chr8:109455806	TTC35	0.56	7.02	0.4	1.89e-11	Dupuytren's disease;
CESC	cis	rs9916302	0.904	rs9905432	chr17:37555918	C/A	cg07936489	chr17:37558343	FBXL20	0.8	11.5	0.58	4.2e-25	Glomerular filtration rate (creatinine);
CESC	cis	rs703842	0.616	rs10877023	chr12:58224199	C/A	cg02175503	chr12:58329896	NA	0.47	5.76	0.33	2.28e-8	Multiple sclerosis;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04902049	chr1:36622448	MAP7D1	0.49	6.57	0.37	2.71e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs8180040	0.587	rs1466741	chr3:47247214	C/T	cg27129171	chr3:47204927	SETD2	-0.65	-9.57	-0.51	8.03e-19	Colorectal cancer;
CESC	cis	rs5758659	0.714	rs2413668	chr22:42505841	G/A	cg15557168	chr22:42548783	NA	0.43	6.72	0.38	1.11e-10	Cognitive function;
CESC	cis	rs12971120	0.947	rs34676212	chr18:72170006	A/G	cg25817165	chr18:72167213	CNDP2	-0.57	-7.93	-0.44	6.09e-14	Refractive error;
CESC	cis	rs1552244	1.000	rs111392584	chr3:10075991	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.88	12.05	0.59	5.97e-27	Alzheimer's disease;
CESC	trans	rs9784649	0.641	rs72755823	chr5:25075537	T/C	cg08600765	chr20:34638493	LOC647979	-0.66	-6.82	-0.39	6.2e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs6460942	0.591	rs62448729	chr7:12333720	G/C	cg20607287	chr7:12443886	VWDE	-0.63	-6.83	-0.39	5.83e-11	Coronary artery disease;
CESC	cis	rs11711311	1.000	rs12497716	chr3:113453258	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.64	8.85	0.48	1.26e-16	IgG glycosylation;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00429618	chr9:99962350	ZNF322B	-0.59	-7.24	-0.41	4.91e-12	Gut microbiome composition (summer);
CESC	cis	rs1707322	0.927	rs6690386	chr1:46253011	C/T	cg03146154	chr1:46216737	IPP	0.79	11.17	0.57	5.6e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7512552	0.839	rs1260367	chr1:150344514	C/T	cg15654264	chr1:150340011	RPRD2	0.39	5.25	0.31	3.16e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs4642101	0.765	rs6791647	chr3:12826425	C/T	cg24848339	chr3:12840334	CAND2	-0.39	-6.07	-0.35	4.37e-9	QRS complex (12-leadsum);
CESC	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg26338869	chr17:61819248	STRADA	0.69	9.21	0.49	1.05e-17	Prudent dietary pattern;
CESC	cis	rs881375	0.715	rs10818482	chr9:123648085	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.41	-5.67	-0.33	3.75e-8	Rheumatoid arthritis;
CESC	cis	rs798766	0.779	rs3134866	chr4:1723265	A/G	cg05874882	chr4:1763078	NA	-0.6	-8.45	-0.46	1.98e-15	Bladder cancer;Urinary bladder cancer;
CESC	cis	rs11696501	0.694	rs6073825	chr20:44258217	T/C	cg11783356	chr20:44313418	WFDC10B	-0.35	-5.38	-0.31	1.63e-7	Brain structure;
CESC	cis	rs1062177	0.756	rs2915817	chr5:151115517	T/C	cg00977110	chr5:151150581	G3BP1	-0.6	-6.41	-0.37	6.53e-10	Preschool internalizing problems;
CESC	cis	rs7647973	0.626	rs2131108	chr3:49665390	C/T	cg06212747	chr3:49208901	KLHDC8B	0.58	7.06	0.4	1.45e-11	Menarche (age at onset);
CESC	cis	rs2576037	0.526	rs1893427	chr18:44434987	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.57	-8.07	-0.44	2.52e-14	Personality dimensions;
CESC	trans	rs11252926	0.565	rs60553947	chr10:474284	T/C	cg00953403	chr17:74099816	EXOC7	-0.55	-7.01	-0.4	2.01e-11	Psychosis in Alzheimer's disease;
CESC	cis	rs6433857	0.536	rs1542035	chr2:181351114	T/C	cg23363182	chr2:181467187	NA	-0.42	-5.93	-0.34	9.42e-9	Body mass index;
CESC	cis	rs2046867	0.862	rs67961837	chr3:72840877	T/G	cg25664220	chr3:72788482	NA	-0.46	-6.57	-0.37	2.63e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CESC	cis	rs12586317	0.547	rs10146699	chr14:35483577	G/A	cg05294307	chr14:35346193	BAZ1A	-0.51	-5.48	-0.32	1.01e-7	Psoriasis;
CESC	cis	rs7772486	0.902	rs2777480	chr6:146309983	T/A	cg05347473	chr6:146136440	FBXO30	0.5	6.72	0.38	1.08e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs568617	1.000	rs641018	chr11:65655393	G/C	cg00576331	chr11:65640516	EFEMP2	-0.45	-5.35	-0.31	1.95e-7	Crohn's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02804028	chr22:31031786	SLC35E4	0.62	6.86	0.39	4.98e-11	Gut microbiome composition (summer);
CESC	cis	rs10504229	0.679	rs16921683	chr8:58053270	T/C	cg02725872	chr8:58115012	NA	-0.33	-5.04	-0.3	8.84e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs12681366	0.537	rs2197004	chr8:95456976	A/G	cg13257157	chr8:95487014	RAD54B	0.45	5.47	0.32	1.05e-7	Nonsyndromic cleft lip with cleft palate;
CESC	cis	rs372883	0.530	rs2832305	chr21:30752964	G/A	cg24692254	chr21:30365293	RNF160	0.48	5.88	0.34	1.21e-8	Pancreatic cancer;
CESC	cis	rs78456975	1.000	rs11891809	chr2:1566001	A/G	cg26248373	chr2:1572462	NA	-0.54	-5.23	-0.31	3.39e-7	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs2832191	0.740	rs2853830	chr21:30416824	A/G	cg24692254	chr21:30365293	RNF160	1.02	18.19	0.75	1.5e-48	Dental caries;
CESC	cis	rs875971	0.862	rs11984115	chr7:65773859	C/T	cg12463550	chr7:65579703	CRCP	-0.45	-5.79	-0.34	1.98e-8	Aortic root size;
CESC	cis	rs4253772	0.591	rs11704586	chr22:46685274	T/C	cg10541313	chr22:46663664	TTC38	0.72	5.15	0.3	5.01e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs2944591	0.505	rs2592127	chr2:233791648	G/T	cg11972305	chr2:233791962	NGEF	-0.33	-5.44	-0.32	1.23e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs10504229	0.683	rs58883273	chr8:58138275	A/G	cg21724239	chr8:58056113	NA	0.58	5.95	0.34	8.29e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs4713118	0.662	rs156744	chr6:27967274	G/A	cg20151795	chr6:28129481	ZNF389	0.42	5.47	0.32	1.03e-7	Parkinson's disease;
CESC	cis	rs72945132	0.660	rs7121703	chr11:70140296	C/T	cg14191688	chr11:70257035	CTTN	0.41	5.27	0.31	2.9e-7	Coronary artery disease;
CESC	cis	rs72781680	1.000	rs963725	chr2:24148231	T/C	cg08917208	chr2:24149416	ATAD2B	1.1	9.84	0.52	1.09e-19	Lymphocyte counts;
CESC	cis	rs3540	0.533	rs4932342	chr15:90982923	C/T	cg22089800	chr15:90895588	ZNF774	0.62	8.35	0.46	3.88e-15	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs10504229	0.683	rs10504225	chr8:58145121	A/T	cg22535103	chr8:58192502	C8orf71	-0.76	-8.74	-0.47	2.65e-16	Developmental language disorder (linguistic errors);
CESC	cis	rs77106637	0.932	rs2886599	chr11:72721271	C/A	cg03713592	chr11:72463424	ARAP1	1.2	10.8	0.55	8.75e-23	Type 2 diabetes;
CESC	cis	rs4780401	0.728	rs6498239	chr16:11780774	T/C	cg01061890	chr16:11836724	TXNDC11	-0.47	-6.22	-0.36	1.93e-9	Rheumatoid arthritis;
CESC	cis	rs873946	0.504	rs3829132	chr10:134579044	A/C	cg27286337	chr10:134555280	INPP5A	0.67	7.89	0.44	8.2e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs1355223	0.902	rs34875830	chr11:34722205	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.47	-6.19	-0.36	2.26e-9	Systemic lupus erythematosus and Systemic sclerosis;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg08231274	chr14:57735852	MUDENG;EXOC5	-0.45	-5.99	-0.35	6.66e-9	Height;
CESC	cis	rs72781680	0.898	rs72796152	chr2:23933626	G/A	cg08917208	chr2:24149416	ATAD2B	0.97	8.89	0.48	9.92e-17	Lymphocyte counts;
CESC	cis	rs7524258	0.868	rs10779678	chr1:7300573	A/G	cg07173049	chr1:7289937	CAMTA1	0.42	6.3	0.36	1.23e-9	Tourette's syndrome or obsessive-compulsive disorder;
CESC	cis	rs66573146	0.572	rs73199995	chr4:6955801	G/C	cg00086871	chr4:6988644	TBC1D14	1.05	6.88	0.39	4.36e-11	Granulocyte percentage of myeloid white cells;
CESC	cis	rs258892	0.895	rs253169	chr5:72118987	G/A	cg21869765	chr5:72125136	TNPO1	-0.44	-5.65	-0.33	4.05e-8	Small cell lung carcinoma;
CESC	cis	rs2033711	0.728	rs4801586	chr19:58934528	A/G	cg13877915	chr19:58951672	ZNF132	0.39	5.81	0.34	1.83e-8	Uric acid clearance;
CESC	cis	rs763121	0.853	rs5750671	chr22:39094619	A/C	cg21395723	chr22:39101663	GTPBP1	0.49	6.67	0.38	1.5e-10	Menopause (age at onset);
CESC	cis	rs2243480	1.000	rs73142122	chr7:65311298	C/A	cg25894440	chr7:65020034	NA	-0.63	-5.42	-0.32	1.33e-7	Diabetic kidney disease;
CESC	cis	rs1153858	1.000	rs11070457	chr15:45686943	A/C	cg14582100	chr15:45693742	SPATA5L1	0.42	5.88	0.34	1.22e-8	Homoarginine levels;
CESC	cis	rs7826238	0.720	rs12546760	chr8:8374836	A/G	cg15556689	chr8:8085844	FLJ10661	-0.47	-5.73	-0.33	2.76e-8	Systolic blood pressure;
CESC	cis	rs7762018	1.000	rs74900588	chr6:170102180	A/C	cg05834625	chr6:170176447	C6orf70	0.63	7.6	0.42	5.01e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs4523957	0.928	rs216183	chr17:2173923	A/G	cg16513277	chr17:2031491	SMG6	0.59	7.99	0.44	4.21e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs868036	0.681	rs4776375	chr15:68085555	G/A	cg08079166	chr15:68083412	MAP2K5	0.35	5.1	0.3	6.47e-7	Restless legs syndrome;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg02139671	chr12:123237174	DENR	-0.42	-5.99	-0.35	6.67e-9	Gambling;
CESC	cis	rs1552244	0.688	rs7645137	chr3:10020549	A/AT	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.78	-9.98	-0.52	4.19e-20	Alzheimer's disease;
CESC	trans	rs61931739	0.517	rs10844738	chr12:34059503	T/A	cg26384229	chr12:38710491	ALG10B	0.52	6.94	0.39	2.96e-11	Morning vs. evening chronotype;
CESC	cis	rs7727544	0.660	rs2631361	chr5:131707380	C/A	cg24060327	chr5:131705240	SLC22A5	0.63	8.33	0.46	4.43e-15	Blood metabolite levels;
CESC	cis	rs11711311	1.000	rs6792447	chr3:113508335	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.72	10.16	0.53	1.1e-20	IgG glycosylation;
CESC	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.89	13.48	0.64	7.04e-32	Prudent dietary pattern;
CESC	cis	rs1448094	0.580	rs11615323	chr12:86282171	T/C	cg02569458	chr12:86230093	RASSF9	0.58	8.51	0.46	1.31e-15	Major depressive disorder;
CESC	cis	rs763121	0.853	rs5750649	chr22:39036769	T/C	cg06544989	chr22:39130855	UNC84B	0.5	9.27	0.49	6.78e-18	Menopause (age at onset);
CESC	cis	rs9287719	0.614	rs10929678	chr2:10723095	T/C	cg00105475	chr2:10696890	NA	0.39	5.27	0.31	2.83e-7	Prostate cancer;
CESC	trans	rs35110281	0.805	rs2838319	chr21:44991901	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.52	6.9	0.39	3.88e-11	Mean corpuscular volume;
CESC	cis	rs10876993	0.789	rs1689600	chr12:58049645	A/T	cg18357645	chr12:58087776	OS9	0.61	9.28	0.5	6.32e-18	Celiac disease or Rheumatoid arthritis;
CESC	cis	rs763121	0.853	rs3788545	chr22:39065172	A/G	cg14440974	chr22:39074834	NA	-0.41	-5.58	-0.32	6.07e-8	Menopause (age at onset);
CESC	cis	rs4660306	1.000	rs6429567	chr1:45956700	C/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.61	-7.69	-0.43	2.86e-13	Homocysteine levels;
CESC	cis	rs8027181	1.000	rs8027181	chr15:73088869	A/T	cg25632853	chr15:73088954	NA	0.37	6.55	0.37	3.02e-10	Triglyceride levels;
CESC	cis	rs2066819	1.000	rs11575231	chr12:56744445	T/C	cg26804944	chr12:56660921	COQ10A	-0.83	-5.03	-0.3	9.17e-7	Psoriasis vulgaris;
CESC	trans	rs352242	0.721	rs9572151	chr13:69863739	T/C	cg15456293	chr8:2044148	MYOM2	-0.35	-6.0	-0.35	6.47e-9	Life satisfaction;
CESC	cis	rs34286592	1.000	rs13331733	chr16:29848417	A/G	cg27338089	chr16:29820515	MAZ	0.48	5.12	0.3	6e-7	Multiple sclerosis;
CESC	cis	rs7714584	1.000	rs12652003	chr5:150231945	T/C	cg22134413	chr5:150180641	NA	0.63	6.08	0.35	4.24e-9	Crohn's disease;
CESC	trans	rs2727020	0.521	rs11039902	chr11:48679467	A/G	cg15704280	chr7:45808275	SEPT13	-0.54	-6.6	-0.38	2.19e-10	Coronary artery disease;
CESC	cis	rs1843834	0.505	rs3820763	chr2:225347270	A/G	cg22509189	chr2:225307070	NA	0.43	5.84	0.34	1.54e-8	IgE levels in asthmatics (D.p. specific);
CESC	cis	rs72781680	0.716	rs2712079	chr2:24082061	G/A	cg08917208	chr2:24149416	ATAD2B	0.54	5.49	0.32	9.3e-8	Lymphocyte counts;
CESC	cis	rs4820539	1.000	rs5751589	chr22:23475762	A/G	cg14186256	chr22:23484241	RTDR1	-0.8	-13.93	-0.65	1.82e-33	Bone mineral density;
CESC	cis	rs853679	0.517	rs9380050	chr6:28048538	A/G	cg23161317	chr6:28129485	ZNF389	0.5	6.31	0.36	1.19e-9	Depression;
CESC	cis	rs7177699	0.557	rs3971829	chr15:79109052	A/G	cg04896959	chr15:78267971	NA	-0.33	-5.11	-0.3	6.19e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
CESC	cis	rs9399137	0.507	rs12664898	chr6:135288663	T/C	cg24558204	chr6:135376177	HBS1L	0.7	9.52	0.5	1.15e-18	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg10869401	chr11:129802046	PRDM10	0.46	6.02	0.35	5.72e-9	Fibrinogen levels;
CESC	cis	rs9814567	0.896	rs58491661	chr3:134355189	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.42	5.65	0.33	4.22e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs8020095	0.571	rs6573752	chr14:67589792	T/G	cg19548862	chr14:67692701	FAM71D	-0.51	-6.26	-0.36	1.56e-9	Depression (quantitative trait);
CESC	cis	rs12477438	0.765	rs12468807	chr2:99691994	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.75	-10.87	-0.56	5.17e-23	Chronic sinus infection;
CESC	cis	rs9486719	1.000	rs3798296	chr6:97052286	G/A	cg18709589	chr6:96969512	KIAA0776	-0.53	-5.76	-0.33	2.36e-8	Migraine;Coronary artery disease;
CESC	cis	rs1552244	0.935	rs35515831	chr3:10071362	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-10.79	-0.55	9.49e-23	Alzheimer's disease;
CESC	cis	rs2014572	0.904	rs10412465	chr19:57753931	T/C	cg12963866	chr19:57752005	ZNF805	-0.52	-6.96	-0.39	2.74e-11	Hyperactive-impulsive symptoms;
CESC	cis	rs72634258	0.945	rs67717282	chr1:8041290	C/T	cg00042356	chr1:8021962	PARK7	0.82	7.56	0.42	6.62e-13	Inflammatory bowel disease;
CESC	cis	rs9322193	0.886	rs4870055	chr6:150169569	C/T	cg13206674	chr6:150067644	NUP43	0.42	5.53	0.32	7.67e-8	Lung cancer;
CESC	cis	rs9393777	0.513	rs9368448	chr6:26649355	T/C	cg14345882	chr6:26364793	BTN3A2	0.41	5.12	0.3	5.79e-7	Intelligence (multi-trait analysis);
CESC	cis	rs9908102	0.740	rs7211210	chr17:12917352	A/G	cg26162695	chr17:12921313	ELAC2	0.55	5.9	0.34	1.12e-8	Schizophrenia;
CESC	cis	rs11098499	0.820	rs13128602	chr4:120459366	C/T	cg09307838	chr4:120376055	NA	-0.88	-12.11	-0.6	3.78e-27	Corneal astigmatism;
CESC	cis	rs3741151	0.773	rs7945825	chr11:73287140	G/C	cg17517138	chr11:73019481	ARHGEF17	1.02	7.43	0.42	1.51e-12	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs1801251	1.000	rs12478564	chr2:233598340	C/T	cg25237894	chr2:233734115	C2orf82	0.45	7.81	0.43	1.36e-13	Coronary artery disease;
CESC	cis	rs2070488	0.896	rs11914389	chr3:38527215	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.94	16.97	0.72	3.05e-44	Electrocardiographic conduction measures;
CESC	trans	rs7839040	0.698	rs13249759	chr8:82931534	A/T	cg14472086	chr9:107730925	NA	-0.48	-6.45	-0.37	5.4e-10	Response to methotrexate in juvenile idiopathic arthritis;
CESC	cis	rs10170846	0.861	rs12694582	chr2:223521955	G/C	cg25565276	chr2:223520875	FARSB	0.5	6.98	0.39	2.39e-11	Schizophrenia (inflammation and infection response interaction);
CESC	cis	rs8067354	0.645	rs72840522	chr17:57829992	G/A	cg02344993	chr17:57696989	CLTC	0.68	8.07	0.44	2.5e-14	Hemoglobin concentration;
CESC	cis	rs4906332	0.868	rs4900578	chr14:103926010	A/T	cg09975044	chr14:104007538	NA	0.47	6.45	0.37	5.25e-10	Coronary artery disease;
CESC	cis	rs858239	0.699	rs858260	chr7:23212934	G/T	cg23682824	chr7:23144976	KLHL7	0.46	5.92	0.34	1.02e-8	Cerebrospinal fluid biomarker levels;
CESC	cis	rs7116495	0.609	rs73543643	chr11:71835596	C/T	cg26138937	chr11:71823887	C11orf51	1.23	7.77	0.43	1.75e-13	Severe influenza A (H1N1) infection;
CESC	cis	rs3785574	0.962	rs7215915	chr17:61828385	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	7.25	0.41	4.65e-12	Height;
CESC	cis	rs7772486	0.790	rs9791313	chr6:146266172	T/C	cg05347473	chr6:146136440	FBXO30	-0.52	-6.88	-0.39	4.23e-11	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg11064206	chr12:123459532	OGFOD2;ABCB9	0.48	6.28	0.36	1.37e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs1797885	0.510	rs2633442	chr3:12609937	A/G	cg26432171	chr3:12704882	RAF1	0.4	5.24	0.31	3.34e-7	Immature fraction of reticulocytes;
CESC	cis	rs1008375	0.864	rs4698196	chr4:17574735	T/C	cg02297831	chr4:17616191	MED28	0.52	5.94	0.34	8.76e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs2180341	0.889	rs9321074	chr6:127618019	G/A	cg27446573	chr6:127587934	RNF146	1.08	16.13	0.7	3.14e-41	Breast cancer;
CESC	cis	rs6963495	0.745	rs73190169	chr7:105160500	A/G	cg02135003	chr7:105160482	PUS7	-0.46	-5.55	-0.32	6.92e-8	Bipolar disorder (body mass index interaction);
CESC	cis	rs8044868	0.586	rs7199261	chr16:72082788	A/G	cg01557791	chr16:72042693	DHODH	-0.43	-5.89	-0.34	1.17e-8	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CESC	cis	rs9487051	0.676	rs4383852	chr6:109594475	G/A	cg12927641	chr6:109611667	NA	-0.37	-5.56	-0.32	6.55e-8	Reticulocyte fraction of red cells;
CESC	cis	rs514406	0.861	rs1412706	chr1:53237721	G/A	cg08736216	chr1:53307985	ZYG11A	0.43	7.24	0.41	4.72e-12	Monocyte count;
CESC	cis	rs145445141	1	rs145445141	chr1:67489169	ATT/A	cg02640540	chr1:67518911	SLC35D1	0.6	6.16	0.35	2.73e-9	Neutrophil percentage of white cells;
CESC	cis	rs4243830	0.737	rs925745	chr1:6615690	A/G	cg04093404	chr1:6614507	TAS1R1;NOL9	0.55	5.04	0.3	8.45e-7	Body mass index;
CESC	cis	rs3096299	0.728	rs1011749	chr16:89510869	G/C	cg02187348	chr16:89574699	SPG7	0.65	9.22	0.49	9.59e-18	Multiple myeloma (IgH translocation);
CESC	cis	rs727505	0.866	rs73227503	chr7:124721044	A/G	cg23710748	chr7:124431027	NA	-0.4	-6.52	-0.37	3.56e-10	Lewy body disease;
CESC	trans	rs4569005	0.610	rs11605578	chr11:21063299	C/G	cg05396178	chr6:27833129	HIST1H2AL	0.63	6.07	0.35	4.51e-9	Adverse response to lamotrigine and phenytoin;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg08265790	chr5:141704696	SPRY4	0.51	6.97	0.39	2.49e-11	Thyroid stimulating hormone;
CESC	cis	rs6714710	0.603	rs1470483	chr2:98393894	C/T	cg26665480	chr2:98280029	ACTR1B	0.67	9.22	0.49	9.72e-18	Posterior cortical atrophy and Alzheimer's disease;
CESC	cis	rs7103648	0.966	rs1377416	chr11:47416746	C/T	cg03711944	chr11:47377212	SPI1	-0.31	-5.06	-0.3	7.99e-7	Diastolic blood pressure;Systolic blood pressure;
CESC	cis	rs9611565	0.592	rs5751101	chr22:41828111	C/T	cg06481639	chr22:41940642	POLR3H	0.63	6.31	0.36	1.18e-9	Vitiligo;
CESC	cis	rs10504229	0.679	rs11781858	chr8:58038406	C/T	cg14926445	chr8:58193284	C8orf71	-0.54	-5.11	-0.3	6.23e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs11098499	0.863	rs11933966	chr4:120476715	G/A	cg09307838	chr4:120376055	NA	0.91	12.68	0.61	4e-29	Corneal astigmatism;
CESC	cis	rs4819052	1.000	rs2838830	chr21:46664227	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.82	10.45	0.54	1.29e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs736801	0.808	rs4705950	chr5:131793286	C/T	cg21138405	chr5:131827807	IRF1	-0.36	-5.38	-0.31	1.63e-7	Breast cancer;Mosquito bite size;
CESC	cis	rs6964587	1.000	rs10234290	chr7:91716951	T/C	cg17063962	chr7:91808500	NA	0.58	8.06	0.44	2.57e-14	Breast cancer;
CESC	cis	rs6540559	0.673	rs6540564	chr1:210019910	T/C	cg23283495	chr1:209979779	IRF6	0.48	5.59	0.32	5.57e-8	Cleft lip with or without cleft palate;
CESC	cis	rs868036	1.000	rs868037	chr15:68054996	A/G	cg08079166	chr15:68083412	MAP2K5	-0.42	-6.59	-0.38	2.35e-10	Restless legs syndrome;
CESC	cis	rs713587	0.607	rs6725517	chr2:25129473	A/G	cg01884057	chr2:25150051	NA	0.34	6.46	0.37	4.88e-10	Body mass index in non-asthmatics;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg13749939	chr11:796434	SLC25A22	0.48	6.39	0.37	7.54e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs4891159	0.548	rs10782013	chr18:74128348	C/T	cg24786174	chr18:74118243	ZNF516	0.84	15.96	0.7	1.24e-40	Longevity;
CESC	cis	rs7520050	0.931	rs6686134	chr1:46378268	A/G	cg03146154	chr1:46216737	IPP	-0.48	-6.19	-0.36	2.33e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs2576037	0.583	rs8086286	chr18:44467515	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.39	-6.23	-0.36	1.84e-9	Personality dimensions;
CESC	cis	rs60871478	0.786	rs55899111	chr7:827843	C/G	cg13798912	chr7:905769	UNC84A	-0.56	-5.63	-0.33	4.56e-8	Cerebrospinal P-tau181p levels;
CESC	trans	rs6084875	0.641	rs4813712	chr20:4722741	A/C	cg10192164	chr16:30419175	ZNF771	-0.5	-6.13	-0.35	3.1e-9	Systemic lupus erythematosus;
CESC	cis	rs1552244	0.938	rs66915020	chr3:10110174	A/G	cg00149659	chr3:10157352	C3orf10	0.7	8.38	0.46	3.2e-15	Alzheimer's disease;
CESC	cis	rs9640161	0.673	rs11773351	chr7:150030963	T/C	cg17279839	chr7:150038598	RARRES2	0.51	5.96	0.34	8.14e-9	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg09177884	chr7:1199841	ZFAND2A	-0.65	-8.85	-0.48	1.27e-16	Longevity;Endometriosis;
CESC	cis	rs1050631	0.592	rs1785932	chr18:33719434	C/T	cg25426722	chr18:33708991	SLC39A6;ELP2	0.53	7.16	0.4	7.87e-12	Esophageal squamous cell cancer (length of survival);
CESC	cis	rs597539	0.652	rs654071	chr11:68653432	A/C	cg21963583	chr11:68658836	MRPL21	0.38	5.59	0.32	5.63e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs10465746	0.935	rs12406984	chr1:84416215	C/G	cg10977910	chr1:84465055	TTLL7	0.48	6.47	0.37	4.67e-10	Obesity-related traits;
CESC	cis	rs3749237	0.964	rs11714957	chr3:49776178	C/T	cg03060546	chr3:49711283	APEH	0.63	7.39	0.41	1.93e-12	Resting heart rate;
CESC	cis	rs3862030	0.503	rs6584506	chr10:104254428	T/C	ch.10.2196322F	chr10:104248062	ACTR1A	0.42	5.08	0.3	6.99e-7	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
CESC	cis	rs9768139	0.733	rs12698208	chr7:158117575	C/T	cg27057461	chr7:158136379	PTPRN2	-0.32	-5.17	-0.3	4.6e-7	Calcium levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10504545	chr14:74769802	ABCD4	0.59	6.69	0.38	1.29e-10	Gut microbiome composition (summer);
CESC	cis	rs992157	0.710	rs7569907	chr2:219070551	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.68	9.56	0.51	8.5e-19	Colorectal cancer;
CESC	cis	rs7017914	0.967	rs13261712	chr8:71732264	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.44	-5.68	-0.33	3.58e-8	Bone mineral density;
CESC	cis	rs9896933	0.723	rs7224189	chr17:80782227	C/T	cg19500275	chr17:80737654	TBCD	0.63	6.52	0.37	3.49e-10	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
CESC	cis	rs12681288	0.523	rs11137122	chr8:954702	A/G	cg15309053	chr8:964076	NA	0.51	8.49	0.46	1.48e-15	Schizophrenia;
CESC	cis	rs1568889	0.712	rs10835306	chr11:28302410	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.8	13.99	0.65	1.11e-33	Bipolar disorder;
CESC	cis	rs5769707	0.642	rs135880	chr22:50018654	T/A	cg05373962	chr22:49881684	NA	-0.33	-5.15	-0.3	5.18e-7	Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs4665809	1.000	rs4665817	chr2:26305167	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.83	-9.25	-0.49	7.55e-18	Gut microbiome composition (summer);
CESC	cis	rs2243480	1.000	rs1618893	chr7:66096119	C/T	cg18252515	chr7:66147081	NA	-0.87	-8.76	-0.47	2.32e-16	Diabetic kidney disease;
CESC	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg02725872	chr8:58115012	NA	-0.43	-5.86	-0.34	1.39e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs6502050	0.835	rs7207947	chr17:80145291	A/T	cg11859384	chr17:80120422	CCDC57	-0.39	-5.29	-0.31	2.51e-7	Life satisfaction;
CESC	cis	rs7618501	1.000	rs3749240	chr3:49750188	T/A	cg24308560	chr3:49941425	MST1R	0.49	6.69	0.38	1.29e-10	Intelligence (multi-trait analysis);
CESC	cis	rs2073300	0.609	rs2295238	chr20:23387946	C/G	cg12062639	chr20:23401060	NAPB	0.85	7.66	0.43	3.47e-13	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs1707322	1.000	rs6695421	chr1:46380207	T/C	cg06784218	chr1:46089804	CCDC17	0.33	5.69	0.33	3.36e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg10304803	chr17:80771384	TBCD	0.51	6.84	0.39	5.5e-11	Fibrinogen levels;
CESC	cis	rs9660992	0.736	rs1180734	chr1:205255438	A/G	cg21643547	chr1:205240462	TMCC2	-0.48	-7.48	-0.42	1.11e-12	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs13108904	0.875	rs73069950	chr4:1276045	C/A	cg22903657	chr4:1355424	KIAA1530	0.41	5.66	0.33	3.87e-8	Obesity-related traits;
CESC	cis	rs75804782	0.521	rs55973123	chr2:239416264	G/A	cg18131467	chr2:239335373	ASB1	-0.62	-5.07	-0.3	7.48e-7	Morning vs. evening chronotype;Chronotype;
CESC	cis	rs1042058	0.565	rs2480297	chr10:30754512	A/G	cg25182066	chr10:30743637	MAP3K8	-0.5	-7.05	-0.4	1.6e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CESC	cis	rs6964587	1.000	rs2299238	chr7:91654517	G/A	cg17063962	chr7:91808500	NA	0.58	8.02	0.44	3.36e-14	Breast cancer;
CESC	cis	rs11785400	0.793	rs6996760	chr8:143722386	G/A	cg10596483	chr8:143751796	JRK	0.4	5.14	0.3	5.32e-7	Schizophrenia;
CESC	cis	rs7336332	0.598	rs45622135	chr13:28011594	T/C	cg22138327	chr13:27999177	GTF3A	0.62	5.82	0.34	1.71e-8	Weight;
CESC	cis	rs2342371	0.545	rs7646273	chr3:196210894	T/C	cg15048948	chr3:196158458	UBXN7	-0.39	-5.5	-0.32	9.12e-8	Fat distribution (HIV);
CESC	cis	rs7945705	0.875	rs10769955	chr11:8784647	G/C	cg12365402	chr11:9010492	NRIP3	0.35	5.33	0.31	2.1e-7	Hemoglobin concentration;
CESC	trans	rs2727020	0.637	rs1164673	chr11:49328356	C/G	cg03929089	chr4:120376271	NA	0.55	6.91	0.39	3.65e-11	Coronary artery disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg07237882	chr5:137090689	HNRNPA0	-0.45	-6.33	-0.36	1.07e-9	Fibrinogen levels;
CESC	cis	rs10208940	0.841	rs7598760	chr2:68837054	A/G	cg12452813	chr2:68675892	NA	0.51	5.12	0.3	5.95e-7	Urate levels in lean individuals;
CESC	cis	rs8067354	0.645	rs2645486	chr17:57885901	T/A	cg13753209	chr17:57696993	CLTC	0.66	8.26	0.45	7.21e-15	Hemoglobin concentration;
CESC	cis	rs7680126	0.536	rs3796841	chr4:10007904	C/T	cg11266682	chr4:10021025	SLC2A9	0.44	5.07	0.3	7.4e-7	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	cis	rs2710642	0.849	rs4671450	chr2:62981869	C/A	cg17519650	chr2:63277830	OTX1	-0.59	-7.61	-0.42	4.72e-13	LDL cholesterol levels;LDL cholesterol;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg08862778	chr1:11322643	MTOR	0.48	6.43	0.37	5.83e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs10851478	0.872	rs4775816	chr15:49871503	A/C	cg08060515	chr15:49448048	GALK2;COPS2	0.43	5.23	0.31	3.45e-7	Oral cavity cancer;
CESC	cis	rs9894429	1.000	rs9747349	chr17:79584297	C/T	cg21984481	chr17:79567631	NPLOC4	-0.49	-8.04	-0.44	2.97e-14	Eye color traits;
CESC	cis	rs9790314	1.000	rs6775627	chr3:160953609	A/G	cg04691961	chr3:161091175	C3orf57	-0.41	-5.2	-0.3	4e-7	Morning vs. evening chronotype;
CESC	cis	rs763121	0.853	rs5750626	chr22:38977890	G/C	cg06022373	chr22:39101656	GTPBP1	0.84	12.24	0.6	1.36e-27	Menopause (age at onset);
CESC	cis	rs7107174	0.681	rs11237443	chr11:78005089	C/A	cg02023728	chr11:77925099	USP35	0.44	6.09	0.35	3.87e-9	Testicular germ cell tumor;
CESC	cis	rs6582630	0.638	rs4882309	chr12:38448595	A/G	cg26384229	chr12:38710491	ALG10B	-0.44	-5.94	-0.34	9.08e-9	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs2278034	0.578	rs881753	chr3:195606770	C/T	cg01181863	chr3:195395398	SDHAP2	0.55	7.6	0.42	5.26e-13	Bronchopulmonary dysplasia;
CESC	cis	rs2032447	0.802	rs199755	chr6:25990367	G/A	cg03517284	chr6:25882590	NA	-0.43	-5.67	-0.33	3.68e-8	Intelligence (multi-trait analysis);
CESC	cis	rs2836974	0.931	rs13625	chr21:40669083	G/T	cg11890956	chr21:40555474	PSMG1	1.17	21.55	0.8	3.39e-60	Cognitive function;
CESC	cis	rs4819052	0.851	rs1999335	chr21:46670613	A/G	cg11663144	chr21:46675770	NA	-0.64	-10.02	-0.52	2.95e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs4819052	0.851	rs2255766	chr21:46683777	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.45	5.65	0.33	4.19e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12432846	chr1:85741899	BCL10	0.58	6.42	0.37	6.4e-10	Gut microbiome composition (summer);
CESC	cis	rs951366	0.677	rs1775140	chr1:205672107	C/A	cg07157834	chr1:205819609	PM20D1	0.73	10.45	0.54	1.22e-21	Menarche (age at onset);
CESC	cis	rs12995491	0.569	rs6724281	chr2:88529531	T/G	cg18302933	chr2:88491318	NA	-0.36	-5.34	-0.31	2e-7	Response to metformin (IC50);
CESC	cis	rs4689388	0.853	rs4293850	chr4:6292020	A/C	cg14416269	chr4:6271139	WFS1	0.43	7.02	0.4	1.86e-11	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs1475911	0.671	rs12483409	chr21:43521902	G/A	cg19766460	chr21:43528205	UMODL1;C21orf128	0.95	13.26	0.63	3.99e-31	IgG glycosylation;
CESC	cis	rs2845885	1.000	rs2845885	chr11:63869062	A/G	cg24431193	chr11:63883947	FLRT1;MACROD1	0.85	7.72	0.43	2.44e-13	Body mass index;
CESC	cis	rs10883723	0.668	rs12414479	chr10:104420902	C/T	cg22532475	chr10:104410764	TRIM8	-0.43	-6.53	-0.37	3.3e-10	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.62	0.38	2e-10	Prudent dietary pattern;
CESC	cis	rs6024905	0.595	rs2022499	chr20:36966531	G/T	cg07053727	chr20:36965646	BPI	0.56	8.97	0.48	5.52e-17	Bipolar disorder and schizophrenia;
CESC	cis	rs6519955	0.796	rs4072455	chr22:46422938	T/C	cg05468064	chr22:46423449	NA	0.46	7.78	0.43	1.63e-13	Dupuytren's disease;
CESC	cis	rs17345786	0.906	rs11708616	chr3:101231731	C/T	cg12386194	chr3:101231763	SENP7	0.6	6.65	0.38	1.71e-10	Colonoscopy-negative controls vs population controls;
CESC	trans	rs629535	0.814	rs558511	chr8:70069908	C/A	cg21567404	chr3:27674614	NA	0.88	10.34	0.54	2.74e-21	Dupuytren's disease;
CESC	trans	rs4665809	0.838	rs2243834	chr2:26357748	A/C	cg09258813	chr8:37823409	ADRB3	0.35	6.04	0.35	5.31e-9	Gut microbiome composition (summer);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg02778551	chr7:1045947	C7orf50	0.49	7.03	0.4	1.71e-11	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs6676180	0.555	rs947430	chr1:119778734	G/A	cg05756136	chr1:119680316	WARS2	-0.41	-5.34	-0.31	1.95e-7	Monobrow;
CESC	cis	rs7927771	0.524	rs61895760	chr11:47794538	G/C	cg18512352	chr11:47633146	NA	0.33	5.17	0.3	4.51e-7	Subjective well-being;
CESC	cis	rs6732160	0.691	rs1960233	chr2:73421378	A/G	cg01422370	chr2:73384389	NA	0.43	7.29	0.41	3.57e-12	Intelligence (multi-trait analysis);
CESC	cis	rs2997447	0.706	rs61776574	chr1:26429492	C/T	cg24596570	chr1:26146463	FAM54B;LOC646471	0.66	5.46	0.32	1.07e-7	QRS complex (12-leadsum);
CESC	cis	rs703842	0.963	rs2291617	chr12:58166403	T/G	cg00677455	chr12:58241039	CTDSP2	0.53	6.97	0.39	2.57e-11	Multiple sclerosis;
CESC	cis	rs2836974	0.932	rs13048178	chr21:40561012	G/T	cg27266027	chr21:40555129	PSMG1	0.45	5.32	0.31	2.19e-7	Cognitive function;
CESC	trans	rs7448080	0.510	rs330446	chr5:123281396	A/G	cg10971134	chr1:56877429	NA	0.94	6.31	0.36	1.15e-9	Alcohol dependence (age at onset);
CESC	cis	rs8067545	0.611	rs12942568	chr17:20117893	G/T	cg13482628	chr17:19912719	NA	-0.43	-5.81	-0.34	1.81e-8	Schizophrenia;
CESC	cis	rs67478160	0.584	rs12433009	chr14:104196405	C/G	cg01849466	chr14:104193079	ZFYVE21	-0.56	-8.26	-0.45	7.02e-15	Schizophrenia;
CESC	cis	rs9300255	0.602	rs1727317	chr12:123618942	T/C	cg00376283	chr12:123451042	ABCB9	0.62	6.59	0.38	2.33e-10	Neutrophil percentage of white cells;
CESC	cis	rs735396	1.000	rs1169310	chr12:121439433	G/A	cg25281562	chr12:121454272	C12orf43	0.39	5.08	0.3	7.26e-7	N-glycan levels;
CESC	cis	rs9840812	0.645	rs9883916	chr3:136208788	C/T	cg15507776	chr3:136538369	TMEM22	0.51	5.62	0.33	4.77e-8	Fibrinogen levels;
CESC	cis	rs7666738	0.830	rs7674095	chr4:99048158	T/A	cg24818145	chr4:99064322	C4orf37	0.38	5.04	0.3	8.49e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs920590	0.721	rs920587	chr8:19663339	C/A	cg01411142	chr8:19674711	INTS10	0.52	5.83	0.34	1.64e-8	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs1008375	0.931	rs2098151	chr4:17577490	T/C	cg27347728	chr4:17578864	LAP3	0.43	5.12	0.3	5.92e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs71403859	0.570	rs78972826	chr16:71454264	A/G	cg08717414	chr16:71523259	ZNF19	-0.84	-8.19	-0.45	1.1e-14	Post bronchodilator FEV1;
CESC	cis	rs4901869	0.931	rs12891570	chr14:59334338	T/A	cg02291164	chr14:59296302	NA	0.44	7.49	0.42	1.05e-12	Panic disorder;
CESC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg11368438	chr3:142751654	SR140	-0.45	-6.48	-0.37	4.54e-10	Breast cancer;
CESC	cis	rs713587	0.520	rs493090	chr2:25303772	G/A	cg01884057	chr2:25150051	NA	-0.32	-5.48	-0.32	9.68e-8	Body mass index in non-asthmatics;
CESC	cis	rs4900538	0.855	rs1209151	chr14:102893756	C/T	cg18135206	chr14:102964638	TECPR2	-0.77	-9.86	-0.52	9.76e-20	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	cis	rs2933343	0.951	rs1055128	chr3:128591048	C/T	cg25356066	chr3:128598488	ACAD9	0.55	6.92	0.39	3.4e-11	IgG glycosylation;
CESC	cis	rs3858526	0.883	rs11039584	chr11:5935251	C/G	cg05234568	chr11:5960015	NA	-0.6	-7.11	-0.4	1.08e-11	DNA methylation (variation);
CESC	cis	rs208520	0.690	rs207108	chr6:66794096	T/C	cg07460842	chr6:66804631	NA	-1.0	-13.33	-0.63	2.21e-31	Exhaled nitric oxide output;
CESC	cis	rs9733	0.744	rs12568757	chr1:150729793	C/T	cg22823121	chr1:150693482	HORMAD1	-0.36	-5.44	-0.32	1.21e-7	Tonsillectomy;
CESC	cis	rs9911578	0.900	rs717828	chr17:56535932	A/G	cg12560992	chr17:57184187	TRIM37	0.92	15.31	0.69	2.4e-38	Intelligence (multi-trait analysis);
CESC	trans	rs561341	0.783	rs512698	chr17:30292507	G/T	cg20587970	chr11:113659929	NA	-1.44	-18.66	-0.75	3.36e-50	Hip circumference adjusted for BMI;
CESC	cis	rs992157	0.560	rs7578940	chr2:219083318	G/T	cg00012203	chr2:219082015	ARPC2	-0.73	-9.67	-0.51	3.83e-19	Colorectal cancer;
CESC	cis	rs7520050	0.966	rs11211234	chr1:46438787	C/A	cg24296786	chr1:45957014	TESK2	0.44	5.5	0.32	8.98e-8	Red blood cell count;Reticulocyte count;
CESC	cis	rs372883	0.613	rs1153289	chr21:30686212	G/T	cg08807101	chr21:30365312	RNF160	-0.45	-5.34	-0.31	1.99e-7	Pancreatic cancer;
CESC	cis	rs7917772	0.503	rs7893155	chr10:104294228	C/A	cg22532475	chr10:104410764	TRIM8	-0.34	-5.81	-0.34	1.82e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs4523957	0.614	rs2984941	chr17:2031543	A/G	cg16513277	chr17:2031491	SMG6	-0.71	-10.13	-0.53	1.37e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs916888	0.821	rs199505	chr17:44859410	A/G	cg01570182	chr17:44337453	NA	-0.87	-10.41	-0.54	1.71e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs3026101	0.671	rs739768	chr17:5290703	G/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.43	5.69	0.33	3.37e-8	Body mass index;
CESC	cis	rs67460515	1.000	rs67460515	chr3:161068566	T/C	cg03342759	chr3:160939853	NMD3	-0.52	-7.69	-0.43	2.88e-13	Parkinson's disease;
CESC	cis	rs34375054	0.738	rs10773145	chr12:125625603	C/T	cg21269045	chr12:125625041	AACS	0.36	5.57	0.32	6.29e-8	Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs6952808	0.582	rs10479762	chr7:2045351	T/C	cg05863683	chr7:1912471	MAD1L1	-0.44	-6.68	-0.38	1.39e-10	Bipolar disorder and schizophrenia;
CESC	cis	rs62064224	0.589	rs9889607	chr17:30785585	A/C	cg18200150	chr17:30822561	MYO1D	-0.42	-5.63	-0.33	4.55e-8	Schizophrenia;
CESC	trans	rs66887589	0.616	rs11098497	chr4:120187068	C/T	cg25214090	chr10:38739885	LOC399744	0.43	6.02	0.35	5.75e-9	Diastolic blood pressure;
CESC	cis	rs7772486	0.597	rs7746618	chr6:146281367	T/C	cg05347473	chr6:146136440	FBXO30	-0.75	-9.41	-0.5	2.47e-18	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2228479	0.850	rs17226519	chr16:89839854	T/C	cg06558623	chr16:89946397	TCF25	1.17	9.29	0.5	5.84e-18	Skin colour saturation;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16572859	chr19:18263815	PIK3R2	0.54	6.34	0.36	9.66e-10	Gut microbiome composition (summer);
CESC	cis	rs736408	0.505	rs2083180	chr3:52668119	G/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	7.7	0.43	2.72e-13	Bipolar disorder;
CESC	cis	rs10504229	0.639	rs16921812	chr8:58106737	C/T	cg24829409	chr8:58192753	C8orf71	-0.56	-7.01	-0.4	1.97e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs9649213	0.593	rs6969731	chr7:97924571	T/G	cg24562669	chr7:97807699	LMTK2	0.48	6.94	0.39	2.98e-11	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7811142	0.830	rs11765869	chr7:99964789	T/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.07	10.49	0.54	9.53e-22	Platelet count;
CESC	cis	rs2295359	1.000	rs963427	chr1:67609347	A/G	cg17031739	chr1:67600172	NA	0.39	5.08	0.3	7.11e-7	Psoriasis;
CESC	cis	rs9487051	0.872	rs9398197	chr6:109609988	C/A	cg12927641	chr6:109611667	NA	-0.44	-6.78	-0.38	7.73e-11	Reticulocyte fraction of red cells;
CESC	cis	rs8092503	0.903	rs12970424	chr18:52472982	G/A	cg12377874	chr18:52495404	RAB27B	0.37	5.94	0.34	8.77e-9	Childhood body mass index;
CESC	cis	rs367943	1.000	rs348946	chr5:112822814	C/T	cg12552261	chr5:112820674	MCC	-0.63	-7.94	-0.44	5.83e-14	Type 2 diabetes;
CESC	cis	rs3540	0.597	rs3539	chr15:91045419	G/T	cg10434728	chr15:90938212	IQGAP1	-0.42	-7.71	-0.43	2.56e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs1062177	0.906	rs2964573	chr5:151160122	A/T	cg00977110	chr5:151150581	G3BP1	0.66	7.04	0.4	1.63e-11	Preschool internalizing problems;
CESC	trans	rs2121875	0.667	rs10941659	chr5:44223360	A/T	cg09056876	chr6:156718398	NA	-0.48	-6.23	-0.36	1.8e-9	Prostate cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06095699	chr12:100594421	ACTR6	-0.53	-6.38	-0.36	8e-10	Gut microbiome composition (summer);
CESC	cis	rs875971	0.895	rs1974769	chr7:65950614	G/A	cg12463550	chr7:65579703	CRCP	0.55	6.87	0.39	4.52e-11	Aortic root size;
CESC	cis	rs7123876	0.830	rs59311588	chr11:72435996	A/G	cg04827223	chr11:72435913	ARAP1	-0.84	-15.39	-0.69	1.27e-38	Body mass index;
CESC	cis	rs798554	1.000	rs798544	chr7:2763102	A/G	cg19717773	chr7:2847554	GNA12	0.58	8.51	0.46	1.33e-15	Height;
CESC	cis	rs854765	0.547	rs12150369	chr17:17911014	G/A	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.54	7.23	0.41	5.11e-12	Total body bone mineral density;
CESC	cis	rs898097	0.783	rs11650335	chr17:80835111	A/G	cg05483915	chr17:80145575	CCDC57	0.43	5.08	0.3	7.1e-7	Breast cancer;
CESC	cis	rs8078723	0.714	rs12940405	chr17:38143768	C/T	cg17467752	chr17:38218738	THRA	-0.57	-8.48	-0.46	1.57e-15	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CESC	cis	rs17376456	0.757	rs10066431	chr5:93198204	A/G	cg25358565	chr5:93447407	FAM172A	1.11	10.79	0.55	9.8e-23	Diabetic retinopathy;
CESC	cis	rs7618915	0.501	rs13079063	chr3:52744460	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.62	8.86	0.48	1.22e-16	Bipolar disorder;
CESC	cis	rs9302635	0.678	rs8054585	chr16:72225314	G/A	cg01557791	chr16:72042693	DHODH	-0.58	-6.72	-0.38	1.08e-10	Blood protein levels;
CESC	cis	rs9910055	0.762	rs11080007	chr17:42265442	A/G	cg13607699	chr17:42295918	UBTF	-0.54	-7.0	-0.4	2.07e-11	Total body bone mineral density;
CESC	cis	rs7937682	0.575	rs7124696	chr11:111747297	A/G	cg22437258	chr11:111473054	SIK2	-0.47	-5.24	-0.31	3.21e-7	Primary sclerosing cholangitis;
CESC	cis	rs258892	0.895	rs10036866	chr5:72068932	A/G	cg21869765	chr5:72125136	TNPO1	-0.43	-5.4	-0.32	1.45e-7	Small cell lung carcinoma;
CESC	cis	rs7851660	0.844	rs907581	chr9:100622189	A/G	cg13688889	chr9:100608707	NA	-0.64	-8.89	-0.48	9.61e-17	Strep throat;
CESC	cis	rs7917772	0.503	rs2031601	chr10:104308064	T/G	ch.10.2196322F	chr10:104248062	ACTR1A	0.43	5.38	0.31	1.64e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs2120019	0.938	rs8030089	chr15:75290377	C/T	cg09165964	chr15:75287851	SCAMP5	-0.78	-9.78	-0.52	1.69e-19	Blood trace element (Zn levels);
CESC	cis	rs12900413	0.603	rs12911871	chr15:90301429	T/C	cg24249390	chr15:90295951	MESP1	-0.4	-5.4	-0.31	1.52e-7	Coronary artery aneurysm in Kawasaki disease;
CESC	cis	rs798554	0.567	rs1182190	chr7:2869391	A/G	cg19717773	chr7:2847554	GNA12	-0.39	-5.82	-0.34	1.72e-8	Height;
CESC	cis	rs7312933	0.558	rs11181483	chr12:42798384	G/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.5	6.4	0.37	7.18e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs1862618	0.853	rs252919	chr5:56124111	T/C	cg24549020	chr5:56110836	MAP3K1	0.68	7.71	0.43	2.61e-13	Initial pursuit acceleration;
CESC	cis	rs6598955	0.543	rs57564009	chr1:26557618	A/T	cg04990556	chr1:26633338	UBXN11	0.83	9.31	0.5	4.92e-18	Obesity-related traits;
CESC	cis	rs17711722	1.000	rs17711722	chr7:65271197	C/T	cg05332525	chr7:65337924	VKORC1L1	-0.52	-6.42	-0.37	6.27e-10	Calcium levels;
CESC	cis	rs1799949	1.000	rs4793197	chr17:41231902	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	8.45	0.46	2e-15	Menopause (age at onset);
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg26162020	chr7:48964031	CDC14C	-0.46	-6.41	-0.37	6.6e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs7524258	0.900	rs6577425	chr1:7306338	G/T	cg07173049	chr1:7289937	CAMTA1	0.35	5.45	0.32	1.17e-7	Tourette's syndrome or obsessive-compulsive disorder;
CESC	cis	rs3796352	1.000	rs11710292	chr3:53117798	T/C	cg07884673	chr3:53033167	SFMBT1	0.66	5.57	0.32	6.4e-8	Immune reponse to smallpox (secreted IL-2);
CESC	cis	rs6088580	0.524	rs2889855	chr20:33276853	A/G	cg08999081	chr20:33150536	PIGU	-0.43	-6.27	-0.36	1.43e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs9549367	0.737	rs11619691	chr13:113904636	T/C	cg18105134	chr13:113819100	PROZ	-0.68	-8.25	-0.45	7.53e-15	Platelet distribution width;
CESC	cis	rs6089584	0.888	rs6061982	chr20:60620673	C/T	cg06108461	chr20:60628389	TAF4	-0.92	-14.55	-0.67	1.22e-35	Body mass index;
CESC	cis	rs1799949	0.860	rs8176279	chr17:41210396	A/C	cg23758822	chr17:41437982	NA	0.98	16.37	0.71	4.38e-42	Menopause (age at onset);
CESC	cis	rs57221529	0.766	rs72706610	chr5:561111	G/A	cg09021430	chr5:549028	NA	-0.43	-5.41	-0.32	1.43e-7	Lung disease severity in cystic fibrosis;
CESC	cis	rs11122272	0.735	rs2355872	chr1:231478489	A/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.45	-6.03	-0.35	5.36e-9	Hemoglobin concentration;
CESC	cis	rs2777491	0.915	rs16971767	chr15:41623308	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.61	-9.27	-0.49	6.62e-18	Ulcerative colitis;
CESC	cis	rs9790314	1.000	rs460508	chr3:161091089	C/G	cg04691961	chr3:161091175	C3orf57	0.44	5.94	0.34	8.8e-9	Morning vs. evening chronotype;
CESC	trans	rs2898290	0.622	rs1478890	chr8:11355602	C/G	cg15556689	chr8:8085844	FLJ10661	-0.49	-6.04	-0.35	5.1e-9	Systolic blood pressure;
CESC	cis	rs12410462	1.000	rs1587158	chr1:227658753	G/A	cg04117972	chr1:227635322	NA	-0.62	-6.2	-0.36	2.11e-9	Major depressive disorder;
CESC	cis	rs6714710	0.603	rs11691494	chr2:98419726	T/A	cg26665480	chr2:98280029	ACTR1B	0.57	8.07	0.44	2.42e-14	Posterior cortical atrophy and Alzheimer's disease;
CESC	cis	rs2228479	0.850	rs2238525	chr16:89809902	T/C	cg06558623	chr16:89946397	TCF25	0.89	7.99	0.44	4.18e-14	Skin colour saturation;
CESC	cis	rs17711722	0.528	rs73138179	chr7:65294482	G/T	cg18876405	chr7:65276391	NA	0.49	6.28	0.36	1.37e-9	Calcium levels;
CESC	cis	rs1023500	0.505	rs134889	chr22:42674350	A/T	cg05082376	chr22:42548792	NA	-0.38	-5.55	-0.32	7.01e-8	Schizophrenia;
CESC	cis	rs651907	0.557	rs34181125	chr3:101490278	A/G	cg12386194	chr3:101231763	SENP7	0.4	5.04	0.3	8.72e-7	Colorectal cancer;
CESC	cis	rs662064	0.963	rs636291	chr1:10556097	G/A	cg20482658	chr1:10539492	PEX14	-0.34	-6.85	-0.39	5.12e-11	Asthma;
CESC	cis	rs2777491	0.915	rs7165675	chr15:41614704	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.6	-8.84	-0.48	1.39e-16	Ulcerative colitis;
CESC	cis	rs637571	0.780	rs677029	chr11:65683531	A/G	cg04055107	chr11:65626734	MUS81;CFL1	0.55	6.7	0.38	1.21e-10	Eosinophil percentage of white cells;
CESC	cis	rs2880765	0.835	rs4340287	chr15:86043737	A/G	cg10818794	chr15:86012489	AKAP13	-0.34	-5.2	-0.3	4.03e-7	Coronary artery disease;
CESC	cis	rs367943	0.712	rs9326889	chr5:112731438	A/G	cg12552261	chr5:112820674	MCC	0.39	5.25	0.31	3.18e-7	Type 2 diabetes;
CESC	cis	rs10744422	1.000	rs10744422	chr12:123336789	T/C	cg22842854	chr12:123319900	HIP1R	-0.67	-5.23	-0.31	3.5e-7	Schizophrenia;
CESC	cis	rs765787	0.505	rs12593605	chr15:45497448	T/A	cg24006582	chr15:45444508	DUOX1	0.53	6.27	0.36	1.44e-9	Uric acid levels;
CESC	cis	rs1499972	0.564	rs62264773	chr3:117647875	G/A	cg07612923	chr3:117604196	NA	0.69	6.15	0.35	2.83e-9	Schizophrenia;
CESC	trans	rs11098499	0.908	rs11098527	chr4:120399906	A/G	cg25214090	chr10:38739885	LOC399744	0.71	9.97	0.52	4.49e-20	Corneal astigmatism;
CESC	cis	rs7647973	0.588	rs9883000	chr3:49667691	A/G	cg07636037	chr3:49044803	WDR6	0.51	5.98	0.34	7.36e-9	Menarche (age at onset);
CESC	cis	rs2032447	0.517	rs7767546	chr6:25904067	T/C	cg18357526	chr6:26021779	HIST1H4A	0.49	6.18	0.35	2.4e-9	Intelligence (multi-trait analysis);
CESC	trans	rs11039798	0.588	rs584899	chr11:48431408	T/C	cg15704280	chr7:45808275	SEPT13	-0.62	-6.25	-0.36	1.63e-9	Axial length;
CESC	cis	rs7824557	0.527	rs57629785	chr8:11235150	C/A	cg21775007	chr8:11205619	TDH	-0.53	-7.87	-0.44	8.89e-14	Retinal vascular caliber;
CESC	cis	rs1879734	0.731	rs61184814	chr1:54160709	G/T	cg23596471	chr1:54105337	GLIS1	0.35	5.56	0.32	6.52e-8	Mitral valve prolapse;
CESC	cis	rs6089829	0.962	rs2872543	chr20:61665017	G/A	cg16240275	chr20:61666158	NCRNA00029	0.5	8.87	0.48	1.12e-16	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs4568518	0.530	rs4721674	chr7:17993377	A/T	cg03009463	chr7:17980271	SNX13	0.45	5.88	0.34	1.21e-8	Measles;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg10315922	chr12:66563928	TMBIM4	0.45	6.46	0.37	4.89e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs1862618	0.573	rs185220	chr5:56205357	A/G	cg20203395	chr5:56204925	C5orf35	-0.49	-5.78	-0.33	2.09e-8	Initial pursuit acceleration;
CESC	cis	rs4722166	0.604	rs2390715	chr7:22783878	A/C	cg05472934	chr7:22766657	IL6	0.86	10.87	0.56	5.47e-23	Lung cancer;
CESC	cis	rs2228479	0.867	rs76885005	chr16:89966668	A/G	cg00800038	chr16:89945340	TCF25	-0.85	-7.67	-0.43	3.2e-13	Skin colour saturation;
CESC	cis	rs7216064	1.000	rs62084251	chr17:65878736	G/A	cg07042672	chr17:66097459	LOC651250	-0.52	-5.4	-0.31	1.5e-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs4665809	0.590	rs7606351	chr2:26292545	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.83	-9.11	-0.49	2.11e-17	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00291661	chr16:30581198	ZNF688	-0.61	-6.65	-0.38	1.71e-10	Gut microbiome composition (summer);
CESC	cis	rs11718455	0.960	rs13060222	chr3:44005046	A/T	cg08738300	chr3:44038990	NA	0.46	6.12	0.35	3.34e-9	Coronary artery disease;
CESC	cis	rs6964587	1.000	rs7806157	chr7:91601930	A/G	cg17063962	chr7:91808500	NA	0.54	7.21	0.4	6e-12	Breast cancer;
CESC	cis	rs4803468	0.905	rs284662	chr19:41932275	T/C	cg09537434	chr19:41945824	ATP5SL	-1.14	-21.08	-0.79	1.31e-58	Height;
CESC	cis	rs9926296	0.568	rs7203907	chr16:89833774	C/G	cg04287289	chr16:89883240	FANCA	0.9	15.16	0.68	8.38e-38	Vitiligo;
CESC	cis	rs66573146	1.000	rs56178503	chr4:6961748	C/T	cg00086871	chr4:6988644	TBC1D14	1.16	6.56	0.37	2.82e-10	Granulocyte percentage of myeloid white cells;
CESC	cis	rs10504229	0.906	rs116341227	chr8:58190532	G/C	cg22535103	chr8:58192502	C8orf71	-1.04	-13.21	-0.63	5.76e-31	Developmental language disorder (linguistic errors);
CESC	cis	rs73206853	0.764	rs28580853	chr12:110826209	C/G	cg12870014	chr12:110450643	ANKRD13A	0.61	5.62	0.33	4.8e-8	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs6723226	0.806	rs2249109	chr2:32750879	G/A	cg02381751	chr2:32503542	YIPF4	0.86	12.44	0.61	2.81e-28	Intelligence (multi-trait analysis);
CESC	cis	rs8099014	0.725	rs4998040	chr18:56093999	G/A	cg12827950	chr18:55968429	NEDD4L	-0.45	-5.06	-0.3	7.91e-7	Platelet count;
CESC	cis	rs3857536	0.813	rs4710580	chr6:66935200	C/T	cg07460842	chr6:66804631	NA	-0.42	-5.34	-0.31	1.96e-7	Blood trace element (Cu levels);
CESC	cis	rs1670533	1.000	rs10084849	chr4:1053586	T/C	cg27284194	chr4:1044797	NA	0.46	5.86	0.34	1.35e-8	Recombination rate (females);
CESC	cis	rs9303401	0.659	rs35539277	chr17:56853833	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.99	11.34	0.57	1.51e-24	Cognitive test performance;
CESC	cis	rs2832077	1.000	rs2832065	chr21:30135362	C/T	cg03476357	chr21:30257390	N6AMT1	-0.48	-5.08	-0.3	7e-7	Cognitive test performance;
CESC	cis	rs11098499	0.954	rs17009122	chr4:120362403	G/A	cg24375607	chr4:120327624	NA	0.47	5.9	0.34	1.11e-8	Corneal astigmatism;
CESC	cis	rs11166629	1.000	rs4909330	chr8:135644369	T/C	cg27224718	chr8:135614730	ZFAT	0.5	6.37	0.36	8.2e-10	Smoking quantity;
CESC	cis	rs258892	0.843	rs34455289	chr5:72053282	G/C	cg21869765	chr5:72125136	TNPO1	-0.43	-5.36	-0.31	1.8e-7	Small cell lung carcinoma;
CESC	cis	rs6952808	0.929	rs34145223	chr7:1926237	G/A	cg21782813	chr7:2030301	MAD1L1	0.45	6.34	0.36	1.01e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs13191362	0.872	rs35672319	chr6:163245464	C/A	cg06582575	chr6:163149167	PACRG;PARK2	0.64	6.3	0.36	1.22e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs6977660	0.507	rs72591449	chr7:19775443	T/C	cg05791153	chr7:19748676	TWISTNB	0.75	6.79	0.38	7.41e-11	Thyroid stimulating hormone;
CESC	cis	rs7666738	0.830	rs7662114	chr4:99019985	A/G	cg03467027	chr4:99064603	C4orf37	0.46	5.81	0.34	1.8e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11563648	0.535	rs1419395	chr7:126992598	T/C	cg25922125	chr7:127225783	GCC1	-0.41	-5.03	-0.3	8.92e-7	Resting heart rate;
CESC	cis	rs7590368	0.640	rs72779433	chr2:10946986	C/T	cg15705551	chr2:10952987	PDIA6	0.55	5.26	0.31	2.99e-7	Educational attainment (years of education);
CESC	trans	rs637571	0.607	rs589253	chr11:65693080	G/A	cg17712092	chr4:129076599	LARP1B	0.79	10.8	0.55	8.7e-23	Eosinophil percentage of white cells;
CESC	cis	rs7208859	0.673	rs2470251	chr17:29095061	T/C	cg13385521	chr17:29058706	SUZ12P	0.59	5.54	0.32	7.29e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs644799	1.000	rs560854	chr11:95584905	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.53	6.22	0.36	1.98e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs6460942	0.597	rs6944517	chr7:12515283	C/T	cg02935154	chr7:12443704	VWDE	-0.48	-5.09	-0.3	6.85e-7	Coronary artery disease;
CESC	cis	rs896854	0.654	rs896846	chr8:95972453	G/A	cg09323728	chr8:95962352	TP53INP1	-0.39	-8.53	-0.46	1.11e-15	Type 2 diabetes;
CESC	cis	rs4975616	0.869	rs370348	chr5:1331219	A/G	cg26373071	chr5:1325741	CLPTM1L	0.43	6.92	0.39	3.37e-11	Lung cancer;
CESC	cis	rs3862260	0.509	rs3795662	chr1:120165135	G/T	cg11530693	chr1:120165357	ZNF697	0.69	10.58	0.55	4.58e-22	Systemic lupus erythematosus;
CESC	cis	rs55871839	0.708	rs4738732	chr8:59809943	A/G	cg07426533	chr8:59803705	TOX	0.47	6.94	0.39	3.04e-11	Pneumonia;
CESC	cis	rs5753037	0.585	rs249401	chr22:30216168	C/T	cg01021169	chr22:30184971	ASCC2	-0.56	-8.33	-0.46	4.35e-15	Type 1 diabetes;
CESC	cis	rs736408	0.540	rs4687637	chr3:52634092	C/T	cg18404041	chr3:52824283	ITIH1	-0.37	-6.3	-0.36	1.26e-9	Bipolar disorder;
CESC	cis	rs7412746	0.658	rs6669855	chr1:150861229	C/T	cg04414720	chr1:150670196	GOLPH3L	0.5	6.46	0.37	5.04e-10	Melanoma;
CESC	cis	rs2074585	0.560	rs12903058	chr15:91061121	G/T	cg22089800	chr15:90895588	ZNF774	-0.5	-6.18	-0.35	2.44e-9	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
CESC	cis	rs11997175	0.624	rs79944133	chr8:33730588	A/G	ch.8.33884649F	chr8:33765107	NA	0.49	6.18	0.36	2.35e-9	Body mass index;
CESC	cis	rs6582630	0.502	rs3902522	chr12:38271203	T/C	cg26384229	chr12:38710491	ALG10B	0.65	9.03	0.49	3.55e-17	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs2880765	0.710	rs11630457	chr15:86004801	T/C	cg10818794	chr15:86012489	AKAP13	-0.33	-5.06	-0.3	7.66e-7	Coronary artery disease;
CESC	cis	rs6467136	0.765	rs4731370	chr7:127210207	G/A	cg25922125	chr7:127225783	GCC1	-0.37	-5.07	-0.3	7.53e-7	Type 2 diabetes;
CESC	cis	rs472109	0.565	rs360141	chr11:9784978	C/T	cg03108697	chr11:9732066	SWAP70	-0.36	-5.15	-0.3	5.18e-7	Coronary artery disease;
CESC	cis	rs7508679	1.000	rs4804411	chr19:7222377	G/C	cg00428638	chr19:7224713	INSR	0.47	7.4	0.41	1.75e-12	Hypothyroidism;
CESC	cis	rs60154123	0.615	rs701943	chr1:210425727	A/G	cg02304930	chr1:210405566	SERTAD4;C1orf133	-0.56	-6.42	-0.37	6.43e-10	Coronary artery disease;
CESC	cis	rs7953249	0.656	rs1732391	chr12:121392341	C/T	cg25281562	chr12:121454272	C12orf43	-0.46	-5.77	-0.33	2.18e-8	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
CESC	cis	rs2075371	0.796	rs10954440	chr7:134005657	C/T	cg11752832	chr7:134001865	SLC35B4	0.52	6.79	0.38	7.4e-11	Mean platelet volume;
CESC	cis	rs599083	0.569	rs685095	chr11:68170376	C/T	cg01657329	chr11:68192670	LRP5	0.45	5.12	0.3	5.76e-7	Bone mineral density (spine);
CESC	cis	rs10504229	1.000	rs73609762	chr8:58192695	A/G	cg05313129	chr8:58192883	C8orf71	-0.55	-6.29	-0.36	1.34e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs4862750	0.832	rs6836076	chr4:187899660	A/C	cg03452623	chr4:187889614	NA	-0.88	-16.16	-0.7	2.39e-41	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs9987353	0.840	rs329994	chr8:9123233	A/G	cg20015168	chr14:57046681	C14orf101	-0.47	-6.14	-0.35	3.02e-9	Recombination measurement;
CESC	cis	rs2535633	0.631	rs6799185	chr3:53101580	C/T	cg07507251	chr3:52567010	NT5DC2	0.32	5.11	0.3	6.31e-7	Body mass index;
CESC	cis	rs7527798	0.571	rs7531923	chr1:207833336	T/G	cg21110645	chr1:207815933	NA	-0.34	-5.88	-0.34	1.26e-8	Erythrocyte sedimentation rate;
CESC	cis	rs1348850	0.958	rs11689550	chr2:178456298	A/G	cg23306229	chr2:178417860	TTC30B	0.47	5.8	0.34	1.85e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs9814567	1.000	rs9851441	chr3:134315091	C/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.41	-5.56	-0.32	6.73e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs4561483	0.801	rs33623	chr16:12007435	A/G	cg08843971	chr16:11963173	GSPT1	0.54	7.97	0.44	4.76e-14	Testicular germ cell tumor;
CESC	cis	rs6933660	0.745	rs9322320	chr6:151751908	C/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.5	-6.67	-0.38	1.5e-10	Menarche (age at onset);
CESC	cis	rs6860806	0.661	rs28472559	chr5:131581611	G/A	cg11843238	chr5:131593191	PDLIM4	0.37	5.36	0.31	1.8e-7	Breast cancer;
CESC	cis	rs9911578	0.704	rs72628393	chr17:56585314	A/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.41	-5.45	-0.32	1.18e-7	Intelligence (multi-trait analysis);
CESC	cis	rs7918232	0.627	rs6482588	chr10:27308307	G/C	cg14240646	chr10:27532245	ACBD5	-0.51	-5.41	-0.32	1.44e-7	Breast cancer;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg05671585	chr4:186064123	SLC25A4	-0.47	-6.06	-0.35	4.79e-9	Fibrinogen levels;
CESC	cis	rs7084402	0.967	rs11006171	chr10:60278487	C/T	cg07615347	chr10:60278583	BICC1	-0.57	-8.75	-0.47	2.54e-16	Refractive error;
CESC	cis	rs9911578	1.000	rs2055779	chr17:57030561	A/G	cg05425664	chr17:57184151	TRIM37	-0.5	-6.92	-0.39	3.39e-11	Intelligence (multi-trait analysis);
CESC	cis	rs2243480	1.000	rs7792391	chr7:65773429	A/G	cg12463550	chr7:65579703	CRCP	-0.74	-5.73	-0.33	2.74e-8	Diabetic kidney disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14774160	chr17:4901081	INCA1;KIF1C	0.53	6.24	0.36	1.73e-9	Gut microbiome composition (summer);
CESC	cis	rs7208859	0.623	rs9911784	chr17:29124580	A/C	cg14008862	chr17:28927542	LRRC37B2	0.65	5.14	0.3	5.34e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17182302	chr1:116961525	C1orf203	0.58	6.61	0.38	2.1e-10	Gut microbiome composition (summer);
CESC	cis	rs2637266	0.703	rs1561676	chr10:78459211	T/C	cg18941641	chr10:78392320	NA	0.39	6.9	0.39	3.74e-11	Pulmonary function;
CESC	cis	rs709400	0.588	rs61996718	chr14:104048834	G/A	cg12935359	chr14:103987150	CKB	-0.55	-6.24	-0.36	1.71e-9	Body mass index;
CESC	cis	rs7799006	0.606	rs34417375	chr7:2315105	C/T	cg08027265	chr7:2291960	NA	-0.58	-9.91	-0.52	6.83e-20	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs4853012	0.887	rs6737314	chr2:74339586	A/G	cg05890377	chr2:74357713	NA	0.58	7.03	0.4	1.8e-11	Gestational age at birth (maternal effect);
CESC	cis	rs977987	0.806	rs35552529	chr16:75405879	G/C	cg03315344	chr16:75512273	CHST6	0.4	5.68	0.33	3.59e-8	Dupuytren's disease;
CESC	cis	rs8031584	0.958	rs61997079	chr15:31238271	G/C	cg08704250	chr15:31115839	NA	-0.63	-8.12	-0.45	1.8e-14	Huntington's disease progression;
CESC	cis	rs9300255	0.596	rs10734901	chr12:123743447	G/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.32	-5.03	-0.3	9.21e-7	Neutrophil percentage of white cells;
CESC	cis	rs9486715	0.793	rs2499777	chr6:97013814	T/C	cg06623918	chr6:96969491	KIAA0776	-0.95	-15.1	-0.68	1.35e-37	Headache;
CESC	cis	rs5758511	0.680	rs17002902	chr22:42625509	C/G	cg00645731	chr22:42541494	CYP2D7P1	0.58	8.64	0.47	5.43e-16	Birth weight;
CESC	cis	rs3816788	0.792	rs7013323	chr8:21869024	C/G	cg17168535	chr8:21777572	XPO7	0.58	8.26	0.45	6.93e-15	Lung cancer in ever smokers;
CESC	trans	rs9650657	0.537	rs4841457	chr8:10773511	T/G	cg15556689	chr8:8085844	FLJ10661	-0.59	-7.46	-0.42	1.23e-12	Neuroticism;
CESC	cis	rs2243480	1.000	rs4149468	chr7:65825690	T/C	cg13147721	chr7:65941812	NA	-0.96	-9.02	-0.48	3.92e-17	Diabetic kidney disease;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg18708365	chr7:103848079	ORC5L	-0.43	-6.14	-0.35	3.02e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs2197308	0.606	rs2218397	chr12:38278307	C/T	cg26384229	chr12:38710491	ALG10B	-0.43	-5.65	-0.33	4.09e-8	Morning vs. evening chronotype;
CESC	cis	rs6088580	0.634	rs7271970	chr20:32987666	A/G	cg08999081	chr20:33150536	PIGU	-0.64	-11.17	-0.57	5.54e-24	Glomerular filtration rate (creatinine);
CESC	cis	rs7845219	0.544	rs9643352	chr8:95918288	C/T	cg16049864	chr8:95962084	TP53INP1	-0.49	-7.22	-0.41	5.48e-12	Type 2 diabetes;
CESC	cis	rs13256369	1.000	rs4841017	chr8:8577093	A/G	cg18904891	chr8:8559673	CLDN23	0.65	7.8	0.43	1.4e-13	Obesity-related traits;
CESC	cis	rs1862618	0.853	rs832551	chr5:56180112	T/G	cg18230493	chr5:56204884	C5orf35	-0.73	-8.57	-0.47	8.93e-16	Initial pursuit acceleration;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg24108215	chr1:39174820	NA	0.4	6.48	0.37	4.53e-10	Gambling;
CESC	cis	rs72781680	0.821	rs55948613	chr2:24094787	A/G	cg08917208	chr2:24149416	ATAD2B	0.58	5.81	0.34	1.82e-8	Lymphocyte counts;
CESC	cis	rs10870270	0.956	rs7894	chr10:133769482	G/C	cg17892150	chr10:133769511	PPP2R2D	-0.86	-12.54	-0.61	1.28e-28	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs8067545	0.611	rs2703814	chr17:20117151	T/C	cg13482628	chr17:19912719	NA	-0.43	-5.81	-0.34	1.81e-8	Schizophrenia;
CESC	cis	rs9623117	0.915	rs9611262	chr22:40475587	A/T	cg05033341	chr22:40419857	FAM83F	-0.49	-5.49	-0.32	9.61e-8	Prostate cancer (SNP x SNP interaction);Prostate cancer;
CESC	cis	rs8103278	0.507	rs7260651	chr19:46260245	G/A	cg11657440	chr19:46296263	DMWD	0.77	11.86	0.59	2.54e-26	Coronary artery disease;
CESC	cis	rs9788682	0.894	rs4461039	chr15:78817447	A/T	cg24631222	chr15:78858424	CHRNA5	-0.72	-9.41	-0.5	2.42e-18	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs34779708	0.931	rs35136660	chr10:35385973	C/A	cg04310649	chr10:35416472	CREM	-0.51	-6.06	-0.35	4.62e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs4481887	1.000	rs4554750	chr1:248496530	C/G	cg00666640	chr1:248458726	OR2T12	0.41	6.6	0.38	2.21e-10	Common traits (Other);
CESC	cis	rs965469	1.000	rs2092990	chr20:3346338	C/T	cg25506879	chr20:3388711	C20orf194	-0.55	-5.85	-0.34	1.43e-8	IFN-related cytopenia;
CESC	cis	rs801193	0.935	rs3800820	chr7:66147178	C/T	cg18876405	chr7:65276391	NA	-0.51	-6.73	-0.38	1.05e-10	Aortic root size;
CESC	cis	rs7959452	0.557	rs899224	chr12:69784774	A/G	cg22834771	chr12:69754056	YEATS4	-0.48	-6.46	-0.37	4.87e-10	Blood protein levels;
CESC	cis	rs514406	0.893	rs512723	chr1:53343880	C/T	cg08859206	chr1:53392774	SCP2	0.59	7.72	0.43	2.37e-13	Monocyte count;
CESC	cis	rs4665809	1.000	rs6546768	chr2:26328800	A/G	cg04944784	chr2:26401820	FAM59B	-0.66	-7.58	-0.42	5.83e-13	Gut microbiome composition (summer);
CESC	cis	rs4243830	0.737	rs11122091	chr1:6609559	C/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.82	-8.84	-0.48	1.4e-16	Body mass index;
CESC	cis	rs801193	0.548	rs2659891	chr7:66201114	A/G	cg11764359	chr7:65958608	NA	0.73	10.6	0.55	4.14e-22	Aortic root size;
CESC	cis	rs2880765	0.566	rs11630381	chr15:86012503	A/G	cg19183879	chr15:85880815	NA	-0.31	-5.9	-0.34	1.12e-8	Coronary artery disease;
CESC	cis	rs9910055	0.762	rs2526020	chr17:42216588	G/T	cg19774624	chr17:42201019	HDAC5	-0.75	-11.07	-0.56	1.19e-23	Total body bone mineral density;
CESC	cis	rs7818688	1.000	rs7008542	chr8:96027863	C/A	cg16049864	chr8:95962084	TP53INP1	0.6	5.77	0.33	2.25e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs7937682	0.562	rs527847	chr11:111369132	A/C	cg09085632	chr11:111637200	PPP2R1B	0.65	8.84	0.48	1.36e-16	Primary sclerosing cholangitis;
CESC	cis	rs79149102	0.579	rs12593476	chr15:75282092	A/C	cg18866210	chr15:74343476	NA	0.53	5.41	0.32	1.42e-7	Lung cancer;
CESC	cis	rs798766	1.000	rs798756	chr4:1707447	T/C	cg05874882	chr4:1763078	NA	-0.56	-7.39	-0.41	1.88e-12	Bladder cancer;Urinary bladder cancer;
CESC	cis	rs875971	0.545	rs66594357	chr7:65792784	G/A	cg11764359	chr7:65958608	NA	0.8	10.13	0.53	1.35e-20	Aortic root size;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg14797243	chr11:68671428	IGHMBP2;MRPL21	0.58	7.6	0.42	5.18e-13	Gut microbiota (bacterial taxa);
CESC	cis	rs7216064	0.953	rs2086744	chr17:65849275	C/G	cg07042672	chr17:66097459	LOC651250	-0.53	-5.57	-0.32	6.1e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs6952809	0.532	rs2057840	chr7:2432797	C/G	cg23289794	chr7:2394357	EIF3B	-0.67	-6.78	-0.38	7.56e-11	Multiple sclerosis;
CESC	cis	rs6087990	0.806	rs875041	chr20:31383530	C/T	cg13636640	chr20:31349939	DNMT3B	0.83	13.59	0.64	2.77e-32	Ulcerative colitis;
CESC	cis	rs2717559	0.561	rs7841267	chr8:143881683	A/C	cg17252645	chr8:143867129	LY6D	-0.33	-5.59	-0.32	5.64e-8	Urinary tract infection frequency;
CESC	cis	rs514406	0.929	rs12354395	chr1:53327663	A/G	cg25767906	chr1:53392781	SCP2	-0.44	-5.63	-0.33	4.57e-8	Monocyte count;
CESC	cis	rs6750795	0.502	rs11685196	chr2:232381298	A/G	cg19187155	chr2:232395269	NMUR1	0.47	7.84	0.43	1.1e-13	Height;
CESC	cis	rs9911578	1.000	rs3744109	chr17:56594197	C/T	cg05425664	chr17:57184151	TRIM37	0.5	7.06	0.4	1.5e-11	Intelligence (multi-trait analysis);
CESC	cis	rs12410462	0.748	rs1495853	chr1:227657336	A/G	cg04117972	chr1:227635322	NA	-0.62	-6.2	-0.36	2.11e-9	Major depressive disorder;
CESC	cis	rs763121	0.853	rs5757141	chr22:38957483	G/A	cg06022373	chr22:39101656	GTPBP1	0.81	11.55	0.58	2.87e-25	Menopause (age at onset);
CESC	cis	rs1729951	0.546	rs12054408	chr3:136677645	T/C	cg03617693	chr3:136751559	NA	0.38	5.31	0.31	2.27e-7	Neuroticism;
CESC	cis	rs6687430	0.526	rs12120962	chr1:10609505	G/A	cg07384165	chr1:10488281	NA	-0.48	-6.55	-0.37	3.02e-10	Hand grip strength;
CESC	cis	rs6723226	0.650	rs6729952	chr2:32764922	T/C	cg02381751	chr2:32503542	YIPF4	0.7	9.57	0.51	7.76e-19	Intelligence (multi-trait analysis);
CESC	cis	rs9323205	0.954	rs4258524	chr14:51638739	A/T	cg23942311	chr14:51606299	NA	-0.42	-5.77	-0.33	2.25e-8	Cancer;
CESC	cis	rs9611565	0.840	rs3788584	chr22:41779073	T/A	cg06481639	chr22:41940642	POLR3H	-0.62	-6.5	-0.37	4.04e-10	Vitiligo;
CESC	cis	rs2635047	0.684	rs7236105	chr18:44757226	G/T	cg24371990	chr18:44770781	NA	0.4	6.48	0.37	4.33e-10	Educational attainment;
CESC	cis	rs9322193	0.962	rs62441335	chr6:150113794	G/A	cg04369109	chr6:150039330	LATS1	-0.39	-5.35	-0.31	1.93e-7	Lung cancer;
CESC	cis	rs6740322	0.841	rs10210507	chr2:43556636	G/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.7	-7.37	-0.41	2.12e-12	Coronary artery disease;
CESC	cis	rs7618915	0.501	rs2109634	chr3:52752075	T/G	cg18337363	chr3:52569053	NT5DC2	0.29	5.28	0.31	2.66e-7	Bipolar disorder;
CESC	cis	rs6540559	1.000	rs6696825	chr1:209982372	A/G	cg12034118	chr1:209979487	IRF6	0.41	5.07	0.3	7.59e-7	Cleft lip with or without cleft palate;
CESC	cis	rs11785400	0.701	rs9297968	chr8:143723009	A/G	cg10596483	chr8:143751796	JRK	0.4	5.14	0.3	5.32e-7	Schizophrenia;
CESC	trans	rs61931739	0.534	rs12372721	chr12:34175301	C/T	cg26384229	chr12:38710491	ALG10B	0.66	9.12	0.49	1.89e-17	Morning vs. evening chronotype;
CESC	cis	rs2425143	1.000	rs11696369	chr20:34378629	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.72	6.65	0.38	1.63e-10	Blood protein levels;
CESC	cis	rs9486715	0.867	rs2499775	chr6:97007340	C/T	cg18709589	chr6:96969512	KIAA0776	-0.47	-6.56	-0.37	2.86e-10	Headache;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg16238933	chr4:668052	ATP5I	-0.5	-6.29	-0.36	1.29e-9	Fibrinogen levels;
CESC	cis	rs7116495	0.609	rs7113436	chr11:71689599	A/T	cg18441811	chr11:71824068	C11orf51	0.89	5.39	0.31	1.59e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs2288073	0.801	rs2384008	chr2:24373150	A/G	cg20701182	chr2:24300061	SF3B14	0.47	5.92	0.34	9.9e-9	Venous thromboembolism (SNP x SNP interaction);
CESC	cis	rs7167736	0.637	rs1689939	chr15:101205180	C/T	cg09499109	chr15:101097659	NA	0.4	5.06	0.3	7.97e-7	Chin dimples;
CESC	cis	rs3126085	1.000	rs11204971	chr1:152259078	A/G	cg03465714	chr1:152285911	FLG	0.49	5.43	0.32	1.24e-7	Atopic dermatitis;
CESC	cis	rs875971	0.545	rs73146609	chr7:65767464	A/G	cg18876405	chr7:65276391	NA	0.46	5.24	0.31	3.3e-7	Aortic root size;
CESC	cis	rs7666738	0.830	rs7678911	chr4:99057430	C/T	cg03676636	chr4:99064102	C4orf37	0.34	5.16	0.3	4.85e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2204008	0.653	rs11182569	chr12:38572452	G/A	cg26384229	chr12:38710491	ALG10B	0.76	11.48	0.58	4.84e-25	Bladder cancer;
CESC	cis	rs7666738	0.791	rs6532725	chr4:99061479	T/C	cg03676636	chr4:99064102	C4orf37	0.34	5.07	0.3	7.32e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7666738	0.830	rs7662114	chr4:99019985	A/G	cg18180107	chr4:99064573	C4orf37	0.41	5.39	0.31	1.57e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs60154123	0.505	rs2206043	chr1:210042983	G/A	cg23283495	chr1:209979779	IRF6	0.52	5.85	0.34	1.42e-8	Coronary artery disease;
CESC	cis	rs7089973	0.668	rs61868024	chr10:116637939	A/G	cg25233709	chr10:116636983	FAM160B1	0.4	6.24	0.36	1.7e-9	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs1005277	0.579	rs1740732	chr10:38491385	C/T	cg25517755	chr10:38738941	LOC399744	-0.44	-5.61	-0.33	5.07e-8	Extrinsic epigenetic age acceleration;
CESC	cis	rs9649213	0.593	rs1468341	chr7:97987696	G/A	cg08684580	chr7:98029266	BAIAP2L1	-0.37	-6.01	-0.35	6.26e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs9522267	0.502	rs9522281	chr13:112222389	G/A	cg10483660	chr13:112241077	NA	-0.33	-5.79	-0.34	1.94e-8	Hepatitis;
CESC	cis	rs921968	0.509	rs10932782	chr2:219353195	C/T	cg02176678	chr2:219576539	TTLL4	0.5	8.98	0.48	5.22e-17	Mean corpuscular hemoglobin concentration;
CESC	cis	rs10504229	0.871	rs16921952	chr8:58163317	A/T	cg05313129	chr8:58192883	C8orf71	-0.44	-5.47	-0.32	1.03e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs7964748	0.769	rs73179274	chr12:103024937	C/T	cg02806658	chr12:102513592	C12orf48;NUP37	-0.57	-5.07	-0.3	7.56e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs17345786	1.000	rs58907984	chr3:101305170	T/G	cg12386194	chr3:101231763	SENP7	0.57	6.55	0.37	3e-10	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4975616	0.804	rs462608	chr5:1336626	T/A	cg26373071	chr5:1325741	CLPTM1L	0.45	7.17	0.4	7.32e-12	Lung cancer;
CESC	cis	rs7772486	0.641	rs2777485	chr6:146334377	G/A	cg23711669	chr6:146136114	FBXO30	0.84	10.88	0.56	5.04e-23	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs3749237	0.595	rs4855839	chr3:49507847	G/A	cg03060546	chr3:49711283	APEH	0.77	11.58	0.58	2.22e-25	Resting heart rate;
CESC	cis	rs1569019	0.790	rs11613786	chr12:131581429	C/T	cg16379671	chr12:131647826	NA	-0.64	-5.07	-0.3	7.61e-7	Height;
CESC	cis	rs300703	0.935	rs12714403	chr2:273070	A/G	cg21211680	chr2:198530	NA	0.91	7.67	0.43	3.27e-13	Blood protein levels;
CESC	cis	rs7618915	0.547	rs13069481	chr3:52666866	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.48	6.89	0.39	4.13e-11	Bipolar disorder;
CESC	cis	rs4862750	0.872	rs6811837	chr4:187898162	G/A	cg11301795	chr4:187892539	NA	-0.75	-12.51	-0.61	1.63e-28	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs8114671	0.562	rs6088635	chr20:33466501	A/G	cg07148914	chr20:33460835	GGT7	0.51	6.76	0.38	8.89e-11	Height;
CESC	cis	rs2299587	0.554	rs3853530	chr8:17748420	C/T	cg08627089	chr8:17753878	FGL1	-0.41	-5.89	-0.34	1.15e-8	Economic and political preferences;
CESC	cis	rs6540559	0.673	rs2357230	chr1:210019498	G/A	cg25204440	chr1:209979598	IRF6	0.59	5.92	0.34	9.82e-9	Cleft lip with or without cleft palate;
CESC	cis	rs7662987	0.517	rs2602866	chr4:100034997	A/G	cg12011299	chr4:100065546	ADH4	0.6	6.56	0.37	2.83e-10	Smoking initiation;
CESC	cis	rs4268898	0.862	rs11125549	chr2:24576240	C/T	cg06627628	chr2:24431161	ITSN2	0.71	8.57	0.47	8.46e-16	Asthma;
CESC	cis	rs736408	0.609	rs2230535	chr3:52800284	T/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.36	6.18	0.36	2.36e-9	Bipolar disorder;
CESC	cis	rs589448	0.538	rs683790	chr12:69751434	T/G	cg14784868	chr12:69753453	YEATS4	0.73	9.43	0.5	2.22e-18	Cerebrospinal fluid biomarker levels;
CESC	cis	rs9611565	0.513	rs739135	chr22:42090069	A/C	cg06481639	chr22:41940642	POLR3H	0.59	5.91	0.34	1.05e-8	Vitiligo;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03304714	chr17:57297813	GDPD1	0.59	6.41	0.37	6.62e-10	Gut microbiome composition (summer);
CESC	cis	rs4555082	0.874	rs1882846	chr14:105717448	G/C	cg13114125	chr14:105738426	BRF1	-0.82	-10.07	-0.53	2.04e-20	Mean platelet volume;Platelet distribution width;
CESC	cis	rs2380220	1.000	rs2380220	chr6:95967412	T/C	cg15832292	chr6:96025679	MANEA	0.62	5.72	0.33	2.84e-8	Behavioural disinhibition (generation interaction);
CESC	cis	rs7762018	1.000	rs11961560	chr6:170130121	T/C	cg05834625	chr6:170176447	C6orf70	0.66	7.86	0.43	9.48e-14	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs765787	0.530	rs10851423	chr15:45515950	G/A	cg24006582	chr15:45444508	DUOX1	0.52	6.25	0.36	1.61e-9	Uric acid levels;
CESC	cis	rs11785400	1.000	rs4327844	chr8:143733540	C/T	cg10596483	chr8:143751796	JRK	-0.42	-5.56	-0.32	6.54e-8	Schizophrenia;
CESC	cis	rs174775	0.513	rs3788411	chr22:29728783	T/C	cg07256473	chr22:29710276	RASL10A	-0.47	-7.23	-0.41	5.04e-12	Immature fraction of reticulocytes;
CESC	cis	rs10189230	0.967	rs13012331	chr2:222350600	G/A	cg14652038	chr2:222343519	EPHA4	0.36	7.46	0.42	1.24e-12	Urate levels in lean individuals;
CESC	cis	rs73206853	0.841	rs73191818	chr12:110918721	T/G	cg12870014	chr12:110450643	ANKRD13A	0.63	5.22	0.31	3.56e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs4835473	0.932	rs1838516	chr4:144883235	A/C	cg25736465	chr4:144833511	NA	0.41	6.11	0.35	3.59e-9	Immature fraction of reticulocytes;
CESC	cis	rs4604732	0.588	rs7552443	chr1:247628583	G/T	cg12754571	chr1:247694271	LOC148824;OR2C3	0.41	5.09	0.3	6.91e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs4662945	0.603	rs10168574	chr2:130267823	C/T	cg05903289	chr2:130345205	NA	-0.43	-6.34	-0.36	9.83e-10	Response to cytidine analogues (gemcitabine);
CESC	cis	rs738322	0.967	rs133017	chr22:38572637	A/C	cg25457927	chr22:38595422	NA	-0.3	-5.46	-0.32	1.1e-7	Cutaneous nevi;
CESC	cis	rs4665809	0.590	rs2033317	chr2:26477650	G/A	cg04944784	chr2:26401820	FAM59B	0.96	10.83	0.55	7.34e-23	Gut microbiome composition (summer);
CESC	cis	rs59918340	0.764	rs9324542	chr8:142227854	A/T	cg23750338	chr8:142222470	SLC45A4	-0.58	-8.5	-0.46	1.38e-15	Immature fraction of reticulocytes;
CESC	cis	rs7903847	0.620	rs9787454	chr10:99155561	A/T	cg20016023	chr10:99160130	RRP12	-0.3	-5.16	-0.3	4.77e-7	Granulocyte percentage of myeloid white cells;
CESC	cis	rs2576037	0.526	rs658756	chr18:44431832	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.71	11.38	0.57	1.04e-24	Personality dimensions;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg00491963	chr11:57335356	UBE2L6	-0.43	-6.14	-0.35	3.02e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs9303401	0.614	rs3887355	chr17:56538639	T/C	cg25039879	chr17:56429692	SUPT4H1	0.53	5.39	0.31	1.55e-7	Cognitive test performance;
CESC	cis	rs17711722	0.727	rs1880555	chr7:65432567	T/C	cg14393609	chr7:65229607	NA	0.52	7.09	0.4	1.19e-11	Calcium levels;
CESC	cis	rs2991971	0.934	rs11580609	chr1:45975856	C/G	cg15605315	chr1:45957053	TESK2	0.5	6.63	0.38	1.83e-10	High light scatter reticulocyte count;
CESC	cis	rs6831352	0.851	rs1230164	chr4:99986023	C/G	cg12011299	chr4:100065546	ADH4	0.61	6.92	0.39	3.35e-11	Alcohol dependence;
CESC	cis	rs9768139	0.935	rs7800718	chr7:158121878	G/A	cg24154853	chr7:158122151	PTPRN2	-0.41	-6.51	-0.37	3.79e-10	Calcium levels;
CESC	cis	rs868036	1.000	rs1471460	chr15:68089299	G/A	cg08079166	chr15:68083412	MAP2K5	0.45	7.05	0.4	1.53e-11	Restless legs syndrome;
CESC	cis	rs9457247	0.565	rs2239823	chr6:167512131	T/C	cg07741184	chr6:167504864	NA	0.43	7.65	0.43	3.84e-13	Crohn's disease;
CESC	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg05564831	chr3:52568323	NT5DC2	0.54	9.53	0.51	1.05e-18	Electroencephalogram traits;
CESC	cis	rs9910055	0.529	rs408282	chr17:42182267	A/G	cg08499158	chr17:42289980	UBTF	0.43	5.13	0.3	5.72e-7	Total body bone mineral density;
CESC	cis	rs718433	0.584	rs8015812	chr14:22215075	C/T	cg02257791	chr14:22217085	NA	-0.32	-5.03	-0.3	9.07e-7	Intraocular pressure;
CESC	cis	rs597539	0.652	rs513359	chr11:68669496	A/T	cg21963583	chr11:68658836	MRPL21	-0.36	-5.32	-0.31	2.26e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs6831352	0.918	rs1126672	chr4:100047812	G/A	cg13256891	chr4:100009986	ADH5	-0.77	-8.43	-0.46	2.27e-15	Alcohol dependence;
CESC	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg04234412	chr22:24373322	LOC391322	0.51	7.36	0.41	2.31e-12	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs769267	0.930	rs751856	chr19:19602945	A/G	cg03709012	chr19:19516395	GATAD2A	1.01	15.76	0.7	6.12e-40	Tonsillectomy;
CESC	cis	rs597539	0.652	rs654071	chr11:68653432	A/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.77	10.1	0.53	1.71e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs11252926	0.527	rs10904093	chr10:436848	A/G	cg16386425	chr10:429943	DIP2C	0.51	6.51	0.37	3.7e-10	Psychosis in Alzheimer's disease;
CESC	cis	rs10504229	0.906	rs66480865	chr8:58187100	C/T	cg22535103	chr8:58192502	C8orf71	-1.05	-13.08	-0.63	1.71e-30	Developmental language disorder (linguistic errors);
CESC	trans	rs4756846	0.810	rs78219844	chr11:16459304	A/T	cg05579622	chr5:10618622	ANKRD33B	0.72	6.55	0.37	2.99e-10	Obesity and osteoporosis;
CESC	cis	rs2637266	0.538	rs11001860	chr10:78473388	G/T	cg18941641	chr10:78392320	NA	-0.33	-5.29	-0.31	2.54e-7	Pulmonary function;
CESC	cis	rs3096299	0.606	rs2965946	chr16:89516612	T/C	cg08845973	chr16:89592071	SPG7	-0.37	-5.07	-0.3	7.46e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs6061231	0.583	rs2427313	chr20:60970675	G/A	cg15674680	chr20:60982522	CABLES2	0.49	5.89	0.34	1.18e-8	Colorectal cancer;
CESC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg12393716	chr11:62495049	TTC9C;HNRNPUL2	0.51	6.86	0.39	4.77e-11	Tetralogy of Fallot;
CESC	cis	rs7618915	0.501	rs13079063	chr3:52744460	A/G	cg18337363	chr3:52569053	NT5DC2	0.28	5.2	0.3	3.94e-7	Bipolar disorder;
CESC	cis	rs704795	0.805	rs1728926	chr2:27612937	A/G	cg22903471	chr2:27725779	GCKR	-0.5	-7.08	-0.4	1.32e-11	Menopause (age at onset);
CESC	cis	rs7107174	1.000	rs10899491	chr11:78106305	T/C	cg02023728	chr11:77925099	USP35	0.47	6.25	0.36	1.63e-9	Testicular germ cell tumor;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg22939043	chr6:170059563	WDR27	0.51	6.66	0.38	1.53e-10	Fibrinogen levels;
CESC	cis	rs6964587	0.843	rs56075286	chr7:91731518	G/A	cg17063962	chr7:91808500	NA	0.55	7.49	0.42	1.06e-12	Breast cancer;
CESC	trans	rs6073597	1.000	rs6031980	chr20:43714384	C/T	cg24914313	chr13:41636195	WBP4	0.43	6.05	0.35	4.97e-9	Positive affect;
CESC	cis	rs6752107	0.967	rs12162308	chr2:234172188	C/G	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.36	5.5	0.32	9.16e-8	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs7520050	0.933	rs6680211	chr1:46315007	C/G	cg03146154	chr1:46216737	IPP	-0.48	-6.36	-0.36	8.91e-10	Red blood cell count;Reticulocyte count;
CESC	cis	rs3741404	0.560	rs2875748	chr11:63915537	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.56	-7.83	-0.43	1.15e-13	Platelet count;
CESC	cis	rs6580649	0.941	rs1018973	chr12:48441692	C/G	cg24011408	chr12:48396354	COL2A1	0.42	5.37	0.31	1.7e-7	Lung cancer;
CESC	cis	rs9611565	0.546	rs739134	chr22:42089623	T/C	cg17376030	chr22:41985996	PMM1	-0.66	-7.16	-0.4	7.77e-12	Vitiligo;
CESC	cis	rs875971	0.862	rs28491091	chr7:65669064	G/T	cg10691866	chr7:65817282	TPST1	0.32	5.3	0.31	2.42e-7	Aortic root size;
CESC	cis	rs7833986	0.501	rs2719261	chr8:56941982	C/G	cg26371346	chr8:56986568	SNORD54;RPS20	0.59	5.49	0.32	9.26e-8	Height;
CESC	cis	rs2228479	0.614	rs1137042	chr16:89975638	A/G	cg00800038	chr16:89945340	TCF25	-0.53	-5.72	-0.33	2.95e-8	Skin colour saturation;
CESC	trans	rs61931739	0.500	rs11053243	chr12:34514155	T/C	cg26384229	chr12:38710491	ALG10B	0.54	7.55	0.42	7.05e-13	Morning vs. evening chronotype;
CESC	trans	rs875971	1.000	rs11974264	chr7:65647582	C/G	cg26939375	chr7:64535504	NA	-0.48	-6.37	-0.36	8.2e-10	Aortic root size;
CESC	cis	rs4727963	0.792	rs6466853	chr7:122719094	C/A	cg03640110	chr7:122635026	TAS2R16	-0.38	-5.89	-0.34	1.14e-8	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
CESC	cis	rs7208859	0.673	rs7211776	chr17:29120196	T/G	cg14008862	chr17:28927542	LRRC37B2	0.57	5.43	0.32	1.3e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs950169	0.922	rs11630507	chr15:85095725	A/G	cg17507749	chr15:85114479	UBE2QP1	0.57	6.37	0.36	8.53e-10	Schizophrenia;
CESC	cis	rs875971	1.000	rs1183245	chr7:65541185	C/T	cg10691866	chr7:65817282	TPST1	0.33	5.21	0.3	3.74e-7	Aortic root size;
CESC	cis	rs7945705	0.869	rs4909952	chr11:8963946	A/G	cg12365402	chr11:9010492	NRIP3	0.37	5.82	0.34	1.68e-8	Hemoglobin concentration;
CESC	cis	rs1957429	0.808	rs4899150	chr14:65344400	A/G	cg23373153	chr14:65346875	NA	1.02	10.46	0.54	1.15e-21	Pediatric areal bone mineral density (radius);
CESC	cis	rs1008375	1.000	rs1558378	chr4:17650351	T/C	cg16339924	chr4:17578868	LAP3	0.65	8.27	0.45	6.38e-15	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs4555082	0.957	rs2816627	chr14:105736109	A/G	cg10792982	chr14:105748885	BRF1	0.4	5.65	0.33	4.21e-8	Mean platelet volume;Platelet distribution width;
CESC	cis	rs763121	0.853	rs6001188	chr22:39062194	T/C	cg21395723	chr22:39101663	GTPBP1	0.46	5.78	0.33	2.08e-8	Menopause (age at onset);
CESC	trans	rs61931739	0.500	rs35030191	chr12:34548865	C/T	cg26384229	chr12:38710491	ALG10B	0.72	10.84	0.55	6.43e-23	Morning vs. evening chronotype;
CESC	cis	rs1957429	0.808	rs6573580	chr14:65331766	C/G	cg23373153	chr14:65346875	NA	0.88	9.2	0.49	1.13e-17	Pediatric areal bone mineral density (radius);
CESC	cis	rs798554	0.616	rs1636252	chr7:2884993	A/C	cg19717773	chr7:2847554	GNA12	-0.48	-7.28	-0.41	3.7e-12	Height;
CESC	cis	rs2040771	0.804	rs2073754	chr22:19221406	G/T	cg02655711	chr22:19163373	SLC25A1	-0.4	-5.77	-0.33	2.23e-8	Metabolite levels (small molecules and protein measures);
CESC	cis	rs6582630	0.502	rs10880388	chr12:38401341	A/T	cg26384229	chr12:38710491	ALG10B	0.72	10.94	0.56	3.12e-23	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs7772486	0.754	rs6921073	chr6:146144377	G/A	cg23711669	chr6:146136114	FBXO30	0.89	13.07	0.63	1.87e-30	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7590720	1.000	rs6435930	chr2:216885852	A/G	cg12620499	chr2:216877984	MREG	0.91	12.4	0.61	3.63e-28	Alcohol dependence;
CESC	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	21.51	0.8	4.47e-60	Prudent dietary pattern;
CESC	cis	rs514406	0.505	rs146750	chr1:53183447	C/G	cg16325326	chr1:53192061	ZYG11B	0.91	16.16	0.7	2.32e-41	Monocyte count;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg20119015	chr4:36245632	ARAP2	-0.38	-6.07	-0.35	4.34e-9	Gambling;
CESC	cis	rs801193	0.548	rs2659891	chr7:66201114	A/G	cg18876405	chr7:65276391	NA	0.44	6.06	0.35	4.76e-9	Aortic root size;
CESC	cis	rs9326248	0.530	rs2000615	chr11:116915819	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.6	5.43	0.32	1.28e-7	Blood protein levels;
CESC	cis	rs17407555	0.520	rs4292327	chr4:9943700	G/A	cg11266682	chr4:10021025	SLC2A9	-0.51	-6.34	-0.36	9.88e-10	Schizophrenia (age at onset);
CESC	cis	rs2721195	0.967	rs1480000	chr8:145702007	C/T	cg17328964	chr8:145687451	CYHR1	0.49	6.62	0.38	2.04e-10	Age at first birth;
CESC	cis	rs6032067	0.929	rs35880287	chr20:43821001	G/A	cg10761708	chr20:43804764	PI3	0.53	6.39	0.37	7.37e-10	Blood protein levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15030636	chr1:246768697	CNST	-0.47	-6.03	-0.35	5.38e-9	Gut microbiome composition (summer);
CESC	cis	rs1153858	1.000	rs1554521	chr15:45664189	A/T	cg14582100	chr15:45693742	SPATA5L1	-0.41	-5.91	-0.34	1.07e-8	Homoarginine levels;
CESC	cis	rs2635047	0.904	rs2635046	chr18:44728429	G/A	cg24371990	chr18:44770781	NA	0.33	5.25	0.31	3.15e-7	Educational attainment;
CESC	cis	rs8067354	0.574	rs7219089	chr17:58032865	C/T	cg13753209	chr17:57696993	CLTC	0.53	5.59	0.32	5.61e-8	Hemoglobin concentration;
CESC	cis	rs1665050	0.534	rs12900291	chr15:59240419	T/C	cg05156742	chr15:59063176	FAM63B	0.5	6.42	0.37	6.18e-10	Atopic dermatitis;
CESC	cis	rs72781680	0.611	rs72783625	chr2:24315540	C/T	cg06627628	chr2:24431161	ITSN2	-0.68	-6.58	-0.37	2.44e-10	Lymphocyte counts;
CESC	cis	rs6547741	1.000	rs6749052	chr2:27772879	A/T	cg27432699	chr2:27873401	GPN1	0.49	6.82	0.39	6.33e-11	Oral cavity cancer;
CESC	cis	rs820218	0.743	rs11652586	chr17:73690287	G/A	cg01592526	chr17:73663357	RECQL5;SAP30BP	-0.44	-6.03	-0.35	5.57e-9	Rotator cuff tears;
CESC	cis	rs11864453	0.647	rs9941346	chr16:72135707	C/G	cg01557791	chr16:72042693	DHODH	-0.43	-5.63	-0.33	4.58e-8	Fibrinogen levels;
CESC	cis	rs11229555	0.645	rs72917641	chr11:58227320	A/C	cg15696309	chr11:58395628	NA	-0.45	-5.22	-0.31	3.63e-7	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20272604	chr1:231004631	C1orf198	0.6	6.89	0.39	4.15e-11	Gut microbiome composition (summer);
CESC	cis	rs4727027	0.840	rs12670633	chr7:148796707	G/A	cg23583168	chr7:148888333	NA	-0.79	-12.1	-0.6	4.02e-27	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs8002861	0.727	rs9533652	chr13:44419532	A/G	cg19180546	chr13:44453867	C13orf31;CCDC122	-0.4	-5.26	-0.31	2.99e-7	Leprosy;
CESC	cis	rs514406	0.893	rs1242315	chr1:53417181	A/G	cg08736216	chr1:53307985	ZYG11A	-0.41	-6.56	-0.37	2.85e-10	Monocyte count;
CESC	cis	rs11098499	0.954	rs9993199	chr4:120392873	A/G	cg09307838	chr4:120376055	NA	-0.97	-14.58	-0.67	9.09e-36	Corneal astigmatism;
CESC	trans	rs1814175	0.647	rs10769646	chr11:49992204	C/A	cg03929089	chr4:120376271	NA	-0.92	-15.24	-0.68	4.38e-38	Height;
CESC	cis	rs7605378	0.528	rs281787	chr2:200784238	C/T	cg17644776	chr2:200775616	C2orf69	-0.52	-6.45	-0.37	5.2e-10	Osteoporosis;
CESC	cis	rs9287719	0.967	rs715247	chr2:10736291	A/G	cg02196655	chr2:10830764	NOL10	-0.37	-5.72	-0.33	2.87e-8	Prostate cancer;
CESC	cis	rs10504229	0.639	rs56066782	chr8:58105857	A/G	cg22535103	chr8:58192502	C8orf71	-0.77	-8.76	-0.47	2.37e-16	Developmental language disorder (linguistic errors);
CESC	cis	rs12142240	0.698	rs56909107	chr1:46808224	A/C	cg00530320	chr1:46809349	NSUN4	0.6	7.98	0.44	4.48e-14	Menopause (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22004443	chr2:10953237	PDIA6	-0.54	-6.37	-0.36	8.22e-10	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16693872	chr5:176882643	PRR7	0.64	7.77	0.43	1.76e-13	Gut microbiome composition (summer);
CESC	cis	rs2839186	0.585	rs2839154	chr21:47637760	C/T	cg13126279	chr21:47581558	C21orf56	0.41	5.24	0.31	3.26e-7	Testicular germ cell tumor;
CESC	trans	rs1829883	0.733	rs2461996	chr5:98721657	T/A	cg23861655	chr4:57411219	NA	0.38	6.12	0.35	3.27e-9	Hemostatic factors and hematological phenotypes;
CESC	cis	rs13191362	1.000	rs35103567	chr6:163183400	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.97	9.3	0.5	5.47e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs8064299	0.597	rs7210318	chr17:72783385	T/C	cg25054828	chr17:72772726	NAT9;TMEM104	0.82	13.99	0.65	1.09e-33	Monocyte count;
CESC	cis	rs2072732	0.861	rs6692292	chr1:2959610	C/T	cg15211996	chr1:2936768	ACTRT2	-0.31	-5.38	-0.31	1.66e-7	Plateletcrit;
CESC	cis	rs832540	0.806	rs10039322	chr5:56260259	A/C	cg14703610	chr5:56206110	C5orf35	0.45	5.91	0.34	1.03e-8	Coronary artery disease;
CESC	cis	rs501120	1.000	rs554565	chr10:44755448	G/A	cg09554077	chr10:44749378	NA	0.54	7.1	0.4	1.14e-11	Coronary artery disease;Coronary heart disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10204999	chr14:103057895	RCOR1	0.53	6.26	0.36	1.51e-9	Gut microbiome composition (summer);
CESC	cis	rs514406	0.800	rs4926930	chr1:53217335	A/G	cg24675658	chr1:53192096	ZYG11B	0.54	6.8	0.39	6.96e-11	Monocyte count;
CESC	cis	rs6570726	0.791	rs6570694	chr6:145911204	C/G	cg23711669	chr6:146136114	FBXO30	0.92	13.58	0.64	3.16e-32	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6580649	0.941	rs1968071	chr12:48489357	A/G	cg24011408	chr12:48396354	COL2A1	-0.41	-5.13	-0.3	5.73e-7	Lung cancer;
CESC	trans	rs9944275	0.860	rs35862958	chr15:97192556	G/A	cg26794346	chr6:16472305	ATXN1	0.75	6.1	0.35	3.64e-9	Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
CESC	trans	rs17613427	1.000	rs112138076	chr2:142238491	G/A	cg16810031	chr17:38024146	ZPBP2	-0.9	-6.22	-0.36	1.89e-9	Left  ventricle systolic dysfunction;
CESC	cis	rs1008375	0.932	rs6449321	chr4:17644472	A/G	cg15017067	chr4:17643749	FAM184B	0.36	5.16	0.3	4.78e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs11264213	0.901	rs72661625	chr1:36401003	T/C	cg27506609	chr1:36549197	TEKT2	0.66	5.55	0.32	6.79e-8	Schizophrenia;
CESC	cis	rs1559088	0.546	rs11881543	chr19:33559372	T/G	cg03563238	chr19:33554763	RHPN2	-0.32	-5.8	-0.34	1.9e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs2486288	0.656	rs2461705	chr15:45570241	A/G	cg09092052	chr15:45571596	NA	0.51	5.96	0.34	8.16e-9	Glomerular filtration rate;
CESC	cis	rs7824557	0.606	rs2736264	chr8:11186639	G/C	cg21775007	chr8:11205619	TDH	0.5	7.23	0.41	5.21e-12	Retinal vascular caliber;
CESC	cis	rs2276314	0.802	rs58906216	chr18:33630297	T/C	cg19628046	chr18:33552617	C18orf21	0.5	5.49	0.32	9.61e-8	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs11098499	0.866	rs12374244	chr4:120281972	A/T	cg09307838	chr4:120376055	NA	0.87	12.16	0.6	2.41e-27	Corneal astigmatism;
CESC	cis	rs12971120	0.891	rs2303463	chr18:72168608	G/A	cg26446133	chr18:72167187	CNDP2	-0.76	-9.63	-0.51	4.99e-19	Refractive error;
CESC	cis	rs2842992	0.750	rs2758354	chr6:160125854	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.74	8.97	0.48	5.73e-17	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs1055129	0.655	rs8067076	chr17:73837142	G/T	cg08125733	chr17:73851984	WBP2	-0.5	-6.88	-0.39	4.23e-11	White matter hyperintensity burden;
CESC	cis	rs7772486	0.875	rs7761033	chr6:146356106	C/T	cg05347473	chr6:146136440	FBXO30	0.5	6.51	0.37	3.72e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6696846	0.716	rs6593921	chr1:205062861	A/G	cg00857998	chr1:205179979	DSTYK	0.52	7.11	0.4	1.06e-11	Red blood cell count;
CESC	cis	rs2573652	1.000	rs2581363	chr15:100513364	G/A	cg00587665	chr15:100533223	ADAMTS17	-0.33	-5.37	-0.31	1.68e-7	Height;
CESC	cis	rs1559088	0.600	rs7255229	chr19:33562807	A/G	cg03563238	chr19:33554763	RHPN2	-0.32	-5.85	-0.34	1.46e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs854765	0.663	rs1108648	chr17:17750558	G/A	cg16928487	chr17:17741425	SREBF1	0.58	10.25	0.53	5.65e-21	Total body bone mineral density;
CESC	cis	rs9303401	0.614	rs28651036	chr17:57080471	G/A	cg12560992	chr17:57184187	TRIM37	0.5	5.21	0.3	3.83e-7	Cognitive test performance;
CESC	cis	rs7945705	0.967	rs56316046	chr11:8876598	G/T	cg12365402	chr11:9010492	NRIP3	0.35	5.36	0.31	1.81e-7	Hemoglobin concentration;
CESC	cis	rs4665809	0.567	rs6546848	chr2:26444414	G/C	cg22920501	chr2:26401640	FAM59B	-0.93	-10.89	-0.56	4.54e-23	Gut microbiome composition (summer);
CESC	cis	rs9660180	0.783	rs1107910	chr1:1692321	C/T	cg03396347	chr1:1875803	NA	-0.33	-5.33	-0.31	2.14e-7	Body mass index;
CESC	cis	rs7927771	1.000	rs7120333	chr11:47817441	C/T	cg05585544	chr11:47624801	NA	-0.49	-7.71	-0.43	2.62e-13	Subjective well-being;
CESC	cis	rs514406	0.861	rs7417821	chr1:53295117	A/G	cg08736216	chr1:53307985	ZYG11A	-0.33	-5.7	-0.33	3.2e-8	Monocyte count;
CESC	trans	rs1728785	1.000	rs1099296	chr16:68588653	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.65	7.82	0.43	1.24e-13	Ulcerative colitis;
CESC	cis	rs9487051	0.714	rs9386797	chr6:109632520	C/A	cg01475377	chr6:109611718	NA	-0.46	-7.2	-0.4	6.15e-12	Reticulocyte fraction of red cells;
CESC	cis	rs2249625	0.874	rs1830335	chr6:72902788	C/T	cg18830697	chr6:72922368	RIMS1	-0.35	-5.06	-0.3	7.97e-7	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CESC	cis	rs34779708	0.966	rs11599606	chr10:35406626	G/A	cg03585969	chr10:35415529	CREM	0.77	10.02	0.52	2.99e-20	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs7714584	1.000	rs11950957	chr5:150253914	G/A	cg22134413	chr5:150180641	NA	0.51	5.92	0.34	9.88e-9	Crohn's disease;
CESC	cis	rs11155671	0.530	rs7758033	chr6:150208135	T/C	cg09699651	chr6:150184138	LRP11	0.55	7.5	0.42	9.65e-13	Testicular germ cell tumor;
CESC	cis	rs7811142	1.000	rs74460138	chr7:100027339	C/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.06	10.39	0.54	1.98e-21	Platelet count;
CESC	cis	rs9916302	0.653	rs11654954	chr17:37745979	C/T	cg20243544	chr17:37824526	PNMT	-0.58	-5.4	-0.31	1.47e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs9291683	0.632	rs10939669	chr4:10045827	A/G	cg11266682	chr4:10021025	SLC2A9	0.68	13.29	0.63	3.1e-31	Bone mineral density;
CESC	cis	rs425277	0.606	rs2459984	chr1:2086312	A/G	cg23803603	chr1:2058230	PRKCZ	0.33	5.81	0.34	1.83e-8	Height;
CESC	cis	rs459571	0.629	rs441233	chr9:136876021	A/G	cg13789015	chr9:136890014	NCRNA00094	-0.48	-6.57	-0.37	2.66e-10	Platelet distribution width;
CESC	cis	rs9902453	0.967	rs56326816	chr17:28492805	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	7.9	0.44	7.44e-14	Coffee consumption (cups per day);
CESC	cis	rs2842992	0.662	rs2273826	chr6:160211421	A/G	cg11366901	chr6:160182831	ACAT2	0.64	8.17	0.45	1.24e-14	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs3806843	1.000	rs10050455	chr5:140204650	A/G	cg26395211	chr5:140044315	WDR55	-0.44	-5.49	-0.32	9.2e-8	Depressive symptoms (multi-trait analysis);
CESC	cis	rs9488822	0.676	rs3798227	chr6:116324898	A/G	cg15226275	chr6:116381976	FRK	0.25	6.22	0.36	1.94e-9	Cholesterol, total;LDL cholesterol;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07318050	chr1:233086124	C1orf57	-0.54	-6.44	-0.37	5.72e-10	Gut microbiome composition (summer);
CESC	trans	rs9325144	0.560	rs11182930	chr12:38633693	A/T	cg23762105	chr12:34175262	ALG10	0.48	6.31	0.36	1.16e-9	Morning vs. evening chronotype;
CESC	cis	rs4665809	0.590	rs11552518	chr2:26455127	G/A	cg27170947	chr2:26402098	FAM59B	0.87	9.85	0.52	1.01e-19	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06370812	chr3:195501042	MUC4	-0.58	-6.78	-0.38	7.77e-11	Gut microbiome composition (summer);
CESC	cis	rs9311474	0.508	rs6805156	chr3:52609362	T/C	cg18337363	chr3:52569053	NT5DC2	0.3	5.58	0.32	5.86e-8	Electroencephalogram traits;
CESC	cis	rs1577917	0.958	rs36053156	chr6:86575509	T/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.51	-6.57	-0.37	2.66e-10	Response to antipsychotic treatment;
CESC	cis	rs7697216	0.668	rs28502453	chr4:175837394	G/A	cg14561282	chr4:175839468	ADAM29	0.44	5.04	0.3	8.63e-7	Breast cancer;
CESC	cis	rs2290720	0.930	rs4764642	chr12:101691922	C/T	cg22051763	chr12:101673672	UTP20	-0.47	-5.8	-0.34	1.88e-8	Brain structure (hippocampal volume);
CESC	cis	rs7412746	0.634	rs4451553	chr1:150937329	C/T	cg04414720	chr1:150670196	GOLPH3L	0.52	6.8	0.39	6.96e-11	Melanoma;
CESC	cis	rs11098499	0.739	rs2203039	chr4:120132347	T/C	cg09307838	chr4:120376055	NA	-0.67	-8.27	-0.45	6.77e-15	Corneal astigmatism;
CESC	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg23224405	chr12:12715060	DUSP16	0.5	6.55	0.37	2.94e-10	Myopia (pathological);
CESC	cis	rs1878931	0.582	rs9937267	chr16:3421073	C/T	cg02880119	chr16:3481970	NA	-0.4	-5.22	-0.31	3.67e-7	Body mass index (adult);
CESC	cis	rs2040771	0.770	rs2518840	chr22:19255856	A/C	cg02655711	chr22:19163373	SLC25A1	0.41	5.92	0.34	9.81e-9	Metabolite levels (small molecules and protein measures);
CESC	cis	rs9796	0.835	rs11856848	chr15:41370961	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.42	-6.23	-0.36	1.78e-9	Menopause (age at onset);
CESC	cis	rs847577	0.506	rs7808528	chr7:97721425	G/T	cg24562669	chr7:97807699	LMTK2	0.82	14.13	0.66	3.71e-34	Breast cancer;
CESC	cis	rs79976124	0.879	rs17511467	chr6:66627293	T/C	cg07460842	chr6:66804631	NA	0.74	8.58	0.47	7.85e-16	Type 2 diabetes;
CESC	cis	rs2933343	0.649	rs728839	chr3:128589359	A/G	cg24203234	chr3:128598194	ACAD9	0.42	5.76	0.33	2.33e-8	IgG glycosylation;
CESC	cis	rs4665809	0.590	rs10179959	chr2:26426403	G/A	cg22920501	chr2:26401640	FAM59B	-0.87	-10.07	-0.53	2.06e-20	Gut microbiome composition (summer);
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg20782850	chr6:117002205	KPNA5	0.52	6.26	0.36	1.58e-9	Thyroid stimulating hormone;
CESC	cis	rs1005277	0.579	rs9299760	chr10:38377920	C/T	cg25427524	chr10:38739819	LOC399744	-0.66	-9.52	-0.5	1.15e-18	Extrinsic epigenetic age acceleration;
CESC	cis	rs6460942	0.597	rs4721105	chr7:12534881	C/T	cg02935154	chr7:12443704	VWDE	-0.57	-5.7	-0.33	3.23e-8	Coronary artery disease;
CESC	cis	rs7208859	0.623	rs11650982	chr17:29129955	A/G	cg14008862	chr17:28927542	LRRC37B2	0.65	5.14	0.3	5.34e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs7618915	0.508	rs7628578	chr3:52628321	A/T	cg18404041	chr3:52824283	ITIH1	-0.4	-6.86	-0.39	4.8e-11	Bipolar disorder;
CESC	trans	rs1814175	0.781	rs2866734	chr11:49886338	A/G	cg03929089	chr4:120376271	NA	-0.91	-15.66	-0.69	1.37e-39	Height;
CESC	cis	rs8068544	0.818	rs79892925	chr17:40171819	A/G	cg18442075	chr17:40169520	DNAJC7;NKIRAS2	-0.94	-8.36	-0.46	3.65e-15	Reticulocyte fraction of red cells;Reticulocyte count;
CESC	cis	rs9309473	0.500	rs12996463	chr2:73655496	T/C	cg20560298	chr2:73613845	ALMS1	0.51	7.2	0.4	6.13e-12	Metabolite levels;
CESC	cis	rs72781680	1.000	rs72781671	chr2:24231123	A/G	cg08917208	chr2:24149416	ATAD2B	1.1	9.63	0.51	5.25e-19	Lymphocyte counts;
CESC	cis	rs4555082	0.957	rs3825762	chr14:105752404	T/C	cg10792982	chr14:105748885	BRF1	0.37	5.06	0.3	7.93e-7	Mean platelet volume;Platelet distribution width;
CESC	cis	rs7605827	0.930	rs11687253	chr2:15655869	A/G	cg19274914	chr2:15703543	NA	-0.31	-5.42	-0.32	1.36e-7	Educational attainment (years of education);
CESC	cis	rs559928	0.556	rs11607903	chr11:63932140	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.66	5.84	0.34	1.55e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CESC	cis	rs12479064	0.604	rs11893359	chr2:99954608	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.62	-7.4	-0.41	1.77e-12	Chronic sinus infection;
CESC	cis	rs262150	0.659	rs2527236	chr7:158796644	C/T	cg09640425	chr7:158790006	NA	-0.39	-6.07	-0.35	4.5e-9	Facial morphology (factor 20);
CESC	cis	rs9300255	0.510	rs1727323	chr12:123698790	T/C	cg00376283	chr12:123451042	ABCB9	0.7	8.83	0.48	1.41e-16	Neutrophil percentage of white cells;
CESC	cis	rs3858526	0.883	rs10769333	chr11:5939685	A/T	cg05234568	chr11:5960015	NA	-0.59	-6.95	-0.39	2.86e-11	DNA methylation (variation);
CESC	cis	rs514406	0.505	rs425520	chr1:53179805	C/G	cg16325326	chr1:53192061	ZYG11B	0.91	15.97	0.7	1.07e-40	Monocyte count;
CESC	cis	rs1881797	1.000	rs10158379	chr1:247686352	C/A	cg05639522	chr1:247681581	NA	0.46	6.02	0.35	5.84e-9	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs7208859	0.623	rs9890862	chr17:29125450	C/A	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.1e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg18538332	chr22:24372958	LOC391322	-0.81	-12.45	-0.61	2.48e-28	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs2839186	0.508	rs6518278	chr21:47640571	A/G	cg09417038	chr21:47716443	C21orf57	0.49	6.73	0.38	1.06e-10	Testicular germ cell tumor;
CESC	cis	rs155076	0.938	rs261375	chr13:21871882	A/G	cg11317459	chr13:21872234	NA	1.14	12.64	0.61	5.7e-29	White matter hyperintensity burden;
CESC	cis	rs2228479	0.850	rs3785281	chr16:89824263	G/C	cg04013166	chr16:89971882	TCF25	0.79	6.75	0.38	9.14e-11	Skin colour saturation;
CESC	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	10.1	0.53	1.64e-20	Prudent dietary pattern;
CESC	cis	rs3796619	0.961	rs11732520	chr4:1074009	C/T	cg27284194	chr4:1044797	NA	0.36	5.47	0.32	1.07e-7	Recombination rate (males);
CESC	cis	rs6466055	0.720	rs2030776	chr7:105008458	C/G	cg04380332	chr7:105027541	SRPK2	-0.43	-5.73	-0.33	2.75e-8	Schizophrenia;
CESC	cis	rs9457247	0.967	rs433191	chr6:167409662	T/A	cg07741184	chr6:167504864	NA	0.3	5.35	0.31	1.86e-7	Crohn's disease;
CESC	cis	rs765787	0.530	rs4238377	chr15:45541981	A/G	cg24006582	chr15:45444508	DUOX1	-0.59	-7.32	-0.41	3.04e-12	Uric acid levels;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg17367356	chr11:45907078	MAPK8IP1	-0.48	-6.36	-0.36	8.65e-10	Fibrinogen levels;
CESC	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg24642844	chr7:1081250	C7orf50	-0.75	-8.99	-0.48	4.94e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2066819	1.000	rs2066808	chr12:56737973	A/G	cg26734620	chr12:56694298	CS	0.88	8.75	0.47	2.56e-16	Psoriasis vulgaris;
CESC	cis	rs4906332	1.000	rs7155980	chr14:103922419	C/G	cg09975044	chr14:104007538	NA	0.47	6.53	0.37	3.32e-10	Coronary artery disease;
CESC	cis	rs7618915	0.547	rs10780035	chr3:52764624	C/T	cg17372223	chr3:52568218	NT5DC2	0.44	6.55	0.37	2.98e-10	Bipolar disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02041137	chr17:3571890	TMEM93;TAX1BP3	0.53	6.15	0.35	2.85e-9	Gut microbiome composition (summer);
CESC	cis	rs7116495	1.000	rs642573	chr11:71780854	G/C	cg26138937	chr11:71823887	C11orf51	-0.78	-6.47	-0.37	4.72e-10	Severe influenza A (H1N1) infection;
CESC	cis	rs1559088	1.000	rs1559088	chr19:33551061	C/T	cg17764715	chr19:33622953	WDR88	0.45	5.65	0.33	4.14e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs728616	0.867	rs61860420	chr10:81739379	G/A	cg05935833	chr10:81318306	SFTPA2	-0.52	-5.06	-0.3	7.72e-7	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs12477438	0.798	rs1453561	chr2:99613924	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.72	-10.25	-0.53	5.55e-21	Chronic sinus infection;
CESC	cis	rs6866344	0.697	rs11748495	chr5:178130000	A/G	cg10224037	chr5:178157518	ZNF354A	-0.64	-7.0	-0.4	2.1e-11	Neutrophil percentage of white cells;
CESC	cis	rs992157	0.835	rs2292551	chr2:219143229	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.67	-8.69	-0.47	3.72e-16	Colorectal cancer;
CESC	cis	rs7071206	0.947	rs4979902	chr10:79399946	C/T	cg00983440	chr10:79422392	NA	0.72	8.85	0.48	1.23e-16	Bone mineral density;
CESC	trans	rs11098499	0.954	rs17046116	chr4:120387259	G/A	cg25214090	chr10:38739885	LOC399744	0.7	9.93	0.52	5.63e-20	Corneal astigmatism;
CESC	cis	rs7828089	0.542	rs7332050	chr8:22265294	G/T	cg12081754	chr8:22256438	SLC39A14	0.63	8.66	0.47	4.61e-16	Verbal declarative memory;
CESC	trans	rs11039798	0.764	rs10838882	chr11:48393035	T/A	cg15704280	chr7:45808275	SEPT13	0.68	6.21	0.36	2.09e-9	Axial length;
CESC	cis	rs6582630	0.519	rs12372510	chr12:38293074	T/C	cg13010199	chr12:38710504	ALG10B	0.43	5.43	0.32	1.25e-7	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs9911578	0.839	rs1871751	chr17:57190368	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.4	5.3	0.31	2.38e-7	Intelligence (multi-trait analysis);
CESC	cis	rs372883	0.583	rs117214	chr21:30720834	A/G	cg24692254	chr21:30365293	RNF160	0.42	5.33	0.31	2.08e-7	Pancreatic cancer;
CESC	cis	rs4919694	1.000	rs78893207	chr10:104796138	T/C	cg04362960	chr10:104952993	NT5C2	0.78	6.76	0.38	8.63e-11	Arsenic metabolism;
CESC	cis	rs6938	0.514	rs56338926	chr15:75259335	C/A	cg17294928	chr15:75287854	SCAMP5	0.51	6.38	0.37	7.72e-10	Breast cancer;
CESC	cis	rs7432375	0.610	rs56163507	chr3:136516056	C/T	cg15507776	chr3:136538369	TMEM22	0.6	7.91	0.44	6.92e-14	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
CESC	cis	rs2282802	0.685	rs1529693	chr5:139678213	A/G	cg26211634	chr5:139558579	C5orf32	0.48	6.99	0.39	2.29e-11	Intelligence (multi-trait analysis);
CESC	cis	rs757110	0.770	rs11024268	chr11:17387982	A/G	cg15432903	chr11:17409602	KCNJ11	0.6	8.5	0.46	1.36e-15	Type 2 diabetes;
CESC	cis	rs1552244	0.752	rs9867091	chr3:10043429	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	10.91	0.56	3.81e-23	Alzheimer's disease;
CESC	cis	rs10504073	0.584	rs4873304	chr8:49922733	G/A	cg00325661	chr8:49890786	NA	0.55	8.31	0.45	5.1e-15	Blood metabolite ratios;
CESC	cis	rs2228479	0.717	rs2286392	chr16:89809549	A/G	cg04287289	chr16:89883240	FANCA	0.71	6.53	0.37	3.42e-10	Skin colour saturation;
CESC	cis	rs7666738	0.761	rs13136913	chr4:98998031	C/T	cg05340658	chr4:99064831	C4orf37	0.8	12.44	0.61	2.83e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7618915	0.524	rs35249778	chr3:52661640	G/C	cg18099408	chr3:52552593	STAB1	-0.3	-5.05	-0.3	8.36e-7	Bipolar disorder;
CESC	cis	rs2243480	1.000	rs313814	chr7:65503293	C/A	cg13147721	chr7:65941812	NA	-0.93	-8.89	-0.48	9.72e-17	Diabetic kidney disease;
CESC	cis	rs7772486	0.681	rs9390343	chr6:146010527	A/T	cg23711669	chr6:146136114	FBXO30	-0.82	-11.42	-0.57	8.12e-25	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs561341	0.941	rs2428341	chr17:30317295	C/T	cg23018236	chr17:30244563	NA	-0.45	-5.57	-0.32	6.34e-8	Hip circumference adjusted for BMI;
CESC	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg18402987	chr7:1209562	NA	0.75	7.45	0.42	1.32e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7903847	0.667	rs7096801	chr10:99140969	T/C	cg20016023	chr10:99160130	RRP12	-0.29	-5.04	-0.3	8.52e-7	Granulocyte percentage of myeloid white cells;
CESC	cis	rs929596	0.561	rs11891311	chr2:234639310	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.61	8.15	0.45	1.45e-14	Total bilirubin levels in HIV-1 infection;
CESC	cis	rs708547	0.874	rs1630798	chr4:57883558	T/C	cg16868167	chr4:57843880	C4orf14;POLR2B	0.69	7.8	0.43	1.45e-13	Response to bleomycin (chromatid breaks);
CESC	trans	rs9693444	0.898	rs4732697	chr8:29519861	A/G	cg01470323	chr11:66139715	SLC29A2	-0.42	-6.07	-0.35	4.31e-9	Breast cancer;
CESC	cis	rs763014	0.898	rs2017567	chr16:637212	T/C	cg09263875	chr16:632152	PIGQ	0.68	11.75	0.59	6.29e-26	Height;
CESC	cis	rs7605827	0.930	rs1852751	chr2:15557320	C/T	cg19274914	chr2:15703543	NA	0.36	6.56	0.37	2.83e-10	Educational attainment (years of education);
CESC	cis	rs704795	0.867	rs7566052	chr2:27628635	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.28	-5.32	-0.31	2.19e-7	Menopause (age at onset);
CESC	cis	rs7122539	0.646	rs543191	chr11:66583779	T/G	cg24851651	chr11:66362959	CCS	0.49	7.11	0.4	1.08e-11	HIV-1 susceptibility;
CESC	cis	rs9649213	0.593	rs6465683	chr7:98026092	C/A	cg21770322	chr7:97807741	LMTK2	0.55	8.28	0.45	5.99e-15	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs67460515	0.892	rs1382429	chr3:161015153	T/C	cg03342759	chr3:160939853	NMD3	-0.52	-7.2	-0.4	6.27e-12	Parkinson's disease;
CESC	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg18402987	chr7:1209562	NA	0.56	6.69	0.38	1.3e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs425277	1.000	rs262657	chr1:2088577	G/A	cg04315214	chr1:2043799	PRKCZ	-0.38	-5.25	-0.31	3.19e-7	Height;
CESC	cis	rs798554	1.000	rs798550	chr7:2760609	A/G	cg13628971	chr7:2884303	GNA12	0.59	7.86	0.43	9.56e-14	Height;
CESC	cis	rs12479064	0.724	rs2305352	chr2:100015124	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.58	-7.01	-0.4	1.98e-11	Chronic sinus infection;
CESC	cis	rs10504229	0.683	rs7827014	chr8:58132230	G/A	cg24829409	chr8:58192753	C8orf71	-0.58	-7.2	-0.4	6.31e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs1862618	0.573	rs185220	chr5:56205357	A/G	cg24549020	chr5:56110836	MAP3K1	0.58	6.41	0.37	6.79e-10	Initial pursuit acceleration;
CESC	cis	rs9311474	0.539	rs12489828	chr3:52567014	G/T	cg05564831	chr3:52568323	NT5DC2	0.52	8.88	0.48	1.04e-16	Electroencephalogram traits;
CESC	cis	rs8060686	0.641	rs75450962	chr16:68210868	C/T	cg26727032	chr16:67993705	SLC12A4	-0.53	-6.03	-0.35	5.55e-9	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs7953249	0.564	rs11065385	chr12:121423386	A/G	cg02403541	chr12:121454288	C12orf43	-0.65	-8.68	-0.47	4.12e-16	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
CESC	cis	rs2019216	0.542	rs7217513	chr17:21933536	C/A	cg22648282	chr17:21454238	C17orf51	-0.39	-5.07	-0.3	7.37e-7	Pelvic organ prolapse;
CESC	cis	rs3785574	0.962	rs2665799	chr17:61919723	A/G	cg07677032	chr17:61819896	STRADA	0.43	5.37	0.31	1.69e-7	Height;
CESC	cis	rs667920	0.500	rs34498968	chr3:136195130	T/C	cg15507776	chr3:136538369	TMEM22	-0.72	-6.1	-0.35	3.66e-9	Coronary artery disease;
CESC	cis	rs2228479	0.541	rs9806913	chr16:89953773	A/G	cg06558623	chr16:89946397	TCF25	0.59	5.84	0.34	1.52e-8	Skin colour saturation;
CESC	cis	rs6964587	0.610	rs2888850	chr7:91430027	T/C	cg17063962	chr7:91808500	NA	0.43	5.87	0.34	1.3e-8	Breast cancer;
CESC	cis	rs10504229	0.953	rs59265461	chr8:58189701	A/T	cg24829409	chr8:58192753	C8orf71	-0.76	-9.93	-0.52	5.87e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs963731	0.649	rs297139	chr2:39318310	A/G	cg04010122	chr2:39346883	SOS1	-0.74	-5.39	-0.31	1.57e-7	Corticobasal degeneration;
CESC	cis	rs3767633	0.925	rs4233380	chr1:161892483	A/C	cg09175582	chr1:161736000	ATF6	0.85	6.98	0.39	2.37e-11	IgG glycosylation;
CESC	cis	rs6460942	1.000	rs2053382	chr7:12400587	A/G	cg06484146	chr7:12443880	VWDE	-0.69	-7.95	-0.44	5.37e-14	Coronary artery disease;
CESC	cis	rs7264396	0.563	rs11906854	chr20:34383634	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.66	6.7	0.38	1.23e-10	Total cholesterol levels;
CESC	cis	rs4819052	0.851	rs4819039	chr21:46659458	G/A	cg11663144	chr21:46675770	NA	-0.63	-10.02	-0.52	3.12e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg18783047	chr19:10420351	ZGLP1	0.5	6.67	0.38	1.51e-10	Fibrinogen levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17411103	chr17:65241599	HELZ	0.63	6.84	0.39	5.5e-11	Gut microbiome composition (summer);
CESC	cis	rs2762353	0.595	rs9467591	chr6:25742699	C/T	cg03517284	chr6:25882590	NA	-0.53	-8.0	-0.44	3.89e-14	Blood metabolite levels;
CESC	cis	rs7680126	0.596	rs10022911	chr4:10140551	A/G	cg00071950	chr4:10020882	SLC2A9	-0.56	-6.36	-0.36	8.77e-10	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	cis	rs11763147	1	rs11763147	chr7:65326821	C/T	cg11764359	chr7:65958608	NA	-0.67	-8.62	-0.47	6.05e-16	Corneal structure;
CESC	cis	rs36051895	0.632	rs1571438	chr9:5140313	A/C	cg02405213	chr9:5042618	JAK2	-0.49	-6.22	-0.36	1.93e-9	Pediatric autoimmune diseases;
CESC	cis	rs16957304	1.000	rs3868142	chr16:67320223	G/A	cg26727032	chr16:67993705	SLC12A4	-0.54	-5.33	-0.31	2.05e-7	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
CESC	cis	rs8017423	0.935	rs2149653	chr14:90669333	G/A	cg14092571	chr14:90743983	NA	-0.56	-8.28	-0.45	5.95e-15	Mortality in heart failure;
CESC	cis	rs10791323	0.581	rs2723608	chr11:133710149	A/G	cg15485101	chr11:133734466	NA	0.4	6.48	0.37	4.47e-10	Childhood ear infection;
CESC	cis	rs684232	0.835	rs1833459	chr17:562244	C/T	cg15660573	chr17:549704	VPS53	-0.43	-5.67	-0.33	3.8e-8	Prostate cancer;
CESC	cis	rs1799949	1.000	rs2037075	chr17:41305826	G/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.44	5.9	0.34	1.13e-8	Menopause (age at onset);
CESC	cis	rs11997175	0.740	rs4733462	chr8:33679904	A/G	ch.8.33884649F	chr8:33765107	NA	0.45	5.68	0.33	3.6e-8	Body mass index;
CESC	cis	rs9486715	0.867	rs9373829	chr6:96897201	A/C	cg06623918	chr6:96969491	KIAA0776	-0.77	-10.89	-0.56	4.4e-23	Headache;
CESC	cis	rs6540559	1.000	rs6659367	chr1:209982408	G/T	cg09509183	chr1:209979624	IRF6	0.5	6.35	0.36	9.56e-10	Cleft lip with or without cleft palate;
CESC	cis	rs736408	0.609	rs1029871	chr3:52797634	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.48	6.48	0.37	4.33e-10	Bipolar disorder;
CESC	cis	rs10861342	1.000	rs10861342	chr12:105458797	C/T	cg23923672	chr12:105501055	KIAA1033	-0.72	-5.36	-0.31	1.77e-7	IgG glycosylation;
CESC	trans	rs1945213	0.625	rs7128190	chr11:55858550	A/T	cg15704280	chr7:45808275	SEPT13	0.76	7.34	0.41	2.57e-12	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs116095464	0.614	rs28736753	chr5:274081	G/A	cg12570787	chr5:219185	SDHA;CCDC127	0.54	5.58	0.32	6.07e-8	Breast cancer;
CESC	cis	rs6754311	0.773	rs2322818	chr2:136775898	T/C	cg07169764	chr2:136633963	MCM6	0.66	8.21	0.45	9.58e-15	Mosquito bite size;
CESC	cis	rs8016982	0.674	rs1951614	chr14:81672106	A/G	cg01989461	chr14:81687754	GTF2A1	-0.74	-11.55	-0.58	2.85e-25	Schizophrenia;
CESC	cis	rs875971	0.798	rs12698522	chr7:65967341	T/C	cg18876405	chr7:65276391	NA	0.52	6.98	0.39	2.44e-11	Aortic root size;
CESC	cis	rs172166	0.637	rs1225597	chr6:28162087	C/T	cg17221315	chr6:27791827	HIST1H4J	0.43	5.57	0.32	6.2e-8	Cardiac Troponin-T levels;
CESC	cis	rs3782089	1.000	rs11605810	chr11:65300619	A/G	cg21890820	chr11:65308645	LTBP3	1.05	7.95	0.44	5.25e-14	Height;
CESC	cis	rs798554	0.679	rs2644281	chr7:2886748	A/G	cg13628971	chr7:2884303	GNA12	0.63	8.76	0.47	2.41e-16	Height;
CESC	cis	rs3096299	0.933	rs889576	chr16:89429653	A/G	cg16743903	chr16:89593216	SPG7	0.41	5.3	0.31	2.38e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs4713118	0.662	rs9380046	chr6:28030499	T/C	cg26335602	chr6:28129616	ZNF389	0.44	5.59	0.32	5.7e-8	Parkinson's disease;
CESC	cis	rs703842	0.642	rs11536137	chr12:58056426	C/A	cg18357645	chr12:58087776	OS9	-0.55	-7.41	-0.41	1.73e-12	Multiple sclerosis;
CESC	cis	rs7539409	0.651	rs970457	chr1:84296540	C/T	cg10977910	chr1:84465055	TTLL7	0.75	7.28	0.41	3.76e-12	Alzheimer's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15679978	chr6:119255801	MCM9	0.63	7.23	0.41	5.16e-12	Gut microbiome composition (summer);
CESC	cis	rs6456156	0.586	rs12528689	chr6:167461746	A/G	cg23791538	chr6:167370224	RNASET2	-0.49	-6.37	-0.36	8.13e-10	Primary biliary cholangitis;
CESC	cis	rs6952808	0.630	rs10239050	chr7:2158390	A/G	cg05863683	chr7:1912471	MAD1L1	0.38	5.57	0.32	6.15e-8	Bipolar disorder and schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15961887	chr4:71554203	UTP3	0.55	6.45	0.37	5.17e-10	Gut microbiome composition (summer);
CESC	cis	rs4969178	0.930	rs11077363	chr17:76397309	C/T	cg05887092	chr17:76393375	PGS1	0.58	9.22	0.49	9.9e-18	HDL cholesterol levels;
CESC	cis	rs6860806	0.531	rs2631359	chr5:131707892	C/T	cg18758796	chr5:131593413	PDLIM4	-0.44	-6.04	-0.35	5.29e-9	Breast cancer;
CESC	cis	rs1218582	0.772	rs2174507	chr1:154887949	C/T	cg16680214	chr1:154839983	KCNN3	-0.44	-6.78	-0.38	7.71e-11	Prostate cancer;
CESC	cis	rs76878669	0.561	rs7117630	chr11:66154777	C/T	cg18002602	chr11:66138449	SLC29A2	-0.42	-7.04	-0.4	1.63e-11	Educational attainment (years of education);
CESC	cis	rs2522056	1.000	rs62385693	chr5:131773674	T/C	cg24060327	chr5:131705240	SLC22A5	0.65	7.52	0.42	8.51e-13	Lymphocyte counts;Fibrinogen;
CESC	cis	rs12541335	0.639	rs35068739	chr8:22201719	T/C	cg02788857	chr8:22132959	PIWIL2	0.32	5.68	0.33	3.54e-8	Hypertriglyceridemia;
CESC	cis	rs1005277	0.579	rs1740745	chr10:38520056	T/C	cg25517755	chr10:38738941	LOC399744	-0.44	-5.72	-0.33	2.85e-8	Extrinsic epigenetic age acceleration;
CESC	cis	rs2276314	0.857	rs4799409	chr18:33592602	C/T	cg05985134	chr18:33552581	C18orf21	0.61	7.33	0.41	2.8e-12	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs7560272	0.538	rs12052539	chr2:73937153	C/T	cg20560298	chr2:73613845	ALMS1	-0.43	-6.12	-0.35	3.41e-9	Schizophrenia;
CESC	cis	rs3931020	0.508	rs2345436	chr1:75198740	A/C	cg10128416	chr1:75198403	TYW3;CRYZ	0.46	5.53	0.32	7.52e-8	Resistin levels;
CESC	cis	rs4308124	0.708	rs61358692	chr2:111965159	T/C	cg04571233	chr2:111982156	NA	-0.63	-6.91	-0.39	3.58e-11	Vitiligo;
CESC	cis	rs453301	0.571	rs2929452	chr8:9084465	G/A	cg06636001	chr8:8085503	FLJ10661	-0.52	-6.75	-0.38	9.56e-11	Joint mobility (Beighton score);
CESC	cis	rs7520050	0.966	rs785503	chr1:46595868	T/C	cg03146154	chr1:46216737	IPP	-0.43	-5.58	-0.32	6e-8	Red blood cell count;Reticulocyte count;
CESC	cis	rs10479542	0.702	rs13183521	chr5:178975606	A/G	cg09060608	chr5:178986726	RUFY1	-0.4	-5.59	-0.33	5.5e-8	Lung cancer;
CESC	cis	rs9311474	0.508	rs7614498	chr3:52618941	A/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.33	5.91	0.34	1.03e-8	Electroencephalogram traits;
CESC	cis	rs644799	1.000	rs3748256	chr11:95521953	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.72	9.58	0.51	7.54e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs40363	0.645	rs1690447	chr16:3519211	T/C	cg22508957	chr16:3507546	NAT15	0.59	9.56	0.51	8.29e-19	Tuberculosis;
CESC	cis	rs1862618	0.853	rs832583	chr5:56178217	A/C	cg12311346	chr5:56204834	C5orf35	-0.75	-8.9	-0.48	8.71e-17	Initial pursuit acceleration;
CESC	cis	rs684232	0.602	rs2543775	chr17:557123	G/A	cg12384639	chr17:618140	VPS53	0.41	5.23	0.31	3.42e-7	Prostate cancer;
CESC	cis	rs12476592	0.602	rs2121351	chr2:63828361	G/A	cg17519650	chr2:63277830	OTX1	-0.45	-5.12	-0.3	5.75e-7	Childhood ear infection;
CESC	cis	rs7210086	0.950	rs7214193	chr17:70641865	A/G	cg04206342	chr17:70636940	NA	-0.3	-5.2	-0.3	4.02e-7	Ulcerative colitis;
CESC	cis	rs6502050	0.765	rs6502074	chr17:80121776	T/C	cg23985595	chr17:80112537	CCDC57	-0.42	-6.63	-0.38	1.85e-10	Life satisfaction;
CESC	cis	rs858239	0.600	rs6967475	chr7:23128982	C/T	cg23682824	chr7:23144976	KLHL7	0.55	7.37	0.41	2.18e-12	Cerebrospinal fluid biomarker levels;
CESC	cis	rs12142240	0.698	rs1057533	chr1:46815836	C/T	cg10495392	chr1:46806563	NSUN4	0.57	6.28	0.36	1.39e-9	Menopause (age at onset);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg10705503	chr12:102513685	C12orf48;NUP37	-0.45	-6.25	-0.36	1.61e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg07167872	chr1:205819463	PM20D1	0.76	11.86	0.59	2.64e-26	Menarche (age at onset);
CESC	cis	rs896854	0.631	rs10097617	chr8:95961626	T/C	cg23172400	chr8:95962367	TP53INP1	-0.5	-10.94	-0.56	3.12e-23	Type 2 diabetes;
CESC	cis	rs7523050	0.643	rs36047249	chr1:109401499	T/C	cg08274380	chr1:109419600	GPSM2	0.86	5.69	0.33	3.36e-8	Fat distribution (HIV);
CESC	cis	rs4713118	0.513	rs183244	chr6:28031838	C/A	cg23281280	chr6:28129359	ZNF389	0.37	5.46	0.32	1.1e-7	Parkinson's disease;
CESC	cis	rs2019216	0.542	rs2221893	chr17:21930012	A/G	cg22648282	chr17:21454238	C17orf51	-0.4	-5.26	-0.31	2.95e-7	Pelvic organ prolapse;
CESC	cis	rs2439831	0.850	rs12441861	chr15:44060883	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.69	8.02	0.44	3.51e-14	Lung cancer in ever smokers;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg02250680	chr11:58346542	LPXN;ZFP91-CNTF;ZFP91	-0.51	-6.55	-0.37	2.92e-10	Ulcerative colitis;
CESC	cis	rs4474465	0.736	rs4945291	chr11:78254413	C/T	cg27205649	chr11:78285834	NARS2	0.42	5.32	0.31	2.16e-7	Alzheimer's disease (survival time);
CESC	cis	rs736408	0.505	rs2083180	chr3:52668119	G/T	cg05564831	chr3:52568323	NT5DC2	0.46	7.37	0.41	2.17e-12	Bipolar disorder;
CESC	cis	rs875971	1.000	rs10257427	chr7:65743208	T/C	cg12463550	chr7:65579703	CRCP	-0.54	-6.92	-0.39	3.37e-11	Aortic root size;
CESC	cis	rs1448094	0.511	rs10863079	chr12:86152700	T/A	cg02569458	chr12:86230093	RASSF9	-0.46	-7.15	-0.4	8.28e-12	Major depressive disorder;
CESC	cis	rs7512552	0.839	rs12045304	chr1:150399818	G/A	cg15654264	chr1:150340011	RPRD2	0.41	5.35	0.31	1.94e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs722599	0.599	rs3825708	chr14:75200697	C/T	cg08847533	chr14:75593920	NEK9	0.44	5.34	0.31	2e-7	IgG glycosylation;
CESC	cis	rs72772090	0.539	rs11743410	chr5:96124453	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.57	-5.26	-0.31	3.01e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs9929218	0.551	rs2296406	chr16:68721340	G/A	cg02972257	chr16:68554789	NA	-0.42	-5.14	-0.3	5.29e-7	Colorectal cancer;
CESC	cis	rs854765	0.583	rs4925126	chr17:17798633	C/T	cg04398451	chr17:18023971	MYO15A	-0.69	-10.06	-0.53	2.22e-20	Total body bone mineral density;
CESC	cis	rs4925386	0.840	rs6143024	chr20:60914229	A/G	cg22307297	chr20:60903441	LAMA5	0.41	5.5	0.32	8.86e-8	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs875971	0.638	rs7793569	chr7:66116633	T/G	cg11764359	chr7:65958608	NA	-0.68	-8.81	-0.48	1.68e-16	Aortic root size;
CESC	cis	rs9303401	1.000	rs9904677	chr17:56873025	A/G	cg12560992	chr17:57184187	TRIM37	0.49	5.54	0.32	7.42e-8	Cognitive test performance;
CESC	cis	rs9488822	0.676	rs11153594	chr6:116354591	A/G	cg26893134	chr6:116381904	FRK	-0.26	-6.33	-0.36	1.07e-9	Cholesterol, total;LDL cholesterol;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg18664336	chr17:57970265	TUBD1;RPS6KB1	-0.46	-6.25	-0.36	1.64e-9	Asthma;
CESC	cis	rs11122272	0.735	rs2437148	chr1:231513979	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.57	-7.82	-0.43	1.29e-13	Hemoglobin concentration;
CESC	cis	rs2439831	0.681	rs524527	chr15:43599116	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.9	-13.08	-0.63	1.75e-30	Lung cancer in ever smokers;
CESC	cis	rs12618769	0.625	rs4850878	chr2:99112180	T/A	cg10123293	chr2:99228465	UNC50	0.39	5.13	0.3	5.6e-7	Bipolar disorder;
CESC	cis	rs4588572	0.688	rs1594055	chr5:77695088	G/A	cg11547950	chr5:77652471	NA	-0.41	-5.71	-0.33	2.99e-8	Triglycerides;
CESC	cis	rs12579753	0.672	rs4509857	chr12:82268017	C/T	cg21193143	chr12:82153300	PPFIA2	-0.34	-5.2	-0.3	4.09e-7	Resting heart rate;
CESC	cis	rs262150	0.544	rs2428780	chr7:158812471	T/A	cg19418458	chr7:158789849	NA	-0.41	-6.22	-0.36	1.88e-9	Facial morphology (factor 20);
CESC	cis	rs2637266	0.690	rs2579730	chr10:78443441	G/T	cg18941641	chr10:78392320	NA	0.4	7.31	0.41	3.07e-12	Pulmonary function;
CESC	cis	rs1878931	0.513	rs35160989	chr16:3405506	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.92	14.05	0.65	7e-34	Body mass index (adult);
CESC	cis	rs9925964	0.933	rs4889530	chr16:31065918	T/A	cg02466173	chr16:30829666	NA	0.32	5.13	0.3	5.55e-7	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs4665809	1.000	rs4233709	chr2:26291493	C/T	cg04944784	chr2:26401820	FAM59B	0.61	6.97	0.39	2.5e-11	Gut microbiome composition (summer);
CESC	cis	rs11112613	0.713	rs73184082	chr12:105951748	T/C	cg03607813	chr12:105948248	NA	0.59	7.41	0.41	1.75e-12	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CESC	cis	rs2777491	0.957	rs316614	chr15:41746625	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.65	-9.9	-0.52	7.01e-20	Ulcerative colitis;
CESC	cis	rs1712517	0.524	rs4917384	chr10:104995788	T/C	cg04362960	chr10:104952993	NT5C2	0.48	5.59	0.32	5.62e-8	Migraine;
CESC	cis	rs6121246	0.529	rs6060359	chr20:30209740	A/G	cg13852791	chr20:30311386	BCL2L1	0.59	5.49	0.32	9.22e-8	Mean corpuscular hemoglobin;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08434295	chr5:175815816	HIGD2A;NOP16	0.53	6.08	0.35	4.25e-9	Gut microbiome composition (summer);
CESC	cis	rs3747547	0.818	rs6476665	chr9:37948238	A/C	cg13774184	chr9:37916125	SHB	-0.56	-5.86	-0.34	1.38e-8	Metabolite levels (Dihydroxy docosatrienoic acid);
CESC	cis	rs4711336	1.000	rs4711336	chr6:33659046	A/G	cg14003231	chr6:33640908	ITPR3	-0.35	-5.86	-0.34	1.35e-8	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11028586	chr17:33307483	LIG3	0.57	6.26	0.36	1.53e-9	Gut microbiome composition (summer);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg18368637	chr6:144179905	LTV1	-0.49	-6.15	-0.35	2.89e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs62005083	1.000	rs62005145	chr14:74588106	A/G	cg05179529	chr14:74551516	LIN52;ALDH6A1	0.7	5.25	0.31	3.08e-7	Mean corpuscular volume;
CESC	cis	rs2075371	0.933	rs1901214	chr7:133945108	C/T	cg20476274	chr7:133979776	SLC35B4	-0.63	-8.99	-0.48	4.94e-17	Mean platelet volume;
CESC	cis	rs12220238	0.841	rs7919010	chr10:76111137	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.52	5.1	0.3	6.35e-7	Soluble interleukin-2 receptor subunit alpha;
CESC	cis	rs10861342	1.000	rs1076	chr12:105562788	C/T	cg23923672	chr12:105501055	KIAA1033	-0.65	-5.14	-0.3	5.25e-7	IgG glycosylation;
CESC	trans	rs17685	0.712	rs7794454	chr7:75776010	A/G	cg19862616	chr7:65841803	NCRNA00174	-0.8	-11.44	-0.57	6.72e-25	Coffee consumption;Coffee consumption (cups per day);
CESC	trans	rs113577745	0.725	rs59015435	chr2:10129252	G/A	cg12379383	chr15:96896940	NA	-0.59	-6.3	-0.36	1.24e-9	Breast cancer;
CESC	cis	rs7589342	0.862	rs10469862	chr2:106509907	C/T	cg14210321	chr2:106509881	NCK2	-0.45	-5.05	-0.3	8.09e-7	Addiction;
CESC	cis	rs35110281	0.748	rs1584918	chr21:45042419	C/T	cg21573476	chr21:45109991	RRP1B	-0.5	-6.86	-0.39	4.89e-11	Mean corpuscular volume;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg01618530	chr8:54755981	ATP6V1H	-0.51	-6.12	-0.35	3.38e-9	Ulcerative colitis;
CESC	cis	rs7520050	0.966	rs12410071	chr1:46358886	T/C	cg24296786	chr1:45957014	TESK2	0.42	5.26	0.31	2.92e-7	Red blood cell count;Reticulocyte count;
CESC	cis	rs2635047	0.811	rs17785603	chr18:44769534	T/A	cg24371990	chr18:44770781	NA	0.43	6.95	0.39	2.92e-11	Educational attainment;
CESC	cis	rs7208859	0.623	rs216445	chr17:28933576	A/G	cg19761014	chr17:28927070	LRRC37B2	0.85	6.59	0.38	2.33e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs10504229	0.683	rs73603874	chr8:58108340	G/A	cg02725872	chr8:58115012	NA	-0.43	-6.81	-0.39	6.53e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs9494142	0.592	rs1547247	chr6:135390836	C/T	cg22676075	chr6:135203613	NA	0.7	8.88	0.48	1.07e-16	Lymphocyte counts;Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg11240327	chr6:90348503	LYRM2	-0.47	-5.99	-0.35	6.64e-9	Ulcerative colitis;
CESC	cis	rs8141529	0.732	rs5762815	chr22:29205076	A/G	cg15103426	chr22:29168792	CCDC117	0.7	9.91	0.52	6.78e-20	Lymphocyte counts;
CESC	cis	rs1008375	0.931	rs6449309	chr4:17573208	C/T	cg02297831	chr4:17616191	MED28	0.53	6.12	0.35	3.31e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs12618769	0.597	rs72819981	chr2:99040696	T/C	cg10123293	chr2:99228465	UNC50	0.39	5.1	0.3	6.52e-7	Bipolar disorder;
CESC	cis	rs79839061	0.518	rs11734537	chr4:869174	A/G	cg07828340	chr4:882639	GAK	1.07	8.28	0.45	6.09e-15	Intelligence (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26530261	chr16:27280164	NSMCE1	0.56	6.05	0.35	5.01e-9	Gut microbiome composition (summer);
CESC	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.55	-6.17	-0.35	2.5e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2276314	0.857	rs28651028	chr18:33638910	G/A	cg05985134	chr18:33552581	C18orf21	0.62	7.36	0.41	2.32e-12	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs6754311	0.551	rs2304599	chr2:136528004	C/G	cg07169764	chr2:136633963	MCM6	-0.73	-9.35	-0.5	3.95e-18	Mosquito bite size;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg10828910	chr2:63850056	LOC388955	0.4	6.01	0.35	6.07e-9	Gambling;
CESC	cis	rs769267	0.965	rs6511026	chr19:19391402	C/T	cg03709012	chr19:19516395	GATAD2A	0.96	14.18	0.66	2.35e-34	Tonsillectomy;
CESC	trans	rs7246760	0.867	rs55846005	chr19:9796709	T/A	cg02900749	chr2:68251473	NA	-0.85	-7.53	-0.42	8.04e-13	Pursuit maintenance gain;
CESC	cis	rs1707322	1.000	rs12060274	chr1:46291062	G/T	cg03146154	chr1:46216737	IPP	0.72	9.83	0.52	1.2e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7647973	0.592	rs6774202	chr3:49687779	T/G	cg03060546	chr3:49711283	APEH	0.69	8.47	0.46	1.73e-15	Menarche (age at onset);
CESC	cis	rs9910055	0.530	rs2269908	chr17:42294198	G/C	cg10896456	chr17:42255109	ASB16;C17orf65	0.34	5.03	0.3	8.93e-7	Total body bone mineral density;
CESC	cis	rs916888	0.821	rs199505	chr17:44859410	A/G	cg15921436	chr17:44337874	NA	-0.68	-7.54	-0.42	7.6e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs11122272	0.735	rs2355872	chr1:231478489	A/T	cg06096015	chr1:231504339	EGLN1	0.43	6.36	0.36	8.84e-10	Hemoglobin concentration;
CESC	cis	rs61935443	0.614	rs11107787	chr12:95311669	C/T	cg21533806	chr12:95267307	NA	0.48	5.29	0.31	2.54e-7	Schizophrenia;
CESC	cis	rs6460942	0.915	rs2192842	chr7:12315752	C/G	cg20607287	chr7:12443886	VWDE	-0.42	-6.21	-0.36	2.09e-9	Coronary artery disease;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg27649522	chr12:12877729	APOLD1	0.45	6.06	0.35	4.78e-9	Systemic lupus erythematosus;
CESC	cis	rs4722166	1.000	rs4722166	chr7:22738762	G/T	cg05472934	chr7:22766657	IL6	0.59	7.28	0.41	3.84e-12	Lung cancer;
CESC	cis	rs2721195	0.967	rs1480000	chr8:145702007	C/T	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.76	-10.97	-0.56	2.42e-23	Age at first birth;
CESC	cis	rs1862618	0.756	rs832548	chr5:56183637	G/C	cg03609598	chr5:56110824	MAP3K1	-0.51	-5.32	-0.31	2.22e-7	Initial pursuit acceleration;
CESC	cis	rs2228479	0.867	rs62056110	chr16:89946388	A/C	cg00800038	chr16:89945340	TCF25	-0.88	-7.85	-0.43	1.01e-13	Skin colour saturation;
CESC	cis	rs11958404	0.615	rs10475649	chr5:157447301	T/C	cg05962755	chr5:157440814	NA	0.38	5.65	0.33	4.21e-8	IgG glycosylation;
CESC	cis	rs10949834	0.838	rs1091811	chr7:73491212	A/G	cg07137043	chr7:73588983	EIF4H	0.66	7.24	0.41	4.99e-12	Verbal memory performance (residualized delayed recall change);
CESC	cis	rs703842	0.963	rs2291617	chr12:58166403	T/G	cg18357645	chr12:58087776	OS9	-0.39	-5.45	-0.32	1.13e-7	Multiple sclerosis;
CESC	cis	rs7811142	0.830	rs76798830	chr7:99952828	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.74	6.19	0.36	2.23e-9	Platelet count;
CESC	trans	rs3198697	1.000	rs3198697	chr16:15129940	C/T	cg04146151	chr16:2155961	PKD1	-0.63	-8.06	-0.44	2.62e-14	Triglycerides;
CESC	cis	rs1881797	1.000	rs1881796	chr1:247688931	G/A	cg21399703	chr1:247681439	NA	0.55	7.36	0.41	2.29e-12	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs4423214	0.592	rs79634040	chr11:71230169	G/C	cg05163923	chr11:71159392	DHCR7	-0.57	-5.92	-0.34	1e-8	Vitamin D levels;
CESC	cis	rs6088580	0.634	rs1205334	chr20:32930369	T/C	cg24642439	chr20:33292090	TP53INP2	-0.51	-6.66	-0.38	1.58e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs9303280	0.901	rs8067378	chr17:38051348	A/G	cg19468946	chr17:37922297	IKZF3	-0.39	-5.34	-0.31	2.02e-7	Self-reported allergy;
CESC	cis	rs1371867	0.846	rs1660353	chr8:101250907	C/T	cg06002616	chr8:101225028	SPAG1	0.31	5.05	0.3	8.34e-7	Atrioventricular conduction;
CESC	cis	rs8177253	0.901	rs9843728	chr3:133501407	C/T	cg01448562	chr3:133502909	NA	-0.44	-6.2	-0.36	2.21e-9	Iron status biomarkers;
CESC	cis	rs4727963	0.846	rs4727961	chr7:122716343	T/A	cg03640110	chr7:122635026	TAS2R16	-0.38	-5.84	-0.34	1.55e-8	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
CESC	cis	rs672059	1.000	rs625917	chr1:183157991	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.54	6.97	0.39	2.51e-11	Hypertriglyceridemia;
CESC	cis	rs9815354	0.680	rs57945879	chr3:42038842	C/G	cg03022575	chr3:42003672	ULK4	0.75	6.57	0.37	2.63e-10	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs1707322	1.000	rs7532204	chr1:46485075	C/G	cg03146154	chr1:46216737	IPP	-0.72	-9.88	-0.52	8.55e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2033711	0.870	rs4801270	chr19:58932762	C/A	cg26874164	chr19:58962979	ZNF324B	0.54	7.41	0.41	1.73e-12	Uric acid clearance;
CESC	trans	rs11039798	0.588	rs12284168	chr11:48555627	C/T	cg03929089	chr4:120376271	NA	0.62	6.07	0.35	4.44e-9	Axial length;
CESC	cis	rs763121	0.853	rs1056610	chr22:39080078	C/T	cg06022373	chr22:39101656	GTPBP1	-0.94	-16.93	-0.72	4.35e-44	Menopause (age at onset);
CESC	cis	rs4604732	0.642	rs7549312	chr1:247640078	C/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.46	6.5	0.37	3.87e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs2760061	0.583	rs708110	chr1:228190805	T/A	cg02753203	chr1:228287806	NA	0.79	11.5	0.58	4.28e-25	Diastolic blood pressure;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00721207	chr19:40337107	FBL	0.58	6.38	0.36	7.81e-10	Gut microbiome composition (summer);
CESC	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg18402987	chr7:1209562	NA	0.75	7.46	0.42	1.25e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs1493916	0.721	rs4471760	chr18:31374233	G/A	cg27147174	chr7:100797783	AP1S1	-0.49	-6.34	-0.36	1e-9	Life satisfaction;
CESC	cis	rs1799949	1.000	rs9646412	chr17:41425893	A/T	cg25072359	chr17:41440525	NA	0.5	6.72	0.38	1.14e-10	Menopause (age at onset);
CESC	cis	rs7727544	0.684	rs272849	chr5:131690241	A/G	cg24060327	chr5:131705240	SLC22A5	-0.59	-7.79	-0.43	1.49e-13	Blood metabolite levels;
CESC	cis	rs7264396	0.563	rs2425132	chr20:34338390	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.81	-10.24	-0.53	5.76e-21	Total cholesterol levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11586605	chr11:108535779	DDX10	0.62	7.52	0.42	8.39e-13	Gut microbiome composition (summer);
CESC	trans	rs7947523	0.813	rs4999940	chr11:80942337	C/T	cg08862778	chr1:11322643	MTOR	0.46	6.29	0.36	1.31e-9	Emphysema imaging phenotypes;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg04329845	chr19:14640100	MIR639;TECR	-0.46	-5.99	-0.35	6.66e-9	Ulcerative colitis;
CESC	cis	rs12410462	0.581	rs77837509	chr1:227559873	C/T	cg23173402	chr1:227635558	NA	0.63	5.39	0.31	1.52e-7	Major depressive disorder;
CESC	cis	rs7659604	0.540	rs11724322	chr4:122697850	A/T	cg19671926	chr4:122722719	EXOSC9	0.65	8.64	0.47	5.34e-16	Type 2 diabetes;
CESC	cis	rs9894429	0.789	rs8074989	chr17:79598728	G/C	cg18240062	chr17:79603768	NPLOC4	0.9	13.2	0.63	6.66e-31	Eye color traits;
CESC	trans	rs853679	0.607	rs17763089	chr6:27835218	G/A	cg06606381	chr12:133084897	FBRSL1	-1.07	-8.89	-0.48	9.48e-17	Depression;
CESC	cis	rs9649465	0.967	rs9641717	chr7:123350060	C/T	cg04330084	chr7:123175371	IQUB	-0.38	-5.18	-0.3	4.34e-7	Migraine;
CESC	cis	rs6502050	0.835	rs7406529	chr17:80080877	C/T	cg23985595	chr17:80112537	CCDC57	0.42	6.53	0.37	3.27e-10	Life satisfaction;
CESC	cis	rs7949030	0.626	rs35587183	chr11:62318656	C/T	cg23462726	chr11:62437636	C11orf83;C11orf48	-0.43	-5.73	-0.33	2.73e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs35306767	0.903	rs11253485	chr10:919362	C/T	cg26597838	chr10:835615	NA	0.87	9.02	0.48	3.81e-17	Eosinophil percentage of granulocytes;
CESC	trans	rs11098499	0.954	rs7681544	chr4:120411255	T/C	cg25214090	chr10:38739885	LOC399744	0.72	10.08	0.53	1.97e-20	Corneal astigmatism;
CESC	cis	rs3793683	0.825	rs3793674	chr10:134555773	C/T	cg18305652	chr10:134549665	INPP5A	-0.34	-5.35	-0.31	1.92e-7	Migraine;
CESC	cis	rs1475911	0.708	rs66994219	chr21:43521647	G/A	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.54	-8.28	-0.45	6.11e-15	IgG glycosylation;
CESC	cis	rs9583531	0.891	rs61969076	chr13:111391568	C/T	cg24331049	chr13:111365604	ING1	-0.71	-7.06	-0.4	1.45e-11	Coronary artery disease;
CESC	cis	rs514406	0.505	rs269293	chr1:53187767	A/C	cg08736216	chr1:53307985	ZYG11A	-0.38	-6.25	-0.36	1.65e-9	Monocyte count;
CESC	cis	rs6089829	0.962	rs1060490	chr20:61665871	A/G	cg16240275	chr20:61666158	NCRNA00029	0.5	8.96	0.48	6.1e-17	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs9311474	0.607	rs34005367	chr3:52558904	A/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.29	5.18	0.3	4.33e-7	Electroencephalogram traits;
CESC	cis	rs5769765	1.000	rs761879	chr22:50241210	G/A	cg04877737	chr22:50155965	NA	0.33	5.35	0.31	1.87e-7	Schizophrenia;
CESC	cis	rs9287719	0.935	rs728283	chr2:10750090	C/T	cg00105475	chr2:10696890	NA	0.38	5.57	0.32	6.34e-8	Prostate cancer;
CESC	cis	rs72945132	0.882	rs67822447	chr11:70230972	G/T	cg00319359	chr11:70116639	PPFIA1	0.73	7.1	0.4	1.11e-11	Coronary artery disease;
CESC	cis	rs854765	0.583	rs62064158	chr17:17826935	T/C	cg04398451	chr17:18023971	MYO15A	-0.67	-9.6	-0.51	6.42e-19	Total body bone mineral density;
CESC	cis	rs7811142	1.000	rs7783550	chr7:99987805	A/G	cg11814155	chr7:99998594	ZCWPW1	-0.49	-5.24	-0.31	3.3e-7	Platelet count;
CESC	cis	rs7777484	0.571	rs2527686	chr7:2834413	G/A	cg09658497	chr7:2847517	GNA12	-0.44	-6.95	-0.39	2.75e-11	Height;
CESC	cis	rs116095464	0.558	rs13356367	chr5:242395	C/T	cg10591111	chr5:226296	SDHA	-0.52	-6.38	-0.36	7.94e-10	Breast cancer;
CESC	cis	rs2806561	0.734	rs667211	chr1:23516142	T/C	cg12483005	chr1:23474871	LUZP1	0.38	6.0	0.35	6.44e-9	Height;
CESC	cis	rs9733	0.526	rs11204696	chr1:150658721	T/C	cg22823121	chr1:150693482	HORMAD1	0.47	7.03	0.4	1.79e-11	Tonsillectomy;
CESC	cis	rs7107174	1.000	rs7111986	chr11:78102266	G/T	cg02023728	chr11:77925099	USP35	0.47	6.3	0.36	1.24e-9	Testicular germ cell tumor;
CESC	cis	rs2625529	0.824	rs4777470	chr15:72207518	T/A	cg16672083	chr15:72433130	SENP8	-0.39	-5.09	-0.3	6.78e-7	Red blood cell count;
CESC	cis	rs36051895	0.664	rs3824433	chr9:5113577	C/T	cg02405213	chr9:5042618	JAK2	-0.49	-6.15	-0.35	2.77e-9	Pediatric autoimmune diseases;
CESC	cis	rs736408	0.570	rs11130327	chr3:52793239	A/G	cg18404041	chr3:52824283	ITIH1	-0.45	-7.48	-0.42	1.1e-12	Bipolar disorder;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg16078886	chr18:29673278	RNF138	-0.48	-6.0	-0.35	6.52e-9	Asthma;
CESC	cis	rs116095464	0.558	rs62347683	chr5:230331	C/T	cg22857025	chr5:266934	NA	-1.28	-18.8	-0.76	1.06e-50	Breast cancer;
CESC	cis	rs35110281	0.626	rs162367	chr21:44934857	A/G	cg21573476	chr21:45109991	RRP1B	-0.36	-5.19	-0.3	4.28e-7	Mean corpuscular volume;
CESC	cis	rs2806561	0.929	rs2746556	chr1:23524541	G/A	cg12483005	chr1:23474871	LUZP1	0.32	5.16	0.3	4.81e-7	Height;
CESC	cis	rs2236918	1.000	rs2526704	chr1:242015820	A/G	cg17736920	chr1:242011382	EXO1	0.75	9.96	0.52	4.79e-20	Menopause (age at onset);
CESC	cis	rs6502050	0.871	rs8066970	chr17:80076051	T/C	cg11859384	chr17:80120422	CCDC57	0.4	5.52	0.32	8.22e-8	Life satisfaction;
CESC	cis	rs2777491	0.574	rs316616	chr15:41746276	G/A	cg20272979	chr15:41787780	ITPKA	0.42	5.18	0.3	4.32e-7	Ulcerative colitis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12882907	chr12:96428593	LTA4H	-0.52	-6.23	-0.36	1.84e-9	Gut microbiome composition (summer);
CESC	cis	rs1552244	1.000	rs61077902	chr3:10126153	T/G	cg00166722	chr3:10149974	C3orf24	0.49	6.3	0.36	1.24e-9	Alzheimer's disease;
CESC	cis	rs2797160	0.651	rs1269176	chr6:126029682	A/T	cg05901451	chr6:126070800	HEY2	-0.51	-7.44	-0.42	1.38e-12	Endometrial cancer;
CESC	cis	rs6831352	0.918	rs29001232	chr4:100046654	G/C	cg13256891	chr4:100009986	ADH5	-0.77	-8.43	-0.46	2.27e-15	Alcohol dependence;
CESC	cis	rs13108904	0.935	rs2199956	chr4:1248919	A/G	cg00684032	chr4:1343700	KIAA1530	0.35	5.41	0.32	1.39e-7	Obesity-related traits;
CESC	cis	rs7772486	0.720	rs702320	chr6:146006654	G/A	cg05347473	chr6:146136440	FBXO30	-0.52	-6.32	-0.36	1.1e-9	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs372883	0.600	rs1153276	chr21:30661694	T/C	cg24692254	chr21:30365293	RNF160	-0.61	-7.76	-0.43	1.82e-13	Pancreatic cancer;
CESC	trans	rs9987353	0.518	rs4841110	chr8:9086023	C/T	cg15556689	chr8:8085844	FLJ10661	0.51	6.05	0.35	5.01e-9	Recombination measurement;
CESC	cis	rs17539620	0.624	rs62432743	chr6:154836214	T/G	cg17771515	chr6:154831774	CNKSR3	0.59	5.87	0.34	1.31e-8	Lipoprotein (a) levels;
CESC	cis	rs2836974	0.899	rs2836957	chr21:40623134	T/C	cg11644478	chr21:40555479	PSMG1	1.01	16.1	0.7	4.01e-41	Cognitive function;
CESC	cis	rs733592	1.000	rs733592	chr12:48429776	C/T	cg24011408	chr12:48396354	COL2A1	-0.51	-8.16	-0.45	1.37e-14	Plateletcrit;
CESC	cis	rs9311474	0.652	rs411457	chr3:52228150	A/T	cg05315796	chr3:52349193	DNAH1	-0.32	-5.59	-0.32	5.75e-8	Electroencephalogram traits;
CESC	cis	rs7666738	0.830	rs13124904	chr4:98856973	T/C	cg03467027	chr4:99064603	C4orf37	0.42	5.16	0.3	4.73e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3026101	0.576	rs56188406	chr17:5316769	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.44	5.58	0.32	5.93e-8	Body mass index;
CESC	cis	rs4727027	0.704	rs7787753	chr7:148901779	A/T	cg23583168	chr7:148888333	NA	-0.94	-17.46	-0.73	5.9e-46	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs61774743	0.521	rs60144015	chr1:41845246	C/A	cg08462924	chr1:41848221	NA	0.43	6.0	0.35	6.55e-9	Intelligence (multi-trait analysis);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg16635483	chr3:96338407	NA	-0.45	-6.03	-0.35	5.49e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs8072100	0.840	rs9900360	chr17:45491979	C/T	cg08085267	chr17:45401833	C17orf57	-0.53	-7.22	-0.41	5.35e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs6582630	0.519	rs12582285	chr12:38298753	C/T	cg13010199	chr12:38710504	ALG10B	0.45	5.65	0.33	4.06e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs9911578	0.805	rs1811202	chr17:56454435	T/G	cg12560992	chr17:57184187	TRIM37	-0.8	-12.62	-0.61	6.74e-29	Intelligence (multi-trait analysis);
CESC	cis	rs3820068	0.603	rs72647128	chr1:15963908	T/C	cg16988262	chr1:15930761	NA	0.34	5.45	0.32	1.16e-7	Systolic blood pressure;
CESC	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.52	-5.82	-0.34	1.71e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2273669	0.667	rs12198182	chr6:109318704	T/G	cg05315195	chr6:109294784	ARMC2	-0.66	-6.28	-0.36	1.36e-9	Prostate cancer;
CESC	cis	rs870825	0.616	rs4443323	chr4:185629805	C/A	cg04058563	chr4:185651563	MLF1IP	0.64	6.48	0.37	4.51e-10	Blood protein levels;
CESC	cis	rs9467711	0.790	rs13195401	chr6:26463574	G/T	cg14345882	chr6:26364793	BTN3A2	0.63	5.15	0.3	4.99e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs72781680	1.000	rs72796388	chr2:24171509	A/C	cg08917208	chr2:24149416	ATAD2B	0.94	8.58	0.47	7.87e-16	Lymphocyte counts;
CESC	cis	rs7208859	0.623	rs9906957	chr17:29157755	C/T	cg13385521	chr17:29058706	SUZ12P	0.72	5.76	0.33	2.3e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs921968	0.565	rs35594672	chr2:219589280	T/A	cg02176678	chr2:219576539	TTLL4	-0.43	-7.59	-0.42	5.51e-13	Mean corpuscular hemoglobin concentration;
CESC	trans	rs7246760	0.867	rs67634928	chr19:9802397	C/G	cg02900749	chr2:68251473	NA	-0.82	-7.19	-0.4	6.67e-12	Pursuit maintenance gain;
CESC	cis	rs1008375	0.966	rs4235389	chr4:17696280	A/G	cg02297831	chr4:17616191	MED28	0.42	5.19	0.3	4.15e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs7666738	0.800	rs7684523	chr4:98983175	G/T	cg18180107	chr4:99064573	C4orf37	0.4	5.19	0.3	4.29e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs829883	0.622	rs7302630	chr12:98959577	C/A	cg25150519	chr12:98850993	NA	-0.6	-7.14	-0.4	8.96e-12	Colorectal adenoma (advanced);
CESC	cis	rs9314323	0.501	rs6557911	chr8:26189230	G/T	cg11498726	chr8:26250323	BNIP3L	-0.43	-6.08	-0.35	4.16e-9	Red cell distribution width;
CESC	cis	rs2576037	0.526	rs7240239	chr18:44460037	T/C	cg19077165	chr18:44547161	KATNAL2	-0.55	-7.99	-0.44	4.2e-14	Personality dimensions;
CESC	cis	rs7520050	0.966	rs4076006	chr1:46438076	C/T	cg24296786	chr1:45957014	TESK2	0.44	5.5	0.32	8.98e-8	Red blood cell count;Reticulocyte count;
CESC	cis	rs4588572	0.706	rs72760906	chr5:77652457	T/C	cg11547950	chr5:77652471	NA	0.46	6.12	0.35	3.41e-9	Triglycerides;
CESC	cis	rs28489187	0.706	rs233113	chr1:85786299	T/A	cg16011679	chr1:85725395	C1orf52	0.48	5.65	0.33	4.1e-8	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	cis	rs7301826	0.651	rs10744483	chr12:131298206	C/A	cg11011512	chr12:131303247	STX2	0.47	5.84	0.34	1.52e-8	Plasma plasminogen activator levels;
CESC	cis	rs6061231	0.583	rs2427313	chr20:60970675	G/A	cg22541963	chr20:60982533	CABLES2	0.51	6.13	0.35	3.13e-9	Colorectal cancer;
CESC	cis	rs9660992	0.710	rs1668867	chr1:205240251	C/T	cg21643547	chr1:205240462	TMCC2	-0.49	-6.94	-0.39	3.04e-11	Mean corpuscular volume;Mean platelet volume;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg10763906	chr12:111052079	TCTN1	-0.43	-6.03	-0.35	5.43e-9	Gambling;
CESC	cis	rs4594175	0.926	rs66625118	chr14:51631062	T/C	cg23942311	chr14:51606299	NA	0.41	6.22	0.36	1.95e-9	Cancer;
CESC	cis	rs2952156	0.920	rs2517953	chr17:37841211	G/C	cg19468946	chr17:37922297	IKZF3	-0.41	-5.18	-0.3	4.35e-7	Asthma;
CESC	cis	rs3749237	0.595	rs7637999	chr3:49535115	C/T	cg03060546	chr3:49711283	APEH	0.77	11.82	0.59	3.5e-26	Resting heart rate;
CESC	cis	rs8020095	0.528	rs73282769	chr14:67780267	A/G	cg19548862	chr14:67692701	FAM71D	-0.45	-5.44	-0.32	1.21e-7	Depression (quantitative trait);
CESC	cis	rs1045714	0.848	rs73033686	chr7:2635085	C/G	cg20813462	chr7:2646259	IQCE	0.68	5.85	0.34	1.48e-8	Urate levels in lean individuals;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg09262732	chr7:100285913	GIGYF1	-0.5	-7.0	-0.4	2.11e-11	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05429508	chr4:517674	PIGG	-0.67	-7.7	-0.43	2.7e-13	Gut microbiome composition (summer);
CESC	cis	rs9322193	0.923	rs35830138	chr6:149989771	T/C	cg07701084	chr6:150067640	NUP43	0.45	6.28	0.36	1.41e-9	Lung cancer;
CESC	cis	rs17666538	0.710	rs7834337	chr8:655828	A/G	cg23958373	chr8:599963	NA	0.81	6.75	0.38	9.46e-11	IgG glycosylation;
CESC	cis	rs941873	0.868	rs7332	chr10:81114060	G/A	cg08514558	chr10:81106712	PPIF	0.36	6.22	0.36	1.94e-9	Height;
CESC	cis	rs116095464	0.558	rs6872854	chr5:209038	G/T	cg22496380	chr5:211416	CCDC127	-0.71	-8.38	-0.46	3.17e-15	Breast cancer;
CESC	cis	rs4722166	0.597	rs2069845	chr7:22770149	G/A	cg05265849	chr7:22767390	IL6	0.41	5.72	0.33	2.88e-8	Lung cancer;
CESC	cis	rs875971	1.000	rs7783613	chr7:65805261	C/T	cg18876405	chr7:65276391	NA	-0.5	-6.83	-0.39	5.93e-11	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12159980	chr4:878727	GAK	-0.49	-6.0	-0.35	6.38e-9	Gut microbiome composition (summer);
CESC	cis	rs916888	0.610	rs199444	chr17:44818276	T/C	cg01570182	chr17:44337453	NA	0.63	8.59	0.47	7.82e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs7044106	0.718	rs10616	chr9:123363533	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.35	5.58	0.32	5.89e-8	Hip circumference adjusted for BMI;
CESC	cis	rs9549260	0.755	rs4429172	chr13:41189143	C/A	cg21288729	chr13:41239152	FOXO1	0.61	7.66	0.43	3.49e-13	Red blood cell count;
CESC	cis	rs7843479	1.000	rs13276082	chr8:21823184	A/G	cg17168535	chr8:21777572	XPO7	0.47	6.3	0.36	1.24e-9	Mean corpuscular volume;
CESC	cis	rs3820068	0.608	rs9660255	chr1:16031891	T/G	cg17385448	chr1:15911702	AGMAT	0.38	6.08	0.35	4.28e-9	Systolic blood pressure;
CESC	cis	rs965469	0.779	rs6037566	chr20:3331414	A/C	cg17110299	chr20:3385021	C20orf194	0.4	5.25	0.31	3.1e-7	IFN-related cytopenia;
CESC	cis	rs3741151	1.000	rs76764824	chr11:73073580	C/T	cg17517138	chr11:73019481	ARHGEF17	1.0	6.71	0.38	1.18e-10	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs11098499	1.000	rs11098499	chr4:120187611	C/T	cg09307838	chr4:120376055	NA	0.88	11.93	0.59	1.55e-26	Corneal astigmatism;
CESC	cis	rs12413816	0.784	rs11258560	chr10:13770137	A/G	cg16485048	chr10:13749193	FRMD4A	0.48	5.89	0.34	1.14e-8	Red cell distribution width;
CESC	cis	rs12476592	0.602	rs11898615	chr2:63748284	C/A	cg17519650	chr2:63277830	OTX1	-0.48	-5.56	-0.32	6.41e-8	Childhood ear infection;
CESC	cis	rs912057	0.526	rs737449	chr6:6733729	A/G	cg06612196	chr6:6737390	NA	-0.47	-8.49	-0.46	1.51e-15	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
CESC	cis	rs4790333	0.537	rs898750	chr17:2255193	A/G	cg02569219	chr17:2266849	SGSM2	0.39	5.06	0.3	7.9e-7	Proinsulin levels;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg24344221	chr1:35658281	SFPQ	0.46	6.21	0.36	2.06e-9	Fibrinogen levels;
CESC	cis	rs4665809	0.627	rs7562192	chr2:26469457	C/G	cg08470875	chr2:26401718	FAM59B	0.76	8.06	0.44	2.69e-14	Gut microbiome composition (summer);
CESC	cis	rs7927592	0.956	rs10896341	chr11:68313180	G/A	cg20283391	chr11:68216788	NA	-0.61	-7.36	-0.41	2.26e-12	Total body bone mineral density;
CESC	cis	rs9649213	0.593	rs1468340	chr7:97987676	T/G	cg08684580	chr7:98029266	BAIAP2L1	-0.35	-5.8	-0.34	1.85e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs2370759	1.000	rs79442609	chr10:32608749	C/T	cg01819863	chr10:32635814	EPC1	1.15	12.33	0.6	6.5e-28	Sexual dysfunction (female);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06400595	chr12:56551642	MYL6B;MYL6	0.66	7.72	0.43	2.42e-13	Gut microbiome composition (summer);
CESC	cis	rs6032067	0.777	rs17332620	chr20:43777506	C/T	cg11264863	chr20:43835661	SEMG1	0.48	5.25	0.31	3.08e-7	Blood protein levels;
CESC	cis	rs9300255	0.602	rs884548	chr12:123634122	A/G	cg00376283	chr12:123451042	ABCB9	0.71	8.76	0.47	2.38e-16	Neutrophil percentage of white cells;
CESC	cis	rs727505	0.866	rs17327181	chr7:124720303	A/G	cg23710748	chr7:124431027	NA	-0.4	-6.52	-0.37	3.55e-10	Lewy body disease;
CESC	cis	rs4665809	1.000	rs1550381	chr2:26266946	A/G	cg08470875	chr2:26401718	FAM59B	-0.48	-5.24	-0.31	3.25e-7	Gut microbiome composition (summer);
CESC	cis	rs3747547	1.000	rs72724184	chr9:37916731	C/T	cg13774184	chr9:37916125	SHB	-0.72	-5.94	-0.34	9.09e-9	Metabolite levels (Dihydroxy docosatrienoic acid);
CESC	cis	rs959260	1.000	rs9900002	chr17:73382018	T/A	cg20590849	chr17:73267439	MIF4GD	-0.57	-6.73	-0.38	1.07e-10	Systemic lupus erythematosus;
CESC	cis	rs6570726	1.000	rs404229	chr6:145868200	G/A	cg23711669	chr6:146136114	FBXO30	0.76	11.13	0.56	7.48e-24	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4853012	0.838	rs4563249	chr2:74354016	G/T	cg05890377	chr2:74357713	NA	0.76	10.02	0.52	3.01e-20	Gestational age at birth (maternal effect);
CESC	cis	rs1568889	0.838	rs10835304	chr11:28296529	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.79	13.44	0.64	9.4e-32	Bipolar disorder;
CESC	cis	rs17376456	0.825	rs10079708	chr5:93261796	G/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.65	5.32	0.31	2.26e-7	Diabetic retinopathy;
CESC	cis	rs8177253	0.665	rs6774822	chr3:133442012	G/T	cg24879335	chr3:133465180	TF	0.34	5.8	0.34	1.85e-8	Iron status biomarkers;
CESC	cis	rs4481887	1.000	rs4593862	chr1:248480176	G/T	cg00666640	chr1:248458726	OR2T12	0.41	6.55	0.37	2.99e-10	Common traits (Other);
CESC	cis	rs367943	1.000	rs2248930	chr5:112811119	G/T	cg12552261	chr5:112820674	MCC	-0.62	-7.73	-0.43	2.27e-13	Type 2 diabetes;
CESC	cis	rs2228479	0.850	rs2238525	chr16:89809902	T/C	cg04013166	chr16:89971882	TCF25	0.69	6.98	0.39	2.4e-11	Skin colour saturation;
CESC	cis	rs11997175	0.713	rs4733455	chr8:33651290	C/T	ch.8.33884649F	chr8:33765107	NA	-0.57	-7.3	-0.41	3.42e-12	Body mass index;
CESC	cis	rs17539620	0.534	rs7768635	chr6:154827861	C/T	cg20019720	chr6:154832845	CNKSR3	0.42	6.17	0.35	2.61e-9	Lipoprotein (a) levels;
CESC	cis	rs1218582	0.772	rs6686873	chr1:154913404	C/G	cg24250549	chr1:154909240	PMVK	0.72	10.45	0.54	1.28e-21	Prostate cancer;
CESC	cis	rs9905704	0.846	rs35082135	chr17:56939694	A/G	cg12560992	chr17:57184187	TRIM37	0.63	7.73	0.43	2.25e-13	Testicular germ cell tumor;
CESC	cis	rs11645898	0.935	rs72787077	chr16:72156674	C/T	cg14768367	chr16:72042858	DHODH	-0.69	-5.95	-0.34	8.43e-9	Blood protein levels;
CESC	cis	rs4076764	0.958	rs11580702	chr1:163385523	C/G	cg24596788	chr1:163392923	NA	-0.5	-7.36	-0.41	2.31e-12	Motion sickness;
CESC	cis	rs763014	0.932	rs2269560	chr16:682442	A/C	cg00802000	chr16:706648	WDR90	-0.4	-6.0	-0.35	6.41e-9	Height;
CESC	cis	rs4888262	0.508	rs4462623	chr16:74692426	C/T	cg01733217	chr16:74700730	RFWD3	0.91	12.26	0.6	1.14e-27	Testicular germ cell tumor;
CESC	cis	rs3105593	0.563	rs8033532	chr15:50959618	G/T	cg08437265	chr15:50716283	USP8	0.41	5.34	0.31	2e-7	QT interval;
CESC	cis	rs17253792	0.822	rs113350960	chr14:56087713	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.77	5.98	0.34	7.23e-9	Putamen volume;
CESC	cis	rs3820928	0.904	rs10933161	chr2:227764872	A/G	cg11843606	chr2:227700838	RHBDD1	-0.4	-5.33	-0.31	2.06e-7	Pulmonary function;
CESC	cis	rs13382862	0.862	rs340595	chr2:20889714	A/G	cg12334488	chr2:20871173	GDF7	-0.37	-5.64	-0.33	4.27e-8	Abdominal aortic aneurysm;
CESC	cis	rs4481887	0.861	rs4644528	chr1:248472508	T/A	cg00666640	chr1:248458726	OR2T12	0.35	5.93	0.34	9.43e-9	Common traits (Other);
CESC	cis	rs6582630	0.524	rs10785494	chr12:38532431	C/G	cg26384229	chr12:38710491	ALG10B	-0.43	-5.78	-0.33	2.15e-8	Drug-induced liver injury (flucloxacillin);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13110034	chr1:145470261	ANKRD34A;POLR3GL	0.68	7.27	0.41	3.98e-12	Gut microbiome composition (summer);
CESC	cis	rs7917772	0.503	rs56397707	chr10:104302693	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.53	7.33	0.41	2.81e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs7727544	0.678	rs7735891	chr5:131597005	C/T	cg14196790	chr5:131705035	SLC22A5	0.38	5.63	0.33	4.5e-8	Blood metabolite levels;
CESC	cis	rs2463822	0.547	rs72917373	chr11:62024403	C/A	cg06239285	chr11:62104954	ASRGL1	-1.01	-7.52	-0.42	8.29e-13	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs3020736	0.500	rs2413669	chr22:42507748	A/C	cg04733989	chr22:42467013	NAGA	-0.78	-11.9	-0.59	1.87e-26	Autism spectrum disorder or schizophrenia;
CESC	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg10862848	chr6:42927986	GNMT	-0.26	-6.63	-0.38	1.89e-10	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs9733	0.596	rs12086472	chr1:150697710	G/A	cg17724175	chr1:150552817	MCL1	0.45	7.31	0.41	3.17e-12	Tonsillectomy;
CESC	cis	rs7829975	0.871	rs7829826	chr8:8578120	T/A	cg17143192	chr8:8559678	CLDN23	-0.44	-5.48	-0.32	9.91e-8	Mood instability;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06819775	chr12:69004359	RAP1B	0.57	6.73	0.38	1.06e-10	Gut microbiome composition (summer);
CESC	cis	rs61931739	0.500	rs11053185	chr12:34428857	A/G	cg06521331	chr12:34319734	NA	-0.38	-5.18	-0.3	4.32e-7	Morning vs. evening chronotype;
CESC	cis	rs7615952	0.641	rs6438951	chr3:125696999	A/G	cg04553112	chr3:125709451	NA	-0.5	-5.45	-0.32	1.13e-7	Blood pressure (smoking interaction);
CESC	cis	rs2415984	0.622	rs10147795	chr14:46936528	C/T	cg14871534	chr14:47121158	RPL10L	-0.34	-5.17	-0.3	4.55e-7	Number of children ever born;
CESC	cis	rs875971	1.000	rs6958277	chr7:65979349	A/G	cg18876405	chr7:65276391	NA	0.47	6.15	0.35	2.9e-9	Aortic root size;
CESC	cis	rs116095464	0.558	rs6882584	chr5:223411	A/C	cg22496380	chr5:211416	CCDC127	-0.72	-8.57	-0.47	8.59e-16	Breast cancer;
CESC	cis	rs478304	0.900	rs502468	chr11:65525119	T/G	cg08755490	chr11:65554678	OVOL1	0.49	6.5	0.37	3.95e-10	Acne (severe);
CESC	cis	rs7584330	0.554	rs55919896	chr2:238428823	A/T	cg14458575	chr2:238380390	NA	0.54	6.16	0.35	2.74e-9	Prostate cancer;
CESC	cis	rs752010	0.684	rs10789402	chr1:42084649	A/G	cg12614395	chr1:42085415	HIVEP3	0.29	5.09	0.3	6.84e-7	Lupus nephritis in systemic lupus erythematosus;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23800573	chr21:45114399	RRP1B	-0.57	-6.72	-0.38	1.12e-10	Gut microbiome composition (summer);
CESC	cis	rs6963495	0.818	rs6961233	chr7:105150469	C/T	cg19920283	chr7:105172520	RINT1	0.66	6.28	0.36	1.36e-9	Bipolar disorder (body mass index interaction);
CESC	cis	rs3087591	0.960	rs2905869	chr17:29519016	C/A	cg24425628	chr17:29625626	OMG;NF1	0.44	5.55	0.32	7.1e-8	Hip circumference;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15639469	chr5:79596224	LOC644936	-0.63	-7.55	-0.42	7.2e-13	Gut microbiome composition (summer);
CESC	cis	rs826838	0.967	rs1486345	chr12:39131677	G/A	cg26384229	chr12:38710491	ALG10B	-0.67	-11.03	-0.56	1.63e-23	Heart rate;
CESC	cis	rs6460942	0.915	rs62447640	chr7:12488282	A/T	cg10578991	chr7:12443926	VWDE	-0.49	-5.22	-0.31	3.59e-7	Coronary artery disease;
CESC	cis	rs11792861	0.816	rs3818932	chr9:111664178	T/C	cg13535736	chr9:111863775	C9orf5	-0.45	-5.87	-0.34	1.33e-8	Menarche (age at onset);
CESC	cis	rs9487051	0.872	rs9487042	chr6:109610443	T/G	cg12927641	chr6:109611667	NA	-0.43	-6.7	-0.38	1.22e-10	Reticulocyte fraction of red cells;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg18782716	chr15:41709119	RTF1	-0.46	-6.03	-0.35	5.52e-9	Height;
CESC	cis	rs9549367	0.789	rs3764124	chr13:113897320	C/T	cg18105134	chr13:113819100	PROZ	-0.7	-8.23	-0.45	8.61e-15	Platelet distribution width;
CESC	cis	rs909002	0.849	rs871634	chr1:32093167	G/C	cg13919466	chr1:32135498	COL16A1	-0.48	-8.26	-0.45	7.11e-15	Intelligence (multi-trait analysis);
CESC	cis	rs3105593	1.000	rs3131578	chr15:50861470	C/T	cg08437265	chr15:50716283	USP8	-0.42	-5.54	-0.32	7.45e-8	QT interval;
CESC	cis	rs801193	0.569	rs13242290	chr7:66121885	G/A	cg18252515	chr7:66147081	NA	0.48	6.45	0.37	5.42e-10	Aortic root size;
CESC	cis	rs12313068	0.709	rs73404675	chr12:110504102	G/A	cg12870014	chr12:110450643	ANKRD13A	0.82	9.18	0.49	1.24e-17	Intelligence (multi-trait analysis);
CESC	trans	rs2207136	0.835	rs2817349	chr6:50891226	T/C	cg06522515	chr3:184090630	THPO	-0.34	-6.03	-0.35	5.53e-9	Myopia;
CESC	cis	rs2250402	0.510	rs2898984	chr15:40324075	G/C	cg16127683	chr15:40268777	EIF2AK4	-0.63	-5.78	-0.33	2.15e-8	Corneal curvature;
CESC	cis	rs539096	0.500	rs2367804	chr1:44314266	C/T	cg23954153	chr1:44402353	ARTN	-0.35	-5.39	-0.31	1.54e-7	Intelligence (multi-trait analysis);
CESC	cis	rs6963495	0.719	rs73190172	chr7:105161210	T/C	cg19920283	chr7:105172520	RINT1	0.69	6.56	0.37	2.85e-10	Bipolar disorder (body mass index interaction);
CESC	cis	rs6121246	0.909	rs6060644	chr20:30265652	G/A	cg13852791	chr20:30311386	BCL2L1	0.77	8.18	0.45	1.17e-14	Mean corpuscular hemoglobin;
CESC	cis	rs1059312	0.966	rs7135968	chr12:129280066	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.74	-10.51	-0.54	8.05e-22	Systemic lupus erythematosus;
CESC	cis	rs9457247	0.602	rs10484530	chr6:167461562	C/T	cg23791538	chr6:167370224	RNASET2	-0.52	-6.87	-0.39	4.45e-11	Crohn's disease;
CESC	cis	rs7552404	0.727	rs7521344	chr1:76318325	C/T	cg22875332	chr1:76189707	ACADM	-0.63	-6.66	-0.38	1.6e-10	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs7824557	0.724	rs2572398	chr8:11178093	A/C	cg21775007	chr8:11205619	TDH	0.41	5.71	0.33	2.97e-8	Retinal vascular caliber;
CESC	cis	rs7103648	0.864	rs12801188	chr11:47388214	G/A	cg20307385	chr11:47447363	PSMC3	0.92	13.54	0.64	4.17e-32	Diastolic blood pressure;Systolic blood pressure;
CESC	cis	rs10504229	0.683	rs55986917	chr8:58137210	C/T	cg21724239	chr8:58056113	NA	0.58	5.95	0.34	8.29e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs7927771	0.832	rs4752990	chr11:47410393	G/A	cg05585544	chr11:47624801	NA	-0.46	-6.9	-0.39	3.94e-11	Subjective well-being;
CESC	cis	rs4243830	0.737	rs56036909	chr1:6608503	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	0.92	8.76	0.47	2.41e-16	Body mass index;
CESC	cis	rs7116495	0.609	rs674319	chr11:71775391	T/C	cg10381502	chr11:71823885	C11orf51	-1.14	-7.14	-0.4	8.75e-12	Severe influenza A (H1N1) infection;
CESC	trans	rs13205180	0.550	rs10948676	chr6:51983591	C/T	cg14179581	chr1:50881502	NA	-0.28	-6.14	-0.35	3.06e-9	Diastolic blood pressure;
CESC	cis	rs7927592	0.763	rs624003	chr11:68231240	C/T	cg16797656	chr11:68205561	LRP5	0.49	7.32	0.41	2.98e-12	Total body bone mineral density;
CESC	cis	rs8072100	0.817	rs9912101	chr17:45547078	A/G	cg25173405	chr17:45401733	C17orf57	-0.47	-6.15	-0.35	2.92e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs561341	1.000	rs117029332	chr17:30266085	C/G	cg12193833	chr17:30244370	NA	-0.71	-6.55	-0.37	3.04e-10	Hip circumference adjusted for BMI;
CESC	cis	rs4665809	0.590	rs4665837	chr2:26434022	C/A	cg08470875	chr2:26401718	FAM59B	-0.74	-7.65	-0.43	3.74e-13	Gut microbiome composition (summer);
CESC	cis	rs6681460	1.000	rs1325263	chr1:67129791	C/A	cg02459107	chr1:67143332	SGIP1	0.38	5.24	0.31	3.28e-7	Presence of antiphospholipid antibodies;
CESC	cis	rs826838	1.000	rs10880826	chr12:38672787	G/C	cg13010199	chr12:38710504	ALG10B	0.59	8.31	0.45	5.12e-15	Heart rate;
CESC	cis	rs12545109	0.800	rs2670026	chr8:57424338	G/T	cg09654669	chr8:57350985	NA	-0.46	-6.31	-0.36	1.18e-9	Obesity-related traits;
CESC	cis	rs7247513	0.897	rs12972944	chr19:12713808	G/A	cg01871581	chr19:12707946	ZNF490	-0.89	-14.6	-0.67	7.84e-36	Bipolar disorder;
CESC	cis	rs9911578	1.000	rs4793952	chr17:56608465	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.42	-5.59	-0.32	5.75e-8	Intelligence (multi-trait analysis);
CESC	cis	rs7727544	0.735	rs272884	chr5:131668654	G/C	cg07395648	chr5:131743802	NA	-0.46	-6.06	-0.35	4.78e-9	Blood metabolite levels;
CESC	cis	rs2066819	1.000	rs2020854	chr12:56743367	T/C	cg26316697	chr12:56727976	PAN2	0.72	6.94	0.39	2.92e-11	Psoriasis vulgaris;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00007036	chr1:33742089	ZNF362	-0.55	-6.25	-0.36	1.59e-9	Gut microbiome composition (summer);
CESC	cis	rs16854884	0.657	rs13078840	chr3:143700753	A/G	cg06585982	chr3:143692056	C3orf58	0.45	5.62	0.33	4.88e-8	Economic and political preferences (feminism/equality);
CESC	cis	rs875971	0.545	rs6460276	chr7:65647277	G/A	cg11764359	chr7:65958608	NA	0.79	9.51	0.5	1.18e-18	Aortic root size;
CESC	cis	rs11711311	1.000	rs13073843	chr3:113449150	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.72	10.27	0.53	4.81e-21	IgG glycosylation;
CESC	cis	rs1152591	0.524	rs1255991	chr14:64661642	G/A	cg23250157	chr14:64679961	SYNE2	0.41	5.81	0.34	1.8e-8	Atrial fibrillation;
CESC	cis	rs11166629	1.000	rs966659	chr8:135639045	C/T	cg27224718	chr8:135614730	ZFAT	-0.5	-6.28	-0.36	1.36e-9	Smoking quantity;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg18924771	chr5:166582591	NA	-0.45	-6.3	-0.36	1.24e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs3096299	0.685	rs3803681	chr16:89544756	C/T	cg08392591	chr16:89556376	ANKRD11	0.56	7.63	0.42	4.29e-13	Multiple myeloma (IgH translocation);
CESC	cis	rs7177699	0.557	rs7178051	chr15:79118296	A/G	cg04896959	chr15:78267971	NA	-0.32	-5.04	-0.3	8.66e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
CESC	trans	rs7618501	0.932	rs4855850	chr3:49761571	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.59	-8.48	-0.46	1.62e-15	Intelligence (multi-trait analysis);
CESC	cis	rs7474896	0.559	rs2738185	chr10:38247736	G/A	cg25427524	chr10:38739819	LOC399744	0.5	5.62	0.33	4.72e-8	Obesity (extreme);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13554667	chr10:62538283	CDK1;CDC2	0.57	6.18	0.35	2.37e-9	Gut microbiome composition (summer);
CESC	cis	rs6952808	0.595	rs3778982	chr7:2166233	T/C	cg23048001	chr7:2026167	MAD1L1	0.45	5.75	0.33	2.44e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs13108904	0.967	rs12502916	chr4:1276349	G/A	cg22903657	chr4:1355424	KIAA1530	0.41	5.66	0.33	3.92e-8	Obesity-related traits;
CESC	cis	rs769267	0.929	rs2905421	chr19:19457908	G/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.42	5.21	0.3	3.79e-7	Tonsillectomy;
CESC	cis	rs709400	1.000	rs55885592	chr14:104126024	C/T	cg24130564	chr14:104152367	KLC1	-0.42	-5.41	-0.32	1.44e-7	Body mass index;
CESC	cis	rs34779708	0.966	rs17499811	chr10:35456215	G/A	cg03585969	chr10:35415529	CREM	0.77	10.32	0.54	3.35e-21	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs9322193	0.923	rs9767309	chr6:150037943	A/G	cg07701084	chr6:150067640	NUP43	0.48	6.69	0.38	1.35e-10	Lung cancer;
CESC	trans	rs2085496	0.764	rs1596751	chr2:193807860	A/G	ch.15.84283968F	chr15:86482964	NA	0.48	6.43	0.37	5.99e-10	Neuroticism;
CESC	cis	rs11785400	1.000	rs4484678	chr8:143730796	A/G	cg10596483	chr8:143751796	JRK	0.41	5.41	0.32	1.43e-7	Schizophrenia;
CESC	cis	rs763014	0.865	rs2018789	chr16:632051	T/C	cg09263875	chr16:632152	PIGQ	0.67	11.24	0.57	3.15e-24	Height;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg01600100	chr12:96794307	CDK17	-0.5	-6.58	-0.37	2.49e-10	Fibrinogen levels;
CESC	cis	rs875971	0.540	rs781152	chr7:65479572	T/A	cg06456125	chr7:65229604	NA	0.43	5.49	0.32	9.18e-8	Aortic root size;
CESC	cis	rs1348850	0.519	rs1527407	chr2:178525630	T/G	cg23306229	chr2:178417860	TTC30B	0.46	5.39	0.31	1.59e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs6674176	0.597	rs9326136	chr1:44390392	A/G	cg13606994	chr1:44402422	ARTN	0.4	6.42	0.37	6.24e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg08063013	chr11:63742144	COX8A	0.47	6.12	0.35	3.28e-9	Systemic lupus erythematosus;
CESC	cis	rs853679	0.517	rs3757185	chr6:28107776	T/A	cg20151795	chr6:28129481	ZNF389	0.46	6.0	0.35	6.52e-9	Depression;
CESC	cis	rs9787249	0.957	rs7547787	chr1:40220806	C/T	cg19912559	chr1:40204330	PPIE	0.4	6.11	0.35	3.53e-9	Blood protein levels;
CESC	cis	rs6089584	0.854	rs2380146	chr20:60632233	C/T	cg13770153	chr20:60521292	NA	-0.47	-6.22	-0.36	1.94e-9	Body mass index;
CESC	cis	rs684232	0.602	rs8064796	chr17:525937	A/C	cg15660573	chr17:549704	VPS53	-0.81	-11.99	-0.59	9.07e-27	Prostate cancer;
CESC	cis	rs17253792	0.822	rs17685102	chr14:56129214	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.81	5.68	0.33	3.46e-8	Putamen volume;
CESC	cis	rs12220238	0.818	rs16931294	chr10:75999169	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.68	7.22	0.41	5.47e-12	Soluble interleukin-2 receptor subunit alpha;
CESC	cis	rs875971	0.862	rs6978028	chr7:65886300	G/C	cg18252515	chr7:66147081	NA	-0.46	-6.05	-0.35	5e-9	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26922706	chr5:133513036	SKP1	-0.54	-6.17	-0.35	2.59e-9	Gut microbiome composition (summer);
CESC	trans	rs116095464	0.558	rs11959126	chr5:283880	T/G	cg00938859	chr5:1591904	SDHAP3	0.65	7.03	0.4	1.73e-11	Breast cancer;
CESC	cis	rs7647973	0.580	rs35218722	chr3:49275805	A/G	cg03060546	chr3:49711283	APEH	0.51	6.97	0.39	2.58e-11	Menarche (age at onset);
CESC	cis	rs722599	0.683	rs10139016	chr14:75274288	T/C	cg08847533	chr14:75593920	NEK9	0.49	5.86	0.34	1.38e-8	IgG glycosylation;
CESC	cis	rs6089829	0.889	rs6062773	chr20:61663262	G/C	cg03213289	chr20:61660250	NA	0.39	6.07	0.35	4.42e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs898097	0.625	rs6502017	chr17:80891135	C/T	cg10494973	chr17:80897199	TBCD	-0.45	-5.6	-0.33	5.37e-8	Breast cancer;
CESC	cis	rs898097	0.578	rs2380173	chr17:80909157	G/T	cg15664640	chr17:80829946	TBCD	-0.39	-5.8	-0.34	1.86e-8	Breast cancer;
CESC	cis	rs10791323	0.660	rs10791332	chr11:133732150	A/G	cg15485101	chr11:133734466	NA	0.39	6.56	0.37	2.86e-10	Childhood ear infection;
CESC	cis	rs2404602	0.669	rs12148877	chr15:76919959	T/G	cg22467129	chr15:76604101	ETFA	-0.36	-5.32	-0.31	2.25e-7	Blood metabolite levels;
CESC	cis	rs34779708	0.733	rs4244997	chr10:35547254	T/C	cg03585969	chr10:35415529	CREM	0.55	6.37	0.36	8.28e-10	Inflammatory bowel disease;Crohn's disease;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg07317108	chr10:11575102	USP6NL	0.42	6.33	0.36	1.04e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs9325144	0.647	rs12822023	chr12:39097964	T/C	cg26384229	chr12:38710491	ALG10B	-0.5	-7.06	-0.4	1.47e-11	Morning vs. evening chronotype;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg26035463	chr12:117627651	FBXO21	0.54	6.77	0.38	8.32e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs7216064	0.953	rs80135947	chr17:65836001	A/C	cg12091567	chr17:66097778	LOC651250	-0.86	-8.83	-0.48	1.49e-16	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg02872018	chr2:192746213	NA	0.45	6.34	0.36	9.6e-10	Ulcerative colitis;
CESC	cis	rs6952808	0.692	rs60755037	chr7:2030104	G/A	cg04267008	chr7:1944627	MAD1L1	-0.63	-7.72	-0.43	2.43e-13	Bipolar disorder and schizophrenia;
CESC	cis	rs698833	0.501	rs12473699	chr2:44507673	G/A	cg04920474	chr2:44395004	PPM1B	0.47	6.71	0.38	1.19e-10	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs6942407	0.696	rs4400318	chr7:86860524	A/C	cg02420886	chr7:86849541	C7orf23	0.54	5.19	0.3	4.27e-7	Food allergy;
CESC	cis	rs2249625	1.000	rs2249625	chr6:72906753	C/T	cg18830697	chr6:72922368	RIMS1	0.41	5.86	0.34	1.38e-8	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CESC	cis	rs4665809	1.000	rs1550382	chr2:26266877	T/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.71	-8.0	-0.44	3.99e-14	Gut microbiome composition (summer);
CESC	cis	rs9322193	0.962	rs4869730	chr6:150129323	A/G	cg13206674	chr6:150067644	NUP43	0.42	5.83	0.34	1.63e-8	Lung cancer;
CESC	cis	rs72781680	0.716	rs78332127	chr2:24150163	C/G	cg08917208	chr2:24149416	ATAD2B	0.61	6.08	0.35	4.2e-9	Lymphocyte counts;
CESC	cis	rs7872515	0.887	rs10820937	chr9:94840206	T/C	cg01248375	chr9:94877805	SPTLC1	0.53	5.94	0.34	8.91e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs561341	0.663	rs72821936	chr17:30224068	C/G	cg13647721	chr17:30228624	UTP6	0.83	10.86	0.55	5.68e-23	Hip circumference adjusted for BMI;
CESC	cis	rs3820928	0.874	rs4234062	chr2:227819050	C/A	cg11843606	chr2:227700838	RHBDD1	-0.43	-5.68	-0.33	3.62e-8	Pulmonary function;
CESC	cis	rs11971779	0.646	rs58682779	chr7:139084712	C/T	cg07862535	chr7:139043722	LUC7L2	0.56	5.65	0.33	4.1e-8	Diisocyanate-induced asthma;
CESC	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg09033563	chr22:24373618	LOC391322	-0.44	-5.66	-0.33	3.88e-8	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs9611565	0.559	rs8139993	chr22:41995335	T/C	cg06481639	chr22:41940642	POLR3H	-0.56	-6.28	-0.36	1.37e-9	Vitiligo;
CESC	cis	rs701145	0.556	rs191651	chr3:153973887	T/G	cg16511985	chr3:153974050	SGEF	0.42	5.64	0.33	4.26e-8	Coronary artery disease;
CESC	cis	rs2075371	0.932	rs11766132	chr7:133993062	T/C	cg00033643	chr7:134001901	SLC35B4	0.43	5.48	0.32	1e-7	Mean platelet volume;
CESC	cis	rs9487051	0.735	rs882074	chr6:109611720	C/T	cg12927641	chr6:109611667	NA	-0.43	-6.63	-0.38	1.91e-10	Reticulocyte fraction of red cells;
CESC	cis	rs11048434	0.736	rs1805724	chr12:9104609	T/C	cg23795048	chr12:9217529	LOC144571	0.36	5.66	0.33	4.02e-8	Sjögren's syndrome;
CESC	cis	rs7605827	0.930	rs1990754	chr2:15615910	A/G	cg19274914	chr2:15703543	NA	0.35	6.13	0.35	3.19e-9	Educational attainment (years of education);
CESC	cis	rs10197940	0.662	rs72860233	chr2:152289767	G/A	cg19508488	chr2:152266495	RIF1	0.51	5.62	0.33	4.95e-8	Lung cancer;
CESC	cis	rs9894429	0.646	rs7406828	chr17:79619226	A/G	cg18240062	chr17:79603768	NPLOC4	-0.47	-6.18	-0.36	2.35e-9	Eye color traits;
CESC	cis	rs67311347	1.000	rs11129876	chr3:40401636	C/T	cg09455208	chr3:40491958	NA	-0.48	-7.9	-0.44	7.38e-14	Renal cell carcinoma;
CESC	cis	rs4713118	0.662	rs9468276	chr6:28027688	A/C	cg23161317	chr6:28129485	ZNF389	0.49	6.19	0.36	2.28e-9	Parkinson's disease;
CESC	trans	rs11098499	0.754	rs714899	chr4:120243035	G/A	cg25214090	chr10:38739885	LOC399744	0.64	9.06	0.49	2.97e-17	Corneal astigmatism;
CESC	cis	rs4819052	0.851	rs2236444	chr21:46678226	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.97	14.35	0.66	5.99e-35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs2018683	0.933	rs12536127	chr7:28985967	T/C	cg19402173	chr7:128379420	CALU	-0.6	-7.89	-0.44	7.74e-14	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CESC	cis	rs6088590	0.603	rs6579186	chr20:33282198	G/C	cg24642439	chr20:33292090	TP53INP2	0.69	9.19	0.49	1.21e-17	Coronary artery disease;
CESC	cis	rs6942756	0.955	rs55638303	chr7:128885770	C/T	cg02491457	chr7:128862824	NA	-0.68	-9.62	-0.51	5.66e-19	White matter hyperintensity burden;
CESC	cis	rs11240074	0.516	rs61838368	chr1:146963986	C/T	cg25205988	chr1:146714368	CHD1L	-0.56	-5.07	-0.3	7.35e-7	Type 2 diabetes;
CESC	cis	rs9611565	0.694	rs202613	chr22:41821993	C/A	cg06634786	chr22:41940651	POLR3H	0.71	7.17	0.4	7.6e-12	Vitiligo;
CESC	cis	rs7666738	0.830	rs13118892	chr4:98968497	T/C	cg03467027	chr4:99064603	C4orf37	0.43	5.42	0.32	1.34e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9894429	0.646	rs8080391	chr17:79566319	A/T	cg18240062	chr17:79603768	NPLOC4	-0.86	-12.65	-0.61	5.01e-29	Eye color traits;
CESC	cis	rs4523957	0.579	rs2270478	chr17:2089848	G/A	cg16513277	chr17:2031491	SMG6	-0.63	-8.81	-0.48	1.7e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs2839186	0.632	rs2839184	chr21:47689013	G/A	cg10351095	chr21:47802916	PCNT	-0.53	-6.45	-0.37	5.32e-10	Testicular germ cell tumor;
CESC	cis	rs11690935	0.921	rs3770445	chr2:172708919	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.95	-14.35	-0.66	5.85e-35	Schizophrenia;
CESC	cis	rs870825	0.860	rs56180712	chr4:185600223	A/G	cg04058563	chr4:185651563	MLF1IP	0.57	5.29	0.31	2.54e-7	Blood protein levels;
CESC	cis	rs238295	0.805	rs6053527	chr20:5582457	G/T	cg24001556	chr20:5591874	RP5-1022P6.2	-0.46	-5.22	-0.31	3.64e-7	Occipital cortical area (total cortical area interaction);
CESC	cis	rs34172651	0.687	rs8044992	chr16:24811207	T/C	cg06505273	chr16:24850292	NA	0.41	5.23	0.31	3.41e-7	Intelligence (multi-trait analysis);
CESC	cis	rs3859192	0.557	rs12602514	chr17:38159745	A/G	cg17344932	chr17:38183730	MED24;SNORD124	0.62	9.18	0.49	1.3e-17	White blood cell count;
CESC	cis	rs7216064	1.000	rs11869819	chr17:65868669	A/C	cg12091567	chr17:66097778	LOC651250	-0.85	-8.7	-0.47	3.61e-16	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs9303401	1.000	rs7218362	chr17:56888299	A/G	cg12560992	chr17:57184187	TRIM37	0.49	5.55	0.32	7.07e-8	Cognitive test performance;
CESC	cis	rs1401999	1.000	rs13317532	chr3:183641669	G/C	cg01324343	chr3:183735012	ABCC5	0.64	13.44	0.64	9.67e-32	Anterior chamber depth;
CESC	cis	rs3091242	0.933	rs11802413	chr1:25760920	A/G	cg02931644	chr1:25747376	RHCE	-0.41	-6.87	-0.39	4.49e-11	Erythrocyte sedimentation rate;
CESC	cis	rs9296736	0.961	rs9370260	chr6:53921674	T/C	cg04374786	chr6:53939321	C6orf142	0.33	5.15	0.3	4.98e-7	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs9322193	0.887	rs3734295	chr6:149915053	C/T	cg13206674	chr6:150067644	NUP43	0.4	5.72	0.33	2.8e-8	Lung cancer;
CESC	cis	rs10463316	0.894	rs10062856	chr5:150768196	C/G	cg03212797	chr5:150827313	SLC36A1	-0.47	-6.15	-0.35	2.86e-9	Metabolite levels (Pyroglutamine);
CESC	cis	rs4665809	0.878	rs4665826	chr2:26367503	A/T	cg25036284	chr2:26402008	FAM59B	0.83	9.66	0.51	4.25e-19	Gut microbiome composition (summer);
CESC	cis	rs4812048	0.649	rs116580814	chr20:57618141	G/T	cg14073986	chr20:57617431	SLMO2	0.78	6.29	0.36	1.3e-9	Mean platelet volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14722716	chr4:48833041	OCIAD1	0.57	6.41	0.37	6.57e-10	Gut microbiome composition (summer);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg27587257	chr11:1002310	AP2A2	0.42	6.26	0.36	1.58e-9	Fibrinogen levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19826439	chr1:226297528	NA	0.66	7.83	0.43	1.16e-13	Gut microbiome composition (summer);
CESC	cis	rs9393777	0.513	rs9379895	chr6:26592707	A/G	cg12292205	chr6:26970375	C6orf41	-0.48	-5.57	-0.32	6.18e-8	Intelligence (multi-trait analysis);
CESC	cis	rs7618915	0.547	rs10780035	chr3:52764624	C/T	cg07507251	chr3:52567010	NT5DC2	0.42	7.37	0.41	2.24e-12	Bipolar disorder;
CESC	cis	rs1055129	0.560	rs3682	chr17:73942150	A/G	cg02678768	chr17:74002944	EVPL	0.37	5.12	0.3	5.96e-7	White matter hyperintensity burden;
CESC	cis	rs763121	0.853	rs3827357	chr22:39079413	A/G	cg14440974	chr22:39074834	NA	-0.42	-5.66	-0.33	3.87e-8	Menopause (age at onset);
CESC	cis	rs761746	0.960	rs4820980	chr22:31917415	A/G	cg25791279	chr22:32026902	PISD	-0.53	-6.14	-0.35	2.94e-9	Intelligence;
CESC	cis	rs8103278	1.000	rs8109951	chr19:46289503	C/T	cg11657440	chr19:46296263	DMWD	-0.61	-7.75	-0.43	1.99e-13	Coronary artery disease;
CESC	cis	rs7216064	0.953	rs1599859	chr17:65837193	C/G	cg12091567	chr17:66097778	LOC651250	-0.8	-9.0	-0.48	4.4e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs10463316	0.894	rs4099170	chr5:150766583	G/A	cg03212797	chr5:150827313	SLC36A1	-0.47	-6.2	-0.36	2.17e-9	Metabolite levels (Pyroglutamine);
CESC	cis	rs637571	0.544	rs500161	chr11:65695438	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.41	5.75	0.33	2.42e-8	Eosinophil percentage of white cells;
CESC	cis	rs854765	0.718	rs6502629	chr17:17869642	A/G	cg09796270	chr17:17721594	SREBF1	0.43	5.74	0.33	2.6e-8	Total body bone mineral density;
CESC	trans	rs2085496	0.764	rs1596751	chr2:193807860	A/G	cg05370988	chr3:186500739	EIF4A2	0.43	6.04	0.35	5.09e-9	Neuroticism;
CESC	cis	rs9322193	0.923	rs12660304	chr6:150060783	A/G	cg13206674	chr6:150067644	NUP43	0.44	6.53	0.37	3.39e-10	Lung cancer;
CESC	cis	rs559928	0.597	rs2096706	chr11:63924446	T/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.66	5.6	0.33	5.22e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CESC	cis	rs9926296	0.605	rs1800287	chr16:89858525	C/G	cg27121462	chr16:89883253	FANCA	0.73	10.57	0.54	5.04e-22	Vitiligo;
CESC	cis	rs2576037	0.526	rs571181	chr18:44376399	T/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.33	5.35	0.31	1.9e-7	Personality dimensions;
CESC	cis	rs514406	0.893	rs2897561	chr1:53388747	C/A	cg16325326	chr1:53192061	ZYG11B	0.9	14.84	0.67	1.12e-36	Monocyte count;
CESC	cis	rs4654899	1.000	rs7537072	chr1:21434533	T/C	cg05370193	chr1:21551575	ECE1	0.38	5.63	0.33	4.66e-8	Superior frontal gyrus grey matter volume;
CESC	cis	rs2742234	0.590	rs2435383	chr10:43675671	T/C	cg07801480	chr10:43725741	RASGEF1A	0.41	5.29	0.31	2.56e-7	Hirschsprung disease;
CESC	cis	rs7818688	0.697	rs75349998	chr8:95990918	G/A	cg16049864	chr8:95962084	TP53INP1	0.56	5.67	0.33	3.78e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs8027181	1.000	rs3850986	chr15:73091283	G/T	cg25632853	chr15:73088954	NA	0.36	6.45	0.37	5.23e-10	Triglyceride levels;
CESC	cis	rs853679	0.517	rs9348794	chr6:28117757	T/A	cg22143856	chr6:28129313	ZNF389	0.53	6.71	0.38	1.2e-10	Depression;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg24905370	chr5:74063138	NSA2;GFM2	-0.45	-6.09	-0.35	3.88e-9	Asthma;
CESC	cis	rs10256972	0.933	rs35696159	chr7:1047194	A/G	cg07308232	chr7:1071921	C7orf50	-0.45	-6.25	-0.36	1.65e-9	Longevity;Endometriosis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05992347	chr16:33964783	MIR1826	-0.58	-6.38	-0.36	7.69e-10	Gut microbiome composition (summer);
CESC	cis	rs2075371	1.000	rs2075372	chr7:133984432	C/T	cg11752832	chr7:134001865	SLC35B4	0.55	7.23	0.41	5.27e-12	Mean platelet volume;
CESC	cis	rs10189230	0.967	rs12613015	chr2:222356119	G/A	cg14652038	chr2:222343519	EPHA4	0.35	7.21	0.41	5.68e-12	Urate levels in lean individuals;
CESC	cis	rs919433	0.857	rs36071109	chr2:198183191	C/A	cg10820045	chr2:198174542	NA	-0.37	-5.13	-0.3	5.66e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs1008375	0.966	rs6832962	chr4:17652133	T/C	cg15017067	chr4:17643749	FAM184B	0.38	5.09	0.3	6.76e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs9462846	0.691	rs7744454	chr6:42914041	C/G	cg02353165	chr6:42928485	GNMT	0.55	6.35	0.36	9.17e-10	Blood protein levels;
CESC	cis	rs3892630	0.588	rs28787932	chr19:33226229	T/C	cg13157960	chr19:33183277	NUDT19	0.54	5.35	0.31	1.88e-7	Red blood cell traits;
CESC	cis	rs72634258	0.945	rs34157438	chr1:8023586	C/T	cg00042356	chr1:8021962	PARK7	0.91	8.22	0.45	9.03e-15	Inflammatory bowel disease;
CESC	cis	rs1008375	0.932	rs11938710	chr4:17670664	G/C	cg02297831	chr4:17616191	MED28	-0.5	-5.84	-0.34	1.55e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs7580658	0.724	rs71414745	chr2:127992588	A/G	cg10021288	chr2:128175891	PROC	-0.37	-5.89	-0.34	1.2e-8	Protein C levels;
CESC	cis	rs12765878	1.000	rs35223321	chr10:105646395	C/T	cg11005552	chr10:105648138	OBFC1	0.36	5.27	0.31	2.85e-7	Coronary artery disease;
CESC	cis	rs7640424	0.716	rs35703078	chr3:107859558	A/G	cg09227934	chr3:107805635	CD47	-0.47	-6.15	-0.35	2.9e-9	Body mass index;
CESC	cis	rs780096	0.587	rs1049817	chr2:27550967	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.34	-7.17	-0.4	7.54e-12	Total body bone mineral density;
CESC	cis	rs4604732	0.536	rs76191272	chr1:247628055	A/T	cg12754571	chr1:247694271	LOC148824;OR2C3	0.41	5.09	0.3	6.91e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs4481887	0.732	rs4526647	chr1:248423788	C/G	cg00666640	chr1:248458726	OR2T12	0.36	6.01	0.35	6.25e-9	Common traits (Other);
CESC	cis	rs6541297	1.000	rs4846838	chr1:230281618	G/A	cg20703242	chr1:230279135	GALNT2	0.66	9.05	0.49	3.16e-17	Coronary artery disease;
CESC	cis	rs62064224	0.702	rs2302277	chr17:30791509	C/G	cg25809561	chr17:30822961	MYO1D	0.63	9.12	0.49	1.92e-17	Schizophrenia;
CESC	cis	rs116095464	1.000	rs6873902	chr5:313337	C/G	cg22857025	chr5:266934	NA	-1.2	-10.6	-0.55	4.2e-22	Breast cancer;
CESC	trans	rs7980799	0.935	rs10844580	chr12:33553867	G/A	cg26384229	chr12:38710491	ALG10B	-0.52	-7.0	-0.4	2.12e-11	Heart rate;Heart rate variability traits (RMSSD);
CESC	cis	rs74781061	0.858	rs8023865	chr15:74853604	G/A	cg17294928	chr15:75287854	SCAMP5	-0.5	-5.4	-0.31	1.46e-7	Endometriosis;
CESC	cis	rs875971	1.000	rs2420820	chr7:66091907	T/C	cg12463550	chr7:65579703	CRCP	-0.56	-7.07	-0.4	1.34e-11	Aortic root size;
CESC	trans	rs116095464	0.558	rs6875291	chr5:264192	T/C	cg00938859	chr5:1591904	SDHAP3	0.63	6.77	0.38	8.38e-11	Breast cancer;
CESC	trans	rs7656342	0.808	rs10003216	chr4:9766749	A/G	cg20118385	chr4:4250070	TMEM128	-0.51	-6.15	-0.35	2.78e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs1008375	1.000	rs4642241	chr4:17617111	T/C	cg15017067	chr4:17643749	FAM184B	0.39	5.6	0.33	5.22e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs7937682	0.632	rs3944619	chr11:111774743	A/G	cg22437258	chr11:111473054	SIK2	-0.5	-5.5	-0.32	8.78e-8	Primary sclerosing cholangitis;
CESC	cis	rs12950390	0.853	rs59513807	chr17:45867925	G/A	cg00777063	chr17:45855553	NA	-0.38	-5.61	-0.33	5.1e-8	IgG glycosylation;
CESC	cis	rs2050392	0.928	rs6481677	chr10:30701816	A/G	cg18806716	chr10:30721971	MAP3K8	-0.4	-5.87	-0.34	1.27e-8	Inflammatory bowel disease;
CESC	cis	rs34172651	0.797	rs12920941	chr16:24830866	T/A	cg06028605	chr16:24865363	SLC5A11	0.34	5.04	0.3	8.67e-7	Intelligence (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25062357	chr20:2821267	VPS16;FAM113A	0.65	7.7	0.43	2.69e-13	Gut microbiome composition (summer);
CESC	cis	rs9916302	0.851	rs11078907	chr17:37662954	C/T	cg19468946	chr17:37922297	IKZF3	-0.39	-5.08	-0.3	7.08e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs9905704	0.846	rs302851	chr17:56685424	G/A	cg12560992	chr17:57184187	TRIM37	0.62	7.84	0.43	1.11e-13	Testicular germ cell tumor;
CESC	cis	rs7618915	1.000	rs34569561	chr3:52287293	T/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.34	5.69	0.33	3.42e-8	Bipolar disorder;
CESC	cis	rs57221529	0.766	rs72706606	chr5:558609	T/C	cg09021430	chr5:549028	NA	-0.42	-5.26	-0.31	2.92e-7	Lung disease severity in cystic fibrosis;
CESC	cis	rs8177253	0.761	rs12490148	chr3:133523973	C/T	cg01448562	chr3:133502909	NA	-0.58	-8.31	-0.45	5.05e-15	Iron status biomarkers;
CESC	cis	rs4862750	0.872	rs7679956	chr4:187900229	C/T	cg06074448	chr4:187884817	NA	-0.47	-7.34	-0.41	2.69e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs950169	0.579	rs12913054	chr15:84664456	A/G	cg17507749	chr15:85114479	UBE2QP1	0.61	5.92	0.34	9.94e-9	Schizophrenia;
CESC	cis	rs7666738	0.830	rs13124689	chr4:98961182	A/T	cg03467027	chr4:99064603	C4orf37	0.44	5.57	0.32	6.41e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9768139	0.901	rs56113702	chr7:158117938	C/T	cg06219351	chr7:158114137	PTPRN2	0.48	7.63	0.42	4.31e-13	Calcium levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04370476	chr3:49761188	GMPPB	0.56	6.47	0.37	4.83e-10	Gut microbiome composition (summer);
CESC	cis	rs10504229	0.683	rs113492050	chr8:58130046	A/G	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg23131131	chr22:24373011	LOC391322	-0.65	-8.79	-0.48	1.95e-16	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs3749237	0.555	rs2117939	chr3:49415179	C/A	cg07636037	chr3:49044803	WDR6	0.59	8.45	0.46	1.98e-15	Resting heart rate;
CESC	cis	rs4595586	0.545	rs17546375	chr12:39407248	C/A	cg26384229	chr12:38710491	ALG10B	0.61	8.64	0.47	5.35e-16	Morning vs. evening chronotype;
CESC	cis	rs887829	0.588	rs6715325	chr2:234635241	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.54	-7.47	-0.42	1.2e-12	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CESC	cis	rs6570726	1.000	rs441477	chr6:145848243	C/T	cg05347473	chr6:146136440	FBXO30	0.44	5.96	0.34	7.98e-9	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs12681288	0.676	rs2701910	chr8:1001246	G/T	cg04851639	chr8:1020857	NA	-0.32	-6.77	-0.38	8.32e-11	Schizophrenia;
CESC	cis	rs4819052	0.851	rs4819042	chr21:46660072	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.75	9.98	0.52	4.1e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs4604732	0.631	rs1106719	chr1:247624713	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	-0.57	-7.33	-0.41	2.83e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs17102884	0.506	rs887746	chr14:75403817	C/T	cg11812906	chr14:75593930	NEK9	-0.42	-5.21	-0.3	3.84e-7	Neuroticism;
CESC	cis	rs60843830	1.000	rs58461606	chr2:267367	G/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.89	12.34	0.6	6.07e-28	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs1577917	1.000	rs884841	chr6:86680300	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.43	-5.64	-0.33	4.45e-8	Response to antipsychotic treatment;
CESC	cis	rs2836974	0.897	rs34035316	chr21:40594023	T/C	cg11890956	chr21:40555474	PSMG1	1.21	23.16	0.82	1.22e-65	Cognitive function;
CESC	cis	rs2072499	0.778	rs2247476	chr1:156190280	C/A	cg24450063	chr1:156163899	SLC25A44	0.9	11.11	0.56	8.37e-24	Testicular germ cell tumor;
CESC	cis	rs9911578	0.935	rs7218105	chr17:57041119	A/G	cg05425664	chr17:57184151	TRIM37	-0.5	-6.96	-0.39	2.66e-11	Intelligence (multi-trait analysis);
CESC	cis	rs137699	0.687	rs4821887	chr22:39756985	C/T	cg02038168	chr22:39784481	NA	-0.5	-5.69	-0.33	3.41e-8	IgG glycosylation;
CESC	cis	rs4595586	0.545	rs7952765	chr12:39375325	C/G	cg26384229	chr12:38710491	ALG10B	0.52	7.31	0.41	3.09e-12	Morning vs. evening chronotype;
CESC	cis	rs2576037	1.000	rs2576037	chr18:44585420	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.64	-9.26	-0.49	7.23e-18	Personality dimensions;
CESC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg04145264	chr11:65190825	NEAT1	0.45	5.99	0.35	6.64e-9	Tetralogy of Fallot;
CESC	trans	rs1557351	0.723	rs8095898	chr18:54723750	A/C	cg11433624	chr6:7146702	RREB1	0.38	6.14	0.35	2.94e-9	Multiple sclerosis (age of onset);
CESC	cis	rs1005277	0.579	rs2505241	chr10:38442421	T/C	cg25517755	chr10:38738941	LOC399744	-0.49	-6.41	-0.37	6.52e-10	Extrinsic epigenetic age acceleration;
CESC	cis	rs17345786	0.906	rs55710435	chr3:101180330	G/A	cg12386194	chr3:101231763	SENP7	0.61	6.64	0.38	1.75e-10	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10463316	0.894	rs7709994	chr5:150753597	A/T	cg03212797	chr5:150827313	SLC36A1	-0.52	-6.83	-0.39	5.78e-11	Metabolite levels (Pyroglutamine);
CESC	cis	rs7539624	0.529	rs7412088	chr1:223899123	T/A	cg10100437	chr1:223903862	CAPN2	0.45	5.94	0.34	8.77e-9	Schizophrenia;
CESC	cis	rs9303542	0.559	rs55859232	chr17:46612645	A/G	cg04904318	chr17:46607828	HOXB1	-0.6	-5.74	-0.33	2.54e-8	Ovarian cancer;Epithelial ovarian cancer;
CESC	cis	rs3015469	0.671	rs35334347	chr14:51217982	G/A	cg26011998	chr14:51135199	SAV1	0.51	5.64	0.33	4.44e-8	Plasma amyloid beta peptide concentrations (ABx-40);
CESC	cis	rs3087591	0.960	rs2952999	chr17:29509801	G/T	cg24425628	chr17:29625626	OMG;NF1	0.44	5.55	0.32	7.1e-8	Hip circumference;
CESC	cis	rs9403521	1.000	rs12208927	chr6:143993634	A/G	cg18240653	chr6:144019428	PHACTR2	-0.51	-5.73	-0.33	2.73e-8	Obesity-related traits;
CESC	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.57	-6.35	-0.36	9.21e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs698833	0.926	rs698827	chr2:44730496	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	-0.53	-6.46	-0.37	4.92e-10	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs644799	0.526	rs534973	chr11:95633624	A/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.55	7.4	0.41	1.81e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs3126085	1.000	rs11590365	chr1:152165489	C/A	cg03465714	chr1:152285911	FLG	0.45	5.05	0.3	8.27e-7	Atopic dermatitis;
CESC	cis	rs7647973	0.925	rs4955439	chr3:49245645	G/T	cg07636037	chr3:49044803	WDR6	-0.62	-8.31	-0.45	5e-15	Menarche (age at onset);
CESC	cis	rs5750830	0.649	rs5757659	chr22:39812409	A/C	cg11247378	chr22:39784982	NA	-0.59	-8.29	-0.45	5.81e-15	Intelligence (multi-trait analysis);
CESC	cis	rs6701037	0.748	rs11583687	chr1:175132049	A/C	cg00321850	chr1:175162397	KIAA0040	0.38	5.73	0.33	2.7e-8	Alcohol dependence;
CESC	trans	rs11165623	0.792	rs6593599	chr1:96911468	C/T	cg10631902	chr5:14652156	NA	-0.55	-8.17	-0.45	1.3e-14	Hip circumference;Waist circumference;
CESC	cis	rs3026101	0.671	rs8081481	chr17:5282763	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.41	5.48	0.32	9.98e-8	Body mass index;
CESC	cis	rs2732480	0.500	rs12829841	chr12:48628739	A/G	cg04545296	chr12:48745243	ZNF641	0.41	6.86	0.39	4.97e-11	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs9487051	0.802	rs6568558	chr6:109592701	A/T	cg21918786	chr6:109611834	NA	-0.39	-6.04	-0.35	5.08e-9	Reticulocyte fraction of red cells;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07398558	chr1:28879201	TRNAU1AP	-0.59	-6.53	-0.37	3.27e-10	Gut microbiome composition (summer);
CESC	trans	rs2658782	0.789	rs56091149	chr11:93073640	A/C	cg13657970	chr12:123333035	HIP1R	-0.45	-6.04	-0.35	5.27e-9	Pulmonary function decline;
CESC	cis	rs7264396	0.832	rs224416	chr20:34138406	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.57	-7.08	-0.4	1.32e-11	Total cholesterol levels;
CESC	cis	rs10788264	0.544	rs10788269	chr10:124022870	A/G	cg09507567	chr10:124027408	NA	0.41	5.56	0.32	6.56e-8	Total body bone mineral density;
CESC	cis	rs1551570	0.755	rs2290687	chr19:10229521	C/T	cg16327482	chr19:10226339	EIF3G	0.48	7.76	0.43	1.83e-13	Narcolepsy;
CESC	cis	rs9399135	0.967	rs1014020	chr6:135334426	C/A	cg24558204	chr6:135376177	HBS1L	0.52	7.18	0.4	6.82e-12	Red blood cell count;
CESC	cis	rs763121	0.853	rs5757193	chr22:39034867	A/G	cg06022373	chr22:39101656	GTPBP1	-0.85	-12.28	-0.6	9.68e-28	Menopause (age at onset);
CESC	cis	rs9322193	0.923	rs2185352	chr6:150035776	T/G	cg04369109	chr6:150039330	LATS1	-0.42	-5.86	-0.34	1.36e-8	Lung cancer;
CESC	cis	rs3767633	0.925	rs4579731	chr1:161766859	G/A	cg09175582	chr1:161736000	ATF6	0.8	6.57	0.37	2.59e-10	IgG glycosylation;
CESC	cis	rs7927771	0.542	rs7122217	chr11:47777920	G/C	cg20307385	chr11:47447363	PSMC3	-0.58	-8.01	-0.44	3.54e-14	Subjective well-being;
CESC	cis	rs798554	0.797	rs798491	chr7:2800521	A/G	cg04166393	chr7:2884313	GNA12	0.59	7.47	0.42	1.14e-12	Height;
CESC	cis	rs514406	0.505	rs431427	chr1:53179094	C/A	cg24675658	chr1:53192096	ZYG11B	-0.49	-6.09	-0.35	3.92e-9	Monocyte count;
CESC	cis	rs7584330	0.554	rs6760913	chr2:238400702	C/T	cg14458575	chr2:238380390	NA	0.77	6.36	0.36	8.89e-10	Prostate cancer;
CESC	cis	rs7429990	0.930	rs71323371	chr3:47945817	A/T	cg11946769	chr3:48343235	NME6	0.46	5.62	0.33	4.91e-8	Educational attainment (years of education);
CESC	cis	rs16917546	1.000	rs16917546	chr10:64397538	T/C	cg03961010	chr10:64397487	ZNF365	-0.37	-6.09	-0.35	4.01e-9	Basal cell carcinoma;
CESC	trans	rs3749237	0.964	rs2234385	chr3:49846041	G/A	cg21659725	chr3:3221576	CRBN	0.53	6.38	0.36	8.01e-10	Resting heart rate;
CESC	cis	rs7084402	0.967	rs1593678	chr10:60291548	A/G	cg07615347	chr10:60278583	BICC1	0.6	9.41	0.5	2.54e-18	Refractive error;
CESC	cis	rs4450798	0.739	rs9840302	chr3:13741999	C/T	cg23332027	chr3:13681764	NA	0.4	5.31	0.31	2.31e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs17376456	0.877	rs12374488	chr5:93481407	A/G	cg21475434	chr5:93447410	FAM172A	0.9	7.77	0.43	1.68e-13	Diabetic retinopathy;
CESC	cis	rs2075371	1.000	rs1862051	chr7:133981021	G/A	cg11752832	chr7:134001865	SLC35B4	0.53	6.86	0.39	4.82e-11	Mean platelet volume;
CESC	cis	rs7107174	0.901	rs2450138	chr11:77924870	C/T	cg02023728	chr11:77925099	USP35	0.49	6.39	0.37	7.56e-10	Testicular germ cell tumor;
CESC	cis	rs10779751	0.690	rs2791646	chr1:11133242	C/T	cg08854313	chr1:11322531	MTOR	0.76	10.24	0.53	5.91e-21	Body mass index;
CESC	trans	rs11098499	0.874	rs6822498	chr4:120120183	T/C	cg25214090	chr10:38739885	LOC399744	0.61	8.12	0.45	1.83e-14	Corneal astigmatism;
CESC	trans	rs1003719	0.715	rs762139	chr21:38568475	A/T	cg17956387	chr1:208418015	PLXNA2	-0.45	-6.38	-0.36	7.95e-10	Eye color traits;
CESC	cis	rs12995491	0.902	rs6737641	chr2:88529471	A/T	cg04511125	chr2:88470314	THNSL2	-0.51	-7.36	-0.41	2.35e-12	Response to metformin (IC50);
CESC	cis	rs7605827	0.897	rs13004112	chr2:15604048	C/T	cg19274914	chr2:15703543	NA	0.35	6.3	0.36	1.21e-9	Educational attainment (years of education);
CESC	cis	rs1348850	0.872	rs10165785	chr2:178293295	C/T	cg23306229	chr2:178417860	TTC30B	0.62	7.92	0.44	6.37e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs9733	0.519	rs10788792	chr1:150638572	T/G	cg22823121	chr1:150693482	HORMAD1	0.47	7.05	0.4	1.6e-11	Tonsillectomy;
CESC	cis	rs9916302	0.861	rs33933929	chr17:37426441	A/C	cg07936489	chr17:37558343	FBXL20	-0.78	-11.38	-0.57	1.08e-24	Glomerular filtration rate (creatinine);
CESC	cis	rs6558174	0.930	rs1038311	chr8:22489247	T/C	cg03733263	chr8:22462867	KIAA1967	0.46	6.33	0.36	1.06e-9	Breast cancer;
CESC	cis	rs10883723	0.810	rs1409311	chr10:104282160	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.54	7.42	0.41	1.57e-12	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs992157	0.798	rs4996257	chr2:219162836	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.7	9.58	0.51	7.29e-19	Colorectal cancer;
CESC	cis	rs8016982	0.610	rs2371570	chr14:81709686	C/T	cg01989461	chr14:81687754	GTF2A1	0.72	11.11	0.56	8.6e-24	Schizophrenia;
CESC	cis	rs2836974	0.863	rs8128026	chr21:40533702	T/C	cg11644478	chr21:40555479	PSMG1	1.03	17.01	0.72	2.21e-44	Cognitive function;
CESC	cis	rs7615952	0.599	rs2333408	chr3:125732098	G/A	cg15145296	chr3:125709740	NA	-0.48	-5.28	-0.31	2.76e-7	Blood pressure (smoking interaction);
CESC	cis	rs1008375	1.000	rs4698199	chr4:17656738	G/C	cg15017067	chr4:17643749	FAM184B	0.35	5.07	0.3	7.59e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs7582720	1.000	rs72926793	chr2:203826396	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.36	0.41	2.34e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs12765878	1.000	rs2902639	chr10:105658588	G/C	cg24587175	chr10:105670608	OBFC1	0.33	5.42	0.32	1.31e-7	Coronary artery disease;
CESC	cis	rs35110281	0.811	rs4819264	chr21:45017349	G/T	cg04455712	chr21:45112962	RRP1B	0.37	5.39	0.31	1.6e-7	Mean corpuscular volume;
CESC	trans	rs4596713	0.538	rs10869961	chr9:71787071	C/T	cg16512924	chr15:28394682	HERC2	0.48	6.07	0.35	4.52e-9	Headache;
CESC	cis	rs7959452	0.649	rs4761239	chr12:69776886	T/A	cg22834771	chr12:69754056	YEATS4	-0.48	-6.35	-0.36	9.41e-10	Blood protein levels;
CESC	trans	rs12599106	0.680	rs34728702	chr16:34896584	A/G	cg11235426	chr6:292522	DUSP22	-0.72	-9.43	-0.5	2.19e-18	Menopause (age at onset);
CESC	cis	rs1729951	0.546	rs12054219	chr3:136677472	G/A	cg25687071	chr3:136751404	NA	0.39	5.1	0.3	6.33e-7	Neuroticism;
CESC	cis	rs2576037	0.583	rs9916891	chr18:44493521	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.33	5.33	0.31	2.12e-7	Personality dimensions;
CESC	cis	rs798554	0.757	rs1182179	chr7:2873648	A/G	cg18446336	chr7:2847575	GNA12	-0.37	-5.67	-0.33	3.67e-8	Height;
CESC	cis	rs514406	0.505	rs427319	chr1:53178807	T/G	cg08736216	chr1:53307985	ZYG11A	-0.39	-6.54	-0.37	3.17e-10	Monocyte count;
CESC	cis	rs7264396	0.677	rs6060553	chr20:34267386	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.87	-10.5	-0.54	8.8e-22	Total cholesterol levels;
CESC	cis	rs763121	0.719	rs138699	chr22:39129708	G/A	cg21395723	chr22:39101663	GTPBP1	0.46	5.68	0.33	3.52e-8	Menopause (age at onset);
CESC	cis	rs62005083	1.000	rs62005075	chr14:74476024	A/T	cg05179529	chr14:74551516	LIN52;ALDH6A1	0.69	5.12	0.3	6.01e-7	Mean corpuscular volume;
CESC	cis	rs116095464	1.000	rs6555160	chr5:311669	A/G	cg02160872	chr5:212506	CCDC127	0.6	5.03	0.3	9.19e-7	Breast cancer;
CESC	cis	rs4665809	0.652	rs6728090	chr2:26524726	C/T	cg08470875	chr2:26401718	FAM59B	-0.5	-5.05	-0.3	8.17e-7	Gut microbiome composition (summer);
CESC	cis	rs77741769	0.571	rs12831094	chr12:121292704	T/C	cg02419362	chr12:121203948	SPPL3	0.34	5.59	0.32	5.6e-8	Mean corpuscular volume;
CESC	cis	rs35110281	0.517	rs11089020	chr21:44939991	C/T	cg01579765	chr21:45077557	HSF2BP	-0.51	-8.67	-0.47	4.41e-16	Mean corpuscular volume;
CESC	cis	rs1538970	0.924	rs4660855	chr1:45899795	A/G	cg24296786	chr1:45957014	TESK2	-0.46	-5.3	-0.31	2.41e-7	Platelet count;
CESC	cis	rs597539	0.616	rs631001	chr11:68642974	C/T	cg18350739	chr11:68623251	NA	-0.48	-6.99	-0.39	2.22e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs1707322	1.000	rs4660905	chr1:46461587	C/T	cg03146154	chr1:46216737	IPP	-0.72	-9.82	-0.52	1.31e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs4253772	0.513	rs6008597	chr22:46703904	A/C	cg00784671	chr22:46762841	CELSR1	-0.48	-5.59	-0.32	5.72e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs6570726	0.537	rs1280279	chr6:145884048	G/T	cg23711669	chr6:146136114	FBXO30	0.88	9.58	0.51	7.35e-19	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs870825	0.616	rs4594761	chr4:185643002	A/C	cg04058563	chr4:185651563	MLF1IP	0.64	7.1	0.4	1.15e-11	Blood protein levels;
CESC	cis	rs1005277	0.522	rs7090858	chr10:38003670	A/C	cg25517755	chr10:38738941	LOC399744	0.39	5.05	0.3	8.29e-7	Extrinsic epigenetic age acceleration;
CESC	cis	rs6088580	0.634	rs6088484	chr20:32985961	T/C	cg06115741	chr20:33292138	TP53INP2	-0.47	-6.03	-0.35	5.36e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs17253792	0.545	rs12893061	chr14:56016097	A/T	cg01858014	chr14:56050164	KTN1	-0.87	-6.37	-0.36	8.34e-10	Putamen volume;
CESC	cis	rs3796352	1.000	rs58660500	chr3:53086573	C/T	cg07884673	chr3:53033167	SFMBT1	0.67	5.75	0.33	2.44e-8	Immune reponse to smallpox (secreted IL-2);
CESC	cis	rs7586879	0.616	rs916485	chr2:25082273	T/C	cg01884057	chr2:25150051	NA	0.37	7.24	0.41	4.89e-12	Body mass index;
CESC	cis	rs763014	0.966	rs4247097	chr16:654224	G/A	cg09263875	chr16:632152	PIGQ	0.69	11.97	0.59	1.09e-26	Height;
CESC	cis	rs2797160	1.000	rs9401843	chr6:126004124	T/C	cg05901451	chr6:126070800	HEY2	-0.46	-6.62	-0.38	1.94e-10	Endometrial cancer;
CESC	trans	rs801193	1.000	rs10234018	chr7:66146284	A/T	cg26939375	chr7:64535504	NA	-0.66	-8.99	-0.48	4.77e-17	Aortic root size;
CESC	cis	rs7833790	0.632	rs6473308	chr8:82707708	G/A	cg17211192	chr8:82754475	SNX16	-0.58	-7.42	-0.41	1.62e-12	Diastolic blood pressure;
CESC	cis	rs1568889	0.877	rs12786351	chr11:28271122	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.69	7.02	0.4	1.82e-11	Bipolar disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12070509	chr1:222638775	NA	0.57	6.06	0.35	4.74e-9	Gut microbiome composition (summer);
CESC	trans	rs9858542	1.000	rs13085791	chr3:49721798	C/A	cg21659725	chr3:3221576	CRBN	-0.54	-6.71	-0.38	1.21e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	trans	rs6572548	0.504	rs1956082	chr14:49665496	A/C	cg18715318	chr22:19420067	HIRA;MRPL40	-0.48	-6.04	-0.35	5.14e-9	Subjective well-being;
CESC	cis	rs514406	0.679	rs541852	chr1:53256834	A/G	cg16325326	chr1:53192061	ZYG11B	-0.53	-7.87	-0.44	8.92e-14	Monocyte count;
CESC	cis	rs6504950	0.566	rs12937360	chr17:53046298	C/T	cg19360675	chr17:53046073	COX11;STXBP4	0.43	5.49	0.32	9.53e-8	Breast cancer;
CESC	cis	rs2228479	0.867	rs62052185	chr16:89969254	C/T	cg04013166	chr16:89971882	TCF25	0.79	7.12	0.4	1.02e-11	Skin colour saturation;
CESC	cis	rs7520050	0.966	rs11579634	chr1:46466391	A/G	cg24296786	chr1:45957014	TESK2	-0.42	-5.16	-0.3	4.96e-7	Red blood cell count;Reticulocyte count;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg23191292	chr6:157099924	ARID1B	-0.47	-6.04	-0.35	5.23e-9	Height;
CESC	cis	rs2479106	0.549	rs1975063	chr9:126397433	C/T	cg16191174	chr9:126692580	DENND1A	0.38	5.2	0.3	3.99e-7	Polycystic ovary syndrome;
CESC	cis	rs2816062	0.965	rs2816061	chr1:18903819	A/G	cg18795169	chr1:18902165	NA	0.87	15.78	0.7	5.09e-40	Urate levels in lean individuals;
CESC	cis	rs116095464	0.867	rs7726582	chr5:215349	C/G	cg22496380	chr5:211416	CCDC127	-0.7	-8.09	-0.45	2.11e-14	Breast cancer;
CESC	cis	rs3820928	0.874	rs10169717	chr2:227796911	T/G	cg05526886	chr2:227700861	RHBDD1	-0.4	-5.1	-0.3	6.49e-7	Pulmonary function;
CESC	cis	rs6089584	0.854	rs8117075	chr20:60613766	T/C	cg24733560	chr20:60626293	TAF4	0.45	6.34	0.36	9.97e-10	Body mass index;
CESC	cis	rs12188164	1.000	rs56042615	chr5:437667	G/A	cg15813090	chr5:442598	EXOC3;C5orf55	0.41	6.22	0.36	1.89e-9	Cystic fibrosis severity;
CESC	cis	rs5750830	0.645	rs756640	chr22:39779300	G/A	cg24399712	chr22:39784796	NA	-0.73	-10.61	-0.55	3.81e-22	Intelligence (multi-trait analysis);
CESC	cis	rs801193	0.548	rs7805152	chr7:66209253	C/T	cg10691866	chr7:65817282	TPST1	-0.32	-5.45	-0.32	1.15e-7	Aortic root size;
CESC	cis	rs2645694	0.626	rs2703136	chr4:77828957	T/A	cg18351406	chr4:77819688	ANKRD56	0.52	6.32	0.36	1.1e-9	Emphysema distribution in smoking;
CESC	cis	rs9831754	0.906	rs2314196	chr3:78411050	C/T	cg06138941	chr3:78371609	NA	-0.52	-6.89	-0.39	4.14e-11	Calcium levels;
CESC	cis	rs17376456	0.877	rs10044066	chr5:93437580	T/C	cg21475434	chr5:93447410	FAM172A	0.82	7.54	0.42	7.63e-13	Diabetic retinopathy;
CESC	cis	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg09720205	chr16:57508738	DOK4	0.36	5.19	0.3	4.1e-7	Gambling;
CESC	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-6.05	-0.35	4.89e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs55728055	0.661	rs9619217	chr22:32043611	A/G	cg01338084	chr22:32026380	PISD	1.22	8.56	0.47	9.19e-16	Age-related hearing impairment;
CESC	cis	rs10256972	0.967	rs7799110	chr7:1039065	A/G	cg04025307	chr7:1156635	C7orf50	0.36	5.6	0.33	5.22e-8	Longevity;Endometriosis;
CESC	cis	rs875971	0.862	rs7782704	chr7:65805366	G/A	cg18252515	chr7:66147081	NA	0.39	5.08	0.3	7.05e-7	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15419852	chr19:39897474	ZFP36	0.54	6.06	0.35	4.72e-9	Gut microbiome composition (summer);
CESC	cis	rs3741404	0.620	rs2236647	chr11:63964605	A/G	cg18225595	chr11:63971243	STIP1	-0.52	-7.36	-0.41	2.29e-12	Platelet count;
CESC	cis	rs9309711	0.666	rs6767	chr2:3483205	C/T	cg15506890	chr2:3487001	NA	-0.48	-6.12	-0.35	3.33e-9	Neurofibrillary tangles;
CESC	cis	rs3736485	0.934	rs28648597	chr15:51856066	T/A	cg08986416	chr15:51914746	DMXL2	-0.4	-5.12	-0.3	5.86e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs853679	0.517	rs9468297	chr6:28118874	G/T	cg08968635	chr6:28129556	ZNF389	0.41	5.28	0.31	2.68e-7	Depression;
CESC	cis	rs4237845	0.537	rs59401446	chr12:58259564	G/A	cg00677455	chr12:58241039	CTDSP2	0.79	10.7	0.55	1.88e-22	Intelligence (multi-trait analysis);
CESC	cis	rs7959452	0.640	rs4274230	chr12:69700772	T/G	cg14784868	chr12:69753453	YEATS4	0.73	10.44	0.54	1.38e-21	Blood protein levels;
CESC	cis	rs769267	0.930	rs7256149	chr19:19566255	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	7.45	0.42	1.34e-12	Tonsillectomy;
CESC	cis	rs3747547	0.892	rs67076718	chr9:38035758	C/T	cg13774184	chr9:37916125	SHB	-0.7	-5.83	-0.34	1.6e-8	Metabolite levels (Dihydroxy docosatrienoic acid);
CESC	cis	rs1552244	0.554	rs17050704	chr3:10045734	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.61	7.88	0.44	8.63e-14	Alzheimer's disease;
CESC	cis	rs9287719	0.967	rs7608498	chr2:10738428	G/A	cg00105475	chr2:10696890	NA	0.39	5.61	0.33	4.96e-8	Prostate cancer;
CESC	cis	rs12477438	1.000	rs12477438	chr2:99841085	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.69	-8.21	-0.45	9.96e-15	Chronic sinus infection;
CESC	cis	rs858239	0.600	rs7790157	chr7:23126998	G/A	cg23682824	chr7:23144976	KLHL7	0.55	7.67	0.43	3.39e-13	Cerebrospinal fluid biomarker levels;
CESC	cis	rs2933343	0.729	rs789230	chr3:128602558	G/A	cg25356066	chr3:128598488	ACAD9	0.66	9.18	0.49	1.27e-17	IgG glycosylation;
CESC	cis	rs763512	0.532	rs3110626	chr17:35896402	A/G	cg16670864	chr17:35848621	DUSP14	-0.44	-5.46	-0.32	1.11e-7	3-hydroxypropylmercapturic acid levels in smokers;
CESC	cis	rs2204008	0.660	rs2874343	chr12:38239096	C/T	cg13010199	chr12:38710504	ALG10B	0.52	6.43	0.37	5.91e-10	Bladder cancer;
CESC	cis	rs8177253	0.665	rs6774822	chr3:133442012	G/T	cg18769074	chr3:133464867	TF	0.29	5.38	0.31	1.63e-7	Iron status biomarkers;
CESC	cis	rs4589502	1.000	rs80263963	chr15:67127228	C/T	cg12317470	chr15:67143691	NA	0.69	5.31	0.31	2.38e-7	Lung cancer (smoking interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09835421	chr16:68378352	PRMT7	-0.56	-6.25	-0.36	1.65e-9	Gut microbiome composition (summer);
CESC	cis	rs72945132	0.562	rs7951959	chr11:70234272	A/G	cg00319359	chr11:70116639	PPFIA1	0.71	6.87	0.39	4.45e-11	Coronary artery disease;
CESC	cis	rs914615	0.508	rs4971079	chr1:155130391	C/T	cg02153340	chr1:155202674	NA	-0.37	-5.44	-0.32	1.19e-7	Urinary albumin-to-creatinine ratio;
CESC	cis	rs4665809	0.590	rs4665840	chr2:26444962	C/T	cg22920501	chr2:26401640	FAM59B	-0.91	-10.33	-0.54	3.07e-21	Gut microbiome composition (summer);
CESC	cis	rs826838	0.967	rs826858	chr12:39116731	A/G	cg26384229	chr12:38710491	ALG10B	-0.67	-11.02	-0.56	1.72e-23	Heart rate;
CESC	cis	rs911555	0.617	rs7156036	chr14:103908142	A/G	cg24130564	chr14:104152367	KLC1	0.5	6.5	0.37	4.05e-10	Intelligence (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27158084	chr6:149813350	NA	-0.58	-6.99	-0.39	2.2e-11	Gut microbiome composition (summer);
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg03672602	chr19:19754555	GMIP	0.45	6.0	0.35	6.56e-9	Systemic lupus erythematosus;
CESC	trans	rs60380162	0.963	rs4278349	chr1:87725833	C/T	cg20163645	chr8:1900353	ARHGEF10	-0.43	-6.03	-0.35	5.48e-9	Loneliness (linear analysis);
CESC	cis	rs17608059	0.901	rs11078215	chr17:13906934	T/C	cg11395062	chr17:14139857	CDRT15	0.5	5.9	0.34	1.1e-8	Temperament;
CESC	cis	rs7829975	0.514	rs2945873	chr8:8260445	C/T	cg08975724	chr8:8085496	FLJ10661	0.41	5.21	0.3	3.82e-7	Mood instability;
CESC	cis	rs2573652	0.722	rs11852383	chr15:100542765	C/T	cg09918751	chr15:100517450	ADAMTS17	-0.34	-6.33	-0.36	1.05e-9	Height;
CESC	cis	rs400736	0.930	rs225119	chr1:8044361	T/C	cg25007680	chr1:8021821	PARK7	0.72	10.22	0.53	7.16e-21	Response to antidepressants and depression;
CESC	cis	rs62064224	0.791	rs2344977	chr17:30720573	C/G	cg18200150	chr17:30822561	MYO1D	0.65	9.74	0.51	2.3e-19	Schizophrenia;
CESC	cis	rs10097731	0.901	rs7823749	chr8:82047828	C/A	cg25230327	chr8:82042993	NA	-0.5	-5.33	-0.31	2.14e-7	Serum total protein level;
CESC	cis	rs780096	0.526	rs2911713	chr2:27640980	G/A	cg12648201	chr2:27665141	KRTCAP3	-0.34	-6.3	-0.36	1.2e-9	Total body bone mineral density;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg19969431	chr14:74321094	PTGR2	0.41	6.21	0.36	2.03e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	trans	rs3741404	0.791	rs7112960	chr11:63907079	A/G	cg15268290	chr11:83690587	DLG2	0.43	6.04	0.35	5.23e-9	Platelet count;
CESC	cis	rs2204008	0.515	rs11495471	chr12:38027178	G/A	cg13010199	chr12:38710504	ALG10B	0.54	6.63	0.38	1.87e-10	Bladder cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04791456	chr3:57505743	DNAH12	-0.62	-6.77	-0.38	8.04e-11	Gut microbiome composition (summer);
CESC	cis	rs1348850	0.574	rs13431105	chr2:178434674	A/G	cg23306229	chr2:178417860	TTC30B	0.8	6.97	0.39	2.55e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs684232	0.835	rs12450003	chr17:519015	T/C	cg15660573	chr17:549704	VPS53	-0.43	-5.7	-0.33	3.2e-8	Prostate cancer;
CESC	cis	rs12497850	0.931	rs7430198	chr3:48988760	T/C	cg06212747	chr3:49208901	KLHDC8B	0.71	9.31	0.5	4.93e-18	Parkinson's disease;
CESC	cis	rs6142102	0.580	rs9753679	chr20:32540860	G/A	cg08999081	chr20:33150536	PIGU	0.34	5.17	0.3	4.61e-7	Skin pigmentation;
CESC	cis	rs727505	1.000	rs66513837	chr7:124492763	A/G	cg23710748	chr7:124431027	NA	-0.48	-7.61	-0.42	4.76e-13	Lewy body disease;
CESC	cis	rs4660306	0.961	rs937290	chr1:45961955	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.61	-7.69	-0.43	2.86e-13	Homocysteine levels;
CESC	cis	rs5758659	0.935	rs134879	chr22:42664201	A/C	cg04733989	chr22:42467013	NAGA	0.42	5.88	0.34	1.23e-8	Cognitive function;
CESC	cis	rs1904096	0.506	rs28701470	chr4:95167088	A/C	cg11021082	chr4:95130006	SMARCAD1	-0.63	-10.06	-0.53	2.19e-20	Type 2 diabetes;
CESC	cis	rs7267979	1.000	rs6107033	chr20:25363591	A/G	cg08601574	chr20:25228251	PYGB	-0.36	-5.2	-0.3	4.01e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs11031096	0.678	rs970329	chr11:4189803	G/T	cg18678763	chr11:4115507	RRM1	-0.4	-5.18	-0.3	4.46e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	cis	rs6032067	0.777	rs2868235	chr20:43794069	T/C	cg10761708	chr20:43804764	PI3	0.56	6.55	0.37	3.01e-10	Blood protein levels;
CESC	cis	rs6540559	0.673	rs6698154	chr1:210007777	A/G	cg21951975	chr1:209979733	IRF6	0.58	7.04	0.4	1.61e-11	Cleft lip with or without cleft palate;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg09423610	chr7:902986	UNC84A	0.46	6.46	0.37	5.07e-10	Fibrinogen levels;
CESC	cis	rs963731	0.579	rs997344	chr2:39281730	G/C	cg04010122	chr2:39346883	SOS1	-0.73	-5.86	-0.34	1.34e-8	Corticobasal degeneration;
CESC	cis	rs3813567	0.759	rs12595350	chr15:78953464	G/A	cg05914723	chr15:78953907	NA	0.46	5.85	0.34	1.48e-8	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
CESC	cis	rs7208859	0.573	rs28779471	chr17:29084369	T/C	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.17e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs3815700	1.000	rs7248273	chr19:33096816	C/T	cg02997394	chr19:33096574	ANKRD27	0.69	6.86	0.39	4.97e-11	Eosinophilic esophagitis;
CESC	cis	rs875971	0.964	rs60193905	chr7:65971260	A/G	cg11764359	chr7:65958608	NA	0.94	14.74	0.67	2.64e-36	Aortic root size;
CESC	cis	rs1552244	0.882	rs13088350	chr3:10044626	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.73	-9.27	-0.5	6.52e-18	Alzheimer's disease;
CESC	cis	rs10447248	0.776	rs7447161	chr5:107899940	T/C	cg25075504	chr5:107899390	NA	-0.38	-5.54	-0.32	7.29e-8	Adiponectin levels;
CESC	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	7.64	0.43	3.85e-13	Prudent dietary pattern;
CESC	cis	rs881375	0.967	rs7039505	chr9:123705945	A/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.39	5.25	0.31	3.13e-7	Rheumatoid arthritis;
CESC	cis	rs7666738	0.927	rs4699328	chr4:99055890	C/T	cg18180107	chr4:99064573	C4orf37	0.4	5.13	0.3	5.54e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2688608	0.592	rs12253429	chr10:75496161	C/G	cg23231163	chr10:75533350	FUT11	-0.35	-5.28	-0.31	2.68e-7	Inflammatory bowel disease;
CESC	cis	rs4555082	0.834	rs2816624	chr14:105733909	A/G	cg06808227	chr14:105710500	BRF1	-0.6	-6.87	-0.39	4.44e-11	Mean platelet volume;Platelet distribution width;
CESC	cis	rs1005277	0.579	rs1780133	chr10:38499509	T/C	cg25517755	chr10:38738941	LOC399744	-0.44	-5.71	-0.33	3.07e-8	Extrinsic epigenetic age acceleration;
CESC	cis	rs873946	0.586	rs3793686	chr10:134569559	A/G	cg27286337	chr10:134555280	INPP5A	0.61	6.95	0.39	2.81e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs11098499	0.754	rs12711071	chr4:120240934	A/G	cg09307838	chr4:120376055	NA	0.8	10.76	0.55	1.18e-22	Corneal astigmatism;
CESC	cis	rs2439831	0.850	rs12101756	chr15:44053887	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.7	8.06	0.44	2.71e-14	Lung cancer in ever smokers;
CESC	cis	rs116095464	0.558	rs6878087	chr5:223117	C/T	cg10591111	chr5:226296	SDHA	0.46	5.84	0.34	1.55e-8	Breast cancer;
CESC	cis	rs1218582	0.772	rs6686873	chr1:154913404	C/G	cg09359103	chr1:154839909	KCNN3	-0.66	-12.33	-0.6	6.72e-28	Prostate cancer;
CESC	cis	rs2243480	0.901	rs778732	chr7:65822360	C/T	cg18252515	chr7:66147081	NA	-1.37	-13.3	-0.63	2.87e-31	Diabetic kidney disease;
CESC	trans	rs5769765	0.773	rs9616208	chr22:50313359	G/A	cg09872104	chr7:134855509	C7orf49	-0.55	-6.2	-0.36	2.14e-9	Schizophrenia;
CESC	cis	rs2836974	0.899	rs6517514	chr21:40527095	G/T	cg11644478	chr21:40555479	PSMG1	1.04	17.85	0.74	2.41e-47	Cognitive function;
CESC	cis	rs2731664	0.792	rs2545795	chr5:176887106	A/C	cg23176889	chr5:176863531	GRK6	-0.64	-11.3	-0.57	2.02e-24	Intelligence (multi-trait analysis);
CESC	cis	rs698833	0.828	rs6745281	chr2:44534472	A/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	6.26	0.36	1.56e-9	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg13787782	chr2:239161568	PER2	0.47	6.3	0.36	1.22e-9	Fibrinogen levels;
CESC	cis	rs9914988	0.943	rs9915673	chr17:27132893	G/C	cg20469991	chr17:27169893	C17orf63	-0.48	-5.25	-0.31	3.18e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CESC	cis	rs4423214	0.840	rs1619577	chr11:71181485	C/T	cg05163923	chr11:71159392	DHCR7	-0.65	-7.77	-0.43	1.71e-13	Vitamin D levels;
CESC	cis	rs1707322	0.928	rs6681068	chr1:46398382	G/A	cg05343316	chr1:45956843	TESK2	0.44	5.42	0.32	1.36e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs939574	0.722	rs72955435	chr2:220087354	A/C	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.89	7.23	0.41	5.27e-12	Platelet distribution width;
CESC	cis	rs1707322	0.964	rs12067716	chr1:46434428	T/A	cg05343316	chr1:45956843	TESK2	0.5	6.11	0.35	3.48e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7666738	0.830	rs1527517	chr4:98931907	C/T	cg17366294	chr4:99064904	C4orf37	0.6	8.22	0.45	9.04e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs853679	0.517	rs9393898	chr6:28130376	G/T	cg08968635	chr6:28129556	ZNF389	0.41	5.37	0.31	1.76e-7	Depression;
CESC	cis	rs10504229	0.639	rs67996345	chr8:58117127	A/G	cg24829409	chr8:58192753	C8orf71	-0.58	-7.2	-0.4	6.31e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs7607369	0.574	rs12990478	chr2:219667463	T/A	cg02176678	chr2:219576539	TTLL4	-0.35	-6.12	-0.35	3.33e-9	Red blood cell count;Amyotrophic lateral sclerosis;
CESC	cis	rs1355223	0.583	rs2941058	chr11:34880245	C/G	cg24088639	chr11:34937564	PDHX;APIP	-0.4	-5.06	-0.3	7.8e-7	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs1799949	0.894	rs36062488	chr17:41337472	C/T	cg23758822	chr17:41437982	NA	-1.02	-17.3	-0.73	2.13e-45	Menopause (age at onset);
CESC	cis	rs7789940	0.904	rs7459185	chr7:75934640	C/G	cg10167463	chr7:75959203	YWHAG	0.42	5.1	0.3	6.42e-7	Multiple sclerosis;
CESC	cis	rs7202877	0.706	rs42472	chr16:75473320	T/A	cg04384234	chr16:75411784	CFDP1	0.5	5.97	0.34	7.54e-9	Type 2 diabetes;Type 1 diabetes;
CESC	cis	rs3733585	0.673	rs6449156	chr4:9956712	G/C	cg02734326	chr4:10020555	SLC2A9	-0.42	-5.94	-0.34	8.96e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs9488822	0.676	rs1999929	chr6:116381994	T/C	cg15226275	chr6:116381976	FRK	0.26	6.52	0.37	3.55e-10	Cholesterol, total;LDL cholesterol;
CESC	cis	rs4692589	0.965	rs7657455	chr4:170958843	C/G	cg19918862	chr4:170955249	NA	0.36	5.9	0.34	1.13e-8	Anxiety disorder;
CESC	cis	rs4563143	0.675	rs56322221	chr19:29270349	A/T	cg14983838	chr19:29218262	NA	0.5	6.16	0.35	2.67e-9	Methadone dose in opioid dependence;
CESC	cis	rs1552244	0.882	rs13063098	chr3:10009919	G/A	cg00149659	chr3:10157352	C3orf10	0.66	7.6	0.42	4.98e-13	Alzheimer's disease;
CESC	trans	rs9325144	0.647	rs11169258	chr12:39113040	C/T	cg23762105	chr12:34175262	ALG10	0.47	6.19	0.36	2.32e-9	Morning vs. evening chronotype;
CESC	cis	rs3540	0.597	rs11639150	chr15:91042071	C/G	cg10434728	chr15:90938212	IQGAP1	-0.42	-7.62	-0.42	4.44e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs1008375	0.966	rs4235391	chr4:17696409	A/G	cg15017067	chr4:17643749	FAM184B	0.37	5.21	0.3	3.74e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs9400271	0.632	rs9374070	chr6:109586455	G/A	cg01475377	chr6:109611718	NA	-0.46	-7.12	-0.4	9.98e-12	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
CESC	cis	rs3733585	0.673	rs4407505	chr4:9953367	T/G	cg11266682	chr4:10021025	SLC2A9	-0.58	-11.0	-0.56	2.04e-23	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs13256369	1.000	rs7843488	chr8:8576217	C/T	cg17143192	chr8:8559678	CLDN23	0.74	8.68	0.47	4.19e-16	Obesity-related traits;
CESC	cis	rs7618915	0.571	rs67539070	chr3:52711974	T/C	cg18404041	chr3:52824283	ITIH1	-0.39	-6.53	-0.37	3.33e-10	Bipolar disorder;
CESC	cis	rs9311474	0.713	rs352169	chr3:52236762	C/T	cg05564831	chr3:52568323	NT5DC2	0.4	6.18	0.36	2.36e-9	Electroencephalogram traits;
CESC	cis	rs2790457	0.958	rs1265829	chr10:28911303	T/C	cg04045419	chr10:28823091	WAC	-0.42	-5.05	-0.3	8.2e-7	Multiple myeloma;
CESC	cis	rs2050392	0.624	rs303444	chr10:30729347	C/T	cg18806716	chr10:30721971	MAP3K8	-0.63	-9.46	-0.5	1.79e-18	Inflammatory bowel disease;
CESC	cis	rs7208859	0.573	rs7214313	chr17:29138596	T/C	cg19761014	chr17:28927070	LRRC37B2	0.73	6.16	0.35	2.71e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs2075371	0.829	rs727202	chr7:133947942	A/G	cg20476274	chr7:133979776	SLC35B4	0.62	8.89	0.48	9.92e-17	Mean platelet volume;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg23879496	chr6:43749477	VEGFA	-0.46	-6.35	-0.36	9.55e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs9457247	0.967	rs388406	chr6:167409562	A/G	cg07741184	chr6:167504864	NA	0.31	5.53	0.32	7.72e-8	Crohn's disease;
CESC	cis	rs873946	0.564	rs2803991	chr10:134557068	A/G	cg18305652	chr10:134549665	INPP5A	0.49	7.6	0.42	5.24e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs12142240	0.698	rs66575205	chr1:46814092	T/G	cg00530320	chr1:46809349	NSUN4	0.58	7.89	0.44	8.17e-14	Menopause (age at onset);
CESC	cis	rs1552244	0.882	rs68153882	chr3:10013110	T/C	cg00166722	chr3:10149974	C3orf24	0.46	5.67	0.33	3.8e-8	Alzheimer's disease;
CESC	cis	rs9486719	1.000	rs2499804	chr6:96861216	A/G	cg06623918	chr6:96969491	KIAA0776	0.78	8.15	0.45	1.44e-14	Migraine;Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02071454	chr1:213446482	RPS6KC1	-0.7	-8.02	-0.44	3.37e-14	Gut microbiome composition (summer);
CESC	cis	rs6582630	0.555	rs34145279	chr12:38405588	T/C	cg26384229	chr12:38710491	ALG10B	0.73	10.79	0.55	9.99e-23	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs875971	0.862	rs1968126	chr7:66057004	A/G	cg18252515	chr7:66147081	NA	0.46	6.0	0.35	6.54e-9	Aortic root size;
CESC	cis	rs7107174	0.681	rs10793301	chr11:78020913	G/T	cg02023728	chr11:77925099	USP35	0.48	6.27	0.36	1.46e-9	Testicular germ cell tumor;
CESC	cis	rs360798	0.532	rs2136737	chr2:62969310	G/C	cg17519650	chr2:63277830	OTX1	-0.54	-6.87	-0.39	4.53e-11	Coronary artery disease;
CESC	cis	rs9399135	0.967	rs9376075	chr6:135296963	A/G	cg24558204	chr6:135376177	HBS1L	0.5	6.75	0.38	9.09e-11	Red blood cell count;
CESC	cis	rs7223966	1.000	rs11871767	chr17:61698723	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.56	0.37	2.82e-10	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs1552244	1.000	rs112847840	chr3:10101652	C/T	cg08888203	chr3:10149979	C3orf24	0.53	6.72	0.38	1.11e-10	Alzheimer's disease;
CESC	cis	rs3008870	0.959	rs2815353	chr1:67483372	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.01	13.78	0.65	5.96e-33	Lymphocyte percentage of white cells;
CESC	trans	rs1728785	0.818	rs1645984	chr16:68628850	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.7	7.98	0.44	4.59e-14	Ulcerative colitis;
CESC	cis	rs10851478	0.872	rs2899434	chr15:49766968	G/A	cg08060515	chr15:49448048	GALK2;COPS2	0.42	5.16	0.3	4.79e-7	Oral cavity cancer;
CESC	cis	rs7904985	0.889	rs1078789	chr10:88110247	C/T	cg07322936	chr10:88137208	NA	-0.4	-5.32	-0.31	2.24e-7	Barrett's esophagus;
CESC	cis	rs1044826	0.692	rs295484	chr3:139231782	A/G	cg00490450	chr3:139108681	COPB2	-0.41	-5.19	-0.3	4.19e-7	Obesity-related traits;
CESC	cis	rs548181	0.668	rs540555	chr11:125486848	T/C	cg03464685	chr11:125439445	EI24	0.91	8.01	0.44	3.76e-14	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs6964587	1.000	rs17164263	chr7:91581566	T/A	cg17063962	chr7:91808500	NA	-0.57	-7.68	-0.43	3.06e-13	Breast cancer;
CESC	cis	rs4472734	1.000	rs11120328	chr1:214628200	G/A	cg00063699	chr1:214624242	PTPN14	-0.33	-5.08	-0.3	7.25e-7	Height;
CESC	cis	rs10979	0.965	rs9496679	chr6:143896741	G/T	cg25407410	chr6:143891975	LOC285740	-0.61	-9.2	-0.49	1.13e-17	Hypospadias;
CESC	cis	rs1348850	0.567	rs3770005	chr2:178528874	A/G	cg22681709	chr2:178499509	PDE11A	-0.5	-8.05	-0.44	2.76e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs2303745	0.589	rs1864116	chr19:17393015	C/T	cg04248312	chr19:17393744	ANKLE1	-0.93	-15.23	-0.68	4.67e-38	Systemic lupus erythematosus;
CESC	cis	rs7666738	0.830	rs13118892	chr4:98968497	T/C	cg05340658	chr4:99064831	C4orf37	0.79	12.28	0.6	9.45e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9549367	0.789	rs12866090	chr13:113869410	G/A	cg18105134	chr13:113819100	PROZ	-0.73	-9.5	-0.5	1.33e-18	Platelet distribution width;
CESC	cis	rs12618769	0.597	rs1961651	chr2:99049674	G/C	cg10123293	chr2:99228465	UNC50	0.41	5.42	0.32	1.31e-7	Bipolar disorder;
CESC	trans	rs2207136	0.868	rs12209596	chr6:50841472	C/T	cg06522515	chr3:184090630	THPO	-0.39	-6.8	-0.39	6.84e-11	Myopia;
CESC	cis	rs909674	0.818	rs8136980	chr22:39844574	G/A	cg02038168	chr22:39784481	NA	-0.66	-8.25	-0.45	7.36e-15	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs7224314	0.895	rs11654663	chr17:65389305	A/C	cg01507342	chr17:65387096	PITPNC1	-0.47	-5.78	-0.33	2.04e-8	Diisocyanate-induced asthma;
CESC	cis	rs10276381	0.786	rs73300665	chr7:28227024	G/A	cg23620719	chr7:28220237	JAZF1	0.83	8.97	0.48	5.68e-17	Crohn's disease;
CESC	trans	rs1814175	0.817	rs28525029	chr11:50045815	A/G	cg15704280	chr7:45808275	SEPT13	-1.05	-21.42	-0.8	9.36e-60	Height;
CESC	cis	rs7192380	0.639	rs7186296	chr16:69808998	A/G	cg15192750	chr16:69999425	NA	-0.37	-5.03	-0.3	8.91e-7	Sjögren's syndrome;
CESC	cis	rs798554	0.679	rs1636253	chr7:2885123	A/G	cg13628971	chr7:2884303	GNA12	0.64	8.78	0.47	2.11e-16	Height;
CESC	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg18402987	chr7:1209562	NA	0.76	7.57	0.42	6.04e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2625529	0.557	rs7496582	chr15:72147831	T/G	cg16672083	chr15:72433130	SENP8	-0.38	-5.66	-0.33	3.97e-8	Red blood cell count;
CESC	cis	rs2576037	0.526	rs2010834	chr18:44560875	C/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.69	-10.89	-0.56	4.48e-23	Personality dimensions;
CESC	cis	rs17376456	0.877	rs10061080	chr5:93420559	A/G	cg25358565	chr5:93447407	FAM172A	1.16	11.74	0.58	6.68e-26	Diabetic retinopathy;
CESC	cis	rs9611565	0.659	rs9607812	chr22:41941243	G/A	cg17376030	chr22:41985996	PMM1	0.68	7.43	0.42	1.46e-12	Vitiligo;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10546176	chr5:34929404	DNAJC21	0.61	6.62	0.38	2.02e-10	Gut microbiome composition (summer);
CESC	cis	rs17401966	0.838	rs946501	chr1:10309580	C/G	cg15208524	chr1:10270712	KIF1B	0.4	5.18	0.3	4.45e-7	Hepatocellular carcinoma;
CESC	cis	rs7666738	0.830	rs13101766	chr4:98957696	C/A	cg17366294	chr4:99064904	C4orf37	0.6	8.47	0.46	1.72e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6580649	0.941	rs7963934	chr12:48477086	C/G	cg24011408	chr12:48396354	COL2A1	-0.4	-5.04	-0.3	8.67e-7	Lung cancer;
CESC	cis	rs11098499	0.820	rs6534140	chr4:120455311	C/T	cg09307838	chr4:120376055	NA	0.91	12.54	0.61	1.24e-28	Corneal astigmatism;
CESC	cis	rs854765	0.583	rs4925129	chr17:17807186	A/G	cg09796270	chr17:17721594	SREBF1	0.46	6.29	0.36	1.32e-9	Total body bone mineral density;
CESC	cis	rs8078723	0.966	rs7021	chr17:38153875	T/A	cg17467752	chr17:38218738	THRA	0.68	10.19	0.53	8.65e-21	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CESC	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg07677032	chr17:61819896	STRADA	-0.46	-6.18	-0.35	2.41e-9	Prudent dietary pattern;
CESC	cis	rs4595586	0.545	rs7136002	chr12:39369168	G/A	cg26384229	chr12:38710491	ALG10B	0.54	7.53	0.42	7.85e-13	Morning vs. evening chronotype;
CESC	cis	rs3785574	0.745	rs2854162	chr17:61975610	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	-0.79	-10.27	-0.53	4.9e-21	Height;
CESC	cis	rs3749237	0.636	rs1568662	chr3:49521263	A/G	cg03060546	chr3:49711283	APEH	0.77	11.7	0.58	8.95e-26	Resting heart rate;
CESC	cis	rs4253772	0.591	rs6008361	chr22:46652372	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	-0.69	-8.14	-0.45	1.55e-14	LDL cholesterol;Cholesterol, total;
CESC	cis	rs7364180	0.582	rs139568	chr22:42210985	C/T	cg03806693	chr22:41940476	POLR3H	0.5	6.06	0.35	4.57e-9	Alzheimer's disease biomarkers;
CESC	cis	rs853679	0.517	rs9468297	chr6:28118874	G/T	cg23281280	chr6:28129359	ZNF389	0.6	8.0	0.44	3.86e-14	Depression;
CESC	cis	rs78456975	1.000	rs11898988	chr2:1560336	G/A	cg01028140	chr2:1542097	TPO	-0.5	-5.37	-0.31	1.69e-7	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs7560272	0.682	rs2421546	chr2:73641077	A/C	cg20560298	chr2:73613845	ALMS1	0.5	7.16	0.4	7.74e-12	Schizophrenia;
CESC	cis	rs12575642	0.660	rs58632573	chr11:63896299	C/T	cg18225595	chr11:63971243	STIP1	0.51	5.13	0.3	5.58e-7	Attention deficit hyperactivity disorder;
CESC	cis	rs6681460	1.000	rs9662943	chr1:67121132	A/G	cg02459107	chr1:67143332	SGIP1	-0.37	-5.42	-0.32	1.36e-7	Presence of antiphospholipid antibodies;
CESC	cis	rs6502050	0.835	rs12938965	chr17:80128646	G/A	cg11859384	chr17:80120422	CCDC57	-0.39	-5.34	-0.31	1.97e-7	Life satisfaction;
CESC	cis	rs2075371	1.000	rs1862050	chr7:133980999	T/C	cg20476274	chr7:133979776	SLC35B4	0.66	9.64	0.51	4.63e-19	Mean platelet volume;
CESC	cis	rs12291225	0.679	rs11023170	chr11:14294909	A/G	cg19336497	chr11:14380999	RRAS2	-0.37	-5.27	-0.31	2.76e-7	Sense of smell;
CESC	cis	rs12477438	1.000	rs12466388	chr2:99916538	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.68	-7.84	-0.43	1.13e-13	Chronic sinus infection;
CESC	cis	rs9611565	0.694	rs5758324	chr22:41787950	G/T	cg06634786	chr22:41940651	POLR3H	-0.45	-5.24	-0.31	3.3e-7	Vitiligo;
CESC	cis	rs477895	0.653	rs3824854	chr11:63885305	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.92	9.75	0.51	2.16e-19	Mean platelet volume;
CESC	cis	rs11638352	1.000	rs4924727	chr15:44280609	T/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.51	-5.16	-0.3	4.84e-7	Lipoprotein phospholipase A2 activity in cardiovascular disease;
CESC	cis	rs3820928	0.874	rs12614648	chr2:227785535	G/A	cg05526886	chr2:227700861	RHBDD1	-0.46	-5.89	-0.34	1.16e-8	Pulmonary function;
CESC	cis	rs73206853	0.698	rs59574270	chr12:111112098	A/C	cg12870014	chr12:110450643	ANKRD13A	0.66	5.48	0.32	9.67e-8	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs4862750	0.914	rs9998558	chr4:187874691	A/G	cg03452623	chr4:187889614	NA	-0.83	-14.22	-0.66	1.8e-34	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs3091242	0.933	rs10903129	chr1:25768937	A/G	cg02931644	chr1:25747376	RHCE	0.39	6.63	0.38	1.91e-10	Erythrocyte sedimentation rate;
CESC	cis	rs12545109	0.800	rs973548	chr8:57416402	C/T	cg09654669	chr8:57350985	NA	-0.45	-6.22	-0.36	1.88e-9	Obesity-related traits;
CESC	trans	rs7945705	0.935	rs2653593	chr11:8877317	G/A	cg10637292	chr12:52960529	KRT74	0.36	6.25	0.36	1.59e-9	Hemoglobin concentration;
CESC	cis	rs7520050	0.645	rs1768809	chr1:46502836	A/C	cg03146154	chr1:46216737	IPP	-0.54	-7.18	-0.4	7.22e-12	Red blood cell count;Reticulocyte count;
CESC	trans	rs11098499	0.618	rs6858383	chr4:120296772	T/C	cg25214090	chr10:38739885	LOC399744	0.68	9.2	0.49	1.14e-17	Corneal astigmatism;
CESC	cis	rs3768617	0.510	rs7414273	chr1:183075017	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.88	14.2	0.66	2.05e-34	Fuchs's corneal dystrophy;
CESC	cis	rs2072732	0.821	rs10909868	chr1:2962207	A/C	cg15211996	chr1:2936768	ACTRT2	0.31	5.53	0.32	7.59e-8	Plateletcrit;
CESC	trans	rs6794880	0.778	rs1125601	chr3:84438338	A/T	cg03554283	chr8:76319451	NA	-0.56	-5.99	-0.35	6.66e-9	Body mass index (joint analysis main effects and smoking interaction);BMI in non-smokers;BMI (adjusted for smoking behaviour);
CESC	cis	rs7044106	0.791	rs7043969	chr9:123493989	A/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.35	5.59	0.32	5.64e-8	Hip circumference adjusted for BMI;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg17818798	chr19:14228473	PRKACA	-0.44	-6.04	-0.35	5.29e-9	Ulcerative colitis;
CESC	cis	rs9322193	0.961	rs9767713	chr6:149909377	T/G	cg04369109	chr6:150039330	LATS1	-0.4	-5.44	-0.32	1.19e-7	Lung cancer;
CESC	cis	rs10754283	0.934	rs6428563	chr1:90111583	T/A	cg21401794	chr1:90099060	LRRC8C	0.7	9.42	0.5	2.27e-18	Amyotrophic lateral sclerosis (sporadic);
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg08167039	chr1:762232	NCRNA00115;LOC643837	-0.5	-6.59	-0.38	2.35e-10	Height;
CESC	cis	rs3213545	0.659	rs2259690	chr12:121457914	T/G	cg25281562	chr12:121454272	C12orf43	0.45	5.69	0.33	3.3e-8	Subjective well-being;Cardiovascular disease risk factors;
CESC	cis	rs1670533	1.000	rs629260	chr4:1086764	A/G	cg04106633	chr4:1044584	NA	0.4	5.08	0.3	6.98e-7	Recombination rate (females);
CESC	cis	rs4253772	0.530	rs9615958	chr22:46751122	A/G	cg18190219	chr22:46762943	CELSR1	-0.63	-6.24	-0.36	1.72e-9	LDL cholesterol;Cholesterol, total;
CESC	cis	rs7666738	0.830	rs17550630	chr4:99008332	G/T	cg17366294	chr4:99064904	C4orf37	0.6	8.61	0.47	6.47e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2737618	0.551	rs2816992	chr1:200069216	C/T	cg21825944	chr1:200113062	NR5A2	0.35	5.17	0.3	4.55e-7	Uric acid levels;
CESC	cis	rs2228479	1.000	rs62052213	chr16:89991963	C/T	cg06558623	chr16:89946397	TCF25	1.17	9.0	0.48	4.39e-17	Skin colour saturation;
CESC	cis	rs75804782	0.521	rs56340711	chr2:239440080	A/T	cg18131467	chr2:239335373	ASB1	-0.7	-5.59	-0.32	5.74e-8	Morning vs. evening chronotype;Chronotype;
CESC	cis	rs2635047	0.565	rs2668759	chr18:44693711	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.43	5.88	0.34	1.23e-8	Educational attainment;
CESC	cis	rs1062177	0.756	rs2964592	chr5:151115688	A/G	cg00977110	chr5:151150581	G3BP1	-0.52	-5.56	-0.32	6.6e-8	Preschool internalizing problems;
CESC	trans	rs3942852	0.868	rs6485808	chr11:48109151	A/G	cg15704280	chr7:45808275	SEPT13	-0.67	-7.07	-0.4	1.34e-11	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs7662987	1.000	rs28730587	chr4:100004341	C/T	cg13256891	chr4:100009986	ADH5	-0.73	-5.23	-0.31	3.39e-7	Smoking initiation;
CESC	cis	rs10779751	1.000	rs2076655	chr1:11289161	A/G	cg08854313	chr1:11322531	MTOR	-0.92	-14.52	-0.67	1.48e-35	Body mass index;
CESC	cis	rs1348850	0.526	rs6433672	chr2:178378175	G/T	cg22681709	chr2:178499509	PDE11A	-0.49	-5.24	-0.31	3.24e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs7107174	1.000	rs1893447	chr11:77973182	A/G	cg02023728	chr11:77925099	USP35	0.39	5.66	0.33	4e-8	Testicular germ cell tumor;
CESC	cis	rs1008375	1.000	rs2215450	chr4:17675394	T/G	cg02297831	chr4:17616191	MED28	0.49	6.15	0.35	2.81e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs1008375	0.932	rs7677212	chr4:17675932	A/G	cg16339924	chr4:17578868	LAP3	-0.58	-6.91	-0.39	3.62e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs9916302	0.851	rs9909064	chr17:37500434	G/T	cg15445000	chr17:37608096	MED1	-0.41	-6.8	-0.39	6.8e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs1670533	0.932	rs3796620	chr4:1095079	A/G	cg27284194	chr4:1044797	NA	-0.47	-6.01	-0.35	6.08e-9	Recombination rate (females);
CESC	cis	rs362272	0.545	rs2239725	chr4:3305739	C/T	cg08886695	chr4:3369023	RGS12	-0.39	-5.15	-0.3	5.2e-7	Serum sulfate level;
CESC	cis	rs2412459	1.000	rs8023482	chr15:40307095	A/C	cg10636054	chr15:40330586	SRP14	0.68	5.49	0.32	9.44e-8	Response to haloperidol in psychosis;
CESC	cis	rs514406	0.825	rs28817407	chr1:53226116	G/A	cg16325326	chr1:53192061	ZYG11B	-0.89	-15.32	-0.69	2.26e-38	Monocyte count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00531924	chr6:111279890	GTF3C6	0.52	6.02	0.35	5.65e-9	Gut microbiome composition (summer);
CESC	cis	rs10504229	0.683	rs6995355	chr8:58113870	C/T	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs5753618	0.509	rs5749224	chr22:31558549	C/T	cg13145458	chr22:31556086	RNF185	0.46	5.18	0.3	4.39e-7	Colorectal cancer;
CESC	cis	rs763014	1.000	rs763014	chr16:675680	T/C	cg07256732	chr16:621771	PIGQ	-0.32	-5.49	-0.32	9.36e-8	Height;
CESC	cis	rs9457247	1.000	rs2769354	chr6:167379771	G/T	cg23791538	chr6:167370224	RNASET2	0.6	8.57	0.47	8.75e-16	Crohn's disease;
CESC	cis	rs7772486	0.558	rs7753273	chr6:146066039	C/T	cg23711669	chr6:146136114	FBXO30	-0.92	-12.48	-0.61	2.03e-28	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs703842	0.585	rs10877022	chr12:58223937	A/G	cg02175503	chr12:58329896	NA	0.48	5.78	0.33	2.13e-8	Multiple sclerosis;
CESC	cis	rs7937682	0.575	rs7114617	chr11:111768173	A/T	cg09085632	chr11:111637200	PPP2R1B	0.91	11.81	0.59	3.87e-26	Primary sclerosing cholangitis;
CESC	cis	rs4835473	0.900	rs35311036	chr4:144655550	T/A	cg25736465	chr4:144833511	NA	-0.33	-5.15	-0.3	5.14e-7	Immature fraction of reticulocytes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18269826	chr15:101459483	LRRK1	0.51	6.3	0.36	1.24e-9	Gut microbiome composition (summer);
CESC	cis	rs6502050	0.835	rs7502078	chr17:80131879	C/A	cg11859384	chr17:80120422	CCDC57	-0.39	-5.3	-0.31	2.41e-7	Life satisfaction;
CESC	cis	rs4595586	0.545	rs4768526	chr12:39402898	A/G	cg13010199	chr12:38710504	ALG10B	0.45	5.63	0.33	4.61e-8	Morning vs. evening chronotype;
CESC	cis	rs9640161	0.750	rs1983440	chr7:150023941	G/C	cg10018233	chr7:150070692	REPIN1	0.42	6.67	0.38	1.48e-10	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs7267979	0.565	rs4815432	chr20:25556403	A/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.69	-10.97	-0.56	2.46e-23	Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs561341	0.739	rs9906455	chr17:30215669	G/A	cg20587970	chr11:113659929	NA	0.59	7.54	0.42	7.58e-13	Hip circumference adjusted for BMI;
CESC	cis	rs17253792	0.822	rs17253744	chr14:56161950	C/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.8	5.57	0.32	6.22e-8	Putamen volume;
CESC	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg26338869	chr17:61819248	STRADA	0.68	8.9	0.48	8.82e-17	Prudent dietary pattern;
CESC	cis	rs6499255	1.000	rs55992518	chr16:69821407	C/T	cg15192750	chr16:69999425	NA	0.46	5.64	0.33	4.46e-8	IgE levels;
CESC	cis	rs13108904	0.901	rs1316394	chr4:1315820	G/A	cg22903657	chr4:1355424	KIAA1530	-0.38	-5.26	-0.31	2.94e-7	Obesity-related traits;
CESC	cis	rs1059312	0.545	rs12303387	chr12:129276733	C/T	cg09035930	chr12:129282057	SLC15A4	-0.5	-6.38	-0.37	7.74e-10	Systemic lupus erythematosus;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25042239	chr6:43021668	CUL7	0.6	6.82	0.39	6.11e-11	Gut microbiome composition (summer);
CESC	cis	rs10504229	1.000	rs113379801	chr8:58173686	C/G	cg22535103	chr8:58192502	C8orf71	-1.03	-12.89	-0.62	7.67e-30	Developmental language disorder (linguistic errors);
CESC	cis	rs6429082	0.755	rs291372	chr1:235694106	G/C	cg26050004	chr1:235667680	B3GALNT2	0.66	8.67	0.47	4.37e-16	Adiposity;
CESC	cis	rs12545109	0.571	rs1370306	chr8:57299137	C/G	cg09654669	chr8:57350985	NA	-0.49	-5.95	-0.34	8.29e-9	Obesity-related traits;
CESC	cis	rs3617	0.573	rs4687680	chr3:52907372	G/A	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.3	5.08	0.3	7.26e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
CESC	cis	rs3806843	1.000	rs13157397	chr5:140184442	G/A	cg26395211	chr5:140044315	WDR55	-0.45	-5.71	-0.33	3.06e-8	Depressive symptoms (multi-trait analysis);
CESC	cis	rs60733400	0.818	rs10909839	chr1:2708430	G/A	cg20673091	chr1:2541236	MMEL1	0.48	7.83	0.43	1.18e-13	Multiple sclerosis;
CESC	cis	rs9311474	0.713	rs352168	chr3:52237970	C/T	cg07507251	chr3:52567010	NT5DC2	0.38	6.72	0.38	1.1e-10	Electroencephalogram traits;
CESC	cis	rs1707322	0.662	rs11211160	chr1:46146229	T/A	cg03146154	chr1:46216737	IPP	0.8	11.28	0.57	2.35e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9929218	0.911	rs4783686	chr16:68834156	C/G	cg02972257	chr16:68554789	NA	0.5	5.8	0.34	1.9e-8	Colorectal cancer;
CESC	cis	rs2625529	0.761	rs3743224	chr15:72466799	C/T	cg16672083	chr15:72433130	SENP8	-0.4	-5.13	-0.3	5.65e-7	Red blood cell count;
CESC	cis	rs11051970	0.559	rs113700251	chr12:32562271	G/A	cg24626660	chr12:32551988	NA	0.36	5.19	0.3	4.24e-7	Response to tocilizumab in rheumatoid arthritis;
CESC	trans	rs1888221	0.580	rs4460459	chr9:117817326	A/G	cg11017500	chr13:111290755	CARKD	-0.46	-6.19	-0.36	2.32e-9	Glucose homeostasis traits;
CESC	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg07677032	chr17:61819896	STRADA	0.44	5.79	0.34	2e-8	Prudent dietary pattern;
CESC	cis	rs4808199	0.895	rs8105094	chr19:19374061	C/T	cg03709012	chr19:19516395	GATAD2A	1.09	11.63	0.58	1.52e-25	Nonalcoholic fatty liver disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10605791	chr12:122242589	SETD1B;LOC338799	0.56	6.4	0.37	6.88e-10	Gut microbiome composition (summer);
CESC	cis	rs6089584	1.000	rs6089580	chr20:60558976	G/A	cg06108461	chr20:60628389	TAF4	-0.78	-11.36	-0.57	1.25e-24	Body mass index;
CESC	cis	rs9486719	1.000	rs4262195	chr6:96929475	T/C	cg18709589	chr6:96969512	KIAA0776	-0.54	-5.97	-0.34	7.42e-9	Migraine;Coronary artery disease;
CESC	cis	rs2836974	0.932	rs2836953	chr21:40617483	G/A	cg27266027	chr21:40555129	PSMG1	0.45	5.42	0.32	1.32e-7	Cognitive function;
CESC	cis	rs9894429	0.646	rs58398000	chr17:79576923	G/A	cg13777783	chr17:79615861	NA	0.36	6.15	0.35	2.83e-9	Eye color traits;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg00634145	chr1:155108588	RAG1AP1	-0.42	-6.0	-0.35	6.42e-9	Gambling;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg03257047	chr6:52860152	GSTA4	-0.49	-6.12	-0.35	3.27e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs12579753	0.871	rs10862364	chr12:82201280	C/T	cg24719984	chr12:82153464	PPFIA2	-0.33	-5.04	-0.3	8.55e-7	Resting heart rate;
CESC	cis	rs61931739	0.534	rs11053072	chr12:34202399	A/C	cg19457237	chr12:34500585	NA	-0.38	-5.33	-0.31	2.12e-7	Morning vs. evening chronotype;
CESC	cis	rs7772486	0.790	rs9399571	chr6:146282061	A/G	cg23711669	chr6:146136114	FBXO30	-0.92	-13.15	-0.63	9.83e-31	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4835473	0.835	rs1450247	chr4:144629682	T/A	cg25736465	chr4:144833511	NA	0.4	6.17	0.35	2.59e-9	Immature fraction of reticulocytes;
CESC	trans	rs13098911	0.540	rs41289622	chr3:46014545	T/G	cg10236987	chr1:228114221	WNT9A	0.55	6.0	0.35	6.33e-9	Celiac disease;
CESC	cis	rs13108904	0.517	rs13134568	chr4:1334289	G/A	cg13395646	chr4:1353034	KIAA1530	-0.49	-6.32	-0.36	1.08e-9	Obesity-related traits;
CESC	cis	rs1005277	0.540	rs116205409	chr10:38478970	G/A	cg25517755	chr10:38738941	LOC399744	-0.49	-6.35	-0.36	9.08e-10	Extrinsic epigenetic age acceleration;
CESC	cis	rs863345	0.604	rs10908670	chr1:158502113	T/C	cg12129480	chr1:158549410	OR10X1	-0.34	-6.84	-0.39	5.41e-11	Pneumococcal bacteremia;
CESC	cis	rs35306767	0.715	rs11253539	chr10:1011347	G/A	cg25019033	chr10:957182	NA	-0.6	-6.19	-0.36	2.24e-9	Eosinophil percentage of granulocytes;
CESC	cis	rs1799949	0.965	rs8176087	chr17:41270666	C/A	cg25072359	chr17:41440525	NA	0.47	6.21	0.36	2.04e-9	Menopause (age at onset);
CESC	cis	rs6570726	0.755	rs451699	chr6:145830594	C/G	cg23711669	chr6:146136114	FBXO30	1.02	15.96	0.7	1.2e-40	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00042657	chr1:171753628	METTL13	-0.53	-6.23	-0.36	1.81e-9	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22368307	chr11:75110460	SNORD15A;RPS3	-0.6	-7.14	-0.4	9.22e-12	Gut microbiome composition (summer);
CESC	trans	rs561341	0.941	rs8066156	chr17:30361629	A/G	cg20587970	chr11:113659929	NA	-1.04	-13.26	-0.63	3.99e-31	Hip circumference adjusted for BMI;
CESC	cis	rs425277	0.628	rs3128340	chr1:2047496	C/G	cg19257562	chr1:2043853	PRKCZ	0.42	6.71	0.38	1.16e-10	Height;
CESC	cis	rs58688157	0.705	rs7122021	chr11:595810	A/G	cg02461776	chr11:598696	PHRF1	0.51	5.92	0.34	1.01e-8	Systemic lupus erythematosus;
CESC	cis	rs2274273	0.564	rs3783649	chr14:55834410	G/A	cg04306507	chr14:55594613	LGALS3	0.3	5.28	0.31	2.65e-7	Protein biomarker;
CESC	cis	rs7216064	0.953	rs11871285	chr17:65840809	G/T	cg12091567	chr17:66097778	LOC651250	-0.86	-8.83	-0.48	1.49e-16	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs2730245	0.593	rs842699	chr7:158663404	T/A	cg15303052	chr7:158526867	ESYT2	-0.4	-5.07	-0.3	7.39e-7	Height;
CESC	cis	rs11264213	0.786	rs72659692	chr1:36292258	A/G	cg27506609	chr1:36549197	TEKT2	0.61	5.04	0.3	8.54e-7	Schizophrenia;
CESC	cis	rs9733	0.596	rs72702580	chr1:150691285	A/T	cg04414720	chr1:150670196	GOLPH3L	0.62	8.86	0.48	1.21e-16	Tonsillectomy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06051576	chr16:2097632	TSC2;NTHL1	0.63	6.77	0.38	8.48e-11	Gut microbiome composition (summer);
CESC	cis	rs9287719	0.781	rs12472807	chr2:10781605	G/A	cg00105475	chr2:10696890	NA	0.36	5.18	0.3	4.37e-7	Prostate cancer;
CESC	cis	rs6088580	0.601	rs6120668	chr20:33099793	A/G	cg24642439	chr20:33292090	TP53INP2	0.51	6.62	0.38	1.99e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs9910055	0.659	rs186603	chr17:42207884	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	-0.73	-10.03	-0.52	2.8e-20	Total body bone mineral density;
CESC	cis	rs3820928	0.934	rs60141402	chr2:227761445	A/C	cg11843606	chr2:227700838	RHBDD1	-0.42	-5.72	-0.33	2.92e-8	Pulmonary function;
CESC	cis	rs7666738	0.830	rs13137808	chr4:99047095	T/C	cg17366294	chr4:99064904	C4orf37	0.61	8.78	0.47	2.13e-16	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07195126	chr1:160370843	VANGL2	-0.54	-6.02	-0.35	5.84e-9	Gut microbiome composition (summer);
CESC	cis	rs11958404	0.932	rs72818113	chr5:157439825	G/T	cg05962755	chr5:157440814	NA	0.62	6.66	0.38	1.57e-10	IgG glycosylation;
CESC	trans	rs4927850	1.000	rs10881563	chr3:195750225	A/G	cg16724585	chr3:197361211	NA	-0.6	-7.61	-0.42	4.83e-13	Pancreatic cancer;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg08943696	chr12:131437802	GPR133	-0.37	-6.01	-0.35	6.28e-9	Gambling;
CESC	cis	rs875971	0.660	rs801192	chr7:66031952	C/G	cg06456125	chr7:65229604	NA	-0.4	-5.27	-0.31	2.8e-7	Aortic root size;
CESC	cis	rs9300255	0.620	rs7313483	chr12:123726834	C/T	cg00376283	chr12:123451042	ABCB9	0.72	8.7	0.47	3.47e-16	Neutrophil percentage of white cells;
CESC	cis	rs10883723	0.810	rs1409311	chr10:104282160	G/A	cg22532475	chr10:104410764	TRIM8	-0.34	-5.88	-0.34	1.23e-8	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs7249698	1	rs7249698	chr19:17210615	G/A	cg19418318	chr19:17219073	MYO9B	0.34	5.58	0.32	6.05e-8	Breast cancer;
CESC	cis	rs13082711	0.911	rs34878935	chr3:27466123	A/C	cg02860705	chr3:27208620	NA	0.58	7.29	0.41	3.49e-12	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CESC	cis	rs6901004	0.570	rs783084	chr6:111477887	T/C	cg15721981	chr6:111408429	SLC16A10	0.53	7.0	0.4	2.04e-11	Blood metabolite levels;
CESC	cis	rs1538970	0.962	rs2153609	chr1:45814058	A/G	cg05343316	chr1:45956843	TESK2	0.72	10.15	0.53	1.14e-20	Platelet count;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg05839636	chr5:137878905	ETF1	-0.44	-6.2	-0.36	2.17e-9	Gambling;
CESC	cis	rs6831352	0.918	rs2602894	chr4:100045647	A/G	cg12011299	chr4:100065546	ADH4	0.59	6.68	0.38	1.41e-10	Alcohol dependence;
CESC	cis	rs1005277	0.579	rs2474587	chr10:38420666	C/T	cg25427524	chr10:38739819	LOC399744	-0.67	-9.71	-0.51	2.79e-19	Extrinsic epigenetic age acceleration;
CESC	cis	rs6570726	0.791	rs408443	chr6:145874643	T/C	cg23711669	chr6:146136114	FBXO30	1.03	15.86	0.7	2.71e-40	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs35955747	0.869	rs5997971	chr22:31792292	C/T	cg25791279	chr22:32026902	PISD	-0.45	-5.48	-0.32	9.94e-8	Neutrophil count;Sum basophil neutrophil counts;
CESC	cis	rs9462846	0.919	rs6936722	chr6:42891311	A/G	cg02353165	chr6:42928485	GNMT	-0.42	-5.06	-0.3	7.82e-7	Blood protein levels;
CESC	cis	rs6429082	0.818	rs453315	chr1:235680585	C/T	cg26050004	chr1:235667680	B3GALNT2	0.62	7.61	0.42	4.89e-13	Adiposity;
CESC	cis	rs8067354	0.789	rs1292068	chr17:57929319	T/C	cg02344993	chr17:57696989	CLTC	0.5	6.61	0.38	2.12e-10	Hemoglobin concentration;
CESC	cis	rs1559088	0.522	rs7254912	chr19:33554151	A/G	cg17764715	chr19:33622953	WDR88	0.59	8.26	0.45	6.91e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs7589342	0.745	rs933793	chr2:106511846	C/T	cg16077055	chr2:106428750	NCK2	-0.37	-5.17	-0.3	4.53e-7	Addiction;
CESC	cis	rs6500395	0.962	rs1386042	chr16:48600332	G/A	cg04672837	chr16:48644449	N4BP1	0.46	5.6	0.33	5.47e-8	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs7772486	0.806	rs2253648	chr6:146199296	G/A	cg05347473	chr6:146136440	FBXO30	0.51	6.75	0.38	9.2e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs12701220	0.604	rs34904312	chr7:1135883	G/A	cg26769984	chr7:1090371	C7orf50	0.65	7.23	0.41	5.05e-12	Bronchopulmonary dysplasia;
CESC	cis	rs7116495	0.609	rs4945392	chr11:71694645	C/T	cg07596299	chr11:71824057	C11orf51	-0.85	-5.48	-0.32	9.86e-8	Severe influenza A (H1N1) infection;
CESC	cis	rs728616	0.681	rs12413174	chr10:82062404	G/A	cg05935833	chr10:81318306	SFTPA2	-0.46	-5.84	-0.34	1.56e-8	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs1005277	0.505	rs200935	chr10:38132810	T/A	cg00409905	chr10:38381863	ZNF37A	-0.54	-7.55	-0.42	7.25e-13	Extrinsic epigenetic age acceleration;
CESC	cis	rs7615952	0.599	rs12486459	chr3:125741465	T/G	cg02807482	chr3:125708958	NA	-0.4	-5.14	-0.3	5.45e-7	Blood pressure (smoking interaction);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg25766537	chr1:168147996	TIPRL	-0.52	-6.13	-0.35	3.19e-9	Ulcerative colitis;
CESC	cis	rs7666738	0.830	rs17484890	chr4:99013778	T/C	cg18180107	chr4:99064573	C4orf37	0.4	5.24	0.31	3.22e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7618915	0.501	rs6804145	chr3:52694198	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.61	8.97	0.48	5.62e-17	Bipolar disorder;
CESC	cis	rs12887734	0.546	rs66676135	chr14:104271504	G/A	cg08213375	chr14:104286397	PPP1R13B	0.42	7.16	0.4	7.84e-12	Schizophrenia;Autism spectrum disorder or schizophrenia;
CESC	cis	rs7666738	0.680	rs11726233	chr4:99079773	G/A	cg24818145	chr4:99064322	C4orf37	0.4	5.14	0.3	5.46e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7666738	0.830	rs10856936	chr4:99011319	T/C	cg18180107	chr4:99064573	C4orf37	0.4	5.24	0.31	3.22e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10256972	0.721	rs6975972	chr7:1070468	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.48	-6.62	-0.38	1.97e-10	Longevity;Endometriosis;
CESC	cis	rs17407555	0.821	rs73215081	chr4:10137326	C/G	cg11266682	chr4:10021025	SLC2A9	-0.48	-5.29	-0.31	2.58e-7	Schizophrenia (age at onset);
CESC	cis	rs7927592	0.956	rs2155730	chr11:68329474	T/C	cg20283391	chr11:68216788	NA	-0.49	-5.87	-0.34	1.29e-8	Total body bone mineral density;
CESC	cis	rs9916302	0.904	rs4795356	chr17:37535631	C/T	cg20243544	chr17:37824526	PNMT	-0.49	-6.24	-0.36	1.75e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs453301	0.571	rs2929453	chr8:9084341	A/G	cg15556689	chr8:8085844	FLJ10661	-0.52	-6.61	-0.38	2.16e-10	Joint mobility (Beighton score);
CESC	trans	rs8073060	0.559	rs72829925	chr17:34049778	C/A	cg19694781	chr19:47549865	TMEM160	0.71	6.55	0.37	3.03e-10	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	cis	rs2730245	1.000	rs2657365	chr7:158722753	A/T	cg15303052	chr7:158526867	ESYT2	0.43	5.11	0.3	6.17e-7	Height;
CESC	cis	rs6860806	0.507	rs2631362	chr5:131707293	A/G	cg04518342	chr5:131593106	PDLIM4	-0.39	-5.62	-0.33	4.83e-8	Breast cancer;
CESC	cis	rs10979	0.597	rs9484776	chr6:143906325	T/C	cg25407410	chr6:143891975	LOC285740	-0.5	-6.68	-0.38	1.42e-10	Hypospadias;
CESC	cis	rs7726839	0.794	rs10474792	chr5:600058	G/A	cg16447950	chr5:562315	NA	-0.49	-5.77	-0.33	2.18e-8	Obesity-related traits;
CESC	cis	rs17125944	0.505	rs17125746	chr14:53236079	C/T	cg00686598	chr14:53173677	PSMC6	1.32	11.44	0.58	6.67e-25	Alzheimer's disease (late onset);
CESC	cis	rs10242455	0.702	rs10251282	chr7:98990236	T/C	cg25640893	chr7:99214727	ZNF498	1.04	6.31	0.36	1.15e-9	Blood metabolite levels;
CESC	cis	rs7623687	0.786	rs73088161	chr3:49465162	C/T	cg19401529	chr3:49056140	DALRD3	0.67	5.13	0.3	5.69e-7	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;
CESC	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg24642844	chr7:1081250	C7orf50	-0.75	-8.99	-0.48	4.9e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs11252926	0.966	rs61831030	chr10:578869	C/T	cg08603382	chr10:743973	NA	-0.6	-7.33	-0.41	2.74e-12	Psychosis in Alzheimer's disease;
CESC	cis	rs910316	0.763	rs175435	chr14:75612025	A/G	cg08847533	chr14:75593920	NEK9	0.89	15.16	0.68	8.13e-38	Height;
CESC	cis	rs7617773	0.925	rs34513961	chr3:48173653	T/C	cg11946769	chr3:48343235	NME6	0.91	11.8	0.59	4.25e-26	Coronary artery disease;
CESC	cis	rs8072100	0.782	rs28507314	chr17:45551402	C/T	cg08085267	chr17:45401833	C17orf57	-0.58	-7.7	-0.43	2.77e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs7216064	1.000	rs12451721	chr17:65939075	G/A	cg07042672	chr17:66097459	LOC651250	-0.52	-5.35	-0.31	1.9e-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs1799949	1.000	rs1973646	chr17:41310495	T/C	cg23758822	chr17:41437982	NA	1.03	15.66	0.69	1.37e-39	Menopause (age at onset);
CESC	cis	rs6582630	0.519	rs12819814	chr12:38332568	G/C	cg26384229	chr12:38710491	ALG10B	0.69	10.38	0.54	2.16e-21	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs748404	0.660	rs2439846	chr15:43740970	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.57	7.61	0.42	4.92e-13	Lung cancer;
CESC	cis	rs1218582	0.772	rs12095061	chr1:154912968	A/T	cg06221963	chr1:154839813	KCNN3	-0.66	-11.17	-0.57	5.33e-24	Prostate cancer;
CESC	cis	rs7107174	0.681	rs10751288	chr11:78072658	A/T	cg02023728	chr11:77925099	USP35	0.47	6.23	0.36	1.82e-9	Testicular germ cell tumor;
CESC	cis	rs9847710	0.566	rs2564951	chr3:53060449	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	-0.34	-5.31	-0.31	2.29e-7	Ulcerative colitis;
CESC	cis	rs1799949	0.894	rs8176160	chr17:41241503	T/C	cg05368731	chr17:41323189	NBR1	0.78	11.14	0.56	6.78e-24	Menopause (age at onset);
CESC	cis	rs899997	1.000	rs11629824	chr15:79005524	T/G	cg04896959	chr15:78267971	NA	0.42	6.35	0.36	9.31e-10	Coronary artery disease or large artery stroke;
CESC	cis	rs7917772	0.503	rs7087665	chr10:104282418	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.55	7.59	0.42	5.46e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg25117505	chr11:66313529	ZDHHC24;ACTN3	-0.54	-6.85	-0.39	5.2e-11	Ulcerative colitis;
CESC	cis	rs7923609	0.846	rs9787438	chr10:65038030	G/C	cg01631684	chr10:65280961	REEP3	-0.44	-5.4	-0.31	1.51e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs6461049	0.638	rs1859993	chr7:2183702	A/G	cg21782813	chr7:2030301	MAD1L1	0.39	5.75	0.33	2.4e-8	Schizophrenia;
CESC	cis	rs17711722	0.565	rs4275112	chr7:65198619	T/G	cg26939375	chr7:64535504	NA	-0.69	-9.98	-0.52	4.16e-20	Calcium levels;
CESC	cis	rs61008539	0.821	rs10950789	chr7:897492	A/G	cg00934597	chr7:893267	UNC84A	-0.55	-7.42	-0.41	1.6e-12	Perceived unattractiveness to mosquitoes;
CESC	cis	rs2073300	1.000	rs6132625	chr20:23444671	C/T	cg12062639	chr20:23401060	NAPB	0.91	6.41	0.37	6.71e-10	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs72945132	0.714	rs66542029	chr11:70196302	A/T	cg00319359	chr11:70116639	PPFIA1	0.72	6.79	0.38	7.38e-11	Coronary artery disease;
CESC	cis	rs6502050	0.871	rs8066970	chr17:80076051	T/C	cg23985595	chr17:80112537	CCDC57	0.41	6.4	0.37	6.88e-10	Life satisfaction;
CESC	cis	rs28374715	0.662	rs72737792	chr15:41515589	G/C	cg18705301	chr15:41695430	NDUFAF1	-0.8	-10.11	-0.53	1.59e-20	Ulcerative colitis;
CESC	cis	rs61935443	0.666	rs11107781	chr12:95301086	T/A	cg21533806	chr12:95267307	NA	0.48	5.24	0.31	3.27e-7	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20756934	chr12:56510353	RPL41	0.64	6.99	0.39	2.19e-11	Gut microbiome composition (summer);
CESC	cis	rs12477438	0.765	rs7591992	chr2:99668954	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.64	-8.73	-0.47	2.94e-16	Chronic sinus infection;
CESC	cis	rs8067545	0.611	rs8066143	chr17:20048355	A/C	cg13482628	chr17:19912719	NA	0.39	5.12	0.3	5.8e-7	Schizophrenia;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg10582045	chr15:43477796	CCNDBP1	-0.47	-6.24	-0.36	1.71e-9	Ulcerative colitis;
CESC	cis	rs7772486	0.875	rs9376975	chr6:146355581	T/G	cg05347473	chr6:146136440	FBXO30	0.5	6.51	0.37	3.72e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4253772	0.591	rs11703435	chr22:46685563	C/T	cg10541313	chr22:46663664	TTC38	0.72	5.15	0.3	5.01e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs7927771	0.965	rs12787112	chr11:47687147	A/G	cg20307385	chr11:47447363	PSMC3	-0.49	-5.99	-0.35	6.84e-9	Subjective well-being;
CESC	cis	rs4713118	0.516	rs4713142	chr6:28106347	T/G	cg26335602	chr6:28129616	ZNF389	0.54	7.3	0.41	3.37e-12	Parkinson's disease;
CESC	cis	rs7116495	1.000	rs7116495	chr11:71762085	C/T	cg26138937	chr11:71823887	C11orf51	-0.81	-6.46	-0.37	4.87e-10	Severe influenza A (H1N1) infection;
CESC	cis	rs62064224	0.902	rs17732573	chr17:30627664	C/T	cg18200150	chr17:30822561	MYO1D	-0.51	-7.42	-0.41	1.62e-12	Schizophrenia;
CESC	cis	rs2011503	0.941	rs72999063	chr19:19380596	G/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.51	5.18	0.3	4.38e-7	Bipolar disorder;
CESC	cis	rs13191362	0.810	rs35509380	chr6:163053028	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.94	9.15	0.49	1.57e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs116095464	0.558	rs10067021	chr5:221490	C/T	cg22496380	chr5:211416	CCDC127	-0.72	-8.57	-0.47	8.59e-16	Breast cancer;
CESC	cis	rs644799	0.965	rs566877	chr11:95528045	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.92	13.87	0.65	2.93e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs7666738	0.830	rs13119995	chr4:99026790	T/C	cg03467027	chr4:99064603	C4orf37	0.49	6.18	0.35	2.44e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs67311347	1.000	rs1123019	chr3:40488280	C/T	cg09455208	chr3:40491958	NA	0.49	8.04	0.44	2.91e-14	Renal cell carcinoma;
CESC	cis	rs7666738	0.830	rs34628820	chr4:99004764	C/T	cg17366294	chr4:99064904	C4orf37	0.6	8.61	0.47	6.47e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs12477438	0.539	rs12999417	chr2:99865548	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.81	-12.82	-0.62	1.36e-29	Chronic sinus infection;
CESC	cis	rs6540559	0.673	rs6694552	chr1:209976459	A/C	cg23283495	chr1:209979779	IRF6	0.53	6.34	0.36	9.65e-10	Cleft lip with or without cleft palate;
CESC	cis	rs477895	0.713	rs11607165	chr11:63963947	T/G	cg18225595	chr11:63971243	STIP1	0.52	5.19	0.3	4.19e-7	Mean platelet volume;
CESC	cis	rs9287719	1.000	rs9287719	chr2:10710730	C/T	cg00105475	chr2:10696890	NA	0.39	5.71	0.33	3.1e-8	Prostate cancer;
CESC	cis	rs9916302	0.904	rs4795356	chr17:37535631	C/T	cg00129232	chr17:37814104	STARD3	0.59	7.88	0.44	8.71e-14	Glomerular filtration rate (creatinine);
CESC	cis	rs798554	0.797	rs798497	chr7:2795957	A/G	cg04166393	chr7:2884313	GNA12	0.6	7.73	0.43	2.27e-13	Height;
CESC	cis	rs9399401	0.601	rs262120	chr6:142842360	C/A	cg03128060	chr6:142623767	GPR126	0.33	5.42	0.32	1.35e-7	Chronic obstructive pulmonary disease;
CESC	cis	rs7937682	0.889	rs497111	chr11:111499512	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.99	-15.77	-0.7	5.94e-40	Primary sclerosing cholangitis;
CESC	cis	rs12497850	0.931	rs9846123	chr3:49088112	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.7	-9.54	-0.51	9.56e-19	Parkinson's disease;
CESC	trans	rs11039798	0.764	rs12277213	chr11:48782176	G/A	cg15704280	chr7:45808275	SEPT13	0.7	6.35	0.36	9.09e-10	Axial length;
CESC	cis	rs28374715	0.528	rs7181982	chr15:41623020	C/G	cg18705301	chr15:41695430	NDUFAF1	-1.05	-15.46	-0.69	6.98e-39	Ulcerative colitis;
CESC	cis	rs875971	1.000	rs1363055	chr7:65943275	A/G	cg10691866	chr7:65817282	TPST1	-0.34	-5.62	-0.33	4.93e-8	Aortic root size;
CESC	cis	rs10504229	0.906	rs2270609	chr8:58194684	G/A	cg02725872	chr8:58115012	NA	-0.35	-5.17	-0.3	4.69e-7	Developmental language disorder (linguistic errors);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03773196	chr1:219786527	NA	-0.39	-6.0	-0.35	6.63e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs1050631	0.960	rs1789512	chr18:33694542	C/T	cg25426722	chr18:33708991	SLC39A6;ELP2	-0.45	-5.81	-0.34	1.82e-8	Esophageal squamous cell cancer (length of survival);
CESC	cis	rs4909189	1.000	rs12698214	chr7:158136204	T/G	cg06219351	chr7:158114137	PTPRN2	-0.58	-7.18	-0.4	6.86e-12	Response to amphetamines;
CESC	cis	rs7264396	0.635	rs6121073	chr20:34457513	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.84	-11.17	-0.57	5.37e-24	Total cholesterol levels;
CESC	cis	rs763014	0.932	rs2384974	chr16:651279	C/G	cg00908189	chr16:619842	PIGQ	0.66	9.4	0.5	2.63e-18	Height;
CESC	trans	rs61931739	0.500	rs7298322	chr12:34445489	A/T	cg26384229	chr12:38710491	ALG10B	0.54	7.5	0.42	9.79e-13	Morning vs. evening chronotype;
CESC	cis	rs9300255	0.602	rs1727296	chr12:123647725	G/C	cg19016782	chr12:123741754	C12orf65	-0.4	-5.77	-0.33	2.27e-8	Neutrophil percentage of white cells;
CESC	cis	rs3733585	0.699	rs13328050	chr4:9951120	G/T	cg11266682	chr4:10021025	SLC2A9	-0.57	-10.45	-0.54	1.27e-21	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs7116495	0.609	rs2852365	chr11:71715218	T/C	cg18441811	chr11:71824068	C11orf51	-0.79	-5.33	-0.31	2.06e-7	Severe influenza A (H1N1) infection;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg21395782	chr19:19626814	NDUFA13;TSSK6	0.47	6.32	0.36	1.11e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs67311347	1.000	rs73080126	chr3:40509153	A/G	cg24209194	chr3:40518798	ZNF619	0.5	6.09	0.35	4.06e-9	Renal cell carcinoma;
CESC	cis	rs7267979	0.932	rs424487	chr20:25468131	C/G	cg08601574	chr20:25228251	PYGB	0.39	5.61	0.33	5.2100000000000003e-08	Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs11098499	0.954	rs71629403	chr4:120372567	C/T	cg25214090	chr10:38739885	LOC399744	0.71	9.8	0.52	1.46e-19	Corneal astigmatism;
CESC	cis	rs3087591	0.960	rs2269855	chr17:29482878	G/A	cg24425628	chr17:29625626	OMG;NF1	0.41	5.13	0.3	5.71e-7	Hip circumference;
CESC	cis	rs5769765	0.862	rs9616774	chr22:50290599	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.45	-5.14	-0.3	5.24e-7	Schizophrenia;
CESC	cis	rs7552404	1.000	rs7548962	chr1:76139266	G/A	cg10523679	chr1:76189770	ACADM	0.72	8.33	0.46	4.38e-15	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs228437	0.609	rs7749956	chr6:134961973	C/T	cg24504307	chr6:134963096	NA	-0.38	-5.13	-0.3	5.5e-7	Melanoma;
CESC	cis	rs9916302	0.800	rs8081220	chr17:37473157	A/C	cg00129232	chr17:37814104	STARD3	0.51	6.35	0.36	9.57e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs4721295	0.573	rs3779000	chr7:2181628	G/A	cg02951883	chr7:2050386	MAD1L1	-0.49	-6.25	-0.36	1.66e-9	Schizophrenia, schizoaffective disorder or bipolar disorder;
CESC	cis	rs1008375	0.806	rs13139898	chr4:17706928	T/G	cg02297831	chr4:17616191	MED28	-0.54	-6.44	-0.37	5.54e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs7412746	0.658	rs12067685	chr1:150952917	T/C	cg04414720	chr1:150670196	GOLPH3L	0.49	6.47	0.37	4.65e-10	Melanoma;
CESC	cis	rs12048904	0.619	rs10783153	chr1:101328230	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.89	12.15	0.6	2.69e-27	Multiple sclerosis;
CESC	cis	rs7666738	0.830	rs114722517	chr4:99042061	G/A	cg03676636	chr4:99064102	C4orf37	0.33	5.12	0.3	5.93e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11785400	0.793	rs11543967	chr8:143739435	A/G	cg24634471	chr8:143751801	JRK	-0.46	-5.68	-0.33	3.49e-8	Schizophrenia;
CESC	cis	rs11122272	0.735	rs2572254	chr1:231512593	T/C	cg06096015	chr1:231504339	EGLN1	0.42	6.11	0.35	3.53e-9	Hemoglobin concentration;
CESC	cis	rs1707322	1.000	rs6693336	chr1:46354595	C/T	cg05343316	chr1:45956843	TESK2	0.44	5.55	0.32	7.05e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg10862848	chr6:42927986	GNMT	-0.3	-7.57	-0.42	6.2e-13	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs2629540	0.889	rs7476729	chr10:126428174	C/G	cg08799069	chr10:126477246	METTL10	-0.67	-8.85	-0.48	1.26e-16	Cocaine dependence;
CESC	cis	rs1198430	0.925	rs2811975	chr1:23801081	A/T	cg22040403	chr1:23858016	E2F2	0.71	5.27	0.31	2.83e-7	Total cholesterol levels;
CESC	cis	rs262147	1.000	rs262147	chr7:158745142	A/G	cg24397884	chr7:158709396	WDR60	0.7	5.52	0.32	8.17e-8	Hippocampal volume;
CESC	cis	rs9403521	0.947	rs7741424	chr6:143981662	G/A	cg21026257	chr6:143998961	PHACTR2	0.46	5.03	0.3	8.88e-7	Obesity-related traits;
CESC	cis	rs9858542	0.953	rs11715915	chr3:49455330	A/G	cg03060546	chr3:49711283	APEH	0.57	6.19	0.36	2.33e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs896543	0.702	rs6711222	chr2:237494444	C/T	cg25295825	chr2:237489920	CXCR7	0.71	9.11	0.49	2.11e-17	Alcohol dependence (age at onset);
CESC	cis	rs897984	0.762	rs7206511	chr16:30950352	G/A	cg00531865	chr16:30841666	NA	0.51	7.01	0.4	1.99e-11	Dementia with Lewy bodies;
CESC	cis	rs7100689	0.784	rs7089058	chr10:82071263	T/C	cg00277334	chr10:82204260	NA	-0.57	-7.29	-0.41	3.53e-12	Post bronchodilator FEV1;
CESC	cis	rs8141529	0.753	rs5752813	chr22:29226570	T/G	cg02153584	chr22:29168773	CCDC117	0.63	9.06	0.49	3.01e-17	Lymphocyte counts;
CESC	cis	rs7666738	0.830	rs4699592	chr4:98974202	A/C	cg05340658	chr4:99064831	C4orf37	0.79	12.26	0.6	1.12e-27	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2075371	0.966	rs2544214	chr7:133985736	G/A	cg00033643	chr7:134001901	SLC35B4	0.44	5.71	0.33	3.05e-8	Mean platelet volume;
CESC	cis	rs2842992	0.789	rs9355748	chr6:160194882	G/A	cg11366901	chr6:160182831	ACAT2	0.83	10.41	0.54	1.65e-21	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs1580019	1.000	rs1580019	chr7:32493169	A/T	cg06627557	chr7:32535165	LSM5;AVL9	-0.78	-10.76	-0.55	1.23e-22	Cognitive ability;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05566397	chr7:104654900	MLL5;LOC100216545	-0.45	-6.28	-0.36	1.37e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs62244186	0.535	rs59726036	chr3:44850074	G/T	cg15225532	chr3:44803084	KIF15;KIAA1143	0.49	6.46	0.37	5.08e-10	Depressive symptoms;
CESC	cis	rs4665809	0.652	rs4665832	chr2:26404775	A/G	cg26314531	chr2:26401878	FAM59B	-0.82	-9.03	-0.48	3.69e-17	Gut microbiome composition (summer);
CESC	cis	rs12477438	0.798	rs1349778	chr2:99645011	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.72	-10.25	-0.53	5.55e-21	Chronic sinus infection;
CESC	cis	rs734999	0.545	rs10752748	chr1:2544640	G/A	cg20673091	chr1:2541236	MMEL1	0.45	7.42	0.41	1.63e-12	Ulcerative colitis;
CESC	cis	rs7084402	0.967	rs7897298	chr10:60274606	T/C	cg07615347	chr10:60278583	BICC1	-0.57	-8.96	-0.48	6.01e-17	Refractive error;
CESC	cis	rs6570726	0.791	rs443628	chr6:145883484	T/C	cg23711669	chr6:146136114	FBXO30	0.98	14.74	0.67	2.54e-36	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs10883723	0.810	rs6584507	chr10:104254623	G/A	ch.10.2196322F	chr10:104248062	ACTR1A	0.42	5.08	0.3	6.99e-7	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs8077889	0.956	rs58242860	chr17:41847300	T/C	cg26893861	chr17:41843967	DUSP3	0.74	8.79	0.48	1.87e-16	Triglycerides;
CESC	cis	rs7647973	0.961	rs6778080	chr3:49317338	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.5	-6.71	-0.38	1.19e-10	Menarche (age at onset);
CESC	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg22907277	chr7:1156413	C7orf50	0.46	6.65	0.38	1.65e-10	Longevity;Endometriosis;
CESC	cis	rs4906332	1.000	rs12896919	chr14:103956713	T/C	cg09975044	chr14:104007538	NA	0.47	6.39	0.37	7.49e-10	Coronary artery disease;
CESC	cis	rs898097	0.690	rs12452304	chr17:80811659	G/A	cg15369054	chr17:80825471	TBCD	0.57	8.08	0.44	2.26e-14	Breast cancer;
CESC	cis	rs4523957	0.757	rs216199	chr17:2200871	C/T	cg16513277	chr17:2031491	SMG6	0.57	7.71	0.43	2.56e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs4561483	0.831	rs33648	chr16:11979622	G/A	cg08843971	chr16:11963173	GSPT1	-0.4	-5.47	-0.32	1.03e-7	Testicular germ cell tumor;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07003673	chr12:123459818	ABCB9;OGFOD2	-0.63	-6.94	-0.39	2.95e-11	Gut microbiome composition (summer);
CESC	cis	rs116095464	0.558	rs10043002	chr5:226753	G/A	cg10591111	chr5:226296	SDHA	-0.55	-6.81	-0.39	6.5e-11	Breast cancer;
CESC	trans	rs2727020	0.729	rs2204366	chr11:49349367	A/C	cg03929089	chr4:120376271	NA	0.79	12.06	0.6	5.6e-27	Coronary artery disease;
CESC	cis	rs15676	0.783	rs2977996	chr9:131582625	C/T	cg00228799	chr9:131580591	ENDOG	0.56	7.2	0.4	6.12e-12	Blood metabolite levels;
CESC	cis	rs875971	0.545	rs73376401	chr7:65639828	G/A	cg18876405	chr7:65276391	NA	0.51	5.96	0.34	7.82e-9	Aortic root size;
CESC	cis	rs425277	0.585	rs3107156	chr1:2060630	T/C	cg24578937	chr1:2090814	PRKCZ	-0.34	-5.87	-0.34	1.31e-8	Height;
CESC	cis	rs61612642	0.523	rs59004693	chr6:42157392	G/A	cg10382835	chr6:42185730	MRPS10	0.67	5.98	0.34	7.16e-9	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Eosinophil counts;
CESC	cis	rs2204008	0.837	rs11612397	chr12:38357455	T/C	cg26384229	chr12:38710491	ALG10B	0.73	10.95	0.56	2.81e-23	Bladder cancer;
CESC	cis	rs9649213	0.593	rs55825602	chr7:98013039	T/C	cg08684580	chr7:98029266	BAIAP2L1	-0.35	-5.68	-0.33	3.51e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs40363	0.672	rs1617722	chr16:3520806	C/T	cg00484396	chr16:3507460	NAT15	-0.41	-6.59	-0.38	2.39e-10	Tuberculosis;
CESC	cis	rs7811142	1.000	rs4463351	chr7:100078226	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.02	11.26	0.57	2.8e-24	Platelet count;
CESC	cis	rs10131894	0.611	rs175001	chr14:75436452	A/C	cg08847533	chr14:75593920	NEK9	0.72	11.04	0.56	1.41e-23	Coronary artery disease;
CESC	cis	rs9303401	0.625	rs66508449	chr17:56691034	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.03	12.55	0.61	1.16e-28	Cognitive test performance;
CESC	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg07308232	chr7:1071921	C7orf50	-0.43	-5.93	-0.34	9.32e-9	Longevity;Endometriosis;
CESC	cis	rs1050631	0.592	rs1785903	chr18:33711642	G/C	cg25426722	chr18:33708991	SLC39A6;ELP2	0.57	7.99	0.44	4.09e-14	Esophageal squamous cell cancer (length of survival);
CESC	cis	rs3741798	1.000	rs61922025	chr12:12486263	G/A	cg08615371	chr12:12503544	MANSC1	0.87	6.35	0.36	9.19e-10	Cerebrospinal fluid biomarker levels;
CESC	cis	rs2404602	0.647	rs12903586	chr15:77168240	G/A	cg23625390	chr15:77176239	SCAPER	-0.45	-6.34	-0.36	1.01e-9	Blood metabolite levels;
CESC	cis	rs8070624	0.543	rs11078409	chr17:17876296	C/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.53	6.69	0.38	1.3100000000000001e-10	Total body bone mineral density;
CESC	cis	rs4604732	0.631	rs12031721	chr1:247623773	G/A	cg12758973	chr1:247694275	LOC148824;OR2C3	0.49	6.04	0.35	5.16e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg14018420	chr1:21766356	NBPF3	-0.42	-6.04	-0.35	5.1e-9	Fibrinogen levels;
CESC	cis	rs7666738	0.830	rs34628820	chr4:99004764	C/T	cg18180107	chr4:99064573	C4orf37	0.4	5.23	0.31	3.41e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs12618769	0.597	rs3754884	chr2:99125376	C/T	cg10123293	chr2:99228465	UNC50	0.39	5.13	0.3	5.6e-7	Bipolar disorder;
CESC	cis	rs116095464	0.558	rs113796397	chr5:246503	A/G	cg12570787	chr5:219185	SDHA;CCDC127	0.52	5.22	0.31	3.58e-7	Breast cancer;
CESC	cis	rs7666738	0.830	rs11097600	chr4:98959564	T/G	cg03467027	chr4:99064603	C4orf37	0.44	5.45	0.32	1.15e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9443645	0.869	rs6926537	chr6:79554193	T/A	cg05283184	chr6:79620031	NA	-0.43	-6.79	-0.38	7.42e-11	Intelligence (multi-trait analysis);
CESC	cis	rs12791968	0.765	rs12790121	chr11:45001089	G/A	cg11846598	chr11:44996168	LOC221122	-0.48	-5.81	-0.34	1.78e-8	Inhibitory control;
CESC	cis	rs5750830	0.620	rs1007337	chr22:39781585	C/T	cg11247378	chr22:39784982	NA	-0.55	-8.48	-0.46	1.6e-15	Intelligence (multi-trait analysis);
CESC	cis	rs12477438	0.715	rs7586608	chr2:99558017	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.63	-8.85	-0.48	1.25e-16	Chronic sinus infection;
CESC	cis	rs10871290	0.801	rs3851726	chr16:74471644	G/C	cg01733217	chr16:74700730	RFWD3	-0.65	-8.7	-0.47	3.57e-16	Breast cancer;
CESC	cis	rs801193	0.660	rs4610622	chr7:66224497	T/C	cg10691866	chr7:65817282	TPST1	-0.36	-6.13	-0.35	3.09e-9	Aortic root size;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg21956150	chr19:1438388	RPS15	0.47	6.75	0.38	9.55e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs4975709	0.609	rs2232373	chr5:1882280	C/G	cg15595755	chr5:1867978	NA	0.48	7.35	0.41	2.4e-12	Cardiovascular disease risk factors;
CESC	cis	rs11098499	0.866	rs7677068	chr4:120291704	C/T	cg24375607	chr4:120327624	NA	0.42	5.19	0.3	4.19e-7	Corneal astigmatism;
CESC	cis	rs853679	0.517	rs9393891	chr6:28079160	C/T	cg12963246	chr6:28129442	ZNF389	0.56	7.63	0.42	4.26e-13	Depression;
CESC	cis	rs7666738	0.830	rs28785514	chr4:98959135	G/A	cg18180107	chr4:99064573	C4orf37	0.4	5.12	0.3	5.85e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs72945132	0.882	rs55738915	chr11:70190019	C/T	cg14191688	chr11:70257035	CTTN	0.44	5.43	0.32	1.31e-7	Coronary artery disease;
CESC	cis	rs754466	0.606	rs10824581	chr10:79599501	A/G	cg17075019	chr10:79541650	NA	-0.87	-13.73	-0.64	8.77e-33	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs3026101	0.671	rs3026129	chr17:5295371	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.43	5.68	0.33	3.57e-8	Body mass index;
CESC	cis	rs7100689	0.622	rs10749595	chr10:82172975	C/T	cg00277334	chr10:82204260	NA	-0.57	-7.07	-0.4	1.38e-11	Post bronchodilator FEV1;
CESC	cis	rs3733585	0.699	rs7677710	chr4:9969517	T/G	cg11266682	chr4:10021025	SLC2A9	-0.57	-10.92	-0.56	3.5e-23	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs79349575	0.870	rs12941262	chr17:46967037	T/A	cg16584676	chr17:46985605	UBE2Z	0.55	6.62	0.38	2.03e-10	Type 2 diabetes;
CESC	cis	rs75477785	0.590	rs76089065	chr1:210298225	T/C	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.77	5.34	0.31	2.03e-7	Cleft lip with or without cleft palate;
CESC	cis	rs634534	0.622	rs593525	chr11:65727799	T/C	cg02202077	chr11:65769826	EIF1AD;BANF1	0.39	5.21	0.3	3.85e-7	Sum eosinophil basophil counts;Eosinophil counts;
CESC	cis	rs3820068	0.705	rs57238793	chr1:15890029	A/G	cg17385448	chr1:15911702	AGMAT	0.41	6.05	0.35	4.91e-9	Systolic blood pressure;
CESC	cis	rs7923609	0.936	rs10740125	chr10:65209609	T/C	cg01631684	chr10:65280961	REEP3	-0.43	-5.39	-0.31	1.55e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs12451471	0.637	rs7567	chr17:78093549	G/T	cg06718696	chr17:78121285	EIF4A3	0.86	10.52	0.54	7.61e-22	Plateletcrit;Mean corpuscular hemoglobin concentration;
CESC	cis	rs873946	0.586	rs3793686	chr10:134569559	A/G	cg18305652	chr10:134549665	INPP5A	0.47	6.77	0.38	8.43e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg27014927	chr22:45403808	PHF21B	-0.36	-6.15	-0.35	2.89e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs1018836	0.851	rs12548741	chr8:91628878	G/A	cg16814680	chr8:91681699	NA	-0.72	-10.07	-0.53	2.16e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs9467773	1.000	rs9295695	chr6:26528250	C/T	cg20266910	chr6:26577678	NA	-0.33	-5.46	-0.32	1.08e-7	Intelligence (multi-trait analysis);
CESC	cis	rs11997175	0.624	rs7001604	chr8:33680979	T/C	ch.8.33884649F	chr8:33765107	NA	0.57	7.38	0.41	2.01e-12	Body mass index;
CESC	cis	rs9623117	0.915	rs9611261	chr22:40466872	A/G	cg05033341	chr22:40419857	FAM83F	-0.43	-5.23	-0.31	3.41e-7	Prostate cancer (SNP x SNP interaction);Prostate cancer;
CESC	cis	rs3008870	0.755	rs2815381	chr1:67514591	G/A	cg02640540	chr1:67518911	SLC35D1	0.71	9.15	0.49	1.54e-17	Lymphocyte percentage of white cells;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23177889	chr7:116502779	CAPZA2	0.52	6.33	0.36	1.07e-9	Gut microbiome composition (summer);
CESC	cis	rs1552244	1.000	rs6768102	chr3:10149380	A/G	cg00166722	chr3:10149974	C3orf24	0.44	5.5	0.32	9.07e-8	Alzheimer's disease;
CESC	cis	rs892961	0.899	rs72896162	chr17:75412521	A/G	cg05865280	chr17:75406074	SEPT9	0.62	12.67	0.61	4.57e-29	Airflow obstruction;
CESC	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg14159672	chr1:205819179	PM20D1	0.93	16.31	0.71	6.74e-42	Menarche (age at onset);
CESC	cis	rs1799949	0.894	rs8176160	chr17:41241503	T/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.44	6.24	0.36	1.71e-9	Menopause (age at onset);
CESC	trans	rs561341	0.941	rs8081016	chr17:30331751	A/G	cg27661571	chr11:113659931	NA	-0.82	-7.6	-0.42	5.24e-13	Hip circumference adjusted for BMI;
CESC	cis	rs2838344	0.776	rs2298561	chr21:45085234	A/G	cg21573476	chr21:45109991	RRP1B	-0.6	-8.91	-0.48	8.59e-17	Coronary artery disease;
CESC	cis	rs1348850	0.874	rs1348848	chr2:178358233	A/C	cg22681709	chr2:178499509	PDE11A	0.42	6.15	0.35	2.9e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs6570726	0.935	rs414222	chr6:145850482	C/T	cg05347473	chr6:146136440	FBXO30	0.49	6.62	0.38	1.96e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs76917914	0.780	rs6478556	chr9:100842005	A/G	cg03040243	chr9:100819229	NANS	-0.48	-5.36	-0.31	1.77e-7	Immature fraction of reticulocytes;
CESC	cis	rs73195822	0.614	rs73194057	chr12:111216913	T/C	cg12870014	chr12:110450643	ANKRD13A	0.7	7.31	0.41	3.17e-12	Itch intensity from mosquito bite;
CESC	cis	rs2730245	0.527	rs62475645	chr7:158656825	G/A	cg24397884	chr7:158709396	WDR60	0.83	8.47	0.46	1.71e-15	Height;
CESC	trans	rs11098499	0.754	rs10212775	chr4:120239244	G/C	cg25214090	chr10:38739885	LOC399744	0.61	8.51	0.46	1.33e-15	Corneal astigmatism;
CESC	cis	rs9399137	0.507	rs10484496	chr6:135299682	T/C	cg22676075	chr6:135203613	NA	0.54	7.06	0.4	1.46e-11	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	cis	rs897984	0.760	rs11076	chr16:30995528	A/G	cg00531865	chr16:30841666	NA	0.52	7.12	0.4	1.01e-11	Dementia with Lewy bodies;
CESC	cis	rs506597	0.920	rs221796	chr7:100284913	C/G	cg10426581	chr7:100472382	SRRT	-0.7	-5.39	-0.31	1.52e-7	Pursuit maintenance gain in psychotic disorders;
CESC	cis	rs769267	0.896	rs2315610	chr19:19597240	T/C	cg03709012	chr19:19516395	GATAD2A	1.01	15.75	0.7	6.47e-40	Tonsillectomy;
CESC	cis	rs9300255	0.569	rs1790115	chr12:123620270	C/G	cg19016782	chr12:123741754	C12orf65	-0.38	-5.15	-0.3	5.16e-7	Neutrophil percentage of white cells;
CESC	cis	rs7666738	0.680	rs11726233	chr4:99079773	G/A	cg03467027	chr4:99064603	C4orf37	0.43	5.21	0.3	3.86e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7605827	0.930	rs12692272	chr2:15680801	C/T	cg19274914	chr2:15703543	NA	0.36	6.38	0.36	8.01e-10	Educational attainment (years of education);
CESC	cis	rs853679	0.517	rs56310871	chr6:28044482	A/G	cg20151795	chr6:28129481	ZNF389	0.44	5.59	0.33	5.5e-8	Depression;
CESC	cis	rs13191362	0.938	rs59067610	chr6:163030440	C/A	cg14584255	chr6:163149320	PACRG;PARK2	0.46	5.11	0.3	6.16e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs853679	0.550	rs1233701	chr6:28168726	C/G	cg23161317	chr6:28129485	ZNF389	-0.45	-5.85	-0.34	1.44e-8	Depression;
CESC	cis	rs9291683	0.527	rs11727087	chr4:10096020	A/G	cg00071950	chr4:10020882	SLC2A9	0.66	10.9	0.56	4.19e-23	Bone mineral density;
CESC	cis	rs9733	0.526	rs6587542	chr1:150907701	G/T	cg22823121	chr1:150693482	HORMAD1	0.36	5.12	0.3	5.88e-7	Tonsillectomy;
CESC	cis	rs9910055	0.718	rs7212854	chr17:42254417	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.4	5.97	0.34	7.44e-9	Total body bone mineral density;
CESC	cis	rs1878047	0.729	rs28536511	chr19:51773511	C/A	cg14884932	chr19:51774451	NA	-0.37	-5.16	-0.3	4.87e-7	Body mass index;
CESC	cis	rs155076	0.625	rs4769159	chr13:21881978	A/C	cg06138931	chr13:21896616	NA	0.51	5.27	0.31	2.8e-7	White matter hyperintensity burden;
CESC	cis	rs113835537	0.877	rs2229456	chr11:66328741	A/C	cg24851651	chr11:66362959	CCS	0.52	5.1	0.3	6.51e-7	Airway imaging phenotypes;
CESC	cis	rs72634258	0.842	rs4325151	chr1:8168917	T/A	cg00042356	chr1:8021962	PARK7	-0.52	-5.62	-0.33	4.76e-8	Inflammatory bowel disease;
CESC	trans	rs9987353	0.840	rs329994	chr8:9123233	A/G	cg09234025	chr7:6145309	USP42	-0.46	-6.09	-0.35	3.85e-9	Recombination measurement;
CESC	cis	rs12971120	1.000	rs2278161	chr18:72176083	T/C	cg26446133	chr18:72167187	CNDP2	-0.75	-9.64	-0.51	4.94e-19	Refractive error;
CESC	cis	rs919433	0.889	rs787998	chr2:198216092	A/G	cg20885578	chr2:198174922	NA	0.4	5.49	0.32	9.48e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs853679	0.517	rs35512245	chr6:28079953	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.58	-6.75	-0.38	9.45e-11	Depression;
CESC	cis	rs9612	0.948	rs12609056	chr19:44258702	G/T	cg08581076	chr19:44259116	C19orf61	0.62	7.11	0.4	1.08e-11	Exhaled nitric oxide output;
CESC	cis	rs943466	0.513	rs943467	chr6:33731811	A/T	cg25922239	chr6:33757077	LEMD2	0.4	5.49	0.32	9.41e-8	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
CESC	cis	rs921968	0.528	rs13382651	chr2:219628191	A/G	cg02176678	chr2:219576539	TTLL4	-0.45	-7.81	-0.43	1.37e-13	Mean corpuscular hemoglobin concentration;
CESC	cis	rs7520050	0.966	rs4545281	chr1:46360054	C/T	cg03146154	chr1:46216737	IPP	-0.44	-5.74	-0.33	2.53e-8	Red blood cell count;Reticulocyte count;
CESC	cis	rs853679	0.517	rs11552219	chr6:28126834	C/T	cg20151795	chr6:28129481	ZNF389	0.44	5.55	0.32	6.85e-8	Depression;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg17492891	chr22:41843204	TOB2	0.48	6.26	0.36	1.52e-9	Systemic lupus erythematosus;
CESC	cis	rs936229	0.511	rs12591513	chr15:75102714	G/A	cg14664628	chr15:75095509	CSK	-0.71	-9.75	-0.51	2.13e-19	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CESC	cis	rs3092073	0.624	rs3848714	chr20:44547176	T/C	cg27529037	chr20:44575021	PCIF1	0.64	9.72	0.51	2.61e-19	Intelligence (multi-trait analysis);
CESC	cis	rs1799949	1.000	rs12950607	chr17:41299928	G/C	cg06001716	chr17:41278141	BRCA1;NBR2	0.39	5.26	0.31	3e-7	Menopause (age at onset);
CESC	cis	rs8005677	1.000	rs8006409	chr14:23396511	A/G	cg01529538	chr14:23388837	RBM23	0.5	6.82	0.39	6.24e-11	Cognitive ability (multi-trait analysis);
CESC	cis	rs7945705	0.967	rs10840148	chr11:8923528	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.53	8.36	0.46	3.52e-15	Hemoglobin concentration;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg00340921	chr19:7600526	PNPLA6	-0.46	-6.21	-0.36	2.08e-9	Fibrinogen levels;
CESC	cis	rs4713118	0.587	rs61471148	chr6:28037032	T/A	cg22143856	chr6:28129313	ZNF389	0.47	5.63	0.33	4.54e-8	Parkinson's disease;
CESC	cis	rs9362426	1.000	rs414013	chr6:88085866	T/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.47	5.93	0.34	9.21e-9	Depressive episodes in bipolar disorder;
CESC	cis	rs2288073	0.801	rs10175668	chr2:24367275	G/A	cg20701182	chr2:24300061	SF3B14	0.48	6.03	0.35	5.34e-9	Venous thromboembolism (SNP x SNP interaction);
CESC	cis	rs514406	0.683	rs6588440	chr1:53209587	C/T	cg08736216	chr1:53307985	ZYG11A	0.4	6.45	0.37	5.35e-10	Monocyte count;
CESC	cis	rs1348850	0.837	rs12619074	chr2:178472336	G/A	cg22681709	chr2:178499509	PDE11A	-0.42	-6.39	-0.37	7.51e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs2180341	0.960	rs7773484	chr6:127670779	T/C	cg27446573	chr6:127587934	RNF146	1.06	15.51	0.69	4.62e-39	Breast cancer;
CESC	cis	rs7666738	0.830	rs10007872	chr4:99001904	T/C	cg03676636	chr4:99064102	C4orf37	0.33	5.13	0.3	5.51e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs738322	0.967	rs6001038	chr22:38570585	A/G	cg25457927	chr22:38595422	NA	-0.3	-5.46	-0.32	1.1e-7	Cutaneous nevi;
CESC	cis	rs11871801	0.517	rs684214	chr17:40696915	C/T	cg14558262	chr17:40713999	COASY	0.46	5.11	0.3	6.03e-7	Crohn's disease;
CESC	cis	rs4129767	0.647	rs1976703	chr17:76401328	C/T	cg05887092	chr17:76393375	PGS1	0.7	11.77	0.59	5.13e-26	HDL cholesterol;
CESC	cis	rs1707322	1.000	rs10789479	chr1:46352500	T/C	cg06784218	chr1:46089804	CCDC17	0.35	5.87	0.34	1.33e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs6028335	0.674	rs68173814	chr20:37621180	A/G	cg16355469	chr20:37678765	NA	0.51	5.05	0.3	8.1e-7	Alcohol and nicotine co-dependence;
CESC	cis	rs9811920	0.609	rs4479633	chr3:99654510	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.64	-10.11	-0.53	1.53e-20	Axial length;
CESC	cis	rs1552244	1.000	rs58275763	chr3:10143274	C/T	cg00149659	chr3:10157352	C3orf10	0.73	8.97	0.48	5.62e-17	Alzheimer's disease;
CESC	cis	rs637571	0.615	rs10160792	chr11:65667149	C/G	cg04055107	chr11:65626734	MUS81;CFL1	0.56	6.75	0.38	9.51e-11	Eosinophil percentage of white cells;
CESC	cis	rs7945705	0.747	rs1123936	chr11:9003306	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.41	-6.78	-0.38	7.63e-11	Hemoglobin concentration;
CESC	trans	rs9929218	0.906	rs4783571	chr16:68806778	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.61	-8.03	-0.44	3.1e-14	Colorectal cancer;
CESC	cis	rs9457247	0.588	rs35171809	chr6:167432766	A/G	cg07741184	chr6:167504864	NA	0.34	6.08	0.35	4.18e-9	Crohn's disease;
CESC	cis	rs916888	0.773	rs199535	chr17:44822662	A/G	cg01570182	chr17:44337453	NA	0.88	10.36	0.54	2.51e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs6459788	0.657	rs887627	chr7:157237391	G/A	cg06271696	chr7:157225062	NA	-0.38	-5.15	-0.3	4.97e-7	Epstein-Barr virus copy number in lymphoblastoid cell lines;
CESC	cis	rs9660992	0.547	rs748012	chr1:205216573	C/T	cg00857998	chr1:205179979	DSTYK	0.54	6.51	0.37	3.83e-10	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs7586879	0.658	rs7563204	chr2:25125075	T/G	cg01884057	chr2:25150051	NA	0.36	7.01	0.4	2.02e-11	Body mass index;
CESC	cis	rs9814567	0.752	rs6764764	chr3:134331167	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	0.37	5.22	0.31	3.66e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs7219021	0.961	rs7209108	chr17:46863898	C/T	cg16584676	chr17:46985605	UBE2Z	-0.69	-7.36	-0.41	2.37e-12	Schizophrenia or bipolar disorder;
CESC	cis	rs17253792	0.915	rs75862063	chr14:56177769	G/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.74	5.1	0.3	6.53e-7	Putamen volume;
CESC	cis	rs9649213	0.593	rs6975156	chr7:97925534	T/C	cg21770322	chr7:97807741	LMTK2	0.54	8.13	0.45	1.67e-14	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs796364	1.000	rs769949	chr2:200729558	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.89	8.76	0.47	2.4e-16	Schizophrenia;
CESC	cis	rs4409675	0.576	rs10751724	chr1:28215631	C/T	cg23691781	chr1:28212827	C1orf38	0.29	5.67	0.33	3.72e-8	Corneal astigmatism;
CESC	cis	rs2439831	0.850	rs16963953	chr15:44081719	A/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.71	6.87	0.39	4.52e-11	Lung cancer in ever smokers;
CESC	cis	rs7208859	0.623	rs7503542	chr17:29073830	A/C	cg14008862	chr17:28927542	LRRC37B2	0.65	5.14	0.3	5.34e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs116095464	0.510	rs7714944	chr5:231765	C/T	cg12570787	chr5:219185	SDHA;CCDC127	0.51	5.36	0.31	1.84e-7	Breast cancer;
CESC	cis	rs875971	0.895	rs12531677	chr7:65769086	G/A	cg19163074	chr7:65112434	INTS4L2	0.41	5.27	0.31	2.89e-7	Aortic root size;
CESC	trans	rs4129059	0.850	rs17023117	chr1:214680818	T/C	cg08821431	chr12:34491090	NA	0.59	6.63	0.38	1.91e-10	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs11673344	0.528	rs579452	chr19:37410838	C/T	cg27390819	chr19:37464633	NA	-0.34	-5.12	-0.3	5.92e-7	Obesity-related traits;
CESC	cis	rs1509123	0.609	rs78980938	chr17:6703825	T/C	cg12642237	chr17:6703447	TEKT1	-0.62	-5.08	-0.3	7.26e-7	Blood metabolite levels;
CESC	cis	rs1552244	1.000	rs6791810	chr3:10124444	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	0.82	11.95	0.59	1.25e-26	Alzheimer's disease;
CESC	cis	rs5167	0.525	rs11083752	chr19:45454363	G/A	cg13119609	chr19:45449297	APOC2	0.49	8.03	0.44	3.23e-14	Blood protein levels;
CESC	cis	rs10870270	0.956	rs10870281	chr10:133762642	G/A	cg26149184	chr10:133730230	NA	0.37	5.09	0.3	6.69e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	trans	rs8073060	0.660	rs34184070	chr17:34003810	A/G	cg19694781	chr19:47549865	TMEM160	-0.71	-6.74	-0.38	9.95e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	cis	rs7618915	0.501	rs13079063	chr3:52744460	A/G	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.64	0.38	1.78e-10	Bipolar disorder;
CESC	cis	rs7772486	0.597	rs7746618	chr6:146281367	T/C	cg23711669	chr6:146136114	FBXO30	-0.93	-12.07	-0.6	4.93e-27	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4604732	0.631	rs74154672	chr1:247625625	C/G	cg12758973	chr1:247694275	LOC148824;OR2C3	0.51	6.36	0.36	8.65e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg16791218	chr16:88105809	BANP	0.46	6.12	0.35	3.31e-9	Fibrinogen levels;
CESC	cis	rs6879260	1.000	rs6879260	chr5:179731014	A/G	cg02891314	chr5:179741120	GFPT2	-0.63	-8.38	-0.46	3.08e-15	Height;
CESC	cis	rs11252926	0.650	rs4880678	chr10:490472	G/A	cg16386425	chr10:429943	DIP2C	-0.49	-6.32	-0.36	1.1e-9	Psychosis in Alzheimer's disease;
CESC	cis	rs2652834	0.904	rs8032506	chr15:63371644	G/A	cg05507819	chr15:63340323	TPM1	-0.7	-6.32	-0.36	1.13e-9	HDL cholesterol;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05759424	chr2:42721296	KCNG3	0.53	6.2	0.36	2.16e-9	Gut microbiome composition (summer);
CESC	cis	rs9473147	0.516	rs10948363	chr6:47487762	A/G	cg20196966	chr6:47445060	CD2AP	0.41	5.33	0.31	2.13e-7	Platelet distribution width;Mean platelet volume;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg11559952	chr10:112064744	SMNDC1	-0.46	-6.06	-0.35	4.7e-9	Ulcerative colitis;
CESC	cis	rs2361710	0.611	rs12451471	chr17:78102517	C/T	cg06718696	chr17:78121285	EIF4A3	0.64	7.89	0.44	7.86e-14	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
CESC	cis	rs8064299	0.636	rs9915279	chr17:72772848	T/C	cg25054828	chr17:72772726	NAT9;TMEM104	0.87	14.53	0.67	1.37e-35	Monocyte count;
CESC	cis	rs5758659	0.652	rs5758553	chr22:42431429	G/A	cg19513890	chr22:42538836	CYP2D7P1	-0.39	-5.75	-0.33	2.46e-8	Cognitive function;
CESC	cis	rs13082711	0.834	rs2172297	chr3:27428423	C/T	cg02860705	chr3:27208620	NA	0.53	6.51	0.37	3.66e-10	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CESC	cis	rs10461617	0.617	rs79742142	chr5:56104377	A/G	cg22800045	chr5:56110881	MAP3K1	0.83	10.09	0.53	1.85e-20	Type 2 diabetes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19630102	chr14:68067023	PIGH	0.56	6.07	0.35	4.29e-9	Gut microbiome composition (summer);
CESC	cis	rs7208859	0.623	rs1061343	chr17:29114276	G/A	cg14008862	chr17:28927542	LRRC37B2	0.65	5.14	0.3	5.34e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs35306767	0.855	rs34251037	chr10:867884	C/T	cg26597838	chr10:835615	NA	1.18	11.47	0.58	5.21e-25	Eosinophil percentage of granulocytes;
CESC	cis	rs6540559	0.673	rs11803382	chr1:209986426	G/A	cg25204440	chr1:209979598	IRF6	0.65	6.61	0.38	2.16e-10	Cleft lip with or without cleft palate;
CESC	cis	rs9902453	0.904	rs7218379	chr17:28402737	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.69	-9.08	-0.49	2.59e-17	Coffee consumption (cups per day);
CESC	cis	rs709400	0.567	rs11624343	chr14:103859156	T/A	cg12935359	chr14:103987150	CKB	-0.5	-7.1	-0.4	1.12e-11	Body mass index;
CESC	trans	rs1814175	0.781	rs2866734	chr11:49886338	A/G	cg15704280	chr7:45808275	SEPT13	-1.03	-20.9	-0.79	5.71e-58	Height;
CESC	cis	rs2380220	0.872	rs2613528	chr6:95939437	C/G	cg15832292	chr6:96025679	MANEA	-0.59	-5.17	-0.3	4.67e-7	Behavioural disinhibition (generation interaction);
CESC	cis	rs2243480	1.000	rs313802	chr7:65516373	A/G	cg25894440	chr7:65020034	NA	-0.61	-5.3	-0.31	2.42e-7	Diabetic kidney disease;
CESC	cis	rs898097	0.812	rs8065641	chr17:80820259	A/G	cg10494973	chr17:80897199	TBCD	0.5	5.76	0.33	2.31e-8	Breast cancer;
CESC	trans	rs11098499	0.863	rs3822191	chr4:120428101	A/T	cg25214090	chr10:38739885	LOC399744	0.71	9.7	0.51	3.06e-19	Corneal astigmatism;
CESC	cis	rs9611565	0.694	rs202665	chr22:41814401	A/G	cg03806693	chr22:41940476	POLR3H	1.16	14.61	0.67	7.1e-36	Vitiligo;
CESC	cis	rs595982	0.559	rs73061632	chr19:49361663	G/A	cg15549821	chr19:49342101	PLEKHA4	-0.7	-7.94	-0.44	5.83e-14	Red cell distribution width;
CESC	cis	rs2576037	0.526	rs1893427	chr18:44434987	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.72	11.51	0.58	4.01e-25	Personality dimensions;
CESC	cis	rs67311347	1.000	rs6762251	chr3:40531136	A/G	cg24209194	chr3:40518798	ZNF619	-0.48	-6.14	-0.35	2.92e-9	Renal cell carcinoma;
CESC	cis	rs769267	0.930	rs3752151	chr19:19616026	T/C	cg03709012	chr19:19516395	GATAD2A	1.02	15.57	0.69	2.98e-39	Tonsillectomy;
CESC	cis	rs963731	0.649	rs297143	chr2:39320067	T/C	cg04010122	chr2:39346883	SOS1	-0.74	-5.39	-0.31	1.54e-7	Corticobasal degeneration;
CESC	cis	rs9322193	0.962	rs9765929	chr6:150090816	T/C	cg13206674	chr6:150067644	NUP43	0.42	5.84	0.34	1.48e-8	Lung cancer;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg19839149	chr2:192542877	OBFC2A	-0.5	-6.44	-0.37	5.65e-10	Fibrinogen levels;
CESC	cis	rs7727544	0.735	rs274557	chr5:131721204	T/C	cg24060327	chr5:131705240	SLC22A5	0.68	9.31	0.5	5.19e-18	Blood metabolite levels;
CESC	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg22029157	chr1:209979665	IRF6	0.8	15.43	0.69	9.32e-39	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
CESC	cis	rs11048434	0.636	rs11047953	chr12:9064923	A/C	cg04155231	chr12:9217510	LOC144571	0.33	5.34	0.31	2.03e-7	Sjögren's syndrome;
CESC	cis	rs12410462	1.000	rs75652886	chr1:227654485	G/T	cg04117972	chr1:227635322	NA	0.63	6.25	0.36	1.61e-9	Major depressive disorder;
CESC	cis	rs977987	0.843	rs6564260	chr16:75447426	A/G	cg03315344	chr16:75512273	CHST6	0.41	5.83	0.34	1.59e-8	Dupuytren's disease;
CESC	trans	rs9929218	0.551	rs2296409	chr16:68713730	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.98	16.94	0.72	4.01e-44	Colorectal cancer;
CESC	cis	rs7927771	1.000	rs11039412	chr11:47841581	G/A	cg05585544	chr11:47624801	NA	-0.49	-7.71	-0.43	2.62e-13	Subjective well-being;
CESC	cis	rs12142240	0.698	rs17361791	chr1:46812519	A/G	cg10495392	chr1:46806563	NSUN4	0.57	6.29	0.36	1.33e-9	Menopause (age at onset);
CESC	cis	rs9916302	0.904	rs7216086	chr17:37709422	G/A	cg00129232	chr17:37814104	STARD3	-0.6	-8.01	-0.44	3.61e-14	Glomerular filtration rate (creatinine);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg25411849	chr6:89855994	PM20D2	0.44	6.15	0.35	2.9e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs78889164	1.000	rs7250283	chr19:33863386	C/T	cg02272751	chr19:33882848	PEPD	-0.5	-6.67	-0.38	1.5e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7124681	0.546	rs7941399	chr11:47890421	A/T	cg18512352	chr11:47633146	NA	0.35	5.42	0.32	1.35e-7	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
CESC	cis	rs853679	0.599	rs156743	chr6:27967089	T/C	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.81	6.71	0.38	1.18e-10	Depression;
CESC	cis	rs1862618	0.853	rs10051747	chr5:56083289	C/A	cg12311346	chr5:56204834	C5orf35	-0.74	-8.78	-0.47	2.02e-16	Initial pursuit acceleration;
CESC	cis	rs6732160	0.934	rs2421390	chr2:73379103	T/C	cg01422370	chr2:73384389	NA	0.51	8.7	0.47	3.52e-16	Intelligence (multi-trait analysis);
CESC	cis	rs826838	1.000	rs851934	chr12:39104453	G/T	cg13010199	chr12:38710504	ALG10B	-0.4	-5.4	-0.31	1.52e-7	Heart rate;
CESC	cis	rs9611565	0.765	rs132914	chr22:41805749	T/C	cg06634786	chr22:41940651	POLR3H	0.71	7.47	0.42	1.16e-12	Vitiligo;
CESC	cis	rs2033711	0.870	rs7259841	chr19:58951123	T/C	cg26874164	chr19:58962979	ZNF324B	0.57	8.1	0.45	2.05e-14	Uric acid clearance;
CESC	cis	rs6539267	0.516	rs17218455	chr12:106716441	C/T	cg00173435	chr12:106696525	TCP11L2	0.63	5.68	0.33	3.59e-8	Tourette syndrome;
CESC	cis	rs1799949	0.965	rs33925201	chr17:41280682	A/G	cg25072359	chr17:41440525	NA	0.43	5.78	0.33	2.04e-8	Menopause (age at onset);
CESC	cis	rs826838	0.967	rs34496261	chr12:39023829	G/A	cg13010199	chr12:38710504	ALG10B	0.58	8.1	0.45	2.01e-14	Heart rate;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11644123	chr17:79936123	ASPSCR1	-0.55	-6.69	-0.38	1.32e-10	Gut microbiome composition (summer);
CESC	cis	rs8180040	0.726	rs61729713	chr3:47027192	A/G	cg27129171	chr3:47204927	SETD2	-0.63	-9.01	-0.48	4.25e-17	Colorectal cancer;
CESC	cis	rs7666738	0.830	rs6532719	chr4:99043691	A/G	cg05340658	chr4:99064831	C4orf37	0.8	12.39	0.61	3.91e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1129187	0.837	rs3763236	chr6:42902508	C/T	cg21280719	chr6:42927975	GNMT	0.29	7.21	0.4	5.99e-12	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs12220238	1.000	rs10824085	chr10:75911984	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.64	6.45	0.37	5.41e-10	Soluble interleukin-2 receptor subunit alpha;
CESC	cis	rs1003719	0.788	rs2835575	chr21:38455936	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.62	8.67	0.47	4.41e-16	Eye color traits;
CESC	cis	rs9902453	1.000	rs9897206	chr17:28406108	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.63	-8.05	-0.44	2.78e-14	Coffee consumption (cups per day);
CESC	cis	rs17253792	0.822	rs10483646	chr14:56103872	A/C	cg01858014	chr14:56050164	KTN1	-0.96	-6.51	-0.37	3.65e-10	Putamen volume;
CESC	cis	rs7107174	1.000	rs2512549	chr11:77940163	A/G	cg02023728	chr11:77925099	USP35	-0.46	-6.71	-0.38	1.17e-10	Testicular germ cell tumor;
CESC	cis	rs4665809	0.590	rs1056389	chr2:26502875	T/C	cg26119090	chr2:26468346	HADHA;HADHB	1.09	11.83	0.59	3.18e-26	Gut microbiome composition (summer);
CESC	cis	rs2033711	0.870	rs4801270	chr19:58932762	C/A	cg00825309	chr19:58991885	ZNF446	-0.54	-7.71	-0.43	2.62e-13	Uric acid clearance;
CESC	cis	rs7412746	0.658	rs8444	chr1:150938571	G/A	cg04414720	chr1:150670196	GOLPH3L	0.51	6.81	0.39	6.39e-11	Melanoma;
CESC	cis	rs854765	0.647	rs62073573	chr17:17976354	G/A	cg16928487	chr17:17741425	SREBF1	-0.52	-8.27	-0.45	6.36e-15	Total body bone mineral density;
CESC	trans	rs7937682	0.924	rs10891284	chr11:111527737	T/C	cg18187862	chr3:45730750	SACM1L	0.48	6.08	0.35	4.15e-9	Primary sclerosing cholangitis;
CESC	cis	rs7777484	0.534	rs2533888	chr7:2831083	T/C	cg09658497	chr7:2847517	GNA12	-0.45	-7.04	-0.4	1.63e-11	Height;
CESC	cis	rs854765	0.693	rs8079321	chr17:17760789	C/T	cg09796270	chr17:17721594	SREBF1	0.4	5.81	0.34	1.79e-8	Total body bone mineral density;
CESC	cis	rs2119480	0.731	rs369788	chr13:111305787	C/T	cg16216153	chr13:111290848	CARKD	-0.35	-5.27	-0.31	2.82e-7	Diastolic blood pressure;
CESC	cis	rs4665809	1.000	rs12471809	chr2:26307140	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.69	-7.8	-0.43	1.42e-13	Gut microbiome composition (summer);
CESC	cis	rs2979489	0.740	rs17554408	chr8:30427531	A/G	cg26383811	chr8:30366931	RBPMS	0.76	9.05	0.49	3.24e-17	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CESC	cis	rs3785574	0.886	rs62077504	chr17:61837734	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.59	7.18	0.4	7.06e-12	Height;
CESC	cis	rs2197308	0.765	rs117216293	chr12:37882982	T/C	cg26384229	chr12:38710491	ALG10B	-0.55	-7.82	-0.43	1.26e-13	Morning vs. evening chronotype;
CESC	cis	rs60871478	0.636	rs7792072	chr7:886239	C/T	cg05535760	chr7:792225	HEATR2	-0.78	-8.24	-0.45	8.16e-15	Cerebrospinal P-tau181p levels;
CESC	cis	rs60154123	0.772	rs701942	chr1:210429392	C/G	cg22029157	chr1:209979665	IRF6	0.49	5.75	0.33	2.4e-8	Coronary artery disease;
CESC	cis	rs10504229	0.680	rs16921675	chr8:58052082	A/G	cg24829409	chr8:58192753	C8orf71	-0.48	-6.1	-0.35	3.75e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs6690583	0.697	rs4907126	chr1:85523453	C/T	cg11262906	chr1:85462892	MCOLN2	0.43	5.21	0.31	3.73e-7	Serum sulfate level;
CESC	cis	rs780096	0.545	rs2280737	chr2:27589810	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.28	-5.35	-0.31	1.89e-7	Total body bone mineral density;
CESC	cis	rs2404602	0.647	rs62026889	chr15:76917885	C/T	cg23625390	chr15:77176239	SCAPER	-0.45	-6.3	-0.36	1.26e-9	Blood metabolite levels;
CESC	cis	rs75064307	0.834	rs4855562	chr3:108116835	C/T	cg03329597	chr3:108125523	MYH15	0.52	5.91	0.34	1.05e-8	Intelligence (multi-trait analysis);
CESC	cis	rs258892	0.793	rs56762233	chr5:72056882	A/G	cg21869765	chr5:72125136	TNPO1	-0.42	-5.24	-0.31	3.2e-7	Small cell lung carcinoma;
CESC	cis	rs7772486	0.806	rs7740785	chr6:146171299	C/A	cg23711669	chr6:146136114	FBXO30	0.84	12.35	0.6	5.79e-28	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs9650657	0.645	rs11774552	chr8:10515679	C/T	cg15556689	chr8:8085844	FLJ10661	-0.5	-6.44	-0.37	5.6e-10	Neuroticism;
CESC	cis	rs28489187	0.706	rs233099	chr1:85826194	T/C	cg16011679	chr1:85725395	C1orf52	0.48	5.55	0.32	7.04e-8	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	cis	rs514406	0.644	rs7552663	chr1:53204352	C/T	cg24675658	chr1:53192096	ZYG11B	0.64	8.84	0.48	1.36e-16	Monocyte count;
CESC	cis	rs9858542	1.000	rs9812791	chr3:49682311	G/A	cg03060546	chr3:49711283	APEH	-0.59	-6.96	-0.39	2.64e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs66530629	0.797	rs12758422	chr1:25078061	T/C	cg22509179	chr1:25234806	RUNX3	-0.48	-6.21	-0.36	2.03e-9	Plateletcrit;
CESC	cis	rs2549003	1.000	rs9282762	chr5:131822055	T/C	cg02551604	chr5:131831745	NA	-0.37	-5.27	-0.31	2.81e-7	Asthma (sex interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11255265	chr4:152246909	NA	-0.59	-7.19	-0.4	6.78e-12	Gut microbiome composition (summer);
CESC	cis	rs2108622	0.727	rs8101038	chr19:15982864	C/T	cg13772218	chr19:15982569	NA	0.29	5.8	0.34	1.85e-8	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CESC	cis	rs2735413	0.837	rs4888735	chr16:78083742	C/T	cg04733911	chr16:78082701	NA	-0.53	-8.89	-0.48	9.44e-17	Systolic blood pressure (alcohol consumption interaction);
CESC	cis	rs763121	0.853	rs9306329	chr22:39072454	C/T	cg06544989	chr22:39130855	UNC84B	0.5	8.88	0.48	1.05e-16	Menopause (age at onset);
CESC	cis	rs7590720	0.731	rs1864253	chr2:216878008	C/G	cg12620499	chr2:216877984	MREG	0.96	15.3	0.68	2.71e-38	Alcohol dependence;
CESC	cis	rs8031584	0.723	rs11632229	chr15:31179534	A/G	cg14298792	chr15:30685198	CHRFAM7A	0.43	5.2	0.3	3.98e-7	Huntington's disease progression;
CESC	cis	rs1270639	0.778	rs2906930	chr7:157446453	T/C	cg13357408	chr7:157437802	PTPRN2	0.61	7.15	0.4	8.33e-12	Colorectal cancer;
CESC	trans	rs11098499	0.954	rs10518331	chr4:120323595	C/T	cg25214090	chr10:38739885	LOC399744	0.7	9.92	0.52	6.5e-20	Corneal astigmatism;
CESC	trans	rs11039798	0.925	rs7929225	chr11:48931739	G/C	cg15704280	chr7:45808275	SEPT13	0.7	6.56	0.37	2.74e-10	Axial length;
CESC	cis	rs8114671	0.967	rs2378337	chr20:33771435	G/A	cg24642439	chr20:33292090	TP53INP2	0.44	5.37	0.31	1.73e-7	Height;
CESC	cis	rs9611519	0.828	rs4822008	chr22:41539206	C/G	cg03806693	chr22:41940476	POLR3H	-0.58	-5.89	-0.34	1.15e-8	Neuroticism;
CESC	cis	rs1998418	0.736	rs4962401	chr10:126423706	G/A	cg03585084	chr10:126284563	LHPP	0.43	5.03	0.3	9.08e-7	Mean platelet volume;
CESC	cis	rs1045902	0.583	rs2303904	chr2:73447775	C/T	cg01422370	chr2:73384389	NA	-0.35	-5.55	-0.32	7.1e-8	Intelligence (multi-trait analysis);
CESC	cis	rs9649213	0.593	rs6465666	chr7:97937258	C/T	cg08684580	chr7:98029266	BAIAP2L1	0.33	5.34	0.31	1.96e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs75477785	0.590	rs12073617	chr1:210259974	G/T	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.83	5.69	0.33	3.36e-8	Cleft lip with or without cleft palate;
CESC	cis	rs3768617	0.510	rs723014	chr1:183076287	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.88	14.2	0.66	2.05e-34	Fuchs's corneal dystrophy;
CESC	cis	rs793571	0.592	rs72745053	chr15:59159259	G/A	cg05156742	chr15:59063176	FAM63B	-0.6	-8.39	-0.46	3.03e-15	Schizophrenia;
CESC	cis	rs6502050	0.871	rs6502051	chr17:80059332	A/C	cg11859384	chr17:80120422	CCDC57	0.39	5.49	0.32	9.6e-8	Life satisfaction;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg06062848	chr18:60194352	ZCCHC2	0.46	6.01	0.35	6.12e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs17666538	0.792	rs1703912	chr8:600643	A/G	cg07234876	chr8:600039	NA	0.82	6.47	0.37	4.82e-10	IgG glycosylation;
CESC	cis	rs4664304	0.900	rs3828327	chr2:160742095	G/A	cg03641300	chr2:160917029	PLA2R1	-0.46	-6.48	-0.37	4.57e-10	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs11098499	0.874	rs17839089	chr4:120111069	A/G	cg09307838	chr4:120376055	NA	0.67	8.32	0.45	4.79e-15	Corneal astigmatism;
CESC	cis	rs875971	0.928	rs2036263	chr7:65800197	C/T	cg12463550	chr7:65579703	CRCP	-0.47	-6.08	-0.35	4.28e-9	Aortic root size;
CESC	cis	rs13191362	1.000	rs34918316	chr6:163005386	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.88	9.1	0.49	2.28e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs524281	0.731	rs2276036	chr11:66033430	C/T	cg14036092	chr11:66035641	RAB1B	-0.54	-5.34	-0.31	2.03e-7	Electroencephalogram traits;
CESC	cis	rs7824557	0.527	rs4634600	chr8:11239017	T/A	cg21775007	chr8:11205619	TDH	-0.52	-7.89	-0.44	7.81e-14	Retinal vascular caliber;
CESC	cis	rs4665809	0.818	rs35413760	chr2:26267137	C/A	cg04944784	chr2:26401820	FAM59B	0.75	8.11	0.45	1.85e-14	Gut microbiome composition (summer);
CESC	cis	rs10504229	0.679	rs7839948	chr8:58130607	A/G	cg21724239	chr8:58056113	NA	0.58	5.95	0.34	8.29e-9	Developmental language disorder (linguistic errors);
CESC	trans	rs1814175	0.586	rs2866862	chr11:49954588	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.41	-6.15	-0.35	2.82e-9	Height;
CESC	cis	rs2836633	0.929	rs62217517	chr21:40033177	T/A	cg12884169	chr21:40033163	ERG	0.38	5.99	0.35	6.69e-9	Coronary artery disease;
CESC	cis	rs738322	0.967	rs132971	chr22:38561911	T/G	cg17652424	chr22:38574118	PLA2G6	-0.34	-6.16	-0.35	2.71e-9	Cutaneous nevi;
CESC	cis	rs9660992	0.686	rs1668870	chr1:205239031	C/G	cg21643547	chr1:205240462	TMCC2	-0.47	-6.34	-0.36	1.01e-9	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs901683	1.000	rs12779281	chr10:45977447	T/C	cg16031567	chr10:46195673	NA	-0.75	-5.04	-0.3	8.78e-7	Red blood cell traits;Mean corpuscular volume;
CESC	cis	rs1707322	0.721	rs12091503	chr1:46107868	T/C	cg05343316	chr1:45956843	TESK2	0.51	6.22	0.36	1.91e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs67311347	1.000	rs12633431	chr3:40505740	C/T	cg01475735	chr3:40494733	NA	0.43	5.32	0.31	2.18e-7	Renal cell carcinoma;
CESC	cis	rs1707322	0.963	rs10789484	chr1:46406978	G/C	cg03146154	chr1:46216737	IPP	0.72	9.82	0.52	1.31e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs72634258	0.945	rs161802	chr1:8042826	G/T	cg00042356	chr1:8021962	PARK7	0.46	5.24	0.31	3.24e-7	Inflammatory bowel disease;
CESC	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg10819733	chr22:24237672	NA	-0.35	-5.07	-0.3	7.33e-7	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs4718428	0.705	rs11028	chr7:66276217	T/C	cg25985355	chr7:65971099	NA	-0.35	-5.14	-0.3	5.27e-7	Corneal structure;
CESC	cis	rs9649213	0.574	rs7790229	chr7:97919338	G/A	cg00277769	chr7:97922759	BAIAP2L1	-0.35	-5.56	-0.32	6.6e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs6089584	0.927	rs3787427	chr20:60579789	T/C	cg06108461	chr20:60628389	TAF4	-0.81	-11.72	-0.58	7.56e-26	Body mass index;
CESC	cis	rs1218582	0.772	rs4845694	chr1:154911651	C/G	cg09359103	chr1:154839909	KCNN3	-0.66	-12.34	-0.6	5.93e-28	Prostate cancer;
CESC	cis	rs7546094	1.000	rs12126277	chr1:113106369	A/G	cg22162597	chr1:113214053	CAPZA1	0.37	5.67	0.33	3.69e-8	Platelet distribution width;
CESC	trans	rs4596713	0.538	rs10125494	chr9:71770861	C/G	cg16512924	chr15:28394682	HERC2	0.5	6.29	0.36	1.33e-9	Headache;
CESC	cis	rs854765	0.583	rs6502622	chr17:17834691	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.56	7.98	0.44	4.3e-14	Total body bone mineral density;
CESC	cis	rs7666738	0.753	rs4699604	chr4:99056353	T/C	cg03676636	chr4:99064102	C4orf37	0.34	5.11	0.3	6.14e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1008375	0.966	rs3775927	chr4:17599894	G/T	cg04450456	chr4:17643702	FAM184B	0.36	5.1	0.3	6.6e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs1934955	0.537	rs7097433	chr10:96776966	C/T	cg09036531	chr10:96991505	NA	-0.37	-5.07	-0.3	7.45e-7	Blood metabolite levels;
CESC	trans	rs6021270	0.678	rs6021264	chr20:50134683	C/T	cg05339727	chr2:165812079	SLC38A11	0.74	6.34	0.36	9.63e-10	Self-reported allergy;
CESC	cis	rs55882075	0.967	rs62404346	chr5:179141391	A/C	cg14593053	chr5:179126677	CANX	0.46	6.03	0.35	5.46e-9	Monocyte percentage of white cells;
CESC	cis	rs17826219	0.706	rs609472	chr17:28951427	T/C	cg14008862	chr17:28927542	LRRC37B2	0.7	6.26	0.36	1.53e-9	Body mass index;
CESC	cis	rs3733585	0.736	rs4543113	chr4:10008305	G/A	cg02734326	chr4:10020555	SLC2A9	0.47	6.43	0.37	5.87e-10	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs61931739	0.517	rs10844802	chr12:34231001	C/A	cg19457237	chr12:34500585	NA	-0.38	-5.29	-0.31	2.52e-7	Morning vs. evening chronotype;
CESC	cis	rs763014	0.865	rs8675	chr16:633843	A/G	cg07256732	chr16:621771	PIGQ	-0.3	-5.15	-0.3	5.06e-7	Height;
CESC	cis	rs9916302	0.904	rs2303316	chr17:37704217	A/G	cg15445000	chr17:37608096	MED1	0.39	6.46	0.37	5.01e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs10461617	0.617	rs6874733	chr5:56069600	A/G	cg22800045	chr5:56110881	MAP3K1	0.62	7.56	0.42	6.71e-13	Type 2 diabetes;
CESC	cis	rs9916302	0.904	rs12600751	chr17:37553651	G/C	cg00129232	chr17:37814104	STARD3	0.54	6.57	0.37	2.66e-10	Glomerular filtration rate (creatinine);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg05046026	chr11:61559981	C11orf10;FEN1;MIR611	-0.5	-6.97	-0.39	2.55e-11	Fibrinogen levels;
CESC	cis	rs684232	0.583	rs2657626	chr17:603052	A/G	cg12384639	chr17:618140	VPS53	0.4	5.3	0.31	2.48e-7	Prostate cancer;
CESC	trans	rs561341	0.689	rs578635	chr17:30289897	A/C	cg20587970	chr11:113659929	NA	-0.56	-7.18	-0.4	6.87e-12	Hip circumference adjusted for BMI;
CESC	trans	rs2727020	0.636	rs11040368	chr11:49453602	C/A	cg03929089	chr4:120376271	NA	-0.82	-12.78	-0.62	1.78e-29	Coronary artery disease;
CESC	cis	rs9640161	0.789	rs10952250	chr7:150025966	T/C	cg10018233	chr7:150070692	REPIN1	0.44	7.32	0.41	2.96e-12	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs4423214	1.000	rs2276360	chr11:71169547	C/G	cg05163923	chr11:71159392	DHCR7	0.8	11.04	0.56	1.41e-23	Vitamin D levels;
CESC	cis	rs780096	0.526	rs10182937	chr2:27651693	T/C	cg24768116	chr2:27665128	KRTCAP3	-0.3	-5.57	-0.32	6.2e-8	Total body bone mineral density;
CESC	cis	rs7666738	0.830	rs4502686	chr4:98765117	T/C	cg03676636	chr4:99064102	C4orf37	0.34	5.12	0.3	5.85e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4665809	0.652	rs2241739	chr2:26411894	C/T	cg25036284	chr2:26402008	FAM59B	-0.8	-9.57	-0.51	8.13e-19	Gut microbiome composition (summer);
CESC	cis	rs9583531	0.600	rs7330080	chr13:111367115	C/T	cg24331049	chr13:111365604	ING1	0.71	10.88	0.56	5.07e-23	Coronary artery disease;
CESC	cis	rs10464366	0.544	rs12701697	chr7:39182165	C/T	cg18850127	chr7:39170497	POU6F2	0.37	5.18	0.3	4.43e-7	IgG glycosylation;
CESC	cis	rs9815354	0.857	rs9816772	chr3:41872877	C/T	cg03022575	chr3:42003672	ULK4	0.49	5.52	0.32	7.99e-8	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs2576037	0.583	rs530205	chr18:44385150	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.76	12.31	0.6	7.38e-28	Personality dimensions;
CESC	cis	rs72615157	0.612	rs7786505	chr7:99817585	G/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.61	6.91	0.39	3.69e-11	Lung function (FEV1/FVC);
CESC	cis	rs2204008	0.837	rs11168504	chr12:37964922	G/T	cg26384229	chr12:38710491	ALG10B	0.73	10.65	0.55	2.71e-22	Bladder cancer;
CESC	cis	rs1670533	1.000	rs7660779	chr4:1075940	A/G	cg27284194	chr4:1044797	NA	0.48	6.06	0.35	4.69e-9	Recombination rate (females);
CESC	cis	rs4330281	0.765	rs7645459	chr3:17808236	C/G	cg20981856	chr3:17787350	NA	0.38	5.4	0.31	1.49e-7	Schizophrenia;
CESC	cis	rs644799	0.544	rs1727165	chr11:95521648	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.61	8.27	0.45	6.69e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs748404	0.660	rs690012	chr15:43719755	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.58	7.55	0.42	7.18e-13	Lung cancer;
CESC	cis	rs9858542	0.953	rs9824092	chr3:49674147	C/G	cg03060546	chr3:49711283	APEH	-0.57	-6.74	-0.38	9.8e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs4588572	0.570	rs6453389	chr5:77727003	T/G	cg11547950	chr5:77652471	NA	-0.4	-5.56	-0.32	6.68e-8	Triglycerides;
CESC	cis	rs7666738	0.830	rs1426669	chr4:98945534	C/T	cg17366294	chr4:99064904	C4orf37	0.6	8.53	0.46	1.15e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10504229	0.861	rs6990617	chr8:58182960	G/T	cg05313129	chr8:58192883	C8orf71	-0.55	-6.29	-0.36	1.34e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs977987	0.806	rs35683383	chr16:75479277	G/T	cg03315344	chr16:75512273	CHST6	0.45	6.55	0.37	2.97e-10	Dupuytren's disease;
CESC	cis	rs3820068	0.532	rs78917815	chr1:15920821	A/G	cg17385448	chr1:15911702	AGMAT	0.42	6.72	0.38	1.13e-10	Systolic blood pressure;
CESC	cis	rs12249377	0.519	rs11599902	chr10:92598823	A/G	cg14313238	chr10:92632228	RPP30	0.45	5.63	0.33	4.62e-8	White matter microstructure (global fractional anisotropy);
CESC	trans	rs208520	0.661	rs4710566	chr6:66848538	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.0	-13.15	-0.63	9.82e-31	Exhaled nitric oxide output;
CESC	trans	rs694739	0.726	rs17857342	chr11:64138905	T/G	cg01888411	chr11:34378293	ABTB2	0.4	6.1	0.35	3.79e-9	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25390656	chr10:92980550	PCGF5	0.53	6.2	0.36	2.21e-9	Gut microbiome composition (summer);
CESC	cis	rs9303542	0.559	rs35621842	chr17:46606222	C/T	cg04904318	chr17:46607828	HOXB1	-0.64	-6.33	-0.36	1.05e-9	Ovarian cancer;Epithelial ovarian cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16322581	chr12:70636648	CNOT2	0.6	7.33	0.41	2.77e-12	Gut microbiome composition (summer);
CESC	cis	rs3106136	0.527	rs4235050	chr4:95157156	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.7	-11.56	-0.58	2.74e-25	Capecitabine sensitivity;
CESC	cis	rs4595586	0.545	rs6580910	chr12:39390052	C/A	cg26384229	chr12:38710491	ALG10B	0.54	7.64	0.42	3.96e-13	Morning vs. evening chronotype;
CESC	cis	rs6714710	0.603	rs116309486	chr2:98493359	A/G	cg26665480	chr2:98280029	ACTR1B	0.6	8.14	0.45	1.57e-14	Posterior cortical atrophy and Alzheimer's disease;
CESC	cis	rs959260	0.557	rs12946365	chr17:73317644	C/T	cg20590849	chr17:73267439	MIF4GD	-0.43	-5.39	-0.31	1.57e-7	Systemic lupus erythematosus;
CESC	cis	rs1670533	1.000	rs2100411	chr4:1074412	T/C	cg27284194	chr4:1044797	NA	0.47	5.91	0.34	1.04e-8	Recombination rate (females);
CESC	cis	rs7107174	0.901	rs7941639	chr11:78116959	A/G	cg02023728	chr11:77925099	USP35	-0.45	-6.13	-0.35	3.09e-9	Testicular germ cell tumor;
CESC	cis	rs9443189	0.774	rs2647405	chr6:76450023	C/T	cg01950844	chr6:76311363	SENP6	-0.59	-6.53	-0.37	3.32e-10	Prostate cancer;
CESC	cis	rs7772486	0.790	rs1854900	chr6:146331382	G/A	cg23711669	chr6:146136114	FBXO30	0.83	12.15	0.6	2.6e-27	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2235642	0.893	rs2076445	chr16:1592266	A/T	cg03771183	chr16:1608904	IFT140	0.41	5.92	0.34	1.02e-8	Coronary artery disease;
CESC	cis	rs6933660	0.800	rs13201167	chr6:151773504	T/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.64	8.94	0.48	6.76e-17	Menarche (age at onset);
CESC	cis	rs28386778	0.799	rs12450683	chr17:61984299	C/G	cg06873352	chr17:61820015	STRADA	0.66	11.67	0.58	1.17e-25	Prudent dietary pattern;
CESC	cis	rs2230307	0.572	rs11805428	chr1:100641716	T/C	cg24955406	chr1:100503596	HIAT1	-0.5	-5.03	-0.3	9.2e-7	Carotid intima media thickness;
CESC	cis	rs7520050	0.807	rs5021934	chr1:46109304	A/G	cg06784218	chr1:46089804	CCDC17	-0.33	-6.08	-0.35	4.22e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs7107174	1.000	rs7939646	chr11:78111613	C/T	cg02023728	chr11:77925099	USP35	-0.37	-5.3	-0.31	2.49e-7	Testicular germ cell tumor;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13975660	chr4:114681840	CAMK2D	-0.52	-6.02	-0.35	5.79e-9	Gut microbiome composition (summer);
CESC	cis	rs634534	0.532	rs12794370	chr11:65770413	G/A	cg02202077	chr11:65769826	EIF1AD;BANF1	0.47	6.47	0.37	4.71e-10	Sum eosinophil basophil counts;Eosinophil counts;
CESC	cis	rs897984	0.762	rs7204459	chr16:30984212	G/A	cg02466173	chr16:30829666	NA	0.48	8.1	0.45	1.99e-14	Dementia with Lewy bodies;
CESC	cis	rs4812048	0.649	rs3761257	chr20:57618787	C/T	cg14073986	chr20:57617431	SLMO2	0.85	7.61	0.42	4.71e-13	Mean platelet volume;
CESC	cis	rs7927771	0.832	rs11607981	chr11:47401060	T/G	cg20307385	chr11:47447363	PSMC3	-0.6	-7.31	-0.41	3.23e-12	Subjective well-being;
CESC	cis	rs8114671	0.901	rs6119581	chr20:33773689	T/A	cg24642439	chr20:33292090	TP53INP2	0.44	5.29	0.31	2.55e-7	Height;
CESC	cis	rs1862618	0.802	rs252900	chr5:56185281	T/A	cg18230493	chr5:56204884	C5orf35	-0.73	-8.57	-0.47	8.93e-16	Initial pursuit acceleration;
CESC	trans	rs27434	0.561	rs35134	chr5:96159523	A/G	cg13971232	chr2:236901460	AGAP1	0.41	6.24	0.36	1.77e-9	Ankylosing spondylitis;
CESC	cis	rs9487051	0.676	rs6568560	chr6:109592851	G/A	cg01475377	chr6:109611718	NA	-0.44	-6.99	-0.39	2.19e-11	Reticulocyte fraction of red cells;
CESC	cis	rs4566357	0.615	rs10190621	chr2:227914484	A/G	cg05526886	chr2:227700861	RHBDD1	-0.46	-6.1	-0.35	3.74e-9	Coronary artery disease;
CESC	cis	rs8072100	0.967	rs8072644	chr17:45653364	A/T	cg08085267	chr17:45401833	C17orf57	0.39	5.12	0.3	5.76e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs6736093	0.769	rs56361454	chr2:112774105	C/T	cg12686935	chr2:112915763	FBLN7	-0.38	-5.24	-0.31	3.26e-7	Coronary artery disease;
CESC	trans	rs11088226	0.681	rs1134747	chr21:33939011	T/A	cg09050820	chr6:167586206	TCP10L2	0.83	7.75	0.43	2.01e-13	Gastritis;
CESC	cis	rs1018836	0.828	rs9297870	chr8:91570691	C/G	cg16814680	chr8:91681699	NA	-0.63	-9.19	-0.49	1.15e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs1023500	0.529	rs133375	chr22:42466509	C/G	cg04733989	chr22:42467013	NAGA	0.79	12.05	0.59	5.98e-27	Schizophrenia;
CESC	cis	rs2932538	0.961	rs2932529	chr1:113193364	G/A	cg22162597	chr1:113214053	CAPZA1	-0.6	-7.51	-0.42	8.99e-13	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CESC	trans	rs7902708	0.920	rs74133652	chr10:54424356	G/C	cg26219051	chr22:43739629	SCUBE1	-0.49	-6.32	-0.36	1.09e-9	Bone properties (heel);
CESC	cis	rs514406	0.861	rs1749907	chr1:53259658	C/T	cg08859206	chr1:53392774	SCP2	0.54	7.13	0.4	9.54e-12	Monocyte count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20044189	chr5:141704548	SPRY4	0.58	6.6	0.38	2.22e-10	Gut microbiome composition (summer);
CESC	cis	rs4919694	0.667	rs117927731	chr10:105112852	C/A	cg04362960	chr10:104952993	NT5C2	0.71	5.69	0.33	3.44e-8	Arsenic metabolism;
CESC	cis	rs7020830	0.825	rs10973248	chr9:37197768	C/T	cg14294708	chr9:37120828	ZCCHC7	1.22	23.77	0.83	1.14e-67	Schizophrenia;
CESC	cis	rs9443645	0.901	rs9448580	chr6:79551812	C/G	cg05283184	chr6:79620031	NA	-0.44	-6.84	-0.39	5.42e-11	Intelligence (multi-trait analysis);
CESC	cis	rs17401966	0.838	rs4333852	chr1:10387704	A/T	cg15208524	chr1:10270712	KIF1B	-0.4	-5.18	-0.3	4.43e-7	Hepatocellular carcinoma;
CESC	cis	rs116095464	0.867	rs7726582	chr5:215349	C/G	cg10591111	chr5:226296	SDHA	-0.52	-6.43	-0.37	5.91e-10	Breast cancer;
CESC	trans	rs4568518	0.740	rs11543650	chr7:18009880	T/C	cg27060346	chr2:234359958	DGKD	-0.42	-6.01	-0.35	6.27e-9	Measles;
CESC	cis	rs7665939	1.000	rs11942826	chr4:190109362	C/T	cg09826759	chr4:190284978	NA	-0.76	-7.68	-0.43	3.1e-13	Amyotrophic lateral sclerosis;
CESC	cis	rs10927875	0.832	rs4661342	chr1:16160773	C/G	cg21385522	chr1:16154831	NA	-0.92	-11.48	-0.58	4.86e-25	Dilated cardiomyopathy;
CESC	cis	rs10504229	0.861	rs116923397	chr8:58185162	T/G	cg22535103	chr8:58192502	C8orf71	-1.05	-13.08	-0.63	1.71e-30	Developmental language disorder (linguistic errors);
CESC	cis	rs2286503	0.780	rs2240727	chr7:22852512	C/T	cg11367502	chr7:22862612	TOMM7	0.39	5.1	0.3	6.41e-7	Fibrinogen;
CESC	cis	rs2839186	0.934	rs17176520	chr21:47682081	T/C	cg10351095	chr21:47802916	PCNT	-0.52	-7.02	-0.4	1.82e-11	Testicular germ cell tumor;
CESC	cis	rs1034435	0.755	rs9615336	chr22:48893090	G/C	cg05992904	chr22:48892994	FAM19A5	-0.57	-9.8	-0.52	1.53e-19	Late-onset Alzheimer's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25935716	chr20:30102579	HM13	0.58	6.09	0.35	3.88e-9	Gut microbiome composition (summer);
CESC	cis	rs425277	1.000	rs262651	chr1:2091397	A/G	cg04315214	chr1:2043799	PRKCZ	-0.38	-5.31	-0.31	2.35e-7	Height;
CESC	cis	rs2070488	0.965	rs3762788	chr3:38493852	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.94	17.16	0.73	6.61e-45	Electrocardiographic conduction measures;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26528255	chr1:27652089	TMEM222	-0.66	-7.4	-0.41	1.84e-12	Gut microbiome composition (summer);
CESC	cis	rs6963495	0.519	rs3892297	chr7:105152173	G/A	cg02135003	chr7:105160482	PUS7	-0.46	-5.48	-0.32	9.86e-8	Bipolar disorder (body mass index interaction);
CESC	cis	rs6089584	0.566	rs6061964	chr20:60607536	G/A	cg06108461	chr20:60628389	TAF4	-0.62	-8.19	-0.45	1.14e-14	Body mass index;
CESC	cis	rs11112613	0.713	rs68053161	chr12:105950035	G/C	cg03607813	chr12:105948248	NA	0.67	8.31	0.45	5.16e-15	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CESC	cis	rs6570726	0.935	rs419847	chr6:145827278	A/G	cg05347473	chr6:146136440	FBXO30	0.49	6.71	0.38	1.21e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7246657	0.943	rs7255785	chr19:37971683	C/T	cg23950597	chr19:37808831	NA	-0.58	-6.44	-0.37	5.71e-10	Coronary artery calcification;
CESC	cis	rs3768617	0.510	rs10911239	chr1:183062450	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.88	14.25	0.66	1.3600000000000001e-34	Fuchs's corneal dystrophy;
CESC	cis	rs921968	1.000	rs921968	chr2:219272294	G/T	cg02176678	chr2:219576539	TTLL4	0.34	5.85	0.34	1.47e-8	Mean corpuscular hemoglobin concentration;
CESC	cis	rs1707322	0.721	rs11211163	chr1:46153548	C/T	cg06784218	chr1:46089804	CCDC17	0.43	7.58	0.42	5.65e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9896933	0.778	rs80112422	chr17:80827719	G/T	cg15664640	chr17:80829946	TBCD	-0.53	-5.62	-0.33	4.83e-8	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
CESC	cis	rs921968	0.541	rs10200507	chr2:219335944	C/A	cg02176678	chr2:219576539	TTLL4	-0.54	-9.87	-0.52	9.03e-20	Mean corpuscular hemoglobin concentration;
CESC	cis	rs9911578	0.935	rs7218105	chr17:57041119	A/G	cg12560992	chr17:57184187	TRIM37	0.92	15.24	0.68	4.34e-38	Intelligence (multi-trait analysis);
CESC	cis	rs6460942	0.915	rs80345607	chr7:12442249	T/C	cg02935154	chr7:12443704	VWDE	-0.59	-6.31	-0.36	1.14e-9	Coronary artery disease;
CESC	cis	rs597539	0.552	rs10896384	chr11:68720011	A/G	cg18350739	chr11:68623251	NA	0.38	5.65	0.33	4.17e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs2708240	0.936	rs2708241	chr7:147578931	A/G	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.35	-5.78	-0.33	2.12e-8	QT interval (drug interaction);
CESC	cis	rs2991971	0.934	rs2991974	chr1:46020654	A/G	cg03146154	chr1:46216737	IPP	-0.43	-5.37	-0.31	1.73e-7	High light scatter reticulocyte count;
CESC	cis	rs7267979	0.966	rs2261794	chr20:25263062	T/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	18.61	0.75	5.02e-50	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs2522056	0.932	rs2522064	chr5:131806488	G/A	cg07395648	chr5:131743802	NA	0.44	5.04	0.3	8.53e-7	Lymphocyte counts;Fibrinogen;
CESC	cis	rs2299587	0.543	rs12546204	chr8:17796871	A/C	cg08627089	chr8:17753878	FGL1	-0.41	-5.51	-0.32	8.7e-8	Economic and political preferences;
CESC	cis	rs734999	0.545	rs10797436	chr1:2538349	G/A	cg18854424	chr1:2615690	NA	0.3	5.81	0.34	1.82e-8	Ulcerative colitis;
CESC	cis	rs1707322	1.000	rs785517	chr1:46567535	A/T	cg03146154	chr1:46216737	IPP	-0.74	-9.64	-0.51	4.75e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs1005277	0.579	rs1780116	chr10:38526621	C/T	cg25427524	chr10:38739819	LOC399744	-0.7	-10.26	-0.53	5.29e-21	Extrinsic epigenetic age acceleration;
CESC	cis	rs12497850	0.764	rs6784111	chr3:49178846	T/C	cg07636037	chr3:49044803	WDR6	1.06	18.4	0.75	2.81e-49	Parkinson's disease;
CESC	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.56	-6.24	-0.36	1.77e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2952156	0.876	rs903504	chr17:37829570	C/G	cg20243544	chr17:37824526	PNMT	0.63	8.15	0.45	1.47e-14	Asthma;
CESC	trans	rs4843747	0.619	rs66508972	chr16:88086385	C/G	cg26811252	chr16:29126840	RRN3P2	0.69	9.39	0.5	2.85e-18	Menopause (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04272052	chr7:99662051	ZNF3;ZSCAN21	-0.68	-7.79	-0.43	1.51e-13	Gut microbiome composition (summer);
CESC	trans	rs4942242	0.967	rs58325557	chr13:44217771	A/G	cg19169023	chr15:41853346	TYRO3	0.46	6.61	0.38	2.05e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs9611565	0.559	rs7290991	chr22:41964361	C/G	cg06634786	chr22:41940651	POLR3H	-0.62	-6.83	-0.39	5.85e-11	Vitiligo;
CESC	cis	rs7208859	0.623	rs55814012	chr17:29077697	T/A	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.1e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs12926788	0.689	rs7186308	chr16:24848471	A/G	cg02428538	chr16:24856791	SLC5A11	-0.56	-6.08	-0.35	4.14e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs9348729	1	rs9348729	chr6:26664268	T/C	cg12292205	chr6:26970375	C6orf41	-0.54	-5.98	-0.34	7.34e-9	Intelligence (multi-trait analysis);
CESC	cis	rs1218582	0.661	rs4845695	chr1:154911798	A/G	cg24250549	chr1:154909240	PMVK	0.57	7.6	0.42	5.29e-13	Prostate cancer;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg24258716	chr8:143820480	NA	-0.46	-6.64	-0.38	1.79e-10	Gambling;
CESC	cis	rs57221529	0.766	rs56216231	chr5:581193	G/A	cg16447950	chr5:562315	NA	-0.62	-6.52	-0.37	3.54e-10	Lung disease severity in cystic fibrosis;
CESC	cis	rs514406	0.929	rs554301	chr1:53321948	A/T	cg24675658	chr1:53192096	ZYG11B	0.57	7.24	0.41	4.86e-12	Monocyte count;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg14650514	chr9:33290567	SUGT1P1;NFX1	-0.43	-6.11	-0.35	3.55e-9	Gambling;
CESC	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg18402987	chr7:1209562	NA	0.73	7.24	0.41	4.93e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs10788264	0.544	rs9630083	chr10:124017423	C/T	cg09507567	chr10:124027408	NA	0.45	6.23	0.36	1.85e-9	Total body bone mineral density;
CESC	cis	rs2479724	0.901	rs2185798	chr6:41773576	G/C	cg17623882	chr6:41773611	USP49	0.41	5.88	0.34	1.23e-8	Menarche (age at onset);
CESC	cis	rs13191362	0.507	rs2849527	chr6:163117932	G/T	cg06582575	chr6:163149167	PACRG;PARK2	0.51	6.13	0.35	3.11e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs2479106	0.791	rs4838083	chr9:126714308	A/C	cg16191174	chr9:126692580	DENND1A	-0.41	-5.48	-0.32	1.01e-7	Polycystic ovary syndrome;
CESC	cis	rs7772486	0.701	rs7772717	chr6:145954854	T/C	cg23711669	chr6:146136114	FBXO30	1.01	15.49	0.69	5.86e-39	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2072732	0.861	rs55873718	chr1:2940012	A/G	cg15211996	chr1:2936768	ACTRT2	0.35	5.74	0.33	2.56e-8	Plateletcrit;
CESC	cis	rs6952808	0.862	rs4721135	chr7:1912222	A/G	cg04267008	chr7:1944627	MAD1L1	-0.56	-7.07	-0.4	1.4e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs2070677	0.935	rs11101869	chr10:135400631	C/T	cg20169779	chr10:135381914	SYCE1	-0.77	-10.36	-0.54	2.46e-21	Gout;
CESC	cis	rs2708240	1.000	rs2538987	chr7:147580505	A/G	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.36	-5.99	-0.35	6.79e-9	QT interval (drug interaction);
CESC	cis	rs7618501	1.000	rs7374277	chr3:49784777	T/C	cg24308560	chr3:49941425	MST1R	0.5	6.71	0.38	1.15e-10	Intelligence (multi-trait analysis);
CESC	cis	rs9303401	0.646	rs9303403	chr17:57219300	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.51	-6.22	-0.36	1.88e-9	Cognitive test performance;
CESC	cis	rs17826219	0.706	rs73271850	chr17:29142140	A/G	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.1e-10	Body mass index;
CESC	cis	rs8060686	0.641	rs59708959	chr16:68123916	A/T	cg26727032	chr16:67993705	SLC12A4	-0.53	-6.0	-0.35	6.53e-9	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs854765	0.647	rs7406744	chr17:17981938	C/G	cg09796270	chr17:17721594	SREBF1	0.38	5.08	0.3	7.23e-7	Total body bone mineral density;
CESC	cis	rs5750830	0.621	rs5757665	chr22:39821641	A/G	cg02038168	chr22:39784481	NA	-0.62	-7.66	-0.43	3.51e-13	Intelligence (multi-trait analysis);
CESC	cis	rs71277158	0.688	rs2287483	chr3:169756846	C/T	cg04067573	chr3:169899625	PHC3	0.55	5.48	0.32	9.92e-8	Prostate cancer;
CESC	trans	rs629535	0.821	rs497398	chr8:70037434	A/T	cg21567404	chr3:27674614	NA	0.93	11.25	0.57	2.83e-24	Dupuytren's disease;
CESC	cis	rs1862618	0.756	rs832548	chr5:56183637	G/C	cg24549020	chr5:56110836	MAP3K1	0.66	7.45	0.42	1.29e-12	Initial pursuit acceleration;
CESC	cis	rs9584850	1.000	rs9584850	chr13:99101426	G/C	cg20750642	chr13:99100586	FARP1	-0.38	-5.74	-0.33	2.61e-8	Neuroticism;
CESC	cis	rs4642101	0.765	rs4321514	chr3:12825901	C/T	cg24848339	chr3:12840334	CAND2	0.38	5.94	0.34	8.89e-9	QRS complex (12-leadsum);
CESC	cis	rs16957304	0.744	rs9934827	chr16:67413003	A/T	cg26727032	chr16:67993705	SLC12A4	-0.51	-5.07	-0.3	7.36e-7	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
CESC	cis	rs2072732	0.861	rs12567620	chr1:2956999	T/G	cg15211996	chr1:2936768	ACTRT2	0.33	5.91	0.34	1.07e-8	Plateletcrit;
CESC	cis	rs950776	0.593	rs588765	chr15:78865425	T/C	cg24631222	chr15:78858424	CHRNA5	0.43	5.44	0.32	1.24e-7	Sudden cardiac arrest;
CESC	cis	rs6831352	0.879	rs56295995	chr4:100060899	C/T	cg12011299	chr4:100065546	ADH4	-0.59	-6.59	-0.38	2.35e-10	Alcohol dependence;
CESC	cis	rs7100689	0.646	rs1340380	chr10:82115619	T/C	cg00277334	chr10:82204260	NA	-0.59	-7.63	-0.42	4.35e-13	Post bronchodilator FEV1;
CESC	cis	rs12545109	0.800	rs1960725	chr8:57411807	C/T	cg09654669	chr8:57350985	NA	-0.46	-6.28	-0.36	1.4e-9	Obesity-related traits;
CESC	cis	rs5769765	1.000	rs1033665	chr22:50252127	A/G	cg26441486	chr22:50317300	CRELD2	0.38	5.37	0.31	1.76e-7	Schizophrenia;
CESC	trans	rs3780486	0.505	rs10758188	chr9:33123386	C/T	cg20290983	chr6:43655470	MRPS18A	-0.77	-12.33	-0.6	6.58e-28	IgG glycosylation;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg13284045	chr12:860787	WNK1	0.46	6.59	0.38	2.42e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs62103177	0.608	rs59300126	chr18:77694439	C/A	cg12964065	chr18:77638022	KCNG2	0.47	5.1	0.3	6.36e-7	Opioid sensitivity;
CESC	cis	rs7589728	0.563	rs75606549	chr2:88466069	T/C	cg18490616	chr2:88469792	THNSL2	0.56	5.41	0.32	1.38e-7	Plasma clusterin levels;
CESC	trans	rs9650657	0.645	rs4841408	chr8:10516336	A/G	cg15556689	chr8:8085844	FLJ10661	-0.49	-6.43	-0.37	5.87e-10	Neuroticism;
CESC	cis	rs854765	0.583	rs7207043	chr17:17819188	A/G	cg04398451	chr17:18023971	MYO15A	-0.67	-9.74	-0.51	2.33e-19	Total body bone mineral density;
CESC	cis	rs1371867	0.846	rs1788204	chr8:101303936	C/T	cg11906718	chr8:101322791	RNF19A	0.54	6.93	0.39	3.24e-11	Atrioventricular conduction;
CESC	cis	rs7552404	0.731	rs17650138	chr1:76398887	C/T	cg22875332	chr1:76189707	ACADM	-0.63	-6.04	-0.35	5.29e-9	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg22105103	chr4:187893119	NA	-0.45	-6.64	-0.38	1.73e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs561341	0.941	rs2428336	chr17:30290577	T/C	cg12193833	chr17:30244370	NA	-0.62	-6.23	-0.36	1.84e-9	Hip circumference adjusted for BMI;
CESC	cis	rs1570884	0.556	rs2146146	chr13:50170368	C/T	cg08779649	chr13:50194554	NA	0.39	6.71	0.38	1.17e-10	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
CESC	cis	rs829883	0.646	rs249838	chr12:98874749	C/G	cg25150519	chr12:98850993	NA	0.41	5.27	0.31	2.85e-7	Colorectal adenoma (advanced);
CESC	cis	rs11785400	1.000	rs10099892	chr8:143734608	C/T	cg10596483	chr8:143751796	JRK	0.43	5.6	0.33	5.24e-8	Schizophrenia;
CESC	cis	rs870825	0.549	rs7699919	chr4:185648610	A/C	cg04058563	chr4:185651563	MLF1IP	0.63	6.96	0.39	2.59e-11	Blood protein levels;
CESC	cis	rs11190604	1.000	rs10883507	chr10:102291275	C/T	cg07080220	chr10:102295463	HIF1AN	0.7	6.48	0.37	4.34e-10	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs853679	0.517	rs9380060	chr6:28132603	G/A	cg12963246	chr6:28129442	ZNF389	0.56	7.38	0.41	1.99e-12	Depression;
CESC	cis	rs6952808	0.543	rs4719436	chr7:2141239	G/A	cg23048001	chr7:2026167	MAD1L1	0.44	5.73	0.33	2.75e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs7584330	0.737	rs13397017	chr2:238361241	G/A	cg14458575	chr2:238380390	NA	0.6	8.32	0.46	4.61e-15	Prostate cancer;
CESC	cis	rs2637266	1.000	rs2579746	chr10:78327674	C/T	cg18941641	chr10:78392320	NA	0.4	7.43	0.42	1.51e-12	Pulmonary function;
CESC	cis	rs1707322	0.752	rs4660880	chr1:46111040	C/T	cg03146154	chr1:46216737	IPP	0.85	12.19	0.6	2.03e-27	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9300255	0.602	rs4372492	chr12:123697357	T/C	cg19016782	chr12:123741754	C12orf65	-0.45	-6.51	-0.37	3.65e-10	Neutrophil percentage of white cells;
CESC	cis	rs12530845	1.000	rs12537555	chr7:135334061	G/A	cg23117316	chr7:135346802	PL-5283	-0.43	-5.33	-0.31	2.13e-7	Red blood cell traits;
CESC	cis	rs5769765	0.773	rs4075331	chr22:50302850	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.48	-5.42	-0.32	1.35e-7	Schizophrenia;
CESC	cis	rs7539624	0.588	rs10916600	chr1:223897012	C/T	cg10100437	chr1:223903862	CAPN2	0.43	5.55	0.32	7.08e-8	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05642746	chr17:8024095	HES7	-0.58	-6.64	-0.38	1.81e-10	Gut microbiome composition (summer);
CESC	cis	rs7829975	0.688	rs7837587	chr8:8378992	T/C	cg15556689	chr8:8085844	FLJ10661	0.53	6.45	0.37	5.3e-10	Mood instability;
CESC	cis	rs524023	0.957	rs10792443	chr11:64395252	G/C	cg07220939	chr11:64358617	SLC22A12	-0.35	-5.42	-0.32	1.32e-7	Urate levels in obese individuals;
CESC	cis	rs8017423	0.935	rs4643251	chr14:90669256	C/T	cg14092571	chr14:90743983	NA	0.51	7.58	0.42	5.73e-13	Mortality in heart failure;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00114008	chr1:27114423	PIGV	0.59	6.63	0.38	1.89e-10	Gut microbiome composition (summer);
CESC	cis	rs6089584	0.889	rs6142923	chr20:60596617	C/T	cg24733560	chr20:60626293	TAF4	-0.42	-5.74	-0.33	2.53e-8	Body mass index;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg15188491	chr1:146644106	PRKAB2	-0.48	-6.87	-0.39	4.65e-11	Gambling;
CESC	cis	rs853679	0.599	rs202906	chr6:28011652	C/T	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	-0.76	-6.29	-0.36	1.29e-9	Depression;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09511246	chr2:172290755	DCAF17;METTL8	0.62	6.83	0.39	5.86e-11	Gut microbiome composition (summer);
CESC	cis	rs853679	0.882	rs4713140	chr6:28097193	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.67	-6.06	-0.35	4.75e-9	Depression;
CESC	cis	rs727505	0.564	rs68107250	chr7:124870200	G/A	cg23710748	chr7:124431027	NA	-0.34	-5.19	-0.3	4.19e-7	Lewy body disease;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg07387570	chr22:46663686	TTC38	0.46	6.24	0.36	1.74e-9	Systemic lupus erythematosus;
CESC	cis	rs7793919	0.652	rs10228886	chr7:4783224	C/T	cg09789173	chr7:4769017	FOXK1	-0.61	-8.7	-0.47	3.55e-16	Mosquito bite size;
CESC	cis	rs7666738	0.830	rs7657490	chr4:99043973	C/T	cg17366294	chr4:99064904	C4orf37	0.61	8.78	0.47	2.13e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7208859	0.573	rs4055105	chr17:29102550	A/G	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.91e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs875971	0.793	rs460678	chr7:65527200	C/G	cg10691866	chr7:65817282	TPST1	-0.34	-5.46	-0.32	1.12e-7	Aortic root size;
CESC	cis	rs929354	0.772	rs7778193	chr7:156980087	C/T	cg05182265	chr7:156933206	UBE3C	-0.51	-7.52	-0.42	8.49e-13	Body mass index;
CESC	cis	rs60154123	0.686	rs227222	chr1:210191272	T/C	cg25204440	chr1:209979598	IRF6	-0.68	-5.38	-0.31	1.65e-7	Coronary artery disease;
CESC	cis	rs11792861	0.926	rs7470160	chr9:111844246	C/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.42	5.18	0.3	4.44e-7	Menarche (age at onset);
CESC	cis	rs9488822	0.676	rs1999929	chr6:116381994	T/C	cg26893134	chr6:116381904	FRK	0.25	6.14	0.35	3.05e-9	Cholesterol, total;LDL cholesterol;
CESC	cis	rs2304069	1.000	rs216126	chr5:149428424	G/C	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.77	9.97	0.52	4.3e-20	HIV-1 control;
CESC	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg22907277	chr7:1156413	C7orf50	0.35	5.19	0.3	4.22e-7	Longevity;Endometriosis;
CESC	cis	rs9388451	0.626	rs9385383	chr6:126086290	G/T	cg05901451	chr6:126070800	HEY2	-0.57	-8.46	-0.46	1.85e-15	Brugada syndrome;
CESC	cis	rs6690583	1.000	rs6690464	chr1:85466369	A/G	cg11262906	chr1:85462892	MCOLN2	-0.53	-6.01	-0.35	5.99e-9	Serum sulfate level;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12593394	chr1:19923846	C1orf151	0.6	6.58	0.37	2.46e-10	Gut microbiome composition (summer);
CESC	cis	rs7772486	0.790	rs2254257	chr6:146203724	C/T	cg23711669	chr6:146136114	FBXO30	0.94	13.98	0.65	1.23e-33	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs12824058	0.737	rs11060829	chr12:130814996	G/T	cg26677194	chr12:130822605	PIWIL1	0.52	6.81	0.39	6.58e-11	Menopause (age at onset);
CESC	cis	rs12824058	0.831	rs12314111	chr12:130813663	G/T	cg24838063	chr12:130822603	PIWIL1	0.62	8.54	0.46	1.09e-15	Menopause (age at onset);
CESC	cis	rs28489187	0.683	rs2177461	chr1:85861976	C/G	cg16011679	chr1:85725395	C1orf52	-0.46	-5.55	-0.32	6.87e-8	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	cis	rs1023500	0.505	rs134887	chr22:42674239	A/G	cg04733989	chr22:42467013	NAGA	0.65	9.88	0.52	8.45e-20	Schizophrenia;
CESC	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.52	-6.57	-0.37	2.71e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2295499	0.643	rs4690086	chr4:2698524	G/A	cg27239842	chr4:2403781	ZFYVE28	-0.31	-5.2	-0.3	3.94e-7	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
CESC	cis	rs7584330	0.518	rs78856668	chr2:238438055	A/C	cg14458575	chr2:238380390	NA	0.72	6.8	0.39	7.06e-11	Prostate cancer;
CESC	cis	rs2841277	0.708	rs4465542	chr14:105407798	A/G	cg14403583	chr14:105418241	AHNAK2	-0.59	-8.26	-0.45	7.03e-15	Rheumatoid arthritis;
CESC	trans	rs11098499	0.820	rs6534140	chr4:120455311	C/T	cg25214090	chr10:38739885	LOC399744	0.7	9.62	0.51	5.47e-19	Corneal astigmatism;
CESC	cis	rs769267	0.740	rs2965185	chr19:19525792	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.49	6.21	0.36	1.99e-9	Tonsillectomy;
CESC	cis	rs2200578	1.000	rs72961173	chr2:99886868	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.5	5.6	0.33	5.23e-8	IgG glycosylation;
CESC	cis	rs10504229	1.000	rs68112919	chr8:58188247	G/A	cg22535103	chr8:58192502	C8orf71	-1.05	-12.99	-0.62	3.48e-30	Developmental language disorder (linguistic errors);
CESC	cis	rs1348850	0.872	rs10165785	chr2:178293295	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.77	10.87	0.56	5.44e-23	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs4523957	0.583	rs2984943	chr17:2030135	T/C	cg16513277	chr17:2031491	SMG6	-0.79	-11.71	-0.58	8.09e-26	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg06370812	chr3:195501042	MUC4	0.47	6.72	0.38	1.11e-10	Fibrinogen levels;
CESC	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.62	0.38	2.01e-10	Prudent dietary pattern;
CESC	cis	rs6502050	0.799	rs6416859	chr17:80111442	G/C	cg23985595	chr17:80112537	CCDC57	-0.42	-6.58	-0.37	2.43e-10	Life satisfaction;
CESC	cis	rs7618501	0.521	rs2883059	chr3:49902160	C/T	cg24110177	chr3:50126178	RBM5	0.53	7.25	0.41	4.7e-12	Intelligence (multi-trait analysis);
CESC	cis	rs1878931	0.624	rs28089	chr16:3446937	G/A	cg22508957	chr16:3507546	NAT15	0.47	5.99	0.35	6.79e-9	Body mass index (adult);
CESC	cis	rs6460942	1.000	rs6944134	chr7:12418036	T/C	cg20607287	chr7:12443886	VWDE	-0.75	-8.83	-0.48	1.51e-16	Coronary artery disease;
CESC	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.45	5.82	0.34	1.69e-8	Lymphocyte counts;
CESC	trans	rs916888	0.821	rs199513	chr17:44856932	A/G	cg23590916	chr17:43697445	MGC57346	-0.57	-6.07	-0.35	4.43e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs9596863	0.950	rs9563182	chr13:54395310	T/C	ch.13.53330881F	chr13:54432880	NA	0.66	5.36	0.31	1.84e-7	Epilepsy and lamotrigine-induced maculopapular eruptions;
CESC	cis	rs3793917	0.894	rs36212731	chr10:124214976	G/T	cg24884230	chr10:124216658	ARMS2	0.3	5.08	0.3	7.19e-7	Age-related macular degeneration;
CESC	cis	rs1670533	1.000	rs6852155	chr4:1067638	T/G	cg27284194	chr4:1044797	NA	0.48	6.09	0.35	3.98e-9	Recombination rate (females);
CESC	cis	rs72627509	0.680	rs66790703	chr4:57773908	G/A	cg26694713	chr4:57773883	REST	0.58	5.73	0.33	2.7e-8	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CESC	cis	rs208520	0.690	rs207112	chr6:66792092	C/T	cg07460842	chr6:66804631	NA	-1.0	-13.33	-0.63	2.21e-31	Exhaled nitric oxide output;
CESC	cis	rs3772130	0.545	rs7340674	chr3:121574215	T/C	cg20356878	chr3:121714668	ILDR1	0.44	6.4	0.37	6.92e-10	Cognitive performance;
CESC	cis	rs4595586	0.525	rs17464772	chr12:39247777	G/A	cg26384229	chr12:38710491	ALG10B	0.68	10.17	0.53	9.91e-21	Morning vs. evening chronotype;
CESC	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	22.16	0.81	2.75e-62	Prudent dietary pattern;
CESC	cis	rs10504229	1.000	rs66796009	chr8:58174529	G/A	cg24829409	chr8:58192753	C8orf71	-0.76	-10.0	-0.52	3.53e-20	Developmental language disorder (linguistic errors);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg25704207	chr3:50649454	CISH	-0.4	-6.1	-0.35	3.84e-9	Gambling;
CESC	cis	rs950776	0.518	rs12906951	chr15:78825562	C/T	cg24631222	chr15:78858424	CHRNA5	-0.42	-5.33	-0.31	2.09e-7	Sudden cardiac arrest;
CESC	cis	rs6951245	0.744	rs1133122	chr7:1192572	C/A	cg24642844	chr7:1081250	C7orf50	-0.63	-8.17	-0.45	1.29e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7116495	0.609	rs6592447	chr11:71641093	A/T	cg18441811	chr11:71824068	C11orf51	-0.73	-5.11	-0.3	6.22e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs9682041	0.696	rs13067560	chr3:170094190	G/A	cg11886554	chr3:170076028	SKIL	0.7	6.5	0.37	3.93e-10	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CESC	cis	rs4819052	0.851	rs28676615	chr21:46676576	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.76	10.1	0.53	1.62e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs7666738	0.830	rs4699331	chr4:99059816	T/C	cg03467027	chr4:99064603	C4orf37	0.48	6.0	0.35	6.56e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10504229	0.815	rs55855654	chr8:58164299	T/G	cg05313129	chr8:58192883	C8orf71	-0.48	-5.18	-0.3	4.41e-7	Developmental language disorder (linguistic errors);
CESC	trans	rs7618501	1.000	rs1049256	chr3:49763338	T/C	cg21582582	chr3:182698605	DCUN1D1	-0.44	-6.01	-0.35	6.18e-9	Intelligence (multi-trait analysis);
CESC	cis	rs1788820	0.917	rs1788819	chr18:21100504	G/A	cg14672496	chr18:21087552	C18orf8	0.53	7.19	0.4	6.58e-12	Body mass index;
CESC	cis	rs9815354	0.761	rs12186051	chr3:41836919	G/A	cg03022575	chr3:42003672	ULK4	0.7	6.04	0.35	5.26e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs1728785	0.818	rs12926059	chr16:68569459	T/C	cg02972257	chr16:68554789	NA	-0.55	-6.36	-0.36	8.6e-10	Ulcerative colitis;
CESC	cis	rs796364	0.806	rs34510964	chr2:201010676	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.67	-6.43	-0.37	5.87e-10	Schizophrenia;
CESC	cis	rs7818688	0.585	rs2599714	chr8:96052050	A/G	cg16049864	chr8:95962084	TP53INP1	-0.49	-5.59	-0.32	5.69e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs12144309	0.554	rs2476599	chr1:114363459	G/A	cg13572289	chr1:114447746	DCLRE1B;AP4B1	0.45	5.24	0.31	3.23e-7	Coronary artery disease;
CESC	cis	rs2243480	0.901	rs73142137	chr7:65343442	A/T	cg13147721	chr7:65941812	NA	-0.9	-8.76	-0.47	2.35e-16	Diabetic kidney disease;
CESC	trans	rs11601239	0.585	rs685374	chr11:105580112	T/C	cg15315312	chr2:176867285	KIAA1715	-0.46	-6.17	-0.35	2.59e-9	Refractive error;
CESC	cis	rs2506889	0.553	rs17035189	chr1:10597024	A/G	cg17425144	chr1:10567563	PEX14	0.36	5.68	0.33	3.59e-8	Breast cancer;
CESC	cis	rs921968	0.612	rs573555	chr2:219348888	A/C	cg02176678	chr2:219576539	TTLL4	0.39	6.77	0.38	8.06e-11	Mean corpuscular hemoglobin concentration;
CESC	cis	rs796364	0.577	rs7574287	chr2:200680999	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.55	5.06	0.3	7.93e-7	Schizophrenia;
CESC	trans	rs7395662	0.548	rs4882000	chr11:48546496	A/G	cg00717180	chr2:96193071	NA	-0.44	-6.06	-0.35	4.58e-9	HDL cholesterol;
CESC	cis	rs10504229	0.635	rs72649130	chr8:58053810	G/T	cg05313129	chr8:58192883	C8orf71	-0.52	-5.21	-0.3	3.78e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs4665809	0.556	rs10221814	chr2:26442759	C/T	cg26314531	chr2:26401878	FAM59B	-0.85	-9.21	-0.49	1.07e-17	Gut microbiome composition (summer);
CESC	cis	rs7618915	0.547	rs2164884	chr3:52629633	C/T	cg07507251	chr3:52567010	NT5DC2	0.4	6.96	0.39	2.7e-11	Bipolar disorder;
CESC	trans	rs1829883	0.733	rs2968352	chr5:98724991	G/T	cg23861655	chr4:57411219	NA	0.38	6.13	0.35	3.13e-9	Hemostatic factors and hematological phenotypes;
CESC	cis	rs35146811	0.586	rs6964754	chr7:99589404	G/A	cg22531904	chr7:99595276	NA	-0.39	-5.15	-0.3	5.12e-7	Coronary artery disease;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg08829281	chr12:133264318	PXMP2;POLE	-0.47	-6.74	-0.38	9.68e-11	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs459571	0.959	rs378740	chr9:136890876	C/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.6	-7.58	-0.42	5.64e-13	Platelet distribution width;
CESC	cis	rs116095464	0.558	rs10068203	chr5:206618	C/T	cg22496380	chr5:211416	CCDC127	-0.95	-10.05	-0.53	2.34e-20	Breast cancer;
CESC	cis	rs2204008	0.744	rs11181635	chr12:38378420	C/T	cg26384229	chr12:38710491	ALG10B	0.74	10.88	0.56	4.92e-23	Bladder cancer;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg03433549	chr12:56498817	PA2G4	-0.44	-6.32	-0.36	1.08e-9	Gambling;
CESC	cis	rs1048238	0.506	rs848195	chr1:16286522	A/G	cg21385522	chr1:16154831	NA	-0.48	-6.2	-0.36	2.21e-9	Systolic blood pressure;
CESC	cis	rs459571	0.804	rs448918	chr9:136885979	G/A	cg13789015	chr9:136890014	NCRNA00094	0.56	7.88	0.44	8.33e-14	Platelet distribution width;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03923838	chr6:132834330	STX7	0.56	6.41	0.37	6.51e-10	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.830	rs7663438	chr4:99014582	C/T	cg17366294	chr4:99064904	C4orf37	0.59	8.58	0.47	7.92e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4604732	0.631	rs74154672	chr1:247625625	C/G	cg12754571	chr1:247694271	LOC148824;OR2C3	0.44	5.44	0.32	1.21e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs2204008	0.837	rs11168334	chr12:37961768	A/G	cg13010199	chr12:38710504	ALG10B	0.52	6.59	0.38	2.36e-10	Bladder cancer;
CESC	cis	rs3820928	1.000	rs2396433	chr2:227772502	A/G	cg05526886	chr2:227700861	RHBDD1	-0.42	-5.54	-0.32	7.19e-8	Pulmonary function;
CESC	cis	rs4523957	0.579	rs4790883	chr17:2087605	T/C	cg16513277	chr17:2031491	SMG6	-0.64	-8.87	-0.48	1.11e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs17639215	0.550	rs4851003	chr2:102909277	T/C	cg09003973	chr2:102972529	NA	0.49	5.06	0.3	7.93e-7	Serum protein levels (sST2);
CESC	cis	rs5758659	0.716	rs5758661	chr22:42624445	A/C	cg00645731	chr22:42541494	CYP2D7P1	-0.3	-5.07	-0.3	7.62e-7	Cognitive function;
CESC	cis	rs8072100	0.575	rs1221385	chr17:45527574	T/G	cg08085267	chr17:45401833	C17orf57	-0.49	-6.21	-0.36	2.02e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs727563	0.636	rs2187795	chr22:42092225	C/A	cg06634786	chr22:41940651	POLR3H	0.65	6.47	0.37	4.73e-10	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs2991971	1.000	rs667626	chr1:46020551	T/C	cg15605315	chr1:45957053	TESK2	0.42	5.3	0.31	2.42e-7	High light scatter reticulocyte count;
CESC	cis	rs6570726	0.846	rs397311	chr6:145806701	C/T	cg23711669	chr6:146136114	FBXO30	-0.86	-12.94	-0.62	5.09e-30	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs10751667	0.666	rs4074235	chr11:977511	C/G	cg20946044	chr11:1010712	AP2A2	-0.39	-5.4	-0.31	1.48e-7	Alzheimer's disease (late onset);
CESC	cis	rs4594175	0.886	rs11157801	chr14:51622918	C/T	cg23942311	chr14:51606299	NA	0.39	6.05	0.35	4.9e-9	Cancer;
CESC	cis	rs61931739	0.500	rs11053211	chr12:34464334	T/C	cg23762105	chr12:34175262	ALG10	-0.4	-5.12	-0.3	5.81e-7	Morning vs. evening chronotype;
CESC	cis	rs896854	0.967	rs896853	chr8:95960855	G/C	cg23172400	chr8:95962367	TP53INP1	-0.5	-11.15	-0.57	6.23e-24	Type 2 diabetes;
CESC	cis	rs12545109	0.765	rs2055985	chr8:57410821	T/A	cg09654669	chr8:57350985	NA	-0.47	-6.5	-0.37	4.05e-10	Obesity-related traits;
CESC	cis	rs7680126	0.633	rs28378345	chr4:10209897	A/G	cg11266682	chr4:10021025	SLC2A9	-0.39	-5.15	-0.3	5.12e-7	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	cis	rs11864453	0.647	rs8043606	chr16:72135319	T/C	cg01557791	chr16:72042693	DHODH	-0.43	-5.63	-0.33	4.58e-8	Fibrinogen levels;
CESC	cis	rs3785574	0.962	rs2247435	chr17:61892862	G/A	cg06873352	chr17:61820015	STRADA	0.47	6.86	0.39	4.85e-11	Height;
CESC	cis	rs7605827	0.930	rs11902167	chr2:15494391	C/T	cg19274914	chr2:15703543	NA	0.31	5.62	0.33	4.89e-8	Educational attainment (years of education);
CESC	cis	rs2694528	0.764	rs112511311	chr5:59872002	G/A	cg11474532	chr5:59995715	DEPDC1B	0.91	6.37	0.36	8.39e-10	Parkinson's disease;
CESC	cis	rs4820539	0.966	rs2301554	chr22:23484254	A/C	cg14186256	chr22:23484241	RTDR1	0.88	16.24	0.71	1.2e-41	Bone mineral density;
CESC	cis	rs7772486	0.806	rs7740785	chr6:146171299	C/A	cg05347473	chr6:146136440	FBXO30	0.51	6.76	0.38	8.64e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7666738	0.606	rs6852813	chr4:99084671	G/A	cg05340658	chr4:99064831	C4orf37	0.65	9.03	0.49	3.66e-17	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2404602	0.692	rs34272342	chr15:77012276	A/C	cg26408565	chr15:76604113	ETFA	-0.38	-5.52	-0.32	8.03e-8	Blood metabolite levels;
CESC	cis	rs1153858	1.000	rs9783731	chr15:45642884	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.8	-10.8	-0.55	9.27e-23	Homoarginine levels;
CESC	cis	rs1552244	0.882	rs55808392	chr3:10054681	C/T	cg00149659	chr3:10157352	C3orf10	0.69	8.09	0.45	2.13e-14	Alzheimer's disease;
CESC	cis	rs6088590	0.965	rs910869	chr20:33292777	C/T	cg08999081	chr20:33150536	PIGU	0.59	8.79	0.48	1.88e-16	Coronary artery disease;
CESC	cis	rs34638657	0.872	rs2967326	chr16:82188246	A/G	cg09439754	chr16:82129088	HSD17B2	-0.35	-5.24	-0.31	3.26e-7	Lung adenocarcinoma;
CESC	cis	rs875971	0.929	rs4122249	chr7:65920936	T/C	cg11764359	chr7:65958608	NA	0.96	15.37	0.69	1.5e-38	Aortic root size;
CESC	cis	rs3820928	0.874	rs56324594	chr2:227868854	C/T	cg11843606	chr2:227700838	RHBDD1	-0.41	-5.28	-0.31	2.66e-7	Pulmonary function;
CESC	cis	rs763014	0.931	rs2071982	chr16:630405	T/G	cg07343612	chr16:622815	PIGQ	-0.58	-8.47	-0.46	1.72e-15	Height;
CESC	cis	rs17209837	0.607	rs2888611	chr7:87103670	C/G	cg00919237	chr7:87102261	ABCB4	0.5	6.5	0.37	3.98e-10	Gallbladder cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08386897	chr10:134073820	STK32C	-0.55	-6.54	-0.37	3.18e-10	Gut microbiome composition (summer);
CESC	cis	rs9611565	0.559	rs5758428	chr22:42106216	G/A	cg06634786	chr22:41940651	POLR3H	0.67	6.72	0.38	1.12e-10	Vitiligo;
CESC	cis	rs73058052	0.935	rs3745473	chr19:50086626	T/C	cg09250473	chr19:50168907	IRF3;BCL2L12	0.58	5.49	0.32	9.49e-8	Fibrinogen levels;
CESC	cis	rs7107174	0.892	rs10899487	chr11:78085474	G/A	cg02023728	chr11:77925099	USP35	0.47	6.23	0.36	1.82e-9	Testicular germ cell tumor;
CESC	cis	rs6500395	1.000	rs11859909	chr16:48668441	T/C	cg04672837	chr16:48644449	N4BP1	0.51	6.43	0.37	6.06e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs1018836	0.892	rs5005585	chr8:91581975	A/G	cg16814680	chr8:91681699	NA	-0.61	-8.57	-0.47	8.45e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs748404	0.697	rs567357	chr15:43571390	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.51	8.03	0.44	3.27e-14	Lung cancer;
CESC	cis	rs6500395	1.000	rs1420701	chr16:48730873	C/T	cg04672837	chr16:48644449	N4BP1	-0.51	-6.41	-0.37	6.64e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg21830480	chr12:72057690	THAP2;ZFC3H1	-0.48	-6.24	-0.36	1.72e-9	Asthma;
CESC	cis	rs28647808	1.000	rs28756699	chr9:136273527	G/C	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.9	5.73	0.33	2.75e-8	Blood protein levels;
CESC	cis	rs6570726	0.791	rs952406	chr6:145925616	C/A	cg23711669	chr6:146136114	FBXO30	0.85	12.48	0.61	2.03e-28	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7659604	0.537	rs6823818	chr4:122731699	G/C	cg20573242	chr4:122745356	CCNA2	0.62	7.44	0.42	1.41e-12	Type 2 diabetes;
CESC	cis	rs8028182	0.636	rs7163907	chr15:75845097	T/C	cg20655648	chr15:75932815	IMP3	0.48	5.93	0.34	9.58e-9	Sudden cardiac arrest;
CESC	cis	rs3213545	0.659	rs2259690	chr12:121457914	T/G	cg02403541	chr12:121454288	C12orf43	0.74	10.68	0.55	2.25e-22	Subjective well-being;Cardiovascular disease risk factors;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg02732671	chr3:134204521	CEP63;ANAPC13	0.48	6.16	0.35	2.71e-9	Thyroid stimulating hormone;
CESC	cis	rs6756513	0.501	rs7581977	chr2:70174054	C/T	cg02498382	chr2:70120550	SNRNP27	0.29	5.06	0.3	7.69e-7	Breast cancer;Platelet count;
CESC	cis	rs6565681	0.883	rs4523980	chr17:78347664	A/G	cg15383979	chr17:78362278	RNF213;LOC100294362	-0.75	-8.4	-0.46	2.75e-15	Moyamoya disease;
CESC	cis	rs11048434	0.736	rs7957321	chr12:9120154	C/T	cg23795048	chr12:9217529	LOC144571	0.35	5.26	0.31	2.94e-7	Sjögren's syndrome;
CESC	cis	rs2952156	1.000	rs2934971	chr17:37854507	G/T	cg19468946	chr17:37922297	IKZF3	-0.42	-5.17	-0.3	4.55e-7	Asthma;
CESC	cis	rs2797160	0.837	rs1739364	chr6:126022383	A/G	cg05901451	chr6:126070800	HEY2	-0.45	-6.63	-0.38	1.89e-10	Endometrial cancer;
CESC	cis	rs4908768	0.501	rs1922983	chr1:8531326	A/G	cg00120948	chr1:8484417	RERE	-0.33	-5.1	-0.3	6.59e-7	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
CESC	cis	rs4699052	0.590	rs4698892	chr4:104261271	C/G	cg16532752	chr4:104119610	CENPE	-0.39	-5.52	-0.32	8.23e-8	Testicular germ cell tumor;
CESC	cis	rs853679	0.517	rs9368550	chr6:28051803	T/A	cg26335602	chr6:28129616	ZNF389	0.53	7.05	0.4	1.55e-11	Depression;
CESC	cis	rs2243480	1.000	rs6959002	chr7:65650496	A/G	cg13147721	chr7:65941812	NA	0.97	9.16	0.49	1.47e-17	Diabetic kidney disease;
CESC	cis	rs6860806	0.661	rs2136188	chr5:131577514	A/G	cg12564285	chr5:131593104	PDLIM4	-0.41	-6.26	-0.36	1.5e-9	Breast cancer;
CESC	cis	rs12995491	0.933	rs12995212	chr2:88527184	C/T	cg07952391	chr2:88470173	THNSL2	-0.53	-7.81	-0.43	1.32e-13	Response to metformin (IC50);
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg19789755	chr7:56950153	NA	-0.43	-6.02	-0.35	5.68e-9	Systemic lupus erythematosus;
CESC	cis	rs853679	0.517	rs2275508	chr6:28094731	T/C	cg08968635	chr6:28129556	ZNF389	0.42	5.73	0.33	2.7e-8	Depression;
CESC	cis	rs854765	0.547	rs2955380	chr17:17944349	A/G	cg04398451	chr17:18023971	MYO15A	0.73	10.55	0.54	5.95e-22	Total body bone mineral density;
CESC	cis	rs7639513	0.767	rs3806661	chr3:12705855	A/G	cg23032965	chr3:12705835	RAF1	0.76	10.79	0.55	9.63e-23	Itch intensity from mosquito bite;
CESC	cis	rs1538970	0.962	rs9429072	chr1:45810091	C/T	cg05343316	chr1:45956843	TESK2	-0.81	-11.5	-0.58	4.2e-25	Platelet count;
CESC	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg06873352	chr17:61820015	STRADA	-0.67	-11.69	-0.58	9.45e-26	Prudent dietary pattern;
CESC	cis	rs35740288	0.539	rs11634553	chr15:86336611	G/A	cg20737812	chr15:86336631	KLHL25	-0.42	-5.28	-0.31	2.71e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
CESC	cis	rs10504229	0.906	rs17805439	chr8:58172400	T/C	cg24829409	chr8:58192753	C8orf71	-0.76	-10.0	-0.52	3.53e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs909674	0.818	rs5750830	chr22:39840828	C/A	cg02038168	chr22:39784481	NA	-0.64	-7.52	-0.42	8.37e-13	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs847577	0.674	rs7790479	chr7:97713101	C/G	cg21770322	chr7:97807741	LMTK2	0.64	10.58	0.55	4.59e-22	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01501135	chr17:16342235	NCRNA00188;SNORD49B;SNORD49A	0.59	6.97	0.39	2.58e-11	Gut microbiome composition (summer);
CESC	cis	rs2651899	0.934	rs1627080	chr1:3081309	T/C	cg07622451	chr1:3079886	PRDM16	0.31	5.36	0.31	1.82e-7	Migraine;
CESC	cis	rs7918232	0.567	rs11015463	chr10:27319258	A/G	cg14240646	chr10:27532245	ACBD5	-0.48	-5.21	-0.3	3.78e-7	Breast cancer;
CESC	cis	rs2070997	0.607	rs2183224	chr9:133665081	G/A	cg11464064	chr9:133710261	ABL1	0.49	5.61	0.33	5.08e-8	Response to amphetamines;
CESC	cis	rs7618915	0.547	rs2289250	chr3:52682946	A/C	cg17372223	chr3:52568218	NT5DC2	-0.43	-6.51	-0.37	3.81e-10	Bipolar disorder;
CESC	cis	rs34779708	0.931	rs59418206	chr10:35331624	G/A	cg04310649	chr10:35416472	CREM	-0.5	-5.96	-0.34	7.83e-9	Inflammatory bowel disease;Crohn's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02839306	chr19:33165564	ANKRD27;RGS9BP	0.61	6.51	0.37	3.72e-10	Gut microbiome composition (summer);
CESC	cis	rs113835537	0.529	rs17065	chr11:66277035	G/A	cg24851651	chr11:66362959	CCS	0.49	5.86	0.34	1.34e-8	Airway imaging phenotypes;
CESC	cis	rs2576037	0.583	rs8098948	chr18:44512332	C/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.37	5.89	0.34	1.2e-8	Personality dimensions;
CESC	cis	rs4851870	0.874	rs59912414	chr2:106449674	C/A	cg16077055	chr2:106428750	NCK2	-0.39	-5.05	-0.3	8.15e-7	Addiction;
CESC	cis	rs1552244	0.808	rs7615088	chr3:10035896	A/T	cg08888203	chr3:10149979	C3orf24	0.48	6.1	0.35	3.84e-9	Alzheimer's disease;
CESC	cis	rs1816752	1.000	rs9511265	chr13:25012359	T/C	cg02811702	chr13:24901961	NA	0.39	5.7	0.33	3.2e-8	Obesity-related traits;
CESC	cis	rs4523957	0.928	rs216223	chr17:2155948	C/T	cg16513277	chr17:2031491	SMG6	0.6	8.23	0.45	8.75e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs2839186	0.605	rs2839174	chr21:47676934	T/C	cg10351095	chr21:47802916	PCNT	-0.49	-6.57	-0.37	2.58e-10	Testicular germ cell tumor;
CESC	cis	rs644799	0.542	rs10831418	chr11:95468828	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.66	9.2	0.49	1.12e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs4662945	0.603	rs13002385	chr2:130276865	T/C	cg05962382	chr2:130345044	NA	-0.5	-7.13	-0.4	9.81e-12	Response to cytidine analogues (gemcitabine);
CESC	cis	rs12681288	0.676	rs2701923	chr8:994605	A/G	cg15309053	chr8:964076	NA	0.4	6.81	0.39	6.66e-11	Schizophrenia;
CESC	cis	rs6426558	0.537	rs6662583	chr1:227383889	A/G	cg10327440	chr1:227177885	CDC42BPA	-0.5	-6.41	-0.37	6.59e-10	Neutrophil percentage of white cells;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg24641901	chr11:93212232	C11orf75	0.51	6.83	0.39	5.93e-11	Fibrinogen levels;
CESC	cis	rs9911578	0.835	rs9788975	chr17:56460800	G/A	cg12560992	chr17:57184187	TRIM37	-0.85	-13.78	-0.65	6.11e-33	Intelligence (multi-trait analysis);
CESC	cis	rs9488822	0.676	rs12196579	chr6:116351724	G/T	cg15226275	chr6:116381976	FRK	0.26	6.48	0.37	4.43e-10	Cholesterol, total;LDL cholesterol;
CESC	cis	rs3812762	0.871	rs3862352	chr11:8818020	C/T	cg03980550	chr11:8754370	ST5	-0.39	-5.49	-0.32	9.43e-8	Hypospadias;
CESC	cis	rs2806561	0.765	rs643492	chr1:23501354	C/T	cg12483005	chr1:23474871	LUZP1	-0.38	-6.02	-0.35	5.88e-9	Height;
CESC	cis	rs72829446	0.530	rs2302761	chr17:7358520	C/T	cg02795151	chr17:7402630	POLR2A	0.51	5.35	0.31	1.87e-7	Androgen levels;
CESC	cis	rs889312	0.500	rs832585	chr5:56125904	T/C	cg22800045	chr5:56110881	MAP3K1	0.41	5.04	0.3	8.55e-7	Breast cancer;Breast cancer (early onset);
CESC	cis	rs9611565	0.921	rs5758297	chr22:41720697	A/G	cg06481639	chr22:41940642	POLR3H	-0.45	-5.36	-0.31	1.83e-7	Vitiligo;
CESC	cis	rs9868809	0.881	rs2310996	chr3:48671834	T/C	cg07636037	chr3:49044803	WDR6	-0.67	-6.07	-0.35	4.36e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs7618915	0.547	rs4687636	chr3:52633929	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.47	6.69	0.38	1.35e-10	Bipolar disorder;
CESC	cis	rs6860806	0.507	rs2631362	chr5:131707293	A/G	cg24060327	chr5:131705240	SLC22A5	0.78	11.17	0.57	5.53e-24	Breast cancer;
CESC	cis	rs12586317	0.545	rs58342373	chr14:35395269	T/C	cg16230307	chr14:35515116	FAM177A1	0.81	8.51	0.46	1.27e-15	Psoriasis;
CESC	cis	rs74181299	1.000	rs74181299	chr2:65283972	T/C	cg05010058	chr2:65284262	CEP68	0.34	6.02	0.35	5.77e-9	Pulse pressure;
CESC	cis	rs1790761	0.587	rs4930430	chr11:67294198	A/G	cg24690094	chr11:67383802	NA	0.34	5.97	0.34	7.65e-9	Mean corpuscular volume;
CESC	cis	rs367615	0.918	rs17161889	chr5:108855251	A/G	cg17395555	chr5:108820864	NA	-0.54	-8.25	-0.45	7.51e-15	Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs977987	0.806	rs766521	chr16:75424154	A/G	cg03315344	chr16:75512273	CHST6	-0.41	-6.05	-0.35	4.96e-9	Dupuytren's disease;
CESC	cis	rs12540874	0.529	rs732215	chr7:50544063	A/C	cg18232548	chr7:50535776	DDC	-0.43	-6.15	-0.35	2.82e-9	Systemic sclerosis;
CESC	cis	rs11931598	1.000	rs11931598	chr4:7047102	A/G	cg26116260	chr4:7069785	GRPEL1	0.38	5.65	0.33	4.21e-8	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg11674231	chr7:5821297	RNF216	-0.5	-7.06	-0.4	1.46e-11	Ulcerative colitis;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg23171573	chr15:41099257	ZFYVE19;DNAJC17	-0.47	-6.0	-0.35	6.37e-9	Ulcerative colitis;
CESC	cis	rs372883	0.648	rs4817279	chr21:30638285	T/C	cg24692254	chr21:30365293	RNF160	-0.54	-6.93	-0.39	3.18e-11	Pancreatic cancer;
CESC	cis	rs989128	0.600	rs916978	chr17:48630452	T/C	cg24438145	chr17:48624694	SPATA20	0.45	5.31	0.31	2.36e-7	Type 2 diabetes;
CESC	cis	rs34779708	0.766	rs16935949	chr10:35551815	T/C	cg04310649	chr10:35416472	CREM	-0.47	-5.31	-0.31	2.33e-7	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs7631605	0.905	rs7615363	chr3:37006262	A/G	cg22985146	chr3:37219077	LRRFIP2	-0.34	-5.41	-0.32	1.39e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs1707322	1.000	rs34444543	chr1:46358862	G/A	cg06784218	chr1:46089804	CCDC17	0.3	5.1	0.3	6.38e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs35110281	0.506	rs13051661	chr21:45111518	A/T	cg04455712	chr21:45112962	RRP1B	0.51	8.0	0.44	3.9e-14	Mean corpuscular volume;
CESC	cis	rs17711722	0.585	rs6942660	chr7:65302406	C/T	cg18876405	chr7:65276391	NA	0.69	9.72	0.51	2.78e-19	Calcium levels;
CESC	cis	rs208520	0.690	rs7739253	chr6:66861052	A/G	cg07460842	chr6:66804631	NA	-1.0	-13.46	-0.64	8.08e-32	Exhaled nitric oxide output;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg08064573	chr19:3700773	PIP5K1C	-0.51	-6.48	-0.37	4.56e-10	Height;
CESC	cis	rs6582630	0.555	rs10880613	chr12:38509553	C/T	cg26384229	chr12:38710491	ALG10B	0.72	10.68	0.55	2.17e-22	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs9322193	0.962	rs3805748	chr6:150093678	C/T	cg05861140	chr6:150128134	PCMT1	-0.37	-5.33	-0.31	2.16e-7	Lung cancer;
CESC	cis	rs6089584	0.566	rs6061963	chr20:60607480	C/G	cg23463467	chr20:60627584	TAF4	0.35	5.06	0.3	7.8e-7	Body mass index;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg16650099	chr1:114471848	HIPK1	-0.45	-6.13	-0.35	3.24e-9	Height;
CESC	cis	rs9911578	0.967	rs4932693	chr17:57110327	T/C	cg05425664	chr17:57184151	TRIM37	0.52	7.19	0.4	6.63e-12	Intelligence (multi-trait analysis);
CESC	cis	rs7589728	0.925	rs80065975	chr2:88502758	G/A	cg04511125	chr2:88470314	THNSL2	0.57	5.47	0.32	1.06e-7	Plasma clusterin levels;
CESC	cis	rs6800768	0.633	rs59461522	chr3:24100377	G/A	cg10674438	chr3:24145617	LOC152024	-0.42	-5.61	-0.33	4.97e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs703842	1.000	rs11172333	chr12:58170335	A/G	cg18357645	chr12:58087776	OS9	-0.42	-5.84	-0.34	1.52e-8	Multiple sclerosis;
CESC	cis	rs7666738	0.791	rs1405766	chr4:98965389	T/C	cg17366294	chr4:99064904	C4orf37	0.6	8.52	0.46	1.2e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1005224	0.895	rs6574252	chr14:76141834	C/T	cg25116370	chr14:76127843	TTLL5;C14orf1	-0.42	-5.75	-0.33	2.5e-8	Large artery stroke;
CESC	cis	rs3820928	0.935	rs113195824	chr2:227769139	A/G	cg11843606	chr2:227700838	RHBDD1	-0.43	-5.7	-0.33	3.11e-8	Pulmonary function;
CESC	trans	rs916888	0.821	rs199506	chr17:44859031	A/G	cg23590916	chr17:43697445	MGC57346	-0.6	-6.27	-0.36	1.47e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs561341	1.000	rs8069199	chr17:30281845	A/G	cg00745463	chr17:30367425	LRRC37B	-0.7	-7.02	-0.4	1.85e-11	Hip circumference adjusted for BMI;
CESC	cis	rs7666738	0.830	rs6831588	chr4:98977356	T/G	cg03676636	chr4:99064102	C4orf37	0.34	5.2	0.3	3.93e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9488822	0.676	rs11757115	chr6:116362619	C/T	cg15226275	chr6:116381976	FRK	0.25	6.41	0.37	6.76e-10	Cholesterol, total;LDL cholesterol;
CESC	cis	rs3767633	0.925	rs1394070	chr1:161814020	T/G	cg09175582	chr1:161736000	ATF6	0.86	6.85	0.39	5.21e-11	IgG glycosylation;
CESC	cis	rs4975709	0.589	rs4975744	chr5:1860049	A/G	cg20790798	chr5:1857306	NA	-0.39	-5.32	-0.31	2.26e-7	Cardiovascular disease risk factors;
CESC	cis	rs9649213	0.593	rs3801256	chr7:97992095	C/G	cg08684580	chr7:98029266	BAIAP2L1	-0.35	-5.8	-0.34	1.85e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs9611565	0.729	rs2413647	chr22:41907148	G/A	cg06481639	chr22:41940642	POLR3H	-0.64	-6.6	-0.38	2.21e-10	Vitiligo;
CESC	cis	rs13191362	0.507	rs6936804	chr6:163069424	A/T	cg06582575	chr6:163149167	PACRG;PARK2	-0.53	-6.22	-0.36	1.98e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs7692995	1.000	rs10516315	chr4:18016877	A/G	cg08925142	chr4:18023851	LCORL	-0.44	-5.07	-0.3	7.47e-7	Height;
CESC	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg07414643	chr4:187882934	NA	0.54	7.39	0.41	1.87e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs690037	0.809	rs690023	chr3:16386354	C/T	cg23474789	chr3:16306055	DPH3;OXNAD1	-0.4	-5.4	-0.32	1.45e-7	Optic nerve measurement (cup-to-disc ratio);Optic nerve measurement (cup area);
CESC	cis	rs4566357	0.539	rs10933164	chr2:227860671	A/G	cg11843606	chr2:227700838	RHBDD1	-0.73	-9.09	-0.49	2.31e-17	Coronary artery disease;
CESC	cis	rs763121	0.813	rs4821807	chr22:39065582	A/G	cg21395723	chr22:39101663	GTPBP1	0.43	5.28	0.31	2.75e-7	Menopause (age at onset);
CESC	cis	rs6540556	0.723	rs6752	chr1:209908100	G/A	cg23920097	chr1:209922102	NA	-0.39	-5.07	-0.3	7.55e-7	Red blood cell count;
CESC	cis	rs7555523	0.778	rs2790052	chr1:165738463	G/C	cg24409356	chr1:165738333	TMCO1	0.97	8.63	0.47	5.95e-16	Intraocular pressure;Glaucoma (high intraocular pressure);
CESC	cis	rs769267	0.930	rs6511038	chr19:19607564	A/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.46	5.93	0.34	9.24e-9	Tonsillectomy;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg06697439	chr19:59031463	ZBTB45	-0.46	-6.43	-0.37	5.76e-10	Asthma;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg00911289	chr3:128840257	RAB43	-0.54	-7.15	-0.4	8.29e-12	Asthma;
CESC	cis	rs6460942	0.591	rs4721078	chr7:12334657	T/A	cg06484146	chr7:12443880	VWDE	-0.66	-7.27	-0.41	4.01e-12	Coronary artery disease;
CESC	cis	rs9325144	0.510	rs7952795	chr12:38720686	C/T	cg26384229	chr12:38710491	ALG10B	0.57	7.96	0.44	4.99e-14	Morning vs. evening chronotype;
CESC	cis	rs763014	0.833	rs916415	chr16:632115	G/A	cg09263875	chr16:632152	PIGQ	0.67	11.24	0.57	3.15e-24	Height;
CESC	cis	rs11098499	0.738	rs28687057	chr4:120280812	A/G	cg24375607	chr4:120327624	NA	0.42	5.19	0.3	4.19e-7	Corneal astigmatism;
CESC	cis	rs1348850	0.597	rs13014417	chr2:178417835	T/G	cg23306229	chr2:178417860	TTC30B	0.89	9.75	0.51	2.11e-19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs4746818	1.000	rs10733850	chr10:70959617	C/T	cg04149295	chr10:70884716	VPS26A	0.58	5.07	0.3	7.44e-7	Left atrial antero-posterior diameter;
CESC	cis	rs73019876	0.680	rs807951	chr19:22120363	A/G	cg11619707	chr19:22235551	ZNF257	0.3	5.71	0.33	2.96e-8	Testicular germ cell tumor;
CESC	cis	rs748404	0.697	rs555001	chr15:43545728	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	7.87	0.44	8.86e-14	Lung cancer;
CESC	cis	rs514406	0.667	rs10788942	chr1:53210521	A/T	cg27535305	chr1:53392650	SCP2	0.35	6.08	0.35	4.18e-9	Monocyte count;
CESC	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg06873352	chr17:61820015	STRADA	0.72	12.67	0.61	4.43e-29	Prudent dietary pattern;
CESC	cis	rs1018836	0.923	rs13262354	chr8:91635731	G/A	cg16814680	chr8:91681699	NA	-0.78	-11.16	-0.57	5.82e-24	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs9611565	0.573	rs9306355	chr22:42111896	A/T	cg03806693	chr22:41940476	POLR3H	0.76	9.27	0.49	6.64e-18	Vitiligo;
CESC	cis	rs7772486	0.875	rs7739371	chr6:146424353	C/G	cg23711669	chr6:146136114	FBXO30	0.85	12.45	0.61	2.6e-28	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7666738	0.830	rs13108705	chr4:99044438	T/C	cg05340658	chr4:99064831	C4orf37	0.82	12.88	0.62	8.44e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2295499	0.754	rs16843291	chr4:2728092	C/G	cg08330972	chr4:2403930	ZFYVE28	-0.31	-5.06	-0.3	7.76e-7	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
CESC	cis	rs473651	0.506	rs561264	chr2:239329979	G/T	cg18131467	chr2:239335373	ASB1	0.89	11.42	0.57	7.98e-25	Multiple system atrophy;
CESC	cis	rs7264396	0.690	rs2425183	chr20:34450621	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.85	-11.57	-0.58	2.57e-25	Total cholesterol levels;
CESC	cis	rs6964587	0.967	rs12531966	chr7:91765840	A/G	cg17063962	chr7:91808500	NA	0.55	7.5	0.42	9.9e-13	Breast cancer;
CESC	cis	rs2820292	0.619	rs11576508	chr1:201824390	G/A	cg06775570	chr1:201857621	SHISA4	-0.31	-5.04	-0.3	8.65e-7	Waist circumference;Body mass index (joint analysis main effects and smoking interaction);Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);
CESC	cis	rs873946	0.504	rs3793681	chr10:134564451	T/C	cg18305652	chr10:134549665	INPP5A	0.49	7.12	0.4	1.01e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs2075371	0.829	rs11770521	chr7:133936251	A/C	cg20476274	chr7:133979776	SLC35B4	0.61	8.74	0.47	2.63e-16	Mean platelet volume;
CESC	cis	rs7100689	0.646	rs4265545	chr10:82119271	G/T	cg00277334	chr10:82204260	NA	-0.59	-7.86	-0.43	9.6e-14	Post bronchodilator FEV1;
CESC	cis	rs10883723	0.773	rs11191313	chr10:104278618	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.59	7.31	0.41	3.18e-12	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs7020830	0.858	rs13293465	chr9:37127678	C/T	cg14294708	chr9:37120828	ZCCHC7	1.24	23.87	0.83	5.52e-68	Schizophrenia;
CESC	trans	rs6089829	0.855	rs6090205	chr20:61665269	A/G	cg23505145	chr19:12996616	KLF1	0.52	6.8	0.39	6.85e-11	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs11190604	1.000	rs2489037	chr10:102319918	A/G	cg07080220	chr10:102295463	HIF1AN	-0.63	-5.73	-0.33	2.74e-8	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs2797160	1.000	rs2747723	chr6:126010790	C/T	cg05901451	chr6:126070800	HEY2	0.47	6.85	0.39	5.01e-11	Endometrial cancer;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg18697049	chr6:111136368	CDK19	0.45	6.03	0.35	5.54e-9	Systemic lupus erythematosus;
CESC	cis	rs1707322	0.682	rs12041197	chr1:46104464	T/C	cg05343316	chr1:45956843	TESK2	0.51	6.35	0.36	9.44e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs3820068	0.581	rs34453754	chr1:15993208	G/C	cg18133145	chr1:16060689	PLEKHM2	-0.43	-5.48	-0.32	1.01e-7	Systolic blood pressure;
CESC	cis	rs1670533	0.872	rs935969	chr4:1062588	A/G	cg27284194	chr4:1044797	NA	0.48	6.03	0.35	5.37e-9	Recombination rate (females);
CESC	cis	rs1552244	0.882	rs13088350	chr3:10044626	T/C	cg08888203	chr3:10149979	C3orf24	0.47	5.96	0.34	7.94e-9	Alzheimer's disease;
CESC	trans	rs9951602	0.512	rs8089108	chr18:76651361	C/T	cg02800362	chr5:177631904	HNRNPAB	0.66	8.64	0.47	5.41e-16	Obesity-related traits;
CESC	cis	rs1670533	0.685	rs56019586	chr4:1059842	C/G	cg04106633	chr4:1044584	NA	0.42	5.3	0.31	2.49e-7	Recombination rate (females);
CESC	cis	rs1018836	0.847	rs2285231	chr8:91545387	G/T	cg16814680	chr8:91681699	NA	-0.7	-10.31	-0.53	3.59e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs4665809	1.000	rs4665304	chr2:26313406	C/T	cg27170947	chr2:26402098	FAM59B	-0.58	-6.91	-0.39	3.69e-11	Gut microbiome composition (summer);
CESC	cis	rs113835537	0.529	rs17147644	chr11:66256660	C/T	cg24851651	chr11:66362959	CCS	0.47	5.77	0.33	2.16e-8	Airway imaging phenotypes;
CESC	cis	rs35306767	0.761	rs11253560	chr10:1047226	T/G	cg26597838	chr10:835615	NA	0.7	6.53	0.37	3.31e-10	Eosinophil percentage of granulocytes;
CESC	cis	rs4563143	0.675	rs55884228	chr19:29243897	G/T	cg12667521	chr19:29218732	NA	0.48	6.4	0.37	6.97e-10	Methadone dose in opioid dependence;
CESC	cis	rs1348850	0.519	rs13034781	chr2:178523550	C/A	cg23306229	chr2:178417860	TTC30B	0.46	5.38	0.31	1.67e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs1862618	0.573	rs1550821	chr5:56242323	C/T	cg20203395	chr5:56204925	C5orf35	0.5	5.83	0.34	1.65e-8	Initial pursuit acceleration;
CESC	cis	rs7577696	0.597	rs7556942	chr2:32295694	G/A	cg02381751	chr2:32503542	YIPF4	-0.42	-5.05	-0.3	8.32e-7	Inflammatory biomarkers;
CESC	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg19723775	chr5:179050963	HNRNPH1	-0.4	-5.33	-0.31	2.09e-7	Lung cancer;
CESC	cis	rs559928	0.692	rs876064	chr11:64037033	G/A	cg18225595	chr11:63971243	STIP1	0.61	5.2	0.3	4.04e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CESC	cis	rs6952808	0.692	rs6950627	chr7:2086672	C/T	cg02951883	chr7:2050386	MAD1L1	-0.49	-6.39	-0.37	7.45e-10	Bipolar disorder and schizophrenia;
CESC	cis	rs6460942	0.915	rs17541464	chr7:12462675	A/G	cg16278512	chr7:12443529	VWDE	-0.45	-5.16	-0.3	4.96e-7	Coronary artery disease;
CESC	cis	rs28647808	1.000	rs6597629	chr9:136270841	A/C	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.9	5.73	0.33	2.75e-8	Blood protein levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27405321	chr20:34359917	PHF20	-0.62	-7.79	-0.43	1.52e-13	Gut microbiome composition (summer);
CESC	cis	rs11640734	0.609	rs11647746	chr16:89806343	C/A	cg00800038	chr16:89945340	TCF25	-0.66	-6.35	-0.36	9.4e-10	Interleukin-17 levels;
CESC	cis	rs2901656	1.000	rs6691993	chr1:172426998	T/G	cg03748243	chr1:172413542	C1orf105;PIGC	0.42	6.35	0.36	9.11e-10	Red cell distribution width;Platelet distribution width;
CESC	cis	rs9329289	0.603	rs2458705	chr10:2541377	A/G	cg05625103	chr10:2543513	NA	0.44	6.01	0.35	6.03e-9	Age-related hearing impairment;
CESC	cis	rs2072732	0.756	rs77415878	chr1:2954047	C/G	cg15211996	chr1:2936768	ACTRT2	0.34	5.78	0.33	2.08e-8	Plateletcrit;
CESC	cis	rs1218582	0.740	rs1977879	chr1:154879743	G/A	cg06221963	chr1:154839813	KCNN3	-0.66	-11.32	-0.57	1.71e-24	Prostate cancer;
CESC	cis	rs3892630	0.824	rs35654350	chr19:33223766	T/C	cg13157960	chr19:33183277	NUDT19	0.54	5.09	0.3	6.83e-7	Red blood cell traits;
CESC	cis	rs7714584	1.000	rs11167518	chr5:150258920	C/A	cg22134413	chr5:150180641	NA	0.47	5.29	0.31	2.5e-7	Crohn's disease;
CESC	cis	rs6904897	0.563	rs4896117	chr6:135229400	T/C	cg24558204	chr6:135376177	HBS1L	-0.55	-7.43	-0.42	1.48e-12	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	cis	rs854765	0.547	rs9894138	chr17:17964345	G/A	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.54	-7.0	-0.4	2.06e-11	Total body bone mineral density;
CESC	cis	rs2658782	0.547	rs4753453	chr11:93041174	T/G	cg15737290	chr11:93063684	CCDC67	0.5	6.83	0.39	5.83e-11	Pulmonary function decline;
CESC	cis	rs477692	1.000	rs553371	chr10:131413676	T/C	cg05714579	chr10:131428358	MGMT	0.45	6.11	0.35	3.5e-9	Response to temozolomide;
CESC	cis	rs1215050	0.765	rs783947	chr4:99012943	T/C	cg05340658	chr4:99064831	C4orf37	-0.55	-7.45	-0.42	1.36e-12	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs6062302	0.522	rs2236503	chr20:62224595	G/A	cg06363034	chr20:62225388	GMEB2	-0.52	-6.69	-0.38	1.3100000000000001e-10	Glioblastoma;
CESC	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.58	-6.39	-0.37	7.38e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs9908102	0.682	rs56338821	chr17:12905125	T/C	cg26162695	chr17:12921313	ELAC2	0.5	5.49	0.32	9.61e-8	Schizophrenia;
CESC	cis	rs7618501	1.000	rs9855505	chr3:49792158	T/G	cg24308560	chr3:49941425	MST1R	0.5	6.71	0.38	1.15e-10	Intelligence (multi-trait analysis);
CESC	cis	rs7216064	1.000	rs8071463	chr17:65938655	C/T	cg07042672	chr17:66097459	LOC651250	0.61	7.32	0.41	2.96e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs854765	0.718	rs12943500	chr17:17790588	C/T	cg04398451	chr17:18023971	MYO15A	0.62	8.31	0.45	5.1e-15	Total body bone mineral density;
CESC	cis	rs4665809	1.000	rs11126375	chr2:26344787	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.67	-7.53	-0.42	7.92e-13	Gut microbiome composition (summer);
CESC	cis	rs4853525	0.617	rs12998878	chr2:191770894	C/T	cg21644426	chr2:191273491	MFSD6	0.46	5.87	0.34	1.31e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
CESC	cis	rs2370759	1.000	rs76998371	chr10:32631785	A/G	cg18270830	chr10:32634957	EPC1	0.71	6.87	0.39	4.58e-11	Sexual dysfunction (female);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg20930514	chr14:77499758	NA	-0.41	-6.18	-0.35	2.45e-9	Gambling;
CESC	cis	rs7666738	0.830	rs1426665	chr4:99027764	C/T	cg03676636	chr4:99064102	C4orf37	0.34	5.18	0.3	4.4e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs151349	1.000	rs151344	chr20:57585301	A/G	cg23907860	chr20:57583709	CTSZ	-0.41	-6.63	-0.38	1.83e-10	Platelet distribution width;
CESC	cis	rs477692	1.000	rs554792	chr10:131423181	A/G	cg05714579	chr10:131428358	MGMT	0.48	6.49	0.37	4.29e-10	Response to temozolomide;
CESC	cis	rs909674	0.514	rs7423	chr22:39781429	C/T	cg11247378	chr22:39784982	NA	-0.51	-7.92	-0.44	6.61e-14	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27502066	chr17:74380231	SPHK1	0.51	6.11	0.35	3.52e-9	Gut microbiome composition (summer);
CESC	cis	rs9911578	1.000	rs2531734	chr17:56550804	T/C	cg12560992	chr17:57184187	TRIM37	-0.92	-15.31	-0.69	2.4e-38	Intelligence (multi-trait analysis);
CESC	cis	rs116095464	0.558	rs10058428	chr5:235608	A/G	cg20965017	chr5:231967	SDHA	-0.45	-5.1	-0.3	6.61e-7	Breast cancer;
CESC	cis	rs447	1.000	rs7804563	chr7:83777694	G/A	cg22846510	chr7:83753280	SEMA3A	-0.42	-5.19	-0.3	4.19e-7	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs7193541	0.684	rs4888262	chr16:74670458	C/T	cg05580060	chr16:74700937	RFWD3	-0.45	-5.71	-0.33	3.06e-8	Multiple myeloma;
CESC	cis	rs9399135	0.967	rs7763836	chr6:135362378	T/C	cg22676075	chr6:135203613	NA	0.52	7.31	0.41	3.07e-12	Red blood cell count;
CESC	cis	rs116095464	0.558	rs9687898	chr5:253952	A/G	cg12570787	chr5:219185	SDHA;CCDC127	0.51	5.28	0.31	2.76e-7	Breast cancer;
CESC	cis	rs938554	0.735	rs12498742	chr4:9944052	A/G	cg00071950	chr4:10020882	SLC2A9	-0.46	-5.68	-0.33	3.54e-8	Blood metabolite levels;
CESC	cis	rs4665809	0.590	rs4665315	chr2:26416036	T/G	cg27170947	chr2:26402098	FAM59B	-0.84	-10.03	-0.52	2.88e-20	Gut microbiome composition (summer);
CESC	cis	rs10088262	0.629	rs7828192	chr8:124804669	C/T	cg02993010	chr8:124780839	FAM91A1	-0.65	-8.13	-0.45	1.69e-14	Pancreatic cancer;
CESC	cis	rs854765	0.520	rs9899355	chr17:17898243	C/T	cg04398451	chr17:18023971	MYO15A	-0.62	-8.58	-0.47	7.9e-16	Total body bone mineral density;
CESC	cis	rs9837602	0.935	rs4928149	chr3:99685686	A/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.42	-5.51	-0.32	8.44e-8	Breast cancer;
CESC	cis	rs6951245	0.572	rs73264028	chr7:1045455	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.65	-6.09	-0.35	3.87e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs1552244	1.000	rs112509186	chr3:10156533	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.88	12.09	0.6	4.15e-27	Alzheimer's disease;
CESC	trans	rs11098499	0.955	rs6815725	chr4:120158410	C/A	cg25214090	chr10:38739885	LOC399744	0.64	8.63	0.47	5.92e-16	Corneal astigmatism;
CESC	cis	rs5498	0.809	rs2228615	chr19:10403368	G/A	cg08845333	chr19:10403403	ICAM5	0.4	5.49	0.32	9.2e-8	Lymphocyte counts;Soluble ICAM-1;Blood protein levels;
CESC	trans	rs875971	1.000	rs937495	chr7:65779798	A/G	cg26939375	chr7:64535504	NA	-0.46	-6.08	-0.35	4.27e-9	Aortic root size;
CESC	cis	rs61776719	0.738	rs7555461	chr1:38444749	T/C	cg17077180	chr1:38461687	NA	-0.52	-7.78	-0.43	1.66e-13	Coronary artery disease;
CESC	trans	rs1545843	0.564	rs2403206	chr12:84889647	C/A	cg03015433	chr16:56623111	MT3	0.33	6.01	0.35	6.09e-9	Major depressive disorder;
CESC	cis	rs6893300	0.524	rs6601073	chr5:179177271	A/G	cg14593053	chr5:179126677	CANX	-0.54	-7.88	-0.44	8.61e-14	Resting heart rate;
CESC	cis	rs6879260	1.000	rs10903252	chr5:179733934	T/C	cg13944838	chr5:179740914	GFPT2	-0.61	-8.18	-0.45	1.18e-14	Height;
CESC	cis	rs6484504	0.652	rs485265	chr11:31407788	G/A	cg14844989	chr11:31128820	NA	0.36	5.05	0.3	8.33e-7	Red blood cell count;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg06130365	chr10:135122020	TUBGCP2;ZNF511	0.46	6.08	0.35	4.22e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs11203032	1.000	rs11203032	chr10:90964614	T/G	cg16672925	chr10:90967113	CH25H	0.74	7.11	0.4	1.09e-11	Heart failure;
CESC	cis	rs1065852	0.906	rs5751232	chr22:42564304	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.6	8.89	0.48	9.89e-17	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
CESC	cis	rs67311347	1.000	rs4973989	chr3:40451543	C/T	cg09455208	chr3:40491958	NA	0.53	8.62	0.47	6.29e-16	Renal cell carcinoma;
CESC	cis	rs13118159	0.742	rs7679860	chr4:1333987	C/T	cg20887711	chr4:1340912	KIAA1530	0.62	8.45	0.46	1.94e-15	Longevity;
CESC	cis	rs9640161	0.830	rs3757423	chr7:150067714	A/G	cg21361702	chr7:150065534	REPIN1	-0.55	-7.41	-0.41	1.65e-12	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs2836950	0.565	rs8134214	chr21:40542367	A/C	cg11644478	chr21:40555479	PSMG1	-0.57	-7.9	-0.44	7.71e-14	Menarche (age at onset);
CESC	cis	rs6879260	1.000	rs6879260	chr5:179731014	A/G	cg23248424	chr5:179741104	GFPT2	-0.64	-8.51	-0.46	1.29e-15	Height;
CESC	cis	rs9291683	0.551	rs62295971	chr4:9978142	G/A	cg00071950	chr4:10020882	SLC2A9	0.78	14.51	0.67	1.66e-35	Bone mineral density;
CESC	cis	rs6499255	1.000	rs4464069	chr16:69816284	C/T	cg15192750	chr16:69999425	NA	0.42	5.29	0.31	2.51e-7	IgE levels;
CESC	cis	rs67257959	0.708	rs11671858	chr19:17201520	T/G	cg16202187	chr19:17186497	HAUS8;MYO9B	0.43	5.19	0.3	4.26e-7	Selective IgA deficiency;
CESC	cis	rs10870270	0.957	rs7074604	chr10:133740373	G/C	cg26149184	chr10:133730230	NA	0.38	5.15	0.3	5.07e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs899997	1.000	rs11072794	chr15:79006582	A/G	cg04896959	chr15:78267971	NA	0.41	6.4	0.37	6.96e-10	Coronary artery disease or large artery stroke;
CESC	cis	rs2996428	0.667	rs7545274	chr1:3744261	G/T	cg13057898	chr1:3703894	LRRC47	0.4	5.46	0.32	1.11e-7	Red cell distribution width;
CESC	cis	rs2019216	0.542	rs12450889	chr17:21889379	A/G	cg22648282	chr17:21454238	C17orf51	-0.41	-5.35	-0.31	1.9e-7	Pelvic organ prolapse;
CESC	cis	rs9902453	0.933	rs2054846	chr17:28507693	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.62	-7.97	-0.44	4.64e-14	Coffee consumption (cups per day);
CESC	cis	rs1348850	0.914	rs1975544	chr2:178465423	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.67	8.61	0.47	6.58e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs963731	0.649	rs1454227	chr2:39249328	T/C	cg04010122	chr2:39346883	SOS1	-0.69	-5.35	-0.31	1.91e-7	Corticobasal degeneration;
CESC	cis	rs7085104	0.572	rs284856	chr10:104574329	A/T	cg04362960	chr10:104952993	NT5C2	-0.47	-6.37	-0.36	8.3e-10	Immature fraction of reticulocytes;Schizophrenia;
CESC	trans	rs1994135	0.647	rs1351681	chr12:33698724	G/A	cg26384229	chr12:38710491	ALG10B	0.54	7.31	0.41	3.17e-12	Resting heart rate;
CESC	cis	rs1218582	0.682	rs12144978	chr1:154850445	G/A	cg03351412	chr1:154909251	PMVK	0.53	6.46	0.37	4.89e-10	Prostate cancer;
CESC	cis	rs3774749	0.565	rs2518796	chr3:50207075	A/G	cg24110177	chr3:50126178	RBM5	-0.39	-5.15	-0.3	5.21e-7	Intelligence (multi-trait analysis);
CESC	cis	rs3785574	0.962	rs62077509	chr17:61848973	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.59	7.21	0.41	5.72e-12	Height;
CESC	cis	rs597539	0.652	rs611046	chr11:68631704	A/G	cg18350739	chr11:68623251	NA	-0.44	-6.3	-0.36	1.24e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs769267	0.965	rs8103496	chr19:19386015	A/G	cg03709012	chr19:19516395	GATAD2A	0.96	14.18	0.66	2.35e-34	Tonsillectomy;
CESC	cis	rs3806843	1.000	rs10072015	chr5:140170655	A/T	cg26395211	chr5:140044315	WDR55	0.41	5.21	0.3	3.79e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	7.61	0.42	4.95e-13	Prudent dietary pattern;
CESC	cis	rs8031584	0.918	rs34693097	chr15:31253984	A/G	cg08704250	chr15:31115839	NA	-0.63	-8.2	-0.45	1.05e-14	Huntington's disease progression;
CESC	cis	rs875971	0.558	rs4433015	chr7:65639723	A/C	cg18876405	chr7:65276391	NA	-0.65	-9.06	-0.49	2.92e-17	Aortic root size;
CESC	cis	rs1799949	1.000	rs8077486	chr17:41212805	C/T	cg25072359	chr17:41440525	NA	0.47	6.86	0.39	4.97e-11	Menopause (age at onset);
CESC	cis	rs4819052	1.000	rs733738	chr21:46666396	A/G	cg11663144	chr21:46675770	NA	0.46	6.35	0.36	9.36e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs7647973	0.600	rs12631989	chr3:49273996	C/T	cg02487422	chr3:49467188	NICN1	0.39	5.3	0.31	2.38e-7	Menarche (age at onset);
CESC	cis	rs12410462	1.000	rs75652886	chr1:227654485	G/T	cg23173402	chr1:227635558	NA	0.56	5.64	0.33	4.28e-8	Major depressive disorder;
CESC	cis	rs9486719	1.000	rs34209750	chr6:96882215	G/T	cg18709589	chr6:96969512	KIAA0776	-0.53	-5.81	-0.34	1.75e-8	Migraine;Coronary artery disease;
CESC	cis	rs853679	0.517	rs9380049	chr6:28048535	A/G	cg19592336	chr6:28129416	ZNF389	0.6	7.97	0.44	4.69e-14	Depression;
CESC	cis	rs7945705	0.747	rs2653605	chr11:8993309	C/G	cg12365402	chr11:9010492	NRIP3	-0.44	-7.44	-0.42	1.38e-12	Hemoglobin concentration;
CESC	cis	rs853679	0.517	rs9368558	chr6:28133306	A/G	cg19592336	chr6:28129416	ZNF389	0.61	8.03	0.44	3.13e-14	Depression;
CESC	trans	rs10506458	1.000	rs1009539	chr12:63414655	A/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	1.27	17.35	0.73	1.48e-45	Hemostatic factors and hematological phenotypes;
CESC	cis	rs9611565	0.649	rs5758442	chr22:42133060	T/C	cg06481639	chr22:41940642	POLR3H	0.5	5.81	0.34	1.78e-8	Vitiligo;
CESC	cis	rs6060717	0.536	rs6058356	chr20:34491530	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.54	5.17	0.3	4.73e-7	Hip circumference adjusted for BMI;
CESC	cis	rs2243480	1.000	rs160644	chr7:65558186	C/T	cg13147721	chr7:65941812	NA	-0.98	-9.11	-0.49	2.06e-17	Diabetic kidney disease;
CESC	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg18538332	chr22:24372958	LOC391322	0.72	9.35	0.5	3.78e-18	Urinary 1,3-butadiene metabolite levels in smokers;
CESC	cis	rs9863	0.861	rs7958691	chr12:124440743	G/T	cg00084347	chr12:124393913	DNAH10	0.27	5.35	0.31	1.91e-7	White blood cell count;
CESC	cis	rs2273669	0.667	rs79285264	chr6:109318279	G/T	cg05315195	chr6:109294784	ARMC2	-0.66	-5.71	-0.33	3.03e-8	Prostate cancer;
CESC	trans	rs3780486	0.846	rs10116966	chr9:33122370	T/A	cg04842962	chr6:43655489	MRPS18A	1.0	19.43	0.77	6.71e-53	IgG glycosylation;
CESC	cis	rs651907	0.557	rs7651406	chr3:101393296	C/T	cg12386194	chr3:101231763	SENP7	0.45	5.71	0.33	3.05e-8	Colorectal cancer;
CESC	cis	rs2603127	0.724	rs2121766	chr3:108482513	G/C	cg03329597	chr3:108125523	MYH15	0.6	5.38	0.31	1.62e-7	Hemostatic factors and hematological phenotypes;
CESC	cis	rs10504229	0.683	rs67492041	chr8:58140077	G/A	cg02725872	chr8:58115012	NA	-0.45	-7.12	-0.4	1.02e-11	Developmental language disorder (linguistic errors);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25020846	chr6:53659618	LRRC1	0.71	8.14	0.45	1.56e-14	Gut microbiome composition (summer);
CESC	cis	rs7953249	0.618	rs7954039	chr12:121398654	A/C	cg25281562	chr12:121454272	C12orf43	-0.46	-5.7	-0.33	3.12e-8	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
CESC	cis	rs11711311	0.869	rs12493635	chr3:113373019	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.47	5.93	0.34	9.45e-9	IgG glycosylation;
CESC	cis	rs9486719	1.000	rs12212614	chr6:97036466	T/G	cg06623918	chr6:96969491	KIAA0776	-0.8	-8.21	-0.45	9.56e-15	Migraine;Coronary artery disease;
CESC	cis	rs2624839	0.704	rs12632110	chr3:50224225	A/G	cg14019146	chr3:50243930	SLC38A3	0.3	5.08	0.3	7.04e-7	Intelligence (multi-trait analysis);
CESC	cis	rs1218582	0.772	rs11264290	chr1:154912300	C/T	cg06221963	chr1:154839813	KCNN3	-0.66	-11.12	-0.56	8.07e-24	Prostate cancer;
CESC	cis	rs3916	0.641	rs2393749	chr12:121131891	C/T	cg26008908	chr12:120799332	MSI1	0.4	6.31	0.36	1.18e-9	Urinary metabolites (H-NMR features);
CESC	cis	rs3768617	0.510	rs1413388	chr1:183096694	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.89	14.39	0.66	4.39e-35	Fuchs's corneal dystrophy;
CESC	cis	rs7599312	0.534	rs2128321	chr2:213405276	G/T	cg16329650	chr2:213403929	ERBB4	0.57	8.68	0.47	4.16e-16	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs548181	0.536	rs503287	chr11:125461788	C/T	cg03464685	chr11:125439445	EI24	0.98	8.07	0.44	2.44e-14	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs727505	1.000	rs6971909	chr7:124525517	C/T	cg23710748	chr7:124431027	NA	-0.4	-6.47	-0.37	4.6e-10	Lewy body disease;
CESC	cis	rs7786877	0.521	rs4729606	chr7:100321790	T/C	cg20848291	chr7:100343083	ZAN	-0.7	-8.55	-0.46	1.02e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs10504229	0.683	rs56058640	chr8:58128862	C/T	cg02725872	chr8:58115012	NA	-0.45	-7.05	-0.4	1.52e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs914615	0.552	rs4421576	chr1:155142210	A/G	cg02153340	chr1:155202674	NA	-0.37	-5.39	-0.31	1.54e-7	Urinary albumin-to-creatinine ratio;
CESC	cis	rs875971	0.825	rs4587224	chr7:65736182	G/A	cg18876405	chr7:65276391	NA	-0.49	-6.75	-0.38	9.38e-11	Aortic root size;
CESC	cis	rs79839061	0.610	rs3736089	chr4:870118	G/A	cg07828340	chr4:882639	GAK	1.07	8.28	0.45	6.09e-15	Intelligence (multi-trait analysis);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg26272228	chr1:95538484	ALG14	-0.47	-6.0	-0.35	6.36e-9	Fibrinogen levels;
CESC	cis	rs9287719	0.967	rs6719701	chr2:10748283	G/A	cg02196655	chr2:10830764	NOL10	-0.38	-5.79	-0.34	1.96e-8	Prostate cancer;
CESC	cis	rs208520	0.661	rs7766144	chr6:66827795	C/T	cg07460842	chr6:66804631	NA	-1.0	-13.37	-0.63	1.62e-31	Exhaled nitric oxide output;
CESC	cis	rs7000551	0.527	rs11783730	chr8:22244897	C/T	cg02463440	chr8:22132932	PIWIL2	0.41	5.1	0.3	6.44e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CESC	cis	rs7726839	0.540	rs61731455	chr5:665295	A/G	cg16447950	chr5:562315	NA	-0.62	-6.54	-0.37	3.09e-10	Obesity-related traits;
CESC	cis	rs7267979	1.000	rs2259873	chr20:25280781	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	18.72	0.75	2.09e-50	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs703842	0.739	rs701008	chr12:58117645	A/G	cg18357645	chr12:58087776	OS9	-0.4	-5.97	-0.34	7.43e-9	Multiple sclerosis;
CESC	cis	rs727505	0.564	rs57841320	chr7:124847732	T/A	cg23710748	chr7:124431027	NA	-0.33	-5.1	-0.3	6.44e-7	Lewy body disease;
CESC	cis	rs2439831	1.000	rs565007	chr15:43716641	A/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.82	12.0	0.59	8.48e-27	Lung cancer in ever smokers;
CESC	cis	rs9611565	0.659	rs12484175	chr22:41953739	A/C	cg03806693	chr22:41940476	POLR3H	-1.23	-16.7	-0.72	2.8e-43	Vitiligo;
CESC	trans	rs561341	0.739	rs8070554	chr17:30216868	A/T	cg20587970	chr11:113659929	NA	0.59	7.53	0.42	7.85e-13	Hip circumference adjusted for BMI;
CESC	cis	rs977987	0.654	rs8054194	chr16:75497160	G/T	cg03315344	chr16:75512273	CHST6	0.48	6.72	0.38	1.12e-10	Dupuytren's disease;
CESC	cis	rs4664304	0.802	rs3792175	chr2:160862804	T/A	cg03641300	chr2:160917029	PLA2R1	-0.51	-7.17	-0.4	7.43e-12	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs597539	0.652	rs544370	chr11:68653232	C/T	cg18350739	chr11:68623251	NA	-0.43	-6.91	-0.39	3.5e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs7818345	0.595	rs12155539	chr8:19316086	G/A	cg11303988	chr8:19266685	CSGALNACT1	0.34	5.26	0.31	2.94e-7	Language performance in older adults (adjusted for episodic memory);
CESC	cis	rs4665809	0.590	rs66477033	chr2:26472497	T/C	cg22920501	chr2:26401640	FAM59B	0.91	10.38	0.54	2.08e-21	Gut microbiome composition (summer);
CESC	cis	rs2549003	1.000	rs2706384	chr5:131826880	G/T	cg02551604	chr5:131831745	NA	0.37	5.25	0.31	3.09e-7	Asthma (sex interaction);
CESC	cis	rs863345	0.967	rs863346	chr1:158535911	T/C	cg12129480	chr1:158549410	OR10X1	-0.32	-6.46	-0.37	5.13e-10	Pneumococcal bacteremia;
CESC	cis	rs875622	0.556	rs4808047	chr19:16527834	T/C	cg10248733	chr19:16607483	C19orf44;CALR3	-0.59	-6.72	-0.38	1.12e-10	White matter integrity;Neutrophil percentage of white cells;
CESC	cis	rs2228479	0.717	rs34027607	chr16:89808939	T/C	cg27121462	chr16:89883253	FANCA	0.63	5.51	0.32	8.36e-8	Skin colour saturation;
CESC	cis	rs9308731	1.000	rs6750599	chr2:111893869	A/T	cg04202892	chr2:111875749	ACOXL	-0.39	-5.61	-0.33	5.06e-8	Chronic lymphocytic leukemia;
CESC	cis	rs9549367	0.789	rs12866090	chr13:113869410	G/A	cg00898013	chr13:113819073	PROZ	-0.53	-7.65	-0.43	3.67e-13	Platelet distribution width;
CESC	cis	rs9399135	0.967	rs9389261	chr6:135371148	C/G	cg22676075	chr6:135203613	NA	0.5	7.06	0.4	1.43e-11	Red blood cell count;
CESC	cis	rs9611565	0.659	rs9607815	chr22:41950671	A/T	cg06481639	chr22:41940642	POLR3H	-0.62	-6.55	-0.37	2.92e-10	Vitiligo;
CESC	cis	rs6540555	0.505	rs11806703	chr1:209882906	A/T	cg05527609	chr1:210001259	C1orf107	-0.72	-7.07	-0.4	1.37e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	trans	rs2155929	0.660	rs16945950	chr18:26607602	C/T	cg25413575	chr17:80870577	TBCD	0.42	6.06	0.35	4.54e-9	Temperament (bipolar disorder);
CESC	cis	rs7264396	0.690	rs2425157	chr20:34419083	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.66	6.69	0.38	1.33e-10	Total cholesterol levels;
CESC	cis	rs116095464	0.558	rs7714335	chr5:263513	T/C	cg12570787	chr5:219185	SDHA;CCDC127	0.53	5.22	0.31	3.67e-7	Breast cancer;
CESC	cis	rs763121	0.853	rs5757162	chr22:38993370	C/T	cg14440974	chr22:39074834	NA	-0.4	-5.26	-0.31	2.98e-7	Menopause (age at onset);
CESC	cis	rs2463822	0.858	rs2463836	chr11:62126494	A/G	cg06239285	chr11:62104954	ASRGL1	0.86	8.63	0.47	5.79e-16	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs1008375	0.932	rs6814465	chr4:17659034	C/T	cg16339924	chr4:17578868	LAP3	0.68	8.66	0.47	4.83e-16	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04826284	chr12:66563885	TMBIM4	0.64	7.24	0.41	4.9e-12	Gut microbiome composition (summer);
CESC	cis	rs8017423	0.935	rs12880102	chr14:90793526	G/T	cg14092571	chr14:90743983	NA	0.54	8.19	0.45	1.11e-14	Mortality in heart failure;
CESC	cis	rs1847202	0.859	rs13075769	chr3:72939295	C/T	cg25664220	chr3:72788482	NA	-0.42	-6.24	-0.36	1.7e-9	Motion sickness;
CESC	cis	rs9611565	0.659	rs17367849	chr22:41923644	G/A	cg03806693	chr22:41940476	POLR3H	-1.2	-16.01	-0.7	8.02e-41	Vitiligo;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04329845	chr19:14640100	MIR639;TECR	0.52	6.07	0.35	4.33e-9	Gut microbiome composition (summer);
CESC	cis	rs1005277	0.579	rs1985707	chr10:38434098	C/T	cg00409905	chr10:38381863	ZNF37A	-0.45	-5.96	-0.34	7.89e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.48	-5.08	-0.3	7.1e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs1552244	1.000	rs9834980	chr3:10065528	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-10.79	-0.55	9.74e-23	Alzheimer's disease;
CESC	cis	rs10779751	0.960	rs4845857	chr1:11285680	T/C	cg08854313	chr1:11322531	MTOR	0.83	11.78	0.59	5.03e-26	Body mass index;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24305770	chr2:97217869	ARID5A	-0.55	-6.12	-0.35	3.37e-9	Gut microbiome composition (summer);
CESC	cis	rs7665590	1	rs7665590	chr4:99796784	T/C	cg12011299	chr4:100065546	ADH4	-0.46	-6.38	-0.36	7.98e-10	Primary biliary cholangitis;
CESC	cis	rs9733	0.596	rs6681990	chr1:150695929	A/G	cg17724175	chr1:150552817	MCL1	0.45	7.31	0.41	3.17e-12	Tonsillectomy;
CESC	cis	rs2197308	0.549	rs10785517	chr12:38577992	G/T	cg26384229	chr12:38710491	ALG10B	0.44	6.28	0.36	1.39e-9	Morning vs. evening chronotype;
CESC	cis	rs763121	0.626	rs5757236	chr22:39073824	T/C	cg21395723	chr22:39101663	GTPBP1	0.42	5.32	0.31	2.17e-7	Menopause (age at onset);
CESC	cis	rs13191362	1.000	rs73035012	chr6:162997279	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.5	5.17	0.3	4.64e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs16854884	0.586	rs4527375	chr3:143735515	A/T	cg06585982	chr3:143692056	C3orf58	-0.53	-7.39	-0.41	1.86e-12	Economic and political preferences (feminism/equality);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06369532	chr7:2155044	MAD1L1	-0.5	-6.22	-0.36	1.93e-9	Gut microbiome composition (summer);
CESC	cis	rs6952808	0.893	rs35487994	chr7:1920171	G/A	cg21782813	chr7:2030301	MAD1L1	0.42	5.91	0.34	1.03e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg11494091	chr17:61959527	GH2	0.72	12.33	0.6	6.37e-28	Prudent dietary pattern;
CESC	trans	rs4332037	0.575	rs55952733	chr7:2070680	G/A	cg11693508	chr17:37793320	STARD3	0.66	6.66	0.38	1.57e-10	Bipolar disorder;
CESC	trans	rs7824557	0.583	rs6601585	chr8:11233659	A/G	cg06636001	chr8:8085503	FLJ10661	-0.5	-6.31	-0.36	1.14e-9	Retinal vascular caliber;
CESC	cis	rs9858542	1.000	rs9858542	chr3:49701983	A/G	cg03060546	chr3:49711283	APEH	0.55	6.59	0.38	2.34e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs10504229	1.000	rs9650139	chr8:58190508	G/T	cg05313129	chr8:58192883	C8orf71	-0.55	-6.49	-0.37	4.09e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	10.45	0.54	1.29e-21	Prudent dietary pattern;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05869119	chr2:176046457	ATP5G3	0.7	8.67	0.47	4.49e-16	Gut microbiome composition (summer);
CESC	cis	rs10256972	0.621	rs10951594	chr7:1088607	C/G	cg09177884	chr7:1199841	ZFAND2A	-0.49	-6.42	-0.37	6.31e-10	Longevity;Endometriosis;
CESC	cis	rs748404	0.697	rs530188	chr15:43545314	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.61	8.07	0.44	2.39e-14	Lung cancer;
CESC	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.54	6.69	0.38	1.3100000000000001e-10	Prudent dietary pattern;
CESC	cis	rs6460942	0.841	rs17444203	chr7:12461864	C/G	cg10578991	chr7:12443926	VWDE	0.49	6.45	0.37	5.37e-10	Coronary artery disease;
CESC	cis	rs11098499	0.863	rs1383533	chr4:120434576	G/A	cg24375607	chr4:120327624	NA	0.43	5.19	0.3	4.27e-7	Corneal astigmatism;
CESC	cis	rs10752881	1.000	rs10797800	chr1:182969828	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.86	13.7	0.64	1.17e-32	Colorectal cancer;
CESC	cis	rs1728785	0.901	rs821169	chr16:68630184	C/T	cg02972257	chr16:68554789	NA	-0.63	-7.01	-0.4	1.94e-11	Ulcerative colitis;
CESC	cis	rs7552404	1.000	rs4949876	chr1:76173377	C/T	cg10523679	chr1:76189770	ACADM	0.72	8.33	0.46	4.31e-15	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs412050	1.000	rs56138298	chr22:22316540	G/A	cg17089214	chr22:22089827	YPEL1	0.68	6.06	0.35	4.56e-9	Attention deficit hyperactivity disorder;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg24103018	chr19:17420930	DDA1	-0.43	-6.08	-0.35	4.23e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs2576037	0.583	rs487386	chr18:44377004	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.76	12.32	0.6	7.05e-28	Personality dimensions;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11956146	chr18:21718974	CABYR	-0.57	-6.74	-0.38	1.01e-10	Gut microbiome composition (summer);
CESC	cis	rs8031584	0.958	rs7168641	chr15:31235452	G/A	cg14298792	chr15:30685198	CHRFAM7A	-0.45	-5.43	-0.32	1.25e-7	Huntington's disease progression;
CESC	cis	rs12986413	0.624	rs2159213	chr19:2136102	T/C	cg09261902	chr19:2140048	AP3D1	0.34	5.35	0.31	1.91e-7	Height;
CESC	cis	rs7833790	1.000	rs28696138	chr8:82770794	G/A	cg02079420	chr8:82753780	SNX16	-0.58	-7.73	-0.43	2.18e-13	Diastolic blood pressure;
CESC	cis	rs425277	0.539	rs3128337	chr1:2045882	A/G	cg16545954	chr1:2118288	C1orf86	-0.31	-5.68	-0.33	3.45e-8	Height;
CESC	cis	rs1045714	0.836	rs56246161	chr7:2644679	G/A	cg20813462	chr7:2646259	IQCE	0.61	5.41	0.32	1.43e-7	Urate levels in lean individuals;
CESC	cis	rs7927771	0.524	rs2869024	chr11:47674101	G/A	cg18512352	chr11:47633146	NA	-0.35	-5.37	-0.31	1.73e-7	Subjective well-being;
CESC	cis	rs2594989	0.943	rs2442769	chr3:11491086	A/G	cg00170343	chr3:11313890	ATG7	-0.57	-5.11	-0.3	6.17e-7	Circulating chemerin levels;
CESC	cis	rs4665809	0.887	rs2384324	chr2:26354239	A/G	cg08470875	chr2:26401718	FAM59B	-0.62	-6.69	-0.38	1.36e-10	Gut microbiome composition (summer);
CESC	cis	rs7605827	0.930	rs6716384	chr2:15608210	A/G	cg19274914	chr2:15703543	NA	0.35	6.13	0.35	3.19e-9	Educational attainment (years of education);
CESC	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg07677032	chr17:61819896	STRADA	0.47	6.29	0.36	1.33e-9	Prudent dietary pattern;
CESC	cis	rs6933660	0.800	rs2046371	chr6:151754744	G/A	cg14262678	chr6:151773367	RMND1;C6orf211	0.62	8.55	0.46	1.02e-15	Menarche (age at onset);
CESC	cis	rs1348850	0.567	rs880899	chr2:178532416	A/G	cg22681709	chr2:178499509	PDE11A	-0.48	-7.75	-0.43	1.95e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs2243480	1.000	rs1723269	chr7:65472786	C/G	cg12463550	chr7:65579703	CRCP	0.68	5.4	0.32	1.45e-7	Diabetic kidney disease;
CESC	cis	rs7599312	0.553	rs6710653	chr2:213404893	A/G	cg20637307	chr2:213403960	ERBB4	0.58	8.99	0.48	4.85e-17	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs1975974	0.748	rs67473406	chr17:21726745	G/A	cg18423549	chr17:21743878	NA	-0.51	-6.94	-0.39	2.95e-11	Psoriasis;
CESC	cis	rs4722166	0.630	rs13311155	chr7:22789789	A/C	cg26061582	chr7:22766209	IL6	0.5	5.47	0.32	1.04e-7	Lung cancer;
CESC	cis	rs1975974	1.000	rs7210944	chr17:21727476	C/T	cg18423549	chr17:21743878	NA	-0.54	-7.65	-0.43	3.81e-13	Psoriasis;
CESC	cis	rs854765	0.505	rs4924832	chr17:17897739	A/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.52	6.8	0.39	6.92e-11	Total body bone mineral density;
CESC	cis	rs4730250	0.669	rs6466160	chr7:106793175	T/A	cg02696742	chr7:106810147	HBP1	0.55	5.18	0.3	4.36e-7	Osteoarthritis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09219019	chr3:182400155	NA	0.58	6.56	0.37	2.87e-10	Gut microbiome composition (summer);
CESC	cis	rs875971	0.825	rs1129531	chr7:65619104	C/T	cg18876405	chr7:65276391	NA	-0.54	-7.58	-0.42	5.72e-13	Aortic root size;
CESC	cis	rs2836950	0.545	rs2836952	chr21:40616651	G/C	cg11644478	chr21:40555479	PSMG1	-0.52	-6.98	-0.39	2.3e-11	Menarche (age at onset);
CESC	cis	rs9303401	0.614	rs68100606	chr17:56500898	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.95	11.43	0.57	7.3e-25	Cognitive test performance;
CESC	cis	rs2836974	0.897	rs1541102	chr21:40628765	C/T	cg17971929	chr21:40555470	PSMG1	1.08	16.32	0.71	6.44e-42	Cognitive function;
CESC	cis	rs1008375	0.835	rs9760627	chr4:17651508	C/T	cg15017067	chr4:17643749	FAM184B	0.37	5.11	0.3	6.26e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg03052760	chr1:35738702	ZMYM4	0.38	6.1	0.35	3.77e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg01998146	chr9:15511358	PSIP1	-0.43	-6.0	-0.35	6.29e-9	Gambling;
CESC	cis	rs9611565	0.729	rs203319	chr22:41914593	C/T	cg03806693	chr22:41940476	POLR3H	-0.86	-11.2	-0.57	4.39e-24	Vitiligo;
CESC	cis	rs9811920	0.809	rs902159	chr3:99747445	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.4	5.21	0.3	3.76e-7	Axial length;
CESC	cis	rs875971	0.545	rs10950027	chr7:65634151	C/T	cg18876405	chr7:65276391	NA	0.51	5.96	0.34	8.21e-9	Aortic root size;
CESC	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	22.02	0.8	8.6e-62	Prudent dietary pattern;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08473553	chr1:236304799	GPR137B	0.6	6.68	0.38	1.38e-10	Gut microbiome composition (summer);
CESC	cis	rs9399135	0.967	rs12527707	chr6:135324511	G/A	cg24558204	chr6:135376177	HBS1L	0.53	7.28	0.41	3.85e-12	Red blood cell count;
CESC	cis	rs1707322	0.717	rs3014246	chr1:46086077	C/T	cg05343316	chr1:45956843	TESK2	-0.52	-6.42	-0.37	6.4e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs12190007	0.604	rs7382308	chr6:169732276	A/C	cg16388071	chr6:169726476	NA	-0.53	-7.77	-0.43	1.78e-13	Obesity-related traits;
CESC	cis	rs763121	0.853	rs5757213	chr22:39053888	C/T	cg06544989	chr22:39130855	UNC84B	0.49	8.52	0.46	1.22e-15	Menopause (age at onset);
CESC	cis	rs2860975	1.000	rs10159983	chr10:96774437	C/T	cg09036531	chr10:96991505	NA	-0.35	-5.05	-0.3	8.17e-7	Immune response to smallpox vaccine (IL-6);
CESC	cis	rs2535633	0.631	rs6799185	chr3:53101580	C/T	cg11645453	chr3:52864694	ITIH4	0.27	5.17	0.3	4.52e-7	Body mass index;
CESC	cis	rs1552244	1.000	rs7622966	chr3:10139833	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-11.53	-0.58	3.4e-25	Alzheimer's disease;
CESC	cis	rs9311474	0.508	rs17052259	chr3:52593138	A/G	cg18099408	chr3:52552593	STAB1	-0.36	-6.1	-0.35	3.79e-9	Electroencephalogram traits;
CESC	cis	rs4862750	0.914	rs1991255	chr4:187875340	G/A	cg22105103	chr4:187893119	NA	0.48	6.77	0.38	8.02e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7582720	1.000	rs114395475	chr2:203769112	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.39	0.41	1.96e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs2228479	0.850	rs17233448	chr16:89816424	G/T	cg04013166	chr16:89971882	TCF25	0.77	6.66	0.38	1.58e-10	Skin colour saturation;
CESC	trans	rs11073464	1.000	rs1550232	chr15:96673131	T/C	cg20048050	chr7:75911126	SRRM3	-0.49	-6.01	-0.35	5.96e-9	Facial morphology (factor 1, breadth of lateral portion of upper face);
CESC	cis	rs7640424	0.659	rs7639774	chr3:107816216	T/G	cg09227934	chr3:107805635	CD47	-0.44	-5.51	-0.32	8.42e-8	Body mass index;
CESC	trans	rs1814175	0.817	rs12295885	chr11:50036762	T/G	cg15704280	chr7:45808275	SEPT13	-1.06	-21.09	-0.79	1.24e-58	Height;
CESC	cis	rs8013055	0.846	rs10151805	chr14:105974781	T/C	cg23356831	chr14:105996513	TMEM121	0.37	5.14	0.3	5.23e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
CESC	trans	rs561341	0.883	rs4795661	chr17:30201774	T/A	cg20587970	chr11:113659929	NA	0.99	11.72	0.58	7.58e-26	Hip circumference adjusted for BMI;
CESC	cis	rs9487051	0.621	rs448496	chr6:109540157	G/T	cg01475377	chr6:109611718	NA	-0.4	-5.3	-0.31	2.41e-7	Reticulocyte fraction of red cells;
CESC	cis	rs2836974	0.623	rs7280326	chr21:40700408	A/G	cg17971929	chr21:40555470	PSMG1	-0.86	-12.5	-0.61	1.75e-28	Cognitive function;
CESC	cis	rs4555082	0.915	rs2816632	chr14:105741355	C/T	cg27165867	chr14:105738592	BRF1	0.48	5.98	0.34	7.25e-9	Mean platelet volume;Platelet distribution width;
CESC	cis	rs9311474	0.569	rs7614981	chr3:52566914	G/T	cg15147215	chr3:52552868	STAB1	-0.37	-6.77	-0.38	8.34e-11	Electroencephalogram traits;
CESC	cis	rs4727027	0.680	rs6464941	chr7:148826352	A/G	cg23583168	chr7:148888333	NA	-0.69	-9.45	-0.5	1.92e-18	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs1008375	1.000	rs11727312	chr4:17669185	C/T	cg16339924	chr4:17578868	LAP3	0.54	6.65	0.38	1.63e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs9457247	0.663	rs2282860	chr6:167440244	T/C	cg25258033	chr6:167368657	RNASET2	0.37	5.4	0.31	1.51e-7	Crohn's disease;
CESC	cis	rs1728785	1.000	rs1645923	chr16:68581051	G/A	cg02972257	chr16:68554789	NA	-0.55	-6.31	-0.36	1.17e-9	Ulcerative colitis;
CESC	cis	rs4746818	1.000	rs4746818	chr10:70884687	G/T	cg04149295	chr10:70884716	VPS26A	0.64	6.93	0.39	3.26e-11	Left atrial antero-posterior diameter;
CESC	cis	rs7618915	0.547	rs13085331	chr3:52627486	G/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.59	0.38	2.35e-10	Bipolar disorder;
CESC	cis	rs2075371	1.000	rs2598294	chr7:133991690	C/T	cg00033643	chr7:134001901	SLC35B4	0.44	5.71	0.33	3.05e-8	Mean platelet volume;
CESC	trans	rs1545843	0.564	rs1459614	chr12:84890003	C/T	cg03015433	chr16:56623111	MT3	0.33	6.1	0.35	3.76e-9	Major depressive disorder;
CESC	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	7.02	0.4	1.89e-11	Bipolar disorder;
CESC	cis	rs734999	0.588	rs60520190	chr1:2533706	G/A	cg18854424	chr1:2615690	NA	0.28	5.41	0.32	1.43e-7	Ulcerative colitis;
CESC	cis	rs367615	0.918	rs17161895	chr5:108855831	T/G	cg17395555	chr5:108820864	NA	0.54	8.01	0.44	3.6e-14	Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs9300255	0.596	rs10734901	chr12:123743447	G/A	cg00376283	chr12:123451042	ABCB9	0.66	8.97	0.48	5.43e-17	Neutrophil percentage of white cells;
CESC	cis	rs858239	0.600	rs6461690	chr7:23135534	A/G	cg23682824	chr7:23144976	KLHL7	0.55	7.61	0.42	4.84e-13	Cerebrospinal fluid biomarker levels;
CESC	cis	rs2777491	1.000	rs2730055	chr15:41735708	C/A	cg02330683	chr15:41787940	ITPKA	0.47	7.03	0.4	1.76e-11	Ulcerative colitis;
CESC	cis	rs7647973	1.000	rs3905330	chr3:49550774	A/G	cg07636037	chr3:49044803	WDR6	0.7	10.31	0.53	3.6e-21	Menarche (age at onset);
CESC	cis	rs6867032	1.000	rs4398675	chr5:2015816	G/A	cg26168224	chr5:2018326	NA	0.96	19.55	0.77	2.72e-53	Gut microbiome composition (winter);
CESC	cis	rs727563	0.636	rs2187795	chr22:42092225	C/A	cg06481639	chr22:41940642	POLR3H	0.59	5.91	0.34	1.05e-8	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs9649213	0.593	rs6465667	chr7:97957885	G/A	cg08684580	chr7:98029266	BAIAP2L1	-0.34	-5.63	-0.33	4.6e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs514406	0.893	rs1242330	chr1:53396842	T/G	cg24675658	chr1:53192096	ZYG11B	-0.52	-6.37	-0.36	8.1e-10	Monocyte count;
CESC	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg11965913	chr1:205819406	PM20D1	0.47	6.95	0.39	2.87e-11	Menarche (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27397943	chr8:81397668	ZBTB10	-0.63	-7.67	-0.43	3.21e-13	Gut microbiome composition (summer);
CESC	cis	rs1190552	0.846	rs1061924	chr14:102975655	C/T	cg18135206	chr14:102964638	TECPR2	0.42	5.33	0.31	2.15e-7	Blood protein levels;
CESC	cis	rs4713118	0.662	rs149947	chr6:27972433	A/T	cg17949981	chr6:28129498	ZNF389	0.43	5.43	0.32	1.29e-7	Parkinson's disease;
CESC	cis	rs9906944	0.713	rs9899580	chr17:47106878	T/G	cg09029085	chr17:47094198	IGF2BP1	0.25	5.06	0.3	7.94e-7	Intelligence (multi-trait analysis);Body fat percentage;
CESC	cis	rs17095355	1.000	rs55897175	chr10:111699190	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.43	-5.23	-0.31	3.37e-7	Biliary atresia;
CESC	cis	rs9467711	0.606	rs9379897	chr6:26601526	T/C	cg14345882	chr6:26364793	BTN3A2	0.56	6.06	0.35	4.58e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs644799	0.544	rs56298021	chr11:95545113	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.57	7.62	0.42	4.45e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs35306767	0.855	rs12761180	chr10:872086	C/T	cg10556349	chr10:835070	NA	0.74	6.29	0.36	1.33e-9	Eosinophil percentage of granulocytes;
CESC	cis	rs7267979	0.966	rs2261698	chr20:25259910	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	18.61	0.75	5.21e-50	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs644799	0.544	rs1254935	chr11:95631470	C/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.47	6.04	0.35	5.3300000000000004e-09	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs77216612	0.877	rs66561220	chr12:12878765	T/C	cg24098013	chr12:12878779	APOLD1	0.57	6.89	0.39	4.1e-11	Lymphocyte counts;
CESC	cis	rs2594989	1.000	rs2594994	chr3:11339960	T/A	cg00170343	chr3:11313890	ATG7	0.59	5.22	0.31	3.7e-7	Circulating chemerin levels;
CESC	cis	rs801193	0.660	rs2659914	chr7:66156914	C/T	cg10691866	chr7:65817282	TPST1	-0.35	-5.86	-0.34	1.41e-8	Aortic root size;
CESC	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg11905131	chr22:24372483	LOC391322	-0.62	-8.61	-0.47	6.55e-16	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs6546550	0.867	rs1551374	chr2:70079633	C/T	cg02498382	chr2:70120550	SNRNP27	-0.37	-6.46	-0.37	5.05e-10	Prevalent atrial fibrillation;
CESC	cis	rs7178572	0.568	rs12916731	chr15:77507021	C/T	cg22256960	chr15:77711686	NA	-0.53	-6.69	-0.38	1.33e-10	Type 2 diabetes;
CESC	trans	rs677325	0.604	rs4561007	chr1:191557292	A/T	cg03168947	chr3:42201649	TRAK1	-0.48	-5.99	-0.35	6.65e-9	Subjective well-being (multi-trait analysis);
CESC	cis	rs3091242	0.933	rs35497030	chr1:25783066	A/G	cg03538708	chr1:25844672	NA	0.4	5.96	0.34	7.85e-9	Erythrocyte sedimentation rate;
CESC	cis	rs6499129	1.000	rs2089401	chr16:67549653	G/C	cg26727032	chr16:67993705	SLC12A4	-0.56	-6.26	-0.36	1.53e-9	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs35110281	0.713	rs1378079	chr21:45011187	A/G	cg01579765	chr21:45077557	HSF2BP	-0.58	-10.18	-0.53	9.14e-21	Mean corpuscular volume;
CESC	trans	rs1814175	0.527	rs7110797	chr11:49644096	T/C	cg15704280	chr7:45808275	SEPT13	-0.88	-10.76	-0.55	1.19e-22	Height;
CESC	cis	rs28680850	0.541	rs4876041	chr8:1370441	T/C	cg06035437	chr8:1398411	NA	-0.49	-5.24	-0.31	3.22e-7	Triglycerides;
CESC	cis	rs9733	0.596	rs2275236	chr1:150669952	A/G	cg09365446	chr1:150670422	GOLPH3L	-0.39	-5.47	-0.32	1.04e-7	Tonsillectomy;
CESC	cis	rs3857536	0.813	rs9360189	chr6:66933424	A/C	cg07460842	chr6:66804631	NA	-0.42	-5.36	-0.31	1.8e-7	Blood trace element (Cu levels);
CESC	cis	rs9399135	0.636	rs7749106	chr6:135268142	G/A	cg24558204	chr6:135376177	HBS1L	0.55	7.84	0.43	1.1e-13	Red blood cell count;
CESC	trans	rs877282	0.898	rs11253352	chr10:766598	C/A	cg22713356	chr15:30763199	NA	1.16	11.4	0.57	9.19e-25	Uric acid levels;
CESC	cis	rs2243480	1.000	rs6964530	chr7:65718851	G/C	cg12463550	chr7:65579703	CRCP	-0.74	-5.8	-0.34	1.86e-8	Diabetic kidney disease;
CESC	cis	rs593982	0.920	rs72939198	chr11:65438079	G/A	cg08755490	chr11:65554678	OVOL1	-1.21	-8.9	-0.48	9.17e-17	Atopic dermatitis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00433081	chr5:179719502	MAPK9	0.51	6.23	0.36	1.8e-9	Gut microbiome composition (summer);
CESC	cis	rs7618915	0.501	rs767418	chr3:52767427	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	8.23	0.45	8.74e-15	Bipolar disorder;
CESC	cis	rs35110281	0.748	rs4997353	chr21:45002329	A/C	cg01579765	chr21:45077557	HSF2BP	-0.57	-9.98	-0.52	3.98e-20	Mean corpuscular volume;
CESC	cis	rs4689388	0.853	rs1079214	chr4:6282157	T/C	cg25554036	chr4:6271136	WFS1	0.55	8.68	0.47	4.02e-16	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs1506636	1.000	rs2215554	chr7:123347063	A/C	cg03229431	chr7:123269106	ASB15	-0.46	-5.84	-0.34	1.49e-8	Plateletcrit;Platelet count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19345821	chr19:41107372	LTBP4	0.58	6.97	0.39	2.44e-11	Gut microbiome composition (summer);
CESC	cis	rs11792861	0.962	rs3750454	chr9:111801325	C/G	cg05043794	chr9:111880884	C9orf5	0.43	7.24	0.41	4.72e-12	Menarche (age at onset);
CESC	cis	rs4604732	0.588	rs7552443	chr1:247628583	G/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.53	6.57	0.37	2.7e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs644799	1.000	rs560854	chr11:95584905	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.92	12.96	0.62	4.42e-30	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs7267979	1.000	rs2257809	chr20:25266476	C/T	cg08601574	chr20:25228251	PYGB	0.39	5.65	0.33	4.08e-8	Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs5756813	0.661	rs2285177	chr22:38205894	A/G	cg19894588	chr14:64061835	NA	-0.62	-7.99	-0.44	4.25e-14	Optic cup area;Vertical cup-disc ratio;
CESC	cis	rs36051895	0.697	rs11788790	chr9:5092263	G/T	cg02405213	chr9:5042618	JAK2	-0.54	-6.57	-0.37	2.58e-10	Pediatric autoimmune diseases;
CESC	cis	rs3818285	0.544	rs7899805	chr10:111671177	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.51	-7.11	-0.4	1.11e-11	Superior crus of antihelix expression;
CESC	cis	rs2637266	0.783	rs846642	chr10:78522318	A/G	cg18941641	chr10:78392320	NA	-0.41	-7.82	-0.43	1.28e-13	Pulmonary function;
CESC	cis	rs854765	0.654	rs11078400	chr17:17757728	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.6	-8.95	-0.48	6.29e-17	Total body bone mineral density;
CESC	cis	rs138880	0.542	rs9616210	chr22:50317346	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.68	-5.5	-0.32	8.95e-8	Schizophrenia;
CESC	cis	rs597539	0.652	rs613128	chr11:68638058	G/T	cg04772025	chr11:68637568	NA	0.55	6.49	0.37	4.17e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs34638657	0.702	rs67612167	chr16:82199598	A/G	cg09439754	chr16:82129088	HSD17B2	-0.37	-6.47	-0.37	4.62e-10	Lung adenocarcinoma;
CESC	cis	rs4819052	0.851	rs2838850	chr21:46671445	G/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.45	5.59	0.32	5.76e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs763121	1.000	rs86796	chr22:38881454	A/C	cg06544989	chr22:39130855	UNC84B	-0.44	-7.77	-0.43	1.68e-13	Menopause (age at onset);
CESC	cis	rs523522	0.962	rs4767904	chr12:120930798	T/G	cg12219531	chr12:120966889	COQ5	0.75	9.9	0.52	7.22e-20	High light scatter reticulocyte count;
CESC	cis	rs7618915	0.547	rs4687548	chr3:52666650	A/T	cg17372223	chr3:52568218	NT5DC2	0.43	6.5	0.37	4.08e-10	Bipolar disorder;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg19786784	chr17:35716113	ACACA	-0.41	-6.1	-0.35	3.66e-9	Gambling;
CESC	cis	rs7684253	0.565	rs13108570	chr4:57807083	G/C	cg21154227	chr4:57904332	IGFBP7	0.37	5.28	0.31	2.67e-7	Migraine;
CESC	cis	rs710216	0.957	rs841570	chr1:43435571	C/G	cg03128534	chr1:43423976	SLC2A1	0.55	6.33	0.36	1.03e-9	Red cell distribution width;
CESC	cis	rs67311347	1.000	rs10510708	chr3:40404770	A/G	cg09455208	chr3:40491958	NA	0.42	7.09	0.4	1.2e-11	Renal cell carcinoma;
CESC	cis	rs6963495	0.818	rs73192144	chr7:105203535	C/T	cg13798780	chr7:105162888	PUS7	0.71	7.06	0.4	1.48e-11	Bipolar disorder (body mass index interaction);
CESC	cis	rs5753037	0.653	rs105311	chr22:30137262	G/A	cg01021169	chr22:30184971	ASCC2	-0.47	-6.6	-0.38	2.23e-10	Type 1 diabetes;
CESC	cis	rs2522056	1.000	rs2522050	chr5:131796609	C/T	cg24060327	chr5:131705240	SLC22A5	0.58	6.48	0.37	4.33e-10	Lymphocyte counts;Fibrinogen;
CESC	cis	rs9549367	0.713	rs3024756	chr13:113822950	G/C	cg00898013	chr13:113819073	PROZ	-0.49	-6.94	-0.39	2.95e-11	Platelet distribution width;
CESC	cis	rs7605827	0.897	rs12692274	chr2:15707711	A/G	cg19274914	chr2:15703543	NA	0.36	6.39	0.37	7.3e-10	Educational attainment (years of education);
CESC	cis	rs2439831	0.867	rs28461955	chr15:43661459	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.92	11.29	0.57	2.11e-24	Lung cancer in ever smokers;
CESC	cis	rs7927771	0.507	rs12366244	chr11:47882130	C/A	cg20307385	chr11:47447363	PSMC3	0.63	8.84	0.48	1.39e-16	Subjective well-being;
CESC	cis	rs116095464	0.558	rs10059907	chr5:205360	G/C	cg16372103	chr5:203701	NA	0.49	5.29	0.31	2.6e-7	Breast cancer;
CESC	trans	rs427691	0.625	rs845739	chr5:109018540	G/T	cg00054525	chr16:88717587	CYBA	-0.61	-6.4	-0.37	7.03e-10	Autism spectrum disorder or schizophrenia;
CESC	trans	rs1814175	0.509	rs60698301	chr11:49877672	G/A	cg15704280	chr7:45808275	SEPT13	-0.98	-18.2	-0.75	1.48e-48	Height;
CESC	cis	rs10927875	0.894	rs34957618	chr1:16320499	G/C	cg21214613	chr1:16344536	HSPB7	-0.38	-5.78	-0.33	2.1e-8	Dilated cardiomyopathy;
CESC	cis	rs7647973	0.667	rs11721148	chr3:49646669	G/A	cg06212747	chr3:49208901	KLHDC8B	0.68	8.05	0.44	2.84e-14	Menarche (age at onset);
CESC	cis	rs6546550	0.935	rs60207187	chr2:70093910	G/A	cg02498382	chr2:70120550	SNRNP27	-0.35	-6.08	-0.35	4.22e-9	Prevalent atrial fibrillation;
CESC	cis	rs10751667	0.666	rs6597966	chr11:950750	T/C	cg06064525	chr11:970664	AP2A2	-0.47	-9.39	-0.5	2.9e-18	Alzheimer's disease (late onset);
CESC	cis	rs4835473	0.897	rs56334914	chr4:144657444	G/C	cg25736465	chr4:144833511	NA	-0.32	-5.07	-0.3	7.49e-7	Immature fraction of reticulocytes;
CESC	cis	rs9916302	0.680	rs2271308	chr17:37817482	T/C	cg07936489	chr17:37558343	FBXL20	-0.55	-6.8	-0.39	7.06e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs7833790	0.724	rs10958045	chr8:82722994	T/C	cg02079420	chr8:82753780	SNX16	0.55	8.2	0.45	1.01e-14	Diastolic blood pressure;
CESC	cis	rs7666738	0.830	rs6819177	chr4:99040907	T/C	cg17366294	chr4:99064904	C4orf37	0.61	8.78	0.47	2.13e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6121246	0.529	rs6060210	chr20:30187681	C/T	cg13852791	chr20:30311386	BCL2L1	0.58	5.56	0.32	6.65e-8	Mean corpuscular hemoglobin;
CESC	cis	rs2243480	1.000	rs2707831	chr7:66062511	G/A	cg18252515	chr7:66147081	NA	-1.39	-14.25	-0.66	1.31e-34	Diabetic kidney disease;
CESC	cis	rs7811142	0.943	rs67196635	chr7:100025564	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.85	8.83	0.48	1.5e-16	Platelet count;
CESC	cis	rs12477438	0.520	rs7605843	chr2:99811894	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.88	15.95	0.7	1.34e-40	Chronic sinus infection;
CESC	cis	rs7809950	0.954	rs2712193	chr7:107125885	A/C	cg23024343	chr7:107201750	COG5	-0.42	-5.86	-0.34	1.37e-8	Coronary artery disease;
CESC	cis	rs6088580	0.634	rs6059866	chr20:33075810	A/C	cg24642439	chr20:33292090	TP53INP2	0.51	7.02	0.4	1.82e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs6088580	0.634	rs6088498	chr20:33020446	A/G	cg24642439	chr20:33292090	TP53INP2	0.49	6.64	0.38	1.76e-10	Glomerular filtration rate (creatinine);
CESC	trans	rs61931739	0.500	rs11053235	chr12:34507899	G/A	cg26384229	chr12:38710491	ALG10B	0.71	10.63	0.55	3.31e-22	Morning vs. evening chronotype;
CESC	cis	rs4660306	1.000	rs6667191	chr1:45982844	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.62	-7.74	-0.43	2.14e-13	Homocysteine levels;
CESC	cis	rs7395581	0.918	rs1375688	chr11:47327217	G/A	cg25783544	chr11:47291846	MADD	0.61	7.92	0.44	6.78e-14	HDL cholesterol;
CESC	cis	rs2742234	0.590	rs741968	chr10:43611708	A/G	cg07801480	chr10:43725741	RASGEF1A	0.42	5.54	0.32	7.23e-8	Hirschsprung disease;
CESC	cis	rs3741404	0.620	rs882147	chr11:63976689	T/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.71	10.17	0.53	9.83e-21	Platelet count;
CESC	cis	rs2228479	0.717	rs1800358	chr16:89809319	T/C	cg14709524	chr16:89940631	TCF25	0.63	5.69	0.33	3.43e-8	Skin colour saturation;
CESC	cis	rs736408	0.774	rs4687551	chr3:52823448	C/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	-0.32	-5.39	-0.31	1.55e-7	Bipolar disorder;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg02660119	chr19:56196747	EPN1	0.5	6.4	0.37	7.07e-10	Fibrinogen levels;
CESC	cis	rs727505	1.000	rs10264060	chr7:124486413	C/A	cg23710748	chr7:124431027	NA	-0.46	-7.35	-0.41	2.4e-12	Lewy body disease;
CESC	cis	rs1008375	1.000	rs2315556	chr4:17670861	T/C	cg16339924	chr4:17578868	LAP3	0.53	6.67	0.38	1.5e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs55728055	0.661	rs9621295	chr22:32007153	G/A	cg01338084	chr22:32026380	PISD	1.18	7.86	0.43	9.68e-14	Age-related hearing impairment;
CESC	cis	rs8050907	0.661	rs17137056	chr16:4524685	G/C	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.9	6.28	0.36	1.39e-9	Obesity-related traits;
CESC	cis	rs11098499	0.909	rs35165976	chr4:120325630	G/A	cg24375607	chr4:120327624	NA	0.47	5.89	0.34	1.14e-8	Corneal astigmatism;
CESC	trans	rs1973993	0.745	rs6686016	chr1:96948002	G/A	cg10631902	chr5:14652156	NA	-0.46	-6.22	-0.36	1.93e-9	Weight;
CESC	trans	rs4843747	0.671	rs28465438	chr16:88103714	G/A	cg26811252	chr16:29126840	RRN3P2	0.68	9.43	0.5	2.15e-18	Menopause (age at onset);
CESC	cis	rs2637266	0.703	rs2583062	chr10:78558472	T/C	cg18941641	chr10:78392320	NA	0.41	7.83	0.43	1.17e-13	Pulmonary function;
CESC	cis	rs514406	0.893	rs1242326	chr1:53399104	C/A	cg08859206	chr1:53392774	SCP2	-0.58	-7.47	-0.42	1.19e-12	Monocyte count;
CESC	trans	rs2659546	1.000	rs2732512	chr4:102033997	C/T	cg08154348	chr6:84562930	RIPPLY2	0.5	6.11	0.35	3.54e-9	Corneal structure;
CESC	cis	rs9814567	0.752	rs6779294	chr3:134329821	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.4	-5.09	-0.3	6.84e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs2228479	0.850	rs17233567	chr16:89813821	G/A	cg06558623	chr16:89946397	TCF25	1.19	9.55	0.51	8.99e-19	Skin colour saturation;
CESC	cis	rs9649213	0.593	rs6970990	chr7:97925382	T/G	cg21770322	chr7:97807741	LMTK2	0.57	8.68	0.47	4.01e-16	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs804280	0.638	rs36038176	chr8:11609995	C/T	cg26752888	chr8:11627280	NEIL2	0.68	6.09	0.35	4.03e-9	Myopia (pathological);
CESC	trans	rs2882926	0.640	rs35460576	chr8:63523665	T/C	cg07243138	chr11:105169034	NA	-0.6	-6.14	-0.35	2.94e-9	Periodontitis (PAL4Q3);
CESC	cis	rs7666738	0.791	rs1405766	chr4:98965389	T/C	cg03676636	chr4:99064102	C4orf37	0.33	5.14	0.3	5.39e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4888262	0.508	rs4888258	chr16:74634198	G/T	cg01733217	chr16:74700730	RFWD3	0.85	11.82	0.59	3.53e-26	Testicular germ cell tumor;
CESC	cis	rs6952808	0.931	rs12537479	chr7:1868995	A/G	cg22963979	chr7:1858916	MAD1L1	0.41	5.68	0.33	3.62e-8	Bipolar disorder and schizophrenia;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg09098825	chr3:47866946	DHX30	-0.47	-6.26	-0.36	1.56e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs10089	1.000	rs7713877	chr5:127428825	G/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.76	10.19	0.53	8.66e-21	Ileal carcinoids;
CESC	cis	rs3733585	0.673	rs4235348	chr4:9951968	T/C	cg11266682	chr4:10021025	SLC2A9	-0.58	-11.0	-0.56	2.04e-23	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs1448094	0.511	rs17279261	chr12:86162714	C/T	cg00310523	chr12:86230176	RASSF9	0.38	5.85	0.34	1.44e-8	Major depressive disorder;
CESC	cis	rs853679	0.517	rs9393891	chr6:28079160	C/T	cg22143856	chr6:28129313	ZNF389	0.52	6.71	0.38	1.21e-10	Depression;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg14280098	chr1:791298	NA	-0.37	-6.31	-0.36	1.17e-9	Gambling;
CESC	cis	rs548181	0.736	rs497344	chr11:125470524	T/C	cg03464685	chr11:125439445	EI24	1.01	8.56	0.47	9.45e-16	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs9522267	0.737	rs7330902	chr13:112227599	C/T	cg10483660	chr13:112241077	NA	-0.3	-5.07	-0.3	7.43e-7	Hepatitis;
CESC	cis	rs116095464	0.558	rs1541822	chr5:269234	A/C	cg22857025	chr5:266934	NA	1.24	17.25	0.73	3.14e-45	Breast cancer;
CESC	cis	rs12325245	0.536	rs17821543	chr16:58540875	C/T	cg02549819	chr16:58548995	SETD6	0.88	6.43	0.37	5.93e-10	Schizophrenia;
CESC	cis	rs60154123	0.730	rs652241	chr1:210465029	A/T	cg23283495	chr1:209979779	IRF6	0.41	5.36	0.31	1.79e-7	Coronary artery disease;
CESC	trans	rs208520	0.690	rs2208442	chr6:66867004	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.99	-12.89	-0.62	7.46e-30	Exhaled nitric oxide output;
CESC	cis	rs8141529	0.509	rs5762853	chr22:29245231	T/G	cg02153584	chr22:29168773	CCDC117	0.57	7.48	0.42	1.1e-12	Lymphocyte counts;
CESC	cis	rs722599	0.748	rs929579	chr14:75330697	C/T	cg11812906	chr14:75593930	NEK9	-0.43	-5.36	-0.31	1.81e-7	IgG glycosylation;
CESC	cis	rs7586879	0.559	rs13387729	chr2:25076126	A/G	cg01884057	chr2:25150051	NA	0.37	7.18	0.4	7.06e-12	Body mass index;
CESC	trans	rs9329221	0.935	rs3750310	chr8:10283426	G/A	cg06636001	chr8:8085503	FLJ10661	-0.56	-6.51	-0.37	3.84e-10	Neuroticism;
CESC	cis	rs4819052	0.851	rs1999334	chr21:46670457	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.72	9.83	0.52	1.25e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs644799	1.000	rs563653	chr11:95561488	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	14.27	0.66	1.19e-34	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs1799949	0.930	rs8176194	chr17:41231221	A/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.64	8.72	0.47	3.03e-16	Menopause (age at onset);
CESC	cis	rs2249625	0.874	rs2463726	chr6:72895193	C/A	cg18830697	chr6:72922368	RIMS1	-0.37	-5.31	-0.31	2.35e-7	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CESC	cis	rs1185460	0.967	rs1784302	chr11:118940957	C/G	cg01677386	chr11:118938358	VPS11	-0.43	-5.47	-0.32	1.05e-7	Coronary artery disease;
CESC	trans	rs1814175	0.645	rs1722000	chr11:49917928	A/C	cg03929089	chr4:120376271	NA	-0.92	-15.2	-0.68	6e-38	Height;
CESC	cis	rs748404	0.631	rs1133395	chr15:43650384	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.53	8.14	0.45	1.54e-14	Lung cancer;
CESC	cis	rs10479542	0.766	rs7733389	chr5:178974997	C/T	cg14820908	chr5:178986412	RUFY1	0.4	5.85	0.34	1.47e-8	Lung cancer;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg08633134	chr19:50935017	MYBPC2	-0.45	-6.07	-0.35	4.41e-9	Fibrinogen levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18346038	chr20:33264828	PIGU	-0.62	-7.34	-0.41	2.57e-12	Gut microbiome composition (summer);
CESC	cis	rs6952808	0.531	rs3779002	chr7:2183219	C/T	cg02951883	chr7:2050386	MAD1L1	-0.48	-6.13	-0.35	3.25e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs6690583	0.524	rs6680422	chr1:85451945	C/T	cg22153463	chr1:85462885	MCOLN2	0.71	7.12	0.4	1.01e-11	Serum sulfate level;
CESC	cis	rs10463316	0.832	rs152087	chr5:150734419	C/T	cg03212797	chr5:150827313	SLC36A1	-0.48	-6.07	-0.35	4.53e-9	Metabolite levels (Pyroglutamine);
CESC	cis	rs72627123	0.867	rs58894370	chr14:74485382	C/T	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.78	5.82	0.34	1.74e-8	Morning vs. evening chronotype;
CESC	cis	rs875971	0.862	rs778724	chr7:65829291	T/C	cg18252515	chr7:66147081	NA	-0.44	-5.74	-0.33	2.62e-8	Aortic root size;
CESC	cis	rs4253772	0.745	rs78023664	chr22:46647844	G/A	cg00784671	chr22:46762841	CELSR1	-0.65	-5.99	-0.35	6.66e-9	LDL cholesterol;Cholesterol, total;
CESC	cis	rs4665809	0.590	rs4665837	chr2:26434022	C/A	cg25036284	chr2:26402008	FAM59B	-0.85	-9.25	-0.49	7.86e-18	Gut microbiome composition (summer);
CESC	trans	rs931812	0.757	rs4734014	chr8:101908844	A/G	cg20993868	chr7:22813445	NA	0.42	6.45	0.37	5.25e-10	Attention deficit hyperactivity disorder and conduct disorder;
CESC	cis	rs4835473	0.932	rs13148097	chr4:144897391	G/A	cg25736465	chr4:144833511	NA	0.4	6.1	0.35	3.74e-9	Immature fraction of reticulocytes;
CESC	cis	rs3785574	0.924	rs2584641	chr17:61862889	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.1	19.57	0.77	2.19e-53	Height;
CESC	cis	rs7666738	0.791	rs12233867	chr4:98950233	A/G	cg03676636	chr4:99064102	C4orf37	0.33	5.09	0.3	6.71e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7107174	1.000	rs55825352	chr11:78034424	C/T	cg02023728	chr11:77925099	USP35	0.52	6.84	0.39	5.45e-11	Testicular germ cell tumor;
CESC	cis	rs12318506	0.826	rs11180452	chr12:75693881	G/T	cg04728562	chr12:75699417	CAPS2	-0.94	-6.7	-0.38	1.24e-10	Coronary artery calcification;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg13546538	chr9:111754815	CTNNAL1	0.43	6.16	0.35	2.66e-9	Fibrinogen levels;
CESC	cis	rs11764590	0.694	rs60626033	chr7:2099719	A/G	cg21782813	chr7:2030301	MAD1L1	-0.43	-5.44	-0.32	1.24e-7	Neuroticism;
CESC	cis	rs4713118	0.621	rs9368548	chr6:28034737	A/G	cg19592336	chr6:28129416	ZNF389	0.58	7.33	0.41	2.75e-12	Parkinson's disease;
CESC	cis	rs6920364	1	rs6920364	chr6:167376466	G/C	cg23791538	chr6:167370224	RNASET2	0.58	8.26	0.45	7.1e-15	Lung cancer;
CESC	cis	rs910316	0.737	rs175071	chr14:75498177	A/G	cg08847533	chr14:75593920	NEK9	-0.91	-16.46	-0.71	2.11e-42	Height;
CESC	cis	rs854765	0.547	rs4643387	chr17:17972973	C/T	cg16928487	chr17:17741425	SREBF1	-0.56	-9.36	-0.5	3.66e-18	Total body bone mineral density;
CESC	cis	rs11252926	0.583	rs4881333	chr10:519164	G/C	cg03684893	chr10:554711	DIP2C	-0.41	-6.26	-0.36	1.56e-9	Psychosis in Alzheimer's disease;
CESC	cis	rs1256061	0.603	rs1256044	chr14:64734027	G/A	cg21174375	chr14:64681225	SYNE2	0.51	6.82	0.39	6.15e-11	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs72772090	0.539	rs11746534	chr5:96124807	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.57	-5.26	-0.31	3.01e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs11722228	0.549	rs62288521	chr4:10099772	G/A	cg14348967	chr4:10160060	NA	-0.41	-5.13	-0.3	5.48e-7	Gout;Urate levels;Serum uric acid levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05993306	chr5:137090649	HNRNPA0	-0.57	-6.46	-0.37	4.85e-10	Gut microbiome composition (summer);
CESC	cis	rs9399137	0.507	rs7771310	chr6:135272535	G/A	cg22676075	chr6:135203613	NA	0.56	7.13	0.4	9.67e-12	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	cis	rs7829975	0.511	rs2980426	chr8:8145609	T/C	cg15556689	chr8:8085844	FLJ10661	0.56	6.78	0.38	7.9e-11	Mood instability;
CESC	cis	rs10504229	1.000	rs73609762	chr8:58192695	A/G	cg14926445	chr8:58193284	C8orf71	-0.51	-5.52	-0.32	8.28e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs2204008	0.687	rs2320523	chr12:38251397	T/C	cg13010199	chr12:38710504	ALG10B	0.46	5.61	0.33	5.13e-8	Bladder cancer;
CESC	cis	rs4423214	0.879	rs1630498	chr11:71150785	A/C	cg05163923	chr11:71159392	DHCR7	-0.59	-6.83	-0.39	5.72e-11	Vitamin D levels;
CESC	cis	rs7927592	0.913	rs67005337	chr11:68307758	A/C	cg20283391	chr11:68216788	NA	-0.62	-7.45	-0.42	1.31e-12	Total body bone mineral density;
CESC	cis	rs2625529	0.526	rs16956623	chr15:72536695	T/C	cg16672083	chr15:72433130	SENP8	0.47	6.86	0.39	4.79e-11	Red blood cell count;
CESC	cis	rs11958404	0.860	rs7723564	chr5:157449396	C/T	cg05962755	chr5:157440814	NA	0.65	7.15	0.4	8.68e-12	IgG glycosylation;
CESC	cis	rs704795	0.836	rs1083865	chr2:27620827	A/G	cg22903471	chr2:27725779	GCKR	-0.49	-6.95	-0.39	2.9100000000000002e-11	Menopause (age at onset);
CESC	cis	rs4077515	0.806	rs3812564	chr9:139271190	A/G	cg14169450	chr9:139327907	INPP5E	0.41	5.9	0.34	1.1e-8	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs34172651	0.517	rs11862923	chr16:24767303	G/T	cg06505273	chr16:24850292	NA	0.53	6.49	0.37	4.27e-10	Intelligence (multi-trait analysis);
CESC	cis	rs4975709	0.569	rs4975743	chr5:1859941	G/T	cg10800226	chr5:1850261	NA	0.36	5.91	0.34	1.06e-8	Cardiovascular disease risk factors;
CESC	cis	rs4319547	0.741	rs4758663	chr12:122939483	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.5	-6.22	-0.36	1.92e-9	Body mass index;
CESC	cis	rs1799949	1.000	rs12944597	chr17:41187684	A/C	cg23758822	chr17:41437982	NA	1.03	14.48	0.66	2.1e-35	Menopause (age at onset);
CESC	trans	rs2797160	0.651	rs1269176	chr6:126029682	A/T	cg05039488	chr6:79577232	IRAK1BP1	-0.49	-6.64	-0.38	1.72e-10	Endometrial cancer;
CESC	cis	rs6500602	0.702	rs17761816	chr16:4548832	C/G	cg08645402	chr16:4508243	NA	0.55	9.03	0.48	3.72e-17	Schizophrenia;
CESC	cis	rs4555082	0.834	rs28489970	chr14:105748862	T/C	cg06808227	chr14:105710500	BRF1	-0.55	-6.17	-0.35	2.56e-9	Mean platelet volume;Platelet distribution width;
CESC	cis	rs7618915	0.547	rs2289250	chr3:52682946	A/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	-0.38	-6.81	-0.39	6.39e-11	Bipolar disorder;
CESC	cis	rs477895	0.568	rs12418035	chr11:63871558	G/A	cg04317338	chr11:64019027	PLCB3	0.83	8.62	0.47	6.11e-16	Mean platelet volume;
CESC	cis	rs9443189	0.570	rs72888705	chr6:76403114	A/G	cg01950844	chr6:76311363	SENP6	0.88	9.29	0.5	6.05e-18	Prostate cancer;
CESC	cis	rs910316	1.000	rs3742778	chr14:75538217	A/C	cg11812906	chr14:75593930	NEK9	-0.89	-14.78	-0.67	1.81e-36	Height;
CESC	cis	rs514406	0.893	rs512723	chr1:53343880	C/T	cg24675658	chr1:53192096	ZYG11B	0.52	6.36	0.36	8.65e-10	Monocyte count;
CESC	cis	rs2070997	0.607	rs3808821	chr9:133712801	G/T	cg11464064	chr9:133710261	ABL1	-0.74	-8.81	-0.48	1.64e-16	Response to amphetamines;
CESC	cis	rs9790314	1.000	rs1993891	chr3:161047467	A/G	cg04691961	chr3:161091175	C3orf57	-0.42	-5.31	-0.31	2.3e-7	Morning vs. evening chronotype;
CESC	cis	rs9902453	0.808	rs10445400	chr17:28183059	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.64	8.19	0.45	1.08e-14	Coffee consumption (cups per day);
CESC	cis	rs561341	1.000	rs564714	chr17:30318404	C/T	cg00745463	chr17:30367425	LRRC37B	-0.86	-7.76	-0.43	1.8e-13	Hip circumference adjusted for BMI;
CESC	trans	rs12492269	0.702	rs41381644	chr3:178161614	A/G	cg23502966	chr3:195789749	TFRC	0.61	6.0	0.35	6.45e-9	Plasma clusterin levels;
CESC	cis	rs2242194	0.844	rs11264295	chr1:154987526	C/T	cg09359103	chr1:154839909	KCNN3	-0.4	-6.38	-0.37	7.66e-10	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06854502	chr1:19923593	C1orf151	0.56	6.26	0.36	1.52e-9	Gut microbiome composition (summer);
CESC	cis	rs832540	0.966	rs252923	chr5:56205662	T/G	cg24531977	chr5:56204891	C5orf35	-0.45	-5.65	-0.33	4.12e-8	Coronary artery disease;
CESC	cis	rs28374715	0.635	rs112547435	chr15:41648737	C/G	cg02330683	chr15:41787940	ITPKA	0.42	5.36	0.31	1.77e-7	Ulcerative colitis;
CESC	cis	rs2120019	0.938	rs8028632	chr15:75321262	T/C	cg09165964	chr15:75287851	SCAMP5	-0.8	-9.94	-0.52	5.37e-20	Blood trace element (Zn levels);
CESC	trans	rs829883	0.932	rs249840	chr12:98871993	T/C	cg04550079	chr16:67212681	KIAA0895L	-0.38	-6.2	-0.36	2.1e-9	Colorectal adenoma (advanced);
CESC	cis	rs2404602	0.660	rs11852777	chr15:76929792	A/G	cg23625390	chr15:77176239	SCAPER	-0.45	-6.25	-0.36	1.62e-9	Blood metabolite levels;
CESC	cis	rs6424115	0.830	rs3123554	chr1:24196401	C/T	cg10978503	chr1:24200527	CNR2	-0.34	-6.83	-0.39	5.94e-11	Immature fraction of reticulocytes;
CESC	cis	rs763014	0.932	rs2384974	chr16:651279	C/G	cg09263875	chr16:632152	PIGQ	0.68	11.94	0.59	1.43e-26	Height;
CESC	cis	rs9811920	0.931	rs7629487	chr3:99860401	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.44	7.04	0.4	1.65e-11	Axial length;
CESC	cis	rs9796	0.621	rs11858678	chr15:41467932	A/G	cg12386646	chr15:41787261	ITPKA	0.33	5.11	0.3	6.05e-7	Menopause (age at onset);
CESC	cis	rs4665809	0.567	rs6711402	chr2:26430983	A/G	cg26314531	chr2:26401878	FAM59B	-0.78	-8.04	-0.44	2.91e-14	Gut microbiome composition (summer);
CESC	cis	rs4566357	0.595	rs6707286	chr2:227911400	A/G	cg05526886	chr2:227700861	RHBDD1	-0.45	-5.99	-0.35	6.98e-9	Coronary artery disease;
CESC	cis	rs1878931	0.726	rs3843728	chr16:3448251	T/C	cg22508957	chr16:3507546	NAT15	-0.45	-6.61	-0.38	2.07e-10	Body mass index (adult);
CESC	cis	rs34172651	0.917	rs200536	chr16:24749203	G/A	cg06028605	chr16:24865363	SLC5A11	-0.41	-6.16	-0.35	2.66e-9	Intelligence (multi-trait analysis);
CESC	cis	rs7296418	0.599	rs2277343	chr12:123794450	A/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.33	-5.25	-0.31	3.09e-7	Platelet count;
CESC	cis	rs9393777	0.623	rs9358947	chr6:26479000	G/A	cg14345882	chr6:26364793	BTN3A2	0.43	5.34	0.31	2.01e-7	Intelligence (multi-trait analysis);
CESC	cis	rs11785400	1.000	rs4518642	chr8:143737396	T/C	cg24634471	chr8:143751801	JRK	0.47	6.24	0.36	1.75e-9	Schizophrenia;
CESC	cis	rs11030122	0.702	rs1013351	chr11:3952303	A/T	cg18678763	chr11:4115507	RRM1	-0.45	-6.05	-0.35	4.94e-9	Mean platelet volume;Platelet distribution width;
CESC	cis	rs10838687	0.800	rs4752977	chr11:47300429	T/C	cg25783544	chr11:47291846	MADD	0.59	6.82	0.39	6.33e-11	Proinsulin levels;
CESC	cis	rs79387448	0.655	rs11891827	chr2:102951182	A/G	cg09003973	chr2:102972529	NA	1.06	8.43	0.46	2.21e-15	Gut microbiota (bacterial taxa);
CESC	cis	rs7914558	1.000	rs4917380	chr10:104775335	C/G	cg08650961	chr10:104748594	CNNM2	0.33	5.52	0.32	7.94e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17952549	chr19:58983050	ZNF324	-0.71	-7.81	-0.43	1.3e-13	Gut microbiome composition (summer);
CESC	cis	rs863345	0.604	rs4313395	chr1:158505135	C/T	cg12129480	chr1:158549410	OR10X1	-0.34	-6.82	-0.39	6.1e-11	Pneumococcal bacteremia;
CESC	cis	rs10883723	0.810	rs11191304	chr10:104255284	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.54	7.43	0.42	1.49e-12	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs6815814	0.950	rs5743794	chr4:38832727	C/T	cg02016764	chr4:38805732	TLR1	-0.61	-6.86	-0.39	4.8e-11	Breast cancer;
CESC	cis	rs7267979	1.000	rs1888999	chr20:25291848	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.84	16.39	0.71	3.48e-42	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs2243480	1.000	rs4718316	chr7:65648731	A/G	cg18252515	chr7:66147081	NA	1.36	13.62	0.64	2.24e-32	Diabetic kidney disease;
CESC	cis	rs710216	0.752	rs841848	chr1:43402545	G/A	cg03128534	chr1:43423976	SLC2A1	0.46	5.31	0.31	2.32e-7	Red cell distribution width;
CESC	trans	rs1555543	0.538	rs7416802	chr1:96909292	G/C	cg01125333	chr16:2835331	PRSS33	-0.52	-6.15	-0.35	2.86e-9	Body mass index;
CESC	cis	rs9584850	0.574	rs17471079	chr13:99168721	C/T	cg20750642	chr13:99100586	FARP1	-0.44	-5.94	-0.34	8.72e-9	Neuroticism;
CESC	cis	rs7827545	1.000	rs7008158	chr8:135565982	T/C	cg17885191	chr8:135476712	NA	0.48	6.28	0.36	1.39e-9	Hypertension (SNP x SNP interaction);
CESC	cis	rs10089	1.000	rs2054444	chr5:127493206	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.69	-8.96	-0.48	6.02e-17	Ileal carcinoids;
CESC	cis	rs875971	0.825	rs28480509	chr7:66099224	A/G	cg18876405	chr7:65276391	NA	-0.49	-6.7	-0.38	1.28e-10	Aortic root size;
CESC	cis	rs10504229	0.679	rs7813252	chr8:58136389	C/G	cg21724239	chr8:58056113	NA	0.58	5.95	0.34	8.29e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs2455799	0.613	rs2246960	chr3:15717693	G/A	cg16303742	chr3:15540471	COLQ	-0.39	-6.03	-0.35	5.51e-9	Mean platelet volume;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg27539627	chr3:122513065	DIRC2;HSPBAP1	0.47	6.1	0.35	3.78e-9	Systemic lupus erythematosus;
CESC	cis	rs6963495	0.799	rs73190201	chr7:105165891	A/C	cg13798780	chr7:105162888	PUS7	0.78	8.06	0.44	2.68e-14	Bipolar disorder (body mass index interaction);
CESC	cis	rs832540	0.931	rs1445996	chr5:56235548	C/T	cg12311346	chr5:56204834	C5orf35	0.4	5.04	0.3	8.68e-7	Coronary artery disease;
CESC	cis	rs1008375	1.000	rs12648232	chr4:17612537	C/T	cg02297831	chr4:17616191	MED28	-0.44	-5.4	-0.31	1.47e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs2688608	0.592	rs7923045	chr10:75487498	A/T	cg23231163	chr10:75533350	FUT11	-0.36	-5.47	-0.32	1.02e-7	Inflammatory bowel disease;
CESC	cis	rs514406	0.644	rs4926928	chr1:53210163	G/T	cg08736216	chr1:53307985	ZYG11A	-0.38	-6.2	-0.36	2.17e-9	Monocyte count;
CESC	cis	rs7666738	0.830	rs60994860	chr4:99046753	G/A	cg24818145	chr4:99064322	C4orf37	0.38	5.04	0.3	8.49e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs72781680	0.898	rs72786270	chr2:24059049	G/A	cg20701182	chr2:24300061	SF3B14	0.64	5.74	0.33	2.57e-8	Lymphocyte counts;
CESC	cis	rs2243480	0.908	rs55876148	chr7:65379800	G/A	cg12463550	chr7:65579703	CRCP	0.71	5.5	0.32	8.79e-8	Diabetic kidney disease;
CESC	cis	rs12824058	0.678	rs11614163	chr12:130814621	C/G	cg24838063	chr12:130822603	PIWIL1	0.64	8.21	0.45	9.51e-15	Menopause (age at onset);
CESC	cis	rs6598955	0.671	rs12142535	chr1:26589698	T/A	cg19743891	chr1:26644573	UBXN11;CD52	0.37	5.19	0.3	4.16e-7	Obesity-related traits;
CESC	cis	rs1552244	1.000	rs35741213	chr3:10087661	A/G	cg08888203	chr3:10149979	C3orf24	0.5	6.34	0.36	9.96e-10	Alzheimer's disease;
CESC	cis	rs2370759	1.000	rs11008865	chr10:32574842	C/T	cg18270830	chr10:32634957	EPC1	0.73	7.28	0.41	3.73e-12	Sexual dysfunction (female);
CESC	cis	rs929354	0.742	rs11980541	chr7:156988776	G/C	cg05182265	chr7:156933206	UBE3C	-0.51	-7.51	-0.42	9.08e-13	Body mass index;
CESC	cis	rs2576037	0.526	rs7240239	chr18:44460037	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.41	6.68	0.38	1.37e-10	Personality dimensions;
CESC	cis	rs7000551	0.581	rs2293145	chr8:22262654	A/T	cg12081754	chr8:22256438	SLC39A14	0.9	12.57	0.61	1.01e-28	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CESC	cis	rs4713118	0.621	rs9295756	chr6:28033396	G/T	cg17949981	chr6:28129498	ZNF389	0.42	5.1	0.3	6.62e-7	Parkinson's disease;
CESC	cis	rs6460942	0.915	rs75732743	chr7:12454095	C/T	cg20607287	chr7:12443886	VWDE	-0.78	-9.15	-0.49	1.61e-17	Coronary artery disease;
CESC	cis	rs7666738	0.830	rs28522896	chr4:99008243	C/T	cg18180107	chr4:99064573	C4orf37	0.4	5.23	0.31	3.41e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3796352	1.000	rs71301808	chr3:53085577	C/G	cg12962167	chr3:53033115	SFMBT1	0.67	5.91	0.34	1.05e-8	Immune reponse to smallpox (secreted IL-2);
CESC	cis	rs4665809	0.627	rs7562192	chr2:26469457	C/G	cg25036284	chr2:26402008	FAM59B	0.88	9.99	0.52	3.79e-20	Gut microbiome composition (summer);
CESC	cis	rs7259376	0.714	rs4358065	chr19:22521132	A/G	cg02657401	chr19:22469223	NA	-0.27	-5.35	-0.31	1.9e-7	Menopause (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24704015	chr2:230931896	SLC16A14	0.53	6.23	0.36	1.82e-9	Gut microbiome composition (summer);
CESC	cis	rs2836950	0.501	rs11088470	chr21:40689162	A/G	cg11890956	chr21:40555474	PSMG1	-0.65	-9.1	-0.49	2.28e-17	Menarche (age at onset);
CESC	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg07677032	chr17:61819896	STRADA	0.45	5.97	0.34	7.74e-9	Prudent dietary pattern;
CESC	cis	rs9393777	0.623	rs2093169	chr6:26495099	C/T	cg12826209	chr6:26865740	GUSBL1	0.66	6.96	0.39	2.61e-11	Intelligence (multi-trait analysis);
CESC	cis	rs7107174	1.000	rs2511177	chr11:77922960	C/T	cg27205649	chr11:78285834	NARS2	-0.41	-5.13	-0.3	5.72e-7	Testicular germ cell tumor;
CESC	cis	rs6430585	0.528	rs614193	chr2:136653925	A/T	cg07169764	chr2:136633963	MCM6	1.06	15.38	0.69	1.39e-38	Corneal structure;
CESC	cis	rs10752881	0.905	rs12132262	chr1:182989949	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.84	13.31	0.63	2.66e-31	Colorectal cancer;
CESC	cis	rs2204008	0.775	rs11182513	chr12:38560252	G/C	cg13010199	chr12:38710504	ALG10B	0.56	7.18	0.4	7.18e-12	Bladder cancer;
CESC	cis	rs2180341	0.883	rs9388568	chr6:127690694	C/A	cg27446573	chr6:127587934	RNF146	1.05	15.58	0.69	2.65e-39	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26186433	chr17:62658397	SMURF2	0.54	6.05	0.35	4.97e-9	Gut microbiome composition (summer);
CESC	cis	rs9581857	0.579	rs9581846	chr13:27987953	A/G	cg01674679	chr13:27998804	GTF3A	-0.65	-5.18	-0.3	4.41e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
CESC	cis	rs9487051	0.621	rs429534	chr6:109523256	A/G	cg01475377	chr6:109611718	NA	-0.39	-5.15	-0.3	5.18e-7	Reticulocyte fraction of red cells;
CESC	cis	rs11785400	1.000	rs11780221	chr8:143748215	T/A	cg24634471	chr8:143751801	JRK	0.48	6.24	0.36	1.71e-9	Schizophrenia;
CESC	cis	rs9787249	0.957	rs41267029	chr1:40214367	A/G	cg19912559	chr1:40204330	PPIE	0.42	6.48	0.37	4.37e-10	Blood protein levels;
CESC	cis	rs7824557	0.564	rs6601584	chr8:11232343	C/G	cg21775007	chr8:11205619	TDH	-0.52	-7.68	-0.43	3.1400000000000003e-13	Retinal vascular caliber;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27247225	chr6:26970382	C6orf41	-0.66	-7.76	-0.43	1.84e-13	Gut microbiome composition (summer);
CESC	cis	rs2742417	0.603	rs2742448	chr3:45764246	C/T	cg04837898	chr3:45731254	SACM1L	0.45	5.34	0.31	2.04e-7	Response to anti-depressant treatment in major depressive disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11015038	chr20:20349568	INSM1	0.51	6.35	0.36	9.13e-10	Gut microbiome composition (summer);
CESC	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg24829409	chr8:58192753	C8orf71	-0.6	-6.88	-0.39	4.43e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs2228479	0.850	rs17227064	chr16:89816314	A/G	cg14709524	chr16:89940631	TCF25	0.93	6.94	0.39	3.03e-11	Skin colour saturation;
CESC	cis	rs2929278	0.546	rs686666	chr15:44161550	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.51	6.5	0.37	4.04e-10	Schizophrenia;
CESC	cis	rs10504229	1.000	rs117231141	chr8:58185465	A/G	cg22535103	chr8:58192502	C8orf71	-1.05	-13.08	-0.63	1.71e-30	Developmental language disorder (linguistic errors);
CESC	cis	rs7666738	0.761	rs28758886	chr4:99059704	C/T	cg03467027	chr4:99064603	C4orf37	0.48	6.0	0.35	6.56e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs425277	1.000	rs262676	chr1:2078482	T/A	cg24578937	chr1:2090814	PRKCZ	0.55	9.54	0.51	9.57e-19	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00167275	chr10:88854588	FAM35A;GLUD1	0.52	6.5	0.37	4.08e-10	Gut microbiome composition (summer);
CESC	cis	rs6504340	0.793	rs12946855	chr17:46608030	G/A	cg04904318	chr17:46607828	HOXB1	-0.68	-7.42	-0.41	1.62e-12	Primary tooth development (number of teeth);
CESC	cis	rs13118159	0.836	rs2293630	chr4:1342521	G/A	cg00684032	chr4:1343700	KIAA1530	0.39	5.71	0.33	3.06e-8	Longevity;
CESC	cis	rs10504229	0.636	rs117439064	chr8:58055279	A/G	cg22535103	chr8:58192502	C8orf71	-0.85	-8.38	-0.46	3.08e-15	Developmental language disorder (linguistic errors);
CESC	cis	rs16917546	1.000	rs7090073	chr10:64423505	G/T	cg03961010	chr10:64397487	ZNF365	-0.37	-6.14	-0.35	2.97e-9	Basal cell carcinoma;
CESC	cis	rs4253772	0.550	rs6008729	chr22:46727428	C/G	cg00784671	chr22:46762841	CELSR1	0.44	5.87	0.34	1.28e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs11098499	0.820	rs2389885	chr4:120533931	C/T	cg24375607	chr4:120327624	NA	0.46	5.41	0.32	1.38e-7	Corneal astigmatism;
CESC	cis	rs10484885	0.648	rs2777848	chr6:90535993	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.88	-11.2	-0.57	4.42e-24	QRS interval (sulfonylurea treatment interaction);
CESC	cis	rs2070677	0.935	rs12256349	chr10:135409632	G/A	cg20169779	chr10:135381914	SYCE1	-0.75	-9.82	-0.52	1.26e-19	Gout;
CESC	cis	rs73206853	0.764	rs17682012	chr12:111094454	A/G	cg12870014	chr12:110450643	ANKRD13A	-0.67	-5.41	-0.32	1.42e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs116095464	1.000	rs28416084	chr5:217640	G/A	cg22496380	chr5:211416	CCDC127	-0.96	-10.08	-0.53	1.95e-20	Breast cancer;
CESC	cis	rs6696846	1.000	rs6696846	chr1:205041952	C/T	cg00857998	chr1:205179979	DSTYK	0.52	7.09	0.4	1.22e-11	Red blood cell count;
CESC	cis	rs4819052	0.918	rs2330013	chr21:46658662	G/T	cg11663144	chr21:46675770	NA	-0.51	-7.13	-0.4	9.49e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs270601	0.909	rs2569265	chr5:131704519	T/C	cg24060327	chr5:131705240	SLC22A5	0.76	10.49	0.54	8.94e-22	Acylcarnitine levels;
CESC	cis	rs8022179	0.580	rs6575979	chr14:103841018	A/G	cg12935359	chr14:103987150	CKB	-0.48	-6.2	-0.36	2.13e-9	Monocyte count;
CESC	cis	rs8064299	0.597	rs4789098	chr17:72781292	C/G	cg25054828	chr17:72772726	NAT9;TMEM104	0.77	12.37	0.61	4.66e-28	Monocyte count;
CESC	cis	rs1570884	0.516	rs9316462	chr13:50176321	A/G	cg03651054	chr13:50194643	NA	0.31	5.1	0.3	6.6e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
CESC	cis	rs7202877	0.610	rs468079	chr16:75428474	G/A	cg04384234	chr16:75411784	CFDP1	0.47	5.82	0.34	1.71e-8	Type 2 diabetes;Type 1 diabetes;
CESC	cis	rs7829975	0.714	rs4841042	chr8:8664622	A/G	cg17143192	chr8:8559678	CLDN23	-0.45	-5.58	-0.32	6.02e-8	Mood instability;
CESC	cis	rs7666738	0.715	rs61114099	chr4:98931270	C/T	cg17366294	chr4:99064904	C4orf37	0.6	8.22	0.45	9.04e-15	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19022780	chr9:134378720	POMT1	-0.62	-6.92	-0.39	3.38e-11	Gut microbiome composition (summer);
CESC	cis	rs748404	0.631	rs4296223	chr15:43645246	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.55	8.52	0.46	1.2e-15	Lung cancer;
CESC	cis	rs853679	0.517	rs67878650	chr6:28142587	G/C	cg23281280	chr6:28129359	ZNF389	0.56	7.61	0.42	4.91e-13	Depression;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg24816464	chr3:86061715	CADM2	-0.45	-6.14	-0.35	2.93e-9	Asthma;
CESC	cis	rs3806843	0.735	rs2563333	chr5:140052271	A/G	cg16179182	chr5:140090404	VTRNA1-1	0.37	5.05	0.3	8.31e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs2882667	0.929	rs34846849	chr5:138360578	T/C	cg04439458	chr5:138467593	SIL1	-0.39	-6.14	-0.35	2.98e-9	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs1018836	0.923	rs12545279	chr8:91636373	C/G	cg16814680	chr8:91681699	NA	-0.72	-10.37	-0.54	2.32e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs897984	0.520	rs4889536	chr16:30871755	G/T	cg02466173	chr16:30829666	NA	0.48	6.88	0.39	4.33e-11	Dementia with Lewy bodies;
CESC	cis	rs3785574	0.925	rs2727340	chr17:61970224	T/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.59	7.14	0.4	8.89e-12	Height;
CESC	cis	rs2070488	0.804	rs2276541	chr3:38512779	G/A	cg24069376	chr3:38537580	EXOG	0.35	6.04	0.35	5.11e-9	Electrocardiographic conduction measures;
CESC	cis	rs7208859	0.524	rs59913838	chr17:29101563	A/T	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.17e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs3106136	0.546	rs4693003	chr4:95145469	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.69	-11.19	-0.57	4.77e-24	Capecitabine sensitivity;
CESC	cis	rs12530845	0.943	rs11984203	chr7:135325947	C/T	cg23117316	chr7:135346802	PL-5283	0.46	5.64	0.33	4.43e-8	Red blood cell traits;
CESC	cis	rs270601	0.739	rs3900945	chr5:131592870	T/C	cg09877947	chr5:131593287	PDLIM4	0.52	6.87	0.39	4.47e-11	Acylcarnitine levels;
CESC	cis	rs6915183	1.000	rs6915183	chr6:166706169	C/T	cg14022523	chr6:166756177	SFT2D1	-0.58	-7.79	-0.43	1.48e-13	Longevity;
CESC	cis	rs116095464	0.558	rs28558836	chr5:285748	C/G	cg12570787	chr5:219185	SDHA;CCDC127	0.5	5.27	0.31	2.84e-7	Breast cancer;
CESC	cis	rs116095464	0.558	rs62346526	chr5:220614	T/C	cg22496380	chr5:211416	CCDC127	-0.72	-8.57	-0.47	8.59e-16	Breast cancer;
CESC	cis	rs4713118	0.587	rs9393899	chr6:28133528	G/C	cg26335602	chr6:28129616	ZNF389	0.52	6.81	0.39	6.59e-11	Parkinson's disease;
CESC	cis	rs10493773	0.566	rs11161659	chr1:86183967	T/C	cg17807903	chr1:86174739	ZNHIT6	-0.44	-6.53	-0.37	3.43e-10	Urate levels in overweight individuals;
CESC	cis	rs6582630	0.576	rs4882258	chr12:38453686	C/T	cg26384229	chr12:38710491	ALG10B	-0.44	-5.92	-0.34	9.96e-9	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs10754283	1.000	rs10754283	chr1:90112431	G/T	cg21401794	chr1:90099060	LRRC8C	0.69	9.34	0.5	4.06e-18	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs13631	0.965	rs7853589	chr9:140003844	A/G	cg14289826	chr9:140003911	NA	-0.37	-6.97	-0.39	2.53e-11	Cerebrospinal fluid biomarker levels;
CESC	cis	rs4237845	0.804	rs10877034	chr12:58286444	T/C	cg02175503	chr12:58329896	NA	0.55	7.29	0.41	3.55e-12	Intelligence (multi-trait analysis);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg26547359	chr10:16859530	RSU1	0.45	6.14	0.35	2.94e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs1865760	0.555	rs2051541	chr6:25945211	C/T	cg16482183	chr6:26056742	HIST1H1C	-0.42	-5.56	-0.32	6.71e-8	Height;
CESC	cis	rs875971	0.545	rs3735147	chr7:65970528	A/C	cg25405998	chr7:65216604	CCT6P1	0.46	5.14	0.3	5.31e-7	Aortic root size;
CESC	cis	rs1046896	1.000	rs1046917	chr17:80685655	A/G	cg02711726	chr17:80685570	FN3KRP	0.6	9.04	0.49	3.37e-17	Glycated hemoglobin levels;
CESC	cis	rs3741404	0.665	rs12418535	chr11:63910980	A/G	cg18225595	chr11:63971243	STIP1	0.74	10.31	0.53	3.67e-21	Platelet count;
CESC	cis	rs2730245	1.000	rs6965685	chr7:158726462	C/T	cg15303052	chr7:158526867	ESYT2	-0.43	-5.25	-0.31	3.2e-7	Height;
CESC	cis	rs9303401	0.661	rs9902820	chr17:56637545	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.54	7.24	0.41	4.92e-12	Cognitive test performance;
CESC	trans	rs9325144	0.647	rs7487395	chr12:38865660	C/A	cg10679878	chr6:156759499	NA	-0.33	-6.0	-0.35	6.61e-9	Morning vs. evening chronotype;
CESC	cis	rs3540	0.574	rs2256388	chr15:90969335	A/C	cg22089800	chr15:90895588	ZNF774	-0.61	-8.36	-0.46	3.69e-15	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs10744422	1.000	rs921808	chr12:123323135	A/G	cg25930673	chr12:123319894	HIP1R	0.65	5.28	0.31	2.72e-7	Schizophrenia;
CESC	cis	rs920590	0.758	rs1826420	chr8:19664878	G/T	cg03894339	chr8:19674705	INTS10	0.62	7.33	0.41	2.83e-12	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs17711722	0.640	rs13237956	chr7:65318029	G/A	cg14393609	chr7:65229607	NA	0.52	7.08	0.4	1.33e-11	Calcium levels;
CESC	cis	rs2880765	0.835	rs7169632	chr15:86044667	T/G	cg19183879	chr15:85880815	NA	-0.26	-5.29	-0.31	2.52e-7	Coronary artery disease;
CESC	cis	rs7811142	0.943	rs67483801	chr7:100031758	G/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.92	9.76	0.51	2.07e-19	Platelet count;
CESC	cis	rs10504229	1.000	rs72652905	chr8:58188355	A/G	cg14926445	chr8:58193284	C8orf71	-0.51	-5.42	-0.32	1.37e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs34779708	0.966	rs878264	chr10:35440581	T/C	cg03585969	chr10:35415529	CREM	0.74	10.0	0.52	3.6e-20	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs7618915	0.571	rs6762457	chr3:52609157	G/A	cg18404041	chr3:52824283	ITIH1	-0.4	-6.63	-0.38	1.89e-10	Bipolar disorder;
CESC	cis	rs9399137	0.507	rs11154791	chr6:135379148	A/G	cg24558204	chr6:135376177	HBS1L	0.69	9.53	0.51	1.08e-18	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	cis	rs28647808	0.786	rs28649804	chr9:136257709	C/T	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.85	5.74	0.33	2.59e-8	Blood protein levels;
CESC	cis	rs892961	0.806	rs35489990	chr17:75412312	T/C	cg05865280	chr17:75406074	SEPT9	0.62	12.68	0.61	4.16e-29	Airflow obstruction;
CESC	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg23131131	chr22:24373011	LOC391322	-0.68	-8.98	-0.48	5.01e-17	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs950169	0.724	rs11632668	chr15:84948687	T/C	cg17507749	chr15:85114479	UBE2QP1	0.59	6.52	0.37	3.46e-10	Schizophrenia;
CESC	cis	rs35306767	0.807	rs34982663	chr10:852521	C/G	cg26597838	chr10:835615	NA	1.2	12.13	0.6	3.18e-27	Eosinophil percentage of granulocytes;
CESC	cis	rs4746818	1.000	rs9299502	chr10:70876934	C/T	cg04149295	chr10:70884716	VPS26A	0.63	6.7	0.38	1.27e-10	Left atrial antero-posterior diameter;
CESC	cis	rs2522056	1.000	rs10900807	chr5:131757480	G/C	cg24060327	chr5:131705240	SLC22A5	0.69	7.73	0.43	2.27e-13	Lymphocyte counts;Fibrinogen;
CESC	cis	rs2153904	0.793	rs71633563	chr1:205735854	C/T	cg23034840	chr1:205782522	SLC41A1	-0.65	-6.44	-0.37	5.68e-10	Prostate-specific antigen levels;
CESC	cis	rs875971	0.505	rs1723275	chr7:65504633	G/C	cg08632164	chr7:65971372	NA	0.32	5.14	0.3	5.29e-7	Aortic root size;
CESC	cis	rs4665809	0.589	rs4665842	chr2:26448954	A/G	cg25036284	chr2:26402008	FAM59B	-0.86	-9.35	-0.5	3.8e-18	Gut microbiome composition (summer);
CESC	cis	rs4474465	0.646	rs10899556	chr11:78278986	C/T	cg27205649	chr11:78285834	NARS2	0.48	6.26	0.36	1.51e-9	Alzheimer's disease (survival time);
CESC	cis	rs7208859	0.623	rs8080882	chr17:29081146	G/A	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.91e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs2806561	0.577	rs488438	chr1:23498999	T/A	cg12483005	chr1:23474871	LUZP1	0.39	6.16	0.35	2.68e-9	Height;
CESC	cis	rs1371867	0.875	rs1371868	chr8:101330267	C/T	cg11906718	chr8:101322791	RNF19A	0.53	6.89	0.39	4.16e-11	Atrioventricular conduction;
CESC	cis	rs4713118	0.621	rs4713132	chr6:28034035	A/G	cg19592336	chr6:28129416	ZNF389	0.57	7.34	0.41	2.64e-12	Parkinson's disease;
CESC	cis	rs3820928	0.874	rs13383070	chr2:227904939	C/T	cg11843606	chr2:227700838	RHBDD1	-0.49	-6.71	-0.38	1.18e-10	Pulmonary function;
CESC	cis	rs7666738	0.830	rs7678911	chr4:99057430	C/T	cg03467027	chr4:99064603	C4orf37	0.48	6.02	0.35	5.66e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11098499	0.863	rs2127823	chr4:120485670	G/T	cg24375607	chr4:120327624	NA	0.43	5.23	0.31	3.44e-7	Corneal astigmatism;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg16427743	chr14:65210080	PLEKHG3	0.45	6.2	0.36	2.2e-9	Fibrinogen levels;
CESC	cis	rs4555082	1.000	rs4555082	chr14:105758964	C/T	cg13114125	chr14:105738426	BRF1	-0.75	-9.55	-0.51	8.88e-19	Mean platelet volume;Platelet distribution width;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14126493	chr5:176831297	F12	0.59	6.45	0.37	5.25e-10	Gut microbiome composition (summer);
CESC	cis	rs765787	0.530	rs4774542	chr15:45526026	A/C	cg24006582	chr15:45444508	DUOX1	0.53	6.21	0.36	2.07e-9	Uric acid levels;
CESC	cis	rs9325144	0.560	rs2387924	chr12:38662883	A/G	cg13010199	chr12:38710504	ALG10B	-0.45	-6.1	-0.35	3.79e-9	Morning vs. evening chronotype;
CESC	trans	rs4756846	1.000	rs17554301	chr11:16402082	C/T	cg05579622	chr5:10618622	ANKRD33B	0.76	6.93	0.39	3.14e-11	Obesity and osteoporosis;
CESC	cis	rs941873	0.868	rs1483733	chr10:81130036	A/G	cg08514558	chr10:81106712	PPIF	0.32	5.77	0.33	2.26e-8	Height;
CESC	cis	rs4718428	0.672	rs13241598	chr7:66300652	A/G	cg06064049	chr7:66057363	NA	0.49	5.07	0.3	7.54e-7	Corneal structure;
CESC	cis	rs763121	0.819	rs8137829	chr22:39061030	G/A	cg21395723	chr22:39101663	GTPBP1	0.43	5.37	0.31	1.74e-7	Menopause (age at onset);
CESC	cis	rs10504229	0.679	rs16920056	chr8:58106218	C/A	cg24829409	chr8:58192753	C8orf71	-0.56	-7.01	-0.4	1.97e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs10845606	1.000	rs10845610	chr12:12839107	G/A	cg09462578	chr12:12878428	APOLD1	-0.66	-7.25	-0.41	4.57e-12	Systemic lupus erythematosus;
CESC	cis	rs72781680	0.904	rs72796340	chr2:24143622	T/A	cg20701182	chr2:24300061	SF3B14	0.63	5.67	0.33	3.79e-8	Lymphocyte counts;
CESC	cis	rs875971	0.571	rs78668714	chr7:65939451	G/A	cg11764359	chr7:65958608	NA	0.83	9.53	0.51	1.09e-18	Aortic root size;
CESC	cis	rs4822044	0.561	rs132781	chr22:42046122	T/G	cg03806693	chr22:41940476	POLR3H	1.04	12.04	0.59	6.41e-27	Cannabis dependence symptom count;
CESC	cis	rs7809950	0.817	rs2237671	chr7:107131528	A/T	cg23024343	chr7:107201750	COG5	-0.58	-7.47	-0.42	1.18e-12	Coronary artery disease;
CESC	cis	rs1348850	0.609	rs1348851	chr2:178418677	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.66	-5.63	-0.33	4.7e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs1475911	0.708	rs56109792	chr21:43520060	A/G	cg03240473	chr21:43526662	UMODL1;C21orf128	-0.5	-6.63	-0.38	1.85e-10	IgG glycosylation;
CESC	cis	rs6762	0.550	rs8672	chr11:838634	C/G	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.74	-9.96	-0.52	4.73e-20	Mean platelet volume;
CESC	cis	rs4862750	0.874	rs6822062	chr4:187895553	T/C	cg03647317	chr4:187891568	NA	-0.39	-5.79	-0.34	1.98e-8	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26568855	chr1:155145228	TRIM46;KRTCAP2	0.6	6.59	0.38	2.36e-10	Gut microbiome composition (summer);
CESC	cis	rs6546550	0.935	rs1377995	chr2:70064155	C/G	cg02498382	chr2:70120550	SNRNP27	-0.39	-6.7	-0.38	1.23e-10	Prevalent atrial fibrillation;
CESC	cis	rs5997397	0.967	rs5752791	chr22:29153547	A/G	cg02153584	chr22:29168773	CCDC117	-0.52	-7.13	-0.4	9.38e-12	Red cell distribution width;
CESC	cis	rs1538970	0.816	rs61788356	chr1:46006675	C/T	cg06784218	chr1:46089804	CCDC17	0.35	5.62	0.33	4.81e-8	Platelet count;
CESC	cis	rs11602339	1	rs11602339	chr11:47761471	C/T	cg20307385	chr11:47447363	PSMC3	-0.52	-6.37	-0.36	8.3e-10	Body mass index;
CESC	cis	rs989128	0.600	rs8082568	chr17:48629312	G/C	cg24438145	chr17:48624694	SPATA20	0.45	5.31	0.31	2.36e-7	Type 2 diabetes;
CESC	cis	rs11252926	0.801	rs11252332	chr10:467318	A/T	cg08603382	chr10:743973	NA	0.52	6.56	0.37	2.87e-10	Psychosis in Alzheimer's disease;
CESC	cis	rs6860806	0.661	rs1588263	chr5:131577158	T/C	cg18758796	chr5:131593413	PDLIM4	0.46	6.62	0.38	1.96e-10	Breast cancer;
CESC	cis	rs875971	0.545	rs6950988	chr7:65976415	C/T	cg18876405	chr7:65276391	NA	0.48	5.59	0.33	5.5e-8	Aortic root size;
CESC	cis	rs9322193	0.923	rs9800614	chr6:149965740	G/A	cg13206674	chr6:150067644	NUP43	0.43	6.22	0.36	1.95e-9	Lung cancer;
CESC	cis	rs7592578	0.771	rs75579212	chr2:191376575	C/T	cg10560079	chr2:191398806	TMEM194B	-0.69	-6.12	-0.35	3.37e-9	Diastolic blood pressure;
CESC	cis	rs10426930	0.700	rs7253212	chr19:5021391	G/A	cg18115693	chr19:4968519	KDM4B	-0.41	-5.19	-0.3	4.1e-7	Monocyte percentage of white cells;
CESC	cis	rs7659604	0.502	rs28435300	chr4:122709412	T/C	cg19748678	chr4:122722346	EXOSC9	-0.42	-5.26	-0.31	2.97e-7	Type 2 diabetes;
CESC	cis	rs7937682	0.847	rs583032	chr11:111432757	C/T	cg22437258	chr11:111473054	SIK2	0.76	9.93	0.52	5.87e-20	Primary sclerosing cholangitis;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg15046927	chr5:170863172	FGF18	0.4	6.24	0.36	1.75e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	trans	rs6089829	0.962	rs6062776	chr20:61663736	A/G	cg23505145	chr19:12996616	KLF1	0.52	6.74	0.38	1e-10	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs2207136	0.868	rs2857487	chr6:50793671	A/G	cg06522515	chr3:184090630	THPO	0.36	6.11	0.35	3.61e-9	Myopia;
CESC	cis	rs3820068	0.554	rs60233444	chr1:15921330	A/C	cg13390004	chr1:15929781	NA	0.33	5.04	0.3	8.45e-7	Systolic blood pressure;
CESC	cis	rs13256369	0.950	rs12548792	chr8:8568031	T/C	cg18904891	chr8:8559673	CLDN23	0.67	7.49	0.42	1.01e-12	Obesity-related traits;
CESC	trans	rs1814175	0.817	rs7947526	chr11:49983654	T/C	cg15704280	chr7:45808275	SEPT13	-1.03	-20.41	-0.78	2.63e-56	Height;
CESC	cis	rs896854	0.936	rs10108430	chr8:95961794	C/T	cg23172400	chr8:95962367	TP53INP1	-0.46	-9.8	-0.52	1.55e-19	Type 2 diabetes;
CESC	cis	rs10461617	0.541	rs832575	chr5:56161787	C/T	cg24549020	chr5:56110836	MAP3K1	0.56	5.32	0.31	2.2e-7	Type 2 diabetes;
CESC	cis	rs2933343	0.661	rs2630259	chr3:128606322	C/T	cg24203234	chr3:128598194	ACAD9	0.43	5.79	0.34	1.97e-8	IgG glycosylation;
CESC	cis	rs6088590	1.000	rs6119524	chr20:33373813	C/T	cg08999081	chr20:33150536	PIGU	0.58	8.9	0.48	9.32e-17	Coronary artery disease;
CESC	cis	rs7648466	0.544	rs2172247	chr3:46214670	T/C	cg19145607	chr3:45983792	CXCR6;FYCO1	0.35	5.42	0.32	1.34e-7	Eotaxin levels;
CESC	cis	rs6912958	0.684	rs2787893	chr6:88387359	C/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.36	-5.85	-0.34	1.48e-8	Monocyte percentage of white cells;
CESC	cis	rs780096	0.526	rs1260341	chr2:27663215	T/A	cg12648201	chr2:27665141	KRTCAP3	-0.35	-6.56	-0.37	2.79e-10	Total body bone mineral density;
CESC	cis	rs12995491	0.933	rs34029976	chr2:88537797	T/C	cg07952391	chr2:88470173	THNSL2	-0.55	-8.4	-0.46	2.72e-15	Response to metformin (IC50);
CESC	cis	rs8020095	0.571	rs7493580	chr14:67580450	T/A	cg19548862	chr14:67692701	FAM71D	-0.49	-5.88	-0.34	1.23e-8	Depression (quantitative trait);
CESC	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg01238044	chr22:24384105	GSTT1	-0.58	-7.53	-0.42	7.74e-13	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs826838	0.967	rs7136593	chr12:39128265	C/T	cg13010199	chr12:38710504	ALG10B	-0.45	-6.26	-0.36	1.51e-9	Heart rate;
CESC	cis	rs7618915	0.524	rs2028216	chr3:52680823	C/T	cg17372223	chr3:52568218	NT5DC2	0.44	6.51	0.37	3.66e-10	Bipolar disorder;
CESC	cis	rs9300255	0.739	rs6633	chr12:123745809	G/T	cg00376283	chr12:123451042	ABCB9	-0.63	-6.54	-0.37	3.21e-10	Neutrophil percentage of white cells;
CESC	cis	rs2204008	0.677	rs1581356	chr12:38391467	T/C	cg26384229	chr12:38710491	ALG10B	0.68	9.91	0.52	6.67e-20	Bladder cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18171715	chr4:852160	GAK	-0.6	-6.39	-0.37	7.33e-10	Gut microbiome composition (summer);
CESC	cis	rs1559088	0.948	rs12608825	chr19:33581219	C/T	cg03563238	chr19:33554763	RHPN2	0.29	5.05	0.3	8.39e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs13191362	0.810	rs13200053	chr6:163011443	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.82	8.22	0.45	9.12e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs17376456	0.877	rs10066791	chr5:93350255	G/T	cg25358565	chr5:93447407	FAM172A	1.05	10.09	0.53	1.77e-20	Diabetic retinopathy;
CESC	cis	rs4975616	0.869	rs380286	chr5:1320247	G/A	cg06550200	chr5:1325588	CLPTM1L	-0.7	-10.91	-0.56	3.78e-23	Lung cancer;
CESC	cis	rs2882667	0.931	rs10074461	chr5:138319815	G/T	cg04439458	chr5:138467593	SIL1	-0.29	-5.1	-0.3	6.58e-7	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs870825	0.616	rs6552804	chr4:185637699	A/G	cg04058563	chr4:185651563	MLF1IP	0.62	6.86	0.39	4.91e-11	Blood protein levels;
CESC	cis	rs2073300	0.609	rs17830281	chr20:23350525	C/T	cg12062639	chr20:23401060	NAPB	0.98	7.59	0.42	5.37e-13	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21831501	chr1:173446253	PRDX6	0.55	6.14	0.35	3.05e-9	Gut microbiome composition (summer);
CESC	cis	rs910316	1.000	rs28626045	chr14:75589195	G/C	cg11812906	chr14:75593930	NEK9	0.89	15.12	0.68	1.11e-37	Height;
CESC	cis	rs9402673	0.558	rs9688342	chr6:135323026	A/T	cg24558204	chr6:135376177	HBS1L	0.53	7.28	0.41	3.85e-12	Reticulocyte count;High light scatter reticulocyte count;
CESC	cis	rs2455799	0.573	rs62243672	chr3:15937200	C/T	cg16303742	chr3:15540471	COLQ	-0.35	-5.27	-0.31	2.79e-7	Mean platelet volume;
CESC	cis	rs3733585	0.805	rs882222	chr4:9981294	G/A	cg02734326	chr4:10020555	SLC2A9	0.46	6.9	0.39	3.73e-11	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs722599	0.562	rs2287400	chr14:75182937	G/A	cg08847533	chr14:75593920	NEK9	0.44	5.32	0.31	2.22e-7	IgG glycosylation;
CESC	cis	rs73058052	0.867	rs57940349	chr19:50097607	C/T	cg09250473	chr19:50168907	IRF3;BCL2L12	0.6	5.29	0.31	2.56e-7	Fibrinogen levels;
CESC	cis	rs10771431	0.597	rs10843144	chr12:9357577	C/T	cg08997352	chr12:9597637	DDX12	-0.72	-8.96	-0.48	5.74e-17	Breast size;
CESC	cis	rs12701220	0.604	rs12702122	chr7:1149494	C/G	cg23978390	chr7:1156363	C7orf50	0.57	5.85	0.34	1.45e-8	Bronchopulmonary dysplasia;
CESC	cis	rs1568889	0.838	rs11030206	chr11:28099747	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.81	13.5	0.64	5.59e-32	Bipolar disorder;
CESC	cis	rs67311347	1.000	rs2085115	chr3:40497540	G/T	cg09455208	chr3:40491958	NA	0.51	8.15	0.45	1.43e-14	Renal cell carcinoma;
CESC	cis	rs2439831	0.702	rs8033995	chr15:44013509	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.67	6.32	0.36	1.13e-9	Lung cancer in ever smokers;
CESC	cis	rs8044868	0.586	rs3844425	chr16:72194325	T/C	cg01557791	chr16:72042693	DHODH	-0.4	-5.37	-0.31	1.71e-7	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CESC	cis	rs10504229	1.000	rs111915672	chr8:58191665	T/C	cg14926445	chr8:58193284	C8orf71	-0.52	-5.53	-0.32	7.54e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs7552404	0.961	rs17587071	chr1:76225083	A/C	cg10523679	chr1:76189770	ACADM	0.73	8.57	0.47	8.98e-16	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs17818399	0.712	rs13008088	chr2:46781580	C/G	cg06386533	chr2:46925753	SOCS5	0.46	5.45	0.32	1.17e-7	Height;
CESC	trans	rs7618501	1.000	rs11130219	chr3:49752427	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.58	-8.44	-0.46	2.11e-15	Intelligence (multi-trait analysis);
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg21194723	chr11:60681294	TMEM109	-0.46	-6.13	-0.35	3.19e-9	Height;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg23162967	chr3:105587981	CBLB	-0.41	-6.04	-0.35	5.17e-9	Gambling;
CESC	cis	rs6912958	0.781	rs2268993	chr6:88184111	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.43	-5.82	-0.34	1.68e-8	Monocyte percentage of white cells;
CESC	cis	rs3806843	1.000	rs2240695	chr5:140168151	G/T	cg26395211	chr5:140044315	WDR55	-0.43	-5.52	-0.32	8.02e-8	Depressive symptoms (multi-trait analysis);
CESC	cis	rs854765	0.562	rs2955381	chr17:17945500	G/C	cg09796270	chr17:17721594	SREBF1	-0.38	-5.07	-0.3	7.66e-7	Total body bone mineral density;
CESC	cis	rs7107174	1.000	rs57738705	chr11:77994489	A/G	cg02023728	chr11:77925099	USP35	0.48	6.64	0.38	1.74e-10	Testicular germ cell tumor;
CESC	cis	rs6674176	0.597	rs12127737	chr1:44402565	G/A	cg23954153	chr1:44402353	ARTN	-0.37	-5.94	-0.34	8.99e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs4950322	0.570	rs72691095	chr1:146769990	G/C	cg22381352	chr1:146742008	CHD1L	-0.46	-5.05	-0.3	8.32e-7	Protein quantitative trait loci;
CESC	cis	rs2932538	0.845	rs6682678	chr1:113206920	A/G	cg22162597	chr1:113214053	CAPZA1	-0.56	-7.04	-0.4	1.66e-11	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CESC	cis	rs2712184	0.967	rs1014680	chr2:217672824	A/G	cg05032264	chr2:217675019	NA	0.38	5.54	0.32	7.31e-8	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
CESC	cis	rs2108622	0.683	rs111388185	chr19:15977414	T/C	cg13772218	chr19:15982569	NA	0.29	5.69	0.33	3.28e-8	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23282051	chr2:239067613	NA	0.56	6.62	0.38	2.04e-10	Gut microbiome composition (summer);
CESC	cis	rs8014204	0.901	rs6574200	chr14:75364451	C/T	cg26191576	chr14:75389716	RPS6KL1	0.36	5.13	0.3	5.56e-7	Caffeine consumption;
CESC	cis	rs9581857	0.615	rs79553479	chr13:28007862	G/A	cg22138327	chr13:27999177	GTF3A	0.66	5.32	0.31	2.17e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
CESC	cis	rs7666738	0.830	rs34671152	chr4:98978177	C/T	cg05340658	chr4:99064831	C4orf37	0.79	12.26	0.6	1.12e-27	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7607369	0.714	rs1344643	chr2:219584975	G/C	cg02176678	chr2:219576539	TTLL4	-0.49	-8.7	-0.47	3.47e-16	Red blood cell count;Amyotrophic lateral sclerosis;
CESC	cis	rs7914558	1.000	rs10509757	chr10:104752960	C/T	cg04362960	chr10:104952993	NT5C2	0.48	6.42	0.37	6.23e-10	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs10751667	0.621	rs10794353	chr11:948740	A/G	cg20946044	chr11:1010712	AP2A2	-0.4	-5.52	-0.32	8.07e-8	Alzheimer's disease (late onset);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg14265927	chr9:139137836	QSOX2	-0.41	-6.08	-0.35	4.1e-9	Gambling;
CESC	cis	rs6141600	0.540	rs1006296	chr20:34717718	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.42	-5.94	-0.34	8.97e-9	Height;Hip circumference;
CESC	cis	rs17376456	0.757	rs1031424	chr5:93139706	G/C	cg21475434	chr5:93447410	FAM172A	0.83	7.39	0.41	1.91e-12	Diabetic retinopathy;
CESC	cis	rs769267	0.825	rs1469713	chr19:19528806	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.49	6.26	0.36	1.5e-9	Tonsillectomy;
CESC	cis	rs9660180	0.935	rs2180311	chr1:1748734	T/C	cg17747265	chr1:1875780	NA	-0.57	-9.24	-0.49	8.4e-18	Body mass index;
CESC	cis	rs514406	0.679	rs499239	chr1:53310594	A/G	cg25767906	chr1:53392781	SCP2	-0.5	-7.07	-0.4	1.39e-11	Monocyte count;
CESC	cis	rs1707322	0.721	rs10890344	chr1:46166090	C/T	cg05343316	chr1:45956843	TESK2	0.51	6.2	0.36	2.19e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg01570182	chr17:44337453	NA	0.94	10.63	0.55	3.24e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs6580649	0.941	rs11612578	chr12:48414798	T/C	cg05342945	chr12:48394962	COL2A1	0.49	5.52	0.32	8.21e-8	Lung cancer;
CESC	cis	rs7089973	0.604	rs7095816	chr10:116585109	T/C	cg03647239	chr10:116582469	FAM160B1	0.45	5.77	0.33	2.19e-8	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg10819733	chr22:24237672	NA	-0.47	-6.76	-0.38	8.96e-11	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs7481584	0.646	rs434114	chr11:3050210	A/G	cg25174290	chr11:3078921	CARS	-0.45	-6.28	-0.36	1.36e-9	Calcium levels;
CESC	cis	rs60871478	0.947	rs4074610	chr7:791755	G/A	cg27478167	chr7:817139	HEATR2	-0.5	-5.91	-0.34	1.06e-8	Cerebrospinal P-tau181p levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14908186	chr13:113863106	CUL4A;PCID2	0.51	6.12	0.35	3.32e-9	Gut microbiome composition (summer);
CESC	cis	rs8040855	0.627	rs12904238	chr15:85639841	A/T	cg08123816	chr15:85640762	PDE8A	-0.41	-6.19	-0.36	2.33e-9	Bulimia nervosa;
CESC	cis	rs2996428	0.629	rs12135894	chr1:3728061	C/T	cg13057898	chr1:3703894	LRRC47	0.46	6.33	0.36	1.06e-9	Red cell distribution width;
CESC	cis	rs7618915	0.570	rs13068293	chr3:52672167	C/A	cg18404041	chr3:52824283	ITIH1	-0.39	-6.56	-0.37	2.86e-10	Bipolar disorder;
CESC	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.89	13.34	0.63	2.04e-31	Prudent dietary pattern;
CESC	trans	rs7839040	0.698	rs2048105	chr8:82931756	C/T	cg14472086	chr9:107730925	NA	-0.48	-6.45	-0.37	5.4e-10	Response to methotrexate in juvenile idiopathic arthritis;
CESC	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg11062466	chr8:58055876	NA	0.45	6.04	0.35	5.28e-9	Developmental language disorder (linguistic errors);
CESC	trans	rs1814175	0.592	rs1794161	chr11:49898825	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.43	-6.26	-0.36	1.51e-9	Height;
CESC	cis	rs6842047	0.706	rs4862667	chr4:187136416	A/G	cg23442198	chr4:187126114	CYP4V2	0.64	5.41	0.32	1.38e-7	Blood protein levels;
CESC	cis	rs9584850	0.834	rs7985565	chr13:99113471	C/G	cg22223119	chr13:99095684	FARP1	-0.35	-5.17	-0.3	4.55e-7	Neuroticism;
CESC	trans	rs11098499	0.955	rs1551	chr4:120158500	T/G	cg25214090	chr10:38739885	LOC399744	0.64	8.63	0.47	5.92e-16	Corneal astigmatism;
CESC	cis	rs6120849	0.901	rs6058193	chr20:33734464	A/G	cg24642439	chr20:33292090	TP53INP2	0.64	6.77	0.38	8.31e-11	Protein C levels;
CESC	cis	rs28374715	0.681	rs11629979	chr15:41626579	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.78	-11.24	-0.57	3.19e-24	Ulcerative colitis;
CESC	trans	rs61931739	0.534	rs10844725	chr12:34009504	C/A	cg26384229	chr12:38710491	ALG10B	0.59	8.19	0.45	1.11e-14	Morning vs. evening chronotype;
CESC	cis	rs2235642	0.928	rs9932984	chr16:1605051	A/G	cg09080909	chr16:1797204	MAPK8IP3	-0.36	-5.06	-0.3	7.83e-7	Coronary artery disease;
CESC	cis	rs3749237	0.964	rs13084243	chr3:49821878	G/C	cg03060546	chr3:49711283	APEH	0.66	7.88	0.44	8.24e-14	Resting heart rate;
CESC	cis	rs57221529	0.709	rs72707023	chr5:667620	G/A	cg09021430	chr5:549028	NA	-0.43	-5.15	-0.3	5.21e-7	Lung disease severity in cystic fibrosis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	ch.15.1220700F	chr15:75682336	SIN3A	-0.54	-6.29	-0.36	1.31e-9	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27370461	chr11:111637044	PPP2R1B	0.6	7.18	0.4	7.19e-12	Gut microbiome composition (summer);
CESC	cis	rs896854	0.846	rs7845219	chr8:95937502	T/C	cg13393036	chr8:95962371	TP53INP1	-0.5	-10.81	-0.55	8.43e-23	Type 2 diabetes;
CESC	cis	rs875971	1.000	rs6961155	chr7:65933295	T/C	cg12463550	chr7:65579703	CRCP	0.56	7.09	0.4	1.2e-11	Aortic root size;
CESC	cis	rs801193	1.000	rs2707856	chr7:66211010	A/T	cg18876405	chr7:65276391	NA	0.56	7.49	0.42	1e-12	Aortic root size;
CESC	cis	rs6952808	0.929	rs12532128	chr7:1925454	T/C	cg02951883	chr7:2050386	MAD1L1	-0.51	-6.79	-0.39	7.2e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs4319547	1.000	rs6489156	chr12:123100397	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.59	-7.11	-0.4	1.07e-11	Body mass index;
CESC	cis	rs9611565	0.512	rs5751147	chr22:42139054	G/A	cg06634786	chr22:41940651	POLR3H	0.68	6.72	0.38	1.13e-10	Vitiligo;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22855052	chr12:6982535	SPSB2	0.58	6.81	0.39	6.34e-11	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22954621	chr10:13514626	BEND7	-0.62	-7.6	-0.42	5.23e-13	Gut microbiome composition (summer);
CESC	cis	rs2204008	0.575	rs10444564	chr12:38043782	T/C	cg13010199	chr12:38710504	ALG10B	0.54	6.63	0.38	1.87e-10	Bladder cancer;
CESC	cis	rs2841277	0.646	rs3742935	chr14:105405599	G/C	cg17340268	chr14:105411764	AHNAK2	-0.52	-6.92	-0.39	3.36e-11	Rheumatoid arthritis;
CESC	cis	rs12477438	0.520	rs2309581	chr2:99784292	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.89	-15.68	-0.69	1.15e-39	Chronic sinus infection;
CESC	cis	rs798554	0.679	rs1636253	chr7:2885123	A/G	cg04166393	chr7:2884313	GNA12	0.61	8.24	0.45	8.02e-15	Height;
CESC	cis	rs9926296	0.533	rs7190823	chr16:89866043	A/G	cg03388025	chr16:89894329	SPIRE2	0.39	7.71	0.43	2.58e-13	Vitiligo;
CESC	cis	rs34779708	0.931	rs11010132	chr10:35517265	C/G	cg03585969	chr10:35415529	CREM	0.68	8.52	0.46	1.23e-15	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs6540559	0.546	rs634601	chr1:210421594	C/T	cg23283495	chr1:209979779	IRF6	0.42	5.53	0.32	7.75e-8	Cleft lip with or without cleft palate;
CESC	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg11905131	chr22:24372483	LOC391322	0.68	9.74	0.51	2.36e-19	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs9796	0.870	rs10851402	chr15:41263438	C/T	cg18705301	chr15:41695430	NDUFAF1	0.4	5.73	0.33	2.73e-8	Menopause (age at onset);
CESC	cis	rs7927771	0.524	rs10742824	chr11:47864842	C/T	cg18512352	chr11:47633146	NA	0.35	5.37	0.31	1.7e-7	Subjective well-being;
CESC	cis	rs1862618	0.671	rs72644088	chr5:56241019	G/A	cg24549020	chr5:56110836	MAP3K1	-0.48	-5.84	-0.34	1.55e-8	Initial pursuit acceleration;
CESC	cis	rs11039389	1	rs11039389	chr11:47796062	T/C	cg18512352	chr11:47633146	NA	-0.6	-9.52	-0.5	1.17e-18	Neuroticism;
CESC	cis	rs1018836	0.892	rs4735210	chr8:91549399	G/T	cg16814680	chr8:91681699	NA	-0.62	-8.84	-0.48	1.38e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs7914558	1.000	rs3740387	chr10:104849468	G/A	cg04362960	chr10:104952993	NT5C2	0.47	6.18	0.35	2.42e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs9486719	0.895	rs3734239	chr6:96996244	A/G	cg18709589	chr6:96969512	KIAA0776	-0.52	-5.69	-0.33	3.43e-8	Migraine;Coronary artery disease;
CESC	cis	rs9894429	1.000	rs3935543	chr17:79579874	T/C	cg13777783	chr17:79615861	NA	-0.35	-5.79	-0.34	1.99e-8	Eye color traits;
CESC	cis	rs12188164	1.000	rs56104584	chr5:437542	T/C	cg15813090	chr5:442598	EXOC3;C5orf55	0.41	6.22	0.36	1.89e-9	Cystic fibrosis severity;
CESC	trans	rs9388451	0.626	rs7748729	chr6:126077381	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.65	-9.14	-0.49	1.67e-17	Brugada syndrome;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg11636702	chr4:11370466	MIR572	0.43	6.36	0.36	8.56e-10	Fibrinogen levels;
CESC	cis	rs2455799	0.613	rs2470547	chr3:15737610	T/C	cg09340198	chr3:15902540	ANKRD28	-0.32	-5.11	-0.3	6.05e-7	Mean platelet volume;
CESC	cis	rs2050392	0.792	rs303434	chr10:30714440	G/A	cg18806716	chr10:30721971	MAP3K8	-0.4	-5.79	-0.33	2.02e-8	Inflammatory bowel disease;
CESC	cis	rs1707322	0.929	rs785500	chr1:46593044	C/T	cg06784218	chr1:46089804	CCDC17	-0.33	-5.63	-0.33	4.67e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs8057939	0.593	rs12597275	chr16:49419305	C/T	cg15532236	chr6:170188124	NA	0.5	6.1	0.35	3.83e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs9400271	0.632	rs9374072	chr6:109591586	A/G	cg01475377	chr6:109611718	NA	-0.45	-7.02	-0.4	1.9e-11	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
CESC	cis	rs2950393	0.857	rs1563896	chr12:57093096	A/G	cg05584118	chr12:57595605	LRP1	-0.37	-5.04	-0.3	8.83e-7	Platelet distribution width;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23167218	chr5:138609385	MATR3;SNHG4	0.52	6.27	0.36	1.43e-9	Gut microbiome composition (summer);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg06604058	chr11:63448992	RTN3	-0.44	-6.33	-0.36	1.03e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs12926788	0.689	rs34365165	chr16:24856208	G/A	cg00339695	chr16:24857497	SLC5A11	0.49	6.06	0.35	4.56e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs6461049	0.638	rs3778994	chr7:2175855	G/T	cg05863683	chr7:1912471	MAD1L1	0.37	5.56	0.32	6.65e-8	Schizophrenia;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg23058863	chr14:24610866	FAM158A	-0.43	-6.04	-0.35	5.18e-9	Gambling;
CESC	cis	rs3733585	0.673	rs4519796	chr4:9955936	A/G	cg11266682	chr4:10021025	SLC2A9	-0.57	-10.92	-0.56	3.75e-23	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs2880765	0.835	rs11856869	chr15:86029097	C/G	cg10818794	chr15:86012489	AKAP13	-0.34	-5.24	-0.31	3.26e-7	Coronary artery disease;
CESC	cis	rs2576037	1.000	rs2576037	chr18:44585420	C/T	cg19077165	chr18:44547161	KATNAL2	0.51	7.06	0.4	1.45e-11	Personality dimensions;
CESC	cis	rs7666738	0.830	rs6853266	chr4:99047528	G/T	cg18180107	chr4:99064573	C4orf37	0.45	5.71	0.33	3.05e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4595586	0.545	rs12823586	chr12:39391677	C/G	cg26384229	chr12:38710491	ALG10B	0.54	7.64	0.42	3.96e-13	Morning vs. evening chronotype;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg02580404	chr16:19729857	C16orf88;IQCK	-0.44	-6.09	-0.35	3.91e-9	Fibrinogen levels;
CESC	cis	rs9905704	0.633	rs2526368	chr17:56470310	G/T	cg12560992	chr17:57184187	TRIM37	-0.61	-5.75	-0.33	2.49e-8	Testicular germ cell tumor;
CESC	cis	rs4819052	0.800	rs4819045	chr21:46660138	C/A	cg11663144	chr21:46675770	NA	-0.63	-10.02	-0.52	3.12e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs2109514	0.967	rs10271007	chr7:116145849	A/G	cg12739419	chr7:116140593	CAV2	-0.35	-6.48	-0.37	4.44e-10	Prevalent atrial fibrillation;
CESC	cis	rs258892	0.895	rs155433	chr5:72139664	G/C	cg21869765	chr5:72125136	TNPO1	0.44	5.48	0.32	9.83e-8	Small cell lung carcinoma;
CESC	cis	rs6987853	0.787	rs2974309	chr8:42426961	G/A	cg09913449	chr8:42400586	C8orf40	0.47	7.86	0.43	9.71e-14	Mean corpuscular hemoglobin concentration;
CESC	cis	rs7666738	0.791	rs11097610	chr4:99011795	C/G	cg05340658	chr4:99064831	C4orf37	0.79	11.98	0.59	1.05e-26	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2273669	0.588	rs78276890	chr6:109305299	G/A	cg05315195	chr6:109294784	ARMC2	-0.65	-6.08	-0.35	4.15e-9	Prostate cancer;
CESC	cis	rs763121	0.853	rs5757234	chr22:39072686	C/T	cg14440974	chr22:39074834	NA	-0.36	-5.21	-0.3	3.78e-7	Menopause (age at onset);
CESC	cis	rs7666738	0.830	rs4401456	chr4:98959902	C/T	cg05340658	chr4:99064831	C4orf37	0.8	12.39	0.61	3.96e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6724607	1.000	rs4321393	chr2:191452899	G/T	cg21644426	chr2:191273491	MFSD6	0.48	6.41	0.37	6.5e-10	Pulse pressure;
CESC	cis	rs7267979	1.000	rs2424704	chr20:25273929	A/G	cg08601574	chr20:25228251	PYGB	0.39	5.57	0.32	6.14e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7208859	0.623	rs76633166	chr17:29113365	C/T	cg14008862	chr17:28927542	LRRC37B2	0.65	5.14	0.3	5.34e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs3091242	0.967	rs1053438	chr1:25687901	T/C	cg12412775	chr1:25698385	RHCE	0.32	5.69	0.33	3.29e-8	Erythrocyte sedimentation rate;
CESC	cis	rs875971	0.660	rs10215132	chr7:66054406	C/A	cg11764359	chr7:65958608	NA	-0.72	-9.54	-0.51	9.82e-19	Aortic root size;
CESC	cis	rs7829975	0.508	rs4841006	chr8:8501474	T/C	cg06636001	chr8:8085503	FLJ10661	-0.41	-5.4	-0.31	1.48e-7	Mood instability;
CESC	cis	rs7927771	0.524	rs12286721	chr11:47701528	G/T	cg20307385	chr11:47447363	PSMC3	-0.58	-8.03	-0.44	3.18e-14	Subjective well-being;
CESC	cis	rs938554	0.577	rs7683856	chr4:10000947	A/G	cg00071950	chr4:10020882	SLC2A9	0.6	7.06	0.4	1.45e-11	Blood metabolite levels;
CESC	cis	rs10479542	0.766	rs7733389	chr5:178974997	C/T	cg09060608	chr5:178986726	RUFY1	0.41	5.96	0.34	8.15e-9	Lung cancer;
CESC	cis	rs9858542	1.000	rs4283605	chr3:49678651	A/G	cg03060546	chr3:49711283	APEH	-0.59	-6.95	-0.39	2.86e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs6752107	1.000	rs6708373	chr2:234172846	A/G	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.36	5.43	0.32	1.25e-7	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs763512	0.504	rs1051838	chr17:35870833	G/A	cg16670864	chr17:35848621	DUSP14	0.52	6.36	0.36	8.6e-10	3-hydroxypropylmercapturic acid levels in smokers;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09537216	chr5:72801264	BTF3	-0.56	-6.86	-0.39	4.74e-11	Gut microbiome composition (summer);
CESC	cis	rs8114671	0.804	rs6088666	chr20:33564570	A/G	cg24642439	chr20:33292090	TP53INP2	0.46	5.47	0.32	1.06e-7	Height;
CESC	cis	rs2249694	0.960	rs7084391	chr10:135412344	A/C	cg20169779	chr10:135381914	SYCE1	-0.4	-5.65	-0.33	4.05e-8	Obesity-related traits;
CESC	cis	rs6963495	0.818	rs116457537	chr7:105152072	A/G	cg13798780	chr7:105162888	PUS7	0.76	7.77	0.43	1.79e-13	Bipolar disorder (body mass index interaction);
CESC	cis	rs2070488	0.965	rs7373828	chr3:38524311	A/G	cg24069376	chr3:38537580	EXOG	0.49	8.78	0.47	2.03e-16	Electrocardiographic conduction measures;
CESC	cis	rs3126085	0.877	rs57597406	chr1:152246619	C/G	cg03465714	chr1:152285911	FLG	-0.45	-5.56	-0.32	6.52e-8	Atopic dermatitis;
CESC	cis	rs10392	0.543	rs6028197	chr20:37534193	C/T	cg27552599	chr20:37590471	DHX35	0.39	5.64	0.33	4.42e-8	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
CESC	cis	rs7647973	0.593	rs4855885	chr3:49690199	G/A	cg13072238	chr3:49761600	GMPPB	-0.5	-5.81	-0.34	1.77e-8	Menarche (age at onset);
CESC	trans	rs7815944	1.000	rs58299386	chr8:129451995	C/G	cg24350771	chr7:18329602	NA	-0.69	-6.05	-0.35	4.9e-9	Atopic dermatitis;
CESC	trans	rs9650657	0.506	rs7823296	chr8:10778546	A/G	cg06636001	chr8:8085503	FLJ10661	-0.51	-6.35	-0.36	9.47e-10	Neuroticism;
CESC	cis	rs875971	0.929	rs6970860	chr7:65976634	A/G	cg10691866	chr7:65817282	TPST1	-0.34	-5.59	-0.32	5.57e-8	Aortic root size;
CESC	cis	rs3785574	0.962	rs7219920	chr17:61811642	C/G	cg07677032	chr17:61819896	STRADA	0.42	5.38	0.31	1.61e-7	Height;
CESC	cis	rs7772486	0.738	rs9485039	chr6:146319387	C/T	cg23711669	chr6:146136114	FBXO30	0.8	11.17	0.57	5.23e-24	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25097514	chr2:219157373	TMBIM1;PNKD	-0.57	-6.29	-0.36	1.28e-9	Gut microbiome composition (summer);
CESC	cis	rs514406	0.929	rs483073	chr1:53314084	T/C	cg08736216	chr1:53307985	ZYG11A	-0.44	-7.35	-0.41	2.52e-12	Monocyte count;
CESC	cis	rs3820928	0.874	rs10195072	chr2:227794452	G/A	cg05526886	chr2:227700861	RHBDD1	-0.4	-5.11	-0.3	6.13e-7	Pulmonary function;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20354231	chr13:53171401	NA	-0.58	-6.76	-0.38	8.7e-11	Gut microbiome composition (summer);
CESC	cis	rs6831352	0.918	rs17218560	chr4:100060794	C/T	cg13256891	chr4:100009986	ADH5	0.65	7.55	0.42	6.98e-13	Alcohol dependence;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26850559	chr10:3214952	PITRM1	0.56	6.0	0.35	6.45e-9	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20795891	chr22:41985901	PMM1	-0.59	-6.45	-0.37	5.42e-10	Gut microbiome composition (summer);
CESC	cis	rs7107174	0.892	rs2511167	chr11:77964698	C/T	cg02023728	chr11:77925099	USP35	0.46	6.47	0.37	4.58e-10	Testicular germ cell tumor;
CESC	cis	rs7618915	0.547	rs2118540	chr3:52629386	T/C	cg05564831	chr3:52568323	NT5DC2	0.46	7.01	0.4	2.01e-11	Bipolar disorder;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg26600917	chr1:110162534	AMPD2	-0.44	-6.22	-0.36	1.88e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs72945132	0.769	rs11235754	chr11:70136092	C/T	cg00319359	chr11:70116639	PPFIA1	0.78	7.67	0.43	3.32e-13	Coronary artery disease;
CESC	cis	rs7086627	0.515	rs6585994	chr10:82191643	A/G	cg00277334	chr10:82204260	NA	-0.59	-9.11	-0.49	2.07e-17	Post bronchodilator FEV1;
CESC	cis	rs826838	0.616	rs1601746	chr12:38626195	G/T	cg26384229	chr12:38710491	ALG10B	-0.44	-6.19	-0.36	2.31e-9	Heart rate;
CESC	cis	rs7833790	0.777	rs1005850	chr8:82692255	G/A	cg06027949	chr8:82754900	SNX16	-0.46	-5.27	-0.31	2.82e-7	Diastolic blood pressure;
CESC	cis	rs7917772	0.503	rs11191320	chr10:104293394	T/C	cg22532475	chr10:104410764	TRIM8	-0.35	-6.02	-0.35	5.75e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs9814567	1.000	rs11706117	chr3:134212526	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.44	-5.99	-0.35	6.73e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs2075371	0.933	rs2544201	chr7:133963561	C/G	cg11752832	chr7:134001865	SLC35B4	0.51	6.61	0.38	2.16e-10	Mean platelet volume;
CESC	cis	rs1005277	0.579	rs1780137	chr10:38501475	C/G	cg00409905	chr10:38381863	ZNF37A	-0.51	-6.8	-0.39	6.98e-11	Extrinsic epigenetic age acceleration;
CESC	trans	rs8057939	0.593	rs11862457	chr16:49442841	C/T	cg15532236	chr6:170188124	NA	0.49	6.11	0.35	3.61e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs5753037	0.504	rs140114	chr22:30133881	C/T	cg01021169	chr22:30184971	ASCC2	-0.55	-7.87	-0.44	9.34e-14	Type 1 diabetes;
CESC	cis	rs1577917	1.000	rs6940458	chr6:86644992	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.43	-5.52	-0.32	8.09e-8	Response to antipsychotic treatment;
CESC	cis	rs11792861	0.926	rs7856626	chr9:111775502	C/G	cg13535736	chr9:111863775	C9orf5	-0.49	-6.48	-0.37	4.34e-10	Menarche (age at onset);
CESC	cis	rs3733585	0.631	rs3822236	chr4:10119961	T/G	cg00071950	chr4:10020882	SLC2A9	-0.62	-9.92	-0.52	6.42e-20	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs28673728	0.897	rs28391281	chr1:38408974	T/C	cg18451016	chr1:38461880	NA	0.4	5.92	0.34	9.92e-9	Red cell distribution width;
CESC	cis	rs7089973	0.872	rs10490908	chr10:116616162	T/C	cg23260525	chr10:116636907	FAM160B1	0.38	6.37	0.36	8.29e-10	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg10784777	chr12:56552019	MYL6	-0.44	-6.14	-0.35	3.06e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs6879260	1.000	rs7730585	chr5:179733440	T/C	cg23248424	chr5:179741104	GFPT2	-0.57	-7.86	-0.43	9.98e-14	Height;
CESC	cis	rs6087990	0.735	rs2424915	chr20:31378448	C/T	cg13636640	chr20:31349939	DNMT3B	0.76	11.98	0.59	1e-26	Ulcerative colitis;
CESC	cis	rs3026101	0.671	rs28409881	chr17:5319100	G/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.4	5.22	0.31	3.64e-7	Body mass index;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg10705951	chr16:29985294	TAOK2	-0.5	-5.99	-0.35	6.67e-9	Asthma;
CESC	cis	rs2204008	0.811	rs4882300	chr12:38415224	A/T	cg26384229	chr12:38710491	ALG10B	-0.63	-9.37	-0.5	3.38e-18	Bladder cancer;
CESC	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg05025164	chr4:1340916	KIAA1530	0.89	11.85	0.59	2.88e-26	Longevity;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19759454	chr14:103058807	RCOR1	0.64	6.87	0.39	4.44e-11	Gut microbiome composition (summer);
CESC	cis	rs9300255	0.602	rs2851450	chr12:123703501	C/T	cg00376283	chr12:123451042	ABCB9	0.7	8.89	0.48	9.66e-17	Neutrophil percentage of white cells;
CESC	cis	rs9929218	0.861	rs4783667	chr16:68752878	C/A	cg02972257	chr16:68554789	NA	0.57	6.54	0.37	3.14e-10	Colorectal cancer;
CESC	cis	rs9486715	0.790	rs2971602	chr6:97022468	C/T	cg06623918	chr6:96969491	KIAA0776	-0.95	-15.09	-0.68	1.48e-37	Headache;
CESC	cis	rs9325144	0.560	rs2387923	chr12:38662677	G/A	cg13010199	chr12:38710504	ALG10B	-0.45	-6.1	-0.35	3.79e-9	Morning vs. evening chronotype;
CESC	cis	rs10751667	0.621	rs7394862	chr11:927500	T/C	cg06064525	chr11:970664	AP2A2	-0.52	-10.25	-0.53	5.74e-21	Alzheimer's disease (late onset);
CESC	cis	rs8072100	0.871	rs7206971	chr17:45425115	A/G	cg08085267	chr17:45401833	C17orf57	0.57	7.79	0.43	1.54e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	trans	rs1814175	0.607	rs11493324	chr11:50011304	T/C	cg15704280	chr7:45808275	SEPT13	-0.83	-11.4	-0.57	8.98e-25	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11695030	chr19:34919128	UBA2	-0.62	-7.3	-0.41	3.28e-12	Gut microbiome composition (summer);
CESC	cis	rs2404602	0.669	rs12916324	chr15:77179603	G/A	cg26408565	chr15:76604113	ETFA	-0.39	-5.72	-0.33	2.92e-8	Blood metabolite levels;
CESC	cis	rs929354	0.772	rs1182360	chr7:157020550	C/G	cg05182265	chr7:156933206	UBE3C	-0.5	-7.35	-0.41	2.4e-12	Body mass index;
CESC	cis	rs6460942	0.841	rs6968277	chr7:12443795	C/A	cg02935154	chr7:12443704	VWDE	-0.59	-7.88	-0.44	8.25e-14	Coronary artery disease;
CESC	cis	rs3815700	1.000	rs7247420	chr19:33096786	G/A	cg02997394	chr19:33096574	ANKRD27	0.7	7.06	0.4	1.5e-11	Eosinophilic esophagitis;
CESC	cis	rs9611565	0.765	rs132920	chr22:41810170	T/C	cg03806693	chr22:41940476	POLR3H	1.04	12.37	0.61	4.76e-28	Vitiligo;
CESC	cis	rs425277	1.000	rs262670	chr1:2082458	C/T	cg16545954	chr1:2118288	C1orf86	0.33	5.6	0.33	5.35e-8	Height;
CESC	cis	rs10911232	0.507	rs10797814	chr1:182990929	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.84	13.31	0.63	2.66e-31	Hypertriglyceridemia;
CESC	cis	rs2204008	0.869	rs34438288	chr12:38211582	G/T	cg26384229	chr12:38710491	ALG10B	0.74	10.7	0.55	1.96e-22	Bladder cancer;
CESC	cis	rs7223966	1.000	rs8081541	chr17:61812483	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.59	0.38	2.33e-10	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs11190604	1.000	rs11190597	chr10:102293676	A/T	cg07080220	chr10:102295463	HIF1AN	0.7	6.48	0.37	4.34e-10	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs7914558	0.933	rs10883814	chr10:104737404	T/C	cg15744005	chr10:104629667	AS3MT	-0.33	-5.2	-0.3	4.01e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs6866344	0.570	rs1079487	chr5:178136005	G/A	cg10224037	chr5:178157518	ZNF354A	0.71	8.36	0.46	3.52e-15	Neutrophil percentage of white cells;
CESC	cis	rs9457247	1.000	rs2149091	chr6:167372786	C/T	cg23791538	chr6:167370224	RNASET2	0.6	8.49	0.46	1.53e-15	Crohn's disease;
CESC	cis	rs875971	0.862	rs12698526	chr7:65969105	T/C	cg12463550	chr7:65579703	CRCP	0.5	6.3	0.36	1.21e-9	Aortic root size;
CESC	trans	rs2109514	0.505	rs1633714	chr7:116022538	C/T	cg01300887	chr4:99477634	TSPAN5	0.4	6.02	0.35	5.9e-9	Prevalent atrial fibrillation;
CESC	cis	rs1552244	0.882	rs9312044	chr3:10037481	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	10.94	0.56	3.23e-23	Alzheimer's disease;
CESC	cis	rs4450798	0.649	rs9861903	chr3:13786821	G/T	cg23332027	chr3:13681764	NA	0.38	5.19	0.3	4.22e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs7178909	0.902	rs10459674	chr15:90438295	G/C	cg19708238	chr15:90437601	AP3S2	0.43	6.19	0.36	2.25e-9	Common traits (Other);
CESC	cis	rs9649213	0.537	rs6465663	chr7:97918883	C/G	cg24562669	chr7:97807699	LMTK2	0.52	7.42	0.41	1.59e-12	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs13191362	0.872	rs73017702	chr6:163257695	C/A	cg14584255	chr6:163149320	PACRG;PARK2	0.5	5.21	0.3	3.83e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs736408	0.924	rs2535629	chr3:52833219	C/T	cg18404041	chr3:52824283	ITIH1	-0.43	-7.15	-0.4	8.53e-12	Bipolar disorder;
CESC	cis	rs898097	0.801	rs68141193	chr17:80878816	C/T	cg19046167	chr17:80928561	B3GNTL1	-0.42	-5.25	-0.31	3.06e-7	Breast cancer;
CESC	cis	rs694739	0.726	rs516124	chr11:64128423	G/T	cg23796481	chr11:64053134	BAD;GPR137	0.58	7.16	0.4	7.76e-12	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CESC	cis	rs2760061	0.599	rs644794	chr1:228148670	T/C	cg02753203	chr1:228287806	NA	-0.5	-7.16	-0.4	8.16e-12	Diastolic blood pressure;
CESC	cis	rs2404602	0.716	rs4886817	chr15:76877702	C/T	cg22467129	chr15:76604101	ETFA	-0.35	-5.19	-0.3	4.11e-7	Blood metabolite levels;
CESC	cis	rs1808579	0.935	rs2510344	chr18:21113285	C/T	cg14672496	chr18:21087552	C18orf8	-0.42	-6.29	-0.36	1.28e-9	Hip circumference;Body mass index;BMI (adjusted for smoking behaviour);
CESC	cis	rs9457247	1.000	rs436707	chr6:167388843	T/C	cg23791538	chr6:167370224	RNASET2	-0.6	-8.65	-0.47	4.96e-16	Crohn's disease;
CESC	cis	rs6570726	0.791	rs6918814	chr6:145906028	G/A	cg23711669	chr6:146136114	FBXO30	0.85	12.51	0.61	1.56e-28	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7811142	1.000	rs4472444	chr7:100070758	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.03	11.82	0.59	3.55e-26	Platelet count;
CESC	cis	rs10504229	0.817	rs35207430	chr8:58167614	G/A	cg05313129	chr8:58192883	C8orf71	-0.48	-5.62	-0.33	4.88e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs2180341	0.576	rs2057224	chr6:127624414	C/G	cg27446573	chr6:127587934	RNF146	0.62	8.53	0.46	1.1e-15	Breast cancer;
CESC	cis	rs6500395	1.000	rs4785247	chr16:48687732	A/C	cg04672837	chr16:48644449	N4BP1	-0.51	-6.36	-0.36	8.64e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs1008375	1.000	rs6449319	chr4:17640283	T/A	cg04450456	chr4:17643702	FAM184B	0.37	5.18	0.3	4.48e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs854765	0.929	rs854766	chr17:18012775	A/G	cg04398451	chr17:18023971	MYO15A	-0.68	-9.32	-0.5	4.89e-18	Total body bone mineral density;
CESC	cis	rs765787	0.530	rs11854690	chr15:45516016	C/T	cg24006582	chr15:45444508	DUOX1	-0.58	-7.12	-0.4	1.04e-11	Uric acid levels;
CESC	cis	rs735396	1.000	rs1169310	chr12:121439433	G/A	cg02403541	chr12:121454288	C12orf43	0.64	9.22	0.49	9.65e-18	N-glycan levels;
CESC	cis	rs10751667	0.666	rs10902242	chr11:949700	G/A	cg20946044	chr11:1010712	AP2A2	-0.38	-5.24	-0.31	3.23e-7	Alzheimer's disease (late onset);
CESC	cis	rs9399135	0.967	rs9373122	chr6:135373534	G/A	cg24558204	chr6:135376177	HBS1L	0.5	6.8	0.39	6.92e-11	Red blood cell count;
CESC	cis	rs6500395	0.832	rs8052733	chr16:48691978	C/T	cg04672837	chr16:48644449	N4BP1	-0.51	-6.36	-0.36	8.64e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs11122272	0.735	rs2808600	chr1:231534723	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.56	-7.66	-0.43	3.45e-13	Hemoglobin concentration;
CESC	cis	rs35146811	0.771	rs6465762	chr7:99620554	G/A	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.49	6.06	0.35	4.59e-9	Coronary artery disease;
CESC	cis	rs7811142	0.779	rs28680963	chr7:99905475	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.89	8.02	0.44	3.31e-14	Platelet count;
CESC	cis	rs9457247	0.663	rs9457258	chr6:167444254	T/C	cg07741184	chr6:167504864	NA	0.34	6.09	0.35	3.9e-9	Crohn's disease;
CESC	cis	rs1797885	0.564	rs2454435	chr3:12586240	T/C	cg26432171	chr3:12704882	RAF1	-0.52	-6.88	-0.39	4.38e-11	Immature fraction of reticulocytes;
CESC	cis	rs514406	0.708	rs546334	chr1:53326210	T/C	cg16325326	chr1:53192061	ZYG11B	0.61	9.25	0.49	7.64e-18	Monocyte count;
CESC	cis	rs10504229	1.000	rs60651159	chr8:58174074	T/C	cg24829409	chr8:58192753	C8orf71	-0.76	-10.0	-0.52	3.53e-20	Developmental language disorder (linguistic errors);
CESC	trans	rs10489896	0.588	rs10159244	chr1:234588171	C/T	cg10395685	chr11:86085715	CCDC81	-0.43	-6.15	-0.35	2.9e-9	Cognitive test performance;
CESC	cis	rs9488822	0.676	rs3798227	chr6:116324898	A/G	cg18764771	chr6:116381957	FRK	0.22	5.44	0.32	1.21e-7	Cholesterol, total;LDL cholesterol;
CESC	trans	rs877282	0.853	rs11593836	chr10:756715	G/A	cg22713356	chr15:30763199	NA	0.93	8.39	0.46	3e-15	Uric acid levels;
CESC	cis	rs2197308	0.740	rs1842595	chr12:37906223	G/A	cg26384229	chr12:38710491	ALG10B	-0.55	-7.84	-0.43	1.13e-13	Morning vs. evening chronotype;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16481032	chr6:26056674	HIST1H1C	0.57	6.52	0.37	3.57e-10	Gut microbiome composition (summer);
CESC	cis	rs1865760	0.613	rs9379801	chr6:25901711	T/C	cg16482183	chr6:26056742	HIST1H1C	0.38	5.36	0.31	1.84e-7	Height;
CESC	cis	rs8067354	0.645	rs2173120	chr17:57892640	A/T	cg02344993	chr17:57696989	CLTC	0.56	6.04	0.35	5.31e-9	Hemoglobin concentration;
CESC	cis	rs9876781	0.559	rs7630053	chr3:48398586	G/A	cg11946769	chr3:48343235	NME6	0.4	5.03	0.3	8.94e-7	Longevity;
CESC	trans	rs7618501	0.735	rs9876508	chr3:49780844	G/A	cg21659725	chr3:3221576	CRBN	-0.83	-13.55	-0.64	3.87e-32	Intelligence (multi-trait analysis);
CESC	cis	rs3733585	0.699	rs2018643	chr4:9947121	C/T	cg11266682	chr4:10021025	SLC2A9	0.57	10.66	0.55	2.67e-22	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs274567	0.501	rs581968	chr5:131710202	G/A	cg07395648	chr5:131743802	NA	0.41	5.35	0.31	1.86e-7	Blood metabolite levels;
CESC	cis	rs1568889	1.000	rs33937991	chr11:28045260	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.79	10.99	0.56	2.12e-23	Bipolar disorder;
CESC	cis	rs1707322	1.000	rs4489497	chr1:46438698	C/T	cg03146154	chr1:46216737	IPP	0.72	9.82	0.52	1.31e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs5758265	1	rs5758265	chr22:41617897	G/A	cg03806693	chr22:41940476	POLR3H	-0.49	-5.44	-0.32	1.19e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs6580649	0.943	rs1859444	chr12:48399403	T/C	cg05342945	chr12:48394962	COL2A1	-0.55	-6.71	-0.38	1.15e-10	Lung cancer;
CESC	cis	rs4948102	0.599	rs2230197	chr7:56126360	T/C	cg09872392	chr7:56161020	PHKG1	-0.45	-7.31	-0.41	3.22e-12	Plasma homocysteine levels (post-methionine load test);
CESC	cis	rs2880765	0.566	rs17553249	chr15:86006694	A/G	cg19183879	chr15:85880815	NA	-0.31	-5.94	-0.34	8.97e-9	Coronary artery disease;
CESC	cis	rs12477438	0.871	rs13396584	chr2:99611768	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.62	7.83	0.43	1.21e-13	Chronic sinus infection;
CESC	trans	rs7089973	0.523	rs34170154	chr10:116740959	C/T	cg17463145	chr7:79084011	MAGI2	0.32	6.36	0.36	8.92e-10	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg22535103	chr8:58192502	C8orf71	-0.92	-10.19	-0.53	8.81e-21	Developmental language disorder (linguistic errors);
CESC	cis	rs7666738	0.830	rs969048	chr4:98988921	T/C	cg17366294	chr4:99064904	C4orf37	0.6	8.59	0.47	7.62e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1669338	0.507	rs4685607	chr3:3179400	C/T	cg16797762	chr3:3221439	CRBN	0.58	6.33	0.36	1.06e-9	White matter integrity;
CESC	cis	rs12545109	0.842	rs2609975	chr8:57401667	T/C	cg09654669	chr8:57350985	NA	-0.57	-7.11	-0.4	1.1e-11	Obesity-related traits;
CESC	cis	rs1559088	0.847	rs8100392	chr19:33605933	T/C	cg17764715	chr19:33622953	WDR88	0.46	5.94	0.34	8.75e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg03188948	chr7:1209495	NA	0.72	6.93	0.39	3.15e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7618915	0.571	rs2289249	chr3:52597664	G/A	cg18099408	chr3:52552593	STAB1	-0.33	-5.44	-0.32	1.21e-7	Bipolar disorder;
CESC	cis	rs9300255	0.739	rs4759415	chr12:123743674	C/T	cg00376283	chr12:123451042	ABCB9	-0.71	-8.94	-0.48	7.04e-17	Neutrophil percentage of white cells;
CESC	cis	rs8005677	1.000	rs4982709	chr14:23394699	C/T	cg01529538	chr14:23388837	RBM23	0.5	6.77	0.38	8.22e-11	Cognitive ability (multi-trait analysis);
CESC	cis	rs736408	0.609	rs1029871	chr3:52797634	G/C	cg05564831	chr3:52568323	NT5DC2	0.43	6.25	0.36	1.67e-9	Bipolar disorder;
CESC	cis	rs7666738	0.753	rs13120995	chr4:98972762	A/G	cg17366294	chr4:99064904	C4orf37	0.59	8.43	0.46	2.31e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs921968	0.565	rs6436083	chr2:219639719	C/T	cg02176678	chr2:219576539	TTLL4	-0.44	-7.74	-0.43	2.15e-13	Mean corpuscular hemoglobin concentration;
CESC	cis	rs3820068	0.603	rs927207	chr1:15990552	A/G	cg17385448	chr1:15911702	AGMAT	0.43	7.11	0.4	1.09e-11	Systolic blood pressure;
CESC	cis	rs8077889	0.672	rs1230400	chr17:41845451	G/A	cg26893861	chr17:41843967	DUSP3	-1.02	-19.07	-0.76	1.3e-51	Triglycerides;
CESC	cis	rs11677416	0.813	rs4848299	chr2:113523454	C/A	cg27083787	chr2:113543245	IL1A	0.41	5.23	0.31	3.45e-7	Response to antipsychotic treatment in schizophrenia (working memory);
CESC	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg24829409	chr8:58192753	C8orf71	-0.67	-8.18	-0.45	1.19e-14	Developmental language disorder (linguistic errors);
CESC	cis	rs7618915	0.571	rs2289249	chr3:52597664	G/A	cg18337363	chr3:52569053	NT5DC2	0.29	5.08	0.3	7.29e-7	Bipolar disorder;
CESC	cis	rs7666738	0.830	rs4699591	chr4:98974171	A/G	cg03467027	chr4:99064603	C4orf37	0.43	5.4	0.31	1.49e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs13088281	1.000	rs13088281	chr3:53147576	A/C	cg15956490	chr3:53032818	SFMBT1	-0.59	-5.05	-0.3	8.23e-7	Immune reponse to smallpox (secreted IL-2);
CESC	trans	rs6700559	0.810	rs2808248	chr1:200592275	T/C	cg13401811	chr12:52345646	ACVR1B	-0.48	-6.12	-0.35	3.36e-9	Coronary artery disease;
CESC	cis	rs36051895	0.632	rs11791281	chr9:5172540	G/A	cg02405213	chr9:5042618	JAK2	-0.52	-6.5	-0.37	3.95e-10	Pediatric autoimmune diseases;
CESC	cis	rs6032067	0.929	rs34412950	chr20:43805132	C/A	cg10761708	chr20:43804764	PI3	0.53	6.37	0.36	8.25e-10	Blood protein levels;
CESC	cis	rs7666738	0.830	rs28465658	chr4:99035866	T/C	cg17366294	chr4:99064904	C4orf37	0.61	8.77	0.47	2.27e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9457247	1.000	rs10946198	chr6:167404432	C/T	cg25258033	chr6:167368657	RNASET2	0.39	5.88	0.34	1.26e-8	Crohn's disease;
CESC	cis	rs17376456	0.825	rs34967135	chr5:93221785	G/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.62	5.38	0.31	1.63e-7	Diabetic retinopathy;
CESC	cis	rs875971	0.964	rs778708	chr7:65856319	T/C	cg11764359	chr7:65958608	NA	0.96	15.23	0.68	4.78e-38	Aortic root size;
CESC	cis	rs2280018	0.581	rs7404524	chr16:15129158	A/G	cg07549590	chr16:15018862	NA	-0.54	-8.65	-0.47	4.92e-16	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	trans	rs11098499	0.691	rs17009144	chr4:120270795	C/T	cg25214090	chr10:38739885	LOC399744	-0.57	-7.96	-0.44	5.12e-14	Corneal astigmatism;
CESC	cis	rs6546537	0.911	rs62133968	chr2:69891910	C/T	cg10773587	chr2:69614142	GFPT1	-0.59	-6.87	-0.39	4.49e-11	Serum thyroid-stimulating hormone levels;
CESC	cis	rs854765	0.583	rs62064156	chr17:17822480	C/T	cg04398451	chr17:18023971	MYO15A	-0.65	-9.11	-0.49	2.08e-17	Total body bone mineral density;
CESC	cis	rs889398	0.677	rs68161338	chr16:69823778	T/G	cg09409435	chr16:70099608	PDXDC2	-0.41	-5.16	-0.3	4.92e-7	Body mass index;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00034416	chr1:155278724	FDPS	0.59	6.21	0.36	2.04e-9	Gut microbiome composition (summer);
CESC	cis	rs7179456	0.593	rs514049	chr15:59042363	A/C	cg05156742	chr15:59063176	FAM63B	-0.74	-10.88	-0.56	4.8e-23	Asperger disorder;
CESC	cis	rs17253792	0.731	rs74823888	chr14:56049800	T/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.85	5.74	0.33	2.53e-8	Putamen volume;
CESC	cis	rs4566357	0.615	rs1800517	chr2:227915832	G/A	cg11843606	chr2:227700838	RHBDD1	-0.51	-6.99	-0.39	2.29e-11	Coronary artery disease;
CESC	cis	rs10463316	0.855	rs13359064	chr5:150765575	G/A	cg03212797	chr5:150827313	SLC36A1	-0.46	-5.96	-0.34	8.11e-9	Metabolite levels (Pyroglutamine);
CESC	trans	rs916888	0.610	rs199530	chr17:44836653	C/T	cg07870213	chr5:140052090	DND1	-0.45	-6.02	-0.35	5.94e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs1448094	0.617	rs7297449	chr12:86468442	A/C	cg02569458	chr12:86230093	RASSF9	-0.35	-5.11	-0.3	6.25e-7	Major depressive disorder;
CESC	cis	rs514406	0.825	rs1242328	chr1:53396869	A/G	cg06600287	chr1:53387719	ECHDC2	-0.29	-5.08	-0.3	7e-7	Monocyte count;
CESC	cis	rs7100689	0.577	rs10749560	chr10:82092801	G/T	cg00277334	chr10:82204260	NA	-0.6	-7.96	-0.44	4.91e-14	Post bronchodilator FEV1;
CESC	cis	rs1552244	1.000	rs7622966	chr3:10139833	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.88	12.14	0.6	2.94e-27	Alzheimer's disease;
CESC	cis	rs2439831	0.850	rs28718261	chr15:44043793	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.7	6.6	0.38	2.25e-10	Lung cancer in ever smokers;
CESC	cis	rs11155671	0.530	rs9383912	chr6:150206615	T/C	cg09699651	chr6:150184138	LRP11	0.56	7.84	0.43	1.08e-13	Testicular germ cell tumor;
CESC	cis	rs17711722	0.585	rs6942660	chr7:65302406	C/T	cg11764359	chr7:65958608	NA	0.66	8.54	0.46	1.06e-15	Calcium levels;
CESC	cis	rs2832191	0.671	rs73346699	chr21:30515529	C/T	cg08807101	chr21:30365312	RNF160	-0.56	-6.46	-0.37	5.04e-10	Dental caries;
CESC	cis	rs77216612	0.835	rs10845621	chr12:12887977	C/T	cg24098013	chr12:12878779	APOLD1	0.58	7.11	0.4	1.06e-11	Lymphocyte counts;
CESC	cis	rs2832191	0.716	rs1888440	chr21:30454484	C/T	cg24692254	chr21:30365293	RNF160	0.99	17.57	0.73	2.33e-46	Dental caries;
CESC	cis	rs7084402	0.967	rs1649058	chr10:60317087	G/A	cg07615347	chr10:60278583	BICC1	0.61	9.59	0.51	7.04e-19	Refractive error;
CESC	cis	rs10504229	0.683	rs16921817	chr8:58107563	A/T	cg21724239	chr8:58056113	NA	0.57	5.9	0.34	1.08e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs735860	0.712	rs3736732	chr6:53160383	G/T	cg10236188	chr6:53219634	NA	-0.35	-5.11	-0.3	6.07e-7	Glaucoma;
CESC	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg22907277	chr7:1156413	C7orf50	0.44	6.43	0.37	5.86e-10	Longevity;Endometriosis;
CESC	cis	rs4713118	0.516	rs7739216	chr6:28079946	G/T	cg08968635	chr6:28129556	ZNF389	0.4	5.36	0.31	1.84e-7	Parkinson's disease;
CESC	cis	rs11723261	0.509	rs61792240	chr4:128619	A/G	cg12746427	chr4:53362	ZNF718;ZNF595	0.44	5.24	0.31	3.25e-7	Immune response to smallpox vaccine (IL-6);
CESC	cis	rs10504229	0.683	rs67048677	chr8:58140023	C/G	cg21724239	chr8:58056113	NA	0.58	5.95	0.34	8.37e-9	Developmental language disorder (linguistic errors);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07272690	chr6:42751244	NA	0.57	6.24	0.36	1.71e-9	Gut microbiome composition (summer);
CESC	cis	rs854765	0.551	rs12600546	chr17:17867614	A/G	cg04398451	chr17:18023971	MYO15A	-0.7	-9.85	-0.52	1.04e-19	Total body bone mineral density;
CESC	trans	rs5758511	0.773	rs1894714	chr22:42349134	T/G	cg15080870	chr19:47770746	CCDC9	-0.5	-6.2	-0.36	2.15e-9	Birth weight;
CESC	trans	rs1908814	0.516	rs13279577	chr8:11793096	C/G	cg15556689	chr8:8085844	FLJ10661	0.54	6.58	0.37	2.47e-10	Neuroticism;
CESC	cis	rs1023500	0.573	rs1807494	chr22:42474138	C/G	cg04733989	chr22:42467013	NAGA	-0.79	-12.05	-0.59	5.98e-27	Schizophrenia;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg16071359	chr2:169312933	LASS6	0.49	6.29	0.36	1.31e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs7605827	0.930	rs13007310	chr2:15710058	A/G	cg19274914	chr2:15703543	NA	-0.36	-6.54	-0.37	3.13e-10	Educational attainment (years of education);
CESC	cis	rs763014	0.898	rs62030902	chr16:638264	C/G	cg00802000	chr16:706648	WDR90	-0.37	-5.33	-0.31	2.07e-7	Height;
CESC	cis	rs853679	0.882	rs4713139	chr6:28092685	C/T	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.77	7.12	0.4	9.97e-12	Depression;
CESC	cis	rs4665809	0.590	rs1056389	chr2:26502875	T/C	cg08470875	chr2:26401718	FAM59B	0.71	7.06	0.4	1.43e-11	Gut microbiome composition (summer);
CESC	cis	rs10504229	0.679	rs11783965	chr8:58130510	T/G	cg24829409	chr8:58192753	C8orf71	-0.58	-7.2	-0.4	6.31e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs13256369	1.000	rs13271966	chr8:8575472	T/C	cg18904891	chr8:8559673	CLDN23	0.69	8.12	0.45	1.82e-14	Obesity-related traits;
CESC	cis	rs36051895	0.632	rs10974993	chr9:5182159	C/T	cg02405213	chr9:5042618	JAK2	-0.5	-6.47	-0.37	4.73e-10	Pediatric autoimmune diseases;
CESC	cis	rs1218582	0.772	rs1109815	chr1:154909268	A/G	cg24250549	chr1:154909240	PMVK	0.73	10.67	0.55	2.38e-22	Prostate cancer;
CESC	cis	rs4713118	0.512	rs2622319	chr6:28120401	G/C	cg22143856	chr6:28129313	ZNF389	0.38	5.33	0.31	2.14e-7	Parkinson's disease;
CESC	cis	rs1538970	0.924	rs4660855	chr1:45899795	A/G	cg05343316	chr1:45956843	TESK2	0.89	12.41	0.61	3.59e-28	Platelet count;
CESC	cis	rs7818345	0.935	rs7016592	chr8:19277735	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.32	5.84	0.34	1.56e-8	Language performance in older adults (adjusted for episodic memory);
CESC	cis	rs8103278	1.000	rs9676288	chr19:46292060	G/T	cg12641515	chr19:46296257	DMWD	-0.51	-5.72	-0.33	2.89e-8	Coronary artery disease;
CESC	cis	rs116988415	0.539	rs17180350	chr14:65249066	C/T	cg25083366	chr14:65239357	SPTB	0.66	5.14	0.3	5.23e-7	Daytime sleep phenotypes;
CESC	cis	rs5769765	0.955	rs1321	chr22:50297435	A/G	cg02269571	chr22:50332266	NA	-0.47	-6.37	-0.36	8.55e-10	Schizophrenia;
CESC	cis	rs2841277	0.708	rs10083496	chr14:105402786	G/A	cg15352829	chr14:105391018	PLD4	-0.6	-10.68	-0.55	2.23e-22	Rheumatoid arthritis;
CESC	cis	rs9649213	0.574	rs9648908	chr7:97945236	C/T	cg08684580	chr7:98029266	BAIAP2L1	-0.36	-5.82	-0.34	1.69e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs1153858	0.945	rs2467854	chr15:45701597	A/G	cg10760299	chr15:45669010	GATM	0.37	5.14	0.3	5.43e-7	Homoarginine levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23165545	chr3:49449548	TCTA;RHOA	-0.54	-6.09	-0.35	3.88e-9	Gut microbiome composition (summer);
CESC	cis	rs6540559	0.673	rs6540560	chr1:209982073	A/G	cg22029157	chr1:209979665	IRF6	-0.71	-8.69	-0.47	3.94e-16	Cleft lip with or without cleft palate;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10700570	chr7:2281743	NUDT1;FTSJ2	0.54	6.65	0.38	1.63e-10	Gut microbiome composition (summer);
CESC	cis	rs2479106	0.963	rs10818864	chr9:126502619	G/T	cg16191174	chr9:126692580	DENND1A	-0.48	-6.61	-0.38	2.05e-10	Polycystic ovary syndrome;
CESC	cis	rs11122272	0.735	rs2486740	chr1:231517552	T/C	cg06096015	chr1:231504339	EGLN1	0.43	6.18	0.35	2.46e-9	Hemoglobin concentration;
CESC	trans	rs2207136	0.869	rs11964803	chr6:50836774	G/A	cg06522515	chr3:184090630	THPO	-0.38	-6.58	-0.37	2.55e-10	Myopia;
CESC	cis	rs4595586	0.545	rs4623945	chr12:39364572	A/T	cg26384229	chr12:38710491	ALG10B	0.54	7.54	0.42	7.28e-13	Morning vs. evening chronotype;
CESC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg16275883	chr3:69129409	UBA3	0.45	6.04	0.35	5.2e-9	Intelligence (multi-trait analysis);
CESC	cis	rs3733585	0.806	rs11723382	chr4:9954660	T/C	cg00071950	chr4:10020882	SLC2A9	-0.78	-14.51	-0.67	1.66e-35	Cleft plate (environmental tobacco smoke interaction);
CESC	trans	rs7618501	0.966	rs2246832	chr3:49881134	A/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.59	8.43	0.46	2.26e-15	Intelligence (multi-trait analysis);
CESC	cis	rs4604732	0.527	rs77361748	chr1:247626475	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.57	7.17	0.4	7.39e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs9815354	0.812	rs7639859	chr3:42001987	C/T	cg03022575	chr3:42003672	ULK4	0.64	5.83	0.34	1.62e-8	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs6598955	0.694	rs4659416	chr1:26580937	T/G	cg00852783	chr1:26633632	UBXN11	0.42	6.15	0.35	2.8e-9	Obesity-related traits;
CESC	cis	rs2637266	1.000	rs2894337	chr10:78344871	C/T	cg18941641	chr10:78392320	NA	0.42	7.79	0.43	1.54e-13	Pulmonary function;
CESC	cis	rs1784581	0.588	rs7752870	chr6:162422510	T/C	cg17173639	chr6:162384350	PARK2	0.56	8.63	0.47	5.61e-16	Itch intensity from mosquito bite;
CESC	cis	rs7429990	0.965	rs11130154	chr3:48069242	C/T	cg11946769	chr3:48343235	NME6	-0.44	-5.37	-0.31	1.69e-7	Educational attainment (years of education);
CESC	cis	rs9894429	1.000	rs12948099	chr17:79600799	C/G	cg13777783	chr17:79615861	NA	-0.35	-5.65	-0.33	4.2e-8	Eye color traits;
CESC	cis	rs6500395	0.775	rs11640119	chr16:48662840	C/T	cg04672837	chr16:48644449	N4BP1	0.49	6.25	0.36	1.63e-9	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs9487051	0.714	rs6930733	chr6:109631587	T/C	cg21918786	chr6:109611834	NA	-0.39	-5.71	-0.33	3.06e-8	Reticulocyte fraction of red cells;
CESC	cis	rs8180040	0.966	rs7628631	chr3:47560863	C/T	cg27129171	chr3:47204927	SETD2	-0.54	-6.96	-0.39	2.72e-11	Colorectal cancer;
CESC	cis	rs990171	0.506	rs6543107	chr2:102750730	A/T	cg22835712	chr2:102737379	NA	0.43	6.06	0.35	4.63e-9	Lymphocyte counts;
CESC	cis	rs11098499	0.908	rs28499576	chr4:120386677	G/A	cg09307838	chr4:120376055	NA	0.96	14.11	0.65	4.38e-34	Corneal astigmatism;
CESC	cis	rs7481584	0.624	rs80871	chr11:3049843	A/C	cg08508325	chr11:3079039	CARS	0.29	5.17	0.3	4.6e-7	Calcium levels;
CESC	cis	rs2243480	1.000	rs35396113	chr7:65495461	C/T	cg18252515	chr7:66147081	NA	-1.21	-11.82	-0.59	3.44e-26	Diabetic kidney disease;
CESC	cis	rs2370759	0.945	rs74625866	chr10:32597618	A/T	cg18270830	chr10:32634957	EPC1	0.73	7.28	0.41	3.82e-12	Sexual dysfunction (female);
CESC	cis	rs7208859	0.573	rs73267829	chr17:29003939	G/A	cg13385521	chr17:29058706	SUZ12P	0.72	5.63	0.33	4.55e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs875971	0.619	rs12533585	chr7:65984605	G/C	cg18876405	chr7:65276391	NA	0.58	7.87	0.44	9.3e-14	Aortic root size;
CESC	cis	rs10851478	0.872	rs11854568	chr15:49843747	T/C	cg08060515	chr15:49448048	GALK2;COPS2	0.42	5.19	0.3	4.12e-7	Oral cavity cancer;
CESC	cis	rs8060686	0.545	rs76836953	chr16:68061763	G/C	cg26727032	chr16:67993705	SLC12A4	-0.54	-6.16	-0.35	2.74e-9	HDL cholesterol;Metabolic syndrome;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01366467	chr20:3185206	DDRGK1	0.56	6.07	0.35	4.41e-9	Gut microbiome composition (summer);
CESC	cis	rs514406	0.929	rs557847	chr1:53333116	A/G	cg24675658	chr1:53192096	ZYG11B	-0.6	-7.61	-0.42	4.79e-13	Monocyte count;
CESC	cis	rs12765878	0.967	rs11598018	chr10:105661315	C/A	cg24587175	chr10:105670608	OBFC1	0.33	5.5	0.32	8.89e-8	Coronary artery disease;
CESC	cis	rs6974235	0.777	rs42070	chr7:95715768	A/T	cg21022364	chr7:95948586	SLC25A13	0.39	5.59	0.32	5.58e-8	Total body bone mineral density;
CESC	cis	rs17345786	0.906	rs59359251	chr3:101146362	A/C	cg12386194	chr3:101231763	SENP7	0.61	6.61	0.38	2.08e-10	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2952156	0.652	rs11869286	chr17:37813856	C/G	cg07936489	chr17:37558343	FBXL20	-0.61	-8.23	-0.45	8.72e-15	Asthma;
CESC	cis	rs11148252	0.553	rs2147692	chr13:53287023	C/G	cg00495681	chr13:53174319	NA	0.63	8.65	0.47	5.19e-16	Lewy body disease;
CESC	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.52	6.38	0.37	7.72e-10	Prudent dietary pattern;
CESC	cis	rs3733585	0.604	rs73215003	chr4:10126317	C/G	cg11266682	chr4:10021025	SLC2A9	-0.57	-10.49	-0.54	9.26e-22	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs6461049	0.734	rs1558465	chr7:2151398	G/C	cg05863683	chr7:1912471	MAD1L1	0.38	5.46	0.32	1.1e-7	Schizophrenia;
CESC	cis	rs6570726	0.791	rs9376945	chr6:145828080	T/A	cg23711669	chr6:146136114	FBXO30	1.02	15.96	0.7	1.2e-40	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-1.12	-22.22	-0.81	1.76e-62	Prudent dietary pattern;
CESC	cis	rs9311474	0.607	rs4475032	chr3:52560021	C/T	cg18099408	chr3:52552593	STAB1	-0.38	-6.47	-0.37	4.69e-10	Electroencephalogram traits;
CESC	cis	rs7666738	0.678	rs7670805	chr4:99008763	A/G	cg05340658	chr4:99064831	C4orf37	0.8	12.44	0.61	2.83e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1707322	0.721	rs10157795	chr1:46228192	G/A	cg05343316	chr1:45956843	TESK2	0.47	6.02	0.35	5.8e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7223966	1.000	rs16947005	chr17:61702989	C/T	cg11494091	chr17:61959527	GH2	-0.38	-5.05	-0.3	8.2e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs478304	0.580	rs11606947	chr11:65508237	A/C	cg27068330	chr11:65405492	SIPA1	-0.45	-5.46	-0.32	1.08e-7	Acne (severe);
CESC	cis	rs116095464	0.558	rs59113266	chr5:279965	T/C	cg12570787	chr5:219185	SDHA;CCDC127	0.52	5.41	0.32	1.38e-7	Breast cancer;
CESC	cis	rs6951245	0.882	rs11764817	chr7:1064610	T/C	cg24642844	chr7:1081250	C7orf50	-0.63	-8.09	-0.45	2.11e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs8072100	0.817	rs9905581	chr17:45547185	C/T	cg08085267	chr17:45401833	C17orf57	-0.58	-7.68	-0.43	3.1400000000000003e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs898097	0.625	rs7406464	chr17:80891460	A/G	cg19046167	chr17:80928561	B3GNTL1	-0.38	-5.2	-0.3	3.92e-7	Breast cancer;
CESC	trans	rs17685	0.712	rs11764119	chr7:75812358	T/G	cg19862616	chr7:65841803	NCRNA00174	0.82	11.62	0.58	1.71e-25	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs9926296	0.632	rs4785716	chr16:89801127	T/C	cg04287289	chr16:89883240	FANCA	0.66	8.97	0.48	5.71e-17	Vitiligo;
CESC	cis	rs11166629	1.000	rs6981735	chr8:135635730	T/C	cg21672855	chr8:135614777	ZFAT	0.4	5.03	0.3	9.02e-7	Smoking quantity;
CESC	cis	rs2806561	0.765	rs1738468	chr1:23510850	T/G	cg12483005	chr1:23474871	LUZP1	0.38	6.01	0.35	6.26e-9	Height;
CESC	cis	rs6502050	0.835	rs8080625	chr17:80115447	G/A	cg11859384	chr17:80120422	CCDC57	-0.38	-5.18	-0.3	4.47e-7	Life satisfaction;
CESC	cis	rs11626933	1.000	rs2236402	chr14:90734378	C/G	cg14092571	chr14:90743983	NA	-0.94	-14.47	-0.66	2.19e-35	Gut microbiota (bacterial taxa);
CESC	cis	rs4566357	0.557	rs2272201	chr2:227912551	T/A	cg05526886	chr2:227700861	RHBDD1	-0.47	-6.28	-0.36	1.35e-9	Coronary artery disease;
CESC	cis	rs72781680	0.898	rs111460347	chr2:24018833	G/A	cg08917208	chr2:24149416	ATAD2B	0.95	8.71	0.47	3.45e-16	Lymphocyte counts;
CESC	cis	rs9322193	0.962	rs11155685	chr6:150102785	A/C	cg04369109	chr6:150039330	LATS1	-0.39	-5.35	-0.31	1.93e-7	Lung cancer;
CESC	cis	rs7264396	0.690	rs2425172	chr20:34443893	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.6	6.93	0.39	3.25e-11	Total cholesterol levels;
CESC	cis	rs1552244	1.000	rs35220123	chr3:10083169	C/T	cg00149659	chr3:10157352	C3orf10	0.77	9.67	0.51	3.91e-19	Alzheimer's disease;
CESC	cis	rs853679	0.517	rs7755442	chr6:28039015	T/C	cg19592336	chr6:28129416	ZNF389	0.6	7.97	0.44	4.69e-14	Depression;
CESC	cis	rs4919087	0.926	rs10882884	chr10:99025611	T/A	cg25902810	chr10:99078978	FRAT1	0.68	9.92	0.52	6.16e-20	Monocyte count;
CESC	cis	rs11190604	1.000	rs2298075	chr10:102247408	C/A	cg07080220	chr10:102295463	HIF1AN	0.55	5.43	0.32	1.3e-7	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs11098499	0.663	rs9996501	chr4:120238918	C/A	cg09307838	chr4:120376055	NA	0.78	10.39	0.54	1.94e-21	Corneal astigmatism;
CESC	cis	rs9611565	0.765	rs28604950	chr22:41785812	A/G	cg03806693	chr22:41940476	POLR3H	-1.06	-12.46	-0.61	2.35e-28	Vitiligo;
CESC	cis	rs2075371	0.897	rs1646702	chr7:134000177	C/G	cg00033643	chr7:134001901	SLC35B4	0.44	5.59	0.32	5.6e-8	Mean platelet volume;
CESC	cis	rs6460942	0.915	rs10488158	chr7:12508894	C/T	cg10578991	chr7:12443926	VWDE	-0.48	-5.14	-0.3	5.44e-7	Coronary artery disease;
CESC	cis	rs7208859	0.623	rs9911173	chr17:29154750	C/T	cg13385521	chr17:29058706	SUZ12P	0.75	5.95	0.34	8.3e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs72829446	0.530	rs59665520	chr17:7383136	C/A	cg02795151	chr17:7402630	POLR2A	0.55	5.86	0.34	1.41e-8	Androgen levels;
CESC	trans	rs7537660	0.562	rs4417105	chr1:248016487	G/T	cg17509220	chr19:13617012	CACNA1A	0.36	6.02	0.35	5.84e-9	Platelet distribution width;
CESC	cis	rs4924935	0.683	rs34413375	chr17:18802028	C/A	cg26378065	chr17:18585709	ZNF286B	-0.49	-5.18	-0.3	4.47e-7	Pancreatic cancer;
CESC	cis	rs3733585	0.699	rs60045583	chr4:9971950	G/A	cg00071950	chr4:10020882	SLC2A9	-0.7	-11.32	-0.57	1.7e-24	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs7927592	0.763	rs3740628	chr11:68381415	A/G	cg01657329	chr11:68192670	LRP5	-0.44	-5.66	-0.33	3.9e-8	Total body bone mineral density;
CESC	cis	rs832540	0.866	rs252894	chr5:56224339	A/C	cg14703610	chr5:56206110	C5orf35	-0.48	-5.85	-0.34	1.44e-8	Coronary artery disease;
CESC	cis	rs875971	0.540	rs35510581	chr7:65578777	G/A	cg06456125	chr7:65229604	NA	-0.39	-5.04	-0.3	8.55e-7	Aortic root size;
CESC	cis	rs189218934	1	rs189218934	chr15:78903987	T/C	cg24631222	chr15:78858424	CHRNA5	-0.8	-10.05	-0.53	2.41e-20	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs61935443	0.720	rs10859784	chr12:95288926	G/A	cg21533806	chr12:95267307	NA	0.55	6.6	0.38	2.17e-10	Schizophrenia;
CESC	cis	rs2228479	0.850	rs12597296	chr16:89822331	C/T	cg04013166	chr16:89971882	TCF25	0.77	6.66	0.38	1.58e-10	Skin colour saturation;
CESC	cis	rs4819052	0.620	rs421619	chr21:46546115	C/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	5.51	0.32	8.43e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs11574514	1.000	rs11861657	chr16:67824395	A/G	cg26727032	chr16:67993705	SLC12A4	-0.57	-5.07	-0.3	7.66e-7	Crohn's disease;
CESC	cis	rs7647973	0.769	rs6772452	chr3:49040462	A/G	cg06212747	chr3:49208901	KLHDC8B	0.57	7.19	0.4	6.51e-12	Menarche (age at onset);
CESC	cis	rs875971	0.895	rs12531677	chr7:65769086	G/A	cg18876405	chr7:65276391	NA	-0.51	-7.07	-0.4	1.39e-11	Aortic root size;
CESC	cis	rs6938	0.534	rs59945415	chr15:75228427	C/A	cg17294928	chr15:75287854	SCAMP5	0.48	6.26	0.36	1.54e-9	Breast cancer;
CESC	cis	rs1707322	0.721	rs10890346	chr1:46223892	C/T	cg06784218	chr1:46089804	CCDC17	-0.4	-7.14	-0.4	8.84e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs4925386	0.681	rs2427295	chr20:60927431	G/A	cg22307297	chr20:60903441	LAMA5	0.37	5.28	0.31	2.65e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs7666738	0.830	rs1426663	chr4:98990092	T/G	cg17366294	chr4:99064904	C4orf37	0.6	8.6	0.47	7.1e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7116495	1.000	rs73543609	chr11:71816619	G/T	cg26138937	chr11:71823887	C11orf51	0.85	6.85	0.39	5.03e-11	Severe influenza A (H1N1) infection;
CESC	cis	rs853679	0.574	rs1233705	chr6:28166447	C/G	cg19592336	chr6:28129416	ZNF389	0.51	7.03	0.4	1.73e-11	Depression;
CESC	cis	rs1790761	0.520	rs4930461	chr11:67394895	A/G	cg24690094	chr11:67383802	NA	0.39	6.62	0.38	1.99e-10	Mean corpuscular volume;
CESC	cis	rs4664308	0.967	rs17241973	chr2:160918601	A/G	cg03641300	chr2:160917029	PLA2R1	-0.67	-10.0	-0.52	3.57e-20	Idiopathic membranous nephropathy;
CESC	cis	rs34779708	0.931	rs11597483	chr10:35285117	A/G	cg04310649	chr10:35416472	CREM	-0.5	-6.06	-0.35	4.78e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs1215050	0.740	rs2695464	chr4:98980929	T/C	cg05340658	chr4:99064831	C4orf37	-0.57	-7.73	-0.43	2.26e-13	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs798554	0.759	rs1182189	chr7:2869522	G/A	cg18446336	chr7:2847575	GNA12	-0.37	-5.53	-0.32	7.69e-8	Height;
CESC	cis	rs933688	1.000	rs6867091	chr5:90734333	C/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.05	13.7	0.64	1.18e-32	Smoking behavior;
CESC	cis	rs2979489	0.786	rs2979514	chr8:30399461	A/C	cg26383811	chr8:30366931	RBPMS	-0.79	-10.0	-0.52	3.48e-20	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CESC	cis	rs2204008	0.652	rs11513964	chr12:37998214	C/G	cg26384229	chr12:38710491	ALG10B	0.74	10.87	0.56	5.15e-23	Bladder cancer;
CESC	cis	rs9649465	1.000	rs2299983	chr7:123356642	C/G	cg04330084	chr7:123175371	IQUB	-0.39	-5.23	-0.31	3.47e-7	Migraine;
CESC	cis	rs2730245	0.550	rs2709860	chr7:158651156	A/T	cg14689365	chr7:158441557	NCAPG2	0.42	5.3	0.31	2.47e-7	Height;
CESC	cis	rs7429990	0.965	rs796566	chr3:47938354	G/C	cg11946769	chr3:48343235	NME6	0.42	5.05	0.3	8.38e-7	Educational attainment (years of education);
CESC	cis	rs9311474	0.508	rs4687629	chr3:52615227	G/C	cg07507251	chr3:52567010	NT5DC2	0.33	5.68	0.33	3.6e-8	Electroencephalogram traits;
CESC	cis	rs7267979	1.000	rs6115146	chr20:25304507	G/A	cg08601574	chr20:25228251	PYGB	-0.39	-5.7	-0.33	3.23e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs60843830	0.964	rs7584915	chr2:264227	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.79	10.49	0.54	9.31e-22	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs801193	1.000	rs1553609	chr7:66197139	T/C	cg11764359	chr7:65958608	NA	0.71	9.39	0.5	2.85e-18	Aortic root size;
CESC	cis	rs72634258	0.945	rs35675666	chr1:8021973	G/T	cg00042356	chr1:8021962	PARK7	0.82	7.85	0.43	1e-13	Inflammatory bowel disease;
CESC	cis	rs11690935	0.843	rs9784123	chr2:172785005	T/A	cg13550731	chr2:172543902	DYNC1I2	-0.84	-12.15	-0.6	2.63e-27	Schizophrenia;
CESC	cis	rs7267979	0.932	rs2260997	chr20:25256266	A/C	cg08601574	chr20:25228251	PYGB	-0.4	-5.88	-0.34	1.22e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs2841277	0.708	rs28454709	chr14:105405942	G/A	cg14403583	chr14:105418241	AHNAK2	-0.57	-7.86	-0.43	9.9e-14	Rheumatoid arthritis;
CESC	cis	rs965513	1.000	rs7030256	chr9:100535203	C/G	cg13688889	chr9:100608707	NA	-0.6	-8.57	-0.47	8.76e-16	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
CESC	cis	rs4665809	1.000	rs10048683	chr2:26320519	C/T	cg08470875	chr2:26401718	FAM59B	-0.49	-5.54	-0.32	7.17e-8	Gut microbiome composition (summer);
CESC	cis	rs854765	0.547	rs7224047	chr17:17932931	G/A	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.5	6.43	0.37	5.86e-10	Total body bone mineral density;
CESC	cis	rs798766	1.000	rs3752749	chr4:1737262	T/C	cg10756475	chr4:1757242	NA	0.46	6.02	0.35	5.9e-9	Bladder cancer;Urinary bladder cancer;
CESC	cis	rs9894429	1.000	rs7406003	chr17:79597597	C/T	cg21984481	chr17:79567631	NPLOC4	-0.49	-7.86	-0.43	9.77e-14	Eye color traits;
CESC	cis	rs1008375	0.966	rs4235392	chr4:17696422	A/G	cg02297831	chr4:17616191	MED28	0.43	5.21	0.3	3.81e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs56104184	0.775	rs55756106	chr19:49403055	A/G	cg21252483	chr19:49399788	TULP2	-0.52	-5.69	-0.33	3.36e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg26675182	chr7:2405750	EIF3B	0.5	6.16	0.35	2.65e-9	Ulcerative colitis;
CESC	cis	rs2637266	0.667	rs2395406	chr10:78380519	G/A	cg18941641	chr10:78392320	NA	0.4	7.34	0.41	2.59e-12	Pulmonary function;
CESC	cis	rs1348850	0.872	rs4893824	chr2:178298104	G/A	cg23306229	chr2:178417860	TTC30B	0.58	6.78	0.38	7.59e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs1552244	0.882	rs67631672	chr3:10004768	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.81	10.27	0.53	4.75e-21	Alzheimer's disease;
CESC	cis	rs12136530	0.774	rs12562821	chr1:19786650	C/T	cg01832549	chr1:19774989	CAPZB	-0.43	-5.98	-0.35	7e-9	Lead levels in blood;
CESC	cis	rs4803468	1.000	rs284649	chr19:41926838	C/T	cg09537434	chr19:41945824	ATP5SL	-1.1	-20.32	-0.78	5.54e-56	Height;
CESC	cis	rs875971	0.662	rs448725	chr7:65514628	A/G	cg26939375	chr7:64535504	NA	0.48	6.19	0.36	2.32e-9	Aortic root size;
CESC	cis	rs6502050	0.799	rs4482345	chr17:80152919	G/A	cg23985595	chr17:80112537	CCDC57	-0.4	-6.33	-0.36	1.05e-9	Life satisfaction;
CESC	cis	rs6933660	0.721	rs2128945	chr6:151767907	A/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.52	-6.87	-0.39	4.66e-11	Menarche (age at onset);
CESC	cis	rs7772486	0.875	rs7767660	chr6:146436550	T/C	cg23711669	chr6:146136114	FBXO30	0.78	11.5	0.58	4.13e-25	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs425277	0.628	rs262668	chr1:2082602	A/G	cg16545954	chr1:2118288	C1orf86	0.35	6.55	0.37	2.95e-10	Height;
CESC	cis	rs1799949	1.000	rs3950989	chr17:41237953	G/A	cg05368731	chr17:41323189	NBR1	0.77	10.96	0.56	2.61e-23	Menopause (age at onset);
CESC	cis	rs4819052	0.851	rs13049337	chr21:46663460	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.75	9.94	0.52	5.31e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs9916302	0.706	rs8073907	chr17:37424149	C/T	cg07936489	chr17:37558343	FBXL20	-0.97	-11.45	-0.58	6.08e-25	Glomerular filtration rate (creatinine);
CESC	cis	rs4713118	0.629	rs149899	chr6:28019979	C/T	cg22143856	chr6:28129313	ZNF389	0.42	5.27	0.31	2.83e-7	Parkinson's disease;
CESC	cis	rs1008375	1.000	rs4698641	chr4:17642630	C/T	cg16339924	chr4:17578868	LAP3	0.64	7.91	0.44	6.79e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs6546550	0.933	rs6546554	chr2:70135706	G/A	cg02498382	chr2:70120550	SNRNP27	-0.4	-7.03	-0.4	1.71e-11	Prevalent atrial fibrillation;
CESC	cis	rs7317038	1.000	rs7317038	chr13:114012898	C/T	cg24344662	chr13:114018021	GRTP1	-0.51	-6.53	-0.37	3.27e-10	Mean platelet volume;
CESC	cis	rs9486719	1.000	rs11757063	chr6:96884886	C/T	cg06623918	chr6:96969491	KIAA0776	-0.75	-7.65	-0.43	3.78e-13	Migraine;Coronary artery disease;
CESC	cis	rs548181	0.609	rs511822	chr11:125534115	C/T	cg03464685	chr11:125439445	EI24	1.06	8.92	0.48	8e-17	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-6.21	-0.36	2.01e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2072499	0.966	rs2842857	chr1:156168736	T/C	cg25208724	chr1:156163844	SLC25A44	1.0	19.1	0.76	9.89e-52	Testicular germ cell tumor;
CESC	cis	rs568617	0.953	rs583887	chr11:65644027	T/C	cg19792802	chr11:65647270	CTSW	-0.35	-5.31	-0.31	2.33e-7	Crohn's disease;
CESC	cis	rs8103278	1.000	rs8108590	chr19:46301620	A/G	cg11657440	chr19:46296263	DMWD	-0.58	-7.23	-0.41	5.09e-12	Coronary artery disease;
CESC	cis	rs11825685	0.887	rs78806216	chr11:134568320	C/T	cg06603561	chr11:134479413	NA	-0.63	-5.41	-0.32	1.39e-7	IgG glycosylation;
CESC	cis	rs17401966	0.964	rs17400510	chr1:10290421	T/C	cg15208524	chr1:10270712	KIF1B	0.47	6.14	0.35	3.07e-9	Hepatocellular carcinoma;
CESC	cis	rs9611565	0.659	rs9611602	chr22:41908405	T/C	cg03806693	chr22:41940476	POLR3H	-1.24	-16.52	-0.71	1.2e-42	Vitiligo;
CESC	cis	rs3806843	0.966	rs2563265	chr5:140137005	C/T	cg16179182	chr5:140090404	VTRNA1-1	0.41	5.41	0.32	1.41e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs10447248	0.674	rs6859569	chr5:107893771	A/G	cg25075504	chr5:107899390	NA	-0.39	-6.0	-0.35	6.42e-9	Adiponectin levels;
CESC	cis	rs2439831	1.000	rs2444250	chr15:43785051	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.83	11.92	0.59	1.68e-26	Lung cancer in ever smokers;
CESC	cis	rs1005277	0.579	rs2474595	chr10:38426782	C/G	cg25427524	chr10:38739819	LOC399744	0.66	9.65	0.51	4.45e-19	Extrinsic epigenetic age acceleration;
CESC	cis	rs11828289	0.660	rs74388652	chr11:23188048	A/G	cg20040320	chr11:23191996	NA	-0.68	-5.87	-0.34	1.31e-8	Cancer;
CESC	cis	rs7589728	1.000	rs2363731	chr2:88521793	C/T	cg04511125	chr2:88470314	THNSL2	0.58	5.62	0.33	4.88e-8	Plasma clusterin levels;
CESC	cis	rs514406	0.893	rs1242326	chr1:53399104	C/A	cg24675658	chr1:53192096	ZYG11B	-0.54	-6.59	-0.38	2.32e-10	Monocyte count;
CESC	cis	rs5753037	0.653	rs140107	chr22:30130516	C/A	cg01021169	chr22:30184971	ASCC2	-0.43	-5.88	-0.34	1.26e-8	Type 1 diabetes;
CESC	cis	rs6968419	0.547	rs72603593	chr7:115894376	T/C	cg02561103	chr7:115862891	TES	-0.4	-5.21	-0.3	3.76e-7	Intraocular pressure;
CESC	cis	rs6545883	0.894	rs4672436	chr2:61603357	A/C	cg15711740	chr2:61764176	XPO1	0.4	5.1	0.3	6.53e-7	Tuberculosis;
CESC	cis	rs796364	0.806	rs74706215	chr2:200941367	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.82	-7.29	-0.41	3.5e-12	Schizophrenia;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg21843114	chr4:26334859	RBPJ	0.43	6.03	0.35	5.61e-9	Fibrinogen levels;
CESC	trans	rs7307889	0.793	rs12308152	chr12:6008861	A/C	cg18407955	chr7:158110685	PTPRN2	-0.72	-6.68	-0.38	1.41e-10	Obesity-related traits;
CESC	cis	rs1707322	1.000	rs4660906	chr1:46470860	C/T	cg05343316	chr1:45956843	TESK2	0.44	5.28	0.31	2.65e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs12477438	0.520	rs12467504	chr2:99543208	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.47	-5.37	-0.31	1.7e-7	Chronic sinus infection;
CESC	cis	rs7829975	0.514	rs2920991	chr8:8259117	T/A	cg06636001	chr8:8085503	FLJ10661	0.53	7.06	0.4	1.45e-11	Mood instability;
CESC	cis	rs9488822	0.676	rs1556857	chr6:116325559	T/C	cg26893134	chr6:116381904	FRK	0.25	6.04	0.35	5.06e-9	Cholesterol, total;LDL cholesterol;
CESC	cis	rs10416265	0.527	rs7508599	chr19:33546512	A/T	cg03563238	chr19:33554763	RHPN2	-0.31	-5.56	-0.32	6.64e-8	Bone properties (heel);
CESC	cis	rs4975709	0.589	rs4975746	chr5:1861069	G/A	cg12288994	chr5:1860383	NA	0.43	7.05	0.4	1.52e-11	Cardiovascular disease risk factors;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg08655493	chr21:33765248	URB1;C21orf119	0.46	6.12	0.35	3.31e-9	Systemic lupus erythematosus;
CESC	cis	rs2835872	0.758	rs1709835	chr21:39037636	A/G	cg06728970	chr21:39037746	KCNJ6	0.3	5.53	0.32	7.57e-8	Electroencephalographic traits in alcoholism;
CESC	cis	rs7116495	0.881	rs1892921	chr11:71702138	G/A	cg10381502	chr11:71823885	C11orf51	-0.68	-5.91	-0.34	1.05e-8	Severe influenza A (H1N1) infection;
CESC	cis	rs1008375	0.966	rs6813375	chr4:17649499	T/G	cg02297831	chr4:17616191	MED28	0.61	7.82	0.43	1.23e-13	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06391473	chr2:238875301	UBE2F	0.59	7.02	0.4	1.84e-11	Gut microbiome composition (summer);
CESC	cis	rs736408	0.609	rs2230534	chr3:52802402	A/C	cg17372223	chr3:52568218	NT5DC2	0.43	6.19	0.36	2.23e-9	Bipolar disorder;
CESC	cis	rs9393777	0.513	rs9393739	chr6:26646966	T/G	cg12826209	chr6:26865740	GUSBL1	0.75	8.45	0.46	1.9e-15	Intelligence (multi-trait analysis);
CESC	cis	rs9326248	0.530	rs1351452	chr11:116943354	G/T	cg01368799	chr11:117014884	PAFAH1B2	-0.56	-5.14	-0.3	5.39e-7	Blood protein levels;
CESC	cis	rs7223966	1.000	rs9899491	chr17:61934384	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.52	6.26	0.36	1.56e-9	Hip circumference adjusted for BMI;Body mass index;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg04067598	chr5:70751409	BDP1	0.46	6.56	0.37	2.84e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs6982240	0.514	rs892362	chr8:142269214	A/G	cg27411547	chr8:142287226	NA	0.51	7.31	0.41	3.11e-12	Tonsillectomy;
CESC	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg11494091	chr17:61959527	GH2	0.72	12.07	0.6	4.86e-27	Prudent dietary pattern;
CESC	cis	rs914615	0.552	rs11264339	chr1:155140648	A/G	cg02153340	chr1:155202674	NA	0.35	5.2	0.3	3.97e-7	Urinary albumin-to-creatinine ratio;
CESC	cis	rs514406	0.727	rs61768342	chr1:53217028	G/A	cg24675658	chr1:53192096	ZYG11B	0.57	7.82	0.43	1.23e-13	Monocyte count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15216925	chr5:179921655	CNOT6	0.61	6.56	0.37	2.89e-10	Gut microbiome composition (summer);
CESC	cis	rs17539620	0.624	rs871069	chr6:154837578	A/C	cg20019720	chr6:154832845	CNKSR3	0.47	6.13	0.35	3.21e-9	Lipoprotein (a) levels;
CESC	trans	rs1814175	0.935	rs1827017	chr11:49632592	C/G	cg03929089	chr4:120376271	NA	-0.87	-13.32	-0.63	2.44e-31	Height;
CESC	cis	rs6540556	0.859	rs12079960	chr1:209937168	A/C	cg23920097	chr1:209922102	NA	-0.35	-5.15	-0.3	5.07e-7	Red blood cell count;
CESC	cis	rs1124376	0.748	rs6771367	chr3:20160266	A/T	cg05072819	chr3:20081367	KAT2B	0.47	5.56	0.32	6.47e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs10089	0.953	rs114881127	chr5:127369661	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.76	9.55	0.51	8.83e-19	Ileal carcinoids;
CESC	cis	rs3820068	0.581	rs59684759	chr1:15919893	A/G	cg13390004	chr1:15929781	NA	0.32	5.06	0.3	7.96e-7	Systolic blood pressure;
CESC	cis	rs7618915	0.570	rs11714088	chr3:52758942	A/C	cg17372223	chr3:52568218	NT5DC2	0.45	6.61	0.38	2.14e-10	Bipolar disorder;
CESC	cis	rs668210	0.947	rs559161	chr11:65761637	A/G	cg02202077	chr11:65769826	EIF1AD;BANF1	0.75	9.25	0.49	7.89e-18	Cerebrospinal fluid biomarker levels;
CESC	cis	rs2274273	0.805	rs60972460	chr14:55571773	A/T	cg04306507	chr14:55594613	LGALS3	0.29	5.79	0.34	1.95e-8	Protein biomarker;
CESC	cis	rs4665809	0.590	rs7588328	chr2:26469788	G/A	cg26314531	chr2:26401878	FAM59B	0.85	9.04	0.49	3.46e-17	Gut microbiome composition (summer);
CESC	cis	rs425277	0.606	rs16824792	chr1:2039521	G/T	cg23803603	chr1:2058230	PRKCZ	-0.37	-6.73	-0.38	1.03e-10	Height;
CESC	trans	rs10506458	0.915	rs17763441	chr12:63418335	T/C	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.34	-18.36	-0.75	3.77e-49	Hemostatic factors and hematological phenotypes;
CESC	cis	rs4481887	0.639	rs10749644	chr1:248414587	A/C	cg00666640	chr1:248458726	OR2T12	0.32	5.37	0.31	1.71e-7	Common traits (Other);
CESC	cis	rs1707322	1.000	rs11211190	chr1:46266255	C/T	cg06784218	chr1:46089804	CCDC17	0.33	5.7	0.33	3.24e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs4689592	0.523	rs3857179	chr4:7070496	T/A	cg19539972	chr4:7069911	GRPEL1	0.78	9.73	0.51	2.48e-19	Monocyte percentage of white cells;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg13445258	chr3:128369860	RPN1	0.51	6.63	0.38	1.82e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs870825	0.860	rs72689297	chr4:185600957	A/T	cg04058563	chr4:185651563	MLF1IP	0.57	5.29	0.31	2.54e-7	Blood protein levels;
CESC	cis	rs9443189	0.855	rs2842554	chr6:76455557	C/A	cg01950844	chr6:76311363	SENP6	-0.6	-6.63	-0.38	1.82e-10	Prostate cancer;
CESC	cis	rs61935443	0.614	rs11107792	chr12:95317126	G/C	cg21533806	chr12:95267307	NA	0.5	5.36	0.31	1.78e-7	Schizophrenia;
CESC	cis	rs1799949	1.000	rs2298862	chr17:41176688	T/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.39	5.12	0.3	5.88e-7	Menopause (age at onset);
CESC	cis	rs7666738	0.830	rs28810677	chr4:99043193	C/T	cg17366294	chr4:99064904	C4orf37	0.61	8.78	0.47	2.13e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9443189	0.526	rs6902898	chr6:76201856	G/A	cg01950844	chr6:76311363	SENP6	0.87	8.92	0.48	7.77e-17	Prostate cancer;
CESC	cis	rs9311474	0.539	rs12489828	chr3:52567014	G/T	cg18099408	chr3:52552593	STAB1	-0.4	-7.29	-0.41	3.59e-12	Electroencephalogram traits;
CESC	cis	rs9815354	0.556	rs113213296	chr3:41873097	G/A	cg03022575	chr3:42003672	ULK4	0.71	6.23	0.36	1.83e-9	Pulse pressure;Diastolic blood pressure;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10835230	chr19:2457145	LMNB2	0.57	6.18	0.35	2.4e-9	Gut microbiome composition (summer);
CESC	cis	rs9649213	0.593	rs6465662	chr7:97917801	A/T	cg24562669	chr7:97807699	LMTK2	0.47	6.73	0.38	1.07e-10	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs11229555	0.645	rs34530191	chr11:58200854	A/G	cg15696309	chr11:58395628	NA	-0.42	-5.05	-0.3	8.13e-7	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs4237845	0.780	rs3751331	chr12:58290278	G/A	cg02175503	chr12:58329896	NA	0.61	7.33	0.41	2.85e-12	Intelligence (multi-trait analysis);
CESC	cis	rs77956314	0.515	rs4238051	chr12:117366299	A/G	cg02017074	chr12:117425053	FBXW8	0.77	8.03	0.44	3.3e-14	Subcortical brain region volumes;Hippocampal volume;
CESC	cis	rs1005277	0.579	rs2505240	chr10:38442419	G/T	cg25427524	chr10:38739819	LOC399744	-0.66	-9.68	-0.51	3.58e-19	Extrinsic epigenetic age acceleration;
CESC	cis	rs72781680	0.950	rs72796343	chr2:24147631	G/A	cg20701182	chr2:24300061	SF3B14	0.79	6.77	0.38	8.12e-11	Lymphocyte counts;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg08243778	chr1:212458726	PPP2R5A	-0.46	-6.37	-0.36	8.31e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs7100689	0.646	rs7894762	chr10:82086779	C/G	cg00277334	chr10:82204260	NA	-0.6	-7.96	-0.44	4.91e-14	Post bronchodilator FEV1;
CESC	trans	rs208520	0.874	rs208481	chr6:66922636	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.84	-9.84	-0.52	1.14e-19	Exhaled nitric oxide output;
CESC	cis	rs6582630	0.519	rs12368889	chr12:38315160	G/A	cg13010199	chr12:38710504	ALG10B	0.51	6.33	0.36	1.07e-9	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs7208859	0.573	rs8078656	chr17:29080971	A/T	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.91e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs6460942	1.000	rs17191008	chr7:12417690	T/G	cg06484146	chr7:12443880	VWDE	-0.8	-9.06	-0.49	3.01e-17	Coronary artery disease;
CESC	cis	rs7560272	0.538	rs6732812	chr2:73922475	T/C	cg20560298	chr2:73613845	ALMS1	0.46	6.3	0.36	1.23e-9	Schizophrenia;
CESC	cis	rs6831352	0.879	rs2602888	chr4:100041706	C/T	cg12011299	chr4:100065546	ADH4	0.6	6.57	0.37	2.59e-10	Alcohol dependence;
CESC	cis	rs6580649	0.941	rs11612970	chr12:48451009	T/C	cg24011408	chr12:48396354	COL2A1	-0.42	-5.28	-0.31	2.67e-7	Lung cancer;
CESC	cis	rs28489187	0.706	rs2300637	chr1:85822772	T/C	cg16011679	chr1:85725395	C1orf52	0.55	6.34	0.36	1e-9	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	cis	rs853679	0.517	rs9357061	chr6:28051772	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.53	-6.09	-0.35	3.91e-9	Depression;
CESC	cis	rs6493487	0.512	rs16953045	chr15:51251122	A/C	cg02338191	chr15:51200825	AP4E1	0.59	5.62	0.33	4.83e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg08984405	chr17:685103	RNMTL1;GLOD4	-0.41	-6.11	-0.35	3.46e-9	Vertical cup-disc ratio;
CESC	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	7.84	0.43	1.14e-13	Prudent dietary pattern;
CESC	cis	rs947211	0.846	rs823155	chr1:205762946	T/C	cg11965913	chr1:205819406	PM20D1	0.39	5.17	0.3	4.73e-7	Parkinson's disease;
CESC	cis	rs11650494	0.706	rs76778410	chr17:47459877	A/T	cg08112188	chr17:47440006	ZNF652	1.27	8.48	0.46	1.62e-15	Prostate cancer;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg24744501	chr2:207024175	NDUFS1;EEF1B2	-0.54	-6.76	-0.38	8.96e-11	Ulcerative colitis;
CESC	cis	rs1448094	0.511	rs10863083	chr12:86226739	C/A	cg00310523	chr12:86230176	RASSF9	0.35	5.57	0.32	6.17e-8	Major depressive disorder;
CESC	cis	rs6952808	0.798	rs28970524	chr7:1927484	C/T	cg00106254	chr7:1943704	MAD1L1	-0.49	-6.05	-0.35	4.88e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs9811920	0.638	rs793440	chr3:99643176	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.4	-5.38	-0.31	1.67e-7	Axial length;
CESC	cis	rs6088580	0.634	rs4911420	chr20:32998654	A/G	cg24642439	chr20:33292090	TP53INP2	-0.52	-7.06	-0.4	1.46e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs941207	0.507	rs73337030	chr12:57046194	T/A	cg05584118	chr12:57595605	LRP1	0.36	5.1	0.3	6.38e-7	Platelet count;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg08483723	chr3:45267960	TMEM158	0.46	6.78	0.38	7.88e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs6032067	1.000	rs6017509	chr20:43830362	A/G	cg10761708	chr20:43804764	PI3	0.52	6.32	0.36	1.07e-9	Blood protein levels;
CESC	cis	rs7312933	0.703	rs10459290	chr12:42613290	T/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.5	6.35	0.36	9.35e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	trans	rs3960554	0.599	rs56090527	chr7:75762125	A/C	cg19862616	chr7:65841803	NCRNA00174	0.58	6.08	0.35	4.12e-9	Eotaxin levels;
CESC	cis	rs9616064	0.531	rs9616086	chr22:47050744	G/A	cg05621596	chr22:47072043	GRAMD4	-0.68	-9.8	-0.52	1.45e-19	Urate levels in obese individuals;
CESC	cis	rs3026101	0.723	rs1544400	chr17:5305924	G/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.45	6.06	0.35	4.6e-9	Body mass index;
CESC	cis	rs2050392	0.590	rs17547917	chr10:30718303	G/A	cg25182066	chr10:30743637	MAP3K8	-0.46	-5.98	-0.34	7.32e-9	Inflammatory bowel disease;
CESC	cis	rs10256972	0.869	rs4720158	chr7:1040325	A/G	cg04025307	chr7:1156635	C7orf50	0.37	5.82	0.34	1.71e-8	Longevity;Endometriosis;
CESC	cis	rs6463523	0.864	rs73047957	chr7:759373	A/T	cg14391382	chr7:866102	UNC84A	0.48	5.97	0.34	7.53e-9	Subjective well-being;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24232869	chr12:48478849	SENP1	-0.64	-7.39	-0.41	1.88e-12	Gut microbiome composition (summer);
CESC	cis	rs714031	0.934	rs2235341	chr22:40068679	T/G	cg21377881	chr22:40064566	CACNA1I	-0.32	-5.15	-0.3	5.15e-7	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00717482	chr1:112531938	KCND3	0.57	6.24	0.36	1.77e-9	Gut microbiome composition (summer);
CESC	cis	rs60871478	1.000	rs62432242	chr7:797715	G/A	cg05535760	chr7:792225	HEATR2	0.84	10.4	0.54	1.75e-21	Cerebrospinal P-tau181p levels;
CESC	cis	rs12822507	0.868	rs12830917	chr12:12792516	C/A	cg11838227	chr12:12764436	CREBL2	-0.41	-5.32	-0.31	2.21e-7	Systemic lupus erythematosus;
CESC	cis	rs6460942	0.597	rs17277369	chr7:12536192	A/G	cg02935154	chr7:12443704	VWDE	-0.57	-5.7	-0.33	3.23e-8	Coronary artery disease;
CESC	cis	rs4862750	0.914	rs1991255	chr4:187875340	G/A	cg10295955	chr4:187884368	NA	-1.02	-18.0	-0.74	7.4e-48	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2629540	0.543	rs2559515	chr10:126513925	A/G	cg08799069	chr10:126477246	METTL10	0.5	5.74	0.33	2.65e-8	Cocaine dependence;
CESC	cis	rs4268898	0.662	rs55661701	chr2:24400769	A/C	cg08917208	chr2:24149416	ATAD2B	0.62	5.7	0.33	3.21e-8	Asthma;
CESC	cis	rs9420	0.961	rs11607056	chr11:57496820	C/T	cg19752551	chr11:57585705	CTNND1	-0.36	-5.07	-0.3	7.55e-7	Schizophrenia;
CESC	cis	rs2708240	0.577	rs2888536	chr7:147566862	G/A	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.4	-6.41	-0.37	6.59e-10	QT interval (drug interaction);
CESC	cis	rs7811142	1.000	rs113738841	chr7:100081306	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.84	8.31	0.45	4.88e-15	Platelet count;
CESC	cis	rs9487051	0.768	rs435611	chr6:109527755	C/T	cg01475377	chr6:109611718	NA	-0.44	-6.65	-0.38	1.71e-10	Reticulocyte fraction of red cells;
CESC	cis	rs4819052	0.819	rs8134084	chr21:46693295	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.92	13.78	0.65	6.16e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs8016982	0.633	rs8019108	chr14:81716781	A/T	cg01989461	chr14:81687754	GTF2A1	0.71	11.02	0.56	1.75e-23	Schizophrenia;
CESC	cis	rs763121	0.853	rs6519120	chr22:38991393	A/C	cg06544989	chr22:39130855	UNC84B	-0.5	-8.31	-0.45	4.92e-15	Menopause (age at onset);
CESC	cis	rs10129255	0.957	rs10136781	chr14:107188690	G/T	cg23076370	chr14:107095027	NA	-0.46	-5.95	-0.34	8.57e-9	Kawasaki disease;
CESC	cis	rs2124969	0.506	rs10497209	chr2:160985586	A/C	cg03641300	chr2:160917029	PLA2R1	-0.56	-5.79	-0.34	2.01e-8	Waist circumference adjusted for body mass index;
CESC	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.55	-6.1	-0.35	3.69e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15327300	chr17:65373795	PITPNC1	0.58	6.78	0.38	8.01e-11	Gut microbiome composition (summer);
CESC	cis	rs8017423	0.647	rs4904673	chr14:90817338	G/A	cg14092571	chr14:90743983	NA	0.44	6.62	0.38	1.93e-10	Mortality in heart failure;
CESC	cis	rs514406	0.929	rs562178	chr1:53319562	T/C	cg24675658	chr1:53192096	ZYG11B	-0.59	-7.51	-0.42	9.17e-13	Monocyte count;
CESC	cis	rs477692	0.629	rs945231	chr10:131294827	A/G	cg05714579	chr10:131428358	MGMT	0.43	5.62	0.33	4.88e-8	Response to temozolomide;
CESC	trans	rs10488821	0.903	rs61884729	chr11:30515682	G/C	cg04407762	chr4:113442791	NA	-0.46	-6.76	-0.38	8.89e-11	QRS complex (12-leadsum);
CESC	cis	rs11608355	0.545	rs4766474	chr12:109908084	G/C	cg05360138	chr12:110035743	NA	0.82	8.92	0.48	7.93e-17	Neuroticism;
CESC	cis	rs929843	1	rs929843	chr16:70045748	A/C	cg09409435	chr16:70099608	PDXDC2	1.05	11.22	0.57	3.6e-24	Menarche (age at onset);
CESC	cis	rs2014572	0.967	rs10427146	chr19:57755998	T/C	cg24459738	chr19:57751996	ZNF805	-0.54	-7.78	-0.43	1.67e-13	Hyperactive-impulsive symptoms;
CESC	cis	rs9818758	0.556	rs116432667	chr3:48947589	C/T	cg00383909	chr3:49044727	WDR6	0.95	6.8	0.39	6.82e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CESC	cis	rs2228479	0.702	rs12599561	chr16:89894358	C/G	cg14709524	chr16:89940631	TCF25	0.87	6.05	0.35	4.99e-9	Skin colour saturation;
CESC	cis	rs4455778	0.536	rs10266289	chr7:48941456	C/T	cg26309511	chr7:48887640	NA	-0.35	-5.13	-0.3	5.51e-7	Lung cancer in never smokers;
CESC	cis	rs1153858	0.945	rs2467854	chr15:45701597	A/G	cg21132104	chr15:45694354	SPATA5L1	0.76	10.15	0.53	1.12e-20	Homoarginine levels;
CESC	cis	rs875971	0.522	rs10807697	chr7:65416170	A/G	cg06456125	chr7:65229604	NA	0.45	5.9	0.34	1.11e-8	Aortic root size;
CESC	trans	rs6073597	1.000	rs6031980	chr20:43714384	C/T	cg21490179	chr3:40494492	NA	0.47	6.69	0.38	1.32e-10	Positive affect;
CESC	cis	rs3806843	1.000	rs12055222	chr5:140165568	T/C	cg16179182	chr5:140090404	VTRNA1-1	-0.4	-5.23	-0.31	3.52e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs11608355	0.545	rs11066737	chr12:109904792	A/G	cg05360138	chr12:110035743	NA	-0.81	-9.03	-0.48	3.74e-17	Neuroticism;
CESC	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg13126279	chr21:47581558	C21orf56	0.48	6.53	0.37	3.26e-10	Testicular germ cell tumor;
CESC	cis	rs61931739	0.534	rs10844801	chr12:34230940	A/T	cg19457237	chr12:34500585	NA	-0.36	-5.08	-0.3	7.09e-7	Morning vs. evening chronotype;
CESC	cis	rs72781680	0.898	rs72796171	chr2:23942667	G/C	cg08917208	chr2:24149416	ATAD2B	1.0	9.21	0.49	1.03e-17	Lymphocyte counts;
CESC	cis	rs2404602	0.692	rs12902452	chr15:76921465	T/C	cg26408565	chr15:76604113	ETFA	-0.39	-5.51	-0.32	8.57e-8	Blood metabolite levels;
CESC	cis	rs12249377	0.519	rs66650915	chr10:92592468	T/C	cg14313238	chr10:92632228	RPP30	0.43	5.25	0.31	3.16e-7	White matter microstructure (global fractional anisotropy);
CESC	cis	rs1348850	0.874	rs4893822	chr2:178285727	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.8	10.45	0.54	1.22e-21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs4595586	0.525	rs35089392	chr12:39414547	T/G	cg13010199	chr12:38710504	ALG10B	0.43	5.33	0.31	2.13e-7	Morning vs. evening chronotype;
CESC	cis	rs2404602	0.716	rs1588961	chr15:76752698	A/G	cg22467129	chr15:76604101	ETFA	-0.38	-5.81	-0.34	1.81e-8	Blood metabolite levels;
CESC	trans	rs2085496	0.764	rs1596751	chr2:193807860	A/G	cg02013274	chr2:28614438	FOSL2	0.46	6.19	0.36	2.29e-9	Neuroticism;
CESC	cis	rs2276314	0.857	rs3737474	chr18:33613595	T/C	cg19628046	chr18:33552617	C18orf21	0.51	5.61	0.33	5.16e-8	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs7959452	0.590	rs11177643	chr12:69785712	T/G	cg22834771	chr12:69754056	YEATS4	-0.48	-6.48	-0.37	4.41e-10	Blood protein levels;
CESC	cis	rs4689388	0.581	rs1801212	chr4:6302519	C/T	cg14416269	chr4:6271139	WFS1	0.39	5.31	0.31	2.38e-7	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs6952808	0.825	rs34922657	chr7:1938655	C/T	cg02951883	chr7:2050386	MAD1L1	-0.48	-6.42	-0.37	6.35e-10	Bipolar disorder and schizophrenia;
CESC	cis	rs9300255	0.602	rs1716160	chr12:123700225	C/T	cg00376283	chr12:123451042	ABCB9	0.7	8.83	0.48	1.45e-16	Neutrophil percentage of white cells;
CESC	cis	rs7552404	0.961	rs1061337	chr1:76227022	A/G	cg22875332	chr1:76189707	ACADM	0.59	6.71	0.38	1.15e-10	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs2235642	0.785	rs1057983	chr16:1660274	A/G	cg03771183	chr16:1608904	IFT140	0.36	5.11	0.3	6.24e-7	Coronary artery disease;
CESC	cis	rs1670533	1.000	rs4690215	chr4:1054619	G/C	cg04106633	chr4:1044584	NA	0.41	5.2	0.3	4.01e-7	Recombination rate (females);
CESC	cis	rs9811920	0.609	rs6809988	chr3:99656615	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.61	-9.63	-0.51	5.16e-19	Axial length;
CESC	cis	rs765787	0.530	rs1706831	chr15:45516230	T/C	cg24006582	chr15:45444508	DUOX1	-0.58	-7.12	-0.4	1.04e-11	Uric acid levels;
CESC	cis	rs9633740	0.773	rs7080009	chr10:82269461	T/C	cg00277334	chr10:82204260	NA	-0.58	-5.78	-0.33	2.15e-8	Post bronchodilator FEV1;
CESC	cis	rs16854884	0.586	rs4616638	chr3:143735423	A/T	cg01302019	chr3:143689584	C3orf58	0.32	5.15	0.3	5.12e-7	Economic and political preferences (feminism/equality);
CESC	cis	rs801193	0.569	rs35070132	chr7:66238083	C/T	cg11764359	chr7:65958608	NA	0.69	9.56	0.51	8.26e-19	Aortic root size;
CESC	trans	rs11039798	1.000	rs12223271	chr11:48417420	G/C	cg15704280	chr7:45808275	SEPT13	0.68	6.21	0.36	2.09e-9	Axial length;
CESC	cis	rs13191362	0.938	rs13213746	chr6:163167777	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.66	6.92	0.39	3.46e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs2180341	0.781	rs7742161	chr6:127571676	T/C	cg24812749	chr6:127587940	RNF146	0.84	11.79	0.59	4.34e-26	Breast cancer;
CESC	cis	rs7412746	0.658	rs4537557	chr1:150734436	A/G	cg22823121	chr1:150693482	HORMAD1	0.47	6.51	0.37	3.7e-10	Melanoma;
CESC	cis	rs9911578	0.935	rs34523895	chr17:57034095	T/C	cg12560992	chr17:57184187	TRIM37	0.81	12.8	0.62	1.55e-29	Intelligence (multi-trait analysis);
CESC	cis	rs7665939	1.000	rs72709206	chr4:190109171	T/C	cg14840187	chr4:190284988	NA	-0.83	-6.89	-0.39	3.99e-11	Amyotrophic lateral sclerosis;
CESC	trans	rs7107217	1.000	rs1873872	chr11:129473993	A/T	cg25266327	chr19:16435660	KLF2	0.44	6.08	0.35	4.08e-9	Breast cancer;Type 2 diabetes;
CESC	cis	rs2108225	0.900	rs4518594	chr7:107451060	G/C	cg18560240	chr7:107437656	SLC26A3	-0.4	-5.31	-0.31	2.34e-7	Ulcerative colitis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00345792	chr1:27877772	AHDC1	-0.51	-6.0	-0.35	6.37e-9	Gut microbiome composition (summer);
CESC	cis	rs7148979	1	rs7148979	chr14:74547318	T/A	cg05179529	chr14:74551516	LIN52;ALDH6A1	0.56	5.19	0.3	4.19e-7	Red cell distribution width;
CESC	cis	rs1707322	0.964	rs7546237	chr1:46285610	A/C	cg03146154	chr1:46216737	IPP	0.72	9.84	0.52	1.14e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs61931739	0.500	rs11053197	chr12:34441949	C/T	cg26384229	chr12:38710491	ALG10B	0.69	10.44	0.54	1.34e-21	Morning vs. evening chronotype;
CESC	cis	rs4835473	0.643	rs34680080	chr4:144718443	A/C	cg25736465	chr4:144833511	NA	-0.36	-5.69	-0.33	3.37e-8	Immature fraction of reticulocytes;
CESC	trans	rs7089973	0.523	rs6585311	chr10:116733575	T/C	cg17463145	chr7:79084011	MAGI2	0.31	6.1	0.35	3.75e-9	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs6831352	0.918	rs29001201	chr4:100053861	T/C	cg12011299	chr4:100065546	ADH4	-0.6	-6.61	-0.38	2.1e-10	Alcohol dependence;
CESC	cis	rs400736	0.860	rs2294890	chr1:8086527	T/G	cg25007680	chr1:8021821	PARK7	0.73	10.32	0.54	3.29e-21	Response to antidepressants and depression;
CESC	cis	rs9291683	0.595	rs11731110	chr4:10037346	T/C	cg11266682	chr4:10021025	SLC2A9	0.7	13.8	0.65	5.02e-33	Bone mineral density;
CESC	cis	rs9900062	0.586	rs35018407	chr17:62690181	A/C	cg02598441	chr17:62777298	LOC146880	-0.62	-6.88	-0.39	4.43e-11	QT interval;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20252016	chr11:64851499	CDCA5;ZFPL1	0.66	8.04	0.44	3.03e-14	Gut microbiome composition (summer);
CESC	cis	rs698833	0.926	rs1067399	chr2:44678648	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.45	5.72	0.33	2.82e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	trans	rs7618501	1.000	rs11130221	chr3:49819102	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.59	8.41	0.46	2.54e-15	Intelligence (multi-trait analysis);
CESC	cis	rs561341	0.709	rs11542477	chr17:30185892	A/G	cg00745463	chr17:30367425	LRRC37B	0.6	5.57	0.32	6.21e-8	Hip circumference adjusted for BMI;
CESC	cis	rs2404602	0.692	rs12911902	chr15:77053575	T/C	cg26408565	chr15:76604113	ETFA	-0.38	-5.52	-0.32	8.03e-8	Blood metabolite levels;
CESC	cis	rs854765	0.663	rs16960744	chr17:17755259	A/G	cg16928487	chr17:17741425	SREBF1	0.61	11.4	0.57	9.47e-25	Total body bone mineral density;
CESC	cis	rs3105593	0.933	rs7174839	chr15:50889624	G/C	cg08437265	chr15:50716283	USP8	0.4	5.17	0.3	4.54e-7	QT interval;
CESC	cis	rs2836974	0.897	rs7280375	chr21:40552408	C/T	cg27266027	chr21:40555129	PSMG1	-0.43	-5.4	-0.32	1.46e-7	Cognitive function;
CESC	cis	rs9902453	1.000	rs4328498	chr17:28344276	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.63	-8.02	-0.44	3.47e-14	Coffee consumption (cups per day);
CESC	cis	rs875971	1.000	rs875971	chr7:65617595	A/G	cg12463550	chr7:65579703	CRCP	-0.57	-7.32	-0.41	2.98e-12	Aortic root size;
CESC	cis	rs853679	0.517	rs9357066	chr6:28129831	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.57	-6.49	-0.37	4.32e-10	Depression;
CESC	cis	rs9487051	0.714	rs7757347	chr6:109633815	G/A	cg12927641	chr6:109611667	NA	-0.37	-5.41	-0.32	1.4e-7	Reticulocyte fraction of red cells;
CESC	cis	rs7267979	0.903	rs6115101	chr20:25229564	C/A	cg08601574	chr20:25228251	PYGB	0.42	5.91	0.34	1.08e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs8177253	0.761	rs13079426	chr3:133522334	A/G	cg18769074	chr3:133464867	TF	0.29	5.08	0.3	7.13e-7	Iron status biomarkers;
CESC	cis	rs1733410	0.504	rs11181874	chr12:37912890	C/A	cg26384229	chr12:38710491	ALG10B	-0.54	-7.66	-0.43	3.57e-13	Morning vs. evening chronotype;
CESC	cis	rs561341	0.941	rs501773	chr17:30314435	T/G	cg19193384	chr17:30244184	NA	-0.6	-6.35	-0.36	9.57e-10	Hip circumference adjusted for BMI;
CESC	cis	rs1152591	0.729	rs1255988	chr14:64657684	C/A	cg21174375	chr14:64681225	SYNE2	0.48	6.44	0.37	5.57e-10	Atrial fibrillation;
CESC	cis	rs116095464	0.558	rs12173244	chr5:269524	G/A	cg12570787	chr5:219185	SDHA;CCDC127	0.52	5.45	0.32	1.14e-7	Breast cancer;
CESC	cis	rs804280	0.662	rs11784693	chr8:11610674	C/T	cg26752888	chr8:11627280	NEIL2	0.58	5.73	0.33	2.77e-8	Myopia (pathological);
CESC	cis	rs2603127	0.768	rs1348998	chr3:108485200	G/A	cg03329597	chr3:108125523	MYH15	0.6	5.38	0.31	1.62e-7	Hemostatic factors and hematological phenotypes;
CESC	cis	rs2997447	0.761	rs61776616	chr1:26455812	C/T	cg24596570	chr1:26146463	FAM54B;LOC646471	0.62	5.41	0.32	1.44e-7	QRS complex (12-leadsum);
CESC	cis	rs6665290	0.901	rs61834001	chr1:227197411	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.22	-33.0	-0.9	7.42e-96	Myeloid white cell count;
CESC	cis	rs3092073	0.624	rs11696623	chr20:44580380	C/T	cg27529037	chr20:44575021	PCIF1	0.63	9.61	0.51	5.92e-19	Intelligence (multi-trait analysis);
CESC	cis	rs71403859	0.502	rs12919417	chr16:71579711	A/G	cg08717414	chr16:71523259	ZNF19	0.68	6.24	0.36	1.7e-9	Post bronchodilator FEV1;
CESC	cis	rs2996428	0.667	rs7538067	chr1:3761772	C/T	cg13057898	chr1:3703894	LRRC47	0.45	6.07	0.35	4.47e-9	Red cell distribution width;
CESC	cis	rs7267979	1.000	rs4813566	chr20:25386465	G/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.88	-18.14	-0.74	2.39e-48	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs910316	1.000	rs4322591	chr14:75600697	C/T	cg16144293	chr14:75469539	EIF2B2	-0.39	-5.13	-0.3	5.63e-7	Height;
CESC	cis	rs4665809	0.652	rs11685594	chr2:26402846	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.06	-12.59	-0.61	8.63e-29	Gut microbiome composition (summer);
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg13805052	chr1:2283063	LOC100129534;MORN1	-0.42	-6.15	-0.35	2.78e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs2243480	1.000	rs13220979	chr7:65363204	G/A	cg12463550	chr7:65579703	CRCP	0.69	5.62	0.33	4.79e-8	Diabetic kidney disease;
CESC	cis	rs7824557	0.591	rs2736282	chr8:11225480	C/T	cg21775007	chr8:11205619	TDH	0.58	8.74	0.47	2.77e-16	Retinal vascular caliber;
CESC	cis	rs67311347	0.956	rs6771527	chr3:40506548	T/C	cg24209194	chr3:40518798	ZNF619	-0.54	-7.1	-0.4	1.13e-11	Renal cell carcinoma;
CESC	cis	rs7552404	0.960	rs4949877	chr1:76201668	C/G	cg03433033	chr1:76189801	ACADM	0.7	8.54	0.46	1.05e-15	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs4665809	0.878	rs892448	chr2:26366205	A/G	cg08470875	chr2:26401718	FAM59B	-0.54	-6.15	-0.35	2.83e-9	Gut microbiome composition (summer);
CESC	cis	rs12477438	0.520	rs11123766	chr2:99780915	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	15.41	0.69	1.09e-38	Chronic sinus infection;
CESC	trans	rs2115172	0.836	rs4835799	chr5:122762229	A/G	cg06666157	chr19:4791552	FEM1A	0.48	6.33	0.36	1.07e-9	Weight;
CESC	cis	rs4819052	0.851	rs2838843	chr21:46669284	T/C	cg11663144	chr21:46675770	NA	-0.65	-10.21	-0.53	7.65e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs2836974	0.563	rs997147	chr21:40695325	A/G	cg22974920	chr21:40686053	BRWD1	-0.43	-5.21	-0.3	3.85e-7	Cognitive function;
CESC	cis	rs12497850	0.864	rs6779394	chr3:49157771	G/A	cg07636037	chr3:49044803	WDR6	1.06	18.45	0.75	1.91e-49	Parkinson's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11141156	chr1:15251288	KIAA1026	0.63	7.04	0.4	1.64e-11	Gut microbiome composition (summer);
CESC	cis	rs1552244	0.882	rs56224841	chr3:10044014	A/C	cg00166722	chr3:10149974	C3orf24	0.48	5.92	0.34	1.01e-8	Alzheimer's disease;
CESC	cis	rs34779708	0.931	rs2384283	chr10:35326789	G/A	cg03585969	chr10:35415529	CREM	0.77	10.16	0.53	1.1e-20	Inflammatory bowel disease;Crohn's disease;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg19243777	chr12:26278767	BHLHE41	0.5	6.7	0.38	1.28e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs898097	0.841	rs8180	chr17:80901036	C/G	cg10494973	chr17:80897199	TBCD	-0.43	-5.11	-0.3	6.09e-7	Breast cancer;
CESC	cis	rs1707322	0.752	rs28623463	chr1:46170758	A/C	cg05343316	chr1:45956843	TESK2	0.51	6.32	0.36	1.09e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs10876993	0.728	rs1082503	chr12:58036717	G/A	cg18357645	chr12:58087776	OS9	0.59	9.2	0.49	1.09e-17	Celiac disease or Rheumatoid arthritis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15092368	chr1:143270427	NA	-0.46	-6.22	-0.36	1.91e-9	Gut microbiome composition (summer);
CESC	cis	rs9894429	0.966	rs10871499	chr17:79589006	G/A	cg21984481	chr17:79567631	NPLOC4	-0.49	-8.03	-0.44	3.13e-14	Eye color traits;
CESC	cis	rs11625487	0.609	rs74063206	chr14:77981045	C/T	cg20045696	chr14:77926864	AHSA1	-0.71	-5.59	-0.32	5.54e-8	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
CESC	cis	rs11168351	0.591	rs4258439	chr12:48468652	A/G	cg24011408	chr12:48396354	COL2A1	-0.5	-8.24	-0.45	7.74e-15	Bipolar disorder and schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02184819	chr13:103249272	TPP2	0.58	6.94	0.39	2.95e-11	Gut microbiome composition (summer);
CESC	cis	rs17608059	0.566	rs6502327	chr17:13946187	T/C	cg11395062	chr17:14139857	CDRT15	0.46	5.7	0.33	3.11e-8	Temperament;
CESC	cis	rs2997447	0.846	rs55912918	chr1:26409801	C/T	cg24596570	chr1:26146463	FAM54B;LOC646471	0.61	5.22	0.31	3.57e-7	QRS complex (12-leadsum);
CESC	cis	rs6547741	0.935	rs12615690	chr2:27851120	T/C	cg27432699	chr2:27873401	GPN1	0.49	6.78	0.38	7.67e-11	Oral cavity cancer;
CESC	cis	rs2204008	0.627	rs10878486	chr12:38148601	T/G	cg26384229	chr12:38710491	ALG10B	0.74	10.58	0.55	4.66e-22	Bladder cancer;
CESC	cis	rs1483890	0.723	rs13061189	chr3:69411453	T/C	cg22125112	chr3:69402811	FRMD4B	0.39	5.24	0.31	3.3e-7	Resting heart rate;
CESC	cis	rs7336332	0.598	rs74563672	chr13:28010660	A/G	cg01674679	chr13:27998804	GTF3A	-0.58	-5.34	-0.31	2.04e-7	Weight;
CESC	cis	rs17376456	0.825	rs10061377	chr5:93174513	T/C	cg21475434	chr5:93447410	FAM172A	0.82	7.32	0.41	2.97e-12	Diabetic retinopathy;
CESC	cis	rs2075371	0.966	rs1619682	chr7:133996703	T/G	cg00033643	chr7:134001901	SLC35B4	0.44	5.6	0.33	5.38e-8	Mean platelet volume;
CESC	cis	rs9399401	0.633	rs1329705	chr6:142753338	G/A	cg03128060	chr6:142623767	GPR126	0.38	6.31	0.36	1.18e-9	Chronic obstructive pulmonary disease;
CESC	cis	rs7937682	0.737	rs663763	chr11:111422217	C/T	cg22437258	chr11:111473054	SIK2	0.61	7.58	0.42	5.87e-13	Primary sclerosing cholangitis;
CESC	cis	rs4713118	0.512	rs2622319	chr6:28120401	G/C	cg23161317	chr6:28129485	ZNF389	0.4	5.6	0.33	5.45e-8	Parkinson's disease;
CESC	cis	rs7044106	0.762	rs1411158	chr9:123464804	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.7	10.15	0.53	1.2e-20	Hip circumference adjusted for BMI;
CESC	cis	rs12912251	0.591	rs10520103	chr15:39006243	C/G	cg10631289	chr15:39006617	NA	0.49	5.22	0.31	3.62e-7	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00197636	chr8:57906363	IMPAD1	0.63	7.27	0.41	4.03e-12	Gut microbiome composition (summer);
CESC	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg04025307	chr7:1156635	C7orf50	0.42	5.85	0.34	1.47e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07208322	chr5:177027175	B4GALT7	0.67	7.45	0.42	1.29e-12	Gut microbiome composition (summer);
CESC	cis	rs3785574	0.962	rs114027117	chr17:61939935	T/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.58	7.3	0.41	3.38e-12	Height;
CESC	cis	rs3796352	1.000	rs34313969	chr3:52995166	A/G	cg12962167	chr3:53033115	SFMBT1	0.62	5.13	0.3	5.63e-7	Immune reponse to smallpox (secreted IL-2);
CESC	cis	rs826838	0.709	rs4882355	chr12:38721462	A/T	cg26384229	chr12:38710491	ALG10B	0.57	7.96	0.44	4.99e-14	Heart rate;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11387286	chr7:35077706	DPY19L1	0.57	6.45	0.37	5.26e-10	Gut microbiome composition (summer);
CESC	cis	rs9549367	0.713	rs4907593	chr13:113830459	C/T	cg00898013	chr13:113819073	PROZ	0.46	6.93	0.39	3.13e-11	Platelet distribution width;
CESC	cis	rs7605827	0.930	rs11680044	chr2:15607103	T/G	cg19274914	chr2:15703543	NA	0.35	6.13	0.35	3.19e-9	Educational attainment (years of education);
CESC	cis	rs2295499	0.833	rs1913448	chr4:2708814	G/A	cg08330972	chr4:2403930	ZFYVE28	-0.33	-5.54	-0.32	7.33e-8	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
CESC	cis	rs10479542	0.784	rs7703730	chr5:178986632	C/A	cg21226059	chr5:178986404	RUFY1	-0.46	-6.83	-0.39	5.77e-11	Lung cancer;
CESC	cis	rs875971	0.830	rs6950137	chr7:65976610	G/A	cg18252515	chr7:66147081	NA	-0.43	-5.62	-0.33	4.9e-8	Aortic root size;
CESC	cis	rs9911578	0.967	rs2643124	chr17:56741672	T/C	cg05425664	chr17:57184151	TRIM37	-0.53	-7.36	-0.41	2.27e-12	Intelligence (multi-trait analysis);
CESC	cis	rs9790314	1.000	rs336591	chr3:161078080	A/G	cg03342759	chr3:160939853	NMD3	-0.46	-6.03	-0.35	5.48e-9	Morning vs. evening chronotype;
CESC	cis	rs13191362	0.872	rs35672319	chr6:163245464	C/A	cg21926612	chr6:163149169	PACRG;PARK2	0.63	6.16	0.35	2.66e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs1008375	0.966	rs1860591	chr4:17577329	A/G	cg16339924	chr4:17578868	LAP3	0.63	8.06	0.44	2.58e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs8141529	0.748	rs5762874	chr22:29269658	C/G	cg15103426	chr22:29168792	CCDC117	0.61	8.04	0.44	2.98e-14	Lymphocyte counts;
CESC	cis	rs2033711	0.837	rs3764535	chr19:58929052	G/A	cg13877915	chr19:58951672	ZNF132	0.39	5.6	0.33	5.28e-8	Uric acid clearance;
CESC	cis	rs9354308	0.933	rs2814131	chr6:66562051	T/A	cg07460842	chr6:66804631	NA	0.66	7.52	0.42	8.27e-13	Metabolite levels;
CESC	cis	rs897080	0.552	rs1068714	chr2:44634063	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	5.91	0.34	1.07e-8	Height;
CESC	cis	rs2795502	0.873	rs2077626	chr10:43410962	A/G	cg20628663	chr10:43360327	NA	0.55	6.29	0.36	1.28e-9	Blood protein levels;
CESC	cis	rs7296418	0.883	rs1727312	chr12:123642220	G/T	cg05973401	chr12:123451056	ABCB9	0.53	6.86	0.39	4.86e-11	Platelet count;
CESC	cis	rs7412746	0.597	rs868751	chr1:150669414	T/G	cg22823121	chr1:150693482	HORMAD1	0.47	7.03	0.4	1.79e-11	Melanoma;
CESC	cis	rs9457247	1.000	rs404222	chr6:167402150	G/A	cg23791538	chr6:167370224	RNASET2	-0.56	-8.02	-0.44	3.42e-14	Crohn's disease;
CESC	cis	rs10781543	0.776	rs4378078	chr9:139375962	A/G	cg14019695	chr9:139328340	INPP5E	0.38	5.77	0.33	2.22e-8	Monocyte percentage of white cells;
CESC	cis	rs1728785	0.901	rs11075687	chr16:68655894	T/C	cg02972257	chr16:68554789	NA	-0.67	-7.31	-0.41	3.17e-12	Ulcerative colitis;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg19296153	chr4:1232112	CTBP1	0.45	6.16	0.35	2.72e-9	Fibrinogen levels;
CESC	cis	rs3092073	0.624	rs34293711	chr20:44587186	C/T	cg00981651	chr20:44574847	PCIF1	0.36	5.44	0.32	1.24e-7	Intelligence (multi-trait analysis);
CESC	cis	rs34891900	0.507	rs2587084	chr22:18140644	T/G	cg19898043	chr22:18121309	BCL2L13	0.58	6.87	0.39	4.45e-11	Sum neutrophil eosinophil counts;
CESC	cis	rs151227923	1	rs151227923	chr7:155106564	C/T	cg04811098	chr7:155088454	INSIG1	0.4	5.91	0.34	1.04e-8	Stem cell growth factor beta levels;
CESC	cis	rs9486715	0.790	rs2971602	chr6:97022468	C/T	cg18709589	chr6:96969512	KIAA0776	-0.47	-6.63	-0.38	1.92e-10	Headache;
CESC	cis	rs1008375	0.931	rs7672369	chr4:17604825	A/G	cg16339924	chr4:17578868	LAP3	0.65	8.49	0.46	1.47e-15	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs1218582	0.651	rs4845396	chr1:154828409	A/G	cg06221963	chr1:154839813	KCNN3	0.4	6.17	0.35	2.55e-9	Prostate cancer;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg24304658	chr2:26950770	KCNK3	0.53	7.39	0.41	1.9e-12	Fibrinogen levels;
CESC	cis	rs1729951	0.575	rs1682333	chr3:136688618	G/A	cg04103450	chr3:136751342	NA	0.4	5.28	0.31	2.64e-7	Neuroticism;
CESC	cis	rs9457247	0.637	rs9459846	chr6:167441023	T/G	cg07741184	chr6:167504864	NA	0.34	6.01	0.35	6.21e-9	Crohn's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13665852	chr10:13146898	OPTN	-0.62	-7.05	-0.4	1.53e-11	Gut microbiome composition (summer);
CESC	cis	rs9488822	0.636	rs6937104	chr6:116375302	A/G	cg05304507	chr6:116381966	FRK	0.26	6.8	0.39	6.77e-11	Cholesterol, total;LDL cholesterol;
CESC	cis	rs933688	1.000	rs985434	chr5:90744509	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.95	11.04	0.56	1.47e-23	Smoking behavior;
CESC	cis	rs4689592	0.503	rs4689064	chr4:7055603	A/G	cg06697600	chr4:7070879	GRPEL1	0.53	6.95	0.39	2.84e-11	Monocyte percentage of white cells;
CESC	cis	rs6499129	1.000	rs55966046	chr16:67466726	C/A	cg26727032	chr16:67993705	SLC12A4	-0.54	-5.68	-0.33	3.59e-8	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs7397814	0.558	rs4764447	chr12:9579109	C/T	cg08997352	chr12:9597637	DDX12	-0.44	-5.28	-0.31	2.67e-7	IgG glycosylation;
CESC	cis	rs2718058	0.519	rs2598072	chr7:37875319	A/C	cg15028436	chr7:37888078	TXNDC3	0.57	7.76	0.43	1.9e-13	Alzheimer's disease (late onset);
CESC	cis	rs752092	1.000	rs11247277	chr15:101784664	A/G	cg19997662	chr15:101784653	CHSY1	-0.57	-7.76	-0.43	1.81e-13	Corneal structure;
CESC	cis	rs11098499	0.863	rs6534141	chr4:120485223	A/T	cg24375607	chr4:120327624	NA	0.44	5.38	0.31	1.6e-7	Corneal astigmatism;
CESC	cis	rs4808199	0.895	rs8105984	chr19:19374068	T/C	cg03709012	chr19:19516395	GATAD2A	1.09	11.63	0.58	1.52e-25	Nonalcoholic fatty liver disease;
CESC	trans	rs4424809	0.614	rs17078995	chr13:85572394	G/A	cg05918002	chr17:5019452	ZNF232	-0.63	-6.08	-0.35	4.29e-9	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs6430585	0.527	rs12467569	chr2:136413847	T/C	cg07169764	chr2:136633963	MCM6	1.06	12.14	0.6	2.95e-27	Corneal structure;
CESC	cis	rs1062177	1.000	rs62394155	chr5:151248069	G/A	cg12924095	chr5:151150029	G3BP1	0.47	5.97	0.34	7.46e-9	Preschool internalizing problems;
CESC	cis	rs9303401	0.614	rs12948536	chr17:56580413	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.01	12.14	0.6	2.94e-27	Cognitive test performance;
CESC	cis	rs7072216	0.763	rs2274243	chr10:100175267	T/C	cg26618903	chr10:100175079	PYROXD2	-0.38	-5.85	-0.34	1.41e-8	Metabolite levels;
CESC	cis	rs875971	0.545	rs316324	chr7:65610614	A/G	cg25405998	chr7:65216604	CCT6P1	-0.45	-5.06	-0.3	7.71e-7	Aortic root size;
CESC	cis	rs1577917	0.629	rs7761762	chr6:86205968	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.48	7.02	0.4	1.91e-11	Response to antipsychotic treatment;
CESC	cis	rs7618915	0.501	rs13085775	chr3:52678370	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.61	8.8	0.48	1.77e-16	Bipolar disorder;
CESC	cis	rs10861342	1.000	rs10861350	chr12:105484913	G/A	cg23923672	chr12:105501055	KIAA1033	0.71	5.31	0.31	2.29e-7	IgG glycosylation;
CESC	trans	rs61931739	0.500	rs34167298	chr12:34534338	G/A	cg13010199	chr12:38710504	ALG10B	0.51	6.58	0.37	2.47e-10	Morning vs. evening chronotype;
CESC	cis	rs2404602	0.583	rs12438741	chr15:76542114	C/A	cg22467129	chr15:76604101	ETFA	-0.39	-6.12	-0.35	3.39e-9	Blood metabolite levels;
CESC	cis	rs875971	0.862	rs2420173	chr7:65645399	A/T	cg11764359	chr7:65958608	NA	-0.78	-11.43	-0.57	7.35e-25	Aortic root size;
CESC	cis	rs1499614	1.000	rs1267818	chr7:66107024	C/T	cg13147721	chr7:65941812	NA	-0.91	-8.45	-0.46	1.99e-15	Gout;
CESC	cis	rs9859260	0.744	rs539816	chr3:195784076	T/A	cg12923728	chr3:195709715	SDHAP1	0.54	6.96	0.39	2.68e-11	Mean corpuscular volume;
CESC	cis	rs2303759	0.709	rs10411679	chr19:49826480	A/T	cg22307029	chr19:49891270	CCDC155	0.55	6.0	0.35	6.6e-9	Multiple sclerosis;
CESC	cis	rs7945705	0.935	rs2568061	chr11:8886260	A/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.38	-6.41	-0.37	6.46e-10	Hemoglobin concentration;
CESC	cis	rs4975709	0.686	rs2307118	chr5:1881916	A/C	cg12288994	chr5:1860383	NA	0.36	5.71	0.33	3.07e-8	Cardiovascular disease risk factors;
CESC	cis	rs9894429	0.505	rs35570626	chr17:79611084	A/G	cg13777783	chr17:79615861	NA	-0.37	-6.2	-0.36	2.14e-9	Eye color traits;
CESC	cis	rs2228479	0.702	rs11649501	chr16:89850957	A/T	cg00800038	chr16:89945340	TCF25	-0.91	-7.52	-0.42	8.29e-13	Skin colour saturation;
CESC	cis	rs9549367	0.577	rs513479	chr13:113815200	C/T	cg18105134	chr13:113819100	PROZ	-0.77	-8.58	-0.47	8.02e-16	Platelet distribution width;
CESC	cis	rs651907	0.535	rs34648996	chr3:101511202	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.43	5.67	0.33	3.81e-8	Colorectal cancer;
CESC	cis	rs1348850	0.914	rs8941	chr2:178406481	C/T	cg22681709	chr2:178499509	PDE11A	-0.41	-5.92	-0.34	1e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs11153306	0.552	rs12196381	chr6:111939400	A/C	cg22127309	chr6:111907043	TRAF3IP2	0.43	6.52	0.37	3.57e-10	Tonsillectomy;
CESC	cis	rs1538970	0.504	rs3790585	chr1:46023356	A/T	cg03146154	chr1:46216737	IPP	0.66	7.03	0.4	1.77e-11	Platelet count;
CESC	cis	rs2274273	0.624	rs8003279	chr14:55864130	A/G	cg04306507	chr14:55594613	LGALS3	0.3	5.25	0.31	3.19e-7	Protein biomarker;
CESC	cis	rs6933660	0.720	rs6914656	chr6:151753421	C/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.5	-6.67	-0.38	1.5e-10	Menarche (age at onset);
CESC	cis	rs1577917	0.958	rs12665542	chr6:86544443	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-6.19	-0.36	2.23e-9	Response to antipsychotic treatment;
CESC	cis	rs9457247	0.765	rs6904946	chr6:167433948	C/T	cg23791538	chr6:167370224	RNASET2	0.54	7.5	0.42	9.9e-13	Crohn's disease;
CESC	cis	rs28386778	0.701	rs2727337	chr17:61991966	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.51	-6.42	-0.37	6.18e-10	Prudent dietary pattern;
CESC	cis	rs7582720	1.000	rs6723704	chr2:203738664	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.32	0.41	3.04e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	trans	rs61931739	0.517	rs1817760	chr12:34106060	A/G	cg26384229	chr12:38710491	ALG10B	0.59	8.18	0.45	1.17e-14	Morning vs. evening chronotype;
CESC	cis	rs7264396	0.709	rs2425073	chr20:34293699	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.63	7.61	0.42	4.66e-13	Total cholesterol levels;
CESC	cis	rs4699052	0.625	rs11734836	chr4:104253203	G/A	cg16532752	chr4:104119610	CENPE	-0.39	-5.47	-0.32	1.02e-7	Testicular germ cell tumor;
CESC	cis	rs1559088	1.000	rs1559088	chr19:33551061	C/T	cg27124370	chr19:33622961	WDR88	0.43	5.37	0.31	1.71e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs6815814	0.898	rs5743562	chr4:38806096	T/C	cg02016764	chr4:38805732	TLR1	-0.63	-7.26	-0.41	4.22e-12	Breast cancer;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg01136232	chr1:25756842	TMEM57	0.45	6.8	0.39	6.84e-11	Gambling;
CESC	cis	rs9486719	0.843	rs976357	chr6:96849679	C/T	cg18709589	chr6:96969512	KIAA0776	0.55	5.67	0.33	3.72e-8	Migraine;Coronary artery disease;
CESC	cis	rs7560272	0.538	rs11126415	chr2:73936500	C/T	cg20560298	chr2:73613845	ALMS1	0.42	5.8	0.34	1.87e-8	Schizophrenia;
CESC	cis	rs1552244	0.938	rs67667957	chr3:10167264	G/C	cg08888203	chr3:10149979	C3orf24	0.45	5.91	0.34	1.06e-8	Alzheimer's disease;
CESC	cis	rs17826219	0.714	rs11650821	chr17:28968150	T/C	cg13385521	chr17:29058706	SUZ12P	0.75	5.43	0.32	1.27e-7	Body mass index;
CESC	cis	rs172166	0.637	rs1225592	chr6:28150242	G/A	cg23281280	chr6:28129359	ZNF389	0.4	5.95	0.34	8.58e-9	Cardiac Troponin-T levels;
CESC	cis	rs523522	0.962	rs7471	chr12:120941215	T/C	cg27279351	chr12:120934652	DYNLL1	0.69	9.07	0.49	2.84e-17	High light scatter reticulocyte count;
CESC	cis	rs782590	0.764	rs2586970	chr2:55829967	A/G	cg18811423	chr2:55921094	PNPT1	0.77	12.1	0.6	4.01e-27	Metabolic syndrome;
CESC	cis	rs561341	0.882	rs563539	chr17:30307958	A/G	cg19193384	chr17:30244184	NA	-0.59	-6.17	-0.35	2.51e-9	Hip circumference adjusted for BMI;
CESC	cis	rs4561483	0.743	rs28653099	chr16:12009150	C/A	cg08843971	chr16:11963173	GSPT1	0.46	6.45	0.37	5.31e-10	Testicular germ cell tumor;
CESC	cis	rs873946	0.529	rs12258248	chr10:134573767	A/G	cg18305652	chr10:134549665	INPP5A	0.49	7.17	0.4	7.3e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs4727027	0.901	rs66800495	chr7:148763702	T/C	cg23158103	chr7:148848205	ZNF398	-0.41	-6.47	-0.37	4.66e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs4973397	0.765	rs13025087	chr2:232264914	A/C	cg09339159	chr2:232260559	B3GNT7	-0.56	-5.85	-0.34	1.47e-8	Anti-saccade response;
CESC	cis	rs4819052	0.851	rs2838836	chr21:46665875	G/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.48	6.02	0.35	5.85e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs9630089	0.746	rs4919084	chr10:98967596	G/A	cg25902810	chr10:99078978	FRAT1	0.56	7.86	0.43	9.47e-14	Neutrophil percentage of white cells;
CESC	cis	rs4713118	0.662	rs9468278	chr6:28028482	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.54	-6.2	-0.36	2.21e-9	Parkinson's disease;
CESC	cis	rs796364	0.906	rs281784	chr2:200749749	T/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.92	8.92	0.48	8.06e-17	Schizophrenia;
CESC	cis	rs7552404	0.924	rs7535991	chr1:76162624	C/T	cg10523679	chr1:76189770	ACADM	0.76	9.99	0.52	3.63e-20	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs7666738	0.830	rs13116691	chr4:98929771	A/C	cg05340658	chr4:99064831	C4orf37	0.82	12.17	0.6	2.24e-27	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2050392	0.517	rs2771242	chr10:30762973	C/T	cg18806716	chr10:30721971	MAP3K8	-0.57	-8.75	-0.47	2.46e-16	Inflammatory bowel disease;
CESC	cis	rs12079745	0.793	rs12740226	chr1:169183257	T/C	cg09363564	chr1:169337483	NME7;BLZF1	-1.0	-6.14	-0.35	3e-9	QT interval;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg17854747	chr18:29672535	RNF138	0.48	6.22	0.36	1.94e-9	Ulcerative colitis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17465697	chr1:228594029	TRIM11	0.65	7.53	0.42	7.92e-13	Gut microbiome composition (summer);
CESC	cis	rs864537	0.676	rs2988279	chr1:167419839	G/A	cg09179987	chr1:167433047	CD247	0.5	7.45	0.42	1.35e-12	Celiac disease or Rheumatoid arthritis;Celiac disease;
CESC	cis	rs853679	0.517	rs4713144	chr6:28106790	C/G	cg19592336	chr6:28129416	ZNF389	0.61	8.24	0.45	8.13e-15	Depression;
CESC	cis	rs17345786	1.000	rs17345528	chr3:101294830	A/C	cg12386194	chr3:101231763	SENP7	-0.52	-5.82	-0.34	1.68e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11608355	0.545	rs2302704	chr12:109898797	A/G	cg05360138	chr12:110035743	NA	0.82	8.92	0.48	7.93e-17	Neuroticism;
CESC	cis	rs477692	0.569	rs871028	chr10:131293478	C/T	cg05714579	chr10:131428358	MGMT	-0.4	-5.42	-0.32	1.33e-7	Response to temozolomide;
CESC	cis	rs9818941	1.000	rs7429574	chr3:157703589	G/A	cg08654915	chr3:157813417	NA	-0.47	-7.83	-0.43	1.19e-13	Height;
CESC	cis	rs16854884	0.586	rs7634145	chr3:143754150	G/A	cg06585982	chr3:143692056	C3orf58	0.5	6.84	0.39	5.62e-11	Economic and political preferences (feminism/equality);
CESC	cis	rs6942756	0.806	rs2718096	chr7:128951000	A/G	cg02491457	chr7:128862824	NA	0.61	8.58	0.47	8.12e-16	White matter hyperintensity burden;
CESC	cis	rs7552404	0.731	rs5745458	chr1:76345429	G/A	cg10523679	chr1:76189770	ACADM	-0.61	-6.16	-0.35	2.75e-9	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs2652822	1.000	rs1126308	chr15:63429086	G/T	cg02713581	chr15:63449717	RPS27L	-0.57	-7.42	-0.41	1.58e-12	Metabolic traits;
CESC	cis	rs11098499	0.865	rs9994730	chr4:120381564	A/C	cg09307838	chr4:120376055	NA	0.93	12.99	0.62	3.33e-30	Corneal astigmatism;
CESC	cis	rs4665809	1.000	rs6546768	chr2:26328800	A/G	cg25036284	chr2:26402008	FAM59B	-0.59	-6.83	-0.39	5.71e-11	Gut microbiome composition (summer);
CESC	cis	rs1008375	0.902	rs12503164	chr4:17656107	C/T	cg02297831	chr4:17616191	MED28	0.53	6.7	0.38	1.24e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs6089584	0.888	rs6089624	chr20:60619907	C/G	cg13770153	chr20:60521292	NA	-0.44	-5.63	-0.33	4.53e-8	Body mass index;
CESC	cis	rs7618915	0.547	rs4687638	chr3:52651966	A/C	cg18099408	chr3:52552593	STAB1	-0.32	-5.19	-0.3	4.2e-7	Bipolar disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03809994	chr4:75023664	MTHFD2L	0.61	7.04	0.4	1.66e-11	Gut microbiome composition (summer);
CESC	cis	rs4835473	0.932	rs4240334	chr4:144792505	G/A	cg25736465	chr4:144833511	NA	0.44	6.58	0.37	2.48e-10	Immature fraction of reticulocytes;
CESC	cis	rs4713118	0.513	rs149950	chr6:28033039	T/G	cg17221315	chr6:27791827	HIST1H4J	0.42	5.4	0.32	1.46e-7	Parkinson's disease;
CESC	cis	rs13242816	1.000	rs34424131	chr7:116119002	G/A	cg04696780	chr7:116139425	CAV2	-0.58	-5.15	-0.3	5.21e-7	P wave duration;
CESC	cis	rs9487051	0.836	rs9487036	chr6:109607449	C/T	cg01475377	chr6:109611718	NA	-0.51	-8.36	-0.46	3.66e-15	Reticulocyte fraction of red cells;
CESC	cis	rs962856	0.619	rs4671181	chr2:67604847	T/C	cg09028215	chr2:67624308	ETAA1	-0.42	-5.1	-0.3	6.56e-7	Pancreatic cancer;
CESC	cis	rs1046896	0.519	rs9900369	chr17:80829807	G/A	cg02398342	chr17:80708632	TBCD;FN3K	0.42	5.12	0.3	5.86e-7	Glycated hemoglobin levels;
CESC	cis	rs6912958	0.525	rs586771	chr6:88064971	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.72	10.88	0.56	4.8e-23	Monocyte percentage of white cells;
CESC	cis	rs2832191	0.636	rs8131283	chr21:30516796	A/G	cg08807101	chr21:30365312	RNF160	-0.56	-6.39	-0.37	7.28e-10	Dental caries;
CESC	cis	rs743757	1.000	rs2282754	chr3:50436827	T/C	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.45	5.06	0.3	8e-7	Diastolic blood pressure;
CESC	cis	rs2404602	0.679	rs12899871	chr15:76757347	T/C	cg26408565	chr15:76604113	ETFA	-0.43	-6.25	-0.36	1.65e-9	Blood metabolite levels;
CESC	cis	rs853679	0.517	rs9393901	chr6:28136797	A/G	cg12963246	chr6:28129442	ZNF389	0.54	7.12	0.4	1.02e-11	Depression;
CESC	cis	rs7666738	0.830	rs35644814	chr4:98886111	G/C	cg05340658	chr4:99064831	C4orf37	0.74	10.96	0.56	2.72e-23	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6460942	0.915	rs1595800	chr7:12439816	G/A	cg17427002	chr7:12443146	VWDE	-0.58	-6.01	-0.35	6.16e-9	Coronary artery disease;
CESC	cis	rs10751667	0.666	rs10902249	chr11:958566	C/T	cg06064525	chr11:970664	AP2A2	0.49	9.71	0.51	2.81e-19	Alzheimer's disease (late onset);
CESC	cis	rs1401999	0.690	rs1402001	chr3:183642751	A/G	cg01324343	chr3:183735012	ABCC5	0.45	8.84	0.48	1.32e-16	Anterior chamber depth;
CESC	cis	rs1008375	0.966	rs6825133	chr4:17577776	C/T	cg02297831	chr4:17616191	MED28	0.5	6.15	0.35	2.82e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs9435341	0.762	rs2878349	chr1:107549245	G/A	cg09367891	chr1:107599246	PRMT6	0.6	6.6	0.38	2.24e-10	Facial morphology (factor 21, depth of nasal alae);
CESC	cis	rs2228479	0.850	rs11076619	chr16:89831243	C/A	cg14709524	chr16:89940631	TCF25	0.91	6.74	0.38	1e-10	Skin colour saturation;
CESC	cis	rs1559088	0.847	rs6510348	chr19:33601946	G/A	cg17764715	chr19:33622953	WDR88	0.48	6.2	0.36	2.2e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs832540	0.552	rs702681	chr5:56218029	C/T	cg24531977	chr5:56204891	C5orf35	-0.56	-7.02	-0.4	1.81e-11	Coronary artery disease;
CESC	cis	rs6537837	1.000	rs7537507	chr1:110131105	G/A	cg05049280	chr1:110155535	GNAT2	0.39	5.29	0.31	2.55e-7	Major depressive disorder;
CESC	cis	rs2404602	0.692	rs1116535	chr15:77009514	C/G	cg22467129	chr15:76604101	ETFA	0.35	5.34	0.31	1.98e-7	Blood metabolite levels;
CESC	cis	rs7116495	0.609	rs73543640	chr11:71834374	G/T	cg10381502	chr11:71823885	C11orf51	1.06	6.77	0.38	8.27e-11	Severe influenza A (H1N1) infection;
CESC	cis	rs11958404	0.932	rs6870115	chr5:157436960	T/C	cg05962755	chr5:157440814	NA	0.62	6.66	0.38	1.57e-10	IgG glycosylation;
CESC	cis	rs9487051	0.502	rs9386781	chr6:109584520	G/A	cg01475377	chr6:109611718	NA	-0.45	-7.04	-0.4	1.6e-11	Reticulocyte fraction of red cells;
CESC	cis	rs2933343	0.679	rs789221	chr3:128591625	A/G	cg25356066	chr3:128598488	ACAD9	0.56	7.83	0.43	1.15e-13	IgG glycosylation;
CESC	cis	rs6429082	0.902	rs704708	chr1:235620134	T/C	cg26050004	chr1:235667680	B3GALNT2	0.4	5.03	0.3	9.03e-7	Adiposity;
CESC	cis	rs2742234	0.541	rs11528481	chr10:43737767	C/A	cg15436174	chr10:43711423	RASGEF1A	0.45	5.13	0.3	5.72e-7	Hirschsprung disease;
CESC	cis	rs897984	0.721	rs4889525	chr16:30989858	T/C	cg02466173	chr16:30829666	NA	0.47	7.96	0.44	4.96e-14	Dementia with Lewy bodies;
CESC	cis	rs4665809	0.531	rs34081866	chr2:26475940	C/T	cg26314531	chr2:26401878	FAM59B	0.85	9.23	0.49	8.65e-18	Gut microbiome composition (summer);
CESC	cis	rs28489187	0.706	rs233115	chr1:85786977	G/A	cg16011679	chr1:85725395	C1orf52	0.49	5.77	0.33	2.15e-8	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	cis	rs6952808	0.689	rs2008263	chr7:2048335	A/G	cg08027265	chr7:2291960	NA	-0.34	-5.08	-0.3	7.23e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs4835473	0.932	rs12512202	chr4:144692401	A/G	cg25736465	chr4:144833511	NA	-0.33	-5.15	-0.3	5e-7	Immature fraction of reticulocytes;
CESC	cis	rs9787249	0.957	rs11206754	chr1:40216234	A/G	cg24920358	chr1:40204285	PPIE	0.45	6.68	0.38	1.43e-10	Blood protein levels;
CESC	cis	rs6460942	1.000	rs77010200	chr7:12290724	G/A	cg06484146	chr7:12443880	VWDE	-0.77	-8.09	-0.45	2.1e-14	Coronary artery disease;
CESC	trans	rs1814175	0.817	rs10769648	chr11:50013992	T/C	cg03929089	chr4:120376271	NA	-0.94	-16.01	-0.7	7.75e-41	Height;
CESC	cis	rs9796	0.621	rs11858678	chr15:41467932	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.45	-6.61	-0.38	2.06e-10	Menopause (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01320780	chr8:22298453	PPP3CC	0.54	6.21	0.36	2.02e-9	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04363097	chr16:74330294	PSMD7	-0.59	-6.99	-0.39	2.24e-11	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.830	rs34244876	chr4:99031336	G/A	cg18180107	chr4:99064573	C4orf37	0.42	5.43	0.32	1.29e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4819052	0.807	rs28715237	chr21:46673768	C/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.49	6.03	0.35	5.48e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26149728	chr3:119182545	TMEM39A	0.59	6.43	0.37	5.89e-10	Gut microbiome composition (summer);
CESC	cis	rs11785400	1.000	rs7002932	chr8:143738816	C/A	cg24634471	chr8:143751801	JRK	0.47	6.21	0.36	2e-9	Schizophrenia;
CESC	cis	rs6674176	0.593	rs3791120	chr1:44431715	T/C	cg13606994	chr1:44402422	ARTN	-0.39	-5.79	-0.34	1.96e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs7927771	1.000	rs10838738	chr11:47663049	A/G	cg20307385	chr11:47447363	PSMC3	-0.49	-5.9	-0.34	1.11e-8	Subjective well-being;
CESC	cis	rs2204008	0.715	rs11514342	chr12:38236710	T/A	cg13010199	chr12:38710504	ALG10B	0.49	6.1	0.35	3.78e-9	Bladder cancer;
CESC	cis	rs863345	0.967	rs1117124	chr1:158509851	G/C	cg12129480	chr1:158549410	OR10X1	-0.32	-6.37	-0.36	8.16e-10	Pneumococcal bacteremia;
CESC	cis	rs11077998	0.935	rs11653926	chr17:80484953	G/A	cg20173014	chr17:80541737	FOXK2	-0.32	-5.07	-0.3	7.37e-7	Reticulocyte fraction of red cells;
CESC	cis	rs7927771	0.507	rs11039432	chr11:47873327	G/A	cg20307385	chr11:47447363	PSMC3	0.61	8.55	0.47	9.73e-16	Subjective well-being;
CESC	cis	rs17376456	0.877	rs10076052	chr5:93317762	C/T	cg21475434	chr5:93447410	FAM172A	0.76	6.88	0.39	4.31e-11	Diabetic retinopathy;
CESC	cis	rs6860806	0.632	rs4330455	chr5:131586349	T/C	cg18301423	chr5:131593218	PDLIM4	0.38	5.44	0.32	1.21e-7	Breast cancer;
CESC	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.55	0.37	2.91e-10	Prudent dietary pattern;
CESC	cis	rs28374715	0.662	rs521890	chr15:41473143	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.74	-9.83	-0.52	1.25e-19	Ulcerative colitis;
CESC	cis	rs875971	0.790	rs10257911	chr7:65743770	A/G	cg19163074	chr7:65112434	INTS4L2	0.4	5.07	0.3	7.58e-7	Aortic root size;
CESC	cis	rs9815354	0.812	rs73081321	chr3:41890231	G/A	cg03022575	chr3:42003672	ULK4	0.71	6.23	0.36	1.84e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs9479482	0.935	rs563278	chr6:150364427	G/C	cg03788504	chr6:150331562	NA	-0.34	-6.4	-0.37	7.1e-10	Alopecia areata;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16550438	chr11:64112387	CCDC88B	-0.56	-6.38	-0.36	7.84e-10	Gut microbiome composition (summer);
CESC	cis	rs9309473	0.519	rs2421584	chr2:73898852	G/A	cg20560298	chr2:73613845	ALMS1	0.53	7.32	0.41	3.04e-12	Metabolite levels;
CESC	cis	rs425277	0.539	rs3107142	chr1:2044542	T/C	cg24578937	chr1:2090814	PRKCZ	-0.35	-5.97	-0.34	7.43e-9	Height;
CESC	cis	rs5750830	0.546	rs4821891	chr22:39785381	C/T	cg11247378	chr22:39784982	NA	-0.63	-9.73	-0.51	2.44e-19	Intelligence (multi-trait analysis);
CESC	cis	rs3785574	0.962	rs13030	chr17:61908556	C/T	cg07677032	chr17:61819896	STRADA	0.42	5.35	0.31	1.92e-7	Height;
CESC	cis	rs2070997	0.548	rs7868336	chr9:133668926	T/C	cg11464064	chr9:133710261	ABL1	0.5	5.75	0.33	2.48e-8	Response to amphetamines;
CESC	cis	rs9302635	0.513	rs8061459	chr16:72156063	C/T	cg01557791	chr16:72042693	DHODH	-0.57	-6.65	-0.38	1.66e-10	Blood protein levels;
CESC	cis	rs2718058	0.639	rs2718036	chr7:37775288	T/A	cg24998770	chr7:37888106	TXNDC3	0.36	5.41	0.32	1.42e-7	Alzheimer's disease (late onset);
CESC	cis	rs5753618	0.561	rs4820963	chr22:31698166	C/T	cg00478049	chr22:31556069	RNF185	0.45	5.07	0.3	7.58e-7	Colorectal cancer;
CESC	trans	rs1814175	0.817	rs1988416	chr11:49932324	G/A	cg03929089	chr4:120376271	NA	-0.93	-16.26	-0.71	1.03e-41	Height;
CESC	cis	rs6540556	0.769	rs6540552	chr1:209927710	C/T	cg05527609	chr1:210001259	C1orf107	0.51	6.17	0.35	2.55e-9	Red blood cell count;
CESC	cis	rs7605827	0.930	rs6733647	chr2:15542159	A/G	cg19274914	chr2:15703543	NA	0.38	6.87	0.39	4.61e-11	Educational attainment (years of education);
CESC	cis	rs916888	0.687	rs199456	chr17:44797919	C/T	cg01570182	chr17:44337453	NA	0.94	10.66	0.55	2.65e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07213289	chr7:73610504	EIF4H	-0.65	-7.97	-0.44	4.8e-14	Gut microbiome composition (summer);
CESC	cis	rs2842992	0.830	rs1998365	chr6:160179535	A/T	cg11366901	chr6:160182831	ACAT2	0.82	10.46	0.54	1.12e-21	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs561341	0.882	rs28649357	chr17:30367190	A/G	cg12193833	chr17:30244370	NA	-0.49	-5.04	-0.3	8.66e-7	Hip circumference adjusted for BMI;
CESC	cis	rs9902453	0.838	rs8064689	chr17:28217053	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.65	8.13	0.45	1.68e-14	Coffee consumption (cups per day);
CESC	trans	rs12229918	0.540	rs10784460	chr12:65863584	C/T	cg24879327	chr17:8191805	RANGRF;SLC25A35	0.51	6.32	0.36	1.12e-9	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
CESC	cis	rs3820068	0.705	rs4646092	chr1:15821673	C/T	cg18192808	chr1:15853278	DNAJC16	0.47	5.78	0.33	2.05e-8	Systolic blood pressure;
CESC	cis	rs1799949	1.000	rs8176103	chr17:41267050	G/A	cg25072359	chr17:41440525	NA	0.43	5.79	0.34	1.98e-8	Menopause (age at onset);
CESC	cis	rs7582720	1.000	rs72936873	chr2:203791333	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.38	0.41	1.99e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs6669072	0.669	rs712031	chr1:91243395	A/G	cg08895590	chr1:91227319	NA	-0.33	-5.65	-0.33	4.2e-8	Cognitive function;
CESC	cis	rs7301826	0.651	rs6486601	chr12:131301237	A/T	cg11011512	chr12:131303247	STX2	-0.44	-5.28	-0.31	2.65e-7	Plasma plasminogen activator levels;
CESC	cis	rs67311347	0.577	rs11129870	chr3:40260406	G/A	cg09455208	chr3:40491958	NA	0.35	5.5	0.32	8.99e-8	Renal cell carcinoma;
CESC	cis	rs10504229	0.689	rs17801390	chr8:58054768	T/C	cg22535103	chr8:58192502	C8orf71	-0.86	-8.78	-0.47	2.07e-16	Developmental language disorder (linguistic errors);
CESC	cis	rs425277	1.000	rs436045	chr1:2071556	A/G	cg16545954	chr1:2118288	C1orf86	-0.32	-5.46	-0.32	1.1e-7	Height;
CESC	cis	rs539096	0.500	rs2367804	chr1:44314266	C/T	cg13606994	chr1:44402422	ARTN	-0.37	-5.71	-0.33	2.97e-8	Intelligence (multi-trait analysis);
CESC	cis	rs3785574	0.962	rs35448669	chr17:61938923	G/A	cg07677032	chr17:61819896	STRADA	0.43	5.64	0.33	4.44e-8	Height;
CESC	cis	rs400736	0.930	rs442862	chr1:8079494	T/C	cg25007680	chr1:8021821	PARK7	0.71	10.26	0.53	5.13e-21	Response to antidepressants and depression;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg17961057	chr2:74645699	C2orf81	-0.44	-6.09	-0.35	3.85e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02471486	chr8:71016278	NA	-0.63	-7.5	-0.42	9.68e-13	Gut microbiome composition (summer);
CESC	cis	rs17253792	0.822	rs10142757	chr14:56074211	C/A	cg01858014	chr14:56050164	KTN1	-0.85	-6.99	-0.39	2.22e-11	Putamen volume;
CESC	cis	rs6570726	0.935	rs377130	chr6:145836632	C/T	cg23711669	chr6:146136114	FBXO30	0.8	12.02	0.59	7.3e-27	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7833986	0.534	rs2976022	chr8:57007843	T/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.62	7.54	0.42	7.58e-13	Height;
CESC	trans	rs9987353	0.840	rs329994	chr8:9123233	A/G	cg17193163	chr11:66056724	YIF1A	-0.46	-6.08	-0.35	4.24e-9	Recombination measurement;
CESC	cis	rs6426558	0.537	rs12039370	chr1:227326472	A/G	cg10327440	chr1:227177885	CDC42BPA	-0.47	-5.9	-0.34	1.13e-8	Neutrophil percentage of white cells;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02861082	chr2:136633712	MCM6	0.67	8.32	0.46	4.62e-15	Gut microbiome composition (summer);
CESC	cis	rs2559856	1.000	rs2695286	chr12:102088507	T/C	cg15068132	chr12:102092402	CHPT1	-0.42	-5.59	-0.32	5.57e-8	Blood protein levels;
CESC	cis	rs1448094	0.511	rs17280643	chr12:86210154	C/T	cg02569458	chr12:86230093	RASSF9	-0.46	-6.96	-0.39	2.62e-11	Major depressive disorder;
CESC	cis	rs9790314	1.000	rs4350933	chr3:160955879	G/T	cg03342759	chr3:160939853	NMD3	-0.53	-7.32	-0.41	3.03e-12	Morning vs. evening chronotype;
CESC	cis	rs7917772	0.503	rs11191321	chr10:104293412	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.53	7.33	0.41	2.81e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs67340775	0.541	rs200968	chr6:27859568	T/C	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.55	5.24	0.31	3.23e-7	Lung cancer in ever smokers;
CESC	cis	rs4237845	0.837	rs7954591	chr12:58299037	A/G	cg00677455	chr12:58241039	CTDSP2	0.43	5.62	0.33	4.88e-8	Intelligence (multi-trait analysis);
CESC	cis	rs250677	0.958	rs17109282	chr5:148416677	A/G	cg18129178	chr5:148520854	ABLIM3	0.47	5.5	0.32	8.97e-8	Breast cancer;
CESC	cis	rs881375	0.678	rs10739581	chr9:123696871	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.39	5.48	0.32	9.71e-8	Rheumatoid arthritis;
CESC	cis	rs2486288	0.586	rs12909625	chr15:45572053	C/A	cg09092052	chr15:45571596	NA	0.44	5.23	0.31	3.44e-7	Glomerular filtration rate;
CESC	cis	rs12477438	0.734	rs4851184	chr2:99666434	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-10.57	-0.54	5.22e-22	Chronic sinus infection;
CESC	cis	rs447	1.000	rs7785708	chr7:83752668	C/T	cg22846510	chr7:83753280	SEMA3A	-0.46	-5.74	-0.33	2.55e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs9911578	0.967	rs7502208	chr17:57165097	G/A	cg12560992	chr17:57184187	TRIM37	1.0	17.6	0.73	1.84e-46	Intelligence (multi-trait analysis);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg03532930	chr1:2246464	NA	-0.45	-6.21	-0.36	2e-9	Fibrinogen levels;
CESC	cis	rs1005277	0.540	rs1987431	chr10:37988887	T/C	cg25427524	chr10:38739819	LOC399744	-0.66	-9.67	-0.51	3.72e-19	Extrinsic epigenetic age acceleration;
CESC	cis	rs10504229	1.000	rs76944716	chr8:58191643	T/C	cg05313129	chr8:58192883	C8orf71	-0.58	-6.61	-0.38	2.12e-10	Developmental language disorder (linguistic errors);
CESC	trans	rs561341	1.000	rs484175	chr17:30309041	G/A	cg27661571	chr11:113659931	NA	-0.83	-7.76	-0.43	1.9e-13	Hip circumference adjusted for BMI;
CESC	cis	rs2204008	0.715	rs12368462	chr12:38336116	C/G	cg13010199	chr12:38710504	ALG10B	0.47	6.02	0.35	5.71e-9	Bladder cancer;
CESC	cis	rs7259376	0.840	rs8106611	chr19:22569618	G/A	cg02657401	chr19:22469223	NA	-0.26	-5.14	-0.3	5.39e-7	Menopause (age at onset);
CESC	cis	rs7659604	0.539	rs11098646	chr4:122729301	T/C	cg20573242	chr4:122745356	CCNA2	0.62	7.47	0.42	1.14e-12	Type 2 diabetes;
CESC	trans	rs7335046	0.901	rs72649510	chr13:99957621	C/T	cg08418111	chr11:18433745	LDHC	0.61	5.99	0.35	6.68e-9	Basal cell carcinoma;
CESC	cis	rs116095464	0.558	rs55664502	chr5:270485	T/C	cg12570787	chr5:219185	SDHA;CCDC127	0.5	5.27	0.31	2.77e-7	Breast cancer;
CESC	cis	rs10256972	0.758	rs9801444	chr7:1080444	A/C	cg07308232	chr7:1071921	C7orf50	0.64	9.02	0.48	3.84e-17	Longevity;Endometriosis;
CESC	cis	rs7246657	0.943	rs10404602	chr19:37825633	A/T	cg23950597	chr19:37808831	NA	-0.62	-6.26	-0.36	1.56e-9	Coronary artery calcification;
CESC	cis	rs10743315	0.732	rs71539461	chr12:19443360	G/A	cg02471346	chr12:19282374	PLEKHA5	0.56	5.03	0.3	9.2e-7	Gut microbiota (bacterial taxa);
CESC	cis	rs4077515	0.901	rs3812573	chr9:139276680	C/T	cg14169450	chr9:139327907	INPP5E	0.38	5.41	0.32	1.39e-7	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs858239	0.896	rs1637192	chr7:23260514	G/A	cg23682824	chr7:23144976	KLHL7	0.43	5.68	0.33	3.58e-8	Cerebrospinal fluid biomarker levels;
CESC	trans	rs2727020	1.000	rs2727020	chr11:49111407	C/G	cg03929089	chr4:120376271	NA	0.71	9.32	0.5	4.8e-18	Coronary artery disease;
CESC	cis	rs40363	0.645	rs1690446	chr16:3519009	T/C	cg00484396	chr16:3507460	NAT15	0.43	6.91	0.39	3.52e-11	Tuberculosis;
CESC	cis	rs10875746	0.768	rs4760609	chr12:48415757	A/C	cg24011408	chr12:48396354	COL2A1	0.41	5.43	0.32	1.25e-7	Longevity (90 years and older);
CESC	cis	rs5769765	0.773	rs138834	chr22:50180497	A/C	cg02269571	chr22:50332266	NA	-0.53	-6.17	-0.35	2.57e-9	Schizophrenia;
CESC	cis	rs6860806	0.661	rs6890009	chr5:131580033	G/T	cg18758796	chr5:131593413	PDLIM4	0.45	6.23	0.36	1.79e-9	Breast cancer;
CESC	cis	rs11671005	0.695	rs8106061	chr19:58917990	G/C	cg00825309	chr19:58991885	ZNF446	-0.84	-13.5	-0.64	5.78e-32	Mean platelet volume;
CESC	trans	rs9467711	0.659	rs13220261	chr6:26499185	C/T	cg01620082	chr3:125678407	NA	-0.8	-6.23	-0.36	1.86e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs10504229	0.679	rs17800895	chr8:58050085	A/G	cg21724239	chr8:58056113	NA	0.59	5.24	0.31	3.25e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs2075371	0.829	rs35897155	chr7:134002711	G/A	cg11752832	chr7:134001865	SLC35B4	0.5	6.31	0.36	1.15e-9	Mean platelet volume;
CESC	cis	rs7666738	0.830	rs13125930	chr4:98654695	G/A	cg17366294	chr4:99064904	C4orf37	0.56	7.61	0.42	4.87e-13	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2979489	0.945	rs34960391	chr8:30332723	G/A	cg26383811	chr8:30366931	RBPMS	-0.84	-9.93	-0.52	5.8e-20	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CESC	cis	rs9649213	0.593	rs36017146	chr7:97974617	C/T	cg24562669	chr7:97807699	LMTK2	0.52	7.7	0.43	2.78e-13	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7762018	0.607	rs79355059	chr6:170062157	T/C	cg19338460	chr6:170058176	WDR27	-0.95	-7.81	-0.43	1.35e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs832540	0.669	rs173764	chr5:56198920	C/T	cg24549020	chr5:56110836	MAP3K1	0.41	5.08	0.3	7.24e-7	Coronary artery disease;
CESC	cis	rs28498503	1.000	rs7238348	chr18:76660408	C/T	cg00806245	chr18:76673096	NA	-0.7	-5.83	-0.34	1.58e-8	Attention function in attention deficit hyperactive disorder;
CESC	cis	rs1670533	1.000	rs7660779	chr4:1075940	A/G	cg04106633	chr4:1044584	NA	0.41	5.17	0.3	4.72e-7	Recombination rate (females);
CESC	cis	rs4654899	0.802	rs10737452	chr1:21199764	C/T	cg05370193	chr1:21551575	ECE1	-0.35	-5.25	-0.31	3.09e-7	Superior frontal gyrus grey matter volume;
CESC	cis	rs4819052	0.851	rs10470247	chr21:46659018	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.74	9.89	0.52	7.86e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04892391	chr12:105478345	ALDH1L2	0.52	6.05	0.35	4.94e-9	Gut microbiome composition (summer);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg01849260	chr5:77072153	TBCA	-0.45	-6.18	-0.35	2.37e-9	Fibrinogen levels;
CESC	cis	rs9311474	0.652	rs614288	chr3:52220203	T/C	cg18337363	chr3:52569053	NT5DC2	0.29	5.29	0.31	2.6e-7	Electroencephalogram traits;
CESC	cis	rs9916302	0.821	rs4795386	chr17:37746847	A/G	cg20243544	chr17:37824526	PNMT	0.57	6.99	0.39	2.29e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs875971	0.830	rs427575	chr7:65519219	A/G	cg26939375	chr7:64535504	NA	0.48	6.11	0.35	3.47e-9	Aortic root size;
CESC	cis	rs67478160	0.572	rs8016014	chr14:104293798	G/C	cg01849466	chr14:104193079	ZFYVE21	-0.5	-7.04	-0.4	1.62e-11	Schizophrenia;
CESC	cis	rs9309473	1.000	rs58603761	chr2:73726605	A/G	cg20560298	chr2:73613845	ALMS1	-0.45	-6.14	-0.35	2.97e-9	Metabolite levels;
CESC	cis	rs10504229	0.683	rs7827014	chr8:58132230	G/A	cg02725872	chr8:58115012	NA	-0.45	-7.05	-0.4	1.52e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs7937682	0.855	rs10891285	chr11:111527775	T/C	cg22437258	chr11:111473054	SIK2	0.69	9.25	0.49	7.9e-18	Primary sclerosing cholangitis;
CESC	cis	rs7044106	0.762	rs4837789	chr9:123426256	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.65	8.77	0.47	2.28e-16	Hip circumference adjusted for BMI;
CESC	cis	rs763121	0.853	rs2072798	chr22:39148483	G/A	cg06022373	chr22:39101656	GTPBP1	0.93	15.87	0.7	2.44e-40	Menopause (age at onset);
CESC	cis	rs6754311	0.550	rs1438307	chr2:136499166	A/C	cg07169764	chr2:136633963	MCM6	0.7	9.05	0.49	3.22e-17	Mosquito bite size;
CESC	cis	rs748404	0.723	rs573169	chr15:43550581	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	7.96	0.44	5.16e-14	Lung cancer;
CESC	cis	rs798554	0.683	rs1636264	chr7:2864586	G/T	cg13628971	chr7:2884303	GNA12	0.67	9.08	0.49	2.53e-17	Height;
CESC	cis	rs1550582	0.917	rs7831961	chr8:135507060	C/G	cg17885191	chr8:135476712	NA	-0.7	-8.95	-0.48	6.29e-17	Educational attainment;
CESC	trans	rs9467711	0.606	rs9379901	chr6:26603866	T/C	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.73	6.12	0.35	3.38e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs2712184	0.756	rs2024487	chr2:217663271	C/T	cg05032264	chr2:217675019	NA	0.36	5.4	0.31	1.5e-7	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
CESC	cis	rs12822507	0.708	rs10845597	chr12:12782068	G/A	cg11838227	chr12:12764436	CREBL2	0.42	5.64	0.33	4.37e-8	Systemic lupus erythematosus;
CESC	cis	rs7666738	0.822	rs28367231	chr4:98845726	G/T	cg05340658	chr4:99064831	C4orf37	0.71	10.18	0.53	9.15e-21	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1832871	0.672	rs7750011	chr6:158746802	A/C	cg07165851	chr6:158734300	TULP4	0.59	6.41	0.37	6.63e-10	Height;
CESC	cis	rs711245	0.670	rs7560321	chr2:36822318	C/G	cg09467607	chr2:36825704	FEZ2	-0.61	-11.77	-0.59	5.06e-26	Height;
CESC	cis	rs7116495	0.609	rs10898812	chr11:71698801	G/A	cg07596299	chr11:71824057	C11orf51	-0.85	-5.48	-0.32	9.86e-8	Severe influenza A (H1N1) infection;
CESC	cis	rs9910055	0.718	rs2526022	chr17:42213216	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	0.44	6.52	0.37	3.58e-10	Total body bone mineral density;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg00945486	chr8:139890004	COL22A1	0.36	6.12	0.35	3.43e-9	Fibrinogen levels;
CESC	cis	rs7829975	0.660	rs10093926	chr8:8549020	A/C	cg06636001	chr8:8085503	FLJ10661	-0.45	-5.85	-0.34	1.47e-8	Mood instability;
CESC	cis	rs7512552	0.809	rs828783	chr1:150376977	C/T	cg15654264	chr1:150340011	RPRD2	0.39	5.18	0.3	4.3e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs9486719	0.857	rs2971606	chr6:97043025	C/G	cg06623918	chr6:96969491	KIAA0776	-0.88	-10.63	-0.55	3.13e-22	Migraine;Coronary artery disease;
CESC	cis	rs1144333	0.850	rs1144342	chr1:76284364	A/G	cg10523679	chr1:76189770	ACADM	-0.54	-5.09	-0.3	6.66e-7	Attention function in attention deficit hyperactive disorder;
CESC	cis	rs4654899	1.000	rs6702110	chr1:21515906	A/G	cg05370193	chr1:21551575	ECE1	0.36	5.53	0.32	7.6e-8	Superior frontal gyrus grey matter volume;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg21676273	chr3:45635931	LIMD1	-0.42	-6.04	-0.35	5.07e-9	Gambling;
CESC	cis	rs2463822	1.000	rs2513071	chr11:62098387	A/C	cg06239285	chr11:62104954	ASRGL1	0.89	8.97	0.48	5.69e-17	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs1348850	0.526	rs4243389	chr2:178379783	G/C	cg23306229	chr2:178417860	TTC30B	0.8	7.39	0.41	1.96e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs1961456	0.542	rs10095159	chr8:18244684	G/A	cg18736775	chr8:18248649	NAT2	-0.47	-5.36	-0.31	1.83e-7	Total cholesterol levels;
CESC	cis	rs6460942	0.915	rs10488158	chr7:12508894	C/T	cg02935154	chr7:12443704	VWDE	-0.56	-5.77	-0.33	2.22e-8	Coronary artery disease;
CESC	trans	rs4843747	0.671	rs28679286	chr16:88106307	C/T	cg26811252	chr16:29126840	RRN3P2	0.67	9.46	0.5	1.77e-18	Menopause (age at onset);
CESC	cis	rs965469	0.779	rs1884563	chr20:3335540	T/C	cg17110299	chr20:3385021	C20orf194	0.4	5.26	0.31	3.02e-7	IFN-related cytopenia;
CESC	cis	rs7107174	1.000	rs7104222	chr11:78007169	G/A	cg02023728	chr11:77925099	USP35	0.44	6.15	0.35	2.87e-9	Testicular germ cell tumor;
CESC	cis	rs977987	0.835	rs3863445	chr16:75371744	C/G	cg03315344	chr16:75512273	CHST6	0.39	5.6	0.33	5.25e-8	Dupuytren's disease;
CESC	cis	rs1348850	0.632	rs13008833	chr2:178514439	G/C	cg22681709	chr2:178499509	PDE11A	-0.58	-9.09	-0.49	2.35e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs1218582	0.774	rs12036859	chr1:154859940	A/C	cg24250549	chr1:154909240	PMVK	-0.58	-7.82	-0.43	1.29e-13	Prostate cancer;
CESC	cis	rs875971	0.638	rs10278816	chr7:66036987	T/C	cg11764359	chr7:65958608	NA	-0.73	-9.77	-0.51	1.93e-19	Aortic root size;
CESC	cis	rs13191362	0.507	rs1079020	chr6:163066596	C/T	cg21926612	chr6:163149169	PACRG;PARK2	-0.59	-7.07	-0.4	1.34e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs35740288	0.539	rs4843101	chr15:86339661	G/T	cg20737812	chr15:86336631	KLHL25	-0.48	-5.49	-0.32	9.46e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04347867	chr16:56965804	HERPUD1	0.44	6.06	0.35	4.55e-9	Gut microbiota (bacterial taxa);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg03662217	chr21:35747882	FAM165B	-0.44	-6.27	-0.36	1.45e-9	Gambling;
CESC	cis	rs933688	1.000	rs2367526	chr5:90740525	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.15	13.7	0.64	1.17e-32	Smoking behavior;
CESC	cis	rs7618915	0.501	rs34754793	chr3:52629177	A/T	cg05564831	chr3:52568323	NT5DC2	0.48	7.64	0.42	4.06e-13	Bipolar disorder;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg07334509	chr8:74361129	STAU2	0.46	6.49	0.37	4.1e-10	Fibrinogen levels;
CESC	cis	rs2574704	0.651	rs2616552	chr3:11666798	G/T	cg07643000	chr3:11666825	VGLL4	-0.38	-5.39	-0.31	1.57e-7	Body mass index;
CESC	cis	rs7666738	1.000	rs13144055	chr4:99026849	A/G	cg18180107	chr4:99064573	C4orf37	0.46	5.71	0.33	3.05e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9527	0.590	rs10786738	chr10:104869451	C/T	cg04362960	chr10:104952993	NT5C2	0.44	5.54	0.32	7.12e-8	Arsenic metabolism;
CESC	cis	rs5771242	0.518	rs5771258	chr22:50675648	C/A	cg16473166	chr22:50639996	SELO	0.59	6.72	0.38	1.08e-10	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg05644321	chr20:20693493	RALGAPA2	-0.43	-6.82	-0.39	6.01e-11	Vertical cup-disc ratio;
CESC	cis	rs6772849	0.930	rs4857914	chr3:128350684	C/T	cg16766828	chr3:128327626	NA	-0.31	-5.15	-0.3	5.17e-7	Monocyte percentage of white cells;Monocyte count;
CESC	cis	rs3785574	0.962	rs56295011	chr17:61850359	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	7.28	0.41	3.92e-12	Height;
CESC	cis	rs1538970	0.924	rs6657284	chr1:45879088	T/C	cg05343316	chr1:45956843	TESK2	0.85	11.89	0.59	1.99e-26	Platelet count;
CESC	cis	rs77972916	0.505	rs6719754	chr2:43526386	A/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.58	-5.88	-0.34	1.21e-8	Granulocyte percentage of myeloid white cells;
CESC	cis	rs2481665	0.902	rs1013293	chr1:62570321	G/A	cg18591186	chr1:62594603	INADL	-0.61	-7.22	-0.41	5.67e-12	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs2859741	0.967	rs592520	chr1:37513503	G/C	cg09363841	chr1:37513479	NA	-0.72	-11.74	-0.58	6.65e-26	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
CESC	cis	rs12200560	0.505	rs211171	chr6:97070579	T/G	cg06623918	chr6:96969491	KIAA0776	0.46	5.75	0.33	2.48e-8	Coronary heart disease;
CESC	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg14159672	chr1:205819179	PM20D1	0.8	11.85	0.59	2.8e-26	Menarche (age at onset);
CESC	cis	rs3857536	0.741	rs2097679	chr6:66937994	T/C	cg07460842	chr6:66804631	NA	-0.42	-5.34	-0.31	1.96e-7	Blood trace element (Cu levels);
CESC	cis	rs4919694	1.000	rs80327774	chr10:104656671	T/C	cg04362960	chr10:104952993	NT5C2	0.78	6.53	0.37	3.35e-10	Arsenic metabolism;
CESC	cis	rs9457247	1.000	rs4710147	chr6:167374239	G/A	cg07741184	chr6:167504864	NA	-0.3	-5.44	-0.32	1.19e-7	Crohn's disease;
CESC	cis	rs6665290	0.904	rs6677602	chr1:227187838	G/T	cg10327440	chr1:227177885	CDC42BPA	-1.07	-22.43	-0.81	3.45e-63	Myeloid white cell count;
CESC	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg26338869	chr17:61819248	STRADA	0.7	9.23	0.49	9e-18	Prudent dietary pattern;
CESC	cis	rs113835537	0.597	rs2075792	chr11:66334556	G/A	cg24851651	chr11:66362959	CCS	0.5	5.86	0.34	1.39e-8	Airway imaging phenotypes;
CESC	trans	rs9833726	0.789	rs28628150	chr3:86196637	A/C	cg10416071	chr15:75628863	COMMD4	0.67	6.38	0.36	7.82e-10	Breast cancer;
CESC	cis	rs6089584	0.850	rs6089634	chr20:60632566	T/C	cg24733560	chr20:60626293	TAF4	0.48	6.83	0.39	5.81e-11	Body mass index;
CESC	cis	rs9314323	0.729	rs7823021	chr8:26224958	G/T	cg13160058	chr8:26243215	BNIP3L	-0.33	-5.16	-0.3	4.78e-7	Red cell distribution width;
CESC	cis	rs990171	0.506	rs4141631	chr2:102757216	A/G	cg22835712	chr2:102737379	NA	0.4	5.7	0.33	3.18e-8	Lymphocyte counts;
CESC	cis	rs875971	0.830	rs809025	chr7:65849819	C/G	cg12463550	chr7:65579703	CRCP	0.49	6.21	0.36	2.07e-9	Aortic root size;
CESC	cis	rs17125944	0.505	rs76219229	chr14:53178346	G/A	cg00686598	chr14:53173677	PSMC6	1.21	10.58	0.55	4.62e-22	Alzheimer's disease (late onset);
CESC	cis	rs10197940	0.662	rs72860233	chr2:152289767	G/A	cg06191203	chr2:152266755	RIF1	-0.45	-5.34	-0.31	2.02e-7	Lung cancer;
CESC	cis	rs7662987	0.938	rs13118409	chr4:99998736	C/G	cg13256891	chr4:100009986	ADH5	-0.83	-6.1	-0.35	3.82e-9	Smoking initiation;
CESC	cis	rs113835537	0.597	rs57288351	chr11:66307489	C/T	cg24851651	chr11:66362959	CCS	0.52	6.23	0.36	1.84e-9	Airway imaging phenotypes;
CESC	cis	rs79057730	0.599	rs6944167	chr7:826274	G/C	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.68	6.29	0.36	1.31e-9	Initial pursuit acceleration;
CESC	cis	rs6793245	0.810	rs1805126	chr3:38592406	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.46	6.18	0.35	2.41e-9	QT interval;
CESC	cis	rs11792861	0.926	rs118011482	chr9:111770626	G/C	cg05043794	chr9:111880884	C9orf5	-0.39	-6.4	-0.37	6.9e-10	Menarche (age at onset);
CESC	cis	rs4835473	0.897	rs1450249	chr4:144645578	C/G	cg25736465	chr4:144833511	NA	0.38	5.72	0.33	2.94e-8	Immature fraction of reticulocytes;
CESC	cis	rs12220238	1.000	rs10824083	chr10:75911342	C/G	cg19889307	chr10:75911429	ADK;AP3M1	0.66	6.68	0.38	1.42e-10	Soluble interleukin-2 receptor subunit alpha;
CESC	trans	rs9398803	0.965	rs2027299	chr6:126685827	G/C	cg03991309	chr1:68237761	GNG12	-0.39	-6.04	-0.35	5.23e-9	Male-pattern baldness;
CESC	cis	rs801193	0.805	rs12532355	chr7:66070584	C/G	cg06456125	chr7:65229604	NA	-0.4	-5.58	-0.32	5.92e-8	Aortic root size;
CESC	cis	rs3806843	1.000	rs3822346	chr5:140187322	C/T	cg26395211	chr5:140044315	WDR55	-0.42	-5.33	-0.31	2.07e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs9522267	0.535	rs9522298	chr13:112234457	C/A	cg10483660	chr13:112241077	NA	-0.33	-5.79	-0.33	2.04e-8	Hepatitis;
CESC	cis	rs6582630	0.537	rs10785436	chr12:38461040	G/C	cg26384229	chr12:38710491	ALG10B	0.67	10.24	0.53	6.11e-21	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs4478858	0.735	rs2271072	chr1:31840426	C/G	cg00250761	chr1:31883323	NA	-0.26	-5.07	-0.3	7.56e-7	Alcohol dependence;
CESC	cis	rs11122272	0.668	rs1538664	chr1:231555295	C/T	cg06096015	chr1:231504339	EGLN1	0.38	5.54	0.32	7.31e-8	Hemoglobin concentration;
CESC	cis	rs2479106	0.892	rs2458490	chr9:126598435	T/C	cg16191174	chr9:126692580	DENND1A	0.47	6.47	0.37	4.79e-10	Polycystic ovary syndrome;
CESC	cis	rs6598955	0.724	rs12096059	chr1:26596709	G/A	cg00852783	chr1:26633632	UBXN11	0.42	6.23	0.36	1.84e-9	Obesity-related traits;
CESC	cis	rs2576037	0.526	rs1789152	chr18:44433092	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.72	11.51	0.58	4.01e-25	Personality dimensions;
CESC	trans	rs6089829	0.962	rs6062780	chr20:61666648	T/C	cg23505145	chr19:12996616	KLF1	0.52	6.8	0.39	6.85e-11	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs3015497	0.527	rs2934672	chr14:51152472	T/A	cg26011998	chr14:51135199	SAV1	-0.58	-6.45	-0.37	5.31e-10	Mean platelet volume;
CESC	cis	rs35306767	0.761	rs34480046	chr10:1027440	A/G	cg26597838	chr10:835615	NA	0.76	7.14	0.4	8.95e-12	Eosinophil percentage of granulocytes;
CESC	cis	rs10504229	0.683	rs72650849	chr8:58140323	A/G	cg02725872	chr8:58115012	NA	-0.45	-7.12	-0.4	1.02e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs12931792	0.846	rs9924308	chr16:30154740	C/T	cg17640201	chr16:30407289	ZNF48	-0.55	-6.9	-0.39	3.8e-11	Tonsillectomy;
CESC	cis	rs7927771	0.832	rs1317164	chr11:47419757	G/T	cg05585544	chr11:47624801	NA	-0.45	-6.74	-0.38	1e-10	Subjective well-being;
CESC	cis	rs7618915	0.547	rs11130313	chr3:52676190	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.48	6.9	0.39	3.79e-11	Bipolar disorder;
CESC	cis	rs1185460	1.000	rs7938944	chr11:118954066	T/C	cg23280166	chr11:118938394	VPS11	0.47	6.24	0.36	1.77e-9	Coronary artery disease;
CESC	cis	rs3815700	0.920	rs10424732	chr19:33096487	C/T	cg24916020	chr19:33096688	ANKRD27	0.63	6.11	0.35	3.58e-9	Eosinophilic esophagitis;
CESC	cis	rs12497850	0.931	rs11920534	chr3:48937761	G/T	cg07636037	chr3:49044803	WDR6	1.0	18.5	0.75	1.29e-49	Parkinson's disease;
CESC	cis	rs6429082	0.755	rs291371	chr1:235693105	C/G	cg26050004	chr1:235667680	B3GALNT2	0.61	8.28	0.45	6.11e-15	Adiposity;
CESC	cis	rs801193	0.569	rs7800620	chr7:66223688	T/C	cg11764359	chr7:65958608	NA	0.7	10.02	0.52	3.02e-20	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03000844	chr2:242641386	ING5	0.62	7.34	0.41	2.57e-12	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16192717	chr8:101170527	SPAG1	0.54	6.23	0.36	1.84e-9	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17641046	chr3:37034473	MLH1;EPM2AIP1	0.62	7.2	0.4	6.07e-12	Gut microbiome composition (summer);
CESC	cis	rs116095464	0.558	rs9688045	chr5:254035	T/C	cg20965017	chr5:231967	SDHA	-0.47	-5.22	-0.31	3.61e-7	Breast cancer;
CESC	cis	rs4689388	0.750	rs12642481	chr4:6301058	G/A	cg00701064	chr4:6280414	WFS1	0.61	9.04	0.49	3.52e-17	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg08975529	chr11:70309722	NA	0.53	7.19	0.4	6.43e-12	Fibrinogen levels;
CESC	cis	rs62064224	0.791	rs11653160	chr17:30717222	A/G	cg12855166	chr17:30846586	MYO1D	0.41	5.3	0.31	2.46e-7	Schizophrenia;
CESC	cis	rs7264396	0.563	rs11906854	chr20:34383634	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.86	-9.6	-0.51	6.45e-19	Total cholesterol levels;
CESC	cis	rs7818688	0.697	rs2904889	chr8:95940598	T/G	cg16049864	chr8:95962084	TP53INP1	0.54	5.38	0.31	1.67e-7	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs992157	0.585	rs62182795	chr2:219100202	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.57	-7.45	-0.42	1.29e-12	Colorectal cancer;
CESC	cis	rs1707322	0.686	rs1250	chr1:46094027	A/G	cg05343316	chr1:45956843	TESK2	0.51	6.25	0.36	1.65e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7666738	0.830	rs4699595	chr4:99012827	A/G	cg18180107	chr4:99064573	C4orf37	0.4	5.3	0.31	2.48e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7647973	0.580	rs2117938	chr3:49263850	A/G	cg02487422	chr3:49467188	NICN1	-0.39	-5.52	-0.32	8.11e-8	Menarche (age at onset);
CESC	trans	rs263156	0.567	rs263125	chr6:142939836	A/G	cg04848858	chr16:87127923	NA	-0.37	-6.15	-0.35	2.9e-9	Ear morphology;Lobe size;Lobe attachment;
CESC	cis	rs4730250	0.707	rs80095766	chr7:106901394	G/T	cg02696742	chr7:106810147	HBP1	-0.52	-5.14	-0.3	5.35e-7	Osteoarthritis;
CESC	cis	rs62432291	0.681	rs447637	chr6:159658726	A/G	cg14500486	chr6:159655392	FNDC1	-0.63	-6.4	-0.37	7.05e-10	Joint mobility (Beighton score);
CESC	cis	rs731174	0.959	rs12747993	chr1:38190852	T/C	cg06917450	chr1:38156652	C1orf109	-0.43	-5.35	-0.31	1.87e-7	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg05598539	chr7:128695331	TNPO3;LOC286016	-0.51	-6.72	-0.38	1.1e-10	Height;
CESC	cis	rs2991971	0.967	rs2356551	chr1:46009318	C/T	cg05343316	chr1:45956843	TESK2	-0.49	-6.41	-0.37	6.77e-10	High light scatter reticulocyte count;
CESC	cis	rs8028182	0.636	rs4886712	chr15:75812888	C/T	cg20655648	chr15:75932815	IMP3	0.48	5.9	0.34	1.08e-8	Sudden cardiac arrest;
CESC	cis	rs6540559	0.740	rs2064163	chr1:210048819	G/T	cg23283495	chr1:209979779	IRF6	0.45	6.88	0.39	4.39e-11	Cleft lip with or without cleft palate;
CESC	cis	rs6088590	0.687	rs6088580	chr20:33285053	G/C	cg08999081	chr20:33150536	PIGU	0.64	10.56	0.54	5.39e-22	Coronary artery disease;
CESC	cis	rs13108904	0.557	rs1680033	chr4:1243404	C/T	cg20887711	chr4:1340912	KIAA1530	-0.64	-8.63	-0.47	5.65e-16	Obesity-related traits;
CESC	cis	rs4819052	1.000	rs13047688	chr21:46669290	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.9	11.82	0.59	3.57e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs873946	0.590	rs7071777	chr10:134559976	T/A	cg27286337	chr10:134555280	INPP5A	0.65	7.34	0.41	2.56e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs2486288	0.656	rs7167146	chr15:45571386	A/G	cg21132104	chr15:45694354	SPATA5L1	0.49	5.52	0.32	8.26e-8	Glomerular filtration rate;
CESC	cis	rs9925964	0.804	rs9926533	chr16:31014179	C/T	cg02466173	chr16:30829666	NA	0.32	5.14	0.3	5.32e-7	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs472402	0.580	rs4702373	chr5:6633222	C/T	cg10789808	chr5:6633262	NSUN2;SRD5A1	-0.53	-6.94	-0.39	2.94e-11	Response to amphetamines;
CESC	cis	rs12188164	1.000	rs55842567	chr5:437586	G/A	cg17553881	chr5:443987	EXOC3;C5orf55	-0.34	-5.45	-0.32	1.17e-7	Cystic fibrosis severity;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg21484680	chr2:27593328	EIF2B4;SNX17	-0.52	-6.34	-0.36	9.9e-10	Ulcerative colitis;
CESC	cis	rs7666738	0.830	rs13102369	chr4:99045912	A/G	cg03676636	chr4:99064102	C4orf37	0.33	5.12	0.3	5.93e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs8180040	0.966	rs7649234	chr3:47494380	G/C	cg27129171	chr3:47204927	SETD2	0.63	9.66	0.51	4.06e-19	Colorectal cancer;
CESC	cis	rs748404	0.578	rs2278856	chr15:43631356	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.55	8.61	0.47	6.76e-16	Lung cancer;
CESC	cis	rs6933660	0.646	rs9397051	chr6:151778325	C/T	cg14262678	chr6:151773367	RMND1;C6orf211	0.71	10.42	0.54	1.61e-21	Menarche (age at onset);
CESC	cis	rs11792861	0.926	rs7870597	chr9:111871864	T/C	cg13535736	chr9:111863775	C9orf5	-0.5	-6.66	-0.38	1.6e-10	Menarche (age at onset);
CESC	cis	rs8072100	0.846	rs4264433	chr17:45737275	A/T	cg08085267	chr17:45401833	C17orf57	0.44	5.8	0.34	1.86e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs4595586	0.505	rs12827136	chr12:39412790	C/T	cg26384229	chr12:38710491	ALG10B	0.51	7.36	0.41	2.36e-12	Morning vs. evening chronotype;
CESC	cis	rs9649213	0.555	rs67132564	chr7:98014900	T/A	cg08684580	chr7:98029266	BAIAP2L1	-0.35	-5.72	-0.33	2.8e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs6964587	0.655	rs6465351	chr7:91773213	T/C	cg17063962	chr7:91808500	NA	0.44	6.38	0.36	8.04e-10	Breast cancer;
CESC	cis	rs2933343	1.000	rs1683811	chr3:128612113	A/C	cg25356066	chr3:128598488	ACAD9	0.6	7.48	0.42	1.09e-12	IgG glycosylation;
CESC	cis	rs78456975	0.527	rs11884165	chr2:1561052	A/G	cg12573674	chr2:1569213	NA	-0.45	-5.3	-0.31	2.46e-7	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs763014	0.833	rs3743902	chr16:632728	T/C	cg00908189	chr16:619842	PIGQ	0.67	9.34	0.5	4.24e-18	Height;
CESC	cis	rs8112211	1.000	rs7253960	chr19:38814725	C/T	cg14299480	chr19:38876666	GGN	-0.43	-5.8	-0.34	1.84e-8	Blood protein levels;
CESC	cis	rs4665809	0.549	rs17527979	chr2:26428132	A/G	cg08470875	chr2:26401718	FAM59B	-0.69	-7.0	-0.39	2.11e-11	Gut microbiome composition (summer);
CESC	cis	rs858239	0.738	rs13225593	chr7:23260307	A/G	cg23682824	chr7:23144976	KLHL7	0.45	5.74	0.33	2.65e-8	Cerebrospinal fluid biomarker levels;
CESC	cis	rs10479542	0.702	rs13183521	chr5:178975606	A/G	cg19626725	chr5:178986131	RUFY1	-0.34	-5.1	-0.3	6.61e-7	Lung cancer;
CESC	cis	rs62432291	0.681	rs438853	chr6:159630352	A/C	cg14500486	chr6:159655392	FNDC1	-0.58	-6.13	-0.35	3.17e-9	Joint mobility (Beighton score);
CESC	trans	rs3942852	0.774	rs2270990	chr11:48184983	G/T	cg15704280	chr7:45808275	SEPT13	-0.75	-8.67	-0.47	4.34e-16	Acute lymphoblastic leukemia (childhood);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05673432	chr3:15919505	NA	-0.75	-8.26	-0.45	6.92e-15	Gut microbiome composition (summer);
CESC	cis	rs7267979	0.816	rs3746337	chr20:25208272	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.68	10.84	0.55	6.53e-23	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs698813	0.674	rs6544753	chr2:44501895	A/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.45	5.07	0.3	7.5e-7	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg25730573	chr18:60987425	BCL2	0.48	6.12	0.35	3.29e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs472109	1.000	rs93139	chr11:9759608	T/C	cg03108697	chr11:9732066	SWAP70	-0.35	-5.33	-0.31	2.15e-7	Coronary artery disease;
CESC	trans	rs208515	0.525	rs10498841	chr6:66663706	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.87	10.74	0.55	1.42e-22	Exhaled nitric oxide levels;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05360402	chr5:110848191	STARD4	0.49	6.51	0.37	3.67e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs17209837	1.000	rs67721532	chr7:87084403	A/G	cg00919237	chr7:87102261	ABCB4	-0.55	-5.61	-0.33	5.09e-8	Gallbladder cancer;
CESC	cis	rs9487051	0.872	rs9386794	chr6:109611521	A/C	cg21918786	chr6:109611834	NA	-0.39	-5.98	-0.34	7.14e-9	Reticulocyte fraction of red cells;
CESC	cis	rs10208940	0.920	rs28361349	chr2:68785579	G/A	cg12452813	chr2:68675892	NA	0.52	5.25	0.31	3.12e-7	Urate levels in lean individuals;
CESC	trans	rs877282	0.853	rs12763400	chr10:763617	C/T	cg22713356	chr15:30763199	NA	1.16	11.35	0.57	1.37e-24	Uric acid levels;
CESC	cis	rs9457247	0.740	rs13195812	chr6:167443902	C/T	cg07741184	chr6:167504864	NA	0.37	6.54	0.37	3.16e-10	Crohn's disease;
CESC	trans	rs61931739	0.500	rs34107854	chr12:34482333	C/A	cg13010199	chr12:38710504	ALG10B	0.5	6.5	0.37	3.92e-10	Morning vs. evening chronotype;
CESC	cis	rs3806843	0.676	rs753280	chr5:140024042	C/T	cg16577123	chr5:140027231	NDUFA2;IK	0.44	5.73	0.33	2.7e-8	Depressive symptoms (multi-trait analysis);
CESC	cis	rs2836974	0.644	rs9978775	chr21:40694526	A/G	cg17971929	chr21:40555470	PSMG1	-0.83	-11.67	-0.58	1.16e-25	Cognitive function;
CESC	cis	rs8017423	0.565	rs4904681	chr14:90835566	A/T	cg14092571	chr14:90743983	NA	0.44	6.46	0.37	4.94e-10	Mortality in heart failure;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg10683658	chr6:97345925	NDUFAF4	0.46	6.0	0.35	6.4e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs743757	1.000	rs2236968	chr3:50465975	A/G	cg10928302	chr3:50126174	RBM5	0.53	5.08	0.3	7.24e-7	Diastolic blood pressure;
CESC	cis	rs7617480	0.585	rs7373072	chr3:48960017	T/A	cg07636037	chr3:49044803	WDR6	0.88	12.98	0.62	3.71e-30	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CESC	cis	rs4450798	0.593	rs4552329	chr3:13785609	T/C	cg05589046	chr3:13742034	LOC285375	0.34	5.21	0.3	3.79e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs1107366	0.750	rs9825571	chr3:125900161	A/G	cg08481491	chr3:125900108	ALDH1L1	-0.36	-5.29	-0.31	2.62e-7	Metabolite levels;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg16116244	chr1:16939841	NBPF1	-0.47	-6.32	-0.36	1.11e-9	Fibrinogen levels;
CESC	cis	rs60843830	1.000	rs58461606	chr2:267367	G/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.8	10.61	0.55	3.67e-22	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs4919044	0.740	rs73319304	chr10:94777045	A/G	cg16508068	chr10:94451736	HHEX	-0.5	-5.49	-0.32	9.61e-8	Coronary artery disease;
CESC	cis	rs2032447	0.869	rs199752	chr6:26012875	C/T	cg12310025	chr6:25882481	NA	-0.49	-6.9	-0.39	3.76e-11	Intelligence (multi-trait analysis);
CESC	cis	rs12893668	0.703	rs729438	chr14:104092789	A/G	cg24130564	chr14:104152367	KLC1	0.43	5.43	0.32	1.3e-7	Reticulocyte count;
CESC	trans	rs60843830	1.000	rs3791220	chr2:227066	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.64	7.97	0.44	4.88e-14	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs9858542	0.953	rs11719996	chr3:49525958	T/C	cg07274523	chr3:49395745	GPX1	0.66	8.05	0.44	2.78e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	trans	rs916888	0.821	rs70602	chr17:44859715	T/C	cg07870213	chr5:140052090	DND1	-0.58	-6.45	-0.37	5.28e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs7927592	0.913	rs4316515	chr11:68308840	A/T	cg20283391	chr11:68216788	NA	0.59	7.12	0.4	1.01e-11	Total body bone mineral density;
CESC	cis	rs7267005	0.661	rs2425085	chr20:34302402	T/C	cg17201900	chr20:34330562	RBM39	0.98	5.28	0.31	2.64e-7	Response to paliperidone in schizophrenia (Multivariate);
CESC	cis	rs1568889	1.000	rs12800354	chr11:28047723	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.69	8.08	0.44	2.26e-14	Bipolar disorder;
CESC	cis	rs3096299	0.606	rs8052103	chr16:89541243	A/T	cg02187348	chr16:89574699	SPG7	-0.52	-6.48	-0.37	4.47e-10	Multiple myeloma (IgH translocation);
CESC	cis	rs12325245	0.536	rs12925676	chr16:58625326	C/T	cg02549819	chr16:58548995	SETD6	0.95	6.11	0.35	3.54e-9	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02247898	chr14:55033728	SAMD4A	-0.57	-6.27	-0.36	1.44e-9	Gut microbiome composition (summer);
CESC	cis	rs2250402	0.510	rs7535	chr15:40328575	G/C	cg10636054	chr15:40330586	SRP14	0.92	7.03	0.4	1.77e-11	Corneal curvature;
CESC	cis	rs7772486	0.743	rs111332144	chr6:146056681	C/T	cg23711669	chr6:146136114	FBXO30	-0.68	-9.94	-0.52	5.56e-20	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg09060608	chr5:178986726	RUFY1	0.57	8.88	0.48	1.06e-16	Lung cancer;
CESC	cis	rs9322193	0.962	rs4869731	chr6:150131208	T/C	cg04369109	chr6:150039330	LATS1	-0.41	-5.54	-0.32	7.16e-8	Lung cancer;
CESC	cis	rs7474896	0.583	rs10827818	chr10:38000856	T/C	cg25427524	chr10:38739819	LOC399744	-0.48	-5.6	-0.33	5.35e-8	Obesity (extreme);
CESC	cis	rs858239	0.539	rs4559148	chr7:23185967	G/A	cg23682824	chr7:23144976	KLHL7	0.46	5.85	0.34	1.45e-8	Cerebrospinal fluid biomarker levels;
CESC	cis	rs11153306	0.677	rs3777921	chr6:111924410	C/T	cg22127309	chr6:111907043	TRAF3IP2	0.39	5.76	0.33	2.38e-8	Tonsillectomy;
CESC	trans	rs208515	0.556	rs12201658	chr6:66678457	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.88	10.9	0.56	4.24e-23	Exhaled nitric oxide levels;
CESC	cis	rs6540559	1.000	rs12070337	chr1:209992127	G/A	cg23283495	chr1:209979779	IRF6	0.55	7.83	0.43	1.15e-13	Cleft lip with or without cleft palate;
CESC	cis	rs1538970	0.924	rs1494812	chr1:45876999	C/T	cg05343316	chr1:45956843	TESK2	0.85	11.89	0.59	1.99e-26	Platelet count;
CESC	cis	rs17023223	0.537	rs12081327	chr1:119686358	A/G	cg05756136	chr1:119680316	WARS2	-0.46	-5.58	-0.32	6.01e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CESC	cis	rs55871839	0.708	rs12114218	chr8:59817454	T/C	cg07426533	chr8:59803705	TOX	-0.5	-7.25	-0.41	4.68e-12	Pneumonia;
CESC	cis	rs4555082	0.957	rs3825762	chr14:105752404	T/C	cg13114125	chr14:105738426	BRF1	-0.71	-9.01	-0.48	4.09e-17	Mean platelet volume;Platelet distribution width;
CESC	cis	rs3026101	0.671	rs1143206	chr17:5284698	A/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.44	5.89	0.34	1.18e-8	Body mass index;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg03961984	chr1:55229700	PARS2	-0.42	-6.08	-0.35	4.17e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs9660180	1.000	rs9660180	chr1:1723031	G/A	cg03396347	chr1:1875803	NA	-0.43	-6.63	-0.38	1.91e-10	Body mass index;
CESC	cis	rs2361718	0.500	rs12451697	chr17:78100690	T/A	cg21238619	chr17:78079768	GAA	-0.4	-6.02	-0.35	5.91e-9	Yeast infection;
CESC	cis	rs8031584	0.672	rs17815726	chr15:31313252	C/G	cg14298792	chr15:30685198	CHRFAM7A	0.51	5.25	0.31	3.11e-7	Huntington's disease progression;
CESC	cis	rs9814567	1.000	rs6766818	chr3:134226159	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.45	-6.05	-0.35	4.82e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs2635047	0.967	rs12960378	chr18:44614090	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.46	6.23	0.36	1.85e-9	Educational attainment;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27030336	chr7:43798661	BLVRA	0.55	6.04	0.35	5.06e-9	Gut microbiome composition (summer);
CESC	cis	rs28489187	0.706	rs233108	chr1:85781720	C/T	cg16011679	chr1:85725395	C1orf52	0.49	5.86	0.34	1.39e-8	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	cis	rs4665809	1.000	rs6729080	chr2:26301282	G/A	cg27170947	chr2:26402098	FAM59B	-0.6	-7.25	-0.41	4.7e-12	Gut microbiome composition (summer);
CESC	cis	rs7605827	0.930	rs4668450	chr2:15675011	C/T	cg19274914	chr2:15703543	NA	0.38	6.8	0.39	7.12e-11	Educational attainment (years of education);
CESC	cis	rs9311474	0.659	rs7638808	chr3:52572056	C/T	cg18404041	chr3:52824283	ITIH1	0.35	6.27	0.36	1.42e-9	Electroencephalogram traits;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg03944810	chr2:208031995	KLF7	0.39	6.08	0.35	4.18e-9	Systemic lupus erythematosus;
CESC	cis	rs9322193	0.923	rs9285524	chr6:150015258	G/A	cg13206674	chr6:150067644	NUP43	0.41	5.77	0.33	2.22e-8	Lung cancer;
CESC	cis	rs7589728	0.563	rs2292868	chr2:88475047	A/G	cg14558114	chr2:88469736	THNSL2	-0.57	-5.25	-0.31	3.05e-7	Plasma clusterin levels;
CESC	cis	rs10504229	0.512	rs117968470	chr8:58014651	C/G	cg22535103	chr8:58192502	C8orf71	-0.9	-8.95	-0.48	6.29e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs9287719	0.901	rs55861579	chr2:10763340	T/A	cg00105475	chr2:10696890	NA	0.37	5.27	0.31	2.81e-7	Prostate cancer;
CESC	cis	rs9467773	0.620	rs2451738	chr6:26618459	A/T	cg26531700	chr6:26746687	NA	0.44	6.91	0.39	3.7e-11	Intelligence (multi-trait analysis);
CESC	trans	rs9693444	0.898	rs4732697	chr8:29519861	A/G	cg07630564	chr3:128445061	RAB7A	-0.44	-6.41	-0.37	6.51e-10	Breast cancer;
CESC	cis	rs12681288	0.644	rs2123058	chr8:1000304	A/G	cg15309053	chr8:964076	NA	0.39	6.61	0.38	2.07e-10	Schizophrenia;
CESC	cis	rs7520050	0.807	rs72688483	chr1:46149209	A/G	cg03146154	chr1:46216737	IPP	0.52	6.86	0.39	4.96e-11	Red blood cell count;Reticulocyte count;
CESC	cis	rs7512552	0.768	rs7517441	chr1:150283643	A/T	cg15654264	chr1:150340011	RPRD2	-0.42	-5.42	-0.32	1.32e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs7582720	1.000	rs72936323	chr2:204050474	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.83	7.07	0.4	1.41e-11	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs7666738	0.830	rs10005120	chr4:99038200	A/G	cg17366294	chr4:99064904	C4orf37	0.61	8.78	0.47	2.11e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7116495	0.737	rs7101553	chr11:71753903	C/T	cg18441811	chr11:71824068	C11orf51	-0.85	-5.38	-0.31	1.65e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs7178909	0.800	rs3825866	chr15:90437638	A/T	cg19708238	chr15:90437601	AP3S2	0.43	6.19	0.36	2.25e-9	Common traits (Other);
CESC	cis	rs7618915	0.501	rs1866268	chr3:52719398	C/A	cg05564831	chr3:52568323	NT5DC2	0.46	7.33	0.41	2.88e-12	Bipolar disorder;
CESC	cis	rs10465746	0.967	rs12120160	chr1:84342835	T/G	cg10977910	chr1:84465055	TTLL7	0.48	6.52	0.37	3.64e-10	Obesity-related traits;
CESC	cis	rs9926296	0.706	rs2159115	chr16:89831819	A/G	cg04287289	chr16:89883240	FANCA	0.58	7.56	0.42	6.42e-13	Vitiligo;
CESC	cis	rs4780401	0.782	rs933573	chr16:11793395	A/G	cg01061890	chr16:11836724	TXNDC11	0.41	5.62	0.33	4.83e-8	Rheumatoid arthritis;
CESC	cis	rs10492096	1.000	rs12422771	chr12:6580273	G/T	cg13857086	chr12:6580257	VAMP1	0.69	6.95	0.39	2.88e-11	Hip geometry;
CESC	cis	rs28647808	1.000	rs28460103	chr9:136278763	G/A	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.89	5.69	0.33	3.41e-8	Blood protein levels;
CESC	cis	rs6570726	0.811	rs375873	chr6:145812371	G/T	cg05347473	chr6:146136440	FBXO30	0.48	6.46	0.37	4.93e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1448094	0.717	rs55811543	chr12:86290936	C/T	cg02569458	chr12:86230093	RASSF9	0.38	5.41	0.32	1.4e-7	Major depressive disorder;
CESC	cis	rs10979	1.000	rs3748072	chr6:143889757	C/T	cg25407410	chr6:143891975	LOC285740	-0.61	-9.14	-0.49	1.72e-17	Hypospadias;
CESC	cis	rs10861342	1.000	rs11112397	chr12:105568381	T/C	cg23923672	chr12:105501055	KIAA1033	0.62	5.38	0.31	1.66e-7	IgG glycosylation;
CESC	cis	rs72781680	0.898	rs12619592	chr2:23971415	C/A	cg08917208	chr2:24149416	ATAD2B	0.96	8.67	0.47	4.28e-16	Lymphocyte counts;
CESC	cis	rs4689388	0.926	rs11725500	chr4:6293919	C/G	cg00701064	chr4:6280414	WFS1	0.68	11.71	0.58	8.68e-26	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs2303759	0.709	rs10414921	chr19:49823047	C/T	cg22307029	chr19:49891270	CCDC155	0.55	6.0	0.35	6.6e-9	Multiple sclerosis;
CESC	cis	rs2839186	0.565	rs2839183	chr21:47687144	G/A	cg12379764	chr21:47803548	PCNT	0.44	5.48	0.32	9.66e-8	Testicular germ cell tumor;
CESC	cis	rs1552244	0.938	rs7625049	chr3:10115619	C/T	cg00149659	chr3:10157352	C3orf10	0.7	8.38	0.46	3.2e-15	Alzheimer's disease;
CESC	cis	rs4237845	0.537	rs12426201	chr12:58259752	C/T	cg00677455	chr12:58241039	CTDSP2	0.77	10.17	0.53	1.03e-20	Intelligence (multi-trait analysis);
CESC	cis	rs7618915	0.547	rs34537256	chr3:52657472	A/G	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.36	6.26	0.36	1.52e-9	Bipolar disorder;
CESC	cis	rs7223966	1.000	rs8080211	chr17:61729882	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.53	6.17	0.35	2.52e-9	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs1062177	1.000	rs973529	chr5:151188158	T/C	cg00977110	chr5:151150581	G3BP1	0.63	6.88	0.39	4.37e-11	Preschool internalizing problems;
CESC	cis	rs7659604	0.539	rs56159666	chr4:122782879	G/A	cg06713675	chr4:122721982	EXOSC9	-0.51	-6.96	-0.39	2.71e-11	Type 2 diabetes;
CESC	trans	rs79976124	0.842	rs7760550	chr6:66628788	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.69	7.95	0.44	5.31e-14	Type 2 diabetes;
CESC	cis	rs2243480	1.000	rs1499613	chr7:65730860	G/A	cg18252515	chr7:66147081	NA	1.41	14.3	0.66	9.43e-35	Diabetic kidney disease;
CESC	cis	rs9910055	0.659	rs8079310	chr17:42270291	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.65	8.59	0.47	7.46e-16	Total body bone mineral density;
CESC	cis	rs6987853	0.761	rs2974321	chr8:42424727	A/G	cg09913449	chr8:42400586	C8orf40	0.46	7.83	0.43	1.17e-13	Mean corpuscular hemoglobin concentration;
CESC	trans	rs1814175	0.817	rs10839465	chr11:49981554	C/A	cg03929089	chr4:120376271	NA	-0.93	-16.32	-0.71	6.51e-42	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08274380	chr1:109419600	GPSM2	0.61	6.58	0.37	2.53e-10	Gut microbiome composition (summer);
CESC	cis	rs12824058	0.831	rs12300308	chr12:130813825	G/A	cg26677194	chr12:130822605	PIWIL1	0.52	6.81	0.39	6.58e-11	Menopause (age at onset);
CESC	cis	rs12618769	0.597	rs12619665	chr2:99126551	A/T	cg10123293	chr2:99228465	UNC50	0.4	5.38	0.31	1.68e-7	Bipolar disorder;
CESC	cis	rs1348850	0.519	rs4144275	chr2:178523368	C/T	cg23306229	chr2:178417860	TTC30B	0.46	5.38	0.31	1.67e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs2243480	1.000	rs2961102	chr7:65424658	A/G	cg13147721	chr7:65941812	NA	-0.9	-8.62	-0.47	6.11e-16	Diabetic kidney disease;
CESC	cis	rs1568889	1.000	rs9783375	chr11:28033667	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.69	8.16	0.45	1.38e-14	Bipolar disorder;
CESC	cis	rs12995491	0.731	rs12992162	chr2:88508773	G/C	cg14558114	chr2:88469736	THNSL2	-0.46	-6.5	-0.37	4.08e-10	Response to metformin (IC50);
CESC	trans	rs7937682	0.889	rs493810	chr11:111491888	G/T	cg18187862	chr3:45730750	SACM1L	0.48	6.01	0.35	6.26e-9	Primary sclerosing cholangitis;
CESC	cis	rs6693567	0.565	rs1776276	chr1:150293078	A/C	cg09579323	chr1:150459698	TARS2	0.47	6.13	0.35	3.18e-9	Migraine;
CESC	cis	rs6120849	0.663	rs6088662	chr20:33547633	A/C	cg24642439	chr20:33292090	TP53INP2	0.67	6.86	0.39	4.87e-11	Protein C levels;
CESC	cis	rs12142240	0.698	rs67142569	chr1:46828460	C/T	cg00530320	chr1:46809349	NSUN4	0.6	8.01	0.44	3.75e-14	Menopause (age at onset);
CESC	cis	rs7809950	1.000	rs10267907	chr7:107184466	C/T	cg23024343	chr7:107201750	COG5	-0.43	-5.9	-0.34	1.13e-8	Coronary artery disease;
CESC	cis	rs9486719	1.000	rs11153067	chr6:97039421	A/T	cg06623918	chr6:96969491	KIAA0776	0.78	7.93	0.44	6.02e-14	Migraine;Coronary artery disease;
CESC	trans	rs9467711	0.790	rs66488313	chr6:26631568	G/T	cg01620082	chr3:125678407	NA	-0.85	-6.44	-0.37	5.75e-10	Autism spectrum disorder or schizophrenia;
CESC	trans	rs7786808	0.712	rs12671981	chr7:158202971	G/A	cg03441993	chr4:55093323	NA	0.4	6.06	0.35	4.71e-9	Obesity-related traits;
CESC	cis	rs651907	0.557	rs13081846	chr3:101383321	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.47	6.08	0.35	4.17e-9	Colorectal cancer;
CESC	cis	rs9309473	1.000	rs3738848	chr2:73761881	G/A	cg20560298	chr2:73613845	ALMS1	-0.46	-6.2	-0.36	2.12e-9	Metabolite levels;
CESC	cis	rs10479542	0.929	rs10078796	chr5:178978883	T/A	cg22764044	chr5:178986830	RUFY1	0.46	6.82	0.39	6.22e-11	Lung cancer;
CESC	cis	rs9308433	0.643	rs955920	chr1:214464309	G/A	cg06198575	chr1:214491504	SMYD2	0.44	5.11	0.3	6.14e-7	IgG glycosylation;
CESC	cis	rs9430161	0.611	rs72644043	chr1:11033051	T/A	cg02454025	chr1:11042201	C1orf127	0.99	16.1	0.7	3.84e-41	Ewing sarcoma;
CESC	cis	rs3747547	0.581	rs943932	chr9:38132048	C/T	cg13774184	chr9:37916125	SHB	-0.65	-5.3	-0.31	2.4e-7	Metabolite levels (Dihydroxy docosatrienoic acid);
CESC	cis	rs10504229	0.683	rs55868006	chr8:58135703	C/T	cg21724239	chr8:58056113	NA	0.58	5.95	0.34	8.29e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs4665809	0.590	rs2033317	chr2:26477650	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.06	12.34	0.6	5.85e-28	Gut microbiome composition (summer);
CESC	cis	rs36051895	0.659	rs7856912	chr9:5184449	G/A	cg02405213	chr9:5042618	JAK2	-0.53	-6.36	-0.36	9.03e-10	Pediatric autoimmune diseases;
CESC	cis	rs2447097	1.000	rs2447097	chr17:2278064	A/C	cg27406664	chr17:2294951	MNT	0.34	5.62	0.33	4.8e-8	Autism spectrum disorder;
CESC	cis	rs17376456	0.877	rs10476598	chr5:93367281	C/T	cg21475434	chr5:93447410	FAM172A	-0.76	-6.88	-0.39	4.34e-11	Diabetic retinopathy;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg07185584	chr20:19997881	NAA20	0.55	7.36	0.41	2.37e-12	Systemic lupus erythematosus;
CESC	cis	rs9287719	0.967	rs6432114	chr2:10744930	C/T	cg00105475	chr2:10696890	NA	0.39	5.64	0.33	4.37e-8	Prostate cancer;
CESC	cis	rs76793172	0.920	rs113577760	chr19:46365177	T/C	cg12641515	chr19:46296257	DMWD	-0.8	-5.04	-0.3	8.66e-7	Eosinophil counts;
CESC	cis	rs34779708	0.868	rs2384352	chr10:35492832	A/G	cg04310649	chr10:35416472	CREM	-0.53	-6.3	-0.36	1.27e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs9905704	0.718	rs4793953	chr17:56613104	C/G	cg12560992	chr17:57184187	TRIM37	-0.64	-6.09	-0.35	4.06e-9	Testicular germ cell tumor;
CESC	cis	rs2070488	0.965	rs1065800	chr3:38566480	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.91	-17.03	-0.72	1.95e-44	Electrocardiographic conduction measures;
CESC	cis	rs703842	0.616	rs4760171	chr12:58225904	A/G	cg00677455	chr12:58241039	CTDSP2	0.73	10.39	0.54	2.01e-21	Multiple sclerosis;
CESC	cis	rs4713118	0.662	rs9468274	chr6:28026077	G/T	cg23161317	chr6:28129485	ZNF389	0.49	6.19	0.36	2.28e-9	Parkinson's disease;
CESC	cis	rs5758511	0.514	rs5751211	chr22:42486056	G/A	cg00645731	chr22:42541494	CYP2D7P1	0.63	9.78	0.52	1.69e-19	Birth weight;
CESC	cis	rs12477438	0.520	rs13012481	chr2:99754290	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	15.16	0.68	8.27e-38	Chronic sinus infection;
CESC	cis	rs66573146	1.000	rs66519732	chr4:6990569	C/G	cg00086871	chr4:6988644	TBC1D14	1.12	6.35	0.36	9.34e-10	Granulocyte percentage of myeloid white cells;
CESC	cis	rs2637266	0.935	rs2583048	chr10:78404507	C/G	cg18941641	chr10:78392320	NA	0.44	8.56	0.47	9.45e-16	Pulmonary function;
CESC	cis	rs9926296	0.512	rs11076626	chr16:89865103	T/A	cg03388025	chr16:89894329	SPIRE2	0.41	7.92	0.44	6.63e-14	Vitiligo;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg02252918	chr12:124458442	ZNF664;CCDC92	0.54	7.06	0.4	1.43e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs12824058	0.799	rs4759656	chr12:130815804	G/A	cg23887609	chr12:130822674	PIWIL1	0.45	5.86	0.34	1.38e-8	Menopause (age at onset);
CESC	cis	rs12545109	0.800	rs2582401	chr8:57401656	A/G	cg09654669	chr8:57350985	NA	-0.56	-6.59	-0.38	2.31e-10	Obesity-related traits;
CESC	cis	rs4595586	0.525	rs11609150	chr12:39408622	A/C	cg13010199	chr12:38710504	ALG10B	0.45	5.57	0.32	6.23e-8	Morning vs. evening chronotype;
CESC	cis	rs763014	0.966	rs7185390	chr16:666382	A/G	cg07256732	chr16:621771	PIGQ	-0.34	-5.88	-0.34	1.22e-8	Height;
CESC	cis	rs253664	0.897	rs1199336	chr3:138088221	T/A	cg17918682	chr3:137893718	DBR1	-0.48	-5.16	-0.3	4.9e-7	Body mass index;
CESC	cis	rs1799949	0.929	rs799905	chr17:41277187	G/C	cg25072359	chr17:41440525	NA	0.48	7.12	0.4	1.04e-11	Menopause (age at onset);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg16025584	chr9:139887217	C9orf142	-0.43	-6.29	-0.36	1.3e-9	Gambling;
CESC	cis	rs7216064	1.000	rs55896768	chr17:65913358	T/C	cg07042672	chr17:66097459	LOC651250	-0.62	-7.72	-0.43	2.34e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs2228479	0.618	rs72477006	chr16:89950299	G/C	cg04013166	chr16:89971882	TCF25	0.73	6.49	0.37	4.21e-10	Skin colour saturation;
CESC	cis	rs10789491	1.000	rs2218191	chr1:47130628	C/T	cg15501359	chr1:47185051	KIAA0494	0.54	6.45	0.37	5.34e-10	Response to hepatitis C treatment;
CESC	cis	rs72615157	0.612	rs7786505	chr7:99817585	G/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.52	5.85	0.34	1.44e-8	Lung function (FEV1/FVC);
CESC	cis	rs7917772	0.503	rs11191328	chr10:104305185	C/T	cg22532475	chr10:104410764	TRIM8	-0.33	-5.65	-0.33	4.19e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs1862618	0.671	rs2591965	chr5:56236176	T/C	cg22800045	chr5:56110881	MAP3K1	-0.6	-7.63	-0.42	4.11e-13	Initial pursuit acceleration;
CESC	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg16132339	chr22:24313637	DDTL;DDT	0.36	5.42	0.32	1.32e-7	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs1799949	0.965	rs9646418	chr17:41425901	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.51	7.31	0.41	3.2e-12	Menopause (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16638425	chr16:2946805	FLYWCH2	-0.54	-6.45	-0.37	5.27e-10	Gut microbiome composition (summer);
CESC	cis	rs727563	0.638	rs4820443	chr22:42193913	A/G	cg06481639	chr22:41940642	POLR3H	-0.55	-5.68	-0.33	3.46e-8	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs1799949	0.602	rs8176235	chr17:41219560	C/T	cg23758822	chr17:41437982	NA	1.02	12.82	0.62	1.29e-29	Menopause (age at onset);
CESC	cis	rs34330	0.562	rs10845615	chr12:12863470	C/T	cg09462578	chr12:12878428	APOLD1	-0.75	-8.47	-0.46	1.7e-15	Systemic lupus erythematosus;
CESC	cis	rs1003719	0.715	rs2252893	chr21:38507572	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-8.47	-0.46	1.69e-15	Eye color traits;
CESC	cis	rs763121	0.819	rs5750629	chr22:38985065	T/C	cg21395723	chr22:39101663	GTPBP1	0.51	6.82	0.39	6.01e-11	Menopause (age at onset);
CESC	cis	rs965469	0.895	rs6051840	chr20:3391483	C/T	cg25506879	chr20:3388711	C20orf194	0.58	6.44	0.37	5.51e-10	IFN-related cytopenia;
CESC	trans	rs4756846	1.000	rs4757400	chr11:16469929	T/C	cg05579622	chr5:10618622	ANKRD33B	0.73	6.85	0.39	5.11e-11	Obesity and osteoporosis;
CESC	cis	rs35306767	0.855	rs12781100	chr10:838636	C/T	cg20503657	chr10:835505	NA	1.08	10.23	0.53	6.64e-21	Eosinophil percentage of granulocytes;
CESC	cis	rs4849845	0.573	rs33971369	chr2:121024987	A/G	cg24070213	chr2:121070622	NA	0.45	6.67	0.38	1.53e-10	Mean platelet volume;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg15731816	chr14:75230414	YLPM1	0.5	6.98	0.39	2.39e-11	Systemic lupus erythematosus;
CESC	cis	rs9611565	0.506	rs4822020	chr22:41700203	C/T	cg06634786	chr22:41940651	POLR3H	-0.51	-5.53	-0.32	7.85e-8	Vitiligo;
CESC	cis	rs4148883	0.645	rs2851287	chr4:100014548	G/A	cg13256891	chr4:100009986	ADH5	0.56	7.17	0.4	7.63e-12	Alcohol dependence;
CESC	cis	rs72781680	0.950	rs72796402	chr2:24180104	A/G	cg08917208	chr2:24149416	ATAD2B	1.12	10.07	0.53	2.16e-20	Lymphocyte counts;
CESC	cis	rs4889855	0.614	rs9898443	chr17:78469357	C/T	cg10586883	chr17:79312681	NA	0.38	5.07	0.3	7.5e-7	Fractional excretion of uric acid;
CESC	cis	rs10504229	0.871	rs60342323	chr8:58154899	T/C	cg24829409	chr8:58192753	C8orf71	-0.63	-8.24	-0.45	8.12e-15	Developmental language disorder (linguistic errors);
CESC	cis	rs2742234	0.541	rs871763	chr10:43734188	C/T	cg15436174	chr10:43711423	RASGEF1A	0.47	5.52	0.32	7.96e-8	Hirschsprung disease;
CESC	cis	rs748404	0.660	rs2467742	chr15:43750237	C/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.53	8.35	0.46	3.89e-15	Lung cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14361189	chr14:19360467	NA	-0.58	-7.51	-0.42	9.07e-13	Gut microbiome composition (summer);
CESC	cis	rs2236918	0.901	rs1776135	chr1:242025530	A/G	cg17736920	chr1:242011382	EXO1	0.72	9.62	0.51	5.63e-19	Menopause (age at onset);
CESC	cis	rs4970988	0.501	rs11204713	chr1:150694623	T/A	cg18016565	chr1:150552671	MCL1	0.34	5.39	0.31	1.53e-7	Urate levels;
CESC	cis	rs6540556	0.954	rs2076150	chr1:209933540	A/G	cg23920097	chr1:209922102	NA	-0.37	-5.54	-0.32	7.2e-8	Red blood cell count;
CESC	cis	rs12142240	0.698	rs72679807	chr1:46846490	G/A	cg00530320	chr1:46809349	NSUN4	0.6	8.3	0.45	5.19e-15	Menopause (age at onset);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg04944291	chr3:195270345	PPP1R2	0.46	6.04	0.35	5.15e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs477895	1.000	rs66968227	chr11:64070930	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.76	6.37	0.36	8.41e-10	Mean platelet volume;
CESC	cis	rs7085104	0.572	rs284860	chr10:104572963	T/C	cg23093090	chr10:104574429	C10orf26	0.34	5.41	0.32	1.39e-7	Immature fraction of reticulocytes;Schizophrenia;
CESC	cis	rs11690935	0.550	rs11676438	chr2:172826668	G/A	cg13550731	chr2:172543902	DYNC1I2	0.46	6.29	0.36	1.31e-9	Schizophrenia;
CESC	trans	rs7618501	1.000	rs6802890	chr3:49832261	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.56	7.94	0.44	5.74e-14	Intelligence (multi-trait analysis);
CESC	cis	rs1642645	0.831	rs7535305	chr1:42489602	C/A	cg16685388	chr1:42384056	HIVEP3	0.37	5.49	0.32	9.65e-8	Left ventricular obstructive tract defect (maternal effect);
CESC	cis	rs2635047	0.638	rs2668784	chr18:44711391	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.41	5.59	0.32	5.7e-8	Educational attainment;
CESC	cis	rs896854	0.530	rs10956934	chr8:95992473	C/A	cg23172400	chr8:95962367	TP53INP1	-0.4	-8.11	-0.45	1.88e-14	Type 2 diabetes;
CESC	trans	rs2115172	0.836	rs4835799	chr5:122762229	A/G	cg11287903	chr10:115613834	DCLRE1A;NHLRC2	0.46	6.01	0.35	6.06e-9	Weight;
CESC	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.54	-8.16	-0.45	1.32e-14	Longevity;Endometriosis;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg15889649	chr15:79055693	ADAMTS7	0.48	6.97	0.39	2.59e-11	Fibrinogen levels;
CESC	cis	rs9788333	0.762	rs4441120	chr13:21886863	T/A	cg23743428	chr13:21893420	NA	-0.33	-5.38	-0.31	1.62e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.47	-5.24	-0.31	3.22e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2066819	1.000	rs1274493	chr12:56682371	C/T	cg26734620	chr12:56694298	CS	-0.93	-9.55	-0.51	9.4e-19	Psoriasis vulgaris;
CESC	cis	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg19803976	chr18:11850907	CHMP1B;GNAL	-0.47	-6.02	-0.35	5.67e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs4835473	0.897	rs1391189	chr4:144612104	T/C	cg25736465	chr4:144833511	NA	-0.34	-5.05	-0.3	8.41e-7	Immature fraction of reticulocytes;
CESC	cis	rs2839186	0.500	rs13052701	chr21:47660045	A/T	cg12516959	chr21:47718080	NA	-0.49	-6.7	-0.38	1.26e-10	Testicular germ cell tumor;
CESC	cis	rs2991971	0.810	rs2036021	chr1:45901370	G/A	cg05343316	chr1:45956843	TESK2	-0.57	-8.16	-0.45	1.32e-14	High light scatter reticulocyte count;
CESC	cis	rs3096299	0.967	rs16965692	chr16:89471482	C/T	cg08822215	chr16:89438651	ANKRD11	-0.4	-6.25	-0.36	1.61e-9	Multiple myeloma (IgH translocation);
CESC	cis	rs10465746	0.570	rs1886769	chr1:84471134	C/A	cg10977910	chr1:84465055	TTLL7	0.44	5.63	0.33	4.57e-8	Obesity-related traits;
CESC	cis	rs12497850	0.931	rs7623023	chr3:48914238	G/A	cg07636037	chr3:49044803	WDR6	0.99	18.24	0.75	1.02e-48	Parkinson's disease;
CESC	cis	rs9388451	0.839	rs3799711	chr6:126075313	C/T	cg05901451	chr6:126070800	HEY2	0.66	9.34	0.5	4.14e-18	Brugada syndrome;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg07869135	chr8:123794843	ZHX2	-0.44	-6.25	-0.36	1.64e-9	Gambling;
CESC	cis	rs75477785	1.000	rs77542756	chr1:209989281	G/A	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.92	6.04	0.35	5.06e-9	Cleft lip with or without cleft palate;
CESC	cis	rs6747952	0.899	rs2880132	chr2:239082976	G/A	cg17459225	chr2:239074497	NA	0.32	5.1	0.3	6.53e-7	Mean corpuscular hemoglobin concentration;
CESC	cis	rs9905704	0.633	rs2680713	chr17:56523900	G/T	cg12560992	chr17:57184187	TRIM37	0.6	5.62	0.33	4.85e-8	Testicular germ cell tumor;
CESC	cis	rs258892	0.895	rs34206264	chr5:72059806	C/G	cg21869765	chr5:72125136	TNPO1	-0.43	-5.35	-0.31	1.93e-7	Small cell lung carcinoma;
CESC	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg14820908	chr5:178986412	RUFY1	0.51	7.97	0.44	4.64e-14	Lung cancer;
CESC	cis	rs7618915	0.501	rs34739010	chr3:52766122	A/G	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.36	6.49	0.37	4.2e-10	Bipolar disorder;
CESC	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg11301795	chr4:187892539	NA	-0.75	-12.33	-0.6	6.74e-28	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs853679	0.517	rs4713143	chr6:28106759	A/C	cg17949981	chr6:28129498	ZNF389	0.45	5.71	0.33	3.07e-8	Depression;
CESC	cis	rs12478296	1.000	rs66612947	chr2:243035962	A/T	cg06360820	chr2:242988706	NA	-0.68	-7.6	-0.42	5.02e-13	Obesity-related traits;
CESC	cis	rs12477438	0.520	rs12621007	chr2:99791946	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.87	16.26	0.71	1.06e-41	Chronic sinus infection;
CESC	cis	rs7811142	0.667	rs3873746	chr7:99935097	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.93	10.65	0.55	2.74e-22	Platelet count;
CESC	cis	rs2439831	1.000	rs689647	chr15:43762196	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.89	10.58	0.54	4.72e-22	Lung cancer in ever smokers;
CESC	cis	rs5753037	0.653	rs131285	chr22:30157940	T/C	cg01021169	chr22:30184971	ASCC2	-0.44	-6.11	-0.35	3.52e-9	Type 1 diabetes;
CESC	cis	rs506597	0.920	rs534043	chr7:100312724	A/G	cg10426581	chr7:100472382	SRRT	-0.62	-5.07	-0.3	7.32e-7	Pursuit maintenance gain in psychotic disorders;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg03442064	chr6:41515050	FOXP4	0.44	6.02	0.35	5.71e-9	Systemic lupus erythematosus;
CESC	cis	rs5744897	0.581	rs35235926	chr12:133304126	G/A	cg17341477	chr12:133246679	POLE	0.57	5.25	0.31	3.16e-7	Urate levels in overweight individuals;
CESC	cis	rs7666738	0.830	rs9995386	chr4:98907826	T/C	cg05340658	chr4:99064831	C4orf37	0.76	11.14	0.56	6.8e-24	Colonoscopy-negative controls vs population controls;
CESC	cis	rs12220238	1.000	rs11000941	chr10:76018301	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.63	5.72	0.33	2.87e-8	Soluble interleukin-2 receptor subunit alpha;
CESC	cis	rs898097	0.625	rs898095	chr17:80890638	T/C	cg15664640	chr17:80829946	TBCD	0.4	5.7	0.33	3.11e-8	Breast cancer;
CESC	cis	rs12142240	0.698	rs17361950	chr1:46864150	C/T	cg10495392	chr1:46806563	NSUN4	0.55	5.93	0.34	9.24e-9	Menopause (age at onset);
CESC	cis	rs9399135	0.967	rs2327578	chr6:135329969	C/T	cg24558204	chr6:135376177	HBS1L	0.53	7.28	0.41	3.85e-12	Red blood cell count;
CESC	cis	rs17376456	0.825	rs10056879	chr5:93282218	C/A	cg25358565	chr5:93447407	FAM172A	1.14	9.72	0.51	2.6e-19	Diabetic retinopathy;
CESC	cis	rs2637266	0.905	rs1907313	chr10:78338072	A/G	cg18941641	chr10:78392320	NA	0.39	7.21	0.41	5.78e-12	Pulmonary function;
CESC	trans	rs11098499	0.865	rs28634456	chr4:120375778	A/G	cg25214090	chr10:38739885	LOC399744	0.69	9.59	0.51	6.76e-19	Corneal astigmatism;
CESC	cis	rs2070488	0.965	rs6599209	chr3:38558197	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.9	-16.53	-0.71	1.16e-42	Electrocardiographic conduction measures;
CESC	trans	rs6445797	0.632	rs2029464	chr3:56661320	T/G	cg15444621	chr13:113611794	NA	0.34	6.1	0.35	3.64e-9	Gastritis;
CESC	cis	rs7552404	0.924	rs1611823	chr1:76221706	T/G	cg22875332	chr1:76189707	ACADM	0.7	9.65	0.51	4.56e-19	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs597539	0.652	rs674654	chr11:68698762	G/T	cg06028808	chr11:68637592	NA	0.41	5.06	0.3	7.97e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs2243480	1.000	rs465359	chr7:65558164	C/T	cg12463550	chr7:65579703	CRCP	0.74	5.71	0.33	3.02e-8	Diabetic kidney disease;
CESC	cis	rs7845219	0.544	rs10956932	chr8:95948202	C/T	cg23172400	chr8:95962367	TP53INP1	0.33	6.11	0.35	3.52e-9	Type 2 diabetes;
CESC	cis	rs2072732	0.861	rs12044848	chr1:2960790	C/T	cg03976712	chr1:2946727	NA	0.35	5.63	0.33	4.52e-8	Plateletcrit;
CESC	cis	rs798554	0.757	rs1713919	chr7:2864706	C/A	cg19717773	chr7:2847554	GNA12	-0.55	-7.78	-0.43	1.59e-13	Height;
CESC	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg23978390	chr7:1156363	C7orf50	0.46	6.24	0.36	1.72e-9	Longevity;Endometriosis;
CESC	cis	rs8067545	0.611	rs7219615	chr17:20132558	T/A	cg13482628	chr17:19912719	NA	-0.42	-5.64	-0.33	4.46e-8	Schizophrenia;
CESC	cis	rs9322193	0.962	rs9397022	chr6:150133188	C/T	cg09699651	chr6:150184138	LRP11	0.4	5.14	0.3	5.29e-7	Lung cancer;
CESC	cis	rs6580649	0.598	rs1793913	chr12:48387025	T/A	cg05342945	chr12:48394962	COL2A1	-0.49	-5.97	-0.34	7.7e-9	Lung cancer;
CESC	trans	rs7107217	1.000	rs1873872	chr11:129473993	A/T	cg09242721	chr3:3168535	TRNT1	0.47	6.25	0.36	1.67e-9	Breast cancer;Type 2 diabetes;
CESC	cis	rs2694528	0.686	rs7729652	chr5:59872414	A/G	cg11474532	chr5:59995715	DEPDC1B	0.9	6.32	0.36	1.1e-9	Parkinson's disease;
CESC	cis	rs9649213	0.593	rs6947340	chr7:97912241	A/G	cg24562669	chr7:97807699	LMTK2	-0.44	-6.4	-0.37	7.11e-10	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs1862618	0.853	rs252887	chr5:56166188	A/G	cg03609598	chr5:56110824	MAP3K1	-0.51	-5.41	-0.32	1.38e-7	Initial pursuit acceleration;
CESC	cis	rs4077515	0.934	rs10781507	chr9:139272058	A/G	cg14169450	chr9:139327907	INPP5E	0.36	5.24	0.31	3.27e-7	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs11785400	0.793	rs4736364	chr8:143742113	C/T	cg24634471	chr8:143751801	JRK	0.46	5.94	0.34	8.96e-9	Schizophrenia;
CESC	cis	rs2932538	0.922	rs3790611	chr1:113067792	A/G	cg22162597	chr1:113214053	CAPZA1	0.51	6.48	0.37	4.54e-10	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CESC	cis	rs2645694	0.911	rs2703147	chr4:77831307	C/T	cg10057126	chr4:77819792	ANKRD56	0.54	7.56	0.42	6.7e-13	Emphysema distribution in smoking;
CESC	cis	rs6963495	0.818	rs1355614	chr7:105179176	A/G	cg02135003	chr7:105160482	PUS7	-0.45	-6.26	-0.36	1.57e-9	Bipolar disorder (body mass index interaction);
CESC	cis	rs17253792	0.822	rs77182097	chr14:56136695	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.81	5.68	0.33	3.46e-8	Putamen volume;
CESC	cis	rs4713118	0.662	rs9468271	chr6:28024570	A/G	cg19592336	chr6:28129416	ZNF389	0.53	6.92	0.39	3.43e-11	Parkinson's disease;
CESC	cis	rs3733585	0.673	rs7377578	chr4:9952775	T/C	cg11266682	chr4:10021025	SLC2A9	-0.57	-10.99	-0.56	2.07e-23	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs6831352	0.879	rs2851255	chr4:100042103	C/G	cg13256891	chr4:100009986	ADH5	0.67	7.56	0.42	6.5e-13	Alcohol dependence;
CESC	cis	rs909002	0.772	rs12740754	chr1:32083273	G/C	cg13919466	chr1:32135498	COL16A1	-0.47	-8.41	-0.46	2.54e-15	Intelligence (multi-trait analysis);
CESC	cis	rs7264396	0.563	rs7264869	chr20:34346502	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.68	7.34	0.41	2.59e-12	Total cholesterol levels;
CESC	cis	rs4969178	0.965	rs11077364	chr17:76400337	C/A	cg05887092	chr17:76393375	PGS1	0.58	9.26	0.49	7e-18	HDL cholesterol levels;
CESC	cis	rs16854884	0.632	rs4563409	chr3:143682122	T/G	cg06585982	chr3:143692056	C3orf58	0.51	6.27	0.36	1.49e-9	Economic and political preferences (feminism/equality);
CESC	cis	rs644799	0.965	rs10831425	chr11:95500628	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.57	7.19	0.4	6.45e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs7666738	0.784	rs4699602	chr4:99034903	T/C	cg05340658	chr4:99064831	C4orf37	0.84	12.75	0.62	2.34e-29	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.55	-6.1	-0.35	3.69e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs78456975	0.941	rs6755875	chr2:1557109	T/C	cg01028140	chr2:1542097	TPO	-0.51	-5.47	-0.32	1.07e-7	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs12477438	0.520	rs11685759	chr2:99766217	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.86	15.04	0.68	2.28e-37	Chronic sinus infection;
CESC	cis	rs59918340	0.728	rs59172574	chr8:142231945	C/G	cg16341495	chr8:142228727	SLC45A4	-0.44	-5.29	-0.31	2.54e-7	Immature fraction of reticulocytes;
CESC	cis	rs2012796	1.000	rs8008024	chr14:81818492	A/G	cg02996355	chr14:81879375	NA	0.57	6.92	0.39	3.41e-11	Night sleep phenotypes;
CESC	cis	rs6460942	0.908	rs112049544	chr7:12242551	A/G	cg06484146	chr7:12443880	VWDE	-0.63	-6.27	-0.36	1.44e-9	Coronary artery disease;
CESC	cis	rs4728302	0.608	rs10254118	chr7:133158353	T/A	cg10665199	chr7:133106180	EXOC4	0.53	7.37	0.41	2.16e-12	Intelligence;Intelligence (multi-trait analysis);
CESC	cis	rs3733585	0.673	rs4407505	chr4:9953367	T/G	cg02734326	chr4:10020555	SLC2A9	-0.39	-5.64	-0.33	4.45e-8	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs4704187	0.687	rs11957125	chr5:74527639	G/A	cg03227963	chr5:74354835	NA	0.28	5.08	0.3	7.28e-7	Response to amphetamines;
CESC	cis	rs3892630	0.588	rs7260037	chr19:33242701	G/A	cg13157960	chr19:33183277	NUDT19	0.53	5.33	0.31	2.09e-7	Red blood cell traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02469461	chr2:231589895	CAB39	-0.53	-6.56	-0.37	2.85e-10	Gut microbiome composition (summer);
CESC	cis	rs137603	0.602	rs9611146	chr22:39718120	G/T	cg01093212	chr22:39715156	SNORD43;RPL3	-0.42	-5.41	-0.32	1.39e-7	Primary biliary cholangitis;
CESC	cis	rs769267	0.825	rs1469713	chr19:19528806	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.57	7.48	0.42	1.09e-12	Tonsillectomy;
CESC	cis	rs1552244	0.554	rs17050705	chr3:10046398	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.56	-7.26	-0.41	4.31e-12	Alzheimer's disease;
CESC	cis	rs4780401	0.609	rs35902600	chr16:11800848	C/T	cg01061890	chr16:11836724	TXNDC11	-0.55	-7.52	-0.42	8.39e-13	Rheumatoid arthritis;
CESC	cis	rs9399135	0.967	rs4896122	chr6:135295081	T/C	cg24558204	chr6:135376177	HBS1L	0.5	6.75	0.38	9.09e-11	Red blood cell count;
CESC	cis	rs853679	0.517	rs1947863	chr6:28099344	G/A	cg17949981	chr6:28129498	ZNF389	0.45	5.71	0.33	3.07e-8	Depression;
CESC	cis	rs8070740	0.731	rs1071648	chr17:5326089	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.51	6.44	0.37	5.73e-10	Menopause (age at onset);
CESC	cis	rs7264396	0.635	rs6060660	chr20:34476649	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.62	7.45	0.42	1.31e-12	Total cholesterol levels;
CESC	cis	rs710216	0.843	rs2297972	chr1:43418026	C/T	cg03128534	chr1:43423976	SLC2A1	-0.6	-7.66	-0.43	3.55e-13	Red cell distribution width;
CESC	cis	rs7811142	0.943	rs111493473	chr7:100049742	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.83	8.32	0.46	4.56e-15	Platelet count;
CESC	cis	rs1483890	0.723	rs6807930	chr3:69411662	C/T	cg22125112	chr3:69402811	FRMD4B	0.38	5.11	0.3	6.08e-7	Resting heart rate;
CESC	cis	rs6460942	0.597	rs7778131	chr7:12543233	T/G	cg20607287	chr7:12443886	VWDE	-0.71	-7.41	-0.41	1.69e-12	Coronary artery disease;
CESC	cis	rs7017914	0.967	rs10448014	chr8:71688165	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.2	-0.3	3.94e-7	Bone mineral density;
CESC	cis	rs7712401	0.601	rs246320	chr5:122308581	A/G	cg19412675	chr5:122181750	SNX24	0.41	5.18	0.3	4.51e-7	Mean platelet volume;
CESC	cis	rs7762018	1.000	rs17860606	chr6:170099561	G/A	cg05834625	chr6:170176447	C6orf70	0.63	7.65	0.43	3.62e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs151234	0.741	rs11644791	chr16:28601186	G/C	cg01378222	chr16:28622494	SULT1A1	-0.57	-7.18	-0.4	7.06e-12	Platelet distribution width;
CESC	cis	rs796364	1.000	rs281774	chr2:200814572	C/T	cg23649088	chr2:200775458	C2orf69	0.54	5.13	0.3	5.5e-7	Schizophrenia;
CESC	cis	rs7945705	0.902	rs2012696	chr11:8995818	A/C	cg09997546	chr11:8931473	C11orf17;ST5	0.37	6.03	0.35	5.45e-9	Hemoglobin concentration;
CESC	cis	rs9811920	0.715	rs6776886	chr3:99906270	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.38	5.84	0.34	1.5e-8	Axial length;
CESC	cis	rs1552244	0.935	rs7621551	chr3:10114205	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.8	-10.46	-0.54	1.15e-21	Alzheimer's disease;
CESC	cis	rs35110281	0.811	rs9980185	chr21:45057905	A/G	cg01579765	chr21:45077557	HSF2BP	-0.55	-8.76	-0.47	2.44e-16	Mean corpuscular volume;
CESC	cis	rs7666738	0.861	rs5010991	chr4:98972179	A/G	cg17366294	chr4:99064904	C4orf37	0.59	8.43	0.46	2.31e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10208940	0.920	rs13400463	chr2:68723912	G/A	cg12452813	chr2:68675892	NA	0.52	5.24	0.31	3.26e-7	Urate levels in lean individuals;
CESC	cis	rs9611565	0.512	rs4820444	chr22:42202606	A/G	cg06634786	chr22:41940651	POLR3H	0.65	6.63	0.38	1.82e-10	Vitiligo;
CESC	cis	rs13256369	0.802	rs11249884	chr8:8561552	C/T	cg17143192	chr8:8559678	CLDN23	-0.7	-7.92	-0.44	6.41e-14	Obesity-related traits;
CESC	cis	rs4253772	0.514	rs11704878	chr22:46714664	C/T	cg10541313	chr22:46663664	TTC38	0.68	5.11	0.3	6.09e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs1878931	0.501	rs9302871	chr16:3415512	T/C	cg22508957	chr16:3507546	NAT15	-0.38	-5.55	-0.32	7.02e-8	Body mass index (adult);
CESC	trans	rs921968	0.542	rs630858	chr2:219409689	C/A	cg15547669	chr20:2781122	CPXM1	0.35	6.0	0.35	6.31e-9	Mean corpuscular hemoglobin concentration;
CESC	cis	rs2645694	0.626	rs2703120	chr4:77822470	G/A	cg18351406	chr4:77819688	ANKRD56	0.51	6.36	0.36	8.93e-10	Emphysema distribution in smoking;
CESC	cis	rs7666738	0.830	rs2865979	chr4:99027137	T/C	cg24818145	chr4:99064322	C4orf37	0.39	5.09	0.3	6.95e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4330281	0.666	rs10433560	chr3:17803974	C/T	cg20981856	chr3:17787350	NA	0.38	5.35	0.31	1.87e-7	Schizophrenia;
CESC	cis	rs17401966	0.838	rs2182326	chr1:10385664	G/A	cg15208524	chr1:10270712	KIF1B	0.42	5.43	0.32	1.26e-7	Hepatocellular carcinoma;
CESC	cis	rs1707322	1.000	rs785468	chr1:46521517	G/A	cg06784218	chr1:46089804	CCDC17	-0.33	-5.65	-0.33	4.08e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2063714	0.532	rs2063713	chr6:157196299	G/T	cg23222435	chr6:157204239	ARID1B	-0.57	-7.21	-0.4	5.86e-12	Sitting height ratio;
CESC	cis	rs1983891	0.908	rs2148342	chr6:41519522	G/A	cg20194872	chr6:41519635	FOXP4	0.58	8.33	0.46	4.25e-15	Prostate cancer;
CESC	trans	rs1814175	0.645	rs7119101	chr11:49955665	G/A	cg03929089	chr4:120376271	NA	-0.92	-15.24	-0.68	4.38e-38	Height;
CESC	cis	rs9611565	0.840	rs9607799	chr22:41777558	A/G	cg03806693	chr22:41940476	POLR3H	-1.07	-13.24	-0.63	4.71e-31	Vitiligo;
CESC	cis	rs9300255	0.516	rs6488868	chr12:123799974	A/G	cg05973401	chr12:123451056	ABCB9	0.45	5.16	0.3	4.88e-7	Neutrophil percentage of white cells;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg25723933	chr1:155099956	EFNA1	-0.46	-6.06	-0.35	4.77e-9	Fibrinogen levels;
CESC	trans	rs76747430	0.504	rs739183	chr22:40673685	T/C	cg06617692	chr9:80262196	GNA14	0.54	6.02	0.35	5.89e-9	Facial morphology (factor 20);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02955050	chr19:59070391	UBE2M;LOC100131691	0.57	6.62	0.38	2.04e-10	Gut microbiome composition (summer);
CESC	cis	rs344364	0.511	rs1742468	chr16:1950243	C/G	cg26617929	chr16:1858877	NA	-0.49	-5.15	-0.3	5.09e-7	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs736408	0.677	rs2286798	chr3:52821177	G/T	cg17372223	chr3:52568218	NT5DC2	-0.38	-5.45	-0.32	1.15e-7	Bipolar disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02730322	chr20:43150917	SERINC3	-0.61	-7.28	-0.41	3.84e-12	Gut microbiome composition (summer);
CESC	cis	rs12824058	0.831	rs11608407	chr12:130805869	G/A	cg23887609	chr12:130822674	PIWIL1	0.45	5.66	0.33	3.87e-8	Menopause (age at onset);
CESC	cis	rs5769707	0.967	rs2071904	chr22:50034477	C/T	cg20744362	chr22:50050164	C22orf34	0.48	8.27	0.45	6.61e-15	Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs7412746	0.621	rs11204749	chr1:150929563	G/A	cg17724175	chr1:150552817	MCL1	0.33	5.09	0.3	6.88e-7	Melanoma;
CESC	cis	rs3733585	0.781	rs13103690	chr4:9972778	T/G	cg11266682	chr4:10021025	SLC2A9	-0.61	-12.17	-0.6	2.26e-27	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs1153858	1.000	rs3809472	chr15:45694318	G/T	cg21132104	chr15:45694354	SPATA5L1	0.86	11.67	0.58	1.14e-25	Homoarginine levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10387458	chr1:93645817	TMED5;CCDC18	0.58	6.98	0.39	2.39e-11	Gut microbiome composition (summer);
CESC	cis	rs896854	0.902	rs896852	chr8:95960886	G/T	cg23172400	chr8:95962367	TP53INP1	-0.5	-10.43	-0.54	1.43e-21	Type 2 diabetes;
CESC	cis	rs1218582	0.772	rs10908448	chr1:154882544	A/G	cg24250549	chr1:154909240	PMVK	-0.7	-10.6	-0.55	4.18e-22	Prostate cancer;
CESC	cis	rs4711336	0.935	rs3818529	chr6:33661106	T/C	cg14003231	chr6:33640908	ITPR3	0.31	5.25	0.31	3.08e-7	Height;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg02759888	chr15:63449753	RPS27L	-0.43	-6.11	-0.35	3.63e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs61841072	0.961	rs12131267	chr1:243138336	G/A	cg02356786	chr1:243265016	LOC731275	0.42	5.34	0.31	2.03e-7	Schizophrenia;
CESC	cis	rs4450798	0.649	rs9847246	chr3:13778888	C/T	cg23332027	chr3:13681764	NA	0.4	5.59	0.32	5.77e-8	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs6032067	0.777	rs55767422	chr20:43802497	A/G	cg11264863	chr20:43835661	SEMG1	0.5	5.38	0.31	1.62e-7	Blood protein levels;
CESC	cis	rs887829	0.569	rs7574296	chr2:234638249	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.56	-7.66	-0.43	3.59e-13	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CESC	cis	rs1879734	0.636	rs1879732	chr1:54175909	C/T	cg23596471	chr1:54105337	GLIS1	0.32	5.17	0.3	4.7e-7	Mitral valve prolapse;
CESC	cis	rs3741404	0.512	rs4980504	chr11:63873083	G/A	cg18225595	chr11:63971243	STIP1	-0.45	-5.76	-0.33	2.27e-8	Platelet count;
CESC	cis	rs2732480	0.557	rs2634682	chr12:48732943	T/C	cg24011408	chr12:48396354	COL2A1	0.42	5.76	0.33	2.27e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs317689	0.819	rs317677	chr12:69691806	G/A	cg14784868	chr12:69753453	YEATS4	0.49	5.29	0.31	2.53e-7	Response to diuretic therapy;
CESC	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg11494091	chr17:61959527	GH2	0.72	12.28	0.6	9.87e-28	Prudent dietary pattern;
CESC	cis	rs801193	0.569	rs35070132	chr7:66238083	C/T	cg10691866	chr7:65817282	TPST1	-0.33	-5.48	-0.32	1e-7	Aortic root size;
CESC	cis	rs2836974	0.831	rs6517521	chr21:40551588	A/G	cg27266027	chr21:40555129	PSMG1	0.43	5.25	0.31	3.13e-7	Cognitive function;
CESC	cis	rs11166629	0.502	rs6577717	chr8:135653832	G/T	cg27224718	chr8:135614730	ZFAT	0.42	5.23	0.31	3.44e-7	Smoking quantity;
CESC	cis	rs9291683	0.546	rs4529049	chr4:10045389	C/T	cg00071950	chr4:10020882	SLC2A9	0.82	13.84	0.65	3.86e-33	Bone mineral density;
CESC	trans	rs2727020	0.553	rs11040400	chr11:49518296	C/A	cg15704280	chr7:45808275	SEPT13	-0.93	-15.36	-0.69	1.63e-38	Coronary artery disease;
CESC	cis	rs6690583	0.623	rs6672362	chr1:85454881	C/G	cg22153463	chr1:85462885	MCOLN2	0.71	7.12	0.4	1.01e-11	Serum sulfate level;
CESC	cis	rs2011503	0.941	rs56135441	chr19:19371370	A/T	cg11584989	chr19:19387371	SF4	0.61	7.33	0.41	2.78e-12	Bipolar disorder;
CESC	cis	rs4665809	0.556	rs4665314	chr2:26415912	T/C	cg26314531	chr2:26401878	FAM59B	-0.83	-9.26	-0.49	7.37e-18	Gut microbiome composition (summer);
CESC	cis	rs7586673	0.578	rs6723840	chr2:161879615	G/T	cg08807892	chr2:162101083	NA	0.4	5.09	0.3	6.64e-7	Intelligence (multi-trait analysis);
CESC	cis	rs7208859	0.673	rs9914271	chr17:29232625	G/A	cg19761014	chr17:28927070	LRRC37B2	0.64	5.32	0.31	2.2e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs7089973	0.604	rs7920216	chr10:116611794	G/A	cg25233709	chr10:116636983	FAM160B1	0.38	5.98	0.34	7.26e-9	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg08555112	chr17:48942811	TOB1	-0.49	-7.34	-0.41	2.7e-12	Gambling;
CESC	cis	rs6032067	0.929	rs6017510	chr20:43831785	A/G	cg11264863	chr20:43835661	SEMG1	0.48	5.29	0.31	2.56e-7	Blood protein levels;
CESC	cis	rs7408868	0.831	rs1548555	chr19:15278057	A/G	cg14696996	chr19:15285081	NOTCH3	1.11	11.94	0.59	1.43e-26	Pulse pressure;
CESC	cis	rs4665809	0.590	rs2891496	chr2:26452605	G/A	cg26314531	chr2:26401878	FAM59B	0.86	9.09	0.49	2.34e-17	Gut microbiome composition (summer);
CESC	cis	rs6484504	0.532	rs2616799	chr11:31319044	T/C	cg14844989	chr11:31128820	NA	0.4	5.49	0.32	9.59e-8	Red blood cell count;
CESC	cis	rs12410462	0.581	rs7547204	chr1:227560909	C/T	cg23173402	chr1:227635558	NA	0.63	5.4	0.32	1.46e-7	Major depressive disorder;
CESC	cis	rs3091242	0.781	rs71652378	chr1:25721457	G/C	cg27572855	chr1:25598939	RHD	0.44	7.25	0.41	4.5e-12	Erythrocyte sedimentation rate;
CESC	cis	rs9915657	0.870	rs4140903	chr17:70133771	C/T	cg09344028	chr17:70110421	NA	0.34	6.15	0.35	2.88e-9	Thyroid hormone levels;
CESC	cis	rs4474465	0.790	rs4945293	chr11:78254554	T/C	cg27205649	chr11:78285834	NARS2	0.42	5.32	0.31	2.16e-7	Alzheimer's disease (survival time);
CESC	cis	rs875971	0.862	rs778686	chr7:65835910	C/T	cg12463550	chr7:65579703	CRCP	0.49	6.27	0.36	1.45e-9	Aortic root size;
CESC	trans	rs916888	0.610	rs199442	chr17:44820122	G/A	cg10053473	chr17:62856997	LRRC37A3	-0.66	-9.2	-0.49	1.13e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs4237845	0.591	rs10431506	chr12:58311524	G/A	cg00677455	chr12:58241039	CTDSP2	0.54	6.38	0.36	7.84e-10	Intelligence (multi-trait analysis);
CESC	cis	rs12497850	0.829	rs8926	chr3:49052785	T/A	cg07636037	chr3:49044803	WDR6	1.05	19.08	0.76	1.13e-51	Parkinson's disease;
CESC	cis	rs854765	0.647	rs2974999	chr17:17997547	T/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.47	5.92	0.34	9.86e-9	Total body bone mineral density;
CESC	cis	rs75477785	0.590	rs11119388	chr1:210174417	A/G	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.92	6.23	0.36	1.82e-9	Cleft lip with or without cleft palate;
CESC	cis	rs3740540	0.507	rs942015	chr10:126289932	G/T	cg04949429	chr10:126290192	LHPP	0.38	5.27	0.31	2.78e-7	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
CESC	cis	rs568617	0.953	rs583887	chr11:65644027	T/C	cg00576331	chr11:65640516	EFEMP2	0.45	5.3	0.31	2.48e-7	Crohn's disease;
CESC	cis	rs3105593	1.000	rs62017189	chr15:50922032	T/A	cg08437265	chr15:50716283	USP8	0.41	5.25	0.31	3.18e-7	QT interval;
CESC	cis	rs6963495	0.818	rs117887993	chr7:105193837	T/G	cg19920283	chr7:105172520	RINT1	0.68	6.27	0.36	1.47e-9	Bipolar disorder (body mass index interaction);
CESC	cis	rs9815354	0.812	rs111967505	chr3:41873157	C/T	cg03022575	chr3:42003672	ULK4	0.71	6.23	0.36	1.83e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs11122272	0.735	rs910822	chr1:231498721	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.56	-7.65	-0.43	3.62e-13	Hemoglobin concentration;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08940762	chr2:233415810	TIGD1;EIF4E2	0.57	6.24	0.36	1.71e-9	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06622735	chr5:473452	SLC9A3;LOC25845	0.61	6.71	0.38	1.16e-10	Gut microbiome composition (summer);
CESC	cis	rs6502050	0.835	rs8067138	chr17:80111026	T/C	cg23985595	chr17:80112537	CCDC57	-0.42	-6.58	-0.37	2.43e-10	Life satisfaction;
CESC	cis	rs2075371	1.000	rs2598285	chr7:133971153	A/T	cg20476274	chr7:133979776	SLC35B4	0.69	10.23	0.53	6.57e-21	Mean platelet volume;
CESC	cis	rs1790761	0.806	rs7114510	chr11:67224594	C/T	cg14500267	chr11:67383377	NA	0.32	5.36	0.31	1.83e-7	Mean corpuscular volume;
CESC	cis	rs12220238	1.000	rs7081350	chr10:75990328	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.62	6.03	0.35	5.57e-9	Soluble interleukin-2 receptor subunit alpha;
CESC	cis	rs2032447	0.507	rs478349	chr6:25894057	T/C	cg03517284	chr6:25882590	NA	-0.66	-9.34	-0.5	4.11e-18	Intelligence (multi-trait analysis);
CESC	cis	rs2952156	0.920	rs2941506	chr17:37833035	A/G	cg20243544	chr17:37824526	PNMT	0.63	8.01	0.44	3.74e-14	Asthma;
CESC	trans	rs629535	0.725	rs639127	chr8:70073251	A/G	cg21567404	chr3:27674614	NA	0.88	10.34	0.54	2.74e-21	Dupuytren's disease;
CESC	cis	rs4237845	0.967	rs4553410	chr12:58301211	G/A	cg02175503	chr12:58329896	NA	0.64	8.5	0.46	1.43e-15	Intelligence (multi-trait analysis);
CESC	cis	rs72781680	1.000	rs72788280	chr2:24095907	A/G	cg20701182	chr2:24300061	SF3B14	0.62	5.68	0.33	3.54e-8	Lymphocyte counts;
CESC	cis	rs4665809	0.887	rs4665814	chr2:26273687	G/T	cg27170947	chr2:26402098	FAM59B	-0.58	-6.79	-0.38	7.52e-11	Gut microbiome composition (summer);
CESC	cis	rs2839186	0.504	rs11702278	chr21:47936295	T/G	cg12379764	chr21:47803548	PCNT	0.64	8.84	0.48	1.34e-16	Testicular germ cell tumor;
CESC	cis	rs6693567	0.507	rs9436120	chr1:150473084	T/C	cg09579323	chr1:150459698	TARS2	0.47	5.73	0.33	2.76e-8	Migraine;
CESC	cis	rs3026101	0.671	rs3026140	chr17:5313522	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.41	5.31	0.31	2.29e-7	Body mass index;
CESC	cis	rs6540559	0.673	rs6540561	chr1:209982255	C/T	cg22029157	chr1:209979665	IRF6	0.76	8.72	0.47	3.02e-16	Cleft lip with or without cleft palate;
CESC	cis	rs17376456	0.569	rs12653528	chr5:93212833	T/C	cg25358565	chr5:93447407	FAM172A	-0.71	-7.53	-0.42	7.86e-13	Diabetic retinopathy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11741956	chr14:103438353	CDC42BPB	-0.64	-6.96	-0.39	2.75e-11	Gut microbiome composition (summer);
CESC	trans	rs2235573	0.570	rs5995529	chr22:38415721	A/G	cg19894588	chr14:64061835	NA	-0.52	-6.65	-0.38	1.64e-10	Glioblastoma;Glioma;
CESC	cis	rs875971	0.798	rs6460304	chr7:65964728	G/A	cg18876405	chr7:65276391	NA	0.49	6.55	0.37	3e-10	Aortic root size;
CESC	cis	rs8177253	1.000	rs8177262	chr3:133480652	A/G	cg12373951	chr3:133503437	NA	-0.43	-6.27	-0.36	1.42e-9	Iron status biomarkers;
CESC	cis	rs2273669	0.667	rs16822	chr6:109307710	G/A	cg05315195	chr6:109294784	ARMC2	-0.65	-6.08	-0.35	4.15e-9	Prostate cancer;
CESC	cis	rs2197308	0.605	rs2387437	chr12:37919367	T/C	cg13010199	chr12:38710504	ALG10B	0.46	5.78	0.33	2.05e-8	Morning vs. evening chronotype;
CESC	cis	rs9322193	0.884	rs9688858	chr6:149959047	C/A	cg13206674	chr6:150067644	NUP43	0.4	5.68	0.33	3.59e-8	Lung cancer;
CESC	cis	rs7605827	0.930	rs13035283	chr2:15500939	G/C	cg19274914	chr2:15703543	NA	0.33	5.91	0.34	1.03e-8	Educational attainment (years of education);
CESC	cis	rs10504229	0.683	rs7838958	chr8:58136968	T/C	cg21724239	chr8:58056113	NA	0.58	5.95	0.34	8.29e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs4253772	0.530	rs9615961	chr22:46754993	T/C	cg00784671	chr22:46762841	CELSR1	-0.64	-6.18	-0.36	2.35e-9	LDL cholesterol;Cholesterol, total;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04674497	chr6:45346044	SUPT3H;RUNX2	0.48	6.18	0.35	2.44e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs7666738	0.830	rs13133355	chr4:98919415	A/G	cg03467027	chr4:99064603	C4orf37	0.43	5.32	0.31	2.26e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs801193	1.000	rs2707850	chr7:66203870	G/T	cg06456125	chr7:65229604	NA	0.4	5.23	0.31	3.51e-7	Aortic root size;
CESC	cis	rs2228479	0.867	rs62056110	chr16:89946388	A/C	cg06558623	chr16:89946397	TCF25	1.06	8.98	0.48	5.17e-17	Skin colour saturation;
CESC	trans	rs8073060	0.544	rs1080352	chr17:34002362	A/G	cg19694781	chr19:47549865	TMEM160	-0.73	-7.2	-0.4	6.17e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg11965913	chr1:205819406	PM20D1	0.82	13.95	0.65	1.49e-33	Menarche (age at onset);
CESC	cis	rs4888262	0.526	rs8057279	chr16:74627303	C/T	cg01733217	chr16:74700730	RFWD3	0.85	11.48	0.58	4.93e-25	Testicular germ cell tumor;
CESC	cis	rs7122539	0.506	rs11227625	chr11:66684151	T/G	cg24851651	chr11:66362959	CCS	0.39	5.73	0.33	2.71e-8	HIV-1 susceptibility;
CESC	cis	rs7772486	0.806	rs4075695	chr6:146250959	A/G	cg23711669	chr6:146136114	FBXO30	-0.77	-10.89	-0.56	4.58e-23	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs3812762	0.879	rs4929934	chr11:8777789	A/G	cg03980550	chr11:8754370	ST5	0.35	5.1	0.3	6.47e-7	Hypospadias;
CESC	cis	rs8177253	1.000	rs8177261	chr3:133480588	A/C	cg11941060	chr3:133502564	NA	-0.48	-6.65	-0.38	1.67e-10	Iron status biomarkers;
CESC	cis	rs6540559	0.673	rs6540564	chr1:210019910	T/C	cg21951975	chr1:209979733	IRF6	0.59	7.16	0.4	8.01e-12	Cleft lip with or without cleft palate;
CESC	cis	rs4713118	0.662	rs149969	chr6:27977737	A/G	cg22143856	chr6:28129313	ZNF389	0.39	5.17	0.3	4.57e-7	Parkinson's disease;
CESC	cis	rs2991971	0.869	rs2453404	chr1:46014735	A/G	cg03146154	chr1:46216737	IPP	-0.45	-5.58	-0.32	5.83e-8	High light scatter reticulocyte count;
CESC	cis	rs11122272	0.735	rs2739510	chr1:231526718	T/C	cg06096015	chr1:231504339	EGLN1	0.43	6.12	0.35	3.28e-9	Hemoglobin concentration;
CESC	cis	rs6732160	0.613	rs10179063	chr2:73385111	T/A	cg01422370	chr2:73384389	NA	0.56	8.74	0.47	2.67e-16	Intelligence (multi-trait analysis);
CESC	cis	rs3749237	0.595	rs17595772	chr3:49409704	G/A	cg02487422	chr3:49467188	NICN1	0.55	7.98	0.44	4.56e-14	Resting heart rate;
CESC	trans	rs208520	0.690	rs4710564	chr6:66823478	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.93	10.82	0.55	7.79e-23	Exhaled nitric oxide output;
CESC	cis	rs2228479	0.850	rs12597296	chr16:89822331	C/T	cg00800038	chr16:89945340	TCF25	-0.91	-7.54	-0.42	7.39e-13	Skin colour saturation;
CESC	cis	rs875971	0.862	rs17747530	chr7:65994729	G/C	cg18876405	chr7:65276391	NA	0.53	7.28	0.41	3.9e-12	Aortic root size;
CESC	cis	rs1552244	1.000	rs7628448	chr3:10146828	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.8	-10.08	-0.53	2.01e-20	Alzheimer's disease;
CESC	cis	rs2576037	0.545	rs9948405	chr18:44494527	C/G	cg19077165	chr18:44547161	KATNAL2	-0.61	-9.16	-0.49	1.5e-17	Personality dimensions;
CESC	cis	rs9614461	0.702	rs3788648	chr22:45727180	G/A	cg22884516	chr22:45809543	SMC1B;RIBC2	0.56	5.15	0.3	4.98e-7	Tonsillectomy;
CESC	cis	rs965469	0.779	rs6515791	chr20:3310443	C/G	cg25506879	chr20:3388711	C20orf194	-0.49	-5.41	-0.32	1.42e-7	IFN-related cytopenia;
CESC	cis	rs2204008	0.744	rs8189486	chr12:38244968	C/T	cg13010199	chr12:38710504	ALG10B	0.51	6.3	0.36	1.24e-9	Bladder cancer;
CESC	cis	rs59918340	0.509	rs11784862	chr8:142203452	T/C	cg18755752	chr8:142205143	DENND3	-0.44	-5.6	-0.33	5.34e-8	Immature fraction of reticulocytes;
CESC	cis	rs7647973	0.667	rs11721148	chr3:49646669	G/A	cg03060546	chr3:49711283	APEH	0.64	7.34	0.41	2.55e-12	Menarche (age at onset);
CESC	trans	rs916888	0.779	rs199528	chr17:44843136	C/T	cg10053473	chr17:62856997	LRRC37A3	-0.7	-7.4	-0.41	1.78e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs7666738	0.830	rs4699574	chr4:98725544	C/T	cg24818145	chr4:99064322	C4orf37	0.39	5.1	0.3	6.51e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs12220238	1.000	rs12256105	chr10:75909634	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.66	6.68	0.38	1.42e-10	Soluble interleukin-2 receptor subunit alpha;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00102808	chr16:620304	PIGQ	0.56	6.35	0.36	9.1e-10	Gut microbiome composition (summer);
CESC	cis	rs10206020	0.921	rs72778005	chr2:1573122	C/G	cg26248373	chr2:1572462	NA	-0.59	-6.98	-0.39	2.31e-11	IgG glycosylation;
CESC	cis	rs4820539	1.000	rs3788347	chr22:23467804	G/A	cg14186256	chr22:23484241	RTDR1	0.81	14.66	0.67	4.99e-36	Bone mineral density;
CESC	cis	rs9341808	0.621	rs2322627	chr6:80806341	T/A	cg08355045	chr6:80787529	NA	0.33	5.12	0.3	5.88e-7	Sitting height ratio;
CESC	cis	rs2708240	1.000	rs2710105	chr7:147574236	G/T	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.35	-5.77	-0.33	2.23e-8	QT interval (drug interaction);
CESC	cis	rs34638657	0.872	rs7202258	chr16:82195013	T/C	cg09439754	chr16:82129088	HSD17B2	-0.37	-5.42	-0.32	1.33e-7	Lung adenocarcinoma;
CESC	cis	rs8177253	0.507	rs4241357	chr3:133475563	A/C	cg16262614	chr3:133464971	TF	-0.3	-5.67	-0.33	3.81e-8	Iron status biomarkers;
CESC	cis	rs3857536	0.813	rs7770349	chr6:66946659	G/T	cg07460842	chr6:66804631	NA	-0.42	-5.29	-0.31	2.55e-7	Blood trace element (Cu levels);
CESC	cis	rs4839827	1	rs4839827	chr6:96853967	C/T	cg06623918	chr6:96969491	KIAA0776	0.62	8.44	0.46	2.05e-15	Migraine;
CESC	cis	rs1538970	0.961	rs4660854	chr1:45854087	A/T	cg24296786	chr1:45957014	TESK2	-0.45	-5.45	-0.32	1.13e-7	Platelet count;
CESC	cis	rs9768139	0.733	rs13225172	chr7:158120334	G/A	cg25566285	chr7:158114605	PTPRN2	0.47	7.32	0.41	2.89e-12	Calcium levels;
CESC	cis	rs9768139	0.935	rs10155946	chr7:158122116	C/T	cg25566285	chr7:158114605	PTPRN2	-0.49	-8.35	-0.46	3.88e-15	Calcium levels;
CESC	cis	rs7666738	0.830	rs4699592	chr4:98974202	A/C	cg03676636	chr4:99064102	C4orf37	0.34	5.2	0.3	3.93e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7147624	1.000	rs2411349	chr14:66214426	T/C	cg03016385	chr14:66212404	NA	-0.5	-5.25	-0.31	3.1e-7	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs11229030	0.893	rs2581925	chr11:57207414	G/A	cg00522883	chr11:57194120	SLC43A3	-0.45	-5.93	-0.34	9.44e-9	Crohn's disease;
CESC	cis	rs4819052	0.851	rs8134392	chr21:46663790	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	-0.48	-6.02	-0.35	5.68e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs7618915	0.547	rs13064064	chr3:52657002	T/C	cg18404041	chr3:52824283	ITIH1	-0.38	-6.34	-0.36	9.62e-10	Bipolar disorder;
CESC	cis	rs6982240	0.569	rs6992278	chr8:142279383	C/G	cg00131261	chr8:142287264	NA	-0.5	-7.33	-0.41	2.82e-12	Tonsillectomy;
CESC	cis	rs6430585	0.583	rs7581814	chr2:136641593	C/G	cg07169764	chr2:136633963	MCM6	-1.27	-19.97	-0.78	9.06e-55	Corneal structure;
CESC	cis	rs7618915	0.501	rs34754793	chr3:52629177	A/T	cg17372223	chr3:52568218	NT5DC2	0.42	6.42	0.37	6.33e-10	Bipolar disorder;
CESC	cis	rs9733	0.596	rs7529998	chr1:150662531	C/T	cg18016565	chr1:150552671	MCL1	0.33	5.16	0.3	4.96e-7	Tonsillectomy;
CESC	cis	rs116095464	0.558	rs9312978	chr5:221930	C/G	cg16372103	chr5:203701	NA	0.49	5.29	0.31	2.58e-7	Breast cancer;
CESC	cis	rs7833986	0.501	rs72653990	chr8:57037115	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.61	7.55	0.42	7e-13	Height;
CESC	cis	rs60843830	1.000	rs114976176	chr2:264621	A/C	cg00108164	chr2:264199	ACP1;SH3YL1	0.82	10.69	0.55	2.14e-22	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs9814567	0.929	rs9815297	chr3:134215052	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.41	-5.67	-0.33	3.79e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs1862618	0.802	rs986049	chr5:56110233	G/A	cg12311346	chr5:56204834	C5orf35	-0.7	-8.58	-0.47	8.32e-16	Initial pursuit acceleration;
CESC	cis	rs748404	0.660	rs2467741	chr15:43742626	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	8.23	0.45	8.36e-15	Lung cancer;
CESC	cis	rs35110281	0.633	rs762400	chr21:45113629	C/G	cg21573476	chr21:45109991	RRP1B	0.57	8.69	0.47	3.9e-16	Mean corpuscular volume;
CESC	cis	rs910316	0.763	rs175014	chr14:75456927	A/G	cg16144293	chr14:75469539	EIF2B2	0.39	5.12	0.3	6.02e-7	Height;
CESC	cis	rs2204008	0.583	rs12820907	chr12:37990931	T/C	cg26384229	chr12:38710491	ALG10B	0.66	9.47	0.5	1.58e-18	Bladder cancer;
CESC	cis	rs769267	1.000	rs3764567	chr19:19440066	C/T	cg03709012	chr19:19516395	GATAD2A	-0.93	-13.62	-0.64	2.27e-32	Tonsillectomy;
CESC	cis	rs2204008	0.777	rs114096617	chr12:38342557	A/C	cg26384229	chr12:38710491	ALG10B	0.73	10.93	0.56	3.37e-23	Bladder cancer;
CESC	cis	rs7044106	0.791	rs4837793	chr9:123483621	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.87	13.96	0.65	1.39e-33	Hip circumference adjusted for BMI;
CESC	cis	rs892961	0.899	rs3650	chr17:75415835	T/C	cg05865280	chr17:75406074	SEPT9	0.63	12.68	0.61	4.09e-29	Airflow obstruction;
CESC	cis	rs9814567	1.000	rs6782563	chr3:134295959	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.41	5.52	0.32	8.13e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs1799949	0.965	rs8176130	chr17:41258043	C/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.45	6.31	0.36	1.15e-9	Menopause (age at onset);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg04571742	chr3:51534000	VPRBP	0.46	6.25	0.36	1.67e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs868036	0.645	rs4776972	chr15:68083436	A/C	cg24579218	chr15:68104479	NA	-0.36	-5.05	-0.3	8.31e-7	Restless legs syndrome;
CESC	trans	rs1814175	0.791	rs10839468	chr11:49986288	A/G	cg15704280	chr7:45808275	SEPT13	-1.05	-20.9	-0.79	5.74e-58	Height;
CESC	cis	rs7613875	0.641	rs6793528	chr3:50100188	C/A	cg24110177	chr3:50126178	RBM5	0.58	8.17	0.45	1.28e-14	Body mass index;
CESC	cis	rs7264396	0.561	rs2050930	chr20:34579397	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-6.81	-0.39	6.41e-11	Total cholesterol levels;
CESC	cis	rs10416265	0.503	rs1981818	chr19:33615122	C/T	cg17764715	chr19:33622953	WDR88	-0.58	-8.46	-0.46	1.88e-15	Bone properties (heel);
CESC	cis	rs1552244	1.000	rs35741213	chr3:10087661	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.8	-10.3	-0.53	3.74e-21	Alzheimer's disease;
CESC	cis	rs12477438	0.520	rs2632277	chr2:99778985	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.85	14.9	0.68	6.73e-37	Chronic sinus infection;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg26027482	chr12:1100598	ERC1	-0.46	-6.38	-0.36	7.66e-10	Gambling;
CESC	cis	rs7618915	0.501	rs3852066	chr3:52621839	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.7	0.38	1.22e-10	Bipolar disorder;
CESC	cis	rs4665809	0.590	rs7579504	chr2:26439995	T/C	cg04944784	chr2:26401820	FAM59B	-0.96	-10.55	-0.54	5.79e-22	Gut microbiome composition (summer);
CESC	cis	rs12477438	0.559	rs6733285	chr2:99725575	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.78	12.89	0.62	7.58e-30	Chronic sinus infection;
CESC	cis	rs4819052	0.807	rs1075788	chr21:46666564	T/G	cg11663144	chr21:46675770	NA	-0.6	-9.45	-0.5	1.9e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs7911712	0.515	rs1771996	chr10:45258544	T/C	cg12743970	chr17:64536520	PRKCA	-0.62	-6.03	-0.35	5.6e-9	Emphysema-related traits;
CESC	cis	rs9611565	0.694	rs202622	chr22:41825342	T/G	cg03806693	chr22:41940476	POLR3H	1.2	14.53	0.67	1.4e-35	Vitiligo;
CESC	cis	rs1003719	0.788	rs2835577	chr21:38457457	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.62	8.67	0.47	4.41e-16	Eye color traits;
CESC	cis	rs6088590	0.931	rs12625149	chr20:33425812	A/C	cg24642439	chr20:33292090	TP53INP2	-0.75	-10.05	-0.53	2.34e-20	Coronary artery disease;
CESC	cis	rs2976388	0.566	rs2585146	chr8:143798641	A/C	cg24634471	chr8:143751801	JRK	0.43	5.18	0.3	4.38e-7	Urinary tract infection frequency;
CESC	cis	rs1552244	0.935	rs35148833	chr3:10116937	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.8	-10.25	-0.53	5.42e-21	Alzheimer's disease;
CESC	cis	rs854765	0.647	rs854790	chr17:18028318	C/G	cg16928487	chr17:17741425	SREBF1	-0.37	-5.48	-0.32	1.01e-7	Total body bone mineral density;
CESC	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	22.27	0.81	1.17e-62	Prudent dietary pattern;
CESC	cis	rs6547741	0.874	rs58737572	chr2:27852118	A/C	cg21248554	chr2:27665150	KRTCAP3	0.25	5.08	0.3	7.27e-7	Oral cavity cancer;
CESC	cis	rs7607369	0.648	rs7599984	chr2:219656713	T/G	cg02176678	chr2:219576539	TTLL4	-0.48	-8.21	-0.45	9.44e-15	Red blood cell count;Amyotrophic lateral sclerosis;
CESC	cis	rs10870270	0.956	rs10781555	chr10:133745720	G/A	cg26149184	chr10:133730230	NA	0.37	5.09	0.3	6.85e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs2708240	0.905	rs2710108	chr7:147574174	T/C	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.35	-5.77	-0.33	2.23e-8	QT interval (drug interaction);
CESC	cis	rs2075371	1.000	rs1868783	chr7:133975087	A/G	cg11752832	chr7:134001865	SLC35B4	0.54	7.09	0.4	1.19e-11	Mean platelet volume;
CESC	cis	rs7927771	0.832	rs6485753	chr11:47410200	C/T	cg05585544	chr11:47624801	NA	0.48	7.13	0.4	9.42e-12	Subjective well-being;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg08052428	chr9:135996421	RALGDS	0.48	6.38	0.36	8.03e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs96067	0.805	rs4652902	chr1:36612955	C/A	cg24686825	chr1:36642396	MAP7D1	-0.5	-5.51	-0.32	8.44e-8	Corneal structure;
CESC	cis	rs225245	0.755	rs7217565	chr17:34024707	C/A	cg05299278	chr17:33885742	SLFN14	0.38	5.51	0.32	8.62e-8	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
CESC	cis	rs1003719	0.762	rs3787787	chr21:38463452	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.63	8.77	0.47	2.14e-16	Eye color traits;
CESC	cis	rs9300255	0.698	rs4759416	chr12:123746357	C/G	cg19016782	chr12:123741754	C12orf65	-0.5	-7.26	-0.41	4.27e-12	Neutrophil percentage of white cells;
CESC	cis	rs6446731	0.734	rs7675084	chr4:3273908	C/T	cg08886695	chr4:3369023	RGS12	-0.35	-5.1	-0.3	6.63e-7	Mean platelet volume;
CESC	cis	rs7258465	0.965	rs2385088	chr19:18545540	A/G	cg25828334	chr19:18545568	ISYNA1	-0.33	-5.28	-0.31	2.74e-7	Breast cancer;
CESC	cis	rs868036	0.560	rs12443086	chr15:68080454	C/A	cg08079166	chr15:68083412	MAP2K5	0.4	6.48	0.37	4.34e-10	Restless legs syndrome;
CESC	cis	rs11785400	0.753	rs9694286	chr8:143737157	G/T	cg24634471	chr8:143751801	JRK	0.46	5.94	0.34	9.01e-9	Schizophrenia;
CESC	cis	rs4253772	0.550	rs715515	chr22:46720921	G/A	cg10541313	chr22:46663664	TTC38	0.68	5.09	0.3	6.74e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs11098499	0.909	rs10017335	chr4:120381523	C/G	cg24375607	chr4:120327624	NA	-0.41	-5.03	-0.3	8.86e-7	Corneal astigmatism;
CESC	trans	rs72996113	0.702	rs75760535	chr11:100519573	G/A	cg20136100	chr11:63974860	FERMT3	-0.52	-6.58	-0.37	2.56e-10	Reticulocyte fraction of red cells;Reticulocyte count;
CESC	cis	rs6582630	0.555	rs10880612	chr12:38509427	A/G	cg13010199	chr12:38710504	ALG10B	0.46	5.91	0.34	1.03e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs2952156	0.920	rs2517955	chr17:37843681	C/T	cg20243544	chr17:37824526	PNMT	0.63	8.1	0.45	1.99e-14	Asthma;
CESC	cis	rs6460942	1.000	rs2033871	chr7:12405098	C/A	cg02935154	chr7:12443704	VWDE	-0.56	-6.1	-0.35	3.8e-9	Coronary artery disease;
CESC	cis	rs1005277	0.579	rs1548255	chr10:38417193	T/C	cg00409905	chr10:38381863	ZNF37A	-0.48	-6.32	-0.36	1.12e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs2273669	0.667	rs76201299	chr6:109344975	T/G	cg05315195	chr6:109294784	ARMC2	-0.67	-6.06	-0.35	4.74e-9	Prostate cancer;
CESC	cis	rs28647808	1.000	rs28540113	chr9:136273463	G/A	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.9	5.73	0.33	2.75e-8	Blood protein levels;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg23773983	chr6:16761891	ATXN1	0.49	6.87	0.39	4.69e-11	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs7301826	0.966	rs10734980	chr12:131294626	T/C	cg11011512	chr12:131303247	STX2	0.4	5.09	0.3	6.83e-7	Plasma plasminogen activator levels;
CESC	cis	rs425277	0.606	rs2503705	chr1:2076741	A/G	cg24578937	chr1:2090814	PRKCZ	0.33	5.9	0.34	1.13e-8	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00140235	chr12:93323273	EEA1	0.51	6.24	0.36	1.7e-9	Gut microbiome composition (summer);
CESC	cis	rs35110281	0.811	rs7275705	chr21:45056453	G/C	cg01579765	chr21:45077557	HSF2BP	-0.55	-9.0	-0.48	4.45e-17	Mean corpuscular volume;
CESC	cis	rs1218582	0.710	rs4845687	chr1:154878911	A/G	cg06221963	chr1:154839813	KCNN3	-0.66	-11.32	-0.57	1.71e-24	Prostate cancer;
CESC	cis	rs12451471	0.667	rs12942002	chr17:78101629	C/G	cg24585782	chr17:78113791	EIF4A3	-0.62	-8.36	-0.46	3.47e-15	Plateletcrit;Mean corpuscular hemoglobin concentration;
CESC	cis	rs12497850	0.931	rs7636057	chr3:48992582	C/T	cg06212747	chr3:49208901	KLHDC8B	0.73	9.91	0.52	6.74e-20	Parkinson's disease;
CESC	cis	rs4975616	0.804	rs456366	chr5:1337070	T/C	cg26373071	chr5:1325741	CLPTM1L	0.43	6.62	0.38	2.01e-10	Lung cancer;
CESC	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg06877462	chr1:205807181	PM20D1	0.39	5.96	0.34	8.07e-9	Menarche (age at onset);
CESC	cis	rs1799949	1.000	rs11079056	chr17:41300799	C/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.45	6.31	0.36	1.17e-9	Menopause (age at onset);
CESC	cis	rs5758659	0.652	rs133303	chr22:42395242	C/G	cg15557168	chr22:42548783	NA	-0.44	-6.47	-0.37	4.61e-10	Cognitive function;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg03168501	chr19:33211891	TDRD12	0.42	6.01	0.35	6.01e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7208859	0.623	rs9911490	chr17:29073013	C/T	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.79e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs7210086	0.752	rs4072601	chr17:70641327	G/A	cg04206342	chr17:70636940	NA	-0.36	-5.19	-0.3	4.28e-7	Ulcerative colitis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18125208	chr1:228297275	MRPL55	0.57	6.02	0.35	5.65e-9	Gut microbiome composition (summer);
CESC	cis	rs16858210	0.874	rs6792309	chr3:183607661	C/T	cg25686905	chr3:183603175	PARL	-0.33	-6.05	-0.35	4.88e-9	Menopause (age at onset);
CESC	cis	rs1953600	0.668	rs751740	chr10:81912179	T/C	cg00277334	chr10:82204260	NA	0.4	5.49	0.32	9.32e-8	Sarcoidosis;
CESC	cis	rs5758659	0.594	rs739292	chr22:42368857	G/A	cg19513890	chr22:42538836	CYP2D7P1	-0.38	-5.27	-0.31	2.86e-7	Cognitive function;
CESC	cis	rs2742234	0.590	rs2435338	chr10:43642115	A/G	cg15436174	chr10:43711423	RASGEF1A	-0.48	-5.61	-0.33	5.11e-8	Hirschsprung disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07628300	chr16:312565	ITFG3	-0.55	-6.07	-0.35	4.48e-9	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.830	rs28451001	chr4:98924544	T/A	cg05340658	chr4:99064831	C4orf37	0.82	12.2	0.6	1.81e-27	Colonoscopy-negative controls vs population controls;
CESC	cis	rs17253792	0.822	rs8013714	chr14:56172286	T/C	cg01858014	chr14:56050164	KTN1	-0.62	-5.67	-0.33	3.78e-8	Putamen volume;
CESC	cis	rs6460942	1.000	rs6460935	chr7:12401317	A/T	cg20607287	chr7:12443886	VWDE	-0.68	-7.81	-0.43	1.33e-13	Coronary artery disease;
CESC	cis	rs9894429	0.646	rs7210026	chr17:79612382	T/C	cg13777783	chr17:79615861	NA	-0.37	-6.2	-0.36	2.14e-9	Eye color traits;
CESC	cis	rs17376456	0.597	rs10866760	chr5:93338335	G/A	cg25358565	chr5:93447407	FAM172A	-0.44	-5.17	-0.3	4.6e-7	Diabetic retinopathy;
CESC	cis	rs7927771	1.000	rs4752857	chr11:47655752	C/T	cg20307385	chr11:47447363	PSMC3	-0.49	-5.98	-0.34	7.29e-9	Subjective well-being;
CESC	cis	rs6952808	0.501	rs3778999	chr7:2180885	G/A	cg02951883	chr7:2050386	MAD1L1	-0.49	-6.44	-0.37	5.57e-10	Bipolar disorder and schizophrenia;
CESC	cis	rs6546550	0.935	rs7563062	chr2:70050725	G/A	cg02498382	chr2:70120550	SNRNP27	-0.39	-6.7	-0.38	1.25e-10	Prevalent atrial fibrillation;
CESC	cis	rs3091242	0.967	rs3091240	chr1:25676935	G/T	cg27572855	chr1:25598939	RHD	0.5	8.45	0.46	1.99e-15	Erythrocyte sedimentation rate;
CESC	cis	rs2933343	0.601	rs1680759	chr3:128594896	C/G	cg24203234	chr3:128598194	ACAD9	0.43	5.88	0.34	1.23e-8	IgG glycosylation;
CESC	cis	rs875971	0.862	rs1612452	chr7:65573896	T/A	cg18876405	chr7:65276391	NA	-0.55	-7.33	-0.41	2.71e-12	Aortic root size;
CESC	trans	rs673604	0.505	rs676614	chr1:36107510	G/T	cg22834172	chr17:37774349	NA	0.54	6.2	0.36	2.15e-9	Endometrial cancer;
CESC	trans	rs561341	1.000	rs55643307	chr17:30263074	T/C	cg27661571	chr11:113659931	NA	-0.83	-7.53	-0.42	7.89e-13	Hip circumference adjusted for BMI;
CESC	cis	rs9467711	0.606	rs9379875	chr6:26444732	C/T	cg12826209	chr6:26865740	GUSBL1	0.67	5.15	0.3	5.15e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs559928	0.606	rs57021319	chr11:63956102	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.66	5.82	0.34	1.7e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CESC	cis	rs1218582	0.774	rs4845679	chr1:154861187	G/T	cg24250549	chr1:154909240	PMVK	0.62	8.52	0.46	1.2e-15	Prostate cancer;
CESC	cis	rs1372520	0.684	rs2583963	chr4:90727088	C/T	cg15133208	chr4:90757351	SNCA	-0.43	-5.79	-0.33	2.02e-8	Neuroticism;
CESC	cis	rs763014	0.898	rs1981484	chr16:630710	A/G	cg00802000	chr16:706648	WDR90	-0.41	-6.12	-0.35	3.35e-9	Height;
CESC	cis	rs3733585	0.699	rs6449178	chr4:9968684	A/G	cg11266682	chr4:10021025	SLC2A9	0.56	10.46	0.54	1.13e-21	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs769267	0.930	rs2288852	chr19:19605348	T/C	cg03709012	chr19:19516395	GATAD2A	1.0	15.51	0.69	4.72e-39	Tonsillectomy;
CESC	cis	rs7772486	0.875	rs9403768	chr6:146406458	A/C	cg23711669	chr6:146136114	FBXO30	0.85	12.48	0.61	2.01e-28	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6912958	1.000	rs6933587	chr6:88175577	T/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.32	-5.43	-0.32	1.26e-7	Monocyte percentage of white cells;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg14782266	chr2:42565367	NA	0.47	6.19	0.36	2.28e-9	Fibrinogen levels;
CESC	cis	rs3015497	1.000	rs4075253	chr14:51107737	G/A	cg26011998	chr14:51135199	SAV1	-0.43	-5.47	-0.32	1.04e-7	Mean platelet volume;
CESC	cis	rs1799949	1.000	rs11079056	chr17:41300799	C/A	cg25072359	chr17:41440525	NA	0.43	5.83	0.34	1.61e-8	Menopause (age at onset);
CESC	cis	rs7666738	0.518	rs13133925	chr4:98706398	G/T	cg05340658	chr4:99064831	C4orf37	0.54	6.56	0.37	2.81e-10	Colonoscopy-negative controls vs population controls;
CESC	cis	rs804280	0.662	rs804283	chr8:11611043	G/A	cg26752888	chr8:11627280	NEIL2	-0.67	-6.09	-0.35	4.02e-9	Myopia (pathological);
CESC	cis	rs4835473	0.715	rs1849124	chr4:144899647	T/A	cg25736465	chr4:144833511	NA	0.4	6.13	0.35	3.19e-9	Immature fraction of reticulocytes;
CESC	cis	rs11252926	0.589	rs12359901	chr10:475068	A/G	cg03684893	chr10:554711	DIP2C	0.37	5.42	0.32	1.35e-7	Psychosis in Alzheimer's disease;
CESC	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg23708337	chr7:1209742	NA	0.52	5.16	0.3	4.88e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs1552244	1.000	rs68067759	chr3:10150535	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	12.39	0.61	4.17e-28	Alzheimer's disease;
CESC	cis	rs9948	1.000	rs12172	chr2:97500852	C/G	cg01990225	chr2:97406019	LMAN2L	-0.75	-5.41	-0.32	1.44e-7	Erectile dysfunction and prostate cancer treatment;
CESC	cis	rs2929278	0.561	rs62018952	chr15:44080737	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	-0.54	-7.14	-0.4	8.76e-12	Schizophrenia;
CESC	cis	rs6690583	0.623	rs2028304	chr1:85488030	G/A	cg11262906	chr1:85462892	MCOLN2	-0.53	-5.26	-0.31	3.04e-7	Serum sulfate level;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10654866	chr19:17631869	PGLS	-0.54	-6.25	-0.36	1.62e-9	Gut microbiome composition (summer);
CESC	cis	rs40363	0.951	rs72778117	chr16:3531827	T/C	cg21433313	chr16:3507492	NAT15	0.67	8.22	0.45	9.05e-15	Tuberculosis;
CESC	cis	rs7124681	0.565	rs2904127	chr11:47817290	A/G	cg18512352	chr11:47633146	NA	0.35	5.33	0.31	2.05e-7	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
CESC	cis	rs2637266	1.000	rs2579749	chr10:78332105	T/C	cg18941641	chr10:78392320	NA	0.41	7.47	0.42	1.18e-12	Pulmonary function;
CESC	cis	rs11676348	0.846	rs4674259	chr2:218991005	C/T	cg00012203	chr2:219082015	ARPC2	-0.58	-7.5	-0.42	9.53e-13	Ulcerative colitis;
CESC	trans	rs634534	0.622	rs1308733	chr11:65720841	T/C	cg17712092	chr4:129076599	LARP1B	-0.61	-7.85	-0.43	1.03e-13	Sum eosinophil basophil counts;Eosinophil counts;
CESC	cis	rs9322193	0.884	rs2095375	chr6:150128173	C/A	cg07701084	chr6:150067640	NUP43	0.43	5.8	0.34	1.87e-8	Lung cancer;
CESC	cis	rs4689388	0.926	rs3821940	chr4:6286711	C/A	cg25554036	chr4:6271136	WFS1	0.52	8.38	0.46	3.2e-15	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs9300255	0.543	rs655293	chr12:123528405	G/A	cg00376283	chr12:123451042	ABCB9	0.77	9.26	0.49	7.28e-18	Neutrophil percentage of white cells;
CESC	cis	rs17376456	0.825	rs10051878	chr5:93064164	T/G	cg21475434	chr5:93447410	FAM172A	0.83	7.39	0.41	1.91e-12	Diabetic retinopathy;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	ch.10.2686225R	chr10:126090281	OAT	-0.47	-6.16	-0.35	2.64e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	trans	rs6011002	0.810	rs6010988	chr20:62278210	G/A	cg17720233	chr1:151128310	TNFAIP8L2	0.84	6.21	0.36	2.07e-9	Dental caries;
CESC	cis	rs3091242	0.933	rs34933589	chr1:25788198	T/C	cg02931644	chr1:25747376	RHCE	-0.39	-6.48	-0.37	4.53e-10	Erythrocyte sedimentation rate;
CESC	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg21226059	chr5:178986404	RUFY1	-0.52	-8.17	-0.45	1.31e-14	Lung cancer;
CESC	cis	rs34638657	0.656	rs1134847	chr16:82203742	C/T	cg09439754	chr16:82129088	HSD17B2	0.34	6.06	0.35	4.64e-9	Lung adenocarcinoma;
CESC	cis	rs2066819	1.000	rs2371494	chr12:56728000	G/A	cg26714650	chr12:56694279	CS	-1.24	-14.98	-0.68	3.75e-37	Psoriasis vulgaris;
CESC	cis	rs3857067	0.806	rs7676797	chr4:95099194	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.55	-8.05	-0.44	2.8e-14	QT interval;
CESC	trans	rs61931739	0.534	rs11053014	chr12:34103519	G/A	cg26384229	chr12:38710491	ALG10B	0.59	8.18	0.45	1.17e-14	Morning vs. evening chronotype;
CESC	cis	rs6542838	0.671	rs6752025	chr2:99505699	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.41	-5.05	-0.3	8.25e-7	Fear of minor pain;
CESC	cis	rs7267979	1.000	rs2257988	chr20:25270003	T/C	cg08601574	chr20:25228251	PYGB	0.39	5.65	0.33	4.08e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7044106	0.791	rs10818473	chr9:123484155	A/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.75	11.1	0.56	9.3e-24	Hip circumference adjusted for BMI;
CESC	cis	rs7100689	0.577	rs1340385	chr10:82058851	G/A	cg00277334	chr10:82204260	NA	-0.51	-6.47	-0.37	4.6e-10	Post bronchodilator FEV1;
CESC	cis	rs4665809	0.531	rs10199898	chr2:26445485	T/G	cg04944784	chr2:26401820	FAM59B	-0.96	-10.55	-0.54	5.79e-22	Gut microbiome composition (summer);
CESC	cis	rs644799	1.000	rs516551	chr11:95588626	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	13.43	0.64	1.02e-31	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs1642645	0.831	rs4660212	chr1:42496399	C/T	cg16685388	chr1:42384056	HIVEP3	-0.37	-5.43	-0.32	1.26e-7	Left ventricular obstructive tract defect (maternal effect);
CESC	cis	rs79057730	0.599	rs4333501	chr7:803244	C/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.83	7.04	0.4	1.61e-11	Initial pursuit acceleration;
CESC	cis	rs7618915	0.501	rs1468638	chr3:52748058	T/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.38	6.76	0.38	8.76e-11	Bipolar disorder;
CESC	cis	rs3793683	0.825	rs3793674	chr10:134555773	C/T	cg26818010	chr10:134567672	INPP5A	0.47	5.87	0.34	1.27e-8	Migraine;
CESC	cis	rs4253772	0.591	rs9615935	chr22:46686115	T/G	cg10541313	chr22:46663664	TTC38	0.72	5.15	0.3	5.01e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs12780046	0.536	rs11190027	chr10:101012664	A/G	cg27143070	chr10:101087766	CNNM1	0.38	5.65	0.33	4.22e-8	Non-glioblastoma glioma;
CESC	cis	rs12476592	0.516	rs6717060	chr2:63568608	G/A	cg17519650	chr2:63277830	OTX1	-0.46	-5.26	-0.31	3.03e-7	Childhood ear infection;
CESC	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg07677032	chr17:61819896	STRADA	0.45	5.92	0.34	1.01e-8	Prudent dietary pattern;
CESC	cis	rs2011503	0.943	rs756997	chr19:19467085	G/C	cg11584989	chr19:19387371	SF4	-0.65	-7.81	-0.43	1.35e-13	Bipolar disorder;
CESC	cis	rs514406	0.929	rs557847	chr1:53333116	A/G	cg16325326	chr1:53192061	ZYG11B	0.82	12.75	0.62	2.35e-29	Monocyte count;
CESC	cis	rs2439831	0.867	rs2584702	chr15:43684914	C/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.86	13.04	0.63	2.26e-30	Lung cancer in ever smokers;
CESC	cis	rs11098499	0.780	rs7692994	chr4:120427489	C/A	cg09307838	chr4:120376055	NA	0.88	11.82	0.59	3.48e-26	Corneal astigmatism;
CESC	cis	rs7666738	0.519	rs13136069	chr4:98819568	C/T	cg17366294	chr4:99064904	C4orf37	0.48	5.85	0.34	1.42e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10883723	0.810	rs2296588	chr10:104248087	T/C	ch.10.2196322F	chr10:104248062	ACTR1A	0.42	5.16	0.3	4.93e-7	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs875971	0.830	rs778715	chr7:65849209	C/T	cg11764359	chr7:65958608	NA	0.81	11.89	0.59	2.11e-26	Aortic root size;
CESC	cis	rs11871801	0.517	rs35635959	chr17:40772288	T/C	cg14558262	chr17:40713999	COASY	0.5	5.83	0.34	1.58e-8	Crohn's disease;
CESC	cis	rs6831352	0.877	rs2602890	chr4:100043179	C/T	cg13256891	chr4:100009986	ADH5	0.75	8.31	0.45	5.11e-15	Alcohol dependence;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01485948	chr17:2296549	MNT	0.61	7.19	0.4	6.62e-12	Gut microbiome composition (summer);
CESC	cis	rs1559088	0.576	rs11084707	chr19:33612873	C/T	cg03563238	chr19:33554763	RHPN2	-0.3	-5.58	-0.32	5.86e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs17433780	0.860	rs10922545	chr1:89492201	C/T	cg09516651	chr1:89888402	LOC400759	0.68	9.49	0.5	1.43e-18	Carotid intima media thickness;
CESC	cis	rs6952808	0.594	rs3778965	chr7:2138296	G/A	cg04267008	chr7:1944627	MAD1L1	-0.61	-7.4	-0.41	1.75e-12	Bipolar disorder and schizophrenia;
CESC	cis	rs875971	1.000	rs4717292	chr7:65895598	G/A	cg11764359	chr7:65958608	NA	0.97	15.5	0.69	5.25e-39	Aortic root size;
CESC	cis	rs459571	0.959	rs392134	chr9:136909008	G/A	cg13789015	chr9:136890014	NCRNA00094	0.56	8.03	0.44	3.28e-14	Platelet distribution width;
CESC	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.52	-5.75	-0.33	2.46e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs11958404	0.932	rs6859826	chr5:157429710	T/C	cg05962755	chr5:157440814	NA	0.62	6.53	0.37	3.41e-10	IgG glycosylation;
CESC	cis	rs3008870	0.959	rs4655658	chr1:67389608	C/T	cg08660285	chr1:67390436	MIER1;WDR78	1.02	14.08	0.65	5.61e-34	Lymphocyte percentage of white cells;
CESC	cis	rs561341	0.941	rs8066156	chr17:30361629	A/G	cg12193833	chr17:30244370	NA	-0.51	-5.27	-0.31	2.88e-7	Hip circumference adjusted for BMI;
CESC	cis	rs9399401	0.667	rs11759653	chr6:142720354	G/A	cg04461802	chr6:142623433	GPR126	0.42	6.04	0.35	5.13e-9	Chronic obstructive pulmonary disease;
CESC	cis	rs12476592	0.602	rs10865340	chr2:63824049	C/G	cg17519650	chr2:63277830	OTX1	-0.46	-5.14	-0.3	5.28e-7	Childhood ear infection;
CESC	cis	rs67311347	1.000	rs7633809	chr3:40517737	A/G	cg09455208	chr3:40491958	NA	-0.51	-8.72	-0.47	3.02e-16	Renal cell carcinoma;
CESC	cis	rs8017423	0.967	rs7151776	chr14:90724803	A/G	cg14092571	chr14:90743983	NA	-0.53	-7.88	-0.44	8.28e-14	Mortality in heart failure;
CESC	cis	rs524281	0.731	rs3814744	chr11:65809763	C/T	cg14036092	chr11:66035641	RAB1B	-0.57	-5.42	-0.32	1.37e-7	Electroencephalogram traits;
CESC	cis	rs6493487	0.512	rs35416047	chr15:51188545	T/C	cg02338191	chr15:51200825	AP4E1	0.6	5.58	0.32	5.79e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs412000	0.553	rs2680702	chr17:56431549	A/G	cg12560992	chr17:57184187	TRIM37	0.59	7.21	0.41	5.69e-12	Primary tooth development (time to first tooth eruption);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg05772935	chr16:1790400	MAPK8IP3	0.55	7.37	0.41	2.22e-12	Fibrinogen levels;
CESC	cis	rs1862618	0.671	rs832531	chr5:56228401	A/G	cg24549020	chr5:56110836	MAP3K1	0.45	5.76	0.33	2.31e-8	Initial pursuit acceleration;
CESC	cis	rs7666738	0.830	rs9998582	chr4:98938949	T/C	cg03467027	chr4:99064603	C4orf37	0.48	5.91	0.34	1.03e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6754311	0.773	rs309130	chr2:136631031	C/A	cg07169764	chr2:136633963	MCM6	-0.69	-8.48	-0.46	1.63e-15	Mosquito bite size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26860113	chr20:361741	TRIB3	0.58	6.47	0.37	4.76e-10	Gut microbiome composition (summer);
CESC	cis	rs7618501	0.501	rs35275715	chr3:49959148	A/G	cg24308560	chr3:49941425	MST1R	-0.6	-8.79	-0.48	1.9e-16	Intelligence (multi-trait analysis);
CESC	trans	rs2727020	0.658	rs4980431	chr11:49350071	G/T	cg15704280	chr7:45808275	SEPT13	-0.87	-14.51	-0.67	1.67e-35	Coronary artery disease;
CESC	cis	rs6952808	0.689	rs58227534	chr7:2046328	A/G	cg04267008	chr7:1944627	MAD1L1	-0.62	-7.57	-0.42	6.35e-13	Bipolar disorder and schizophrenia;
CESC	cis	rs3540	0.512	rs3930162	chr15:91075129	C/T	cg10434728	chr15:90938212	IQGAP1	-0.38	-6.71	-0.38	1.18e-10	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs2075371	0.933	rs2544191	chr7:133954248	A/G	cg20476274	chr7:133979776	SLC35B4	0.68	9.88	0.52	8.59e-20	Mean platelet volume;
CESC	cis	rs6681460	0.866	rs1856318	chr1:67024215	T/C	cg02459107	chr1:67143332	SGIP1	0.38	5.13	0.3	5.55e-7	Presence of antiphospholipid antibodies;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15461550	chr8:4644719	CSMD1	-0.51	-6.36	-0.36	8.69e-10	Gut microbiome composition (summer);
CESC	cis	rs9796	0.870	rs2925345	chr15:41311799	T/C	cg18705301	chr15:41695430	NDUFAF1	0.4	5.94	0.34	8.72e-9	Menopause (age at onset);
CESC	cis	rs1198872	0.526	rs57282335	chr2:10928207	G/A	cg25617230	chr2:10952979	PDIA6	0.44	5.12	0.3	5.83e-7	Cardiac Troponin-T levels;
CESC	cis	rs873946	0.586	rs36084869	chr10:134566069	G/A	cg26818010	chr10:134567672	INPP5A	-0.94	-11.42	-0.57	7.62e-25	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs939658	0.805	rs35832166	chr15:79417994	G/T	cg17916960	chr15:79447300	NA	-0.37	-6.08	-0.35	4.15e-9	Refractive error;
CESC	cis	rs854765	0.583	rs4534911	chr17:17852330	A/G	cg16928487	chr17:17741425	SREBF1	-0.59	-9.86	-0.52	9.9e-20	Total body bone mineral density;
CESC	cis	rs35110281	0.782	rs2329442	chr21:45041790	T/C	cg01579765	chr21:45077557	HSF2BP	-0.55	-9.2	-0.49	1.12e-17	Mean corpuscular volume;
CESC	cis	rs1005277	0.603	rs1998062	chr10:38457652	G/C	cg25517755	chr10:38738941	LOC399744	-0.48	-6.18	-0.35	2.4e-9	Extrinsic epigenetic age acceleration;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg02004021	chr12:95868393	METAP2	-0.47	-6.8	-0.39	7.13e-11	Gambling;
CESC	cis	rs7301826	0.651	rs4759521	chr12:131297313	C/T	cg11011512	chr12:131303247	STX2	0.47	5.84	0.34	1.52e-8	Plasma plasminogen activator levels;
CESC	cis	rs2860975	0.620	rs7087256	chr10:96795524	T/C	cg09036531	chr10:96991505	NA	-0.35	-5.06	-0.3	7.67e-7	Immune response to smallpox vaccine (IL-6);
CESC	cis	rs9611565	0.592	rs5751129	chr22:42015765	C/T	cg03806693	chr22:41940476	POLR3H	0.86	10.37	0.54	2.26e-21	Vitiligo;
CESC	cis	rs6963495	0.818	rs73190189	chr7:105164452	G/A	cg13798780	chr7:105162888	PUS7	0.79	8.16	0.45	1.36e-14	Bipolar disorder (body mass index interaction);
CESC	cis	rs1691799	0.867	rs1168316	chr12:66746239	A/G	cg16791601	chr12:66731901	HELB	-0.79	-14.55	-0.67	1.18e-35	White blood cell count (basophil);
CESC	cis	rs12477438	0.798	rs10196680	chr2:99628617	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.75	-10.87	-0.56	5.17e-23	Chronic sinus infection;
CESC	cis	rs2191566	0.576	rs396786	chr19:44494351	A/G	cg20607764	chr19:44506953	ZNF230	0.44	5.16	0.3	4.82e-7	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs28374715	0.681	rs11629979	chr15:41626579	A/G	cg02330683	chr15:41787940	ITPKA	0.47	6.28	0.36	1.35e-9	Ulcerative colitis;
CESC	cis	rs736408	0.521	rs13074853	chr3:52779801	T/C	cg18404041	chr3:52824283	ITIH1	-0.39	-6.55	-0.37	2.91e-10	Bipolar disorder;
CESC	cis	rs7937682	0.632	rs57414412	chr11:111769431	G/A	cg22437258	chr11:111473054	SIK2	-0.5	-5.53	-0.32	7.78e-8	Primary sclerosing cholangitis;
CESC	cis	rs9512730	0.553	rs6491212	chr13:28049631	T/C	cg04070771	chr13:27998621	GTF3A	0.45	5.14	0.3	5.37e-7	Schizophrenia;
CESC	cis	rs6446731	0.593	rs7656026	chr4:3273625	G/C	cg08886695	chr4:3369023	RGS12	-0.38	-5.51	-0.32	8.38e-8	Mean platelet volume;
CESC	cis	rs2066819	1.000	rs808919	chr12:56647911	C/G	cg26734620	chr12:56694298	CS	-0.89	-9.02	-0.48	3.78e-17	Psoriasis vulgaris;
CESC	trans	rs7656342	0.808	rs10003216	chr4:9766749	A/G	cg23424268	chr15:41056053	GCHFR	-0.57	-6.61	-0.38	2.09e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs34638657	0.732	rs11645372	chr16:82202136	C/T	cg09439754	chr16:82129088	HSD17B2	-0.35	-6.12	-0.35	3.29e-9	Lung adenocarcinoma;
CESC	cis	rs514406	0.929	rs555741	chr1:53318851	T/G	cg08859206	chr1:53392774	SCP2	-0.65	-8.93	-0.48	7.24e-17	Monocyte count;
CESC	cis	rs875971	1.000	rs10215948	chr7:65747786	G/A	cg10691866	chr7:65817282	TPST1	0.33	5.64	0.33	4.3e-8	Aortic root size;
CESC	trans	rs884366	1.000	rs1006081	chr6:109625550	C/T	cg04557294	chr14:70119254	KIAA0247	-0.43	-6.36	-0.36	8.93e-10	HDL cholesterol levels;HDL cholesterol;
CESC	cis	rs6570726	0.935	rs413916	chr6:145831400	T/C	cg05347473	chr6:146136440	FBXO30	0.5	6.74	0.38	9.63e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2842992	0.789	rs9355748	chr6:160194882	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.77	9.93	0.52	5.92e-20	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs13064411	0.696	rs6773497	chr3:113186514	T/C	cg18753928	chr3:113234510	CCDC52	-0.49	-5.87	-0.34	1.31e-8	Response to simvastatin treatment (PCSK9 protein level change);
CESC	cis	rs7937682	0.883	rs631490	chr11:111452040	G/C	cg09085632	chr11:111637200	PPP2R1B	-0.91	-13.83	-0.65	3.94e-33	Primary sclerosing cholangitis;
CESC	cis	rs9888739	1.000	rs7190018	chr16:31301478	G/A	cg15817542	chr16:31343056	ITGAM	-0.41	-5.03	-0.3	9.14e-7	Systemic lupus erythematosus;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg07094533	chr2:233415452	TIGD1;EIF4E2	-0.47	-6.2	-0.36	2.18e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7824557	0.767	rs10104728	chr8:11171300	A/G	cg21775007	chr8:11205619	TDH	0.46	6.59	0.38	2.35e-10	Retinal vascular caliber;
CESC	cis	rs780096	0.546	rs12473776	chr2:27636474	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.34	-7.08	-0.4	1.27e-11	Total body bone mineral density;
CESC	cis	rs7666738	0.830	rs3911282	chr4:99037602	T/A	cg18180107	chr4:99064573	C4orf37	0.41	5.29	0.31	2.52e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs362272	0.505	rs3129310	chr4:3301388	T/G	cg08886695	chr4:3369023	RGS12	-0.41	-5.58	-0.32	5.79e-8	Serum sulfate level;
CESC	cis	rs875971	0.540	rs4717275	chr7:65265180	C/T	cg14393609	chr7:65229607	NA	-0.52	-6.97	-0.39	2.45e-11	Aortic root size;
CESC	trans	rs9325144	0.647	rs34311455	chr12:39060889	C/T	cg23762105	chr12:34175262	ALG10	0.46	6.01	0.35	6.05e-9	Morning vs. evening chronotype;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg09791812	chr7:44121910	POLM	-0.55	-6.77	-0.38	8.37e-11	Ulcerative colitis;
CESC	trans	rs9693444	0.898	rs4732697	chr8:29519861	A/G	cg12703194	chr16:3086867	CCDC64B	-0.39	-6.03	-0.35	5.62e-9	Breast cancer;
CESC	cis	rs6696846	0.936	rs1042831	chr1:205043250	G/C	cg00857998	chr1:205179979	DSTYK	0.55	7.11	0.4	1.1e-11	Red blood cell count;
CESC	cis	rs3733585	0.648	rs7378305	chr4:9954893	C/T	cg11266682	chr4:10021025	SLC2A9	-0.57	-10.89	-0.56	4.42e-23	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs1552244	0.938	rs34750074	chr3:10091740	G/A	cg08888203	chr3:10149979	C3orf24	0.48	6.05	0.35	4.97e-9	Alzheimer's disease;
CESC	cis	rs17253792	0.822	rs13379343	chr14:56050205	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.82	5.8	0.34	1.89e-8	Putamen volume;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg21638374	chr5:147763491	FBXO38	-0.47	-6.38	-0.36	7.87e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs5769765	0.657	rs8136116	chr22:50256886	T/A	cg02269571	chr22:50332266	NA	0.46	5.46	0.32	1.08e-7	Schizophrenia;
CESC	cis	rs9913156	0.748	rs55959711	chr17:4562581	C/A	cg19197139	chr17:4613644	ARRB2	0.92	10.46	0.54	1.18e-21	Lymphocyte counts;
CESC	cis	rs597539	0.616	rs72945243	chr11:68633358	T/C	cg04772025	chr11:68637568	NA	0.54	6.36	0.36	8.64e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs881375	0.631	rs10739577	chr9:123668854	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.47	6.83	0.39	5.66e-11	Rheumatoid arthritis;
CESC	cis	rs2735413	0.875	rs8045975	chr16:78090187	C/G	cg04733911	chr16:78082701	NA	0.53	8.82	0.48	1.53e-16	Systolic blood pressure (alcohol consumption interaction);
CESC	cis	rs12541635	0.677	rs1496181	chr8:107027141	C/T	cg10147462	chr8:107024639	NA	0.43	6.42	0.37	6.17e-10	Age of smoking initiation;
CESC	cis	rs977987	0.835	rs4888379	chr16:75340231	A/T	cg03315344	chr16:75512273	CHST6	0.41	5.95	0.34	8.43e-9	Dupuytren's disease;
CESC	trans	rs11098499	0.739	rs10031033	chr4:120151452	C/T	cg25214090	chr10:38739885	LOC399744	0.51	6.76	0.38	8.87e-11	Corneal astigmatism;
CESC	cis	rs6089584	0.528	rs4925334	chr20:60626769	C/T	cg06108461	chr20:60628389	TAF4	-0.61	-8.18	-0.45	1.16e-14	Body mass index;
CESC	cis	rs933688	1.000	rs6866191	chr5:90746852	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.07	11.86	0.59	2.53e-26	Smoking behavior;
CESC	cis	rs977987	0.815	rs1364078	chr16:75396881	T/C	cg03315344	chr16:75512273	CHST6	0.39	5.64	0.33	4.44e-8	Dupuytren's disease;
CESC	cis	rs9640161	0.789	rs1464753	chr7:150021350	G/C	cg13722127	chr7:150037890	RARRES2	0.34	5.11	0.3	6.29e-7	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs6867032	0.834	rs10043083	chr5:1995687	C/G	cg26168224	chr5:2018326	NA	-0.85	-14.02	-0.65	8.87e-34	Gut microbiome composition (winter);
CESC	cis	rs7818382	0.967	rs7812465	chr8:96050557	C/T	cg16049864	chr8:95962084	TP53INP1	0.55	9.28	0.5	6.29e-18	Alzheimer's disease (late onset);
CESC	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg11494091	chr17:61959527	GH2	0.73	12.58	0.61	8.77e-29	Prudent dietary pattern;
CESC	cis	rs7953249	0.564	rs11065385	chr12:121423386	A/G	cg25281562	chr12:121454272	C12orf43	-0.55	-6.95	-0.39	2.81e-11	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
CESC	cis	rs113835537	0.935	rs117480267	chr11:66398596	C/T	cg24851651	chr11:66362959	CCS	0.63	5.74	0.33	2.59e-8	Airway imaging phenotypes;
CESC	cis	rs9916302	0.861	rs8081033	chr17:37506650	A/G	cg00129232	chr17:37814104	STARD3	0.57	7.44	0.42	1.38e-12	Glomerular filtration rate (creatinine);
CESC	cis	rs7618915	0.547	rs4687636	chr3:52633929	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	6.67	0.38	1.48e-10	Bipolar disorder;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg05561555	chr12:131648301	LOC116437	0.43	6.04	0.35	5.07e-9	Fibrinogen levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02343648	chr10:102133165	C10orf75	-0.69	-8.27	-0.45	6.65e-15	Gut microbiome composition (summer);
CESC	cis	rs1707322	1.000	rs10890375	chr1:46406581	G/A	cg05343316	chr1:45956843	TESK2	0.44	5.42	0.32	1.36e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs1814175	0.817	rs7932683	chr11:49983640	G/A	cg03929089	chr4:120376271	NA	-0.93	-16.32	-0.71	6.51e-42	Height;
CESC	cis	rs863345	0.967	rs1418847	chr1:158484378	A/T	cg12129480	chr1:158549410	OR10X1	-0.29	-5.8	-0.34	1.9e-8	Pneumococcal bacteremia;
CESC	cis	rs7762018	1.000	rs6942332	chr6:170131934	A/G	cg05834625	chr6:170176447	C6orf70	0.62	7.35	0.41	2.51e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs6570726	0.935	rs392014	chr6:145843691	A/C	cg23711669	chr6:146136114	FBXO30	0.77	11.49	0.58	4.76e-25	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs72781680	1.000	rs72781680	chr2:24238928	C/T	cg08917208	chr2:24149416	ATAD2B	1.13	9.83	0.52	1.17e-19	Lymphocyte counts;
CESC	cis	rs12701220	0.655	rs10215292	chr7:1135263	A/G	cg23978390	chr7:1156363	C7orf50	0.67	6.49	0.37	4.2e-10	Bronchopulmonary dysplasia;
CESC	cis	rs17253792	0.822	rs78522049	chr14:56071203	A/C	cg01858014	chr14:56050164	KTN1	-0.85	-6.99	-0.39	2.22e-11	Putamen volume;
CESC	cis	rs7647973	0.626	rs1586827	chr3:49671224	T/C	cg03060546	chr3:49711283	APEH	0.68	8.32	0.46	4.7e-15	Menarche (age at onset);
CESC	cis	rs7662987	0.517	rs3018047	chr4:100014510	C/T	cg12011299	chr4:100065546	ADH4	-0.59	-6.86	-0.39	4.93e-11	Smoking initiation;
CESC	cis	rs62283056	0.512	rs4568307	chr4:6284965	A/G	cg00701064	chr4:6280414	WFS1	0.67	9.53	0.51	1.09e-18	Cisplatin-induced ototoxicity;
CESC	cis	rs7914558	0.899	rs7913682	chr10:104684392	T/A	cg04362960	chr10:104952993	NT5C2	0.44	5.6	0.33	5.35e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs7833790	0.963	rs28823280	chr8:82777716	G/A	cg17211192	chr8:82754475	SNX16	0.7	8.28	0.45	6.1e-15	Diastolic blood pressure;
CESC	cis	rs4862750	0.914	rs9998558	chr4:187874691	A/G	cg06074448	chr4:187884817	NA	-0.36	-5.17	-0.3	4.63e-7	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7666738	0.546	rs13141117	chr4:98892798	G/A	cg05340658	chr4:99064831	C4orf37	0.54	6.57	0.37	2.63e-10	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1451375	0.642	rs6963996	chr7:50559300	T/C	cg14593290	chr7:50529359	DDC	-0.5	-6.27	-0.36	1.47e-9	Malaria;
CESC	cis	rs2522056	1.000	rs7730247	chr5:131781288	A/C	cg24060327	chr5:131705240	SLC22A5	0.65	7.73	0.43	2.23e-13	Lymphocyte counts;Fibrinogen;
CESC	cis	rs61996546	0.635	rs61998671	chr15:26853000	T/C	cg14859324	chr15:26874363	GABRB3	-0.37	-5.06	-0.3	7.97e-7	Response to methotrexate in juvenile idiopathic arthritis;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg16136840	chr5:95997740	CAST	-0.45	-6.25	-0.36	1.61e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs9926296	0.568	rs886950	chr16:89836872	T/C	cg07648498	chr16:89883185	FANCA	0.43	5.21	0.3	3.81e-7	Vitiligo;
CESC	cis	rs8060686	0.641	rs12599880	chr16:68152035	A/G	cg26727032	chr16:67993705	SLC12A4	-0.54	-6.05	-0.35	4.92e-9	HDL cholesterol;Metabolic syndrome;
CESC	trans	rs848353	1.000	rs11768328	chr7:108596014	A/G	cg03555276	chr13:113260139	NA	0.58	6.33	0.36	1.06e-9	Smoking behavior;
CESC	cis	rs7527798	0.592	rs2296159	chr1:207851760	G/A	cg09232269	chr1:207846808	CR1L	-0.28	-5.14	-0.3	5.27e-7	Erythrocyte sedimentation rate;
CESC	cis	rs2576037	0.526	rs2571024	chr18:44557877	G/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.55	7.6	0.42	5.28e-13	Personality dimensions;
CESC	cis	rs1552244	1.000	rs9834980	chr3:10065528	G/A	cg08888203	chr3:10149979	C3orf24	0.5	6.33	0.36	1.05e-9	Alzheimer's disease;
CESC	cis	rs9837602	0.529	rs793495	chr3:99507934	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.48	5.97	0.34	7.58e-9	Breast cancer;
CESC	cis	rs2625529	0.652	rs2957734	chr15:72261385	A/G	cg16672083	chr15:72433130	SENP8	0.46	6.78	0.38	7.78e-11	Red blood cell count;
CESC	cis	rs12079745	0.793	rs113426965	chr1:169406545	T/C	cg09363564	chr1:169337483	NME7;BLZF1	-1.26	-7.33	-0.41	2.72e-12	QT interval;
CESC	cis	rs5750830	0.594	rs6001568	chr22:39775786	G/A	cg01416388	chr22:39784598	NA	-0.6	-7.58	-0.42	5.87e-13	Intelligence (multi-trait analysis);
CESC	cis	rs3749237	0.537	rs4459909	chr3:49469217	T/C	cg02487422	chr3:49467188	NICN1	0.58	8.47	0.46	1.7e-15	Resting heart rate;
CESC	cis	rs736408	0.716	rs2300149	chr3:52822921	C/T	cg18404041	chr3:52824283	ITIH1	-0.46	-7.72	-0.43	2.45e-13	Bipolar disorder;
CESC	cis	rs853679	0.550	rs1233701	chr6:28168726	C/G	cg08968635	chr6:28129556	ZNF389	-0.36	-5.06	-0.3	7.72e-7	Depression;
CESC	cis	rs2204008	0.837	rs2387317	chr12:38235319	T/C	cg26384229	chr12:38710491	ALG10B	0.69	9.8	0.52	1.51e-19	Bladder cancer;
CESC	cis	rs2832191	0.791	rs2251517	chr21:30531951	T/G	cg24692254	chr21:30365293	RNF160	0.89	14.56	0.67	1.13e-35	Dental caries;
CESC	cis	rs7208859	0.623	rs9890558	chr17:29110355	T/C	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.91e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg01806965	chr8:144378397	ZNF696	0.53	6.92	0.39	3.49e-11	Fibrinogen levels;
CESC	cis	rs9287719	0.967	rs4669596	chr2:10720572	C/T	cg00105475	chr2:10696890	NA	0.39	5.75	0.33	2.43e-8	Prostate cancer;
CESC	cis	rs7267979	1.000	rs2258066	chr20:25271326	C/T	cg08601574	chr20:25228251	PYGB	0.39	5.65	0.33	4.13e-8	Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs8073060	0.586	rs225265	chr17:33961972	C/T	cg19694781	chr19:47549865	TMEM160	-0.73	-7.03	-0.4	1.79e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	cis	rs2742234	0.910	rs2503866	chr10:43646261	T/A	cg07801480	chr10:43725741	RASGEF1A	0.39	5.64	0.33	4.27e-8	Hirschsprung disease;
CESC	cis	rs454510	0.826	rs347903	chr1:120192431	C/T	cg11530693	chr1:120165357	ZNF697	0.44	5.67	0.33	3.67e-8	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
CESC	cis	rs270601	0.837	rs367805	chr5:131701279	T/C	cg18758796	chr5:131593413	PDLIM4	0.39	5.21	0.3	3.84e-7	Acylcarnitine levels;
CESC	cis	rs35110281	0.720	rs162400	chr21:44950305	A/C	cg21573476	chr21:45109991	RRP1B	-0.42	-5.79	-0.34	2.01e-8	Mean corpuscular volume;
CESC	cis	rs12579753	0.827	rs7958100	chr12:82200782	G/A	cg24719984	chr12:82153464	PPFIA2	-0.34	-5.08	-0.3	7.15e-7	Resting heart rate;
CESC	cis	rs3785574	0.962	rs4480868	chr17:61788859	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.44	5.31	0.31	2.37e-7	Height;
CESC	cis	rs7845219	0.506	rs12548999	chr8:95929843	C/T	cg13393036	chr8:95962371	TP53INP1	-0.4	-7.56	-0.42	6.54e-13	Type 2 diabetes;
CESC	cis	rs875971	0.862	rs6978028	chr7:65886300	G/C	cg11764359	chr7:65958608	NA	0.78	11.31	0.57	1.86e-24	Aortic root size;
CESC	cis	rs61931739	0.500	rs3924705	chr12:34557825	A/T	cg06521331	chr12:34319734	NA	-0.36	-5.03	-0.3	9.01e-7	Morning vs. evening chronotype;
CESC	cis	rs9623117	0.874	rs6519216	chr22:40472399	G/A	cg05033341	chr22:40419857	FAM83F	-0.46	-5.2	-0.3	4.05e-7	Prostate cancer (SNP x SNP interaction);Prostate cancer;
CESC	cis	rs4794106	0.792	rs11365	chr17:48211533	T/G	cg13127421	chr17:48202128	SAMD14	-0.53	-7.68	-0.43	3e-13	Temporomandibular joint disorder;
CESC	cis	rs8017423	0.967	rs17188605	chr14:90722579	C/T	cg14092571	chr14:90743983	NA	-0.55	-8.31	-0.45	5.06e-15	Mortality in heart failure;
CESC	cis	rs769267	0.930	rs9917108	chr19:19572785	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.47	5.87	0.34	1.33e-8	Tonsillectomy;
CESC	cis	rs909674	0.818	rs5750833	chr22:39843091	C/A	cg05872129	chr22:39784769	NA	-0.82	-10.84	-0.55	6.5e-23	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs13256369	0.708	rs11249886	chr8:8562021	T/A	cg18904891	chr8:8559673	CLDN23	0.73	8.46	0.46	1.83e-15	Obesity-related traits;
CESC	cis	rs892961	1.000	rs11077907	chr17:75400706	G/A	cg05865280	chr17:75406074	SEPT9	0.57	10.08	0.53	1.92e-20	Airflow obstruction;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg02374837	chr16:8891602	PMM2;TMEM186	-0.49	-6.75	-0.38	9.4e-11	Gambling;
CESC	cis	rs9649465	0.967	rs13244694	chr7:123329879	T/C	cg04330084	chr7:123175371	IQUB	-0.38	-5.22	-0.31	3.69e-7	Migraine;
CESC	cis	rs939574	1.000	rs2071385	chr2:220118782	T/G	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.8	6.86	0.39	4.9e-11	Platelet distribution width;
CESC	cis	rs13256369	1.000	rs12550458	chr8:8567832	G/A	cg17143192	chr8:8559678	CLDN23	0.71	7.92	0.44	6.78e-14	Obesity-related traits;
CESC	cis	rs4689592	0.523	rs3857179	chr4:7070496	T/A	cg06697600	chr4:7070879	GRPEL1	-0.47	-6.85	-0.39	5.02e-11	Monocyte percentage of white cells;
CESC	trans	rs11039798	0.545	rs7118670	chr11:48532056	C/T	cg15704280	chr7:45808275	SEPT13	0.66	6.68	0.38	1.4e-10	Axial length;
CESC	trans	rs6964833	0.786	rs35633336	chr7:74058292	G/T	cg07504079	chr7:72649617	NCF1B	-0.54	-6.15	-0.35	2.87e-9	Menarche (age at onset);
CESC	cis	rs1799949	1.000	rs4793189	chr17:41190715	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	8.25	0.45	7.5e-15	Menopause (age at onset);
CESC	cis	rs77633900	0.892	rs2469216	chr15:76613477	C/T	cg09663584	chr15:77347405	TSPAN3	0.58	5.1	0.3	6.39e-7	Non-glioblastoma glioma;Glioma;
CESC	cis	rs4820539	0.966	rs5759600	chr22:23483769	C/A	cg14186256	chr22:23484241	RTDR1	0.83	14.76	0.67	2.18e-36	Bone mineral density;
CESC	cis	rs9811920	0.638	rs2452321	chr3:99638836	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.57	7.02	0.4	1.84e-11	Axial length;
CESC	cis	rs910316	0.967	rs4903285	chr14:75609268	A/T	cg08847533	chr14:75593920	NEK9	1.03	20.54	0.78	9.98e-57	Height;
CESC	cis	rs6546550	0.901	rs6739780	chr2:70138111	G/A	cg02498382	chr2:70120550	SNRNP27	-0.4	-7.03	-0.4	1.71e-11	Prevalent atrial fibrillation;
CESC	cis	rs875971	0.522	rs4502988	chr7:65297746	A/G	cg18876405	chr7:65276391	NA	0.7	9.83	0.52	1.18e-19	Aortic root size;
CESC	cis	rs7712401	0.601	rs27976	chr5:122206460	C/T	cg19412675	chr5:122181750	SNX24	-0.41	-5.04	-0.3	8.57e-7	Mean platelet volume;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg05859395	chr5:203595	NA	0.47	6.17	0.35	2.48e-9	Fibrinogen levels;
CESC	cis	rs3091242	0.933	rs35530120	chr1:25785451	A/G	cg27572855	chr1:25598939	RHD	-0.43	-7.13	-0.4	9.46e-12	Erythrocyte sedimentation rate;
CESC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg09378111	chr2:211036309	C2orf67	0.48	6.08	0.35	4.08e-9	Tetralogy of Fallot;
CESC	cis	rs3126085	0.935	rs11588174	chr1:152175970	C/T	cg03465714	chr1:152285911	FLG	0.46	5.67	0.33	3.77e-8	Atopic dermatitis;
CESC	cis	rs1185460	0.967	rs1786690	chr11:118942067	A/G	cg01677386	chr11:118938358	VPS11	-0.45	-5.52	-0.32	8.16e-8	Coronary artery disease;
CESC	cis	rs17401966	0.931	rs12409754	chr1:10457540	T/C	cg15208524	chr1:10270712	KIF1B	0.42	5.25	0.31	3.09e-7	Hepatocellular carcinoma;
CESC	cis	rs718433	0.584	rs10133988	chr14:22214659	A/C	cg02257791	chr14:22217085	NA	-0.32	-5.09	-0.3	6.83e-7	Intraocular pressure;
CESC	cis	rs17376456	0.877	rs7728736	chr5:93404277	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.6	5.23	0.31	3.49e-7	Diabetic retinopathy;
CESC	cis	rs12586317	0.620	rs7147571	chr14:35530236	T/C	cg16230307	chr14:35515116	FAM177A1	0.93	9.86	0.52	9.69e-20	Psoriasis;
CESC	cis	rs7618915	0.547	rs1561337	chr3:52659963	C/T	cg18337363	chr3:52569053	NT5DC2	0.29	5.23	0.31	3.4e-7	Bipolar disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15013526	chr3:170588137	RPL22L1	0.62	7.2	0.4	6.21e-12	Gut microbiome composition (summer);
CESC	cis	rs60843830	0.661	rs11674477	chr2:105822	C/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.5	6.01	0.35	6.07e-9	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs116095464	0.558	rs6866776	chr5:264495	C/T	cg22496380	chr5:211416	CCDC127	-0.74	-8.46	-0.46	1.86e-15	Breast cancer;
CESC	cis	rs4253772	0.591	rs6008545	chr22:46686375	C/T	cg09491104	chr22:46646882	C22orf40	-0.55	-7.58	-0.42	5.65e-13	LDL cholesterol;Cholesterol, total;
CESC	cis	rs13191362	1.000	rs13214516	chr6:163121583	A/T	cg06582575	chr6:163149167	PACRG;PARK2	1.02	10.3	0.53	3.86e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs9346455	0.614	rs2208845	chr6:71997278	T/C	cg27238071	chr6:71998145	OGFRL1	0.6	5.93	0.34	9.65e-9	Antipsychotic drug-induced weight gain (time interaction);Antipsychotic drug-induced weight gain;
CESC	cis	rs11608355	0.521	rs4766469	chr12:109836890	C/G	cg19025524	chr12:109796872	NA	0.52	7.36	0.41	2.32e-12	Neuroticism;
CESC	cis	rs1707322	0.752	rs28568986	chr1:46207743	C/T	cg03146154	chr1:46216737	IPP	0.82	11.53	0.58	3.39e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg18512092	chr2:27274554	AGBL5	-0.4	-6.05	-0.35	4.87e-9	Gambling;
CESC	cis	rs7666738	0.830	rs6532719	chr4:99043691	A/G	cg18180107	chr4:99064573	C4orf37	0.4	5.2	0.3	4.08e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9916302	0.706	rs1054488	chr17:37687968	A/G	cg00129232	chr17:37814104	STARD3	-0.55	-5.69	-0.33	3.39e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs7833986	0.501	rs72651502	chr8:56875533	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.55	6.75	0.38	9.26e-11	Height;
CESC	cis	rs7267979	1.000	rs6083809	chr20:25329309	A/G	cg08601574	chr20:25228251	PYGB	-0.38	-5.51	-0.32	8.54e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs6963495	0.818	rs117887993	chr7:105193837	T/G	cg13798780	chr7:105162888	PUS7	0.77	7.64	0.42	4.08e-13	Bipolar disorder (body mass index interaction);
CESC	cis	rs8070740	1.000	rs8076900	chr17:5327927	C/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.52	6.29	0.36	1.34e-9	Menopause (age at onset);
CESC	trans	rs12912184	0.633	rs2079596	chr15:92752148	G/A	cg17173639	chr6:162384350	PARK2	-0.59	-6.14	-0.35	2.97e-9	Smoking initiation;
CESC	cis	rs9303280	0.806	rs9909593	chr17:37970149	C/T	cg19468946	chr17:37922297	IKZF3	0.41	5.57	0.32	6.39e-8	Self-reported allergy;
CESC	cis	rs7116495	0.609	rs1541304	chr11:71714078	T/C	cg07596299	chr11:71824057	C11orf51	-0.82	-5.33	-0.31	2.13e-7	Severe influenza A (H1N1) infection;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg01185801	chr11:65265397	MALAT1	-0.45	-6.03	-0.35	5.35e-9	Height;
CESC	cis	rs17818399	0.547	rs35178974	chr2:46763898	T/C	cg06386533	chr2:46925753	SOCS5	0.46	5.05	0.3	8.27e-7	Height;
CESC	cis	rs7666738	0.830	rs1593573	chr4:98925293	T/C	cg05340658	chr4:99064831	C4orf37	0.82	12.2	0.6	1.81e-27	Colonoscopy-negative controls vs population controls;
CESC	cis	rs992157	0.560	rs10932763	chr2:219085863	G/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.57	-7.45	-0.42	1.29e-12	Colorectal cancer;
CESC	trans	rs7448080	0.510	rs1604403	chr5:123259166	T/G	cg10971134	chr1:56877429	NA	0.93	6.27	0.36	1.5e-9	Alcohol dependence (age at onset);
CESC	cis	rs8114671	0.967	rs3746427	chr20:33730464	A/G	cg06115741	chr20:33292138	TP53INP2	0.42	5.14	0.3	5.44e-7	Height;
CESC	cis	rs1983891	0.742	rs4711677	chr6:41555862	G/A	cg20194872	chr6:41519635	FOXP4	0.48	6.75	0.38	9.41e-11	Prostate cancer;
CESC	cis	rs4664308	0.870	rs2305818	chr2:161029218	G/A	cg03641300	chr2:160917029	PLA2R1	-0.61	-8.95	-0.48	6.4e-17	Idiopathic membranous nephropathy;
CESC	cis	rs4930561	0.765	rs34493482	chr11:67969508	T/C	cg16338278	chr11:67432957	ALDH3B2	0.42	5.27	0.31	2.77e-7	Breast cancer in childhood cancer survivors;IgG glycosylation;
CESC	cis	rs7809950	0.817	rs4727679	chr7:107085018	T/C	cg23024343	chr7:107201750	COG5	-0.56	-7.2	-0.4	6.06e-12	Coronary artery disease;
CESC	cis	rs17433780	0.857	rs12144445	chr1:89465238	C/T	cg09516651	chr1:89888402	LOC400759	0.67	9.0	0.48	4.53e-17	Carotid intima media thickness;
CESC	cis	rs7116495	0.609	rs11235444	chr11:71831859	G/A	cg18441811	chr11:71824068	C11orf51	0.84	5.35	0.31	1.93e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs9818758	0.607	rs113186424	chr3:49272726	T/C	cg00383909	chr3:49044727	WDR6	0.81	6.24	0.36	1.74e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CESC	cis	rs72829446	0.530	rs4796430	chr17:7401903	A/G	cg02795151	chr17:7402630	POLR2A	0.62	6.59	0.38	2.34e-10	Androgen levels;
CESC	cis	rs425277	0.606	rs424079	chr1:2071340	C/A	cg04315214	chr1:2043799	PRKCZ	0.47	7.66	0.43	3.6e-13	Height;
CESC	cis	rs2839186	0.872	rs13052495	chr21:47707474	G/A	cg10351095	chr21:47802916	PCNT	-0.5	-6.8	-0.39	7.02e-11	Testicular germ cell tumor;
CESC	cis	rs6963495	0.818	rs73190158	chr7:105153943	T/C	cg02135003	chr7:105160482	PUS7	-0.46	-5.55	-0.32	6.92e-8	Bipolar disorder (body mass index interaction);
CESC	cis	rs2228479	0.850	rs62054638	chr16:89821131	G/C	cg19635926	chr16:89946313	TCF25	0.67	5.09	0.3	6.82e-7	Skin colour saturation;
CESC	cis	rs2070488	0.804	rs13063978	chr3:38476538	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.82	13.18	0.63	7.62e-31	Electrocardiographic conduction measures;
CESC	cis	rs8044868	0.586	rs6499557	chr16:72082654	A/G	cg01557791	chr16:72042693	DHODH	-0.43	-5.89	-0.34	1.17e-8	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CESC	cis	rs875971	0.862	rs12698521	chr7:65939489	T/C	cg10691866	chr7:65817282	TPST1	-0.34	-5.67	-0.33	3.76e-8	Aortic root size;
CESC	trans	rs4950322	0.580	rs17359629	chr1:146593119	C/T	cg04954894	chr8:38089920	DDHD2	-0.6	-6.69	-0.38	1.3e-10	Protein quantitative trait loci;
CESC	cis	rs66573146	0.572	rs66611116	chr4:6953270	A/G	cg26116260	chr4:7069785	GRPEL1	-0.8	-5.33	-0.31	2.08e-7	Granulocyte percentage of myeloid white cells;
CESC	cis	rs8082590	1	rs8082590	chr17:17958402	G/A	cg04398451	chr17:18023971	MYO15A	0.72	10.46	0.54	1.15e-21	Schizophrenia;
CESC	cis	rs12586317	0.620	rs17091786	chr14:35565856	A/T	cg16230307	chr14:35515116	FAM177A1	0.95	10.08	0.53	1.9e-20	Psoriasis;
CESC	trans	rs7615952	0.512	rs1077621	chr3:125819799	A/G	cg07211511	chr3:129823064	LOC729375	-0.57	-6.28	-0.36	1.38e-9	Blood pressure (smoking interaction);
CESC	trans	rs1814175	0.645	rs1851844	chr11:50021773	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.42	-6.13	-0.35	3.1e-9	Height;
CESC	cis	rs35520189	0.845	rs12479173	chr2:113649210	G/A	cg06156847	chr2:113672199	IL1F7	0.37	5.62	0.33	4.77e-8	Obstructive sleep apnea trait (apnea hypopnea index);
CESC	cis	rs9443645	0.901	rs9343844	chr6:79586463	T/A	cg05283184	chr6:79620031	NA	-0.43	-6.55	-0.37	2.95e-10	Intelligence (multi-trait analysis);
CESC	cis	rs12477438	0.765	rs7340412	chr2:99661148	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.62	-8.67	-0.47	4.43e-16	Chronic sinus infection;
CESC	cis	rs6088590	1.000	rs3787222	chr20:33333040	T/A	cg06115741	chr20:33292138	TP53INP2	0.6	7.34	0.41	2.7e-12	Coronary artery disease;
CESC	cis	rs57221529	0.766	rs72706608	chr5:559203	C/T	cg16447950	chr5:562315	NA	-0.7	-7.76	-0.43	1.9e-13	Lung disease severity in cystic fibrosis;
CESC	cis	rs4268898	0.931	rs7603997	chr2:24524958	C/T	cg08917208	chr2:24149416	ATAD2B	0.47	5.37	0.31	1.73e-7	Asthma;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26101466	chr14:64108700	WDR89	0.54	6.42	0.37	6.29e-10	Gut microbiome composition (summer);
CESC	cis	rs7927771	0.524	rs10838771	chr11:47831332	A/G	cg20307385	chr11:47447363	PSMC3	-0.58	-7.99	-0.44	4.29e-14	Subjective well-being;
CESC	cis	rs10191773	0.589	rs72831639	chr2:112949291	A/G	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.7	-6.53	-0.37	3.41e-10	Yeast infection;
CESC	cis	rs6831352	0.918	rs13113166	chr4:100050528	A/G	cg12011299	chr4:100065546	ADH4	-0.59	-6.52	-0.37	3.62e-10	Alcohol dependence;
CESC	cis	rs11122272	0.735	rs971534	chr1:231521971	C/A	cg06096015	chr1:231504339	EGLN1	0.43	6.18	0.35	2.46e-9	Hemoglobin concentration;
CESC	cis	rs12930096	1.000	rs55947021	chr16:11678949	C/A	cg07439791	chr16:11680400	LITAF	0.61	5.66	0.33	3.84e-8	QT interval;
CESC	cis	rs1559088	0.948	rs12610071	chr19:33582687	A/C	cg17764715	chr19:33622953	WDR88	0.5	6.46	0.37	4.9e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs2247341	0.894	rs2592831	chr4:1711404	T/C	cg07465881	chr4:1713556	SLBP	-0.53	-6.64	-0.38	1.73e-10	Hip circumference adjusted for BMI;Height;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg22119665	chr22:23745131	ZDHHC8P	0.41	6.33	0.36	1.04e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs965469	0.947	rs6139087	chr20:3329062	T/C	cg25506879	chr20:3388711	C20orf194	-0.54	-5.78	-0.33	2.14e-8	IFN-related cytopenia;
CESC	cis	rs1559088	0.895	rs7259582	chr19:33593979	A/G	cg27124370	chr19:33622961	WDR88	0.45	6.0	0.35	6.49e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs4523957	0.890	rs9895551	chr17:2115922	C/G	cg16513277	chr17:2031491	SMG6	0.64	8.95	0.48	6.57e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs7552404	0.824	rs1251079	chr1:76189445	C/T	cg22875332	chr1:76189707	ACADM	0.76	11.73	0.58	7.41e-26	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs10504229	0.906	rs58251024	chr8:58172259	G/C	cg24829409	chr8:58192753	C8orf71	-0.76	-9.91	-0.52	6.75e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs1008375	0.966	rs6813375	chr4:17649499	T/G	cg16339924	chr4:17578868	LAP3	0.65	8.27	0.45	6.38e-15	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs9309473	0.948	rs13392691	chr2:73748980	G/A	cg20560298	chr2:73613845	ALMS1	-0.54	-6.84	-0.39	5.52e-11	Metabolite levels;
CESC	cis	rs7674212	0.541	rs2615539	chr4:104081106	C/G	cg16532752	chr4:104119610	CENPE	-0.45	-6.18	-0.36	2.37e-9	Type 2 diabetes;
CESC	cis	rs6748734	1.000	rs6724662	chr2:241831560	A/G	cg04034577	chr2:241836375	C2orf54	-0.48	-8.04	-0.44	2.98e-14	Urinary metabolites;
CESC	cis	rs7267979	0.816	rs6076358	chr20:25519403	G/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.77	-14.19	-0.66	2.27e-34	Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs561341	0.769	rs559228	chr17:30294527	T/C	cg20587970	chr11:113659929	NA	-1.43	-18.65	-0.75	3.85e-50	Hip circumference adjusted for BMI;
CESC	cis	rs9322193	0.847	rs12191643	chr6:149950048	C/T	cg13206674	chr6:150067644	NUP43	0.43	6.23	0.36	1.82e-9	Lung cancer;
CESC	cis	rs4665809	1.000	rs10170359	chr2:26272219	G/T	cg25036284	chr2:26402008	FAM59B	-0.71	-8.23	-0.45	8.41e-15	Gut microbiome composition (summer);
CESC	cis	rs6496667	0.632	rs6496658	chr15:90884105	A/G	cg22089800	chr15:90895588	ZNF774	0.49	5.92	0.34	9.75e-9	Rheumatoid arthritis;
CESC	cis	rs2708240	0.666	rs2710104	chr7:147592649	A/C	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.37	-6.16	-0.35	2.71e-9	QT interval (drug interaction);
CESC	cis	rs11792861	0.926	rs2271878	chr9:111868885	G/A	cg13535736	chr9:111863775	C9orf5	-0.5	-6.66	-0.38	1.6e-10	Menarche (age at onset);
CESC	cis	rs6952809	0.532	rs7803015	chr7:2432143	G/A	cg23289794	chr7:2394357	EIF3B	-0.66	-6.57	-0.37	2.72e-10	Multiple sclerosis;
CESC	trans	rs875971	1.000	rs11974219	chr7:65647410	C/T	cg26939375	chr7:64535504	NA	-0.48	-6.31	-0.36	1.17e-9	Aortic root size;
CESC	cis	rs9911578	0.967	rs2429369	chr17:56501420	A/G	cg05425664	chr17:57184151	TRIM37	-0.48	-6.79	-0.38	7.4e-11	Intelligence (multi-trait analysis);
CESC	cis	rs35306767	0.953	rs12357633	chr10:957246	C/T	cg20503657	chr10:835505	NA	0.9	9.27	0.49	6.58e-18	Eosinophil percentage of granulocytes;
CESC	cis	rs11785693	0.862	rs11780705	chr8:4988221	G/A	cg26367366	chr8:4980734	NA	0.93	8.78	0.47	2.12e-16	Neuroticism (multi-trait analysis);Neuroticism;
CESC	cis	rs4919044	0.688	rs59539045	chr10:94776594	C/A	cg00487187	chr10:94451625	HHEX	-0.45	-5.05	-0.3	8.21e-7	Coronary artery disease;
CESC	cis	rs6860806	0.661	rs334902	chr5:131586559	C/G	cg18758796	chr5:131593413	PDLIM4	0.45	6.41	0.37	6.79e-10	Breast cancer;
CESC	cis	rs9311474	0.629	rs13081028	chr3:52555316	G/A	cg15147215	chr3:52552868	STAB1	-0.39	-7.1	-0.4	1.15e-11	Electroencephalogram traits;
CESC	cis	rs853679	0.517	rs3757185	chr6:28107776	T/A	cg18032046	chr6:28092343	ZSCAN16	-0.55	-6.44	-0.37	5.7e-10	Depression;
CESC	cis	rs3008870	1.000	rs2815361	chr1:67494591	G/T	cg08660285	chr1:67390436	MIER1;WDR78	0.98	13.07	0.63	1.83e-30	Lymphocyte percentage of white cells;
CESC	cis	rs9811920	0.838	rs12488245	chr3:99835254	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.43	6.86	0.39	4.97e-11	Axial length;
CESC	cis	rs35306767	0.903	rs11253475	chr10:907262	C/A	cg25019033	chr10:957182	NA	-0.57	-6.07	-0.35	4.31e-9	Eosinophil percentage of granulocytes;
CESC	cis	rs9649213	0.593	rs13246868	chr7:97986453	T/C	cg00277769	chr7:97922759	BAIAP2L1	-0.33	-5.41	-0.32	1.41e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs4975616	0.839	rs2447853	chr5:1333077	A/G	cg26373071	chr5:1325741	CLPTM1L	0.43	6.76	0.38	8.72e-11	Lung cancer;
CESC	trans	rs7246760	1.000	rs59771283	chr19:9854958	G/A	cg02900749	chr2:68251473	NA	-0.84	-7.32	-0.41	2.99e-12	Pursuit maintenance gain;
CESC	cis	rs7713065	0.765	rs28655019	chr5:131770881	C/A	cg10809880	chr5:131517096	NA	-0.46	-5.2	-0.3	3.92e-7	Lung function (FEV1/FVC);
CESC	cis	rs875971	1.000	rs937495	chr7:65779798	A/G	cg10691866	chr7:65817282	TPST1	0.35	5.82	0.34	1.66e-8	Aortic root size;
CESC	cis	rs3733585	0.673	rs4455410	chr4:9953297	C/T	cg02734326	chr4:10020555	SLC2A9	0.39	5.45	0.32	1.17e-7	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs853679	0.517	rs9380065	chr6:28144751	A/G	cg20151795	chr6:28129481	ZNF389	0.41	5.28	0.31	2.69e-7	Depression;
CESC	cis	rs61776719	0.520	rs17465651	chr1:38418496	C/T	cg26398791	chr1:38455867	SF3A3	-0.44	-5.64	-0.33	4.46e-8	Coronary artery disease;
CESC	cis	rs919433	0.750	rs788010	chr2:198230949	T/C	cg10820045	chr2:198174542	NA	0.41	5.93	0.34	9.6e-9	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs9549260	0.755	rs2721069	chr13:41143720	C/T	cg21288729	chr13:41239152	FOXO1	0.66	8.4	0.46	2.69e-15	Red blood cell count;
CESC	cis	rs12497850	0.931	rs4974079	chr3:48906469	T/G	cg06212747	chr3:49208901	KLHDC8B	0.66	8.74	0.47	2.71e-16	Parkinson's disease;
CESC	cis	rs6570726	0.846	rs426874	chr6:145880630	A/C	cg23711669	chr6:146136114	FBXO30	0.87	12.84	0.62	1.13e-29	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4319547	0.915	rs11058402	chr12:122981053	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.66	-7.6	-0.42	5.09e-13	Body mass index;
CESC	cis	rs9308433	0.505	rs6695148	chr1:214497861	G/T	cg06198575	chr1:214491504	SMYD2	0.49	5.98	0.34	7.22e-9	IgG glycosylation;
CESC	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg10295955	chr4:187884368	NA	-1.05	-18.46	-0.75	1.69e-49	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4234284	0.556	rs13072737	chr3:126948835	C/T	cg27326032	chr3:127006922	NA	-0.42	-5.71	-0.33	2.95e-8	Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel);
CESC	cis	rs67311347	0.956	rs9817233	chr3:40425618	G/T	cg24209194	chr3:40518798	ZNF619	0.49	6.15	0.35	2.83e-9	Renal cell carcinoma;
CESC	cis	rs769267	0.929	rs34538000	chr19:19481379	G/T	cg17414380	chr19:19431394	KIAA0892;SF4	-0.48	-6.18	-0.35	2.39e-9	Tonsillectomy;
CESC	cis	rs1153858	0.945	rs7182300	chr15:45634928	G/A	cg14582100	chr15:45693742	SPATA5L1	0.42	6.08	0.35	4.2e-9	Homoarginine levels;
CESC	cis	rs875971	0.543	rs801191	chr7:66032955	G/A	cg14393609	chr7:65229607	NA	-0.41	-5.77	-0.33	2.21e-8	Aortic root size;
CESC	cis	rs73206853	0.925	rs12310834	chr12:110762756	A/G	cg12870014	chr12:110450643	ANKRD13A	0.63	5.96	0.34	7.9e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs11608355	0.521	rs9888353	chr12:109843594	G/A	cg19025524	chr12:109796872	NA	-0.53	-7.28	-0.41	3.84e-12	Neuroticism;
CESC	cis	rs17433780	0.928	rs12127787	chr1:89458761	T/C	cg09516651	chr1:89888402	LOC400759	0.67	9.09	0.49	2.48e-17	Carotid intima media thickness;
CESC	trans	rs1038903	0.893	rs6448593	chr4:28757802	A/G	cg15651925	chr7:156259219	NA	0.48	6.11	0.35	3.51e-9	Menarche (age at onset);
CESC	cis	rs514406	0.825	rs497535	chr1:53284677	A/G	cg16325326	chr1:53192061	ZYG11B	-0.9	-15.35	-0.69	1.7e-38	Monocyte count;
CESC	cis	rs7143963	0.666	rs8017944	chr14:103320048	T/G	cg24154132	chr14:103367632	TRAF3	0.37	6.59	0.38	2.35e-10	Body mass index;
CESC	cis	rs2228479	0.681	rs62052184	chr16:89967217	T/C	cg04013166	chr16:89971882	TCF25	0.71	8.29	0.45	5.65e-15	Skin colour saturation;
CESC	cis	rs10927875	0.597	rs61782184	chr1:16150976	G/A	cg21385522	chr1:16154831	NA	-1.01	-16.01	-0.7	8.12e-41	Dilated cardiomyopathy;
CESC	cis	rs9682041	0.740	rs6444929	chr3:170150076	C/T	cg11886554	chr3:170076028	SKIL	0.68	5.59	0.32	5.54e-8	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CESC	cis	rs736801	0.504	rs2070721	chr5:131825842	T/G	cg21138405	chr5:131827807	IRF1	0.38	6.42	0.37	6.3e-10	Breast cancer;Mosquito bite size;
CESC	cis	rs57506017	0.585	rs7785189	chr7:12257527	C/T	cg23422036	chr7:12250390	TMEM106B	0.38	5.11	0.3	6.06e-7	Neuroticism;
CESC	cis	rs5758511	0.679	rs55867855	chr22:42623258	G/A	cg00645731	chr22:42541494	CYP2D7P1	0.58	8.64	0.47	5.58e-16	Birth weight;
CESC	cis	rs739401	0.572	rs739400	chr11:3016520	G/A	cg08508325	chr11:3079039	CARS	-0.54	-10.37	-0.54	2.27e-21	Longevity;
CESC	cis	rs8017423	0.935	rs8012299	chr14:90715822	G/T	cg14092571	chr14:90743983	NA	-0.58	-8.8	-0.48	1.84e-16	Mortality in heart failure;
CESC	cis	rs3096299	0.685	rs4785571	chr16:89565169	A/G	cg00750074	chr16:89608354	SPG7	-0.41	-6.02	-0.35	5.87e-9	Multiple myeloma (IgH translocation);
CESC	cis	rs568617	0.953	rs645900	chr11:65648135	G/A	cg00576331	chr11:65640516	EFEMP2	0.45	5.3	0.31	2.48e-7	Crohn's disease;
CESC	cis	rs1005277	0.579	rs1780116	chr10:38526621	C/T	cg00409905	chr10:38381863	ZNF37A	-0.51	-6.77	-0.38	8.46e-11	Extrinsic epigenetic age acceleration;
CESC	cis	rs853679	0.517	rs4713146	chr6:28111536	A/T	cg12963246	chr6:28129442	ZNF389	0.58	7.55	0.42	7e-13	Depression;
CESC	cis	rs9486719	1.000	rs4078038	chr6:96904366	A/G	cg06623918	chr6:96969491	KIAA0776	-0.8	-8.08	-0.44	2.23e-14	Migraine;Coronary artery disease;
CESC	cis	rs116095464	0.558	rs12173244	chr5:269524	G/A	cg22496380	chr5:211416	CCDC127	-0.75	-8.61	-0.47	6.58e-16	Breast cancer;
CESC	cis	rs1008375	1.000	rs12648232	chr4:17612537	C/T	cg16339924	chr4:17578868	LAP3	-0.57	-7.2	-0.4	6.14e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs3741798	1.000	rs118108016	chr12:12482820	C/A	cg08615371	chr12:12503544	MANSC1	0.85	5.98	0.34	7.16e-9	Cerebrospinal fluid biomarker levels;
CESC	cis	rs8114671	0.839	rs2104084	chr20:33649217	G/C	cg24642439	chr20:33292090	TP53INP2	-0.47	-5.71	-0.33	3.09e-8	Height;
CESC	cis	rs1707322	0.721	rs28501477	chr1:46199084	A/G	cg06784218	chr1:46089804	CCDC17	0.43	7.58	0.42	5.65e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs4975616	0.686	rs37008	chr5:1351538	C/T	cg07493874	chr5:1342172	CLPTM1L	-0.41	-7.98	-0.44	4.52e-14	Lung cancer;
CESC	cis	rs9814567	0.712	rs4955545	chr3:134332926	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.4	-5.12	-0.3	5.84e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs6963495	0.745	rs73190169	chr7:105160500	A/G	cg19920283	chr7:105172520	RINT1	0.69	6.56	0.37	2.85e-10	Bipolar disorder (body mass index interaction);
CESC	cis	rs4689388	0.889	rs10026334	chr4:6294607	G/A	cg25554036	chr4:6271136	WFS1	0.51	8.37	0.46	3.31e-15	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs7618915	0.501	rs3774366	chr3:52641255	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.6	8.5	0.46	1.42e-15	Bipolar disorder;
CESC	cis	rs2228479	0.850	rs12598276	chr16:89829196	G/C	cg14709524	chr16:89940631	TCF25	0.89	6.55	0.37	2.99e-10	Skin colour saturation;
CESC	cis	rs8077889	0.719	rs2079006	chr17:41865745	C/G	cg26893861	chr17:41843967	DUSP3	0.98	17.65	0.74	1.24e-46	Triglycerides;
CESC	cis	rs9916302	0.752	rs6503513	chr17:37561613	A/G	cg07936489	chr17:37558343	FBXL20	0.98	13.6	0.64	2.6e-32	Glomerular filtration rate (creatinine);
CESC	cis	rs6912958	0.703	rs12207825	chr6:88098292	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.72	10.33	0.54	2.98e-21	Monocyte percentage of white cells;
CESC	cis	rs875971	1.000	rs6958271	chr7:65979331	A/C	cg18876405	chr7:65276391	NA	0.47	6.15	0.35	2.9e-9	Aortic root size;
CESC	cis	rs4704187	0.687	rs1422698	chr5:74443132	C/T	cg03227963	chr5:74354835	NA	0.3	5.52	0.32	8.21e-8	Response to amphetamines;
CESC	cis	rs742614	0.533	rs2626547	chr20:32404921	G/A	cg06304546	chr20:32448765	NA	-0.41	-5.24	-0.31	3.28e-7	Stearic acid (18:0) levels;
CESC	cis	rs1448094	0.549	rs12308898	chr12:86233678	G/A	cg19622623	chr12:86230825	RASSF9	-0.45	-5.42	-0.32	1.31e-7	Major depressive disorder;
CESC	cis	rs77741769	0.571	rs7969140	chr12:121303626	T/C	cg02419362	chr12:121203948	SPPL3	0.34	5.59	0.32	5.6e-8	Mean corpuscular volume;
CESC	cis	rs3820068	0.603	rs16851884	chr1:15961871	A/G	cg17385448	chr1:15911702	AGMAT	0.42	6.89	0.39	4.06e-11	Systolic blood pressure;
CESC	cis	rs7615952	0.641	rs7640158	chr3:125808011	G/A	cg15145296	chr3:125709740	NA	-0.56	-5.97	-0.34	7.65e-9	Blood pressure (smoking interaction);
CESC	cis	rs7666738	0.830	rs991169	chr4:98928567	C/A	cg17366294	chr4:99064904	C4orf37	0.6	8.23	0.45	8.65e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6089829	0.925	rs2277767	chr20:61666937	G/A	cg08564027	chr20:61660810	NA	0.9	15.37	0.69	1.54e-38	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs1799949	0.894	rs36062488	chr17:41337472	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	-0.52	-7.27	-0.41	4.01e-12	Menopause (age at onset);
CESC	cis	rs1018836	0.923	rs7812970	chr8:91541229	G/A	cg16814680	chr8:91681699	NA	-0.71	-10.57	-0.54	4.94e-22	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs1048238	0.506	rs598371	chr1:16212739	G/A	cg21385522	chr1:16154831	NA	-0.43	-5.32	-0.31	2.18e-7	Systolic blood pressure;
CESC	cis	rs9303280	0.742	rs11557466	chr17:38024626	C/T	cg20243544	chr17:37824526	PNMT	0.53	6.92	0.39	3.47e-11	Self-reported allergy;
CESC	cis	rs897080	0.552	rs1067323	chr2:44630018	T/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	5.91	0.34	1.07e-8	Height;
CESC	cis	rs7264396	1.000	rs224436	chr20:34154124	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.51	-6.04	-0.35	5.27e-9	Total cholesterol levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09247534	chr1:172502038	C1orf9	0.53	6.06	0.35	4.72e-9	Gut microbiome composition (summer);
CESC	cis	rs6906287	0.625	rs7764272	chr6:118692498	A/C	cg21191810	chr6:118973309	C6orf204	0.31	5.04	0.3	8.62e-7	Electrocardiographic conduction measures;
CESC	cis	rs926392	0.589	rs6093115	chr20:37693817	T/C	cg16355469	chr20:37678765	NA	0.46	5.16	0.3	4.75e-7	Dialysis-related mortality;
CESC	cis	rs477692	0.673	rs1078847	chr10:131352115	T/C	cg24747557	chr10:131355152	MGMT	-0.38	-5.22	-0.31	3.59e-7	Response to temozolomide;
CESC	trans	rs7866350	0.604	rs1935389	chr9:100994470	A/G	cg00021576	chr1:244211966	NA	0.46	6.32	0.36	1.12e-9	Post-traumatic stress disorder;
CESC	cis	rs1475911	0.671	rs12483409	chr21:43521902	G/A	cg03240473	chr21:43526662	UMODL1;C21orf128	-0.52	-7.04	-0.4	1.64e-11	IgG glycosylation;
CESC	cis	rs7100689	0.753	rs1361458	chr10:82090339	A/T	cg00277334	chr10:82204260	NA	-0.59	-7.48	-0.42	1.11e-12	Post bronchodilator FEV1;
CESC	cis	rs6665290	0.935	rs6704144	chr1:227201030	C/G	cg10327440	chr1:227177885	CDC42BPA	-1.08	-22.77	-0.81	2.5e-64	Myeloid white cell count;
CESC	cis	rs854765	0.693	rs8080061	chr17:17776389	C/T	cg09796270	chr17:17721594	SREBF1	-0.42	-6.0	-0.35	6.4e-9	Total body bone mineral density;
CESC	cis	rs3008870	1.000	rs11208976	chr1:67434411	A/G	cg02640540	chr1:67518911	SLC35D1	-0.51	-5.58	-0.32	5.89e-8	Lymphocyte percentage of white cells;
CESC	cis	rs12681288	0.676	rs1562921	chr8:1021986	G/T	cg04851639	chr8:1020857	NA	-0.38	-8.41	-0.46	2.5e-15	Schizophrenia;
CESC	cis	rs35306767	0.855	rs11253468	chr10:903261	G/A	cg26597838	chr10:835615	NA	0.86	8.92	0.48	8.09e-17	Eosinophil percentage of granulocytes;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg10692753	chr16:23464628	COG7	-0.44	-6.15	-0.35	2.87e-9	Asthma;
CESC	cis	rs801193	0.569	rs2659893	chr7:66199993	G/A	cg12463550	chr7:65579703	CRCP	0.49	6.35	0.36	9.51e-10	Aortic root size;
CESC	cis	rs2072732	0.904	rs9660819	chr1:2952823	C/T	cg15211996	chr1:2936768	ACTRT2	0.34	5.95	0.34	8.31e-9	Plateletcrit;
CESC	cis	rs2777491	0.915	rs7165675	chr15:41614704	T/C	cg02330683	chr15:41787940	ITPKA	0.45	6.56	0.37	2.73e-10	Ulcerative colitis;
CESC	cis	rs1950626	0.833	rs67456801	chr14:101399169	C/T	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.8	10.74	0.55	1.4e-22	Pelvic organ prolapse (moderate/severe);
CESC	cis	rs10256972	0.869	rs1007766	chr7:1034903	G/A	cg04025307	chr7:1156635	C7orf50	0.38	5.89	0.34	1.16e-8	Longevity;Endometriosis;
CESC	cis	rs2795502	1.000	rs2795496	chr10:43337842	G/A	cg27426351	chr10:43362370	NA	-0.44	-5.45	-0.32	1.17e-7	Blood protein levels;
CESC	cis	rs9611565	0.546	rs5758426	chr22:42098763	T/G	cg03806693	chr22:41940476	POLR3H	0.79	9.48	0.5	1.49e-18	Vitiligo;
CESC	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg07677032	chr17:61819896	STRADA	0.46	6.21	0.36	2.06e-9	Prudent dietary pattern;
CESC	cis	rs7264396	0.563	rs2425100	chr20:34310115	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.63	6.75	0.38	9.35e-11	Total cholesterol levels;
CESC	cis	rs4555082	0.874	rs3000075	chr14:105713219	C/T	cg27165867	chr14:105738592	BRF1	0.55	6.33	0.36	1.02e-9	Mean platelet volume;Platelet distribution width;
CESC	cis	rs8067354	0.645	rs2645487	chr17:57886125	T/G	cg02344993	chr17:57696989	CLTC	0.67	8.16	0.45	1.33e-14	Hemoglobin concentration;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg18909525	chr9:132403873	ASB6	-0.45	-6.28	-0.36	1.35e-9	Gambling;
CESC	cis	rs2404602	0.583	rs12907668	chr15:76589767	A/T	cg22467129	chr15:76604101	ETFA	-0.39	-5.91	-0.34	1.06e-8	Blood metabolite levels;
CESC	cis	rs428668	0.523	rs6898671	chr5:150677643	A/T	cg14086364	chr5:150678334	SLC36A3	0.5	7.32	0.41	2.93e-12	Skin aging (microtopography measurement);
CESC	cis	rs8177253	0.665	rs10935074	chr3:133441692	T/G	cg24879335	chr3:133465180	TF	0.36	6.32	0.36	1.1e-9	Iron status biomarkers;
CESC	cis	rs6088580	0.634	rs6059851	chr20:33047945	G/A	cg24642439	chr20:33292090	TP53INP2	0.52	6.82	0.39	6.01e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs4728302	0.869	rs6467510	chr7:133607968	A/G	cg10665199	chr7:133106180	EXOC4	0.4	5.61	0.33	4.98e-8	Intelligence;Intelligence (multi-trait analysis);
CESC	cis	rs7927771	0.524	rs7110300	chr11:47848442	T/G	cg18512352	chr11:47633146	NA	0.35	5.33	0.31	2.05e-7	Subjective well-being;
CESC	cis	rs13385	0.769	rs12717954	chr5:139595299	C/T	cg26211634	chr5:139558579	C5orf32	0.46	5.13	0.3	5.68e-7	Atrial fibrillation;
CESC	cis	rs2228479	0.717	rs34027607	chr16:89808939	T/C	cg14709524	chr16:89940631	TCF25	0.63	5.69	0.33	3.43e-8	Skin colour saturation;
CESC	cis	rs1018836	0.608	rs1015994	chr8:91465011	T/C	cg16814680	chr8:91681699	NA	-0.51	-7.15	-0.4	8.32e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs1801251	0.896	rs2197563	chr2:233687080	G/A	cg08000102	chr2:233561755	GIGYF2	-0.72	-11.45	-0.58	6.41e-25	Coronary artery disease;
CESC	cis	rs1878931	0.501	rs28735976	chr16:3418419	G/A	cg22508957	chr16:3507546	NAT15	-0.38	-5.54	-0.32	7.15e-8	Body mass index (adult);
CESC	cis	rs17826219	0.561	rs4085382	chr17:29071202	T/C	cg14008862	chr17:28927542	LRRC37B2	0.63	5.27	0.31	2.89e-7	Body mass index;
CESC	cis	rs769267	0.930	rs10419912	chr19:19597055	A/G	cg03709012	chr19:19516395	GATAD2A	-1.01	-15.62	-0.69	2.01e-39	Tonsillectomy;
CESC	cis	rs10885582	0.781	rs10159811	chr10:116293820	G/A	cg17056676	chr10:116301354	ABLIM1	-0.28	-5.14	-0.3	5.47e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7116495	0.609	rs10450664	chr11:71636655	A/G	cg26138937	chr11:71823887	C11orf51	-1.29	-8.25	-0.45	7.45e-15	Severe influenza A (H1N1) infection;
CESC	cis	rs1475911	1.000	rs55645900	chr21:43515728	G/T	cg03240473	chr21:43526662	UMODL1;C21orf128	-0.42	-5.3	-0.31	2.42e-7	IgG glycosylation;
CESC	cis	rs1568889	0.838	rs10835283	chr11:28214985	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.79	12.93	0.62	5.7e-30	Bipolar disorder;
CESC	cis	rs60871478	0.730	rs62432226	chr7:792973	T/C	cg15782153	chr7:917662	C7orf20	-0.47	-5.04	-0.3	8.47e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs826838	0.967	rs12823908	chr12:38845686	T/C	cg26384229	chr12:38710491	ALG10B	0.83	14.57	0.67	1.05e-35	Heart rate;
CESC	cis	rs1949733	1.000	rs2140337	chr4:8502112	A/G	cg11789530	chr4:8429930	ACOX3	0.76	10.74	0.55	1.45e-22	Response to antineoplastic agents;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02778551	chr7:1045947	C7orf50	-0.54	-6.3	-0.36	1.26e-9	Gut microbiome composition (summer);
CESC	cis	rs2228479	0.867	rs12930056	chr16:89946649	C/A	cg06558623	chr16:89946397	TCF25	1.06	8.98	0.48	5.17e-17	Skin colour saturation;
CESC	cis	rs9682041	0.627	rs3772172	chr3:170077713	C/T	cg11886554	chr3:170076028	SKIL	-0.51	-5.19	-0.3	4.2e-7	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CESC	cis	rs2204008	0.627	rs1851117	chr12:38398987	G/T	cg26384229	chr12:38710491	ALG10B	0.72	10.63	0.55	3.37e-22	Bladder cancer;
CESC	cis	rs2576037	0.501	rs7227700	chr18:44537102	T/G	cg19077165	chr18:44547161	KATNAL2	-0.53	-7.54	-0.42	7.6e-13	Personality dimensions;
CESC	cis	rs6088580	0.634	rs6088471	chr20:32932643	C/A	cg24642439	chr20:33292090	TP53INP2	-0.53	-7.01	-0.4	2.02e-11	Glomerular filtration rate (creatinine);
CESC	trans	rs61931739	0.613	rs61927732	chr12:33678166	T/C	cg26384229	chr12:38710491	ALG10B	-0.44	-6.26	-0.36	1.54e-9	Morning vs. evening chronotype;
CESC	cis	rs1005224	0.782	rs34882722	chr14:76153896	C/T	cg25116370	chr14:76127843	TTLL5;C14orf1	-0.41	-5.65	-0.33	4.13e-8	Large artery stroke;
CESC	cis	rs1448094	0.511	rs61930579	chr12:86157044	G/A	cg00310523	chr12:86230176	RASSF9	0.35	5.42	0.32	1.34e-7	Major depressive disorder;
CESC	cis	rs9910055	0.529	rs228764	chr17:42185469	A/G	cg19774624	chr17:42201019	HDAC5	0.58	7.84	0.43	1.07e-13	Total body bone mineral density;
CESC	cis	rs13256369	1.000	rs873064	chr8:8572380	G/A	cg18904891	chr8:8559673	CLDN23	0.71	8.39	0.46	2.99e-15	Obesity-related traits;
CESC	cis	rs736408	0.634	rs11717836	chr3:52807736	A/G	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.36	6.18	0.36	2.37e-9	Bipolar disorder;
CESC	cis	rs6089829	0.962	rs4809455	chr20:61660781	G/C	cg08564027	chr20:61660810	NA	0.9	15.36	0.69	1.69e-38	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs5750830	0.649	rs4337572	chr22:39800704	C/G	cg24399712	chr22:39784796	NA	-0.74	-9.09	-0.49	2.32e-17	Intelligence (multi-trait analysis);
CESC	cis	rs10924970	0.649	rs4659492	chr1:235482207	T/G	cg26050004	chr1:235667680	B3GALNT2	0.44	5.11	0.3	6.16e-7	Asthma;
CESC	cis	rs2635047	0.713	rs28666933	chr18:44762408	C/T	cg24371990	chr18:44770781	NA	0.41	6.68	0.38	1.38e-10	Educational attainment;
CESC	cis	rs9814567	0.752	rs6764764	chr3:134331167	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.49	6.44	0.37	5.44e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg03983811	chr10:99400441	PI4K2A	-0.48	-6.41	-0.37	6.71e-10	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs2228479	0.850	rs17227064	chr16:89816314	A/G	cg06558623	chr16:89946397	TCF25	1.16	9.28	0.5	6.08e-18	Skin colour saturation;
CESC	cis	rs9323205	0.723	rs61985121	chr14:51705925	A/G	cg23942311	chr14:51606299	NA	-0.48	-5.45	-0.32	1.13e-7	Cancer;
CESC	cis	rs11583043	1.000	rs35445887	chr1:101523639	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.51	5.64	0.33	4.44e-8	Ulcerative colitis;Inflammatory bowel disease;
CESC	cis	rs7216064	1.000	rs7216064	chr17:65898809	G/A	cg12091567	chr17:66097778	LOC651250	-0.75	-7.69	-0.43	2.84e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs9937943	0.673	rs12922972	chr16:74494522	T/A	cg01733217	chr16:74700730	RFWD3	0.63	5.48	0.32	1.01e-7	Neutrophil percentage of white cells;
CESC	cis	rs854765	0.547	rs4072739	chr17:17884660	G/A	cg16928487	chr17:17741425	SREBF1	-0.48	-8.15	-0.45	1.43e-14	Total body bone mineral density;
CESC	cis	rs6088590	1.000	rs2295353	chr20:33356511	C/T	cg06115741	chr20:33292138	TP53INP2	0.6	7.24	0.41	4.87e-12	Coronary artery disease;
CESC	cis	rs2228479	0.850	rs62054599	chr16:89808850	C/G	cg06558623	chr16:89946397	TCF25	1.17	9.44	0.5	1.96e-18	Skin colour saturation;
CESC	cis	rs7618915	0.501	rs7611731	chr3:52692721	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	7.86	0.43	9.89e-14	Bipolar disorder;
CESC	cis	rs3862030	0.503	rs6584506	chr10:104254428	T/C	cg22532475	chr10:104410764	TRIM8	-0.34	-5.73	-0.33	2.77e-8	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
CESC	cis	rs1005277	0.579	rs1780121	chr10:38529437	C/A	cg25427524	chr10:38739819	LOC399744	-0.7	-10.26	-0.53	5.29e-21	Extrinsic epigenetic age acceleration;
CESC	cis	rs12220238	0.818	rs10824082	chr10:75904080	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.66	6.68	0.38	1.42e-10	Soluble interleukin-2 receptor subunit alpha;
CESC	cis	rs34172651	0.876	rs11074653	chr16:24795959	C/T	cg06028605	chr16:24865363	SLC5A11	0.41	6.22	0.36	1.94e-9	Intelligence (multi-trait analysis);
CESC	cis	rs7584330	0.554	rs10176035	chr2:238433449	T/C	cg14458575	chr2:238380390	NA	0.49	5.42	0.32	1.35e-7	Prostate cancer;
CESC	cis	rs514406	0.823	rs501006	chr1:53368292	T/A	cg16325326	chr1:53192061	ZYG11B	0.82	12.71	0.62	3.3e-29	Monocyte count;
CESC	cis	rs7267979	0.966	rs4815414	chr20:25361701	A/G	cg08601574	chr20:25228251	PYGB	-0.38	-5.55	-0.32	6.88e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs9640161	0.789	rs4554381	chr7:150025567	G/A	cg10018233	chr7:150070692	REPIN1	0.46	7.48	0.42	1.12e-12	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs7615952	0.534	rs1503072	chr3:125754691	C/T	cg06494592	chr3:125709126	NA	-0.48	-5.09	-0.3	6.89e-7	Blood pressure (smoking interaction);
CESC	cis	rs7666738	0.830	rs4472144	chr4:98956494	G/A	cg05340658	chr4:99064831	C4orf37	0.78	11.83	0.59	3.21e-26	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9399137	0.507	rs7772031	chr6:135259734	G/A	cg24558204	chr6:135376177	HBS1L	-0.69	-9.42	-0.5	2.34e-18	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	cis	rs3008870	0.755	rs4655660	chr1:67402953	G/A	cg02640540	chr1:67518911	SLC35D1	0.46	5.58	0.32	5.81e-8	Lymphocyte percentage of white cells;
CESC	cis	rs7824557	0.806	rs34171564	chr8:11095346	C/A	cg21775007	chr8:11205619	TDH	-0.35	-5.12	-0.3	5.89e-7	Retinal vascular caliber;
CESC	cis	rs4237845	0.837	rs7963992	chr12:58295949	G/C	cg02175503	chr12:58329896	NA	0.56	7.28	0.41	3.7e-12	Intelligence (multi-trait analysis);
CESC	cis	rs2204008	0.744	rs11181337	chr12:38322083	C/A	cg26384229	chr12:38710491	ALG10B	0.58	8.32	0.46	4.65e-15	Bladder cancer;
CESC	cis	rs8180040	0.726	rs7625070	chr3:47095518	A/G	cg27129171	chr3:47204927	SETD2	0.72	11.05	0.56	1.3e-23	Colorectal cancer;
CESC	cis	rs4665809	1.000	rs1470097	chr2:26312840	A/G	cg26314531	chr2:26401878	FAM59B	-0.61	-6.93	-0.39	3.12e-11	Gut microbiome composition (summer);
CESC	cis	rs4665809	0.531	rs3892649	chr2:26457267	T/G	cg08470875	chr2:26401718	FAM59B	0.75	7.78	0.43	1.63e-13	Gut microbiome composition (summer);
CESC	cis	rs6831352	0.959	rs4699710	chr4:100051819	C/T	cg12011299	chr4:100065546	ADH4	0.69	8.43	0.46	2.17e-15	Alcohol dependence;
CESC	cis	rs7615952	0.512	rs1077621	chr3:125819799	A/G	cg02807482	chr3:125708958	NA	-0.39	-5.11	-0.3	6.29e-7	Blood pressure (smoking interaction);
CESC	cis	rs4713118	0.516	rs7739216	chr6:28079946	G/T	cg23161317	chr6:28129485	ZNF389	0.51	6.53	0.37	3.44e-10	Parkinson's disease;
CESC	cis	rs7249142	0.549	rs12609573	chr19:19297567	C/T	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	-0.39	-5.24	-0.31	3.22e-7	IgG glycosylation;
CESC	cis	rs1008375	0.932	rs6835077	chr4:17653285	A/T	cg16339924	chr4:17578868	LAP3	0.71	8.87	0.48	1.09e-16	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs8103278	0.507	rs7246377	chr19:46292259	G/A	cg02376097	chr19:46275166	DMPK	0.38	5.48	0.32	9.84e-8	Coronary artery disease;
CESC	cis	rs9894429	0.690	rs11869779	chr17:79570067	C/T	cg13777783	chr17:79615861	NA	0.33	5.35	0.31	1.86e-7	Eye color traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20308213	chr1:153700488	INTS3	0.54	6.34	0.36	1e-9	Gut microbiome composition (summer);
CESC	cis	rs265548	0.538	rs36688	chr19:17911212	A/C	cg04517722	chr19:17905589	B3GNT3	0.43	5.65	0.33	4.17e-8	Tumor biomarkers;
CESC	cis	rs796364	0.806	rs74938253	chr2:201008386	T/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.64	-6.04	-0.35	5.26e-9	Schizophrenia;
CESC	cis	rs12042938	0.935	rs823167	chr1:231767230	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.45	6.24	0.36	1.71e-9	Neuranatomic and neurocognitive phenotypes;
CESC	cis	rs3743266	0.507	rs10162677	chr15:60748568	C/T	cg22293140	chr15:60689852	ANXA2	-0.72	-7.62	-0.42	4.52e-13	Menarche (age at onset);
CESC	cis	rs1799949	1.000	rs4793212	chr17:41302750	T/C	cg23758822	chr17:41437982	NA	1.01	15.21	0.68	5.44e-38	Menopause (age at onset);
CESC	cis	rs7666738	0.830	rs6532724	chr4:99060993	C/T	cg05340658	chr4:99064831	C4orf37	0.83	12.91	0.62	6.52e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9300255	0.602	rs1790098	chr12:123655481	A/C	cg19016782	chr12:123741754	C12orf65	-0.45	-6.34	-0.36	9.76e-10	Neutrophil percentage of white cells;
CESC	cis	rs1005277	0.602	rs1780141	chr10:38504299	T/C	cg25427524	chr10:38739819	LOC399744	-0.73	-10.93	-0.56	3.43e-23	Extrinsic epigenetic age acceleration;
CESC	cis	rs7618915	0.547	rs10865973	chr3:52718154	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.5	7.17	0.4	7.53e-12	Bipolar disorder;
CESC	cis	rs4924935	1.000	rs2158100	chr17:18811479	A/G	cg26378065	chr17:18585709	ZNF286B	-0.51	-6.22	-0.36	1.9e-9	Pancreatic cancer;
CESC	cis	rs5758511	0.514	rs5758626	chr22:42572363	G/A	cg00645731	chr22:42541494	CYP2D7P1	0.6	9.07	0.49	2.73e-17	Birth weight;
CESC	cis	rs9733	0.687	rs11204735	chr1:150841667	T/C	cg18016565	chr1:150552671	MCL1	-0.35	-5.74	-0.33	2.55e-8	Tonsillectomy;
CESC	cis	rs13082711	0.516	rs1388786	chr3:27372222	G/A	cg02860705	chr3:27208620	NA	-0.48	-5.98	-0.34	7.26e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CESC	cis	rs12497850	0.931	rs28642807	chr3:48926816	A/G	cg06212747	chr3:49208901	KLHDC8B	0.64	8.56	0.47	8.99e-16	Parkinson's disease;
CESC	cis	rs6582630	0.519	rs8189461	chr12:38374870	G/T	cg26384229	chr12:38710491	ALG10B	0.73	10.95	0.56	2.81e-23	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs2070997	0.667	rs10901291	chr9:133717881	C/T	cg11464064	chr9:133710261	ABL1	0.67	7.43	0.42	1.49e-12	Response to amphetamines;
CESC	trans	rs916888	0.821	rs70602	chr17:44859715	T/C	cg01341218	chr17:43662625	NA	-0.85	-10.25	-0.53	5.55e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs7301826	0.627	rs4334059	chr12:131314214	T/C	cg11011512	chr12:131303247	STX2	0.48	5.76	0.33	2.34e-8	Plasma plasminogen activator levels;
CESC	cis	rs6432018	0.927	rs11674777	chr2:9734350	T/A	cg23886495	chr2:9695866	ADAM17	0.43	5.08	0.3	7.2e-7	Heart rate variability traits;
CESC	cis	rs11098499	0.955	rs35197422	chr4:120169314	T/G	cg09307838	chr4:120376055	NA	0.86	11.39	0.57	9.73e-25	Corneal astigmatism;
CESC	cis	rs113835537	0.935	rs75863187	chr11:66443461	G/A	cg22134325	chr11:66188745	NPAS4	0.51	5.84	0.34	1.55e-8	Airway imaging phenotypes;
CESC	cis	rs2932538	0.922	rs12401734	chr1:113071834	A/G	cg22162597	chr1:113214053	CAPZA1	0.59	7.13	0.4	9.26e-12	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CESC	cis	rs3008870	1.000	rs2065001	chr1:67486509	C/G	cg02640540	chr1:67518911	SLC35D1	0.48	5.04	0.3	8.7e-7	Lymphocyte percentage of white cells;
CESC	cis	rs12956009	0.518	rs4458096	chr18:44819555	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.49	-6.52	-0.37	3.48e-10	Educational attainment (years of education);
CESC	cis	rs4077515	0.577	rs3812584	chr9:139312719	C/T	cg14169450	chr9:139327907	INPP5E	-0.49	-7.27	-0.41	3.99e-12	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs1448094	0.512	rs12314274	chr12:86249196	A/G	cg00310523	chr12:86230176	RASSF9	0.35	5.39	0.31	1.59e-7	Major depressive disorder;
CESC	cis	rs9549367	0.713	rs510160	chr13:113822481	A/G	cg00898013	chr13:113819073	PROZ	0.44	6.56	0.37	2.82e-10	Platelet distribution width;
CESC	cis	rs12410462	0.681	rs115959512	chr1:227599578	T/C	cg04117972	chr1:227635322	NA	0.81	6.43	0.37	5.82e-10	Major depressive disorder;
CESC	cis	rs71403859	0.502	rs8051974	chr16:71488771	C/T	cg08717414	chr16:71523259	ZNF19	-0.9	-9.4	-0.5	2.63e-18	Post bronchodilator FEV1;
CESC	cis	rs2273669	0.588	rs11153151	chr6:109316754	C/G	cg05315195	chr6:109294784	ARMC2	-0.66	-6.28	-0.36	1.36e-9	Prostate cancer;
CESC	cis	rs40363	0.645	rs250631	chr16:3523215	G/C	cg21433313	chr16:3507492	NAT15	0.5	7.91	0.44	7.08e-14	Tuberculosis;
CESC	cis	rs62012628	0.527	rs12438008	chr15:79084680	C/T	cg00639195	chr15:79103007	ADAMTS7	0.46	5.99	0.35	6.92e-9	Diastolic blood pressure;
CESC	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg11494091	chr17:61959527	GH2	0.57	8.84	0.48	1.34e-16	Prudent dietary pattern;
CESC	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg11235426	chr6:292522	DUSP22	0.72	9.52	0.5	1.17e-18	Menopause (age at onset);
CESC	cis	rs9660992	0.710	rs1151787	chr1:205254238	G/A	cg00857998	chr1:205179979	DSTYK	0.47	5.36	0.31	1.81e-7	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs12780046	0.611	rs2488344	chr10:100944931	T/C	cg27143070	chr10:101087766	CNNM1	-0.41	-5.74	-0.33	2.53e-8	Non-glioblastoma glioma;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg21068339	chr6:7542819	DSP	-0.49	-6.57	-0.37	2.65e-10	Height;
CESC	cis	rs6860806	0.631	rs4705931	chr5:131588345	T/C	cg18758796	chr5:131593413	PDLIM4	0.46	6.59	0.38	2.35e-10	Breast cancer;
CESC	cis	rs904251	0.523	rs914348	chr6:37484729	G/A	cg01843034	chr6:37503916	NA	-0.29	-5.35	-0.31	1.89e-7	Cognitive performance;
CESC	cis	rs12477438	0.765	rs4374423	chr2:99662348	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.62	-8.67	-0.47	4.43e-16	Chronic sinus infection;
CESC	cis	rs2635047	0.967	rs1355593	chr18:44746460	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.45	5.93	0.34	9.28e-9	Educational attainment;
CESC	cis	rs2576037	0.521	rs4986227	chr18:44595031	G/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.44	5.84	0.34	1.54e-8	Personality dimensions;
CESC	cis	rs921968	0.573	rs684776	chr2:219324016	T/C	cg02176678	chr2:219576539	TTLL4	0.5	8.91	0.48	8.22e-17	Mean corpuscular hemoglobin concentration;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg26796815	chr5:134094372	DDX46	-0.43	-6.05	-0.35	5.01e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs4689388	0.926	rs4416547	chr4:6293967	G/A	cg00701064	chr4:6280414	WFS1	0.68	11.71	0.58	8.68e-26	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs7660520	0.524	rs12643521	chr4:183728242	C/G	cg12483801	chr4:183727862	NA	0.75	7.04	0.4	1.62e-11	Pediatric autoimmune diseases;
CESC	cis	rs2629540	0.544	rs2629529	chr10:126534415	A/C	cg08799069	chr10:126477246	METTL10	0.5	5.73	0.33	2.7e-8	Cocaine dependence;
CESC	cis	rs10788264	0.569	rs10749454	chr10:124029654	C/T	cg09507567	chr10:124027408	NA	0.39	6.13	0.35	3.15e-9	Total body bone mineral density;
CESC	cis	rs7927771	0.832	rs4752994	chr11:47411065	A/T	cg05585544	chr11:47624801	NA	0.47	6.95	0.39	2.88e-11	Subjective well-being;
CESC	cis	rs7523050	0.730	rs34182354	chr1:109416340	C/T	cg08274380	chr1:109419600	GPSM2	0.94	6.44	0.37	5.73e-10	Fat distribution (HIV);
CESC	cis	rs1665050	0.901	rs1665051	chr15:59295224	A/G	cg05156742	chr15:59063176	FAM63B	0.42	5.24	0.31	3.31e-7	Atopic dermatitis;
CESC	cis	rs704	0.585	rs3093680	chr17:26664806	T/C	cg10494684	chr17:26645200	TMEM97	-0.4	-5.54	-0.32	7.38e-8	Osteoprotegerin levels;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg06722069	chr3:113822382	NA	-0.47	-6.48	-0.37	4.33e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs6489785	0.562	rs494632	chr12:121189116	C/T	cg02419362	chr12:121203948	SPPL3	0.34	5.45	0.32	1.13e-7	Longevity;Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs6693567	0.565	rs11205371	chr1:150398510	A/G	cg09579323	chr1:150459698	TARS2	0.48	5.99	0.35	6.73e-9	Migraine;
CESC	cis	rs9747201	0.862	rs57596657	chr17:80147978	C/T	cg09264619	chr17:80180166	NA	-0.42	-5.05	-0.3	8.04e-7	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs8099014	0.725	rs4940691	chr18:56095378	T/G	cg12827950	chr18:55968429	NEDD4L	-0.48	-5.15	-0.3	5.19e-7	Platelet count;
CESC	cis	rs2204008	0.713	rs2320522	chr12:38251438	C/T	cg26384229	chr12:38710491	ALG10B	0.72	10.26	0.53	5.3e-21	Bladder cancer;
CESC	cis	rs10540	1.000	rs61876326	chr11:467368	A/G	cg03352830	chr11:487213	PTDSS2	0.71	7.25	0.41	4.71e-12	Body mass index;
CESC	cis	rs4076764	0.846	rs10753616	chr1:163415855	G/T	cg24596788	chr1:163392923	NA	0.4	5.62	0.33	4.88e-8	Motion sickness;
CESC	cis	rs10504229	1.000	rs67913746	chr8:58177825	A/G	cg24829409	chr8:58192753	C8orf71	-0.76	-10.0	-0.52	3.53e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs6942756	0.955	rs2056694	chr7:128923817	C/T	cg02491457	chr7:128862824	NA	-0.69	-9.23	-0.49	8.71e-18	White matter hyperintensity burden;
CESC	cis	rs3785574	0.962	rs2584630	chr17:61887561	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.1	19.39	0.77	9.4e-53	Height;
CESC	cis	rs35146811	0.586	rs10267212	chr7:99595422	T/C	cg22531904	chr7:99595276	NA	-0.38	-5.04	-0.3	8.84e-7	Coronary artery disease;
CESC	cis	rs9522267	0.535	rs9515451	chr13:112234382	A/G	cg10483660	chr13:112241077	NA	-0.33	-5.79	-0.33	2.04e-8	Hepatitis;
CESC	cis	rs2932538	0.922	rs12125361	chr1:113144779	C/T	cg22162597	chr1:113214053	CAPZA1	0.58	7.29	0.41	3.64e-12	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CESC	cis	rs4722166	0.645	rs1404006	chr7:22795077	T/C	cg13104385	chr7:22767384	IL6	0.39	5.78	0.33	2.11e-8	Lung cancer;
CESC	cis	rs10504229	0.683	rs72649187	chr8:58108320	A/G	cg24829409	chr8:58192753	C8orf71	-0.56	-7.01	-0.4	1.97e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs7091068	0.522	rs11187621	chr10:95483074	T/C	cg20715218	chr10:95462985	C10orf4	0.5	5.89	0.34	1.14e-8	Urinary tract infection frequency;
CESC	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg26338869	chr17:61819248	STRADA	0.69	9.08	0.49	2.62e-17	Prudent dietary pattern;
CESC	cis	rs7264396	0.790	rs4519606	chr20:34324648	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.73	-10.23	-0.53	6.57e-21	Total cholesterol levels;
CESC	cis	rs10504229	1.000	rs66477954	chr8:58187810	C/T	cg24829409	chr8:58192753	C8orf71	-0.76	-9.93	-0.52	5.87e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs4253772	0.550	rs6007761	chr22:46670394	C/T	cg09491104	chr22:46646882	C22orf40	0.52	7.98	0.44	4.54e-14	LDL cholesterol;Cholesterol, total;
CESC	cis	rs9322193	0.566	rs5024811	chr6:150246034	A/G	cg01145232	chr6:150245071	RAET1G	-0.49	-6.54	-0.37	3.13e-10	Lung cancer;
CESC	cis	rs853679	0.517	rs4713150	chr6:28136212	G/A	cg12963246	chr6:28129442	ZNF389	0.54	7.12	0.4	1.02e-11	Depression;
CESC	cis	rs3768617	0.811	rs4396114	chr1:183007441	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.65	8.79	0.48	1.91e-16	Fuchs's corneal dystrophy;
CESC	cis	rs4243830	0.579	rs10779794	chr1:6612651	C/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.79	-7.84	-0.43	1.12e-13	Body mass index;
CESC	cis	rs8044868	0.530	rs7940	chr16:72146441	C/G	cg16558253	chr16:72132732	DHX38	-0.39	-6.08	-0.35	4.07e-9	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CESC	cis	rs8005677	0.828	rs4981451	chr14:23410281	T/C	cg01529538	chr14:23388837	RBM23	0.44	5.83	0.34	1.63e-8	Cognitive ability (multi-trait analysis);
CESC	cis	rs7666738	0.830	rs13145011	chr4:98993410	G/A	cg03467027	chr4:99064603	C4orf37	0.44	5.51	0.32	8.65e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs13095912	0.785	rs62291882	chr3:185313278	T/C	cg11274856	chr3:185301563	NA	0.4	6.07	0.35	4.38e-9	Systolic blood pressure;
CESC	cis	rs1215050	0.765	rs687795	chr4:98754912	C/G	cg05340658	chr4:99064831	C4orf37	0.51	6.65	0.38	1.63e-10	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs9487051	0.837	rs1915834	chr6:109597624	C/A	cg12927641	chr6:109611667	NA	-0.41	-6.43	-0.37	6e-10	Reticulocyte fraction of red cells;
CESC	trans	rs61931739	0.534	rs1490113	chr12:34132394	A/G	cg26384229	chr12:38710491	ALG10B	0.6	8.37	0.46	3.38e-15	Morning vs. evening chronotype;
CESC	cis	rs1799949	1.000	rs34942571	chr17:41273379	G/C	cg25072359	chr17:41440525	NA	0.47	6.17	0.35	2.61e-9	Menopause (age at onset);
CESC	cis	rs1552244	1.000	rs9845756	chr3:10067548	G/C	cg00149659	chr3:10157352	C3orf10	0.74	9.14	0.49	1.63e-17	Alzheimer's disease;
CESC	trans	rs12356475	0.710	rs10822686	chr10:67733250	C/T	cg18386867	chr2:39347986	SOS1	0.48	6.07	0.35	4.42e-9	Psoriatic arthritis;
CESC	cis	rs916888	0.610	rs199536	chr17:44820425	T/C	cg01570182	chr17:44337453	NA	-0.62	-8.41	-0.46	2.56e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs10504229	0.683	rs7820559	chr8:58142662	C/T	cg02725872	chr8:58115012	NA	-0.42	-6.64	-0.38	1.79e-10	Developmental language disorder (linguistic errors);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04204557	chr21:46065774	KRTAP10-11;C21orf29	-0.58	-7.03	-0.4	1.75e-11	Gut microbiome composition (summer);
CESC	cis	rs1862618	0.627	rs744023	chr5:56197078	C/T	cg12311346	chr5:56204834	C5orf35	-0.84	-9.86	-0.52	1e-19	Initial pursuit acceleration;
CESC	cis	rs10504229	0.593	rs77607045	chr8:58010464	T/C	cg22535103	chr8:58192502	C8orf71	-0.9	-8.95	-0.48	6.29e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs4253772	0.513	rs9615345	chr22:46713631	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.78	9.06	0.49	2.86e-17	LDL cholesterol;Cholesterol, total;
CESC	cis	rs4268898	0.662	rs72795832	chr2:24441855	C/A	cg20701182	chr2:24300061	SF3B14	0.61	6.56	0.37	2.85e-10	Asthma;
CESC	cis	rs2228479	0.850	rs17232910	chr16:89839766	G/C	cg00800038	chr16:89945340	TCF25	-0.92	-7.64	-0.42	4.02e-13	Skin colour saturation;
CESC	cis	rs10883723	0.810	rs7094366	chr10:104274730	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.58	7.73	0.43	2.29e-13	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs2777491	0.872	rs7163649	chr15:41586798	A/G	cg02330683	chr15:41787940	ITPKA	0.42	6.13	0.35	3.21e-9	Ulcerative colitis;
CESC	cis	rs798554	1.000	rs798536	chr7:2766383	G/A	cg18446336	chr7:2847575	GNA12	-0.41	-6.28	-0.36	1.38e-9	Height;
CESC	cis	rs1799949	1.000	rs12942277	chr17:41187974	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.61	7.83	0.43	1.21e-13	Menopause (age at onset);
CESC	cis	rs11098499	0.775	rs10029303	chr4:120286755	T/A	cg09307838	chr4:120376055	NA	0.87	12.16	0.6	2.41e-27	Corneal astigmatism;
CESC	cis	rs4944092	1.000	rs7125695	chr11:75908131	A/G	cg04588336	chr11:75916460	WNT11	0.48	7.6	0.42	5.29e-13	PR interval;
CESC	cis	rs72945132	0.769	rs680571	chr11:70187441	G/A	cg00319359	chr11:70116639	PPFIA1	0.71	6.92	0.39	3.49e-11	Coronary artery disease;
CESC	cis	rs34638657	0.872	rs6420437	chr16:82187181	T/C	cg09439754	chr16:82129088	HSD17B2	-0.35	-5.24	-0.31	3.26e-7	Lung adenocarcinoma;
CESC	cis	rs77216612	1.000	rs77216612	chr12:12877983	A/G	cg09462578	chr12:12878428	APOLD1	-1.01	-15.31	-0.69	2.4e-38	Lymphocyte counts;
CESC	cis	rs17490626	0.568	rs12416520	chr10:71211945	A/G	cg12610070	chr10:71211762	TSPAN15	-0.32	-6.95	-0.39	2.87e-11	Thrombosis;
CESC	cis	rs7772486	0.875	rs2492855	chr6:146296926	A/G	cg23711669	chr6:146136114	FBXO30	0.75	10.79	0.55	9.68e-23	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs877282	0.898	rs2004478	chr10:770709	C/A	cg22713356	chr15:30763199	NA	1.15	11.42	0.57	7.63e-25	Uric acid levels;
CESC	cis	rs7829975	0.742	rs12547493	chr8:8661534	C/T	cg15556689	chr8:8085844	FLJ10661	-0.52	-6.22	-0.36	1.97e-9	Mood instability;
CESC	cis	rs2011503	0.891	rs2965190	chr19:19451591	A/G	cg11584989	chr19:19387371	SF4	-0.63	-7.55	-0.42	7.15e-13	Bipolar disorder;
CESC	cis	rs4535700	0.501	rs57153841	chr7:55995093	G/A	cg09872392	chr7:56161020	PHKG1	0.41	5.76	0.33	2.37e-8	Macular telangiectasia type 2;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09872104	chr7:134855509	C7orf49	0.55	6.54	0.37	3.12e-10	Gut microbiome composition (summer);
CESC	cis	rs13064411	0.660	rs1872747	chr3:113175785	T/A	cg18753928	chr3:113234510	CCDC52	-0.48	-5.19	-0.3	4.16e-7	Response to simvastatin treatment (PCSK9 protein level change);
CESC	cis	rs1707322	1.000	rs946527	chr1:46485970	C/T	cg05343316	chr1:45956843	TESK2	0.44	5.46	0.32	1.08e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9488822	0.596	rs13206506	chr6:116324460	A/G	cg05304507	chr6:116381966	FRK	0.22	5.43	0.32	1.26e-7	Cholesterol, total;LDL cholesterol;
CESC	cis	rs4812048	0.901	rs151354	chr20:57606971	A/G	cg14073986	chr20:57617431	SLMO2	0.54	5.73	0.33	2.72e-8	Mean platelet volume;
CESC	cis	rs4689592	0.503	rs66885632	chr4:7053738	T/C	cg06697600	chr4:7070879	GRPEL1	0.49	5.89	0.34	1.16e-8	Monocyte percentage of white cells;
CESC	cis	rs7618915	0.501	rs3755798	chr3:52741160	G/A	cg17372223	chr3:52568218	NT5DC2	0.42	6.45	0.37	5.23e-10	Bipolar disorder;
CESC	cis	rs2249625	0.967	rs1973843	chr6:72919181	A/G	cg18830697	chr6:72922368	RIMS1	-0.42	-5.85	-0.34	1.48e-8	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CESC	cis	rs7940866	0.845	rs2324314	chr11:130834589	A/C	cg12179176	chr11:130786555	SNX19	0.65	9.18	0.49	1.31e-17	Schizophrenia;
CESC	cis	rs447	0.945	rs4141151	chr7:83737361	A/G	cg22846510	chr7:83753280	SEMA3A	-0.43	-5.27	-0.31	2.81e-7	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs9309473	0.500	rs4286298	chr2:73882108	T/A	cg20560298	chr2:73613845	ALMS1	0.5	6.96	0.39	2.61e-11	Metabolite levels;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg17274881	chr4:79103244	FRAS1	0.42	6.01	0.35	6.23e-9	Fibrinogen levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19586661	chr11:66079705	NA	0.6	7.19	0.4	6.66e-12	Gut microbiome composition (summer);
CESC	cis	rs8049040	0.609	rs11866859	chr16:71478888	G/A	cg08717414	chr16:71523259	ZNF19	-0.65	-7.25	-0.41	4.51e-12	Blood protein levels;
CESC	cis	rs910316	0.810	rs77939209	chr14:75670070	A/G	cg08847533	chr14:75593920	NEK9	-0.95	-17.02	-0.72	2.09e-44	Height;
CESC	cis	rs9291683	0.509	rs10939671	chr4:10050815	T/C	cg02734326	chr4:10020555	SLC2A9	0.45	6.45	0.37	5.27e-10	Bone mineral density;
CESC	cis	rs4417704	0.551	rs4675841	chr2:241876580	A/G	cg05025159	chr2:241905733	NA	0.33	5.19	0.3	4.28e-7	Joint mobility (Beighton score);
CESC	cis	rs9611565	0.649	rs79009	chr22:41860864	C/A	cg06634786	chr22:41940651	POLR3H	0.72	7.43	0.42	1.46e-12	Vitiligo;
CESC	cis	rs1552244	0.572	rs7645759	chr3:10157368	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.75	-8.12	-0.45	1.72e-14	Alzheimer's disease;
CESC	cis	rs2073300	0.609	rs2295238	chr20:23387946	C/G	cg16736954	chr20:23401023	NAPB	0.65	5.67	0.33	3.67e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs2075671	0.903	rs11979818	chr7:100293639	A/G	cg20848291	chr7:100343083	ZAN	0.76	9.8	0.52	1.55e-19	Other erythrocyte phenotypes;
CESC	trans	rs11098499	0.566	rs17051356	chr4:120585308	C/T	cg25214090	chr10:38739885	LOC399744	0.61	8.15	0.45	1.5e-14	Corneal astigmatism;
CESC	cis	rs2991971	0.933	rs2356553	chr1:46009313	G/C	cg05343316	chr1:45956843	TESK2	-0.52	-6.69	-0.38	1.33e-10	High light scatter reticulocyte count;
CESC	cis	rs12220238	1.000	rs7909664	chr10:75869754	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.69	6.75	0.38	9.49e-11	Soluble interleukin-2 receptor subunit alpha;
CESC	cis	rs853679	0.517	rs9380055	chr6:28081629	A/G	cg22143856	chr6:28129313	ZNF389	0.52	6.71	0.38	1.21e-10	Depression;
CESC	cis	rs597539	0.652	rs660614	chr11:68659488	G/A	cg04772025	chr11:68637568	NA	0.5	5.88	0.34	1.2e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs539096	0.540	rs3011217	chr1:44303266	C/T	cg12908607	chr1:44402522	ARTN	0.46	6.79	0.39	7.21e-11	Intelligence (multi-trait analysis);
CESC	cis	rs7914558	0.966	rs10748835	chr10:104660256	C/T	cg15744005	chr10:104629667	AS3MT	-0.34	-5.27	-0.31	2.82e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs8067354	0.645	rs2645489	chr17:57883371	T/G	cg02344993	chr17:57696989	CLTC	0.67	8.16	0.45	1.33e-14	Hemoglobin concentration;
CESC	cis	rs6540556	0.517	rs11119328	chr1:209885318	C/A	cg05527609	chr1:210001259	C1orf107	-0.73	-7.23	-0.41	5.07e-12	Red blood cell count;
CESC	cis	rs1670533	0.872	rs6854793	chr4:1055768	T/C	cg27284194	chr4:1044797	NA	0.47	5.99	0.35	6.72e-9	Recombination rate (females);
CESC	cis	rs7811142	0.830	rs11768967	chr7:99967644	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.89	10.07	0.53	2.12e-20	Platelet count;
CESC	cis	rs1215050	0.765	rs644839	chr4:98716357	C/A	cg05340658	chr4:99064831	C4orf37	0.51	6.48	0.37	4.45e-10	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs4727027	0.866	rs3735311	chr7:148877737	T/C	cg23158103	chr7:148848205	ZNF398	-0.4	-6.3	-0.36	1.22e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs9910055	0.530	rs8072954	chr17:42294722	G/A	cg10896456	chr17:42255109	ASB16;C17orf65	0.35	5.14	0.3	5.28e-7	Total body bone mineral density;
CESC	cis	rs2050392	0.517	rs2480299	chr10:30743197	G/A	cg25182066	chr10:30743637	MAP3K8	-0.56	-8.22	-0.45	9.2e-15	Inflammatory bowel disease;
CESC	cis	rs4604732	0.578	rs79203328	chr1:247626581	C/G	cg12758973	chr1:247694275	LOC148824;OR2C3	0.51	6.36	0.36	8.65e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs2425143	1.000	rs11699044	chr20:34312713	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.79	8.19	0.45	1.08e-14	Blood protein levels;
CESC	cis	rs9309711	0.643	rs4264589	chr2:3481098	G/T	cg15541040	chr2:3486749	NA	-0.44	-5.52	-0.32	7.89e-8	Neurofibrillary tangles;
CESC	cis	rs4803468	1.000	rs166925	chr19:41926098	T/C	cg09537434	chr19:41945824	ATP5SL	-1.1	-20.33	-0.78	5.18e-56	Height;
CESC	cis	rs2072499	0.966	rs2853643	chr1:156184831	G/A	cg24450063	chr1:156163899	SLC25A44	0.92	14.14	0.66	3.37e-34	Testicular germ cell tumor;
CESC	cis	rs4665809	0.590	rs10179959	chr2:26426403	G/A	cg25036284	chr2:26402008	FAM59B	-0.85	-9.51	-0.5	1.22e-18	Gut microbiome composition (summer);
CESC	cis	rs3857536	0.706	rs2157963	chr6:66945449	A/T	cg07460842	chr6:66804631	NA	-0.42	-5.29	-0.31	2.55e-7	Blood trace element (Cu levels);
CESC	cis	rs13191362	1.000	rs13209100	chr6:163159350	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.48	5.44	0.32	1.22e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs9910055	0.529	rs228749	chr17:42174570	A/G	cg19774624	chr17:42201019	HDAC5	0.57	7.47	0.42	1.18e-12	Total body bone mineral density;
CESC	cis	rs875971	0.895	rs1974769	chr7:65950614	G/A	cg18876405	chr7:65276391	NA	0.5	6.5	0.37	3.98e-10	Aortic root size;
CESC	cis	rs8070624	0.543	rs4299203	chr17:17878159	T/G	cg04398451	chr17:18023971	MYO15A	-0.69	-9.51	-0.5	1.19e-18	Total body bone mineral density;
CESC	cis	rs11148252	0.508	rs6561671	chr13:53182314	G/A	cg00495681	chr13:53174319	NA	0.53	7.23	0.41	5.15e-12	Lewy body disease;
CESC	cis	rs514406	0.825	rs487453	chr1:53271225	T/C	cg08859206	chr1:53392774	SCP2	0.62	9.09	0.49	2.37e-17	Monocyte count;
CESC	cis	rs1538970	0.924	rs1494812	chr1:45876999	C/T	cg06784218	chr1:46089804	CCDC17	0.33	5.49	0.32	9.28e-8	Platelet count;
CESC	cis	rs514406	0.565	rs897732	chr1:53382816	A/C	cg16325326	chr1:53192061	ZYG11B	0.61	8.92	0.48	8.04e-17	Monocyte count;
CESC	cis	rs7799006	0.929	rs35629140	chr7:2257171	G/C	cg12745145	chr7:2261452	MAD1L1	-0.43	-6.56	-0.37	2.89e-10	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs763014	0.932	rs34498660	chr16:666149	A/G	cg00908189	chr16:619842	PIGQ	0.64	8.96	0.48	6.04e-17	Height;
CESC	cis	rs4555082	0.834	rs11849607	chr14:105745383	G/A	cg10792982	chr14:105748885	BRF1	0.42	5.36	0.31	1.81e-7	Mean platelet volume;Platelet distribution width;
CESC	cis	rs9814567	1.000	rs9289478	chr3:134268619	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.43	-5.82	-0.34	1.69e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	trans	rs1814175	0.533	rs4528310	chr11:49983106	C/A	cg03929089	chr4:120376271	NA	-0.92	-15.24	-0.68	4.49e-38	Height;
CESC	cis	rs6456156	0.586	rs12528323	chr6:167461645	A/G	cg07741184	chr6:167504864	NA	0.35	6.0	0.35	6.57e-9	Primary biliary cholangitis;
CESC	cis	rs7412746	0.611	rs10888395	chr1:150762171	C/T	cg22823121	chr1:150693482	HORMAD1	0.48	6.59	0.38	2.39e-10	Melanoma;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg07148452	chr15:90176987	KIF7	0.53	7.0	0.4	2.16e-11	Fibrinogen levels;
CESC	cis	rs2299587	0.527	rs10112643	chr8:17726019	A/G	cg08627089	chr8:17753878	FGL1	-0.39	-5.56	-0.32	6.49e-8	Economic and political preferences;
CESC	cis	rs875971	0.862	rs4718383	chr7:66108409	T/C	cg11764359	chr7:65958608	NA	-0.7	-9.73	-0.51	2.51e-19	Aortic root size;
CESC	cis	rs1008375	0.932	rs1008894	chr4:17704667	C/T	cg16339924	chr4:17578868	LAP3	-0.65	-7.88	-0.44	8.45e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs9733	0.596	rs3087960	chr1:150620569	C/G	cg04414720	chr1:150670196	GOLPH3L	0.62	8.72	0.47	3.14e-16	Tonsillectomy;
CESC	cis	rs796364	0.806	rs10931887	chr2:200968905	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.75	-6.49	-0.37	4.2e-10	Schizophrenia;
CESC	cis	rs9311474	0.508	rs7614498	chr3:52618941	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.5	7.34	0.41	2.56e-12	Electroencephalogram traits;
CESC	cis	rs9733	0.596	rs2867301	chr1:150653795	C/T	cg18016565	chr1:150552671	MCL1	0.33	5.14	0.3	5.34e-7	Tonsillectomy;
CESC	cis	rs11785400	0.928	rs10100287	chr8:143734836	C/T	cg24634471	chr8:143751801	JRK	0.46	5.9	0.34	1.14e-8	Schizophrenia;
CESC	cis	rs2204008	0.571	rs7970136	chr12:38531951	G/C	cg26384229	chr12:38710491	ALG10B	-0.41	-5.44	-0.32	1.18e-7	Bladder cancer;
CESC	cis	rs75477785	1.000	rs76145088	chr1:209989232	A/G	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.92	6.04	0.35	5.06e-9	Cleft lip with or without cleft palate;
CESC	cis	rs7680126	0.500	rs4697933	chr4:10146493	G/A	cg00071950	chr4:10020882	SLC2A9	-0.54	-6.15	-0.35	2.82e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	cis	rs769267	0.965	rs2315025	chr19:19426609	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.45	5.44	0.32	1.21e-7	Tonsillectomy;
CESC	cis	rs3845702	1.000	rs3845702	chr2:180848488	A/C	cg01881094	chr2:180872142	CWC22	0.66	7.36	0.41	2.26e-12	Schizophrenia;
CESC	cis	rs3768617	0.510	rs2224933	chr1:183095765	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.89	14.39	0.66	4.39e-35	Fuchs's corneal dystrophy;
CESC	cis	rs10504229	0.639	rs2318145	chr8:58114867	A/G	cg02725872	chr8:58115012	NA	-0.45	-7.05	-0.4	1.52e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs898097	0.812	rs55794221	chr17:80849003	G/A	cg15664640	chr17:80829946	TBCD	-0.66	-9.37	-0.5	3.34e-18	Breast cancer;
CESC	cis	rs6460942	1.000	rs2053381	chr7:12400710	C/A	cg13733410	chr7:12443478	VWDE	-0.53	-5.26	-0.31	2.95e-7	Coronary artery disease;
CESC	cis	rs7000551	0.689	rs6993341	chr8:22310933	T/C	cg12081754	chr8:22256438	SLC39A14	0.41	5.3	0.31	2.39e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CESC	cis	rs4891159	0.756	rs55763305	chr18:74161249	G/C	cg24786174	chr18:74118243	ZNF516	-0.7	-10.27	-0.53	4.72e-21	Longevity;
CESC	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg07677032	chr17:61819896	STRADA	0.55	7.64	0.42	4e-13	Prudent dietary pattern;
CESC	cis	rs1005277	0.505	rs7099777	chr10:38183569	A/C	cg00409905	chr10:38381863	ZNF37A	0.56	7.82	0.43	1.28e-13	Extrinsic epigenetic age acceleration;
CESC	cis	rs12701220	0.947	rs1007765	chr7:1032805	G/C	cg26769984	chr7:1090371	C7orf50	0.65	7.19	0.4	6.74e-12	Bronchopulmonary dysplasia;
CESC	cis	rs7772486	0.875	rs9322048	chr6:146400439	A/G	cg23711669	chr6:146136114	FBXO30	0.76	11.21	0.57	3.86e-24	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6546537	0.562	rs1985342	chr2:69758927	C/T	cg10773587	chr2:69614142	GFPT1	-0.53	-6.57	-0.37	2.58e-10	Serum thyroid-stimulating hormone levels;
CESC	cis	rs9487051	0.872	rs7772602	chr6:109608661	C/G	cg21918786	chr6:109611834	NA	0.4	5.95	0.34	8.24e-9	Reticulocyte fraction of red cells;
CESC	cis	rs796364	0.806	rs203765	chr2:200903020	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.87	-8.14	-0.45	1.58e-14	Schizophrenia;
CESC	cis	rs7772486	0.875	rs2328712	chr6:146344563	T/C	cg23711669	chr6:146136114	FBXO30	0.77	11.07	0.56	1.17e-23	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6714710	0.603	rs12995673	chr2:98409046	G/A	cg26665480	chr2:98280029	ACTR1B	0.65	8.99	0.48	4.71e-17	Posterior cortical atrophy and Alzheimer's disease;
CESC	cis	rs4870684	1.000	rs4870684	chr7:57699151	C/T	cg01314568	chr7:57830625	NA	-0.49	-6.44	-0.37	5.62e-10	Bipolar disorder and schizophrenia;
CESC	cis	rs1008375	1.000	rs4698634	chr4:17630192	A/C	cg02297831	chr4:17616191	MED28	-0.52	-6.62	-0.38	2.01e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs763121	0.853	rs1062687	chr22:39134715	T/C	cg06544989	chr22:39130855	UNC84B	0.5	9.5	0.5	1.34e-18	Menopause (age at onset);
CESC	trans	rs11098499	0.955	rs1511018	chr4:120161580	G/T	cg25214090	chr10:38739885	LOC399744	0.64	8.58	0.47	8.37e-16	Corneal astigmatism;
CESC	cis	rs6938	0.514	rs35556055	chr15:75253414	G/A	cg14664628	chr15:75095509	CSK	-0.53	-6.73	-0.38	1.04e-10	Breast cancer;
CESC	cis	rs7165102	1.000	rs17809330	chr15:65889250	C/T	cg11441148	chr15:65824328	PTPLAD1	-0.31	-5.12	-0.3	5.77e-7	Mean corpuscular hemoglobin;
CESC	cis	rs666930	0.519	rs662602	chr1:120266903	C/G	cg19096424	chr1:120255104	PHGDH	0.72	8.28	0.45	6.19e-15	Breast cancer;
CESC	cis	rs9322193	0.923	rs9372044	chr6:150102003	G/A	cg05861140	chr6:150128134	PCMT1	-0.37	-5.3	-0.31	2.42e-7	Lung cancer;
CESC	cis	rs738322	0.935	rs2413503	chr22:38568944	A/T	cg17652424	chr22:38574118	PLA2G6	-0.34	-6.03	-0.35	5.34e-9	Cutaneous nevi;
CESC	cis	rs9291683	0.552	rs10939655	chr4:10014642	A/T	cg00071950	chr4:10020882	SLC2A9	0.91	17.5	0.73	4.16e-46	Bone mineral density;
CESC	cis	rs9831754	0.756	rs9817660	chr3:78426373	T/C	cg06138941	chr3:78371609	NA	-0.49	-6.27	-0.36	1.5e-9	Calcium levels;
CESC	cis	rs926938	0.527	rs360685	chr1:115499795	G/C	cg12756093	chr1:115239321	AMPD1	0.45	6.15	0.35	2.84e-9	Autism;
CESC	cis	rs2033711	0.783	rs8113810	chr19:58932106	A/G	cg11952622	chr19:58962976	ZNF324B	0.46	6.13	0.35	3.16e-9	Uric acid clearance;
CESC	cis	rs1799949	1.000	rs2070834	chr17:41242285	T/G	cg23758822	chr17:41437982	NA	0.99	15.34	0.69	1.98e-38	Menopause (age at onset);
CESC	cis	rs875971	1.000	rs1144895	chr7:65541307	C/G	cg12463550	chr7:65579703	CRCP	-0.61	-7.52	-0.42	8.3e-13	Aortic root size;
CESC	cis	rs7949030	0.626	rs71490390	chr11:62329185	A/G	cg02375832	chr11:62437615	C11orf48	-0.35	-5.06	-0.3	7.83e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs9325144	0.555	rs12424003	chr12:38688140	C/T	cg26384229	chr12:38710491	ALG10B	-0.6	-8.5	-0.46	1.44e-15	Morning vs. evening chronotype;
CESC	cis	rs6669072	0.647	rs814547	chr1:91238821	T/C	cg08895590	chr1:91227319	NA	-0.34	-5.86	-0.34	1.39e-8	Cognitive function;
CESC	cis	rs42648	0.869	rs1015402	chr7:89913269	C/T	cg23697855	chr7:89950296	NA	0.27	5.05	0.3	8.24e-7	Homocysteine levels;
CESC	cis	rs897080	0.515	rs2850290	chr2:44636055	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.45	5.5	0.32	9e-8	Height;
CESC	cis	rs3096299	0.967	rs2965827	chr16:89457350	A/C	cg16743903	chr16:89593216	SPG7	0.44	5.77	0.33	2.19e-8	Multiple myeloma (IgH translocation);
CESC	cis	rs7246865	0.724	rs10424674	chr19:17183185	G/A	cg16202187	chr19:17186497	HAUS8;MYO9B	0.45	5.35	0.31	1.94e-7	Reticulocyte fraction of red cells;
CESC	cis	rs8141529	0.732	rs2239815	chr22:29192670	C/T	cg02153584	chr22:29168773	CCDC117	-0.64	-9.45	-0.5	1.88e-18	Lymphocyte counts;
CESC	cis	rs1218582	0.682	rs12046459	chr1:154912017	A/C	cg16680214	chr1:154839983	KCNN3	-0.45	-6.87	-0.39	4.46e-11	Prostate cancer;
CESC	cis	rs57244997	0.725	rs7754703	chr6:162440488	T/C	cg17173639	chr6:162384350	PARK2	-0.44	-5.15	-0.3	5.14e-7	Mosquito bite size;
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg11255513	chr11:113644528	ZW10	-0.45	-6.75	-0.38	9.21e-11	Vertical cup-disc ratio;
CESC	cis	rs7246657	0.943	rs7258692	chr19:37818829	C/A	cg23950597	chr19:37808831	NA	-0.59	-6.14	-0.35	3.07e-9	Coronary artery calcification;
CESC	cis	rs10504229	0.575	rs4590436	chr8:57996539	A/C	cg24829409	chr8:58192753	C8orf71	-0.42	-5.5	-0.32	8.75e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs8092503	1.000	rs62091462	chr18:52488698	T/C	cg12377874	chr18:52495404	RAB27B	0.39	6.42	0.37	6.43e-10	Childhood body mass index;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12546181	chr19:48902029	GRIN2D	0.53	6.07	0.35	4.46e-9	Gut microbiome composition (summer);
CESC	trans	rs208520	0.526	rs6455072	chr6:66797215	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.11	-24.95	-0.84	1.67e-71	Exhaled nitric oxide output;
CESC	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.89	13.28	0.63	3.39e-31	Prudent dietary pattern;
CESC	cis	rs9611565	0.765	rs132908	chr22:41801795	G/A	cg03806693	chr22:41940476	POLR3H	1.09	12.57	0.61	9.68e-29	Vitiligo;
CESC	cis	rs4481887	1.000	rs4372295	chr1:248464871	G/T	cg00666640	chr1:248458726	OR2T12	0.37	6.1	0.35	3.82e-9	Common traits (Other);
CESC	cis	rs11030122	0.702	rs12223176	chr11:3982537	T/G	cg18678763	chr11:4115507	RRM1	-0.49	-6.59	-0.38	2.4e-10	Mean platelet volume;Platelet distribution width;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05698020	chr13:111163978	COL4A2	-0.43	-6.39	-0.37	7.23e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs7917772	0.503	rs7100753	chr10:104300979	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.54	7.49	0.42	9.98e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs1775715	0.707	rs1541261	chr10:32179523	G/A	cg18675610	chr10:32216311	ARHGAP12	0.36	5.53	0.32	7.75e-8	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs644799	0.965	rs11021305	chr11:95498269	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.88	13.37	0.63	1.64e-31	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs4803468	0.935	rs13346603	chr19:41945837	T/A	cg08639244	chr19:41945921	ATP5SL	0.43	5.33	0.31	2.12e-7	Height;
CESC	cis	rs950776	0.518	rs62008174	chr15:78808947	C/T	cg06917634	chr15:78832804	PSMA4	0.78	11.36	0.57	1.26e-24	Sudden cardiac arrest;
CESC	cis	rs2286503	1.000	rs2286499	chr7:22857477	A/G	cg13679077	chr7:22862647	TOMM7	0.41	5.25	0.31	3.08e-7	Fibrinogen;
CESC	cis	rs807669	0.565	rs5746682	chr22:19185526	C/T	cg02655711	chr22:19163373	SLC25A1	0.75	11.55	0.58	2.93e-25	Metabolite levels;
CESC	cis	rs1707322	1.000	rs4641257	chr1:46353589	G/A	cg03146154	chr1:46216737	IPP	0.71	9.86	0.52	9.69e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9926296	0.682	rs467357	chr16:89717397	A/G	cg01097406	chr16:89675127	NA	0.38	5.41	0.32	1.42e-7	Vitiligo;
CESC	cis	rs67311347	1.000	rs9968170	chr3:40494274	A/G	cg09455208	chr3:40491958	NA	-0.46	-7.59	-0.42	5.49e-13	Renal cell carcinoma;
CESC	cis	rs7772486	0.875	rs2777477	chr6:146305491	A/G	cg23711669	chr6:146136114	FBXO30	0.78	11.25	0.57	2.92e-24	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs67460515	0.892	rs4856757	chr3:160999418	A/T	cg03342759	chr3:160939853	NMD3	-0.53	-7.55	-0.42	7.23e-13	Parkinson's disease;
CESC	trans	rs61931739	0.500	rs11053210	chr12:34461771	A/G	cg13010199	chr12:38710504	ALG10B	-0.53	-6.38	-0.36	7.64e-10	Morning vs. evening chronotype;
CESC	cis	rs8018967	1.000	rs8018967	chr14:73976934	A/G	cg09844916	chr14:74004424	HEATR4;ACOT1	0.45	5.74	0.33	2.57e-8	Blood metabolite ratios;
CESC	cis	rs35110281	0.776	rs9306159	chr21:45061839	G/T	cg01579765	chr21:45077557	HSF2BP	-0.55	-9.0	-0.48	4.45e-17	Mean corpuscular volume;
CESC	cis	rs13242816	1.000	rs55833477	chr7:116110375	C/G	cg04696780	chr7:116139425	CAV2	-0.59	-5.24	-0.31	3.3e-7	P wave duration;
CESC	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg26338869	chr17:61819248	STRADA	0.69	9.1	0.49	2.22e-17	Prudent dietary pattern;
CESC	cis	rs193541	0.593	rs246309	chr5:122269719	A/C	cg19412675	chr5:122181750	SNX24	0.42	5.04	0.3	8.46e-7	Glucose homeostasis traits;
CESC	cis	rs6942756	0.531	rs9649530	chr7:128927406	G/A	cg02491457	chr7:128862824	NA	0.44	6.19	0.36	2.34e-9	White matter hyperintensity burden;
CESC	cis	rs7917772	0.503	rs10883732	chr10:104293461	G/A	ch.10.2196322F	chr10:104248062	ACTR1A	0.42	5.17	0.3	4.66e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs763121	0.853	rs4821810	chr22:39072098	C/G	cg14440974	chr22:39074834	NA	-0.36	-5.21	-0.3	3.78e-7	Menopause (age at onset);
CESC	cis	rs10464366	0.571	rs13233049	chr7:39187536	C/T	cg18850127	chr7:39170497	POU6F2	0.38	5.28	0.31	2.65e-7	IgG glycosylation;
CESC	cis	rs28386778	0.734	rs12946669	chr17:62006007	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.45	0.37	5.41e-10	Prudent dietary pattern;
CESC	cis	rs9811920	0.535	rs704571	chr3:99481946	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.33	-5.42	-0.32	1.37e-7	Axial length;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25005279	chr10:135113451	TUBGCP2	-0.63	-6.93	-0.39	3.23e-11	Gut microbiome composition (summer);
CESC	trans	rs61931739	0.517	rs12815556	chr12:34319670	G/A	cg26384229	chr12:38710491	ALG10B	0.65	9.19	0.49	1.16e-17	Morning vs. evening chronotype;
CESC	cis	rs1008375	1.000	rs2315560	chr4:17677305	C/G	cg16339924	chr4:17578868	LAP3	0.51	6.44	0.37	5.73e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs8017423	0.935	rs11624295	chr14:90695612	T/G	cg14092571	chr14:90743983	NA	-0.56	-8.19	-0.45	1.12e-14	Mortality in heart failure;
CESC	cis	rs780096	0.526	rs780117	chr2:27698343	C/G	cg17158414	chr2:27665306	KRTCAP3	-0.32	-6.01	-0.35	6e-9	Total body bone mineral density;
CESC	cis	rs6460942	0.915	rs2192842	chr7:12315752	C/G	cg06484146	chr7:12443880	VWDE	-0.39	-5.81	-0.34	1.82e-8	Coronary artery disease;
CESC	cis	rs4319547	0.697	rs7974262	chr12:122896385	C/T	cg05707623	chr12:122985044	ZCCHC8	0.55	6.21	0.36	2.01e-9	Body mass index;
CESC	cis	rs9287719	0.967	rs2024431	chr2:10731327	A/G	cg00105475	chr2:10696890	NA	0.39	5.69	0.33	3.35e-8	Prostate cancer;
CESC	cis	rs7116495	0.609	rs2511120	chr11:71786211	C/T	cg07596299	chr11:71824057	C11orf51	-0.85	-5.3	-0.31	2.42e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs853679	0.546	rs200950	chr6:27835772	A/G	cg02228804	chr6:27775720	HIST1H2AI;HIST1H2BL	0.64	5.44	0.32	1.21e-7	Depression;
CESC	cis	rs1559088	0.947	rs12461219	chr19:33550633	C/G	cg17764715	chr19:33622953	WDR88	0.45	5.67	0.33	3.76e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	trans	rs11098499	0.909	rs28668716	chr4:120309875	T/C	cg25214090	chr10:38739885	LOC399744	0.68	9.2	0.49	1.14e-17	Corneal astigmatism;
CESC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg15207953	chr20:29522467	NA	0.47	6.26	0.36	1.53e-9	Lung cancer in ever smokers;
CESC	cis	rs4409675	0.576	rs6691656	chr1:28221130	C/G	cg23691781	chr1:28212827	C1orf38	0.3	5.81	0.34	1.83e-8	Corneal astigmatism;
CESC	cis	rs7927771	0.864	rs60075622	chr11:47449101	T/G	cg05585544	chr11:47624801	NA	-0.48	-6.98	-0.39	2.34e-11	Subjective well-being;
CESC	cis	rs1215050	0.846	rs1839903	chr4:98791414	C/T	cg05340658	chr4:99064831	C4orf37	0.54	6.42	0.37	6.44e-10	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs1005277	0.579	rs2505257	chr10:38372664	A/G	cg00409905	chr10:38381863	ZNF37A	-0.45	-6.04	-0.35	5.25e-9	Extrinsic epigenetic age acceleration;
CESC	trans	rs7618501	1.000	rs1049256	chr3:49763338	T/C	cg21659725	chr3:3221576	CRBN	-0.83	-13.62	-0.64	2.29e-32	Intelligence (multi-trait analysis);
CESC	cis	rs17376456	0.877	rs10062711	chr5:93348659	G/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.6	5.04	0.3	8.63e-7	Diabetic retinopathy;
CESC	cis	rs10752881	1.000	rs6424880	chr1:182986679	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.84	13.3	0.63	2.79e-31	Colorectal cancer;
CESC	cis	rs8141529	0.509	rs7287124	chr22:29239157	A/G	cg15103426	chr22:29168792	CCDC117	0.62	8.09	0.45	2.14e-14	Lymphocyte counts;
CESC	cis	rs7107174	1.000	rs72931642	chr11:78037862	A/T	cg02023728	chr11:77925099	USP35	0.52	6.86	0.39	4.74e-11	Testicular germ cell tumor;
CESC	cis	rs1707322	0.827	rs6694302	chr1:46245645	A/T	cg03146154	chr1:46216737	IPP	0.8	11.18	0.57	4.85e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2953174	0.507	rs2953172	chr2:241525316	C/T	cg07929629	chr2:241523174	NA	0.64	8.13	0.45	1.7e-14	Bipolar disorder;
CESC	cis	rs2836950	0.520	rs11911087	chr21:40665192	G/A	cg17971929	chr21:40555470	PSMG1	-0.56	-7.2	-0.4	6.35e-12	Menarche (age at onset);
CESC	cis	rs7552404	0.727	rs2172507	chr1:76331320	A/G	cg22875332	chr1:76189707	ACADM	-0.63	-6.56	-0.37	2.83e-10	Blood metabolite levels;Acylcarnitine levels;
CESC	trans	rs9929218	0.559	rs12923775	chr16:68756450	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.86	13.85	0.65	3.35e-33	Colorectal cancer;
CESC	cis	rs6952808	0.531	rs3800922	chr7:2184505	A/G	cg05863683	chr7:1912471	MAD1L1	0.39	5.55	0.32	7.08e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs10791097	0.967	rs4366492	chr11:130717256	T/C	cg14779329	chr11:130786720	SNX19	0.38	5.88	0.34	1.22e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs4727027	0.635	rs12111923	chr7:148885877	G/A	cg23583168	chr7:148888333	NA	-0.85	-11.83	-0.59	3.34e-26	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs9814567	1.000	rs1863913	chr3:134200205	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.42	-5.76	-0.33	2.28e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs172166	0.694	rs1225716	chr6:28113746	A/C	cg18032046	chr6:28092343	ZSCAN16	-0.48	-6.22	-0.36	1.98e-9	Cardiac Troponin-T levels;
CESC	cis	rs12950390	0.853	rs56387656	chr17:45860189	C/G	cg00777063	chr17:45855553	NA	-0.38	-5.68	-0.33	3.49e-8	IgG glycosylation;
CESC	cis	rs7726839	0.540	rs72705102	chr5:659437	T/C	cg16447950	chr5:562315	NA	-0.61	-6.43	-0.37	5.93e-10	Obesity-related traits;
CESC	cis	rs897984	0.647	rs8060857	chr16:31002720	G/A	cg02466173	chr16:30829666	NA	0.48	7.93	0.44	6.03e-14	Dementia with Lewy bodies;
CESC	cis	rs7412746	0.658	rs6677420	chr1:150946490	G/A	cg17724175	chr1:150552817	MCL1	0.36	5.46	0.32	1.08e-7	Melanoma;
CESC	cis	rs7666738	0.830	rs62318906	chr4:99037110	C/T	cg03467027	chr4:99064603	C4orf37	0.47	5.97	0.34	7.51e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1008375	0.900	rs10019460	chr4:17686337	T/C	cg02297831	chr4:17616191	MED28	-0.48	-5.68	-0.33	3.59e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs3785574	0.962	rs2727329	chr17:61924566	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.58	7.04	0.4	1.67e-11	Height;
CESC	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg07308232	chr7:1071921	C7orf50	-0.6	-8.45	-0.46	1.94e-15	Longevity;Endometriosis;
CESC	cis	rs137699	0.652	rs2413589	chr22:39755689	C/T	cg05872129	chr22:39784769	NA	0.51	5.74	0.33	2.6e-8	IgG glycosylation;
CESC	cis	rs11098499	0.818	rs55825515	chr4:120486402	A/G	cg24375607	chr4:120327624	NA	0.45	5.52	0.32	8.26e-8	Corneal astigmatism;
CESC	cis	rs460214	0.564	rs464519	chr21:40024182	A/G	cg05519781	chr21:40033154	ERG	-0.47	-6.06	-0.35	4.64e-9	Response to cognitive-behavioural therapy in anxiety disorder;
CESC	cis	rs10504229	0.679	rs11783557	chr8:58030644	A/G	cg22535103	chr8:58192502	C8orf71	-0.57	-6.56	-0.37	2.78e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs8180040	0.654	rs1466740	chr3:47245883	C/T	cg27129171	chr3:47204927	SETD2	-0.66	-9.64	-0.51	4.74e-19	Colorectal cancer;
CESC	cis	rs4919687	0.550	rs17784294	chr10:104479385	G/T	cg04362960	chr10:104952993	NT5C2	0.48	5.61	0.33	5e-8	Colorectal cancer;
CESC	cis	rs1552244	0.938	rs9873794	chr3:10074153	T/G	cg00149659	chr3:10157352	C3orf10	0.76	9.49	0.5	1.43e-18	Alzheimer's disease;
CESC	cis	rs208520	0.802	rs851600	chr6:66893754	T/C	cg07460842	chr6:66804631	NA	-0.93	-11.86	-0.59	2.64e-26	Exhaled nitric oxide output;
CESC	cis	rs12477438	0.735	rs12474477	chr2:99690408	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.75	-10.87	-0.56	5.14e-23	Chronic sinus infection;
CESC	cis	rs896543	0.702	rs12692189	chr2:237496112	A/G	cg25295825	chr2:237489920	CXCR7	-0.72	-9.59	-0.51	6.83e-19	Alcohol dependence (age at onset);
CESC	cis	rs2882667	0.858	rs7724108	chr5:138410922	A/G	cg04439458	chr5:138467593	SIL1	0.39	6.12	0.35	3.27e-9	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs15676	0.947	rs2977994	chr9:131585216	G/T	cg00228799	chr9:131580591	ENDOG	0.45	5.66	0.33	4.03e-8	Blood metabolite levels;
CESC	cis	rs12148488	0.763	rs2304902	chr15:75340727	G/T	cg09165964	chr15:75287851	SCAMP5	0.61	8.15	0.45	1.41e-14	Caffeine consumption;
CESC	trans	rs9853921	0.963	rs9881954	chr3:117896366	A/G	cg19688222	chr4:4199452	OTOP1	-0.39	-6.08	-0.35	4.17e-9	JT interval (sulfonylurea treatment interaction);
CESC	cis	rs9611565	0.592	rs4822044	chr22:41979668	G/C	cg06634786	chr22:41940651	POLR3H	-0.66	-6.54	-0.37	3.13e-10	Vitiligo;
CESC	cis	rs13266463	1.000	rs13266463	chr8:143403693	A/G	cg16886403	chr8:143471632	TSNARE1	-0.47	-6.01	-0.35	6.27e-9	Schizophrenia;
CESC	cis	rs1580019	0.523	rs13236410	chr7:32690663	G/A	cg06627557	chr7:32535165	LSM5;AVL9	1.04	17.86	0.74	2.19e-47	Cognitive ability;
CESC	cis	rs2006771	0.836	rs7285777	chr22:31982241	C/G	cg25791279	chr22:32026902	PISD	-0.43	-5.07	-0.3	7.39e-7	Nonsyndromic cleft lip with cleft palate;
CESC	cis	rs3740713	1.000	rs73438687	chr11:18459859	A/G	cg23797887	chr11:18477753	LDHAL6A	-0.53	-5.11	-0.3	6.1e-7	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs7843479	0.544	rs4872110	chr8:21784989	A/G	cg17168535	chr8:21777572	XPO7	0.7	10.95	0.56	2.84e-23	Mean corpuscular volume;
CESC	cis	rs7666738	0.830	rs6846739	chr4:99016647	G/A	cg18180107	chr4:99064573	C4orf37	0.41	5.4	0.31	1.48e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6545883	0.965	rs3771258	chr2:61764140	C/T	cg15711740	chr2:61764176	XPO1	-0.44	-5.34	-0.31	1.95e-7	Tuberculosis;
CESC	cis	rs6570726	0.935	rs447247	chr6:145812678	G/T	cg23711669	chr6:146136114	FBXO30	0.83	12.23	0.6	1.41e-27	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9660992	0.590	rs1779411	chr1:205238530	C/T	cg00857998	chr1:205179979	DSTYK	0.47	5.35	0.31	1.87e-7	Mean corpuscular volume;Mean platelet volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22087053	chr5:140751506	PCDHGA4;PCDHGB3;PCDHGA1;PCDHGA5;PCDHGB1;PCDHGA3;PCDHGA2;PCDHGB2	-0.53	-6.39	-0.37	7.43e-10	Gut microbiome composition (summer);
CESC	cis	rs6912958	0.559	rs242270	chr6:88062190	C/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.34	-5.75	-0.33	2.49e-8	Monocyte percentage of white cells;
CESC	cis	rs12142240	0.698	rs41294476	chr1:46818374	C/A	cg10495392	chr1:46806563	NSUN4	0.57	6.27	0.36	1.47e-9	Menopause (age at onset);
CESC	cis	rs9905704	0.633	rs2680687	chr17:56491966	T/C	cg12560992	chr17:57184187	TRIM37	0.6	5.67	0.33	3.76e-8	Testicular germ cell tumor;
CESC	cis	rs7078219	0.505	rs10883373	chr10:101292484	G/A	cg09788492	chr10:101292477	NKX2-3	0.34	6.41	0.37	6.45e-10	Dental caries;
CESC	cis	rs11122272	0.732	rs2808605	chr1:231540187	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.55	-7.47	-0.42	1.14e-12	Hemoglobin concentration;
CESC	cis	rs7267979	0.527	rs6083891	chr20:25574272	C/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.7	-11.29	-0.57	2.15e-24	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs4664308	0.806	rs4665162	chr2:161060184	A/G	cg03641300	chr2:160917029	PLA2R1	-0.64	-9.5	-0.5	1.34e-18	Idiopathic membranous nephropathy;
CESC	cis	rs3733585	0.699	rs6815001	chr4:9958662	G/C	cg02734326	chr4:10020555	SLC2A9	-0.43	-6.01	-0.35	6.1e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs1413885	0.516	rs10158872	chr1:65836230	T/C	cg14976592	chr1:65886160	LEPROT;LEPR	0.46	5.91	0.34	1.03e-8	Anticoagulant levels;
CESC	cis	rs873946	0.648	rs12767283	chr10:134557094	C/G	cg27286337	chr10:134555280	INPP5A	0.68	7.64	0.42	4.05e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs514406	0.929	rs1242224	chr1:53314887	G/A	cg01802117	chr1:53393560	SCP2	-0.4	-5.13	-0.3	5.57e-7	Monocyte count;
CESC	cis	rs6460942	0.687	rs74753576	chr7:12463926	G/A	cg02935154	chr7:12443704	VWDE	-0.57	-7.08	-0.4	1.29e-11	Coronary artery disease;
CESC	trans	rs9929218	0.581	rs12185157	chr16:68784587	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.85	13.09	0.63	1.61e-30	Colorectal cancer;
CESC	cis	rs17293817	0.958	rs12771141	chr10:1442709	A/G	cg08482957	chr10:1437944	ADARB2	0.35	5.1	0.3	6.54e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs73001065	0.636	rs8182472	chr19:19539891	A/G	cg03709012	chr19:19516395	GATAD2A	0.82	6.97	0.39	2.52e-11	LDL cholesterol;
CESC	cis	rs7223966	1.000	rs8078862	chr17:61854068	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.73	0.38	1.06e-10	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs2230307	0.536	rs561119	chr1:100603891	G/A	cg24955406	chr1:100503596	HIAT1	-0.49	-5.18	-0.3	4.29e-7	Carotid intima media thickness;
CESC	cis	rs7714584	1.000	rs7734778	chr5:150256556	G/A	cg22134413	chr5:150180641	NA	0.53	6.21	0.36	2.05e-9	Crohn's disease;
CESC	trans	rs2727020	0.658	rs1851992	chr11:49438110	C/T	cg03929089	chr4:120376271	NA	-0.81	-12.55	-0.61	1.11e-28	Coronary artery disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg26102683	chr11:82904715	ANKRD42	-0.53	-7.13	-0.4	9.4e-12	Fibrinogen levels;
CESC	cis	rs9660992	0.573	rs1172158	chr1:205208948	G/A	cg00857998	chr1:205179979	DSTYK	0.56	6.88	0.39	4.29e-11	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs2836974	0.627	rs8127986	chr21:40687211	A/T	cg11644478	chr21:40555479	PSMG1	-0.8	-11.95	-0.59	1.32e-26	Cognitive function;
CESC	cis	rs4665809	0.652	rs6727974	chr2:26524639	A/G	cg26314531	chr2:26401878	FAM59B	0.56	5.99	0.35	6.95e-9	Gut microbiome composition (summer);
CESC	cis	rs17253792	0.822	rs74051609	chr14:56171132	G/A	cg01858014	chr14:56050164	KTN1	-0.75	-6.5	-0.37	3.96e-10	Putamen volume;
CESC	cis	rs7680126	0.500	rs4640669	chr4:10145733	A/G	cg00071950	chr4:10020882	SLC2A9	0.59	6.83	0.39	5.7e-11	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	cis	rs1942	0.837	rs12440045	chr15:41782684	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.54	-7.73	-0.43	2.22e-13	Eosinophil percentage of granulocytes;
CESC	cis	rs597539	0.652	rs11603827	chr11:68719221	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.78	9.27	0.49	6.73e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs270601	0.770	rs61352298	chr5:131600589	G/C	cg12564285	chr5:131593104	PDLIM4	0.38	5.8	0.34	1.92e-8	Acylcarnitine levels;
CESC	cis	rs7267979	1.000	rs2259928	chr20:25281834	G/C	cg08601574	chr20:25228251	PYGB	0.39	5.57	0.32	6.14e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs631288	0.557	rs920682	chr1:146657523	C/A	cg25205988	chr1:146714368	CHD1L	1.04	6.66	0.38	1.58e-10	PR interval in Tripanosoma cruzi seropositivity;
CESC	cis	rs7666738	0.830	rs13328042	chr4:99055406	A/G	cg17366294	chr4:99064904	C4orf37	0.62	8.79	0.47	1.99e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9894429	0.966	rs6565604	chr17:79589242	G/A	cg13777783	chr17:79615861	NA	-0.35	-5.79	-0.34	1.98e-8	Eye color traits;
CESC	trans	rs1667255	0.830	rs2034404	chr18:29156302	A/G	cg22637730	chr3:160473554	PPM1L	0.48	6.08	0.35	4.21e-9	Retinol levels;
CESC	cis	rs4253772	0.591	rs6008362	chr22:46652737	G/A	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.69	8.15	0.45	1.5e-14	LDL cholesterol;Cholesterol, total;
CESC	cis	rs597539	0.652	rs611046	chr11:68631704	A/G	cg04772025	chr11:68637568	NA	0.55	6.14	0.35	2.95e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs7618915	0.501	rs7622694	chr3:52663882	G/A	cg18337363	chr3:52569053	NT5DC2	0.28	5.12	0.3	5.85e-7	Bipolar disorder;
CESC	cis	rs9649213	0.574	rs7791321	chr7:97944125	G/C	cg24562669	chr7:97807699	LMTK2	0.51	7.63	0.42	4.28e-13	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10985647	chr6:150326596	RAET1K	-0.71	-8.45	-0.46	1.96e-15	Gut microbiome composition (summer);
CESC	cis	rs3126085	0.696	rs41266112	chr1:152185762	C/G	cg26876637	chr1:152193138	HRNR	0.48	5.5	0.32	8.93e-8	Atopic dermatitis;
CESC	cis	rs12477438	0.734	rs4851184	chr2:99666434	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.75	-10.87	-0.56	5.17e-23	Chronic sinus infection;
CESC	cis	rs1878931	0.697	rs10048148	chr16:3417450	C/G	cg22508957	chr16:3507546	NAT15	-0.4	-5.81	-0.34	1.77e-8	Body mass index (adult);
CESC	cis	rs1008375	1.000	rs7673500	chr4:17621383	C/T	cg04450456	chr4:17643702	FAM184B	0.39	5.63	0.33	4.55e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs2120019	1.000	rs1867146	chr15:75354971	C/G	cg17294928	chr15:75287854	SCAMP5	-0.65	-6.96	-0.39	2.66e-11	Blood trace element (Zn levels);
CESC	cis	rs6964587	1.000	rs2282974	chr7:91761617	G/A	cg17063962	chr7:91808500	NA	0.59	8.13	0.45	1.69e-14	Breast cancer;
CESC	cis	rs17666538	0.642	rs7821983	chr8:643696	A/G	cg13264159	chr8:625131	ERICH1	-0.61	-5.32	-0.31	2.21e-7	IgG glycosylation;
CESC	cis	rs4629180	0.606	rs13390891	chr2:102111943	T/C	cg04415270	chr2:102091202	RFX8	-0.31	-5.45	-0.32	1.18e-7	Chronic rhinosinusitis with nasal polyps;
CESC	cis	rs8031584	0.958	rs8034856	chr15:31240957	T/C	cg08109568	chr15:31115862	NA	-0.71	-9.44	-0.5	2.03e-18	Huntington's disease progression;
CESC	cis	rs9611519	1.000	rs9611519	chr22:41613188	C/T	cg03806693	chr22:41940476	POLR3H	-0.62	-6.45	-0.37	5.16e-10	Neuroticism;
CESC	cis	rs12893668	0.637	rs4525427	chr14:104072793	C/A	cg08213375	chr14:104286397	PPP1R13B	0.33	5.16	0.3	4.79e-7	Reticulocyte count;
CESC	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg07308232	chr7:1071921	C7orf50	-0.58	-8.08	-0.44	2.36e-14	Longevity;Endometriosis;
CESC	cis	rs10504229	0.817	rs10504230	chr8:58197150	A/G	cg05313129	chr8:58192883	C8orf71	0.5	5.32	0.31	2.23e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs1799949	0.965	rs6503727	chr17:41312859	C/T	cg23758822	chr17:41437982	NA	1.02	18.3	0.75	6.21e-49	Menopause (age at onset);
CESC	cis	rs7267979	1.000	rs6050573	chr20:25366065	C/G	cg08601574	chr20:25228251	PYGB	0.37	5.33	0.31	2.09e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs734999	0.566	rs6424092	chr1:2532899	C/A	cg20673091	chr1:2541236	MMEL1	-0.44	-7.39	-0.41	1.95e-12	Ulcerative colitis;
CESC	cis	rs7520050	0.966	rs11211199	chr1:46287869	T/C	cg03146154	chr1:46216737	IPP	-0.47	-6.15	-0.35	2.87e-9	Red blood cell count;Reticulocyte count;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg19092721	chr12:122260723	SETD1B	0.42	6.06	0.35	4.74e-9	Fibrinogen levels;
CESC	cis	rs4975616	0.836	rs421629	chr5:1320136	G/A	cg06550200	chr5:1325588	CLPTM1L	-0.69	-10.49	-0.54	9.55e-22	Lung cancer;
CESC	cis	rs2404602	0.692	rs34478400	chr15:76923510	C/T	cg26408565	chr15:76604113	ETFA	-0.39	-5.51	-0.32	8.57e-8	Blood metabolite levels;
CESC	cis	rs2274273	0.967	rs17832359	chr14:55615941	T/C	cg04306507	chr14:55594613	LGALS3	0.29	5.41	0.32	1.44e-7	Protein biomarker;
CESC	cis	rs6089584	0.627	rs35560719	chr20:60561917	A/C	cg06108461	chr20:60628389	TAF4	-0.52	-6.87	-0.39	4.66e-11	Body mass index;
CESC	cis	rs7772486	0.682	rs1337840	chr6:146042558	T/C	cg23711669	chr6:146136114	FBXO30	-0.82	-12.04	-0.59	6.45e-27	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs11098499	0.954	rs12508504	chr4:120410607	A/C	cg24375607	chr4:120327624	NA	0.45	5.72	0.33	2.93e-8	Corneal astigmatism;
CESC	cis	rs9649213	0.593	rs6955647	chr7:98004562	T/C	cg21770322	chr7:97807741	LMTK2	0.55	8.22	0.45	9.38e-15	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs2806561	0.929	rs10917357	chr1:23535161	C/T	cg12483005	chr1:23474871	LUZP1	0.33	5.24	0.31	3.25e-7	Height;
CESC	cis	rs8031584	0.678	rs3122	chr15:31170290	A/T	cg14829155	chr15:31115871	NA	0.79	10.93	0.56	3.32e-23	Huntington's disease progression;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15419313	chr20:3026568	MRPS26	0.53	6.08	0.35	4.16e-9	Gut microbiome composition (summer);
CESC	cis	rs780096	0.526	rs809058	chr2:27616790	T/C	cg12648201	chr2:27665141	KRTCAP3	-0.34	-6.26	-0.36	1.54e-9	Total body bone mineral density;
CESC	cis	rs875971	0.964	rs6945019	chr7:65922458	C/G	cg10691866	chr7:65817282	TPST1	-0.35	-5.64	-0.33	4.46e-8	Aortic root size;
CESC	cis	rs2380220	0.574	rs9400526	chr6:95998441	T/C	cg15832292	chr6:96025679	MANEA	0.63	7.18	0.4	7.12e-12	Behavioural disinhibition (generation interaction);
CESC	cis	rs873946	0.586	rs12251911	chr10:134570595	A/G	cg27286337	chr10:134555280	INPP5A	0.61	6.98	0.39	2.31e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg13896604	chr17:73043189	ATP5H;KCTD2	-0.43	-6.29	-0.36	1.3e-9	Gambling;
CESC	cis	rs10949834	0.689	rs2269081	chr7:73519887	T/G	cg07137043	chr7:73588983	EIF4H	-0.68	-6.21	-0.36	1.99e-9	Verbal memory performance (residualized delayed recall change);
CESC	cis	rs1005277	0.579	rs2023351	chr10:38378814	A/G	cg25517755	chr10:38738941	LOC399744	-0.48	-6.23	-0.36	1.82e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs16866061	1.000	rs11681451	chr2:225334104	T/C	cg12698349	chr2:225449008	CUL3	0.71	10.62	0.55	3.56e-22	Acute graft versus host disease in bone marrow transplantation (recipient effect);
CESC	cis	rs6714710	0.603	rs78006955	chr2:98455510	G/C	cg26665480	chr2:98280029	ACTR1B	0.57	8.02	0.44	3.49e-14	Posterior cortical atrophy and Alzheimer's disease;
CESC	cis	rs4720575	1.000	rs917108	chr7:47088047	A/G	cg00036614	chr7:47093842	NA	-0.42	-6.53	-0.37	3.3e-10	Angiotensin-converting enzyme inhibitor intolerance;
CESC	cis	rs6582630	0.519	rs11495700	chr12:38288240	A/G	cg26384229	chr12:38710491	ALG10B	0.73	10.52	0.54	7.46e-22	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs9399135	1.000	rs6569988	chr6:135352303	C/A	cg24558204	chr6:135376177	HBS1L	0.49	6.72	0.38	1.09e-10	Red blood cell count;
CESC	cis	rs7000551	0.619	rs2443506	chr8:22373383	T/C	cg12081754	chr8:22256438	SLC39A14	0.39	5.31	0.31	2.34e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CESC	cis	rs2066819	1.000	rs74496027	chr12:56726340	C/T	cg26714650	chr12:56694279	CS	-1.39	-9.17	-0.49	1.33e-17	Psoriasis vulgaris;
CESC	cis	rs2549003	1.000	rs2070728	chr5:131819977	C/T	cg00255919	chr5:131827918	IRF1	0.51	8.59	0.47	7.76e-16	Asthma (sex interaction);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg14012233	chr17:27276799	PHF12	-0.49	-6.8	-0.39	6.9e-11	Fibrinogen levels;
CESC	cis	rs4268898	0.610	rs55860688	chr2:24451534	T/C	cg06627628	chr2:24431161	ITSN2	-0.99	-11.27	-0.57	2.58e-24	Asthma;
CESC	cis	rs2075371	1.000	rs447266	chr7:133989543	A/G	cg20476274	chr7:133979776	SLC35B4	0.64	9.27	0.49	6.83e-18	Mean platelet volume;
CESC	cis	rs10751667	0.666	rs7394958	chr11:965944	C/G	cg06064525	chr11:970664	AP2A2	-0.48	-9.29	-0.5	5.99e-18	Alzheimer's disease (late onset);
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg09233161	chr9:37079712	NA	-0.45	-6.7	-0.38	1.24e-10	Vertical cup-disc ratio;
CESC	cis	rs2302190	0.882	rs8072873	chr17:56669049	G/C	cg25885038	chr17:56607967	SEPT4	-0.4	-5.43	-0.32	1.27e-7	Vitamin D levels;
CESC	cis	rs7631605	0.544	rs61493618	chr3:37173775	A/T	cg22985146	chr3:37219077	LRRFIP2	-0.33	-5.23	-0.31	3.44e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs1153858	1.000	rs2461701	chr15:45703391	G/A	cg10760299	chr15:45669010	GATM	0.37	5.14	0.3	5.43e-7	Homoarginine levels;
CESC	cis	rs3105593	1.000	rs3109888	chr15:50860694	C/A	cg08437265	chr15:50716283	USP8	0.4	5.21	0.3	3.84e-7	QT interval;
CESC	cis	rs56346965	0.967	rs11900804	chr2:191533767	T/C	cg27211696	chr2:191398769	TMEM194B	-0.42	-5.57	-0.32	6.32e-8	Bone mineral density (Ward's triangle area);
CESC	cis	rs9549367	0.756	rs3861723	chr13:113910926	A/G	cg00898013	chr13:113819073	PROZ	-0.49	-7.12	-0.4	1e-11	Platelet distribution width;
CESC	cis	rs10911251	0.528	rs10911266	chr1:183115097	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.87	13.8	0.65	5.11e-33	Colorectal cancer;
CESC	cis	rs12497850	0.931	rs12493289	chr3:48905161	G/A	cg07636037	chr3:49044803	WDR6	1.02	18.99	0.76	2.3e-51	Parkinson's disease;
CESC	cis	rs1552244	1.000	rs34179822	chr3:10140017	A/G	cg00166722	chr3:10149974	C3orf24	0.46	5.89	0.34	1.18e-8	Alzheimer's disease;
CESC	cis	rs10089	0.953	rs1985268	chr5:127375931	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.78	10.15	0.53	1.14e-20	Ileal carcinoids;
CESC	cis	rs5757676	1.000	rs5757676	chr22:39841700	T/C	cg01416388	chr22:39784598	NA	-0.65	-6.78	-0.38	7.71e-11	IgG glycosylation;
CESC	cis	rs2180341	0.960	rs1964130	chr6:127677391	C/G	cg24812749	chr6:127587940	RNF146	0.97	13.04	0.63	2.4e-30	Breast cancer;
CESC	cis	rs3126085	1.000	rs2338555	chr1:152309380	G/A	cg03465714	chr1:152285911	FLG	0.43	5.22	0.31	3.62e-7	Atopic dermatitis;
CESC	cis	rs9309711	0.506	rs9284794	chr2:3492052	G/A	cg15506890	chr2:3487001	NA	-0.52	-6.69	-0.38	1.32e-10	Neurofibrillary tangles;
CESC	cis	rs17655565	0.581	rs1622677	chr12:52762444	A/G	cg00777198	chr12:52828273	KRT75	-0.38	-5.62	-0.33	4.95e-8	Plasma amyloid beta peptide concentrations (ABx-42);
CESC	cis	rs780096	0.506	rs2288155	chr2:27714526	T/C	cg02592271	chr2:27665507	KRTCAP3	-0.27	-5.27	-0.31	2.86e-7	Total body bone mineral density;
CESC	cis	rs10504229	0.817	rs114173899	chr8:58170640	G/T	cg22535103	chr8:58192502	C8orf71	-1.05	-12.93	-0.62	5.44e-30	Developmental language disorder (linguistic errors);
CESC	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg23978390	chr7:1156363	C7orf50	0.59	8.05	0.44	2.77e-14	Longevity;Endometriosis;
CESC	cis	rs2576037	0.583	rs545344	chr18:44367079	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.37	5.82	0.34	1.71e-8	Personality dimensions;
CESC	cis	rs7208859	0.614	rs216412	chr17:28903394	A/G	cg17105886	chr17:28927953	LRRC37B2	-0.63	-5.95	-0.34	8.28e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs4561483	0.645	rs2192645	chr16:11928019	C/T	cg08843971	chr16:11963173	GSPT1	-0.47	-6.6	-0.38	2.28e-10	Testicular germ cell tumor;
CESC	cis	rs1218582	0.772	rs10908448	chr1:154882544	A/G	cg03351412	chr1:154909251	PMVK	-0.68	-9.41	-0.5	2.47e-18	Prostate cancer;
CESC	cis	rs7264396	0.747	rs2425158	chr20:34419664	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.83	-11.28	-0.57	2.4e-24	Total cholesterol levels;
CESC	cis	rs425277	0.606	rs3128295	chr1:2068480	C/T	cg19257562	chr1:2043853	PRKCZ	0.34	5.33	0.31	2.13e-7	Height;
CESC	cis	rs7772486	0.754	rs1415746	chr6:146077107	A/G	cg05347473	chr6:146136440	FBXO30	-0.59	-7.61	-0.42	4.8e-13	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs524281	0.692	rs2302884	chr11:65824084	C/T	cg14036092	chr11:66035641	RAB1B	-0.58	-6.32	-0.36	1.08e-9	Electroencephalogram traits;
CESC	cis	rs6963495	0.818	rs73190181	chr7:105162907	A/C	cg19920283	chr7:105172520	RINT1	0.69	6.56	0.37	2.85e-10	Bipolar disorder (body mass index interaction);
CESC	cis	rs7130144	0.541	rs28402217	chr11:130459644	C/G	cg26307797	chr11:130446613	NA	-0.74	-6.36	-0.36	8.72e-10	Urate levels in lean individuals;
CESC	cis	rs7552404	0.924	rs2153126	chr1:76199345	C/G	cg10523679	chr1:76189770	ACADM	0.8	10.96	0.56	2.71e-23	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs13102973	1.000	rs7439938	chr4:135897696	G/A	cg14419869	chr4:135874104	NA	-0.36	-5.41	-0.32	1.38e-7	Subjective well-being;
CESC	cis	rs7917772	0.503	rs746552	chr10:104342501	A/G	ch.10.2196322F	chr10:104248062	ACTR1A	0.42	5.16	0.3	4.94e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs1559088	0.895	rs13345542	chr19:33586739	G/C	cg17764715	chr19:33622953	WDR88	0.49	6.32	0.36	1.11e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs6460942	0.591	rs6942432	chr7:12338393	A/G	cg20607287	chr7:12443886	VWDE	-0.59	-6.52	-0.37	3.45e-10	Coronary artery disease;
CESC	cis	rs9790314	1.000	rs459697	chr3:161093420	G/A	cg03342759	chr3:160939853	NMD3	-0.48	-6.04	-0.35	5.32e-9	Morning vs. evening chronotype;
CESC	cis	rs10791323	0.604	rs2723607	chr11:133711018	C/G	cg15485101	chr11:133734466	NA	0.41	6.54	0.37	3.09e-10	Childhood ear infection;
CESC	cis	rs7119	0.717	rs11632729	chr15:77722006	G/A	cg17802220	chr15:77601643	NA	-0.5	-6.97	-0.39	2.51e-11	Type 2 diabetes;
CESC	cis	rs34524635	1	rs34524635	chr10:65261176	CT/C	cg01631684	chr10:65280961	REEP3	-0.45	-5.63	-0.33	4.59e-8	Vascular endothelial growth factor levels;
CESC	cis	rs72781680	0.898	rs55841168	chr2:24007926	T/C	cg20701182	chr2:24300061	SF3B14	0.63	5.65	0.33	4.21e-8	Lymphocyte counts;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23239052	chr17:79008930	FLJ90757;BAIAP2	0.65	7.93	0.44	6.01e-14	Gut microbiome composition (summer);
CESC	cis	rs2836974	0.897	rs35123057	chr21:40711689	C/T	cg27266027	chr21:40555129	PSMG1	0.44	5.25	0.31	3.16e-7	Cognitive function;
CESC	trans	rs7120489	0.748	rs57628814	chr11:12456399	G/A	cg05526731	chr17:185263	RPH3AL	0.8	6.06	0.35	4.69e-9	Mortality in heart failure;
CESC	cis	rs2599510	0.729	rs1135484	chr2:32749060	G/A	cg02381751	chr2:32503542	YIPF4	0.48	5.87	0.34	1.27e-8	Interleukin-18 levels;
CESC	cis	rs3815700	1.000	rs8104726	chr19:33094675	G/A	cg24916020	chr19:33096688	ANKRD27	0.59	5.75	0.33	2.5e-8	Eosinophilic esophagitis;
CESC	cis	rs2795502	0.882	rs2744095	chr10:43337949	A/T	cg27426351	chr10:43362370	NA	-0.44	-5.45	-0.32	1.17e-7	Blood protein levels;
CESC	cis	rs2180341	1.000	rs6569482	chr6:127631371	C/T	cg27446573	chr6:127587934	RNF146	1.09	16.33	0.71	5.73e-42	Breast cancer;
CESC	cis	rs9322193	0.962	rs6899661	chr6:150139229	T/C	cg07701084	chr6:150067640	NUP43	0.43	5.8	0.34	1.92e-8	Lung cancer;
CESC	cis	rs56399783	0.708	rs56208415	chr7:2813806	G/A	cg19731401	chr7:2775893	GNA12	0.65	5.95	0.34	8.4e-9	Childhood ear infection;
CESC	cis	rs6570726	0.846	rs4896824	chr6:145927048	C/T	cg05347473	chr6:146136440	FBXO30	0.48	6.39	0.37	7.61e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs11608355	0.515	rs11611011	chr12:109936948	C/T	cg05360138	chr12:110035743	NA	0.82	8.85	0.48	1.27e-16	Neuroticism;
CESC	cis	rs10504229	0.683	rs113492050	chr8:58130046	A/G	cg02725872	chr8:58115012	NA	-0.45	-7.05	-0.4	1.52e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs1355223	0.902	rs836462	chr11:34743263	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.48	-6.44	-0.37	5.45e-10	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs727505	0.789	rs9641761	chr7:124735205	A/T	cg23710748	chr7:124431027	NA	-0.4	-6.5	-0.37	4.07e-10	Lewy body disease;
CESC	cis	rs12464483	0.591	rs4952171	chr2:30886903	G/A	cg12454169	chr2:30669597	LCLAT1	0.64	6.32	0.36	1.13e-9	Pre-treatment pain in head and neck squamous cell carcinoma;
CESC	cis	rs6500395	1.000	rs1120276	chr16:48598517	C/G	cg04672837	chr16:48644449	N4BP1	0.5	6.12	0.35	3.33e-9	Response to tocilizumab in rheumatoid arthritis;
CESC	trans	rs7395662	0.500	rs10838984	chr11:48640485	C/T	cg03929089	chr4:120376271	NA	-0.52	-6.02	-0.35	5.81e-9	HDL cholesterol;
CESC	cis	rs863345	0.604	rs2873594	chr1:158504790	T/C	cg12129480	chr1:158549410	OR10X1	-0.34	-6.84	-0.39	5.41e-11	Pneumococcal bacteremia;
CESC	cis	rs597539	0.652	rs478647	chr11:68700424	C/T	cg21963583	chr11:68658836	MRPL21	0.4	5.79	0.34	1.96e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs875971	1.000	rs1981798	chr7:65954903	G/T	cg12463550	chr7:65579703	CRCP	0.54	6.7	0.38	1.25e-10	Aortic root size;
CESC	cis	rs7613875	0.580	rs12634780	chr3:50043341	A/T	cg24110177	chr3:50126178	RBM5	0.57	7.98	0.44	4.45e-14	Body mass index;
CESC	cis	rs4713118	0.527	rs9461433	chr6:28095172	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.56	-6.49	-0.37	4.23e-10	Parkinson's disease;
CESC	cis	rs10256972	0.758	rs4723649	chr7:1071905	T/C	cg07308232	chr7:1071921	C7orf50	-0.61	-8.59	-0.47	7.45e-16	Longevity;Endometriosis;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg06785624	chr8:144990484	PLEC1	0.47	6.13	0.35	3.21e-9	Fibrinogen levels;
CESC	cis	rs7640424	0.620	rs17231503	chr3:107817299	C/T	cg09227934	chr3:107805635	CD47	-0.46	-5.64	-0.33	4.44e-8	Body mass index;
CESC	cis	rs8072100	0.967	rs8074149	chr17:45583375	A/C	cg08085267	chr17:45401833	C17orf57	0.43	5.64	0.33	4.28e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs2637266	0.597	rs2583065	chr10:78555915	A/G	cg18941641	chr10:78392320	NA	0.41	7.79	0.43	1.51e-13	Pulmonary function;
CESC	cis	rs5758659	1.000	rs134869	chr22:42652074	G/A	cg05082376	chr22:42548792	NA	-0.39	-5.84	-0.34	1.55e-8	Cognitive function;
CESC	cis	rs13202913	0.837	rs9397054	chr6:151789912	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.65	5.08	0.3	7.08e-7	Epstein-Barr virus copy number in lymphoblastoid cell lines;
CESC	cis	rs1707322	0.785	rs10890348	chr1:46242423	G/T	cg05343316	chr1:45956843	TESK2	0.48	5.84	0.34	1.53e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs35306767	0.903	rs12250937	chr10:900209	C/T	cg26597838	chr10:835615	NA	0.86	8.93	0.48	7.33e-17	Eosinophil percentage of granulocytes;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg12626377	chr20:34330591	RBM39	-0.5	-6.66	-0.38	1.58e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs7659604	0.540	rs9998385	chr4:122676673	C/T	cg19671926	chr4:122722719	EXOSC9	0.53	6.7	0.38	1.21e-10	Type 2 diabetes;
CESC	cis	rs35955747	0.902	rs7288643	chr22:31679669	C/A	cg25791279	chr22:32026902	PISD	-0.5	-6.0	-0.35	6.61e-9	Neutrophil count;Sum basophil neutrophil counts;
CESC	cis	rs7084402	0.905	rs1649031	chr10:60279742	G/A	cg07615347	chr10:60278583	BICC1	-0.59	-9.45	-0.5	1.94e-18	Refractive error;
CESC	cis	rs748404	0.697	rs471122	chr15:43558574	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.5	-7.51	-0.42	8.96e-13	Lung cancer;
CESC	cis	rs9790314	1.000	rs336591	chr3:161078080	A/G	cg04691961	chr3:161091175	C3orf57	-0.41	-5.3	-0.31	2.44e-7	Morning vs. evening chronotype;
CESC	cis	rs758324	0.606	rs247276	chr5:131469004	C/T	cg20547724	chr5:131607888	PDLIM4	0.41	5.16	0.3	4.89e-7	Alzheimer's disease in APOE e4- carriers;
CESC	cis	rs9926296	0.656	rs2376882	chr16:89827002	T/C	cg27121462	chr16:89883253	FANCA	0.54	6.79	0.39	7.27e-11	Vitiligo;
CESC	cis	rs9303401	0.659	rs12940212	chr17:56674474	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.0	11.47	0.58	5.4e-25	Cognitive test performance;
CESC	cis	rs1348850	0.793	rs13027299	chr2:178455501	T/G	cg23306229	chr2:178417860	TTC30B	0.44	5.35	0.31	1.87e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs6570726	0.791	rs385729	chr6:145855465	T/C	cg23711669	chr6:146136114	FBXO30	1.01	15.52	0.69	4.59e-39	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs3858526	0.628	rs4237762	chr11:5956626	A/C	cg25319279	chr11:5960081	NA	-0.42	-5.92	-0.34	9.78e-9	DNA methylation (variation);
CESC	cis	rs9393777	0.623	rs9358946	chr6:26478927	G/A	cg14345882	chr6:26364793	BTN3A2	0.43	5.34	0.31	2.01e-7	Intelligence (multi-trait analysis);
CESC	cis	rs2486288	0.656	rs8039138	chr15:45551592	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.54	-6.55	-0.37	3.03e-10	Glomerular filtration rate;
CESC	cis	rs9322193	0.923	rs2297932	chr6:150039361	C/G	cg04369109	chr6:150039330	LATS1	-0.41	-5.81	-0.34	1.82e-8	Lung cancer;
CESC	cis	rs2066819	1.000	rs77768890	chr12:56725121	A/G	cg26714650	chr12:56694279	CS	-1.47	-9.75	-0.51	2.09e-19	Psoriasis vulgaris;
CESC	trans	rs4332037	0.586	rs62442944	chr7:2015047	T/G	cg11693508	chr17:37793320	STARD3	0.66	6.62	0.38	2.01e-10	Bipolar disorder;
CESC	cis	rs28386778	0.700	rs11079515	chr17:62005645	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.66	-8.85	-0.48	1.24e-16	Prudent dietary pattern;
CESC	cis	rs10751667	0.666	rs4072741	chr11:976565	T/C	cg06064525	chr11:970664	AP2A2	-0.46	-8.93	-0.48	7.1e-17	Alzheimer's disease (late onset);
CESC	cis	rs7927592	0.913	rs12363722	chr11:68236291	A/C	cg20283391	chr11:68216788	NA	-0.61	-7.29	-0.41	3.64e-12	Total body bone mineral density;
CESC	cis	rs910316	0.503	rs4903273	chr14:75441795	G/A	cg11812906	chr14:75593930	NEK9	-0.63	-8.94	-0.48	6.78e-17	Height;
CESC	cis	rs11098499	0.954	rs1022145	chr4:120230979	A/G	cg09307838	chr4:120376055	NA	0.93	12.78	0.62	1.83e-29	Corneal astigmatism;
CESC	cis	rs9300255	0.508	rs1716176	chr12:123655467	T/G	cg19016782	chr12:123741754	C12orf65	-0.45	-6.34	-0.36	9.76e-10	Neutrophil percentage of white cells;
CESC	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg12419862	chr22:24373484	LOC391322	-0.7	-9.66	-0.51	4.09e-19	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs2797160	1.000	rs2797161	chr6:126010789	A/G	cg05901451	chr6:126070800	HEY2	0.47	6.85	0.39	5.01e-11	Endometrial cancer;
CESC	cis	rs9649213	0.593	rs7789380	chr7:97956180	G/A	cg21770322	chr7:97807741	LMTK2	0.53	8.04	0.44	2.97e-14	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7618501	0.633	rs6771546	chr3:49968572	T/C	cg24110177	chr3:50126178	RBM5	-0.54	-7.55	-0.42	7.08e-13	Intelligence (multi-trait analysis);
CESC	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg20887711	chr4:1340912	KIAA1530	0.87	11.48	0.58	4.82e-25	Longevity;
CESC	cis	rs7095944	0.584	rs4962693	chr10:126424835	C/T	cg08799069	chr10:126477246	METTL10	-0.39	-5.55	-0.32	6.81e-8	Asthma;
CESC	cis	rs34172651	0.517	rs874484	chr16:24803242	T/C	cg06505273	chr16:24850292	NA	0.52	5.92	0.34	9.94e-9	Intelligence (multi-trait analysis);
CESC	cis	rs2404602	0.583	rs12907668	chr15:76589767	A/T	cg26408565	chr15:76604113	ETFA	-0.41	-6.07	-0.35	4.43e-9	Blood metabolite levels;
CESC	cis	rs7553864	0.605	rs7531038	chr1:87605049	C/G	cg17420885	chr1:87600446	LOC339524	-0.42	-5.67	-0.33	3.7e-8	Smoking behavior;
CESC	cis	rs1348850	0.634	rs1534304	chr2:178489264	C/T	cg23306229	chr2:178417860	TTC30B	0.55	6.16	0.35	2.69e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs28489187	0.706	rs233060	chr1:85798943	C/T	cg16011679	chr1:85725395	C1orf52	0.48	5.68	0.33	3.58e-8	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	cis	rs11792861	0.781	rs72607159	chr9:111764270	C/T	cg05043794	chr9:111880884	C9orf5	-0.36	-5.81	-0.34	1.76e-8	Menarche (age at onset);
CESC	cis	rs769267	0.896	rs2315610	chr19:19597240	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.47	5.89	0.34	1.19e-8	Tonsillectomy;
CESC	cis	rs727563	0.565	rs132774	chr22:42031953	C/G	cg17376030	chr22:41985996	PMM1	0.48	5.56	0.32	6.72e-8	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs7078219	0.505	rs7908704	chr10:101293318	G/A	cg09788492	chr10:101292477	NKX2-3	0.32	5.99	0.35	6.65e-9	Dental caries;
CESC	cis	rs1799949	0.930	rs3765640	chr17:41276247	A/G	cg05368731	chr17:41323189	NBR1	0.8	11.32	0.57	1.66e-24	Menopause (age at onset);
CESC	cis	rs9911578	0.967	rs8082544	chr17:57185807	C/T	cg12560992	chr17:57184187	TRIM37	-1.0	-17.6	-0.73	1.9e-46	Intelligence (multi-trait analysis);
CESC	cis	rs11077998	0.967	rs12185229	chr17:80499065	G/C	cg10255544	chr17:80519551	FOXK2	0.55	8.85	0.48	1.27e-16	Reticulocyte fraction of red cells;
CESC	cis	rs7412746	0.658	rs10305714	chr1:150800655	C/T	cg09365446	chr1:150670422	GOLPH3L	-0.38	-5.08	-0.3	6.97e-7	Melanoma;
CESC	cis	rs2836974	0.899	rs8127087	chr21:40544502	C/T	cg17971929	chr21:40555470	PSMG1	1.05	16.19	0.71	1.86e-41	Cognitive function;
CESC	cis	rs34779708	0.931	rs2244100	chr10:35323636	G/A	cg04310649	chr10:35416472	CREM	0.5	6.19	0.36	2.28e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs41563	0.674	rs2192932	chr7:104653265	A/G	cg04380332	chr7:105027541	SRPK2	0.38	5.46	0.32	1.12e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs10504229	0.679	rs16921677	chr8:58052431	T/C	cg22535103	chr8:58192502	C8orf71	-0.66	-7.26	-0.41	4.29e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs11792861	0.816	rs3763643	chr9:111695607	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.52	6.7	0.38	1.21e-10	Menarche (age at onset);
CESC	cis	rs7208859	0.673	rs9898858	chr17:29156211	A/T	cg19761014	chr17:28927070	LRRC37B2	0.74	6.03	0.35	5.43e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs7949030	0.588	rs2512563	chr11:62311249	C/G	cg02375832	chr11:62437615	C11orf48	-0.36	-5.34	-0.31	1.98e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs2991971	0.967	rs512026	chr1:46009946	G/T	cg15605315	chr1:45957053	TESK2	0.47	6.18	0.35	2.42e-9	High light scatter reticulocyte count;
CESC	cis	rs4862750	0.914	rs1991256	chr4:187875330	A/G	cg03452623	chr4:187889614	NA	-0.86	-14.21	-0.66	1.82e-34	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg07677032	chr17:61819896	STRADA	0.46	6.1	0.35	3.83e-9	Prudent dietary pattern;
CESC	cis	rs34779708	0.931	rs7920095	chr10:35303334	G/A	cg04310649	chr10:35416472	CREM	-0.5	-5.98	-0.34	7.34e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs17253792	0.822	rs76205307	chr14:56166038	C/T	cg01858014	chr14:56050164	KTN1	-0.97	-7.54	-0.42	7.36e-13	Putamen volume;
CESC	cis	rs4974559	0.947	rs12639938	chr4:1343135	G/C	cg02980000	chr4:1222292	CTBP1	0.68	6.25	0.36	1.6e-9	Systolic blood pressure;
CESC	cis	rs36051895	0.659	rs3780365	chr9:5068520	T/C	cg02405213	chr9:5042618	JAK2	-0.48	-5.91	-0.34	1.06e-8	Pediatric autoimmune diseases;
CESC	cis	rs2288073	0.801	rs72797831	chr2:24366829	G/A	cg20701182	chr2:24300061	SF3B14	0.45	5.47	0.32	1.04e-7	Venous thromboembolism (SNP x SNP interaction);
CESC	cis	rs7618915	0.547	rs2286800	chr3:52778051	C/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.31	5.43	0.32	1.25e-7	Bipolar disorder;
CESC	cis	rs9768139	0.935	rs10949715	chr7:158117246	G/T	cg06219351	chr7:158114137	PTPRN2	-0.45	-7.22	-0.41	5.61e-12	Calcium levels;
CESC	cis	rs4665809	0.590	rs17528653	chr2:26507724	T/C	cg26119090	chr2:26468346	HADHA;HADHB	1.08	11.71	0.58	8.24e-26	Gut microbiome composition (summer);
CESC	cis	rs644799	0.965	rs2508713	chr11:95547927	T/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	13.69	0.64	1.25e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	trans	rs13098911	0.540	rs35772789	chr3:46095104	A/G	cg10236987	chr1:228114221	WNT9A	0.63	6.2	0.36	2.12e-9	Celiac disease;
CESC	cis	rs1034435	0.547	rs5768686	chr22:48899214	G/A	cg05992904	chr22:48892994	FAM19A5	-0.45	-6.67	-0.38	1.48e-10	Late-onset Alzheimer's disease;
CESC	cis	rs9443645	0.838	rs946022	chr6:79672133	G/T	cg05283184	chr6:79620031	NA	-0.41	-6.41	-0.37	6.48e-10	Intelligence (multi-trait analysis);
CESC	cis	rs7666738	0.830	rs10470893	chr4:99038756	C/T	cg03676636	chr4:99064102	C4orf37	0.33	5.12	0.3	5.93e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7666738	0.830	rs115279324	chr4:99042114	T/C	cg03467027	chr4:99064603	C4orf37	0.47	5.96	0.34	8.08e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs17384381	1.000	rs12128907	chr1:85891385	A/G	cg16011679	chr1:85725395	C1orf52	0.74	7.65	0.43	3.82e-13	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs57221529	0.599	rs72707027	chr5:671294	C/G	cg16447950	chr5:562315	NA	-0.67	-7.03	-0.4	1.75e-11	Lung disease severity in cystic fibrosis;
CESC	cis	rs2635047	0.756	rs34939493	chr18:44795621	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.41	5.33	0.31	2.1e-7	Educational attainment;
CESC	cis	rs1707322	1.000	rs10158032	chr1:46332701	T/C	cg03146154	chr1:46216737	IPP	0.72	9.9	0.52	7.12e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs12497850	0.897	rs9884022	chr3:48956862	G/C	cg03060546	chr3:49711283	APEH	0.45	5.63	0.33	4.6e-8	Parkinson's disease;
CESC	cis	rs6685188	0.920	rs6593964	chr1:205662337	G/T	cg07167872	chr1:205819463	PM20D1	0.44	6.27	0.36	1.49e-9	White blood cell count (basophil);Basophil percentage of white cells;
CESC	cis	rs7247513	0.759	rs8110545	chr19:12754898	C/T	cg06417478	chr19:12876846	HOOK2	0.43	5.3	0.31	2.47e-7	Bipolar disorder;
CESC	trans	rs7103648	0.553	rs12803857	chr11:47890172	G/A	cg15704280	chr7:45808275	SEPT13	-0.53	-6.24	-0.36	1.69e-9	Diastolic blood pressure;Systolic blood pressure;
CESC	cis	rs9372253	1.000	rs9372253	chr6:110716136	C/T	cg19196401	chr6:110721138	DDO	-0.39	-5.65	-0.33	4.21e-8	Platelet distribution width;
CESC	cis	rs4629710	0.592	rs35017713	chr6:131581212	G/A	cg12606694	chr6:131520996	AKAP7	0.48	5.82	0.34	1.68e-8	Multiple myeloma (IgH translocation);
CESC	cis	rs6500602	0.893	rs934888	chr16:4462832	C/T	cg08645402	chr16:4508243	NA	0.38	5.38	0.31	1.68e-7	Schizophrenia;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg25104118	chr12:125621344	AACS	0.47	6.52	0.37	3.45e-10	Fibrinogen levels;
CESC	cis	rs9039	1.000	rs1128001	chr16:9207003	T/C	cg08831531	chr16:9218945	NA	-0.43	-6.01	-0.35	6.23e-9	Menopause (age at onset);
CESC	cis	rs116095464	0.558	rs28729548	chr5:229025	C/T	cg10591111	chr5:226296	SDHA	-0.54	-6.65	-0.38	1.72e-10	Breast cancer;
CESC	cis	rs2304069	0.909	rs8073	chr5:149362400	T/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.87	-10.57	-0.54	5.16e-22	HIV-1 control;
CESC	cis	rs2239547	0.522	rs7652131	chr3:52997154	C/T	cg11645453	chr3:52864694	ITIH4	0.33	5.64	0.33	4.37e-8	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00758816	chr15:69843549	NA	-0.53	-6.24	-0.36	1.7e-9	Gut microbiome composition (summer);
CESC	cis	rs4853012	0.838	rs58759652	chr2:74344902	A/T	cg19729930	chr2:74357872	NA	0.84	12.54	0.61	1.2e-28	Gestational age at birth (maternal effect);
CESC	cis	rs11166629	1.000	rs6992668	chr8:135645129	T/C	cg21672855	chr8:135614777	ZFAT	0.4	5.09	0.3	6.9e-7	Smoking quantity;
CESC	cis	rs1707322	1.000	rs7547189	chr1:46319514	C/A	cg03146154	chr1:46216737	IPP	0.71	9.86	0.52	9.69e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs963731	0.649	rs2123881	chr2:39247742	G/A	cg04010122	chr2:39346883	SOS1	-0.73	-5.39	-0.31	1.54e-7	Corticobasal degeneration;
CESC	cis	rs698833	0.798	rs1067391	chr2:44639434	T/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	6.61	0.38	2.16e-10	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23709117	chr6:108882119	FOXO3	0.54	6.12	0.35	3.27e-9	Gut microbiome composition (summer);
CESC	cis	rs2404602	0.716	rs4886813	chr15:76838221	C/T	cg26408565	chr15:76604113	ETFA	0.4	5.98	0.34	7.24e-9	Blood metabolite levels;
CESC	cis	rs10484885	0.793	rs1465954	chr6:90475013	G/A	cg13799429	chr6:90582589	CASP8AP2	0.7	7.94	0.44	5.6e-14	QRS interval (sulfonylurea treatment interaction);
CESC	cis	rs875971	0.830	rs809025	chr7:65849819	C/G	cg10691866	chr7:65817282	TPST1	-0.32	-5.25	-0.31	3.06e-7	Aortic root size;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg06434972	chr7:44122219	POLM	0.51	6.62	0.38	1.93e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs6963495	0.745	rs73192152	chr7:105212258	A/C	cg13798780	chr7:105162888	PUS7	0.77	7.56	0.42	6.63e-13	Bipolar disorder (body mass index interaction);
CESC	trans	rs61931739	0.500	rs7311284	chr12:34478477	C/G	cg13010199	chr12:38710504	ALG10B	0.5	6.47	0.37	4.76e-10	Morning vs. evening chronotype;
CESC	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg23131131	chr22:24373011	LOC391322	-0.66	-9.03	-0.49	3.54e-17	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs4718428	0.705	rs4717328	chr7:66352665	T/C	cg12165864	chr7:66369176	NA	-0.65	-7.39	-0.41	1.87e-12	Corneal structure;
CESC	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg27094323	chr7:1216898	NA	-0.42	-5.8	-0.34	1.93e-8	Longevity;Endometriosis;
CESC	cis	rs6121246	0.529	rs58757492	chr20:30181425	G/A	cg13852791	chr20:30311386	BCL2L1	0.57	5.5	0.32	9.14e-8	Mean corpuscular hemoglobin;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg11698548	chr7:43769233	C7orf44	-0.44	-6.02	-0.35	5.85e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs950169	0.887	rs3860265	chr15:84945185	C/T	cg17507749	chr15:85114479	UBE2QP1	0.59	6.52	0.37	3.46e-10	Schizophrenia;
CESC	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg07677032	chr17:61819896	STRADA	0.44	6.05	0.35	4.85e-9	Prudent dietary pattern;
CESC	cis	rs7833790	1.000	rs1463259	chr8:82737745	A/G	cg17211192	chr8:82754475	SNX16	-0.69	-8.22	-0.45	9.26e-15	Diastolic blood pressure;
CESC	cis	rs6456156	0.526	rs1854853	chr6:167533062	A/G	cg07741184	chr6:167504864	NA	-0.32	-5.49	-0.32	9.52e-8	Primary biliary cholangitis;
CESC	cis	rs4132509	0.779	rs3006939	chr1:243677834	G/A	cg21452805	chr1:244014465	NA	0.41	5.1	0.3	6.55e-7	RR interval (heart rate);
CESC	cis	rs8092503	1.000	rs12454204	chr18:52500011	G/T	cg12377874	chr18:52495404	RAB27B	0.4	6.06	0.35	4.56e-9	Childhood body mass index;
CESC	cis	rs13191362	1.000	rs66534429	chr6:163003322	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.79	8.31	0.45	5.17e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs5758659	0.504	rs133367	chr22:42463366	A/G	cg04733989	chr22:42467013	NAGA	-0.59	-8.79	-0.48	1.92e-16	Cognitive function;
CESC	cis	rs2404602	0.692	rs57178708	chr15:76904069	T/C	cg26408565	chr15:76604113	ETFA	-0.4	-5.73	-0.33	2.68e-8	Blood metabolite levels;
CESC	cis	rs7666738	0.830	rs4699589	chr4:98973889	A/G	cg03467027	chr4:99064603	C4orf37	0.43	5.4	0.31	1.49e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs875971	0.660	rs6460308	chr7:66084740	T/C	cg25985355	chr7:65971099	NA	0.31	5.13	0.3	5.64e-7	Aortic root size;
CESC	cis	rs6088590	1.000	rs6120747	chr20:33449769	T/C	cg24642439	chr20:33292090	TP53INP2	0.86	11.97	0.59	1.12e-26	Coronary artery disease;
CESC	cis	rs597539	0.521	rs2060982	chr11:68612927	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.4	5.14	0.3	5.29e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs7520050	1.000	rs12143096	chr1:46469763	G/A	cg03146154	chr1:46216737	IPP	-0.46	-5.87	-0.34	1.31e-8	Red blood cell count;Reticulocyte count;
CESC	cis	rs6460942	0.915	rs7803056	chr7:12306913	A/C	cg20607287	chr7:12443886	VWDE	-0.49	-6.77	-0.38	8.08e-11	Coronary artery disease;
CESC	cis	rs597539	0.652	rs559032	chr11:68710847	G/T	cg04772025	chr11:68637568	NA	0.5	6.06	0.35	4.71e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs2985684	0.901	rs2354448	chr14:50098296	G/A	cg15316458	chr14:50087796	RPL36AL;MGAT2	0.45	5.15	0.3	4.99e-7	Carotid intima media thickness;
CESC	cis	rs7119	0.717	rs12898281	chr15:77786903	C/T	cg17802220	chr15:77601643	NA	0.49	6.77	0.38	8.28e-11	Type 2 diabetes;
CESC	cis	rs7666738	0.830	rs13112131	chr4:98976784	G/A	cg03676636	chr4:99064102	C4orf37	0.34	5.2	0.3	3.93e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2204008	0.548	rs2320740	chr12:38166421	G/A	cg26384229	chr12:38710491	ALG10B	0.72	10.46	0.54	1.18e-21	Bladder cancer;
CESC	cis	rs7160336	0.568	rs10146294	chr14:74681382	A/G	cg08255017	chr14:74727001	VSX2	-0.38	-5.53	-0.32	7.71e-8	Blood protein levels;
CESC	cis	rs9287719	0.934	rs10201077	chr2:10752426	A/C	cg02196655	chr2:10830764	NOL10	-0.37	-5.68	-0.33	3.54e-8	Prostate cancer;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg21656748	chr4:77135347	SCARB2	-0.47	-6.32	-0.36	1.12e-9	Asthma;
CESC	cis	rs559928	0.593	rs112275221	chr11:63936994	C/T	cg18225595	chr11:63971243	STIP1	0.74	6.28	0.36	1.39e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CESC	cis	rs2439831	0.867	rs935901	chr15:43651256	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.92	9.25	0.49	7.78e-18	Lung cancer in ever smokers;
CESC	cis	rs3087591	0.960	rs2905872	chr17:29525027	C/A	cg24425628	chr17:29625626	OMG;NF1	0.44	5.55	0.32	7.1e-8	Hip circumference;
CESC	trans	rs11098499	0.866	rs7677068	chr4:120291704	C/T	cg25214090	chr10:38739885	LOC399744	0.65	9.11	0.49	2.04e-17	Corneal astigmatism;
CESC	cis	rs9399401	0.710	rs10484733	chr6:142710988	C/G	cg03128060	chr6:142623767	GPR126	0.39	6.4	0.37	6.94e-10	Chronic obstructive pulmonary disease;
CESC	cis	rs1878931	0.545	rs28603	chr16:3449479	A/G	cg22508957	chr16:3507546	NAT15	0.5	6.52	0.37	3.55e-10	Body mass index (adult);
CESC	cis	rs4843747	0.636	rs11864872	chr16:88105966	A/G	cg17633681	chr16:88106987	BANP	0.76	10.42	0.54	1.55e-21	Menopause (age at onset);
CESC	cis	rs4835473	0.615	rs6857432	chr4:144893065	C/G	cg25736465	chr4:144833511	NA	0.39	5.97	0.34	7.43e-9	Immature fraction of reticulocytes;
CESC	cis	rs6747952	0.899	rs1374387	chr2:239085687	A/C	cg17459225	chr2:239074497	NA	0.33	5.34	0.31	1.96e-7	Mean corpuscular hemoglobin concentration;
CESC	cis	rs6558174	0.965	rs7831119	chr8:22489678	C/T	cg03733263	chr8:22462867	KIAA1967	-0.47	-6.34	-0.36	9.91e-10	Breast cancer;
CESC	cis	rs4919694	0.611	rs75182663	chr10:105058104	A/G	cg04362960	chr10:104952993	NT5C2	0.68	5.65	0.33	4.11e-8	Arsenic metabolism;
CESC	cis	rs78456975	0.943	rs13385274	chr2:1576791	A/T	cg26248373	chr2:1572462	NA	-0.52	-5.11	-0.3	6.08e-7	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs6120849	0.901	rs6088733	chr20:33744904	A/G	cg24642439	chr20:33292090	TP53INP2	0.58	6.27	0.36	1.49e-9	Protein C levels;
CESC	cis	rs7727544	0.660	rs274563	chr5:131717859	C/A	cg24060327	chr5:131705240	SLC22A5	0.63	8.45	0.46	1.99e-15	Blood metabolite levels;
CESC	cis	rs35306767	0.855	rs11253459	chr10:886402	C/T	cg26597838	chr10:835615	NA	0.86	9.04	0.49	3.46e-17	Eosinophil percentage of granulocytes;
CESC	cis	rs898097	0.801	rs68141193	chr17:80878816	C/T	cg10494973	chr17:80897199	TBCD	0.45	5.27	0.31	2.8e-7	Breast cancer;
CESC	cis	rs854765	0.533	rs2955354	chr17:17948716	G/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.62	-8.81	-0.48	1.7e-16	Total body bone mineral density;
CESC	cis	rs7666738	0.924	rs62318940	chr4:99064768	C/T	cg17366294	chr4:99064904	C4orf37	0.59	7.68	0.43	3.1400000000000003e-13	Colonoscopy-negative controls vs population controls;
CESC	cis	rs12926788	0.542	rs6497759	chr16:24801737	G/A	cg00339695	chr16:24857497	SLC5A11	0.5	6.53	0.37	3.25e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs7618915	0.501	rs10865974	chr3:52718280	A/C	cg18337363	chr3:52569053	NT5DC2	-0.29	-5.44	-0.32	1.23e-7	Bipolar disorder;
CESC	cis	rs6964587	0.626	rs34404183	chr7:91551249	T/C	cg17063962	chr7:91808500	NA	-0.45	-6.29	-0.36	1.29e-9	Breast cancer;
CESC	trans	rs9693444	0.898	rs4732697	chr8:29519861	A/G	cg02624704	chr1:173446429	PRDX6	-0.42	-6.5	-0.37	3.96e-10	Breast cancer;
CESC	cis	rs4906332	0.933	rs34606394	chr14:103915636	G/A	cg09975044	chr14:104007538	NA	0.47	6.53	0.37	3.32e-10	Coronary artery disease;
CESC	cis	rs1552244	0.515	rs67626468	chr3:10161518	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.68	-7.56	-0.42	6.59e-13	Alzheimer's disease;
CESC	cis	rs6460942	1.000	rs6970095	chr7:12403840	G/A	cg02935154	chr7:12443704	VWDE	-0.56	-6.1	-0.35	3.8e-9	Coronary artery disease;
CESC	cis	rs921968	0.643	rs537520	chr2:219381852	A/G	cg02176678	chr2:219576539	TTLL4	0.42	7.31	0.41	3.16e-12	Mean corpuscular hemoglobin concentration;
CESC	cis	rs753778	0.570	rs10875465	chr8:142210500	A/G	cg18755752	chr8:142205143	DENND3	-0.63	-9.24	-0.49	8.39e-18	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23214207	chr17:18476059	NA	-0.67	-7.92	-0.44	6.59e-14	Gut microbiome composition (summer);
CESC	cis	rs12422267	0.536	rs7976530	chr12:132609140	C/T	cg09764611	chr12:132620959	NA	-0.51	-6.61	-0.38	2.15e-10	Plasma amyloid beta peptide concentrations (ABx-40);
CESC	cis	rs9837602	0.507	rs1718244	chr3:99512608	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.49	-5.91	-0.34	1.02e-8	Breast cancer;
CESC	cis	rs6912958	0.712	rs4498321	chr6:88339251	G/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.32	-5.24	-0.31	3.32e-7	Monocyte percentage of white cells;
CESC	cis	rs4268898	0.662	rs72793967	chr2:24422902	C/T	cg08917208	chr2:24149416	ATAD2B	0.55	5.31	0.31	2.27e-7	Asthma;
CESC	cis	rs7833986	0.501	rs2953897	chr8:56980569	C/T	cg26371346	chr8:56986568	SNORD54;RPS20	0.57	5.16	0.3	4.9e-7	Height;
CESC	cis	rs4975709	0.589	rs931508	chr5:1861224	C/G	cg15595755	chr5:1867978	NA	0.51	8.4	0.46	2.68e-15	Cardiovascular disease risk factors;
CESC	cis	rs9910055	0.530	rs2269907	chr17:42294215	G/A	cg10896456	chr17:42255109	ASB16;C17orf65	0.34	5.03	0.3	8.93e-7	Total body bone mineral density;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg11080062	chr12:53615449	RARG	-0.42	-6.01	-0.35	5.99e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs7666738	0.830	rs28444709	chr4:99028496	A/T	cg03467027	chr4:99064603	C4orf37	0.49	6.18	0.35	2.44e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs898097	1.000	rs898098	chr17:80904564	G/A	cg15369054	chr17:80825471	TBCD	-0.44	-6.06	-0.35	4.76e-9	Breast cancer;
CESC	cis	rs9486719	0.857	rs4265039	chr6:96878929	T/C	cg06623918	chr6:96969491	KIAA0776	0.88	10.92	0.56	3.63e-23	Migraine;Coronary artery disease;
CESC	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.52	0.37	3.63e-10	Prudent dietary pattern;
CESC	cis	rs6598955	0.724	rs12068388	chr1:26621596	G/A	cg04990556	chr1:26633338	UBXN11	-0.74	-10.36	-0.54	2.51e-21	Obesity-related traits;
CESC	cis	rs7301826	0.651	rs12820597	chr12:131280185	T/C	cg11011512	chr12:131303247	STX2	-0.44	-5.3	-0.31	2.48e-7	Plasma plasminogen activator levels;
CESC	cis	rs2072510	0.593	rs2540499	chr12:96399869	A/C	cg09636302	chr12:96389483	HAL	0.42	5.1	0.3	6.34e-7	Metabolite levels (small molecules and protein measures);
CESC	cis	rs35306767	0.953	rs10904581	chr10:964685	A/T	cg26597838	chr10:835615	NA	0.79	9.43	0.5	2.18e-18	Eosinophil percentage of granulocytes;
CESC	cis	rs11098499	0.863	rs1480939	chr4:120456927	T/C	cg09307838	chr4:120376055	NA	0.91	12.54	0.61	1.24e-28	Corneal astigmatism;
CESC	cis	rs1048238	0.506	rs1262788	chr1:16215608	G/C	cg22431228	chr1:16359049	CLCNKA	0.37	6.56	0.37	2.75e-10	Systolic blood pressure;
CESC	cis	rs9911578	1.000	rs2531732	chr17:56548420	T/A	cg10487724	chr17:56770010	TEX14;RAD51C	-0.41	-5.41	-0.32	1.38e-7	Intelligence (multi-trait analysis);
CESC	cis	rs7219451	0.655	rs11869809	chr17:38961122	G/A	cg17985300	chr17:38952333	KRT28	-0.32	-5.38	-0.31	1.67e-7	Glucose homeostasis traits;
CESC	trans	rs17685	0.632	rs1859793	chr7:75821283	G/A	cg19862616	chr7:65841803	NCRNA00174	0.73	10.11	0.53	1.55e-20	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs6901004	0.803	rs405948	chr6:111540372	C/T	cg15721981	chr6:111408429	SLC16A10	-0.36	-5.29	-0.31	2.6e-7	Blood metabolite levels;
CESC	cis	rs8177253	0.829	rs6794945	chr3:133518463	A/G	cg11941060	chr3:133502564	NA	0.52	7.22	0.41	5.44e-12	Iron status biomarkers;
CESC	cis	rs4604732	0.536	rs4433437	chr1:247636580	A/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.62	8.19	0.45	1.11e-14	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs7633857	0.532	rs9839984	chr3:160768912	C/T	cg03342759	chr3:160939853	NMD3	-0.44	-5.85	-0.34	1.45e-8	Educational attainment (years of education);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13694824	chr11:111957265	TIMM8B;SDHD	0.54	6.02	0.35	5.91e-9	Gut microbiome composition (summer);
CESC	cis	rs947211	0.846	rs823155	chr1:205762946	T/C	cg17178900	chr1:205818956	PM20D1	0.42	5.57	0.32	6.18e-8	Parkinson's disease;
CESC	cis	rs10256972	0.521	rs7457418	chr7:1110255	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.45	-5.74	-0.33	2.62e-8	Longevity;Endometriosis;
CESC	cis	rs875971	0.964	rs60193905	chr7:65971260	A/G	cg10691866	chr7:65817282	TPST1	-0.34	-5.65	-0.33	4.21e-8	Aortic root size;
CESC	cis	rs7249142	0.549	rs12609573	chr19:19297567	C/T	cg27384695	chr19:19271486	LOC729991-MEF2B;MEF2B	-0.29	-5.37	-0.31	1.74e-7	IgG glycosylation;
CESC	cis	rs9611565	0.659	rs4822036	chr22:41936019	A/G	cg17376030	chr22:41985996	PMM1	0.68	7.52	0.42	8.57e-13	Vitiligo;
CESC	cis	rs1023500	0.552	rs5758566	chr22:42454354	G/A	cg15557168	chr22:42548783	NA	-0.45	-6.45	-0.37	5.4e-10	Schizophrenia;
CESC	cis	rs7666738	0.830	rs11935588	chr4:98979862	A/G	cg03467027	chr4:99064603	C4orf37	-0.42	-5.4	-0.31	1.48e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9443645	0.509	rs9352668	chr6:79572678	A/G	cg05283184	chr6:79620031	NA	-0.41	-6.16	-0.35	2.74e-9	Intelligence (multi-trait analysis);
CESC	cis	rs4919687	0.550	rs4264100	chr10:104454113	C/G	cg04362960	chr10:104952993	NT5C2	0.44	5.18	0.3	4.47e-7	Colorectal cancer;
CESC	cis	rs7412746	0.611	rs4970984	chr1:150887377	T/C	cg17724175	chr1:150552817	MCL1	0.33	5.08	0.3	7.16e-7	Melanoma;
CESC	cis	rs7914558	0.966	rs1591915	chr10:104646849	C/T	cg04362960	chr10:104952993	NT5C2	0.46	6.01	0.35	6.14e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs2290405	0.527	rs7663192	chr4:923947	T/C	cg04824913	chr4:887549	GAK	0.68	9.18	0.49	1.28e-17	Systemic sclerosis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11869233	chr2:48009809	MSH6	-0.55	-6.35	-0.36	9.48e-10	Gut microbiome composition (summer);
CESC	cis	rs10751667	0.666	rs7395402	chr11:950293	A/G	cg06064525	chr11:970664	AP2A2	0.48	9.49	0.5	1.46e-18	Alzheimer's disease (late onset);
CESC	trans	rs11039798	0.588	rs12284168	chr11:48555627	C/T	cg15704280	chr7:45808275	SEPT13	0.66	6.67	0.38	1.46e-10	Axial length;
CESC	cis	rs1448094	0.549	rs10863085	chr12:86236328	G/A	cg00310523	chr12:86230176	RASSF9	0.37	5.58	0.32	5.98e-8	Major depressive disorder;
CESC	cis	rs6963495	0.818	rs55740553	chr7:105159551	A/G	cg19920283	chr7:105172520	RINT1	0.69	6.56	0.37	2.85e-10	Bipolar disorder (body mass index interaction);
CESC	cis	rs12142240	0.698	rs12385696	chr1:46818836	A/G	cg00530320	chr1:46809349	NSUN4	0.57	7.8	0.43	1.39e-13	Menopause (age at onset);
CESC	cis	rs1707322	0.686	rs3014251	chr1:46077428	G/C	cg06784218	chr1:46089804	CCDC17	-0.43	-7.41	-0.41	1.7e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2976388	0.566	rs6998746	chr8:143802456	A/C	cg20862496	chr8:143823734	SLURP1	-0.34	-5.28	-0.31	2.65e-7	Urinary tract infection frequency;
CESC	cis	rs898097	0.625	rs2125479	chr17:80890262	A/G	cg19046167	chr17:80928561	B3GNTL1	-0.44	-5.57	-0.32	6.22e-8	Breast cancer;
CESC	cis	rs3733585	0.631	rs7699671	chr4:10125874	C/T	cg02734326	chr4:10020555	SLC2A9	-0.39	-5.38	-0.31	1.62e-7	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs881375	0.631	rs2416808	chr9:123706283	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.52	7.54	0.42	7.34e-13	Rheumatoid arthritis;
CESC	cis	rs9611565	0.921	rs8137373	chr22:41729216	A/G	cg06634786	chr22:41940651	POLR3H	0.61	6.59	0.38	2.32e-10	Vitiligo;
CESC	cis	rs10870270	1.000	rs10870232	chr10:133738537	T/G	cg17892150	chr10:133769511	PPP2R2D	-0.85	-12.62	-0.61	6.83e-29	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg20382057	chr2:69969052	ANXA4	-0.47	-5.99	-0.35	6.66e-9	Ulcerative colitis;
CESC	cis	rs2486288	0.656	rs11632778	chr15:45551056	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.54	-6.55	-0.37	3.03e-10	Glomerular filtration rate;
CESC	cis	rs6674176	0.542	rs803675	chr1:44353237	G/A	cg13606994	chr1:44402422	ARTN	-0.37	-5.18	-0.3	4.38e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs7089973	0.872	rs7909566	chr10:116629136	A/G	cg23260525	chr10:116636907	FAM160B1	0.38	6.42	0.37	6.35e-10	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs74225573	1	rs74225573	chr1:11280994	T/C	cg18435880	chr1:11160013	EXOSC10	0.97	6.61	0.38	2.08e-10	Corneal curvature;
CESC	cis	rs477895	1.000	rs2286614	chr11:64068310	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.76	6.61	0.38	2.05e-10	Mean platelet volume;
CESC	cis	rs1862618	0.671	rs2255726	chr5:56243128	T/C	cg24531977	chr5:56204891	C5orf35	0.69	9.31	0.5	5.13e-18	Initial pursuit acceleration;
CESC	cis	rs10504229	1.000	rs66479724	chr8:58188309	T/G	cg24829409	chr8:58192753	C8orf71	-0.78	-10.18	-0.53	9.38e-21	Developmental language disorder (linguistic errors);
CESC	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	20.43	0.78	2.3e-56	Prudent dietary pattern;
CESC	cis	rs875971	0.964	rs697969	chr7:65558478	C/A	cg25985355	chr7:65971099	NA	0.31	5.06	0.3	7.77e-7	Aortic root size;
CESC	cis	rs798554	0.836	rs798500	chr7:2790685	C/T	cg09658497	chr7:2847517	GNA12	0.4	5.65	0.33	4.06e-8	Height;
CESC	cis	rs9487051	0.676	rs2222392	chr6:109602303	T/C	cg01475377	chr6:109611718	NA	-0.45	-7.08	-0.4	1.3e-11	Reticulocyte fraction of red cells;
CESC	cis	rs1348850	0.526	rs2141157	chr2:178374112	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.68	6.17	0.35	2.52e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs8017423	0.935	rs11624890	chr14:90738165	T/A	cg14092571	chr14:90743983	NA	0.56	8.62	0.47	6.32e-16	Mortality in heart failure;
CESC	cis	rs9733	0.544	rs72700902	chr1:150633347	C/T	cg09365446	chr1:150670422	GOLPH3L	0.41	5.82	0.34	1.7e-8	Tonsillectomy;
CESC	cis	rs9291683	0.530	rs6449196	chr4:9973660	C/T	cg00071950	chr4:10020882	SLC2A9	-0.78	-14.51	-0.67	1.64e-35	Bone mineral density;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27555392	chr1:16679092	FBXO42	0.59	6.72	0.38	1.1e-10	Gut microbiome composition (summer);
CESC	cis	rs798766	1.000	rs2236786	chr4:1719294	T/C	cg10756475	chr4:1757242	NA	-0.51	-6.03	-0.35	5.53e-9	Bladder cancer;Urinary bladder cancer;
CESC	cis	rs116095464	0.558	rs28636067	chr5:199415	G/A	cg16372103	chr5:203701	NA	0.49	5.3	0.31	2.43e-7	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25954914	chr2:54785183	SPTBN1	0.61	6.95	0.39	2.9e-11	Gut microbiome composition (summer);
CESC	cis	rs10256972	0.528	rs7784607	chr7:1178694	A/G	cg04025307	chr7:1156635	C7orf50	0.59	10.22	0.53	7.13e-21	Longevity;Endometriosis;
CESC	cis	rs1448094	0.512	rs10779216	chr12:86240315	A/G	cg19622623	chr12:86230825	RASSF9	0.46	5.93	0.34	9.2e-9	Major depressive disorder;
CESC	cis	rs11601602	0.576	rs4075635	chr11:28511643	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.67	8.21	0.45	9.97e-15	Obesity-related traits;
CESC	cis	rs1355223	0.525	rs7129517	chr11:34872236	A/C	cg11058730	chr11:34937778	PDHX;APIP	-0.54	-6.57	-0.37	2.66e-10	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs10754283	0.967	rs6428562	chr1:90102665	G/A	cg21401794	chr1:90099060	LRRC8C	0.7	9.42	0.5	2.35e-18	Amyotrophic lateral sclerosis (sporadic);
CESC	trans	rs7395662	0.591	rs4882233	chr11:48739653	A/G	cg00717180	chr2:96193071	NA	-0.45	-6.11	-0.35	3.51e-9	HDL cholesterol;
CESC	cis	rs7772486	0.790	rs2814879	chr6:146201743	T/C	cg05347473	chr6:146136440	FBXO30	0.55	7.26	0.41	4.4e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1729951	0.575	rs361245	chr3:136695706	A/G	cg15507776	chr3:136538369	TMEM22	0.41	5.19	0.3	4.2e-7	Neuroticism;
CESC	cis	rs16854884	0.580	rs34924831	chr3:143863020	A/G	cg06585982	chr3:143692056	C3orf58	0.43	5.5	0.32	8.85e-8	Economic and political preferences (feminism/equality);
CESC	cis	rs1707322	1.000	rs4074225	chr1:46392364	G/C	cg03146154	chr1:46216737	IPP	0.78	10.77	0.55	1.17e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs17685	0.712	rs60232511	chr7:75800082	A/G	cg19862616	chr7:65841803	NCRNA00174	0.86	12.2	0.6	1.87e-27	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs10504229	0.871	rs10504226	chr8:58159283	A/G	cg05313129	chr8:58192883	C8orf71	-0.43	-5.03	-0.3	8.84e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs7666738	0.830	rs28456179	chr4:98991439	A/G	cg05340658	chr4:99064831	C4orf37	0.81	12.5	0.61	1.75e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6964587	0.626	rs10234074	chr7:91520119	C/T	cg17063962	chr7:91808500	NA	-0.46	-6.48	-0.37	4.53e-10	Breast cancer;
CESC	cis	rs7605378	0.688	rs769961	chr2:200712141	C/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.47	5.34	0.31	2.04e-7	Osteoporosis;
CESC	cis	rs12701220	0.894	rs12701348	chr7:1039457	C/T	cg26769984	chr7:1090371	C7orf50	0.6	6.83	0.39	5.8e-11	Bronchopulmonary dysplasia;
CESC	cis	rs34779708	0.966	rs4934735	chr10:35496730	C/T	cg03585969	chr10:35415529	CREM	-0.75	-9.78	-0.51	1.8e-19	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs7552404	0.590	rs1565717	chr1:76320441	T/C	cg10523679	chr1:76189770	ACADM	-0.65	-6.63	-0.38	1.85e-10	Blood metabolite levels;Acylcarnitine levels;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg07940793	chr17:79603854	NPLOC4	-0.45	-6.57	-0.37	2.67e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs2836974	0.931	rs12151994	chr21:40690397	A/C	cg17971929	chr21:40555470	PSMG1	1.03	15.1	0.68	1.31e-37	Cognitive function;
CESC	cis	rs1799949	0.501	rs9675035	chr17:41415016	A/T	cg25072359	chr17:41440525	NA	0.47	6.36	0.36	8.86e-10	Menopause (age at onset);
CESC	cis	rs7208859	0.524	rs57670615	chr17:29069498	A/G	cg14008862	chr17:28927542	LRRC37B2	0.65	5.14	0.3	5.34e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs769267	0.896	rs2074298	chr19:19377716	C/G	cg03709012	chr19:19516395	GATAD2A	0.95	13.82	0.65	4.52e-33	Tonsillectomy;
CESC	cis	rs7618915	0.547	rs4130905	chr3:52709831	A/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	5.6	0.33	5.42e-8	Bipolar disorder;
CESC	cis	rs7618915	0.570	rs11130312	chr3:52675055	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.48	6.96	0.39	2.64e-11	Bipolar disorder;
CESC	cis	rs4819052	0.851	rs2330012	chr21:46658592	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.75	9.98	0.52	4.1e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs11098499	0.954	rs6848389	chr4:120402622	A/G	cg24375607	chr4:120327624	NA	0.46	5.69	0.33	3.36e-8	Corneal astigmatism;
CESC	cis	rs12983728	0.831	rs35081008	chr19:58662235	C/T	cg24884572	chr19:58661833	ZNF329	0.58	5.19	0.3	4.16e-7	Cholesterol, total;
CESC	cis	rs10504229	0.595	rs116490935	chr8:58117531	A/G	cg24829409	chr8:58192753	C8orf71	-0.58	-7.21	-0.41	5.76e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs7618915	0.501	rs34739010	chr3:52766122	A/G	cg07507251	chr3:52567010	NT5DC2	0.33	5.67	0.33	3.64e-8	Bipolar disorder;
CESC	cis	rs11098499	0.644	rs10012252	chr4:120559139	T/C	cg09307838	chr4:120376055	NA	0.75	9.97	0.52	4.4e-20	Corneal astigmatism;
CESC	cis	rs9300255	0.602	rs4372492	chr12:123697357	T/C	cg00376283	chr12:123451042	ABCB9	0.7	8.83	0.48	1.41e-16	Neutrophil percentage of white cells;
CESC	cis	rs7116495	0.609	rs12275171	chr11:71835373	C/T	cg07596299	chr11:71824057	C11orf51	0.79	5.03	0.3	9.07e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs2073300	0.609	rs6137937	chr20:23385419	G/A	cg12062639	chr20:23401060	NAPB	1.07	8.85	0.48	1.29e-16	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs1707322	0.721	rs10789471	chr1:46215619	G/A	cg06784218	chr1:46089804	CCDC17	0.41	7.21	0.41	5.75e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs734999	0.549	rs2764845	chr1:2528999	G/T	cg18854424	chr1:2615690	NA	-0.27	-5.46	-0.32	1.12e-7	Ulcerative colitis;
CESC	trans	rs6138458	0.828	rs6132785	chr20:24993414	T/C	cg13316061	chr18:47798969	MBD1	0.44	6.04	0.35	5.07e-9	Blood protein levels;
CESC	trans	rs11098499	0.774	rs11098505	chr4:120284627	C/T	cg25214090	chr10:38739885	LOC399744	0.65	9.11	0.49	2.04e-17	Corneal astigmatism;
CESC	cis	rs11608355	0.618	rs11066368	chr12:109790342	C/T	cg19025524	chr12:109796872	NA	-0.51	-7.44	-0.42	1.38e-12	Neuroticism;
CESC	cis	rs9341808	0.600	rs2505930	chr6:80837058	A/G	cg08355045	chr6:80787529	NA	0.34	5.04	0.3	8.52e-7	Sitting height ratio;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05062679	chr10:94000186	CPEB3	-0.53	-6.0	-0.35	6.57e-9	Gut microbiome composition (summer);
CESC	cis	rs7927771	0.839	rs3817334	chr11:47650993	C/T	cg18512352	chr11:47633146	NA	-0.43	-6.56	-0.37	2.82e-10	Subjective well-being;
CESC	cis	rs6088580	0.602	rs6059840	chr20:33030405	G/A	cg24642439	chr20:33292090	TP53INP2	0.52	6.8	0.39	7.08e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs4727027	0.933	rs1058059	chr7:148879134	A/T	cg23583168	chr7:148888333	NA	-0.82	-12.55	-0.61	1.15e-28	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs6088580	0.634	rs2378134	chr20:32938085	C/T	cg08999081	chr20:33150536	PIGU	-0.64	-11.0	-0.56	2.0500000000000001e-23	Glomerular filtration rate (creatinine);
CESC	cis	rs9911578	0.967	rs4076229	chr17:56937256	C/T	cg12560992	chr17:57184187	TRIM37	0.94	15.75	0.7	6.57e-40	Intelligence (multi-trait analysis);
CESC	cis	rs7666738	0.830	rs11726604	chr4:99000969	T/C	cg03467027	chr4:99064603	C4orf37	0.44	5.51	0.32	8.65e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs736408	0.812	rs1076425	chr3:52825462	A/G	cg17372223	chr3:52568218	NT5DC2	0.4	5.58	0.32	5.95e-8	Bipolar disorder;
CESC	trans	rs62103177	0.673	rs7242867	chr18:77603270	A/T	cg05926928	chr17:57297772	GDPD1	0.75	7.99	0.44	4.26e-14	Opioid sensitivity;
CESC	cis	rs67311347	0.955	rs4974067	chr3:40374551	C/T	cg09455208	chr3:40491958	NA	0.49	8.73	0.47	2.86e-16	Renal cell carcinoma;
CESC	cis	rs77106637	0.932	rs7109082	chr11:72707441	A/C	cg04827223	chr11:72435913	ARAP1	-0.5	-5.37	-0.31	1.69e-7	Type 2 diabetes;
CESC	cis	rs546131	0.928	rs547504	chr11:34847225	G/T	cg06937548	chr11:34938143	PDHX;APIP	0.48	5.85	0.34	1.46e-8	Lung disease severity in cystic fibrosis;
CESC	cis	rs8133932	0.690	rs432338	chr21:47347757	C/T	cg14185626	chr21:47401492	COL6A1	-0.48	-5.33	-0.31	2.07e-7	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	ch.7.2254086F	chr7:105135578	PUS7	-0.57	-6.63	-0.38	1.87e-10	Gut microbiome composition (summer);
CESC	cis	rs11792861	0.591	rs4978763	chr9:111728067	C/T	cg13535736	chr9:111863775	C9orf5	-0.39	-5.64	-0.33	4.25e-8	Menarche (age at onset);
CESC	cis	rs7412746	0.611	rs11204747	chr1:150927152	A/G	cg22823121	chr1:150693482	HORMAD1	-0.38	-5.48	-0.32	9.81e-8	Melanoma;
CESC	cis	rs3931020	0.508	rs4145871	chr1:75218704	C/T	cg26855724	chr1:75198818	TYW3;CRYZ	0.44	5.17	0.3	4.69e-7	Resistin levels;
CESC	cis	rs5769765	0.955	rs7511159	chr22:50307896	A/G	cg02269571	chr22:50332266	NA	-0.5	-6.51	-0.37	3.79e-10	Schizophrenia;
CESC	cis	rs3008870	1.000	rs3008859	chr1:67390999	G/C	cg02640540	chr1:67518911	SLC35D1	0.49	5.29	0.31	2.6e-7	Lymphocyte percentage of white cells;
CESC	cis	rs832540	0.931	rs1466008	chr5:56213406	G/C	cg24531977	chr5:56204891	C5orf35	-0.44	-5.56	-0.32	6.56e-8	Coronary artery disease;
CESC	cis	rs6540559	1.000	rs17015259	chr1:209982923	G/A	cg21951975	chr1:209979733	IRF6	0.6	9.51	0.5	1.18e-18	Cleft lip with or without cleft palate;
CESC	trans	rs853679	0.882	rs9380064	chr6:28143118	A/G	cg06606381	chr12:133084897	FBRSL1	-0.66	-6.19	-0.36	2.24e-9	Depression;
CESC	cis	rs7666738	0.830	rs13138063	chr4:99050438	A/C	cg17366294	chr4:99064904	C4orf37	0.61	8.68	0.47	4.24e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs116095464	0.558	rs13356367	chr5:242395	C/T	cg20965017	chr5:231967	SDHA	-0.47	-5.38	-0.31	1.65e-7	Breast cancer;
CESC	cis	rs2933343	0.729	rs1680781	chr3:128612830	C/A	cg24203234	chr3:128598194	ACAD9	0.4	5.21	0.3	3.78e-7	IgG glycosylation;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25416230	chr7:148921410	ZNF282	-0.53	-6.14	-0.35	2.98e-9	Gut microbiome composition (summer);
CESC	cis	rs7520050	0.933	rs12565042	chr1:46299110	C/A	cg24296786	chr1:45957014	TESK2	0.42	5.42	0.32	1.33e-7	Red blood cell count;Reticulocyte count;
CESC	cis	rs10504229	0.683	rs56192850	chr8:58135356	A/G	cg21724239	chr8:58056113	NA	0.58	5.95	0.34	8.29e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs10504229	0.724	rs73603871	chr8:58107612	A/G	cg22535103	chr8:58192502	C8orf71	-0.77	-8.76	-0.47	2.37e-16	Developmental language disorder (linguistic errors);
CESC	cis	rs853679	0.517	rs868987	chr6:28110148	A/G	cg17949981	chr6:28129498	ZNF389	-0.47	-5.79	-0.33	2.03e-8	Depression;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05725452	chr22:21996709	SDF2L1	-0.56	-6.63	-0.38	1.92e-10	Gut microbiome composition (summer);
CESC	cis	rs2637266	0.678	rs1074181	chr10:78463486	C/T	cg18941641	chr10:78392320	NA	0.38	6.85	0.39	5.13e-11	Pulmonary function;
CESC	cis	rs2549003	1.000	rs2070726	chr5:131821738	C/A	cg21138405	chr5:131827807	IRF1	0.54	9.32	0.5	4.74e-18	Asthma (sex interaction);
CESC	cis	rs75920871	0.589	rs73008568	chr11:117065007	C/G	cg01368799	chr11:117014884	PAFAH1B2	-0.76	-5.59	-0.32	5.54e-8	Subjective well-being;
CESC	cis	rs9611565	0.694	rs202637	chr22:41853928	A/G	cg06634786	chr22:41940651	POLR3H	0.69	6.82	0.39	6.19e-11	Vitiligo;
CESC	trans	rs2963826	0.589	rs298091	chr5:58996603	A/T	cg13108601	chr6:41748242	FRS3;PRICKLE4	0.48	6.15	0.35	2.85e-9	Obesity-related traits;
CESC	cis	rs9911578	1.000	rs1494977	chr17:56863064	C/T	cg05425664	chr17:57184151	TRIM37	-0.48	-6.55	-0.37	3.03e-10	Intelligence (multi-trait analysis);
CESC	cis	rs7662987	1.000	rs13146416	chr4:99999160	T/C	cg13256891	chr4:100009986	ADH5	-0.83	-6.06	-0.35	4.63e-9	Smoking initiation;
CESC	cis	rs1472360	0.505	rs1496526	chr8:86273899	G/A	cg21346043	chr8:86351067	CA3	-0.4	-5.61	-0.33	5.15e-8	Mean corpuscular hemoglobin concentration;
CESC	cis	rs801193	0.548	rs6975044	chr7:66227482	C/T	cg18876405	chr7:65276391	NA	0.47	6.34	0.36	9.84e-10	Aortic root size;
CESC	cis	rs1552244	1.000	rs6804473	chr3:10060425	C/T	cg08888203	chr3:10149979	C3orf24	0.5	6.33	0.36	1.05e-9	Alzheimer's disease;
CESC	cis	rs4803468	0.967	rs1077856	chr19:41885221	T/C	cg09537434	chr19:41945824	ATP5SL	-1.02	-18.01	-0.74	6.8e-48	Height;
CESC	cis	rs3796619	0.961	rs62294748	chr4:1082999	G/A	cg27284194	chr4:1044797	NA	0.37	5.57	0.32	6.24e-8	Recombination rate (males);
CESC	cis	rs9875589	0.509	rs1873005	chr3:14060223	G/A	cg19554555	chr3:13937349	NA	-0.44	-5.6	-0.33	5.43e-8	Ovarian reserve;
CESC	cis	rs8060686	0.546	rs8047343	chr16:68143745	G/A	cg26727032	chr16:67993705	SLC12A4	-0.6	-8.89	-0.48	9.96e-17	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs1707322	0.686	rs2991977	chr1:46053683	G/A	cg06784218	chr1:46089804	CCDC17	-0.43	-7.47	-0.42	1.19e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs1775715	0.737	rs2799017	chr10:32203460	A/G	cg18675610	chr10:32216311	ARHGAP12	0.35	5.34	0.31	1.99e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs9549367	0.577	rs513479	chr13:113815200	C/T	cg00898013	chr13:113819073	PROZ	-0.53	-6.45	-0.37	5.37e-10	Platelet distribution width;
CESC	trans	rs116095464	0.558	rs62346508	chr5:203668	T/C	cg00938859	chr5:1591904	SDHAP3	0.66	6.25	0.36	1.66e-9	Breast cancer;
CESC	cis	rs4242434	0.927	rs11136092	chr8:22466488	T/G	cg03733263	chr8:22462867	KIAA1967	0.97	14.04	0.65	7.58e-34	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CESC	cis	rs6665290	0.904	rs10495273	chr1:227183359	T/G	cg10327440	chr1:227177885	CDC42BPA	-1.22	-34.87	-0.91	5.17e-101	Myeloid white cell count;
CESC	cis	rs11048434	0.666	rs12371786	chr12:9090086	G/A	cg23795048	chr12:9217529	LOC144571	0.38	5.89	0.34	1.18e-8	Sjögren's syndrome;
CESC	cis	rs12476592	0.571	rs68183503	chr2:63802888	C/T	cg17519650	chr2:63277830	OTX1	-0.48	-5.42	-0.32	1.34e-7	Childhood ear infection;
CESC	cis	rs1552244	0.882	rs68153882	chr3:10013110	T/C	cg08888203	chr3:10149979	C3orf24	0.48	5.96	0.34	7.91e-9	Alzheimer's disease;
CESC	cis	rs7726839	0.578	rs10080150	chr5:593160	C/T	cg16447950	chr5:562315	NA	0.52	7.52	0.42	8.68e-13	Obesity-related traits;
CESC	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg09177884	chr7:1199841	ZFAND2A	-0.54	-6.08	-0.35	4.25e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg25219047	chr19:3500813	DOHH	-0.46	-6.63	-0.38	1.87e-10	Gambling;
CESC	trans	rs1814175	0.754	rs28663627	chr11:50048829	C/T	cg03929089	chr4:120376271	NA	-0.95	-16.28	-0.71	9.18e-42	Height;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg09060823	chr12:56862504	SPRYD4	0.56	7.35	0.41	2.44e-12	Gut microbiota (bacterial taxa);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22349489	chr6:27114943	HIST1H2BK;HIST1H2AH	-0.62	-7.27	-0.41	4.02e-12	Gut microbiome composition (summer);
CESC	cis	rs10504229	0.953	rs72650891	chr8:58179697	T/G	cg14926445	chr8:58193284	C8orf71	-0.51	-5.47	-0.32	1.03e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs7267979	0.966	rs2424715	chr20:25420077	A/G	cg08601574	chr20:25228251	PYGB	0.38	5.64	0.33	4.32e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs9611565	0.559	rs12483860	chr22:41961916	C/T	cg03806693	chr22:41940476	POLR3H	-0.97	-12.07	-0.6	4.96e-27	Vitiligo;
CESC	cis	rs13191362	0.935	rs7763118	chr6:162954720	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.75	7.65	0.43	3.73e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs853679	0.517	rs1947863	chr6:28099344	G/A	cg19592336	chr6:28129416	ZNF389	0.61	8.24	0.45	8.13e-15	Depression;
CESC	cis	rs7909074	1.000	rs7079573	chr10:45400406	G/A	cg05187965	chr10:45406764	TMEM72	-0.33	-5.06	-0.3	7.94e-7	Mean corpuscular volume;
CESC	cis	rs4664308	1.000	rs6719686	chr2:160908292	T/G	cg03641300	chr2:160917029	PLA2R1	-0.67	-10.16	-0.53	1.08e-20	Idiopathic membranous nephropathy;
CESC	cis	rs11098499	0.954	rs71629403	chr4:120372567	C/T	cg09307838	chr4:120376055	NA	0.92	12.77	0.62	2.08e-29	Corneal astigmatism;
CESC	cis	rs35740288	0.571	rs11631009	chr15:86318653	G/A	cg20737812	chr15:86336631	KLHL25	-0.46	-5.41	-0.32	1.38e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
CESC	cis	rs2380220	0.808	rs2716074	chr6:95907662	T/C	cg15832292	chr6:96025679	MANEA	-0.65	-5.95	-0.34	8.46e-9	Behavioural disinhibition (generation interaction);
CESC	cis	rs9329289	0.632	rs2452187	chr10:2551147	C/G	cg18171855	chr10:2543474	NA	0.37	5.49	0.32	9.53e-8	Age-related hearing impairment;
CESC	cis	rs9322193	0.923	rs1080670	chr6:149941297	C/G	cg13206674	chr6:150067644	NUP43	0.43	6.27	0.36	1.44e-9	Lung cancer;
CESC	cis	rs7208859	0.573	rs7222803	chr17:29119897	A/G	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.79e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs1552244	1.000	rs6804473	chr3:10060425	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.89	11.97	0.59	1.14e-26	Alzheimer's disease;
CESC	cis	rs7927592	0.956	rs11228251	chr11:68244558	G/T	cg01657329	chr11:68192670	LRP5	-0.4	-5.18	-0.3	4.46e-7	Total body bone mineral density;
CESC	cis	rs367943	0.712	rs13359330	chr5:112708529	T/C	cg12552261	chr5:112820674	MCC	0.4	5.29	0.31	2.55e-7	Type 2 diabetes;
CESC	cis	rs6693567	0.565	rs7544900	chr1:150262333	A/C	cg09579323	chr1:150459698	TARS2	-0.46	-5.74	-0.33	2.58e-8	Migraine;
CESC	cis	rs875971	0.964	rs2277911	chr7:65958625	T/G	cg11764359	chr7:65958608	NA	0.96	15.06	0.68	1.89e-37	Aortic root size;
CESC	cis	rs1862618	0.853	rs33325	chr5:56142547	G/C	cg03609598	chr5:56110824	MAP3K1	-0.51	-5.54	-0.32	7.13e-8	Initial pursuit acceleration;
CESC	cis	rs4523957	0.890	rs216191	chr17:2188639	C/T	cg16513277	chr17:2031491	SMG6	0.6	8.11	0.45	1.95e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs600231	0.706	rs3782091	chr11:65336483	G/T	cg17120908	chr11:65337727	SSSCA1	0.53	5.91	0.34	1.07e-8	Bone mineral density;
CESC	cis	rs710216	0.843	rs844501	chr1:43440783	G/A	cg03128534	chr1:43423976	SLC2A1	0.49	5.41	0.32	1.38e-7	Red cell distribution width;
CESC	trans	rs11098499	0.863	rs6858777	chr4:120475966	A/G	cg25214090	chr10:38739885	LOC399744	0.66	9.03	0.49	3.57e-17	Corneal astigmatism;
CESC	cis	rs644799	1.000	rs505220	chr11:95563228	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	9.15	0.49	1.57e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs1568889	1.000	rs61889026	chr11:28274803	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.71	8.36	0.46	3.6e-15	Bipolar disorder;
CESC	cis	rs854765	0.583	rs9904163	chr17:17830553	C/T	cg16928487	chr17:17741425	SREBF1	-0.57	-9.74	-0.51	2.41e-19	Total body bone mineral density;
CESC	cis	rs2342371	0.527	rs7643192	chr3:196210590	A/G	cg15048948	chr3:196158458	UBXN7	-0.4	-5.57	-0.32	6.36e-8	Fat distribution (HIV);
CESC	cis	rs4853012	0.838	rs4452177	chr2:74345206	A/G	cg05776053	chr2:74358815	NA	0.4	5.07	0.3	7.39e-7	Gestational age at birth (maternal effect);
CESC	cis	rs1348850	0.519	rs1544002	chr2:178529534	C/T	cg23306229	chr2:178417860	TTC30B	0.46	5.29	0.31	2.6e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs10463316	0.894	rs7710277	chr5:150767405	T/C	cg03212797	chr5:150827313	SLC36A1	-0.47	-6.2	-0.36	2.17e-9	Metabolite levels (Pyroglutamine);
CESC	cis	rs7615952	0.641	rs7632497	chr3:125783086	A/C	cg04553112	chr3:125709451	NA	-0.53	-5.69	-0.33	3.27e-8	Blood pressure (smoking interaction);
CESC	cis	rs7845219	0.544	rs7015841	chr8:95920193	A/C	cg23172400	chr8:95962367	TP53INP1	-0.38	-7.08	-0.4	1.3e-11	Type 2 diabetes;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg18266620	chr1:110882148	RBM15	-0.48	-6.08	-0.35	4.08e-9	Fibrinogen levels;
CESC	cis	rs9814567	0.806	rs4074522	chr3:134325626	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.4	5.25	0.31	3.19e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs12136530	0.651	rs10753561	chr1:19711939	T/C	cg01832549	chr1:19774989	CAPZB	-0.36	-5.33	-0.31	2.08e-7	Lead levels in blood;
CESC	trans	rs11115322	1.000	rs11115323	chr12:83019495	C/T	cg10309835	chr19:48894715	KDELR1	-0.92	-6.03	-0.35	5.36e-9	Immune response to smallpox vaccine (IL-6);
CESC	cis	rs10751667	0.643	rs10902238	chr11:944810	G/A	cg20946044	chr11:1010712	AP2A2	-0.4	-5.54	-0.32	7.24e-8	Alzheimer's disease (late onset);
CESC	cis	rs736408	0.736	rs4687550	chr3:52823430	T/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.39	5.15	0.3	5.1e-7	Bipolar disorder;
CESC	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg04025307	chr7:1156635	C7orf50	0.41	5.32	0.31	2.23e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs9858542	1.000	rs9836291	chr3:49697459	G/A	cg07274523	chr3:49395745	GPX1	0.68	8.72	0.47	3.1e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs4555082	0.830	rs2255575	chr14:105727251	T/C	cg27165867	chr14:105738592	BRF1	-0.56	-6.26	-0.36	1.51e-9	Mean platelet volume;Platelet distribution width;
CESC	cis	rs9910055	1.000	rs2071167	chr17:42287519	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	-0.39	-5.3	-0.31	2.38e-7	Total body bone mineral density;
CESC	cis	rs4555082	1.000	rs7146683	chr14:105759385	A/G	cg10792982	chr14:105748885	BRF1	0.37	5.08	0.3	7.25e-7	Mean platelet volume;Platelet distribution width;
CESC	cis	rs7666738	0.784	rs4699602	chr4:99034903	T/C	cg03676636	chr4:99064102	C4orf37	0.35	5.26	0.31	3.02e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7927771	0.832	rs6485753	chr11:47410200	C/T	cg25783544	chr11:47291846	MADD	0.45	5.19	0.3	4.12e-7	Subjective well-being;
CESC	cis	rs2839186	0.588	rs7280110	chr21:47619039	G/A	cg00815214	chr21:47717953	NA	0.43	6.27	0.36	1.49e-9	Testicular germ cell tumor;
CESC	cis	rs1862618	0.853	rs1423621	chr5:56101035	G/T	cg18230493	chr5:56204884	C5orf35	-0.67	-8.26	-0.45	7.07e-15	Initial pursuit acceleration;
CESC	cis	rs12118280	0.512	rs7418288	chr1:108754099	G/A	cg11967332	chr1:108735228	SLC25A24	0.65	6.56	0.37	2.76e-10	Myeloid white cell count;
CESC	cis	rs7666738	0.830	rs62321565	chr4:98976571	G/A	cg03676636	chr4:99064102	C4orf37	0.33	5.12	0.3	5.91e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs8060686	0.545	rs12598630	chr16:68258852	T/G	cg26727032	chr16:67993705	SLC12A4	-0.48	-5.18	-0.3	4.5e-7	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg07157834	chr1:205819609	PM20D1	0.76	12.05	0.59	5.9e-27	Menarche (age at onset);
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg02004021	chr12:95868393	METAP2	-0.49	-6.42	-0.37	6.12e-10	Height;
CESC	cis	rs7811142	0.830	rs11761426	chr7:99956893	A/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.72	6.41	0.37	6.71e-10	Platelet count;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg07661849	chr4:146686236	ZNF827	0.44	6.13	0.35	3.16e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs8072100	0.811	rs9889709	chr17:45445229	C/T	cg08085267	chr17:45401833	C17orf57	-0.56	-7.4	-0.41	1.81e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs7100689	0.753	rs4934125	chr10:82147466	T/C	cg00277334	chr10:82204260	NA	-0.6	-7.5	-0.42	9.66e-13	Post bronchodilator FEV1;
CESC	cis	rs13242816	0.892	rs34645128	chr7:116078382	T/A	cg04696780	chr7:116139425	CAV2	-0.65	-5.7	-0.33	3.2e-8	P wave duration;
CESC	cis	rs4319547	1.000	rs4319547	chr12:123079035	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.59	-6.81	-0.39	6.63e-11	Body mass index;
CESC	cis	rs7216064	0.953	rs12450907	chr17:65870644	T/G	cg12091567	chr17:66097778	LOC651250	-0.85	-8.7	-0.47	3.61e-16	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs113835537	0.529	rs3892818	chr11:66240191	C/T	cg24851651	chr11:66362959	CCS	0.45	5.9	0.34	1.1e-8	Airway imaging phenotypes;
CESC	cis	rs7666738	0.830	rs34244876	chr4:99031336	G/A	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.58e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg25195416	chr21:46696626	POFUT2	0.57	7.65	0.43	3.67e-13	Fibrinogen levels;
CESC	cis	rs1799949	1.000	rs4793189	chr17:41190715	G/A	cg05368731	chr17:41323189	NBR1	0.8	10.68	0.55	2.29e-22	Menopause (age at onset);
CESC	trans	rs9858542	1.000	rs34762726	chr3:49689210	G/A	cg21659725	chr3:3221576	CRBN	-0.53	-6.49	-0.37	4.09e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs4862750	0.872	rs13101408	chr4:187894777	G/A	cg22105103	chr4:187893119	NA	0.51	7.33	0.41	2.79e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4132509	0.779	rs6656918	chr1:243706224	G/A	cg21452805	chr1:244014465	NA	-0.43	-5.31	-0.31	2.33e-7	RR interval (heart rate);
CESC	trans	rs7618501	1.000	rs7372730	chr3:49790682	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.59	-8.4	-0.46	2.72e-15	Intelligence (multi-trait analysis);
CESC	cis	rs2075371	0.865	rs2544172	chr7:133931338	T/C	cg20476274	chr7:133979776	SLC35B4	0.67	9.82	0.52	1.31e-19	Mean platelet volume;
CESC	cis	rs4970966	1.000	rs4970966	chr1:150584103	A/C	cg13175981	chr1:150552382	MCL1	-0.53	-5.89	-0.34	1.15e-8	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs72781680	0.752	rs55801864	chr2:23922325	C/T	cg08917208	chr2:24149416	ATAD2B	1.12	10.1	0.53	1.66e-20	Lymphocyte counts;
CESC	cis	rs6032067	0.929	rs2233898	chr20:43850525	A/G	cg10761708	chr20:43804764	PI3	0.52	6.22	0.36	1.92e-9	Blood protein levels;
CESC	cis	rs8180040	0.620	rs4683322	chr3:47093189	T/C	cg27129171	chr3:47204927	SETD2	0.67	9.83	0.52	1.18e-19	Colorectal cancer;
CESC	cis	rs6121246	0.567	rs6060295	chr20:30198473	C/T	cg13852791	chr20:30311386	BCL2L1	0.58	5.47	0.32	1.03e-7	Mean corpuscular hemoglobin;
CESC	cis	rs6964587	0.626	rs7807765	chr7:91531974	C/A	cg17063962	chr7:91808500	NA	-0.45	-6.39	-0.37	7.49e-10	Breast cancer;
CESC	cis	rs898097	0.841	rs2271918	chr17:80861206	A/G	cg05255149	chr17:80675120	FN3KRP	-0.5	-5.65	-0.33	4.13e-8	Breast cancer;
CESC	cis	rs9308731	1.000	rs6746608	chr2:111892984	C/T	cg04202892	chr2:111875749	ACOXL	-0.38	-5.45	-0.32	1.17e-7	Chronic lymphocytic leukemia;
CESC	cis	rs6032067	1.000	rs6017509	chr20:43830362	A/G	cg11264863	chr20:43835661	SEMG1	0.48	5.29	0.31	2.56e-7	Blood protein levels;
CESC	cis	rs7267979	0.739	rs6138555	chr20:25242910	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.73	11.8	0.59	4.01e-26	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	22.27	0.81	1.17e-62	Prudent dietary pattern;
CESC	cis	rs367943	0.666	rs7717422	chr5:112704089	A/G	cg12552261	chr5:112820674	MCC	0.42	5.53	0.32	7.73e-8	Type 2 diabetes;
CESC	cis	rs16966142	1.000	rs3890534	chr16:89835289	A/G	cg04287289	chr16:89883240	FANCA	-0.67	-6.02	-0.35	5.79e-9	Caffeine consumption;
CESC	cis	rs11112613	1.000	rs11112613	chr12:106003786	A/G	cg03607813	chr12:105948248	NA	0.53	5.48	0.32	9.79e-8	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CESC	cis	rs10733682	0.524	rs10987419	chr9:129462594	T/C	cg00232160	chr9:129468157	NA	0.42	6.63	0.38	1.9e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg06419771	chr15:42264912	EHD4	0.46	6.06	0.35	4.63e-9	Systemic lupus erythematosus;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg22465281	chr5:65017296	NLN;SGTB	-0.44	-6.24	-0.36	1.69e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs2836633	0.929	rs62217519	chr21:40034390	G/A	cg12884169	chr21:40033163	ERG	0.37	5.77	0.33	2.19e-8	Coronary artery disease;
CESC	cis	rs2573652	1.000	rs1469829	chr15:100517332	A/G	cg09918751	chr15:100517450	ADAMTS17	-0.44	-8.45	-0.46	1.95e-15	Height;
CESC	cis	rs6502050	0.835	rs7503225	chr17:80099639	C/A	cg23985595	chr17:80112537	CCDC57	-0.42	-6.57	-0.37	2.72e-10	Life satisfaction;
CESC	cis	rs9910055	0.639	rs11656871	chr17:42269141	G/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.65	8.44	0.46	2.12e-15	Total body bone mineral density;
CESC	cis	rs2486288	0.656	rs12910009	chr15:45572408	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.56	-6.7	-0.38	1.22e-10	Glomerular filtration rate;
CESC	cis	rs3733585	0.699	rs6449177	chr4:9968050	T/C	cg00071950	chr4:10020882	SLC2A9	-0.68	-10.88	-0.56	5.05e-23	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs8072100	0.676	rs9908049	chr17:45502096	G/C	cg25173405	chr17:45401733	C17orf57	-0.43	-5.43	-0.32	1.26e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs875971	0.862	rs10256544	chr7:65675128	A/G	cg11764359	chr7:65958608	NA	0.79	11.38	0.57	1.11e-24	Aortic root size;
CESC	cis	rs2836974	0.829	rs8128191	chr21:40527311	A/G	cg27266027	chr21:40555129	PSMG1	0.49	6.01	0.35	6.02e-9	Cognitive function;
CESC	cis	rs2952156	0.684	rs1877031	chr17:37814080	G/A	cg00129232	chr17:37814104	STARD3	-0.82	-12.26	-0.6	1.11e-27	Asthma;
CESC	cis	rs864537	0.676	rs1773560	chr1:167421763	A/G	cg09179987	chr1:167433047	CD247	0.5	7.43	0.42	1.54e-12	Celiac disease or Rheumatoid arthritis;Celiac disease;
CESC	cis	rs12079745	0.793	rs11802239	chr1:169128802	C/T	cg09363564	chr1:169337483	NME7;BLZF1	-1.13	-6.54	-0.37	3.19e-10	QT interval;
CESC	cis	rs17666538	0.585	rs1669733	chr8:606696	C/T	cg26554054	chr8:600488	NA	-0.7	-5.39	-0.31	1.57e-7	IgG glycosylation;
CESC	trans	rs7980799	0.935	rs9888363	chr12:33529288	A/G	cg26384229	chr12:38710491	ALG10B	-0.48	-6.67	-0.38	1.53e-10	Heart rate;Heart rate variability traits (RMSSD);
CESC	cis	rs11098499	0.954	rs10005644	chr4:120298477	T/C	cg09307838	chr4:120376055	NA	0.92	12.66	0.61	4.96e-29	Corneal astigmatism;
CESC	cis	rs780096	0.506	rs1262430	chr2:27673798	T/C	cg21248554	chr2:27665150	KRTCAP3	-0.36	-7.38	-0.41	2.05e-12	Total body bone mineral density;
CESC	cis	rs3845702	0.736	rs6433818	chr2:180810264	A/T	cg01881094	chr2:180872142	CWC22	-1.05	-8.97	-0.48	5.56e-17	Schizophrenia;
CESC	cis	rs7590368	0.600	rs3856466	chr2:10916770	C/T	cg15705551	chr2:10952987	PDIA6	0.58	5.24	0.31	3.2e-7	Educational attainment (years of education);
CESC	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg18402987	chr7:1209562	NA	0.77	7.88	0.44	8.56e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs3820068	0.581	rs72645871	chr1:15926142	G/A	cg13390004	chr1:15929781	NA	0.35	5.58	0.32	5.83e-8	Systolic blood pressure;
CESC	cis	rs12477438	0.520	rs34766932	chr2:99737273	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.88	15.55	0.69	3.41e-39	Chronic sinus infection;
CESC	cis	rs873946	0.648	rs12766166	chr10:134556403	G/C	cg06453172	chr10:134556979	INPP5A	-0.42	-5.47	-0.32	1.04e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs4664308	0.967	rs62175559	chr2:160955833	G/A	cg03641300	chr2:160917029	PLA2R1	-0.66	-9.7	-0.51	3.12e-19	Idiopathic membranous nephropathy;
CESC	cis	rs9399137	0.507	rs13197750	chr6:135312380	G/A	cg24558204	chr6:135376177	HBS1L	0.72	10.08	0.53	1.92e-20	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	cis	rs4588572	0.686	rs67689570	chr5:77676843	T/C	cg11547950	chr5:77652471	NA	0.46	5.91	0.34	1.06e-8	Triglycerides;
CESC	cis	rs7666738	0.830	rs10022331	chr4:98960392	C/A	cg03676636	chr4:99064102	C4orf37	0.33	5.14	0.3	5.39e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4803468	0.967	rs4802116	chr19:41905540	C/T	cg14132834	chr19:41945861	ATP5SL	-0.61	-7.74	-0.43	2.09e-13	Height;
CESC	cis	rs514406	0.929	rs1242224	chr1:53314887	G/A	cg25767906	chr1:53392781	SCP2	-0.46	-5.98	-0.34	7.09e-9	Monocyte count;
CESC	cis	rs9486719	0.857	rs2971609	chr6:97039665	A/G	cg06623918	chr6:96969491	KIAA0776	-0.86	-10.51	-0.54	8.28e-22	Migraine;Coronary artery disease;
CESC	cis	rs9948	0.786	rs62156227	chr2:97417942	C/A	cg01990225	chr2:97406019	LMAN2L	-0.94	-7.51	-0.42	9.27e-13	Erectile dysfunction and prostate cancer treatment;
CESC	cis	rs4218	0.636	rs4775116	chr15:59427807	A/G	cg10589330	chr15:60383523	NA	-0.24	-5.03	-0.3	8.93e-7	Social communication problems;
CESC	cis	rs10504229	0.683	rs61241336	chr8:58106585	A/G	cg24829409	chr8:58192753	C8orf71	-0.56	-7.01	-0.4	1.97e-11	Developmental language disorder (linguistic errors);
CESC	trans	rs9329221	0.619	rs591346	chr8:9818065	C/T	cg06636001	chr8:8085503	FLJ10661	-0.51	-6.6	-0.38	2.2e-10	Neuroticism;
CESC	cis	rs7408868	0.831	rs7245850	chr19:15274585	A/C	cg14696996	chr19:15285081	NOTCH3	1.12	11.42	0.57	8.06e-25	Pulse pressure;
CESC	cis	rs7123876	0.504	rs1157343	chr11:72429141	A/G	cg04827223	chr11:72435913	ARAP1	0.57	9.61	0.51	5.75e-19	Body mass index;
CESC	cis	rs12545109	0.765	rs2610047	chr8:57412106	T/C	cg09654669	chr8:57350985	NA	-0.46	-6.28	-0.36	1.4e-9	Obesity-related traits;
CESC	cis	rs4563143	0.647	rs34218744	chr19:29256821	A/T	cg12756686	chr19:29218302	NA	0.59	7.62	0.42	4.52e-13	Methadone dose in opioid dependence;
CESC	cis	rs2070488	0.804	rs6764551	chr3:38460305	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.79	12.28	0.6	9.75e-28	Electrocardiographic conduction measures;
CESC	cis	rs644799	1.000	rs3177463	chr11:95502128	G/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.55	6.87	0.39	4.5e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs68170813	0.559	rs2249043	chr7:106960515	C/T	cg02696742	chr7:106810147	HBP1	-0.55	-5.2	-0.3	3.95e-7	Coronary artery disease;
CESC	cis	rs4268898	0.662	rs72793213	chr2:24524725	A/G	cg06627628	chr2:24431161	ITSN2	-0.99	-11.33	-0.57	1.59e-24	Asthma;
CESC	cis	rs854765	0.505	rs4506969	chr17:17899839	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.61	8.76	0.47	2.4e-16	Total body bone mineral density;
CESC	cis	rs17023223	0.537	rs12065809	chr1:119724535	A/T	cg05756136	chr1:119680316	WARS2	-0.47	-5.69	-0.33	3.34e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CESC	cis	rs748404	0.631	rs3809482	chr15:43661802	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.61	8.0	0.44	3.8e-14	Lung cancer;
CESC	cis	rs2303745	0.589	rs7246262	chr19:17392483	C/G	cg04248312	chr19:17393744	ANKLE1	-0.93	-15.31	-0.69	2.39e-38	Systemic lupus erythematosus;
CESC	trans	rs877282	0.898	rs11253343	chr10:765117	C/T	cg22713356	chr15:30763199	NA	1.16	11.35	0.57	1.37e-24	Uric acid levels;
CESC	cis	rs9303542	0.559	rs2229302	chr17:46620402	G/A	cg04904318	chr17:46607828	HOXB1	-0.57	-5.51	-0.32	8.4e-8	Ovarian cancer;Epithelial ovarian cancer;
CESC	cis	rs9911578	0.935	rs117819974	chr17:57002324	C/T	cg12560992	chr17:57184187	TRIM37	0.94	15.56	0.69	3.21e-39	Intelligence (multi-trait analysis);
CESC	cis	rs826838	1.000	rs11610522	chr12:38687575	C/T	cg26384229	chr12:38710491	ALG10B	0.84	14.86	0.67	9.58e-37	Heart rate;
CESC	cis	rs9733	0.519	rs11800855	chr1:150800995	G/A	cg04414720	chr1:150670196	GOLPH3L	0.47	6.42	0.37	6.09e-10	Tonsillectomy;
CESC	trans	rs2727020	0.521	rs7107178	chr11:49526668	G/A	cg03929089	chr4:120376271	NA	0.69	7.8	0.43	1.43e-13	Coronary artery disease;
CESC	cis	rs12200560	0.505	rs59296768	chr6:97075535	C/T	cg06623918	chr6:96969491	KIAA0776	0.5	6.49	0.37	4.13e-10	Coronary heart disease;
CESC	cis	rs7412746	0.622	rs72704654	chr1:150826410	G/A	cg04414720	chr1:150670196	GOLPH3L	0.56	7.41	0.41	1.7e-12	Melanoma;
CESC	cis	rs10504229	0.683	rs57866073	chr8:58139138	A/G	cg02725872	chr8:58115012	NA	-0.48	-7.55	-0.42	7.13e-13	Developmental language disorder (linguistic errors);
CESC	cis	rs8060686	0.641	rs7204192	chr16:68039309	A/G	cg26727032	chr16:67993705	SLC12A4	-0.55	-7.31	-0.41	3.24e-12	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs7647973	0.710	rs12637313	chr3:49645458	A/G	cg07636037	chr3:49044803	WDR6	0.61	7.16	0.4	8.07e-12	Menarche (age at onset);
CESC	cis	rs5769765	1.000	rs4824112	chr22:50284345	A/G	cg26441486	chr22:50317300	CRELD2	0.4	5.16	0.3	4.95e-7	Schizophrenia;
CESC	cis	rs9467773	0.620	rs9467810	chr6:26608261	A/C	cg26531700	chr6:26746687	NA	-0.42	-6.43	-0.37	6.02e-10	Intelligence (multi-trait analysis);
CESC	cis	rs854765	0.583	rs4925125	chr17:17794444	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.64	-9.44	-0.5	2e-18	Total body bone mineral density;
CESC	cis	rs10504229	0.683	rs34859456	chr8:58117722	A/C	cg02725872	chr8:58115012	NA	-0.45	-7.05	-0.4	1.52e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs9916302	0.904	rs2338798	chr17:37547269	T/C	cg15445000	chr17:37608096	MED1	-0.39	-6.43	-0.37	5.89e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs6570726	0.875	rs368744	chr6:145812622	A/G	cg05347473	chr6:146136440	FBXO30	0.48	6.46	0.37	4.93e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7254114	0.618	rs7250652	chr19:11302606	A/G	cg02815516	chr19:11306319	KANK2	-0.37	-6.21	-0.36	2.05e-9	Immature fraction of reticulocytes;
CESC	cis	rs854765	0.552	rs11078407	chr17:17841083	T/C	cg16928487	chr17:17741425	SREBF1	-0.53	-9.09	-0.49	2.48e-17	Total body bone mineral density;
CESC	cis	rs11640734	0.609	rs11647746	chr16:89806343	C/A	cg04287289	chr16:89883240	FANCA	0.65	5.67	0.33	3.66e-8	Interleukin-17 levels;
CESC	cis	rs1050631	1.000	rs2236718	chr18:33705135	G/T	cg25426722	chr18:33708991	SLC39A6;ELP2	0.4	5.28	0.31	2.69e-7	Esophageal squamous cell cancer (length of survival);
CESC	cis	rs769267	0.896	rs2074298	chr19:19377716	C/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.42	5.26	0.31	2.97e-7	Tonsillectomy;
CESC	cis	rs9926296	0.682	rs645019	chr16:89716883	C/T	cg04287289	chr16:89883240	FANCA	-0.48	-5.94	-0.34	9.05e-9	Vitiligo;
CESC	cis	rs11077998	0.844	rs1109123	chr17:80522391	T/C	cg10255544	chr17:80519551	FOXK2	0.55	8.78	0.47	2.02e-16	Reticulocyte fraction of red cells;
CESC	cis	rs56309584	0.715	rs77224069	chr17:8124268	G/C	cg06726167	chr17:8076949	TMEM107	-0.5	-5.07	-0.3	7.42e-7	Initial pursuit acceleration;
CESC	cis	rs3008870	0.755	rs2815360	chr1:67494458	C/T	cg02640540	chr1:67518911	SLC35D1	0.44	5.36	0.31	1.84e-7	Lymphocyte percentage of white cells;
CESC	cis	rs4629710	0.568	rs9492883	chr6:131573872	A/T	cg12606694	chr6:131520996	AKAP7	0.48	5.9	0.34	1.08e-8	Multiple myeloma (IgH translocation);
CESC	cis	rs763121	0.785	rs5757199	chr22:39040617	T/G	cg14440974	chr22:39074834	NA	-0.4	-5.48	-0.32	9.77e-8	Menopause (age at onset);
CESC	cis	rs6120849	0.851	rs13040631	chr20:33747714	T/C	cg24642439	chr20:33292090	TP53INP2	0.6	6.37	0.36	8.21e-10	Protein C levels;
CESC	cis	rs7833790	0.700	rs7834483	chr8:82704828	A/G	cg06027949	chr8:82754900	SNX16	-0.44	-5.32	-0.31	2.21e-7	Diastolic blood pressure;
CESC	cis	rs6964587	0.967	rs13233496	chr7:91813035	T/C	cg17063962	chr7:91808500	NA	0.57	7.79	0.43	1.56e-13	Breast cancer;
CESC	cis	rs2070677	0.935	rs11101880	chr10:135412888	T/C	cg20169779	chr10:135381914	SYCE1	-0.76	-10.04	-0.53	2.53e-20	Gout;
CESC	cis	rs8141529	0.719	rs2097461	chr22:29191879	T/C	cg15103426	chr22:29168792	CCDC117	0.71	10.08	0.53	1.98e-20	Lymphocyte counts;
CESC	cis	rs17711722	0.727	rs35850374	chr7:65357776	A/G	cg18876405	chr7:65276391	NA	0.68	9.54	0.51	9.97e-19	Calcium levels;
CESC	cis	rs7772486	0.875	rs2748482	chr6:146336532	T/C	cg05347473	chr6:146136440	FBXO30	0.52	6.71	0.38	1.17e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs950776	0.531	rs12915652	chr15:78831928	G/A	cg06917634	chr15:78832804	PSMA4	0.81	12.07	0.6	5.08e-27	Sudden cardiac arrest;
CESC	cis	rs3109167	0.524	rs2713182	chr7:83097221	T/A	cg14519356	chr7:83097669	SEMA3E	0.43	5.84	0.34	1.53e-8	Blood protein levels;
CESC	cis	rs9324022	0.929	rs12888043	chr14:101170436	A/G	cg18089426	chr14:101175970	NA	-0.59	-6.87	-0.39	4.67e-11	Plateletcrit;
CESC	trans	rs6759922	1.000	rs7599198	chr2:22451138	A/T	cg21162304	chr4:80247171	NAA11	0.37	6.13	0.35	3.24e-9	Subjective well-being (multi-trait analysis);
CESC	cis	rs13191362	0.872	rs13194619	chr6:163203657	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.06	10.27	0.53	4.91e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs992157	0.798	rs4674284	chr2:219161241	C/T	cg00012203	chr2:219082015	ARPC2	-0.74	-9.46	-0.5	1.7e-18	Colorectal cancer;
CESC	cis	rs1878931	0.582	rs27225	chr16:3428060	G/A	cg02880119	chr16:3481970	NA	0.41	5.21	0.3	3.81e-7	Body mass index (adult);
CESC	cis	rs6831352	1.000	rs6831352	chr4:100063525	T/C	cg13256891	chr4:100009986	ADH5	0.7	8.0	0.44	3.83e-14	Alcohol dependence;
CESC	cis	rs6580649	0.941	rs1793931	chr12:48396505	G/T	cg24011408	chr12:48396354	COL2A1	0.41	5.31	0.31	2.28e-7	Lung cancer;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg09145139	chr10:95256412	CEP55	-0.46	-6.5	-0.37	3.99e-10	Gambling;
CESC	cis	rs7552404	1.000	rs4949674	chr1:76213715	C/A	cg22875332	chr1:76189707	ACADM	0.64	7.7	0.43	2.76e-13	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs6537837	0.887	rs1889470	chr1:110141421	A/G	cg05049280	chr1:110155535	GNAT2	0.31	5.11	0.3	6.32e-7	Major depressive disorder;
CESC	cis	rs727563	0.520	rs132773	chr22:42031768	T/A	cg17376030	chr22:41985996	PMM1	-0.8	-9.14	-0.49	1.64e-17	Crohn's disease;Inflammatory bowel disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18105612	chr14:71289522	NA	0.53	6.13	0.35	3.22e-9	Gut microbiome composition (summer);
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg17510320	chr11:66360559	CCS;CCDC87	0.46	6.03	0.35	5.35e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs801193	0.569	rs2013908	chr7:66121069	A/T	cg18252515	chr7:66147081	NA	0.48	6.43	0.37	5.77e-10	Aortic root size;
CESC	cis	rs910316	0.967	rs8007539	chr14:75664953	T/C	cg11812906	chr14:75593930	NEK9	-0.85	-14.12	-0.66	4e-34	Height;
CESC	cis	rs11711311	0.911	rs9831422	chr3:113398195	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.67	8.6	0.47	7.08e-16	IgG glycosylation;
CESC	cis	rs75064307	0.834	rs4855560	chr3:108116129	G/C	cg03329597	chr3:108125523	MYH15	0.51	5.68	0.33	3.48e-8	Intelligence (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10315922	chr12:66563928	TMBIM4	-0.55	-6.53	-0.37	3.44e-10	Gut microbiome composition (summer);
CESC	cis	rs2637266	0.775	rs2579744	chr10:78311824	A/G	cg18941641	chr10:78392320	NA	0.34	6.14	0.35	2.94e-9	Pulmonary function;
CESC	cis	rs12042938	0.935	rs1417585	chr1:231803604	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.44	6.15	0.35	2.8e-9	Neuranatomic and neurocognitive phenotypes;
CESC	cis	rs919433	0.927	rs3843857	chr2:198195965	T/C	cg10820045	chr2:198174542	NA	-0.43	-6.11	-0.35	3.54e-9	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs1799949	0.930	rs56729776	chr17:41422131	C/T	cg05368731	chr17:41323189	NBR1	0.78	10.59	0.55	4.23e-22	Menopause (age at onset);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg06742978	chr12:50451907	ACCN2	-0.42	-6.36	-0.36	8.68e-10	Gambling;
CESC	cis	rs798554	0.679	rs1639066	chr7:2892972	A/G	cg18446336	chr7:2847575	GNA12	-0.34	-5.19	-0.3	4.29e-7	Height;
CESC	cis	rs7605827	0.930	rs2160691	chr2:15598197	G/A	cg19274914	chr2:15703543	NA	0.36	6.39	0.37	7.33e-10	Educational attainment (years of education);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04407233	chr1:10042538	NMNAT1	-0.65	-7.51	-0.42	9.09e-13	Gut microbiome composition (summer);
CESC	cis	rs921968	0.541	rs733925	chr2:219302466	G/A	cg02176678	chr2:219576539	TTLL4	-0.45	-7.85	-0.43	1.04e-13	Mean corpuscular hemoglobin concentration;
CESC	cis	rs1670533	1.000	rs10031302	chr4:1059664	G/A	cg04106633	chr4:1044584	NA	0.41	5.33	0.31	2.11e-7	Recombination rate (females);
CESC	cis	rs910316	0.967	rs175505	chr14:75529619	C/T	cg11812906	chr14:75593930	NEK9	-0.88	-15.0	-0.68	3.01e-37	Height;
CESC	cis	rs9287719	0.934	rs4622695	chr2:10744327	C/T	cg00105475	chr2:10696890	NA	0.39	5.64	0.33	4.44e-8	Prostate cancer;
CESC	cis	rs10479542	1.000	rs10479542	chr5:178981241	T/A	cg26516362	chr5:178986906	RUFY1	0.44	7.03	0.4	1.7e-11	Lung cancer;
CESC	cis	rs2228479	1.000	rs11642267	chr16:89957635	T/C	cg14709524	chr16:89940631	TCF25	0.87	6.44	0.37	5.45e-10	Skin colour saturation;
CESC	cis	rs1707322	1.000	rs1613296	chr1:46546852	A/C	cg03146154	chr1:46216737	IPP	-0.59	-6.67	-0.38	1.5e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs4332037	0.707	rs4721096	chr7:1877311	T/C	cg13880726	chr7:1868755	MAD1L1	0.54	5.41	0.32	1.4e-7	Bipolar disorder;
CESC	cis	rs7580658	0.864	rs3088374	chr2:128062048	T/C	cg10021288	chr2:128175891	PROC	-0.35	-5.7	-0.33	3.21e-8	Protein C levels;
CESC	cis	rs4523957	0.928	rs4790071	chr17:2173184	A/G	cg16513277	chr17:2031491	SMG6	-0.6	-8.01	-0.44	3.55e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs10504229	0.906	rs7842482	chr8:58167720	A/T	cg22535103	chr8:58192502	C8orf71	-0.93	-12.03	-0.59	6.97e-27	Developmental language disorder (linguistic errors);
CESC	cis	rs6582630	0.502	rs11181214	chr12:38298313	C/A	cg13010199	chr12:38710504	ALG10B	0.46	5.88	0.34	1.26e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs2635047	0.530	rs4986228	chr18:44595259	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.48	-5.94	-0.34	8.95e-9	Educational attainment;
CESC	trans	rs9916302	0.752	rs6503513	chr17:37561613	A/G	cg04245439	chr3:142607978	PCOLCE2	-0.51	-6.19	-0.36	2.33e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs3785574	0.962	rs2727332	chr17:61878584	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.58	7.15	0.4	8.48e-12	Height;
CESC	cis	rs4072980	0.524	rs28477803	chr1:38398694	C/T	cg26528311	chr1:38462546	FHL3	0.33	5.04	0.3	8.66e-7	Coronary artery disease;
CESC	cis	rs875971	0.964	rs1643388	chr7:65844562	T/C	cg12463550	chr7:65579703	CRCP	0.59	7.42	0.41	1.55e-12	Aortic root size;
CESC	cis	rs992157	0.796	rs55680399	chr2:219160621	T/C	cg20019365	chr2:219134978	PNKD;AAMP	0.7	9.53	0.51	1.06e-18	Colorectal cancer;
CESC	trans	rs11098499	0.954	rs11940028	chr4:120411907	T/C	cg25214090	chr10:38739885	LOC399744	0.72	10.08	0.53	1.97e-20	Corneal astigmatism;
CESC	cis	rs7474896	0.583	rs34185758	chr10:37990854	T/C	cg25427524	chr10:38739819	LOC399744	-0.49	-5.39	-0.31	1.57e-7	Obesity (extreme);
CESC	cis	rs6800768	0.663	rs59911620	chr3:24092004	G/C	cg10674438	chr3:24145617	LOC152024	-0.42	-5.77	-0.33	2.26e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs523395	0.630	rs616111	chr1:120269991	C/G	cg19096424	chr1:120255104	PHGDH	-0.61	-7.64	-0.42	3.93e-13	Red blood cell count;
CESC	cis	rs6964587	0.626	rs4422709	chr7:91510968	A/G	cg17063962	chr7:91808500	NA	-0.44	-6.25	-0.36	1.65e-9	Breast cancer;
CESC	cis	rs7666738	0.830	rs28818180	chr4:98953625	A/G	cg05340658	chr4:99064831	C4orf37	0.8	12.4	0.61	3.76e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11945232	1.000	rs28609242	chr4:88342497	T/C	cg23841344	chr4:88312519	HSD17B11	-0.63	-7.81	-0.43	1.32e-13	Intelligence (multi-trait analysis);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg02471319	chr12:4647845	RAD51AP1;C12orf4	0.38	6.04	0.35	5.16e-9	Gambling;
CESC	cis	rs3806843	0.771	rs801174	chr5:140112712	C/T	cg16179182	chr5:140090404	VTRNA1-1	0.44	5.77	0.33	2.25e-8	Depressive symptoms (multi-trait analysis);
CESC	cis	rs757081	0.738	rs1073443	chr11:17350394	C/T	cg15432903	chr11:17409602	KCNJ11	-0.5	-6.24	-0.36	1.72e-9	Systolic blood pressure;
CESC	cis	rs7666738	0.830	rs11932942	chr4:98998939	T/C	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.62e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs57506017	0.585	rs3815535	chr7:12270519	G/A	cg23422036	chr7:12250390	TMEM106B	0.39	5.17	0.3	4.56e-7	Neuroticism;
CESC	cis	rs11122272	0.637	rs2808593	chr1:231524228	G/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.57	-7.82	-0.43	1.29e-13	Hemoglobin concentration;
CESC	cis	rs858239	0.508	rs10242104	chr7:23220450	C/T	cg23682824	chr7:23144976	KLHL7	0.45	5.81	0.34	1.8e-8	Cerebrospinal fluid biomarker levels;
CESC	cis	rs875971	0.545	rs1065265	chr7:65841203	C/T	cg18876405	chr7:65276391	NA	0.49	5.38	0.31	1.63e-7	Aortic root size;
CESC	cis	rs870825	0.860	rs72703518	chr4:185602109	T/C	cg04058563	chr4:185651563	MLF1IP	0.6	5.43	0.32	1.28e-7	Blood protein levels;
CESC	cis	rs2836950	0.565	rs7276046	chr21:40581293	T/C	cg11890956	chr21:40555474	PSMG1	-0.67	-9.52	-0.5	1.14e-18	Menarche (age at onset);
CESC	cis	rs7666738	0.830	rs13122456	chr4:98936011	A/G	cg03467027	chr4:99064603	C4orf37	0.48	5.91	0.34	1.03e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2243480	1.000	rs34637256	chr7:65360131	G/A	cg12463550	chr7:65579703	CRCP	0.68	5.51	0.32	8.7e-8	Diabetic kidney disease;
CESC	cis	rs2406342	0.528	rs75536638	chr18:74499060	G/T	cg24983120	chr18:74499380	NA	0.45	6.04	0.35	5.29e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin);
CESC	cis	rs7917772	0.582	rs12779854	chr10:104358474	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.4	-5.4	-0.31	1.5e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs8180040	0.620	rs11720139	chr3:47036756	C/G	cg27129171	chr3:47204927	SETD2	-0.66	-9.5	-0.5	1.31e-18	Colorectal cancer;
CESC	cis	rs17253792	0.822	rs10483650	chr14:56145312	A/G	cg01858014	chr14:56050164	KTN1	-0.97	-7.54	-0.42	7.36e-13	Putamen volume;
CESC	trans	rs2658782	0.789	rs56091149	chr11:93073640	A/C	cg03479527	chr8:145637966	SLC39A4	0.42	6.07	0.35	4.39e-9	Pulmonary function decline;
CESC	cis	rs765787	0.530	rs4775831	chr15:45534722	A/C	cg24006582	chr15:45444508	DUOX1	-0.59	-7.23	-0.41	5.15e-12	Uric acid levels;
CESC	cis	rs7264396	0.747	rs2425151	chr20:34394541	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.63	7.66	0.43	3.58e-13	Total cholesterol levels;
CESC	cis	rs853679	0.517	rs9393886	chr6:28050039	T/G	cg12963246	chr6:28129442	ZNF389	0.55	7.35	0.41	2.46e-12	Depression;
CESC	cis	rs875971	0.929	rs12535036	chr7:65964063	G/T	cg12463550	chr7:65579703	CRCP	0.56	7.07	0.4	1.39e-11	Aortic root size;
CESC	cis	rs78366141	0.649	rs78959409	chr4:89659712	C/T	cg01026744	chr4:89619053	NAP1L5;HERC3	0.88	5.86	0.34	1.34e-8	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
CESC	cis	rs780096	0.526	rs11682621	chr2:27749669	G/A	cg24768116	chr2:27665128	KRTCAP3	-0.29	-5.34	-0.31	1.97e-7	Total body bone mineral density;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg16208271	chr20:25176149	ENTPD6	-0.43	-6.14	-0.35	3.05e-9	Gambling;
CESC	cis	rs9660180	0.875	rs4648727	chr1:1776269	C/A	cg23982607	chr1:1823379	GNB1	0.5	7.17	0.4	7.35e-12	Body mass index;
CESC	cis	rs1707322	0.752	rs7541962	chr1:46235117	G/A	cg05343316	chr1:45956843	TESK2	0.52	6.49	0.37	4.25e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs4523957	0.583	rs903159	chr17:2055109	C/T	cg16513277	chr17:2031491	SMG6	-0.76	-11.02	-0.56	1.68e-23	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	trans	rs561341	1.000	rs4795668	chr17:30244554	G/A	cg20587970	chr11:113659929	NA	-1.11	-13.47	-0.64	7.57e-32	Hip circumference adjusted for BMI;
CESC	cis	rs13191362	1.000	rs34637087	chr6:163004064	T/G	cg21926612	chr6:163149169	PACRG;PARK2	0.88	9.16	0.49	1.46e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs35110281	0.714	rs2282526	chr21:45080552	A/T	cg04455712	chr21:45112962	RRP1B	0.42	6.04	0.35	5.25e-9	Mean corpuscular volume;
CESC	trans	rs916888	0.821	rs199507	chr17:44858855	A/G	cg01341218	chr17:43662625	NA	-0.85	-10.53	-0.54	6.95e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs7267979	0.932	rs449370	chr20:25451180	A/G	cg08601574	chr20:25228251	PYGB	-0.38	-5.5	-0.32	9.11e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7666738	0.830	rs4492007	chr4:98959848	A/T	cg05340658	chr4:99064831	C4orf37	0.8	12.37	0.61	4.65e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs12079745	0.623	rs2901092	chr1:169456393	A/G	cg09363564	chr1:169337483	NME7;BLZF1	-0.91	-6.0	-0.35	6.28e-9	QT interval;
CESC	cis	rs523522	0.962	rs4766968	chr12:120947788	G/C	cg27279351	chr12:120934652	DYNLL1	0.69	9.11	0.49	2.02e-17	High light scatter reticulocyte count;
CESC	cis	rs748404	0.697	rs1095389	chr15:43566671	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.61	7.82	0.43	1.29e-13	Lung cancer;
CESC	cis	rs2832077	0.506	rs2832093	chr21:30164855	C/T	cg24692254	chr21:30365293	RNF160	-0.51	-6.15	-0.35	2.85e-9	Cognitive test performance;
CESC	cis	rs1707322	0.721	rs12049027	chr1:46118184	A/T	cg05343316	chr1:45956843	TESK2	0.5	6.12	0.35	3.43e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs116095464	0.558	rs7714335	chr5:263513	T/C	cg00938859	chr5:1591904	SDHAP3	0.7	7.2	0.4	6.24e-12	Breast cancer;
CESC	cis	rs853679	0.517	rs1947863	chr6:28099344	G/A	cg20151795	chr6:28129481	ZNF389	0.45	5.92	0.34	9.77e-9	Depression;
CESC	trans	rs11770686	0.967	rs4728289	chr7:75348505	C/T	cg00742472	chr14:31889912	NA	-0.41	-6.21	-0.36	2.03e-9	Essential tremor;
CESC	cis	rs1506636	0.886	rs6945841	chr7:123266094	G/A	cg03229431	chr7:123269106	ASB15	-0.51	-6.83	-0.39	5.89e-11	Plateletcrit;Platelet count;
CESC	cis	rs2742234	0.503	rs1254968	chr10:43691691	C/T	cg15436174	chr10:43711423	RASGEF1A	0.5	5.88	0.34	1.21e-8	Hirschsprung disease;
CESC	cis	rs4889855	0.530	rs4889863	chr17:78550468	C/T	cg16591659	chr17:78472290	NA	-0.35	-5.75	-0.33	2.43e-8	Fractional excretion of uric acid;
CESC	cis	rs6570726	0.967	rs365515	chr6:145802833	C/T	cg23711669	chr6:146136114	FBXO30	-0.72	-10.43	-0.54	1.41e-21	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs3096299	0.503	rs9940093	chr16:89558705	G/A	cg16743903	chr16:89593216	SPG7	-0.43	-5.35	-0.31	1.93e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs9291683	0.538	rs11727199	chr4:10036190	C/T	cg11266682	chr4:10021025	SLC2A9	0.67	12.99	0.62	3.52e-30	Bone mineral density;
CESC	cis	rs12497850	0.931	rs9835307	chr3:48857805	T/C	cg06212747	chr3:49208901	KLHDC8B	0.66	8.74	0.47	2.71e-16	Parkinson's disease;
CESC	cis	rs7927771	0.524	rs7116346	chr11:47883880	G/A	cg18512352	chr11:47633146	NA	-0.36	-5.59	-0.32	5.72e-8	Subjective well-being;
CESC	cis	rs1847202	0.787	rs13071878	chr3:72951084	G/A	cg25664220	chr3:72788482	NA	-0.39	-5.64	-0.33	4.29e-8	Motion sickness;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16592623	chr1:181057846	IER5	0.6	6.98	0.39	2.3e-11	Gut microbiome composition (summer);
CESC	cis	rs9910055	0.708	rs2631298	chr17:42219832	T/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.68	9.0	0.48	4.4e-17	Total body bone mineral density;
CESC	cis	rs7618915	0.547	rs11714419	chr3:52628816	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.49	7.06	0.4	1.47e-11	Bipolar disorder;
CESC	trans	rs17685	0.712	rs6954569	chr7:75738885	T/A	cg19862616	chr7:65841803	NCRNA00174	0.83	11.96	0.59	1.23e-26	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs2836974	0.897	rs2776308	chr21:40715175	A/G	cg11890956	chr21:40555474	PSMG1	1.02	15.6	0.69	2.21e-39	Cognitive function;
CESC	cis	rs11230563	0.501	rs599856	chr11:60818176	G/A	cg10158843	chr11:60776172	CD6	-0.36	-5.37	-0.31	1.69e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs2228479	0.850	rs1800355	chr16:89813194	C/T	cg14709524	chr16:89940631	TCF25	0.93	6.9	0.39	3.78e-11	Skin colour saturation;
CESC	cis	rs7524258	0.868	rs8179413	chr1:7267729	T/G	cg07173049	chr1:7289937	CAMTA1	0.45	6.65	0.38	1.67e-10	Tourette's syndrome or obsessive-compulsive disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18752785	chr20:3996394	RNF24	0.57	6.08	0.35	4.17e-9	Gut microbiome composition (summer);
CESC	cis	rs6693567	0.545	rs11205382	chr1:150442466	G/A	cg09579323	chr1:150459698	TARS2	-0.47	-5.95	-0.34	8.27e-9	Migraine;
CESC	cis	rs698833	0.780	rs2005203	chr2:44541725	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.49	6.06	0.35	4.77e-9	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs7666738	0.830	rs2865980	chr4:99027422	T/G	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.58e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs12541635	0.966	rs6469028	chr8:107014552	C/T	cg10147462	chr8:107024639	NA	0.42	5.88	0.34	1.24e-8	Age of smoking initiation;
CESC	cis	rs4835473	0.712	rs12509607	chr4:144658047	C/T	cg25736465	chr4:144833511	NA	-0.33	-5.11	-0.3	6.26e-7	Immature fraction of reticulocytes;
CESC	cis	rs8062405	0.754	rs151179	chr16:28487056	A/G	cg08761264	chr16:28874980	SH2B1	-0.45	-5.38	-0.31	1.63e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs4919087	0.683	rs1687372	chr10:98978185	A/T	cg25902810	chr10:99078978	FRAT1	-0.5	-5.66	-0.33	4.02e-8	Monocyte count;
CESC	cis	rs7618915	0.570	rs11130319	chr3:52755592	A/T	cg18404041	chr3:52824283	ITIH1	-0.42	-6.98	-0.39	2.35e-11	Bipolar disorder;
CESC	cis	rs17711722	0.565	rs4275112	chr7:65198619	T/G	cg14393609	chr7:65229607	NA	-0.48	-6.7	-0.38	1.22e-10	Calcium levels;
CESC	trans	rs11039798	0.764	rs1121450	chr11:48897476	C/T	cg15704280	chr7:45808275	SEPT13	0.7	6.55	0.37	3.06e-10	Axial length;
CESC	cis	rs1005277	0.541	rs1740741	chr10:38515334	C/T	cg25517755	chr10:38738941	LOC399744	-0.44	-5.7	-0.33	3.12e-8	Extrinsic epigenetic age acceleration;
CESC	cis	rs2652822	0.525	rs12148434	chr15:63510114	A/G	cg02713581	chr15:63449717	RPS27L	0.49	6.35	0.36	9.23e-10	Metabolic traits;
CESC	cis	rs3008870	0.755	rs2815360	chr1:67494458	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.61	7.91	0.44	7.21e-14	Lymphocyte percentage of white cells;
CESC	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg23708337	chr7:1209742	NA	0.52	5.31	0.31	2.35e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg03757819	chr2:191002320	C2orf88	0.39	6.07	0.35	4.4e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs2708240	0.875	rs2710120	chr7:147572711	A/G	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.33	-5.58	-0.32	5.99e-8	QT interval (drug interaction);
CESC	cis	rs9902453	0.765	rs2628191	chr17:28051140	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.76	-10.15	-0.53	1.14e-20	Coffee consumption (cups per day);
CESC	cis	rs72945132	0.882	rs12274436	chr11:70132204	T/C	cg00319359	chr11:70116639	PPFIA1	0.78	7.78	0.43	1.6e-13	Coronary artery disease;
CESC	cis	rs12249377	0.519	rs35987367	chr10:92591992	C/T	cg14313238	chr10:92632228	RPP30	0.42	5.1	0.3	6.45e-7	White matter microstructure (global fractional anisotropy);
CESC	cis	rs4711336	0.935	rs754404	chr6:33664730	T/C	cg14003231	chr6:33640908	ITPR3	0.31	5.41	0.32	1.45e-7	Height;
CESC	trans	rs2764766	0.721	rs245195	chr5:127187017	C/T	cg15764593	chr10:829463	NA	-0.4	-6.19	-0.36	2.3e-9	Schizophrenia;
CESC	cis	rs3768617	0.510	rs4652776	chr1:183091920	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.89	14.39	0.66	4.39e-35	Fuchs's corneal dystrophy;
CESC	cis	rs7264396	0.635	rs6058366	chr20:34512172	A/G	cg17201900	chr20:34330562	RBM39	0.49	5.13	0.3	5.54e-7	Total cholesterol levels;
CESC	cis	rs6570726	0.967	rs6903252	chr6:145922777	A/G	cg05347473	chr6:146136440	FBXO30	0.46	6.12	0.35	3.32e-9	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1941023	0.606	rs3825020	chr11:60184191	G/A	cg08716584	chr11:60157161	MS4A7	-0.43	-6.34	-0.36	1.01e-9	Congenital heart disease (maternal effect);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg25804860	chr16:47178250	NETO2	0.46	6.13	0.35	3.14e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs17253792	0.822	rs75232282	chr14:56067290	G/C	cg01858014	chr14:56050164	KTN1	-0.88	-7.15	-0.4	8.55e-12	Putamen volume;
CESC	cis	rs6831352	0.879	rs7672728	chr4:100055173	A/G	cg12011299	chr4:100065546	ADH4	-0.6	-6.62	-0.38	2.04e-10	Alcohol dependence;
CESC	cis	rs4555082	0.874	rs11625098	chr14:105756891	A/G	cg06808227	chr14:105710500	BRF1	-0.5	-5.33	-0.31	2.09e-7	Mean platelet volume;Platelet distribution width;
CESC	cis	rs72781680	1.000	rs7588286	chr2:24071427	A/G	cg20701182	chr2:24300061	SF3B14	0.62	5.6	0.33	5.24e-8	Lymphocyte counts;
CESC	cis	rs6547741	0.816	rs10201652	chr2:27874332	A/C	cg27432699	chr2:27873401	GPN1	-0.55	-7.99	-0.44	4.19e-14	Oral cavity cancer;
CESC	cis	rs2072499	0.750	rs909269	chr1:156192028	C/T	cg25208724	chr1:156163844	SLC25A44	0.91	11.22	0.57	3.58e-24	Testicular germ cell tumor;
CESC	cis	rs9399135	0.967	rs13191501	chr6:135366880	T/C	cg22676075	chr6:135203613	NA	0.5	7.06	0.4	1.49e-11	Red blood cell count;
CESC	cis	rs425277	0.583	rs12059660	chr1:2041461	C/T	cg19257562	chr1:2043853	PRKCZ	0.33	5.43	0.32	1.25e-7	Height;
CESC	trans	rs7618501	0.540	rs11130241	chr3:50131459	A/T	cg21659725	chr3:3221576	CRBN	-0.52	-7.23	-0.41	5.32e-12	Intelligence (multi-trait analysis);
CESC	trans	rs11098499	0.908	rs1002152	chr4:120273387	C/A	cg25214090	chr10:38739885	LOC399744	0.68	9.28	0.5	6.46e-18	Corneal astigmatism;
CESC	cis	rs6570726	1.000	rs373778	chr6:145873252	C/T	cg23711669	chr6:146136114	FBXO30	0.77	11.24	0.57	3.15e-24	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01345365	chr2:12163619	NA	-0.6	-7.62	-0.42	4.45e-13	Gut microbiome composition (summer);
CESC	cis	rs801193	0.839	rs6968619	chr7:66068867	T/C	cg19163074	chr7:65112434	INTS4L2	0.43	5.49	0.32	9.49e-8	Aortic root size;
CESC	cis	rs6695640	0.820	rs6702471	chr1:17752873	A/C	cg01904812	chr1:17746340	RCC2	0.35	5.06	0.3	8.01e-7	Mean platelet volume;
CESC	cis	rs4946717	0.740	rs9480634	chr6:106468486	C/T	cg02270332	chr6:106475062	NA	0.31	5.33	0.31	2.1e-7	Inflammatory bowel disease;
CESC	cis	rs2816062	1.000	rs2816062	chr1:18903902	G/A	cg18795169	chr1:18902165	NA	-0.88	-15.93	-0.7	1.6e-40	Urate levels in lean individuals;
CESC	cis	rs826838	0.904	rs10876086	chr12:39188208	C/A	cg26384229	chr12:38710491	ALG10B	0.78	13.13	0.63	1.09e-30	Heart rate;
CESC	cis	rs76419734	0.510	rs6820671	chr4:106613821	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.72	9.2	0.49	1.12e-17	Post bronchodilator FEV1;
CESC	cis	rs7973683	0.541	rs57078519	chr12:124388784	G/A	cg00084347	chr12:124393913	DNAH10	0.29	6.06	0.35	4.73e-9	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
CESC	cis	rs12477438	1.000	rs6542873	chr2:99824965	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.66	-7.59	-0.42	5.31e-13	Chronic sinus infection;
CESC	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg11494091	chr17:61959527	GH2	0.72	12.32	0.6	7.12e-28	Prudent dietary pattern;
CESC	cis	rs372883	0.648	rs382732	chr21:30719010	A/G	cg08807101	chr21:30365312	RNF160	0.44	5.23	0.31	3.41e-7	Pancreatic cancer;
CESC	cis	rs17376456	0.569	rs1026279	chr5:93209581	C/A	cg25358565	chr5:93447407	FAM172A	-0.72	-7.65	-0.43	3.63e-13	Diabetic retinopathy;
CESC	cis	rs1572438	0.896	rs9405366	chr6:858296	A/C	cg13447295	chr6:887704	NA	-0.38	-5.12	-0.3	5.86e-7	Aging;
CESC	cis	rs4853012	0.941	rs2421752	chr2:74341615	A/G	cg19729930	chr2:74357872	NA	0.84	11.42	0.57	8.06e-25	Gestational age at birth (maternal effect);
CESC	cis	rs1707322	0.686	rs2152078	chr1:46055600	C/T	cg06784218	chr1:46089804	CCDC17	-0.41	-7.11	-0.4	1.07e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs3820928	0.874	rs12614648	chr2:227785535	G/A	cg11843606	chr2:227700838	RHBDD1	-0.49	-6.59	-0.38	2.33e-10	Pulmonary function;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19758054	chr2:176032603	ATF2;MIR933	0.55	6.38	0.36	7.92e-10	Gut microbiome composition (summer);
CESC	cis	rs3126085	0.877	rs2338431	chr1:152169305	A/G	cg03465714	chr1:152285911	FLG	-0.47	-5.68	-0.33	3.59e-8	Atopic dermatitis;
CESC	cis	rs959260	1.000	rs6501786	chr17:73378775	A/T	cg20590849	chr17:73267439	MIF4GD	0.56	6.65	0.38	1.69e-10	Systemic lupus erythematosus;
CESC	cis	rs317689	0.819	rs317677	chr12:69691806	G/A	cg20891283	chr12:69753455	YEATS4	0.47	5.04	0.3	8.79e-7	Response to diuretic therapy;
CESC	cis	rs17376456	0.877	rs13153245	chr5:93374891	G/A	cg25358565	chr5:93447407	FAM172A	1.11	11.1	0.56	9.57e-24	Diabetic retinopathy;
CESC	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg07414643	chr4:187882934	NA	0.57	8.41	0.46	2.53e-15	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs265548	0.608	rs36690	chr19:17910483	C/T	cg00024989	chr19:17902242	NA	0.46	7.95	0.44	5.43e-14	Tumor biomarkers;
CESC	cis	rs6674176	0.660	rs2108202	chr1:44395786	A/G	cg12908607	chr1:44402522	ARTN	0.49	7.33	0.41	2.8e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs4589502	0.800	rs4776855	chr15:67202075	T/C	cg12317470	chr15:67143691	NA	-0.71	-8.51	-0.46	1.35e-15	Lung cancer (smoking interaction);
CESC	cis	rs6500602	0.727	rs6500607	chr16:4503631	C/T	cg08645402	chr16:4508243	NA	0.54	8.54	0.46	1.08e-15	Schizophrenia;
CESC	cis	rs3820068	0.603	rs6696286	chr1:15968770	C/T	cg16988262	chr1:15930761	NA	0.32	5.23	0.31	3.49e-7	Systolic blood pressure;
CESC	cis	rs3020736	0.500	rs8143153	chr22:42515637	G/C	cg04733989	chr22:42467013	NAGA	-0.83	-12.55	-0.61	1.18e-28	Autism spectrum disorder or schizophrenia;
CESC	cis	rs7799006	0.634	rs34502289	chr7:2311266	G/A	cg08027265	chr7:2291960	NA	-0.6	-10.22	-0.53	6.78e-21	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04322344	chr3:131221642	MRPL3	0.47	6.12	0.35	3.32e-9	Gut microbiota (bacterial taxa);
CESC	trans	rs7615952	0.641	rs4422257	chr3:125774363	A/G	cg07211511	chr3:129823064	LOC729375	-0.6	-6.66	-0.38	1.53e-10	Blood pressure (smoking interaction);
CESC	cis	rs8114671	0.836	rs6060165	chr20:33619480	A/C	cg06115741	chr20:33292138	TP53INP2	-0.44	-5.37	-0.31	1.71e-7	Height;
CESC	cis	rs9549260	0.564	rs6563844	chr13:41298190	T/C	cg21288729	chr13:41239152	FOXO1	0.59	7.35	0.41	2.51e-12	Red blood cell count;
CESC	trans	rs7615952	0.641	rs66520539	chr3:125780374	G/A	cg07211511	chr3:129823064	LOC729375	-0.59	-6.53	-0.37	3.37e-10	Blood pressure (smoking interaction);
CESC	cis	rs941873	0.836	rs6480931	chr10:81108482	T/C	cg08514558	chr10:81106712	PPIF	0.34	5.77	0.33	2.21e-8	Height;
CESC	cis	rs854765	0.547	rs2955377	chr17:17932818	G/A	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.5	6.43	0.37	5.86e-10	Total body bone mineral density;
CESC	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg04025307	chr7:1156635	C7orf50	0.41	5.68	0.33	3.49e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs17376456	0.569	rs7701114	chr5:93096028	T/C	cg25358565	chr5:93447407	FAM172A	0.68	7.25	0.41	4.53e-12	Diabetic retinopathy;
CESC	cis	rs12497850	0.931	rs9682444	chr3:48852639	A/G	cg06212747	chr3:49208901	KLHDC8B	0.66	8.74	0.47	2.71e-16	Parkinson's disease;
CESC	cis	rs2204008	0.846	rs2030416	chr12:38465118	A/G	cg26384229	chr12:38710491	ALG10B	-0.64	-9.53	-0.51	1.07e-18	Bladder cancer;
CESC	cis	rs7666738	0.830	rs7674095	chr4:99048158	T/A	cg17366294	chr4:99064904	C4orf37	0.61	8.78	0.47	2.13e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3785574	0.962	rs35448669	chr17:61938923	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.78	10.59	0.55	4.33e-22	Height;
CESC	cis	rs523522	0.962	rs651627	chr12:121009198	C/T	cg27279351	chr12:120934652	DYNLL1	0.69	8.91	0.48	8.41e-17	High light scatter reticulocyte count;
CESC	cis	rs6570726	0.846	rs372904	chr6:145887425	T/C	cg05347473	chr6:146136440	FBXO30	0.54	7.09	0.4	1.24e-11	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg08273200	chr1:39338480	MYCBP	0.5	6.38	0.36	7.99e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs4835473	0.897	rs56324738	chr4:144657450	A/T	cg25736465	chr4:144833511	NA	-0.32	-5.07	-0.3	7.49e-7	Immature fraction of reticulocytes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13662628	chr9:127572244	OLFML2A	-0.51	-6.1	-0.35	3.78e-9	Gut microbiome composition (summer);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg05117058	chr20:3209220	SLC4A11	0.47	6.46	0.37	5.13e-10	Fibrinogen levels;
CESC	cis	rs7618915	0.570	rs11130312	chr3:52675055	A/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.36	6.46	0.37	4.98e-10	Bipolar disorder;
CESC	cis	rs992157	0.710	rs12996912	chr2:219110555	A/G	cg20019365	chr2:219134978	PNKD;AAMP	0.67	9.37	0.5	3.39e-18	Colorectal cancer;
CESC	cis	rs35110281	0.805	rs2838319	chr21:44991901	A/G	cg04455712	chr21:45112962	RRP1B	0.37	5.48	0.32	1.01e-7	Mean corpuscular volume;
CESC	trans	rs12310956	0.532	rs11052930	chr12:33964824	A/G	cg26384229	chr12:38710491	ALG10B	0.59	8.35	0.46	3.79e-15	Morning vs. evening chronotype;
CESC	cis	rs4665809	1.000	rs2384321	chr2:26290054	A/G	cg04944784	chr2:26401820	FAM59B	-0.8	-8.93	-0.48	7.17e-17	Gut microbiome composition (summer);
CESC	trans	rs274437	0.739	rs12197788	chr6:104791156	G/A	cg24439334	chr1:2345374	PEX10	0.55	6.0	0.35	6.49e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs8013055	0.846	rs10147392	chr14:105978537	T/G	cg23356831	chr14:105996513	TMEM121	0.37	5.27	0.31	2.82e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
CESC	cis	rs4555082	0.794	rs2735829	chr14:105708472	C/T	cg27165867	chr14:105738592	BRF1	-0.48	-5.16	-0.3	4.75e-7	Mean platelet volume;Platelet distribution width;
CESC	cis	rs3820068	0.581	rs72645889	chr1:15930251	T/G	cg17385448	chr1:15911702	AGMAT	0.41	6.69	0.38	1.33e-10	Systolic blood pressure;
CESC	cis	rs3096299	0.719	rs2965817	chr16:89513234	C/T	cg08392591	chr16:89556376	ANKRD11	0.58	7.87	0.44	8.84e-14	Multiple myeloma (IgH translocation);
CESC	cis	rs7520050	0.966	rs7540325	chr1:46338217	A/T	cg24296786	chr1:45957014	TESK2	0.43	5.41	0.32	1.4e-7	Red blood cell count;Reticulocyte count;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg06014083	chr17:81052928	NA	0.45	6.21	0.36	2.09e-9	Fibrinogen levels;
CESC	cis	rs6429082	0.714	rs184108	chr1:235646160	A/G	cg26050004	chr1:235667680	B3GALNT2	0.62	7.83	0.43	1.19e-13	Adiposity;
CESC	cis	rs7772486	0.875	rs1331644	chr6:146398660	T/C	cg23711669	chr6:146136114	FBXO30	0.82	12.45	0.61	2.54e-28	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7296418	0.518	rs28825193	chr12:123878262	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.33	-5.07	-0.3	7.35e-7	Platelet count;
CESC	trans	rs6089829	0.962	rs7267951	chr20:61665979	A/G	cg23505145	chr19:12996616	KLF1	0.52	6.8	0.39	6.85e-11	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs9902453	0.935	rs7220151	chr17:28334710	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.62	-7.83	-0.43	1.15e-13	Coffee consumption (cups per day);
CESC	cis	rs7208859	0.524	rs11653098	chr17:29122501	C/T	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.1e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs763121	0.853	rs6519120	chr22:38991393	A/C	cg06022373	chr22:39101656	GTPBP1	-0.88	-13.18	-0.63	7.81e-31	Menopause (age at onset);
CESC	cis	rs2242663	0.581	rs2511224	chr11:66262606	T/C	cg04006266	chr11:66300458	BBS1	-0.35	-5.33	-0.31	2.08e-7	Bipolar disorder;
CESC	cis	rs10465746	1.000	rs10465746	chr1:84387632	T/G	cg10977910	chr1:84465055	TTLL7	0.48	6.46	0.37	4.85e-10	Obesity-related traits;
CESC	cis	rs875971	0.767	rs1643394	chr7:65836094	A/G	cg11764359	chr7:65958608	NA	0.81	11.84	0.59	3.02e-26	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08168689	chr14:76455272	C14orf179	-0.6	-6.34	-0.36	9.98e-10	Gut microbiome composition (summer);
CESC	cis	rs950169	0.922	rs17531523	chr15:85132449	C/G	cg17507749	chr15:85114479	UBE2QP1	0.54	6.09	0.35	3.99e-9	Schizophrenia;
CESC	cis	rs250677	0.652	rs168751	chr5:148438264	C/T	cg18129178	chr5:148520854	ABLIM3	-0.54	-5.4	-0.31	1.48e-7	Breast cancer;
CESC	cis	rs11098499	0.865	rs10032158	chr4:120391632	C/T	cg09307838	chr4:120376055	NA	0.94	13.94	0.65	1.68e-33	Corneal astigmatism;
CESC	cis	rs11792861	0.619	rs2289481	chr9:111712924	G/C	cg13535736	chr9:111863775	C9orf5	-0.39	-5.72	-0.33	2.92e-8	Menarche (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24335355	chr19:41770635	HNRNPUL1	0.54	6.52	0.37	3.53e-10	Gut microbiome composition (summer);
CESC	cis	rs1707322	1.000	rs9429186	chr1:46539687	C/T	cg05343316	chr1:45956843	TESK2	-0.44	-5.26	-0.31	2.94e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2932538	0.961	rs2932539	chr1:113215786	A/G	cg22162597	chr1:113214053	CAPZA1	-0.57	-7.2	-0.4	6.14e-12	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CESC	cis	rs801193	1.000	rs2659906	chr7:66165310	T/C	cg14393609	chr7:65229607	NA	0.47	6.31	0.36	1.17e-9	Aortic root size;
CESC	cis	rs3820928	0.874	rs4234062	chr2:227819050	C/A	cg05526886	chr2:227700861	RHBDD1	-0.4	-5.1	-0.3	6.52e-7	Pulmonary function;
CESC	cis	rs9388451	0.626	rs2875881	chr6:126072853	C/G	cg05901451	chr6:126070800	HEY2	-0.62	-9.3	-0.5	5.52e-18	Brugada syndrome;
CESC	cis	rs2070488	0.775	rs2186457	chr3:38553965	A/G	cg24069376	chr3:38537580	EXOG	0.32	5.55	0.32	6.79e-8	Electrocardiographic conduction measures;
CESC	cis	rs722599	0.599	rs8003660	chr14:75227098	T/C	cg08847533	chr14:75593920	NEK9	0.48	5.88	0.34	1.25e-8	IgG glycosylation;
CESC	cis	rs3126085	0.935	rs12063165	chr1:152176357	C/T	cg26876637	chr1:152193138	HRNR	0.47	5.4	0.31	1.49e-7	Atopic dermatitis;
CESC	cis	rs4132509	1.000	rs12403316	chr1:243956903	C/T	cg21452805	chr1:244014465	NA	0.5	6.15	0.35	2.78e-9	RR interval (heart rate);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15692031	chr10:93683614	BTAF1	0.58	6.46	0.37	5.07e-10	Gut microbiome composition (summer);
CESC	cis	rs7552404	0.824	rs1251077	chr1:76189745	C/G	cg10523679	chr1:76189770	ACADM	-0.87	-13.69	-0.64	1.21e-32	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs8070624	0.543	rs11078409	chr17:17876296	C/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.68	9.67	0.51	3.79e-19	Total body bone mineral density;
CESC	cis	rs4315565	0.688	rs6546478	chr2:69282132	C/T	cg12800200	chr2:69260302	ANTXR1	-0.38	-5.34	-0.31	1.97e-7	Height;
CESC	cis	rs2933343	0.700	rs1680778	chr3:128614185	A/C	cg24203234	chr3:128598194	ACAD9	0.38	5.04	0.3	8.69e-7	IgG glycosylation;
CESC	cis	rs9828933	0.882	rs3816156	chr3:63999712	A/T	cg16258503	chr3:63850278	ATXN7;THOC7	-0.59	-5.97	-0.34	7.67e-9	Type 2 diabetes;
CESC	cis	rs17253792	0.822	rs75560658	chr14:56079896	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.76	5.39	0.31	1.56e-7	Putamen volume;
CESC	cis	rs853679	0.517	rs17774663	chr6:28120898	G/A	cg12963246	chr6:28129442	ZNF389	0.59	7.7	0.43	2.7e-13	Depression;
CESC	cis	rs1552244	0.882	rs34706481	chr3:10004123	G/A	cg08888203	chr3:10149979	C3orf24	0.46	5.49	0.32	9.51e-8	Alzheimer's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05310613	chr6:139456890	HECA	0.6	7.22	0.41	5.44e-12	Gut microbiome composition (summer);
CESC	cis	rs2573652	0.723	rs4577068	chr15:100515959	T/A	cg00587665	chr15:100533223	ADAMTS17	-0.34	-5.25	-0.31	3.18e-7	Height;
CESC	cis	rs10504229	1.000	rs66477954	chr8:58187810	C/T	cg14926445	chr8:58193284	C8orf71	-0.51	-5.52	-0.32	8.28e-8	Developmental language disorder (linguistic errors);
CESC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg15127867	chr2:128457218	SFT2D3	-0.42	-6.06	-0.35	4.62e-9	Breast cancer;
CESC	cis	rs2732480	0.577	rs2732479	chr12:48736260	A/C	cg04545296	chr12:48745243	ZNF641	0.44	7.22	0.41	5.44e-12	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs9788333	0.962	rs34853044	chr13:21883784	C/T	cg23743428	chr13:21893420	NA	-0.39	-6.64	-0.38	1.78e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs10861342	1.000	rs10861356	chr12:105526965	G/T	cg23923672	chr12:105501055	KIAA1033	0.73	6.35	0.36	9.44e-10	IgG glycosylation;
CESC	cis	rs1552244	0.935	rs7618815	chr3:10151045	A/G	cg08888203	chr3:10149979	C3orf24	0.47	5.91	0.34	1.05e-8	Alzheimer's disease;
CESC	cis	rs7584330	0.780	rs2292884	chr2:238443226	A/G	cg14458575	chr2:238380390	NA	0.56	7.87	0.44	9.06e-14	Prostate cancer;
CESC	cis	rs7945705	0.870	rs10840142	chr11:8906078	A/G	cg09997546	chr11:8931473	C11orf17;ST5	0.37	5.97	0.34	7.77e-9	Hemoglobin concentration;
CESC	cis	rs711830	0.576	rs72916141	chr2:177069364	G/T	cg13092806	chr2:177043255	NA	-0.58	-6.51	-0.37	3.68e-10	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
CESC	cis	rs80130819	0.688	rs6580660	chr12:48588112	T/C	cg05342945	chr12:48394962	COL2A1	-0.5	-5.85	-0.34	1.43e-8	Prostate cancer;
CESC	cis	rs4665809	0.652	rs6728090	chr2:26524726	C/T	cg04944784	chr2:26401820	FAM59B	-0.67	-7.04	-0.4	1.65e-11	Gut microbiome composition (summer);
CESC	cis	rs7633770	0.664	rs7373994	chr3:46701114	C/G	cg11219411	chr3:46661640	NA	-0.37	-6.04	-0.35	5.14e-9	Coronary artery disease;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04084132	chr16:84538323	KIAA1609	0.49	6.22	0.36	1.96e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs875971	0.798	rs12698522	chr7:65967341	T/C	cg10691866	chr7:65817282	TPST1	-0.33	-5.42	-0.32	1.34e-7	Aortic root size;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg11668638	chr6:42952412	PPP2R5D	0.48	6.27	0.36	1.45e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs2236918	0.710	rs1776174	chr1:242031839	G/T	cg17736920	chr1:242011382	EXO1	0.55	6.86	0.39	4.91e-11	Menopause (age at onset);
CESC	cis	rs7666738	0.830	rs28587201	chr4:98991733	C/T	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.62e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9549367	0.713	rs3024764	chr13:113824314	A/G	cg00898013	chr13:113819073	PROZ	-0.48	-6.75	-0.38	9.35e-11	Platelet distribution width;
CESC	cis	rs1355223	0.902	rs2185700	chr11:34724204	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.48	-6.21	-0.36	2.02e-9	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs7615952	0.641	rs12495947	chr3:125771698	C/T	cg15145296	chr3:125709740	NA	-0.52	-5.47	-0.32	1.06e-7	Blood pressure (smoking interaction);
CESC	cis	rs9311474	0.569	rs7614981	chr3:52566914	G/T	cg18337363	chr3:52569053	NT5DC2	0.34	6.55	0.37	2.99e-10	Electroencephalogram traits;
CESC	cis	rs2191566	0.540	rs391267	chr19:44492487	C/T	cg20607764	chr19:44506953	ZNF230	0.45	5.66	0.33	3.92e-8	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs1568889	1.000	rs78140392	chr11:28203231	C/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.74	9.35	0.5	3.75e-18	Bipolar disorder;
CESC	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg23708337	chr7:1209742	NA	0.55	5.41	0.32	1.38e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs6570726	0.791	rs440477	chr6:145854188	C/T	cg23711669	chr6:146136114	FBXO30	1.01	15.52	0.69	4.59e-39	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs798554	0.797	rs798486	chr7:2803037	A/G	cg04166393	chr7:2884313	GNA12	0.6	7.6	0.42	5.22e-13	Height;
CESC	cis	rs1538970	1.000	rs17395553	chr1:45864761	C/T	cg24296786	chr1:45957014	TESK2	-0.42	-5.05	-0.3	8.43e-7	Platelet count;
CESC	cis	rs7647973	0.600	rs12631989	chr3:49273996	C/T	cg06212747	chr3:49208901	KLHDC8B	0.7	10.45	0.54	1.24e-21	Menarche (age at onset);
CESC	cis	rs6433857	0.594	rs17364750	chr2:181524361	C/G	cg23363182	chr2:181467187	NA	-0.47	-6.45	-0.37	5.23e-10	Body mass index;
CESC	cis	rs7605827	0.866	rs6745922	chr2:15537931	G/C	cg19274914	chr2:15703543	NA	0.36	6.45	0.37	5.17e-10	Educational attainment (years of education);
CESC	cis	rs3857536	0.611	rs7748258	chr6:66932840	A/G	cg07460842	chr6:66804631	NA	-0.42	-5.36	-0.31	1.8e-7	Blood trace element (Cu levels);
CESC	cis	rs4689388	0.853	rs13114527	chr4:6294655	T/G	cg00701064	chr4:6280414	WFS1	0.68	11.71	0.58	8.68e-26	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs62229266	0.839	rs11088335	chr21:37470335	C/T	cg12218747	chr21:37451666	NA	-0.48	-6.77	-0.38	8.03e-11	Mitral valve prolapse;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19275838	chr7:45115588	CCM2	-0.57	-6.27	-0.36	1.45e-9	Gut microbiome composition (summer);
CESC	cis	rs4595586	0.679	rs11169992	chr12:39317207	C/T	cg26384229	chr12:38710491	ALG10B	0.41	6.09	0.35	3.94e-9	Morning vs. evening chronotype;
CESC	cis	rs7546094	1.000	rs3103450	chr1:113197730	G/A	cg22162597	chr1:113214053	CAPZA1	-0.39	-6.08	-0.35	4.18e-9	Platelet distribution width;
CESC	cis	rs7312933	0.558	rs11181463	chr12:42763636	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.47	6.03	0.35	5.41e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs826838	1.000	rs4575342	chr12:38663831	G/A	cg13010199	chr12:38710504	ALG10B	0.59	8.31	0.45	4.93e-15	Heart rate;
CESC	cis	rs881375	0.933	rs4837804	chr9:123705304	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.39	5.24	0.31	3.35e-7	Rheumatoid arthritis;
CESC	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg07308232	chr7:1071921	C7orf50	-0.42	-5.62	-0.33	4.77e-8	Longevity;Endometriosis;
CESC	cis	rs2243480	1.000	rs35735127	chr7:65300423	G/T	cg13147721	chr7:65941812	NA	-0.84	-8.42	-0.46	2.36e-15	Diabetic kidney disease;
CESC	cis	rs6690583	0.623	rs893620	chr1:85425821	T/C	cg11262906	chr1:85462892	MCOLN2	0.54	5.1	0.3	6.51e-7	Serum sulfate level;
CESC	cis	rs854765	0.583	rs4925126	chr17:17798633	C/T	cg09796270	chr17:17721594	SREBF1	0.41	5.8	0.34	1.86e-8	Total body bone mineral density;
CESC	trans	rs801193	1.000	rs1553610	chr7:66197233	T/C	cg26939375	chr7:64535504	NA	0.64	8.77	0.47	2.19e-16	Aortic root size;
CESC	cis	rs17401966	0.838	rs4846209	chr1:10322054	G/A	cg15208524	chr1:10270712	KIF1B	0.39	5.14	0.3	5.37e-7	Hepatocellular carcinoma;
CESC	cis	rs2439831	1.000	rs2467739	chr15:43740196	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.8	11.71	0.58	8.62e-26	Lung cancer in ever smokers;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg10446143	chr21:44394730	PKNOX1	0.48	6.43	0.37	5.86e-10	Systemic lupus erythematosus;
CESC	cis	rs6089829	0.692	rs6122349	chr20:61664096	T/C	cg16240275	chr20:61666158	NCRNA00029	0.42	6.17	0.35	2.61e-9	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs9467711	0.606	rs12174639	chr6:26373121	G/A	cg06606381	chr12:133084897	FBRSL1	-0.76	-7.07	-0.4	1.4e-11	Autism spectrum disorder or schizophrenia;
CESC	cis	rs6952808	0.564	rs55865401	chr7:2145720	G/C	cg23048001	chr7:2026167	MAD1L1	0.42	5.43	0.32	1.25e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs4853012	0.887	rs77148265	chr2:74339519	C/T	cg05890377	chr2:74357713	NA	0.66	8.0	0.44	3.85e-14	Gestational age at birth (maternal effect);
CESC	cis	rs736408	0.660	rs2019065	chr3:52809525	C/T	cg07507251	chr3:52567010	NT5DC2	-0.35	-5.98	-0.34	7.15e-9	Bipolar disorder;
CESC	cis	rs4722166	0.630	rs13311199	chr7:22789793	A/C	cg26061582	chr7:22766209	IL6	0.5	5.47	0.32	1.04e-7	Lung cancer;
CESC	cis	rs6495122	0.651	rs11636952	chr15:75114322	T/C	cg14664628	chr15:75095509	CSK	-0.82	-12.94	-0.62	5.1e-30	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
CESC	cis	rs3126085	0.799	rs11589532	chr1:152176539	G/A	cg03465714	chr1:152285911	FLG	0.47	5.55	0.32	6.93e-8	Atopic dermatitis;
CESC	cis	rs10504229	0.600	rs6987243	chr8:58115406	T/C	cg22535103	chr8:58192502	C8orf71	-0.81	-9.14	-0.49	1.73e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs854765	0.583	rs8078138	chr17:17811251	C/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.49	6.36	0.36	8.89e-10	Total body bone mineral density;
CESC	cis	rs7647973	1.000	rs1982861	chr3:49577665	A/G	cg07636037	chr3:49044803	WDR6	0.72	10.34	0.54	2.84e-21	Menarche (age at onset);
CESC	cis	rs644799	1.000	rs3177463	chr11:95502128	G/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.71	9.36	0.5	3.61e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	trans	rs916888	0.773	rs199445	chr17:44817408	C/T	cg27125505	chr17:43679177	LOC644172	0.48	6.39	0.37	7.63e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs875971	0.830	rs28714531	chr7:65968237	G/A	cg19163074	chr7:65112434	INTS4L2	-0.42	-5.26	-0.31	2.93e-7	Aortic root size;
CESC	cis	rs116095464	0.558	rs56043030	chr5:220917	A/G	cg22857025	chr5:266934	NA	-1.27	-18.89	-0.76	5.51e-51	Breast cancer;
CESC	cis	rs7809950	0.834	rs2712199	chr7:107140239	A/G	cg23024343	chr7:107201750	COG5	-0.42	-6.0	-0.35	6.33e-9	Coronary artery disease;
CESC	cis	rs9649213	0.593	rs12728	chr7:97922851	C/T	cg24562669	chr7:97807699	LMTK2	0.53	7.79	0.43	1.55e-13	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs9311474	0.508	rs11720159	chr3:52617802	T/G	cg18404041	chr3:52824283	ITIH1	-0.39	-6.71	-0.38	1.17e-10	Electroencephalogram traits;
CESC	cis	rs62432291	0.681	rs402388	chr6:159654994	A/C	cg14500486	chr6:159655392	FNDC1	-0.62	-6.21	-0.36	2.04e-9	Joint mobility (Beighton score);
CESC	trans	rs10808739	0.660	rs4258041	chr8:65701101	C/G	cg19896198	chr1:12123262	TNFRSF8	0.36	6.02	0.35	5.91e-9	HIV-1 susceptibility;
CESC	cis	rs6460942	0.597	rs13221702	chr7:12519076	A/G	cg02935154	chr7:12443704	VWDE	0.52	5.22	0.31	3.57e-7	Coronary artery disease;
CESC	cis	rs7520050	0.808	rs11211195	chr1:46282295	T/C	cg03146154	chr1:46216737	IPP	-0.47	-6.19	-0.36	2.34e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs12458462	0.892	rs2242175	chr18:77464406	G/A	cg23301140	chr18:77439876	CTDP1	0.57	7.65	0.43	3.62e-13	Monocyte count;
CESC	cis	rs2204008	0.688	rs12824232	chr12:38175901	G/A	cg13010199	chr12:38710504	ALG10B	0.54	6.69	0.38	1.28e-10	Bladder cancer;
CESC	cis	rs367943	1.000	rs348955	chr5:112821643	C/T	cg12552261	chr5:112820674	MCC	-0.63	-8.02	-0.44	3.43e-14	Type 2 diabetes;
CESC	cis	rs9486719	1.000	rs12190397	chr6:97036465	G/A	cg18709589	chr6:96969512	KIAA0776	-0.5	-5.44	-0.32	1.21e-7	Migraine;Coronary artery disease;
CESC	cis	rs1707322	0.752	rs28568986	chr1:46207743	C/T	cg05343316	chr1:45956843	TESK2	0.51	6.32	0.36	1.09e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs10411936	0.962	rs10402422	chr19:16475388	G/A	cg10248733	chr19:16607483	C19orf44;CALR3	0.54	6.37	0.36	8.36e-10	White blood cell count;Multiple sclerosis;
CESC	cis	rs8020095	0.571	rs8012776	chr14:67587878	C/T	cg19548862	chr14:67692701	FAM71D	-0.49	-6.12	-0.35	3.34e-9	Depression (quantitative trait);
CESC	cis	rs34779708	0.966	rs4934725	chr10:35398236	T/C	cg03585969	chr10:35415529	CREM	0.77	10.1	0.53	1.71e-20	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs6460942	0.597	rs62449509	chr7:12515013	C/T	cg06484146	chr7:12443880	VWDE	-0.71	-7.63	-0.42	4.31e-13	Coronary artery disease;
CESC	cis	rs6500602	0.702	rs56895104	chr16:4548132	G/A	cg08645402	chr16:4508243	NA	0.56	9.21	0.49	1.02e-17	Schizophrenia;
CESC	cis	rs7552404	1.000	rs7548962	chr1:76139266	G/A	cg03433033	chr1:76189801	ACADM	0.68	8.11	0.45	1.9e-14	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs2635047	0.967	rs2247784	chr18:44746997	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.47	6.32	0.36	1.1e-9	Educational attainment;
CESC	cis	rs72781680	0.752	rs72796114	chr2:23906133	C/G	cg20701182	chr2:24300061	SF3B14	0.79	6.83	0.39	5.68e-11	Lymphocyte counts;
CESC	cis	rs35146811	0.961	rs11771139	chr7:99736059	C/T	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.43	5.12	0.3	5.99e-7	Coronary artery disease;
CESC	cis	rs10242455	0.557	rs34943973	chr7:99032517	G/A	cg18809830	chr7:99032528	PTCD1	-0.95	-6.42	-0.37	6.27e-10	Blood metabolite levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26254453	chr1:46152494	TMEM69;GPBP1L1	0.63	7.18	0.4	6.89e-12	Gut microbiome composition (summer);
CESC	cis	rs7191439	0.858	rs7205626	chr16:88780472	T/C	cg02389323	chr16:88786976	FAM38A	0.86	7.42	0.41	1.58e-12	Plateletcrit;
CESC	cis	rs4588572	0.686	rs34262593	chr5:77666427	T/C	cg11547950	chr5:77652471	NA	0.43	5.45	0.32	1.14e-7	Triglycerides;
CESC	cis	rs9660180	0.967	rs6687065	chr1:1778469	A/G	cg13866156	chr1:1669148	SLC35E2	-0.5	-6.66	-0.38	1.58e-10	Body mass index;
CESC	cis	rs7666738	0.927	rs6832373	chr4:99051967	A/G	cg03467027	chr4:99064603	C4orf37	0.47	5.97	0.34	7.58e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6570726	0.846	rs439035	chr6:145887990	G/C	cg05347473	chr6:146136440	FBXO30	0.49	6.51	0.37	3.84e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9916302	0.851	rs6503502	chr17:37501855	A/G	cg00129232	chr17:37814104	STARD3	0.57	7.67	0.43	3.29e-13	Glomerular filtration rate (creatinine);
CESC	cis	rs9303401	0.538	rs8078280	chr17:56473132	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.9	10.99	0.56	2.11e-23	Cognitive test performance;
CESC	cis	rs1580019	0.587	rs1597555	chr7:32546118	T/G	cg07520158	chr7:32535189	LSM5;AVL9	0.51	6.39	0.37	7.42e-10	Cognitive ability;
CESC	cis	rs9399135	0.967	rs9376077	chr6:135299713	C/G	cg22676075	chr6:135203613	NA	0.51	7.02	0.4	1.84e-11	Red blood cell count;
CESC	cis	rs3733585	0.699	rs7435196	chr4:9967556	A/C	cg11266682	chr4:10021025	SLC2A9	-0.58	-10.97	-0.56	2.51e-23	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs9393777	0.588	rs3799380	chr6:26467182	C/T	cg12826209	chr6:26865740	GUSBL1	-0.62	-7.76	-0.43	1.81e-13	Intelligence (multi-trait analysis);
CESC	cis	rs4713118	0.662	rs149970	chr6:27980220	C/T	cg12963246	chr6:28129442	ZNF389	0.4	5.48	0.32	9.73e-8	Parkinson's disease;
CESC	cis	rs2742234	0.541	rs1059484	chr10:43679800	T/G	cg15436174	chr10:43711423	RASGEF1A	-0.5	-5.84	-0.34	1.5e-8	Hirschsprung disease;
CESC	cis	rs36051895	0.589	rs10491650	chr9:5203054	C/T	cg02405213	chr9:5042618	JAK2	0.47	5.63	0.33	4.6e-8	Pediatric autoimmune diseases;
CESC	cis	rs875971	0.862	rs6460307	chr7:66060871	A/G	cg10691866	chr7:65817282	TPST1	-0.35	-5.95	-0.34	8.41e-9	Aortic root size;
CESC	cis	rs10129255	0.500	rs6576226	chr14:107186374	G/A	cg07958169	chr14:107095056	NA	-0.54	-8.49	-0.46	1.51e-15	Kawasaki disease;
CESC	cis	rs873946	0.504	rs4880275	chr10:134576552	C/T	cg27286337	chr10:134555280	INPP5A	0.65	7.62	0.42	4.39e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs28489187	0.706	rs233091	chr1:85823044	G/C	cg16011679	chr1:85725395	C1orf52	0.47	5.45	0.32	1.14e-7	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	cis	rs3749237	0.595	rs1464568	chr3:49458266	G/A	cg03060546	chr3:49711283	APEH	0.76	11.69	0.58	9.43e-26	Resting heart rate;
CESC	cis	rs4665809	0.556	rs4665314	chr2:26415912	T/C	cg08470875	chr2:26401718	FAM59B	-0.73	-7.97	-0.44	4.87e-14	Gut microbiome composition (summer);
CESC	cis	rs7264396	0.563	rs2425131	chr20:34337074	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.89	-10.71	-0.55	1.83e-22	Total cholesterol levels;
CESC	cis	rs2073300	0.609	rs2281434	chr20:23378101	C/A	cg12062639	chr20:23401060	NAPB	1.07	8.85	0.48	1.29e-16	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs1986734	0.576	rs2068063	chr4:77417203	C/T	cg20311846	chr4:77356250	SHROOM3	0.27	5.44	0.32	1.2e-7	Eosinophilic esophagitis (pediatric);Metabolite levels (small molecules and protein measures);
CESC	cis	rs9611565	0.694	rs202617	chr22:41822793	C/T	cg06481639	chr22:41940642	POLR3H	0.64	6.5	0.37	3.91e-10	Vitiligo;
CESC	cis	rs9303401	0.527	rs34835800	chr17:56764990	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.05	12.38	0.61	4.37e-28	Cognitive test performance;
CESC	trans	rs2235573	0.551	rs139895	chr22:38397034	A/G	cg19894588	chr14:64061835	NA	-0.57	-7.55	-0.42	7.06e-13	Glioblastoma;Glioma;
CESC	cis	rs875971	0.862	rs2024192	chr7:66041447	G/T	cg18876405	chr7:65276391	NA	-0.53	-7.25	-0.41	4.64e-12	Aortic root size;
CESC	cis	rs514406	0.861	rs1749907	chr1:53259658	C/T	cg08736216	chr1:53307985	ZYG11A	0.43	7.24	0.41	4.86e-12	Monocyte count;
CESC	cis	rs778371	0.723	rs1022329	chr2:233591239	T/C	cg08000102	chr2:233561755	GIGYF2	0.84	14.62	0.67	6.79e-36	Schizophrenia;
CESC	cis	rs7829975	0.846	rs11779061	chr8:8549432	G/A	cg06636001	chr8:8085503	FLJ10661	-0.45	-5.85	-0.34	1.45e-8	Mood instability;
CESC	cis	rs780096	0.527	rs59644396	chr2:27646083	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.29	-5.52	-0.32	8.2e-8	Total body bone mineral density;
CESC	cis	rs10197940	0.624	rs6731486	chr2:152410732	C/T	cg06191203	chr2:152266755	RIF1	0.45	5.71	0.33	3.05e-8	Lung cancer;
CESC	cis	rs10465746	0.780	rs12145258	chr1:84401211	G/A	cg10977910	chr1:84465055	TTLL7	0.51	6.95	0.39	2.89e-11	Obesity-related traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13497155	chr3:50374949	RASSF1	-0.63	-7.03	-0.4	1.71e-11	Gut microbiome composition (summer);
CESC	cis	rs9487051	0.872	rs9386789	chr6:109603218	A/G	cg01475377	chr6:109611718	NA	-0.5	-8.37	-0.46	3.34e-15	Reticulocyte fraction of red cells;
CESC	cis	rs36051895	0.658	rs72699574	chr9:5020089	G/A	cg02405213	chr9:5042618	JAK2	-0.5	-5.48	-0.32	9.73e-8	Pediatric autoimmune diseases;
CESC	cis	rs4974559	0.740	rs11933854	chr4:1315172	G/A	cg02980000	chr4:1222292	CTBP1	0.64	7.16	0.4	8.08e-12	Systolic blood pressure;
CESC	cis	rs7818688	0.697	rs78802294	chr8:95977974	G/A	cg16049864	chr8:95962084	TP53INP1	0.57	5.73	0.33	2.79e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg03790324	chr7:76143302	UPK3B	0.52	6.92	0.39	3.33e-11	Fibrinogen levels;
CESC	cis	rs73019876	0.901	rs2666440	chr19:22139345	G/T	cg11619707	chr19:22235551	ZNF257	-0.27	-5.11	-0.3	6.12e-7	Testicular germ cell tumor;
CESC	cis	rs8040855	0.627	rs4980357	chr15:85608109	G/T	cg08123816	chr15:85640762	PDE8A	-0.41	-6.07	-0.35	4.31e-9	Bulimia nervosa;
CESC	cis	rs7618915	0.547	rs2336542	chr3:52710636	A/G	cg07507251	chr3:52567010	NT5DC2	0.4	7.1	0.4	1.14e-11	Bipolar disorder;
CESC	cis	rs2066819	1.000	rs118130855	chr12:56677979	T/A	cg26714650	chr12:56694279	CS	-1.52	-10.39	-0.54	1.95e-21	Psoriasis vulgaris;
CESC	cis	rs910316	1.000	rs4899546	chr14:75594946	G/C	cg11812906	chr14:75593930	NEK9	0.9	15.35	0.69	1.8e-38	Height;
CESC	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg05313129	chr8:58192883	C8orf71	-0.48	-5.27	-0.31	2.89e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs11676348	0.818	rs7425447	chr2:218980183	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.46	-6.16	-0.35	2.67e-9	Ulcerative colitis;
CESC	cis	rs9611565	0.879	rs5758307	chr22:41750219	A/G	cg03806693	chr22:41940476	POLR3H	-0.72	-8.72	-0.47	3.14e-16	Vitiligo;
CESC	cis	rs853679	0.517	rs9380047	chr6:28037893	G/T	cg20151795	chr6:28129481	ZNF389	0.43	5.46	0.32	1.11e-7	Depression;
CESC	cis	rs11122272	0.735	rs2808583	chr1:231512587	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.57	-7.82	-0.43	1.25e-13	Hemoglobin concentration;
CESC	cis	rs1784581	0.546	rs1954917	chr6:162447490	C/T	cg17173639	chr6:162384350	PARK2	0.61	9.45	0.5	1.87e-18	Itch intensity from mosquito bite;
CESC	cis	rs6748734	1.000	rs3936203	chr2:241834654	C/T	cg04034577	chr2:241836375	C2orf54	0.51	8.89	0.48	9.34e-17	Urinary metabolites;
CESC	cis	rs35306767	0.761	rs11253559	chr10:1044809	T/C	cg26597838	chr10:835615	NA	0.7	6.38	0.36	7.93e-10	Eosinophil percentage of granulocytes;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg23187205	chr6:109416245	SESN1;C6orf182	-0.46	-6.18	-0.35	2.45e-9	Height;
CESC	cis	rs875971	0.662	rs448725	chr7:65514628	A/G	cg10691866	chr7:65817282	TPST1	-0.34	-5.49	-0.32	9.58e-8	Aortic root size;
CESC	cis	rs1707322	0.964	rs7512395	chr1:46361177	G/A	cg05343316	chr1:45956843	TESK2	0.49	5.96	0.34	7.98e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs1788820	0.917	rs1788785	chr18:21142340	T/C	cg14672496	chr18:21087552	C18orf8	0.55	7.43	0.42	1.5e-12	Body mass index;
CESC	cis	rs9488822	0.676	rs12196579	chr6:116351724	G/T	cg18764771	chr6:116381957	FRK	0.23	5.71	0.33	3.07e-8	Cholesterol, total;LDL cholesterol;
CESC	trans	rs2749592	0.505	rs7915670	chr10:37870212	T/C	cg12057190	chr19:54976211	LENG9;CDC42EP5	-0.42	-6.0	-0.35	6.62e-9	Age-related hearing impairment (SNP x SNP interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06854353	chr6:109704291	CD164	-0.55	-6.33	-0.36	1.03e-9	Gut microbiome composition (summer);
CESC	cis	rs4423214	1.000	rs2282621	chr11:71183474	C/T	cg24826892	chr11:71159390	DHCR7	0.46	5.24	0.31	3.2e-7	Vitamin D levels;
CESC	trans	rs330071	0.686	rs10087406	chr8:9246598	C/T	cg15556689	chr8:8085844	FLJ10661	-0.51	-6.1	-0.35	3.65e-9	Acne (severe);
CESC	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg26338869	chr17:61819248	STRADA	0.69	9.18	0.49	1.31e-17	Prudent dietary pattern;
CESC	cis	rs11676348	0.755	rs6436026	chr2:218951738	T/A	cg00012203	chr2:219082015	ARPC2	-0.52	-6.85	-0.39	5e-11	Ulcerative colitis;
CESC	cis	rs654950	0.807	rs941970	chr1:41990867	G/A	cg06885757	chr1:42089581	HIVEP3	-0.44	-6.84	-0.39	5.39e-11	Airway imaging phenotypes;
CESC	cis	rs9527	0.545	rs7100369	chr10:104956218	C/A	cg04362960	chr10:104952993	NT5C2	0.44	5.56	0.32	6.74e-8	Arsenic metabolism;
CESC	cis	rs4563143	0.675	rs34113156	chr19:29270822	G/A	cg12667521	chr19:29218732	NA	0.48	6.4	0.37	6.97e-10	Methadone dose in opioid dependence;
CESC	cis	rs6570726	0.791	rs6570693	chr6:145910841	C/T	cg05347473	chr6:146136440	FBXO30	0.57	7.44	0.42	1.37e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs10504229	1.000	rs17805656	chr8:58180318	T/C	cg05313129	chr8:58192883	C8orf71	-0.55	-6.37	-0.36	8.42e-10	Developmental language disorder (linguistic errors);
CESC	trans	rs3087243	0.755	rs231735	chr2:204693876	A/C	cg01841312	chr10:38069945	NA	-0.41	-6.98	-0.39	2.34e-11	Rheumatoid arthritis;Hypothyroidism;Type 1 diabetes;
CESC	cis	rs6570726	0.811	rs375873	chr6:145812371	G/T	cg23711669	chr6:146136114	FBXO30	0.78	11.22	0.57	3.67e-24	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1218582	0.682	rs12046459	chr1:154912017	A/C	cg09359103	chr1:154839909	KCNN3	-0.65	-11.98	-0.59	1.01e-26	Prostate cancer;
CESC	trans	rs8056446	0.710	rs8059793	chr16:78189298	A/C	cg22855052	chr12:6982535	SPSB2	0.44	6.09	0.35	3.91e-9	Pulmonary function (smoking interaction);
CESC	cis	rs10080237	0.564	rs2490224	chr6:80809833	G/A	cg08355045	chr6:80787529	NA	0.34	5.19	0.3	4.19e-7	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
CESC	cis	rs9640161	0.750	rs3735167	chr7:150039555	C/T	cg13722127	chr7:150037890	RARRES2	0.39	5.29	0.31	2.56e-7	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs12220238	1.000	rs11000912	chr10:75948477	A/C	cg19889307	chr10:75911429	ADK;AP3M1	0.59	5.12	0.3	5.78e-7	Soluble interleukin-2 receptor subunit alpha;
CESC	cis	rs17345786	0.906	rs59359251	chr3:101146362	A/C	cg11279151	chr3:101281821	RG9MTD1	-0.45	-5.03	-0.3	8.92e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7834588	0.523	rs4739023	chr8:63831674	C/G	cg20602954	chr8:63776762	NKAIN3	-0.31	-5.29	-0.31	2.61e-7	Response to Vitamin E supplementation;
CESC	cis	rs2296342	0.652	rs2296338	chr6:33630816	G/A	cg14003231	chr6:33640908	ITPR3	0.3	5.13	0.3	5.53e-7	Schizophrenia;
CESC	cis	rs7666738	0.830	rs4292342	chr4:98959870	A/T	cg17366294	chr4:99064904	C4orf37	0.6	8.47	0.46	1.76e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9488822	0.676	rs1556857	chr6:116325559	T/C	cg18764771	chr6:116381957	FRK	0.22	5.44	0.32	1.21e-7	Cholesterol, total;LDL cholesterol;
CESC	trans	rs12599106	0.584	rs12929704	chr16:34898258	C/A	cg21548813	chr6:291882	DUSP22	-0.73	-9.81	-0.52	1.38e-19	Menopause (age at onset);
CESC	cis	rs2839186	0.647	rs9976233	chr21:47616913	G/A	cg00815214	chr21:47717953	NA	0.43	6.27	0.36	1.49e-9	Testicular germ cell tumor;
CESC	trans	rs35110281	0.807	rs2838328	chr21:45023234	G/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.5	6.54	0.37	3.14e-10	Mean corpuscular volume;
CESC	cis	rs2425143	1.000	rs78877130	chr20:34344947	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.67	5.76	0.33	2.31e-8	Blood protein levels;
CESC	cis	rs9911578	1.000	rs2567911	chr17:56734977	A/G	cg12560992	chr17:57184187	TRIM37	0.93	15.58	0.69	2.6e-39	Intelligence (multi-trait analysis);
CESC	cis	rs6460942	1.000	rs6970095	chr7:12403840	G/A	cg20607287	chr7:12443886	VWDE	-0.68	-7.91	-0.44	6.85e-14	Coronary artery disease;
CESC	cis	rs9467773	0.620	rs2451738	chr6:26618459	A/T	cg05192639	chr6:26864778	GUSBL1	-0.27	-5.11	-0.3	6.25e-7	Intelligence (multi-trait analysis);
CESC	cis	rs13118159	0.550	rs10016557	chr4:1363628	C/T	cg16405210	chr4:1374714	KIAA1530	0.78	10.15	0.53	1.12e-20	Longevity;
CESC	cis	rs2075371	0.966	rs1646646	chr7:133996905	G/T	cg11752832	chr7:134001865	SLC35B4	0.55	7.22	0.41	5.43e-12	Mean platelet volume;
CESC	cis	rs6542838	0.588	rs4851174	chr2:99530113	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.47	-5.97	-0.34	7.71e-9	Fear of minor pain;
CESC	cis	rs7666738	0.830	rs62318503	chr4:98935479	T/C	cg03467027	chr4:99064603	C4orf37	0.48	5.91	0.34	1.03e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2486288	0.656	rs12904150	chr15:45547605	T/C	cg21132104	chr15:45694354	SPATA5L1	-0.54	-6.54	-0.37	3.21e-10	Glomerular filtration rate;
CESC	cis	rs7851660	0.935	rs12347191	chr9:100619719	C/T	cg13688889	chr9:100608707	NA	-0.7	-10.61	-0.55	3.91e-22	Strep throat;
CESC	cis	rs7618501	0.699	rs2777888	chr3:49898000	A/G	cg24308560	chr3:49941425	MST1R	-0.69	-10.31	-0.54	3.58e-21	Intelligence (multi-trait analysis);
CESC	cis	rs9815354	0.680	rs73073285	chr3:42027566	T/G	cg03022575	chr3:42003672	ULK4	0.75	6.64	0.38	1.72e-10	Pulse pressure;Diastolic blood pressure;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg12019576	chr4:154388535	KIAA0922	-0.43	-6.2	-0.36	2.19e-9	Gambling;
CESC	cis	rs72781680	1.000	rs12614452	chr2:24194608	C/T	cg08917208	chr2:24149416	ATAD2B	0.94	8.54	0.46	1.09e-15	Lymphocyte counts;
CESC	cis	rs1008375	0.900	rs12650220	chr4:17595365	A/T	cg04450456	chr4:17643702	FAM184B	0.36	5.11	0.3	6.31e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs10129255	0.518	rs8004895	chr14:107193377	T/C	cg07958169	chr14:107095056	NA	-0.54	-8.32	-0.45	4.77e-15	Kawasaki disease;
CESC	cis	rs2228479	0.850	rs117285117	chr16:89910250	T/G	cg06558623	chr16:89946397	TCF25	1.12	8.22	0.45	9.28e-15	Skin colour saturation;
CESC	cis	rs7552404	0.727	rs7547056	chr1:76279267	C/T	cg22875332	chr1:76189707	ACADM	0.64	6.52	0.37	3.52e-10	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs2033711	0.870	rs7408188	chr19:58939389	T/G	cg26874164	chr19:58962979	ZNF324B	0.54	7.47	0.42	1.2e-12	Uric acid clearance;
CESC	cis	rs4665809	0.590	rs7582341	chr2:26416301	A/G	cg26314531	chr2:26401878	FAM59B	-0.83	-9.26	-0.49	7.29e-18	Gut microbiome composition (summer);
CESC	cis	rs568617	0.768	rs12225345	chr11:65647105	A/G	cg19792802	chr11:65647270	CTSW	0.39	5.2	0.3	4e-7	Crohn's disease;
CESC	cis	rs1728785	0.786	rs1728770	chr16:68564124	G/C	cg02972257	chr16:68554789	NA	-0.62	-6.95	-0.39	2.88e-11	Ulcerative colitis;
CESC	cis	rs977987	0.966	rs6564261	chr16:75492242	C/T	cg03315344	chr16:75512273	CHST6	0.53	7.82	0.43	1.22e-13	Dupuytren's disease;
CESC	cis	rs10504073	0.525	rs10081464	chr8:50058707	A/G	cg00325661	chr8:49890786	NA	0.41	5.83	0.34	1.63e-8	Blood metabolite ratios;
CESC	cis	rs561341	0.941	rs2428336	chr17:30290577	T/C	cg00745463	chr17:30367425	LRRC37B	-0.69	-6.8	-0.39	6.97e-11	Hip circumference adjusted for BMI;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg22692790	chr10:70748415	KIAA1279	0.53	7.46	0.42	1.26e-12	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs798554	0.548	rs1639064	chr7:2896544	G/A	cg19717773	chr7:2847554	GNA12	-0.49	-7.43	-0.42	1.54e-12	Height;
CESC	cis	rs926938	0.527	rs360684	chr1:115499001	A/G	cg12756093	chr1:115239321	AMPD1	0.44	6.06	0.35	4.58e-9	Autism;
CESC	cis	rs8014204	0.967	rs1319171	chr14:75334096	G/T	cg26191576	chr14:75389716	RPS6KL1	0.37	5.28	0.31	2.73e-7	Caffeine consumption;
CESC	cis	rs2228479	0.717	rs11644967	chr16:89806614	T/A	cg04013166	chr16:89971882	TCF25	0.78	8.27	0.45	6.71e-15	Skin colour saturation;
CESC	trans	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg13565492	chr6:43139072	SRF	-0.61	-6.4	-0.37	6.96e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs3768617	0.510	rs10458355	chr1:183063993	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.88	14.24	0.66	1.45e-34	Fuchs's corneal dystrophy;
CESC	cis	rs727505	1.000	rs7790856	chr7:124459852	C/T	cg23710748	chr7:124431027	NA	-0.38	-6.05	-0.35	4.82e-9	Lewy body disease;
CESC	cis	rs11785693	0.862	rs73189843	chr8:5000915	C/T	cg26367366	chr8:4980734	NA	0.8	7.66	0.43	3.47e-13	Neuroticism (multi-trait analysis);Neuroticism;
CESC	cis	rs597539	0.652	rs501799	chr11:68631240	G/T	cg01988459	chr11:68622903	NA	-0.46	-6.53	-0.37	3.28e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs9487051	0.799	rs830553	chr6:109550017	T/G	cg01475377	chr6:109611718	NA	-0.4	-5.89	-0.34	1.18e-8	Reticulocyte fraction of red cells;
CESC	cis	rs6693567	0.545	rs1694380	chr1:150292341	A/G	cg09579323	chr1:150459698	TARS2	0.47	6.13	0.35	3.18e-9	Migraine;
CESC	cis	rs12618769	0.656	rs3769735	chr2:99092302	C/T	cg10123293	chr2:99228465	UNC50	0.4	5.38	0.31	1.68e-7	Bipolar disorder;
CESC	cis	rs2933343	0.649	rs1683786	chr3:128626952	T/C	cg24203234	chr3:128598194	ACAD9	0.43	5.82	0.34	1.74e-8	IgG glycosylation;
CESC	cis	rs7274811	0.744	rs209677	chr20:32140287	C/T	cg21523528	chr20:32077966	CBFA2T2	-0.42	-5.11	-0.3	6.2e-7	Height;
CESC	cis	rs780096	0.525	rs13388159	chr2:27648284	A/T	cg22903471	chr2:27725779	GCKR	-0.59	-8.48	-0.46	1.65e-15	Total body bone mineral density;
CESC	cis	rs7264396	0.563	rs56941405	chr20:34313426	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.89	-10.78	-0.55	1.03e-22	Total cholesterol levels;
CESC	trans	rs1497546	0.867	rs73853752	chr3:97940423	T/C	cg12626411	chr1:186265765	PRG4;MIR548F1	0.85	6.36	0.36	8.62e-10	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs1799949	1.000	rs33926631	chr17:41304463	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.67	9.37	0.5	3.2e-18	Menopause (age at onset);
CESC	cis	rs10789491	1.000	rs618505	chr1:47144532	T/C	cg15501359	chr1:47185051	KIAA0494	0.8	8.63	0.47	5.59e-16	Response to hepatitis C treatment;
CESC	cis	rs8072100	0.748	rs9908016	chr17:45551361	G/A	cg08085267	chr17:45401833	C17orf57	-0.58	-7.7	-0.43	2.77e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	trans	rs12310956	0.532	rs10844707	chr12:33936089	T/C	cg26384229	chr12:38710491	ALG10B	0.57	7.96	0.44	5.09e-14	Morning vs. evening chronotype;
CESC	cis	rs6088590	1.000	rs6087625	chr20:33342477	A/G	cg06115741	chr20:33292138	TP53INP2	-0.58	-7.16	-0.4	7.99e-12	Coronary artery disease;
CESC	cis	rs801193	0.935	rs3800820	chr7:66147178	C/T	cg11764359	chr7:65958608	NA	-0.69	-9.06	-0.49	2.98e-17	Aortic root size;
CESC	trans	rs9693444	0.898	rs4732697	chr8:29519861	A/G	cg22696252	chr3:97540975	NA	-0.4	-6.04	-0.35	5.1e-9	Breast cancer;
CESC	cis	rs9815354	0.812	rs113300894	chr3:41984243	G/C	cg03022575	chr3:42003672	ULK4	0.67	5.92	0.34	9.77e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs2304069	0.913	rs7734382	chr5:149383241	A/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.88	11.21	0.57	4.03e-24	HIV-1 control;
CESC	cis	rs896854	0.654	rs13274945	chr8:95986626	C/T	cg26343298	chr8:95960752	TP53INP1	0.37	6.14	0.35	3.07e-9	Type 2 diabetes;
CESC	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg14893161	chr1:205819251	PM20D1	0.88	14.01	0.65	9.2e-34	Menarche (age at onset);
CESC	cis	rs1862618	0.671	rs2591961	chr5:56238597	A/G	cg18230493	chr5:56204884	C5orf35	0.61	8.0	0.44	3.99e-14	Initial pursuit acceleration;
CESC	cis	rs7666738	0.830	rs34628820	chr4:99004764	C/T	cg03467027	chr4:99064603	C4orf37	0.44	5.51	0.32	8.65e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs77106637	0.860	rs7129793	chr11:72455885	C/T	cg04827223	chr11:72435913	ARAP1	-0.58	-5.53	-0.32	7.67e-8	Type 2 diabetes;
CESC	cis	rs13118159	0.836	rs12647145	chr4:1338618	C/A	cg00684032	chr4:1343700	KIAA1530	0.42	6.58	0.37	2.55e-10	Longevity;
CESC	cis	rs2302190	0.882	rs11650105	chr17:56588072	C/T	cg25885038	chr17:56607967	SEPT4	-0.42	-5.7	-0.33	3.22e-8	Vitamin D levels;
CESC	cis	rs1348850	0.914	rs4893950	chr2:178304885	T/C	cg22681709	chr2:178499509	PDE11A	-0.43	-6.07	-0.35	4.34e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	trans	rs13098911	0.540	rs36023124	chr3:46039060	G/C	cg10236987	chr1:228114221	WNT9A	0.66	6.54	0.37	3.11e-10	Celiac disease;
CESC	cis	rs7714584	1.000	rs6579804	chr5:150255931	T/C	cg22134413	chr5:150180641	NA	0.51	5.92	0.34	9.88e-9	Crohn's disease;
CESC	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg07677032	chr17:61819896	STRADA	0.45	5.91	0.34	1.03e-8	Prudent dietary pattern;
CESC	cis	rs9916302	0.861	rs33933929	chr17:37426441	A/C	cg15445000	chr17:37608096	MED1	0.39	6.38	0.36	7.82e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs875971	0.798	rs57739047	chr7:65972566	A/T	cg11764359	chr7:65958608	NA	0.81	11.74	0.58	6.73e-26	Aortic root size;
CESC	cis	rs1348850	0.914	rs11893448	chr2:178280013	T/C	cg23306229	chr2:178417860	TTC30B	0.65	8.41	0.46	2.59e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs7824557	0.603	rs7016671	chr8:11182455	A/G	cg21775007	chr8:11205619	TDH	0.54	8.4	0.46	2.77e-15	Retinal vascular caliber;
CESC	cis	rs3741404	0.791	rs11603192	chr11:63927695	A/G	cg18225595	chr11:63971243	STIP1	0.74	10.23	0.53	6.64e-21	Platelet count;
CESC	cis	rs769267	0.930	rs1054930	chr19:19648346	G/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.48	6.08	0.35	4.15e-9	Tonsillectomy;
CESC	cis	rs9894429	0.608	rs7406382	chr17:79597786	T/C	cg13777783	chr17:79615861	NA	-0.37	-6.15	-0.35	2.83e-9	Eye color traits;
CESC	cis	rs3733585	0.699	rs7437120	chr4:9967683	T/A	cg00071950	chr4:10020882	SLC2A9	-0.7	-11.47	-0.58	5.33e-25	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs863345	0.933	rs10908659	chr1:158465858	G/A	cg12129480	chr1:158549410	OR10X1	-0.3	-6.01	-0.35	6.09e-9	Pneumococcal bacteremia;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg07797367	chr6:84136471	ME1	0.43	6.39	0.37	7.38e-10	Cleft plate (environmental tobacco smoke interaction);
CESC	trans	rs4332037	0.901	rs7791899	chr7:1935988	T/C	cg11693508	chr17:37793320	STARD3	0.65	6.11	0.35	3.55e-9	Bipolar disorder;
CESC	cis	rs11997175	0.503	rs7013967	chr8:33826107	T/G	ch.8.33884649F	chr8:33765107	NA	0.6	7.48	0.42	1.1e-12	Body mass index;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01471259	chr16:2645846	PDPK1	-0.61	-6.86	-0.39	4.88e-11	Gut microbiome composition (summer);
CESC	trans	rs62103177	0.673	rs62096717	chr18:77616819	C/T	cg05926928	chr17:57297772	GDPD1	0.78	8.19	0.45	1.08e-14	Opioid sensitivity;
CESC	cis	rs1008375	1.000	rs2058339	chr4:17678456	C/T	cg16339924	chr4:17578868	LAP3	0.51	6.6	0.38	2.21e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs10927875	0.597	rs61782184	chr1:16150976	G/A	cg18973939	chr1:16164122	FLJ37453	0.38	5.66	0.33	4.01e-8	Dilated cardiomyopathy;
CESC	cis	rs2180341	0.960	rs7751865	chr6:127683040	G/A	cg27446573	chr6:127587934	RNF146	1.06	15.88	0.7	2.39e-40	Breast cancer;
CESC	cis	rs1552244	1.000	rs9834980	chr3:10065528	G/A	cg00166722	chr3:10149974	C3orf24	0.51	6.38	0.37	7.76e-10	Alzheimer's disease;
CESC	cis	rs703842	0.963	rs2069506	chr12:58142854	C/A	cg18357645	chr12:58087776	OS9	-0.43	-6.13	-0.35	3.19e-9	Multiple sclerosis;
CESC	cis	rs798554	0.836	rs2260230	chr7:2822986	T/A	cg19346786	chr7:2764209	NA	-0.51	-7.4	-0.41	1.77e-12	Height;
CESC	cis	rs9314614	0.933	rs2741098	chr8:6690276	C/T	cg27319216	chr8:6693540	XKR5	0.37	5.39	0.31	1.54e-7	IgA nephropathy;White blood cell count (basophil);
CESC	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg24846343	chr22:24311635	DDTL	-0.45	-6.36	-0.36	8.61e-10	Urinary 1,3-butadiene metabolite levels in smokers;
CESC	cis	rs1670533	0.932	rs13140341	chr4:1054235	T/C	cg27284194	chr4:1044797	NA	0.46	5.82	0.34	1.68e-8	Recombination rate (females);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19345149	chr11:116658875	ZNF259	0.72	8.57	0.47	8.67e-16	Gut microbiome composition (summer);
CESC	cis	rs853679	0.517	rs9357061	chr6:28051772	A/G	cg23161317	chr6:28129485	ZNF389	0.5	6.31	0.36	1.19e-9	Depression;
CESC	cis	rs17407555	0.909	rs56133633	chr4:10291351	G/T	cg11266682	chr4:10021025	SLC2A9	-0.48	-5.69	-0.33	3.42e-8	Schizophrenia (age at onset);
CESC	cis	rs8022179	0.566	rs959083	chr14:103822687	A/G	cg12935359	chr14:103987150	CKB	-0.47	-5.77	-0.33	2.17e-8	Monocyte count;
CESC	cis	rs75064307	0.834	rs10511271	chr3:108114572	A/G	cg03329597	chr3:108125523	MYH15	-0.5	-5.66	-0.33	3.86e-8	Intelligence (multi-trait analysis);
CESC	cis	rs71277158	0.688	rs73030653	chr3:169841926	G/A	cg04067573	chr3:169899625	PHC3	0.67	6.88	0.39	4.23e-11	Prostate cancer;
CESC	cis	rs6540559	0.808	rs11119358	chr1:210042456	T/C	cg21951975	chr1:209979733	IRF6	0.6	8.61	0.47	6.58e-16	Cleft lip with or without cleft palate;
CESC	cis	rs7937682	0.889	rs11213969	chr11:111528441	A/G	cg22437258	chr11:111473054	SIK2	0.69	9.25	0.49	7.9e-18	Primary sclerosing cholangitis;
CESC	cis	rs1153858	1.000	rs56669689	chr15:45637729	A/C	cg14582100	chr15:45693742	SPATA5L1	0.42	6.08	0.35	4.2e-9	Homoarginine levels;
CESC	cis	rs5750830	0.645	rs4821890	chr22:39777523	G/A	cg24399712	chr22:39784796	NA	-0.72	-10.59	-0.55	4.38e-22	Intelligence (multi-trait analysis);
CESC	cis	rs7223966	1.000	rs1877316	chr17:61766880	C/A	cg11494091	chr17:61959527	GH2	0.37	5.04	0.3	8.73e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg07167872	chr1:205819463	PM20D1	0.72	11.5	0.58	4.39e-25	Menarche (age at onset);
CESC	cis	rs10256972	0.621	rs10951594	chr7:1088607	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.48	-7.02	-0.4	1.8e-11	Longevity;Endometriosis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03846689	chr6:111135840	CDK19	0.6	7.35	0.41	2.51e-12	Gut microbiome composition (summer);
CESC	cis	rs7071206	0.853	rs114936111	chr10:79430143	G/A	cg07817648	chr10:79422355	NA	-0.78	-10.21	-0.53	7.37e-21	Bone mineral density;
CESC	cis	rs2404602	0.716	rs1125932	chr15:76820540	C/T	cg22467129	chr15:76604101	ETFA	-0.35	-5.31	-0.31	2.33e-7	Blood metabolite levels;
CESC	trans	rs7618501	1.000	rs3749240	chr3:49750188	T/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.58	-8.35	-0.46	3.8e-15	Intelligence (multi-trait analysis);
CESC	cis	rs9910055	0.659	rs186603	chr17:42207884	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	-0.53	-8.06	-0.44	2.64e-14	Total body bone mineral density;
CESC	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg03452623	chr4:187889614	NA	0.88	15.11	0.68	1.26e-37	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs8017423	0.967	rs11627429	chr14:90689232	G/A	cg14092571	chr14:90743983	NA	0.52	7.58	0.42	6e-13	Mortality in heart failure;
CESC	cis	rs5167	0.506	rs7257916	chr19:45482884	T/C	cg20090143	chr19:45452003	APOC2	-0.34	-5.37	-0.31	1.72e-7	Blood protein levels;
CESC	cis	rs9457247	1.000	rs385863	chr6:167386615	C/G	cg25258033	chr6:167368657	RNASET2	0.39	5.87	0.34	1.31e-8	Crohn's disease;
CESC	cis	rs10791323	0.604	rs2723598	chr11:133711652	G/A	cg06766960	chr11:133703094	NA	-0.39	-5.45	-0.32	1.14e-7	Childhood ear infection;
CESC	cis	rs7618915	0.571	rs6805539	chr3:52609710	T/A	cg18337363	chr3:52569053	NT5DC2	0.29	5.14	0.3	5.27e-7	Bipolar disorder;
CESC	cis	rs9322193	0.923	rs12195866	chr6:150014470	A/G	cg13206674	chr6:150067644	NUP43	0.41	5.77	0.33	2.22e-8	Lung cancer;
CESC	cis	rs8005677	1.000	rs2295683	chr14:23388382	A/C	cg01529538	chr14:23388837	RBM23	0.51	6.87	0.39	4.64e-11	Cognitive ability (multi-trait analysis);
CESC	cis	rs10504229	0.593	rs16921626	chr8:58040359	C/T	cg24829409	chr8:58192753	C8orf71	-0.49	-5.99	-0.35	6.9e-9	Developmental language disorder (linguistic errors);
CESC	trans	rs916888	0.821	rs199505	chr17:44859410	A/G	cg23590916	chr17:43697445	MGC57346	-0.6	-6.3	-0.36	1.23e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs11779988	0.598	rs6980962	chr8:17909992	G/A	cg18067069	chr8:17937731	ASAH1	-0.39	-5.17	-0.3	4.57e-7	Breast cancer;
CESC	cis	rs4523957	0.579	rs2307143	chr17:2089754	G/A	cg16513277	chr17:2031491	SMG6	-0.63	-8.81	-0.48	1.7e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs6952808	0.656	rs11764212	chr7:2067593	C/A	cg02951883	chr7:2050386	MAD1L1	-0.54	-7.09	-0.4	1.24e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs11122272	0.735	rs2009873	chr1:231499236	C/T	cg06096015	chr1:231504339	EGLN1	0.43	6.27	0.36	1.47e-9	Hemoglobin concentration;
CESC	cis	rs10504229	0.683	rs2005392	chr8:58106896	T/C	cg22535103	chr8:58192502	C8orf71	-0.77	-8.76	-0.47	2.37e-16	Developmental language disorder (linguistic errors);
CESC	cis	rs734999	0.588	rs4648653	chr1:2535895	C/T	cg18854424	chr1:2615690	NA	0.27	5.26	0.31	3e-7	Ulcerative colitis;
CESC	cis	rs2637266	0.678	rs11498047	chr10:78464839	G/A	cg18941641	chr10:78392320	NA	0.38	6.86	0.39	4.82e-11	Pulmonary function;
CESC	cis	rs798554	0.679	rs1636249	chr7:2884283	T/G	cg13628971	chr7:2884303	GNA12	0.65	9.09	0.49	2.36e-17	Height;
CESC	cis	rs7178572	1.000	rs952472	chr15:77776562	A/C	cg22256960	chr15:77711686	NA	-0.6	-8.09	-0.44	2.19e-14	Type 2 diabetes;
CESC	cis	rs6691722	0.503	rs1064842	chr1:24706269	A/G	cg02336364	chr1:24764700	NIPAL3	0.33	6.8	0.39	6.86e-11	Response to interferon beta in multiple sclerosis;
CESC	cis	rs9549367	0.789	rs3794422	chr13:113893729	G/A	cg00898013	chr13:113819073	PROZ	-0.53	-7.36	-0.41	2.37e-12	Platelet distribution width;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05290708	chr7:140372864	ADCK2	0.57	6.02	0.35	5.71e-9	Gut microbiome composition (summer);
CESC	cis	rs7551345	0.563	rs4949365	chr1:31690861	C/T	cg25010788	chr1:31654453	NKAIN1	-0.36	-5.25	-0.31	3.16e-7	Schizophrenia;
CESC	cis	rs9811920	0.516	rs793485	chr3:99492383	C/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.34	-5.47	-0.32	1.03e-7	Axial length;
CESC	cis	rs11122272	0.735	rs2250719	chr1:231486208	G/A	cg06096015	chr1:231504339	EGLN1	0.43	6.21	0.36	2.03e-9	Hemoglobin concentration;
CESC	cis	rs6088580	0.619	rs1205335	chr20:32927507	C/T	cg08999081	chr20:33150536	PIGU	-0.64	-11.02	-0.56	1.75e-23	Glomerular filtration rate (creatinine);
CESC	trans	rs4950322	0.542	rs28381210	chr1:146673507	C/A	cg04954894	chr8:38089920	DDHD2	-0.62	-6.34	-0.36	9.73e-10	Protein quantitative trait loci;
CESC	cis	rs7927592	0.731	rs10896350	chr11:68386373	A/C	cg16797656	chr11:68205561	LRP5	0.46	6.77	0.38	8.45e-11	Total body bone mineral density;
CESC	cis	rs769267	0.930	rs747050	chr19:19584987	C/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.46	5.93	0.34	9.3e-9	Tonsillectomy;
CESC	cis	rs4727027	0.840	rs12670633	chr7:148796707	G/A	cg23158103	chr7:148848205	ZNF398	-0.42	-6.84	-0.39	5.49e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs7786877	0.626	rs11767547	chr7:100221635	C/T	cg27028030	chr7:100209634	MOSPD3	0.59	5.65	0.33	4.13e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs9291683	0.609	rs12507050	chr4:10007305	G/T	cg11266682	chr4:10021025	SLC2A9	0.68	14.2	0.66	2.03e-34	Bone mineral density;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09924173	chr13:32526671	EEF1DP3	-0.58	-7.21	-0.4	5.68e-12	Gut microbiome composition (summer);
CESC	cis	rs1003719	0.788	rs4816560	chr21:38487561	G/T	cg10648535	chr21:38446584	PIGP;TTC3	0.6	8.38	0.46	3.07e-15	Eye color traits;
CESC	trans	rs9858542	1.000	rs6770670	chr3:49686682	T/C	cg21659725	chr3:3221576	CRBN	-0.53	-6.49	-0.37	4.09e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs710216	0.957	rs12041787	chr1:43432275	G/C	cg03128534	chr1:43423976	SLC2A1	0.55	6.36	0.36	8.7e-10	Red cell distribution width;
CESC	cis	rs66561647	0.719	rs3739380	chr8:128944507	G/T	cg05480350	chr8:128972681	MIR1205;PVT1	0.46	6.01	0.35	6.15e-9	Hemoglobin concentration;
CESC	cis	rs17253792	0.822	rs75016910	chr14:56050466	C/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.84	5.66	0.33	3.84e-8	Putamen volume;
CESC	cis	rs7429990	0.932	rs2166772	chr3:48047874	C/T	cg11946769	chr3:48343235	NME6	-0.44	-5.28	-0.31	2.75e-7	Educational attainment (years of education);
CESC	cis	rs5758511	0.689	rs62240864	chr22:42563889	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.58	7.09	0.4	1.25e-11	Birth weight;
CESC	cis	rs858239	0.600	rs2072368	chr7:23146112	C/T	cg23682824	chr7:23144976	KLHL7	0.55	7.51	0.42	9.26e-13	Cerebrospinal fluid biomarker levels;
CESC	cis	rs1538970	0.851	rs61788285	chr1:45919234	A/C	cg24296786	chr1:45957014	TESK2	-0.46	-5.15	-0.3	5.16e-7	Platelet count;
CESC	trans	rs1386330	1.000	rs1386330	chr11:87819427	C/T	cg08079596	chr2:85999628	ATOH8	-0.54	-6.19	-0.36	2.28e-9	Multiple sclerosis (age of onset);
CESC	cis	rs3820928	0.874	rs10174073	chr2:227794944	A/G	cg11843606	chr2:227700838	RHBDD1	-0.5	-6.72	-0.38	1.09e-10	Pulmonary function;
CESC	cis	rs4595586	0.545	rs6580893	chr12:39371885	G/T	cg26384229	chr12:38710491	ALG10B	0.54	7.53	0.42	7.85e-13	Morning vs. evening chronotype;
CESC	cis	rs9837602	1.000	rs4279135	chr3:99733096	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.54	7.51	0.42	9.05e-13	Breast cancer;
CESC	cis	rs7089973	0.604	rs10885620	chr10:116630048	A/T	cg03647239	chr10:116582469	FAM160B1	0.47	6.13	0.35	3.11e-9	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs7100689	0.646	rs7919380	chr10:82133380	C/T	cg00277334	chr10:82204260	NA	-0.58	-7.76	-0.43	1.84e-13	Post bronchodilator FEV1;
CESC	cis	rs13385	0.769	rs4913075	chr5:139613571	A/G	cg26211634	chr5:139558579	C5orf32	0.49	5.41	0.32	1.41e-7	Atrial fibrillation;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01799560	chr17:80846075	TBCD	-0.54	-6.1	-0.35	3.68e-9	Gut microbiome composition (summer);
CESC	cis	rs2820315	0.505	rs10800792	chr1:201811144	G/A	cg06775570	chr1:201857621	SHISA4	0.31	5.22	0.31	3.57e-7	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
CESC	cis	rs9660180	0.935	rs9786942	chr1:1759213	A/G	cg23982607	chr1:1823379	GNB1	-0.78	-12.66	-0.61	4.62e-29	Body mass index;
CESC	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg03188948	chr7:1209495	NA	0.56	6.54	0.37	3.19e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg07677032	chr17:61819896	STRADA	0.49	6.7	0.38	1.22e-10	Prudent dietary pattern;
CESC	trans	rs1814175	0.619	rs847644	chr11:49918418	G/A	cg03929089	chr4:120376271	NA	-0.92	-15.2	-0.68	6e-38	Height;
CESC	cis	rs1008375	1.000	rs1006722	chr4:17618713	A/G	cg15017067	chr4:17643749	FAM184B	-0.39	-5.68	-0.33	3.58e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs10887741	0.690	rs7908056	chr10:89444650	G/A	cg13926569	chr10:89418898	PAPSS2	0.38	5.52	0.32	7.96e-8	Exercise (leisure time);
CESC	cis	rs7662987	1.000	rs28730591	chr4:100003747	G/A	cg13256891	chr4:100009986	ADH5	-0.72	-5.39	-0.31	1.52e-7	Smoking initiation;
CESC	cis	rs7592578	0.766	rs62182865	chr2:191434180	T/C	cg27211696	chr2:191398769	TMEM194B	-0.64	-5.54	-0.32	7.42e-8	Diastolic blood pressure;
CESC	cis	rs10504229	0.683	rs11786074	chr8:58133532	A/G	cg21724239	chr8:58056113	NA	0.58	5.95	0.34	8.29e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs9649213	0.593	rs13246942	chr7:97915021	C/T	cg00277769	chr7:97922759	BAIAP2L1	-0.34	-5.54	-0.32	7.11e-8	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs9833726	0.589	rs9990223	chr3:86134368	A/G	cg10416071	chr15:75628863	COMMD4	0.62	6.19	0.36	2.28e-9	Breast cancer;
CESC	cis	rs12545109	0.800	rs1837617	chr8:57417592	C/T	cg09654669	chr8:57350985	NA	-0.53	-6.42	-0.37	6.27e-10	Obesity-related traits;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg01744729	chr13:113474194	ATP11A	0.51	7.1	0.4	1.17e-11	Fibrinogen levels;
CESC	cis	rs7666738	0.830	rs2865951	chr4:99040191	C/T	cg05340658	chr4:99064831	C4orf37	0.81	12.49	0.61	1.85e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs116095464	0.558	rs6878087	chr5:223117	C/T	cg22857025	chr5:266934	NA	1.19	17.44	0.73	6.79e-46	Breast cancer;
CESC	trans	rs9364687	0.966	rs13202733	chr6:163802590	G/A	cg08378220	chr11:102678779	NA	-0.39	-6.18	-0.35	2.39e-9	Body mass index;
CESC	trans	rs13098911	0.540	rs34863575	chr3:46094063	A/G	cg10236987	chr1:228114221	WNT9A	0.63	6.2	0.36	2.12e-9	Celiac disease;
CESC	cis	rs780096	0.526	rs704795	chr2:27716494	G/A	cg22903471	chr2:27725779	GCKR	-0.56	-8.05	-0.44	2.86e-14	Total body bone mineral density;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12050434	chr12:43030949	NA	-0.63	-7.47	-0.42	1.13e-12	Gut microbiome composition (summer);
CESC	cis	rs4975709	0.589	rs4975707	chr5:1864028	C/T	cg07747251	chr5:1868357	NA	0.32	5.4	0.32	1.46e-7	Cardiovascular disease risk factors;
CESC	cis	rs2274273	0.967	rs67756714	chr14:55589823	G/A	cg04306507	chr14:55594613	LGALS3	0.31	5.69	0.33	3.29e-8	Protein biomarker;
CESC	trans	rs9771228	1.000	rs215599	chr7:32330129	C/T	cg22296808	chr11:2560641	KCNQ1	-0.39	-6.01	-0.35	6.13e-9	Cognitive ability;Verbal-numerical reasoning;
CESC	cis	rs7666738	1.000	rs13116475	chr4:99054843	C/T	cg18180107	chr4:99064573	C4orf37	-0.46	-5.61	-0.33	5.19e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs8141529	0.778	rs7287806	chr22:29213011	G/A	cg15103426	chr22:29168792	CCDC117	0.68	9.74	0.51	2.29e-19	Lymphocyte counts;
CESC	cis	rs7267979	0.966	rs2261698	chr20:25259910	A/G	cg08601574	chr20:25228251	PYGB	0.39	5.65	0.33	4.14e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs921968	0.565	rs692049	chr2:219622778	G/A	cg02176678	chr2:219576539	TTLL4	-0.39	-6.81	-0.39	6.45e-11	Mean corpuscular hemoglobin concentration;
CESC	cis	rs875971	0.545	rs2279757	chr7:65828663	T/C	cg18876405	chr7:65276391	NA	0.49	5.38	0.31	1.63e-7	Aortic root size;
CESC	cis	rs753778	0.629	rs2278447	chr8:142206905	G/C	cg18755752	chr8:142205143	DENND3	-0.67	-9.8	-0.52	1.51e-19	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	cis	rs17253792	0.822	rs75351812	chr14:56082192	G/A	cg01858014	chr14:56050164	KTN1	-0.85	-6.99	-0.39	2.22e-11	Putamen volume;
CESC	cis	rs8177253	1.000	rs8177261	chr3:133480588	A/C	cg12373951	chr3:133503437	NA	0.43	6.3	0.36	1.24e-9	Iron status biomarkers;
CESC	cis	rs1005277	0.579	rs2505241	chr10:38442421	T/C	cg00409905	chr10:38381863	ZNF37A	-0.45	-6.01	-0.35	6.11e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg24503407	chr1:205819492	PM20D1	0.8	12.91	0.62	6.65e-30	Menarche (age at onset);
CESC	cis	rs7666738	0.830	rs13134819	chr4:98919885	G/C	cg03676636	chr4:99064102	C4orf37	0.34	5.15	0.3	5.17e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs12711979	0.765	rs13030772	chr2:3821280	T/C	cg17052675	chr2:3827356	NA	-0.41	-6.47	-0.37	4.64e-10	Itch intensity from mosquito bite adjusted by bite size;
CESC	cis	rs8114671	0.527	rs6060068	chr20:33415820	T/A	cg08999081	chr20:33150536	PIGU	0.39	5.52	0.32	7.98e-8	Height;
CESC	cis	rs611744	0.647	rs1457211	chr8:109261318	C/T	cg21045802	chr8:109455806	TTC35	-0.49	-6.04	-0.35	5.2e-9	Dupuytren's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19681528	chr10:69644405	SIRT1	0.55	6.42	0.37	6.32e-10	Gut microbiome composition (summer);
CESC	cis	rs2625529	0.652	rs2929508	chr15:72246964	A/T	cg16672083	chr15:72433130	SENP8	0.37	5.54	0.32	7.27e-8	Red blood cell count;
CESC	cis	rs2439831	0.867	rs76542740	chr15:43891512	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.83	8.72	0.47	3.08e-16	Lung cancer in ever smokers;
CESC	cis	rs3806843	1.000	rs12055222	chr5:140165568	T/C	cg26395211	chr5:140044315	WDR55	-0.43	-5.47	-0.32	1.05e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs7246657	1.000	rs7246657	chr19:37747108	C/T	cg23950597	chr19:37808831	NA	0.54	6.02	0.35	5.82e-9	Coronary artery calcification;
CESC	trans	rs9874872	0.744	rs12488837	chr3:31517150	T/C	cg22073152	chr1:198633497	PTPRC	-0.59	-6.02	-0.35	5.72e-9	Urinary uric acid to urinary creatinine ratio;
CESC	cis	rs8177253	0.665	rs10935074	chr3:133441692	T/G	cg16262614	chr3:133464971	TF	0.28	5.06	0.3	7.95e-7	Iron status biomarkers;
CESC	cis	rs9926296	0.632	rs9935559	chr16:89800529	C/T	cg27121462	chr16:89883253	FANCA	-0.63	-7.86	-0.43	9.46e-14	Vitiligo;
CESC	cis	rs17039065	0.920	rs73838440	chr4:109457882	A/G	cg16022748	chr4:109541635	LOC285456;RPL34	0.66	6.18	0.35	2.47e-9	Gut microbiome composition (summer);
CESC	cis	rs1178968	0.901	rs1178970	chr7:72750345	G/A	cg25889504	chr7:72793014	NA	0.44	5.09	0.3	6.71e-7	Triglyceride levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23199886	chr2:107199044	NA	-0.58	-7.0	-0.4	2.12e-11	Gut microbiome composition (summer);
CESC	cis	rs2985684	0.789	rs7161649	chr14:50064028	A/G	cg10008539	chr14:50087325	RPL36AL;MGAT2	-0.46	-5.58	-0.32	6.08e-8	Carotid intima media thickness;
CESC	cis	rs11764590	0.813	rs11768212	chr7:1992582	A/C	cg23422044	chr7:1970798	MAD1L1	-0.5	-5.36	-0.31	1.77e-7	Neuroticism;
CESC	cis	rs9790314	0.669	rs7630768	chr3:160864879	T/A	cg03342759	chr3:160939853	NMD3	-0.4	-5.49	-0.32	9.28e-8	Morning vs. evening chronotype;
CESC	cis	rs8020095	0.517	rs10047902	chr14:67349147	G/A	cg19548862	chr14:67692701	FAM71D	-0.47	-5.72	-0.33	2.94e-8	Depression (quantitative trait);
CESC	cis	rs4819052	0.851	rs2838834	chr21:46665208	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.91	12.92	0.62	6.01e-30	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs123509	0.731	rs73087348	chr3:42811571	C/T	cg12982090	chr3:42733453	KBTBD5	-0.64	-7.16	-0.4	7.89e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs6088590	0.687	rs8115656	chr20:33282780	G/C	cg06115741	chr20:33292138	TP53INP2	0.52	6.45	0.37	5.4e-10	Coronary artery disease;
CESC	trans	rs9949291	0.565	rs58553001	chr18:61362456	C/T	cg18704691	chr1:221052468	HLX	-0.39	-6.15	-0.35	2.89e-9	Eosinophil percentage of white cells;
CESC	cis	rs6701037	0.782	rs12760073	chr1:175139295	G/T	cg00321850	chr1:175162397	KIAA0040	-0.42	-6.06	-0.35	4.53e-9	Alcohol dependence;
CESC	cis	rs644799	0.526	rs506180	chr11:95623109	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.5	6.48	0.37	4.45e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	trans	rs1814175	0.817	rs1851860	chr11:49861310	A/C	cg15704280	chr7:45808275	SEPT13	-1.0	-18.83	-0.76	8.9e-51	Height;
CESC	cis	rs644799	0.542	rs10831416	chr11:95467220	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.66	9.39	0.5	2.87e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs7568458	0.660	rs55692129	chr2:85792404	A/T	cg02493740	chr2:85810744	VAMP5	-0.58	-8.14	-0.45	1.56e-14	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20086523	chr13:52378287	DHRS12	0.58	6.56	0.37	2.73e-10	Gut microbiome composition (summer);
CESC	cis	rs35146811	0.844	rs4424195	chr7:99642745	A/G	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.45	5.7	0.33	3.24e-8	Coronary artery disease;
CESC	cis	rs9487051	0.872	rs9480923	chr6:109607369	G/C	cg21918786	chr6:109611834	NA	-0.41	-6.13	-0.35	3.24e-9	Reticulocyte fraction of red cells;
CESC	cis	rs11098499	0.954	rs34858317	chr4:120387110	A/C	cg09307838	chr4:120376055	NA	0.95	13.96	0.65	1.42e-33	Corneal astigmatism;
CESC	cis	rs8092503	1.000	rs12960257	chr18:52481438	T/G	cg12377874	chr18:52495404	RAB27B	0.38	6.2	0.36	2.13e-9	Childhood body mass index;
CESC	cis	rs4665809	0.549	rs3828255	chr2:26413252	G/A	cg26314531	chr2:26401878	FAM59B	0.73	7.58	0.42	5.85e-13	Gut microbiome composition (summer);
CESC	cis	rs752010	0.630	rs12134174	chr1:42105942	C/T	cg06885757	chr1:42089581	HIVEP3	0.53	8.35	0.46	3.83e-15	Lupus nephritis in systemic lupus erythematosus;
CESC	trans	rs4513299	1.000	rs7581142	chr2:115070817	C/G	cg26275355	chr4:12252318	NA	-0.35	-6.0	-0.35	6.45e-9	Inflammatory biomarkers;
CESC	cis	rs6860806	0.661	rs3763112	chr5:131586480	A/G	cg18758796	chr5:131593413	PDLIM4	0.44	6.17	0.35	2.61e-9	Breast cancer;
CESC	cis	rs3858526	0.676	rs10838752	chr11:5887243	A/G	cg13902645	chr11:5959945	NA	-0.61	-7.63	-0.42	4.34e-13	DNA methylation (variation);
CESC	cis	rs6460942	1.000	rs2033871	chr7:12405098	C/A	cg17427002	chr7:12443146	VWDE	-0.52	-5.27	-0.31	2.82e-7	Coronary artery disease;
CESC	cis	rs7618915	0.570	rs13068293	chr3:52672167	C/A	cg17372223	chr3:52568218	NT5DC2	0.43	6.49	0.37	4.29e-10	Bipolar disorder;
CESC	cis	rs4727027	0.933	rs917123	chr7:148848358	G/A	cg23158103	chr7:148848205	ZNF398	-0.43	-7.11	-0.4	1.06e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg10295955	chr4:187884368	NA	-1.05	-18.46	-0.75	1.69e-49	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs11645898	0.748	rs3852785	chr16:72198642	G/A	cg14768367	chr16:72042858	DHODH	-0.75	-6.06	-0.35	4.74e-9	Blood protein levels;
CESC	cis	rs7615952	0.611	rs7632305	chr3:125634767	C/T	cg05084668	chr3:125655381	ALG1L	-0.77	-7.77	-0.43	1.75e-13	Blood pressure (smoking interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12559670	chr7:1610220	PSMG3;KIAA1908	0.56	6.36	0.36	8.92e-10	Gut microbiome composition (summer);
CESC	cis	rs11098499	0.863	rs3775858	chr4:120486028	A/G	cg24375607	chr4:120327624	NA	0.44	5.38	0.31	1.6e-7	Corneal astigmatism;
CESC	cis	rs2228479	0.850	rs11640336	chr16:89941153	T/C	cg06558623	chr16:89946397	TCF25	0.95	7.72	0.43	2.36e-13	Skin colour saturation;
CESC	cis	rs8002861	0.875	rs11616803	chr13:44457109	A/G	cg14210620	chr13:44453864	C13orf31;CCDC122	-0.44	-5.58	-0.32	5.88e-8	Leprosy;
CESC	cis	rs6430585	0.583	rs111837148	chr2:136612036	G/A	cg07169764	chr2:136633963	MCM6	1.29	19.97	0.78	9.47e-55	Corneal structure;
CESC	cis	rs7006290	0.518	rs13282526	chr8:41641151	T/C	cg08923054	chr8:41654455	ANK1	0.45	5.27	0.31	2.79e-7	Pulmonary function decline;
CESC	cis	rs7937682	0.883	rs1789358	chr11:111474116	G/A	cg22437258	chr11:111473054	SIK2	0.74	9.86	0.52	9.59e-20	Primary sclerosing cholangitis;
CESC	cis	rs9863	0.828	rs12303933	chr12:124482256	T/C	cg17562584	chr12:124393655	DNAH10	0.3	5.22	0.31	3.67e-7	White blood cell count;
CESC	cis	rs4819852	1.000	rs1034565	chr22:19984211	A/G	cg07821417	chr22:19972146	ARVCF	-0.26	-5.05	-0.3	8.27e-7	Pulse pressure;
CESC	cis	rs8114671	0.562	rs6120739	chr20:33405227	A/G	cg07148914	chr20:33460835	GGT7	0.42	5.38	0.31	1.64e-7	Height;
CESC	cis	rs7615952	0.599	rs12485717	chr3:125707075	C/T	cg15145296	chr3:125709740	NA	0.49	5.35	0.31	1.9e-7	Blood pressure (smoking interaction);
CESC	cis	rs7208859	0.725	rs9910051	chr17:29161202	A/T	cg19761014	chr17:28927070	LRRC37B2	0.57	5.64	0.33	4.37e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs9311474	0.507	rs4687644	chr3:52746541	T/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.53	7.89	0.44	7.99e-14	Electroencephalogram traits;
CESC	cis	rs4268898	0.662	rs35624938	chr2:24576651	T/C	cg06627628	chr2:24431161	ITSN2	-1.04	-11.91	-0.59	1.81e-26	Asthma;
CESC	cis	rs11083475	0.599	rs7250443	chr19:39267345	T/C	cg26703956	chr19:39260304	NA	-0.29	-5.48	-0.32	9.78e-8	Heart rate;
CESC	cis	rs736408	0.540	rs4687637	chr3:52634092	C/T	cg17372223	chr3:52568218	NT5DC2	0.4	5.99	0.35	6.76e-9	Bipolar disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07899956	chr17:74261249	FAM100B	0.58	7.14	0.4	9.04e-12	Gut microbiome composition (summer);
CESC	cis	rs2760061	0.598	rs673726	chr1:228120173	T/C	cg02753203	chr1:228287806	NA	-0.51	-7.43	-0.42	1.5e-12	Diastolic blood pressure;
CESC	cis	rs8027181	0.839	rs8024986	chr15:73024868	A/G	cg25632853	chr15:73088954	NA	-0.29	-5.09	-0.3	6.84e-7	Triglyceride levels;
CESC	trans	rs123509	0.913	rs339686	chr3:42769688	T/C	cg22035501	chr5:112073398	APC	0.56	5.99	0.35	6.71e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs35306767	0.903	rs12763396	chr10:927357	C/A	cg26597838	chr10:835615	NA	0.86	9.51	0.5	1.21e-18	Eosinophil percentage of granulocytes;
CESC	cis	rs9309473	1.000	rs13398956	chr2:73720258	C/A	cg20560298	chr2:73613845	ALMS1	-0.55	-7.15	-0.4	8.23e-12	Metabolite levels;
CESC	cis	rs561341	1.000	rs554078	chr17:30330109	A/C	cg00745463	chr17:30367425	LRRC37B	-0.86	-7.79	-0.43	1.53e-13	Hip circumference adjusted for BMI;
CESC	cis	rs2425143	1.000	rs1118233	chr20:34228349	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.82	-7.43	-0.42	1.49e-12	Blood protein levels;
CESC	cis	rs4568518	0.530	rs6461364	chr7:17992404	G/T	cg03009463	chr7:17980271	SNX13	0.41	5.38	0.31	1.68e-7	Measles;
CESC	cis	rs9916302	0.904	rs600010	chr17:37433517	T/C	cg15445000	chr17:37608096	MED1	0.39	6.42	0.37	6.17e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs11608355	0.508	rs2075434	chr12:109797051	G/A	cg19025524	chr12:109796872	NA	-0.45	-5.54	-0.32	7.31e-8	Neuroticism;
CESC	trans	rs17581137	0.591	rs2397804	chr15:96179023	C/T	cg18848301	chr6:44590128	NA	-0.37	-6.22	-0.36	1.95e-9	Coronary artery disease;
CESC	cis	rs9322193	0.923	rs4421206	chr6:150004027	A/C	cg00933542	chr6:150070202	PCMT1	0.29	5.06	0.3	7.67e-7	Lung cancer;
CESC	trans	rs34421088	0.560	rs2618434	chr8:11398865	A/G	cg15556689	chr8:8085844	FLJ10661	-0.51	-6.0	-0.35	6.33e-9	Neuroticism;
CESC	cis	rs6062302	0.522	rs3787112	chr20:62222411	G/A	cg09650180	chr20:62225654	GMEB2	-0.79	-8.96	-0.48	6.01e-17	Glioblastoma;
CESC	cis	rs1008375	0.966	rs6833808	chr4:17652526	T/A	cg16339924	chr4:17578868	LAP3	0.66	8.41	0.46	2.52e-15	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs9916302	0.706	rs9646419	chr17:37597185	A/G	cg07936489	chr17:37558343	FBXL20	-0.9	-9.82	-0.52	1.32e-19	Glomerular filtration rate (creatinine);
CESC	cis	rs13108904	0.557	rs1250098	chr4:1238256	A/T	cg02018176	chr4:1364513	KIAA1530	-0.38	-5.07	-0.3	7.43e-7	Obesity-related traits;
CESC	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg24642844	chr7:1081250	C7orf50	-0.74	-8.81	-0.48	1.64e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2842992	0.789	rs6908680	chr6:160218209	G/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.76	9.9	0.52	7.05e-20	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs1843834	0.505	rs7585047	chr2:225373897	C/T	cg22455342	chr2:225449267	CUL3	0.72	9.87	0.52	9.27e-20	IgE levels in asthmatics (D.p. specific);
CESC	cis	rs999943	0.846	rs9366826	chr6:33619184	C/G	cg14003231	chr6:33640908	ITPR3	0.63	11.16	0.57	5.66e-24	Obesity (extreme);
CESC	cis	rs116095464	0.614	rs78905930	chr5:246560	G/A	cg12570787	chr5:219185	SDHA;CCDC127	0.51	5.31	0.31	2.36e-7	Breast cancer;
CESC	cis	rs7223966	0.960	rs7212379	chr17:61706122	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.56	6.69	0.38	1.28e-10	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs853679	0.517	rs6932109	chr6:28078303	A/G	cg22143856	chr6:28129313	ZNF389	-0.49	-6.41	-0.37	6.52e-10	Depression;
CESC	cis	rs6500395	1.000	rs871902	chr16:48593779	A/G	cg04672837	chr16:48644449	N4BP1	0.5	6.23	0.36	1.78e-9	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs853679	0.550	rs6901017	chr6:28152583	T/C	cg17949981	chr6:28129498	ZNF389	0.41	5.33	0.31	2.09e-7	Depression;
CESC	cis	rs17376456	0.877	rs10078194	chr5:93364310	A/C	cg25358565	chr5:93447407	FAM172A	1.1	10.88	0.56	4.74e-23	Diabetic retinopathy;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg00844078	chr2:26098817	ASXL2	0.41	6.58	0.37	2.45e-10	Cleft plate (environmental tobacco smoke interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19730813	chr7:128470217	FLNC	-0.51	-6.03	-0.35	5.49e-9	Gut microbiome composition (summer);
CESC	cis	rs9527	0.830	rs11191440	chr10:104641511	G/A	cg04362960	chr10:104952993	NT5C2	0.45	5.28	0.31	2.69e-7	Arsenic metabolism;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg05910615	chr19:36248877	HSPB6;C19orf55	-0.48	-6.45	-0.37	5.23e-10	Ulcerative colitis;
CESC	cis	rs1375194	0.606	rs2044644	chr2:33817559	A/G	cg04131969	chr2:33951647	MYADML	-0.51	-6.43	-0.37	5.8e-10	Response to antidepressants in depression;
CESC	cis	rs6089829	0.962	rs4997812	chr20:61663153	T/G	cg16240275	chr20:61666158	NCRNA00029	0.5	8.94	0.48	6.63e-17	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg24044651	chr1:24105262	C1orf128	-0.48	-6.97	-0.39	2.48e-11	Gambling;
CESC	cis	rs13102973	0.965	rs6535051	chr4:135874869	G/A	cg14419869	chr4:135874104	NA	-0.37	-5.78	-0.33	2.06e-8	Subjective well-being;
CESC	cis	rs11264213	0.681	rs114705982	chr1:36232075	T/C	cg27506609	chr1:36549197	TEKT2	0.65	5.34	0.31	1.97e-7	Schizophrenia;
CESC	cis	rs2197308	0.631	rs4882308	chr12:38446252	G/C	cg26384229	chr12:38710491	ALG10B	-0.44	-5.95	-0.34	8.28e-9	Morning vs. evening chronotype;
CESC	cis	rs2658782	1.000	rs2608216	chr11:93149172	G/A	cg15737290	chr11:93063684	CCDC67	0.52	6.34	0.36	1e-9	Pulmonary function decline;
CESC	cis	rs1580019	0.587	rs7804457	chr7:32557981	A/G	cg06627557	chr7:32535165	LSM5;AVL9	1.06	19.17	0.76	5.81e-52	Cognitive ability;
CESC	cis	rs425277	0.538	rs169037	chr1:2095582	G/T	cg24578937	chr1:2090814	PRKCZ	0.37	6.61	0.38	2.16e-10	Height;
CESC	trans	rs9929218	0.529	rs8060790	chr16:68729112	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.9	14.97	0.68	3.79e-37	Colorectal cancer;
CESC	cis	rs977987	1.000	rs977985	chr16:75506947	C/G	cg03315344	chr16:75512273	CHST6	0.57	8.21	0.45	9.79e-15	Dupuytren's disease;
CESC	cis	rs7000551	0.751	rs2469768	chr8:22381362	G/A	cg12081754	chr8:22256438	SLC39A14	0.42	5.64	0.33	4.24e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CESC	cis	rs10751667	0.666	rs10902235	chr11:938892	T/C	cg20946044	chr11:1010712	AP2A2	-0.39	-5.44	-0.32	1.23e-7	Alzheimer's disease (late onset);
CESC	cis	rs2243480	0.522	rs1638736	chr7:66092308	A/T	cg25985355	chr7:65971099	NA	-0.51	-5.05	-0.3	8.22e-7	Diabetic kidney disease;
CESC	cis	rs2304069	0.507	rs13167061	chr5:149388624	T/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.48	6.51	0.37	3.82e-10	HIV-1 control;
CESC	cis	rs11112613	0.713	rs10507192	chr12:105948247	A/G	cg03607813	chr12:105948248	NA	0.64	8.75	0.47	2.48e-16	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CESC	cis	rs939658	0.805	rs35602654	chr15:79417527	T/A	cg17916960	chr15:79447300	NA	-0.37	-6.1	-0.35	3.75e-9	Refractive error;
CESC	cis	rs2836974	0.897	rs35064900	chr21:40555492	A/G	cg11644478	chr21:40555479	PSMG1	1.06	17.91	0.74	1.44e-47	Cognitive function;
CESC	cis	rs6141600	0.760	rs2590986	chr20:34686496	C/A	cg07747181	chr20:34652970	NA	-0.38	-5.14	-0.3	5.25e-7	Height;Hip circumference;
CESC	cis	rs72627123	0.867	rs8020310	chr14:74494437	A/G	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.74	5.72	0.33	2.85e-8	Morning vs. evening chronotype;
CESC	cis	rs10504229	0.953	rs72652908	chr8:58191324	G/A	cg22535103	chr8:58192502	C8orf71	-1.05	-13.08	-0.63	1.71e-30	Developmental language disorder (linguistic errors);
CESC	cis	rs35110281	0.641	rs4818858	chr21:45083097	C/T	cg01579765	chr21:45077557	HSF2BP	0.53	8.7	0.47	3.59e-16	Mean corpuscular volume;
CESC	cis	rs9467711	0.606	rs34104395	chr6:26478252	C/T	cg14345882	chr6:26364793	BTN3A2	0.64	5.21	0.3	3.75e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs6912958	0.781	rs2325064	chr6:88224467	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-5.11	-0.3	6.11e-7	Monocyte percentage of white cells;
CESC	cis	rs4268898	0.662	rs2288074	chr2:24413595	C/T	cg06627628	chr2:24431161	ITSN2	-1.01	-10.41	-0.54	1.68e-21	Asthma;
CESC	cis	rs9733	0.519	rs11204717	chr1:150709129	T/A	cg22823121	chr1:150693482	HORMAD1	0.48	7.1	0.4	1.17e-11	Tonsillectomy;
CESC	cis	rs4862750	0.872	rs6553030	chr4:187899234	T/C	cg06074448	chr4:187884817	NA	-0.37	-5.5	-0.32	9.14e-8	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs888194	0.677	rs7956194	chr12:109877825	C/T	cg19025524	chr12:109796872	NA	-0.41	-6.24	-0.36	1.73e-9	Neuroticism;
CESC	cis	rs6032067	0.777	rs62208382	chr20:43785549	C/T	cg10761708	chr20:43804764	PI3	0.56	6.55	0.37	3.01e-10	Blood protein levels;
CESC	cis	rs3750965	0.839	rs921670	chr11:68871639	C/T	cg01403660	chr11:68851641	TPCN2	0.48	6.43	0.37	5.95e-10	Hair color;
CESC	cis	rs11098499	0.675	rs11098534	chr4:120556772	T/G	cg24375607	chr4:120327624	NA	0.4	5.09	0.3	6.82e-7	Corneal astigmatism;
CESC	trans	rs116095464	0.558	rs7715108	chr5:264661	A/G	cg00938859	chr5:1591904	SDHAP3	0.63	6.77	0.38	8.38e-11	Breast cancer;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg05232067	chr8:26240888	BNIP3L	-0.47	-6.89	-0.39	4.05e-11	Gambling;
CESC	cis	rs1218582	0.651	rs4845396	chr1:154828409	A/G	cg09359103	chr1:154839909	KCNN3	0.38	6.29	0.36	1.31e-9	Prostate cancer;
CESC	cis	rs61996546	0.622	rs17560758	chr15:26836402	C/T	cg14859324	chr15:26874363	GABRB3	-0.38	-5.12	-0.3	6e-7	Response to methotrexate in juvenile idiopathic arthritis;
CESC	trans	rs12599106	0.792	rs12597352	chr16:34638507	A/T	cg01516881	chr6:292596	DUSP22	-0.53	-6.92	-0.39	3.32e-11	Menopause (age at onset);
CESC	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg26338869	chr17:61819248	STRADA	0.7	9.28	0.5	6.22e-18	Prudent dietary pattern;
CESC	cis	rs2797160	1.000	rs6934435	chr6:126017481	T/G	cg05901451	chr6:126070800	HEY2	0.45	6.46	0.37	5e-10	Endometrial cancer;
CESC	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg06877462	chr1:205807181	PM20D1	0.35	5.09	0.3	6.88e-7	Menarche (age at onset);
CESC	cis	rs1568889	1.000	rs6484346	chr11:28040767	C/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.78	10.91	0.56	3.96e-23	Bipolar disorder;
CESC	cis	rs853679	0.517	rs9393893	chr6:28109262	T/C	cg22143856	chr6:28129313	ZNF389	0.51	6.55	0.37	3e-10	Depression;
CESC	cis	rs11690935	0.632	rs12991740	chr2:172885996	C/T	cg13550731	chr2:172543902	DYNC1I2	0.47	6.47	0.37	4.61e-10	Schizophrenia;
CESC	cis	rs7909791	0.809	rs12570462	chr10:105613329	A/G	cg24587175	chr10:105670608	OBFC1	-0.39	-5.67	-0.33	3.78e-8	White matter hyperintensity burden;
CESC	cis	rs8018808	0.967	rs4903579	chr14:77850940	T/A	cg20045696	chr14:77926864	AHSA1	-0.43	-5.81	-0.34	1.82e-8	Myeloid white cell count;
CESC	cis	rs7772486	0.754	rs9497419	chr6:146142609	T/C	cg23711669	chr6:146136114	FBXO30	0.89	13.07	0.63	1.87e-30	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9467711	0.606	rs66823108	chr6:26377939	G/A	cg14345882	chr6:26364793	BTN3A2	0.62	6.24	0.36	1.75e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs898097	0.841	rs11656358	chr17:80853956	G/A	cg15664640	chr17:80829946	TBCD	-0.65	-9.4	-0.5	2.75e-18	Breast cancer;
CESC	cis	rs889312	0.500	rs252920	chr5:56148741	C/A	cg14703610	chr5:56206110	C5orf35	0.49	6.36	0.36	8.89e-10	Breast cancer;Breast cancer (early onset);
CESC	cis	rs9811920	0.638	rs796978	chr3:99564321	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.6	-9.93	-0.52	5.9e-20	Axial length;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg06469955	chr17:78915146	RPTOR	0.49	7.29	0.41	3.64e-12	Fibrinogen levels;
CESC	trans	rs10463316	0.894	rs7703283	chr5:150764904	C/T	cg24389359	chr12:111284228	CCDC63	-0.33	-6.02	-0.35	5.68e-9	Metabolite levels (Pyroglutamine);
CESC	cis	rs868036	0.918	rs4238411	chr15:68079424	A/T	cg08079166	chr15:68083412	MAP2K5	0.41	6.45	0.37	5.41e-10	Restless legs syndrome;
CESC	cis	rs2836974	0.568	rs452377	chr21:40537183	T/C	cg11644478	chr21:40555479	PSMG1	0.83	12.81	0.62	1.5e-29	Cognitive function;
CESC	cis	rs7726839	0.578	rs10080150	chr5:593160	C/T	cg09021430	chr5:549028	NA	0.69	14.23	0.66	1.59e-34	Obesity-related traits;
CESC	trans	rs2727020	0.521	rs10839296	chr11:49537617	T/C	cg03929089	chr4:120376271	NA	0.7	7.9	0.44	7.44e-14	Coronary artery disease;
CESC	cis	rs6991838	0.584	rs6991731	chr8:66555467	A/G	cg13398993	chr8:66546079	ARMC1	0.49	5.89	0.34	1.18e-8	Intelligence (multi-trait analysis);
CESC	cis	rs9926296	0.533	rs10852623	chr16:89865242	T/C	cg27121462	chr16:89883253	FANCA	0.79	11.82	0.59	3.58e-26	Vitiligo;
CESC	cis	rs7927771	0.524	rs11039415	chr11:47845814	A/G	cg20307385	chr11:47447363	PSMC3	0.62	8.62	0.47	6.37e-16	Subjective well-being;
CESC	cis	rs9790314	1.000	rs9870059	chr3:161017240	T/C	cg04691961	chr3:161091175	C3orf57	-0.44	-5.73	-0.33	2.74e-8	Morning vs. evening chronotype;
CESC	cis	rs1784581	0.855	rs1790002	chr6:162384397	G/T	cg17173639	chr6:162384350	PARK2	-0.81	-13.3	-0.63	2.97e-31	Itch intensity from mosquito bite;
CESC	trans	rs7944735	0.671	rs7106731	chr11:48003392	T/G	cg03929089	chr4:120376271	NA	0.54	6.33	0.36	1.05e-9	Intraocular pressure;
CESC	cis	rs7017914	0.967	rs2100908	chr8:71583310	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.09	-0.3	6.93e-7	Bone mineral density;
CESC	cis	rs116979167	0.545	rs1706914	chr7:105196445	A/T	cg19920283	chr7:105172520	RINT1	0.5	5.7	0.33	3.17e-8	Bipolar disorder (body mass index interaction);
CESC	cis	rs6088580	0.567	rs6088520	chr20:33132364	A/G	cg06115741	chr20:33292138	TP53INP2	-0.43	-5.36	-0.31	1.78e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs793571	0.505	rs16940589	chr15:58898684	C/T	cg05156742	chr15:59063176	FAM63B	0.49	5.05	0.3	8.29e-7	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20681219	chr4:185396108	IRF2	0.53	6.08	0.35	4.22e-9	Gut microbiome composition (summer);
CESC	cis	rs1552244	1.000	rs56270432	chr3:10087517	G/C	cg08888203	chr3:10149979	C3orf24	0.5	6.33	0.36	1.04e-9	Alzheimer's disease;
CESC	cis	rs637571	0.522	rs3016868	chr11:65764383	C/T	cg02202077	chr11:65769826	EIF1AD;BANF1	0.46	6.13	0.35	3.1e-9	Eosinophil percentage of white cells;
CESC	cis	rs9916302	0.821	rs412430	chr17:37737094	C/G	cg15445000	chr17:37608096	MED1	0.39	6.19	0.36	2.31e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs2980439	0.556	rs2921059	chr8:8317887	G/T	cg15556689	chr8:8085844	FLJ10661	0.63	8.51	0.46	1.31e-15	Neuroticism;
CESC	cis	rs2204008	0.688	rs12824232	chr12:38175901	G/A	cg26384229	chr12:38710491	ALG10B	0.74	10.7	0.55	1.96e-22	Bladder cancer;
CESC	cis	rs5769765	1.000	rs4824106	chr22:50267822	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	0.46	5.32	0.31	2.21e-7	Schizophrenia;
CESC	cis	rs2404602	0.716	rs8039545	chr15:76707247	A/G	cg22467129	chr15:76604101	ETFA	-0.38	-5.68	-0.33	3.56e-8	Blood metabolite levels;
CESC	cis	rs798554	0.759	rs1182189	chr7:2869522	G/A	cg04166393	chr7:2884313	GNA12	0.58	7.19	0.4	6.45e-12	Height;
CESC	cis	rs10045504	0.502	rs57589709	chr5:38733853	C/T	cg15396434	chr5:38725168	NA	-0.69	-6.6	-0.38	2.17e-10	Night sleep phenotypes;
CESC	cis	rs71403859	0.730	rs71386933	chr16:71821800	A/T	cg08717414	chr16:71523259	ZNF19	-0.71	-5.87	-0.34	1.26e-8	Post bronchodilator FEV1;
CESC	cis	rs854765	0.647	rs62073573	chr17:17976354	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.64	8.98	0.48	5.26e-17	Total body bone mineral density;
CESC	cis	rs8103278	0.507	rs7260651	chr19:46260245	G/A	cg14061069	chr19:46274453	DMPK	0.52	8.23	0.45	8.37e-15	Coronary artery disease;
CESC	cis	rs832540	0.629	rs10055224	chr5:56081201	C/T	cg12311346	chr5:56204834	C5orf35	0.42	5.32	0.31	2.24e-7	Coronary artery disease;
CESC	cis	rs8028182	0.636	rs28623700	chr15:75849714	T/A	cg20655648	chr15:75932815	IMP3	0.49	6.04	0.35	5.32e-9	Sudden cardiac arrest;
CESC	cis	rs736408	0.562	rs2072390	chr3:52780509	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.63	8.92	0.48	7.86e-17	Bipolar disorder;
CESC	cis	rs7267979	0.966	rs2261785	chr20:25262403	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	18.61	0.75	5.18e-50	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7208859	0.524	rs11653605	chr17:29088385	T/G	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.17e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs9611565	0.568	rs2413656	chr22:42129357	G/T	cg06634786	chr22:41940651	POLR3H	0.45	5.09	0.3	6.82e-7	Vitiligo;
CESC	cis	rs4853012	0.838	rs4429500	chr2:74345336	A/G	cg05890377	chr2:74357713	NA	0.72	9.58	0.51	7.61e-19	Gestational age at birth (maternal effect);
CESC	cis	rs4901869	0.966	rs431343	chr14:59345530	C/T	cg02291164	chr14:59296302	NA	0.42	7.11	0.4	1.06e-11	Panic disorder;
CESC	cis	rs6762	0.748	rs7929032	chr11:839078	G/A	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.68	-8.35	-0.46	3.76e-15	Mean platelet volume;
CESC	cis	rs4665809	0.590	rs5001914	chr2:26415429	A/G	cg04944784	chr2:26401820	FAM59B	-0.93	-10.7	-0.55	1.94e-22	Gut microbiome composition (summer);
CESC	cis	rs459571	0.606	rs457420	chr9:136909261	A/G	cg13789015	chr9:136890014	NCRNA00094	-0.48	-7.32	-0.41	2.89e-12	Platelet distribution width;
CESC	cis	rs4665809	0.878	rs6720312	chr2:26364934	A/G	cg22920501	chr2:26401640	FAM59B	0.65	7.92	0.44	6.66e-14	Gut microbiome composition (summer);
CESC	cis	rs9303401	0.659	rs17822735	chr17:56620167	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.02	12.92	0.62	6.16e-30	Cognitive test performance;
CESC	cis	rs2014572	0.933	rs8107516	chr19:57758445	A/G	cg12963866	chr19:57752005	ZNF805	-0.46	-6.15	-0.35	2.82e-9	Hyperactive-impulsive symptoms;
CESC	cis	rs9611565	0.694	rs9607816	chr22:41950897	G/A	cg03806693	chr22:41940476	POLR3H	-1.22	-16.24	-0.71	1.23e-41	Vitiligo;
CESC	cis	rs78456975	1.000	rs28742145	chr2:1562671	T/C	cg01028140	chr2:1542097	TPO	-0.5	-5.35	-0.31	1.89e-7	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs963731	0.522	rs297128	chr2:39298403	C/G	cg04010122	chr2:39346883	SOS1	-0.76	-5.76	-0.33	2.32e-8	Corticobasal degeneration;
CESC	cis	rs2991971	0.810	rs12119202	chr1:45925931	A/T	cg15605315	chr1:45957053	TESK2	-0.39	-5.31	-0.31	2.28e-7	High light scatter reticulocyte count;
CESC	cis	rs1862618	0.573	rs832532	chr5:56221938	T/C	cg20203395	chr5:56204925	C5orf35	-0.52	-6.0	-0.35	6.42e-9	Initial pursuit acceleration;
CESC	cis	rs1865721	0.682	rs35282535	chr18:73141206	G/A	cg26385618	chr18:73139727	C18orf62	-0.48	-7.73	-0.43	2.24e-13	Intelligence;
CESC	cis	rs16867321	0.950	rs1919148	chr2:181501758	G/A	cg23363182	chr2:181467187	NA	-0.43	-5.69	-0.33	3.39e-8	Obesity;
CESC	cis	rs10504229	0.683	rs16921819	chr8:58107936	G/T	cg02725872	chr8:58115012	NA	-0.43	-6.81	-0.39	6.53e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs1008375	1.000	rs2215450	chr4:17675394	T/G	cg16339924	chr4:17578868	LAP3	0.54	6.64	0.38	1.76e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs6963495	0.818	rs73192113	chr7:105169603	C/T	cg19920283	chr7:105172520	RINT1	0.69	6.54	0.37	3.15e-10	Bipolar disorder (body mass index interaction);
CESC	cis	rs1707322	1.000	rs4073847	chr1:46463012	A/C	cg06784218	chr1:46089804	CCDC17	-0.36	-6.18	-0.35	2.45e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7845219	0.544	rs10956932	chr8:95948202	C/T	cg09323728	chr8:95962352	TP53INP1	0.28	5.47	0.32	1.02e-7	Type 2 diabetes;
CESC	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg21724239	chr8:58056113	NA	0.6	5.48	0.32	1e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs11822910	0.911	rs61886978	chr11:57194848	G/C	cg00522883	chr11:57194120	SLC43A3	0.57	6.77	0.38	8.46e-11	Platelet distribution width;
CESC	cis	rs72945132	0.882	rs7928686	chr11:70134528	T/C	cg00319359	chr11:70116639	PPFIA1	0.78	7.74	0.43	2.13e-13	Coronary artery disease;
CESC	cis	rs4555082	0.834	rs2816652	chr14:105712493	C/T	cg13114125	chr14:105738426	BRF1	-0.81	-9.8	-0.52	1.56e-19	Mean platelet volume;Platelet distribution width;
CESC	cis	rs763121	0.925	rs9835	chr22:39130971	A/G	cg06544989	chr22:39130855	UNC84B	0.44	8.08	0.44	2.27e-14	Menopause (age at onset);
CESC	cis	rs13108904	0.539	rs13145722	chr4:1338422	T/A	cg13395646	chr4:1353034	KIAA1530	-0.49	-6.32	-0.36	1.08e-9	Obesity-related traits;
CESC	cis	rs1707322	0.717	rs10890345	chr1:46213927	C/T	cg03146154	chr1:46216737	IPP	0.82	11.53	0.58	3.39e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs34375054	0.624	rs12580033	chr12:125676083	A/T	cg25124228	chr12:125621409	AACS	-0.46	-5.24	-0.31	3.23e-7	Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs3785574	0.962	rs2727329	chr17:61924566	C/T	cg06420487	chr17:61919686	SMARCD2	0.47	5.63	0.33	4.6e-8	Height;
CESC	cis	rs3785574	0.962	rs2584614	chr17:61929445	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.1	19.75	0.77	5.46e-54	Height;
CESC	cis	rs6540559	1.000	rs17015259	chr1:209982923	G/A	cg25204440	chr1:209979598	IRF6	0.62	8.03	0.44	3.12e-14	Cleft lip with or without cleft palate;
CESC	cis	rs9916302	0.904	rs4794813	chr17:37670994	A/T	cg00129232	chr17:37814104	STARD3	-0.51	-6.4	-0.37	7.19e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs1153858	1.000	rs7167900	chr15:45639471	A/G	cg14582100	chr15:45693742	SPATA5L1	0.42	6.08	0.35	4.2e-9	Homoarginine levels;
CESC	cis	rs7937682	0.883	rs549143	chr11:111463779	C/T	cg22437258	chr11:111473054	SIK2	0.71	9.19	0.49	1.16e-17	Primary sclerosing cholangitis;
CESC	cis	rs10779751	0.960	rs6661859	chr1:11301063	T/C	cg08854313	chr1:11322531	MTOR	0.84	11.96	0.59	1.16e-26	Body mass index;
CESC	cis	rs6964587	0.967	rs7783414	chr7:91785957	C/T	cg17063962	chr7:91808500	NA	0.58	8.04	0.44	2.92e-14	Breast cancer;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg17156276	chr1:44126005	KDM4A	0.39	6.09	0.35	4e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs938554	0.612	rs4385059	chr4:9989233	A/G	cg11266682	chr4:10021025	SLC2A9	-0.46	-6.03	-0.35	5.49e-9	Blood metabolite levels;
CESC	cis	rs2576037	0.583	rs1970668	chr18:44523220	A/G	cg19077165	chr18:44547161	KATNAL2	-0.63	-9.53	-0.51	1.07e-18	Personality dimensions;
CESC	cis	rs72627123	0.867	rs73303135	chr14:74495090	C/G	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.73	5.68	0.33	3.63e-8	Morning vs. evening chronotype;
CESC	cis	rs7130144	0.534	rs74855511	chr11:130460751	G/A	cg26307797	chr11:130446613	NA	-0.8	-6.53	-0.37	3.43e-10	Urate levels in lean individuals;
CESC	cis	rs55794721	0.509	rs11249248	chr1:25753051	T/C	cg27572855	chr1:25598939	RHD	0.43	7.14	0.4	9.07e-12	Plateletcrit;Mean corpuscular volume;
CESC	cis	rs1862618	0.853	rs832582	chr5:56177743	G/A	cg24531977	chr5:56204891	C5orf35	-0.88	-10.98	-0.56	2.26e-23	Initial pursuit acceleration;
CESC	cis	rs12410462	1.000	rs80168344	chr1:227655804	C/T	cg04117972	chr1:227635322	NA	0.63	6.25	0.36	1.61e-9	Major depressive disorder;
CESC	cis	rs75804782	0.521	rs113497020	chr2:239370813	C/T	cg18131467	chr2:239335373	ASB1	-0.73	-5.69	-0.33	3.41e-8	Morning vs. evening chronotype;Chronotype;
CESC	trans	rs11098499	0.908	rs11729050	chr4:120300066	T/C	cg25214090	chr10:38739885	LOC399744	0.68	9.2	0.49	1.14e-17	Corneal astigmatism;
CESC	trans	rs10506458	0.915	rs12426017	chr12:63396272	T/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.35	-18.82	-0.76	9.08e-51	Hemostatic factors and hematological phenotypes;
CESC	cis	rs7914558	0.966	rs12569617	chr10:104729996	T/C	cg04362960	chr10:104952993	NT5C2	0.45	5.76	0.33	2.33e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs7552404	0.889	rs1250874	chr1:76190978	A/G	cg03433033	chr1:76189801	ACADM	0.71	9.79	0.52	1.65e-19	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs1552244	1.000	rs6782602	chr3:10116541	G/T	cg08888203	chr3:10149979	C3orf24	0.53	6.83	0.39	5.8200000000000003e-11	Alzheimer's disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg13039021	chr17:80888278	TBCD	0.49	6.81	0.39	6.53e-11	Fibrinogen levels;
CESC	trans	rs561341	1.000	rs501957	chr17:30314504	C/T	cg27661571	chr11:113659931	NA	-0.8	-7.48	-0.42	1.08e-12	Hip circumference adjusted for BMI;
CESC	cis	rs2629540	0.806	rs10901812	chr10:126419384	A/G	cg08799069	chr10:126477246	METTL10	-0.6	-7.88	-0.44	8.49e-14	Cocaine dependence;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26149738	chr19:34287125	KCTD15	-0.51	-6.18	-0.35	2.37e-9	Gut microbiome composition (summer);
CESC	cis	rs10751667	0.643	rs7396951	chr11:927355	G/A	cg06064525	chr11:970664	AP2A2	-0.52	-10.25	-0.53	5.74e-21	Alzheimer's disease (late onset);
CESC	cis	rs4660306	0.961	rs12145526	chr1:45969036	G/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.61	-7.69	-0.43	2.86e-13	Homocysteine levels;
CESC	cis	rs6964587	0.933	rs13230837	chr7:91779017	A/G	cg17063962	chr7:91808500	NA	0.55	7.54	0.42	7.56e-13	Breast cancer;
CESC	cis	rs7917772	0.582	rs10786680	chr10:104317192	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.42	5.59	0.32	5.61e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs853679	0.517	rs9380061	chr6:28132803	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.57	-6.49	-0.37	4.32e-10	Depression;
CESC	cis	rs2839186	0.559	rs2277826	chr21:47639492	C/G	cg00815214	chr21:47717953	NA	0.35	5.3	0.31	2.39e-7	Testicular germ cell tumor;
CESC	cis	rs7116495	0.609	rs2511120	chr11:71786211	C/T	cg26138937	chr11:71823887	C11orf51	-1.3	-7.96	-0.44	4.95e-14	Severe influenza A (H1N1) infection;
CESC	cis	rs60871478	0.578	rs62432900	chr7:826794	G/C	cg15782153	chr7:917662	C7orf20	-0.49	-5.41	-0.32	1.4e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg24829409	chr8:58192753	C8orf71	-0.65	-7.36	-0.41	2.29e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs9487051	0.872	rs7773331	chr6:109609208	C/T	cg01475377	chr6:109611718	NA	-0.51	-8.36	-0.46	3.66e-15	Reticulocyte fraction of red cells;
CESC	cis	rs7208859	0.623	rs216439	chr17:28927884	T/C	cg14008862	chr17:28927542	LRRC37B2	0.73	5.52	0.32	8.23e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs3924048	0.559	rs6541037	chr1:12626155	A/G	cg00291366	chr1:12616550	NA	0.36	6.3	0.36	1.23e-9	Optic cup area;
CESC	cis	rs67366981	0.800	rs55939042	chr14:77691186	T/A	cg22824376	chr14:77648248	TMEM63C	0.71	5.89	0.34	1.18e-8	Obsessive-compulsive symptoms;
CESC	cis	rs644148	0.730	rs2117383	chr19:44978298	A/C	cg15540054	chr19:45004280	ZNF180	0.61	6.74	0.38	1e-10	Personality dimensions;
CESC	cis	rs8062405	0.755	rs4788076	chr16:28570005	C/T	cg07382826	chr16:28625726	SULT1A1	0.39	6.46	0.37	4.92e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs1799949	0.965	rs33925201	chr17:41280682	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.67	9.34	0.5	3.98e-18	Menopause (age at onset);
CESC	cis	rs7605827	0.930	rs13016997	chr2:15699240	A/T	cg19274914	chr2:15703543	NA	0.36	6.45	0.37	5.2e-10	Educational attainment (years of education);
CESC	cis	rs116095464	0.510	rs60844864	chr5:267000	A/G	cg22857025	chr5:266934	NA	-1.31	-18.31	-0.75	6.05e-49	Breast cancer;
CESC	cis	rs9916302	0.904	rs7503705	chr17:37669704	A/G	cg15445000	chr17:37608096	MED1	0.41	6.81	0.39	6.64e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs713587	0.626	rs62140636	chr2:25233811	T/C	cg01884057	chr2:25150051	NA	-0.38	-7.26	-0.41	4.32e-12	Body mass index in non-asthmatics;
CESC	cis	rs17253792	0.822	rs79873916	chr14:56172631	G/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.81	5.68	0.33	3.46e-8	Putamen volume;
CESC	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg23708337	chr7:1209742	NA	0.52	5.27	0.31	2.85e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs10751667	0.961	rs6597971	chr11:928598	T/A	cg01483505	chr11:975446	AP2A2	0.39	5.07	0.3	7.63e-7	Alzheimer's disease (late onset);
CESC	cis	rs801193	0.569	rs6978178	chr7:66123084	G/A	cg12463550	chr7:65579703	CRCP	-0.49	-6.42	-0.37	6.41e-10	Aortic root size;
CESC	cis	rs2836974	0.897	rs8133146	chr21:40614298	T/C	cg11644478	chr21:40555479	PSMG1	1.01	15.97	0.7	1.12e-40	Cognitive function;
CESC	trans	rs7656342	0.808	rs10003216	chr4:9766749	A/G	cg18652453	chr5:68665041	TAF9;RAD17	-0.57	-6.49	-0.37	4.27e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs2204008	0.665	rs11179830	chr12:38220966	T/C	cg13010199	chr12:38710504	ALG10B	0.48	5.88	0.34	1.25e-8	Bladder cancer;
CESC	cis	rs2749592	0.531	rs994804	chr10:37900140	A/C	cg25427524	chr10:38739819	LOC399744	0.56	7.89	0.44	7.91e-14	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg06877462	chr1:205807181	PM20D1	0.37	5.35	0.31	1.88e-7	Menarche (age at onset);
CESC	cis	rs933688	0.526	rs9293565	chr5:90609736	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.53	5.83	0.34	1.6e-8	Smoking behavior;
CESC	cis	rs9303280	0.806	rs4795395	chr17:37962987	T/A	cg20243544	chr17:37824526	PNMT	0.52	7.01	0.4	1.99e-11	Self-reported allergy;
CESC	cis	rs7264396	0.790	rs6121020	chr20:34252006	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.86	-11.84	-0.59	2.93e-26	Total cholesterol levels;
CESC	cis	rs4474465	0.688	rs7937225	chr11:78278126	T/A	cg27205649	chr11:78285834	NARS2	0.52	7.06	0.4	1.5e-11	Alzheimer's disease (survival time);
CESC	cis	rs10028773	0.515	rs9994651	chr4:120587803	C/T	cg09307838	chr4:120376055	NA	0.68	8.94	0.48	6.92e-17	Educational attainment;
CESC	cis	rs9322193	0.962	rs7740784	chr6:150154500	C/T	cg04369109	chr6:150039330	LATS1	-0.46	-6.28	-0.36	1.4e-9	Lung cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21953508	chr4:38690502	KLF3	-0.58	-6.27	-0.36	1.45e-9	Gut microbiome composition (summer);
CESC	trans	rs1728785	1.000	rs1170433	chr16:68606081	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.65	7.93	0.44	6e-14	Ulcerative colitis;
CESC	cis	rs1862618	0.853	rs832553	chr5:56114786	A/G	cg24531977	chr5:56204891	C5orf35	-0.88	-11.7	-0.58	9.28e-26	Initial pursuit acceleration;
CESC	cis	rs780096	0.506	rs56076827	chr2:27676287	A/T	cg24768116	chr2:27665128	KRTCAP3	-0.28	-5.07	-0.3	7.42e-7	Total body bone mineral density;
CESC	cis	rs212524	0.544	rs2038089	chr1:21551457	C/T	cg05370193	chr1:21551575	ECE1	-0.41	-6.6	-0.38	2.18e-10	Height;
CESC	cis	rs6500602	0.701	rs1362626	chr16:4549226	C/G	cg08645402	chr16:4508243	NA	0.43	6.81	0.39	6.57e-11	Schizophrenia;
CESC	cis	rs9926296	0.632	rs7206546	chr16:89799079	C/T	cg27121462	chr16:89883253	FANCA	-0.63	-8.05	-0.44	2.77e-14	Vitiligo;
CESC	cis	rs56104184	0.775	rs117744769	chr19:49402686	G/T	cg15549821	chr19:49342101	PLEKHA4	-0.6	-5.99	-0.35	6.95e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	cis	rs4835473	0.900	rs34569841	chr4:144659213	C/A	cg25736465	chr4:144833511	NA	-0.32	-5.16	-0.3	4.85e-7	Immature fraction of reticulocytes;
CESC	cis	rs13082711	0.522	rs9310842	chr3:27369765	A/T	cg02860705	chr3:27208620	NA	-0.51	-6.69	-0.38	1.34e-10	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CESC	cis	rs769267	0.929	rs2905421	chr19:19457908	G/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	7.77	0.43	1.78e-13	Tonsillectomy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00852768	chr6:163834924	QKI	0.6	7.07	0.4	1.39e-11	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.927	rs6832373	chr4:99051967	A/G	cg18180107	chr4:99064573	C4orf37	0.42	5.5	0.32	9.08e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9916302	0.904	rs7503069	chr17:37697128	C/G	cg07936489	chr17:37558343	FBXL20	-0.8	-11.62	-0.58	1.73e-25	Glomerular filtration rate (creatinine);
CESC	cis	rs9894429	0.752	rs6565610	chr17:79592652	A/G	cg13777783	chr17:79615861	NA	-0.33	-5.23	-0.31	3.45e-7	Eye color traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14715482	chr5:10377171	MARCH6	-0.59	-6.38	-0.36	7.84e-10	Gut microbiome composition (summer);
CESC	cis	rs4665809	0.590	rs4665840	chr2:26444962	C/T	cg04944784	chr2:26401820	FAM59B	-0.96	-10.55	-0.54	5.79e-22	Gut microbiome composition (summer);
CESC	cis	rs9314614	0.901	rs2978902	chr8:6690173	C/G	cg27319216	chr8:6693540	XKR5	0.39	5.7	0.33	3.24e-8	IgA nephropathy;White blood cell count (basophil);
CESC	cis	rs7560272	0.538	rs7370393	chr2:73925636	A/C	cg20560298	chr2:73613845	ALMS1	0.45	6.26	0.36	1.51e-9	Schizophrenia;
CESC	cis	rs7949030	0.588	rs2509961	chr11:62310909	T/C	cg13298116	chr11:62369859	EML3;MTA2	0.58	8.57	0.47	8.59e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs1552244	1.000	rs6414438	chr3:10073824	G/C	cg08888203	chr3:10149979	C3orf24	0.46	5.94	0.34	8.69e-9	Alzheimer's disease;
CESC	cis	rs854765	0.583	rs11078404	chr17:17820487	A/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.56	7.99	0.44	4.08e-14	Total body bone mineral density;
CESC	cis	rs11764590	0.694	rs6461115	chr7:2103668	A/G	cg21782813	chr7:2030301	MAD1L1	-0.39	-5.11	-0.3	6.14e-7	Neuroticism;
CESC	cis	rs4900538	0.963	rs1190554	chr14:102918686	T/C	cg18135206	chr14:102964638	TECPR2	0.76	10.01	0.52	3.22e-20	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	trans	rs11098499	0.754	rs9999724	chr4:120239944	C/T	cg25214090	chr10:38739885	LOC399744	0.64	9.1	0.49	2.29e-17	Corneal astigmatism;
CESC	cis	rs1552244	0.882	rs36006511	chr3:10054191	C/T	cg08888203	chr3:10149979	C3orf24	0.49	6.17	0.35	2.51e-9	Alzheimer's disease;
CESC	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg22105103	chr4:187893119	NA	0.5	7.43	0.42	1.48e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7107174	1.000	rs2244508	chr11:77948515	T/A	cg03754400	chr11:77348600	CLNS1A	0.47	5.08	0.3	7e-7	Testicular germ cell tumor;
CESC	cis	rs12130219	0.500	rs1552991	chr1:152165878	C/T	cg26879891	chr1:152191343	HRNR	-0.42	-6.51	-0.37	3.72e-10	Inflammatory skin disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15697355	chr19:6414982	KHSRP	-0.51	-6.18	-0.35	2.37e-9	Gut microbiome composition (summer);
CESC	cis	rs1448094	0.512	rs7953318	chr12:86245929	G/A	cg02569458	chr12:86230093	RASSF9	0.49	7.27	0.41	3.98e-12	Major depressive disorder;
CESC	cis	rs8031584	0.958	rs34909055	chr15:31284170	C/T	cg08109568	chr15:31115862	NA	-0.58	-7.53	-0.42	7.77e-13	Huntington's disease progression;
CESC	cis	rs67478160	0.572	rs8015603	chr14:104293678	C/G	cg08213375	chr14:104286397	PPP1R13B	0.54	10.57	0.54	5.25e-22	Schizophrenia;
CESC	cis	rs3008870	0.755	rs2815368	chr1:67500778	C/T	cg02640540	chr1:67518911	SLC35D1	0.46	5.64	0.33	4.33e-8	Lymphocyte percentage of white cells;
CESC	cis	rs11711311	1.000	rs1073040	chr3:113522123	C/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.58	7.63	0.42	4.27e-13	IgG glycosylation;
CESC	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg11060661	chr22:24314208	DDT;DDTL	0.32	5.1	0.3	6.41e-7	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs8114671	0.869	rs2038503	chr20:33675900	G/A	cg24642439	chr20:33292090	TP53INP2	-0.47	-5.62	-0.33	4.82e-8	Height;
CESC	cis	rs6502050	0.835	rs9900128	chr17:80087920	A/T	cg11859384	chr17:80120422	CCDC57	-0.38	-5.14	-0.3	5.31e-7	Life satisfaction;
CESC	cis	rs933688	1.000	rs10045280	chr5:90717675	T/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.08	14.34	0.66	6.68e-35	Smoking behavior;
CESC	cis	rs7312933	0.528	rs10880238	chr12:42489613	A/G	cg17420585	chr12:42539391	GXYLT1	-0.34	-5.07	-0.3	7.33e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs1799949	1.000	rs2292595	chr17:41290674	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.67	9.36	0.5	3.44e-18	Menopause (age at onset);
CESC	cis	rs9926296	0.593	rs6500456	chr16:89888341	T/C	cg04287289	chr16:89883240	FANCA	0.6	7.91	0.44	6.93e-14	Vitiligo;
CESC	cis	rs9435341	0.896	rs1730850	chr1:107597988	C/T	cg09367891	chr1:107599246	PRMT6	-0.71	-8.41	-0.46	2.5e-15	Facial morphology (factor 21, depth of nasal alae);
CESC	cis	rs2072732	0.821	rs12039548	chr1:2947909	C/T	cg15211996	chr1:2936768	ACTRT2	-0.33	-5.63	-0.33	4.66e-8	Plateletcrit;
CESC	cis	rs736408	0.648	rs3774354	chr3:52817675	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.46	6.22	0.36	1.96e-9	Bipolar disorder;
CESC	cis	rs6982240	0.514	rs9324543	chr8:142275662	T/C	cg27411547	chr8:142287226	NA	-0.53	-7.4	-0.41	1.76e-12	Tonsillectomy;
CESC	cis	rs10754283	0.901	rs10922683	chr1:90116068	G/A	cg21401794	chr1:90099060	LRRC8C	0.7	9.37	0.5	3.37e-18	Amyotrophic lateral sclerosis (sporadic);
CESC	trans	rs11039798	0.557	rs683180	chr11:48463949	A/G	cg15704280	chr7:45808275	SEPT13	-0.6	-6.32	-0.36	1.11e-9	Axial length;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg14806418	chr10:131904271	NA	0.48	6.77	0.38	8.05e-11	Fibrinogen levels;
CESC	cis	rs3767633	0.925	rs10737502	chr1:161792321	G/A	cg09175582	chr1:161736000	ATF6	0.77	6.03	0.35	5.38e-9	IgG glycosylation;
CESC	cis	rs8180040	0.726	rs2305638	chr3:47046842	G/C	cg27129171	chr3:47204927	SETD2	0.69	10.3	0.53	3.86e-21	Colorectal cancer;
CESC	cis	rs2439831	1.000	rs561863	chr15:43761352	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.83	12.17	0.6	2.26e-27	Lung cancer in ever smokers;
CESC	cis	rs4699052	0.590	rs1156669	chr4:104288204	A/C	cg16532752	chr4:104119610	CENPE	-0.38	-5.34	-0.31	1.98e-7	Testicular germ cell tumor;
CESC	cis	rs17711722	0.565	rs4275112	chr7:65198619	T/G	cg25405998	chr7:65216604	CCT6P1	-0.44	-5.61	-0.33	5.04e-8	Calcium levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13114696	chr21:47808953	PCNT	-0.53	-6.11	-0.35	3.48e-9	Gut microbiome composition (summer);
CESC	cis	rs2191566	0.576	rs448692	chr19:44494730	A/G	cg20607764	chr19:44506953	ZNF230	-0.45	-5.63	-0.33	4.66e-8	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs938554	0.692	rs13111638	chr4:9996890	A/G	cg00071950	chr4:10020882	SLC2A9	0.6	6.4	0.37	6.98e-10	Blood metabolite levels;
CESC	cis	rs853679	0.546	rs200952	chr6:27836976	C/T	cg26587870	chr6:27730563	NA	-0.6	-5.29	-0.31	2.58e-7	Depression;
CESC	cis	rs6973256	0.605	rs13237435	chr7:133347570	C/T	cg10665199	chr7:133106180	EXOC4	-0.47	-6.34	-0.36	9.86e-10	Intelligence (multi-trait analysis);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03891344	chr16:19533212	GDE1	0.5	6.34	0.36	1.01e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs1552244	0.938	rs56274701	chr3:10167790	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.87	12.51	0.61	1.61e-28	Alzheimer's disease;
CESC	cis	rs12618769	0.597	rs17031139	chr2:99036530	A/G	cg10123293	chr2:99228465	UNC50	-0.41	-5.42	-0.32	1.36e-7	Bipolar disorder;
CESC	cis	rs2011503	0.941	rs56044734	chr19:19366927	G/A	cg11584989	chr19:19387371	SF4	0.6	7.23	0.41	5.2e-12	Bipolar disorder;
CESC	cis	rs4808199	0.948	rs757001	chr19:19448808	G/A	cg03709012	chr19:19516395	GATAD2A	1.14	12.23	0.6	1.49e-27	Nonalcoholic fatty liver disease;
CESC	cis	rs7098414	0.511	rs10749592	chr10:82150891	C/T	cg00277334	chr10:82204260	NA	-0.5	-7.53	-0.42	7.97e-13	Post bronchodilator FEV1;
CESC	cis	rs9325144	0.647	rs11168104	chr12:38857616	G/T	cg26384229	chr12:38710491	ALG10B	-0.56	-7.89	-0.44	8.02e-14	Morning vs. evening chronotype;
CESC	cis	rs9640161	0.673	rs11773351	chr7:150030963	T/C	cg21361702	chr7:150065534	REPIN1	0.58	6.05	0.35	5.02e-9	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs7726839	0.540	rs72703078	chr5:594987	A/C	cg16447950	chr5:562315	NA	-0.6	-6.08	-0.35	4.21e-9	Obesity-related traits;
CESC	cis	rs3733585	0.762	rs6449217	chr4:10009151	T/A	cg11266682	chr4:10021025	SLC2A9	0.67	12.64	0.61	5.55e-29	Cleft plate (environmental tobacco smoke interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05596626	chr16:22277970	EEF2K	-0.52	-6.02	-0.35	5.7e-9	Gut microbiome composition (summer);
CESC	cis	rs999943	0.846	rs1570760	chr6:33622933	C/T	cg14003231	chr6:33640908	ITPR3	0.69	12.08	0.6	4.81e-27	Obesity (extreme);
CESC	cis	rs11864453	0.611	rs1050361	chr16:72130203	C/G	cg01557791	chr16:72042693	DHODH	-0.43	-5.63	-0.33	4.52e-8	Fibrinogen levels;
CESC	cis	rs875971	0.862	rs4368860	chr7:65608482	C/G	cg12463550	chr7:65579703	CRCP	-0.5	-6.43	-0.37	5.82e-10	Aortic root size;
CESC	cis	rs1707322	0.716	rs6699444	chr1:46135120	G/C	cg05343316	chr1:45956843	TESK2	0.51	6.24	0.36	1.7e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs6933660	0.720	rs6914656	chr6:151753421	C/G	cg14262678	chr6:151773367	RMND1;C6orf211	0.67	9.57	0.51	8.08e-19	Menarche (age at onset);
CESC	cis	rs782590	0.807	rs782572	chr2:55912120	T/C	cg18811423	chr2:55921094	PNPT1	0.8	12.84	0.62	1.18e-29	Metabolic syndrome;
CESC	cis	rs7267979	0.844	rs4815413	chr20:25359229	G/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.79	-14.75	-0.67	2.44e-36	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs6496667	0.730	rs7176776	chr15:91049140	T/G	cg13834112	chr15:90361639	NA	0.41	5.38	0.31	1.68e-7	Rheumatoid arthritis;
CESC	cis	rs11786130	1.000	rs4733812	chr8:128999640	C/T	cg01765152	chr8:129005526	PVT1	-0.33	-5.39	-0.31	1.54e-7	Eosinophil counts;Sum eosinophil basophil counts;
CESC	cis	rs593982	1.000	rs576663	chr11:65498942	G/T	cg08755490	chr11:65554678	OVOL1	1.31	20.14	0.78	2.41e-55	Atopic dermatitis;
CESC	cis	rs7809950	0.817	rs17154091	chr7:107084790	T/C	cg23024343	chr7:107201750	COG5	-0.55	-7.11	-0.4	1.05e-11	Coronary artery disease;
CESC	cis	rs9796	0.870	rs3214068	chr15:41313064	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.46	-6.89	-0.39	4e-11	Menopause (age at onset);
CESC	cis	rs863345	0.604	rs6669271	chr1:158471999	A/G	cg12129480	chr1:158549410	OR10X1	-0.36	-7.44	-0.42	1.39e-12	Pneumococcal bacteremia;
CESC	cis	rs13108904	0.967	rs4428235	chr4:1278891	C/T	cg22903657	chr4:1355424	KIAA1530	-0.38	-5.23	-0.31	3.48e-7	Obesity-related traits;
CESC	trans	rs66573146	1.000	rs56074877	chr4:6990374	C/T	cg07817883	chr1:32538562	TMEM39B	1.09	7.0	0.4	2.06e-11	Granulocyte percentage of myeloid white cells;
CESC	cis	rs13191362	0.507	rs6936804	chr6:163069424	A/T	cg21926612	chr6:163149169	PACRG;PARK2	-0.59	-7.07	-0.4	1.34e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs8103278	0.507	rs522769	chr19:46284520	G/A	cg12641515	chr19:46296257	DMWD	0.72	9.4	0.5	2.67e-18	Coronary artery disease;
CESC	cis	rs9715521	0.677	rs11944208	chr4:59860652	G/A	cg11281224	chr4:60001000	NA	-0.56	-7.8	-0.43	1.39e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs1218582	0.772	rs6683557	chr1:154852307	C/G	cg16680214	chr1:154839983	KCNN3	-0.45	-6.94	-0.39	3.06e-11	Prostate cancer;
CESC	cis	rs7216064	0.953	rs11868959	chr17:65840810	T/C	cg07042672	chr17:66097459	LOC651250	-0.54	-5.67	-0.33	3.73e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs10751667	0.666	rs7124480	chr11:971601	G/A	cg06064525	chr11:970664	AP2A2	-0.5	-9.85	-0.52	1.08e-19	Alzheimer's disease (late onset);
CESC	cis	rs965469	1.000	rs6051762	chr20:3321590	T/C	cg25506879	chr20:3388711	C20orf194	-0.53	-5.61	-0.33	5.15e-8	IFN-related cytopenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04408576	chr16:1524927	CLCN7	0.59	6.67	0.38	1.5e-10	Gut microbiome composition (summer);
CESC	cis	rs2243480	1.000	rs6460260	chr7:65215455	T/C	cg13147721	chr7:65941812	NA	0.88	8.1	0.45	1.96e-14	Diabetic kidney disease;
CESC	cis	rs1475911	0.708	rs56109792	chr21:43520060	A/G	cg19766460	chr21:43528205	UMODL1;C21orf128	0.99	13.67	0.64	1.47e-32	IgG glycosylation;
CESC	cis	rs7618915	0.571	rs34115864	chr3:52612178	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.47	6.55	0.37	2.89e-10	Bipolar disorder;
CESC	cis	rs1443512	0.812	rs1975472	chr12:54337083	A/G	cg17410650	chr12:54324560	NA	-0.48	-8.07	-0.44	2.5e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
CESC	cis	rs524281	0.861	rs11227411	chr11:65879478	C/T	cg14036092	chr11:66035641	RAB1B	-0.63	-6.43	-0.37	5.84e-10	Electroencephalogram traits;
CESC	trans	rs6076960	0.509	rs3747923	chr20:6182577	C/T	cg27123975	chr17:57697125	CLTC	-0.49	-6.03	-0.35	5.56e-9	Smooth-surface caries;
CESC	cis	rs6540559	0.673	rs926346	chr1:209962204	A/T	cg09509183	chr1:209979624	IRF6	0.56	5.86	0.34	1.4e-8	Cleft lip with or without cleft palate;
CESC	cis	rs1557765	0.527	rs4756887	chr11:17394597	T/G	cg15432903	chr11:17409602	KCNJ11	0.43	6.21	0.36	2e-9	Body mass index;Social communication problems;
CESC	cis	rs919433	0.963	rs7582736	chr2:198170342	A/G	cg03934865	chr2:198174659	NA	-0.41	-5.46	-0.32	1.11e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs77741769	0.529	rs525425	chr12:121195625	A/G	cg02419362	chr12:121203948	SPPL3	0.34	5.5	0.32	9e-8	Mean corpuscular volume;
CESC	cis	rs10479542	0.642	rs6879665	chr5:178974581	T/A	cg22764044	chr5:178986830	RUFY1	0.41	5.61	0.33	4.96e-8	Lung cancer;
CESC	cis	rs7648466	0.592	rs7616215	chr3:46205686	A/G	cg19145607	chr3:45983792	CXCR6;FYCO1	-0.36	-5.52	-0.32	8e-8	Eotaxin levels;
CESC	cis	rs7680126	0.500	rs11735668	chr4:10148655	C/G	cg00071950	chr4:10020882	SLC2A9	-0.57	-6.29	-0.36	1.3e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	cis	rs2243480	0.615	rs34363376	chr7:65939536	T/C	cg13147721	chr7:65941812	NA	-0.94	-8.65	-0.47	4.93e-16	Diabetic kidney disease;
CESC	cis	rs9303280	0.743	rs2941522	chr17:37910368	C/T	cg20243544	chr17:37824526	PNMT	-0.53	-7.32	-0.41	3.05e-12	Self-reported allergy;
CESC	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-6.21	-0.36	2.01e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg10295955	chr4:187884368	NA	1.03	18.84	0.76	8.28e-51	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs733175	0.855	rs10016075	chr4:10006663	G/T	cg11266682	chr4:10021025	SLC2A9	0.39	5.21	0.3	3.88e-7	Psychosis and Alzheimer's disease;
CESC	cis	rs2243480	1.000	rs36033484	chr7:65390558	T/G	cg13147721	chr7:65941812	NA	-0.88	-8.15	-0.45	1.47e-14	Diabetic kidney disease;
CESC	cis	rs7264396	0.563	rs2425136	chr20:34344782	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.68	7.27	0.41	3.97e-12	Total cholesterol levels;
CESC	cis	rs116095464	0.558	rs10462755	chr5:246748	T/C	cg10591111	chr5:226296	SDHA	-0.51	-6.28	-0.36	1.38e-9	Breast cancer;
CESC	cis	rs7635838	0.892	rs34830847	chr3:11437798	A/C	cg00170343	chr3:11313890	ATG7	0.42	5.54	0.32	7.14e-8	HDL cholesterol;
CESC	cis	rs875971	0.862	rs10278014	chr7:66051264	C/T	cg18252515	chr7:66147081	NA	0.46	5.96	0.34	8.03e-9	Aortic root size;
CESC	cis	rs7208859	0.623	rs216423	chr17:28942109	G/C	cg19761014	chr17:28927070	LRRC37B2	0.79	7.49	0.42	1.06e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs4555082	0.874	rs2816606	chr14:105716034	C/T	cg06808227	chr14:105710500	BRF1	-0.51	-5.79	-0.34	1.96e-8	Mean platelet volume;Platelet distribution width;
CESC	cis	rs57506017	0.585	rs6966757	chr7:12265952	A/T	cg23422036	chr7:12250390	TMEM106B	0.38	5.11	0.3	6.03e-7	Neuroticism;
CESC	cis	rs78456975	1.000	rs10205916	chr2:1558451	A/T	cg01028140	chr2:1542097	TPO	0.54	5.64	0.33	4.38e-8	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs208520	0.874	rs208514	chr6:66945520	G/A	cg07460842	chr6:66804631	NA	-0.82	-9.87	-0.52	8.78e-20	Exhaled nitric oxide output;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg21395147	chr1:211849137	NEK2	-0.44	-6.01	-0.35	5.98e-9	Fibrinogen levels;
CESC	cis	rs6500602	0.701	rs11643057	chr16:4544505	C/T	cg08645402	chr16:4508243	NA	0.44	6.86	0.39	4.83e-11	Schizophrenia;
CESC	cis	rs2243480	0.803	rs34004500	chr7:65312178	A/T	cg18252515	chr7:66147081	NA	-1.01	-9.73	-0.51	2.51e-19	Diabetic kidney disease;
CESC	cis	rs3857067	0.806	rs2171384	chr4:95103545	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.6	-9.01	-0.48	4.22e-17	QT interval;
CESC	cis	rs447	0.895	rs1468345	chr7:83748974	A/G	cg22846510	chr7:83753280	SEMA3A	-0.48	-5.87	-0.34	1.27e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09580147	chr16:22431764	RRN3P3	-0.57	-7.35	-0.41	2.54e-12	Gut microbiome composition (summer);
CESC	cis	rs9549367	0.774	rs9549696	chr13:113875062	C/T	cg00898013	chr13:113819073	PROZ	-0.51	-7.25	-0.41	4.57e-12	Platelet distribution width;
CESC	cis	rs875971	0.545	rs316306	chr7:65618674	G/A	cg19163074	chr7:65112434	INTS4L2	0.46	5.05	0.3	8.07e-7	Aortic root size;
CESC	cis	rs2243480	1.000	rs35421653	chr7:65363429	C/A	cg18252515	chr7:66147081	NA	-1.18	-10.99	-0.56	2.15e-23	Diabetic kidney disease;
CESC	cis	rs34172651	0.517	rs2547040	chr16:24736408	G/C	cg00339695	chr16:24857497	SLC5A11	-0.52	-6.69	-0.38	1.34e-10	Intelligence (multi-trait analysis);
CESC	cis	rs34779708	0.897	rs12764820	chr10:35386321	G/A	cg03585969	chr10:35415529	CREM	0.77	10.07	0.53	2.06e-20	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs3960554	0.808	rs57721466	chr7:75710049	C/T	cg17325771	chr7:75508891	RHBDD2	-0.37	-5.38	-0.31	1.68e-7	Eotaxin levels;
CESC	cis	rs7965445	0.892	rs61937079	chr12:131928863	G/A	cg08164151	chr12:131118432	NA	0.66	5.06	0.3	7.98e-7	Mortality in heart failure;
CESC	cis	rs873946	0.504	rs12775990	chr10:134575836	C/T	cg18305652	chr10:134549665	INPP5A	0.47	6.64	0.38	1.76e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs7589728	0.563	rs78685993	chr2:88447026	T/C	cg04511125	chr2:88470314	THNSL2	0.68	6.66	0.38	1.61e-10	Plasma clusterin levels;
CESC	cis	rs72781680	0.898	rs72786276	chr2:24062566	G/A	cg20701182	chr2:24300061	SF3B14	0.78	6.86	0.39	4.98e-11	Lymphocyte counts;
CESC	cis	rs875971	1.000	rs1363055	chr7:65943275	A/G	cg12463550	chr7:65579703	CRCP	0.56	7.09	0.4	1.2e-11	Aortic root size;
CESC	cis	rs10870270	1.000	rs7077744	chr10:133770201	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.59	-7.57	-0.42	6.29e-13	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs5750830	0.649	rs5750814	chr22:39797987	T/C	cg01416388	chr22:39784598	NA	-0.58	-7.27	-0.41	4.15e-12	Intelligence (multi-trait analysis);
CESC	cis	rs7208859	0.623	rs11656844	chr17:29060597	G/T	cg19761014	chr17:28927070	LRRC37B2	0.76	6.25	0.36	1.66e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs12586317	0.547	rs12435454	chr14:35466997	A/G	cg16230307	chr14:35515116	FAM177A1	0.98	10.57	0.54	5.04e-22	Psoriasis;
CESC	cis	rs5753618	0.583	rs2273251	chr22:31843567	G/C	cg00478049	chr22:31556069	RNF185	-0.44	-5.23	-0.31	3.4e-7	Colorectal cancer;
CESC	trans	rs8073060	0.586	rs6505487	chr17:33996850	A/G	cg19694781	chr19:47549865	TMEM160	-0.74	-6.85	-0.39	5.24e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	cis	rs798554	0.679	rs1639036	chr7:2885089	G/A	cg19717773	chr7:2847554	GNA12	-0.45	-6.58	-0.37	2.44e-10	Height;
CESC	trans	rs1493916	0.905	rs1586988	chr18:31396001	G/C	cg27147174	chr7:100797783	AP1S1	-0.52	-6.92	-0.39	3.48e-11	Life satisfaction;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg00923803	chr7:5862740	ZNF815	0.45	7.06	0.4	1.5e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs1008375	1.000	rs10939747	chr4:17691166	C/A	cg02297831	chr4:17616191	MED28	0.5	5.88	0.34	1.24e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs4654899	0.802	rs17449966	chr1:21203996	A/G	cg05370193	chr1:21551575	ECE1	0.4	5.74	0.33	2.61e-8	Superior frontal gyrus grey matter volume;
CESC	cis	rs5757673	1	rs5757673	chr22:39837920	T/C	cg05872129	chr22:39784769	NA	-0.86	-10.38	-0.54	2.09e-21	Post bronchodilator FEV1;
CESC	cis	rs559928	0.606	rs11600628	chr11:63976027	C/T	cg18225595	chr11:63971243	STIP1	0.67	6.16	0.35	2.67e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CESC	cis	rs5997397	0.967	rs5752791	chr22:29153547	A/G	cg15103426	chr22:29168792	CCDC117	-0.43	-5.69	-0.33	3.44e-8	Red cell distribution width;
CESC	cis	rs73129298	0.551	rs6020179	chr20:48604276	T/C	cg25655593	chr20:48599521	SNAI1	0.49	5.22	0.31	3.67e-7	Inflammatory skin disease;
CESC	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	22.02	0.8	8.62e-62	Prudent dietary pattern;
CESC	cis	rs1707322	0.721	rs7520123	chr1:46235219	C/G	cg03146154	chr1:46216737	IPP	0.75	10.64	0.55	3.1e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs12971120	0.891	rs71359051	chr18:72169723	G/A	cg26446133	chr18:72167187	CNDP2	-0.76	-9.71	-0.51	2.84e-19	Refractive error;
CESC	cis	rs1375194	0.582	rs13391166	chr2:33805314	C/T	cg04131969	chr2:33951647	MYADML	0.52	6.67	0.38	1.45e-10	Response to antidepressants in depression;
CESC	cis	rs1348850	0.914	rs1453370	chr2:178327727	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.88	12.54	0.61	1.28e-28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs1348850	0.747	rs1047884	chr2:178488281	C/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.51	6.61	0.38	2.13e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs9916302	0.904	rs7208274	chr17:37513796	C/T	cg15445000	chr17:37608096	MED1	-0.41	-6.81	-0.39	6.37e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs4727027	0.704	rs10952805	chr7:148907849	G/A	cg23583168	chr7:148888333	NA	-0.93	-16.25	-0.71	1.16e-41	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg22535103	chr8:58192502	C8orf71	-0.93	-10.32	-0.54	3.27e-21	Developmental language disorder (linguistic errors);
CESC	cis	rs769267	0.965	rs2023882	chr19:19405405	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	7.46	0.42	1.24e-12	Tonsillectomy;
CESC	cis	rs7769051	0.522	rs73554461	chr6:133139087	T/G	cg22852734	chr6:133119734	C6orf192	0.91	6.59	0.38	2.4e-10	Type 2 diabetes nephropathy;
CESC	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-6.21	-0.36	2.01e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs4835473	0.864	rs4257604	chr4:144901414	G/C	cg25736465	chr4:144833511	NA	0.41	6.2	0.36	2.14e-9	Immature fraction of reticulocytes;
CESC	trans	rs17685	0.884	rs3823882	chr7:75631913	T/C	cg19862616	chr7:65841803	NCRNA00174	-0.67	-8.69	-0.47	3.91e-16	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs7666738	0.753	rs10033138	chr4:98981922	A/C	cg03467027	chr4:99064603	C4orf37	0.44	5.54	0.32	7.12e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs5769765	0.825	rs7511620	chr22:50307932	T/C	cg26441486	chr22:50317300	CRELD2	0.42	5.32	0.31	2.25e-7	Schizophrenia;
CESC	cis	rs780096	0.565	rs10169261	chr2:27727314	C/T	cg02592271	chr2:27665507	KRTCAP3	-0.36	-7.22	-0.41	5.53e-12	Total body bone mineral density;
CESC	cis	rs12476592	0.571	rs1031221	chr2:63742810	C/T	cg17519650	chr2:63277830	OTX1	0.47	5.32	0.31	2.18e-7	Childhood ear infection;
CESC	cis	rs875971	0.767	rs12668005	chr7:65909021	T/C	cg11764359	chr7:65958608	NA	0.79	11.19	0.57	4.69e-24	Aortic root size;
CESC	trans	rs10242455	0.571	rs73713594	chr7:99326498	A/G	cg09045935	chr12:6379348	NA	0.76	6.38	0.36	7.87e-10	Blood metabolite levels;
CESC	cis	rs7089973	0.668	rs7077148	chr10:116644896	A/G	cg23260525	chr10:116636907	FAM160B1	0.37	6.63	0.38	1.91e-10	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs6752107	1.000	rs2289472	chr2:234182240	C/T	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.37	5.58	0.32	5.94e-8	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs6547741	1.000	rs1528404	chr2:27846603	C/T	cg27432699	chr2:27873401	GPN1	-0.49	-6.81	-0.39	6.57e-11	Oral cavity cancer;
CESC	cis	rs6912958	0.781	rs9444524	chr6:88311260	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-5.07	-0.3	7.45e-7	Monocyte percentage of white cells;
CESC	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg22764044	chr5:178986830	RUFY1	-0.47	-6.99	-0.39	2.29e-11	Lung cancer;
CESC	cis	rs10129255	0.957	rs8009638	chr14:107185809	G/A	cg23076370	chr14:107095027	NA	-0.49	-6.18	-0.35	2.44e-9	Kawasaki disease;
CESC	cis	rs2072499	0.722	rs61462713	chr1:156161682	C/T	cg24450063	chr1:156163899	SLC25A44	0.98	11.99	0.59	9.64e-27	Testicular germ cell tumor;
CESC	cis	rs6942407	0.649	rs6952384	chr7:86859551	T/C	cg02420886	chr7:86849541	C7orf23	0.53	5.05	0.3	8.2e-7	Food allergy;
CESC	cis	rs10751667	0.643	rs7396407	chr11:929374	A/T	cg20946044	chr11:1010712	AP2A2	-0.39	-5.26	-0.31	2.96e-7	Alzheimer's disease (late onset);
CESC	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg22535103	chr8:58192502	C8orf71	-0.92	-10.19	-0.53	8.81e-21	Developmental language disorder (linguistic errors);
CESC	cis	rs6912958	0.678	rs9450733	chr6:88250081	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-6.56	-0.37	2.75e-10	Monocyte percentage of white cells;
CESC	cis	rs11640533	0.901	rs11862250	chr16:53415038	C/A	cg08681685	chr16:53407594	NA	0.39	5.1	0.3	6.55e-7	Intelligence (multi-trait analysis);
CESC	cis	rs7811142	0.779	rs28680963	chr7:99905475	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.12	10.62	0.55	3.59e-22	Platelet count;
CESC	cis	rs2075371	1.000	rs2244700	chr7:133987374	A/G	cg00033643	chr7:134001901	SLC35B4	0.44	5.66	0.33	3.97e-8	Mean platelet volume;
CESC	cis	rs9790314	1.000	rs7638668	chr3:161047283	G/A	cg04691961	chr3:161091175	C3orf57	-0.42	-5.31	-0.31	2.3e-7	Morning vs. evening chronotype;
CESC	cis	rs2274273	0.840	rs28568813	chr14:55794114	C/G	cg04306507	chr14:55594613	LGALS3	0.32	6.38	0.36	8.01e-10	Protein biomarker;
CESC	trans	rs10776614	0.799	rs7071480	chr10:49764061	A/T	cg19218067	chr2:181235115	NA	0.5	6.1	0.35	3.7e-9	Self-employment;
CESC	cis	rs2075371	0.796	rs12154724	chr7:133943443	G/A	cg20476274	chr7:133979776	SLC35B4	0.6	8.64	0.47	5.53e-16	Mean platelet volume;
CESC	cis	rs9649465	1.000	rs1006764	chr7:123337873	C/T	cg04330084	chr7:123175371	IQUB	-0.37	-5.06	-0.3	7.81e-7	Migraine;
CESC	cis	rs6963495	0.818	rs55983796	chr7:105170941	C/T	cg02135003	chr7:105160482	PUS7	-0.46	-5.45	-0.32	1.13e-7	Bipolar disorder (body mass index interaction);
CESC	cis	rs718433	0.584	rs10438076	chr14:22210067	T/C	cg02257791	chr14:22217085	NA	-0.33	-5.19	-0.3	4.29e-7	Intraocular pressure;
CESC	cis	rs6815814	0.851	rs4274855	chr4:38777471	C/T	cg02016764	chr4:38805732	TLR1	-0.68	-8.09	-0.45	2.13e-14	Breast cancer;
CESC	cis	rs7107174	0.901	rs2510053	chr11:77959435	T/C	cg27205649	chr11:78285834	NARS2	-0.4	-5.09	-0.3	6.88e-7	Testicular germ cell tumor;
CESC	cis	rs798554	0.591	rs1182193	chr7:2869240	A/G	cg19717773	chr7:2847554	GNA12	-0.48	-7.22	-0.41	5.35e-12	Height;
CESC	cis	rs28489187	0.706	rs233127	chr1:85793801	A/G	cg16011679	chr1:85725395	C1orf52	0.49	5.76	0.33	2.39e-8	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	cis	rs853679	0.517	rs868987	chr6:28110148	A/G	cg20151795	chr6:28129481	ZNF389	-0.47	-6.09	-0.35	3.92e-9	Depression;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02458384	chr16:2021763	TBL3	0.64	7.22	0.41	5.45e-12	Gut microbiome composition (summer);
CESC	cis	rs10752881	1.000	rs6658501	chr1:182991417	C/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.84	-13.21	-0.63	5.78e-31	Colorectal cancer;
CESC	cis	rs8177253	1.000	rs1358023	chr3:133484393	T/C	cg12373951	chr3:133503437	NA	0.39	5.75	0.33	2.49e-8	Iron status biomarkers;
CESC	cis	rs4629710	0.568	rs67021539	chr6:131552900	A/G	cg12606694	chr6:131520996	AKAP7	0.49	6.1	0.35	3.78e-9	Multiple myeloma (IgH translocation);
CESC	cis	rs801193	0.591	rs721717	chr7:66130292	G/T	cg18876405	chr7:65276391	NA	-0.45	-6.18	-0.35	2.43e-9	Aortic root size;
CESC	cis	rs9926296	0.605	rs8046243	chr16:89852133	A/G	cg04287289	chr16:89883240	FANCA	0.94	16.41	0.71	2.95e-42	Vitiligo;
CESC	cis	rs9911578	0.835	rs723991	chr17:56482039	G/A	cg12560992	chr17:57184187	TRIM37	-0.87	-14.48	-0.66	2.13e-35	Intelligence (multi-trait analysis);
CESC	trans	rs17685	0.753	rs869806	chr7:75688623	C/T	cg19862616	chr7:65841803	NCRNA00174	0.81	11.99	0.59	9.33e-27	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs3008870	0.916	rs2025608	chr1:67422550	C/T	cg08660285	chr1:67390436	MIER1;WDR78	1.06	15.19	0.68	6.65e-38	Lymphocyte percentage of white cells;
CESC	cis	rs11792861	0.591	rs2282206	chr9:111746267	A/G	cg13535736	chr9:111863775	C9orf5	-0.39	-5.62	-0.33	4.77e-8	Menarche (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22251877	chr8:125551349	TATDN1;NDUFB9	0.59	6.46	0.37	5.04e-10	Gut microbiome composition (summer);
CESC	cis	rs6502050	0.799	rs12603050	chr17:80104631	A/G	cg23985595	chr17:80112537	CCDC57	-0.42	-6.57	-0.37	2.72e-10	Life satisfaction;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg08365438	chr10:21683093	NA	0.53	7.59	0.42	5.36e-13	Fibrinogen levels;
CESC	cis	rs7666738	0.830	rs28802909	chr4:99039410	G/A	cg18180107	chr4:99064573	C4orf37	0.41	5.29	0.31	2.51e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7249142	0.549	rs10854012	chr19:19295719	C/T	cg27384695	chr19:19271486	LOC729991-MEF2B;MEF2B	0.3	5.35	0.31	1.91e-7	IgG glycosylation;
CESC	cis	rs875971	1.000	rs6970030	chr7:65968679	T/C	cg10691866	chr7:65817282	TPST1	-0.34	-5.59	-0.32	5.57e-8	Aortic root size;
CESC	cis	rs6500602	0.647	rs3747600	chr16:4586222	A/G	cg08645402	chr16:4508243	NA	0.49	7.91	0.44	7.06e-14	Schizophrenia;
CESC	cis	rs2228479	0.867	rs12930606	chr16:89946682	A/G	cg04013166	chr16:89971882	TCF25	0.77	7.14	0.4	8.86e-12	Skin colour saturation;
CESC	cis	rs10883723	0.962	rs1056740	chr10:104236552	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.54	7.34	0.41	2.67e-12	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs8027181	0.959	rs11631352	chr15:73086473	A/G	cg25632853	chr15:73088954	NA	-0.33	-5.8	-0.34	1.85e-8	Triglyceride levels;
CESC	cis	rs9399135	0.967	rs2297340	chr6:135376058	T/C	cg22676075	chr6:135203613	NA	0.53	7.42	0.41	1.58e-12	Red blood cell count;
CESC	cis	rs780096	0.546	rs1060525	chr2:27635582	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.28	-5.67	-0.33	3.74e-8	Total body bone mineral density;
CESC	cis	rs909002	0.772	rs7525618	chr1:32073766	C/T	cg13919466	chr1:32135498	COL16A1	-0.47	-8.52	-0.46	1.24e-15	Intelligence (multi-trait analysis);
CESC	cis	rs4555082	0.834	rs2816653	chr14:105713973	A/G	cg10792982	chr14:105748885	BRF1	0.39	5.19	0.3	4.19e-7	Mean platelet volume;Platelet distribution width;
CESC	cis	rs2795502	1.000	rs2473119	chr10:43339038	A/T	cg27426351	chr10:43362370	NA	-0.45	-5.5	-0.32	8.91e-8	Blood protein levels;
CESC	cis	rs7116495	1.000	rs17161991	chr11:71839960	T/C	cg10381502	chr11:71823885	C11orf51	0.7	5.7	0.33	3.17e-8	Severe influenza A (H1N1) infection;
CESC	cis	rs7851660	0.933	rs894673	chr9:100612270	A/T	cg13688889	chr9:100608707	NA	-0.68	-10.64	-0.55	3.08e-22	Strep throat;
CESC	cis	rs7249921	0.728	rs1627280	chr19:35652248	C/T	cg15419183	chr19:35660584	FXYD5	0.43	6.78	0.38	7.58e-11	Platelet count;
CESC	cis	rs9399135	0.844	rs13209789	chr6:135367916	A/G	cg22676075	chr6:135203613	NA	0.51	7.29	0.41	3.6e-12	Red blood cell count;
CESC	cis	rs425277	0.585	rs3128294	chr1:2065343	G/C	cg19257562	chr1:2043853	PRKCZ	0.34	5.35	0.31	1.95e-7	Height;
CESC	cis	rs4253772	0.591	rs6008384	chr22:46655948	T/C	cg09491104	chr22:46646882	C22orf40	-0.6	-9.22	-0.49	9.82e-18	LDL cholesterol;Cholesterol, total;
CESC	cis	rs2991971	0.967	rs11211130	chr1:45986852	G/C	cg15605315	chr1:45957053	TESK2	0.5	6.62	0.38	1.96e-10	High light scatter reticulocyte count;
CESC	trans	rs1814175	0.817	rs10769613	chr11:49769692	G/A	cg03929089	chr4:120376271	NA	-0.9	-14.81	-0.67	1.43e-36	Height;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg16025584	chr9:139887217	C9orf142	0.48	6.5	0.37	4.02e-10	Systemic lupus erythematosus;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24504843	chr4:56896641	CEP135	-0.58	-6.27	-0.36	1.46e-9	Gut microbiome composition (summer);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg19758033	chr1:20987701	DDOST	-0.46	-6.48	-0.37	4.35e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg06397424	chr16:15737279	NDE1;KIAA0430	-0.5	-6.81	-0.39	6.35e-11	Asthma;
CESC	cis	rs10464366	0.614	rs62442213	chr7:39146933	C/T	cg18850127	chr7:39170497	POU6F2	0.39	5.49	0.32	9.55e-8	IgG glycosylation;
CESC	cis	rs9616064	0.853	rs7284865	chr22:46996529	C/T	cg05621596	chr22:47072043	GRAMD4	-0.51	-7.17	-0.4	7.33e-12	Urate levels in obese individuals;
CESC	cis	rs3820068	0.506	rs17448966	chr1:15990983	T/G	cg17385448	chr1:15911702	AGMAT	0.44	7.64	0.42	4.05e-13	Systolic blood pressure;
CESC	cis	rs561341	1.000	rs473356	chr17:30321762	G/C	cg12193833	chr17:30244370	NA	-0.72	-6.68	-0.38	1.42e-10	Hip circumference adjusted for BMI;
CESC	cis	rs9398803	0.865	rs4422634	chr6:126806676	A/G	cg19875578	chr6:126661172	C6orf173	0.43	5.92	0.34	1.01e-8	Male-pattern baldness;
CESC	cis	rs965469	0.895	rs6051841	chr20:3392871	A/G	cg25506879	chr20:3388711	C20orf194	-0.63	-6.63	-0.38	1.92e-10	IFN-related cytopenia;
CESC	cis	rs10189230	0.967	rs13012429	chr2:222350788	C/T	cg14652038	chr2:222343519	EPHA4	0.36	7.56	0.42	6.58e-13	Urate levels in lean individuals;
CESC	cis	rs1003719	0.679	rs2835638	chr21:38534533	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.59	-8.06	-0.44	2.72e-14	Eye color traits;
CESC	cis	rs4835473	0.932	rs11736609	chr4:144754029	G/A	cg25736465	chr4:144833511	NA	-0.45	-6.75	-0.38	9.22e-11	Immature fraction of reticulocytes;
CESC	cis	rs9549260	0.739	rs7330614	chr13:41199421	G/A	cg21288729	chr13:41239152	FOXO1	0.64	8.26	0.45	7.14e-15	Red blood cell count;
CESC	cis	rs2228479	0.867	rs11642451	chr16:89958127	T/C	cg04013166	chr16:89971882	TCF25	0.78	7.19	0.4	6.56e-12	Skin colour saturation;
CESC	cis	rs4665809	0.590	rs2891496	chr2:26452605	G/A	cg22920501	chr2:26401640	FAM59B	0.92	10.43	0.54	1.42e-21	Gut microbiome composition (summer);
CESC	cis	rs10754283	0.901	rs6663526	chr1:90110862	T/C	cg21401794	chr1:90099060	LRRC8C	0.69	9.34	0.5	4.06e-18	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs367943	0.698	rs10050530	chr5:112971042	A/C	cg12552261	chr5:112820674	MCC	0.44	5.63	0.33	4.63e-8	Type 2 diabetes;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg21813473	chr20:40247231	CHD6	0.43	6.99	0.39	2.26e-11	Gambling;
CESC	cis	rs11971779	0.793	rs11764426	chr7:139024050	C/G	cg07862535	chr7:139043722	LUC7L2	0.49	5.58	0.32	6.08e-8	Diisocyanate-induced asthma;
CESC	cis	rs9768139	0.708	rs10233815	chr7:158114348	C/T	cg24154853	chr7:158122151	PTPRN2	0.41	6.44	0.37	5.53e-10	Calcium levels;
CESC	cis	rs1832871	0.672	rs9457337	chr6:158726292	C/T	cg07165851	chr6:158734300	TULP4	0.6	6.65	0.38	1.68e-10	Height;
CESC	cis	rs2074585	0.839	rs11638780	chr15:91041896	G/T	cg22089800	chr15:90895588	ZNF774	-0.65	-8.96	-0.48	5.83e-17	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
CESC	cis	rs11098499	0.697	rs6832410	chr4:120296800	A/G	cg24375607	chr4:120327624	NA	0.46	5.55	0.32	6.98e-8	Corneal astigmatism;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23200371	chr12:56367680	RAB5B	0.57	6.09	0.35	3.92e-9	Gut microbiome composition (summer);
CESC	cis	rs7843479	0.870	rs1809498	chr8:21836384	C/G	cg17168535	chr8:21777572	XPO7	-0.55	-7.88	-0.44	8.6e-14	Mean corpuscular volume;
CESC	cis	rs7666738	0.830	rs13110498	chr4:98959150	G/A	cg03676636	chr4:99064102	C4orf37	0.33	5.12	0.3	5.76e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs116095464	0.510	rs60844864	chr5:267000	A/G	cg00938859	chr5:1591904	SDHAP3	0.63	6.73	0.38	1.02e-10	Breast cancer;
CESC	cis	rs8114671	0.562	rs3818273	chr20:33509275	G/A	cg06115741	chr20:33292138	TP53INP2	0.48	5.79	0.34	1.97e-8	Height;
CESC	cis	rs5753618	0.519	rs5997939	chr22:31677130	C/G	cg13145458	chr22:31556086	RNF185	0.51	5.68	0.33	3.46e-8	Colorectal cancer;
CESC	cis	rs9894429	0.789	rs35887231	chr17:79587126	G/A	cg21984481	chr17:79567631	NPLOC4	-0.58	-9.48	-0.5	1.5e-18	Eye color traits;
CESC	cis	rs1046896	0.627	rs7225515	chr17:80795783	C/T	cg19500275	chr17:80737654	TBCD	0.45	5.19	0.3	4.13e-7	Glycated hemoglobin levels;
CESC	cis	rs4665809	1.000	rs4665306	chr2:26319124	C/T	cg22920501	chr2:26401640	FAM59B	-0.68	-8.21	-0.45	9.56e-15	Gut microbiome composition (summer);
CESC	cis	rs561341	0.609	rs7214626	chr17:30190989	G/A	cg13647721	chr17:30228624	UTP6	-0.74	-8.56	-0.47	9.61e-16	Hip circumference adjusted for BMI;
CESC	cis	rs5753618	0.561	rs9606830	chr22:31717799	T/G	cg13145458	chr22:31556086	RNF185	-0.48	-5.37	-0.31	1.69e-7	Colorectal cancer;
CESC	cis	rs10504229	1.000	rs58053450	chr8:58173348	T/C	cg22535103	chr8:58192502	C8orf71	-1.05	-13.27	-0.63	3.63e-31	Developmental language disorder (linguistic errors);
CESC	cis	rs736408	0.522	rs11130310	chr3:52674667	C/T	cg05564831	chr3:52568323	NT5DC2	0.47	7.52	0.42	8.51e-13	Bipolar disorder;
CESC	cis	rs8038465	0.967	rs3935942	chr15:73971361	C/A	cg15420318	chr15:73925796	NPTN	0.44	6.26	0.36	1.52e-9	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs7618915	0.547	rs10780035	chr3:52764624	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.38	6.6	0.38	2.18e-10	Bipolar disorder;
CESC	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg06873352	chr17:61820015	STRADA	0.72	12.67	0.61	4.43e-29	Prudent dietary pattern;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg12506373	chr2:27440548	CAD	-0.45	-6.62	-0.38	1.94e-10	Gambling;
CESC	cis	rs6460942	1.000	rs62448565	chr7:12400458	G/A	cg13733410	chr7:12443478	VWDE	-0.53	-5.23	-0.31	3.41e-7	Coronary artery disease;
CESC	cis	rs9611565	0.592	rs8779	chr22:42070276	T/C	cg03806693	chr22:41940476	POLR3H	1.09	12.68	0.61	4.09e-29	Vitiligo;
CESC	cis	rs1348850	0.554	rs1374438	chr2:178376684	A/G	cg23306229	chr2:178417860	TTC30B	0.81	7.5	0.42	9.42e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14172532	chr2:242447907	STK25	0.55	6.26	0.36	1.56e-9	Gut microbiome composition (summer);
CESC	cis	rs9733	0.818	rs4970924	chr1:150633079	A/G	cg22823121	chr1:150693482	HORMAD1	-0.4	-6.27	-0.36	1.42e-9	Tonsillectomy;
CESC	cis	rs11711311	1.000	rs2566963	chr3:113531849	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	-0.57	-7.35	-0.41	2.41e-12	IgG glycosylation;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg18604876	chr3:5164258	ARL8B	-0.46	-6.8	-0.39	6.73e-11	Fibrinogen levels;
CESC	cis	rs6121246	0.567	rs6060249	chr20:30190944	G/A	cg13852791	chr20:30311386	BCL2L1	0.58	5.56	0.32	6.65e-8	Mean corpuscular hemoglobin;
CESC	cis	rs2415984	0.520	rs60342772	chr14:46935394	C/A	cg14871534	chr14:47121158	RPL10L	0.39	5.69	0.33	3.39e-8	Number of children ever born;
CESC	cis	rs7107174	1.000	rs2512532	chr11:77968641	T/C	cg02023728	chr11:77925099	USP35	0.45	6.35	0.36	9.37e-10	Testicular germ cell tumor;
CESC	trans	rs3934047	0.869	rs8032149	chr15:82044488	C/G	cg23228694	chr20:35089521	DLGAP4	-0.43	-6.01	-0.35	6.08e-9	Response to paliperidone in schizophrenia (positive Marder score);
CESC	cis	rs2625529	0.617	rs7175792	chr15:72431883	C/G	cg16672083	chr15:72433130	SENP8	-0.45	-6.88	-0.39	4.23e-11	Red blood cell count;
CESC	cis	rs4819052	0.807	rs4819047	chr21:46665139	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.48	6.08	0.35	4.09e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg02628353	chr7:26241504	HNRNPA2B1;CBX3	-0.44	-6.21	-0.36	2.06e-9	Gambling;
CESC	cis	rs709400	1.000	rs861539	chr14:104165753	G/A	cg12935359	chr14:103987150	CKB	-0.46	-6.22	-0.36	1.92e-9	Body mass index;
CESC	cis	rs2243480	1.000	rs160643	chr7:65558222	C/T	cg13147721	chr7:65941812	NA	-0.81	-7.64	-0.42	3.97e-13	Diabetic kidney disease;
CESC	cis	rs1552244	0.882	rs34706481	chr3:10004123	G/A	cg00166722	chr3:10149974	C3orf24	0.46	5.45	0.32	1.17e-7	Alzheimer's disease;
CESC	cis	rs12995491	0.933	rs13023008	chr2:88530933	G/A	cg14558114	chr2:88469736	THNSL2	-0.49	-7.1	-0.4	1.13e-11	Response to metformin (IC50);
CESC	cis	rs7635838	0.892	rs6792718	chr3:11434380	A/G	cg00170343	chr3:11313890	ATG7	0.43	5.61	0.33	5.16e-8	HDL cholesterol;
CESC	cis	rs4434138	0.683	rs13063160	chr3:52602274	T/C	cg18404041	chr3:52824283	ITIH1	-0.39	-6.73	-0.38	1.06e-10	Intelligence (multi-trait analysis);
CESC	cis	rs116095464	0.558	rs56127718	chr5:270273	G/T	cg12570787	chr5:219185	SDHA;CCDC127	0.52	5.45	0.32	1.14e-7	Breast cancer;
CESC	cis	rs8112211	0.911	rs2286475	chr19:38847431	T/C	cg14299480	chr19:38876666	GGN	-0.44	-5.65	-0.33	4.19e-8	Blood protein levels;
CESC	trans	rs1038304	0.742	rs10872676	chr6:151943977	C/T	cg23736843	chr12:113541915	RASAL1	0.39	6.03	0.35	5.57e-9	Bone mineral density (spine);Bone mineral density (hip);Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs9311474	0.607	rs34005367	chr3:52558904	A/T	cg18099408	chr3:52552593	STAB1	-0.38	-6.46	-0.37	5.02e-10	Electroencephalogram traits;
CESC	cis	rs703842	1.000	rs11172351	chr12:58213485	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.7	8.77	0.47	2.23e-16	Multiple sclerosis;
CESC	cis	rs514406	0.893	rs522287	chr1:53365493	C/T	cg08859206	chr1:53392774	SCP2	-0.63	-8.33	-0.46	4.29e-15	Monocyte count;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg25377475	chr1:236030556	LYST	0.44	6.32	0.36	1.11e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs116095464	0.558	rs10043002	chr5:226753	G/A	cg12570787	chr5:219185	SDHA;CCDC127	0.53	5.64	0.33	4.4e-8	Breast cancer;
CESC	cis	rs6674176	0.561	rs7161	chr1:44438974	A/G	cg13606994	chr1:44402422	ARTN	0.42	6.6	0.38	2.27e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs7264396	0.790	rs3787168	chr20:34233278	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.61	7.45	0.42	1.3e-12	Total cholesterol levels;
CESC	cis	rs7666738	0.606	rs4637413	chr4:99088151	A/G	cg17366294	chr4:99064904	C4orf37	0.43	5.77	0.33	2.15e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9311474	0.713	rs352170	chr3:52236077	A/G	cg17372223	chr3:52568218	NT5DC2	0.34	5.14	0.3	5.23e-7	Electroencephalogram traits;
CESC	cis	rs1707322	0.758	rs10789474	chr1:46250040	G/T	cg05343316	chr1:45956843	TESK2	0.47	5.7	0.33	3.21e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7246657	0.823	rs4802236	chr19:37919246	A/G	cg23950597	chr19:37808831	NA	-0.6	-6.18	-0.35	2.39e-9	Coronary artery calcification;
CESC	cis	rs17376456	0.877	rs2085960	chr5:93399934	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.6	5.03	0.3	9.19e-7	Diabetic retinopathy;
CESC	cis	rs9291683	0.632	rs13137074	chr4:10042842	C/T	cg11266682	chr4:10021025	SLC2A9	0.67	13.02	0.62	2.72e-30	Bone mineral density;
CESC	cis	rs4722166	0.630	rs2091115	chr7:22810166	G/T	cg05472934	chr7:22766657	IL6	0.8	10.46	0.54	1.15e-21	Lung cancer;
CESC	trans	rs561341	1.000	rs546748	chr17:30324293	A/C	cg20587970	chr11:113659929	NA	-0.85	-10.99	-0.56	2.11e-23	Hip circumference adjusted for BMI;
CESC	cis	rs7542091	0.666	rs7537070	chr1:210043565	A/G	cg22029157	chr1:209979665	IRF6	0.5	7.98	0.44	4.32e-14	Monobrow;
CESC	cis	rs9894429	0.966	rs10871499	chr17:79589006	G/A	cg13777783	chr17:79615861	NA	-0.35	-5.76	-0.33	2.29e-8	Eye color traits;
CESC	cis	rs7264396	0.563	rs59064961	chr20:34307950	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.63	6.75	0.38	9.35e-11	Total cholesterol levels;
CESC	cis	rs9393777	0.513	rs3999471	chr6:26650306	T/C	cg12292205	chr6:26970375	C6orf41	-0.53	-5.76	-0.33	2.33e-8	Intelligence (multi-trait analysis);
CESC	trans	rs7839040	0.647	rs7824911	chr8:82929567	T/C	cg14472086	chr9:107730925	NA	-0.48	-6.33	-0.36	1.03e-9	Response to methotrexate in juvenile idiopathic arthritis;
CESC	trans	rs9929218	0.954	rs35444713	chr16:68824492	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.65	-8.16	-0.45	1.33e-14	Colorectal cancer;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg17330983	chr14:23770641	PPP1R3E	-0.42	-6.01	-0.35	6.06e-9	Gambling;
CESC	cis	rs2108225	0.837	rs6958729	chr7:107451211	A/G	cg18560240	chr7:107437656	SLC26A3	0.42	5.73	0.33	2.68e-8	Ulcerative colitis;
CESC	cis	rs561341	1.000	rs56903735	chr17:30254393	T/A	cg00745463	chr17:30367425	LRRC37B	-0.7	-6.9	-0.39	3.75e-11	Hip circumference adjusted for BMI;
CESC	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg11301795	chr4:187892539	NA	-0.81	-14.18	-0.66	2.37e-34	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs896854	0.654	rs13248607	chr8:95986637	T/G	cg09323728	chr8:95962352	TP53INP1	-0.41	-8.93	-0.48	7.13e-17	Type 2 diabetes;
CESC	cis	rs2836633	0.929	rs62217517	chr21:40033177	T/A	cg05519781	chr21:40033154	ERG	0.79	13.49	0.64	6.12e-32	Coronary artery disease;
CESC	cis	rs16910800	0.731	rs16910738	chr11:23189455	C/T	cg20040320	chr11:23191996	NA	-0.67	-6.66	-0.38	1.53e-10	Cancer;
CESC	cis	rs2832191	0.716	rs1984012	chr21:30392472	T/C	cg08807101	chr21:30365312	RNF160	0.96	14.95	0.68	4.69e-37	Dental caries;
CESC	cis	rs6460942	0.591	rs62448728	chr7:12332915	A/T	cg20607287	chr7:12443886	VWDE	-0.63	-6.83	-0.39	5.83e-11	Coronary artery disease;
CESC	cis	rs3096299	0.967	rs2911257	chr16:89484134	C/G	cg16743903	chr16:89593216	SPG7	-0.42	-5.42	-0.32	1.36e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs1799949	0.965	rs11651623	chr17:41329847	G/A	cg25072359	chr17:41440525	NA	0.51	6.82	0.39	6.26e-11	Menopause (age at onset);
CESC	cis	rs10751667	1.000	rs7395632	chr11:958789	C/T	cg06064525	chr11:970664	AP2A2	0.36	6.55	0.37	3.01e-10	Alzheimer's disease (late onset);
CESC	cis	rs2976388	0.566	rs4736373	chr8:143792357	G/C	cg20862496	chr8:143823734	SLURP1	0.33	5.2	0.3	4.05e-7	Urinary tract infection frequency;
CESC	cis	rs514406	0.792	rs481440	chr1:53344976	C/T	cg25767906	chr1:53392781	SCP2	-0.57	-8.18	-0.45	1.22e-14	Monocyte count;
CESC	cis	rs10276381	1.000	rs10260837	chr7:28181129	C/T	cg23620719	chr7:28220237	JAZF1	0.7	7.22	0.41	5.61e-12	Crohn's disease;
CESC	trans	rs2018683	0.707	rs10279610	chr7:28975696	C/G	cg19402173	chr7:128379420	CALU	0.49	6.46	0.37	5.06e-10	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CESC	cis	rs10779751	0.734	rs2748878	chr1:11129434	T/C	cg08854313	chr1:11322531	MTOR	0.76	10.26	0.53	4.97e-21	Body mass index;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg00322698	chr6:41069048	NFYA;LOC221442	0.52	7.29	0.41	3.58e-12	Fibrinogen levels;
CESC	cis	rs10504229	0.683	rs16921819	chr8:58107936	G/T	cg24829409	chr8:58192753	C8orf71	-0.56	-7.01	-0.4	1.97e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs1862618	0.802	rs986049	chr5:56110233	G/A	cg03609598	chr5:56110824	MAP3K1	-0.49	-5.32	-0.31	2.16e-7	Initial pursuit acceleration;
CESC	cis	rs7618915	0.547	rs10865973	chr3:52718154	A/T	cg18099408	chr3:52552593	STAB1	-0.31	-5.18	-0.3	4.4e-7	Bipolar disorder;
CESC	cis	rs3106136	0.609	rs72665612	chr4:95101183	T/G	cg11021082	chr4:95130006	SMARCAD1	-0.46	-6.23	-0.36	1.8e-9	Capecitabine sensitivity;
CESC	cis	rs801193	1.000	rs6975195	chr7:66124774	T/A	cg11764359	chr7:65958608	NA	-0.68	-8.81	-0.48	1.68e-16	Aortic root size;
CESC	cis	rs2354432	0.607	rs59606861	chr1:146761478	G/A	cg25205988	chr1:146714368	CHD1L	-0.95	-8.2	-0.45	1.05e-14	Mitochondrial DNA levels;
CESC	cis	rs6466055	0.666	rs4730081	chr7:105006850	C/T	cg04380332	chr7:105027541	SRPK2	-0.41	-5.31	-0.31	2.38e-7	Schizophrenia;
CESC	cis	rs7208859	0.623	rs56812022	chr17:29068733	A/G	cg13385521	chr17:29058706	SUZ12P	0.81	6.48	0.37	4.4e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs344364	0.511	rs56077812	chr16:1948870	T/G	cg26617929	chr16:1858877	NA	-0.49	-5.15	-0.3	5.09e-7	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs875971	0.862	rs11760844	chr7:65739883	C/G	cg18876405	chr7:65276391	NA	-0.49	-6.75	-0.38	9.38e-11	Aortic root size;
CESC	cis	rs8031584	0.678	rs4779496	chr15:31151054	A/G	cg14298792	chr15:30685198	CHRFAM7A	-0.46	-5.51	-0.32	8.35e-8	Huntington's disease progression;
CESC	cis	rs4835473	0.932	rs4516663	chr4:144901944	G/C	cg25736465	chr4:144833511	NA	0.41	6.2	0.36	2.14e-9	Immature fraction of reticulocytes;
CESC	cis	rs7659604	0.502	rs4315813	chr4:122674866	G/A	cg19671926	chr4:122722719	EXOSC9	0.53	6.7	0.38	1.21e-10	Type 2 diabetes;
CESC	cis	rs2797160	1.000	rs2797160	chr6:126010116	A/G	cg05901451	chr6:126070800	HEY2	0.45	6.6	0.38	2.19e-10	Endometrial cancer;
CESC	trans	rs7395662	0.553	rs4882155	chr11:48705801	T/C	cg15704280	chr7:45808275	SEPT13	-0.51	-6.12	-0.35	3.31e-9	HDL cholesterol;
CESC	cis	rs72781680	0.948	rs72796319	chr2:24133027	T/C	cg08917208	chr2:24149416	ATAD2B	0.93	8.42	0.46	2.35e-15	Lymphocyte counts;
CESC	cis	rs12586317	0.547	rs2383693	chr14:35500205	A/C	cg16230307	chr14:35515116	FAM177A1	1.06	11.29	0.57	2.17e-24	Psoriasis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04282497	chr4:82350883	RASGEF1B	-0.65	-7.27	-0.41	3.92e-12	Gut microbiome composition (summer);
CESC	cis	rs6942756	0.774	rs891545	chr7:128866616	A/C	cg02491457	chr7:128862824	NA	0.66	9.86	0.52	9.46e-20	White matter hyperintensity burden;
CESC	cis	rs1799949	1.000	rs1399323	chr17:41332330	T/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.41	5.57	0.32	6.16e-8	Menopause (age at onset);
CESC	cis	rs11642862	1.000	rs11645367	chr16:30770074	C/T	cg02466173	chr16:30829666	NA	-0.6	-6.07	-0.35	4.4e-9	Tonsillectomy;
CESC	cis	rs9910055	0.529	rs2523161	chr17:42179405	C/T	cg13607699	chr17:42295918	UBTF	-0.56	-7.35	-0.41	2.47e-12	Total body bone mineral density;
CESC	cis	rs11676348	0.808	rs4674267	chr2:219046437	C/T	cg00012203	chr2:219082015	ARPC2	-0.4	-5.05	-0.3	8.09e-7	Ulcerative colitis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00164301	chr17:80351457	C17orf101	-0.5	-6.1	-0.35	3.69e-9	Gut microbiome composition (summer);
CESC	cis	rs977987	0.835	rs1010630	chr16:75328591	G/T	cg03315344	chr16:75512273	CHST6	0.38	5.56	0.32	6.54e-8	Dupuytren's disease;
CESC	cis	rs4474465	0.688	rs7945812	chr11:78280509	T/C	cg27205649	chr11:78285834	NARS2	0.52	7.14	0.4	9.17e-12	Alzheimer's disease (survival time);
CESC	cis	rs965469	0.779	rs6037543	chr20:3289505	A/G	cg25506879	chr20:3388711	C20orf194	-0.48	-5.31	-0.31	2.36e-7	IFN-related cytopenia;
CESC	cis	rs10779751	0.881	rs2744820	chr1:11365015	G/A	cg08854313	chr1:11322531	MTOR	-0.78	-11.0	-0.56	1.98e-23	Body mass index;
CESC	cis	rs2730245	0.661	rs842696	chr7:158662698	T/C	cg15303052	chr7:158526867	ESYT2	-0.4	-5.07	-0.3	7.39e-7	Height;
CESC	cis	rs769267	0.965	rs2965188	chr19:19522557	G/A	cg03709012	chr19:19516395	GATAD2A	0.99	15.45	0.69	7.85e-39	Tonsillectomy;
CESC	cis	rs3785574	0.962	rs114027117	chr17:61939935	T/A	cg11494091	chr17:61959527	GH2	0.36	5.08	0.3	7.19e-7	Height;
CESC	cis	rs6545883	0.965	rs11887205	chr2:61774473	T/G	cg15711740	chr2:61764176	XPO1	-0.44	-5.37	-0.31	1.7e-7	Tuberculosis;
CESC	cis	rs7520050	0.966	rs61783200	chr1:46297403	T/C	cg03146154	chr1:46216737	IPP	-0.48	-6.3	-0.36	1.25e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs4819052	0.851	rs2838844	chr21:46670733	A/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.75	9.89	0.52	7.53e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs6060717	0.536	rs7271036	chr20:34467215	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	-0.66	-5.7	-0.33	3.16e-8	Hip circumference adjusted for BMI;
CESC	cis	rs4253772	0.591	rs9615343	chr22:46690824	C/G	cg24881330	chr22:46731750	TRMU	0.73	5.24	0.31	3.32e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.89	13.67	0.64	1.49e-32	Prudent dietary pattern;
CESC	cis	rs1797885	0.564	rs2596822	chr3:12596844	C/T	cg26432171	chr3:12704882	RAF1	0.51	6.15	0.35	2.79e-9	Immature fraction of reticulocytes;
CESC	cis	rs13191362	1.000	rs13220048	chr6:163004325	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.88	9.16	0.49	1.46e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs909674	0.524	rs5750821	chr22:39825492	A/T	cg01416388	chr22:39784598	NA	-0.56	-6.99	-0.39	2.21e-11	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs916888	0.738	rs199515	chr17:44856641	C/G	cg01570182	chr17:44337453	NA	-0.87	-10.82	-0.55	7.56e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	trans	rs9467711	0.606	rs28362606	chr6:26365586	T/C	cg06606381	chr12:133084897	FBRSL1	-0.76	-6.94	-0.39	3.06e-11	Autism spectrum disorder or schizophrenia;
CESC	cis	rs34172651	0.571	rs9922156	chr16:24704329	C/A	cg06028605	chr16:24865363	SLC5A11	-0.45	-6.75	-0.38	9.54e-11	Intelligence (multi-trait analysis);
CESC	cis	rs12477438	0.520	rs11890338	chr2:99767868	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	15.46	0.69	7.45e-39	Chronic sinus infection;
CESC	cis	rs35110281	0.807	rs4818850	chr21:45028071	T/G	cg01579765	chr21:45077557	HSF2BP	-0.59	-10.08	-0.53	1.87e-20	Mean corpuscular volume;
CESC	cis	rs6951245	0.832	rs79808627	chr7:1092519	C/G	cg26875135	chr7:1221192	NA	-0.43	-5.16	-0.3	4.89e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs9549260	0.755	rs7338669	chr13:41200091	C/T	cg21288729	chr13:41239152	FOXO1	-0.6	-7.78	-0.43	1.58e-13	Red blood cell count;
CESC	cis	rs2637266	1.000	rs2395410	chr10:78381767	C/T	cg18941641	chr10:78392320	NA	0.41	7.89	0.44	7.78e-14	Pulmonary function;
CESC	cis	rs7927592	0.913	rs12283755	chr11:68371658	A/G	cg20283391	chr11:68216788	NA	-0.6	-7.17	-0.4	7.57e-12	Total body bone mineral density;
CESC	cis	rs763014	0.898	rs916414	chr16:632073	C/T	cg00802000	chr16:706648	WDR90	-0.41	-6.12	-0.35	3.33e-9	Height;
CESC	trans	rs12599106	0.625	rs12923277	chr16:34896261	G/A	cg11235426	chr6:292522	DUSP22	-0.71	-9.33	-0.5	4.49e-18	Menopause (age at onset);
CESC	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.63	7.16	0.4	7.99e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7188697	0.922	rs2243463	chr16:58571189	T/C	cg21335942	chr16:58549945	SETD6	0.46	5.36	0.31	1.84e-7	QT interval;
CESC	trans	rs4295623	0.559	rs4841600	chr8:11688148	T/C	cg06636001	chr8:8085503	FLJ10661	0.52	6.49	0.37	4.28e-10	Morning vs. evening chronotype;
CESC	cis	rs72720396	1.000	rs72720396	chr1:91191582	A/G	cg13456504	chr1:91191583	NA	0.61	8.34	0.46	4.17e-15	Morning vs. evening chronotype;Chronotype;
CESC	cis	rs73110464	0.609	rs11170348	chr12:53355588	A/G	cg25025879	chr12:53359317	NA	-0.61	-7.97	-0.44	4.59e-14	Cancer (pleiotropy);
CESC	cis	rs780094	0.544	rs780108	chr2:27684957	T/C	cg21248554	chr2:27665150	KRTCAP3	-0.28	-6.05	-0.35	4.97e-9	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
CESC	cis	rs9549367	0.713	rs3024747	chr13:113821787	C/G	cg00898013	chr13:113819073	PROZ	-0.49	-6.96	-0.39	2.69e-11	Platelet distribution width;
CESC	cis	rs763121	0.853	rs5757166	chr22:38995385	G/T	cg06544989	chr22:39130855	UNC84B	0.51	9.34	0.5	4.01e-18	Menopause (age at onset);
CESC	cis	rs228769	0.673	rs228787	chr17:42099488	C/T	cg19774624	chr17:42201019	HDAC5	0.52	6.29	0.36	1.29e-9	Bone mineral density (hip);Bone mineral density (spine);
CESC	cis	rs7980687	0.628	rs2102949	chr12:123676763	G/A	cg00376283	chr12:123451042	ABCB9	0.67	9.28	0.5	6.47e-18	Height;Educational attainment;Head circumference (infant);
CESC	cis	rs73019876	0.869	rs1849006	chr19:22142764	A/C	cg11619707	chr19:22235551	ZNF257	-0.27	-5.12	-0.3	5.94e-7	Testicular germ cell tumor;
CESC	trans	rs16893526	1.000	rs16893491	chr6:82496625	G/A	cg22476893	chr17:7210162	EIF5A	0.78	6.06	0.35	4.53e-9	Coronary heart disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01487461	chr9:2017199	SMARCA2	-0.6	-6.49	-0.37	4.18e-10	Gut microbiome composition (summer);
CESC	cis	rs62229266	0.804	rs998383	chr21:37445739	C/G	cg08632701	chr21:37451849	NA	-0.39	-5.35	-0.31	1.91e-7	Mitral valve prolapse;
CESC	cis	rs2282802	0.685	rs6580473	chr5:139646962	C/T	cg26211634	chr5:139558579	C5orf32	-0.5	-7.38	-0.41	2.02e-12	Intelligence (multi-trait analysis);
CESC	cis	rs12497850	0.897	rs6446252	chr3:48911125	C/T	cg03060546	chr3:49711283	APEH	0.45	5.5	0.32	9e-8	Parkinson's disease;
CESC	trans	rs10776614	0.799	rs11101382	chr10:49766377	G/A	cg19218067	chr2:181235115	NA	0.49	6.0	0.35	6.35e-9	Self-employment;
CESC	cis	rs6460942	0.915	rs62448602	chr7:12457145	T/G	cg02935154	chr7:12443704	VWDE	-0.58	-6.16	-0.35	2.73e-9	Coronary artery disease;
CESC	cis	rs10504229	1.000	rs61212428	chr8:58173963	G/A	cg24829409	chr8:58192753	C8orf71	-0.76	-10.0	-0.52	3.53e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs1707322	0.717	rs1135812	chr1:46095272	T/C	cg05343316	chr1:45956843	TESK2	0.51	6.35	0.36	9.45e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs1814175	0.817	rs11040651	chr11:49938395	G/A	cg15704280	chr7:45808275	SEPT13	-1.03	-20.27	-0.78	8.31e-56	Height;
CESC	cis	rs55882075	0.690	rs12374485	chr5:179131395	G/C	cg14593053	chr5:179126677	CANX	0.59	8.49	0.46	1.53e-15	Monocyte percentage of white cells;
CESC	cis	rs7666738	0.791	rs2903142	chr4:99040071	C/T	cg03467027	chr4:99064603	C4orf37	0.47	5.98	0.34	7.19e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs763121	0.853	rs4821809	chr22:39065743	G/C	cg06022373	chr22:39101656	GTPBP1	0.88	13.81	0.65	4.88e-33	Menopause (age at onset);
CESC	cis	rs2073300	1.000	rs6137982	chr20:23468892	T/A	cg12062639	chr20:23401060	NAPB	0.92	5.89	0.34	1.18e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs2425143	1.000	rs78421482	chr20:34376486	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.69	5.95	0.34	8.54e-9	Blood protein levels;
CESC	cis	rs12711979	0.509	rs13021385	chr2:3826387	T/C	cg17052675	chr2:3827356	NA	-0.67	-11.05	-0.56	1.35e-23	Itch intensity from mosquito bite adjusted by bite size;
CESC	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	7.56	0.42	6.72e-13	Prudent dietary pattern;
CESC	cis	rs576982	1	rs576982	chr15:78870803	C/T	cg24631222	chr15:78858424	CHRNA5	0.81	10.22	0.53	6.76e-21	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs72781680	0.611	rs7596820	chr2:24335036	G/C	cg20701182	chr2:24300061	SF3B14	0.91	10.51	0.54	7.88e-22	Lymphocyte counts;
CESC	cis	rs11098499	0.697	rs10016448	chr4:120298845	A/G	cg09307838	chr4:120376055	NA	0.92	12.66	0.61	4.96e-29	Corneal astigmatism;
CESC	cis	rs2652822	0.550	rs72747098	chr15:63525249	G/A	cg02713581	chr15:63449717	RPS27L	0.48	6.01	0.35	6.02e-9	Metabolic traits;
CESC	cis	rs9322193	0.962	rs10872653	chr6:150100043	A/C	cg07701084	chr6:150067640	NUP43	0.42	5.78	0.33	2.08e-8	Lung cancer;
CESC	cis	rs7613875	0.620	rs3774734	chr3:50108792	C/A	cg24110177	chr3:50126178	RBM5	0.54	7.46	0.42	1.25e-12	Body mass index;
CESC	cis	rs7666738	0.830	rs11721726	chr4:98996314	T/C	cg17366294	chr4:99064904	C4orf37	0.6	8.61	0.47	6.47e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg18402987	chr7:1209562	NA	0.59	7.08	0.4	1.33e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7078219	1.000	rs11190130	chr10:101275206	C/T	cg09788492	chr10:101292477	NKX2-3	0.29	5.21	0.31	3.73e-7	Dental caries;
CESC	cis	rs11696501	0.688	rs6124726	chr20:44307866	T/A	cg11783356	chr20:44313418	WFDC10B	-0.32	-5.12	-0.3	5.77e-7	Brain structure;
CESC	cis	rs684232	0.800	rs371318	chr17:555816	A/G	cg15660573	chr17:549704	VPS53	-0.42	-5.7	-0.33	3.13e-8	Prostate cancer;
CESC	cis	rs6952808	0.689	rs871924	chr7:2047845	A/G	cg23048001	chr7:2026167	MAD1L1	0.48	6.29	0.36	1.33e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs4925386	0.921	rs11204472	chr20:60920887	G/A	cg24112000	chr20:60950667	NA	0.49	7.28	0.41	3.7e-12	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs3857067	0.806	rs72665629	chr4:95112160	T/A	cg11021082	chr4:95130006	SMARCAD1	-0.6	-9.12	-0.49	1.97e-17	QT interval;
CESC	cis	rs853679	0.517	rs9468286	chr6:28079428	C/T	cg12963246	chr6:28129442	ZNF389	0.56	7.63	0.42	4.26e-13	Depression;
CESC	trans	rs11098499	0.697	rs10016448	chr4:120298845	A/G	cg25214090	chr10:38739885	LOC399744	0.68	9.2	0.49	1.14e-17	Corneal astigmatism;
CESC	cis	rs11969893	0.850	rs9390713	chr6:101424262	G/A	cg12253828	chr6:101329408	ASCC3	0.95	6.16	0.35	2.68e-9	Economic and political preferences (immigration/crime);
CESC	cis	rs61931739	0.534	rs11053131	chr12:34282109	A/G	cg19457237	chr12:34500585	NA	-0.36	-5.06	-0.3	7.97e-7	Morning vs. evening chronotype;
CESC	cis	rs2072499	0.750	rs2241109	chr1:156173082	C/T	cg24450063	chr1:156163899	SLC25A44	0.96	12.2	0.6	1.78e-27	Testicular germ cell tumor;
CESC	cis	rs6967414	0.681	rs11979878	chr7:6753803	A/G	cg09896999	chr7:6746977	ZNF12	-0.51	-6.29	-0.36	1.29e-9	Hematocrit;Hemoglobin concentration;
CESC	cis	rs9868809	0.505	rs73080312	chr3:48737847	C/T	cg00383909	chr3:49044727	WDR6	0.91	5.6	0.33	5.41e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs4971059	0.629	rs11264333	chr1:155108287	G/A	cg22049894	chr1:155113146	DPM3	0.45	5.87	0.34	1.28e-8	Breast cancer;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg04633058	chr17:48474099	LRRC59	-0.44	-6.19	-0.36	2.26e-9	Height;
CESC	cis	rs6963495	0.818	rs6944787	chr7:105147309	C/T	cg02135003	chr7:105160482	PUS7	-0.47	-5.61	-0.33	5.12e-8	Bipolar disorder (body mass index interaction);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg24769158	chr12:123351868	VPS37B	0.45	6.07	0.35	4.39e-9	Fibrinogen levels;
CESC	cis	rs7618915	0.547	rs33967311	chr3:52683864	G/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.48	7.25	0.41	4.6e-12	Bipolar disorder;
CESC	cis	rs9287719	0.967	rs6755548	chr2:10746126	A/G	cg02196655	chr2:10830764	NOL10	-0.38	-5.78	-0.33	2.05e-8	Prostate cancer;
CESC	cis	rs7208859	0.524	rs59923796	chr17:29064919	G/A	cg14008862	chr17:28927542	LRRC37B2	0.64	5.11	0.3	6.29e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs9733	0.744	rs12125650	chr1:150760174	A/G	cg18016565	chr1:150552671	MCL1	-0.36	-5.89	-0.34	1.19e-8	Tonsillectomy;
CESC	cis	rs2839186	0.619	rs2187118	chr21:47611310	C/T	cg12379764	chr21:47803548	PCNT	-0.53	-6.74	-0.38	1.01e-10	Testicular germ cell tumor;
CESC	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg26354017	chr1:205819088	PM20D1	0.84	13.67	0.64	1.51e-32	Menarche (age at onset);
CESC	cis	rs9583531	0.574	rs7319459	chr13:111352408	T/C	cg15841412	chr13:111365552	ING1	-0.49	-6.3	-0.36	1.2e-9	Coronary artery disease;
CESC	cis	rs1348850	0.914	rs8941	chr2:178406481	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.87	12.42	0.61	3.15e-28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs4900538	0.892	rs4906208	chr14:102956489	G/C	cg18135206	chr14:102964638	TECPR2	0.84	11.44	0.58	6.53e-25	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	cis	rs11532322	1	rs11532322	chr12:123731423	A/G	cg00376283	chr12:123451042	ABCB9	0.67	8.89	0.48	9.54e-17	Schizophrenia;
CESC	cis	rs796364	0.616	rs2689765	chr2:200696352	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	0.62	6.12	0.35	3.42e-9	Schizophrenia;
CESC	cis	rs6540556	0.769	rs10157973	chr1:209924425	C/T	cg05527609	chr1:210001259	C1orf107	-0.49	-5.89	-0.34	1.17e-8	Red blood cell count;
CESC	cis	rs10782582	0.593	rs11578480	chr1:76208989	T/G	cg10523679	chr1:76189770	ACADM	-0.48	-5.57	-0.32	6.16e-8	Daytime sleep phenotypes;
CESC	cis	rs7618915	0.547	rs3774365	chr3:52642487	T/C	cg05564831	chr3:52568323	NT5DC2	0.45	6.82	0.39	5.99e-11	Bipolar disorder;
CESC	cis	rs1348850	0.914	rs7573763	chr2:178249808	C/T	cg23306229	chr2:178417860	TTC30B	0.65	8.11	0.45	1.95e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg00585742	chr6:160219791	NA	0.4	6.03	0.35	5.35e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs7666738	0.830	rs13108871	chr4:98803872	T/C	cg05340658	chr4:99064831	C4orf37	0.77	11.88	0.59	2.27e-26	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7267979	1.000	rs4813562	chr20:25352588	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.88	-18.14	-0.74	2.23e-48	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs9303401	0.659	rs36093395	chr17:56957357	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.01	12.69	0.61	3.78e-29	Cognitive test performance;
CESC	cis	rs1800795	0.652	rs7802307	chr7:22766433	T/A	cg26061582	chr7:22766209	IL6	0.45	5.14	0.3	5.34e-7	Cerebrospinal fluid clusterin levels in APOEe4- carriers;
CESC	cis	rs12360000	0.770	rs12251959	chr10:1902277	C/T	cg26364871	chr10:1889757	NA	-0.4	-5.35	-0.31	1.88e-7	Metabolite levels (Dihydroxy docosatrienoic acid);
CESC	cis	rs920590	0.758	rs62496731	chr8:19659543	C/G	cg17834443	chr8:19674713	INTS10	0.6	6.71	0.38	1.17e-10	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs2180341	0.842	rs9375492	chr6:127545492	C/T	cg24812749	chr6:127587940	RNF146	-0.99	-11.99	-0.59	9.5e-27	Breast cancer;
CESC	cis	rs4237845	0.537	rs10747787	chr12:58260657	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.47	5.51	0.32	8.7e-8	Intelligence (multi-trait analysis);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg03376029	chr16:89133406	NA	0.32	6.06	0.35	4.53e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs1506636	1.000	rs12333705	chr7:123356062	C/T	cg03229431	chr7:123269106	ASB15	-0.52	-6.91	-0.39	3.58e-11	Plateletcrit;Platelet count;
CESC	trans	rs6964833	1.000	rs4717907	chr7:74086493	C/T	cg07504079	chr7:72649617	NCF1B	-0.54	-6.21	-0.36	2.08e-9	Menarche (age at onset);
CESC	cis	rs3015497	0.789	rs2934688	chr14:51112360	G/A	cg09863266	chr14:51125203	SAV1	-0.34	-5.26	-0.31	3.04e-7	Mean platelet volume;
CESC	cis	rs4843747	0.636	rs11864872	chr16:88105966	A/G	cg06374794	chr16:88002281	BANP	0.39	5.15	0.3	5.02e-7	Menopause (age at onset);
CESC	cis	rs9905704	0.627	rs6503867	chr17:56621359	T/C	cg12560992	chr17:57184187	TRIM37	-0.64	-6.09	-0.35	4.06e-9	Testicular germ cell tumor;
CESC	cis	rs2243480	1.000	rs313832	chr7:65550891	G/T	cg18252515	chr7:66147081	NA	-1.38	-13.59	-0.64	2.8099999999999997e-32	Diabetic kidney disease;
CESC	cis	rs56235845	0.694	rs11738681	chr5:176761535	A/G	cg06060754	chr5:176797920	RGS14	0.41	5.18	0.3	4.44e-7	Hemoglobin concentration;Hematocrit;
CESC	trans	rs13063635	0.915	rs34338823	chr3:45928769	G/A	cg10236987	chr1:228114221	WNT9A	0.63	6.49	0.37	4.17e-10	Eosinophil percentage of granulocytes;
CESC	cis	rs9768139	0.708	rs921615	chr7:158117935	A/G	cg25566285	chr7:158114605	PTPRN2	0.5	8.17	0.45	1.27e-14	Calcium levels;
CESC	cis	rs7264396	0.733	rs6058305	chr20:34310757	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.86	-11.83	-0.59	3.3e-26	Total cholesterol levels;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg14616479	chr3:155588124	GMPS	-0.45	-6.52	-0.37	3.57e-10	Gambling;
CESC	cis	rs7666738	0.791	rs13128640	chr4:99003918	A/C	cg05340658	chr4:99064831	C4orf37	0.8	12.44	0.61	2.83e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3815700	1.000	rs8104729	chr19:33093979	C/T	cg02997394	chr19:33096574	ANKRD27	0.73	7.3	0.41	3.26e-12	Eosinophilic esophagitis;
CESC	cis	rs864537	0.590	rs1214596	chr1:167427170	A/T	cg09179987	chr1:167433047	CD247	-0.53	-7.97	-0.44	4.7e-14	Celiac disease or Rheumatoid arthritis;Celiac disease;
CESC	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg06873352	chr17:61820015	STRADA	0.72	12.79	0.62	1.65e-29	Prudent dietary pattern;
CESC	trans	rs7752903	0.793	rs5029939	chr6:138195723	C/G	cg02519892	chr21:43198586	NA	-0.72	-6.2	-0.36	2.2e-9	Rheumatoid arthritis;
CESC	trans	rs11098499	0.644	rs7693919	chr4:120540571	G/A	cg25214090	chr10:38739885	LOC399744	0.63	8.87	0.48	1.14e-16	Corneal astigmatism;
CESC	cis	rs6910061	1.000	rs6910061	chr6:11101918	A/T	cg27233058	chr6:11094804	LOC221710	-0.46	-5.1	-0.3	6.35e-7	Diabetic kidney disease;
CESC	cis	rs7084402	0.565	rs11006188	chr10:60333471	G/C	cg07615347	chr10:60278583	BICC1	0.41	5.98	0.34	7.21e-9	Refractive error;
CESC	cis	rs938554	0.692	rs6449213	chr4:9994215	A/G	cg00071950	chr4:10020882	SLC2A9	-0.6	-6.72	-0.38	1.13e-10	Blood metabolite levels;
CESC	cis	rs35146811	0.844	rs13223792	chr7:99675659	T/G	cg22906224	chr7:99728672	NA	0.43	5.28	0.31	2.66e-7	Coronary artery disease;
CESC	cis	rs6570726	0.791	rs4335004	chr6:145904764	G/A	cg23711669	chr6:146136114	FBXO30	0.99	15.01	0.68	2.93e-37	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9902453	0.765	rs2628180	chr17:28101723	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-10.34	-0.54	2.82e-21	Coffee consumption (cups per day);
CESC	cis	rs2991971	0.903	rs2991973	chr1:46020632	G/A	cg03146154	chr1:46216737	IPP	-0.43	-5.35	-0.31	1.87e-7	High light scatter reticulocyte count;
CESC	trans	rs916888	0.773	rs199439	chr17:44793503	A/G	cg07870213	chr5:140052090	DND1	0.63	6.77	0.38	8.36e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs17666538	0.585	rs6559064	chr8:623061	G/A	cg07234876	chr8:600039	NA	0.85	6.02	0.35	5.83e-9	IgG glycosylation;
CESC	cis	rs7811142	0.666	rs28401739	chr7:99905684	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.93	9.74	0.51	2.3e-19	Platelet count;
CESC	cis	rs7666738	0.830	rs11731478	chr4:99001686	A/G	cg03467027	chr4:99064603	C4orf37	0.44	5.51	0.32	8.65e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11785400	0.793	rs7017851	chr8:143722038	G/T	cg24634471	chr8:143751801	JRK	0.43	5.38	0.31	1.64e-7	Schizophrenia;
CESC	cis	rs11630290	0.736	rs4777370	chr15:64160104	G/A	cg12036633	chr15:63758958	NA	0.5	5.38	0.31	1.63e-7	Iris characteristics;
CESC	cis	rs2625529	0.712	rs2054601	chr15:72184968	T/C	cg16672083	chr15:72433130	SENP8	-0.39	-5.05	-0.3	8.1e-7	Red blood cell count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19332102	chr11:124588484	NA	-0.58	-6.94	-0.39	3.01e-11	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.830	rs1426667	chr4:98949772	T/C	cg03467027	chr4:99064603	C4orf37	0.45	5.67	0.33	3.69e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs42648	1.000	rs42658	chr7:89981915	T/A	cg23697855	chr7:89950296	NA	0.28	5.09	0.3	6.83e-7	Homocysteine levels;
CESC	cis	rs3733585	0.699	rs4339211	chr4:9947658	C/T	cg02734326	chr4:10020555	SLC2A9	-0.42	-5.91	-0.34	1.05e-8	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs56309584	0.673	rs56256903	chr17:8123128	T/G	cg06726167	chr17:8076949	TMEM107	-0.5	-5.1	-0.3	6.44e-7	Initial pursuit acceleration;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg01452438	chr16:4303710	NA	0.45	6.0	0.35	6.47e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs763121	0.853	rs2072796	chr22:39064230	A/G	cg21395723	chr22:39101663	GTPBP1	0.43	5.39	0.31	1.58e-7	Menopause (age at onset);
CESC	cis	rs9302635	0.640	rs9933009	chr16:72190650	G/A	cg16558253	chr16:72132732	DHX38	-0.41	-5.32	-0.31	2.17e-7	Blood protein levels;
CESC	trans	rs11098499	0.954	rs56270433	chr4:120406030	C/T	cg25214090	chr10:38739885	LOC399744	0.72	10.18	0.53	9.16e-21	Corneal astigmatism;
CESC	cis	rs7680126	0.633	rs2024280	chr4:10291813	A/G	cg00071950	chr4:10020882	SLC2A9	-0.49	-5.04	-0.3	8.78e-7	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	cis	rs8048576	0.512	rs8063863	chr16:84400850	C/T	cg03548384	chr16:84403863	ATP2C2	-0.4	-5.05	-0.3	8.39e-7	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs6988985	0.560	rs3753122	chr8:143926927	G/T	cg10324643	chr8:143916377	GML	0.34	5.12	0.3	5.95e-7	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
CESC	cis	rs34734847	0.933	rs998727	chr12:121149064	T/G	cg21892295	chr12:121157589	UNC119B	-0.4	-6.31	-0.36	1.16e-9	Mean corpuscular volume;
CESC	cis	rs2549003	1.000	rs2549002	chr5:131829578	C/A	cg02551604	chr5:131831745	NA	0.38	5.42	0.32	1.31e-7	Asthma (sex interaction);
CESC	cis	rs4332037	0.624	rs73046339	chr7:1889300	G/A	cg23422044	chr7:1970798	MAD1L1	-0.49	-5.34	-0.31	1.95e-7	Bipolar disorder;
CESC	cis	rs524281	0.814	rs10896093	chr11:65958411	C/G	cg14036092	chr11:66035641	RAB1B	-0.59	-6.26	-0.36	1.54e-9	Electroencephalogram traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15734422	chr10:121356865	TIAL1	0.62	7.05	0.4	1.52e-11	Gut microbiome composition (summer);
CESC	cis	rs7116495	0.609	rs2735787	chr11:71717873	T/C	cg10381502	chr11:71823885	C11orf51	-1.13	-7.53	-0.42	7.8e-13	Severe influenza A (H1N1) infection;
CESC	cis	rs1348850	0.526	rs9288003	chr2:178446572	T/G	cg23306229	chr2:178417860	TTC30B	0.57	5.57	0.32	6.21e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs7618915	0.571	rs17264436	chr3:52610651	T/A	cg18099408	chr3:52552593	STAB1	-0.33	-5.49	-0.32	9.3e-8	Bipolar disorder;
CESC	cis	rs1018836	0.637	rs7843684	chr8:91470035	G/C	cg16814680	chr8:91681699	NA	-0.52	-7.17	-0.4	7.6e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs9910055	0.659	rs7214540	chr17:42256604	A/G	cg19774624	chr17:42201019	HDAC5	-0.82	-12.61	-0.61	7.15e-29	Total body bone mineral density;
CESC	cis	rs3008870	0.755	rs3736905	chr1:67392614	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.64	8.39	0.46	2.87e-15	Lymphocyte percentage of white cells;
CESC	cis	rs9486719	0.948	rs11153059	chr6:97014537	T/A	cg06623918	chr6:96969491	KIAA0776	-0.8	-8.3	-0.45	5.39e-15	Migraine;Coronary artery disease;
CESC	cis	rs524281	0.861	rs7120326	chr11:65849256	C/T	cg14036092	chr11:66035641	RAB1B	-0.57	-5.78	-0.33	2.06e-8	Electroencephalogram traits;
CESC	cis	rs6460942	0.915	rs62448598	chr7:12453762	T/C	cg20607287	chr7:12443886	VWDE	-0.78	-9.15	-0.49	1.61e-17	Coronary artery disease;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg01693652	chr20:60961553	RPS21	0.45	6.44	0.37	5.45e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs36051895	0.695	rs2183137	chr9:5026293	A/G	cg02405213	chr9:5042618	JAK2	-0.51	-6.11	-0.35	3.52e-9	Pediatric autoimmune diseases;
CESC	cis	rs172166	0.611	rs203882	chr6:28078502	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.48	-6.22	-0.36	1.92e-9	Cardiac Troponin-T levels;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg00828305	chr2:178077190	HNRNPA3	-0.49	-6.26	-0.36	1.51e-9	Ulcerative colitis;
CESC	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg02353165	chr6:42928485	GNMT	0.86	14.33	0.66	7.06e-35	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs34172651	0.517	rs12920774	chr16:24830750	T/C	cg02428538	chr16:24856791	SLC5A11	-0.61	-6.14	-0.35	2.98e-9	Intelligence (multi-trait analysis);
CESC	cis	rs2456568	0.548	rs1607402	chr11:93660732	T/G	cg26875233	chr11:93583750	C11orf90	-0.32	-5.55	-0.32	7.1e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
CESC	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.43	-5.41	-0.32	1.42e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs4555082	0.874	rs56263609	chr14:105756944	C/T	cg06808227	chr14:105710500	BRF1	-0.5	-5.34	-0.31	1.99e-7	Mean platelet volume;Platelet distribution width;
CESC	cis	rs7666738	0.830	rs13122456	chr4:98936011	A/G	cg17366294	chr4:99064904	C4orf37	0.61	8.56	0.47	9.36e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9457247	0.730	rs9459841	chr6:167431949	G/A	cg07741184	chr6:167504864	NA	0.36	6.56	0.37	2.77e-10	Crohn's disease;
CESC	cis	rs514406	0.861	rs503015	chr1:53254456	T/C	cg08736216	chr1:53307985	ZYG11A	0.43	7.24	0.41	4.86e-12	Monocyte count;
CESC	cis	rs12142240	0.698	rs112089006	chr1:46812360	C/T	cg00530320	chr1:46809349	NSUN4	0.58	7.85	0.43	1.05e-13	Menopause (age at onset);
CESC	cis	rs34779708	0.931	rs7920095	chr10:35303334	G/A	cg03585969	chr10:35415529	CREM	0.76	10.03	0.52	2.79e-20	Inflammatory bowel disease;Crohn's disease;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg16200569	chr12:56436204	RPS26	0.46	6.01	0.35	6.11e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs4820539	1.000	rs4822361	chr22:23482718	A/G	cg14186256	chr22:23484241	RTDR1	-0.81	-15.04	-0.68	2.29e-37	Bone mineral density;
CESC	cis	rs662064	0.925	rs669701	chr1:10544725	A/G	cg20482658	chr1:10539492	PEX14	-0.39	-7.88	-0.44	8.7e-14	Asthma;
CESC	trans	rs116095464	0.558	rs61492827	chr5:225774	A/G	cg00938859	chr5:1591904	SDHAP3	0.61	6.78	0.38	7.58e-11	Breast cancer;
CESC	cis	rs7216064	1.000	rs6504542	chr17:65836642	T/C	cg12091567	chr17:66097778	LOC651250	-0.8	-9.08	-0.49	2.62e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs6570726	0.791	rs6915094	chr6:145883540	C/G	cg23711669	chr6:146136114	FBXO30	1.03	15.8	0.7	4.47e-40	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1862618	0.671	rs2591961	chr5:56238597	A/G	cg24549020	chr5:56110836	MAP3K1	-0.47	-5.68	-0.33	3.5e-8	Initial pursuit acceleration;
CESC	cis	rs6987853	0.787	rs2923448	chr8:42406008	G/A	cg09913449	chr8:42400586	C8orf40	0.45	7.6	0.42	5.18e-13	Mean corpuscular hemoglobin concentration;
CESC	cis	rs9859260	0.744	rs419059	chr3:195782184	C/T	cg12923728	chr3:195709715	SDHAP1	0.53	6.93	0.39	3.14e-11	Mean corpuscular volume;
CESC	cis	rs4141404	0.851	rs5749222	chr22:31556759	C/G	cg13145458	chr22:31556086	RNF185	0.53	6.39	0.37	7.43e-10	Paclitaxel-induced neuropathy;
CESC	cis	rs35306767	0.903	rs17159950	chr10:875287	T/G	cg26597838	chr10:835615	NA	0.91	9.48	0.5	1.56e-18	Eosinophil percentage of granulocytes;
CESC	cis	rs7236492	0.748	rs7228738	chr18:77231307	C/T	cg15644404	chr18:77186268	NFATC1	-0.68	-5.18	-0.3	4.45e-7	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs2857078	0.720	rs9906669	chr17:42305706	A/G	cg08499158	chr17:42289980	UBTF	-0.41	-5.1	-0.3	6.39e-7	Red cell distribution width;Reticulocyte count;
CESC	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg11766577	chr21:47581405	C21orf56	0.46	6.35	0.36	9.38e-10	Testicular germ cell tumor;
CESC	cis	rs7829975	0.902	rs777707	chr8:8584344	A/G	cg06636001	chr8:8085503	FLJ10661	0.45	5.92	0.34	9.72e-9	Mood instability;
CESC	cis	rs832540	0.656	rs832567	chr5:56152416	C/A	cg12311346	chr5:56204834	C5orf35	-0.45	-5.46	-0.32	1.09e-7	Coronary artery disease;
CESC	trans	rs1941023	0.672	rs2155710	chr11:60269240	C/T	cg14715327	chr11:55109885	OR4A16	0.48	5.99	0.35	6.7e-9	Congenital heart disease (maternal effect);
CESC	cis	rs3780486	1.000	rs12342831	chr9:33124872	A/G	cg13443165	chr9:33130375	B4GALT1	0.42	5.56	0.32	6.46e-8	IgG glycosylation;
CESC	cis	rs6444746	1.000	rs904881	chr3:193506621	G/T	cg22553634	chr3:193489233	NA	-0.41	-5.04	-0.3	8.64e-7	Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
CESC	cis	rs9733	0.818	rs11204695	chr1:150657011	T/G	cg04414720	chr1:150670196	GOLPH3L	-0.37	-5.19	-0.3	4.14e-7	Tonsillectomy;
CESC	trans	rs1373453	0.808	rs78212762	chr12:70080191	G/A	cg19702771	chr4:82058885	PRKG2	0.76	6.07	0.35	4.35e-9	Orofacial clefts;
CESC	cis	rs2736345	0.535	rs4366049	chr8:11398504	A/G	cg09528494	chr8:11338675	NA	0.31	5.78	0.33	2.15e-8	Sjögren's syndrome;Systemic lupus erythematosus;
CESC	cis	rs939574	0.656	rs113370390	chr2:220132837	T/C	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.82	6.1	0.35	3.64e-9	Platelet distribution width;
CESC	cis	rs6690583	0.623	rs7522239	chr1:85484366	C/T	cg11262906	chr1:85462892	MCOLN2	0.52	5.08	0.3	7.03e-7	Serum sulfate level;
CESC	cis	rs2832191	1.000	rs2832184	chr21:30483265	C/T	cg24692254	chr21:30365293	RNF160	-0.74	-11.15	-0.57	6.22e-24	Dental caries;
CESC	trans	rs2840044	0.554	rs225267	chr17:33964228	T/C	cg19694781	chr19:47549865	TMEM160	-0.73	-7.03	-0.4	1.79e-11	Response to radiotherapy in cancer (late toxicity);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08826281	chr19:49655176	HRC	0.6	7.08	0.4	1.31e-11	Gut microbiome composition (summer);
CESC	cis	rs10838687	0.736	rs4647754	chr11:47257340	C/T	cg25783544	chr11:47291846	MADD	0.55	6.32	0.36	1.09e-9	Proinsulin levels;
CESC	cis	rs10992471	0.702	rs10820967	chr9:95101729	C/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.46	-5.74	-0.33	2.57e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CESC	trans	rs12599106	0.754	rs11640596	chr16:34347277	T/C	cg01516881	chr6:292596	DUSP22	-0.52	-6.78	-0.38	7.86e-11	Menopause (age at onset);
CESC	cis	rs2408955	0.522	rs973398	chr12:48491048	A/G	cg04545296	chr12:48745243	ZNF641	-0.35	-6.11	-0.35	3.47e-9	Glycated hemoglobin levels;
CESC	cis	rs7949030	0.504	rs2516633	chr11:62371773	A/C	cg11742103	chr11:62369870	EML3;MTA2	-0.51	-7.29	-0.41	3.52e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs4665809	0.590	rs72809668	chr2:26467653	C/T	cg25036284	chr2:26402008	FAM59B	0.86	9.4	0.5	2.74e-18	Gut microbiome composition (summer);
CESC	cis	rs17376456	0.877	rs10076052	chr5:93317762	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.61	5.33	0.31	2.15e-7	Diabetic retinopathy;
CESC	cis	rs55871839	0.684	rs6988143	chr8:59810572	C/T	cg07426533	chr8:59803705	TOX	-0.47	-7.01	-0.4	1.95e-11	Pneumonia;
CESC	cis	rs6963495	0.818	rs6973263	chr7:105170293	A/G	cg19920283	chr7:105172520	RINT1	0.69	6.54	0.37	3.15e-10	Bipolar disorder (body mass index interaction);
CESC	cis	rs9611565	0.512	rs9607842	chr22:42192722	G/A	cg17376030	chr22:41985996	PMM1	0.78	8.32	0.46	4.56e-15	Vitiligo;
CESC	cis	rs6908843	0.532	rs79555858	chr6:166666497	G/A	cg06878426	chr6:166666287	NA	0.46	5.36	0.31	1.8e-7	Macrophage inflammatory protein 1b levels;
CESC	cis	rs9911578	0.967	rs2429369	chr17:56501420	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.39	5.26	0.31	2.93e-7	Intelligence (multi-trait analysis);
CESC	cis	rs7267979	0.565	rs6107059	chr20:25592431	C/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.71	-11.57	-0.58	2.56e-25	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs12410462	0.681	rs113984727	chr1:227553917	C/A	cg04117972	chr1:227635322	NA	0.67	5.8	0.34	1.92e-8	Major depressive disorder;
CESC	cis	rs6570726	0.935	rs400968	chr6:145819718	A/G	cg05347473	chr6:146136440	FBXO30	0.42	5.72	0.33	2.93e-8	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs950776	0.714	rs472054	chr15:78887994	A/G	cg06917634	chr15:78832804	PSMA4	-0.52	-6.21	-0.36	2.09e-9	Sudden cardiac arrest;
CESC	cis	rs7647973	1.000	rs7644148	chr3:49545241	G/A	cg06212747	chr3:49208901	KLHDC8B	-0.59	-7.8	-0.43	1.43e-13	Menarche (age at onset);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg26570804	chr1:6352357	ACOT7	0.48	6.67	0.38	1.47e-10	Fibrinogen levels;
CESC	cis	rs9611565	0.592	rs4822044	chr22:41979668	G/C	cg03806693	chr22:41940476	POLR3H	-1.14	-13.06	-0.63	1.98e-30	Vitiligo;
CESC	cis	rs7208859	0.673	rs11651802	chr17:29159660	T/C	cg19761014	chr17:28927070	LRRC37B2	0.72	5.68	0.33	3.48e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs853679	0.574	rs1233705	chr6:28166447	C/G	cg18032046	chr6:28092343	ZSCAN16	-0.48	-5.69	-0.33	3.41e-8	Depression;
CESC	cis	rs7666738	0.830	rs11735193	chr4:98761900	C/T	cg03676636	chr4:99064102	C4orf37	0.34	5.12	0.3	5.85e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7089973	0.934	rs68085797	chr10:116632130	A/T	cg23260525	chr10:116636907	FAM160B1	0.37	5.89	0.34	1.16e-8	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg05596267	chr15:34331198	CHRM5;AVEN	-0.34	-5.11	-0.3	6.15e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs3796352	1.000	rs2564926	chr3:53094730	G/A	cg12962167	chr3:53033115	SFMBT1	-0.61	-5.7	-0.33	3.19e-8	Immune reponse to smallpox (secreted IL-2);
CESC	cis	rs6582630	0.537	rs8189533	chr12:38391068	A/G	cg26384229	chr12:38710491	ALG10B	0.74	10.56	0.54	5.68e-22	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs962856	0.619	rs6546297	chr2:67580520	G/T	cg09028215	chr2:67624308	ETAA1	-0.44	-5.24	-0.31	3.29e-7	Pancreatic cancer;
CESC	cis	rs4713118	0.662	rs149947	chr6:27972433	A/T	cg20151795	chr6:28129481	ZNF389	0.42	5.43	0.32	1.28e-7	Parkinson's disease;
CESC	cis	rs904092	0.720	rs1230025	chr4:100186376	A/T	cg12011299	chr4:100065546	ADH4	0.52	6.09	0.35	3.95e-9	Alcohol dependence;
CESC	cis	rs1552244	1.000	rs9820598	chr3:10117912	C/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.85	-11.68	-0.58	1.06e-25	Alzheimer's disease;
CESC	cis	rs2797160	1.000	rs1739374	chr6:126011825	C/T	cg05901451	chr6:126070800	HEY2	0.46	6.63	0.38	1.87e-10	Endometrial cancer;
CESC	cis	rs2637266	0.703	rs7084374	chr10:78479940	C/T	cg18941641	chr10:78392320	NA	0.39	7.28	0.41	3.82e-12	Pulmonary function;
CESC	cis	rs9733	0.596	rs11586422	chr1:150679358	C/T	cg09365446	chr1:150670422	GOLPH3L	0.42	5.86	0.34	1.37e-8	Tonsillectomy;
CESC	cis	rs116095464	0.614	rs10059220	chr5:242813	C/T	cg22857025	chr5:266934	NA	-1.26	-13.65	-0.64	1.67e-32	Breast cancer;
CESC	cis	rs8077577	0.945	rs997315	chr17:18085286	A/G	cg16794390	chr17:18148240	FLII	0.42	5.6	0.33	5.42e-8	Obesity-related traits;
CESC	cis	rs9457247	1.000	rs365189	chr6:167384545	G/A	cg25258033	chr6:167368657	RNASET2	0.39	5.87	0.34	1.27e-8	Crohn's disease;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg05341670	chr1:54518153	TMEM59;C1orf83	0.49	6.84	0.39	5.31e-11	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs1670533	1.000	rs10902752	chr4:1056199	C/T	cg27284194	chr4:1044797	NA	0.48	6.06	0.35	4.7e-9	Recombination rate (females);
CESC	trans	rs7726839	0.507	rs72703100	chr5:614291	C/T	cg25482853	chr8:67687455	SGK3	1.02	9.93	0.52	5.72e-20	Obesity-related traits;
CESC	cis	rs7618915	0.547	rs12486847	chr3:52691112	T/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.31	5.52	0.32	7.95e-8	Bipolar disorder;
CESC	cis	rs7799006	0.582	rs7781284	chr7:2339405	G/T	cg08027265	chr7:2291960	NA	-0.47	-7.96	-0.44	4.92e-14	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs7666738	0.830	rs7678911	chr4:99057430	C/T	cg18180107	chr4:99064573	C4orf37	0.42	5.35	0.31	1.95e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4835473	0.639	rs5029916	chr4:144911837	G/A	cg25736465	chr4:144833511	NA	0.43	6.5	0.37	3.87e-10	Immature fraction of reticulocytes;
CESC	cis	rs3126085	1.000	rs12567463	chr1:152180128	T/A	cg26876637	chr1:152193138	HRNR	-0.45	-5.09	-0.3	6.95e-7	Atopic dermatitis;
CESC	cis	rs9322193	0.923	rs10747276	chr6:150079875	G/A	cg04369109	chr6:150039330	LATS1	-0.46	-6.57	-0.37	2.65e-10	Lung cancer;
CESC	cis	rs7086627	0.515	rs10887899	chr10:82210214	G/A	cg03267442	chr10:82210566	NA	-0.33	-5.38	-0.31	1.67e-7	Post bronchodilator FEV1;
CESC	cis	rs9916302	0.904	rs6503507	chr17:37525274	C/T	cg19468946	chr17:37922297	IKZF3	0.4	5.15	0.3	5.12e-7	Glomerular filtration rate (creatinine);
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg22638185	chr17:42385946	RUNDC3A	0.46	6.12	0.35	3.42e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs7660520	0.524	rs4862101	chr4:183733177	T/C	cg09197432	chr4:183729176	NA	0.58	5.63	0.33	4.56e-8	Pediatric autoimmune diseases;
CESC	cis	rs7020830	0.931	rs9775431	chr9:37130433	G/A	cg14294708	chr9:37120828	ZCCHC7	1.13	21.18	0.79	6.25e-59	Schizophrenia;
CESC	cis	rs6599388	0.803	rs11248057	chr4:906131	C/G	cg20814179	chr4:940893	TMEM175	-0.41	-5.39	-0.31	1.58e-7	Parkinson's disease;
CESC	cis	rs853679	0.599	rs149943	chr6:28002388	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.7	-5.6	-0.33	5.38e-8	Depression;
CESC	cis	rs559928	0.597	rs2186572	chr11:63895887	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.68	5.74	0.33	2.56e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CESC	cis	rs1624802	1.000	rs1707934	chr12:130497611	C/T	cg15444478	chr12:130494697	NA	0.27	5.39	0.31	1.52e-7	Obesity-related traits;
CESC	cis	rs4604732	0.642	rs7515859	chr1:247640057	A/G	cg12758973	chr1:247694275	LOC148824;OR2C3	0.38	5.38	0.31	1.63e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs10504229	1.000	rs67594249	chr8:58180521	T/A	cg14926445	chr8:58193284	C8orf71	-0.51	-5.47	-0.32	1.03e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs644799	1.000	rs487609	chr11:95588102	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	13.4	0.64	1.26e-31	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs763121	0.853	rs2281021	chr22:39064667	T/C	cg14440974	chr22:39074834	NA	-0.42	-5.82	-0.34	1.69e-8	Menopause (age at onset);
CESC	cis	rs72781680	0.644	rs72783627	chr2:24315685	A/C	cg20701182	chr2:24300061	SF3B14	0.92	10.55	0.54	6.09e-22	Lymphocyte counts;
CESC	cis	rs12220238	1.000	rs2395077	chr10:75932001	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.62	6.02	0.35	5.83e-9	Soluble interleukin-2 receptor subunit alpha;
CESC	cis	rs710216	0.797	rs1770811	chr1:43400547	A/T	cg03128534	chr1:43423976	SLC2A1	0.44	5.13	0.3	5.62e-7	Red cell distribution width;
CESC	cis	rs6502050	0.769	rs8068708	chr17:80120424	T/C	cg23985595	chr17:80112537	CCDC57	-0.4	-6.17	-0.35	2.56e-9	Life satisfaction;
CESC	cis	rs854765	0.583	rs66531105	chr17:17809001	C/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.55	7.25	0.41	4.49e-12	Total body bone mineral density;
CESC	cis	rs1707322	1.000	rs785519	chr1:46568562	C/T	cg03146154	chr1:46216737	IPP	-0.69	-9.13	-0.49	1.84e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs8002861	0.846	rs56408817	chr13:44471983	A/G	cg19180546	chr13:44453867	C13orf31;CCDC122	-0.47	-5.91	-0.34	1.06e-8	Leprosy;
CESC	cis	rs654950	0.934	rs641974	chr1:42002137	G/A	cg06885757	chr1:42089581	HIVEP3	-0.64	-10.35	-0.54	2.65e-21	Airway imaging phenotypes;
CESC	cis	rs13191362	0.935	rs13219926	chr6:163004213	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.5	5.17	0.3	4.64e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs7552404	0.924	rs2173378	chr1:76201992	G/T	cg03433033	chr1:76189801	ACADM	0.73	10.16	0.53	1.07e-20	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs2404602	0.692	rs12910734	chr15:77149931	A/G	cg26408565	chr15:76604113	ETFA	-0.39	-5.63	-0.33	4.54e-8	Blood metabolite levels;
CESC	cis	rs6499129	1.000	rs9922624	chr16:67478976	C/T	cg26727032	chr16:67993705	SLC12A4	-0.54	-5.7	-0.33	3.13e-8	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs7666738	0.888	rs13110683	chr4:98983368	G/C	cg05340658	chr4:99064831	C4orf37	0.59	7.9	0.44	7.64e-14	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1008375	0.800	rs10008598	chr4:17607323	T/C	cg02297831	chr4:17616191	MED28	0.56	7.03	0.4	1.78e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs2836974	0.666	rs1888487	chr21:40683259	A/G	cg17971929	chr21:40555470	PSMG1	-0.87	-12.28	-0.6	9.93e-28	Cognitive function;
CESC	cis	rs34172651	0.517	rs874484	chr16:24803242	T/C	cg06028605	chr16:24865363	SLC5A11	0.57	7.97	0.44	4.76e-14	Intelligence (multi-trait analysis);
CESC	cis	rs478304	0.654	rs1074155	chr11:65458197	C/T	cg27068330	chr11:65405492	SIPA1	0.43	5.28	0.31	2.68e-7	Acne (severe);
CESC	cis	rs7703051	0.829	rs4704219	chr5:74748505	C/T	cg03227963	chr5:74354835	NA	0.29	5.3	0.31	2.44e-7	LDL cholesterol;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
CESC	cis	rs7618501	0.633	rs7628058	chr3:50039474	C/T	cg24110177	chr3:50126178	RBM5	-0.54	-7.45	-0.42	1.33e-12	Intelligence (multi-trait analysis);
CESC	cis	rs6580649	0.941	rs72644847	chr12:48516093	C/A	cg05342945	chr12:48394962	COL2A1	0.58	6.39	0.37	7.35e-10	Lung cancer;
CESC	cis	rs4803468	1.000	rs2304242	chr19:41944616	G/T	cg09537434	chr19:41945824	ATP5SL	1.13	21.82	0.8	4.09e-61	Height;
CESC	cis	rs4319547	0.662	rs35417323	chr12:123090572	G/T	cg05707623	chr12:122985044	ZCCHC8	-0.42	-5.12	-0.3	5.85e-7	Body mass index;
CESC	cis	rs7772486	0.754	rs857881	chr6:145970793	C/A	cg23711669	chr6:146136114	FBXO30	-1.02	-15.75	-0.7	6.82e-40	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs8077889	0.917	rs28694735	chr17:41912144	A/G	cg26893861	chr17:41843967	DUSP3	0.74	9.32	0.5	4.61e-18	Triglycerides;
CESC	cis	rs9287719	0.967	rs7566875	chr2:10754792	T/C	cg02196655	chr2:10830764	NOL10	-0.37	-5.69	-0.33	3.39e-8	Prostate cancer;
CESC	cis	rs2380220	0.606	rs7747776	chr6:96005852	C/T	cg04719120	chr6:96025338	MANEA	0.46	5.46	0.32	1.12e-7	Behavioural disinhibition (generation interaction);
CESC	cis	rs7917772	0.503	rs7915589	chr10:104299264	G/A	cg22532475	chr10:104410764	TRIM8	-0.34	-5.76	-0.33	2.3e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	22.34	0.81	6.93e-63	Prudent dietary pattern;
CESC	cis	rs7703051	0.634	rs6892023	chr5:74611574	G/T	cg03227963	chr5:74354835	NA	0.28	5.1	0.3	6.5e-7	LDL cholesterol;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
CESC	cis	rs9902453	0.845	rs72823935	chr17:28008595	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.68	8.77	0.47	2.21e-16	Coffee consumption (cups per day);
CESC	cis	rs644799	0.562	rs1254989	chr11:95508121	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.52	7.1	0.4	1.16e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs6089584	1.000	rs6089591	chr20:60570548	A/C	cg24733560	chr20:60626293	TAF4	0.35	5.09	0.3	6.75e-7	Body mass index;
CESC	cis	rs2070488	0.775	rs6599208	chr3:38558104	A/C	cg24069376	chr3:38537580	EXOG	-0.34	-5.89	-0.34	1.18e-8	Electrocardiographic conduction measures;
CESC	cis	rs2204008	0.837	rs2892296	chr12:37969785	C/T	cg26384229	chr12:38710491	ALG10B	-0.56	-8.05	-0.44	2.74e-14	Bladder cancer;
CESC	trans	rs35110281	0.776	rs62226866	chr21:45024186	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.55	7.28	0.41	3.82e-12	Mean corpuscular volume;
CESC	cis	rs11031096	0.678	rs10767872	chr11:4184239	T/G	cg18678763	chr11:4115507	RRM1	-0.43	-5.84	-0.34	1.53e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	trans	rs1728785	1.000	rs1170431	chr16:68605639	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.65	7.93	0.44	6e-14	Ulcerative colitis;
CESC	cis	rs561341	1.000	rs55962687	chr17:30260369	C/T	cg00745463	chr17:30367425	LRRC37B	-0.76	-6.96	-0.39	2.69e-11	Hip circumference adjusted for BMI;
CESC	cis	rs9611565	0.512	rs139572	chr22:42214532	C/T	cg06634786	chr22:41940651	POLR3H	-0.55	-5.21	-0.3	3.87e-7	Vitiligo;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg14375786	chr9:139757366	EDF1	0.46	6.2	0.36	2.21e-9	Fibrinogen levels;
CESC	cis	rs875971	0.862	rs10261398	chr7:65750164	A/G	cg12463550	chr7:65579703	CRCP	-0.46	-5.86	-0.34	1.34e-8	Aortic root size;
CESC	cis	rs34779708	0.706	rs36027395	chr10:35550323	T/A	cg03585969	chr10:35415529	CREM	0.55	6.25	0.36	1.61e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs6831352	0.918	rs17218162	chr4:100056060	G/A	cg12011299	chr4:100065546	ADH4	-0.6	-6.62	-0.38	2.04e-10	Alcohol dependence;
CESC	cis	rs2274273	0.905	rs10134800	chr14:55635209	A/G	cg04306507	chr14:55594613	LGALS3	0.3	5.97	0.34	7.51e-9	Protein biomarker;
CESC	cis	rs7927771	0.524	rs7116346	chr11:47883880	G/A	cg20307385	chr11:47447363	PSMC3	-0.58	-8.11	-0.45	1.88e-14	Subjective well-being;
CESC	cis	rs71403859	0.803	rs34381861	chr16:71640230	T/C	cg08717414	chr16:71523259	ZNF19	-0.79	-6.93	-0.39	3.19e-11	Post bronchodilator FEV1;
CESC	cis	rs7598759	0.675	rs6727530	chr2:232332058	T/C	cg19187155	chr2:232395269	NMUR1	0.39	6.12	0.35	3.36e-9	Noise-induced hearing loss;
CESC	cis	rs13191362	0.872	rs35443919	chr6:163055804	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.87	8.78	0.47	2.07e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs7264396	0.943	rs224431	chr20:34153599	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.51	-6.04	-0.35	5.27e-9	Total cholesterol levels;
CESC	cis	rs7824557	0.579	rs10098322	chr8:11196295	C/G	cg21775007	chr8:11205619	TDH	0.56	8.89	0.48	9.82e-17	Retinal vascular caliber;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg07845895	chr21:34776100	IFNGR2	0.46	6.13	0.35	3.24e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs62432291	0.681	rs433786	chr6:159665946	T/A	cg14500486	chr6:159655392	FNDC1	-0.65	-6.12	-0.35	3.27e-9	Joint mobility (Beighton score);
CESC	cis	rs11958404	0.860	rs7730844	chr5:157461208	C/T	cg05962755	chr5:157440814	NA	0.62	7.2	0.4	6.04e-12	IgG glycosylation;
CESC	cis	rs2549003	0.933	rs7719499	chr5:131814091	C/G	cg00255919	chr5:131827918	IRF1	0.51	8.25	0.45	7.38e-15	Asthma (sex interaction);
CESC	cis	rs75804782	0.641	rs72987327	chr2:239359833	T/G	cg18131467	chr2:239335373	ASB1	-0.7	-5.89	-0.34	1.18e-8	Morning vs. evening chronotype;Chronotype;
CESC	cis	rs7951870	0.645	rs2070852	chr11:46744925	C/G	cg25783544	chr11:47291846	MADD	-0.41	-5.18	-0.3	4.39e-7	Schizophrenia;
CESC	cis	rs7044106	0.708	rs10984992	chr9:123473416	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.69	10.12	0.53	1.48e-20	Hip circumference adjusted for BMI;
CESC	cis	rs9649213	0.574	rs6979373	chr7:97961844	T/C	cg08684580	chr7:98029266	BAIAP2L1	-0.35	-5.76	-0.33	2.34e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs9929218	0.529	rs35854485	chr16:68730855	C/G	cg01251360	chr16:68772225	CDH1	-0.22	-5.05	-0.3	8.24e-7	Colorectal cancer;
CESC	cis	rs7552404	1.000	rs6672180	chr1:76123973	C/G	cg22875332	chr1:76189707	ACADM	0.67	7.99	0.44	4.13e-14	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs2073300	0.609	rs2277765	chr20:23425163	C/T	cg12062639	chr20:23401060	NAPB	1.09	8.31	0.45	5.13e-15	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs9354308	0.901	rs2814121	chr6:66566915	G/C	cg07460842	chr6:66804631	NA	0.68	7.68	0.43	3.08e-13	Metabolite levels;
CESC	cis	rs3096299	0.967	rs2911256	chr16:89485096	G/C	cg02034447	chr16:89574710	SPG7	0.45	5.65	0.33	4.17e-8	Multiple myeloma (IgH translocation);
CESC	cis	rs873946	0.586	rs3793684	chr10:134568645	G/A	cg26818010	chr10:134567672	INPP5A	-0.94	-11.42	-0.57	7.62e-25	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs2836974	0.897	rs2026267	chr21:40711477	C/A	cg11890956	chr21:40555474	PSMG1	1.04	16.54	0.71	1.1e-42	Cognitive function;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg18415483	chr3:3221365	CRBN	-0.51	-6.9	-0.39	3.72e-11	Fibrinogen levels;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg07448460	chr8:63951879	GGH	-0.42	-6.25	-0.36	1.67e-9	Gambling;
CESC	cis	rs11098499	0.618	rs28491261	chr4:120294900	C/A	cg24375607	chr4:120327624	NA	0.44	5.22	0.31	3.66e-7	Corneal astigmatism;
CESC	cis	rs9902453	0.935	rs4310926	chr17:28433275	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	8.62	0.47	5.99e-16	Coffee consumption (cups per day);
CESC	cis	rs9399135	0.967	rs9389258	chr6:135361140	T/C	cg24558204	chr6:135376177	HBS1L	0.52	7.14	0.4	9.2e-12	Red blood cell count;
CESC	cis	rs6540559	0.673	rs6540561	chr1:209982255	C/T	cg10074409	chr1:209979377	IRF6	0.39	5.12	0.3	5.88e-7	Cleft lip with or without cleft palate;
CESC	cis	rs1943345	0.830	rs571055	chr11:82898829	G/C	cg07047830	chr11:82868014	PCF11	0.55	6.17	0.35	2.57e-9	Obesity-related traits;
CESC	cis	rs1215050	0.740	rs185468	chr4:98756242	C/T	cg05340658	chr4:99064831	C4orf37	0.51	6.66	0.38	1.61e-10	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs941873	0.868	rs2181080	chr10:81121960	A/G	cg11057378	chr10:81107060	PPIF	0.36	5.69	0.33	3.29e-8	Height;
CESC	cis	rs2688608	0.592	rs7908825	chr10:75554541	C/G	cg23231163	chr10:75533350	FUT11	0.35	5.36	0.31	1.81e-7	Inflammatory bowel disease;
CESC	cis	rs765787	0.530	rs3759892	chr15:45542709	A/G	cg24006582	chr15:45444508	DUOX1	0.57	6.84	0.39	5.6e-11	Uric acid levels;
CESC	cis	rs3785574	1.000	rs7223257	chr17:61787684	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.8	10.64	0.55	2.93e-22	Height;
CESC	cis	rs7618915	0.571	rs6762457	chr3:52609157	G/A	cg05564831	chr3:52568323	NT5DC2	0.46	6.93	0.39	3.11e-11	Bipolar disorder;
CESC	cis	rs17209837	0.607	rs4148813	chr7:87092376	A/G	cg00919237	chr7:87102261	ABCB4	-0.49	-6.39	-0.37	7.37e-10	Gallbladder cancer;
CESC	cis	rs9322193	0.923	rs9800736	chr6:149982417	A/G	cg09699651	chr6:150184138	LRP11	0.4	5.24	0.31	3.29e-7	Lung cancer;
CESC	cis	rs12477438	1.000	rs995617	chr2:99857904	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.65	7.63	0.42	4.13e-13	Chronic sinus infection;
CESC	cis	rs1799949	0.930	rs33968979	chr17:41297992	G/T	cg25072359	chr17:41440525	NA	0.43	5.83	0.34	1.61e-8	Menopause (age at onset);
CESC	cis	rs10782582	0.593	rs17848068	chr1:76190216	G/A	cg22875332	chr1:76189707	ACADM	-0.45	-5.49	-0.32	9.26e-8	Daytime sleep phenotypes;
CESC	cis	rs9733	0.596	rs12089989	chr1:150715782	G/A	cg22823121	chr1:150693482	HORMAD1	0.42	6.3	0.36	1.26e-9	Tonsillectomy;
CESC	cis	rs1801251	0.963	rs13021246	chr2:233623111	T/C	cg25237894	chr2:233734115	C2orf82	0.45	7.9	0.44	7.6e-14	Coronary artery disease;
CESC	cis	rs875971	0.862	rs778680	chr7:65840414	G/A	cg10691866	chr7:65817282	TPST1	-0.32	-5.27	-0.31	2.89e-7	Aortic root size;
CESC	cis	rs7615952	0.515	rs7630575	chr3:125682330	A/G	cg05084668	chr3:125655381	ALG1L	-0.49	-5.58	-0.32	5.99e-8	Blood pressure (smoking interaction);
CESC	cis	rs10788264	0.652	rs9633732	chr10:124056473	G/T	cg09507567	chr10:124027408	NA	0.39	5.82	0.34	1.71e-8	Total body bone mineral density;
CESC	trans	rs2727020	0.538	rs61885230	chr11:49128958	T/C	cg03929089	chr4:120376271	NA	-0.55	-6.61	-0.38	2.12e-10	Coronary artery disease;
CESC	cis	rs568617	0.903	rs601863	chr11:65646557	C/A	cg19792802	chr11:65647270	CTSW	-0.35	-5.31	-0.31	2.33e-7	Crohn's disease;
CESC	cis	rs1862618	0.853	rs3099459	chr5:56137170	G/C	cg24549020	chr5:56110836	MAP3K1	0.68	7.76	0.43	1.85e-13	Initial pursuit acceleration;
CESC	cis	rs1008375	1.000	rs7688682	chr4:17693794	A/G	cg02297831	chr4:17616191	MED28	-0.46	-5.59	-0.32	5.75e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20782286	chr6:56298173	NA	-0.58	-6.3	-0.36	1.2e-9	Gut microbiome composition (summer);
CESC	cis	rs6459804	1.000	rs58278053	chr7:157512934	A/T	cg05731713	chr7:157510257	PTPRN2	0.39	6.25	0.36	1.59e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs72781680	0.611	rs55788848	chr2:24268721	C/T	cg20701182	chr2:24300061	SF3B14	0.94	10.66	0.55	2.67e-22	Lymphocyte counts;
CESC	cis	rs34779708	0.801	rs12098720	chr10:35538683	G/A	cg04310649	chr10:35416472	CREM	-0.47	-5.36	-0.31	1.83e-7	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs10979	1.000	rs9399448	chr6:143896315	G/T	cg25407410	chr6:143891975	LOC285740	-0.61	-9.2	-0.49	1.13e-17	Hypospadias;
CESC	cis	rs6741892	0.536	rs7590835	chr2:38893950	A/G	cg23643435	chr2:38893251	GALM	0.63	8.81	0.48	1.64e-16	5-HTT brain serotonin transporter levels;
CESC	cis	rs4423214	0.569	rs12806918	chr11:71119018	G/T	cg05163923	chr11:71159392	DHCR7	0.6	8.09	0.44	2.17e-14	Vitamin D levels;
CESC	cis	rs977987	0.806	rs8051407	chr16:75448659	A/G	cg03315344	chr16:75512273	CHST6	0.41	5.81	0.34	1.79e-8	Dupuytren's disease;
CESC	cis	rs6952808	0.601	rs3778978	chr7:2159817	A/G	cg23048001	chr7:2026167	MAD1L1	0.45	5.88	0.34	1.24e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs9549367	0.789	rs12869947	chr13:113896156	A/G	cg00898013	chr13:113819073	PROZ	-0.52	-7.09	-0.4	1.23e-11	Platelet distribution width;
CESC	cis	rs798554	0.567	rs1182191	chr7:2869364	A/T	cg13628971	chr7:2884303	GNA12	0.43	5.74	0.33	2.55e-8	Height;
CESC	cis	rs3785574	0.962	rs2727280	chr17:61918082	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.74	9.17	0.49	1.32e-17	Height;
CESC	cis	rs4704187	0.532	rs75392670	chr5:74394968	A/G	cg03227963	chr5:74354835	NA	0.32	5.89	0.34	1.17e-8	Response to amphetamines;
CESC	cis	rs7662987	0.793	rs7684735	chr4:99991506	C/T	cg13256891	chr4:100009986	ADH5	-0.6	-5.19	-0.3	4.24e-7	Smoking initiation;
CESC	cis	rs963731	0.649	rs297130	chr2:39299314	C/T	cg04010122	chr2:39346883	SOS1	0.82	6.34	0.36	9.73e-10	Corticobasal degeneration;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02654935	chr6:12514489	NA	-0.51	-6.47	-0.37	4.75e-10	Gut microbiome composition (summer);
CESC	cis	rs6952808	0.689	rs871924	chr7:2047845	A/G	cg21782813	chr7:2030301	MAD1L1	0.5	7.18	0.4	6.92e-12	Bipolar disorder and schizophrenia;
CESC	cis	rs875971	0.660	rs7807944	chr7:66087195	C/G	cg25985355	chr7:65971099	NA	0.31	5.06	0.3	7.78e-7	Aortic root size;
CESC	cis	rs9910055	0.530	rs8072954	chr17:42294722	G/A	cg19774624	chr17:42201019	HDAC5	-0.6	-8.66	-0.47	4.63e-16	Total body bone mineral density;
CESC	cis	rs3733585	0.806	rs7375599	chr4:9954918	C/T	cg00071950	chr4:10020882	SLC2A9	0.77	13.99	0.65	1.09e-33	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs7395581	0.877	rs7127907	chr11:47324472	A/C	cg25783544	chr11:47291846	MADD	0.6	7.85	0.43	1.04e-13	HDL cholesterol;
CESC	cis	rs2455799	0.533	rs2470513	chr3:15750056	G/A	cg16303742	chr3:15540471	COLQ	-0.39	-6.23	-0.36	1.87e-9	Mean platelet volume;
CESC	cis	rs2243480	0.706	rs6460257	chr7:65196780	C/T	cg13147721	chr7:65941812	NA	-0.52	-5.54	-0.32	7.27e-8	Diabetic kidney disease;
CESC	cis	rs4862750	0.872	rs6836781	chr4:187899701	G/A	cg03647317	chr4:187891568	NA	-0.37	-5.56	-0.32	6.44e-8	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7589342	0.839	rs11895235	chr2:106432355	C/G	cg16077055	chr2:106428750	NCK2	0.52	7.44	0.42	1.42e-12	Addiction;
CESC	cis	rs1144333	1.000	rs112401426	chr1:76466103	T/A	cg10523679	chr1:76189770	ACADM	0.55	5.14	0.3	5.24e-7	Attention function in attention deficit hyperactive disorder;
CESC	cis	rs7949030	0.620	rs2428551	chr11:62329758	T/A	cg23462726	chr11:62437636	C11orf83;C11orf48	-0.4	-5.34	-0.31	2.03e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs7520050	0.902	rs7514192	chr1:46248977	A/G	cg24296786	chr1:45957014	TESK2	0.44	5.57	0.32	6.19e-8	Red blood cell count;Reticulocyte count;
CESC	cis	rs6691722	0.503	rs12135404	chr1:24704263	C/T	cg18323236	chr1:24743029	NIPAL3	-0.34	-5.08	-0.3	6.98e-7	Response to interferon beta in multiple sclerosis;
CESC	cis	rs7552404	0.731	rs1770885	chr1:76402212	C/T	cg10523679	chr1:76189770	ACADM	-0.6	-6.31	-0.36	1.2e-9	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs12545109	0.800	rs1595940	chr8:57398309	T/C	cg09654669	chr8:57350985	NA	-0.55	-6.57	-0.37	2.68e-10	Obesity-related traits;
CESC	cis	rs7666738	0.830	rs28769113	chr4:98950371	T/G	cg05340658	chr4:99064831	C4orf37	0.8	12.48	0.61	2e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9322193	0.884	rs9383864	chr6:150173105	T/C	cg13206674	chr6:150067644	NUP43	0.38	5.12	0.3	5.81e-7	Lung cancer;
CESC	cis	rs2637266	0.935	rs1907323	chr10:78336015	C/T	cg18941641	chr10:78392320	NA	0.4	7.52	0.42	8.48e-13	Pulmonary function;
CESC	cis	rs698833	0.886	rs4953086	chr2:44561532	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	6.39	0.37	7.31e-10	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs698833	0.892	rs2603257	chr2:44731588	T/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	5.77	0.33	2.24e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs7772486	0.558	rs2142978	chr6:146012061	T/C	cg23711669	chr6:146136114	FBXO30	-0.94	-11.89	-0.59	2.05e-26	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs11718455	0.767	rs6782500	chr3:43990260	A/G	cg08738300	chr3:44038990	NA	-0.46	-6.09	-0.35	3.85e-9	Coronary artery disease;
CESC	cis	rs763014	0.833	rs3743903	chr16:632736	T/C	cg07343612	chr16:622815	PIGQ	-0.57	-8.23	-0.45	8.47e-15	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01076405	chr8:99057832	RPL30	0.59	6.57	0.37	2.72e-10	Gut microbiome composition (summer);
CESC	cis	rs66569888	0.754	rs6719028	chr2:106895212	T/C	cg23109721	chr2:106886537	NA	0.51	5.7	0.33	3.26e-8	Facial morphology (factor 23);
CESC	cis	rs60871478	0.735	rs4721501	chr7:862166	G/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	-0.56	-5.29	-0.31	2.57e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs40363	0.729	rs6501176	chr16:3522197	A/G	cg22508957	chr16:3507546	NAT15	-0.56	-7.78	-0.43	1.61e-13	Tuberculosis;
CESC	cis	rs116095464	0.558	rs7708182	chr5:234788	C/G	cg12570787	chr5:219185	SDHA;CCDC127	0.5	5.23	0.31	3.39e-7	Breast cancer;
CESC	cis	rs644799	0.965	rs687529	chr11:95545587	T/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.92	13.87	0.65	2.93e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs8062405	1.000	rs9972693	chr16:28859802	A/G	cg08761264	chr16:28874980	SH2B1	-0.47	-5.85	-0.34	1.42e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	trans	rs12310956	0.532	rs10844719	chr12:33987714	A/G	cg26384229	chr12:38710491	ALG10B	0.47	6.5	0.37	4.04e-10	Morning vs. evening chronotype;
CESC	cis	rs4835473	0.897	rs11728121	chr4:144628232	C/T	cg25736465	chr4:144833511	NA	0.44	6.65	0.38	1.64e-10	Immature fraction of reticulocytes;
CESC	cis	rs3749237	0.595	rs11130199	chr3:49538799	T/C	cg07636037	chr3:49044803	WDR6	0.64	9.26	0.49	7.21e-18	Resting heart rate;
CESC	cis	rs7412746	0.646	rs10399947	chr1:150861960	G/A	cg17724175	chr1:150552817	MCL1	0.34	5.24	0.31	3.34e-7	Melanoma;
CESC	cis	rs4862750	0.914	rs1991256	chr4:187875330	A/G	cg22105103	chr4:187893119	NA	0.48	6.77	0.38	8.02e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9796	0.689	rs9888718	chr15:41446254	T/G	cg18705301	chr15:41695430	NDUFAF1	-0.48	-7.09	-0.4	1.25e-11	Menopause (age at onset);
CESC	cis	rs7580658	0.963	rs12052483	chr2:128136820	T/G	cg10021288	chr2:128175891	PROC	-0.41	-6.47	-0.37	4.66e-10	Protein C levels;
CESC	cis	rs2933343	0.700	rs1680779	chr3:128614770	G/A	cg25356066	chr3:128598488	ACAD9	0.62	8.45	0.46	1.94e-15	IgG glycosylation;
CESC	cis	rs6964587	0.900	rs6972027	chr7:91781380	T/C	cg17063962	chr7:91808500	NA	0.59	8.24	0.45	8.03e-15	Breast cancer;
CESC	cis	rs9487051	0.714	rs7755970	chr6:109602359	A/G	cg01475377	chr6:109611718	NA	-0.44	-7.0	-0.39	2.15e-11	Reticulocyte fraction of red cells;
CESC	cis	rs9457247	0.967	rs2769355	chr6:167380493	G/A	cg25258033	chr6:167368657	RNASET2	-0.42	-6.24	-0.36	1.77e-9	Crohn's disease;
CESC	cis	rs780096	0.526	rs72819536	chr2:27682850	G/T	cg02592271	chr2:27665507	KRTCAP3	-0.27	-5.32	-0.31	2.21e-7	Total body bone mineral density;
CESC	cis	rs40363	0.723	rs757269	chr16:3538003	A/G	cg00484396	chr16:3507460	NAT15	-0.54	-6.04	-0.35	5.1e-9	Tuberculosis;
CESC	cis	rs1799949	0.896	rs8176098	chr17:41268206	A/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.67	9.4	0.5	2.72e-18	Menopause (age at onset);
CESC	cis	rs7193541	0.585	rs7978	chr16:74486189	T/C	cg05580060	chr16:74700937	RFWD3	0.42	5.26	0.31	2.98e-7	Multiple myeloma;
CESC	cis	rs2979489	0.786	rs1106352	chr8:30404671	C/T	cg26383811	chr8:30366931	RBPMS	-0.78	-9.85	-0.52	1.05e-19	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12199165	chr10:103577593	MGEA5	0.6	7.22	0.41	5.65e-12	Gut microbiome composition (summer);
CESC	cis	rs4665809	1.000	rs2053367	chr2:26293413	T/C	cg26314531	chr2:26401878	FAM59B	-0.58	-6.53	-0.37	3.34e-10	Gut microbiome composition (summer);
CESC	cis	rs9611565	0.570	rs12159188	chr22:42121125	A/T	cg06481639	chr22:41940642	POLR3H	0.56	6.12	0.35	3.29e-9	Vitiligo;
CESC	cis	rs870825	0.616	rs4256263	chr4:185622959	C/A	cg04058563	chr4:185651563	MLF1IP	0.64	7.05	0.4	1.59e-11	Blood protein levels;
CESC	cis	rs73019876	0.686	rs1989119	chr19:22205665	T/G	cg11619707	chr19:22235551	ZNF257	-0.27	-5.06	-0.3	7.69e-7	Testicular germ cell tumor;
CESC	cis	rs597539	0.652	rs514833	chr11:68657734	C/T	cg01988459	chr11:68622903	NA	-0.39	-5.42	-0.32	1.31e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs7621025	0.630	rs1681818	chr3:136473673	A/G	cg15507776	chr3:136538369	TMEM22	-0.56	-6.53	-0.37	3.43e-10	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
CESC	cis	rs6088590	0.965	rs6058108	chr20:33288655	A/G	cg24642439	chr20:33292090	TP53INP2	0.81	11.44	0.58	6.52e-25	Coronary artery disease;
CESC	cis	rs8072100	0.544	rs9284377	chr17:45386412	C/T	cg25173405	chr17:45401733	C17orf57	-0.42	-5.25	-0.31	3.19e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs2479106	0.549	rs1975064	chr9:126397618	T/A	cg16191174	chr9:126692580	DENND1A	0.39	5.4	0.31	1.49e-7	Polycystic ovary syndrome;
CESC	cis	rs10752881	0.901	rs10911201	chr1:183001622	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.84	13.19	0.63	6.74e-31	Colorectal cancer;
CESC	cis	rs34779708	0.900	rs73262807	chr10:35496386	C/T	cg03585969	chr10:35415529	CREM	0.75	9.92	0.52	6.22e-20	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs2180341	0.960	rs9398840	chr6:127669744	G/A	cg24812749	chr6:127587940	RNF146	1.05	15.07	0.68	1.77e-37	Breast cancer;
CESC	cis	rs7666738	0.753	rs13111199	chr4:98953705	A/G	cg05340658	chr4:99064831	C4orf37	0.8	12.4	0.61	3.76e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2806561	0.765	rs623988	chr1:23519477	C/T	cg12483005	chr1:23474871	LUZP1	0.38	6.03	0.35	5.41e-9	Height;
CESC	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg04025307	chr7:1156635	C7orf50	0.54	9.1	0.49	2.21e-17	Longevity;Endometriosis;
CESC	cis	rs9916302	0.904	rs8070695	chr17:37478062	C/T	cg19468946	chr17:37922297	IKZF3	0.42	5.22	0.31	3.62e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	7.64	0.42	4.1e-13	Prudent dietary pattern;
CESC	cis	rs8064299	0.503	rs11653346	chr17:72773333	A/G	cg25054828	chr17:72772726	NAT9;TMEM104	0.58	7.92	0.44	6.67e-14	Monocyte count;
CESC	cis	rs6540559	1.000	rs17015259	chr1:209982923	G/A	cg10074409	chr1:209979377	IRF6	0.35	5.68	0.33	3.46e-8	Cleft lip with or without cleft palate;
CESC	cis	rs3806843	1.000	rs3756340	chr5:140180451	T/G	cg16179182	chr5:140090404	VTRNA1-1	-0.41	-5.24	-0.31	3.26e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs79839061	0.610	rs3775122	chr4:893287	A/G	cg07828340	chr4:882639	GAK	-0.99	-7.66	-0.43	3.51e-13	Intelligence (multi-trait analysis);
CESC	cis	rs782590	0.774	rs782629	chr2:55900283	C/T	cg18811423	chr2:55921094	PNPT1	-0.77	-13.31	-0.63	2.71e-31	Metabolic syndrome;
CESC	cis	rs9399135	0.967	rs7750300	chr6:135350950	C/G	cg24558204	chr6:135376177	HBS1L	0.51	7.09	0.4	1.2e-11	Red blood cell count;
CESC	cis	rs7666738	0.830	rs2865990	chr4:99067399	C/A	cg05340658	chr4:99064831	C4orf37	0.84	13.05	0.63	2.09e-30	Colonoscopy-negative controls vs population controls;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg08187083	chr17:30186506	C17orf79	-0.45	-6.01	-0.35	6.1e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs9788682	0.747	rs8042494	chr15:78908010	C/T	cg24631222	chr15:78858424	CHRNA5	0.77	9.42	0.5	2.33e-18	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs6460942	1.000	rs7791634	chr7:12401482	A/T	cg13733410	chr7:12443478	VWDE	-0.54	-5.35	-0.31	1.9e-7	Coronary artery disease;
CESC	cis	rs7851660	0.935	rs4460498	chr9:100620412	T/C	cg13688889	chr9:100608707	NA	-0.7	-10.5	-0.54	8.43e-22	Strep throat;
CESC	cis	rs2228479	0.557	rs11641726	chr16:89891619	G/A	cg06558623	chr16:89946397	TCF25	1.12	8.24	0.45	7.86e-15	Skin colour saturation;
CESC	trans	rs4665809	1.000	rs6546768	chr2:26328800	A/G	cg09258813	chr8:37823409	ADRB3	-0.37	-6.1	-0.35	3.65e-9	Gut microbiome composition (summer);
CESC	trans	rs72681920	0.881	rs17028765	chr4:100188396	T/C	cg22948791	chr15:71404101	CT62	-0.54	-6.07	-0.35	4.35e-9	Alcohol dependence;
CESC	trans	rs1493916	0.905	rs9956315	chr18:31405546	G/C	cg27147174	chr7:100797783	AP1S1	-0.55	-7.39	-0.41	1.87e-12	Life satisfaction;
CESC	cis	rs4242434	0.854	rs13258100	chr8:22451116	A/T	cg03733263	chr8:22462867	KIAA1967	0.9	12.75	0.62	2.28e-29	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CESC	cis	rs2243480	1.000	rs316334	chr7:65602126	G/T	cg18252515	chr7:66147081	NA	-1.42	-14.5	-0.67	1.8e-35	Diabetic kidney disease;
CESC	cis	rs2996428	0.601	rs10909804	chr1:3770929	A/G	cg23277830	chr1:3704460	LRRC47	-0.35	-5.32	-0.31	2.25e-7	Red cell distribution width;
CESC	cis	rs6570726	0.902	rs9390326	chr6:145791222	A/G	cg05347473	chr6:146136440	FBXO30	-0.42	-5.63	-0.33	4.54e-8	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs796364	0.806	rs34582889	chr2:201010527	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.67	-6.43	-0.37	5.87e-10	Schizophrenia;
CESC	cis	rs921968	0.608	rs11678428	chr2:219352598	C/T	cg02176678	chr2:219576539	TTLL4	0.39	6.72	0.38	1.09e-10	Mean corpuscular hemoglobin concentration;
CESC	cis	rs9393777	0.513	rs13195210	chr6:26646521	C/T	cg14345882	chr6:26364793	BTN3A2	0.42	5.17	0.3	4.56e-7	Intelligence (multi-trait analysis);
CESC	trans	rs7618501	0.633	rs2883057	chr3:49998282	C/T	cg21659725	chr3:3221576	CRBN	0.55	7.6	0.42	5.29e-13	Intelligence (multi-trait analysis);
CESC	cis	rs6460942	0.597	rs13232817	chr7:12551909	C/A	cg06484146	chr7:12443880	VWDE	-0.71	-7.15	-0.4	8.67e-12	Coronary artery disease;
CESC	cis	rs1949733	1.000	rs3103072	chr4:8508431	C/T	cg11789530	chr4:8429930	ACOX3	-0.74	-10.13	-0.53	1.38e-20	Response to antineoplastic agents;
CESC	cis	rs853679	0.517	rs1904841	chr6:28108085	C/T	cg26335602	chr6:28129616	ZNF389	0.55	7.32	0.41	2.89e-12	Depression;
CESC	cis	rs15676	0.783	rs2417126	chr9:131562457	C/T	cg00228799	chr9:131580591	ENDOG	-0.49	-6.09	-0.35	3.93e-9	Blood metabolite levels;
CESC	cis	rs4665809	1.000	rs2384322	chr2:26291146	C/G	cg27170947	chr2:26402098	FAM59B	-0.72	-8.31	-0.45	5.18e-15	Gut microbiome composition (summer);
CESC	cis	rs4970988	0.556	rs6695123	chr1:150563483	T/C	cg17724175	chr1:150552817	MCL1	-0.5	-7.81	-0.43	1.35e-13	Urate levels;
CESC	cis	rs7772486	0.686	rs857880	chr6:145971115	T/C	cg23711669	chr6:146136114	FBXO30	-0.94	-14.45	-0.66	2.66e-35	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7580658	0.750	rs6731176	chr2:128071003	C/T	cg10021288	chr2:128175891	PROC	-0.37	-5.98	-0.35	7.04e-9	Protein C levels;
CESC	cis	rs7116495	0.609	rs73531955	chr11:71687794	A/C	cg18441811	chr11:71824068	C11orf51	0.8	5.13	0.3	5.49e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs3736485	0.966	rs11636170	chr15:51767087	G/T	cg08986416	chr15:51914746	DMXL2	-0.4	-5.21	-0.3	3.85e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.91	13.81	0.65	4.68e-33	Prudent dietary pattern;
CESC	cis	rs910316	0.870	rs7147712	chr14:75670707	C/G	cg11812906	chr14:75593930	NEK9	-0.81	-13.08	-0.63	1.7e-30	Height;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg02951021	chr12:120934296	DYNLL1	-0.4	-6.22	-0.36	1.96e-9	Gambling;
CESC	cis	rs11997175	0.509	rs67427312	chr8:33674377	A/G	ch.8.33884649F	chr8:33765107	NA	0.5	6.33	0.36	1.05e-9	Body mass index;
CESC	cis	rs9911578	0.967	rs8182277	chr17:57144367	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.4	5.19	0.3	4.11e-7	Intelligence (multi-trait analysis);
CESC	cis	rs853679	0.517	rs9393891	chr6:28079160	C/T	cg23161317	chr6:28129485	ZNF389	0.51	6.53	0.37	3.44e-10	Depression;
CESC	cis	rs1215050	0.776	rs1627946	chr4:98844416	G/A	cg05340658	chr4:99064831	C4orf37	-0.5	-6.42	-0.37	6.44e-10	Waist-to-hip ratio adjusted for body mass index;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg16326609	chr14:70883772	SYNJ2BP	-0.48	-6.05	-0.35	4.85e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs8177253	0.555	rs4481157	chr3:133464684	G/A	cg18769074	chr3:133464867	TF	0.3	5.69	0.33	3.35e-8	Iron status biomarkers;
CESC	cis	rs9287719	0.934	rs12692416	chr2:10745627	A/G	cg00105475	chr2:10696890	NA	0.38	5.55	0.32	6.76e-8	Prostate cancer;
CESC	cis	rs6121246	0.909	rs6060812	chr20:30292803	C/T	cg13852791	chr20:30311386	BCL2L1	0.79	8.37	0.46	3.41e-15	Mean corpuscular hemoglobin;
CESC	cis	rs644799	0.930	rs587123	chr11:95560539	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	14.25	0.66	1.39e-34	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs10504229	0.683	rs72649187	chr8:58108320	A/G	cg22535103	chr8:58192502	C8orf71	-0.77	-8.76	-0.47	2.37e-16	Developmental language disorder (linguistic errors);
CESC	cis	rs7917772	0.560	rs10786697	chr10:104378563	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.38	5.27	0.31	2.82e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs3785574	0.962	rs9944483	chr17:61783553	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.58	-7.28	-0.41	3.78e-12	Height;
CESC	cis	rs7072216	0.806	rs9804285	chr10:100169472	C/T	cg26618903	chr10:100175079	PYROXD2	-0.37	-5.7	-0.33	3.16e-8	Metabolite levels;
CESC	cis	rs3096299	0.900	rs3114867	chr16:89428967	A/C	cg02187348	chr16:89574699	SPG7	0.47	6.17	0.35	2.59e-9	Multiple myeloma (IgH translocation);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg18253787	chr19:2757657	SGTA	0.45	6.12	0.35	3.44e-9	Fibrinogen levels;
CESC	cis	rs290986	0.857	rs167080	chr9:93553577	T/C	cg02608019	chr9:93564028	SYK	-0.53	-5.63	-0.33	4.66e-8	Multiple sclerosis;
CESC	cis	rs7635838	0.892	rs9310379	chr3:11434143	C/T	cg00170343	chr3:11313890	ATG7	-0.42	-5.55	-0.32	6.85e-8	HDL cholesterol;
CESC	cis	rs1348850	0.598	rs1405717	chr2:178500101	G/T	cg22681709	chr2:178499509	PDE11A	-0.56	-8.88	-0.48	1.06e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs10832963	1.000	rs2084220	chr11:18656932	C/T	cg20219074	chr11:18656078	SPTY2D1	0.8	11.72	0.58	7.97e-26	Breast cancer;
CESC	cis	rs4237845	0.636	rs11172371	chr12:58286188	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.51	5.45	0.32	1.13e-7	Intelligence (multi-trait analysis);
CESC	cis	rs875971	0.520	rs2420597	chr7:65915986	A/G	cg18252515	chr7:66147081	NA	-0.43	-5.6	-0.33	5.39e-8	Aortic root size;
CESC	cis	rs35110281	0.667	rs2070533	chr21:45122753	G/A	cg21573476	chr21:45109991	RRP1B	-0.58	-8.47	-0.46	1.7e-15	Mean corpuscular volume;
CESC	cis	rs17253792	0.915	rs17832389	chr14:56185836	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.72	5.06	0.3	7.74e-7	Putamen volume;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg04436474	chr3:49977685	RBM6	-0.43	-6.24	-0.36	1.72e-9	Gambling;
CESC	cis	rs1372520	0.577	rs748849	chr4:90734961	G/A	cg15133208	chr4:90757351	SNCA	-0.41	-5.55	-0.32	6.81e-8	Neuroticism;
CESC	cis	rs769267	0.965	rs735273	chr19:19385411	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.42	5.38	0.31	1.66e-7	Tonsillectomy;
CESC	cis	rs12155623	0.668	rs6472114	chr8:49789561	T/C	cg22283653	chr8:49824208	NA	-0.38	-6.09	-0.35	3.94e-9	Sudden cardiac arrest;
CESC	cis	rs853679	0.550	rs1233707	chr6:28172953	G/A	cg20151795	chr6:28129481	ZNF389	0.41	5.56	0.32	6.63e-8	Depression;
CESC	cis	rs875971	0.540	rs781152	chr7:65479572	T/A	cg11987759	chr7:65425863	GUSB	-0.43	-5.75	-0.33	2.46e-8	Aortic root size;
CESC	cis	rs11792861	0.641	rs10979586	chr9:111647764	C/T	cg13535736	chr9:111863775	C9orf5	-0.43	-5.6	-0.33	5.28e-8	Menarche (age at onset);
CESC	cis	rs1691799	0.899	rs1183272	chr12:66735421	T/C	cg16791601	chr12:66731901	HELB	-0.79	-14.29	-0.66	9.69e-35	White blood cell count (basophil);
CESC	cis	rs2108225	0.658	rs1476673	chr7:107435945	C/G	cg18560240	chr7:107437656	SLC26A3	-0.5	-7.0	-0.39	2.12e-11	Ulcerative colitis;
CESC	cis	rs7613875	0.620	rs7634441	chr3:50071677	G/A	cg24308560	chr3:49941425	MST1R	0.6	8.65	0.47	5.02e-16	Body mass index;
CESC	cis	rs847577	0.630	rs6967926	chr7:97715088	C/T	cg21770322	chr7:97807741	LMTK2	0.84	15.22	0.68	5.14e-38	Breast cancer;
CESC	cis	rs73206853	0.841	rs74503171	chr12:111061652	A/G	cg12870014	chr12:110450643	ANKRD13A	0.62	5.17	0.3	4.63e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	trans	rs1814175	0.645	rs10128731	chr11:50023554	G/T	cg03929089	chr4:120376271	NA	-0.9	-14.7	-0.67	3.47e-36	Height;
CESC	cis	rs523522	0.962	rs4767905	chr12:120930835	C/T	cg12219531	chr12:120966889	COQ5	0.74	9.94	0.52	5.49e-20	High light scatter reticulocyte count;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg18530282	chr10:115439379	CASP7	-0.45	-6.14	-0.35	3.04e-9	Fibrinogen levels;
CESC	cis	rs875971	0.867	rs1002053	chr7:65798545	G/A	cg10691866	chr7:65817282	TPST1	0.34	5.61	0.33	5.03e-8	Aortic root size;
CESC	cis	rs7666738	0.830	rs28867388	chr4:98962794	A/T	cg03467027	chr4:99064603	C4orf37	0.44	5.57	0.32	6.41e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs863345	0.604	rs923664	chr1:158507691	A/T	cg12129480	chr1:158549410	OR10X1	-0.35	-7.03	-0.4	1.73e-11	Pneumococcal bacteremia;
CESC	cis	rs933688	0.532	rs12514092	chr5:90540522	T/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.42	-5.03	-0.3	9.14e-7	Smoking behavior;
CESC	cis	rs2228479	0.867	rs11646448	chr16:89966357	A/T	cg00800038	chr16:89945340	TCF25	-0.84	-8.15	-0.45	1.42e-14	Skin colour saturation;
CESC	cis	rs3916	0.641	rs7964786	chr12:121132100	C/T	cg20569203	chr12:120799911	MSI1	0.3	5.07	0.3	7.58e-7	Urinary metabolites (H-NMR features);
CESC	cis	rs1707322	0.963	rs12145287	chr1:46325002	C/G	cg06784218	chr1:46089804	CCDC17	0.35	5.87	0.34	1.33e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7255436	0.965	rs11666233	chr19:8452045	G/T	cg10174797	chr19:8464628	RAB11B	0.38	5.43	0.32	1.28e-7	HDL cholesterol;
CESC	cis	rs7666738	0.830	rs13141752	chr4:98893128	G/A	cg17366294	chr4:99064904	C4orf37	0.56	7.75	0.43	1.99e-13	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9902453	1.000	rs9902453	chr17:28349095	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.62	-7.85	-0.43	1.04e-13	Coffee consumption (cups per day);
CESC	cis	rs9287719	0.967	rs7600820	chr2:10740044	A/G	cg02196655	chr2:10830764	NOL10	-0.37	-5.72	-0.33	2.87e-8	Prostate cancer;
CESC	cis	rs6964587	0.626	rs2269810	chr7:91508837	T/C	cg17063962	chr7:91808500	NA	-0.44	-6.18	-0.35	2.45e-9	Breast cancer;
CESC	cis	rs2180341	0.960	rs7745944	chr6:127709574	A/G	cg27446573	chr6:127587934	RNF146	1.04	14.72	0.67	2.91e-36	Breast cancer;
CESC	cis	rs6460942	0.514	rs118124486	chr7:12470381	T/G	cg10578991	chr7:12443926	VWDE	-0.36	-5.36	-0.31	1.77e-7	Coronary artery disease;
CESC	cis	rs9486719	1.000	rs12201449	chr6:96959382	C/T	cg18709589	chr6:96969512	KIAA0776	-0.57	-6.26	-0.36	1.53e-9	Migraine;Coronary artery disease;
CESC	cis	rs9916302	0.680	rs2271308	chr17:37817482	T/C	cg20243544	chr17:37824526	PNMT	0.58	7.14	0.4	8.81e-12	Glomerular filtration rate (creatinine);
CESC	cis	rs61008539	0.815	rs6960062	chr7:884665	A/G	cg07138768	chr7:917805	C7orf20	0.34	5.39	0.31	1.57e-7	Perceived unattractiveness to mosquitoes;
CESC	cis	rs2243480	1.000	rs68189316	chr7:65409169	C/G	cg12463550	chr7:65579703	CRCP	0.7	5.58	0.32	5.87e-8	Diabetic kidney disease;
CESC	trans	rs61931739	0.534	rs4547187	chr12:34041259	T/C	cg26384229	chr12:38710491	ALG10B	0.5	6.75	0.38	9.3e-11	Morning vs. evening chronotype;
CESC	cis	rs6815814	0.950	rs56408159	chr4:38812116	T/A	cg02016764	chr4:38805732	TLR1	-0.62	-7.43	-0.42	1.5e-12	Breast cancer;
CESC	cis	rs34779708	0.966	rs7913615	chr10:35422957	T/G	cg04310649	chr10:35416472	CREM	-0.49	-5.85	-0.34	1.41e-8	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs796364	0.806	rs74771155	chr2:200913743	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.84	-7.75	-0.43	1.94e-13	Schizophrenia;
CESC	cis	rs1538970	0.924	rs3790582	chr1:45887288	T/C	cg24296786	chr1:45957014	TESK2	-0.46	-5.29	-0.31	2.54e-7	Platelet count;
CESC	cis	rs9660180	0.967	rs6603803	chr1:1812688	A/G	cg03396347	chr1:1875803	NA	-0.45	-7.07	-0.4	1.34e-11	Body mass index;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23145915	chr12:58146234	CDK4	0.59	6.81	0.39	6.35e-11	Gut microbiome composition (summer);
CESC	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg26354017	chr1:205819088	PM20D1	0.98	17.44	0.73	6.64e-46	Menarche (age at onset);
CESC	cis	rs3741151	0.892	rs76854106	chr11:73027110	G/A	cg17517138	chr11:73019481	ARHGEF17	1.11	7.88	0.44	8.34e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs7617773	0.817	rs3731555	chr3:48206102	G/A	cg11946769	chr3:48343235	NME6	0.88	11.55	0.58	2.84e-25	Coronary artery disease;
CESC	cis	rs3747547	0.581	rs7467749	chr9:38136965	A/T	cg13774184	chr9:37916125	SHB	0.63	5.41	0.32	1.42e-7	Metabolite levels (Dihydroxy docosatrienoic acid);
CESC	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg03395511	chr6:291903	DUSP22	-0.73	-9.47	-0.5	1.59e-18	Menopause (age at onset);
CESC	trans	rs4335177	0.963	rs6477534	chr9:109365066	G/A	cg12580783	chr12:49362475	WNT10B	-0.32	-6.19	-0.36	2.25e-9	Response to paliperidone in schizophrenia (positive Marder score);
CESC	cis	rs9291683	0.527	rs3822247	chr4:10094671	G/A	cg11266682	chr4:10021025	SLC2A9	-0.56	-10.49	-0.54	9.03e-22	Bone mineral density;
CESC	cis	rs17376456	0.569	rs896729	chr5:93222178	A/G	cg25358565	chr5:93447407	FAM172A	-0.62	-6.65	-0.38	1.64e-10	Diabetic retinopathy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24928378	chr12:49259415	RND1	-0.65	-7.62	-0.42	4.64e-13	Gut microbiome composition (summer);
CESC	cis	rs17826219	0.714	rs11650821	chr17:28968150	T/C	cg14008862	chr17:28927542	LRRC37B2	0.75	5.5	0.32	9.05e-8	Body mass index;
CESC	cis	rs12497850	0.897	rs7373778	chr3:48836392	C/G	cg06212747	chr3:49208901	KLHDC8B	0.66	8.79	0.47	1.99e-16	Parkinson's disease;
CESC	cis	rs6867032	0.958	rs4975798	chr5:2015580	G/A	cg26168224	chr5:2018326	NA	0.96	19.64	0.77	1.3e-53	Gut microbiome composition (winter);
CESC	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg11905131	chr22:24372483	LOC391322	0.81	12.19	0.6	1.91e-27	Liver enzyme levels (gamma-glutamyl transferase);
CESC	trans	rs11039798	0.588	rs666165	chr11:48457439	C/T	cg15704280	chr7:45808275	SEPT13	-0.6	-6.32	-0.36	1.11e-9	Axial length;
CESC	cis	rs7914558	0.933	rs10786729	chr10:104719378	A/G	cg08650961	chr10:104748594	CNNM2	0.32	5.17	0.3	4.66e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs11098499	0.789	rs9991166	chr4:120237851	G/A	cg09307838	chr4:120376055	NA	0.79	10.77	0.55	1.17e-22	Corneal astigmatism;
CESC	cis	rs7647973	1.000	rs7647973	chr3:49510931	G/A	cg06212747	chr3:49208901	KLHDC8B	-0.56	-6.93	-0.39	3.22e-11	Menarche (age at onset);
CESC	cis	rs13191362	1.000	rs34655790	chr6:163202739	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.58	5.76	0.33	2.36e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs8028182	0.636	rs7495610	chr15:75784441	T/C	cg20655648	chr15:75932815	IMP3	0.48	5.97	0.34	7.42e-9	Sudden cardiac arrest;
CESC	cis	rs9487051	0.676	rs7773213	chr6:109601885	C/T	cg12927641	chr6:109611667	NA	-0.37	-5.51	-0.32	8.39e-8	Reticulocyte fraction of red cells;
CESC	cis	rs35306767	0.715	rs12777801	chr10:1036285	T/A	cg20503657	chr10:835505	NA	0.63	5.49	0.32	9.26e-8	Eosinophil percentage of granulocytes;
CESC	trans	rs9858542	1.000	rs9882740	chr3:49702484	T/C	cg21659725	chr3:3221576	CRBN	-0.53	-6.56	-0.37	2.83e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs7959452	0.535	rs2305641	chr12:69646914	C/T	cg14784868	chr12:69753453	YEATS4	0.71	10.3	0.53	3.85e-21	Blood protein levels;
CESC	cis	rs116095464	0.558	rs10462754	chr5:246669	T/C	cg10591111	chr5:226296	SDHA	-0.51	-6.28	-0.36	1.38e-9	Breast cancer;
CESC	cis	rs6439153	0.901	rs2630263	chr3:128688318	A/G	cg24203234	chr3:128598194	ACAD9	0.42	5.49	0.32	9.48e-8	Pneumococcal bacteremia;
CESC	cis	rs514406	0.661	rs562641	chr1:53374666	C/T	cg25767906	chr1:53392781	SCP2	-0.54	-7.54	-0.42	7.6e-13	Monocyte count;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg22225685	chr22:38203998	GCAT	-0.42	-6.13	-0.35	3.1e-9	Fibrinogen levels;
CESC	cis	rs853679	0.517	rs9357065	chr6:28129580	T/C	cg20151795	chr6:28129481	ZNF389	0.43	5.5	0.32	9.14e-8	Depression;
CESC	cis	rs1707322	1.000	rs7547284	chr1:46319565	C/G	cg05343316	chr1:45956843	TESK2	0.44	5.55	0.32	7.05e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs3857067	0.839	rs12505694	chr4:95042940	T/G	cg11021082	chr4:95130006	SMARCAD1	-0.51	-7.74	-0.43	2.06e-13	QT interval;
CESC	cis	rs14057	0.896	rs2235566	chr1:6655053	G/A	cg06778853	chr1:6672620	PHF13	-0.28	-5.12	-0.3	5.83e-7	Systolic blood pressure;
CESC	trans	rs629535	0.508	rs56207225	chr8:70146628	C/A	cg21567404	chr3:27674614	NA	-0.83	-9.14	-0.49	1.69e-17	Dupuytren's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03241502	chr19:7505149	ARHGEF18	-0.63	-6.89	-0.39	3.95e-11	Gut microbiome composition (summer);
CESC	cis	rs17401966	0.931	rs1002076	chr1:10438892	G/A	cg15208524	chr1:10270712	KIF1B	0.41	5.24	0.31	3.26e-7	Hepatocellular carcinoma;
CESC	cis	rs7818345	0.967	rs6992893	chr8:19287504	G/A	cg11303988	chr8:19266685	CSGALNACT1	0.36	6.63	0.38	1.9e-10	Language performance in older adults (adjusted for episodic memory);
CESC	cis	rs7666738	0.830	rs2903154	chr4:99048151	A/G	cg18180107	chr4:99064573	C4orf37	0.4	5.2	0.3	4.08e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2228479	0.717	rs1061647	chr16:89806063	G/C	cg04013166	chr16:89971882	TCF25	0.78	6.57	0.37	2.64e-10	Skin colour saturation;
CESC	cis	rs1215050	0.765	rs783947	chr4:99012943	T/C	cg17366294	chr4:99064904	C4orf37	-0.39	-5.2	-0.3	4.06e-7	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs9911578	0.835	rs9303398	chr17:56484257	T/C	cg05425664	chr17:57184151	TRIM37	0.44	6.14	0.35	3.03e-9	Intelligence (multi-trait analysis);
CESC	cis	rs4268898	0.679	rs2543666	chr2:24446042	C/T	cg06627628	chr2:24431161	ITSN2	0.86	10.42	0.54	1.61e-21	Asthma;
CESC	cis	rs765787	0.530	rs7165889	chr15:45531640	T/C	cg24006582	chr15:45444508	DUOX1	-0.59	-7.23	-0.41	5.15e-12	Uric acid levels;
CESC	cis	rs6690583	0.512	rs7547224	chr1:85456902	T/C	cg22153463	chr1:85462885	MCOLN2	0.77	7.18	0.4	6.91e-12	Serum sulfate level;
CESC	cis	rs8027181	0.710	rs34117151	chr15:73097221	T/A	cg25632853	chr15:73088954	NA	0.31	5.69	0.33	3.39e-8	Triglyceride levels;
CESC	cis	rs6500602	0.927	rs7200817	chr16:4480598	G/C	cg08645402	chr16:4508243	NA	0.45	7.11	0.4	1.05e-11	Schizophrenia;
CESC	cis	rs7590720	1.000	rs4674048	chr2:216900023	G/A	cg12620499	chr2:216877984	MREG	0.91	12.53	0.61	1.38e-28	Alcohol dependence;
CESC	trans	rs1814175	0.645	rs7115592	chr11:50013243	A/G	cg15704280	chr7:45808275	SEPT13	-1.0	-18.49	-0.75	1.41e-49	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08857194	chr17:77078518	ENGASE	-0.69	-7.89	-0.44	8.07e-14	Gut microbiome composition (summer);
CESC	trans	rs11098499	0.913	rs11098496	chr4:120167466	C/G	cg25214090	chr10:38739885	LOC399744	0.61	8.09	0.45	2.23e-14	Corneal astigmatism;
CESC	trans	rs9929218	0.954	rs2961	chr16:68818903	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.65	-8.62	-0.47	5.99e-16	Colorectal cancer;
CESC	cis	rs300703	0.542	rs376385	chr2:190245	G/A	cg21211680	chr2:198530	NA	0.9	9.65	0.51	4.45e-19	Blood protein levels;
CESC	cis	rs9814567	0.896	rs1357764	chr3:134344928	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.43	5.7	0.33	3.13e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs7666738	0.830	rs17558193	chr4:99049593	A/G	cg03467027	chr4:99064603	C4orf37	0.47	5.98	0.34	7.19e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10751667	0.643	rs7396046	chr11:937176	T/C	cg01483505	chr11:975446	AP2A2	0.38	5.18	0.3	4.33e-7	Alzheimer's disease (late onset);
CESC	cis	rs11264213	0.901	rs116757422	chr1:36349560	G/A	cg27506609	chr1:36549197	TEKT2	0.66	5.55	0.32	6.79e-8	Schizophrenia;
CESC	cis	rs2425143	1.000	rs12481228	chr20:34218673	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.88	-7.85	-0.43	1.02e-13	Blood protein levels;
CESC	cis	rs2204008	0.702	rs8175764	chr12:38363690	T/C	cg13010199	chr12:38710504	ALG10B	0.48	6.06	0.35	4.62e-9	Bladder cancer;
CESC	cis	rs9388451	0.807	rs1268065	chr6:126042783	G/A	cg10911889	chr6:126070802	HEY2	-0.37	-5.28	-0.31	2.65e-7	Brugada syndrome;
CESC	cis	rs9322193	0.923	rs35967444	chr6:149996724	G/A	cg13206674	chr6:150067644	NUP43	0.43	6.15	0.35	2.86e-9	Lung cancer;
CESC	cis	rs9487051	0.676	rs1608044	chr6:109594076	T/C	cg21918786	chr6:109611834	NA	-0.37	-5.38	-0.31	1.62e-7	Reticulocyte fraction of red cells;
CESC	cis	rs2929278	0.617	rs663214	chr15:44113782	T/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.54	-6.98	-0.39	2.33e-11	Schizophrenia;
CESC	cis	rs9329289	0.610	rs10903783	chr10:2540623	C/T	cg15501526	chr10:2543763	NA	0.48	7.74	0.43	2.13e-13	Age-related hearing impairment;
CESC	cis	rs7223966	1.000	rs16947014	chr17:61719032	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.45	-5.14	-0.3	5.32e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs651907	0.535	rs11716558	chr3:101528481	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.46	6.05	0.35	4.95e-9	Colorectal cancer;
CESC	cis	rs1790761	0.667	rs1254123	chr11:67334812	T/C	cg24690094	chr11:67383802	NA	0.35	5.78	0.33	2.12e-8	Mean corpuscular volume;
CESC	cis	rs1050631	1.000	rs1785914	chr18:33700796	A/G	cg25426722	chr18:33708991	SLC39A6;ELP2	-0.42	-5.43	-0.32	1.27e-7	Esophageal squamous cell cancer (length of survival);
CESC	cis	rs9488822	0.702	rs12196154	chr6:116327471	T/G	cg05304507	chr6:116381966	FRK	0.26	6.56	0.37	2.86e-10	Cholesterol, total;LDL cholesterol;
CESC	cis	rs7714584	1.000	rs10463240	chr5:150256853	A/C	cg22134413	chr5:150180641	NA	0.51	5.92	0.34	9.88e-9	Crohn's disease;
CESC	cis	rs67340775	0.541	rs200966	chr6:27862152	T/C	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.55	5.27	0.31	2.78e-7	Lung cancer in ever smokers;
CESC	cis	rs66887589	0.748	rs28439855	chr4:120262256	G/A	cg09307838	chr4:120376055	NA	0.55	7.45	0.42	1.28e-12	Diastolic blood pressure;
CESC	cis	rs736408	0.507	rs6445531	chr3:52717282	T/C	cg18404041	chr3:52824283	ITIH1	-0.38	-6.53	-0.37	3.29e-10	Bipolar disorder;
CESC	cis	rs4141404	0.787	rs4820042	chr22:31589056	T/C	cg13145458	chr22:31556086	RNF185	0.49	5.52	0.32	7.94e-8	Paclitaxel-induced neuropathy;
CESC	cis	rs2797160	1.000	rs1612249	chr6:126014916	C/A	cg05901451	chr6:126070800	HEY2	0.45	6.41	0.37	6.75e-10	Endometrial cancer;
CESC	cis	rs4595586	0.545	rs1607041	chr12:39368206	C/T	cg26384229	chr12:38710491	ALG10B	0.62	8.69	0.47	3.89e-16	Morning vs. evening chronotype;
CESC	cis	rs34638657	0.872	rs2967352	chr16:82196676	T/C	cg09439754	chr16:82129088	HSD17B2	-0.36	-5.27	-0.31	2.85e-7	Lung adenocarcinoma;
CESC	cis	rs3796352	1.000	rs13078971	chr3:53103645	G/C	cg07884673	chr3:53033167	SFMBT1	0.67	5.73	0.33	2.67e-8	Immune reponse to smallpox (secreted IL-2);
CESC	cis	rs4664308	0.692	rs13009231	chr2:160964057	G/T	cg03641300	chr2:160917029	PLA2R1	-0.44	-6.19	-0.36	2.29e-9	Idiopathic membranous nephropathy;
CESC	cis	rs9311474	1.000	rs7614727	chr3:52295895	C/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.33	6.35	0.36	9.17e-10	Electroencephalogram traits;
CESC	cis	rs9948	0.881	rs3731941	chr2:97476219	A/G	cg01990225	chr2:97406019	LMAN2L	-0.85	-5.92	-0.34	9.78e-9	Erectile dysfunction and prostate cancer treatment;
CESC	trans	rs3816788	0.792	rs7013323	chr8:21869024	C/G	cg16253641	chr1:85929949	DDAH1	-0.39	-6.13	-0.35	3.15e-9	Lung cancer in ever smokers;
CESC	cis	rs57221529	0.766	rs72703026	chr5:572383	G/A	cg16447950	chr5:562315	NA	-0.7	-7.05	-0.4	1.59e-11	Lung disease severity in cystic fibrosis;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg23682007	chr1:167523064	CREG1	-0.46	-6.58	-0.37	2.56e-10	Asthma;
CESC	cis	rs2658782	1.000	rs2658778	chr11:93148948	C/G	cg15737290	chr11:93063684	CCDC67	0.49	6.11	0.35	3.52e-9	Pulmonary function decline;
CESC	cis	rs7618915	0.571	rs2289249	chr3:52597664	G/A	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.39	6.75	0.38	9.2e-11	Bipolar disorder;
CESC	cis	rs172166	0.694	rs1770131	chr6:28086413	C/T	cg12963246	chr6:28129442	ZNF389	0.43	6.31	0.36	1.15e-9	Cardiac Troponin-T levels;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg05133009	chr12:121711847	CAMKK2	0.57	7.8	0.43	1.41e-13	Fibrinogen levels;
CESC	cis	rs3026101	0.671	rs1806258	chr17:5314956	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.41	5.36	0.31	1.8e-7	Body mass index;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26120680	chr9:34612489	C9orf23	-0.55	-6.37	-0.36	8.42e-10	Gut microbiome composition (summer);
CESC	cis	rs2576037	0.526	rs6507714	chr18:44519574	A/G	cg19077165	chr18:44547161	KATNAL2	-0.5	-6.99	-0.39	2.26e-11	Personality dimensions;
CESC	cis	rs1267303	0.600	rs57100184	chr1:47004710	A/C	cg25110126	chr1:46999211	NA	1.08	11.9	0.59	1.88e-26	Monobrow;
CESC	cis	rs910316	0.789	rs4899552	chr14:75667921	C/A	cg08847533	chr14:75593920	NEK9	-0.85	-13.7	-0.64	1.17e-32	Height;
CESC	cis	rs8114671	0.804	rs6088666	chr20:33564570	A/G	cg06115741	chr20:33292138	TP53INP2	0.46	5.46	0.32	1.09e-7	Height;
CESC	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg07677032	chr17:61819896	STRADA	0.45	5.97	0.34	7.74e-9	Prudent dietary pattern;
CESC	cis	rs798554	0.679	rs13230995	chr7:2887284	G/A	cg19717773	chr7:2847554	GNA12	-0.44	-6.46	-0.37	4.99e-10	Height;
CESC	cis	rs12449000	1	rs12449000	chr16:89872970	T/C	cg27121462	chr16:89883253	FANCA	0.71	9.78	0.51	1.79e-19	Schizophrenia;
CESC	cis	rs35110281	0.714	rs2282526	chr21:45080552	A/T	cg21573476	chr21:45109991	RRP1B	-0.55	-7.58	-0.42	6.01e-13	Mean corpuscular volume;
CESC	cis	rs2635047	0.811	rs12957869	chr18:44786869	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.43	5.64	0.33	4.41e-8	Educational attainment;
CESC	cis	rs17253792	0.545	rs35466279	chr14:56017022	C/T	cg01858014	chr14:56050164	KTN1	-0.87	-6.37	-0.36	8.34e-10	Putamen volume;
CESC	cis	rs2625529	0.775	rs4777466	chr15:72136872	C/T	cg16672083	chr15:72433130	SENP8	-0.49	-7.15	-0.4	8.24e-12	Red blood cell count;
CESC	trans	rs561341	1.000	rs56903735	chr17:30254393	T/A	cg27661571	chr11:113659931	NA	-0.69	-6.93	-0.39	3.28e-11	Hip circumference adjusted for BMI;
CESC	cis	rs3820068	0.581	rs72645895	chr1:15931709	G/A	cg13390004	chr1:15929781	NA	0.35	5.58	0.32	5.83e-8	Systolic blood pressure;
CESC	cis	rs875971	0.862	rs2088655	chr7:65795711	T/C	cg18252515	chr7:66147081	NA	0.45	5.88	0.34	1.22e-8	Aortic root size;
CESC	cis	rs72627123	0.619	rs79575309	chr14:74590230	T/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.73	5.05	0.3	8.41e-7	Morning vs. evening chronotype;
CESC	cis	rs11250464	1.000	rs11250464	chr10:1406364	A/G	cg26394196	chr10:1453818	ADARB2	-0.4	-5.41	-0.32	1.44e-7	Radiation response;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg11254527	chr1:35873695	ZMYM4	0.39	6.02	0.35	5.89e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	trans	rs7839040	0.698	rs10094060	chr8:82930327	G/C	cg14472086	chr9:107730925	NA	-0.48	-6.45	-0.37	5.4e-10	Response to methotrexate in juvenile idiopathic arthritis;
CESC	cis	rs7116495	1.000	rs3018302	chr11:71790942	A/C	cg26138937	chr11:71823887	C11orf51	-0.88	-7.11	-0.4	1.08e-11	Severe influenza A (H1N1) infection;
CESC	cis	rs801193	0.548	rs2659904	chr7:66178602	C/A	cg12463550	chr7:65579703	CRCP	0.54	6.86	0.39	4.77e-11	Aortic root size;
CESC	cis	rs11785400	0.963	rs4579507	chr8:143733663	C/G	cg24634471	chr8:143751801	JRK	0.46	6.14	0.35	3.02e-9	Schizophrenia;
CESC	cis	rs7412746	0.634	rs2124952	chr1:150923774	T/A	cg17724175	chr1:150552817	MCL1	0.38	5.9	0.34	1.13e-8	Melanoma;
CESC	cis	rs2836974	0.932	rs2150415	chr21:40615367	A/G	cg11890956	chr21:40555474	PSMG1	1.03	16.48	0.71	1.71e-42	Cognitive function;
CESC	cis	rs2439831	0.681	rs999047	chr15:43688916	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.8	11.56	0.58	2.63e-25	Lung cancer in ever smokers;
CESC	cis	rs3105593	0.933	rs11633404	chr15:50899309	C/A	cg08437265	chr15:50716283	USP8	0.43	5.54	0.32	7.32e-8	QT interval;
CESC	cis	rs2108622	0.727	rs3093207	chr19:15988658	T/C	cg13772218	chr19:15982569	NA	0.31	5.89	0.34	1.18e-8	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CESC	cis	rs9733	0.596	rs1336898	chr1:150665050	G/A	cg18016565	chr1:150552671	MCL1	0.33	5.16	0.3	4.96e-7	Tonsillectomy;
CESC	cis	rs9322193	1.000	rs9399693	chr6:149933854	C/T	cg13206674	chr6:150067644	NUP43	0.4	5.69	0.33	3.34e-8	Lung cancer;
CESC	cis	rs6089584	0.627	rs55875402	chr20:60559925	G/A	cg06108461	chr20:60628389	TAF4	-0.52	-6.87	-0.39	4.66e-11	Body mass index;
CESC	cis	rs7937682	0.737	rs679032	chr11:111423286	G/T	cg22437258	chr11:111473054	SIK2	0.61	7.51	0.42	8.99e-13	Primary sclerosing cholangitis;
CESC	cis	rs734999	0.545	rs10910106	chr1:2538886	G/T	cg20673091	chr1:2541236	MMEL1	0.46	7.59	0.42	5.5e-13	Ulcerative colitis;
CESC	cis	rs12586317	0.514	rs74590021	chr14:35490113	T/G	cg05294307	chr14:35346193	BAZ1A	-0.51	-5.43	-0.32	1.26e-7	Psoriasis;
CESC	cis	rs3740713	1.000	rs73440604	chr11:18463671	C/T	cg23797887	chr11:18477753	LDHAL6A	-0.53	-5.13	-0.3	5.58e-7	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs12477438	0.765	rs13406288	chr2:99589585	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.62	-8.67	-0.47	4.46e-16	Chronic sinus infection;
CESC	cis	rs67478160	0.608	rs4906368	chr14:104242397	A/C	cg01849466	chr14:104193079	ZFYVE21	-0.55	-8.0	-0.44	4.01e-14	Schizophrenia;
CESC	cis	rs787274	0.867	rs786978	chr9:115460239	A/G	cg13803584	chr9:115635662	SNX30	-0.51	-5.2	-0.3	4.01e-7	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs9322193	0.884	rs7450246	chr6:150023653	C/T	cg13206674	chr6:150067644	NUP43	0.45	6.52	0.37	3.57e-10	Lung cancer;
CESC	cis	rs798502	0.541	rs2644307	chr7:2832973	G/A	cg19346786	chr7:2764209	NA	-0.38	-5.76	-0.33	2.34e-8	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Inflammatory bowel disease;Waist circumference adjusted for BMI in non-smokers;Ulcerative colitis;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
CESC	cis	rs992157	0.798	rs12053514	chr2:219167965	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.65	-8.49	-0.46	1.5e-15	Colorectal cancer;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg17955575	chr17:73761019	GALK1	-0.48	-6.18	-0.35	2.35e-9	Asthma;
CESC	cis	rs477895	0.838	rs11607007	chr11:64007976	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.9	10.3	0.53	3.74e-21	Mean platelet volume;
CESC	cis	rs854765	0.551	rs56886154	chr17:17831473	C/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.52	7.22	0.41	5.4e-12	Total body bone mineral density;
CESC	cis	rs8044868	0.521	rs7203821	chr16:72101165	T/C	cg01557791	chr16:72042693	DHODH	-0.41	-5.57	-0.32	6.1e-8	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13896783	chr2:159313876	CCDC148;PKP4	0.52	6.06	0.35	4.66e-9	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.830	rs1593569	chr4:99017485	C/G	cg03676636	chr4:99064102	C4orf37	0.33	5.07	0.3	7.6e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7772486	0.534	rs34541797	chr6:146205304	A/G	cg23711669	chr6:146136114	FBXO30	0.95	12.52	0.61	1.41e-28	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1005277	0.579	rs2474568	chr10:38383147	A/T	cg00409905	chr10:38381863	ZNF37A	-0.47	-6.29	-0.36	1.31e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs897080	0.552	rs1067365	chr2:44655398	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	5.92	0.34	9.71e-9	Height;
CESC	cis	rs3096299	0.933	rs2965824	chr16:89455306	A/G	cg00750074	chr16:89608354	SPG7	-0.37	-5.26	-0.31	2.99e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs6028335	0.867	rs67114385	chr20:37696401	C/T	cg16355469	chr20:37678765	NA	0.55	5.29	0.31	2.54e-7	Alcohol and nicotine co-dependence;
CESC	cis	rs11098499	0.739	rs6534130	chr4:120131339	A/T	cg09307838	chr4:120376055	NA	-0.66	-8.14	-0.45	1.52e-14	Corneal astigmatism;
CESC	cis	rs6502050	0.799	rs28376857	chr17:80104351	G/A	cg23985595	chr17:80112537	CCDC57	-0.42	-6.57	-0.37	2.72e-10	Life satisfaction;
CESC	cis	rs2236918	0.710	rs2797602	chr1:242029206	G/T	cg17736920	chr1:242011382	EXO1	0.55	6.97	0.39	2.5e-11	Menopause (age at onset);
CESC	cis	rs1348850	0.668	rs13010396	chr2:178492934	T/C	cg23306229	chr2:178417860	TTC30B	0.56	6.57	0.37	2.69e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs11098499	0.570	rs6832740	chr4:120546136	T/C	cg09307838	chr4:120376055	NA	0.74	9.88	0.52	8.51e-20	Corneal astigmatism;
CESC	cis	rs17209837	1.000	rs17149640	chr7:87086039	A/C	cg00919237	chr7:87102261	ABCB4	-0.5	-5.83	-0.34	1.6e-8	Gallbladder cancer;
CESC	cis	rs6424115	1.000	rs7514394	chr1:24100223	A/G	cg15997130	chr1:24165203	NA	-0.43	-6.08	-0.35	4.24e-9	Immature fraction of reticulocytes;
CESC	cis	rs4595586	0.644	rs10437944	chr12:39308786	A/C	cg26384229	chr12:38710491	ALG10B	0.42	6.12	0.35	3.31e-9	Morning vs. evening chronotype;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg15422644	chr12:52116112	SCN8A	-0.43	-6.2	-0.36	2.2e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs1879734	0.731	rs59020945	chr1:54162635	A/G	cg23596471	chr1:54105337	GLIS1	0.33	5.41	0.32	1.38e-7	Mitral valve prolapse;
CESC	cis	rs1707322	0.964	rs7512395	chr1:46361177	G/A	cg06784218	chr1:46089804	CCDC17	0.35	5.87	0.34	1.33e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs472402	0.623	rs7727273	chr5:6635933	A/C	cg10789808	chr5:6633262	NSUN2;SRD5A1	-0.48	-6.32	-0.36	1.1e-9	Response to amphetamines;
CESC	cis	rs561341	0.941	rs112569713	chr17:30271738	C/T	cg23018236	chr17:30244563	NA	-0.47	-5.15	-0.3	5.04e-7	Hip circumference adjusted for BMI;
CESC	cis	rs9322193	0.962	rs9393175	chr6:149998723	A/G	cg04369109	chr6:150039330	LATS1	-0.43	-5.83	-0.34	1.6e-8	Lung cancer;
CESC	cis	rs1046896	0.594	rs9914570	chr17:80783721	C/T	cg02398342	chr17:80708632	TBCD;FN3K	0.48	5.63	0.33	4.48e-8	Glycated hemoglobin levels;
CESC	cis	rs7615952	0.599	rs6779141	chr3:125709995	A/T	cg02807482	chr3:125708958	NA	-0.38	-5.05	-0.3	8.26e-7	Blood pressure (smoking interaction);
CESC	cis	rs11785400	0.642	rs4256574	chr8:143725705	C/T	cg24634471	chr8:143751801	JRK	0.46	5.82	0.34	1.73e-8	Schizophrenia;
CESC	cis	rs9399135	0.844	rs13209789	chr6:135367916	A/G	cg24558204	chr6:135376177	HBS1L	0.51	7.07	0.4	1.4e-11	Red blood cell count;
CESC	cis	rs6740322	0.748	rs6756625	chr2:43489313	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.7	8.19	0.45	1.09e-14	Coronary artery disease;
CESC	cis	rs1008375	1.000	rs13106338	chr4:17676871	G/T	cg02297831	chr4:17616191	MED28	-0.49	-5.83	-0.34	1.58e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs875971	0.756	rs2901210	chr7:66017505	G/A	cg19163074	chr7:65112434	INTS4L2	0.43	5.33	0.31	2.1e-7	Aortic root size;
CESC	cis	rs977987	0.933	rs1834014	chr16:75501274	G/A	cg03315344	chr16:75512273	CHST6	0.53	7.74	0.43	2.09e-13	Dupuytren's disease;
CESC	cis	rs5750830	0.649	rs5757657	chr22:39798429	G/T	cg02038168	chr22:39784481	NA	-0.64	-8.25	-0.45	7.52e-15	Intelligence (multi-trait analysis);
CESC	cis	rs2268241	0.938	rs11088251	chr21:34770810	A/C	cg14850771	chr21:34775459	IFNGR2	0.78	9.77	0.51	1.91e-19	Obesity-related traits;
CESC	cis	rs2576037	0.526	rs605487	chr18:44444778	G/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.71	11.32	0.57	1.65e-24	Personality dimensions;
CESC	cis	rs9733	0.687	rs11204735	chr1:150841667	T/C	cg13175981	chr1:150552382	MCL1	0.5	6.82	0.39	5.97e-11	Tonsillectomy;
CESC	cis	rs681343	0.746	rs633372	chr19:49209226	G/A	cg21064579	chr19:49206444	FUT2	0.52	7.26	0.41	4.33e-12	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
CESC	cis	rs3126085	1.000	rs11485508	chr1:152253167	T/G	cg03465714	chr1:152285911	FLG	-0.46	-5.75	-0.33	2.42e-8	Atopic dermatitis;
CESC	cis	rs6701037	1.000	rs6702010	chr1:175123858	C/A	cg00321850	chr1:175162397	KIAA0040	-0.42	-5.85	-0.34	1.45e-8	Alcohol dependence;
CESC	cis	rs2651899	0.872	rs207199	chr1:3076857	T/G	cg22674798	chr1:3096360	PRDM16	0.39	7.57	0.42	6.36e-13	Migraine;
CESC	trans	rs677673	0.951	rs649067	chr20:10461575	T/C	cg16021678	chr13:55475951	NA	0.5	6.2	0.36	2.1e-9	Body mass index (change over time) in chronic obstructive pulmonary disease;
CESC	cis	rs1413885	0.516	rs10158873	chr1:65836244	T/C	cg14976592	chr1:65886160	LEPROT;LEPR	0.47	5.95	0.34	8.66e-9	Anticoagulant levels;
CESC	trans	rs9937837	0.918	rs34927056	chr16:31317427	T/C	cg04903759	chr3:167238645	WDR49	0.53	6.63	0.38	1.89e-10	Systemic lupus erythematosus;
CESC	cis	rs12142240	0.698	rs41534051	chr1:46828734	A/G	cg10495392	chr1:46806563	NSUN4	0.57	6.02	0.35	5.89e-9	Menopause (age at onset);
CESC	cis	rs35740288	0.689	rs11630688	chr15:86253279	C/T	cg20737812	chr15:86336631	KLHL25	-0.37	-5.07	-0.3	7.37e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
CESC	cis	rs853679	0.517	rs4713144	chr6:28106790	C/G	cg08968635	chr6:28129556	ZNF389	0.42	5.72	0.33	2.82e-8	Depression;
CESC	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg01238044	chr22:24384105	GSTT1	-0.74	-10.16	-0.53	1.08e-20	Liver enzyme levels (gamma-glutamyl transferase);
CESC	trans	rs1545843	0.593	rs4761068	chr12:84793969	G/C	cg03015433	chr16:56623111	MT3	-0.34	-6.12	-0.35	3.37e-9	Major depressive disorder;
CESC	cis	rs2204008	0.774	rs11180977	chr12:38263094	G/T	cg13010199	chr12:38710504	ALG10B	0.51	6.29	0.36	1.29e-9	Bladder cancer;
CESC	cis	rs514406	0.505	rs374662	chr1:53164549	C/A	cg08736216	chr1:53307985	ZYG11A	-0.4	-6.79	-0.38	7.53e-11	Monocyte count;
CESC	cis	rs2204008	0.807	rs12816136	chr12:38456037	A/G	cg26384229	chr12:38710491	ALG10B	-0.64	-9.53	-0.51	1.09e-18	Bladder cancer;
CESC	cis	rs9611519	0.894	rs4821998	chr22:41468273	C/G	cg03806693	chr22:41940476	POLR3H	-0.57	-5.91	-0.34	1.05e-8	Neuroticism;
CESC	cis	rs9916302	0.861	rs8081033	chr17:37506650	A/G	cg07936489	chr17:37558343	FBXL20	0.82	11.93	0.59	1.54e-26	Glomerular filtration rate (creatinine);
CESC	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg26338869	chr17:61819248	STRADA	0.69	9.11	0.49	2.04e-17	Prudent dietary pattern;
CESC	cis	rs3857067	1.000	rs4693364	chr4:95012284	T/A	cg11021082	chr4:95130006	SMARCAD1	-0.5	-7.53	-0.42	8.12e-13	QT interval;
CESC	cis	rs77972916	0.611	rs10495899	chr2:43602304	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.59	-5.81	-0.34	1.75e-8	Granulocyte percentage of myeloid white cells;
CESC	cis	rs992157	0.965	rs13427681	chr2:219167563	G/C	cg20019365	chr2:219134978	PNKD;AAMP	0.77	10.91	0.56	3.92e-23	Colorectal cancer;
CESC	cis	rs8067354	0.645	rs72838857	chr17:57836767	A/G	cg13753209	chr17:57696993	CLTC	0.56	6.1	0.35	3.83e-9	Hemoglobin concentration;
CESC	trans	rs4942242	0.663	rs9525815	chr13:44223692	T/C	cg19169023	chr15:41853346	TYRO3	-0.59	-7.22	-0.41	5.54e-12	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs3862260	0.509	rs1045827	chr1:120162442	C/T	cg16322792	chr1:120165303	ZNF697	-0.59	-11.08	-0.56	1.08e-23	Systemic lupus erythematosus;
CESC	trans	rs7866350	0.604	rs1935389	chr9:100994470	A/G	cg22087390	chr7:98050531	NA	0.42	6.16	0.35	2.73e-9	Post-traumatic stress disorder;
CESC	cis	rs12893668	0.703	rs4906338	chr14:104050357	A/G	cg24130564	chr14:104152367	KLC1	-0.47	-5.82	-0.34	1.66e-8	Reticulocyte count;
CESC	cis	rs7312774	0.618	rs7953093	chr12:107334540	G/A	cg16260113	chr12:107380972	MTERFD3	0.79	6.83	0.39	5.68e-11	Severe influenza A (H1N1) infection;
CESC	cis	rs6088580	0.505	rs6141503	chr20:33274469	G/A	cg08999081	chr20:33150536	PIGU	-0.45	-6.51	-0.37	3.73e-10	Glomerular filtration rate (creatinine);
CESC	trans	rs1814175	0.527	rs3974435	chr11:49619533	G/A	cg03929089	chr4:120376271	NA	-0.72	-8.32	-0.46	4.77e-15	Height;
CESC	cis	rs4523957	0.553	rs9909515	chr17:2039733	T/C	cg16513277	chr17:2031491	SMG6	-0.78	-11.57	-0.58	2.42e-25	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs1059312	0.808	rs4760533	chr12:129297651	A/G	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.81	11.84	0.59	3.02e-26	Systemic lupus erythematosus;
CESC	cis	rs11112613	0.775	rs7959699	chr12:105959848	C/A	cg03607813	chr12:105948248	NA	0.59	6.86	0.39	4.87e-11	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CESC	cis	rs9291683	0.588	rs3756238	chr4:10013202	C/T	cg00071950	chr4:10020882	SLC2A9	0.91	17.5	0.73	4.16e-46	Bone mineral density;
CESC	cis	rs35110281	0.782	rs7282933	chr21:45046988	A/G	cg04455712	chr21:45112962	RRP1B	0.41	6.06	0.35	4.78e-9	Mean corpuscular volume;
CESC	trans	rs7246657	0.943	rs4802136	chr19:37849811	T/A	cg24637308	chr11:6592297	DNHD1	0.53	6.05	0.35	4.83e-9	Coronary artery calcification;
CESC	cis	rs5758659	0.652	rs133301	chr22:42390093	C/T	cg04733989	chr22:42467013	NAGA	0.43	5.74	0.33	2.61e-8	Cognitive function;
CESC	cis	rs7666738	1.000	rs13106934	chr4:99028685	C/T	cg18180107	chr4:99064573	C4orf37	0.46	5.71	0.33	3.05e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs12500824	0.564	rs62300859	chr4:77285754	T/A	cg20311846	chr4:77356250	SHROOM3	0.37	6.86	0.39	4.82e-11	Coronary artery disease;
CESC	cis	rs17376456	0.877	rs7728736	chr5:93404277	C/T	cg25358565	chr5:93447407	FAM172A	1.13	11.34	0.57	1.45e-24	Diabetic retinopathy;
CESC	cis	rs4665809	0.877	rs34536218	chr2:26287376	T/A	cg27170947	chr2:26402098	FAM59B	0.66	7.33	0.41	2.81e-12	Gut microbiome composition (summer);
CESC	cis	rs7527798	0.501	rs12125256	chr1:207851361	C/T	cg21110645	chr1:207815933	NA	-0.32	-5.7	-0.33	3.22e-8	Erythrocyte sedimentation rate;
CESC	cis	rs1799949	1.000	rs11653253	chr17:41182662	G/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.4	5.15	0.3	4.99e-7	Menopause (age at onset);
CESC	cis	rs6460942	0.597	rs13245635	chr7:12526454	T/A	cg10578991	chr7:12443926	VWDE	-0.49	-5.13	-0.3	5.63e-7	Coronary artery disease;
CESC	cis	rs7833790	0.654	rs7835342	chr8:82698092	A/G	cg06027949	chr8:82754900	SNX16	-0.43	-5.22	-0.31	3.66e-7	Diastolic blood pressure;
CESC	cis	rs7772486	0.714	rs1883365	chr6:146076749	C/T	cg05347473	chr6:146136440	FBXO30	-0.53	-6.96	-0.39	2.69e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4948102	0.595	rs7793921	chr7:56120881	G/A	cg09872392	chr7:56161020	PHKG1	-0.42	-6.84	-0.39	5.32e-11	Plasma homocysteine levels (post-methionine load test);
CESC	trans	rs4689592	0.619	rs2359011	chr4:7066052	T/G	cg07817883	chr1:32538562	TMEM39B	-0.53	-6.14	-0.35	2.98e-9	Monocyte percentage of white cells;
CESC	cis	rs76878669	0.561	rs4930178	chr11:66129442	C/G	cg18002602	chr11:66138449	SLC29A2	0.4	6.65	0.38	1.71e-10	Educational attainment (years of education);
CESC	trans	rs877282	1.000	rs11253369	chr10:773610	C/G	cg22713356	chr15:30763199	NA	0.92	9.21	0.49	1.05e-17	Uric acid levels;
CESC	cis	rs9611565	0.918	rs73176685	chr22:41781094	C/G	cg06481639	chr22:41940642	POLR3H	-0.6	-6.51	-0.37	3.68e-10	Vitiligo;
CESC	cis	rs2404602	1.000	rs2404741	chr15:76851735	C/T	cg26408565	chr15:76604113	ETFA	-0.37	-5.29	-0.31	2.56e-7	Blood metabolite levels;
CESC	trans	rs57221529	0.766	rs12522303	chr5:555564	A/C	cg25482853	chr8:67687455	SGK3	1.11	11.94	0.59	1.39e-26	Lung disease severity in cystic fibrosis;
CESC	cis	rs11098499	0.779	rs7699346	chr4:120310542	C/T	cg24375607	chr4:120327624	NA	0.46	5.61	0.33	5.19e-8	Corneal astigmatism;
CESC	cis	rs9393777	0.513	rs6936555	chr6:26640886	C/T	cg12826209	chr6:26865740	GUSBL1	0.75	8.79	0.48	1.88e-16	Intelligence (multi-trait analysis);
CESC	cis	rs6815814	0.731	rs11734342	chr4:38773109	A/G	cg02016764	chr4:38805732	TLR1	-0.44	-5.98	-0.34	7.2e-9	Breast cancer;
CESC	cis	rs9399137	0.507	rs11759077	chr6:135381351	A/G	cg24558204	chr6:135376177	HBS1L	0.69	9.52	0.5	1.12e-18	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	cis	rs12973672	0.812	rs2073899	chr19:35752917	C/T	cg12095397	chr19:35769544	USF2	0.44	5.49	0.32	9.31e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	trans	rs526821	0.595	rs499446	chr11:55355722	A/G	cg15704280	chr7:45808275	SEPT13	-0.52	-6.55	-0.37	2.99e-10	Pediatric bone mineral density (spine);
CESC	cis	rs7560272	0.501	rs12992607	chr2:73959960	G/T	cg20560298	chr2:73613845	ALMS1	0.45	6.14	0.35	3.03e-9	Schizophrenia;
CESC	cis	rs8020095	0.571	rs6573728	chr14:67343903	G/A	cg19548862	chr14:67692701	FAM71D	-0.49	-5.94	-0.34	8.74e-9	Depression (quantitative trait);
CESC	cis	rs10504229	1.000	rs76023408	chr8:58193345	A/G	cg24829409	chr8:58192753	C8orf71	-0.73	-9.55	-0.51	9.16e-19	Developmental language disorder (linguistic errors);
CESC	cis	rs17401966	0.838	rs10864449	chr1:10296922	A/T	cg15208524	chr1:10270712	KIF1B	0.4	5.24	0.31	3.33e-7	Hepatocellular carcinoma;
CESC	cis	rs1577917	1.000	rs13217384	chr6:86720000	C/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-6.26	-0.36	1.5e-9	Response to antipsychotic treatment;
CESC	cis	rs2404602	0.692	rs12594556	chr15:77165363	G/A	cg22467129	chr15:76604101	ETFA	-0.35	-5.23	-0.31	3.42e-7	Blood metabolite levels;
CESC	cis	rs6545883	0.929	rs3732171	chr2:61749690	C/T	cg15711740	chr2:61764176	XPO1	-0.42	-5.12	-0.3	5.78e-7	Tuberculosis;
CESC	trans	rs57221529	0.655	rs11948381	chr5:568413	A/T	cg25482853	chr8:67687455	SGK3	0.99	11.03	0.56	1.58e-23	Lung disease severity in cystic fibrosis;
CESC	cis	rs6662572	0.737	rs11211214	chr1:46347328	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.45	-5.03	-0.3	8.85e-7	Blood protein levels;
CESC	cis	rs12545109	0.800	rs2670054	chr8:57421616	C/T	cg09654669	chr8:57350985	NA	-0.45	-6.27	-0.36	1.47e-9	Obesity-related traits;
CESC	cis	rs9611519	0.929	rs926914	chr22:41418154	C/T	cg03806693	chr22:41940476	POLR3H	-0.58	-5.92	-0.34	9.79e-9	Neuroticism;
CESC	cis	rs9479482	0.935	rs9479513	chr6:150367320	G/T	cg03788504	chr6:150331562	NA	-0.34	-6.18	-0.35	2.42e-9	Alopecia areata;
CESC	cis	rs6500395	1.000	rs8058362	chr16:48645316	T/C	cg04672837	chr16:48644449	N4BP1	0.5	6.07	0.35	4.3e-9	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs847577	0.677	rs4729403	chr7:97707841	G/C	cg24562669	chr7:97807699	LMTK2	-0.5	-7.64	-0.43	3.87e-13	Breast cancer;
CESC	cis	rs7224314	1.000	rs62084081	chr17:65387148	G/C	cg01507342	chr17:65387096	PITPNC1	-0.47	-5.73	-0.33	2.79e-8	Diisocyanate-induced asthma;
CESC	cis	rs4819052	1.000	rs2297284	chr21:46705345	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.88	11.36	0.57	1.28e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs916888	0.647	rs199449	chr17:44808902	G/A	cg15921436	chr17:44337874	NA	0.44	5.62	0.33	4.95e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs1790761	0.667	rs598811	chr11:67311676	C/T	cg00290607	chr11:67383545	NA	0.39	5.47	0.32	1.04e-7	Mean corpuscular volume;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg15222563	chr19:7745491	TRAPPC5	-0.44	-6.34	-0.36	9.9e-10	Gambling;
CESC	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg24846343	chr22:24311635	DDTL	-0.64	-11.15	-0.56	6.53e-24	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs514406	0.505	rs416968	chr1:53183513	A/G	cg27535305	chr1:53392650	SCP2	-0.32	-5.5	-0.32	9e-8	Monocyte count;
CESC	cis	rs7811142	1.000	rs2406255	chr7:100053690	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.77	6.42	0.37	6.12e-10	Platelet count;
CESC	cis	rs1008375	0.931	rs6837181	chr4:17701253	A/C	cg16339924	chr4:17578868	LAP3	0.63	7.72	0.43	2.33e-13	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs6460942	0.732	rs73677576	chr7:12286535	G/A	cg06484146	chr7:12443880	VWDE	-0.59	-6.3	-0.36	1.25e-9	Coronary artery disease;
CESC	cis	rs798554	0.797	rs1182183	chr7:2873136	C/T	cg19346786	chr7:2764209	NA	-0.46	-6.85	-0.39	5.17e-11	Height;
CESC	cis	rs7520050	0.966	rs6695809	chr1:46285461	T/C	cg24296786	chr1:45957014	TESK2	0.43	5.42	0.32	1.34e-7	Red blood cell count;Reticulocyte count;
CESC	cis	rs12142240	0.698	rs66483119	chr1:46838389	T/C	cg00530320	chr1:46809349	NSUN4	0.6	7.92	0.44	6.39e-14	Menopause (age at onset);
CESC	cis	rs72945132	0.882	rs11235755	chr11:70136323	A/G	cg14191688	chr11:70257035	CTTN	0.41	5.27	0.31	2.9e-7	Coronary artery disease;
CESC	cis	rs7523050	0.643	rs34920128	chr1:109400889	C/T	cg08274380	chr1:109419600	GPSM2	0.86	5.66	0.33	3.86e-8	Fat distribution (HIV);
CESC	cis	rs7914558	1.000	rs943038	chr10:104826261	T/C	cg08650961	chr10:104748594	CNNM2	0.31	5.19	0.3	4.18e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs9916302	0.904	rs7503069	chr17:37697128	C/G	cg00129232	chr17:37814104	STARD3	-0.57	-7.44	-0.42	1.39e-12	Glomerular filtration rate (creatinine);
CESC	cis	rs7666738	0.830	rs62318906	chr4:99037110	C/T	cg24818145	chr4:99064322	C4orf37	0.38	5.04	0.3	8.81e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3008870	0.755	rs1535365	chr1:67497613	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.61	7.91	0.44	7.21e-14	Lymphocyte percentage of white cells;
CESC	trans	rs7937682	0.889	rs551825	chr11:111480116	C/G	cg18187862	chr3:45730750	SACM1L	0.48	6.11	0.35	3.49e-9	Primary sclerosing cholangitis;
CESC	trans	rs12599106	0.629	rs1391904	chr16:34548934	C/T	cg01516881	chr6:292596	DUSP22	-0.55	-7.12	-0.4	1.02e-11	Menopause (age at onset);
CESC	cis	rs4764487	0.687	rs3181300	chr12:6345199	C/T	cg08284733	chr12:6341482	CD9	0.34	5.07	0.3	7.64e-7	Mean platelet volume;
CESC	cis	rs7523050	0.643	rs35050241	chr1:109404876	T/C	cg08274380	chr1:109419600	GPSM2	0.85	5.82	0.34	1.74e-8	Fat distribution (HIV);
CESC	cis	rs7927771	0.524	rs2290851	chr11:47753370	C/T	cg20307385	chr11:47447363	PSMC3	-0.57	-8.01	-0.44	3.63e-14	Subjective well-being;
CESC	cis	rs798766	1.000	rs1374469	chr4:1724799	C/T	cg10756475	chr4:1757242	NA	0.45	5.81	0.34	1.75e-8	Bladder cancer;Urinary bladder cancer;
CESC	cis	rs7618915	0.679	rs6802320	chr3:52241835	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.38	5.04	0.3	8.82e-7	Bipolar disorder;
CESC	cis	rs854765	0.583	rs9913724	chr17:17819101	A/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.55	7.34	0.41	2.67e-12	Total body bone mineral density;
CESC	cis	rs72634258	0.842	rs6668846	chr1:8152102	C/G	cg00042356	chr1:8021962	PARK7	-0.49	-5.04	-0.3	8.63e-7	Inflammatory bowel disease;
CESC	cis	rs919433	0.889	rs10931782	chr2:198211579	G/A	cg10820045	chr2:198174542	NA	-0.41	-5.93	-0.34	9.17e-9	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs7662987	0.517	rs2602872	chr4:100038996	A/G	cg13256891	chr4:100009986	ADH5	0.71	7.8	0.43	1.39e-13	Smoking initiation;
CESC	trans	rs7615952	0.512	rs4679430	chr3:125357893	T/C	cg07211511	chr3:129823064	LOC729375	-0.59	-7.28	-0.41	3.84e-12	Blood pressure (smoking interaction);
CESC	cis	rs11209002	0.567	rs2815385	chr1:67542083	A/G	cg02640540	chr1:67518911	SLC35D1	0.45	5.08	0.3	7.04e-7	Crohn's disease;
CESC	cis	rs1008375	0.863	rs2058336	chr4:17608299	T/C	cg27347728	chr4:17578864	LAP3	0.44	5.32	0.31	2.17e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs8062405	0.754	rs3859172	chr16:28566158	G/T	cg08761264	chr16:28874980	SH2B1	-0.42	-5.08	-0.3	7.04e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs9894429	0.538	rs9747080	chr17:79606704	A/G	cg21984481	chr17:79567631	NPLOC4	-0.41	-6.14	-0.35	2.99e-9	Eye color traits;
CESC	cis	rs4604732	0.631	rs12036460	chr1:247626928	A/G	cg12758973	chr1:247694275	LOC148824;OR2C3	0.51	6.36	0.36	8.65e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	trans	rs10743315	0.557	rs17505123	chr12:19301353	G/A	cg09562322	chr12:119419143	SRRM4	-0.5	-6.51	-0.37	3.65e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg11062466	chr8:58055876	NA	0.47	6.31	0.36	1.18e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs875971	0.862	rs6944374	chr7:65686929	C/G	cg18252515	chr7:66147081	NA	0.47	6.05	0.35	4.93e-9	Aortic root size;
CESC	cis	rs875971	0.965	rs28682868	chr7:65689809	C/T	cg18876405	chr7:65276391	NA	-0.52	-7.13	-0.4	9.48e-12	Aortic root size;
CESC	cis	rs7618915	0.571	rs7623199	chr3:52605974	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	6.78	0.38	7.94e-11	Bipolar disorder;
CESC	cis	rs7666738	0.962	rs11728816	chr4:98951767	C/T	cg05340658	chr4:99064831	C4orf37	0.59	7.59	0.42	5.45e-13	Colonoscopy-negative controls vs population controls;
CESC	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg17178900	chr1:205818956	PM20D1	0.49	7.35	0.41	2.43e-12	Menarche (age at onset);
CESC	cis	rs7811142	1.000	rs6975514	chr7:100056220	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.11	11.01	0.56	1.89e-23	Platelet count;
CESC	cis	rs2836950	0.565	rs8134214	chr21:40542367	A/C	cg11890956	chr21:40555474	PSMG1	-0.69	-9.97	-0.52	4.48e-20	Menarche (age at onset);
CESC	cis	rs10751667	0.666	rs7396059	chr11:970490	C/A	cg06064525	chr11:970664	AP2A2	-0.47	-9.13	-0.49	1.87e-17	Alzheimer's disease (late onset);
CESC	cis	rs2380220	1.000	rs2380222	chr6:95975395	C/T	cg15832292	chr6:96025679	MANEA	0.68	6.31	0.36	1.14e-9	Behavioural disinhibition (generation interaction);
CESC	cis	rs3858526	0.833	rs4758184	chr11:5926719	A/G	cg13902645	chr11:5959945	NA	-0.62	-7.3	-0.41	3.35e-12	DNA methylation (variation);
CESC	cis	rs2066819	0.818	rs773652	chr12:56674766	G/A	cg26714650	chr12:56694279	CS	1.29	16.3	0.71	7.7e-42	Psoriasis vulgaris;
CESC	trans	rs11088226	0.681	rs1015047	chr21:33949423	A/G	cg09050820	chr6:167586206	TCP10L2	0.92	10.22	0.53	6.75e-21	Gastritis;
CESC	trans	rs7819412	0.505	rs67849263	chr8:11007544	G/T	cg06636001	chr8:8085503	FLJ10661	-0.54	-6.44	-0.37	5.59e-10	Triglycerides;
CESC	cis	rs1878931	0.697	rs1044390	chr16:3432594	T/A	cg00484396	chr16:3507460	NAT15	-0.41	-6.36	-0.36	8.95e-10	Body mass index (adult);
CESC	cis	rs5750830	0.649	rs7949	chr22:39827553	G/A	cg01416388	chr22:39784598	NA	-0.56	-6.94	-0.39	3.04e-11	Intelligence (multi-trait analysis);
CESC	cis	rs853679	0.517	rs4713137	chr6:28083521	C/G	cg19592336	chr6:28129416	ZNF389	0.6	7.98	0.44	4.4e-14	Depression;
CESC	cis	rs1003719	0.788	rs2835593	chr21:38465873	G/C	cg10648535	chr21:38446584	PIGP;TTC3	0.63	8.78	0.47	2.02e-16	Eye color traits;
CESC	cis	rs2836974	0.897	rs1984022	chr21:40596085	G/A	cg11890956	chr21:40555474	PSMG1	1.18	21.96	0.8	1.36e-61	Cognitive function;
CESC	cis	rs4563143	0.514	rs73030738	chr19:29312328	G/A	cg12756686	chr19:29218302	NA	0.54	6.48	0.37	4.43e-10	Methadone dose in opioid dependence;
CESC	cis	rs7666738	0.753	rs1830230	chr4:99026186	G/C	cg05340658	chr4:99064831	C4orf37	0.83	13.1	0.63	1.43e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7223966	0.960	rs7212379	chr17:61706122	G/A	cg11494091	chr17:61959527	GH2	0.4	5.44	0.32	1.22e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs8040855	0.627	rs11630697	chr15:85606445	C/G	cg08123816	chr15:85640762	PDE8A	-0.4	-6.0	-0.35	6.36e-9	Bulimia nervosa;
CESC	cis	rs2486012	0.649	rs1354261	chr1:44256682	A/C	cg12908607	chr1:44402522	ARTN	-0.44	-5.13	-0.3	5.62e-7	Intelligence (multi-trait analysis);
CESC	cis	rs2836974	0.897	rs2836924	chr21:40525639	C/T	cg11644478	chr21:40555479	PSMG1	1.04	17.8	0.74	3.62e-47	Cognitive function;
CESC	cis	rs6456156	0.586	rs2001114	chr6:167486578	A/G	cg07741184	chr6:167504864	NA	0.36	6.15	0.35	2.85e-9	Primary biliary cholangitis;
CESC	cis	rs2051211	0.895	rs17037798	chr3:38555474	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.63	-7.22	-0.41	5.52e-12	QRS duration;
CESC	cis	rs7845219	0.544	rs7017487	chr8:95922752	A/G	cg23172400	chr8:95962367	TP53INP1	0.39	7.35	0.41	2.43e-12	Type 2 diabetes;
CESC	cis	rs1799949	0.965	rs33925201	chr17:41280682	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.45	6.3	0.36	1.21e-9	Menopause (age at onset);
CESC	cis	rs1062177	0.724	rs2964590	chr5:151118146	C/G	cg00977110	chr5:151150581	G3BP1	-0.61	-6.31	-0.36	1.14e-9	Preschool internalizing problems;
CESC	trans	rs9325144	0.647	rs10875953	chr12:39050536	G/C	cg23762105	chr12:34175262	ALG10	0.46	6.01	0.35	6.13e-9	Morning vs. evening chronotype;
CESC	cis	rs6142102	0.625	rs9753690	chr20:32540801	C/G	cg08999081	chr20:33150536	PIGU	0.34	5.12	0.3	5.84e-7	Skin pigmentation;
CESC	cis	rs1005277	0.579	rs2474571	chr10:38384639	T/G	cg00409905	chr10:38381863	ZNF37A	-0.47	-6.26	-0.36	1.52e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs10754283	0.967	rs6428561	chr1:90102619	G/A	cg21401794	chr1:90099060	LRRC8C	0.7	9.42	0.5	2.35e-18	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs4237845	0.735	rs11172375	chr12:58291574	G/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.47	5.19	0.3	4.24e-7	Intelligence (multi-trait analysis);
CESC	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg11494091	chr17:61959527	GH2	0.66	10.9	0.56	4.09e-23	Prudent dietary pattern;
CESC	cis	rs12200560	0.505	rs211183	chr6:97074723	G/T	cg06623918	chr6:96969491	KIAA0776	-0.41	-5.44	-0.32	1.24e-7	Coronary heart disease;
CESC	trans	rs591166	0.935	rs574988	chr18:57813648	G/C	cg05268347	chr19:41218064	ADCK4	-0.4	-6.42	-0.37	6.44e-10	Body mass index;
CESC	cis	rs9303280	0.901	rs8067378	chr17:38051348	A/G	cg20243544	chr17:37824526	PNMT	0.52	7.07	0.4	1.36e-11	Self-reported allergy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04783338	chr16:23160430	USP31	0.53	6.03	0.35	5.52e-9	Gut microbiome composition (summer);
CESC	cis	rs9549367	0.789	rs34448227	chr13:113884754	A/C	cg00898013	chr13:113819073	PROZ	-0.5	-6.82	-0.39	6.03e-11	Platelet distribution width;
CESC	cis	rs2279817	0.863	rs11203441	chr1:18026725	C/T	cg21791023	chr1:18019539	ARHGEF10L	0.55	8.06	0.44	2.71e-14	Neuroticism;
CESC	cis	rs7940866	0.804	rs3910267	chr11:130810282	C/T	cg12179176	chr11:130786555	SNX19	0.67	10.33	0.54	2.97e-21	Schizophrenia;
CESC	cis	rs4561483	0.801	rs33619	chr16:12008941	T/G	cg08843971	chr16:11963173	GSPT1	-0.54	-7.95	-0.44	5.3e-14	Testicular germ cell tumor;
CESC	cis	rs796364	0.715	rs1106399	chr2:201003837	A/C	cg23649088	chr2:200775458	C2orf69	-0.58	-5.71	-0.33	3.07e-8	Schizophrenia;
CESC	cis	rs7264396	0.676	rs58372200	chr20:34555445	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.77	-10.29	-0.53	4.22e-21	Total cholesterol levels;
CESC	cis	rs1322639	0.614	rs9364356	chr6:169567108	G/A	cg04662567	chr6:169592167	NA	-0.51	-5.1	-0.3	6.59e-7	Pulse pressure;
CESC	cis	rs6952808	0.531	rs4721441	chr7:2184060	A/G	cg05863683	chr7:1912471	MAD1L1	0.36	5.39	0.31	1.54e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs35110281	0.667	rs9941787	chr21:45116042	A/G	cg01579765	chr21:45077557	HSF2BP	-0.53	-8.67	-0.47	4.28e-16	Mean corpuscular volume;
CESC	cis	rs7833986	0.501	rs72653951	chr8:56961837	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.6	7.34	0.41	2.58e-12	Height;
CESC	cis	rs5760092	0.755	rs915589	chr22:24261004	C/T	cg24846343	chr22:24311635	DDTL	-0.43	-5.6	-0.33	5.4e-8	Urinary 1,3-butadiene metabolite levels in smokers;
CESC	cis	rs4819052	1.000	rs28628220	chr21:46663741	G/C	cg11663144	chr21:46675770	NA	-0.51	-7.1	-0.4	1.14e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs875971	0.543	rs801191	chr7:66032955	G/A	cg18252515	chr7:66147081	NA	0.39	5.18	0.3	4.4e-7	Aortic root size;
CESC	cis	rs57221529	0.655	rs11948381	chr5:568413	A/T	cg16447950	chr5:562315	NA	-0.67	-7.85	-0.43	1.03e-13	Lung disease severity in cystic fibrosis;
CESC	cis	rs67478160	0.643	rs34813623	chr14:104263294	A/G	cg08213375	chr14:104286397	PPP1R13B	0.54	10.82	0.55	7.82e-23	Schizophrenia;
CESC	cis	rs853679	0.542	rs9393892	chr6:28081394	A/G	cg23161317	chr6:28129485	ZNF389	0.53	6.79	0.39	7.21e-11	Depression;
CESC	cis	rs2204008	0.748	rs11514352	chr12:38246954	C/T	cg13010199	chr12:38710504	ALG10B	0.51	6.3	0.36	1.24e-9	Bladder cancer;
CESC	trans	rs9929218	0.529	rs11075694	chr16:68730366	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.88	14.6	0.67	8.08e-36	Colorectal cancer;
CESC	cis	rs3791556	0.842	rs55840142	chr2:240106884	G/A	cg03281426	chr2:240109471	HDAC4	0.54	6.95	0.39	2.81e-11	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs9715521	0.868	rs62301181	chr4:59834246	A/G	cg11281224	chr4:60001000	NA	-0.51	-6.74	-0.38	9.64e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs7605827	0.930	rs2287263	chr2:15637366	C/T	cg19274914	chr2:15703543	NA	0.31	5.46	0.32	1.08e-7	Educational attainment (years of education);
CESC	trans	rs3780486	0.505	rs10813959	chr9:33166234	C/T	cg04842962	chr6:43655489	MRPS18A	-0.67	-10.2	-0.53	8.02e-21	IgG glycosylation;
CESC	cis	rs514406	0.683	rs6588440	chr1:53209587	C/T	cg16325326	chr1:53192061	ZYG11B	-0.98	-17.51	-0.73	3.83e-46	Monocyte count;
CESC	trans	rs916888	0.773	rs199457	chr17:44795469	C/T	cg04282206	chr17:62833786	PLEKHM1P	0.57	6.57	0.37	2.6e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs2836974	0.932	rs35571600	chr21:40590624	A/C	cg17971929	chr21:40555470	PSMG1	1.07	16.37	0.71	4.17e-42	Cognitive function;
CESC	cis	rs9311474	0.508	rs11720243	chr3:52618018	T/C	cg17372223	chr3:52568218	NT5DC2	0.42	6.33	0.36	1.05e-9	Electroencephalogram traits;
CESC	cis	rs1691799	0.899	rs1168302	chr12:66737518	C/T	cg16791601	chr12:66731901	HELB	-0.78	-14.03	-0.65	8.41e-34	White blood cell count (basophil);
CESC	cis	rs6499129	1.000	rs9933206	chr16:67539022	C/T	cg26727032	chr16:67993705	SLC12A4	0.52	5.66	0.33	3.97e-8	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs66731853	0.769	rs477679	chr1:20894618	A/G	cg04087271	chr1:20915334	CDA	0.56	7.27	0.41	4.03e-12	Mean corpuscular volume;
CESC	cis	rs6783573	0.535	rs12637699	chr3:46628443	C/T	cg21489266	chr3:46619131	LRRC2;TDGF1	-0.46	-6.76	-0.38	8.99e-11	Cerebrospinal fluid biomarker levels;
CESC	cis	rs3008870	0.755	rs2815366	chr1:67499930	C/T	cg02640540	chr1:67518911	SLC35D1	0.46	5.64	0.33	4.33e-8	Lymphocyte percentage of white cells;
CESC	cis	rs7589342	0.501	rs12995849	chr2:106443111	C/T	cg16077055	chr2:106428750	NCK2	0.4	6.17	0.35	2.56e-9	Addiction;
CESC	cis	rs6740322	0.895	rs6744746	chr2:43555805	A/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.61	6.68	0.38	1.44e-10	Coronary artery disease;
CESC	cis	rs644148	0.933	rs565819	chr19:44967714	A/G	cg15540054	chr19:45004280	ZNF180	0.71	8.73	0.47	2.89e-16	Personality dimensions;
CESC	cis	rs2228479	0.850	rs74251570	chr16:89910068	C/A	cg14709524	chr16:89940631	TCF25	0.88	6.1	0.35	3.82e-9	Skin colour saturation;
CESC	cis	rs593982	1.000	rs118030231	chr11:65501905	G/A	cg08755490	chr11:65554678	OVOL1	-1.27	-10.6	-0.55	3.99e-22	Atopic dermatitis;
CESC	cis	rs2842992	0.789	rs4276525	chr6:160193612	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.78	9.43	0.5	2.15e-18	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs7618915	0.531	rs77146033	chr3:52701501	G/T	cg07507251	chr3:52567010	NT5DC2	0.4	7.1	0.4	1.15e-11	Bipolar disorder;
CESC	cis	rs1799949	1.000	rs12936831	chr17:41331816	C/T	cg23758822	chr17:41437982	NA	1.03	15.5	0.69	5.3e-39	Menopause (age at onset);
CESC	cis	rs826838	1.000	rs10875717	chr12:38911174	T/C	cg13010199	chr12:38710504	ALG10B	0.6	8.42	0.46	2.38e-15	Heart rate;
CESC	cis	rs9522267	0.535	rs9522304	chr13:112237316	C/T	cg10483660	chr13:112241077	NA	-0.33	-5.78	-0.33	2.14e-8	Hepatitis;
CESC	cis	rs1878931	0.597	rs2680221	chr16:3462595	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.76	-9.04	-0.49	3.5e-17	Body mass index (adult);
CESC	cis	rs7116495	1.000	rs2511114	chr11:71792147	T/C	cg26138937	chr11:71823887	C11orf51	-0.87	-7.07	-0.4	1.36e-11	Severe influenza A (H1N1) infection;
CESC	cis	rs2425143	1.000	rs45595739	chr20:34320759	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.6	5.3	0.31	2.46e-7	Blood protein levels;
CESC	cis	rs2952156	1.000	rs2088126	chr17:37879030	A/G	cg20243544	chr17:37824526	PNMT	0.63	7.66	0.43	3.41e-13	Asthma;
CESC	cis	rs3126085	0.867	rs12027899	chr1:152253954	C/A	cg03465714	chr1:152285911	FLG	-0.45	-5.51	-0.32	8.65e-8	Atopic dermatitis;
CESC	cis	rs68170813	0.559	rs12536574	chr7:106810997	A/T	cg02696742	chr7:106810147	HBP1	-0.54	-5.13	-0.3	5.7e-7	Coronary artery disease;
CESC	trans	rs6054906	0.710	rs6117744	chr20:7265038	A/C	cg09175718	chr10:97453958	TCTN3	0.42	6.23	0.36	1.84e-9	Response to amphetamines;
CESC	cis	rs12188164	1.000	rs55842567	chr5:437586	G/A	cg26850624	chr5:429559	AHRR	-0.48	-6.63	-0.38	1.85e-10	Cystic fibrosis severity;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05481041	chr18:72922694	ZADH2;TSHZ1	0.45	6.12	0.35	3.4e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs950776	0.518	rs12916999	chr15:78826912	C/T	cg24631222	chr15:78858424	CHRNA5	-0.42	-5.33	-0.31	2.09e-7	Sudden cardiac arrest;
CESC	cis	rs2108225	0.934	rs2190392	chr7:107452685	T/C	cg18560240	chr7:107437656	SLC26A3	-0.4	-5.28	-0.31	2.66e-7	Ulcerative colitis;
CESC	cis	rs17376456	0.877	rs10057814	chr5:93399092	C/G	cg21475434	chr5:93447410	FAM172A	0.78	7.07	0.4	1.36e-11	Diabetic retinopathy;
CESC	cis	rs898097	0.805	rs60233158	chr17:80896612	A/G	cg15369054	chr17:80825471	TBCD	-0.5	-7.12	-0.4	1.04e-11	Breast cancer;
CESC	cis	rs7582720	1.000	rs72932574	chr2:203866336	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.36	0.41	2.34e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs17253792	0.822	rs78143160	chr14:56150097	A/G	cg01858014	chr14:56050164	KTN1	-0.97	-7.54	-0.42	7.36e-13	Putamen volume;
CESC	cis	rs9611565	0.512	rs45500192	chr22:42177899	A/G	cg17376030	chr22:41985996	PMM1	0.78	8.14	0.45	1.57e-14	Vitiligo;
CESC	cis	rs9311474	0.659	rs1133415	chr3:52575831	G/A	cg18337363	chr3:52569053	NT5DC2	0.29	5.36	0.31	1.82e-7	Electroencephalogram traits;
CESC	cis	rs9814567	0.896	rs10935123	chr3:134345327	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.42	-5.67	-0.33	3.63e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs4853012	0.838	rs6707729	chr2:74344685	G/A	cg01017244	chr2:74357527	NA	0.68	9.87	0.52	8.77e-20	Gestational age at birth (maternal effect);
CESC	cis	rs854765	0.583	rs8078583	chr17:17811465	C/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.48	6.23	0.36	1.85e-9	Total body bone mineral density;
CESC	cis	rs12541635	0.677	rs1603357	chr8:107000565	G/C	cg10147462	chr8:107024639	NA	0.44	6.55	0.37	3.01e-10	Age of smoking initiation;
CESC	cis	rs3736485	0.966	rs8041514	chr15:51866054	T/C	cg08986416	chr15:51914746	DMXL2	-0.4	-5.12	-0.3	5.86e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg09031165	chr17:17586474	RAI1	-0.49	-6.46	-0.37	5.04e-10	Height;
CESC	cis	rs2066819	0.892	rs75274818	chr12:56627619	A/G	cg26734620	chr12:56694298	CS	1.02	6.33	0.36	1.03e-9	Psoriasis vulgaris;
CESC	cis	rs6088580	0.634	rs3746455	chr20:32957216	G/A	cg08999081	chr20:33150536	PIGU	-0.65	-11.49	-0.58	4.77e-25	Glomerular filtration rate (creatinine);
CESC	cis	rs7666738	0.830	rs11727235	chr4:98946331	T/C	cg17366294	chr4:99064904	C4orf37	0.6	8.53	0.46	1.15e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7618501	0.602	rs2526743	chr3:50115245	G/A	cg24308560	chr3:49941425	MST1R	0.61	8.83	0.48	1.49e-16	Intelligence (multi-trait analysis);
CESC	cis	rs2985684	1.000	rs2985684	chr14:50101682	C/G	cg15316458	chr14:50087796	RPL36AL;MGAT2	0.45	5.15	0.3	4.99e-7	Carotid intima media thickness;
CESC	trans	rs1814175	0.645	rs2140602	chr11:50022800	G/C	cg15704280	chr7:45808275	SEPT13	-1.0	-18.54	-0.75	9.01e-50	Height;
CESC	cis	rs2073300	0.609	rs56334525	chr20:23365812	A/G	cg12062639	chr20:23401060	NAPB	1.06	8.37	0.46	3.42e-15	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg23697400	chr5:64064613	SDCCAG10;SFRS12IP1	0.45	6.24	0.36	1.72e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs9291683	0.546	rs12504565	chr4:10045145	G/A	cg11266682	chr4:10021025	SLC2A9	0.65	12.28	0.6	9.55e-28	Bone mineral density;
CESC	cis	rs2576037	0.526	rs564113	chr18:44364389	A/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.32	5.12	0.3	5.75e-7	Personality dimensions;
CESC	cis	rs7267979	1.000	rs3002702	chr20:25268920	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.88	18.33	0.75	4.99e-49	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs1865760	0.566	rs1800702	chr6:26086463	C/G	cg16482183	chr6:26056742	HIST1H1C	0.38	5.11	0.3	6.19e-7	Height;
CESC	cis	rs7223966	0.921	rs7225092	chr17:61864005	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.63	0.38	1.85e-10	Hip circumference adjusted for BMI;Body mass index;
CESC	trans	rs6089829	0.962	rs3746749	chr20:61667333	T/C	cg23505145	chr19:12996616	KLF1	0.51	6.68	0.38	1.37e-10	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs10242455	0.702	rs73713531	chr7:99222379	C/T	cg09045935	chr12:6379348	NA	0.83	6.29	0.36	1.32e-9	Blood metabolite levels;
CESC	cis	rs6432018	1.000	rs7569485	chr2:9738774	C/T	cg23886495	chr2:9695866	ADAM17	0.43	5.2	0.3	3.93e-7	Heart rate variability traits;
CESC	trans	rs634534	0.563	rs470192	chr11:65724291	C/T	cg17712092	chr4:129076599	LARP1B	0.7	9.65	0.51	4.53e-19	Sum eosinophil basophil counts;Eosinophil counts;
CESC	cis	rs10504229	0.679	rs60869047	chr8:58053221	G/A	cg22535103	chr8:58192502	C8orf71	-0.65	-7.25	-0.41	4.69e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg06873352	chr17:61820015	STRADA	0.69	11.99	0.59	9.76e-27	Prudent dietary pattern;
CESC	trans	rs208520	1.000	rs72884025	chr6:66994185	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.84	9.14	0.49	1.65e-17	Exhaled nitric oxide output;
CESC	cis	rs6991838	0.584	rs4737221	chr8:66481310	G/A	cg13398993	chr8:66546079	ARMC1	-0.45	-5.45	-0.32	1.16e-7	Intelligence (multi-trait analysis);
CESC	trans	rs367943	1.000	rs348961	chr5:112819944	A/C	cg06453915	chr11:62538484	TAF6L	-0.56	-6.08	-0.35	4.18e-9	Type 2 diabetes;
CESC	cis	rs644799	1.000	rs509720	chr11:95562771	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.55	6.76	0.38	8.51e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs9467711	0.516	rs523383	chr6:25869848	A/G	cg08501292	chr6:25962987	TRIM38	0.55	5.96	0.34	7.97e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs769267	0.931	rs15622	chr19:19468734	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.63	-8.04	-0.44	3.09e-14	Tonsillectomy;
CESC	cis	rs8103278	0.507	rs4802275	chr19:46260375	C/T	cg06577658	chr19:46296270	DMWD	0.43	5.17	0.3	4.55e-7	Coronary artery disease;
CESC	cis	rs11853189	0.938	rs77185764	chr15:78556076	G/A	cg22935921	chr15:78556834	DNAJA4	0.63	5.27	0.31	2.88e-7	Red cell distribution width;
CESC	cis	rs763121	0.819	rs3747173	chr22:39069045	A/G	cg06022373	chr22:39101656	GTPBP1	0.89	14.42	0.66	3.47e-35	Menopause (age at onset);
CESC	cis	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg05863683	chr7:1912471	MAD1L1	0.43	6.59	0.38	2.42e-10	Bipolar disorder and schizophrenia;
CESC	cis	rs6466055	0.611	rs3213742	chr7:104643230	C/A	cg04380332	chr7:105027541	SRPK2	-0.38	-5.46	-0.32	1.12e-7	Schizophrenia;
CESC	trans	rs7618501	1.000	rs11130221	chr3:49819102	C/G	cg21659725	chr3:3221576	CRBN	0.83	13.44	0.64	9.18e-32	Intelligence (multi-trait analysis);
CESC	cis	rs1005277	0.541	rs2472177	chr10:38384015	T/G	cg00409905	chr10:38381863	ZNF37A	-0.52	-7.09	-0.4	1.22e-11	Extrinsic epigenetic age acceleration;
CESC	cis	rs959260	1.000	rs4789184	chr17:73383314	A/G	cg20590849	chr17:73267439	MIF4GD	-0.57	-6.73	-0.38	1.07e-10	Systemic lupus erythematosus;
CESC	cis	rs763014	0.898	rs916414	chr16:632073	C/T	cg09263875	chr16:632152	PIGQ	0.67	11.24	0.57	3.15e-24	Height;
CESC	cis	rs4555082	0.789	rs2816649	chr14:105708326	A/G	cg13114125	chr14:105738426	BRF1	-0.67	-8.35	-0.46	3.79e-15	Mean platelet volume;Platelet distribution width;
CESC	trans	rs116095464	0.558	rs62344345	chr5:257420	C/T	cg00938859	chr5:1591904	SDHAP3	0.63	6.77	0.38	8.35e-11	Breast cancer;
CESC	trans	rs10421328	0.950	rs55831814	chr19:19777644	C/T	cg10278149	chr2:208016923	KLF7	0.51	6.11	0.35	3.62e-9	Parental longevity (combined parental age at death);
CESC	cis	rs780096	0.526	rs11126999	chr2:27670307	G/A	cg12648201	chr2:27665141	KRTCAP3	-0.31	-5.65	-0.33	4.22e-8	Total body bone mineral density;
CESC	cis	rs6446731	0.517	rs2071668	chr4:3269905	A/G	cg08886695	chr4:3369023	RGS12	0.39	5.67	0.33	3.69e-8	Mean platelet volume;
CESC	cis	rs2732480	0.557	rs2409004	chr12:48721451	T/C	cg24011408	chr12:48396354	COL2A1	0.4	5.76	0.33	2.31e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05522046	chr3:52931664	TMEM110	0.5	6.39	0.37	7.53e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs7395581	0.959	rs326222	chr11:47259668	A/G	cg25783544	chr11:47291846	MADD	-0.53	-6.86	-0.39	4.72e-11	HDL cholesterol;
CESC	cis	rs6088580	0.601	rs6120668	chr20:33099793	A/G	cg08999081	chr20:33150536	PIGU	0.65	11.26	0.57	2.65e-24	Glomerular filtration rate (creatinine);
CESC	cis	rs3008870	1.000	rs3008871	chr1:67419089	A/G	cg02640540	chr1:67518911	SLC35D1	-0.52	-5.6	-0.33	5.4e-8	Lymphocyte percentage of white cells;
CESC	cis	rs962856	0.633	rs6755775	chr2:67598583	G/C	cg09028215	chr2:67624308	ETAA1	-0.41	-5.42	-0.32	1.33e-7	Pancreatic cancer;
CESC	trans	rs3780486	0.846	rs913214	chr9:33135085	G/A	cg04842962	chr6:43655489	MRPS18A	1.0	19.06	0.76	1.32e-51	IgG glycosylation;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg24513045	chr20:62711519	RGS19;OPRL1	-0.47	-6.86	-0.39	4.96e-11	Gambling;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04151384	chr11:10315732	SBF2	0.64	6.88	0.39	4.29e-11	Gut microbiome composition (summer);
CESC	trans	rs11098499	0.731	rs6846966	chr4:120293208	A/G	cg25214090	chr10:38739885	LOC399744	0.66	9.15	0.49	1.54e-17	Corneal astigmatism;
CESC	cis	rs4888262	0.526	rs7193508	chr16:74628630	G/T	cg01733217	chr16:74700730	RFWD3	0.86	11.88	0.59	2.16e-26	Testicular germ cell tumor;
CESC	cis	rs3733585	0.605	rs4235354	chr4:10122942	C/A	cg00071950	chr4:10020882	SLC2A9	-0.65	-9.64	-0.51	4.77e-19	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs2075371	0.932	rs2241332	chr7:133969439	A/G	cg20476274	chr7:133979776	SLC35B4	0.63	8.81	0.48	1.7e-16	Mean platelet volume;
CESC	cis	rs7267979	1.000	rs4815420	chr20:25383979	C/T	cg08601574	chr20:25228251	PYGB	-0.38	-5.41	-0.32	1.4e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs4727027	0.901	rs1137432	chr7:148801658	C/T	cg23158103	chr7:148848205	ZNF398	-0.42	-6.89	-0.39	4.11e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs2996428	0.561	rs12134919	chr1:3744641	G/A	cg13057898	chr1:3703894	LRRC47	0.38	5.66	0.33	3.84e-8	Red cell distribution width;
CESC	cis	rs9814567	1.000	rs6787371	chr3:134254991	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.44	-5.97	-0.34	7.51e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs8077889	0.917	rs60335331	chr17:41907509	A/G	cg26893861	chr17:41843967	DUSP3	0.77	10.29	0.53	4.25e-21	Triglycerides;
CESC	cis	rs7959452	0.557	rs7980883	chr12:69778914	C/T	cg14784868	chr12:69753453	YEATS4	0.84	13.21	0.63	6.15e-31	Blood protein levels;
CESC	cis	rs17666538	0.585	rs336444	chr8:633123	C/G	cg07234876	chr8:600039	NA	-0.66	-5.7	-0.33	3.2e-8	IgG glycosylation;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16594066	chr16:30569726	ZNF764	0.56	6.73	0.38	1.04e-10	Gut microbiome composition (summer);
CESC	cis	rs8078723	0.966	rs57065891	chr17:38168227	C/T	cg17467752	chr17:38218738	THRA	0.67	10.03	0.52	2.9e-20	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CESC	cis	rs1559088	0.948	rs10410778	chr19:33592301	C/A	cg17764715	chr19:33622953	WDR88	0.49	6.32	0.36	1.11e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs7666738	0.830	rs17484890	chr4:99013778	T/C	cg17366294	chr4:99064904	C4orf37	0.59	8.43	0.46	2.18e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.49	-6.41	-0.37	6.59e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs826838	1.000	rs9795768	chr12:39012479	T/C	cg26384229	chr12:38710491	ALG10B	0.8	13.91	0.65	2.13e-33	Heart rate;
CESC	trans	rs916888	0.821	rs199509	chr17:44858728	G/A	cg07870213	chr5:140052090	DND1	-0.61	-6.87	-0.39	4.47e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs35110281	0.713	rs1378079	chr21:45011187	A/G	cg21573476	chr21:45109991	RRP1B	-0.46	-6.49	-0.37	4.16e-10	Mean corpuscular volume;
CESC	trans	rs11039798	0.588	rs643668	chr11:48413399	C/G	cg15704280	chr7:45808275	SEPT13	-0.63	-6.3	-0.36	1.22e-9	Axial length;
CESC	cis	rs8016982	0.633	rs9944085	chr14:81717620	A/T	cg01989461	chr14:81687754	GTF2A1	-0.72	-11.35	-0.57	1.37e-24	Schizophrenia;
CESC	cis	rs7666738	0.830	rs7657497	chr4:99044028	A/G	cg17366294	chr4:99064904	C4orf37	0.61	8.78	0.47	2.13e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9611565	0.512	rs5751145	chr22:42133552	C/T	cg06634786	chr22:41940651	POLR3H	0.68	6.62	0.38	1.94e-10	Vitiligo;
CESC	cis	rs9916302	0.851	rs11078904	chr17:37650569	G/A	cg07936489	chr17:37558343	FBXL20	-0.81	-11.96	-0.59	1.17e-26	Glomerular filtration rate (creatinine);
CESC	cis	rs616402	0.527	rs11584327	chr1:10578791	T/C	cg20482658	chr1:10539492	PEX14	-0.28	-5.9	-0.34	1.11e-8	Breast size;
CESC	cis	rs2652822	0.530	rs7165016	chr15:63439590	T/A	cg02713581	chr15:63449717	RPS27L	0.48	5.46	0.32	1.08e-7	Metabolic traits;
CESC	trans	rs66573146	0.831	rs6832482	chr4:7023433	A/T	cg07817883	chr1:32538562	TMEM39B	0.95	6.14	0.35	3.07e-9	Granulocyte percentage of myeloid white cells;
CESC	cis	rs2439831	1.000	rs2444029	chr15:43737484	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.81	11.86	0.59	2.71e-26	Lung cancer in ever smokers;
CESC	trans	rs11098499	0.874	rs13139045	chr4:120168588	T/C	cg25214090	chr10:38739885	LOC399744	0.61	8.16	0.45	1.34e-14	Corneal astigmatism;
CESC	cis	rs2832191	0.791	rs2065270	chr21:30485420	T/C	cg24692254	chr21:30365293	RNF160	-0.79	-12.51	-0.61	1.62e-28	Dental caries;
CESC	trans	rs11971186	0.765	rs1204526	chr7:126512514	C/T	cg10894441	chr11:111169905	C11orf92;C11orf93	-0.49	-6.26	-0.36	1.51e-9	Chemerin levels;
CESC	cis	rs7412746	0.658	rs11204723	chr1:150731618	T/C	cg17724175	chr1:150552817	MCL1	0.42	6.43	0.37	5.8e-10	Melanoma;
CESC	cis	rs1511802	0.666	rs2292424	chr4:187120625	G/A	cg24794857	chr4:187113578	CYP4V2	0.43	5.55	0.32	6.87e-8	Blood protein levels;
CESC	cis	rs4713118	0.621	rs10484403	chr6:28033523	A/G	cg19592336	chr6:28129416	ZNF389	0.55	7.35	0.41	2.39e-12	Parkinson's disease;
CESC	cis	rs2569991	0.541	rs2596905	chr3:12937672	A/C	cg22481960	chr3:13008800	IQSEC1	-0.55	-6.52	-0.37	3.47e-10	Periodontitis (DPAL);
CESC	cis	rs6750795	0.569	rs1667308	chr2:232406344	T/C	cg19187155	chr2:232395269	NMUR1	0.63	11.18	0.57	5.03e-24	Height;
CESC	cis	rs71277158	0.688	rs73879182	chr3:169879695	C/T	cg04067573	chr3:169899625	PHC3	0.71	7.07	0.4	1.39e-11	Prostate cancer;
CESC	cis	rs798554	0.634	rs6970963	chr7:2821271	C/T	cg09658497	chr7:2847517	GNA12	-0.36	-5.51	-0.32	8.41e-8	Height;
CESC	cis	rs7772486	0.875	rs6938972	chr6:146410608	G/A	cg05347473	chr6:146136440	FBXO30	0.51	6.68	0.38	1.37e-10	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg04342999	chr5:138629163	MATR3	0.48	6.49	0.37	4.13e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs66887589	0.967	rs1480933	chr4:120433248	C/T	cg09307838	chr4:120376055	NA	0.49	6.49	0.37	4.28e-10	Diastolic blood pressure;
CESC	cis	rs9815354	1.000	rs9866092	chr3:41895967	A/C	cg03022575	chr3:42003672	ULK4	0.45	5.23	0.31	3.48e-7	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs10504229	0.639	rs56066782	chr8:58105857	A/G	cg24829409	chr8:58192753	C8orf71	-0.56	-7.01	-0.4	1.97e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs9611565	0.546	rs5758430	chr22:42109844	G/T	cg06634786	chr22:41940651	POLR3H	0.66	6.76	0.38	8.7e-11	Vitiligo;
CESC	cis	rs7188697	0.882	rs9921370	chr16:58611935	C/A	cg21335942	chr16:58549945	SETD6	-0.45	-5.2	-0.3	4.06e-7	QT interval;
CESC	cis	rs853679	0.517	rs9380050	chr6:28048538	A/G	cg26335602	chr6:28129616	ZNF389	0.53	7.05	0.4	1.55e-11	Depression;
CESC	cis	rs7833986	0.501	rs2668007	chr8:56944111	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.54	6.23	0.36	1.79e-9	Height;
CESC	trans	rs7107217	1.000	rs1873872	chr11:129473993	A/T	cg04914231	chr16:30006637	INO80E;HIRIP3	0.45	6.08	0.35	4.2e-9	Breast cancer;Type 2 diabetes;
CESC	cis	rs6952808	1.000	rs6957894	chr7:1887362	G/A	cg21782813	chr7:2030301	MAD1L1	0.37	5.19	0.3	4.19e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs9911578	0.935	rs12948039	chr17:57045184	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.37	5.05	0.3	8.18e-7	Intelligence (multi-trait analysis);
CESC	cis	rs6460942	0.730	rs73053536	chr7:12323131	C/G	cg02935154	chr7:12443704	VWDE	-0.6	-5.72	-0.33	2.83e-8	Coronary artery disease;
CESC	cis	rs8072100	0.840	rs12453233	chr17:45454570	C/T	cg25173405	chr17:45401733	C17orf57	-0.43	-5.64	-0.33	4.46e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs9649213	0.593	rs3823740	chr7:97957104	T/G	cg21770322	chr7:97807741	LMTK2	0.57	8.72	0.47	3.09e-16	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7208859	0.623	rs216423	chr17:28942109	G/C	cg17105886	chr17:28927953	LRRC37B2	0.62	5.61	0.33	5.18e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs7116495	1.000	rs1939247	chr11:71740521	A/T	cg26138937	chr11:71823887	C11orf51	-0.79	-6.43	-0.37	5.96e-10	Severe influenza A (H1N1) infection;
CESC	cis	rs6500602	0.727	rs4786509	chr16:4568769	C/G	cg08645402	chr16:4508243	NA	-0.57	-9.43	-0.5	2.18e-18	Schizophrenia;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg06825833	chr13:111566802	ANKRD10	-0.48	-6.87	-0.39	4.58e-11	Gambling;
CESC	cis	rs2228479	1.000	rs11642267	chr16:89957635	T/C	cg00800038	chr16:89945340	TCF25	-0.94	-7.87	-0.44	9.24e-14	Skin colour saturation;
CESC	cis	rs6565180	1.000	rs8049108	chr16:30376486	A/G	cg17640201	chr16:30407289	ZNF48	-0.87	-14.27	-0.66	1.11e-34	Tonsillectomy;
CESC	cis	rs12579753	0.879	rs7131927	chr12:82166313	T/C	cg24719984	chr12:82153464	PPFIA2	-0.37	-5.35	-0.31	1.9e-7	Resting heart rate;
CESC	cis	rs875971	1.000	rs6961717	chr7:65587537	C/T	cg10691866	chr7:65817282	TPST1	0.34	5.54	0.32	7.19e-8	Aortic root size;
CESC	cis	rs8027181	0.839	rs998020	chr15:72999635	C/T	cg25632853	chr15:73088954	NA	0.29	5.05	0.3	8.32e-7	Triglyceride levels;
CESC	cis	rs6460942	1.000	rs73053531	chr7:12317474	T/C	cg20607287	chr7:12443886	VWDE	-0.79	-8.51	-0.46	1.32e-15	Coronary artery disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg17114200	chr7:4822807	KIAA0415	0.49	7.11	0.4	1.09e-11	Fibrinogen levels;
CESC	cis	rs2777491	0.789	rs316617	chr15:41795900	C/T	cg20272979	chr15:41787780	ITPKA	-0.47	-6.92	-0.39	3.38e-11	Ulcerative colitis;
CESC	cis	rs798554	0.644	rs1639040	chr7:2884116	G/T	cg18446336	chr7:2847575	GNA12	-0.35	-5.56	-0.32	6.7e-8	Height;
CESC	cis	rs736408	0.521	rs13074853	chr3:52779801	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	8.16	0.45	1.36e-14	Bipolar disorder;
CESC	cis	rs9660180	0.934	rs34849348	chr1:1762757	C/T	cg17747265	chr1:1875780	NA	-0.57	-9.25	-0.49	7.79e-18	Body mass index;
CESC	cis	rs17253792	0.822	rs9972180	chr14:56073732	G/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.79	5.91	0.34	1.06e-8	Putamen volume;
CESC	cis	rs4728302	0.869	rs6969899	chr7:133597490	A/G	cg10665199	chr7:133106180	EXOC4	0.41	5.71	0.33	3.03e-8	Intelligence;Intelligence (multi-trait analysis);
CESC	cis	rs74181299	0.964	rs1009358	chr2:65276452	C/T	cg05010058	chr2:65284262	CEP68	-0.3	-5.28	-0.31	2.74e-7	Pulse pressure;
CESC	cis	rs2075671	0.903	rs62483570	chr7:100300649	C/T	cg16850897	chr7:100343110	ZAN	-0.7	-8.74	-0.47	2.7e-16	Other erythrocyte phenotypes;
CESC	cis	rs1538970	1.000	rs4660852	chr1:45848931	A/C	cg03146154	chr1:46216737	IPP	-0.45	-5.48	-0.32	1.01e-7	Platelet count;
CESC	cis	rs7552404	0.731	rs61770552	chr1:76373050	T/C	cg03433033	chr1:76189801	ACADM	0.57	5.57	0.32	6.26e-8	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs11203032	1.000	rs17117124	chr10:90963997	C/G	cg16672925	chr10:90967113	CH25H	0.74	7.11	0.4	1.05e-11	Heart failure;
CESC	cis	rs9858542	0.953	rs3811697	chr3:49590770	C/T	cg07274523	chr3:49395745	GPX1	0.66	8.52	0.46	1.21e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs10504229	0.683	rs7460059	chr8:58111561	C/T	cg21724239	chr8:58056113	NA	0.58	5.93	0.34	9.45e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs3818285	0.504	rs1973972	chr10:111651133	A/T	cg00817464	chr10:111662876	XPNPEP1	0.52	7.29	0.41	3.51e-12	Superior crus of antihelix expression;
CESC	cis	rs1691799	0.899	rs1168358	chr12:66748664	A/G	cg16791601	chr12:66731901	HELB	-0.62	-10.14	-0.53	1.22e-20	White blood cell count (basophil);
CESC	cis	rs9916302	0.904	rs13341996	chr17:37536862	C/T	cg20243544	chr17:37824526	PNMT	-0.49	-6.24	-0.36	1.75e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs116095464	0.614	rs10061564	chr5:271329	T/C	cg10591111	chr5:226296	SDHA	-0.53	-6.39	-0.37	7.44e-10	Breast cancer;
CESC	cis	rs6540559	0.546	rs7551944	chr1:210029430	G/C	cg23283495	chr1:209979779	IRF6	0.5	5.08	0.3	6.99e-7	Cleft lip with or without cleft palate;
CESC	cis	rs853679	0.550	rs9295762	chr6:28155418	C/T	cg23161317	chr6:28129485	ZNF389	-0.41	-5.39	-0.31	1.58e-7	Depression;
CESC	cis	rs16854884	0.657	rs35085196	chr3:143712210	C/T	cg01302019	chr3:143689584	C3orf58	-0.34	-5.19	-0.3	4.14e-7	Economic and political preferences (feminism/equality);
CESC	cis	rs1707322	1.000	rs4641257	chr1:46353589	G/A	cg05343316	chr1:45956843	TESK2	0.44	5.55	0.32	7.05e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2836974	0.829	rs8128191	chr21:40527311	A/G	cg11890956	chr21:40555474	PSMG1	1.18	23.93	0.83	3.5e-68	Cognitive function;
CESC	cis	rs6430585	0.528	rs309154	chr2:136726567	C/T	cg07169764	chr2:136633963	MCM6	1.13	15.63	0.69	1.78e-39	Corneal structure;
CESC	cis	rs2130392	1.000	rs2130392	chr4:185639169	A/G	cg21366198	chr4:185655624	MLF1IP	-0.41	-6.0	-0.35	6.55e-9	Kawasaki disease;
CESC	cis	rs4689592	0.503	rs11937667	chr4:7057037	C/G	cg06697600	chr4:7070879	GRPEL1	0.51	6.11	0.35	3.49e-9	Monocyte percentage of white cells;
CESC	cis	rs1577917	0.958	rs13201730	chr6:86556647	T/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-6.14	-0.35	2.93e-9	Response to antipsychotic treatment;
CESC	cis	rs6598955	0.671	rs12139514	chr1:26575939	G/A	cg19743891	chr1:26644573	UBXN11;CD52	0.37	5.19	0.3	4.16e-7	Obesity-related traits;
CESC	cis	rs2842992	0.789	rs10945635	chr6:160214487	C/A	cg26839252	chr6:160211577	TCP1;MRPL18	0.44	5.05	0.3	8.32e-7	Age-related macular degeneration (geographic atrophy);
CESC	trans	rs2727020	0.619	rs1829979	chr11:49436875	T/G	cg03929089	chr4:120376271	NA	-0.68	-7.62	-0.42	4.63e-13	Coronary artery disease;
CESC	trans	rs11264799	0.716	rs1113662	chr1:157635825	T/C	cg22691776	chr3:15032403	NR2C2	0.33	6.21	0.36	2e-9	IgA nephropathy;
CESC	cis	rs875971	1.000	rs709597	chr7:65825983	A/G	cg12463550	chr7:65579703	CRCP	-0.54	-6.94	-0.39	2.92e-11	Aortic root size;
CESC	cis	rs6750795	0.765	rs6742387	chr2:232354832	G/T	cg19187155	chr2:232395269	NMUR1	0.62	10.27	0.53	4.87e-21	Height;
CESC	cis	rs2279817	1.000	rs10788681	chr1:18019524	C/A	cg21791023	chr1:18019539	ARHGEF10L	0.58	8.5	0.46	1.36e-15	Neuroticism;
CESC	cis	rs1048238	0.506	rs10927867	chr1:16177285	A/G	cg21385522	chr1:16154831	NA	0.43	5.41	0.32	1.4e-7	Systolic blood pressure;
CESC	cis	rs875971	0.522	rs709604	chr7:65497434	A/G	cg11987759	chr7:65425863	GUSB	0.46	6.29	0.36	1.29e-9	Aortic root size;
CESC	cis	rs1552244	0.882	rs67762674	chr3:10014485	C/T	cg00149659	chr3:10157352	C3orf10	0.71	8.29	0.45	5.55e-15	Alzheimer's disease;
CESC	cis	rs3096299	0.719	rs2965817	chr16:89513234	C/T	cg02187348	chr16:89574699	SPG7	0.63	8.85	0.48	1.25e-16	Multiple myeloma (IgH translocation);
CESC	cis	rs1552244	1.000	rs9809061	chr3:10085130	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.88	12.07	0.6	5.1e-27	Alzheimer's disease;
CESC	cis	rs35306767	0.715	rs11253550	chr10:1028288	C/G	cg25019033	chr10:957182	NA	-0.65	-6.53	-0.37	3.33e-10	Eosinophil percentage of granulocytes;
CESC	cis	rs9916302	0.861	rs11078912	chr17:37671490	A/G	cg20243544	chr17:37824526	PNMT	0.45	5.94	0.34	8.69e-9	Glomerular filtration rate (creatinine);
CESC	trans	rs61931739	0.500	rs11053210	chr12:34461771	A/G	cg26384229	chr12:38710491	ALG10B	-0.73	-10.18	-0.53	9.44e-21	Morning vs. evening chronotype;
CESC	cis	rs3135071	1.000	rs3135071	chr4:2406321	C/T	cg01601518	chr4:2404284	ZFYVE28	0.63	5.83	0.34	1.61e-8	Influenza A (H1N1) severity;
CESC	cis	rs1552244	0.515	rs67342818	chr3:10166406	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.68	-7.7	-0.43	2.64e-13	Alzheimer's disease;
CESC	cis	rs826838	0.935	rs11183940	chr12:38851642	A/G	cg13010199	chr12:38710504	ALG10B	0.6	8.53	0.46	1.18e-15	Heart rate;
CESC	cis	rs7255436	0.830	rs4350678	chr19:8447366	A/G	cg16745616	chr19:8428856	ANGPTL4	-0.37	-5.54	-0.32	7.2e-8	HDL cholesterol;
CESC	cis	rs875971	1.000	rs778685	chr7:65836176	G/T	cg11764359	chr7:65958608	NA	0.98	15.78	0.7	5.36e-40	Aortic root size;
CESC	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg09509183	chr1:209979624	IRF6	0.62	9.72	0.51	2.61e-19	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
CESC	cis	rs763121	0.925	rs1056661	chr22:39080245	A/G	cg14440974	chr22:39074834	NA	-0.35	-5.09	-0.3	6.78e-7	Menopause (age at onset);
CESC	cis	rs826838	0.935	rs11168761	chr12:38997211	C/A	cg26384229	chr12:38710491	ALG10B	0.83	14.62	0.67	6.88e-36	Heart rate;
CESC	cis	rs2276314	0.857	rs28379448	chr18:33604364	C/A	cg19628046	chr18:33552617	C18orf21	0.49	5.33	0.31	2.11e-7	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs6912958	0.754	rs7762864	chr6:88236213	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.55	-7.43	-0.42	1.46e-12	Monocyte percentage of white cells;
CESC	cis	rs17253792	0.822	rs118027213	chr14:56039076	T/C	cg01858014	chr14:56050164	KTN1	-0.99	-7.46	-0.42	1.21e-12	Putamen volume;
CESC	cis	rs2735413	0.781	rs11649473	chr16:78077238	C/T	cg04733911	chr16:78082701	NA	-0.53	-9.01	-0.48	4.08e-17	Systolic blood pressure (alcohol consumption interaction);
CESC	cis	rs300703	0.654	rs300771	chr2:117241	A/G	cg21211680	chr2:198530	NA	-0.99	-10.25	-0.53	5.38e-21	Blood protein levels;
CESC	cis	rs7772486	0.790	rs1062068	chr6:146207465	A/G	cg05347473	chr6:146136440	FBXO30	0.57	7.32	0.41	2.93e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7129220	0.512	rs11042666	chr11:10227393	A/T	cg01453529	chr11:10209919	SBF2	-0.46	-5.63	-0.33	4.63e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CESC	cis	rs1862618	0.853	rs9283717	chr5:56078659	G/A	cg24531977	chr5:56204891	C5orf35	-0.87	-11.09	-0.56	9.93e-24	Initial pursuit acceleration;
CESC	trans	rs7246657	0.943	rs8109632	chr19:37931125	A/T	cg01833234	chr11:6592585	DNHD1	0.52	6.0	0.35	6.5e-9	Coronary artery calcification;
CESC	cis	rs11958404	0.932	rs72816585	chr5:157433901	A/C	cg05962755	chr5:157440814	NA	0.62	6.56	0.37	2.74e-10	IgG glycosylation;
CESC	cis	rs9611565	0.512	rs4820444	chr22:42202606	A/G	cg03806693	chr22:41940476	POLR3H	1.13	13.53	0.64	4.53e-32	Vitiligo;
CESC	cis	rs4725617	0.686	rs4283960	chr7:143103380	C/T	cg03150622	chr7:143105826	EPHA1	0.63	5.44	0.32	1.21e-7	Blood protein levels;
CESC	cis	rs34779708	0.966	rs4934540	chr10:35474699	T/C	cg04310649	chr10:35416472	CREM	-0.52	-6.38	-0.37	7.67e-10	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs9790314	1.000	rs9870059	chr3:161017240	T/C	cg03342759	chr3:160939853	NMD3	-0.44	-5.77	-0.33	2.15e-8	Morning vs. evening chronotype;
CESC	cis	rs2228479	0.850	rs2238531	chr16:89856217	C/G	cg00800038	chr16:89945340	TCF25	-0.9	-7.5	-0.42	9.55e-13	Skin colour saturation;
CESC	cis	rs7666738	0.830	rs921521	chr4:98838339	A/G	cg17366294	chr4:99064904	C4orf37	0.52	7.03	0.4	1.75e-11	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1348850	0.801	rs11890163	chr2:178327134	G/A	cg23306229	chr2:178417860	TTC30B	0.72	6.02	0.35	5.72e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	trans	rs55704346	0.566	rs7661300	chr4:25385874	T/C	cg01822600	chr1:245751692	KIF26B	0.43	6.26	0.36	1.55e-9	Tonsillectomy;
CESC	cis	rs9322193	0.962	rs7745915	chr6:150155247	C/T	cg13206674	chr6:150067644	NUP43	0.42	5.87	0.34	1.32e-8	Lung cancer;
CESC	cis	rs4132509	1.000	rs4565696	chr1:243918083	C/T	cg21452805	chr1:244014465	NA	0.45	5.6	0.33	5.43e-8	RR interval (heart rate);
CESC	cis	rs2124969	0.548	rs62175391	chr2:161022588	A/G	cg03641300	chr2:160917029	PLA2R1	-0.58	-6.01	-0.35	6.14e-9	Waist circumference adjusted for body mass index;
CESC	cis	rs6831352	0.589	rs2924584	chr4:99988208	A/G	cg12011299	chr4:100065546	ADH4	0.75	11.75	0.59	6.04e-26	Alcohol dependence;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg17914881	chr12:121838395	RNF34	0.49	6.3	0.36	1.22e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs548181	0.736	rs540436	chr11:125512619	A/G	cg03464685	chr11:125439445	EI24	0.9	7.62	0.42	4.55e-13	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs3825932	0.961	rs11072815	chr15:79232319	C/T	cg25744700	chr15:79237217	CTSH	-0.48	-6.58	-0.37	2.48e-10	Type 1 diabetes;
CESC	cis	rs734999	0.588	rs3748819	chr1:2524966	C/T	cg20673091	chr1:2541236	MMEL1	0.43	7.01	0.4	1.97e-11	Ulcerative colitis;
CESC	cis	rs727505	0.865	rs10253613	chr7:124508929	G/A	cg23710748	chr7:124431027	NA	-0.48	-7.52	-0.42	8.73e-13	Lewy body disease;
CESC	cis	rs13088281	1.000	rs13088281	chr3:53147576	A/C	cg12962167	chr3:53033115	SFMBT1	-0.66	-5.96	-0.34	8.08e-9	Immune reponse to smallpox (secreted IL-2);
CESC	trans	rs3780486	0.522	rs1328898	chr9:33163271	A/G	cg20290983	chr6:43655470	MRPS18A	0.73	11.48	0.58	5.05e-25	IgG glycosylation;
CESC	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg26338869	chr17:61819248	STRADA	0.66	8.55	0.46	1.02e-15	Prudent dietary pattern;
CESC	cis	rs4555082	0.874	rs1008628	chr14:105722726	T/C	cg06808227	chr14:105710500	BRF1	-0.64	-7.65	-0.43	3.72e-13	Mean platelet volume;Platelet distribution width;
CESC	cis	rs12048904	0.647	rs7528268	chr1:101329295	A/G	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.64	7.51	0.42	9.22e-13	Multiple sclerosis;
CESC	cis	rs7296418	0.630	rs11608305	chr12:123791165	C/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.32	-5.14	-0.3	5.27e-7	Platelet count;
CESC	cis	rs1691799	0.899	rs903590	chr12:66745777	C/G	cg16791601	chr12:66731901	HELB	-0.62	-10.31	-0.53	3.66e-21	White blood cell count (basophil);
CESC	cis	rs1044826	0.642	rs295470	chr3:139213903	A/G	cg15131784	chr3:139108705	COPB2	0.41	5.07	0.3	7.34e-7	Obesity-related traits;
CESC	cis	rs11122272	0.735	rs973253	chr1:231520874	C/T	cg06096015	chr1:231504339	EGLN1	0.43	6.18	0.35	2.46e-9	Hemoglobin concentration;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05321656	chr10:69991522	ATOH7	-0.61	-7.29	-0.41	3.51e-12	Gut microbiome composition (summer);
CESC	cis	rs9811920	0.609	rs793501	chr3:99591638	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.59	7.22	0.41	5.61e-12	Axial length;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15163603	chr12:132403897	ULK1	-0.51	-6.69	-0.38	1.3e-10	Gut microbiome composition (summer);
CESC	trans	rs7922314	0.571	rs59286975	chr10:64736664	G/A	cg06935979	chr1:232941706	KIAA1383	-0.69	-6.41	-0.37	6.71e-10	Cutaneous psoriasis;
CESC	cis	rs9660992	0.710	rs1172111	chr1:205232980	C/T	cg21643547	chr1:205240462	TMCC2	-0.48	-6.81	-0.39	6.59e-11	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs8177179	0.967	rs4078166	chr3:133435979	C/A	cg18769074	chr3:133464867	TF	0.3	5.68	0.33	3.46e-8	Iron status biomarkers (transferrin levels);
CESC	cis	rs9733	0.715	rs12402006	chr1:150869829	G/A	cg18016565	chr1:150552671	MCL1	-0.33	-5.16	-0.3	4.95e-7	Tonsillectomy;
CESC	cis	rs2576037	0.899	rs2246877	chr18:44577005	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.58	7.65	0.43	3.74e-13	Personality dimensions;
CESC	cis	rs1577917	0.665	rs4304137	chr6:86217448	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.57	7.74	0.43	2.16e-13	Response to antipsychotic treatment;
CESC	cis	rs6540556	0.954	rs6685077	chr1:209933331	A/G	cg23920097	chr1:209922102	NA	-0.37	-5.54	-0.32	7.2e-8	Red blood cell count;
CESC	cis	rs4713118	0.662	rs464312	chr6:27967591	T/A	cg18032046	chr6:28092343	ZSCAN16	-0.55	-6.76	-0.38	8.6e-11	Parkinson's disease;
CESC	cis	rs8031584	0.678	rs8028173	chr15:31155749	A/G	cg14298792	chr15:30685198	CHRFAM7A	-0.46	-5.51	-0.32	8.35e-8	Huntington's disease progression;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg09058860	chr1:173837788	SNORD74;ZBTB37;GAS5	-0.45	-6.35	-0.36	9.46e-10	Asthma;
CESC	trans	rs12286929	0.651	rs12274772	chr11:115098768	C/T	cg20957193	chr16:75032774	ZNRF1	-0.55	-6.07	-0.35	4.46e-9	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs1218582	0.772	rs10908445	chr1:154849590	A/G	cg09359103	chr1:154839909	KCNN3	0.67	13.48	0.64	6.75e-32	Prostate cancer;
CESC	cis	rs2120019	1.000	rs2120019	chr15:75334184	T/C	cg09165964	chr15:75287851	SCAMP5	-0.78	-9.31	-0.5	5.02e-18	Blood trace element (Zn levels);
CESC	cis	rs7216064	0.700	rs4791295	chr17:65997317	G/A	cg07042672	chr17:66097459	LOC651250	-0.5	-5.59	-0.32	5.67e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs9325144	0.555	rs4882358	chr12:38726640	A/G	cg26384229	chr12:38710491	ALG10B	0.56	7.99	0.44	4.24e-14	Morning vs. evening chronotype;
CESC	cis	rs10911251	0.546	rs2147578	chr1:183107699	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.84	13.2	0.63	6.6e-31	Colorectal cancer;
CESC	cis	rs2836974	0.644	rs11088471	chr21:40699313	A/G	cg11890956	chr21:40555474	PSMG1	-0.93	-14.73	-0.67	2.85e-36	Cognitive function;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13150400	chr6:135819157	C6orf217;AHI1	0.55	6.31	0.36	1.15e-9	Gut microbiome composition (summer);
CESC	cis	rs9311474	0.507	rs4687644	chr3:52746541	T/G	cg18337363	chr3:52569053	NT5DC2	0.29	5.28	0.31	2.66e-7	Electroencephalogram traits;
CESC	cis	rs7246657	0.943	rs10415358	chr19:37808863	C/A	cg23950597	chr19:37808831	NA	-0.63	-6.45	-0.37	5.42e-10	Coronary artery calcification;
CESC	cis	rs12477438	0.765	rs12470471	chr2:99689141	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.63	8.61	0.47	6.57e-16	Chronic sinus infection;
CESC	cis	rs9733	0.628	rs7540874	chr1:150702663	A/C	cg09365446	chr1:150670422	GOLPH3L	0.42	5.84	0.34	1.55e-8	Tonsillectomy;
CESC	cis	rs6570726	0.935	rs419850	chr6:145827281	A/G	cg23711669	chr6:146136114	FBXO30	0.79	11.77	0.59	5.16e-26	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs3820068	0.705	rs41270255	chr1:15892980	G/A	cg18192808	chr1:15853278	DNAJC16	0.43	5.17	0.3	4.6e-7	Systolic blood pressure;
CESC	cis	rs73206853	0.764	rs67828368	chr12:110546298	C/T	cg12870014	chr12:110450643	ANKRD13A	0.62	5.32	0.31	2.16e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs11051970	0.513	rs4931013	chr12:32560722	C/A	cg24626660	chr12:32551988	NA	0.36	5.2	0.3	4.09e-7	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs1865760	0.566	rs9295686	chr6:26081983	G/C	cg16482183	chr6:26056742	HIST1H1C	0.38	5.11	0.3	6.19e-7	Height;
CESC	cis	rs8180040	0.522	rs749512	chr3:47035900	C/T	cg27129171	chr3:47204927	SETD2	-0.66	-9.25	-0.49	7.9e-18	Colorectal cancer;
CESC	cis	rs514406	0.861	rs1749907	chr1:53259658	C/T	cg16325326	chr1:53192061	ZYG11B	-0.88	-14.98	-0.68	3.69e-37	Monocyte count;
CESC	cis	rs72781680	1.000	rs72796337	chr2:24142957	G/A	cg08917208	chr2:24149416	ATAD2B	0.93	8.42	0.46	2.35e-15	Lymphocyte counts;
CESC	cis	rs10214930	0.697	rs10256550	chr7:27906927	A/C	cg05786569	chr7:27702416	HIBADH	0.46	5.43	0.32	1.3e-7	Hypospadias;
CESC	cis	rs9354308	0.903	rs9360158	chr6:66558164	C/T	cg07460842	chr6:66804631	NA	-0.47	-5.72	-0.33	2.81e-8	Metabolite levels;
CESC	cis	rs9914988	0.943	rs11651867	chr17:27147248	T/G	cg20469991	chr17:27169893	C17orf63	-0.48	-5.25	-0.31	3.18e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CESC	cis	rs477895	0.713	rs7952318	chr11:63961242	G/A	cg18225595	chr11:63971243	STIP1	0.53	5.51	0.32	8.36e-8	Mean platelet volume;
CESC	cis	rs13031619	0.615	rs4849974	chr2:3698865	C/G	cg19052272	chr2:3704530	ALLC	0.7	7.38	0.41	2.03e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg17287814	chr8:26149013	PPP2R2A	-0.46	-6.71	-0.38	1.2e-10	Gambling;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14580081	chr19:45873861	ERCC2	0.58	7.0	0.4	2.11e-11	Gut microbiome composition (summer);
CESC	cis	rs4595586	0.545	rs1303886	chr12:39366876	G/A	cg26384229	chr12:38710491	ALG10B	0.54	7.53	0.42	7.85e-13	Morning vs. evening chronotype;
CESC	cis	rs1218582	0.772	rs4845400	chr1:154872523	C/T	cg24250549	chr1:154909240	PMVK	0.74	11.09	0.56	1.01e-23	Prostate cancer;
CESC	cis	rs1707322	0.821	rs10749857	chr1:46248143	C/T	cg03146154	chr1:46216737	IPP	0.8	11.17	0.57	5.31e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2274273	0.837	rs8011329	chr14:55677255	G/A	cg04306507	chr14:55594613	LGALS3	0.3	5.9	0.34	1.09e-8	Protein biomarker;
CESC	trans	rs11098499	0.954	rs2389802	chr4:120325732	C/A	cg25214090	chr10:38739885	LOC399744	0.7	9.93	0.52	5.65e-20	Corneal astigmatism;
CESC	cis	rs7927771	0.832	rs7924485	chr11:47419129	A/G	cg18512352	chr11:47633146	NA	0.53	7.86	0.43	9.6e-14	Subjective well-being;
CESC	cis	rs28489187	0.683	rs11161607	chr1:85855855	T/C	cg16011679	chr1:85725395	C1orf52	0.53	6.17	0.35	2.49e-9	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg11354908	chr19:18255899	MAST3	0.48	6.25	0.36	1.65e-9	Fibrinogen levels;
CESC	cis	rs258892	0.842	rs10060065	chr5:72065830	T/C	cg21869765	chr5:72125136	TNPO1	-0.43	-5.35	-0.31	1.93e-7	Small cell lung carcinoma;
CESC	cis	rs7208859	0.623	rs73271872	chr17:29152228	C/G	cg19761014	chr17:28927070	LRRC37B2	0.74	6.03	0.35	5.43e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs12497850	0.931	rs7430198	chr3:48988760	T/C	cg03060546	chr3:49711283	APEH	0.5	6.05	0.35	4.94e-9	Parkinson's disease;
CESC	cis	rs7674212	0.539	rs6854709	chr4:104129786	A/G	cg16532752	chr4:104119610	CENPE	-0.4	-5.58	-0.32	6.05e-8	Type 2 diabetes;
CESC	cis	rs10088262	0.591	rs13270541	chr8:124794849	G/A	cg02993010	chr8:124780839	FAM91A1	-0.67	-8.55	-0.46	1.01e-15	Pancreatic cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02501984	chr12:133263946	POLE;PXMP2	0.56	6.72	0.38	1.08e-10	Gut microbiome composition (summer);
CESC	cis	rs9894429	0.752	rs7502883	chr17:79588557	T/C	cg21984481	chr17:79567631	NPLOC4	-0.58	-9.48	-0.5	1.5e-18	Eye color traits;
CESC	cis	rs7772486	0.719	rs702307	chr6:145993454	C/G	cg05347473	chr6:146136440	FBXO30	-0.55	-7.07	-0.4	1.41e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs11051970	0.559	rs73086036	chr12:32564585	C/T	cg24626660	chr12:32551988	NA	0.35	5.03	0.3	9.04e-7	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs6502050	0.799	rs6502078	chr17:80124364	G/A	cg23985595	chr17:80112537	CCDC57	-0.41	-6.57	-0.37	2.6200000000000003e-10	Life satisfaction;
CESC	cis	rs2404602	0.716	rs2164101	chr15:76749117	A/G	cg26408565	chr15:76604113	ETFA	-0.43	-6.25	-0.36	1.65e-9	Blood metabolite levels;
CESC	cis	rs4253772	0.530	rs11704350	chr22:46671507	C/T	cg10541313	chr22:46663664	TTC38	0.71	5.29	0.31	2.56e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs40363	0.729	rs6501176	chr16:3522197	A/G	cg21433313	chr16:3507492	NAT15	-0.5	-6.91	-0.39	3.68e-11	Tuberculosis;
CESC	cis	rs6120849	0.708	rs6087659	chr20:33606383	C/A	cg24642439	chr20:33292090	TP53INP2	0.68	6.76	0.38	8.82e-11	Protein C levels;
CESC	cis	rs2066819	1.000	rs80317430	chr12:56727705	G/A	cg26734620	chr12:56694298	CS	0.98	5.95	0.34	8.45e-9	Psoriasis vulgaris;
CESC	cis	rs62064224	0.546	rs1018866	chr17:30829664	A/C	cg25809561	chr17:30822961	MYO1D	0.64	9.05	0.49	3.17e-17	Schizophrenia;
CESC	cis	rs2777491	0.957	rs1757454	chr15:41777934	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.69	-10.64	-0.55	2.98e-22	Ulcerative colitis;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg04090604	chr21:46222557	UBE2G2	0.42	6.76	0.38	8.99e-11	Gambling;
CESC	cis	rs3749237	0.615	rs11130202	chr3:49566715	C/T	cg06212747	chr3:49208901	KLHDC8B	0.47	6.37	0.36	8.2e-10	Resting heart rate;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg13453711	chr1:212482804	PPP2R5A	-0.46	-6.14	-0.35	2.97e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs12134245	0.755	rs11164928	chr1:92012678	G/A	cg25838465	chr1:92012736	NA	-0.63	-9.72	-0.51	2.61e-19	Breast cancer;
CESC	cis	rs7267979	0.844	rs6083845	chr20:25388090	G/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.79	-14.65	-0.67	5.42e-36	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs2425143	1.000	rs10485510	chr20:34445164	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.66	5.72	0.33	2.88e-8	Blood protein levels;
CESC	cis	rs4727027	0.933	rs4725800	chr7:148862516	C/G	cg23583168	chr7:148888333	NA	-0.78	-11.33	-0.57	1.54e-24	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	trans	rs61931739	0.517	rs10772139	chr12:34186178	A/T	cg13010199	chr12:38710504	ALG10B	0.48	5.99	0.35	6.66e-9	Morning vs. evening chronotype;
CESC	cis	rs367943	0.698	rs12719164	chr5:112960802	A/C	cg12552261	chr5:112820674	MCC	0.45	5.8	0.34	1.88e-8	Type 2 diabetes;
CESC	cis	rs7829975	0.535	rs4841005	chr8:8501230	A/G	cg06636001	chr8:8085503	FLJ10661	-0.41	-5.28	-0.31	2.63e-7	Mood instability;
CESC	trans	rs801193	1.000	rs2286684	chr7:66129830	G/T	cg26939375	chr7:64535504	NA	-0.64	-8.57	-0.47	8.53e-16	Aortic root size;
CESC	cis	rs4665809	0.941	rs6735145	chr2:26270302	T/C	cg08470875	chr2:26401718	FAM59B	-0.48	-5.18	-0.3	4.31e-7	Gut microbiome composition (summer);
CESC	cis	rs10504229	1.000	rs77120900	chr8:58170368	C/T	cg22535103	chr8:58192502	C8orf71	-1.05	-12.98	-0.62	3.88e-30	Developmental language disorder (linguistic errors);
CESC	cis	rs9322193	0.923	rs10747276	chr6:150079875	G/A	cg09699651	chr6:150184138	LRP11	0.41	5.36	0.31	1.85e-7	Lung cancer;
CESC	cis	rs7914558	0.966	rs1890185	chr10:104748718	A/G	cg15744005	chr10:104629667	AS3MT	-0.34	-5.45	-0.32	1.18e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs9486719	0.843	rs3860231	chr6:97036563	G/A	cg06623918	chr6:96969491	KIAA0776	-0.88	-10.52	-0.54	7.14e-22	Migraine;Coronary artery disease;
CESC	cis	rs4665809	0.878	rs4665826	chr2:26367503	A/T	cg26314531	chr2:26401878	FAM59B	0.76	8.45	0.46	1.91e-15	Gut microbiome composition (summer);
CESC	cis	rs6500602	0.964	rs13335685	chr16:4469284	T/C	cg08645402	chr16:4508243	NA	0.4	5.99	0.35	6.9e-9	Schizophrenia;
CESC	cis	rs11792861	0.591	rs11791855	chr9:111684139	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.56	8.14	0.45	1.6e-14	Menarche (age at onset);
CESC	cis	rs1595825	0.891	rs73056840	chr2:198783466	C/A	cg10820045	chr2:198174542	NA	0.41	5.06	0.3	7.8e-7	Ulcerative colitis;
CESC	cis	rs9916302	0.904	rs8079355	chr17:37473018	G/A	cg19468946	chr17:37922297	IKZF3	0.4	5.13	0.3	5.56e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs1371867	0.875	rs1125706	chr8:101326739	T/A	cg11906718	chr8:101322791	RNF19A	0.54	6.89	0.39	4.05e-11	Atrioventricular conduction;
CESC	cis	rs854765	0.654	rs11078400	chr17:17757728	A/G	cg16928487	chr17:17741425	SREBF1	0.55	9.61	0.51	6.15e-19	Total body bone mineral density;
CESC	cis	rs35110281	0.774	rs162344	chr21:44954522	G/A	cg21573476	chr21:45109991	RRP1B	-0.39	-5.42	-0.32	1.37e-7	Mean corpuscular volume;
CESC	trans	rs853679	0.546	rs35353359	chr6:28324378	C/T	cg06606381	chr12:133084897	FBRSL1	-1.12	-8.6	-0.47	7.06e-16	Depression;
CESC	cis	rs6088580	0.660	rs6087592	chr20:33114503	A/G	cg24642439	chr20:33292090	TP53INP2	0.51	6.63	0.38	1.83e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs9486715	0.809	rs9486467	chr6:96971803	C/T	cg06623918	chr6:96969491	KIAA0776	0.96	14.96	0.68	4.24e-37	Headache;
CESC	cis	rs896854	0.654	rs13274945	chr8:95986626	C/T	cg09323728	chr8:95962352	TP53INP1	-0.41	-8.93	-0.48	7.13e-17	Type 2 diabetes;
CESC	cis	rs36051895	0.664	rs3780372	chr9:5097544	C/T	cg02405213	chr9:5042618	JAK2	-0.5	-6.18	-0.35	2.44e-9	Pediatric autoimmune diseases;
CESC	cis	rs9910055	0.502	rs1684662	chr17:42180822	T/A	cg19774624	chr17:42201019	HDAC5	0.58	7.92	0.44	6.47e-14	Total body bone mineral density;
CESC	cis	rs4689388	0.853	rs13108780	chr4:6294630	A/G	cg14416269	chr4:6271139	WFS1	0.46	7.76	0.43	1.79e-13	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs1005277	0.522	rs289645	chr10:37943642	T/C	cg25517755	chr10:38738941	LOC399744	-0.4	-5.16	-0.3	4.73e-7	Extrinsic epigenetic age acceleration;
CESC	cis	rs2304069	0.913	rs9324637	chr5:149390947	T/C	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.92	11.55	0.58	3e-25	HIV-1 control;
CESC	cis	rs748404	0.697	rs530683	chr15:43568999	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.61	-7.82	-0.43	1.29e-13	Lung cancer;
CESC	cis	rs1448094	0.506	rs61930640	chr12:86173333	T/C	cg02569458	chr12:86230093	RASSF9	0.55	7.96	0.44	5.13e-14	Major depressive disorder;
CESC	cis	rs736408	0.716	rs2239549	chr3:52823126	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.43	5.79	0.33	2.02e-8	Bipolar disorder;
CESC	cis	rs1451375	0.617	rs12671474	chr7:50591395	C/A	cg14593290	chr7:50529359	DDC	0.49	5.9	0.34	1.12e-8	Malaria;
CESC	cis	rs4595586	0.525	rs4441057	chr12:39420620	T/A	cg26384229	chr12:38710491	ALG10B	0.59	7.99	0.44	4.11e-14	Morning vs. evening chronotype;
CESC	cis	rs6963495	0.818	rs73190200	chr7:105165856	T/C	cg13798780	chr7:105162888	PUS7	0.78	8.06	0.44	2.68e-14	Bipolar disorder (body mass index interaction);
CESC	cis	rs938554	0.779	rs6449173	chr4:9966105	A/C	cg11266682	chr4:10021025	SLC2A9	-0.42	-5.72	-0.33	2.88e-8	Blood metabolite levels;
CESC	cis	rs4919087	1.000	rs11189122	chr10:99072595	G/A	cg25902810	chr10:99078978	FRAT1	0.72	10.54	0.54	6.22e-22	Monocyte count;
CESC	cis	rs9322193	0.923	rs11155683	chr6:150100477	T/C	cg05861140	chr6:150128134	PCMT1	-0.37	-5.3	-0.31	2.42e-7	Lung cancer;
CESC	cis	rs9311474	0.713	rs352168	chr3:52237970	C/T	cg15147215	chr3:52552868	STAB1	-0.3	-5.18	-0.3	4.5e-7	Electroencephalogram traits;
CESC	cis	rs4547160	0.962	rs12229749	chr12:63503447	C/T	cg26727693	chr12:63544175	AVPR1A	-0.35	-5.46	-0.32	1.12e-7	Morning vs. evening chronotype;
CESC	cis	rs6964587	1.000	rs7797369	chr7:91570615	C/A	cg17063962	chr7:91808500	NA	-0.57	-7.62	-0.42	4.53e-13	Breast cancer;
CESC	cis	rs10189230	1.000	rs10189230	chr2:222357961	T/A	cg14652038	chr2:222343519	EPHA4	0.35	7.05	0.4	1.59e-11	Urate levels in lean individuals;
CESC	cis	rs7917772	0.502	rs2296584	chr10:104244323	T/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.55	7.65	0.43	3.63e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs9457247	0.935	rs2757046	chr6:167374353	C/T	cg23791538	chr6:167370224	RNASET2	0.6	8.47	0.46	1.73e-15	Crohn's disease;
CESC	cis	rs11122272	0.705	rs2572260	chr1:231486189	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.51	-6.97	-0.39	2.52e-11	Hemoglobin concentration;
CESC	cis	rs2304069	0.779	rs245050	chr5:149346960	C/G	cg12661370	chr5:149340060	SLC26A2	-0.44	-5.13	-0.3	5.53e-7	HIV-1 control;
CESC	cis	rs2066819	1.000	rs79436528	chr12:56686997	C/T	cg26804944	chr12:56660921	COQ10A	-0.85	-5.19	-0.3	4.22e-7	Psoriasis vulgaris;
CESC	cis	rs10905065	0.866	rs10795547	chr10:5827074	A/G	cg11519256	chr10:5708881	ASB13	-0.41	-5.52	-0.32	8.1e-8	Menopause (age at onset);
CESC	cis	rs9303401	0.659	rs17222621	chr17:56695923	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.03	13.13	0.63	1.12e-30	Cognitive test performance;
CESC	cis	rs6933660	0.760	rs1825368	chr6:151775259	C/A	cg02564969	chr6:151773285	C6orf211;RMND1	0.62	8.49	0.46	1.47e-15	Menarche (age at onset);
CESC	cis	rs72627123	0.867	rs113257091	chr14:74461121	C/T	cg08255017	chr14:74727001	VSX2	0.61	5.06	0.3	7.74e-7	Morning vs. evening chronotype;
CESC	cis	rs9875589	0.628	rs62234602	chr3:14002170	A/G	cg19554555	chr3:13937349	NA	0.46	5.42	0.32	1.36e-7	Ovarian reserve;
CESC	cis	rs9811920	0.770	rs4928237	chr3:99731330	A/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.48	-7.99	-0.44	4.15e-14	Axial length;
CESC	cis	rs796364	0.951	rs2881593	chr2:201000347	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.57	-5.83	-0.34	1.57e-8	Schizophrenia;
CESC	cis	rs1832871	0.711	rs9459904	chr6:158700982	C/T	cg07165851	chr6:158734300	TULP4	0.6	6.45	0.37	5.23e-10	Height;
CESC	cis	rs4862750	0.832	rs6836076	chr4:187899660	A/C	cg22105103	chr4:187893119	NA	0.51	7.69	0.43	2.88e-13	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs977987	0.843	rs59155720	chr16:75483806	A/G	cg03315344	chr16:75512273	CHST6	0.43	6.18	0.36	2.37e-9	Dupuytren's disease;
CESC	cis	rs861020	1.000	rs861020	chr1:209977111	A/G	cg05527609	chr1:210001259	C1orf107	1.05	13.15	0.63	1e-30	Orofacial clefts;
CESC	cis	rs10461617	0.541	rs860581	chr5:56150537	A/G	cg18230493	chr5:56204884	C5orf35	-0.64	-6.0	-0.35	6.38e-9	Type 2 diabetes;
CESC	cis	rs138857	0.515	rs9616375	chr22:50310600	G/A	cg02269571	chr22:50332266	NA	-0.7	-6.85	-0.39	5.18e-11	Mean platelet volume;
CESC	cis	rs875971	1.000	rs55962648	chr7:65625751	C/G	cg10691866	chr7:65817282	TPST1	0.33	5.51	0.32	8.45e-8	Aortic root size;
CESC	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg21782813	chr7:2030301	MAD1L1	0.44	6.16	0.35	2.7e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg24642844	chr7:1081250	C7orf50	-0.75	-9.1	-0.49	2.29e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs12464559	0.522	rs4414677	chr2:152624932	A/C	cg01189475	chr2:152685088	ARL5A	-0.65	-6.26	-0.36	1.56e-9	Response to cognitive-behavioural therapy in anxiety disorder;
CESC	cis	rs4665809	1.000	rs4665823	chr2:26312723	A/G	cg25036284	chr2:26402008	FAM59B	-0.59	-6.84	-0.39	5.35e-11	Gut microbiome composition (summer);
CESC	trans	rs11098499	0.863	rs1480936	chr4:120462861	C/T	cg25214090	chr10:38739885	LOC399744	0.67	9.26	0.49	7.17e-18	Corneal astigmatism;
CESC	cis	rs2204008	0.837	rs12581130	chr12:38319387	A/G	cg13010199	chr12:38710504	ALG10B	0.42	5.29	0.31	2.51e-7	Bladder cancer;
CESC	cis	rs2576037	0.583	rs644731	chr18:44426877	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.78	13.27	0.63	3.73e-31	Personality dimensions;
CESC	cis	rs9910055	0.659	rs2251165	chr17:42234748	T/C	cg19774624	chr17:42201019	HDAC5	-0.84	-13.28	-0.63	3.4e-31	Total body bone mineral density;
CESC	cis	rs10751667	0.666	rs10902255	chr11:967268	T/C	cg06064525	chr11:970664	AP2A2	-0.48	-9.29	-0.5	5.99e-18	Alzheimer's disease (late onset);
CESC	cis	rs9858542	0.953	rs9878943	chr3:49434654	G/A	cg03060546	chr3:49711283	APEH	-0.54	-6.16	-0.35	2.67e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs6963495	0.745	rs73192150	chr7:105211610	A/C	cg19920283	chr7:105172520	RINT1	0.7	6.36	0.36	8.94e-10	Bipolar disorder (body mass index interaction);
CESC	cis	rs6121246	0.511	rs879982	chr20:30398510	A/G	cg13852791	chr20:30311386	BCL2L1	0.87	11.25	0.57	2.82e-24	Mean corpuscular hemoglobin;
CESC	cis	rs3820928	0.874	rs6740108	chr2:227889559	G/T	cg05526886	chr2:227700861	RHBDD1	0.46	5.95	0.34	8.43e-9	Pulmonary function;
CESC	cis	rs875971	0.508	rs10253883	chr7:66061138	T/C	cg18876405	chr7:65276391	NA	-0.54	-7.7	-0.43	2.66e-13	Aortic root size;
CESC	cis	rs8077889	1.000	rs59044152	chr17:41888747	A/G	cg26893861	chr17:41843967	DUSP3	0.82	9.6	0.51	6.18e-19	Triglycerides;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg20058270	chr6:43149950	CUL9	-0.51	-6.76	-0.38	8.79e-11	Ulcerative colitis;
CESC	trans	rs7246657	0.943	rs8109632	chr19:37931125	A/T	cg24637308	chr11:6592297	DNHD1	0.54	6.34	0.36	1.01e-9	Coronary artery calcification;
CESC	cis	rs2303759	0.709	rs7256363	chr19:49827804	C/T	cg22590775	chr19:49891494	CCDC155	0.45	5.04	0.3	8.62e-7	Multiple sclerosis;
CESC	trans	rs12356475	0.710	rs10822686	chr10:67733250	C/T	cg23001456	chr17:2615074	KIAA0664	0.58	6.58	0.37	2.5e-10	Psoriatic arthritis;
CESC	cis	rs2280018	0.963	rs4985147	chr16:15168760	T/C	cg07549590	chr16:15018862	NA	-0.48	-7.78	-0.43	1.6e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs7267979	0.966	rs3827014	chr20:25371559	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.88	-18.23	-0.75	1.11e-48	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs8070128	0.637	rs4925133	chr17:17884801	A/G	cg04398451	chr17:18023971	MYO15A	-0.6	-8.32	-0.46	4.64e-15	Total body bone mineral density;
CESC	cis	rs4689592	0.546	rs10937782	chr4:7057106	G/C	cg19539972	chr4:7069911	GRPEL1	0.8	10.59	0.55	4.49e-22	Monocyte percentage of white cells;
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg18632527	chr7:6120830	NA	-0.46	-6.66	-0.38	1.56e-10	Vertical cup-disc ratio;
CESC	cis	rs2046867	0.818	rs34582798	chr3:72882778	A/C	cg25664220	chr3:72788482	NA	-0.47	-6.51	-0.37	3.72e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CESC	trans	rs681383	1.000	rs57486401	chr18:8331377	T/G	cg27042584	chr16:51168485	NA	0.49	5.99	0.35	6.68e-9	Sitting height ratio;
CESC	cis	rs10200159	1.000	rs111707510	chr2:55824236	T/C	cg13617705	chr2:55845095	SMEK2	0.68	5.13	0.3	5.67e-7	Vitiligo;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25964517	chr4:78034545	NA	-0.54	-6.55	-0.37	3.02e-10	Gut microbiome composition (summer);
CESC	cis	rs9346455	1.000	rs9364153	chr6:72012064	G/A	cg27238071	chr6:71998145	OGFRL1	0.62	5.52	0.32	8.14e-8	Antipsychotic drug-induced weight gain (time interaction);Antipsychotic drug-induced weight gain;
CESC	cis	rs28374715	0.662	rs28382348	chr15:41487934	G/C	cg18705301	chr15:41695430	NDUFAF1	-0.8	-10.46	-0.54	1.15e-21	Ulcerative colitis;
CESC	cis	rs2439831	1.000	rs2439831	chr15:43784475	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.87	9.86	0.52	9.94e-20	Lung cancer in ever smokers;
CESC	cis	rs6502050	0.835	rs35857672	chr17:80078303	G/A	cg11859384	chr17:80120422	CCDC57	0.38	5.16	0.3	4.82e-7	Life satisfaction;
CESC	cis	rs72781680	0.664	rs2712076	chr2:23993366	T/C	cg08917208	chr2:24149416	ATAD2B	0.6	5.91	0.34	1.04e-8	Lymphocyte counts;
CESC	cis	rs11674184	0.659	rs11679605	chr2:11722468	G/A	cg07314298	chr2:11723111	GREB1	-0.62	-9.02	-0.48	3.9e-17	Endometriosis;
CESC	cis	rs9863	0.828	rs4765562	chr12:124472571	T/C	cg17562584	chr12:124393655	DNAH10	0.32	5.47	0.32	1.04e-7	White blood cell count;
CESC	cis	rs1580019	0.883	rs6945294	chr7:32472099	G/A	cg06627557	chr7:32535165	LSM5;AVL9	0.84	11.42	0.57	8.06e-25	Cognitive ability;
CESC	cis	rs34779708	0.801	rs34592588	chr10:35540134	A/G	cg04310649	chr10:35416472	CREM	-0.47	-5.38	-0.31	1.67e-7	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs9291683	0.609	rs4622999	chr4:10003395	C/G	cg02734326	chr4:10020555	SLC2A9	0.47	6.67	0.38	1.52e-10	Bone mineral density;
CESC	cis	rs6952808	0.594	rs3778964	chr7:2138109	C/T	cg23048001	chr7:2026167	MAD1L1	0.45	5.76	0.33	2.33e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs853679	0.546	rs200954	chr6:27838764	C/G	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.86	7.61	0.42	4.8e-13	Depression;
CESC	cis	rs2836974	0.831	rs4375956	chr21:40521788	G/A	cg17971929	chr21:40555470	PSMG1	1.02	14.69	0.67	3.69e-36	Cognitive function;
CESC	cis	rs4665809	0.793	rs6546715	chr2:26261520	G/A	cg25036284	chr2:26402008	FAM59B	-0.57	-6.54	-0.37	3.12e-10	Gut microbiome composition (summer);
CESC	cis	rs7772486	0.790	rs7742333	chr6:146159029	A/G	cg23711669	chr6:146136114	FBXO30	-0.95	-13.88	-0.65	2.7e-33	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7267979	1.000	rs6050632	chr20:25432601	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.87	18.11	0.74	3e-48	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs12249377	0.519	rs10881838	chr10:92590233	A/G	cg14313238	chr10:92632228	RPP30	0.43	5.22	0.31	3.56e-7	White matter microstructure (global fractional anisotropy);
CESC	cis	rs9311474	0.713	rs352169	chr3:52236762	C/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.29	5.35	0.31	1.87e-7	Electroencephalogram traits;
CESC	cis	rs617791	0.508	rs10791837	chr11:65774596	C/T	cg04055107	chr11:65626734	MUS81;CFL1	-0.46	-5.28	-0.31	2.65e-7	Breast cancer;
CESC	cis	rs9322193	0.923	rs9800614	chr6:149965740	G/A	cg04369109	chr6:150039330	LATS1	-0.37	-5.05	-0.3	8.32e-7	Lung cancer;
CESC	cis	rs2732480	0.500	rs2450991	chr12:48651621	A/G	cg24011408	chr12:48396354	COL2A1	0.44	6.22	0.36	1.95e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs7914558	1.000	rs7067970	chr10:104913870	C/T	cg04362960	chr10:104952993	NT5C2	0.45	5.89	0.34	1.19e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs9479482	1.000	rs5017316	chr6:150333489	A/T	cg03788504	chr6:150331562	NA	-0.35	-6.91	-0.39	3.55e-11	Alopecia areata;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01166564	chr2:26987492	C2orf18	0.6	6.59	0.38	2.39e-10	Gut microbiome composition (summer);
CESC	trans	rs9300039	0.522	rs75135849	chr11:41964746	T/C	cg09735851	chr15:40615289	NA	-0.7	-6.05	-0.35	5.04e-9	Type 2 diabetes;
CESC	cis	rs4689388	0.816	rs13147655	chr4:6293474	A/G	cg00701064	chr4:6280414	WFS1	0.68	11.71	0.58	8.68e-26	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs6547741	1.000	rs6756238	chr2:27841305	G/A	cg21248554	chr2:27665150	KRTCAP3	0.25	5.06	0.3	7.8e-7	Oral cavity cancer;
CESC	cis	rs2836974	0.644	rs1882779	chr21:40690938	T/C	cg11890956	chr21:40555474	PSMG1	-0.9	-14.22	-0.66	1.78e-34	Cognitive function;
CESC	cis	rs57506017	0.585	rs3173615	chr7:12269417	C/G	cg23422036	chr7:12250390	TMEM106B	0.38	5.13	0.3	5.58e-7	Neuroticism;
CESC	cis	rs10751667	0.621	rs7396107	chr11:970029	C/T	cg20946044	chr11:1010712	AP2A2	-0.39	-5.4	-0.31	1.47e-7	Alzheimer's disease (late onset);
CESC	cis	rs10851478	0.872	rs12907918	chr15:49816682	G/A	cg08060515	chr15:49448048	GALK2;COPS2	0.42	5.19	0.3	4.12e-7	Oral cavity cancer;
CESC	cis	rs7809950	1.000	rs2250414	chr7:107140987	T/G	cg23024343	chr7:107201750	COG5	-0.42	-5.91	-0.34	1.05e-8	Coronary artery disease;
CESC	cis	rs2576037	0.583	rs9960463	chr18:44522808	T/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.35	5.51	0.32	8.56e-8	Personality dimensions;
CESC	trans	rs10489896	0.541	rs66638830	chr1:234591064	T/G	cg23817893	chr11:86085932	CCDC81	-0.45	-6.2	-0.36	2.14e-9	Cognitive test performance;
CESC	cis	rs644799	0.710	rs1852535	chr11:95501241	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.8	11.91	0.59	1.72e-26	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs4450798	0.793	rs9882340	chr3:13755427	G/C	cg23332027	chr3:13681764	NA	0.42	5.65	0.33	4.2e-8	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs7937682	0.889	rs578022	chr11:111490552	G/T	cg22437258	chr11:111473054	SIK2	0.72	9.66	0.51	4.24e-19	Primary sclerosing cholangitis;
CESC	cis	rs6570726	0.935	rs432086	chr6:145841593	C/T	cg05347473	chr6:146136440	FBXO30	-0.49	-6.65	-0.38	1.68e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6456156	0.526	rs3093025	chr6:167532731	A/G	cg07741184	chr6:167504864	NA	-0.32	-5.54	-0.32	7.23e-8	Primary biliary cholangitis;
CESC	trans	rs5769765	0.862	rs9616381	chr22:50312382	G/A	cg09872104	chr7:134855509	C7orf49	-0.55	-6.27	-0.36	1.47e-9	Schizophrenia;
CESC	cis	rs863345	0.967	rs1418846	chr1:158484285	A/C	cg12129480	chr1:158549410	OR10X1	-0.3	-5.87	-0.34	1.28e-8	Pneumococcal bacteremia;
CESC	cis	rs78889164	1.000	rs7255274	chr19:33859589	A/G	cg02272751	chr19:33882848	PEPD	0.5	6.8	0.39	6.92e-11	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs2018683	0.899	rs10479816	chr7:28978021	G/A	cg19402173	chr7:128379420	CALU	-0.54	-7.22	-0.41	5.44e-12	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CESC	trans	rs1814175	0.935	rs11040438	chr11:49622521	G/A	cg15704280	chr7:45808275	SEPT13	-1.0	-17.77	-0.74	4.61e-47	Height;
CESC	cis	rs2625529	0.590	rs12442886	chr15:72473611	T/C	cg16672083	chr15:72433130	SENP8	0.42	6.09	0.35	3.86e-9	Red blood cell count;
CESC	cis	rs73206853	0.764	rs73191817	chr12:110918673	G/A	cg12870014	chr12:110450643	ANKRD13A	0.65	5.59	0.32	5.78e-8	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs694739	0.595	rs11542299	chr11:64138805	T/C	cg23796481	chr11:64053134	BAD;GPR137	0.59	7.17	0.4	7.64e-12	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CESC	cis	rs9768139	0.733	rs921617	chr7:158118198	A/G	cg06219351	chr7:158114137	PTPRN2	-0.5	-7.84	-0.43	1.1e-13	Calcium levels;
CESC	cis	rs9902453	0.967	rs56129908	chr17:28421382	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	7.93	0.44	6.25e-14	Coffee consumption (cups per day);
CESC	cis	rs2109514	1.000	rs4727833	chr7:116147908	C/G	cg12739419	chr7:116140593	CAV2	-0.36	-6.62	-0.38	2.02e-10	Prevalent atrial fibrillation;
CESC	cis	rs7589728	0.563	rs78168096	chr2:88473575	G/A	cg04511125	chr2:88470314	THNSL2	0.71	6.72	0.38	1.13e-10	Plasma clusterin levels;
CESC	cis	rs7208859	0.623	rs1054397	chr17:29110196	T/C	cg19761014	chr17:28927070	LRRC37B2	0.76	6.24	0.36	1.76e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs9815354	0.812	rs59873855	chr3:41929538	T/C	cg03022575	chr3:42003672	ULK4	0.63	5.98	0.34	7.35e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs4730250	0.654	rs6947857	chr7:106787266	T/G	cg02696742	chr7:106810147	HBP1	0.56	5.3	0.31	2.45e-7	Osteoarthritis;
CESC	cis	rs9611565	0.559	rs132771	chr22:42025350	A/G	cg06481639	chr22:41940642	POLR3H	0.57	5.97	0.34	7.74e-9	Vitiligo;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00872270	chr16:3190814	ZNF213	-0.54	-6.24	-0.36	1.68e-9	Gut microbiome composition (summer);
CESC	cis	rs1799949	0.536	rs4793227	chr17:41412250	A/C	cg05368731	chr17:41323189	NBR1	0.62	8.58	0.47	8.33e-16	Menopause (age at onset);
CESC	cis	rs10781543	0.839	rs4379550	chr9:139376426	C/T	cg14169450	chr9:139327907	INPP5E	-0.5	-7.71	-0.43	2.59e-13	Monocyte percentage of white cells;
CESC	cis	rs8013055	0.846	rs10139300	chr14:105974501	A/G	cg23356831	chr14:105996513	TMEM121	0.37	5.14	0.3	5.23e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
CESC	cis	rs7592578	0.882	rs16832765	chr2:191468762	T/C	cg27211696	chr2:191398769	TMEM194B	-0.61	-5.32	-0.31	2.25e-7	Diastolic blood pressure;
CESC	cis	rs7264396	0.563	rs2425137	chr20:34345396	G/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.65	7.05	0.4	1.58e-11	Total cholesterol levels;
CESC	cis	rs3820068	0.705	rs16851731	chr1:15860240	A/G	cg17385448	chr1:15911702	AGMAT	0.36	5.61	0.33	5.03e-8	Systolic blood pressure;
CESC	cis	rs977987	0.843	rs67409275	chr16:75457212	T/C	cg03315344	chr16:75512273	CHST6	0.41	5.98	0.34	7.31e-9	Dupuytren's disease;
CESC	cis	rs7640424	0.649	rs35876429	chr3:107928557	C/T	cg09227934	chr3:107805635	CD47	-0.45	-5.82	-0.34	1.66e-8	Body mass index;
CESC	cis	rs4629180	1.000	rs974374	chr2:102105846	C/T	cg01388757	chr2:102091195	RFX8	0.44	6.83	0.39	5.91e-11	Chronic rhinosinusitis with nasal polyps;
CESC	cis	rs9322193	0.923	rs9767309	chr6:150037943	A/G	cg04369109	chr6:150039330	LATS1	-0.39	-5.43	-0.32	1.28e-7	Lung cancer;
CESC	cis	rs2439831	0.717	rs10518820	chr15:43888976	G/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.72	6.32	0.36	1.1e-9	Lung cancer in ever smokers;
CESC	cis	rs2404602	0.716	rs12902174	chr15:76863540	T/C	cg22467129	chr15:76604101	ETFA	-0.35	-5.24	-0.31	3.24e-7	Blood metabolite levels;
CESC	cis	rs933688	0.502	rs4916858	chr5:90601290	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	-0.44	-5.55	-0.32	6.76e-8	Smoking behavior;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg01187952	chr3:63850081	THOC7;ATXN7	0.44	6.29	0.36	1.31e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs2243480	1.000	rs4718269	chr7:65200778	C/G	cg18252515	chr7:66147081	NA	1.17	11.11	0.56	8.37e-24	Diabetic kidney disease;
CESC	cis	rs3767633	0.764	rs6687226	chr1:161891556	G/T	cg09175582	chr1:161736000	ATF6	-0.78	-5.35	-0.31	1.9e-7	IgG glycosylation;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg21551704	chr5:80550860	RNU5E;RNU5D;CKMT2	0.48	6.68	0.38	1.37e-10	Fibrinogen levels;
CESC	cis	rs35306767	0.859	rs11817793	chr10:878895	C/T	cg20503657	chr10:835505	NA	0.77	7.75	0.43	1.93e-13	Eosinophil percentage of granulocytes;
CESC	cis	rs6762	0.719	rs1130698	chr11:838542	C/T	cg23754390	chr11:835074	CD151	0.33	5.9	0.34	1.1e-8	Mean platelet volume;
CESC	cis	rs7872515	1.000	rs7872515	chr9:94822540	A/G	cg01248375	chr9:94877805	SPTLC1	-0.6	-6.11	-0.35	3.52e-9	Bipolar disorder and schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24088639	chr11:34937564	PDHX;APIP	0.57	6.04	0.35	5.18e-9	Gut microbiome composition (summer);
CESC	cis	rs7618915	0.547	rs11130317	chr3:52731483	C/T	cg17372223	chr3:52568218	NT5DC2	0.44	6.62	0.38	1.95e-10	Bipolar disorder;
CESC	cis	rs7809799	1.000	rs4454228	chr7:98753158	A/G	cg05967295	chr7:98741636	SMURF1	-0.72	-5.32	-0.31	2.25e-7	Ulcerative colitis;
CESC	cis	rs6570726	0.764	rs76635693	chr6:145834070	T/C	cg05347473	chr6:146136440	FBXO30	0.59	7.56	0.42	6.43e-13	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4665809	0.590	rs2303892	chr2:26461733	C/G	cg04944784	chr2:26401820	FAM59B	0.96	10.5	0.54	8.76e-22	Gut microbiome composition (summer);
CESC	cis	rs1552244	1.000	rs7619340	chr3:10108178	C/T	cg00166722	chr3:10149974	C3orf24	0.53	6.65	0.38	1.64e-10	Alzheimer's disease;
CESC	cis	rs9443189	0.527	rs775059	chr6:76370130	G/T	cg01950844	chr6:76311363	SENP6	0.87	9.27	0.49	6.59e-18	Prostate cancer;
CESC	cis	rs35306767	0.761	rs12359796	chr10:1021479	G/C	cg25019033	chr10:957182	NA	-0.65	-6.53	-0.37	3.28e-10	Eosinophil percentage of granulocytes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20449833	chr2:46770299	RHOQ	0.55	6.11	0.35	3.46e-9	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.830	rs6852015	chr4:99054373	C/A	cg03676636	chr4:99064102	C4orf37	0.33	5.12	0.3	5.93e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1153858	1.000	rs1346268	chr15:45673029	T/C	cg21132104	chr15:45694354	SPATA5L1	0.86	11.62	0.58	1.67e-25	Homoarginine levels;
CESC	cis	rs748404	0.660	rs2444251	chr15:43788595	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	8.21	0.45	9.59e-15	Lung cancer;
CESC	cis	rs11190604	1.000	rs4604805	chr10:102261409	C/G	cg07080220	chr10:102295463	HIF1AN	0.61	6.25	0.36	1.6e-9	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs72848980	0.512	rs11191749	chr10:105378840	A/G	cg00126946	chr10:105363258	SH3PXD2A	0.6	8.52	0.46	1.2e-15	White matter hyperintensity burden;
CESC	cis	rs4409675	0.576	rs1474908	chr1:28213213	C/T	cg23691781	chr1:28212827	C1orf38	-0.26	-5.07	-0.3	7.31e-7	Corneal astigmatism;
CESC	cis	rs4555082	0.718	rs2816619	chr14:105732551	G/C	cg06808227	chr14:105710500	BRF1	-0.56	-6.2	-0.36	2.18e-9	Mean platelet volume;Platelet distribution width;
CESC	cis	rs2425143	1.000	rs2425143	chr20:34350666	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.72	6.81	0.39	6.58e-11	Blood protein levels;
CESC	cis	rs4423214	1.000	rs12789751	chr11:71164471	G/A	cg05163923	chr11:71159392	DHCR7	0.76	10.16	0.53	1.05e-20	Vitamin D levels;
CESC	cis	rs2865126	0.743	rs10502403	chr18:10749140	T/C	cg21165219	chr18:10698044	FAM38B	-0.51	-5.16	-0.3	4.83e-7	Metabolite levels (5-HIAA/ MHPG Ratio);
CESC	cis	rs611744	0.870	rs613179	chr8:109166006	G/A	cg21045802	chr8:109455806	TTC35	0.45	5.49	0.32	9.39e-8	Dupuytren's disease;
CESC	cis	rs2880765	0.743	rs6497194	chr15:86014116	C/T	cg10818794	chr15:86012489	AKAP13	-0.34	-5.32	-0.31	2.25e-7	Coronary artery disease;
CESC	cis	rs4970988	0.556	rs6695123	chr1:150563483	T/C	cg04414720	chr1:150670196	GOLPH3L	-0.45	-5.7	-0.33	3.23e-8	Urate levels;
CESC	trans	rs11250098	0.574	rs4240672	chr8:10767917	G/A	cg15556689	chr8:8085844	FLJ10661	-0.54	-6.67	-0.38	1.5e-10	Morning vs. evening chronotype;
CESC	cis	rs6920965	0.507	rs12203025	chr6:126192034	C/T	cg05901451	chr6:126070800	HEY2	-0.41	-5.29	-0.31	2.52e-7	High light scatter reticulocyte count;
CESC	trans	rs208520	0.802	rs1342959	chr6:66883329	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.92	-11.49	-0.58	4.62e-25	Exhaled nitric oxide output;
CESC	trans	rs2115172	0.836	rs4835799	chr5:122762229	A/G	cg03115081	chr17:74722049	C17orf95;JMJD6	0.44	6.11	0.35	3.49e-9	Weight;
CESC	cis	rs9522267	0.535	rs7323631	chr13:112232269	A/G	cg10483660	chr13:112241077	NA	-0.33	-5.83	-0.34	1.65e-8	Hepatitis;
CESC	cis	rs3762637	1.000	rs55853677	chr3:122140616	G/A	cg24169773	chr3:122142474	KPNA1	-0.52	-6.24	-0.36	1.72e-9	LDL cholesterol levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21986422	chr20:44519582	CTSA;NEURL2	0.54	6.52	0.37	3.61e-10	Gut microbiome composition (summer);
CESC	cis	rs796364	0.806	rs11674293	chr2:201026743	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.78	-6.71	-0.38	1.2e-10	Schizophrenia;
CESC	cis	rs4727963	0.846	rs11765455	chr7:122736081	C/T	cg03640110	chr7:122635026	TAS2R16	-0.36	-5.42	-0.32	1.32e-7	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
CESC	cis	rs4523957	0.583	rs2641437	chr17:2019158	G/A	cg16513277	chr17:2031491	SMG6	-0.69	-9.54	-0.51	9.69e-19	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs2342371	0.565	rs13084212	chr3:196212211	G/T	cg15048948	chr3:196158458	UBXN7	-0.39	-5.5	-0.32	9.12e-8	Fat distribution (HIV);
CESC	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg06873352	chr17:61820015	STRADA	0.72	12.81	0.62	1.48e-29	Prudent dietary pattern;
CESC	cis	rs56399783	0.901	rs73033408	chr7:2879755	C/T	cg19731401	chr7:2775893	GNA12	0.63	5.31	0.31	2.34e-7	Childhood ear infection;
CESC	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg14338887	chr6:42928500	GNMT	0.35	5.09	0.3	6.83e-7	Alzheimer's disease in APOE e4+ carriers;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09975659	chr16:88050166	BANP	-0.6	-6.97	-0.39	2.58e-11	Gut microbiome composition (summer);
CESC	cis	rs2243480	1.000	rs462853	chr7:65558167	G/C	cg13147721	chr7:65941812	NA	-0.98	-9.11	-0.49	2.06e-17	Diabetic kidney disease;
CESC	trans	rs8073060	0.544	rs225258	chr17:33956883	C/T	cg19694781	chr19:47549865	TMEM160	-0.71	-7.25	-0.41	4.54e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	cis	rs910316	0.763	rs4556	chr14:75476071	G/C	cg08847533	chr14:75593920	NEK9	0.9	15.59	0.69	2.45e-39	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15945262	chr7:1881887	MAD1L1	-0.68	-8.14	-0.45	1.55e-14	Gut microbiome composition (summer);
CESC	cis	rs3892630	0.878	rs66788054	chr19:33190146	G/T	cg22980127	chr19:33182716	NUDT19	1.02	11.54	0.58	3.23e-25	Red blood cell traits;
CESC	cis	rs6964587	0.933	rs28671255	chr7:91770705	A/G	cg17063962	chr7:91808500	NA	0.56	7.79	0.43	1.53e-13	Breast cancer;
CESC	cis	rs2576037	0.583	rs8086286	chr18:44467515	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.76	-12.5	-0.61	1.71e-28	Personality dimensions;
CESC	cis	rs911555	0.519	rs8014069	chr14:104004311	A/C	cg12935359	chr14:103987150	CKB	-0.52	-7.87	-0.44	9.11e-14	Intelligence (multi-trait analysis);
CESC	cis	rs7267979	0.528	rs6076366	chr20:25564626	G/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.69	-11.03	-0.56	1.57e-23	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs17711722	0.727	rs2658585	chr7:65461941	A/T	cg06456125	chr7:65229604	NA	0.46	5.97	0.34	7.56e-9	Calcium levels;
CESC	cis	rs34311866	0.808	rs11728344	chr4:963755	T/C	cg07828340	chr4:882639	GAK	0.86	6.68	0.38	1.37e-10	Parkinson's disease;
CESC	cis	rs9900062	0.586	rs6504250	chr17:62680553	T/C	cg02097616	chr17:62675921	NA	0.42	5.14	0.3	5.46e-7	QT interval;
CESC	cis	rs2404602	0.716	rs7164813	chr15:76708066	T/C	cg22467129	chr15:76604101	ETFA	-0.38	-5.68	-0.33	3.56e-8	Blood metabolite levels;
CESC	cis	rs7255436	0.928	rs7250870	chr19:8453682	C/T	cg16745616	chr19:8428856	ANGPTL4	-0.39	-5.86	-0.34	1.36e-8	HDL cholesterol;
CESC	trans	rs2832077	0.527	rs2142375	chr21:30223742	G/A	cg14791747	chr16:20752902	THUMPD1	0.53	7.48	0.42	1.12e-12	Cognitive test performance;
CESC	cis	rs6460942	0.544	rs34644264	chr7:12536090	C/A	cg02935154	chr7:12443704	VWDE	-0.57	-5.7	-0.33	3.23e-8	Coronary artery disease;
CESC	cis	rs77956314	0.515	rs12299065	chr12:117442304	A/G	cg16111737	chr12:117408163	FBXW8	-0.45	-5.46	-0.32	1.08e-7	Subcortical brain region volumes;Hippocampal volume;
CESC	cis	rs9487051	1.000	rs9487048	chr6:109615603	G/T	cg01475377	chr6:109611718	NA	-0.42	-6.43	-0.37	6.01e-10	Reticulocyte fraction of red cells;
CESC	cis	rs4925386	0.840	rs6142738	chr20:60919960	C/T	cg22633769	chr20:60982531	CABLES2	-0.51	-5.42	-0.32	1.36e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs7555523	0.778	rs4233408	chr1:165712960	G/A	cg24409356	chr1:165738333	TMCO1	0.68	6.27	0.36	1.47e-9	Intraocular pressure;Glaucoma (high intraocular pressure);
CESC	cis	rs3815700	1.000	rs3815700	chr19:33093252	T/C	cg24916020	chr19:33096688	ANKRD27	0.6	5.84	0.34	1.56e-8	Eosinophilic esophagitis;
CESC	cis	rs7618501	0.633	rs4688758	chr3:50028385	G/A	cg24110177	chr3:50126178	RBM5	-0.53	-7.23	-0.41	5.13e-12	Intelligence (multi-trait analysis);
CESC	trans	rs7618501	0.633	rs4688757	chr3:50035323	T/C	cg21659725	chr3:3221576	CRBN	0.53	7.41	0.41	1.71e-12	Intelligence (multi-trait analysis);
CESC	cis	rs2014572	1.000	rs3746231	chr19:57760057	G/A	cg24459738	chr19:57751996	ZNF805	-0.53	-7.44	-0.42	1.38e-12	Hyperactive-impulsive symptoms;
CESC	cis	rs2721195	0.719	rs4925811	chr8:145802447	G/T	cg15320075	chr8:145703422	NA	-0.42	-5.66	-0.33	3.84e-8	Age at first birth;
CESC	cis	rs763121	0.889	rs1043402	chr22:38879688	G/A	cg06544989	chr22:39130855	UNC84B	0.45	7.36	0.41	2.34e-12	Menopause (age at onset);
CESC	cis	rs644799	0.544	rs687559	chr11:95598629	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	-0.5	-6.46	-0.37	4.96e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs7772486	0.875	rs9322045	chr6:146384950	C/G	cg05347473	chr6:146136440	FBXO30	0.49	6.55	0.37	2.97e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs12946454	0.621	rs11651809	chr17:43255681	C/G	cg10701640	chr17:43249399	NA	0.45	8.08	0.44	2.31e-14	Systolic blood pressure;
CESC	cis	rs6964587	1.000	rs10274756	chr7:91740796	G/A	cg17063962	chr7:91808500	NA	0.56	7.8	0.43	1.38e-13	Breast cancer;
CESC	cis	rs6460942	0.915	rs6460907	chr7:12304449	G/A	cg06484146	chr7:12443880	VWDE	-0.4	-5.64	-0.33	4.38e-8	Coronary artery disease;
CESC	cis	rs4971059	0.654	rs4971073	chr1:155113104	G/T	cg22049894	chr1:155113146	DPM3	0.51	6.55	0.37	2.97e-10	Breast cancer;
CESC	cis	rs801193	0.569	rs10950050	chr7:66239588	A/C	cg10691866	chr7:65817282	TPST1	-0.3	-5.31	-0.31	2.28e-7	Aortic root size;
CESC	cis	rs7618915	0.501	rs2336149	chr3:52692124	G/A	cg18337363	chr3:52569053	NT5DC2	0.28	5.24	0.31	3.22e-7	Bipolar disorder;
CESC	cis	rs6546550	0.901	rs12613947	chr2:70161342	A/G	cg02498382	chr2:70120550	SNRNP27	-0.41	-7.13	-0.4	9.44e-12	Prevalent atrial fibrillation;
CESC	cis	rs634534	0.622	rs1308733	chr11:65720841	T/C	cg26695010	chr11:65641043	EFEMP2	0.42	5.32	0.31	2.25e-7	Sum eosinophil basophil counts;Eosinophil counts;
CESC	cis	rs6088580	0.634	rs6088508	chr20:33060081	A/G	cg24642439	chr20:33292090	TP53INP2	0.52	6.83	0.39	5.96e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs1799949	0.965	rs35954893	chr17:41333786	A/G	cg25072359	chr17:41440525	NA	0.48	6.46	0.37	4.98e-10	Menopause (age at onset);
CESC	cis	rs9814567	0.806	rs13076825	chr3:134317239	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.42	5.52	0.32	8e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs9916302	0.904	rs6503507	chr17:37525274	C/T	cg15445000	chr17:37608096	MED1	-0.41	-6.69	-0.38	1.36e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs7197653	0.519	rs55757091	chr16:68323654	G/A	cg26727032	chr16:67993705	SLC12A4	-0.6	-6.99	-0.39	2.28e-11	Magnesium levels;
CESC	cis	rs1506636	1.000	rs600774	chr7:123397831	C/T	cg03229431	chr7:123269106	ASB15	0.47	6.2	0.36	2.15e-9	Plateletcrit;Platelet count;
CESC	cis	rs2050392	0.789	rs303438	chr10:30733493	C/T	cg25182066	chr10:30743637	MAP3K8	0.43	5.82	0.34	1.68e-8	Inflammatory bowel disease;
CESC	trans	rs12480534	0.515	rs62215621	chr20:44761854	C/T	cg14765646	chr2:154334450	RPRM	-0.72	-6.31	-0.36	1.15e-9	Response to amphetamines;
CESC	cis	rs801193	0.935	rs2659899	chr7:66186721	A/G	cg14393609	chr7:65229607	NA	0.48	6.5	0.37	4e-10	Aortic root size;
CESC	cis	rs7927592	0.913	rs11228293	chr11:68384646	T/C	cg20283391	chr11:68216788	NA	-0.61	-7.3	-0.41	3.45e-12	Total body bone mineral density;
CESC	cis	rs9916302	0.851	rs7225096	chr17:37664443	T/C	cg07936489	chr17:37558343	FBXL20	-0.81	-11.96	-0.59	1.17e-26	Glomerular filtration rate (creatinine);
CESC	cis	rs7666738	0.830	rs2167892	chr4:99048503	G/C	cg24818145	chr4:99064322	C4orf37	0.38	5.04	0.3	8.49e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9399401	0.633	rs262118	chr6:142843054	C/A	cg04461802	chr6:142623433	GPR126	0.4	5.53	0.32	7.53e-8	Chronic obstructive pulmonary disease;
CESC	cis	rs6967414	0.786	rs3757482	chr7:6748927	A/G	cg09896999	chr7:6746977	ZNF12	-0.58	-7.08	-0.4	1.32e-11	Hematocrit;Hemoglobin concentration;
CESC	cis	rs7851660	0.967	rs4743135	chr9:100599493	C/T	cg13688889	chr9:100608707	NA	-0.68	-10.61	-0.55	3.8e-22	Strep throat;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21080633	chr12:132263633	SFRS8	-0.66	-7.19	-0.4	6.55e-12	Gut microbiome composition (summer);
CESC	cis	rs12893668	0.572	rs7148857	chr14:104143237	C/G	cg24130564	chr14:104152367	KLC1	-0.48	-6.32	-0.36	1.07e-9	Reticulocyte count;
CESC	cis	rs734999	0.545	rs4074789	chr1:2537464	A/G	cg20673091	chr1:2541236	MMEL1	0.45	7.86	0.43	9.78e-14	Ulcerative colitis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27622633	chr4:120133607	USP53	0.59	6.68	0.38	1.42e-10	Gut microbiome composition (summer);
CESC	cis	rs9640161	0.830	rs17173681	chr7:150059414	A/G	cg17279839	chr7:150038598	RARRES2	-0.42	-5.39	-0.31	1.55e-7	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs748404	0.560	rs572837	chr15:43823813	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.49	7.47	0.42	1.15e-12	Lung cancer;
CESC	cis	rs6088580	0.634	rs6120642	chr20:33012531	A/G	cg06115741	chr20:33292138	TP53INP2	0.48	6.13	0.35	3.18e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs6120849	0.754	rs3746435	chr20:33587198	G/C	cg24642439	chr20:33292090	TP53INP2	0.66	6.52	0.37	3.59e-10	Protein C levels;
CESC	trans	rs7980799	0.716	rs1351683	chr12:33598563	G/A	cg26384229	chr12:38710491	ALG10B	-0.57	-8.23	-0.45	8.3e-15	Heart rate;Heart rate variability traits (RMSSD);
CESC	cis	rs2836974	0.644	rs2836981	chr21:40688365	C/T	cg11644478	chr21:40555479	PSMG1	-0.78	-11.6	-0.58	1.92e-25	Cognitive function;
CESC	trans	rs7246760	1.000	rs7246772	chr19:9886283	C/T	cg02900749	chr2:68251473	NA	-0.82	-7.08	-0.4	1.33e-11	Pursuit maintenance gain;
CESC	cis	rs116095464	0.867	rs10061296	chr5:312253	G/A	cg10591111	chr5:226296	SDHA	-0.61	-5.71	-0.33	3.05e-8	Breast cancer;
CESC	cis	rs12618769	0.597	rs7593615	chr2:99030598	C/A	cg10123293	chr2:99228465	UNC50	0.4	5.32	0.31	2.21e-7	Bipolar disorder;
CESC	cis	rs9400271	0.632	rs9384705	chr6:109588244	T/C	cg01475377	chr6:109611718	NA	-0.46	-7.13	-0.4	9.29e-12	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
CESC	cis	rs7395581	0.959	rs2013867	chr11:47260272	A/G	cg25783544	chr11:47291846	MADD	0.58	7.45	0.42	1.29e-12	HDL cholesterol;
CESC	cis	rs9486715	0.659	rs9399930	chr6:96854444	G/T	cg06623918	chr6:96969491	KIAA0776	0.87	12.52	0.61	1.42e-28	Headache;
CESC	trans	rs6948772	0.923	rs6948795	chr7:155400949	T/C	cg19946641	chr12:130909093	RIMBP2	-0.32	-5.99	-0.35	6.68e-9	Colorectal cancer;
CESC	cis	rs17818399	0.612	rs4952834	chr2:46777462	C/G	cg06386533	chr2:46925753	SOCS5	0.5	6.13	0.35	3.13e-9	Height;
CESC	cis	rs8028182	0.636	rs11637068	chr15:75743002	G/A	cg20655648	chr15:75932815	IMP3	0.48	6.11	0.35	3.62e-9	Sudden cardiac arrest;
CESC	cis	rs826838	1.000	rs7975243	chr12:38849220	C/T	cg26384229	chr12:38710491	ALG10B	0.83	14.57	0.67	1.05e-35	Heart rate;
CESC	cis	rs7666738	0.830	rs10012003	chr4:99064881	A/G	cg17366294	chr4:99064904	C4orf37	0.62	8.8	0.48	1.82e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6752107	0.503	rs2304776	chr2:234227693	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.39	5.06	0.3	7.94e-7	Crohn's disease;Inflammatory bowel disease;
CESC	trans	rs6560039	1	rs6560039	chr9:90474946	C/T	cg24436365	chr6:63940138	NA	0.56	10.72	0.55	1.68e-22	Gait variability;
CESC	cis	rs1448094	0.511	rs17345299	chr12:86166005	C/G	cg02569458	chr12:86230093	RASSF9	0.49	7.68	0.43	3.04e-13	Major depressive disorder;
CESC	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg11494091	chr17:61959527	GH2	0.72	12.38	0.61	4.46e-28	Prudent dietary pattern;
CESC	cis	rs4819052	0.851	rs2236445	chr21:46678453	T/C	cg11663144	chr21:46675770	NA	-0.56	-8.41	-0.46	2.52e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs6495122	0.699	rs1378940	chr15:75083494	C/A	cg09165964	chr15:75287851	SCAMP5	0.4	5.21	0.31	3.72e-7	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
CESC	cis	rs1568889	0.887	rs2062269	chr11:28116537	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.8	13.53	0.64	4.71e-32	Bipolar disorder;
CESC	cis	rs12142240	0.731	rs6681857	chr1:46850124	T/C	cg00530320	chr1:46809349	NSUN4	0.6	8.05	0.44	2.83e-14	Menopause (age at onset);
CESC	cis	rs761746	0.960	rs9621279	chr22:31949800	T/A	cg25791279	chr22:32026902	PISD	0.49	5.61	0.33	5.09e-8	Intelligence;
CESC	cis	rs7089973	0.604	rs11196937	chr10:116589500	G/C	cg25233709	chr10:116636983	FAM160B1	0.38	5.9	0.34	1.12e-8	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs9322193	0.607	rs10457852	chr6:150201720	C/T	cg01145232	chr6:150245071	RAET1G	0.49	5.95	0.34	8.24e-9	Lung cancer;
CESC	cis	rs751728	1.000	rs6920075	chr6:33731797	C/T	cg15252951	chr6:33757062	LEMD2	0.45	5.84	0.34	1.53e-8	Crohn's disease;
CESC	cis	rs2455799	0.613	rs1345157	chr3:15895581	C/G	cg16303742	chr3:15540471	COLQ	-0.37	-5.51	-0.32	8.42e-8	Mean platelet volume;
CESC	cis	rs2991971	1.000	rs622798	chr1:46015271	T/G	cg15605315	chr1:45957053	TESK2	0.42	5.3	0.31	2.42e-7	High light scatter reticulocyte count;
CESC	cis	rs6570726	0.935	rs367612	chr6:145828987	A/G	cg05347473	chr6:146136440	FBXO30	0.42	5.7	0.33	3.11e-8	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9649213	0.593	rs10808107	chr7:97951671	T/C	cg21770322	chr7:97807741	LMTK2	0.54	8.15	0.45	1.45e-14	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7618915	0.524	rs10433615	chr3:52638482	C/T	cg07507251	chr3:52567010	NT5DC2	0.4	6.96	0.39	2.7e-11	Bipolar disorder;
CESC	cis	rs9512730	0.553	rs9512702	chr13:28033485	A/G	cg04070771	chr13:27998621	GTF3A	0.48	5.44	0.32	1.23e-7	Schizophrenia;
CESC	cis	rs3892630	0.824	rs35654350	chr19:33223766	T/C	cg22980127	chr19:33182716	NUDT19	1.03	11.32	0.57	1.67e-24	Red blood cell traits;
CESC	cis	rs34779708	0.931	rs4934731	chr10:35431636	T/C	cg03585969	chr10:35415529	CREM	0.75	9.84	0.52	1.11e-19	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs6860806	0.661	rs334902	chr5:131586559	C/G	cg09877947	chr5:131593287	PDLIM4	0.46	6.0	0.35	6.47e-9	Breast cancer;
CESC	trans	rs2853203	0.610	rs2595585	chr20:3602060	A/G	cg08803490	chr12:80288661	PPP1R12A	-0.57	-6.03	-0.35	5.63e-9	High light scatter reticulocyte count;Reticulocyte fraction of red cells;Reticulocyte count;
CESC	cis	rs4654899	0.865	rs6693020	chr1:21378057	A/G	cg05370193	chr1:21551575	ECE1	0.42	6.16	0.35	2.75e-9	Superior frontal gyrus grey matter volume;
CESC	cis	rs12618769	0.543	rs58778964	chr2:99110599	G/C	cg10123293	chr2:99228465	UNC50	0.4	5.38	0.31	1.64e-7	Bipolar disorder;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg17446970	chr1:167683495	NA	-0.49	-6.0	-0.35	6.51e-9	Ulcerative colitis;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg06397424	chr16:15737279	NDE1;KIAA0430	0.46	6.38	0.36	7.89e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs7697216	0.604	rs1319629	chr4:175821735	C/T	cg14561282	chr4:175839468	ADAM29	-0.48	-5.56	-0.32	6.75e-8	Breast cancer;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg26297968	chr2:211035960	C2orf67	-0.49	-7.24	-0.41	4.83e-12	Gut microbiota (bacterial taxa);
CESC	cis	rs708547	0.914	rs2412760	chr4:57735192	A/T	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.62	-6.73	-0.38	1.06e-10	Response to bleomycin (chromatid breaks);
CESC	cis	rs13191362	1.000	rs34344906	chr6:162993378	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.82	8.34	0.46	4.2e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs9583531	0.629	rs7991766	chr13:111380684	A/G	cg24331049	chr13:111365604	ING1	0.69	9.86	0.52	9.59e-20	Coronary artery disease;
CESC	cis	rs977987	0.778	rs4243112	chr16:75321031	T/C	cg03315344	chr16:75512273	CHST6	0.38	5.43	0.32	1.3e-7	Dupuytren's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16376438	chr16:69458483	CYB5B	-0.54	-6.19	-0.36	2.23e-9	Gut microbiome composition (summer);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg14418275	chr11:66243281	PELI3	0.52	7.02	0.4	1.89e-11	Fibrinogen levels;
CESC	cis	rs6032067	0.852	rs17424613	chr20:43806441	C/T	cg11264863	chr20:43835661	SEMG1	0.51	5.56	0.32	6.5e-8	Blood protein levels;
CESC	cis	rs769267	0.965	rs2965191	chr19:19453521	T/G	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.43	-5.43	-0.32	1.24e-7	Tonsillectomy;
CESC	cis	rs2839186	0.647	rs9976233	chr21:47616913	G/A	cg12379764	chr21:47803548	PCNT	0.47	6.04	0.35	5.07e-9	Testicular germ cell tumor;
CESC	cis	rs5769765	0.778	rs8137331	chr22:50313358	G/C	cg26441486	chr22:50317300	CRELD2	0.42	5.61	0.33	5.04e-8	Schizophrenia;
CESC	cis	rs7772486	0.806	rs2247317	chr6:146217570	C/T	cg05347473	chr6:146136440	FBXO30	0.49	6.45	0.37	5.3e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs763121	0.853	rs5757232	chr22:39071677	C/T	cg06022373	chr22:39101656	GTPBP1	0.89	14.42	0.66	3.47e-35	Menopause (age at onset);
CESC	cis	rs933688	0.941	rs6452954	chr5:90735692	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.9	11.83	0.59	3.41e-26	Smoking behavior;
CESC	cis	rs2735413	0.918	rs1922612	chr16:78052983	G/C	cg04733911	chr16:78082701	NA	-0.41	-6.26	-0.36	1.54e-9	Systolic blood pressure (alcohol consumption interaction);
CESC	cis	rs7618915	0.501	rs2164885	chr3:52731269	T/C	cg18099408	chr3:52552593	STAB1	-0.3	-5.05	-0.3	8.07e-7	Bipolar disorder;
CESC	trans	rs2018683	0.677	rs12531456	chr7:28970611	A/C	cg19402173	chr7:128379420	CALU	-0.53	-7.04	-0.4	1.61e-11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CESC	cis	rs35306767	0.953	rs1106064	chr10:957211	G/A	cg20503657	chr10:835505	NA	0.74	8.11	0.45	1.89e-14	Eosinophil percentage of granulocytes;
CESC	cis	rs1983891	1.000	rs4714483	chr6:41528214	G/A	cg20194872	chr6:41519635	FOXP4	0.56	8.09	0.45	2.16e-14	Prostate cancer;
CESC	cis	rs72781680	0.611	rs72783605	chr2:24287864	A/G	cg08917208	chr2:24149416	ATAD2B	0.54	5.2	0.3	4e-7	Lymphocyte counts;
CESC	cis	rs5760092	0.755	rs915589	chr22:24261004	C/T	cg11905131	chr22:24372483	LOC391322	0.65	7.63	0.42	4.17e-13	Urinary 1,3-butadiene metabolite levels in smokers;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg02025656	chr7:668612	PRKAR1B	0.44	6.13	0.35	3.1e-9	Fibrinogen levels;
CESC	cis	rs9614461	0.702	rs3788648	chr22:45727180	G/A	cg01808030	chr22:45809952	RIBC2;SMC1B	0.71	7.4	0.41	1.81e-12	Tonsillectomy;
CESC	cis	rs9650657	0.645	rs11774552	chr8:10515679	C/T	cg27411982	chr8:10470053	RP1L1	-0.4	-5.21	-0.3	3.74e-7	Neuroticism;
CESC	cis	rs7809950	1.000	rs12667527	chr7:107086969	T/C	cg23024343	chr7:107201750	COG5	-0.42	-6.0	-0.35	6.39e-9	Coronary artery disease;
CESC	cis	rs7605827	0.930	rs2111454	chr2:15522331	G/A	cg19274914	chr2:15703543	NA	0.35	6.27	0.36	1.43e-9	Educational attainment (years of education);
CESC	cis	rs911555	0.755	rs12435516	chr14:103954404	T/C	cg24130564	chr14:104152367	KLC1	0.48	6.21	0.36	2.09e-9	Intelligence (multi-trait analysis);
CESC	cis	rs10540	1.000	rs61876335	chr11:488878	T/C	cg21784768	chr11:537496	LRRC56	-0.53	-5.08	-0.3	7.16e-7	Body mass index;
CESC	cis	rs13191362	1.000	rs13206253	chr6:163166902	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.68	7.18	0.4	7.2e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs7618915	0.547	rs6976	chr3:52728804	C/T	cg17372223	chr3:52568218	NT5DC2	0.43	6.37	0.36	8.21e-10	Bipolar disorder;
CESC	cis	rs116095464	0.614	rs4371799	chr5:268192	C/A	cg10591111	chr5:226296	SDHA	-0.51	-6.25	-0.36	1.67e-9	Breast cancer;
CESC	cis	rs4654899	1.000	rs10916938	chr1:21446883	A/G	cg05370193	chr1:21551575	ECE1	0.38	5.65	0.33	4.17e-8	Superior frontal gyrus grey matter volume;
CESC	cis	rs7666738	0.791	rs6853608	chr4:99047916	A/G	cg24818145	chr4:99064322	C4orf37	0.38	5.04	0.3	8.49e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs225245	0.817	rs225269	chr17:33967931	G/T	cg05299278	chr17:33885742	SLFN14	0.38	5.52	0.32	8.1e-8	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
CESC	cis	rs3857536	0.719	rs9363555	chr6:66930332	T/C	cg07460842	chr6:66804631	NA	-0.41	-5.19	-0.3	4.18e-7	Blood trace element (Cu levels);
CESC	cis	rs11958404	0.860	rs72818111	chr5:157438361	A/G	cg05962755	chr5:157440814	NA	0.62	6.66	0.38	1.57e-10	IgG glycosylation;
CESC	cis	rs1552244	0.882	rs55840655	chr3:10042690	C/T	cg00149659	chr3:10157352	C3orf10	0.7	8.26	0.45	6.82e-15	Alzheimer's disease;
CESC	cis	rs3105593	0.965	rs11070801	chr15:50943685	A/T	cg08437265	chr15:50716283	USP8	0.42	5.45	0.32	1.14e-7	QT interval;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg23008136	chr2:55743936	NA	0.42	6.41	0.37	6.67e-10	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs9584850	0.834	rs4294654	chr13:99119607	G/A	cg20750642	chr13:99100586	FARP1	-0.39	-5.9	-0.34	1.12e-8	Neuroticism;
CESC	cis	rs9486715	0.830	rs2255552	chr6:96999643	A/G	cg18709589	chr6:96969512	KIAA0776	-0.45	-6.37	-0.36	8.1e-10	Headache;
CESC	cis	rs9457247	0.588	rs35171809	chr6:167432766	A/G	cg23791538	chr6:167370224	RNASET2	-0.54	-7.3	-0.41	3.28e-12	Crohn's disease;
CESC	cis	rs12971120	0.947	rs7241558	chr18:72169267	A/T	cg26446133	chr18:72167187	CNDP2	-0.74	-11.03	-0.56	1.57e-23	Refractive error;
CESC	cis	rs9309473	0.607	rs2421489	chr2:73593448	A/G	cg20560298	chr2:73613845	ALMS1	-0.45	-5.93	-0.34	9.21e-9	Metabolite levels;
CESC	cis	rs2404602	0.735	rs11632222	chr15:76712927	C/G	cg00316803	chr15:76480434	C15orf27	0.37	5.07	0.3	7.52e-7	Blood metabolite levels;
CESC	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg26338869	chr17:61819248	STRADA	0.69	9.1	0.49	2.2e-17	Prudent dietary pattern;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05382772	chr11:65686513	DRAP1;C11orf68	-0.59	-6.82	-0.39	6.32e-11	Gut microbiome composition (summer);
CESC	cis	rs637571	0.522	rs12792888	chr11:65761446	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.43	6.25	0.36	1.61e-9	Eosinophil percentage of white cells;
CESC	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	21.35	0.8	1.61e-59	Prudent dietary pattern;
CESC	cis	rs6499255	0.951	rs75815213	chr16:69702854	C/T	cg15192750	chr16:69999425	NA	0.47	5.4	0.31	1.5e-7	IgE levels;
CESC	cis	rs736408	0.562	rs2072390	chr3:52780509	A/T	cg18404041	chr3:52824283	ITIH1	-0.36	-6.05	-0.35	4.82e-9	Bipolar disorder;
CESC	cis	rs11785400	0.762	rs1137522	chr8:143739020	A/C	cg10596483	chr8:143751796	JRK	0.42	5.31	0.31	2.32e-7	Schizophrenia;
CESC	cis	rs875971	0.862	rs35378740	chr7:65987712	C/A	cg18876405	chr7:65276391	NA	0.53	7.28	0.41	3.9e-12	Aortic root size;
CESC	cis	rs72945132	0.882	rs67093918	chr11:70198999	C/A	cg00319359	chr11:70116639	PPFIA1	0.73	6.96	0.39	2.63e-11	Coronary artery disease;
CESC	cis	rs2839186	0.770	rs2330353	chr21:47669648	T/A	cg13012494	chr21:47604986	C21orf56	0.49	6.54	0.37	3.17e-10	Testicular germ cell tumor;
CESC	cis	rs769267	1.000	rs2301669	chr19:19453560	C/A	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.43	-5.43	-0.32	1.24e-7	Tonsillectomy;
CESC	cis	rs76878669	0.561	rs55998145	chr11:66152586	A/G	cg18002602	chr11:66138449	SLC29A2	0.42	6.99	0.39	2.22e-11	Educational attainment (years of education);
CESC	cis	rs7927592	0.673	rs2510392	chr11:68394457	C/G	cg01657329	chr11:68192670	LRP5	-0.46	-5.83	-0.34	1.6e-8	Total body bone mineral density;
CESC	cis	rs8180040	1.000	rs295461	chr3:47368010	T/C	cg27129171	chr3:47204927	SETD2	0.66	10.0	0.52	3.6e-20	Colorectal cancer;
CESC	trans	rs11098499	0.821	rs28665282	chr4:120384186	C/T	cg25214090	chr10:38739885	LOC399744	0.69	9.79	0.52	1.58e-19	Corneal astigmatism;
CESC	cis	rs782590	0.934	rs17369191	chr2:55757885	T/C	cg18811423	chr2:55921094	PNPT1	0.81	12.92	0.62	6.08e-30	Metabolic syndrome;
CESC	cis	rs644799	1.000	rs680134	chr11:95559517	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.92	14.08	0.65	5.5e-34	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	trans	rs6751744	0.855	rs35019796	chr2:160367155	A/G	cg08183425	chr2:86037857	NA	0.35	6.04	0.35	5.22e-9	Dysphagia;
CESC	cis	rs4481887	0.927	rs4376768	chr1:248476088	A/G	cg00666640	chr1:248458726	OR2T12	-0.35	-5.91	-0.34	1.02e-8	Common traits (Other);
CESC	cis	rs57786342	0.624	rs4899262	chr14:69283545	G/A	cg03189333	chr14:69283534	NA	-0.44	-5.03	-0.3	8.88e-7	Macrophage inflammatory protein 1a levels;
CESC	trans	rs11989744	1.000	rs17089546	chr8:23571807	G/A	cg03492747	chr16:86543808	FOXF1	0.68	7.75	0.43	1.92e-13	Waist-hip ratio;
CESC	cis	rs35306767	0.903	rs12250936	chr10:870109	C/T	cg25019033	chr10:957182	NA	-0.58	-6.13	-0.35	3.11e-9	Eosinophil percentage of granulocytes;
CESC	cis	rs10851478	0.872	rs17479589	chr15:49753532	T/C	cg08060515	chr15:49448048	GALK2;COPS2	0.42	5.16	0.3	4.79e-7	Oral cavity cancer;
CESC	cis	rs2228479	1.000	rs11642267	chr16:89957635	T/C	cg06558623	chr16:89946397	TCF25	1.17	9.37	0.5	3.29e-18	Skin colour saturation;
CESC	cis	rs1801251	1.000	rs67013068	chr2:233608253	G/C	cg08000102	chr2:233561755	GIGYF2	0.64	9.09	0.49	2.37e-17	Coronary artery disease;
CESC	cis	rs1707322	1.000	rs10890355	chr1:46317348	G/A	cg05343316	chr1:45956843	TESK2	0.44	5.55	0.32	7.05e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs11864453	0.826	rs9941087	chr16:72118324	G/A	cg01557791	chr16:72042693	DHODH	-0.56	-7.33	-0.41	2.78e-12	Fibrinogen levels;
CESC	trans	rs61931739	0.500	rs10844864	chr12:34532468	A/G	cg26384229	chr12:38710491	ALG10B	0.54	7.53	0.42	8.03e-13	Morning vs. evening chronotype;
CESC	trans	rs11098499	0.754	rs2036856	chr4:120249288	G/A	cg25214090	chr10:38739885	LOC399744	0.62	8.64	0.47	5.24e-16	Corneal astigmatism;
CESC	cis	rs9916302	0.904	rs9898170	chr17:37510092	T/C	cg00129232	chr17:37814104	STARD3	0.52	6.49	0.37	4.13e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs9815354	0.767	rs12185934	chr3:41836558	A/C	cg03022575	chr3:42003672	ULK4	0.7	6.04	0.35	5.26e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs736408	0.648	rs3774354	chr3:52817675	G/A	cg17372223	chr3:52568218	NT5DC2	0.4	5.7	0.33	3.14e-8	Bipolar disorder;
CESC	cis	rs7851660	0.933	rs1867277	chr9:100615914	A/G	cg13688889	chr9:100608707	NA	-0.69	-10.57	-0.54	4.92e-22	Strep throat;
CESC	cis	rs10256972	0.527	rs28671326	chr7:1174973	G/A	cg15112475	chr7:1198522	ZFAND2A	-0.38	-6.01	-0.35	5.98e-9	Longevity;Endometriosis;
CESC	cis	rs898097	0.691	rs7222745	chr17:80907253	C/T	cg19046167	chr17:80928561	B3GNTL1	-0.39	-5.08	-0.3	7.23e-7	Breast cancer;
CESC	cis	rs80130819	0.748	rs2732477	chr12:48700282	C/T	cg05342945	chr12:48394962	COL2A1	0.52	5.72	0.33	2.95e-8	Prostate cancer;
CESC	cis	rs4665809	0.590	rs1122972	chr2:26418788	A/C	cg26314531	chr2:26401878	FAM59B	-0.83	-9.19	-0.49	1.22e-17	Gut microbiome composition (summer);
CESC	cis	rs11645898	0.683	rs72787038	chr16:72066102	A/C	cg14768367	chr16:72042858	DHODH	-0.65	-5.55	-0.32	6.86e-8	Blood protein levels;
CESC	cis	rs2797160	0.935	rs6940748	chr6:125994080	C/T	cg05901451	chr6:126070800	HEY2	-0.45	-6.5	-0.37	3.89e-10	Endometrial cancer;
CESC	cis	rs17376456	0.597	rs11135401	chr5:93365716	G/A	cg25358565	chr5:93447407	FAM172A	-0.47	-5.53	-0.32	7.81e-8	Diabetic retinopathy;
CESC	cis	rs7084402	0.967	rs1649080	chr10:60293294	C/T	cg07615347	chr10:60278583	BICC1	0.58	9.43	0.5	2.24e-18	Refractive error;
CESC	cis	rs875971	0.545	rs1267814	chr7:66044409	G/A	cg11764359	chr7:65958608	NA	-0.81	-9.98	-0.52	4.19e-20	Aortic root size;
CESC	cis	rs9815354	0.812	rs17215883	chr3:41841873	C/T	cg03022575	chr3:42003672	ULK4	0.7	6.04	0.35	5.26e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs9733	0.596	rs72702556	chr1:150680115	C/T	cg22823121	chr1:150693482	HORMAD1	0.48	7.09	0.4	1.2e-11	Tonsillectomy;
CESC	cis	rs1465370	0.720	rs7811463	chr7:130017488	G/A	cg04743876	chr7:130013617	NA	0.31	5.87	0.34	1.27e-8	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
CESC	cis	rs453301	0.606	rs6981060	chr8:8908235	C/A	cg15556689	chr8:8085844	FLJ10661	-0.5	-5.96	-0.34	7.83e-9	Joint mobility (Beighton score);
CESC	cis	rs477692	0.655	rs7906680	chr10:131442671	C/G	cg24747557	chr10:131355152	MGMT	0.39	5.5	0.32	9.15e-8	Response to temozolomide;
CESC	cis	rs9399401	0.845	rs263178	chr6:142865106	C/T	cg03128060	chr6:142623767	GPR126	0.26	5.05	0.3	8.17e-7	Chronic obstructive pulmonary disease;
CESC	cis	rs7662987	0.517	rs2602878	chr4:100039953	T/G	cg12011299	chr4:100065546	ADH4	0.6	6.48	0.37	4.4e-10	Smoking initiation;
CESC	cis	rs8002861	0.905	rs12874535	chr13:44433565	A/G	cg19180546	chr13:44453867	C13orf31;CCDC122	-0.41	-5.16	-0.3	4.82e-7	Leprosy;
CESC	cis	rs2301436	0.512	rs6925969	chr6:167501738	C/A	cg07741184	chr6:167504864	NA	0.39	6.49	0.37	4.23e-10	Crohn's disease;
CESC	cis	rs5498	0.869	rs2569702	chr19:10403947	A/G	cg10604476	chr19:10403908	ICAM5	0.45	6.37	0.36	8.14e-10	Lymphocyte counts;Soluble ICAM-1;Blood protein levels;
CESC	cis	rs208520	0.754	rs851592	chr6:66875175	G/T	cg07460842	chr6:66804631	NA	-0.99	-13.04	-0.63	2.24e-30	Exhaled nitric oxide output;
CESC	cis	rs73206853	0.925	rs12318836	chr12:110642190	A/C	cg12870014	chr12:110450643	ANKRD13A	0.65	6.23	0.36	1.81e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs7666738	0.830	rs6532723	chr4:99052147	A/T	cg17366294	chr4:99064904	C4orf37	0.61	8.78	0.47	2.13e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1843834	0.929	rs4674934	chr2:225516468	A/T	cg22455342	chr2:225449267	CUL3	-0.51	-6.63	-0.38	1.9e-10	IgE levels in asthmatics (D.p. specific);
CESC	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg24829409	chr8:58192753	C8orf71	-0.67	-8.05	-0.44	2.82e-14	Developmental language disorder (linguistic errors);
CESC	cis	rs7089973	0.604	rs11196947	chr10:116601372	G/A	cg25233709	chr10:116636983	FAM160B1	0.38	6.08	0.35	4.13e-9	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs1023500	0.573	rs133378	chr22:42467695	G/C	cg15557168	chr22:42548783	NA	-0.45	-6.51	-0.37	3.78e-10	Schizophrenia;
CESC	cis	rs9393777	0.545	rs56303243	chr6:26485727	G/A	cg12826209	chr6:26865740	GUSBL1	0.67	7.01	0.4	2.02e-11	Intelligence (multi-trait analysis);
CESC	cis	rs3762637	0.943	rs72960447	chr3:122235105	G/A	cg24169773	chr3:122142474	KPNA1	-0.59	-6.97	-0.39	2.48e-11	LDL cholesterol levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25481680	chr10:105110878	PCGF6	0.57	6.35	0.36	9.47e-10	Gut microbiome composition (summer);
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg00419759	chr1:114301964	PHTF1	-0.48	-6.3	-0.36	1.2e-9	Height;
CESC	cis	rs9796	0.689	rs576336	chr15:41452771	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.46	-6.61	-0.38	2.16e-10	Menopause (age at onset);
CESC	cis	rs4689388	0.890	rs4342257	chr4:6290037	G/C	cg25554036	chr4:6271136	WFS1	0.53	8.69	0.47	3.77e-16	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs10504229	1.000	rs17216620	chr8:58169412	A/G	cg22535103	chr8:58192502	C8orf71	-1.05	-13.27	-0.63	3.63e-31	Developmental language disorder (linguistic errors);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02930876	chr14:24584326	DCAF11	-0.6	-6.35	-0.36	9.45e-10	Gut microbiome composition (summer);
CESC	cis	rs637571	0.522	rs649000	chr11:65742933	T/C	cg02202077	chr11:65769826	EIF1AD;BANF1	0.45	5.9	0.34	1.08e-8	Eosinophil percentage of white cells;
CESC	cis	rs11997175	0.624	rs67643247	chr8:33700790	G/A	ch.8.33884649F	chr8:33765107	NA	0.54	6.87	0.39	4.59e-11	Body mass index;
CESC	cis	rs12458462	0.892	rs12456692	chr18:77482189	C/T	cg23301140	chr18:77439876	CTDP1	0.56	7.34	0.41	2.68e-12	Monocyte count;
CESC	trans	rs17556665	0.808	rs2031014	chr11:14051977	C/T	cg13843613	chr1:177140126	FAM5B	0.5	6.17	0.35	2.61e-9	Inflammatory biomarkers;
CESC	cis	rs2273669	0.667	rs7761290	chr6:109326621	T/G	cg05315195	chr6:109294784	ARMC2	-0.66	-6.28	-0.36	1.36e-9	Prostate cancer;
CESC	cis	rs875971	0.522	rs2949690	chr7:65483242	C/T	cg05332525	chr7:65337924	VKORC1L1	-0.49	-6.13	-0.35	3.24e-9	Aortic root size;
CESC	cis	rs13108904	0.934	rs13149952	chr4:1308437	C/G	cg22903657	chr4:1355424	KIAA1530	-0.38	-5.26	-0.31	3.03e-7	Obesity-related traits;
CESC	cis	rs12479064	0.724	rs62153852	chr2:99934713	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.59	-7.1	-0.4	1.13e-11	Chronic sinus infection;
CESC	cis	rs910316	0.737	rs398896	chr14:75482827	C/A	cg08847533	chr14:75593920	NEK9	-0.9	-15.44	-0.69	8.26e-39	Height;
CESC	cis	rs1018836	0.828	rs1858673	chr8:91551526	C/A	cg16814680	chr8:91681699	NA	-0.64	-9.21	-0.49	1.05e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg21754773	chr3:58477622	KCTD6	0.51	6.47	0.37	4.59e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs909674	0.524	rs5757670	chr22:39829736	G/A	cg01416388	chr22:39784598	NA	-0.55	-6.65	-0.38	1.68e-10	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19825186	chr1:207495562	CD55	0.6	6.6	0.38	2.28e-10	Gut microbiome composition (summer);
CESC	cis	rs2953174	0.786	rs2975749	chr2:241519093	A/G	cg07929629	chr2:241523174	NA	0.62	5.63	0.33	4.52e-8	Bipolar disorder;
CESC	cis	rs7811142	1.000	rs2406253	chr7:100077273	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.86	8.86	0.48	1.18e-16	Platelet count;
CESC	cis	rs769267	1.000	rs8103197	chr19:19443466	C/T	cg15052019	chr19:19431593	KIAA0892;SF4	-0.43	-5.49	-0.32	9.31e-8	Tonsillectomy;
CESC	cis	rs4665809	1.000	rs13030858	chr2:26315451	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.7	-8.01	-0.44	3.69e-14	Gut microbiome composition (summer);
CESC	cis	rs870825	0.616	rs4444872	chr4:185628405	A/G	cg04058563	chr4:185651563	MLF1IP	0.65	7.07	0.4	1.36e-11	Blood protein levels;
CESC	cis	rs2742234	0.541	rs11238483	chr10:43728780	A/G	cg07801480	chr10:43725741	RASGEF1A	-0.42	-5.32	-0.31	2.19e-7	Hirschsprung disease;
CESC	cis	rs1707322	0.963	rs10890373	chr1:46393755	A/C	cg03146154	chr1:46216737	IPP	0.78	10.78	0.55	1.06e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs4253772	0.550	rs6008601	chr22:46705326	C/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.62	5.76	0.33	2.34e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs12824058	0.831	rs11060825	chr12:130807905	A/G	cg23887609	chr12:130822674	PIWIL1	0.45	5.87	0.34	1.28e-8	Menopause (age at onset);
CESC	cis	rs13191362	1.000	rs35723993	chr6:163008197	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.82	8.29	0.45	5.87e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13859212	chr4:99580143	TSPAN5	0.54	6.71	0.38	1.18e-10	Gut microbiome composition (summer);
CESC	cis	rs798554	0.757	rs2533878	chr7:2878707	A/G	cg09658497	chr7:2847517	GNA12	0.41	5.99	0.35	6.82e-9	Height;
CESC	cis	rs11650494	0.710	rs2165701	chr17:47475822	A/G	cg08112188	chr17:47440006	ZNF652	1.18	7.8	0.43	1.43e-13	Prostate cancer;
CESC	cis	rs10911363	0.592	rs2761581	chr1:183474850	G/C	cg09173681	chr1:183549694	NCF2	0.51	7.36	0.41	2.28e-12	Systemic lupus erythematosus;
CESC	cis	rs131777	0.547	rs131753	chr22:51022862	A/G	cg25309564	chr22:51001381	C22orf41	0.62	7.99	0.44	4.25e-14	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	cis	rs4713118	0.516	rs7739216	chr6:28079946	G/T	cg12963246	chr6:28129442	ZNF389	0.56	7.63	0.42	4.26e-13	Parkinson's disease;
CESC	cis	rs8031584	0.958	rs11637469	chr15:31238783	T/C	cg14298792	chr15:30685198	CHRFAM7A	-0.46	-5.51	-0.32	8.59e-8	Huntington's disease progression;
CESC	cis	rs8053891	0.906	rs28714527	chr16:71997862	C/G	cg04254540	chr16:71951199	KIAA0174	-0.44	-5.46	-0.32	1.07e-7	Coronary artery disease;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg25062197	chr8:90894030	NA	0.37	5.99	0.35	6.69e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs9467711	0.606	rs72836482	chr6:26359241	A/T	cg14345882	chr6:26364793	BTN3A2	0.59	6.06	0.35	4.66e-9	Autism spectrum disorder or schizophrenia;
CESC	trans	rs208520	0.754	rs12204635	chr6:66740779	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.96	12.2	0.6	1.84e-27	Exhaled nitric oxide output;
CESC	trans	rs62103177	0.564	rs1864529	chr18:77748975	G/A	cg05926928	chr17:57297772	GDPD1	-0.7	-7.61	-0.42	4.81e-13	Opioid sensitivity;
CESC	cis	rs17376456	0.825	rs10058331	chr5:93279115	T/G	cg25358565	chr5:93447407	FAM172A	1.15	9.92	0.52	6.06e-20	Diabetic retinopathy;
CESC	cis	rs3924048	0.559	rs4075304	chr1:12626803	C/T	cg00291366	chr1:12616550	NA	0.35	6.13	0.35	3.24e-9	Optic cup area;
CESC	trans	rs1814175	0.684	rs1827015	chr11:49585241	A/G	cg03929089	chr4:120376271	NA	-0.82	-11.46	-0.58	5.79e-25	Height;
CESC	cis	rs3026101	0.671	rs14231	chr17:5294976	T/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.43	5.68	0.33	3.57e-8	Body mass index;
CESC	cis	rs9393777	0.513	rs9348728	chr6:26634436	G/A	cg12826209	chr6:26865740	GUSBL1	0.75	8.82	0.48	1.62e-16	Intelligence (multi-trait analysis);
CESC	cis	rs929354	0.739	rs1182439	chr7:157027367	G/A	cg05182265	chr7:156933206	UBE3C	0.48	7.11	0.4	1.05e-11	Body mass index;
CESC	cis	rs9291683	0.632	rs13101785	chr4:10042915	T/A	cg00071950	chr4:10020882	SLC2A9	0.83	14.41	0.66	3.63e-35	Bone mineral density;
CESC	cis	rs75804782	0.521	rs56227677	chr2:239449867	C/T	cg18131467	chr2:239335373	ASB1	-0.68	-5.47	-0.32	1.04e-7	Morning vs. evening chronotype;Chronotype;
CESC	cis	rs2404602	0.669	rs17464903	chr15:77195486	A/G	cg26408565	chr15:76604113	ETFA	-0.4	-5.91	-0.34	1.03e-8	Blood metabolite levels;
CESC	cis	rs1218582	0.772	rs11264290	chr1:154912300	C/T	cg09359103	chr1:154839909	KCNN3	-0.66	-12.34	-0.6	5.94e-28	Prostate cancer;
CESC	cis	rs6582630	0.537	rs7299661	chr12:38527713	C/T	cg13010199	chr12:38710504	ALG10B	0.42	5.53	0.32	7.64e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs329122	0.528	rs329121	chr5:133863352	G/C	cg26284174	chr5:133860141	NA	0.49	5.74	0.33	2.63e-8	Body mass index;Type 2 diabetes;
CESC	cis	rs11711311	1.000	rs11719303	chr3:113494524	A/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.71	9.99	0.52	3.72e-20	IgG glycosylation;
CESC	cis	rs344364	0.511	rs1742462	chr16:1946062	A/C	cg26617929	chr16:1858877	NA	-0.49	-5.15	-0.3	5.09e-7	Glomerular filtration rate in chronic kidney disease;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg12390003	chr1:160068671	IGSF8	-0.51	-6.2	-0.36	2.2e-9	Ulcerative colitis;
CESC	cis	rs1728785	1.000	rs698712	chr16:68561879	G/A	cg02972257	chr16:68554789	NA	-0.55	-6.45	-0.37	5.28e-10	Ulcerative colitis;
CESC	cis	rs2842992	0.830	rs2025190	chr6:160138241	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.73	8.85	0.48	1.24e-16	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs8060686	0.623	rs2301814	chr16:68105171	C/G	cg26727032	chr16:67993705	SLC12A4	-0.57	-7.63	-0.42	4.3e-13	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs17384381	1.000	rs12133722	chr1:85873237	C/T	cg16011679	chr1:85725395	C1orf52	0.79	8.03	0.44	3.2e-14	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs875971	0.790	rs10257911	chr7:65743770	A/G	cg11764359	chr7:65958608	NA	-0.79	-11.67	-0.58	1.16e-25	Aortic root size;
CESC	cis	rs7605378	0.528	rs281767	chr2:200823281	C/A	cg23649088	chr2:200775458	C2orf69	0.73	9.23	0.49	9.22e-18	Osteoporosis;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg01143145	chr6:33547969	BAK1	0.47	6.01	0.35	6.27e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs4911259	0.552	rs13038881	chr20:31468113	T/C	cg13636640	chr20:31349939	DNMT3B	-0.53	-7.32	-0.41	2.98e-12	Inflammatory bowel disease;
CESC	cis	rs4919694	1.000	rs77318450	chr10:104733098	A/G	cg04362960	chr10:104952993	NT5C2	0.7	5.52	0.32	8.1e-8	Arsenic metabolism;
CESC	cis	rs2180341	1.000	rs2144743	chr6:127633810	A/T	cg24812749	chr6:127587940	RNF146	1.07	15.48	0.69	6.31e-39	Breast cancer;
CESC	cis	rs514406	0.661	rs550561	chr1:53375134	C/T	cg08859206	chr1:53392774	SCP2	-0.68	-10.01	-0.52	3.33e-20	Monocyte count;
CESC	cis	rs2075371	1.000	rs2075373	chr7:133984683	A/C	cg00033643	chr7:134001901	SLC35B4	0.44	5.6	0.33	5.4e-8	Mean platelet volume;
CESC	cis	rs853679	0.517	rs9357061	chr6:28051772	A/G	cg17949981	chr6:28129498	ZNF389	0.45	5.62	0.33	4.9e-8	Depression;
CESC	cis	rs3749237	0.595	rs4955412	chr3:49418168	A/C	cg06212747	chr3:49208901	KLHDC8B	0.53	7.2	0.4	6.14e-12	Resting heart rate;
CESC	cis	rs1413885	0.516	rs10789183	chr1:65856779	G/C	cg14976592	chr1:65886160	LEPROT;LEPR	0.48	6.38	0.37	7.66e-10	Anticoagulant levels;
CESC	trans	rs7263120	1.000	rs4331584	chr20:23727735	G/A	cg00618312	chr13:41556559	ELF1	-0.58	-6.15	-0.35	2.87e-9	Blood protein levels;
CESC	cis	rs12618769	0.652	rs3754871	chr2:99224309	A/T	cg10123293	chr2:99228465	UNC50	0.41	5.35	0.31	1.88e-7	Bipolar disorder;
CESC	cis	rs8044868	0.530	rs12918956	chr16:72224335	A/G	cg16558253	chr16:72132732	DHX38	0.4	6.13	0.35	3.1e-9	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CESC	cis	rs7527798	0.501	rs12125256	chr1:207851361	C/T	cg09232269	chr1:207846808	CR1L	-0.28	-5.06	-0.3	7.78e-7	Erythrocyte sedimentation rate;
CESC	cis	rs9486719	1.000	rs12208449	chr6:96903253	A/G	cg06623918	chr6:96969491	KIAA0776	0.71	6.99	0.39	2.29e-11	Migraine;Coronary artery disease;
CESC	cis	rs8062405	0.755	rs111693583	chr16:28583610	C/T	cg07382826	chr16:28625726	SULT1A1	0.4	6.53	0.37	3.32e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs9302635	0.513	rs8044555	chr16:72152755	T/C	cg01557791	chr16:72042693	DHODH	-0.56	-6.54	-0.37	3.07e-10	Blood protein levels;
CESC	cis	rs9611565	0.918	rs73176685	chr22:41781094	C/G	cg17376030	chr22:41985996	PMM1	0.52	5.65	0.33	4.04e-8	Vitiligo;
CESC	cis	rs6952808	0.578	rs6949478	chr7:1841342	A/G	cg13880726	chr7:1868755	MAD1L1	-0.44	-5.67	-0.33	3.77e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs28719689	0.541	rs28376074	chr8:1274394	A/T	cg22761795	chr8:1265118	NA	0.71	6.37	0.36	8.33e-10	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9929218	1.000	rs13334471	chr16:68800452	T/C	cg02972257	chr16:68554789	NA	0.43	5.22	0.31	3.65e-7	Colorectal cancer;
CESC	cis	rs7107174	0.892	rs2512519	chr11:77953015	C/T	cg02023728	chr11:77925099	USP35	0.54	7.47	0.42	1.13e-12	Testicular germ cell tumor;
CESC	cis	rs897080	0.515	rs786617	chr2:44593158	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.49	5.8	0.34	1.87e-8	Height;
CESC	cis	rs1551570	0.755	rs11667630	chr19:10229297	A/C	cg00593900	chr19:10206746	ANGPTL6	-0.35	-5.74	-0.33	2.64e-8	Narcolepsy;
CESC	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg10150615	chr22:24372951	LOC391322	-0.56	-7.73	-0.43	2.2e-13	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs10392	0.543	rs4812332	chr20:37534665	C/T	cg27552599	chr20:37590471	DHX35	0.38	5.38	0.31	1.61e-7	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
CESC	cis	rs853679	0.517	rs9368550	chr6:28051803	T/A	cg17949981	chr6:28129498	ZNF389	0.45	5.62	0.33	4.9e-8	Depression;
CESC	cis	rs2050392	0.894	rs2480277	chr10:30703513	G/T	cg25182066	chr10:30743637	MAP3K8	0.39	5.15	0.3	5.1e-7	Inflammatory bowel disease;
CESC	cis	rs7267979	0.933	rs2261109	chr20:25259200	T/C	cg08601574	chr20:25228251	PYGB	0.39	5.65	0.33	4.14e-8	Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12792894	chr1:115123975	BCAS2	-0.54	-6.47	-0.37	4.71e-10	Gut microbiome composition (summer);
CESC	cis	rs4319547	0.737	rs10846921	chr12:122943376	G/T	cg05707623	chr12:122985044	ZCCHC8	0.52	6.5	0.37	4.08e-10	Body mass index;
CESC	cis	rs12476592	0.602	rs10469944	chr2:63816672	C/G	cg17519650	chr2:63277830	OTX1	-0.45	-5.12	-0.3	5.75e-7	Childhood ear infection;
CESC	cis	rs35110281	0.807	rs9976441	chr21:45046591	G/A	cg04455712	chr21:45112962	RRP1B	0.42	6.22	0.36	1.89e-9	Mean corpuscular volume;
CESC	cis	rs736408	0.509	rs1108842	chr3:52720080	A/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.39	7.6	0.42	5.07e-13	Bipolar disorder;
CESC	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg03188948	chr7:1209495	NA	0.68	6.53	0.37	3.42e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7772486	0.764	rs7745696	chr6:146162829	T/C	cg23711669	chr6:146136114	FBXO30	0.9	13.27	0.63	3.71e-31	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9443189	0.762	rs1321162	chr6:76456347	C/T	cg01950844	chr6:76311363	SENP6	0.66	7.08	0.4	1.29e-11	Prostate cancer;
CESC	cis	rs853679	0.517	rs9368558	chr6:28133306	A/G	cg12963246	chr6:28129442	ZNF389	0.56	7.38	0.41	1.99e-12	Depression;
CESC	cis	rs9815354	1.000	rs9874513	chr3:41909508	G/A	cg03022575	chr3:42003672	ULK4	0.57	5.88	0.34	1.2e-8	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs6752107	1.000	rs12994997	chr2:234173503	G/A	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.36	5.39	0.31	1.54e-7	Crohn's disease;Inflammatory bowel disease;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg15092368	chr1:143270427	NA	-0.41	-6.68	-0.38	1.41e-10	Gut microbiota (bacterial taxa);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg25202390	chr2:99797622	MRPL30;MITD1	-0.48	-6.41	-0.37	6.48e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs875971	0.898	rs6977501	chr7:65693342	T/C	cg18876405	chr7:65276391	NA	-0.49	-6.74	-0.38	9.59e-11	Aortic root size;
CESC	cis	rs4555082	0.874	rs28785556	chr14:105745388	A/T	cg13114125	chr14:105738426	BRF1	-0.89	-10.33	-0.54	2.97e-21	Mean platelet volume;Platelet distribution width;
CESC	cis	rs651907	0.535	rs61396602	chr3:101509046	T/C	cg12386194	chr3:101231763	SENP7	0.42	5.24	0.31	3.3e-7	Colorectal cancer;
CESC	cis	rs1348850	0.567	rs4893838	chr2:178531436	T/C	cg23306229	chr2:178417860	TTC30B	0.53	6.37	0.36	8.45e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs6963495	0.818	rs73190156	chr7:105153567	C/T	cg02135003	chr7:105160482	PUS7	-0.46	-5.55	-0.32	6.92e-8	Bipolar disorder (body mass index interaction);
CESC	cis	rs12477438	0.677	rs12475034	chr2:99699464	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.62	-7.77	-0.43	1.71e-13	Chronic sinus infection;
CESC	cis	rs425277	0.585	rs3107143	chr1:2045372	G/C	cg16545954	chr1:2118288	C1orf86	-0.32	-5.98	-0.34	7.26e-9	Height;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg13076329	chr4:114682704	CAMK2D	-0.47	-6.16	-0.35	2.72e-9	Fibrinogen levels;
CESC	cis	rs763121	0.853	rs8142098	chr22:39058757	T/G	cg21395723	chr22:39101663	GTPBP1	0.43	5.37	0.31	1.74e-7	Menopause (age at onset);
CESC	cis	rs4563143	0.647	rs73029014	chr19:29257655	G/C	cg04546413	chr19:29218101	NA	0.57	8.0	0.44	3.87e-14	Methadone dose in opioid dependence;
CESC	cis	rs2439831	0.850	rs7168158	chr15:44050376	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.72	6.83	0.39	5.8200000000000003e-11	Lung cancer in ever smokers;
CESC	cis	rs2625529	0.689	rs12050794	chr15:72169466	G/A	cg16672083	chr15:72433130	SENP8	0.37	5.6	0.33	5.47e-8	Red blood cell count;
CESC	cis	rs838147	0.505	rs1688264	chr19:49209560	T/G	cg21064579	chr19:49206444	FUT2	0.51	7.12	0.4	9.95e-12	Dietary macronutrient intake;
CESC	cis	rs9457247	1.000	rs408087	chr6:167398952	C/T	cg07741184	chr6:167504864	NA	0.29	5.29	0.31	2.55e-7	Crohn's disease;
CESC	cis	rs763121	0.853	rs4820345	chr22:39091151	T/C	cg06022373	chr22:39101656	GTPBP1	0.86	12.58	0.61	8.71e-29	Menopause (age at onset);
CESC	cis	rs1348850	0.645	rs11889272	chr2:178432378	C/T	cg23306229	chr2:178417860	TTC30B	0.86	9.17	0.49	1.33e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs7208859	0.623	rs216423	chr17:28942109	G/C	cg13385521	chr17:29058706	SUZ12P	0.58	5.04	0.3	8.45e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs71403859	0.570	rs76231867	chr16:71449926	G/A	cg08717414	chr16:71523259	ZNF19	-0.84	-8.19	-0.45	1.1e-14	Post bronchodilator FEV1;
CESC	cis	rs2836974	0.897	rs2836923	chr21:40524236	T/C	cg27266027	chr21:40555129	PSMG1	0.47	5.53	0.32	7.79e-8	Cognitive function;
CESC	cis	rs17854409	0.764	rs73613593	chr20:61471582	T/C	cg07645718	chr20:61493192	TCFL5	0.96	5.08	0.3	7.06e-7	Obesity-related traits;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg17602823	chr1:28586543	SESN2	0.49	6.86	0.39	4.91e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs4132509	0.516	rs10927031	chr1:243685760	G/C	cg21452805	chr1:244014465	NA	0.55	6.12	0.35	3.39e-9	RR interval (heart rate);
CESC	cis	rs7937682	0.632	rs7112886	chr11:111743232	T/C	cg09085632	chr11:111637200	PPP2R1B	0.86	10.86	0.55	5.71e-23	Primary sclerosing cholangitis;
CESC	cis	rs6674176	0.660	rs11210936	chr1:44391438	A/T	cg23954153	chr1:44402353	ARTN	-0.35	-5.46	-0.32	1.08e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs7937682	0.632	rs11214028	chr11:111761149	T/C	cg09085632	chr11:111637200	PPP2R1B	0.87	11.02	0.56	1.67e-23	Primary sclerosing cholangitis;
CESC	cis	rs11608355	0.521	rs6606706	chr12:109830173	C/T	cg19025524	chr12:109796872	NA	-0.54	-7.7	-0.43	2.8e-13	Neuroticism;
CESC	cis	rs7208859	0.673	rs9895815	chr17:29138033	A/G	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.1e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	trans	rs5756813	0.688	rs2413483	chr22:38127950	C/T	cg19894588	chr14:64061835	NA	-0.65	-7.41	-0.41	1.7e-12	Optic cup area;Vertical cup-disc ratio;
CESC	cis	rs2576037	0.583	rs644731	chr18:44426877	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.34	5.51	0.32	8.53e-8	Personality dimensions;
CESC	cis	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg05863683	chr7:1912471	MAD1L1	0.42	6.21	0.36	2.09e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs6867032	1.000	rs16902318	chr5:2013568	A/G	cg26168224	chr5:2018326	NA	0.91	17.91	0.74	1.45e-47	Gut microbiome composition (winter);
CESC	cis	rs9318086	0.663	rs2312295	chr13:24457744	A/T	cg25267304	chr13:24462978	PCOTH;MIPEP	0.46	6.48	0.37	4.37e-10	Myopia (pathological);
CESC	cis	rs4253772	0.872	rs14843	chr22:46639462	A/T	cg00784671	chr22:46762841	CELSR1	-0.57	-5.61	-0.33	5.1e-8	LDL cholesterol;Cholesterol, total;
CESC	trans	rs1493916	1.000	rs990882	chr18:31398180	T/G	cg27147174	chr7:100797783	AP1S1	-0.52	-7.1	-0.4	1.14e-11	Life satisfaction;
CESC	cis	rs9611519	1.000	rs5751069	chr22:41627775	C/G	cg03806693	chr22:41940476	POLR3H	-0.47	-5.2	-0.3	3.92e-7	Neuroticism;
CESC	cis	rs10089	0.953	rs6595807	chr5:127531603	G/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.7	9.04	0.49	3.36e-17	Ileal carcinoids;
CESC	cis	rs11077998	0.967	rs901373	chr17:80506559	A/G	cg10255544	chr17:80519551	FOXK2	0.5	8.09	0.44	2.2e-14	Reticulocyte fraction of red cells;
CESC	cis	rs9488822	0.676	rs4354188	chr6:116327936	T/C	cg05304507	chr6:116381966	FRK	0.26	6.56	0.37	2.86e-10	Cholesterol, total;LDL cholesterol;
CESC	trans	rs1545843	0.593	rs10746319	chr12:84783530	C/G	cg03015433	chr16:56623111	MT3	0.33	6.03	0.35	5.39e-9	Major depressive disorder;
CESC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg11958594	chr17:80055299	FASN	-0.46	-6.04	-0.35	5.25e-9	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs11190604	1.000	rs7088827	chr10:102303865	C/G	cg07080220	chr10:102295463	HIF1AN	0.64	5.84	0.34	1.54e-8	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs7824557	0.614	rs2736286	chr8:11227104	A/G	cg21775007	chr8:11205619	TDH	-0.51	-7.95	-0.44	5.25e-14	Retinal vascular caliber;
CESC	cis	rs2637266	0.678	rs2894345	chr10:78454561	A/C	cg18941641	chr10:78392320	NA	0.4	7.32	0.41	2.91e-12	Pulmonary function;
CESC	cis	rs7618915	0.547	rs7642198	chr3:52677960	T/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.3	5.43	0.32	1.27e-7	Bipolar disorder;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg13489694	chr12:96337059	AMDHD1;CCDC38	-0.45	-6.05	-0.35	4.88e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs875971	0.508	rs10950045	chr7:66066373	T/C	cg11764359	chr7:65958608	NA	-0.54	-7.08	-0.4	1.32e-11	Aortic root size;
CESC	cis	rs9487051	0.676	rs7753697	chr6:109593292	A/G	cg12927641	chr6:109611667	NA	-0.37	-5.56	-0.32	6.55e-8	Reticulocyte fraction of red cells;
CESC	cis	rs1218582	0.741	rs2335407	chr1:154843347	A/G	cg16680214	chr1:154839983	KCNN3	0.54	8.5	0.46	1.36e-15	Prostate cancer;
CESC	cis	rs2832191	0.755	rs2832193	chr21:30493589	T/C	cg08807101	chr21:30365312	RNF160	-0.72	-9.88	-0.52	8.3e-20	Dental caries;
CESC	cis	rs7500321	1.000	rs7500321	chr16:28977020	G/A	cg05966235	chr16:28915196	ATP2A1	-0.37	-5.23	-0.31	3.45e-7	Intelligence (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22963863	chr17:47022211	SNF8	0.61	6.81	0.39	6.47e-11	Gut microbiome composition (summer);
CESC	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	21.26	0.79	3.33e-59	Prudent dietary pattern;
CESC	cis	rs2629540	0.781	rs11245362	chr10:126458649	T/C	cg08799069	chr10:126477246	METTL10	-0.68	-9.32	-0.5	4.61e-18	Cocaine dependence;
CESC	cis	rs7666738	0.784	rs4699602	chr4:99034903	T/C	cg18180107	chr4:99064573	C4orf37	0.4	5.05	0.3	8.24e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg26604191	chr7:5372559	TNRC18	0.48	6.31	0.36	1.17e-9	Fibrinogen levels;
CESC	cis	rs7542091	0.648	rs688464	chr1:209992539	C/T	cg22029157	chr1:209979665	IRF6	-0.59	-9.17	-0.49	1.39e-17	Monobrow;
CESC	cis	rs1881797	0.932	rs2387038	chr1:247674919	G/A	cg05639522	chr1:247681581	NA	0.5	6.31	0.36	1.16e-9	Acute lymphoblastic leukemia (childhood);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19320564	chr1:40157253	HPCAL4	0.58	6.57	0.37	2.7e-10	Gut microbiome composition (summer);
CESC	cis	rs921968	0.608	rs678814	chr2:219359287	T/C	cg02176678	chr2:219576539	TTLL4	0.43	7.54	0.42	7.27e-13	Mean corpuscular hemoglobin concentration;
CESC	cis	rs3733585	0.577	rs28558552	chr4:9964913	G/A	cg11266682	chr4:10021025	SLC2A9	-0.58	-10.28	-0.53	4.51e-21	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs7927771	0.801	rs12798028	chr11:47604639	C/T	cg18512352	chr11:47633146	NA	-0.46	-7.06	-0.4	1.44e-11	Subjective well-being;
CESC	cis	rs72781680	0.898	rs111460347	chr2:24018833	G/A	cg20701182	chr2:24300061	SF3B14	0.63	5.65	0.33	4.21e-8	Lymphocyte counts;
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg26782824	chr11:82867961	PCF11	-0.39	-6.08	-0.35	4.14e-9	Vertical cup-disc ratio;
CESC	cis	rs9314323	0.729	rs7007256	chr8:26203081	G/A	cg13160058	chr8:26243215	BNIP3L	-0.34	-5.19	-0.3	4.21e-7	Red cell distribution width;
CESC	cis	rs4805272	0.626	rs12610050	chr19:29331324	A/T	cg12756686	chr19:29218302	NA	0.42	5.87	0.34	1.3e-8	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
CESC	cis	rs7589342	0.839	rs12997003	chr2:106436413	C/T	cg16077055	chr2:106428750	NCK2	0.53	7.53	0.42	8e-13	Addiction;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg19952014	chr10:3186114	PITRM1	-0.47	-6.09	-0.35	3.85e-9	Systemic lupus erythematosus;
CESC	cis	rs10504229	1.000	rs116444534	chr8:58181915	A/G	cg02725872	chr8:58115012	NA	-0.37	-5.61	-0.33	5.1e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs1799949	1.000	rs8176120	chr17:41261233	C/T	cg23758822	chr17:41437982	NA	1.01	15.76	0.7	6.41e-40	Menopause (age at onset);
CESC	cis	rs6088580	0.634	rs3736762	chr20:33037336	C/T	cg24642439	chr20:33292090	TP53INP2	0.52	6.82	0.39	6.28e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs2072499	0.750	rs909269	chr1:156192028	C/T	cg24450063	chr1:156163899	SLC25A44	0.9	10.96	0.56	2.73e-23	Testicular germ cell tumor;
CESC	cis	rs1018836	0.923	rs10956720	chr8:91576222	C/T	cg16814680	chr8:91681699	NA	-0.71	-10.1	-0.53	1.67e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs10504229	0.683	rs11785260	chr8:58132906	A/G	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs3091242	0.934	rs686631	chr1:25719599	A/T	cg02931644	chr1:25747376	RHCE	0.39	6.39	0.37	7.63e-10	Erythrocyte sedimentation rate;
CESC	cis	rs9322193	0.923	rs3798761	chr6:150004779	A/G	cg04369109	chr6:150039330	LATS1	-0.42	-5.81	-0.34	1.81e-8	Lung cancer;
CESC	cis	rs2380220	0.872	rs2613529	chr6:95945036	C/T	cg15832292	chr6:96025679	MANEA	-0.64	-5.71	-0.33	2.99e-8	Behavioural disinhibition (generation interaction);
CESC	cis	rs1670533	1.000	rs935970	chr4:1045323	C/G	cg27284194	chr4:1044797	NA	-0.49	-6.14	-0.35	3.08e-9	Recombination rate (females);
CESC	cis	rs2180341	0.814	rs7768435	chr6:127737038	A/C	cg27446573	chr6:127587934	RNF146	0.83	12.03	0.59	6.99e-27	Breast cancer;
CESC	cis	rs3105593	0.563	rs12439561	chr15:50962156	C/T	cg08437265	chr15:50716283	USP8	0.4	5.06	0.3	8.01e-7	QT interval;
CESC	cis	rs67311347	1.000	rs2887995	chr3:40409029	C/G	cg01475735	chr3:40494733	NA	-0.39	-5.06	-0.3	7.93e-7	Renal cell carcinoma;
CESC	cis	rs11642862	1.000	rs112234000	chr16:30778808	G/A	cg02466173	chr16:30829666	NA	-0.6	-6.08	-0.35	4.15e-9	Tonsillectomy;
CESC	cis	rs854765	0.583	rs6502622	chr17:17834691	A/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.55	7.35	0.41	2.5e-12	Total body bone mineral density;
CESC	cis	rs8114671	0.836	rs2038504	chr20:33648187	T/C	cg07148914	chr20:33460835	GGT7	-0.4	-5.11	-0.3	6.21e-7	Height;
CESC	cis	rs660498	0.507	rs4018735	chr10:27741298	T/C	cg25705717	chr10:27608719	NA	0.47	5.73	0.33	2.73e-8	Asthma (childhood onset);
CESC	cis	rs4689592	0.503	rs66885632	chr4:7053738	T/C	cg19539972	chr4:7069911	GRPEL1	-0.75	-7.44	-0.42	1.43e-12	Monocyte percentage of white cells;
CESC	cis	rs801193	0.548	rs2109297	chr7:66122384	G/A	cg10691866	chr7:65817282	TPST1	0.31	5.34	0.31	2e-7	Aortic root size;
CESC	cis	rs6502050	0.842	rs9894129	chr17:80075700	A/G	cg23985595	chr17:80112537	CCDC57	0.41	6.42	0.37	6.41e-10	Life satisfaction;
CESC	trans	rs1814175	0.565	rs4881721	chr11:49761851	G/A	cg03929089	chr4:120376271	NA	-0.7	-8.94	-0.48	7e-17	Height;
CESC	trans	rs17764205	0.929	rs10422137	chr19:3256521	C/T	cg27384338	chr17:2031545	SMG6	-0.64	-6.08	-0.35	4.2e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs763014	0.966	rs4144003	chr16:645968	C/T	cg00908189	chr16:619842	PIGQ	0.65	9.09	0.49	2.36e-17	Height;
CESC	trans	rs1814175	0.727	rs2140597	chr11:49873946	G/A	cg15704280	chr7:45808275	SEPT13	-1.02	-19.98	-0.78	8.73e-55	Height;
CESC	cis	rs7771547	0.573	rs517890	chr6:36397786	G/C	cg04289385	chr6:36355825	ETV7	0.38	5.57	0.32	6.41e-8	Platelet distribution width;
CESC	cis	rs1799949	1.000	rs4793191	chr17:41204377	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.41	5.6	0.33	5.36e-8	Menopause (age at onset);
CESC	cis	rs6580649	0.941	rs1793933	chr12:48396450	G/T	cg24011408	chr12:48396354	COL2A1	0.41	5.31	0.31	2.28e-7	Lung cancer;
CESC	cis	rs6546550	0.867	rs7592647	chr2:70139134	C/T	cg02498382	chr2:70120550	SNRNP27	-0.38	-6.6	-0.38	2.17e-10	Prevalent atrial fibrillation;
CESC	cis	rs4974559	0.739	rs2335937	chr4:1321516	C/A	cg02980000	chr4:1222292	CTBP1	0.81	7.22	0.41	5.48e-12	Systolic blood pressure;
CESC	cis	rs6445797	0.632	rs7626378	chr3:56602885	A/T	cg13792233	chr3:56591045	CCDC66	0.39	5.11	0.3	6.18e-7	Gastritis;
CESC	cis	rs10504229	0.861	rs6990617	chr8:58182960	G/T	cg24829409	chr8:58192753	C8orf71	-0.76	-9.93	-0.52	5.87e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs4595586	0.525	rs1878227	chr12:39355719	A/T	cg13010199	chr12:38710504	ALG10B	0.45	5.65	0.33	4.09e-8	Morning vs. evening chronotype;
CESC	cis	rs3733585	0.673	rs6814664	chr4:9956228	C/T	cg11266682	chr4:10021025	SLC2A9	-0.59	-11.16	-0.57	5.9e-24	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs898097	0.841	rs8180	chr17:80901036	C/G	cg15369054	chr17:80825471	TBCD	-0.47	-6.67	-0.38	1.51e-10	Breast cancer;
CESC	cis	rs2836974	0.605	rs2836971	chr21:40652040	A/C	cg11890956	chr21:40555474	PSMG1	-0.95	-15.4	-0.69	1.2e-38	Cognitive function;
CESC	cis	rs896854	0.608	rs6991067	chr8:95875676	A/G	cg23172400	chr8:95962367	TP53INP1	-0.4	-8.19	-0.45	1.12e-14	Type 2 diabetes;
CESC	cis	rs10851478	0.708	rs11639111	chr15:49749735	C/T	cg08060515	chr15:49448048	GALK2;COPS2	0.41	5.46	0.32	1.11e-7	Oral cavity cancer;
CESC	cis	rs514406	0.505	rs431459	chr1:53183230	T/G	cg16325326	chr1:53192061	ZYG11B	0.9	16.03	0.7	7.12e-41	Monocyte count;
CESC	cis	rs798554	0.610	rs2527696	chr7:2858315	T/C	cg04166393	chr7:2884313	GNA12	0.39	5.15	0.3	5.07e-7	Height;
CESC	cis	rs909002	1.000	rs1474182	chr1:32136398	C/T	cg13919466	chr1:32135498	COL16A1	-0.51	-9.76	-0.51	1.95e-19	Intelligence (multi-trait analysis);
CESC	cis	rs8031584	0.678	rs3122	chr15:31170290	A/T	cg08704250	chr15:31115839	NA	0.69	9.09	0.49	2.46e-17	Huntington's disease progression;
CESC	cis	rs4595586	0.679	rs4768471	chr12:39325960	G/A	cg26384229	chr12:38710491	ALG10B	0.43	6.25	0.36	1.62e-9	Morning vs. evening chronotype;
CESC	cis	rs7255436	1.000	rs7255436	chr19:8433196	C/A	cg10174797	chr19:8464628	RAB11B	0.4	5.81	0.34	1.8e-8	HDL cholesterol;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23885512	chr19:45515293	RELB	-0.52	-6.37	-0.36	8.28e-10	Gut microbiome composition (summer);
CESC	cis	rs2120019	0.938	rs8030089	chr15:75290377	C/T	cg17294928	chr15:75287854	SCAMP5	-0.76	-8.91	-0.48	8.57e-17	Blood trace element (Zn levels);
CESC	cis	rs7647973	0.626	rs9830730	chr3:49675875	G/C	cg13072238	chr3:49761600	GMPPB	-0.45	-5.47	-0.32	1.04e-7	Menarche (age at onset);
CESC	cis	rs875971	0.862	rs7798630	chr7:65771479	G/C	cg18876405	chr7:65276391	NA	-0.51	-7.07	-0.4	1.39e-11	Aortic root size;
CESC	cis	rs397969	0.596	rs4925064	chr17:19901405	T/C	cg12073167	chr17:19770448	ULK2	-0.46	-5.28	-0.31	2.63e-7	Platelet count;
CESC	cis	rs911555	0.504	rs4444269	chr14:104072724	G/C	cg12935359	chr14:103987150	CKB	-0.52	-7.55	-0.42	7.03e-13	Intelligence (multi-trait analysis);
CESC	cis	rs244293	1.000	rs183618	chr17:53235974	C/T	cg19360675	chr17:53046073	COX11;STXBP4	0.39	5.06	0.3	7.98e-7	Menarche (age at onset);
CESC	cis	rs1448094	0.512	rs4488288	chr12:86245450	A/C	cg02569458	chr12:86230093	RASSF9	0.49	7.27	0.41	3.98e-12	Major depressive disorder;
CESC	cis	rs258892	0.846	rs266441	chr5:72197677	A/G	cg21869765	chr5:72125136	TNPO1	0.43	5.32	0.31	2.22e-7	Small cell lung carcinoma;
CESC	cis	rs4268898	0.717	rs3731626	chr2:24427864	G/A	cg20701182	chr2:24300061	SF3B14	0.56	6.18	0.35	2.4e-9	Asthma;
CESC	cis	rs9325144	0.581	rs2653758	chr12:38946233	G/T	cg26384229	chr12:38710491	ALG10B	-0.59	-9.0	-0.48	4.56e-17	Morning vs. evening chronotype;
CESC	cis	rs11264213	0.786	rs72659677	chr1:36257353	A/T	cg27506609	chr1:36549197	TEKT2	0.61	5.04	0.3	8.54e-7	Schizophrenia;
CESC	cis	rs1371867	0.846	rs959022	chr8:101295992	T/A	cg11906718	chr8:101322791	RNF19A	0.54	6.93	0.39	3.24e-11	Atrioventricular conduction;
CESC	cis	rs11098499	0.644	rs7676296	chr4:120555687	A/G	cg09307838	chr4:120376055	NA	0.77	10.24	0.53	5.82e-21	Corneal astigmatism;
CESC	cis	rs10129255	0.556	rs9324093	chr14:107139910	C/T	cg23076370	chr14:107095027	NA	-0.53	-7.36	-0.41	2.27e-12	Kawasaki disease;
CESC	cis	rs703842	0.616	rs7489290	chr12:58228588	C/G	cg00677455	chr12:58241039	CTDSP2	0.77	10.41	0.54	1.74e-21	Multiple sclerosis;
CESC	cis	rs1559088	0.947	rs10403238	chr19:33552405	A/G	cg27124370	chr19:33622961	WDR88	0.42	5.34	0.31	1.98e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	trans	rs11098499	0.954	rs67265404	chr4:120359270	C/T	cg25214090	chr10:38739885	LOC399744	0.71	9.89	0.52	7.9e-20	Corneal astigmatism;
CESC	cis	rs8067545	0.611	rs7212500	chr17:20045658	A/G	cg13482628	chr17:19912719	NA	0.43	5.72	0.33	2.88e-8	Schizophrenia;
CESC	cis	rs9322193	0.962	rs4869731	chr6:150131208	T/C	cg13206674	chr6:150067644	NUP43	0.42	5.82	0.34	1.66e-8	Lung cancer;
CESC	cis	rs10276381	0.579	rs73072543	chr7:28146850	A/G	cg23620719	chr7:28220237	JAZF1	0.65	5.19	0.3	4.13e-7	Crohn's disease;
CESC	cis	rs3540	0.553	rs8042861	chr15:90977333	G/T	cg10434728	chr15:90938212	IQGAP1	0.38	7.02	0.4	1.82e-11	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs13191362	1.000	rs60719662	chr6:163006643	A/C	cg06582575	chr6:163149167	PACRG;PARK2	0.78	8.21	0.45	9.97e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs9399401	0.601	rs643975	chr6:142844251	C/G	cg03128060	chr6:142623767	GPR126	-0.31	-5.24	-0.31	3.31e-7	Chronic obstructive pulmonary disease;
CESC	cis	rs11711311	1.000	rs9811200	chr3:113531180	A/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.74	10.46	0.54	1.12e-21	IgG glycosylation;
CESC	cis	rs12497850	0.931	rs7643368	chr3:48992855	T/G	cg03060546	chr3:49711283	APEH	0.5	6.16	0.35	2.75e-9	Parkinson's disease;
CESC	cis	rs7191439	0.790	rs8060966	chr16:88777329	A/G	cg02389323	chr16:88786976	FAM38A	0.79	6.85	0.39	5.16e-11	Plateletcrit;
CESC	cis	rs6740322	0.895	rs10210125	chr2:43556433	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.7	-7.43	-0.42	1.52e-12	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10957254	chr1:54411942	LRRC42;HSPB11	0.55	6.18	0.35	2.34e-9	Gut microbiome composition (summer);
CESC	cis	rs708547	0.581	rs781661	chr4:57780307	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.51	-6.59	-0.38	2.31e-10	Response to bleomycin (chromatid breaks);
CESC	cis	rs896854	0.654	rs28716845	chr8:95974485	A/G	cg16049864	chr8:95962084	TP53INP1	-0.65	-11.4	-0.57	9.17e-25	Type 2 diabetes;
CESC	cis	rs7914558	0.966	rs10748836	chr10:104693917	G/A	cg04362960	chr10:104952993	NT5C2	0.43	5.53	0.32	7.76e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs7666738	0.830	rs6819047	chr4:98866902	G/A	cg03467027	chr4:99064603	C4orf37	0.42	5.16	0.3	4.73e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2404602	0.692	rs8024476	chr15:76983954	T/C	cg26408565	chr15:76604113	ETFA	-0.38	-5.44	-0.32	1.2e-7	Blood metabolite levels;
CESC	cis	rs57221529	0.545	rs55955015	chr5:575182	A/G	cg16447950	chr5:562315	NA	-0.64	-6.8	-0.39	7.01e-11	Lung disease severity in cystic fibrosis;
CESC	cis	rs4718428	0.672	rs4718412	chr7:66286867	C/T	cg18252515	chr7:66147081	NA	0.5	5.37	0.31	1.75e-7	Corneal structure;
CESC	cis	rs6430585	0.528	rs895285	chr2:136710554	A/G	cg07169764	chr2:136633963	MCM6	1.27	17.82	0.74	3.19e-47	Corneal structure;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06111627	chr3:127309564	TPRA1	-0.61	-7.05	-0.4	1.54e-11	Gut microbiome composition (summer);
CESC	cis	rs7917772	0.505	rs61869211	chr10:104449836	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.51	5.83	0.34	1.65e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg05783302	chr2:47143505	MCFD2	0.46	6.71	0.38	1.2e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs3733585	0.624	rs58130873	chr4:9972081	T/C	cg02734326	chr4:10020555	SLC2A9	-0.39	-5.52	-0.32	8.08e-8	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs2637266	0.678	rs1797495	chr10:78577602	G/A	cg18941641	chr10:78392320	NA	0.39	7.5	0.42	9.5e-13	Pulmonary function;
CESC	cis	rs875971	0.862	rs880166	chr7:65670762	T/C	cg11764359	chr7:65958608	NA	-0.79	-11.5	-0.58	4.33e-25	Aortic root size;
CESC	cis	rs1144333	0.850	rs1146651	chr1:76273594	C/A	cg22875332	chr1:76189707	ACADM	-0.53	-5.15	-0.3	5.11e-7	Attention function in attention deficit hyperactive disorder;
CESC	cis	rs8060686	0.920	rs60769312	chr16:67732186	C/T	cg26727032	chr16:67993705	SLC12A4	-0.57	-6.0	-0.35	6.41e-9	HDL cholesterol;Metabolic syndrome;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07697561	chr5:140998635	DIAPH1	0.55	6.41	0.37	6.61e-10	Gut microbiome composition (summer);
CESC	cis	rs2760061	0.598	rs1774755	chr1:228115282	T/G	cg01973587	chr1:228161476	NA	0.35	5.32	0.31	2.17e-7	Diastolic blood pressure;
CESC	cis	rs6938	0.618	rs11633472	chr15:75184084	T/G	cg09165964	chr15:75287851	SCAMP5	0.45	6.19	0.36	2.28e-9	Breast cancer;
CESC	cis	rs9322193	0.962	rs952165	chr6:150120036	T/C	cg04369109	chr6:150039330	LATS1	-0.39	-5.35	-0.31	1.93e-7	Lung cancer;
CESC	cis	rs1448094	0.511	rs10779207	chr12:86152913	A/G	cg00310523	chr12:86230176	RASSF9	-0.31	-5.04	-0.3	8.55e-7	Major depressive disorder;
CESC	trans	rs11098499	0.754	rs2036860	chr4:120248934	A/G	cg25214090	chr10:38739885	LOC399744	0.62	8.71	0.47	3.41e-16	Corneal astigmatism;
CESC	cis	rs1008375	0.898	rs7670500	chr4:17586957	A/G	cg16339924	chr4:17578868	LAP3	0.73	9.53	0.51	1.03e-18	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs3749237	0.615	rs6792911	chr3:49429856	C/T	cg06212747	chr3:49208901	KLHDC8B	0.5	6.82	0.39	6.12e-11	Resting heart rate;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14521523	chr1:115212675	DENND2C	0.56	6.81	0.39	6.52e-11	Gut microbiome composition (summer);
CESC	cis	rs796364	1.000	rs10178177	chr2:200829993	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.85	8.43	0.46	2.18e-15	Schizophrenia;
CESC	cis	rs9814567	0.712	rs9838119	chr3:134331980	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.4	-5.1	-0.3	6.38e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs1552244	1.000	rs58275763	chr3:10143274	C/T	cg16606324	chr3:10149918	C3orf24	0.41	5.09	0.3	6.8e-7	Alzheimer's disease;
CESC	cis	rs6088580	0.634	rs6059835	chr20:33020141	A/G	cg06115741	chr20:33292138	TP53INP2	0.48	6.14	0.35	3e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs67311347	0.824	rs59922539	chr3:40337110	G/A	cg24209194	chr3:40518798	ZNF619	0.44	5.51	0.32	8.39e-8	Renal cell carcinoma;
CESC	cis	rs8020095	0.571	rs2281676	chr14:67638455	C/G	cg19548862	chr14:67692701	FAM71D	0.48	5.87	0.34	1.29e-8	Depression (quantitative trait);
CESC	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg23708337	chr7:1209742	NA	0.55	5.42	0.32	1.33e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs1707322	1.000	rs7538978	chr1:46505054	C/T	cg06784218	chr1:46089804	CCDC17	-0.34	-5.86	-0.34	1.34e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9818758	0.556	rs9880309	chr3:49304329	G/C	cg00383909	chr3:49044727	WDR6	0.81	6.16	0.35	2.63e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CESC	cis	rs9487051	0.872	rs6924776	chr6:109612276	A/G	cg12927641	chr6:109611667	NA	-0.43	-6.75	-0.38	9.5e-11	Reticulocyte fraction of red cells;
CESC	cis	rs2303759	0.676	rs7248378	chr19:49908144	C/A	cg22307029	chr19:49891270	CCDC155	0.62	7.28	0.41	3.8e-12	Multiple sclerosis;
CESC	cis	rs763121	0.853	rs5750621	chr22:38956166	C/T	cg06544989	chr22:39130855	UNC84B	0.49	8.16	0.45	1.35e-14	Menopause (age at onset);
CESC	cis	rs853679	0.517	rs9380062	chr6:28137569	G/A	cg23281280	chr6:28129359	ZNF389	0.56	7.62	0.42	4.55e-13	Depression;
CESC	cis	rs4523957	0.651	rs8082485	chr17:2060407	A/G	cg16513277	chr17:2031491	SMG6	-0.72	-10.2	-0.53	8.12e-21	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08730051	chr6:4018948	NA	0.58	6.24	0.36	1.69e-9	Gut microbiome composition (summer);
CESC	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.6	0.38	2.17e-10	Prudent dietary pattern;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05157023	chr16:2027451	TBL3	-0.55	-6.8	-0.39	7.09e-11	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.830	rs6851253	chr4:99029980	A/G	cg24818145	chr4:99064322	C4orf37	0.39	5.09	0.3	6.95e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1707322	1.000	rs785470	chr1:46519622	C/A	cg03146154	chr1:46216737	IPP	-0.72	-9.73	-0.51	2.49e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs4319547	0.956	rs9988963	chr12:122991478	C/G	cg23029597	chr12:123009494	RSRC2	-0.48	-5.28	-0.31	2.65e-7	Body mass index;
CESC	cis	rs11638352	1.000	rs2957581	chr15:44410082	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	-0.61	-5.62	-0.33	4.75e-8	Lipoprotein phospholipase A2 activity in cardiovascular disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06203126	chr5:43313815	HMGCS1	-0.63	-7.43	-0.42	1.47e-12	Gut microbiome composition (summer);
CESC	cis	rs6459788	0.527	rs6980250	chr7:157228710	C/T	cg06271696	chr7:157225062	NA	-0.48	-8.21	-0.45	9.6e-15	Epstein-Barr virus copy number in lymphoblastoid cell lines;
CESC	cis	rs7772486	0.597	rs9386136	chr6:146158300	A/T	cg23711669	chr6:146136114	FBXO30	0.95	12.44	0.61	2.75e-28	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1008375	1.000	rs2286771	chr4:17643848	G/A	cg15017067	chr4:17643749	FAM184B	0.35	5.07	0.3	7.59e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs4808199	0.649	rs17216693	chr19:19666574	T/C	cg03709012	chr19:19516395	GATAD2A	0.99	8.48	0.46	1.56e-15	Nonalcoholic fatty liver disease;
CESC	cis	rs6540556	0.723	rs6702301	chr1:209923154	C/T	cg23920097	chr1:209922102	NA	-0.36	-5.04	-0.3	8.5e-7	Red blood cell count;
CESC	cis	rs2882667	0.858	rs11242447	chr5:138426173	T/C	cg04439458	chr5:138467593	SIL1	-0.44	-6.79	-0.39	7.19e-11	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs9733	0.650	rs1971378	chr1:150597261	C/T	cg18016565	chr1:150552671	MCL1	-0.42	-7.02	-0.4	1.89e-11	Tonsillectomy;
CESC	cis	rs3026445	0.714	rs28764794	chr12:110843797	T/G	cg12870014	chr12:110450643	ANKRD13A	0.41	5.03	0.3	9.17e-7	QT interval;
CESC	cis	rs3733585	0.624	rs76574510	chr4:9953252	T/A	cg11266682	chr4:10021025	SLC2A9	-0.58	-11.0	-0.56	2.04e-23	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs12410462	0.582	rs12408978	chr1:227596235	A/T	cg23173402	chr1:227635558	NA	-0.69	-6.57	-0.37	2.63e-10	Major depressive disorder;
CESC	cis	rs208346	0.612	rs208356	chr7:2775825	A/T	cg09658497	chr7:2847517	GNA12	0.44	6.74	0.38	9.72e-11	Loneliness (linear analysis);
CESC	cis	rs1707322	1.000	rs7539800	chr1:46262129	C/G	cg06784218	chr1:46089804	CCDC17	-0.36	-6.04	-0.35	5.11e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs67311347	0.866	rs56331709	chr3:40356558	A/C	cg24209194	chr3:40518798	ZNF619	0.4	5.06	0.3	7.92e-7	Renal cell carcinoma;
CESC	cis	rs17376456	0.825	rs1470150	chr5:93138654	C/T	cg21475434	chr5:93447410	FAM172A	-0.63	-5.93	-0.34	9.5e-9	Diabetic retinopathy;
CESC	cis	rs7520050	0.778	rs3014218	chr1:46026328	A/C	cg24296786	chr1:45957014	TESK2	0.5	6.37	0.36	8.3e-10	Red blood cell count;Reticulocyte count;
CESC	cis	rs3106136	0.967	rs7435106	chr4:95169772	T/A	cg11021082	chr4:95130006	SMARCAD1	-0.46	-6.81	-0.39	6.61e-11	Capecitabine sensitivity;
CESC	cis	rs9287719	0.967	rs6432121	chr2:10753804	G/C	cg00105475	chr2:10696890	NA	0.38	5.42	0.32	1.34e-7	Prostate cancer;
CESC	cis	rs6942756	0.806	rs2718115	chr7:128871532	A/G	cg02491457	chr7:128862824	NA	0.65	9.69	0.51	3.3e-19	White matter hyperintensity burden;
CESC	cis	rs11190604	1.000	rs3793772	chr10:102222825	A/G	cg07080220	chr10:102295463	HIF1AN	0.56	5.82	0.34	1.74e-8	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.64	7.2	0.4	6.15e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs9611565	0.649	rs139559	chr22:42191636	A/G	cg06634786	chr22:41940651	POLR3H	-0.46	-5.12	-0.3	5.88e-7	Vitiligo;
CESC	cis	rs7615952	0.932	rs13325495	chr3:125637416	T/G	cg05084668	chr3:125655381	ALG1L	-0.5	-5.64	-0.33	4.29e-8	Blood pressure (smoking interaction);
CESC	cis	rs7267979	0.934	rs4815423	chr20:25387521	A/G	cg08601574	chr20:25228251	PYGB	-0.37	-5.39	-0.31	1.55e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs72615157	0.561	rs113844570	chr7:99873778	A/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.66	6.25	0.36	1.6e-9	Lung function (FEV1/FVC);
CESC	cis	rs17854409	0.881	rs68066790	chr20:61487150	T/A	cg05147244	chr20:61493195	TCFL5	0.95	6.68	0.38	1.44e-10	Obesity-related traits;
CESC	cis	rs9948	0.655	rs3731940	chr2:97377883	A/G	cg01990225	chr2:97406019	LMAN2L	0.84	7.22	0.41	5.49e-12	Erectile dysfunction and prostate cancer treatment;
CESC	cis	rs738322	0.967	rs133021	chr22:38573338	T/C	cg17652424	chr22:38574118	PLA2G6	-0.36	-6.21	-0.36	2.05e-9	Cutaneous nevi;
CESC	cis	rs2228479	0.867	rs11646448	chr16:89966357	A/T	cg04013166	chr16:89971882	TCF25	0.72	7.22	0.41	5.46e-12	Skin colour saturation;
CESC	cis	rs10540	1.000	rs61876336	chr11:489537	C/T	cg03576123	chr11:487126	PTDSS2	-1.08	-10.46	-0.54	1.12e-21	Body mass index;
CESC	cis	rs9929218	1.000	rs9282650	chr16:68809640	T/A	cg02972257	chr16:68554789	NA	0.43	5.12	0.3	5.89e-7	Colorectal cancer;
CESC	cis	rs6831352	0.879	rs34360292	chr4:100051303	T/C	cg13256891	chr4:100009986	ADH5	-0.77	-8.43	-0.46	2.27e-15	Alcohol dependence;
CESC	cis	rs8141529	0.748	rs132528	chr22:29295898	C/T	cg02153584	chr22:29168773	CCDC117	-0.58	-7.63	-0.42	4.31e-13	Lymphocyte counts;
CESC	cis	rs2721195	0.719	rs4925812	chr8:145808035	C/T	cg17328964	chr8:145687451	CYHR1	-0.44	-5.88	-0.34	1.22e-8	Age at first birth;
CESC	cis	rs17711722	0.510	rs11767457	chr7:65290615	C/T	cg26939375	chr7:64535504	NA	0.65	8.76	0.47	2.34e-16	Calcium levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23031969	chr7:5014415	RNF216L	0.53	6.52	0.37	3.44e-10	Gut microbiome composition (summer);
CESC	cis	rs73110464	0.609	rs6580923	chr12:53358352	A/G	cg14581129	chr12:53358946	NA	-0.58	-7.83	-0.43	1.19e-13	Cancer (pleiotropy);
CESC	cis	rs12701220	0.503	rs12702047	chr7:1132720	G/A	cg23978390	chr7:1156363	C7orf50	0.58	5.12	0.3	5.78e-7	Bronchopulmonary dysplasia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01728866	chr1:43638014	WDR65;EBNA1BP2	0.62	6.39	0.37	7.52e-10	Gut microbiome composition (summer);
CESC	cis	rs2549003	0.811	rs10072700	chr5:131816903	A/C	cg21138405	chr5:131827807	IRF1	0.44	5.63	0.33	4.68e-8	Asthma (sex interaction);
CESC	cis	rs6062302	0.522	rs3810492	chr20:62219740	G/A	cg09650180	chr20:62225654	GMEB2	-0.76	-8.5	-0.46	1.43e-15	Glioblastoma;
CESC	cis	rs6540559	0.611	rs11810817	chr1:210011747	C/G	cg23283495	chr1:209979779	IRF6	0.48	5.62	0.33	4.86e-8	Cleft lip with or without cleft palate;
CESC	cis	rs1975974	1.000	rs111981054	chr17:21725592	C/G	cg18423549	chr17:21743878	NA	-0.5	-6.92	-0.39	3.31e-11	Psoriasis;
CESC	cis	rs9894429	0.683	rs112612275	chr17:79552604	C/A	cg21984481	chr17:79567631	NPLOC4	0.57	9.29	0.5	5.85e-18	Eye color traits;
CESC	cis	rs7618915	0.547	rs11177	chr3:52721305	G/A	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.31	5.61	0.33	5.08e-8	Bipolar disorder;
CESC	cis	rs875971	0.862	rs13232191	chr7:65986648	A/G	cg12463550	chr7:65579703	CRCP	0.51	6.36	0.36	8.66e-10	Aortic root size;
CESC	trans	rs9929218	0.817	rs3114400	chr16:68719430	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.84	-11.02	-0.56	1.68e-23	Colorectal cancer;
CESC	cis	rs854765	0.583	rs6502627	chr17:17849671	C/T	cg16928487	chr17:17741425	SREBF1	-0.57	-9.57	-0.51	7.66e-19	Total body bone mineral density;
CESC	cis	rs12220238	1.000	rs7897778	chr10:75916105	T/G	cg19889307	chr10:75911429	ADK;AP3M1	0.63	6.2	0.36	2.13e-9	Soluble interleukin-2 receptor subunit alpha;
CESC	cis	rs2531992	0.702	rs1045475	chr16:4015316	A/G	cg05927578	chr16:4029543	ADCY9	0.46	6.1	0.35	3.72e-9	Waist circumference;
CESC	cis	rs853679	0.517	rs9393894	chr6:28112562	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.58	-6.54	-0.37	3.12e-10	Depression;
CESC	cis	rs116095464	0.510	rs7714944	chr5:231765	C/T	cg10591111	chr5:226296	SDHA	-0.49	-5.9	-0.34	1.14e-8	Breast cancer;
CESC	cis	rs2718058	0.519	rs2722243	chr7:37873467	A/C	cg15028436	chr7:37888078	TXNDC3	0.44	6.58	0.37	2.5e-10	Alzheimer's disease (late onset);
CESC	cis	rs2228479	0.850	rs62056065	chr16:89905115	C/G	cg14709524	chr16:89940631	TCF25	0.88	6.1	0.35	3.82e-9	Skin colour saturation;
CESC	cis	rs1499614	1.000	rs1267818	chr7:66107024	C/T	cg18252515	chr7:66147081	NA	-1.4	-14.2	-0.66	2.03e-34	Gout;
CESC	cis	rs870825	0.616	rs28620459	chr4:185627132	G/C	cg04058563	chr4:185651563	MLF1IP	0.65	7.08	0.4	1.31e-11	Blood protein levels;
CESC	cis	rs1862618	0.526	rs2591963	chr5:56237135	T/A	cg18230493	chr5:56204884	C5orf35	0.8	9.57	0.51	8.02e-19	Initial pursuit acceleration;
CESC	cis	rs6933660	0.800	rs6930557	chr6:151755806	G/A	cg14416726	chr6:151773293	C6orf211;RMND1	-0.5	-6.66	-0.38	1.53e-10	Menarche (age at onset);
CESC	cis	rs7746199	0.736	rs34573979	chr6:27480526	C/T	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.87	6.22	0.36	1.96e-9	Gait speed in old age;Autism spectrum disorder or schizophrenia;
CESC	cis	rs6540559	1.000	rs1044516	chr1:209959614	G/T	cg09509183	chr1:209979624	IRF6	0.45	5.61	0.33	5.18e-8	Cleft lip with or without cleft palate;
CESC	cis	rs11640533	0.901	rs11862250	chr16:53415038	C/A	cg09744766	chr16:53407421	NA	0.41	5.32	0.31	2.24e-7	Intelligence (multi-trait analysis);
CESC	cis	rs262150	0.659	rs2527237	chr7:158798494	A/G	cg19418458	chr7:158789849	NA	0.5	8.02	0.44	3.42e-14	Facial morphology (factor 20);
CESC	cis	rs4409675	0.548	rs1000432	chr1:28225119	T/C	cg23691781	chr1:28212827	C1orf38	0.28	5.64	0.33	4.46e-8	Corneal astigmatism;
CESC	cis	rs7746199	0.736	rs34573979	chr6:27480526	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.73	-5.08	-0.3	6.98e-7	Gait speed in old age;Autism spectrum disorder or schizophrenia;
CESC	cis	rs1799949	0.930	rs4445938	chr17:41337900	A/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.62	8.39	0.46	2.99e-15	Menopause (age at onset);
CESC	cis	rs7107356	1	rs7107356	chr11:47676170	A/G	cg18512352	chr11:47633146	NA	0.41	6.43	0.37	5.94e-10	Neuroticism;Neuroticism (multi-trait analysis);
CESC	cis	rs2115630	0.691	rs61322921	chr15:85163638	T/C	cg11189052	chr15:85197271	WDR73	-0.46	-6.15	-0.35	2.77e-9	P wave terminal force;
CESC	trans	rs7107217	1.000	rs1873872	chr11:129473993	A/T	cg06134974	chr12:51477539	CSRNP2	0.46	6.16	0.35	2.76e-9	Breast cancer;Type 2 diabetes;
CESC	trans	rs561341	0.709	rs8068049	chr17:30183857	T/C	cg27661571	chr11:113659931	NA	0.68	6.13	0.35	3.22e-9	Hip circumference adjusted for BMI;
CESC	cis	rs910316	0.935	rs175422	chr14:75627319	T/A	cg08847533	chr14:75593920	NEK9	-0.97	-17.65	-0.74	1.22e-46	Height;
CESC	trans	rs7246657	0.941	rs7256130	chr19:37933981	T/C	cg01833234	chr11:6592585	DNHD1	0.52	6.03	0.35	5.4e-9	Coronary artery calcification;
CESC	cis	rs10781543	0.845	rs36066734	chr9:139340351	A/G	cg14169450	chr9:139327907	INPP5E	0.52	7.91	0.44	7.04e-14	Monocyte percentage of white cells;
CESC	cis	rs910316	0.763	rs175057	chr14:75489632	C/T	cg16144293	chr14:75469539	EIF2B2	0.41	5.27	0.31	2.83e-7	Height;
CESC	cis	rs10791097	1.000	rs10791097	chr11:130718630	G/T	cg14779329	chr11:130786720	SNX19	-0.39	-6.02	-0.35	5.8e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs12579753	0.810	rs1922565	chr12:82135348	T/C	cg23701643	chr12:82153290	PPFIA2	-0.33	-5.03	-0.3	9.06e-7	Resting heart rate;
CESC	cis	rs7605827	0.930	rs11691286	chr2:15558580	G/T	cg19274914	chr2:15703543	NA	0.36	6.56	0.37	2.83e-10	Educational attainment (years of education);
CESC	cis	rs597539	0.616	rs513476	chr11:68698996	C/T	cg04772025	chr11:68637568	NA	0.53	6.44	0.37	5.59e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs12144309	0.554	rs1217375	chr1:114346904	G/A	cg13572289	chr1:114447746	DCLRE1B;AP4B1	0.46	5.42	0.32	1.36e-7	Coronary artery disease;
CESC	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg18402987	chr7:1209562	NA	0.6	7.02	0.4	1.87e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs6598163	0.517	rs10902453	chr12:132297091	G/T	cg10319629	chr12:132285459	NA	-0.39	-5.32	-0.31	2.25e-7	Migraine;
CESC	cis	rs853679	0.517	rs9468297	chr6:28118874	G/T	cg12963246	chr6:28129442	ZNF389	0.59	7.68	0.43	3e-13	Depression;
CESC	cis	rs2708240	1.000	rs2710102	chr7:147574390	A/G	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.35	-5.77	-0.33	2.23e-8	QT interval (drug interaction);
CESC	cis	rs709400	0.663	rs62007683	chr14:103894071	G/T	cg12935359	chr14:103987150	CKB	-0.56	-8.22	-0.45	8.94e-15	Body mass index;
CESC	cis	rs41563	0.607	rs6955349	chr7:104601236	G/A	cg04380332	chr7:105027541	SRPK2	-0.38	-5.49	-0.32	9.44e-8	Autism spectrum disorder or schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17098829	chr15:71056133	UACA	0.58	6.92	0.39	3.36e-11	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00560722	chr10:101989177	CHUK	0.65	7.43	0.42	1.51e-12	Gut microbiome composition (summer);
CESC	cis	rs4566357	0.615	rs12328878	chr2:227918962	G/A	cg05526886	chr2:227700861	RHBDD1	-0.55	-6.97	-0.39	2.59e-11	Coronary artery disease;
CESC	cis	rs863345	0.565	rs7549123	chr1:158444920	A/T	cg12129480	chr1:158549410	OR10X1	-0.34	-6.69	-0.38	1.29e-10	Pneumococcal bacteremia;
CESC	cis	rs9303280	0.806	rs13380815	chr17:38027583	A/G	cg20243544	chr17:37824526	PNMT	0.5	6.43	0.37	5.86e-10	Self-reported allergy;
CESC	cis	rs7144547	0.803	rs8008602	chr14:81890171	T/A	cg02996355	chr14:81879375	NA	-0.89	-10.05	-0.53	2.48e-20	Prudent dietary pattern;
CESC	cis	rs79349575	0.716	rs595767	chr17:46957987	A/G	cg16584676	chr17:46985605	UBE2Z	0.54	6.51	0.37	3.67e-10	Type 2 diabetes;
CESC	cis	rs7267979	1.000	rs7020	chr20:25278600	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.86	17.06	0.72	1.54e-44	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7129220	0.588	rs7950718	chr11:10086624	C/A	cg01453529	chr11:10209919	SBF2	-0.47	-5.31	-0.31	2.32e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12344046	chr22:30819716	SEC14L2	0.57	6.77	0.38	8.43e-11	Gut microbiome composition (summer);
CESC	cis	rs3806843	0.966	rs7737424	chr5:140146345	C/T	cg16179182	chr5:140090404	VTRNA1-1	-0.37	-5.03	-0.3	9.19e-7	Depressive symptoms (multi-trait analysis);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg21041512	chr17:79196677	AZI1	-0.37	-6.02	-0.35	5.78e-9	Gambling;
CESC	cis	rs2243480	1.000	rs73150014	chr7:65450919	A/C	cg18252515	chr7:66147081	NA	-1.21	-11.82	-0.59	3.44e-26	Diabetic kidney disease;
CESC	trans	rs1993709	0.558	rs2821248	chr1:72575560	A/G	cg01017228	chr4:745235	PCGF3	0.66	6.06	0.35	4.72e-9	Obesity (early onset extreme);
CESC	cis	rs11997175	0.600	rs6468188	chr8:33639478	T/C	ch.8.33884649F	chr8:33765107	NA	0.55	6.88	0.39	4.24e-11	Body mass index;
CESC	cis	rs34779708	0.966	rs10508816	chr10:35459976	G/A	cg03585969	chr10:35415529	CREM	0.77	10.23	0.53	6.59e-21	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs7208859	0.623	rs9911784	chr17:29124580	A/C	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.79e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs1707322	1.000	rs11211223	chr1:46380605	C/T	cg03146154	chr1:46216737	IPP	0.75	10.26	0.53	5.08e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs1322639	0.614	rs9455889	chr6:169566087	A/T	cg03254818	chr6:169586852	NA	0.51	5.51	0.32	8.35e-8	Pulse pressure;
CESC	cis	rs3857536	0.813	rs2188589	chr6:66939570	C/T	cg07460842	chr6:66804631	NA	-0.42	-5.34	-0.31	1.96e-7	Blood trace element (Cu levels);
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg27343303	chr11:34380546	NA	0.45	6.07	0.35	4.39e-9	Systemic lupus erythematosus;
CESC	cis	rs870825	0.616	rs56232457	chr4:185628153	T/G	cg04058563	chr4:185651563	MLF1IP	0.64	7.03	0.4	1.8e-11	Blood protein levels;
CESC	cis	rs79387448	0.638	rs76255660	chr2:103091028	T/C	cg09003973	chr2:102972529	NA	0.9	7.15	0.4	8.25e-12	Gut microbiota (bacterial taxa);
CESC	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	-0.82	-12.18	-0.6	2.07e-27	Prudent dietary pattern;
CESC	cis	rs1371867	0.846	rs1788205	chr8:101306546	G/C	cg11906718	chr8:101322791	RNF19A	0.54	6.93	0.39	3.24e-11	Atrioventricular conduction;
CESC	cis	rs9811920	0.609	rs812657	chr3:99566329	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.51	-6.18	-0.35	2.42e-9	Axial length;
CESC	cis	rs1008375	0.966	rs12509962	chr4:17680292	G/A	cg02297831	chr4:17616191	MED28	0.45	5.76	0.33	2.32e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs6120849	0.663	rs6119548	chr20:33552612	A/G	cg24642439	chr20:33292090	TP53INP2	0.69	6.9	0.39	3.78e-11	Protein C levels;
CESC	cis	rs727505	0.954	rs28728448	chr7:124532938	T/A	cg23710748	chr7:124431027	NA	-0.46	-7.24	-0.41	4.98e-12	Lewy body disease;
CESC	cis	rs7267979	1.000	rs6115182	chr20:25410259	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.86	-18.04	-0.74	5.11e-48	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7336332	0.598	rs9581850	chr13:28012265	A/G	cg01674679	chr13:27998804	GTF3A	-0.58	-5.34	-0.31	2.04e-7	Weight;
CESC	cis	rs7095944	0.585	rs7080838	chr10:126419841	A/G	cg08799069	chr10:126477246	METTL10	0.44	6.64	0.38	1.82e-10	Asthma;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07972541	chr16:28961971	NFATC2IP	0.6	7.33	0.41	2.81e-12	Gut microbiome composition (summer);
CESC	cis	rs6598955	0.724	rs884533	chr1:26585657	G/T	cg00852783	chr1:26633632	UBXN11	0.42	6.1	0.35	3.84e-9	Obesity-related traits;
CESC	cis	rs4819052	0.851	rs2236444	chr21:46678226	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.78	10.22	0.53	6.76e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg04683551	chr10:14880332	HSPA14;CDNF	0.47	6.51	0.37	3.65e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs2243480	1.000	rs186378	chr7:65582058	A/C	cg13147721	chr7:65941812	NA	-0.99	-9.36	-0.5	3.5e-18	Diabetic kidney disease;
CESC	cis	rs4919087	0.962	rs10882883	chr10:99013312	A/G	cg25902810	chr10:99078978	FRAT1	0.66	9.41	0.5	2.54e-18	Monocyte count;
CESC	cis	rs4665809	1.000	rs750450	chr2:26324631	A/G	cg04944784	chr2:26401820	FAM59B	-0.7	-8.09	-0.45	2.12e-14	Gut microbiome composition (summer);
CESC	cis	rs2200578	1.000	rs62153845	chr2:99887162	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.48	5.05	0.3	8.33e-7	IgG glycosylation;
CESC	cis	rs9303401	0.538	rs2240258	chr17:56458183	C/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.91	9.5	0.5	1.27e-18	Cognitive test performance;
CESC	cis	rs4654899	0.601	rs6668094	chr1:21464387	C/T	cg05370193	chr1:21551575	ECE1	-0.36	-5.32	-0.31	2.25e-7	Superior frontal gyrus grey matter volume;
CESC	cis	rs10493773	0.609	rs11161651	chr1:86177816	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.44	-6.59	-0.38	2.4e-10	Urate levels in overweight individuals;
CESC	cis	rs835154	1.000	rs835154	chr5:14876569	A/G	cg18064842	chr5:14874549	NA	0.37	5.57	0.32	6.33e-8	Blood metabolite levels;
CESC	cis	rs2836950	0.501	rs35994303	chr21:40686020	C/T	cg17971929	chr21:40555470	PSMG1	-0.54	-6.88	-0.39	4.3e-11	Menarche (age at onset);
CESC	cis	rs12586317	0.547	rs74462850	chr14:35500093	G/T	cg16230307	chr14:35515116	FAM177A1	0.99	10.61	0.55	3.72e-22	Psoriasis;
CESC	cis	rs34779708	0.931	rs7099593	chr10:35366878	A/C	cg03585969	chr10:35415529	CREM	0.76	10.09	0.53	1.8e-20	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs2629540	0.889	rs4962699	chr10:126477209	A/G	cg08799069	chr10:126477246	METTL10	-0.7	-9.66	-0.51	4.21e-19	Cocaine dependence;
CESC	cis	rs4132509	1.000	rs320320	chr1:243835186	A/G	cg21452805	chr1:244014465	NA	0.46	5.6	0.33	5.3e-8	RR interval (heart rate);
CESC	cis	rs2404602	0.655	rs10444809	chr15:77124536	G/C	cg23625390	chr15:77176239	SCAPER	-0.37	-5.15	-0.3	5.01e-7	Blood metabolite levels;
CESC	cis	rs933688	0.938	rs12110065	chr5:90718474	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.1	13.37	0.63	1.64e-31	Smoking behavior;
CESC	cis	rs9611565	0.512	rs5751145	chr22:42133552	C/T	cg03806693	chr22:41940476	POLR3H	1.18	13.5	0.64	5.99e-32	Vitiligo;
CESC	cis	rs1044826	0.642	rs167187	chr3:139237008	C/T	cg15131784	chr3:139108705	COPB2	-0.42	-5.14	-0.3	5.4e-7	Obesity-related traits;
CESC	cis	rs796364	0.951	rs2881593	chr2:201000347	A/G	cg23649088	chr2:200775458	C2orf69	-0.56	-6.0	-0.35	6.5e-9	Schizophrenia;
CESC	cis	rs897984	0.568	rs72799330	chr16:30893555	C/A	cg02466173	chr16:30829666	NA	-0.48	-6.87	-0.39	4.61e-11	Dementia with Lewy bodies;
CESC	cis	rs7937682	0.564	rs1944114	chr11:111366460	T/C	cg09085632	chr11:111637200	PPP2R1B	0.46	5.41	0.32	1.4e-7	Primary sclerosing cholangitis;
CESC	cis	rs6840258	1.000	rs17012234	chr4:87911691	A/C	cg08197287	chr4:87952173	AFF1	0.42	5.79	0.33	2.01e-8	Mean corpuscular volume;Basophil percentage of granulocytes;
CESC	cis	rs6088580	0.634	rs6059897	chr20:33113224	A/G	cg08999081	chr20:33150536	PIGU	0.66	11.53	0.58	3.26e-25	Glomerular filtration rate (creatinine);
CESC	cis	rs10504229	0.817	rs58957714	chr8:58195864	G/A	cg22535103	chr8:58192502	C8orf71	-1.05	-10.82	-0.55	7.5e-23	Developmental language disorder (linguistic errors);
CESC	cis	rs7666738	0.830	rs58696666	chr4:99006913	C/T	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.62e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7666738	0.791	rs1405766	chr4:98965389	T/C	cg18180107	chr4:99064573	C4orf37	0.4	5.14	0.3	5.26e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6762	0.748	rs28735718	chr11:839629	A/G	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.66	-8.65	-0.47	4.99e-16	Mean platelet volume;
CESC	cis	rs58235267	0.543	rs2539990	chr2:63170185	C/T	cg17519650	chr2:63277830	OTX1	0.57	8.0	0.44	3.82e-14	Prostate-specific antigen levels (conditioned on lead SNPs);
CESC	cis	rs11252926	0.550	rs10795122	chr10:466830	C/T	cg18196295	chr10:418757	DIP2C	0.5	6.67	0.38	1.53e-10	Psychosis in Alzheimer's disease;
CESC	cis	rs10504073	0.584	rs72641612	chr8:49947986	C/T	cg00325661	chr8:49890786	NA	0.58	8.73	0.47	3.01e-16	Blood metabolite ratios;
CESC	cis	rs7208859	0.673	rs9889968	chr17:29220128	C/A	cg19761014	chr17:28927070	LRRC37B2	0.73	5.77	0.33	2.22e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	trans	rs9951602	0.512	rs1599634	chr18:76643645	T/C	cg02800362	chr5:177631904	HNRNPAB	0.62	8.1	0.45	1.96e-14	Obesity-related traits;
CESC	cis	rs4253772	0.530	rs9627387	chr22:46684678	A/G	cg07012999	chr22:46692446	CN5H6.4;GTSE1	0.54	5.67	0.33	3.74e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs57244997	0.556	rs73030428	chr6:162437606	T/C	cg17173639	chr6:162384350	PARK2	-0.55	-5.99	-0.35	6.73e-9	Mosquito bite size;
CESC	cis	rs2354432	0.556	rs6593777	chr1:146884013	C/G	cg25205988	chr1:146714368	CHD1L	1.02	8.94	0.48	6.66e-17	Mitochondrial DNA levels;
CESC	cis	rs727563	0.562	rs5758458	chr22:42154132	G/A	cg03806693	chr22:41940476	POLR3H	1.19	14.07	0.65	6.09e-34	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs8067354	0.645	rs2645491	chr17:57877049	C/T	cg13753209	chr17:57696993	CLTC	0.66	8.34	0.46	4.12e-15	Hemoglobin concentration;
CESC	cis	rs5769765	0.955	rs8135816	chr22:50291976	G/C	cg26441486	chr22:50317300	CRELD2	0.39	5.37	0.31	1.76e-7	Schizophrenia;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg19310307	chr4:174291107	SAP30	-0.44	-6.73	-0.38	1.05e-10	Gambling;
CESC	cis	rs17641971	0.645	rs186891	chr8:50038758	T/C	cg00325661	chr8:49890786	NA	0.38	5.14	0.3	5.44e-7	Blood metabolite levels;
CESC	cis	rs875971	0.862	rs801209	chr7:66019390	G/T	cg18876405	chr7:65276391	NA	-0.53	-7.22	-0.41	5.6e-12	Aortic root size;
CESC	cis	rs9649213	0.593	rs34129434	chr7:97926464	C/T	cg08684580	chr7:98029266	BAIAP2L1	-0.35	-5.68	-0.33	3.49e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7666738	0.830	rs7672720	chr4:98938760	A/T	cg05340658	chr4:99064831	C4orf37	0.82	12.48	0.61	1.93e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6088580	0.542	rs6059882	chr20:33090167	T/C	cg08999081	chr20:33150536	PIGU	0.66	11.53	0.58	3.26e-25	Glomerular filtration rate (creatinine);
CESC	cis	rs3092073	0.624	rs34293711	chr20:44587186	C/T	cg27529037	chr20:44575021	PCIF1	0.58	9.02	0.48	3.96e-17	Intelligence (multi-trait analysis);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg23879496	chr6:43749477	VEGFA	0.45	6.28	0.36	1.36e-9	Fibrinogen levels;
CESC	trans	rs1814175	0.645	rs847627	chr11:49927177	G/A	cg15704280	chr7:45808275	SEPT13	-1.01	-18.94	-0.76	3.64e-51	Height;
CESC	cis	rs3820068	0.608	rs10927831	chr1:16028373	T/G	cg13390004	chr1:15929781	NA	0.33	5.13	0.3	5.64e-7	Systolic blood pressure;
CESC	trans	rs10463316	0.894	rs6875014	chr5:150754345	C/T	cg24389359	chr12:111284228	CCDC63	-0.34	-6.13	-0.35	3.25e-9	Metabolite levels (Pyroglutamine);
CESC	cis	rs7903847	0.596	rs10786340	chr10:99156563	G/C	cg20016023	chr10:99160130	RRP12	-0.3	-5.19	-0.3	4.18e-7	Granulocyte percentage of myeloid white cells;
CESC	cis	rs3096299	0.967	rs2911253	chr16:89488587	T/G	cg00750074	chr16:89608354	SPG7	-0.38	-5.55	-0.32	7.08e-8	Multiple myeloma (IgH translocation);
CESC	cis	rs35110281	0.837	rs7279968	chr21:45077398	C/G	cg04455712	chr21:45112962	RRP1B	0.4	5.98	0.34	7.33e-9	Mean corpuscular volume;
CESC	cis	rs911555	0.723	rs6575982	chr14:103862681	G/A	cg24130564	chr14:104152367	KLC1	0.47	6.05	0.35	4.98e-9	Intelligence (multi-trait analysis);
CESC	cis	rs8062405	0.755	rs17707300	chr16:28593347	A/G	cg07382826	chr16:28625726	SULT1A1	0.41	6.75	0.38	9.08e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg06814102	chr11:64880135	TM7SF2	-0.44	-6.06	-0.35	4.54e-9	Asthma;
CESC	cis	rs854765	0.718	rs12943500	chr17:17790588	C/T	cg16928487	chr17:17741425	SREBF1	0.57	9.44	0.5	2.03e-18	Total body bone mineral density;
CESC	cis	rs6430585	0.591	rs77096272	chr2:136663605	C/A	cg07169764	chr2:136633963	MCM6	1.23	16.56	0.71	8.67e-43	Corneal structure;
CESC	cis	rs796364	1.000	rs4410273	chr2:200818258	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	0.91	9.03	0.49	3.55e-17	Schizophrenia;
CESC	cis	rs12711979	0.765	rs6705742	chr2:3820672	C/T	cg17052675	chr2:3827356	NA	-0.41	-6.41	-0.37	6.5e-10	Itch intensity from mosquito bite adjusted by bite size;
CESC	cis	rs9400271	0.504	rs9784763	chr6:109624937	A/G	cg01475377	chr6:109611718	NA	0.41	6.12	0.35	3.29e-9	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
CESC	trans	rs9834373	0.573	rs4680931	chr3:78524616	T/G	cg21593409	chr16:88706389	IL17C	-0.42	-6.04	-0.35	5.2e-9	Protein quantitative trait loci;
CESC	cis	rs4853012	0.838	rs6715351	chr2:74346119	G/A	cg19729930	chr2:74357872	NA	0.85	12.96	0.62	4.55e-30	Gestational age at birth (maternal effect);
CESC	cis	rs9611565	0.921	rs3927	chr22:41722864	A/G	cg03806693	chr22:41940476	POLR3H	-0.91	-10.36	-0.54	2.4e-21	Vitiligo;
CESC	cis	rs10504229	0.636	rs10958525	chr8:58051528	C/A	cg22535103	chr8:58192502	C8orf71	-0.68	-7.48	-0.42	1.12e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs870825	0.655	rs67798981	chr4:185619567	A/T	cg04058563	chr4:185651563	MLF1IP	0.64	7.05	0.4	1.59e-11	Blood protein levels;
CESC	cis	rs2979489	0.891	rs2979508	chr8:30388444	C/T	cg26383811	chr8:30366931	RBPMS	-0.78	-9.93	-0.52	5.94e-20	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CESC	cis	rs6952808	0.723	rs11766575	chr7:2005747	T/C	cg02951883	chr7:2050386	MAD1L1	-0.51	-6.57	-0.37	2.72e-10	Bipolar disorder and schizophrenia;
CESC	cis	rs35110281	0.600	rs914198	chr21:45117456	A/C	cg04455712	chr21:45112962	RRP1B	0.47	7.13	0.4	9.39e-12	Mean corpuscular volume;
CESC	cis	rs2980436	1	rs2980436	chr8:8092025	A/G	cg15556689	chr8:8085844	FLJ10661	-0.67	-8.21	-0.45	9.5e-15	Schizophrenia;
CESC	cis	rs709400	0.663	rs62007719	chr14:103943130	G/T	cg12935359	chr14:103987150	CKB	-0.57	-8.39	-0.46	2.88e-15	Body mass index;
CESC	cis	rs4604732	0.631	rs1106720	chr1:247624681	T/C	cg12754571	chr1:247694271	LOC148824;OR2C3	0.44	5.44	0.32	1.21e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs477895	0.653	rs7102327	chr11:63908720	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.93	10.18	0.53	9.01e-21	Mean platelet volume;
CESC	cis	rs13082711	0.911	rs34981505	chr3:27437322	A/T	cg02860705	chr3:27208620	NA	0.5	6.18	0.35	2.41e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CESC	cis	rs1475911	0.744	rs12481958	chr21:43517269	A/G	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.43	-6.4	-0.37	6.89e-10	IgG glycosylation;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg12149777	chr4:139937459	CCRN4L	0.44	6.07	0.35	4.43e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs6502050	0.835	rs6502067	chr17:80111205	A/G	cg23985595	chr17:80112537	CCDC57	-0.42	-6.58	-0.37	2.43e-10	Life satisfaction;
CESC	trans	rs2018683	1.000	rs2018683	chr7:29014195	G/T	cg19402173	chr7:128379420	CALU	-0.64	-8.7	-0.47	3.59e-16	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CESC	cis	rs4665809	0.590	rs1865324	chr2:26417533	C/A	cg26119090	chr2:26468346	HADHA;HADHB	-1.08	-13.11	-0.63	1.34e-30	Gut microbiome composition (summer);
CESC	cis	rs9815354	0.812	rs17283677	chr3:41926148	C/T	cg03022575	chr3:42003672	ULK4	-0.58	-5.41	-0.32	1.38e-7	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs7666738	0.830	rs17027090	chr4:98897923	G/T	cg03676636	chr4:99064102	C4orf37	0.34	5.15	0.3	5e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg01911186	chr12:12765398	CREBL2	-0.48	-6.6	-0.38	2.26e-10	Height;
CESC	cis	rs1799949	1.000	rs8176077	chr17:41276348	T/C	cg23758822	chr17:41437982	NA	1.02	15.6	0.69	2.35e-39	Menopause (age at onset);
CESC	cis	rs2576037	0.583	rs12386118	chr18:44540376	C/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.36	5.73	0.33	2.78e-8	Personality dimensions;
CESC	cis	rs796364	0.806	rs11679676	chr2:201040981	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.9	-7.12	-0.4	1.02e-11	Schizophrenia;
CESC	cis	rs68170813	0.559	rs60255281	chr7:106963913	C/T	cg02696742	chr7:106810147	HBP1	-0.57	-5.42	-0.32	1.37e-7	Coronary artery disease;
CESC	cis	rs8077577	0.945	rs8065026	chr17:18046290	A/G	cg16794390	chr17:18148240	FLII	0.46	6.28	0.36	1.38e-9	Obesity-related traits;
CESC	cis	rs12360000	0.897	rs7921481	chr10:1898756	A/C	cg26364871	chr10:1889757	NA	0.43	6.15	0.35	2.91e-9	Metabolite levels (Dihydroxy docosatrienoic acid);
CESC	cis	rs921968	0.643	rs4674305	chr2:219293326	C/T	cg02176678	chr2:219576539	TTLL4	0.39	6.71	0.38	1.18e-10	Mean corpuscular hemoglobin concentration;
CESC	cis	rs7666738	0.830	rs10012167	chr4:99048579	T/C	cg03467027	chr4:99064603	C4orf37	0.47	5.98	0.34	7.19e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs35306767	0.761	rs12770173	chr10:1027108	A/C	cg20503657	chr10:835505	NA	0.74	6.69	0.38	1.28e-10	Eosinophil percentage of granulocytes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19933320	chr7:64125401	ZNF107	-0.64	-7.5	-0.42	9.76e-13	Gut microbiome composition (summer);
CESC	cis	rs853679	0.517	rs9468298	chr6:28122345	A/G	cg22143856	chr6:28129313	ZNF389	0.52	6.6	0.38	2.24e-10	Depression;
CESC	cis	rs2749592	0.550	rs7917262	chr10:37874602	A/C	cg25427524	chr10:38739819	LOC399744	0.55	7.64	0.43	3.88e-13	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs3857067	0.967	rs1472984	chr4:95036553	T/A	cg11021082	chr4:95130006	SMARCAD1	-0.51	-7.74	-0.43	2.04e-13	QT interval;
CESC	cis	rs9788721	1.000	rs931794	chr15:78826180	G/A	cg18825076	chr15:78729989	IREB2	0.37	5.13	0.3	5.7e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
CESC	cis	rs6484504	0.532	rs1475558	chr11:31263428	A/G	cg14844989	chr11:31128820	NA	-0.39	-5.59	-0.33	5.5e-8	Red blood cell count;
CESC	cis	rs853679	0.517	rs9380055	chr6:28081629	A/G	cg08968635	chr6:28129556	ZNF389	0.4	5.36	0.31	1.84e-7	Depression;
CESC	cis	rs5167	0.504	rs3760628	chr19:45457225	G/A	cg13119609	chr19:45449297	APOC2	0.49	8.03	0.44	3.23e-14	Blood protein levels;
CESC	cis	rs1475911	0.671	rs12483409	chr21:43521902	G/A	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.53	-8.2	-0.45	1.08e-14	IgG glycosylation;
CESC	cis	rs9649213	0.593	rs6961438	chr7:98005849	T/C	cg08684580	chr7:98029266	BAIAP2L1	-0.35	-5.67	-0.33	3.8e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs3820068	0.529	rs79570154	chr1:15990912	T/C	cg18133145	chr1:16060689	PLEKHM2	-0.4	-5.11	-0.3	6.13e-7	Systolic blood pressure;
CESC	cis	rs2180341	0.920	rs6906717	chr6:127596782	C/A	cg24812749	chr6:127587940	RNF146	1.06	15.23	0.68	4.52e-38	Breast cancer;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg24243429	chr4:148653539	ARHGAP10	0.47	6.2	0.36	2.17e-9	Systemic lupus erythematosus;
CESC	cis	rs10791323	0.592	rs2851115	chr11:133705381	C/A	cg06766960	chr11:133703094	NA	-0.38	-5.42	-0.32	1.35e-7	Childhood ear infection;
CESC	trans	rs4596713	0.539	rs953812	chr9:71787631	T/C	cg16512924	chr15:28394682	HERC2	0.48	6.1	0.35	3.69e-9	Headache;
CESC	cis	rs6570726	0.791	rs392612	chr6:145881586	C/G	cg05347473	chr6:146136440	FBXO30	-0.53	-6.86	-0.39	4.72e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs829883	0.724	rs11109507	chr12:98904160	C/T	cg25150519	chr12:98850993	NA	0.63	7.79	0.43	1.5700000000000001e-13	Colorectal adenoma (advanced);
CESC	cis	rs2439831	0.867	rs2470134	chr15:43849886	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.7	-8.47	-0.46	1.67e-15	Lung cancer in ever smokers;
CESC	cis	rs7980687	0.678	rs7132277	chr12:123593382	C/T	cg00376283	chr12:123451042	ABCB9	-0.68	-7.17	-0.4	7.5e-12	Height;Educational attainment;Head circumference (infant);
CESC	cis	rs12497850	0.864	rs4279134	chr3:49156676	A/G	cg03060546	chr3:49711283	APEH	0.53	6.39	0.37	7.49e-10	Parkinson's disease;
CESC	cis	rs8038465	0.622	rs17185294	chr15:73858415	C/T	cg15420318	chr15:73925796	NPTN	-0.4	-5.61	-0.33	5.19e-8	Liver enzyme levels (gamma-glutamyl transferase);
CESC	trans	rs1814175	0.645	rs11040661	chr11:49952146	G/T	cg15704280	chr7:45808275	SEPT13	-0.98	-18.56	-0.75	7.41e-50	Height;
CESC	cis	rs2425143	1.000	rs28685274	chr20:34358527	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.72	6.82	0.39	6.12e-11	Blood protein levels;
CESC	cis	rs208520	0.690	rs12197578	chr6:66725905	C/T	cg07460842	chr6:66804631	NA	0.96	12.77	0.62	2e-29	Exhaled nitric oxide output;
CESC	cis	rs8060686	0.641	rs9932251	chr16:68131732	G/A	cg26727032	chr16:67993705	SLC12A4	-0.52	-6.3	-0.36	1.24e-9	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs7666738	0.830	rs7678557	chr4:99057329	A/G	cg17366294	chr4:99064904	C4orf37	0.61	8.6	0.47	7.18e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7618915	0.621	rs6788993	chr3:52605136	T/C	cg17372223	chr3:52568218	NT5DC2	0.4	6.1	0.35	3.72e-9	Bipolar disorder;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg19947233	chr4:90032727	TIGD2	-0.49	-6.28	-0.36	1.35e-9	Fibrinogen levels;
CESC	cis	rs7666738	0.830	rs7659593	chr4:98934823	T/C	cg05340658	chr4:99064831	C4orf37	0.82	12.54	0.61	1.29e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs34734847	0.787	rs695949	chr12:121149736	A/G	cg21892295	chr12:121157589	UNC119B	-0.36	-5.86	-0.34	1.35e-8	Mean corpuscular volume;
CESC	cis	rs2455799	0.613	rs2470549	chr3:15737698	T/C	cg09340198	chr3:15902540	ANKRD28	-0.32	-5.11	-0.3	6.05e-7	Mean platelet volume;
CESC	cis	rs11098499	0.863	rs10019674	chr4:120443489	C/T	cg09307838	chr4:120376055	NA	-0.85	-11.41	-0.57	8.22e-25	Corneal astigmatism;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg03664992	chr1:39957393	BMP8A	0.46	6.01	0.35	6.03e-9	Systemic lupus erythematosus;
CESC	cis	rs752010	1.000	rs2077172	chr1:42093340	A/G	cg06885757	chr1:42089581	HIVEP3	0.49	8.15	0.45	1.5e-14	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs10504229	0.679	rs6995378	chr8:58113933	C/T	cg24829409	chr8:58192753	C8orf71	-0.59	-7.32	-0.41	2.94e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs7772486	0.790	rs2253307	chr6:146196181	T/G	cg05347473	chr6:146136440	FBXO30	0.58	7.45	0.42	1.31e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1799949	1.000	rs8176220	chr17:41222462	A/G	cg25072359	chr17:41440525	NA	0.46	6.14	0.35	2.95e-9	Menopause (age at onset);
CESC	trans	rs916888	0.610	rs199453	chr17:44800946	C/T	cg10053473	chr17:62856997	LRRC37A3	-0.65	-8.98	-0.48	5.21e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs6032067	0.929	rs35475980	chr20:43821080	A/T	cg10761708	chr20:43804764	PI3	0.53	6.36	0.36	8.83e-10	Blood protein levels;
CESC	cis	rs637571	0.558	rs10896064	chr11:65641033	G/C	cg04055107	chr11:65626734	MUS81;CFL1	-0.73	-9.4	-0.5	2.71e-18	Eosinophil percentage of white cells;
CESC	cis	rs3540	0.574	rs2256388	chr15:90969335	A/C	cg10434728	chr15:90938212	IQGAP1	-0.41	-7.42	-0.41	1.62e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs698833	0.788	rs1142523	chr2:44545576	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.54	6.67	0.38	1.47e-10	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs9584850	0.834	rs9584854	chr13:99118590	C/T	cg20750642	chr13:99100586	FARP1	-0.39	-5.87	-0.34	1.27e-8	Neuroticism;
CESC	cis	rs3824867	0.920	rs3740684	chr11:47468820	C/T	cg20307385	chr11:47447363	PSMC3	0.49	5.97	0.34	7.78e-9	Mean corpuscular hemoglobin;
CESC	cis	rs1927790	0.648	rs2389631	chr13:96932868	A/C	cg02571835	chr13:96230311	CLDN10	-0.35	-5.3	-0.31	2.43e-7	Body mass index;
CESC	cis	rs2637266	0.935	rs12772269	chr10:78394292	C/A	cg18941641	chr10:78392320	NA	0.45	8.6	0.47	6.93e-16	Pulmonary function;
CESC	cis	rs17572109	0.666	rs11696005	chr2:219229641	T/C	cg00012203	chr2:219082015	ARPC2	-0.52	-5.38	-0.31	1.67e-7	Platelet count;Platelet distribution width;Mean platelet volume;
CESC	cis	rs9929218	0.871	rs1862748	chr16:68832943	C/T	cg02972257	chr16:68554789	NA	0.5	5.9	0.34	1.14e-8	Colorectal cancer;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg22856972	chr6:134275178	TBPL1	-0.52	-7.05	-0.4	1.51e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs854765	0.506	rs7210400	chr17:17949957	C/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.55	-7.27	-0.41	4.15e-12	Total body bone mineral density;
CESC	cis	rs6540556	0.954	rs643118	chr1:209934841	C/T	cg23920097	chr1:209922102	NA	-0.38	-5.69	-0.33	3.39e-8	Red blood cell count;
CESC	cis	rs274567	0.501	rs2631368	chr5:131705297	T/G	cg07395648	chr5:131743802	NA	0.42	5.46	0.32	1.09e-7	Blood metabolite levels;
CESC	cis	rs7216064	0.953	rs8073510	chr17:65839210	A/G	cg07042672	chr17:66097459	LOC651250	-0.54	-5.67	-0.33	3.73e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs8114671	0.836	rs745849	chr20:33572178	G/A	cg07148914	chr20:33460835	GGT7	-0.42	-5.41	-0.32	1.41e-7	Height;
CESC	cis	rs17376456	0.877	rs9314100	chr5:93447394	T/C	cg21475434	chr5:93447410	FAM172A	0.9	7.81	0.43	1.31e-13	Diabetic retinopathy;
CESC	cis	rs1008375	0.933	rs4698637	chr4:17632843	A/T	cg16339924	chr4:17578868	LAP3	0.65	8.2	0.45	1.07e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs2228479	0.850	rs17232630	chr16:89851179	C/T	cg06558623	chr16:89946397	TCF25	1.18	9.42	0.5	2.3e-18	Skin colour saturation;
CESC	cis	rs2404602	0.583	rs12898415	chr15:76574232	C/T	cg26408565	chr15:76604113	ETFA	-0.4	-5.93	-0.34	9.36e-9	Blood metabolite levels;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg20899383	chr2:176046573	ATP5G3	-0.49	-6.46	-0.37	5.09e-10	Height;
CESC	cis	rs514406	0.798	rs575138	chr1:53328394	C/G	cg16325326	chr1:53192061	ZYG11B	0.72	10.81	0.55	8.67e-23	Monocyte count;
CESC	cis	rs919433	0.963	rs4850787	chr2:198181750	G/A	cg03934865	chr2:198174659	NA	-0.44	-6.18	-0.36	2.35e-9	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs7916697	0.520	rs12246624	chr10:70036562	C/T	cg06988349	chr10:69991859	ATOH7	0.34	5.29	0.31	2.6e-7	Optic disc area;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg24156905	chr11:6440470	APBB1	-0.42	-6.13	-0.35	3.19e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs629535	0.814	rs488231	chr8:70064993	T/C	cg21567404	chr3:27674614	NA	0.88	10.43	0.54	1.5e-21	Dupuytren's disease;
CESC	cis	rs73001065	0.636	rs11668104	chr19:19426181	G/A	cg03709012	chr19:19516395	GATAD2A	0.9	6.75	0.38	9.08e-11	LDL cholesterol;
CESC	trans	rs55704346	0.536	rs10005866	chr4:25394900	T/G	cg01822600	chr1:245751692	KIF26B	0.42	6.17	0.35	2.58e-9	Tonsillectomy;
CESC	cis	rs11711311	1.000	rs9288982	chr3:113470149	A/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.67	9.01	0.48	4.07e-17	IgG glycosylation;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg04671591	chr1:147400503	GPR89B	0.43	6.02	0.35	5.8e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs6894249	0.874	rs11745587	chr5:131796922	A/G	cg21138405	chr5:131827807	IRF1	-0.31	-5.08	-0.3	7.05e-7	Asthma;
CESC	cis	rs6754311	0.773	rs309180	chr2:136614255	A/G	cg07169764	chr2:136633963	MCM6	0.69	8.48	0.46	1.62e-15	Mosquito bite size;
CESC	cis	rs6695640	0.756	rs1555661	chr1:17730812	A/G	cg01904812	chr1:17746340	RCC2	0.35	5.19	0.3	4.15e-7	Mean platelet volume;
CESC	cis	rs13088281	1.000	rs13088281	chr3:53147576	A/C	cg07884673	chr3:53033167	SFMBT1	-0.61	-5.34	-0.31	1.97e-7	Immune reponse to smallpox (secreted IL-2);
CESC	cis	rs763121	0.853	rs2281020	chr22:39064406	A/G	cg06022373	chr22:39101656	GTPBP1	0.88	13.95	0.65	1.51e-33	Menopause (age at onset);
CESC	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.47	-6.26	-0.36	1.53e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs5753618	0.583	rs9606839	chr22:31802710	A/C	cg13145458	chr22:31556086	RNF185	-0.49	-5.83	-0.34	1.62e-8	Colorectal cancer;
CESC	trans	rs7746199	0.668	rs34864796	chr6:27459923	G/A	cg06606381	chr12:133084897	FBRSL1	-1.07	-8.79	-0.48	1.92e-16	Gait speed in old age;Autism spectrum disorder or schizophrenia;
CESC	cis	rs875971	0.660	rs10272357	chr7:66063074	G/A	cg18876405	chr7:65276391	NA	-0.59	-7.87	-0.44	9.35e-14	Aortic root size;
CESC	cis	rs875971	0.867	rs13227219	chr7:65844062	T/A	cg11764359	chr7:65958608	NA	0.96	15.02	0.68	2.67e-37	Aortic root size;
CESC	cis	rs9457247	0.967	rs382009	chr6:167403121	G/C	cg25258033	chr6:167368657	RNASET2	0.39	5.87	0.34	1.27e-8	Crohn's disease;
CESC	cis	rs7937682	0.575	rs7950926	chr11:111776437	G/C	cg09085632	chr11:111637200	PPP2R1B	0.87	11.86	0.59	2.58e-26	Primary sclerosing cholangitis;
CESC	cis	rs506597	0.525	rs3757859	chr7:100241163	A/C	cg10426581	chr7:100472382	SRRT	0.59	5.07	0.3	7.37e-7	Pursuit maintenance gain in psychotic disorders;
CESC	cis	rs6570726	0.526	rs9376934	chr6:145738702	A/G	cg23711669	chr6:146136114	FBXO30	0.55	7.29	0.41	3.54e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6570726	0.935	rs449377	chr6:145852437	C/G	cg05347473	chr6:146136440	FBXO30	0.49	6.76	0.38	8.85e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs3820928	0.874	rs4675128	chr2:227814757	T/C	cg11843606	chr2:227700838	RHBDD1	-0.48	-6.38	-0.37	7.64e-10	Pulmonary function;
CESC	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg11494091	chr17:61959527	GH2	0.73	12.52	0.61	1.41e-28	Prudent dietary pattern;
CESC	cis	rs875971	0.755	rs10228885	chr7:65780529	C/G	cg19163074	chr7:65112434	INTS4L2	0.41	5.21	0.3	3.75e-7	Aortic root size;
CESC	cis	rs1538970	0.924	rs11211111	chr1:45908782	C/T	cg24296786	chr1:45957014	TESK2	-0.46	-5.25	-0.31	3.14e-7	Platelet count;
CESC	cis	rs7216064	0.953	rs58141639	chr17:65864902	C/T	cg12091567	chr17:66097778	LOC651250	-0.85	-8.7	-0.47	3.61e-16	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs9527	0.590	rs10883818	chr10:104759586	A/G	cg04362960	chr10:104952993	NT5C2	0.42	5.31	0.31	2.33e-7	Arsenic metabolism;
CESC	cis	rs7726839	0.561	rs72703044	chr5:579737	G/A	cg16447950	chr5:562315	NA	-0.58	-6.74	-0.38	9.99e-11	Obesity-related traits;
CESC	cis	rs10504229	1.000	rs56350499	chr8:58178139	C/T	cg22535103	chr8:58192502	C8orf71	-1.05	-13.27	-0.63	3.63e-31	Developmental language disorder (linguistic errors);
CESC	cis	rs55788414	0.932	rs7185658	chr16:81189336	A/G	cg06400318	chr16:81190750	PKD1L2	-0.6	-6.7	-0.38	1.24e-10	Left ventricular obstructive tract defect (maternal effect);
CESC	cis	rs2011503	1.000	rs16996127	chr19:19627310	T/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.5	5.09	0.3	6.7e-7	Bipolar disorder;
CESC	cis	rs3820928	1.000	rs10193316	chr2:227777650	A/G	cg05526886	chr2:227700861	RHBDD1	-0.44	-5.8	-0.34	1.92e-8	Pulmonary function;
CESC	cis	rs2011503	1.000	rs76095338	chr19:19633908	G/A	cg11584989	chr19:19387371	SF4	0.61	7.03	0.4	1.79e-11	Bipolar disorder;
CESC	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	21.45	0.8	7.14e-60	Prudent dietary pattern;
CESC	cis	rs910316	0.737	rs108622	chr14:75481908	A/G	cg08847533	chr14:75593920	NEK9	-0.9	-15.43	-0.69	9.04e-39	Height;
CESC	cis	rs4604732	0.631	rs12038880	chr1:247624603	A/G	cg12758973	chr1:247694275	LOC148824;OR2C3	0.48	6.43	0.37	5.79e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	trans	rs913655	0.688	rs12220519	chr10:19020881	C/T	cg11356571	chr19:48219924	EHD2	0.53	6.0	0.35	6.29e-9	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);
CESC	cis	rs12912251	0.948	rs34281605	chr15:38989674	G/A	cg01338139	chr15:38987640	C15orf53	-0.46	-5.27	-0.31	2.89e-7	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
CESC	cis	rs2191566	0.845	rs7258517	chr19:44535999	G/T	cg20607764	chr19:44506953	ZNF230	-0.59	-7.45	-0.42	1.28e-12	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs11098499	0.863	rs1552092	chr4:120488496	C/T	cg24375607	chr4:120327624	NA	0.45	5.54	0.32	7.33e-8	Corneal astigmatism;
CESC	cis	rs73206853	0.563	rs7960749	chr12:111164369	T/C	cg12870014	chr12:110450643	ANKRD13A	0.64	5.66	0.33	3.91e-8	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs2204008	0.580	rs1315373	chr12:38179114	T/G	cg26384229	chr12:38710491	ALG10B	-0.4	-5.34	-0.31	1.96e-7	Bladder cancer;
CESC	cis	rs9916302	0.904	rs12450559	chr17:37694709	G/A	cg00129232	chr17:37814104	STARD3	-0.57	-7.53	-0.42	7.83e-13	Glomerular filtration rate (creatinine);
CESC	cis	rs514406	0.627	rs485128	chr1:53344583	T/C	cg08859206	chr1:53392774	SCP2	-0.72	-10.12	-0.53	1.47e-20	Monocyte count;
CESC	cis	rs7909791	0.632	rs3818278	chr10:105665323	G/T	cg24587175	chr10:105670608	OBFC1	0.45	6.27	0.36	1.46e-9	White matter hyperintensity burden;
CESC	cis	rs149163995	1	rs149163995	chr2:203777226	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.38	0.41	1.99e-12	Migraine;
CESC	cis	rs2742234	0.590	rs2075912	chr10:43622217	T/C	cg15436174	chr10:43711423	RASGEF1A	-0.46	-5.4	-0.31	1.51e-7	Hirschsprung disease;
CESC	cis	rs10791323	0.593	rs11223599	chr11:133717902	A/T	cg15485101	chr11:133734466	NA	-0.33	-5.49	-0.32	9.19e-8	Childhood ear infection;
CESC	cis	rs911555	0.755	rs2756132	chr14:103967820	C/G	cg24130564	chr14:104152367	KLC1	0.46	6.08	0.35	4.23e-9	Intelligence (multi-trait analysis);
CESC	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.55	-6.1	-0.35	3.69e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs3780486	0.801	rs3780495	chr9:33125942	A/C	cg20290983	chr6:43655470	MRPS18A	0.98	18.02	0.74	6.31e-48	IgG glycosylation;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg17025142	chr5:99871651	FAM174A	-0.45	-6.2	-0.36	2.11e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs7429990	0.965	rs319684	chr3:47932274	C/T	cg11946769	chr3:48343235	NME6	0.42	5.11	0.3	6.05e-7	Educational attainment (years of education);
CESC	cis	rs12477438	0.798	rs6716913	chr2:99580641	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.7	-10.22	-0.53	6.79e-21	Chronic sinus infection;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg21897413	chr5:176944084	DDX41	-0.54	-6.56	-0.37	2.84e-10	Ulcerative colitis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22396454	chr6:42896723	CNPY3	-0.57	-6.84	-0.39	5.56e-11	Gut microbiome composition (summer);
CESC	trans	rs7656342	0.808	rs10003216	chr4:9766749	A/G	cg10255097	chr10:114711603	TCF7L2	-0.55	-6.33	-0.36	1.03e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs1008375	1.000	rs28501187	chr4:17643620	G/A	cg15017067	chr4:17643749	FAM184B	0.36	5.11	0.3	6.3e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs10754283	0.557	rs1215508	chr1:90088697	C/T	cg21401794	chr1:90099060	LRRC8C	0.56	7.86	0.43	9.83e-14	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs6772849	1.000	rs2712373	chr3:128308055	T/C	cg16766828	chr3:128327626	NA	-0.31	-5.06	-0.3	7.77e-7	Monocyte percentage of white cells;Monocyte count;
CESC	cis	rs9309473	1.000	rs7586463	chr2:73798476	T/C	cg20560298	chr2:73613845	ALMS1	-0.54	-7.03	-0.4	1.7e-11	Metabolite levels;
CESC	trans	rs11992162	0.560	rs13276386	chr8:11797421	T/A	cg15556689	chr8:8085844	FLJ10661	0.51	6.35	0.36	9.34e-10	Monocyte count;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg07791476	chr4:8456156	C4orf23	-0.45	-6.33	-0.36	1.03e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs67311347	1.000	rs11714912	chr3:40494065	A/G	cg09455208	chr3:40491958	NA	-0.43	-7.39	-0.41	1.88e-12	Renal cell carcinoma;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg11698762	chr2:74648964	WDR54	-0.46	-6.65	-0.38	1.67e-10	Gambling;
CESC	cis	rs12995491	0.698	rs34352413	chr2:88498754	T/G	cg04169830	chr2:88471460	THNSL2	0.33	5.09	0.3	6.64e-7	Response to metformin (IC50);
CESC	cis	rs7927771	1.000	rs12361031	chr11:47783076	G/A	cg05585544	chr11:47624801	NA	-0.5	-7.88	-0.44	8.28e-14	Subjective well-being;
CESC	cis	rs34330	0.562	rs11055023	chr12:12853197	A/G	cg04607235	chr12:12878440	APOLD1	-0.85	-9.22	-0.49	9.72e-18	Systemic lupus erythematosus;
CESC	cis	rs9733	0.519	rs11807450	chr1:150677719	C/T	cg22823121	chr1:150693482	HORMAD1	0.48	7.04	0.4	1.65e-11	Tonsillectomy;
CESC	cis	rs514406	0.505	rs269293	chr1:53187767	A/C	cg27535305	chr1:53392650	SCP2	-0.33	-5.38	-0.31	1.62e-7	Monocyte count;
CESC	cis	rs4862750	0.872	rs1991254	chr4:187875375	T/G	cg07414643	chr4:187882934	NA	0.53	7.2	0.4	6.04e-12	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01151424	chr11:17411006	KCNJ11	0.59	6.84	0.39	5.57e-11	Gut microbiome composition (summer);
CESC	cis	rs72781680	0.611	rs72783625	chr2:24315540	C/T	cg08917208	chr2:24149416	ATAD2B	0.55	5.3	0.31	2.47e-7	Lymphocyte counts;
CESC	cis	rs2014572	0.967	rs10427146	chr19:57755998	T/C	cg12963866	chr19:57752005	ZNF805	-0.49	-6.49	-0.37	4.09e-10	Hyperactive-impulsive symptoms;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg03724728	chr17:38231199	THRA	-0.36	-6.22	-0.36	1.92e-9	Gambling;
CESC	cis	rs9916302	0.904	rs12952384	chr17:37669536	T/C	cg19468946	chr17:37922297	IKZF3	-0.39	-5.06	-0.3	7.91e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs4704187	0.687	rs115403098	chr5:74397384	A/G	cg03227963	chr5:74354835	NA	0.32	5.92	0.34	9.97e-9	Response to amphetamines;
CESC	cis	rs6952808	0.929	rs12532128	chr7:1925454	T/C	cg21782813	chr7:2030301	MAD1L1	0.45	6.34	0.36	1.01e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs67311347	0.824	rs73073561	chr3:40357298	G/T	cg09455208	chr3:40491958	NA	0.45	7.44	0.42	1.42e-12	Renal cell carcinoma;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg02614658	chr16:476729	RAB11FIP3	0.44	6.05	0.35	4.8e-9	Systemic lupus erythematosus;
CESC	cis	rs636291	0.517	rs670666	chr1:10549380	C/T	cg20482658	chr1:10539492	PEX14	0.27	5.71	0.33	3.04e-8	Prostate cancer;
CESC	cis	rs7927592	1.000	rs7927592	chr11:68369960	G/A	cg16797656	chr11:68205561	LRP5	0.39	5.42	0.32	1.33e-7	Total body bone mineral density;
CESC	cis	rs875971	0.825	rs6951503	chr7:65718936	T/G	cg18876405	chr7:65276391	NA	-0.52	-7.19	-0.4	6.73e-12	Aortic root size;
CESC	cis	rs2228479	0.867	rs12930056	chr16:89946649	C/A	cg04013166	chr16:89971882	TCF25	0.77	7.14	0.4	8.86e-12	Skin colour saturation;
CESC	cis	rs614226	1.000	rs1167727	chr12:120965508	C/A	cg01236616	chr12:121019343	POP5	1.55	19.98	0.78	8.29e-55	Type 1 diabetes nephropathy;
CESC	cis	rs9303401	0.659	rs72828726	chr17:56951217	C/G	cg10487724	chr17:56770010	TEX14;RAD51C	1.01	12.52	0.61	1.4e-28	Cognitive test performance;
CESC	cis	rs6674176	0.628	rs2301993	chr1:44426025	G/A	cg12908607	chr1:44402522	ARTN	-0.46	-6.61	-0.38	2.08e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs9640161	0.659	rs11975886	chr7:150010362	G/A	cg10018233	chr7:150070692	REPIN1	0.46	7.32	0.41	2.89e-12	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs4132509	0.793	rs7538011	chr1:243703344	A/G	cg21452805	chr1:244014465	NA	0.61	6.57	0.37	2.65e-10	RR interval (heart rate);
CESC	cis	rs425277	0.628	rs10797427	chr1:2060732	C/T	cg21194808	chr1:2205498	SKI	-0.33	-5.1	-0.3	6.36e-7	Height;
CESC	cis	rs9911578	0.835	rs1990008	chr17:56459408	C/G	cg05425664	chr17:57184151	TRIM37	0.47	6.48	0.37	4.34e-10	Intelligence (multi-trait analysis);
CESC	cis	rs12190007	0.517	rs3006183	chr6:169808263	T/C	cg15038512	chr6:170123185	PHF10	-0.48	-6.81	-0.39	6.6e-11	Obesity-related traits;
CESC	cis	rs875971	0.862	rs3893216	chr7:65790707	G/C	cg12463550	chr7:65579703	CRCP	-0.49	-6.14	-0.35	2.95e-9	Aortic root size;
CESC	cis	rs7429990	0.965	rs7430913	chr3:48032357	G/T	cg11946769	chr3:48343235	NME6	-0.44	-5.42	-0.32	1.36e-7	Educational attainment (years of education);
CESC	cis	rs72781680	0.898	rs17762609	chr2:24114729	G/T	cg08917208	chr2:24149416	ATAD2B	0.93	8.63	0.47	5.68e-16	Lymphocyte counts;
CESC	cis	rs2839186	0.770	rs2839171	chr21:47673247	C/T	cg10351095	chr21:47802916	PCNT	0.49	6.73	0.38	1.02e-10	Testicular germ cell tumor;
CESC	cis	rs523522	0.962	rs4767914	chr12:120993817	C/T	cg12219531	chr12:120966889	COQ5	0.74	9.75	0.51	2.17e-19	High light scatter reticulocyte count;
CESC	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.76	6.69	0.38	1.3e-10	Platelet count;
CESC	cis	rs7618915	0.547	rs2268027	chr3:52766606	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.49	6.96	0.39	2.69e-11	Bipolar disorder;
CESC	trans	rs561341	0.882	rs2521594	chr17:30302087	C/T	cg20587970	chr11:113659929	NA	-1.41	-18.23	-0.75	1.08e-48	Hip circumference adjusted for BMI;
CESC	cis	rs875971	0.755	rs76288834	chr7:66069802	G/A	cg19163074	chr7:65112434	INTS4L2	0.4	5.03	0.3	8.98e-7	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07097265	chr17:17727093	SREBF1	0.52	6.18	0.35	2.45e-9	Gut microbiome composition (summer);
CESC	cis	rs4722166	0.630	rs10950916	chr7:22799667	C/T	cg05472934	chr7:22766657	IL6	0.87	10.63	0.55	3.14e-22	Lung cancer;
CESC	cis	rs13118159	0.714	rs6843025	chr4:1334418	C/G	cg05025164	chr4:1340916	KIAA1530	0.52	7.3	0.41	3.26e-12	Longevity;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg13686143	chr2:201828163	ORC2L	0.54	7.01	0.4	1.93e-11	Gut microbiota (bacterial taxa);
CESC	trans	rs3008706	0.850	rs2987037	chr9:15997752	C/A	cg09705784	chr17:76565232	DNAH17	0.58	6.04	0.35	5.09e-9	Bilirubin levels;
CESC	cis	rs1008375	0.931	rs3796814	chr4:17602033	G/C	cg27347728	chr4:17578864	LAP3	0.43	5.22	0.31	3.57e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs2066819	0.818	rs703830	chr12:56701872	T/C	cg26714650	chr12:56694279	CS	1.28	15.86	0.7	2.7e-40	Psoriasis vulgaris;
CESC	trans	rs11098499	0.743	rs10003567	chr4:120241674	C/T	cg25214090	chr10:38739885	LOC399744	0.61	8.47	0.46	1.73e-15	Corneal astigmatism;
CESC	cis	rs2439831	0.850	rs28707214	chr15:44131623	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.68	7.43	0.42	1.45e-12	Lung cancer in ever smokers;
CESC	cis	rs2243480	1.000	rs160643	chr7:65558222	C/T	cg12463550	chr7:65579703	CRCP	0.69	5.58	0.32	6e-8	Diabetic kidney disease;
CESC	cis	rs13256369	0.951	rs10503394	chr8:8565775	A/G	cg00074818	chr8:8560427	CLDN23	0.36	5.3	0.31	2.42e-7	Obesity-related traits;
CESC	cis	rs7188697	0.809	rs4784956	chr16:58596291	A/C	cg21335942	chr16:58549945	SETD6	-0.45	-5.2	-0.3	4.06e-7	QT interval;
CESC	cis	rs898097	0.812	rs56274787	chr17:80862682	C/T	cg05255149	chr17:80675120	FN3KRP	-0.47	-5.45	-0.32	1.13e-7	Breast cancer;
CESC	cis	rs7084402	0.902	rs3001715	chr10:60285509	A/G	cg07615347	chr10:60278583	BICC1	0.61	9.69	0.51	3.28e-19	Refractive error;
CESC	cis	rs854765	0.619	rs1101727	chr17:18016148	T/C	cg09796270	chr17:17721594	SREBF1	0.39	5.21	0.3	3.86e-7	Total body bone mineral density;
CESC	cis	rs611744	0.647	rs7015240	chr8:109262204	G/A	cg21045802	chr8:109455806	TTC35	0.46	5.67	0.33	3.65e-8	Dupuytren's disease;
CESC	cis	rs7666738	0.830	rs10012167	chr4:99048579	T/C	cg03676636	chr4:99064102	C4orf37	0.33	5.12	0.3	5.93e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9790314	1.000	rs336567	chr3:161073046	A/G	cg04691961	chr3:161091175	C3orf57	-0.4	-5.04	-0.3	8.47e-7	Morning vs. evening chronotype;
CESC	cis	rs7949030	0.591	rs35156678	chr11:62369881	G/A	cg02375832	chr11:62437615	C11orf48	-0.37	-5.13	-0.3	5.56e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs4819052	0.851	rs2838842	chr21:46669217	C/T	cg11663144	chr21:46675770	NA	-0.64	-10.05	-0.53	2.42e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs7412746	0.658	rs59024312	chr1:150909005	T/G	cg04414720	chr1:150670196	GOLPH3L	0.52	6.88	0.39	4.32e-11	Melanoma;
CESC	cis	rs10504229	0.861	rs114700910	chr8:58170642	C/T	cg24829409	chr8:58192753	C8orf71	-0.76	-10.0	-0.52	3.39e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs9911578	1.000	rs9898916	chr17:57048660	C/T	cg05425664	chr17:57184151	TRIM37	-0.5	-6.96	-0.39	2.66e-11	Intelligence (multi-trait analysis);
CESC	cis	rs2380220	0.576	rs4368819	chr6:96031109	T/G	cg15832292	chr6:96025679	MANEA	0.74	7.81	0.43	1.37e-13	Behavioural disinhibition (generation interaction);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg10551016	chr22:41252963	ST13;XPNPEP3	0.45	6.31	0.36	1.2e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs7772486	0.748	rs2748484	chr6:146333653	C/T	cg05347473	chr6:146136440	FBXO30	0.48	6.35	0.36	9.54e-10	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20877507	chr13:50464614	LOC220429	-0.54	-6.29	-0.36	1.28e-9	Gut microbiome composition (summer);
CESC	cis	rs3785574	0.886	rs62077504	chr17:61837734	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.58	7.18	0.4	7.21e-12	Height;
CESC	cis	rs7829975	0.623	rs7010753	chr8:8373956	A/G	cg15556689	chr8:8085844	FLJ10661	0.5	6.2	0.36	2.21e-9	Mood instability;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg01133655	chr6:3140601	BPHL	0.45	6.44	0.37	5.67e-10	Fibrinogen levels;
CESC	cis	rs6912958	0.535	rs1753154	chr6:88032843	G/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.79	11.96	0.59	1.16e-26	Monocyte percentage of white cells;
CESC	cis	rs8002861	0.664	rs2325089	chr13:44450222	C/G	cg19180546	chr13:44453867	C13orf31;CCDC122	-0.39	-5.13	-0.3	5.48e-7	Leprosy;
CESC	cis	rs853679	0.517	rs9393897	chr6:28127710	G/T	cg18032046	chr6:28092343	ZSCAN16	-0.57	-6.48	-0.37	4.36e-10	Depression;
CESC	cis	rs8060686	0.641	rs16957696	chr16:68039850	C/T	cg26727032	chr16:67993705	SLC12A4	-0.54	-6.15	-0.35	2.78e-9	HDL cholesterol;Metabolic syndrome;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg05627390	chr13:108871167	ABHD13;LIG4	0.49	6.31	0.36	1.15e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs10751667	1.000	rs10902246	chr11:953674	T/C	cg01483505	chr11:975446	AP2A2	0.39	5.24	0.31	3.32e-7	Alzheimer's disease (late onset);
CESC	cis	rs7949030	0.626	rs1061093	chr11:62334908	G/C	cg22862634	chr11:62369728	EML3;MTA2	0.59	8.23	0.45	8.31e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs3785574	0.962	rs4480868	chr17:61788859	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.07	18.23	0.75	1.15e-48	Height;
CESC	cis	rs9300255	0.679	rs4759409	chr12:123719585	G/C	cg00376283	chr12:123451042	ABCB9	0.72	8.81	0.48	1.66e-16	Neutrophil percentage of white cells;
CESC	cis	rs4319547	0.695	rs11836188	chr12:122865507	T/C	cg05707623	chr12:122985044	ZCCHC8	0.53	5.91	0.34	1.06e-8	Body mass index;
CESC	cis	rs7811142	0.779	rs111312383	chr7:99905325	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.89	8.02	0.44	3.31e-14	Platelet count;
CESC	cis	rs10791097	0.694	rs7940027	chr11:130745591	A/G	cg12179176	chr11:130786555	SNX19	0.64	9.87	0.52	8.97e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs11190604	1.000	rs11816840	chr10:102309220	G/C	cg07080220	chr10:102295463	HIF1AN	0.66	6.08	0.35	4.13e-9	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs7635838	0.892	rs9310384	chr3:11491980	A/G	cg00170343	chr3:11313890	ATG7	0.44	6.06	0.35	4.77e-9	HDL cholesterol;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg16097330	chr5:171615472	STK10	0.47	6.18	0.35	2.43e-9	Systemic lupus erythematosus;
CESC	cis	rs6598955	0.671	rs17162105	chr1:26591255	A/G	cg19743891	chr1:26644573	UBXN11;CD52	0.37	5.19	0.3	4.16e-7	Obesity-related traits;
CESC	cis	rs2204008	0.539	rs1283295	chr12:38146014	A/C	cg26384229	chr12:38710491	ALG10B	-0.41	-5.67	-0.33	3.66e-8	Bladder cancer;
CESC	cis	rs13191362	1.000	rs34714518	chr6:163080778	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.95	9.59	0.51	7e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs9911578	0.967	rs8072712	chr17:57162464	A/T	cg12560992	chr17:57184187	TRIM37	1.01	17.93	0.74	1.24e-47	Intelligence (multi-trait analysis);
CESC	cis	rs6120849	0.617	rs12480442	chr20:33648388	C/G	cg24642439	chr20:33292090	TP53INP2	0.68	6.81	0.39	6.42e-11	Protein C levels;
CESC	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg11494091	chr17:61959527	GH2	0.72	12.16	0.6	2.58e-27	Prudent dietary pattern;
CESC	trans	rs2797160	0.935	rs926855	chr6:126021782	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.46	6.16	0.35	2.67e-9	Endometrial cancer;
CESC	cis	rs4595586	0.545	rs1588970	chr12:39403122	C/A	cg26384229	chr12:38710491	ALG10B	0.54	7.64	0.42	3.96e-13	Morning vs. evening chronotype;
CESC	cis	rs7940866	0.834	rs2324315	chr11:130839772	C/G	cg12179176	chr11:130786555	SNX19	0.65	10.02	0.52	3.01e-20	Schizophrenia;
CESC	cis	rs2243480	1.000	rs2420170	chr7:65656053	T/C	cg13147721	chr7:65941812	NA	0.97	9.16	0.49	1.47e-17	Diabetic kidney disease;
CESC	cis	rs478304	0.627	rs11604568	chr11:65511336	G/A	cg10518572	chr11:65560635	OVOL1	-0.32	-6.53	-0.37	3.33e-10	Acne (severe);
CESC	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg24642844	chr7:1081250	C7orf50	-0.77	-9.41	-0.5	2.48e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs3096299	0.967	rs753853	chr16:89446525	G/T	cg00750074	chr16:89608354	SPG7	-0.39	-5.38	-0.31	1.65e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs514406	0.505	rs448788	chr1:53161620	A/G	cg08859206	chr1:53392774	SCP2	0.56	7.35	0.41	2.41e-12	Monocyte count;
CESC	cis	rs2997447	0.595	rs3008425	chr1:26385660	T/C	cg19633962	chr1:26362018	EXTL1	-0.49	-5.15	-0.3	5.03e-7	QRS complex (12-leadsum);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04911280	chr6:44281184	AARS2	0.67	7.7	0.43	2.72e-13	Gut microbiome composition (summer);
CESC	cis	rs67478160	0.643	rs7147171	chr14:104264857	G/A	cg08213375	chr14:104286397	PPP1R13B	0.54	10.8	0.55	8.68e-23	Schizophrenia;
CESC	trans	rs650950	0.528	rs646660	chr11:35528452	C/T	cg04078658	chr7:2054064	MAD1L1	-0.43	-6.16	-0.35	2.73e-9	Bronchopulmonary dysplasia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01571169	chr16:87367721	FBXO31	-0.6	-6.42	-0.37	6.15e-10	Gut microbiome composition (summer);
CESC	cis	rs9322193	0.962	rs9689269	chr6:150112997	G/A	cg04369109	chr6:150039330	LATS1	-0.39	-5.35	-0.31	1.93e-7	Lung cancer;
CESC	cis	rs11122272	0.766	rs2790870	chr1:231543823	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.59	-7.97	-0.44	4.66e-14	Hemoglobin concentration;
CESC	cis	rs7296418	0.663	rs11057284	chr12:123830692	G/C	cg05973401	chr12:123451056	ABCB9	0.42	5.32	0.31	2.16e-7	Platelet count;
CESC	cis	rs4665809	0.627	rs13014338	chr2:26463024	C/T	cg08470875	chr2:26401718	FAM59B	0.75	7.79	0.43	1.49e-13	Gut microbiome composition (summer);
CESC	cis	rs12474201	0.928	rs17822019	chr2:46934505	T/C	cg06386533	chr2:46925753	SOCS5	0.92	12.64	0.61	5.7e-29	Height;
CESC	cis	rs12960472	0.577	rs7228682	chr18:52398155	C/A	cg12377874	chr18:52495404	RAB27B	-0.34	-5.08	-0.3	7.2e-7	Positive affect;
CESC	cis	rs4555082	0.957	rs3000073	chr14:105729792	G/A	cg13114125	chr14:105738426	BRF1	-0.75	-9.72	-0.51	2.62e-19	Mean platelet volume;Platelet distribution width;
CESC	cis	rs17711722	0.523	rs365896	chr7:65510697	A/G	cg06456125	chr7:65229604	NA	-0.38	-5.15	-0.3	4.99e-7	Calcium levels;
CESC	cis	rs1050631	0.960	rs4799848	chr18:33686292	G/A	cg25426722	chr18:33708991	SLC39A6;ELP2	0.42	5.44	0.32	1.22e-7	Esophageal squamous cell cancer (length of survival);
CESC	cis	rs910316	0.763	rs175490	chr14:75545685	A/G	cg16144293	chr14:75469539	EIF2B2	-0.39	-5.15	-0.3	5.08e-7	Height;
CESC	cis	rs2760061	0.784	rs708116	chr1:228198196	C/A	cg18477163	chr1:228402036	OBSCN	0.32	5.62	0.33	4.75e-8	Diastolic blood pressure;
CESC	cis	rs10504229	0.906	rs2270607	chr8:58194699	A/G	cg05313129	chr8:58192883	C8orf71	-0.45	-5.41	-0.32	1.43e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs17711722	0.701	rs55773927	chr7:65337902	T/C	cg11987759	chr7:65425863	GUSB	-0.48	-6.57	-0.37	2.58e-10	Calcium levels;
CESC	cis	rs1046896	0.553	rs72634343	chr17:80827392	T/C	cg19046167	chr17:80928561	B3GNTL1	0.48	5.85	0.34	1.43e-8	Glycated hemoglobin levels;
CESC	cis	rs4955124	0.558	rs77566631	chr3:32018805	C/T	cg05935571	chr3:32023257	ZNF860;OSBPL10	0.97	8.8	0.48	1.83e-16	Schizophrenia;
CESC	cis	rs2836974	0.568	rs429955	chr21:40539760	G/A	cg11644478	chr21:40555479	PSMG1	0.83	12.79	0.62	1.73e-29	Cognitive function;
CESC	cis	rs4242434	0.927	rs7843828	chr8:22463623	C/T	cg03733263	chr8:22462867	KIAA1967	0.95	15.11	0.68	1.22e-37	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CESC	cis	rs4141404	0.673	rs1968023	chr22:31942770	A/G	cg13145458	chr22:31556086	RNF185	0.54	5.95	0.34	8.53e-9	Paclitaxel-induced neuropathy;
CESC	cis	rs8114671	0.562	rs6088640	chr20:33472509	C/T	cg07148914	chr20:33460835	GGT7	0.46	6.11	0.35	3.46e-9	Height;
CESC	cis	rs4891159	0.548	rs689902	chr18:74119969	C/T	cg24786174	chr18:74118243	ZNF516	-0.85	-16.91	-0.72	5.11e-44	Longevity;
CESC	cis	rs854765	0.693	rs35451946	chr17:17764061	C/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.53	-7.64	-0.42	3.91e-13	Total body bone mineral density;
CESC	cis	rs9640161	0.871	rs56156367	chr7:150047201	A/T	cg27494647	chr7:150038898	RARRES2	0.41	5.04	0.3	8.48e-7	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs7647973	0.925	rs6446257	chr3:49253492	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.56	-6.7	-0.38	1.22e-10	Menarche (age at onset);
CESC	cis	rs1552244	1.000	rs9811771	chr3:10133949	A/G	cg00166722	chr3:10149974	C3orf24	0.46	5.81	0.34	1.83e-8	Alzheimer's disease;
CESC	cis	rs2066819	1.000	rs2643623	chr12:56689725	G/C	cg26734620	chr12:56694298	CS	-0.93	-9.55	-0.51	9.4e-19	Psoriasis vulgaris;
CESC	cis	rs7927771	0.965	rs35985502	chr11:47847428	G/A	cg05585544	chr11:47624801	NA	-0.49	-7.71	-0.43	2.62e-13	Subjective well-being;
CESC	cis	rs736408	0.527	rs2577831	chr3:52628056	C/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.37	-5.44	-0.32	1.2e-7	Bipolar disorder;
CESC	cis	rs4819052	0.851	rs13049337	chr21:46663460	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.9	13.15	0.63	1e-30	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs2243480	1.000	rs316330	chr7:65605372	C/A	cg12463550	chr7:65579703	CRCP	0.75	5.84	0.34	1.56e-8	Diabetic kidney disease;
CESC	cis	rs514406	0.644	rs7530078	chr1:53204861	G/T	cg25767906	chr1:53392781	SCP2	0.43	5.85	0.34	1.42e-8	Monocyte count;
CESC	cis	rs10899021	0.790	rs11236180	chr11:74342928	A/G	cg25880958	chr11:74394337	NA	-0.74	-7.86	-0.43	9.76e-14	Response to metformin (IC50);
CESC	cis	rs4919087	1.000	rs10786326	chr10:99070377	G/A	cg25902810	chr10:99078978	FRAT1	0.72	10.73	0.55	1.48e-22	Monocyte count;
CESC	cis	rs6674176	0.561	rs12127226	chr1:44395309	C/T	cg13606994	chr1:44402422	ARTN	-0.41	-6.27	-0.36	1.44e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs4434138	0.594	rs7653028	chr3:52763000	A/T	cg07507251	chr3:52567010	NT5DC2	0.34	5.73	0.33	2.73e-8	Intelligence (multi-trait analysis);
CESC	trans	rs1814175	0.527	rs3974435	chr11:49619533	G/A	cg15704280	chr7:45808275	SEPT13	-0.84	-10.44	-0.54	1.37e-21	Height;
CESC	cis	rs4631830	0.869	rs4131357	chr10:51537292	C/A	cg16070123	chr10:51489643	NA	-0.34	-5.07	-0.3	7.4e-7	Prostate-specific antigen levels;
CESC	cis	rs10927875	0.619	rs7537101	chr1:16150384	T/C	cg21385522	chr1:16154831	NA	-0.74	-10.42	-0.54	1.52e-21	Dilated cardiomyopathy;
CESC	cis	rs736408	0.736	rs4687550	chr3:52823430	T/G	cg18337363	chr3:52569053	NT5DC2	0.3	5.12	0.3	5.78e-7	Bipolar disorder;
CESC	cis	rs10504229	0.906	rs58559296	chr8:58171714	T/C	cg22535103	chr8:58192502	C8orf71	-1.05	-13.27	-0.63	3.63e-31	Developmental language disorder (linguistic errors);
CESC	cis	rs9311474	1.000	rs2276834	chr3:52325759	A/G	cg17372223	chr3:52568218	NT5DC2	0.4	6.08	0.35	4.1e-9	Electroencephalogram traits;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg15890103	chr11:86663160	FZD4	-0.38	-6.9	-0.39	3.72e-11	Gambling;
CESC	cis	rs4268898	0.760	rs7597919	chr2:24563646	A/G	cg06627628	chr2:24431161	ITSN2	0.56	7.13	0.4	9.38e-12	Asthma;
CESC	cis	rs10743315	0.557	rs17271690	chr12:19450236	A/G	cg02471346	chr12:19282374	PLEKHA5	0.78	5.68	0.33	3.49e-8	Gut microbiota (bacterial taxa);
CESC	trans	rs10510102	0.748	rs11200297	chr10:123732431	A/G	cg14125468	chr9:132113996	NA	-0.56	-6.03	-0.35	5.57e-9	Breast cancer;
CESC	cis	rs77106637	1.000	rs76793820	chr11:72619860	G/A	cg04827223	chr11:72435913	ARAP1	-0.55	-5.72	-0.33	2.8e-8	Type 2 diabetes;
CESC	cis	rs7680126	0.596	rs10939723	chr4:10139105	G/T	cg00071950	chr4:10020882	SLC2A9	-0.46	-5.36	-0.31	1.82e-7	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	cis	rs3741404	0.620	rs2236647	chr11:63964605	A/G	cg05555928	chr11:63887634	MACROD1	0.36	5.46	0.32	1.07e-7	Platelet count;
CESC	cis	rs73001065	0.818	rs16996185	chr19:19720788	G/T	cg03709012	chr19:19516395	GATAD2A	-0.91	-7.1	-0.4	1.14e-11	LDL cholesterol;
CESC	cis	rs17376456	0.741	rs10036829	chr5:93309897	G/C	cg21475434	chr5:93447410	FAM172A	0.76	6.88	0.39	4.31e-11	Diabetic retinopathy;
CESC	cis	rs9649213	0.593	rs12704983	chr7:97927045	G/A	cg00277769	chr7:97922759	BAIAP2L1	-0.34	-5.62	-0.33	4.89e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs829883	0.664	rs829874	chr12:98840615	G/A	cg25150519	chr12:98850993	NA	0.87	14.71	0.67	3.18e-36	Colorectal adenoma (advanced);
CESC	cis	rs2295359	0.892	rs6688383	chr1:67655954	C/T	cg17031739	chr1:67600172	NA	-0.42	-5.51	-0.32	8.32e-8	Psoriasis;
CESC	cis	rs56104184	0.775	rs117744769	chr19:49402686	G/T	cg21252483	chr19:49399788	TULP2	-0.52	-5.69	-0.33	3.36e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	cis	rs2440129	0.611	rs434473	chr17:6904934	A/G	cg19536664	chr17:6899085	ALOX12	-0.37	-7.72	-0.43	2.37e-13	Tonsillectomy;
CESC	cis	rs28374715	0.662	rs72737793	chr15:41516823	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.8	-10.11	-0.53	1.59e-20	Ulcerative colitis;
CESC	cis	rs172166	0.694	rs203884	chr6:28077374	G/T	cg23281280	chr6:28129359	ZNF389	0.4	5.61	0.33	5.2100000000000003e-08	Cardiac Troponin-T levels;
CESC	cis	rs6879260	1.000	rs7730585	chr5:179733440	T/C	cg13944838	chr5:179740914	GFPT2	-0.62	-8.31	-0.45	5.16e-15	Height;
CESC	cis	rs11630290	0.592	rs11071767	chr15:64154635	A/G	cg12036633	chr15:63758958	NA	-0.43	-5.29	-0.31	2.52e-7	Iris characteristics;
CESC	cis	rs8067545	0.611	rs1974745	chr17:20059824	C/G	cg13482628	chr17:19912719	NA	0.41	5.45	0.32	1.17e-7	Schizophrenia;
CESC	cis	rs933688	1.000	rs2839728	chr5:90727412	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.08	13.6	0.64	2.51e-32	Smoking behavior;
CESC	cis	rs6032067	0.929	rs6017503	chr20:43815103	G/A	cg10761708	chr20:43804764	PI3	0.53	6.38	0.36	7.98e-10	Blood protein levels;
CESC	cis	rs6952808	0.531	rs73039217	chr7:2178731	G/A	cg02951883	chr7:2050386	MAD1L1	-0.48	-6.21	-0.36	2.04e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs1707322	0.716	rs6694889	chr1:46101806	A/C	cg06784218	chr1:46089804	CCDC17	0.4	6.99	0.39	2.23e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs72945132	0.660	rs12292191	chr11:70122426	T/C	cg00319359	chr11:70116639	PPFIA1	0.78	7.78	0.43	1.6e-13	Coronary artery disease;
CESC	cis	rs3008870	0.709	rs62883160	chr1:67392889	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.64	8.32	0.45	4.78e-15	Lymphocyte percentage of white cells;
CESC	cis	rs13385	0.769	rs4912707	chr5:139624461	A/G	cg26211634	chr5:139558579	C5orf32	0.49	5.24	0.31	3.26e-7	Atrial fibrillation;
CESC	cis	rs28489187	0.660	rs6576767	chr1:85876316	G/A	cg16011679	chr1:85725395	C1orf52	-0.46	-5.51	-0.32	8.69e-8	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	cis	rs1707322	0.717	rs3014237	chr1:46090252	A/G	cg05343316	chr1:45956843	TESK2	-0.53	-6.44	-0.37	5.64e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs589448	1.000	rs589448	chr12:69752200	A/G	cg14784868	chr12:69753453	YEATS4	0.91	14.57	0.67	1.05e-35	Cerebrospinal fluid biomarker levels;
CESC	cis	rs10744422	0.800	rs2343110	chr12:123343571	T/G	cg25930673	chr12:123319894	HIP1R	-0.81	-6.32	-0.36	1.09e-9	Schizophrenia;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg05031202	chr17:7738649	NA	0.45	6.15	0.35	2.92e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs2637266	0.703	rs7086368	chr10:78489041	A/G	cg18941641	chr10:78392320	NA	0.4	7.68	0.43	3.08e-13	Pulmonary function;
CESC	cis	rs7542091	0.704	rs12022221	chr1:210046178	A/C	cg21951975	chr1:209979733	IRF6	0.47	8.32	0.46	4.66e-15	Monobrow;
CESC	cis	rs11098499	0.908	rs9995234	chr4:120321827	A/G	cg24375607	chr4:120327624	NA	0.46	5.48	0.32	9.93e-8	Corneal astigmatism;
CESC	cis	rs854765	0.547	rs2955380	chr17:17944349	A/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.5	-6.33	-0.36	1.03e-9	Total body bone mineral density;
CESC	cis	rs2439831	0.850	rs28509275	chr15:44098105	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.66	5.44	0.32	1.22e-7	Lung cancer in ever smokers;
CESC	cis	rs35110281	0.807	rs2838325	chr21:45014284	A/T	cg04455712	chr21:45112962	RRP1B	-0.42	-6.69	-0.38	1.33e-10	Mean corpuscular volume;
CESC	cis	rs652260	1.000	rs604938	chr19:7903484	A/G	cg26014689	chr19:7917955	EVI5L	0.45	6.32	0.36	1.08e-9	Menarche (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10524888	chr4:39529563	UGDH	0.6	7.05	0.4	1.52e-11	Gut microbiome composition (summer);
CESC	cis	rs9388451	0.839	rs10457469	chr6:126083658	G/A	cg10911889	chr6:126070802	HEY2	0.4	5.4	0.31	1.47e-7	Brugada syndrome;
CESC	cis	rs7520050	0.833	rs1085242	chr1:46544224	T/A	cg03146154	chr1:46216737	IPP	-0.43	-5.56	-0.32	6.54e-8	Red blood cell count;Reticulocyte count;
CESC	cis	rs11809207	0.522	rs3762459	chr1:26494886	C/G	cg00147160	chr1:26503991	CNKSR1	0.28	5.35	0.31	1.95e-7	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07059151	chr22:24236617	MIF	0.59	6.22	0.36	1.92e-9	Gut microbiome composition (summer);
CESC	cis	rs7560272	0.538	rs13006448	chr2:73924424	G/T	cg20560298	chr2:73613845	ALMS1	0.45	6.1	0.35	3.71e-9	Schizophrenia;
CESC	cis	rs344364	0.511	rs337284	chr16:1954799	A/C	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.51	-5.8	-0.34	1.93e-8	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-1.12	-22.85	-0.81	1.38e-64	Prudent dietary pattern;
CESC	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg11494091	chr17:61959527	GH2	0.72	12.22	0.6	1.56e-27	Prudent dietary pattern;
CESC	cis	rs9527	0.590	rs7901197	chr10:104840433	C/T	cg04362960	chr10:104952993	NT5C2	0.44	5.63	0.33	4.71e-8	Arsenic metabolism;
CESC	cis	rs9486715	0.867	rs4839828	chr6:96863326	G/A	cg18709589	chr6:96969512	KIAA0776	0.44	6.27	0.36	1.49e-9	Headache;
CESC	cis	rs4819052	0.851	rs13048789	chr21:46660714	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.75	9.98	0.52	4.1e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs7618915	0.571	rs7623199	chr3:52605974	C/T	cg18099408	chr3:52552593	STAB1	-0.33	-5.45	-0.32	1.17e-7	Bipolar disorder;
CESC	cis	rs3087591	1.000	rs7406983	chr17:29703374	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.44	-5.39	-0.31	1.54e-7	Hip circumference;
CESC	cis	rs9910055	0.529	rs408282	chr17:42182267	A/G	cg19774624	chr17:42201019	HDAC5	0.58	7.65	0.43	3.73e-13	Total body bone mineral density;
CESC	cis	rs2594989	0.943	rs2454501	chr3:11500089	A/G	cg00170343	chr3:11313890	ATG7	0.56	5.1	0.3	6.55e-7	Circulating chemerin levels;
CESC	cis	rs4132509	0.744	rs58594024	chr1:243862702	C/A	cg21452805	chr1:244014465	NA	0.53	5.9	0.34	1.11e-8	RR interval (heart rate);
CESC	cis	rs17711722	0.523	rs365896	chr7:65510697	A/G	cg11764359	chr7:65958608	NA	-0.5	-6.39	-0.37	7.63e-10	Calcium levels;
CESC	cis	rs4819052	0.788	rs9978857	chr21:46705155	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.79	10.36	0.54	2.41e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs1728785	0.818	rs1069289	chr16:68585317	C/A	cg02972257	chr16:68554789	NA	-0.62	-6.86	-0.39	4.94e-11	Ulcerative colitis;
CESC	cis	rs875971	0.862	rs778707	chr7:65857027	G/A	cg18252515	chr7:66147081	NA	-0.46	-6.05	-0.35	5e-9	Aortic root size;
CESC	cis	rs6687430	0.532	rs12028449	chr1:10617034	A/G	cg20482658	chr1:10539492	PEX14	-0.4	-7.9	-0.44	7.42e-14	Hand grip strength;
CESC	cis	rs7666738	0.830	rs10050008	chr4:99025313	T/G	cg03467027	chr4:99064603	C4orf37	0.49	6.18	0.35	2.44e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3617	0.572	rs2256332	chr3:52855865	A/G	cg11645453	chr3:52864694	ITIH4	-0.26	-5.1	-0.3	6.37e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
CESC	cis	rs4713118	0.662	rs9380045	chr6:28025279	A/G	cg26335602	chr6:28129616	ZNF389	0.44	5.61	0.33	5.19e-8	Parkinson's disease;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg11108432	chr8:10697698	PINX1	0.49	6.54	0.37	3.24e-10	Systemic lupus erythematosus;
CESC	trans	rs7246657	0.882	rs28623164	chr19:37913453	G/A	cg24637308	chr11:6592297	DNHD1	0.54	6.34	0.36	1.01e-9	Coronary artery calcification;
CESC	cis	rs55788414	0.932	rs57461213	chr16:81185419	G/C	cg06400318	chr16:81190750	PKD1L2	-0.6	-6.82	-0.39	6.19e-11	Left ventricular obstructive tract defect (maternal effect);
CESC	cis	rs7666738	0.800	rs28427190	chr4:98989106	A/G	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.6e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1707322	0.663	rs3935296	chr1:46180470	T/C	cg06784218	chr1:46089804	CCDC17	-0.43	-7.58	-0.42	5.65e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2842992	0.830	rs2758320	chr6:160070676	T/G	cg11366901	chr6:160182831	ACAT2	0.79	9.68	0.51	3.46e-19	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs3091242	0.933	rs34933589	chr1:25788198	T/C	cg12412775	chr1:25698385	RHCE	0.28	5.05	0.3	8.25e-7	Erythrocyte sedimentation rate;
CESC	cis	rs7208859	0.623	rs12103508	chr17:29086781	T/G	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.91e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs55882075	0.936	rs34646062	chr5:179186318	A/G	cg14593053	chr5:179126677	CANX	-0.43	-5.73	-0.33	2.69e-8	Monocyte percentage of white cells;
CESC	cis	rs7666738	0.791	rs1426674	chr4:98924247	C/A	cg17366294	chr4:99064904	C4orf37	0.6	8.23	0.45	8.65e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4481887	0.927	rs4390209	chr1:248472613	A/T	cg00666640	chr1:248458726	OR2T12	0.35	5.93	0.34	9.43e-9	Common traits (Other);
CESC	cis	rs2797160	0.967	rs1343120	chr6:125992810	A/G	cg05901451	chr6:126070800	HEY2	-0.45	-6.62	-0.38	1.93e-10	Endometrial cancer;
CESC	cis	rs7811142	0.830	rs10085549	chr7:99983135	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.76	7.63	0.42	4.19e-13	Platelet count;
CESC	cis	rs2576037	0.583	rs2571028	chr18:44561100	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.78	-12.89	-0.62	7.79e-30	Personality dimensions;
CESC	cis	rs4629710	0.592	rs13200165	chr6:131549167	G/C	cg12606694	chr6:131520996	AKAP7	0.48	5.97	0.34	7.68e-9	Multiple myeloma (IgH translocation);
CESC	cis	rs2816062	0.735	rs2816054	chr1:18896431	C/T	cg18795169	chr1:18902165	NA	-0.94	-19.04	-0.76	1.61e-51	Urate levels in lean individuals;
CESC	cis	rs7945705	0.818	rs2742537	chr11:8908389	G/A	cg12365402	chr11:9010492	NRIP3	-0.34	-5.49	-0.32	9.58e-8	Hemoglobin concentration;
CESC	cis	rs832540	0.656	rs832573	chr5:56159578	T/C	cg24531977	chr5:56204891	C5orf35	-0.49	-6.06	-0.35	4.62e-9	Coronary artery disease;
CESC	cis	rs734999	0.545	rs9970196	chr1:2574078	T/C	cg18854424	chr1:2615690	NA	-0.31	-5.88	-0.34	1.2e-8	Ulcerative colitis;
CESC	trans	rs1728785	1.000	rs1728781	chr16:68567794	A/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.61	7.43	0.42	1.5e-12	Ulcerative colitis;
CESC	trans	rs1973993	0.691	rs1989141	chr1:96898520	C/T	cg10631902	chr5:14652156	NA	0.61	9.43	0.5	2.18e-18	Weight;
CESC	cis	rs1788820	0.871	rs1623003	chr18:21165163	C/T	cg14672496	chr18:21087552	C18orf8	0.48	6.33	0.36	1.05e-9	Body mass index;
CESC	cis	rs9309473	0.950	rs10207264	chr2:73714097	G/A	cg20560298	chr2:73613845	ALMS1	-0.49	-6.69	-0.38	1.3e-10	Metabolite levels;
CESC	trans	rs12681287	0.547	rs13267858	chr8:87510871	G/A	cg27317242	chr8:23145699	R3HCC1	-0.53	-6.34	-0.36	9.67e-10	Caudate activity during reward;
CESC	trans	rs1814175	0.645	rs28445479	chr11:50047999	A/G	cg15704280	chr7:45808275	SEPT13	-1.01	-18.51	-0.75	1.12e-49	Height;
CESC	cis	rs704795	0.902	rs11887784	chr2:27679919	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.27	-5.32	-0.31	2.21e-7	Menopause (age at onset);
CESC	cis	rs10504229	0.639	rs11781834	chr8:58133422	C/T	cg22535103	chr8:58192502	C8orf71	-0.79	-8.79	-0.48	1.94e-16	Developmental language disorder (linguistic errors);
CESC	cis	rs6964587	1.000	rs17164275	chr7:91590408	A/G	cg17063962	chr7:91808500	NA	0.57	7.74	0.43	2.03e-13	Breast cancer;
CESC	trans	rs1728785	1.000	rs1069288	chr16:68585285	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.62	7.5	0.42	9.69e-13	Ulcerative colitis;
CESC	cis	rs7044106	0.791	rs10739572	chr9:123489815	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.72	10.63	0.55	3.29e-22	Hip circumference adjusted for BMI;
CESC	trans	rs11098499	0.908	rs2017057	chr4:120257711	A/G	cg25214090	chr10:38739885	LOC399744	0.71	10.11	0.53	1.6e-20	Corneal astigmatism;
CESC	cis	rs400736	0.740	rs225096	chr1:8105600	G/C	cg25007680	chr1:8021821	PARK7	0.71	9.97	0.52	4.51e-20	Response to antidepressants and depression;
CESC	cis	rs7264396	0.528	rs3787174	chr20:34487921	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.67	6.85	0.39	5.04e-11	Total cholesterol levels;
CESC	trans	rs629535	0.514	rs55653755	chr8:70154383	A/C	cg21567404	chr3:27674614	NA	-0.83	-9.14	-0.49	1.69e-17	Dupuytren's disease;
CESC	trans	rs2115172	0.836	rs4835799	chr5:122762229	A/G	cg22217807	chr16:8768618	ABAT	0.48	6.28	0.36	1.35e-9	Weight;
CESC	cis	rs7666738	0.830	rs6853266	chr4:99047528	G/T	cg03467027	chr4:99064603	C4orf37	0.48	5.94	0.34	8.7e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg18402987	chr7:1209562	NA	0.63	7.37	0.41	2.12e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7666738	0.791	rs12233867	chr4:98950233	A/G	cg17366294	chr4:99064904	C4orf37	0.59	8.52	0.46	1.24e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3740540	0.530	rs2362505	chr10:126290739	T/G	cg04949429	chr10:126290192	LHPP	0.4	5.6	0.33	5.23e-8	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
CESC	cis	rs7520050	0.933	rs9787208	chr1:46314616	C/A	cg03146154	chr1:46216737	IPP	-0.48	-6.36	-0.36	8.91e-10	Red blood cell count;Reticulocyte count;
CESC	cis	rs898097	0.812	rs56405605	chr17:80843663	T/C	cg05255149	chr17:80675120	FN3KRP	-0.46	-5.2	-0.3	3.94e-7	Breast cancer;
CESC	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg18402987	chr7:1209562	NA	0.76	7.55	0.42	7.26e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs11792861	0.962	rs11789624	chr9:111796231	T/C	cg13535736	chr9:111863775	C9orf5	-0.51	-6.76	-0.38	8.87e-11	Menarche (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26692046	chr20:443277	TBC1D20	0.55	6.18	0.35	2.42e-9	Gut microbiome composition (summer);
CESC	cis	rs72945132	0.882	rs59681006	chr11:70179401	T/C	cg14191688	chr11:70257035	CTTN	0.43	5.38	0.31	1.62e-7	Coronary artery disease;
CESC	cis	rs35306767	0.953	rs12354639	chr10:963681	G/A	cg25019033	chr10:957182	NA	-0.64	-7.94	-0.44	5.61e-14	Eosinophil percentage of granulocytes;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg11612470	chr12:3068051	TEAD4	-0.44	-6.02	-0.35	5.91e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs7089973	0.836	rs7895551	chr10:116625481	C/T	cg23260525	chr10:116636907	FAM160B1	0.38	6.42	0.37	6.35e-10	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs514406	0.861	rs7524476	chr1:53240212	C/T	cg08859206	chr1:53392774	SCP2	0.54	7.15	0.4	8.22e-12	Monocyte count;
CESC	cis	rs9926296	0.744	rs154656	chr16:89708003	T/A	cg03605463	chr16:89740564	NA	0.63	7.64	0.42	4.07e-13	Vitiligo;
CESC	cis	rs2404602	0.647	rs11633869	chr15:77133322	G/T	cg23625390	chr15:77176239	SCAPER	0.47	6.64	0.38	1.75e-10	Blood metabolite levels;
CESC	cis	rs4665809	1.000	rs6546744	chr2:26302161	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.69	-7.83	-0.43	1.18e-13	Gut microbiome composition (summer);
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg19243777	chr12:26278767	BHLHE41	-0.48	-7.17	-0.4	7.4e-12	Vertical cup-disc ratio;
CESC	cis	rs754466	0.914	rs12219971	chr10:79701526	T/C	cg17075019	chr10:79541650	NA	-0.68	-8.29	-0.45	5.91e-15	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs2929278	0.617	rs575082	chr15:44110142	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.47	-7.25	-0.41	4.44e-12	Schizophrenia;
CESC	cis	rs10870270	0.500	rs9419217	chr10:133758379	A/G	cg17892150	chr10:133769511	PPP2R2D	-0.6	-8.56	-0.47	9.58e-16	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs763014	0.898	rs4984897	chr16:632180	G/C	cg07256732	chr16:621771	PIGQ	-0.3	-5.14	-0.3	5.22e-7	Height;
CESC	cis	rs7107174	1.000	rs10899454	chr11:77997513	T/C	cg02023728	chr11:77925099	USP35	0.51	7.03	0.4	1.74e-11	Testicular germ cell tumor;
CESC	cis	rs7216064	0.953	rs4790981	chr17:65921834	A/G	cg07042672	chr17:66097459	LOC651250	-0.6	-7.33	-0.41	2.85e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs10899021	1.000	rs7102084	chr11:74358132	T/C	cg25880958	chr11:74394337	NA	-0.72	-7.14	-0.4	8.93e-12	Response to metformin (IC50);
CESC	cis	rs7818345	0.935	rs12542575	chr8:19286558	A/T	cg11303988	chr8:19266685	CSGALNACT1	0.35	6.39	0.37	7.35e-10	Language performance in older adults (adjusted for episodic memory);
CESC	cis	rs7618915	0.547	rs11720432	chr3:52672742	T/C	cg07507251	chr3:52567010	NT5DC2	0.41	7.28	0.41	3.83e-12	Bipolar disorder;
CESC	cis	rs4819052	0.959	rs8130866	chr21:46672112	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.88	11.73	0.58	7.05e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs6952808	1.000	rs6953693	chr7:1886388	C/G	cg21782813	chr7:2030301	MAD1L1	0.38	5.26	0.31	2.99e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs1878931	0.535	rs55732163	chr16:3411518	A/C	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.67	-8.09	-0.44	2.17e-14	Body mass index (adult);
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg13981078	chr14:105885112	MTA1	-0.38	-6.16	-0.35	2.64e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs17345786	0.798	rs4257518	chr3:101281709	C/T	cg11279151	chr3:101281821	RG9MTD1	0.46	6.15	0.35	2.9e-9	Colonoscopy-negative controls vs population controls;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg11692369	chr8:54755880	ATP6V1H	0.44	6.16	0.35	2.75e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs4665809	1.000	rs4665819	chr2:26309073	A/G	cg22920501	chr2:26401640	FAM59B	-0.67	-8.12	-0.45	1.72e-14	Gut microbiome composition (summer);
CESC	cis	rs736408	0.774	rs4687551	chr3:52823448	C/T	cg18337363	chr3:52569053	NT5DC2	-0.3	-5.23	-0.31	3.47e-7	Bipolar disorder;
CESC	cis	rs77140172	0.655	rs79387006	chr4:89672775	A/T	cg01026744	chr4:89619053	NAP1L5;HERC3	0.79	5.64	0.33	4.32e-8	Post bronchodilator FEV1;
CESC	trans	rs72991	0.681	rs674803	chr11:121259993	G/C	cg17871993	chr7:65673056	TPST1	-0.34	-6.12	-0.35	3.4e-9	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs12079745	0.793	rs11809180	chr1:169100095	C/T	cg09363564	chr1:169337483	NME7;BLZF1	-0.71	-5.68	-0.33	3.45e-8	QT interval;
CESC	cis	rs6539267	0.741	rs2279759	chr12:106694988	T/C	cg02476566	chr12:106696527	TCP11L2	0.6	7.1	0.4	1.15e-11	Tourette syndrome;
CESC	cis	rs10256972	0.967	rs1881122	chr7:1040946	A/T	cg07308232	chr7:1071921	C7orf50	-0.45	-6.25	-0.36	1.65e-9	Longevity;Endometriosis;
CESC	cis	rs703842	0.964	rs10431552	chr12:58178148	G/A	cg00677455	chr12:58241039	CTDSP2	0.54	7.02	0.4	1.9e-11	Multiple sclerosis;
CESC	cis	rs9549367	0.789	rs9604040	chr13:113910611	A/G	cg00898013	chr13:113819073	PROZ	0.52	7.54	0.42	7.44e-13	Platelet distribution width;
CESC	cis	rs4803468	1.000	rs4803465	chr19:41918158	A/G	cg14132834	chr19:41945861	ATP5SL	0.59	7.51	0.42	9.11e-13	Height;
CESC	cis	rs9309473	0.607	rs58962779	chr2:73555801	T/C	cg20560298	chr2:73613845	ALMS1	-0.51	-7.05	-0.4	1.56e-11	Metabolite levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01042287	chr16:28884343	SH2B1	-0.54	-6.29	-0.36	1.27e-9	Gut microbiome composition (summer);
CESC	cis	rs9549367	0.865	rs9549366	chr13:113907644	G/A	cg18105134	chr13:113819100	PROZ	-0.68	-8.71	-0.47	3.37e-16	Platelet distribution width;
CESC	cis	rs1153858	1.000	rs2467858	chr15:45711492	A/G	cg10760299	chr15:45669010	GATM	0.37	5.14	0.3	5.43e-7	Homoarginine levels;
CESC	cis	rs11792861	0.926	rs76689835	chr9:111833792	G/A	cg13535736	chr9:111863775	C9orf5	-0.52	-6.9	-0.39	3.71e-11	Menarche (age at onset);
CESC	cis	rs2933343	0.729	rs789228	chr3:128601050	A/G	cg24203234	chr3:128598194	ACAD9	0.43	5.78	0.33	2.04e-8	IgG glycosylation;
CESC	cis	rs1799949	1.000	rs11653231	chr17:41331460	G/A	cg05368731	chr17:41323189	NBR1	0.77	10.72	0.55	1.69e-22	Menopause (age at onset);
CESC	cis	rs6754311	0.731	rs892715	chr2:136576577	T/C	cg07169764	chr2:136633963	MCM6	-0.66	-7.98	-0.44	4.39e-14	Mosquito bite size;
CESC	trans	rs12659622	0.850	rs76376130	chr5:15678147	T/A	cg22457238	chr19:58570995	ZNF135	-0.51	-6.03	-0.35	5.42e-9	Obesity-related traits;
CESC	trans	rs11098499	0.663	rs9996501	chr4:120238918	C/A	cg25214090	chr10:38739885	LOC399744	0.59	8.11	0.45	1.85e-14	Corneal astigmatism;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg02114786	chr21:46293672	PTTG1IP	-0.43	-6.16	-0.35	2.62e-9	Gambling;
CESC	cis	rs7618915	0.501	rs13079063	chr3:52744460	A/G	cg18099408	chr3:52552593	STAB1	-0.3	-5.09	-0.3	6.8e-7	Bipolar disorder;
CESC	cis	rs4665809	0.590	rs3806514	chr2:26466772	C/T	cg27170947	chr2:26402098	FAM59B	0.87	10.16	0.53	1.05e-20	Gut microbiome composition (summer);
CESC	cis	rs9488822	0.651	rs3798228	chr6:116321156	T/C	cg26893134	chr6:116381904	FRK	0.25	6.04	0.35	5.06e-9	Cholesterol, total;LDL cholesterol;
CESC	cis	rs875971	0.638	rs6960778	chr7:66071597	C/T	cg25985355	chr7:65971099	NA	0.33	5.38	0.31	1.63e-7	Aortic root size;
CESC	cis	rs4803468	1.000	rs2241711	chr19:41911980	T/C	cg14132834	chr19:41945861	ATP5SL	-0.67	-8.31	-0.45	5.08e-15	Height;
CESC	cis	rs9916302	0.861	rs752314	chr17:37410700	C/T	cg20243544	chr17:37824526	PNMT	0.47	5.84	0.34	1.55e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs7605827	0.930	rs4140715	chr2:15515899	G/A	cg19274914	chr2:15703543	NA	0.32	5.55	0.32	6.84e-8	Educational attainment (years of education);
CESC	cis	rs9300255	0.544	rs1716175	chr12:123658388	A/T	cg05973401	chr12:123451056	ABCB9	0.49	5.37	0.31	1.75e-7	Neutrophil percentage of white cells;
CESC	cis	rs1153858	1.000	rs1153849	chr15:45695695	G/A	cg21132104	chr15:45694354	SPATA5L1	0.78	10.4	0.54	1.79e-21	Homoarginine levels;
CESC	cis	rs7824557	0.564	rs11782430	chr8:11226071	A/G	cg21775007	chr8:11205619	TDH	-0.47	-6.56	-0.37	2.78e-10	Retinal vascular caliber;
CESC	trans	rs7395662	0.500	rs1304199	chr11:48699032	A/G	cg00717180	chr2:96193071	NA	-0.45	-6.1	-0.35	3.83e-9	HDL cholesterol;
CESC	cis	rs684232	0.583	rs2543776	chr17:557149	G/A	cg15660573	chr17:549704	VPS53	-0.74	-10.95	-0.56	2.87e-23	Prostate cancer;
CESC	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg06873352	chr17:61820015	STRADA	0.72	12.62	0.61	6.62e-29	Prudent dietary pattern;
CESC	trans	rs60843830	1.000	rs17713396	chr2:227201	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.67	8.17	0.45	1.31e-14	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs11711311	1.000	rs2305545	chr3:113499733	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.68	9.33	0.5	4.28e-18	IgG glycosylation;
CESC	cis	rs4555082	0.957	rs2816629	chr14:105737261	G/A	cg10792982	chr14:105748885	BRF1	0.41	5.74	0.33	2.52e-8	Mean platelet volume;Platelet distribution width;
CESC	cis	rs922182	0.547	rs6494458	chr15:64271095	A/C	cg24729988	chr15:64271149	DAPK2	-0.59	-9.12	-0.49	1.94e-17	Blood protein levels;
CESC	cis	rs2439831	0.681	rs28578454	chr15:43603032	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.82	8.05	0.44	2.73e-14	Lung cancer in ever smokers;
CESC	cis	rs72945132	0.882	rs7116191	chr11:70159781	G/A	cg14191688	chr11:70257035	CTTN	0.42	5.34	0.31	1.95e-7	Coronary artery disease;
CESC	cis	rs11190604	1.000	rs2495739	chr10:102335507	C/T	cg07080220	chr10:102295463	HIF1AN	0.59	5.56	0.32	6.64e-8	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs2860975	0.501	rs602941	chr10:96961184	G/A	cg09036531	chr10:96991505	NA	-0.64	-10.17	-0.53	9.72e-21	Immune response to smallpox vaccine (IL-6);
CESC	cis	rs9399137	0.507	rs11754021	chr6:135308375	A/G	cg22676075	chr6:135203613	NA	0.54	7.06	0.4	1.46e-11	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	cis	rs9916302	0.653	rs11657058	chr17:37699378	T/G	cg20243544	chr17:37824526	PNMT	0.53	5.26	0.31	3.03e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs896854	0.654	rs1453377	chr8:95969947	C/T	cg23172400	chr8:95962367	TP53INP1	-0.43	-8.81	-0.48	1.65e-16	Type 2 diabetes;
CESC	cis	rs644799	0.965	rs1944080	chr11:95503636	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.72	9.66	0.51	4.04e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs4819052	0.808	rs2838825	chr21:46655651	C/T	cg11663144	chr21:46675770	NA	-0.61	-9.31	-0.5	5.26e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs1008375	0.866	rs12233712	chr4:17570063	T/A	cg16339924	chr4:17578868	LAP3	0.63	7.93	0.44	6.15e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs17253792	0.822	rs17253716	chr14:56153661	G/C	cg01858014	chr14:56050164	KTN1	-0.97	-7.54	-0.42	7.36e-13	Putamen volume;
CESC	cis	rs11718455	0.921	rs35872933	chr3:44028515	T/G	cg08738300	chr3:44038990	NA	0.48	6.47	0.37	4.83e-10	Coronary artery disease;
CESC	cis	rs7615952	0.599	rs7631268	chr3:125755664	T/A	cg15145296	chr3:125709740	NA	-0.51	-5.35	-0.31	1.92e-7	Blood pressure (smoking interaction);
CESC	cis	rs2380220	0.720	rs9400397	chr6:95980623	C/A	cg23517279	chr6:96025343	MANEA	0.53	5.63	0.33	4.68e-8	Behavioural disinhibition (generation interaction);
CESC	cis	rs6061231	0.544	rs2427314	chr20:60973666	C/T	cg15674680	chr20:60982522	CABLES2	0.54	6.72	0.38	1.08e-10	Colorectal cancer;
CESC	trans	rs9951602	0.541	rs12454297	chr18:76654445	A/G	cg02800362	chr5:177631904	HNRNPAB	0.66	8.63	0.47	5.9e-16	Obesity-related traits;
CESC	cis	rs2439831	0.717	rs28495368	chr15:43895642	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.69	8.54	0.46	1.03e-15	Lung cancer in ever smokers;
CESC	cis	rs9457247	0.935	rs2757046	chr6:167374353	C/T	cg07741184	chr6:167504864	NA	-0.3	-5.44	-0.32	1.19e-7	Crohn's disease;
CESC	cis	rs12142240	0.698	rs68112720	chr1:46813888	T/C	cg10495392	chr1:46806563	NSUN4	0.57	6.28	0.36	1.39e-9	Menopause (age at onset);
CESC	cis	rs4865169	0.691	rs1056364	chr4:57889677	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.38	-5.23	-0.31	3.42e-7	Breast cancer;
CESC	cis	rs35110281	0.807	rs1598206	chr21:45058776	A/G	cg04455712	chr21:45112962	RRP1B	0.42	6.24	0.36	1.75e-9	Mean corpuscular volume;
CESC	cis	rs798554	0.796	rs2158694	chr7:2863443	T/G	cg19717773	chr7:2847554	GNA12	-0.54	-7.62	-0.42	4.43e-13	Height;
CESC	trans	rs7980799	0.591	rs10844614	chr12:33605702	A/C	cg26384229	chr12:38710491	ALG10B	-0.57	-8.24	-0.45	8.04e-15	Heart rate;Heart rate variability traits (RMSSD);
CESC	cis	rs7680126	0.633	rs4698040	chr4:10352550	C/T	cg11266682	chr4:10021025	SLC2A9	-0.42	-5.44	-0.32	1.21e-7	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	cis	rs11650494	0.516	rs9907942	chr17:47513891	C/T	cg08112188	chr17:47440006	ZNF652	0.78	5.16	0.3	4.88e-7	Prostate cancer;
CESC	cis	rs9837602	0.688	rs793492	chr3:99499736	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.45	-5.74	-0.33	2.58e-8	Breast cancer;
CESC	cis	rs763014	0.966	rs12935215	chr16:670605	T/C	cg00908189	chr16:619842	PIGQ	0.64	8.94	0.48	6.68e-17	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16321116	chr14:59655311	DAAM1	0.68	7.6	0.42	5.21e-13	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22669566	chr12:679287	NINJ2	0.65	7.17	0.4	7.41e-12	Gut microbiome composition (summer);
CESC	cis	rs1552244	0.882	rs34779351	chr3:10021801	A/G	cg00166722	chr3:10149974	C3orf24	0.49	5.98	0.34	7.37e-9	Alzheimer's disease;
CESC	cis	rs36051895	0.603	rs11795305	chr9:5179920	G/C	cg02405213	chr9:5042618	JAK2	-0.46	-5.32	-0.31	2.24e-7	Pediatric autoimmune diseases;
CESC	cis	rs2066819	1.000	rs11171806	chr12:56733531	A/G	cg26714650	chr12:56694279	CS	1.3	8.93	0.48	7.55e-17	Psoriasis vulgaris;
CESC	cis	rs637571	0.522	rs649000	chr11:65742933	T/C	cg02427764	chr11:65769310	BANF1;EIF1AD	0.74	10.58	0.54	4.74e-22	Eosinophil percentage of white cells;
CESC	cis	rs3741151	0.773	rs73546720	chr11:73252409	C/T	cg17517138	chr11:73019481	ARHGEF17	1.05	7.72	0.43	2.46e-13	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs6762	0.748	rs7929032	chr11:839078	G/A	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.74	-9.68	-0.51	3.62e-19	Mean platelet volume;
CESC	cis	rs3820928	1.000	rs11686072	chr2:227777493	A/T	cg05526886	chr2:227700861	RHBDD1	-0.44	-5.75	-0.33	2.45e-8	Pulmonary function;
CESC	cis	rs7666738	0.830	rs34135615	chr4:99001325	C/T	cg18180107	chr4:99064573	C4orf37	0.4	5.23	0.31	3.41e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9916302	0.904	rs602282	chr17:37433021	C/T	cg19468946	chr17:37922297	IKZF3	-0.4	-5.22	-0.31	3.56e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs12142240	0.698	rs17413701	chr1:46818452	A/G	cg10495392	chr1:46806563	NSUN4	0.57	6.27	0.36	1.47e-9	Menopause (age at onset);
CESC	cis	rs9457247	0.765	rs9459838	chr6:167426599	C/G	cg23791538	chr6:167370224	RNASET2	-0.54	-7.39	-0.41	1.98e-12	Crohn's disease;
CESC	cis	rs3106136	0.546	rs7685121	chr4:95175682	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.67	-11.02	-0.56	1.7e-23	Capecitabine sensitivity;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg07898084	chr13:53029385	CKAP2	0.48	6.29	0.36	1.33e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs3785574	0.962	rs4968660	chr17:61792221	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.58	7.15	0.4	8.41e-12	Height;
CESC	cis	rs3096299	0.967	rs2911257	chr16:89484134	C/G	cg02034447	chr16:89574710	SPG7	0.42	5.38	0.31	1.65e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs2839186	0.771	rs2280959	chr21:47641996	C/G	cg11766577	chr21:47581405	C21orf56	-0.46	-6.36	-0.36	8.76e-10	Testicular germ cell tumor;
CESC	cis	rs72901758	0.810	rs61740716	chr17:76244648	G/A	cg23302638	chr17:76210176	BIRC5	0.49	5.38	0.31	1.63e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
CESC	cis	rs72781680	0.904	rs72796340	chr2:24143622	T/A	cg08917208	chr2:24149416	ATAD2B	0.93	8.42	0.46	2.35e-15	Lymphocyte counts;
CESC	cis	rs3796352	1.000	rs113995589	chr3:53132372	A/T	cg12962167	chr3:53033115	SFMBT1	0.54	5.13	0.3	5.5e-7	Immune reponse to smallpox (secreted IL-2);
CESC	cis	rs798554	0.680	rs2533889	chr7:2900309	G/C	cg19717773	chr7:2847554	GNA12	-0.47	-6.56	-0.37	2.73e-10	Height;
CESC	cis	rs7937682	0.883	rs490492	chr11:111465150	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.9	-12.87	-0.62	9.33e-30	Primary sclerosing cholangitis;
CESC	trans	rs877282	0.533	rs10904565	chr10:819991	G/T	cg22713356	chr15:30763199	NA	1.07	9.68	0.51	3.6e-19	Uric acid levels;
CESC	cis	rs9916302	0.768	rs11078900	chr17:37614641	C/T	cg15445000	chr17:37608096	MED1	0.41	6.83	0.39	5.8200000000000003e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs6912958	0.781	rs9450739	chr6:88268271	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-6.58	-0.37	2.55e-10	Monocyte percentage of white cells;
CESC	cis	rs10744422	1.000	rs897385	chr12:123341297	A/G	cg22842854	chr12:123319900	HIP1R	-0.67	-5.28	-0.31	2.69e-7	Schizophrenia;
CESC	cis	rs7927771	0.524	rs3758655	chr11:47703943	T/C	cg18512352	chr11:47633146	NA	0.35	5.39	0.31	1.53e-7	Subjective well-being;
CESC	cis	rs7580658	0.929	rs11886231	chr2:128028130	G/A	cg10021288	chr2:128175891	PROC	-0.41	-6.45	-0.37	5.16e-10	Protein C levels;
CESC	cis	rs7786877	0.582	rs2075674	chr7:100225031	G/A	cg27028030	chr7:100209634	MOSPD3	0.58	5.49	0.32	9.24e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs4629710	0.617	rs28360555	chr6:131538952	C/A	cg12606694	chr6:131520996	AKAP7	0.45	5.55	0.32	6.8e-8	Multiple myeloma (IgH translocation);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg03111502	chr11:124609885	NRGN	0.47	6.0	0.35	6.57e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	10.88	0.56	4.81e-23	Prudent dietary pattern;
CESC	cis	rs2204008	0.640	rs2320744	chr12:38162389	A/G	cg26384229	chr12:38710491	ALG10B	0.75	10.86	0.55	5.81e-23	Bladder cancer;
CESC	cis	rs9916302	0.904	rs8068427	chr17:37511517	G/A	cg00129232	chr17:37814104	STARD3	0.52	6.49	0.37	4.13e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs6964587	0.934	rs7811328	chr7:91720931	A/T	cg17063962	chr7:91808500	NA	0.55	7.59	0.42	5.51e-13	Breast cancer;
CESC	cis	rs936229	0.798	rs1869959	chr15:75147332	A/C	cg14664628	chr15:75095509	CSK	-0.76	-10.48	-0.54	1.04e-21	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CESC	cis	rs2836974	0.965	rs8131126	chr21:40655754	A/G	cg17971929	chr21:40555470	PSMG1	1.03	14.25	0.66	1.39e-34	Cognitive function;
CESC	cis	rs10540	1.000	rs61876342	chr11:496193	T/G	cg03352830	chr11:487213	PTDSS2	0.74	7.2	0.4	6.15e-12	Body mass index;
CESC	cis	rs829661	0.512	rs11676852	chr2:30792898	A/C	cg12454169	chr2:30669597	LCLAT1	-0.44	-5.47	-0.32	1.04e-7	Midgestational circulating levels of PBDEs (fetal genetic effect);
CESC	cis	rs7814319	1.000	rs6468495	chr8:97259953	C/A	cg20787634	chr8:97240163	UQCRB	-0.52	-6.78	-0.38	7.88e-11	Lung function (FVC);
CESC	cis	rs4253772	0.550	rs715515	chr22:46720921	G/A	cg00784671	chr22:46762841	CELSR1	-0.56	-5.71	-0.33	3.09e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs7809950	1.000	rs3801948	chr7:107238447	A/T	cg23024343	chr7:107201750	COG5	-0.41	-5.77	-0.33	2.19e-8	Coronary artery disease;
CESC	cis	rs9649465	1.000	rs4588795	chr7:123349924	A/G	cg04330084	chr7:123175371	IQUB	0.38	5.13	0.3	5.56e-7	Migraine;
CESC	cis	rs672059	1.000	rs559476	chr1:183160704	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.54	7.01	0.4	1.93e-11	Hypertriglyceridemia;
CESC	cis	rs599083	0.530	rs686921	chr11:68170833	G/T	cg16797656	chr11:68205561	LRP5	-0.38	-5.06	-0.3	7.91e-7	Bone mineral density (spine);
CESC	cis	rs9291683	0.588	rs12507330	chr4:10002195	G/A	cg00071950	chr4:10020882	SLC2A9	0.8	14.44	0.66	2.93e-35	Bone mineral density;
CESC	cis	rs1564271	0.528	rs2489589	chr10:26983095	A/G	cg13837822	chr10:26931731	LOC731789	0.42	6.46	0.37	4.93e-10	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;
CESC	cis	rs1799949	0.501	rs9675035	chr17:41415016	A/T	cg23758822	chr17:41437982	NA	1.05	16.25	0.71	1.17e-41	Menopause (age at onset);
CESC	cis	rs1008375	1.000	rs10939748	chr4:17691230	T/C	cg02297831	chr4:17616191	MED28	0.5	5.88	0.34	1.24e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs5758659	1.000	rs134882	chr22:42670965	A/G	cg05082376	chr22:42548792	NA	-0.39	-5.9	-0.34	1.09e-8	Cognitive function;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07148452	chr15:90176987	KIF7	-0.68	-7.48	-0.42	1.09e-12	Gut microbiome composition (summer);
CESC	cis	rs35362007	0.530	rs17835086	chr14:96012465	A/G	cg13511115	chr14:96000878	GLRX5;SNHG10;SCARNA13	0.66	5.36	0.31	1.81e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	cis	rs2816062	0.721	rs2816047	chr1:18893728	A/C	cg18795169	chr1:18902165	NA	-0.95	-19.06	-0.76	1.32e-51	Urate levels in lean individuals;
CESC	cis	rs2439831	0.867	rs76542740	chr15:43891512	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.7	8.6	0.47	6.89e-16	Lung cancer in ever smokers;
CESC	cis	rs933688	0.938	rs6866923	chr5:90669352	A/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.15	15.15	0.68	8.88e-38	Smoking behavior;
CESC	cis	rs4906332	0.966	rs35799018	chr14:103893475	G/A	cg09975044	chr14:104007538	NA	0.46	6.38	0.36	7.81e-10	Coronary artery disease;
CESC	cis	rs4237845	0.715	rs4760340	chr12:58275176	A/T	cg00677455	chr12:58241039	CTDSP2	0.55	7.2	0.4	6.21e-12	Intelligence (multi-trait analysis);
CESC	cis	rs9649213	0.613	rs6961129	chr7:97975542	T/G	cg00277769	chr7:97922759	BAIAP2L1	-0.33	-5.41	-0.32	1.41e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7918232	0.941	rs1755399	chr10:27394958	A/G	cg14442939	chr10:27389572	ANKRD26	0.68	6.47	0.37	4.78e-10	Breast cancer;
CESC	trans	rs7582180	0.700	rs1437971	chr2:100986964	A/C	cg02956372	chr4:967467	DGKQ	0.62	6.09	0.35	3.93e-9	Intelligence (multi-trait analysis);
CESC	cis	rs6879260	1.000	rs6874653	chr5:179730843	A/G	cg23248424	chr5:179741104	GFPT2	-0.68	-9.2	-0.49	1.11e-17	Height;
CESC	cis	rs4819052	0.851	rs914214	chr21:46697820	G/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.46	5.76	0.33	2.27e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs6828523	0.698	rs73869046	chr4:175854498	C/T	cg14561282	chr4:175839468	ADAM29	0.44	5.15	0.3	5.09e-7	Breast cancer;
CESC	cis	rs7412746	0.658	rs2230061	chr1:150727539	G/A	cg22823121	chr1:150693482	HORMAD1	0.45	6.26	0.36	1.52e-9	Melanoma;
CESC	cis	rs2294693	0.945	rs2073015	chr6:41008747	A/G	cg14418226	chr6:40996092	UNC5CL	0.51	5.89	0.34	1.18e-8	Gastric cancer;Non-cardia gastric cancer;
CESC	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg11905131	chr22:24372483	LOC391322	-0.71	-10.17	-0.53	9.93e-21	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs2075371	1.000	rs2544211	chr7:133973230	A/G	cg20476274	chr7:133979776	SLC35B4	0.66	9.47	0.5	1.6e-18	Mean platelet volume;
CESC	trans	rs637571	0.615	rs10160792	chr11:65667149	C/G	cg17712092	chr4:129076599	LARP1B	0.85	11.64	0.58	1.48e-25	Eosinophil percentage of white cells;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg25810379	chr11:64578055	MEN1	-0.44	-6.31	-0.36	1.16e-9	Gambling;
CESC	cis	rs4927850	0.709	rs6783079	chr3:195652708	T/C	cg01181863	chr3:195395398	SDHAP2	-0.69	-7.75	-0.43	1.94e-13	Pancreatic cancer;
CESC	cis	rs875971	0.756	rs2901210	chr7:66017505	G/A	cg11764359	chr7:65958608	NA	-0.78	-11.2	-0.57	4.25e-24	Aortic root size;
CESC	cis	rs7044106	0.791	rs4836831	chr9:123496570	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.75	10.99	0.56	2.18e-23	Hip circumference adjusted for BMI;
CESC	cis	rs6570726	0.967	rs9497316	chr6:145792387	G/T	cg23711669	chr6:146136114	FBXO30	-0.69	-10.03	-0.52	2.86e-20	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11027325	chr2:239148674	HES6	0.56	6.08	0.35	4.19e-9	Gut microbiome composition (summer);
CESC	cis	rs736408	0.570	rs11130327	chr3:52793239	A/G	cg18099408	chr3:52552593	STAB1	-0.33	-5.41	-0.32	1.44e-7	Bipolar disorder;
CESC	trans	rs561341	0.882	rs28649357	chr17:30367190	A/G	cg20587970	chr11:113659929	NA	-1.02	-12.66	-0.61	4.61e-29	Hip circumference adjusted for BMI;
CESC	cis	rs947211	0.846	rs708726	chr1:205762139	G/T	cg17178900	chr1:205818956	PM20D1	-0.41	-5.66	-0.33	3.86e-8	Parkinson's disease;
CESC	cis	rs853679	0.517	rs9380057	chr6:28104634	G/T	cg18032046	chr6:28092343	ZSCAN16	-0.55	-6.39	-0.37	7.41e-10	Depression;
CESC	cis	rs12530845	0.943	rs3800762	chr7:135347601	T/A	cg23117316	chr7:135346802	PL-5283	-0.45	-5.54	-0.32	7.36e-8	Red blood cell traits;
CESC	cis	rs6570726	0.599	rs9403725	chr6:145897622	A/T	cg05347473	chr6:146136440	FBXO30	-0.61	-7.24	-0.41	4.91e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs258892	0.947	rs266446	chr5:72182030	T/G	cg21869765	chr5:72125136	TNPO1	0.45	5.6	0.33	5.35e-8	Small cell lung carcinoma;
CESC	cis	rs67311347	1.000	rs1466236	chr3:40462162	C/T	cg01475735	chr3:40494733	NA	-0.4	-5.11	-0.3	6.1e-7	Renal cell carcinoma;
CESC	cis	rs2991971	1.000	rs518365	chr1:46010652	A/G	cg15605315	chr1:45957053	TESK2	0.43	5.48	0.32	9.9e-8	High light scatter reticulocyte count;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg20139898	chr1:26437522	PDIK1L	-0.43	-6.15	-0.35	2.82e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs6933660	0.800	rs2046371	chr6:151754744	G/A	cg02564969	chr6:151773285	C6orf211;RMND1	0.6	8.04	0.44	3.09e-14	Menarche (age at onset);
CESC	cis	rs7432375	0.610	rs6793936	chr3:136509793	A/C	cg15507776	chr3:136538369	TMEM22	0.6	7.86	0.43	9.73e-14	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
CESC	cis	rs11122272	0.735	rs2437150	chr1:231488524	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.53	7.51	0.42	9.13e-13	Hemoglobin concentration;
CESC	cis	rs17253792	0.822	rs8013831	chr14:56172898	G/A	cg01858014	chr14:56050164	KTN1	-0.62	-5.67	-0.33	3.78e-8	Putamen volume;
CESC	cis	rs1879734	0.731	rs12086451	chr1:54157640	C/T	cg23596471	chr1:54105337	GLIS1	0.34	5.41	0.32	1.42e-7	Mitral valve prolapse;
CESC	cis	rs9840812	0.535	rs695983	chr3:136064547	C/T	cg15507776	chr3:136538369	TMEM22	0.47	5.9	0.34	1.11e-8	Fibrinogen levels;
CESC	cis	rs597539	0.652	rs11603827	chr11:68719221	C/T	cg18350739	chr11:68623251	NA	-0.47	-6.86	-0.39	4.93e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs1008375	0.932	rs4698628	chr4:17608620	A/G	cg16339924	chr4:17578868	LAP3	0.64	8.22	0.45	9.39e-15	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs7662987	0.517	rs2602882	chr4:100040765	C/T	cg12011299	chr4:100065546	ADH4	0.6	6.57	0.37	2.59e-10	Smoking initiation;
CESC	cis	rs7607369	0.648	rs7559629	chr2:219657013	A/T	cg02176678	chr2:219576539	TTLL4	-0.48	-8.21	-0.45	9.44e-15	Red blood cell count;Amyotrophic lateral sclerosis;
CESC	cis	rs6963495	0.818	rs711430	chr7:105167969	A/G	cg02135003	chr7:105160482	PUS7	-0.43	-5.98	-0.34	7.27e-9	Bipolar disorder (body mass index interaction);
CESC	cis	rs7100689	0.577	rs2185427	chr10:82056667	G/T	cg00277334	chr10:82204260	NA	0.53	7.0	0.4	2.05e-11	Post bronchodilator FEV1;
CESC	cis	rs9914988	0.887	rs28873200	chr17:27149512	A/G	cg20469991	chr17:27169893	C17orf63	-0.48	-5.25	-0.31	3.18e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CESC	cis	rs6500602	0.702	rs2058812	chr16:4524443	C/G	cg08645402	chr16:4508243	NA	0.53	8.44	0.46	2.06e-15	Schizophrenia;
CESC	cis	rs2404602	0.647	rs11072620	chr15:77048770	T/A	cg23625390	chr15:77176239	SCAPER	-0.47	-6.54	-0.37	3.2e-10	Blood metabolite levels;
CESC	cis	rs4803468	1.000	rs55986560	chr19:41939835	C/T	cg09537434	chr19:41945824	ATP5SL	1.06	19.91	0.77	1.51e-54	Height;
CESC	cis	rs950776	0.720	rs11633223	chr15:78935476	T/C	cg06917634	chr15:78832804	PSMA4	0.56	6.66	0.38	1.53e-10	Sudden cardiac arrest;
CESC	cis	rs1218582	0.804	rs869506	chr1:154859581	A/C	cg16680214	chr1:154839983	KCNN3	-0.45	-6.94	-0.39	2.95e-11	Prostate cancer;
CESC	cis	rs9902453	0.904	rs12939344	chr17:28328819	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.73	-9.44	-0.5	1.96e-18	Coffee consumption (cups per day);
CESC	cis	rs1552244	0.572	rs59074548	chr3:10164347	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.68	-7.55	-0.42	6.87e-13	Alzheimer's disease;
CESC	cis	rs7582720	0.887	rs72934591	chr2:204019762	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	7.04	0.4	1.7e-11	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	trans	rs116095464	0.510	rs7723883	chr5:270798	T/C	cg00938859	chr5:1591904	SDHAP3	0.64	6.95	0.39	2.77e-11	Breast cancer;
CESC	cis	rs514406	0.505	rs269286	chr1:53169018	C/T	cg24675658	chr1:53192096	ZYG11B	0.57	7.64	0.42	4.08e-13	Monocyte count;
CESC	trans	rs698833	0.669	rs1584885	chr2:44647038	A/C	cg18595293	chr21:44527201	U2AF1	-0.44	-6.01	-0.35	6.03e-9	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs10744422	1.000	rs4993320	chr12:123338092	T/C	cg25930673	chr12:123319894	HIP1R	-0.76	-5.88	-0.34	1.26e-8	Schizophrenia;
CESC	cis	rs72781680	0.950	rs56128748	chr2:24126809	T/G	cg08917208	chr2:24149416	ATAD2B	0.88	7.96	0.44	5.07e-14	Lymphocyte counts;
CESC	cis	rs4237845	0.537	rs11172367	chr12:58272486	T/G	cg00677455	chr12:58241039	CTDSP2	0.78	10.4	0.54	1.76e-21	Intelligence (multi-trait analysis);
CESC	cis	rs7811142	1.000	rs11761784	chr7:100039970	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.12	12.99	0.62	3.48e-30	Platelet count;
CESC	cis	rs11625487	0.609	rs78371022	chr14:77971029	G/A	cg20045696	chr14:77926864	AHSA1	-0.71	-5.29	-0.31	2.52e-7	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
CESC	cis	rs17253792	0.822	rs74609892	chr14:56053002	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.84	5.63	0.33	4.57e-8	Putamen volume;
CESC	cis	rs734999	0.505	rs4278312	chr1:2539555	A/G	cg18854424	chr1:2615690	NA	0.29	5.87	0.34	1.29e-8	Ulcerative colitis;
CESC	trans	rs7615952	1.000	rs9289275	chr3:125648659	A/T	cg07211511	chr3:129823064	LOC729375	-1.11	-14.85	-0.67	1.03e-36	Blood pressure (smoking interaction);
CESC	cis	rs6084875	1.000	rs6084875	chr20:4742705	A/G	cg05143360	chr20:4741328	NA	-0.41	-5.41	-0.32	1.42e-7	Systemic lupus erythematosus;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg08377800	chr16:31885014	ZNF267	-0.54	-7.4	-0.41	1.8e-12	Asthma;
CESC	cis	rs12597458	0.789	rs7186207	chr16:72035359	C/T	cg16558253	chr16:72132732	DHX38	-0.4	-5.81	-0.34	1.81e-8	Prostate cancer;
CESC	cis	rs7246657	0.943	rs10417844	chr19:37837587	C/T	cg23950597	chr19:37808831	NA	-0.55	-6.09	-0.35	3.96e-9	Coronary artery calcification;
CESC	cis	rs7662987	0.517	rs1453873	chr4:100022571	T/C	cg12011299	chr4:100065546	ADH4	0.6	6.6	0.38	2.23e-10	Smoking initiation;
CESC	cis	rs1005277	0.579	rs2474575	chr10:38387901	C/T	cg25427524	chr10:38739819	LOC399744	-0.66	-9.5	-0.5	1.29e-18	Extrinsic epigenetic age acceleration;
CESC	cis	rs9300255	0.539	rs1969355	chr12:123742061	G/A	cg05973401	chr12:123451056	ABCB9	0.44	5.32	0.31	2.23e-7	Neutrophil percentage of white cells;
CESC	cis	rs12579753	0.692	rs9943807	chr12:82279404	T/A	cg21193143	chr12:82153300	PPFIA2	-0.36	-5.44	-0.32	1.18e-7	Resting heart rate;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg20940661	chr2:18060086	KCNS3	-0.4	-6.47	-0.37	4.76e-10	Gambling;
CESC	cis	rs7904368	0.806	rs1130684	chr10:16859335	C/G	cg14835575	chr10:16859367	RSU1	0.65	7.46	0.42	1.21e-12	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
CESC	cis	rs6540559	0.673	rs2357230	chr1:210019498	G/A	cg22029157	chr1:209979665	IRF6	0.7	7.88	0.44	8.64e-14	Cleft lip with or without cleft palate;
CESC	cis	rs9361491	0.510	rs1507151	chr6:79483246	T/C	cg05283184	chr6:79620031	NA	-0.36	-5.03	-0.3	9e-7	Intelligence (multi-trait analysis);
CESC	cis	rs55728055	0.661	rs7285893	chr22:32010042	A/G	cg01338084	chr22:32026380	PISD	1.06	7.47	0.42	1.16e-12	Age-related hearing impairment;
CESC	cis	rs6460942	0.597	rs35317839	chr7:12524397	C/A	cg02935154	chr7:12443704	VWDE	-0.55	-5.53	-0.32	7.71e-8	Coronary artery disease;
CESC	cis	rs11785400	0.793	rs11785376	chr8:143730412	C/T	cg10596483	chr8:143751796	JRK	0.42	5.33	0.31	2.06e-7	Schizophrenia;
CESC	cis	rs10789491	1.000	rs4553120	chr1:47165729	C/T	cg15501359	chr1:47185051	KIAA0494	0.79	8.81	0.48	1.66e-16	Response to hepatitis C treatment;
CESC	cis	rs4808199	0.895	rs10403731	chr19:19469296	G/A	cg03709012	chr19:19516395	GATAD2A	1.08	12.14	0.6	2.97e-27	Nonalcoholic fatty liver disease;
CESC	cis	rs6701037	0.681	rs1894709	chr1:175132371	G/T	cg00321850	chr1:175162397	KIAA0040	-0.41	-5.87	-0.34	1.29e-8	Alcohol dependence;
CESC	cis	rs12701220	0.689	rs6973645	chr7:1112246	C/T	cg26769984	chr7:1090371	C7orf50	0.56	5.68	0.33	3.52e-8	Bronchopulmonary dysplasia;
CESC	cis	rs7927771	0.832	rs11601603	chr11:47401171	A/C	cg05585544	chr11:47624801	NA	-0.48	-7.04	-0.4	1.67e-11	Subjective well-being;
CESC	cis	rs4803468	1.000	rs2241709	chr19:41912250	C/T	cg09537434	chr19:41945824	ATP5SL	-1.03	-18.3	-0.75	6.27e-49	Height;
CESC	cis	rs72781680	0.752	rs55801864	chr2:23922325	C/T	cg20701182	chr2:24300061	SF3B14	0.78	6.78	0.38	7.89e-11	Lymphocyte counts;
CESC	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg22907277	chr7:1156413	C7orf50	0.46	6.56	0.37	2.79e-10	Longevity;Endometriosis;
CESC	cis	rs8114671	0.562	rs4911164	chr20:33479488	G/C	cg07148914	chr20:33460835	GGT7	0.53	7.02	0.4	1.91e-11	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09704553	chr12:27167052	TM7SF3	0.59	6.71	0.38	1.18e-10	Gut microbiome composition (summer);
CESC	cis	rs4555082	0.830	rs3803319	chr14:105752458	G/A	cg06808227	chr14:105710500	BRF1	-0.55	-6.15	-0.35	2.82e-9	Mean platelet volume;Platelet distribution width;
CESC	cis	rs9811920	0.609	rs7638900	chr3:99670773	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.57	-6.98	-0.39	2.42e-11	Axial length;
CESC	cis	rs2380220	0.808	rs2263180	chr6:95902309	G/A	cg15832292	chr6:96025679	MANEA	-0.65	-5.95	-0.34	8.46e-9	Behavioural disinhibition (generation interaction);
CESC	cis	rs796364	0.806	rs6743396	chr2:200860138	T/C	cg23649088	chr2:200775458	C2orf69	0.6	5.37	0.31	1.74e-7	Schizophrenia;
CESC	cis	rs796364	0.951	rs1105964	chr2:201000776	T/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.69	-6.83	-0.39	5.64e-11	Schizophrenia;
CESC	cis	rs10743315	0.557	rs80051304	chr12:19286086	G/A	cg02471346	chr12:19282374	PLEKHA5	0.71	5.34	0.31	1.96e-7	Gut microbiota (bacterial taxa);
CESC	cis	rs12155623	0.803	rs6987879	chr8:49808062	T/C	cg22283653	chr8:49824208	NA	-0.38	-5.35	-0.31	1.9e-7	Sudden cardiac arrest;
CESC	cis	rs12541635	0.739	rs10955412	chr8:107075592	T/C	cg10147462	chr8:107024639	NA	-0.37	-5.2	-0.3	4.05e-7	Age of smoking initiation;
CESC	trans	rs11148252	0.532	rs9526975	chr13:53255804	C/T	cg18335740	chr13:41363409	SLC25A15	0.52	6.85	0.39	5.13e-11	Lewy body disease;
CESC	cis	rs7143963	0.666	rs66970053	chr14:103307655	G/C	cg24154132	chr14:103367632	TRAF3	0.36	6.59	0.38	2.34e-10	Body mass index;
CESC	cis	rs853679	0.546	rs34295134	chr6:27828151	T/A	cg02228804	chr6:27775720	HIST1H2AI;HIST1H2BL	0.61	5.2	0.3	4.03e-7	Depression;
CESC	cis	rs1448094	0.512	rs6539927	chr12:86244486	T/C	cg19622623	chr12:86230825	RASSF9	-0.47	-5.96	-0.34	7.92e-9	Major depressive disorder;
CESC	cis	rs56114371	0.777	rs200483	chr6:27774824	C/T	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.82	7.59	0.42	5.46e-13	Breast cancer;
CESC	cis	rs9660180	1.000	rs9660180	chr1:1723031	G/A	cg20999797	chr1:1681921	NA	0.27	5.2	0.3	4.06e-7	Body mass index;
CESC	cis	rs6089584	1.000	rs3787425	chr20:60559256	C/T	cg13770153	chr20:60521292	NA	-0.45	-5.9	-0.34	1.12e-8	Body mass index;
CESC	cis	rs9911578	1.000	rs172565	chr17:56808996	A/T	cg05425664	chr17:57184151	TRIM37	-0.51	-7.16	-0.4	7.78e-12	Intelligence (multi-trait analysis);
CESC	cis	rs10129255	0.957	rs12590735	chr14:107187899	A/G	cg23076370	chr14:107095027	NA	-0.44	-5.4	-0.31	1.48e-7	Kawasaki disease;
CESC	cis	rs12477438	0.700	rs10190421	chr2:99670711	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.75	-10.87	-0.56	5.17e-23	Chronic sinus infection;
CESC	cis	rs6964587	0.967	rs34040612	chr7:91798916	G/T	cg17063962	chr7:91808500	NA	0.55	7.46	0.42	1.25e-12	Breast cancer;
CESC	cis	rs9660180	0.967	rs10907191	chr1:1774820	A/T	cg17747265	chr1:1875780	NA	-0.57	-9.25	-0.49	7.79e-18	Body mass index;
CESC	cis	rs7666738	0.830	rs4699601	chr4:99034429	G/A	cg03676636	chr4:99064102	C4orf37	0.34	5.14	0.3	5.47e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs34779708	0.966	rs17499247	chr10:35426755	A/G	cg04310649	chr10:35416472	CREM	-0.52	-6.45	-0.37	5.15e-10	Inflammatory bowel disease;Crohn's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25922032	chr5:112043407	APC	0.54	6.19	0.36	2.32e-9	Gut microbiome composition (summer);
CESC	cis	rs561341	0.505	rs548298	chr17:30297494	C/A	cg19193384	chr17:30244184	NA	-0.61	-6.41	-0.37	6.51e-10	Hip circumference adjusted for BMI;
CESC	cis	rs950169	0.922	rs12910334	chr15:84958318	G/A	cg17507749	chr15:85114479	UBE2QP1	0.6	6.59	0.38	2.42e-10	Schizophrenia;
CESC	cis	rs10788972	0.844	rs6588502	chr1:54563156	A/G	cg25741118	chr1:54482237	LDLRAD1	-0.24	-5.67	-0.33	3.72e-8	Parkinson disease and lewy body pathology;
CESC	cis	rs2991971	1.000	rs667626	chr1:46020551	T/C	cg24296786	chr1:45957014	TESK2	0.63	8.16	0.45	1.37e-14	High light scatter reticulocyte count;
CESC	cis	rs763014	0.898	rs4984897	chr16:632180	G/C	cg07343612	chr16:622815	PIGQ	-0.57	-8.23	-0.45	8.47e-15	Height;
CESC	cis	rs3733585	0.699	rs6815001	chr4:9958662	G/C	cg00071950	chr4:10020882	SLC2A9	-0.73	-11.79	-0.59	4.58e-26	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs9596863	1.000	rs9568946	chr13:54430220	T/C	ch.13.53330881F	chr13:54432880	NA	0.66	5.25	0.31	3.08e-7	Epilepsy and lamotrigine-induced maculopapular eruptions;
CESC	cis	rs9916302	0.707	rs11078903	chr17:37631924	G/A	cg07936489	chr17:37558343	FBXL20	-0.8	-11.68	-0.58	1.06e-25	Glomerular filtration rate (creatinine);
CESC	cis	rs79349575	0.783	rs9747646	chr17:47016882	C/T	cg16584676	chr17:46985605	UBE2Z	0.54	6.67	0.38	1.46e-10	Type 2 diabetes;
CESC	cis	rs2839186	0.770	rs2330353	chr21:47669648	T/A	cg11766577	chr21:47581405	C21orf56	-0.47	-6.32	-0.36	1.13e-9	Testicular germ cell tumor;
CESC	cis	rs6460942	0.915	rs2216051	chr7:12304054	G/A	cg06484146	chr7:12443880	VWDE	-0.4	-5.63	-0.33	4.48e-8	Coronary artery disease;
CESC	cis	rs881375	0.678	rs10760130	chr9:123701990	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.45	6.36	0.36	8.95e-10	Rheumatoid arthritis;
CESC	cis	rs6570726	0.905	rs396492	chr6:145816180	C/G	cg05347473	chr6:146136440	FBXO30	0.49	6.66	0.38	1.53e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs193541	0.632	rs6878609	chr5:122095549	C/G	cg19412675	chr5:122181750	SNX24	0.44	5.06	0.3	7.91e-7	Glucose homeostasis traits;
CESC	cis	rs1552244	1.000	rs12152512	chr3:10143770	C/T	cg00166722	chr3:10149974	C3orf24	0.44	5.7	0.33	3.27e-8	Alzheimer's disease;
CESC	cis	rs9322193	0.923	rs9372044	chr6:150102003	G/A	cg13206674	chr6:150067644	NUP43	0.41	5.78	0.33	2.05e-8	Lung cancer;
CESC	cis	rs4665809	0.590	rs4665319	chr2:26424583	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.94	-11.51	-0.58	4.07e-25	Gut microbiome composition (summer);
CESC	trans	rs1977584	0.725	rs61853973	chr10:45388595	T/C	cg09262100	chr14:103416268	CDC42BPB	0.62	6.21	0.36	2.02e-9	Selective IgA deficiency;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg02920897	chr13:50699344	DLEU2	0.47	6.19	0.36	2.25e-9	Thyroid stimulating hormone;
CESC	cis	rs2749592	0.918	rs1208653	chr10:38253826	C/G	cg00409905	chr10:38381863	ZNF37A	0.43	5.46	0.32	1.11e-7	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs7605827	0.930	rs3796002	chr2:15567649	T/C	cg19274914	chr2:15703543	NA	0.36	6.6	0.38	2.24e-10	Educational attainment (years of education);
CESC	cis	rs7927771	0.524	rs10742817	chr11:47689343	A/G	cg18512352	chr11:47633146	NA	-0.34	-5.3	-0.31	2.4e-7	Subjective well-being;
CESC	cis	rs35110281	0.776	rs62226866	chr21:45024186	T/C	cg04455712	chr21:45112962	RRP1B	0.37	5.36	0.31	1.82e-7	Mean corpuscular volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09872009	chr21:10990119	TPTE	-0.52	-6.43	-0.37	6e-10	Gut microbiome composition (summer);
CESC	cis	rs546131	0.928	rs547504	chr11:34847225	G/T	cg11058730	chr11:34937778	PDHX;APIP	0.44	5.5	0.32	8.87e-8	Lung disease severity in cystic fibrosis;
CESC	cis	rs208520	0.690	rs12202401	chr6:66760544	A/G	cg07460842	chr6:66804631	NA	0.96	12.67	0.61	4.52e-29	Exhaled nitric oxide output;
CESC	cis	rs2974760	0.606	rs2858918	chr16:201183	T/C	cg08400316	chr16:204221	HBZ	0.61	10.14	0.53	1.26e-20	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	cis	rs9549260	0.753	rs10507486	chr13:41186501	A/G	cg21288729	chr13:41239152	FOXO1	-0.51	-5.32	-0.31	2.26e-7	Red blood cell count;
CESC	cis	rs7777484	0.534	rs2533888	chr7:2831083	T/C	cg18446336	chr7:2847575	GNA12	-0.41	-6.84	-0.39	5.44e-11	Height;
CESC	cis	rs7927592	0.913	rs7106010	chr11:68365212	C/T	cg20283391	chr11:68216788	NA	-0.62	-7.48	-0.42	1.09e-12	Total body bone mineral density;
CESC	cis	rs4076764	0.958	rs11590567	chr1:163396438	A/G	cg06092702	chr1:163392909	NA	-0.42	-6.06	-0.35	4.74e-9	Motion sickness;
CESC	cis	rs4819052	0.851	rs10470246	chr21:46659017	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.74	9.89	0.52	7.86e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs7208859	0.623	rs77544470	chr17:28934550	C/A	cg13385521	chr17:29058706	SUZ12P	0.78	5.67	0.33	3.78e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs4594175	0.926	rs113095693	chr14:51600511	G/C	cg23942311	chr14:51606299	NA	0.4	5.94	0.34	9.07e-9	Cancer;
CESC	cis	rs919433	1.000	rs6761919	chr2:198163328	A/G	cg03934865	chr2:198174659	NA	-0.46	-6.99	-0.39	2.23e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs7666738	0.519	rs13136069	chr4:98819568	C/T	cg05340658	chr4:99064831	C4orf37	0.54	6.4	0.37	6.9e-10	Colonoscopy-negative controls vs population controls;
CESC	trans	rs1814175	0.869	rs10769600	chr11:49681832	C/T	cg03929089	chr4:120376271	NA	-0.87	-13.36	-0.63	1.83e-31	Height;
CESC	cis	rs7084402	0.967	rs1649018	chr10:60288150	T/G	cg07615347	chr10:60278583	BICC1	0.6	9.41	0.5	2.54e-18	Refractive error;
CESC	cis	rs1348850	0.567	rs7605493	chr2:178534983	C/G	cg22681709	chr2:178499509	PDE11A	-0.49	-7.27	-0.41	4.12e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg14835113	chr13:111303423	CARS2	0.62	8.71	0.47	3.41e-16	Fibrinogen levels;
CESC	cis	rs1552244	0.882	rs13063098	chr3:10009919	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.75	-9.46	-0.5	1.7e-18	Alzheimer's disease;
CESC	cis	rs9354308	0.903	rs1938064	chr6:66559172	T/C	cg07460842	chr6:66804631	NA	-0.51	-6.17	-0.35	2.6e-9	Metabolite levels;
CESC	cis	rs2455799	0.613	rs11712323	chr3:15891360	T/C	cg16303742	chr3:15540471	COLQ	-0.35	-5.28	-0.31	2.66e-7	Mean platelet volume;
CESC	cis	rs61931739	0.890	rs1705750	chr12:34142648	C/T	cg19457237	chr12:34500585	NA	-0.39	-5.34	-0.31	2e-7	Morning vs. evening chronotype;
CESC	cis	rs7726839	0.794	rs11739663	chr5:594083	A/G	cg16447950	chr5:562315	NA	-0.5	-5.96	-0.34	7.92e-9	Obesity-related traits;
CESC	cis	rs7809950	1.000	rs2237676	chr7:107198079	C/A	cg23024343	chr7:107201750	COG5	-0.42	-5.89	-0.34	1.14e-8	Coronary artery disease;
CESC	cis	rs7904368	0.659	rs3740169	chr10:16873547	C/T	cg23933602	chr10:16859644	RSU1	0.62	7.03	0.4	1.7e-11	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
CESC	cis	rs4665809	1.000	rs12471809	chr2:26307140	A/G	cg22920501	chr2:26401640	FAM59B	-0.67	-8.05	-0.44	2.82e-14	Gut microbiome composition (summer);
CESC	cis	rs7359276	1	rs7359276	chr15:78892661	C/T	cg24631222	chr15:78858424	CHRNA5	-0.82	-10.1	-0.53	1.7e-20	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs7666738	0.791	rs6851549	chr4:99029827	G/A	cg05340658	chr4:99064831	C4orf37	0.84	13.14	0.63	1.04e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7223966	0.921	rs6504186	chr17:61863932	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.74	0.38	9.84e-11	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs7618915	0.571	rs1961958	chr3:52585990	A/G	cg05564831	chr3:52568323	NT5DC2	0.45	6.72	0.38	1.13e-10	Bipolar disorder;
CESC	cis	rs2404602	0.647	rs11632765	chr15:76974261	A/T	cg23625390	chr15:77176239	SCAPER	0.46	6.44	0.37	5.6e-10	Blood metabolite levels;
CESC	cis	rs6502050	0.805	rs4789720	chr17:80157490	G/C	cg23985595	chr17:80112537	CCDC57	-0.39	-6.24	-0.36	1.76e-9	Life satisfaction;
CESC	cis	rs12586317	0.924	rs4981276	chr14:35696818	A/G	cg16230307	chr14:35515116	FAM177A1	0.76	7.94	0.44	5.78e-14	Psoriasis;
CESC	cis	rs10206020	0.885	rs6720923	chr2:1574197	T/C	cg26248373	chr2:1572462	NA	-0.59	-6.93	-0.39	3.22e-11	IgG glycosylation;
CESC	cis	rs155076	1.000	rs261423	chr13:21852331	A/C	cg11317459	chr13:21872234	NA	-1.05	-11.58	-0.58	2.37e-25	White matter hyperintensity burden;
CESC	cis	rs5769707	0.935	rs5770594	chr22:50018497	G/A	cg05373962	chr22:49881684	NA	-0.38	-6.73	-0.38	1.04e-10	Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs12476592	0.602	rs6546004	chr2:63639529	T/C	cg17519650	chr2:63277830	OTX1	-0.46	-5.08	-0.3	7.09e-7	Childhood ear infection;
CESC	cis	rs5769765	0.908	rs9616213	chr22:50317851	T/G	cg26441486	chr22:50317300	CRELD2	0.48	5.75	0.33	2.44e-8	Schizophrenia;
CESC	cis	rs7809950	0.678	rs6949634	chr7:106984684	G/T	cg23024343	chr7:107201750	COG5	-0.54	-6.99	-0.39	2.2e-11	Coronary artery disease;
CESC	cis	rs1552244	1.000	rs67569278	chr3:10149893	T/C	cg00149659	chr3:10157352	C3orf10	0.69	7.84	0.43	1.13e-13	Alzheimer's disease;
CESC	cis	rs17854409	0.803	rs3210314	chr20:61472117	C/A	cg07645718	chr20:61493192	TCFL5	0.79	5.2	0.3	3.98e-7	Obesity-related traits;
CESC	cis	rs8092503	1.000	rs2311117	chr18:52473793	A/G	cg12377874	chr18:52495404	RAB27B	0.37	5.92	0.34	9.78e-9	Childhood body mass index;
CESC	cis	rs9291683	0.588	rs3796829	chr4:10019138	C/G	cg00071950	chr4:10020882	SLC2A9	0.91	17.5	0.73	4.14e-46	Bone mineral density;
CESC	cis	rs9611519	0.590	rs4821980	chr22:41415479	C/G	cg03806693	chr22:41940476	POLR3H	-0.51	-6.05	-0.35	4.93e-9	Neuroticism;
CESC	cis	rs7618501	0.521	rs55692411	chr3:49911155	G/A	cg24308560	chr3:49941425	MST1R	-0.65	-9.26	-0.49	7.13e-18	Intelligence (multi-trait analysis);
CESC	cis	rs8180040	0.903	rs12487736	chr3:47459679	C/T	cg27129171	chr3:47204927	SETD2	0.6	8.91	0.48	8.2e-17	Colorectal cancer;
CESC	cis	rs2797160	1.000	rs1630556	chr6:126013155	A/G	cg05901451	chr6:126070800	HEY2	0.46	6.56	0.37	2.81e-10	Endometrial cancer;
CESC	cis	rs10883723	0.810	rs10883729	chr10:104273943	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.54	7.41	0.41	1.65e-12	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs2797160	0.547	rs9401837	chr6:125956853	T/C	cg05901451	chr6:126070800	HEY2	-0.39	-5.4	-0.32	1.45e-7	Endometrial cancer;
CESC	cis	rs7607369	0.648	rs7559490	chr2:219656867	A/T	cg02176678	chr2:219576539	TTLL4	-0.48	-8.21	-0.45	9.44e-15	Red blood cell count;Amyotrophic lateral sclerosis;
CESC	cis	rs1562975	0.609	rs62316329	chr4:109419399	A/G	cg16022748	chr4:109541635	LOC285456;RPL34	0.42	5.39	0.31	1.54e-7	Height;
CESC	cis	rs6121246	0.909	rs1075698	chr20:30387992	G/C	cg13852791	chr20:30311386	BCL2L1	0.8	8.55	0.46	1.01e-15	Mean corpuscular hemoglobin;
CESC	cis	rs7116495	1.000	rs3750908	chr11:71822401	A/G	cg26138937	chr11:71823887	C11orf51	0.85	6.86	0.39	4.92e-11	Severe influenza A (H1N1) infection;
CESC	cis	rs1475911	1.000	rs55645900	chr21:43515728	G/T	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.39	-5.75	-0.33	2.48e-8	IgG glycosylation;
CESC	cis	rs6860806	0.507	rs270606	chr5:131650867	A/G	cg18758796	chr5:131593413	PDLIM4	0.43	5.91	0.34	1.03e-8	Breast cancer;
CESC	trans	rs7746199	0.736	rs6904596	chr6:27491299	G/A	cg06606381	chr12:133084897	FBRSL1	-0.98	-8.34	-0.46	4.16e-15	Gait speed in old age;Autism spectrum disorder or schizophrenia;
CESC	cis	rs959260	1.000	rs9892325	chr17:73394449	A/C	cg12999837	chr17:73267436	MIF4GD	-0.53	-5.99	-0.35	6.65e-9	Systemic lupus erythematosus;
CESC	cis	rs7618501	0.602	rs2526754	chr3:50125996	G/A	cg24110177	chr3:50126178	RBM5	0.52	7.23	0.41	5.09e-12	Intelligence (multi-trait analysis);
CESC	cis	rs950776	0.518	rs12916999	chr15:78826912	C/T	cg06917634	chr15:78832804	PSMA4	0.8	12.12	0.6	3.34e-27	Sudden cardiac arrest;
CESC	cis	rs9443189	0.813	rs2748948	chr6:76437994	T/A	cg01950844	chr6:76311363	SENP6	-0.65	-7.14	-0.4	8.95e-12	Prostate cancer;
CESC	trans	rs4335177	0.762	rs2054980	chr9:109385024	T/C	cg16874583	chr12:7781004	NA	-0.46	-6.07	-0.35	4.37e-9	Response to paliperidone in schizophrenia (positive Marder score);
CESC	cis	rs2841277	0.708	rs11623422	chr14:105407031	A/G	cg21017887	chr14:105400489	NA	0.41	6.65	0.38	1.65e-10	Rheumatoid arthritis;
CESC	cis	rs9911578	0.900	rs8067264	chr17:57182793	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.07	0.3	7.47e-7	Intelligence (multi-trait analysis);
CESC	cis	rs35306767	0.953	rs12357633	chr10:957246	C/T	cg25019033	chr10:957182	NA	-0.6	-6.42	-0.37	6.2e-10	Eosinophil percentage of granulocytes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00122254	chr1:46769320	LRRC41;UQCRH	-0.59	-6.78	-0.38	7.61e-11	Gut microbiome composition (summer);
CESC	cis	rs4689388	0.890	rs6446481	chr4:6295583	C/A	cg14416269	chr4:6271139	WFS1	0.45	7.57	0.42	6.15e-13	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	trans	rs2321882	0.958	rs6561987	chr13:59394319	C/T	cg20914879	chr14:56566808	NA	-0.43	-6.17	-0.35	2.51e-9	Body mass index;
CESC	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg11494091	chr17:61959527	GH2	0.72	12.38	0.61	4.46e-28	Prudent dietary pattern;
CESC	cis	rs2074585	0.647	rs2601188	chr15:90929563	A/G	cg22089800	chr15:90895588	ZNF774	-0.67	-9.49	-0.5	1.36e-18	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg04640194	chr12:56754023	STAT2	-0.48	-6.38	-0.36	7.81e-10	Height;
CESC	cis	rs11264213	0.901	rs72661643	chr1:36451599	A/G	cg27506609	chr1:36549197	TEKT2	0.67	5.56	0.32	6.59e-8	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01812826	chr8:123793836	ZHX2	0.58	6.77	0.38	8.09e-11	Gut microbiome composition (summer);
CESC	cis	rs2637266	0.643	rs7914732	chr10:78476336	A/G	cg18941641	chr10:78392320	NA	0.39	7.28	0.41	3.82e-12	Pulmonary function;
CESC	cis	rs17539620	0.624	rs4566892	chr6:154837346	C/T	cg20019720	chr6:154832845	CNKSR3	0.47	6.13	0.35	3.21e-9	Lipoprotein (a) levels;
CESC	cis	rs796364	0.539	rs6738494	chr2:200697058	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.56	5.42	0.32	1.34e-7	Schizophrenia;
CESC	cis	rs6582630	0.555	rs10785443	chr12:38463792	A/C	cg13010199	chr12:38710504	ALG10B	0.43	5.69	0.33	3.35e-8	Drug-induced liver injury (flucloxacillin);
CESC	trans	rs875971	0.619	rs10278371	chr7:66051540	C/A	cg26939375	chr7:64535504	NA	-0.67	-8.95	-0.48	6.39e-17	Aortic root size;
CESC	cis	rs1670533	1.000	rs6858612	chr4:1053353	C/T	cg27284194	chr4:1044797	NA	0.45	5.8	0.34	1.85e-8	Recombination rate (females);
CESC	cis	rs9399135	0.967	rs4376365	chr6:135307740	T/C	cg22676075	chr6:135203613	NA	0.52	7.22	0.41	5.65e-12	Red blood cell count;
CESC	cis	rs4523957	0.928	rs12949991	chr17:2197185	G/A	cg16513277	chr17:2031491	SMG6	0.6	8.3	0.45	5.29e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs7772486	0.875	rs2814869	chr6:146315509	G/A	cg05347473	chr6:146136440	FBXO30	0.52	6.91	0.39	3.63e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9910055	0.821	rs4473241	chr17:42281282	G/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.56	6.9	0.39	3.86e-11	Total body bone mineral density;
CESC	cis	rs7116495	1.000	rs517837	chr11:71802359	A/G	cg10381502	chr11:71823885	C11orf51	-0.66	-5.4	-0.31	1.51e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs4566357	0.964	rs6436648	chr2:227923004	C/A	cg11843606	chr2:227700838	RHBDD1	-0.42	-5.28	-0.31	2.76e-7	Coronary artery disease;
CESC	trans	rs208520	1.000	rs12193164	chr6:66978962	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.84	9.33	0.5	4.5e-18	Exhaled nitric oxide output;
CESC	cis	rs7666738	0.724	rs28451676	chr4:98966990	C/T	cg03467027	chr4:99064603	C4orf37	0.43	5.47	0.32	1.03e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6831352	0.819	rs1230155	chr4:99989259	C/T	cg12011299	chr4:100065546	ADH4	0.58	7.25	0.41	4.7e-12	Alcohol dependence;
CESC	cis	rs2072499	0.833	rs2251636	chr1:156202809	G/C	cg24450063	chr1:156163899	SLC25A44	0.9	15.07	0.68	1.72e-37	Testicular germ cell tumor;
CESC	cis	rs9300255	0.544	rs1790130	chr12:123701270	A/C	cg19016782	chr12:123741754	C12orf65	-0.45	-6.5	-0.37	3.89e-10	Neutrophil percentage of white cells;
CESC	cis	rs4253772	0.872	rs41362646	chr22:46633505	G/A	cg00784671	chr22:46762841	CELSR1	-0.57	-5.62	-0.33	4.78e-8	LDL cholesterol;Cholesterol, total;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg11642829	chr17:4607740	PELP1	-0.48	-6.34	-0.36	9.62e-10	Ulcerative colitis;
CESC	cis	rs748404	0.518	rs480108	chr15:43817406	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.5	7.65	0.43	3.68e-13	Lung cancer;
CESC	cis	rs3008870	1.000	rs1118393	chr1:67366668	A/G	cg02640540	chr1:67518911	SLC35D1	0.48	5.18	0.3	4.32e-7	Lymphocyte percentage of white cells;
CESC	cis	rs4950928	0.823	rs2494277	chr1:203168092	A/G	cg14085262	chr1:203155938	CHI3L1	-0.47	-5.12	-0.3	5.89e-7	YKL-40 levels;
CESC	cis	rs7539409	0.651	rs7521788	chr1:84309320	G/T	cg10977910	chr1:84465055	TTLL7	0.8	7.69	0.43	2.9e-13	Alzheimer's disease;
CESC	trans	rs2109514	0.505	rs1633714	chr7:116022538	C/T	cg06859321	chr19:41643199	NA	0.46	6.42	0.37	6.22e-10	Prevalent atrial fibrillation;
CESC	cis	rs6991838	0.557	rs7812390	chr8:66506217	A/G	cg13398993	chr8:66546079	ARMC1	-0.47	-5.59	-0.32	5.56e-8	Intelligence (multi-trait analysis);
CESC	cis	rs9486719	0.857	rs3798293	chr6:97033370	A/G	cg18709589	chr6:96969512	KIAA0776	-0.46	-5.11	-0.3	6.27e-7	Migraine;Coronary artery disease;
CESC	cis	rs8014204	0.901	rs2080087	chr14:75365062	C/T	cg26191576	chr14:75389716	RPS6KL1	-0.38	-5.43	-0.32	1.29e-7	Caffeine consumption;
CESC	cis	rs9916302	0.706	rs11657153	chr17:37699729	A/G	cg20243544	chr17:37824526	PNMT	0.53	5.26	0.31	3.03e-7	Glomerular filtration rate (creatinine);
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg11753193	chr8:94753277	RBM12B	-0.45	-6.23	-0.36	1.82e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs34779708	0.966	rs1057108	chr10:35484949	T/G	cg04310649	chr10:35416472	CREM	-0.52	-6.34	-0.36	9.86e-10	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs8141529	0.719	rs5762880	chr22:29287816	T/G	cg15103426	chr22:29168792	CCDC117	0.6	7.75	0.43	1.97e-13	Lymphocyte counts;
CESC	cis	rs7202877	0.656	rs977986	chr16:75506696	T/G	cg04384234	chr16:75411784	CFDP1	-0.47	-5.65	-0.33	4.24e-8	Type 2 diabetes;Type 1 diabetes;
CESC	cis	rs2276314	1.000	rs4799834	chr18:33566243	T/C	cg05985134	chr18:33552581	C18orf21	0.63	7.42	0.41	1.6e-12	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs727563	0.594	rs132807	chr22:42071584	T/C	cg06481639	chr22:41940642	POLR3H	0.57	5.74	0.33	2.58e-8	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg00080972	chr5:178986291	RUFY1	0.49	7.96	0.44	4.96e-14	Lung cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08926035	chr11:64521052	PYGM	-0.53	-6.37	-0.36	8.31e-10	Gut microbiome composition (summer);
CESC	cis	rs1552244	1.000	rs55822690	chr3:10128003	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.8	-10.83	-0.55	7.31e-23	Alzheimer's disease;
CESC	cis	rs7582720	1.000	rs72934735	chr2:203740010	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.32	0.41	3.04e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs16895831	0.549	rs3749900	chr6:42613379	A/G	cg10605015	chr6:42532144	UBR2	-0.5	-5.52	-0.32	8.27e-8	Granulocyte percentage of myeloid white cells;Neutrophil percentage of white cells;Eosinophil percentage of white cells;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Neutrophil count;Sum basophil neutrophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
CESC	cis	rs9303401	1.000	rs9303401	chr17:56847945	C/T	cg12560992	chr17:57184187	TRIM37	0.49	5.54	0.32	7.42e-8	Cognitive test performance;
CESC	cis	rs7615952	0.599	rs6779141	chr3:125709995	A/T	cg04553112	chr3:125709451	NA	-0.51	-5.58	-0.32	5.94e-8	Blood pressure (smoking interaction);
CESC	cis	rs4253772	0.550	rs6008598	chr22:46704243	C/T	cg09491104	chr22:46646882	C22orf40	-0.51	-6.15	-0.35	2.76e-9	LDL cholesterol;Cholesterol, total;
CESC	cis	rs8044868	0.548	rs12930702	chr16:72077000	C/G	cg16558253	chr16:72132732	DHX38	-0.39	-6.08	-0.35	4.12e-9	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CESC	cis	rs8067354	0.574	rs2250526	chr17:57951973	G/A	cg02344993	chr17:57696989	CLTC	0.53	5.64	0.33	4.43e-8	Hemoglobin concentration;
CESC	cis	rs2294693	0.947	rs9296351	chr6:40988102	T/C	cg14418226	chr6:40996092	UNC5CL	0.43	5.51	0.32	8.4e-8	Gastric cancer;Non-cardia gastric cancer;
CESC	cis	rs694739	0.964	rs2510066	chr11:64052447	C/T	cg23796481	chr11:64053134	BAD;GPR137	0.66	8.39	0.46	2.85e-15	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CESC	cis	rs6860806	0.507	rs274570	chr5:131713226	C/T	cg18758796	chr5:131593413	PDLIM4	-0.43	-5.84	-0.34	1.52e-8	Breast cancer;
CESC	trans	rs1814175	0.616	rs1851848	chr11:49992254	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.42	-6.16	-0.35	2.76e-9	Height;
CESC	cis	rs1448094	0.512	rs6539929	chr12:86244932	T/C	cg19622623	chr12:86230825	RASSF9	-0.46	-5.89	-0.34	1.14e-8	Major depressive disorder;
CESC	cis	rs16858210	0.826	rs35494670	chr3:183606357	T/G	cg25686905	chr3:183603175	PARL	-0.34	-6.23	-0.36	1.84e-9	Menopause (age at onset);
CESC	cis	rs854765	0.547	rs7223696	chr17:17915791	G/T	cg16928487	chr17:17741425	SREBF1	-0.57	-10.18	-0.53	8.98e-21	Total body bone mineral density;
CESC	cis	rs514406	0.547	rs377808	chr1:53190359	T/G	cg16325326	chr1:53192061	ZYG11B	0.98	16.92	0.72	4.94e-44	Monocyte count;
CESC	cis	rs801193	1.000	rs6958520	chr7:66151453	T/C	cg11764359	chr7:65958608	NA	0.69	9.06	0.49	2.98e-17	Aortic root size;
CESC	cis	rs11677370	0.561	rs12711973	chr2:3825339	C/G	cg17052675	chr2:3827356	NA	-0.42	-5.39	-0.31	1.54e-7	Type 2 diabetes;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg01856141	chr3:52804944	NEK4	-0.42	-6.5	-0.37	3.88e-10	Gambling;
CESC	trans	rs12713956	0.748	rs550619	chr2:21260601	G/A	cg13097573	chr17:47957986	NA	-0.79	-6.06	-0.35	4.59e-9	LDL cholesterol;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg26387956	chr15:41407860	INO80	-0.48	-6.15	-0.35	2.78e-9	Ulcerative colitis;
CESC	cis	rs7107174	0.892	rs2512540	chr11:77979299	A/G	cg02023728	chr11:77925099	USP35	0.48	6.63	0.38	1.82e-10	Testicular germ cell tumor;
CESC	cis	rs875971	0.522	rs4718286	chr7:65292764	A/G	cg11764359	chr7:65958608	NA	0.66	8.54	0.46	1.06e-15	Aortic root size;
CESC	cis	rs1005224	0.853	rs6574251	chr14:76136883	C/T	cg25116370	chr14:76127843	TTLL5;C14orf1	-0.44	-6.02	-0.35	5.77e-9	Large artery stroke;
CESC	cis	rs7089973	0.585	rs7907837	chr10:116610690	G/T	cg03647239	chr10:116582469	FAM160B1	0.48	6.17	0.35	2.52e-9	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg15383120	chr6:291909	DUSP22	-0.68	-8.75	-0.47	2.47e-16	Menopause (age at onset);
CESC	cis	rs8067354	0.574	rs1292042	chr17:57934995	A/G	cg13753209	chr17:57696993	CLTC	0.53	5.7	0.33	3.13e-8	Hemoglobin concentration;
CESC	cis	rs34375054	0.525	rs7133614	chr12:125605957	C/T	cg25124228	chr12:125621409	AACS	-0.53	-6.65	-0.38	1.66e-10	Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs4665809	0.590	rs7260	chr2:26413917	C/T	cg26314531	chr2:26401878	FAM59B	-0.77	-8.69	-0.47	3.87e-16	Gut microbiome composition (summer);
CESC	cis	rs6860806	0.507	rs270601	chr5:131656997	T/C	cg07395648	chr5:131743802	NA	-0.46	-6.0	-0.35	6.55e-9	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03987003	chr1:145516092	GNRHR2;PEX11B	0.56	6.16	0.35	2.74e-9	Gut microbiome composition (summer);
CESC	cis	rs9303401	0.703	rs9910629	chr17:57210301	C/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.59	7.75	0.43	2e-13	Cognitive test performance;
CESC	cis	rs7666738	0.830	rs4443293	chr4:99063120	G/A	cg03676636	chr4:99064102	C4orf37	0.33	5.04	0.3	8.47e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs798766	1.000	rs1665364	chr4:1727206	A/G	cg10756475	chr4:1757242	NA	-0.48	-6.45	-0.37	5.13e-10	Bladder cancer;Urinary bladder cancer;
CESC	cis	rs10743315	0.557	rs74669613	chr12:19313696	T/C	cg02471346	chr12:19282374	PLEKHA5	0.75	5.64	0.33	4.25e-8	Gut microbiota (bacterial taxa);
CESC	cis	rs1062177	0.855	rs6896664	chr5:151265274	A/G	cg00977110	chr5:151150581	G3BP1	0.51	5.85	0.34	1.45e-8	Preschool internalizing problems;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg04408576	chr16:1524927	CLCN7	-0.45	-6.08	-0.35	4.1e-9	Fibrinogen levels;
CESC	cis	rs11098499	0.954	rs3733524	chr4:120423729	T/C	cg09307838	chr4:120376055	NA	0.93	12.84	0.62	1.19e-29	Corneal astigmatism;
CESC	cis	rs116095464	1.000	rs62331562	chr5:349298	G/C	cg22857025	chr5:266934	NA	-0.83	-5.11	-0.3	6.24e-7	Breast cancer;
CESC	cis	rs11997175	0.624	rs4593494	chr8:33692621	C/T	ch.8.33884649F	chr8:33765107	NA	0.48	5.87	0.34	1.33e-8	Body mass index;
CESC	cis	rs2933343	0.729	rs6790091	chr3:128608751	G/C	cg24203234	chr3:128598194	ACAD9	0.43	5.79	0.34	1.97e-8	IgG glycosylation;
CESC	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.54	6.72	0.38	1.09e-10	Prudent dietary pattern;
CESC	cis	rs1499972	0.618	rs6795060	chr3:117642675	C/A	cg07612923	chr3:117604196	NA	0.72	6.61	0.38	2.1e-10	Schizophrenia;
CESC	cis	rs933688	1.000	rs6862125	chr5:90724598	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.0	13.06	0.63	2.05e-30	Smoking behavior;
CESC	cis	rs7762018	0.891	rs1981069	chr6:170148837	G/A	cg05834625	chr6:170176447	C6orf70	0.65	7.17	0.4	7.57e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs853679	0.517	rs9283884	chr6:28135660	C/G	cg12963246	chr6:28129442	ZNF389	-0.55	-7.3	-0.41	3.37e-12	Depression;
CESC	cis	rs28374715	0.532	rs11854632	chr15:41682094	A/G	cg20272979	chr15:41787780	ITPKA	-0.43	-5.4	-0.31	1.51e-7	Ulcerative colitis;
CESC	cis	rs9311474	0.581	rs4687626	chr3:52569098	G/A	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.38	6.8	0.39	7.06e-11	Electroencephalogram traits;
CESC	cis	rs1030268	0.607	rs34218501	chr7:133210375	G/A	cg10665199	chr7:133106180	EXOC4	0.48	5.47	0.32	1.02e-7	Intelligence (multi-trait analysis);
CESC	cis	rs6942756	1.000	rs6980385	chr7:128943615	G/A	cg02491457	chr7:128862824	NA	-0.69	-9.25	-0.49	7.51e-18	White matter hyperintensity burden;
CESC	cis	rs7618915	0.571	rs33964154	chr3:52596914	A/G	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	5.74	0.33	2.6e-8	Bipolar disorder;
CESC	trans	rs1814175	0.645	rs2140602	chr11:50022800	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.42	-6.13	-0.35	3.1e-9	Height;
CESC	cis	rs3780486	0.846	rs10813954	chr9:33137596	A/C	cg13443165	chr9:33130375	B4GALT1	0.46	6.78	0.38	7.98e-11	IgG glycosylation;
CESC	cis	rs3096299	0.838	rs3102384	chr16:89411661	T/G	cg08822215	chr16:89438651	ANKRD11	-0.43	-6.19	-0.36	2.29e-9	Multiple myeloma (IgH translocation);
CESC	cis	rs2842992	0.830	rs2273819	chr6:160183325	G/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.71	8.4	0.46	2.77e-15	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs514406	0.861	rs72637996	chr1:53249618	A/T	cg16325326	chr1:53192061	ZYG11B	-0.71	-11.85	-0.59	2.92e-26	Monocyte count;
CESC	cis	rs7666738	0.791	rs7658177	chr4:99035192	T/C	cg17366294	chr4:99064904	C4orf37	0.62	8.86	0.48	1.22e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9457247	0.967	rs376097	chr6:167410878	A/G	cg07741184	chr6:167504864	NA	0.3	5.52	0.32	8.06e-8	Crohn's disease;
CESC	cis	rs875971	0.508	rs6947808	chr7:66045082	A/G	cg19163074	chr7:65112434	INTS4L2	0.43	5.51	0.32	8.54e-8	Aortic root size;
CESC	cis	rs12357919	0.542	rs3740471	chr10:105363289	T/C	cg00126946	chr10:105363258	SH3PXD2A	0.6	8.53	0.46	1.14e-15	White matter hyperintensity burden;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg25187967	chr11:77024606	NA	-0.45	-6.02	-0.35	5.69e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs7666738	0.800	rs2865987	chr4:99067852	A/C	cg18180107	chr4:99064573	C4orf37	0.4	5.06	0.3	7.74e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9291683	0.595	rs35501905	chr4:10053431	C/T	cg11266682	chr4:10021025	SLC2A9	0.66	13.28	0.63	3.46e-31	Bone mineral density;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13154104	chr2:10443632	HPCAL1	-0.57	-6.99	-0.39	2.27e-11	Gut microbiome composition (summer);
CESC	cis	rs2073300	0.609	rs6137930	chr20:23376732	G/A	cg16736954	chr20:23401023	NAPB	0.8	6.25	0.36	1.67e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	trans	rs12599106	0.584	rs12929704	chr16:34898258	C/A	cg01171360	chr6:293285	DUSP22	-0.66	-8.58	-0.47	8.08e-16	Menopause (age at onset);
CESC	cis	rs561341	1.000	rs1681718	chr17:30296445	G/A	cg12193833	chr17:30244370	NA	-0.71	-6.53	-0.37	3.38e-10	Hip circumference adjusted for BMI;
CESC	trans	rs763361	1.000	rs1790947	chr18:67527760	A/C	cg04590956	chr2:70057467	GMCL1	0.45	6.01	0.35	6.05e-9	Type 1 diabetes;
CESC	cis	rs875971	0.862	rs2420173	chr7:65645399	A/T	cg12463550	chr7:65579703	CRCP	-0.49	-6.21	-0.36	2.06e-9	Aortic root size;
CESC	trans	rs1506636	0.886	rs6466878	chr7:123272278	T/C	cg12383159	chr11:1262597	MUC5B	0.36	6.12	0.35	3.31e-9	Plateletcrit;Platelet count;
CESC	cis	rs7264396	0.635	rs6058351	chr20:34486093	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.8	-11.03	-0.56	1.54e-23	Total cholesterol levels;
CESC	cis	rs2576037	0.901	rs2060416	chr18:44576240	G/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.43	5.66	0.33	3.9e-8	Personality dimensions;
CESC	cis	rs7618501	0.633	rs11130228	chr3:50003246	C/T	cg24110177	chr3:50126178	RBM5	-0.53	-7.35	-0.41	2.48e-12	Intelligence (multi-trait analysis);
CESC	cis	rs7777484	0.534	rs2533886	chr7:2834869	C/T	cg09658497	chr7:2847517	GNA12	-0.44	-6.82	-0.39	6.3e-11	Height;
CESC	cis	rs514406	0.525	rs269291	chr1:53189297	C/T	cg08736216	chr1:53307985	ZYG11A	-0.38	-5.93	-0.34	9.35e-9	Monocyte count;
CESC	cis	rs7552404	0.691	rs61770550	chr1:76366966	C/T	cg10523679	chr1:76189770	ACADM	0.63	6.08	0.35	4.14e-9	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs7998202	0.667	rs695163	chr13:113363300	G/A	cg02820901	chr13:113351484	ATP11A	0.65	5.61	0.33	5.2e-8	Glycated hemoglobin levels;
CESC	cis	rs17407555	0.606	rs3775945	chr4:10011996	A/T	cg00071950	chr4:10020882	SLC2A9	-0.56	-5.73	-0.33	2.69e-8	Schizophrenia (age at onset);
CESC	cis	rs1707322	0.752	rs28812624	chr1:46203736	T/A	cg06784218	chr1:46089804	CCDC17	0.41	7.21	0.41	5.75e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg16975985	chr12:49524048	TUBA1B	-0.47	-6.83	-0.39	5.79e-11	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs3741404	0.620	rs2236647	chr11:63964605	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.57	-8.03	-0.44	3.29e-14	Platelet count;
CESC	cis	rs798554	0.679	rs2533877	chr7:2882421	G/A	cg04166393	chr7:2884313	GNA12	0.62	8.46	0.46	1.85e-15	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14107975	chr11:96076498	MAML2	0.57	6.91	0.39	3.63e-11	Gut microbiome composition (summer);
CESC	cis	rs7927771	0.832	rs10769262	chr11:47411581	G/A	cg18512352	chr11:47633146	NA	0.54	8.0	0.44	3.78e-14	Subjective well-being;
CESC	cis	rs7520050	0.966	rs12564541	chr1:46380237	G/A	cg24296786	chr1:45957014	TESK2	0.44	5.52	0.32	8.12e-8	Red blood cell count;Reticulocyte count;
CESC	trans	rs9951602	0.512	rs1599635	chr18:76643819	G/A	cg02800362	chr5:177631904	HNRNPAB	0.62	8.1	0.45	1.96e-14	Obesity-related traits;
CESC	cis	rs17711722	1.000	rs17711722	chr7:65271197	C/T	cg11764359	chr7:65958608	NA	-0.67	-8.59	-0.47	7.69e-16	Calcium levels;
CESC	cis	rs1003719	0.788	rs13050757	chr21:38465345	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.63	8.77	0.47	2.14e-16	Eye color traits;
CESC	cis	rs9916302	0.752	rs8071300	chr17:37508524	G/C	cg07936489	chr17:37558343	FBXL20	0.89	9.69	0.51	3.45e-19	Glomerular filtration rate (creatinine);
CESC	cis	rs9287719	0.649	rs9973374	chr2:10716384	C/T	cg00105475	chr2:10696890	NA	0.38	5.25	0.31	3.08e-7	Prostate cancer;
CESC	cis	rs13108904	0.557	rs1680033	chr4:1243404	C/T	cg16405210	chr4:1374714	KIAA1530	0.76	10.41	0.54	1.66e-21	Obesity-related traits;
CESC	cis	rs6831352	0.918	rs29001232	chr4:100046654	G/C	cg12011299	chr4:100065546	ADH4	-0.59	-6.52	-0.37	3.62e-10	Alcohol dependence;
CESC	cis	rs4561483	0.801	rs4511557	chr16:11949458	T/C	cg08843971	chr16:11963173	GSPT1	0.54	7.8	0.43	1.42e-13	Testicular germ cell tumor;
CESC	cis	rs4523957	0.890	rs216222	chr17:2155701	T/A	cg16513277	chr17:2031491	SMG6	0.57	7.69	0.43	2.83e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs6088590	0.687	rs6088582	chr20:33286798	G/A	cg06115741	chr20:33292138	TP53INP2	0.53	6.64	0.38	1.8e-10	Coronary artery disease;
CESC	cis	rs67460515	0.892	rs10513564	chr3:161059762	A/G	cg03342759	chr3:160939853	NMD3	-0.53	-7.63	-0.42	4.17e-13	Parkinson's disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg21694044	chr22:41215540	SLC25A17	-0.46	-6.18	-0.35	2.45e-9	Fibrinogen levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20014778	chr1:229761614	URB2;TAF5L	0.62	7.39	0.41	1.88e-12	Gut microbiome composition (summer);
CESC	cis	rs992157	0.661	rs17653757	chr2:219109364	G/C	cg20019365	chr2:219134978	PNKD;AAMP	0.66	9.17	0.49	1.39e-17	Colorectal cancer;
CESC	cis	rs7044106	0.762	rs10984972	chr9:123409864	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.36	5.8	0.34	1.85e-8	Hip circumference adjusted for BMI;
CESC	cis	rs698833	0.886	rs698802	chr2:44697624	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.43	5.18	0.3	4.47e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs367615	0.679	rs10070786	chr5:108815081	T/G	cg17395555	chr5:108820864	NA	0.66	11.23	0.57	3.41e-24	Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs6674176	1.000	rs11210937	chr1:44405563	T/C	cg12908607	chr1:44402522	ARTN	-0.45	-6.19	-0.36	2.34e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs12200560	0.505	rs1334318	chr6:97079610	A/G	cg06623918	chr6:96969491	KIAA0776	-0.45	-5.83	-0.34	1.57e-8	Coronary heart disease;
CESC	cis	rs6570726	0.905	rs388728	chr6:145816419	T/C	cg05347473	chr6:146136440	FBXO30	0.5	6.71	0.38	1.15e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs780096	0.506	rs56076827	chr2:27676287	A/T	cg22903471	chr2:27725779	GCKR	-0.55	-7.77	-0.43	1.69e-13	Total body bone mineral density;
CESC	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg27094323	chr7:1216898	NA	-0.38	-5.17	-0.3	4.62e-7	Longevity;Endometriosis;
CESC	cis	rs4805272	0.539	rs1075733	chr19:29324460	C/T	cg14983838	chr19:29218262	NA	0.46	5.45	0.32	1.16e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
CESC	cis	rs9875589	0.509	rs6768383	chr3:14076952	G/A	cg19554555	chr3:13937349	NA	-0.44	-5.62	-0.33	4.74e-8	Ovarian reserve;
CESC	cis	rs78707713	0.560	rs2394563	chr10:71238618	G/A	cg12610070	chr10:71211762	TSPAN15	-0.33	-6.85	-0.39	5.18e-11	Venous thromboembolism;
CESC	cis	rs7267979	0.933	rs11699203	chr20:25435169	G/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.86	17.57	0.73	2.33e-46	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs894734	1.000	rs894734	chr12:54319727	A/G	cg17410650	chr12:54324560	NA	-0.31	-5.4	-0.31	1.51e-7	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
CESC	cis	rs7666738	0.830	rs6854902	chr4:99033416	T/G	cg18180107	chr4:99064573	C4orf37	0.42	5.43	0.32	1.29e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11030122	0.702	rs67300156	chr11:3953949	C/T	cg18678763	chr11:4115507	RRM1	-0.45	-6.05	-0.35	4.94e-9	Mean platelet volume;Platelet distribution width;
CESC	cis	rs1862618	0.573	rs2591962	chr5:56237155	G/A	cg20203395	chr5:56204925	C5orf35	0.5	5.77	0.33	2.24e-8	Initial pursuit acceleration;
CESC	cis	rs12618769	0.543	rs3769728	chr2:99103001	G/A	cg10123293	chr2:99228465	UNC50	0.39	5.14	0.3	5.22e-7	Bipolar disorder;
CESC	cis	rs12048904	0.505	rs4517368	chr1:101255052	C/T	cg15686842	chr1:101360669	SLC30A7;EXTL2	-0.49	-5.49	-0.32	9.65e-8	Multiple sclerosis;
CESC	cis	rs7618915	0.547	rs62253703	chr3:52632357	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	6.69	0.38	1.29e-10	Bipolar disorder;
CESC	cis	rs853679	0.550	rs1233707	chr6:28172953	G/A	cg19592336	chr6:28129416	ZNF389	0.52	7.22	0.41	5.5e-12	Depression;
CESC	cis	rs9322193	0.962	rs10872653	chr6:150100043	A/C	cg05861140	chr6:150128134	PCMT1	-0.37	-5.3	-0.31	2.39e-7	Lung cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27262702	chr16:88878803	APRT	0.55	6.42	0.37	6.09e-10	Gut microbiome composition (summer);
CESC	cis	rs17539620	0.624	rs111868524	chr6:154839960	G/C	cg17771515	chr6:154831774	CNKSR3	0.56	5.35	0.31	1.94e-7	Lipoprotein (a) levels;
CESC	cis	rs8017423	0.630	rs4900038	chr14:90821677	A/G	cg14092571	chr14:90743983	NA	0.45	6.82	0.39	6.23e-11	Mortality in heart failure;
CESC	cis	rs4835473	0.771	rs4261935	chr4:144900904	C/T	cg25736465	chr4:144833511	NA	0.41	6.14	0.35	2.97e-9	Immature fraction of reticulocytes;
CESC	cis	rs34375054	0.526	rs117431213	chr12:125675271	C/G	cg05341575	chr12:125625032	AACS	-0.37	-5.39	-0.31	1.57e-7	Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs2730245	0.661	rs842696	chr7:158662698	T/C	cg14689365	chr7:158441557	NCAPG2	0.42	5.26	0.31	2.98e-7	Height;
CESC	trans	rs4843747	0.605	rs28399183	chr16:88107277	G/A	cg26811252	chr16:29126840	RRN3P2	0.68	9.57	0.51	7.78e-19	Menopause (age at onset);
CESC	cis	rs7674212	0.539	rs2866635	chr4:104121576	G/A	cg16532752	chr4:104119610	CENPE	-0.4	-5.46	-0.32	1.09e-7	Type 2 diabetes;
CESC	cis	rs12701220	0.553	rs7782024	chr7:1157502	G/T	cg23978390	chr7:1156363	C7orf50	0.61	6.15	0.35	2.81e-9	Bronchopulmonary dysplasia;
CESC	cis	rs6964587	0.869	rs13237856	chr7:91551788	G/A	cg17063962	chr7:91808500	NA	-0.53	-7.09	-0.4	1.21e-11	Breast cancer;
CESC	cis	rs7520050	0.966	rs785489	chr1:46576390	A/G	cg03146154	chr1:46216737	IPP	-0.43	-5.57	-0.32	6.33e-8	Red blood cell count;Reticulocyte count;
CESC	cis	rs6952808	0.636	rs6964522	chr7:1953523	C/T	cg05279229	chr7:1896384	MAD1L1	-0.39	-5.11	-0.3	6.13e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs9948	0.786	rs62156234	chr2:97436292	C/G	cg01990225	chr2:97406019	LMAN2L	-0.93	-7.53	-0.42	8.09e-13	Erectile dysfunction and prostate cancer treatment;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25944898	chr11:64085532	PRDX5;TRMT112	0.6	6.65	0.38	1.68e-10	Gut microbiome composition (summer);
CESC	cis	rs1568889	1.000	rs34140872	chr11:28335872	A/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.77	10.13	0.53	1.38e-20	Bipolar disorder;
CESC	cis	rs3126085	0.877	rs4415568	chr1:152181207	G/A	cg26876637	chr1:152193138	HRNR	0.48	5.44	0.32	1.21e-7	Atopic dermatitis;
CESC	cis	rs2070433	0.851	rs1029231	chr21:47931653	A/G	cg12379764	chr21:47803548	PCNT	0.47	5.76	0.33	2.34e-8	Lymphocyte counts;
CESC	cis	rs911555	0.755	rs10148970	chr14:103892000	G/A	cg24130564	chr14:104152367	KLC1	-0.53	-7.07	-0.4	1.34e-11	Intelligence (multi-trait analysis);
CESC	cis	rs853679	0.517	rs9380058	chr6:28127444	T/C	cg12963246	chr6:28129442	ZNF389	0.58	7.72	0.43	2.41e-13	Depression;
CESC	cis	rs2243480	0.522	rs1638736	chr7:66092308	A/T	cg08632164	chr7:65971372	NA	-0.53	-5.17	-0.3	4.72e-7	Diabetic kidney disease;
CESC	cis	rs67478160	0.643	rs2295141	chr14:104212949	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.5	-7.06	-0.4	1.45e-11	Schizophrenia;
CESC	cis	rs7666738	0.830	rs3911282	chr4:99037602	T/A	cg17366294	chr4:99064904	C4orf37	0.61	8.77	0.47	2.27e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1005277	0.579	rs2505194	chr10:38393881	C/T	cg25427524	chr10:38739819	LOC399744	-0.64	-9.09	-0.49	2.36e-17	Extrinsic epigenetic age acceleration;
CESC	cis	rs4660306	0.961	rs7546268	chr1:45965340	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.61	-7.69	-0.43	2.86e-13	Homocysteine levels;
CESC	trans	rs9399401	1.000	rs972982	chr6:142666861	A/G	cg09897639	chr1:178063342	RASAL2;LOC100302401	-0.45	-6.13	-0.35	3.11e-9	Chronic obstructive pulmonary disease;
CESC	cis	rs7131987	0.903	rs7302129	chr12:29415280	A/T	cg09582351	chr12:29534625	ERGIC2	-0.36	-5.67	-0.33	3.66e-8	QT interval;
CESC	cis	rs62344088	0.590	rs62345236	chr5:283519	G/A	cg10591111	chr5:226296	SDHA	-0.72	-5.91	-0.34	1.03e-8	Asthma (childhood onset);
CESC	cis	rs2204008	0.577	rs2623049	chr12:38018831	G/A	cg26384229	chr12:38710491	ALG10B	-0.53	-7.49	-0.42	1.06e-12	Bladder cancer;
CESC	cis	rs9479482	0.967	rs1853664	chr6:150355266	A/G	cg03788504	chr6:150331562	NA	-0.31	-6.12	-0.35	3.41e-9	Alopecia areata;
CESC	cis	rs2979489	0.891	rs2979504	chr8:30386641	C/T	cg26383811	chr8:30366931	RBPMS	-0.8	-9.94	-0.52	5.43e-20	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CESC	cis	rs6952808	0.594	rs3778964	chr7:2138109	C/T	cg08027265	chr7:2291960	NA	-0.45	-6.96	-0.39	2.75e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs875971	0.862	rs1695820	chr7:65844563	G/A	cg18252515	chr7:66147081	NA	-0.43	-5.59	-0.32	5.73e-8	Aortic root size;
CESC	cis	rs1843834	0.611	rs1058360	chr2:225449242	A/T	cg22509189	chr2:225307070	NA	-0.42	-5.61	-0.33	4.97e-8	IgE levels in asthmatics (D.p. specific);
CESC	cis	rs8031584	0.918	rs61997140	chr15:31277312	A/G	cg14829155	chr15:31115871	NA	-0.73	-9.66	-0.51	4.04e-19	Huntington's disease progression;
CESC	trans	rs2593957	0.503	rs9850121	chr3:108739965	G/A	cg20104688	chr17:76183078	TK1;AFMID	-0.56	-6.07	-0.35	4.47e-9	Colorectal cancer (diet interaction);
CESC	cis	rs12893668	0.581	rs34843146	chr14:104079864	G/A	cg24130564	chr14:104152367	KLC1	-0.51	-6.4	-0.37	7.05e-10	Reticulocyte count;
CESC	cis	rs7635838	0.686	rs347588	chr3:11287504	C/T	cg00170343	chr3:11313890	ATG7	0.52	7.33	0.41	2.75e-12	HDL cholesterol;
CESC	cis	rs1497406	0.590	rs3818162	chr1:16528600	G/A	cg00949922	chr1:16514382	NA	0.41	5.63	0.33	4.64e-8	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs6433857	0.536	rs1971135	chr2:181351508	G/A	cg23363182	chr2:181467187	NA	-0.42	-5.93	-0.34	9.42e-9	Body mass index;
CESC	cis	rs11122272	0.735	rs2486741	chr1:231516450	G/C	cg06096015	chr1:231504339	EGLN1	0.43	6.18	0.35	2.46e-9	Hemoglobin concentration;
CESC	cis	rs11098499	0.909	rs1546504	chr4:120241179	C/T	cg09307838	chr4:120376055	NA	0.91	12.64	0.61	5.82e-29	Corneal astigmatism;
CESC	cis	rs3858526	0.883	rs7481882	chr11:5944221	A/G	cg13902645	chr11:5959945	NA	-0.68	-8.03	-0.44	3.16e-14	DNA methylation (variation);
CESC	cis	rs7945705	0.902	rs2568059	chr11:8884161	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.47	-7.97	-0.44	4.85e-14	Hemoglobin concentration;
CESC	cis	rs7666738	0.791	rs1559860	chr4:99024422	C/T	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.58e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg20376421	chr12:56546193	MYL6B	-0.47	-6.17	-0.35	2.55e-9	Ulcerative colitis;
CESC	trans	rs116095464	0.558	rs10475136	chr5:232796	A/G	cg00938859	chr5:1591904	SDHAP3	0.63	6.87	0.39	4.6e-11	Breast cancer;
CESC	cis	rs6088580	0.634	rs6120642	chr20:33012531	A/G	cg24642439	chr20:33292090	TP53INP2	0.53	6.95	0.39	2.87e-11	Glomerular filtration rate (creatinine);
CESC	trans	rs1728785	1.000	rs1170436	chr16:68607486	T/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.67	8.11	0.45	1.92e-14	Ulcerative colitis;
CESC	cis	rs7914558	1.000	rs1890184	chr10:104748459	A/C	cg08650961	chr10:104748594	CNNM2	0.32	5.34	0.31	2.04e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs9399401	0.626	rs3817928	chr6:142750516	A/G	cg03128060	chr6:142623767	GPR126	0.37	6.23	0.36	1.82e-9	Chronic obstructive pulmonary disease;
CESC	cis	rs3820928	0.845	rs2177596	chr2:227890283	A/T	cg11843606	chr2:227700838	RHBDD1	-0.47	-6.17	-0.35	2.61e-9	Pulmonary function;
CESC	cis	rs798554	0.704	rs798503	chr7:2789704	G/A	cg09658497	chr7:2847517	GNA12	-0.36	-5.51	-0.32	8.61e-8	Height;
CESC	cis	rs910316	0.935	rs175448	chr14:75591071	G/A	cg16144293	chr14:75469539	EIF2B2	0.4	5.25	0.31	3.15e-7	Height;
CESC	cis	rs3733585	0.624	rs7376154	chr4:9952587	C/A	cg02734326	chr4:10020555	SLC2A9	-0.39	-5.64	-0.33	4.45e-8	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs8072100	0.713	rs3871595	chr17:45511388	C/T	cg25173405	chr17:45401733	C17orf57	-0.43	-5.43	-0.32	1.26e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs863345	0.604	rs11265010	chr1:158498853	G/A	cg12129480	chr1:158549410	OR10X1	-0.34	-6.84	-0.39	5.41e-11	Pneumococcal bacteremia;
CESC	cis	rs2836974	0.644	rs2836981	chr21:40688365	C/T	cg22974920	chr21:40686053	BRWD1	-0.46	-5.74	-0.33	2.57e-8	Cognitive function;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg10831391	chr10:3109765	PFKP	-0.47	-6.31	-0.36	1.16e-9	Ulcerative colitis;
CESC	cis	rs7666738	0.830	rs13134819	chr4:98919885	G/C	cg03467027	chr4:99064603	C4orf37	0.44	5.44	0.32	1.2e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11677416	1.000	rs6542094	chr2:113528625	A/G	cg27083787	chr2:113543245	IL1A	0.41	5.16	0.3	4.75e-7	Response to antipsychotic treatment in schizophrenia (working memory);
CESC	cis	rs10540	1.000	rs35811812	chr11:498442	G/A	cg03934478	chr11:495069	RNH1	0.57	5.78	0.33	2.07e-8	Body mass index;
CESC	cis	rs4474465	0.790	rs7481910	chr11:78264202	G/C	cg27205649	chr11:78285834	NARS2	0.41	5.24	0.31	3.29e-7	Alzheimer's disease (survival time);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg00543840	chr1:22213376	HSPG2	-0.45	-7.44	-0.42	1.39e-12	Gambling;
CESC	cis	rs9650657	0.547	rs11250099	chr8:10818657	C/T	cg21775007	chr8:11205619	TDH	0.38	5.46	0.32	1.09e-7	Neuroticism;
CESC	cis	rs13191362	1.000	rs28360546	chr6:163210973	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.99	9.07	0.49	2.67e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs2000999	0.514	rs35930480	chr16:72217681	G/A	cg04254540	chr16:71951199	KIAA0174	-0.71	-6.1	-0.35	3.73e-9	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
CESC	cis	rs769267	0.895	rs1858999	chr19:19497669	C/G	cg15052019	chr19:19431593	KIAA0892;SF4	-0.4	-5.13	-0.3	5.54e-7	Tonsillectomy;
CESC	cis	rs1552244	1.000	rs7652935	chr3:10151138	T/C	cg00149659	chr3:10157352	C3orf10	0.73	8.81	0.48	1.65e-16	Alzheimer's disease;
CESC	cis	rs1552244	0.882	rs17050699	chr3:10037167	G/A	cg00166722	chr3:10149974	C3orf24	0.48	5.99	0.35	6.66e-9	Alzheimer's disease;
CESC	cis	rs9303280	0.806	rs9907088	chr17:38035116	G/A	cg20243544	chr17:37824526	PNMT	0.5	6.54	0.37	3.21e-10	Self-reported allergy;
CESC	trans	rs11098499	0.954	rs7687843	chr4:120421211	C/T	cg25214090	chr10:38739885	LOC399744	0.7	9.81	0.52	1.36e-19	Corneal astigmatism;
CESC	cis	rs1832871	0.711	rs6920506	chr6:158695017	T/A	cg07165851	chr6:158734300	TULP4	0.57	5.97	0.34	7.78e-9	Height;
CESC	cis	rs1707322	0.752	rs3811436	chr1:46125880	T/C	cg05343316	chr1:45956843	TESK2	0.51	6.24	0.36	1.7e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs6570726	0.846	rs453834	chr6:145886261	T/C	cg05347473	chr6:146136440	FBXO30	0.48	6.49	0.37	4.31e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg21280719	chr6:42927975	GNMT	-0.3	-6.94	-0.39	3.09e-11	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs2635047	0.648	rs4986203	chr18:44597092	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.55	7.95	0.44	5.34e-14	Educational attainment;
CESC	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg07167872	chr1:205819463	PM20D1	0.76	12.94	0.62	5.37e-30	Menarche (age at onset);
CESC	cis	rs11112613	0.713	rs11112591	chr12:105951620	C/T	cg03607813	chr12:105948248	NA	0.6	7.41	0.41	1.69e-12	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg10992590	chr2:130940487	SMPD4;FAM128B	0.5	7.09	0.4	1.23e-11	Gut microbiota (bacterial taxa);
CESC	trans	rs11039798	0.858	rs7121333	chr11:48332138	C/T	cg15704280	chr7:45808275	SEPT13	0.68	6.31	0.36	1.19e-9	Axial length;
CESC	cis	rs863345	0.548	rs857687	chr1:158577998	T/C	cg12129480	chr1:158549410	OR10X1	-0.28	-5.3	-0.31	2.41e-7	Pneumococcal bacteremia;
CESC	cis	rs853679	0.517	rs9380061	chr6:28132803	T/C	cg19592336	chr6:28129416	ZNF389	0.61	8.03	0.44	3.13e-14	Depression;
CESC	cis	rs6543140	0.601	rs7558013	chr2:102992806	G/T	cg04239558	chr2:103089729	SLC9A4	0.43	5.08	0.3	7.24e-7	Blood protein levels;
CESC	cis	rs11122272	0.735	rs2790889	chr1:231520240	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.56	-7.61	-0.42	4.66e-13	Hemoglobin concentration;
CESC	cis	rs7824557	0.767	rs7837036	chr8:11175489	A/G	cg21775007	chr8:11205619	TDH	0.49	7.0	0.39	2.15e-11	Retinal vascular caliber;
CESC	trans	rs7819412	0.540	rs2409726	chr8:11043138	T/C	cg06636001	chr8:8085503	FLJ10661	-0.53	-6.16	-0.35	2.7e-9	Triglycerides;
CESC	cis	rs10489525	0.530	rs11102884	chr1:115612947	A/G	cg01522456	chr1:115632236	TSPAN2	-0.4	-5.17	-0.3	4.67e-7	Autism;
CESC	cis	rs72634258	0.554	rs12745962	chr1:7919825	C/T	cg00042356	chr1:8021962	PARK7	0.59	5.65	0.33	4.15e-8	Inflammatory bowel disease;
CESC	cis	rs2243480	1.000	rs422164	chr7:65586605	C/G	cg13147721	chr7:65941812	NA	-0.99	-9.4	-0.5	2.68e-18	Diabetic kidney disease;
CESC	trans	rs11088226	0.681	rs4547609	chr21:33953542	G/A	cg09050820	chr6:167586206	TCP10L2	0.91	8.89	0.48	9.91e-17	Gastritis;
CESC	trans	rs61931739	0.500	rs56404399	chr12:34543101	A/G	cg13010199	chr12:38710504	ALG10B	0.51	6.58	0.37	2.47e-10	Morning vs. evening chronotype;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg06790019	chr1:44435457	DPH2	-0.47	-6.6	-0.38	2.24e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs2070433	0.556	rs8129460	chr21:47822544	C/T	cg12379764	chr21:47803548	PCNT	0.63	7.22	0.41	5.43e-12	Lymphocyte counts;
CESC	cis	rs1799949	1.000	rs34942571	chr17:41273379	G/C	cg05368731	chr17:41323189	NBR1	0.8	10.93	0.56	3.31e-23	Menopause (age at onset);
CESC	trans	rs9354308	0.901	rs55832318	chr6:66560086	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.7	7.85	0.43	1.04e-13	Metabolite levels;
CESC	cis	rs9916302	0.706	rs1877030	chr17:37740161	T/C	cg20243544	chr17:37824526	PNMT	0.56	5.17	0.3	4.52e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs9488822	0.676	rs11153594	chr6:116354591	A/G	cg15226275	chr6:116381976	FRK	-0.26	-6.55	-0.37	2.9e-10	Cholesterol, total;LDL cholesterol;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg17520942	chr15:93632611	RGMA	0.44	6.94	0.39	2.98e-11	Systemic lupus erythematosus;
CESC	cis	rs787274	0.867	rs786983	chr9:115458629	T/C	cg13803584	chr9:115635662	SNX30	0.51	5.2	0.3	4.01e-7	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs2070488	0.861	rs2067082	chr3:38438182	C/G	cg24069376	chr3:38537580	EXOG	0.47	8.3	0.45	5.34e-15	Electrocardiographic conduction measures;
CESC	cis	rs1005277	0.522	rs289649	chr10:37975384	T/C	cg00409905	chr10:38381863	ZNF37A	-0.51	-7.08	-0.4	1.3e-11	Extrinsic epigenetic age acceleration;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16901991	chr2:24272451	FKBP1B	-0.65	-7.55	-0.42	6.83e-13	Gut microbiome composition (summer);
CESC	cis	rs853679	0.517	rs9368558	chr6:28133306	A/G	cg26335602	chr6:28129616	ZNF389	0.52	6.81	0.39	6.59e-11	Depression;
CESC	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	20.91	0.79	5.29e-58	Prudent dietary pattern;
CESC	cis	rs17376456	0.932	rs3940842	chr5:93534858	C/A	cg25358565	chr5:93447407	FAM172A	1.18	11.18	0.57	4.83e-24	Diabetic retinopathy;
CESC	cis	rs10504229	0.645	rs35142596	chr8:58128151	C/T	cg21724239	chr8:58056113	NA	0.58	5.96	0.34	7.87e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs4780401	0.527	rs4780402	chr16:11839809	C/T	cg01061890	chr16:11836724	TXNDC11	-0.54	-7.19	-0.4	6.51e-12	Rheumatoid arthritis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13892647	chr9:37485877	POLR1E	0.69	7.68	0.43	3.06e-13	Gut microbiome composition (summer);
CESC	cis	rs7618915	1.000	rs3852063	chr3:52349204	A/G	cg05315796	chr3:52349193	DNAH1	0.42	6.63	0.38	1.84e-10	Bipolar disorder;
CESC	cis	rs2735413	0.881	rs12920025	chr16:78083005	C/T	cg04733911	chr16:78082701	NA	-0.53	-8.89	-0.48	9.44e-17	Systolic blood pressure (alcohol consumption interaction);
CESC	cis	rs34779708	0.833	rs12777517	chr10:35473927	T/G	cg03585969	chr10:35415529	CREM	0.76	10.13	0.53	1.3e-20	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg03188948	chr7:1209495	NA	0.55	7.59	0.42	5.31e-13	Longevity;Endometriosis;
CESC	trans	rs55704346	0.566	rs2292407	chr4:25393889	C/T	cg01822600	chr1:245751692	KIF26B	0.42	6.17	0.35	2.58e-9	Tonsillectomy;
CESC	cis	rs3617	0.652	rs7630552	chr3:52891570	G/C	cg07507251	chr3:52567010	NT5DC2	-0.32	-5.33	-0.31	2.07e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
CESC	trans	rs35365539	1	rs35365539	chr3:49794347	A/AC	cg21659725	chr3:3221576	CRBN	-0.83	-13.63	-0.64	2.04e-32	Blood protein levels;
CESC	cis	rs62064224	0.589	rs9903650	chr17:30689370	T/A	cg18200150	chr17:30822561	MYO1D	0.39	5.09	0.3	6.69e-7	Schizophrenia;
CESC	cis	rs757110	0.866	rs5213	chr11:17408404	C/T	cg01153817	chr11:17409509	KCNJ11	0.35	5.31	0.31	2.35e-7	Type 2 diabetes;
CESC	cis	rs13191362	0.938	rs35760705	chr6:163020637	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.48	5.1	0.3	6.62e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs9911578	0.867	rs72628394	chr17:57121313	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.4	-5.25	-0.31	3.18e-7	Intelligence (multi-trait analysis);
CESC	cis	rs7772486	0.875	rs2180192	chr6:146322284	T/C	cg23711669	chr6:146136114	FBXO30	0.86	12.47	0.61	2.22e-28	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6424115	0.830	rs2502992	chr1:24201919	T/C	cg15997130	chr1:24165203	NA	0.39	5.09	0.3	6.8e-7	Immature fraction of reticulocytes;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg01790346	chr8:119634302	SAMD12	-0.47	-6.85	-0.39	5.14e-11	Gambling;
CESC	cis	rs9435341	0.826	rs17496332	chr1:107546375	C/T	cg09367891	chr1:107599246	PRMT6	-0.6	-7.02	-0.4	1.83e-11	Facial morphology (factor 21, depth of nasal alae);
CESC	cis	rs870825	0.616	rs56844261	chr4:185632478	T/C	cg04058563	chr4:185651563	MLF1IP	0.63	6.89	0.39	3.95e-11	Blood protein levels;
CESC	cis	rs66782572	1	rs66782572	chr3:52567617	A/G	cg17372223	chr3:52568218	NT5DC2	0.56	9.63	0.51	5e-19	Hemoglobin concentration;
CESC	cis	rs9303401	0.555	rs8073699	chr17:57236317	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.66	8.46	0.46	1.79e-15	Cognitive test performance;
CESC	cis	rs2288912	0.807	rs10423208	chr19:45453656	G/A	cg13119609	chr19:45449297	APOC2	0.49	8.03	0.44	3.23e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs561341	1.000	rs2344312	chr17:30243583	G/T	cg12193833	chr17:30244370	NA	-0.5	-5.47	-0.32	1.02e-7	Hip circumference adjusted for BMI;
CESC	trans	rs12356475	0.710	rs10822686	chr10:67733250	C/T	cg09112190	chr21:44722858	NA	-0.45	-6.2	-0.36	2.17e-9	Psoriatic arthritis;
CESC	trans	rs7615952	0.736	rs9866347	chr3:125669925	C/T	cg07211511	chr3:129823064	LOC729375	-0.86	-7.2	-0.4	6.33e-12	Blood pressure (smoking interaction);
CESC	cis	rs2262909	1.000	rs2078089	chr19:22209753	A/T	cg11619707	chr19:22235551	ZNF257	-0.35	-5.7	-0.33	3.19e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
CESC	cis	rs10791323	0.628	rs2851118	chr11:133705995	A/C	cg15485101	chr11:133734466	NA	0.4	6.59	0.38	2.35e-10	Childhood ear infection;
CESC	cis	rs4594175	0.926	rs9323207	chr14:51621908	A/G	cg23942311	chr14:51606299	NA	-0.4	-6.0	-0.35	6.47e-9	Cancer;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg21983178	chr1:45120676	TMEM53	-0.52	-6.91	-0.39	3.51e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs1499614	0.901	rs2178742	chr7:66197799	G/A	cg13147721	chr7:65941812	NA	-0.94	-8.9	-0.48	9.08e-17	Gout;
CESC	cis	rs4713118	0.621	rs9295755	chr6:28033174	C/T	cg19592336	chr6:28129416	ZNF389	-0.6	-7.92	-0.44	6.46e-14	Parkinson's disease;
CESC	cis	rs7086627	0.515	rs10887894	chr10:82209952	A/G	cg00277334	chr10:82204260	NA	-0.91	-15.92	-0.7	1.67e-40	Post bronchodilator FEV1;
CESC	cis	rs2985684	0.894	rs8005990	chr14:50022248	G/A	cg04989706	chr14:50066350	PPIL5	-0.44	-5.05	-0.3	8.21e-7	Carotid intima media thickness;
CESC	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg06873352	chr17:61820015	STRADA	0.74	13.19	0.63	7.17e-31	Prudent dietary pattern;
CESC	cis	rs4843747	0.671	rs72818576	chr16:88111019	C/G	cg06915872	chr16:87998081	BANP	0.44	5.22	0.31	3.64e-7	Menopause (age at onset);
CESC	cis	rs801193	0.548	rs7805152	chr7:66209253	C/T	cg12463550	chr7:65579703	CRCP	0.49	6.33	0.36	1.03e-9	Aortic root size;
CESC	cis	rs2230307	0.536	rs522696	chr1:100476662	G/A	cg24955406	chr1:100503596	HIAT1	0.55	5.48	0.32	9.85e-8	Carotid intima media thickness;
CESC	cis	rs9649465	1.000	rs6951138	chr7:123362070	G/A	cg04330084	chr7:123175371	IQUB	-0.39	-5.23	-0.31	3.47e-7	Migraine;
CESC	cis	rs1059312	0.808	rs900982	chr12:129304369	G/A	cg09035930	chr12:129282057	SLC15A4	0.69	9.12	0.49	1.96e-17	Systemic lupus erythematosus;
CESC	cis	rs7945705	0.902	rs10769979	chr11:9010659	C/T	cg12365402	chr11:9010492	NRIP3	0.42	7.05	0.4	1.51e-11	Hemoglobin concentration;
CESC	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg14338887	chr6:42928500	GNMT	0.36	5.32	0.31	2.25e-7	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs6540559	0.543	rs664097	chr1:210422179	C/T	cg23283495	chr1:209979779	IRF6	0.42	5.52	0.32	7.89e-8	Cleft lip with or without cleft palate;
CESC	cis	rs854765	0.534	rs7207461	chr17:17949789	T/G	cg04398451	chr17:18023971	MYO15A	0.74	10.81	0.55	8.17e-23	Total body bone mineral density;
CESC	cis	rs7267979	0.565	rs6076364	chr20:25556801	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.69	-10.97	-0.56	2.46e-23	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs9916302	0.861	rs7503514	chr17:37669884	G/C	cg20243544	chr17:37824526	PNMT	0.48	6.1	0.35	3.71e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg22105103	chr4:187893119	NA	0.51	7.6	0.42	5.13e-13	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs17253792	0.822	rs75437558	chr14:56066798	C/T	cg01858014	chr14:56050164	KTN1	-0.85	-6.79	-0.38	7.45e-11	Putamen volume;
CESC	cis	rs2191566	0.639	rs7257749	chr19:44548666	G/A	cg20607764	chr19:44506953	ZNF230	-0.43	-5.52	-0.32	8.25e-8	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs9549367	0.713	rs9549352	chr13:113833221	A/G	cg18105134	chr13:113819100	PROZ	-0.69	-8.18	-0.45	1.23e-14	Platelet distribution width;
CESC	cis	rs28374715	0.662	rs10851403	chr15:41466087	T/G	cg18705301	chr15:41695430	NDUFAF1	-0.78	-10.29	-0.53	4e-21	Ulcerative colitis;
CESC	cis	rs3820928	0.874	rs13393902	chr2:227880554	A/G	cg05526886	chr2:227700861	RHBDD1	-0.43	-5.48	-0.32	9.75e-8	Pulmonary function;
CESC	cis	rs748404	0.697	rs471122	chr15:43558574	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.6	-7.65	-0.43	3.7e-13	Lung cancer;
CESC	cis	rs2408955	0.522	rs10875721	chr12:48413593	A/G	cg24011408	chr12:48396354	COL2A1	-0.58	-8.73	-0.47	2.83e-16	Glycated hemoglobin levels;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg13137891	chr2:60779450	BCL11A	-0.47	-6.61	-0.38	2.05e-10	Asthma;
CESC	cis	rs9768139	0.903	rs10262701	chr7:158114591	G/A	cg24154853	chr7:158122151	PTPRN2	-0.38	-5.98	-0.34	7.19e-9	Calcium levels;
CESC	cis	rs9303401	0.614	rs34683543	chr17:56520036	C/A	cg25039879	chr17:56429692	SUPT4H1	0.53	5.47	0.32	1.05e-7	Cognitive test performance;
CESC	cis	rs7116495	0.609	rs4477459	chr11:71720616	T/C	cg07596299	chr11:71824057	C11orf51	-0.82	-5.33	-0.31	2.13e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs3820068	0.581	rs59684759	chr1:15919893	A/G	cg17385448	chr1:15911702	AGMAT	0.41	6.59	0.38	2.36e-10	Systolic blood pressure;
CESC	cis	rs7666738	0.830	rs4443295	chr4:99044935	G/A	cg18180107	chr4:99064573	C4orf37	0.4	5.2	0.3	4.08e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00881883	chr6:42897299	CNPY3	0.58	6.13	0.35	3.09e-9	Gut microbiome composition (summer);
CESC	cis	rs599083	0.530	rs686921	chr11:68170833	G/T	cg01657329	chr11:68192670	LRP5	0.44	5.16	0.3	4.74e-7	Bone mineral density (spine);
CESC	cis	rs9815354	0.812	rs73073358	chr3:41842527	G/A	cg03022575	chr3:42003672	ULK4	0.7	6.04	0.35	5.26e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs2625529	0.526	rs11637611	chr15:72551712	C/T	cg16672083	chr15:72433130	SENP8	0.43	6.48	0.37	4.54e-10	Red blood cell count;
CESC	cis	rs875971	0.825	rs1860472	chr7:66082723	T/C	cg11764359	chr7:65958608	NA	-0.79	-11.33	-0.57	1.53e-24	Aortic root size;
CESC	cis	rs1799949	0.965	rs34616041	chr17:41188786	G/A	cg25072359	chr17:41440525	NA	0.51	6.62	0.38	1.95e-10	Menopause (age at onset);
CESC	cis	rs6952808	0.723	rs60995052	chr7:2030007	G/C	cg04267008	chr7:1944627	MAD1L1	-0.63	-7.72	-0.43	2.43e-13	Bipolar disorder and schizophrenia;
CESC	cis	rs2032447	0.839	rs199751	chr6:26015583	T/C	cg03517284	chr6:25882590	NA	-0.48	-6.34	-0.36	1.01e-9	Intelligence (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11201273	chr8:38088865	DDHD2	0.59	6.43	0.37	5.88e-10	Gut microbiome composition (summer);
CESC	cis	rs3785574	0.962	rs58131426	chr17:61854375	T/C	cg06873352	chr17:61820015	STRADA	0.48	7.0	0.4	2.07e-11	Height;
CESC	cis	rs977987	0.806	rs12444589	chr16:75454404	A/T	cg03315344	chr16:75512273	CHST6	-0.41	-6.03	-0.35	5.55e-9	Dupuytren's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04925196	chr12:51592141	POU6F1	-0.59	-6.35	-0.36	9.29e-10	Gut microbiome composition (summer);
CESC	cis	rs2730245	0.527	rs2527205	chr7:158706393	G/T	cg24397884	chr7:158709396	WDR60	-0.7	-7.75	-0.43	1.96e-13	Height;
CESC	cis	rs4819052	0.851	rs2838842	chr21:46669217	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.46	5.65	0.33	4.23e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs2479106	0.824	rs1752169	chr9:126586563	C/A	cg16191174	chr9:126692580	DENND1A	0.47	6.47	0.37	4.79e-10	Polycystic ovary syndrome;
CESC	cis	rs3785574	1.000	rs3785574	chr17:61763185	T/C	cg11494091	chr17:61959527	GH2	0.39	5.21	0.3	3.86e-7	Height;
CESC	cis	rs1267303	0.675	rs1745370	chr1:46982863	C/G	cg25110126	chr1:46999211	NA	-0.89	-9.86	-0.52	9.97e-20	Monobrow;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17930852	chr1:45957182	TESK2	-0.63	-6.7	-0.38	1.25e-10	Gut microbiome composition (summer);
CESC	cis	rs11030122	0.702	rs10500590	chr11:3964724	T/C	cg18678763	chr11:4115507	RRM1	-0.5	-6.64	-0.38	1.78e-10	Mean platelet volume;Platelet distribution width;
CESC	cis	rs2354432	0.607	rs7553584	chr1:146693429	A/G	cg25205988	chr1:146714368	CHD1L	-1.19	-9.08	-0.49	2.58e-17	Mitochondrial DNA levels;
CESC	cis	rs4664304	0.739	rs2162500	chr2:160708645	C/G	cg03641300	chr2:160917029	PLA2R1	0.39	5.36	0.31	1.8e-7	Crohn's disease;Inflammatory bowel disease;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg10730208	chr12:58290540	NA	-0.44	-6.09	-0.35	3.93e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs11190604	1.000	rs4244338	chr10:102272802	A/G	cg07080220	chr10:102295463	HIF1AN	0.67	6.22	0.36	1.91e-9	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs9583531	0.689	rs9521905	chr13:111352600	G/A	cg24331049	chr13:111365604	ING1	-0.75	-10.2	-0.53	7.79e-21	Coronary artery disease;
CESC	cis	rs7666738	0.830	rs28615340	chr4:98896922	T/C	cg17366294	chr4:99064904	C4orf37	0.55	7.61	0.42	4.88e-13	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9486719	1.000	rs12208884	chr6:96885572	G/A	cg18709589	chr6:96969512	KIAA0776	-0.53	-5.81	-0.34	1.75e-8	Migraine;Coronary artery disease;
CESC	cis	rs360071	0.870	rs360074	chr1:226091150	A/G	cg17950169	chr1:226067900	TMEM63A	0.31	5.03	0.3	9.23e-7	Response to radiotherapy in prostate cancer (toxicity, rectal bleeding);
CESC	trans	rs1814175	0.817	rs1621090	chr11:49895868	C/A	cg15704280	chr7:45808275	SEPT13	-1.03	-20.9	-0.79	5.71e-58	Height;
CESC	cis	rs7520050	0.966	rs946529	chr1:46485548	G/T	cg03146154	chr1:46216737	IPP	-0.47	-6.03	-0.35	5.46e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs2836974	0.897	rs35391055	chr21:40525516	G/A	cg11644478	chr21:40555479	PSMG1	1.04	17.8	0.74	3.62e-47	Cognitive function;
CESC	cis	rs4523957	0.620	rs1565764	chr17:2074303	G/A	cg16513277	chr17:2031491	SMG6	-0.77	-11.17	-0.57	5.39e-24	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs1538970	0.924	rs1006216	chr1:45909994	A/G	cg24296786	chr1:45957014	TESK2	-0.46	-5.25	-0.31	3.14e-7	Platelet count;
CESC	cis	rs10504229	0.683	rs6999351	chr8:58127227	C/T	cg02725872	chr8:58115012	NA	-0.45	-6.84	-0.39	5.31e-11	Developmental language disorder (linguistic errors);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01108697	chr16:1812618	MAPK8IP3	-0.5	-6.06	-0.35	4.62e-9	Gut microbiome composition (summer);
CESC	cis	rs2228479	0.850	rs1800344	chr16:89816367	T/G	cg04013166	chr16:89971882	TCF25	0.77	6.66	0.38	1.58e-10	Skin colour saturation;
CESC	cis	rs4665809	1.000	rs6546768	chr2:26328800	A/G	cg22920501	chr2:26401640	FAM59B	-0.68	-8.18	-0.45	1.21e-14	Gut microbiome composition (summer);
CESC	trans	rs9325144	0.625	rs11534879	chr12:38968165	A/G	cg23762105	chr12:34175262	ALG10	0.48	6.42	0.37	6.16e-10	Morning vs. evening chronotype;
CESC	cis	rs7945705	0.902	rs2016942	chr11:8938787	A/G	cg09997546	chr11:8931473	C11orf17;ST5	0.38	6.13	0.35	3.18e-9	Hemoglobin concentration;
CESC	cis	rs1799949	1.000	rs36036395	chr17:41181297	T/C	cg25072359	chr17:41440525	NA	0.49	6.41	0.37	6.64e-10	Menopause (age at onset);
CESC	cis	rs4969178	0.560	rs4969182	chr17:76393030	T/C	cg05887092	chr17:76393375	PGS1	0.69	11.66	0.58	1.25e-25	HDL cholesterol levels;
CESC	cis	rs9486719	0.901	rs13206547	chr6:97006942	T/C	cg06623918	chr6:96969491	KIAA0776	-0.8	-8.3	-0.45	5.39e-15	Migraine;Coronary artery disease;
CESC	cis	rs9621305	0.502	rs738684	chr22:32012634	C/T	cg25791279	chr22:32026902	PISD	0.52	5.09	0.3	6.85e-7	Intelligence;
CESC	cis	rs7408868	0.908	rs757474	chr19:15273624	T/C	cg14696996	chr19:15285081	NOTCH3	1.11	11.47	0.58	5.57e-25	Pulse pressure;
CESC	cis	rs9733	0.565	rs7524620	chr1:150616699	C/T	cg18016565	chr1:150552671	MCL1	-0.33	-5.13	-0.3	5.71e-7	Tonsillectomy;
CESC	trans	rs9929218	0.529	rs8059194	chr16:68749663	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.9	14.52	0.67	1.51e-35	Colorectal cancer;
CESC	cis	rs7914558	0.966	rs1591915	chr10:104646849	C/T	cg08650961	chr10:104748594	CNNM2	0.33	5.37	0.31	1.71e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs7412746	0.658	rs6658066	chr1:150918937	T/G	cg22823121	chr1:150693482	HORMAD1	0.37	5.19	0.3	4.1e-7	Melanoma;
CESC	cis	rs4472734	1.000	rs4472734	chr1:214618185	C/T	cg00063699	chr1:214624242	PTPN14	-0.34	-5.4	-0.32	1.46e-7	Height;
CESC	cis	rs10876993	0.890	rs7976852	chr12:58100551	T/G	cg18357645	chr12:58087776	OS9	0.64	10.5	0.54	8.52e-22	Celiac disease or Rheumatoid arthritis;
CESC	cis	rs733175	0.857	rs10018663	chr4:10004797	C/T	cg00071950	chr4:10020882	SLC2A9	0.51	5.85	0.34	1.41e-8	Psychosis and Alzheimer's disease;
CESC	trans	rs1814175	0.616	rs10839388	chr11:49842603	C/T	cg15704280	chr7:45808275	SEPT13	-0.98	-17.93	-0.74	1.3e-47	Height;
CESC	trans	rs208520	0.661	rs6937856	chr6:66867468	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.99	-12.89	-0.62	7.46e-30	Exhaled nitric oxide output;
CESC	cis	rs5769707	0.632	rs1476037	chr22:49991377	G/A	cg05373962	chr22:49881684	NA	-0.35	-5.11	-0.3	6.07e-7	Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg18765753	chr7:1198926	ZFAND2A	-0.6	-9.64	-0.51	4.91e-19	Longevity;Endometriosis;
CESC	cis	rs7666738	0.753	rs4699604	chr4:99056353	T/C	cg17366294	chr4:99064904	C4orf37	0.61	8.57	0.47	8.43e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7618915	0.501	rs34739010	chr3:52766122	A/G	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.31	5.59	0.32	5.76e-8	Bipolar disorder;
CESC	cis	rs9611565	0.580	rs5758449	chr22:42140160	C/T	cg06634786	chr22:41940651	POLR3H	0.49	5.5	0.32	8.83e-8	Vitiligo;
CESC	cis	rs798554	0.679	rs7784066	chr7:2819727	T/A	cg19717773	chr7:2847554	GNA12	-0.57	-8.14	-0.45	1.52e-14	Height;
CESC	cis	rs7223966	1.000	rs16947014	chr17:61719032	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.62	0.38	1.93e-10	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs9309711	0.666	rs6767	chr2:3483205	C/T	cg10845886	chr2:3471009	TTC15	-0.67	-9.29	-0.5	5.87e-18	Neurofibrillary tangles;
CESC	cis	rs887829	0.588	rs4663969	chr2:234655313	C/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.53	-6.92	-0.39	3.34e-11	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CESC	cis	rs6570726	0.846	rs4896824	chr6:145927048	C/T	cg23711669	chr6:146136114	FBXO30	0.83	12.33	0.6	6.39e-28	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4727027	0.870	rs1534196	chr7:148790591	G/A	cg23583168	chr7:148888333	NA	-0.78	-12.16	-0.6	2.45e-27	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg02214188	chr4:104020949	BDH2	0.53	6.78	0.38	7.62e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs11958404	0.932	rs72818109	chr5:157438340	A/T	cg05962755	chr5:157440814	NA	0.62	6.66	0.38	1.57e-10	IgG glycosylation;
CESC	cis	rs3892630	0.878	rs8112955	chr19:33191192	C/T	cg22980127	chr19:33182716	NUDT19	1.02	11.58	0.58	2.23e-25	Red blood cell traits;
CESC	cis	rs9322193	0.884	rs11155689	chr6:150129606	T/C	cg07701084	chr6:150067640	NUP43	0.43	5.8	0.34	1.87e-8	Lung cancer;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg17976829	chr10:131934431	GLRX3	0.47	6.0	0.35	6.53e-9	Gut microbiota (bacterial taxa);
CESC	trans	rs2727020	0.857	rs1917324	chr11:49371759	G/C	cg15704280	chr7:45808275	SEPT13	-0.76	-9.47	-0.5	1.61e-18	Coronary artery disease;
CESC	cis	rs3824867	0.920	rs9734013	chr11:47451517	G/T	cg20307385	chr11:47447363	PSMC3	-0.47	-5.48	-0.32	9.68e-8	Mean corpuscular hemoglobin;
CESC	cis	rs72615157	0.561	rs113401658	chr7:99858505	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.66	6.21	0.36	2e-9	Lung function (FEV1/FVC);
CESC	cis	rs3733585	0.699	rs62294331	chr4:9959889	A/G	cg00071950	chr4:10020882	SLC2A9	-0.73	-11.79	-0.59	4.58e-26	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs9291683	0.588	rs35866697	chr4:10018604	C/A	cg11266682	chr4:10021025	SLC2A9	0.71	14.52	0.67	1.5e-35	Bone mineral density;
CESC	cis	rs1152591	0.524	rs1255992	chr14:64662895	A/G	cg21174375	chr14:64681225	SYNE2	0.56	7.88	0.44	8.58e-14	Atrial fibrillation;
CESC	cis	rs10751667	0.600	rs14346	chr11:1011829	T/C	cg06064525	chr11:970664	AP2A2	-0.33	-5.58	-0.32	6.04e-8	Alzheimer's disease (late onset);
CESC	cis	rs4722166	0.695	rs7808122	chr7:22798080	A/G	cg13104385	chr7:22767384	IL6	0.39	5.78	0.33	2.15e-8	Lung cancer;
CESC	cis	rs7044106	0.762	rs7357638	chr9:123389204	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.63	8.52	0.46	1.18e-15	Hip circumference adjusted for BMI;
CESC	cis	rs7551222	0.752	rs12032733	chr1:204481209	G/A	cg20240347	chr1:204465584	NA	-0.28	-5.7	-0.33	3.27e-8	Schizophrenia;
CESC	cis	rs10463316	0.862	rs10071166	chr5:150768795	T/C	cg03212797	chr5:150827313	SLC36A1	-0.45	-5.78	-0.33	2.13e-8	Metabolite levels (Pyroglutamine);
CESC	cis	rs2576037	0.583	rs892586	chr18:44560429	C/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.35	-5.53	-0.32	7.8e-8	Personality dimensions;
CESC	cis	rs12579753	0.810	rs10862355	chr12:82162698	C/T	cg21193143	chr12:82153300	PPFIA2	-0.33	-5.31	-0.31	2.38e-7	Resting heart rate;
CESC	cis	rs858239	0.571	rs2390755	chr7:23190716	A/T	cg23682824	chr7:23144976	KLHL7	0.51	6.8	0.39	6.75e-11	Cerebrospinal fluid biomarker levels;
CESC	cis	rs2075371	0.829	rs11770764	chr7:134003308	T/C	cg11752832	chr7:134001865	SLC35B4	0.52	6.61	0.38	2.14e-10	Mean platelet volume;
CESC	cis	rs11098499	0.954	rs4577559	chr4:120404043	T/G	cg24375607	chr4:120327624	NA	0.45	5.52	0.32	8.1e-8	Corneal astigmatism;
CESC	trans	rs801193	0.935	rs11772264	chr7:66176387	T/C	cg26939375	chr7:64535504	NA	0.64	8.76	0.47	2.31e-16	Aortic root size;
CESC	cis	rs67460515	0.563	rs1585481	chr3:160901481	C/T	cg03342759	chr3:160939853	NMD3	-0.54	-7.21	-0.4	5.86e-12	Parkinson's disease;
CESC	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.48	-5.2	-0.3	4.05e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs61776719	0.520	rs12569027	chr1:38449163	C/T	cg17077180	chr1:38461687	NA	0.47	7.22	0.41	5.37e-12	Coronary artery disease;
CESC	cis	rs6460942	0.915	rs62448619	chr7:12457743	C/T	cg02935154	chr7:12443704	VWDE	-0.58	-6.16	-0.35	2.73e-9	Coronary artery disease;
CESC	cis	rs3858526	0.920	rs11511938	chr11:5928793	A/G	cg05234568	chr11:5960015	NA	-0.55	-6.36	-0.36	8.79e-10	DNA methylation (variation);
CESC	cis	rs2836974	0.897	rs2836923	chr21:40524236	T/C	cg11890956	chr21:40555474	PSMG1	1.17	21.04	0.79	1.8e-58	Cognitive function;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05262316	chr6:64345491	NA	-0.59	-6.99	-0.39	2.17e-11	Gut microbiome composition (summer);
CESC	cis	rs116095464	1.000	rs10475185	chr5:306981	C/T	cg22857025	chr5:266934	NA	-1.25	-7.67	-0.43	3.19e-13	Breast cancer;
CESC	cis	rs6089584	1.000	rs6142910	chr20:60562181	C/A	cg13770153	chr20:60521292	NA	-0.45	-5.9	-0.34	1.12e-8	Body mass index;
CESC	cis	rs563538	1	rs563538	chr13:37433721	A/G	cg18983090	chr13:37575004	EXOSC8	-0.69	-5.29	-0.31	2.6e-7	Spontaneous preterm birth (preterm birth);
CESC	cis	rs10504229	0.679	rs16921623	chr8:58039473	G/C	cg24829409	chr8:58192753	C8orf71	-0.49	-6.18	-0.36	2.35e-9	Developmental language disorder (linguistic errors);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13612175	chr14:69259241	ZFP36L1	-0.54	-6.48	-0.37	4.53e-10	Gut microbiome composition (summer);
CESC	trans	rs7672847	0.547	rs72974740	chr4:170479434	T/C	cg19308436	chr1:237949471	RYR2	0.65	7.03	0.4	1.79e-11	Subjective well-being;
CESC	cis	rs875971	0.862	rs28470208	chr7:65584700	A/G	cg12463550	chr7:65579703	CRCP	-0.52	-6.48	-0.37	4.33e-10	Aortic root size;
CESC	cis	rs736408	0.812	rs9324	chr3:52825585	T/C	cg17372223	chr3:52568218	NT5DC2	0.41	5.71	0.33	3.05e-8	Bipolar disorder;
CESC	cis	rs6430585	0.640	rs6716070	chr2:136544651	G/T	cg07169764	chr2:136633963	MCM6	-1.19	-17.18	-0.73	5.7e-45	Corneal structure;
CESC	cis	rs3820928	1.000	rs7561378	chr2:227772248	T/C	cg11843606	chr2:227700838	RHBDD1	-0.43	-5.74	-0.33	2.55e-8	Pulmonary function;
CESC	cis	rs7927771	1.000	rs34128973	chr11:47851376	C/T	cg18512352	chr11:47633146	NA	-0.61	-9.51	-0.5	1.24e-18	Subjective well-being;
CESC	cis	rs2929278	0.617	rs12908467	chr15:44047430	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.49	-7.83	-0.43	1.16e-13	Schizophrenia;
CESC	trans	rs12960505	0.506	rs1125627	chr18:51004270	C/T	cg06077405	chr7:2313805	SNX8	-0.49	-6.17	-0.35	2.56e-9	Intelligence (multi-trait analysis);
CESC	cis	rs1707322	1.000	rs11211190	chr1:46266255	C/T	cg05343316	chr1:45956843	TESK2	0.42	5.2	0.3	3.95e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs2797160	0.837	rs1739364	chr6:126022383	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.46	-6.3	-0.36	1.25e-9	Endometrial cancer;
CESC	cis	rs60871478	1.000	rs62432899	chr7:826542	G/C	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.57	5.61	0.33	4.98e-8	Cerebrospinal P-tau181p levels;
CESC	cis	rs75477785	0.590	rs72649914	chr1:210077882	C/A	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.96	6.81	0.39	6.53e-11	Cleft lip with or without cleft palate;
CESC	trans	rs10995245	0.840	rs4746525	chr10:64438271	A/G	cg05827312	chr13:28394966	NA	0.34	6.1	0.35	3.81e-9	Narcolepsy;
CESC	cis	rs4665809	0.531	rs3892649	chr2:26457267	T/G	cg26314531	chr2:26401878	FAM59B	0.85	9.04	0.49	3.46e-17	Gut microbiome composition (summer);
CESC	cis	rs2637266	0.967	rs4553314	chr10:78358244	C/T	cg18941641	chr10:78392320	NA	0.44	8.21	0.45	9.93e-15	Pulmonary function;
CESC	cis	rs9747201	0.925	rs8072670	chr17:80159566	T/C	cg09264619	chr17:80180166	NA	-0.44	-5.22	-0.31	3.67e-7	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs4975709	0.589	rs4975707	chr5:1864028	C/T	cg17650747	chr5:1873721	NA	0.43	6.13	0.35	3.22e-9	Cardiovascular disease risk factors;
CESC	cis	rs9311474	0.659	rs1133415	chr3:52575831	G/A	cg15147215	chr3:52552868	STAB1	-0.29	-5.06	-0.3	7.67e-7	Electroencephalogram traits;
CESC	cis	rs1799949	1.000	rs34572725	chr17:41428666	G/A	cg23758822	chr17:41437982	NA	1.03	15.87	0.7	2.47e-40	Menopause (age at onset);
CESC	cis	rs1003719	0.591	rs2835633	chr21:38525019	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.56	-7.2	-0.4	6.24e-12	Eye color traits;
CESC	cis	rs763014	0.931	rs2071980	chr16:626346	A/C	cg07343612	chr16:622815	PIGQ	-0.57	-8.24	-0.45	7.87e-15	Height;
CESC	cis	rs6964587	0.692	rs2027950	chr7:91863700	C/G	cg17063962	chr7:91808500	NA	-0.45	-6.5	-0.37	3.9e-10	Breast cancer;
CESC	cis	rs6570726	0.935	rs415590	chr6:145851244	T/C	cg23711669	chr6:146136114	FBXO30	0.8	11.89	0.59	1.98e-26	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2243480	1.000	rs1873494	chr7:65649899	T/C	cg13147721	chr7:65941812	NA	0.97	9.16	0.49	1.47e-17	Diabetic kidney disease;
CESC	cis	rs71277158	0.688	rs2287479	chr3:169787423	G/C	cg04067573	chr3:169899625	PHC3	0.72	7.1	0.4	1.16e-11	Prostate cancer;
CESC	trans	rs7615952	0.512	rs11921452	chr3:125359750	A/G	cg21747405	chr11:67723411	NA	-0.44	-6.69	-0.38	1.3100000000000001e-10	Blood pressure (smoking interaction);
CESC	trans	rs10841784	0.958	rs7962263	chr12:21466117	A/G	cg00566759	chr18:28682345	DSC2	-0.48	-6.55	-0.37	2.95e-10	Childhood ear infection;
CESC	cis	rs11997175	1.000	rs11997175	chr8:33770070	A/G	ch.8.33884649F	chr8:33765107	NA	-0.61	-7.72	-0.43	2.42e-13	Body mass index;
CESC	cis	rs13256369	0.951	rs12679360	chr8:8566269	G/T	cg18904891	chr8:8559673	CLDN23	-0.67	-8.01	-0.44	3.64e-14	Obesity-related traits;
CESC	cis	rs6493487	0.512	rs34874493	chr15:51312751	G/A	cg02338191	chr15:51200825	AP4E1	0.58	5.47	0.32	1.02e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	trans	rs12310956	0.532	rs1352210	chr12:33983187	A/G	cg26384229	chr12:38710491	ALG10B	0.45	6.22	0.36	1.98e-9	Morning vs. evening chronotype;
CESC	cis	rs9287719	0.967	rs6712304	chr2:10754375	A/C	cg00105475	chr2:10696890	NA	0.38	5.42	0.32	1.34e-7	Prostate cancer;
CESC	cis	rs7552404	0.727	rs6678348	chr1:76332463	C/T	cg03433033	chr1:76189801	ACADM	0.63	6.35	0.36	9.5e-10	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs71277158	0.688	rs6808506	chr3:169839239	G/C	cg04067573	chr3:169899625	PHC3	0.71	7.11	0.4	1.06e-11	Prostate cancer;
CESC	cis	rs854765	0.647	rs8066764	chr17:17974668	C/T	cg04398451	chr17:18023971	MYO15A	-0.75	-11.02	-0.56	1.65e-23	Total body bone mineral density;
CESC	cis	rs798554	0.679	rs7784066	chr7:2819727	T/A	cg19346786	chr7:2764209	NA	-0.48	-6.81	-0.39	6.5e-11	Height;
CESC	cis	rs7666738	0.830	rs11735193	chr4:98761900	C/T	cg17366294	chr4:99064904	C4orf37	0.57	7.98	0.44	4.33e-14	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06818126	chr11:68850279	TPCN2	-0.61	-6.68	-0.38	1.36e-10	Gut microbiome composition (summer);
CESC	cis	rs12701220	0.655	rs10215292	chr7:1135263	A/G	cg04025307	chr7:1156635	C7orf50	0.45	5.04	0.3	8.56e-7	Bronchopulmonary dysplasia;
CESC	cis	rs6121246	0.609	rs6060948	chr20:30376393	C/G	cg13852791	chr20:30311386	BCL2L1	0.82	10.47	0.54	1.07e-21	Mean corpuscular hemoglobin;
CESC	cis	rs3540	0.512	rs3862437	chr15:91084632	A/G	cg22089800	chr15:90895588	ZNF774	-0.6	-7.74	-0.43	2.16e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26594522	chr4:1138272	NA	-0.51	-6.05	-0.35	5e-9	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27265637	chr10:75504303	SEC24C	-0.64	-7.44	-0.42	1.41e-12	Gut microbiome composition (summer);
CESC	cis	rs2070677	0.935	rs12242613	chr10:135419831	C/T	cg20169779	chr10:135381914	SYCE1	-0.73	-9.56	-0.51	8.51e-19	Gout;
CESC	cis	rs1448094	0.512	rs2405632	chr12:86252456	A/G	cg19622623	chr12:86230825	RASSF9	-0.48	-6.22	-0.36	1.91e-9	Major depressive disorder;
CESC	cis	rs6460942	0.597	rs35589221	chr7:12535841	T/G	cg02935154	chr7:12443704	VWDE	-0.57	-5.7	-0.33	3.23e-8	Coronary artery disease;
CESC	cis	rs4423214	1.000	rs28364617	chr11:71159764	T/G	cg24826892	chr11:71159390	DHCR7	0.47	5.55	0.32	6.97e-8	Vitamin D levels;
CESC	cis	rs1200821	0.529	rs4934856	chr10:37807847	T/C	cg25427524	chr10:38739819	LOC399744	0.42	5.43	0.32	1.27e-7	Hemostatic factors and hematological phenotypes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14330119	chr7:73668867	RFC2	0.54	6.39	0.37	7.29e-10	Gut microbiome composition (summer);
CESC	cis	rs7829975	0.871	rs777709	chr8:8583872	T/C	cg06636001	chr8:8085503	FLJ10661	-0.44	-5.58	-0.32	5.79e-8	Mood instability;
CESC	cis	rs35110281	0.616	rs2236666	chr21:45109856	T/C	cg21573476	chr21:45109991	RRP1B	-0.58	-8.35	-0.46	3.84e-15	Mean corpuscular volume;
CESC	cis	rs9457247	0.935	rs2757050	chr6:167377165	G/T	cg23791538	chr6:167370224	RNASET2	0.6	8.57	0.47	8.75e-16	Crohn's disease;
CESC	cis	rs1707322	1.000	rs4073847	chr1:46463012	A/C	cg05343316	chr1:45956843	TESK2	-0.45	-5.46	-0.32	1.1e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs11583043	0.708	rs3861735	chr1:101530191	C/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.52	5.5	0.32	8.99e-8	Ulcerative colitis;Inflammatory bowel disease;
CESC	cis	rs6681460	0.966	rs10749763	chr1:67062126	G/A	cg02459107	chr1:67143332	SGIP1	0.36	5.08	0.3	7.08e-7	Presence of antiphospholipid antibodies;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg12703194	chr16:3086867	CCDC64B	-0.46	-6.53	-0.37	3.35e-10	Fibrinogen levels;
CESC	cis	rs12824058	0.549	rs4759453	chr12:130824565	C/G	cg26677194	chr12:130822605	PIWIL1	0.61	7.48	0.42	1.12e-12	Menopause (age at onset);
CESC	trans	rs877282	0.755	rs2790388	chr10:786084	T/C	cg22713356	chr15:30763199	NA	1.09	11.81	0.59	3.82e-26	Uric acid levels;
CESC	cis	rs2228479	0.850	rs17233497	chr16:89815152	G/A	cg00800038	chr16:89945340	TCF25	-0.93	-6.34	-0.36	9.69e-10	Skin colour saturation;
CESC	cis	rs875971	0.545	rs2173571	chr7:65770379	G/A	cg25405998	chr7:65216604	CCT6P1	0.51	5.71	0.33	2.95e-8	Aortic root size;
CESC	cis	rs9381040	0.655	rs6903444	chr6:41014220	C/T	cg04346459	chr6:41068666	NFYA;LOC221442	0.4	5.54	0.32	7.36e-8	Alzheimer's disease (late onset);
CESC	cis	rs7208859	0.673	rs216424	chr17:28943064	T/G	cg04154034	chr17:28927549	LRRC37B2	0.72	6.35	0.36	9.3e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs1538970	0.962	rs9429075	chr1:45818421	G/A	cg05343316	chr1:45956843	TESK2	0.82	11.17	0.57	5.6e-24	Platelet count;
CESC	cis	rs73019876	0.869	rs2359815	chr19:22187760	C/A	cg11619707	chr19:22235551	ZNF257	-0.28	-5.03	-0.3	8.97e-7	Testicular germ cell tumor;
CESC	cis	rs8058578	0.943	rs35629860	chr16:30671532	G/A	cg02466173	chr16:30829666	NA	-0.48	-7.34	-0.41	2.56e-12	Multiple myeloma;
CESC	cis	rs1552244	1.000	rs17032268	chr3:10067972	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-10.95	-0.56	2.82e-23	Alzheimer's disease;
CESC	cis	rs2842992	0.724	rs2273823	chr6:160211485	T/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.85	12.01	0.59	8.38e-27	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs6967414	0.579	rs11980762	chr7:6756878	G/A	cg00387323	chr7:6746715	ZNF12	0.61	5.77	0.33	2.21e-8	Hematocrit;Hemoglobin concentration;
CESC	cis	rs637571	0.522	rs556643	chr11:65733289	C/T	cg04055107	chr11:65626734	MUS81;CFL1	0.43	5.29	0.31	2.61e-7	Eosinophil percentage of white cells;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg03664139	chr6:101329504	ASCC3	-0.46	-6.07	-0.35	4.35e-9	Height;
CESC	cis	rs10256972	0.685	rs10263665	chr7:1110628	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.4	-5.58	-0.32	5.92e-8	Longevity;Endometriosis;
CESC	cis	rs727563	0.638	rs4820443	chr22:42193913	A/G	cg06634786	chr22:41940651	POLR3H	-0.67	-6.89	-0.39	4e-11	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs78889164	0.876	rs3786893	chr19:33880000	C/G	cg02272751	chr19:33882848	PEPD	-0.54	-7.8	-0.43	1.39e-13	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs11630290	0.592	rs11071769	chr15:64156842	G/C	cg12036633	chr15:63758958	NA	0.45	5.45	0.32	1.14e-7	Iris characteristics;
CESC	cis	rs6502050	0.835	rs35131307	chr17:80128439	G/A	cg23985595	chr17:80112537	CCDC57	-0.41	-6.57	-0.37	2.61e-10	Life satisfaction;
CESC	cis	rs9611565	0.592	rs9611613	chr22:41961831	T/C	cg06634786	chr22:41940651	POLR3H	-0.62	-6.87	-0.39	4.56e-11	Vitiligo;
CESC	cis	rs9926296	0.533	rs9938865	chr16:89867797	A/G	cg03388025	chr16:89894329	SPIRE2	0.4	7.64	0.42	4.09e-13	Vitiligo;
CESC	trans	rs11098499	0.675	rs11098534	chr4:120556772	T/G	cg25214090	chr10:38739885	LOC399744	0.62	8.7	0.47	3.52e-16	Corneal astigmatism;
CESC	cis	rs67478160	0.655	rs4900598	chr14:104281541	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.51	-7.08	-0.4	1.33e-11	Schizophrenia;
CESC	cis	rs11098499	0.954	rs6820115	chr4:120398182	T/C	cg09307838	chr4:120376055	NA	0.87	12.39	0.61	4.17e-28	Corneal astigmatism;
CESC	cis	rs1707322	1.000	rs785480	chr1:46492164	C/G	cg05343316	chr1:45956843	TESK2	0.44	5.44	0.32	1.22e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7772486	0.686	rs9497380	chr6:145955305	T/C	cg05347473	chr6:146136440	FBXO30	0.53	6.89	0.39	3.99e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9549367	0.712	rs2316443	chr13:113864837	G/A	cg18105134	chr13:113819100	PROZ	-0.7	-9.09	-0.49	2.37e-17	Platelet distribution width;
CESC	cis	rs1143633	0.530	rs2723163	chr2:113694339	A/G	cg12858261	chr2:113808755	IL1F8	0.46	5.53	0.32	7.77e-8	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs113835537	0.529	rs17496250	chr11:66270774	C/G	cg24851651	chr11:66362959	CCS	0.48	5.75	0.33	2.42e-8	Airway imaging phenotypes;
CESC	cis	rs875971	0.789	rs7808013	chr7:66071196	A/G	cg12463550	chr7:65579703	CRCP	-0.53	-6.77	-0.38	8.05e-11	Aortic root size;
CESC	cis	rs9322193	0.887	rs9767113	chr6:150039293	T/C	cg07701084	chr6:150067640	NUP43	0.43	5.82	0.34	1.67e-8	Lung cancer;
CESC	cis	rs9896933	0.832	rs75552659	chr17:80804630	G/A	cg15369054	chr17:80825471	TBCD	0.48	5.06	0.3	8e-7	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
CESC	cis	rs8040855	0.603	rs10520585	chr15:85661506	C/G	cg08123816	chr15:85640762	PDE8A	0.37	5.12	0.3	5.93e-7	Bulimia nervosa;
CESC	cis	rs4409675	0.619	rs12070173	chr1:28231955	G/C	cg23691781	chr1:28212827	C1orf38	0.28	5.62	0.33	4.73e-8	Corneal astigmatism;
CESC	cis	rs761746	0.672	rs5753684	chr22:31939973	A/G	cg25791279	chr22:32026902	PISD	0.63	7.1	0.4	1.18e-11	Intelligence;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg20540327	chr15:72668275	HEXA;C15orf34	0.49	6.39	0.37	7.63e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs7107174	1.000	rs2450123	chr11:77952771	T/C	cg02023728	chr11:77925099	USP35	0.53	7.24	0.41	4.92e-12	Testicular germ cell tumor;
CESC	cis	rs6831352	0.918	rs2602896	chr4:100046207	C/T	cg12011299	chr4:100065546	ADH4	-0.6	-6.82	-0.39	6.28e-11	Alcohol dependence;
CESC	cis	rs2933343	0.679	rs789229	chr3:128602526	C/T	cg24203234	chr3:128598194	ACAD9	0.43	5.79	0.34	1.97e-8	IgG glycosylation;
CESC	cis	rs2836974	0.674	rs1011413	chr21:40638241	A/G	cg11890956	chr21:40555474	PSMG1	-0.98	-15.95	-0.7	1.36e-40	Cognitive function;
CESC	cis	rs9388451	0.513	rs1268069	chr6:126039994	A/C	cg05901451	chr6:126070800	HEY2	-0.55	-8.1	-0.45	2.05e-14	Brugada syndrome;
CESC	cis	rs11098499	0.866	rs9995136	chr4:120286845	A/G	cg09307838	chr4:120376055	NA	0.87	12.16	0.6	2.41e-27	Corneal astigmatism;
CESC	cis	rs9303401	0.659	rs16943326	chr17:57050365	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.98	12.47	0.61	2.09e-28	Cognitive test performance;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg01246405	chr11:3876562	STIM1	-0.42	-6.17	-0.35	2.53e-9	Gambling;
CESC	cis	rs7044106	0.708	rs959558	chr9:123368911	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.8	12.27	0.6	1.07e-27	Hip circumference adjusted for BMI;
CESC	cis	rs7122539	0.734	rs4930391	chr11:66645254	A/G	cg24851651	chr11:66362959	CCS	-0.46	-6.61	-0.38	2.05e-10	HIV-1 susceptibility;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg26355472	chr1:47134199	ATPAF1	0.48	6.3	0.36	1.21e-9	Systemic lupus erythematosus;
CESC	cis	rs3859192	0.599	rs34933056	chr17:38162983	G/A	cg17344932	chr17:38183730	MED24;SNORD124	0.61	9.08	0.49	2.59e-17	White blood cell count;
CESC	cis	rs17362650	1.000	rs1056204	chr2:9647091	A/C	cg12832956	chr2:9616023	IAH1	-0.52	-5.09	-0.3	6.69e-7	Alcohol dependence (age at onset);
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg07568437	chr12:123942694	SNRNP35	0.56	7.6	0.42	5.19e-13	Systemic lupus erythematosus;
CESC	cis	rs933688	1.000	rs1964292	chr5:90743608	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.15	13.7	0.64	1.17e-32	Smoking behavior;
CESC	cis	rs9287719	0.601	rs6751436	chr2:10723862	C/T	cg00105475	chr2:10696890	NA	0.39	5.27	0.31	2.83e-7	Prostate cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23222197	chr11:64578325	MEN1	0.52	6.28	0.36	1.37e-9	Gut microbiome composition (summer);
CESC	cis	rs3747547	0.642	rs72726060	chr9:38082767	A/T	cg13774184	chr9:37916125	SHB	-0.63	-5.43	-0.32	1.25e-7	Metabolite levels (Dihydroxy docosatrienoic acid);
CESC	cis	rs1018836	0.668	rs9297857	chr8:91480964	A/C	cg16814680	chr8:91681699	NA	-0.62	-8.42	-0.46	2.37e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs12136530	0.774	rs2014772	chr1:19781247	C/T	cg01832549	chr1:19774989	CAPZB	-0.49	-6.71	-0.38	1.18e-10	Lead levels in blood;
CESC	cis	rs12579753	0.879	rs12829053	chr12:82161926	T/A	cg23701643	chr12:82153290	PPFIA2	-0.36	-5.1	-0.3	6.61e-7	Resting heart rate;
CESC	cis	rs3820928	0.874	rs13403281	chr2:227880769	G/A	cg05526886	chr2:227700861	RHBDD1	-0.41	-5.18	-0.3	4.49e-7	Pulmonary function;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06755612	chr14:45603778	FKBP3;FANCM	0.54	6.5	0.37	3.94e-10	Gut microbiome composition (summer);
CESC	trans	rs9329221	0.620	rs6601427	chr8:10156025	A/G	cg06636001	chr8:8085503	FLJ10661	-0.49	-6.2	-0.36	2.2e-9	Neuroticism;
CESC	cis	rs3617	0.625	rs2245647	chr3:52862753	A/G	cg07507251	chr3:52567010	NT5DC2	0.32	5.54	0.32	7.14e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg18803079	chr1:64014643	EFCAB7;DLEU2L	0.49	6.56	0.37	2.83e-10	Fibrinogen levels;
CESC	trans	rs6794880	0.778	rs12630839	chr3:84436203	A/G	cg03554283	chr8:76319451	NA	-0.56	-5.99	-0.35	6.66e-9	Body mass index (joint analysis main effects and smoking interaction);BMI in non-smokers;BMI (adjusted for smoking behaviour);
CESC	trans	rs10242455	0.702	rs73397499	chr7:99039627	T/C	cg09045935	chr12:6379348	NA	0.91	7.16	0.4	7.89e-12	Blood metabolite levels;
CESC	cis	rs6089829	0.925	rs11086152	chr20:61664656	T/C	cg16240275	chr20:61666158	NCRNA00029	0.5	8.97	0.48	5.67e-17	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs8067354	0.830	rs57510610	chr17:57889406	T/A	cg13753209	chr17:57696993	CLTC	0.5	6.83	0.39	5.83e-11	Hemoglobin concentration;
CESC	cis	rs3733585	0.673	rs4459990	chr4:9954005	T/C	cg00071950	chr4:10020882	SLC2A9	-0.69	-11.34	-0.57	1.42e-24	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs3096299	0.869	rs748941	chr16:89440754	T/A	cg16743903	chr16:89593216	SPG7	-0.44	-5.6	-0.33	5.49e-8	Multiple myeloma (IgH translocation);
CESC	cis	rs7666738	0.830	rs28687737	chr4:99009226	G/A	cg18180107	chr4:99064573	C4orf37	0.4	5.3	0.31	2.48e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2228479	0.850	rs117285117	chr16:89910250	T/G	cg00800038	chr16:89945340	TCF25	-0.89	-6.89	-0.39	4.13e-11	Skin colour saturation;
CESC	cis	rs17376456	0.825	rs10053405	chr5:93275403	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.68	-5.43	-0.32	1.31e-7	Diabetic retinopathy;
CESC	cis	rs2273669	0.667	rs12202145	chr6:109357829	A/G	cg05315195	chr6:109294784	ARMC2	-0.67	-6.32	-0.36	1.13e-9	Prostate cancer;
CESC	cis	rs7666738	0.830	rs2903150	chr4:99027184	T/C	cg05340658	chr4:99064831	C4orf37	0.83	13.1	0.63	1.43e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9611565	0.694	rs7285041	chr22:41829149	G/T	cg03806693	chr22:41940476	POLR3H	1.2	14.53	0.67	1.4e-35	Vitiligo;
CESC	cis	rs2066819	1.000	rs17118439	chr12:56667604	C/T	cg26734620	chr12:56694298	CS	-0.92	-5.79	-0.34	2.01e-8	Psoriasis vulgaris;
CESC	cis	rs4862750	0.872	rs4862747	chr4:187877236	A/T	cg11301795	chr4:187892539	NA	0.74	11.89	0.59	2.03e-26	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs12410462	0.681	rs6681096	chr1:227609720	G/A	cg04117972	chr1:227635322	NA	0.8	6.95	0.39	2.81e-11	Major depressive disorder;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg00882685	chr2:232528498	NA	-0.44	-6.44	-0.37	5.47e-10	Asthma;
CESC	cis	rs3008870	1.000	rs12137403	chr1:67437043	C/T	cg02640540	chr1:67518911	SLC35D1	-0.5	-5.49	-0.32	9.53e-8	Lymphocyte percentage of white cells;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg27343303	chr11:34380546	NA	0.49	6.48	0.37	4.35e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs16917546	0.935	rs10995271	chr10:64438486	G/C	cg03961010	chr10:64397487	ZNF365	-0.35	-5.75	-0.33	2.43e-8	Basal cell carcinoma;
CESC	cis	rs6783573	0.535	rs6442006	chr3:46629382	C/G	cg21489266	chr3:46619131	LRRC2;TDGF1	-0.44	-6.08	-0.35	4.23e-9	Cerebrospinal fluid biomarker levels;
CESC	cis	rs754466	0.561	rs11002343	chr10:79705871	G/A	cg17075019	chr10:79541650	NA	-0.68	-6.31	-0.36	1.16e-9	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs17253792	0.822	rs112418863	chr14:56114079	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.8	5.65	0.33	4.2e-8	Putamen volume;
CESC	cis	rs425277	0.917	rs262656	chr1:2088754	A/C	cg24578937	chr1:2090814	PRKCZ	0.55	9.53	0.51	1.09e-18	Height;
CESC	cis	rs873946	0.648	rs12771651	chr10:134554482	C/A	cg26818010	chr10:134567672	INPP5A	-0.91	-11.23	-0.57	3.39e-24	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs873946	0.586	rs12783078	chr10:134569706	C/T	cg26818010	chr10:134567672	INPP5A	-0.94	-11.42	-0.57	7.99e-25	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs6089584	1.000	rs6089580	chr20:60558976	G/A	cg24733560	chr20:60626293	TAF4	0.4	5.77	0.33	2.15e-8	Body mass index;
CESC	cis	rs9790314	1.000	rs9872514	chr3:161042833	T/C	cg03342759	chr3:160939853	NMD3	-0.53	-7.22	-0.41	5.58e-12	Morning vs. evening chronotype;
CESC	cis	rs7772486	0.743	rs1292339	chr6:145967086	C/T	cg23711669	chr6:146136114	FBXO30	-0.81	-11.85	-0.59	2.91e-26	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9595066	1.000	rs9595066	chr13:44706268	C/T	cg04068111	chr13:44716778	NA	-0.44	-6.5	-0.37	4.04e-10	Schizophrenia;
CESC	cis	rs11626933	0.851	rs2282031	chr14:90730943	A/G	cg14092571	chr14:90743983	NA	-0.78	-12.16	-0.6	2.4e-27	Gut microbiota (bacterial taxa);
CESC	cis	rs6087990	0.871	rs2424905	chr20:31352927	T/C	cg13636640	chr20:31349939	DNMT3B	0.85	14.86	0.67	9.36e-37	Ulcerative colitis;
CESC	cis	rs6540559	0.605	rs3753518	chr1:209977964	G/C	cg23283495	chr1:209979779	IRF6	0.54	6.32	0.36	1.1e-9	Cleft lip with or without cleft palate;
CESC	cis	rs6502050	0.805	rs7406137	chr17:80084465	T/C	cg01763666	chr17:80159506	CCDC57	0.36	5.05	0.3	8.07e-7	Life satisfaction;
CESC	cis	rs11685299	1	rs11685299	chr2:225391296	C/A	cg12698349	chr2:225449008	CUL3	0.76	11.0	0.56	1.91e-23	Schizophrenia;
CESC	cis	rs3096299	0.967	rs2911253	chr16:89488587	T/G	cg02034447	chr16:89574710	SPG7	0.41	5.22	0.31	3.58e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs9443189	0.570	rs9343316	chr6:76411800	G/A	cg01950844	chr6:76311363	SENP6	0.88	9.29	0.5	6.05e-18	Prostate cancer;
CESC	cis	rs7395581	0.797	rs10742801	chr11:47342220	A/C	cg25783544	chr11:47291846	MADD	0.59	7.69	0.43	2.88e-13	HDL cholesterol;
CESC	cis	rs1348850	0.914	rs2121430	chr2:178318375	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.69	9.48	0.5	1.48e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs11249608	0.548	rs11960161	chr5:178453837	A/G	cg21905437	chr5:178450457	ZNF879	0.6	8.72	0.47	3.05e-16	Pubertal anthropometrics;
CESC	cis	rs17253792	0.822	rs10139905	chr14:56170031	T/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.69	5.94	0.34	8.99e-9	Putamen volume;
CESC	cis	rs916888	0.773	rs199443	chr17:44819565	C/T	cg27589368	chr17:43923255	LOC100128977;IMP5	-0.39	-5.49	-0.32	9.47e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs13040088	1.000	rs12480117	chr20:61558274	G/A	cg23096297	chr20:61557774	DIDO1	1.03	11.02	0.56	1.75e-23	Menopause (age at onset);
CESC	cis	rs2836974	0.897	rs34035316	chr21:40594023	T/C	cg27266027	chr21:40555129	PSMG1	0.46	5.43	0.32	1.25e-7	Cognitive function;
CESC	cis	rs6430585	0.697	rs1050115	chr2:136511817	A/G	cg07169764	chr2:136633963	MCM6	1.27	16.86	0.72	7.59e-44	Corneal structure;
CESC	cis	rs2295359	0.724	rs10489630	chr1:67662622	G/T	cg03340356	chr1:67600835	NA	-0.3	-5.03	-0.3	9.23e-7	Psoriasis;
CESC	cis	rs3820928	0.874	rs10202239	chr2:227901819	C/T	cg11843606	chr2:227700838	RHBDD1	-0.5	-6.54	-0.37	3.09e-10	Pulmonary function;
CESC	cis	rs1799949	1.000	rs8176233	chr17:41219804	T/C	cg25072359	chr17:41440525	NA	0.45	6.07	0.35	4.5e-9	Menopause (age at onset);
CESC	cis	rs116095464	0.558	rs57335027	chr5:262907	A/G	cg22857025	chr5:266934	NA	-1.3	-18.55	-0.75	8.05e-50	Breast cancer;
CESC	cis	rs2404602	0.716	rs12437627	chr15:76845050	T/C	cg22467129	chr15:76604101	ETFA	-0.39	-5.86	-0.34	1.39e-8	Blood metabolite levels;
CESC	cis	rs8114671	0.527	rs2295352	chr20:33320055	C/G	cg24642439	chr20:33292090	TP53INP2	-0.44	-5.2	-0.3	3.99e-7	Height;
CESC	cis	rs6964587	1.000	rs7802668	chr7:91648939	A/G	cg17063962	chr7:91808500	NA	0.58	8.02	0.44	3.36e-14	Breast cancer;
CESC	cis	rs4790333	0.967	rs2002863	chr17:2269769	C/T	cg02569219	chr17:2266849	SGSM2	0.45	5.54	0.32	7.19e-8	Proinsulin levels;
CESC	cis	rs7095944	0.614	rs3824765	chr10:126433570	C/G	cg08799069	chr10:126477246	METTL10	-0.37	-5.29	-0.31	2.58e-7	Asthma;
CESC	trans	rs61931739	0.517	rs7958755	chr12:34294699	T/C	cg26384229	chr12:38710491	ALG10B	0.62	8.67	0.47	4.48e-16	Morning vs. evening chronotype;
CESC	cis	rs1008375	0.966	rs3796813	chr4:17591648	A/G	cg02297831	chr4:17616191	MED28	0.5	6.18	0.35	2.4e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs79349575	0.783	rs4793991	chr17:47001801	A/G	cg26022315	chr17:47021804	SNF8	0.39	5.18	0.3	4.5e-7	Type 2 diabetes;
CESC	cis	rs939658	0.805	rs4778924	chr15:79443363	T/C	cg17916960	chr15:79447300	NA	-0.34	-5.74	-0.33	2.64e-8	Refractive error;
CESC	cis	rs1475911	1.000	rs2839465	chr21:43511232	C/T	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.36	-5.34	-0.31	1.95e-7	IgG glycosylation;
CESC	cis	rs6502050	0.835	rs8065556	chr17:80091176	G/C	cg11859384	chr17:80120422	CCDC57	-0.38	-5.14	-0.3	5.31e-7	Life satisfaction;
CESC	cis	rs10504229	0.773	rs60466370	chr8:58171248	A/C	cg05313129	chr8:58192883	C8orf71	-0.46	-5.73	-0.33	2.74e-8	Developmental language disorder (linguistic errors);
CESC	trans	rs7824557	0.510	rs4841524	chr8:11243126	C/G	cg15556689	chr8:8085844	FLJ10661	-0.5	-6.14	-0.35	2.95e-9	Retinal vascular caliber;
CESC	cis	rs6121246	0.738	rs2376996	chr20:30316667	T/A	cg13852791	chr20:30311386	BCL2L1	0.8	8.55	0.46	1.02e-15	Mean corpuscular hemoglobin;
CESC	cis	rs12887734	0.546	rs4900597	chr14:104266664	A/G	cg08213375	chr14:104286397	PPP1R13B	-0.41	-7.02	-0.4	1.87e-11	Schizophrenia;Autism spectrum disorder or schizophrenia;
CESC	cis	rs5760092	0.755	rs4585126	chr22:24270005	T/C	cg04234412	chr22:24373322	LOC391322	0.64	8.83	0.48	1.44e-16	Urinary 1,3-butadiene metabolite levels in smokers;
CESC	cis	rs9322193	0.736	rs3805750	chr6:150112201	G/A	cg05861140	chr6:150128134	PCMT1	-0.38	-5.52	-0.32	7.97e-8	Lung cancer;
CESC	cis	rs8114671	0.869	rs6060199	chr20:33654773	A/G	cg06115741	chr20:33292138	TP53INP2	-0.44	-5.31	-0.31	2.27e-7	Height;
CESC	cis	rs6540556	0.723	rs1415542	chr1:209902110	T/C	cg05527609	chr1:210001259	C1orf107	-0.66	-7.27	-0.41	3.94e-12	Red blood cell count;
CESC	trans	rs7628583	0.877	rs12494731	chr3:64082003	G/T	cg14419393	chr17:79953059	ASPSCR1	0.51	6.05	0.35	4.93e-9	Parental extreme longevity (95 years and older);
CESC	cis	rs1552244	0.572	rs6797536	chr3:10168802	C/T	cg00149659	chr3:10157352	C3orf10	-1.05	-12.46	-0.61	2.34e-28	Alzheimer's disease;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg22159483	chr17:1588198	PRPF8	-0.44	-6.36	-0.36	8.8e-10	Gambling;
CESC	cis	rs6933660	0.760	rs3806982	chr6:151774916	G/A	cg10883421	chr6:151773342	RMND1;C6orf211	0.83	13.29	0.63	3.04e-31	Menarche (age at onset);
CESC	cis	rs9309473	1.000	rs6753344	chr2:73653138	C/T	cg20560298	chr2:73613845	ALMS1	0.51	6.57	0.37	2.7e-10	Metabolite levels;
CESC	cis	rs514406	0.861	rs7513052	chr1:53241360	C/T	cg08859206	chr1:53392774	SCP2	0.6	8.96	0.48	5.76e-17	Monocyte count;
CESC	cis	rs7666738	0.753	rs4699604	chr4:99056353	T/C	cg03467027	chr4:99064603	C4orf37	0.48	6.01	0.35	5.95e-9	Colonoscopy-negative controls vs population controls;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg03066081	chr17:77784036	NA	-0.47	-6.38	-0.36	7.67e-10	Height;
CESC	cis	rs5769765	0.955	rs2319465	chr22:50265784	A/C	cg02269571	chr22:50332266	NA	0.46	6.28	0.36	1.39e-9	Schizophrenia;
CESC	cis	rs1878931	0.507	rs4429296	chr16:3408277	T/G	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.71	-8.82	-0.48	1.57e-16	Body mass index (adult);
CESC	cis	rs12079745	1.000	rs3766063	chr1:169154574	G/A	cg09363564	chr1:169337483	NME7;BLZF1	-0.71	-5.51	-0.32	8.29e-8	QT interval;
CESC	cis	rs28498503	0.573	rs59797828	chr18:76653107	C/T	cg00806245	chr18:76673096	NA	-0.68	-5.66	-0.33	3.98e-8	Attention function in attention deficit hyperactive disorder;
CESC	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg23708337	chr7:1209742	NA	0.52	5.11	0.3	6.12e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs9467711	0.524	rs13216484	chr6:26762087	C/T	cg01620082	chr3:125678407	NA	-0.74	-6.32	-0.36	1.11e-9	Autism spectrum disorder or schizophrenia;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg13355623	chr17:26898935	PIGS	0.48	6.45	0.37	5.23e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs6460942	0.841	rs17444203	chr7:12461864	C/G	cg13733410	chr7:12443478	VWDE	0.45	5.09	0.3	6.8e-7	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09559324	chr16:31475905	ARMC5	-0.59	-6.41	-0.37	6.77e-10	Gut microbiome composition (summer);
CESC	cis	rs644148	1.000	rs644148	chr19:44970935	T/G	cg15540054	chr19:45004280	ZNF180	-0.72	-8.77	-0.47	2.23e-16	Personality dimensions;
CESC	cis	rs514406	0.708	rs514881	chr1:53336737	A/G	cg25767906	chr1:53392781	SCP2	0.51	7.27	0.41	4.04e-12	Monocyte count;
CESC	cis	rs757110	0.770	rs1557765	chr11:17403639	T/C	cg15432903	chr11:17409602	KCNJ11	0.63	8.88	0.48	1.06e-16	Type 2 diabetes;
CESC	cis	rs7659604	0.605	rs2071486	chr4:122740162	C/T	cg20573242	chr4:122745356	CCNA2	0.75	10.17	0.53	1e-20	Type 2 diabetes;
CESC	cis	rs760805	1.000	rs3845302	chr1:25259884	C/G	cg22509179	chr1:25234806	RUNX3	-0.6	-8.55	-0.46	1.01e-15	Allergic disease (asthma, hay fever or eczema);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg07509094	chr11:60674167	PRPF19	-0.45	-6.45	-0.37	5.2e-10	Gambling;
CESC	cis	rs2000999	0.573	rs34139543	chr16:72158477	C/T	cg04254540	chr16:71951199	KIAA0174	-0.74	-6.16	-0.35	2.76e-9	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg08495027	chr22:31364830	MORC2;TUG1	0.48	6.2	0.36	2.15e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs6867032	0.527	rs9312971	chr5:2012888	C/A	cg26168224	chr5:2018326	NA	0.72	12.15	0.6	2.62e-27	Gut microbiome composition (winter);
CESC	cis	rs9733	0.596	rs6661872	chr1:150628357	C/G	cg04414720	chr1:150670196	GOLPH3L	0.63	9.04	0.49	3.47e-17	Tonsillectomy;
CESC	cis	rs9311474	0.508	rs7614498	chr3:52618941	A/T	cg07507251	chr3:52567010	NT5DC2	0.34	5.84	0.34	1.5e-8	Electroencephalogram traits;
CESC	cis	rs7811142	1.000	rs73161759	chr7:100009994	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.08	10.6	0.55	3.94e-22	Platelet count;
CESC	cis	rs6775745	0.654	rs10470437	chr3:131782733	A/T	cg12213930	chr3:131751605	CPNE4	0.45	5.19	0.3	4.22e-7	Neutrophil count;
CESC	trans	rs12310956	0.532	rs35366144	chr12:33992000	C/G	cg26384229	chr12:38710491	ALG10B	0.58	8.09	0.45	2.13e-14	Morning vs. evening chronotype;
CESC	cis	rs4665809	0.941	rs2289021	chr2:26362515	A/C	cg26314531	chr2:26401878	FAM59B	0.55	6.65	0.38	1.66e-10	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09998692	chr4:83934395	LIN54	0.59	6.51	0.37	3.64e-10	Gut microbiome composition (summer);
CESC	cis	rs875971	0.522	rs1880556	chr7:65432544	T/C	cg05332525	chr7:65337924	VKORC1L1	0.47	5.56	0.32	6.64e-8	Aortic root size;
CESC	cis	rs1018836	0.798	rs4735295	chr8:91671608	C/A	cg16814680	chr8:91681699	NA	-0.89	-13.93	-0.65	1.85e-33	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs875971	0.862	rs10240949	chr7:65804417	A/G	cg10691866	chr7:65817282	TPST1	0.31	5.23	0.31	3.43e-7	Aortic root size;
CESC	cis	rs2299587	0.554	rs2073566	chr8:17743655	G/A	cg08627089	chr8:17753878	FGL1	-0.4	-5.76	-0.33	2.37e-8	Economic and political preferences;
CESC	cis	rs67311347	0.955	rs6599100	chr3:40447362	C/T	cg01475735	chr3:40494733	NA	-0.42	-5.34	-0.31	2e-7	Renal cell carcinoma;
CESC	cis	rs4713118	0.513	rs149950	chr6:28033039	T/G	cg23161317	chr6:28129485	ZNF389	0.38	5.35	0.31	1.92e-7	Parkinson's disease;
CESC	cis	rs7264396	0.616	rs6142476	chr20:34581216	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.49	5.77	0.33	2.21e-8	Total cholesterol levels;
CESC	cis	rs1570884	0.516	rs9535268	chr13:50175478	C/A	cg08779649	chr13:50194554	NA	0.39	6.71	0.38	1.17e-10	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
CESC	cis	rs7542091	0.669	rs7540534	chr1:210044824	A/T	cg21951975	chr1:209979733	IRF6	0.47	8.25	0.45	7.51e-15	Monobrow;
CESC	cis	rs4843747	0.709	rs72818521	chr16:88058751	C/G	cg17633681	chr16:88106987	BANP	0.7	8.57	0.47	8.97e-16	Menopause (age at onset);
CESC	cis	rs12474201	0.925	rs1058157	chr2:46988275	G/A	cg06386533	chr2:46925753	SOCS5	0.88	12.19	0.6	1.92e-27	Height;
CESC	cis	rs9311474	0.659	rs7638808	chr3:52572056	C/T	cg07507251	chr3:52567010	NT5DC2	-0.33	-6.13	-0.35	3.22e-9	Electroencephalogram traits;
CESC	cis	rs7914558	0.966	rs746293	chr10:104897254	G/T	cg04362960	chr10:104952993	NT5C2	0.46	5.92	0.34	9.98e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs2576037	0.583	rs9916891	chr18:44493521	C/T	cg19077165	chr18:44547161	KATNAL2	-0.6	-8.97	-0.48	5.73e-17	Personality dimensions;
CESC	cis	rs425277	0.606	rs2503705	chr1:2076741	A/G	cg12718519	chr1:2058417	PRKCZ	0.26	5.59	0.32	5.64e-8	Height;
CESC	cis	rs3096299	0.658	rs4785679	chr16:89566113	G/T	cg00750074	chr16:89608354	SPG7	-0.45	-6.49	-0.37	4.19e-10	Multiple myeloma (IgH translocation);
CESC	cis	rs71277158	0.688	rs7651554	chr3:169768485	C/G	cg04067573	chr3:169899625	PHC3	0.51	5.29	0.31	2.51e-7	Prostate cancer;
CESC	trans	rs4349753	0.640	rs28509278	chr5:144088800	C/T	cg25299750	chr6:35109124	TCP11	0.49	6.04	0.35	5.06e-9	Photic sneeze reflex;
CESC	cis	rs4803468	0.763	rs17318596	chr19:41937095	A/G	cg14132834	chr19:41945861	ATP5SL	-0.65	-7.89	-0.44	7.72e-14	Height;
CESC	cis	rs7618915	0.547	rs3774365	chr3:52642487	T/C	cg18404041	chr3:52824283	ITIH1	-0.39	-6.53	-0.37	3.4e-10	Bipolar disorder;
CESC	cis	rs4728302	0.869	rs6955240	chr7:133581873	G/A	cg10665199	chr7:133106180	EXOC4	0.4	5.51	0.32	8.66e-8	Intelligence;Intelligence (multi-trait analysis);
CESC	cis	rs910316	1.000	rs175426	chr14:75624134	C/T	cg16144293	chr14:75469539	EIF2B2	0.39	5.19	0.3	4.09e-7	Height;
CESC	cis	rs11583043	0.708	rs12754497	chr1:101571888	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.49	-5.35	-0.31	1.86e-7	Ulcerative colitis;Inflammatory bowel disease;
CESC	cis	rs734999	0.588	rs10910099	chr1:2533552	G/T	cg18854424	chr1:2615690	NA	-0.28	-5.41	-0.32	1.44e-7	Ulcerative colitis;
CESC	cis	rs546131	0.928	rs558967	chr11:34827168	T/A	cg06937548	chr11:34938143	PDHX;APIP	0.49	6.24	0.36	1.7e-9	Lung disease severity in cystic fibrosis;
CESC	cis	rs7811142	0.830	rs10085549	chr7:99983135	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.11	13.27	0.63	3.72e-31	Platelet count;
CESC	cis	rs7772486	0.790	rs9403756	chr6:146257761	C/G	cg05347473	chr6:146136440	FBXO30	-0.52	-6.64	-0.38	1.75e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9894429	0.572	rs112417725	chr17:79578219	A/G	cg21984481	chr17:79567631	NPLOC4	0.35	5.52	0.32	8.09e-8	Eye color traits;
CESC	cis	rs76525880	0.538	rs9221	chr17:46675813	C/T	cg06593406	chr17:46696139	NA	-0.65	-6.16	-0.35	2.76e-9	Colorectal or endometrial cancer;
CESC	cis	rs2242116	0.796	rs9852082	chr3:46972377	T/C	cg27129171	chr3:47204927	SETD2	0.54	6.87	0.39	4.7e-11	Birth weight;
CESC	cis	rs7618915	0.571	rs7623199	chr3:52605974	C/T	cg17372223	chr3:52568218	NT5DC2	0.43	6.36	0.36	9.03e-10	Bipolar disorder;
CESC	cis	rs17666538	0.535	rs1669658	chr8:607380	A/G	cg07234876	chr8:600039	NA	0.84	6.25	0.36	1.62e-9	IgG glycosylation;
CESC	cis	rs1048238	0.506	rs848195	chr1:16286522	A/G	cg22431228	chr1:16359049	CLCNKA	0.36	6.39	0.37	7.32e-10	Systolic blood pressure;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg14212983	chr1:21985742	RAP1GAP	-0.49	-6.62	-0.38	1.99e-10	Ulcerative colitis;
CESC	cis	rs2842992	0.789	rs9364536	chr6:160225559	G/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.77	9.45	0.5	1.84e-18	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs637571	0.607	rs574586	chr11:65697083	G/A	cg04055107	chr11:65626734	MUS81;CFL1	0.47	5.72	0.33	2.83e-8	Eosinophil percentage of white cells;
CESC	cis	rs1862618	0.529	rs978406	chr5:56259808	A/T	cg22800045	chr5:56110881	MAP3K1	-0.67	-7.89	-0.44	8.06e-14	Initial pursuit acceleration;
CESC	cis	rs763014	0.966	rs7198877	chr16:661439	A/G	cg00908189	chr16:619842	PIGQ	0.62	8.6	0.47	6.86e-16	Height;
CESC	cis	rs9443189	0.763	rs2647411	chr6:76433692	C/T	cg01950844	chr6:76311363	SENP6	-0.64	-7.1	-0.4	1.14e-11	Prostate cancer;
CESC	cis	rs77741769	0.571	rs12371178	chr12:121309129	T/C	cg02419362	chr12:121203948	SPPL3	0.34	5.59	0.32	5.6e-8	Mean corpuscular volume;
CESC	cis	rs17125944	0.505	rs80211268	chr14:53265483	C/G	cg00686598	chr14:53173677	PSMC6	1.41	11.85	0.59	2.77e-26	Alzheimer's disease (late onset);
CESC	cis	rs6860806	0.661	rs6890009	chr5:131580033	G/T	cg11843238	chr5:131593191	PDLIM4	0.36	5.11	0.3	6.06e-7	Breast cancer;
CESC	cis	rs4253772	0.591	rs12167567	chr22:46659942	G/C	cg09491104	chr22:46646882	C22orf40	-0.57	-8.72	-0.47	3.18e-16	LDL cholesterol;Cholesterol, total;
CESC	cis	rs7829975	0.714	rs7823757	chr8:8670177	T/A	cg17143192	chr8:8559678	CLDN23	0.42	5.24	0.31	3.28e-7	Mood instability;
CESC	cis	rs4563143	0.675	rs55884228	chr19:29243897	G/T	cg04546413	chr19:29218101	NA	0.56	7.91	0.44	6.84e-14	Methadone dose in opioid dependence;
CESC	cis	rs2243480	1.000	rs1723270	chr7:65469830	T/G	cg18252515	chr7:66147081	NA	-1.21	-11.82	-0.59	3.44e-26	Diabetic kidney disease;
CESC	cis	rs9905704	0.918	rs302880	chr17:56761411	C/T	cg12560992	chr17:57184187	TRIM37	0.59	7.04	0.4	1.67e-11	Testicular germ cell tumor;
CESC	cis	rs9911578	1.000	rs9904879	chr17:56864422	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.24	0.31	3.23e-7	Intelligence (multi-trait analysis);
CESC	trans	rs7618501	1.000	rs4855867	chr3:49745822	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.58	-8.44	-0.46	2.11e-15	Intelligence (multi-trait analysis);
CESC	cis	rs2463822	0.583	rs7129536	chr11:62030829	C/T	cg06239285	chr11:62104954	ASRGL1	-1.03	-8.31	-0.45	5.01e-15	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs9787249	0.957	rs12086750	chr1:40210468	G/C	cg02773041	chr1:40204384	PPIE	0.54	7.68	0.43	3.02e-13	Blood protein levels;
CESC	trans	rs9325144	0.625	rs12227353	chr12:38734542	C/T	cg23762105	chr12:34175262	ALG10	0.48	6.23	0.36	1.81e-9	Morning vs. evening chronotype;
CESC	cis	rs2996428	0.561	rs2275827	chr1:3746585	T/G	cg10555106	chr1:3691387	LOC388588	0.37	5.4	0.31	1.46e-7	Red cell distribution width;
CESC	cis	rs3780486	0.846	rs10758192	chr9:33131651	G/A	cg13443165	chr9:33130375	B4GALT1	0.45	6.46	0.37	5e-10	IgG glycosylation;
CESC	cis	rs9399135	0.935	rs987690	chr6:135350379	A/G	cg24558204	chr6:135376177	HBS1L	0.52	7.29	0.41	3.48e-12	Red blood cell count;
CESC	cis	rs9303401	0.632	rs7222087	chr17:57221619	A/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.55	7.27	0.41	4.06e-12	Cognitive test performance;
CESC	cis	rs3008870	1.000	rs3008859	chr1:67390999	G/C	cg08660285	chr1:67390436	MIER1;WDR78	1.06	15.03	0.68	2.49e-37	Lymphocyte percentage of white cells;
CESC	cis	rs1670533	1.000	rs10003009	chr4:1050849	G/A	cg27284194	chr4:1044797	NA	0.44	5.49	0.32	9.49e-8	Recombination rate (females);
CESC	cis	rs7937682	0.883	rs566647	chr11:111466607	A/G	cg09085632	chr11:111637200	PPP2R1B	0.9	11.89	0.59	2.01e-26	Primary sclerosing cholangitis;
CESC	cis	rs514406	0.621	rs928452	chr1:53195926	G/C	cg24675658	chr1:53192096	ZYG11B	0.64	7.96	0.44	5.13e-14	Monocyte count;
CESC	cis	rs9916302	0.861	rs644173	chr17:37430519	T/C	cg19468946	chr17:37922297	IKZF3	-0.39	-5.09	-0.3	6.82e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs7680126	0.500	rs4697717	chr4:10149784	C/G	cg11266682	chr4:10021025	SLC2A9	-0.5	-6.36	-0.36	8.85e-10	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	cis	rs12701220	0.655	rs12702117	chr7:1148702	T/C	cg23978390	chr7:1156363	C7orf50	0.57	5.91	0.34	1.04e-8	Bronchopulmonary dysplasia;
CESC	cis	rs7666738	0.830	rs6839277	chr4:99015563	C/T	cg05340658	chr4:99064831	C4orf37	0.8	12.51	0.61	1.52e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6547741	0.935	rs4665384	chr2:27848397	A/G	cg27432699	chr2:27873401	GPN1	0.49	6.77	0.38	8.27e-11	Oral cavity cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00090103	chr1:155920763	ARHGEF2	-0.56	-6.2	-0.36	2.19e-9	Gut microbiome composition (summer);
CESC	cis	rs1552244	0.882	rs68153882	chr3:10013110	T/C	cg00149659	chr3:10157352	C3orf10	0.7	8.25	0.45	7.27e-15	Alzheimer's disease;
CESC	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.89	13.48	0.64	7.04e-32	Prudent dietary pattern;
CESC	cis	rs7507204	0.767	rs12982509	chr19:3412057	C/T	cg08380311	chr19:3435252	NFIC	-0.6	-6.69	-0.38	1.33e-10	Height;
CESC	cis	rs4073221	0.520	rs13065273	chr3:18194852	T/C	cg07694806	chr3:18168406	NA	-0.69	-5.62	-0.33	4.77e-8	Parkinson's disease;
CESC	cis	rs1878931	0.535	rs55732163	chr16:3411518	A/C	cg02880119	chr16:3481970	NA	0.43	5.47	0.32	1.06e-7	Body mass index (adult);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg18764291	chr5:122110994	SNX2	-0.46	-6.23	-0.36	1.87e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs2074585	0.708	rs2601190	chr15:90932966	A/C	cg10434728	chr15:90938212	IQGAP1	0.44	8.25	0.45	7.51e-15	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
CESC	cis	rs11122272	0.667	rs2244992	chr1:231537220	T/C	cg06096015	chr1:231504339	EGLN1	0.42	6.07	0.35	4.33e-9	Hemoglobin concentration;
CESC	cis	rs2455799	0.594	rs11928773	chr3:15925135	A/G	cg16303742	chr3:15540471	COLQ	-0.37	-5.73	-0.33	2.7e-8	Mean platelet volume;
CESC	cis	rs6570726	0.791	rs621382	chr6:145799144	T/C	cg05347473	chr6:146136440	FBXO30	0.57	7.34	0.41	2.59e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2439831	0.717	rs2470132	chr15:43835481	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.8	8.65	0.47	5.16e-16	Lung cancer in ever smokers;
CESC	cis	rs72781680	0.582	rs72783611	chr2:24291445	C/T	cg06627628	chr2:24431161	ITSN2	-0.67	-6.48	-0.37	4.54e-10	Lymphocyte counts;
CESC	cis	rs892961	0.899	rs66749226	chr17:75412826	G/A	cg05865280	chr17:75406074	SEPT9	0.62	12.43	0.61	2.89e-28	Airflow obstruction;
CESC	cis	rs2295499	0.660	rs11490068	chr4:2639106	A/C	cg08330972	chr4:2403930	ZFYVE28	-0.32	-5.23	-0.31	3.4e-7	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
CESC	cis	rs67311347	0.544	rs1902073	chr3:40333497	C/T	cg09455208	chr3:40491958	NA	0.35	6.27	0.36	1.43e-9	Renal cell carcinoma;
CESC	cis	rs2404602	0.735	rs11857015	chr15:76649390	T/C	cg00316803	chr15:76480434	C15orf27	0.38	5.24	0.31	3.27e-7	Blood metabolite levels;
CESC	cis	rs514406	0.861	rs11206026	chr1:53281708	G/A	cg16325326	chr1:53192061	ZYG11B	0.9	15.4	0.69	1.16e-38	Monocyte count;
CESC	cis	rs875971	0.666	rs13242072	chr7:65765988	A/G	cg18876405	chr7:65276391	NA	-0.65	-8.77	-0.47	2.18e-16	Aortic root size;
CESC	cis	rs644799	0.930	rs587123	chr11:95560539	T/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.56	6.8	0.39	6.73e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs9309711	0.689	rs4535075	chr2:3481716	T/C	cg15541040	chr2:3486749	NA	-0.43	-5.48	-0.32	1.01e-7	Neurofibrillary tangles;
CESC	cis	rs4862750	0.872	rs9997374	chr4:187877549	T/A	cg22105103	chr4:187893119	NA	0.47	6.73	0.38	1.07e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs62229266	0.804	rs2255858	chr21:37412752	T/C	cg12218747	chr21:37451666	NA	-0.41	-5.77	-0.33	2.15e-8	Mitral valve prolapse;
CESC	cis	rs344364	0.511	rs62040569	chr16:1948137	C/T	cg26617929	chr16:1858877	NA	-0.49	-5.15	-0.3	5.09e-7	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs13223928	0.592	rs4722439	chr7:3155858	C/T	cg19214707	chr7:3157722	NA	0.42	5.85	0.34	1.46e-8	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
CESC	cis	rs7208859	0.673	rs9895684	chr17:29242600	G/A	cg19761014	chr17:28927070	LRRC37B2	0.72	5.7	0.33	3.12e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs1008375	1.000	rs4698634	chr4:17630192	A/C	cg16339924	chr4:17578868	LAP3	-0.58	-7.53	-0.42	8.15e-13	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs73072330	1.000	rs17729010	chr3:47912703	A/G	cg09665691	chr3:47563885	NA	-0.8	-5.36	-0.31	1.79e-7	Stem cell growth factor beta levels;
CESC	cis	rs3106136	0.903	rs67552174	chr4:95203097	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.45	-6.72	-0.38	1.14e-10	Capecitabine sensitivity;
CESC	cis	rs9815354	1.000	rs56158380	chr3:41885588	G/A	cg03022575	chr3:42003672	ULK4	0.58	6.01	0.35	5.96e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs35306767	0.855	rs61830931	chr10:932497	T/C	cg26597838	chr10:835615	NA	1.16	11.37	0.57	1.12e-24	Eosinophil percentage of granulocytes;
CESC	cis	rs6547741	1.000	rs6706610	chr2:27778091	G/A	cg21248554	chr2:27665150	KRTCAP3	0.25	5.21	0.31	3.71e-7	Oral cavity cancer;
CESC	cis	rs3096299	0.719	rs2965945	chr16:89514017	T/C	cg02034447	chr16:89574710	SPG7	0.47	5.99	0.35	6.7e-9	Multiple myeloma (IgH translocation);
CESC	cis	rs9811920	0.809	rs4928151	chr3:99767553	A/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.45	-7.5	-0.42	9.66e-13	Axial length;
CESC	cis	rs1609391	0.543	rs9859810	chr3:136629986	A/G	cg15507776	chr3:136538369	TMEM22	0.81	11.89	0.59	2.08e-26	Neuroticism;
CESC	cis	rs9394159	0.583	rs6457738	chr6:33617464	C/T	cg14003231	chr6:33640908	ITPR3	-0.42	-7.68	-0.43	3.05e-13	Graves' disease;
CESC	cis	rs10779751	1.000	rs11121702	chr1:11293147	C/T	cg08854313	chr1:11322531	MTOR	0.79	10.67	0.55	2.4e-22	Body mass index;
CESC	cis	rs10504229	0.683	rs55637580	chr8:58135419	C/T	cg21724239	chr8:58056113	NA	0.58	5.95	0.34	8.29e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs4604732	0.631	rs11490200	chr1:247625915	G/T	cg12758973	chr1:247694275	LOC148824;OR2C3	0.51	6.36	0.36	8.65e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs11640734	0.619	rs2293586	chr16:89962394	A/G	cg00800038	chr16:89945340	TCF25	-0.6	-6.48	-0.37	4.48e-10	Interleukin-17 levels;
CESC	cis	rs8028182	0.636	rs12708519	chr15:75803200	T/C	cg20655648	chr15:75932815	IMP3	0.48	5.87	0.34	1.3e-8	Sudden cardiac arrest;
CESC	cis	rs3733585	0.638	rs17185835	chr4:9958180	T/G	cg11266682	chr4:10021025	SLC2A9	-0.6	-11.09	-0.56	1.01e-23	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs71277158	0.688	rs7631178	chr3:169766424	G/T	cg04067573	chr3:169899625	PHC3	-0.48	-5.06	-0.3	7.88e-7	Prostate cancer;
CESC	cis	rs644799	1.000	rs7749	chr11:95565789	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.69	8.73	0.47	2.87e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	trans	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg13565492	chr6:43139072	SRF	-0.7	-8.12	-0.45	1.8e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2033711	0.840	rs3764533	chr19:58929194	A/G	cg00825309	chr19:58991885	ZNF446	-0.58	-8.21	-0.45	9.46e-15	Uric acid clearance;
CESC	cis	rs7772486	0.686	rs9399564	chr6:146078907	C/T	cg23711669	chr6:146136114	FBXO30	-0.89	-13.4	-0.64	1.33e-31	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs3733585	0.673	rs6843873	chr4:9958788	A/C	cg11266682	chr4:10021025	SLC2A9	-0.6	-11.19	-0.57	4.73e-24	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs7259376	0.869	rs6511346	chr19:22537574	T/C	cg02657401	chr19:22469223	NA	-0.26	-5.08	-0.3	7.07e-7	Menopause (age at onset);
CESC	cis	rs7267979	0.966	rs2151144	chr20:25414924	G/C	cg08601574	chr20:25228251	PYGB	-0.36	-5.08	-0.3	7.02e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs6964587	1.000	rs10228334	chr7:91713972	C/T	cg17063962	chr7:91808500	NA	0.57	7.92	0.44	6.54e-14	Breast cancer;
CESC	cis	rs8016982	1.000	rs12147118	chr14:81652975	A/C	cg01989461	chr14:81687754	GTF2A1	-0.53	-6.84	-0.39	5.57e-11	Schizophrenia;
CESC	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg24642844	chr7:1081250	C7orf50	-0.75	-9.03	-0.49	3.61e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs9303401	0.659	rs12602389	chr17:56779778	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.03	12.82	0.62	1.31e-29	Cognitive test performance;
CESC	cis	rs769267	0.930	rs3752151	chr19:19616026	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.46	5.8	0.34	1.85e-8	Tonsillectomy;
CESC	cis	rs2228479	0.681	rs7196840	chr16:89959647	A/G	cg00800038	chr16:89945340	TCF25	-0.63	-7.0	-0.4	2.1e-11	Skin colour saturation;
CESC	cis	rs2243480	1.000	rs313831	chr7:65551226	C/T	cg12463550	chr7:65579703	CRCP	0.7	5.41	0.32	1.4e-7	Diabetic kidney disease;
CESC	cis	rs7615952	0.551	rs6438945	chr3:125634473	G/A	cg05084668	chr3:125655381	ALG1L	-0.49	-5.52	-0.32	8e-8	Blood pressure (smoking interaction);
CESC	cis	rs453301	0.686	rs3989373	chr8:8911308	G/T	cg15556689	chr8:8085844	FLJ10661	-0.48	-6.04	-0.35	5.13e-9	Joint mobility (Beighton score);
CESC	cis	rs2046867	0.818	rs17690720	chr3:72866030	T/C	cg25664220	chr3:72788482	NA	-0.45	-6.63	-0.38	1.85e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CESC	trans	rs7716219	0.731	rs7704138	chr5:54944262	C/T	cg16867680	chr6:47382645	NA	0.41	6.45	0.37	5.33e-10	Height;
CESC	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.63	7.27	0.41	4.09e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs60871478	1.000	rs6460801	chr7:810506	T/C	cg00475322	chr7:917719	C7orf20	-0.45	-5.05	-0.3	8.27e-7	Cerebrospinal P-tau181p levels;
CESC	trans	rs74054849	0.850	rs6674904	chr1:16013448	A/T	cg06826283	chr7:600452	PRKAR1B	0.7	6.25	0.36	1.66e-9	Alcoholic chronic pancreatitis;
CESC	cis	rs73206853	0.609	rs7306167	chr12:110892449	A/G	cg12870014	chr12:110450643	ANKRD13A	0.63	5.18	0.3	4.34e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs4077515	0.874	rs3812575	chr9:139293259	T/C	cg14169450	chr9:139327907	INPP5E	0.39	5.57	0.32	6.2e-8	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs11711311	0.955	rs11715350	chr3:113418376	G/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.6	7.82	0.43	1.22e-13	IgG glycosylation;
CESC	cis	rs6460942	0.730	rs7780477	chr7:12233750	G/C	cg06484146	chr7:12443880	VWDE	-0.47	-5.22	-0.31	3.54e-7	Coronary artery disease;
CESC	cis	rs1707322	1.000	rs785486	chr1:46575148	G/C	cg03146154	chr1:46216737	IPP	-0.69	-9.13	-0.49	1.84e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25263898	chr1:36774223	C1orf113	-0.66	-7.5	-0.42	9.68e-13	Gut microbiome composition (summer);
CESC	cis	rs12497850	0.931	rs7627404	chr3:48819668	A/C	cg02487422	chr3:49467188	NICN1	0.4	5.08	0.3	6.98e-7	Parkinson's disease;
CESC	cis	rs1577917	0.958	rs12213331	chr6:86504797	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.49	-6.45	-0.37	5.18e-10	Response to antipsychotic treatment;
CESC	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.61	7.94	0.44	5.84e-14	Prudent dietary pattern;
CESC	cis	rs938554	0.612	rs13113918	chr4:9998493	A/G	cg00071950	chr4:10020882	SLC2A9	0.62	7.37	0.41	2.23e-12	Blood metabolite levels;
CESC	cis	rs896854	0.936	rs10108430	chr8:95961794	C/T	cg13393036	chr8:95962371	TP53INP1	-0.53	-11.65	-0.58	1.3e-25	Type 2 diabetes;
CESC	cis	rs8031584	0.678	rs36047941	chr15:31159235	A/G	cg08704250	chr15:31115839	NA	-0.68	-9.07	-0.49	2.76e-17	Huntington's disease progression;
CESC	cis	rs9649465	1.000	rs3779260	chr7:123348315	A/G	cg04330084	chr7:123175371	IQUB	0.38	5.18	0.3	4.49e-7	Migraine;
CESC	cis	rs3862260	0.509	rs10754416	chr1:120163531	A/G	cg11530693	chr1:120165357	ZNF697	0.68	10.52	0.54	7.68e-22	Systemic lupus erythematosus;
CESC	cis	rs11792861	0.816	rs744980	chr9:111690388	C/T	cg13535736	chr9:111863775	C9orf5	-0.46	-6.09	-0.35	3.87e-9	Menarche (age at onset);
CESC	cis	rs13191362	1.000	rs13209728	chr6:162997533	A/C	cg14584255	chr6:163149320	PACRG;PARK2	0.49	5.34	0.31	2.01e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs10504229	0.645	rs56670121	chr8:58138872	C/T	cg24829409	chr8:58192753	C8orf71	-0.59	-7.31	-0.41	3.16e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs258892	0.841	rs266425	chr5:72132531	T/C	cg21869765	chr5:72125136	TNPO1	0.44	5.68	0.33	3.61e-8	Small cell lung carcinoma;
CESC	cis	rs763014	0.966	rs35642938	chr16:642249	T/C	cg00802000	chr16:706648	WDR90	-0.41	-6.25	-0.36	1.66e-9	Height;
CESC	cis	rs2635047	1.000	rs2277717	chr18:44702718	C/A	cg24371990	chr18:44770781	NA	0.32	5.04	0.3	8.56e-7	Educational attainment;
CESC	cis	rs4253772	0.591	rs6008362	chr22:46652737	G/A	cg10231785	chr22:46692440	CN5H6.4;GTSE1	0.49	5.15	0.3	5.12e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs9905704	0.918	rs390524	chr17:56674173	A/G	cg12560992	chr17:57184187	TRIM37	0.6	6.95	0.39	2.8e-11	Testicular germ cell tumor;
CESC	cis	rs16866061	1.000	rs34345163	chr2:225459080	A/G	cg12698349	chr2:225449008	CUL3	0.74	10.31	0.53	3.62e-21	Acute graft versus host disease in bone marrow transplantation (recipient effect);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01382900	chr6:13615583	NOL7	0.58	6.39	0.37	7.33e-10	Gut microbiome composition (summer);
CESC	cis	rs7520050	0.966	rs10789487	chr1:46420221	G/A	cg24296786	chr1:45957014	TESK2	0.44	5.49	0.32	9.54e-8	Red blood cell count;Reticulocyte count;
CESC	cis	rs12541635	0.966	rs55729609	chr8:107056034	A/C	cg10147462	chr8:107024639	NA	0.43	6.01	0.35	6.12e-9	Age of smoking initiation;
CESC	trans	rs1814175	0.791	rs10839395	chr11:49846274	G/T	cg03929089	chr4:120376271	NA	-0.91	-15.2	-0.68	5.94e-38	Height;
CESC	cis	rs10504229	0.683	rs11786843	chr8:58133629	T/C	cg24829409	chr8:58192753	C8orf71	-0.58	-7.12	-0.4	1.02e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs897080	0.589	rs1067380	chr2:44646834	A/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	5.89	0.34	1.14e-8	Height;
CESC	cis	rs2228479	0.850	rs11648689	chr16:89806732	G/A	cg04013166	chr16:89971882	TCF25	0.79	6.72	0.38	1.12e-10	Skin colour saturation;
CESC	cis	rs6541297	1.000	rs6682741	chr1:230279090	T/C	cg20703242	chr1:230279135	GALNT2	0.68	10.84	0.55	6.89e-23	Coronary artery disease;
CESC	cis	rs736408	0.609	rs13095332	chr3:52787242	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	6.71	0.38	1.19e-10	Bipolar disorder;
CESC	cis	rs9831754	0.906	rs7611939	chr3:78392751	A/C	cg06138941	chr3:78371609	NA	-0.65	-7.71	-0.43	2.58e-13	Calcium levels;
CESC	trans	rs650950	0.528	rs646660	chr11:35528452	C/T	cg02386725	chr1:162467755	UHMK1	0.43	6.06	0.35	4.55e-9	Bronchopulmonary dysplasia;
CESC	cis	rs875971	1.000	rs1544549	chr7:66090663	T/A	cg13147721	chr7:65941812	NA	0.37	5.06	0.3	7.87e-7	Aortic root size;
CESC	cis	rs6502050	0.667	rs9892469	chr17:80093657	T/C	cg11859384	chr17:80120422	CCDC57	-0.38	-5.14	-0.3	5.34e-7	Life satisfaction;
CESC	cis	rs2839186	0.770	rs2839984	chr21:47671690	A/G	cg05896524	chr21:47604654	C21orf56	0.43	5.57	0.32	6.14e-8	Testicular germ cell tumor;
CESC	cis	rs10504229	0.815	rs16921955	chr8:58164553	C/T	cg24829409	chr8:58192753	C8orf71	-0.64	-8.53	-0.46	1.18e-15	Developmental language disorder (linguistic errors);
CESC	cis	rs5753618	0.539	rs4820962	chr22:31689951	A/G	cg13145458	chr22:31556086	RNF185	0.48	5.42	0.32	1.33e-7	Colorectal cancer;
CESC	cis	rs34779708	0.733	rs7087099	chr10:35541982	C/T	cg04310649	chr10:35416472	CREM	-0.48	-5.45	-0.32	1.12e-7	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs11711311	0.955	rs10934241	chr3:113394705	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.66	8.53	0.46	1.11e-15	IgG glycosylation;
CESC	cis	rs4665809	0.652	rs2384360	chr2:26405016	C/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.06	-12.68	-0.61	3.95e-29	Gut microbiome composition (summer);
CESC	cis	rs6499255	1.000	rs12596679	chr16:69822680	A/G	cg15192750	chr16:69999425	NA	-0.47	-5.94	-0.34	9e-9	IgE levels;
CESC	cis	rs617791	0.569	rs11227370	chr11:65747693	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.44	-5.2	-0.3	4e-7	Breast cancer;
CESC	cis	rs12618769	0.597	rs72820002	chr2:99075259	T/A	cg10123293	chr2:99228465	UNC50	0.41	5.42	0.32	1.36e-7	Bipolar disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02466749	chr9:98054877	FANCC	-0.58	-6.29	-0.36	1.32e-9	Gut microbiome composition (summer);
CESC	cis	rs7259376	0.840	rs1808668	chr19:22518657	A/G	cg02657401	chr19:22469223	NA	-0.25	-5.2	-0.3	3.97e-7	Menopause (age at onset);
CESC	cis	rs2760061	0.626	rs2527614	chr1:228126470	A/G	cg01973587	chr1:228161476	NA	0.38	5.84	0.34	1.54e-8	Diastolic blood pressure;
CESC	cis	rs965469	1.000	rs1331215	chr20:3376565	T/C	cg25506879	chr20:3388711	C20orf194	-0.57	-5.97	-0.34	7.44e-9	IFN-related cytopenia;
CESC	cis	rs897984	0.568	rs56083427	chr16:30881298	C/T	cg02466173	chr16:30829666	NA	-0.47	-6.87	-0.39	4.6e-11	Dementia with Lewy bodies;
CESC	cis	rs9430161	0.645	rs12081186	chr1:11034195	T/C	cg02454025	chr1:11042201	C1orf127	0.99	16.1	0.7	3.84e-41	Ewing sarcoma;
CESC	cis	rs314370	0.904	rs314373	chr7:100456595	G/A	cg10426581	chr7:100472382	SRRT	0.82	7.99	0.44	4.27e-14	Resting heart rate;
CESC	cis	rs1691799	0.899	rs1168317	chr12:66746225	C/T	cg16791601	chr12:66731901	HELB	-0.8	-14.72	-0.67	2.96e-36	White blood cell count (basophil);
CESC	cis	rs1862618	0.671	rs28397234	chr5:56248428	T/G	cg14703610	chr5:56206110	C5orf35	-0.41	-5.08	-0.3	7.23e-7	Initial pursuit acceleration;
CESC	cis	rs7914558	1.000	rs67908413	chr10:104764989	T/C	cg08650961	chr10:104748594	CNNM2	0.33	5.47	0.32	1.03e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25341937	chr6:17706893	NUP153	0.65	7.64	0.42	4.03e-13	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27632268	chr1:221915475	DUSP10	-0.6	-6.7	-0.38	1.23e-10	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05273006	chr15:62534197	NA	-0.56	-7.25	-0.41	4.44e-12	Gut microbiome composition (summer);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg23850707	chr15:55582494	RAB27A	-0.44	-6.19	-0.36	2.22e-9	Fibrinogen levels;
CESC	trans	rs916888	0.779	rs199498	chr17:44865603	A/G	cg10053473	chr17:62856997	LRRC37A3	-0.57	-6.78	-0.38	7.66e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	trans	rs916888	0.821	rs415430	chr17:44859144	C/T	cg23590916	chr17:43697445	MGC57346	-0.61	-6.5	-0.37	3.94e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs2985684	0.625	rs4900931	chr14:50022793	A/T	cg02151108	chr14:50098012	C14orf104	-0.4	-5.38	-0.31	1.62e-7	Carotid intima media thickness;
CESC	cis	rs826838	0.967	rs1486345	chr12:39131677	G/A	cg13010199	chr12:38710504	ALG10B	-0.45	-6.27	-0.36	1.48e-9	Heart rate;
CESC	cis	rs9611565	0.512	rs139572	chr22:42214532	C/T	cg17376030	chr22:41985996	PMM1	0.78	8.09	0.45	2.12e-14	Vitiligo;
CESC	cis	rs9457247	0.765	rs3752520	chr6:167436159	T/C	cg23791538	chr6:167370224	RNASET2	-0.55	-7.51	-0.42	8.97e-13	Crohn's disease;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg08990514	chr17:48672483	CACNA1G	-0.41	-6.18	-0.35	2.4e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg20743544	chr7:32982957	RP9P	0.47	6.03	0.35	5.6e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs6088590	0.965	rs6120730	chr20:33385102	G/C	cg24642439	chr20:33292090	TP53INP2	0.85	11.66	0.58	1.22e-25	Coronary artery disease;
CESC	cis	rs10504229	0.683	rs67492041	chr8:58140077	G/A	cg24829409	chr8:58192753	C8orf71	-0.59	-7.31	-0.41	3.16e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs1215050	0.765	rs588851	chr4:98678247	C/T	cg05340658	chr4:99064831	C4orf37	0.47	6.04	0.35	5.08e-9	Waist-to-hip ratio adjusted for body mass index;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06264303	chr10:38299291	ZNF33A	-0.59	-6.55	-0.37	3e-10	Gut microbiome composition (summer);
CESC	cis	rs6546550	0.835	rs3755389	chr2:70119469	T/C	cg02498382	chr2:70120550	SNRNP27	-0.42	-7.49	-0.42	1.04e-12	Prevalent atrial fibrillation;
CESC	cis	rs7259376	0.807	rs6511348	chr19:22557374	G/A	cg02657401	chr19:22469223	NA	-0.26	-5.17	-0.3	4.7e-7	Menopause (age at onset);
CESC	cis	rs11676348	0.846	rs3890158	chr2:218990292	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.46	-6.16	-0.35	2.74e-9	Ulcerative colitis;
CESC	cis	rs8092503	1.000	rs8089801	chr18:52479764	G/A	cg12377874	chr18:52495404	RAB27B	0.38	6.27	0.36	1.46e-9	Childhood body mass index;
CESC	cis	rs933688	1.000	rs933688	chr5:90762748	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.83	10.71	0.55	1.74e-22	Smoking behavior;
CESC	cis	rs3857536	0.605	rs36040831	chr6:66876588	G/A	cg07460842	chr6:66804631	NA	-0.72	-10.39	-0.54	1.98e-21	Blood trace element (Cu levels);
CESC	cis	rs4853525	0.522	rs7574840	chr2:191584236	C/G	cg10560079	chr2:191398806	TMEM194B	-0.44	-5.51	-0.32	8.34e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
CESC	cis	rs7703051	0.901	rs4704220	chr5:74757556	G/A	cg03227963	chr5:74354835	NA	0.29	5.33	0.31	2.13e-7	LDL cholesterol;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
CESC	cis	rs6674176	0.660	rs6680421	chr1:44408969	A/C	cg23954153	chr1:44402353	ARTN	0.34	5.26	0.31	2.95e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs660899	0.894	rs6429637	chr1:44198531	A/G	cg19743044	chr1:44115203	KDM4A	0.44	5.25	0.31	3.16e-7	Hypertension risk in short sleep duration;
CESC	cis	rs4665809	1.000	rs17040322	chr2:26351274	G/C	cg08470875	chr2:26401718	FAM59B	-0.47	-5.24	-0.31	3.31e-7	Gut microbiome composition (summer);
CESC	cis	rs3026101	0.671	rs56061343	chr17:5318502	A/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.4	5.22	0.31	3.64e-7	Body mass index;
CESC	cis	rs7917772	0.536	rs3961456	chr10:104425304	A/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.57	-7.4	-0.41	1.8e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs10791323	0.628	rs2851118	chr11:133705995	A/C	cg06766960	chr11:133703094	NA	-0.39	-5.61	-0.33	4.96e-8	Childhood ear infection;
CESC	cis	rs7216064	1.000	rs7223813	chr17:65945840	A/G	cg07042672	chr17:66097459	LOC651250	-0.54	-5.86	-0.34	1.37e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs3091242	0.900	rs669063	chr1:25721154	A/G	cg27572855	chr1:25598939	RHD	0.5	8.55	0.46	9.98e-16	Erythrocyte sedimentation rate;
CESC	cis	rs4604732	0.574	rs111928142	chr1:247625229	G/T	cg12758973	chr1:247694275	LOC148824;OR2C3	0.51	6.39	0.37	7.32e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs637571	0.615	rs10160792	chr11:65667149	C/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.59	7.39	0.41	1.97e-12	Eosinophil percentage of white cells;
CESC	trans	rs7618501	0.633	rs2526748	chr3:50080439	A/G	cg21659725	chr3:3221576	CRBN	-0.49	-6.88	-0.39	4.2e-11	Intelligence (multi-trait analysis);
CESC	cis	rs1862618	0.853	rs252916	chr5:56121788	G/C	cg24531977	chr5:56204891	C5orf35	-0.88	-11.52	-0.58	3.54e-25	Initial pursuit acceleration;
CESC	cis	rs11825685	0.775	rs115695236	chr11:134569427	A/T	cg06603561	chr11:134479413	NA	-0.66	-5.68	-0.33	3.45e-8	IgG glycosylation;
CESC	cis	rs9905704	0.756	rs389389	chr17:56676368	A/G	cg12560992	chr17:57184187	TRIM37	0.58	5.51	0.32	8.4e-8	Testicular germ cell tumor;
CESC	cis	rs875971	0.862	rs6944374	chr7:65686929	C/G	cg13147721	chr7:65941812	NA	0.41	5.57	0.32	6.39e-8	Aortic root size;
CESC	cis	rs7937	0.693	rs17726276	chr19:41291119	A/G	cg09274963	chr19:41633902	CYP2F1	0.36	5.44	0.32	1.23e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Chronic obstructive pulmonary disease;Emphysema imaging phenotypes;
CESC	cis	rs739401	0.611	rs12284275	chr11:3024384	T/C	cg25174290	chr11:3078921	CARS	0.56	7.47	0.42	1.16e-12	Longevity;
CESC	cis	rs8044868	0.530	rs2288002	chr16:72057282	A/G	cg16558253	chr16:72132732	DHX38	-0.36	-5.48	-0.32	1.01e-7	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CESC	trans	rs941207	0.514	rs6581105	chr12:57185968	T/C	cg26462586	chr2:11164677	NA	0.39	6.17	0.35	2.59e-9	Platelet count;
CESC	cis	rs2295359	0.892	rs56920441	chr1:67652012	A/G	cg17031739	chr1:67600172	NA	0.39	5.3	0.31	2.4e-7	Psoriasis;
CESC	cis	rs1023500	0.505	rs134889	chr22:42674350	A/T	cg04733989	chr22:42467013	NAGA	0.65	9.83	0.52	1.18e-19	Schizophrenia;
CESC	cis	rs11098499	0.820	rs28578366	chr4:120536905	A/G	cg09307838	chr4:120376055	NA	-0.87	-11.88	-0.59	2.2e-26	Corneal astigmatism;
CESC	cis	rs7666738	0.830	rs28729647	chr4:99059552	T/C	cg05340658	chr4:99064831	C4orf37	0.84	12.91	0.62	6.47e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs748404	0.723	rs11853991	chr15:43557549	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.39	5.08	0.3	7.01e-7	Lung cancer;
CESC	cis	rs3806843	1.000	rs13184940	chr5:140172918	T/C	cg26395211	chr5:140044315	WDR55	-0.41	-5.26	-0.31	2.97e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs1218582	0.745	rs1580943	chr1:154865125	G/A	cg09359103	chr1:154839909	KCNN3	-0.65	-12.4	-0.61	3.83e-28	Prostate cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01947930	chr5:141016379	RELL2;HDAC3	0.53	6.09	0.35	4.04e-9	Gut microbiome composition (summer);
CESC	cis	rs3026101	0.671	rs2871203	chr17:5298490	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.43	5.68	0.33	3.57e-8	Body mass index;
CESC	cis	rs1707322	0.785	rs10890348	chr1:46242423	G/T	cg06784218	chr1:46089804	CCDC17	0.37	6.33	0.36	1.02e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs1879734	0.689	rs11206201	chr1:54170963	C/A	cg23596471	chr1:54105337	GLIS1	0.35	5.58	0.32	5.97e-8	Mitral valve prolapse;
CESC	cis	rs6964587	0.872	rs57969083	chr7:91665627	A/T	cg17063962	chr7:91808500	NA	0.56	7.79	0.43	1.54e-13	Breast cancer;
CESC	cis	rs698833	0.758	rs7586188	chr2:44544955	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.48	5.84	0.34	1.56e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs643506	1.000	rs647080	chr11:111609174	A/G	cg09085632	chr11:111637200	PPP2R1B	0.54	7.0	0.39	2.11e-11	Breast cancer;
CESC	cis	rs1348850	0.645	rs11887886	chr2:178425730	C/T	cg22681709	chr2:178499509	PDE11A	-0.53	-6.64	-0.38	1.72e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs6502050	0.835	rs8077772	chr17:80117220	A/G	cg23985595	chr17:80112537	CCDC57	0.37	5.76	0.33	2.36e-8	Life satisfaction;
CESC	cis	rs9303280	0.901	rs1008723	chr17:38066267	G/T	cg20243544	chr17:37824526	PNMT	0.52	6.85	0.39	5.09e-11	Self-reported allergy;
CESC	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.57	7.09	0.4	1.19e-11	Prudent dietary pattern;
CESC	cis	rs9303401	0.659	rs714959	chr17:56628601	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	1.0	12.72	0.62	2.99e-29	Cognitive test performance;
CESC	cis	rs898097	0.578	rs8069697	chr17:80908110	T/C	cg15369054	chr17:80825471	TBCD	-0.39	-5.59	-0.32	5.76e-8	Breast cancer;
CESC	cis	rs7666738	0.830	rs7686456	chr4:99019695	T/C	cg03676636	chr4:99064102	C4orf37	0.33	5.15	0.3	5.05e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs853679	0.517	rs4713148	chr6:28115921	G/A	cg23281280	chr6:28129359	ZNF389	0.6	8.0	0.44	3.86e-14	Depression;
CESC	cis	rs738322	0.967	rs132985	chr22:38563471	C/T	cg25457927	chr22:38595422	NA	-0.3	-5.72	-0.33	2.87e-8	Cutaneous nevi;
CESC	cis	rs6499255	1.000	rs11075734	chr16:69801397	G/T	cg15192750	chr16:69999425	NA	0.47	5.79	0.34	1.94e-8	IgE levels;
CESC	cis	rs3733418	0.860	rs13142064	chr4:165943549	G/A	cg10852876	chr4:165953100	TRIM60	-0.49	-5.87	-0.34	1.29e-8	Obesity-related traits;
CESC	cis	rs9486719	0.948	rs11152970	chr6:96909077	A/G	cg18709589	chr6:96969512	KIAA0776	-0.56	-6.11	-0.35	3.51e-9	Migraine;Coronary artery disease;
CESC	cis	rs2288073	0.965	rs10173949	chr2:24410256	A/C	cg06627628	chr2:24431161	ITSN2	-0.73	-8.64	-0.47	5.5e-16	Venous thromboembolism (SNP x SNP interaction);
CESC	cis	rs11098499	0.954	rs11722872	chr4:120233030	G/C	cg24375607	chr4:120327624	NA	0.46	5.57	0.32	6.18e-8	Corneal astigmatism;
CESC	cis	rs12134245	0.747	rs35654098	chr1:92001452	T/A	cg07090678	chr1:91966139	CDC7	0.41	5.63	0.33	4.52e-8	Breast cancer;
CESC	cis	rs870825	0.616	rs6843185	chr4:185649878	A/C	cg04058563	chr4:185651563	MLF1IP	0.65	7.2	0.4	6.19e-12	Blood protein levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09551172	chr1:100315427	AGL	0.58	6.79	0.38	7.52e-11	Gut microbiome composition (summer);
CESC	cis	rs896854	0.684	rs2340534	chr8:95992330	G/A	cg09323728	chr8:95962352	TP53INP1	-0.39	-8.59	-0.47	7.58e-16	Type 2 diabetes;
CESC	cis	rs8103278	0.507	rs16939	chr19:46276056	C/A	cg12641515	chr19:46296257	DMWD	0.73	9.62	0.51	5.43e-19	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00624332	chr10:103880351	LDB1	0.54	6.06	0.35	4.78e-9	Gut microbiome composition (summer);
CESC	cis	rs9309473	1.000	rs6711033	chr2:73746643	T/C	cg20560298	chr2:73613845	ALMS1	-0.47	-6.47	-0.37	4.73e-10	Metabolite levels;
CESC	cis	rs12586317	0.511	rs75552348	chr14:35385747	G/A	cg16230307	chr14:35515116	FAM177A1	1.07	10.65	0.55	2.72e-22	Psoriasis;
CESC	cis	rs7336332	0.598	rs7669	chr13:28009851	C/T	cg01674679	chr13:27998804	GTF3A	-0.63	-5.95	-0.34	8.23e-9	Weight;
CESC	cis	rs2637266	0.703	rs846620	chr10:78545387	G/A	cg18941641	chr10:78392320	NA	0.4	7.64	0.42	3.93e-13	Pulmonary function;
CESC	cis	rs9902453	0.935	rs9911794	chr17:28349466	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.62	-7.83	-0.43	1.15e-13	Coffee consumption (cups per day);
CESC	cis	rs4746818	1.000	rs7916991	chr10:70895373	C/A	cg04149295	chr10:70884716	VPS26A	0.56	5.03	0.3	8.94e-7	Left atrial antero-posterior diameter;
CESC	cis	rs6831352	0.918	rs7694646	chr4:100059732	T/A	cg13256891	chr4:100009986	ADH5	-0.75	-8.21	-0.45	9.89e-15	Alcohol dependence;
CESC	cis	rs4474465	0.646	rs7937417	chr11:78284470	A/G	cg01578073	chr11:78285783	NARS2	-0.44	-5.12	-0.3	5.99e-7	Alzheimer's disease (survival time);
CESC	cis	rs712039	0.583	rs853223	chr17:35791149	T/C	cg16670864	chr17:35848621	DUSP14	0.41	5.13	0.3	5.52e-7	Tuberculosis;
CESC	cis	rs7618915	0.501	rs11714030	chr3:52765882	C/T	cg07507251	chr3:52567010	NT5DC2	0.34	5.73	0.33	2.7e-8	Bipolar disorder;
CESC	cis	rs4843747	0.573	rs7499959	chr16:88110422	C/G	cg17633681	chr16:88106987	BANP	0.55	7.08	0.4	1.27e-11	Menopause (age at onset);
CESC	trans	rs637571	0.522	rs556643	chr11:65733289	C/T	cg17712092	chr4:129076599	LARP1B	0.69	9.36	0.5	3.63e-18	Eosinophil percentage of white cells;
CESC	cis	rs734999	0.545	rs4074789	chr1:2537464	A/G	cg18854424	chr1:2615690	NA	0.3	6.15	0.35	2.81e-9	Ulcerative colitis;
CESC	cis	rs870825	0.616	rs14969	chr4:185615764	C/A	cg04058563	chr4:185651563	MLF1IP	0.65	7.14	0.4	9.11e-12	Blood protein levels;
CESC	cis	rs13191362	0.938	rs35395472	chr6:163008493	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.82	8.29	0.45	5.87e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs769267	0.501	rs2965187	chr19:19522970	T/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.5	5.38	0.31	1.68e-7	Tonsillectomy;
CESC	cis	rs77216612	0.840	rs11055030	chr12:12878349	G/C	cg04607235	chr12:12878440	APOLD1	-1.05	-16.31	-0.71	6.68e-42	Lymphocyte counts;
CESC	cis	rs9916302	0.904	rs10852933	chr17:37698194	G/T	cg15445000	chr17:37608096	MED1	0.42	6.91	0.39	3.53e-11	Glomerular filtration rate (creatinine);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16424138	chr5:14581771	FAM105A	0.53	6.19	0.36	2.32e-9	Gut microbiome composition (summer);
CESC	cis	rs4129585	0.928	rs13262595	chr8:143316970	A/G	cg16886403	chr8:143471632	TSNARE1	0.43	5.28	0.31	2.76e-7	Schizophrenia;Autism spectrum disorder or schizophrenia;
CESC	cis	rs9815354	0.904	rs73079327	chr3:41864697	A/T	cg03022575	chr3:42003672	ULK4	0.46	5.29	0.31	2.57e-7	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs2295499	0.873	rs4690085	chr4:2697300	A/G	cg27239842	chr4:2403781	ZFYVE28	-0.31	-5.42	-0.32	1.34e-7	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
CESC	cis	rs875971	0.861	rs801215	chr7:66011938	A/T	cg18252515	chr7:66147081	NA	0.47	6.08	0.35	4.25e-9	Aortic root size;
CESC	trans	rs875971	0.558	rs4433015	chr7:65639723	A/C	cg26939375	chr7:64535504	NA	-0.6	-8.07	-0.44	2.5e-14	Aortic root size;
CESC	cis	rs597539	0.652	rs496616	chr11:68672800	G/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.77	9.81	0.52	1.38e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs4713118	0.597	rs172166	chr6:28020820	C/G	cg26335602	chr6:28129616	ZNF389	0.45	5.75	0.33	2.5e-8	Parkinson's disease;
CESC	cis	rs1009170	0.794	rs9919953	chr14:92582974	C/A	cg10324096	chr14:92587714	CPSF2;NDUFB1	0.55	5.11	0.3	6.15e-7	Dialysis-related mortality;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg03041730	chr4:903314	GAK	0.56	7.42	0.41	1.55e-12	Fibrinogen levels;
CESC	trans	rs2207136	0.835	rs10948579	chr6:50871405	G/A	cg06522515	chr3:184090630	THPO	-0.36	-6.24	-0.36	1.69e-9	Myopia;
CESC	cis	rs13191362	1.000	rs34619021	chr6:163029767	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.81	8.44	0.46	2.13e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs1862618	0.526	rs2591963	chr5:56237135	T/A	cg12311346	chr5:56204834	C5orf35	0.87	10.78	0.55	1.05e-22	Initial pursuit acceleration;
CESC	cis	rs1552244	1.000	rs66838678	chr3:10150350	G/A	cg00149659	chr3:10157352	C3orf10	0.73	8.81	0.48	1.65e-16	Alzheimer's disease;
CESC	cis	rs4654899	0.965	rs4654907	chr1:21521094	C/T	cg05370193	chr1:21551575	ECE1	0.41	6.25	0.36	1.62e-9	Superior frontal gyrus grey matter volume;
CESC	cis	rs1371867	0.726	rs1660333	chr8:101309989	A/G	cg11906718	chr8:101322791	RNF19A	0.51	6.75	0.38	9.5e-11	Atrioventricular conduction;
CESC	cis	rs10751667	0.714	rs7933889	chr11:972270	C/T	cg20946044	chr11:1010712	AP2A2	-0.39	-5.4	-0.31	1.49e-7	Alzheimer's disease (late onset);
CESC	cis	rs4790333	0.539	rs67887169	chr17:2256828	G/A	cg02569219	chr17:2266849	SGSM2	0.39	5.14	0.3	5.3e-7	Proinsulin levels;
CESC	cis	rs896854	0.625	rs4735336	chr8:95973410	A/C	cg16049864	chr8:95962084	TP53INP1	0.64	11.34	0.57	1.5e-24	Type 2 diabetes;
CESC	cis	rs9905704	0.918	rs9891129	chr17:56630474	T/C	cg12560992	chr17:57184187	TRIM37	-0.61	-7.02	-0.4	1.8e-11	Testicular germ cell tumor;
CESC	trans	rs7824557	0.564	rs2736301	chr8:11236413	C/T	cg06636001	chr8:8085503	FLJ10661	-0.49	-6.15	-0.35	2.9e-9	Retinal vascular caliber;
CESC	cis	rs2033711	0.728	rs4801586	chr19:58934528	A/G	cg26874164	chr19:58962979	ZNF324B	0.54	7.41	0.41	1.73e-12	Uric acid clearance;
CESC	cis	rs72634258	0.836	rs7545687	chr1:7997183	G/A	cg00042356	chr1:8021962	PARK7	0.9	8.11	0.45	1.9e-14	Inflammatory bowel disease;
CESC	cis	rs9398803	0.965	rs2027299	chr6:126685827	G/C	cg19875578	chr6:126661172	C6orf173	0.48	6.73	0.38	1.06e-10	Male-pattern baldness;
CESC	cis	rs7264396	0.635	rs6060675	chr20:34493614	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.58	7.05	0.4	1.57e-11	Total cholesterol levels;
CESC	trans	rs6601327	0.775	rs12156017	chr8:9406837	C/G	cg15556689	chr8:8085844	FLJ10661	-0.52	-6.42	-0.37	6.2e-10	Multiple myeloma (hyperdiploidy);
CESC	trans	rs35110281	0.743	rs2329443	chr21:45059431	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.53	6.76	0.38	8.53e-11	Mean corpuscular volume;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg01936430	chr1:204380496	PPP1R15B	-0.5	-6.57	-0.37	2.69e-10	Ulcerative colitis;
CESC	cis	rs7833790	0.926	rs72686467	chr8:82758929	T/G	cg02079420	chr8:82753780	SNX16	-0.58	-7.73	-0.43	2.18e-13	Diastolic blood pressure;
CESC	cis	rs7726839	0.526	rs55647623	chr5:567747	T/C	cg16447950	chr5:562315	NA	-0.63	-7.22	-0.41	5.35e-12	Obesity-related traits;
CESC	cis	rs67460515	0.563	rs7618924	chr3:160855599	A/G	cg03342759	chr3:160939853	NMD3	-0.55	-7.33	-0.41	2.7e-12	Parkinson's disease;
CESC	cis	rs78889164	0.956	rs16968029	chr19:33869175	C/T	cg02272751	chr19:33882848	PEPD	-0.52	-6.88	-0.39	4.24e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs11190604	0.943	rs11190588	chr10:102273565	C/T	cg07080220	chr10:102295463	HIF1AN	0.66	5.98	0.34	7.36e-9	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs12530845	0.887	rs61360007	chr7:135316879	G/A	cg23117316	chr7:135346802	PL-5283	-0.48	-5.83	-0.34	1.58e-8	Red blood cell traits;
CESC	cis	rs9399135	0.904	rs4895438	chr6:135317665	G/T	cg24558204	chr6:135376177	HBS1L	0.53	7.2	0.4	6.1e-12	Red blood cell count;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg07541443	chr13:114260546	TFDP1	-0.49	-6.39	-0.37	7.35e-10	Systemic lupus erythematosus;
CESC	cis	rs10504073	0.647	rs12546839	chr8:50009020	C/T	cg00325661	chr8:49890786	NA	0.57	8.45	0.46	1.97e-15	Blood metabolite ratios;
CESC	cis	rs7267979	1.000	rs1077889	chr20:25267893	A/G	cg08601574	chr20:25228251	PYGB	0.4	5.77	0.33	2.2e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs2797160	0.714	rs1777220	chr6:126022602	G/T	cg05901451	chr6:126070800	HEY2	0.49	7.05	0.4	1.59e-11	Endometrial cancer;
CESC	cis	rs1448094	0.511	rs17279338	chr12:86162874	G/A	cg02569458	chr12:86230093	RASSF9	0.49	7.62	0.42	4.61e-13	Major depressive disorder;
CESC	cis	rs853679	0.599	rs149943	chr6:28002388	G/A	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.8	6.55	0.37	2.92e-10	Depression;
CESC	cis	rs9858542	1.000	rs9823546	chr3:49705512	T/A	cg03060546	chr3:49711283	APEH	-0.57	-6.79	-0.38	7.39e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs17818399	0.547	rs4953400	chr2:46777208	T/A	cg02822958	chr2:46747628	ATP6V1E2	0.42	5.26	0.31	2.96e-7	Height;
CESC	cis	rs6570726	0.577	rs441982	chr6:145842848	A/G	cg05347473	chr6:146136440	FBXO30	0.72	9.11	0.49	2.04e-17	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7592578	0.882	rs2192010	chr2:191462133	C/T	cg10560079	chr2:191398806	TMEM194B	-0.67	-5.81	-0.34	1.76e-8	Diastolic blood pressure;
CESC	cis	rs3008870	1.000	rs3008870	chr1:67418027	C/T	cg02640540	chr1:67518911	SLC35D1	0.51	5.58	0.32	5.89e-8	Lymphocyte percentage of white cells;
CESC	cis	rs3096299	0.563	rs4600467	chr16:89562516	C/T	cg16743903	chr16:89593216	SPG7	-0.47	-6.11	-0.35	3.5e-9	Multiple myeloma (IgH translocation);
CESC	cis	rs1552244	0.554	rs7638846	chr3:10048601	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.64	8.26	0.45	6.96e-15	Alzheimer's disease;
CESC	cis	rs4253772	0.530	rs9627387	chr22:46684678	A/G	cg09491104	chr22:46646882	C22orf40	-0.57	-8.52	-0.46	1.21e-15	LDL cholesterol;Cholesterol, total;
CESC	cis	rs7618915	0.501	rs2164885	chr3:52731269	T/C	cg18404041	chr3:52824283	ITIH1	-0.39	-6.69	-0.38	1.3e-10	Bipolar disorder;
CESC	cis	rs12579753	0.917	rs10862375	chr12:82254809	C/G	cg23701643	chr12:82153290	PPFIA2	0.35	5.11	0.3	6.11e-7	Resting heart rate;
CESC	cis	rs6570726	0.846	rs7773939	chr6:145927384	C/T	cg05347473	chr6:146136440	FBXO30	-0.47	-6.12	-0.35	3.44e-9	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg07332563	chr6:291687	DUSP22	0.67	8.75	0.47	2.6e-16	Menopause (age at onset);
CESC	cis	rs9486719	0.947	rs11755945	chr6:96908038	G/C	cg18709589	chr6:96969512	KIAA0776	-0.56	-6.11	-0.35	3.51e-9	Migraine;Coronary artery disease;
CESC	trans	rs650950	0.528	rs646660	chr11:35528452	C/T	cg07204069	chr17:72772514	TMEM104;NAT9	0.46	6.23	0.36	1.83e-9	Bronchopulmonary dysplasia;
CESC	cis	rs6089584	0.888	rs6061973	chr20:60610870	C/T	cg06108461	chr20:60628389	TAF4	-0.93	-14.52	-0.67	1.46e-35	Body mass index;
CESC	cis	rs4073582	0.595	rs708471	chr11:65931008	A/G	cg14036092	chr11:66035641	RAB1B	0.54	7.53	0.42	7.89e-13	Gout;
CESC	cis	rs3785574	0.927	rs2854160	chr17:61977248	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.02	16.64	0.71	4.66e-43	Height;
CESC	cis	rs7666738	0.830	rs4699590	chr4:98974030	A/C	cg05340658	chr4:99064831	C4orf37	0.79	12.26	0.6	1.12e-27	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3096299	0.967	rs2965827	chr16:89457350	A/C	cg08392591	chr16:89556376	ANKRD11	-0.4	-5.19	-0.3	4.22e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs6724607	0.905	rs10173771	chr2:191439248	T/C	cg10560079	chr2:191398806	TMEM194B	0.49	6.85	0.39	5.15e-11	Pulse pressure;
CESC	cis	rs8031584	0.958	rs11637469	chr15:31238783	T/C	cg14829155	chr15:31115871	NA	-0.72	-9.72	-0.51	2.73e-19	Huntington's disease progression;
CESC	cis	rs6088580	0.542	rs6059882	chr20:33090167	T/C	cg06115741	chr20:33292138	TP53INP2	0.44	5.59	0.32	5.74e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs9487051	1.000	rs9386795	chr6:109616528	G/A	cg01475377	chr6:109611718	NA	-0.42	-6.43	-0.37	6.01e-10	Reticulocyte fraction of red cells;
CESC	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.89	13.59	0.64	2.72e-32	Prudent dietary pattern;
CESC	cis	rs12497850	0.931	rs1134591	chr3:48972892	C/T	cg03060546	chr3:49711283	APEH	0.53	6.51	0.37	3.65e-10	Parkinson's disease;
CESC	cis	rs7107174	1.000	rs10793303	chr11:78060750	G/A	cg02023728	chr11:77925099	USP35	0.47	6.25	0.36	1.63e-9	Testicular germ cell tumor;
CESC	cis	rs3015497	0.603	rs955879	chr14:51081974	G/A	cg26011998	chr14:51135199	SAV1	-0.45	-5.21	-0.3	3.84e-7	Mean platelet volume;
CESC	trans	rs12310956	0.532	rs10844712	chr12:33961022	G/A	cg26384229	chr12:38710491	ALG10B	0.52	7.15	0.4	8.38e-12	Morning vs. evening chronotype;
CESC	cis	rs17253792	0.822	rs13379353	chr14:56050478	G/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.81	5.86	0.34	1.36e-8	Putamen volume;
CESC	trans	rs7618501	0.966	rs9882639	chr3:49799475	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.59	8.5	0.46	1.36e-15	Intelligence (multi-trait analysis);
CESC	cis	rs6142102	0.625	rs1883706	chr20:32552877	G/A	cg08999081	chr20:33150536	PIGU	0.34	5.1	0.3	6.63e-7	Skin pigmentation;
CESC	cis	rs116095464	0.558	rs7708182	chr5:234788	C/G	cg22857025	chr5:266934	NA	-1.29	-18.85	-0.76	7.33e-51	Breast cancer;
CESC	cis	rs67311347	1.000	rs9849992	chr3:40402140	C/T	cg09455208	chr3:40491958	NA	0.52	8.94	0.48	6.71e-17	Renal cell carcinoma;
CESC	cis	rs10927875	0.619	rs2102664	chr1:16130169	A/G	cg21385522	chr1:16154831	NA	-0.76	-10.68	-0.55	2.15e-22	Dilated cardiomyopathy;
CESC	cis	rs13256369	0.802	rs11249883	chr8:8561537	G/A	cg17143192	chr8:8559678	CLDN23	0.75	8.46	0.46	1.78e-15	Obesity-related traits;
CESC	cis	rs300703	0.935	rs300704	chr2:240255	A/C	cg21211680	chr2:198530	NA	0.97	7.77	0.43	1.68e-13	Blood protein levels;
CESC	cis	rs67478160	0.625	rs7141473	chr14:104316055	A/C	cg08213375	chr14:104286397	PPP1R13B	-0.54	-10.49	-0.54	9.46e-22	Schizophrenia;
CESC	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg10819733	chr22:24237672	NA	-0.42	-5.92	-0.34	9.84e-9	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs7178572	0.568	rs4243045	chr15:77455914	A/C	cg22256960	chr15:77711686	NA	-0.53	-6.69	-0.38	1.33e-10	Type 2 diabetes;
CESC	cis	rs12477438	0.520	rs11678456	chr2:99708237	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.92	15.86	0.7	2.85e-40	Chronic sinus infection;
CESC	cis	rs4727027	0.737	rs10278971	chr7:148780659	A/T	cg23158103	chr7:148848205	ZNF398	-0.39	-5.99	-0.35	6.83e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs921968	0.608	rs495855	chr2:219357858	A/G	cg02176678	chr2:219576539	TTLL4	0.39	6.69	0.38	1.32e-10	Mean corpuscular hemoglobin concentration;
CESC	cis	rs4664308	0.905	rs7567781	chr2:160999537	A/G	cg03641300	chr2:160917029	PLA2R1	-0.65	-9.52	-0.5	1.1e-18	Idiopathic membranous nephropathy;
CESC	cis	rs3126085	0.935	rs4845734	chr1:152167473	T/C	cg03465714	chr1:152285911	FLG	-0.47	-5.73	-0.33	2.74e-8	Atopic dermatitis;
CESC	cis	rs9287719	0.934	rs6432111	chr2:10744620	A/C	cg02196655	chr2:10830764	NOL10	-0.38	-5.83	-0.34	1.61e-8	Prostate cancer;
CESC	cis	rs9309473	1.000	rs13432605	chr2:73810981	C/G	cg20560298	chr2:73613845	ALMS1	-0.53	-6.93	-0.39	3.24e-11	Metabolite levels;
CESC	cis	rs1864400	0.690	rs7098237	chr10:43740513	T/A	cg15436174	chr10:43711423	RASGEF1A	0.46	5.3	0.31	2.44e-7	Hirschsprung disease;
CESC	cis	rs2531992	0.925	rs2531993	chr16:4014245	A/G	cg05927578	chr16:4029543	ADCY9	0.45	5.64	0.33	4.37e-8	Waist circumference;
CESC	cis	rs2882667	0.964	rs2288824	chr5:138298396	C/T	cg04439458	chr5:138467593	SIL1	-0.37	-5.75	-0.33	2.51e-8	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs13108904	0.557	rs1680041	chr4:1238521	C/T	cg16405210	chr4:1374714	KIAA1530	0.76	10.52	0.54	7.19e-22	Obesity-related traits;
CESC	cis	rs476633	0.691	rs6492997	chr15:41541171	G/A	cg12386646	chr15:41787261	ITPKA	0.36	5.36	0.31	1.78e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs2115536	0.967	rs934137	chr15:80211768	T/C	cg11839771	chr15:80205821	ST20	-0.37	-5.38	-0.31	1.62e-7	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CESC	trans	rs61931739	0.534	rs1352207	chr12:34036862	C/T	cg26384229	chr12:38710491	ALG10B	-0.5	-6.9	-0.39	3.85e-11	Morning vs. evening chronotype;
CESC	cis	rs7100689	0.577	rs10749551	chr10:82054001	A/C	cg09936400	chr10:82049201	MAT1A	0.39	5.93	0.34	9.23e-9	Post bronchodilator FEV1;
CESC	cis	rs9660180	0.967	rs11260623	chr1:1781456	G/T	cg17747265	chr1:1875780	NA	-0.56	-9.17	-0.49	1.39e-17	Body mass index;
CESC	cis	rs9487051	0.639	rs2884012	chr6:109598221	C/T	cg12927641	chr6:109611667	NA	-0.37	-5.5	-0.32	8.91e-8	Reticulocyte fraction of red cells;
CESC	cis	rs561341	1.000	rs72823785	chr17:30273784	C/T	cg19193384	chr17:30244184	NA	-0.72	-6.84	-0.39	5.61e-11	Hip circumference adjusted for BMI;
CESC	cis	rs1218582	0.661	rs4845695	chr1:154911798	A/G	cg16680214	chr1:154839983	KCNN3	-0.46	-6.84	-0.39	5.44e-11	Prostate cancer;
CESC	cis	rs6460942	1.000	rs7792759	chr7:12311715	A/G	cg06484146	chr7:12443880	VWDE	0.66	7.22	0.41	5.52e-12	Coronary artery disease;
CESC	cis	rs6460942	0.915	rs1595800	chr7:12439816	G/A	cg06484146	chr7:12443880	VWDE	-0.74	-8.94	-0.48	6.6e-17	Coronary artery disease;
CESC	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.5	-6.34	-0.36	9.61e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs4665809	1.000	rs4665823	chr2:26312723	A/G	cg08470875	chr2:26401718	FAM59B	-0.48	-5.29	-0.31	2.58e-7	Gut microbiome composition (summer);
CESC	cis	rs9611565	0.694	rs202628	chr22:41849513	A/G	cg17376030	chr22:41985996	PMM1	0.55	6.19	0.36	2.23e-9	Vitiligo;
CESC	cis	rs12134245	0.776	rs61548854	chr1:92001536	C/T	cg25838465	chr1:92012736	NA	-0.61	-8.91	-0.48	8.65e-17	Breast cancer;
CESC	cis	rs3096299	0.685	rs4329923	chr16:89560178	C/T	cg02034447	chr16:89574710	SPG7	0.54	7.08	0.4	1.32e-11	Multiple myeloma (IgH translocation);
CESC	cis	rs12824058	0.831	rs11608406	chr12:130805866	G/C	cg26677194	chr12:130822605	PIWIL1	0.48	6.19	0.36	2.3e-9	Menopause (age at onset);
CESC	cis	rs9300255	0.602	rs1727315	chr12:123638930	A/G	cg00376283	chr12:123451042	ABCB9	-0.71	-8.85	-0.48	1.27e-16	Neutrophil percentage of white cells;
CESC	cis	rs2075371	0.796	rs1646644	chr7:134011817	A/T	cg11752832	chr7:134001865	SLC35B4	0.49	6.1	0.35	3.68e-9	Mean platelet volume;
CESC	cis	rs6088580	0.634	rs1205344	chr20:32918298	G/A	cg06115741	chr20:33292138	TP53INP2	-0.45	-5.67	-0.33	3.66e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs2204008	0.774	rs10400552	chr12:38393577	C/G	cg26384229	chr12:38710491	ALG10B	0.71	10.57	0.54	5.24e-22	Bladder cancer;
CESC	cis	rs3916	0.662	rs2138249	chr12:121124142	A/C	cg20569203	chr12:120799911	MSI1	0.29	5.09	0.3	6.9e-7	Urinary metabolites (H-NMR features);
CESC	cis	rs4713118	0.527	rs9461433	chr6:28095172	C/T	cg17949981	chr6:28129498	ZNF389	0.44	5.58	0.32	5.97e-8	Parkinson's disease;
CESC	cis	rs10736390	0.640	rs10888858	chr1:55108978	A/G	cg01517571	chr1:55089959	ACOT11;FAM151A	-0.57	-7.73	-0.43	2.29e-13	Survival in pancreatic cancer;
CESC	cis	rs9916302	0.861	rs4795376	chr17:37669043	T/C	cg00129232	chr17:37814104	STARD3	-0.56	-7.49	-0.42	1e-12	Glomerular filtration rate (creatinine);
CESC	cis	rs7772486	0.692	rs2265915	chr6:146194332	A/T	cg05347473	chr6:146136440	FBXO30	0.6	7.7	0.43	2.66e-13	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2836950	0.527	rs2836958	chr21:40623526	T/C	cg17971929	chr21:40555470	PSMG1	-0.6	-7.86	-0.43	9.65e-14	Menarche (age at onset);
CESC	cis	rs10242455	0.571	rs6955162	chr7:99184400	T/G	cg25640893	chr7:99214727	ZNF498	1.16	7.57	0.42	6.25e-13	Blood metabolite levels;
CESC	cis	rs2228479	0.850	rs17233455	chr16:89816407	A/G	cg00800038	chr16:89945340	TCF25	-0.91	-7.54	-0.42	7.39e-13	Skin colour saturation;
CESC	cis	rs1552244	1.000	rs3826	chr3:10141065	T/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.85	-12.15	-0.6	2.74e-27	Alzheimer's disease;
CESC	cis	rs4727027	0.901	rs7794500	chr7:148819519	C/T	cg23158103	chr7:148848205	ZNF398	0.41	6.55	0.37	2.94e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	trans	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg13565492	chr6:43139072	SRF	-0.72	-8.44	-0.46	2.12e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs4819052	0.851	rs2255774	chr21:46683851	A/T	cg11663144	chr21:46675770	NA	-0.43	-6.9	-0.39	3.76e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs12824058	0.831	rs12831363	chr12:130814013	C/T	cg26677194	chr12:130822605	PIWIL1	-0.52	-6.86	-0.39	4.77e-11	Menopause (age at onset);
CESC	cis	rs644799	1.000	rs474252	chr11:95619292	G/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.61	7.66	0.43	3.46e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs2841233	0.692	rs2028416	chr14:105348552	C/T	cg16576083	chr14:105354267	KIAA0284	0.48	7.69	0.43	2.9e-13	IgG glycosylation;
CESC	cis	rs4665809	1.000	rs11126364	chr2:26314515	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.7	-8.01	-0.44	3.69e-14	Gut microbiome composition (summer);
CESC	cis	rs10845606	1.000	rs10845606	chr12:12834894	G/T	cg09462578	chr12:12878428	APOLD1	-0.63	-6.92	-0.39	3.4e-11	Systemic lupus erythematosus;
CESC	cis	rs60871478	0.578	rs62432900	chr7:826794	G/C	cg13798912	chr7:905769	UNC84A	0.56	5.7	0.33	3.11e-8	Cerebrospinal P-tau181p levels;
CESC	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg26338869	chr17:61819248	STRADA	0.68	8.87	0.48	1.08e-16	Prudent dietary pattern;
CESC	cis	rs12956009	0.583	rs12327454	chr18:44863964	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.5	6.45	0.37	5.28e-10	Educational attainment (years of education);
CESC	cis	rs9583531	0.600	rs6492305	chr13:111361400	C/T	cg24331049	chr13:111365604	ING1	0.75	10.98	0.56	2.28e-23	Coronary artery disease;
CESC	cis	rs146201400	1	rs146201400	chr1:26645955	G/GA	cg00852783	chr1:26633632	UBXN11	0.5	7.0	0.39	2.16e-11	Monocyte percentage of white cells;
CESC	cis	rs6502050	0.698	rs36043222	chr17:80117822	G/T	cg23985595	chr17:80112537	CCDC57	-0.41	-6.47	-0.37	4.81e-10	Life satisfaction;
CESC	cis	rs3782089	1.000	rs3782089	chr11:65336819	C/T	cg21890820	chr11:65308645	LTBP3	0.96	7.81	0.43	1.33e-13	Height;
CESC	cis	rs4689388	0.926	rs28420833	chr4:6279504	G/A	cg00701064	chr4:6280414	WFS1	0.75	13.59	0.64	2.91e-32	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs763014	0.898	rs8060585	chr16:635794	C/G	cg07343612	chr16:622815	PIGQ	-0.55	-7.99	-0.44	4.25e-14	Height;
CESC	cis	rs2878628	0.596	rs57039206	chr3:52758570	T/A	cg18337363	chr3:52569053	NT5DC2	0.29	5.3	0.31	2.43e-7	Intelligence (multi-trait analysis);
CESC	cis	rs7666738	0.830	rs7678557	chr4:99057329	A/G	cg03676636	chr4:99064102	C4orf37	0.34	5.12	0.3	5.96e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs35306767	0.903	rs13377166	chr10:886259	G/A	cg26597838	chr10:835615	NA	0.87	9.16	0.49	1.48e-17	Eosinophil percentage of granulocytes;
CESC	cis	rs921968	0.548	rs13427522	chr2:219438359	C/T	cg02176678	chr2:219576539	TTLL4	0.41	7.15	0.4	8.68e-12	Mean corpuscular hemoglobin concentration;
CESC	cis	rs2635047	0.638	rs12968552	chr18:44702502	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.42	5.68	0.33	3.46e-8	Educational attainment;
CESC	cis	rs5167	0.505	rs7257468	chr19:45453144	C/T	cg20090143	chr19:45452003	APOC2	0.37	6.39	0.37	7.54e-10	Blood protein levels;
CESC	trans	rs11098499	0.863	rs3822192	chr4:120445720	A/C	cg25214090	chr10:38739885	LOC399744	0.7	9.46	0.5	1.75e-18	Corneal astigmatism;
CESC	cis	rs3096299	0.967	rs2965937	chr16:89488779	A/T	cg08822215	chr16:89438651	ANKRD11	-0.38	-5.86	-0.34	1.38e-8	Multiple myeloma (IgH translocation);
CESC	trans	rs7866350	0.604	rs1935389	chr9:100994470	A/G	cg24799514	chr20:44420531	WFDC3;DNTTIP1	0.47	6.18	0.35	2.36e-9	Post-traumatic stress disorder;
CESC	trans	rs9354308	0.866	rs2802054	chr6:66544766	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.6	6.62	0.38	1.93e-10	Metabolite levels;
CESC	cis	rs3096299	0.866	rs4238829	chr16:89462262	G/A	cg08822215	chr16:89438651	ANKRD11	-0.46	-7.15	-0.4	8.58e-12	Multiple myeloma (IgH translocation);
CESC	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.38	7.53	0.42	7.77e-13	Bipolar disorder;
CESC	cis	rs801193	0.967	rs2707853	chr7:66214010	G/A	cg18876405	chr7:65276391	NA	0.52	6.87	0.39	4.64e-11	Aortic root size;
CESC	cis	rs9926296	0.572	rs8046872	chr16:89841552	T/C	cg27121462	chr16:89883253	FANCA	0.55	6.88	0.39	4.18e-11	Vitiligo;
CESC	cis	rs8060686	0.641	rs55790290	chr16:68180242	A/G	cg26727032	chr16:67993705	SLC12A4	-0.53	-6.02	-0.35	5.67e-9	HDL cholesterol;Metabolic syndrome;
CESC	trans	rs10518765	0.945	rs17237564	chr15:54660722	C/T	cg09098624	chr8:11558334	NA	0.55	6.04	0.35	5.11e-9	Select biomarker traits;
CESC	cis	rs854765	0.647	rs854814	chr17:18003648	G/A	cg16928487	chr17:17741425	SREBF1	-0.52	-8.39	-0.46	2.92e-15	Total body bone mineral density;
CESC	cis	rs6540556	0.723	rs6702301	chr1:209923154	C/T	cg05527609	chr1:210001259	C1orf107	-0.51	-6.21	-0.36	2.08e-9	Red blood cell count;
CESC	cis	rs2710642	0.564	rs7558681	chr2:62840987	G/A	cg17519650	chr2:63277830	OTX1	0.48	6.42	0.37	6.39e-10	LDL cholesterol levels;LDL cholesterol;
CESC	cis	rs9987353	0.519	rs11779181	chr8:9063027	A/G	cg06636001	chr8:8085503	FLJ10661	0.51	6.21	0.36	2.07e-9	Recombination measurement;
CESC	cis	rs3820068	0.581	rs59684759	chr1:15919893	A/G	cg16988262	chr1:15930761	NA	0.35	5.59	0.32	5.74e-8	Systolic blood pressure;
CESC	cis	rs3936840	0.539	rs3742445	chr14:102975552	T/A	cg18135206	chr14:102964638	TECPR2	0.46	5.83	0.34	1.57e-8	Plateletcrit;
CESC	cis	rs17818399	0.716	rs62134741	chr2:46782189	G/A	cg02822958	chr2:46747628	ATP6V1E2	0.45	5.29	0.31	2.55e-7	Height;
CESC	cis	rs58785573	0.504	rs3860067	chr4:38611905	T/C	cg18361445	chr4:38666374	KLF3;FLJ13197	0.46	6.25	0.36	1.61e-9	Lymphocyte percentage of white cells;
CESC	trans	rs8005745	0.505	rs710047	chr14:62118819	C/G	cg22828804	chr20:3140466	UBOX5;FASTKD5	-0.41	-6.03	-0.35	5.5e-9	Select biomarker traits;
CESC	cis	rs6087990	0.842	rs4911105	chr20:31330413	G/A	cg13636640	chr20:31349939	DNMT3B	0.83	14.67	0.67	4.65e-36	Ulcerative colitis;
CESC	cis	rs965469	1.000	rs6051712	chr20:3265029	T/A	cg25506879	chr20:3388711	C20orf194	-0.55	-6.0	-0.35	6.41e-9	IFN-related cytopenia;
CESC	cis	rs35306767	0.903	rs12244355	chr10:944465	T/C	cg10556349	chr10:835070	NA	0.58	5.57	0.32	6.1e-8	Eosinophil percentage of granulocytes;
CESC	cis	rs11204677	1	rs11204677	chr1:150574695	C/G	cg22823121	chr1:150693482	HORMAD1	-0.36	-5.29	-0.31	2.6e-7	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
CESC	cis	rs2839186	0.560	rs9975345	chr21:47843004	T/C	cg10351095	chr21:47802916	PCNT	0.49	6.76	0.38	8.55e-11	Testicular germ cell tumor;
CESC	cis	rs9291683	0.668	rs2241474	chr4:10086015	T/C	cg11266682	chr4:10021025	SLC2A9	0.58	10.58	0.54	4.84e-22	Bone mineral density;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24522804	chr11:86666307	FZD4	0.62	7.06	0.4	1.42e-11	Gut microbiome composition (summer);
CESC	cis	rs798554	0.591	rs1182156	chr7:2901084	G/T	cg18446336	chr7:2847575	GNA12	-0.32	-5.13	-0.3	5.6e-7	Height;
CESC	trans	rs9987353	0.840	rs329994	chr8:9123233	A/G	cg13531596	chr19:39894559	NA	-0.48	-6.38	-0.36	8.02e-10	Recombination measurement;
CESC	cis	rs881375	0.967	rs7034492	chr9:123687211	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.39	5.24	0.31	3.22e-7	Rheumatoid arthritis;
CESC	cis	rs561341	0.824	rs1978115	chr17:30220776	A/C	cg00745463	chr17:30367425	LRRC37B	-0.62	-6.33	-0.36	1.04e-9	Hip circumference adjusted for BMI;
CESC	cis	rs2243480	1.000	rs906134	chr7:65444288	G/C	cg25894440	chr7:65020034	NA	-0.68	-5.88	-0.34	1.23e-8	Diabetic kidney disease;
CESC	cis	rs4423214	1.000	rs4944959	chr11:71168234	C/T	cg24826892	chr11:71159390	DHCR7	-0.46	-5.39	-0.31	1.59e-7	Vitamin D levels;
CESC	cis	rs9811920	0.660	rs11719468	chr3:99671848	G/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.39	-6.39	-0.37	7.62e-10	Axial length;
CESC	cis	rs4481887	0.927	rs4345830	chr1:248474845	G/C	cg00666640	chr1:248458726	OR2T12	0.35	5.93	0.34	9.43e-9	Common traits (Other);
CESC	cis	rs3785574	0.962	rs114027117	chr17:61939935	T/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.41	5.07	0.3	7.56e-7	Height;
CESC	cis	rs4423214	0.535	rs1540129	chr11:71129523	C/G	cg05163923	chr11:71159392	DHCR7	0.57	7.13	0.4	9.77e-12	Vitamin D levels;
CESC	cis	rs9487051	0.676	rs6568566	chr6:109596792	G/A	cg01475377	chr6:109611718	NA	-0.45	-7.04	-0.4	1.6e-11	Reticulocyte fraction of red cells;
CESC	cis	rs3091242	0.933	rs926438	chr1:25753638	C/T	cg02931644	chr1:25747376	RHCE	0.39	6.5	0.37	3.99e-10	Erythrocyte sedimentation rate;
CESC	cis	rs9611519	0.929	rs4820425	chr22:41431342	C/A	cg03806693	chr22:41940476	POLR3H	-0.57	-5.91	-0.34	1.02e-8	Neuroticism;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02533120	chr21:33031840	SOD1	0.65	7.65	0.43	3.75e-13	Gut microbiome composition (summer);
CESC	cis	rs1005277	0.579	rs2472183	chr10:38392495	T/G	cg25427524	chr10:38739819	LOC399744	-0.66	-9.5	-0.5	1.29e-18	Extrinsic epigenetic age acceleration;
CESC	cis	rs7707921	0.767	rs862245	chr5:81585737	A/C	cg15871215	chr5:81402204	ATG10	-0.38	-5.28	-0.31	2.71e-7	Breast cancer;
CESC	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg07308232	chr7:1071921	C7orf50	-0.41	-5.52	-0.32	8.17e-8	Longevity;Endometriosis;
CESC	cis	rs4319547	0.656	rs7294559	chr12:122837564	C/A	cg05707623	chr12:122985044	ZCCHC8	-0.57	-6.51	-0.37	3.74e-10	Body mass index;
CESC	cis	rs12912251	1.000	rs12901215	chr15:38992893	G/A	cg01338139	chr15:38987640	C15orf53	-0.47	-5.32	-0.31	2.2e-7	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
CESC	cis	rs977987	0.806	rs4888404	chr16:75428097	G/A	cg03315344	chr16:75512273	CHST6	0.4	5.71	0.33	3e-8	Dupuytren's disease;
CESC	cis	rs1843834	0.505	rs940317	chr2:225358118	C/T	cg22509189	chr2:225307070	NA	-0.41	-5.42	-0.32	1.34e-7	IgE levels in asthmatics (D.p. specific);
CESC	trans	rs6084875	0.620	rs4815735	chr20:4722641	T/C	cg10192164	chr16:30419175	ZNF771	-0.5	-6.16	-0.35	2.7e-9	Systemic lupus erythematosus;
CESC	cis	rs72781680	0.581	rs116520786	chr2:24272645	C/T	cg20701182	chr2:24300061	SF3B14	0.93	10.41	0.54	1.73e-21	Lymphocyte counts;
CESC	cis	rs1728785	0.901	rs1103286	chr16:68578625	C/T	cg02972257	chr16:68554789	NA	-0.55	-6.31	-0.36	1.17e-9	Ulcerative colitis;
CESC	cis	rs75229567	0.618	rs11177848	chr12:70180892	A/G	cg10114359	chr12:70132523	RAB3IP	1.34	8.38	0.46	3.17e-15	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
CESC	cis	rs72627509	0.767	rs6853156	chr4:57774843	C/T	cg26694713	chr4:57773883	REST	0.58	5.58	0.32	5.81e-8	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CESC	cis	rs9457247	0.967	rs1187532	chr6:167382020	G/A	cg25258033	chr6:167368657	RNASET2	0.39	5.87	0.34	1.27e-8	Crohn's disease;
CESC	cis	rs1348850	0.914	rs7604673	chr2:178392346	A/G	cg22681709	chr2:178499509	PDE11A	-0.41	-5.83	-0.34	1.59e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs1559088	0.901	rs12610053	chr19:33582606	A/G	cg27124370	chr19:33622961	WDR88	0.47	6.15	0.35	2.91e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	10.52	0.54	7.57e-22	Prudent dietary pattern;
CESC	cis	rs7666738	0.830	rs4699601	chr4:99034429	G/A	cg05340658	chr4:99064831	C4orf37	0.83	12.92	0.62	5.86e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6120849	0.754	rs6087666	chr20:33640242	G/A	cg24642439	chr20:33292090	TP53INP2	0.68	6.77	0.38	8.46e-11	Protein C levels;
CESC	cis	rs3820928	1.000	rs3731593	chr2:227773924	A/G	cg05526886	chr2:227700861	RHBDD1	-0.43	-5.53	-0.32	7.83e-8	Pulmonary function;
CESC	cis	rs12477438	0.520	rs13004491	chr2:99738008	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.86	15.87	0.7	2.48e-40	Chronic sinus infection;
CESC	cis	rs4268898	0.552	rs11125454	chr2:24373669	T/C	cg06627628	chr2:24431161	ITSN2	0.6	8.23	0.45	8.28e-15	Asthma;
CESC	cis	rs67311347	1.000	rs2276868	chr3:40498845	C/T	cg24209194	chr3:40518798	ZNF619	-0.46	-6.04	-0.35	5.1e-9	Renal cell carcinoma;
CESC	cis	rs4148883	0.675	rs116265877	chr4:100096896	G/A	cg13256891	chr4:100009986	ADH5	0.53	6.93	0.39	3.27e-11	Alcohol dependence;
CESC	cis	rs1018836	0.608	rs7843149	chr8:91474961	C/T	cg16814680	chr8:91681699	NA	-0.54	-7.48	-0.42	1.09e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs9815354	0.812	rs60927633	chr3:41844010	C/T	cg03022575	chr3:42003672	ULK4	0.7	6.04	0.35	5.26e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs761746	0.847	rs4820976	chr22:31876466	G/A	cg25791279	chr22:32026902	PISD	-0.5	-5.57	-0.32	6.21e-8	Intelligence;
CESC	cis	rs2204008	0.658	rs11495742	chr12:38395688	C/A	cg13010199	chr12:38710504	ALG10B	0.54	6.67	0.38	1.45e-10	Bladder cancer;
CESC	cis	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg04267008	chr7:1944627	MAD1L1	-0.57	-6.93	-0.39	3.2e-11	Bipolar disorder and schizophrenia;
CESC	trans	rs17685	0.753	rs4728550	chr7:75670988	C/A	cg19862616	chr7:65841803	NCRNA00174	-0.84	-12.47	-0.61	2.15e-28	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs10203711	0.901	rs907104	chr2:239564564	T/G	cg14580085	chr2:239553406	NA	0.34	5.09	0.3	6.77e-7	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs926938	0.527	rs360665	chr1:115478503	A/T	cg12756093	chr1:115239321	AMPD1	0.45	6.18	0.35	2.44e-9	Autism;
CESC	cis	rs56399783	0.901	rs757788	chr7:2836433	A/G	cg19731401	chr7:2775893	GNA12	0.65	5.71	0.33	2.96e-8	Childhood ear infection;
CESC	trans	rs9833726	0.799	rs11710933	chr3:86136781	A/T	cg10416071	chr15:75628863	COMMD4	0.59	6.12	0.35	3.37e-9	Breast cancer;
CESC	cis	rs1728785	0.901	rs1170437	chr16:68607943	C/T	cg02972257	chr16:68554789	NA	-0.6	-6.82	-0.39	6.06e-11	Ulcerative colitis;
CESC	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.48	6.29	0.36	1.32e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7914558	1.000	rs10786733	chr10:104794947	G/A	cg04362960	chr10:104952993	NT5C2	0.47	6.23	0.36	1.8e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs1008375	0.932	rs12500912	chr4:17603318	C/T	cg16339924	chr4:17578868	LAP3	0.68	8.73	0.47	2.9e-16	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs936229	0.749	rs4886633	chr15:75178207	G/A	cg10253484	chr15:75165896	SCAMP2	-0.45	-5.14	-0.3	5.28e-7	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg08156809	chr7:74071310	GTF2I	-0.44	-6.21	-0.36	1.99e-9	Fibrinogen levels;
CESC	cis	rs72781680	0.948	rs72796319	chr2:24133027	T/C	cg20701182	chr2:24300061	SF3B14	0.63	5.67	0.33	3.79e-8	Lymphocyte counts;
CESC	cis	rs1256061	0.603	rs1256039	chr14:64738979	G/C	cg21174375	chr14:64681225	SYNE2	0.51	6.82	0.39	6.15e-11	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	trans	rs11088226	1.000	rs11088226	chr21:33925531	C/G	cg09050820	chr6:167586206	TCP10L2	0.63	6.31	0.36	1.18e-9	Gastritis;
CESC	cis	rs875971	0.862	rs10263690	chr7:65766453	G/C	cg18252515	chr7:66147081	NA	0.43	5.73	0.33	2.67e-8	Aortic root size;
CESC	cis	rs3733585	0.673	rs4311316	chr4:9955971	A/C	cg00071950	chr4:10020882	SLC2A9	0.66	10.7	0.55	1.99e-22	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs2730245	0.636	rs710421	chr7:158668575	T/C	cg14689365	chr7:158441557	NCAPG2	0.42	5.23	0.31	3.5e-7	Height;
CESC	cis	rs56104184	0.775	rs73061697	chr19:49400000	C/T	cg21252483	chr19:49399788	TULP2	-0.52	-5.69	-0.33	3.36e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.54	-7.19	-0.4	6.76e-12	Longevity;Endometriosis;
CESC	cis	rs425277	0.606	rs262663	chr1:2084598	T/C	cg16545954	chr1:2118288	C1orf86	0.37	7.11	0.4	1.05e-11	Height;
CESC	cis	rs7116495	1.000	rs1939247	chr11:71740521	A/T	cg10381502	chr11:71823885	C11orf51	-0.67	-5.51	-0.32	8.66e-8	Severe influenza A (H1N1) infection;
CESC	cis	rs17826219	0.706	rs609472	chr17:28951427	T/C	cg13385521	chr17:29058706	SUZ12P	0.6	5.16	0.3	4.89e-7	Body mass index;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12038521	chr19:2111714	AP3D1	-0.63	-7.17	-0.4	7.47e-12	Gut microbiome composition (summer);
CESC	trans	rs62103177	0.810	rs62103197	chr18:77632923	G/A	cg05926928	chr17:57297772	GDPD1	1.23	10.32	0.54	3.37e-21	Opioid sensitivity;
CESC	cis	rs6545883	1.000	rs6545883	chr2:61772257	A/G	cg15711740	chr2:61764176	XPO1	-0.43	-5.7	-0.33	3.23e-8	Tuberculosis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11662452	chr6:126964983	NA	-0.54	-6.96	-0.39	2.75e-11	Gut microbiome composition (summer);
CESC	cis	rs9549367	0.713	rs2480949	chr13:113853149	T/C	cg00898013	chr13:113819073	PROZ	0.46	6.9	0.39	3.81e-11	Platelet distribution width;
CESC	cis	rs888194	1.000	rs888194	chr12:109986918	C/G	cg19025524	chr12:109796872	NA	-0.37	-5.48	-0.32	9.75e-8	Neuroticism;
CESC	cis	rs9443189	0.570	rs6903124	chr6:76290079	A/C	cg01950844	chr6:76311363	SENP6	0.87	9.54	0.51	9.61e-19	Prostate cancer;
CESC	cis	rs9513593	1.000	rs12875982	chr13:99850615	C/T	cg21788972	chr13:99853209	UBAC2	0.63	7.14	0.4	8.76e-12	Psoriasis;
CESC	cis	rs17826219	0.636	rs2449770	chr17:29101064	G/T	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.91e-10	Body mass index;
CESC	cis	rs4563143	0.592	rs12151001	chr19:29283386	C/G	cg12667521	chr19:29218732	NA	0.48	5.92	0.34	1.02e-8	Methadone dose in opioid dependence;
CESC	cis	rs6032067	0.777	rs116517830	chr20:43784872	G/A	cg10761708	chr20:43804764	PI3	0.55	6.51	0.37	3.7e-10	Blood protein levels;
CESC	cis	rs2486288	0.656	rs11637364	chr15:45579238	C/T	cg09092052	chr15:45571596	NA	0.45	5.29	0.31	2.58e-7	Glomerular filtration rate;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg21207699	chr9:8713788	PTPRD	-0.36	-6.0	-0.35	6.48e-9	Gambling;
CESC	trans	rs995758	0.647	rs1489761	chr4:145455491	A/G	cg03219697	chr8:145653915	VPS28	0.43	6.23	0.36	1.81e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;
CESC	cis	rs7561273	0.609	rs3795953	chr2:24345707	C/G	cg20701182	chr2:24300061	SF3B14	0.46	6.01	0.35	6.27e-9	Quantitative traits;
CESC	cis	rs2303759	0.874	rs10411630	chr19:49891314	C/A	cg24324837	chr19:49891574	CCDC155	0.52	5.92	0.34	9.74e-9	Multiple sclerosis;
CESC	cis	rs926938	0.584	rs6689326	chr1:115369112	T/A	cg12756093	chr1:115239321	AMPD1	-0.45	-6.09	-0.35	3.95e-9	Autism;
CESC	cis	rs7659604	0.628	rs6838153	chr4:122720999	A/G	cg20573242	chr4:122745356	CCNA2	0.57	6.92	0.39	3.45e-11	Type 2 diabetes;
CESC	cis	rs28829049	0.597	rs71645438	chr1:19502349	G/A	cg13387374	chr1:19411106	UBR4	0.43	5.45	0.32	1.13e-7	QRS duration in Tripanosoma cruzi seropositivity;
CESC	cis	rs7223966	1.000	rs11657120	chr17:61857218	G/A	cg11494091	chr17:61959527	GH2	0.38	5.18	0.3	4.33e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs7312774	0.618	rs3803122	chr12:107354680	G/A	cg16260113	chr12:107380972	MTERFD3	0.82	7.48	0.42	1.11e-12	Severe influenza A (H1N1) infection;
CESC	cis	rs798766	1.000	rs2166580	chr4:1743169	G/A	cg05874882	chr4:1763078	NA	-0.56	-7.19	-0.4	6.5e-12	Bladder cancer;Urinary bladder cancer;
CESC	cis	rs909674	0.731	rs6001594	chr22:39837472	C/T	cg11247378	chr22:39784982	NA	-0.61	-8.63	-0.47	5.91e-16	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg15112475	chr7:1198522	ZFAND2A	-0.45	-7.28	-0.41	3.84e-12	Longevity;Endometriosis;
CESC	cis	rs12348691	0.503	rs4743138	chr9:100614296	C/T	cg13688889	chr9:100608707	NA	0.88	13.78	0.65	6.04e-33	Alopecia areata;
CESC	cis	rs11098499	0.863	rs10030660	chr4:120436704	G/A	cg24375607	chr4:120327624	NA	0.43	5.13	0.3	5.73e-7	Corneal astigmatism;
CESC	cis	rs13191362	0.935	rs34009353	chr6:163007668	T/G	cg06582575	chr6:163149167	PACRG;PARK2	0.78	8.21	0.45	9.97e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs916888	0.773	rs199535	chr17:44822662	A/G	cg17911788	chr17:44343683	NA	-0.61	-8.3	-0.45	5.38e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs7115242	0.748	rs1035237	chr11:116727850	G/C	cg01368799	chr11:117014884	PAFAH1B2	0.59	5.19	0.3	4.26e-7	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11989942	chr17:80067146	CCDC57	-0.58	-6.72	-0.38	1.11e-10	Gut microbiome composition (summer);
CESC	cis	rs4665809	0.627	rs13014338	chr2:26463024	C/T	cg27170947	chr2:26402098	FAM59B	0.87	9.89	0.52	7.6e-20	Gut microbiome composition (summer);
CESC	trans	rs11098499	0.874	rs9995277	chr4:120108603	G/A	cg25214090	chr10:38739885	LOC399744	0.58	7.69	0.43	2.87e-13	Corneal astigmatism;
CESC	cis	rs1008375	0.966	rs2191504	chr4:17675592	C/G	cg16339924	chr4:17578868	LAP3	0.51	6.44	0.37	5.73e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs1799949	1.000	rs8070085	chr17:41341984	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	-0.55	-7.52	-0.42	8.28e-13	Menopause (age at onset);
CESC	cis	rs9457247	0.967	rs385460	chr6:167403888	A/T	cg23791538	chr6:167370224	RNASET2	-0.59	-8.42	-0.46	2.44e-15	Crohn's disease;
CESC	cis	rs7811142	0.943	rs67196635	chr7:100025564	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.92	9.76	0.51	2.07e-19	Platelet count;
CESC	cis	rs11122272	0.764	rs4486439	chr1:231477470	C/T	cg06096015	chr1:231504339	EGLN1	0.4	5.95	0.34	8.37e-9	Hemoglobin concentration;
CESC	cis	rs9733	0.596	rs12089989	chr1:150715782	G/A	cg17724175	chr1:150552817	MCL1	0.4	6.54	0.37	3.2e-10	Tonsillectomy;
CESC	cis	rs9658691	0.607	rs3740281	chr10:90772150	G/A	cg03111039	chr10:90751583	FAS;ACTA2	-0.61	-5.34	-0.31	2e-7	Mosquito bite size;
CESC	cis	rs9457247	1.000	rs932644	chr6:167404187	A/C	cg23791538	chr6:167370224	RNASET2	-0.59	-8.42	-0.46	2.44e-15	Crohn's disease;
CESC	cis	rs4819052	0.851	rs13047598	chr21:46660777	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.75	9.98	0.52	4.1e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs1865721	0.839	rs59718187	chr18:73144032	C/T	cg26385618	chr18:73139727	C18orf62	-0.52	-8.31	-0.45	5.15e-15	Intelligence;
CESC	cis	rs11078597	0.767	rs4525526	chr17:1650125	T/C	cg18436246	chr17:1640651	WDR81	0.61	7.31	0.41	3.24e-12	Serum albumin level;
CESC	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg14893161	chr1:205819251	PM20D1	0.89	14.74	0.67	2.48e-36	Menarche (age at onset);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg00114008	chr1:27114423	PIGV	-0.45	-6.11	-0.35	3.61e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs17666538	0.585	rs10090260	chr8:608034	T/C	cg07234876	chr8:600039	NA	0.86	6.49	0.37	4.23e-10	IgG glycosylation;
CESC	cis	rs7605827	0.866	rs9287665	chr2:15667263	A/T	cg19274914	chr2:15703543	NA	0.38	6.8	0.39	7.12e-11	Educational attainment (years of education);
CESC	cis	rs780096	0.526	rs809058	chr2:27616790	T/C	cg22903471	chr2:27725779	GCKR	-0.5	-7.08	-0.4	1.31e-11	Total body bone mineral density;
CESC	cis	rs13256369	0.865	rs13282523	chr8:8577293	C/G	cg18904891	chr8:8559673	CLDN23	0.64	7.44	0.42	1.45e-12	Obesity-related traits;
CESC	cis	rs1005277	0.579	rs2504143	chr10:38383706	C/T	cg00409905	chr10:38381863	ZNF37A	-0.44	-5.88	-0.34	1.22e-8	Extrinsic epigenetic age acceleration;
CESC	cis	rs9309473	0.948	rs2421550	chr2:73658686	A/G	cg20560298	chr2:73613845	ALMS1	-0.47	-6.35	-0.36	9.42e-10	Metabolite levels;
CESC	cis	rs4588572	0.643	rs10043027	chr5:77792707	T/C	cg11547950	chr5:77652471	NA	-0.43	-5.53	-0.32	7.68e-8	Triglycerides;
CESC	cis	rs75804782	0.521	rs55988884	chr2:239396930	G/A	cg18131467	chr2:239335373	ASB1	-0.69	-5.73	-0.33	2.66e-8	Morning vs. evening chronotype;Chronotype;
CESC	cis	rs7474896	0.616	rs2474561	chr10:38373544	C/T	cg25427524	chr10:38739819	LOC399744	-0.56	-6.0	-0.35	6.41e-9	Obesity (extreme);
CESC	cis	rs7605827	0.930	rs6725454	chr2:15692879	C/A	cg19274914	chr2:15703543	NA	0.37	6.7	0.38	1.22e-10	Educational attainment (years of education);
CESC	cis	rs2486288	0.656	rs11631021	chr15:45556829	A/G	cg09092052	chr15:45571596	NA	0.48	5.62	0.33	4.73e-8	Glomerular filtration rate;
CESC	trans	rs7618501	0.966	rs2246832	chr3:49881134	A/T	cg21659725	chr3:3221576	CRBN	0.81	12.82	0.62	1.34e-29	Intelligence (multi-trait analysis);
CESC	cis	rs7786808	0.586	rs7794256	chr7:158206214	T/G	cg09998033	chr7:158218633	PTPRN2	0.38	5.58	0.32	5.97e-8	Obesity-related traits;
CESC	cis	rs4478858	0.698	rs6669381	chr1:31833506	A/G	cg00250761	chr1:31883323	NA	-0.26	-5.07	-0.3	7.56e-7	Alcohol dependence;
CESC	cis	rs2412459	1.000	rs8023482	chr15:40307095	A/C	cg20255370	chr15:40268687	EIF2AK4	-0.53	-5.23	-0.31	3.51e-7	Response to haloperidol in psychosis;
CESC	cis	rs1799949	0.602	rs4600503	chr17:41414324	C/G	cg23758822	chr17:41437982	NA	1.05	16.25	0.71	1.17e-41	Menopause (age at onset);
CESC	trans	rs61931739	0.534	rs1817761	chr12:34105719	C/T	cg26384229	chr12:38710491	ALG10B	0.59	8.18	0.45	1.17e-14	Morning vs. evening chronotype;
CESC	cis	rs863345	0.604	rs12044288	chr1:158463863	C/A	cg12129480	chr1:158549410	OR10X1	-0.35	-6.97	-0.39	2.55e-11	Pneumococcal bacteremia;
CESC	cis	rs9733	0.596	rs12089989	chr1:150715782	G/A	cg18016565	chr1:150552671	MCL1	0.34	5.3	0.31	2.44e-7	Tonsillectomy;
CESC	cis	rs67311347	1.000	rs73078123	chr3:40458963	G/A	cg24209194	chr3:40518798	ZNF619	0.52	6.48	0.37	4.52e-10	Renal cell carcinoma;
CESC	cis	rs3820928	0.605	rs10186145	chr2:227781150	A/G	cg05526886	chr2:227700861	RHBDD1	-0.56	-7.74	-0.43	2.12e-13	Pulmonary function;
CESC	cis	rs4689388	0.926	rs10012946	chr4:6293350	C/T	cg14416269	chr4:6271139	WFS1	-0.47	-6.45	-0.37	5.26e-10	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs12476592	0.602	rs10865337	chr2:63720906	C/T	cg17519650	chr2:63277830	OTX1	-0.49	-5.43	-0.32	1.3e-7	Childhood ear infection;
CESC	trans	rs5769765	0.862	rs9616384	chr22:50313082	C/T	cg09872104	chr7:134855509	C7orf49	-0.55	-6.31	-0.36	1.19e-9	Schizophrenia;
CESC	cis	rs2070488	0.775	rs2070489	chr3:38519424	A/G	cg24069376	chr3:38537580	EXOG	0.34	5.77	0.33	2.26e-8	Electrocardiographic conduction measures;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg19167683	chr11:57194495	SLC43A3	-0.48	-6.0	-0.35	6.35e-9	Ulcerative colitis;
CESC	trans	rs877282	0.898	rs10904546	chr10:757222	A/G	cg22713356	chr15:30763199	NA	1.05	9.16	0.49	1.45e-17	Uric acid levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10011777	chr1:2451511	PANK4	-0.54	-6.42	-0.37	6.29e-10	Gut microbiome composition (summer);
CESC	cis	rs8060686	0.641	rs73598006	chr16:68074454	C/G	cg26727032	chr16:67993705	SLC12A4	-0.52	-6.4	-0.37	6.82e-10	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs17293817	0.589	rs36106483	chr10:1418362	A/G	cg04271617	chr10:1416546	ADARB2	0.35	5.6	0.33	5.24e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs5760092	0.755	rs4585126	chr22:24270005	T/C	cg10150615	chr22:24372951	LOC391322	0.5	6.27	0.36	1.44e-9	Urinary 1,3-butadiene metabolite levels in smokers;
CESC	cis	rs9796	0.558	rs4445868	chr15:41531991	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.45	-6.47	-0.37	4.78e-10	Menopause (age at onset);
CESC	cis	rs3768617	0.510	rs10752900	chr1:183086238	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.89	14.36	0.66	5.49e-35	Fuchs's corneal dystrophy;
CESC	cis	rs13108904	0.935	rs4246685	chr4:1279727	T/C	cg00684032	chr4:1343700	KIAA1530	0.39	5.43	0.32	1.27e-7	Obesity-related traits;
CESC	cis	rs7809950	0.954	rs2520241	chr7:107135443	A/G	cg23024343	chr7:107201750	COG5	-0.43	-6.21	-0.36	2.03e-9	Coronary artery disease;
CESC	cis	rs7772486	0.686	rs1337841	chr6:146059487	A/G	cg05347473	chr6:146136440	FBXO30	-0.53	-6.88	-0.39	4.18e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs8114671	0.562	rs2273683	chr20:33509523	C/T	cg07148914	chr20:33460835	GGT7	0.52	6.79	0.39	7.24e-11	Height;
CESC	cis	rs694739	0.930	rs574087	chr11:64102948	A/G	cg23796481	chr11:64053134	BAD;GPR137	0.68	8.67	0.47	4.4e-16	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CESC	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.48	-5.2	-0.3	3.9e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs67478160	0.634	rs941473	chr14:104201869	C/G	cg01849466	chr14:104193079	ZFYVE21	-0.54	-7.83	-0.43	1.14e-13	Schizophrenia;
CESC	trans	rs11098499	0.779	rs10857066	chr4:120286596	C/T	cg25214090	chr10:38739885	LOC399744	0.65	9.04	0.49	3.36e-17	Corneal astigmatism;
CESC	cis	rs1267303	0.675	rs1267309	chr1:46987342	G/A	cg25110126	chr1:46999211	NA	-0.72	-8.88	-0.48	1.04e-16	Monobrow;
CESC	cis	rs7193541	0.965	rs28616016	chr16:74676964	T/C	cg01733217	chr16:74700730	RFWD3	0.93	13.38	0.63	1.58e-31	Multiple myeloma;
CESC	cis	rs9487051	0.768	rs458740	chr6:109525527	C/T	cg01475377	chr6:109611718	NA	-0.46	-6.91	-0.39	3.56e-11	Reticulocyte fraction of red cells;
CESC	cis	rs1953600	0.729	rs2819872	chr10:81906269	A/G	cg00277334	chr10:82204260	NA	0.52	7.71	0.43	2.55e-13	Sarcoidosis;
CESC	cis	rs7084402	0.967	rs7087528	chr10:60301294	A/T	cg07615347	chr10:60278583	BICC1	-0.57	-8.6	-0.47	7.13e-16	Refractive error;
CESC	cis	rs9322193	0.923	rs9478291	chr6:150050570	A/G	cg13206674	chr6:150067644	NUP43	0.46	6.63	0.38	1.84e-10	Lung cancer;
CESC	cis	rs637571	0.584	rs659824	chr11:65636509	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.42	-5.1	-0.3	6.54e-7	Eosinophil percentage of white cells;
CESC	cis	rs1878931	0.615	rs4786412	chr16:3440390	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	1.03	17.14	0.73	7.81e-45	Body mass index (adult);
CESC	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg11965913	chr1:205819406	PM20D1	0.83	13.74	0.64	8.48e-33	Menarche (age at onset);
CESC	trans	rs1814175	0.645	rs847639	chr11:49919603	C/T	cg15704280	chr7:45808275	SEPT13	-1.01	-18.94	-0.76	3.64e-51	Height;
CESC	cis	rs2836974	0.584	rs6517535	chr21:40653352	G/C	cg11890956	chr21:40555474	PSMG1	-0.97	-15.94	-0.7	1.46e-40	Cognitive function;
CESC	cis	rs4555082	0.874	rs2816611	chr14:105722976	G/C	cg27165867	chr14:105738592	BRF1	-0.56	-6.26	-0.36	1.51e-9	Mean platelet volume;Platelet distribution width;
CESC	cis	rs67311347	1.000	rs4973998	chr3:40460352	C/T	cg09455208	chr3:40491958	NA	0.52	8.48	0.46	1.56e-15	Renal cell carcinoma;
CESC	cis	rs2032447	0.839	rs199750	chr6:26016462	A/G	cg03517284	chr6:25882590	NA	0.43	5.86	0.34	1.37e-8	Intelligence (multi-trait analysis);
CESC	trans	rs11098499	0.954	rs10031483	chr4:120422636	T/C	cg25214090	chr10:38739885	LOC399744	0.7	9.78	0.51	1.7e-19	Corneal astigmatism;
CESC	cis	rs12477438	0.520	rs6717723	chr2:99756930	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.86	15.04	0.68	2.28e-37	Chronic sinus infection;
CESC	cis	rs8114671	0.804	rs6060139	chr20:33566499	T/C	cg06115741	chr20:33292138	TP53INP2	0.46	5.48	0.32	1e-7	Height;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg07005173	chr17:7977057	ALOX12B	0.43	6.01	0.35	6.11e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs9303401	0.573	rs62081879	chr17:57181524	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.0	12.4	0.61	3.86e-28	Cognitive test performance;
CESC	cis	rs2204008	0.744	rs11182316	chr12:38499552	G/A	cg13010199	chr12:38710504	ALG10B	0.53	6.71	0.38	1.21e-10	Bladder cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22122542	chr4:113486179	C4orf21	-0.56	-6.64	-0.38	1.82e-10	Gut microbiome composition (summer);
CESC	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg24642844	chr7:1081250	C7orf50	-0.77	-9.63	-0.51	5.27e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs12586317	0.547	rs13379372	chr14:35483882	A/C	cg16230307	chr14:35515116	FAM177A1	0.98	10.57	0.54	5.22e-22	Psoriasis;
CESC	cis	rs4450798	0.793	rs60991429	chr3:13751113	G/A	cg05589046	chr3:13742034	LOC285375	0.38	5.6	0.33	5.41e-8	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs6546550	0.935	rs10865380	chr2:70091246	T/C	cg02498382	chr2:70120550	SNRNP27	-0.35	-5.97	-0.34	7.62e-9	Prevalent atrial fibrillation;
CESC	cis	rs2997447	0.761	rs61776585	chr1:26438498	G/C	cg24596570	chr1:26146463	FAM54B;LOC646471	0.62	5.33	0.31	2.07e-7	QRS complex (12-leadsum);
CESC	cis	rs13191362	0.935	rs7769048	chr6:163010040	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.82	8.22	0.45	9.12e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs10479542	0.583	rs4131080	chr5:179044292	G/A	cg05457628	chr5:178986728	RUFY1	0.5	7.09	0.4	1.2e-11	Lung cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16101703	chr5:65440440	SFRS12	0.51	6.09	0.35	3.95e-9	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.830	rs10005120	chr4:99038200	A/G	cg05340658	chr4:99064831	C4orf37	0.82	12.88	0.62	8.45e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs12136530	0.774	rs4911996	chr1:19765205	C/G	cg01832549	chr1:19774989	CAPZB	0.47	6.49	0.37	4.25e-10	Lead levels in blood;
CESC	cis	rs7762018	1.000	rs4716375	chr6:170071218	A/C	cg05834625	chr6:170176447	C6orf70	0.62	7.46	0.42	1.25e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs9611565	0.649	rs5751144	chr22:42128097	A/G	cg06481639	chr22:41940642	POLR3H	-0.46	-5.38	-0.31	1.62e-7	Vitiligo;
CESC	cis	rs9733	0.566	rs112967224	chr1:150677263	G/A	cg18016565	chr1:150552671	MCL1	0.33	5.14	0.3	5.43e-7	Tonsillectomy;
CESC	cis	rs6089584	0.546	rs4925337	chr20:60637637	T/C	cg06108461	chr20:60628389	TAF4	-0.56	-7.34	-0.41	2.61e-12	Body mass index;
CESC	cis	rs6460942	0.915	rs75732743	chr7:12454095	C/T	cg06484146	chr7:12443880	VWDE	-0.78	-9.14	-0.49	1.68e-17	Coronary artery disease;
CESC	cis	rs67478160	0.619	rs12885018	chr14:104273812	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.51	-7.19	-0.4	6.56e-12	Schizophrenia;
CESC	cis	rs9311474	0.508	rs6805156	chr3:52609362	T/C	cg07507251	chr3:52567010	NT5DC2	0.32	5.63	0.33	4.6e-8	Electroencephalogram traits;
CESC	cis	rs873946	0.504	rs12254034	chr10:134571007	T/C	cg18305652	chr10:134549665	INPP5A	0.48	7.01	0.4	1.94e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs7618915	0.501	rs2159644	chr3:52774530	C/T	cg17372223	chr3:52568218	NT5DC2	0.43	6.5	0.37	4.03e-10	Bipolar disorder;
CESC	cis	rs1707322	1.000	rs7526369	chr1:46390560	G/C	cg03146154	chr1:46216737	IPP	0.72	9.82	0.52	1.31e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs5750830	0.594	rs6001587	chr22:39819008	T/C	cg11247378	chr22:39784982	NA	-0.62	-9.06	-0.49	2.88e-17	Intelligence (multi-trait analysis);
CESC	cis	rs7829975	0.593	rs2921061	chr8:8317615	A/T	cg15556689	chr8:8085844	FLJ10661	0.62	8.11	0.45	1.85e-14	Mood instability;
CESC	cis	rs796364	0.951	rs281793	chr2:200847990	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.89	8.77	0.47	2.23e-16	Schizophrenia;
CESC	cis	rs933688	1.000	rs332531	chr5:90790451	G/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.8	10.1	0.53	1.62e-20	Smoking behavior;
CESC	cis	rs15676	0.783	rs10988134	chr9:131595407	C/T	cg00228799	chr9:131580591	ENDOG	-0.55	-7.0	-0.4	2.1e-11	Blood metabolite levels;
CESC	cis	rs4665809	0.590	rs3806514	chr2:26466772	C/T	cg22920501	chr2:26401640	FAM59B	0.93	10.89	0.56	4.54e-23	Gut microbiome composition (summer);
CESC	cis	rs3857067	0.806	rs7669168	chr4:95104881	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.61	-9.07	-0.49	2.67e-17	QT interval;
CESC	cis	rs1348850	0.914	rs12469386	chr2:178358281	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.71	-9.95	-0.52	5.04e-20	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs3809863	0.646	rs9899121	chr17:45395144	C/T	cg08085267	chr17:45401833	C17orf57	-0.69	-9.19	-0.49	1.16e-17	Glaucoma (primary open-angle);
CESC	cis	rs2072732	0.821	rs7339938	chr1:2963493	G/C	cg03976712	chr1:2946727	NA	0.33	5.78	0.33	2.08e-8	Plateletcrit;
CESC	cis	rs933688	0.938	rs10063683	chr5:90714595	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.99	11.82	0.59	3.43e-26	Smoking behavior;
CESC	cis	rs7824557	0.564	rs2572389	chr8:11236392	T/C	cg21775007	chr8:11205619	TDH	-0.54	-8.07	-0.44	2.52e-14	Retinal vascular caliber;
CESC	cis	rs2645694	0.626	rs2703119	chr4:77823640	C/T	cg10057126	chr4:77819792	ANKRD56	0.58	8.4	0.46	2.79e-15	Emphysema distribution in smoking;
CESC	cis	rs8177253	0.665	rs9869535	chr3:133451581	G/A	cg24879335	chr3:133465180	TF	0.37	6.47	0.37	4.62e-10	Iron status biomarkers;
CESC	cis	rs9487051	0.872	rs9487032	chr6:109605323	G/T	cg21918786	chr6:109611834	NA	-0.4	-5.94	-0.34	8.87e-9	Reticulocyte fraction of red cells;
CESC	cis	rs2731664	0.792	rs652242	chr5:176873010	C/G	cg23176889	chr5:176863531	GRK6	-0.63	-10.9	-0.56	4.08e-23	Intelligence (multi-trait analysis);
CESC	cis	rs36051895	0.623	rs10118267	chr9:5243736	T/C	cg02405213	chr9:5042618	JAK2	-0.52	-6.22	-0.36	1.96e-9	Pediatric autoimmune diseases;
CESC	cis	rs2979489	0.891	rs2915591	chr8:30395948	C/G	cg26383811	chr8:30366931	RBPMS	-0.81	-10.03	-0.52	2.89e-20	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CESC	cis	rs735396	1.000	rs2464195	chr12:121435475	G/A	cg25281562	chr12:121454272	C12orf43	0.39	5.12	0.3	5.93e-7	N-glycan levels;
CESC	cis	rs6460942	0.908	rs6956500	chr7:12232120	T/C	cg06484146	chr7:12443880	VWDE	-0.47	-5.09	-0.3	6.93e-7	Coronary artery disease;
CESC	cis	rs7267979	1.000	rs6037095	chr20:25335687	A/G	cg08601574	chr20:25228251	PYGB	-0.38	-5.49	-0.32	9.3e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7617773	0.817	rs9834095	chr3:48327751	G/A	cg11946769	chr3:48343235	NME6	0.8	10.89	0.56	4.71e-23	Coronary artery disease;
CESC	cis	rs910316	0.763	rs13712	chr14:75483812	T/C	cg11812906	chr14:75593930	NEK9	0.82	13.58	0.64	3.1e-32	Height;
CESC	cis	rs2820292	0.619	rs11576508	chr1:201824390	G/A	cg11586189	chr1:201857591	SHISA4	-0.36	-5.81	-0.34	1.75e-8	Waist circumference;Body mass index (joint analysis main effects and smoking interaction);Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);
CESC	cis	rs35110281	0.667	rs4818859	chr21:45117120	G/A	cg04455712	chr21:45112962	RRP1B	0.47	7.13	0.4	9.39e-12	Mean corpuscular volume;
CESC	cis	rs6009527	1.000	rs6009527	chr22:49570587	C/T	cg12746016	chr22:49560550	NA	0.35	5.44	0.32	1.19e-7	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);
CESC	cis	rs10465746	0.725	rs4907185	chr1:84336047	T/C	cg10977910	chr1:84465055	TTLL7	0.56	7.78	0.43	1.64e-13	Obesity-related traits;
CESC	cis	rs9916302	0.904	rs679995	chr17:37441679	A/T	cg00129232	chr17:37814104	STARD3	0.48	6.05	0.35	5e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs1023500	0.505	rs134885	chr22:42673811	C/G	cg15557168	chr22:42548783	NA	-0.47	-7.35	-0.41	2.46e-12	Schizophrenia;
CESC	cis	rs769267	0.899	rs67720221	chr19:19440864	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.44	-5.61	-0.33	5.03e-8	Tonsillectomy;
CESC	cis	rs644799	1.000	rs527899	chr11:95529242	T/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.53	6.41	0.37	6.77e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs10129255	0.556	rs6576224	chr14:107186236	G/A	cg23076370	chr14:107095027	NA	-0.65	-9.62	-0.51	5.59e-19	Kawasaki disease;
CESC	cis	rs1552244	1.000	rs7651058	chr3:10066964	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-10.95	-0.56	2.82e-23	Alzheimer's disease;
CESC	cis	rs4819052	0.851	rs7276591	chr21:46680156	C/T	cg11663144	chr21:46675770	NA	-0.61	-9.69	-0.51	3.44e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs1538970	0.962	rs2185549	chr1:45814103	C/T	cg05343316	chr1:45956843	TESK2	-0.83	-11.34	-0.57	1.46e-24	Platelet count;
CESC	cis	rs4713118	0.516	rs4713142	chr6:28106347	T/G	cg19592336	chr6:28129416	ZNF389	0.61	8.24	0.45	8.13e-15	Parkinson's disease;
CESC	cis	rs1949733	1.000	rs2631740	chr4:8484106	C/A	cg11789530	chr4:8429930	ACOX3	-0.78	-11.13	-0.56	7.31e-24	Response to antineoplastic agents;
CESC	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	7.59	0.42	5.31e-13	Prudent dietary pattern;
CESC	cis	rs7208859	0.673	rs7211776	chr17:29120196	T/G	cg19761014	chr17:28927070	LRRC37B2	0.68	6.72	0.38	1.11e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs4689388	0.856	rs3200	chr4:6304878	C/T	cg25554036	chr4:6271136	WFS1	0.57	9.38	0.5	3.11e-18	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs9326248	0.648	rs11216257	chr11:116932561	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.47	5.06	0.3	7.69e-7	Blood protein levels;
CESC	cis	rs35160687	0.644	rs4832264	chr2:86486834	A/G	cg01119172	chr2:86362222	SNORD94;PTCD3	-0.39	-5.23	-0.31	3.51e-7	Night sleep phenotypes;
CESC	cis	rs763121	0.853	rs6001204	chr22:39100239	T/C	cg21395723	chr22:39101663	GTPBP1	0.5	6.81	0.39	6.57e-11	Menopause (age at onset);
CESC	cis	rs9868809	0.542	rs9873726	chr3:48712367	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.59	-5.19	-0.3	4.1e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs9443645	0.901	rs1027813	chr6:79552118	G/T	cg05283184	chr6:79620031	NA	0.41	6.48	0.37	4.41e-10	Intelligence (multi-trait analysis);
CESC	cis	rs9888739	0.668	rs9933520	chr16:31343386	A/G	cg15817542	chr16:31343056	ITGAM	-0.54	-7.68	-0.43	3.13e-13	Systemic lupus erythematosus;
CESC	cis	rs35955747	0.902	rs739427	chr22:31659101	C/G	cg02404636	chr22:31891804	SFI1	0.37	5.06	0.3	7.96e-7	Neutrophil count;Sum basophil neutrophil counts;
CESC	cis	rs597539	0.652	rs544370	chr11:68653232	C/T	cg21963583	chr11:68658836	MRPL21	0.38	5.71	0.33	2.96e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs9527	0.501	rs12244388	chr10:104640052	G/A	cg04362960	chr10:104952993	NT5C2	0.49	6.13	0.35	3.15e-9	Arsenic metabolism;
CESC	cis	rs6088580	0.505	rs6142219	chr20:33256345	G/A	cg08999081	chr20:33150536	PIGU	-0.46	-6.42	-0.37	6.23e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs801193	0.935	rs11772264	chr7:66176387	T/C	cg06456125	chr7:65229604	NA	0.4	5.3	0.31	2.4e-7	Aortic root size;
CESC	cis	rs9733	0.818	rs12130363	chr1:150688596	T/C	cg04414720	chr1:150670196	GOLPH3L	-0.37	-5.26	-0.31	3.03e-7	Tonsillectomy;
CESC	cis	rs950776	0.714	rs17408276	chr15:78881618	T/C	cg06917634	chr15:78832804	PSMA4	0.6	7.2	0.4	6.09e-12	Sudden cardiac arrest;
CESC	cis	rs910316	0.789	rs12894419	chr14:75471802	C/T	cg08847533	chr14:75593920	NEK9	0.89	15.53	0.69	3.94e-39	Height;
CESC	cis	rs3761847	0.593	rs1468673	chr9:123809890	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.36	5.2	0.3	4.03e-7	Rheumatoid arthritis;
CESC	cis	rs7927771	0.524	rs10838777	chr11:47860954	A/C	cg20307385	chr11:47447363	PSMC3	0.63	8.77	0.47	2.17e-16	Subjective well-being;
CESC	cis	rs637571	0.676	rs1151523	chr11:65665200	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.51	-6.5	-0.37	3.91e-10	Eosinophil percentage of white cells;
CESC	cis	rs2295499	0.673	rs2298964	chr4:2699607	G/C	cg27239842	chr4:2403781	ZFYVE28	-0.32	-5.33	-0.31	2.11e-7	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
CESC	cis	rs7666738	0.830	rs4699331	chr4:99059816	T/C	cg03676636	chr4:99064102	C4orf37	0.34	5.09	0.3	6.74e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.11	13.24	0.63	4.75e-31	Platelet count;
CESC	trans	rs9467711	0.606	rs2073529	chr6:26375159	C/T	cg06606381	chr12:133084897	FBRSL1	0.82	6.9	0.39	3.82e-11	Autism spectrum disorder or schizophrenia;
CESC	cis	rs17431357	1.000	rs73230308	chr12:120986986	G/A	cg25045489	chr12:120971538	RNF10	-0.93	-5.46	-0.32	1.1e-7	Insulin resistance/response;
CESC	cis	rs780096	0.546	rs8179225	chr2:27737181	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.33	-6.36	-0.36	8.88e-10	Total body bone mineral density;
CESC	cis	rs7647973	0.600	rs11920267	chr3:49275964	G/A	cg03060546	chr3:49711283	APEH	0.52	7.03	0.4	1.7e-11	Menarche (age at onset);
CESC	cis	rs854765	0.583	rs11871899	chr17:17826748	C/G	cg09796270	chr17:17721594	SREBF1	0.46	6.42	0.37	6.23e-10	Total body bone mineral density;
CESC	cis	rs6580649	0.941	rs7310579	chr12:48427523	G/A	cg24011408	chr12:48396354	COL2A1	-0.42	-5.26	-0.31	2.93e-7	Lung cancer;
CESC	cis	rs4713118	0.629	rs203887	chr6:28021269	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.51	-5.38	-0.31	1.61e-7	Parkinson's disease;
CESC	cis	rs3126085	0.877	rs4456098	chr1:152176034	C/T	cg26876637	chr1:152193138	HRNR	0.45	5.14	0.3	5.28e-7	Atopic dermatitis;
CESC	cis	rs9399401	0.667	rs1329707	chr6:142724439	T/C	cg04461802	chr6:142623433	GPR126	0.42	6.02	0.35	5.68e-9	Chronic obstructive pulmonary disease;
CESC	cis	rs4819052	0.851	rs10470245	chr21:46658912	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.91	13.24	0.63	4.51e-31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs896854	0.967	rs10956933	chr8:95967688	C/G	cg16049864	chr8:95962084	TP53INP1	-0.68	-12.35	-0.6	5.62e-28	Type 2 diabetes;
CESC	cis	rs1552244	0.572	rs59132826	chr3:10169725	G/A	cg00149659	chr3:10157352	C3orf10	0.98	11.92	0.59	1.59e-26	Alzheimer's disease;
CESC	cis	rs853679	0.546	rs200996	chr6:27811828	G/A	cg26587870	chr6:27730563	NA	-0.55	-5.05	-0.3	8.28e-7	Depression;
CESC	cis	rs736408	0.716	rs2239550	chr3:52822509	G/C	cg18404041	chr3:52824283	ITIH1	-0.46	-7.44	-0.42	1.45e-12	Bipolar disorder;
CESC	cis	rs7666738	0.830	rs10019087	chr4:99030211	C/T	cg05340658	chr4:99064831	C4orf37	0.83	13.1	0.63	1.43e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs514406	0.861	rs4926577	chr1:53226788	C/A	cg08736216	chr1:53307985	ZYG11A	0.42	7.11	0.4	1.06e-11	Monocyte count;
CESC	cis	rs4665809	1.000	rs6729080	chr2:26301282	G/A	cg08470875	chr2:26401718	FAM59B	-0.48	-5.27	-0.31	2.79e-7	Gut microbiome composition (summer);
CESC	cis	rs4927850	1.000	rs10881563	chr3:195750225	A/G	cg18569988	chr3:195679450	NA	0.37	5.07	0.3	7.6e-7	Pancreatic cancer;
CESC	cis	rs7666738	0.724	rs28451676	chr4:98966990	C/T	cg03676636	chr4:99064102	C4orf37	0.33	5.2	0.3	4.01e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7523050	0.642	rs12044219	chr1:109481236	T/C	cg08274380	chr1:109419600	GPSM2	0.77	5.45	0.32	1.18e-7	Fat distribution (HIV);
CESC	cis	rs7542091	0.669	rs11119357	chr1:210042382	C/T	cg09509183	chr1:209979624	IRF6	0.39	5.53	0.32	7.6e-8	Monobrow;
CESC	cis	rs1008375	0.932	rs4698650	chr4:17692878	G/C	cg16339924	chr4:17578868	LAP3	0.6	7.44	0.42	1.45e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs911555	0.755	rs9671414	chr14:103967299	C/T	cg24130564	chr14:104152367	KLC1	0.49	6.12	0.35	3.37e-9	Intelligence (multi-trait analysis);
CESC	cis	rs7412746	0.566	rs2864871	chr1:150766964	T/C	cg22823121	chr1:150693482	HORMAD1	0.46	6.41	0.37	6.7e-10	Melanoma;
CESC	cis	rs798554	0.679	rs2527677	chr7:2882621	A/G	cg09658497	chr7:2847517	GNA12	-0.35	-5.09	-0.3	6.89e-7	Height;
CESC	cis	rs113835537	0.529	rs4930378	chr11:66255515	T/C	cg24851651	chr11:66362959	CCS	0.44	5.73	0.33	2.76e-8	Airway imaging phenotypes;
CESC	cis	rs7927771	0.507	rs7111606	chr11:47787538	G/A	cg20307385	chr11:47447363	PSMC3	0.61	8.59	0.47	7.41e-16	Subjective well-being;
CESC	cis	rs7267979	0.966	rs7270835	chr20:25435067	C/T	cg08601574	chr20:25228251	PYGB	0.36	5.12	0.3	5.95e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7395581	0.959	rs2167079	chr11:47270255	C/T	cg25783544	chr11:47291846	MADD	0.59	7.65	0.43	3.78e-13	HDL cholesterol;
CESC	cis	rs688020	1.000	rs673500	chr7:4229445	C/G	cg24441899	chr7:4244372	SDK1	-0.3	-5.12	-0.3	5.86e-7	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease;
CESC	cis	rs4835473	0.932	rs17762299	chr4:144698349	A/G	cg25736465	chr4:144833511	NA	-0.33	-5.18	-0.3	4.39e-7	Immature fraction of reticulocytes;
CESC	cis	rs1044826	0.597	rs6803593	chr3:139193987	T/C	cg00490450	chr3:139108681	COPB2	0.44	5.37	0.31	1.77e-7	Obesity-related traits;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg03289602	chr19:11708437	ZNF627	-0.46	-6.34	-0.36	9.74e-10	Fibrinogen levels;
CESC	cis	rs10751667	1.000	rs10794357	chr11:973374	T/C	cg06064525	chr11:970664	AP2A2	-0.37	-6.49	-0.37	4.32e-10	Alzheimer's disease (late onset);
CESC	cis	rs2882667	0.858	rs11948429	chr5:138458584	G/A	cg04439458	chr5:138467593	SIL1	-0.34	-5.29	-0.31	2.52e-7	Age-related hearing impairment (SNP x SNP interaction);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg03576530	chr14:105167973	INF2	0.44	6.18	0.35	2.44e-9	Fibrinogen levels;
CESC	cis	rs2235642	0.592	rs743963	chr16:1657350	A/T	cg09080909	chr16:1797204	MAPK8IP3	-0.39	-5.28	-0.31	2.72e-7	Coronary artery disease;
CESC	cis	rs875971	0.862	rs908915	chr7:65614651	G/T	cg11764359	chr7:65958608	NA	-0.77	-11.27	-0.57	2.43e-24	Aortic root size;
CESC	cis	rs17711722	0.701	rs781143	chr7:65439879	G/C	cg11987759	chr7:65425863	GUSB	-0.47	-6.32	-0.36	1.08e-9	Calcium levels;
CESC	cis	rs17376456	0.825	rs74825443	chr5:93254973	T/C	cg21475434	chr5:93447410	FAM172A	0.74	6.22	0.36	1.9e-9	Diabetic retinopathy;
CESC	trans	rs6073597	1.000	rs6031980	chr20:43714384	C/T	cg23962285	chr1:108743536	SLC25A24	0.46	6.64	0.38	1.79e-10	Positive affect;
CESC	cis	rs10789491	1.000	rs10789491	chr1:47179310	A/G	cg15501359	chr1:47185051	KIAA0494	0.77	8.56	0.47	9.21e-16	Response to hepatitis C treatment;
CESC	cis	rs477895	0.653	rs11231701	chr11:63893702	G/A	cg18225595	chr11:63971243	STIP1	0.51	5.13	0.3	5.7e-7	Mean platelet volume;
CESC	cis	rs9926296	0.546	rs6500442	chr16:89828862	T/C	cg03388025	chr16:89894329	SPIRE2	0.42	8.31	0.45	4.93e-15	Vitiligo;
CESC	cis	rs6860806	0.507	rs270601	chr5:131656997	T/C	cg24060327	chr5:131705240	SLC22A5	-0.77	-10.72	-0.55	1.68e-22	Breast cancer;
CESC	trans	rs7615952	0.673	rs34209763	chr3:125599595	G/A	cg07211511	chr3:129823064	LOC729375	-0.87	-8.83	-0.48	1.45e-16	Blood pressure (smoking interaction);
CESC	cis	rs13418410	0.539	rs11677468	chr2:33839053	T/C	cg04131969	chr2:33951647	MYADML	-0.61	-7.37	-0.41	2.24e-12	Non-response to antidepressants and depression;
CESC	cis	rs7666738	0.830	rs1813642	chr4:98852225	G/A	cg03676636	chr4:99064102	C4orf37	0.33	5.1	0.3	6.4e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg18836229	chr2:112655713	MERTK	-0.5	-6.82	-0.39	5.97e-11	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs9788333	0.762	rs4441120	chr13:21886863	T/A	cg06138931	chr13:21896616	NA	0.54	7.22	0.41	5.45e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs34366173	1	rs34366173	chr15:63998914	CTT/C	cg12036633	chr15:63758958	NA	-0.44	-5.22	-0.31	3.63e-7	Reticulocyte fraction of red cells;
CESC	cis	rs7618915	0.501	rs2336146	chr3:52626646	A/G	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.7	0.38	1.22e-10	Bipolar disorder;
CESC	cis	rs684232	0.666	rs838373	chr17:567171	T/C	cg15660573	chr17:549704	VPS53	-0.64	-8.78	-0.47	2.09e-16	Prostate cancer;
CESC	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg23283495	chr1:209979779	IRF6	0.63	11.92	0.59	1.69e-26	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
CESC	cis	rs875971	0.862	rs6460279	chr7:65662761	T/C	cg10691866	chr7:65817282	TPST1	0.32	5.36	0.31	1.8e-7	Aortic root size;
CESC	cis	rs7264396	0.747	rs73283043	chr20:34383863	G/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.64	7.84	0.43	1.08e-13	Total cholesterol levels;
CESC	cis	rs9291683	0.632	rs11734375	chr4:10046298	A/G	cg00071950	chr4:10020882	SLC2A9	0.85	14.82	0.67	1.3e-36	Bone mineral density;
CESC	trans	rs7819412	0.645	rs4841508	chr8:11065003	C/A	cg15556689	chr8:8085844	FLJ10661	-0.54	-6.0	-0.35	6.53e-9	Triglycerides;
CESC	cis	rs2637266	0.549	rs4633402	chr10:78414244	C/A	cg18941641	chr10:78392320	NA	-0.32	-5.25	-0.31	3.12e-7	Pulmonary function;
CESC	cis	rs12497850	0.931	rs1134591	chr3:48972892	C/T	cg02487422	chr3:49467188	NICN1	0.4	5.12	0.3	5.75e-7	Parkinson's disease;
CESC	cis	rs561341	0.769	rs559228	chr17:30294527	T/C	cg12193833	chr17:30244370	NA	-0.71	-6.53	-0.37	3.38e-10	Hip circumference adjusted for BMI;
CESC	trans	rs1373453	0.808	rs76680279	chr12:70073173	C/T	cg19702771	chr4:82058885	PRKG2	0.74	6.01	0.35	6.27e-9	Orofacial clefts;
CESC	cis	rs2997447	0.761	rs55815920	chr1:26457662	A/C	cg24596570	chr1:26146463	FAM54B;LOC646471	0.59	5.16	0.3	4.76e-7	QRS complex (12-leadsum);
CESC	cis	rs6987853	0.814	rs1349471	chr8:42454011	C/T	cg09913449	chr8:42400586	C8orf40	0.42	7.03	0.4	1.8e-11	Mean corpuscular hemoglobin concentration;
CESC	cis	rs6964587	1.000	rs416	chr7:91580571	A/G	cg17063962	chr7:91808500	NA	-0.57	-7.62	-0.42	4.53e-13	Breast cancer;
CESC	cis	rs6691722	0.583	rs7537875	chr1:24695151	A/T	cg02336364	chr1:24764700	NIPAL3	0.28	6.02	0.35	5.94e-9	Response to interferon beta in multiple sclerosis;
CESC	cis	rs2235642	0.891	rs2281231	chr16:1601879	A/G	cg07639376	chr16:1584516	IFT140;TMEM204	-0.31	-5.06	-0.3	7.98e-7	Coronary artery disease;
CESC	cis	rs6547741	1.000	rs10165098	chr2:27796526	C/T	cg21248554	chr2:27665150	KRTCAP3	0.25	5.11	0.3	6.04e-7	Oral cavity cancer;
CESC	cis	rs10504229	0.773	rs1874374	chr8:58194422	A/G	cg14926445	chr8:58193284	C8orf71	-0.54	-5.27	-0.31	2.78e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs1983891	0.553	rs3800283	chr6:41558358	A/G	cg20194872	chr6:41519635	FOXP4	0.45	6.3	0.36	1.22e-9	Prostate cancer;
CESC	cis	rs9549260	0.785	rs6563842	chr13:41244297	G/T	cg21288729	chr13:41239152	FOXO1	0.68	8.52	0.46	1.24e-15	Red blood cell count;
CESC	cis	rs9910055	0.552	rs12937114	chr17:42325073	A/G	cg08499158	chr17:42289980	UBTF	-0.49	-5.96	-0.34	7.87e-9	Total body bone mineral density;
CESC	cis	rs6963495	0.818	rs73190133	chr7:105147821	G/C	cg02135003	chr7:105160482	PUS7	-0.47	-5.61	-0.33	5.12e-8	Bipolar disorder (body mass index interaction);
CESC	cis	rs2242194	0.844	rs11264295	chr1:154987526	C/T	cg24250549	chr1:154909240	PMVK	0.41	5.27	0.31	2.79e-7	Schizophrenia;
CESC	cis	rs8067354	0.831	rs2333617	chr17:57896220	T/A	cg13753209	chr17:57696993	CLTC	-0.52	-7.03	-0.4	1.71e-11	Hemoglobin concentration;
CESC	cis	rs780096	0.526	rs13391837	chr2:27649375	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.36	-6.73	-0.38	1.07e-10	Total body bone mineral density;
CESC	cis	rs5753618	0.504	rs5753671	chr22:31910734	T/C	cg13145458	chr22:31556086	RNF185	-0.48	-5.69	-0.33	3.33e-8	Colorectal cancer;
CESC	cis	rs9815354	0.812	rs56983571	chr3:41994473	T/C	cg03022575	chr3:42003672	ULK4	0.67	5.88	0.34	1.23e-8	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs2549003	1.000	rs7735073	chr5:131815357	G/A	cg00255919	chr5:131827918	IRF1	0.51	8.71	0.47	3.26e-16	Asthma (sex interaction);
CESC	cis	rs4865169	0.811	rs6841086	chr4:57903268	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.44	5.99	0.35	6.78e-9	Breast cancer;
CESC	cis	rs2228479	0.850	rs11645916	chr16:89835234	G/A	cg14709524	chr16:89940631	TCF25	0.91	6.74	0.38	1e-10	Skin colour saturation;
CESC	cis	rs7937682	0.889	rs516263	chr11:111484719	A/C	cg22437258	chr11:111473054	SIK2	0.72	9.66	0.51	4.1e-19	Primary sclerosing cholangitis;
CESC	cis	rs688020	1.000	rs688020	chr7:4228553	C/T	cg24441899	chr7:4244372	SDK1	0.29	5.07	0.3	7.38e-7	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease;
CESC	cis	rs854765	0.619	rs6502636	chr17:17983817	A/T	cg16928487	chr17:17741425	SREBF1	-0.52	-8.46	-0.46	1.8e-15	Total body bone mineral density;
CESC	cis	rs2439831	0.850	rs60883262	chr15:44076503	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.7	6.73	0.38	1.02e-10	Lung cancer in ever smokers;
CESC	cis	rs1552244	0.882	rs7633769	chr3:10020622	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.78	-9.93	-0.52	5.93e-20	Alzheimer's disease;
CESC	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.51	6.93	0.39	3.15e-11	Lymphocyte counts;
CESC	trans	rs61931739	0.534	rs1384860	chr12:34045388	T/C	cg26384229	chr12:38710491	ALG10B	0.53	7.22	0.41	5.44e-12	Morning vs. evening chronotype;
CESC	cis	rs10504229	0.545	rs56394419	chr8:58128982	T/C	cg02725872	chr8:58115012	NA	-0.45	-7.05	-0.4	1.52e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs9486719	1.000	rs2472887	chr6:96865437	A/G	cg06623918	chr6:96969491	KIAA0776	0.81	8.29	0.45	5.61e-15	Migraine;Coronary artery disease;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg03749393	chr13:31191824	USPL1	-0.47	-6.23	-0.36	1.87e-9	Asthma;
CESC	cis	rs524281	0.861	rs10896085	chr11:65913832	A/T	cg14036092	chr11:66035641	RAB1B	-0.58	-5.89	-0.34	1.17e-8	Electroencephalogram traits;
CESC	trans	rs931812	0.895	rs13251731	chr8:101902528	C/G	cg20993868	chr7:22813445	NA	0.56	8.27	0.45	6.58e-15	Attention deficit hyperactivity disorder and conduct disorder;
CESC	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.36	6.99	0.39	2.23e-11	Electroencephalogram traits;
CESC	cis	rs2273669	0.667	rs12374597	chr6:109346184	A/G	cg05315195	chr6:109294784	ARMC2	-0.67	-6.32	-0.36	1.13e-9	Prostate cancer;
CESC	cis	rs13095912	0.962	rs7644758	chr3:185328197	G/T	cg11274856	chr3:185301563	NA	-0.35	-5.5	-0.32	8.96e-8	Systolic blood pressure;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14645085	chr6:13712693	RANBP9	-0.46	-6.19	-0.36	2.24e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs9660180	1.000	rs3737628	chr1:1722932	C/T	cg13866156	chr1:1669148	SLC35E2	-0.49	-6.31	-0.36	1.19e-9	Body mass index;
CESC	trans	rs1450833	0.506	rs1194322	chr7:113884794	C/T	cg23384340	chr11:57479802	MED19;TMX2	-0.49	-6.1	-0.35	3.76e-9	Neuroticism;
CESC	cis	rs12497850	0.863	rs4858799	chr3:48728204	G/C	cg03060546	chr3:49711283	APEH	0.45	5.63	0.33	4.68e-8	Parkinson's disease;
CESC	trans	rs877282	0.628	rs11253435	chr10:824169	T/C	cg22713356	chr15:30763199	NA	1.03	9.77	0.51	1.92e-19	Uric acid levels;
CESC	cis	rs17376456	0.825	rs10038831	chr5:93124115	C/T	cg21475434	chr5:93447410	FAM172A	0.8	7.22	0.41	5.48e-12	Diabetic retinopathy;
CESC	cis	rs2197308	0.667	rs11181073	chr12:37898543	A/G	cg26384229	chr12:38710491	ALG10B	0.67	9.61	0.51	6.07e-19	Morning vs. evening chronotype;
CESC	cis	rs12477438	0.539	rs720228	chr2:99704547	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	15.03	0.68	2.4e-37	Chronic sinus infection;
CESC	trans	rs9858542	0.903	rs35999162	chr3:49597230	C/G	cg21659725	chr3:3221576	CRBN	-0.52	-6.47	-0.37	4.72e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs2535633	0.631	rs9823697	chr3:53002150	A/G	cg11645453	chr3:52864694	ITIH4	0.27	5.06	0.3	8.01e-7	Body mass index;
CESC	cis	rs1270639	0.778	rs1465250	chr7:157439075	C/G	cg13357408	chr7:157437802	PTPRN2	0.6	6.95	0.39	2.8e-11	Colorectal cancer;
CESC	cis	rs34375054	0.558	rs12578774	chr12:125681761	A/G	cg05341575	chr12:125625032	AACS	0.36	5.25	0.31	3.2e-7	Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs3768617	0.811	rs12066082	chr1:183054863	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.66	9.17	0.49	1.37e-17	Fuchs's corneal dystrophy;
CESC	cis	rs55788414	0.789	rs4630561	chr16:81183108	T/C	cg06400318	chr16:81190750	PKD1L2	-0.57	-6.64	-0.38	1.79e-10	Left ventricular obstructive tract defect (maternal effect);
CESC	cis	rs748404	0.697	rs475227	chr15:43546446	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.51	8.01	0.44	3.59e-14	Lung cancer;
CESC	cis	rs2820292	0.619	rs12562614	chr1:201814994	A/G	cg11586189	chr1:201857591	SHISA4	-0.36	-5.83	-0.34	1.6e-8	Waist circumference;Body mass index (joint analysis main effects and smoking interaction);Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);
CESC	cis	rs780096	0.506	rs1647265	chr2:27692261	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.36	-7.38	-0.41	2.02e-12	Total body bone mineral density;
CESC	cis	rs67478160	0.643	rs8004408	chr14:104203938	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.5	-7.06	-0.4	1.43e-11	Schizophrenia;
CESC	cis	rs10504229	0.683	rs16921831	chr8:58111142	G/A	cg24829409	chr8:58192753	C8orf71	-0.59	-7.32	-0.41	2.94e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs7618915	0.501	rs13085775	chr3:52678370	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.36	6.59	0.38	2.36e-10	Bipolar disorder;
CESC	cis	rs9916302	0.808	rs12943928	chr17:37611330	G/A	cg15445000	chr17:37608096	MED1	0.41	6.76	0.38	8.83e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs9926296	0.529	rs7195906	chr16:89806347	A/T	cg04287289	chr16:89883240	FANCA	0.92	16.16	0.7	2.38e-41	Vitiligo;
CESC	cis	rs599083	0.530	rs491347	chr11:68169688	G/A	cg01657329	chr11:68192670	LRP5	0.44	5.13	0.3	5.71e-7	Bone mineral density (spine);
CESC	trans	rs116095464	0.558	rs10058428	chr5:235608	A/G	cg00938859	chr5:1591904	SDHAP3	0.63	6.98	0.39	2.36e-11	Breast cancer;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	ch.5.389453F	chr5:14788101	ANKH	-0.43	-6.13	-0.35	3.18e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs9611565	0.921	rs8137373	chr22:41729216	A/G	cg06481639	chr22:41940642	POLR3H	0.57	6.12	0.35	3.3e-9	Vitiligo;
CESC	cis	rs73110464	0.609	rs4919752	chr12:53359229	G/C	cg05393297	chr12:53359155	NA	-0.72	-10.44	-0.54	1.31e-21	Cancer (pleiotropy);
CESC	cis	rs2635047	0.713	rs8086549	chr18:44756421	G/T	cg24371990	chr18:44770781	NA	-0.35	-5.61	-0.33	5.11e-8	Educational attainment;
CESC	cis	rs75887402	1.000	rs73799308	chr5:122739242	T/C	cg27033705	chr5:122759302	CEP120	0.81	5.54	0.32	7.3e-8	Breast cancer;
CESC	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.58	7.22	0.41	5.54e-12	Prudent dietary pattern;
CESC	cis	rs7116495	1.000	rs12293885	chr11:71816092	T/A	cg10381502	chr11:71823885	C11orf51	0.66	5.35	0.31	1.93e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs7829975	0.501	rs2980769	chr8:8320291	G/A	cg06636001	chr8:8085503	FLJ10661	0.52	6.99	0.39	2.21e-11	Mood instability;
CESC	cis	rs6502050	0.698	rs67143649	chr17:80117772	C/G	cg11859384	chr17:80120422	CCDC57	-0.38	-5.18	-0.3	4.43e-7	Life satisfaction;
CESC	cis	rs2075371	0.932	rs1862052	chr7:133981227	G/A	cg20476274	chr7:133979776	SLC35B4	0.64	9.15	0.49	1.61e-17	Mean platelet volume;
CESC	cis	rs11098499	0.954	rs66506550	chr4:120371445	T/A	cg09307838	chr4:120376055	NA	0.94	13.7	0.64	1.18e-32	Corneal astigmatism;
CESC	cis	rs5753618	0.561	rs2040533	chr22:31679110	G/C	cg00478049	chr22:31556069	RNF185	0.44	5.04	0.3	8.82e-7	Colorectal cancer;
CESC	cis	rs35306767	0.903	rs11816064	chr10:931176	A/C	cg26597838	chr10:835615	NA	0.85	9.27	0.49	6.87e-18	Eosinophil percentage of granulocytes;
CESC	cis	rs34638657	0.732	rs62045963	chr16:82200661	A/G	cg09439754	chr16:82129088	HSD17B2	-0.36	-6.24	-0.36	1.71e-9	Lung adenocarcinoma;
CESC	cis	rs1448094	0.522	rs12313658	chr12:86271063	C/T	cg19622623	chr12:86230825	RASSF9	-0.47	-6.02	-0.35	5.87e-9	Major depressive disorder;
CESC	cis	rs4728302	0.838	rs13231095	chr7:133604436	A/G	cg10665199	chr7:133106180	EXOC4	0.4	5.56	0.32	6.62e-8	Intelligence;Intelligence (multi-trait analysis);
CESC	cis	rs6598955	0.694	rs6659387	chr1:26634307	G/A	cg04990556	chr1:26633338	UBXN11	-0.79	-11.16	-0.57	5.72e-24	Obesity-related traits;
CESC	cis	rs6502050	0.635	rs9889327	chr17:80087839	G/A	cg01763666	chr17:80159506	CCDC57	-0.37	-5.1	-0.3	6.55e-7	Life satisfaction;
CESC	cis	rs7666738	0.830	rs9999200	chr4:99030690	A/C	cg18180107	chr4:99064573	C4orf37	0.42	5.43	0.32	1.29e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6963495	0.745	rs56239334	chr7:105165351	G/A	cg02135003	chr7:105160482	PUS7	-0.47	-5.59	-0.33	5.51e-8	Bipolar disorder (body mass index interaction);
CESC	trans	rs11039798	0.591	rs74992349	chr11:49019252	G/A	cg03929089	chr4:120376271	NA	0.61	6.01	0.35	6.02e-9	Axial length;
CESC	cis	rs1707322	0.964	rs7546237	chr1:46285610	A/C	cg06784218	chr1:46089804	CCDC17	0.31	5.42	0.32	1.36e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs1814175	0.616	rs1794131	chr11:49904194	A/G	cg03929089	chr4:120376271	NA	-0.92	-15.2	-0.68	6e-38	Height;
CESC	cis	rs3785574	0.962	rs16947051	chr17:61790917	G/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.8	10.78	0.55	1.03e-22	Height;
CESC	cis	rs637571	0.522	rs528736	chr11:65705108	A/G	cg04055107	chr11:65626734	MUS81;CFL1	0.44	5.41	0.32	1.39e-7	Eosinophil percentage of white cells;
CESC	cis	rs5769707	0.521	rs739244	chr22:50060158	A/G	cg05373962	chr22:49881684	NA	-0.36	-5.58	-0.32	5.9e-8	Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs2832191	0.692	rs2245734	chr21:30359965	C/T	cg24692254	chr21:30365293	RNF160	0.98	17.73	0.74	6.71e-47	Dental caries;
CESC	cis	rs12451471	0.559	rs12452263	chr17:78079310	T/C	cg24585782	chr17:78113791	EIF4A3	-0.57	-7.53	-0.42	7.79e-13	Plateletcrit;Mean corpuscular hemoglobin concentration;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg06747863	chr12:118810789	TAOK3	-0.45	-6.67	-0.38	1.52e-10	Gambling;
CESC	cis	rs6502050	0.835	rs6502070	chr17:80112634	G/A	cg11859384	chr17:80120422	CCDC57	-0.39	-5.34	-0.31	2e-7	Life satisfaction;
CESC	cis	rs7246657	0.943	rs4801759	chr19:37954985	G/A	cg23950597	chr19:37808831	NA	-0.62	-6.3	-0.36	1.26e-9	Coronary artery calcification;
CESC	cis	rs637571	0.544	rs500161	chr11:65695438	C/T	cg04055107	chr11:65626734	MUS81;CFL1	0.48	5.84	0.34	1.53e-8	Eosinophil percentage of white cells;
CESC	trans	rs561341	1.000	rs693116	chr17:30246124	C/T	cg27661571	chr11:113659931	NA	-0.87	-7.9	-0.44	7.5e-14	Hip circumference adjusted for BMI;
CESC	cis	rs2243480	0.901	rs2456483	chr7:65461575	T/C	cg12463550	chr7:65579703	CRCP	0.72	5.92	0.34	9.68e-9	Diabetic kidney disease;
CESC	cis	rs9457247	0.602	rs9459854	chr6:167465882	C/T	cg07741184	chr6:167504864	NA	0.37	6.49	0.37	4.2e-10	Crohn's disease;
CESC	trans	rs10489896	0.588	rs10159244	chr1:234588171	C/T	cg23817893	chr11:86085932	CCDC81	-0.45	-6.2	-0.36	2.14e-9	Cognitive test performance;
CESC	cis	rs9303401	0.659	rs12948133	chr17:56673602	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.03	13.03	0.62	2.54e-30	Cognitive test performance;
CESC	trans	rs17508449	0.819	rs17359281	chr1:114185959	C/T	cg23028848	chr11:57092561	TNKS1BP1	0.74	6.16	0.35	2.73e-9	Leprosy;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg05881034	chr3:42623675	SEC22C	-0.48	-6.37	-0.36	8.24e-10	Fibrinogen levels;
CESC	cis	rs3126085	0.515	rs2275264	chr1:152331533	T/G	cg03465714	chr1:152285911	FLG	0.4	5.15	0.3	5.16e-7	Atopic dermatitis;
CESC	cis	rs7937682	0.924	rs513425	chr11:111504861	C/T	cg22437258	chr11:111473054	SIK2	0.7	9.35	0.5	3.83e-18	Primary sclerosing cholangitis;
CESC	cis	rs6701037	0.681	rs1057246	chr1:175127534	C/G	cg00321850	chr1:175162397	KIAA0040	0.39	5.87	0.34	1.33e-8	Alcohol dependence;
CESC	trans	rs55704346	0.566	rs4317194	chr4:25394477	T/C	cg01822600	chr1:245751692	KIF26B	0.42	6.17	0.35	2.58e-9	Tonsillectomy;
CESC	cis	rs11098499	0.908	rs1002152	chr4:120273387	C/A	cg09307838	chr4:120376055	NA	0.94	13.05	0.63	2.15e-30	Corneal astigmatism;
CESC	cis	rs2204008	0.653	rs11182569	chr12:38572452	G/A	cg13010199	chr12:38710504	ALG10B	0.55	7.05	0.4	1.59e-11	Bladder cancer;
CESC	cis	rs9916302	0.904	rs4794813	chr17:37670994	A/T	cg07936489	chr17:37558343	FBXL20	-0.8	-11.19	-0.57	4.59e-24	Glomerular filtration rate (creatinine);
CESC	cis	rs5771069	0.669	rs137879	chr22:50457041	C/T	cg03721641	chr22:50451245	IL17REL	0.3	5.19	0.3	4.22e-7	Ulcerative colitis;
CESC	trans	rs1814175	0.645	rs4598671	chr11:50003191	C/A	cg15704280	chr7:45808275	SEPT13	-1.0	-18.49	-0.75	1.41e-49	Height;
CESC	cis	rs9640161	0.830	rs3735165	chr7:150068371	T/C	cg10018233	chr7:150070692	REPIN1	0.5	9.45	0.5	1.92e-18	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs863345	0.967	rs10797028	chr1:158523241	T/A	cg12129480	chr1:158549410	OR10X1	-0.32	-6.43	-0.37	5.96e-10	Pneumococcal bacteremia;
CESC	cis	rs1775715	0.707	rs1541262	chr10:32179771	A/G	cg18675610	chr10:32216311	ARHGAP12	0.35	5.33	0.31	2.08e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs896854	0.684	rs10098778	chr8:95992020	C/T	cg13393036	chr8:95962371	TP53INP1	-0.48	-10.6	-0.55	4.12e-22	Type 2 diabetes;
CESC	cis	rs3768617	0.510	rs2296288	chr1:183072590	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.88	14.27	0.66	1.19e-34	Fuchs's corneal dystrophy;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg12268263	chr8:143359879	TSNARE1	0.44	6.48	0.37	4.49e-10	Fibrinogen levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24132523	chr1:145827062	GPR89A	-0.58	-6.85	-0.39	5.21e-11	Gut microbiome composition (summer);
CESC	cis	rs5760092	0.572	rs738806	chr22:24234172	A/G	cg12419862	chr22:24373484	LOC391322	-0.66	-7.78	-0.43	1.59e-13	Urinary 1,3-butadiene metabolite levels in smokers;
CESC	cis	rs1799949	0.931	rs34474989	chr17:41445410	A/T	cg23758822	chr17:41437982	NA	0.98	17.21	0.73	4.39e-45	Menopause (age at onset);
CESC	cis	rs55882075	1.000	rs55882075	chr5:179210115	C/G	cg14593053	chr5:179126677	CANX	0.42	5.58	0.32	5.84e-8	Monocyte percentage of white cells;
CESC	cis	rs2236918	1.000	rs1776133	chr1:242025098	C/T	cg17736920	chr1:242011382	EXO1	0.68	8.87	0.48	1.14e-16	Menopause (age at onset);
CESC	cis	rs9457247	0.663	rs2237277	chr6:167442107	G/A	cg07741184	chr6:167504864	NA	0.34	6.09	0.35	3.9e-9	Crohn's disease;
CESC	cis	rs4805272	0.626	rs12608533	chr19:29331405	C/G	cg14983838	chr19:29218262	NA	0.45	6.11	0.35	3.51e-9	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
CESC	cis	rs3749237	0.964	rs62260719	chr3:49852419	G/A	cg03060546	chr3:49711283	APEH	0.61	7.07	0.4	1.41e-11	Resting heart rate;
CESC	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg23708337	chr7:1209742	NA	0.52	5.16	0.3	4.88e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2228479	0.850	rs11076624	chr16:89855749	T/C	cg14709524	chr16:89940631	TCF25	0.94	7.06	0.4	1.5e-11	Skin colour saturation;
CESC	cis	rs1005277	0.579	rs1740737	chr10:38499365	G/T	cg00409905	chr10:38381863	ZNF37A	-0.51	-6.82	-0.39	6.22e-11	Extrinsic epigenetic age acceleration;
CESC	cis	rs7772486	0.754	rs9390358	chr6:146145678	C/T	cg23711669	chr6:146136114	FBXO30	0.96	13.94	0.65	1.74e-33	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2985684	1.000	rs8014170	chr14:50071694	C/G	cg10008539	chr14:50087325	RPL36AL;MGAT2	-0.46	-5.39	-0.31	1.55e-7	Carotid intima media thickness;
CESC	cis	rs16854884	0.586	rs7639366	chr3:143752034	T/G	cg06585982	chr3:143692056	C3orf58	0.51	6.92	0.39	3.46e-11	Economic and political preferences (feminism/equality);
CESC	cis	rs9926296	0.605	rs886952	chr16:89836781	G/A	cg03388025	chr16:89894329	SPIRE2	0.42	8.12	0.45	1.83e-14	Vitiligo;
CESC	cis	rs9926296	0.528	rs4785721	chr16:89839997	G/A	cg03388025	chr16:89894329	SPIRE2	0.39	7.32	0.41	2.91e-12	Vitiligo;
CESC	cis	rs9916302	0.784	rs4795361	chr17:37573446	G/A	cg20243544	chr17:37824526	PNMT	0.5	6.37	0.36	8.48e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs3020736	0.500	rs2413669	chr22:42507748	A/C	cg15557168	chr22:42548783	NA	0.45	6.51	0.37	3.78e-10	Autism spectrum disorder or schizophrenia;
CESC	cis	rs12136530	0.774	rs12137162	chr1:19763396	G/T	cg01832549	chr1:19774989	CAPZB	-0.45	-6.5	-0.37	4.07e-10	Lead levels in blood;
CESC	cis	rs34779708	0.649	rs34421369	chr10:35550275	G/C	cg04310649	chr10:35416472	CREM	-0.46	-5.2	-0.3	3.93e-7	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs6964587	1.000	rs6951972	chr7:91689446	T/G	cg17063962	chr7:91808500	NA	0.6	8.37	0.46	3.45e-15	Breast cancer;
CESC	cis	rs6460942	0.822	rs13340498	chr7:12233877	G/T	cg06484146	chr7:12443880	VWDE	-0.46	-5.19	-0.3	4.09e-7	Coronary artery disease;
CESC	cis	rs1218582	0.772	rs1976559	chr1:154879788	A/T	cg09359103	chr1:154839909	KCNN3	-0.65	-12.31	-0.6	7.76e-28	Prostate cancer;
CESC	cis	rs7845219	0.544	rs6987400	chr8:95921295	T/C	cg13393036	chr8:95962371	TP53INP1	-0.42	-7.77	-0.43	1.69e-13	Type 2 diabetes;
CESC	cis	rs1003719	0.788	rs7275582	chr21:38451130	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.62	8.53	0.46	1.12e-15	Eye color traits;
CESC	cis	rs10504229	0.683	rs11786527	chr8:58131344	G/C	cg21724239	chr8:58056113	NA	0.58	5.95	0.34	8.29e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs72634258	0.645	rs59523164	chr1:7971827	G/A	cg00042356	chr1:8021962	PARK7	0.83	7.54	0.42	7.31e-13	Inflammatory bowel disease;
CESC	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg02353165	chr6:42928485	GNMT	0.83	13.47	0.64	7.62e-32	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs2625529	0.652	rs11634608	chr15:72255718	A/G	cg16672083	chr15:72433130	SENP8	0.46	6.78	0.38	7.78e-11	Red blood cell count;
CESC	cis	rs3126085	0.935	rs10749670	chr1:152220467	G/A	cg03465714	chr1:152285911	FLG	-0.45	-5.53	-0.32	7.55e-8	Atopic dermatitis;
CESC	cis	rs7927771	0.698	rs34467936	chr11:47915299	A/G	cg20307385	chr11:47447363	PSMC3	-0.44	-5.17	-0.3	4.55e-7	Subjective well-being;
CESC	cis	rs9916302	0.680	rs2271308	chr17:37817482	T/C	cg00129232	chr17:37814104	STARD3	-0.75	-10.14	-0.53	1.22e-20	Glomerular filtration rate (creatinine);
CESC	cis	rs17253792	0.822	rs75049893	chr14:56089158	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.75	5.34	0.31	2.05e-7	Putamen volume;
CESC	cis	rs1577917	0.874	rs11756621	chr6:86740063	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-6.13	-0.35	3.11e-9	Response to antipsychotic treatment;
CESC	cis	rs7666738	0.830	rs28785514	chr4:98959135	G/A	cg05340658	chr4:99064831	C4orf37	0.8	12.33	0.6	6.31e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs722599	0.748	rs731165	chr14:75352555	T/C	cg08847533	chr14:75593920	NEK9	-0.45	-5.51	-0.32	8.52e-8	IgG glycosylation;
CESC	cis	rs748404	0.578	rs4547312	chr15:43632138	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.59	9.34	0.5	4e-18	Lung cancer;
CESC	cis	rs798554	0.757	rs1182179	chr7:2873648	A/G	cg19717773	chr7:2847554	GNA12	-0.56	-8.13	-0.45	1.65e-14	Height;
CESC	cis	rs4604732	0.603	rs4546958	chr1:247639478	G/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.46	6.5	0.37	3.87e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs1506636	1.000	rs656425	chr7:123424525	A/C	cg03229431	chr7:123269106	ASB15	0.49	6.54	0.37	3.11e-10	Plateletcrit;Platelet count;
CESC	cis	rs780096	0.565	rs13022659	chr2:27743630	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.28	-5.09	-0.3	6.77e-7	Total body bone mineral density;
CESC	trans	rs11088226	0.681	rs2833902	chr21:33940458	A/G	cg09050820	chr6:167586206	TCP10L2	0.83	7.8	0.43	1.46e-13	Gastritis;
CESC	trans	rs208520	1.000	rs12191403	chr6:66978137	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.84	9.33	0.5	4.5e-18	Exhaled nitric oxide output;
CESC	cis	rs780096	0.526	rs13391837	chr2:27649375	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.37	-7.6	-0.42	4.99e-13	Total body bone mineral density;
CESC	cis	rs6991838	0.584	rs1053087	chr8:66515865	A/G	cg13398993	chr8:66546079	ARMC1	-0.46	-5.45	-0.32	1.14e-7	Intelligence (multi-trait analysis);
CESC	cis	rs367615	0.680	rs385728	chr5:108966009	A/G	cg17395555	chr5:108820864	NA	-0.4	-5.52	-0.32	7.97e-8	Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs11734570	0.581	rs4461531	chr4:38603576	C/T	cg18361445	chr4:38666374	KLF3;FLJ13197	0.6	7.37	0.41	2.17e-12	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs4919694	1.000	rs12254254	chr10:104765605	C/T	cg04362960	chr10:104952993	NT5C2	0.74	6.35	0.36	9.25e-10	Arsenic metabolism;
CESC	cis	rs9311474	0.507	rs4687644	chr3:52746541	T/G	cg17372223	chr3:52568218	NT5DC2	0.44	6.64	0.38	1.8e-10	Electroencephalogram traits;
CESC	cis	rs1552244	1.000	rs722509	chr3:10102377	T/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	11.94	0.59	1.43e-26	Alzheimer's disease;
CESC	cis	rs7666738	0.861	rs13139309	chr4:99020916	A/G	cg17366294	chr4:99064904	C4orf37	0.61	8.76	0.47	2.35e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10504229	0.593	rs113184543	chr8:58042950	A/G	cg22535103	chr8:58192502	C8orf71	-0.62	-6.91	-0.39	3.62e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs1348850	0.567	rs3770012	chr2:178538023	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.56	-7.06	-0.4	1.48e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg08077726	chr17:74734280	SFRS2;MFSD11	0.45	6.04	0.35	5.18e-9	Systemic lupus erythematosus;
CESC	cis	rs6964587	0.867	rs12704637	chr7:91874686	C/T	cg17063962	chr7:91808500	NA	0.51	6.12	0.35	3.3e-9	Breast cancer;
CESC	cis	rs8141529	0.732	rs5752798	chr22:29181868	A/G	cg15103426	chr22:29168792	CCDC117	0.7	9.85	0.52	1.06e-19	Lymphocyte counts;
CESC	cis	rs7789940	0.951	rs7779014	chr7:75975586	C/T	cg10167463	chr7:75959203	YWHAG	-0.56	-7.09	-0.4	1.23e-11	Multiple sclerosis;
CESC	cis	rs13256369	0.851	rs13271698	chr8:8567539	C/A	cg17143192	chr8:8559678	CLDN23	0.71	7.92	0.44	6.78e-14	Obesity-related traits;
CESC	cis	rs9596863	1.000	rs7318666	chr13:54418960	C/G	ch.13.53330881F	chr13:54432880	NA	-0.58	-5.08	-0.3	7.09e-7	Epilepsy and lamotrigine-induced maculopapular eruptions;
CESC	cis	rs769267	0.825	rs1469713	chr19:19528806	A/G	cg03709012	chr19:19516395	GATAD2A	0.99	15.8	0.7	4.37e-40	Tonsillectomy;
CESC	cis	rs13256369	0.755	rs12680167	chr8:8562467	A/G	cg00074818	chr8:8560427	CLDN23	0.36	5.29	0.31	2.5e-7	Obesity-related traits;
CESC	cis	rs1008375	1.000	rs4698198	chr4:17656536	G/A	cg15017067	chr4:17643749	FAM184B	0.36	5.17	0.3	4.73e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs4631830	0.900	rs7914347	chr10:51537431	C/T	cg16070123	chr10:51489643	NA	-0.34	-5.07	-0.3	7.4e-7	Prostate-specific antigen levels;
CESC	cis	rs9287719	0.967	rs10203785	chr2:10752508	T/C	cg02196655	chr2:10830764	NOL10	-0.37	-5.69	-0.33	3.39e-8	Prostate cancer;
CESC	cis	rs17666538	0.535	rs4338080	chr8:615598	A/G	cg23958373	chr8:599963	NA	0.81	6.0	0.35	6.49e-9	IgG glycosylation;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg08882774	chr16:28875105	SH2B1	0.43	6.83	0.39	5.9e-11	Gambling;
CESC	cis	rs4474465	0.646	rs10793335	chr11:78279005	C/G	cg27205649	chr11:78285834	NARS2	0.48	6.26	0.36	1.51e-9	Alzheimer's disease (survival time);
CESC	cis	rs3096299	0.719	rs2911265	chr16:89511328	G/A	cg16743903	chr16:89593216	SPG7	-0.39	-5.07	-0.3	7.37e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs2239547	0.657	rs2071040	chr3:52864860	A/G	cg11645453	chr3:52864694	ITIH4	0.35	5.86	0.34	1.35e-8	Schizophrenia;
CESC	cis	rs6540559	0.673	rs17015309	chr1:210007218	C/T	cg25204440	chr1:209979598	IRF6	0.66	6.47	0.37	4.79e-10	Cleft lip with or without cleft palate;
CESC	cis	rs11098499	0.913	rs67073020	chr4:120152557	C/T	cg09307838	chr4:120376055	NA	0.87	11.37	0.57	1.21e-24	Corneal astigmatism;
CESC	cis	rs6500602	0.627	rs841231	chr16:4583147	C/T	cg08645402	chr16:4508243	NA	-0.4	-6.01	-0.35	6.23e-9	Schizophrenia;
CESC	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	7.86	0.43	9.54e-14	Prudent dietary pattern;
CESC	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.66	-9.23	-0.49	8.97e-18	Prudent dietary pattern;
CESC	cis	rs2243480	1.000	rs313807	chr7:65499481	C/T	cg18252515	chr7:66147081	NA	-1.13	-10.9	-0.56	4.18e-23	Diabetic kidney disease;
CESC	cis	rs12458462	0.859	rs34242155	chr18:77425192	G/A	cg11879182	chr18:77439856	CTDP1	0.85	12.59	0.61	8.64e-29	Monocyte count;
CESC	cis	rs17102884	0.506	rs4899540	chr14:75403408	G/A	cg11812906	chr14:75593930	NEK9	-0.44	-5.41	-0.32	1.44e-7	Neuroticism;
CESC	cis	rs6570726	0.764	rs1912023	chr6:145824278	C/A	cg23711669	chr6:146136114	FBXO30	1.02	16.0	0.7	8.93e-41	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs644799	0.544	rs498553	chr11:95534441	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.48	6.25	0.36	1.67e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs7208859	0.673	rs12103759	chr17:29235687	G/A	cg19761014	chr17:28927070	LRRC37B2	0.71	5.63	0.33	4.48e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs9486719	1.000	rs4839837	chr6:96908706	G/A	cg18709589	chr6:96969512	KIAA0776	0.48	5.7	0.33	3.19e-8	Migraine;Coronary artery disease;
CESC	cis	rs9908102	0.740	rs4792309	chr17:12908204	T/C	cg26162695	chr17:12921313	ELAC2	0.52	5.55	0.32	6.91e-8	Schizophrenia;
CESC	cis	rs524281	0.861	rs10791858	chr11:65978396	A/G	cg14036092	chr11:66035641	RAB1B	-0.58	-5.92	-0.34	9.73e-9	Electroencephalogram traits;
CESC	cis	rs6690583	0.623	rs61768852	chr1:85454613	T/C	cg22153463	chr1:85462885	MCOLN2	0.71	7.12	0.4	1.01e-11	Serum sulfate level;
CESC	cis	rs8177253	0.507	rs4241357	chr3:133475563	A/C	cg24879335	chr3:133465180	TF	-0.35	-6.29	-0.36	1.34e-9	Iron status biomarkers;
CESC	trans	rs9906155	0.748	rs60104171	chr17:75669249	C/A	cg14889768	chr6:146864529	RAB32	0.79	6.04	0.35	5.1e-9	Body mass index;
CESC	trans	rs1493916	1.000	rs4799729	chr18:31393521	C/T	cg27147174	chr7:100797783	AP1S1	0.52	7.02	0.4	1.81e-11	Life satisfaction;
CESC	cis	rs9914578	1.000	rs8082647	chr17:2010597	C/T	cg16513277	chr17:2031491	SMG6	0.62	7.1	0.4	1.16e-11	Body mass index;
CESC	cis	rs425277	0.527	rs3107144	chr1:2045380	C/A	cg24578937	chr1:2090814	PRKCZ	-0.34	-6.01	-0.35	5.99e-9	Height;
CESC	trans	rs4824093	0.610	rs73441745	chr22:50237606	G/A	cg09872104	chr7:134855509	C7orf49	-0.99	-6.91	-0.39	3.58e-11	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs9297145	0.565	rs6952161	chr7:98733337	A/G	cg05967295	chr7:98741636	SMURF1	0.62	8.4	0.46	2.68e-15	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
CESC	cis	rs13118159	0.934	rs4974608	chr4:1356780	C/T	cg02018176	chr4:1364513	KIAA1530	0.4	5.76	0.33	2.29e-8	Longevity;
CESC	cis	rs7520050	1.000	rs785511	chr1:46534498	T/C	cg03146154	chr1:46216737	IPP	-0.44	-5.73	-0.33	2.78e-8	Red blood cell count;Reticulocyte count;
CESC	cis	rs763121	0.819	rs138700	chr22:39129999	A/G	cg21395723	chr22:39101663	GTPBP1	0.5	6.61	0.38	2.15e-10	Menopause (age at onset);
CESC	cis	rs9790314	0.875	rs55688744	chr3:160944222	G/A	cg03342759	chr3:160939853	NMD3	-0.54	-7.61	-0.42	4.69e-13	Morning vs. evening chronotype;
CESC	cis	rs28830936	0.510	rs11858843	chr15:42092915	C/A	cg17847044	chr15:42102381	MAPKBP1	-0.45	-7.89	-0.44	7.89e-14	Diastolic blood pressure;
CESC	cis	rs2204008	0.715	rs11495369	chr12:38238673	T/C	cg26384229	chr12:38710491	ALG10B	0.69	9.8	0.52	1.51e-19	Bladder cancer;
CESC	cis	rs9815354	1.000	rs9856633	chr3:42013850	C/T	cg03022575	chr3:42003672	ULK4	0.43	5.03	0.3	9.16e-7	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs6460942	1.000	rs6460942	chr7:12420989	T/C	cg02935154	chr7:12443704	VWDE	-0.6	-6.57	-0.37	2.71e-10	Coronary artery disease;
CESC	cis	rs11792861	1.000	rs11792861	chr9:111809295	A/C	cg14384093	chr9:111878565	C9orf5	-0.42	-5.2	-0.3	3.91e-7	Menarche (age at onset);
CESC	cis	rs8177253	0.665	rs9831392	chr3:133451473	A/T	cg16262614	chr3:133464971	TF	0.3	5.46	0.32	1.11e-7	Iron status biomarkers;
CESC	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg19626725	chr5:178986131	RUFY1	-0.42	-7.0	-0.4	2.09e-11	Lung cancer;
CESC	cis	rs2742234	1.000	rs1864395	chr10:43655697	G/A	cg07801480	chr10:43725741	RASGEF1A	0.4	5.75	0.33	2.5e-8	Hirschsprung disease;
CESC	cis	rs1044826	0.642	rs432387	chr3:139231853	T/G	cg00490450	chr3:139108681	COPB2	-0.45	-5.52	-0.32	7.99e-8	Obesity-related traits;
CESC	cis	rs4237845	0.761	rs11172378	chr12:58298161	C/T	cg00677455	chr12:58241039	CTDSP2	0.61	7.64	0.42	4.04e-13	Intelligence (multi-trait analysis);
CESC	trans	rs687914	0.710	rs938662	chr2:45864578	A/G	cg01511534	chr16:3284640	ZNF200	0.63	6.82	0.39	6.09e-11	Diastolic blood pressure;
CESC	cis	rs7618915	0.547	rs2289250	chr3:52682946	A/C	cg07507251	chr3:52567010	NT5DC2	-0.4	-6.96	-0.39	2.71e-11	Bipolar disorder;
CESC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg10920302	chr3:45430089	LARS2	0.48	6.75	0.38	9.06e-11	Intelligence (multi-trait analysis);
CESC	cis	rs11864453	1.000	rs2278027	chr16:72051369	A/G	cg16558253	chr16:72132732	DHX38	-0.5	-7.21	-0.4	6e-12	Fibrinogen levels;
CESC	cis	rs11122272	0.735	rs2244986	chr1:231537452	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.53	-7.27	-0.41	4.07e-12	Hemoglobin concentration;
CESC	trans	rs1814175	0.935	rs6485999	chr11:49658986	G/C	cg15704280	chr7:45808275	SEPT13	-1.01	-17.87	-0.74	2.03e-47	Height;
CESC	cis	rs9291683	0.632	rs7679916	chr4:10042160	C/T	cg11266682	chr4:10021025	SLC2A9	0.67	13.02	0.62	2.72e-30	Bone mineral density;
CESC	cis	rs9291683	0.546	rs13139055	chr4:10038924	G/T	cg00071950	chr4:10020882	SLC2A9	0.82	13.72	0.64	9.99e-33	Bone mineral density;
CESC	cis	rs2359239	0.519	rs8007145	chr14:75185748	T/A	cg08847533	chr14:75593920	NEK9	0.47	5.71	0.33	3e-8	Neuroticism (multi-trait analysis);
CESC	cis	rs514406	0.893	rs2897561	chr1:53388747	C/A	cg25767906	chr1:53392781	SCP2	-0.44	-5.5	-0.32	8.72e-8	Monocyte count;
CESC	cis	rs9470366	0.527	rs733590	chr6:36645203	A/G	cg08179530	chr6:36648295	CDKN1A	0.67	10.05	0.53	2.49e-20	QRS duration;
CESC	cis	rs4604732	0.588	rs9943231	chr1:247629829	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.52	6.38	0.36	7.89e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs36051895	0.664	rs17425819	chr9:5114773	C/T	cg02405213	chr9:5042618	JAK2	-0.51	-6.07	-0.35	4.3e-9	Pediatric autoimmune diseases;
CESC	cis	rs17376456	0.569	rs7736892	chr5:93205597	G/A	cg25358565	chr5:93447407	FAM172A	-0.7	-7.43	-0.42	1.45e-12	Diabetic retinopathy;
CESC	cis	rs3858526	0.834	rs7128847	chr11:6003111	C/T	cg13902645	chr11:5959945	NA	-0.47	-5.59	-0.32	5.66e-8	DNA methylation (variation);
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg03373518	chr20:54933821	C20orf108	-0.49	-6.66	-0.38	1.62e-10	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs2832077	0.506	rs2832088	chr21:30158620	G/A	cg08807101	chr21:30365312	RNF160	-0.45	-5.09	-0.3	6.91e-7	Cognitive test performance;
CESC	cis	rs11098499	0.954	rs3733524	chr4:120423729	T/C	cg24375607	chr4:120327624	NA	0.49	6.07	0.35	4.32e-9	Corneal astigmatism;
CESC	cis	rs4803468	1.000	rs2231940	chr19:41944237	T/C	cg08639244	chr19:41945921	ATP5SL	0.43	5.32	0.31	2.22e-7	Height;
CESC	cis	rs6460942	0.597	rs4721107	chr7:12535105	T/G	cg02935154	chr7:12443704	VWDE	-0.57	-5.7	-0.33	3.23e-8	Coronary artery disease;
CESC	cis	rs7224737	1.000	rs7224737	chr17:40289364	A/G	cg20291162	chr17:40259547	DHX58	0.43	5.76	0.33	2.32e-8	Fibrinogen levels;
CESC	cis	rs780096	0.565	rs813592	chr2:27721971	T/C	cg21248554	chr2:27665150	KRTCAP3	-0.38	-7.9	-0.44	7.53e-14	Total body bone mineral density;
CESC	cis	rs514406	0.793	rs12402415	chr1:53218539	G/T	cg27535305	chr1:53392650	SCP2	0.31	5.47	0.32	1.02e-7	Monocyte count;
CESC	cis	rs12497850	0.931	rs1134591	chr3:48972892	C/T	cg07636037	chr3:49044803	WDR6	1.05	19.18	0.76	5.19e-52	Parkinson's disease;
CESC	cis	rs7618915	0.501	rs55678971	chr3:52717229	T/A	cg18337363	chr3:52569053	NT5DC2	0.3	5.39	0.31	1.54e-7	Bipolar disorder;
CESC	cis	rs1005277	0.579	rs2505237	chr10:38438898	T/G	cg25517755	chr10:38738941	LOC399744	-0.49	-6.35	-0.36	9.09e-10	Extrinsic epigenetic age acceleration;
CESC	cis	rs2404602	0.692	rs2117369	chr15:76748861	A/T	cg26408565	chr15:76604113	ETFA	-0.43	-6.25	-0.36	1.65e-9	Blood metabolite levels;
CESC	cis	rs3806843	0.735	rs2530235	chr5:140072647	G/T	cg26395211	chr5:140044315	WDR55	0.46	5.91	0.34	1.03e-8	Depressive symptoms (multi-trait analysis);
CESC	trans	rs11039798	0.844	rs11040177	chr11:48976211	G/C	cg15704280	chr7:45808275	SEPT13	0.69	6.44	0.37	5.66e-10	Axial length;
CESC	cis	rs5758659	0.714	rs5758578	chr22:42490292	A/C	cg19513890	chr22:42538836	CYP2D7P1	0.37	5.52	0.32	7.95e-8	Cognitive function;
CESC	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg26668828	chr6:292823	DUSP22	-0.71	-9.56	-0.51	8.46e-19	Menopause (age at onset);
CESC	cis	rs2073300	0.609	rs3736755	chr20:23377642	C/T	cg12062639	chr20:23401060	NAPB	1.03	8.3	0.45	5.34e-15	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs853679	0.517	rs2275508	chr6:28094731	T/C	cg23161317	chr6:28129485	ZNF389	0.53	6.97	0.39	2.54e-11	Depression;
CESC	trans	rs9325144	0.560	rs6582561	chr12:38666821	G/A	cg23762105	chr12:34175262	ALG10	0.48	6.31	0.36	1.15e-9	Morning vs. evening chronotype;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18551660	chr20:50769044	ZFP64	-0.56	-6.3	-0.36	1.2e-9	Gut microbiome composition (summer);
CESC	cis	rs8060686	0.641	rs76646352	chr16:68044797	C/A	cg26727032	chr16:67993705	SLC12A4	-0.54	-6.15	-0.35	2.78e-9	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs796364	0.760	rs56225698	chr2:200910653	A/C	cg23649088	chr2:200775458	C2orf69	-0.55	-5.05	-0.3	8.29e-7	Schizophrenia;
CESC	cis	rs9532580	0.620	rs2701859	chr13:41141232	T/C	cg21288729	chr13:41239152	FOXO1	0.67	7.9	0.44	7.31e-14	Mean corpuscular hemoglobin;
CESC	cis	rs875971	0.792	rs6971752	chr7:65737986	G/A	cg12463550	chr7:65579703	CRCP	-0.45	-5.72	-0.33	2.86e-8	Aortic root size;
CESC	cis	rs7923609	0.967	rs4486511	chr10:65264266	C/T	cg01631684	chr10:65280961	REEP3	-0.43	-5.4	-0.31	1.47e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7666738	0.830	rs4699594	chr4:98980775	T/C	cg17366294	chr4:99064904	C4orf37	0.59	8.46	0.46	1.8e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6445797	0.632	rs9881005	chr3:56604425	A/T	cg13792233	chr3:56591045	CCDC66	0.39	5.11	0.3	6.18e-7	Gastritis;
CESC	cis	rs4233802	0.737	rs74749038	chr2:151177761	G/A	cg25300694	chr2:151184358	NA	-0.95	-7.19	-0.4	6.55e-12	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
CESC	cis	rs514406	0.607	rs11206000	chr1:53205923	A/C	cg16325326	chr1:53192061	ZYG11B	-0.7	-11.18	-0.57	5.14e-24	Monocyte count;
CESC	cis	rs10504229	0.953	rs66509078	chr8:58174734	G/C	cg24829409	chr8:58192753	C8orf71	-0.76	-9.91	-0.52	6.75e-20	Developmental language disorder (linguistic errors);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10822447	chr10:70748436	KIAA1279	-0.6	-6.81	-0.39	6.63e-11	Gut microbiome composition (summer);
CESC	trans	rs561341	0.941	rs7215147	chr17:30266711	G/A	cg20587970	chr11:113659929	NA	-0.84	-10.79	-0.55	9.49e-23	Hip circumference adjusted for BMI;
CESC	cis	rs78456975	1.000	rs10189336	chr2:1558015	G/A	cg01028140	chr2:1542097	TPO	-0.54	-5.65	-0.33	4.12e-8	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs7799006	0.606	rs12535174	chr7:2310974	C/T	cg12745145	chr7:2261452	MAD1L1	-0.33	-5.25	-0.31	3.14e-7	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs9611565	0.559	rs132768	chr22:42013523	C/A	cg06634786	chr22:41940651	POLR3H	0.61	6.13	0.35	3.21e-9	Vitiligo;
CESC	trans	rs864643	0.773	rs11129837	chr3:39589963	A/G	cg15990800	chr14:55738852	FBXO34	0.57	7.52	0.42	8.46e-13	Attention deficit hyperactivity disorder;
CESC	cis	rs896854	0.846	rs13254283	chr8:95914103	G/T	cg23172400	chr8:95962367	TP53INP1	-0.46	-9.61	-0.51	5.95e-19	Type 2 diabetes;
CESC	cis	rs6831352	1.000	rs10017466	chr4:100055800	C/T	cg12011299	chr4:100065546	ADH4	0.68	8.63	0.47	5.75e-16	Alcohol dependence;
CESC	trans	rs9858542	1.000	rs13316695	chr3:49684917	C/G	cg21659725	chr3:3221576	CRBN	-0.53	-6.49	-0.37	4.09e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs34638657	0.732	rs11859473	chr16:82201072	T/C	cg09439754	chr16:82129088	HSD17B2	-0.36	-6.24	-0.36	1.71e-9	Lung adenocarcinoma;
CESC	cis	rs875971	0.522	rs2949690	chr7:65483242	C/T	cg11987759	chr7:65425863	GUSB	0.47	6.51	0.37	3.68e-10	Aortic root size;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg27588646	chr5:72469145	TMEM174	-0.44	-6.32	-0.36	1.08e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs1799949	1.000	rs1799966	chr17:41223094	T/C	cg06001716	chr17:41278141	BRCA1;NBR2	0.4	5.35	0.31	1.9e-7	Menopause (age at onset);
CESC	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg11905131	chr22:24372483	LOC391322	0.65	9.19	0.49	1.19e-17	Liver enzyme levels (gamma-glutamyl transferase);
CESC	trans	rs62103177	0.673	rs4438371	chr18:77615988	C/T	cg05926928	chr17:57297772	GDPD1	0.77	7.96	0.44	5.07e-14	Opioid sensitivity;
CESC	cis	rs9858542	1.000	rs11130213	chr3:49712297	C/T	cg07274523	chr3:49395745	GPX1	0.66	8.53	0.46	1.13e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs854765	0.583	rs11656840	chr17:17837354	C/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.55	7.28	0.41	3.7e-12	Total body bone mineral density;
CESC	cis	rs3105593	1.000	rs12442787	chr15:50918107	G/T	cg08437265	chr15:50716283	USP8	0.4	5.13	0.3	5.69e-7	QT interval;
CESC	cis	rs4665809	1.000	rs6720314	chr2:26334852	G/A	cg22920501	chr2:26401640	FAM59B	-0.78	-9.21	-0.49	1.03e-17	Gut microbiome composition (summer);
CESC	cis	rs9322193	0.962	rs1889473	chr6:150146621	C/G	cg13206674	chr6:150067644	NUP43	0.41	5.85	0.34	1.46e-8	Lung cancer;
CESC	cis	rs18122	0.881	rs7585530	chr2:67618256	C/T	cg09028215	chr2:67624308	ETAA1	-0.44	-5.26	-0.31	3.01e-7	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs75229567	0.618	rs78294090	chr12:70209959	G/T	cg10114359	chr12:70132523	RAB3IP	1.16	7.31	0.41	3.11e-12	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13639345	chr22:39052718	CBY1;LOC646851	-0.55	-6.14	-0.35	2.96e-9	Gut microbiome composition (summer);
CESC	trans	rs1728785	1.000	rs4783656	chr16:68580722	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.61	7.49	0.42	1.04e-12	Ulcerative colitis;
CESC	cis	rs7165102	1.000	rs11636148	chr15:65796880	C/T	cg11441148	chr15:65824328	PTPLAD1	-0.32	-5.31	-0.31	2.32e-7	Mean corpuscular hemoglobin;
CESC	cis	rs8078723	1.000	rs4794824	chr17:38179290	G/A	cg17467752	chr17:38218738	THRA	0.69	10.73	0.55	1.52e-22	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CESC	cis	rs6952809	0.532	rs2057840	chr7:2432797	C/G	cg25507518	chr7:2405875	EIF3B	0.45	5.03	0.3	8.93e-7	Multiple sclerosis;
CESC	trans	rs1814175	0.817	rs10839401	chr11:49876144	C/T	cg15704280	chr7:45808275	SEPT13	-1.02	-19.86	-0.77	2.27e-54	Height;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg15356780	chr14:90422831	TDP1	0.47	6.13	0.35	3.19e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs1878931	0.555	rs27228	chr16:3431933	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.76	-8.67	-0.47	4.35e-16	Body mass index (adult);
CESC	cis	rs3820928	1.000	rs10197757	chr2:227763244	A/C	cg05526886	chr2:227700861	RHBDD1	-0.41	-5.33	-0.31	2.09e-7	Pulmonary function;
CESC	cis	rs9733	0.565	rs7524620	chr1:150616699	C/T	cg09365446	chr1:150670422	GOLPH3L	-0.42	-5.87	-0.34	1.27e-8	Tonsillectomy;
CESC	cis	rs933688	0.652	rs4916856	chr5:90596403	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	-0.52	-6.22	-0.36	1.89e-9	Smoking behavior;
CESC	cis	rs2599510	0.811	rs2583713	chr2:32822729	A/G	cg02381751	chr2:32503542	YIPF4	0.5	6.16	0.35	2.62e-9	Interleukin-18 levels;
CESC	cis	rs6429082	0.627	rs2016437	chr1:235539355	T/G	cg26050004	chr1:235667680	B3GALNT2	-0.54	-6.76	-0.38	8.92e-11	Adiposity;
CESC	trans	rs561341	0.941	rs8066558	chr17:30272879	G/T	cg27661571	chr11:113659931	NA	-0.68	-6.86	-0.39	4.92e-11	Hip circumference adjusted for BMI;
CESC	trans	rs4950322	0.518	rs56151278	chr1:146589003	T/C	cg04954894	chr8:38089920	DDHD2	-0.59	-6.34	-0.36	9.74e-10	Protein quantitative trait loci;
CESC	cis	rs8180040	1.000	rs553989	chr3:47400328	A/G	cg27129171	chr3:47204927	SETD2	-0.66	-10.43	-0.54	1.43e-21	Colorectal cancer;
CESC	cis	rs727563	0.520	rs132773	chr22:42031768	T/A	cg06634786	chr22:41940651	POLR3H	0.59	6.01	0.35	6.19e-9	Crohn's disease;Inflammatory bowel disease;
CESC	trans	rs916888	0.773	rs538628	chr17:44787313	G/C	cg22968622	chr17:43663579	NA	1.32	18.29	0.75	6.72e-49	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs11098499	0.818	rs55825515	chr4:120486402	A/G	cg09307838	chr4:120376055	NA	0.91	12.65	0.61	5.08e-29	Corneal astigmatism;
CESC	cis	rs2479724	0.840	rs10498752	chr6:41768510	T/C	cg17623882	chr6:41773611	USP49	0.42	5.8	0.34	1.87e-8	Menarche (age at onset);
CESC	cis	rs8067545	0.532	rs67217337	chr17:20236432	C/T	cg13482628	chr17:19912719	NA	-0.41	-5.22	-0.31	3.61e-7	Schizophrenia;
CESC	cis	rs9325144	0.600	rs1825807	chr12:38737007	T/C	cg26384229	chr12:38710491	ALG10B	0.55	7.79	0.43	1.53e-13	Morning vs. evening chronotype;
CESC	trans	rs1814175	0.587	rs847628	chr11:49927064	A/T	cg15704280	chr7:45808275	SEPT13	-1.01	-18.94	-0.76	3.64e-51	Height;
CESC	cis	rs7402982	0.625	rs4966008	chr15:99203445	A/G	cg03437748	chr15:99193247	IGF1R	-0.61	-8.08	-0.44	2.26e-14	Birth weight;
CESC	trans	rs11039798	0.614	rs11039954	chr11:48741818	A/G	cg15704280	chr7:45808275	SEPT13	0.7	6.42	0.37	6.38e-10	Axial length;
CESC	cis	rs7666738	0.830	rs10012003	chr4:99064881	A/G	cg05340658	chr4:99064831	C4orf37	0.84	13.04	0.63	2.35e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg23708337	chr7:1209742	NA	0.53	5.34	0.31	1.98e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs3820928	0.605	rs13410141	chr2:227805529	A/G	cg11843606	chr2:227700838	RHBDD1	-0.56	-7.97	-0.44	4.7e-14	Pulmonary function;
CESC	cis	rs13108904	0.967	rs13149715	chr4:1278255	C/A	cg22903657	chr4:1355424	KIAA1530	-0.38	-5.23	-0.31	3.48e-7	Obesity-related traits;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg18194353	chr1:100315666	AGL	-0.46	-6.75	-0.38	9.22e-11	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs73019876	0.805	rs2522106	chr19:22140621	T/A	cg11619707	chr19:22235551	ZNF257	-0.27	-5.11	-0.3	6.12e-7	Testicular germ cell tumor;
CESC	cis	rs11098499	0.779	rs7674500	chr4:120303593	C/T	cg09307838	chr4:120376055	NA	0.92	12.66	0.61	4.96e-29	Corneal astigmatism;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02149193	chr12:132512069	EP400	-0.59	-6.57	-0.37	2.72e-10	Gut microbiome composition (summer);
CESC	cis	rs875971	0.862	rs6460282	chr7:65691246	T/C	cg10691866	chr7:65817282	TPST1	0.31	5.09	0.3	6.78e-7	Aortic root size;
CESC	trans	rs1285495	0.627	rs10912059	chr1:187354887	C/T	cg22647065	chr19:19612767	GATAD2A	0.48	6.02	0.35	5.64e-9	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
CESC	cis	rs1218582	0.772	rs4845689	chr1:154885524	A/G	cg24250549	chr1:154909240	PMVK	0.75	11.19	0.57	4.57e-24	Prostate cancer;
CESC	cis	rs7191439	0.584	rs7193436	chr16:88748736	T/C	cg27087555	chr16:88793112	FAM38A	-1.03	-6.22	-0.36	1.94e-9	Plateletcrit;
CESC	cis	rs637571	0.544	rs12361552	chr11:65701204	G/A	cg26695010	chr11:65641043	EFEMP2	0.44	5.49	0.32	9.2e-8	Eosinophil percentage of white cells;
CESC	cis	rs8067545	0.578	rs4925087	chr17:20024582	A/C	cg13482628	chr17:19912719	NA	0.4	5.35	0.31	1.86e-7	Schizophrenia;
CESC	cis	rs10911232	0.507	rs6664995	chr1:183017345	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.87	13.5	0.64	5.78e-32	Hypertriglyceridemia;
CESC	cis	rs7949030	0.590	rs12225213	chr11:62350248	T/A	cg11742103	chr11:62369870	EML3;MTA2	0.67	10.01	0.52	3.28e-20	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs637571	0.522	rs3016868	chr11:65764383	C/T	cg04055107	chr11:65626734	MUS81;CFL1	0.42	5.18	0.3	4.38e-7	Eosinophil percentage of white cells;
CESC	cis	rs9911578	0.935	rs117819974	chr17:57002324	C/T	cg05425664	chr17:57184151	TRIM37	-0.51	-7.05	-0.4	1.52e-11	Intelligence (multi-trait analysis);
CESC	cis	rs1552244	1.000	rs13319597	chr3:10126312	A/C	cg16606324	chr3:10149918	C3orf24	-0.42	-5.37	-0.31	1.76e-7	Alzheimer's disease;
CESC	cis	rs1008375	1.000	rs4698651	chr4:17694223	A/G	cg02297831	chr4:17616191	MED28	0.47	5.72	0.33	2.91e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs9399135	0.967	rs1590975	chr6:135352088	C/T	cg22676075	chr6:135203613	NA	0.49	6.97	0.39	2.45e-11	Red blood cell count;
CESC	cis	rs7666738	0.791	rs11729596	chr4:99045461	A/G	cg03467027	chr4:99064603	C4orf37	0.47	5.98	0.34	7.19e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4132509	0.739	rs79367267	chr1:243689543	C/A	cg21452805	chr1:244014465	NA	0.58	6.23	0.36	1.8e-9	RR interval (heart rate);
CESC	cis	rs644799	0.965	rs573758	chr11:95539591	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.92	13.87	0.65	2.93e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs9346455	1.000	rs9342828	chr6:71993657	T/C	cg27238071	chr6:71998145	OGFRL1	0.56	5.08	0.3	7e-7	Antipsychotic drug-induced weight gain (time interaction);Antipsychotic drug-induced weight gain;
CESC	cis	rs12995491	0.933	rs13008732	chr2:88528771	G/A	cg18490616	chr2:88469792	THNSL2	-0.53	-7.9	-0.44	7.33e-14	Response to metformin (IC50);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19524972	chr12:121647936	P2RX4	0.56	6.2	0.36	2.16e-9	Gut microbiome composition (summer);
CESC	cis	rs1008375	0.966	rs2159582	chr4:17695655	T/C	cg04450456	chr4:17643702	FAM184B	0.38	5.35	0.31	1.95e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	trans	rs2571521	0.887	rs9298879	chr9:26097224	A/C	cg27287808	chr1:45266048	PLK3	0.76	6.1	0.35	3.76e-9	Pursuit maintenance gain in psychotic disorders;
CESC	cis	rs7914558	0.899	rs7913682	chr10:104684392	T/A	cg15744005	chr10:104629667	AS3MT	-0.36	-5.57	-0.32	6.31e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs6502050	0.835	rs12051747	chr17:80114814	T/C	cg11859384	chr17:80120422	CCDC57	-0.38	-5.18	-0.3	4.47e-7	Life satisfaction;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg07051796	chr16:72982538	ZFHX3	0.44	6.18	0.35	2.43e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs13191362	0.810	rs28360533	chr6:162996742	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.88	9.16	0.49	1.46e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs265548	0.646	rs36692	chr19:17906839	C/T	cg04517722	chr19:17905589	B3GNT3	0.43	5.78	0.33	2.12e-8	Tumor biomarkers;
CESC	cis	rs9322193	0.926	rs9383546	chr6:150143879	T/A	cg09699651	chr6:150184138	LRP11	0.4	5.1	0.3	6.46e-7	Lung cancer;
CESC	cis	rs9894429	0.646	rs9902264	chr17:79613828	G/A	cg21984481	chr17:79567631	NPLOC4	-0.33	-5.17	-0.3	4.68e-7	Eye color traits;
CESC	cis	rs62103177	0.810	rs62103175	chr18:77622467	C/T	cg12964065	chr18:77638022	KCNG2	0.57	5.41	0.32	1.4e-7	Opioid sensitivity;
CESC	cis	rs977987	0.864	rs37595	chr16:75496963	G/C	cg03315344	chr16:75512273	CHST6	-0.46	-6.48	-0.37	4.48e-10	Dupuytren's disease;
CESC	cis	rs4481887	0.927	rs6689193	chr1:248482900	T/A	cg00666640	chr1:248458726	OR2T12	0.36	6.07	0.35	4.47e-9	Common traits (Other);
CESC	cis	rs6752107	0.967	rs12162308	chr2:234172188	C/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.49	6.86	0.39	4.91e-11	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs2243480	0.901	rs2456483	chr7:65461575	T/C	cg13147721	chr7:65941812	NA	-0.86	-8.36	-0.46	3.7e-15	Diabetic kidney disease;
CESC	cis	rs7267979	1.000	rs2297497	chr20:25297909	C/T	cg08601574	chr20:25228251	PYGB	-0.39	-5.57	-0.32	6.21e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs28386778	0.965	rs2854154	chr17:61981696	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	-1.04	-18.01	-0.74	6.5e-48	Prudent dietary pattern;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11387077	chr7:30544503	GGCT	0.56	6.58	0.37	2.49e-10	Gut microbiome composition (summer);
CESC	cis	rs67478160	0.654	rs1997913	chr14:104213960	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.5	-7.01	-0.4	1.98e-11	Schizophrenia;
CESC	cis	rs863345	0.604	rs10797012	chr1:158465485	C/T	cg12129480	chr1:158549410	OR10X1	-0.35	-7.03	-0.4	1.78e-11	Pneumococcal bacteremia;
CESC	cis	rs7666738	0.719	rs35184673	chr4:99050945	T/C	cg05340658	chr4:99064831	C4orf37	0.56	5.76	0.33	2.31e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs524281	0.814	rs1055615	chr11:65846922	C/G	cg14036092	chr11:66035641	RAB1B	-0.55	-5.85	-0.34	1.45e-8	Electroencephalogram traits;
CESC	cis	rs2455799	0.593	rs2062823	chr3:15732256	G/T	cg16303742	chr3:15540471	COLQ	-0.38	-5.92	-0.34	9.86e-9	Mean platelet volume;
CESC	cis	rs6690583	0.623	rs12041012	chr1:85515644	G/A	cg22488158	chr1:85528044	WDR63	0.57	5.51	0.32	8.47e-8	Serum sulfate level;
CESC	cis	rs769267	0.931	rs2965197	chr19:19470910	C/T	cg03709012	chr19:19516395	GATAD2A	-0.98	-14.29	-0.66	1.02e-34	Tonsillectomy;
CESC	cis	rs9649213	0.593	rs3823740	chr7:97957104	T/G	cg24562669	chr7:97807699	LMTK2	0.52	7.64	0.42	3.99e-13	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs2075371	0.547	rs12666682	chr7:134021784	C/A	cg20476274	chr7:133979776	SLC35B4	0.51	6.7	0.38	1.26e-10	Mean platelet volume;
CESC	trans	rs9987353	0.840	rs329994	chr8:9123233	A/G	cg07911682	chr1:51425659	FAF1	-0.47	-6.53	-0.37	3.39e-10	Recombination measurement;
CESC	cis	rs875971	0.964	rs6978721	chr7:65883204	A/G	cg18876405	chr7:65276391	NA	0.5	6.68	0.38	1.43e-10	Aortic root size;
CESC	cis	rs7927592	0.763	rs7129248	chr11:68263276	A/T	cg16797656	chr11:68205561	LRP5	0.47	7.17	0.4	7.54e-12	Total body bone mineral density;
CESC	cis	rs9649213	0.593	rs35983874	chr7:97916461	C/T	cg24562669	chr7:97807699	LMTK2	0.47	6.74	0.38	9.62e-11	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7666738	0.830	rs2098934	chr4:98992403	A/G	cg05340658	chr4:99064831	C4orf37	0.8	12.44	0.61	2.83e-28	Colonoscopy-negative controls vs population controls;
CESC	trans	rs12356475	0.710	rs10822686	chr10:67733250	C/T	cg20756934	chr12:56510353	RPL41	0.54	6.12	0.35	3.33e-9	Psoriatic arthritis;
CESC	cis	rs1568889	1.000	rs7949057	chr11:28255053	A/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.82	11.78	0.59	4.79e-26	Bipolar disorder;
CESC	cis	rs2988277	0.713	rs10800313	chr1:167429985	C/T	cg09179987	chr1:167433047	CD247	-0.35	-5.21	-0.31	3.73e-7	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs4862750	0.874	rs6822062	chr4:187895553	T/C	cg11301795	chr4:187892539	NA	-0.76	-12.44	-0.61	2.73e-28	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg25276849	chr3:195808919	TFRC	-0.43	-6.23	-0.36	1.78e-9	Gambling;
CESC	cis	rs4409675	0.527	rs1884469	chr1:28239434	G/A	cg23691781	chr1:28212827	C1orf38	0.28	5.48	0.32	1.01e-7	Corneal astigmatism;
CESC	cis	rs559928	0.606	rs55942618	chr11:63936005	C/T	cg18225595	chr11:63971243	STIP1	0.69	6.22	0.36	1.88e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CESC	cis	rs6963495	0.745	rs73192151	chr7:105211876	A/G	cg02135003	chr7:105160482	PUS7	-0.48	-5.51	-0.32	8.52e-8	Bipolar disorder (body mass index interaction);
CESC	cis	rs35306767	0.761	rs11253540	chr10:1011958	C/T	cg20503657	chr10:835505	NA	-0.7	-6.61	-0.38	2.12e-10	Eosinophil percentage of granulocytes;
CESC	cis	rs1046896	0.514	rs67735447	chr17:80823042	G/T	cg19500275	chr17:80737654	TBCD	0.46	5.28	0.31	2.68e-7	Glycated hemoglobin levels;
CESC	cis	rs116095464	0.558	rs55664502	chr5:270485	T/C	cg10591111	chr5:226296	SDHA	-0.51	-6.24	-0.36	1.71e-9	Breast cancer;
CESC	cis	rs8177253	0.666	rs8177197	chr3:133469530	G/A	cg01448562	chr3:133502909	NA	-0.48	-6.41	-0.37	6.74e-10	Iron status biomarkers;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05614267	chr16:69373129	NIP7;COG8	0.61	7.66	0.43	3.59e-13	Gut microbiome composition (summer);
CESC	cis	rs1801251	1.000	rs283468	chr2:233658309	C/T	cg25237894	chr2:233734115	C2orf82	0.46	8.02	0.44	3.47e-14	Coronary artery disease;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg19345149	chr11:116658875	ZNF259	-0.48	-6.02	-0.35	5.93e-9	Ulcerative colitis;
CESC	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg07414643	chr4:187882934	NA	0.56	8.14	0.45	1.53e-14	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2732480	0.500	rs7966829	chr12:48615603	G/T	cg04545296	chr12:48745243	ZNF641	0.39	6.45	0.37	5.34e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs6800768	0.633	rs6807599	chr3:24145588	A/C	cg10674438	chr3:24145617	LOC152024	-0.44	-6.11	-0.35	3.49e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs780096	0.527	rs12471703	chr2:27738854	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.31	-5.42	-0.32	1.35e-7	Total body bone mineral density;
CESC	cis	rs12142240	0.698	rs72677592	chr1:46818288	A/G	cg10495392	chr1:46806563	NSUN4	0.57	6.27	0.36	1.47e-9	Menopause (age at onset);
CESC	cis	rs3008870	0.755	rs2208577	chr1:67513574	A/C	cg08660285	chr1:67390436	MIER1;WDR78	0.55	6.75	0.38	9.11e-11	Lymphocyte percentage of white cells;
CESC	cis	rs6815814	0.950	rs73236632	chr4:38836071	G/A	cg02016764	chr4:38805732	TLR1	-0.61	-6.79	-0.38	7.42e-11	Breast cancer;
CESC	cis	rs10751667	0.643	rs10902245	chr11:953014	C/T	cg06064525	chr11:970664	AP2A2	0.51	9.99	0.52	3.63e-20	Alzheimer's disease (late onset);
CESC	cis	rs35306767	1.000	rs35306767	chr10:989437	A/T	cg26597838	chr10:835615	NA	0.81	8.67	0.47	4.32e-16	Eosinophil percentage of granulocytes;
CESC	cis	rs9905704	0.918	rs68139131	chr17:56717249	A/G	cg12560992	chr17:57184187	TRIM37	0.59	6.98	0.39	2.34e-11	Testicular germ cell tumor;
CESC	cis	rs9926296	0.533	rs7190823	chr16:89866043	A/G	cg27121462	chr16:89883253	FANCA	0.78	11.75	0.59	6.03e-26	Vitiligo;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12122961	chr3:197355151	LOC220729	0.54	6.12	0.35	3.33e-9	Gut microbiome composition (summer);
CESC	cis	rs7917772	0.503	rs7914389	chr10:104295402	T/C	cg22532475	chr10:104410764	TRIM8	-0.34	-5.81	-0.34	1.82e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs7811142	0.943	rs67483801	chr7:100031758	G/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.03	11.56	0.58	2.62e-25	Platelet count;
CESC	cis	rs250677	1.000	rs250677	chr5:148433549	T/C	cg18129178	chr5:148520854	ABLIM3	-0.45	-5.31	-0.31	2.31e-7	Breast cancer;
CESC	cis	rs752010	0.967	rs2038978	chr1:42094719	A/G	cg06885757	chr1:42089581	HIVEP3	0.49	8.07	0.44	2.48e-14	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs9660992	1.000	rs9660992	chr1:205249450	A/G	cg21643547	chr1:205240462	TMCC2	-0.44	-7.09	-0.4	1.24e-11	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs2243480	1.000	rs313814	chr7:65503293	C/A	cg12463550	chr7:65579703	CRCP	0.69	5.41	0.32	1.39e-7	Diabetic kidney disease;
CESC	cis	rs7130144	0.686	rs12288732	chr11:130434267	A/G	cg26307797	chr11:130446613	NA	-0.59	-5.42	-0.32	1.31e-7	Urate levels in lean individuals;
CESC	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.54	7.1	0.4	1.17e-11	Lymphocyte counts;
CESC	cis	rs9790314	1.000	rs336585	chr3:161081670	A/G	cg03342759	chr3:160939853	NMD3	-0.47	-6.05	-0.35	4.83e-9	Morning vs. evening chronotype;
CESC	cis	rs7312933	0.670	rs10880269	chr12:42606135	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.49	6.51	0.37	3.8e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg22368307	chr11:75110460	SNORD15A;RPS3	-0.44	-6.16	-0.35	2.74e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs1552244	1.000	rs61052895	chr3:10147516	G/A	cg00166722	chr3:10149974	C3orf24	0.45	5.67	0.33	3.82e-8	Alzheimer's disease;
CESC	cis	rs514406	0.861	rs505444	chr1:53251860	C/T	cg25767906	chr1:53392781	SCP2	-0.39	-5.07	-0.3	7.31e-7	Monocyte count;
CESC	cis	rs7208859	0.623	rs216445	chr17:28933576	A/G	cg13385521	chr17:29058706	SUZ12P	0.77	5.67	0.33	3.8e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg14159672	chr1:205819179	PM20D1	0.89	15.28	0.68	3.25e-38	Menarche (age at onset);
CESC	trans	rs7980799	0.649	rs7972688	chr12:33653477	T/C	cg26384229	chr12:38710491	ALG10B	-0.57	-7.96	-0.44	5.02e-14	Heart rate;Heart rate variability traits (RMSSD);
CESC	cis	rs801193	0.761	rs2659888	chr7:66230171	T/G	cg10691866	chr7:65817282	TPST1	-0.32	-5.15	-0.3	5.14e-7	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07823935	chr2:183902842	NCKAP1	-0.69	-7.89	-0.44	7.99e-14	Gut microbiome composition (summer);
CESC	cis	rs3824867	1.000	rs3824867	chr11:47468569	A/G	cg20307385	chr11:47447363	PSMC3	0.51	6.27	0.36	1.43e-9	Mean corpuscular hemoglobin;
CESC	cis	rs9625935	0.518	rs245008	chr22:30315736	T/C	cg01021169	chr22:30184971	ASCC2	-0.44	-6.87	-0.39	4.46e-11	Tonsillectomy;
CESC	cis	rs909674	0.541	rs5757655	chr22:39797178	C/G	cg02038168	chr22:39784481	NA	0.62	7.95	0.44	5.37e-14	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs1178968	0.818	rs2262777	chr7:72786490	A/T	cg25889504	chr7:72793014	NA	0.49	5.18	0.3	4.46e-7	Triglyceride levels;
CESC	cis	rs7584330	0.868	rs13386290	chr2:238393136	G/C	cg14458575	chr2:238380390	NA	0.71	9.71	0.51	2.79e-19	Prostate cancer;
CESC	trans	rs629535	0.814	rs56326813	chr8:70107736	T/A	cg21567404	chr3:27674614	NA	-0.87	-10.05	-0.53	2.43e-20	Dupuytren's disease;
CESC	cis	rs2576037	0.583	rs2576050	chr18:44558912	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.77	-12.76	-0.62	2.17e-29	Personality dimensions;
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg10808102	chr17:25783956	NA	0.4	6.11	0.35	3.6e-9	Vertical cup-disc ratio;
CESC	cis	rs4704187	0.687	rs1477937	chr5:74524837	A/G	cg03227963	chr5:74354835	NA	0.28	5.13	0.3	5.48e-7	Response to amphetamines;
CESC	cis	rs2797160	1.000	rs4895798	chr6:126000162	A/G	cg05901451	chr6:126070800	HEY2	-0.45	-6.67	-0.38	1.44e-10	Endometrial cancer;
CESC	cis	rs4077515	0.527	rs10870146	chr9:139308054	G/A	cg14169450	chr9:139327907	INPP5E	0.52	7.82	0.43	1.22e-13	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs854765	0.647	rs854814	chr17:18003648	G/A	cg04398451	chr17:18023971	MYO15A	-0.78	-11.51	-0.58	3.94e-25	Total body bone mineral density;
CESC	cis	rs4819052	0.851	rs4819040	chr21:46659762	T/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.44	5.72	0.33	2.9e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs7923609	1.000	rs4400684	chr10:65012687	A/G	cg01631684	chr10:65280961	REEP3	-0.44	-5.48	-0.32	9.99e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs1670533	1.000	rs11731320	chr4:1057916	T/A	cg27284194	chr4:1044797	NA	0.48	6.06	0.35	4.7e-9	Recombination rate (females);
CESC	cis	rs28374715	0.532	rs28463309	chr15:41666716	A/G	cg20272979	chr15:41787780	ITPKA	0.43	5.39	0.31	1.59e-7	Ulcerative colitis;
CESC	cis	rs654950	0.841	rs2810549	chr1:41991761	C/T	cg06885757	chr1:42089581	HIVEP3	-0.44	-6.75	-0.38	9.38e-11	Airway imaging phenotypes;
CESC	cis	rs1801251	1.000	rs11676216	chr2:233706368	C/T	cg08000102	chr2:233561755	GIGYF2	-0.7	-10.11	-0.53	1.51e-20	Coronary artery disease;
CESC	cis	rs8177253	0.930	rs12595	chr3:133496553	T/C	cg11941060	chr3:133502564	NA	-0.44	-5.84	-0.34	1.56e-8	Iron status biomarkers;
CESC	cis	rs7149242	0.922	rs9671394	chr14:101159674	C/T	cg18089426	chr14:101175970	NA	-0.36	-5.91	-0.34	1.07e-8	Platelet count;
CESC	cis	rs963731	0.649	rs10779924	chr2:39208057	G/T	cg04010122	chr2:39346883	SOS1	-0.68	-5.11	-0.3	6.11e-7	Corticobasal degeneration;
CESC	cis	rs12530845	1.000	rs12540325	chr7:135334111	T/C	cg23117316	chr7:135346802	PL-5283	-0.43	-5.38	-0.31	1.61e-7	Red blood cell traits;
CESC	trans	rs11098499	0.691	rs9307471	chr4:120261262	G/A	cg25214090	chr10:38739885	LOC399744	0.61	8.68	0.47	4.06e-16	Corneal astigmatism;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05139649	chr11:108368923	KDELC2	0.54	6.34	0.36	9.6e-10	Gut microbiome composition (summer);
CESC	cis	rs8078723	0.690	rs56326707	chr17:38130139	C/T	cg17467752	chr17:38218738	THRA	0.57	8.43	0.46	2.28e-15	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg09041756	chr7:5570314	ACTB	-0.5	-6.3	-0.36	1.21e-9	Ulcerative colitis;
CESC	cis	rs55692411	0.537	rs13071931	chr3:50062878	G/A	cg24308560	chr3:49941425	MST1R	-0.53	-6.52	-0.37	3.51e-10	Intelligence (multi-trait analysis);
CESC	cis	rs9682041	0.696	rs6798399	chr3:170086482	G/A	cg11886554	chr3:170076028	SKIL	0.7	6.49	0.37	4.1e-10	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CESC	trans	rs4455778	0.579	rs10265045	chr7:49131824	G/T	cg25315252	chr10:81839033	LOC219347;C10orf57	-0.41	-6.09	-0.35	3.92e-9	Lung cancer in never smokers;
CESC	cis	rs4665809	1.000	rs11678157	chr2:26321526	T/C	cg08470875	chr2:26401718	FAM59B	-0.47	-5.29	-0.31	2.56e-7	Gut microbiome composition (summer);
CESC	cis	rs6963495	0.818	rs73192124	chr7:105171528	C/T	cg19920283	chr7:105172520	RINT1	0.68	6.44	0.37	5.53e-10	Bipolar disorder (body mass index interaction);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg03093995	chr9:114393414	DNAJC25-GNG10;DNAJC25	-0.5	-7.14	-0.4	8.79e-12	Gambling;
CESC	cis	rs950169	0.887	rs35986397	chr15:84955107	G/A	cg17507749	chr15:85114479	UBE2QP1	0.6	6.56	0.37	2.82e-10	Schizophrenia;
CESC	cis	rs9948	0.655	rs75763821	chr2:97392694	G/A	cg01990225	chr2:97406019	LMAN2L	-1.02	-7.78	-0.43	1.58e-13	Erectile dysfunction and prostate cancer treatment;
CESC	cis	rs4665809	0.838	rs6546780	chr2:26352857	T/C	cg22920501	chr2:26401640	FAM59B	-0.67	-8.02	-0.44	3.47e-14	Gut microbiome composition (summer);
CESC	cis	rs4819052	0.819	rs13046807	chr21:46672286	A/G	cg11663144	chr21:46675770	NA	-0.59	-9.01	-0.48	4.07e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs875971	0.505	rs1723275	chr7:65504633	G/C	cg26939375	chr7:64535504	NA	-0.75	-10.73	-0.55	1.52e-22	Aortic root size;
CESC	cis	rs8177253	0.761	rs1830084	chr3:133508464	A/T	cg11941060	chr3:133502564	NA	0.52	7.03	0.4	1.78e-11	Iron status biomarkers;
CESC	cis	rs35110281	0.720	rs230647	chr21:44919654	C/T	cg01579765	chr21:45077557	HSF2BP	0.54	8.49	0.46	1.52e-15	Mean corpuscular volume;
CESC	cis	rs17431357	1.000	rs73225208	chr12:120932576	G/A	cg25045489	chr12:120971538	RNF10	-0.93	-5.46	-0.32	1.1e-7	Insulin resistance/response;
CESC	cis	rs6964587	1.000	rs2188154	chr7:91595138	T/A	cg17063962	chr7:91808500	NA	0.57	7.82	0.43	1.22e-13	Breast cancer;
CESC	cis	rs7666738	0.680	rs11097613	chr4:99079991	G/T	cg03467027	chr4:99064603	C4orf37	0.43	5.21	0.3	3.86e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9649465	0.967	rs10269196	chr7:123321073	G/T	cg04330084	chr7:123175371	IQUB	-0.38	-5.2	-0.3	3.94e-7	Migraine;
CESC	cis	rs9303401	0.614	rs28687626	chr17:57191904	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.99	11.18	0.57	5e-24	Cognitive test performance;
CESC	cis	rs7116495	0.609	rs1894004	chr11:71759817	G/A	cg18441811	chr11:71824068	C11orf51	-0.83	-5.34	-0.31	1.98e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs738322	0.967	rs4380	chr22:38569529	T/C	cg25457927	chr22:38595422	NA	-0.3	-5.57	-0.32	6.3e-8	Cutaneous nevi;
CESC	cis	rs3785574	0.962	rs2584623	chr17:61906679	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.09	19.2	0.76	4.43e-52	Height;
CESC	cis	rs7927771	0.929	rs66749409	chr11:47568074	C/T	cg05585544	chr11:47624801	NA	-0.52	-8.03	-0.44	3.23e-14	Subjective well-being;
CESC	cis	rs2228479	0.850	rs62056091	chr16:89930414	G/A	cg06558623	chr16:89946397	TCF25	1.17	8.95	0.48	6.17e-17	Skin colour saturation;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02632185	chr5:66299786	MAST4	-0.57	-6.02	-0.35	5.84e-9	Gut microbiome composition (summer);
CESC	trans	rs459571	0.959	rs2810491	chr9:136923331	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	0.65	8.49	0.46	1.53e-15	Platelet distribution width;
CESC	cis	rs2463822	0.669	rs72919496	chr11:62052730	T/C	cg06239285	chr11:62104954	ASRGL1	-1.12	-8.88	-0.48	1.03e-16	Chronic obstructive pulmonary disease-related biomarkers;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04730839	chr6:42985884	KLHDC3	0.45	6.73	0.38	1.04e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs1215050	0.740	rs783938	chr4:99010336	A/T	cg17366294	chr4:99064904	C4orf37	-0.39	-5.12	-0.3	5.98e-7	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs72829446	0.530	rs4796424	chr17:7387973	T/C	cg02795151	chr17:7402630	POLR2A	0.55	5.86	0.34	1.41e-8	Androgen levels;
CESC	cis	rs4243830	0.737	rs4908923	chr1:6614535	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.79	-8.22	-0.45	8.87e-15	Body mass index;
CESC	cis	rs6991838	0.557	rs57419568	chr8:66510868	G/A	cg13398993	chr8:66546079	ARMC1	-0.47	-5.59	-0.32	5.56e-8	Intelligence (multi-trait analysis);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg13581475	chr14:64854533	MTHFD1	0.46	6.28	0.36	1.39e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs17711722	0.701	rs55773927	chr7:65337902	T/C	cg26939375	chr7:64535504	NA	0.76	10.79	0.55	9.56e-23	Calcium levels;
CESC	cis	rs6860806	0.661	rs6871350	chr5:131580220	A/G	cg04518342	chr5:131593106	PDLIM4	0.41	6.2	0.36	2.1e-9	Breast cancer;
CESC	cis	rs9399135	0.967	rs952674	chr6:135349157	A/G	cg24558204	chr6:135376177	HBS1L	0.52	7.29	0.41	3.48e-12	Red blood cell count;
CESC	cis	rs736408	0.716	rs2239549	chr3:52823126	C/T	cg18404041	chr3:52824283	ITIH1	-0.49	-8.1	-0.45	2.08e-14	Bipolar disorder;
CESC	cis	rs763121	0.853	rs5757200	chr22:39043491	T/G	cg21395723	chr22:39101663	GTPBP1	0.43	5.33	0.31	2.09e-7	Menopause (age at onset);
CESC	cis	rs7727544	0.645	rs272857	chr5:131685297	G/A	cg24060327	chr5:131705240	SLC22A5	-0.6	-7.77	-0.43	1.74e-13	Blood metabolite levels;
CESC	trans	rs17764205	0.852	rs10412307	chr19:3251994	C/T	cg22364819	chr2:127864926	BIN1	0.63	6.05	0.35	4.81e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.89	13.67	0.64	1.49e-32	Prudent dietary pattern;
CESC	cis	rs35306767	0.903	rs35968821	chr10:910225	A/G	cg25019033	chr10:957182	NA	-0.59	-6.35	-0.36	9.39e-10	Eosinophil percentage of granulocytes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19402173	chr7:128379420	CALU	0.58	6.24	0.36	1.7e-9	Gut microbiome composition (summer);
CESC	cis	rs709400	1.000	rs55885592	chr14:104126024	C/T	cg12935359	chr14:103987150	CKB	-0.45	-6.08	-0.35	4.23e-9	Body mass index;
CESC	cis	rs9790314	1.000	rs6765269	chr3:160948542	T/C	cg03342759	chr3:160939853	NMD3	-0.45	-5.73	-0.33	2.78e-8	Morning vs. evening chronotype;
CESC	cis	rs7618915	0.547	rs6976	chr3:52728804	C/T	cg18404041	chr3:52824283	ITIH1	-0.41	-6.93	-0.39	3.2e-11	Bipolar disorder;
CESC	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg26338869	chr17:61819248	STRADA	0.66	8.6	0.47	7.02e-16	Prudent dietary pattern;
CESC	cis	rs10504229	0.861	rs67042991	chr8:58191749	G/C	cg24829409	chr8:58192753	C8orf71	-0.76	-9.93	-0.52	5.87e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs875971	0.862	rs3893216	chr7:65790707	G/C	cg10691866	chr7:65817282	TPST1	0.32	5.4	0.31	1.49e-7	Aortic root size;
CESC	cis	rs2235642	0.928	rs9932984	chr16:1605051	A/G	cg07639376	chr16:1584516	IFT140;TMEM204	-0.32	-5.27	-0.31	2.86e-7	Coronary artery disease;
CESC	cis	rs1790761	0.587	rs4930431	chr11:67294308	C/T	cg08355456	chr11:67383691	NA	-0.34	-5.47	-0.32	1.03e-7	Mean corpuscular volume;
CESC	cis	rs920590	0.758	rs1907799	chr8:19664668	A/G	cg17834443	chr8:19674713	INTS10	-0.53	-6.23	-0.36	1.87e-9	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs514406	0.505	rs448788	chr1:53161620	A/G	cg08736216	chr1:53307985	ZYG11A	0.39	6.32	0.36	1.12e-9	Monocyte count;
CESC	cis	rs9611565	0.659	rs73178641	chr22:41952075	A/T	cg06634786	chr22:41940651	POLR3H	-0.7	-7.21	-0.4	5.83e-12	Vitiligo;
CESC	cis	rs7395581	0.918	rs3781622	chr11:47348702	T/C	cg25783544	chr11:47291846	MADD	0.6	7.79	0.43	1.49e-13	HDL cholesterol;
CESC	cis	rs1983891	0.955	rs9381076	chr6:41517564	G/A	cg20194872	chr6:41519635	FOXP4	0.59	8.45	0.46	1.9e-15	Prostate cancer;
CESC	cis	rs959260	1.000	rs2033609	chr17:73367021	C/T	cg20590849	chr17:73267439	MIF4GD	-0.55	-6.4	-0.37	6.95e-10	Systemic lupus erythematosus;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg05640069	chr1:94312038	MIR760	-0.48	-6.01	-0.35	5.96e-9	Ulcerative colitis;
CESC	cis	rs875971	0.862	rs6959268	chr7:65812966	G/A	cg18876405	chr7:65276391	NA	-0.51	-7.03	-0.4	1.8e-11	Aortic root size;
CESC	cis	rs4478858	0.735	rs2889730	chr1:31827159	C/T	cg00250761	chr1:31883323	NA	-0.26	-5.07	-0.3	7.56e-7	Alcohol dependence;
CESC	cis	rs644799	1.000	rs568668	chr11:95528209	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.92	13.84	0.65	3.87e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs597539	0.617	rs598353	chr11:68635770	C/A	cg21963583	chr11:68658836	MRPL21	0.4	5.52	0.32	8.06e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs4588572	0.644	rs6870646	chr5:77741082	G/A	cg11547950	chr5:77652471	NA	-0.4	-5.56	-0.32	6.42e-8	Triglycerides;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04107082	chr2:61245442	PEX13;PUS10	0.66	7.79	0.43	1.54e-13	Gut microbiome composition (summer);
CESC	trans	rs5758511	0.773	rs9623482	chr22:42360574	T/C	cg15080870	chr19:47770746	CCDC9	0.51	6.27	0.36	1.45e-9	Birth weight;
CESC	cis	rs477692	0.673	rs1970197	chr10:131359588	C/T	cg24747557	chr10:131355152	MGMT	-0.38	-5.17	-0.3	4.55e-7	Response to temozolomide;
CESC	cis	rs2797685	1.000	rs697691	chr1:7885354	A/G	cg04725166	chr1:7887271	PER3	-0.45	-6.26	-0.36	1.55e-9	Crohn's disease;
CESC	cis	rs10465746	0.933	rs2224990	chr1:84436275	C/A	cg10977910	chr1:84465055	TTLL7	0.47	6.32	0.36	1.13e-9	Obesity-related traits;
CESC	cis	rs2637266	0.714	rs4475870	chr10:78450724	T/A	cg18941641	chr10:78392320	NA	0.43	7.78	0.43	1.68e-13	Pulmonary function;
CESC	cis	rs12145833	0.596	rs12026068	chr1:243440352	A/G	cg02356786	chr1:243265016	LOC731275	0.75	5.66	0.33	3.99e-8	Obesity (early onset extreme);
CESC	cis	rs9649213	0.593	rs12704983	chr7:97927045	G/A	cg24562669	chr7:97807699	LMTK2	0.48	6.92	0.39	3.3e-11	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs11098499	0.909	rs28793658	chr4:120307214	A/C	cg09307838	chr4:120376055	NA	0.92	12.66	0.61	4.96e-29	Corneal astigmatism;
CESC	cis	rs5758511	0.680	rs1001586	chr22:42670293	G/T	cg00645731	chr22:42541494	CYP2D7P1	0.58	8.66	0.47	4.81e-16	Birth weight;
CESC	cis	rs9486719	0.857	rs4486027	chr6:96911886	T/C	cg06623918	chr6:96969491	KIAA0776	-0.79	-9.15	-0.49	1.55e-17	Migraine;Coronary artery disease;
CESC	cis	rs12618769	0.597	rs3754881	chr2:99132093	G/A	cg10123293	chr2:99228465	UNC50	0.41	5.44	0.32	1.24e-7	Bipolar disorder;
CESC	cis	rs698833	0.562	rs13402006	chr2:44726040	T/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.41	5.16	0.3	4.84e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs7590368	0.673	rs55648622	chr2:10932765	C/T	cg15705551	chr2:10952987	PDIA6	0.55	5.26	0.31	2.96e-7	Educational attainment (years of education);
CESC	cis	rs9549367	0.789	rs9549716	chr13:113908478	G/A	cg00898013	chr13:113819073	PROZ	-0.52	-7.45	-0.42	1.31e-12	Platelet distribution width;
CESC	cis	rs2243480	1.000	rs11538349	chr7:65421871	C/T	cg12463550	chr7:65579703	CRCP	0.66	5.61	0.33	4.98e-8	Diabetic kidney disease;
CESC	cis	rs3733585	0.673	rs6836706	chr4:9964251	T/A	cg00071950	chr4:10020882	SLC2A9	-0.73	-11.79	-0.59	4.58e-26	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs7267979	0.966	rs2424715	chr20:25420077	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.87	18.11	0.74	3.04e-48	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs9443189	0.813	rs3798439	chr6:76566734	T/G	cg01950844	chr6:76311363	SENP6	-0.58	-6.13	-0.35	3.2e-9	Prostate cancer;
CESC	cis	rs7216064	0.953	rs80135947	chr17:65836001	A/C	cg07042672	chr17:66097459	LOC651250	-0.54	-5.67	-0.33	3.73e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs11122272	0.766	rs2790867	chr1:231548059	A/C	cg06096015	chr1:231504339	EGLN1	-0.41	-5.78	-0.33	2.13e-8	Hemoglobin concentration;
CESC	cis	rs11583043	0.793	rs3903905	chr1:101420957	G/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.55	6.12	0.35	3.39e-9	Ulcerative colitis;Inflammatory bowel disease;
CESC	cis	rs6502050	0.835	rs6502079	chr17:80124454	T/A	cg23985595	chr17:80112537	CCDC57	-0.41	-6.57	-0.37	2.6200000000000003e-10	Life satisfaction;
CESC	cis	rs7584330	0.738	rs4402703	chr2:238374957	T/A	cg14458575	chr2:238380390	NA	0.62	8.3	0.45	5.37e-15	Prostate cancer;
CESC	cis	rs9811920	0.683	rs10936003	chr3:99667565	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.39	-6.38	-0.37	7.68e-10	Axial length;
CESC	trans	rs877282	0.898	rs11253339	chr10:759640	C/T	cg22713356	chr15:30763199	NA	1.15	11.38	0.57	1.05e-24	Uric acid levels;
CESC	cis	rs963731	0.649	rs12620071	chr2:39345873	G/A	cg04010122	chr2:39346883	SOS1	0.73	5.17	0.3	4.6e-7	Corticobasal degeneration;
CESC	cis	rs2836950	0.565	rs3171465	chr21:40552307	A/G	cg11890956	chr21:40555474	PSMG1	-0.62	-8.69	-0.47	3.94e-16	Menarche (age at onset);
CESC	cis	rs873946	0.648	rs3750578	chr10:134563366	A/G	cg27286337	chr10:134555280	INPP5A	0.68	7.7	0.43	2.8e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs2576037	0.526	rs8095373	chr18:44527895	C/T	cg19077165	chr18:44547161	KATNAL2	-0.53	-7.79	-0.43	1.54e-13	Personality dimensions;
CESC	cis	rs80130819	0.748	rs2634679	chr12:48735304	G/T	cg05342945	chr12:48394962	COL2A1	-0.53	-5.6	-0.33	5.26e-8	Prostate cancer;
CESC	cis	rs9314323	0.729	rs7823021	chr8:26224958	G/T	cg11498726	chr8:26250323	BNIP3L	-0.46	-6.5	-0.37	3.89e-10	Red cell distribution width;
CESC	cis	rs9549367	0.789	rs3764124	chr13:113897320	C/T	cg00898013	chr13:113819073	PROZ	-0.54	-7.22	-0.41	5.39e-12	Platelet distribution width;
CESC	cis	rs5769765	0.865	rs10854860	chr22:50320029	G/T	cg26441486	chr22:50317300	CRELD2	0.48	5.78	0.33	2.08e-8	Schizophrenia;
CESC	cis	rs6952808	0.500	rs3800902	chr7:2144378	C/T	cg21782813	chr7:2030301	MAD1L1	0.49	7.04	0.4	1.68e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg10819733	chr22:24237672	NA	0.51	7.44	0.42	1.39e-12	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs9611565	0.592	rs5758406	chr22:42076641	A/G	cg03806693	chr22:41940476	POLR3H	1.01	11.96	0.59	1.19e-26	Vitiligo;
CESC	cis	rs11997175	0.656	rs2350007	chr8:33585353	C/G	ch.8.33884649F	chr8:33765107	NA	0.5	6.59	0.38	2.4e-10	Body mass index;
CESC	cis	rs1552244	0.554	rs3732965	chr3:10048760	A/C	cg00149659	chr3:10157352	C3orf10	0.54	6.63	0.38	1.89e-10	Alzheimer's disease;
CESC	cis	rs1577917	0.958	rs72907388	chr6:86440207	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.56	-7.24	-0.41	4.9e-12	Response to antipsychotic treatment;
CESC	cis	rs9660180	1.000	rs3737628	chr1:1722932	C/T	cg05132306	chr1:1846340	CALML6	-0.29	-5.81	-0.34	1.77e-8	Body mass index;
CESC	cis	rs2832077	0.689	rs2832055	chr21:30132382	C/G	cg24692254	chr21:30365293	RNF160	0.48	5.78	0.33	2.06e-8	Cognitive test performance;
CESC	cis	rs6547741	1.000	rs6547741	chr2:27855924	G/A	cg27432699	chr2:27873401	GPN1	0.46	6.43	0.37	5.87e-10	Oral cavity cancer;
CESC	cis	rs9300255	0.602	rs4372492	chr12:123697357	T/C	cg05973401	chr12:123451056	ABCB9	0.49	5.63	0.33	4.63e-8	Neutrophil percentage of white cells;
CESC	cis	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg01386335	chr7:17704951	NA	0.43	5.87	0.34	1.33e-8	Fibrinogen levels;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg16236679	chr11:96123321	JRKL;CCDC82	-0.47	-6.59	-0.38	2.38e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs4253772	0.575	rs9615956	chr22:46749634	C/T	cg18190219	chr22:46762943	CELSR1	-0.74	-6.46	-0.37	4.98e-10	LDL cholesterol;Cholesterol, total;
CESC	cis	rs12476592	0.516	rs6734648	chr2:63801525	A/G	cg17519650	chr2:63277830	OTX1	-0.48	-5.42	-0.32	1.34e-7	Childhood ear infection;
CESC	cis	rs5769765	0.778	rs8137331	chr22:50313358	G/C	cg02269571	chr22:50332266	NA	-0.55	-7.09	-0.4	1.22e-11	Schizophrenia;
CESC	cis	rs11048434	0.636	rs11614970	chr12:9060053	G/A	cg04155231	chr12:9217510	LOC144571	0.31	5.06	0.3	8.03e-7	Sjögren's syndrome;
CESC	cis	rs1153858	1.000	rs7181167	chr15:45686236	C/G	cg21132104	chr15:45694354	SPATA5L1	0.86	11.67	0.58	1.14e-25	Homoarginine levels;
CESC	cis	rs9399137	0.507	rs11758774	chr6:135383789	T/G	cg24558204	chr6:135376177	HBS1L	0.7	9.59	0.51	6.85e-19	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	cis	rs3741404	0.594	rs11231704	chr11:63898182	C/T	cg05555928	chr11:63887634	MACROD1	0.62	9.65	0.51	4.37e-19	Platelet count;
CESC	cis	rs9815354	0.767	rs73077390	chr3:41860255	T/C	cg03022575	chr3:42003672	ULK4	0.66	5.8	0.34	1.87e-8	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs72945132	0.882	rs6592537	chr11:70172975	C/T	cg14191688	chr11:70257035	CTTN	0.43	5.46	0.32	1.11e-7	Coronary artery disease;
CESC	cis	rs4835473	0.932	rs1511425	chr4:144906275	C/T	cg25736465	chr4:144833511	NA	0.41	6.29	0.36	1.28e-9	Immature fraction of reticulocytes;
CESC	cis	rs7613875	0.600	rs2247510	chr3:50126215	A/C	cg24308560	chr3:49941425	MST1R	-0.57	-8.18	-0.45	1.19e-14	Body mass index;
CESC	cis	rs2075371	0.933	rs431306	chr7:133955974	A/T	cg00033643	chr7:134001901	SLC35B4	0.4	5.03	0.3	9.11e-7	Mean platelet volume;
CESC	cis	rs2708240	1.000	rs2538977	chr7:147584571	T/C	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.33	-5.33	-0.31	2.06e-7	QT interval (drug interaction);
CESC	cis	rs71277158	0.688	rs9757709	chr3:169906407	T/G	cg04067573	chr3:169899625	PHC3	0.7	6.72	0.38	1.09e-10	Prostate cancer;
CESC	cis	rs11252926	0.537	rs61836851	chr10:447231	T/C	cg03684893	chr10:554711	DIP2C	-0.35	-5.1	-0.3	6.52e-7	Psychosis in Alzheimer's disease;
CESC	cis	rs7149337	0.837	rs10132658	chr14:51677599	C/T	cg23942311	chr14:51606299	NA	0.43	7.12	0.4	1e-11	Cancer;
CESC	cis	rs7617773	0.539	rs11130165	chr3:48384721	G/T	cg11946769	chr3:48343235	NME6	0.66	8.34	0.46	4.12e-15	Coronary artery disease;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg01213445	chr15:91537450	PRC1	-0.5	-6.14	-0.35	3.05e-9	Ulcerative colitis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09695362	chr17:43324895	LOC100133991	0.59	6.54	0.37	3.24e-10	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08536481	chr12:123459152	ABCB9;OGFOD2	0.65	7.92	0.44	6.4e-14	Gut microbiome composition (summer);
CESC	cis	rs3858526	0.514	rs4595572	chr11:5864045	T/G	cg05234568	chr11:5960015	NA	-0.66	-9.75	-0.51	2.12e-19	DNA methylation (variation);
CESC	cis	rs9362426	0.708	rs4707365	chr6:88100912	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.51	6.16	0.35	2.75e-9	Depressive episodes in bipolar disorder;
CESC	cis	rs6088590	1.000	rs6120750	chr20:33465289	A/C	cg24642439	chr20:33292090	TP53INP2	0.88	12.03	0.59	6.64e-27	Coronary artery disease;
CESC	trans	rs5769765	0.825	rs7511620	chr22:50307932	T/C	cg09872104	chr7:134855509	C7orf49	-0.55	-6.22	-0.36	1.9e-9	Schizophrenia;
CESC	cis	rs80130819	0.748	rs2732440	chr12:48660429	G/A	cg05342945	chr12:48394962	COL2A1	-0.48	-5.23	-0.31	3.4e-7	Prostate cancer;
CESC	cis	rs6543140	0.929	rs6742530	chr2:103082280	G/A	cg04239558	chr2:103089729	SLC9A4	0.47	6.16	0.35	2.64e-9	Blood protein levels;
CESC	cis	rs6674176	0.597	rs6671164	chr1:44403489	G/T	cg15962314	chr1:44399869	ARTN	0.27	5.06	0.3	7.66e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs6500602	0.964	rs62039173	chr16:4463846	G/A	cg08645402	chr16:4508243	NA	0.46	7.02	0.4	1.88e-11	Schizophrenia;
CESC	trans	rs11098499	0.866	rs72676074	chr4:120359841	A/C	cg25214090	chr10:38739885	LOC399744	0.71	10.0	0.52	3.37e-20	Corneal astigmatism;
CESC	cis	rs6688613	0.649	rs2280995	chr1:166846069	A/G	cg07049167	chr1:166818506	POGK	0.44	5.07	0.3	7.32e-7	Refractive astigmatism;
CESC	cis	rs290268	0.874	rs290991	chr9:93561450	A/C	cg02608019	chr9:93564028	SYK	-0.6	-9.8	-0.52	1.53e-19	Platelet count;
CESC	cis	rs710865	0.723	rs710870	chr1:19549759	G/A	cg13387374	chr1:19411106	UBR4	0.49	6.47	0.37	4.6e-10	Brain structure;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg15291980	chr2:36441749	NA	-0.45	-6.28	-0.36	1.41e-9	Systemic lupus erythematosus;
CESC	cis	rs668210	0.947	rs610497	chr11:65765551	C/T	cg02202077	chr11:65769826	EIF1AD;BANF1	0.74	9.23	0.49	9.03e-18	Cerebrospinal fluid biomarker levels;
CESC	cis	rs910316	1.000	rs3742780	chr14:75505008	G/C	cg08847533	chr14:75593920	NEK9	0.99	17.95	0.74	1.1e-47	Height;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg14170117	chr10:126490218	FAM175B	-0.47	-6.26	-0.36	1.52e-9	Fibrinogen levels;
CESC	cis	rs477895	0.713	rs11607165	chr11:63963947	T/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.95	10.43	0.54	1.45e-21	Mean platelet volume;
CESC	cis	rs7267979	1.000	rs2500446	chr20:25339664	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.86	-16.6	-0.71	6.43e-43	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7618501	0.602	rs6780731	chr3:50017478	A/G	cg24308560	chr3:49941425	MST1R	-0.62	-8.93	-0.48	7.32e-17	Intelligence (multi-trait analysis);
CESC	trans	rs17685	0.753	rs2302435	chr7:75676987	G/A	cg19862616	chr7:65841803	NCRNA00174	-0.86	-12.65	-0.61	4.99e-29	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs4820539	1.000	rs5759598	chr22:23480962	T/G	cg14186256	chr22:23484241	RTDR1	0.79	13.6	0.64	2.55e-32	Bone mineral density;
CESC	cis	rs4665809	0.838	rs6546749	chr2:26306288	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.83	-9.25	-0.49	7.55e-18	Gut microbiome composition (summer);
CESC	cis	rs910316	0.737	rs175077	chr14:75506875	G/A	cg16144293	chr14:75469539	EIF2B2	0.39	5.1	0.3	6.55e-7	Height;
CESC	cis	rs1799949	1.000	rs2037076	chr17:41305883	G/A	cg25072359	chr17:41440525	NA	0.43	5.82	0.34	1.68e-8	Menopause (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10029411	chr13:50746245	FAM10A4	-0.65	-8.09	-0.45	2.11e-14	Gut microbiome composition (summer);
CESC	cis	rs4423214	1.000	rs4944959	chr11:71168234	C/T	cg05163923	chr11:71159392	DHCR7	-0.81	-11.25	-0.57	2.83e-24	Vitamin D levels;
CESC	cis	rs2228479	0.850	rs2302162	chr16:89845287	A/G	cg06558623	chr16:89946397	TCF25	1.16	9.23	0.49	8.91e-18	Skin colour saturation;
CESC	cis	rs2832077	0.527	rs2776210	chr21:30268558	A/G	cg24692254	chr21:30365293	RNF160	0.66	8.89	0.48	9.41e-17	Cognitive test performance;
CESC	cis	rs870825	0.616	rs10025167	chr4:185649551	A/C	cg04058563	chr4:185651563	MLF1IP	0.63	6.96	0.39	2.59e-11	Blood protein levels;
CESC	cis	rs875971	0.862	rs2901152	chr7:65765004	G/A	cg18876405	chr7:65276391	NA	-0.5	-6.92	-0.39	3.36e-11	Aortic root size;
CESC	cis	rs7666738	0.546	rs34159897	chr4:98787367	T/C	cg17366294	chr4:99064904	C4orf37	0.52	6.61	0.38	2.09e-10	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2730245	0.527	rs2527194	chr7:158732959	G/A	cg24397884	chr7:158709396	WDR60	-0.86	-9.02	-0.48	3.88e-17	Height;
CESC	cis	rs870825	0.587	rs6826883	chr4:185616167	A/C	cg04058563	chr4:185651563	MLF1IP	0.64	7.05	0.4	1.59e-11	Blood protein levels;
CESC	cis	rs9584850	0.834	rs3803253	chr13:99117149	G/A	cg20750642	chr13:99100586	FARP1	-0.4	-6.02	-0.35	5.8e-9	Neuroticism;
CESC	cis	rs5167	0.506	rs35193317	chr19:45470344	C/T	cg20090143	chr19:45452003	APOC2	-0.34	-5.48	-0.32	9.95e-8	Blood protein levels;
CESC	cis	rs10861342	1.000	rs10861346	chr12:105473245	G/T	cg23923672	chr12:105501055	KIAA1033	0.7	5.53	0.32	7.7e-8	IgG glycosylation;
CESC	trans	rs61931739	0.534	rs11053131	chr12:34282109	A/G	cg26384229	chr12:38710491	ALG10B	0.45	6.12	0.35	3.28e-9	Morning vs. evening chronotype;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23611233	chr1:249133059	ZNF672	0.6	6.64	0.38	1.73e-10	Gut microbiome composition (summer);
CESC	cis	rs72781680	0.898	rs718139	chr2:23975911	G/A	cg20701182	chr2:24300061	SF3B14	0.78	6.76	0.38	8.82e-11	Lymphocyte counts;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg25746746	chr12:109531439	ALKBH2	-0.46	-6.39	-0.37	7.4e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs4660306	1.000	rs11211132	chr1:45990516	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.61	-7.72	-0.43	2.33e-13	Homocysteine levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27607583	chr16:3767744	TRAP1	0.57	6.47	0.37	4.66e-10	Gut microbiome composition (summer);
CESC	cis	rs17021463	0.617	rs35368920	chr4:95325588	C/T	cg11021082	chr4:95130006	SMARCAD1	0.46	6.08	0.35	4.23e-9	Testicular germ cell tumor;
CESC	cis	rs858239	0.665	rs858306	chr7:23242754	A/T	cg23682824	chr7:23144976	KLHL7	0.44	5.99	0.35	6.76e-9	Cerebrospinal fluid biomarker levels;
CESC	cis	rs10089	0.953	rs2016015	chr5:127527253	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.75	10.02	0.52	2.96e-20	Ileal carcinoids;
CESC	cis	rs1538970	0.962	rs9429076	chr1:45819489	A/G	cg24296786	chr1:45957014	TESK2	-0.48	-5.58	-0.32	5.96e-8	Platelet count;
CESC	cis	rs1799949	1.000	rs34534709	chr17:41302940	C/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.42	5.76	0.33	2.3e-8	Menopause (age at onset);
CESC	cis	rs10493773	0.609	rs12097932	chr1:86182216	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.44	-6.5	-0.37	3.98e-10	Urate levels in overweight individuals;
CESC	cis	rs9623117	0.915	rs28837144	chr22:40461508	T/C	cg05033341	chr22:40419857	FAM83F	-0.47	-5.33	-0.31	2.13e-7	Prostate cancer (SNP x SNP interaction);Prostate cancer;
CESC	cis	rs9910055	0.529	rs575798	chr17:42181796	A/C	cg19774624	chr17:42201019	HDAC5	0.58	7.65	0.43	3.73e-13	Total body bone mineral density;
CESC	cis	rs12042052	1.000	rs12042052	chr1:232935719	C/T	cg06935979	chr1:232941706	KIAA1383	-0.73	-5.97	-0.34	7.61e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg14019672	chr1:145507353	RBM8A	0.44	6.19	0.36	2.25e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs9902453	0.817	rs67206808	chr17:28190096	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.65	8.26	0.45	7.02e-15	Coffee consumption (cups per day);
CESC	cis	rs1801251	0.963	rs13424351	chr2:233573629	A/G	cg08000102	chr2:233561755	GIGYF2	0.64	8.5	0.46	1.38e-15	Coronary artery disease;
CESC	cis	rs2228479	0.717	rs11649210	chr16:89807233	C/G	cg06558623	chr16:89946397	TCF25	0.77	7.2	0.4	6.07e-12	Skin colour saturation;
CESC	cis	rs2011503	1.000	rs11671253	chr19:19604206	C/T	cg11584989	chr19:19387371	SF4	0.62	7.13	0.4	9.66e-12	Bipolar disorder;
CESC	cis	rs67311347	1.000	rs6762997	chr3:40478151	C/T	cg24209194	chr3:40518798	ZNF619	0.49	6.52	0.37	3.55e-10	Renal cell carcinoma;
CESC	cis	rs1552244	1.000	rs7631678	chr3:10078816	T/G	cg08888203	chr3:10149979	C3orf24	0.46	5.9	0.34	1.11e-8	Alzheimer's disease;
CESC	cis	rs10504229	0.906	rs7846666	chr8:58172302	T/C	cg22535103	chr8:58192502	C8orf71	-0.87	-11.35	-0.57	1.38e-24	Developmental language disorder (linguistic errors);
CESC	cis	rs2249625	0.526	rs17781511	chr6:72845455	C/T	cg18830697	chr6:72922368	RIMS1	0.43	6.23	0.36	1.81e-9	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CESC	cis	rs7552404	0.731	rs10732723	chr1:76392437	C/T	cg22875332	chr1:76189707	ACADM	-0.5	-5.35	-0.31	1.86e-7	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs67478160	0.679	rs8011109	chr14:104279974	G/A	cg08213375	chr14:104286397	PPP1R13B	0.54	10.69	0.55	2.07e-22	Schizophrenia;
CESC	cis	rs7191439	0.790	rs2306046	chr16:88781419	A/G	cg02389323	chr16:88786976	FAM38A	0.87	7.46	0.42	1.27e-12	Plateletcrit;
CESC	cis	rs7247513	0.930	rs35275129	chr19:12716493	G/A	cg11738485	chr19:12877000	HOOK2	0.41	5.06	0.3	7.98e-7	Bipolar disorder;
CESC	cis	rs4595586	0.545	rs1156707	chr12:39372451	G/T	cg26384229	chr12:38710491	ALG10B	0.54	7.53	0.42	7.85e-13	Morning vs. evening chronotype;
CESC	cis	rs208520	0.690	rs12208310	chr6:66730108	G/C	cg07460842	chr6:66804631	NA	0.96	12.77	0.62	2e-29	Exhaled nitric oxide output;
CESC	cis	rs7772486	0.875	rs2748497	chr6:146319417	C/T	cg05347473	chr6:146136440	FBXO30	0.49	6.55	0.37	3.05e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs3858526	0.959	rs61876223	chr11:5943393	G/A	cg02574844	chr11:5959923	NA	-0.42	-5.29	-0.31	2.52e-7	DNA methylation (variation);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05126138	chr4:83821944	THAP9	0.6	6.95	0.39	2.87e-11	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05523449	chr17:8396080	MYH10	-0.59	-6.34	-0.36	9.78e-10	Gut microbiome composition (summer);
CESC	cis	rs4555082	0.957	rs2735818	chr14:105714751	A/G	cg10792982	chr14:105748885	BRF1	0.4	5.52	0.32	7.87e-8	Mean platelet volume;Platelet distribution width;
CESC	cis	rs965469	0.779	rs2207994	chr20:3294304	C/T	cg25506879	chr20:3388711	C20orf194	-0.48	-5.35	-0.31	1.92e-7	IFN-related cytopenia;
CESC	cis	rs2549003	1.000	rs3846732	chr5:131816087	T/C	cg00255919	chr5:131827918	IRF1	0.51	8.57	0.47	8.55e-16	Asthma (sex interaction);
CESC	cis	rs9291683	0.551	rs2240720	chr4:10020480	C/T	cg02734326	chr4:10020555	SLC2A9	0.52	7.49	0.42	9.99e-13	Bone mineral density;
CESC	cis	rs4975709	0.838	rs4975753	chr5:1880865	T/C	cg12288994	chr5:1860383	NA	0.37	5.92	0.34	1.02e-8	Cardiovascular disease risk factors;
CESC	cis	rs796364	1.000	rs1509835	chr2:200814809	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.78	7.89	0.44	7.93e-14	Schizophrenia;
CESC	cis	rs734999	0.505	rs10797438	chr1:2540262	C/T	cg20673091	chr1:2541236	MMEL1	0.45	7.87	0.44	9.22e-14	Ulcerative colitis;
CESC	cis	rs6831352	0.819	rs13832	chr4:99993075	C/A	cg13256891	chr4:100009986	ADH5	0.7	8.27	0.45	6.71e-15	Alcohol dependence;
CESC	cis	rs3820928	0.874	rs4675138	chr2:227884118	G/A	cg11843606	chr2:227700838	RHBDD1	-0.45	-5.84	-0.34	1.56e-8	Pulmonary function;
CESC	cis	rs12220238	1.000	rs11000888	chr10:75901929	G/C	cg19889307	chr10:75911429	ADK;AP3M1	0.64	6.52	0.37	3.45e-10	Soluble interleukin-2 receptor subunit alpha;
CESC	cis	rs4481887	0.927	rs4409694	chr1:248485498	C/T	cg00666640	chr1:248458726	OR2T12	0.33	5.79	0.33	2.02e-8	Common traits (Other);
CESC	cis	rs921968	0.541	rs17462853	chr2:219345637	T/G	cg02176678	chr2:219576539	TTLL4	-0.55	-9.93	-0.52	5.91e-20	Mean corpuscular hemoglobin concentration;
CESC	cis	rs8016982	0.698	rs8011097	chr14:81702736	T/C	cg01989461	chr14:81687754	GTF2A1	0.69	10.32	0.54	3.32e-21	Schizophrenia;
CESC	cis	rs2836950	0.501	rs13047518	chr21:40707307	G/A	cg11890956	chr21:40555474	PSMG1	-0.63	-8.65	-0.47	5.06e-16	Menarche (age at onset);
CESC	cis	rs10504229	0.679	rs16921606	chr8:58034477	A/C	cg22535103	chr8:58192502	C8orf71	-0.56	-6.48	-0.37	4.55e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs2637266	0.716	rs2579734	chr10:78441306	A/G	cg18941641	chr10:78392320	NA	0.42	7.78	0.43	1.61e-13	Pulmonary function;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg25275331	chr1:40723935	ZMPSTE24	-0.45	-6.13	-0.35	3.26e-9	Fibrinogen levels;
CESC	cis	rs17095355	1.000	rs11194923	chr10:111695762	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.45	-5.25	-0.31	3.18e-7	Biliary atresia;
CESC	cis	rs2806561	0.754	rs10917344	chr1:23342193	C/G	cg12483005	chr1:23474871	LUZP1	-0.34	-5.47	-0.32	1.03e-7	Height;
CESC	cis	rs853679	0.517	rs2275508	chr6:28094731	T/C	cg12963246	chr6:28129442	ZNF389	0.6	8.28	0.45	5.95e-15	Depression;
CESC	cis	rs258892	0.843	rs16901116	chr5:72053382	A/G	cg21869765	chr5:72125136	TNPO1	-0.43	-5.36	-0.31	1.8e-7	Small cell lung carcinoma;
CESC	cis	rs4148883	0.675	rs10000357	chr4:100099942	G/C	cg12011299	chr4:100065546	ADH4	0.66	9.72	0.51	2.67e-19	Alcohol dependence;
CESC	cis	rs861020	0.606	rs4844903	chr1:210006267	C/T	cg05527609	chr1:210001259	C1orf107	0.74	9.67	0.51	3.97e-19	Orofacial clefts;
CESC	cis	rs11971779	0.941	rs6954453	chr7:139031794	C/T	cg07862535	chr7:139043722	LUC7L2	0.53	5.55	0.32	6.92e-8	Diisocyanate-induced asthma;
CESC	cis	rs11792861	0.816	rs28361186	chr9:111704064	G/A	cg05043794	chr9:111880884	C9orf5	-0.39	-6.4	-0.37	7.07e-10	Menarche (age at onset);
CESC	cis	rs5769765	0.819	rs9616377	chr22:50310880	T/C	cg02269571	chr22:50332266	NA	-0.57	-6.94	-0.39	3.01e-11	Schizophrenia;
CESC	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg06873352	chr17:61820015	STRADA	0.72	12.79	0.62	1.75e-29	Prudent dietary pattern;
CESC	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg01238044	chr22:24384105	GSTT1	-0.51	-6.48	-0.37	4.34e-10	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs2841277	0.708	rs11851053	chr14:105407208	T/C	cg21017887	chr14:105400489	NA	0.41	6.65	0.38	1.65e-10	Rheumatoid arthritis;
CESC	cis	rs7618915	0.547	rs2286800	chr3:52778051	C/T	cg05564831	chr3:52568323	NT5DC2	0.44	6.64	0.38	1.77e-10	Bipolar disorder;
CESC	cis	rs2243480	1.000	rs35058610	chr7:65390925	G/A	cg18252515	chr7:66147081	NA	-1.06	-9.79	-0.52	1.67e-19	Diabetic kidney disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15202251	chr7:100183972	FBXO24;LRCH4	-0.56	-6.44	-0.37	5.66e-10	Gut microbiome composition (summer);
CESC	cis	rs7811142	0.887	rs111972532	chr7:100069088	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.03	9.72	0.51	2.77e-19	Platelet count;
CESC	cis	rs7264396	0.561	rs66483315	chr20:34573575	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.71	-8.9	-0.48	9.01e-17	Total cholesterol levels;
CESC	cis	rs72945132	0.882	rs60780459	chr11:70162468	A/G	cg00319359	chr11:70116639	PPFIA1	0.78	7.71	0.43	2.52e-13	Coronary artery disease;
CESC	cis	rs17711722	0.503	rs453835	chr7:65511159	T/A	cg12143784	chr7:64541923	NA	-0.41	-5.56	-0.32	6.67e-8	Calcium levels;
CESC	trans	rs11098499	0.535	rs7671759	chr4:120248094	A/C	cg25214090	chr10:38739885	LOC399744	0.62	8.54	0.46	1.03e-15	Corneal astigmatism;
CESC	cis	rs875971	0.964	rs11765965	chr7:65842221	A/G	cg12463550	chr7:65579703	CRCP	0.59	7.45	0.42	1.29e-12	Aortic root size;
CESC	cis	rs9837602	1.000	rs4075038	chr3:99680086	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.54	-7.42	-0.41	1.63e-12	Breast cancer;
CESC	cis	rs763014	0.593	rs28455838	chr16:681966	T/C	cg09781414	chr16:715207	WDR90	-0.34	-5.22	-0.31	3.58e-7	Height;
CESC	cis	rs1799949	0.965	rs4793204	chr17:41279298	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.45	6.3	0.36	1.21e-9	Menopause (age at onset);
CESC	cis	rs17711722	0.522	rs4642526	chr7:65216742	G/T	cg11764359	chr7:65958608	NA	0.45	5.63	0.33	4.51e-8	Calcium levels;
CESC	cis	rs6674176	0.935	rs4314918	chr1:44377503	G/A	cg13606994	chr1:44402422	ARTN	-0.41	-6.01	-0.35	6.08e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs6456156	0.792	rs4710183	chr6:167514083	A/G	cg07741184	chr6:167504864	NA	-0.38	-6.85	-0.39	5.01e-11	Primary biliary cholangitis;
CESC	cis	rs2404602	0.583	rs12592501	chr15:76554790	C/A	cg05617483	chr15:76483344	C15orf27	0.42	5.62	0.33	4.95e-8	Blood metabolite levels;
CESC	cis	rs875971	0.545	rs1267814	chr7:66044409	G/A	cg18876405	chr7:65276391	NA	-0.5	-5.91	-0.34	1.05e-8	Aortic root size;
CESC	cis	rs1023500	0.573	rs13057094	chr22:42470317	T/C	cg15557168	chr22:42548783	NA	-0.39	-5.32	-0.31	2.19e-7	Schizophrenia;
CESC	trans	rs10435719	0.902	rs12681142	chr8:11802601	T/C	cg15556689	chr8:8085844	FLJ10661	0.52	6.63	0.38	1.91e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
CESC	cis	rs7746199	0.668	rs34864796	chr6:27459923	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.77	-5.3	-0.31	2.45e-7	Gait speed in old age;Autism spectrum disorder or schizophrenia;
CESC	cis	rs3780486	0.846	rs3780487	chr9:33139237	T/C	cg13443165	chr9:33130375	B4GALT1	0.44	6.37	0.36	8.54e-10	IgG glycosylation;
CESC	cis	rs7264396	0.690	rs2425175	chr20:34445563	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.85	-11.57	-0.58	2.56e-25	Total cholesterol levels;
CESC	cis	rs7914558	1.000	rs10509757	chr10:104752960	C/T	cg08650961	chr10:104748594	CNNM2	0.32	5.33	0.31	2.11e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs7312933	0.576	rs11181364	chr12:42567800	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.48	6.15	0.35	2.89e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs4665809	0.590	rs10197494	chr2:26445550	A/G	cg26314531	chr2:26401878	FAM59B	-0.85	-9.04	-0.49	3.44e-17	Gut microbiome composition (summer);
CESC	cis	rs1878931	0.597	rs2680221	chr16:3462595	A/G	cg02880119	chr16:3481970	NA	0.44	5.43	0.32	1.28e-7	Body mass index (adult);
CESC	cis	rs6582630	0.555	rs7969922	chr12:38529491	C/T	cg26384229	chr12:38710491	ALG10B	0.71	10.81	0.55	8.51e-23	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs1847202	0.859	rs13090900	chr3:72946560	C/A	cg25664220	chr3:72788482	NA	-0.39	-5.71	-0.33	2.97e-8	Motion sickness;
CESC	cis	rs7178572	0.568	rs1565757	chr15:77657682	C/T	cg22256960	chr15:77711686	NA	-0.5	-6.45	-0.37	5.33e-10	Type 2 diabetes;
CESC	cis	rs1862618	0.641	rs2591954	chr5:56245044	G/C	cg24549020	chr5:56110836	MAP3K1	-0.52	-6.46	-0.37	4.87e-10	Initial pursuit acceleration;
CESC	cis	rs55788414	0.932	rs9929066	chr16:81182157	G/A	cg06400318	chr16:81190750	PKD1L2	-0.59	-7.04	-0.4	1.62e-11	Left ventricular obstructive tract defect (maternal effect);
CESC	cis	rs11098499	0.908	rs28559989	chr4:120386627	C/T	cg09307838	chr4:120376055	NA	0.95	13.96	0.65	1.42e-33	Corneal astigmatism;
CESC	cis	rs61931739	0.534	rs7133262	chr12:34279444	G/A	cg19457237	chr12:34500585	NA	-0.37	-5.19	-0.3	4.1e-7	Morning vs. evening chronotype;
CESC	cis	rs13118159	0.651	rs4974599	chr4:1314430	A/C	cg16405210	chr4:1374714	KIAA1530	-0.64	-8.68	-0.47	4.09e-16	Longevity;
CESC	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.89	13.67	0.64	1.49e-32	Prudent dietary pattern;
CESC	cis	rs1005277	0.579	rs2472176	chr10:38382921	T/C	cg00409905	chr10:38381863	ZNF37A	-0.45	-6.0	-0.35	6.61e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs514406	0.505	rs856721	chr1:53162156	C/A	cg16325326	chr1:53192061	ZYG11B	0.94	16.55	0.71	9.47e-43	Monocyte count;
CESC	cis	rs4319547	0.656	rs10161534	chr12:122873864	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.52	-6.21	-0.36	2.05e-9	Body mass index;
CESC	cis	rs2592394	0.591	rs711820	chr2:176987112	T/G	cg13092806	chr2:177043255	NA	0.5	5.64	0.33	4.34e-8	Magnesium levels;Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs2120019	1.000	rs7167285	chr15:75368769	A/G	cg09165964	chr15:75287851	SCAMP5	-0.66	-7.99	-0.44	4.25e-14	Blood trace element (Zn levels);
CESC	cis	rs1799949	1.000	rs8176234	chr17:41219780	T/C	cg06001716	chr17:41278141	BRCA1;NBR2	0.39	5.3	0.31	2.46e-7	Menopause (age at onset);
CESC	cis	rs6693567	0.565	rs35784258	chr1:150405882	T/C	cg09579323	chr1:150459698	TARS2	0.48	6.08	0.35	4.16e-9	Migraine;
CESC	cis	rs2243480	1.000	rs56985706	chr7:65394562	C/T	cg18252515	chr7:66147081	NA	-1.0	-9.22	-0.49	9.27e-18	Diabetic kidney disease;
CESC	cis	rs11608355	0.545	rs55902232	chr12:109902305	G/A	cg05360138	chr12:110035743	NA	0.82	8.92	0.48	7.93e-17	Neuroticism;
CESC	cis	rs1559088	0.847	rs8100392	chr19:33605933	T/C	cg27124370	chr19:33622961	WDR88	0.42	5.49	0.32	9.52e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs1594829	0.553	rs7003030	chr8:26172699	G/T	cg11498726	chr8:26250323	BNIP3L	-0.4	-6.11	-0.35	3.54e-9	Height;
CESC	cis	rs4481233	0.528	rs115776655	chr4:10381329	C/T	cg11266682	chr4:10021025	SLC2A9	-0.44	-5.75	-0.33	2.45e-8	Metabolic traits;
CESC	cis	rs17641971	0.662	rs10435575	chr8:49996107	C/T	cg00325661	chr8:49890786	NA	0.39	5.48	0.32	9.71e-8	Blood metabolite levels;
CESC	cis	rs11098499	0.908	rs11098527	chr4:120399906	A/G	cg24375607	chr4:120327624	NA	0.45	5.44	0.32	1.19e-7	Corneal astigmatism;
CESC	cis	rs2502731	0.539	rs3003610	chr9:130985525	G/A	cg13642260	chr9:130955380	CIZ1	0.45	6.71	0.38	1.18e-10	Attention deficit hyperactivity disorder;
CESC	cis	rs1538970	0.962	rs2153607	chr1:45813820	G/A	cg05343316	chr1:45956843	TESK2	0.77	10.78	0.55	1.05e-22	Platelet count;
CESC	cis	rs78707713	0.841	rs79069746	chr10:71205473	T/C	cg12610070	chr10:71211762	TSPAN15	-0.43	-7.27	-0.41	4.12e-12	Venous thromboembolism;
CESC	cis	rs2576037	0.501	rs557661	chr18:44365657	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.7	11.02	0.56	1.68e-23	Personality dimensions;
CESC	cis	rs6460942	0.915	rs6966791	chr7:12439714	T/C	cg17427002	chr7:12443146	VWDE	-0.53	-5.18	-0.3	4.34e-7	Coronary artery disease;
CESC	cis	rs7851660	0.844	rs10984103	chr9:100639275	G/T	cg13688889	chr9:100608707	NA	0.62	8.65	0.47	5.19e-16	Strep throat;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13751213	chr7:148581913	EZH2	0.6	7.02	0.4	1.83e-11	Gut microbiome composition (summer);
CESC	cis	rs7618915	0.501	rs2164885	chr3:52731269	T/C	cg17372223	chr3:52568218	NT5DC2	0.43	6.58	0.37	2.51e-10	Bipolar disorder;
CESC	cis	rs832540	0.593	rs252912	chr5:56195792	C/T	cg24531977	chr5:56204891	C5orf35	-0.5	-6.18	-0.35	2.46e-9	Coronary artery disease;
CESC	cis	rs4243830	0.737	rs925745	chr1:6615690	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.8	-8.28	-0.45	5.96e-15	Body mass index;
CESC	cis	rs6541297	0.645	rs4846920	chr1:230301574	A/G	cg20703242	chr1:230279135	GALNT2	0.47	5.88	0.34	1.2e-8	Coronary artery disease;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg14925012	chr15:60771315	NARG2	-0.46	-6.53	-0.37	3.33e-10	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg21487830	chr17:48943706	NA	0.48	6.28	0.36	1.41e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10173275	chr17:77783551	NA	0.6	6.53	0.37	3.33e-10	Gut microbiome composition (summer);
CESC	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg03647317	chr4:187891568	NA	-0.38	-5.33	-0.31	2.09e-7	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs9951602	0.512	rs7232551	chr18:76650702	G/A	cg02800362	chr5:177631904	HNRNPAB	0.66	8.66	0.47	4.55e-16	Obesity-related traits;
CESC	cis	rs2797160	1.000	rs983543	chr6:126005767	G/A	cg05901451	chr6:126070800	HEY2	-0.45	-6.53	-0.37	3.43e-10	Endometrial cancer;
CESC	cis	rs2279817	1.000	rs905389	chr1:18021406	T/C	cg21791023	chr1:18019539	ARHGEF10L	0.57	8.3	0.45	5.45e-15	Neuroticism;
CESC	cis	rs4720575	1.000	rs4507670	chr7:47097526	C/T	cg00036614	chr7:47093842	NA	-0.42	-6.52	-0.37	3.53e-10	Angiotensin-converting enzyme inhibitor intolerance;
CESC	cis	rs4144743	1.000	rs4144744	chr17:45323262	A/G	cg18085866	chr17:45331354	ITGB3	-0.66	-7.64	-0.43	3.87e-13	Body mass index;
CESC	cis	rs447	1.000	rs12707619	chr7:83748427	T/C	cg22846510	chr7:83753280	SEMA3A	-0.48	-5.87	-0.34	1.27e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs7208859	0.673	rs73271887	chr17:29154935	T/C	cg13385521	chr17:29058706	SUZ12P	0.75	6.0	0.35	6.29e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs2228479	0.850	rs62056066	chr16:89906563	G/A	cg06558623	chr16:89946397	TCF25	1.12	8.22	0.45	9.28e-15	Skin colour saturation;
CESC	cis	rs7762018	0.891	rs3749882	chr6:170151766	C/T	cg13891659	chr6:170190454	C6orf122;C6orf208	0.67	6.53	0.37	3.28e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs780096	0.506	rs780100	chr2:27652153	G/T	cg24768116	chr2:27665128	KRTCAP3	-0.3	-5.58	-0.32	5.8e-8	Total body bone mineral density;
CESC	trans	rs1728785	1.000	rs864742	chr16:68575309	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.61	7.49	0.42	1.04e-12	Ulcerative colitis;
CESC	cis	rs13392177	0.672	rs1877715	chr2:219052546	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.6	7.75	0.43	1.98e-13	Pyoderma gangrenosum in inflammatory bowel disease;
CESC	cis	rs12130219	0.500	rs4845737	chr1:152177539	G/A	cg26879891	chr1:152191343	HRNR	-0.39	-6.11	-0.35	3.63e-9	Inflammatory skin disease;
CESC	cis	rs7811142	0.945	rs6955362	chr7:100056166	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.05	10.31	0.54	3.54e-21	Platelet count;
CESC	trans	rs11098499	0.863	rs3822190	chr4:120428098	G/A	cg25214090	chr10:38739885	LOC399744	0.71	9.7	0.51	3.06e-19	Corneal astigmatism;
CESC	cis	rs798554	0.679	rs798499	chr7:2792013	G/A	cg09658497	chr7:2847517	GNA12	-0.35	-5.39	-0.31	1.59e-7	Height;
CESC	cis	rs7762018	0.607	rs79355059	chr6:170062157	T/C	cg15199489	chr6:170068458	WDR27	0.67	5.2	0.3	3.98e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs4555082	0.834	rs2816624	chr14:105733909	A/G	cg27165867	chr14:105738592	BRF1	-0.54	-5.82	-0.34	1.72e-8	Mean platelet volume;Platelet distribution width;
CESC	cis	rs7666738	0.830	rs17558193	chr4:99049593	A/G	cg17366294	chr4:99064904	C4orf37	0.61	8.78	0.47	2.13e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs35110281	0.667	rs7282122	chr21:45082365	G/A	cg21573476	chr21:45109991	RRP1B	-0.53	-7.96	-0.44	5.15e-14	Mean corpuscular volume;
CESC	cis	rs34375054	0.573	rs12579211	chr12:125647752	C/T	cg25124228	chr12:125621409	AACS	-0.52	-5.64	-0.33	4.33e-8	Post bronchodilator FEV1/FVC ratio;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21662326	chr11:14521493	COPB1	0.6	6.73	0.38	1.02e-10	Gut microbiome composition (summer);
CESC	cis	rs1552244	0.935	rs28815328	chr3:10062227	G/A	cg00166722	chr3:10149974	C3orf24	0.5	6.35	0.36	9.36e-10	Alzheimer's disease;
CESC	trans	rs634534	0.532	rs12794370	chr11:65770413	G/A	cg17712092	chr4:129076599	LARP1B	0.69	9.68	0.51	3.54e-19	Sum eosinophil basophil counts;Eosinophil counts;
CESC	cis	rs2730245	0.527	rs712199	chr7:158662250	A/G	cg24397884	chr7:158709396	WDR60	0.82	8.32	0.46	4.73e-15	Height;
CESC	cis	rs853679	0.517	rs9368553	chr6:28082265	T/C	cg19592336	chr6:28129416	ZNF389	0.6	7.98	0.44	4.4e-14	Depression;
CESC	trans	rs61931739	0.534	rs11052984	chr12:34045904	T/C	cg26384229	chr12:38710491	ALG10B	0.53	7.22	0.41	5.44e-12	Morning vs. evening chronotype;
CESC	trans	rs7395662	0.534	rs12418219	chr11:48988091	G/T	cg00717180	chr2:96193071	NA	-0.45	-6.07	-0.35	4.52e-9	HDL cholesterol;
CESC	cis	rs7824557	0.534	rs10092549	chr8:11089079	C/G	cg21775007	chr8:11205619	TDH	-0.34	-5.08	-0.3	7.12e-7	Retinal vascular caliber;
CESC	cis	rs4253772	0.637	rs6008357	chr22:46652104	T/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.69	8.18	0.45	1.16e-14	LDL cholesterol;Cholesterol, total;
CESC	cis	rs17253792	0.822	rs80321745	chr14:56162947	T/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.81	5.68	0.33	3.46e-8	Putamen volume;
CESC	cis	rs9910055	0.529	rs615070	chr17:42176591	A/G	cg19774624	chr17:42201019	HDAC5	-0.56	-7.46	-0.42	1.21e-12	Total body bone mineral density;
CESC	cis	rs1552244	0.810	rs35711405	chr3:10116939	C/T	cg00166722	chr3:10149974	C3orf24	0.54	6.61	0.38	2.15e-10	Alzheimer's disease;
CESC	cis	rs10129255	0.536	rs8004835	chr14:107142378	A/C	cg07958169	chr14:107095056	NA	-0.46	-6.92	-0.39	3.33e-11	Kawasaki disease;
CESC	trans	rs6073597	1.000	rs6031980	chr20:43714384	C/T	cg07484894	chr20:34330300	RBM39	0.42	6.13	0.35	3.16e-9	Positive affect;
CESC	cis	rs9611565	0.608	rs202652	chr22:41838792	A/G	cg03806693	chr22:41940476	POLR3H	1.13	15.27	0.68	3.52e-38	Vitiligo;
CESC	cis	rs16895831	0.519	rs16895863	chr6:42571346	A/T	cg10605015	chr6:42532144	UBR2	-0.52	-5.75	-0.33	2.44e-8	Granulocyte percentage of myeloid white cells;Neutrophil percentage of white cells;Eosinophil percentage of white cells;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Neutrophil count;Sum basophil neutrophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
CESC	cis	rs889312	0.500	rs702691	chr5:56114526	T/G	cg14703610	chr5:56206110	C5orf35	0.49	6.6	0.38	2.17e-10	Breast cancer;Breast cancer (early onset);
CESC	cis	rs9513627	0.573	rs7325697	chr13:100117793	A/G	cg25919922	chr13:100150906	NA	0.61	5.99	0.35	6.63e-9	Obesity-related traits;
CESC	cis	rs6570726	0.967	rs373704	chr6:145860618	C/A	cg23711669	chr6:146136114	FBXO30	0.76	11.07	0.56	1.15e-23	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs597539	0.616	rs631001	chr11:68642974	C/T	cg01988459	chr11:68622903	NA	-0.4	-5.23	-0.31	3.38e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs9911578	0.935	rs6503878	chr17:56884581	T/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.24	0.31	3.23e-7	Intelligence (multi-trait analysis);
CESC	cis	rs10979	0.928	rs6924967	chr6:143906235	C/T	cg25407410	chr6:143891975	LOC285740	-0.62	-9.16	-0.49	1.42e-17	Hypospadias;
CESC	cis	rs654950	0.875	rs633297	chr1:41985453	A/C	cg06885757	chr1:42089581	HIVEP3	0.43	6.87	0.39	4.6e-11	Airway imaging phenotypes;
CESC	cis	rs875971	1.000	rs1540651	chr7:65650121	C/T	cg18876405	chr7:65276391	NA	-0.52	-7.03	-0.4	1.71e-11	Aortic root size;
CESC	cis	rs1018836	0.923	rs10956749	chr8:91621573	G/A	cg16814680	chr8:91681699	NA	-0.72	-10.07	-0.53	2.11e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg21300382	chr19:13248092	NACC1	0.47	6.61	0.38	2.06e-10	Fibrinogen levels;
CESC	cis	rs4819052	0.851	rs8127834	chr21:46696109	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.77	10.24	0.53	5.91e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs6942756	0.956	rs13235668	chr7:128879710	A/G	cg02491457	chr7:128862824	NA	-0.7	-10.17	-0.53	9.75e-21	White matter hyperintensity burden;
CESC	cis	rs2228479	0.702	rs2074903	chr16:89811663	T/C	cg00800038	chr16:89945340	TCF25	-0.9	-7.51	-0.42	9.11e-13	Skin colour saturation;
CESC	cis	rs6502050	0.835	rs67682841	chr17:80117745	T/C	cg23985595	chr17:80112537	CCDC57	-0.41	-6.47	-0.37	4.81e-10	Life satisfaction;
CESC	cis	rs12477438	0.520	rs11123765	chr2:99768064	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.86	16.02	0.7	7.14e-41	Chronic sinus infection;
CESC	cis	rs4746818	0.901	rs4746816	chr10:70874866	G/T	cg11621586	chr10:70884670	VPS26A	0.87	8.48	0.46	1.56e-15	Left atrial antero-posterior diameter;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09349940	chr16:22218118	EEF2K	-0.65	-7.44	-0.42	1.38e-12	Gut microbiome composition (summer);
CESC	cis	rs6831352	0.918	rs17817359	chr4:100054197	G/T	cg12011299	chr4:100065546	ADH4	-0.6	-6.62	-0.38	2.04e-10	Alcohol dependence;
CESC	cis	rs6570726	0.791	rs6914203	chr6:145899975	C/A	cg23711669	chr6:146136114	FBXO30	0.9	13.68	0.64	1.38e-32	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7843479	1.000	rs2054711	chr8:21818060	A/G	cg17168535	chr8:21777572	XPO7	0.49	6.73	0.38	1.02e-10	Mean corpuscular volume;
CESC	trans	rs11098499	0.754	rs1980027	chr4:120251577	C/T	cg25214090	chr10:38739885	LOC399744	0.62	8.81	0.48	1.69e-16	Corneal astigmatism;
CESC	cis	rs7582720	0.943	rs72926800	chr2:203829225	A/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.36	0.41	2.34e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs7520050	0.778	rs2934857	chr1:46039612	A/G	cg03146154	chr1:46216737	IPP	0.5	6.53	0.37	3.31e-10	Red blood cell count;Reticulocyte count;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg17237603	chr7:148876528	ZNF398	0.46	6.5	0.37	3.86e-10	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs7666738	0.830	rs13101766	chr4:98957696	C/A	cg03676636	chr4:99064102	C4orf37	0.33	5.11	0.3	6.05e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs933688	1.000	rs2059207	chr5:90731931	C/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.1	15.13	0.68	1.06e-37	Smoking behavior;
CESC	cis	rs9322193	1.000	rs9399693	chr6:149933854	C/T	cg07701084	chr6:150067640	NUP43	0.42	5.87	0.34	1.3e-8	Lung cancer;
CESC	cis	rs4835473	0.932	rs4835126	chr4:144918893	A/G	cg25736465	chr4:144833511	NA	0.42	6.28	0.36	1.38e-9	Immature fraction of reticulocytes;
CESC	cis	rs826838	0.806	rs826873	chr12:39121305	G/A	cg13010199	chr12:38710504	ALG10B	-0.46	-6.44	-0.37	5.5e-10	Heart rate;
CESC	cis	rs274567	0.550	rs272885	chr5:131667736	A/G	cg07395648	chr5:131743802	NA	-0.43	-5.67	-0.33	3.73e-8	Blood metabolite levels;
CESC	cis	rs881375	0.715	rs11794516	chr9:123640230	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.44	6.21	0.36	2.03e-9	Rheumatoid arthritis;
CESC	cis	rs7666738	0.830	rs7662948	chr4:99020132	G/C	cg05340658	chr4:99064831	C4orf37	0.82	12.91	0.62	6.51e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs56104184	0.775	rs17272707	chr19:49404535	T/G	cg21252483	chr19:49399788	TULP2	-0.49	-5.56	-0.32	6.67e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	cis	rs9399135	0.967	rs11754783	chr6:135347661	T/A	cg24558204	chr6:135376177	HBS1L	0.52	7.29	0.41	3.48e-12	Red blood cell count;
CESC	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.65	7.41	0.41	1.72e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7552404	0.924	rs7535991	chr1:76162624	C/T	cg22875332	chr1:76189707	ACADM	0.69	9.24	0.49	8.13e-18	Blood metabolite levels;Acylcarnitine levels;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg03969138	chr6:7390163	RIOK1;CAGE1	0.45	6.01	0.35	5.96e-9	Systemic lupus erythematosus;
CESC	cis	rs6867032	0.527	rs1017924	chr5:1976187	C/T	cg26168224	chr5:2018326	NA	0.78	11.69	0.58	9.73e-26	Gut microbiome composition (winter);
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg02905599	chr12:133249096	POLE	-0.44	-6.28	-0.36	1.41e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs929354	0.772	rs1002389	chr7:156968323	C/G	cg05182265	chr7:156933206	UBE3C	-0.5	-7.3	-0.41	3.28e-12	Body mass index;
CESC	cis	rs7762018	0.943	rs11546265	chr6:170108363	G/A	cg05834625	chr6:170176447	C6orf70	0.64	7.81	0.43	1.37e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27600497	chr7:155091023	INSIG1	-0.57	-6.51	-0.37	3.85e-10	Gut microbiome composition (summer);
CESC	cis	rs2115630	0.846	rs8024538	chr15:85368419	A/T	cg12501888	chr15:85177176	SCAND2	-0.43	-5.49	-0.32	9.45e-8	P wave terminal force;
CESC	cis	rs8070128	0.534	rs2955350	chr17:17953548	G/A	cg16928487	chr17:17741425	SREBF1	0.55	9.13	0.49	1.86e-17	Total body bone mineral density;
CESC	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg22535103	chr8:58192502	C8orf71	-0.92	-10.16	-0.53	1.04e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs9611565	0.512	rs5751153	chr22:42156561	T/C	cg03806693	chr22:41940476	POLR3H	1.19	14.07	0.65	6.09e-34	Vitiligo;
CESC	cis	rs4919044	0.756	rs2486686	chr10:94778511	G/T	cg16508068	chr10:94451736	HHEX	-0.5	-5.49	-0.32	9.61e-8	Coronary artery disease;
CESC	cis	rs9291683	0.632	rs12508991	chr4:10041104	C/T	cg00071950	chr4:10020882	SLC2A9	0.83	14.41	0.66	3.63e-35	Bone mineral density;
CESC	cis	rs1005277	0.579	rs1780115	chr10:38524773	C/T	cg25517755	chr10:38738941	LOC399744	-0.44	-5.72	-0.33	2.85e-8	Extrinsic epigenetic age acceleration;
CESC	cis	rs7216064	1.000	rs9897982	chr17:65879592	G/T	cg12091567	chr17:66097778	LOC651250	-0.83	-9.57	-0.51	8.04e-19	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs9815354	1.000	rs9815354	chr3:41912651	G/A	cg03022575	chr3:42003672	ULK4	0.58	5.91	0.34	1.05e-8	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs13118159	0.771	rs13117476	chr4:1334721	A/G	cg19318889	chr4:1322082	MAEA	0.46	6.32	0.36	1.08e-9	Longevity;
CESC	cis	rs8020095	0.571	rs7157126	chr14:67488230	C/G	cg19548862	chr14:67692701	FAM71D	-0.49	-6.03	-0.35	5.44e-9	Depression (quantitative trait);
CESC	cis	rs7618915	0.547	rs11130314	chr3:52697082	T/C	cg17372223	chr3:52568218	NT5DC2	0.44	6.63	0.38	1.86e-10	Bipolar disorder;
CESC	cis	rs703842	1.000	rs10877014	chr12:58167661	A/G	cg00677455	chr12:58241039	CTDSP2	0.53	6.99	0.39	2.23e-11	Multiple sclerosis;
CESC	cis	rs1153858	1.000	rs2461702	chr15:45647427	A/G	cg21132104	chr15:45694354	SPATA5L1	0.76	10.17	0.53	1.03e-20	Homoarginine levels;
CESC	cis	rs727563	0.638	rs4820443	chr22:42193913	A/G	cg03806693	chr22:41940476	POLR3H	-1.12	-13.57	-0.64	3.28e-32	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs250677	0.652	rs250675	chr5:148438565	A/C	cg18129178	chr5:148520854	ABLIM3	0.53	5.77	0.33	2.17e-8	Breast cancer;
CESC	trans	rs9929218	0.551	rs2296408	chr16:68713823	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.97	-17.29	-0.73	2.32e-45	Colorectal cancer;
CESC	cis	rs6120849	0.901	rs6058194	chr20:33739831	G/A	cg24642439	chr20:33292090	TP53INP2	0.62	6.58	0.37	2.54e-10	Protein C levels;
CESC	cis	rs7264396	0.635	rs6058382	chr20:34553948	C/T	cg17201900	chr20:34330562	RBM39	0.51	5.31	0.31	2.37e-7	Total cholesterol levels;
CESC	cis	rs9910055	0.530	rs2269908	chr17:42294198	G/C	cg08499158	chr17:42289980	UBTF	-0.41	-5.26	-0.31	3e-7	Total body bone mineral density;
CESC	cis	rs7927771	0.864	rs7107726	chr11:47429245	T/A	cg18512352	chr11:47633146	NA	-0.52	-7.48	-0.42	1.11e-12	Subjective well-being;
CESC	cis	rs7666738	0.830	rs28729647	chr4:99059552	T/C	cg03676636	chr4:99064102	C4orf37	0.33	5.04	0.3	8.47e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs13242816	1.000	rs4292624	chr7:116102724	A/C	cg04696780	chr7:116139425	CAV2	-0.62	-5.69	-0.33	3.31e-8	P wave duration;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg18502522	chr15:75165624	SCAMP2	-0.47	-6.11	-0.35	3.62e-9	Ulcerative colitis;
CESC	cis	rs6815814	0.950	rs66922907	chr4:38812537	A/G	cg02016764	chr4:38805732	TLR1	-0.62	-7.43	-0.42	1.5e-12	Breast cancer;
CESC	cis	rs1465370	0.682	rs741486	chr7:130024010	C/T	cg04743876	chr7:130013617	NA	-0.29	-5.5	-0.32	8.89e-8	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
CESC	cis	rs9513593	1.000	rs2182954	chr13:99937082	A/G	cg21788972	chr13:99853209	UBAC2	0.54	6.47	0.37	4.77e-10	Psoriasis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16280098	chr14:23790882	PABPN1	0.58	6.64	0.38	1.81e-10	Gut microbiome composition (summer);
CESC	cis	rs6690583	0.623	rs893618	chr1:85513770	C/T	cg11262906	chr1:85462892	MCOLN2	0.52	5.21	0.3	3.82e-7	Serum sulfate level;
CESC	cis	rs4975709	0.610	rs4975705	chr5:1860359	T/C	cg17650747	chr5:1873721	NA	0.41	5.69	0.33	3.31e-8	Cardiovascular disease risk factors;
CESC	cis	rs4561483	0.734	rs33655	chr16:11970381	C/T	cg08843971	chr16:11963173	GSPT1	-0.56	-8.39	-0.46	2.93e-15	Testicular germ cell tumor;
CESC	cis	rs9902453	0.808	rs4595850	chr17:28206326	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.65	8.12	0.45	1.77e-14	Coffee consumption (cups per day);
CESC	cis	rs28489187	0.638	rs233055	chr1:85798486	A/C	cg16011679	chr1:85725395	C1orf52	0.46	5.52	0.32	7.91e-8	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	cis	rs2576037	0.501	rs7227700	chr18:44537102	T/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.66	10.03	0.52	2.84e-20	Personality dimensions;
CESC	cis	rs2295499	0.673	rs4690016	chr4:2707132	G/A	cg27239842	chr4:2403781	ZFYVE28	-0.34	-5.66	-0.33	3.98e-8	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
CESC	cis	rs8077577	0.747	rs1925	chr17:18177715	G/A	cg16794390	chr17:18148240	FLII	0.42	6.59	0.38	2.32e-10	Obesity-related traits;
CESC	cis	rs523522	0.962	rs10849754	chr12:120940418	A/C	cg12219531	chr12:120966889	COQ5	0.75	9.99	0.52	3.7e-20	High light scatter reticulocyte count;
CESC	trans	rs9929218	0.954	rs2059254	chr16:68817439	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.62	-8.38	-0.46	3.2e-15	Colorectal cancer;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg14339556	chr9:36572881	MELK	-0.44	-7.29	-0.41	3.56e-12	Gambling;
CESC	cis	rs12477438	0.834	rs1563107	chr2:99701276	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.67	9.13	0.49	1.8e-17	Chronic sinus infection;
CESC	cis	rs644799	0.710	rs10831429	chr11:95508524	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	11.75	0.59	6.37e-26	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs6987853	0.712	rs2974343	chr8:42400679	G/A	cg09913449	chr8:42400586	C8orf40	0.45	7.63	0.42	4.28e-13	Mean corpuscular hemoglobin concentration;
CESC	trans	rs8135828	0.770	rs5763300	chr22:29927704	T/C	cg17961835	chr3:126195582	ZXDC	-0.45	-6.11	-0.35	3.53e-9	Lipid traits;
CESC	cis	rs1862618	0.853	rs2113078	chr5:56087190	C/T	cg12311346	chr5:56204834	C5orf35	-0.75	-8.79	-0.48	1.93e-16	Initial pursuit acceleration;
CESC	cis	rs6860806	0.507	rs272872	chr5:131675864	C/T	cg04518342	chr5:131593106	PDLIM4	-0.36	-5.14	-0.3	5.39e-7	Breast cancer;
CESC	cis	rs6089829	0.692	rs6122349	chr20:61664096	T/C	cg08564027	chr20:61660810	NA	0.79	9.99	0.52	3.8e-20	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs9311474	0.713	rs352170	chr3:52236077	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.37	5.32	0.31	2.24e-7	Electroencephalogram traits;
CESC	cis	rs2228479	0.850	rs17226666	chr16:89835401	G/A	cg06558623	chr16:89946397	TCF25	1.17	9.29	0.5	5.84e-18	Skin colour saturation;
CESC	cis	rs6724607	1.000	rs4853513	chr2:191479455	C/T	cg10560079	chr2:191398806	TMEM194B	-0.49	-7.05	-0.4	1.51e-11	Pulse pressure;
CESC	cis	rs2836974	0.897	rs2026265	chr21:40595517	G/A	cg11644478	chr21:40555479	PSMG1	1.03	16.6	0.71	6.66e-43	Cognitive function;
CESC	cis	rs941408	1.000	rs1640271	chr19:2799979	C/T	cg06609049	chr19:2785107	THOP1	0.7	10.51	0.54	7.95e-22	Total cholesterol levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10651637	chr15:45315642	SORD	0.52	6.38	0.36	7.77e-10	Gut microbiome composition (summer);
CESC	cis	rs2066819	1.000	rs2695788	chr12:56697110	G/A	cg26714650	chr12:56694279	CS	1.29	16.3	0.71	7.7e-42	Psoriasis vulgaris;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06212607	chr1:235491708	GGPS1;ARID4B	-0.56	-6.56	-0.37	2.74e-10	Gut microbiome composition (summer);
CESC	cis	rs977987	0.806	rs4887824	chr16:75441613	T/C	cg03315344	chr16:75512273	CHST6	0.41	5.86	0.34	1.35e-8	Dupuytren's disease;
CESC	cis	rs1215050	0.791	rs165239	chr4:98682549	C/T	cg05340658	chr4:99064831	C4orf37	0.47	6.04	0.35	5.08e-9	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs12474201	0.572	rs7596521	chr2:46918665	A/G	cg06386533	chr2:46925753	SOCS5	0.52	6.3	0.36	1.27e-9	Height;
CESC	cis	rs4604732	0.631	rs75600450	chr1:247625492	C/T	cg12754571	chr1:247694271	LOC148824;OR2C3	0.43	5.35	0.31	1.88e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs7267979	1.000	rs6050544	chr20:25320228	T/A	cg08601574	chr20:25228251	PYGB	-0.38	-5.42	-0.32	1.33e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs3736485	0.934	rs8036821	chr15:51861646	A/G	cg08986416	chr15:51914746	DMXL2	-0.4	-5.12	-0.3	5.86e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs3126085	0.877	rs868304	chr1:152178568	G/A	cg03465714	chr1:152285911	FLG	-0.43	-5.16	-0.3	4.81e-7	Atopic dermatitis;
CESC	cis	rs10465746	0.780	rs7529293	chr1:84331981	A/G	cg10977910	chr1:84465055	TTLL7	0.5	6.99	0.39	2.19e-11	Obesity-related traits;
CESC	cis	rs3008870	0.677	rs2815354	chr1:67483642	A/T	cg08660285	chr1:67390436	MIER1;WDR78	1.0	11.1	0.56	8.91e-24	Lymphocyte percentage of white cells;
CESC	cis	rs965469	0.724	rs6037527	chr20:3254412	T/G	cg25506879	chr20:3388711	C20orf194	-0.49	-5.36	-0.31	1.8e-7	IFN-related cytopenia;
CESC	cis	rs8049040	0.547	rs12929335	chr16:71435752	G/A	cg08717414	chr16:71523259	ZNF19	-0.6	-6.65	-0.38	1.63e-10	Blood protein levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17173397	chr1:20539594	NA	0.59	6.59	0.38	2.34e-10	Gut microbiome composition (summer);
CESC	cis	rs2760061	0.598	rs632832	chr1:228121838	G/T	cg01973587	chr1:228161476	NA	0.37	5.66	0.33	4e-8	Diastolic blood pressure;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg27304813	chr3:120068385	LRRC58	-0.48	-6.92	-0.39	3.4e-11	Gambling;
CESC	cis	rs2836974	0.932	rs13048178	chr21:40561012	G/T	cg11890956	chr21:40555474	PSMG1	1.17	21.69	0.8	1.08e-60	Cognitive function;
CESC	cis	rs5769707	0.967	rs4524218	chr22:50018639	G/A	cg20744362	chr22:50050164	C22orf34	0.46	8.08	0.44	2.23e-14	Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs6921919	0.583	rs9468355	chr6:28341877	A/G	cg04861640	chr6:28234605	ZNF187	-0.36	-5.04	-0.3	8.71e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs11645898	0.935	rs8047881	chr16:72193906	A/G	cg14768367	chr16:72042858	DHODH	-0.56	-5.05	-0.3	8.18e-7	Blood protein levels;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg02034563	chr2:179060011	OSBPL6	0.47	6.65	0.38	1.65e-10	Systemic lupus erythematosus;
CESC	cis	rs4642101	0.793	rs12714880	chr3:12832101	G/A	cg05775895	chr3:12838266	CAND2	0.35	5.32	0.31	2.25e-7	QRS complex (12-leadsum);
CESC	cis	rs12681366	0.734	rs2931633	chr8:95422720	G/A	cg13257157	chr8:95487014	RAD54B	0.38	5.13	0.3	5.47e-7	Nonsyndromic cleft lip with cleft palate;
CESC	cis	rs12541635	0.966	rs55762012	chr8:107033218	T/C	cg10147462	chr8:107024639	NA	0.42	5.9	0.34	1.12e-8	Age of smoking initiation;
CESC	cis	rs80130819	0.591	rs10875783	chr12:48649736	G/A	cg05342945	chr12:48394962	COL2A1	-0.49	-5.33	-0.31	2.14e-7	Prostate cancer;
CESC	cis	rs7927592	0.956	rs7104877	chr11:68377602	G/T	cg16797656	chr11:68205561	LRP5	-0.38	-5.47	-0.32	1.04e-7	Total body bone mineral density;
CESC	cis	rs13256369	0.901	rs13251887	chr8:8568678	G/A	cg18904891	chr8:8559673	CLDN23	0.68	7.56	0.42	6.58e-13	Obesity-related traits;
CESC	cis	rs4654899	0.865	rs960564	chr1:21416435	G/T	cg05370193	chr1:21551575	ECE1	0.44	6.76	0.38	8.66e-11	Superior frontal gyrus grey matter volume;
CESC	trans	rs875971	0.965	rs9969301	chr7:65781655	G/A	cg26939375	chr7:64535504	NA	-0.45	-6.04	-0.35	5.31e-9	Aortic root size;
CESC	cis	rs2066819	1.000	rs79718165	chr12:56644251	C/T	cg26714650	chr12:56694279	CS	-1.42	-10.05	-0.53	2.39e-20	Psoriasis vulgaris;
CESC	cis	rs4474465	1.000	rs12277701	chr11:78140726	A/T	cg27205649	chr11:78285834	NARS2	-0.42	-5.1	-0.3	6.41e-7	Alzheimer's disease (survival time);
CESC	cis	rs6860806	0.695	rs11952099	chr5:131576772	A/G	cg11843238	chr5:131593191	PDLIM4	0.35	5.21	0.3	3.8e-7	Breast cancer;
CESC	cis	rs4481887	0.893	rs4576683	chr1:248472390	T/C	cg00666640	chr1:248458726	OR2T12	0.34	5.89	0.34	1.18e-8	Common traits (Other);
CESC	cis	rs514406	0.861	rs12141260	chr1:53300127	C/T	cg08859206	chr1:53392774	SCP2	-0.57	-7.47	-0.42	1.17e-12	Monocyte count;
CESC	cis	rs7949030	0.626	rs11231144	chr11:62328038	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.61	8.6	0.47	6.91e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs9814567	1.000	rs9864439	chr3:134298671	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.4	-5.44	-0.32	1.23e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs7247513	0.701	rs8107642	chr19:12766370	C/T	cg23899408	chr19:12877188	HOOK2	0.45	5.41	0.32	1.44e-7	Bipolar disorder;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg17896229	chr20:5294595	PROKR2	-0.43	-6.68	-0.38	1.38e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs7552404	0.727	rs5745390	chr1:76306591	A/C	cg03433033	chr1:76189801	ACADM	0.62	6.27	0.36	1.49e-9	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs1707322	0.686	rs11211179	chr1:46228082	A/C	cg06784218	chr1:46089804	CCDC17	0.4	7.33	0.41	2.85e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs1862618	0.671	rs28397234	chr5:56248428	T/G	cg22800045	chr5:56110881	MAP3K1	-0.61	-7.68	-0.43	3.13e-13	Initial pursuit acceleration;
CESC	cis	rs9435341	0.896	rs1623927	chr1:107596120	T/C	cg09367891	chr1:107599246	PRMT6	-0.71	-8.35	-0.46	3.85e-15	Facial morphology (factor 21, depth of nasal alae);
CESC	cis	rs854765	0.583	rs62064158	chr17:17826935	T/C	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.55	7.28	0.41	3.9e-12	Total body bone mineral density;
CESC	cis	rs7666738	0.830	rs1967979	chr4:98966201	G/T	cg17366294	chr4:99064904	C4orf37	0.6	8.52	0.46	1.2e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9329289	0.603	rs2458705	chr10:2541377	A/G	cg15501526	chr10:2543763	NA	0.64	10.86	0.55	5.83e-23	Age-related hearing impairment;
CESC	cis	rs3096299	0.967	rs753853	chr16:89446525	G/T	cg08822215	chr16:89438651	ANKRD11	-0.42	-6.35	-0.36	9.47e-10	Multiple myeloma (IgH translocation);
CESC	cis	rs1506636	1.000	rs2429616	chr7:123406034	C/T	cg03229431	chr7:123269106	ASB15	0.5	6.73	0.38	1.03e-10	Plateletcrit;Platelet count;
CESC	cis	rs2486288	0.656	rs8039352	chr15:45551790	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.59	-6.96	-0.39	2.67e-11	Glomerular filtration rate;
CESC	cis	rs875971	0.545	rs67688847	chr7:65626051	G/A	cg18876405	chr7:65276391	NA	0.51	5.96	0.34	8.21e-9	Aortic root size;
CESC	cis	rs2953145	0.568	rs2975752	chr2:241521327	A/G	cg03371404	chr2:241525653	CAPN10	-0.56	-6.02	-0.35	5.67e-9	Bipolar disorder;
CESC	cis	rs3820068	0.580	rs12746773	chr1:16001588	C/T	cg18133145	chr1:16060689	PLEKHM2	-0.43	-5.22	-0.31	3.7e-7	Systolic blood pressure;
CESC	cis	rs7615952	1.000	rs7615952	chr3:125649403	A/C	cg05084668	chr3:125655381	ALG1L	0.48	5.99	0.35	6.65e-9	Blood pressure (smoking interaction);
CESC	cis	rs734999	0.588	rs2764848	chr1:2530694	G/A	cg20673091	chr1:2541236	MMEL1	-0.44	-7.28	-0.41	3.75e-12	Ulcerative colitis;
CESC	cis	rs9487051	0.768	rs12176068	chr6:109521629	C/T	cg01475377	chr6:109611718	NA	-0.46	-6.93	-0.39	3.18e-11	Reticulocyte fraction of red cells;
CESC	cis	rs7914558	0.933	rs2066323	chr10:104871361	A/G	cg04362960	chr10:104952993	NT5C2	0.46	5.92	0.34	9.98e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg13665852	chr10:13146898	OPTN	0.51	7.04	0.4	1.61e-11	Fibrinogen levels;
CESC	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg18402987	chr7:1209562	NA	0.76	7.55	0.42	7.26e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs9929218	1.000	rs4783681	chr16:68806508	C/A	cg02972257	chr16:68554789	NA	0.43	5.12	0.3	5.89e-7	Colorectal cancer;
CESC	cis	rs10744422	1.000	rs10847869	chr12:123328359	C/G	cg25930673	chr12:123319894	HIP1R	-0.65	-5.28	-0.31	2.72e-7	Schizophrenia;
CESC	cis	rs2933343	0.700	rs789239	chr3:128633808	T/C	cg24203234	chr3:128598194	ACAD9	0.39	5.27	0.31	2.78e-7	IgG glycosylation;
CESC	cis	rs801193	0.569	rs6951302	chr7:66132512	T/C	cg18252515	chr7:66147081	NA	0.48	6.43	0.37	5.77e-10	Aortic root size;
CESC	cis	rs6484504	0.576	rs169623	chr11:31184157	T/C	cg14844989	chr11:31128820	NA	-0.43	-6.07	-0.35	4.34e-9	Red blood cell count;
CESC	cis	rs9486715	1.000	rs3798297	chr6:97062835	C/T	cg18709589	chr6:96969512	KIAA0776	-0.44	-6.2	-0.36	2.17e-9	Headache;
CESC	cis	rs17253792	0.822	rs78143160	chr14:56150097	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.81	5.68	0.33	3.46e-8	Putamen volume;
CESC	cis	rs3093024	0.595	rs4458654	chr6:167476068	A/C	cg07741184	chr6:167504864	NA	0.38	6.7	0.38	1.22e-10	Rheumatoid arthritis;
CESC	cis	rs7395581	0.797	rs10838681	chr11:47275064	C/T	cg25783544	chr11:47291846	MADD	0.58	6.93	0.39	3.16e-11	HDL cholesterol;
CESC	trans	rs35110281	0.715	rs2838320	chr21:44995037	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.53	7.12	0.4	9.96e-12	Mean corpuscular volume;
CESC	cis	rs7605827	0.893	rs7590540	chr2:15719652	A/T	cg19274914	chr2:15703543	NA	0.33	6.02	0.35	5.69e-9	Educational attainment (years of education);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16757658	chr11:126138769	SRPR;FOXRED1	0.61	7.42	0.41	1.59e-12	Gut microbiome composition (summer);
CESC	cis	rs826838	0.935	rs1684407	chr12:39127270	C/T	cg26384229	chr12:38710491	ALG10B	-0.67	-10.95	-0.56	2.81e-23	Heart rate;
CESC	cis	rs2204008	0.527	rs8189480	chr12:38345648	C/T	cg26384229	chr12:38710491	ALG10B	-0.5	-6.69	-0.38	1.3e-10	Bladder cancer;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg07404466	chr20:56064128	HMGB1L1	-0.43	-6.18	-0.35	2.38e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs736408	0.570	rs11130327	chr3:52793239	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.47	6.42	0.37	6.09e-10	Bipolar disorder;
CESC	cis	rs4076764	0.801	rs4571944	chr1:163367975	T/C	cg06092702	chr1:163392909	NA	-0.39	-5.6	-0.33	5.37e-8	Motion sickness;
CESC	cis	rs7520050	0.778	rs2934857	chr1:46039612	A/G	cg06784218	chr1:46089804	CCDC17	0.33	5.9	0.34	1.12e-8	Red blood cell count;Reticulocyte count;
CESC	trans	rs11098499	0.662	rs13108589	chr4:120268102	G/C	cg25214090	chr10:38739885	LOC399744	0.62	8.49	0.46	1.46e-15	Corneal astigmatism;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg19319069	chr7:129593010	UBE2H	0.46	6.43	0.37	5.8e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs28386778	0.669	rs12603821	chr17:62006432	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	-0.81	-11.35	-0.57	1.34e-24	Prudent dietary pattern;
CESC	trans	rs208520	1.000	rs72884033	chr6:66995747	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.84	9.14	0.49	1.65e-17	Exhaled nitric oxide output;
CESC	cis	rs9796	0.689	rs561301	chr15:41444723	C/T	cg12426344	chr15:41135900	SPINT1	-0.25	-5.41	-0.32	1.43e-7	Menopause (age at onset);
CESC	cis	rs9486715	0.838	rs9400034	chr6:96954566	C/T	cg06623918	chr6:96969491	KIAA0776	0.93	14.38	0.66	4.75e-35	Headache;
CESC	cis	rs1799949	0.602	rs8176235	chr17:41219560	C/T	cg04277193	chr17:41438351	NA	0.48	5.07	0.3	7.51e-7	Menopause (age at onset);
CESC	cis	rs8067354	0.574	rs7219089	chr17:58032865	C/T	cg02344993	chr17:57696989	CLTC	0.52	5.33	0.31	2.1e-7	Hemoglobin concentration;
CESC	cis	rs7412746	0.658	rs2864869	chr1:150734655	G/A	cg22823121	chr1:150693482	HORMAD1	0.47	6.51	0.37	3.7e-10	Melanoma;
CESC	trans	rs17135859	0.817	rs6889348	chr5:112965145	A/G	cg21932672	chr1:95584445	TMEM56	0.42	6.27	0.36	1.43e-9	F-cell distribution;
CESC	cis	rs933688	1.000	rs1035477	chr5:90743325	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.15	13.7	0.64	1.17e-32	Smoking behavior;
CESC	cis	rs13256369	0.950	rs13248096	chr8:8577476	C/T	cg18904891	chr8:8559673	CLDN23	0.68	8.07	0.44	2.48e-14	Obesity-related traits;
CESC	cis	rs7659604	0.702	rs6826506	chr4:122710865	T/G	cg06713675	chr4:122721982	EXOSC9	-0.47	-6.56	-0.37	2.87e-10	Type 2 diabetes;
CESC	cis	rs910316	0.934	rs8016330	chr14:75657507	G/T	cg08847533	chr14:75593920	NEK9	-0.9	-15.59	-0.69	2.49e-39	Height;
CESC	cis	rs1348850	0.526	rs9288003	chr2:178446572	T/G	cg22681709	chr2:178499509	PDE11A	-0.45	-5.24	-0.31	3.27e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs10504229	0.773	rs1874373	chr8:58194423	T/C	cg22535103	chr8:58192502	C8orf71	-1.07	-13.57	-0.64	3.2e-32	Developmental language disorder (linguistic errors);
CESC	cis	rs9660992	0.674	rs17345837	chr1:205263122	C/T	cg00857998	chr1:205179979	DSTYK	0.48	5.48	0.32	9.88e-8	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs9916302	0.904	rs679995	chr17:37441679	A/T	cg20243544	chr17:37824526	PNMT	-0.45	-5.44	-0.32	1.23e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs3008870	0.920	rs12132532	chr1:67457015	G/T	cg02640540	chr1:67518911	SLC35D1	-0.52	-5.66	-0.33	3.9e-8	Lymphocyte percentage of white cells;
CESC	cis	rs35306767	0.807	rs11253513	chr10:968450	C/T	cg26597838	chr10:835615	NA	0.79	9.46	0.5	1.69e-18	Eosinophil percentage of granulocytes;
CESC	cis	rs7044106	0.762	rs7357638	chr9:123389204	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.76	10.99	0.56	2.18e-23	Hip circumference adjusted for BMI;
CESC	cis	rs4523957	0.786	rs59428454	chr17:2114063	T/A	cg16513277	chr17:2031491	SMG6	-0.64	-8.9	-0.48	9.15e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs2635047	0.967	rs2576060	chr18:44637106	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.53	-7.26	-0.41	4.26e-12	Educational attainment;
CESC	cis	rs1878931	0.507	rs35214904	chr16:3410017	C/A	cg02880119	chr16:3481970	NA	0.42	5.38	0.31	1.65e-7	Body mass index (adult);
CESC	cis	rs1808579	0.935	rs57440424	chr18:21108614	G/A	cg14672496	chr18:21087552	C18orf8	0.41	6.29	0.36	1.33e-9	Hip circumference;Body mass index;BMI (adjusted for smoking behaviour);
CESC	cis	rs9399137	0.507	rs10484496	chr6:135299682	T/C	cg24558204	chr6:135376177	HBS1L	0.7	9.61	0.51	5.93e-19	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	cis	rs2180341	1.000	rs6569478	chr6:127598619	G/A	cg27446573	chr6:127587934	RNF146	1.07	15.98	0.7	1e-40	Breast cancer;
CESC	cis	rs4927850	0.918	rs4361313	chr3:195752260	A/G	cg12923728	chr3:195709715	SDHAP1	-0.68	-9.13	-0.49	1.76e-17	Pancreatic cancer;
CESC	cis	rs853679	0.517	rs9348796	chr6:28126202	A/G	cg22143856	chr6:28129313	ZNF389	0.49	6.24	0.36	1.73e-9	Depression;
CESC	cis	rs4665809	1.000	rs2384322	chr2:26291146	C/G	cg25036284	chr2:26402008	FAM59B	-0.74	-8.4	-0.46	2.72e-15	Gut microbiome composition (summer);
CESC	cis	rs1865721	1.000	rs17284077	chr18:73204128	C/T	cg26385618	chr18:73139727	C18orf62	-0.52	-7.75	-0.43	1.96e-13	Intelligence;
CESC	cis	rs11690935	0.959	rs6758704	chr2:172655097	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.96	-14.76	-0.67	2.21e-36	Schizophrenia;
CESC	cis	rs2651899	0.867	rs207200	chr1:3073555	T/C	cg07622451	chr1:3079886	PRDM16	0.3	5.42	0.32	1.37e-7	Migraine;
CESC	cis	rs1790761	0.504	rs61894496	chr11:67391907	C/T	cg00864171	chr11:67383662	NA	0.34	5.08	0.3	7.24e-7	Mean corpuscular volume;
CESC	cis	rs910316	1.000	rs12589876	chr14:75544189	G/A	cg11812906	chr14:75593930	NEK9	0.9	15.28	0.68	3.01e-38	Height;
CESC	cis	rs1008375	0.932	rs6449317	chr4:17631253	T/C	cg27347728	chr4:17578864	LAP3	0.44	5.07	0.3	7.43e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs2243480	1.000	rs13247184	chr7:65358928	A/G	cg25894440	chr7:65020034	NA	-0.63	-5.42	-0.32	1.33e-7	Diabetic kidney disease;
CESC	cis	rs6570726	0.935	rs395948	chr6:145820185	G/A	cg23711669	chr6:146136114	FBXO30	0.81	12.04	0.59	6.44e-27	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6762	0.748	rs1130719	chr11:838760	T/A	cg23754390	chr11:835074	CD151	0.33	5.96	0.34	8.2e-9	Mean platelet volume;
CESC	cis	rs11077998	0.935	rs11653926	chr17:80484953	G/A	cg10255544	chr17:80519551	FOXK2	0.55	9.01	0.48	4.32e-17	Reticulocyte fraction of red cells;
CESC	cis	rs9287719	0.967	rs13034061	chr2:10739651	C/T	cg02196655	chr2:10830764	NOL10	-0.37	-5.72	-0.33	2.87e-8	Prostate cancer;
CESC	cis	rs6460942	1.000	rs62448563	chr7:12400040	G/A	cg06484146	chr7:12443880	VWDE	-0.69	-7.97	-0.44	4.71e-14	Coronary artery disease;
CESC	cis	rs4629180	0.920	rs4851458	chr2:102108794	T/C	cg01388757	chr2:102091195	RFX8	-0.43	-6.61	-0.38	2.12e-10	Chronic rhinosinusitis with nasal polyps;
CESC	cis	rs1862618	0.671	rs2591964	chr5:56236900	T/G	cg24531977	chr5:56204891	C5orf35	0.69	9.4	0.5	2.69e-18	Initial pursuit acceleration;
CESC	cis	rs2439831	0.867	rs933941	chr15:43632226	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.9	10.48	0.54	1.04e-21	Lung cancer in ever smokers;
CESC	cis	rs6964587	1.000	rs13245393	chr7:91641928	A/G	cg17063962	chr7:91808500	NA	0.56	7.76	0.43	1.79e-13	Breast cancer;
CESC	cis	rs9457247	1.000	rs10946198	chr6:167404432	C/T	cg23791538	chr6:167370224	RNASET2	-0.59	-8.42	-0.46	2.44e-15	Crohn's disease;
CESC	cis	rs901683	1.000	rs12775527	chr10:46024990	G/A	cg16031567	chr10:46195673	NA	-0.77	-5.04	-0.3	8.57e-7	Red blood cell traits;Mean corpuscular volume;
CESC	cis	rs711830	1.000	rs711830	chr2:177037311	C/T	cg13092806	chr2:177043255	NA	-0.86	-11.92	-0.59	1.69e-26	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
CESC	cis	rs10504229	0.683	rs6998040	chr8:58110155	G/T	cg22535103	chr8:58192502	C8orf71	0.8	8.72	0.47	3.07e-16	Developmental language disorder (linguistic errors);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg11450715	chr2:171627404	NA	-0.46	-6.6	-0.38	2.27e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs9322193	0.962	rs7745915	chr6:150155247	C/T	cg05861140	chr6:150128134	PCMT1	-0.36	-5.2	-0.3	4.08e-7	Lung cancer;
CESC	cis	rs2485892	0.581	rs2484032	chr1:210317225	G/A	cg21951975	chr1:209979733	IRF6	0.44	5.65	0.33	4.19e-8	Manic episodes in bipolar disorder;
CESC	cis	rs9905704	0.846	rs302861	chr17:56697040	G/C	cg12560992	chr17:57184187	TRIM37	0.62	7.73	0.43	2.17e-13	Testicular germ cell tumor;
CESC	cis	rs1915146	0.546	rs2454055	chr10:126859832	T/C	cg23000734	chr10:126850823	CTBP2	0.54	8.0	0.44	3.93e-14	Menarche (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22798412	chr1:1156246	SDF4	-0.56	-6.57	-0.37	2.64e-10	Gut microbiome composition (summer);
CESC	cis	rs4665809	0.590	rs1049987	chr2:26413817	C/T	cg04944784	chr2:26401820	FAM59B	0.93	10.54	0.54	6.17e-22	Gut microbiome composition (summer);
CESC	cis	rs270601	0.739	rs3900945	chr5:131592870	T/C	cg18758796	chr5:131593413	PDLIM4	0.52	7.64	0.42	3.97e-13	Acylcarnitine levels;
CESC	cis	rs9311474	0.597	rs6778735	chr3:52565100	T/C	cg18591801	chr3:52553433	STAB1	-0.3	-5.78	-0.33	2.1e-8	Electroencephalogram traits;
CESC	cis	rs7523050	0.643	rs34114412	chr1:109402866	C/T	cg08274380	chr1:109419600	GPSM2	0.86	5.69	0.33	3.36e-8	Fat distribution (HIV);
CESC	cis	rs8070128	0.583	rs7406982	chr17:17942613	C/T	cg09796270	chr17:17721594	SREBF1	0.38	5.07	0.3	7.66e-7	Total body bone mineral density;
CESC	cis	rs873946	0.590	rs7071777	chr10:134559976	T/A	cg26818010	chr10:134567672	INPP5A	-0.9	-10.89	-0.56	4.7e-23	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs854765	0.547	rs28537385	chr17:17902135	G/A	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.5	6.51	0.37	3.74e-10	Total body bone mineral density;
CESC	cis	rs763121	0.853	rs138709	chr22:39139216	C/G	cg06544989	chr22:39130855	UNC84B	0.49	9.36	0.5	3.5e-18	Menopause (age at onset);
CESC	cis	rs7659604	0.582	rs3217780	chr4:122737278	T/C	cg20573242	chr4:122745356	CCNA2	0.62	7.64	0.42	3.94e-13	Type 2 diabetes;
CESC	cis	rs7666738	0.830	rs4441757	chr4:98927059	T/C	cg03467027	chr4:99064603	C4orf37	0.46	5.59	0.32	5.78e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6860806	0.631	rs7736284	chr5:131588151	T/C	cg11843238	chr5:131593191	PDLIM4	0.36	5.33	0.31	2.14e-7	Breast cancer;
CESC	cis	rs4253772	0.513	rs9615345	chr22:46713631	C/T	cg18190219	chr22:46762943	CELSR1	-0.48	-6.12	-0.35	3.28e-9	LDL cholesterol;Cholesterol, total;
CESC	cis	rs801193	0.660	rs1962050	chr7:66240008	C/T	cg18876405	chr7:65276391	NA	-0.49	-6.7	-0.38	1.27e-10	Aortic root size;
CESC	cis	rs9487051	0.646	rs11153167	chr6:109622582	A/T	cg01475377	chr6:109611718	NA	0.41	5.5	0.32	8.94e-8	Reticulocyte fraction of red cells;
CESC	cis	rs17023223	0.509	rs7542832	chr1:119762729	T/C	cg05756136	chr1:119680316	WARS2	-0.49	-5.97	-0.34	7.55e-9	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg07556773	chr1:155294010	RUSC1;C1orf104	-0.43	-6.01	-0.35	5.97e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs4764487	0.685	rs740839	chr12:6338637	C/T	cg08284733	chr12:6341482	CD9	0.42	6.18	0.36	2.38e-9	Mean platelet volume;
CESC	cis	rs875971	1.000	rs11971949	chr7:65626014	A/G	cg18876405	chr7:65276391	NA	-0.52	-7.02	-0.4	1.83e-11	Aortic root size;
CESC	cis	rs2985684	0.948	rs12886130	chr14:50082753	T/C	cg02151108	chr14:50098012	C14orf104	-0.4	-5.21	-0.3	3.75e-7	Carotid intima media thickness;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14852625	chr3:127309519	TPRA1	0.69	8.06	0.44	2.66e-14	Gut microbiome composition (summer);
CESC	cis	rs7937682	0.889	rs1789361	chr11:111485334	T/C	cg09085632	chr11:111637200	PPP2R1B	-0.95	-14.72	-0.67	3.1e-36	Primary sclerosing cholangitis;
CESC	cis	rs3091242	1.000	rs646867	chr1:25709258	A/C	cg03538708	chr1:25844672	NA	-0.38	-5.52	-0.32	7.89e-8	Erythrocyte sedimentation rate;
CESC	cis	rs3780486	0.629	rs10971439	chr9:33180813	C/T	cg13443165	chr9:33130375	B4GALT1	-0.42	-5.05	-0.3	8.3e-7	IgG glycosylation;
CESC	cis	rs17376456	0.877	rs12716457	chr5:93397627	T/C	cg25358565	chr5:93447407	FAM172A	1.11	10.75	0.55	1.35e-22	Diabetic retinopathy;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg25282353	chr6:144416767	SF3B5	-0.46	-6.21	-0.36	2.01e-9	Fibrinogen levels;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg14871650	chr4:170541668	CLCN3	-0.47	-6.1	-0.35	3.83e-9	Fibrinogen levels;
CESC	cis	rs7666738	0.830	rs4699574	chr4:98725544	C/T	cg03467027	chr4:99064603	C4orf37	0.44	5.45	0.32	1.18e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs870825	0.616	rs7694899	chr4:185625390	C/T	cg04058563	chr4:185651563	MLF1IP	0.61	6.71	0.38	1.21e-10	Blood protein levels;
CESC	cis	rs6665290	0.904	rs1186	chr1:227177731	A/T	cg10327440	chr1:227177885	CDC42BPA	-1.23	-34.55	-0.9	3.8e-100	Myeloid white cell count;
CESC	cis	rs35110281	0.720	rs162375	chr21:44927015	C/T	cg01579765	chr21:45077557	HSF2BP	0.52	9.02	0.48	3.87e-17	Mean corpuscular volume;
CESC	cis	rs911555	0.755	rs8018400	chr14:103901085	A/G	cg24130564	chr14:104152367	KLC1	0.5	6.62	0.38	2.02e-10	Intelligence (multi-trait analysis);
CESC	cis	rs6541297	0.941	rs2144299	chr1:230280366	A/G	cg20703242	chr1:230279135	GALNT2	0.66	9.34	0.5	4.12e-18	Coronary artery disease;
CESC	cis	rs1256061	0.528	rs10143616	chr14:64740175	G/A	cg23250157	chr14:64679961	SYNE2	0.37	5.05	0.3	8.39e-7	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs9549367	0.789	rs9604040	chr13:113910611	A/G	cg18105134	chr13:113819100	PROZ	0.62	7.75	0.43	1.91e-13	Platelet distribution width;
CESC	trans	rs13098911	0.540	rs13075758	chr3:46025048	G/A	cg10236987	chr1:228114221	WNT9A	0.6	6.17	0.35	2.61e-9	Celiac disease;
CESC	cis	rs6998277	0.830	rs6468836	chr8:103602630	A/G	cg10187029	chr8:103597600	NA	0.75	9.9	0.52	7.14e-20	Migraine;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01593421	chr7:65303149	NA	-0.72	-8.83	-0.48	1.49e-16	Gut microbiome composition (summer);
CESC	cis	rs1267303	0.642	rs2404611	chr1:46997127	C/G	cg25110126	chr1:46999211	NA	0.92	10.3	0.53	3.79e-21	Monobrow;
CESC	cis	rs7917772	0.503	rs1536308	chr10:104288777	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.53	7.33	0.41	2.81e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs796364	0.806	rs78037592	chr2:201105734	G/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.77	-6.33	-0.36	1.05e-9	Schizophrenia;
CESC	cis	rs7618915	0.524	rs12488461	chr3:52698417	T/C	cg05564831	chr3:52568323	NT5DC2	0.44	6.72	0.38	1.13e-10	Bipolar disorder;
CESC	cis	rs1048238	0.506	rs848212	chr1:16263452	A/G	cg21385522	chr1:16154831	NA	-0.43	-5.47	-0.32	1.04e-7	Systolic blood pressure;
CESC	cis	rs4665809	1.000	rs6546766	chr2:26328680	T/C	cg26314531	chr2:26401878	FAM59B	-0.62	-7.01	-0.4	2.02e-11	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.830	rs7684646	chr4:99071062	C/T	cg17366294	chr4:99064904	C4orf37	0.59	8.34	0.46	4.13e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11098499	0.863	rs6853998	chr4:120475860	C/A	cg24375607	chr4:120327624	NA	0.45	5.51	0.32	8.55e-8	Corneal astigmatism;
CESC	cis	rs2370759	1.000	rs75984055	chr10:32591276	T/C	cg01819863	chr10:32635814	EPC1	1.16	13.25	0.63	4.48e-31	Sexual dysfunction (female);
CESC	cis	rs11249608	0.548	rs2047354	chr5:178455247	T/C	cg01312482	chr5:178451176	ZNF879	-0.46	-6.42	-0.37	6.42e-10	Pubertal anthropometrics;
CESC	cis	rs4253772	0.530	rs11090875	chr22:46785301	C/T	cg00784671	chr22:46762841	CELSR1	-0.59	-5.63	-0.33	4.66e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs4835473	0.900	rs13140028	chr4:144703348	T/C	cg25736465	chr4:144833511	NA	-0.42	-6.42	-0.37	6.21e-10	Immature fraction of reticulocytes;
CESC	cis	rs9311474	0.597	rs13303	chr3:52558008	T/C	cg15147215	chr3:52552868	STAB1	-0.37	-6.68	-0.38	1.39e-10	Electroencephalogram traits;
CESC	cis	rs6565180	1.000	rs11646130	chr16:30376959	T/C	cg17640201	chr16:30407289	ZNF48	-0.94	-13.81	-0.65	4.82e-33	Tonsillectomy;
CESC	trans	rs9834373	0.573	rs9828144	chr3:78523315	T/G	cg21593409	chr16:88706389	IL17C	-0.42	-6.04	-0.35	5.2e-9	Protein quantitative trait loci;
CESC	cis	rs12618769	0.597	rs3769730	chr2:99101453	T/C	cg10123293	chr2:99228465	UNC50	0.39	5.14	0.3	5.22e-7	Bipolar disorder;
CESC	cis	rs1775715	0.707	rs2808087	chr10:32146444	C/G	cg18675610	chr10:32216311	ARHGAP12	0.34	5.4	0.31	1.47e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs7412746	0.553	rs59337856	chr1:150746406	G/T	cg17724175	chr1:150552817	MCL1	0.42	6.34	0.36	1e-9	Melanoma;
CESC	cis	rs2115536	0.967	rs4778734	chr15:80210851	A/G	cg00225070	chr15:80189496	MTHFS	0.54	7.38	0.41	2.05e-12	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10120645	chr8:125486635	RNF139	0.58	6.73	0.38	1.06e-10	Gut microbiome composition (summer);
CESC	cis	rs12497850	0.931	rs9867373	chr3:48960938	A/T	cg06212747	chr3:49208901	KLHDC8B	0.68	9.34	0.5	3.96e-18	Parkinson's disease;
CESC	cis	rs1552244	0.935	rs41520445	chr3:10153141	A/C	cg08888203	chr3:10149979	C3orf24	-0.46	-6.07	-0.35	4.53e-9	Alzheimer's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19924025	chr1:65720054	NA	0.62	7.16	0.4	8.03e-12	Gut microbiome composition (summer);
CESC	cis	rs6860806	0.507	rs156322	chr5:131653925	C/T	cg24060327	chr5:131705240	SLC22A5	-0.73	-9.78	-0.51	1.77e-19	Breast cancer;
CESC	cis	rs1862618	0.525	rs2662016	chr5:56269047	A/G	cg22800045	chr5:56110881	MAP3K1	-0.66	-7.57	-0.42	6.14e-13	Initial pursuit acceleration;
CESC	cis	rs61925898	1	rs61925898	chr12:66779537	A/G	cg16791601	chr12:66731901	HELB	-0.68	-11.17	-0.57	5.34e-24	Basophil percentage of granulocytes;Basophil percentage of white cells;
CESC	cis	rs9868809	0.542	rs9873726	chr3:48712367	C/T	cg03060546	chr3:49711283	APEH	-0.63	-5.58	-0.32	5.98e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs1691799	0.899	rs1168315	chr12:66746694	A/G	cg16791601	chr12:66731901	HELB	-0.77	-13.71	-0.64	1.08e-32	White blood cell count (basophil);
CESC	cis	rs3806843	1.000	rs11167600	chr5:140174865	G/C	cg26395211	chr5:140044315	WDR55	-0.41	-5.18	-0.3	4.29e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs10504229	0.516	rs58244172	chr8:57987805	G/A	cg22535103	chr8:58192502	C8orf71	-0.47	-5.88	-0.34	1.24e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs35110281	0.659	rs11702544	chr21:45091861	C/T	cg04455712	chr21:45112962	RRP1B	0.47	7.35	0.41	2.53e-12	Mean corpuscular volume;
CESC	cis	rs2635047	0.811	rs12957869	chr18:44786869	C/G	cg24371990	chr18:44770781	NA	0.41	6.53	0.37	3.33e-10	Educational attainment;
CESC	cis	rs7512552	0.809	rs696618	chr1:150376139	T/G	cg15654264	chr1:150340011	RPRD2	0.39	5.13	0.3	5.65e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs9443645	0.869	rs9343848	chr6:79621101	C/T	cg05283184	chr6:79620031	NA	-0.43	-6.5	-0.37	3.95e-10	Intelligence (multi-trait analysis);
CESC	cis	rs35306767	0.855	rs12761180	chr10:872086	C/T	cg20503657	chr10:835505	NA	1.08	9.93	0.52	5.96e-20	Eosinophil percentage of granulocytes;
CESC	cis	rs9815354	1.000	rs28733681	chr3:41863444	C/A	cg03022575	chr3:42003672	ULK4	0.49	5.51	0.32	8.46e-8	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs10887741	0.690	rs12781358	chr10:89444367	C/T	cg13926569	chr10:89418898	PAPSS2	0.36	5.4	0.32	1.45e-7	Exercise (leisure time);
CESC	cis	rs2842992	0.789	rs4709376	chr6:160226337	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.74	8.81	0.48	1.73e-16	Age-related macular degeneration (geographic atrophy);
CESC	trans	rs459571	0.920	rs460154	chr9:136909309	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.55	-7.2	-0.4	6.13e-12	Platelet distribution width;
CESC	cis	rs1030877	0.515	rs1020064	chr2:105897740	T/G	cg02079111	chr2:105885981	TGFBRAP1	0.49	6.51	0.37	3.66e-10	Obesity-related traits;
CESC	cis	rs73001065	0.551	rs79954596	chr19:19548643	T/G	cg03709012	chr19:19516395	GATAD2A	1.0	8.08	0.44	2.3e-14	LDL cholesterol;
CESC	cis	rs9488822	0.702	rs6909746	chr6:116352750	C/T	cg05304507	chr6:116381966	FRK	0.25	6.54	0.37	3.07e-10	Cholesterol, total;LDL cholesterol;
CESC	cis	rs4722166	0.598	rs4722179	chr7:22803861	C/A	cg05472934	chr7:22766657	IL6	0.42	5.77	0.33	2.23e-8	Lung cancer;
CESC	cis	rs2991971	0.967	rs2275276	chr1:45973928	C/T	cg24296786	chr1:45957014	TESK2	0.66	9.13	0.49	1.8e-17	High light scatter reticulocyte count;
CESC	cis	rs7188697	0.922	rs7199856	chr16:58584772	A/C	cg21335942	chr16:58549945	SETD6	0.46	5.6	0.33	5.33e-8	QT interval;
CESC	cis	rs8067545	0.518	rs7222987	chr17:20055765	A/G	cg13482628	chr17:19912719	NA	0.41	5.43	0.32	1.25e-7	Schizophrenia;
CESC	cis	rs116095464	0.558	rs10052012	chr5:231908	T/C	cg10591111	chr5:226296	SDHA	-0.52	-6.37	-0.36	8.3e-10	Breast cancer;
CESC	cis	rs9309473	0.861	rs6546857	chr2:73837955	A/G	cg20560298	chr2:73613845	ALMS1	-0.49	-6.34	-0.36	9.96e-10	Metabolite levels;
CESC	cis	rs6580649	0.831	rs1635528	chr12:48395900	C/T	cg05342945	chr12:48394962	COL2A1	-0.52	-6.25	-0.36	1.65e-9	Lung cancer;
CESC	cis	rs9287719	0.967	rs2884233	chr2:10745303	G/A	cg00105475	chr2:10696890	NA	0.38	5.55	0.32	6.76e-8	Prostate cancer;
CESC	cis	rs5771242	0.769	rs4838865	chr22:50664612	A/G	cg08875078	chr22:50639485	SELO	0.62	7.05	0.4	1.58e-11	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00529053	chr6:158589440	GTF2H5;SERAC1	0.58	6.72	0.38	1.13e-10	Gut microbiome composition (summer);
CESC	trans	rs916888	0.821	rs199525	chr17:44847834	T/G	cg01341218	chr17:43662625	NA	0.92	10.78	0.55	1.08e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs9322193	0.923	rs9479494	chr6:150060244	A/G	cg09699651	chr6:150184138	LRP11	0.4	5.13	0.3	5.5e-7	Lung cancer;
CESC	cis	rs9837602	0.507	rs1059905	chr3:99516879	A/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.43	-7.04	-0.4	1.65e-11	Breast cancer;
CESC	cis	rs7665939	0.929	rs13353755	chr4:190100646	T/C	cg14840187	chr4:190284988	NA	-0.64	-6.6	-0.38	2.28e-10	Amyotrophic lateral sclerosis;
CESC	cis	rs7165102	1.000	rs352476	chr15:65805389	T/C	cg11441148	chr15:65824328	PTPLAD1	-0.31	-5.27	-0.31	2.8e-7	Mean corpuscular hemoglobin;
CESC	cis	rs875971	0.862	rs6959268	chr7:65812966	G/A	cg12463550	chr7:65579703	CRCP	-0.47	-6.08	-0.35	4.28e-9	Aortic root size;
CESC	cis	rs1048238	0.506	rs7525608	chr1:16141901	A/G	cg21385522	chr1:16154831	NA	0.44	5.63	0.33	4.69e-8	Systolic blood pressure;
CESC	cis	rs2228479	0.850	rs2238532	chr16:89863672	T/C	cg19635926	chr16:89946313	TCF25	0.67	5.05	0.3	8.42e-7	Skin colour saturation;
CESC	cis	rs5750830	0.649	rs5757663	chr22:39821319	T/C	cg05872129	chr22:39784769	NA	-0.82	-10.83	-0.55	6.99e-23	Intelligence (multi-trait analysis);
CESC	cis	rs6076065	0.594	rs6048755	chr20:23337233	A/G	cg11657817	chr20:23433608	CST11	0.4	6.02	0.35	5.91e-9	Facial morphology (factor 15, philtrum width);
CESC	cis	rs2921036	0.545	rs4840975	chr8:8363258	C/T	cg06636001	chr8:8085503	FLJ10661	-0.47	-5.19	-0.3	4.13e-7	Neuroticism;
CESC	cis	rs7542091	0.739	rs10863793	chr1:210037420	G/A	cg05527609	chr1:210001259	C1orf107	-0.45	-5.67	-0.33	3.75e-8	Monobrow;
CESC	cis	rs11690961	0.778	rs6724315	chr2:46363699	T/C	cg12428440	chr2:46370979	PRKCE	0.49	5.09	0.3	6.83e-7	Pulse pressure;
CESC	cis	rs2191566	1.000	rs2191566	chr19:44511389	A/C	cg20607764	chr19:44506953	ZNF230	0.57	7.39	0.41	1.95e-12	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs11122272	0.735	rs2749704	chr1:231526243	A/G	cg06096015	chr1:231504339	EGLN1	0.43	6.15	0.35	2.78e-9	Hemoglobin concentration;
CESC	cis	rs7916697	0.947	rs56238729	chr10:70001640	T/C	cg06988349	chr10:69991859	ATOH7	0.39	6.38	0.37	7.68e-10	Optic disc area;
CESC	trans	rs6089829	0.889	rs6122348	chr20:61663921	C/T	cg23505145	chr19:12996616	KLF1	0.52	6.74	0.38	1e-10	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs9894429	0.621	rs7502337	chr17:79588470	T/C	cg13777783	chr17:79615861	NA	-0.36	-5.99	-0.35	6.7e-9	Eye color traits;
CESC	cis	rs13191362	0.935	rs67889271	chr6:163045753	T/G	cg14584255	chr6:163149320	PACRG;PARK2	0.53	5.94	0.34	9.08e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs6570726	0.935	rs391524	chr6:145823844	A/G	cg05347473	chr6:146136440	FBXO30	0.49	6.71	0.38	1.2e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6831352	0.959	rs6848050	chr4:100053733	T/C	cg12011299	chr4:100065546	ADH4	0.69	8.57	0.47	8.82e-16	Alcohol dependence;
CESC	cis	rs853679	0.882	rs9468300	chr6:28126840	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.76	-6.55	-0.37	3.04e-10	Depression;
CESC	cis	rs9921222	0.521	rs78867928	chr16:368986	C/T	cg00101154	chr16:420108	MRPL28	-0.43	-5.06	-0.3	7.89e-7	Bone mineral density (spine);Bone mineral density;
CESC	cis	rs6089584	0.888	rs6061983	chr20:60621202	T/C	cg06108461	chr20:60628389	TAF4	-0.92	-14.55	-0.67	1.22e-35	Body mass index;
CESC	cis	rs4713118	0.621	rs9295755	chr6:28033174	C/T	cg20151795	chr6:28129481	ZNF389	-0.42	-5.34	-0.31	2e-7	Parkinson's disease;
CESC	trans	rs2727020	0.521	rs7131163	chr11:49574774	C/T	cg03929089	chr4:120376271	NA	-0.71	-8.18	-0.45	1.21e-14	Coronary artery disease;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg23207985	chr11:67034251	ADRBK1	-0.49	-6.97	-0.39	2.49e-11	Gambling;
CESC	cis	rs9457247	0.765	rs10484531	chr6:167454434	G/A	cg23791538	chr6:167370224	RNASET2	-0.55	-7.65	-0.43	3.82e-13	Crohn's disease;
CESC	cis	rs2404602	0.583	rs35707798	chr15:76565026	G/C	cg26408565	chr15:76604113	ETFA	-0.41	-6.01	-0.35	6.2e-9	Blood metabolite levels;
CESC	cis	rs1499972	0.668	rs4146338	chr3:117493964	C/T	cg07612923	chr3:117604196	NA	-0.64	-5.96	-0.34	8.13e-9	Schizophrenia;
CESC	cis	rs55823223	0.564	rs936391	chr17:73847799	A/G	cg23806715	chr17:73775811	H3F3B	-0.5	-5.76	-0.33	2.31e-8	Psoriasis;
CESC	cis	rs6942756	1.000	rs4440569	chr7:128923907	T/A	cg02491457	chr7:128862824	NA	-0.68	-9.03	-0.49	3.55e-17	White matter hyperintensity burden;
CESC	cis	rs1371867	0.846	rs1660329	chr8:101304048	G/T	cg11906718	chr8:101322791	RNF19A	0.54	6.93	0.39	3.24e-11	Atrioventricular conduction;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12736146	chr10:116391608	ABLIM1	-0.56	-6.73	-0.38	1.03e-10	Gut microbiome composition (summer);
CESC	cis	rs2463822	0.583	rs72919467	chr11:62040102	G/A	cg06239285	chr11:62104954	ASRGL1	-1.06	-8.65	-0.47	4.87e-16	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs6860806	0.661	rs6890009	chr5:131580033	G/T	cg12564285	chr5:131593104	PDLIM4	0.38	5.69	0.33	3.4e-8	Breast cancer;
CESC	cis	rs1832871	0.672	rs111782080	chr6:158765385	G/A	cg07165851	chr6:158734300	TULP4	0.58	6.18	0.36	2.36e-9	Height;
CESC	cis	rs7923609	0.846	rs10740116	chr10:65094992	T/C	cg01631684	chr10:65280961	REEP3	-0.42	-5.26	-0.31	3.04e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs72781680	1.000	rs72781649	chr2:24210864	A/G	cg20701182	chr2:24300061	SF3B14	0.63	5.58	0.32	6.04e-8	Lymphocyte counts;
CESC	cis	rs965469	1.000	rs6051753	chr20:3315513	G/A	cg25506879	chr20:3388711	C20orf194	-0.53	-5.8	-0.34	1.84e-8	IFN-related cytopenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09166705	chr1:151170883	PIP5K1A	0.53	6.05	0.35	4.91e-9	Gut microbiome composition (summer);
CESC	cis	rs1538970	0.962	rs9429077	chr1:45820667	C/A	cg06784218	chr1:46089804	CCDC17	0.31	5.15	0.3	5.19e-7	Platelet count;
CESC	cis	rs875971	0.545	rs6950988	chr7:65976415	C/T	cg11764359	chr7:65958608	NA	0.8	9.71	0.51	2.85e-19	Aortic root size;
CESC	cis	rs2932538	0.922	rs12739994	chr1:113131159	T/C	cg22162597	chr1:113214053	CAPZA1	0.6	6.99	0.39	2.26e-11	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CESC	cis	rs4853012	0.941	rs2421752	chr2:74341615	A/G	cg20891558	chr2:74357851	NA	0.76	10.0	0.52	3.55e-20	Gestational age at birth (maternal effect);
CESC	cis	rs2836974	0.897	rs8133146	chr21:40614298	T/C	cg11890956	chr21:40555474	PSMG1	1.15	21.07	0.79	1.46e-58	Cognitive function;
CESC	trans	rs72766638	0.806	rs56303154	chr9:136936376	C/T	cg10765909	chr12:53715428	AAAS	-0.7	-6.18	-0.35	2.37e-9	Mosquito bite size;
CESC	cis	rs6502050	0.830	rs8074436	chr17:80158422	A/G	cg23985595	chr17:80112537	CCDC57	-0.39	-6.24	-0.36	1.76e-9	Life satisfaction;
CESC	cis	rs12586317	0.547	rs2254990	chr14:35465565	T/C	cg05294307	chr14:35346193	BAZ1A	-0.51	-5.45	-0.32	1.16e-7	Psoriasis;
CESC	cis	rs9291683	0.588	rs4697705	chr4:10108127	G/A	cg00071950	chr4:10020882	SLC2A9	-0.55	-8.53	-0.46	1.17e-15	Bone mineral density;
CESC	cis	rs172166	0.637	rs1225592	chr6:28150242	G/A	cg17221315	chr6:27791827	HIST1H4J	0.44	5.78	0.33	2.06e-8	Cardiac Troponin-T levels;
CESC	cis	rs6502050	0.835	rs3935403	chr17:80114145	C/T	cg23985595	chr17:80112537	CCDC57	-0.42	-6.64	-0.38	1.72e-10	Life satisfaction;
CESC	cis	rs698833	0.962	rs786409	chr2:44731344	C/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.56	6.89	0.39	3.97e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs5769765	0.913	rs8135071	chr22:50299587	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.49	-5.54	-0.32	7.17e-8	Schizophrenia;
CESC	cis	rs6570726	0.935	rs406343	chr6:145874388	A/G	cg23711669	chr6:146136114	FBXO30	0.8	11.82	0.59	3.5e-26	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2425143	0.818	rs11700299	chr20:34548865	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.65	5.58	0.32	5.8e-8	Blood protein levels;
CESC	cis	rs4718428	0.672	rs12530806	chr7:66390724	A/G	cg25985355	chr7:65971099	NA	-0.34	-5.07	-0.3	7.49e-7	Corneal structure;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10557139	chr6:43507079	XPO5	-0.62	-7.48	-0.42	1.1e-12	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16248618	chr11:65819774	SF3B2	0.56	6.1	0.35	3.79e-9	Gut microbiome composition (summer);
CESC	cis	rs796364	0.664	rs3106089	chr2:200884615	A/C	cg23649088	chr2:200775458	C2orf69	0.6	5.41	0.32	1.43e-7	Schizophrenia;
CESC	cis	rs113835537	0.597	rs7939759	chr11:66337964	C/T	cg22134325	chr11:66188745	NPAS4	0.37	5.56	0.32	6.61e-8	Airway imaging phenotypes;
CESC	trans	rs11098499	0.954	rs6846442	chr4:120326323	G/A	cg25214090	chr10:38739885	LOC399744	0.7	9.92	0.52	6.5e-20	Corneal astigmatism;
CESC	cis	rs2777491	0.574	rs72739644	chr15:41719706	A/G	cg20272979	chr15:41787780	ITPKA	0.42	5.14	0.3	5.47e-7	Ulcerative colitis;
CESC	cis	rs7408868	1.000	rs10422818	chr19:15285272	A/G	cg14696996	chr19:15285081	NOTCH3	1.05	11.0	0.56	1.94e-23	Pulse pressure;
CESC	cis	rs1864400	0.696	rs2742239	chr10:43621712	A/G	cg07801480	chr10:43725741	RASGEF1A	0.4	5.2	0.3	4e-7	Hirschsprung disease;
CESC	cis	rs1799949	1.000	rs11656097	chr17:41290613	G/T	cg25072359	chr17:41440525	NA	0.43	5.83	0.34	1.61e-8	Menopause (age at onset);
CESC	cis	rs7208859	0.623	rs3794796	chr17:29130880	G/C	cg13385521	chr17:29058706	SUZ12P	0.84	6.62	0.38	1.98e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs1728785	1.000	rs4783656	chr16:68580722	C/T	cg02972257	chr16:68554789	NA	-0.55	-6.31	-0.36	1.17e-9	Ulcerative colitis;
CESC	cis	rs72634258	0.786	rs7537362	chr1:8177564	C/T	cg00042356	chr1:8021962	PARK7	0.57	6.04	0.35	5.32e-9	Inflammatory bowel disease;
CESC	cis	rs148803332	1	rs148803332	chr17:65958250	CAAAAGAAA/C	cg07042672	chr17:66097459	LOC651250	0.62	7.53	0.42	7.95e-13	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;
CESC	cis	rs3008870	1.000	rs12039172	chr1:67447450	A/G	cg02640540	chr1:67518911	SLC35D1	-0.52	-5.59	-0.33	5.5e-8	Lymphocyte percentage of white cells;
CESC	cis	rs6582630	0.555	rs11182429	chr12:38526679	A/C	cg13010199	chr12:38710504	ALG10B	0.45	5.97	0.34	7.47e-9	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs654950	0.806	rs2759251	chr1:42041749	C/G	cg06885757	chr1:42089581	HIVEP3	-0.64	-10.14	-0.53	1.22e-20	Airway imaging phenotypes;
CESC	cis	rs1862618	0.853	rs832582	chr5:56177743	G/A	cg12311346	chr5:56204834	C5orf35	-0.74	-8.85	-0.48	1.25e-16	Initial pursuit acceleration;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20564664	chr21:37432585	SETD4	0.59	6.33	0.36	1.05e-9	Gut microbiome composition (summer);
CESC	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg26338869	chr17:61819248	STRADA	0.68	8.89	0.48	9.5e-17	Prudent dietary pattern;
CESC	cis	rs801193	1.000	rs2707845	chr7:66198798	C/T	cg06456125	chr7:65229604	NA	0.4	5.23	0.31	3.51e-7	Aortic root size;
CESC	cis	rs4474465	0.646	rs6592794	chr11:78275743	A/G	cg27205649	chr11:78285834	NARS2	0.46	6.04	0.35	5.25e-9	Alzheimer's disease (survival time);
CESC	cis	rs12142240	0.738	rs17361749	chr1:46806480	C/T	cg10495392	chr1:46806563	NSUN4	0.59	6.36	0.36	8.9e-10	Menopause (age at onset);
CESC	cis	rs9354352	0.818	rs9453548	chr6:66691885	T/C	cg07460842	chr6:66804631	NA	-0.64	-9.24	-0.49	8.55e-18	Initial pursuit acceleration in psychotic disorders;
CESC	cis	rs1580019	0.713	rs2122632	chr7:32524686	A/G	cg07520158	chr7:32535189	LSM5;AVL9	-0.51	-6.36	-0.36	8.68e-10	Cognitive ability;
CESC	cis	rs10423674	0.526	rs2023878	chr19:18834124	A/G	cg14292368	chr19:18793705	CRTC1	0.4	5.12	0.3	5.76e-7	Menarche (age at onset);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04742505	chr7:72936528	BAZ1B	0.47	6.02	0.35	5.64e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs4253772	0.515	rs9615969	chr22:46773592	C/G	cg18190219	chr22:46762943	CELSR1	-0.67	-5.58	-0.32	6.05e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs2404602	0.692	rs35170561	chr15:77130695	C/T	cg26408565	chr15:76604113	ETFA	-0.37	-5.43	-0.32	1.26e-7	Blood metabolite levels;
CESC	cis	rs2276314	0.857	rs28791905	chr18:33602213	G/A	cg19628046	chr18:33552617	C18orf21	0.48	5.2	0.3	4.06e-7	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs2270431	1	rs2270431	chr14:75270635	T/C	cg11812906	chr14:75593930	NEK9	0.42	5.19	0.3	4.11e-7	Neuroticism;
CESC	cis	rs7917772	0.503	rs7904955	chr10:104367092	C/T	ch.10.2196322F	chr10:104248062	ACTR1A	0.47	5.48	0.32	9.73e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs2635047	0.512	rs9962436	chr18:44599109	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.52	7.53	0.42	7.88e-13	Educational attainment;
CESC	cis	rs7618915	0.532	rs13060675	chr3:52674300	T/G	cg17372223	chr3:52568218	NT5DC2	0.43	6.47	0.37	4.6e-10	Bipolar disorder;
CESC	cis	rs9790314	0.875	rs336580	chr3:161082982	A/T	cg04691961	chr3:161091175	C3orf57	-0.39	-5.08	-0.3	7.17e-7	Morning vs. evening chronotype;
CESC	trans	rs10028773	0.666	rs35231872	chr4:120248376	A/T	cg25214090	chr10:38739885	LOC399744	0.62	8.36	0.46	3.48e-15	Educational attainment;
CESC	cis	rs1355223	0.902	rs1453387	chr11:34707898	C/G	cg11058730	chr11:34937778	PDHX;APIP	-0.48	-6.43	-0.37	5.95e-10	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs2988277	0.737	rs1723015	chr1:167432894	T/C	cg09179987	chr1:167433047	CD247	0.46	6.99	0.39	2.19e-11	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs2011503	1.000	rs2965194	chr19:19460702	C/T	cg11584989	chr19:19387371	SF4	-0.65	-7.81	-0.43	1.35e-13	Bipolar disorder;
CESC	cis	rs7833986	0.501	rs2667999	chr8:56950474	T/C	cg26371346	chr8:56986568	SNORD54;RPS20	0.57	5.16	0.3	4.9e-7	Height;
CESC	trans	rs9325144	0.647	rs11168819	chr12:39011082	C/A	cg23762105	chr12:34175262	ALG10	0.48	6.41	0.37	6.45e-10	Morning vs. evening chronotype;
CESC	cis	rs7116495	0.609	rs2511120	chr11:71786211	C/T	cg18441811	chr11:71824068	C11orf51	-0.83	-5.18	-0.3	4.47e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs796364	0.951	rs7586320	chr2:201068209	C/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.61	5.71	0.33	3.07e-8	Schizophrenia;
CESC	trans	rs5756813	0.727	rs58765732	chr22:38160794	A/C	cg19894588	chr14:64061835	NA	-0.69	-8.63	-0.47	5.6e-16	Optic cup area;Vertical cup-disc ratio;
CESC	cis	rs11190604	1.000	rs2489040	chr10:102331298	G/A	cg07080220	chr10:102295463	HIF1AN	0.56	5.36	0.31	1.77e-7	Palmitoleic acid (16:1n-7) levels;
CESC	trans	rs17767392	0.748	rs55896578	chr14:71712185	G/A	cg23339363	chr7:44261644	CAMK2B	0.43	6.14	0.35	3.04e-9	Mitral valve prolapse;
CESC	cis	rs13108904	0.521	rs4974609	chr4:1356924	A/C	cg16405210	chr4:1374714	KIAA1530	0.44	5.47	0.32	1.06e-7	Obesity-related traits;
CESC	trans	rs2207136	0.835	rs3846904	chr6:50872761	C/T	cg06522515	chr3:184090630	THPO	-0.36	-6.24	-0.36	1.69e-9	Myopia;
CESC	cis	rs9287719	0.967	rs4669596	chr2:10720572	C/T	cg02196655	chr2:10830764	NOL10	-0.36	-5.63	-0.33	4.63e-8	Prostate cancer;
CESC	cis	rs9287719	0.967	rs4453662	chr2:10739128	G/A	cg02196655	chr2:10830764	NOL10	-0.37	-5.72	-0.33	2.87e-8	Prostate cancer;
CESC	cis	rs8017423	0.967	rs2277516	chr14:90722824	G/C	cg14092571	chr14:90743983	NA	-0.55	-8.31	-0.45	5.06e-15	Mortality in heart failure;
CESC	cis	rs11997175	0.646	rs12678266	chr8:33689254	A/G	ch.8.33884649F	chr8:33765107	NA	0.56	7.37	0.41	2.13e-12	Body mass index;
CESC	cis	rs7615952	0.576	rs2276726	chr3:125826287	C/G	cg06494592	chr3:125709126	NA	-0.51	-5.91	-0.34	1.07e-8	Blood pressure (smoking interaction);
CESC	cis	rs4589502	0.920	rs77518050	chr15:67138089	T/C	cg12317470	chr15:67143691	NA	0.68	5.32	0.31	2.18e-7	Lung cancer (smoking interaction);
CESC	cis	rs344364	0.511	rs2982453	chr16:1949520	G/A	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.55	-6.2	-0.36	2.15e-9	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs2839186	0.564	rs4819215	chr21:47623573	G/A	cg12379764	chr21:47803548	PCNT	-0.46	-5.86	-0.34	1.39e-8	Testicular germ cell tumor;
CESC	cis	rs3916	0.641	rs7964786	chr12:121132100	C/T	cg26008908	chr12:120799332	MSI1	0.38	6.11	0.35	3.5e-9	Urinary metabolites (H-NMR features);
CESC	cis	rs748404	0.534	rs489509	chr15:43586907	T/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.61	7.8	0.43	1.4e-13	Lung cancer;
CESC	cis	rs597539	0.652	rs627731	chr11:68698663	A/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.79	9.8	0.52	1.52e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs4803468	1.000	rs2288871	chr19:41917868	C/T	cg14132834	chr19:41945861	ATP5SL	-0.58	-7.23	-0.41	5.22e-12	Height;
CESC	cis	rs1215050	0.874	rs2167893	chr4:99048464	A/T	cg05340658	chr4:99064831	C4orf37	0.55	6.81	0.39	6.48e-11	Waist-to-hip ratio adjusted for body mass index;
CESC	trans	rs2727020	0.681	rs1976901	chr11:49378697	T/C	cg15704280	chr7:45808275	SEPT13	-0.87	-14.47	-0.66	2.28e-35	Coronary artery disease;
CESC	cis	rs7927771	0.826	rs2293578	chr11:47437403	C/T	cg20307385	chr11:47447363	PSMC3	-0.64	-7.63	-0.42	4.21e-13	Subjective well-being;
CESC	trans	rs12356475	0.710	rs10822686	chr10:67733250	C/T	cg08259472	chr6:43603507	MAD2L1BP	0.49	6.02	0.35	5.65e-9	Psoriatic arthritis;
CESC	cis	rs5753618	0.555	rs5749286	chr22:31900359	G/T	cg00478049	chr22:31556069	RNF185	-0.46	-5.53	-0.32	7.68e-8	Colorectal cancer;
CESC	cis	rs853679	0.517	rs3757187	chr6:28107654	T/C	cg26335602	chr6:28129616	ZNF389	0.54	7.25	0.41	4.45e-12	Depression;
CESC	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg26338869	chr17:61819248	STRADA	0.68	8.94	0.48	6.9e-17	Prudent dietary pattern;
CESC	cis	rs270601	0.739	rs3900945	chr5:131592870	T/C	cg12564285	chr5:131593104	PDLIM4	0.41	6.39	0.37	7.3e-10	Acylcarnitine levels;
CESC	cis	rs853679	1.000	rs68141011	chr6:28217797	G/T	cg12740337	chr6:28058973	ZSCAN12L1	0.32	5.03	0.3	9.18e-7	Depression;
CESC	cis	rs2425143	1.000	rs6060591	chr20:34351476	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.72	6.82	0.39	6.12e-11	Blood protein levels;
CESC	cis	rs2576037	0.526	rs2156050	chr18:44455873	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.72	11.53	0.58	3.49e-25	Personality dimensions;
CESC	cis	rs12893668	0.667	rs71417869	chr14:104077434	A/G	cg08213375	chr14:104286397	PPP1R13B	0.33	5.21	0.3	3.76e-7	Reticulocyte count;
CESC	trans	rs1814175	0.817	rs7924619	chr11:49620632	G/A	cg15704280	chr7:45808275	SEPT13	-1.01	-19.21	-0.76	3.92e-52	Height;
CESC	cis	rs7772486	0.754	rs9497434	chr6:146260753	C/T	cg23711669	chr6:146136114	FBXO30	-0.94	-13.66	-0.64	1.66e-32	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9393777	0.513	rs9379905	chr6:26630990	G/A	cg14345882	chr6:26364793	BTN3A2	0.41	5.35	0.31	1.94e-7	Intelligence (multi-trait analysis);
CESC	cis	rs763121	0.853	rs5750633	chr22:38993467	A/G	cg21395723	chr22:39101663	GTPBP1	0.51	6.82	0.39	6.01e-11	Menopause (age at onset);
CESC	trans	rs7726839	0.540	rs72705102	chr5:659437	T/C	cg25482853	chr8:67687455	SGK3	1.02	10.32	0.54	3.29e-21	Obesity-related traits;
CESC	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg22907277	chr7:1156413	C7orf50	0.39	5.66	0.33	3.92e-8	Longevity;Endometriosis;
CESC	cis	rs7568458	0.709	rs2043675	chr2:85769975	C/T	cg02493740	chr2:85810744	VAMP5	0.55	8.12	0.45	1.8e-14	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CESC	cis	rs9486719	0.843	rs2472876	chr6:96845723	A/G	cg18709589	chr6:96969512	KIAA0776	0.55	5.64	0.33	4.26e-8	Migraine;Coronary artery disease;
CESC	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg07507251	chr3:52567010	NT5DC2	0.45	8.52	0.46	1.19e-15	Electroencephalogram traits;
CESC	cis	rs4689388	0.926	rs4689391	chr4:6280449	G/A	cg25554036	chr4:6271136	WFS1	0.56	9.36	0.5	3.62e-18	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs6424115	0.708	rs2076343	chr1:24129126	A/G	cg15997130	chr1:24165203	NA	-0.44	-5.39	-0.31	1.57e-7	Immature fraction of reticulocytes;
CESC	trans	rs7839040	0.698	rs1507096	chr8:82927443	C/T	cg14472086	chr9:107730925	NA	-0.47	-6.33	-0.36	1.02e-9	Response to methotrexate in juvenile idiopathic arthritis;
CESC	cis	rs425277	0.583	rs12059660	chr1:2041461	C/T	cg16545954	chr1:2118288	C1orf86	-0.31	-5.86	-0.34	1.34e-8	Height;
CESC	cis	rs35306767	0.761	rs12771539	chr10:1050653	A/G	cg26597838	chr10:835615	NA	0.7	6.53	0.37	3.31e-10	Eosinophil percentage of granulocytes;
CESC	cis	rs769267	0.965	rs10419245	chr19:19383755	G/A	cg03709012	chr19:19516395	GATAD2A	0.96	14.14	0.66	3.35e-34	Tonsillectomy;
CESC	cis	rs6456156	0.586	rs1358883	chr6:167467433	C/G	cg23791538	chr6:167370224	RNASET2	0.52	6.71	0.38	1.16e-10	Primary biliary cholangitis;
CESC	cis	rs6460942	0.597	rs35317839	chr7:12524397	C/A	cg06484146	chr7:12443880	VWDE	-0.71	-7.69	-0.43	2.88e-13	Coronary artery disease;
CESC	cis	rs6693567	0.545	rs9436009	chr1:150459426	T/A	cg09579323	chr1:150459698	TARS2	0.48	5.88	0.34	1.21e-8	Migraine;
CESC	cis	rs2439831	0.867	rs2245715	chr15:43818052	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.77	8.39	0.46	3.02e-15	Lung cancer in ever smokers;
CESC	cis	rs12822507	0.732	rs10845596	chr12:12780390	T/C	cg11838227	chr12:12764436	CREBL2	0.42	5.63	0.33	4.59e-8	Systemic lupus erythematosus;
CESC	cis	rs11098499	1.000	rs58601355	chr4:120186367	T/C	cg09307838	chr4:120376055	NA	0.89	11.77	0.59	5.26e-26	Corneal astigmatism;
CESC	cis	rs765787	0.530	rs11636404	chr15:45535861	C/G	cg24006582	chr15:45444508	DUOX1	-0.55	-6.82	-0.39	6.05e-11	Uric acid levels;
CESC	cis	rs926938	0.527	rs360594	chr1:115472401	G/A	cg12756093	chr1:115239321	AMPD1	0.45	6.18	0.35	2.44e-9	Autism;
CESC	cis	rs4665809	0.838	rs6546749	chr2:26306288	T/C	cg04944784	chr2:26401820	FAM59B	-0.8	-8.93	-0.48	7.17e-17	Gut microbiome composition (summer);
CESC	cis	rs2742234	0.955	rs2503841	chr10:43675721	C/T	cg15436174	chr10:43711423	RASGEF1A	-0.39	-5.1	-0.3	6.62e-7	Hirschsprung disease;
CESC	cis	rs9733	0.628	rs11807409	chr1:150683423	C/T	cg18016565	chr1:150552671	MCL1	0.35	5.36	0.31	1.86e-7	Tonsillectomy;
CESC	cis	rs7552404	0.731	rs11588578	chr1:76400539	T/G	cg10523679	chr1:76189770	ACADM	0.55	5.33	0.31	2.13e-7	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs3820068	0.581	rs72645864	chr1:15921153	C/T	cg13390004	chr1:15929781	NA	0.33	5.04	0.3	8.45e-7	Systolic blood pressure;
CESC	cis	rs9894429	1.000	rs7223613	chr17:79574803	C/T	cg21984481	chr17:79567631	NPLOC4	0.49	8.04	0.44	2.97e-14	Eye color traits;
CESC	cis	rs10089	1.000	rs10061367	chr5:127449021	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.78	10.85	0.55	6.27e-23	Ileal carcinoids;
CESC	cis	rs875971	0.928	rs2036263	chr7:65800197	C/T	cg18876405	chr7:65276391	NA	-0.51	-7.03	-0.4	1.8e-11	Aortic root size;
CESC	cis	rs7666738	0.715	rs116787789	chr4:98718720	G/A	cg17366294	chr4:99064904	C4orf37	0.57	7.94	0.44	5.82e-14	Colonoscopy-negative controls vs population controls;
CESC	trans	rs9329221	0.935	rs3750311	chr8:10283602	C/A	cg17143192	chr8:8559678	CLDN23	-0.56	-6.3	-0.36	1.2e-9	Neuroticism;
CESC	cis	rs2880765	0.805	rs34598679	chr15:86042205	G/A	cg19183879	chr15:85880815	NA	-0.26	-5.38	-0.31	1.67e-7	Coronary artery disease;
CESC	cis	rs61931739	0.500	rs34997501	chr12:34549828	C/G	cg19457237	chr12:34500585	NA	-0.37	-5.08	-0.3	6.97e-7	Morning vs. evening chronotype;
CESC	cis	rs12926788	0.542	rs11862971	chr16:24767574	C/A	cg04756594	chr16:24857601	SLC5A11	0.45	5.52	0.32	8.21e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs7829975	0.846	rs1879957	chr8:8544808	T/C	cg06636001	chr8:8085503	FLJ10661	-0.49	-6.54	-0.37	3.11e-10	Mood instability;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01281426	chr5:180618016	NA	-0.75	-9.07	-0.49	2.81e-17	Gut microbiome composition (summer);
CESC	cis	rs6087771	0.851	rs6087775	chr20:30325765	G/A	cg13852791	chr20:30311386	BCL2L1	0.81	10.36	0.54	2.4e-21	Subcortical brain region volumes;Putamen volume;
CESC	cis	rs6754311	0.731	rs12988076	chr2:136569848	C/A	cg07169764	chr2:136633963	MCM6	-0.66	-7.98	-0.44	4.39e-14	Mosquito bite size;
CESC	cis	rs17431357	1.000	rs73221381	chr12:120913895	G/A	cg25045489	chr12:120971538	RNF10	-0.93	-5.46	-0.32	1.1e-7	Insulin resistance/response;
CESC	cis	rs9372253	1.000	rs9384740	chr6:110716207	G/A	cg19196401	chr6:110721138	DDO	-0.39	-5.65	-0.33	4.06e-8	Platelet distribution width;
CESC	cis	rs7165102	1.000	rs2456009	chr15:65840082	C/A	cg11441148	chr15:65824328	PTPLAD1	-0.32	-5.39	-0.31	1.54e-7	Mean corpuscular hemoglobin;
CESC	cis	rs2075371	0.933	rs1421481	chr7:133964380	A/C	cg11752832	chr7:134001865	SLC35B4	0.52	6.69	0.38	1.33e-10	Mean platelet volume;
CESC	cis	rs870825	0.860	rs72703526	chr4:185605676	A/T	cg04058563	chr4:185651563	MLF1IP	0.54	5.24	0.31	3.27e-7	Blood protein levels;
CESC	cis	rs2637266	1.000	rs12774835	chr10:78352226	C/G	cg18941641	chr10:78392320	NA	0.42	7.79	0.43	1.49e-13	Pulmonary function;
CESC	cis	rs1483890	0.642	rs1843049	chr3:69404078	T/C	cg22125112	chr3:69402811	FRMD4B	0.39	5.34	0.31	1.98e-7	Resting heart rate;
CESC	cis	rs6088580	0.634	rs1205334	chr20:32930369	T/C	cg06115741	chr20:33292138	TP53INP2	-0.45	-5.72	-0.33	2.87e-8	Glomerular filtration rate (creatinine);
CESC	trans	rs561341	1.000	rs111454793	chr17:30319267	T/C	cg27661571	chr11:113659931	NA	-0.83	-7.7	-0.43	2.79e-13	Hip circumference adjusted for BMI;
CESC	cis	rs963731	0.649	rs77498284	chr2:39349726	C/A	cg04010122	chr2:39346883	SOS1	0.73	5.17	0.3	4.6e-7	Corticobasal degeneration;
CESC	cis	rs889312	0.500	rs185219	chr5:56136492	A/G	cg14703610	chr5:56206110	C5orf35	0.5	6.63	0.38	1.84e-10	Breast cancer;Breast cancer (early onset);
CESC	cis	rs9649465	0.561	rs2429621	chr7:123430316	A/G	cg03229431	chr7:123269106	ASB15	0.4	5.52	0.32	8.08e-8	Migraine;
CESC	cis	rs11190604	1.000	rs2489049	chr10:102350732	G/A	cg07080220	chr10:102295463	HIF1AN	0.54	5.34	0.31	2.03e-7	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs524281	0.692	rs2452681	chr11:65814842	G/A	cg14036092	chr11:66035641	RAB1B	0.43	5.07	0.3	7.33e-7	Electroencephalogram traits;
CESC	trans	rs10411161	0.702	rs11879319	chr19:52389592	C/T	cg22319618	chr22:45562946	NUP50	-0.7	-7.06	-0.4	1.47e-11	Breast cancer;
CESC	cis	rs3858526	0.959	rs11039699	chr11:5951091	G/A	cg02574844	chr11:5959923	NA	-0.44	-5.53	-0.32	7.81e-8	DNA methylation (variation);
CESC	cis	rs2985684	0.894	rs2281837	chr14:50065359	C/G	cg02151108	chr14:50098012	C14orf104	-0.38	-5.04	-0.3	8.58e-7	Carotid intima media thickness;
CESC	cis	rs7772486	0.905	rs9373486	chr6:146446024	C/G	cg05347473	chr6:146136440	FBXO30	-0.48	-6.22	-0.36	1.88e-9	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs929354	1.000	rs1182377	chr7:157048403	T/C	cg05182265	chr7:156933206	UBE3C	0.44	6.06	0.35	4.69e-9	Body mass index;
CESC	trans	rs6677604	1.000	rs35253683	chr1:196704039	G/A	cg02859443	chr16:53737878	RPGRIP1L;FTO	-0.65	-6.2	-0.36	2.21e-9	IgA nephropathy;Nephropathy;Blood protein levels;
CESC	cis	rs2072732	0.904	rs2981857	chr1:2971521	T/C	cg15211996	chr1:2936768	ACTRT2	0.33	5.98	0.34	7.26e-9	Plateletcrit;
CESC	cis	rs1950626	0.623	rs66722144	chr14:101457434	C/T	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.67	8.97	0.48	5.38e-17	Pelvic organ prolapse (moderate/severe);
CESC	cis	rs1552244	1.000	rs7652935	chr3:10151138	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	12.27	0.6	1.07e-27	Alzheimer's disease;
CESC	cis	rs9911578	1.000	rs999431	chr17:56854441	A/G	cg05425664	chr17:57184151	TRIM37	-0.47	-6.5	-0.37	4.06e-10	Intelligence (multi-trait analysis);
CESC	cis	rs9649465	0.935	rs7780086	chr7:123378471	C/A	cg04330084	chr7:123175371	IQUB	-0.38	-5.18	-0.3	4.46e-7	Migraine;
CESC	cis	rs1292059	1	rs1292059	chr17:57957888	T/A	cg13753209	chr17:57696993	CLTC	0.54	5.83	0.34	1.59e-8	Eosinophil percentage of granulocytes;
CESC	cis	rs1915919	0.794	rs12488378	chr3:20022495	C/G	cg05072819	chr3:20081367	KAT2B	0.44	6.3	0.36	1.21e-9	Post-traumatic stress disorder;
CESC	cis	rs8016982	0.674	rs1951615	chr14:81671762	G/A	cg01989461	chr14:81687754	GTF2A1	0.74	11.57	0.58	2.49e-25	Schizophrenia;
CESC	cis	rs4665809	0.567	rs12999875	chr2:26414847	A/C	cg08470875	chr2:26401718	FAM59B	0.74	7.93	0.44	6.22e-14	Gut microbiome composition (summer);
CESC	trans	rs61931739	0.892	rs73309466	chr12:34093146	A/G	cg26384229	chr12:38710491	ALG10B	-0.47	-6.56	-0.37	2.76e-10	Morning vs. evening chronotype;
CESC	cis	rs10540	1.000	rs35898083	chr11:484469	C/T	cg03576123	chr11:487126	PTDSS2	-1.08	-11.26	-0.57	2.77e-24	Body mass index;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02738677	chr3:133265129	NA	-0.72	-8.4	-0.46	2.67e-15	Gut microbiome composition (summer);
CESC	cis	rs1799949	1.000	rs2292595	chr17:41290674	G/C	cg25072359	chr17:41440525	NA	0.43	5.83	0.34	1.61e-8	Menopause (age at onset);
CESC	cis	rs17401966	1.000	rs17410793	chr1:10391886	A/G	cg15208524	chr1:10270712	KIF1B	0.49	6.25	0.36	1.65e-9	Hepatocellular carcinoma;
CESC	trans	rs9693444	0.898	rs4732697	chr8:29519861	A/G	cg19624444	chr7:2048497	MAD1L1	0.34	6.02	0.35	5.77e-9	Breast cancer;
CESC	cis	rs7927771	0.524	rs10838775	chr11:47856382	C/G	cg20307385	chr11:47447363	PSMC3	0.62	8.68	0.47	4.02e-16	Subjective well-being;
CESC	cis	rs631288	0.793	rs6667498	chr1:146708029	C/G	cg25205988	chr1:146714368	CHD1L	-0.86	-5.13	-0.3	5.58e-7	PR interval in Tripanosoma cruzi seropositivity;
CESC	cis	rs4523957	0.614	rs7212964	chr17:2059319	C/T	cg16513277	chr17:2031491	SMG6	-0.72	-10.2	-0.53	8.12e-21	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs7584330	0.780	rs7582828	chr2:238378476	A/C	cg14458575	chr2:238380390	NA	-0.69	-10.11	-0.53	1.57e-20	Prostate cancer;
CESC	trans	rs1814175	0.645	rs1851845	chr11:49982396	C/T	cg15704280	chr7:45808275	SEPT13	-1.01	-19.02	-0.76	1.83e-51	Height;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg01148786	chr3:97540262	NA	0.45	6.06	0.35	4.63e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs3857067	0.806	rs4693001	chr4:95115097	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.6	-9.12	-0.49	1.97e-17	QT interval;
CESC	cis	rs9325144	0.555	rs4882359	chr12:38726679	T/C	cg26384229	chr12:38710491	ALG10B	0.56	7.99	0.44	4.24e-14	Morning vs. evening chronotype;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg08680260	chr22:31298152	OSBP2	0.42	6.4	0.37	6.88e-10	Gambling;
CESC	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg05552183	chr6:42928497	GNMT	0.83	14.06	0.65	6.26e-34	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs6460942	0.908	rs77894875	chr7:12248257	T/C	cg20607287	chr7:12443886	VWDE	-0.64	-6.37	-0.36	8.3e-10	Coronary artery disease;
CESC	cis	rs17376456	0.778	rs10440717	chr5:93424852	C/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.61	5.33	0.31	2.12e-7	Diabetic retinopathy;
CESC	cis	rs6736093	0.966	rs74182850	chr2:112681337	C/T	cg12686935	chr2:112915763	FBLN7	-0.43	-5.56	-0.32	6.75e-8	Coronary artery disease;
CESC	cis	rs42648	0.902	rs17874789	chr7:90001160	A/T	cg23697855	chr7:89950296	NA	-0.28	-5.38	-0.31	1.66e-7	Homocysteine levels;
CESC	cis	rs17253792	0.822	rs77250916	chr14:56042208	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.84	5.73	0.33	2.76e-8	Putamen volume;
CESC	trans	rs3942852	0.955	rs6485809	chr11:48112468	C/T	cg03929089	chr4:120376271	NA	-0.58	-6.12	-0.35	3.43e-9	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs7666738	1.000	rs880471	chr4:98922541	C/T	cg05340658	chr4:99064831	C4orf37	0.65	8.54	0.46	1.04e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs72781680	0.846	rs55770503	chr2:24030126	A/T	cg20701182	chr2:24300061	SF3B14	0.63	5.65	0.33	4.21e-8	Lymphocyte counts;
CESC	trans	rs11098499	0.866	rs12513310	chr4:120288039	T/A	cg25214090	chr10:38739885	LOC399744	0.65	9.11	0.49	2.04e-17	Corneal astigmatism;
CESC	cis	rs12142240	0.667	rs55887761	chr1:46826587	C/A	cg00530320	chr1:46809349	NSUN4	0.6	8.04	0.44	2.96e-14	Menopause (age at onset);
CESC	cis	rs7666738	0.830	rs4699594	chr4:98980775	T/C	cg05340658	chr4:99064831	C4orf37	0.79	12.32	0.6	7.31e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs71277158	0.624	rs61493476	chr3:169887831	C/A	cg04067573	chr3:169899625	PHC3	0.7	6.85	0.39	5.01e-11	Prostate cancer;
CESC	cis	rs4819052	0.565	rs35776291	chr21:46706142	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.85	12.73	0.62	2.85e-29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs9467711	0.606	rs2073529	chr6:26375159	C/T	cg12826209	chr6:26865740	GUSBL1	-0.67	-5.29	-0.31	2.59e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs2486288	0.656	rs12440356	chr15:45567529	T/C	cg09092052	chr15:45571596	NA	-0.51	-5.92	-0.34	9.94e-9	Glomerular filtration rate;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg14455541	chr20:49203350	FAM65C	0.46	6.35	0.36	9.17e-10	Fibrinogen levels;
CESC	cis	rs228437	0.913	rs73554512	chr6:134941513	G/A	cg24504307	chr6:134963096	NA	-0.57	-6.06	-0.35	4.76e-9	Melanoma;
CESC	cis	rs56235845	0.694	rs6876677	chr5:176755342	T/C	cg06060754	chr5:176797920	RGS14	0.44	5.63	0.33	4.68e-8	Hemoglobin concentration;Hematocrit;
CESC	cis	rs1707322	1.000	rs1707303	chr1:46598273	A/C	cg06784218	chr1:46089804	CCDC17	-0.36	-5.83	-0.34	1.61e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs6952808	0.743	rs4719308	chr7:1877502	T/G	cg04267008	chr7:1944627	MAD1L1	-0.5	-5.86	-0.34	1.34e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs826838	0.586	rs10880753	chr12:38628147	C/A	cg26384229	chr12:38710491	ALG10B	-0.44	-5.93	-0.34	9.67e-9	Heart rate;
CESC	cis	rs7551222	0.749	rs6682208	chr1:204566183	T/C	cg20240347	chr1:204465584	NA	-0.26	-5.39	-0.31	1.57e-7	Schizophrenia;
CESC	cis	rs9926296	0.744	rs6860	chr16:89711120	C/T	cg01097406	chr16:89675127	NA	0.37	5.28	0.31	2.69e-7	Vitiligo;
CESC	cis	rs7267979	0.932	rs372678	chr20:25465248	G/A	cg08601574	chr20:25228251	PYGB	0.36	5.28	0.31	2.76e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs28386778	0.769	rs6504179	chr17:61812995	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.05	18.47	0.75	1.61e-49	Prudent dietary pattern;
CESC	cis	rs76878669	0.561	rs12420203	chr11:66163794	T/C	cg18002602	chr11:66138449	SLC29A2	0.39	6.41	0.37	6.45e-10	Educational attainment (years of education);
CESC	cis	rs736408	0.609	rs13082208	chr3:52781539	T/G	cg18099408	chr3:52552593	STAB1	-0.33	-5.47	-0.32	1.02e-7	Bipolar disorder;
CESC	cis	rs4242434	0.927	rs11778693	chr8:22462852	T/C	cg03733263	chr8:22462867	KIAA1967	0.95	15.08	0.68	1.64e-37	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CESC	cis	rs6032067	0.929	rs13039108	chr20:43829584	T/C	cg10761708	chr20:43804764	PI3	0.52	6.3	0.36	1.27e-9	Blood protein levels;
CESC	cis	rs875971	0.540	rs781152	chr7:65479572	T/A	cg26939375	chr7:64535504	NA	0.71	9.75	0.51	2.13e-19	Aortic root size;
CESC	cis	rs459571	0.920	rs460154	chr9:136909309	C/T	cg13789015	chr9:136890014	NCRNA00094	0.51	7.4	0.41	1.86e-12	Platelet distribution width;
CESC	cis	rs4974559	0.739	rs28444605	chr4:1290281	C/A	cg02980000	chr4:1222292	CTBP1	0.81	7.39	0.41	1.88e-12	Systolic blood pressure;
CESC	trans	rs6084875	0.686	rs2065035	chr20:4718398	C/T	cg10192164	chr16:30419175	ZNF771	-0.5	-6.07	-0.35	4.38e-9	Systemic lupus erythematosus;
CESC	cis	rs896854	0.846	rs13254283	chr8:95914103	G/T	cg16049864	chr8:95962084	TP53INP1	-0.68	-12.13	-0.6	3.14e-27	Type 2 diabetes;
CESC	cis	rs4889855	0.530	rs8079792	chr17:78609394	A/G	cg16591659	chr17:78472290	NA	-0.34	-5.49	-0.32	9.53e-8	Fractional excretion of uric acid;
CESC	cis	rs34779708	0.931	rs13377158	chr10:35370465	A/C	cg04310649	chr10:35416472	CREM	0.52	6.5	0.37	3.96e-10	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs7772486	0.875	rs1331645	chr6:146398407	C/G	cg05347473	chr6:146136440	FBXO30	0.48	6.5	0.37	4.01e-10	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs561341	0.941	rs8066156	chr17:30361629	A/G	cg27661571	chr11:113659931	NA	-0.61	-6.43	-0.37	5.84e-10	Hip circumference adjusted for BMI;
CESC	cis	rs17490626	0.533	rs5030925	chr10:71211150	A/C	cg12610070	chr10:71211762	TSPAN15	-0.32	-6.87	-0.39	4.44e-11	Thrombosis;
CESC	cis	rs73071352	0.588	rs55744136	chr3:41812293	A/C	cg03022575	chr3:42003672	ULK4	0.7	6.17	0.35	2.5e-9	Multiple myeloma and monoclonal gammopathy;Multiple myeloma;
CESC	cis	rs459571	0.959	rs456205	chr9:136911146	G/A	cg13789015	chr9:136890014	NCRNA00094	0.57	8.06	0.44	2.59e-14	Platelet distribution width;
CESC	cis	rs514406	0.607	rs1930305	chr1:53195481	G/T	cg16325326	chr1:53192061	ZYG11B	-1.01	-17.88	-0.74	1.89e-47	Monocyte count;
CESC	cis	rs780096	0.506	rs780100	chr2:27652153	G/T	cg12648201	chr2:27665141	KRTCAP3	-0.35	-6.54	-0.37	3.08e-10	Total body bone mineral density;
CESC	cis	rs11792861	0.816	rs72607157	chr9:111748001	T/G	cg05043794	chr9:111880884	C9orf5	-0.37	-5.93	-0.34	9.17e-9	Menarche (age at onset);
CESC	cis	rs5753618	0.583	rs738657	chr22:31841749	T/A	cg02404636	chr22:31891804	SFI1	0.43	6.01	0.35	6.08e-9	Colorectal cancer;
CESC	cis	rs116095464	0.558	rs7725227	chr5:233517	G/A	cg22496380	chr5:211416	CCDC127	-0.75	-8.74	-0.47	2.64e-16	Breast cancer;
CESC	cis	rs17376456	0.825	rs6874766	chr5:93213807	C/G	cg25358565	chr5:93447407	FAM172A	-1.11	-10.19	-0.53	8.9e-21	Diabetic retinopathy;
CESC	cis	rs9733	0.744	rs12125650	chr1:150760174	A/G	cg13175981	chr1:150552382	MCL1	0.52	7.24	0.41	4.84e-12	Tonsillectomy;
CESC	cis	rs7772486	0.686	rs1292337	chr6:145967807	A/G	cg23711669	chr6:146136114	FBXO30	-0.88	-13.04	-0.63	2.31e-30	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs34779708	0.897	rs12830	chr10:35302705	C/T	cg04310649	chr10:35416472	CREM	-0.5	-5.99	-0.35	6.73e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs11098499	0.954	rs6838814	chr4:120392443	G/A	cg24375607	chr4:120327624	NA	0.45	5.59	0.32	5.56e-8	Corneal astigmatism;
CESC	cis	rs2243480	1.000	rs4718270	chr7:65202407	A/G	cg18252515	chr7:66147081	NA	-1.21	-11.36	-0.57	1.22e-24	Diabetic kidney disease;
CESC	cis	rs116095464	0.558	rs6866632	chr5:264429	C/G	cg10591111	chr5:226296	SDHA	-0.47	-5.16	-0.3	4.9e-7	Breast cancer;
CESC	cis	rs910316	0.967	rs4899545	chr14:75568138	A/G	cg11812906	chr14:75593930	NEK9	0.91	15.59	0.69	2.58e-39	Height;
CESC	cis	rs6460942	0.915	rs62447638	chr7:12484667	G/A	cg06484146	chr7:12443880	VWDE	-0.76	-8.5	-0.46	1.38e-15	Coronary artery disease;
CESC	cis	rs919433	0.889	rs787995	chr2:198216853	T/G	cg20885578	chr2:198174922	NA	0.4	5.42	0.32	1.31e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs78456975	1.000	rs72778004	chr2:1571892	T/A	cg26248373	chr2:1572462	NA	-0.55	-5.23	-0.31	3.51e-7	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs6831352	0.703	rs3133152	chr4:100031721	C/G	cg12011299	chr4:100065546	ADH4	0.57	6.88	0.39	4.34e-11	Alcohol dependence;
CESC	cis	rs17376456	1.000	rs13181660	chr5:93533658	A/G	cg25358565	chr5:93447407	FAM172A	1.13	11.09	0.56	9.68e-24	Diabetic retinopathy;
CESC	trans	rs208520	0.955	rs12202599	chr6:67001573	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.77	8.7	0.47	3.56e-16	Exhaled nitric oxide output;
CESC	cis	rs72945132	0.709	rs28634008	chr11:70225719	A/C	cg00319359	chr11:70116639	PPFIA1	0.71	6.52	0.37	3.46e-10	Coronary artery disease;
CESC	cis	rs1348850	0.598	rs12616259	chr2:178503803	C/T	cg23306229	chr2:178417860	TTC30B	0.58	7.32	0.41	3.02e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs6831352	1.000	rs1126671	chr4:100048414	T/C	cg13256891	chr4:100009986	ADH5	0.72	8.45	0.46	1.94e-15	Alcohol dependence;
CESC	cis	rs28498503	1.000	rs7243231	chr18:76658728	C/T	cg00806245	chr18:76673096	NA	-0.7	-5.6	-0.33	5.46e-8	Attention function in attention deficit hyperactive disorder;
CESC	cis	rs2050392	1.000	rs2250714	chr10:30697396	G/C	cg18806716	chr10:30721971	MAP3K8	-0.42	-6.16	-0.35	2.62e-9	Inflammatory bowel disease;
CESC	cis	rs1005277	0.522	rs7090858	chr10:38003670	A/C	cg25427524	chr10:38739819	LOC399744	0.65	9.46	0.5	1.72e-18	Extrinsic epigenetic age acceleration;
CESC	cis	rs2841277	0.708	rs10083490	chr14:105402418	A/G	cg21017887	chr14:105400489	NA	-0.43	-7.07	-0.4	1.36e-11	Rheumatoid arthritis;
CESC	cis	rs13082711	0.554	rs73055750	chr3:27401505	C/G	cg02860705	chr3:27208620	NA	0.74	8.35	0.46	3.88e-15	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CESC	cis	rs3617	0.539	rs9880619	chr3:52953055	G/A	cg17372223	chr3:52568218	NT5DC2	-0.37	-5.15	-0.3	5.2e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
CESC	trans	rs11165623	0.792	rs1931180	chr1:96914049	C/T	cg10631902	chr5:14652156	NA	-0.57	-8.53	-0.46	1.11e-15	Hip circumference;Waist circumference;
CESC	cis	rs11690935	0.550	rs55653103	chr2:172861816	T/C	cg13550731	chr2:172543902	DYNC1I2	0.5	6.87	0.39	4.62e-11	Schizophrenia;
CESC	trans	rs208520	0.909	rs62414639	chr6:67023706	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.81	7.66	0.43	3.51e-13	Exhaled nitric oxide output;
CESC	cis	rs1707322	1.000	rs4539075	chr1:46358010	C/T	cg06784218	chr1:46089804	CCDC17	0.32	5.57	0.32	6.35e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9910055	0.529	rs228748	chr17:42174390	G/A	cg19774624	chr17:42201019	HDAC5	0.64	8.85	0.48	1.3e-16	Total body bone mineral density;
CESC	cis	rs17125944	0.686	rs7160582	chr14:53341445	G/T	cg00686598	chr14:53173677	PSMC6	0.93	7.23	0.41	5.1e-12	Alzheimer's disease (late onset);
CESC	trans	rs12356475	0.710	rs10822686	chr10:67733250	C/T	cg09859272	chr12:118454420	RFC5	0.57	6.27	0.36	1.47e-9	Psoriatic arthritis;
CESC	cis	rs73206853	0.764	rs28569834	chr12:110826208	T/G	cg12870014	chr12:110450643	ANKRD13A	0.61	5.62	0.33	4.8e-8	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs561341	0.941	rs112569713	chr17:30271738	C/T	cg00745463	chr17:30367425	LRRC37B	-0.7	-7.1	-0.4	1.18e-11	Hip circumference adjusted for BMI;
CESC	cis	rs2243480	0.803	rs55700941	chr7:65389800	T/A	cg13147721	chr7:65941812	NA	-0.88	-8.07	-0.44	2.5e-14	Diabetic kidney disease;
CESC	cis	rs6460942	0.597	rs6977059	chr7:12535157	T/G	cg02935154	chr7:12443704	VWDE	-0.57	-5.7	-0.33	3.23e-8	Coronary artery disease;
CESC	cis	rs4253772	0.591	rs6008538	chr22:46685963	G/A	cg18190219	chr22:46762943	CELSR1	-0.43	-5.3	-0.31	2.5e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs7208859	0.623	rs8075163	chr17:29106310	A/G	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.91e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs875971	0.756	rs2901210	chr7:66017505	G/A	cg12463550	chr7:65579703	CRCP	-0.5	-6.32	-0.36	1.1e-9	Aortic root size;
CESC	cis	rs9291683	0.588	rs6844329	chr4:10018544	T/C	cg11266682	chr4:10021025	SLC2A9	0.72	14.87	0.67	8.73e-37	Bone mineral density;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg06051243	chr13:28024682	MTIF3	-0.49	-6.86	-0.39	4.9e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs832540	0.629	rs10940512	chr5:56082094	G/C	cg24531977	chr5:56204891	C5orf35	-0.51	-6.17	-0.35	2.51e-9	Coronary artery disease;
CESC	cis	rs7666738	0.830	rs34890015	chr4:99023769	A/T	cg03467027	chr4:99064603	C4orf37	0.47	5.96	0.34	8.19e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs881375	0.678	rs1014530	chr9:123685092	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.45	6.52	0.37	3.48e-10	Rheumatoid arthritis;
CESC	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg06873352	chr17:61820015	STRADA	0.73	12.99	0.62	3.49e-30	Prudent dietary pattern;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16416718	chr1:6844519	CAMTA1	0.64	7.55	0.42	7.05e-13	Gut microbiome composition (summer);
CESC	cis	rs6495122	0.644	rs62029217	chr15:75261899	C/T	cg14664628	chr15:75095509	CSK	-0.53	-6.69	-0.38	1.29e-10	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
CESC	cis	rs7267979	0.932	rs1541061	chr20:25521057	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.76	13.66	0.64	1.58e-32	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs3820068	0.603	rs6429768	chr1:15963531	G/A	cg17385448	chr1:15911702	AGMAT	0.42	6.89	0.39	4.06e-11	Systolic blood pressure;
CESC	cis	rs9467711	0.606	rs28362606	chr6:26365586	T/C	cg12826209	chr6:26865740	GUSBL1	0.62	5.22	0.31	3.63e-7	Autism spectrum disorder or schizophrenia;
CESC	trans	rs17685	0.753	rs12531559	chr7:75631697	C/T	cg19862616	chr7:65841803	NCRNA00174	-0.81	-11.93	-0.59	1.56e-26	Coffee consumption;Coffee consumption (cups per day);
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg04590956	chr2:70057467	GMCL1	-0.47	-6.22	-0.36	1.93e-9	Height;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg15213732	chr10:860677	LARP4B	0.5	6.75	0.38	9.52e-11	Fibrinogen levels;
CESC	cis	rs2836974	0.897	rs2776308	chr21:40715175	A/G	cg11644478	chr21:40555479	PSMG1	0.93	13.54	0.64	4.15e-32	Cognitive function;
CESC	cis	rs9359856	0.564	rs72913975	chr6:90387116	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.65	-6.38	-0.36	7.94e-10	Bipolar disorder;
CESC	cis	rs11997175	0.569	rs36034014	chr8:33814219	G/A	ch.8.33884649F	chr8:33765107	NA	-0.49	-5.84	-0.34	1.5e-8	Body mass index;
CESC	cis	rs736408	0.522	rs6445535	chr3:52771468	T/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.36	6.52	0.37	3.48e-10	Bipolar disorder;
CESC	cis	rs9894429	1.000	rs35435780	chr17:79579602	G/T	cg21984481	chr17:79567631	NPLOC4	-0.49	-8.04	-0.44	2.97e-14	Eye color traits;
CESC	cis	rs1799949	0.965	rs11656945	chr17:41330265	A/G	cg05368731	chr17:41323189	NBR1	0.77	10.49	0.54	9.35e-22	Menopause (age at onset);
CESC	cis	rs1401999	0.650	rs3749445	chr3:183638506	C/T	cg01324343	chr3:183735012	ABCC5	0.46	8.93	0.48	7.18e-17	Anterior chamber depth;
CESC	cis	rs9640161	0.789	rs3735174	chr7:150020489	T/C	cg10018233	chr7:150070692	REPIN1	0.48	7.66	0.43	3.42e-13	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs1983891	0.954	rs4714481	chr6:41521110	T/C	cg20194872	chr6:41519635	FOXP4	0.57	8.19	0.45	1.12e-14	Prostate cancer;
CESC	cis	rs7520050	0.933	rs4504835	chr1:46455571	G/A	cg24296786	chr1:45957014	TESK2	0.44	5.5	0.32	8.88e-8	Red blood cell count;Reticulocyte count;
CESC	cis	rs17826219	0.500	rs57005940	chr17:29066329	C/G	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.79e-10	Body mass index;
CESC	cis	rs1538970	0.962	rs9429077	chr1:45820667	C/A	cg05343316	chr1:45956843	TESK2	0.82	11.17	0.57	5.6e-24	Platelet count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13305883	chr1:145438423	TXNIP	0.54	6.01	0.35	5.96e-9	Gut microbiome composition (summer);
CESC	cis	rs2658782	0.789	rs3020073	chr11:93103830	T/C	cg15737290	chr11:93063684	CCDC67	0.57	7.26	0.41	4.36e-12	Pulmonary function decline;
CESC	cis	rs6062302	0.522	rs2282157	chr20:62227180	C/G	cg09650180	chr20:62225654	GMEB2	-0.81	-9.13	-0.49	1.76e-17	Glioblastoma;
CESC	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg11494091	chr17:61959527	GH2	0.72	12.22	0.6	1.56e-27	Prudent dietary pattern;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg24830314	chr6:83775579	UBE2CBP	0.43	6.03	0.35	5.6e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs7223966	1.000	rs8067064	chr17:61825984	A/C	cg11494091	chr17:61959527	GH2	0.39	5.25	0.31	3.18e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs4819052	0.851	rs8126930	chr21:46671715	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.46	6.0	0.35	6.63e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs9457247	1.000	rs389956	chr6:167407254	T/G	cg23791538	chr6:167370224	RNASET2	-0.59	-8.54	-0.46	1.09e-15	Crohn's disease;
CESC	cis	rs477692	0.625	rs4751104	chr10:131405358	G/A	cg05714579	chr10:131428358	MGMT	-0.67	-9.69	-0.51	3.27e-19	Response to temozolomide;
CESC	cis	rs9322193	0.736	rs3805750	chr6:150112201	G/A	cg07701084	chr6:150067640	NUP43	0.44	5.95	0.34	8.4e-9	Lung cancer;
CESC	cis	rs9916302	0.861	rs11658219	chr17:37709782	G/A	cg15445000	chr17:37608096	MED1	0.4	6.45	0.37	5.32e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs561341	1.000	rs72825712	chr17:30316119	A/T	cg12193833	chr17:30244370	NA	-0.76	-6.94	-0.39	2.92e-11	Hip circumference adjusted for BMI;
CESC	cis	rs7829975	0.623	rs10092965	chr8:8373485	A/G	cg15556689	chr8:8085844	FLJ10661	0.51	6.28	0.36	1.36e-9	Mood instability;
CESC	cis	rs3740713	1.000	rs113497813	chr11:18453674	A/G	cg23797887	chr11:18477753	LDHAL6A	-0.53	-5.11	-0.3	6.1e-7	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs887829	0.588	rs4663971	chr2:234674252	C/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.53	-6.9	-0.39	3.79e-11	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CESC	cis	rs4654899	0.628	rs11589969	chr1:21505464	A/T	cg05370193	chr1:21551575	ECE1	0.36	5.48	0.32	9.65e-8	Superior frontal gyrus grey matter volume;
CESC	cis	rs2404602	0.692	rs12902452	chr15:76921465	T/C	cg22467129	chr15:76604101	ETFA	-0.36	-5.32	-0.31	2.25e-7	Blood metabolite levels;
CESC	cis	rs1448094	0.511	rs10863083	chr12:86226739	C/A	cg02569458	chr12:86230093	RASSF9	0.45	6.77	0.38	8.29e-11	Major depressive disorder;
CESC	cis	rs1008375	0.966	rs3775925	chr4:17588437	A/G	cg27347728	chr4:17578864	LAP3	0.46	5.56	0.32	6.52e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs938554	0.694	rs4697700	chr4:9945792	C/G	cg00071950	chr4:10020882	SLC2A9	0.53	6.22	0.36	1.92e-9	Blood metabolite levels;
CESC	cis	rs1862618	0.802	rs33327	chr5:56142693	T/G	cg22800045	chr5:56110881	MAP3K1	0.83	9.99	0.52	3.69e-20	Initial pursuit acceleration;
CESC	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.65	0.38	1.71e-10	Prudent dietary pattern;
CESC	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg03188948	chr7:1209495	NA	0.73	7.02	0.4	1.85e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs6429082	0.783	rs390539	chr1:235679690	A/C	cg26050004	chr1:235667680	B3GALNT2	0.61	7.67	0.43	3.28e-13	Adiposity;
CESC	cis	rs1065852	0.503	rs9620006	chr22:42399547	T/A	cg22189786	chr22:42395067	WBP2NL	0.43	5.37	0.31	1.72e-7	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
CESC	cis	rs1371867	0.846	rs1788191	chr8:101260844	C/T	cg11906718	chr8:101322791	RNF19A	-0.48	-6.24	-0.36	1.75e-9	Atrioventricular conduction;
CESC	cis	rs17711722	0.528	rs73138179	chr7:65294482	G/T	cg06456125	chr7:65229604	NA	0.41	5.22	0.31	3.7e-7	Calcium levels;
CESC	cis	rs7071206	0.947	rs716255	chr10:79419679	A/T	cg00983440	chr10:79422392	NA	-0.67	-8.15	-0.45	1.5e-14	Bone mineral density;
CESC	cis	rs13191362	1.000	rs35044651	chr6:163004142	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.5	5.17	0.3	4.51e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs7824557	0.527	rs2572449	chr8:11239137	A/G	cg21775007	chr8:11205619	TDH	0.5	7.68	0.43	3.04e-13	Retinal vascular caliber;
CESC	cis	rs76878669	0.561	rs10750784	chr11:66110666	A/G	cg18002602	chr11:66138449	SLC29A2	-0.39	-6.42	-0.37	6.29e-10	Educational attainment (years of education);
CESC	cis	rs8018808	0.935	rs8018711	chr14:77921749	G/A	cg20045696	chr14:77926864	AHSA1	0.43	5.98	0.34	7.38e-9	Myeloid white cell count;
CESC	cis	rs11098499	0.954	rs12510138	chr4:120423935	C/G	cg24375607	chr4:120327624	NA	0.43	5.36	0.31	1.85e-7	Corneal astigmatism;
CESC	cis	rs7949030	0.588	rs2512563	chr11:62311249	C/G	cg11742103	chr11:62369870	EML3;MTA2	0.57	8.63	0.47	5.87e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg19558049	chr19:306297	MIER2	0.49	6.5	0.37	4.03e-10	Fibrinogen levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19998654	chr2:37458983	CEBPZ;C2orf56	0.63	7.72	0.43	2.4e-13	Gut microbiome composition (summer);
CESC	cis	rs896854	0.812	rs4582532	chr8:95969257	G/A	cg23172400	chr8:95962367	TP53INP1	-0.46	-9.62	-0.51	5.59e-19	Type 2 diabetes;
CESC	cis	rs763014	0.838	rs4984670	chr16:641044	A/G	cg00802000	chr16:706648	WDR90	-0.37	-5.29	-0.31	2.55e-7	Height;
CESC	cis	rs2985684	0.841	rs7158577	chr14:50058633	C/T	cg10008539	chr14:50087325	RPL36AL;MGAT2	-0.44	-5.32	-0.31	2.17e-7	Carotid intima media thickness;
CESC	cis	rs7267979	1.000	rs401166	chr20:25446308	C/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.86	17.57	0.73	2.33e-46	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs2243480	1.000	rs73142121	chr7:65311206	C/T	cg13147721	chr7:65941812	NA	-0.87	-8.7	-0.47	3.54e-16	Diabetic kidney disease;
CESC	cis	rs9443189	0.813	rs2842561	chr6:76434273	A/C	cg01950844	chr6:76311363	SENP6	-0.63	-7.0	-0.39	2.13e-11	Prostate cancer;
CESC	cis	rs834811	0.829	rs834818	chr7:135895070	A/G	cg01726295	chr7:135938950	NA	0.37	6.27	0.36	1.42e-9	Post-traumatic stress disorder;
CESC	cis	rs708547	0.697	rs67479587	chr4:57878884	A/G	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.42	-5.58	-0.32	6.06e-8	Response to bleomycin (chromatid breaks);
CESC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg22859714	chr11:64678510	ATG2A	-0.43	-6.28	-0.36	1.35e-9	Intelligence (multi-trait analysis);
CESC	cis	rs4727027	1.000	rs4727027	chr7:148869277	C/T	cg23158103	chr7:148848205	ZNF398	-0.41	-6.68	-0.38	1.44e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs3741404	0.537	rs1123251	chr11:63917601	G/T	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.47	-6.16	-0.35	2.69e-9	Platelet count;
CESC	trans	rs6073597	1.000	rs6031980	chr20:43714384	C/T	cg03252340	chr4:83293766	HNRNPD	0.42	6.11	0.35	3.59e-9	Positive affect;
CESC	cis	rs9611565	0.512	rs5758439	chr22:42131762	C/T	cg06481639	chr22:41940642	POLR3H	0.59	5.84	0.34	1.51e-8	Vitiligo;
CESC	cis	rs9311474	0.508	rs6805156	chr3:52609362	T/C	cg17372223	chr3:52568218	NT5DC2	0.42	6.35	0.36	9.14e-10	Electroencephalogram traits;
CESC	cis	rs17125944	0.686	rs7144029	chr14:53333616	G/T	cg00686598	chr14:53173677	PSMC6	-0.74	-6.27	-0.36	1.48e-9	Alzheimer's disease (late onset);
CESC	cis	rs1008375	1.000	rs1860597	chr4:17657650	C/T	cg02297831	chr4:17616191	MED28	0.53	6.75	0.38	9.49e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	trans	rs4662834	0.933	rs11684311	chr2:129483795	T/C	cg12497543	chr10:97515377	ENTPD1	0.38	6.32	0.36	1.1e-9	Response to bleomycin (chromatid breaks);
CESC	cis	rs9487051	0.676	rs6568566	chr6:109596792	G/A	cg12927641	chr6:109611667	NA	-0.37	-5.5	-0.32	8.91e-8	Reticulocyte fraction of red cells;
CESC	cis	rs9837602	1.000	rs9873878	chr3:99711816	G/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.53	7.24	0.41	4.82e-12	Breast cancer;
CESC	trans	rs4471313	0.956	rs3119837	chr1:170352113	C/T	cg14876685	chr7:99177937	NA	-0.4	-6.11	-0.35	3.53e-9	Waist-hip ratio;
CESC	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.89	13.56	0.64	3.66e-32	Prudent dietary pattern;
CESC	cis	rs17021463	0.673	rs1426566	chr4:95292086	T/G	cg11021082	chr4:95130006	SMARCAD1	0.5	6.74	0.38	9.77e-11	Testicular germ cell tumor;
CESC	cis	rs3540	0.574	rs2657947	chr15:90968977	C/T	cg22089800	chr15:90895588	ZNF774	-0.6	-7.92	-0.44	6.77e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	trans	rs3942852	0.712	rs2174129	chr11:48108557	A/C	cg03929089	chr4:120376271	NA	-0.62	-7.14	-0.4	9.13e-12	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs1448094	0.511	rs61930588	chr12:86158991	A/G	cg02569458	chr12:86230093	RASSF9	0.48	7.44	0.42	1.4e-12	Major depressive disorder;
CESC	cis	rs8016982	0.674	rs6574631	chr14:81675772	C/T	cg01989461	chr14:81687754	GTF2A1	0.75	11.74	0.59	6.44e-26	Schizophrenia;
CESC	cis	rs4835473	0.932	rs11100824	chr4:144885998	C/T	cg25736465	chr4:144833511	NA	0.41	6.25	0.36	1.64e-9	Immature fraction of reticulocytes;
CESC	cis	rs13191362	0.872	rs73020362	chr6:163005737	A/C	cg14584255	chr6:163149320	PACRG;PARK2	0.5	5.19	0.3	4.29e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs637571	0.522	rs542332	chr11:65744421	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.73	10.63	0.55	3.17e-22	Eosinophil percentage of white cells;
CESC	cis	rs769267	0.930	rs4808955	chr19:19552413	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.45	5.46	0.32	1.11e-7	Tonsillectomy;
CESC	cis	rs763121	0.853	rs5757208	chr22:39049230	A/C	cg06022373	chr22:39101656	GTPBP1	0.88	13.91	0.65	2.06e-33	Menopause (age at onset);
CESC	cis	rs4665809	0.590	rs6730310	chr2:26419470	C/G	cg27170947	chr2:26402098	FAM59B	-0.84	-10.04	-0.52	2.68e-20	Gut microbiome composition (summer);
CESC	cis	rs637571	0.676	rs1151523	chr11:65665200	C/T	cg26695010	chr11:65641043	EFEMP2	0.5	6.43	0.37	5.84e-10	Eosinophil percentage of white cells;
CESC	cis	rs4820539	0.966	rs5759594	chr22:23470660	G/A	cg14186256	chr22:23484241	RTDR1	0.83	15.0	0.68	3.12e-37	Bone mineral density;
CESC	cis	rs6987853	0.814	rs2923411	chr8:42455206	T/C	cg09913449	chr8:42400586	C8orf40	0.42	7.02	0.4	1.88e-11	Mean corpuscular hemoglobin concentration;
CESC	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg03452623	chr4:187889614	NA	-0.88	-16.16	-0.7	2.39e-41	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs35110281	0.667	rs4819288	chr21:45120173	C/G	cg01579765	chr21:45077557	HSF2BP	-0.52	-8.59	-0.47	7.47e-16	Mean corpuscular volume;
CESC	trans	rs2727020	0.894	rs1917328	chr11:49359606	G/A	cg15704280	chr7:45808275	SEPT13	-0.75	-9.43	-0.5	2.16e-18	Coronary artery disease;
CESC	cis	rs34172651	0.606	rs7194189	chr16:24703484	G/T	cg06505273	chr16:24850292	NA	-0.45	-5.62	-0.33	4.89e-8	Intelligence (multi-trait analysis);
CESC	cis	rs514406	0.679	rs11585495	chr1:53244331	T/C	cg08736216	chr1:53307985	ZYG11A	0.36	6.32	0.36	1.09e-9	Monocyte count;
CESC	cis	rs11785400	1.000	rs3824208	chr8:143743653	C/G	cg24634471	chr8:143751801	JRK	0.47	6.21	0.36	2e-9	Schizophrenia;
CESC	cis	rs1023500	0.552	rs133368	chr22:42463689	T/C	cg15557168	chr22:42548783	NA	-0.47	-6.81	-0.39	6.59e-11	Schizophrenia;
CESC	cis	rs7618915	0.532	rs13060675	chr3:52674300	T/G	cg18404041	chr3:52824283	ITIH1	-0.39	-6.55	-0.37	2.91e-10	Bipolar disorder;
CESC	cis	rs17253792	0.822	rs74968702	chr14:56076818	A/T	cg01858014	chr14:56050164	KTN1	-0.83	-7.03	-0.4	1.7e-11	Putamen volume;
CESC	cis	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg03009463	chr7:17980271	SNX13	-0.42	-5.36	-0.31	1.79e-7	Fibrinogen levels;
CESC	cis	rs1062177	1.000	rs2347596	chr5:151179199	T/C	cg12924095	chr5:151150029	G3BP1	0.49	6.44	0.37	5.67e-10	Preschool internalizing problems;
CESC	cis	rs1035144	0.785	rs12323356	chr14:81464279	A/G	cg06600135	chr14:81408086	NA	0.4	5.33	0.31	2.14e-7	Male sexual orientation;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11279933	chr10:71211301	TSPAN15	0.58	6.41	0.37	6.82e-10	Gut microbiome composition (summer);
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg09706721	chr3:196664468	NCBP2	-0.49	-6.64	-0.38	1.74e-10	Systemic lupus erythematosus;
CESC	cis	rs13242816	1.000	rs56309428	chr7:116150137	G/T	cg04696780	chr7:116139425	CAV2	-0.61	-5.55	-0.32	7.01e-8	P wave duration;
CESC	cis	rs17818399	0.547	rs12997164	chr2:46758746	A/C	cg02822958	chr2:46747628	ATP6V1E2	0.42	5.2	0.3	4.08e-7	Height;
CESC	trans	rs7120489	0.748	rs57628814	chr11:12456399	G/A	cg20690916	chr5:140700301	TAF7	-0.95	-6.34	-0.36	9.6e-10	Mortality in heart failure;
CESC	cis	rs2074585	0.560	rs1973537	chr15:91062901	T/C	cg10434728	chr15:90938212	IQGAP1	-0.31	-5.08	-0.3	7.28e-7	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
CESC	cis	rs7826238	0.535	rs2979179	chr8:8320029	C/T	cg15556689	chr8:8085844	FLJ10661	0.6	8.25	0.45	7.27e-15	Systolic blood pressure;
CESC	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg26338869	chr17:61819248	STRADA	0.71	9.47	0.5	1.6e-18	Prudent dietary pattern;
CESC	cis	rs738322	0.935	rs4384	chr22:38572440	G/C	cg25457927	chr22:38595422	NA	-0.31	-5.77	-0.33	2.17e-8	Cutaneous nevi;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg17655527	chr19:56128027	NA	0.53	6.95	0.39	2.8e-11	Fibrinogen levels;
CESC	cis	rs2836974	0.931	rs13625	chr21:40669083	G/T	cg17971929	chr21:40555470	PSMG1	1.04	15.61	0.69	2.11e-39	Cognitive function;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11450001	chr12:10365596	GABARAPL1	0.58	6.52	0.37	3.5e-10	Gut microbiome composition (summer);
CESC	cis	rs1707322	1.000	rs1612419	chr1:46546945	T/C	cg06784218	chr1:46089804	CCDC17	-0.35	-5.86	-0.34	1.36e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17237320	chr3:10053000	LOC401052	0.57	6.06	0.35	4.66e-9	Gut microbiome composition (summer);
CESC	cis	rs1878931	0.543	rs17612463	chr16:3420479	G/C	cg02880119	chr16:3481970	NA	-0.4	-5.22	-0.31	3.67e-7	Body mass index (adult);
CESC	cis	rs7607369	0.559	rs13027908	chr2:219660374	T/C	cg02176678	chr2:219576539	TTLL4	-0.4	-7.1	-0.4	1.18e-11	Red blood cell count;Amyotrophic lateral sclerosis;
CESC	cis	rs896854	0.625	rs4735335	chr8:95973327	G/C	cg09323728	chr8:95962352	TP53INP1	-0.39	-8.53	-0.46	1.11e-15	Type 2 diabetes;
CESC	trans	rs2823962	0.697	rs9984100	chr21:18016486	C/A	cg06419850	chr17:4688683	VMO1	-0.43	-6.17	-0.35	2.48e-9	Amyotrophic lateral sclerosis;
CESC	cis	rs920590	0.758	rs35896770	chr8:19665616	G/C	cg17834443	chr8:19674713	INTS10	0.6	6.79	0.38	7.33e-11	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs9815354	0.680	rs79211428	chr3:41921810	C/T	cg03022575	chr3:42003672	ULK4	0.59	5.49	0.32	9.55e-8	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs30380	0.632	rs26498	chr5:96138812	C/T	cg16492584	chr5:96139282	ERAP1	0.48	6.71	0.38	1.17e-10	Cerebrospinal fluid biomarker levels;
CESC	cis	rs13256369	0.851	rs13249700	chr8:8563637	C/T	cg17143192	chr8:8559678	CLDN23	0.78	8.81	0.48	1.65e-16	Obesity-related traits;
CESC	cis	rs2841277	0.708	rs4465542	chr14:105407798	A/G	cg19901468	chr14:105411992	AHNAK2	-0.57	-8.26	-0.45	6.94e-15	Rheumatoid arthritis;
CESC	cis	rs72945132	0.882	rs67927691	chr11:70128786	C/A	cg00319359	chr11:70116639	PPFIA1	0.78	7.78	0.43	1.6e-13	Coronary artery disease;
CESC	trans	rs7618501	0.633	rs6446193	chr3:50059758	T/C	cg21659725	chr3:3221576	CRBN	-0.48	-6.74	-0.38	9.75e-11	Intelligence (multi-trait analysis);
CESC	cis	rs2549003	0.966	rs2706386	chr5:131832687	C/T	cg00255919	chr5:131827918	IRF1	-0.58	-9.99	-0.52	3.86e-20	Asthma (sex interaction);
CESC	cis	rs853679	0.517	rs4711165	chr6:28115184	T/G	cg22143856	chr6:28129313	ZNF389	0.53	6.71	0.38	1.2e-10	Depression;
CESC	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg07157834	chr1:205819609	PM20D1	0.72	10.78	0.55	1.06e-22	Menarche (age at onset);
CESC	cis	rs9291683	0.655	rs3822242	chr4:10094904	T/C	cg11266682	chr4:10021025	SLC2A9	-0.49	-9.21	-0.49	9.99e-18	Bone mineral density;
CESC	trans	rs1814175	0.645	rs7952104	chr11:49964180	C/T	cg15704280	chr7:45808275	SEPT13	-1.01	-19.02	-0.76	1.83e-51	Height;
CESC	cis	rs9488822	0.636	rs12524932	chr6:116330266	G/A	cg18764771	chr6:116381957	FRK	0.22	5.37	0.31	1.68e-7	Cholesterol, total;LDL cholesterol;
CESC	cis	rs5769765	0.862	rs9616380	chr22:50312225	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.58	-6.21	-0.36	2.01e-9	Schizophrenia;
CESC	cis	rs1707322	1.000	rs12060274	chr1:46291062	G/T	cg06784218	chr1:46089804	CCDC17	0.32	5.47	0.32	1.04e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs1729951	0.575	rs361242	chr3:136698330	C/G	cg03617693	chr3:136751559	NA	0.39	5.53	0.32	7.62e-8	Neuroticism;
CESC	cis	rs2832191	0.511	rs7278227	chr21:30482707	C/T	cg24692254	chr21:30365293	RNF160	-0.59	-8.05	-0.44	2.84e-14	Dental caries;
CESC	cis	rs7666738	0.715	rs116787789	chr4:98718720	G/A	cg05340658	chr4:99064831	C4orf37	0.76	11.18	0.57	4.88e-24	Colonoscopy-negative controls vs population controls;
CESC	cis	rs614226	0.516	rs1794748	chr12:120953758	A/G	cg01236616	chr12:121019343	POP5	1.55	19.98	0.78	8.29e-55	Type 1 diabetes nephropathy;
CESC	cis	rs2268241	0.938	rs9978223	chr21:34770358	G/A	cg14850771	chr21:34775459	IFNGR2	0.93	11.49	0.58	4.73e-25	Obesity-related traits;
CESC	cis	rs807669	0.868	rs762529	chr22:19170205	C/G	cg02655711	chr22:19163373	SLC25A1	0.95	14.43	0.66	3.1e-35	Metabolite levels;
CESC	cis	rs9303401	0.659	rs12948133	chr17:56673602	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.04	12.83	0.62	1.23e-29	Cognitive test performance;
CESC	cis	rs3820068	0.581	rs6693694	chr1:15980135	G/T	cg16988262	chr1:15930761	NA	0.33	5.4	0.31	1.47e-7	Systolic blood pressure;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg06963844	chr1:11724238	FBXO6	0.46	6.31	0.36	1.17e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs1775715	0.811	rs1775741	chr10:32267284	C/T	cg18675610	chr10:32216311	ARHGAP12	-0.33	-5.04	-0.3	8.46e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs4704187	0.687	rs13359143	chr5:74433360	T/C	cg03227963	chr5:74354835	NA	0.3	5.55	0.32	6.82e-8	Response to amphetamines;
CESC	trans	rs1908814	0.516	rs13252853	chr8:11792974	T/C	cg15556689	chr8:8085844	FLJ10661	0.54	6.58	0.37	2.47e-10	Neuroticism;
CESC	trans	rs11148252	0.553	rs2147692	chr13:53287023	C/G	cg18335740	chr13:41363409	SLC25A15	0.54	7.29	0.41	3.56e-12	Lewy body disease;
CESC	cis	rs9926296	0.546	rs6500442	chr16:89828862	T/C	cg04287289	chr16:89883240	FANCA	0.88	15.13	0.68	1.09e-37	Vitiligo;
CESC	cis	rs270601	0.739	rs3900945	chr5:131592870	T/C	cg22638593	chr5:131593259	PDLIM4	0.39	5.04	0.3	8.45e-7	Acylcarnitine levels;
CESC	trans	rs7246657	0.943	rs3760825	chr19:37945601	C/T	cg01833234	chr11:6592585	DNHD1	0.52	6.0	0.35	6.5e-9	Coronary artery calcification;
CESC	cis	rs1862618	0.671	rs2591961	chr5:56238597	A/G	cg24531977	chr5:56204891	C5orf35	0.69	9.38	0.5	3.14e-18	Initial pursuit acceleration;
CESC	cis	rs9487051	0.837	rs2356817	chr6:109642675	G/A	cg01475377	chr6:109611718	NA	-0.51	-8.18	-0.45	1.19e-14	Reticulocyte fraction of red cells;
CESC	cis	rs2439831	0.571	rs2470121	chr15:43937618	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.81	8.46	0.46	1.81e-15	Lung cancer in ever smokers;
CESC	cis	rs3820928	0.874	rs10933165	chr2:227883648	C/G	cg11843606	chr2:227700838	RHBDD1	0.45	5.79	0.34	1.95e-8	Pulmonary function;
CESC	cis	rs523522	0.923	rs2235217	chr12:120884328	C/T	cg27279351	chr12:120934652	DYNLL1	0.67	8.43	0.46	2.18e-15	High light scatter reticulocyte count;
CESC	cis	rs3785574	0.962	rs2584633	chr17:61879501	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.8	10.57	0.54	4.93e-22	Height;
CESC	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg06877462	chr1:205807181	PM20D1	0.39	5.84	0.34	1.51e-8	Menarche (age at onset);
CESC	cis	rs6963495	0.556	rs818481	chr7:105158467	G/C	cg19920283	chr7:105172520	RINT1	0.54	6.28	0.36	1.35e-9	Bipolar disorder (body mass index interaction);
CESC	cis	rs7666738	0.830	rs35560671	chr4:99069095	G/A	cg17366294	chr4:99064904	C4orf37	0.61	8.5	0.46	1.41e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7617480	0.648	rs4858800	chr3:48755820	A/G	cg07636037	chr3:49044803	WDR6	0.78	10.07	0.53	2.11e-20	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CESC	cis	rs79387448	0.701	rs11465586	chr2:102982709	C/G	cg09003973	chr2:102972529	NA	1.21	9.49	0.5	1.45e-18	Gut microbiota (bacterial taxa);
CESC	cis	rs3806843	1.000	rs7710794	chr5:140209467	T/G	cg26395211	chr5:140044315	WDR55	-0.41	-5.05	-0.3	8.38e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs7927771	0.864	rs11604680	chr11:47457539	A/G	cg18512352	chr11:47633146	NA	-0.57	-7.96	-0.44	5.22e-14	Subjective well-being;
CESC	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg03647317	chr4:187891568	NA	-0.37	-5.56	-0.32	6.44e-8	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs12586317	1.000	rs12586317	chr14:35682172	T/C	cg16230307	chr14:35515116	FAM177A1	0.77	8.09	0.45	2.16e-14	Psoriasis;
CESC	cis	rs10465746	0.935	rs4907189	chr1:84374982	G/T	cg10977910	chr1:84465055	TTLL7	0.47	6.37	0.36	8.2e-10	Obesity-related traits;
CESC	cis	rs6723226	0.842	rs2754522	chr2:32801257	C/G	cg02381751	chr2:32503542	YIPF4	0.84	12.32	0.6	7.12e-28	Intelligence (multi-trait analysis);
CESC	cis	rs12926788	0.542	rs6497759	chr16:24801737	G/A	cg06505273	chr16:24850292	NA	0.53	6.51	0.37	3.7e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs854765	0.616	rs8070624	chr17:17843396	G/A	cg09796270	chr17:17721594	SREBF1	0.45	6.05	0.35	4.93e-9	Total body bone mineral density;
CESC	cis	rs7666738	0.830	rs62321569	chr4:98984250	T/A	cg17366294	chr4:99064904	C4orf37	0.59	8.57	0.47	8.46e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11645898	0.688	rs398580	chr16:72095453	A/G	cg14768367	chr16:72042858	DHODH	-0.79	-6.25	-0.36	1.65e-9	Blood protein levels;
CESC	cis	rs4862750	0.914	rs11943333	chr4:187872455	A/G	cg03452623	chr4:187889614	NA	-0.67	-10.86	-0.55	5.81e-23	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7666738	0.830	rs11942114	chr4:99066261	C/G	cg18180107	chr4:99064573	C4orf37	0.4	5.05	0.3	8.26e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs711830	1.000	rs1051929	chr2:177036754	T/C	cg13092806	chr2:177043255	NA	0.87	11.84	0.59	3.15e-26	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
CESC	cis	rs10857712	0.904	rs2265641	chr10:135221869	G/A	cg01444801	chr10:135216882	MTG1	0.47	5.66	0.33	3.99e-8	Systemic lupus erythematosus;
CESC	cis	rs10465746	0.714	rs12141272	chr1:84434517	C/T	cg10977910	chr1:84465055	TTLL7	0.52	7.06	0.4	1.44e-11	Obesity-related traits;
CESC	cis	rs7618915	0.547	rs35211965	chr3:52685305	C/G	cg18099408	chr3:52552593	STAB1	-0.31	-5.19	-0.3	4.27e-7	Bipolar disorder;
CESC	cis	rs9818758	0.607	rs35673421	chr3:49139406	G/A	cg00383909	chr3:49044727	WDR6	0.89	6.57	0.37	2.68e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CESC	cis	rs7618501	0.633	rs11925192	chr3:50038664	G/A	cg24110177	chr3:50126178	RBM5	-0.51	-7.09	-0.4	1.21e-11	Intelligence (multi-trait analysis);
CESC	cis	rs3091242	0.933	rs10903129	chr1:25768937	A/G	cg03538708	chr1:25844672	NA	-0.37	-5.72	-0.33	2.91e-8	Erythrocyte sedimentation rate;
CESC	cis	rs751728	1.000	rs3806108	chr6:33767579	C/G	cg25922239	chr6:33757077	LEMD2	0.56	7.77	0.43	1.75e-13	Crohn's disease;
CESC	cis	rs7666738	0.830	rs4292341	chr4:98959724	C/T	cg00999950	chr4:99064541	C4orf37	0.46	6.81	0.39	6.7e-11	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1552244	0.748	rs113890152	chr3:10085986	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.87	11.81	0.59	3.88e-26	Alzheimer's disease;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg06836181	chr2:64995545	NA	-0.45	-6.53	-0.37	3.37e-10	Gambling;
CESC	cis	rs9815354	0.812	rs35263917	chr3:41952852	T/C	cg03022575	chr3:42003672	ULK4	0.68	5.92	0.34	9.9e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs9300255	0.537	rs1716182	chr12:123686127	A/C	cg19016782	chr12:123741754	C12orf65	-0.45	-6.4	-0.37	6.92e-10	Neutrophil percentage of white cells;
CESC	cis	rs16854884	0.710	rs9829796	chr3:143801416	C/T	cg06585982	chr3:143692056	C3orf58	0.45	5.82	0.34	1.66e-8	Economic and political preferences (feminism/equality);
CESC	cis	rs9581857	0.685	rs9319373	chr13:28042835	A/G	cg22138327	chr13:27999177	GTF3A	0.62	5.22	0.31	3.69e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
CESC	cis	rs6952808	0.929	rs11761270	chr7:1923695	C/T	cg04267008	chr7:1944627	MAD1L1	-0.7	-8.87	-0.48	1.12e-16	Bipolar disorder and schizophrenia;
CESC	cis	rs796364	0.806	rs74266489	chr2:201005732	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.75	-6.83	-0.39	5.71e-11	Schizophrenia;
CESC	cis	rs7552404	0.731	rs11161845	chr1:76367559	T/C	cg22875332	chr1:76189707	ACADM	0.58	5.73	0.33	2.66e-8	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs791888	0.858	rs1555434	chr10:89419143	G/C	cg13926569	chr10:89418898	PAPSS2	-0.53	-7.62	-0.42	4.58e-13	Magnesium levels;
CESC	cis	rs4843747	0.636	rs11117358	chr16:88105053	T/A	cg06374794	chr16:88002281	BANP	0.39	5.14	0.3	5.47e-7	Menopause (age at onset);
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg20975532	chr1:184939506	FAM129A	0.37	6.02	0.35	5.78e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs17039065	1.000	rs4449483	chr4:109401379	C/A	cg16022748	chr4:109541635	LOC285456;RPL34	0.67	5.63	0.33	4.68e-8	Gut microbiome composition (summer);
CESC	cis	rs3796352	1.000	rs6445557	chr3:53083969	C/T	cg07884673	chr3:53033167	SFMBT1	-0.57	-5.62	-0.33	4.74e-8	Immune reponse to smallpox (secreted IL-2);
CESC	cis	rs9660992	0.674	rs1151784	chr1:205232447	C/T	cg21643547	chr1:205240462	TMCC2	-0.47	-6.34	-0.36	1.01e-9	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs7726839	0.794	rs10053310	chr5:595661	C/G	cg09021430	chr5:549028	NA	-0.44	-6.17	-0.35	2.54e-9	Obesity-related traits;
CESC	cis	rs7769051	0.522	rs73554461	chr6:133139087	T/G	cg07930552	chr6:133119739	C6orf192	0.94	6.82	0.39	6.26e-11	Type 2 diabetes nephropathy;
CESC	cis	rs9314323	0.729	rs7007256	chr8:26203081	G/A	cg11498726	chr8:26250323	BNIP3L	-0.5	-6.98	-0.39	2.39e-11	Red cell distribution width;
CESC	cis	rs6545883	0.931	rs11125885	chr2:61755728	G/C	cg15711740	chr2:61764176	XPO1	-0.44	-5.37	-0.31	1.73e-7	Tuberculosis;
CESC	cis	rs1881797	1.000	rs12071797	chr1:247686871	A/G	cg21399703	chr1:247681439	NA	0.55	7.37	0.41	2.13e-12	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs7666738	0.688	rs4632667	chr4:98748299	A/G	cg17366294	chr4:99064904	C4orf37	0.56	5.96	0.34	8.11e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2273669	0.667	rs12206423	chr6:109353216	C/T	cg05315195	chr6:109294784	ARMC2	-0.67	-6.33	-0.36	1.04e-9	Prostate cancer;
CESC	cis	rs9322193	0.923	rs62441284	chr6:150072678	C/A	cg07701084	chr6:150067640	NUP43	0.49	6.78	0.38	7.65e-11	Lung cancer;
CESC	cis	rs611744	0.647	rs2298603	chr8:109271426	C/T	cg21045802	chr8:109455806	TTC35	0.51	6.59	0.38	2.39e-10	Dupuytren's disease;
CESC	cis	rs2576037	0.796	rs2571033	chr18:44578552	C/T	cg19077165	chr18:44547161	KATNAL2	0.52	7.41	0.41	1.74e-12	Personality dimensions;
CESC	cis	rs861020	0.604	rs3766612	chr1:210020013	G/T	cg05527609	chr1:210001259	C1orf107	-0.98	-12.67	-0.61	4.28e-29	Orofacial clefts;
CESC	cis	rs202629	1	rs202629	chr22:41849975	C/T	cg03806693	chr22:41940476	POLR3H	1.14	15.52	0.69	4.45e-39	Cannabis dependence symptom count;
CESC	cis	rs853679	0.542	rs2295594	chr6:28053097	G/A	cg20151795	chr6:28129481	ZNF389	0.44	5.59	0.33	5.5e-8	Depression;
CESC	cis	rs7618915	0.547	rs11177	chr3:52721305	G/A	cg17372223	chr3:52568218	NT5DC2	0.44	6.57	0.37	2.59e-10	Bipolar disorder;
CESC	cis	rs798554	0.591	rs1182193	chr7:2869240	A/G	cg04166393	chr7:2884313	GNA12	0.41	5.31	0.31	2.32e-7	Height;
CESC	cis	rs8180040	0.764	rs11712716	chr3:47193432	T/C	cg27129171	chr3:47204927	SETD2	0.69	10.44	0.54	1.33e-21	Colorectal cancer;
CESC	cis	rs11650494	0.710	rs2233666	chr17:47484286	T/C	cg08112188	chr17:47440006	ZNF652	1.12	7.26	0.41	4.22e-12	Prostate cancer;
CESC	cis	rs2017305	0.834	rs12244293	chr10:70783580	A/G	cg01024728	chr10:70782572	NA	0.58	5.87	0.34	1.33e-8	Depression (quantitative trait);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08887952	chr4:16257948	FLJ39653	-0.49	-6.0	-0.35	6.48e-9	Gut microbiome composition (summer);
CESC	cis	rs3820068	0.705	rs4646031	chr1:15834648	A/G	cg17385448	chr1:15911702	AGMAT	0.37	5.91	0.34	1.03e-8	Systolic blood pressure;
CESC	cis	rs3820928	0.904	rs4414671	chr2:227816200	T/A	cg11843606	chr2:227700838	RHBDD1	-0.48	-6.38	-0.37	7.64e-10	Pulmonary function;
CESC	cis	rs6912958	0.781	rs3757368	chr6:88224495	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.51	-6.83	-0.39	5.94e-11	Monocyte percentage of white cells;
CESC	cis	rs2204008	0.837	rs34381557	chr12:38181983	T/C	cg26384229	chr12:38710491	ALG10B	0.74	10.7	0.55	1.96e-22	Bladder cancer;
CESC	cis	rs1799949	1.000	rs11655505	chr17:41278377	G/A	cg05368731	chr17:41323189	NBR1	0.8	11.32	0.57	1.66e-24	Menopause (age at onset);
CESC	cis	rs4635969	0.718	rs27068	chr5:1347239	C/T	cg07493874	chr5:1342172	CLPTM1L	-0.44	-6.37	-0.36	8.51e-10	Testicular germ cell tumor;Testicular germ cell cancer;
CESC	cis	rs6495122	0.699	rs1378942	chr15:75077367	A/C	cg09165964	chr15:75287851	SCAMP5	-0.4	-5.23	-0.31	3.42e-7	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
CESC	cis	rs2479106	0.569	rs4838071	chr9:126366539	C/A	cg16191174	chr9:126692580	DENND1A	0.38	5.3	0.31	2.4e-7	Polycystic ovary syndrome;
CESC	cis	rs637571	0.522	rs550435	chr11:65732651	G/A	cg02202077	chr11:65769826	EIF1AD;BANF1	0.47	6.28	0.36	1.35e-9	Eosinophil percentage of white cells;
CESC	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg07092213	chr7:1199455	ZFAND2A	-0.39	-5.37	-0.31	1.74e-7	Longevity;Endometriosis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02577487	chr10:11653628	USP6NL	0.57	6.63	0.38	1.87e-10	Gut microbiome composition (summer);
CESC	cis	rs7586879	0.639	rs2033654	chr2:25103108	C/A	cg01884057	chr2:25150051	NA	0.37	7.21	0.41	5.78e-12	Body mass index;
CESC	cis	rs2251381	0.741	rs2735966	chr21:30538174	G/A	cg24692254	chr21:30365293	RNF160	0.77	10.56	0.54	5.36e-22	Selective IgA deficiency;
CESC	cis	rs8177253	0.761	rs1830083	chr3:133508551	G/A	cg24879335	chr3:133465180	TF	0.31	5.15	0.3	5.03e-7	Iron status biomarkers;
CESC	cis	rs763121	0.853	rs2072795	chr22:39064209	A/G	cg06544989	chr22:39130855	UNC84B	-0.49	-8.48	-0.46	1.59e-15	Menopause (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14219290	chr14:34420499	EGLN3	-0.57	-6.47	-0.37	4.64e-10	Gut microbiome composition (summer);
CESC	cis	rs7980687	0.657	rs10744151	chr12:123723735	G/C	cg05973401	chr12:123451056	ABCB9	0.45	5.46	0.32	1.08e-7	Height;Educational attainment;Head circumference (infant);
CESC	cis	rs4073582	0.595	rs474005	chr11:66033301	C/T	cg14036092	chr11:66035641	RAB1B	0.56	7.87	0.44	9.14e-14	Gout;
CESC	cis	rs1413885	0.549	rs4593866	chr1:65850968	G/C	cg14976592	chr1:65886160	LEPROT;LEPR	0.47	6.16	0.35	2.64e-9	Anticoagulant levels;
CESC	cis	rs3857067	1.000	rs1904095	chr4:95012530	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.5	-7.53	-0.42	8.12e-13	QT interval;
CESC	cis	rs1707322	1.000	rs10789486	chr1:46408667	A/G	cg03146154	chr1:46216737	IPP	0.7	9.46	0.5	1.75e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs72781680	0.898	rs7563564	chr2:23993404	T/C	cg20701182	chr2:24300061	SF3B14	0.63	5.65	0.33	4.21e-8	Lymphocyte counts;
CESC	cis	rs35110281	0.693	rs3819161	chr21:45092653	A/G	cg21573476	chr21:45109991	RRP1B	-0.58	-7.98	-0.44	4.37e-14	Mean corpuscular volume;
CESC	cis	rs67311347	0.544	rs9814779	chr3:40340431	T/C	cg09455208	chr3:40491958	NA	0.36	6.35	0.36	9.37e-10	Renal cell carcinoma;
CESC	cis	rs3733585	0.726	rs4306953	chr4:9955776	G/A	cg02734326	chr4:10020555	SLC2A9	-0.4	-5.77	-0.33	2.19e-8	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs7216064	0.531	rs62084683	chr17:66031725	A/G	cg07042672	chr17:66097459	LOC651250	0.66	8.86	0.48	1.21e-16	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs11638352	1.000	rs2555385	chr15:44419459	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.59	-5.42	-0.32	1.33e-7	Lipoprotein phospholipase A2 activity in cardiovascular disease;
CESC	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg02353165	chr6:42928485	GNMT	0.82	12.73	0.62	2.68e-29	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs4566357	0.615	rs6436644	chr2:227914275	T/A	cg11843606	chr2:227700838	RHBDD1	-0.48	-6.58	-0.37	2.45e-10	Coronary artery disease;
CESC	cis	rs6580649	0.941	rs11612578	chr12:48414798	T/C	cg24011408	chr12:48396354	COL2A1	-0.42	-5.18	-0.3	4.39e-7	Lung cancer;
CESC	cis	rs597539	0.654	rs655816	chr11:68626405	A/G	cg18350739	chr11:68623251	NA	-0.44	-6.49	-0.37	4.25e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs6741892	0.536	rs6761563	chr2:38891406	A/T	cg01546378	chr2:38892901	GALM	-0.53	-7.11	-0.4	1.05e-11	5-HTT brain serotonin transporter levels;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg00627621	chr8:126442449	TRIB1	0.41	6.26	0.36	1.58e-9	Gambling;
CESC	cis	rs1050631	0.564	rs8098627	chr18:33721636	T/G	cg25426722	chr18:33708991	SLC39A6;ELP2	0.59	8.21	0.45	9.51e-15	Esophageal squamous cell cancer (length of survival);
CESC	cis	rs897984	0.762	rs4889599	chr16:30968589	C/T	cg02466173	chr16:30829666	NA	0.47	7.92	0.44	6.36e-14	Dementia with Lewy bodies;
CESC	cis	rs829883	0.902	rs829884	chr12:98879500	C/G	cg25150519	chr12:98850993	NA	0.68	9.06	0.49	2.94e-17	Colorectal adenoma (advanced);
CESC	cis	rs9847710	0.524	rs11712910	chr3:53094194	C/A	cg18337363	chr3:52569053	NT5DC2	-0.32	-5.13	-0.3	5.56e-7	Ulcerative colitis;
CESC	cis	rs7927771	0.896	rs12794570	chr11:47658314	C/T	cg20307385	chr11:47447363	PSMC3	-0.49	-5.92	-0.34	1.02e-8	Subjective well-being;
CESC	cis	rs6598955	0.572	rs12089219	chr1:26638751	C/T	cg19743891	chr1:26644573	UBXN11;CD52	0.36	5.21	0.3	3.85e-7	Obesity-related traits;
CESC	cis	rs5753618	0.583	rs8138596	chr22:31786961	T/A	cg13145458	chr22:31556086	RNF185	-0.52	-6.17	-0.35	2.6e-9	Colorectal cancer;
CESC	cis	rs5750830	0.649	rs4821893	chr22:39797779	G/A	cg05872129	chr22:39784769	NA	-0.83	-11.27	-0.57	2.51e-24	Intelligence (multi-trait analysis);
CESC	cis	rs2658782	0.950	rs2446061	chr11:93149277	C/T	cg15737290	chr11:93063684	CCDC67	0.52	6.34	0.36	1e-9	Pulmonary function decline;
CESC	cis	rs11920090	0.858	rs66683764	chr3:170720960	A/G	cg09710316	chr3:170744871	SLC2A2	0.47	5.38	0.31	1.62e-7	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
CESC	cis	rs7395581	0.918	rs4752824	chr11:47324666	A/T	cg25783544	chr11:47291846	MADD	0.58	7.46	0.42	1.23e-12	HDL cholesterol;
CESC	cis	rs7772486	0.686	rs7739735	chr6:146123536	G/A	cg05347473	chr6:146136440	FBXO30	0.52	6.84	0.39	5.37e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs35849525	0.814	rs7635601	chr3:50044006	A/T	cg24110177	chr3:50126178	RBM5	-0.45	-5.59	-0.33	5.5e-8	Intelligence (multi-trait analysis);
CESC	cis	rs7202877	0.656	rs3851736	chr16:75387332	T/C	cg04384234	chr16:75411784	CFDP1	-0.49	-5.93	-0.34	9.17e-9	Type 2 diabetes;Type 1 diabetes;
CESC	cis	rs4481887	1.000	rs10888362	chr1:248483975	A/G	cg00666640	chr1:248458726	OR2T12	-0.39	-6.44	-0.37	5.47e-10	Common traits (Other);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg14361641	chr2:70056642	GMCL1	0.5	6.45	0.37	5.36e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs798766	1.000	rs1665362	chr4:1726367	T/A	cg07041428	chr4:1763019	NA	-0.4	-5.75	-0.33	2.45e-8	Bladder cancer;Urinary bladder cancer;
CESC	cis	rs769267	1.000	rs8103197	chr19:19443466	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.42	-5.36	-0.31	1.8e-7	Tonsillectomy;
CESC	cis	rs10504229	0.871	rs10504227	chr8:58162005	G/A	cg24829409	chr8:58192753	C8orf71	-0.64	-8.48	-0.46	1.61e-15	Developmental language disorder (linguistic errors);
CESC	cis	rs9322193	0.962	rs1413655	chr6:150142951	A/G	cg13206674	chr6:150067644	NUP43	0.41	5.67	0.33	3.73e-8	Lung cancer;
CESC	cis	rs12134245	0.747	rs11164929	chr1:92012836	G/C	cg21854759	chr1:92012499	NA	-0.47	-6.03	-0.35	5.57e-9	Breast cancer;
CESC	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg07677032	chr17:61819896	STRADA	0.46	6.22	0.36	1.92e-9	Prudent dietary pattern;
CESC	cis	rs10504229	0.593	rs76118562	chr8:57988110	G/C	cg05313129	chr8:58192883	C8orf71	-0.51	-5.06	-0.3	7.87e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs9858542	0.953	rs9821311	chr3:49543656	C/T	cg07274523	chr3:49395745	GPX1	0.66	8.05	0.44	2.82e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs4835473	0.742	rs6537238	chr4:144917616	T/C	cg25736465	chr4:144833511	NA	0.42	6.28	0.36	1.38e-9	Immature fraction of reticulocytes;
CESC	cis	rs4253772	0.550	rs6007830	chr22:46711323	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.67	6.53	0.37	3.43e-10	LDL cholesterol;Cholesterol, total;
CESC	cis	rs9399137	0.507	rs12663447	chr6:135317026	A/C	cg22676075	chr6:135203613	NA	0.53	7.09	0.4	1.22e-11	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	cis	rs7809950	0.723	rs62483633	chr7:106876644	T/G	cg23024343	chr7:107201750	COG5	-0.54	-6.86	-0.39	4.97e-11	Coronary artery disease;
CESC	cis	rs57221529	0.766	rs56278696	chr5:582669	A/G	cg16447950	chr5:562315	NA	-0.62	-6.48	-0.37	4.46e-10	Lung disease severity in cystic fibrosis;
CESC	cis	rs897984	0.513	rs17839568	chr16:31099783	T/C	cg00531865	chr16:30841666	NA	-0.39	-5.35	-0.31	1.93e-7	Dementia with Lewy bodies;
CESC	cis	rs7605827	0.930	rs4668927	chr2:15706683	C/T	cg19274914	chr2:15703543	NA	0.36	6.43	0.37	5.91e-10	Educational attainment (years of education);
CESC	cis	rs11098499	0.908	rs71614449	chr4:120387055	C/T	cg24375607	chr4:120327624	NA	0.44	5.48	0.32	9.91e-8	Corneal astigmatism;
CESC	cis	rs4595586	0.545	rs12816546	chr12:39398913	C/T	cg26384229	chr12:38710491	ALG10B	0.53	7.47	0.42	1.16e-12	Morning vs. evening chronotype;
CESC	cis	rs9905704	0.633	rs917016	chr17:56454156	C/T	cg12560992	chr17:57184187	TRIM37	-0.62	-5.78	-0.33	2.13e-8	Testicular germ cell tumor;
CESC	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg14338887	chr6:42928500	GNMT	0.37	5.32	0.31	2.17e-7	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	10.25	0.53	5.71e-21	Prudent dietary pattern;
CESC	cis	rs10870270	0.956	rs11146425	chr10:133734261	C/T	cg26149184	chr10:133730230	NA	0.38	5.15	0.3	5.07e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs3204270	0.639	rs62077183	chr17:79658940	C/A	cg18367735	chr17:79674897	NA	0.66	5.62	0.33	4.87e-8	Dental caries;
CESC	cis	rs66782572	1	rs66782572	chr3:52567617	A/G	cg15147215	chr3:52552868	STAB1	-0.33	-5.89	-0.34	1.17e-8	Hemoglobin concentration;
CESC	cis	rs4563143	0.675	rs56293553	chr19:29270455	A/G	cg12667521	chr19:29218732	NA	0.48	6.4	0.37	6.97e-10	Methadone dose in opioid dependence;
CESC	cis	rs7552404	0.731	rs2029683	chr1:76341643	T/G	cg22875332	chr1:76189707	ACADM	-0.6	-6.25	-0.36	1.67e-9	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs796364	0.616	rs7574313	chr2:200681040	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.55	5.06	0.3	7.93e-7	Schizophrenia;
CESC	cis	rs1050631	0.564	rs1625385	chr18:33717364	C/A	cg25426722	chr18:33708991	SLC39A6;ELP2	0.59	8.21	0.45	9.51e-15	Esophageal squamous cell cancer (length of survival);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24129618	chr8:22102425	POLR3D	0.63	7.51	0.42	8.97e-13	Gut microbiome composition (summer);
CESC	cis	rs7552404	0.731	rs11161857	chr1:76370228	G/C	cg03433033	chr1:76189801	ACADM	0.58	5.63	0.33	4.51e-8	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs1707322	0.752	rs61784798	chr1:46173481	C/T	cg05343316	chr1:45956843	TESK2	0.51	6.32	0.36	1.09e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs34779708	0.966	rs35146199	chr10:35460939	T/C	cg03585969	chr10:35415529	CREM	0.77	10.17	0.53	1.03e-20	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs6088580	0.634	rs2378134	chr20:32938085	C/T	cg24642439	chr20:33292090	TP53INP2	-0.52	-6.73	-0.38	1.04e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs7917772	0.503	rs7087665	chr10:104282418	T/C	ch.10.2196322F	chr10:104248062	ACTR1A	0.42	5.18	0.3	4.34e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg24642844	chr7:1081250	C7orf50	-0.77	-9.41	-0.5	2.48e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs4819052	0.851	rs2838864	chr21:46711474	A/T	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.7	-9.42	-0.5	2.31e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs863345	0.584	rs10797024	chr1:158497163	G/A	cg12129480	chr1:158549410	OR10X1	-0.35	-6.86	-0.39	4.78e-11	Pneumococcal bacteremia;
CESC	cis	rs7107174	1.000	rs2511157	chr11:77972632	G/A	cg02023728	chr11:77925099	USP35	0.48	6.35	0.36	9.5e-10	Testicular germ cell tumor;
CESC	cis	rs1577917	0.740	rs6926049	chr6:86266133	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.56	7.83	0.43	1.15e-13	Response to antipsychotic treatment;
CESC	cis	rs9916302	0.904	rs11078910	chr17:37671269	G/T	cg15445000	chr17:37608096	MED1	0.42	7.04	0.4	1.69e-11	Glomerular filtration rate (creatinine);
CESC	trans	rs561341	1.000	rs4795669	chr17:30244701	C/T	cg20587970	chr11:113659929	NA	-1.11	-13.47	-0.64	7.57e-32	Hip circumference adjusted for BMI;
CESC	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg07308232	chr7:1071921	C7orf50	-0.5	-7.19	-0.4	6.5e-12	Longevity;Endometriosis;
CESC	cis	rs875971	0.862	rs13536	chr7:66019190	G/A	cg12463550	chr7:65579703	CRCP	-0.5	-6.32	-0.36	1.08e-9	Aortic root size;
CESC	cis	rs4006360	0.505	rs9916287	chr17:39286884	T/G	cg18442075	chr17:40169520	DNAJC7;NKIRAS2	-0.42	-5.33	-0.31	2.11e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs9611565	0.573	rs9306355	chr22:42111896	A/T	cg06634786	chr22:41940651	POLR3H	0.45	5.07	0.3	7.43e-7	Vitiligo;
CESC	cis	rs875971	1.000	rs6961990	chr7:65888570	C/A	cg12463550	chr7:65579703	CRCP	0.56	7.16	0.4	8.17e-12	Aortic root size;
CESC	cis	rs875971	0.862	rs10282433	chr7:65721439	G/A	cg10691866	chr7:65817282	TPST1	0.31	5.34	0.31	1.95e-7	Aortic root size;
CESC	cis	rs7811142	0.775	rs6946768	chr7:99954393	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.02	9.43	0.5	2.11e-18	Platelet count;
CESC	cis	rs3791556	1.000	rs2411429	chr2:240113928	A/G	cg03281426	chr2:240109471	HDAC4	0.49	5.64	0.33	4.44e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs6582630	0.513	rs11181246	chr12:38302670	C/T	cg26384229	chr12:38710491	ALG10B	0.7	10.34	0.54	2.92e-21	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs9611565	0.506	rs2024567	chr22:41699206	G/C	cg17376030	chr22:41985996	PMM1	0.49	5.43	0.32	1.26e-7	Vitiligo;
CESC	cis	rs3749237	0.964	rs35210174	chr3:49812606	C/T	cg03060546	chr3:49711283	APEH	0.64	7.52	0.42	8.71e-13	Resting heart rate;
CESC	cis	rs820218	0.798	rs9912282	chr17:73673796	G/A	cg01592526	chr17:73663357	RECQL5;SAP30BP	-0.43	-5.88	-0.34	1.25e-8	Rotator cuff tears;
CESC	cis	rs4665809	1.000	rs2053367	chr2:26293413	T/C	cg27170947	chr2:26402098	FAM59B	-0.59	-7.07	-0.4	1.39e-11	Gut microbiome composition (summer);
CESC	cis	rs13191362	1.000	rs34773528	chr6:163088796	G/C	cg06582575	chr6:163149167	PACRG;PARK2	0.99	10.2	0.53	8.22e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs7659604	0.539	rs11731917	chr4:122783233	G/A	cg06713675	chr4:122721982	EXOSC9	-0.51	-6.96	-0.39	2.71e-11	Type 2 diabetes;
CESC	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg26338869	chr17:61819248	STRADA	0.7	9.28	0.5	6.1e-18	Prudent dietary pattern;
CESC	cis	rs4665809	1.000	rs4665298	chr2:26256378	G/A	cg08470875	chr2:26401718	FAM59B	-0.48	-5.35	-0.31	1.89e-7	Gut microbiome composition (summer);
CESC	cis	rs9303401	0.659	rs34170300	chr17:56789905	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.05	12.77	0.62	1.94e-29	Cognitive test performance;
CESC	trans	rs35110281	1.000	rs35110281	chr21:45068947	T/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.53	6.85	0.39	5.04e-11	Mean corpuscular volume;
CESC	cis	rs875971	0.862	rs28491091	chr7:65669064	G/T	cg19163074	chr7:65112434	INTS4L2	0.44	5.47	0.32	1.05e-7	Aortic root size;
CESC	cis	rs7103648	1.000	rs12292911	chr11:47449072	C/T	cg20307385	chr11:47447363	PSMC3	1.01	17.71	0.74	7.61e-47	Diastolic blood pressure;Systolic blood pressure;
CESC	cis	rs1878931	0.597	rs37816	chr16:3456371	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.77	-9.09	-0.49	2.41e-17	Body mass index (adult);
CESC	cis	rs447735	0.507	rs11645271	chr16:89729125	G/T	cg03605463	chr16:89740564	NA	-0.41	-5.07	-0.3	7.45e-7	Hemoglobin concentration;
CESC	cis	rs1008375	1.000	rs10027755	chr4:17615954	G/C	cg15017067	chr4:17643749	FAM184B	0.4	5.72	0.33	2.8e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs4237845	0.804	rs10877034	chr12:58286444	T/C	cg00677455	chr12:58241039	CTDSP2	0.42	5.38	0.31	1.6e-7	Intelligence (multi-trait analysis);
CESC	cis	rs9858542	0.953	rs6997	chr3:49453834	C/T	cg03060546	chr3:49711283	APEH	-0.55	-6.64	-0.38	1.74e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs7202877	0.656	rs9923834	chr16:75507253	T/A	cg04384234	chr16:75411784	CFDP1	-0.44	-5.42	-0.32	1.34e-7	Type 2 diabetes;Type 1 diabetes;
CESC	cis	rs8114671	0.562	rs1018447	chr20:33401707	A/G	cg06115741	chr20:33292138	TP53INP2	-0.42	-5.23	-0.31	3.38e-7	Height;
CESC	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg06074448	chr4:187884817	NA	-0.38	-5.31	-0.31	2.3e-7	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs3806843	0.838	rs2563289	chr5:140122766	T/A	cg16179182	chr5:140090404	VTRNA1-1	0.39	5.07	0.3	7.42e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs41264869	0.600	rs73083129	chr1:205186206	T/C	cg21643547	chr1:205240462	TMCC2	0.35	5.23	0.31	3.44e-7	Blood protein levels;
CESC	cis	rs854765	0.964	rs72827413	chr17:17988299	C/T	cg09796270	chr17:17721594	SREBF1	-0.38	-5.16	-0.3	4.76e-7	Total body bone mineral density;
CESC	cis	rs35306767	0.761	rs12773961	chr10:1013215	C/G	cg26597838	chr10:835615	NA	0.76	7.34	0.41	2.62e-12	Eosinophil percentage of granulocytes;
CESC	cis	rs35306767	0.807	rs61831436	chr10:837882	G/A	cg26597838	chr10:835615	NA	1.18	12.03	0.59	6.79e-27	Eosinophil percentage of granulocytes;
CESC	cis	rs597539	0.580	rs7935851	chr11:68731122	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.78	9.54	0.51	9.59e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	trans	rs6572548	0.504	rs1956082	chr14:49665496	A/C	cg00360600	chr2:38152299	FAM82A1	-0.56	-6.48	-0.37	4.48e-10	Subjective well-being;
CESC	cis	rs2228479	0.850	rs2238525	chr16:89809902	T/C	cg00800038	chr16:89945340	TCF25	-0.77	-7.46	-0.42	1.26e-12	Skin colour saturation;
CESC	cis	rs12681366	0.708	rs2930962	chr8:95445505	G/C	cg13257157	chr8:95487014	RAD54B	0.38	5.14	0.3	5.25e-7	Nonsyndromic cleft lip with cleft palate;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg16919567	chr17:19015961	NA	0.49	6.39	0.37	7.26e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg20017464	chr17:30677219	MIR632;ZNF207	0.45	6.41	0.37	6.63e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs12282928	0.704	rs4980430	chr11:48298269	G/A	cg26585981	chr11:48327164	OR4S1	-0.38	-5.3	-0.31	2.44e-7	Migraine - clinic-based;
CESC	cis	rs1799949	0.773	rs2137990	chr17:41317896	T/A	cg19454999	chr17:41278357	BRCA1;NBR2	-0.51	-7.24	-0.41	4.98e-12	Menopause (age at onset);
CESC	trans	rs1814175	0.615	rs11040654	chr11:49939485	T/G	cg03929089	chr4:120376271	NA	-0.92	-15.2	-0.68	6e-38	Height;
CESC	cis	rs73206853	0.841	rs73191826	chr12:110943001	G/T	cg12870014	chr12:110450643	ANKRD13A	0.63	5.22	0.31	3.56e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs644799	0.710	rs10831433	chr11:95519787	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.73	10.87	0.56	5.24e-23	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs2288073	0.965	rs10173173	chr2:24415461	G/T	cg06627628	chr2:24431161	ITSN2	0.75	8.99	0.48	4.79e-17	Venous thromboembolism (SNP x SNP interaction);
CESC	cis	rs1801251	1.000	rs283474	chr2:233654627	A/G	cg25237894	chr2:233734115	C2orf82	0.46	7.97	0.44	4.73e-14	Coronary artery disease;
CESC	cis	rs919433	0.680	rs7582536	chr2:198436103	C/T	cg03934865	chr2:198174659	NA	-0.39	-5.27	-0.31	2.83e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs17253792	0.822	rs28513551	chr14:56094993	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.79	5.91	0.34	1.06e-8	Putamen volume;
CESC	cis	rs3091242	0.967	rs1053438	chr1:25687901	T/C	cg27572855	chr1:25598939	RHD	-0.44	-7.2	-0.4	6.33e-12	Erythrocyte sedimentation rate;
CESC	cis	rs3125734	0.633	rs4979773	chr10:63967731	G/C	cg09941381	chr10:64027924	RTKN2	-0.32	-5.17	-0.3	4.6e-7	Rheumatoid arthritis;
CESC	cis	rs67311347	1.000	rs28434528	chr3:40484893	A/G	cg24209194	chr3:40518798	ZNF619	0.46	5.99	0.35	6.78e-9	Renal cell carcinoma;
CESC	trans	rs4332037	0.707	rs62435130	chr7:1890002	C/T	cg11693508	chr17:37793320	STARD3	0.61	6.18	0.35	2.45e-9	Bipolar disorder;
CESC	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg12419862	chr22:24373484	LOC391322	0.98	16.37	0.71	4.41e-42	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs910316	0.967	rs4903285	chr14:75609268	A/T	cg16144293	chr14:75469539	EIF2B2	-0.39	-5.03	-0.3	9.07e-7	Height;
CESC	cis	rs2243480	1.000	rs778679	chr7:65840911	A/G	cg12463550	chr7:65579703	CRCP	0.71	5.49	0.32	9.37e-8	Diabetic kidney disease;
CESC	trans	rs1814175	0.676	rs1851859	chr11:49860405	A/T	cg03929089	chr4:120376271	NA	-0.89	-14.21	-0.66	1.89e-34	Height;
CESC	cis	rs597539	0.652	rs602805	chr11:68662076	A/T	cg01988459	chr11:68622903	NA	-0.39	-5.4	-0.31	1.49e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs6460942	0.908	rs59410610	chr7:12282847	A/G	cg20607287	chr7:12443886	VWDE	-0.55	-5.86	-0.34	1.38e-8	Coronary artery disease;
CESC	cis	rs3105593	1.000	rs28817917	chr15:50965846	T/C	cg08437265	chr15:50716283	USP8	0.46	6.07	0.35	4.49e-9	QT interval;
CESC	cis	rs2239547	0.603	rs2276825	chr3:52886605	T/C	cg11645453	chr3:52864694	ITIH4	0.33	6.08	0.35	4.27e-9	Schizophrenia;
CESC	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.48	-5.08	-0.3	7.1e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04810377	chr16:11761964	SNN	0.54	6.35	0.36	9.4e-10	Gut microbiome composition (summer);
CESC	cis	rs26868	0.740	rs26869	chr16:2248786	T/C	cg02248941	chr16:2239361	CASKIN1	0.39	6.13	0.35	3.13e-9	Height;
CESC	cis	rs17021463	0.615	rs4626213	chr4:95297241	G/A	cg11021082	chr4:95130006	SMARCAD1	0.56	7.79	0.43	1.5700000000000001e-13	Testicular germ cell tumor;
CESC	cis	rs7589728	0.858	rs79992736	chr2:88530575	A/C	cg18490616	chr2:88469792	THNSL2	0.53	6.01	0.35	6.01e-9	Plasma clusterin levels;
CESC	cis	rs7274811	0.744	rs55651102	chr20:32188068	A/T	cg21523528	chr20:32077966	CBFA2T2	0.62	7.16	0.4	7.82e-12	Height;
CESC	cis	rs7618915	0.547	rs12486847	chr3:52691112	T/C	cg07507251	chr3:52567010	NT5DC2	0.42	7.25	0.41	4.61e-12	Bipolar disorder;
CESC	cis	rs7772486	0.686	rs1011596	chr6:146076433	A/G	cg05347473	chr6:146136440	FBXO30	0.52	6.8	0.39	6.74e-11	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg13319975	chr6:146136371	FBXO30	-0.44	-6.3	-0.36	1.2e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs4566357	0.930	rs13398295	chr2:227926873	A/G	cg11843606	chr2:227700838	RHBDD1	-0.43	-5.45	-0.32	1.16e-7	Coronary artery disease;
CESC	trans	rs1545843	0.564	rs2446668	chr12:84888491	T/C	cg03015433	chr16:56623111	MT3	0.34	6.04	0.35	5.19e-9	Major depressive disorder;
CESC	cis	rs965469	0.843	rs6037580	chr20:3351374	A/G	cg25506879	chr20:3388711	C20orf194	-0.57	-6.12	-0.35	3.41e-9	IFN-related cytopenia;
CESC	cis	rs1691799	0.867	rs1168356	chr12:66750469	A/G	cg16791601	chr12:66731901	HELB	-0.62	-10.14	-0.53	1.22e-20	White blood cell count (basophil);
CESC	trans	rs6073597	1.000	rs6031980	chr20:43714384	C/T	cg10826053	chr4:108641834	PAPSS1	0.44	6.12	0.35	3.4e-9	Positive affect;
CESC	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg11905131	chr22:24372483	LOC391322	-0.82	-12.36	-0.6	5.28e-28	Liver enzyme levels (gamma-glutamyl transferase);
CESC	trans	rs6716963	0.870	rs6748251	chr2:194468524	A/G	cg13252710	chr13:20134915	NA	0.41	6.09	0.35	3.98e-9	Schizophrenia;
CESC	cis	rs853679	0.517	rs9393898	chr6:28130376	G/T	cg26335602	chr6:28129616	ZNF389	0.53	6.95	0.39	2.83e-11	Depression;
CESC	cis	rs9302635	0.513	rs8050238	chr16:72154187	C/T	cg16558253	chr16:72132732	DHX38	-0.43	-5.52	-0.32	8.09e-8	Blood protein levels;
CESC	cis	rs4819052	0.851	rs4819044	chr21:46660118	G/A	cg11663144	chr21:46675770	NA	-0.62	-9.74	-0.51	2.36e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs9346455	0.568	rs9364155	chr6:72023794	A/G	cg27238071	chr6:71998145	OGFRL1	0.56	5.36	0.31	1.83e-7	Antipsychotic drug-induced weight gain (time interaction);Antipsychotic drug-induced weight gain;
CESC	cis	rs58235267	0.553	rs1025132	chr2:63360639	G/A	cg17519650	chr2:63277830	OTX1	0.56	7.31	0.41	3.18e-12	Prostate-specific antigen levels (conditioned on lead SNPs);
CESC	cis	rs6032067	0.777	rs17423897	chr20:43780307	T/C	cg11264863	chr20:43835661	SEMG1	0.5	5.37	0.31	1.75e-7	Blood protein levels;
CESC	cis	rs644799	0.601	rs662168	chr11:95586982	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.57	8.33	0.46	4.41e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs853679	1.000	rs853676	chr6:28299687	C/T	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.73	7.43	0.42	1.51e-12	Depression;
CESC	cis	rs17666538	0.585	rs1037393	chr8:622634	G/C	cg23958373	chr8:599963	NA	0.82	5.92	0.34	1.02e-8	IgG glycosylation;
CESC	cis	rs1801251	1.000	rs7606090	chr2:233606740	T/C	cg25237894	chr2:233734115	C2orf82	0.44	7.57	0.42	6.22e-13	Coronary artery disease;
CESC	cis	rs9611565	0.503	rs5751156	chr22:42170025	A/G	cg06481639	chr22:41940642	POLR3H	0.6	5.91	0.34	1.02e-8	Vitiligo;
CESC	trans	rs637571	0.546	rs10791827	chr11:65596546	C/A	cg17712092	chr4:129076599	LARP1B	-0.63	-7.96	-0.44	5.2e-14	Eosinophil percentage of white cells;
CESC	cis	rs3762637	1.000	rs9882100	chr3:122169908	T/C	cg24169773	chr3:122142474	KPNA1	-0.54	-6.33	-0.36	1.04e-9	LDL cholesterol levels;
CESC	cis	rs7772486	0.790	rs1832362	chr6:146179955	C/T	cg23711669	chr6:146136114	FBXO30	0.9	13.27	0.63	3.71e-31	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg02294249	chr13:34392492	RFC3	0.47	6.1	0.35	3.71e-9	Gut microbiota (bacterial taxa);
CESC	trans	rs9937837	1.000	rs7499077	chr16:31317505	G/A	cg04903759	chr3:167238645	WDR49	0.52	6.55	0.37	3.05e-10	Systemic lupus erythematosus;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg13456812	chr6:167369504	RNASET2	-0.43	-6.48	-0.37	4.37e-10	Gambling;
CESC	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg18402987	chr7:1209562	NA	0.41	5.3	0.31	2.39e-7	Longevity;Endometriosis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26291818	chr8:61429582	RAB2A	0.65	7.69	0.43	2.98e-13	Gut microbiome composition (summer);
CESC	cis	rs10979	0.597	rs10782290	chr6:143906340	T/C	cg25407410	chr6:143891975	LOC285740	-0.51	-6.75	-0.38	9.09e-11	Hypospadias;
CESC	cis	rs3857536	0.706	rs1418854	chr6:66893284	C/T	cg07460842	chr6:66804631	NA	-0.42	-5.45	-0.32	1.15e-7	Blood trace element (Cu levels);
CESC	cis	rs10911232	0.507	rs4072709	chr1:183028855	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.87	13.58	0.64	3e-32	Hypertriglyceridemia;
CESC	cis	rs9611565	0.694	rs79008	chr22:41850500	C/T	cg03806693	chr22:41940476	POLR3H	-1.13	-14.0	-0.65	1.03e-33	Vitiligo;
CESC	trans	rs9467711	0.606	rs1977	chr6:26377546	A/G	cg06606381	chr12:133084897	FBRSL1	-0.74	-7.3	-0.41	3.35e-12	Autism spectrum disorder or schizophrenia;
CESC	trans	rs6952808	1.000	rs10233560	chr7:1885415	T/C	cg24247370	chr13:99142703	STK24	-0.41	-6.14	-0.35	2.99e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs4853012	0.838	rs4563249	chr2:74354016	G/T	cg01017244	chr2:74357527	NA	0.74	10.89	0.56	4.72e-23	Gestational age at birth (maternal effect);
CESC	cis	rs826838	1.000	rs10875991	chr12:39108886	G/C	cg26384229	chr12:38710491	ALG10B	0.8	13.72	0.64	9.71e-33	Heart rate;
CESC	cis	rs2230307	0.505	rs641458	chr1:100578672	G/C	cg24955406	chr1:100503596	HIAT1	-0.53	-5.31	-0.31	2.35e-7	Carotid intima media thickness;
CESC	cis	rs9916302	0.904	rs12450559	chr17:37694709	G/A	cg15445000	chr17:37608096	MED1	0.42	6.97	0.39	2.52e-11	Glomerular filtration rate (creatinine);
CESC	trans	rs561341	1.000	rs72821971	chr17:30269343	T/G	cg27661571	chr11:113659931	NA	-0.83	-7.82	-0.43	1.26e-13	Hip circumference adjusted for BMI;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11208313	chr17:27276484	PHF12	-0.6	-7.02	-0.4	1.9e-11	Gut microbiome composition (summer);
CESC	cis	rs1707322	0.686	rs2991986	chr1:46081282	A/G	cg03146154	chr1:46216737	IPP	-0.8	-10.89	-0.56	4.66e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs1814175	0.588	rs10839463	chr11:49971643	A/G	cg15704280	chr7:45808275	SEPT13	-1.01	-19.02	-0.76	1.83e-51	Height;
CESC	cis	rs7084402	0.934	rs1158212	chr10:60318276	G/A	cg07615347	chr10:60278583	BICC1	0.61	9.76	0.51	2.03e-19	Refractive error;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg16372595	chr14:20774003	TTC5	0.54	6.85	0.39	5.12e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs4819052	0.851	rs13047104	chr21:46673562	T/G	cg11663144	chr21:46675770	NA	-0.63	-9.84	-0.52	1.12e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs28830936	1.000	rs17677991	chr15:42032383	C/G	cg11010575	chr15:42129464	JMJD7-PLA2G4B;JMJD7	-0.37	-5.43	-0.32	1.25e-7	Diastolic blood pressure;
CESC	cis	rs11098499	0.820	rs13122709	chr4:120555356	T/A	cg24375607	chr4:120327624	NA	0.46	5.72	0.33	2.94e-8	Corneal astigmatism;
CESC	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg22535103	chr8:58192502	C8orf71	-0.9	-9.52	-0.5	1.13e-18	Developmental language disorder (linguistic errors);
CESC	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg07308232	chr7:1071921	C7orf50	-0.6	-8.45	-0.46	1.94e-15	Longevity;Endometriosis;
CESC	cis	rs9309711	0.772	rs9309714	chr2:3491830	G/C	cg10845886	chr2:3471009	TTC15	-0.84	-11.38	-0.57	1.08e-24	Neurofibrillary tangles;
CESC	cis	rs798554	0.797	rs798497	chr7:2795957	A/G	cg19346786	chr7:2764209	NA	-0.49	-7.09	-0.4	1.19e-11	Height;
CESC	cis	rs3762318	1.000	rs12069782	chr1:67600101	C/T	cg17031739	chr1:67600172	NA	0.52	5.55	0.32	7.04e-8	Leprosy;
CESC	cis	rs7631605	0.905	rs11716414	chr3:37258835	G/A	cg22985146	chr3:37219077	LRRFIP2	-0.35	-5.45	-0.32	1.14e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs3091242	1.000	rs3091242	chr1:25674785	C/T	cg02931644	chr1:25747376	RHCE	0.47	7.99	0.44	4.14e-14	Erythrocyte sedimentation rate;
CESC	cis	rs34172651	0.517	rs7204288	chr16:24784531	A/G	cg00339695	chr16:24857497	SLC5A11	0.5	6.53	0.37	3.25e-10	Intelligence (multi-trait analysis);
CESC	cis	rs7618915	0.547	rs13064064	chr3:52657002	T/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.35	6.23	0.36	1.78e-9	Bipolar disorder;
CESC	cis	rs2070488	0.775	rs961179	chr3:38509618	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.83	13.43	0.64	9.82e-32	Electrocardiographic conduction measures;
CESC	cis	rs7192750	0.583	rs2550043	chr16:72067491	T/C	cg14768367	chr16:72042858	DHODH	0.73	5.12	0.3	5.88e-7	LDL cholesterol levels;Total cholesterol levels;
CESC	cis	rs3106136	0.967	rs11097409	chr4:95168515	C/A	cg11021082	chr4:95130006	SMARCAD1	-0.45	-6.76	-0.38	8.72e-11	Capecitabine sensitivity;
CESC	cis	rs6565681	1.000	rs6565681	chr17:78348494	A/G	cg15383979	chr17:78362278	RNF213;LOC100294362	-0.75	-8.4	-0.46	2.75e-15	Moyamoya disease;
CESC	cis	rs2228479	0.850	rs1800355	chr16:89813194	C/T	cg00800038	chr16:89945340	TCF25	-0.88	-7.23	-0.41	5.21e-12	Skin colour saturation;
CESC	cis	rs470119	1.000	rs131801	chr22:50966634	G/T	cg12969734	chr22:50962224	SCO2	0.36	5.54	0.32	7.23e-8	Mean corpuscular hemoglobin;
CESC	cis	rs116095464	0.558	rs7708182	chr5:234788	C/G	cg20965017	chr5:231967	SDHA	-0.45	-5.1	-0.3	6.61e-7	Breast cancer;
CESC	cis	rs2439831	0.850	rs10163054	chr15:44047638	G/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.7	6.6	0.38	2.25e-10	Lung cancer in ever smokers;
CESC	cis	rs17376456	0.877	rs35747258	chr5:93310129	C/T	cg21475434	chr5:93447410	FAM172A	0.76	6.88	0.39	4.31e-11	Diabetic retinopathy;
CESC	cis	rs7666738	0.830	rs17548431	chr4:98923768	C/G	cg05340658	chr4:99064831	C4orf37	0.82	12.2	0.6	1.81e-27	Colonoscopy-negative controls vs population controls;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg02737830	chr12:64616354	C12orf66	0.48	6.53	0.37	3.29e-10	Systemic lupus erythematosus;
CESC	cis	rs3106136	0.934	rs17376404	chr4:95224046	T/A	cg11021082	chr4:95130006	SMARCAD1	-0.46	-6.87	-0.39	4.64e-11	Capecitabine sensitivity;
CESC	cis	rs2832191	0.791	rs2832198	chr21:30498240	C/T	cg24692254	chr21:30365293	RNF160	0.78	12.04	0.59	6.57e-27	Dental caries;
CESC	cis	rs9488822	0.676	rs1338667	chr6:116323910	T/A	cg18764771	chr6:116381957	FRK	0.22	5.44	0.32	1.21e-7	Cholesterol, total;LDL cholesterol;
CESC	cis	rs13102973	0.965	rs13131455	chr4:135883112	A/C	cg14419869	chr4:135874104	NA	-0.34	-5.37	-0.31	1.73e-7	Subjective well-being;
CESC	cis	rs113835537	0.529	rs11227525	chr11:66308065	T/G	cg24851651	chr11:66362959	CCS	0.52	6.23	0.36	1.84e-9	Airway imaging phenotypes;
CESC	cis	rs11098499	0.954	rs3733519	chr4:120423448	A/G	cg24375607	chr4:120327624	NA	0.49	6.03	0.35	5.52e-9	Corneal astigmatism;
CESC	cis	rs7267979	0.586	rs6050431	chr20:25183908	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.66	10.78	0.55	1.07e-22	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs1707322	0.752	rs10789467	chr1:46118745	C/G	cg05343316	chr1:45956843	TESK2	0.5	6.12	0.35	3.43e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs875971	0.895	rs4718349	chr7:65909011	C/G	cg11764359	chr7:65958608	NA	0.95	14.99	0.68	3.2e-37	Aortic root size;
CESC	cis	rs1005277	0.683	rs7923868	chr10:37989766	T/C	cg25427524	chr10:38739819	LOC399744	-0.6	-8.37	-0.46	3.42e-15	Extrinsic epigenetic age acceleration;
CESC	cis	rs10504229	0.953	rs66509078	chr8:58174734	G/C	cg05313129	chr8:58192883	C8orf71	-0.54	-6.23	-0.36	1.82e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs742614	0.533	rs6059498	chr20:32447282	T/C	cg06304546	chr20:32448765	NA	-0.48	-6.17	-0.35	2.6e-9	Stearic acid (18:0) levels;
CESC	cis	rs798554	1.000	rs798560	chr7:2758309	A/G	cg04166393	chr7:2884313	GNA12	0.52	6.53	0.37	3.36e-10	Height;
CESC	cis	rs853679	0.517	rs11552219	chr6:28126834	C/T	cg22143856	chr6:28129313	ZNF389	0.49	6.24	0.36	1.73e-9	Depression;
CESC	cis	rs7666738	0.830	rs6839277	chr4:99015563	C/T	cg03467027	chr4:99064603	C4orf37	0.44	5.63	0.33	4.57e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs12681288	0.862	rs935821	chr8:1022455	G/A	cg04851639	chr8:1020857	NA	-0.4	-8.95	-0.48	6.31e-17	Schizophrenia;
CESC	cis	rs6952808	0.689	rs4719391	chr7:2048136	T/C	cg04267008	chr7:1944627	MAD1L1	-0.56	-6.59	-0.38	2.37e-10	Bipolar disorder and schizophrenia;
CESC	cis	rs6060717	0.654	rs8122716	chr20:34607001	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.5	-5.6	-0.33	5.45e-8	Hip circumference adjusted for BMI;
CESC	cis	rs7617773	0.817	rs13068265	chr3:48301614	A/C	cg11946769	chr3:48343235	NME6	0.86	11.61	0.58	1.78e-25	Coronary artery disease;
CESC	cis	rs6860806	0.507	rs270608	chr5:131648406	C/T	cg18758796	chr5:131593413	PDLIM4	0.44	6.05	0.35	4.85e-9	Breast cancer;
CESC	cis	rs11098499	0.530	rs114866537	chr4:120258608	A/T	cg09307838	chr4:120376055	NA	0.76	10.33	0.54	3.02e-21	Corneal astigmatism;
CESC	cis	rs9905704	0.589	rs2680696	chr17:56473013	C/T	cg12560992	chr17:57184187	TRIM37	-0.62	-5.7	-0.33	3.16e-8	Testicular germ cell tumor;
CESC	cis	rs8141529	0.702	rs132536	chr22:29302906	A/G	cg15103426	chr22:29168792	CCDC117	-0.61	-8.0	-0.44	4.02e-14	Lymphocyte counts;
CESC	cis	rs7618915	0.508	rs7628578	chr3:52628321	A/T	cg07507251	chr3:52567010	NT5DC2	0.33	5.74	0.33	2.64e-8	Bipolar disorder;
CESC	cis	rs7980687	0.628	rs1727332	chr12:123718301	C/T	cg00376283	chr12:123451042	ABCB9	0.68	9.21	0.49	1.04e-17	Height;Educational attainment;Head circumference (infant);
CESC	cis	rs7188697	0.848	rs40187	chr16:58556566	T/C	cg02549819	chr16:58548995	SETD6	-0.41	-5.22	-0.31	3.7e-7	QT interval;
CESC	cis	rs1799949	0.965	rs6503726	chr17:41284742	T/C	cg05368731	chr17:41323189	NBR1	0.55	7.65	0.43	3.69e-13	Menopause (age at onset);
CESC	cis	rs514406	0.621	rs2003250	chr1:53196666	T/C	cg08736216	chr1:53307985	ZYG11A	0.4	6.33	0.36	1.04e-9	Monocyte count;
CESC	cis	rs4835473	0.545	rs10022856	chr4:144714310	A/T	cg25736465	chr4:144833511	NA	0.33	5.42	0.32	1.31e-7	Immature fraction of reticulocytes;
CESC	cis	rs17253792	0.822	rs17683728	chr14:56060389	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.85	6.13	0.35	3.15e-9	Putamen volume;
CESC	cis	rs514406	0.679	rs12563825	chr1:53238324	G/T	cg08736216	chr1:53307985	ZYG11A	0.36	6.48	0.37	4.55e-10	Monocyte count;
CESC	cis	rs2204008	0.807	rs8186948	chr12:38325101	C/G	cg13010199	chr12:38710504	ALG10B	0.44	5.68	0.33	3.51e-8	Bladder cancer;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg15598754	chr1:21551903	ECE1	0.47	6.49	0.37	4.16e-10	Fibrinogen levels;
CESC	cis	rs2290159	0.948	rs7956	chr3:12624763	C/T	cg23032965	chr3:12705835	RAF1	-0.52	-5.97	-0.34	7.39e-9	Cholesterol, total;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10360323	chr17:41437877	NA	-0.6	-6.85	-0.39	5.04e-11	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25536300	chr19:797459	PTBP1	0.61	7.3	0.41	3.37e-12	Gut microbiome composition (summer);
CESC	cis	rs2249694	0.960	rs7084391	chr10:135412344	A/C	cg19469447	chr10:135341870	CYP2E1	0.36	5.09	0.3	6.96e-7	Obesity-related traits;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg05972502	chr5:132073061	KIF3A	-0.49	-6.17	-0.35	2.55e-9	Ulcerative colitis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06905970	chr19:41222748	ADCK4;ITPKC	0.59	7.27	0.41	4.03e-12	Gut microbiome composition (summer);
CESC	cis	rs854765	0.693	rs12936037	chr17:17777245	A/G	cg04398451	chr17:18023971	MYO15A	0.63	8.91	0.48	8.3e-17	Total body bone mineral density;
CESC	cis	rs7824557	0.564	rs2736300	chr8:11235579	T/G	cg21775007	chr8:11205619	TDH	-0.53	-7.86	-0.44	9.39e-14	Retinal vascular caliber;
CESC	cis	rs34779708	0.931	rs4934535	chr10:35432721	G/T	cg04310649	chr10:35416472	CREM	-0.51	-6.14	-0.35	3.02e-9	Inflammatory bowel disease;Crohn's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09192942	chr16:75682004	KARS;TERF2IP	0.59	7.23	0.41	5.1e-12	Gut microbiome composition (summer);
CESC	cis	rs28374715	0.557	rs11855854	chr15:41434729	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.82	-10.29	-0.53	4.1e-21	Ulcerative colitis;
CESC	cis	rs6540559	1.000	rs7522250	chr1:209962539	T/C	cg12034118	chr1:209979487	IRF6	0.44	5.41	0.32	1.39e-7	Cleft lip with or without cleft palate;
CESC	cis	rs4523957	0.928	rs8065650	chr17:2180823	A/G	cg16513277	chr17:2031491	SMG6	0.6	8.38	0.46	3.16e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs11166927	0.703	rs2126128	chr8:140788299	A/G	cg16909799	chr8:140841666	TRAPPC9	-0.45	-6.3	-0.36	1.23e-9	Pediatric non-alcoholic fatty liver disease activity score;
CESC	cis	rs2243480	1.000	rs160633	chr7:65528228	T/C	cg13147721	chr7:65941812	NA	-0.91	-9.0	-0.48	4.55e-17	Diabetic kidney disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27401539	chr15:41048027	FAM82A2	-0.59	-6.63	-0.38	1.87e-10	Gut microbiome composition (summer);
CESC	cis	rs11098499	0.954	rs11098526	chr4:120390359	C/T	cg09307838	chr4:120376055	NA	0.93	13.11	0.63	1.3e-30	Corneal astigmatism;
CESC	cis	rs61931739	0.817	rs10743842	chr12:34306859	C/T	cg19457237	chr12:34500585	NA	-0.39	-5.37	-0.31	1.69e-7	Morning vs. evening chronotype;
CESC	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg18402987	chr7:1209562	NA	0.76	7.79	0.43	1.5e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs11750568	0.967	rs10464079	chr5:178525779	G/A	cg10208897	chr5:178548229	ADAMTS2	0.37	5.25	0.31	3.17e-7	Height;
CESC	cis	rs1552244	0.882	rs13074282	chr3:10024699	T/G	cg00149659	chr3:10157352	C3orf10	0.71	8.4	0.46	2.72e-15	Alzheimer's disease;
CESC	cis	rs9581857	0.547	rs78273785	chr13:28052884	T/C	cg01674679	chr13:27998804	GTF3A	-0.65	-5.19	-0.3	4.24e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
CESC	cis	rs9359856	0.529	rs72919916	chr6:90489773	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.65	-6.61	-0.38	2.13e-10	Bipolar disorder;
CESC	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	7.75	0.43	2.03e-13	Prudent dietary pattern;
CESC	cis	rs9322193	0.923	rs9688938	chr6:150110077	G/A	cg07701084	chr6:150067640	NUP43	0.43	5.85	0.34	1.45e-8	Lung cancer;
CESC	cis	rs425277	0.606	rs2503705	chr1:2076741	A/G	cg16545954	chr1:2118288	C1orf86	0.37	7.1	0.4	1.18e-11	Height;
CESC	cis	rs3087591	0.960	rs2905793	chr17:29470072	C/T	cg24425628	chr17:29625626	OMG;NF1	0.41	5.13	0.3	5.71e-7	Hip circumference;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg09564133	chr5:176738847	MXD3	0.45	6.02	0.35	5.84e-9	Systemic lupus erythematosus;
CESC	trans	rs7618501	0.933	rs1128535	chr3:49866392	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.59	8.32	0.46	4.72e-15	Intelligence (multi-trait analysis);
CESC	cis	rs2933343	1.000	rs2933343	chr3:128658492	G/A	cg25356066	chr3:128598488	ACAD9	0.63	7.66	0.43	3.51e-13	IgG glycosylation;
CESC	cis	rs4950322	0.570	rs72692907	chr1:146773610	A/G	cg22381352	chr1:146742008	CHD1L	-0.47	-5.11	-0.3	6.24e-7	Protein quantitative trait loci;
CESC	cis	rs7703051	0.901	rs6878990	chr5:74689249	T/C	cg03227963	chr5:74354835	NA	0.28	5.06	0.3	7.66e-7	LDL cholesterol;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
CESC	cis	rs13118159	0.742	rs34947293	chr4:1335034	T/C	cg02018176	chr4:1364513	KIAA1530	0.41	5.91	0.34	1.04e-8	Longevity;
CESC	cis	rs2440129	0.611	rs434473	chr17:6904934	A/G	cg03407747	chr17:6899364	ALOX12	-0.41	-6.59	-0.38	2.37e-10	Tonsillectomy;
CESC	cis	rs6963495	0.818	rs1721498	chr7:105178819	A/C	cg13798780	chr7:105162888	PUS7	-0.62	-7.29	-0.41	3.68e-12	Bipolar disorder (body mass index interaction);
CESC	cis	rs2124969	0.522	rs6432608	chr2:161034991	C/T	cg03641300	chr2:160917029	PLA2R1	-0.38	-5.43	-0.32	1.25e-7	Waist circumference adjusted for body mass index;
CESC	cis	rs7481584	0.924	rs16925010	chr11:3013996	C/T	cg25174290	chr11:3078921	CARS	-0.43	-5.22	-0.31	3.65e-7	Calcium levels;
CESC	cis	rs796364	0.806	rs79333757	chr2:200915716	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.85	-7.93	-0.44	6.07e-14	Schizophrenia;
CESC	cis	rs3820928	0.874	rs10188770	chr2:227877037	G/A	cg05526886	chr2:227700861	RHBDD1	-0.46	-5.68	-0.33	3.52e-8	Pulmonary function;
CESC	cis	rs12545109	0.800	rs1913278	chr8:57403725	T/C	cg09654669	chr8:57350985	NA	-0.57	-7.19	-0.4	6.61e-12	Obesity-related traits;
CESC	cis	rs4819052	0.851	rs1056099	chr21:46678892	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.88	12.92	0.62	6.11e-30	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs8062405	0.755	rs4788073	chr16:28594549	A/G	cg01378222	chr16:28622494	SULT1A1	0.31	5.24	0.31	3.28e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs6942756	1.000	rs12112374	chr7:128950071	A/G	cg02491457	chr7:128862824	NA	-0.67	-9.22	-0.49	9.66e-18	White matter hyperintensity burden;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg01604592	chr1:44679056	DMAP1	-0.55	-6.53	-0.37	3.29e-10	Ulcerative colitis;
CESC	cis	rs7666738	0.830	rs11097600	chr4:98959564	T/G	cg18180107	chr4:99064573	C4orf37	0.39	5.09	0.3	6.82e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9916302	0.752	rs9901219	chr17:37558369	T/G	cg15445000	chr17:37608096	MED1	-0.36	-5.28	-0.31	2.71e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs4699052	0.963	rs6533066	chr4:104163607	C/G	cg16532752	chr4:104119610	CENPE	-0.38	-5.06	-0.3	7.7e-7	Testicular germ cell tumor;
CESC	cis	rs3785574	0.962	rs62077509	chr17:61848973	A/G	cg06873352	chr17:61820015	STRADA	0.48	7.07	0.4	1.37e-11	Height;
CESC	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.41	-5.35	-0.31	1.89e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs875971	1.000	rs709595	chr7:65817333	G/C	cg11764359	chr7:65958608	NA	0.95	15.41	0.69	1.05e-38	Aortic root size;
CESC	cis	rs7618915	0.547	rs4687638	chr3:52651966	A/C	cg07507251	chr3:52567010	NT5DC2	0.41	7.2	0.4	6.38e-12	Bipolar disorder;
CESC	cis	rs6952808	0.692	rs12666575	chr7:2004421	C/T	cg05863683	chr7:1912471	MAD1L1	0.42	6.04	0.35	5.12e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs3020736	0.500	rs4147640	chr22:42485292	T/C	cg04733989	chr22:42467013	NAGA	-0.79	-12.03	-0.59	6.75e-27	Autism spectrum disorder or schizophrenia;
CESC	cis	rs10733682	0.524	rs10987422	chr9:129462687	C/A	cg00232160	chr9:129468157	NA	0.42	6.56	0.37	2.75e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs9815354	0.812	rs59583650	chr3:41809063	A/G	cg03022575	chr3:42003672	ULK4	0.68	6.06	0.35	4.7e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs875971	0.545	rs67688847	chr7:65626051	G/A	cg19163074	chr7:65112434	INTS4L2	-0.46	-5.05	-0.3	8.07e-7	Aortic root size;
CESC	trans	rs10832139	0.553	rs16913431	chr11:13942063	T/G	cg11511669	chr12:131556214	GPR133	0.5	6.06	0.35	4.74e-9	P wave terminal force;
CESC	cis	rs2576037	0.899	rs2571034	chr18:44578565	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.38	-5.94	-0.34	8.96e-9	Personality dimensions;
CESC	cis	rs4722166	0.508	rs2069832	chr7:22767433	A/G	cg05472934	chr7:22766657	IL6	0.84	11.19	0.57	4.68e-24	Lung cancer;
CESC	cis	rs933688	1.000	rs11948075	chr5:90680579	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.99	11.87	0.59	2.36e-26	Smoking behavior;
CESC	cis	rs514406	0.708	rs536621	chr1:53309097	A/G	cg16325326	chr1:53192061	ZYG11B	0.61	9.22	0.49	9.55e-18	Monocyte count;
CESC	cis	rs2404602	0.583	rs12913096	chr15:76551852	C/T	cg26408565	chr15:76604113	ETFA	-0.41	-6.21	-0.36	2.04e-9	Blood metabolite levels;
CESC	cis	rs13256369	0.755	rs12680167	chr8:8562467	A/G	cg17143192	chr8:8559678	CLDN23	0.78	9.15	0.49	1.62e-17	Obesity-related traits;
CESC	trans	rs7615952	0.558	rs7641353	chr3:125339879	T/C	cg21747405	chr11:67723411	NA	-0.43	-6.74	-0.38	1.01e-10	Blood pressure (smoking interaction);
CESC	cis	rs1348850	0.526	rs4144278	chr2:178412378	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.71	6.61	0.38	2.13e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs2836974	0.897	rs34599551	chr21:40594898	C/A	cg11644478	chr21:40555479	PSMG1	1.07	17.94	0.74	1.16e-47	Cognitive function;
CESC	cis	rs5769765	0.955	rs8139758	chr22:50261123	G/T	cg26441486	chr22:50317300	CRELD2	-0.39	-5.5	-0.32	8.72e-8	Schizophrenia;
CESC	cis	rs7474896	0.583	rs11011346	chr10:38009483	C/T	cg00409905	chr10:38381863	ZNF37A	-0.49	-5.5	-0.32	8.75e-8	Obesity (extreme);
CESC	cis	rs2288912	0.872	rs9304646	chr19:45450408	T/C	cg13119609	chr19:45449297	APOC2	0.51	8.12	0.45	1.76e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs13082711	0.558	rs640912	chr3:27364092	C/A	cg02860705	chr3:27208620	NA	0.4	5.33	0.31	2.14e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CESC	cis	rs929354	0.685	rs1808217	chr7:157002741	T/C	cg05182265	chr7:156933206	UBE3C	-0.49	-7.25	-0.41	4.51e-12	Body mass index;
CESC	cis	rs4727027	0.901	rs12671341	chr7:148805282	T/C	cg23158103	chr7:148848205	ZNF398	-0.41	-6.46	-0.37	4.89e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs7586879	0.681	rs6752483	chr2:25120086	C/T	cg01884057	chr2:25150051	NA	0.36	7.01	0.4	1.97e-11	Body mass index;
CESC	cis	rs2228479	0.850	rs62056102	chr16:89941438	T/C	cg06558623	chr16:89946397	TCF25	1.13	8.89	0.48	9.9900000000000006e-17	Skin colour saturation;
CESC	cis	rs6963495	0.818	rs117028299	chr7:105162310	T/C	cg13798780	chr7:105162888	PUS7	0.78	8.04	0.44	2.99e-14	Bipolar disorder (body mass index interaction);
CESC	cis	rs1874326	0.524	rs6947999	chr7:138109868	A/G	cg18008034	chr7:138118925	NA	-0.41	-5.14	-0.3	5.34e-7	Quantitative traits;
CESC	cis	rs60154123	0.667	rs650854	chr1:210465315	G/C	cg22029157	chr1:209979665	IRF6	0.48	5.75	0.33	2.41e-8	Coronary artery disease;
CESC	cis	rs10752881	0.967	rs6695746	chr1:182991355	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.84	13.31	0.63	2.66e-31	Colorectal cancer;
CESC	cis	rs796364	1.000	rs166845	chr2:200823360	T/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.9	9.16	0.49	1.48e-17	Schizophrenia;
CESC	cis	rs1215050	0.682	rs6839343	chr4:98839732	G/A	cg05340658	chr4:99064831	C4orf37	0.45	5.08	0.3	6.97e-7	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs1005277	0.540	rs116205409	chr10:38478970	G/A	cg00409905	chr10:38381863	ZNF37A	-0.47	-6.33	-0.36	1.04e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs8070128	0.688	rs59304093	chr17:17875407	A/G	cg09796270	chr17:17721594	SREBF1	0.43	5.68	0.33	3.48e-8	Total body bone mineral density;
CESC	cis	rs6430585	0.702	rs746857	chr2:136554890	G/A	cg07169764	chr2:136633963	MCM6	-1.21	-17.62	-0.73	1.65e-46	Corneal structure;
CESC	cis	rs1018836	0.632	rs9642910	chr8:91475724	G/T	cg16814680	chr8:91681699	NA	-0.61	-8.4	-0.46	2.8e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg07507251	chr3:52567010	NT5DC2	0.37	7.0	0.39	2.13e-11	Bipolar disorder;
CESC	cis	rs798554	0.959	rs798556	chr7:2759002	C/A	cg09658497	chr7:2847517	GNA12	-0.38	-5.33	-0.31	2.08e-7	Height;
CESC	cis	rs7811142	0.830	rs73401451	chr7:99981895	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.08	11.01	0.56	1.83e-23	Platelet count;
CESC	cis	rs2845885	0.793	rs3751120	chr11:63884453	C/T	cg24431193	chr11:63883947	FLRT1;MACROD1	0.76	8.93	0.48	7.38e-17	Body mass index;
CESC	cis	rs6570726	0.791	rs1935612	chr6:145906090	T/A	cg23711669	chr6:146136114	FBXO30	0.9	13.51	0.64	5.42e-32	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs919433	0.783	rs788007	chr2:198233676	T/G	cg20885578	chr2:198174922	NA	0.41	5.36	0.31	1.79e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs17711722	0.522	rs62469933	chr7:65265639	G/A	cg26939375	chr7:64535504	NA	0.67	9.52	0.5	1.17e-18	Calcium levels;
CESC	cis	rs8177253	1.000	rs8177271	chr3:133482230	G/A	cg12373951	chr3:133503437	NA	0.41	5.82	0.34	1.73e-8	Iron status biomarkers;
CESC	cis	rs1552244	0.748	rs113890152	chr3:10085986	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.78	-10.32	-0.54	3.18e-21	Alzheimer's disease;
CESC	cis	rs4563143	0.663	rs73025068	chr19:29238998	G/A	cg04546413	chr19:29218101	NA	0.56	8.15	0.45	1.43e-14	Methadone dose in opioid dependence;
CESC	trans	rs916888	0.773	rs199533	chr17:44828931	G/A	cg27125505	chr17:43679177	LOC644172	0.5	6.72	0.38	1.12e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs3824867	0.770	rs11820680	chr11:47452744	C/T	cg20307385	chr11:47447363	PSMC3	-0.49	-5.94	-0.34	9.16e-9	Mean corpuscular hemoglobin;
CESC	cis	rs875971	1.000	rs11974219	chr7:65647410	C/T	cg10691866	chr7:65817282	TPST1	0.33	5.52	0.32	7.93e-8	Aortic root size;
CESC	cis	rs7666738	0.830	rs17027090	chr4:98897923	G/T	cg03467027	chr4:99064603	C4orf37	0.43	5.28	0.31	2.66e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs561341	0.941	rs2428336	chr17:30290577	T/C	cg19193384	chr17:30244184	NA	-0.63	-6.54	-0.37	3.19e-10	Hip circumference adjusted for BMI;
CESC	cis	rs4481887	0.741	rs11488133	chr1:248548380	T/C	cg26353448	chr1:248524236	OR2T4	-0.37	-5.2	-0.3	4.05e-7	Common traits (Other);
CESC	cis	rs561341	1.000	rs527256	chr17:30321293	C/G	cg23018236	chr17:30244563	NA	-0.52	-5.11	-0.3	6.12e-7	Hip circumference adjusted for BMI;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09444120	chr8:107227878	NA	-0.54	-6.32	-0.36	1.09e-9	Gut microbiome composition (summer);
CESC	cis	rs12478296	0.792	rs57482298	chr2:243011148	C/A	cg06360820	chr2:242988706	NA	-0.93	-9.9	-0.52	7.37e-20	Obesity-related traits;
CESC	cis	rs1669338	0.588	rs7629889	chr3:3187643	C/T	cg16797762	chr3:3221439	CRBN	-0.57	-6.09	-0.35	3.99e-9	White matter integrity;
CESC	cis	rs68170813	0.641	rs12539895	chr7:107091849	C/A	cg02696742	chr7:106810147	HBP1	-0.56	-5.19	-0.3	4.1e-7	Coronary artery disease;
CESC	cis	rs1707322	0.752	rs11211169	chr1:46166709	A/G	cg05343316	chr1:45956843	TESK2	0.51	6.32	0.36	1.09e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7208859	0.562	rs216408	chr17:28907757	C/G	cg17105886	chr17:28927953	LRRC37B2	-0.62	-5.61	-0.33	5e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs7568069	0.669	rs12478953	chr2:71618599	T/C	cg07138437	chr2:71787615	DYSF	-0.3	-5.04	-0.3	8.64e-7	Height;
CESC	cis	rs875971	0.638	rs35986979	chr7:66088990	G/A	cg18876405	chr7:65276391	NA	-0.55	-7.16	-0.4	8.17e-12	Aortic root size;
CESC	cis	rs67311347	0.955	rs6764102	chr3:40378153	C/G	cg24209194	chr3:40518798	ZNF619	0.42	5.44	0.32	1.2e-7	Renal cell carcinoma;
CESC	cis	rs873946	0.648	rs12769533	chr10:134548685	C/T	cg06453172	chr10:134556979	INPP5A	0.42	5.69	0.33	3.41e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs12681288	0.712	rs2600488	chr8:1021266	A/C	cg15309053	chr8:964076	NA	0.37	6.5	0.37	4.01e-10	Schizophrenia;
CESC	cis	rs4862750	0.872	rs6830828	chr4:187897472	T/G	cg07414643	chr4:187882934	NA	0.55	7.99	0.44	4.15e-14	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2115630	0.691	rs2292462	chr15:85200754	G/T	cg11189052	chr15:85197271	WDR73	-0.48	-6.54	-0.37	3.08e-10	P wave terminal force;
CESC	cis	rs12681288	0.792	rs4735972	chr8:998618	A/C	cg15309053	chr8:964076	NA	0.3	5.25	0.31	3.13e-7	Schizophrenia;
CESC	cis	rs11122272	0.525	rs2739517	chr1:231537914	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.55	-7.48	-0.42	1.11e-12	Hemoglobin concentration;
CESC	cis	rs7267979	0.966	rs2482948	chr20:25296499	T/C	cg08601574	chr20:25228251	PYGB	-0.36	-5.13	-0.3	5.74e-7	Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01326135	chr16:87351364	NA	-0.57	-6.26	-0.36	1.51e-9	Gut microbiome composition (summer);
CESC	cis	rs7914558	1.000	rs12780843	chr10:104769335	G/C	cg04362960	chr10:104952993	NT5C2	0.44	5.87	0.34	1.3e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs5758659	0.652	rs133300	chr22:42389839	A/G	cg15557168	chr22:42548783	NA	-0.45	-6.62	-0.38	1.93e-10	Cognitive function;
CESC	cis	rs9549367	0.713	rs3024745	chr13:113821598	A/G	cg18105134	chr13:113819100	PROZ	-0.69	-8.26	-0.45	7.09e-15	Platelet distribution width;
CESC	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg07167872	chr1:205819463	PM20D1	0.76	12.89	0.62	7.57e-30	Menarche (age at onset);
CESC	cis	rs4665809	0.590	rs11897162	chr2:26503654	T/C	cg26314531	chr2:26401878	FAM59B	0.73	7.65	0.43	3.64e-13	Gut microbiome composition (summer);
CESC	cis	rs3768617	0.745	rs4546885	chr1:183025555	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.66	9.15	0.49	1.55e-17	Fuchs's corneal dystrophy;
CESC	cis	rs9486719	0.895	rs34051754	chr6:97007754	A/T	cg18709589	chr6:96969512	KIAA0776	-0.52	-5.69	-0.33	3.43e-8	Migraine;Coronary artery disease;
CESC	cis	rs17253792	0.915	rs78498383	chr14:56177585	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.73	5.13	0.3	5.7e-7	Putamen volume;
CESC	cis	rs6942756	0.747	rs692697	chr7:129112576	C/T	cg02491457	chr7:128862824	NA	0.54	7.46	0.42	1.24e-12	White matter hyperintensity burden;
CESC	cis	rs2455799	0.613	rs1532767	chr3:15733600	A/T	cg16303742	chr3:15540471	COLQ	-0.33	-5.16	-0.3	4.93e-7	Mean platelet volume;
CESC	cis	rs58688157	0.705	rs7928902	chr11:609068	G/A	cg02461776	chr11:598696	PHRF1	0.47	5.17	0.3	4.67e-7	Systemic lupus erythematosus;
CESC	cis	rs9640161	0.789	rs13223702	chr7:150058968	G/A	cg27494647	chr7:150038898	RARRES2	0.44	5.4	0.32	1.45e-7	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs12887734	0.524	rs17791722	chr14:104286210	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.42	-5.51	-0.32	8.42e-8	Schizophrenia;Autism spectrum disorder or schizophrenia;
CESC	cis	rs1707322	0.721	rs10890343	chr1:46157922	C/T	cg06784218	chr1:46089804	CCDC17	0.43	7.73	0.43	2.2e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7044106	0.762	rs10491783	chr9:123450155	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.81	12.82	0.62	1.3e-29	Hip circumference adjusted for BMI;
CESC	cis	rs1878931	0.697	rs1044390	chr16:3432594	T/A	cg22508957	chr16:3507546	NAT15	-0.4	-5.91	-0.34	1.03e-8	Body mass index (adult);
CESC	cis	rs1348850	0.632	rs12467363	chr2:178502512	C/T	cg23306229	chr2:178417860	TTC30B	0.6	7.47	0.42	1.18e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs472109	1.000	rs472109	chr11:9770318	G/C	cg03108697	chr11:9732066	SWAP70	-0.34	-5.14	-0.3	5.23e-7	Coronary artery disease;
CESC	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg01238044	chr22:24384105	GSTT1	0.44	5.48	0.32	9.68e-8	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs4665809	1.000	rs6749855	chr2:26255263	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.8	-8.94	-0.48	7.05e-17	Gut microbiome composition (summer);
CESC	cis	rs7818345	1.000	rs11204041	chr8:19291371	G/A	cg11303988	chr8:19266685	CSGALNACT1	0.34	6.17	0.35	2.54e-9	Language performance in older adults (adjusted for episodic memory);
CESC	cis	rs7481584	0.926	rs10833024	chr11:3010390	C/T	cg25174290	chr11:3078921	CARS	-0.48	-6.02	-0.35	5.82e-9	Calcium levels;
CESC	cis	rs1799949	1.000	rs12952790	chr17:41299607	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.67	9.36	0.5	3.44e-18	Menopause (age at onset);
CESC	cis	rs6964587	1.000	rs10270598	chr7:91700827	T/C	cg17063962	chr7:91808500	NA	0.6	8.37	0.46	3.45e-15	Breast cancer;
CESC	cis	rs7949030	1.000	rs7949030	chr11:62394881	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.42	6.24	0.36	1.69e-9	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs9916302	0.800	rs9892675	chr17:37549200	C/T	cg07936489	chr17:37558343	FBXL20	0.97	12.55	0.61	1.14e-28	Glomerular filtration rate (creatinine);
CESC	cis	rs2243480	0.803	rs160649	chr7:65543199	C/T	cg18252515	chr7:66147081	NA	-1.34	-13.59	-0.64	2.89e-32	Diabetic kidney disease;
CESC	cis	rs10979	1.000	rs9376761	chr6:143887165	G/A	cg25407410	chr6:143891975	LOC285740	-0.61	-9.14	-0.49	1.72e-17	Hypospadias;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13900113	chr1:41131309	RIMS3	0.53	6.38	0.36	7.86e-10	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15440392	chr20:36156634	BLCAP	0.62	6.9	0.39	3.77e-11	Gut microbiome composition (summer);
CESC	cis	rs11997175	0.603	rs6468205	chr8:33778642	T/A	ch.8.33884649F	chr8:33765107	NA	0.5	5.97	0.34	7.59e-9	Body mass index;
CESC	cis	rs1707322	1.000	rs11211244	chr1:46456673	G/A	cg03146154	chr1:46216737	IPP	0.72	9.82	0.52	1.31e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs10751667	0.666	rs10902239	chr11:946484	A/G	cg20946044	chr11:1010712	AP2A2	0.39	5.39	0.31	1.57e-7	Alzheimer's disease (late onset);
CESC	cis	rs3126085	1.000	rs2338556	chr1:152309427	T/A	cg03465714	chr1:152285911	FLG	0.42	5.18	0.3	4.36e-7	Atopic dermatitis;
CESC	cis	rs6860806	0.661	rs1588263	chr5:131577158	T/C	cg04518342	chr5:131593106	PDLIM4	0.41	6.09	0.35	3.86e-9	Breast cancer;
CESC	cis	rs10504229	0.609	rs56289889	chr8:58116276	G/C	cg02725872	chr8:58115012	NA	-0.45	-7.05	-0.4	1.52e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs9649213	0.593	rs2107716	chr7:97944744	G/A	cg24562669	chr7:97807699	LMTK2	0.48	7.0	0.4	2.09e-11	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs55794721	0.509	rs7554255	chr1:25778106	C/T	cg02931644	chr1:25747376	RHCE	0.46	7.97	0.44	4.84e-14	Plateletcrit;Mean corpuscular volume;
CESC	cis	rs7666738	0.791	rs1593571	chr4:98963763	T/C	cg18180107	chr4:99064573	C4orf37	0.4	5.14	0.3	5.26e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7193541	1.000	rs7193541	chr16:74664743	C/T	cg01733217	chr16:74700730	RFWD3	-0.88	-13.3	-0.63	2.91e-31	Multiple myeloma;
CESC	cis	rs66887589	0.967	rs6844263	chr4:120433807	A/G	cg09307838	chr4:120376055	NA	0.5	6.74	0.38	9.75e-11	Diastolic blood pressure;
CESC	cis	rs941873	0.805	rs8837	chr10:81114813	C/G	cg09469691	chr10:81107165	PPIF	0.55	7.3	0.41	3.43e-12	Height;
CESC	cis	rs2262909	0.962	rs409835	chr19:22230671	T/C	cg11619707	chr19:22235551	ZNF257	-0.32	-5.26	-0.31	2.94e-7	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
CESC	cis	rs10751667	0.643	rs10902245	chr11:953014	C/T	cg20946044	chr11:1010712	AP2A2	0.39	5.36	0.31	1.83e-7	Alzheimer's disease (late onset);
CESC	cis	rs59698941	0.765	rs12163971	chr5:132226669	C/A	cg02081065	chr5:132209139	LEAP2	-0.52	-5.11	-0.3	6.08e-7	Apolipoprotein A-IV levels;
CESC	cis	rs1018697	0.518	rs284843	chr10:104553566	C/T	cg04362960	chr10:104952993	NT5C2	-0.55	-6.25	-0.36	1.6e-9	Colorectal adenoma (advanced);
CESC	cis	rs6691722	0.544	rs7551707	chr1:24696892	G/A	cg02336364	chr1:24764700	NIPAL3	0.34	6.96	0.39	2.72e-11	Response to interferon beta in multiple sclerosis;
CESC	cis	rs3096299	0.754	rs2965816	chr16:89514183	G/T	cg16743903	chr16:89593216	SPG7	0.46	6.07	0.35	4.51e-9	Multiple myeloma (IgH translocation);
CESC	cis	rs7267979	1.000	rs2258201	chr20:25272490	G/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	18.72	0.75	2.09e-50	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs12971120	0.891	rs3794955	chr18:72174827	C/T	cg25817165	chr18:72167213	CNDP2	-0.63	-7.69	-0.43	2.8e-13	Refractive error;
CESC	cis	rs10751667	0.961	rs7482484	chr11:927020	C/T	cg06064525	chr11:970664	AP2A2	-0.43	-7.7	-0.43	2.8e-13	Alzheimer's disease (late onset);
CESC	cis	rs1552244	0.882	rs7636817	chr3:10014876	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.86	11.09	0.56	9.7e-24	Alzheimer's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21943418	chr22:41460240	NA	-0.53	-6.07	-0.35	4.32e-9	Gut microbiome composition (summer);
CESC	cis	rs1218582	0.688	rs2135219	chr1:154857217	G/A	cg09359103	chr1:154839909	KCNN3	-0.58	-10.01	-0.52	3.22e-20	Prostate cancer;
CESC	cis	rs796364	1.000	rs1704186	chr2:200769539	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.79	7.71	0.43	2.56e-13	Schizophrenia;
CESC	cis	rs4523957	0.855	rs143499	chr17:2132324	T/C	cg16513277	chr17:2031491	SMG6	0.64	8.9	0.48	9.15e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs7100689	0.646	rs7077854	chr10:82124070	C/T	cg00277334	chr10:82204260	NA	-0.58	-7.76	-0.43	1.84e-13	Post bronchodilator FEV1;
CESC	cis	rs3736485	0.934	rs4143723	chr15:51867172	A/G	cg08986416	chr15:51914746	DMXL2	-0.4	-5.12	-0.3	5.86e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	trans	rs4927850	0.752	rs7624460	chr3:195748530	C/T	cg16724585	chr3:197361211	NA	-0.56	-7.27	-0.41	4.02e-12	Pancreatic cancer;
CESC	cis	rs3809863	0.602	rs2317677	chr17:45393407	G/A	cg08085267	chr17:45401833	C17orf57	-0.68	-9.15	-0.49	1.55e-17	Glaucoma (primary open-angle);
CESC	cis	rs2354432	0.599	rs6693667	chr1:146817245	A/T	cg25205988	chr1:146714368	CHD1L	0.8	8.26	0.45	6.93e-15	Mitochondrial DNA levels;
CESC	cis	rs858239	0.539	rs2178140	chr7:23191625	G/C	cg23682824	chr7:23144976	KLHL7	0.51	6.77	0.38	8.05e-11	Cerebrospinal fluid biomarker levels;
CESC	cis	rs708547	0.533	rs3806746	chr4:57773330	C/T	cg25525207	chr4:57843836	C4orf14;POLR2B	0.43	5.12	0.3	5.78e-7	Response to bleomycin (chromatid breaks);
CESC	cis	rs9329289	0.632	rs2452187	chr10:2551147	C/G	cg15501526	chr10:2543763	NA	0.58	9.24	0.49	8.61e-18	Age-related hearing impairment;
CESC	cis	rs425277	1.000	rs1401138	chr1:2063149	C/T	cg04315214	chr1:2043799	PRKCZ	-0.43	-5.95	-0.34	8.34e-9	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08720189	chr9:140500208	ARRDC1	0.63	7.35	0.41	2.47e-12	Gut microbiome composition (summer);
CESC	cis	rs6598955	0.724	rs6656716	chr1:26563105	G/A	cg04990556	chr1:26633338	UBXN11	-0.78	-11.12	-0.56	7.96e-24	Obesity-related traits;
CESC	cis	rs34779708	0.733	rs60616028	chr10:35543802	G/A	cg04310649	chr10:35416472	CREM	-0.47	-5.14	-0.3	5.31e-7	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs7937682	0.562	rs12275761	chr11:111367083	T/A	cg09085632	chr11:111637200	PPP2R1B	0.58	7.27	0.41	3.98e-12	Primary sclerosing cholangitis;
CESC	cis	rs834811	0.796	rs2349456	chr7:135901545	G/T	cg01726295	chr7:135938950	NA	-0.38	-6.38	-0.36	8.01e-10	Post-traumatic stress disorder;
CESC	cis	rs78707713	0.560	rs61848436	chr10:71247714	C/T	cg12610070	chr10:71211762	TSPAN15	-0.31	-6.47	-0.37	4.69e-10	Venous thromboembolism;
CESC	trans	rs7980799	0.653	rs10844613	chr12:33605362	A/G	cg26384229	chr12:38710491	ALG10B	-0.55	-7.85	-0.43	1.07e-13	Heart rate;Heart rate variability traits (RMSSD);
CESC	cis	rs344364	0.529	rs186941	chr16:1930088	T/C	cg09830162	chr16:1889614	FAHD1;C16orf73	0.55	6.16	0.35	2.7e-9	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs2635047	0.624	rs2289036	chr18:44595809	A/T	cg19077165	chr18:44547161	KATNAL2	0.39	5.26	0.31	3.03e-7	Educational attainment;
CESC	cis	rs17209837	0.607	rs1558376	chr7:87079103	T/A	cg00919237	chr7:87102261	ABCB4	-0.52	-6.67	-0.38	1.45e-10	Gallbladder cancer;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg17114573	chr13:108868021	LIG4	-0.42	-6.17	-0.35	2.55e-9	Gambling;
CESC	cis	rs3858526	0.665	rs10839170	chr11:6003512	C/T	cg13902645	chr11:5959945	NA	-0.41	-5.18	-0.3	4.42e-7	DNA methylation (variation);
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg24333206	chr3:140660642	SLC25A36	-0.49	-6.78	-0.38	7.75e-11	Asthma;
CESC	cis	rs172166	0.637	rs1225595	chr6:28151340	A/T	cg23281280	chr6:28129359	ZNF389	0.4	5.95	0.34	8.58e-9	Cardiac Troponin-T levels;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	ch.13.1677809R	chr13:106622364	NA	0.45	6.42	0.37	6.13e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs3204270	0.639	rs7215738	chr17:79659847	C/T	cg18367735	chr17:79674897	NA	0.67	5.65	0.33	4.08e-8	Dental caries;
CESC	cis	rs9457247	1.000	rs376574	chr6:167389956	A/T	cg07741184	chr6:167504864	NA	0.31	5.53	0.32	7.87e-8	Crohn's disease;
CESC	cis	rs12681366	0.762	rs67639046	chr8:95385780	G/C	cg13257157	chr8:95487014	RAD54B	0.37	5.09	0.3	6.92e-7	Nonsyndromic cleft lip with cleft palate;
CESC	cis	rs6598955	0.950	rs6700455	chr1:26545864	T/C	cg01614726	chr1:26633154	UBXN11	-0.45	-5.23	-0.31	3.38e-7	Obesity-related traits;
CESC	cis	rs10838687	0.800	rs3729802	chr11:47354068	G/A	cg25783544	chr11:47291846	MADD	0.56	6.33	0.36	1.02e-9	Proinsulin levels;
CESC	cis	rs35146811	0.844	rs12705070	chr7:99656927	A/G	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.44	5.52	0.32	7.96e-8	Coronary artery disease;
CESC	cis	rs16854884	0.558	rs60367530	chr3:143719294	G/A	cg06585982	chr3:143692056	C3orf58	0.45	5.36	0.31	1.77e-7	Economic and political preferences (feminism/equality);
CESC	cis	rs853679	0.517	rs9357061	chr6:28051772	A/G	cg19592336	chr6:28129416	ZNF389	0.6	7.97	0.44	4.69e-14	Depression;
CESC	cis	rs2439831	0.867	rs2255042	chr15:43834318	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.72	-9.62	-0.51	5.44e-19	Lung cancer in ever smokers;
CESC	cis	rs929596	0.585	rs2018985	chr2:234648860	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.58	-7.49	-0.42	1.01e-12	Total bilirubin levels in HIV-1 infection;
CESC	cis	rs9311474	0.507	rs6787154	chr3:52784416	C/T	cg18337363	chr3:52569053	NT5DC2	0.28	5.1	0.3	6.43e-7	Electroencephalogram traits;
CESC	trans	rs9354308	0.840	rs17508021	chr6:66569748	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.71	7.96	0.44	5.21e-14	Metabolite levels;
CESC	cis	rs6570726	1.000	rs441477	chr6:145848243	C/T	cg23711669	chr6:146136114	FBXO30	0.78	11.55	0.58	2.8e-25	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2996428	0.628	rs6667526	chr1:3774603	G/A	cg17848003	chr1:3704513	LRRC47	0.39	5.17	0.3	4.62e-7	Red cell distribution width;
CESC	cis	rs1878931	0.501	rs17136359	chr16:3420814	C/T	cg05754148	chr16:3507555	NAT15	0.39	5.18	0.3	4.49e-7	Body mass index (adult);
CESC	trans	rs1814175	0.717	rs11040450	chr11:49650638	G/A	cg15704280	chr7:45808275	SEPT13	-1.0	-17.65	-0.74	1.25e-46	Height;
CESC	cis	rs7618915	0.547	rs34610878	chr3:52759169	G/C	cg17372223	chr3:52568218	NT5DC2	0.45	6.61	0.38	2.14e-10	Bipolar disorder;
CESC	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg21724239	chr8:58056113	NA	0.6	5.45	0.32	1.17e-7	Developmental language disorder (linguistic errors);
CESC	trans	rs2121875	0.638	rs10941660	chr5:44223787	G/C	cg07292773	chr6:156718177	NA	-0.47	-6.09	-0.35	3.99e-9	Prostate cancer;
CESC	cis	rs589448	0.872	rs315111	chr12:69784695	G/A	cg14784868	chr12:69753453	YEATS4	0.85	12.93	0.62	5.5e-30	Cerebrospinal fluid biomarker levels;
CESC	cis	rs34779708	0.966	rs11010122	chr10:35493518	A/C	cg03585969	chr10:35415529	CREM	0.75	9.89	0.52	7.86e-20	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs8177179	0.904	rs1130459	chr3:133465283	A/G	cg17775713	chr3:133465469	TF	0.32	5.71	0.33	3.1e-8	Iron status biomarkers (transferrin levels);
CESC	trans	rs1814175	0.509	rs60698301	chr11:49877672	G/A	cg03929089	chr4:120376271	NA	-0.87	-14.17	-0.66	2.64e-34	Height;
CESC	cis	rs7095944	0.582	rs10901823	chr10:126488660	C/T	cg08799069	chr10:126477246	METTL10	-0.39	-5.58	-0.32	5.92e-8	Asthma;
CESC	cis	rs6987853	0.966	rs2974342	chr8:42436651	A/C	cg09913449	chr8:42400586	C8orf40	0.41	6.46	0.37	4.88e-10	Mean corpuscular hemoglobin concentration;
CESC	cis	rs4853012	0.838	rs61521879	chr2:74346208	T/C	cg01017244	chr2:74357527	NA	0.71	10.57	0.54	4.91e-22	Gestational age at birth (maternal effect);
CESC	cis	rs5769765	0.955	rs9616367	chr22:50303515	A/C	cg26441486	chr22:50317300	CRELD2	0.42	5.29	0.31	2.57e-7	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18184349	chr14:75593719	NEK9	0.64	7.4	0.41	1.77e-12	Gut microbiome composition (summer);
CESC	cis	rs523522	0.962	rs1050187	chr12:120902111	A/G	cg27279351	chr12:120934652	DYNLL1	-0.7	-8.97	-0.48	5.71e-17	High light scatter reticulocyte count;
CESC	cis	rs644799	0.930	rs3802764	chr11:95514599	T/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.72	9.58	0.51	7.54e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs4843747	0.671	rs28671027	chr16:88116323	G/A	cg17633681	chr16:88106987	BANP	0.75	9.98	0.52	4.14e-20	Menopause (age at onset);
CESC	cis	rs79976124	0.797	rs78317899	chr6:66652896	C/A	cg07460842	chr6:66804631	NA	0.74	8.77	0.47	2.22e-16	Type 2 diabetes;
CESC	cis	rs1620921	0.505	rs4708888	chr6:161206490	A/C	cg01280913	chr6:161186852	NA	-0.36	-5.27	-0.31	2.81e-7	Lipoprotein (a) - cholesterol levels;
CESC	cis	rs1953600	1.000	rs1953600	chr10:81911725	A/G	cg00277334	chr10:82204260	NA	0.45	6.39	0.37	7.3e-10	Sarcoidosis;
CESC	cis	rs116095464	0.558	rs55776650	chr5:273826	G/A	cg10591111	chr5:226296	SDHA	-0.53	-6.39	-0.37	7.44e-10	Breast cancer;
CESC	cis	rs7917772	0.536	rs4919667	chr10:104426011	A/G	cg22532475	chr10:104410764	TRIM8	0.41	6.72	0.38	1.1e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs72945132	0.556	rs57172967	chr11:70160060	G/A	cg14191688	chr11:70257035	CTTN	0.42	5.34	0.31	1.95e-7	Coronary artery disease;
CESC	cis	rs2070488	0.804	rs4678605	chr3:38444489	T/A	cg24069376	chr3:38537580	EXOG	0.36	6.02	0.35	5.88e-9	Electrocardiographic conduction measures;
CESC	cis	rs870825	0.655	rs2310104	chr4:185619967	A/G	cg04058563	chr4:185651563	MLF1IP	0.64	7.05	0.4	1.59e-11	Blood protein levels;
CESC	cis	rs10927875	0.632	rs904911	chr1:16126932	C/T	cg21385522	chr1:16154831	NA	-1.03	-16.84	-0.72	9.42e-44	Dilated cardiomyopathy;
CESC	cis	rs2288912	0.807	rs10423208	chr19:45453656	G/A	cg09555818	chr19:45449301	APOC2	0.41	6.54	0.37	3.08e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs7927771	0.524	rs7124396	chr11:47787434	T/G	cg05585544	chr11:47624801	NA	-0.32	-5.11	-0.3	6.09e-7	Subjective well-being;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg18345844	chr7:140400218	NDUFB2	0.42	6.35	0.36	9.09e-10	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs8077577	0.945	rs11871039	chr17:18078904	C/G	cg16794390	chr17:18148240	FLII	0.47	5.89	0.34	1.17e-8	Obesity-related traits;
CESC	cis	rs76878669	0.561	rs4630308	chr11:66162587	G/A	cg18002602	chr11:66138449	SLC29A2	0.39	6.41	0.37	6.45e-10	Educational attainment (years of education);
CESC	cis	rs933688	1.000	rs4382199	chr5:90744228	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.16	13.56	0.64	3.5e-32	Smoking behavior;
CESC	cis	rs8060686	0.641	rs113790673	chr16:68244347	C/T	cg26727032	chr16:67993705	SLC12A4	-0.53	-5.95	-0.34	8.65e-9	HDL cholesterol;Metabolic syndrome;
CESC	trans	rs10028773	0.666	rs12498657	chr4:120262866	G/C	cg25214090	chr10:38739885	LOC399744	0.6	8.26	0.45	6.93e-15	Educational attainment;
CESC	cis	rs8092503	1.000	rs12457101	chr18:52476797	A/G	cg12377874	chr18:52495404	RAB27B	0.38	6.27	0.36	1.46e-9	Childhood body mass index;
CESC	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	21.72	0.8	8.88e-61	Prudent dietary pattern;
CESC	cis	rs875971	0.660	rs6460308	chr7:66084740	T/C	cg14393609	chr7:65229607	NA	-0.47	-6.26	-0.36	1.55e-9	Aortic root size;
CESC	cis	rs1904096	0.506	rs7439869	chr4:95173779	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.64	-9.49	-0.5	1.42e-18	Type 2 diabetes;
CESC	cis	rs6938	0.618	rs11638130	chr15:75183935	G/A	cg09165964	chr15:75287851	SCAMP5	0.46	6.22	0.36	1.97e-9	Breast cancer;
CESC	cis	rs1448094	0.549	rs10863085	chr12:86236328	G/A	cg02569458	chr12:86230093	RASSF9	0.52	7.54	0.42	7.47e-13	Major depressive disorder;
CESC	cis	rs42648	0.869	rs3810890	chr7:89908833	G/T	cg23697855	chr7:89950296	NA	0.27	5.14	0.3	5.43e-7	Homocysteine levels;
CESC	cis	rs17345786	1.000	rs55641278	chr3:101290577	G/A	cg12386194	chr3:101231763	SENP7	0.59	6.55	0.37	2.93e-10	Colonoscopy-negative controls vs population controls;
CESC	cis	rs801193	0.591	rs4506088	chr7:66135457	G/A	cg18876405	chr7:65276391	NA	-0.46	-6.23	-0.36	1.86e-9	Aortic root size;
CESC	cis	rs2730245	0.527	rs2527187	chr7:158716912	T/C	cg24397884	chr7:158709396	WDR60	-0.84	-9.14	-0.49	1.64e-17	Height;
CESC	cis	rs9311474	0.508	rs4687629	chr3:52615227	G/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.6	8.62	0.47	6.18e-16	Electroencephalogram traits;
CESC	cis	rs1153858	0.887	rs7164139	chr15:45670851	G/A	cg21132104	chr15:45694354	SPATA5L1	0.86	11.62	0.58	1.67e-25	Homoarginine levels;
CESC	cis	rs1799949	0.501	rs35399157	chr17:41411602	G/C	cg25072359	chr17:41440525	NA	0.47	6.36	0.36	8.86e-10	Menopause (age at onset);
CESC	cis	rs1008375	1.000	rs2058338	chr4:17678600	A/G	cg02297831	chr4:17616191	MED28	-0.46	-5.91	-0.34	1.03e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs9527	0.590	rs7088200	chr10:104793235	G/A	cg04362960	chr10:104952993	NT5C2	0.42	5.42	0.32	1.33e-7	Arsenic metabolism;
CESC	cis	rs7659604	0.676	rs4516739	chr4:122699741	G/T	cg20573242	chr4:122745356	CCNA2	0.53	6.59	0.38	2.36e-10	Type 2 diabetes;
CESC	cis	rs17666538	0.585	rs6559065	chr8:623156	G/C	cg07234876	chr8:600039	NA	0.85	6.02	0.35	5.83e-9	IgG glycosylation;
CESC	cis	rs244293	0.657	rs4829	chr17:53039315	C/T	cg19360675	chr17:53046073	COX11;STXBP4	-0.45	-6.14	-0.35	3.02e-9	Menarche (age at onset);
CESC	cis	rs3857067	1.000	rs1397027	chr4:95013562	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.5	-7.53	-0.42	8.12e-13	QT interval;
CESC	cis	rs2836974	0.965	rs2836967	chr21:40639102	T/G	cg11890956	chr21:40555474	PSMG1	1.16	21.11	0.79	1.03e-58	Cognitive function;
CESC	cis	rs2404602	0.655	rs4886824	chr15:76969256	A/G	cg22467129	chr15:76604101	ETFA	-0.34	-5.08	-0.3	7.27e-7	Blood metabolite levels;
CESC	cis	rs7116495	1.000	rs542752	chr11:71810644	T/A	cg26138937	chr11:71823887	C11orf51	0.85	6.85	0.39	5.03e-11	Severe influenza A (H1N1) infection;
CESC	cis	rs7659604	0.560	rs769238	chr4:122744942	G/A	cg20573242	chr4:122745356	CCNA2	0.63	7.73	0.43	2.3e-13	Type 2 diabetes;
CESC	cis	rs6952808	0.760	rs11764960	chr7:1950532	G/A	cg04267008	chr7:1944627	MAD1L1	-0.75	-9.86	-0.52	9.46e-20	Bipolar disorder and schizophrenia;
CESC	cis	rs2011503	1.000	rs4808970	chr19:19651140	A/G	cg11584989	chr19:19387371	SF4	0.58	6.67	0.38	1.52e-10	Bipolar disorder;
CESC	cis	rs798554	0.797	rs798494	chr7:2798294	C/A	cg13628971	chr7:2884303	GNA12	0.63	8.14	0.45	1.53e-14	Height;
CESC	cis	rs7692995	1.000	rs7694606	chr4:18028987	G/A	cg08925142	chr4:18023851	LCORL	-0.43	-5.03	-0.3	9e-7	Height;
CESC	cis	rs7845219	0.544	rs2123647	chr8:95931782	A/G	cg23172400	chr8:95962367	TP53INP1	0.38	7.11	0.4	1.09e-11	Type 2 diabetes;
CESC	cis	rs896854	0.812	rs12546365	chr8:95911477	T/C	cg23172400	chr8:95962367	TP53INP1	-0.46	-9.61	-0.51	5.87e-19	Type 2 diabetes;
CESC	cis	rs9815354	1.000	rs56776628	chr3:41866856	A/G	cg03022575	chr3:42003672	ULK4	0.49	5.52	0.32	7.99e-8	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs853679	0.882	rs2743555	chr6:28241081	G/A	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.71	7.37	0.41	2.16e-12	Depression;
CESC	cis	rs7843479	0.965	rs13278159	chr8:21799737	C/A	cg17168535	chr8:21777572	XPO7	0.51	7.08	0.4	1.32e-11	Mean corpuscular volume;
CESC	cis	rs9815354	0.680	rs73073266	chr3:42021116	A/G	cg03022575	chr3:42003672	ULK4	0.74	6.59	0.38	2.33e-10	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs13191362	1.000	rs68144677	chr6:163149024	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.67	6.68	0.38	1.38e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs2228479	0.702	rs62056087	chr16:89920383	C/A	cg04013166	chr16:89971882	TCF25	0.74	5.83	0.34	1.59e-8	Skin colour saturation;
CESC	cis	rs8038465	0.622	rs56712926	chr15:73886849	G/T	cg15420318	chr15:73925796	NPTN	0.49	6.89	0.39	4.17e-11	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs6963495	0.818	rs117907809	chr7:105168472	C/A	cg19920283	chr7:105172520	RINT1	0.69	6.48	0.37	4.45e-10	Bipolar disorder (body mass index interaction);
CESC	cis	rs3126085	0.935	rs4845733	chr1:152162568	T/C	cg03465714	chr1:152285911	FLG	-0.43	-5.29	-0.31	2.56e-7	Atopic dermatitis;
CESC	cis	rs367615	0.704	rs11747622	chr5:108844720	G/A	cg17395555	chr5:108820864	NA	0.63	11.15	0.57	6.1e-24	Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.5	-5.9	-0.34	1.12e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs60154123	0.730	rs588197	chr1:210463515	A/T	cg21951975	chr1:209979733	IRF6	0.45	6.26	0.36	1.58e-9	Coronary artery disease;
CESC	cis	rs3785574	0.962	rs9944483	chr17:61783553	G/T	cg22520471	chr17:61851767	DDX42;CCDC47	-0.56	-6.91	-0.39	3.62e-11	Height;
CESC	cis	rs9911578	0.967	rs8182277	chr17:57144367	C/T	cg12560992	chr17:57184187	TRIM37	1.01	17.95	0.74	1.13e-47	Intelligence (multi-trait analysis);
CESC	cis	rs116988415	0.584	rs17180252	chr14:65239316	G/A	cg25083366	chr14:65239357	SPTB	0.73	5.47	0.32	1.04e-7	Daytime sleep phenotypes;
CESC	cis	rs10504229	0.953	rs116564484	chr8:58172818	T/C	cg14926445	chr8:58193284	C8orf71	-0.49	-5.29	-0.31	2.6e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs9311474	0.629	rs13081028	chr3:52555316	G/A	cg18337363	chr3:52569053	NT5DC2	0.37	7.29	0.41	3.6e-12	Electroencephalogram traits;
CESC	cis	rs9900062	0.546	rs2676289	chr17:62705738	A/G	cg02097616	chr17:62675921	NA	-0.44	-5.41	-0.32	1.42e-7	QT interval;
CESC	cis	rs4535700	0.501	rs11765577	chr7:55997938	G/T	cg09872392	chr7:56161020	PHKG1	0.41	5.86	0.34	1.41e-8	Macular telangiectasia type 2;
CESC	cis	rs7267979	1.000	rs6515651	chr20:25414539	T/G	cg08601574	chr20:25228251	PYGB	-0.38	-5.57	-0.32	6.24e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs8077577	0.747	rs8081155	chr17:18191948	C/G	cg16794390	chr17:18148240	FLII	0.41	6.45	0.37	5.26e-10	Obesity-related traits;
CESC	cis	rs4919044	0.688	rs59539045	chr10:94776594	C/A	cg26979504	chr10:94451518	HHEX	-0.47	-5.15	-0.3	5.16e-7	Coronary artery disease;
CESC	cis	rs13191362	1.000	rs13193282	chr6:163015442	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.5	5.19	0.3	4.29e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs9611565	0.659	rs202653	chr22:41840158	C/T	cg17376030	chr22:41985996	PMM1	-0.56	-6.22	-0.36	1.92e-9	Vitiligo;
CESC	cis	rs9325144	0.555	rs28738714	chr12:38706912	G/A	cg26384229	chr12:38710491	ALG10B	-0.6	-8.5	-0.46	1.36e-15	Morning vs. evening chronotype;
CESC	cis	rs765787	0.530	rs2433228	chr15:45515371	A/C	cg24006582	chr15:45444508	DUOX1	-0.58	-7.12	-0.4	1.04e-11	Uric acid levels;
CESC	cis	rs911555	0.755	rs11620897	chr14:103944861	T/G	cg09975044	chr14:104007538	NA	0.43	5.28	0.31	2.68e-7	Intelligence (multi-trait analysis);
CESC	cis	rs6582630	0.555	rs10880611	chr12:38509316	C/G	cg13010199	chr12:38710504	ALG10B	0.46	5.91	0.34	1.03e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs9486715	0.838	rs9486275	chr6:96901187	C/T	cg18709589	chr6:96969512	KIAA0776	0.47	6.61	0.38	2.16e-10	Headache;
CESC	trans	rs1728785	1.000	rs1728801	chr16:68571457	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.61	7.44	0.42	1.41e-12	Ulcerative colitis;
CESC	cis	rs9309473	0.607	rs1522926	chr2:73591241	T/C	cg20560298	chr2:73613845	ALMS1	-0.46	-6.55	-0.37	3.03e-10	Metabolite levels;
CESC	cis	rs2204008	0.775	rs2387809	chr12:38363338	T/A	cg13010199	chr12:38710504	ALG10B	0.48	6.06	0.35	4.62e-9	Bladder cancer;
CESC	cis	rs13720	0.915	rs184673	chr20:57567543	A/G	cg23907860	chr20:57583709	CTSZ	-0.46	-5.5	-0.32	8.93e-8	Platelet distribution width;
CESC	cis	rs3733585	0.605	rs4235354	chr4:10122942	C/A	cg11266682	chr4:10021025	SLC2A9	-0.57	-10.19	-0.53	8.72e-21	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs910316	0.737	rs175043	chr14:75471803	G/A	cg08847533	chr14:75593920	NEK9	-0.87	-14.32	-0.66	7.93e-35	Height;
CESC	cis	rs7818688	0.614	rs12056808	chr8:95876868	G/A	cg16049864	chr8:95962084	TP53INP1	0.51	5.28	0.31	2.7e-7	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs875971	0.737	rs7803424	chr7:65880605	T/C	cg11764359	chr7:65958608	NA	0.96	15.23	0.68	4.78e-38	Aortic root size;
CESC	cis	rs2730245	0.593	rs842699	chr7:158663404	T/A	cg24397884	chr7:158709396	WDR60	0.69	10.14	0.53	1.23e-20	Height;
CESC	cis	rs7208859	0.623	rs60890550	chr17:29030861	A/G	cg13385521	chr17:29058706	SUZ12P	0.77	6.05	0.35	4.79e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs597539	0.727	rs632984	chr11:68620271	C/T	cg21963583	chr11:68658836	MRPL21	0.4	5.42	0.32	1.36e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs4566357	0.615	rs3769645	chr2:227913717	A/G	cg11843606	chr2:227700838	RHBDD1	-0.48	-6.65	-0.38	1.63e-10	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05917225	chr6:11233042	NEDD9	-0.54	-6.12	-0.35	3.34e-9	Gut microbiome composition (summer);
CESC	cis	rs8177253	0.634	rs6798547	chr3:133448499	G/A	cg24879335	chr3:133465180	TF	0.37	6.45	0.37	5.33e-10	Iron status biomarkers;
CESC	trans	rs6089829	0.962	rs6062778	chr20:61663959	A/G	cg23505145	chr19:12996616	KLF1	0.52	6.74	0.38	1e-10	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs4713118	0.868	rs10484401	chr6:27746590	A/T	cg18032046	chr6:28092343	ZSCAN16	0.51	5.83	0.34	1.58e-8	Parkinson's disease;
CESC	cis	rs2361718	0.500	rs4889818	chr17:78085228	A/G	cg20811857	chr17:78079795	GAA	-0.42	-5.98	-0.34	7.08e-9	Yeast infection;
CESC	cis	rs9322193	0.884	rs9480009	chr6:150079638	A/G	cg09699651	chr6:150184138	LRP11	0.4	5.08	0.3	7.23e-7	Lung cancer;
CESC	cis	rs4819052	0.679	rs28623526	chr21:46712324	T/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.47	6.16	0.35	2.75e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs7264396	0.690	rs2425165	chr20:34438059	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.62	7.35	0.41	2.49e-12	Total cholesterol levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24615751	chr1:40723984	ZMPSTE24	-0.62	-7.43	-0.42	1.51e-12	Gut microbiome composition (summer);
CESC	cis	rs12410462	1.000	rs75360545	chr1:227625419	T/C	cg04117972	chr1:227635322	NA	0.62	6.34	0.36	9.91e-10	Major depressive disorder;
CESC	cis	rs1577917	0.958	rs2875456	chr6:86602284	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.45	-5.78	-0.33	2.13e-8	Response to antipsychotic treatment;
CESC	cis	rs4595586	0.545	rs11615584	chr12:39409350	C/G	cg26384229	chr12:38710491	ALG10B	0.63	8.92	0.48	7.92e-17	Morning vs. evening chronotype;
CESC	cis	rs9322193	0.567	rs7742692	chr6:150213499	A/G	cg09699651	chr6:150184138	LRP11	0.53	7.42	0.41	1.6e-12	Lung cancer;
CESC	cis	rs2014572	0.967	rs4801452	chr19:57768066	A/G	cg12963866	chr19:57752005	ZNF805	-0.48	-6.5	-0.37	3.96e-10	Hyperactive-impulsive symptoms;
CESC	cis	rs9322193	0.923	rs9688861	chr6:149959060	G/T	cg07701084	chr6:150067640	NUP43	0.46	6.52	0.37	3.54e-10	Lung cancer;
CESC	cis	rs7772486	0.806	rs4075696	chr6:146250947	T/C	cg05347473	chr6:146136440	FBXO30	-0.48	-6.42	-0.37	6.21e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg24642844	chr7:1081250	C7orf50	-0.74	-8.93	-0.48	7.18e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs10870270	0.956	rs67378218	chr10:133752420	A/C	cg17892150	chr10:133769511	PPP2R2D	-0.86	-12.71	-0.62	3.22e-29	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs1552244	0.935	rs4441636	chr3:10083876	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.78	-10.37	-0.54	2.24e-21	Alzheimer's disease;
CESC	cis	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg05863683	chr7:1912471	MAD1L1	0.43	6.27	0.36	1.45e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs1707322	1.000	rs6661500	chr1:46465662	T/C	cg03146154	chr1:46216737	IPP	0.72	9.65	0.51	4.58e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs1775715	0.737	rs1419171	chr10:32214831	C/A	cg04359828	chr10:32216031	ARHGAP12	0.37	5.15	0.3	5.1e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs950776	0.518	rs1979907	chr15:78842239	T/C	cg06917634	chr15:78832804	PSMA4	-0.76	-11.38	-0.57	1.04e-24	Sudden cardiac arrest;
CESC	cis	rs7264396	0.580	rs6060648	chr20:34456704	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.66	6.72	0.38	1.1e-10	Total cholesterol levels;
CESC	cis	rs9303401	0.659	rs34818467	chr17:56643109	C/T	cg12560992	chr17:57184187	TRIM37	-0.48	-5.12	-0.3	6e-7	Cognitive test performance;
CESC	cis	rs2228479	0.850	rs11641147	chr16:89813589	C/T	cg00800038	chr16:89945340	TCF25	-0.9	-7.51	-0.42	9.11e-13	Skin colour saturation;
CESC	cis	rs7267979	0.714	rs2474763	chr20:25241295	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.71	11.37	0.57	1.18e-24	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs736408	0.716	rs2239549	chr3:52823126	C/T	cg05564831	chr3:52568323	NT5DC2	0.46	6.72	0.38	1.08e-10	Bipolar disorder;
CESC	trans	rs2842169	0.908	rs1025642	chr10:128307100	A/G	cg27010096	chr5:1060613	SLC12A7	0.81	6.02	0.35	5.91e-9	Response to radiotherapy in prostate cancer (overall toxicity);
CESC	cis	rs3858526	0.508	rs10838734	chr11:5876325	T/G	cg05234568	chr11:5960015	NA	-0.55	-6.89	-0.39	4.14e-11	DNA methylation (variation);
CESC	cis	rs1448094	0.556	rs2061686	chr12:86170951	C/T	cg00310523	chr12:86230176	RASSF9	-0.39	-6.0	-0.35	6.4e-9	Major depressive disorder;
CESC	cis	rs9291683	0.566	rs13115776	chr4:10040189	C/G	cg11266682	chr4:10021025	SLC2A9	0.66	12.58	0.61	9.01e-29	Bone mineral density;
CESC	cis	rs4819052	0.851	rs8133045	chr21:46658137	A/G	cg11663144	chr21:46675770	NA	-0.63	-9.96	-0.52	4.74e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs9649465	1.000	rs2052128	chr7:123380405	T/A	cg04330084	chr7:123175371	IQUB	-0.38	-5.12	-0.3	5.79e-7	Migraine;
CESC	cis	rs8114671	0.562	rs6087651	chr20:33518353	C/T	cg06115741	chr20:33292138	TP53INP2	0.48	5.79	0.34	1.97e-8	Height;
CESC	cis	rs7927771	0.757	rs1057233	chr11:47376448	G/A	cg05585544	chr11:47624801	NA	0.48	6.88	0.39	4.3e-11	Subjective well-being;
CESC	cis	rs6500395	0.926	rs9936446	chr16:48645807	G/C	cg04672837	chr16:48644449	N4BP1	0.47	5.57	0.32	6.4e-8	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs7639513	0.767	rs9861271	chr3:12707620	A/C	cg23032965	chr3:12705835	RAF1	0.76	10.86	0.55	5.83e-23	Itch intensity from mosquito bite;
CESC	cis	rs7937682	0.774	rs59921976	chr11:111473088	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.94	-13.94	-0.65	1.62e-33	Primary sclerosing cholangitis;
CESC	cis	rs1448094	0.512	rs4540904	chr12:86235472	A/G	cg00310523	chr12:86230176	RASSF9	0.35	5.42	0.32	1.35e-7	Major depressive disorder;
CESC	cis	rs4604732	0.578	rs12036417	chr1:247624805	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.57	7.17	0.4	7.39e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs11166927	0.524	rs2035088	chr8:140831403	A/G	cg16909799	chr8:140841666	TRAPPC9	-0.62	-9.68	-0.51	3.66e-19	Pediatric non-alcoholic fatty liver disease activity score;
CESC	cis	rs7833790	0.927	rs61020899	chr8:82757090	C/T	cg07697082	chr8:82753677	SNX16	-0.38	-5.26	-0.31	3.01e-7	Diastolic blood pressure;
CESC	cis	rs933688	1.000	rs2052553	chr5:90729906	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.13	14.43	0.66	3.18e-35	Smoking behavior;
CESC	cis	rs9457247	0.579	rs2181059	chr6:167441624	T/C	cg07741184	chr6:167504864	NA	0.34	6.09	0.35	3.9e-9	Crohn's disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg24232053	chr12:121177221	ACADS	0.48	6.7	0.38	1.24e-10	Fibrinogen levels;
CESC	cis	rs9916302	0.904	rs9898773	chr17:37532507	C/G	cg20243544	chr17:37824526	PNMT	-0.49	-6.21	-0.36	2.05e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs9649213	0.574	rs6979373	chr7:97961844	T/C	cg24562669	chr7:97807699	LMTK2	0.49	7.16	0.4	7.94e-12	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs1538970	0.962	rs4660301	chr1:45820149	T/A	cg06784218	chr1:46089804	CCDC17	0.31	5.15	0.3	5.19e-7	Platelet count;
CESC	cis	rs7666738	0.830	rs10012271	chr4:99065154	A/C	cg03467027	chr4:99064603	C4orf37	0.48	5.95	0.34	8.67e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs66887589	0.934	rs56843000	chr4:120516597	T/C	cg09307838	chr4:120376055	NA	-0.53	-7.07	-0.4	1.35e-11	Diastolic blood pressure;
CESC	cis	rs514406	0.505	rs269290	chr1:53167027	A/T	cg08736216	chr1:53307985	ZYG11A	-0.4	-6.79	-0.38	7.53e-11	Monocyte count;
CESC	cis	rs35995292	0.534	rs11980627	chr7:38907533	T/C	cg19327137	chr7:38886074	VPS41	0.64	10.72	0.55	1.68e-22	Subjective well-being (multi-trait analysis);
CESC	cis	rs739401	0.527	rs423236	chr11:3065916	C/T	cg25174290	chr11:3078921	CARS	0.61	8.61	0.47	6.66e-16	Longevity;
CESC	cis	rs7945705	0.905	rs2568054	chr11:8876029	A/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.38	-6.42	-0.37	6.23e-10	Hemoglobin concentration;
CESC	cis	rs9916302	0.629	rs9972882	chr17:37807698	A/C	cg07936489	chr17:37558343	FBXL20	-0.55	-6.64	-0.38	1.73e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs61990749	0.544	rs11628888	chr14:78161506	T/C	cg21497246	chr14:78225524	SNW1;C14orf178	0.47	5.11	0.3	6.21e-7	Fibroblast growth factor basic levels;
CESC	cis	rs4474465	0.920	rs4945285	chr11:78221698	C/T	cg27205649	chr11:78285834	NARS2	0.44	5.27	0.31	2.83e-7	Alzheimer's disease (survival time);
CESC	cis	rs7666738	0.830	rs9999200	chr4:99030690	A/C	cg03467027	chr4:99064603	C4orf37	0.49	6.18	0.35	2.44e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs34172651	0.517	rs2547040	chr16:24736408	G/C	cg02428538	chr16:24856791	SLC5A11	0.49	5.09	0.3	6.82e-7	Intelligence (multi-trait analysis);
CESC	cis	rs4563143	0.577	rs73025093	chr19:29254618	T/G	cg12667521	chr19:29218732	NA	0.48	6.4	0.37	6.97e-10	Methadone dose in opioid dependence;
CESC	cis	rs763121	0.819	rs3747173	chr22:39069045	A/G	cg21395723	chr22:39101663	GTPBP1	0.42	5.32	0.31	2.17e-7	Menopause (age at onset);
CESC	cis	rs7216064	0.861	rs62084252	chr17:65879578	G/C	cg12091567	chr17:66097778	LOC651250	-0.83	-9.53	-0.51	1.07e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs6933660	0.720	rs6914656	chr6:151753421	C/G	cg02564969	chr6:151773285	C6orf211;RMND1	0.61	8.46	0.46	1.89e-15	Menarche (age at onset);
CESC	cis	rs2576037	0.583	rs545344	chr18:44367079	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.76	12.28	0.6	9.53e-28	Personality dimensions;
CESC	cis	rs703842	1.000	rs10783848	chr12:58196528	G/A	cg18357645	chr12:58087776	OS9	-0.39	-5.56	-0.32	6.57e-8	Multiple sclerosis;
CESC	cis	rs1878931	0.501	rs9921169	chr16:3421261	A/T	cg05754148	chr16:3507555	NAT15	-0.39	-5.31	-0.31	2.37e-7	Body mass index (adult);
CESC	cis	rs9815354	0.812	rs77732985	chr3:41945872	G/A	cg03022575	chr3:42003672	ULK4	0.71	6.45	0.37	5.42e-10	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs2075371	0.966	rs2544225	chr7:133995838	A/C	cg11752832	chr7:134001865	SLC35B4	0.54	7.06	0.4	1.42e-11	Mean platelet volume;
CESC	cis	rs4919044	0.545	rs9420603	chr10:94777490	T/C	cg00487187	chr10:94451625	HHEX	-0.45	-5.05	-0.3	8.21e-7	Coronary artery disease;
CESC	cis	rs7927771	0.832	rs4992357	chr11:47393638	C/T	cg20307385	chr11:47447363	PSMC3	-0.52	-6.25	-0.36	1.6e-9	Subjective well-being;
CESC	cis	rs736408	0.812	rs6778329	chr3:52824610	G/A	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.34	5.69	0.33	3.42e-8	Bipolar disorder;
CESC	cis	rs17401966	1.000	rs11576866	chr1:10414432	A/G	cg15208524	chr1:10270712	KIF1B	0.49	6.27	0.36	1.49e-9	Hepatocellular carcinoma;
CESC	cis	rs57024841	0.562	rs2071006	chr9:139839904	G/T	cg00693599	chr9:139836323	FBXW5	-0.43	-6.2	-0.36	2.16e-9	Beta-trace protein levels;
CESC	cis	rs4836694	0.517	rs1017112	chr9:132936804	A/G	cg05251000	chr9:132935664	FREQ	0.44	5.87	0.34	1.32e-8	Alzheimer's disease (cognitive decline);
CESC	cis	rs1847202	0.826	rs1979884	chr3:72948515	T/C	cg10804678	chr3:72788309	NA	-0.38	-5.17	-0.3	4.65e-7	Motion sickness;
CESC	cis	rs9818758	0.607	rs11716445	chr3:49406095	C/T	cg00383909	chr3:49044727	WDR6	0.95	6.02	0.35	5.77e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CESC	cis	rs2250402	0.510	rs2291621	chr15:40324837	C/T	cg10636054	chr15:40330586	SRP14	0.95	7.2	0.4	6.08e-12	Corneal curvature;
CESC	cis	rs5758659	0.652	rs133327	chr22:42407689	T/C	cg04733989	chr22:42467013	NAGA	0.44	5.85	0.34	1.41e-8	Cognitive function;
CESC	cis	rs6466055	0.720	rs4730080	chr7:105001133	T/C	cg04380332	chr7:105027541	SRPK2	-0.42	-5.46	-0.32	1.07e-7	Schizophrenia;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg15606692	chr11:124669480	C11orf61	0.42	6.59	0.38	2.33e-10	Gambling;
CESC	cis	rs9322193	0.884	rs11155689	chr6:150129606	T/C	cg13206674	chr6:150067644	NUP43	0.42	5.83	0.34	1.64e-8	Lung cancer;
CESC	cis	rs9457247	0.663	rs6456143	chr6:167415440	C/A	cg07741184	chr6:167504864	NA	0.35	6.24	0.36	1.75e-9	Crohn's disease;
CESC	cis	rs9322193	0.962	rs4380763	chr6:149999222	A/G	cg13206674	chr6:150067644	NUP43	0.44	6.2	0.36	2.19e-9	Lung cancer;
CESC	cis	rs4665809	0.590	rs66477033	chr2:26472497	T/C	cg26119090	chr2:26468346	HADHA;HADHB	1.1	12.71	0.62	3.31e-29	Gut microbiome composition (summer);
CESC	cis	rs9814567	1.000	rs7374325	chr3:134275601	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.47	-6.37	-0.36	8.41e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs3026101	0.671	rs739767	chr17:5290681	A/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.43	5.69	0.33	3.37e-8	Body mass index;
CESC	cis	rs9911578	1.000	rs7223955	chr17:56917053	C/A	cg12560992	chr17:57184187	TRIM37	0.94	15.75	0.7	6.57e-40	Intelligence (multi-trait analysis);
CESC	cis	rs10752881	1.000	rs4420053	chr1:182976133	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.83	13.29	0.63	3.24e-31	Colorectal cancer;
CESC	cis	rs2228479	0.867	rs34272502	chr16:89949000	G/C	cg00800038	chr16:89945340	TCF25	-0.88	-7.85	-0.43	1.01e-13	Skin colour saturation;
CESC	cis	rs172166	0.694	rs9295760	chr6:28147385	G/A	cg23161317	chr6:28129485	ZNF389	0.37	5.17	0.3	4.53e-7	Cardiac Troponin-T levels;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg21872608	chr12:54121322	CALCOCO1	-0.48	-6.15	-0.35	2.91e-9	Fibrinogen levels;
CESC	cis	rs708547	0.874	rs1401190	chr4:57885174	T/C	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.52	-5.51	-0.32	8.64e-8	Response to bleomycin (chromatid breaks);
CESC	cis	rs9858213	1	rs9858213	chr3:49731861	G/T	cg07274523	chr3:49395745	GPX1	0.66	8.37	0.46	3.45e-15	Educational attainment;
CESC	cis	rs61935443	0.832	rs7308359	chr12:95272904	G/T	cg21533806	chr12:95267307	NA	0.55	6.85	0.39	5e-11	Schizophrenia;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg18073432	chr5:86180679	NA	-0.43	-6.14	-0.35	2.97e-9	Gut microbiota (bacterial taxa);
CESC	trans	rs208520	0.690	rs207102	chr6:66795671	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.0	-12.83	-0.62	1.2e-29	Exhaled nitric oxide output;
CESC	cis	rs9400271	0.632	rs6930698	chr6:109590304	A/G	cg01475377	chr6:109611718	NA	-0.46	-7.13	-0.4	9.29e-12	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
CESC	cis	rs11158198	0.738	rs910880	chr14:58571274	G/A	cg15908186	chr14:58618357	C14orf37	0.34	5.17	0.3	4.73e-7	Dementia and core Alzheimer's disease neuropathologic changes;
CESC	cis	rs9916302	0.851	rs12947620	chr17:37605364	T/C	cg07936489	chr17:37558343	FBXL20	-0.81	-11.96	-0.59	1.17e-26	Glomerular filtration rate (creatinine);
CESC	trans	rs2085496	0.764	rs1596751	chr2:193807860	A/G	cg00622204	chr4:107238002	TBCK;AIMP1	0.46	6.18	0.35	2.43e-9	Neuroticism;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13790785	chr9:68412296	NA	-0.44	-6.16	-0.35	2.75e-9	Gut microbiome composition (summer);
CESC	cis	rs66573146	1.000	rs6838250	chr4:6973184	C/G	cg00086871	chr4:6988644	TBC1D14	1.07	6.24	0.36	1.72e-9	Granulocyte percentage of myeloid white cells;
CESC	cis	rs3857536	0.706	rs7755994	chr6:66891747	T/C	cg07460842	chr6:66804631	NA	-0.4	-5.23	-0.31	3.47e-7	Blood trace element (Cu levels);
CESC	cis	rs2836633	0.929	rs62217518	chr21:40033189	T/G	cg12884169	chr21:40033163	ERG	0.38	5.99	0.35	6.69e-9	Coronary artery disease;
CESC	trans	rs4498364	0.541	rs1206156	chr6:97550063	T/G	cg09636063	chr6:158957850	TMEM181	0.43	6.12	0.35	3.33e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
CESC	cis	rs2304069	0.954	rs10068537	chr5:149403193	G/A	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.86	10.92	0.56	3.63e-23	HIV-1 control;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg21584983	chr19:11640070	ECSIT	0.47	6.63	0.38	1.83e-10	Systemic lupus erythematosus;
CESC	cis	rs67478160	0.595	rs67768834	chr14:104221085	C/G	cg08213375	chr14:104286397	PPP1R13B	0.55	11.19	0.57	4.64e-24	Schizophrenia;
CESC	cis	rs9457247	0.663	rs2282861	chr6:167440128	C/T	cg23791538	chr6:167370224	RNASET2	-0.57	-7.7	-0.43	2.7e-13	Crohn's disease;
CESC	cis	rs10876993	0.784	rs10083154	chr12:58020933	G/A	cg18357645	chr12:58087776	OS9	-0.57	-8.67	-0.47	4.36e-16	Celiac disease or Rheumatoid arthritis;
CESC	cis	rs798554	1.000	rs798559	chr7:2758341	T/C	cg04166393	chr7:2884313	GNA12	0.52	6.62	0.38	2.01e-10	Height;
CESC	cis	rs6831352	0.918	rs4699714	chr4:100060538	A/G	cg13256891	chr4:100009986	ADH5	-0.75	-8.21	-0.45	9.89e-15	Alcohol dependence;
CESC	cis	rs2288327	0.643	rs1559908	chr2:179336347	C/T	cg11548914	chr2:179343871	FKBP7;PLEKHA3;MIR548N	-0.49	-5.12	-0.3	6e-7	Atrial fibrillation;
CESC	cis	rs4423214	0.610	rs3763856	chr11:71125345	G/A	cg05163923	chr11:71159392	DHCR7	0.61	8.03	0.44	3.1e-14	Vitamin D levels;
CESC	cis	rs8017423	0.647	rs1958346	chr14:90824011	G/T	cg14092571	chr14:90743983	NA	0.44	6.77	0.38	8.12e-11	Mortality in heart failure;
CESC	cis	rs2415984	0.622	rs2123126	chr14:46926609	C/T	cg14871534	chr14:47121158	RPL10L	-0.36	-5.29	-0.31	2.51e-7	Number of children ever born;
CESC	cis	rs597539	0.652	rs478647	chr11:68700424	C/T	cg18350739	chr11:68623251	NA	-0.44	-6.89	-0.39	3.96e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg06938235	chr12:56498303	PA2G4	-0.46	-6.03	-0.35	5.46e-9	Fibrinogen levels;
CESC	cis	rs3806843	1.000	rs10477034	chr5:140169730	A/G	cg26395211	chr5:140044315	WDR55	-0.43	-5.46	-0.32	1.1e-7	Depressive symptoms (multi-trait analysis);
CESC	trans	rs7866350	0.604	rs1935389	chr9:100994470	A/G	cg23093116	chr1:117489843	PTGFRN	0.43	6.22	0.36	1.97e-9	Post-traumatic stress disorder;
CESC	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.63	7.27	0.41	4.09e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs12142240	0.698	rs17361833	chr1:46828700	A/G	cg00530320	chr1:46809349	NSUN4	0.6	8.01	0.44	3.75e-14	Menopause (age at onset);
CESC	cis	rs3733585	0.673	rs4314284	chr4:9956096	C/T	cg00071950	chr4:10020882	SLC2A9	-0.68	-11.25	-0.57	2.91e-24	Cleft plate (environmental tobacco smoke interaction);
CESC	trans	rs17508449	0.865	rs75419513	chr1:114132796	A/T	cg23028848	chr11:57092561	TNKS1BP1	-0.79	-6.26	-0.36	1.54e-9	Leprosy;
CESC	cis	rs6430585	0.583	rs2304371	chr2:136561557	A/G	cg07169764	chr2:136633963	MCM6	1.11	15.69	0.69	1.11e-39	Corneal structure;
CESC	cis	rs712039	0.652	rs2946340	chr17:35749716	C/T	cg16670864	chr17:35848621	DUSP14	0.46	5.94	0.34	8.79e-9	Tuberculosis;
CESC	cis	rs2839186	0.605	rs2839170	chr21:47671305	A/G	cg10351095	chr21:47802916	PCNT	-0.47	-6.32	-0.36	1.13e-9	Testicular germ cell tumor;
CESC	cis	rs4072980	0.545	rs12120737	chr1:38422544	C/T	cg26528311	chr1:38462546	FHL3	0.35	5.4	0.31	1.48e-7	Coronary artery disease;
CESC	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.12	11.36	0.57	1.25e-24	Platelet count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06950873	chr5:170814540	NPM1	0.53	6.01	0.35	6.26e-9	Gut microbiome composition (summer);
CESC	cis	rs60871478	0.588	rs56205589	chr7:910419	G/A	cg15782153	chr7:917662	C7orf20	0.5	5.32	0.31	2.23e-7	Cerebrospinal P-tau181p levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18805285	chr7:152134019	FABP5L3;MLL3	0.57	6.27	0.36	1.43e-9	Gut microbiome composition (summer);
CESC	cis	rs7927771	0.832	rs7924485	chr11:47419129	A/G	cg05585544	chr11:47624801	NA	0.46	6.82	0.39	6.06e-11	Subjective well-being;
CESC	cis	rs1879734	0.773	rs4927025	chr1:54131753	C/T	cg23596471	chr1:54105337	GLIS1	0.35	5.41	0.32	1.39e-7	Mitral valve prolapse;
CESC	cis	rs2836974	0.666	rs35182074	chr21:40685284	A/C	cg11890956	chr21:40555474	PSMG1	-0.94	-15.15	-0.68	8.9e-38	Cognitive function;
CESC	cis	rs780096	0.506	rs1647285	chr2:27714511	A/C	cg22903471	chr2:27725779	GCKR	-0.51	-7.16	-0.4	7.71e-12	Total body bone mineral density;
CESC	cis	rs2991971	1.000	rs2934859	chr1:46017836	C/T	cg03146154	chr1:46216737	IPP	-0.44	-5.5	-0.32	9.01e-8	High light scatter reticulocyte count;
CESC	cis	rs2204008	0.774	rs12810027	chr12:38212165	A/G	cg26384229	chr12:38710491	ALG10B	0.74	10.7	0.55	1.96e-22	Bladder cancer;
CESC	cis	rs9623117	0.958	rs7288667	chr22:40464936	A/G	cg05033341	chr22:40419857	FAM83F	-0.43	-5.24	-0.31	3.28e-7	Prostate cancer (SNP x SNP interaction);Prostate cancer;
CESC	cis	rs875971	1.000	rs6957199	chr7:65978519	T/C	cg18876405	chr7:65276391	NA	0.48	6.31	0.36	1.16e-9	Aortic root size;
CESC	cis	rs2072499	1.000	rs2072499	chr1:156169610	A/G	cg25208724	chr1:156163844	SLC25A44	0.98	18.17	0.74	1.8e-48	Testicular germ cell tumor;
CESC	cis	rs3785574	0.962	rs62077512	chr17:61851435	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.11	19.57	0.77	2.18e-53	Height;
CESC	cis	rs2228479	0.702	rs2074903	chr16:89811663	T/C	cg14709524	chr16:89940631	TCF25	0.95	7.1	0.4	1.18e-11	Skin colour saturation;
CESC	cis	rs6688613	0.694	rs12062326	chr1:166820186	G/A	cg07049167	chr1:166818506	POGK	0.52	6.41	0.37	6.8e-10	Refractive astigmatism;
CESC	cis	rs6547741	1.000	rs1919125	chr2:27801403	C/G	cg27432699	chr2:27873401	GPN1	0.5	7.01	0.4	2.01e-11	Oral cavity cancer;
CESC	cis	rs11122272	0.735	rs2244994	chr1:231537127	C/G	cg06096015	chr1:231504339	EGLN1	0.43	6.08	0.35	4.22e-9	Hemoglobin concentration;
CESC	cis	rs9611565	0.659	rs9607813	chr22:41941479	G/A	cg06634786	chr22:41940651	POLR3H	-0.64	-6.72	-0.38	1.11e-10	Vitiligo;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20361540	chr12:123380447	VPS37B	0.57	6.3	0.36	1.24e-9	Gut microbiome composition (summer);
CESC	cis	rs1387259	0.899	rs7307566	chr12:48604682	A/G	cg24011408	chr12:48396354	COL2A1	0.43	6.11	0.35	3.5e-9	Obstructive sleep apnea trait (apnea hypopnea index);
CESC	cis	rs2228479	0.850	rs45567439	chr16:89814604	G/A	cg19635926	chr16:89946313	TCF25	0.67	5.09	0.3	6.82e-7	Skin colour saturation;
CESC	cis	rs7615952	0.611	rs2971298	chr3:125602713	G/A	cg05084668	chr3:125655381	ALG1L	-0.59	-6.82	-0.39	5.98e-11	Blood pressure (smoking interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02166927	chr17:18761443	PRPSAP2	0.64	7.47	0.42	1.14e-12	Gut microbiome composition (summer);
CESC	cis	rs9302635	0.513	rs7184169	chr16:72152933	C/T	cg16558253	chr16:72132732	DHX38	-0.46	-5.9	-0.34	1.11e-8	Blood protein levels;
CESC	cis	rs10504229	0.724	rs72649117	chr8:58037639	A/G	cg24829409	chr8:58192753	C8orf71	-0.46	-5.84	-0.34	1.53e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs7116495	0.609	rs73543640	chr11:71834374	G/T	cg26138937	chr11:71823887	C11orf51	1.23	7.77	0.43	1.75e-13	Severe influenza A (H1N1) infection;
CESC	cis	rs875971	0.522	rs1880556	chr7:65432544	T/C	cg11764359	chr7:65958608	NA	0.67	8.42	0.46	2.4e-15	Aortic root size;
CESC	cis	rs10540	0.908	rs1044707	chr11:491334	G/T	cg03934478	chr11:495069	RNH1	-0.56	-5.38	-0.31	1.63e-7	Body mass index;
CESC	cis	rs950776	0.518	rs12591557	chr15:78811732	A/G	cg24631222	chr15:78858424	CHRNA5	-0.4	-5.09	-0.3	6.79e-7	Sudden cardiac arrest;
CESC	trans	rs916888	0.610	rs142167	chr17:44795234	C/T	cg22433210	chr17:43662623	NA	-0.59	-7.57	-0.42	6.02e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs870825	0.616	rs28442259	chr4:185646962	T/G	cg04058563	chr4:185651563	MLF1IP	0.63	6.96	0.39	2.59e-11	Blood protein levels;
CESC	cis	rs514406	0.644	rs7529978	chr1:53204705	G/A	cg24675658	chr1:53192096	ZYG11B	0.64	8.84	0.48	1.36e-16	Monocyte count;
CESC	cis	rs116095464	0.558	rs10057674	chr5:266813	C/T	cg20965017	chr5:231967	SDHA	-0.48	-5.43	-0.32	1.25e-7	Breast cancer;
CESC	cis	rs921665	0.831	rs921666	chr2:3192141	G/C	cg02624386	chr2:3182749	NA	0.53	5.17	0.3	4.68e-7	World class endurance athleticism;
CESC	cis	rs61931739	0.500	rs11053198	chr12:34444013	G/C	cg23762105	chr12:34175262	ALG10	-0.4	-5.22	-0.31	3.7e-7	Morning vs. evening chronotype;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg00367532	chr15:74703141	SEMA7A	0.42	6.12	0.35	3.38e-9	Fibrinogen levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04306489	chr17:16593582	CCDC144A	-0.55	-6.55	-0.37	3.01e-10	Gut microbiome composition (summer);
CESC	cis	rs875971	1.000	rs55962648	chr7:65625751	C/G	cg12463550	chr7:65579703	CRCP	-0.57	-7.35	-0.41	2.54e-12	Aortic root size;
CESC	cis	rs7267979	0.527	rs6076369	chr20:25576783	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.69	-10.95	-0.56	2.95e-23	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs35110281	0.712	rs162345	chr21:44954155	T/G	cg04455712	chr21:45112962	RRP1B	0.34	5.21	0.3	3.84e-7	Mean corpuscular volume;
CESC	cis	rs7829975	0.742	rs12547493	chr8:8661534	C/T	cg06636001	chr8:8085503	FLJ10661	-0.46	-5.54	-0.32	7.44e-8	Mood instability;
CESC	cis	rs4819052	0.851	rs2838839	chr21:46667858	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.92	-13.55	-0.64	3.81e-32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs11792861	0.816	rs11791845	chr9:111683898	G/A	cg13535736	chr9:111863775	C9orf5	-0.46	-6.11	-0.35	3.51e-9	Menarche (age at onset);
CESC	cis	rs8017423	0.967	rs59006192	chr14:90706456	C/T	cg14092571	chr14:90743983	NA	-0.58	-8.54	-0.46	1.04e-15	Mortality in heart failure;
CESC	cis	rs6964587	0.869	rs2374519	chr7:91541481	T/C	cg17063962	chr7:91808500	NA	-0.53	-7.17	-0.4	7.67e-12	Breast cancer;
CESC	cis	rs28647808	0.881	rs28494844	chr9:136266188	T/C	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.84	5.73	0.33	2.7e-8	Blood protein levels;
CESC	cis	rs9649213	0.593	rs10953255	chr7:97923198	A/G	cg08684580	chr7:98029266	BAIAP2L1	-0.34	-5.42	-0.32	1.33e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7833790	0.700	rs7834483	chr8:82704828	A/G	cg07697082	chr8:82753677	SNX16	0.38	5.94	0.34	9.05e-9	Diastolic blood pressure;
CESC	cis	rs4076764	0.958	rs12022261	chr1:163398422	A/G	cg24596788	chr1:163392923	NA	-0.5	-7.17	-0.4	7.57e-12	Motion sickness;
CESC	cis	rs1707322	0.752	rs11211168	chr1:46163647	C/T	cg06784218	chr1:46089804	CCDC17	0.41	7.24	0.41	4.84e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs892961	1.000	rs1075457	chr17:75400737	A/G	cg05865280	chr17:75406074	SEPT9	-0.62	-11.76	-0.59	5.74e-26	Airflow obstruction;
CESC	cis	rs9733	0.596	rs56058687	chr1:150635066	C/T	cg17724175	chr1:150552817	MCL1	0.44	7.24	0.41	4.91e-12	Tonsillectomy;
CESC	cis	rs514406	0.679	rs541852	chr1:53256834	A/G	cg08736216	chr1:53307985	ZYG11A	0.36	6.32	0.36	1.09e-9	Monocyte count;
CESC	cis	rs734999	0.572	rs2985857	chr1:2532624	C/T	cg20673091	chr1:2541236	MMEL1	-0.44	-7.14	-0.4	8.9e-12	Ulcerative colitis;
CESC	cis	rs938554	0.571	rs7696092	chr4:10025320	C/A	cg02734326	chr4:10020555	SLC2A9	0.48	5.48	0.32	9.91e-8	Blood metabolite levels;
CESC	cis	rs7246657	0.943	rs10422074	chr19:37894236	T/C	cg23950597	chr19:37808831	NA	-0.62	-6.3	-0.36	1.22e-9	Coronary artery calcification;
CESC	cis	rs986417	0.901	rs8020084	chr14:61001495	C/T	cg00859478	chr14:60978094	SIX6	0.45	5.12	0.3	5.82e-7	Gut microbiota (bacterial taxa);
CESC	cis	rs9457247	0.765	rs10946203	chr6:167446735	A/C	cg07741184	chr6:167504864	NA	0.35	6.32	0.36	1.11e-9	Crohn's disease;
CESC	cis	rs7927771	1.000	rs35624992	chr11:47615798	G/C	cg20135002	chr11:47629003	NA	-0.4	-5.11	-0.3	6.04e-7	Subjective well-being;
CESC	cis	rs6598955	0.671	rs17163751	chr1:26568698	A/G	cg19743891	chr1:26644573	UBXN11;CD52	0.38	5.44	0.32	1.21e-7	Obesity-related traits;
CESC	cis	rs6570726	0.935	rs406343	chr6:145874388	A/G	cg05347473	chr6:146136440	FBXO30	0.47	6.36	0.36	8.62e-10	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12931616	chr22:38528856	PLA2G6	-0.58	-6.81	-0.39	6.6e-11	Gut microbiome composition (summer);
CESC	cis	rs7044106	0.762	rs7024046	chr9:123419178	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.64	8.74	0.47	2.72e-16	Hip circumference adjusted for BMI;
CESC	cis	rs1862618	0.853	rs33325	chr5:56142547	G/C	cg24549020	chr5:56110836	MAP3K1	0.65	7.56	0.42	6.72e-13	Initial pursuit acceleration;
CESC	cis	rs7582720	0.887	rs115600411	chr2:204121145	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.79	6.77	0.38	8.4e-11	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs6582630	0.519	rs8186881	chr12:38310285	A/G	cg13010199	chr12:38710504	ALG10B	0.46	5.79	0.34	1.95e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs9672608	0.687	rs5019044	chr15:78796282	T/A	cg24631222	chr15:78858424	CHRNA5	0.63	7.03	0.4	1.79e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs10857712	0.754	rs1052582	chr10:135233840	C/G	cg01444801	chr10:135216882	MTG1	-0.45	-5.3	-0.31	2.45e-7	Systemic lupus erythematosus;
CESC	cis	rs6540559	0.673	rs17015330	chr1:210012795	T/G	cg23283495	chr1:209979779	IRF6	0.48	5.58	0.32	5.98e-8	Cleft lip with or without cleft palate;
CESC	cis	rs8062405	0.755	rs4788073	chr16:28594549	A/G	cg07382826	chr16:28625726	SULT1A1	0.4	6.72	0.38	1.11e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs2576037	0.899	rs2246877	chr18:44577005	A/G	cg19077165	chr18:44547161	KATNAL2	0.48	6.43	0.37	5.81e-10	Personality dimensions;
CESC	cis	rs7147624	1.000	rs2411354	chr14:66062132	T/C	cg03016385	chr14:66212404	NA	-0.5	-5.21	-0.3	3.86e-7	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs9910055	0.573	rs228768	chr17:42191893	A/C	cg13607699	chr17:42295918	UBTF	0.59	7.78	0.43	1.64e-13	Total body bone mineral density;
CESC	cis	rs7246865	0.510	rs2305757	chr19:17169758	G/C	cg16202187	chr19:17186497	HAUS8;MYO9B	0.49	6.38	0.37	7.74e-10	Reticulocyte fraction of red cells;
CESC	cis	rs7503807	0.651	rs901065	chr17:78599655	G/T	cg09596252	chr17:78655493	RPTOR	0.39	5.43	0.32	1.3e-7	Obesity;
CESC	cis	rs7520050	0.931	rs35743647	chr1:46407252	T/C	cg03146154	chr1:46216737	IPP	-0.47	-6.1	-0.35	3.66e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs12618769	0.597	rs3769743	chr2:99063653	C/T	cg10123293	chr2:99228465	UNC50	0.41	5.42	0.32	1.31e-7	Bipolar disorder;
CESC	cis	rs78456975	0.699	rs17091772	chr2:1519679	A/C	cg01028140	chr2:1542097	TPO	-0.47	-5.34	-0.31	1.99e-7	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs7223966	1.000	rs15637	chr17:61772050	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.46	-5.58	-0.32	5.85e-8	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs72945132	0.882	rs59398290	chr11:70134819	G/A	cg14191688	chr11:70257035	CTTN	0.41	5.27	0.31	2.9e-7	Coronary artery disease;
CESC	cis	rs10479542	0.766	rs6894980	chr5:178974592	C/T	cg14820908	chr5:178986412	RUFY1	0.38	5.34	0.31	2.03e-7	Lung cancer;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg21815882	chr7:26241064	CBX3;HNRNPA2B1	0.49	6.45	0.37	5.2e-10	Systemic lupus erythematosus;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14765172	chr6:153304972	FBXO5	-0.67	-8.01	-0.44	3.69e-14	Gut microbiome composition (summer);
CESC	cis	rs7103648	0.966	rs10769263	chr11:47417183	A/C	cg20307385	chr11:47447363	PSMC3	0.96	16.71	0.72	2.58e-43	Diastolic blood pressure;Systolic blood pressure;
CESC	cis	rs6089584	0.888	rs6142927	chr20:60605848	A/G	cg24733560	chr20:60626293	TAF4	0.44	6.03	0.35	5.46e-9	Body mass index;
CESC	cis	rs1799949	0.896	rs33933393	chr17:41317432	C/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.42	5.74	0.33	2.63e-8	Menopause (age at onset);
CESC	cis	rs57506017	0.585	rs11509137	chr7:12263799	T/C	cg23422036	chr7:12250390	TMEM106B	0.39	5.23	0.31	3.47e-7	Neuroticism;
CESC	cis	rs6540559	0.546	rs59435160	chr1:210030730	C/A	cg25204440	chr1:209979598	IRF6	0.56	5.47	0.32	1.02e-7	Cleft lip with or without cleft palate;
CESC	cis	rs853679	0.546	rs35016036	chr6:28314880	C/T	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.87	5.95	0.34	8.27e-9	Depression;
CESC	cis	rs7772486	0.623	rs735535	chr6:146036829	C/T	cg05347473	chr6:146136440	FBXO30	-0.53	-6.99	-0.39	2.19e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7829975	0.840	rs555617	chr8:8592845	C/G	cg17143192	chr8:8559678	CLDN23	-0.46	-5.67	-0.33	3.71e-8	Mood instability;
CESC	cis	rs7772486	0.846	rs2144478	chr6:146381445	A/G	cg23711669	chr6:146136114	FBXO30	0.78	11.55	0.58	2.95e-25	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6693567	0.526	rs698918	chr1:150319762	A/G	cg09579323	chr1:150459698	TARS2	0.49	6.28	0.36	1.35e-9	Migraine;
CESC	cis	rs7927771	1.000	rs35902101	chr11:47795169	C/T	cg20307385	chr11:47447363	PSMC3	-0.51	-6.25	-0.36	1.62e-9	Subjective well-being;
CESC	cis	rs9814567	1.000	rs9835204	chr3:134261342	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.45	-6.15	-0.35	2.87e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs5769765	0.773	rs7290751	chr22:50318312	T/C	cg02269571	chr22:50332266	NA	-0.56	-6.5	-0.37	3.94e-10	Schizophrenia;
CESC	cis	rs344364	0.511	rs2982452	chr16:1949511	G/A	cg03013636	chr16:1946785	NA	0.48	6.62	0.38	2.02e-10	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs921968	0.643	rs2178019	chr2:219316303	G/A	cg02176678	chr2:219576539	TTLL4	0.36	6.2	0.36	2.15e-9	Mean corpuscular hemoglobin concentration;
CESC	cis	rs9611565	0.625	rs73178625	chr22:41928320	G/C	cg03806693	chr22:41940476	POLR3H	-1.23	-17.18	-0.73	5.78e-45	Vitiligo;
CESC	cis	rs1215050	0.740	rs783932	chr4:98973936	C/G	cg05340658	chr4:99064831	C4orf37	-0.56	-7.55	-0.42	7e-13	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs3820068	0.603	rs72647138	chr1:15980929	C/T	cg17385448	chr1:15911702	AGMAT	0.42	6.89	0.39	4.17e-11	Systolic blood pressure;
CESC	cis	rs72781680	0.699	rs72796125	chr2:23919169	C/T	cg20701182	chr2:24300061	SF3B14	0.79	6.88	0.39	4.25e-11	Lymphocyte counts;
CESC	cis	rs875971	0.545	rs12671152	chr7:65776127	G/T	cg11764359	chr7:65958608	NA	0.81	9.31	0.5	5.14e-18	Aortic root size;
CESC	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg10819733	chr22:24237672	NA	-0.41	-5.91	-0.34	1.05e-8	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs2408955	0.522	rs2051851	chr12:48485940	G/C	cg24011408	chr12:48396354	COL2A1	-0.49	-7.34	-0.41	2.63e-12	Glycated hemoglobin levels;
CESC	cis	rs6060717	0.654	rs6060686	chr20:34512606	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.8	-9.3	-0.5	5.39e-18	Hip circumference adjusted for BMI;
CESC	trans	rs2727020	0.521	rs11040408	chr11:49534880	A/T	cg15704280	chr7:45808275	SEPT13	0.72	9.04	0.49	3.3e-17	Coronary artery disease;
CESC	cis	rs6840258	1.000	rs7682652	chr4:87913444	C/T	cg08197287	chr4:87952173	AFF1	-0.42	-5.71	-0.33	3.09e-8	Mean corpuscular volume;Basophil percentage of granulocytes;
CESC	cis	rs2985684	0.901	rs7146248	chr14:50112067	C/T	cg10008539	chr14:50087325	RPL36AL;MGAT2	-0.46	-5.36	-0.31	1.83e-7	Carotid intima media thickness;
CESC	cis	rs4975709	0.959	rs9312959	chr5:1877008	G/A	cg15595755	chr5:1867978	NA	0.46	7.33	0.41	2.84e-12	Cardiovascular disease risk factors;
CESC	cis	rs6089584	0.566	rs6061972	chr20:60610245	C/T	cg24733560	chr20:60626293	TAF4	0.44	6.54	0.37	3.15e-10	Body mass index;
CESC	cis	rs3026101	0.671	rs1989946	chr17:5313152	T/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.45	6.03	0.35	5.47e-9	Body mass index;
CESC	cis	rs2019216	0.524	rs1518049	chr17:21922055	C/T	cg22648282	chr17:21454238	C17orf51	-0.43	-5.67	-0.33	3.72e-8	Pelvic organ prolapse;
CESC	cis	rs4665809	0.590	rs3806515	chr2:26466975	C/T	cg25036284	chr2:26402008	FAM59B	0.86	9.4	0.5	2.74e-18	Gut microbiome composition (summer);
CESC	cis	rs12540874	0.698	rs13234331	chr7:50560314	G/T	cg18232548	chr7:50535776	DDC	-0.41	-5.73	-0.33	2.74e-8	Systemic sclerosis;
CESC	cis	rs1008375	0.900	rs7658447	chr4:17579415	T/C	cg16339924	chr4:17578868	LAP3	0.83	10.53	0.54	6.69e-22	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	trans	rs12479064	0.694	rs4341989	chr2:100046783	C/T	cg20598333	chr11:3663511	ART5	0.49	6.0	0.35	6.48e-9	Chronic sinus infection;
CESC	cis	rs9796	0.689	rs28409432	chr15:41447454	G/A	cg12426344	chr15:41135900	SPINT1	-0.25	-5.51	-0.32	8.63e-8	Menopause (age at onset);
CESC	cis	rs6860806	0.661	rs6890009	chr5:131580033	G/T	cg09877947	chr5:131593287	PDLIM4	0.45	5.77	0.33	2.21e-8	Breast cancer;
CESC	cis	rs2273669	0.667	rs7765732	chr6:109347057	A/C	cg05315195	chr6:109294784	ARMC2	-0.67	-6.32	-0.36	1.13e-9	Prostate cancer;
CESC	cis	rs7726839	0.574	rs12517345	chr5:628294	G/A	cg16447950	chr5:562315	NA	-0.58	-5.87	-0.34	1.3e-8	Obesity-related traits;
CESC	cis	rs16854884	0.632	rs35362423	chr3:143687441	C/A	cg06585982	chr3:143692056	C3orf58	0.48	6.01	0.35	6.11e-9	Economic and political preferences (feminism/equality);
CESC	cis	rs8103278	0.507	rs3745802	chr19:46271177	G/T	cg06577658	chr19:46296270	DMWD	0.43	5.2	0.3	3.94e-7	Coronary artery disease;
CESC	cis	rs7635838	0.750	rs2648463	chr3:11403857	G/A	cg00170343	chr3:11313890	ATG7	0.5	7.09	0.4	1.25e-11	HDL cholesterol;
CESC	cis	rs2228479	1.000	rs62052213	chr16:89991963	C/T	cg04013166	chr16:89971882	TCF25	0.79	6.58	0.37	2.57e-10	Skin colour saturation;
CESC	cis	rs9660992	0.710	rs1172136	chr1:205247097	T/G	cg00857998	chr1:205179979	DSTYK	0.46	5.21	0.3	3.77e-7	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs3806843	0.868	rs2531349	chr5:140120953	G/A	cg26395211	chr5:140044315	WDR55	0.43	5.59	0.32	5.69e-8	Depressive symptoms (multi-trait analysis);
CESC	cis	rs909674	0.818	rs5757680	chr22:39844793	C/T	cg24399712	chr22:39784796	NA	0.75	9.77	0.51	1.92e-19	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs5769765	0.671	rs138833	chr22:50178917	A/G	cg02269571	chr22:50332266	NA	-0.45	-5.89	-0.34	1.17e-8	Schizophrenia;
CESC	cis	rs3785574	0.927	rs2854183	chr17:61968002	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.76	9.74	0.51	2.37e-19	Height;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg20306180	chr22:32340197	C22orf24;YWHAH	-0.44	-6.14	-0.35	2.92e-9	Asthma;
CESC	cis	rs5750830	0.649	rs5750818	chr22:39820885	A/G	cg24399712	chr22:39784796	NA	-0.83	-11.2	-0.57	4.21e-24	Intelligence (multi-trait analysis);
CESC	cis	rs12142240	0.698	rs7515284	chr1:46809419	A/G	cg10495392	chr1:46806563	NSUN4	0.59	6.34	0.36	9.65e-10	Menopause (age at onset);
CESC	cis	rs10789491	1.000	rs2083485	chr1:47170091	G/C	cg15501359	chr1:47185051	KIAA0494	0.79	8.81	0.48	1.66e-16	Response to hepatitis C treatment;
CESC	cis	rs2204008	0.837	rs12369089	chr12:38060263	G/A	cg13010199	chr12:38710504	ALG10B	0.54	6.69	0.38	1.3100000000000001e-10	Bladder cancer;
CESC	cis	rs7091068	0.567	rs1572773	chr10:95432968	T/C	cg20715218	chr10:95462985	C10orf4	0.47	6.07	0.35	4.47e-9	Urinary tract infection frequency;
CESC	trans	rs13098911	0.540	rs17282238	chr3:46174605	A/G	cg10236987	chr1:228114221	WNT9A	0.59	6.17	0.35	2.61e-9	Celiac disease;
CESC	cis	rs2072732	0.904	rs1138513	chr1:2976816	T/C	cg22517653	chr1:2918612	NA	-0.41	-5.58	-0.32	5.93e-8	Plateletcrit;
CESC	cis	rs4072980	0.524	rs16824514	chr1:38395947	A/T	cg12658694	chr1:38397304	INPP5B	0.72	10.12	0.53	1.5e-20	Coronary artery disease;
CESC	cis	rs875971	0.830	rs7799834	chr7:65880694	A/C	cg11764359	chr7:65958608	NA	0.96	15.23	0.68	4.78e-38	Aortic root size;
CESC	cis	rs1691799	0.867	rs1168333	chr12:66761377	G/A	cg16791601	chr12:66731901	HELB	-0.57	-9.25	-0.49	7.88e-18	White blood cell count (basophil);
CESC	cis	rs959260	0.557	rs12943902	chr17:73400627	G/C	cg20590849	chr17:73267439	MIF4GD	-0.59	-6.55	-0.37	3.01e-10	Systemic lupus erythematosus;
CESC	cis	rs2404602	0.692	rs2137307	chr15:77149020	T/A	cg22467129	chr15:76604101	ETFA	-0.35	-5.23	-0.31	3.42e-7	Blood metabolite levels;
CESC	cis	rs9916302	0.861	rs632202	chr17:37453294	C/A	cg19468946	chr17:37922297	IKZF3	0.41	5.26	0.31	3.04e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs1799949	1.000	rs8176233	chr17:41219804	T/C	cg23758822	chr17:41437982	NA	1.02	15.55	0.69	3.45e-39	Menopause (age at onset);
CESC	trans	rs9393777	0.920	rs13195040	chr6:27413924	C/T	cg06606381	chr12:133084897	FBRSL1	0.92	7.4	0.41	1.8e-12	Intelligence (multi-trait analysis);
CESC	cis	rs6142102	0.625	rs6141436	chr20:32554571	T/A	cg08999081	chr20:33150536	PIGU	0.34	5.1	0.3	6.63e-7	Skin pigmentation;
CESC	cis	rs10465746	0.967	rs1570690	chr1:84377515	G/T	cg10977910	chr1:84465055	TTLL7	0.46	6.13	0.35	3.22e-9	Obesity-related traits;
CESC	cis	rs4304924	0.500	rs7339081	chr13:79235501	A/G	cg01819759	chr13:79234251	RNF219	0.46	6.41	0.37	6.6e-10	Large artery stroke;
CESC	cis	rs9309473	0.948	rs7603647	chr2:73817238	G/A	cg20560298	chr2:73613845	ALMS1	-0.54	-7.17	-0.4	7.48e-12	Metabolite levels;
CESC	trans	rs4800995	0.508	rs2126787	chr18:53462608	C/T	cg11058942	chr7:1287561	NA	0.42	6.0	0.35	6.54e-9	Cancer;
CESC	cis	rs2414059	0.518	rs56398519	chr15:50773432	A/G	cg08437265	chr15:50716283	USP8	-0.48	-6.41	-0.37	6.77e-10	QT interval;
CESC	cis	rs9322193	0.923	rs9688861	chr6:149959060	G/T	cg13206674	chr6:150067644	NUP43	0.44	6.4	0.37	7e-10	Lung cancer;
CESC	trans	rs1545843	0.593	rs4761124	chr12:84789792	A/T	cg03015433	chr16:56623111	MT3	-0.34	-6.13	-0.35	3.22e-9	Major depressive disorder;
CESC	cis	rs6089584	0.888	rs6061966	chr20:60607936	C/G	cg06108461	chr20:60628389	TAF4	-0.93	-14.39	-0.66	4.43e-35	Body mass index;
CESC	trans	rs3008870	0.583	rs11208978	chr1:67442210	C/T	cg19754094	chr2:74055942	STAMBP	-0.62	-6.0	-0.35	6.49e-9	Lymphocyte percentage of white cells;
CESC	cis	rs7666738	0.830	rs7696568	chr4:99005333	A/T	cg17366294	chr4:99064904	C4orf37	0.6	8.61	0.47	6.47e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1552244	0.816	rs56271597	chr3:10042790	C/T	cg00149659	chr3:10157352	C3orf10	0.69	8.2	0.45	1.02e-14	Alzheimer's disease;
CESC	cis	rs6714710	0.603	rs12104810	chr2:98443658	C/T	cg26665480	chr2:98280029	ACTR1B	0.58	8.13	0.45	1.7e-14	Posterior cortical atrophy and Alzheimer's disease;
CESC	cis	rs863345	0.604	rs12041348	chr1:158482042	A/C	cg12129480	chr1:158549410	OR10X1	-0.34	-6.74	-0.38	9.86e-11	Pneumococcal bacteremia;
CESC	cis	rs4595586	0.525	rs7977228	chr12:39395060	A/G	cg26384229	chr12:38710491	ALG10B	0.54	7.64	0.42	3.96e-13	Morning vs. evening chronotype;
CESC	cis	rs873946	0.586	rs12767391	chr10:134573844	A/G	cg27297192	chr10:134578999	INPP5A	-0.42	-5.75	-0.33	2.4e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs11792861	0.962	rs72607162	chr9:111793719	T/C	cg13535736	chr9:111863775	C9orf5	-0.51	-6.69	-0.38	1.32e-10	Menarche (age at onset);
CESC	cis	rs4975709	0.589	rs4975747	chr5:1862836	G/A	cg17650747	chr5:1873721	NA	0.42	5.79	0.34	2.01e-8	Cardiovascular disease risk factors;
CESC	cis	rs875971	0.964	rs160635	chr7:65528918	T/C	cg26939375	chr7:64535504	NA	0.5	6.45	0.37	5.2400000000000005e-10	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23100370	chr2:109336342	RANBP2	0.53	6.16	0.35	2.63e-9	Gut microbiome composition (summer);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg22395807	chr22:46068466	ATXN10	0.44	6.06	0.35	4.69e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs2073300	0.609	rs74273791	chr20:23418067	A/T	cg16736954	chr20:23401023	NAPB	0.78	5.78	0.33	2.05e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	trans	rs1285495	0.627	rs10912059	chr1:187354887	C/T	cg26859862	chr16:30389551	SEPT1	-0.49	-6.13	-0.35	3.16e-9	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
CESC	cis	rs9611565	0.512	rs9611667	chr22:42187015	C/T	cg06481639	chr22:41940642	POLR3H	-0.6	-5.83	-0.34	1.65e-8	Vitiligo;
CESC	cis	rs614226	1.000	rs616157	chr12:120925795	T/C	cg01236616	chr12:121019343	POP5	-1.49	-16.4	-0.71	3.39e-42	Type 1 diabetes nephropathy;
CESC	cis	rs2304069	1.000	rs2304069	chr5:149406733	G/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.85	11.23	0.57	3.37e-24	HIV-1 control;
CESC	cis	rs7086627	0.515	rs2125040	chr10:82208422	G/C	cg00277334	chr10:82204260	NA	-0.91	-15.94	-0.7	1.42e-40	Post bronchodilator FEV1;
CESC	cis	rs6582630	0.533	rs2120464	chr12:38280289	A/C	cg26384229	chr12:38710491	ALG10B	0.45	5.8	0.34	1.87e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs1499614	1.000	rs2659903	chr7:66180931	G/A	cg13147721	chr7:65941812	NA	-0.94	-8.9	-0.48	9.08e-17	Gout;
CESC	cis	rs17711722	0.522	rs62469933	chr7:65265639	G/A	cg06456125	chr7:65229604	NA	0.38	5.15	0.3	5.09e-7	Calcium levels;
CESC	trans	rs7824557	0.524	rs7835318	chr8:10953874	G/A	cg06636001	chr8:8085503	FLJ10661	-0.49	-6.19	-0.36	2.33e-9	Retinal vascular caliber;
CESC	cis	rs7914558	0.966	rs12766205	chr10:104893568	A/G	cg04362960	chr10:104952993	NT5C2	0.46	5.92	0.34	9.98e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs12822507	0.732	rs4555	chr12:12796872	T/C	cg11838227	chr12:12764436	CREBL2	0.41	5.48	0.32	9.95e-8	Systemic lupus erythematosus;
CESC	cis	rs7107174	1.000	rs2512542	chr11:77981780	G/A	cg02023728	chr11:77925099	USP35	0.38	5.73	0.33	2.76e-8	Testicular germ cell tumor;
CESC	trans	rs7849270	1.000	rs7021449	chr9:131899312	T/C	cg05583848	chr6:35265411	DEF6	-0.44	-6.12	-0.35	3.28e-9	Blood metabolite ratios;
CESC	cis	rs9322193	0.926	rs9285525	chr6:150122389	C/G	cg07701084	chr6:150067640	NUP43	0.42	5.78	0.33	2.07e-8	Lung cancer;
CESC	cis	rs6489785	0.643	rs2015462	chr12:121238204	G/C	cg02419362	chr12:121203948	SPPL3	0.36	5.87	0.34	1.28e-8	Longevity;Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs7618501	0.633	rs9814664	chr3:50078541	C/T	cg24308560	chr3:49941425	MST1R	0.63	9.38	0.5	3.2e-18	Intelligence (multi-trait analysis);
CESC	cis	rs1707322	1.000	rs4641257	chr1:46353589	G/A	cg06784218	chr1:46089804	CCDC17	0.32	5.57	0.32	6.35e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs1707322	0.686	rs3014251	chr1:46077428	G/C	cg05343316	chr1:45956843	TESK2	-0.53	-6.45	-0.37	5.42e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2249625	0.523	rs1969530	chr6:72861276	A/C	cg18830697	chr6:72922368	RIMS1	-0.42	-6.22	-0.36	1.92e-9	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CESC	cis	rs10267417	0.544	rs2072185	chr7:19748700	G/A	cg07541023	chr7:19748670	TWISTNB	0.94	10.69	0.55	2.12e-22	Night sleep phenotypes;
CESC	cis	rs4665809	0.589	rs4665842	chr2:26448954	A/G	cg22920501	chr2:26401640	FAM59B	-0.91	-10.28	-0.53	4.37e-21	Gut microbiome composition (summer);
CESC	cis	rs3105593	0.933	rs3109882	chr15:50840057	G/A	cg08437265	chr15:50716283	USP8	0.44	5.69	0.33	3.44e-8	QT interval;
CESC	cis	rs3026101	0.671	rs3026109	chr17:5284480	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	-0.42	-5.53	-0.32	7.63e-8	Body mass index;
CESC	cis	rs6060717	0.536	rs8125966	chr20:34511823	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.77	-6.96	-0.39	2.63e-11	Hip circumference adjusted for BMI;
CESC	cis	rs7084402	0.967	rs1649081	chr10:60292444	G/A	cg07615347	chr10:60278583	BICC1	0.6	9.49	0.5	1.45e-18	Refractive error;
CESC	cis	rs116095464	1.000	rs56095714	chr5:311256	C/T	cg22496380	chr5:211416	CCDC127	-0.89	-5.63	-0.33	4.52e-8	Breast cancer;
CESC	cis	rs9611565	0.512	rs139562	chr22:42196684	G/C	cg06634786	chr22:41940651	POLR3H	-0.66	-6.61	-0.38	2.11e-10	Vitiligo;
CESC	cis	rs208520	0.690	rs12204512	chr6:66710486	C/T	cg07460842	chr6:66804631	NA	0.97	13.04	0.63	2.3e-30	Exhaled nitric oxide output;
CESC	trans	rs1814175	0.817	rs80244685	chr11:49763292	C/A	cg03929089	chr4:120376271	NA	-0.9	-13.84	-0.65	3.9e-33	Height;
CESC	cis	rs9911578	1.000	rs2009948	chr17:56611920	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	-0.41	-5.53	-0.32	7.63e-8	Intelligence (multi-trait analysis);
CESC	cis	rs916888	0.779	rs199498	chr17:44865603	A/G	cg17911788	chr17:44343683	NA	-0.38	-5.27	-0.31	2.83e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	trans	rs6572548	0.504	rs1956082	chr14:49665496	A/C	cg10302505	chr8:128748092	MYC	-0.5	-6.19	-0.36	2.22e-9	Subjective well-being;
CESC	cis	rs2404602	0.692	rs2304920	chr15:76993867	T/C	cg26408565	chr15:76604113	ETFA	-0.39	-5.58	-0.32	6.05e-8	Blood metabolite levels;
CESC	cis	rs1008375	1.000	rs3733579	chr4:17694943	A/G	cg02297831	chr4:17616191	MED28	0.44	5.38	0.31	1.65e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs4689388	0.890	rs9993624	chr4:6286528	C/T	cg00701064	chr4:6280414	WFS1	0.76	13.6	0.64	2.55e-32	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs6089584	0.888	rs2181590	chr20:60622843	T/C	cg06108461	chr20:60628389	TAF4	-0.92	-14.55	-0.67	1.22e-35	Body mass index;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg23307708	chr5:133561976	PPP2CA	-0.45	-6.1	-0.35	3.69e-9	Fibrinogen levels;
CESC	cis	rs4595586	0.545	rs1319791	chr12:39372486	G/T	cg26384229	chr12:38710491	ALG10B	0.62	8.69	0.47	3.89e-16	Morning vs. evening chronotype;
CESC	cis	rs7107174	1.000	rs2511166	chr11:77964331	T/C	cg02023728	chr11:77925099	USP35	0.41	6.06	0.35	4.65e-9	Testicular germ cell tumor;
CESC	cis	rs67460515	0.892	rs2054710	chr3:161090616	C/T	cg03342759	chr3:160939853	NMD3	-0.53	-7.52	-0.42	8.32e-13	Parkinson's disease;
CESC	cis	rs3096299	0.719	rs2911265	chr16:89511328	G/A	cg00750074	chr16:89608354	SPG7	-0.42	-6.1	-0.35	3.69e-9	Multiple myeloma (IgH translocation);
CESC	cis	rs9733	0.596	rs6686525	chr1:150635811	C/T	cg17724175	chr1:150552817	MCL1	0.44	7.24	0.41	4.8e-12	Tonsillectomy;
CESC	trans	rs77688320	0.535	rs7561048	chr2:202253039	G/A	cg13208159	chr1:68516518	DIRAS3	0.39	6.01	0.35	6.19e-9	Breast cancer;
CESC	cis	rs1707322	0.964	rs785509	chr1:46527300	G/A	cg03146154	chr1:46216737	IPP	-0.7	-9.16	-0.49	1.46e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs6998277	1.000	rs4281092	chr8:103647956	A/G	cg10187029	chr8:103597600	NA	-0.45	-5.26	-0.31	3e-7	Migraine;
CESC	cis	rs10089	0.953	rs7713860	chr5:127428789	G/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.75	10.19	0.53	8.58e-21	Ileal carcinoids;
CESC	cis	rs2594989	1.000	rs2606756	chr3:11358181	G/A	cg00170343	chr3:11313890	ATG7	0.59	5.25	0.31	3.1e-7	Circulating chemerin levels;
CESC	cis	rs10479542	0.549	rs4376229	chr5:179042971	A/G	cg19626725	chr5:178986131	RUFY1	0.34	5.05	0.3	8.06e-7	Lung cancer;
CESC	cis	rs66887589	0.616	rs13113885	chr4:120221176	G/C	cg09307838	chr4:120376055	NA	0.63	8.38	0.46	3.09e-15	Diastolic blood pressure;
CESC	cis	rs6540559	0.673	rs17015224	chr1:209968918	G/A	cg23283495	chr1:209979779	IRF6	0.53	6.34	0.36	9.65e-10	Cleft lip with or without cleft palate;
CESC	cis	rs7772486	0.625	rs9390355	chr6:146112942	C/T	cg05347473	chr6:146136440	FBXO30	-0.53	-7.0	-0.39	2.13e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs34172651	0.583	rs200541	chr16:24733141	A/G	cg02428538	chr16:24856791	SLC5A11	0.6	6.1	0.35	3.72e-9	Intelligence (multi-trait analysis);
CESC	cis	rs763121	0.925	rs4821815	chr22:39105707	G/A	cg06022373	chr22:39101656	GTPBP1	0.89	15.89	0.7	2.08e-40	Menopause (age at onset);
CESC	cis	rs6500395	1.000	rs4517800	chr16:48677404	T/A	cg04672837	chr16:48644449	N4BP1	0.51	6.31	0.36	1.16e-9	Response to tocilizumab in rheumatoid arthritis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24847481	chr1:100435557	SLC35A3	0.59	6.39	0.37	7.56e-10	Gut microbiome composition (summer);
CESC	cis	rs2075371	1.000	rs2075372	chr7:133984432	C/T	cg00033643	chr7:134001901	SLC35B4	0.44	5.71	0.33	3.05e-8	Mean platelet volume;
CESC	cis	rs4835473	0.897	rs2089835	chr4:144886280	G/A	cg25736465	chr4:144833511	NA	0.41	6.4	0.37	6.85e-10	Immature fraction of reticulocytes;
CESC	cis	rs798554	0.757	rs2644312	chr7:2841164	G/A	cg09658497	chr7:2847517	GNA12	-0.43	-6.09	-0.35	4.02e-9	Height;
CESC	cis	rs1005277	0.638	rs1005278	chr10:38218748	G/A	cg25427524	chr10:38739819	LOC399744	0.6	8.24	0.45	7.78e-15	Extrinsic epigenetic age acceleration;
CESC	cis	rs1005277	0.579	rs1780133	chr10:38499509	T/C	cg25427524	chr10:38739819	LOC399744	-0.73	-10.94	-0.56	3.15e-23	Extrinsic epigenetic age acceleration;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27279809	chr12:49183212	ADCY6	0.55	6.37	0.36	8.28e-10	Gut microbiome composition (summer);
CESC	cis	rs9457247	0.765	rs9457252	chr6:167433925	A/G	cg23791538	chr6:167370224	RNASET2	0.55	7.62	0.42	4.54e-13	Crohn's disease;
CESC	cis	rs875971	0.577	rs35072105	chr7:65609817	A/G	cg14393609	chr7:65229607	NA	-0.41	-5.45	-0.32	1.16e-7	Aortic root size;
CESC	cis	rs9487051	1.000	rs9386795	chr6:109616528	G/A	cg21918786	chr6:109611834	NA	-0.35	-5.03	-0.3	8.9e-7	Reticulocyte fraction of red cells;
CESC	cis	rs9322193	0.923	rs9505823	chr6:149950035	A/C	cg07701084	chr6:150067640	NUP43	0.46	6.45	0.37	5.26e-10	Lung cancer;
CESC	cis	rs853679	0.550	rs9295762	chr6:28155418	C/T	cg26335602	chr6:28129616	ZNF389	-0.46	-6.41	-0.37	6.57e-10	Depression;
CESC	cis	rs853679	0.550	rs1225599	chr6:28165190	C/T	cg12963246	chr6:28129442	ZNF389	0.5	6.95	0.39	2.85e-11	Depression;
CESC	cis	rs7044106	0.791	rs747819	chr9:123488441	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.75	10.83	0.55	7.25e-23	Hip circumference adjusted for BMI;
CESC	cis	rs1550582	1.000	rs754234	chr8:135512875	A/G	cg17885191	chr8:135476712	NA	0.63	7.33	0.41	2.73e-12	Educational attainment;
CESC	cis	rs13031619	1.000	rs6724730	chr2:3697987	G/C	cg19052272	chr2:3704530	ALLC	0.51	6.63	0.38	1.89e-10	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CESC	cis	rs10447248	0.674	rs6887376	chr5:107896807	G/A	cg25075504	chr5:107899390	NA	-0.39	-5.91	-0.34	1.05e-8	Adiponectin levels;
CESC	cis	rs8028182	0.636	rs4486847	chr15:75728531	C/G	cg20655648	chr15:75932815	IMP3	0.49	6.24	0.36	1.68e-9	Sudden cardiac arrest;
CESC	cis	rs7223966	1.000	rs6504170	chr17:61709168	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.57	7.18	0.4	6.94e-12	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs6121246	0.909	rs57726761	chr20:30314046	A/G	cg13852791	chr20:30311386	BCL2L1	0.82	8.61	0.47	6.59e-16	Mean corpuscular hemoglobin;
CESC	trans	rs61931739	0.890	rs11053018	chr12:34105962	T/G	cg26384229	chr12:38710491	ALG10B	-0.47	-6.54	-0.37	3.11e-10	Morning vs. evening chronotype;
CESC	cis	rs3092073	0.819	rs3848715	chr20:44564682	G/A	cg27529037	chr20:44575021	PCIF1	-0.45	-6.92	-0.39	3.46e-11	Intelligence (multi-trait analysis);
CESC	cis	rs12042938	0.507	rs1765778	chr1:231732356	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.58	-8.44	-0.46	2.13e-15	Neuranatomic and neurocognitive phenotypes;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg12819747	chr12:112622701	C12orf51	0.43	6.07	0.35	4.49e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7216064	1.000	rs9915108	chr17:65874463	T/C	cg12091567	chr17:66097778	LOC651250	-0.81	-9.16	-0.49	1.48e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs11723261	0.582	rs6830247	chr4:150683	G/A	cg12746427	chr4:53362	ZNF718;ZNF595	0.48	6.12	0.35	3.28e-9	Immune response to smallpox vaccine (IL-6);
CESC	cis	rs11098499	0.826	rs4472123	chr4:120236630	T/A	cg09307838	chr4:120376055	NA	0.79	10.57	0.54	5.14e-22	Corneal astigmatism;
CESC	cis	rs11122272	0.735	rs2749723	chr1:231493302	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.58	-7.97	-0.44	4.68e-14	Hemoglobin concentration;
CESC	cis	rs7726839	0.526	rs11960158	chr5:568665	C/T	cg09021430	chr5:549028	NA	-0.49	-6.71	-0.38	1.19e-10	Obesity-related traits;
CESC	cis	rs9715521	0.900	rs72634623	chr4:59827419	T/C	cg11281224	chr4:60001000	NA	-0.5	-6.57	-0.37	2.6200000000000003e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs16854884	0.739	rs1898265	chr3:143776096	A/G	cg06585982	chr3:143692056	C3orf58	-0.47	-6.15	-0.35	2.77e-9	Economic and political preferences (feminism/equality);
CESC	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg21724239	chr8:58056113	NA	0.6	5.56	0.32	6.59e-8	Developmental language disorder (linguistic errors);
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg13920838	chr9:35095103	PIGO	-0.46	-6.12	-0.35	3.44e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs9287719	0.967	rs4669599	chr2:10758029	T/C	cg00105475	chr2:10696890	NA	0.37	5.4	0.31	1.52e-7	Prostate cancer;
CESC	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg26338869	chr17:61819248	STRADA	0.69	9.11	0.49	2.04e-17	Prudent dietary pattern;
CESC	cis	rs6032067	0.636	rs6032093	chr20:43912167	A/G	cg10761708	chr20:43804764	PI3	0.41	5.32	0.31	2.25e-7	Blood protein levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01975877	chr1:9324232	H6PD	-0.61	-7.37	-0.41	2.2e-12	Gut microbiome composition (summer);
CESC	cis	rs4595586	0.545	rs4438082	chr12:39363870	C/T	cg26384229	chr12:38710491	ALG10B	0.54	7.54	0.42	7.28e-13	Morning vs. evening chronotype;
CESC	cis	rs3793917	0.901	rs36212733	chr10:124215211	T/C	cg24884230	chr10:124216658	ARMS2	0.31	5.15	0.3	5.08e-7	Age-related macular degeneration;
CESC	cis	rs2354432	0.607	rs6689243	chr1:146710559	A/T	cg25205988	chr1:146714368	CHD1L	-1.02	-8.75	-0.47	2.49e-16	Mitochondrial DNA levels;
CESC	cis	rs1577917	0.958	rs10944144	chr6:86537755	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.51	-6.61	-0.38	2.11e-10	Response to antipsychotic treatment;
CESC	trans	rs7937682	0.961	rs17113227	chr11:111620491	A/G	cg18187862	chr3:45730750	SACM1L	0.51	6.16	0.35	2.64e-9	Primary sclerosing cholangitis;
CESC	cis	rs7927592	0.763	rs10896327	chr11:68235275	G/C	cg16797656	chr11:68205561	LRP5	0.48	7.29	0.41	3.63e-12	Total body bone mineral density;
CESC	trans	rs3942852	0.568	rs4412719	chr11:48101660	T/A	cg15704280	chr7:45808275	SEPT13	-0.72	-9.41	-0.5	2.58e-18	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs7520050	0.902	rs7514192	chr1:46248977	A/G	cg03146154	chr1:46216737	IPP	-0.49	-6.35	-0.36	9.45e-10	Red blood cell count;Reticulocyte count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13474011	chr10:49515374	NA	-0.59	-6.35	-0.36	9.25e-10	Gut microbiome composition (summer);
CESC	cis	rs116095464	0.558	rs10036253	chr5:238519	A/C	cg22496380	chr5:211416	CCDC127	-0.75	-8.78	-0.47	2.13e-16	Breast cancer;
CESC	cis	rs7631605	0.743	rs9839933	chr3:37195162	G/T	cg22985146	chr3:37219077	LRRFIP2	-0.33	-5.12	-0.3	6e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs11958404	0.932	rs59246968	chr5:157418180	T/C	cg05962755	chr5:157440814	NA	0.58	6.53	0.37	3.31e-10	IgG glycosylation;
CESC	cis	rs1568889	1.000	rs12808162	chr11:28067027	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.78	10.85	0.55	5.96e-23	Bipolar disorder;
CESC	cis	rs7918232	0.941	rs7907988	chr10:27444344	T/G	cg14240646	chr10:27532245	ACBD5	-0.72	-6.87	-0.39	4.7e-11	Breast cancer;
CESC	cis	rs4253772	0.591	rs6007727	chr22:46650959	G/A	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.69	8.18	0.45	1.16e-14	LDL cholesterol;Cholesterol, total;
CESC	cis	rs9914544	0.564	rs1859083	chr17:18843306	C/T	cg26378065	chr17:18585709	ZNF286B	-0.49	-7.06	-0.4	1.47e-11	Educational attainment (years of education);
CESC	cis	rs4704187	0.687	rs10942729	chr5:74364300	C/T	cg03227963	chr5:74354835	NA	0.31	5.74	0.33	2.58e-8	Response to amphetamines;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13803048	chr20:10414896	C20orf94;MKKS	0.6	6.75	0.38	9.32e-11	Gut microbiome composition (summer);
CESC	cis	rs9311474	0.508	rs7652191	chr3:52610415	T/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.38	6.9	0.39	3.73e-11	Electroencephalogram traits;
CESC	cis	rs7903847	0.667	rs3818787	chr10:99145179	T/C	cg20016023	chr10:99160130	RRP12	-0.29	-5.09	-0.3	6.83e-7	Granulocyte percentage of myeloid white cells;
CESC	cis	rs473651	0.692	rs579511	chr2:239334914	C/G	cg21699342	chr2:239360505	ASB1	0.53	8.7	0.47	3.6e-16	Multiple system atrophy;
CESC	cis	rs1707322	0.682	rs12037459	chr1:46094959	T/G	cg05343316	chr1:45956843	TESK2	0.53	6.54	0.37	3.2e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9902453	0.817	rs2617881	chr17:28063275	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.74	-9.54	-0.51	9.82e-19	Coffee consumption (cups per day);
CESC	cis	rs1256061	0.624	rs1256046	chr14:64729356	A/C	cg21174375	chr14:64681225	SYNE2	0.51	6.82	0.39	6.15e-11	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs4665809	0.590	rs2891496	chr2:26452605	G/A	cg04944784	chr2:26401820	FAM59B	0.96	10.53	0.54	6.93e-22	Gut microbiome composition (summer);
CESC	cis	rs883565	0.916	rs12636980	chr3:39124132	C/T	cg26331595	chr3:39149181	GORASP1;TTC21A	-0.45	-5.81	-0.34	1.75e-8	Handedness;
CESC	cis	rs10870270	1.000	rs11146324	chr10:133767445	A/C	cg08754478	chr10:133766260	PPP2R2D	-0.58	-7.52	-0.42	8.4e-13	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs7927771	0.832	rs67116452	chr11:47385194	G/A	cg20307385	chr11:47447363	PSMC3	-0.59	-7.05	-0.4	1.56e-11	Subjective well-being;
CESC	cis	rs887829	0.569	rs6431628	chr2:234647478	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.5	-6.59	-0.38	2.36e-10	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CESC	cis	rs7927771	0.507	rs7111606	chr11:47787538	G/A	cg18512352	chr11:47633146	NA	0.34	5.24	0.31	3.22e-7	Subjective well-being;
CESC	cis	rs2243480	1.000	rs34703416	chr7:65300642	A/G	cg12463550	chr7:65579703	CRCP	0.67	5.5	0.32	9.08e-8	Diabetic kidney disease;
CESC	cis	rs7772486	0.875	rs6570736	chr6:146388320	C/T	cg23711669	chr6:146136114	FBXO30	0.86	12.94	0.62	5.03e-30	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs12541635	0.677	rs2029879	chr8:107024695	T/A	cg10147462	chr8:107024639	NA	0.48	7.39	0.41	1.94e-12	Age of smoking initiation;
CESC	cis	rs9649213	0.531	rs35216698	chr7:97896175	C/T	cg00277769	chr7:97922759	BAIAP2L1	-0.32	-5.05	-0.3	8.06e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs2354432	1.000	rs6680778	chr1:146747153	T/C	cg25205988	chr1:146714368	CHD1L	1.11	16.73	0.72	2.26e-43	Mitochondrial DNA levels;
CESC	cis	rs12477438	0.520	rs2969379	chr2:99776686	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.86	15.08	0.68	1.62e-37	Chronic sinus infection;
CESC	cis	rs2730245	0.851	rs2657333	chr7:158728743	G/A	cg15303052	chr7:158526867	ESYT2	0.42	5.09	0.3	6.68e-7	Height;
CESC	trans	rs561341	1.000	rs484175	chr17:30309041	G/A	cg20587970	chr11:113659929	NA	-1.41	-18.23	-0.75	1.08e-48	Hip circumference adjusted for BMI;
CESC	cis	rs6120849	0.754	rs7268266	chr20:33581889	T/C	cg24642439	chr20:33292090	TP53INP2	0.67	6.62	0.38	1.94e-10	Protein C levels;
CESC	cis	rs2075371	0.966	rs2544223	chr7:133995787	A/G	cg20476274	chr7:133979776	SLC35B4	0.68	9.93	0.52	5.8e-20	Mean platelet volume;
CESC	cis	rs6952808	0.723	rs4721295	chr7:2036669	G/T	cg04267008	chr7:1944627	MAD1L1	0.61	7.59	0.42	5.5e-13	Bipolar disorder and schizophrenia;
CESC	cis	rs1211375	0.628	rs3859141	chr16:245079	T/C	cg00126636	chr16:237282	NA	-0.42	-6.34	-0.36	9.62e-10	Hematology traits;Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	cis	rs6500395	1.000	rs7202551	chr16:48728984	A/G	cg04672837	chr16:48644449	N4BP1	-0.49	-5.94	-0.34	8.78e-9	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs5498	0.809	rs2228615	chr19:10403368	G/A	cg21994045	chr19:10403936	ICAM5	0.45	6.36	0.36	8.75e-10	Lymphocyte counts;Soluble ICAM-1;Blood protein levels;
CESC	cis	rs7044106	0.708	rs920745	chr9:123429943	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.36	5.83	0.34	1.58e-8	Hip circumference adjusted for BMI;
CESC	cis	rs829880	0.570	rs4488248	chr12:98853688	G/C	cg25150519	chr12:98850993	NA	0.84	11.16	0.57	5.76e-24	Colonoscopy-negative controls vs population controls;
CESC	cis	rs5753618	0.504	rs9609303	chr22:31896309	C/T	cg02404636	chr22:31891804	SFI1	0.42	5.64	0.33	4.35e-8	Colorectal cancer;
CESC	cis	rs3785574	0.962	rs35448669	chr17:61938923	G/A	cg06873352	chr17:61820015	STRADA	0.47	7.03	0.4	1.74e-11	Height;
CESC	cis	rs300703	0.816	rs449725	chr2:202993	C/G	cg21211680	chr2:198530	NA	-0.78	-7.3	-0.41	3.3e-12	Blood protein levels;
CESC	cis	rs9487051	0.621	rs351747	chr6:109531855	G/T	cg01475377	chr6:109611718	NA	-0.39	-5.16	-0.3	4.76e-7	Reticulocyte fraction of red cells;
CESC	cis	rs1670533	0.932	rs610218	chr4:1080083	C/G	cg04106633	chr4:1044584	NA	0.4	5.09	0.3	6.88e-7	Recombination rate (females);
CESC	cis	rs1552244	0.872	rs35988239	chr3:10074145	G/T	cg16606324	chr3:10149918	C3orf24	0.46	5.06	0.3	8.03e-7	Alzheimer's disease;
CESC	cis	rs34172651	0.517	rs200526	chr16:24760511	C/T	cg04756594	chr16:24857601	SLC5A11	-0.45	-5.52	-0.32	8.21e-8	Intelligence (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03395546	chr19:41222599	ADCK4;ITPKC	0.55	6.85	0.39	5.15e-11	Gut microbiome composition (summer);
CESC	cis	rs2415984	0.579	rs1389608	chr14:46957777	C/A	cg14871534	chr14:47121158	RPL10L	-0.35	-5.22	-0.31	3.62e-7	Number of children ever born;
CESC	cis	rs1953600	0.870	rs1049550	chr10:81926702	G/A	cg00277334	chr10:82204260	NA	-0.42	-5.89	-0.34	1.17e-8	Sarcoidosis;
CESC	cis	rs66530629	0.874	rs4648876	chr1:25097392	A/G	cg22509179	chr1:25234806	RUNX3	-0.47	-6.08	-0.35	4.08e-9	Plateletcrit;
CESC	cis	rs12500824	0.564	rs57987880	chr4:77318460	G/A	cg20311846	chr4:77356250	SHROOM3	0.38	7.46	0.42	1.24e-12	Coronary artery disease;
CESC	cis	rs2836974	0.590	rs11911822	chr21:40607843	C/T	cg17971929	chr21:40555470	PSMG1	-0.87	-12.79	-0.62	1.75e-29	Cognitive function;
CESC	cis	rs1218582	0.710	rs4845687	chr1:154878911	A/G	cg09359103	chr1:154839909	KCNN3	-0.65	-12.31	-0.6	7.76e-28	Prostate cancer;
CESC	cis	rs5747327	0.874	rs715532	chr22:18159946	A/G	cg19898043	chr22:18121309	BCL2L13	-0.41	-5.26	-0.31	2.99e-7	Myeloid white cell count;Granulocyte count;
CESC	cis	rs367943	1.000	rs348960	chr5:112820651	C/A	cg12552261	chr5:112820674	MCC	0.64	8.05	0.44	2.83e-14	Type 2 diabetes;
CESC	cis	rs10242455	0.717	rs776745	chr7:99291337	T/G	cg07715041	chr7:99302981	CYP3A7	0.44	5.56	0.32	6.73e-8	Blood metabolite levels;
CESC	cis	rs798554	0.634	rs1182180	chr7:2873279	G/T	cg13628971	chr7:2884303	GNA12	0.4	5.5	0.32	8.77e-8	Height;
CESC	cis	rs7615952	0.599	rs16834938	chr3:125706046	C/T	cg06494592	chr3:125709126	NA	-0.44	-5.08	-0.3	7.09e-7	Blood pressure (smoking interaction);
CESC	cis	rs7666738	0.716	rs1426660	chr4:98876792	T/A	cg03467027	chr4:99064603	C4orf37	0.42	5.16	0.3	4.73e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04377525	chr19:2977344	TLE6	0.57	6.51	0.37	3.72e-10	Gut microbiome composition (summer);
CESC	cis	rs2230307	0.572	rs621212	chr1:100559281	T/C	cg24955406	chr1:100503596	HIAT1	0.53	5.39	0.31	1.56e-7	Carotid intima media thickness;
CESC	cis	rs7618915	0.547	rs13064064	chr3:52657002	T/C	cg05564831	chr3:52568323	NT5DC2	0.44	6.76	0.38	8.84e-11	Bipolar disorder;
CESC	cis	rs597539	0.652	rs546382	chr11:68704264	C/T	cg01988459	chr11:68622903	NA	-0.45	-6.36	-0.36	8.85e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs2361718	0.564	rs2304844	chr17:78084507	G/C	cg21238619	chr17:78079768	GAA	-0.44	-6.79	-0.39	7.15e-11	Yeast infection;
CESC	cis	rs6570726	0.764	rs9403726	chr6:145901686	G/T	cg23711669	chr6:146136114	FBXO30	0.9	13.47	0.64	7.7e-32	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13973351	chr11:60928923	VPS37C	0.6	6.62	0.38	1.99e-10	Gut microbiome composition (summer);
CESC	trans	rs208520	0.690	rs12202913	chr6:66734198	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.95	12.27	0.6	1.08e-27	Exhaled nitric oxide output;
CESC	cis	rs7208859	0.673	rs73263981	chr17:28920502	A/G	cg14008862	chr17:28927542	LRRC37B2	0.68	6.0	0.35	6.32e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg13580096	chr8:66546317	ARMC1	-0.48	-6.06	-0.35	4.61e-9	Ulcerative colitis;
CESC	cis	rs1499972	0.941	rs6769144	chr3:117624517	C/T	cg07612923	chr3:117604196	NA	0.88	7.62	0.42	4.47e-13	Schizophrenia;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg01071279	chr10:70939636	SUPV3L1	0.46	6.31	0.36	1.17e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs1552244	0.938	rs56274701	chr3:10167790	G/A	cg00149659	chr3:10157352	C3orf10	0.72	9.27	0.49	6.61e-18	Alzheimer's disease;
CESC	cis	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg23708337	chr7:1209742	NA	0.53	5.24	0.31	3.28e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7824557	0.603	rs11250130	chr8:11214455	C/T	cg21775007	chr8:11205619	TDH	-0.56	-8.6	-0.47	7.2e-16	Retinal vascular caliber;
CESC	cis	rs7674212	0.570	rs12501621	chr4:104095505	T/G	cg16532752	chr4:104119610	CENPE	-0.44	-5.97	-0.34	7.58e-9	Type 2 diabetes;
CESC	cis	rs7552404	0.727	rs7547508	chr1:76327958	A/G	cg03433033	chr1:76189801	ACADM	-0.62	-6.52	-0.37	3.45e-10	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs9894429	0.646	rs58398000	chr17:79576923	G/A	cg18240062	chr17:79603768	NPLOC4	-0.54	-7.18	-0.4	7.17e-12	Eye color traits;
CESC	cis	rs9790314	1.000	rs336548	chr3:161058412	T/C	cg04691961	chr3:161091175	C3orf57	-0.4	-5.11	-0.3	6.05e-7	Morning vs. evening chronotype;
CESC	cis	rs7811142	0.830	rs6965458	chr7:99973402	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.91	8.47	0.46	1.68e-15	Platelet count;
CESC	cis	rs7584330	0.652	rs7607231	chr2:238372896	T/C	cg14458575	chr2:238380390	NA	0.6	8.41	0.46	2.49e-15	Prostate cancer;
CESC	cis	rs559928	0.557	rs7122408	chr11:63898826	G/T	cg18225595	chr11:63971243	STIP1	0.66	5.64	0.33	4.29e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CESC	cis	rs863345	0.604	rs1578761	chr1:158497572	G/A	cg12129480	chr1:158549410	OR10X1	-0.35	-6.86	-0.39	4.78e-11	Pneumococcal bacteremia;
CESC	cis	rs9902453	0.838	rs7217638	chr17:28336772	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.62	-7.83	-0.43	1.15e-13	Coffee consumption (cups per day);
CESC	cis	rs9649213	0.593	rs6973775	chr7:98004685	G/A	cg21770322	chr7:97807741	LMTK2	0.57	8.65	0.47	5.18e-16	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs208520	1.000	rs12194996	chr6:66973366	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.7	7.86	0.43	9.45e-14	Exhaled nitric oxide output;
CESC	cis	rs1799949	1.000	rs12936816	chr17:41301709	C/T	cg25072359	chr17:41440525	NA	0.43	5.83	0.34	1.61e-8	Menopause (age at onset);
CESC	cis	rs12142240	0.698	rs68012736	chr1:46839510	A/G	cg00530320	chr1:46809349	NSUN4	0.6	7.92	0.44	6.39e-14	Menopause (age at onset);
CESC	cis	rs7267979	1.000	rs4815407	chr20:25341478	G/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.85	-16.46	-0.71	2.08e-42	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs2070488	1.000	rs1841777	chr3:38484819	T/C	cg24069376	chr3:38537580	EXOG	0.48	8.72	0.47	3.05e-16	Electrocardiographic conduction measures;
CESC	cis	rs3815700	1.000	rs7247420	chr19:33096786	G/A	cg24916020	chr19:33096688	ANKRD27	0.58	5.72	0.33	2.82e-8	Eosinophilic esophagitis;
CESC	cis	rs80282103	0.618	rs17155886	chr10:1145182	A/G	cg08668510	chr10:1095578	IDI1	0.75	6.25	0.36	1.65e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs6504663	0.525	rs557	chr17:48563234	C/T	cg03611598	chr17:48586076	MYCBPAP	0.53	6.17	0.35	2.54e-9	Visceral fat;
CESC	cis	rs12478296	1.000	rs11899408	chr2:243014630	A/G	cg06360820	chr2:242988706	NA	-0.76	-8.58	-0.47	8.05e-16	Obesity-related traits;
CESC	cis	rs12497850	0.931	rs28642807	chr3:48926816	A/G	cg02487422	chr3:49467188	NICN1	0.39	5.03	0.3	9.01e-7	Parkinson's disease;
CESC	cis	rs9611565	0.546	rs5758431	chr22:42109917	A/G	cg06481639	chr22:41940642	POLR3H	0.64	6.55	0.37	2.94e-10	Vitiligo;
CESC	trans	rs2115172	0.836	rs4835799	chr5:122762229	A/G	cg01140101	chr1:202113040	ARL8A	0.46	6.02	0.35	5.77e-9	Weight;
CESC	cis	rs1008375	0.966	rs3775927	chr4:17599894	G/T	cg15017067	chr4:17643749	FAM184B	0.36	5.11	0.3	6.19e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs853679	0.542	rs9393892	chr6:28081394	A/G	cg08968635	chr6:28129556	ZNF389	0.41	5.5	0.32	9.04e-8	Depression;
CESC	cis	rs35110281	0.811	rs2838339	chr21:45075750	A/G	cg01579765	chr21:45077557	HSF2BP	0.57	9.49	0.5	1.36e-18	Mean corpuscular volume;
CESC	cis	rs9929218	1.000	rs12599517	chr16:68814590	T/C	cg02972257	chr16:68554789	NA	0.44	5.23	0.31	3.4e-7	Colorectal cancer;
CESC	cis	rs2304069	0.644	rs216131	chr5:149431223	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.68	7.76	0.43	1.86e-13	HIV-1 control;
CESC	cis	rs2011503	0.941	rs55765017	chr19:19368264	G/A	cg11584989	chr19:19387371	SF4	0.63	7.52	0.42	8.34e-13	Bipolar disorder;
CESC	cis	rs597539	0.652	rs584108	chr11:68630282	A/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	-0.77	-9.67	-0.51	3.84e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs7772486	0.790	rs2265919	chr6:146221753	A/G	cg23711669	chr6:146136114	FBXO30	0.92	13.36	0.63	1.78e-31	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7647973	0.626	rs2131108	chr3:49665390	C/T	cg07636037	chr3:49044803	WDR6	0.47	5.68	0.33	3.62e-8	Menarche (age at onset);
CESC	cis	rs12497850	0.864	rs12493001	chr3:49181885	A/G	cg07636037	chr3:49044803	WDR6	1.06	18.4	0.75	2.81e-49	Parkinson's disease;
CESC	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg03188948	chr7:1209495	NA	0.73	7.05	0.4	1.54e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs10752881	1.000	rs4593781	chr1:182984983	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.84	13.3	0.63	2.79e-31	Colorectal cancer;
CESC	cis	rs7208859	0.623	rs11658945	chr17:29122509	T/C	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.1e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs9303401	0.614	rs3803752	chr17:56540267	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.94	10.69	0.55	2.01e-22	Cognitive test performance;
CESC	cis	rs6957923	0.655	rs10232644	chr7:23591920	A/G	cg20265043	chr7:23510089	IGF2BP3	0.41	5.06	0.3	7.93e-7	Height;
CESC	cis	rs9549260	0.755	rs9549236	chr13:41147158	C/T	cg21288729	chr13:41239152	FOXO1	-0.44	-5.48	-0.32	9.73e-8	Red blood cell count;
CESC	cis	rs1008375	0.931	rs6449309	chr4:17573208	C/T	cg27347728	chr4:17578864	LAP3	0.49	5.6	0.33	5.36e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs1124376	1.000	rs6774367	chr3:20163077	G/A	cg05072819	chr3:20081367	KAT2B	0.47	5.37	0.31	1.71e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs8141529	0.504	rs6005915	chr22:29233262	A/G	cg15103426	chr22:29168792	CCDC117	0.57	6.87	0.39	4.6e-11	Lymphocyte counts;
CESC	cis	rs1707322	0.717	rs2253862	chr1:46081960	C/T	cg03146154	chr1:46216737	IPP	-0.8	-11.01	-0.56	1.87e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2294693	0.891	rs9369256	chr6:40998344	G/C	cg14769373	chr6:40998127	UNC5CL	-0.48	-6.64	-0.38	1.73e-10	Gastric cancer;Non-cardia gastric cancer;
CESC	cis	rs1799949	1.000	rs2271574	chr17:41327648	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	8.55	0.46	1.02e-15	Menopause (age at onset);
CESC	cis	rs7116495	1.000	rs6592448	chr11:71670044	C/T	cg26138937	chr11:71823887	C11orf51	0.78	6.77	0.38	8.24e-11	Severe influenza A (H1N1) infection;
CESC	cis	rs72945132	0.882	rs67529561	chr11:70162055	G/T	cg14191688	chr11:70257035	CTTN	0.42	5.34	0.31	1.95e-7	Coronary artery disease;
CESC	cis	rs9487051	0.768	rs351729	chr6:109511668	T/C	cg01475377	chr6:109611718	NA	0.37	5.48	0.32	9.72e-8	Reticulocyte fraction of red cells;
CESC	cis	rs3824867	0.920	rs4282946	chr11:47456202	G/A	cg20307385	chr11:47447363	PSMC3	0.5	6.09	0.35	3.87e-9	Mean corpuscular hemoglobin;
CESC	cis	rs9916302	0.904	rs11654018	chr17:37703740	C/T	cg15445000	chr17:37608096	MED1	-0.39	-6.31	-0.36	1.16e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs769267	0.896	rs7253807	chr19:19631444	A/T	cg03709012	chr19:19516395	GATAD2A	1.0	15.01	0.68	2.76e-37	Tonsillectomy;
CESC	cis	rs13256369	0.802	rs34762800	chr8:8559294	G/A	cg18904891	chr8:8559673	CLDN23	0.72	8.02	0.44	3.5e-14	Obesity-related traits;
CESC	cis	rs12497850	0.931	rs9835307	chr3:48857805	T/C	cg07636037	chr3:49044803	WDR6	1.03	18.76	0.76	1.49e-50	Parkinson's disease;
CESC	cis	rs35110281	0.807	rs9984002	chr21:45061501	T/C	cg21573476	chr21:45109991	RRP1B	-0.5	-6.92	-0.39	3.44e-11	Mean corpuscular volume;
CESC	cis	rs7219021	0.886	rs9915337	chr17:46857421	T/A	cg16584676	chr17:46985605	UBE2Z	-0.56	-6.32	-0.36	1.08e-9	Schizophrenia or bipolar disorder;
CESC	cis	rs9911578	0.817	rs304264	chr17:56749628	A/G	cg05425664	chr17:57184151	TRIM37	-0.52	-7.19	-0.4	6.72e-12	Intelligence (multi-trait analysis);
CESC	cis	rs4888262	0.526	rs6564142	chr16:74590047	T/C	cg01733217	chr16:74700730	RFWD3	0.81	11.35	0.57	1.4e-24	Testicular germ cell tumor;
CESC	cis	rs1878931	0.582	rs10048083	chr16:3417465	A/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.75	9.58	0.51	7.13e-19	Body mass index (adult);
CESC	cis	rs1568889	1.000	rs61889027	chr11:28281908	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.71	8.28	0.45	6.08e-15	Bipolar disorder;
CESC	cis	rs4604732	0.578	rs112449432	chr1:247624180	T/C	cg12754571	chr1:247694271	LOC148824;OR2C3	0.44	5.4	0.31	1.5e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs2274273	0.624	rs7152390	chr14:55811701	C/T	cg04306507	chr14:55594613	LGALS3	0.29	5.13	0.3	5.66e-7	Protein biomarker;
CESC	cis	rs8020095	0.528	rs7147570	chr14:67391903	T/C	cg19548862	chr14:67692701	FAM71D	-0.5	-6.1	-0.35	3.83e-9	Depression (quantitative trait);
CESC	cis	rs1538970	0.924	rs11211108	chr1:45891152	C/T	cg05343316	chr1:45956843	TESK2	0.89	12.41	0.61	3.59e-28	Platelet count;
CESC	cis	rs9611565	0.512	rs132784	chr22:42052363	G/A	cg06634786	chr22:41940651	POLR3H	0.59	5.93	0.34	9.66e-9	Vitiligo;
CESC	cis	rs887829	0.569	rs4663967	chr2:234653184	A/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.49	-6.37	-0.36	8.39e-10	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CESC	cis	rs7590368	0.600	rs56143168	chr2:10916233	A/G	cg15705551	chr2:10952987	PDIA6	0.58	5.23	0.31	3.52e-7	Educational attainment (years of education);
CESC	trans	rs61931739	0.500	rs11053166	chr12:34385898	A/C	cg13010199	chr12:38710504	ALG10B	-0.55	-6.69	-0.38	1.33e-10	Morning vs. evening chronotype;
CESC	cis	rs9905704	0.589	rs2632509	chr17:56487887	C/T	cg12560992	chr17:57184187	TRIM37	-0.61	-5.54	-0.32	7.25e-8	Testicular germ cell tumor;
CESC	cis	rs10504229	1.000	rs73607863	chr8:58170178	A/G	cg22535103	chr8:58192502	C8orf71	-1.05	-12.98	-0.62	3.88e-30	Developmental language disorder (linguistic errors);
CESC	cis	rs10411262	0.506	rs6509290	chr19:47183840	T/C	cg13467550	chr19:47212573	PRKD2	0.34	5.05	0.3	8.15e-7	Tonsillectomy;
CESC	cis	rs7116495	0.609	rs2155145	chr11:71719619	G/T	cg26138937	chr11:71823887	C11orf51	-1.31	-8.57	-0.47	8.98e-16	Severe influenza A (H1N1) infection;
CESC	cis	rs372883	0.613	rs1153290	chr21:30687404	G/T	cg24692254	chr21:30365293	RNF160	-0.49	-6.24	-0.36	1.69e-9	Pancreatic cancer;
CESC	cis	rs62229266	0.804	rs2835231	chr21:37390598	C/T	cg12218747	chr21:37451666	NA	-0.44	-6.27	-0.36	1.46e-9	Mitral valve prolapse;
CESC	cis	rs7666738	0.761	rs28758886	chr4:99059704	C/T	cg05340658	chr4:99064831	C4orf37	0.83	12.92	0.62	5.92e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7264396	0.790	rs2425160	chr20:34425968	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.61	7.32	0.41	2.9e-12	Total cholesterol levels;
CESC	cis	rs35306767	0.903	rs12761424	chr10:967295	C/T	cg20503657	chr10:835505	NA	0.7	7.85	0.43	1.04e-13	Eosinophil percentage of granulocytes;
CESC	cis	rs7085104	0.632	rs3781287	chr10:104595420	A/C	cg15744005	chr10:104629667	AS3MT	-0.32	-5.08	-0.3	7e-7	Immature fraction of reticulocytes;Schizophrenia;
CESC	cis	rs1707322	1.000	rs4074225	chr1:46392364	G/C	cg06784218	chr1:46089804	CCDC17	0.36	6.01	0.35	5.95e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs10504229	1.000	rs60454728	chr8:58173781	G/A	cg14926445	chr8:58193284	C8orf71	-0.51	-5.47	-0.32	1.03e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs7927771	0.965	rs56400411	chr11:47586376	T/G	cg20307385	chr11:47447363	PSMC3	-0.5	-6.09	-0.35	4.06e-9	Subjective well-being;
CESC	cis	rs7666738	0.830	rs6532720	chr4:99043781	C/T	cg03676636	chr4:99064102	C4orf37	0.33	5.12	0.3	5.93e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7666738	0.830	rs9307218	chr4:99024885	T/C	cg03467027	chr4:99064603	C4orf37	0.48	6.15	0.35	2.83e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3026101	0.697	rs2107152	chr17:5297350	A/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.43	5.68	0.33	3.57e-8	Body mass index;
CESC	cis	rs9311474	0.507	rs6787154	chr3:52784416	C/T	cg18099408	chr3:52552593	STAB1	-0.31	-5.17	-0.3	4.54e-7	Electroencephalogram traits;
CESC	cis	rs12541635	0.677	rs6997487	chr8:106965511	A/C	cg10147462	chr8:107024639	NA	0.43	6.28	0.36	1.42e-9	Age of smoking initiation;
CESC	cis	rs10870270	0.956	rs7915388	chr10:133734972	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.86	-12.69	-0.61	3.83e-29	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs11190604	1.000	rs11190596	chr10:102293238	C/G	cg07080220	chr10:102295463	HIF1AN	0.69	6.37	0.36	8.1e-10	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs73110464	0.562	rs2363634	chr12:53354683	A/G	cg14581129	chr12:53358946	NA	-0.59	-7.85	-0.43	1.01e-13	Cancer (pleiotropy);
CESC	cis	rs7666738	0.830	rs28456179	chr4:98991439	A/G	cg18180107	chr4:99064573	C4orf37	0.4	5.21	0.31	3.73e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7851660	0.809	rs7866436	chr9:100650096	G/A	cg13688889	chr9:100608707	NA	-0.6	-8.42	-0.46	2.33e-15	Strep throat;
CESC	cis	rs74181299	0.684	rs9797989	chr2:65336529	T/C	cg05010058	chr2:65284262	CEP68	-0.32	-5.14	-0.3	5.37e-7	Pulse pressure;
CESC	cis	rs7264396	0.690	rs2425183	chr20:34450621	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.62	7.41	0.41	1.67e-12	Total cholesterol levels;
CESC	cis	rs1018836	0.892	rs10105142	chr8:91547420	C/T	cg16814680	chr8:91681699	NA	-0.61	-8.85	-0.48	1.32e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	trans	rs35110281	0.712	rs8133523	chr21:45062403	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.56	7.29	0.41	3.61e-12	Mean corpuscular volume;
CESC	cis	rs73206853	0.764	rs7299230	chr12:110618512	A/T	cg12870014	chr12:110450643	ANKRD13A	0.65	5.62	0.33	4.79e-8	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs1023500	0.573	rs4822088	chr22:42470589	G/C	cg15557168	chr22:42548783	NA	-0.44	-6.19	-0.36	2.31e-9	Schizophrenia;
CESC	cis	rs2299587	0.554	rs2073567	chr8:17754034	G/A	cg08627089	chr8:17753878	FGL1	-0.39	-5.63	-0.33	4.49e-8	Economic and political preferences;
CESC	cis	rs6665290	0.839	rs6699400	chr1:227190497	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.23	-34.46	-0.9	6.86e-100	Myeloid white cell count;
CESC	cis	rs67478160	0.619	rs12886363	chr14:104273786	T/C	cg08213375	chr14:104286397	PPP1R13B	0.52	9.81	0.52	1.44e-19	Schizophrenia;
CESC	cis	rs7666738	0.716	rs13136721	chr4:99085602	G/A	cg05340658	chr4:99064831	C4orf37	0.73	10.38	0.54	2.13e-21	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6570726	0.791	rs414297	chr6:145887556	C/T	cg23711669	chr6:146136114	FBXO30	0.92	13.93	0.65	1.83e-33	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs3091242	0.933	rs1534954	chr1:25761924	A/T	cg27572855	chr1:25598939	RHD	0.47	7.77	0.43	1.77e-13	Erythrocyte sedimentation rate;
CESC	cis	rs10504229	1.000	rs79561699	chr8:58170601	A/G	cg05313129	chr8:58192883	C8orf71	-0.53	-6.08	-0.35	4.23e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs10465746	0.780	rs1570691	chr1:84370393	A/C	cg10977910	chr1:84465055	TTLL7	0.51	7.01	0.4	2.02e-11	Obesity-related traits;
CESC	cis	rs853679	0.517	rs56310871	chr6:28044482	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.53	-6.09	-0.35	3.91e-9	Depression;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg17977795	chr5:55290997	IL6ST	-0.46	-6.28	-0.36	1.38e-9	Fibrinogen levels;
CESC	cis	rs7552404	0.690	rs11161620	chr1:76255228	A/G	cg03433033	chr1:76189801	ACADM	-0.63	-6.38	-0.36	8.01e-10	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs9487051	0.714	rs6930733	chr6:109631587	T/C	cg12927641	chr6:109611667	NA	-0.37	-5.51	-0.32	8.68e-8	Reticulocyte fraction of red cells;
CESC	cis	rs7811142	0.667	rs3873746	chr7:99935097	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.73	7.49	0.42	1.01e-12	Platelet count;
CESC	cis	rs36051895	0.632	rs10974987	chr9:5169302	G/T	cg02405213	chr9:5042618	JAK2	-0.45	-5.34	-0.31	1.95e-7	Pediatric autoimmune diseases;
CESC	cis	rs9303401	0.659	rs2072316	chr17:56604813	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.03	12.7	0.62	3.54e-29	Cognitive test performance;
CESC	cis	rs11864453	0.826	rs6499560	chr16:72147666	G/T	cg01557791	chr16:72042693	DHODH	0.52	6.87	0.39	4.53e-11	Fibrinogen levels;
CESC	cis	rs6502050	0.835	rs8065210	chr17:80090960	G/A	cg01763666	chr17:80159506	CCDC57	-0.37	-5.1	-0.3	6.55e-7	Life satisfaction;
CESC	cis	rs6546537	0.824	rs13011186	chr2:69778558	C/T	cg10773587	chr2:69614142	GFPT1	-0.66	-8.33	-0.46	4.28e-15	Serum thyroid-stimulating hormone levels;
CESC	cis	rs17376456	0.877	rs12153501	chr5:93360866	T/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.6	5.2	0.3	3.98e-7	Diabetic retinopathy;
CESC	cis	rs910316	0.763	rs12588981	chr14:75460561	A/G	cg11812906	chr14:75593930	NEK9	0.78	12.12	0.6	3.38e-27	Height;
CESC	cis	rs734999	0.545	rs10752748	chr1:2544640	G/A	cg18854424	chr1:2615690	NA	0.29	5.56	0.32	6.62e-8	Ulcerative colitis;
CESC	cis	rs3806843	0.518	rs2569191	chr5:140013903	C/T	cg26395211	chr5:140044315	WDR55	0.4	5.05	0.3	8.11e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs2228479	0.867	rs62052185	chr16:89969254	C/T	cg00800038	chr16:89945340	TCF25	-0.87	-7.53	-0.42	7.78e-13	Skin colour saturation;
CESC	cis	rs2742234	0.541	rs1059484	chr10:43679800	T/G	cg07801480	chr10:43725741	RASGEF1A	0.41	5.29	0.31	2.56e-7	Hirschsprung disease;
CESC	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg03452623	chr4:187889614	NA	-0.88	-16.16	-0.7	2.39e-41	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2952156	0.883	rs1495100	chr17:37832279	C/T	cg00129232	chr17:37814104	STARD3	-0.78	-11.13	-0.56	7.12e-24	Asthma;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07049977	chr2:37458536	CEBPZ;C2orf56	0.57	6.14	0.35	2.96e-9	Gut microbiome composition (summer);
CESC	cis	rs9487051	0.768	rs1269172	chr6:109522080	G/C	cg01475377	chr6:109611718	NA	-0.46	-6.93	-0.39	3.18e-11	Reticulocyte fraction of red cells;
CESC	cis	rs4862307	0.836	rs11132220	chr4:184997247	A/T	cg06737308	chr4:185021514	ENPP6	-0.42	-5.76	-0.33	2.34e-8	Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	cis	rs791888	0.723	rs1980648	chr10:89422369	T/C	cg13926569	chr10:89418898	PAPSS2	0.52	7.22	0.41	5.67e-12	Magnesium levels;
CESC	cis	rs793571	0.566	rs610877	chr15:59103328	C/A	cg05156742	chr15:59063176	FAM63B	0.58	7.62	0.42	4.54e-13	Schizophrenia;
CESC	cis	rs854765	0.693	rs8080061	chr17:17776389	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.54	-7.8	-0.43	1.39e-13	Total body bone mineral density;
CESC	cis	rs208520	0.586	rs208442	chr6:66900618	T/A	cg07460842	chr6:66804631	NA	-0.69	-8.81	-0.48	1.69e-16	Exhaled nitric oxide output;
CESC	cis	rs4523957	0.583	rs2641444	chr17:2037402	T/C	cg16513277	chr17:2031491	SMG6	-0.79	-11.73	-0.58	6.95e-26	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs4665809	1.000	rs6546727	chr2:26275282	C/T	cg08470875	chr2:26401718	FAM59B	-0.48	-5.19	-0.3	4.26e-7	Gut microbiome composition (summer);
CESC	cis	rs1552244	1.000	rs17032268	chr3:10067972	C/T	cg00149659	chr3:10157352	C3orf10	0.73	9.0	0.48	4.43e-17	Alzheimer's disease;
CESC	cis	rs116095464	0.558	rs6555055	chr5:226160	A/C	cg20965017	chr5:231967	SDHA	-0.44	-5.04	-0.3	8.77e-7	Breast cancer;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg00387170	chr6:41514002	FOXP4	-0.47	-6.44	-0.37	5.7e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs10208940	0.920	rs11894861	chr2:68706723	C/G	cg12452813	chr2:68675892	NA	0.52	5.25	0.31	3.09e-7	Urate levels in lean individuals;
CESC	cis	rs7524258	0.903	rs4908609	chr1:7292910	G/A	cg07173049	chr1:7289937	CAMTA1	0.47	7.14	0.4	9e-12	Tourette's syndrome or obsessive-compulsive disorder;
CESC	trans	rs3885907	0.542	rs4254166	chr13:31322949	T/C	cg22352122	chr11:453757	PTDSS2	-0.38	-6.06	-0.35	4.63e-9	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+epirubicin+/-5FU);
CESC	cis	rs35110281	0.748	rs9981460	chr21:45030965	T/A	cg01579765	chr21:45077557	HSF2BP	-0.57	-9.46	-0.5	1.73e-18	Mean corpuscular volume;
CESC	cis	rs17039065	1.000	rs17039068	chr4:109385975	C/A	cg16022748	chr4:109541635	LOC285456;RPL34	0.61	5.28	0.31	2.68e-7	Gut microbiome composition (summer);
CESC	cis	rs826838	1.000	rs11168218	chr12:38884466	A/G	cg26384229	chr12:38710491	ALG10B	0.83	14.68	0.67	4e-36	Heart rate;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	ch.4.3470285F	chr4:187530505	FAT1	-0.55	-6.66	-0.38	1.59e-10	Gut microbiome composition (summer);
CESC	cis	rs3008870	0.755	rs6657065	chr1:67384639	T/G	cg02640540	chr1:67518911	SLC35D1	0.45	5.38	0.31	1.61e-7	Lymphocyte percentage of white cells;
CESC	cis	rs6088580	0.609	rs2378205	chr20:33110803	C/G	cg08999081	chr20:33150536	PIGU	0.65	11.26	0.57	2.65e-24	Glomerular filtration rate (creatinine);
CESC	cis	rs6502050	0.835	rs8067875	chr17:80092778	C/T	cg01763666	chr17:80159506	CCDC57	-0.37	-5.09	-0.3	6.83e-7	Life satisfaction;
CESC	cis	rs769267	1.000	rs769267	chr19:19446936	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.65	8.46	0.46	1.77e-15	Tonsillectomy;
CESC	cis	rs9309473	0.950	rs6745480	chr2:73840055	C/T	cg20560298	chr2:73613845	ALMS1	-0.43	-5.68	-0.33	3.53e-8	Metabolite levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22622495	chr1:91966418	CDC7	0.59	7.18	0.4	6.99e-12	Gut microbiome composition (summer);
CESC	cis	rs11122272	0.735	rs2790877	chr1:231535427	A/G	cg06096015	chr1:231504339	EGLN1	0.43	6.08	0.35	4.14e-9	Hemoglobin concentration;
CESC	cis	rs6570726	0.791	rs4332001	chr6:145934841	T/C	cg23711669	chr6:146136114	FBXO30	0.87	12.74	0.62	2.52e-29	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1797885	0.651	rs1552484	chr3:12580246	C/G	cg26432171	chr3:12704882	RAF1	-0.48	-6.28	-0.36	1.37e-9	Immature fraction of reticulocytes;
CESC	cis	rs6942756	0.758	rs13226649	chr7:128977598	C/T	cg02491457	chr7:128862824	NA	-0.62	-8.81	-0.48	1.67e-16	White matter hyperintensity burden;
CESC	cis	rs4664308	1.000	rs6759924	chr2:160912747	G/A	cg03641300	chr2:160917029	PLA2R1	-0.68	-9.96	-0.52	4.8e-20	Idiopathic membranous nephropathy;
CESC	cis	rs863345	0.933	rs11265020	chr1:158511642	T/C	cg12129480	chr1:158549410	OR10X1	-0.32	-6.47	-0.37	4.61e-10	Pneumococcal bacteremia;
CESC	cis	rs873946	0.648	rs12783354	chr10:134557235	T/A	cg06453172	chr10:134556979	INPP5A	-0.42	-5.32	-0.31	2.19e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs116095464	0.614	rs62344292	chr5:244630	G/A	cg22496380	chr5:211416	CCDC127	-0.74	-8.63	-0.47	5.66e-16	Breast cancer;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg10633746	chr17:18164442	SMCR7	0.45	6.28	0.36	1.38e-9	Systemic lupus erythematosus;
CESC	cis	rs61931739	0.817	rs2203086	chr12:34232590	T/C	cg19457237	chr12:34500585	NA	-0.41	-5.61	-0.33	4.99e-8	Morning vs. evening chronotype;
CESC	cis	rs34779708	0.931	rs4934700	chr10:35310842	A/G	cg04310649	chr10:35416472	CREM	-0.5	-5.98	-0.34	7.34e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs2991971	0.967	rs7526665	chr1:46005832	G/T	cg06784218	chr1:46089804	CCDC17	-0.29	-5.09	-0.3	6.87e-7	High light scatter reticulocyte count;
CESC	cis	rs651907	0.557	rs13099674	chr3:101489629	G/A	cg12386194	chr3:101231763	SENP7	0.41	5.14	0.3	5.28e-7	Colorectal cancer;
CESC	cis	rs1008375	1.000	rs12507142	chr4:17656103	A/G	cg16339924	chr4:17578868	LAP3	0.64	7.91	0.44	6.79e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs2404602	0.669	rs1875885	chr15:76638081	G/A	cg22467129	chr15:76604101	ETFA	-0.38	-5.71	-0.33	3.1e-8	Blood metabolite levels;
CESC	cis	rs780096	0.546	rs4425043	chr2:27733452	G/A	cg21248554	chr2:27665150	KRTCAP3	-0.38	-7.53	-0.42	8.15e-13	Total body bone mineral density;
CESC	trans	rs916888	0.821	rs199504	chr17:44861003	C/T	cg07870213	chr5:140052090	DND1	-0.59	-6.53	-0.37	3.4e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs875971	1.000	rs778696	chr7:65870813	C/G	cg10691866	chr7:65817282	TPST1	-0.34	-5.51	-0.32	8.3e-8	Aortic root size;
CESC	cis	rs5769765	0.955	rs8135816	chr22:50291976	G/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.45	-5.2	-0.3	4.01e-7	Schizophrenia;
CESC	cis	rs2281558	0.837	rs67676850	chr20:25369417	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.61	8.25	0.45	7.67e-15	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;
CESC	cis	rs6933660	0.676	rs3757316	chr6:151774339	A/G	cg14416726	chr6:151773293	C6orf211;RMND1	0.49	6.18	0.35	2.42e-9	Menarche (age at onset);
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg02764006	chr17:65029280	CACNG4	-0.41	-6.07	-0.35	4.29e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs2730245	0.636	rs710421	chr7:158668575	T/C	cg15303052	chr7:158526867	ESYT2	-0.41	-5.21	-0.3	3.76e-7	Height;
CESC	cis	rs10242455	0.867	rs2687076	chr7:99307268	G/A	cg07715041	chr7:99302981	CYP3A7	-0.43	-5.42	-0.32	1.36e-7	Blood metabolite levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04533189	chr17:64298763	PRKCA	0.52	6.32	0.36	1.11e-9	Gut microbiome composition (summer);
CESC	cis	rs8114671	0.742	rs6058161	chr20:33620026	C/T	cg06115741	chr20:33292138	TP53INP2	-0.44	-5.29	-0.31	2.53e-7	Height;
CESC	cis	rs9640161	0.742	rs11983355	chr7:150016697	A/C	cg21361702	chr7:150065534	REPIN1	0.54	6.12	0.35	3.39e-9	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs1129187	0.837	rs4714634	chr6:42901120	G/A	cg02353165	chr6:42928485	GNMT	0.81	12.41	0.61	3.61e-28	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs1707322	0.963	rs11211202	chr1:46292382	C/T	cg03146154	chr1:46216737	IPP	0.71	9.79	0.52	1.63e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9818758	0.607	rs73082362	chr3:49113729	C/T	cg00383909	chr3:49044727	WDR6	0.89	5.26	0.31	3.03e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CESC	cis	rs9457247	0.663	rs1894603	chr6:167434686	C/T	cg23791538	chr6:167370224	RNASET2	0.52	6.98	0.39	2.41e-11	Crohn's disease;
CESC	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg18402987	chr7:1209562	NA	0.76	7.57	0.42	6.04e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs2075371	0.932	rs1862048	chr7:133978167	C/G	cg16409651	chr16:11680980	LITAF	0.53	6.13	0.35	3.23e-9	Mean platelet volume;
CESC	cis	rs250677	0.958	rs36067	chr5:148417553	T/G	cg18129178	chr5:148520854	ABLIM3	-0.52	-5.8	-0.34	1.86e-8	Breast cancer;
CESC	cis	rs7520050	0.966	rs4660317	chr1:46326226	G/A	cg03146154	chr1:46216737	IPP	-0.48	-6.22	-0.36	1.98e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs733592	0.507	rs10747529	chr12:48473369	G/A	cg04545296	chr12:48745243	ZNF641	-0.29	-5.44	-0.32	1.18e-7	Plateletcrit;
CESC	trans	rs9325144	0.600	rs34138871	chr12:38735261	A/G	cg23762105	chr12:34175262	ALG10	-0.45	-6.01	-0.35	5.97e-9	Morning vs. evening chronotype;
CESC	trans	rs11098499	0.913	rs35271032	chr4:120156659	C/T	cg25214090	chr10:38739885	LOC399744	0.64	8.57	0.47	8.82e-16	Corneal astigmatism;
CESC	cis	rs9399401	0.710	rs12197866	chr6:142706063	C/T	cg04461802	chr6:142623433	GPR126	0.39	5.6	0.33	5.47e-8	Chronic obstructive pulmonary disease;
CESC	cis	rs1552244	0.882	rs68080705	chr3:10025743	C/T	cg00166722	chr3:10149974	C3orf24	0.49	6.08	0.35	4.28e-9	Alzheimer's disease;
CESC	cis	rs2991971	0.967	rs7526665	chr1:46005832	G/T	cg24296786	chr1:45957014	TESK2	0.63	8.26	0.45	6.93e-15	High light scatter reticulocyte count;
CESC	cis	rs7772486	0.875	rs2073287	chr6:146350264	T/C	cg05347473	chr6:146136440	FBXO30	0.48	6.33	0.36	1.07e-9	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs360798	0.532	rs360800	chr2:62954326	C/T	cg17519650	chr2:63277830	OTX1	-0.53	-6.51	-0.37	3.71e-10	Coronary artery disease;
CESC	cis	rs9311474	0.713	rs352166	chr3:52238677	C/T	cg07507251	chr3:52567010	NT5DC2	0.33	5.59	0.32	5.74e-8	Electroencephalogram traits;
CESC	cis	rs853679	0.517	rs9393895	chr6:28127621	T/C	cg20151795	chr6:28129481	ZNF389	0.44	5.55	0.32	6.85e-8	Depression;
CESC	cis	rs780096	0.526	rs7602534	chr2:27592423	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.31	-5.6	-0.33	5.46e-8	Total body bone mineral density;
CESC	trans	rs12356475	0.710	rs10822686	chr10:67733250	C/T	cg06761076	chr22:21056301	TMEM191A	0.51	6.09	0.35	3.92e-9	Psoriatic arthritis;
CESC	cis	rs597539	0.652	rs1249474	chr11:68654774	C/T	cg18350739	chr11:68623251	NA	-0.4	-6.18	-0.36	2.36e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs7084402	1.000	rs1427201	chr10:60269755	G/T	cg07615347	chr10:60278583	BICC1	-0.57	-8.71	-0.47	3.43e-16	Refractive error;
CESC	cis	rs7116495	0.609	rs577435	chr11:71794681	C/T	cg18441811	chr11:71824068	C11orf51	-0.78	-5.03	-0.3	9.03e-7	Severe influenza A (H1N1) infection;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg00145757	chr11:118478637	PHLDB1	-0.42	-6.13	-0.35	3.18e-9	Gambling;
CESC	cis	rs172166	0.694	rs1770131	chr6:28086413	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.48	-6.22	-0.36	1.92e-9	Cardiac Troponin-T levels;
CESC	cis	rs12545109	0.800	rs1437278	chr8:57357024	T/C	cg09654669	chr8:57350985	NA	-0.6	-6.95	-0.39	2.78e-11	Obesity-related traits;
CESC	trans	rs10411161	0.702	rs8110461	chr19:52383569	A/C	cg22319618	chr22:45562946	NUP50	-0.69	-6.75	-0.38	9.37e-11	Breast cancer;
CESC	cis	rs2072732	0.756	rs12041634	chr1:2951034	A/T	cg03976712	chr1:2946727	NA	0.33	5.45	0.32	1.17e-7	Plateletcrit;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20388062	chr1:46713403	RAD54L	0.6	6.76	0.38	8.88e-11	Gut microbiome composition (summer);
CESC	cis	rs11098499	0.644	rs17517414	chr4:120262101	G/C	cg09307838	chr4:120376055	NA	0.76	10.27	0.53	4.94e-21	Corneal astigmatism;
CESC	cis	rs9309711	0.623	rs7569694	chr2:3483390	T/G	cg15541040	chr2:3486749	NA	-0.43	-5.48	-0.32	1.01e-7	Neurofibrillary tangles;
CESC	trans	rs9834373	0.550	rs4485681	chr3:78529018	C/G	cg21593409	chr16:88706389	IL17C	0.41	6.11	0.35	3.53e-9	Protein quantitative trait loci;
CESC	cis	rs7617480	0.558	rs12715430	chr3:48942855	A/C	cg06212747	chr3:49208901	KLHDC8B	0.49	5.65	0.33	4.11e-8	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CESC	cis	rs2228479	0.850	rs45567439	chr16:89814604	G/A	cg00800038	chr16:89945340	TCF25	-0.91	-7.54	-0.42	7.39e-13	Skin colour saturation;
CESC	cis	rs57506017	0.585	rs10950391	chr7:12261829	A/G	cg23422036	chr7:12250390	TMEM106B	0.38	5.08	0.3	7.16e-7	Neuroticism;
CESC	trans	rs7615952	0.611	rs2971298	chr3:125602713	G/A	cg07211511	chr3:129823064	LOC729375	-0.87	-9.6	-0.51	6.4e-19	Blood pressure (smoking interaction);
CESC	trans	rs11098499	0.542	rs7677836	chr4:120310638	T/A	cg25214090	chr10:38739885	LOC399744	0.68	9.2	0.49	1.14e-17	Corneal astigmatism;
CESC	cis	rs6952808	0.825	rs34922657	chr7:1938655	C/T	cg21782813	chr7:2030301	MAD1L1	0.39	5.43	0.32	1.29e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs9733	0.596	rs11803569	chr1:150664077	C/T	cg04414720	chr1:150670196	GOLPH3L	0.63	9.02	0.48	3.87e-17	Tonsillectomy;
CESC	cis	rs7546094	0.967	rs1006298	chr1:113061959	G/C	cg22162597	chr1:113214053	CAPZA1	0.37	5.71	0.33	3.06e-8	Platelet distribution width;
CESC	trans	rs17685	0.712	rs28456330	chr7:75810542	A/G	cg19862616	chr7:65841803	NCRNA00174	0.84	11.79	0.59	4.43e-26	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs10461617	0.531	rs2662033	chr5:56213410	T/G	cg12311346	chr5:56204834	C5orf35	-0.72	-9.08	-0.49	2.64e-17	Type 2 diabetes;
CESC	cis	rs7666738	0.830	rs3896704	chr4:99034252	C/T	cg05340658	chr4:99064831	C4orf37	0.83	12.92	0.62	5.86e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4834770	1.000	rs6823963	chr4:120242164	A/C	cg09307838	chr4:120376055	NA	0.45	5.37	0.31	1.74e-7	Blood protein levels;
CESC	cis	rs7618915	0.547	rs10865973	chr3:52718154	A/T	cg05564831	chr3:52568323	NT5DC2	0.44	6.68	0.38	1.43e-10	Bipolar disorder;
CESC	trans	rs877282	0.891	rs34383514	chr10:800181	T/C	cg22713356	chr15:30763199	NA	1.36	13.53	0.64	4.71e-32	Uric acid levels;
CESC	cis	rs7618501	0.602	rs34831713	chr3:50118748	T/C	cg24308560	chr3:49941425	MST1R	0.62	9.0	0.48	4.41e-17	Intelligence (multi-trait analysis);
CESC	cis	rs6997458	0.742	rs3758076	chr8:86375535	G/C	cg21346043	chr8:86351067	CA3	-0.34	-5.1	-0.3	6.48e-7	Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	cis	rs62064224	0.553	rs6505297	chr17:30765767	A/G	cg18200150	chr17:30822561	MYO1D	0.43	5.39	0.31	1.54e-7	Schizophrenia;
CESC	cis	rs1538970	1.000	rs61791368	chr1:45867944	T/C	cg06784218	chr1:46089804	CCDC17	0.32	5.26	0.31	2.96e-7	Platelet count;
CESC	cis	rs8020095	0.528	rs6573768	chr14:67824953	T/C	cg19548862	chr14:67692701	FAM71D	-0.45	-5.34	-0.31	2.04e-7	Depression (quantitative trait);
CESC	trans	rs7944735	0.507	rs10742827	chr11:48102350	C/T	cg15704280	chr7:45808275	SEPT13	0.62	7.61	0.42	4.85e-13	Intraocular pressure;
CESC	cis	rs8014204	0.604	rs2159906	chr14:75390912	G/T	cg26191576	chr14:75389716	RPS6KL1	-0.39	-5.68	-0.33	3.52e-8	Caffeine consumption;
CESC	cis	rs10191773	0.589	rs72831638	chr2:112949212	C/G	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.71	-6.9	-0.39	3.9e-11	Yeast infection;
CESC	cis	rs2439831	0.850	rs28891769	chr15:44072860	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.7	6.72	0.38	1.14e-10	Lung cancer in ever smokers;
CESC	cis	rs8103278	0.507	rs4802276	chr19:46260748	T/C	cg02376097	chr19:46275166	DMPK	0.38	5.48	0.32	9.91e-8	Coronary artery disease;
CESC	cis	rs2072732	0.821	rs1005471	chr1:2952614	T/C	cg22517653	chr1:2918612	NA	-0.35	-5.04	-0.3	8.48e-7	Plateletcrit;
CESC	cis	rs2795502	0.882	rs2744093	chr10:43339243	A/G	cg20628663	chr10:43360327	NA	-0.63	-7.47	-0.42	1.16e-12	Blood protein levels;
CESC	cis	rs2180341	0.842	rs6569476	chr6:127553539	G/A	cg24812749	chr6:127587940	RNF146	0.92	10.95	0.56	2.93e-23	Breast cancer;
CESC	cis	rs4253772	0.938	rs41329344	chr22:46636930	C/T	cg18190219	chr22:46762943	CELSR1	-0.61	-5.84	-0.34	1.52e-8	LDL cholesterol;Cholesterol, total;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg18470468	chr7:98985742	ARPC1B	0.47	6.29	0.36	1.31e-9	Fibrinogen levels;
CESC	cis	rs8014204	0.935	rs1799900	chr14:75367740	G/A	cg08847533	chr14:75593920	NEK9	-0.47	-5.79	-0.34	1.94e-8	Caffeine consumption;
CESC	cis	rs3820068	0.603	rs2236215	chr1:15892415	A/C	cg13390004	chr1:15929781	NA	0.33	5.22	0.31	3.69e-7	Systolic blood pressure;
CESC	cis	rs765787	0.530	rs1706837	chr15:45519036	A/G	cg24006582	chr15:45444508	DUOX1	-0.59	-7.2	-0.4	6.28e-12	Uric acid levels;
CESC	cis	rs2204008	0.748	rs11180579	chr12:38237830	A/G	cg13010199	chr12:38710504	ALG10B	0.52	6.43	0.37	5.91e-10	Bladder cancer;
CESC	cis	rs10791323	0.572	rs4412766	chr11:133742811	A/C	cg03690763	chr11:133734501	NA	-0.33	-5.68	-0.33	3.62e-8	Childhood ear infection;
CESC	cis	rs826838	0.967	rs11168299	chr12:38902028	G/T	cg13010199	chr12:38710504	ALG10B	0.6	8.42	0.46	2.38e-15	Heart rate;
CESC	cis	rs10242455	0.702	rs73713531	chr7:99222379	C/T	cg07338983	chr7:99679036	ZNF3	0.71	5.07	0.3	7.63e-7	Blood metabolite levels;
CESC	cis	rs2836974	0.966	rs7283516	chr21:40690537	A/G	cg17971929	chr21:40555470	PSMG1	1.03	15.1	0.68	1.31e-37	Cognitive function;
CESC	cis	rs2273669	0.667	rs12206834	chr6:109303967	T/G	cg05315195	chr6:109294784	ARMC2	-0.65	-6.08	-0.35	4.15e-9	Prostate cancer;
CESC	cis	rs7666738	0.830	rs3911282	chr4:99037602	T/A	cg24818145	chr4:99064322	C4orf37	0.38	5.04	0.3	8.81e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10791097	0.935	rs4601795	chr11:130729430	T/C	cg14779329	chr11:130786720	SNX19	0.37	5.8	0.34	1.85e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs9486719	1.000	rs2472880	chr6:96860130	G/A	cg18709589	chr6:96969512	KIAA0776	0.5	5.31	0.31	2.29e-7	Migraine;Coronary artery disease;
CESC	cis	rs7712401	0.601	rs28892	chr5:122283826	A/G	cg19412675	chr5:122181750	SNX24	-0.42	-5.13	-0.3	5.58e-7	Mean platelet volume;
CESC	cis	rs12477438	1.000	rs57846982	chr2:99921574	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.67	-7.72	-0.43	2.35e-13	Chronic sinus infection;
CESC	cis	rs4594175	0.926	rs4617765	chr14:51598843	T/C	cg23942311	chr14:51606299	NA	0.4	5.94	0.34	9.07e-9	Cancer;
CESC	cis	rs11971779	0.793	rs4728464	chr7:139017670	C/T	cg07862535	chr7:139043722	LUC7L2	-0.48	-5.91	-0.34	1.03e-8	Diisocyanate-induced asthma;
CESC	cis	rs6060717	0.610	rs6060755	chr20:34606915	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.48	-5.41	-0.32	1.41e-7	Hip circumference adjusted for BMI;
CESC	cis	rs9488822	0.702	rs10872141	chr6:116323246	C/A	cg26893134	chr6:116381904	FRK	0.25	6.04	0.35	5.06e-9	Cholesterol, total;LDL cholesterol;
CESC	cis	rs9583531	0.600	rs9555726	chr13:111368316	C/T	cg15841412	chr13:111365552	ING1	0.46	5.83	0.34	1.6e-8	Coronary artery disease;
CESC	cis	rs35110281	0.511	rs2298562	chr21:45085236	A/G	cg04455712	chr21:45112962	RRP1B	0.47	7.68	0.43	3.16e-13	Mean corpuscular volume;
CESC	cis	rs72781680	0.651	rs13019016	chr2:23894773	C/G	cg08917208	chr2:24149416	ATAD2B	0.91	8.46	0.46	1.84e-15	Lymphocyte counts;
CESC	cis	rs11764590	0.694	rs11762413	chr7:2090387	C/G	cg21782813	chr7:2030301	MAD1L1	-0.41	-5.22	-0.31	3.69e-7	Neuroticism;
CESC	cis	rs597539	0.616	rs473997	chr11:68639481	C/T	cg04772025	chr11:68637568	NA	0.54	6.14	0.35	2.97e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	trans	rs2727020	0.688	rs4929894	chr11:49196333	G/C	cg15704280	chr7:45808275	SEPT13	-0.84	-13.4	-0.64	1.29e-31	Coronary artery disease;
CESC	cis	rs4629180	0.593	rs6707517	chr2:102089878	C/T	cg04415270	chr2:102091202	RFX8	-0.45	-7.39	-0.41	1.97e-12	Chronic rhinosinusitis with nasal polyps;
CESC	cis	rs875971	0.862	rs801194	chr7:66028495	T/C	cg19163074	chr7:65112434	INTS4L2	0.42	5.25	0.31	3.16e-7	Aortic root size;
CESC	cis	rs3806843	0.676	rs2245640	chr5:140029958	A/G	cg26395211	chr5:140044315	WDR55	0.52	6.73	0.38	1.06e-10	Depressive symptoms (multi-trait analysis);
CESC	cis	rs12042938	0.600	rs823165	chr1:231769446	T/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.42	5.57	0.32	6.23e-8	Neuranatomic and neurocognitive phenotypes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05306006	chr2:210867127	RPE	-0.59	-6.69	-0.38	1.34e-10	Gut microbiome composition (summer);
CESC	cis	rs514406	0.861	rs505444	chr1:53251860	C/T	cg08859206	chr1:53392774	SCP2	-0.52	-7.0	-0.4	2.09e-11	Monocyte count;
CESC	cis	rs10504229	1.000	rs17805549	chr8:58179653	T/C	cg24829409	chr8:58192753	C8orf71	-0.76	-10.0	-0.52	3.53e-20	Developmental language disorder (linguistic errors);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg00512374	chr17:38599682	IGFBP4	-0.48	-6.07	-0.35	4.31e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs7833790	1.000	rs7833790	chr8:82731157	T/C	cg27398817	chr8:82754497	SNX16	-0.49	-5.62	-0.33	4.85e-8	Diastolic blood pressure;
CESC	cis	rs6088590	0.561	rs6088528	chr20:33156742	G/A	cg06115741	chr20:33292138	TP53INP2	0.51	6.53	0.37	3.3e-10	Coronary artery disease;
CESC	cis	rs870825	0.616	rs9631783	chr4:185626511	C/T	cg04058563	chr4:185651563	MLF1IP	0.64	7.05	0.4	1.59e-11	Blood protein levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18551892	chr11:86667149	FZD4	0.6	7.01	0.4	2.01e-11	Gut microbiome composition (summer);
CESC	cis	rs35306767	0.903	rs35957139	chr10:884889	C/T	cg20503657	chr10:835505	NA	1.09	9.95	0.52	4.95e-20	Eosinophil percentage of granulocytes;
CESC	cis	rs7945705	0.747	rs11042150	chr11:9010819	T/C	cg12365402	chr11:9010492	NRIP3	-0.4	-6.95	-0.39	2.92e-11	Hemoglobin concentration;
CESC	trans	rs1814175	0.817	rs1621090	chr11:49895868	C/A	cg03929089	chr4:120376271	NA	-0.91	-15.66	-0.69	1.37e-39	Height;
CESC	trans	rs9329221	0.651	rs2975648	chr8:10135976	C/T	cg06636001	chr8:8085503	FLJ10661	-0.48	-6.3	-0.36	1.26e-9	Neuroticism;
CESC	cis	rs7833790	0.929	rs28464834	chr8:82797356	A/T	cg27398817	chr8:82754497	SNX16	0.57	6.86	0.39	4.96e-11	Diastolic blood pressure;
CESC	cis	rs7385804	0.796	rs2432930	chr7:100299024	A/G	cg16850897	chr7:100343110	ZAN	0.52	7.17	0.4	7.34e-12	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
CESC	cis	rs3749237	0.595	rs11130199	chr3:49538799	T/C	cg06212747	chr3:49208901	KLHDC8B	0.51	6.82	0.39	6.09e-11	Resting heart rate;
CESC	cis	rs3820068	0.705	rs11584209	chr1:15885041	G/T	cg18192808	chr1:15853278	DNAJC16	0.44	5.19	0.3	4.21e-7	Systolic blood pressure;
CESC	cis	rs1953600	0.645	rs7071579	chr10:81910278	A/G	cg00277334	chr10:82204260	NA	0.41	5.53	0.32	7.61e-8	Sarcoidosis;
CESC	cis	rs763121	0.925	rs1043312	chr22:39131727	T/G	cg06022373	chr22:39101656	GTPBP1	0.79	12.94	0.62	5.14e-30	Menopause (age at onset);
CESC	trans	rs1850744	0.510	rs4697901	chr4:9863698	G/T	cg06372015	chr11:43602000	MIR129-2	0.59	6.0	0.35	6.4e-9	Economic and political preferences;
CESC	cis	rs875971	0.862	rs6971059	chr7:66067032	A/G	cg18876405	chr7:65276391	NA	-0.53	-7.2	-0.4	6.41e-12	Aortic root size;
CESC	cis	rs6088580	0.634	rs6059835	chr20:33020141	A/G	cg24642439	chr20:33292090	TP53INP2	0.52	6.79	0.39	7.18e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs1728785	1.000	rs698716	chr16:68560296	C/T	cg02972257	chr16:68554789	NA	-0.62	-7.02	-0.4	1.83e-11	Ulcerative colitis;
CESC	cis	rs2034088	0.965	rs4968070	chr17:446162	A/G	cg13332499	chr17:408570	NA	0.46	7.23	0.41	5.14e-12	Hip circumference adjusted for BMI;
CESC	cis	rs34638657	0.732	rs10514532	chr16:82200337	C/T	cg09439754	chr16:82129088	HSD17B2	0.36	6.34	0.36	9.62e-10	Lung adenocarcinoma;
CESC	cis	rs854765	0.693	rs11657074	chr17:17770355	G/A	cg16928487	chr17:17741425	SREBF1	0.6	10.79	0.55	9.76e-23	Total body bone mineral density;
CESC	cis	rs1799949	0.931	rs9912203	chr17:41445145	A/G	cg25072359	chr17:41440525	NA	-0.45	-6.7	-0.38	1.28e-10	Menopause (age at onset);
CESC	cis	rs7914558	1.000	rs7911789	chr10:104756374	T/C	cg15744005	chr10:104629667	AS3MT	-0.34	-5.65	-0.33	4.05e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs3733585	0.699	rs1079128	chr4:9951221	T/C	cg02734326	chr4:10020555	SLC2A9	-0.41	-5.8	-0.34	1.89e-8	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs8114671	0.935	rs6060282	chr20:33767066	C/T	cg24642439	chr20:33292090	TP53INP2	0.44	5.26	0.31	2.95e-7	Height;
CESC	cis	rs9300255	0.602	rs1790126	chr12:123683563	C/T	cg05973401	chr12:123451056	ABCB9	0.5	5.74	0.33	2.53e-8	Neutrophil percentage of white cells;
CESC	cis	rs2839186	0.681	rs13047198	chr21:47701835	T/C	cg10351095	chr21:47802916	PCNT	-0.49	-6.48	-0.37	4.46e-10	Testicular germ cell tumor;
CESC	cis	rs4568518	0.710	rs12699929	chr7:18012257	G/C	cg03009463	chr7:17980271	SNX13	0.46	6.0	0.35	6.38e-9	Measles;
CESC	cis	rs4660261	0.545	rs803682	chr1:44362623	G/A	cg13606994	chr1:44402422	ARTN	-0.38	-6.05	-0.35	4.82e-9	Intelligence (multi-trait analysis);
CESC	cis	rs5995756	0.761	rs5995759	chr22:40006626	T/C	cg03390717	chr22:39966585	CACNA1I	-0.35	-6.16	-0.35	2.73e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs853679	0.550	rs1233699	chr6:28169158	A/T	cg17949981	chr6:28129498	ZNF389	0.43	5.67	0.33	3.66e-8	Depression;
CESC	cis	rs9911578	0.967	rs4132925	chr17:56938016	C/G	cg12560992	chr17:57184187	TRIM37	-0.92	-15.42	-0.69	9.73e-39	Intelligence (multi-trait analysis);
CESC	cis	rs7680126	0.596	rs12511337	chr4:10311972	A/G	cg00071950	chr4:10020882	SLC2A9	0.46	5.13	0.3	5.61e-7	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	trans	rs254562	0.739	rs254577	chr5:134422204	C/T	cg23533927	chr7:150548934	ABP1	-0.38	-6.22	-0.36	1.96e-9	Ulcerative colitis;
CESC	cis	rs7395581	0.918	rs1449627	chr11:47290984	T/G	cg25783544	chr11:47291846	MADD	0.62	8.26	0.45	6.99e-15	HDL cholesterol;
CESC	cis	rs17384381	1.000	rs12135333	chr1:85890494	C/A	cg16011679	chr1:85725395	C1orf52	0.72	7.42	0.41	1.58e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs854572	0.870	rs757158	chr7:94955528	C/T	cg04871131	chr7:94954202	PON1	-0.49	-6.69	-0.38	1.32e-10	Paraoxonase activity;
CESC	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg23708337	chr7:1209742	NA	0.55	5.41	0.32	1.41e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2274273	1.000	rs61508494	chr14:55587297	T/C	cg04306507	chr14:55594613	LGALS3	0.32	6.49	0.37	4.2e-10	Protein biomarker;
CESC	cis	rs1030268	0.651	rs12707121	chr7:133496379	A/G	cg10665199	chr7:133106180	EXOC4	0.55	5.43	0.32	1.27e-7	Intelligence (multi-trait analysis);
CESC	cis	rs2439831	0.850	rs61390361	chr15:44159842	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.63	5.6	0.33	5.26e-8	Lung cancer in ever smokers;
CESC	cis	rs5769765	0.773	rs4075331	chr22:50302850	A/G	cg02269571	chr22:50332266	NA	-0.5	-6.47	-0.37	4.6e-10	Schizophrenia;
CESC	cis	rs9733	0.519	rs11204717	chr1:150709129	T/A	cg17724175	chr1:150552817	MCL1	0.46	7.48	0.42	1.07e-12	Tonsillectomy;
CESC	cis	rs7917772	0.582	rs7907760	chr10:104345197	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.41	5.64	0.33	4.41e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs9900062	0.586	rs6504249	chr17:62676149	A/G	cg02598441	chr17:62777298	LOC146880	-0.49	-5.13	-0.3	5.56e-7	QT interval;
CESC	cis	rs7247513	0.759	rs8110545	chr19:12754898	C/T	cg11738485	chr19:12877000	HOOK2	0.49	6.04	0.35	5.21e-9	Bipolar disorder;
CESC	cis	rs6860806	0.661	rs2171247	chr5:131580234	G/T	cg18758796	chr5:131593413	PDLIM4	0.45	6.4	0.37	6.83e-10	Breast cancer;
CESC	cis	rs2688608	0.653	rs12775558	chr10:75570868	G/A	cg23231163	chr10:75533350	FUT11	-0.33	-5.07	-0.3	7.65e-7	Inflammatory bowel disease;
CESC	cis	rs4819052	0.565	rs35776291	chr21:46706142	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.69	9.4	0.5	2.76e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs9470366	0.848	rs66761782	chr6:36636080	T/C	cg08179530	chr6:36648295	CDKN1A	0.51	6.31	0.36	1.14e-9	QRS duration;
CESC	cis	rs1185460	0.967	rs4545564	chr11:118937518	T/C	cg23280166	chr11:118938394	VPS11	0.57	8.01	0.44	3.63e-14	Coronary artery disease;
CESC	cis	rs7395581	0.918	rs1052373	chr11:47354787	A/G	cg25783544	chr11:47291846	MADD	-0.6	-7.91	-0.44	7.01e-14	HDL cholesterol;
CESC	trans	rs9929218	1.000	rs12448448	chr16:68802516	T/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.63	-8.44	-0.46	2.13e-15	Colorectal cancer;
CESC	cis	rs9649213	0.593	rs62478233	chr7:98023092	T/C	cg00277769	chr7:97922759	BAIAP2L1	-0.31	-5.07	-0.3	7.35e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs6502050	0.799	rs7501461	chr17:80109806	C/T	cg11859384	chr17:80120422	CCDC57	-0.38	-5.11	-0.3	6.21e-7	Life satisfaction;
CESC	cis	rs155076	1.000	rs261432	chr13:21865915	G/C	cg11317459	chr13:21872234	NA	-1.09	-12.49	-0.61	1.86e-28	White matter hyperintensity burden;
CESC	cis	rs2857078	0.772	rs2079008	chr17:42322132	C/A	cg19774624	chr17:42201019	HDAC5	0.51	6.65	0.38	1.69e-10	Red cell distribution width;Reticulocyte count;
CESC	cis	rs7084402	0.967	rs3001717	chr10:60329125	A/G	cg07615347	chr10:60278583	BICC1	0.59	9.18	0.49	1.26e-17	Refractive error;
CESC	cis	rs12220238	1.000	rs7905536	chr10:75997209	G/C	cg19889307	chr10:75911429	ADK;AP3M1	0.64	6.32	0.36	1.1e-9	Soluble interleukin-2 receptor subunit alpha;
CESC	cis	rs35306767	0.761	rs11253537	chr10:1010735	G/A	cg26597838	chr10:835615	NA	0.76	7.38	0.41	2.08e-12	Eosinophil percentage of granulocytes;
CESC	cis	rs11098499	0.618	rs6858383	chr4:120296772	T/C	cg09307838	chr4:120376055	NA	0.92	12.66	0.61	4.96e-29	Corneal astigmatism;
CESC	cis	rs6460942	0.687	rs74753576	chr7:12463926	G/A	cg20607287	chr7:12443886	VWDE	-0.76	-10.63	-0.55	3.23e-22	Coronary artery disease;
CESC	trans	rs9929218	0.529	rs2296404	chr16:68729525	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.89	14.39	0.66	4.4e-35	Colorectal cancer;
CESC	cis	rs10887741	0.646	rs2077773	chr10:89435501	G/A	cg13926569	chr10:89418898	PAPSS2	0.47	7.15	0.4	8.25e-12	Exercise (leisure time);
CESC	cis	rs4665809	1.000	rs4665811	chr2:26260017	A/G	cg26314531	chr2:26401878	FAM59B	-0.62	-6.88	-0.39	4.38e-11	Gut microbiome composition (summer);
CESC	cis	rs6456156	1.000	rs6456156	chr6:167522300	T/C	cg23791538	chr6:167370224	RNASET2	-0.4	-5.05	-0.3	8.04e-7	Primary biliary cholangitis;
CESC	cis	rs3096299	0.679	rs3102338	chr16:89442250	C/G	cg08822215	chr16:89438651	ANKRD11	-0.47	-7.46	-0.42	1.27e-12	Multiple myeloma (IgH translocation);
CESC	cis	rs7666738	0.830	rs35822567	chr4:98654138	G/A	cg05340658	chr4:99064831	C4orf37	0.76	10.99	0.56	2.11e-23	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9916302	0.904	rs68178216	chr17:37526241	A/C	cg15445000	chr17:37608096	MED1	-0.41	-6.54	-0.37	3.23e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs4665809	1.000	rs7573118	chr2:26308086	A/G	cg22920501	chr2:26401640	FAM59B	-0.67	-8.12	-0.45	1.72e-14	Gut microbiome composition (summer);
CESC	cis	rs113835537	0.529	rs117112180	chr11:66293273	A/G	cg22134325	chr11:66188745	NPAS4	0.45	6.74	0.38	9.86e-11	Airway imaging phenotypes;
CESC	cis	rs9921192	1.000	rs2892165	chr16:4324293	A/T	cg00021532	chr16:4324280	TFAP4	0.9	13.97	0.65	1.33e-33	Prostate-specific antigen levels;
CESC	cis	rs6570726	0.967	rs374728	chr6:145854598	T/A	cg05347473	chr6:146136440	FBXO30	0.48	6.44	0.37	5.7e-10	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg22359107	chr11:18655812	SPTY2D1	-0.43	-6.2	-0.36	2.15e-9	Gambling;
CESC	cis	rs3857067	1.000	rs6532454	chr4:95019067	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.52	-8.0	-0.44	3.9e-14	QT interval;
CESC	cis	rs7618915	0.501	rs7611731	chr3:52692721	T/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.75	0.38	9.1e-11	Bipolar disorder;
CESC	cis	rs2836974	0.605	rs2836988	chr21:40707975	A/G	cg17971929	chr21:40555470	PSMG1	-0.86	-12.62	-0.61	6.59e-29	Cognitive function;
CESC	cis	rs7659604	1.000	rs28433617	chr4:122664138	C/A	cg19671926	chr4:122722719	EXOSC9	-0.44	-5.16	-0.3	4.8e-7	Type 2 diabetes;
CESC	cis	rs6502050	0.835	rs7220639	chr17:80146866	G/A	cg23985595	chr17:80112537	CCDC57	-0.41	-6.54	-0.37	3.19e-10	Life satisfaction;
CESC	cis	rs1499614	1.000	rs2659911	chr7:66158420	G/A	cg12463550	chr7:65579703	CRCP	0.73	5.73	0.33	2.78e-8	Gout;
CESC	cis	rs4930561	0.765	rs7931502	chr11:67959607	A/C	cg16338278	chr11:67432957	ALDH3B2	-0.44	-5.53	-0.32	7.83e-8	Breast cancer in childhood cancer survivors;IgG glycosylation;
CESC	cis	rs9911578	1.000	rs3744109	chr17:56594197	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.39	-5.16	-0.3	4.83e-7	Intelligence (multi-trait analysis);
CESC	trans	rs7824557	0.564	rs2736290	chr8:11234298	C/T	cg06636001	chr8:8085503	FLJ10661	-0.5	-6.25	-0.36	1.65e-9	Retinal vascular caliber;
CESC	cis	rs951366	1.000	rs951366	chr1:205685352	C/T	cg24503407	chr1:205819492	PM20D1	0.42	5.9	0.34	1.1e-8	Menarche (age at onset);
CESC	cis	rs7247513	0.701	rs8107642	chr19:12766370	C/T	cg01871581	chr19:12707946	ZNF490	-0.85	-13.32	-0.63	2.57e-31	Bipolar disorder;
CESC	cis	rs854765	0.647	rs7212447	chr17:17987067	G/A	cg04398451	chr17:18023971	MYO15A	-0.75	-11.06	-0.56	1.21e-23	Total body bone mineral density;
CESC	cis	rs4568518	0.530	rs7802064	chr7:17994853	A/G	cg03009463	chr7:17980271	SNX13	0.45	5.88	0.34	1.21e-8	Measles;
CESC	cis	rs8177253	0.965	rs4854762	chr3:133499063	A/G	cg12373951	chr3:133503437	NA	-0.4	-5.7	-0.33	3.25e-8	Iron status biomarkers;
CESC	cis	rs1949733	0.655	rs2631736	chr4:8478421	C/G	cg11789530	chr4:8429930	ACOX3	-0.7	-9.91	-0.52	6.83e-20	Response to antineoplastic agents;
CESC	cis	rs7116495	0.867	rs612255	chr11:71778664	A/G	cg10381502	chr11:71823885	C11orf51	-1.15	-7.22	-0.41	5.52e-12	Severe influenza A (H1N1) infection;
CESC	cis	rs7116495	0.881	rs7930544	chr11:71737354	C/T	cg10381502	chr11:71823885	C11orf51	-0.64	-5.21	-0.3	3.81e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs740698	0.529	rs9895414	chr17:60793399	A/C	cg13195520	chr17:60813227	MARCH10	-0.34	-5.65	-0.33	4.14e-8	Pulse pressure;
CESC	cis	rs965469	0.901	rs7270135	chr20:3247922	T/C	cg25506879	chr20:3388711	C20orf194	-0.63	-6.67	-0.38	1.52e-10	IFN-related cytopenia;
CESC	cis	rs2933343	0.700	rs876754	chr3:128627753	T/C	cg11901034	chr3:128598214	ACAD9	-0.34	-5.04	-0.3	8.49e-7	IgG glycosylation;
CESC	cis	rs2013441	0.670	rs4924802	chr17:19955895	G/T	cg12073167	chr17:19770448	ULK2	-0.43	-5.11	-0.3	6.19e-7	Obesity-related traits;
CESC	cis	rs9815354	0.812	rs73071203	chr3:41977464	A/C	cg03022575	chr3:42003672	ULK4	0.67	5.95	0.34	8.63e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs9733	0.650	rs11204680	chr1:150587140	T/G	cg18016565	chr1:150552671	MCL1	-0.43	-7.12	-0.4	1.02e-11	Tonsillectomy;
CESC	cis	rs7827545	0.545	rs1867062	chr8:135559079	G/A	cg17885191	chr8:135476712	NA	0.54	5.95	0.34	8.57e-9	Hypertension (SNP x SNP interaction);
CESC	cis	rs9512730	0.871	rs7992877	chr13:28066866	C/G	cg08193333	chr13:27998609	GTF3A	-0.39	-5.46	-0.32	1.07e-7	Schizophrenia;
CESC	cis	rs3091242	0.935	rs3093632	chr1:25684012	C/T	cg12412775	chr1:25698385	RHCE	-0.31	-5.49	-0.32	9.57e-8	Erythrocyte sedimentation rate;
CESC	cis	rs2295359	0.892	rs10789224	chr1:67605134	C/T	cg17031739	chr1:67600172	NA	-0.39	-5.32	-0.31	2.18e-7	Psoriasis;
CESC	cis	rs9649213	0.593	rs7789380	chr7:97956180	G/A	cg00277769	chr7:97922759	BAIAP2L1	-0.34	-5.67	-0.33	3.68e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs1008375	1.000	rs10011865	chr4:17645710	G/A	cg02297831	chr4:17616191	MED28	0.53	6.71	0.38	1.2e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs34779708	0.897	rs4934716	chr10:35369299	A/G	cg03585969	chr10:35415529	CREM	0.76	10.09	0.53	1.8e-20	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs66887589	0.837	rs7661498	chr4:120408108	T/C	cg09307838	chr4:120376055	NA	0.53	7.12	0.4	1.04e-11	Diastolic blood pressure;
CESC	cis	rs10504229	0.679	rs11783444	chr8:58131267	A/G	cg02725872	chr8:58115012	NA	-0.45	-7.05	-0.4	1.52e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs7552404	0.961	rs17587071	chr1:76225083	A/C	cg22875332	chr1:76189707	ACADM	0.66	7.87	0.44	9.37e-14	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs7666738	0.830	rs34273190	chr4:99004568	C/T	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.62e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9649213	0.555	rs7785612	chr7:97933867	T/A	cg21770322	chr7:97807741	LMTK2	0.59	9.02	0.48	4.02e-17	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs2243480	0.901	rs2456483	chr7:65461575	T/C	cg18252515	chr7:66147081	NA	-1.13	-10.9	-0.56	4.18e-23	Diabetic kidney disease;
CESC	cis	rs2576037	0.796	rs2576041	chr18:44580919	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.61	-8.65	-0.47	4.91e-16	Personality dimensions;
CESC	cis	rs921968	0.542	rs630858	chr2:219409689	C/A	cg02176678	chr2:219576539	TTLL4	0.5	9.0	0.48	4.36e-17	Mean corpuscular hemoglobin concentration;
CESC	trans	rs9325144	0.600	rs7965877	chr12:38743697	G/T	cg23762105	chr12:34175262	ALG10	-0.45	-6.02	-0.35	5.64e-9	Morning vs. evening chronotype;
CESC	cis	rs8062405	1.000	rs7205323	chr16:28865892	C/T	cg08761264	chr16:28874980	SH2B1	-0.47	-5.85	-0.34	1.42e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs2243480	1.000	rs451396	chr7:65484074	T/A	cg13147721	chr7:65941812	NA	-0.89	-8.55	-0.47	9.65e-16	Diabetic kidney disease;
CESC	cis	rs10242455	0.557	rs34943973	chr7:99032517	G/A	cg25640893	chr7:99214727	ZNF498	1.11	6.71	0.38	1.2e-10	Blood metabolite levels;
CESC	cis	rs6496667	1.000	rs7178496	chr15:90896959	C/T	cg22089800	chr15:90895588	ZNF774	0.57	5.76	0.33	2.27e-8	Rheumatoid arthritis;
CESC	cis	rs1983170	0.736	rs11589162	chr1:91974743	C/G	cg02896835	chr1:92012615	NA	0.56	6.03	0.35	5.56e-9	Eosinophil percentage of white cells;
CESC	cis	rs7412746	0.586	rs2864882	chr1:150883037	C/T	cg17724175	chr1:150552817	MCL1	0.33	5.08	0.3	6.98e-7	Melanoma;
CESC	cis	rs6500602	0.623	rs9929311	chr16:4510426	T/C	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.36	5.25	0.31	3.11e-7	Schizophrenia;
CESC	cis	rs67478160	0.643	rs11847468	chr14:104220295	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.49	-6.81	-0.39	6.38e-11	Schizophrenia;
CESC	cis	rs861020	0.630	rs685248	chr1:210008367	C/G	cg05527609	chr1:210001259	C1orf107	0.73	9.57	0.51	8.2e-19	Orofacial clefts;
CESC	cis	rs6502050	0.835	rs9900128	chr17:80087920	A/T	cg23985595	chr17:80112537	CCDC57	-0.42	-6.6	-0.38	2.18e-10	Life satisfaction;
CESC	cis	rs8180040	0.620	rs11917361	chr3:47070497	G/T	cg27129171	chr3:47204927	SETD2	-0.66	-10.41	-0.54	1.7e-21	Colorectal cancer;
CESC	cis	rs4253772	0.514	rs11704878	chr22:46714664	C/T	cg00784671	chr22:46762841	CELSR1	-0.56	-5.74	-0.33	2.63e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs6484504	0.576	rs158140	chr11:31212971	T/C	cg14844989	chr11:31128820	NA	-0.41	-5.86	-0.34	1.34e-8	Red blood cell count;
CESC	cis	rs854765	0.547	rs2955378	chr17:17930253	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.59	8.41	0.46	2.62e-15	Total body bone mineral density;
CESC	cis	rs561341	1.000	rs530715	chr17:30320544	T/G	cg12193833	chr17:30244370	NA	-0.59	-5.99	-0.35	6.95e-9	Hip circumference adjusted for BMI;
CESC	cis	rs6674176	0.660	rs2108202	chr1:44395786	A/G	cg13606994	chr1:44402422	ARTN	0.39	6.09	0.35	4.01e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs7116495	0.786	rs4479013	chr11:71673732	C/G	cg26138937	chr11:71823887	C11orf51	-0.79	-6.51	-0.37	3.77e-10	Severe influenza A (H1N1) infection;
CESC	cis	rs7666738	0.830	rs7673385	chr4:99024922	T/G	cg03676636	chr4:99064102	C4orf37	0.34	5.18	0.3	4.4e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1035144	0.713	rs2284730	chr14:81464901	T/C	cg06600135	chr14:81408086	NA	0.43	5.61	0.33	5.1e-8	Male sexual orientation;
CESC	cis	rs4604732	0.631	rs34330532	chr1:247626844	G/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.57	7.17	0.4	7.39e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs5167	0.505	rs7257468	chr19:45453144	C/T	cg13119609	chr19:45449297	APOC2	0.49	8.03	0.44	3.21e-14	Blood protein levels;
CESC	cis	rs7666738	0.791	rs11729596	chr4:99045461	A/G	cg24818145	chr4:99064322	C4orf37	0.38	5.04	0.3	8.49e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs61148964	0.826	rs58430765	chr22:37235632	G/A	cg22032385	chr2:236721769	AGAP1	0.57	6.25	0.36	1.64e-9	Scarlet fever;
CESC	cis	rs11122272	0.735	rs2790880	chr1:231534259	C/T	cg06096015	chr1:231504339	EGLN1	0.39	5.6	0.33	5.38e-8	Hemoglobin concentration;
CESC	cis	rs13191362	1.000	rs36042757	chr6:163004744	A/C	cg14584255	chr6:163149320	PACRG;PARK2	0.49	5.36	0.31	1.78e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs3105593	0.563	rs4775899	chr15:50967723	T/C	cg08437265	chr15:50716283	USP8	0.41	5.2	0.3	4e-7	QT interval;
CESC	trans	rs2727020	0.823	rs7102374	chr11:49261795	G/A	cg15704280	chr7:45808275	SEPT13	0.81	10.94	0.56	3.07e-23	Coronary artery disease;
CESC	cis	rs10504229	1.000	rs66840104	chr8:58190001	C/T	cg22535103	chr8:58192502	C8orf71	-1.05	-13.08	-0.63	1.71e-30	Developmental language disorder (linguistic errors);
CESC	cis	rs3096299	0.509	rs4785691	chr16:89597221	A/G	cg02187348	chr16:89574699	SPG7	0.73	10.36	0.54	2.47e-21	Multiple myeloma (IgH translocation);
CESC	cis	rs2635047	0.967	rs2684820	chr18:44664304	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.48	6.4	0.37	6.95e-10	Educational attainment;
CESC	cis	rs2276314	1.000	rs58054756	chr18:33554053	G/C	cg19628046	chr18:33552617	C18orf21	0.57	6.41	0.37	6.53e-10	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs7208859	0.673	rs73277986	chr17:29196197	C/T	cg19761014	chr17:28927070	LRRC37B2	0.63	5.27	0.31	2.88e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs7296418	0.619	rs7139321	chr12:123719528	T/G	cg00376283	chr12:123451042	ABCB9	0.63	8.76	0.47	2.42e-16	Platelet count;
CESC	cis	rs11750568	0.967	rs1549602	chr5:178512136	A/G	cg10208897	chr5:178548229	ADAMTS2	-0.39	-5.44	-0.32	1.23e-7	Height;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg14995492	chr5:122971951	NA	-0.38	-6.09	-0.35	4.03e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs2180341	0.814	rs6914131	chr6:127737489	T/C	cg24812749	chr6:127587940	RNF146	0.85	12.06	0.6	5.49e-27	Breast cancer;
CESC	cis	rs72945132	0.882	rs17160777	chr11:70163723	T/C	cg00319359	chr11:70116639	PPFIA1	0.78	7.71	0.43	2.52e-13	Coronary artery disease;
CESC	cis	rs9322193	0.923	rs11155674	chr6:150032247	T/C	cg09699651	chr6:150184138	LRP11	0.39	5.04	0.3	8.83e-7	Lung cancer;
CESC	cis	rs7615952	0.599	rs6803160	chr3:125709554	G/T	cg15145296	chr3:125709740	NA	-0.48	-5.24	-0.31	3.22e-7	Blood pressure (smoking interaction);
CESC	cis	rs9435341	0.965	rs2335104	chr1:107583641	A/T	cg09367891	chr1:107599246	PRMT6	0.6	7.18	0.4	7.15e-12	Facial morphology (factor 21, depth of nasal alae);
CESC	cis	rs10493773	0.775	rs12739713	chr1:86150378	C/T	cg17807903	chr1:86174739	ZNHIT6	-0.38	-5.24	-0.31	3.3e-7	Urate levels in overweight individuals;
CESC	cis	rs9309473	0.579	rs1852644	chr2:73597718	A/G	cg20560298	chr2:73613845	ALMS1	-0.46	-6.55	-0.37	3.03e-10	Metabolite levels;
CESC	trans	rs2908835	0.705	rs2965701	chr12:11637026	G/A	cg09915232	chr8:1879280	ARHGEF10	-0.62	-6.13	-0.35	3.2e-9	Information processing speed;
CESC	cis	rs910316	1.000	rs10142626	chr14:75555636	A/T	cg08847533	chr14:75593920	NEK9	1.01	19.43	0.77	6.73e-53	Height;
CESC	cis	rs6460942	0.915	rs62448593	chr7:12436845	G/C	cg17427002	chr7:12443146	VWDE	-0.53	-5.18	-0.3	4.34e-7	Coronary artery disease;
CESC	cis	rs9916302	0.904	rs4794814	chr17:37696852	G/A	cg15445000	chr17:37608096	MED1	0.42	6.97	0.39	2.52e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs9611565	0.512	rs5758450	chr22:42141640	G/A	cg06634786	chr22:41940651	POLR3H	0.69	6.8	0.39	6.88e-11	Vitiligo;
CESC	trans	rs7937682	0.924	rs10891288	chr11:111552053	G/T	cg18187862	chr3:45730750	SACM1L	-0.5	-6.47	-0.37	4.66e-10	Primary sclerosing cholangitis;
CESC	cis	rs524281	0.648	rs10896089	chr11:65936292	A/G	cg14036092	chr11:66035641	RAB1B	-0.53	-5.22	-0.31	3.65e-7	Electroencephalogram traits;
CESC	cis	rs9322193	0.847	rs9505972	chr6:150096391	A/C	cg13206674	chr6:150067644	NUP43	0.42	5.77	0.33	2.16e-8	Lung cancer;
CESC	cis	rs10751667	0.643	rs10751671	chr11:944479	T/G	cg20946044	chr11:1010712	AP2A2	-0.39	-5.43	-0.32	1.24e-7	Alzheimer's disease (late onset);
CESC	cis	rs7100689	0.577	rs9420359	chr10:82054873	C/T	cg00277334	chr10:82204260	NA	-0.54	-7.07	-0.4	1.35e-11	Post bronchodilator FEV1;
CESC	cis	rs2204008	0.743	rs11182052	chr12:38450421	T/C	cg26384229	chr12:38710491	ALG10B	0.66	10.22	0.53	6.79e-21	Bladder cancer;
CESC	trans	rs10242455	0.702	rs3823813	chr7:99049389	G/A	cg09045935	chr12:6379348	NA	0.9	6.5	0.37	3.97e-10	Blood metabolite levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10548669	chr15:37782940	NA	-0.54	-6.39	-0.37	7.24e-10	Gut microbiome composition (summer);
CESC	trans	rs2963826	0.589	rs298091	chr5:58996603	A/T	cg08204369	chr17:73150733	HN1	0.45	6.05	0.35	4.97e-9	Obesity-related traits;
CESC	cis	rs3820068	0.603	rs72647118	chr1:15956535	G/T	cg13390004	chr1:15929781	NA	0.37	5.9	0.34	1.12e-8	Systolic blood pressure;
CESC	cis	rs34286592	0.929	rs1057452	chr16:29833714	A/G	cg27338089	chr16:29820515	MAZ	-0.54	-5.35	-0.31	1.88e-7	Multiple sclerosis;
CESC	cis	rs7429990	0.965	rs9814961	chr3:48017617	A/G	cg11946769	chr3:48343235	NME6	0.44	5.36	0.31	1.83e-7	Educational attainment (years of education);
CESC	cis	rs9911578	0.730	rs55759249	chr17:57027135	A/G	cg05425664	chr17:57184151	TRIM37	0.46	5.36	0.31	1.77e-7	Intelligence (multi-trait analysis);
CESC	cis	rs1218582	0.772	rs6669791	chr1:154845484	G/T	cg06221963	chr1:154839813	KCNN3	-0.7	-12.33	-0.6	6.34e-28	Prostate cancer;
CESC	cis	rs7523050	0.643	rs71655970	chr1:109403895	A/G	cg08274380	chr1:109419600	GPSM2	0.86	5.77	0.33	2.2e-8	Fat distribution (HIV);
CESC	cis	rs7408868	0.908	rs10418660	chr19:15278635	A/G	cg14696996	chr19:15285081	NOTCH3	1.11	11.94	0.59	1.43e-26	Pulse pressure;
CESC	cis	rs6933660	0.666	rs9371516	chr6:151739642	G/A	cg14262678	chr6:151773367	RMND1;C6orf211	0.66	9.39	0.5	2.8e-18	Menarche (age at onset);
CESC	cis	rs13191362	0.872	rs13215538	chr6:163037975	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.85	9.4	0.5	2.76e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs7089973	0.585	rs7907837	chr10:116610690	G/T	cg25233709	chr10:116636983	FAM160B1	0.4	6.63	0.38	1.93e-10	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg06192289	chr12:102513805	NUP37;C12orf48	-0.43	-6.0	-0.35	6.42e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs2652822	1.000	rs2652822	chr15:63422772	C/T	cg02713581	chr15:63449717	RPS27L	-0.55	-7.28	-0.41	3.89e-12	Metabolic traits;
CESC	cis	rs651907	0.557	rs62284198	chr3:101474699	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.51	6.77	0.38	8.14e-11	Colorectal cancer;
CESC	cis	rs1799949	0.965	rs33988650	chr17:41287880	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.45	6.31	0.36	1.17e-9	Menopause (age at onset);
CESC	cis	rs4665809	1.000	rs750451	chr2:26324241	G/A	cg22920501	chr2:26401640	FAM59B	-0.67	-8.03	-0.44	3.28e-14	Gut microbiome composition (summer);
CESC	cis	rs1023500	0.505	rs134885	chr22:42673811	C/G	cg05082376	chr22:42548792	NA	-0.39	-5.86	-0.34	1.37e-8	Schizophrenia;
CESC	cis	rs2439831	1.000	rs2245054	chr15:43751909	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.83	12.14	0.6	2.88e-27	Lung cancer in ever smokers;
CESC	cis	rs5758659	0.569	rs133294	chr22:42382805	C/T	cg15557168	chr22:42548783	NA	-0.47	-6.92	-0.39	3.46e-11	Cognitive function;
CESC	cis	rs11677416	1.000	rs1878320	chr2:113544467	T/C	cg27083787	chr2:113543245	IL1A	0.42	5.28	0.31	2.72e-7	Response to antipsychotic treatment in schizophrenia (working memory);
CESC	cis	rs2839186	0.869	rs17176513	chr21:47682428	A/G	cg00815214	chr21:47717953	NA	-0.35	-5.12	-0.3	5.98e-7	Testicular germ cell tumor;
CESC	cis	rs9916302	0.904	rs602282	chr17:37433021	C/T	cg15445000	chr17:37608096	MED1	0.4	6.47	0.37	4.67e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs2115536	0.730	rs4238512	chr15:80183898	A/C	cg00225070	chr15:80189496	MTHFS	-0.5	-6.85	-0.39	5.21e-11	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CESC	cis	rs3026101	0.624	rs1065483	chr17:5284770	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.49	6.59	0.38	2.41e-10	Body mass index;
CESC	cis	rs7044106	0.690	rs10739569	chr9:123361027	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.62	8.61	0.47	6.81e-16	Hip circumference adjusted for BMI;
CESC	cis	rs1144333	0.850	rs1144341	chr1:76282659	T/G	cg10523679	chr1:76189770	ACADM	-0.58	-5.53	-0.32	7.84e-8	Attention function in attention deficit hyperactive disorder;
CESC	cis	rs7247513	0.701	rs8107642	chr19:12766370	C/T	cg11738485	chr19:12877000	HOOK2	0.48	5.93	0.34	9.25e-9	Bipolar disorder;
CESC	cis	rs6120849	0.901	rs6088738	chr20:33747331	A/G	cg24642439	chr20:33292090	TP53INP2	-0.57	-6.24	-0.36	1.75e-9	Protein C levels;
CESC	trans	rs877282	0.755	rs11253399	chr10:790030	T/A	cg22713356	chr15:30763199	NA	1.11	11.99	0.59	9.56e-27	Uric acid levels;
CESC	trans	rs459571	0.629	rs441233	chr9:136876021	A/G	cg10765909	chr12:53715428	AAAS	0.51	6.1	0.35	3.7e-9	Platelet distribution width;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16681104	chr6:159550158	NA	-0.56	-6.79	-0.38	7.37e-11	Gut microbiome composition (summer);
CESC	cis	rs922692	0.773	rs2904220	chr15:79076704	G/T	cg04896959	chr15:78267971	NA	0.35	5.1	0.3	6.61e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
CESC	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg12419862	chr22:24373484	LOC391322	0.71	9.55	0.51	9.07e-19	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs7618915	0.547	rs34610142	chr3:52708429	G/A	cg18099408	chr3:52552593	STAB1	-0.31	-5.19	-0.3	4.19e-7	Bipolar disorder;
CESC	cis	rs12136530	0.550	rs904964	chr1:19697065	T/C	cg01832549	chr1:19774989	CAPZB	-0.41	-5.27	-0.31	2.8e-7	Lead levels in blood;
CESC	cis	rs1552244	1.000	rs7652935	chr3:10151138	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.82	-10.94	-0.56	3.04e-23	Alzheimer's disease;
CESC	cis	rs7829975	0.501	rs2980769	chr8:8320291	G/A	cg15556689	chr8:8085844	FLJ10661	0.63	8.52	0.46	1.2e-15	Mood instability;
CESC	cis	rs2249625	0.874	rs1819067	chr6:72849139	A/C	cg18830697	chr6:72922368	RIMS1	-0.41	-5.89	-0.34	1.17e-8	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CESC	cis	rs7833790	0.724	rs10958045	chr8:82722994	T/C	cg07697082	chr8:82753677	SNX16	0.41	6.24	0.36	1.69e-9	Diastolic blood pressure;
CESC	cis	rs9611565	0.592	rs4822038	chr22:41958495	G/A	cg06481639	chr22:41940642	POLR3H	-0.65	-6.55	-0.37	2.98e-10	Vitiligo;
CESC	cis	rs1975974	0.574	rs17052370	chr17:21736353	A/G	cg18423549	chr17:21743878	NA	0.64	9.68	0.51	3.62e-19	Psoriasis;
CESC	cis	rs1707322	1.000	rs1613296	chr1:46546852	A/C	cg06784218	chr1:46089804	CCDC17	-0.33	-5.08	-0.3	7.18e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23860436	chr12:58378763	NA	-0.63	-7.22	-0.41	5.65e-12	Gut microbiome composition (summer);
CESC	cis	rs4665809	0.549	rs3828255	chr2:26413252	G/A	cg22920501	chr2:26401640	FAM59B	0.78	8.59	0.47	7.48e-16	Gut microbiome composition (summer);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg02970861	chr11:62359288	TUT1	-0.47	-6.65	-0.38	1.65e-10	Gambling;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg01708236	chr6:44233446	NFKBIE	-0.47	-6.17	-0.35	2.6e-9	Fibrinogen levels;
CESC	cis	rs7684253	0.565	rs12641030	chr4:57803505	A/G	cg21154227	chr4:57904332	IGFBP7	0.37	5.4	0.31	1.47e-7	Migraine;
CESC	cis	rs2549003	0.933	rs3846731	chr5:131814264	T/C	cg00255919	chr5:131827918	IRF1	0.51	8.71	0.47	3.26e-16	Asthma (sex interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10211485	chr17:655108	ELP2P;GEMIN4	-0.61	-7.2	-0.4	6.13e-12	Gut microbiome composition (summer);
CESC	cis	rs6089584	0.889	rs6142923	chr20:60596617	C/T	cg13770153	chr20:60521292	NA	0.53	6.71	0.38	1.15e-10	Body mass index;
CESC	cis	rs7208859	0.623	rs8075341	chr17:29136565	A/G	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.79e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs4563143	0.663	rs73025068	chr19:29238998	G/A	cg12667521	chr19:29218732	NA	0.49	6.69	0.38	1.32e-10	Methadone dose in opioid dependence;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg25535789	chr19:6211926	MLLT1	-0.42	-6.27	-0.36	1.46e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs7208859	0.573	rs8064686	chr17:29134839	C/T	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.1e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs1348850	0.574	rs4893834	chr2:178442288	C/T	cg23306229	chr2:178417860	TTC30B	-0.57	-5.57	-0.32	6.27e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs2404602	0.552	rs4886823	chr15:76965402	A/G	cg00316803	chr15:76480434	C15orf27	0.4	5.67	0.33	3.8e-8	Blood metabolite levels;
CESC	cis	rs909674	0.818	rs5757678	chr22:39843409	A/G	cg11247378	chr22:39784982	NA	0.62	9.02	0.48	3.97e-17	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs116095464	0.558	rs56342538	chr5:225796	T/C	cg10591111	chr5:226296	SDHA	-0.52	-6.52	-0.37	3.47e-10	Breast cancer;
CESC	cis	rs2836950	0.561	rs34705151	chr21:40553344	G/A	cg17971929	chr21:40555470	PSMG1	-0.54	-7.05	-0.4	1.56e-11	Menarche (age at onset);
CESC	cis	rs2070488	0.804	rs2268755	chr3:38501916	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.8	-13.05	-0.63	2.09e-30	Electrocardiographic conduction measures;
CESC	cis	rs9443645	0.901	rs9352664	chr6:79566162	G/T	cg05283184	chr6:79620031	NA	-0.43	-6.76	-0.38	8.6e-11	Intelligence (multi-trait analysis);
CESC	trans	rs2727020	0.636	rs11040368	chr11:49453602	C/A	cg15704280	chr7:45808275	SEPT13	-0.91	-15.85	-0.7	3.05e-40	Coronary artery disease;
CESC	cis	rs7260538	0.773	rs1552223	chr19:41525952	A/G	cg27089200	chr19:41531976	NA	-0.34	-5.17	-0.3	4.69e-7	DDT metabolite (p,p'-DDE levels);
CESC	cis	rs7772486	0.875	rs10457795	chr6:146415665	A/G	cg23711669	chr6:146136114	FBXO30	0.83	12.44	0.61	2.65e-28	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs873946	0.586	rs57431984	chr10:134567697	C/T	cg27297192	chr10:134578999	INPP5A	0.4	5.13	0.3	5.54e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs4975709	0.569	rs2077269	chr5:1863506	C/T	cg14773178	chr5:1868261	NA	0.32	5.76	0.33	2.3e-8	Cardiovascular disease risk factors;
CESC	trans	rs7107217	1.000	rs1873872	chr11:129473993	A/T	cg07049977	chr2:37458536	CEBPZ;C2orf56	0.5	6.55	0.37	3e-10	Breast cancer;Type 2 diabetes;
CESC	cis	rs2075371	0.764	rs1643034	chr7:134006176	A/G	cg11752832	chr7:134001865	SLC35B4	0.51	6.65	0.38	1.69e-10	Mean platelet volume;
CESC	cis	rs3091242	1.000	rs9689	chr1:25688276	A/G	cg12412775	chr1:25698385	RHCE	-0.31	-5.55	-0.32	7.06e-8	Erythrocyte sedimentation rate;
CESC	cis	rs10465746	0.653	rs11163877	chr1:84441848	T/A	cg10977910	chr1:84465055	TTLL7	0.52	7.06	0.4	1.44e-11	Obesity-related traits;
CESC	cis	rs6762	0.719	rs28655651	chr11:837121	G/C	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.76	-10.27	-0.53	4.83e-21	Mean platelet volume;
CESC	cis	rs9322193	0.962	rs9397357	chr6:150133601	G/A	cg04369109	chr6:150039330	LATS1	-0.43	-6.11	-0.35	3.56e-9	Lung cancer;
CESC	cis	rs1707322	0.716	rs6699444	chr1:46135120	G/C	cg06784218	chr1:46089804	CCDC17	0.41	7.12	0.4	1.04e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2404602	0.716	rs56351018	chr15:76824591	T/C	cg26408565	chr15:76604113	ETFA	-0.42	-6.2	-0.36	2.16e-9	Blood metabolite levels;
CESC	cis	rs10779751	1.000	rs6670821	chr1:11308762	T/C	cg08854313	chr1:11322531	MTOR	0.8	10.83	0.55	6.99e-23	Body mass index;
CESC	cis	rs9911578	0.835	rs58647683	chr17:56483194	T/C	cg05425664	chr17:57184151	TRIM37	0.46	6.36	0.36	8.86e-10	Intelligence (multi-trait analysis);
CESC	cis	rs2836974	0.583	rs9636957	chr21:40705847	G/A	cg11644478	chr21:40555479	PSMG1	-0.79	-11.71	-0.58	8.34e-26	Cognitive function;
CESC	cis	rs12711979	0.509	rs10191674	chr2:3827891	C/T	cg17052675	chr2:3827356	NA	-0.61	-10.33	-0.54	3.04e-21	Itch intensity from mosquito bite adjusted by bite size;
CESC	cis	rs7674212	0.570	rs2126470	chr4:104061762	T/C	cg16532752	chr4:104119610	CENPE	-0.45	-6.22	-0.36	1.95e-9	Type 2 diabetes;
CESC	cis	rs2228479	1.000	rs2228479	chr16:89985940	G/A	cg06558623	chr16:89946397	TCF25	1.14	8.77	0.47	2.27e-16	Skin colour saturation;
CESC	cis	rs9322193	0.923	rs9767105	chr6:149980727	A/G	cg04369109	chr6:150039330	LATS1	-0.45	-6.23	-0.36	1.78e-9	Lung cancer;
CESC	cis	rs12497850	0.931	rs7636057	chr3:48992582	C/T	cg07636037	chr3:49044803	WDR6	1.07	19.82	0.77	3.09e-54	Parkinson's disease;
CESC	cis	rs9611565	0.568	rs5758441	chr22:42132888	C/A	cg03806693	chr22:41940476	POLR3H	0.78	9.54	0.51	9.81e-19	Vitiligo;
CESC	cis	rs6088580	0.634	rs9789792	chr20:32957709	G/A	cg24642439	chr20:33292090	TP53INP2	-0.52	-6.83	-0.39	5.7e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs2737618	0.698	rs2737681	chr1:200091864	C/T	cg21825944	chr1:200113062	NR5A2	-0.38	-5.4	-0.31	1.49e-7	Uric acid levels;
CESC	cis	rs7666738	0.830	rs11097608	chr4:99011693	T/C	cg17366294	chr4:99064904	C4orf37	0.6	8.53	0.46	1.15e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6496667	1.000	rs75444304	chr15:90894246	C/T	cg22089800	chr15:90895588	ZNF774	0.51	5.17	0.3	4.67e-7	Rheumatoid arthritis;
CESC	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg22907277	chr7:1156413	C7orf50	0.37	5.41	0.32	1.38e-7	Longevity;Endometriosis;
CESC	cis	rs938554	0.737	rs11723439	chr4:9951819	C/T	cg00071950	chr4:10020882	SLC2A9	-0.66	-7.02	-0.4	1.85e-11	Blood metabolite levels;
CESC	cis	rs9549367	0.789	rs8001506	chr13:113867153	A/C	cg18105134	chr13:113819100	PROZ	-0.72	-9.4	-0.5	2.68e-18	Platelet distribution width;
CESC	cis	rs9549260	0.816	rs7328594	chr13:41253764	T/C	cg21288729	chr13:41239152	FOXO1	0.64	8.19	0.45	1.09e-14	Red blood cell count;
CESC	cis	rs4665809	0.590	rs62128455	chr2:26466530	G/A	cg25036284	chr2:26402008	FAM59B	0.86	9.4	0.5	2.74e-18	Gut microbiome composition (summer);
CESC	cis	rs56046484	0.703	rs12439802	chr15:85520329	C/G	cg08123816	chr15:85640762	PDE8A	-0.44	-5.32	-0.31	2.2e-7	Testicular germ cell tumor;
CESC	cis	rs2075371	0.863	rs34231360	chr7:133944988	A/C	cg11752832	chr7:134001865	SLC35B4	0.51	6.49	0.37	4.14e-10	Mean platelet volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02522952	chr6:119671260	MAN1A1	0.55	6.61	0.38	2.15e-10	Gut microbiome composition (summer);
CESC	cis	rs7998202	0.667	rs914018	chr13:113354819	A/G	cg02820901	chr13:113351484	ATP11A	0.65	5.78	0.33	2.05e-8	Glycated hemoglobin levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16856100	chr3:17783647	TBC1D5	0.61	6.91	0.39	3.67e-11	Gut microbiome composition (summer);
CESC	cis	rs7772486	0.754	rs2328707	chr6:146053498	G/A	cg23711669	chr6:146136114	FBXO30	-1.0	-15.4	-0.69	1.15e-38	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7666738	0.830	rs115712871	chr4:98954535	A/T	cg17366294	chr4:99064904	C4orf37	0.6	8.47	0.46	1.72e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg11494091	chr17:61959527	GH2	0.73	12.49	0.61	1.88e-28	Prudent dietary pattern;
CESC	cis	rs6088580	0.634	rs3736762	chr20:33037336	C/T	cg08999081	chr20:33150536	PIGU	0.65	11.42	0.57	7.86e-25	Glomerular filtration rate (creatinine);
CESC	cis	rs11098499	0.644	rs7676296	chr4:120555687	A/G	cg24375607	chr4:120327624	NA	0.41	5.14	0.3	5.23e-7	Corneal astigmatism;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg16266895	chr12:101674004	UTP20	-0.48	-6.92	-0.39	3.49e-11	Gambling;
CESC	cis	rs17401966	1.000	rs3748578	chr1:10420918	A/G	cg15208524	chr1:10270712	KIF1B	-0.43	-5.5	-0.32	8.87e-8	Hepatocellular carcinoma;
CESC	cis	rs4803468	1.000	rs4803468	chr19:41922352	A/G	cg09537434	chr19:41945824	ATP5SL	-1.11	-20.39	-0.78	3.11e-56	Height;
CESC	cis	rs1008375	0.966	rs6449329	chr4:17703677	T/C	cg02297831	chr4:17616191	MED28	0.48	5.79	0.33	2.01e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs4843747	0.671	rs8062855	chr16:88106941	T/C	cg03395651	chr16:88107091	BANP	0.46	5.36	0.31	1.85e-7	Menopause (age at onset);
CESC	cis	rs3768617	0.510	rs4651143	chr1:183097398	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.89	14.27	0.66	1.13e-34	Fuchs's corneal dystrophy;
CESC	cis	rs60871478	1.000	rs34086011	chr7:805430	C/T	cg05535760	chr7:792225	HEATR2	0.88	11.01	0.56	1.78e-23	Cerebrospinal P-tau181p levels;
CESC	cis	rs644799	0.648	rs1255182	chr11:95472391	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.47	6.81	0.39	6.49e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	trans	rs1044826	1.000	rs747346	chr3:139231914	A/C	cg05129325	chr1:215255161	KCNK2	-0.31	-6.11	-0.35	3.53e-9	Obesity-related traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23614413	chr1:45120431	TMEM53	-0.54	-6.11	-0.35	3.48e-9	Gut microbiome composition (summer);
CESC	cis	rs6120849	0.754	rs6120813	chr20:33642112	T/C	cg24642439	chr20:33292090	TP53INP2	0.68	6.77	0.38	8.46e-11	Protein C levels;
CESC	cis	rs10504229	0.683	rs11786043	chr8:58133174	T/C	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs3126085	0.935	rs11204947	chr1:152218257	G/T	cg03465714	chr1:152285911	FLG	0.45	5.37	0.31	1.73e-7	Atopic dermatitis;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg25300318	chr2:200527297	NA	0.5	6.9	0.39	3.76e-11	Fibrinogen levels;
CESC	cis	rs7412746	0.658	rs2089082	chr1:150800090	T/G	cg22823121	chr1:150693482	HORMAD1	0.45	6.37	0.36	8.45e-10	Melanoma;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16759895	chr16:3451202	ZNF174;ZNF434	0.55	6.08	0.35	4.19e-9	Gut microbiome composition (summer);
CESC	cis	rs9929218	1.000	rs12446575	chr16:68791644	C/G	cg02972257	chr16:68554789	NA	0.54	6.25	0.36	1.59e-9	Colorectal cancer;
CESC	cis	rs6582630	0.519	rs12366667	chr12:38332632	C/T	cg13010199	chr12:38710504	ALG10B	0.48	6.11	0.35	3.53e-9	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs950776	0.593	rs601079	chr15:78869579	T/A	cg24631222	chr15:78858424	CHRNA5	0.44	5.61	0.33	5.17e-8	Sudden cardiac arrest;
CESC	cis	rs6669072	0.647	rs814546	chr1:91239355	G/T	cg08895590	chr1:91227319	NA	-0.32	-5.52	-0.32	8.16e-8	Cognitive function;
CESC	cis	rs1862618	0.713	rs832549	chr5:56183542	C/T	cg24549020	chr5:56110836	MAP3K1	0.66	7.43	0.42	1.49e-12	Initial pursuit acceleration;
CESC	cis	rs4819052	0.851	rs2838842	chr21:46669217	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.75	9.76	0.51	1.99e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs4566357	0.615	rs2894626	chr2:227916039	T/C	cg05526886	chr2:227700861	RHBDD1	-0.51	-6.79	-0.38	7.47e-11	Coronary artery disease;
CESC	trans	rs12356475	0.710	rs10822686	chr10:67733250	C/T	cg02846228	chr16:31102495	VKORC1	-0.51	-6.26	-0.36	1.5e-9	Psoriatic arthritis;
CESC	cis	rs3093024	1.000	rs3093023	chr6:167534290	A/G	cg23791538	chr6:167370224	RNASET2	0.42	5.21	0.3	3.82e-7	Rheumatoid arthritis;
CESC	cis	rs889398	0.738	rs7196842	chr16:69923333	T/C	cg09409435	chr16:70099608	PDXDC2	0.41	5.06	0.3	7.98e-7	Body mass index;
CESC	cis	rs4150161	0.591	rs3759977	chr16:84221170	T/A	cg10106505	chr16:84220380	TAF1C	-0.78	-5.68	-0.33	3.51e-8	Systolic blood pressure response to hydrochlorothiazide in hypertension;
CESC	cis	rs7666738	0.830	rs1967977	chr4:98966141	A/G	cg03467027	chr4:99064603	C4orf37	0.44	5.57	0.32	6.41e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7208859	0.573	rs7222803	chr17:29119897	A/G	cg14008862	chr17:28927542	LRRC37B2	0.65	5.14	0.3	5.34e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs2455799	0.593	rs2047852	chr3:15732539	T/G	cg16303742	chr3:15540471	COLQ	-0.38	-5.99	-0.35	6.73e-9	Mean platelet volume;
CESC	cis	rs10434923	1.000	rs2091154	chr7:156257405	A/G	cg10571168	chr7:156583547	LMBR1	0.6	5.2	0.3	3.99e-7	Childhood ear infection;
CESC	cis	rs7044106	0.664	rs7861679	chr9:123375589	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.76	-11.68	-0.58	1.08e-25	Hip circumference adjusted for BMI;
CESC	cis	rs4523957	0.963	rs216178	chr17:2168840	T/C	cg16513277	chr17:2031491	SMG6	0.59	8.06	0.44	2.6e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs2075371	0.897	rs1643033	chr7:134004662	T/C	cg00033643	chr7:134001901	SLC35B4	0.41	5.34	0.31	1.98e-7	Mean platelet volume;
CESC	cis	rs8020095	0.571	rs10136026	chr14:67410107	C/T	cg19548862	chr14:67692701	FAM71D	-0.49	-5.98	-0.35	7.01e-9	Depression (quantitative trait);
CESC	cis	rs6460942	0.915	rs62448596	chr7:12446869	C/T	cg17427002	chr7:12443146	VWDE	-0.56	-5.85	-0.34	1.42e-8	Coronary artery disease;
CESC	cis	rs561341	1.000	rs8073186	chr17:30244956	T/C	cg23018236	chr17:30244563	NA	-0.45	-5.06	-0.3	7.86e-7	Hip circumference adjusted for BMI;
CESC	cis	rs10191773	0.535	rs72833432	chr2:113102746	T/C	cg07905836	chr2:113190072	RGPD8;RGPD5	0.59	5.1	0.3	6.51e-7	Yeast infection;
CESC	cis	rs637571	0.522	rs3016868	chr11:65764383	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.45	6.68	0.38	1.44e-10	Eosinophil percentage of white cells;
CESC	cis	rs950776	0.518	rs11632604	chr15:78821914	T/C	cg06917634	chr15:78832804	PSMA4	0.8	12.12	0.6	3.34e-27	Sudden cardiac arrest;
CESC	cis	rs6502050	0.835	rs7207947	chr17:80145291	A/T	cg23985595	chr17:80112537	CCDC57	-0.42	-6.62	-0.38	2.01e-10	Life satisfaction;
CESC	cis	rs4727027	0.866	rs12666477	chr7:148812322	A/G	cg23583168	chr7:148888333	NA	-0.74	-10.77	-0.55	1.13e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs35110281	0.720	rs162374	chr21:44927089	T/C	cg21573476	chr21:45109991	RRP1B	0.43	5.92	0.34	9.84e-9	Mean corpuscular volume;
CESC	cis	rs7937682	0.737	rs518294	chr11:111424716	A/T	cg22437258	chr11:111473054	SIK2	0.61	7.58	0.42	5.87e-13	Primary sclerosing cholangitis;
CESC	cis	rs35110281	0.744	rs230646	chr21:44918788	A/G	cg01579765	chr21:45077557	HSF2BP	-0.52	-8.79	-0.47	1.98e-16	Mean corpuscular volume;
CESC	cis	rs2645694	0.626	rs2703122	chr4:77821418	A/C	cg10057126	chr4:77819792	ANKRD56	0.59	8.61	0.47	6.84e-16	Emphysema distribution in smoking;
CESC	cis	rs4481887	0.927	rs4244187	chr1:248493511	T/C	cg00666640	chr1:248458726	OR2T12	0.35	5.84	0.34	1.55e-8	Common traits (Other);
CESC	cis	rs854765	0.522	rs63721860	chr17:17829576	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.64	9.36	0.5	3.61e-18	Total body bone mineral density;
CESC	cis	rs6088590	0.561	rs6087605	chr20:33180624	G/T	cg08999081	chr20:33150536	PIGU	0.7	12.4	0.61	3.7e-28	Coronary artery disease;
CESC	cis	rs8005677	1.000	rs8005677	chr14:23376678	T/C	cg01529538	chr14:23388837	RBM23	0.51	6.99	0.39	2.25e-11	Cognitive ability (multi-trait analysis);
CESC	cis	rs6570726	0.902	rs4895678	chr6:145935510	C/T	cg05347473	chr6:146136440	FBXO30	0.4	5.53	0.32	7.52e-8	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9300255	0.543	rs520088	chr12:123522150	C/G	cg00376283	chr12:123451042	ABCB9	0.76	9.53	0.51	1.08e-18	Neutrophil percentage of white cells;
CESC	cis	rs6032067	0.777	rs13039211	chr20:43784396	C/T	cg10761708	chr20:43804764	PI3	0.56	6.55	0.37	3.01e-10	Blood protein levels;
CESC	cis	rs7666738	0.830	rs13119995	chr4:99026790	T/C	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.58e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10493773	0.630	rs3753790	chr1:86174772	T/C	cg17807903	chr1:86174739	ZNHIT6	-0.44	-6.5	-0.37	3.91e-10	Urate levels in overweight individuals;
CESC	cis	rs2130392	0.503	rs2871418	chr4:185654723	A/G	cg21366198	chr4:185655624	MLF1IP	0.43	5.83	0.34	1.57e-8	Kawasaki disease;
CESC	cis	rs6543140	0.964	rs2141781	chr2:103082906	G/A	cg04239558	chr2:103089729	SLC9A4	0.48	6.16	0.35	2.64e-9	Blood protein levels;
CESC	cis	rs7089973	0.604	rs11196943	chr10:116598865	T/C	cg03647239	chr10:116582469	FAM160B1	0.44	5.55	0.32	6.83e-8	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs921665	0.915	rs11127382	chr2:3185675	A/T	cg00496484	chr2:3153332	NA	-0.46	-5.03	-0.3	9.09e-7	World class endurance athleticism;
CESC	cis	rs6502050	0.835	rs7221544	chr17:80087337	C/T	cg23985595	chr17:80112537	CCDC57	0.42	6.53	0.37	3.29e-10	Life satisfaction;
CESC	cis	rs6461049	0.608	rs3800923	chr7:2184673	A/G	cg02951883	chr7:2050386	MAD1L1	-0.43	-5.64	-0.33	4.4e-8	Schizophrenia;
CESC	cis	rs172166	0.637	rs1071893	chr6:28167635	G/C	cg18032046	chr6:28092343	ZSCAN16	-0.43	-5.48	-0.32	9.85e-8	Cardiac Troponin-T levels;
CESC	cis	rs7918232	0.941	rs4749228	chr10:27433618	C/T	cg14240646	chr10:27532245	ACBD5	0.69	6.42	0.37	6.15e-10	Breast cancer;
CESC	cis	rs2032447	0.670	rs198848	chr6:26106325	A/G	cg03264133	chr6:25882463	NA	-0.44	-6.32	-0.36	1.12e-9	Intelligence (multi-trait analysis);
CESC	cis	rs172166	0.637	rs1071893	chr6:28167635	G/C	cg12963246	chr6:28129442	ZNF389	0.41	5.91	0.34	1.04e-8	Cardiac Troponin-T levels;
CESC	cis	rs1728785	1.000	rs1728765	chr16:68589433	G/A	cg02972257	chr16:68554789	NA	-0.59	-6.79	-0.38	7.32e-11	Ulcerative colitis;
CESC	cis	rs9811920	0.609	rs7638900	chr3:99670773	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.4	5.44	0.32	1.19e-7	Axial length;
CESC	cis	rs9322193	0.962	rs952165	chr6:150120036	T/C	cg05861140	chr6:150128134	PCMT1	-0.37	-5.3	-0.31	2.42e-7	Lung cancer;
CESC	cis	rs9911578	0.704	rs72628393	chr17:56585314	A/T	cg05425664	chr17:57184151	TRIM37	0.49	6.77	0.38	8.43e-11	Intelligence (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04441191	chr3:48130393	MAP4	0.62	7.0	0.4	2.07e-11	Gut microbiome composition (summer);
CESC	cis	rs722599	0.562	rs2193597	chr14:75234329	G/A	cg08847533	chr14:75593920	NEK9	0.5	6.17	0.35	2.57e-9	IgG glycosylation;
CESC	cis	rs453301	0.686	rs6601281	chr8:8911004	A/G	cg15556689	chr8:8085844	FLJ10661	-0.51	-6.29	-0.36	1.31e-9	Joint mobility (Beighton score);
CESC	cis	rs9916302	0.851	rs9904919	chr17:37556431	G/C	cg07936489	chr17:37558343	FBXL20	0.79	11.49	0.58	4.71e-25	Glomerular filtration rate (creatinine);
CESC	cis	rs7044106	0.762	rs10760107	chr9:123383630	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.63	8.66	0.47	4.68e-16	Hip circumference adjusted for BMI;
CESC	cis	rs61542988	0.535	rs10807813	chr7:22829961	C/T	cg11367502	chr7:22862612	TOMM7	0.52	6.16	0.35	2.73e-9	Fibrinogen levels;
CESC	cis	rs6732160	0.588	rs7578991	chr2:73376171	A/G	cg01422370	chr2:73384389	NA	0.57	9.1	0.49	2.21e-17	Intelligence (multi-trait analysis);
CESC	trans	rs722599	0.748	rs17102884	chr14:75374899	C/T	cg00095594	chr1:236228625	NID1	-0.4	-6.17	-0.35	2.5e-9	IgG glycosylation;
CESC	cis	rs1552244	1.000	rs67134728	chr3:10151431	G/C	cg00149659	chr3:10157352	C3orf10	0.74	9.04	0.49	3.31e-17	Alzheimer's disease;
CESC	cis	rs7250872	0.647	rs2304613	chr19:1817943	G/C	cg05970437	chr19:1864622	KLF16	0.47	5.49	0.32	9.4e-8	Bipolar disorder;
CESC	cis	rs1799949	1.000	rs35956818	chr17:41422985	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.64	8.58	0.47	8.12e-16	Menopause (age at onset);
CESC	cis	rs1218582	0.741	rs7544528	chr1:154844585	C/T	cg09359103	chr1:154839909	KCNN3	-0.7	-13.7	-0.64	1.12e-32	Prostate cancer;
CESC	trans	rs8113263	1	rs8113263	chr19:13179662	C/A	cg24196017	chr15:43021976	CDAN1	-0.76	-6.03	-0.35	5.61e-9	Body mass index;
CESC	cis	rs4076764	1.000	rs4469696	chr1:163424565	C/T	cg06092702	chr1:163392909	NA	-0.37	-5.48	-0.32	9.9e-8	Motion sickness;
CESC	cis	rs7818345	0.874	rs56298301	chr8:19305937	C/A	cg11303988	chr8:19266685	CSGALNACT1	0.38	6.8	0.39	6.8e-11	Language performance in older adults (adjusted for episodic memory);
CESC	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg18110333	chr6:292329	DUSP22	-0.76	-10.27	-0.53	4.94e-21	Menopause (age at onset);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg13150282	chr12:109531243	ALKBH2	-0.46	-6.1	-0.35	3.66e-9	Fibrinogen levels;
CESC	cis	rs3820068	0.580	rs7512308	chr1:16006604	C/A	cg17385448	chr1:15911702	AGMAT	0.39	6.02	0.35	5.82e-9	Systolic blood pressure;
CESC	cis	rs9902453	1.000	rs28664971	chr17:28437410	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.68	8.78	0.47	2.02e-16	Coffee consumption (cups per day);
CESC	cis	rs829661	0.947	rs829665	chr2:30724701	T/A	cg12454169	chr2:30669597	LCLAT1	1.01	9.28	0.5	6.5e-18	Midgestational circulating levels of PBDEs (fetal genetic effect);
CESC	cis	rs6952808	0.531	rs3800922	chr7:2184505	A/G	cg21782813	chr7:2030301	MAD1L1	0.5	7.12	0.4	9.93e-12	Bipolar disorder and schizophrenia;
CESC	cis	rs6502050	0.731	rs12150589	chr17:80158233	A/T	cg23985595	chr17:80112537	CCDC57	-0.4	-6.37	-0.36	8.38e-10	Life satisfaction;
CESC	cis	rs2559856	1.000	rs2695292	chr12:102087290	G/A	cg15068132	chr12:102092402	CHPT1	-0.39	-5.18	-0.3	4.38e-7	Blood protein levels;
CESC	cis	rs8177253	0.665	rs10935074	chr3:133441692	T/G	cg18769074	chr3:133464867	TF	0.31	5.87	0.34	1.31e-8	Iron status biomarkers;
CESC	cis	rs5753618	0.561	rs9606831	chr22:31732512	C/T	cg13145458	chr22:31556086	RNF185	-0.49	-5.51	-0.32	8.62e-8	Colorectal cancer;
CESC	cis	rs16854884	0.657	rs34683397	chr3:143723559	C/T	cg06585982	chr3:143692056	C3orf58	0.48	6.0	0.35	6.59e-9	Economic and political preferences (feminism/equality);
CESC	cis	rs1552244	0.938	rs7652951	chr3:10063763	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-10.79	-0.55	9.74e-23	Alzheimer's disease;
CESC	cis	rs9612	1.000	rs12669	chr19:44235535	G/A	cg08581076	chr19:44259116	C19orf61	0.58	6.6	0.38	2.17e-10	Exhaled nitric oxide output;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg19321118	chr6:26322387	NA	-0.43	-6.14	-0.35	3.01e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg18402987	chr7:1209562	NA	0.43	5.54	0.32	7.32e-8	Longevity;Endometriosis;
CESC	cis	rs6546550	0.901	rs6754896	chr2:70138170	T/C	cg02498382	chr2:70120550	SNRNP27	-0.41	-7.26	-0.41	4.34e-12	Prevalent atrial fibrillation;
CESC	cis	rs7107174	1.000	rs10899477	chr11:78052104	A/T	cg02023728	chr11:77925099	USP35	0.47	6.25	0.36	1.63e-9	Testicular germ cell tumor;
CESC	cis	rs6540559	0.673	rs6540560	chr1:209982073	A/G	cg10074409	chr1:209979377	IRF6	-0.37	-5.2	-0.3	4.05e-7	Cleft lip with or without cleft palate;
CESC	cis	rs9611565	0.729	rs202654	chr22:41841034	G/A	cg06634786	chr22:41940651	POLR3H	0.43	5.06	0.3	7.84e-7	Vitiligo;
CESC	cis	rs4665809	0.938	rs4665822	chr2:26312555	C/G	cg27170947	chr2:26402098	FAM59B	-0.59	-7.02	-0.4	1.84e-11	Gut microbiome composition (summer);
CESC	cis	rs9611565	0.512	rs6002474	chr22:42168181	A/G	cg17376030	chr22:41985996	PMM1	-0.79	-8.37	-0.46	3.43e-15	Vitiligo;
CESC	cis	rs9660992	0.674	rs12122105	chr1:205256818	C/T	cg00857998	chr1:205179979	DSTYK	0.47	5.34	0.31	2.02e-7	Mean corpuscular volume;Mean platelet volume;
CESC	trans	rs17508449	0.819	rs77042378	chr1:114209101	G/T	cg04711050	chr9:4490757	SLC1A1	-0.66	-6.08	-0.35	4.19e-9	Leprosy;
CESC	cis	rs7829975	0.688	rs7826654	chr8:8379106	C/T	cg06636001	chr8:8085503	FLJ10661	0.51	6.35	0.36	9.5e-10	Mood instability;
CESC	cis	rs4253772	0.614	rs11090859	chr22:46687460	T/G	cg24881330	chr22:46731750	TRMU	0.86	9.19	0.49	1.19e-17	LDL cholesterol;Cholesterol, total;
CESC	cis	rs3858526	0.523	rs10769290	chr11:5886947	T/A	cg05234568	chr11:5960015	NA	-0.66	-9.96	-0.52	4.63e-20	DNA methylation (variation);
CESC	cis	rs9322193	0.847	rs56103941	chr6:150137231	A/G	cg13206674	chr6:150067644	NUP43	0.41	5.6	0.33	5.42e-8	Lung cancer;
CESC	cis	rs736408	0.522	rs6445535	chr3:52771468	T/C	cg18404041	chr3:52824283	ITIH1	-0.39	-6.55	-0.37	2.91e-10	Bipolar disorder;
CESC	cis	rs597539	0.690	rs615644	chr11:68621806	G/C	cg18350739	chr11:68623251	NA	-0.45	-6.59	-0.38	2.34e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs1620921	0.505	rs11756434	chr6:161201356	T/C	cg01280913	chr6:161186852	NA	-0.36	-5.27	-0.31	2.81e-7	Lipoprotein (a) - cholesterol levels;
CESC	cis	rs7208859	0.623	rs7208441	chr17:29143863	C/T	cg14008862	chr17:28927542	LRRC37B2	0.65	5.19	0.3	4.23e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs4727027	0.835	rs6959224	chr7:148784495	A/G	cg23583168	chr7:148888333	NA	-0.66	-9.21	-0.49	1.04e-17	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs3096299	0.642	rs12934829	chr16:89523349	T/A	cg02187348	chr16:89574699	SPG7	0.64	8.82	0.48	1.54e-16	Multiple myeloma (IgH translocation);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg07998558	chr7:150648497	KCNH2	0.43	6.1	0.35	3.66e-9	Fibrinogen levels;
CESC	cis	rs10504229	1.000	rs6987435	chr8:58177334	G/A	cg02725872	chr8:58115012	NA	-0.34	-5.05	-0.3	8.26e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs1878931	0.696	rs35984213	chr16:3451030	G/A	cg21433313	chr16:3507492	NAT15	-0.37	-5.37	-0.31	1.74e-7	Body mass index (adult);
CESC	cis	rs7584330	0.554	rs116656801	chr2:238431257	A/G	cg14458575	chr2:238380390	NA	0.48	5.24	0.31	3.29e-7	Prostate cancer;
CESC	cis	rs4665809	1.000	rs2289022	chr2:26350136	G/T	cg04944784	chr2:26401820	FAM59B	-0.66	-7.62	-0.42	4.62e-13	Gut microbiome composition (summer);
CESC	cis	rs7845219	0.544	rs34293080	chr8:95908078	G/T	cg13393036	chr8:95962371	TP53INP1	-0.44	-8.46	-0.46	1.89e-15	Type 2 diabetes;
CESC	cis	rs8031584	0.958	rs3512	chr15:31235005	G/C	cg14829155	chr15:31115871	NA	-0.72	-9.65	-0.51	4.49e-19	Huntington's disease progression;
CESC	cis	rs2710642	0.927	rs1468748	chr2:63204611	C/T	cg17519650	chr2:63277830	OTX1	0.51	6.6	0.38	2.25e-10	LDL cholesterol levels;LDL cholesterol;
CESC	cis	rs9611565	0.659	rs12483998	chr22:41935362	A/G	cg06481639	chr22:41940642	POLR3H	-0.62	-6.32	-0.36	1.11e-9	Vitiligo;
CESC	cis	rs2011503	0.843	rs2860494	chr19:19470426	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	-0.5	-5.04	-0.3	8.68e-7	Bipolar disorder;
CESC	cis	rs1775715	0.678	rs2105360	chr10:32210198	C/T	cg26784012	chr10:32216390	ARHGAP12	0.39	5.16	0.3	4.96e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs8177253	1.000	rs8177253	chr3:133480192	A/G	cg11941060	chr3:133502564	NA	0.48	6.68	0.38	1.42e-10	Iron status biomarkers;
CESC	cis	rs7116495	1.000	rs4944232	chr11:71642258	A/G	cg26138937	chr11:71823887	C11orf51	0.81	6.7	0.38	1.26e-10	Severe influenza A (H1N1) infection;
CESC	cis	rs7481584	0.581	rs366422	chr11:3053873	C/T	cg25174290	chr11:3078921	CARS	-0.45	-6.34	-0.36	9.61e-10	Calcium levels;
CESC	cis	rs7617773	0.817	rs9818937	chr3:48325281	G/A	cg11946769	chr3:48343235	NME6	0.82	11.11	0.56	8.34e-24	Coronary artery disease;
CESC	cis	rs9388451	0.874	rs3734634	chr6:126111800	G/A	cg05901451	chr6:126070800	HEY2	-0.61	-8.63	-0.47	5.71e-16	Brugada syndrome;
CESC	cis	rs13385	0.769	rs10060203	chr5:139599319	T/G	cg26211634	chr5:139558579	C5orf32	0.46	5.12	0.3	5.97e-7	Atrial fibrillation;
CESC	cis	rs5758659	0.967	rs5751250	chr22:42639645	T/G	cg05082376	chr22:42548792	NA	-0.36	-5.41	-0.32	1.39e-7	Cognitive function;
CESC	cis	rs61931739	0.500	rs7313094	chr12:34457508	T/C	cg23762105	chr12:34175262	ALG10	-0.41	-5.23	-0.31	3.42e-7	Morning vs. evening chronotype;
CESC	cis	rs1707322	1.000	rs785498	chr1:46592414	C/T	cg03146154	chr1:46216737	IPP	-0.69	-9.1	-0.49	2.16e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs684232	0.602	rs10521107	chr17:511156	G/A	cg12384639	chr17:618140	VPS53	0.44	5.55	0.32	6.92e-8	Prostate cancer;
CESC	cis	rs6121246	0.821	rs6058448	chr20:30332396	C/T	cg13852791	chr20:30311386	BCL2L1	0.82	8.74	0.47	2.63e-16	Mean corpuscular hemoglobin;
CESC	cis	rs4727963	0.846	rs6466851	chr7:122699206	G/A	cg03640110	chr7:122635026	TAS2R16	-0.37	-5.71	-0.33	3.07e-8	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
CESC	cis	rs10461617	0.531	rs2662033	chr5:56213410	T/G	cg24531977	chr5:56204891	C5orf35	-0.9	-12.15	-0.6	2.64e-27	Type 2 diabetes;
CESC	cis	rs12543725	0.601	rs7018178	chr8:142239210	C/T	cg23750338	chr8:142222470	SLC45A4	-0.37	-5.18	-0.3	4.36e-7	Birth weight;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01630199	chr7:66369076	NA	-0.58	-6.25	-0.36	1.65e-9	Gut microbiome composition (summer);
CESC	cis	rs55883249	1.000	rs11692112	chr2:9723732	G/T	cg23886495	chr2:9695866	ADAM17	0.59	5.56	0.32	6.72e-8	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
CESC	cis	rs6987853	0.814	rs1947296	chr8:42452999	T/C	cg09913449	chr8:42400586	C8orf40	0.43	7.1	0.4	1.12e-11	Mean corpuscular hemoglobin concentration;
CESC	cis	rs875971	0.862	rs12698521	chr7:65939489	T/C	cg11764359	chr7:65958608	NA	0.94	14.96	0.68	4.3e-37	Aortic root size;
CESC	cis	rs763121	0.815	rs9306328	chr22:39028913	C/T	cg06022373	chr22:39101656	GTPBP1	0.72	11.0	0.56	1.92e-23	Menopause (age at onset);
CESC	cis	rs780096	0.526	rs780106	chr2:27681598	A/C	cg22903471	chr2:27725779	GCKR	-0.52	-7.39	-0.41	1.88e-12	Total body bone mineral density;
CESC	cis	rs8141529	0.509	rs12628211	chr22:29239250	T/C	cg15103426	chr22:29168792	CCDC117	0.62	8.07	0.44	2.48e-14	Lymphocyte counts;
CESC	cis	rs263063	0.506	rs12611002	chr19:5051655	C/T	cg18473234	chr19:5097819	KDM4B	0.64	5.07	0.3	7.6e-7	Periodontitis (CDC/AAP);
CESC	cis	rs9314323	0.798	rs2019239	chr8:26217354	G/A	cg13160058	chr8:26243215	BNIP3L	-0.32	-5.15	-0.3	5.13e-7	Red cell distribution width;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00162751	chr1:220921532	MOSC2	-0.59	-7.28	-0.41	3.85e-12	Gut microbiome composition (summer);
CESC	cis	rs2075371	1.000	rs2598294	chr7:133991690	C/T	cg11752832	chr7:134001865	SLC35B4	0.55	7.23	0.41	5.27e-12	Mean platelet volume;
CESC	trans	rs11098499	0.604	rs10022185	chr4:120571765	C/G	cg25214090	chr10:38739885	LOC399744	0.6	7.88	0.44	8.29e-14	Corneal astigmatism;
CESC	cis	rs1545257	0.538	rs729921	chr2:24633124	T/G	cg06627628	chr2:24431161	ITSN2	-0.47	-5.71	-0.33	3.04e-8	Sjögren's syndrome;
CESC	cis	rs6087990	0.735	rs2424920	chr20:31385452	T/C	cg13636640	chr20:31349939	DNMT3B	0.8	12.87	0.62	8.95e-30	Ulcerative colitis;
CESC	cis	rs7945705	0.935	rs2653593	chr11:8877317	G/A	cg09997546	chr11:8931473	C11orf17;ST5	-0.37	-6.42	-0.37	6.4e-10	Hemoglobin concentration;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05994294	chr4:1374658	KIAA1530	-0.43	-6.03	-0.35	5.62e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs10242455	0.571	rs11734	chr7:99229768	C/G	cg25640893	chr7:99214727	ZNF498	-0.8	-6.35	-0.36	9.2e-10	Blood metabolite levels;
CESC	cis	rs13191362	1.000	rs13213408	chr6:162998049	A/T	cg14584255	chr6:163149320	PACRG;PARK2	0.49	5.14	0.3	5.45e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs12824058	0.831	rs11616174	chr12:130814503	A/G	cg23887609	chr12:130822674	PIWIL1	0.45	5.82	0.34	1.69e-8	Menopause (age at onset);
CESC	cis	rs6693567	0.565	rs834235	chr1:150362154	C/T	cg09579323	chr1:150459698	TARS2	0.48	6.03	0.35	5.58e-9	Migraine;
CESC	cis	rs3105593	0.555	rs3098169	chr15:50754339	G/A	cg05456662	chr15:50716270	USP8	0.39	5.19	0.3	4.22e-7	QT interval;
CESC	cis	rs6088590	0.561	rs2295444	chr20:33173883	C/T	cg06115741	chr20:33292138	TP53INP2	0.51	6.53	0.37	3.27e-10	Coronary artery disease;
CESC	cis	rs12042052	1.000	rs10910623	chr1:232938699	G/A	cg00951395	chr1:232941775	KIAA1383	0.57	5.65	0.33	4.16e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CESC	cis	rs9611565	0.546	rs132793	chr22:42063681	A/G	cg03806693	chr22:41940476	POLR3H	1.06	11.79	0.59	4.4e-26	Vitiligo;
CESC	cis	rs6502050	0.835	rs7209474	chr17:80136418	C/T	cg11859384	chr17:80120422	CCDC57	-0.38	-5.2	-0.3	3.89e-7	Life satisfaction;
CESC	trans	rs61931739	0.500	rs10844863	chr12:34532284	C/T	cg26384229	chr12:38710491	ALG10B	0.54	7.53	0.42	8.03e-13	Morning vs. evening chronotype;
CESC	cis	rs11711311	0.712	rs10804510	chr3:113340700	T/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.48	6.27	0.36	1.43e-9	IgG glycosylation;
CESC	cis	rs10751667	0.666	rs10794347	chr11:939863	G/A	cg20946044	chr11:1010712	AP2A2	-0.39	-5.44	-0.32	1.23e-7	Alzheimer's disease (late onset);
CESC	cis	rs1008375	1.000	rs2058338	chr4:17678600	A/G	cg16339924	chr4:17578868	LAP3	-0.5	-6.37	-0.36	8.11e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs6088580	0.619	rs1205335	chr20:32927507	C/T	cg24642439	chr20:33292090	TP53INP2	-0.52	-6.77	-0.38	8.14e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs1707322	0.963	rs12076580	chr1:46258159	G/A	cg06784218	chr1:46089804	CCDC17	0.37	6.37	0.36	8.49e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs4555082	0.834	rs2816607	chr14:105718385	A/T	cg06808227	chr14:105710500	BRF1	-0.53	-5.9	-0.34	1.08e-8	Mean platelet volume;Platelet distribution width;
CESC	cis	rs5758511	0.680	rs5758667	chr22:42633204	G/A	cg00645731	chr22:42541494	CYP2D7P1	0.56	8.32	0.46	4.6e-15	Birth weight;
CESC	cis	rs4948102	0.686	rs7801467	chr7:56160977	A/G	cg09872392	chr7:56161020	PHKG1	-0.47	-7.44	-0.42	1.45e-12	Plasma homocysteine levels (post-methionine load test);
CESC	cis	rs2415984	0.622	rs17672908	chr14:46934527	T/C	cg14871534	chr14:47121158	RPL10L	-0.35	-5.31	-0.31	2.37e-7	Number of children ever born;
CESC	cis	rs561341	1.000	rs15654	chr17:30326360	A/C	cg12193833	chr17:30244370	NA	-0.72	-6.68	-0.38	1.42e-10	Hip circumference adjusted for BMI;
CESC	cis	rs1371867	0.846	rs2919471	chr8:101232701	T/C	cg11906718	chr8:101322791	RNF19A	-0.5	-6.19	-0.36	2.22e-9	Atrioventricular conduction;
CESC	cis	rs933688	1.000	rs12656350	chr5:90751343	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.1	12.55	0.61	1.13e-28	Smoking behavior;
CESC	cis	rs921968	0.541	rs7603816	chr2:219396255	C/T	cg02176678	chr2:219576539	TTLL4	-0.54	-9.78	-0.51	1.78e-19	Mean corpuscular hemoglobin concentration;
CESC	trans	rs11098499	0.909	rs1809406	chr4:120377122	G/A	cg25214090	chr10:38739885	LOC399744	0.7	9.91	0.52	6.89e-20	Corneal astigmatism;
CESC	cis	rs208515	0.525	rs4145045	chr6:66678949	T/C	cg07460842	chr6:66804631	NA	0.85	10.63	0.55	3.24e-22	Exhaled nitric oxide levels;
CESC	cis	rs7208859	0.623	rs3794796	chr17:29130880	G/C	cg19761014	chr17:28927070	LRRC37B2	0.78	6.23	0.36	1.81e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg16866257	chr17:61905183	FTSJ3;PSMC5	-0.46	-6.6	-0.38	2.25e-10	Gambling;
CESC	cis	rs873946	0.517	rs7071784	chr10:134559980	T/C	cg06453172	chr10:134556979	INPP5A	-0.38	-5.09	-0.3	6.89e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs56104184	0.723	rs1058483	chr19:49407660	G/A	cg21252483	chr19:49399788	TULP2	-0.52	-5.68	-0.33	3.59e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	cis	rs12188164	0.965	rs11739543	chr5:443676	G/A	cg17553881	chr5:443987	EXOC3;C5orf55	-0.38	-6.14	-0.35	2.97e-9	Cystic fibrosis severity;
CESC	cis	rs2479724	0.935	rs2254936	chr6:41846569	A/G	cg08135965	chr6:41755394	TOMM6	0.39	5.43	0.32	1.26e-7	Menarche (age at onset);
CESC	cis	rs2625529	0.652	rs12148078	chr15:72300471	G/C	cg16672083	chr15:72433130	SENP8	0.42	6.39	0.37	7.32e-10	Red blood cell count;
CESC	cis	rs2645694	0.626	rs2703119	chr4:77823640	C/T	cg18351406	chr4:77819688	ANKRD56	0.53	6.57	0.37	2.68e-10	Emphysema distribution in smoking;
CESC	cis	rs1018836	0.892	rs4735224	chr8:91567046	C/A	cg16814680	chr8:91681699	NA	-0.6	-8.37	-0.46	3.34e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs9911578	1.000	rs7216680	chr17:56988243	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.39	5.05	0.3	8.3e-7	Intelligence (multi-trait analysis);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg12532653	chr5:140090559	VTRNA1-1	0.42	6.86	0.39	4.75e-11	Gambling;
CESC	cis	rs854765	0.583	rs8065970	chr17:17858771	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.59	8.26	0.45	7.24e-15	Total body bone mineral density;
CESC	cis	rs12618769	0.597	rs72821951	chr2:99157009	A/C	cg10123293	chr2:99228465	UNC50	0.4	5.23	0.31	3.4e-7	Bipolar disorder;
CESC	cis	rs10911232	0.526	rs41475048	chr1:183058452	C/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.58	-6.29	-0.36	1.33e-9	Hypertriglyceridemia;
CESC	cis	rs763014	0.931	rs10903017	chr16:627920	T/C	cg07256732	chr16:621771	PIGQ	-0.3	-5.13	-0.3	5.63e-7	Height;
CESC	cis	rs11630290	0.736	rs28621516	chr15:64156314	G/A	cg12036633	chr15:63758958	NA	-0.52	-5.29	-0.31	2.5e-7	Iris characteristics;
CESC	cis	rs6499255	1.000	rs6499253	chr16:69802672	C/T	cg15192750	chr16:69999425	NA	0.46	5.63	0.33	4.55e-8	IgE levels;
CESC	cis	rs5750830	0.594	rs5757647	chr22:39775047	C/A	cg11247378	chr22:39784982	NA	-0.51	-7.72	-0.43	2.36e-13	Intelligence (multi-trait analysis);
CESC	cis	rs9640161	0.871	rs56156367	chr7:150047201	A/T	cg17279839	chr7:150038598	RARRES2	0.49	5.9	0.34	1.13e-8	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs2439831	1.000	rs2467740	chr15:43746792	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.82	11.97	0.59	1.11e-26	Lung cancer in ever smokers;
CESC	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg23131131	chr22:24373011	LOC391322	-0.69	-9.51	-0.5	1.23e-18	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs4319547	0.956	rs9988963	chr12:122991478	C/G	cg05707623	chr12:122985044	ZCCHC8	-0.58	-6.76	-0.38	8.92e-11	Body mass index;
CESC	cis	rs75887402	1.000	rs7726814	chr5:122725497	A/G	cg27033705	chr5:122759302	CEP120	0.86	6.49	0.37	4.32e-10	Breast cancer;
CESC	cis	rs698833	0.892	rs786418	chr2:44688413	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.47	5.88	0.34	1.21e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs7762018	0.891	rs4716343	chr6:170143817	C/G	cg13891659	chr6:170190454	C6orf122;C6orf208	0.65	6.46	0.37	5e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs55794721	0.509	rs2375313	chr1:25748235	G/A	cg27572855	chr1:25598939	RHD	0.49	8.35	0.46	3.85e-15	Plateletcrit;Mean corpuscular volume;
CESC	cis	rs6424115	0.692	rs573361	chr1:24053674	A/T	cg10978503	chr1:24200527	CNR2	0.27	5.35	0.31	1.94e-7	Immature fraction of reticulocytes;
CESC	cis	rs1799949	1.000	rs12936816	chr17:41301709	C/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.45	6.31	0.36	1.17e-9	Menopause (age at onset);
CESC	cis	rs9649213	0.593	rs13232181	chr7:97935671	C/G	cg08684580	chr7:98029266	BAIAP2L1	-0.36	-5.62	-0.33	4.89e-8	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs916888	0.610	rs199442	chr17:44820122	G/A	cg01341218	chr17:43662625	NA	0.56	7.51	0.42	9.22e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs651907	0.557	rs36002990	chr3:101437862	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.45	5.88	0.34	1.22e-8	Colorectal cancer;
CESC	cis	rs9322193	0.962	rs3805748	chr6:150093678	C/T	cg13206674	chr6:150067644	NUP43	0.42	5.85	0.34	1.47e-8	Lung cancer;
CESC	cis	rs763121	0.853	rs5750622	chr22:38956464	C/G	cg06022373	chr22:39101656	GTPBP1	0.83	12.01	0.59	8.36e-27	Menopause (age at onset);
CESC	cis	rs3762637	1.000	rs3762637	chr3:122145324	C/T	cg24169773	chr3:122142474	KPNA1	-0.56	-6.65	-0.38	1.68e-10	LDL cholesterol levels;
CESC	cis	rs853679	0.550	rs1237875	chr6:28173010	A/G	cg20151795	chr6:28129481	ZNF389	-0.39	-5.08	-0.3	7.23e-7	Depression;
CESC	cis	rs2273669	0.667	rs76367548	chr6:109356589	C/T	cg05315195	chr6:109294784	ARMC2	-0.67	-6.32	-0.36	1.13e-9	Prostate cancer;
CESC	cis	rs10789491	0.767	rs4660359	chr1:47190019	C/G	cg15501359	chr1:47185051	KIAA0494	0.67	6.62	0.38	2e-10	Response to hepatitis C treatment;
CESC	cis	rs7084402	0.565	rs11006187	chr10:60333383	A/G	cg07615347	chr10:60278583	BICC1	-0.41	-6.0	-0.35	6.44e-9	Refractive error;
CESC	cis	rs2625529	0.627	rs1037680	chr15:72514319	T/C	cg16672083	chr15:72433130	SENP8	-0.41	-5.41	-0.32	1.38e-7	Red blood cell count;
CESC	trans	rs6073597	1.000	rs6031980	chr20:43714384	C/T	cg08307039	chr5:64920116	TRIM23;C5orf44	0.44	6.19	0.36	2.34e-9	Positive affect;
CESC	cis	rs780096	0.546	rs1104	chr2:27599875	T/G	cg02592271	chr2:27665507	KRTCAP3	-0.28	-5.73	-0.33	2.73e-8	Total body bone mineral density;
CESC	cis	rs3820068	0.603	rs41270279	chr1:15988878	A/G	cg18133145	chr1:16060689	PLEKHM2	-0.39	-5.04	-0.3	8.55e-7	Systolic blood pressure;
CESC	cis	rs4718428	0.672	rs13241598	chr7:66300652	A/G	cg12165864	chr7:66369176	NA	-0.63	-7.14	-0.4	8.84e-12	Corneal structure;
CESC	cis	rs875971	0.862	rs3893216	chr7:65790707	G/C	cg18252515	chr7:66147081	NA	0.44	5.7	0.33	3.18e-8	Aortic root size;
CESC	cis	rs7618915	0.547	rs4687638	chr3:52651966	A/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.36	6.26	0.36	1.52e-9	Bipolar disorder;
CESC	cis	rs919433	0.927	rs6759834	chr2:198204860	C/T	cg03934865	chr2:198174659	NA	-0.41	-5.52	-0.32	8.25e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs10504229	0.683	rs56408763	chr8:58137276	G/A	cg21724239	chr8:58056113	NA	0.58	5.95	0.34	8.29e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs9733	0.688	rs12725667	chr1:150766070	A/T	cg13175981	chr1:150552382	MCL1	0.52	7.24	0.41	4.84e-12	Tonsillectomy;
CESC	trans	rs2571521	0.887	rs9298879	chr9:26097224	A/C	cg21041764	chr15:49103369	CEP152	0.74	6.09	0.35	3.96e-9	Pursuit maintenance gain in psychotic disorders;
CESC	cis	rs710216	0.843	rs3768043	chr1:43419354	C/A	cg03128534	chr1:43423976	SLC2A1	-0.6	-7.66	-0.43	3.55e-13	Red cell distribution width;
CESC	cis	rs2120019	1.000	rs12898259	chr15:75369780	G/A	cg09165964	chr15:75287851	SCAMP5	-0.67	-8.12	-0.45	1.76e-14	Blood trace element (Zn levels);
CESC	cis	rs7818688	0.697	rs11784212	chr8:95976995	G/A	cg16049864	chr8:95962084	TP53INP1	0.57	5.73	0.33	2.79e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs17376456	0.825	rs17372057	chr5:93071916	C/A	cg21475434	chr5:93447410	FAM172A	0.79	7.22	0.41	5.39e-12	Diabetic retinopathy;
CESC	cis	rs2066819	1.000	rs2695789	chr12:56694261	C/A	cg26734620	chr12:56694298	CS	-0.93	-9.55	-0.51	9.4e-19	Psoriasis vulgaris;
CESC	cis	rs7662987	0.517	rs2924580	chr4:100032168	C/G	cg13256891	chr4:100009986	ADH5	0.77	8.45	0.46	1.95e-15	Smoking initiation;
CESC	cis	rs2645694	0.626	rs904050	chr4:77826089	T/G	cg10057126	chr4:77819792	ANKRD56	0.61	8.78	0.47	2.1e-16	Emphysema distribution in smoking;
CESC	cis	rs875971	0.545	rs10950029	chr7:65634321	A/C	cg11764359	chr7:65958608	NA	0.78	9.28	0.5	6.36e-18	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00385906	chr1:117910225	MAN1A2	0.57	7.21	0.4	5.92e-12	Gut microbiome composition (summer);
CESC	cis	rs721399	0.553	rs13262341	chr8:18243097	A/G	cg18736775	chr8:18248649	NAT2	-0.53	-5.52	-0.32	8.18e-8	Blood metabolite levels;
CESC	cis	rs6456156	0.524	rs6932740	chr6:167466439	G/A	cg23791538	chr6:167370224	RNASET2	-0.49	-6.37	-0.36	8.13e-10	Primary biliary cholangitis;
CESC	cis	rs2836974	0.932	rs6517527	chr21:40581751	G/A	cg11890956	chr21:40555474	PSMG1	1.17	21.83	0.8	3.83e-61	Cognitive function;
CESC	cis	rs13108904	0.905	rs11247983	chr4:1281951	C/G	cg22903657	chr4:1355424	KIAA1530	-0.38	-5.18	-0.3	4.5e-7	Obesity-related traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02330494	chr15:41786605	ITPKA	0.62	7.14	0.4	8.78e-12	Gut microbiome composition (summer);
CESC	cis	rs17125944	0.505	rs2274275	chr14:53235728	G/T	cg00686598	chr14:53173677	PSMC6	1.42	11.99	0.59	9.42e-27	Alzheimer's disease (late onset);
CESC	cis	rs875971	0.508	rs10253883	chr7:66061138	T/C	cg18252515	chr7:66147081	NA	0.39	5.2	0.3	4.09e-7	Aortic root size;
CESC	cis	rs11249608	0.548	rs7704565	chr5:178473923	G/C	cg01312482	chr5:178451176	ZNF879	-0.44	-5.82	-0.34	1.73e-8	Pubertal anthropometrics;
CESC	cis	rs7937682	0.924	rs10891284	chr11:111527737	T/C	cg09085632	chr11:111637200	PPP2R1B	-1.0	-16.56	-0.71	9.02e-43	Primary sclerosing cholangitis;
CESC	cis	rs3015469	0.671	rs61985508	chr14:51218537	G/A	cg26011998	chr14:51135199	SAV1	0.52	5.74	0.33	2.63e-8	Plasma amyloid beta peptide concentrations (ABx-40);
CESC	cis	rs6964587	0.967	rs41371748	chr7:91708219	A/G	cg17063962	chr7:91808500	NA	0.53	6.2	0.36	2.12e-9	Breast cancer;
CESC	cis	rs6693295	0.877	rs12065115	chr1:246296690	A/T	cg11798871	chr1:246315928	SMYD3	0.4	5.26	0.31	2.92e-7	Migraine - clinic-based;Migraine with aura;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg10451977	chr15:45507901	NA	0.5	6.11	0.35	3.52e-9	Ulcerative colitis;
CESC	cis	rs6088580	0.634	rs6059892	chr20:33105766	A/G	cg24642439	chr20:33292090	TP53INP2	0.51	6.62	0.38	1.99e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs2066819	1.000	rs58852079	chr12:56706922	A/C	cg26734620	chr12:56694298	CS	1.03	6.25	0.36	1.65e-9	Psoriasis vulgaris;
CESC	cis	rs2836950	0.501	rs62223052	chr21:40708702	A/C	cg11890956	chr21:40555474	PSMG1	-0.68	-9.57	-0.51	7.95e-19	Menarche (age at onset);
CESC	trans	rs10411161	0.702	rs6509591	chr19:52391940	A/T	cg22319618	chr22:45562946	NUP50	-0.58	-6.09	-0.35	3.97e-9	Breast cancer;
CESC	cis	rs9858542	0.903	rs11917431	chr3:49644012	C/T	cg03060546	chr3:49711283	APEH	-0.54	-6.36	-0.36	8.92e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs9039	1.000	rs11862745	chr16:9218887	C/T	cg08831531	chr16:9218945	NA	0.43	6.19	0.36	2.22e-9	Menopause (age at onset);
CESC	cis	rs514406	0.798	rs504816	chr1:53307957	T/G	cg08859206	chr1:53392774	SCP2	-0.63	-8.71	-0.47	3.43e-16	Monocyte count;
CESC	cis	rs7208859	0.623	rs56812022	chr17:29068733	A/G	cg19761014	chr17:28927070	LRRC37B2	0.77	6.33	0.36	1.04e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs1862618	0.671	rs2591970	chr5:56232595	T/C	cg12311346	chr5:56204834	C5orf35	0.64	8.79	0.48	1.95e-16	Initial pursuit acceleration;
CESC	cis	rs1348850	0.561	rs4893956	chr2:178373452	C/T	cg23306229	chr2:178417860	TTC30B	0.8	7.39	0.41	1.96e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs11587400	0.532	rs2268700	chr1:115228879	T/G	cg12756093	chr1:115239321	AMPD1	-0.52	-7.35	-0.41	2.45e-12	Autism;
CESC	cis	rs72781680	0.898	rs72798064	chr2:23982832	T/C	cg08917208	chr2:24149416	ATAD2B	0.96	8.7	0.47	3.55e-16	Lymphocyte counts;
CESC	trans	rs916888	0.773	rs199535	chr17:44822662	A/G	cg27125505	chr17:43679177	LOC644172	0.46	6.2	0.36	2.11e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs3096299	0.933	rs2965938	chr16:89491336	C/T	cg16743903	chr16:89593216	SPG7	-0.42	-5.46	-0.32	1.1e-7	Multiple myeloma (IgH translocation);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02250680	chr11:58346542	LPXN;ZFP91-CNTF;ZFP91	0.58	6.67	0.38	1.53e-10	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08855361	chr16:58718334	SLC38A7	0.6	6.78	0.38	7.69e-11	Gut microbiome composition (summer);
CESC	cis	rs62064224	0.533	rs11657826	chr17:30790386	T/A	cg12855166	chr17:30846586	MYO1D	0.4	5.18	0.3	4.31e-7	Schizophrenia;
CESC	cis	rs1799949	0.965	rs8176161	chr17:41241390	C/A	cg25072359	chr17:41440525	NA	0.44	6.07	0.35	4.52e-9	Menopause (age at onset);
CESC	cis	rs1552244	0.938	rs56274701	chr3:10167790	G/A	cg08888203	chr3:10149979	C3orf24	0.45	5.91	0.34	1.06e-8	Alzheimer's disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg14559409	chr10:65930703	NA	0.45	6.39	0.37	7.53e-10	Fibrinogen levels;
CESC	cis	rs8031584	0.918	rs61997138	chr15:31270776	C/T	cg14829155	chr15:31115871	NA	-0.73	-9.66	-0.51	4.04e-19	Huntington's disease progression;
CESC	cis	rs875971	0.545	rs7787063	chr7:65628999	G/A	cg19163074	chr7:65112434	INTS4L2	-0.46	-5.05	-0.3	8.07e-7	Aortic root size;
CESC	cis	rs73206853	0.764	rs60339427	chr12:110824471	G/A	cg12870014	chr12:110450643	ANKRD13A	0.63	5.23	0.31	3.48e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg18404041	chr3:52824283	ITIH1	-0.34	-6.02	-0.35	5.72e-9	Bipolar disorder;
CESC	cis	rs7786808	0.707	rs62479983	chr7:158227613	G/A	cg09998033	chr7:158218633	PTPRN2	-0.44	-6.53	-0.37	3.39e-10	Obesity-related traits;
CESC	cis	rs9291683	0.588	rs3756237	chr4:10013378	G/A	cg11266682	chr4:10021025	SLC2A9	0.72	14.87	0.67	8.7e-37	Bone mineral density;
CESC	cis	rs2603127	0.768	rs6789985	chr3:108480476	G/A	cg03329597	chr3:108125523	MYH15	0.6	5.35	0.31	1.91e-7	Hemostatic factors and hematological phenotypes;
CESC	cis	rs7811142	0.779	rs77370288	chr7:99947897	A/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.92	8.92	0.48	8e-17	Platelet count;
CESC	cis	rs7618915	0.547	rs2289250	chr3:52682946	A/C	cg18404041	chr3:52824283	ITIH1	0.37	6.12	0.35	3.33e-9	Bipolar disorder;
CESC	cis	rs2228479	0.618	rs17233623	chr16:89811209	C/T	cg04013166	chr16:89971882	TCF25	0.75	7.4	0.41	1.86e-12	Skin colour saturation;
CESC	cis	rs634534	0.562	rs1151505	chr11:65734539	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.43	6.44	0.37	5.64e-10	Sum eosinophil basophil counts;Eosinophil counts;
CESC	cis	rs734999	0.566	rs10752747	chr1:2524915	G/T	cg20673091	chr1:2541236	MMEL1	0.43	6.9	0.39	3.84e-11	Ulcerative colitis;
CESC	cis	rs7666738	0.830	rs9994346	chr4:99037986	A/G	cg05340658	chr4:99064831	C4orf37	0.82	12.36	0.6	5.16e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6087990	0.735	rs6058891	chr20:31386347	T/C	cg13636640	chr20:31349939	DNMT3B	0.79	12.85	0.62	1.1e-29	Ulcerative colitis;
CESC	cis	rs1153858	1.000	rs12439274	chr15:45636667	A/G	cg14582100	chr15:45693742	SPATA5L1	0.43	6.2	0.36	2.17e-9	Homoarginine levels;
CESC	cis	rs853679	0.550	rs1233701	chr6:28168726	C/G	cg18032046	chr6:28092343	ZSCAN16	0.47	5.56	0.32	6.44e-8	Depression;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg04458869	chr2:169312687	LASS6	-0.45	-6.21	-0.36	2e-9	Asthma;
CESC	trans	rs12991495	0.531	rs11686210	chr2:25433366	A/G	cg19377421	chr1:156697041	ISG20L2;C1orf66	0.49	6.02	0.35	5.76e-9	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
CESC	cis	rs7949030	0.620	rs2428551	chr11:62329758	T/A	cg13298116	chr11:62369859	EML3;MTA2	0.61	9.11	0.49	2.05e-17	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs7772486	0.686	rs1415744	chr6:146022531	C/T	cg23711669	chr6:146136114	FBXO30	0.89	12.86	0.62	9.66e-30	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs7716219	0.731	rs7704138	chr5:54944262	C/T	cg18226868	chr15:50646438	GABPB1;FLJ10038;LOC100129387	-0.43	-6.01	-0.35	6.12e-9	Height;
CESC	cis	rs875971	0.545	rs316305	chr7:65617971	G/A	cg25405998	chr7:65216604	CCT6P1	-0.45	-5.06	-0.3	7.71e-7	Aortic root size;
CESC	cis	rs929354	0.772	rs3802124	chr7:156970609	G/A	cg05182265	chr7:156933206	UBE3C	-0.5	-7.3	-0.41	3.28e-12	Body mass index;
CESC	cis	rs9611565	0.765	rs9607800	chr22:41784562	A/G	cg06481639	chr22:41940642	POLR3H	-0.62	-6.47	-0.37	4.82e-10	Vitiligo;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10957584	chr16:5148097	FAM86A	-0.57	-6.39	-0.37	7.44e-10	Gut microbiome composition (summer);
CESC	cis	rs2549003	1.000	rs10214312	chr5:131821866	T/G	cg02551604	chr5:131831745	NA	-0.37	-5.27	-0.31	2.81e-7	Asthma (sex interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20798677	chr17:39968547	FKBP10;SC65	0.6	6.48	0.37	4.39e-10	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19410790	chr1:112282146	C1orf183	0.6	6.63	0.38	1.87e-10	Gut microbiome composition (summer);
CESC	cis	rs787274	0.850	rs10739378	chr9:115639631	C/T	cg13803584	chr9:115635662	SNX30	-0.7	-5.43	-0.32	1.26e-7	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs240764	0.764	rs2213594	chr6:100931400	G/A	cg21058520	chr6:100914733	NA	0.39	6.18	0.36	2.37e-9	Neuroticism;
CESC	cis	rs7590720	1.000	rs7592663	chr2:216894978	T/C	cg12620499	chr2:216877984	MREG	0.88	12.19	0.6	2.02e-27	Alcohol dependence;
CESC	cis	rs56235845	0.694	rs11749830	chr5:176766547	G/A	cg17509989	chr5:176798049	RGS14	0.48	5.78	0.33	2.12e-8	Hemoglobin concentration;Hematocrit;
CESC	cis	rs9457247	0.967	rs387733	chr6:167409771	C/T	cg23791538	chr6:167370224	RNASET2	0.61	8.61	0.47	6.74e-16	Crohn's disease;
CESC	cis	rs6032067	0.586	rs13044116	chr20:43754444	T/C	cg10761708	chr20:43804764	PI3	0.49	5.16	0.3	4.81e-7	Blood protein levels;
CESC	cis	rs12200560	0.505	rs211182	chr6:97074513	G/A	cg06623918	chr6:96969491	KIAA0776	0.51	6.55	0.37	2.93e-10	Coronary heart disease;
CESC	cis	rs4919087	1.000	rs4919089	chr10:99087905	G/A	cg25902810	chr10:99078978	FRAT1	-0.66	-8.61	-0.47	6.57e-16	Monocyte count;
CESC	trans	rs35110281	0.805	rs2838318	chr21:44991825	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.46	6.18	0.35	2.4e-9	Mean corpuscular volume;
CESC	cis	rs4713118	0.662	rs9468276	chr6:28027688	A/C	cg22143856	chr6:28129313	ZNF389	0.42	5.26	0.31	2.91e-7	Parkinson's disease;
CESC	cis	rs8060686	0.641	rs79719939	chr16:68240216	A/G	cg26727032	chr16:67993705	SLC12A4	-0.53	-5.95	-0.34	8.65e-9	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs6952808	0.531	rs3778998	chr7:2180753	C/A	cg05863683	chr7:1912471	MAD1L1	0.38	5.71	0.33	3.07e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs1799949	1.000	rs8176109	chr17:41265776	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.67	9.4	0.5	2.72e-18	Menopause (age at onset);
CESC	cis	rs3026101	0.671	rs57774467	chr17:5300205	A/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.42	5.6	0.33	5.31e-8	Body mass index;
CESC	cis	rs67460515	0.563	rs6772723	chr3:160895074	C/G	cg03342759	chr3:160939853	NMD3	-0.55	-7.4	-0.41	1.76e-12	Parkinson's disease;
CESC	cis	rs2302190	0.882	rs3809709	chr17:56590559	C/T	cg25885038	chr17:56607967	SEPT4	-0.42	-5.7	-0.33	3.22e-8	Vitamin D levels;
CESC	cis	rs1552244	0.882	rs3755782	chr3:10029305	T/C	cg00166722	chr3:10149974	C3orf24	0.49	6.04	0.35	5.3e-9	Alzheimer's disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg16841327	chr22:46466183	NA	-0.48	-6.42	-0.37	6.32e-10	Fibrinogen levels;
CESC	cis	rs6570726	0.764	rs4896821	chr6:145896181	G/A	cg23711669	chr6:146136114	FBXO30	0.83	12.51	0.61	1.62e-28	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs12545109	0.679	rs1973628	chr8:57429360	T/C	cg09654669	chr8:57350985	NA	-0.61	-6.56	-0.37	2.88e-10	Obesity-related traits;
CESC	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.89	13.67	0.64	1.49e-32	Prudent dietary pattern;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10415122	chr15:75981489	CSPG4	-0.5	-6.08	-0.35	4.19e-9	Gut microbiome composition (summer);
CESC	cis	rs1707322	0.721	rs6429574	chr1:46134054	A/G	cg05343316	chr1:45956843	TESK2	0.49	6.21	0.36	2e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs116095464	0.764	rs10069197	chr5:230822	G/C	cg22857025	chr5:266934	NA	-1.28	-18.8	-0.76	1.06e-50	Breast cancer;
CESC	cis	rs9486719	1.000	rs12529248	chr6:96895377	T/G	cg18709589	chr6:96969512	KIAA0776	-0.53	-5.81	-0.34	1.75e-8	Migraine;Coronary artery disease;
CESC	cis	rs6496667	0.779	rs7163632	chr15:91039020	C/T	cg13834112	chr15:90361639	NA	0.4	5.37	0.31	1.71e-7	Rheumatoid arthritis;
CESC	cis	rs1005277	0.579	rs1780136	chr10:38501453	A/G	cg25427524	chr10:38739819	LOC399744	-0.73	-10.93	-0.56	3.43e-23	Extrinsic epigenetic age acceleration;
CESC	trans	rs2963826	0.589	rs298091	chr5:58996603	A/T	cg01337508	chr17:40540572	STAT3	0.48	6.28	0.36	1.39e-9	Obesity-related traits;
CESC	cis	rs2933343	1.000	rs789232	chr3:128603080	T/G	cg25356066	chr3:128598488	ACAD9	0.6	7.48	0.42	1.09e-12	IgG glycosylation;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg12508534	chr6:34855789	TAF11;ANKS1A	-0.47	-6.1	-0.35	3.72e-9	Ulcerative colitis;
CESC	cis	rs6430585	0.528	rs3112496	chr2:136711064	C/T	cg07169764	chr2:136633963	MCM6	1.08	15.17	0.68	7.79e-38	Corneal structure;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21412001	chr3:47517510	SCAP	0.51	6.09	0.35	4.06e-9	Gut microbiome composition (summer);
CESC	cis	rs10838687	0.867	rs2633082	chr11:47248050	C/G	cg25783544	chr11:47291846	MADD	-0.59	-7.41	-0.41	1.66e-12	Proinsulin levels;
CESC	cis	rs7772486	0.875	rs10457796	chr6:146416087	T/G	cg05347473	chr6:146136440	FBXO30	0.48	6.51	0.37	3.83e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7666738	0.791	rs2865958	chr4:99040732	G/T	cg03467027	chr4:99064603	C4orf37	0.47	5.98	0.34	7.19e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2836974	0.899	rs34433511	chr21:40618883	A/C	cg11644478	chr21:40555479	PSMG1	1.01	16.12	0.7	3.2e-41	Cognitive function;
CESC	cis	rs425277	0.583	rs3128334	chr1:2038662	G/A	cg12718519	chr1:2058417	PRKCZ	-0.24	-5.07	-0.3	7.6e-7	Height;
CESC	cis	rs6867032	0.958	rs9312970	chr5:2002415	C/A	cg26168224	chr5:2018326	NA	-0.83	-13.46	-0.64	8.33e-32	Gut microbiome composition (winter);
CESC	cis	rs7412746	0.658	rs17660092	chr1:150797748	T/C	cg17724175	chr1:150552817	MCL1	0.4	6.28	0.36	1.42e-9	Melanoma;
CESC	cis	rs7666738	0.830	rs4699331	chr4:99059816	T/C	cg17366294	chr4:99064904	C4orf37	0.62	8.89	0.48	9.9900000000000006e-17	Colonoscopy-negative controls vs population controls;
CESC	cis	rs67311347	1.000	rs7628796	chr3:40507332	G/A	cg09455208	chr3:40491958	NA	-0.48	-8.31	-0.45	5.16e-15	Renal cell carcinoma;
CESC	cis	rs1005277	0.505	rs1208689	chr10:38097775	C/G	cg25427524	chr10:38739819	LOC399744	-0.68	-10.07	-0.53	2.1e-20	Extrinsic epigenetic age acceleration;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg12129103	chr5:134369903	PITX1	-0.5	-7.37	-0.41	2.2e-12	Gambling;
CESC	cis	rs3858526	0.642	rs10838783	chr11:5900282	T/G	cg13902645	chr11:5959945	NA	-0.56	-7.14	-0.4	9.07e-12	DNA methylation (variation);
CESC	trans	rs877282	0.947	rs12358875	chr10:757531	T/C	cg22713356	chr15:30763199	NA	1.05	9.16	0.49	1.45e-17	Uric acid levels;
CESC	cis	rs4481233	0.528	rs115776655	chr4:10381329	C/T	cg00071950	chr4:10020882	SLC2A9	-0.54	-6.12	-0.35	3.33e-9	Metabolic traits;
CESC	cis	rs6540556	0.906	rs6540554	chr1:209932297	A/T	cg05527609	chr1:210001259	C1orf107	0.44	5.77	0.33	2.17e-8	Red blood cell count;
CESC	cis	rs17666538	0.535	rs168062	chr8:632444	T/A	cg02524346	chr8:600233	NA	0.8	6.05	0.35	4.91e-9	IgG glycosylation;
CESC	cis	rs7666738	0.830	rs4699594	chr4:98980775	T/C	cg03676636	chr4:99064102	C4orf37	0.33	5.18	0.3	4.43e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs72781680	0.898	rs72782138	chr2:24048162	T/C	cg08917208	chr2:24149416	ATAD2B	0.95	8.71	0.47	3.45e-16	Lymphocyte counts;
CESC	cis	rs4835473	0.932	rs4287958	chr4:144908872	T/C	cg25736465	chr4:144833511	NA	0.42	6.43	0.37	6.02e-10	Immature fraction of reticulocytes;
CESC	cis	rs2576037	0.583	rs12386118	chr18:44540376	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.77	12.48	0.61	1.96e-28	Personality dimensions;
CESC	cis	rs67478160	0.643	rs11628332	chr14:104241141	C/T	cg08213375	chr14:104286397	PPP1R13B	0.53	10.49	0.54	9.33e-22	Schizophrenia;
CESC	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.42	-5.32	-0.31	2.17e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs798554	0.616	rs1636252	chr7:2884993	A/C	cg04166393	chr7:2884313	GNA12	0.43	5.61	0.33	5.09e-8	Height;
CESC	cis	rs2652822	0.935	rs7162825	chr15:63439186	A/G	cg02713581	chr15:63449717	RPS27L	-0.54	-6.98	-0.39	2.32e-11	Metabolic traits;
CESC	cis	rs7772486	0.682	rs1337840	chr6:146042558	T/C	cg05347473	chr6:146136440	FBXO30	-0.48	-6.45	-0.37	5.16e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9814567	1.000	rs13087875	chr3:134261123	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.45	6.08	0.35	4.21e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs2228479	0.702	rs3819574	chr16:89826630	G/A	cg14709524	chr16:89940631	TCF25	0.91	6.75	0.38	9.26e-11	Skin colour saturation;
CESC	cis	rs477895	0.653	rs2015226	chr11:63902534	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.93	10.18	0.53	9.01e-21	Mean platelet volume;
CESC	cis	rs8067354	0.574	rs2526354	chr17:57976658	A/G	cg02344993	chr17:57696989	CLTC	0.5	5.34	0.31	1.96e-7	Hemoglobin concentration;
CESC	cis	rs12464559	0.649	rs3768658	chr2:152677674	T/C	cg01189475	chr2:152685088	ARL5A	0.66	5.81	0.34	1.74e-8	Response to cognitive-behavioural therapy in anxiety disorder;
CESC	cis	rs742320	0.756	rs3765263	chr16:840378	A/G	cg03433313	chr16:819064	MIR662	-0.44	-5.86	-0.34	1.34e-8	Mean corpuscular volume;
CESC	cis	rs4555082	0.874	rs28822720	chr14:105746282	T/C	cg13114125	chr14:105738426	BRF1	-0.83	-10.59	-0.55	4.35e-22	Mean platelet volume;Platelet distribution width;
CESC	cis	rs12986413	0.624	rs12460763	chr19:2138507	A/G	cg09261902	chr19:2140048	AP3D1	0.34	5.44	0.32	1.24e-7	Height;
CESC	cis	rs698833	0.548	rs6721421	chr2:44535686	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.52	5.29	0.31	2.55e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs6831352	0.691	rs2602887	chr4:100041473	A/G	cg12011299	chr4:100065546	ADH4	0.57	6.14	0.35	3.08e-9	Alcohol dependence;
CESC	cis	rs1008375	0.966	rs11722132	chr4:17697217	T/C	cg02297831	chr4:17616191	MED28	0.44	5.4	0.32	1.45e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs79349575	0.811	rs60708039	chr17:46999373	C/G	cg16584676	chr17:46985605	UBE2Z	0.54	6.7	0.38	1.24e-10	Type 2 diabetes;
CESC	cis	rs67311347	0.866	rs3214006	chr3:40352134	C/T	cg24209194	chr3:40518798	ZNF619	0.41	5.16	0.3	4.89e-7	Renal cell carcinoma;
CESC	trans	rs8017423	1.000	rs4900028	chr14:90685594	C/T	cg01911440	chr17:78818045	RPTOR	-0.4	-6.01	-0.35	6.24e-9	Mortality in heart failure;
CESC	cis	rs9649213	0.593	rs6970990	chr7:97925382	T/G	cg08684580	chr7:98029266	BAIAP2L1	-0.34	-5.55	-0.32	6.96e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs863345	0.604	rs10908654	chr1:158455790	A/T	cg12129480	chr1:158549410	OR10X1	-0.36	-7.14	-0.4	8.77e-12	Pneumococcal bacteremia;
CESC	cis	rs6163	0.588	rs67506723	chr10:104509064	G/T	cg04362960	chr10:104952993	NT5C2	0.41	5.58	0.32	5.9e-8	Waist circumference;Hip circumference;
CESC	cis	rs1707322	0.685	rs11211177	chr1:46226349	A/G	cg06784218	chr1:46089804	CCDC17	0.37	6.55	0.37	2.99e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs6952808	0.893	rs35487994	chr7:1920171	G/A	cg23048001	chr7:2026167	MAD1L1	0.43	5.58	0.32	6.09e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs6752107	0.782	rs12692254	chr2:234161211	A/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.48	6.74	0.38	9.59e-11	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs1351164	0.591	rs9752576	chr2:218269445	G/A	cg15335768	chr2:218268053	DIRC3	-0.35	-5.11	-0.3	6.24e-7	Height;
CESC	cis	rs9787249	0.957	rs11809515	chr1:40205326	C/A	cg24920358	chr1:40204285	PPIE	0.43	6.47	0.37	4.72e-10	Blood protein levels;
CESC	cis	rs16866061	0.926	rs1523919	chr2:225403615	G/A	cg12698349	chr2:225449008	CUL3	0.75	10.61	0.55	3.82e-22	Acute graft versus host disease in bone marrow transplantation (recipient effect);
CESC	trans	rs561341	1.000	rs483301	chr17:30293398	G/T	cg27661571	chr11:113659931	NA	-0.87	-8.06	-0.44	2.57e-14	Hip circumference adjusted for BMI;
CESC	cis	rs16854884	0.789	rs34096668	chr3:143794483	C/T	cg06585982	chr3:143692056	C3orf58	0.43	5.29	0.31	2.63e-7	Economic and political preferences (feminism/equality);
CESC	cis	rs698813	0.604	rs768007	chr2:44487486	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.51	5.68	0.33	3.49e-8	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
CESC	cis	rs13256369	1.000	rs13271966	chr8:8575472	T/C	cg17143192	chr8:8559678	CLDN23	0.73	8.7	0.47	3.69e-16	Obesity-related traits;
CESC	cis	rs2742234	0.590	rs2115817	chr10:43686552	C/T	cg15436174	chr10:43711423	RASGEF1A	-0.5	-5.84	-0.34	1.5e-8	Hirschsprung disease;
CESC	cis	rs9649213	0.593	rs34776142	chr7:97899873	C/T	cg24562669	chr7:97807699	LMTK2	0.52	7.41	0.41	1.66e-12	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs34172651	0.517	rs2303084	chr16:24834581	G/C	cg06028605	chr16:24865363	SLC5A11	0.53	7.24	0.41	4.83e-12	Intelligence (multi-trait analysis);
CESC	cis	rs4555082	1.000	rs7146012	chr14:105757566	G/A	cg27165867	chr14:105738592	BRF1	-0.45	-5.1	-0.3	6.61e-7	Mean platelet volume;Platelet distribution width;
CESC	cis	rs61008539	0.853	rs10950611	chr7:861094	G/T	cg15782153	chr7:917662	C7orf20	0.49	7.07	0.4	1.39e-11	Perceived unattractiveness to mosquitoes;
CESC	trans	rs800888	0.772	rs13271228	chr8:116597409	A/C	cg19047077	chr12:105044897	CHST11	-0.47	-6.1	-0.35	3.84e-9	Monocyte percentage of white cells;
CESC	cis	rs763121	0.819	rs5757160	chr22:38989646	T/C	cg21395723	chr22:39101663	GTPBP1	0.51	6.82	0.39	6.01e-11	Menopause (age at onset);
CESC	cis	rs4919087	0.962	rs3740522	chr10:99019144	C/T	cg25902810	chr10:99078978	FRAT1	0.68	9.9	0.52	7.23e-20	Monocyte count;
CESC	cis	rs1448094	0.717	rs7305873	chr12:86290831	G/C	cg02569458	chr12:86230093	RASSF9	0.38	5.49	0.32	9.45e-8	Major depressive disorder;
CESC	cis	rs7084402	0.967	rs1658425	chr10:60331547	G/C	cg07615347	chr10:60278583	BICC1	0.57	8.46	0.46	1.84e-15	Refractive error;
CESC	cis	rs2280018	1.000	rs2280017	chr16:15151361	A/G	cg27102117	chr16:15229624	NA	-0.47	-7.37	-0.41	2.14e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs6570726	0.791	rs370112	chr6:145859853	T/G	cg23711669	chr6:146136114	FBXO30	1.01	15.52	0.69	4.59e-39	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs1728785	0.901	rs1728797	chr16:68570989	A/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.61	7.44	0.42	1.41e-12	Ulcerative colitis;
CESC	cis	rs9311474	0.508	rs6805156	chr3:52609362	T/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.38	6.95	0.39	2.86e-11	Electroencephalogram traits;
CESC	cis	rs9910055	0.659	rs721769	chr17:42261588	T/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.5	7.41	0.41	1.72e-12	Total body bone mineral density;
CESC	cis	rs9611565	0.765	rs202663	chr22:41812819	T/C	cg17376030	chr22:41985996	PMM1	-0.59	-6.28	-0.36	1.4e-9	Vitiligo;
CESC	trans	rs17764205	0.777	rs113305163	chr19:3252194	G/C	cg22364819	chr2:127864926	BIN1	0.73	6.02	0.35	5.75e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg06074448	chr4:187884817	NA	-0.38	-5.31	-0.31	2.3e-7	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs116095464	0.558	rs28729548	chr5:229025	C/T	cg22496380	chr5:211416	CCDC127	-0.74	-8.65	-0.47	5.2e-16	Breast cancer;
CESC	cis	rs6061231	0.631	rs2427317	chr20:60975725	C/T	cg22541963	chr20:60982533	CABLES2	0.41	5.27	0.31	2.79e-7	Colorectal cancer;
CESC	cis	rs933688	1.000	rs10041402	chr5:90738948	A/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.15	15.79	0.7	4.73e-40	Smoking behavior;
CESC	cis	rs11792861	0.962	rs11789624	chr9:111796231	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.47	5.88	0.34	1.2e-8	Menarche (age at onset);
CESC	cis	rs6089829	0.962	rs6122350	chr20:61664617	A/G	cg08564027	chr20:61660810	NA	0.9	15.42	0.69	9.97e-39	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7919006	1.000	rs2395127	chr10:76772778	A/T	cg01390419	chr10:76803856	DUPD1	0.4	6.21	0.36	2.08e-9	Weight;
CESC	cis	rs60843830	1.000	rs55753056	chr2:243929	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.89	12.38	0.61	4.3e-28	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs36051895	0.622	rs13440043	chr9:5268264	A/G	cg02405213	chr9:5042618	JAK2	-0.54	-6.22	-0.36	1.93e-9	Pediatric autoimmune diseases;
CESC	cis	rs4689592	0.503	rs10516184	chr4:7060959	C/T	cg06697600	chr4:7070879	GRPEL1	-0.5	-6.32	-0.36	1.13e-9	Monocyte percentage of white cells;
CESC	cis	rs3741404	0.825	rs2845597	chr11:63954370	G/A	cg18225595	chr11:63971243	STIP1	0.74	10.4	0.54	1.79e-21	Platelet count;
CESC	cis	rs933688	0.938	rs7720235	chr5:90659329	A/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.97	12.87	0.62	9.11e-30	Smoking behavior;
CESC	trans	rs4129059	1.000	rs61443257	chr1:214673211	G/A	cg08821431	chr12:34491090	NA	0.56	6.06	0.35	4.7e-9	Age-related hearing impairment (SNP x SNP interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26164440	chr3:39195354	CSRNP1	0.54	6.13	0.35	3.17e-9	Gut microbiome composition (summer);
CESC	cis	rs896854	0.875	rs4735333	chr8:95955074	G/A	cg26343298	chr8:95960752	TP53INP1	0.38	6.36	0.36	8.72e-10	Type 2 diabetes;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg02851751	chr10:73574918	CDH23	-0.46	-6.0	-0.35	6.33e-9	Systemic lupus erythematosus;
CESC	cis	rs2839186	0.934	rs2839197	chr21:47708133	A/G	cg10351095	chr21:47802916	PCNT	-0.5	-6.8	-0.39	7.02e-11	Testicular germ cell tumor;
CESC	cis	rs7666738	0.830	rs36047842	chr4:99004902	C/A	cg17366294	chr4:99064904	C4orf37	0.6	8.61	0.47	6.47e-16	Colonoscopy-negative controls vs population controls;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg26401633	chr14:73925225	NUMB	0.45	6.34	0.36	9.62e-10	Fibrinogen levels;
CESC	cis	rs9322193	0.962	rs3805749	chr6:150093682	C/T	cg13206674	chr6:150067644	NUP43	0.43	5.9	0.34	1.1e-8	Lung cancer;
CESC	cis	rs7666738	0.830	rs4392515	chr4:98957431	A/G	cg05340658	chr4:99064831	C4orf37	0.8	12.4	0.61	3.76e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4919087	1.000	rs12221430	chr10:99061386	C/G	cg25902810	chr10:99078978	FRAT1	0.74	10.75	0.55	1.34e-22	Monocyte count;
CESC	cis	rs910316	1.000	rs876402	chr14:75601862	C/T	cg11812906	chr14:75593930	NEK9	-0.91	-15.73	-0.69	7.72e-40	Height;
CESC	cis	rs10504229	0.906	rs59336968	chr8:58176857	T/C	cg14926445	chr8:58193284	C8orf71	-0.51	-5.47	-0.32	1.03e-7	Developmental language disorder (linguistic errors);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02624737	chr8:144921531	NRBP2	-0.49	-6.08	-0.35	4.14e-9	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.791	rs6840669	chr4:99016020	G/T	cg03467027	chr4:99064603	C4orf37	0.44	5.63	0.33	4.57e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9796	0.866	rs516156	chr15:41381257	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.42	-6.23	-0.36	1.78e-9	Menopause (age at onset);
CESC	cis	rs459571	0.959	rs465535	chr9:136910905	C/T	cg13789015	chr9:136890014	NCRNA00094	0.52	7.56	0.42	6.52e-13	Platelet distribution width;
CESC	cis	rs6968419	0.788	rs7459377	chr7:115825608	G/A	cg02561103	chr7:115862891	TES	-0.39	-5.26	-0.31	2.91e-7	Intraocular pressure;
CESC	cis	rs4722166	0.630	rs6969258	chr7:22782528	C/T	cg26061582	chr7:22766209	IL6	0.51	5.55	0.32	6.82e-8	Lung cancer;
CESC	cis	rs11098499	0.909	rs28668716	chr4:120309875	T/C	cg09307838	chr4:120376055	NA	0.92	12.66	0.61	4.96e-29	Corneal astigmatism;
CESC	trans	rs2908835	0.672	rs11613136	chr12:11646428	C/G	cg09915232	chr8:1879280	ARHGEF10	-0.65	-6.39	-0.37	7.56e-10	Information processing speed;
CESC	cis	rs3768617	0.510	rs2027083	chr1:183088330	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.89	14.36	0.66	5.49e-35	Fuchs's corneal dystrophy;
CESC	cis	rs2075371	0.932	rs1035328	chr7:133978419	T/C	cg11752832	chr7:134001865	SLC35B4	0.57	7.52	0.42	8.7e-13	Mean platelet volume;
CESC	cis	rs2070997	0.607	rs3847190	chr9:133715590	C/T	cg11464064	chr9:133710261	ABL1	0.67	7.55	0.42	6.92e-13	Response to amphetamines;
CESC	cis	rs3096299	0.728	rs1011749	chr16:89510869	G/C	cg00750074	chr16:89608354	SPG7	-0.43	-6.29	-0.36	1.29e-9	Multiple myeloma (IgH translocation);
CESC	cis	rs2204008	0.641	rs66876045	chr12:38205713	G/A	cg26384229	chr12:38710491	ALG10B	0.71	10.3	0.53	3.96e-21	Bladder cancer;
CESC	cis	rs76793172	0.623	rs8107744	chr19:46300848	C/A	cg11657440	chr19:46296263	DMWD	0.57	5.05	0.3	8.34e-7	Eosinophil counts;
CESC	cis	rs1215050	0.904	rs9307215	chr4:98813965	A/G	cg05340658	chr4:99064831	C4orf37	0.52	6.23	0.36	1.85e-9	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs13102973	0.965	rs4597893	chr4:135863043	C/T	cg14419869	chr4:135874104	NA	-0.39	-6.16	-0.35	2.69e-9	Subjective well-being;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14824382	chr8:144680115	EEF1D;TIGD5	0.63	6.97	0.39	2.47e-11	Gut microbiome composition (summer);
CESC	cis	rs1153858	1.000	rs9783731	chr15:45642884	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.4	-5.79	-0.34	1.97e-8	Homoarginine levels;
CESC	cis	rs7202877	0.706	rs247438	chr16:75432649	C/G	cg04384234	chr16:75411784	CFDP1	0.51	6.17	0.35	2.52e-9	Type 2 diabetes;Type 1 diabetes;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg12799349	chr18:9475500	RALBP1	-0.36	-6.01	-0.35	6.2e-9	Gambling;
CESC	cis	rs12701220	0.604	rs12702122	chr7:1149494	C/G	cg26769984	chr7:1090371	C7orf50	0.54	6.33	0.36	1.02e-9	Bronchopulmonary dysplasia;
CESC	cis	rs938554	0.513	rs3775946	chr4:9995256	A/G	cg00071950	chr4:10020882	SLC2A9	0.67	8.7	0.47	3.66e-16	Blood metabolite levels;
CESC	cis	rs7927771	0.524	rs10742824	chr11:47864842	C/T	cg20307385	chr11:47447363	PSMC3	0.63	8.77	0.47	2.17e-16	Subjective well-being;
CESC	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg18402987	chr7:1209562	NA	0.63	7.35	0.41	2.5e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs4434138	0.683	rs13063160	chr3:52602274	T/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.38	6.93	0.39	3.18e-11	Intelligence (multi-trait analysis);
CESC	cis	rs6089584	0.927	rs6089593	chr20:60572312	G/A	cg24733560	chr20:60626293	TAF4	0.39	5.58	0.32	5.9e-8	Body mass index;
CESC	cis	rs9614461	0.702	rs2294202	chr22:45738327	A/T	cg23503501	chr22:45809793	SMC1B;RIBC2	0.64	6.2	0.36	2.21e-9	Tonsillectomy;
CESC	cis	rs6991838	0.584	rs6993876	chr8:66513475	C/T	cg13398993	chr8:66546079	ARMC1	0.45	5.56	0.32	6.5e-8	Intelligence (multi-trait analysis);
CESC	cis	rs863345	0.604	rs11264977	chr1:158447852	G/T	cg12129480	chr1:158549410	OR10X1	-0.36	-7.18	-0.4	7.1e-12	Pneumococcal bacteremia;
CESC	cis	rs4713118	0.662	rs149947	chr6:27972433	A/T	cg23281280	chr6:28129359	ZNF389	0.51	6.93	0.39	3.16e-11	Parkinson's disease;
CESC	cis	rs1371867	0.875	rs1788184	chr8:101335106	A/G	cg11906718	chr8:101322791	RNF19A	0.46	5.91	0.34	1.03e-8	Atrioventricular conduction;
CESC	trans	rs629535	0.814	rs62513376	chr8:70086881	C/T	cg21567404	chr3:27674614	NA	-0.87	-10.34	-0.54	2.9e-21	Dupuytren's disease;
CESC	cis	rs7666738	0.830	rs62321564	chr4:98976496	C/G	cg03467027	chr4:99064603	C4orf37	0.43	5.4	0.31	1.49e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6963495	0.818	rs73192107	chr7:105168095	G/A	cg19920283	chr7:105172520	RINT1	0.69	6.54	0.37	3.15e-10	Bipolar disorder (body mass index interaction);
CESC	cis	rs478222	1.000	rs567359	chr2:25304574	C/T	cg01884057	chr2:25150051	NA	0.31	5.42	0.32	1.32e-7	Type 1 diabetes;
CESC	cis	rs4862750	0.914	rs11943333	chr4:187872455	A/G	cg07414643	chr4:187882934	NA	0.36	5.16	0.3	4.87e-7	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7772486	0.754	rs2328709	chr6:146106819	A/G	cg05347473	chr6:146136440	FBXO30	-0.53	-6.64	-0.38	1.75e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4711336	1.000	rs2296741	chr6:33659557	C/T	cg14003231	chr6:33640908	ITPR3	0.32	5.55	0.32	7.05e-8	Height;
CESC	cis	rs2180341	0.924	rs877661	chr6:127587915	T/G	cg27446573	chr6:127587934	RNF146	1.07	15.9	0.7	1.99e-40	Breast cancer;
CESC	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg01238044	chr22:24384105	GSTT1	-0.5	-6.19	-0.36	2.28e-9	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs7267979	1.000	rs6050629	chr20:25430680	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.87	18.11	0.74	3e-48	Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs11750092	0.525	rs6884129	chr5:159378582	C/G	cg20411384	chr7:90670577	CDK14	0.58	6.13	0.35	3.18e-9	Migraine;
CESC	cis	rs1322639	0.571	rs13204417	chr6:169575355	G/A	cg04662567	chr6:169592167	NA	0.41	5.85	0.34	1.41e-8	Pulse pressure;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg14179065	chr9:71682302	FXN	0.48	6.21	0.36	2.08e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs2742234	0.579	rs2503881	chr10:43686026	T/C	cg15436174	chr10:43711423	RASGEF1A	-0.5	-5.84	-0.34	1.5e-8	Hirschsprung disease;
CESC	cis	rs1559088	0.948	rs6510346	chr19:33598526	T/A	cg27124370	chr19:33622961	WDR88	0.46	6.11	0.35	3.64e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs62432291	0.681	rs2501176	chr6:159655383	A/G	cg14500486	chr6:159655392	FNDC1	-0.62	-6.21	-0.36	2.04e-9	Joint mobility (Beighton score);
CESC	cis	rs6545883	0.929	rs12617911	chr2:61740825	A/G	cg15711740	chr2:61764176	XPO1	-0.43	-5.23	-0.31	3.39e-7	Tuberculosis;
CESC	cis	rs1620921	0.505	rs9458032	chr6:161210205	G/T	cg01280913	chr6:161186852	NA	-0.39	-5.56	-0.32	6.49e-8	Lipoprotein (a) - cholesterol levels;
CESC	cis	rs763121	0.962	rs2071887	chr22:38879010	A/T	cg06022373	chr22:39101656	GTPBP1	0.66	9.34	0.5	4.03e-18	Menopause (age at onset);
CESC	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg23708337	chr7:1209742	NA	0.55	5.42	0.32	1.33e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs1018836	0.923	rs4735260	chr8:91617157	C/G	cg16814680	chr8:91681699	NA	0.7	9.85	0.52	1.05e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs56346965	0.967	rs2159819	chr2:191532737	C/G	cg27211696	chr2:191398769	TMEM194B	-0.42	-5.53	-0.32	7.69e-8	Bone mineral density (Ward's triangle area);
CESC	cis	rs11190604	1.000	rs2495758	chr10:102321900	C/G	cg07080220	chr10:102295463	HIF1AN	0.62	5.57	0.32	6.31e-8	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs4665809	0.590	rs6730310	chr2:26419470	C/G	cg25036284	chr2:26402008	FAM59B	-0.84	-9.62	-0.51	5.37e-19	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26027796	chr19:55962686	NA	-0.49	-6.14	-0.35	3.04e-9	Gut microbiome composition (summer);
CESC	cis	rs5758511	0.514	rs5758629	chr22:42574555	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.61	9.33	0.5	4.4e-18	Birth weight;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24999111	chr2:85830196	TMEM150A	0.58	6.2	0.36	2.12e-9	Gut microbiome composition (summer);
CESC	cis	rs6580649	0.941	rs4760615	chr12:48428150	A/G	cg24011408	chr12:48396354	COL2A1	0.41	5.16	0.3	4.88e-7	Lung cancer;
CESC	cis	rs763121	0.853	rs5757203	chr22:39044152	G/C	cg06544989	chr22:39130855	UNC84B	0.5	8.66	0.47	4.63e-16	Menopause (age at onset);
CESC	cis	rs9393777	0.623	rs3734544	chr6:26468660	G/A	cg12826209	chr6:26865740	GUSBL1	0.69	7.47	0.42	1.14e-12	Intelligence (multi-trait analysis);
CESC	cis	rs6502050	0.835	rs4789678	chr17:80101078	C/T	cg23985595	chr17:80112537	CCDC57	-0.42	-6.59	-0.38	2.39e-10	Life satisfaction;
CESC	cis	rs9486715	0.838	rs9400034	chr6:96954566	C/T	cg18709589	chr6:96969512	KIAA0776	0.46	6.48	0.37	4.41e-10	Headache;
CESC	cis	rs1153858	1.000	rs2114501	chr15:45670316	G/A	cg14582100	chr15:45693742	SPATA5L1	0.42	5.95	0.34	8.38e-9	Homoarginine levels;
CESC	cis	rs6545883	0.965	rs6718887	chr2:61727215	G/A	cg15711740	chr2:61764176	XPO1	-0.41	-5.24	-0.31	3.23e-7	Tuberculosis;
CESC	cis	rs2836974	0.863	rs6517519	chr21:40540245	A/G	cg27266027	chr21:40555129	PSMG1	0.46	5.55	0.32	6.87e-8	Cognitive function;
CESC	cis	rs6912958	0.559	rs445434	chr6:88041849	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	0.34	5.55	0.32	6.92e-8	Monocyte percentage of white cells;
CESC	cis	rs12701220	0.655	rs6955290	chr7:1151066	A/G	cg23978390	chr7:1156363	C7orf50	-0.57	-5.87	-0.34	1.32e-8	Bronchopulmonary dysplasia;
CESC	cis	rs3925075	0.966	rs7195945	chr16:31344309	T/C	cg02846316	chr16:31340340	ITGAM	0.42	6.76	0.38	8.91e-11	IgA nephropathy;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg09672890	chr17:70536484	NA	-0.42	-6.11	-0.35	3.57e-9	Height;
CESC	cis	rs7264396	0.635	rs6060682	chr20:34506331	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.59	7.17	0.4	7.68e-12	Total cholesterol levels;
CESC	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg23034840	chr1:205782522	SLC41A1	0.72	8.67	0.47	4.43e-16	Menarche (age at onset);
CESC	cis	rs4450798	0.739	rs3856821	chr3:13742240	G/T	cg05589046	chr3:13742034	LOC285375	-0.34	-5.47	-0.32	1.04e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	trans	rs6089829	0.962	rs2277769	chr20:61666805	C/T	cg23505145	chr19:12996616	KLF1	0.52	6.92	0.39	3.36e-11	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs4819052	0.724	rs1304487	chr21:46657283	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.72	-9.75	-0.51	2.17e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs28386778	0.769	rs6504179	chr17:61812995	T/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	7.65	0.43	3.65e-13	Prudent dietary pattern;
CESC	cis	rs2836974	0.897	rs1984022	chr21:40596085	G/A	cg17971929	chr21:40555470	PSMG1	1.04	15.59	0.69	2.46e-39	Cognitive function;
CESC	cis	rs17384381	0.834	rs12130380	chr1:85901309	T/C	cg16011679	chr1:85725395	C1orf52	0.62	6.58	0.37	2.5e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9487051	0.597	rs351746	chr6:109529321	G/A	cg01475377	chr6:109611718	NA	-0.39	-5.16	-0.3	4.76e-7	Reticulocyte fraction of red cells;
CESC	cis	rs2985684	1.000	rs2224949	chr14:50096560	A/G	cg02151108	chr14:50098012	C14orf104	0.4	5.44	0.32	1.21e-7	Carotid intima media thickness;
CESC	cis	rs4835473	0.864	rs5015762	chr4:144658926	G/A	cg25736465	chr4:144833511	NA	-0.33	-5.18	-0.3	4.3e-7	Immature fraction of reticulocytes;
CESC	cis	rs11250464	0.804	rs11250463	chr10:1406228	T/C	cg26394196	chr10:1453818	ADARB2	-0.39	-5.2	-0.3	3.9e-7	Radiation response;
CESC	cis	rs2439831	1.000	rs690316	chr15:43737880	C/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.88	10.54	0.54	6.3e-22	Lung cancer in ever smokers;
CESC	cis	rs4780401	0.755	rs8191285	chr16:11765408	A/G	cg01061890	chr16:11836724	TXNDC11	-0.39	-5.07	-0.3	7.41e-7	Rheumatoid arthritis;
CESC	cis	rs2637266	0.765	rs2395391	chr10:78359932	G/A	cg18941641	chr10:78392320	NA	0.41	7.64	0.42	3.93e-13	Pulmonary function;
CESC	trans	rs877282	0.945	rs12782447	chr10:771870	C/T	cg22713356	chr15:30763199	NA	1.19	11.91	0.59	1.78e-26	Uric acid levels;
CESC	cis	rs11583043	0.575	rs7528842	chr1:101583663	G/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.48	-5.31	-0.31	2.27e-7	Ulcerative colitis;Inflammatory bowel disease;
CESC	cis	rs9929218	0.953	rs11075696	chr16:68731365	A/G	cg02972257	chr16:68554789	NA	0.58	7.05	0.4	1.58e-11	Colorectal cancer;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg09299307	chr5:86709023	CCNH	-0.45	-6.58	-0.37	2.54e-10	Gambling;
CESC	cis	rs7639513	0.767	rs13060705	chr3:12710016	C/A	cg23032965	chr3:12705835	RAF1	0.76	10.86	0.55	5.83e-23	Itch intensity from mosquito bite;
CESC	cis	rs17362650	0.694	rs10929582	chr2:9585200	C/G	cg12832956	chr2:9616023	IAH1	0.53	6.42	0.37	6.17e-10	Alcohol dependence (age at onset);
CESC	cis	rs7116495	0.737	rs661290	chr11:71766014	A/G	cg18441811	chr11:71824068	C11orf51	-0.81	-5.07	-0.3	7.54e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs769267	0.965	rs2965188	chr19:19522557	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	7.56	0.42	6.43e-13	Tonsillectomy;
CESC	cis	rs2832077	0.527	rs1048546	chr21:30244877	G/T	cg03476357	chr21:30257390	N6AMT1	-0.44	-5.51	-0.32	8.68e-8	Cognitive test performance;
CESC	cis	rs853679	0.517	rs6941992	chr6:28106141	T/C	cg20151795	chr6:28129481	ZNF389	0.45	5.92	0.34	9.77e-9	Depression;
CESC	cis	rs7613875	0.600	rs1061474	chr3:50144951	T/C	cg24308560	chr3:49941425	MST1R	0.58	8.02	0.44	3.52e-14	Body mass index;
CESC	cis	rs425277	0.606	rs451061	chr1:2075068	C/G	cg23803603	chr1:2058230	PRKCZ	0.31	5.29	0.31	2.51e-7	Height;
CESC	cis	rs875971	1.000	rs4717300	chr7:65947380	T/C	cg18876405	chr7:65276391	NA	0.5	6.61	0.38	2.05e-10	Aortic root size;
CESC	cis	rs614226	0.938	rs787824	chr12:120924638	A/G	cg01236616	chr12:121019343	POP5	-1.37	-16.82	-0.72	1.1e-43	Type 1 diabetes nephropathy;
CESC	cis	rs10838687	0.800	rs7124958	chr11:47347260	C/T	cg25783544	chr11:47291846	MADD	0.57	6.53	0.37	3.43e-10	Proinsulin levels;
CESC	cis	rs561341	0.609	rs7209493	chr17:30197323	A/G	cg13647721	chr17:30228624	UTP6	-0.74	-8.47	-0.46	1.72e-15	Hip circumference adjusted for BMI;
CESC	cis	rs736408	0.812	rs9324	chr3:52825585	T/C	cg18337363	chr3:52569053	NT5DC2	0.32	5.5	0.32	8.72e-8	Bipolar disorder;
CESC	cis	rs6733011	0.518	rs12992214	chr2:99466337	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.42	-5.19	-0.3	4.2e-7	Bipolar disorder;
CESC	cis	rs113835537	0.529	rs17580784	chr11:66214859	T/A	cg24851651	chr11:66362959	CCS	0.54	6.47	0.37	4.8e-10	Airway imaging phenotypes;
CESC	cis	rs35160687	0.509	rs35723061	chr2:86549088	G/A	cg01119172	chr2:86362222	SNORD94;PTCD3	-0.43	-5.73	-0.33	2.77e-8	Night sleep phenotypes;
CESC	cis	rs2072732	0.861	rs12042403	chr1:2950872	T/C	cg15211996	chr1:2936768	ACTRT2	0.34	5.95	0.34	8.31e-9	Plateletcrit;
CESC	cis	rs2204008	0.837	rs73112346	chr12:38357606	C/T	cg26384229	chr12:38710491	ALG10B	0.73	10.65	0.55	2.87e-22	Bladder cancer;
CESC	cis	rs9896933	0.887	rs78483419	chr17:80870884	T/C	cg15664640	chr17:80829946	TBCD	-0.52	-5.43	-0.32	1.28e-7	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg14793835	chr3:28283034	CMC1	-0.57	-8.06	-0.44	2.56e-14	Gut microbiota (bacterial taxa);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19452060	chr12:57914632	DDIT3	0.61	7.45	0.42	1.3e-12	Gut microbiome composition (summer);
CESC	cis	rs17253792	0.822	rs28754619	chr14:56088394	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.77	5.98	0.34	7.23e-9	Putamen volume;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg03700121	chr11:60610004	CCDC86	-0.43	-6.09	-0.35	4.02e-9	Fibrinogen levels;
CESC	cis	rs9512730	0.592	rs9581865	chr13:28054578	A/C	cg08193333	chr13:27998609	GTF3A	0.44	5.17	0.3	4.53e-7	Schizophrenia;
CESC	trans	rs66573146	0.831	rs56300156	chr4:6990813	G/C	cg07817883	chr1:32538562	TMEM39B	1.09	7.0	0.4	2.06e-11	Granulocyte percentage of myeloid white cells;
CESC	cis	rs9291683	0.679	rs2241483	chr4:10099831	A/G	cg11266682	chr4:10021025	SLC2A9	-0.49	-9.03	-0.49	3.67e-17	Bone mineral density;
CESC	cis	rs9768139	0.627	rs57920447	chr7:158121243	A/G	cg25566285	chr7:158114605	PTPRN2	0.49	7.96	0.44	5.07e-14	Calcium levels;
CESC	cis	rs9435341	0.860	rs12406721	chr1:107563243	G/T	cg09367891	chr1:107599246	PRMT6	0.71	8.24	0.45	8.08e-15	Facial morphology (factor 21, depth of nasal alae);
CESC	trans	rs9329221	0.537	rs6601415	chr8:9976805	C/A	cg06636001	chr8:8085503	FLJ10661	0.51	6.66	0.38	1.56e-10	Neuroticism;
CESC	cis	rs2228479	0.717	rs2286392	chr16:89809549	A/G	cg04013166	chr16:89971882	TCF25	0.72	7.87	0.44	9.3e-14	Skin colour saturation;
CESC	cis	rs3762637	1.000	rs12630576	chr3:122139517	A/C	cg24169773	chr3:122142474	KPNA1	-0.52	-6.18	-0.36	2.38e-9	LDL cholesterol levels;
CESC	cis	rs7520050	0.933	rs6694340	chr1:46289416	C/T	cg03146154	chr1:46216737	IPP	-0.48	-6.36	-0.36	8.91e-10	Red blood cell count;Reticulocyte count;
CESC	cis	rs662064	0.852	rs2483677	chr1:10580891	C/T	cg20482658	chr1:10539492	PEX14	0.37	7.72	0.43	2.38e-13	Asthma;
CESC	cis	rs6674970	0.627	rs2864700	chr1:151028929	C/T	cg11822372	chr1:151115635	SEMA6C	0.42	5.98	0.35	7.05e-9	Childhood ear infection;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02388999	chr6:131384671	EPB41L2	0.6	7.18	0.4	7.12e-12	Gut microbiome composition (summer);
CESC	cis	rs1847202	0.859	rs4501056	chr3:72948908	A/T	cg25664220	chr3:72788482	NA	-0.35	-5.3	-0.31	2.48e-7	Motion sickness;
CESC	cis	rs4835473	0.742	rs1838519	chr4:144893395	T/C	cg25736465	chr4:144833511	NA	0.4	6.08	0.35	4.15e-9	Immature fraction of reticulocytes;
CESC	cis	rs3820928	1.000	rs61067328	chr2:227761256	G/A	cg11843606	chr2:227700838	RHBDD1	-0.44	-5.84	-0.34	1.54e-8	Pulmonary function;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26821823	chr11:75875926	NA	-0.5	-6.23	-0.36	1.83e-9	Gut microbiome composition (summer);
CESC	cis	rs736408	0.509	rs13083798	chr3:52649748	A/G	cg25934064	chr3:52569026	NT5DC2	0.25	5.32	0.31	2.24e-7	Bipolar disorder;
CESC	cis	rs12048904	0.505	rs4517368	chr1:101255052	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.57	-6.75	-0.38	9.04e-11	Multiple sclerosis;
CESC	cis	rs2075371	0.933	rs1421482	chr7:133964383	A/G	cg20476274	chr7:133979776	SLC35B4	0.68	10.15	0.53	1.19e-20	Mean platelet volume;
CESC	cis	rs2635047	0.935	rs2461247	chr18:44698537	T/G	cg19077165	chr18:44547161	KATNAL2	-0.45	-6.06	-0.35	4.56e-9	Educational attainment;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg09430689	chr14:76127296	C14orf1;TTLL5	-0.42	-6.27	-0.36	1.46e-9	Gambling;
CESC	cis	rs13191362	0.688	rs73035006	chr6:162997083	G/T	cg14584255	chr6:163149320	PACRG;PARK2	0.5	5.17	0.3	4.64e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs7017914	0.934	rs6992879	chr8:71699283	A/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.42	-5.3	-0.31	2.38e-7	Bone mineral density;
CESC	cis	rs910316	1.000	rs4903281	chr14:75554361	G/C	cg11812906	chr14:75593930	NEK9	0.9	15.29	0.68	2.87e-38	Height;
CESC	cis	rs7618915	0.547	rs1561337	chr3:52659963	C/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.34	6.03	0.35	5.51e-9	Bipolar disorder;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg17597744	chr8:53627099	RB1CC1	-0.51	-6.85	-0.39	5.08e-11	Fibrinogen levels;
CESC	cis	rs941764	1.000	rs941764	chr14:91841069	C/T	cg10511902	chr14:91842949	CCDC88C	-0.45	-6.74	-0.38	1.01e-10	Breast cancer;
CESC	cis	rs4853012	0.539	rs9789534	chr2:74362990	A/T	cg19729930	chr2:74357872	NA	0.68	8.71	0.47	3.39e-16	Gestational age at birth (maternal effect);
CESC	cis	rs4843747	0.671	rs74729706	chr16:88104159	C/T	cg17633681	chr16:88106987	BANP	0.76	10.41	0.54	1.68e-21	Menopause (age at onset);
CESC	cis	rs35740288	0.580	rs34635893	chr15:86340248	C/T	cg20737812	chr15:86336631	KLHL25	-0.42	-5.34	-0.31	2e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
CESC	cis	rs11785400	0.793	rs9774627	chr8:143731267	G/A	cg10596483	chr8:143751796	JRK	0.42	5.31	0.31	2.33e-7	Schizophrenia;
CESC	cis	rs6088580	0.608	rs8114616	chr20:32969092	G/T	cg08999081	chr20:33150536	PIGU	-0.63	-10.85	-0.55	6.37e-23	Glomerular filtration rate (creatinine);
CESC	cis	rs12618769	0.597	rs2278213	chr2:99136059	A/G	cg10123293	chr2:99228465	UNC50	0.39	5.17	0.3	4.62e-7	Bipolar disorder;
CESC	cis	rs4727027	0.933	rs12154382	chr7:148862284	C/T	cg23583168	chr7:148888333	NA	-0.81	-12.68	-0.61	4.05e-29	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs863345	0.534	rs10797009	chr1:158446048	T/A	cg12129480	chr1:158549410	OR10X1	-0.34	-6.69	-0.38	1.29e-10	Pneumococcal bacteremia;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg01586524	chr8:67341819	RRS1	0.49	6.25	0.36	1.65e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs4819052	1.000	rs4818769	chr21:46667451	C/T	cg11663144	chr21:46675770	NA	-0.5	-6.86	-0.39	4.87e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs9399135	1.000	rs35123050	chr6:135302740	G/A	cg22676075	chr6:135203613	NA	0.5	6.96	0.39	2.62e-11	Red blood cell count;
CESC	cis	rs2404602	0.716	rs7179142	chr15:76698268	G/A	cg22467129	chr15:76604101	ETFA	-0.38	-5.67	-0.33	3.67e-8	Blood metabolite levels;
CESC	cis	rs17711722	0.701	rs4467826	chr7:65368708	A/G	cg26939375	chr7:64535504	NA	0.8	11.57	0.58	2.47e-25	Calcium levels;
CESC	cis	rs9733	0.519	rs6700022	chr1:150670484	G/T	cg04414720	chr1:150670196	GOLPH3L	-0.6	-8.51	-0.46	1.27e-15	Tonsillectomy;
CESC	cis	rs798554	0.757	rs1182198	chr7:2862906	C/T	cg19346786	chr7:2764209	NA	-0.51	-7.13	-0.4	9.3e-12	Height;
CESC	cis	rs11112613	0.713	rs73184081	chr12:105951745	C/T	cg03607813	chr12:105948248	NA	0.61	7.56	0.42	6.56e-13	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CESC	cis	rs9549260	0.755	rs7324319	chr13:41233505	G/C	cg21288729	chr13:41239152	FOXO1	0.66	8.61	0.47	6.55e-16	Red blood cell count;
CESC	cis	rs9486719	1.000	rs3906199	chr6:97049899	C/A	cg18709589	chr6:96969512	KIAA0776	-0.53	-5.78	-0.33	2.12e-8	Migraine;Coronary artery disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg27138088	chr11:842605	TSPAN4;POLR2L	-0.47	-6.21	-0.36	2e-9	Fibrinogen levels;
CESC	cis	rs9815354	1.000	rs9873207	chr3:41884750	C/T	cg03022575	chr3:42003672	ULK4	0.58	6.01	0.35	5.96e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs791888	0.929	rs791887	chr10:89411554	A/G	cg13926569	chr10:89418898	PAPSS2	-0.45	-6.5	-0.37	4.05e-10	Magnesium levels;
CESC	trans	rs10007810	0.760	rs7674041	chr4:41590808	A/G	cg05088549	chr3:183978344	ECE2;CAMK2N2	-0.48	-6.0	-0.35	6.44e-9	Longevity (90 years and older);
CESC	cis	rs9549367	0.789	rs2316442	chr13:113877487	C/T	cg18105134	chr13:113819100	PROZ	-0.67	-8.26	-0.45	7.17e-15	Platelet distribution width;
CESC	cis	rs13191362	1.000	rs34918316	chr6:163005386	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.5	5.19	0.3	4.18e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs9443645	0.901	rs1890229	chr6:79695029	C/T	cg05283184	chr6:79620031	NA	-0.42	-6.44	-0.37	5.55e-10	Intelligence (multi-trait analysis);
CESC	cis	rs13031619	0.660	rs35668314	chr2:3702673	C/T	cg19052272	chr2:3704530	ALLC	-0.79	-8.83	-0.48	1.5e-16	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CESC	cis	rs7666738	0.830	rs28818218	chr4:98880575	A/C	cg05340658	chr4:99064831	C4orf37	0.78	11.74	0.58	6.77e-26	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7666738	0.830	rs34212748	chr4:99068708	G/A	cg05340658	chr4:99064831	C4orf37	0.83	12.82	0.62	1.36e-29	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11792861	0.591	rs7027874	chr9:111717112	A/G	cg05043794	chr9:111880884	C9orf5	-0.31	-5.64	-0.33	4.4e-8	Menarche (age at onset);
CESC	cis	rs17253792	0.822	rs75288952	chr14:56034010	C/T	cg01858014	chr14:56050164	KTN1	-0.94	-6.82	-0.39	6.11e-11	Putamen volume;
CESC	cis	rs7666738	0.830	rs1876192	chr4:98727555	T/C	cg03467027	chr4:99064603	C4orf37	0.43	5.3	0.31	2.39e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg16132339	chr22:24313637	DDTL;DDT	0.4	6.05	0.35	4.95e-9	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs3820068	0.581	rs72645895	chr1:15931709	G/A	cg16988262	chr1:15930761	NA	0.35	5.65	0.33	4.18e-8	Systolic blood pressure;
CESC	cis	rs1862618	0.853	rs252898	chr5:56188931	T/C	cg20203395	chr5:56204925	C5orf35	-0.43	-5.06	-0.3	7.66e-7	Initial pursuit acceleration;
CESC	cis	rs9649213	0.593	rs7803372	chr7:97992257	A/G	cg00277769	chr7:97922759	BAIAP2L1	-0.33	-5.55	-0.32	7.08e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7917772	0.503	rs61871067	chr10:104295382	C/T	cg22532475	chr10:104410764	TRIM8	-0.44	-6.87	-0.39	4.45e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs9733	0.596	rs2175615	chr1:150624101	A/G	cg18016565	chr1:150552671	MCL1	0.33	5.13	0.3	5.67e-7	Tonsillectomy;
CESC	cis	rs514406	0.627	rs485128	chr1:53344583	T/C	cg16325326	chr1:53192061	ZYG11B	0.72	10.54	0.54	6.57e-22	Monocyte count;
CESC	trans	rs5756813	0.727	rs4820303	chr22:38134166	G/A	cg19894588	chr14:64061835	NA	-0.66	-7.81	-0.43	1.35e-13	Optic cup area;Vertical cup-disc ratio;
CESC	cis	rs9549260	0.564	rs12184871	chr13:41291928	C/A	cg21288729	chr13:41239152	FOXO1	0.56	7.25	0.41	4.67e-12	Red blood cell count;
CESC	cis	rs9788682	0.747	rs7183604	chr15:78899213	T/C	cg24631222	chr15:78858424	CHRNA5	-0.81	-10.17	-0.53	1.03e-20	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs7714584	1.000	rs17111376	chr5:150226899	T/C	cg22134413	chr5:150180641	NA	0.52	5.64	0.33	4.31e-8	Crohn's disease;
CESC	cis	rs116095464	0.614	rs10061564	chr5:271329	T/C	cg22857025	chr5:266934	NA	-1.3	-18.75	-0.76	1.71e-50	Breast cancer;
CESC	cis	rs453301	0.571	rs2929454	chr8:9083854	A/C	cg06636001	chr8:8085503	FLJ10661	-0.53	-6.82	-0.39	6.09e-11	Joint mobility (Beighton score);
CESC	cis	rs7605827	0.930	rs1469016	chr2:15687627	A/G	cg19274914	chr2:15703543	NA	0.37	6.67	0.38	1.5e-10	Educational attainment (years of education);
CESC	cis	rs9768139	0.935	rs7782393	chr7:158120486	G/A	cg24154853	chr7:158122151	PTPRN2	-0.38	-5.95	-0.34	8.46e-9	Calcium levels;
CESC	cis	rs9291683	0.546	rs13129453	chr4:10044784	T/C	cg02734326	chr4:10020555	SLC2A9	0.45	6.19	0.36	2.29e-9	Bone mineral density;
CESC	cis	rs1008375	1.000	rs10032326	chr4:17630717	A/T	cg15017067	chr4:17643749	FAM184B	0.4	5.75	0.33	2.46e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs4481887	0.962	rs6587452	chr1:248485931	C/T	cg00666640	chr1:248458726	OR2T12	0.41	6.74	0.38	9.64e-11	Common traits (Other);
CESC	cis	rs250677	0.687	rs3095947	chr5:148436728	T/C	cg18129178	chr5:148520854	ABLIM3	-0.48	-5.48	-0.32	1e-7	Breast cancer;
CESC	cis	rs9487051	0.735	rs1341272	chr6:109507533	C/T	cg01475377	chr6:109611718	NA	0.37	5.48	0.32	9.72e-8	Reticulocyte fraction of red cells;
CESC	cis	rs9733	0.526	rs11204696	chr1:150658721	T/C	cg09365446	chr1:150670422	GOLPH3L	0.41	5.76	0.33	2.36e-8	Tonsillectomy;
CESC	cis	rs425277	0.606	rs377283	chr1:2075570	T/C	cg19257562	chr1:2043853	PRKCZ	-0.32	-5.05	-0.3	8.39e-7	Height;
CESC	cis	rs9916302	0.731	rs11868030	chr17:37650332	A/G	cg00129232	chr17:37814104	STARD3	-0.54	-7.14	-0.4	9.08e-12	Glomerular filtration rate (creatinine);
CESC	cis	rs2180341	1.000	rs6569482	chr6:127631371	C/T	cg24812749	chr6:127587940	RNF146	1.07	15.48	0.69	6e-39	Breast cancer;
CESC	cis	rs898097	0.625	rs6502017	chr17:80891135	C/T	cg15664640	chr17:80829946	TBCD	0.41	5.83	0.34	1.61e-8	Breast cancer;
CESC	cis	rs514406	0.929	rs564273	chr1:53332445	G/C	cg24675658	chr1:53192096	ZYG11B	-0.59	-7.38	-0.41	2.07e-12	Monocyte count;
CESC	cis	rs11587400	0.634	rs4839385	chr1:115121461	A/G	cg12756093	chr1:115239321	AMPD1	0.42	5.69	0.33	3.33e-8	Autism;
CESC	cis	rs4604732	0.685	rs4925673	chr1:247636800	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.46	6.57	0.37	2.73e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs28489187	0.577	rs6697083	chr1:85887775	A/T	cg16011679	chr1:85725395	C1orf52	-0.43	-5.13	-0.3	5.74e-7	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	cis	rs4665809	0.941	rs7602922	chr2:26265782	C/T	cg25036284	chr2:26402008	FAM59B	-0.75	-8.44	-0.46	2.15e-15	Gut microbiome composition (summer);
CESC	cis	rs539096	0.500	rs2527776	chr1:44345292	G/A	cg12908607	chr1:44402522	ARTN	-0.49	-7.4	-0.41	1.82e-12	Intelligence (multi-trait analysis);
CESC	cis	rs2777491	0.957	rs919961	chr15:41651721	A/G	cg20272979	chr15:41787780	ITPKA	0.35	5.1	0.3	6.42e-7	Ulcerative colitis;
CESC	cis	rs1552244	1.000	rs17032278	chr3:10077955	A/G	cg00166722	chr3:10149974	C3orf24	0.46	5.88	0.34	1.21e-8	Alzheimer's disease;
CESC	cis	rs4906332	1.000	rs7155822	chr14:103922390	A/G	cg09975044	chr14:104007538	NA	0.45	6.17	0.35	2.59e-9	Coronary artery disease;
CESC	cis	rs113835537	0.529	rs11824771	chr11:66262550	T/C	cg22134325	chr11:66188745	NPAS4	0.35	5.58	0.32	5.8e-8	Airway imaging phenotypes;
CESC	cis	rs13108904	0.870	rs13110563	chr4:1255772	G/C	cg00684032	chr4:1343700	KIAA1530	0.41	5.78	0.33	2.04e-8	Obesity-related traits;
CESC	cis	rs11997175	0.646	rs4609158	chr8:33693420	A/G	ch.8.33884649F	chr8:33765107	NA	0.56	7.36	0.41	2.29e-12	Body mass index;
CESC	cis	rs1465370	0.800	rs62471721	chr7:130016470	G/A	cg04743876	chr7:130013617	NA	0.27	5.05	0.3	8.28e-7	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
CESC	cis	rs10861342	1.000	rs10861337	chr12:105452442	G/A	cg23923672	chr12:105501055	KIAA1033	0.72	5.32	0.31	2.21e-7	IgG glycosylation;
CESC	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg22535103	chr8:58192502	C8orf71	-0.92	-10.19	-0.53	8.81e-21	Developmental language disorder (linguistic errors);
CESC	cis	rs7584330	0.737	rs1497128	chr2:238369211	A/G	cg14458575	chr2:238380390	NA	0.53	7.47	0.42	1.14e-12	Prostate cancer;
CESC	cis	rs7429990	0.965	rs6772396	chr3:47959770	A/G	cg11946769	chr3:48343235	NME6	0.42	5.17	0.3	4.73e-7	Educational attainment (years of education);
CESC	cis	rs1499614	1.000	rs2707838	chr7:66159201	C/T	cg13147721	chr7:65941812	NA	-0.94	-8.9	-0.48	9.08e-17	Gout;
CESC	cis	rs3733585	0.605	rs4235354	chr4:10122942	C/A	cg02734326	chr4:10020555	SLC2A9	-0.37	-5.03	-0.3	8.89e-7	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs561341	0.882	rs72825748	chr17:30367396	G/A	cg12193833	chr17:30244370	NA	-0.71	-6.35	-0.36	9.53e-10	Hip circumference adjusted for BMI;
CESC	cis	rs4835473	0.798	rs11100829	chr4:144905914	G/C	cg25736465	chr4:144833511	NA	0.41	6.11	0.35	3.5e-9	Immature fraction of reticulocytes;
CESC	cis	rs7827545	1.000	rs7827545	chr8:135566567	C/T	cg17885191	chr8:135476712	NA	0.48	6.31	0.36	1.17e-9	Hypertension (SNP x SNP interaction);
CESC	cis	rs6496667	0.509	rs2253419	chr15:90945875	A/G	cg10434728	chr15:90938212	IQGAP1	0.33	5.81	0.34	1.75e-8	Rheumatoid arthritis;
CESC	cis	rs10883723	0.810	rs3781289	chr10:104244991	G/T	ch.10.2196322F	chr10:104248062	ACTR1A	0.43	5.21	0.3	3.78e-7	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs910316	0.789	rs12894419	chr14:75471802	C/T	cg11812906	chr14:75593930	NEK9	0.77	12.19	0.6	2.01e-27	Height;
CESC	cis	rs6087771	0.714	rs6058259	chr20:30235302	A/G	cg13852791	chr20:30311386	BCL2L1	0.77	9.66	0.51	4.05e-19	Subcortical brain region volumes;Putamen volume;
CESC	cis	rs2191566	0.691	rs8104437	chr19:44588789	C/T	cg20607764	chr19:44506953	ZNF230	-0.4	-5.31	-0.31	2.3e-7	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs798554	1.000	rs798540	chr7:2764130	G/A	cg19346786	chr7:2764209	NA	-0.51	-7.54	-0.42	7.64e-13	Height;
CESC	cis	rs367615	0.680	rs31595	chr5:108979318	T/C	cg17395555	chr5:108820864	NA	0.41	5.82	0.34	1.69e-8	Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs2120019	0.938	rs13056	chr15:75312187	A/G	cg17294928	chr15:75287854	SCAMP5	-0.73	-8.69	-0.47	3.87e-16	Blood trace element (Zn levels);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg15854934	chr14:55518152	MAPK1IP1L	-0.44	-6.19	-0.36	2.3e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs9815354	1.000	rs9840037	chr3:41827522	C/T	cg03022575	chr3:42003672	ULK4	0.47	5.15	0.3	4.98e-7	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs7666738	0.830	rs11725652	chr4:98878362	G/A	cg03467027	chr4:99064603	C4orf37	0.42	5.15	0.3	5.16e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7017697	0.642	rs3927029	chr8:19681933	G/A	cg03894339	chr8:19674705	INTS10	-0.54	-5.77	-0.33	2.15e-8	Breast cancer;
CESC	cis	rs6088590	0.648	rs6058105	chr20:33271719	C/T	cg06115741	chr20:33292138	TP53INP2	0.56	6.92	0.39	3.49e-11	Coronary artery disease;
CESC	trans	rs6570726	0.791	rs379040	chr6:145889035	T/C	cg03826317	chr10:25465503	LOC100128811;GPR158	0.31	6.03	0.35	5.38e-9	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs5753618	0.583	rs5749268	chr22:31809152	G/A	cg00478049	chr22:31556069	RNF185	-0.43	-5.11	-0.3	6.22e-7	Colorectal cancer;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg03700279	chr2:44576358	PREPL	0.42	6.8	0.39	6.85e-11	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs9296736	0.885	rs9349693	chr6:53939724	A/G	cg04374786	chr6:53939321	C6orf142	0.35	5.5	0.32	9.06e-8	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs35306767	0.903	rs35957139	chr10:884889	C/T	cg10556349	chr10:835070	NA	0.76	6.35	0.36	9.42e-10	Eosinophil percentage of granulocytes;
CESC	cis	rs9322193	0.923	rs11155677	chr6:150078089	C/G	cg09699651	chr6:150184138	LRP11	0.4	5.08	0.3	7.23e-7	Lung cancer;
CESC	cis	rs11690935	0.610	rs3770458	chr2:172651287	C/T	cg13550731	chr2:172543902	DYNC1I2	0.55	7.6	0.42	4.99e-13	Schizophrenia;
CESC	cis	rs6499255	0.951	rs57488237	chr16:69741571	T/C	cg15192750	chr16:69999425	NA	0.5	6.01	0.35	5.97e-9	IgE levels;
CESC	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.89	13.28	0.63	3.39e-31	Prudent dietary pattern;
CESC	cis	rs2777491	1.000	rs66538814	chr15:41685917	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.63	-9.59	-0.51	6.63e-19	Ulcerative colitis;
CESC	cis	rs2742234	0.590	rs2435377	chr10:43683600	A/G	cg15436174	chr10:43711423	RASGEF1A	0.48	5.6	0.33	5.46e-8	Hirschsprung disease;
CESC	trans	rs116095464	0.558	rs7708182	chr5:234788	C/G	cg00938859	chr5:1591904	SDHAP3	0.63	6.98	0.39	2.36e-11	Breast cancer;
CESC	cis	rs7100689	0.753	rs1361458	chr10:82090339	A/T	cg09936400	chr10:82049201	MAT1A	0.37	5.28	0.31	2.75e-7	Post bronchodilator FEV1;
CESC	cis	rs2797685	1.000	rs2859390	chr1:7847529	A/G	cg04725166	chr1:7887271	PER3	-0.46	-6.36	-0.36	8.98e-10	Crohn's disease;
CESC	cis	rs769267	0.930	rs3752151	chr19:19616026	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.59	7.4	0.41	1.75e-12	Tonsillectomy;
CESC	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg11905131	chr22:24372483	LOC391322	-0.83	-12.91	-0.62	6.48e-30	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs2439831	0.867	rs2899082	chr15:43656043	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.93	11.25	0.57	2.98e-24	Lung cancer in ever smokers;
CESC	cis	rs9311474	0.508	rs11718420	chr3:52611413	T/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.71	0.38	1.16e-10	Electroencephalogram traits;
CESC	cis	rs4243830	0.737	rs11122083	chr1:6593532	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.81	-6.51	-0.37	3.7e-10	Body mass index;
CESC	cis	rs7772486	0.686	rs1569540	chr6:146069112	A/G	cg23711669	chr6:146136114	FBXO30	-0.88	-13.21	-0.63	5.93e-31	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4665809	0.590	rs9309474	chr2:26448830	T/A	cg22920501	chr2:26401640	FAM59B	-0.91	-10.33	-0.54	3.07e-21	Gut microbiome composition (summer);
CESC	cis	rs478304	0.651	rs4014195	chr11:65506822	C/G	cg10518572	chr11:65560635	OVOL1	0.34	7.12	0.4	1.04e-11	Acne (severe);
CESC	cis	rs7927771	0.524	rs7943464	chr11:47886639	T/A	cg20307385	chr11:47447363	PSMC3	0.63	8.84	0.48	1.39e-16	Subjective well-being;
CESC	cis	rs36051895	0.695	rs10974921	chr9:5024427	T/A	cg02405213	chr9:5042618	JAK2	-0.5	-5.63	-0.33	4.66e-8	Pediatric autoimmune diseases;
CESC	cis	rs68170813	0.559	rs2023892	chr7:106847686	C/T	cg02696742	chr7:106810147	HBP1	0.5	5.03	0.3	9.04e-7	Coronary artery disease;
CESC	cis	rs3540	0.533	rs2352601	chr15:91053125	G/A	cg22089800	chr15:90895588	ZNF774	-0.63	-8.41	-0.46	2.49e-15	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs12220238	1.000	rs11000916	chr10:75953909	T/A	cg19889307	chr10:75911429	ADK;AP3M1	0.6	5.44	0.32	1.24e-7	Soluble interleukin-2 receptor subunit alpha;
CESC	cis	rs1707322	0.721	rs28442079	chr1:46172001	A/G	cg03146154	chr1:46216737	IPP	0.82	11.54	0.58	3.18e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg06873352	chr17:61820015	STRADA	0.68	11.14	0.56	6.69e-24	Prudent dietary pattern;
CESC	cis	rs17711722	0.653	rs2460421	chr7:65491123	A/T	cg11764359	chr7:65958608	NA	-0.46	-5.72	-0.33	2.88e-8	Calcium levels;
CESC	trans	rs10506458	0.915	rs1009540	chr12:63414872	C/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.33	-18.64	-0.75	4.04e-50	Hemostatic factors and hematological phenotypes;
CESC	cis	rs116095464	0.681	rs9687745	chr5:229309	C/T	cg22857025	chr5:266934	NA	-1.27	-18.52	-0.75	1.07e-49	Breast cancer;
CESC	cis	rs2439831	0.850	rs8023458	chr15:44080939	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.71	6.87	0.39	4.52e-11	Lung cancer in ever smokers;
CESC	cis	rs9303401	0.659	rs12150264	chr17:56939927	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.01	12.69	0.61	3.78e-29	Cognitive test performance;
CESC	cis	rs11785400	0.793	rs9774627	chr8:143731267	G/A	cg24634471	chr8:143751801	JRK	0.45	5.75	0.33	2.43e-8	Schizophrenia;
CESC	cis	rs10504229	0.683	rs2101864	chr8:58113226	C/T	cg02725872	chr8:58115012	NA	-0.45	-7.04	-0.4	1.66e-11	Developmental language disorder (linguistic errors);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07926482	chr16:84651521	COTL1	0.71	7.72	0.43	2.38e-13	Gut microbiome composition (summer);
CESC	cis	rs6570726	0.818	rs399516	chr6:145810849	C/A	cg05347473	chr6:146136440	FBXO30	0.52	6.93	0.39	3.29e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7552404	0.961	rs1061337	chr1:76227022	A/G	cg10523679	chr1:76189770	ACADM	0.66	7.45	0.42	1.34e-12	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs1728785	0.901	rs1645934	chr16:68564490	T/A	cg02972257	chr16:68554789	NA	-0.55	-6.37	-0.36	8.21e-10	Ulcerative colitis;
CESC	cis	rs9894429	0.816	rs9747093	chr17:79584280	G/A	cg18240062	chr17:79603768	NPLOC4	0.71	10.24	0.53	5.93e-21	Eye color traits;
CESC	cis	rs9916302	0.904	rs12452880	chr17:37591149	G/C	cg20243544	chr17:37824526	PNMT	0.5	6.37	0.36	8.48e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs3761218	0.738	rs6084472	chr20:3771858	G/T	cg25011176	chr20:3776985	CDC25B	-0.46	-6.03	-0.35	5.63e-9	Bipolar disorder;
CESC	cis	rs2130392	0.962	rs35613786	chr4:185625657	A/G	cg21366198	chr4:185655624	MLF1IP	0.43	6.06	0.35	4.64e-9	Kawasaki disease;
CESC	cis	rs12477438	0.765	rs56167745	chr2:99600478	T/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.64	-9.2	-0.49	1.14e-17	Chronic sinus infection;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg08958952	chr8:142262761	NA	0.44	6.03	0.35	5.57e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs367943	0.712	rs1120091	chr5:112684229	C/A	cg12552261	chr5:112820674	MCC	0.41	5.3	0.31	2.49e-7	Type 2 diabetes;
CESC	cis	rs12681288	0.862	rs2701898	chr8:1020812	C/T	cg04851639	chr8:1020857	NA	-0.38	-8.16	-0.45	1.39e-14	Schizophrenia;
CESC	cis	rs6952808	0.792	rs11771973	chr7:1950440	C/G	cg21782813	chr7:2030301	MAD1L1	0.41	5.83	0.34	1.61e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs1862618	0.853	rs863840	chr5:56128999	C/G	cg22800045	chr5:56110881	MAP3K1	0.7	8.3	0.45	5.23e-15	Initial pursuit acceleration;
CESC	cis	rs3820068	0.554	rs60233444	chr1:15921330	A/C	cg16988262	chr1:15930761	NA	0.35	5.63	0.33	4.6e-8	Systolic blood pressure;
CESC	cis	rs34375054	0.558	rs67041765	chr12:125672913	T/G	cg25124228	chr12:125621409	AACS	-0.52	-6.11	-0.35	3.52e-9	Post bronchodilator FEV1/FVC ratio;
CESC	trans	rs317865	0.520	rs75252501	chr4:16337280	C/T	cg26256793	chr1:103574469	COL11A1	-0.66	-6.25	-0.36	1.65e-9	Kidney disease (early stage) in type 1 diabetes;
CESC	cis	rs7613875	0.600	rs2624826	chr3:50155468	T/G	cg24308560	chr3:49941425	MST1R	0.54	7.56	0.42	6.56e-13	Body mass index;
CESC	cis	rs477692	0.699	rs509017	chr10:131367174	T/G	cg05714579	chr10:131428358	MGMT	0.4	5.17	0.3	4.61e-7	Response to temozolomide;
CESC	cis	rs9303280	0.776	rs11078926	chr17:38062976	G/A	cg19468946	chr17:37922297	IKZF3	-0.39	-5.2	-0.3	4.07e-7	Self-reported allergy;
CESC	cis	rs2836950	0.585	rs1029004	chr21:40615343	A/G	cg11644478	chr21:40555479	PSMG1	-0.51	-6.96	-0.39	2.64e-11	Menarche (age at onset);
CESC	cis	rs3096299	0.685	rs12935112	chr16:89542858	C/T	cg00750074	chr16:89608354	SPG7	0.41	6.09	0.35	3.9e-9	Multiple myeloma (IgH translocation);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00214165	chr5:7869652	MTRR;FASTKD3	0.6	6.55	0.37	2.92e-10	Gut microbiome composition (summer);
CESC	cis	rs3845702	0.736	rs56401468	chr2:180857757	C/T	cg01881094	chr2:180872142	CWC22	1.11	9.6	0.51	6.33e-19	Schizophrenia;
CESC	cis	rs7647973	0.667	rs4241405	chr3:49642027	C/T	cg03060546	chr3:49711283	APEH	0.64	7.27	0.41	4.1e-12	Menarche (age at onset);
CESC	cis	rs6502050	0.835	rs6502065	chr17:80095642	T/C	cg01763666	chr17:80159506	CCDC57	-0.37	-5.1	-0.3	6.61e-7	Life satisfaction;
CESC	cis	rs2708240	0.666	rs2708270	chr7:147594647	T/C	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.37	-6.16	-0.35	2.71e-9	QT interval (drug interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12568776	chr9:112083456	EPB41L4B	-0.55	-6.2	-0.36	2.15e-9	Gut microbiome composition (summer);
CESC	cis	rs28386778	0.769	rs6504179	chr17:61812995	T/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.85	12.31	0.6	7.61e-28	Prudent dietary pattern;
CESC	cis	rs8067545	0.750	rs3862152	chr17:19959693	C/T	cg13482628	chr17:19912719	NA	0.4	5.41	0.32	1.39e-7	Schizophrenia;
CESC	cis	rs9894429	0.646	rs9904137	chr17:79613925	C/T	cg18240062	chr17:79603768	NPLOC4	0.51	6.76	0.38	8.81e-11	Eye color traits;
CESC	trans	rs11989744	1.000	rs34389484	chr8:23572963	T/G	cg03492747	chr16:86543808	FOXF1	0.69	7.71	0.43	2.59e-13	Waist-hip ratio;
CESC	cis	rs2243480	1.000	rs4718333	chr7:65772758	T/C	cg13147721	chr7:65941812	NA	0.98	9.24	0.49	8.25e-18	Diabetic kidney disease;
CESC	cis	rs763121	0.815	rs4821799	chr22:39021326	T/G	cg06544989	chr22:39130855	UNC84B	0.47	8.5	0.46	1.41e-15	Menopause (age at onset);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg23104823	chr14:45553408	PRPF39	0.53	7.31	0.41	3.18e-12	Gut microbiota (bacterial taxa);
CESC	cis	rs4665809	1.000	rs4665309	chr2:26335502	T/C	cg08470875	chr2:26401718	FAM59B	-0.47	-5.24	-0.31	3.31e-7	Gut microbiome composition (summer);
CESC	cis	rs61332075	0.501	rs56387323	chr2:239387399	T/C	cg18131467	chr2:239335373	ASB1	-0.73	-5.88	-0.34	1.23e-8	Lung function (FEV1/FVC);
CESC	cis	rs1048238	0.506	rs56352596	chr1:16297592	G/A	cg22431228	chr1:16359049	CLCNKA	-0.36	-6.42	-0.37	6.43e-10	Systolic blood pressure;
CESC	cis	rs17711722	0.585	rs6942660	chr7:65302406	C/T	cg05332525	chr7:65337924	VKORC1L1	0.52	6.43	0.37	6.04e-10	Calcium levels;
CESC	cis	rs6460942	0.915	rs79232243	chr7:12459494	G/A	cg02935154	chr7:12443704	VWDE	-0.58	-6.25	-0.36	1.67e-9	Coronary artery disease;
CESC	cis	rs6502050	0.835	rs8073351	chr17:80127625	A/G	cg23985595	chr17:80112537	CCDC57	-0.41	-6.57	-0.37	2.61e-10	Life satisfaction;
CESC	cis	rs7666738	0.861	rs28829607	chr4:98964325	G/C	cg03467027	chr4:99064603	C4orf37	0.44	5.57	0.32	6.41e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9926296	0.656	rs11861084	chr16:89875710	G/T	cg04287289	chr16:89883240	FANCA	-0.62	-8.33	-0.46	4.39e-15	Vitiligo;
CESC	cis	rs453301	0.592	rs4841084	chr8:8883905	C/T	cg15556689	chr8:8085844	FLJ10661	0.49	6.32	0.36	1.11e-9	Joint mobility (Beighton score);
CESC	cis	rs12586317	0.620	rs58320987	chr14:35587726	T/C	cg16230307	chr14:35515116	FAM177A1	0.93	10.09	0.53	1.81e-20	Psoriasis;
CESC	cis	rs11204677	1	rs11204677	chr1:150574695	C/G	cg17724175	chr1:150552817	MCL1	-0.33	-5.24	-0.31	3.23e-7	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
CESC	cis	rs2797160	1.000	rs1418639	chr6:125999940	C/T	cg05901451	chr6:126070800	HEY2	-0.45	-6.67	-0.38	1.44e-10	Endometrial cancer;
CESC	cis	rs4409675	0.576	rs10794507	chr1:28216072	T/C	cg23691781	chr1:28212827	C1orf38	0.28	5.77	0.33	2.2e-8	Corneal astigmatism;
CESC	cis	rs10504229	1.000	rs66840104	chr8:58190001	C/T	cg05313129	chr8:58192883	C8orf71	-0.55	-6.29	-0.36	1.34e-9	Developmental language disorder (linguistic errors);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg19473056	chr3:41996898	ULK4	0.47	6.17	0.35	2.6e-9	Fibrinogen levels;
CESC	cis	rs11203032	0.831	rs4511206	chr10:90968759	C/T	cg16672925	chr10:90967113	CH25H	0.73	7.09	0.4	1.23e-11	Heart failure;
CESC	cis	rs9733	0.596	rs1336898	chr1:150665050	G/A	cg04414720	chr1:150670196	GOLPH3L	0.63	9.02	0.48	3.87e-17	Tonsillectomy;
CESC	cis	rs11997175	0.625	rs4733171	chr8:33615617	C/G	ch.8.33884649F	chr8:33765107	NA	-0.5	-6.19	-0.36	2.26e-9	Body mass index;
CESC	trans	rs7726839	0.540	rs72703095	chr5:601789	T/C	cg25482853	chr8:67687455	SGK3	1.04	10.09	0.53	1.78e-20	Obesity-related traits;
CESC	cis	rs9649465	1.000	rs6950659	chr7:123361910	C/T	cg04330084	chr7:123175371	IQUB	-0.38	-5.18	-0.3	4.33e-7	Migraine;
CESC	cis	rs17711722	1.000	rs17711722	chr7:65271197	C/T	cg11987759	chr7:65425863	GUSB	0.48	6.51	0.37	3.76e-10	Calcium levels;
CESC	cis	rs4665809	0.590	rs66477033	chr2:26472497	T/C	cg25036284	chr2:26402008	FAM59B	0.86	9.36	0.5	3.44e-18	Gut microbiome composition (summer);
CESC	cis	rs12477438	0.798	rs6705583	chr2:99602625	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.73	-11.02	-0.56	1.73e-23	Chronic sinus infection;
CESC	cis	rs1707322	0.752	rs8179296	chr1:46143791	G/A	cg06784218	chr1:46089804	CCDC17	0.43	7.58	0.42	5.65e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs2727020	0.521	rs7126835	chr11:49594658	T/C	cg03929089	chr4:120376271	NA	-0.73	-8.36	-0.46	3.57e-15	Coronary artery disease;
CESC	cis	rs7666738	0.830	rs6819177	chr4:99040907	T/C	cg03467027	chr4:99064603	C4orf37	0.47	5.98	0.34	7.19e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs736408	0.509	rs1108842	chr3:52720080	A/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.34	-5.07	-0.3	7.32e-7	Bipolar disorder;
CESC	cis	rs4660306	0.961	rs4660871	chr1:45995232	C/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.51	-6.59	-0.38	2.31e-10	Homocysteine levels;
CESC	trans	rs66573146	0.803	rs59742225	chr4:6969942	C/T	cg07817883	chr1:32538562	TMEM39B	1.49	9.04	0.49	3.38e-17	Granulocyte percentage of myeloid white cells;
CESC	cis	rs62064224	0.791	rs2344977	chr17:30720573	C/G	cg24550644	chr17:30846204	MYO1D	-0.37	-5.32	-0.31	2.26e-7	Schizophrenia;
CESC	cis	rs7666738	0.830	rs7698771	chr4:98986479	T/G	cg18180107	chr4:99064573	C4orf37	0.4	5.19	0.3	4.29e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4975616	0.869	rs401681	chr5:1322087	C/T	cg07493874	chr5:1342172	CLPTM1L	-0.39	-7.52	-0.42	8.27e-13	Lung cancer;
CESC	cis	rs2073300	0.609	rs6137913	chr20:23357725	C/T	cg16736954	chr20:23401023	NAPB	0.6	5.16	0.3	4.96e-7	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg12163800	chr17:74475355	RHBDF2	0.44	6.74	0.38	1.01e-10	Fibrinogen levels;
CESC	cis	rs4566357	0.615	rs12328878	chr2:227918962	G/A	cg11843606	chr2:227700838	RHBDD1	-0.54	-7.02	-0.4	1.84e-11	Coronary artery disease;
CESC	cis	rs11098499	1.000	rs1011054	chr4:120202387	A/G	cg09307838	chr4:120376055	NA	-0.87	-11.6	-0.58	1.92e-25	Corneal astigmatism;
CESC	cis	rs9929218	1.000	rs9937664	chr16:68784603	T/C	cg02972257	chr16:68554789	NA	0.53	6.0	0.35	6.54e-9	Colorectal cancer;
CESC	cis	rs4423214	0.879	rs1792284	chr11:71134966	A/G	cg05163923	chr11:71159392	DHCR7	0.66	7.61	0.42	4.68e-13	Vitamin D levels;
CESC	cis	rs910316	1.000	rs10873275	chr14:75531460	A/T	cg11812906	chr14:75593930	NEK9	0.89	14.87	0.67	8.9e-37	Height;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg10808102	chr17:25783956	NA	-0.43	-6.02	-0.35	5.87e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs853679	0.556	rs34588114	chr6:28080628	C/A	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.85	5.58	0.32	6.04e-8	Depression;
CESC	cis	rs16854884	0.586	rs6440212	chr3:143748526	T/C	cg06585982	chr3:143692056	C3orf58	0.51	6.92	0.39	3.46e-11	Economic and political preferences (feminism/equality);
CESC	cis	rs6991838	0.584	rs10092109	chr8:66539918	C/T	cg13398993	chr8:66546079	ARMC1	0.46	5.65	0.33	4.19e-8	Intelligence (multi-trait analysis);
CESC	cis	rs854765	0.616	rs8076747	chr17:17853595	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.65	9.41	0.5	2.47e-18	Total body bone mineral density;
CESC	cis	rs6032067	0.925	rs35751129	chr20:43847658	C/A	cg10761708	chr20:43804764	PI3	0.51	6.04	0.35	5.34e-9	Blood protein levels;
CESC	cis	rs9303401	0.592	rs66583824	chr17:56639853	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.03	12.7	0.62	3.56e-29	Cognitive test performance;
CESC	cis	rs17431357	1.000	rs73225225	chr12:120960474	G/A	cg25045489	chr12:120971538	RNF10	-0.93	-5.46	-0.32	1.1e-7	Insulin resistance/response;
CESC	cis	rs7296418	0.883	rs1727312	chr12:123642220	G/T	cg00376283	chr12:123451042	ABCB9	0.68	9.61	0.51	5.81e-19	Platelet count;
CESC	trans	rs1814175	0.645	rs12364337	chr11:49942580	A/T	cg03929089	chr4:120376271	NA	-0.92	-15.2	-0.68	6e-38	Height;
CESC	cis	rs72627123	0.582	rs62005101	chr14:74500585	A/T	cg05179529	chr14:74551516	LIN52;ALDH6A1	0.56	5.57	0.32	6.34e-8	Morning vs. evening chronotype;
CESC	cis	rs8141529	0.509	rs5762853	chr22:29245231	T/G	cg15103426	chr22:29168792	CCDC117	0.61	7.96	0.44	5.03e-14	Lymphocyte counts;
CESC	cis	rs4594175	0.962	rs7157823	chr14:51633170	C/T	cg23942311	chr14:51606299	NA	0.4	6.11	0.35	3.51e-9	Cancer;
CESC	cis	rs4472734	1.000	rs4655346	chr1:214609127	T/G	cg00063699	chr1:214624242	PTPN14	-0.34	-5.41	-0.32	1.4e-7	Height;
CESC	cis	rs2836974	0.897	rs13339986	chr21:40605982	T/C	cg11644478	chr21:40555479	PSMG1	0.99	14.27	0.66	1.18e-34	Cognitive function;
CESC	cis	rs3096299	0.582	rs12935119	chr16:89542874	A/T	cg02187348	chr16:89574699	SPG7	0.53	7.14	0.4	9.2e-12	Multiple myeloma (IgH translocation);
CESC	cis	rs9894429	0.646	rs7220310	chr17:79606056	C/A	cg13777783	chr17:79615861	NA	-0.36	-6.12	-0.35	3.32e-9	Eye color traits;
CESC	cis	rs11098499	0.754	rs12506610	chr4:120241659	T/C	cg09307838	chr4:120376055	NA	0.79	10.62	0.55	3.51e-22	Corneal astigmatism;
CESC	cis	rs4819052	0.959	rs9976074	chr21:46655638	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.82	9.91	0.52	6.87e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs6964587	1.000	rs10243241	chr7:91705696	A/G	cg17063962	chr7:91808500	NA	0.59	8.09	0.45	2.1e-14	Breast cancer;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg19227446	chr19:48247023	NA	-0.46	-6.04	-0.35	5.26e-9	Fibrinogen levels;
CESC	cis	rs6493487	0.512	rs17599863	chr15:51219962	G/A	cg02338191	chr15:51200825	AP4E1	0.6	5.43	0.32	1.26e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs11098499	0.863	rs1010740	chr4:120463409	C/T	cg24375607	chr4:120327624	NA	-0.45	-5.41	-0.32	1.39e-7	Corneal astigmatism;
CESC	cis	rs12530845	0.623	rs73721664	chr7:135343575	A/C	cg23117316	chr7:135346802	PL-5283	-0.59	-6.54	-0.37	3.15e-10	Red blood cell traits;
CESC	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.45	5.48	0.32	9.97e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7845219	0.544	rs9643351	chr8:95917290	C/T	cg09323728	chr8:95962352	TP53INP1	-0.33	-6.35	-0.36	9.17e-10	Type 2 diabetes;
CESC	cis	rs270601	0.690	rs162904	chr5:131595784	C/T	cg18301423	chr5:131593218	PDLIM4	-0.39	-5.28	-0.31	2.67e-7	Acylcarnitine levels;
CESC	cis	rs9649213	0.593	rs1859482	chr7:97983774	C/T	cg21770322	chr7:97807741	LMTK2	0.57	8.84	0.48	1.39e-16	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs116095464	0.558	rs55833259	chr5:286728	G/A	cg22857025	chr5:266934	NA	-1.32	-14.16	-0.66	2.9e-34	Breast cancer;
CESC	cis	rs9399137	0.507	rs12663447	chr6:135317026	A/C	cg24558204	chr6:135376177	HBS1L	0.72	10.08	0.53	1.92e-20	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	cis	rs12618769	0.597	rs55978998	chr2:99049014	A/G	cg10123293	chr2:99228465	UNC50	0.41	5.42	0.32	1.31e-7	Bipolar disorder;
CESC	cis	rs5769765	0.908	rs2319464	chr22:50265777	A/G	cg26441486	chr22:50317300	CRELD2	-0.39	-5.5	-0.32	9.11e-8	Schizophrenia;
CESC	cis	rs4849845	0.637	rs4077564	chr2:121004241	C/T	cg24070213	chr2:121070622	NA	0.43	6.21	0.36	1.98e-9	Mean platelet volume;
CESC	cis	rs9291683	0.526	rs6827785	chr4:10018205	C/T	cg02734326	chr4:10020555	SLC2A9	0.42	5.76	0.33	2.3e-8	Bone mineral density;
CESC	cis	rs7666738	0.515	rs13142498	chr4:98792443	G/T	cg17366294	chr4:99064904	C4orf37	0.5	6.19	0.36	2.34e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2836950	0.501	rs4818018	chr21:40694072	C/T	cg11644478	chr21:40555479	PSMG1	-0.55	-7.42	-0.41	1.55e-12	Menarche (age at onset);
CESC	cis	rs832540	0.695	rs702686	chr5:56201350	A/G	cg14703610	chr5:56206110	C5orf35	0.4	5.05	0.3	8.23e-7	Coronary artery disease;
CESC	cis	rs6679073	1.000	rs10494874	chr1:205754688	C/G	cg11965913	chr1:205819406	PM20D1	0.44	6.18	0.35	2.43e-9	Prostate-specific antigen levels;
CESC	cis	rs11190604	1.000	rs2495751	chr10:102327260	A/G	cg07080220	chr10:102295463	HIF1AN	0.58	5.48	0.32	9.69e-8	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs7089973	0.872	rs7072364	chr10:116620840	G/A	cg23260525	chr10:116636907	FAM160B1	0.38	6.35	0.36	9.27e-10	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16102063	chr8:22298240	PPP3CC	0.53	6.37	0.36	8.43e-10	Gut microbiome composition (summer);
CESC	cis	rs17376456	0.825	rs10476590	chr5:93244884	A/T	cg25358565	chr5:93447407	FAM172A	1.13	10.1	0.53	1.69e-20	Diabetic retinopathy;
CESC	cis	rs9549328	0.800	rs9549619	chr13:113632620	C/G	cg16421871	chr13:113634978	MCF2L	-0.35	-5.05	-0.3	8.26e-7	Systolic blood pressure;
CESC	cis	rs9894429	0.646	rs6565612	chr17:79602820	C/T	cg21984481	chr17:79567631	NPLOC4	0.34	5.22	0.31	3.67e-7	Eye color traits;
CESC	trans	rs208520	0.874	rs208517	chr6:66947040	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.86	-9.95	-0.52	5.07e-20	Exhaled nitric oxide output;
CESC	cis	rs12137294	0.866	rs1172140	chr1:205213024	G/A	cg21643547	chr1:205240462	TMCC2	-0.34	-5.46	-0.32	1.11e-7	Red cell distribution width;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg01002995	chr12:8185077	FOXJ2	-0.47	-6.32	-0.36	1.13e-9	Fibrinogen levels;
CESC	cis	rs1559088	0.847	rs8110181	chr19:33605939	G/A	cg27124370	chr19:33622961	WDR88	0.42	5.49	0.32	9.52e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs9322193	0.923	rs9766886	chr6:149958184	T/C	cg13206674	chr6:150067644	NUP43	0.43	6.18	0.35	2.39e-9	Lung cancer;
CESC	cis	rs2836974	0.897	rs2836933	chr21:40564202	C/G	cg11644478	chr21:40555479	PSMG1	1.03	16.67	0.72	3.67e-43	Cognitive function;
CESC	cis	rs9487051	0.872	rs9487038	chr6:109610152	T/C	cg12927641	chr6:109611667	NA	-0.43	-6.7	-0.38	1.22e-10	Reticulocyte fraction of red cells;
CESC	cis	rs1878931	0.507	rs1218762	chr16:3405986	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.7	-8.77	-0.47	2.28e-16	Body mass index (adult);
CESC	cis	rs11030122	0.661	rs12290747	chr11:3939650	T/C	cg18678763	chr11:4115507	RRM1	-0.44	-5.84	-0.34	1.54e-8	Mean platelet volume;Platelet distribution width;
CESC	cis	rs7432375	0.610	rs4420814	chr3:136513282	T/C	cg15507776	chr3:136538369	TMEM22	0.6	7.81	0.43	1.32e-13	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
CESC	cis	rs2952156	0.883	rs907089	chr17:37833600	C/T	cg20243544	chr17:37824526	PNMT	0.6	7.8	0.43	1.39e-13	Asthma;
CESC	cis	rs853679	0.517	rs9368553	chr6:28082265	T/C	cg23161317	chr6:28129485	ZNF389	0.51	6.53	0.37	3.44e-10	Depression;
CESC	cis	rs2710642	0.721	rs6545969	chr2:62891474	C/T	cg17519650	chr2:63277830	OTX1	-0.56	-6.88	-0.39	4.38e-11	LDL cholesterol levels;LDL cholesterol;
CESC	cis	rs1577917	0.958	rs1591437	chr6:86525305	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-6.28	-0.36	1.4e-9	Response to antipsychotic treatment;
CESC	cis	rs72781680	0.611	rs7596060	chr2:24334361	A/G	cg20701182	chr2:24300061	SF3B14	-0.9	-10.4	-0.54	1.85e-21	Lymphocyte counts;
CESC	cis	rs72781680	1.000	rs72798408	chr2:24181845	G/C	cg20701182	chr2:24300061	SF3B14	0.79	6.83	0.39	5.75e-11	Lymphocyte counts;
CESC	cis	rs2836974	0.897	rs2836973	chr21:40654928	A/G	cg11644478	chr21:40555479	PSMG1	1.08	17.93	0.74	1.24e-47	Cognitive function;
CESC	cis	rs7811142	1.000	rs60844404	chr7:100080474	A/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.13	13.1	0.63	1.4e-30	Platelet count;
CESC	cis	rs1348850	0.526	rs4893829	chr2:178399810	A/G	cg23306229	chr2:178417860	TTC30B	-0.78	-7.32	-0.41	2.88e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs6860806	0.661	rs3763112	chr5:131586480	A/G	cg18301423	chr5:131593218	PDLIM4	0.39	5.48	0.32	1.01e-7	Breast cancer;
CESC	cis	rs3096299	0.748	rs2965822	chr16:89444677	A/T	cg08392591	chr16:89556376	ANKRD11	0.43	5.42	0.32	1.34e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs9443645	0.803	rs1547731	chr6:79776104	A/G	cg05283184	chr6:79620031	NA	-0.44	-6.8	-0.39	6.74e-11	Intelligence (multi-trait analysis);
CESC	cis	rs36051895	0.623	rs2146041	chr9:5262911	A/G	cg02405213	chr9:5042618	JAK2	-0.52	-6.39	-0.37	7.54e-10	Pediatric autoimmune diseases;
CESC	cis	rs780096	0.506	rs2303369	chr2:27715416	C/T	cg12648201	chr2:27665141	KRTCAP3	-0.31	-5.65	-0.33	4.22e-8	Total body bone mineral density;
CESC	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg24846343	chr22:24311635	DDTL	0.63	10.71	0.55	1.71e-22	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs1874326	0.545	rs4626544	chr7:138110301	C/G	cg18008034	chr7:138118925	NA	-0.41	-5.14	-0.3	5.34e-7	Quantitative traits;
CESC	cis	rs34779708	0.733	rs12243593	chr10:35549045	C/T	cg03585969	chr10:35415529	CREM	0.55	6.37	0.36	8.28e-10	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs611744	0.647	rs579162	chr8:109254842	A/G	cg21045802	chr8:109455806	TTC35	0.49	6.06	0.35	4.71e-9	Dupuytren's disease;
CESC	cis	rs898097	0.812	rs56405605	chr17:80843663	T/C	cg15664640	chr17:80829946	TBCD	-0.64	-9.06	-0.49	2.98e-17	Breast cancer;
CESC	cis	rs6570726	0.791	rs440477	chr6:145854188	C/T	cg05347473	chr6:146136440	FBXO30	0.57	7.3	0.41	3.36e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2836974	0.932	rs6517523	chr21:40557332	T/C	cg11890956	chr21:40555474	PSMG1	1.16	21.87	0.8	2.81e-61	Cognitive function;
CESC	cis	rs13382862	0.862	rs340595	chr2:20889714	A/G	cg05481257	chr2:20870211	GDF7	-0.37	-5.62	-0.33	4.72e-8	Abdominal aortic aneurysm;
CESC	cis	rs780096	0.587	rs10205219	chr2:27568565	T/C	cg02592271	chr2:27665507	KRTCAP3	-0.3	-6.24	-0.36	1.77e-9	Total body bone mineral density;
CESC	cis	rs9630089	0.521	rs4917761	chr10:98967236	C/T	cg25902810	chr10:99078978	FRAT1	0.5	6.59	0.38	2.42e-10	Neutrophil percentage of white cells;
CESC	cis	rs1448094	0.556	rs11614513	chr12:86167756	G/C	cg00310523	chr12:86230176	RASSF9	0.41	6.23	0.36	1.85e-9	Major depressive disorder;
CESC	cis	rs1267303	0.682	rs1998545	chr1:46954587	C/T	cg25110126	chr1:46999211	NA	0.49	5.59	0.32	5.63e-8	Monobrow;
CESC	cis	rs3008870	1.000	rs3008848	chr1:67379284	C/T	cg08660285	chr1:67390436	MIER1;WDR78	1.05	14.57	0.67	9.8e-36	Lymphocyte percentage of white cells;
CESC	cis	rs965469	1.000	rs965469	chr20:3381549	T/C	cg25506879	chr20:3388711	C20orf194	-0.57	-6.1	-0.35	3.75e-9	IFN-related cytopenia;
CESC	cis	rs67311347	1.000	rs1047855	chr3:40468896	A/G	cg09455208	chr3:40491958	NA	-0.5	-8.09	-0.45	2.09e-14	Renal cell carcinoma;
CESC	cis	rs12188164	0.965	rs11743639	chr5:450710	C/T	cg26850624	chr5:429559	AHRR	-0.5	-6.67	-0.38	1.52e-10	Cystic fibrosis severity;
CESC	cis	rs262150	0.819	rs6956589	chr7:158769301	C/T	cg09640425	chr7:158790006	NA	-0.35	-5.34	-0.31	1.98e-7	Facial morphology (factor 20);
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg17589437	chr7:87563717	ADAM22	0.45	6.3	0.36	1.24e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg06335301	chr2:27593335	EIF2B4;SNX17	-0.49	-6.19	-0.36	2.22e-9	Ulcerative colitis;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg25085038	chr20:3897636	PANK2;MIR103-2	0.41	6.46	0.37	5e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs9308731	0.583	rs4848406	chr2:111933758	G/A	cg04202892	chr2:111875749	ACOXL	0.44	6.01	0.35	6.08e-9	Chronic lymphocytic leukemia;
CESC	cis	rs3820068	0.581	rs6429762	chr1:15945595	A/C	cg17385448	chr1:15911702	AGMAT	0.42	6.98	0.39	2.3e-11	Systolic blood pressure;
CESC	cis	rs2228479	0.850	rs2283565	chr16:89827556	G/T	cg00800038	chr16:89945340	TCF25	-0.92	-7.62	-0.42	4.38e-13	Skin colour saturation;
CESC	cis	rs644799	0.710	rs522536	chr11:95528714	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.76	10.93	0.56	3.47e-23	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs853679	0.517	rs9348796	chr6:28126202	A/G	cg26335602	chr6:28129616	ZNF389	0.52	6.81	0.39	6.59e-11	Depression;
CESC	cis	rs2842992	0.789	rs7765490	chr6:160204326	C/T	cg11366901	chr6:160182831	ACAT2	0.75	9.02	0.48	3.9e-17	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs1707322	1.000	rs4460583	chr1:46449918	C/G	cg05343316	chr1:45956843	TESK2	0.44	5.42	0.32	1.36e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs10504229	0.638	rs7826839	chr8:58132075	G/T	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs60871478	0.786	rs62432898	chr7:826102	G/A	cg05535760	chr7:792225	HEATR2	0.96	11.11	0.56	8.35e-24	Cerebrospinal P-tau181p levels;
CESC	cis	rs9796	0.717	rs476633	chr15:41392134	C/G	cg12426344	chr15:41135900	SPINT1	-0.23	-5.1	-0.3	6.58e-7	Menopause (age at onset);
CESC	cis	rs611744	0.647	rs2848620	chr8:109249551	G/T	cg21045802	chr8:109455806	TTC35	0.46	5.67	0.33	3.65e-8	Dupuytren's disease;
CESC	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg03188948	chr7:1209495	NA	0.72	6.98	0.39	2.42e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs9325144	0.534	rs1843866	chr12:38703160	G/T	cg23762105	chr12:34175262	ALG10	-0.46	-6.24	-0.36	1.71e-9	Morning vs. evening chronotype;
CESC	cis	rs10504229	0.593	rs74760806	chr8:58024785	C/T	cg24829409	chr8:58192753	C8orf71	-0.5	-6.08	-0.35	4.13e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs11920090	0.789	rs6785233	chr3:170756985	A/C	cg09710316	chr3:170744871	SLC2A2	0.44	5.17	0.3	4.7e-7	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
CESC	cis	rs959260	1.000	rs4789180	chr17:73374396	G/T	cg12999837	chr17:73267436	MIF4GD	-0.51	-5.8	-0.34	1.91e-8	Systemic lupus erythematosus;
CESC	cis	rs561341	1.000	rs55978022	chr17:30275937	T/C	cg19193384	chr17:30244184	NA	-0.73	-6.87	-0.39	4.66e-11	Hip circumference adjusted for BMI;
CESC	trans	rs35110281	0.776	rs229357	chr21:44982717	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.59	7.93	0.44	6.34e-14	Mean corpuscular volume;
CESC	cis	rs13106227	0.602	rs9996922	chr4:77437749	G/A	cg20311846	chr4:77356250	SHROOM3	-0.28	-5.2	-0.3	4.02e-7	Eosinophilic esophagitis (pediatric);
CESC	cis	rs7605827	0.897	rs7586068	chr2:15596747	T/A	cg19274914	chr2:15703543	NA	0.32	5.69	0.33	3.38e-8	Educational attainment (years of education);
CESC	cis	rs9818941	0.826	rs2673547	chr3:157646627	A/G	cg08654915	chr3:157813417	NA	0.46	7.55	0.42	6.94e-13	Height;
CESC	cis	rs8077889	0.956	rs4793025	chr17:41841621	T/C	cg26893861	chr17:41843967	DUSP3	0.86	9.73	0.51	2.48e-19	Triglycerides;
CESC	cis	rs4924935	1.000	rs4924935	chr17:18753870	C/T	cg26378065	chr17:18585709	ZNF286B	0.46	5.85	0.34	1.43e-8	Pancreatic cancer;
CESC	cis	rs28374715	0.681	rs7165396	chr15:41586947	T/C	cg18705301	chr15:41695430	NDUFAF1	-1.0	-14.54	-0.67	1.34e-35	Ulcerative colitis;
CESC	cis	rs11792861	0.816	rs3763643	chr9:111695607	T/C	cg05043794	chr9:111880884	C9orf5	-0.37	-6.09	-0.35	3.98e-9	Menarche (age at onset);
CESC	cis	rs35306767	0.951	rs55742421	chr10:961037	A/C	cg20503657	chr10:835505	NA	0.9	9.27	0.49	6.58e-18	Eosinophil percentage of granulocytes;
CESC	cis	rs2635047	0.811	rs10502880	chr18:44770746	T/C	cg24371990	chr18:44770781	NA	0.43	6.98	0.39	2.42e-11	Educational attainment;
CESC	cis	rs4819052	1.000	rs2838830	chr21:46664227	T/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.57	6.85	0.39	5.23e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03437924	chr16:25123326	LCMT1	0.69	8.2	0.45	1.05e-14	Gut microbiome composition (summer);
CESC	cis	rs1552244	0.810	rs6809572	chr3:10100145	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-10.19	-0.53	8.64e-21	Alzheimer's disease;
CESC	cis	rs12477438	0.501	rs13033012	chr2:99795149	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.75	12.51	0.61	1.6e-28	Chronic sinus infection;
CESC	cis	rs8114671	0.836	rs17404569	chr20:33674077	A/C	cg06115741	chr20:33292138	TP53INP2	-0.44	-5.31	-0.31	2.27e-7	Height;
CESC	cis	rs4243830	0.850	rs1064835	chr1:6585539	A/G	cg04093404	chr1:6614507	TAS1R1;NOL9	-0.56	-5.22	-0.31	3.57e-7	Body mass index;
CESC	cis	rs2573652	0.722	rs12904962	chr15:100544113	A/G	cg00587665	chr15:100533223	ADAMTS17	0.46	7.46	0.42	1.24e-12	Height;
CESC	cis	rs514406	0.861	rs6588443	chr1:53250650	G/A	cg16325326	chr1:53192061	ZYG11B	-0.88	-14.93	-0.68	5.58e-37	Monocyte count;
CESC	cis	rs798554	0.679	rs1636253	chr7:2885123	A/G	cg18446336	chr7:2847575	GNA12	-0.35	-5.56	-0.32	6.7e-8	Height;
CESC	cis	rs2070433	0.904	rs11701571	chr21:47963149	A/G	cg12379764	chr21:47803548	PCNT	0.49	5.8	0.34	1.88e-8	Lymphocyte counts;
CESC	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg04025307	chr7:1156635	C7orf50	0.57	9.94	0.52	5.44e-20	Longevity;Endometriosis;
CESC	cis	rs8067354	0.645	rs2271304	chr17:57814641	A/G	cg02344993	chr17:57696989	CLTC	0.57	5.97	0.34	7.53e-9	Hemoglobin concentration;
CESC	cis	rs116095464	0.558	rs10059907	chr5:205360	G/C	cg22857025	chr5:266934	NA	-1.28	-14.21	-0.66	1.88e-34	Breast cancer;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg19006050	chr10:131904236	NA	-0.5	-6.86	-0.39	4.96e-11	Systemic lupus erythematosus;
CESC	cis	rs8049040	0.547	rs12934168	chr16:71436778	C/T	cg08717414	chr16:71523259	ZNF19	-0.62	-6.81	-0.39	6.39e-11	Blood protein levels;
CESC	cis	rs7666738	0.830	rs12233741	chr4:98950296	C/T	cg03676636	chr4:99064102	C4orf37	0.33	5.09	0.3	6.71e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs853679	0.550	rs1150689	chr6:28165099	T/C	cg22143856	chr6:28129313	ZNF389	0.43	5.75	0.33	2.42e-8	Depression;
CESC	cis	rs36051895	0.632	rs12337480	chr9:5134567	T/A	cg02405213	chr9:5042618	JAK2	-0.47	-5.85	-0.34	1.42e-8	Pediatric autoimmune diseases;
CESC	cis	rs2235642	0.928	rs56289115	chr16:1608934	A/G	cg08296037	chr16:1584118	IFT140;TMEM204	-0.32	-5.22	-0.31	3.65e-7	Coronary artery disease;
CESC	cis	rs3740540	0.530	rs2362503	chr10:126290538	T/C	cg04949429	chr10:126290192	LHPP	0.39	5.48	0.32	9.85e-8	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
CESC	cis	rs28489187	0.558	rs12044537	chr1:85846385	T/A	cg16011679	chr1:85725395	C1orf52	0.44	5.28	0.31	2.69e-7	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	cis	rs7811142	1.000	rs73161762	chr7:100014846	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.07	9.41	0.5	2.44e-18	Platelet count;
CESC	cis	rs11608355	0.545	rs7315846	chr12:109908617	T/C	cg05360138	chr12:110035743	NA	0.81	8.75	0.47	2.52e-16	Neuroticism;
CESC	cis	rs12464559	0.649	rs3922996	chr2:152609668	A/G	cg01189475	chr2:152685088	ARL5A	0.66	5.57	0.32	6.29e-8	Response to cognitive-behavioural therapy in anxiety disorder;
CESC	cis	rs9354308	0.933	rs2802064	chr6:66564352	C/T	cg07460842	chr6:66804631	NA	0.67	7.56	0.42	6.71e-13	Metabolite levels;
CESC	cis	rs514406	0.560	rs1889033	chr1:53211887	A/G	cg24675658	chr1:53192096	ZYG11B	0.6	7.55	0.42	7.08e-13	Monocyte count;
CESC	cis	rs9443645	0.901	rs2174739	chr6:79659170	C/T	cg05283184	chr6:79620031	NA	0.36	5.48	0.32	9.88e-8	Intelligence (multi-trait analysis);
CESC	cis	rs11785693	0.862	rs11786657	chr8:5001792	T/C	cg26367366	chr8:4980734	NA	0.79	7.56	0.42	6.43e-13	Neuroticism (multi-trait analysis);Neuroticism;
CESC	cis	rs7264396	0.563	rs2425084	chr20:34301871	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.85	-10.76	-0.55	1.24e-22	Total cholesterol levels;
CESC	cis	rs6570726	0.902	rs396681	chr6:145853603	T/C	cg23711669	chr6:146136114	FBXO30	0.79	11.44	0.57	6.96e-25	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1552244	0.872	rs35988239	chr3:10074145	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.88	10.07	0.53	2.09e-20	Alzheimer's disease;
CESC	cis	rs6456156	0.792	rs4710183	chr6:167514083	A/G	cg23791538	chr6:167370224	RNASET2	0.42	5.52	0.32	8.27e-8	Primary biliary cholangitis;
CESC	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg07167872	chr1:205819463	PM20D1	0.76	12.12	0.6	3.34e-27	Menarche (age at onset);
CESC	cis	rs60515486	0.702	rs11827106	chr11:47402615	G/A	cg25783544	chr11:47291846	MADD	0.55	5.22	0.31	3.68e-7	Lymphocyte counts;
CESC	cis	rs9322193	0.961	rs2064520	chr6:149924786	A/T	cg07701084	chr6:150067640	NUP43	0.41	5.83	0.34	1.57e-8	Lung cancer;
CESC	cis	rs60843830	0.508	rs300750	chr2:208794	T/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.54	7.08	0.4	1.29e-11	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs55794721	0.509	rs6699896	chr1:25762902	A/T	cg27572855	chr1:25598939	RHD	0.5	8.54	0.46	1.06e-15	Plateletcrit;Mean corpuscular volume;
CESC	trans	rs73201076	0.915	rs7782005	chr7:111029564	C/T	cg02312559	chr3:133973256	NA	0.52	6.02	0.35	5.69e-9	Schizophrenia;
CESC	cis	rs5753618	0.504	rs9606846	chr22:31897571	C/T	cg00478049	chr22:31556069	RNF185	-0.44	-5.17	-0.3	4.68e-7	Colorectal cancer;
CESC	cis	rs7845219	0.544	rs4735332	chr8:95923660	C/T	cg13393036	chr8:95962371	TP53INP1	-0.43	-8.22	-0.45	9.34e-15	Type 2 diabetes;
CESC	cis	rs7833790	0.724	rs4739627	chr8:82734657	A/G	cg02079420	chr8:82753780	SNX16	0.54	8.28	0.45	6.23e-15	Diastolic blood pressure;
CESC	cis	rs1348850	0.632	rs12616288	chr2:178503813	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.58	7.43	0.42	1.54e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09754991	chr13:107220236	ARGLU1	-0.55	-6.34	-0.36	9.84e-10	Gut microbiome composition (summer);
CESC	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.44	0.37	5.54e-10	Prudent dietary pattern;
CESC	cis	rs2708240	0.666	rs2710121	chr7:147608448	C/T	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.31	-5.13	-0.3	5.69e-7	QT interval (drug interaction);
CESC	cis	rs2731664	0.792	rs466256	chr5:176875956	C/A	cg23176889	chr5:176863531	GRK6	-0.63	-10.96	-0.56	2.69e-23	Intelligence (multi-trait analysis);
CESC	cis	rs9300255	0.569	rs1716170	chr12:123716513	C/T	cg19016782	chr12:123741754	C12orf65	-0.5	-7.1	-0.4	1.18e-11	Neutrophil percentage of white cells;
CESC	trans	rs650950	0.528	rs646660	chr11:35528452	C/T	cg16538604	chr4:2010703	WHSC2	0.46	6.2	0.36	2.11e-9	Bronchopulmonary dysplasia;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05843257	chr22:24951377	SNRPD3;C22orf13	-0.48	-6.53	-0.37	3.26e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs9303280	0.868	rs11650661	chr17:38026286	A/T	cg19468946	chr17:37922297	IKZF3	-0.43	-5.85	-0.34	1.48e-8	Self-reported allergy;
CESC	cis	rs763121	0.853	rs2072794	chr22:39150543	G/T	cg14440974	chr22:39074834	NA	-0.4	-5.38	-0.31	1.62e-7	Menopause (age at onset);
CESC	cis	rs7208859	0.673	rs73263981	chr17:28920502	A/G	cg19761014	chr17:28927070	LRRC37B2	0.79	7.21	0.4	6.02e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg14022721	chr22:25507536	KIAA1671	0.47	6.0	0.35	6.42e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs3806843	1.000	rs3733708	chr5:140181734	A/G	cg26395211	chr5:140044315	WDR55	-0.42	-5.35	-0.31	1.9e-7	Depressive symptoms (multi-trait analysis);
CESC	trans	rs1814175	0.935	rs11040462	chr11:49683158	G/A	cg15704280	chr7:45808275	SEPT13	-0.99	-17.45	-0.73	6.22e-46	Height;
CESC	cis	rs780096	0.526	rs2010087	chr2:27637235	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.3	-5.54	-0.32	7.22e-8	Total body bone mineral density;
CESC	cis	rs3820068	0.705	rs4646083	chr1:15825564	G/A	cg18192808	chr1:15853278	DNAJC16	0.47	5.66	0.33	3.93e-8	Systolic blood pressure;
CESC	cis	rs6582630	0.622	rs11182004	chr12:38441254	G/A	cg26384229	chr12:38710491	ALG10B	-0.44	-5.95	-0.34	8.28e-9	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs636291	0.517	rs55935829	chr1:10540926	A/T	cg20482658	chr1:10539492	PEX14	-0.28	-5.88	-0.34	1.26e-8	Prostate cancer;
CESC	cis	rs372883	0.638	rs117213	chr21:30720536	G/A	cg08807101	chr21:30365312	RNF160	-0.45	-5.18	-0.3	4.41e-7	Pancreatic cancer;
CESC	cis	rs6449957	0.639	rs251397	chr5:67508511	A/G	cg23036683	chr5:67512108	NA	0.42	5.65	0.33	4.21e-8	Cleft lip with or without cleft palate;
CESC	cis	rs9291683	0.530	rs35908990	chr4:9976105	G/A	cg11266682	chr4:10021025	SLC2A9	0.61	12.55	0.61	1.12e-28	Bone mineral density;
CESC	cis	rs965513	1.000	rs1588635	chr9:100537802	A/C	cg13688889	chr9:100608707	NA	-0.55	-7.58	-0.42	5.9e-13	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
CESC	trans	rs4716602	0.609	rs12386633	chr7:156158232	G/C	cg07175507	chr18:77160758	NFATC1	-0.45	-6.14	-0.35	3e-9	Anti-saccade response;
CESC	cis	rs4595586	0.545	rs12810822	chr12:39391807	T/A	cg26384229	chr12:38710491	ALG10B	0.54	7.64	0.42	3.96e-13	Morning vs. evening chronotype;
CESC	cis	rs9549367	0.789	rs912012	chr13:113886152	G/A	cg00898013	chr13:113819073	PROZ	-0.52	-7.24	-0.41	4.75e-12	Platelet distribution width;
CESC	cis	rs290986	0.812	rs290258	chr9:93555739	A/G	cg02608019	chr9:93564028	SYK	0.52	5.65	0.33	4.09e-8	Multiple sclerosis;
CESC	trans	rs7752903	0.793	rs2230926	chr6:138196066	T/G	cg02519892	chr21:43198586	NA	0.77	6.35	0.36	9.56e-10	Rheumatoid arthritis;
CESC	cis	rs1218582	0.804	rs4845678	chr1:154853295	A/G	cg06221963	chr1:154839813	KCNN3	-0.62	-10.54	-0.54	6.47e-22	Prostate cancer;
CESC	cis	rs3761218	1.000	rs4815603	chr20:3772527	A/T	cg25011176	chr20:3776985	CDC25B	-0.45	-5.71	-0.33	3.03e-8	Bipolar disorder;
CESC	cis	rs796364	1.000	rs281763	chr2:200794870	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.9	9.29	0.5	5.66e-18	Schizophrenia;
CESC	cis	rs1580019	0.587	rs10951338	chr7:32560089	A/G	cg06627557	chr7:32535165	LSM5;AVL9	1.06	19.17	0.76	5.81e-52	Cognitive ability;
CESC	trans	rs7726839	0.794	rs10053310	chr5:595661	C/G	cg25482853	chr8:67687455	SGK3	0.62	6.37	0.36	8.09e-10	Obesity-related traits;
CESC	cis	rs2072499	0.833	rs2251636	chr1:156202809	G/C	cg25208724	chr1:156163844	SLC25A44	0.88	14.86	0.67	9.92e-37	Testicular germ cell tumor;
CESC	cis	rs67311347	1.000	rs9860162	chr3:40403875	C/T	cg09455208	chr3:40491958	NA	0.52	8.86	0.48	1.19e-16	Renal cell carcinoma;
CESC	cis	rs1030268	0.651	rs13222377	chr7:133466346	C/T	cg10665199	chr7:133106180	EXOC4	0.56	5.89	0.34	1.14e-8	Intelligence (multi-trait analysis);
CESC	cis	rs6089829	0.962	rs1060490	chr20:61665871	A/G	cg08564027	chr20:61660810	NA	0.9	15.37	0.69	1.54e-38	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs10832963	1.000	rs10128711	chr11:18632984	A/G	cg09201001	chr11:18656081	SPTY2D1	0.81	12.28	0.6	9.56e-28	Breast cancer;
CESC	cis	rs9815354	0.537	rs73073272	chr3:42022446	G/A	cg03022575	chr3:42003672	ULK4	0.75	6.64	0.38	1.72e-10	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs12971120	0.891	rs3794955	chr18:72174827	C/T	cg26446133	chr18:72167187	CNDP2	-0.77	-9.6	-0.51	6.53e-19	Refractive error;
CESC	cis	rs58688157	0.705	rs936469	chr11:606749	G/A	cg02461776	chr11:598696	PHRF1	0.49	5.54	0.32	7.46e-8	Systemic lupus erythematosus;
CESC	cis	rs9322193	0.923	rs10872644	chr6:150062955	T/C	cg04369109	chr6:150039330	LATS1	-0.42	-5.86	-0.34	1.34e-8	Lung cancer;
CESC	cis	rs10838687	1.000	rs6485751	chr11:47336442	G/C	cg25783544	chr11:47291846	MADD	0.59	7.37	0.41	2.23e-12	Proinsulin levels;
CESC	cis	rs9300255	0.602	rs1402274	chr12:123686224	T/C	cg00376283	chr12:123451042	ABCB9	0.71	8.92	0.48	7.69e-17	Neutrophil percentage of white cells;
CESC	cis	rs736408	0.546	rs3733046	chr3:52621627	C/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	5.88	0.34	1.2e-8	Bipolar disorder;
CESC	cis	rs11711311	1.000	rs28394480	chr3:113485143	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.73	10.31	0.54	3.51e-21	IgG glycosylation;
CESC	cis	rs7202877	0.706	rs4888393	chr16:75413673	C/T	cg04384234	chr16:75411784	CFDP1	-0.49	-5.89	-0.34	1.16e-8	Type 2 diabetes;Type 1 diabetes;
CESC	cis	rs7959452	0.527	rs4761157	chr12:69780907	A/G	cg22834771	chr12:69754056	YEATS4	-0.48	-6.46	-0.37	4.87e-10	Blood protein levels;
CESC	cis	rs61931739	0.500	rs56056630	chr12:34543465	T/C	cg06521331	chr12:34319734	NA	-0.36	-5.03	-0.3	9.01e-7	Morning vs. evening chronotype;
CESC	cis	rs1059312	0.772	rs11609637	chr12:129300202	T/G	cg09035930	chr12:129282057	SLC15A4	0.68	9.0	0.48	4.39e-17	Systemic lupus erythematosus;
CESC	cis	rs1018836	0.770	rs13266461	chr8:91652817	T/C	cg16814680	chr8:91681699	NA	-0.85	-12.78	-0.62	1.85e-29	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs10504229	0.638	rs6981055	chr8:58113941	T/C	cg24829409	chr8:58192753	C8orf71	-0.59	-7.32	-0.41	2.94e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs911555	0.723	rs11160751	chr14:103925740	T/C	cg12935359	chr14:103987150	CKB	-0.6	-8.57	-0.47	8.78e-16	Intelligence (multi-trait analysis);
CESC	cis	rs3780486	0.846	rs10116966	chr9:33122370	T/A	cg13443165	chr9:33130375	B4GALT1	0.44	6.45	0.37	5.18e-10	IgG glycosylation;
CESC	cis	rs9611565	0.659	rs116959331	chr22:41932774	A/G	cg03806693	chr22:41940476	POLR3H	-1.25	-17.05	-0.72	1.64e-44	Vitiligo;
CESC	trans	rs10242455	0.850	rs57367781	chr7:99116819	G/A	cg09045935	chr12:6379348	NA	0.91	7.48	0.42	1.07e-12	Blood metabolite levels;
CESC	cis	rs7264396	0.690	rs2425178	chr20:34446395	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.62	7.36	0.41	2.25e-12	Total cholesterol levels;
CESC	cis	rs9894429	1.000	rs9748176	chr17:79584043	C/G	cg21984481	chr17:79567631	NPLOC4	-0.49	-8.01	-0.44	3.72e-14	Eye color traits;
CESC	cis	rs2108622	0.727	rs12610189	chr19:15978641	T/G	cg13772218	chr19:15982569	NA	0.29	5.69	0.33	3.28e-8	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CESC	cis	rs2380220	0.808	rs2613548	chr6:95910559	C/T	cg15832292	chr6:96025679	MANEA	-0.65	-5.95	-0.34	8.46e-9	Behavioural disinhibition (generation interaction);
CESC	cis	rs4713118	0.662	rs149946	chr6:27970031	A/C	cg18032046	chr6:28092343	ZSCAN16	0.6	6.89	0.39	4.02e-11	Parkinson's disease;
CESC	cis	rs9300255	0.537	rs1790101	chr12:123704844	T/C	cg19016782	chr12:123741754	C12orf65	-0.45	-6.55	-0.37	2.97e-10	Neutrophil percentage of white cells;
CESC	trans	rs5756813	0.754	rs4821711	chr22:38181115	C/T	cg19894588	chr14:64061835	NA	-0.65	-8.27	-0.45	6.52e-15	Optic cup area;Vertical cup-disc ratio;
CESC	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg18110333	chr6:292329	DUSP22	0.75	10.08	0.53	1.99e-20	Menopause (age at onset);
CESC	cis	rs239198	0.602	rs9377236	chr6:101289960	A/G	cg09795085	chr6:101329169	ASCC3	0.41	5.08	0.3	7.23e-7	Menarche (age at onset);
CESC	cis	rs9488822	0.596	rs6568921	chr6:116373616	C/T	cg15226275	chr6:116381976	FRK	0.23	5.6	0.33	5.22e-8	Cholesterol, total;LDL cholesterol;
CESC	cis	rs7640424	0.680	rs68147515	chr3:107903216	T/A	cg09227934	chr3:107805635	CD47	-0.45	-5.82	-0.34	1.66e-8	Body mass index;
CESC	cis	rs7914558	1.000	rs943038	chr10:104826261	T/C	cg15744005	chr10:104629667	AS3MT	-0.34	-5.49	-0.32	9.49e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs9901225	1	rs9901225	chr17:40755811	C/T	cg07694864	chr17:40700509	NA	-0.47	-6.8	-0.39	6.95e-11	Colorectal or endometrial cancer;
CESC	cis	rs55692468	0.540	rs4664586	chr2:153324071	C/T	cg04681845	chr2:153283485	FMNL2	-0.27	-5.56	-0.32	6.54e-8	Intraocular pressure;
CESC	cis	rs990171	0.607	rs10153578	chr2:102764609	C/T	cg22835712	chr2:102737379	NA	-0.44	-6.12	-0.35	3.29e-9	Lymphocyte counts;
CESC	cis	rs7615952	0.641	rs6805074	chr3:125772274	T/A	cg02807482	chr3:125708958	NA	-0.4	-5.2	-0.3	3.94e-7	Blood pressure (smoking interaction);
CESC	cis	rs4242434	0.672	rs10099266	chr8:22484268	C/G	cg03733263	chr8:22462867	KIAA1967	0.72	10.31	0.54	3.52e-21	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg04170460	chr16:29985301	TAOK2	-0.44	-6.53	-0.37	3.26e-10	Vertical cup-disc ratio;
CESC	cis	rs2243480	1.000	rs13220979	chr7:65363204	G/A	cg13147721	chr7:65941812	NA	-0.83	-7.97	-0.44	4.85e-14	Diabetic kidney disease;
CESC	cis	rs2361718	0.564	rs2304844	chr17:78084507	G/C	cg23534315	chr17:78082725	GAA	0.4	5.7	0.33	3.12e-8	Yeast infection;
CESC	cis	rs79349575	0.749	rs519537	chr17:46971140	G/A	cg26022315	chr17:47021804	SNF8	0.38	5.04	0.3	8.49e-7	Type 2 diabetes;
CESC	cis	rs10504229	0.683	rs11786527	chr8:58131344	G/C	cg24829409	chr8:58192753	C8orf71	-0.58	-7.2	-0.4	6.31e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs854765	0.647	rs2056842	chr17:18009028	C/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.49	6.19	0.36	2.29e-9	Total body bone mineral density;
CESC	cis	rs2836950	0.501	rs13047518	chr21:40707307	G/A	cg11644478	chr21:40555479	PSMG1	-0.55	-7.39	-0.41	1.87e-12	Menarche (age at onset);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg03812994	chr10:81205453	ZCCHC24	0.47	6.34	0.36	1.01e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs7429990	0.965	rs7426976	chr3:48022573	A/C	cg11946769	chr3:48343235	NME6	-0.43	-5.2	-0.3	4e-7	Educational attainment (years of education);
CESC	cis	rs1475911	0.744	rs12481958	chr21:43517269	A/G	cg19766460	chr21:43528205	UMODL1;C21orf128	0.48	5.43	0.32	1.3e-7	IgG glycosylation;
CESC	cis	rs5750830	0.649	rs6001588	chr22:39819049	G/C	cg01416388	chr22:39784598	NA	-0.58	-7.11	-0.4	1.1e-11	Intelligence (multi-trait analysis);
CESC	cis	rs258892	0.793	rs61141607	chr5:72056883	T/A	cg21869765	chr5:72125136	TNPO1	-0.42	-5.24	-0.31	3.2e-7	Small cell lung carcinoma;
CESC	cis	rs9733	0.650	rs11204684	chr1:150608894	A/G	cg17724175	chr1:150552817	MCL1	-0.33	-5.23	-0.31	3.42e-7	Tonsillectomy;
CESC	cis	rs6835098	1.000	rs1054497	chr4:174089048	A/T	cg08422745	chr4:174089978	GALNT7	0.82	11.84	0.59	3.06e-26	Dementia and core Alzheimer's disease neuropathologic changes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05089059	chr7:128049863	IMPDH1	0.56	6.06	0.35	4.63e-9	Gut microbiome composition (summer);
CESC	cis	rs11229555	1.000	rs12787765	chr11:58400686	G/A	cg15696309	chr11:58395628	NA	-0.44	-5.72	-0.33	2.82e-8	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CESC	trans	rs35110281	0.720	rs162375	chr21:44927015	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.51	-6.94	-0.39	3.1e-11	Mean corpuscular volume;
CESC	cis	rs3096299	0.719	rs12934708	chr16:89523790	C/T	cg02187348	chr16:89574699	SPG7	0.65	8.91	0.48	8.14e-17	Multiple myeloma (IgH translocation);
CESC	cis	rs2191566	0.664	rs7255512	chr19:44574700	C/T	cg20607764	chr19:44506953	ZNF230	-0.49	-6.34	-0.36	9.61e-10	Acute lymphoblastic leukemia (childhood);
CESC	trans	rs12310956	0.532	rs1352209	chr12:33983408	G/A	cg26384229	chr12:38710491	ALG10B	0.48	6.64	0.38	1.82e-10	Morning vs. evening chronotype;
CESC	cis	rs7618915	0.571	rs34954168	chr3:52612159	C/T	cg18337363	chr3:52569053	NT5DC2	0.29	5.19	0.3	4.09e-7	Bipolar disorder;
CESC	cis	rs6121246	0.567	rs6120879	chr20:30202961	T/C	cg13852791	chr20:30311386	BCL2L1	0.57	5.29	0.31	2.54e-7	Mean corpuscular hemoglobin;
CESC	cis	rs2072499	0.966	rs2842869	chr1:156160696	A/G	cg24450063	chr1:156163899	SLC25A44	1.11	23.64	0.82	3.21e-67	Testicular germ cell tumor;
CESC	cis	rs2243480	1.000	rs458291	chr7:65520479	C/A	cg18252515	chr7:66147081	NA	-1.25	-12.55	-0.61	1.18e-28	Diabetic kidney disease;
CESC	cis	rs2842992	0.915	rs2758350	chr6:160118056	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.65	7.91	0.44	7.12e-14	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs7851660	0.874	rs1955143	chr9:100634579	A/T	cg13688889	chr9:100608707	NA	-0.61	-8.52	-0.46	1.22e-15	Strep throat;
CESC	cis	rs853679	0.517	rs4711164	chr6:28115156	C/T	cg26335602	chr6:28129616	ZNF389	0.53	6.75	0.38	9.35e-11	Depression;
CESC	cis	rs7605827	0.930	rs7605274	chr2:15604269	A/T	cg19274914	chr2:15703543	NA	0.35	6.11	0.35	3.48e-9	Educational attainment (years of education);
CESC	cis	rs11792861	0.962	rs3750454	chr9:111801325	C/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	-0.44	-5.54	-0.32	7.28e-8	Menarche (age at onset);
CESC	cis	rs1153858	0.943	rs12439575	chr15:45684816	T/G	cg14582100	chr15:45693742	SPATA5L1	0.42	5.95	0.34	8.38e-9	Homoarginine levels;
CESC	cis	rs17376456	1.000	rs34013242	chr5:93507947	C/T	cg25358565	chr5:93447407	FAM172A	1.16	11.25	0.57	2.83e-24	Diabetic retinopathy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20786061	chr20:48429238	SLC9A8	0.63	7.46	0.42	1.25e-12	Gut microbiome composition (summer);
CESC	cis	rs10838687	0.736	rs2242262	chr11:47266540	G/T	cg25783544	chr11:47291846	MADD	0.57	6.63	0.38	1.91e-10	Proinsulin levels;
CESC	cis	rs1048257	0.553	rs2819421	chr14:105408811	A/G	cg19901468	chr14:105411992	AHNAK2	-0.62	-8.9	-0.48	8.75e-17	Systemic lupus erythematosus;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg00543632	chr16:19098067	NA	-0.45	-6.18	-0.35	2.38e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs644148	0.676	rs2571114	chr19:44997579	A/G	cg15540054	chr19:45004280	ZNF180	-0.46	-5.59	-0.33	5.51e-8	Personality dimensions;
CESC	cis	rs1167827	1.000	rs1167827	chr7:75163169	A/G	cg04681579	chr7:75027559	TRIM73;TRIM74	-0.55	-7.62	-0.42	4.45e-13	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs9287719	0.967	rs10191883	chr2:10744136	A/G	cg02196655	chr2:10830764	NOL10	-0.38	-5.83	-0.34	1.61e-8	Prostate cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26643908	chr2:36825150	FEZ2	0.57	6.14	0.35	2.94e-9	Gut microbiome composition (summer);
CESC	cis	rs9457247	0.765	rs10946203	chr6:167446735	A/C	cg23791538	chr6:167370224	RNASET2	-0.55	-7.59	-0.42	5.54e-13	Crohn's disease;
CESC	cis	rs4819052	0.918	rs34886433	chr21:46680538	G/C	cg11663144	chr21:46675770	NA	-0.49	-6.41	-0.37	6.74e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs425277	0.561	rs925906	chr1:2044054	A/C	cg19257562	chr1:2043853	PRKCZ	0.41	6.62	0.38	1.99e-10	Height;
CESC	cis	rs7552404	0.731	rs12078299	chr1:76365764	T/A	cg22875332	chr1:76189707	ACADM	0.57	5.63	0.33	4.52e-8	Blood metabolite levels;Acylcarnitine levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11110978	chr21:44527518	U2AF1	0.53	6.16	0.35	2.7e-9	Gut microbiome composition (summer);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg25124639	chr7:23221621	NUPL2	-0.39	-6.14	-0.35	2.96e-9	Gambling;
CESC	cis	rs12477438	0.798	rs17708218	chr2:99696284	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-10.69	-0.55	2.12e-22	Chronic sinus infection;
CESC	cis	rs4862750	0.872	rs7672831	chr4:187898882	C/T	cg22105103	chr4:187893119	NA	0.52	7.81	0.43	1.36e-13	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs1814175	0.754	rs10219245	chr11:49645052	C/T	cg15704280	chr7:45808275	SEPT13	-1.04	-20.29	-0.78	7.14e-56	Height;
CESC	cis	rs9733	0.596	rs2175615	chr1:150624101	A/G	cg17724175	chr1:150552817	MCL1	0.44	7.21	0.41	5.75e-12	Tonsillectomy;
CESC	cis	rs4819052	0.851	rs7276828	chr21:46695039	T/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.46	5.69	0.33	3.35e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs7552167	0.925	rs11249021	chr1:24512881	G/T	cg01960748	chr1:24522592	NA	-0.4	-5.41	-0.32	1.41e-7	Psoriasis vulgaris;
CESC	cis	rs977987	0.806	rs7199132	chr16:75450039	C/T	cg03315344	chr16:75512273	CHST6	0.41	5.81	0.34	1.79e-8	Dupuytren's disease;
CESC	cis	rs4665809	0.590	rs17528590	chr2:26505858	A/G	cg27170947	chr2:26402098	FAM59B	0.83	8.97	0.48	5.73e-17	Gut microbiome composition (summer);
CESC	cis	rs17539620	0.624	rs117591255	chr6:154839118	G/A	cg17771515	chr6:154831774	CNKSR3	0.58	5.76	0.33	2.36e-8	Lipoprotein (a) levels;
CESC	cis	rs4434138	0.664	rs62255364	chr3:52701502	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	7.04	0.4	1.62e-11	Intelligence (multi-trait analysis);
CESC	cis	rs67311347	0.956	rs9822870	chr3:40514890	A/C	cg24209194	chr3:40518798	ZNF619	-0.57	-7.68	-0.43	3.11e-13	Renal cell carcinoma;
CESC	cis	rs798554	0.679	rs2644281	chr7:2886748	A/G	cg19717773	chr7:2847554	GNA12	-0.44	-6.46	-0.37	4.99e-10	Height;
CESC	cis	rs2836974	0.568	rs428602	chr21:40547004	A/G	cg17971929	chr21:40555470	PSMG1	0.86	12.56	0.61	1.07e-28	Cognitive function;
CESC	cis	rs8040855	0.597	rs12902942	chr15:85584804	C/T	cg08123816	chr15:85640762	PDE8A	-0.38	-5.51	-0.32	8.51e-8	Bulimia nervosa;
CESC	trans	rs8073060	0.561	rs225260	chr17:33958422	T/C	cg19694781	chr19:47549865	TMEM160	-0.77	-7.47	-0.42	1.14e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	cis	rs9733	0.519	rs12095002	chr1:150649249	G/A	cg17724175	chr1:150552817	MCL1	0.44	7.21	0.41	5.8e-12	Tonsillectomy;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05112967	chr7:63353492	NA	-0.49	-6.99	-0.39	2.28e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs7130144	0.541	rs79187796	chr11:130461670	G/A	cg26307797	chr11:130446613	NA	-0.83	-5.92	-0.34	1e-8	Urate levels in lean individuals;
CESC	cis	rs1355223	0.583	rs1828298	chr11:34870439	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.82	12.62	0.61	6.79e-29	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs72781680	0.898	rs56413706	chr2:24086961	G/A	cg20701182	chr2:24300061	SF3B14	0.78	6.93	0.39	3.11e-11	Lymphocyte counts;
CESC	cis	rs6964587	0.967	rs2282969	chr7:91583772	T/C	cg17063962	chr7:91808500	NA	-0.59	-7.86	-0.43	9.61e-14	Breast cancer;
CESC	cis	rs2625529	0.761	rs4776582	chr15:72207520	A/T	cg16672083	chr15:72433130	SENP8	-0.39	-5.09	-0.3	6.78e-7	Red blood cell count;
CESC	cis	rs4642101	0.824	rs9835677	chr3:12845158	G/A	cg05775895	chr3:12838266	CAND2	0.39	5.78	0.33	2.1e-8	QRS complex (12-leadsum);
CESC	cis	rs7617773	0.817	rs936426	chr3:48215253	C/T	cg11946769	chr3:48343235	NME6	0.77	10.19	0.53	8.62e-21	Coronary artery disease;
CESC	cis	rs6570726	0.791	rs7755253	chr6:145858893	C/G	cg05347473	chr6:146136440	FBXO30	0.57	7.3	0.41	3.36e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7188697	0.769	rs9932944	chr16:58616165	C/T	cg02549819	chr16:58548995	SETD6	0.44	5.4	0.31	1.47e-7	QT interval;
CESC	cis	rs7246657	0.941	rs67293224	chr19:37803248	C/T	cg23950597	chr19:37808831	NA	-0.63	-6.43	-0.37	5.83e-10	Coronary artery calcification;
CESC	cis	rs763014	0.931	rs710925	chr16:633354	G/A	cg00908189	chr16:619842	PIGQ	0.67	9.34	0.5	4.24e-18	Height;
CESC	cis	rs1799949	1.000	rs8176077	chr17:41276348	T/C	cg06001716	chr17:41278141	BRCA1;NBR2	0.39	5.28	0.31	2.75e-7	Menopause (age at onset);
CESC	cis	rs28374715	0.532	rs7164211	chr15:41705041	A/T	cg18705301	chr15:41695430	NDUFAF1	-1.01	-16.07	-0.7	5.07e-41	Ulcerative colitis;
CESC	cis	rs7727544	0.735	rs272884	chr5:131668654	G/C	cg24060327	chr5:131705240	SLC22A5	-0.67	-8.93	-0.48	7.2e-17	Blood metabolite levels;
CESC	cis	rs10089	1.000	rs6595806	chr5:127499764	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.74	9.81	0.52	1.39e-19	Ileal carcinoids;
CESC	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg01238044	chr22:24384105	GSTT1	-0.58	-7.42	-0.41	1.63e-12	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs7953508	0.506	rs1316740	chr12:93968288	C/A	cg18151635	chr12:93972918	NA	-0.44	-5.89	-0.34	1.19e-8	Pubertal anthropometrics;
CESC	cis	rs714031	1.000	rs5757765	chr22:40067840	T/C	cg21377881	chr22:40064566	CACNA1I	-0.33	-5.26	-0.31	2.96e-7	Schizophrenia;
CESC	cis	rs6867032	0.834	rs4526149	chr5:1990166	G/A	cg26168224	chr5:2018326	NA	-0.79	-11.78	-0.59	4.84e-26	Gut microbiome composition (winter);
CESC	cis	rs3747547	1.000	rs72724195	chr9:37948063	C/T	cg13774184	chr9:37916125	SHB	-0.74	-6.3	-0.36	1.24e-9	Metabolite levels (Dihydroxy docosatrienoic acid);
CESC	cis	rs1372520	0.684	rs184810	chr4:90697979	T/C	cg15133208	chr4:90757351	SNCA	0.42	5.4	0.31	1.5e-7	Neuroticism;
CESC	cis	rs2204008	0.547	rs12318267	chr12:38250905	T/G	cg26384229	chr12:38710491	ALG10B	-0.44	-5.73	-0.33	2.66e-8	Bladder cancer;
CESC	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg11494091	chr17:61959527	GH2	0.73	12.58	0.61	8.77e-29	Prudent dietary pattern;
CESC	cis	rs7116495	1.000	rs73543609	chr11:71816619	G/T	cg10381502	chr11:71823885	C11orf51	0.66	5.35	0.31	1.93e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs60515486	0.527	rs56756748	chr11:47392568	C/G	cg25783544	chr11:47291846	MADD	0.54	5.26	0.31	2.91e-7	Lymphocyte counts;
CESC	cis	rs10028773	0.666	rs12498657	chr4:120262866	G/C	cg09307838	chr4:120376055	NA	0.76	10.02	0.52	3.03e-20	Educational attainment;
CESC	cis	rs28374715	0.783	rs11630656	chr15:41570909	T/G	cg18705301	chr15:41695430	NDUFAF1	-0.98	-14.25	-0.66	1.37e-34	Ulcerative colitis;
CESC	cis	rs3820068	0.705	rs11583306	chr1:15860803	A/G	cg17385448	chr1:15911702	AGMAT	-0.38	-5.87	-0.34	1.28e-8	Systolic blood pressure;
CESC	cis	rs8141529	0.732	rs2347447	chr22:29179739	C/A	cg15103426	chr22:29168792	CCDC117	0.7	9.86	0.52	9.91e-20	Lymphocyte counts;
CESC	cis	rs10504229	0.683	rs59679713	chr8:58134370	G/C	cg02725872	chr8:58115012	NA	-0.45	-7.07	-0.4	1.39e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs1799949	1.000	rs8176133	chr17:41257458	A/C	cg25072359	chr17:41440525	NA	0.47	6.39	0.37	7.42e-10	Menopause (age at onset);
CESC	cis	rs11608355	0.545	rs6606721	chr12:109891999	G/A	cg05360138	chr12:110035743	NA	0.82	8.92	0.48	7.93e-17	Neuroticism;
CESC	cis	rs3213545	0.659	rs2259693	chr12:121457995	G/A	cg25281562	chr12:121454272	C12orf43	0.45	5.69	0.33	3.3e-8	Subjective well-being;Cardiovascular disease risk factors;
CESC	cis	rs9457247	0.663	rs10946205	chr6:167451311	A/G	cg07741184	chr6:167504864	NA	0.35	6.27	0.36	1.43e-9	Crohn's disease;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg03117951	chr6:57036288	BAG2	0.39	6.0	0.35	6.29e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	trans	rs7615952	0.800	rs35390120	chr3:125599809	G/A	cg07211511	chr3:129823064	LOC729375	-0.87	-8.85	-0.48	1.28e-16	Blood pressure (smoking interaction);
CESC	cis	rs9039	0.921	rs9929699	chr16:9218270	A/G	cg08831531	chr16:9218945	NA	-0.41	-6.21	-0.36	2.05e-9	Menopause (age at onset);
CESC	cis	rs7089973	0.604	rs2420065	chr10:116583753	A/G	cg25233709	chr10:116636983	FAM160B1	0.35	5.47	0.32	1.05e-7	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs6831352	0.918	rs13113166	chr4:100050528	A/G	cg13256891	chr4:100009986	ADH5	-0.77	-8.43	-0.46	2.27e-15	Alcohol dependence;
CESC	cis	rs853679	0.517	rs9393886	chr6:28050039	T/G	cg18032046	chr6:28092343	ZSCAN16	-0.53	-6.09	-0.35	3.91e-9	Depression;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03550773	chr14:35163458	NA	-0.65	-7.71	-0.43	2.58e-13	Gut microbiome composition (summer);
CESC	cis	rs10028773	0.632	rs34481394	chr4:120248374	C/T	cg09307838	chr4:120376055	NA	0.74	9.42	0.5	2.28e-18	Educational attainment;
CESC	cis	rs6570726	0.764	rs366673	chr6:145814628	T/A	cg05347473	chr6:146136440	FBXO30	0.58	7.53	0.42	7.78e-13	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs77106637	0.932	rs74439784	chr11:72649396	A/T	cg04827223	chr11:72435913	ARAP1	-0.49	-5.27	-0.31	2.9e-7	Type 2 diabetes;
CESC	trans	rs11039798	0.844	rs7126949	chr11:48972166	A/G	cg15704280	chr7:45808275	SEPT13	0.7	6.56	0.37	2.74e-10	Axial length;
CESC	cis	rs4927850	1.000	rs7627868	chr3:195753473	A/T	cg01181863	chr3:195395398	SDHAP2	-0.48	-5.71	-0.33	3.03e-8	Pancreatic cancer;
CESC	cis	rs34779708	0.742	rs35912711	chr10:35312996	T/C	cg04310649	chr10:35416472	CREM	-0.5	-5.97	-0.34	7.64e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs9811920	0.609	rs809415	chr3:99582242	G/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.63	-10.11	-0.53	1.61e-20	Axial length;
CESC	cis	rs67478160	0.619	rs2368560	chr14:104273311	C/T	cg08213375	chr14:104286397	PPP1R13B	0.54	10.75	0.55	1.33e-22	Schizophrenia;
CESC	cis	rs1729951	0.575	rs361245	chr3:136695706	A/G	cg04103450	chr3:136751342	NA	0.4	5.3	0.31	2.45e-7	Neuroticism;
CESC	cis	rs514406	0.621	rs881198	chr1:53196440	C/T	cg08736216	chr1:53307985	ZYG11A	0.37	6.02	0.35	5.92e-9	Monocyte count;
CESC	trans	rs7824557	0.564	rs2572399	chr8:11234520	A/G	cg06636001	chr8:8085503	FLJ10661	-0.49	-6.09	-0.35	3.85e-9	Retinal vascular caliber;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg01307007	chr19:3522587	FZR1	0.49	6.6	0.38	2.27e-10	Fibrinogen levels;
CESC	cis	rs35955747	0.633	rs5998002	chr22:31881169	A/G	cg25791279	chr22:32026902	PISD	-0.43	-5.11	-0.3	6.26e-7	Neutrophil count;Sum basophil neutrophil counts;
CESC	cis	rs7808935	0.628	rs9791862	chr7:27950760	G/A	cg05786569	chr7:27702416	HIBADH	0.53	5.94	0.34	8.97e-9	Prostate cancer;
CESC	cis	rs11640533	1.000	rs11640533	chr16:53412862	A/G	cg04653913	chr16:53407753	NA	-0.43	-5.7	-0.33	3.13e-8	Intelligence (multi-trait analysis);
CESC	cis	rs6674176	0.593	rs6675620	chr1:44417630	C/T	cg12908607	chr1:44402522	ARTN	-0.45	-6.45	-0.37	5.26e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs1153858	1.000	rs4774577	chr15:45644685	A/C	cg14582100	chr15:45693742	SPATA5L1	0.42	5.95	0.34	8.45e-9	Homoarginine levels;
CESC	cis	rs16910800	0.689	rs4491218	chr11:23163977	G/A	cg20040320	chr11:23191996	NA	-0.6	-5.41	-0.32	1.44e-7	Cancer;
CESC	cis	rs977987	0.931	rs1424013	chr16:75495986	T/C	cg03315344	chr16:75512273	CHST6	0.55	8.01	0.44	3.67e-14	Dupuytren's disease;
CESC	trans	rs1144403	0.778	rs1147019	chr11:104591863	A/G	cg05575375	chr4:3692375	NA	0.32	6.0	0.35	6.63e-9	Schizophrenia;
CESC	cis	rs7605378	0.528	rs7592587	chr2:200786516	C/G	cg17644776	chr2:200775616	C2orf69	0.47	5.65	0.33	4.16e-8	Osteoporosis;
CESC	cis	rs4819052	0.724	rs1304487	chr21:46657283	C/G	cg20896738	chr21:46707857	POFUT2;LOC642852	-0.44	-5.63	-0.33	4.53e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs9796	0.870	rs2412574	chr15:41259707	G/C	cg18705301	chr15:41695430	NDUFAF1	-0.47	-7.04	-0.4	1.61e-11	Menopause (age at onset);
CESC	cis	rs3806843	0.676	rs2245640	chr5:140029958	A/G	cg16179182	chr5:140090404	VTRNA1-1	0.42	5.35	0.31	1.9e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs7666738	0.830	rs1426665	chr4:99027764	C/T	cg18180107	chr4:99064573	C4orf37	0.41	5.32	0.31	2.16e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4700695	0.719	rs27079	chr5:65443966	C/T	cg21114390	chr5:65439923	SFRS12	-0.5	-6.1	-0.35	3.72e-9	Facial morphology (factor 19);
CESC	cis	rs660498	0.526	rs610451	chr10:27705152	A/G	cg25705717	chr10:27608719	NA	-0.47	-5.82	-0.34	1.66e-8	Asthma (childhood onset);
CESC	cis	rs6060717	0.536	rs6060699	chr20:34523833	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.64	6.47	0.37	4.58e-10	Hip circumference adjusted for BMI;
CESC	cis	rs6088580	0.634	rs6142157	chr20:32984172	C/G	cg24642439	chr20:33292090	TP53INP2	-0.53	-6.97	-0.39	2.55e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs3008870	0.959	rs2815359	chr1:67494374	T/C	cg02640540	chr1:67518911	SLC35D1	0.51	5.43	0.32	1.25e-7	Lymphocyte percentage of white cells;
CESC	cis	rs7727544	0.684	rs274560	chr5:131719450	T/C	cg24060327	chr5:131705240	SLC22A5	0.63	8.42	0.46	2.38e-15	Blood metabolite levels;
CESC	cis	rs11958404	0.929	rs72816533	chr5:157413352	G/T	cg05962755	chr5:157440814	NA	0.62	6.67	0.38	1.5e-10	IgG glycosylation;
CESC	cis	rs644799	1.000	rs593665	chr11:95574302	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.69	8.53	0.46	1.12e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs858239	0.539	rs10247268	chr7:23187179	G/A	cg23682824	chr7:23144976	KLHL7	0.46	5.85	0.34	1.45e-8	Cerebrospinal fluid biomarker levels;
CESC	cis	rs11577318	0.853	rs17645	chr1:26646730	A/G	cg00813993	chr1:26644493	UBXN11;CD52	-0.4	-6.36	-0.36	8.77e-10	Granulocyte percentage of myeloid white cells;
CESC	cis	rs67311347	1.000	rs17078941	chr3:40450888	A/G	cg24209194	chr3:40518798	ZNF619	-0.46	-5.64	-0.33	4.35e-8	Renal cell carcinoma;
CESC	cis	rs3858526	0.883	rs10769333	chr11:5939685	A/T	cg13902645	chr11:5959945	NA	-0.64	-7.67	-0.43	3.24e-13	DNA methylation (variation);
CESC	cis	rs873946	0.648	rs35417213	chr10:134553749	A/G	cg27297192	chr10:134578999	INPP5A	0.38	5.04	0.3	8.72e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	trans	rs677673	1.000	rs62185061	chr20:10474918	A/G	cg16021678	chr13:55475951	NA	0.51	6.4	0.37	7.15e-10	Body mass index (change over time) in chronic obstructive pulmonary disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01700524	chr14:24803014	ADCY4	0.55	6.34	0.36	9.64e-10	Gut microbiome composition (summer);
CESC	cis	rs793571	0.505	rs9920042	chr15:58901396	C/T	cg05156742	chr15:59063176	FAM63B	0.5	5.29	0.31	2.54e-7	Schizophrenia;
CESC	cis	rs35306767	0.855	rs12774985	chr10:904245	C/T	cg20503657	chr10:835505	NA	1.09	9.82	0.52	1.29e-19	Eosinophil percentage of granulocytes;
CESC	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg23131131	chr22:24373011	LOC391322	-0.64	-8.63	-0.47	5.78e-16	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs6754311	0.731	rs2236783	chr2:136594158	G/A	cg07169764	chr2:136633963	MCM6	-0.71	-8.41	-0.46	2.56e-15	Mosquito bite size;
CESC	cis	rs7267979	1.000	rs2482930	chr20:25334115	G/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.86	-16.6	-0.71	6.43e-43	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs514406	0.708	rs480299	chr1:53320274	G/T	cg27535305	chr1:53392650	SCP2	-0.32	-5.42	-0.32	1.34e-7	Monocyte count;
CESC	cis	rs2576037	0.583	rs11660085	chr18:44529603	A/G	cg19077165	chr18:44547161	KATNAL2	0.6	8.8	0.48	1.75e-16	Personality dimensions;
CESC	cis	rs60843830	0.928	rs2306060	chr2:230912	A/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.88	11.92	0.59	1.59e-26	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs2576037	0.526	rs9304340	chr18:44526582	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.67	10.06	0.53	2.21e-20	Personality dimensions;
CESC	cis	rs7116495	1.000	rs671681	chr11:71782812	T/C	cg26138937	chr11:71823887	C11orf51	-0.84	-6.79	-0.38	7.37e-11	Severe influenza A (H1N1) infection;
CESC	cis	rs3744061	0.557	rs9889902	chr17:74648034	T/C	cg27546012	chr17:74684504	MXRA7	-0.39	-5.32	-0.31	2.23e-7	Retinal arteriolar caliber;
CESC	cis	rs698813	0.572	rs12712914	chr2:44478649	C/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.49	5.53	0.32	7.62e-8	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
CESC	cis	rs367943	0.666	rs12332129	chr5:112977983	A/G	cg12552261	chr5:112820674	MCC	0.4	5.19	0.3	4.14e-7	Type 2 diabetes;
CESC	cis	rs6598955	0.515	rs61776655	chr1:26541430	T/C	cg00852783	chr1:26633632	UBXN11	0.4	5.87	0.34	1.32e-8	Obesity-related traits;
CESC	cis	rs3936840	1.000	rs3936840	chr14:102984274	G/C	cg18135206	chr14:102964638	TECPR2	0.49	6.44	0.37	5.66e-10	Plateletcrit;
CESC	cis	rs763121	0.925	rs9611008	chr22:39098787	T/C	cg06544989	chr22:39130855	UNC84B	0.54	10.41	0.54	1.69e-21	Menopause (age at onset);
CESC	cis	rs4665809	0.759	rs62128394	chr2:26364026	T/G	cg22920501	chr2:26401640	FAM59B	0.76	8.74	0.47	2.69e-16	Gut microbiome composition (summer);
CESC	cis	rs523516	0.645	rs658589	chr17:37319293	T/C	cg20555674	chr17:37321631	ARL5C	0.37	6.18	0.36	2.36e-9	IgG glycosylation;
CESC	trans	rs11098499	0.644	rs10009566	chr4:120558608	A/G	cg25214090	chr10:38739885	LOC399744	0.61	8.79	0.48	1.87e-16	Corneal astigmatism;
CESC	cis	rs1878931	0.582	rs27225	chr16:3428060	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.68	-8.24	-0.45	8.01e-15	Body mass index (adult);
CESC	cis	rs72945132	0.882	rs17425511	chr11:70183737	C/G	cg14191688	chr11:70257035	CTTN	0.46	5.5	0.32	8.8e-8	Coronary artery disease;
CESC	trans	rs7902708	0.920	rs7095115	chr10:54425442	G/A	cg26219051	chr22:43739629	SCUBE1	-0.48	-6.07	-0.35	4.3e-9	Bone properties (heel);
CESC	cis	rs11122272	0.766	rs2790870	chr1:231543823	A/G	cg06096015	chr1:231504339	EGLN1	0.41	5.71	0.33	3e-8	Hemoglobin concentration;
CESC	cis	rs801193	0.569	rs2659908	chr7:66160822	G/A	cg18252515	chr7:66147081	NA	-0.47	-6.41	-0.37	6.57e-10	Aortic root size;
CESC	cis	rs17253792	0.822	rs10148983	chr14:56051879	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.86	6.17	0.35	2.52e-9	Putamen volume;
CESC	cis	rs7845219	0.544	rs4570121	chr8:95917088	C/T	cg09323728	chr8:95962352	TP53INP1	-0.33	-6.47	-0.37	4.66e-10	Type 2 diabetes;
CESC	cis	rs1552244	1.000	rs7611218	chr3:10063960	T/C	cg08888203	chr3:10149979	C3orf24	0.5	6.33	0.36	1.05e-9	Alzheimer's disease;
CESC	cis	rs2228479	0.850	rs11648689	chr16:89806732	G/A	cg00800038	chr16:89945340	TCF25	-0.87	-7.07	-0.4	1.4e-11	Skin colour saturation;
CESC	cis	rs858239	0.670	rs3807452	chr7:23162081	C/T	cg23682824	chr7:23144976	KLHL7	-0.47	-6.62	-0.38	2.02e-10	Cerebrospinal fluid biomarker levels;
CESC	cis	rs73206853	0.660	rs12313068	chr12:110597304	C/T	cg12870014	chr12:110450643	ANKRD13A	0.66	6.93	0.39	3.27e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs9303401	0.659	rs11079358	chr17:56920949	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.01	12.69	0.61	3.78e-29	Cognitive test performance;
CESC	cis	rs7647973	0.580	rs11716334	chr3:49230096	G/A	cg02487422	chr3:49467188	NICN1	0.37	5.07	0.3	7.51e-7	Menarche (age at onset);
CESC	cis	rs7412746	0.658	rs4537557	chr1:150734436	A/G	cg17724175	chr1:150552817	MCL1	0.42	6.45	0.37	5.2400000000000005e-10	Melanoma;
CESC	cis	rs9911578	1.000	rs11870671	chr17:56605360	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	-0.39	-5.16	-0.3	4.83e-7	Intelligence (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04446112	chr11:64008349	FKBP2	0.6	6.59	0.38	2.4e-10	Gut microbiome composition (summer);
CESC	cis	rs250677	0.687	rs40149	chr5:148444275	A/T	cg18129178	chr5:148520854	ABLIM3	-0.53	-5.84	-0.34	1.53e-8	Breast cancer;
CESC	cis	rs7811142	0.830	rs6955367	chr7:99961194	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.76	8.26	0.45	6.79e-15	Platelet count;
CESC	cis	rs9309473	0.948	rs13391552	chr2:73818936	C/T	cg20560298	chr2:73613845	ALMS1	-0.52	-6.85	-0.39	5.27e-11	Metabolite levels;
CESC	cis	rs3858526	0.508	rs10838734	chr11:5876325	T/G	cg25319279	chr11:5960081	NA	-0.38	-5.33	-0.31	2.06e-7	DNA methylation (variation);
CESC	cis	rs921968	0.565	rs3755045	chr2:219609162	T/G	cg02176678	chr2:219576539	TTLL4	-0.46	-8.23	-0.45	8.59e-15	Mean corpuscular hemoglobin concentration;
CESC	cis	rs3812049	0.784	rs3749748	chr5:127350549	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.92	-11.49	-0.58	4.48e-25	Lymphocyte counts;Red cell distribution width;
CESC	cis	rs7084402	0.967	rs1649091	chr10:60289440	T/A	cg07615347	chr10:60278583	BICC1	0.6	9.41	0.5	2.54e-18	Refractive error;
CESC	cis	rs7618915	0.547	rs34017441	chr3:52742413	T/C	cg18404041	chr3:52824283	ITIH1	-0.41	-6.97	-0.39	2.54e-11	Bipolar disorder;
CESC	cis	rs870825	0.616	rs7678949	chr4:185635018	G/C	cg04058563	chr4:185651563	MLF1IP	0.63	6.89	0.39	3.95e-11	Blood protein levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12592908	chr6:36954170	MTCH1	0.56	6.38	0.36	7.73e-10	Gut microbiome composition (summer);
CESC	cis	rs514406	0.548	rs6670871	chr1:53212082	A/C	cg08859206	chr1:53392774	SCP2	0.54	6.88	0.39	4.27e-11	Monocyte count;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05310613	chr6:139456890	HECA	0.47	6.65	0.38	1.7e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs9916302	0.851	rs612209	chr17:37442713	G/C	cg00129232	chr17:37814104	STARD3	0.53	6.84	0.39	5.58e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs6860806	0.507	rs2631364	chr5:131706914	C/G	cg24060327	chr5:131705240	SLC22A5	0.76	10.63	0.55	3.22e-22	Breast cancer;
CESC	cis	rs13256369	0.951	rs13259955	chr8:8565885	C/G	cg00074818	chr8:8560427	CLDN23	0.37	5.43	0.32	1.26e-7	Obesity-related traits;
CESC	cis	rs7666738	0.830	rs28802909	chr4:99039410	G/A	cg24818145	chr4:99064322	C4orf37	0.38	5.04	0.3	8.49e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6542838	0.641	rs6724477	chr2:99537074	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.48	6.02	0.35	5.76e-9	Fear of minor pain;
CESC	trans	rs9467711	0.606	rs9366655	chr6:26377385	C/G	cg06606381	chr12:133084897	FBRSL1	-0.71	-6.7	-0.38	1.27e-10	Autism spectrum disorder or schizophrenia;
CESC	cis	rs6860806	0.632	rs4330455	chr5:131586349	T/C	cg12564285	chr5:131593104	PDLIM4	0.39	5.82	0.34	1.7e-8	Breast cancer;
CESC	cis	rs7615952	0.576	rs4646759	chr3:125822946	G/C	cg06494592	chr3:125709126	NA	-0.51	-5.44	-0.32	1.22e-7	Blood pressure (smoking interaction);
CESC	cis	rs7208859	0.623	rs7220289	chr17:29103762	G/T	cg13385521	chr17:29058706	SUZ12P	0.77	6.18	0.35	2.41e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	trans	rs3780486	0.505	rs10758194	chr9:33157419	G/T	cg20290983	chr6:43655470	MRPS18A	0.73	11.38	0.57	1.06e-24	IgG glycosylation;
CESC	cis	rs7772486	0.654	rs702321	chr6:146006695	A/G	cg05347473	chr6:146136440	FBXO30	-0.52	-6.6	-0.38	2.19e-10	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg05593479	chr2:233415006	TIGD1;EIF4E2	0.42	6.08	0.35	4.26e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs798766	1.000	rs7682402	chr4:1743343	G/A	cg05874882	chr4:1763078	NA	-0.57	-7.37	-0.41	2.15e-12	Bladder cancer;Urinary bladder cancer;
CESC	cis	rs8077889	0.917	rs58283314	chr17:41905963	T/G	cg26893861	chr17:41843967	DUSP3	0.74	9.46	0.5	1.75e-18	Triglycerides;
CESC	cis	rs6582630	0.615	rs3914894	chr12:38480280	C/T	cg26384229	chr12:38710491	ALG10B	-0.43	-5.85	-0.34	1.44e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs16867321	0.639	rs12466864	chr2:181441417	C/G	cg23363182	chr2:181467187	NA	0.47	6.99	0.39	2.17e-11	Obesity;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg13497155	chr3:50374949	RASSF1	0.54	7.25	0.41	4.59e-12	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs9768139	0.733	rs13309408	chr7:158122261	C/T	cg24154853	chr7:158122151	PTPRN2	0.4	6.09	0.35	3.98e-9	Calcium levels;
CESC	trans	rs7618501	1.000	rs11130219	chr3:49752427	C/T	cg21659725	chr3:3221576	CRBN	-0.82	-13.57	-0.64	3.35e-32	Intelligence (multi-trait analysis);
CESC	cis	rs10870270	1.000	rs10870270	chr10:133754334	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.59	-7.67	-0.43	3.19e-13	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs7432375	0.610	rs7633629	chr3:136517028	T/A	cg15507776	chr3:136538369	TMEM22	0.6	8.0	0.44	3.8e-14	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
CESC	cis	rs1843834	0.898	rs11887386	chr2:225526975	T/G	cg22455342	chr2:225449267	CUL3	0.52	6.54	0.37	3.19e-10	IgE levels in asthmatics (D.p. specific);
CESC	cis	rs651907	0.557	rs62284199	chr3:101478531	T/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.43	5.45	0.32	1.15e-7	Colorectal cancer;
CESC	cis	rs67478160	0.575	rs8014294	chr14:104322983	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.51	-7.52	-0.42	8.34e-13	Schizophrenia;
CESC	cis	rs2274273	1.000	rs2274273	chr14:55614636	A/G	cg04306507	chr14:55594613	LGALS3	-0.29	-5.36	-0.31	1.83e-7	Protein biomarker;
CESC	cis	rs116095464	0.558	rs62346506	chr5:201594	T/C	cg22496380	chr5:211416	CCDC127	-0.95	-10.44	-0.54	1.37e-21	Breast cancer;
CESC	cis	rs7772486	0.727	rs12190966	chr6:146146820	T/G	cg05347473	chr6:146136440	FBXO30	0.52	6.61	0.38	2.05e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg23708337	chr7:1209742	NA	0.54	5.4	0.31	1.48e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs1552244	1.000	rs2272123	chr3:10140115	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.88	12.02	0.59	7.31e-27	Alzheimer's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26163375	chr1:1209720	UBE2J2	0.54	6.24	0.36	1.71e-9	Gut microbiome composition (summer);
CESC	cis	rs9916302	0.904	rs2338755	chr17:37419317	C/T	cg07936489	chr17:37558343	FBXL20	0.82	12.27	0.6	1.03e-27	Glomerular filtration rate (creatinine);
CESC	cis	rs10927875	0.518	rs732286	chr1:16344360	A/G	cg22431228	chr1:16359049	CLCNKA	-0.52	-10.02	-0.52	3.09e-20	Dilated cardiomyopathy;
CESC	cis	rs61008539	0.821	rs10950789	chr7:897492	A/G	cg15782153	chr7:917662	C7orf20	0.47	6.79	0.38	7.35e-11	Perceived unattractiveness to mosquitoes;
CESC	cis	rs1788820	0.917	rs1624695	chr18:21142992	A/T	cg14672496	chr18:21087552	C18orf8	0.54	7.35	0.41	2.42e-12	Body mass index;
CESC	cis	rs7666738	0.830	rs10029849	chr4:99059362	T/C	cg03676636	chr4:99064102	C4orf37	0.34	5.11	0.3	6.07e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1552244	0.935	rs7649243	chr3:10089470	T/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	11.78	0.59	4.93e-26	Alzheimer's disease;
CESC	cis	rs3793683	0.597	rs12767469	chr10:134587261	C/G	cg27297192	chr10:134578999	INPP5A	0.4	5.2	0.3	4.03e-7	Migraine;
CESC	cis	rs17376456	0.825	rs10052662	chr5:93271385	A/G	cg21475434	chr5:93447410	FAM172A	0.76	6.33	0.36	1.04e-9	Diabetic retinopathy;
CESC	cis	rs9457247	1.000	rs436707	chr6:167388843	T/C	cg07741184	chr6:167504864	NA	0.31	5.53	0.32	7.87e-8	Crohn's disease;
CESC	cis	rs6460942	0.915	rs79232243	chr7:12459494	G/A	cg20607287	chr7:12443886	VWDE	-0.79	-9.27	-0.49	6.78e-18	Coronary artery disease;
CESC	cis	rs6502050	0.835	rs8065981	chr17:80091393	G/T	cg23985595	chr17:80112537	CCDC57	-0.42	-6.6	-0.38	2.18e-10	Life satisfaction;
CESC	cis	rs7927771	0.800	rs12146565	chr11:47398963	G/A	cg18512352	chr11:47633146	NA	-0.56	-7.98	-0.44	4.37e-14	Subjective well-being;
CESC	cis	rs76878669	0.561	rs10791876	chr11:66169646	C/T	cg18002602	chr11:66138449	SLC29A2	-0.43	-7.09	-0.4	1.22e-11	Educational attainment (years of education);
CESC	cis	rs2228479	0.867	rs34604714	chr16:89948985	A/G	cg06558623	chr16:89946397	TCF25	1.06	8.98	0.48	5.17e-17	Skin colour saturation;
CESC	cis	rs2576037	0.899	rs2571034	chr18:44578565	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.62	-8.97	-0.48	5.55e-17	Personality dimensions;
CESC	cis	rs3126085	0.935	rs1552993	chr1:152171483	A/G	cg03465714	chr1:152285911	FLG	-0.43	-5.28	-0.31	2.72e-7	Atopic dermatitis;
CESC	trans	rs10435719	0.902	rs7006538	chr8:11804982	A/G	cg15556689	chr8:8085844	FLJ10661	0.52	6.57	0.37	2.66e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg08187779	chr8:102217898	ZNF706	0.45	6.02	0.35	5.92e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08606227	chr7:128095950	C7orf68	0.6	7.01	0.4	1.94e-11	Gut microbiome composition (summer);
CESC	cis	rs10870270	0.912	rs7079991	chr10:133736130	A/G	cg17892150	chr10:133769511	PPP2R2D	-0.86	-12.69	-0.61	3.83e-29	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs3806843	0.900	rs2563280	chr5:140131530	G/C	cg26395211	chr5:140044315	WDR55	0.39	5.09	0.3	6.79e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs2952156	0.684	rs881844	chr17:37810218	C/G	cg07936489	chr17:37558343	FBXL20	-0.63	-8.24	-0.45	8.25e-15	Asthma;
CESC	cis	rs17293817	0.589	rs2387655	chr10:1420493	A/G	cg04271617	chr10:1416546	ADARB2	0.36	5.73	0.33	2.68e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs9487051	0.837	rs9480920	chr6:109605322	C/A	cg01475377	chr6:109611718	NA	-0.51	-8.5	-0.46	1.44e-15	Reticulocyte fraction of red cells;
CESC	cis	rs2262909	0.962	rs73019842	chr19:22249909	T/G	cg11619707	chr19:22235551	ZNF257	0.33	5.17	0.3	4.65e-7	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
CESC	cis	rs9660180	0.935	rs2180311	chr1:1748734	T/C	cg05132306	chr1:1846340	CALML6	-0.31	-6.57	-0.37	2.6e-10	Body mass index;
CESC	cis	rs9322193	0.884	rs2064521	chr6:149946472	A/C	cg07701084	chr6:150067640	NUP43	-0.47	-6.54	-0.37	3.18e-10	Lung cancer;
CESC	cis	rs5753618	0.561	rs737887	chr22:31696615	A/G	cg13145458	chr22:31556086	RNF185	0.51	5.78	0.33	2.14e-8	Colorectal cancer;
CESC	cis	rs7707921	0.541	rs10066167	chr5:81495445	C/T	cg15871215	chr5:81402204	ATG10	0.47	6.81	0.39	6.36e-11	Breast cancer;
CESC	cis	rs4819052	0.679	rs2255761	chr21:46683622	A/G	cg11663144	chr21:46675770	NA	-0.43	-6.61	-0.38	2.09e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs2562152	0.744	rs1045001	chr16:107275	G/T	cg02949481	chr16:131562	MPG	-0.54	-6.43	-0.37	5.76e-10	Glioblastoma;
CESC	cis	rs6570726	0.935	rs401888	chr6:145831535	A/G	cg23711669	chr6:146136114	FBXO30	0.8	12.02	0.59	7.3e-27	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs1814175	0.715	rs11040586	chr11:49858432	T/A	cg03929089	chr4:120376271	NA	-0.91	-15.11	-0.68	1.3e-37	Height;
CESC	cis	rs13191362	1.000	rs35424047	chr6:163029715	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.51	5.53	0.32	7.85e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs2439831	0.850	rs7169988	chr15:44060435	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.7	7.93	0.44	6.03e-14	Lung cancer in ever smokers;
CESC	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.05	19.06	0.76	1.35e-51	Prudent dietary pattern;
CESC	cis	rs12474201	0.862	rs13025595	chr2:46977893	A/G	cg06386533	chr2:46925753	SOCS5	0.84	11.56	0.58	2.69e-25	Height;
CESC	cis	rs1707322	1.000	rs6677777	chr1:46475836	A/G	cg05343316	chr1:45956843	TESK2	0.45	5.22	0.31	3.7e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7429990	0.965	rs11707679	chr3:47956506	T/C	cg11946769	chr3:48343235	NME6	0.46	5.59	0.32	5.54e-8	Educational attainment (years of education);
CESC	cis	rs155076	1.000	rs261404	chr13:21858162	T/G	cg11317459	chr13:21872234	NA	-0.97	-11.01	-0.56	1.78e-23	White matter hyperintensity burden;
CESC	cis	rs2816062	0.813	rs2816040	chr1:18889536	C/T	cg18795169	chr1:18902165	NA	0.9	17.43	0.73	7.63e-46	Urate levels in lean individuals;
CESC	cis	rs1799949	0.965	rs4793233	chr17:41435437	G/C	cg23758822	chr17:41437982	NA	1.04	16.13	0.7	2.93e-41	Menopause (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17189435	chr8:141467699	TRAPPC9	0.53	6.31	0.36	1.19e-9	Gut microbiome composition (summer);
CESC	cis	rs11098499	0.863	rs2170276	chr4:120485824	A/C	cg09307838	chr4:120376055	NA	0.9	12.45	0.61	2.6e-28	Corneal astigmatism;
CESC	cis	rs4853012	0.838	rs59570457	chr2:74344282	T/C	cg05776053	chr2:74358815	NA	0.41	5.15	0.3	5.01e-7	Gestational age at birth (maternal effect);
CESC	cis	rs798766	1.000	rs11732213	chr4:1704244	T/C	cg05874882	chr4:1763078	NA	0.55	6.7	0.38	1.28e-10	Bladder cancer;Urinary bladder cancer;
CESC	cis	rs4713118	0.662	rs469228	chr6:27970704	A/G	cg19592336	chr6:28129416	ZNF389	0.46	6.19	0.36	2.28e-9	Parkinson's disease;
CESC	cis	rs589448	0.933	rs523398	chr12:69752775	C/T	cg14784868	chr12:69753453	YEATS4	0.91	14.57	0.67	1.05e-35	Cerebrospinal fluid biomarker levels;
CESC	cis	rs853679	0.517	rs34716816	chr6:28046169	C/A	cg17949981	chr6:28129498	ZNF389	0.45	5.62	0.33	4.9e-8	Depression;
CESC	cis	rs9291683	0.655	rs3822242	chr4:10094904	T/C	cg00071950	chr4:10020882	SLC2A9	-0.59	-9.56	-0.51	8.41e-19	Bone mineral density;
CESC	cis	rs9549260	0.591	rs9577115	chr13:41276553	T/C	cg21288729	chr13:41239152	FOXO1	0.57	7.59	0.42	5.49e-13	Red blood cell count;
CESC	trans	rs61931739	0.500	rs7303318	chr12:34467789	T/C	cg26384229	chr12:38710491	ALG10B	0.54	7.51	0.42	9.28e-13	Morning vs. evening chronotype;
CESC	trans	rs9325144	0.555	rs1973292	chr12:38679626	T/C	cg23762105	chr12:34175262	ALG10	-0.48	-6.5	-0.37	3.86e-10	Morning vs. evening chronotype;
CESC	cis	rs7829975	0.714	rs11784052	chr8:8671962	C/T	cg15556689	chr8:8085844	FLJ10661	0.43	5.34	0.31	2e-7	Mood instability;
CESC	cis	rs11122272	0.735	rs2808604	chr1:231538916	T/C	cg06096015	chr1:231504339	EGLN1	0.42	6.05	0.35	4.97e-9	Hemoglobin concentration;
CESC	cis	rs9902453	0.704	rs2628179	chr17:28071796	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.68	-8.48	-0.46	1.64e-15	Coffee consumption (cups per day);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg17553389	chr17:66243667	AMZ2	-0.51	-6.48	-0.37	4.44e-10	Ulcerative colitis;
CESC	trans	rs3780486	0.846	rs7849148	chr9:33138352	A/T	cg20290983	chr6:43655470	MRPS18A	0.98	17.7	0.74	8.37e-47	IgG glycosylation;
CESC	cis	rs7959452	0.557	rs899224	chr12:69784774	A/G	cg20891283	chr12:69753455	YEATS4	0.91	15.03	0.68	2.41e-37	Blood protein levels;
CESC	cis	rs10504229	0.861	rs6990796	chr8:58183097	G/C	cg14926445	chr8:58193284	C8orf71	-0.51	-5.52	-0.32	8.28e-8	Developmental language disorder (linguistic errors);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18865796	chr19:11457210	TMEM205;CCDC159	0.52	6.05	0.35	4.87e-9	Gut microbiome composition (summer);
CESC	cis	rs7084402	0.934	rs1658455	chr10:60306089	G/C	cg07615347	chr10:60278583	BICC1	0.59	9.34	0.5	4.23e-18	Refractive error;
CESC	cis	rs9527	0.590	rs7897663	chr10:104905604	T/C	cg04362960	chr10:104952993	NT5C2	0.44	5.54	0.32	7.12e-8	Arsenic metabolism;
CESC	cis	rs35306767	0.903	rs11253488	chr10:922482	G/C	cg26597838	chr10:835615	NA	0.86	8.88	0.48	1.05e-16	Eosinophil percentage of granulocytes;
CESC	cis	rs4843747	0.671	rs74729706	chr16:88104159	C/T	cg06374794	chr16:88002281	BANP	0.39	5.08	0.3	7.04e-7	Menopause (age at onset);
CESC	cis	rs2228479	0.702	rs17233176	chr16:89832751	G/C	cg06558623	chr16:89946397	TCF25	1.17	9.29	0.5	5.84e-18	Skin colour saturation;
CESC	cis	rs847577	0.748	rs940431	chr7:97716495	C/T	cg24562669	chr7:97807699	LMTK2	0.63	10.15	0.53	1.13e-20	Breast cancer;
CESC	cis	rs6681460	0.934	rs4655635	chr1:67068240	T/G	cg02459107	chr1:67143332	SGIP1	0.35	5.13	0.3	5.51e-7	Presence of antiphospholipid antibodies;
CESC	cis	rs2997447	0.633	rs6665062	chr1:26362001	C/T	cg19633962	chr1:26362018	EXTL1	-0.62	-5.88	-0.34	1.25e-8	QRS complex (12-leadsum);
CESC	trans	rs57221529	0.654	rs12515813	chr5:671826	A/T	cg25482853	chr8:67687455	SGK3	0.97	9.47	0.5	1.67e-18	Lung disease severity in cystic fibrosis;
CESC	cis	rs10791323	0.598	rs10750550	chr11:133736083	A/G	cg15485101	chr11:133734466	NA	0.33	5.73	0.33	2.73e-8	Childhood ear infection;
CESC	cis	rs2243480	1.000	rs7804223	chr7:65664559	T/G	cg18252515	chr7:66147081	NA	1.36	13.62	0.64	2.25e-32	Diabetic kidney disease;
CESC	cis	rs2289583	0.503	rs12050494	chr15:75260896	G/A	cg14664628	chr15:75095509	CSK	0.52	6.07	0.35	4.51e-9	Systemic lupus erythematosus;
CESC	cis	rs10242455	0.867	rs2687141	chr7:99321479	T/C	cg07715041	chr7:99302981	CYP3A7	-0.43	-5.42	-0.32	1.36e-7	Blood metabolite levels;
CESC	cis	rs7811142	0.830	rs78256546	chr7:99952970	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.08	11.0	0.56	1.98e-23	Platelet count;
CESC	cis	rs7267979	0.966	rs2482948	chr20:25296499	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.84	-16.08	-0.7	4.65e-41	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs10751667	0.643	rs10751669	chr11:942344	C/G	cg06064525	chr11:970664	AP2A2	0.52	10.32	0.54	3.35e-21	Alzheimer's disease (late onset);
CESC	cis	rs4664308	0.875	rs7593593	chr2:160933811	C/T	cg03641300	chr2:160917029	PLA2R1	-0.67	-9.84	-0.52	1.11e-19	Idiopathic membranous nephropathy;
CESC	cis	rs9311474	0.508	rs4687546	chr3:52605943	T/A	cg18404041	chr3:52824283	ITIH1	-0.38	-6.5	-0.37	4e-10	Electroencephalogram traits;
CESC	cis	rs9329289	0.550	rs11251294	chr10:2562328	C/T	cg15501526	chr10:2543763	NA	-0.39	-5.92	-0.34	1.01e-8	Age-related hearing impairment;
CESC	cis	rs11997175	0.603	rs7464053	chr8:33786938	C/A	ch.8.33884649F	chr8:33765107	NA	0.48	5.79	0.33	2.01e-8	Body mass index;
CESC	cis	rs7212590	0.618	rs7219051	chr17:58032710	G/A	cg20303301	chr17:57937339	TUBD1	-0.55	-5.57	-0.32	6.25e-8	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs727505	0.721	rs56269941	chr7:124768732	T/A	cg23710748	chr7:124431027	NA	-0.37	-6.18	-0.35	2.43e-9	Lewy body disease;
CESC	cis	rs66573146	1.000	rs9942188	chr4:6984181	C/T	cg00086871	chr4:6988644	TBC1D14	1.12	6.94	0.39	2.96e-11	Granulocyte percentage of myeloid white cells;
CESC	cis	rs9611565	0.659	rs4822034	chr22:41931010	T/C	cg03806693	chr22:41940476	POLR3H	-1.25	-17.05	-0.72	1.64e-44	Vitiligo;
CESC	cis	rs4315565	0.688	rs6546477	chr2:69281345	G/T	cg12800200	chr2:69260302	ANTXR1	-0.39	-5.59	-0.32	5.64e-8	Height;
CESC	cis	rs1008375	1.000	rs114490726	chr4:17680898	T/C	cg02297831	chr4:17616191	MED28	0.45	5.76	0.33	2.29e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs7814319	0.933	rs7827095	chr8:97239126	C/T	cg20787634	chr8:97240163	UQCRB	0.54	7.12	0.4	1.04e-11	Lung function (FVC);
CESC	cis	rs34779708	0.733	rs60553075	chr10:35542462	T/A	cg03585969	chr10:35415529	CREM	0.56	6.42	0.37	6.15e-10	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs7582720	1.000	rs72936882	chr2:203794439	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.38	0.41	1.99e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs72634258	0.836	rs9658012	chr1:7989022	C/T	cg00042356	chr1:8021962	PARK7	0.86	7.94	0.44	5.73e-14	Inflammatory bowel disease;
CESC	cis	rs933688	1.000	rs9293568	chr5:90737845	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.95	11.09	0.56	1.03e-23	Smoking behavior;
CESC	cis	rs72781680	0.898	rs72780121	chr2:23995918	T/C	cg08917208	chr2:24149416	ATAD2B	0.95	8.71	0.47	3.45e-16	Lymphocyte counts;
CESC	cis	rs9322193	1.000	rs9377228	chr6:149921998	G/A	cg07701084	chr6:150067640	NUP43	0.44	6.27	0.36	1.47e-9	Lung cancer;
CESC	cis	rs10927875	0.541	rs1763596	chr1:16343835	C/T	cg22431228	chr1:16359049	CLCNKA	-0.52	-9.9	-0.52	7.22e-20	Dilated cardiomyopathy;
CESC	cis	rs2033711	0.837	rs3764535	chr19:58929052	G/A	cg26874164	chr19:58962979	ZNF324B	0.59	8.0	0.44	3.88e-14	Uric acid clearance;
CESC	cis	rs6736093	0.933	rs6754526	chr2:112729669	A/G	cg12686935	chr2:112915763	FBLN7	-0.42	-5.57	-0.32	6.33e-8	Coronary artery disease;
CESC	cis	rs769267	0.930	rs1047361	chr19:19606634	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.59	7.48	0.42	1.1e-12	Tonsillectomy;
CESC	cis	rs7809950	1.000	rs2520269	chr7:107191327	T/C	cg23024343	chr7:107201750	COG5	-0.45	-6.07	-0.35	4.38e-9	Coronary artery disease;
CESC	cis	rs7772486	0.720	rs1890171	chr6:146072114	T/C	cg05347473	chr6:146136440	FBXO30	-0.57	-7.26	-0.41	4.42e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs889398	0.771	rs4985448	chr16:69899395	A/G	cg09409435	chr16:70099608	PDXDC2	0.4	5.07	0.3	7.64e-7	Body mass index;
CESC	cis	rs3092073	0.624	rs13040315	chr20:44585793	A/G	cg17986701	chr20:44574422	PCIF1	0.33	5.13	0.3	5.51e-7	Intelligence (multi-trait analysis);
CESC	cis	rs6456156	0.792	rs4710181	chr6:167513998	T/C	cg07741184	chr6:167504864	NA	0.38	6.92	0.39	3.46e-11	Primary biliary cholangitis;
CESC	cis	rs736408	0.812	rs2270197	chr3:52824095	T/G	cg17372223	chr3:52568218	NT5DC2	0.4	5.58	0.32	6.05e-8	Bipolar disorder;
CESC	cis	rs6138458	1.000	rs6114981	chr20:24974401	C/T	cg06937882	chr20:24974362	C20orf3	0.33	5.15	0.3	4.99e-7	Blood protein levels;
CESC	cis	rs2617583	0.967	rs2550948	chr5:1450444	C/T	cg07151155	chr5:1473589	LPCAT1	-0.34	-5.24	-0.31	3.34e-7	Breast cancer;
CESC	cis	rs11098499	0.954	rs10008459	chr4:120394231	T/C	cg09307838	chr4:120376055	NA	0.94	13.97	0.65	1.31e-33	Corneal astigmatism;
CESC	cis	rs2011503	0.941	rs2074302	chr19:19381728	G/C	cg11584989	chr19:19387371	SF4	0.6	7.21	0.4	5.96e-12	Bipolar disorder;
CESC	cis	rs12900413	0.687	rs34284515	chr15:90308061	T/G	cg24249390	chr15:90295951	MESP1	-0.39	-5.47	-0.32	1.03e-7	Coronary artery aneurysm in Kawasaki disease;
CESC	cis	rs56104184	0.775	rs73061689	chr19:49397214	C/T	cg15549821	chr19:49342101	PLEKHA4	-0.58	-5.8	-0.34	1.9e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	cis	rs875971	0.798	rs12698522	chr7:65967341	T/C	cg19163074	chr7:65112434	INTS4L2	-0.42	-5.26	-0.31	2.93e-7	Aortic root size;
CESC	cis	rs9837602	0.935	rs9810235	chr3:99736538	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.54	7.51	0.42	9.05e-13	Breast cancer;
CESC	cis	rs6963495	0.818	rs6944787	chr7:105147309	C/T	cg13798780	chr7:105162888	PUS7	0.76	7.8	0.43	1.47e-13	Bipolar disorder (body mass index interaction);
CESC	trans	rs61931739	0.929	rs2389272	chr12:34067771	T/C	cg26384229	chr12:38710491	ALG10B	-0.46	-6.6	-0.38	2.21e-10	Morning vs. evening chronotype;
CESC	cis	rs12410462	0.892	rs35341041	chr1:227653885	G/A	cg04117972	chr1:227635322	NA	0.62	6.0	0.35	6.56e-9	Major depressive disorder;
CESC	cis	rs9311474	0.508	rs4687629	chr3:52615227	G/C	cg05564831	chr3:52568323	NT5DC2	0.48	7.76	0.43	1.88e-13	Electroencephalogram traits;
CESC	cis	rs6952808	0.594	rs3778969	chr7:2139990	A/G	cg05863683	chr7:1912471	MAD1L1	-0.39	-5.68	-0.33	3.49e-8	Bipolar disorder and schizophrenia;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg11768411	chr8:144329279	ZFP41	-0.45	-6.12	-0.35	3.27e-9	Fibrinogen levels;
CESC	cis	rs13082711	0.911	rs73046191	chr3:27454398	T/A	cg02860705	chr3:27208620	NA	0.54	7.0	0.39	2.13e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CESC	cis	rs8014204	0.836	rs7154256	chr14:75252587	A/G	cg08847533	chr14:75593920	NEK9	0.46	5.84	0.34	1.53e-8	Caffeine consumption;
CESC	cis	rs9560113	0.508	rs2774425	chr13:112235077	A/G	cg10483660	chr13:112241077	NA	-0.43	-7.39	-0.41	1.96e-12	Menarche (age at onset);
CESC	cis	rs727505	0.607	rs17387389	chr7:124784751	T/C	cg23710748	chr7:124431027	NA	-0.4	-6.24	-0.36	1.73e-9	Lewy body disease;
CESC	cis	rs7937682	0.889	rs484013	chr11:111495779	G/A	cg22437258	chr11:111473054	SIK2	0.72	9.69	0.51	3.38e-19	Primary sclerosing cholangitis;
CESC	cis	rs791888	0.858	rs2180968	chr10:89418730	A/C	cg13926569	chr10:89418898	PAPSS2	0.49	6.83	0.39	5.67e-11	Magnesium levels;
CESC	cis	rs10751667	0.643	rs7394524	chr11:933865	T/C	cg06064525	chr11:970664	AP2A2	-0.52	-10.37	-0.54	2.34e-21	Alzheimer's disease (late onset);
CESC	trans	rs12986445	0.744	rs10209951	chr2:26144986	C/G	ch.17.1742593R	chr17:65528935	PITPNC1	0.51	6.05	0.35	4.87e-9	Multiple myeloma and monoclonal gammopathy;Multiple myeloma;
CESC	cis	rs7666738	0.819	rs13139560	chr4:99081188	C/T	cg05340658	chr4:99064831	C4orf37	0.61	7.1	0.4	1.17e-11	Colonoscopy-negative controls vs population controls;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg22627950	chr7:44622302	TMED4	-0.42	-6.06	-0.35	4.6e-9	Gambling;
CESC	cis	rs7520050	0.966	rs7515491	chr1:46355079	A/G	cg24296786	chr1:45957014	TESK2	0.42	5.41	0.32	1.43e-7	Red blood cell count;Reticulocyte count;
CESC	cis	rs10744422	0.528	rs6489245	chr12:123360151	G/A	cg25930673	chr12:123319894	HIP1R	-0.74	-5.67	-0.33	3.7e-8	Schizophrenia;
CESC	cis	rs8141529	0.702	rs469990	chr22:29304200	A/T	cg02153584	chr22:29168773	CCDC117	0.56	7.39	0.41	1.94e-12	Lymphocyte counts;
CESC	cis	rs1799949	0.965	rs8176323	chr17:41195711	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	8.59	0.47	7.39e-16	Menopause (age at onset);
CESC	cis	rs853679	0.550	rs1233704	chr6:28166923	A/G	cg19592336	chr6:28129416	ZNF389	-0.5	-6.87	-0.39	4.44e-11	Depression;
CESC	cis	rs9457247	1.000	rs2013815	chr6:167373812	T/A	cg23791538	chr6:167370224	RNASET2	0.6	8.49	0.46	1.54e-15	Crohn's disease;
CESC	cis	rs6785206	0.803	rs2712380	chr3:128338661	A/C	cg16766828	chr3:128327626	NA	-0.63	-6.49	-0.37	4.31e-10	Lymphocyte percentage of white cells;
CESC	cis	rs1580019	0.922	rs766658	chr7:32499391	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.73	10.1	0.53	1.62e-20	Cognitive ability;
CESC	cis	rs1799949	1.000	rs16942	chr17:41244000	T/C	cg06001716	chr17:41278141	BRCA1;NBR2	0.39	5.4	0.31	1.51e-7	Menopause (age at onset);
CESC	cis	rs6967414	0.685	rs6944332	chr7:6758018	G/A	cg00387323	chr7:6746715	ZNF12	0.61	5.77	0.33	2.21e-8	Hematocrit;Hemoglobin concentration;
CESC	cis	rs9905704	0.574	rs35952494	chr17:57074467	C/T	cg12560992	chr17:57184187	TRIM37	0.67	5.91	0.34	1.07e-8	Testicular germ cell tumor;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg09666561	chr16:30406910	ZNF48	-0.47	-6.4	-0.37	7.2e-10	Fibrinogen levels;
CESC	cis	rs7615952	0.641	rs12495947	chr3:125771698	C/T	cg06494592	chr3:125709126	NA	-0.49	-5.2	-0.3	3.92e-7	Blood pressure (smoking interaction);
CESC	cis	rs9309473	0.848	rs17009159	chr2:73797762	A/T	cg20560298	chr2:73613845	ALMS1	-0.54	-7.11	-0.4	1.1e-11	Metabolite levels;
CESC	cis	rs863345	0.967	rs11265029	chr1:158529281	C/T	cg12129480	chr1:158549410	OR10X1	-0.32	-6.52	-0.37	3.64e-10	Pneumococcal bacteremia;
CESC	cis	rs6076065	0.707	rs2024746	chr20:23356862	G/A	cg11657817	chr20:23433608	CST11	0.41	6.29	0.36	1.29e-9	Facial morphology (factor 15, philtrum width);
CESC	cis	rs1799949	1.000	rs8176103	chr17:41267050	G/A	cg05368731	chr17:41323189	NBR1	0.79	11.13	0.56	7.24e-24	Menopause (age at onset);
CESC	trans	rs61931739	0.500	rs11053223	chr12:34481947	T/A	cg13010199	chr12:38710504	ALG10B	0.5	6.5	0.37	3.92e-10	Morning vs. evening chronotype;
CESC	cis	rs7917772	0.582	rs7906115	chr10:104327164	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.41	5.61	0.33	5.05e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs2637266	1.000	rs1077916	chr10:78381951	G/A	cg18941641	chr10:78392320	NA	0.42	7.87	0.44	8.96e-14	Pulmonary function;
CESC	cis	rs9527	0.590	rs11191544	chr10:104827198	C/G	cg04362960	chr10:104952993	NT5C2	0.44	5.76	0.33	2.38e-8	Arsenic metabolism;
CESC	cis	rs13108904	0.517	rs13128825	chr4:1334007	G/A	cg00684032	chr4:1343700	KIAA1530	0.56	8.59	0.47	7.56e-16	Obesity-related traits;
CESC	cis	rs8078723	1.000	rs8078723	chr17:38166879	A/G	cg17467752	chr17:38218738	THRA	0.7	10.64	0.55	3.04e-22	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CESC	cis	rs2239547	0.618	rs3733047	chr3:52871929	A/G	cg11645453	chr3:52864694	ITIH4	-0.37	-6.51	-0.37	3.75e-10	Schizophrenia;
CESC	cis	rs9905704	0.918	rs72828707	chr17:56883236	A/G	cg12560992	chr17:57184187	TRIM37	0.61	7.16	0.4	7.98e-12	Testicular germ cell tumor;
CESC	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg06074448	chr4:187884817	NA	-0.37	-5.43	-0.32	1.27e-7	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs79057730	0.599	rs6944167	chr7:826274	G/C	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.7	6.63	0.38	1.85e-10	Initial pursuit acceleration;
CESC	cis	rs6121246	0.697	rs6088864	chr20:30228157	G/A	cg13852791	chr20:30311386	BCL2L1	0.77	7.79	0.43	1.48e-13	Mean corpuscular hemoglobin;
CESC	cis	rs7727544	0.684	rs272869	chr5:131677997	A/G	cg07395648	chr5:131743802	NA	-0.39	-5.17	-0.3	4.58e-7	Blood metabolite levels;
CESC	cis	rs1799949	1.000	rs2037076	chr17:41305883	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.66	9.22	0.49	9.27e-18	Menopause (age at onset);
CESC	cis	rs1577917	0.917	rs35038582	chr6:86721305	T/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-6.03	-0.35	5.34e-9	Response to antipsychotic treatment;
CESC	cis	rs4665809	0.938	rs4665822	chr2:26312555	C/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.7	-7.95	-0.44	5.54e-14	Gut microbiome composition (summer);
CESC	trans	rs9951602	0.512	rs9304070	chr18:76654890	A/C	cg02800362	chr5:177631904	HNRNPAB	0.66	9.41	0.5	2.41e-18	Obesity-related traits;
CESC	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.49	6.46	0.37	5.09e-10	Lymphocyte counts;
CESC	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg05313129	chr8:58192883	C8orf71	-0.49	-5.32	-0.31	2.23e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs875971	0.522	rs1968127	chr7:66056803	C/T	cg25985355	chr7:65971099	NA	0.32	5.23	0.31	3.43e-7	Aortic root size;
CESC	cis	rs4974559	0.739	rs6599298	chr4:1298122	A/G	cg02980000	chr4:1222292	CTBP1	0.78	7.13	0.4	9.41e-12	Systolic blood pressure;
CESC	cis	rs4835473	0.932	rs1842484	chr4:144714982	G/C	cg25736465	chr4:144833511	NA	0.33	5.43	0.32	1.29e-7	Immature fraction of reticulocytes;
CESC	cis	rs3741151	0.773	rs17310361	chr11:73233724	T/C	cg17517138	chr11:73019481	ARHGEF17	0.78	6.37	0.36	8.35e-10	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs9814567	0.858	rs4955548	chr3:134341060	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.43	-5.67	-0.33	3.78e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	trans	rs7107217	1.000	rs1873872	chr11:129473993	A/T	cg06397424	chr16:15737279	NDE1;KIAA0430	-0.44	-5.99	-0.35	6.64e-9	Breast cancer;Type 2 diabetes;
CESC	cis	rs1153858	1.000	rs56850226	chr15:45633118	T/C	cg14582100	chr15:45693742	SPATA5L1	0.44	6.28	0.36	1.38e-9	Homoarginine levels;
CESC	trans	rs2727020	0.523	rs4115783	chr11:49556026	G/A	cg03929089	chr4:120376271	NA	0.73	8.46	0.46	1.79e-15	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08519270	chr4:190861788	FRG1	0.67	7.63	0.42	4.19e-13	Gut microbiome composition (summer);
CESC	cis	rs854765	0.547	rs2955372	chr17:17970229	T/C	cg09796270	chr17:17721594	SREBF1	-0.38	-5.07	-0.3	7.49e-7	Total body bone mineral density;
CESC	cis	rs9911578	1.000	rs7216680	chr17:56988243	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.41	5.4	0.31	1.48e-7	Intelligence (multi-trait analysis);
CESC	trans	rs4927850	1.000	rs10881563	chr3:195750225	A/G	cg21051086	chr3:73046214	PPP4R2	-0.45	-6.27	-0.36	1.45e-9	Pancreatic cancer;
CESC	cis	rs67311347	0.577	rs1880763	chr3:40283255	C/T	cg09455208	chr3:40491958	NA	-0.35	-5.59	-0.33	5.5e-8	Renal cell carcinoma;
CESC	cis	rs4722166	0.630	rs12537614	chr7:22789551	C/G	cg13104385	chr7:22767384	IL6	0.45	6.12	0.35	3.38e-9	Lung cancer;
CESC	cis	rs7917772	0.503	rs11191320	chr10:104293394	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.53	7.24	0.41	4.83e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs7833790	0.724	rs6473309	chr8:82707880	A/G	cg02079420	chr8:82753780	SNX16	0.53	8.0	0.44	3.95e-14	Diastolic blood pressure;
CESC	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.89	13.59	0.64	2.8e-32	Prudent dietary pattern;
CESC	cis	rs4889855	0.556	rs11651818	chr17:78530300	A/G	cg16591659	chr17:78472290	NA	0.38	6.31	0.36	1.14e-9	Fractional excretion of uric acid;
CESC	cis	rs10832963	0.847	rs4237722	chr11:18639363	T/C	cg20219074	chr11:18656078	SPTY2D1	0.77	10.66	0.55	2.51e-22	Breast cancer;
CESC	cis	rs7474896	0.515	rs594594	chr10:38307723	A/G	cg25427524	chr10:38739819	LOC399744	0.49	5.48	0.32	1.01e-7	Obesity (extreme);
CESC	cis	rs10242455	0.702	rs73403290	chr7:99157828	C/T	cg25640893	chr7:99214727	ZNF498	0.71	5.21	0.3	3.87e-7	Blood metabolite levels;
CESC	cis	rs9325144	0.671	rs12818797	chr12:39019409	A/G	cg26384229	chr12:38710491	ALG10B	-0.52	-7.27	-0.41	4e-12	Morning vs. evening chronotype;
CESC	cis	rs7666738	0.830	rs35491210	chr4:99003364	T/C	cg05340658	chr4:99064831	C4orf37	0.78	11.87	0.59	2.5e-26	Colonoscopy-negative controls vs population controls;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg00852768	chr6:163834924	QKI	0.44	6.07	0.35	4.4e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs79911532	0.515	rs10245109	chr7:75846115	G/T	cg06959773	chr7:76033795	SRCRB4D;ZP3	0.56	5.24	0.31	3.23e-7	Mononucleosis;
CESC	cis	rs17376456	0.542	rs2084916	chr5:93194961	A/T	cg21475434	chr5:93447410	FAM172A	-0.52	-5.25	-0.31	3.13e-7	Diabetic retinopathy;
CESC	cis	rs763014	0.833	rs3743903	chr16:632736	T/C	cg00908189	chr16:619842	PIGQ	0.67	9.34	0.5	4.24e-18	Height;
CESC	cis	rs763121	0.853	rs5757196	chr22:39039855	G/C	cg14440974	chr22:39074834	NA	-0.4	-5.48	-0.32	9.77e-8	Menopause (age at onset);
CESC	cis	rs7618915	0.679	rs6802320	chr3:52241835	T/C	cg05315796	chr3:52349193	DNAH1	0.37	6.34	0.36	9.71e-10	Bipolar disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02801482	chr2:159824941	TANC1	0.56	6.3	0.36	1.21e-9	Gut microbiome composition (summer);
CESC	cis	rs7660520	0.524	rs4862100	chr4:183732709	G/T	cg04181038	chr4:183730758	NA	0.63	6.9	0.39	3.91e-11	Pediatric autoimmune diseases;
CESC	cis	rs8177253	0.761	rs1830083	chr3:133508551	G/A	cg12373951	chr3:133503437	NA	0.5	7.43	0.42	1.53e-12	Iron status biomarkers;
CESC	cis	rs8177179	0.967	rs9820225	chr3:133449189	A/G	cg16262614	chr3:133464971	TF	0.43	8.64	0.47	5.58e-16	Iron status biomarkers (transferrin levels);
CESC	cis	rs7647973	0.580	rs7652746	chr3:49262307	C/T	cg03060546	chr3:49711283	APEH	-0.51	-6.82	-0.39	6.32e-11	Menarche (age at onset);
CESC	cis	rs637571	0.522	rs3016868	chr11:65764383	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.74	10.73	0.55	1.58e-22	Eosinophil percentage of white cells;
CESC	cis	rs734999	0.588	rs2260976	chr1:2527678	A/G	cg20673091	chr1:2541236	MMEL1	-0.44	-7.23	-0.41	5.08e-12	Ulcerative colitis;
CESC	cis	rs11098499	0.863	rs7657849	chr4:120455494	T/C	cg09307838	chr4:120376055	NA	0.91	12.54	0.61	1.24e-28	Corneal astigmatism;
CESC	cis	rs4635969	0.718	rs27071	chr5:1346081	T/C	cg07493874	chr5:1342172	CLPTM1L	-0.43	-6.19	-0.36	2.3e-9	Testicular germ cell tumor;Testicular germ cell cancer;
CESC	cis	rs7481584	0.669	rs12421922	chr11:3035070	A/G	cg25174290	chr11:3078921	CARS	-0.44	-5.87	-0.34	1.31e-8	Calcium levels;
CESC	cis	rs2279817	0.735	rs12075624	chr1:17991573	A/G	cg21791023	chr1:18019539	ARHGEF10L	-0.6	-7.65	-0.43	3.74e-13	Neuroticism;
CESC	cis	rs1552244	0.882	rs35056669	chr3:10014171	C/T	cg00149659	chr3:10157352	C3orf10	0.73	8.58	0.47	7.94e-16	Alzheimer's disease;
CESC	cis	rs6088580	0.634	rs6141471	chr20:33006730	A/G	cg24642439	chr20:33292090	TP53INP2	-0.53	-6.98	-0.39	2.39e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs796364	1.000	rs4263095	chr2:200830137	A/C	cg23649088	chr2:200775458	C2orf69	-0.53	-5.2	-0.3	4.06e-7	Schizophrenia;
CESC	cis	rs1801251	0.752	rs2592126	chr2:233751377	A/G	cg08000102	chr2:233561755	GIGYF2	-0.58	-7.81	-0.43	1.38e-13	Coronary artery disease;
CESC	cis	rs8180040	1.000	rs8180040	chr3:47388947	A/T	cg27129171	chr3:47204927	SETD2	0.65	9.9	0.52	7.51e-20	Colorectal cancer;
CESC	cis	rs10752881	0.602	rs9425569	chr1:182942202	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.56	7.08	0.4	1.27e-11	Colorectal cancer;
CESC	cis	rs938554	0.513	rs3775947	chr4:9995240	C/T	cg00071950	chr4:10020882	SLC2A9	0.67	8.59	0.47	7.72e-16	Blood metabolite levels;
CESC	trans	rs11098499	0.863	rs59732491	chr4:120489588	G/C	cg25214090	chr10:38739885	LOC399744	0.65	8.73	0.47	2.86e-16	Corneal astigmatism;
CESC	cis	rs9747201	0.963	rs4789729	chr17:80146089	G/A	cg09264619	chr17:80180166	NA	-0.43	-5.08	-0.3	7.24e-7	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs4713118	0.662	rs149948	chr6:27974817	C/G	cg23281280	chr6:28129359	ZNF389	0.46	6.39	0.37	7.42e-10	Parkinson's disease;
CESC	cis	rs4555082	0.756	rs76863138	chr14:105736379	C/T	cg06808227	chr14:105710500	BRF1	-0.6	-6.74	-0.38	9.78e-11	Mean platelet volume;Platelet distribution width;
CESC	cis	rs1215050	0.791	rs1506438	chr4:98789542	C/T	cg17366294	chr4:99064904	C4orf37	0.39	5.04	0.3	8.81e-7	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs7927771	1.000	rs9909	chr11:47799775	C/G	cg05585544	chr11:47624801	NA	-0.5	-7.81	-0.43	1.38e-13	Subjective well-being;
CESC	cis	rs7927592	0.513	rs7950129	chr11:68202903	A/G	cg16797656	chr11:68205561	LRP5	0.63	9.97	0.52	4.43e-20	Total body bone mineral density;
CESC	cis	rs4253772	0.515	rs8142080	chr22:46647429	G/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.62	5.29	0.31	2.55e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs1348850	0.914	rs12616443	chr2:178315751	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.72	9.95	0.52	5.01e-20	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs875971	0.798	rs57739047	chr7:65972566	A/T	cg12463550	chr7:65579703	CRCP	0.49	6.11	0.35	3.61e-9	Aortic root size;
CESC	cis	rs9303401	0.734	rs8073316	chr17:57211381	A/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.65	-8.05	-0.44	2.89e-14	Cognitive test performance;
CESC	cis	rs7618915	0.501	rs2079929	chr3:52765646	C/T	cg17372223	chr3:52568218	NT5DC2	0.43	6.42	0.37	6.1e-10	Bipolar disorder;
CESC	cis	rs9612	0.718	rs346535	chr19:44251425	C/T	cg08581076	chr19:44259116	C19orf61	0.43	5.24	0.31	3.2e-7	Exhaled nitric oxide output;
CESC	cis	rs6502050	0.842	rs9894129	chr17:80075700	A/G	cg11859384	chr17:80120422	CCDC57	0.4	5.5	0.32	8.88e-8	Life satisfaction;
CESC	cis	rs2932538	0.922	rs6691917	chr1:113137043	G/C	cg22162597	chr1:113214053	CAPZA1	0.48	6.42	0.37	6.28e-10	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CESC	cis	rs1003719	0.591	rs1053984	chr21:38574018	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.59	-7.74	-0.43	2.09e-13	Eye color traits;
CESC	cis	rs17376456	0.825	rs55724660	chr5:93276636	A/G	cg25358565	chr5:93447407	FAM172A	1.13	10.24	0.53	6.15e-21	Diabetic retinopathy;
CESC	cis	rs2072499	0.865	rs2758603	chr1:156198994	T/C	cg25208724	chr1:156163844	SLC25A44	0.83	13.17	0.63	8.26e-31	Testicular germ cell tumor;
CESC	cis	rs7772486	0.764	rs9399569	chr6:146242942	C/T	cg23711669	chr6:146136114	FBXO30	-0.82	-11.64	-0.58	1.47e-25	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs650950	0.528	rs646660	chr11:35528452	C/T	cg11303561	chr19:1206399	STK11	0.46	6.0	0.35	6.33e-9	Bronchopulmonary dysplasia;
CESC	cis	rs727505	0.583	rs17147421	chr7:124383948	C/T	cg23710748	chr7:124431027	NA	-0.39	-5.79	-0.34	1.98e-8	Lewy body disease;
CESC	cis	rs7264396	0.790	rs6121015	chr20:34243017	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.64	7.7	0.43	2.63e-13	Total cholesterol levels;
CESC	cis	rs12048904	0.930	rs11166529	chr1:101333733	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.58	7.65	0.43	3.71e-13	Multiple sclerosis;
CESC	cis	rs16854884	0.582	rs35211123	chr3:143640171	A/T	cg01302019	chr3:143689584	C3orf58	-0.34	-5.16	-0.3	4.89e-7	Economic and political preferences (feminism/equality);
CESC	cis	rs1133146	1.000	rs1133146	chr19:53666660	A/G	cg09412792	chr19:54664028	TMC4;LENG1	0.4	5.17	0.3	4.63e-7	Yu-Zhi constitution type in type 2 diabetes;
CESC	cis	rs9486715	1.000	rs6905737	chr6:97066659	A/T	cg06623918	chr6:96969491	KIAA0776	-0.86	-12.44	-0.61	2.82e-28	Headache;
CESC	cis	rs9359856	0.564	rs61739327	chr6:90340446	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.62	-5.6	-0.33	5.29e-8	Bipolar disorder;
CESC	cis	rs10979	0.597	rs9399449	chr6:143908376	C/T	cg25407410	chr6:143891975	LOC285740	-0.49	-6.35	-0.36	9.21e-10	Hypospadias;
CESC	cis	rs9916302	0.904	rs1619021	chr17:37739274	G/A	cg07936489	chr17:37558343	FBXL20	-0.78	-10.54	-0.54	6.5600000000000005e-22	Glomerular filtration rate (creatinine);
CESC	trans	rs829883	1.000	rs829883	chr12:98879606	G/A	cg04550079	chr16:67212681	KIAA0895L	-0.37	-6.07	-0.35	4.34e-9	Colorectal adenoma (advanced);
CESC	cis	rs7561273	0.586	rs11892283	chr2:24317850	T/C	cg01493198	chr2:24299560	SF3B14	0.42	5.13	0.3	5.69e-7	Quantitative traits;
CESC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg23142935	chr16:22385308	CDR2	-0.55	-6.23	-0.36	1.83e-9	Lung cancer in ever smokers;
CESC	cis	rs10751667	0.666	rs6597962	chr11:976351	C/T	cg20946044	chr11:1010712	AP2A2	-0.4	-5.46	-0.32	1.11e-7	Alzheimer's disease (late onset);
CESC	cis	rs10256972	0.684	rs2363279	chr7:1096143	A/G	cg23978390	chr7:1156363	C7orf50	0.56	7.44	0.42	1.44e-12	Longevity;Endometriosis;
CESC	cis	rs12971120	0.504	rs11665154	chr18:72147006	A/C	cg26446133	chr18:72167187	CNDP2	-0.55	-7.94	-0.44	5.67e-14	Refractive error;
CESC	cis	rs7666738	0.830	rs10010698	chr4:98981594	C/T	cg18180107	chr4:99064573	C4orf37	0.39	5.13	0.3	5.6e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6541297	1.000	rs6541297	chr1:230283506	G/A	cg20703242	chr1:230279135	GALNT2	0.65	10.46	0.54	1.13e-21	Coronary artery disease;
CESC	cis	rs1957429	0.901	rs1951490	chr14:65346957	G/T	cg23373153	chr14:65346875	NA	0.96	11.51	0.58	4.06e-25	Pediatric areal bone mineral density (radius);
CESC	cis	rs9388451	0.839	rs4897157	chr6:126102981	A/T	cg10911889	chr6:126070802	HEY2	0.37	5.15	0.3	5.13e-7	Brugada syndrome;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04667467	chr16:90089176	GAS8	0.56	6.54	0.37	3.14e-10	Gut microbiome composition (summer);
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg02328807	chr16:75269564	BCAR1	0.42	6.05	0.35	5.01e-9	Asthma;
CESC	cis	rs4969178	0.932	rs3744219	chr17:76400236	G/A	cg20026190	chr17:76395443	PGS1	0.46	7.35	0.41	2.41e-12	HDL cholesterol levels;
CESC	cis	rs3796352	1.000	rs116616340	chr3:53132371	C/G	cg12962167	chr3:53033115	SFMBT1	0.54	5.13	0.3	5.5e-7	Immune reponse to smallpox (secreted IL-2);
CESC	cis	rs597539	0.690	rs615644	chr11:68621806	G/C	cg21963583	chr11:68658836	MRPL21	0.4	5.39	0.31	1.52e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs9443645	0.527	rs10943600	chr6:79611505	G/A	cg05283184	chr6:79620031	NA	-0.36	-5.16	-0.3	4.91e-7	Intelligence (multi-trait analysis);
CESC	cis	rs2573652	1.000	rs2581359	chr15:100513707	A/G	cg09918751	chr15:100517450	ADAMTS17	-0.39	-7.49	-0.42	1.04e-12	Height;
CESC	cis	rs4700695	0.668	rs153393	chr5:65428707	A/G	cg21114390	chr5:65439923	SFRS12	-0.49	-5.84	-0.34	1.49e-8	Facial morphology (factor 19);
CESC	trans	rs7937682	0.889	rs3017767	chr11:111508098	A/G	cg18187862	chr3:45730750	SACM1L	0.51	6.47	0.37	4.81e-10	Primary sclerosing cholangitis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09592456	chr22:19780308	GNB1L	-0.59	-7.11	-0.4	1.09e-11	Gut microbiome composition (summer);
CESC	cis	rs6089584	0.850	rs6142939	chr20:60627729	A/G	cg06108461	chr20:60628389	TAF4	-0.92	-14.32	-0.66	7.92e-35	Body mass index;
CESC	cis	rs4975709	0.610	rs4975705	chr5:1860359	T/C	cg20790798	chr5:1857306	NA	-0.38	-5.11	-0.3	6.21e-7	Cardiovascular disease risk factors;
CESC	cis	rs2456568	0.709	rs1354765	chr11:93637776	G/T	cg26875233	chr11:93583750	C11orf90	0.3	5.26	0.31	2.91e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
CESC	cis	rs2668423	0.502	rs2074898	chr19:1391361	A/G	cg02639931	chr19:1387894	NDUFS7	-0.7	-14.28	-0.66	1.06e-34	Nonalcoholic fatty liver disease;
CESC	cis	rs7772486	0.846	rs6908063	chr6:146403618	T/C	cg23711669	chr6:146136114	FBXO30	0.78	11.61	0.58	1.77e-25	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7267979	0.899	rs442834	chr20:25458096	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.78	14.78	0.67	1.87e-36	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs9614461	0.609	rs9614653	chr22:45767391	A/G	cg01808030	chr22:45809952	RIBC2;SMC1B	-0.66	-7.26	-0.41	4.37e-12	Tonsillectomy;
CESC	cis	rs1552244	0.882	rs13100734	chr3:10022878	A/G	cg00149659	chr3:10157352	C3orf10	0.7	8.16	0.45	1.35e-14	Alzheimer's disease;
CESC	cis	rs2075371	0.829	rs1993058	chr7:133930361	G/A	cg00033643	chr7:134001901	SLC35B4	0.41	5.22	0.31	3.65e-7	Mean platelet volume;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg26464252	chr10:6186649	PFKFB3	-0.46	-6.1	-0.35	3.73e-9	Fibrinogen levels;
CESC	cis	rs4555082	0.834	rs2735816	chr14:105721603	C/G	cg10792982	chr14:105748885	BRF1	-0.44	-5.75	-0.33	2.47e-8	Mean platelet volume;Platelet distribution width;
CESC	cis	rs8072100	0.967	rs8075411	chr17:45676760	C/T	cg08085267	chr17:45401833	C17orf57	0.4	5.15	0.3	5.18e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs9894429	0.671	rs6565616	chr17:79612161	C/T	cg21984481	chr17:79567631	NPLOC4	-0.35	-5.4	-0.31	1.49e-7	Eye color traits;
CESC	cis	rs1728785	1.000	rs1749793	chr16:68569312	C/T	cg02972257	chr16:68554789	NA	-0.62	-6.93	-0.39	3.14e-11	Ulcerative colitis;
CESC	cis	rs9911578	1.000	rs2567905	chr17:56782297	T/C	cg05425664	chr17:57184151	TRIM37	-0.51	-7.19	-0.4	6.81e-12	Intelligence (multi-trait analysis);
CESC	cis	rs8031584	0.918	rs3817498	chr15:31268781	T/C	cg08109568	chr15:31115862	NA	-0.63	-8.2	-0.45	1.03e-14	Huntington's disease progression;
CESC	cis	rs1003719	0.788	rs2835599	chr21:38466937	G/T	cg10648535	chr21:38446584	PIGP;TTC3	0.63	8.62	0.47	6.08e-16	Eye color traits;
CESC	cis	rs5753618	0.561	rs2078803	chr22:31652852	G/A	cg13145458	chr22:31556086	RNF185	0.46	5.26	0.31	2.98e-7	Colorectal cancer;
CESC	cis	rs1799949	0.864	rs60309406	chr17:41435665	C/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.39	5.34	0.31	2.02e-7	Menopause (age at onset);
CESC	cis	rs9948	0.655	rs62156213	chr2:97399100	T/C	cg01990225	chr2:97406019	LMAN2L	-1.02	-7.77	-0.43	1.76e-13	Erectile dysfunction and prostate cancer treatment;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14293898	chr9:37780721	EXOSC3	-0.59	-7.45	-0.42	1.34e-12	Gut microbiome composition (summer);
CESC	cis	rs1008375	0.931	rs7672369	chr4:17604825	A/G	cg27347728	chr4:17578864	LAP3	0.44	5.45	0.32	1.14e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg09610735	chr10:22609918	BMI1	-0.45	-6.01	-0.35	6.11e-9	Height;
CESC	cis	rs10791097	0.967	rs6590512	chr11:130717916	A/G	cg14779329	chr11:130786720	SNX19	-0.34	-5.55	-0.32	6.96e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs911555	0.570	rs11625397	chr14:104027557	A/G	cg24130564	chr14:104152367	KLC1	0.67	11.11	0.56	8.44e-24	Intelligence (multi-trait analysis);
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg15988263	chr1:44412313	IPO13	-0.46	-6.05	-0.35	4.83e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs3820928	0.904	rs2396431	chr2:227765488	G/A	cg11843606	chr2:227700838	RHBDD1	-0.45	-5.93	-0.34	9.45e-9	Pulmonary function;
CESC	cis	rs3762637	0.943	rs9822345	chr3:122245598	A/G	cg24169773	chr3:122142474	KPNA1	-0.59	-6.88	-0.39	4.42e-11	LDL cholesterol levels;
CESC	cis	rs9487051	0.714	rs6903695	chr6:109631422	C/G	cg21918786	chr6:109611834	NA	0.37	5.46	0.32	1.12e-7	Reticulocyte fraction of red cells;
CESC	cis	rs9814567	1.000	rs13322305	chr3:134310791	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.4	-5.44	-0.32	1.21e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs939658	0.805	rs8035606	chr15:79420245	C/T	cg17916960	chr15:79447300	NA	-0.36	-5.95	-0.34	8.39e-9	Refractive error;
CESC	trans	rs3942852	0.955	rs1910364	chr11:48113232	A/G	cg15704280	chr7:45808275	SEPT13	-0.67	-7.47	-0.42	1.18e-12	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs6952808	0.624	rs60137119	chr7:2083664	A/G	cg02951883	chr7:2050386	MAD1L1	-0.56	-7.35	-0.41	2.42e-12	Bipolar disorder and schizophrenia;
CESC	cis	rs67478160	0.575	rs8014294	chr14:104322983	A/G	cg08213375	chr14:104286397	PPP1R13B	0.38	7.18	0.4	6.85e-12	Schizophrenia;
CESC	cis	rs2820292	0.710	rs2047264	chr1:201886402	C/T	cg06775570	chr1:201857621	SHISA4	0.31	5.09	0.3	6.77e-7	Waist circumference;Body mass index (joint analysis main effects and smoking interaction);Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);
CESC	cis	rs875971	0.545	rs316328	chr7:65608838	A/G	cg18876405	chr7:65276391	NA	-0.45	-5.46	-0.32	1.08e-7	Aortic root size;
CESC	cis	rs6461049	0.608	rs3800923	chr7:2184673	A/G	cg21782813	chr7:2030301	MAD1L1	0.4	5.75	0.33	2.5e-8	Schizophrenia;
CESC	cis	rs4253772	0.745	rs78023664	chr22:46647844	G/A	cg24881330	chr22:46731750	TRMU	0.81	5.56	0.32	6.73e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs59918340	0.548	rs10102728	chr8:142205964	G/A	cg18755752	chr8:142205143	DENND3	-0.46	-6.06	-0.35	4.56e-9	Immature fraction of reticulocytes;
CESC	cis	rs1799949	1.000	rs8176289	chr17:41206056	T/C	cg25072359	chr17:41440525	NA	0.45	5.96	0.34	7.83e-9	Menopause (age at onset);
CESC	cis	rs9929218	0.679	rs9924886	chr16:68743939	A/C	cg02972257	chr16:68554789	NA	0.58	6.55	0.37	2.97e-10	Colorectal cancer;
CESC	cis	rs7089973	0.584	rs4752322	chr10:116613258	A/C	cg25233709	chr10:116636983	FAM160B1	0.4	6.63	0.38	1.87e-10	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs2576037	0.562	rs477826	chr18:44397649	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.35	5.69	0.33	3.38e-8	Personality dimensions;
CESC	cis	rs7829975	0.688	rs7817376	chr8:8380530	C/T	cg15556689	chr8:8085844	FLJ10661	-0.55	-6.79	-0.38	7.38e-11	Mood instability;
CESC	cis	rs965469	0.779	rs6051710	chr20:3264661	T/C	cg25506879	chr20:3388711	C20orf194	-0.47	-5.17	-0.3	4.66e-7	IFN-related cytopenia;
CESC	trans	rs9354308	0.933	rs12203567	chr6:66589062	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.68	7.63	0.42	4.23e-13	Metabolite levels;
CESC	cis	rs963731	0.649	rs1454223	chr2:39224351	G/T	cg04010122	chr2:39346883	SOS1	-0.76	-5.6	-0.33	5.44e-8	Corticobasal degeneration;
CESC	trans	rs7107217	1.000	rs1873872	chr11:129473993	A/T	cg09115837	chr10:79541592	NA	-0.48	-6.02	-0.35	5.81e-9	Breast cancer;Type 2 diabetes;
CESC	cis	rs9790314	0.967	rs336586	chr3:161081347	G/A	cg04691961	chr3:161091175	C3orf57	-0.41	-5.24	-0.31	3.27e-7	Morning vs. evening chronotype;
CESC	cis	rs514406	0.755	rs10888754	chr1:53228751	C/G	cg08859206	chr1:53392774	SCP2	0.6	8.84	0.48	1.36e-16	Monocyte count;
CESC	cis	rs924840	0.634	rs2869030	chr15:78711803	A/C	cg24631222	chr15:78858424	CHRNA5	0.52	6.92	0.39	3.32e-11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg15337887	chr5:68389678	SLC30A5	0.47	6.04	0.35	5.26e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	22.13	0.81	3.58e-62	Prudent dietary pattern;
CESC	cis	rs2549003	1.000	rs2070727	chr5:131820275	C/A	cg00255919	chr5:131827918	IRF1	0.51	8.59	0.47	7.76e-16	Asthma (sex interaction);
CESC	cis	rs875971	0.830	rs6976714	chr7:65891461	G/A	cg18252515	chr7:66147081	NA	-0.43	-5.6	-0.33	5.39e-8	Aortic root size;
CESC	cis	rs6460942	1.000	rs62448566	chr7:12403662	G/A	cg20607287	chr7:12443886	VWDE	-0.68	-7.91	-0.44	6.85e-14	Coronary artery disease;
CESC	cis	rs72945132	0.882	rs12279046	chr11:70130388	A/G	cg00319359	chr11:70116639	PPFIA1	0.78	7.78	0.43	1.6e-13	Coronary artery disease;
CESC	cis	rs7666738	0.791	rs10017624	chr4:98984009	G/T	cg18180107	chr4:99064573	C4orf37	0.4	5.19	0.3	4.29e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs910316	0.737	rs175071	chr14:75498177	A/G	cg15467112	chr14:75489610	MLH3	-0.33	-5.14	-0.3	5.31e-7	Height;
CESC	trans	rs9329221	0.683	rs688491	chr8:9884823	C/G	cg06636001	chr8:8085503	FLJ10661	-0.54	-7.11	-0.4	1.1e-11	Neuroticism;
CESC	cis	rs3796352	0.892	rs9756317	chr3:53088815	T/C	cg12962167	chr3:53033115	SFMBT1	-0.59	-5.7	-0.33	3.22e-8	Immune reponse to smallpox (secreted IL-2);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg20041257	chr19:10828819	DNM2;MIR638	-0.43	-6.44	-0.37	5.59e-10	Gambling;
CESC	cis	rs863345	0.604	rs11265016	chr1:158503785	C/T	cg12129480	chr1:158549410	OR10X1	-0.34	-6.85	-0.39	5.15e-11	Pneumococcal bacteremia;
CESC	cis	rs13191362	0.938	rs13192618	chr6:163132822	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.93	10.0	0.52	3.4e-20	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs35110281	0.591	rs86139	chr21:44932802	G/A	cg21573476	chr21:45109991	RRP1B	-0.38	-5.44	-0.32	1.19e-7	Mean corpuscular volume;
CESC	cis	rs170557	0.573	rs12401646	chr1:210182369	A/G	cg21951975	chr1:209979733	IRF6	-0.38	-5.13	-0.3	5.66e-7	Alopecia areata;
CESC	cis	rs7264396	0.790	rs1040695	chr20:34244829	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.86	-11.73	-0.58	7e-26	Total cholesterol levels;
CESC	cis	rs1799949	0.965	rs11650913	chr17:41331597	T/C	cg25072359	chr17:41440525	NA	0.5	6.77	0.38	8.41e-11	Menopause (age at onset);
CESC	cis	rs7607369	0.536	rs6436089	chr2:219668813	A/G	cg02176678	chr2:219576539	TTLL4	-0.36	-6.16	-0.35	2.75e-9	Red blood cell count;Amyotrophic lateral sclerosis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14529146	chr17:39968600	FKBP10;SC65	-0.6	-6.71	-0.38	1.15e-10	Gut microbiome composition (summer);
CESC	cis	rs6952808	0.543	rs4719436	chr7:2141239	G/A	cg21782813	chr7:2030301	MAD1L1	0.49	7.06	0.4	1.5e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs911555	0.723	rs56227024	chr14:103861706	A/G	cg12935359	chr14:103987150	CKB	0.56	8.61	0.47	6.7e-16	Intelligence (multi-trait analysis);
CESC	cis	rs2108225	0.967	rs7785790	chr7:107449896	C/T	cg18560240	chr7:107437656	SLC26A3	0.4	5.5	0.32	9.09e-8	Ulcerative colitis;
CESC	cis	rs875971	0.638	rs801205	chr7:66022144	C/A	cg06456125	chr7:65229604	NA	-0.39	-5.1	-0.3	6.54e-7	Aortic root size;
CESC	cis	rs7927592	0.871	rs17603185	chr11:68376241	C/T	cg20283391	chr11:68216788	NA	-0.6	-7.2	-0.4	6.05e-12	Total body bone mineral density;
CESC	trans	rs1814175	0.538	rs1684260	chr11:49224231	G/A	cg15704280	chr7:45808275	SEPT13	0.84	13.52	0.64	4.91e-32	Height;
CESC	cis	rs7927771	0.965	rs56400411	chr11:47586376	T/G	cg18512352	chr11:47633146	NA	-0.6	-9.28	-0.5	6.06e-18	Subjective well-being;
CESC	cis	rs2439831	0.867	rs486301	chr15:43836949	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.81	8.87	0.48	1.13e-16	Lung cancer in ever smokers;
CESC	cis	rs6952808	0.792	rs12531315	chr7:1953650	C/G	cg02951883	chr7:2050386	MAD1L1	-0.5	-6.84	-0.39	5.53e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs7618915	0.508	rs12498066	chr3:52627660	G/A	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	5.62	0.33	4.92e-8	Bipolar disorder;
CESC	cis	rs1691799	0.836	rs1184552	chr12:66756215	A/G	cg16791601	chr12:66731901	HELB	-0.79	-13.76	-0.65	7.13e-33	White blood cell count (basophil);
CESC	cis	rs6570726	1.000	rs373778	chr6:145873252	C/T	cg05347473	chr6:146136440	FBXO30	0.43	5.83	0.34	1.63e-8	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2046867	0.862	rs7648954	chr3:72838756	C/A	cg25664220	chr3:72788482	NA	-0.44	-6.47	-0.37	4.7e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CESC	cis	rs829883	0.622	rs4762498	chr12:98964737	A/G	cg25150519	chr12:98850993	NA	-0.61	-7.19	-0.4	6.71e-12	Colorectal adenoma (advanced);
CESC	cis	rs9733	0.596	rs17658705	chr1:150678071	A/C	cg09365446	chr1:150670422	GOLPH3L	-0.43	-5.98	-0.34	7.25e-9	Tonsillectomy;
CESC	cis	rs7666738	0.830	rs969049	chr4:98988857	C/T	cg03467027	chr4:99064603	C4orf37	0.44	5.56	0.32	6.57e-8	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg12691366	chr2:64681733	HSPC159	-0.52	-6.74	-0.38	9.95e-11	Asthma;
CESC	cis	rs9611565	0.512	rs7291736	chr22:42124874	C/A	cg17376030	chr22:41985996	PMM1	-0.79	-8.55	-0.46	1e-15	Vitiligo;
CESC	cis	rs7084402	0.902	rs1649016	chr10:60288540	T/A	cg07615347	chr10:60278583	BICC1	0.59	9.2	0.49	1.13e-17	Refractive error;
CESC	cis	rs875971	0.862	rs6460290	chr7:65809106	G/A	cg12463550	chr7:65579703	CRCP	-0.48	-6.18	-0.35	2.45e-9	Aortic root size;
CESC	cis	rs763014	0.932	rs2269560	chr16:682442	A/C	cg00908189	chr16:619842	PIGQ	0.64	8.84	0.48	1.35e-16	Height;
CESC	cis	rs12545109	0.765	rs2438063	chr8:57384360	A/G	cg19413350	chr8:57351067	NA	0.37	5.26	0.31	2.96e-7	Obesity-related traits;
CESC	cis	rs470119	1.000	rs470119	chr22:50966914	C/T	cg12969734	chr22:50962224	SCO2	-0.36	-5.53	-0.32	7.65e-8	Mean corpuscular hemoglobin;
CESC	cis	rs6690583	0.562	rs11588919	chr1:85442813	A/T	cg22153463	chr1:85462885	MCOLN2	0.77	7.26	0.41	4.35e-12	Serum sulfate level;
CESC	cis	rs4474465	0.688	rs7942527	chr11:78280322	A/G	cg27205649	chr11:78285834	NARS2	0.52	7.14	0.4	9.17e-12	Alzheimer's disease (survival time);
CESC	cis	rs1559088	0.948	rs7247748	chr19:33594023	T/C	cg27124370	chr19:33622961	WDR88	0.46	6.14	0.35	3.05e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs6430585	0.528	rs6430594	chr2:136719173	C/T	cg07169764	chr2:136633963	MCM6	-1.28	-19.81	-0.77	3.29e-54	Corneal structure;
CESC	cis	rs898097	0.812	rs72859941	chr17:80837459	G/A	cg05483915	chr17:80145575	CCDC57	0.45	5.38	0.31	1.68e-7	Breast cancer;
CESC	cis	rs11250464	0.833	rs11250466	chr10:1409378	C/T	cg08668359	chr10:1443807	ADARB2	0.59	7.35	0.41	2.44e-12	Radiation response;
CESC	cis	rs1797885	0.934	rs12714871	chr3:12518729	T/C	cg26432171	chr3:12704882	RAF1	-0.5	-6.28	-0.36	1.39e-9	Immature fraction of reticulocytes;
CESC	cis	rs2777491	1.000	rs316609	chr15:41743828	T/A	cg18705301	chr15:41695430	NDUFAF1	-0.65	-10.02	-0.52	3.12e-20	Ulcerative colitis;
CESC	cis	rs10129255	0.518	rs10150460	chr14:107133196	C/G	cg07470598	chr14:107239068	NA	-0.35	-5.05	-0.3	8.26e-7	Kawasaki disease;
CESC	cis	rs3126085	0.867	rs36033453	chr1:152221226	T/G	cg26876637	chr1:152193138	HRNR	-0.45	-5.11	-0.3	6.14e-7	Atopic dermatitis;
CESC	cis	rs4253772	0.550	rs55926596	chr22:46682955	C/T	cg10541313	chr22:46663664	TTC38	0.79	5.78	0.33	2.13e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs4253772	0.530	rs9615990	chr22:46804154	G/A	cg00784671	chr22:46762841	CELSR1	-0.48	-5.1	-0.3	6.34e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs35123781	0.696	rs356429	chr5:139073143	C/T	cg10513866	chr5:139070639	NA	0.42	5.84	0.34	1.55e-8	Schizophrenia;
CESC	cis	rs6752107	1.000	rs10165561	chr2:234172915	G/C	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.36	5.43	0.32	1.25e-7	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs6912958	0.535	rs242283	chr6:88030931	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.33	5.36	0.31	1.81e-7	Monocyte percentage of white cells;
CESC	cis	rs6723226	0.750	rs10182170	chr2:32704186	G/A	cg02381751	chr2:32503542	YIPF4	0.78	11.02	0.56	1.64e-23	Intelligence (multi-trait analysis);
CESC	trans	rs116095464	0.558	rs9687621	chr5:229194	C/T	cg00938859	chr5:1591904	SDHAP3	0.69	6.39	0.37	7.33e-10	Breast cancer;
CESC	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg17178900	chr1:205818956	PM20D1	0.8	13.19	0.63	7.15e-31	Menarche (age at onset);
CESC	cis	rs61996546	0.622	rs12912641	chr15:26844242	C/T	cg15066197	chr15:26874202	GABRB3	-0.34	-5.09	-0.3	6.78e-7	Response to methotrexate in juvenile idiopathic arthritis;
CESC	cis	rs9733	0.596	rs1136808	chr1:150702717	G/C	cg17724175	chr1:150552817	MCL1	0.45	7.31	0.41	3.17e-12	Tonsillectomy;
CESC	cis	rs9300255	0.508	rs1716176	chr12:123655467	T/G	cg00376283	chr12:123451042	ABCB9	0.7	8.57	0.47	8.55e-16	Neutrophil percentage of white cells;
CESC	cis	rs2836974	0.627	rs8127986	chr21:40687211	A/T	cg17971929	chr21:40555470	PSMG1	-0.85	-12.28	-0.6	9.53e-28	Cognitive function;
CESC	cis	rs34638657	0.687	rs2303261	chr16:82203768	G/T	cg09439754	chr16:82129088	HSD17B2	-0.35	-6.17	-0.35	2.57e-9	Lung adenocarcinoma;
CESC	cis	rs4642101	0.737	rs6767504	chr3:12826667	C/T	cg24848339	chr3:12840334	CAND2	0.38	5.8	0.34	1.89e-8	QRS complex (12-leadsum);
CESC	cis	rs9487051	0.597	rs9400265	chr6:109594932	A/C	cg01475377	chr6:109611718	NA	-0.39	-5.04	-0.3	8.81e-7	Reticulocyte fraction of red cells;
CESC	cis	rs6754311	0.731	rs6719488	chr2:136575199	G/T	cg07169764	chr2:136633963	MCM6	-0.66	-7.98	-0.44	4.39e-14	Mosquito bite size;
CESC	cis	rs12497850	0.931	rs4072859	chr3:49032205	G/C	cg06212747	chr3:49208901	KLHDC8B	0.71	9.33	0.5	4.55e-18	Parkinson's disease;
CESC	cis	rs9910055	0.659	rs8079310	chr17:42270291	A/G	cg08499158	chr17:42289980	UBTF	-0.48	-6.01	-0.35	6.1e-9	Total body bone mineral density;
CESC	cis	rs951366	1.000	rs951366	chr1:205685352	C/T	cg26354017	chr1:205819088	PM20D1	0.44	6.05	0.35	4.8e-9	Menarche (age at onset);
CESC	cis	rs6540556	0.954	rs3753606	chr1:209937212	C/T	cg05527609	chr1:210001259	C1orf107	0.5	6.25	0.36	1.66e-9	Red blood cell count;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg19857114	chr3:176741225	TBL1XR1	-0.48	-6.21	-0.36	2.01e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg09177884	chr7:1199841	ZFAND2A	-0.65	-8.68	-0.47	4.06e-16	Longevity;Endometriosis;
CESC	cis	rs1799949	0.929	rs12937015	chr17:41307473	A/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.45	6.24	0.36	1.69e-9	Menopause (age at onset);
CESC	cis	rs854765	0.618	rs8068820	chr17:17834119	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.57	8.17	0.45	1.29e-14	Total body bone mineral density;
CESC	cis	rs7412746	0.658	rs1027699	chr1:150811712	T/C	cg04414720	chr1:150670196	GOLPH3L	0.55	7.37	0.41	2.11e-12	Melanoma;
CESC	cis	rs2404602	0.692	rs55729975	chr15:76803226	G/A	cg26408565	chr15:76604113	ETFA	-0.39	-5.66	-0.33	3.91e-8	Blood metabolite levels;
CESC	cis	rs4629710	0.568	rs9492880	chr6:131565962	G/T	cg12606694	chr6:131520996	AKAP7	0.47	5.76	0.33	2.33e-8	Multiple myeloma (IgH translocation);
CESC	cis	rs6952808	0.529	rs73038442	chr7:2139457	C/T	cg04267008	chr7:1944627	MAD1L1	-0.61	-7.4	-0.41	1.75e-12	Bipolar disorder and schizophrenia;
CESC	cis	rs514406	0.683	rs10157120	chr1:53210888	A/G	cg24675658	chr1:53192096	ZYG11B	-0.61	-7.54	-0.42	7.33e-13	Monocyte count;
CESC	cis	rs7772486	0.875	rs10457794	chr6:146415608	A/G	cg23711669	chr6:146136114	FBXO30	0.86	12.72	0.62	2.98e-29	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7927771	0.832	rs11605672	chr11:47413733	A/G	cg18512352	chr11:47633146	NA	-0.52	-7.6	-0.42	5.17e-13	Subjective well-being;
CESC	cis	rs1126510	0.897	rs12459883	chr19:47126614	C/G	cg07844738	chr19:47129343	PTGIR	0.32	5.12	0.3	5.83e-7	Ulcerative colitis;
CESC	cis	rs2637266	0.875	rs115333453	chr10:78369011	G/A	cg18941641	chr10:78392320	NA	0.4	7.49	0.42	1.02e-12	Pulmonary function;
CESC	cis	rs7618915	0.547	rs62253703	chr3:52632357	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.48	6.81	0.39	6.45e-11	Bipolar disorder;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	ch.10.1020819F	chr10:44585416	NA	0.49	7.0	0.4	2.04e-11	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs12422267	0.536	rs12423631	chr12:132606886	C/T	cg09764611	chr12:132620959	NA	-0.57	-6.79	-0.38	7.52e-11	Plasma amyloid beta peptide concentrations (ABx-40);
CESC	cis	rs477895	0.838	rs72922039	chr11:64013116	A/C	cg04317338	chr11:64019027	PLCB3	0.92	10.01	0.52	3.13e-20	Mean platelet volume;
CESC	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.54	6.73	0.38	1.05e-10	Prudent dietary pattern;
CESC	cis	rs2295499	0.903	rs16843281	chr4:2721132	C/G	cg08330972	chr4:2403930	ZFYVE28	0.31	5.13	0.3	5.59e-7	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02889909	chr14:75760889	NA	0.62	7.06	0.4	1.48e-11	Gut microbiome composition (summer);
CESC	cis	rs3741151	0.773	rs7925226	chr11:73137362	A/G	cg17517138	chr11:73019481	ARHGEF17	0.94	6.86	0.39	4.87e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs6061231	0.793	rs2427320	chr20:60976723	A/G	cg06197360	chr20:60970103	CABLES2	-0.47	-5.57	-0.32	6.32e-8	Colorectal cancer;
CESC	cis	rs1506636	0.962	rs7811830	chr7:123320183	G/C	cg03229431	chr7:123269106	ASB15	-0.51	-6.74	-0.38	9.6e-11	Plateletcrit;Platelet count;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg07636870	chr10:104262614	SUFU;ACTR1A	0.45	6.07	0.35	4.46e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs7666738	0.830	rs35235971	chr4:98999833	G/T	cg18180107	chr4:99064573	C4orf37	0.4	5.23	0.31	3.41e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs13382862	0.895	rs2289082	chr2:20881958	A/T	cg09074113	chr2:20870087	GDF7	0.39	6.77	0.38	8.18e-11	Abdominal aortic aneurysm;
CESC	cis	rs4654899	0.865	rs61779075	chr1:21417027	T/C	cg05370193	chr1:21551575	ECE1	0.45	6.78	0.38	7.88e-11	Superior frontal gyrus grey matter volume;
CESC	cis	rs9611565	0.503	rs5751156	chr22:42170025	A/G	cg03806693	chr22:41940476	POLR3H	1.19	14.07	0.65	5.68e-34	Vitiligo;
CESC	cis	rs6439153	0.933	rs11711812	chr3:128708554	G/A	cg25356066	chr3:128598488	ACAD9	0.55	7.17	0.4	7.55e-12	Pneumococcal bacteremia;
CESC	cis	rs72781680	0.898	rs72780118	chr2:23994431	G/A	cg20701182	chr2:24300061	SF3B14	0.63	5.65	0.33	4.21e-8	Lymphocyte counts;
CESC	cis	rs4423214	0.515	rs4944042	chr11:71118788	C/A	cg05163923	chr11:71159392	DHCR7	0.56	7.34	0.41	2.6e-12	Vitamin D levels;
CESC	cis	rs2243480	0.708	rs13242216	chr7:65898277	T/C	cg18252515	chr7:66147081	NA	-1.41	-14.24	-0.66	1.46e-34	Diabetic kidney disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg03552401	chr19:54974983	LENG9	-0.51	-6.74	-0.38	9.91e-11	Fibrinogen levels;
CESC	cis	rs11997175	0.902	rs7462140	chr8:33717880	A/G	ch.8.33884649F	chr8:33765107	NA	0.62	7.94	0.44	5.75e-14	Body mass index;
CESC	cis	rs2273669	0.588	rs12201102	chr6:109317388	A/G	cg05315195	chr6:109294784	ARMC2	-0.66	-6.28	-0.36	1.36e-9	Prostate cancer;
CESC	cis	rs9611565	0.649	rs126092	chr22:42178441	A/G	cg06481639	chr22:41940642	POLR3H	0.48	5.36	0.31	1.78e-7	Vitiligo;
CESC	cis	rs2594714	0.515	rs10411270	chr19:13940838	A/T	cg18576835	chr19:13944261	NA	-0.39	-5.08	-0.3	7.01e-7	Breast cancer;
CESC	cis	rs4434138	0.594	rs7653028	chr3:52763000	A/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.38	6.71	0.38	1.17e-10	Intelligence (multi-trait analysis);
CESC	cis	rs6951245	0.882	rs56048221	chr7:1092533	A/G	cg18402987	chr7:1209562	NA	0.64	6.85	0.39	5.08e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg19932523	chr11:72145623	CLPB	-0.49	-6.56	-0.37	2.81e-10	Height;
CESC	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg24101359	chr6:42928495	GNMT	0.6	8.91	0.48	8.14e-17	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs853679	0.517	rs9380049	chr6:28048535	A/G	cg17949981	chr6:28129498	ZNF389	0.45	5.62	0.33	4.9e-8	Depression;
CESC	cis	rs4835473	0.932	rs13129702	chr4:144706285	C/T	cg25736465	chr4:144833511	NA	0.31	5.03	0.3	8.85e-7	Immature fraction of reticulocytes;
CESC	cis	rs4474465	0.850	rs4559714	chr11:78257302	C/T	cg27205649	chr11:78285834	NARS2	0.42	5.4	0.31	1.49e-7	Alzheimer's disease (survival time);
CESC	cis	rs34172651	0.517	rs2303084	chr16:24834581	G/C	cg06505273	chr16:24850292	NA	0.5	5.59	0.32	5.78e-8	Intelligence (multi-trait analysis);
CESC	cis	rs7552404	1.000	rs11161521	chr1:76216330	T/C	cg10523679	chr1:76189770	ACADM	0.67	7.61	0.42	4.79e-13	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs2228479	0.764	rs7186976	chr16:89961593	A/G	cg06558623	chr16:89946397	TCF25	0.68	5.89	0.34	1.17e-8	Skin colour saturation;
CESC	cis	rs11098499	0.866	rs12374352	chr4:120281977	C/T	cg09307838	chr4:120376055	NA	0.87	12.16	0.6	2.41e-27	Corneal astigmatism;
CESC	cis	rs6120849	0.754	rs3818253	chr20:33596876	C/T	cg24642439	chr20:33292090	TP53INP2	0.67	6.74	0.38	9.78e-11	Protein C levels;
CESC	cis	rs4481887	0.927	rs4307598	chr1:248474544	T/C	cg00666640	chr1:248458726	OR2T12	0.36	6.12	0.35	3.33e-9	Common traits (Other);
CESC	cis	rs7223966	1.000	rs28463311	chr17:61919643	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.46	-5.14	-0.3	5.4e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs977987	0.645	rs10871311	chr16:75450912	T/A	cg03315344	chr16:75512273	CHST6	0.4	5.77	0.33	2.17e-8	Dupuytren's disease;
CESC	cis	rs7312774	0.529	rs12314792	chr12:107333672	T/C	cg16260113	chr12:107380972	MTERFD3	0.79	7.12	0.4	9.88e-12	Severe influenza A (H1N1) infection;
CESC	trans	rs4332037	0.851	rs1403175	chr7:1964357	A/T	cg11693508	chr17:37793320	STARD3	-0.66	-6.56	-0.37	2.79e-10	Bipolar disorder;
CESC	cis	rs7692995	1.000	rs11936911	chr4:17948668	A/G	cg08925142	chr4:18023851	LCORL	-0.46	-5.42	-0.32	1.34e-7	Height;
CESC	cis	rs769267	0.930	rs3794993	chr19:19611550	G/T	cg03709012	chr19:19516395	GATAD2A	0.97	15.05	0.68	2.07e-37	Tonsillectomy;
CESC	cis	rs6831352	0.959	rs6532795	chr4:100042221	C/T	cg13256891	chr4:100009986	ADH5	-0.7	-8.07	-0.44	2.47e-14	Alcohol dependence;
CESC	cis	rs6964587	0.692	rs418	chr7:91583334	C/T	cg17063962	chr7:91808500	NA	-0.45	-6.23	-0.36	1.84e-9	Breast cancer;
CESC	cis	rs1957429	0.901	rs59876171	chr14:65384429	C/T	cg23373153	chr14:65346875	NA	-0.9	-9.7	-0.51	3.21e-19	Pediatric areal bone mineral density (radius);
CESC	cis	rs12681288	0.792	rs12678495	chr8:1000858	C/G	cg04851639	chr8:1020857	NA	-0.32	-7.17	-0.4	7.66e-12	Schizophrenia;
CESC	cis	rs853679	0.517	rs9357065	chr6:28129580	T/C	cg23281280	chr6:28129359	ZNF389	0.59	7.88	0.44	8.68e-14	Depression;
CESC	cis	rs8114671	0.967	rs2069952	chr20:33763951	C/T	cg24642439	chr20:33292090	TP53INP2	0.44	5.37	0.31	1.73e-7	Height;
CESC	cis	rs9359856	0.564	rs72913976	chr6:90390233	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.65	-6.38	-0.36	7.94e-10	Bipolar disorder;
CESC	cis	rs7833790	0.654	rs6415652	chr8:82702257	G/A	cg07697082	chr8:82753677	SNX16	0.36	5.54	0.32	7.16e-8	Diastolic blood pressure;
CESC	cis	rs9378357	0.850	rs9391986	chr6:3290583	A/G	cg08754725	chr6:3293098	SLC22A23	0.62	5.06	0.3	7.85e-7	Obesity-related traits;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg19806062	chr19:11319688	DOCK6	0.47	6.38	0.36	7.91e-10	Fibrinogen levels;
CESC	cis	rs853679	0.517	rs9380060	chr6:28132603	G/A	cg26335602	chr6:28129616	ZNF389	0.52	6.81	0.39	6.59e-11	Depression;
CESC	cis	rs7618915	0.501	rs10865974	chr3:52718280	A/C	cg18404041	chr3:52824283	ITIH1	0.35	6.16	0.35	2.69e-9	Bipolar disorder;
CESC	cis	rs7927771	0.864	rs112060627	chr11:47426956	G/A	cg18512352	chr11:47633146	NA	-0.52	-7.44	-0.42	1.38e-12	Subjective well-being;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg06498398	chr8:11627480	NEIL2	-0.45	-6.54	-0.37	3.11e-10	Gambling;
CESC	trans	rs7618501	0.699	rs2681781	chr3:49898273	A/G	cg21659725	chr3:3221576	CRBN	0.59	8.31	0.45	5.04e-15	Intelligence (multi-trait analysis);
CESC	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg11965913	chr1:205819406	PM20D1	0.81	13.37	0.63	1.63e-31	Menarche (age at onset);
CESC	cis	rs9556958	0.588	rs9556964	chr13:99159306	T/C	cg20750642	chr13:99100586	FARP1	0.39	6.29	0.36	1.33e-9	Educational attainment (years of education);
CESC	cis	rs7539624	0.588	rs28370014	chr1:223903167	A/G	cg10100437	chr1:223903862	CAPN2	0.41	5.27	0.31	2.77e-7	Schizophrenia;
CESC	cis	rs870825	0.550	rs57301026	chr4:185646505	C/G	cg04058563	chr4:185651563	MLF1IP	0.63	6.96	0.39	2.59e-11	Blood protein levels;
CESC	cis	rs7662987	0.517	rs2602877	chr4:100039847	T/A	cg12011299	chr4:100065546	ADH4	0.6	6.56	0.37	2.83e-10	Smoking initiation;
CESC	cis	rs17125944	0.505	rs75661138	chr14:53259262	G/A	cg13660082	chr14:53194042	PSMC6	-0.66	-5.7	-0.33	3.26e-8	Alzheimer's disease (late onset);
CESC	cis	rs8067354	0.958	rs8081468	chr17:57836924	A/G	cg13753209	chr17:57696993	CLTC	0.51	6.85	0.39	5.04e-11	Hemoglobin concentration;
CESC	cis	rs7312933	0.533	rs17551006	chr12:42848738	G/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.49	6.34	0.36	9.95e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs9322193	0.923	rs7753812	chr6:150011286	C/T	cg13206674	chr6:150067644	NUP43	0.41	5.77	0.33	2.19e-8	Lung cancer;
CESC	cis	rs6582630	0.555	rs10880544	chr12:38473464	G/C	cg26384229	chr12:38710491	ALG10B	0.71	10.82	0.55	7.82e-23	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs7618915	0.547	rs13065019	chr3:52685244	T/C	cg18404041	chr3:52824283	ITIH1	-0.39	-6.54	-0.37	3.18e-10	Bipolar disorder;
CESC	cis	rs6963495	0.818	rs56165465	chr7:105180384	C/T	cg02135003	chr7:105160482	PUS7	-0.42	-5.42	-0.32	1.34e-7	Bipolar disorder (body mass index interaction);
CESC	cis	rs8018808	0.935	rs176772	chr14:77881808	A/G	cg20045696	chr14:77926864	AHSA1	0.5	6.97	0.39	2.55e-11	Myeloid white cell count;
CESC	cis	rs9911578	0.967	rs11656413	chr17:57082013	A/C	cg05425664	chr17:57184151	TRIM37	0.51	7.0	0.4	2.04e-11	Intelligence (multi-trait analysis);
CESC	cis	rs888194	0.568	rs10850141	chr12:109876128	C/T	cg19025524	chr12:109796872	NA	-0.39	-5.35	-0.31	1.86e-7	Neuroticism;
CESC	cis	rs8180040	0.764	rs4683324	chr3:47251284	T/C	cg27129171	chr3:47204927	SETD2	0.7	10.58	0.55	4.6e-22	Colorectal cancer;
CESC	cis	rs7959452	0.570	rs10878964	chr12:69720691	T/G	cg22834771	chr12:69754056	YEATS4	-0.4	-5.13	-0.3	5.49e-7	Blood protein levels;
CESC	cis	rs2732480	0.577	rs2634681	chr12:48733084	C/T	cg24011408	chr12:48396354	COL2A1	-0.39	-5.73	-0.33	2.73e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs2836974	0.831	rs4375956	chr21:40521788	G/A	cg27266027	chr21:40555129	PSMG1	0.45	5.36	0.31	1.84e-7	Cognitive function;
CESC	cis	rs7618915	0.547	rs12496476	chr3:52708737	A/G	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.31	5.59	0.32	5.58e-8	Bipolar disorder;
CESC	cis	rs72781680	0.784	rs12616678	chr2:24181159	G/T	cg08917208	chr2:24149416	ATAD2B	0.66	6.5	0.37	3.98e-10	Lymphocyte counts;
CESC	cis	rs2898857	0.545	rs12602382	chr17:47356805	C/A	cg08112188	chr17:47440006	ZNF652	0.46	5.79	0.34	1.97e-8	Cancer;
CESC	cis	rs3540	0.597	rs1978151	chr15:91037300	C/T	cg22089800	chr15:90895588	ZNF774	0.63	8.35	0.46	3.82e-15	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg06861343	chr3:52739491	GLT8D1;SPCS1	0.44	6.14	0.35	3.05e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs9457247	0.663	rs9459835	chr6:167417551	G/T	cg25258033	chr6:167368657	RNASET2	0.36	5.16	0.3	4.87e-7	Crohn's disease;
CESC	cis	rs1801251	1.000	rs1947105	chr2:233721455	A/G	cg25237894	chr2:233734115	C2orf82	0.47	8.14	0.45	1.57e-14	Coronary artery disease;
CESC	trans	rs2727020	0.595	rs11040416	chr11:49566429	C/T	cg15704280	chr7:45808275	SEPT13	-0.95	-17.21	-0.73	4.31e-45	Coronary artery disease;
CESC	cis	rs7561273	0.586	rs4149372	chr2:24305512	T/G	cg06627628	chr2:24431161	ITSN2	-0.48	-5.62	-0.33	4.91e-8	Quantitative traits;
CESC	cis	rs875971	1.000	rs11974219	chr7:65647410	C/T	cg12463550	chr7:65579703	CRCP	-0.56	-7.25	-0.41	4.5e-12	Aortic root size;
CESC	cis	rs798554	0.836	rs798502	chr7:2789880	G/T	cg18446336	chr7:2847575	GNA12	0.39	5.96	0.34	8.22e-9	Height;
CESC	cis	rs589448	0.902	rs315134	chr12:69762713	G/A	cg14784868	chr12:69753453	YEATS4	0.89	14.23	0.66	1.66e-34	Cerebrospinal fluid biomarker levels;
CESC	cis	rs2370759	0.945	rs3740237	chr10:32557592	G/C	cg18270830	chr10:32634957	EPC1	0.67	5.25	0.31	3.19e-7	Sexual dysfunction (female);
CESC	cis	rs35771425	0.619	rs7538812	chr1:211442186	A/G	cg25617285	chr1:211431773	RCOR3	-0.38	-5.34	-0.31	2e-7	Educational attainment (years of education);
CESC	cis	rs2463822	1.000	rs1881534	chr11:62085083	A/G	cg06239285	chr11:62104954	ASRGL1	0.99	8.89	0.48	9.58e-17	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs2637266	0.561	rs11492375	chr10:78513974	T/C	cg18941641	chr10:78392320	NA	-0.32	-5.12	-0.3	5.96e-7	Pulmonary function;
CESC	cis	rs12618769	0.656	rs56091613	chr2:99103761	A/G	cg10123293	chr2:99228465	UNC50	0.39	5.13	0.3	5.6e-7	Bipolar disorder;
CESC	cis	rs4713118	0.586	rs9468290	chr6:28087674	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.58	-6.75	-0.38	9.45e-11	Parkinson's disease;
CESC	cis	rs2073300	0.609	rs2277765	chr20:23425163	C/T	cg16736954	chr20:23401023	NAPB	0.73	5.23	0.31	3.38e-7	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs11098499	0.780	rs10013652	chr4:120292256	A/G	cg24375607	chr4:120327624	NA	0.43	5.26	0.31	3.02e-7	Corneal astigmatism;
CESC	cis	rs9611565	0.559	rs9611619	chr22:41986714	C/T	cg06634786	chr22:41940651	POLR3H	-0.67	-6.46	-0.37	4.85e-10	Vitiligo;
CESC	cis	rs11168351	0.926	rs10875719	chr12:48411158	T/C	cg24011408	chr12:48396354	COL2A1	0.53	8.03	0.44	3.26e-14	Bipolar disorder and schizophrenia;
CESC	cis	rs9910055	0.540	rs609292	chr17:42180436	G/A	cg13607699	chr17:42295918	UBTF	-0.56	-7.35	-0.41	2.47e-12	Total body bone mineral density;
CESC	trans	rs8073060	0.504	rs225271	chr17:33969836	C/T	cg19694781	chr19:47549865	TMEM160	-0.72	-7.25	-0.41	4.51e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	cis	rs4665809	1.000	rs2384321	chr2:26290054	A/G	cg25036284	chr2:26402008	FAM59B	-0.74	-8.4	-0.46	2.72e-15	Gut microbiome composition (summer);
CESC	cis	rs8141529	0.719	rs9625619	chr22:29272328	T/A	cg15103426	chr22:29168792	CCDC117	0.62	8.01	0.44	3.62e-14	Lymphocyte counts;
CESC	cis	rs950027	0.620	rs1719245	chr15:45623782	T/C	cg21132104	chr15:45694354	SPATA5L1	0.68	8.74	0.47	2.81e-16	Response to fenofibrate (adiponectin levels);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04703844	chr8:74207197	RPL7;RDH10	0.49	6.19	0.36	2.31e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs854765	0.583	rs5002487	chr17:17832460	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.49	6.82	0.39	6.31e-11	Total body bone mineral density;
CESC	cis	rs9346455	1.000	rs9342830	chr6:72024809	T/A	cg27238071	chr6:71998145	OGFRL1	0.61	5.27	0.31	2.9e-7	Antipsychotic drug-induced weight gain (time interaction);Antipsychotic drug-induced weight gain;
CESC	cis	rs10256972	0.869	rs13236369	chr7:1033799	G/T	cg23978390	chr7:1156363	C7orf50	0.4	5.29	0.31	2.55e-7	Longevity;Endometriosis;
CESC	cis	rs7843479	0.511	rs4379446	chr8:21777595	C/G	cg17168535	chr8:21777572	XPO7	0.74	12.02	0.59	7.45e-27	Mean corpuscular volume;
CESC	cis	rs7520050	0.808	rs11211196	chr1:46282296	A/T	cg24296786	chr1:45957014	TESK2	0.43	5.41	0.32	1.38e-7	Red blood cell count;Reticulocyte count;
CESC	cis	rs9911578	0.967	rs2611781	chr17:56703124	C/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.38	5.07	0.3	7.52e-7	Intelligence (multi-trait analysis);
CESC	cis	rs4523957	0.788	rs11651451	chr17:2098417	C/T	cg16513277	chr17:2031491	SMG6	-0.57	-7.84	-0.43	1.13e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs11122272	0.735	rs2739513	chr1:231515201	C/T	cg06096015	chr1:231504339	EGLN1	0.45	6.39	0.37	7.53e-10	Hemoglobin concentration;
CESC	cis	rs4713118	0.586	rs6905522	chr6:28086479	A/C	cg26335602	chr6:28129616	ZNF389	0.53	7.06	0.4	1.48e-11	Parkinson's disease;
CESC	cis	rs2749592	0.531	rs10764134	chr10:37856660	T/C	cg00409905	chr10:38381863	ZNF37A	0.42	5.51	0.32	8.48e-8	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs79839061	0.610	rs62297087	chr4:913289	T/A	cg07828340	chr4:882639	GAK	0.99	7.03	0.4	1.78e-11	Intelligence (multi-trait analysis);
CESC	cis	rs7772486	0.764	rs9399569	chr6:146242942	C/T	cg05347473	chr6:146136440	FBXO30	-0.53	-6.92	-0.39	3.46e-11	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs7107217	1.000	rs1873872	chr11:129473993	A/T	cg11450001	chr12:10365596	GABARAPL1	0.49	6.5	0.37	3.87e-10	Breast cancer;Type 2 diabetes;
CESC	cis	rs7605827	0.704	rs3732001	chr2:15536872	T/C	cg19274914	chr2:15703543	NA	0.35	6.39	0.37	7.22e-10	Educational attainment (years of education);
CESC	cis	rs9486719	0.947	rs12208556	chr6:96903486	C/T	cg18709589	chr6:96969512	KIAA0776	-0.48	-5.48	-0.32	1e-7	Migraine;Coronary artery disease;
CESC	cis	rs7713065	1.000	rs3749833	chr5:131799626	T/C	cg09877947	chr5:131593287	PDLIM4	-0.44	-5.1	-0.3	6.33e-7	Lung function (FEV1/FVC);
CESC	cis	rs6120849	0.707	rs6120799	chr20:33614955	T/C	cg24642439	chr20:33292090	TP53INP2	0.68	6.77	0.38	8.46e-11	Protein C levels;
CESC	cis	rs13392177	0.684	rs11695527	chr2:219068103	A/G	cg20019365	chr2:219134978	PNKD;AAMP	0.52	6.62	0.38	1.99e-10	Pyoderma gangrenosum in inflammatory bowel disease;
CESC	cis	rs9323205	0.911	rs12587611	chr14:51641399	C/T	cg23942311	chr14:51606299	NA	-0.41	-5.73	-0.33	2.69e-8	Cancer;
CESC	cis	rs34375054	0.525	rs7133614	chr12:125605957	C/T	cg00522288	chr12:125625016	AACS	-0.31	-5.04	-0.3	8.49e-7	Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs798554	0.679	rs1639036	chr7:2885089	G/A	cg18446336	chr7:2847575	GNA12	-0.34	-5.46	-0.32	1.1e-7	Height;
CESC	cis	rs7927771	0.864	rs3781626	chr11:47442893	A/T	cg18512352	chr11:47633146	NA	-0.42	-6.13	-0.35	3.12e-9	Subjective well-being;
CESC	cis	rs7666738	0.830	rs6854902	chr4:99033416	T/G	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.58e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs116095464	0.558	rs56342538	chr5:225796	T/C	cg12570787	chr5:219185	SDHA;CCDC127	0.52	5.65	0.33	4.24e-8	Breast cancer;
CESC	cis	rs9916302	0.706	rs8069074	chr17:37685401	C/T	cg07936489	chr17:37558343	FBXL20	0.95	11.17	0.57	5.24e-24	Glomerular filtration rate (creatinine);
CESC	cis	rs7527798	0.592	rs960087	chr1:207826858	C/G	cg21110645	chr1:207815933	NA	-0.33	-5.66	-0.33	3.83e-8	Erythrocyte sedimentation rate;
CESC	cis	rs7927771	0.524	rs4752860	chr11:47705015	C/A	cg20307385	chr11:47447363	PSMC3	-0.57	-7.85	-0.43	1.02e-13	Subjective well-being;
CESC	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.44	-5.61	-0.33	5.04e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7666738	0.830	rs2865951	chr4:99040191	C/T	cg03467027	chr4:99064603	C4orf37	0.48	6.09	0.35	4.06e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2880765	0.835	rs12708553	chr15:86046833	C/G	cg10818794	chr15:86012489	AKAP13	0.35	5.35	0.31	1.89e-7	Coronary artery disease;
CESC	cis	rs6696846	0.749	rs7553876	chr1:205079915	A/G	cg00857998	chr1:205179979	DSTYK	0.5	6.85	0.39	5.06e-11	Red blood cell count;
CESC	cis	rs9303401	0.614	rs2007993	chr17:56590643	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.99	12.53	0.61	1.36e-28	Cognitive test performance;
CESC	cis	rs7772486	0.875	rs2777477	chr6:146305491	A/G	cg05347473	chr6:146136440	FBXO30	0.53	7.12	0.4	1.02e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs17376456	1.000	rs34068652	chr5:93563319	G/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.61	5.05	0.3	8.14e-7	Diabetic retinopathy;
CESC	cis	rs6674176	0.597	rs4660262	chr1:44382524	G/A	cg12908607	chr1:44402522	ARTN	-0.51	-7.86	-0.43	9.86e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs7216064	0.954	rs4790973	chr17:65951133	C/T	cg12091567	chr17:66097778	LOC651250	-0.7	-7.16	-0.4	7.85e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs875971	0.830	rs1167406	chr7:65556936	G/C	cg18876405	chr7:65276391	NA	-0.57	-7.55	-0.42	6.85e-13	Aortic root size;
CESC	cis	rs10504229	1.000	rs61212428	chr8:58173963	G/A	cg22535103	chr8:58192502	C8orf71	-1.05	-13.27	-0.63	3.63e-31	Developmental language disorder (linguistic errors);
CESC	cis	rs9916302	0.731	rs11868030	chr17:37650332	A/G	cg15445000	chr17:37608096	MED1	0.41	6.76	0.38	8.83e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs910316	1.000	rs3742778	chr14:75538217	A/C	cg08847533	chr14:75593920	NEK9	-1.0	-18.88	-0.76	5.99e-51	Height;
CESC	cis	rs28374715	0.532	rs316607	chr15:41772693	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.08	-17.26	-0.73	2.91e-45	Ulcerative colitis;
CESC	cis	rs924607	1.000	rs11746907	chr5:598224	G/A	cg09021430	chr5:549028	NA	0.38	6.64	0.38	1.81e-10	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs9916302	0.904	rs3964723	chr17:37403979	C/T	cg20243544	chr17:37824526	PNMT	0.49	6.03	0.35	5.46e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs921968	0.643	rs62191565	chr2:219482017	C/T	cg02176678	chr2:219576539	TTLL4	0.38	6.7	0.38	1.23e-10	Mean corpuscular hemoglobin concentration;
CESC	cis	rs2066819	0.892	rs17118431	chr12:56667100	A/G	cg26714650	chr12:56694279	CS	-1.41	-9.99	-0.52	3.69e-20	Psoriasis vulgaris;
CESC	cis	rs56399783	0.901	rs17132624	chr7:2778496	G/A	cg19731401	chr7:2775893	GNA12	0.68	6.14	0.35	3.07e-9	Childhood ear infection;
CESC	cis	rs4253772	0.591	rs6008545	chr22:46686375	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.72	7.97	0.44	4.75e-14	LDL cholesterol;Cholesterol, total;
CESC	cis	rs2354432	1.000	rs10900325	chr1:146692174	C/T	cg25205988	chr1:146714368	CHD1L	-1.06	-11.38	-0.57	1.06e-24	Mitochondrial DNA levels;
CESC	trans	rs61931739	0.517	rs11053063	chr12:34181011	C/T	cg26384229	chr12:38710491	ALG10B	0.65	9.11	0.49	2.1e-17	Morning vs. evening chronotype;
CESC	cis	rs4853012	0.941	rs60291089	chr2:74344890	T/G	cg05776053	chr2:74358815	NA	0.4	5.05	0.3	8.18e-7	Gestational age at birth (maternal effect);
CESC	cis	rs4474465	0.688	rs7108439	chr11:78277708	A/T	cg27205649	chr11:78285834	NARS2	0.48	6.3	0.36	1.27e-9	Alzheimer's disease (survival time);
CESC	cis	rs9300255	0.512	rs2851436	chr12:123667354	G/T	cg19016782	chr12:123741754	C12orf65	-0.45	-6.21	-0.36	2.01e-9	Neutrophil percentage of white cells;
CESC	cis	rs3126085	0.935	rs10788824	chr1:152161694	A/G	cg03465714	chr1:152285911	FLG	-0.44	-5.36	-0.31	1.85e-7	Atopic dermatitis;
CESC	cis	rs6461049	0.765	rs4719431	chr7:2140312	T/C	cg05863683	chr7:1912471	MAD1L1	0.35	5.12	0.3	5.82e-7	Schizophrenia;
CESC	cis	rs62408225	1.000	rs11757155	chr6:90941240	C/T	cg06866423	chr6:90926672	BACH2	0.48	5.99	0.35	6.93e-9	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.65	7.41	0.41	1.72e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs796364	0.951	rs59695400	chr2:201021325	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.65	-6.67	-0.38	1.5e-10	Schizophrenia;
CESC	cis	rs12477438	0.501	rs6542868	chr2:99782848	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.77	12.84	0.62	1.16e-29	Chronic sinus infection;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg11688874	chr10:28822482	WAC	0.48	6.5	0.37	3.97e-10	Gut microbiota (bacterial taxa);
CESC	trans	rs324780	0.544	rs3112096	chr12:83887311	C/T	cg22140261	chr22:42466895	NAGA	0.47	6.03	0.35	5.38e-9	Vertical cup-disc ratio;
CESC	cis	rs911555	0.755	rs8010247	chr14:103933556	A/G	cg12935359	chr14:103987150	CKB	0.66	9.68	0.51	3.48e-19	Intelligence (multi-trait analysis);
CESC	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg00738919	chr7:1100172	C7orf50	0.54	5.46	0.32	1.07e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs1814175	0.715	rs7479622	chr11:49673340	T/G	cg15704280	chr7:45808275	SEPT13	-1.0	-17.79	-0.74	4.02e-47	Height;
CESC	cis	rs7666738	0.830	rs62321597	chr4:99014221	C/A	cg05340658	chr4:99064831	C4orf37	0.8	12.51	0.61	1.52e-28	Colonoscopy-negative controls vs population controls;
CESC	trans	rs6073597	1.000	rs6031980	chr20:43714384	C/T	cg06203126	chr5:43313815	HMGCS1	0.42	6.04	0.35	5.18e-9	Positive affect;
CESC	cis	rs4843747	0.697	rs72818533	chr16:88073841	G/A	cg17633681	chr16:88106987	BANP	0.71	9.22	0.49	9.71e-18	Menopause (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07218578	chr22:31556156	RNF185	0.63	6.79	0.38	7.35e-11	Gut microbiome composition (summer);
CESC	cis	rs1153858	1.000	rs11070456	chr15:45686835	G/A	cg21132104	chr15:45694354	SPATA5L1	0.86	11.62	0.58	1.71e-25	Homoarginine levels;
CESC	cis	rs10504229	0.906	rs73607869	chr8:58172665	G/T	cg24829409	chr8:58192753	C8orf71	-0.76	-10.0	-0.52	3.53e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs7071206	0.704	rs11002234	chr10:79434458	A/G	cg00983440	chr10:79422392	NA	-0.57	-7.04	-0.4	1.64e-11	Bone mineral density;
CESC	cis	rs3026101	0.671	rs748486	chr17:5290824	C/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.43	5.69	0.33	3.37e-8	Body mass index;
CESC	trans	rs9833726	0.799	rs7623220	chr3:86140049	G/A	cg10416071	chr15:75628863	COMMD4	0.59	6.12	0.35	3.37e-9	Breast cancer;
CESC	cis	rs12136530	0.577	rs4481878	chr1:19791086	C/A	cg01832549	chr1:19774989	CAPZB	0.37	5.25	0.31	3.17e-7	Lead levels in blood;
CESC	cis	rs561341	0.941	rs4795664	chr17:30233467	C/T	cg13647721	chr17:30228624	UTP6	0.6	5.49	0.32	9.34e-8	Hip circumference adjusted for BMI;
CESC	trans	rs61931739	0.500	rs10844844	chr12:34380350	G/T	cg26384229	chr12:38710491	ALG10B	0.67	10.1	0.53	1.64e-20	Morning vs. evening chronotype;
CESC	cis	rs9640161	0.742	rs2108852	chr7:150019628	T/C	cg21361702	chr7:150065534	REPIN1	0.56	6.54	0.37	3.2e-10	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs9811920	0.514	rs1287283	chr3:99515750	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.4	5.33	0.31	2.12e-7	Axial length;
CESC	cis	rs17572109	0.666	rs4674297	chr2:219229147	A/G	cg00012203	chr2:219082015	ARPC2	0.51	5.36	0.31	1.79e-7	Platelet count;Platelet distribution width;Mean platelet volume;
CESC	cis	rs9322193	0.923	rs9689716	chr6:149976798	G/A	cg04369109	chr6:150039330	LATS1	-0.4	-5.54	-0.32	7.28e-8	Lung cancer;
CESC	cis	rs8072100	0.905	rs8078686	chr17:45735706	T/C	cg08085267	chr17:45401833	C17orf57	0.44	5.79	0.33	2.02e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs868036	0.918	rs4776967	chr15:68033922	T/C	cg08079166	chr15:68083412	MAP2K5	0.42	6.52	0.37	3.47e-10	Restless legs syndrome;
CESC	cis	rs7267979	1.000	rs6132835	chr20:25434667	A/G	cg08601574	chr20:25228251	PYGB	0.38	5.42	0.32	1.37e-7	Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg25228510	chr10:62538235	CDK1;CDC2	-0.49	-6.53	-0.37	3.42e-10	Ulcerative colitis;
CESC	cis	rs7666738	0.753	rs9991512	chr4:99007205	T/C	cg18180107	chr4:99064573	C4orf37	0.4	5.23	0.31	3.41e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13495574	chr1:173793781	CENPL;DARS2	0.55	6.35	0.36	9.49e-10	Gut microbiome composition (summer);
CESC	cis	rs916888	0.821	rs199506	chr17:44859031	A/G	cg17911788	chr17:44343683	NA	0.55	7.39	0.41	1.92e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs9660992	0.573	rs12126439	chr1:205200720	C/T	cg21643547	chr1:205240462	TMCC2	-0.39	-5.37	-0.31	1.76e-7	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs8114671	0.935	rs6058198	chr20:33748253	T/A	cg24642439	chr20:33292090	TP53INP2	0.43	5.11	0.3	6.32e-7	Height;
CESC	cis	rs9911578	0.967	rs1588322	chr17:56990099	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.39	5.05	0.3	8.26e-7	Intelligence (multi-trait analysis);
CESC	cis	rs7727544	0.618	rs2631367	chr5:131705458	C/G	cg14196790	chr5:131705035	SLC22A5	-0.43	-6.6	-0.38	2.21e-10	Blood metabolite levels;
CESC	cis	rs754466	0.580	rs12354903	chr10:79536465	T/C	cg17075019	chr10:79541650	NA	-0.87	-13.57	-0.64	3.29e-32	Liver enzyme levels (gamma-glutamyl transferase);
CESC	trans	rs61931739	0.500	rs12829125	chr12:34314789	A/G	cg26384229	chr12:38710491	ALG10B	0.63	8.95	0.48	6.59e-17	Morning vs. evening chronotype;
CESC	cis	rs3767633	0.925	rs10753666	chr1:161861147	C/G	cg09175582	chr1:161736000	ATF6	0.86	6.95	0.39	2.83e-11	IgG glycosylation;
CESC	cis	rs2050392	1.000	rs2050392	chr10:30691503	G/A	cg25182066	chr10:30743637	MAP3K8	-0.38	-5.08	-0.3	6.99e-7	Inflammatory bowel disease;
CESC	cis	rs1707322	1.000	rs4660906	chr1:46470860	C/T	cg06784218	chr1:46089804	CCDC17	0.35	5.9	0.34	1.09e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7584330	0.740	rs13418586	chr2:238445593	A/G	cg14458575	chr2:238380390	NA	0.5	7.47	0.42	1.14e-12	Prostate cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25730142	chr20:32031702	SNTA1	0.57	6.71	0.38	1.17e-10	Gut microbiome composition (summer);
CESC	cis	rs2204008	0.837	rs11169157	chr12:37980047	T/C	cg26384229	chr12:38710491	ALG10B	0.67	9.51	0.5	1.2e-18	Bladder cancer;
CESC	cis	rs3960554	0.610	rs10265696	chr7:75766712	G/A	cg17325771	chr7:75508891	RHBDD2	-0.34	-5.06	-0.3	7.71e-7	Eotaxin levels;
CESC	cis	rs875971	0.862	rs1083554	chr7:65852341	T/C	cg12463550	chr7:65579703	CRCP	0.51	6.41	0.37	6.58e-10	Aortic root size;
CESC	cis	rs2204008	0.805	rs11179579	chr12:38213957	A/C	cg13010199	chr12:38710504	ALG10B	0.51	6.45	0.37	5.18e-10	Bladder cancer;
CESC	cis	rs10789491	1.000	rs10749863	chr1:47174328	C/T	cg15501359	chr1:47185051	KIAA0494	0.79	9.02	0.48	4.04e-17	Response to hepatitis C treatment;
CESC	cis	rs5753618	0.504	rs9606846	chr22:31897571	C/T	cg13145458	chr22:31556086	RNF185	-0.53	-6.2	-0.36	2.11e-9	Colorectal cancer;
CESC	cis	rs1707322	1.000	rs2458400	chr1:46530798	C/T	cg06784218	chr1:46089804	CCDC17	-0.33	-5.55	-0.32	7e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2952156	0.920	rs9675194	chr17:37833805	A/G	cg00129232	chr17:37814104	STARD3	-0.74	-10.88	-0.56	4.97e-23	Asthma;
CESC	cis	rs9457247	0.663	rs9459839	chr6:167431829	T/C	cg07741184	chr6:167504864	NA	0.34	6.07	0.35	4.41e-9	Crohn's disease;
CESC	cis	rs10504229	0.953	rs2270610	chr8:58194669	A/G	cg05313129	chr8:58192883	C8orf71	-0.54	-6.25	-0.36	1.68e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs8028182	0.636	rs28737338	chr15:75768679	C/T	cg20655648	chr15:75932815	IMP3	0.48	6.1	0.35	3.77e-9	Sudden cardiac arrest;
CESC	cis	rs9388451	0.839	rs3799709	chr6:126078361	A/G	cg10911889	chr6:126070802	HEY2	0.38	5.22	0.31	3.54e-7	Brugada syndrome;
CESC	cis	rs2842992	0.692	rs9347342	chr6:160193129	T/C	cg26839252	chr6:160211577	TCP1;MRPL18	0.49	6.14	0.35	3.08e-9	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs11971779	0.793	rs11772447	chr7:139033589	T/G	cg07862535	chr7:139043722	LUC7L2	0.52	5.8	0.34	1.87e-8	Diisocyanate-induced asthma;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg17250947	chr3:42642016	NKTR	-0.42	-6.03	-0.35	5.43e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs57506017	0.606	rs7797705	chr7:12277773	G/A	cg23422036	chr7:12250390	TMEM106B	0.39	5.17	0.3	4.51e-7	Neuroticism;
CESC	cis	rs8072100	0.748	rs9908016	chr17:45551361	G/A	cg25173405	chr17:45401733	C17orf57	-0.47	-6.16	-0.35	2.75e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs654950	0.774	rs941972	chr1:42040740	T/C	cg06885757	chr1:42089581	HIVEP3	-0.63	-10.19	-0.53	8.56e-21	Airway imaging phenotypes;
CESC	cis	rs7524258	0.868	rs2157499	chr1:7271472	C/T	cg07173049	chr1:7289937	CAMTA1	0.38	5.62	0.33	4.74e-8	Tourette's syndrome or obsessive-compulsive disorder;
CESC	cis	rs3026101	0.578	rs59605950	chr17:5303493	A/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.42	5.6	0.33	5.31e-8	Body mass index;
CESC	cis	rs858239	0.539	rs10280815	chr7:23188370	A/C	cg23682824	chr7:23144976	KLHL7	0.51	6.83	0.39	5.81e-11	Cerebrospinal fluid biomarker levels;
CESC	cis	rs12188164	0.930	rs72717436	chr5:448291	C/A	cg15813090	chr5:442598	EXOC3;C5orf55	0.42	6.26	0.36	1.51e-9	Cystic fibrosis severity;
CESC	cis	rs9457247	0.602	rs10484530	chr6:167461562	C/T	cg07741184	chr6:167504864	NA	0.37	6.49	0.37	4.2e-10	Crohn's disease;
CESC	cis	rs559928	0.606	rs60394481	chr11:63909035	G/A	cg18225595	chr11:63971243	STIP1	0.64	5.82	0.34	1.73e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CESC	cis	rs7223966	1.000	rs8077265	chr17:61732727	A/G	cg11494091	chr17:61959527	GH2	0.38	5.42	0.32	1.34e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs6582630	0.502	rs10880388	chr12:38401341	A/T	cg13010199	chr12:38710504	ALG10B	0.48	6.21	0.36	2.03e-9	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs10823500	0.777	rs7919014	chr10:71944577	T/C	cg02100629	chr10:71892760	AIFM2	-0.34	-5.24	-0.31	3.33e-7	Blood protein levels;
CESC	cis	rs7772486	0.603	rs2223411	chr6:146028767	T/C	cg05347473	chr6:146136440	FBXO30	-0.7	-8.98	-0.48	5.21e-17	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs909002	0.849	rs10798881	chr1:32101775	G/C	cg13919466	chr1:32135498	COL16A1	-0.47	-8.09	-0.44	2.22e-14	Intelligence (multi-trait analysis);
CESC	cis	rs1862618	0.627	rs744023	chr5:56197078	C/T	cg18230493	chr5:56204884	C5orf35	-0.81	-9.36	-0.5	3.64e-18	Initial pursuit acceleration;
CESC	cis	rs2243480	0.831	rs7806717	chr7:65393174	A/G	cg25894440	chr7:65020034	NA	0.59	5.07	0.3	7.57e-7	Diabetic kidney disease;
CESC	cis	rs651907	0.535	rs12633089	chr3:101528763	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.46	6.03	0.35	5.45e-9	Colorectal cancer;
CESC	cis	rs9611565	0.659	rs9611603	chr22:41912750	A/G	cg06481639	chr22:41940642	POLR3H	-0.62	-6.52	-0.37	3.5e-10	Vitiligo;
CESC	cis	rs9910055	0.659	rs7216294	chr17:42251095	T/C	cg08499158	chr17:42289980	UBTF	-0.46	-5.66	-0.33	4e-8	Total body bone mineral density;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02445447	chr2:106015594	FHL2	0.59	7.22	0.41	5.41e-12	Gut microbiome composition (summer);
CESC	cis	rs2439831	1.000	rs9920763	chr15:43760508	T/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.73	5.85	0.34	1.42e-8	Lung cancer in ever smokers;
CESC	trans	rs875971	0.660	rs6460308	chr7:66084740	T/C	cg26939375	chr7:64535504	NA	-0.64	-8.62	-0.47	6.36e-16	Aortic root size;
CESC	cis	rs1008375	0.800	rs10008598	chr4:17607323	T/C	cg16339924	chr4:17578868	LAP3	0.67	8.66	0.47	4.55e-16	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs3733585	0.781	rs57250714	chr4:9984529	C/T	cg02734326	chr4:10020555	SLC2A9	0.44	6.19	0.36	2.22e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs9487051	0.773	rs421790	chr6:109543428	T/A	cg01475377	chr6:109611718	NA	-0.37	-5.35	-0.31	1.92e-7	Reticulocyte fraction of red cells;
CESC	cis	rs6496667	1.000	rs16944254	chr15:90898527	C/T	cg22089800	chr15:90895588	ZNF774	0.57	5.76	0.33	2.27e-8	Rheumatoid arthritis;
CESC	cis	rs921968	0.521	rs56923478	chr2:219638539	A/G	cg02176678	chr2:219576539	TTLL4	-0.43	-7.66	-0.43	3.42e-13	Mean corpuscular hemoglobin concentration;
CESC	cis	rs9660992	0.548	rs1172152	chr1:205220718	T/A	cg21643547	chr1:205240462	TMCC2	-0.41	-5.72	-0.33	2.88e-8	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs6088590	0.965	rs13040449	chr20:33358901	T/A	cg24642439	chr20:33292090	TP53INP2	0.85	11.66	0.58	1.21e-25	Coronary artery disease;
CESC	cis	rs11723261	0.582	rs114199753	chr4:163520	G/C	cg12746427	chr4:53362	ZNF718;ZNF595	0.45	5.66	0.33	3.9e-8	Immune response to smallpox vaccine (IL-6);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22273042	chr8:81083829	TPD52	0.55	6.52	0.37	3.48e-10	Gut microbiome composition (summer);
CESC	cis	rs7618915	0.501	rs34754793	chr3:52629177	A/T	cg18099408	chr3:52552593	STAB1	-0.3	-5.11	-0.3	6.18e-7	Bipolar disorder;
CESC	cis	rs801193	0.805	rs12532355	chr7:66070584	C/G	cg11764359	chr7:65958608	NA	-0.54	-7.04	-0.4	1.6e-11	Aortic root size;
CESC	cis	rs8031584	0.958	rs11629793	chr15:31238423	G/A	cg08704250	chr15:31115839	NA	-0.63	-8.17	-0.45	1.28e-14	Huntington's disease progression;
CESC	cis	rs6696846	0.765	rs61822565	chr1:205077332	T/C	cg00857998	chr1:205179979	DSTYK	0.55	7.28	0.41	3.77e-12	Red blood cell count;
CESC	cis	rs17209837	0.607	rs2270187	chr7:87080698	T/C	cg00919237	chr7:87102261	ABCB4	-0.51	-6.61	-0.38	2.1e-10	Gallbladder cancer;
CESC	cis	rs10791097	0.667	rs12363163	chr11:130744509	A/G	cg12179176	chr11:130786555	SNX19	0.64	9.86	0.52	9.69e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs4604732	0.631	rs1106720	chr1:247624681	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.57	7.17	0.4	7.39e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs853679	0.517	rs56364346	chr6:28050762	T/G	cg22143856	chr6:28129313	ZNF389	0.49	6.3	0.36	1.2e-9	Depression;
CESC	cis	rs7385804	0.796	rs2432930	chr7:100299024	A/G	cg20848291	chr7:100343083	ZAN	0.55	7.55	0.42	6.97e-13	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
CESC	cis	rs593982	0.688	rs3897552	chr11:65560880	C/T	cg08755490	chr11:65554678	OVOL1	-1.24	-12.39	-0.61	4.22e-28	Atopic dermatitis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22897130	chr10:89419623	PAPSS2	0.53	6.2	0.36	2.21e-9	Gut microbiome composition (summer);
CESC	cis	rs1499614	1.000	rs2707830	chr7:66167645	T/C	cg13147721	chr7:65941812	NA	-0.94	-8.9	-0.48	9.08e-17	Gout;
CESC	cis	rs741677	0.679	rs11655839	chr17:468945	G/C	cg15660573	chr17:549704	VPS53	0.41	5.32	0.31	2.25e-7	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
CESC	cis	rs6732160	0.588	rs11126392	chr2:73374454	A/G	cg01422370	chr2:73384389	NA	0.57	9.1	0.49	2.21e-17	Intelligence (multi-trait analysis);
CESC	cis	rs7666738	0.830	rs6532723	chr4:99052147	A/T	cg03676636	chr4:99064102	C4orf37	0.33	5.12	0.3	5.93e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs9858542	0.953	rs11710037	chr3:49675334	C/G	cg21659725	chr3:3221576	CRBN	-0.52	-6.32	-0.36	1.13e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs7089973	0.872	rs35010779	chr10:116631816	A/C	cg23260525	chr10:116636907	FAM160B1	0.37	6.15	0.35	2.84e-9	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs12042107	1.000	rs12042107	chr1:91196176	T/C	cg13456504	chr1:91191583	NA	0.37	6.64	0.38	1.81e-10	Educational attainment;
CESC	cis	rs9322193	0.884	rs9322210	chr6:150016576	G/A	cg07701084	chr6:150067640	NUP43	0.47	6.67	0.38	1.46e-10	Lung cancer;
CESC	cis	rs208520	0.661	rs7740835	chr6:66865548	G/A	cg07460842	chr6:66804631	NA	-1.0	-13.46	-0.64	7.8e-32	Exhaled nitric oxide output;
CESC	cis	rs2108225	0.837	rs6466186	chr7:107446966	G/C	cg18560240	chr7:107437656	SLC26A3	-0.38	-5.26	-0.31	2.92e-7	Ulcerative colitis;
CESC	cis	rs116095464	0.558	rs56043030	chr5:220917	A/G	cg12570787	chr5:219185	SDHA;CCDC127	0.53	5.74	0.33	2.63e-8	Breast cancer;
CESC	cis	rs514406	0.755	rs11206015	chr1:53242187	T/C	cg08736216	chr1:53307985	ZYG11A	0.32	5.74	0.33	2.59e-8	Monocyte count;
CESC	cis	rs12681288	0.676	rs2701910	chr8:1001246	G/T	cg15309053	chr8:964076	NA	0.38	6.47	0.37	4.6e-10	Schizophrenia;
CESC	cis	rs698833	0.926	rs1067353	chr2:44666626	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.47	5.88	0.34	1.26e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs12325245	0.536	rs71375919	chr16:58547522	C/T	cg27113419	chr16:58533979	NDRG4	-0.66	-5.08	-0.3	7.04e-7	Schizophrenia;
CESC	cis	rs910316	1.000	rs12889309	chr14:75593902	C/T	cg11812906	chr14:75593930	NEK9	0.91	15.82	0.7	3.78e-40	Height;
CESC	cis	rs2637266	0.934	rs2395408	chr10:78380929	G/A	cg18941641	chr10:78392320	NA	0.43	8.26	0.45	6.94e-15	Pulmonary function;
CESC	cis	rs5167	0.504	rs8100120	chr19:45466058	T/C	cg13119609	chr19:45449297	APOC2	0.46	7.39	0.41	1.94e-12	Blood protein levels;
CESC	cis	rs11650494	0.908	rs11658111	chr17:47383994	C/T	cg08112188	chr17:47440006	ZNF652	0.94	6.74	0.38	1.01e-10	Prostate cancer;
CESC	cis	rs1215050	0.791	rs165254	chr4:98763564	C/T	cg05340658	chr4:99064831	C4orf37	0.51	6.65	0.38	1.63e-10	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs4665809	0.590	rs17528590	chr2:26505858	A/G	cg26314531	chr2:26401878	FAM59B	0.81	8.1	0.45	2.06e-14	Gut microbiome composition (summer);
CESC	trans	rs3794271	0.706	rs9971816	chr12:20826911	C/T	cg13577194	chr9:95378173	IPPK	0.44	6.12	0.35	3.38e-9	Response to TNF-alpha inhibitors in rheumatoid arthritis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26459114	chr12:124827635	NCOR2	-0.54	-6.13	-0.35	3.25e-9	Gut microbiome composition (summer);
CESC	cis	rs9611565	0.729	rs73176686	chr22:41782119	C/T	cg06634786	chr22:41940651	POLR3H	-0.73	-7.69	-0.43	2.96e-13	Vitiligo;
CESC	cis	rs3785574	0.745	rs2854162	chr17:61975610	T/C	cg07677032	chr17:61819896	STRADA	-0.44	-5.49	-0.32	9.22e-8	Height;
CESC	cis	rs11098499	0.909	rs10014719	chr4:120320715	G/A	cg24375607	chr4:120327624	NA	0.48	5.87	0.34	1.28e-8	Corneal astigmatism;
CESC	cis	rs9814567	1.000	rs11927068	chr3:134266321	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.45	6.08	0.35	4.21e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs514406	0.584	rs12095247	chr1:53193796	A/C	cg24675658	chr1:53192096	ZYG11B	0.64	7.91	0.44	6.88e-14	Monocyte count;
CESC	cis	rs4948102	0.653	rs6593294	chr7:56063201	G/C	cg09872392	chr7:56161020	PHKG1	-0.46	-7.13	-0.4	9.47e-12	Plasma homocysteine levels (post-methionine load test);
CESC	cis	rs7267979	0.657	rs6107073	chr20:25716363	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.71	11.43	0.57	7.05e-25	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs9322193	0.923	rs12526675	chr6:150050676	A/C	cg07701084	chr6:150067640	NUP43	-0.43	-5.88	-0.34	1.26e-8	Lung cancer;
CESC	trans	rs853679	0.546	rs200981	chr6:27833174	A/G	cg06606381	chr12:133084897	FBRSL1	-0.79	-7.5	-0.42	9.37e-13	Depression;
CESC	cis	rs2816062	0.786	rs2816059	chr1:18902977	G/A	cg18795169	chr1:18902165	NA	-0.93	-18.04	-0.74	5.04e-48	Urate levels in lean individuals;
CESC	cis	rs7582720	0.945	rs116773016	chr2:203811902	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.36	0.41	2.34e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs17376456	0.825	rs10072232	chr5:93398890	G/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.6	5.03	0.3	9.15e-7	Diabetic retinopathy;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg23506944	chr17:28257236	EFCAB5;SSH2	0.46	6.54	0.37	3.21e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs875971	1.000	rs6956179	chr7:65806659	C/T	cg12463550	chr7:65579703	CRCP	-0.53	-6.61	-0.38	2.05e-10	Aortic root size;
CESC	cis	rs9929218	0.953	rs9939049	chr16:68812301	A/T	cg02972257	chr16:68554789	NA	0.43	5.14	0.3	5.28e-7	Colorectal cancer;
CESC	cis	rs514406	0.505	rs269289	chr1:53167151	A/C	cg08736216	chr1:53307985	ZYG11A	-0.36	-6.07	-0.35	4.31e-9	Monocyte count;
CESC	cis	rs9302635	0.513	rs13334151	chr16:72189727	A/C	cg16558253	chr16:72132732	DHX38	-0.43	-5.34	-0.31	2.03e-7	Blood protein levels;
CESC	cis	rs7937682	0.883	rs529529	chr11:111461128	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.9	-12.8	-0.62	1.63e-29	Primary sclerosing cholangitis;
CESC	cis	rs1003719	0.788	rs4817843	chr21:38447040	C/A	cg10648535	chr21:38446584	PIGP;TTC3	0.62	8.7	0.47	3.48e-16	Eye color traits;
CESC	cis	rs2836633	0.895	rs62217513	chr21:40024416	A/T	cg05519781	chr21:40033154	ERG	0.79	13.36	0.63	1.84e-31	Coronary artery disease;
CESC	cis	rs4074961	0.544	rs11264067	chr1:37991458	C/T	cg13401533	chr1:37979913	MEAF6	0.6	8.22	0.45	8.88e-15	Axial length;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg16418817	chr21:40198485	NA	0.44	6.46	0.37	4.9e-10	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs9911578	1.000	rs304299	chr17:56838472	C/G	cg05425664	chr17:57184151	TRIM37	-0.48	-6.72	-0.38	1.12e-10	Intelligence (multi-trait analysis);
CESC	cis	rs1008375	0.966	rs7675735	chr4:17587137	T/A	cg02297831	chr4:17616191	MED28	0.51	6.18	0.35	2.44e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	trans	rs11098499	0.863	rs10034450	chr4:120455649	A/G	cg25214090	chr10:38739885	LOC399744	0.7	9.62	0.51	5.47e-19	Corneal astigmatism;
CESC	trans	rs7943203	0.962	rs2118308	chr11:108315463	C/G	cg24643211	chr18:11851603	GNAL;CHMP1B	-0.47	-6.14	-0.35	3.07e-9	Red blood cell count;Mean corpuscular volume;
CESC	cis	rs801193	1.000	rs2286684	chr7:66129830	G/T	cg25985355	chr7:65971099	NA	0.32	5.23	0.31	3.53e-7	Aortic root size;
CESC	cis	rs9303401	1.000	rs1390006	chr17:56890663	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.74	-9.48	-0.5	1.49e-18	Cognitive test performance;
CESC	cis	rs8017423	0.967	rs60548738	chr14:90724399	G/A	cg14092571	chr14:90743983	NA	-0.55	-8.33	-0.46	4.28e-15	Mortality in heart failure;
CESC	cis	rs10276381	1.000	rs10276381	chr7:28190121	A/G	cg23620719	chr7:28220237	JAZF1	-0.75	-7.76	-0.43	1.89e-13	Crohn's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26389465	chr11:112097071	PTS	0.49	6.2	0.36	2.2e-9	Gut microbiome composition (summer);
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg26959303	chr3:133375668	TOPBP1	0.38	6.38	0.36	8.01e-10	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs2985684	1.000	rs3007030	chr14:50086563	C/T	cg02151108	chr14:50098012	C14orf104	-0.47	-6.1	-0.35	3.83e-9	Carotid intima media thickness;
CESC	cis	rs7552404	0.731	rs11161836	chr1:76354333	C/T	cg10523679	chr1:76189770	ACADM	0.65	6.12	0.35	3.39e-9	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs9926296	0.572	rs2079671	chr16:89884981	T/C	cg07648498	chr16:89883185	FANCA	0.42	5.03	0.3	8.92e-7	Vitiligo;
CESC	cis	rs8014204	0.762	rs7144654	chr14:75298637	A/G	cg08847533	chr14:75593920	NEK9	0.43	5.6	0.33	5.27e-8	Caffeine consumption;
CESC	cis	rs7223966	1.000	rs12325866	chr17:61755974	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.44	-5.16	-0.3	4.73e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs7772486	0.754	rs702318	chr6:146005873	G/T	cg05347473	chr6:146136440	FBXO30	-0.58	-6.93	-0.39	3.21e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9287719	0.934	rs6727884	chr2:10757557	C/T	cg00105475	chr2:10696890	NA	-0.38	-5.54	-0.32	7.18e-8	Prostate cancer;
CESC	cis	rs2273669	0.667	rs76430494	chr6:109350128	C/A	cg05315195	chr6:109294784	ARMC2	-0.66	-6.28	-0.36	1.37e-9	Prostate cancer;
CESC	cis	rs116095464	0.558	rs10059907	chr5:205360	G/C	cg22496380	chr5:211416	CCDC127	-0.95	-10.05	-0.53	2.34e-20	Breast cancer;
CESC	cis	rs10504229	0.683	rs16921843	chr8:58113338	T/C	cg21724239	chr8:58056113	NA	0.58	5.93	0.34	9.45e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs6582630	0.519	rs4002438	chr12:38484880	C/T	cg26384229	chr12:38710491	ALG10B	0.69	10.39	0.54	1.95e-21	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs6460942	0.556	rs10228123	chr7:12374025	A/C	cg20607287	chr7:12443886	VWDE	-0.53	-7.64	-0.43	3.86e-13	Coronary artery disease;
CESC	cis	rs2380220	0.606	rs4571572	chr6:96004823	T/C	cg04719120	chr6:96025338	MANEA	0.46	5.26	0.31	2.97e-7	Behavioural disinhibition (generation interaction);
CESC	cis	rs9611519	0.929	rs9611509	chr22:41565827	A/G	cg03806693	chr22:41940476	POLR3H	-0.56	-5.76	-0.33	2.28e-8	Neuroticism;
CESC	cis	rs6831352	0.840	rs29001223	chr4:100047433	C/T	cg13256891	chr4:100009986	ADH5	-0.77	-8.43	-0.46	2.27e-15	Alcohol dependence;
CESC	cis	rs17253792	0.908	rs9972177	chr14:56073206	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.77	5.98	0.34	7.23e-9	Putamen volume;
CESC	cis	rs4835473	0.900	rs4835449	chr4:144879983	C/G	cg25736465	chr4:144833511	NA	0.41	6.11	0.35	3.59e-9	Immature fraction of reticulocytes;
CESC	cis	rs1799949	0.965	rs34616041	chr17:41188786	G/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.39	5.06	0.3	7.92e-7	Menopause (age at onset);
CESC	cis	rs425277	0.958	rs262639	chr1:2107061	G/T	cg16545954	chr1:2118288	C1orf86	0.32	5.48	0.32	9.85e-8	Height;
CESC	cis	rs7188697	0.883	rs4485352	chr16:58601410	A/G	cg21335942	chr16:58549945	SETD6	-0.45	-5.24	-0.31	3.34e-7	QT interval;
CESC	cis	rs7520050	0.966	rs6672898	chr1:46290588	G/A	cg24296786	chr1:45957014	TESK2	0.43	5.42	0.32	1.32e-7	Red blood cell count;Reticulocyte count;
CESC	trans	rs6137287	0.924	rs6047279	chr20:21142353	C/T	cg03786336	chr3:193854201	HES1	-0.4	-6.01	-0.35	6.07e-9	Height;
CESC	cis	rs1348850	0.914	rs12693120	chr2:178283288	A/G	cg23306229	chr2:178417860	TTC30B	0.65	8.48	0.46	1.56e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs9311474	0.607	rs4687625	chr3:52563718	C/T	cg18099408	chr3:52552593	STAB1	-0.38	-6.47	-0.37	4.69e-10	Electroencephalogram traits;
CESC	cis	rs7927771	1.000	rs12363232	chr11:47623890	C/T	cg05585544	chr11:47624801	NA	-0.53	-8.2	-0.45	1.05e-14	Subjective well-being;
CESC	cis	rs60154123	0.730	rs652241	chr1:210465029	A/T	cg21951975	chr1:209979733	IRF6	0.45	6.15	0.35	2.92e-9	Coronary artery disease;
CESC	trans	rs12356475	0.710	rs10822686	chr10:67733250	C/T	cg23375431	chr12:122242145	LOC338799;SETD1B	0.49	6.02	0.35	5.92e-9	Psoriatic arthritis;
CESC	cis	rs2243480	1.000	rs313824	chr7:65581207	C/T	cg18252515	chr7:66147081	NA	-1.39	-13.92	-0.65	1.93e-33	Diabetic kidney disease;
CESC	cis	rs7666738	0.800	rs13107586	chr4:99028788	G/C	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.58e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9905704	0.918	rs12949138	chr17:56934865	A/C	cg12560992	chr17:57184187	TRIM37	0.6	7.0	0.39	2.11e-11	Testicular germ cell tumor;
CESC	cis	rs5758511	0.680	rs5758662	chr22:42628088	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.58	8.64	0.47	5.43e-16	Birth weight;
CESC	cis	rs896854	0.967	rs13257021	chr8:95965695	A/G	cg23172400	chr8:95962367	TP53INP1	-0.47	-9.9	-0.52	7.45e-20	Type 2 diabetes;
CESC	cis	rs7264396	0.561	rs6058388	chr20:34571846	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.49	5.65	0.33	4.21e-8	Total cholesterol levels;
CESC	cis	rs8177253	0.798	rs9871148	chr3:133507509	T/C	cg12373951	chr3:133503437	NA	0.49	6.88	0.39	4.21e-11	Iron status biomarkers;
CESC	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg18402987	chr7:1209562	NA	0.62	7.24	0.41	4.95e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7223966	1.000	rs7211213	chr17:61769456	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.94	0.39	3.1e-11	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs13256369	0.802	rs12681925	chr8:8561649	G/A	cg18904891	chr8:8559673	CLDN23	0.72	8.03	0.44	3.21e-14	Obesity-related traits;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg09992653	chr13:53226650	SUGT1	-0.46	-6.48	-0.37	4.43e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs7264396	0.790	rs2207889	chr20:34224898	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.86	-11.84	-0.59	3.02e-26	Total cholesterol levels;
CESC	cis	rs10242455	0.557	rs73403272	chr7:99134208	T/G	cg25640893	chr7:99214727	ZNF498	0.76	5.91	0.34	1.05e-8	Blood metabolite levels;
CESC	cis	rs9733	0.596	rs11803569	chr1:150664077	C/T	cg22823121	chr1:150693482	HORMAD1	0.48	7.1	0.4	1.14e-11	Tonsillectomy;
CESC	cis	rs2297440	0.506	rs2236504	chr20:62224762	C/T	cg09650180	chr20:62225654	GMEB2	-0.82	-9.28	-0.5	6.11e-18	Glioma;Non-glioblastoma glioma;Glioblastoma;
CESC	cis	rs858239	0.896	rs1637193	chr7:23260251	G/T	cg23682824	chr7:23144976	KLHL7	0.48	6.54	0.37	3.12e-10	Cerebrospinal fluid biomarker levels;
CESC	cis	rs4629180	0.538	rs6746761	chr2:102122390	G/T	cg04415270	chr2:102091202	RFX8	-0.32	-5.5	-0.32	9.09e-8	Chronic rhinosinusitis with nasal polyps;
CESC	cis	rs3008870	1.000	rs2815348	chr1:67472165	G/C	cg08660285	chr1:67390436	MIER1;WDR78	1.03	14.0	0.65	1e-33	Lymphocyte percentage of white cells;
CESC	cis	rs2953145	0.568	rs1133352	chr2:241522252	A/G	cg07929629	chr2:241523174	NA	-0.55	-6.89	-0.39	3.99e-11	Bipolar disorder;
CESC	cis	rs698833	0.892	rs786408	chr2:44733156	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.52	6.37	0.36	8.3e-10	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs9649213	0.574	rs36099592	chr7:98002331	T/C	cg24562669	chr7:97807699	LMTK2	0.51	7.63	0.42	4.29e-13	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs9346455	0.614	rs9360445	chr6:72000866	G/T	cg27238071	chr6:71998145	OGFRL1	0.63	6.1	0.35	3.76e-9	Antipsychotic drug-induced weight gain (time interaction);Antipsychotic drug-induced weight gain;
CESC	cis	rs7208859	0.673	rs450585	chr17:28951039	G/A	cg19761014	chr17:28927070	LRRC37B2	0.79	7.38	0.41	2.05e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg15112475	chr7:1198522	ZFAND2A	-0.39	-6.1	-0.35	3.65e-9	Longevity;Endometriosis;
CESC	cis	rs10504229	0.610	rs6993531	chr8:58147283	A/G	cg22535103	chr8:58192502	C8orf71	-0.75	-8.89	-0.48	9.37e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs601339	1.000	rs4759361	chr12:123178280	T/A	cg11919336	chr12:123188078	GPR109A	0.46	5.93	0.34	9.17e-9	Adiponectin levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09260603	chr1:206809102	DYRK3	0.62	7.01	0.4	2.02e-11	Gut microbiome composition (summer);
CESC	cis	rs36051895	0.622	rs10815143	chr9:5009541	G/A	cg02405213	chr9:5042618	JAK2	-0.48	-5.8	-0.34	1.89e-8	Pediatric autoimmune diseases;
CESC	cis	rs10504229	0.683	rs7464038	chr8:58111908	T/C	cg22535103	chr8:58192502	C8orf71	-0.81	-8.91	-0.48	8.46e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs734999	0.545	rs6666788	chr1:2567500	A/G	cg20673091	chr1:2541236	MMEL1	-0.48	-8.1	-0.45	2.01e-14	Ulcerative colitis;
CESC	cis	rs1552244	1.000	rs61052895	chr3:10147516	G/A	cg00149659	chr3:10157352	C3orf10	0.73	8.83	0.48	1.44e-16	Alzheimer's disease;
CESC	cis	rs7666738	0.830	rs35865860	chr4:98968822	C/T	cg03676636	chr4:99064102	C4orf37	0.34	5.2	0.3	4.04e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.65	7.41	0.41	1.72e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs8062405	0.721	rs151303	chr16:28492510	C/A	cg08761264	chr16:28874980	SH2B1	-0.45	-5.29	-0.31	2.5e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs854765	0.583	rs4341796	chr17:17839024	C/A	cg09796270	chr17:17721594	SREBF1	0.47	6.52	0.37	3.49e-10	Total body bone mineral density;
CESC	cis	rs7666738	0.830	rs7664340	chr4:99037820	C/T	cg03467027	chr4:99064603	C4orf37	0.47	5.95	0.34	8.45e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7811142	0.943	rs111493473	chr7:100049742	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.87	9.17	0.49	1.38e-17	Platelet count;
CESC	cis	rs1670533	1.000	rs7669399	chr4:1058478	T/G	cg04106633	chr4:1044584	NA	0.4	5.09	0.3	6.7e-7	Recombination rate (females);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg06197760	chr6:7585736	DSP	0.44	6.03	0.35	5.42e-9	Fibrinogen levels;
CESC	cis	rs727563	0.569	rs73178647	chr22:41964168	G/A	cg03806693	chr22:41940476	POLR3H	-1.14	-13.12	-0.63	1.26e-30	Crohn's disease;Inflammatory bowel disease;
CESC	trans	rs9650657	0.538	rs11250093	chr8:10798828	C/T	cg15556689	chr8:8085844	FLJ10661	0.53	6.41	0.37	6.64e-10	Neuroticism;
CESC	cis	rs116095464	0.558	rs2288457	chr5:231270	C/T	cg22857025	chr5:266934	NA	-1.28	-18.2	-0.75	1.47e-48	Breast cancer;
CESC	cis	rs78707713	0.592	rs3829182	chr10:71251384	A/G	cg12610070	chr10:71211762	TSPAN15	-0.31	-6.47	-0.37	4.8e-10	Venous thromboembolism;
CESC	cis	rs1691799	0.799	rs10784525	chr12:66772766	G/A	cg16791601	chr12:66731901	HELB	-0.59	-9.64	-0.51	4.7e-19	White blood cell count (basophil);
CESC	cis	rs7605827	0.930	rs4668448	chr2:15521740	T/C	cg19274914	chr2:15703543	NA	0.38	6.76	0.38	8.66e-11	Educational attainment (years of education);
CESC	cis	rs7584330	0.868	rs2325839	chr2:238386286	T/C	cg11271282	chr2:238384023	NA	0.48	5.49	0.32	9.18e-8	Prostate cancer;
CESC	cis	rs992157	0.835	rs34353396	chr2:219153982	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.66	-8.75	-0.47	2.45e-16	Colorectal cancer;
CESC	cis	rs13256369	1.000	rs13266699	chr8:8570313	A/T	cg00074818	chr8:8560427	CLDN23	-0.37	-5.38	-0.31	1.65e-7	Obesity-related traits;
CESC	cis	rs2880765	0.743	rs8039049	chr15:86007629	A/G	cg10818794	chr15:86012489	AKAP13	-0.33	-5.12	-0.3	6.02e-7	Coronary artery disease;
CESC	cis	rs589448	0.933	rs2249093	chr12:69753512	G/C	cg14784868	chr12:69753453	YEATS4	0.92	14.62	0.67	6.85e-36	Cerebrospinal fluid biomarker levels;
CESC	cis	rs2274273	0.905	rs28429419	chr14:55574793	T/C	cg04306507	chr14:55594613	LGALS3	0.28	5.58	0.32	5.89e-8	Protein biomarker;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg19882093	chr20:23969397	GGTLC1	0.38	6.07	0.35	4.37e-9	Ulcerative colitis;
CESC	cis	rs1799949	1.000	rs3950989	chr17:41237953	G/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.45	6.4	0.37	6.85e-10	Menopause (age at onset);
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg16522107	chr15:65579214	PARP16	0.5	6.46	0.37	5.11e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs28374715	0.532	rs28463309	chr15:41666716	A/G	cg02330683	chr15:41787940	ITPKA	0.42	5.19	0.3	4.26e-7	Ulcerative colitis;
CESC	cis	rs9902453	0.704	rs1972305	chr17:28533880	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.58	6.96	0.39	2.6e-11	Coffee consumption (cups per day);
CESC	cis	rs1862618	0.853	rs252922	chr5:56136343	G/T	cg12311346	chr5:56204834	C5orf35	-0.72	-8.82	-0.48	1.62e-16	Initial pursuit acceleration;
CESC	cis	rs11715604	1	rs11715604	chr3:136589549	A/T	cg15507776	chr3:136538369	TMEM22	-0.72	-7.14	-0.4	8.94e-12	B-cell malignancies (chronic lymphocytic leukemia, Hodgkin lymphoma or multiple myeloma) (pleiotropy);
CESC	cis	rs796364	0.755	rs203762	chr2:200905136	C/A	cg23649088	chr2:200775458	C2orf69	-0.56	-5.08	-0.3	7.14e-7	Schizophrenia;
CESC	trans	rs1814175	0.817	rs1988416	chr11:49932324	G/A	cg15704280	chr7:45808275	SEPT13	-1.03	-21.21	-0.79	4.77e-59	Height;
CESC	cis	rs875971	0.862	rs13226170	chr7:65999298	G/A	cg18252515	chr7:66147081	NA	-0.47	-6.08	-0.35	4.25e-9	Aortic root size;
CESC	cis	rs13392177	0.660	rs12988046	chr2:219073804	A/G	cg00012203	chr2:219082015	ARPC2	-0.64	-7.88	-0.44	8.42e-14	Pyoderma gangrenosum in inflammatory bowel disease;
CESC	cis	rs10504229	0.683	rs62621195	chr8:58133964	G/A	cg21724239	chr8:58056113	NA	0.58	5.95	0.34	8.29e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs7937682	0.855	rs571462	chr11:111487106	C/G	cg09085632	chr11:111637200	PPP2R1B	-0.95	-14.6	-0.67	8.26e-36	Primary sclerosing cholangitis;
CESC	cis	rs6502050	0.835	rs55679819	chr17:80105450	C/T	cg23985595	chr17:80112537	CCDC57	-0.42	-6.52	-0.37	3.51e-10	Life satisfaction;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg12583927	chr10:61469753	SLC16A9	-0.45	-6.03	-0.35	5.39e-9	Fibrinogen levels;
CESC	cis	rs290268	0.647	rs1333637	chr9:93557066	C/T	cg02608019	chr9:93564028	SYK	-0.49	-6.86	-0.39	4.94e-11	Platelet count;
CESC	trans	rs11992162	0.621	rs13268810	chr8:11797430	A/T	cg15556689	chr8:8085844	FLJ10661	0.51	6.35	0.36	9.34e-10	Monocyte count;
CESC	cis	rs61841072	0.961	rs7517403	chr1:243135892	C/T	cg02356786	chr1:243265016	LOC731275	0.43	5.64	0.33	4.46e-8	Schizophrenia;
CESC	cis	rs6714710	0.603	rs11684749	chr2:98420142	G/C	cg26665480	chr2:98280029	ACTR1B	0.56	7.96	0.44	5.02e-14	Posterior cortical atrophy and Alzheimer's disease;
CESC	cis	rs79349575	0.729	rs62075824	chr17:46986679	A/G	cg16584676	chr17:46985605	UBE2Z	0.53	6.6	0.38	2.25e-10	Type 2 diabetes;
CESC	cis	rs801193	1.000	rs2707856	chr7:66211010	A/T	cg11764359	chr7:65958608	NA	0.7	9.17	0.49	1.39e-17	Aortic root size;
CESC	cis	rs2637266	0.756	rs846607	chr10:78561254	A/T	cg18941641	chr10:78392320	NA	0.41	7.8	0.43	1.42e-13	Pulmonary function;
CESC	trans	rs6934970	0.789	rs6908498	chr6:112984103	G/A	cg05146922	chr2:10634174	NA	-0.37	-6.17	-0.35	2.53e-9	Bipolar disorder (body mass index interaction);
CESC	trans	rs3780486	0.846	rs7873903	chr9:33142728	G/A	cg04842962	chr6:43655489	MRPS18A	0.99	17.9	0.74	1.59e-47	IgG glycosylation;
CESC	cis	rs7296418	0.922	rs1790134	chr12:123697898	T/C	cg00376283	chr12:123451042	ABCB9	0.67	9.58	0.51	7.62e-19	Platelet count;
CESC	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg07677032	chr17:61819896	STRADA	0.44	5.88	0.34	1.21e-8	Prudent dietary pattern;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg09369792	chr10:118886279	NA	-0.39	-6.07	-0.35	4.34e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs208520	1.000	rs72884017	chr6:66992513	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.84	9.14	0.49	1.65e-17	Exhaled nitric oxide output;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg19813935	chr1:153959405	RAB13	-0.43	-6.37	-0.36	8.35e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs9902453	0.765	rs2729448	chr17:28091953	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-10.42	-0.54	1.51e-21	Coffee consumption (cups per day);
CESC	cis	rs7811142	1.000	rs11763414	chr7:100016844	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.16	11.7	0.58	8.86e-26	Platelet count;
CESC	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg27588902	chr6:42928151	GNMT	-0.28	-5.25	-0.31	3.17e-7	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs9902453	0.808	rs62068617	chr17:28144728	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	8.47	0.46	1.74e-15	Coffee consumption (cups per day);
CESC	cis	rs5758659	0.652	rs133349	chr22:42428727	A/T	cg19513890	chr22:42538836	CYP2D7P1	-0.39	-5.77	-0.33	2.27e-8	Cognitive function;
CESC	cis	rs36051895	0.603	rs10974972	chr9:5130146	G/A	cg02405213	chr9:5042618	JAK2	-0.5	-6.26	-0.36	1.55e-9	Pediatric autoimmune diseases;
CESC	cis	rs6089584	0.854	rs6061985	chr20:60622362	T/C	cg06108461	chr20:60628389	TAF4	-0.92	-14.55	-0.67	1.22e-35	Body mass index;
CESC	cis	rs7618915	0.501	rs13079063	chr3:52744460	A/G	cg17372223	chr3:52568218	NT5DC2	0.43	6.54	0.37	3.21e-10	Bipolar disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21813591	chr1:147071537	BCL9	0.61	6.65	0.38	1.65e-10	Gut microbiome composition (summer);
CESC	trans	rs453301	0.571	rs330048	chr8:9087278	A/C	cg15556689	chr8:8085844	FLJ10661	-0.5	-6.31	-0.36	1.18e-9	Joint mobility (Beighton score);
CESC	cis	rs7394190	0.748	rs3781216	chr10:75522404	G/A	cg07699608	chr10:75541558	CHCHD1	0.6	5.08	0.3	7.13e-7	Incident atrial fibrillation;
CESC	cis	rs4588572	0.606	rs4290994	chr5:77742253	C/T	cg11547950	chr5:77652471	NA	-0.4	-5.56	-0.32	6.42e-8	Triglycerides;
CESC	cis	rs12541635	0.677	rs1496180	chr8:106973877	T/G	cg10147462	chr8:107024639	NA	0.43	6.28	0.36	1.42e-9	Age of smoking initiation;
CESC	cis	rs2228479	0.850	rs62054601	chr16:89811751	C/G	cg06558623	chr16:89946397	TCF25	1.15	9.12	0.49	1.99e-17	Skin colour saturation;
CESC	cis	rs1348850	0.874	rs13013752	chr2:178456862	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.61	8.32	0.46	4.74e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs72781680	0.561	rs72783615	chr2:24296397	C/A	cg06627628	chr2:24431161	ITSN2	-0.67	-6.33	-0.36	1.06e-9	Lymphocyte counts;
CESC	cis	rs9916302	0.768	rs62077464	chr17:37656056	C/G	cg19468946	chr17:37922297	IKZF3	-0.4	-5.19	-0.3	4.22e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs10504229	0.593	rs79615400	chr8:57988740	C/T	cg05313129	chr8:58192883	C8orf71	-0.51	-5.07	-0.3	7.46e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs40363	0.645	rs250629	chr16:3525431	C/A	cg21433313	chr16:3507492	NAT15	0.52	8.59	0.47	7.52e-16	Tuberculosis;
CESC	cis	rs1023500	0.573	rs133380	chr22:42468910	C/T	cg04733989	chr22:42467013	NAGA	0.64	9.46	0.5	1.76e-18	Schizophrenia;
CESC	cis	rs10752881	1.000	rs10752887	chr1:182990834	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.84	13.31	0.63	2.66e-31	Colorectal cancer;
CESC	cis	rs9322193	0.923	rs12526675	chr6:150050676	A/C	cg09699651	chr6:150184138	LRP11	-0.44	-5.66	-0.33	3.96e-8	Lung cancer;
CESC	trans	rs5758511	0.773	rs11913631	chr22:42347371	G/T	cg15080870	chr19:47770746	CCDC9	0.49	6.15	0.35	2.86e-9	Birth weight;
CESC	cis	rs2479106	0.791	rs57187369	chr9:126712127	C/A	cg16191174	chr9:126692580	DENND1A	0.42	5.64	0.33	4.33e-8	Polycystic ovary syndrome;
CESC	cis	rs3096299	0.967	rs2965937	chr16:89488779	A/T	cg00750074	chr16:89608354	SPG7	-0.4	-5.77	-0.33	2.22e-8	Multiple myeloma (IgH translocation);
CESC	cis	rs6831352	0.918	rs2851251	chr4:100044111	A/G	cg13256891	chr4:100009986	ADH5	0.74	8.21	0.45	9.57e-15	Alcohol dependence;
CESC	cis	rs3008870	0.651	rs2815376	chr1:67508531	G/A	cg02640540	chr1:67518911	SLC35D1	0.63	8.35	0.46	3.76e-15	Lymphocyte percentage of white cells;
CESC	cis	rs7520050	0.807	rs28647556	chr1:46206399	G/A	cg06784218	chr1:46089804	CCDC17	0.32	5.84	0.34	1.55e-8	Red blood cell count;Reticulocyte count;
CESC	cis	rs16866061	1.000	rs7588380	chr2:225341304	A/T	cg12698349	chr2:225449008	CUL3	-0.73	-10.68	-0.55	2.29e-22	Acute graft versus host disease in bone marrow transplantation (recipient effect);
CESC	cis	rs9467711	0.606	rs66827971	chr6:26365766	T/C	cg12826209	chr6:26865740	GUSBL1	0.61	5.17	0.3	4.59e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs9814567	1.000	rs7427492	chr3:134261654	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.47	-6.37	-0.36	8.41e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs10463316	0.817	rs6880228	chr5:150778145	A/T	cg03212797	chr5:150827313	SLC36A1	0.4	5.16	0.3	4.86e-7	Metabolite levels (Pyroglutamine);
CESC	trans	rs12310956	0.532	rs10506119	chr12:33963684	A/G	cg26384229	chr12:38710491	ALG10B	0.59	8.35	0.46	3.79e-15	Morning vs. evening chronotype;
CESC	cis	rs11630290	0.592	rs8028348	chr15:64156465	A/G	cg12036633	chr15:63758958	NA	0.43	5.31	0.31	2.36e-7	Iris characteristics;
CESC	trans	rs10463316	0.855	rs13359064	chr5:150765575	G/A	cg24389359	chr12:111284228	CCDC63	-0.34	-6.2	-0.36	2.19e-9	Metabolite levels (Pyroglutamine);
CESC	cis	rs12893597	0.715	rs74639969	chr14:76832150	A/G	cg20290672	chr14:76816747	NA	-0.4	-5.62	-0.33	4.95e-8	Maximal oxygen uptake response;
CESC	cis	rs7618915	0.501	rs2336146	chr3:52626646	A/G	cg18337363	chr3:52569053	NT5DC2	0.29	5.27	0.31	2.85e-7	Bipolar disorder;
CESC	cis	rs709400	0.663	rs7145113	chr14:103945414	A/G	cg12935359	chr14:103987150	CKB	-0.54	-7.98	-0.44	4.4e-14	Body mass index;
CESC	cis	rs9486715	0.867	rs211159	chr6:97023026	G/A	cg18709589	chr6:96969512	KIAA0776	-0.46	-6.58	-0.37	2.52e-10	Headache;
CESC	cis	rs4253772	0.938	rs41355347	chr22:46637511	G/A	cg18190219	chr22:46762943	CELSR1	-0.61	-5.84	-0.34	1.52e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs6088580	0.634	rs6059829	chr20:33017074	G/A	cg08999081	chr20:33150536	PIGU	0.65	11.36	0.57	1.22e-24	Glomerular filtration rate (creatinine);
CESC	cis	rs37004	0.748	rs380145	chr5:1328897	C/T	cg06550200	chr5:1325588	CLPTM1L	-0.6	-5.9	-0.34	1.1e-8	Prostate-specific antigen levels;
CESC	cis	rs1707322	1.000	rs785504	chr1:46595696	C/T	cg03146154	chr1:46216737	IPP	-0.69	-9.04	-0.49	3.51e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs736408	0.540	rs4687637	chr3:52634092	C/T	cg07507251	chr3:52567010	NT5DC2	0.32	5.57	0.32	6.41e-8	Bipolar disorder;
CESC	cis	rs3768617	0.510	rs20558	chr1:183094547	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.89	14.39	0.66	4.39e-35	Fuchs's corneal dystrophy;
CESC	cis	rs7824557	0.545	rs2736303	chr8:11236850	C/T	cg21775007	chr8:11205619	TDH	-0.54	-8.05	-0.44	2.77e-14	Retinal vascular caliber;
CESC	cis	rs9926296	0.605	rs12448860	chr16:89849629	T/A	cg07648498	chr16:89883185	FANCA	0.45	5.48	0.32	9.69e-8	Vitiligo;
CESC	cis	rs4911259	0.552	rs13038017	chr20:31467551	T/C	cg13636640	chr20:31349939	DNMT3B	-0.54	-7.44	-0.42	1.45e-12	Inflammatory bowel disease;
CESC	cis	rs4253772	0.591	rs6008384	chr22:46655948	T/C	cg24881330	chr22:46731750	TRMU	0.89	10.11	0.53	1.55e-20	LDL cholesterol;Cholesterol, total;
CESC	cis	rs734999	0.588	rs2843404	chr1:2530558	T/C	cg20673091	chr1:2541236	MMEL1	-0.44	-7.2	-0.4	6.32e-12	Ulcerative colitis;
CESC	cis	rs875971	0.862	rs7783779	chr7:65796626	A/G	cg11764359	chr7:65958608	NA	-0.78	-11.43	-0.57	7.29e-25	Aortic root size;
CESC	cis	rs6662572	1.000	rs3014232	chr1:46131873	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.49	5.64	0.33	4.28e-8	Blood protein levels;
CESC	cis	rs1046896	0.731	rs8067667	chr17:80785875	A/G	cg19500275	chr17:80737654	TBCD	0.5	5.57	0.32	6.15e-8	Glycated hemoglobin levels;
CESC	cis	rs9910055	0.762	rs2240226	chr17:42266218	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.64	8.62	0.47	6.34e-16	Total body bone mineral density;
CESC	cis	rs7267979	0.780	rs6050679	chr20:25537827	A/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.69	11.99	0.59	9.5e-27	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7017914	0.967	rs13258584	chr8:71671579	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.2	-0.3	3.94e-7	Bone mineral density;
CESC	cis	rs2243480	0.711	rs2420172	chr7:65635341	T/C	cg13147721	chr7:65941812	NA	0.97	9.19	0.49	1.2e-17	Diabetic kidney disease;
CESC	cis	rs9815354	0.767	rs60764195	chr3:41812522	G/C	cg03022575	chr3:42003672	ULK4	0.7	6.14	0.35	2.98e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs7945705	0.747	rs2568020	chr11:8994715	C/T	cg12365402	chr11:9010492	NRIP3	-0.46	-7.82	-0.43	1.23e-13	Hemoglobin concentration;
CESC	cis	rs12579753	0.833	rs12579530	chr12:82163930	A/C	cg21193143	chr12:82153300	PPFIA2	-0.35	-5.18	-0.3	4.31e-7	Resting heart rate;
CESC	cis	rs17711722	0.565	rs4275112	chr7:65198619	T/G	cg18876405	chr7:65276391	NA	-0.42	-5.57	-0.32	6.38e-8	Calcium levels;
CESC	cis	rs2295499	0.873	rs4690085	chr4:2697300	A/G	cg08330972	chr4:2403930	ZFYVE28	-0.32	-5.33	-0.31	2.06e-7	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
CESC	cis	rs2243480	1.000	rs13237037	chr7:65997882	T/C	cg13147721	chr7:65941812	NA	-0.95	-8.91	-0.48	8.34e-17	Diabetic kidney disease;
CESC	cis	rs42648	0.869	rs1015403	chr7:89913702	A/G	cg23697855	chr7:89950296	NA	0.27	5.05	0.3	8.24e-7	Homocysteine levels;
CESC	cis	rs9660992	0.626	rs61823972	chr1:205201325	A/C	cg21643547	chr1:205240462	TMCC2	-0.38	-5.59	-0.32	5.74e-8	Mean corpuscular volume;Mean platelet volume;
CESC	trans	rs11073464	1.000	rs11852643	chr15:96674664	T/C	cg20048050	chr7:75911126	SRRM3	-0.49	-6.01	-0.35	5.96e-9	Facial morphology (factor 1, breadth of lateral portion of upper face);
CESC	cis	rs7666738	0.830	rs13121766	chr4:98935766	A/C	cg05340658	chr4:99064831	C4orf37	0.79	11.72	0.58	7.71e-26	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7264396	0.836	rs41293080	chr20:34187697	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.6	-7.1	-0.4	1.15e-11	Total cholesterol levels;
CESC	cis	rs873946	0.504	rs3829132	chr10:134579044	A/C	cg27297192	chr10:134578999	INPP5A	0.38	5.18	0.3	4.41e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs7267979	1.000	rs6115191	chr20:25440478	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.83	15.81	0.7	4.28e-40	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs3820928	0.874	rs12105952	chr2:227864521	G/A	cg11843606	chr2:227700838	RHBDD1	-0.46	-5.92	-0.34	9.69e-9	Pulmonary function;
CESC	cis	rs17376456	0.877	rs7734897	chr5:93305402	G/A	cg21475434	chr5:93447410	FAM172A	0.75	6.78	0.38	7.96e-11	Diabetic retinopathy;
CESC	cis	rs16910800	0.731	rs7125729	chr11:23181637	A/G	cg20040320	chr11:23191996	NA	-0.67	-6.66	-0.38	1.53e-10	Cancer;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg08007990	chr2:231276624	NA	-0.45	-6.02	-0.35	5.73e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs597539	0.552	rs10896384	chr11:68720011	A/G	cg21963583	chr11:68658836	MRPL21	-0.41	-5.71	-0.33	3.04e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg21515243	chr18:21033072	RIOK3	0.48	6.41	0.37	6.75e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs4076764	0.801	rs6675964	chr1:163375960	A/G	cg06092702	chr1:163392909	NA	-0.39	-5.58	-0.32	6.08e-8	Motion sickness;
CESC	cis	rs9467711	0.659	rs13195509	chr6:26463660	C/T	cg14345882	chr6:26364793	BTN3A2	0.63	5.84	0.34	1.56e-8	Autism spectrum disorder or schizophrenia;
CESC	cis	rs400736	0.602	rs4601608	chr1:8168808	A/G	cg25007680	chr1:8021821	PARK7	-0.57	-7.67	-0.43	3.36e-13	Response to antidepressants and depression;
CESC	cis	rs1538970	0.924	rs7531253	chr1:45890183	T/C	cg24296786	chr1:45957014	TESK2	-0.46	-5.3	-0.31	2.41e-7	Platelet count;
CESC	cis	rs3096299	0.967	rs28644774	chr16:89472181	G/C	cg08822215	chr16:89438651	ANKRD11	-0.41	-6.45	-0.37	5.2400000000000005e-10	Multiple myeloma (IgH translocation);
CESC	cis	rs9583531	0.689	rs9521913	chr13:111382058	C/T	cg24331049	chr13:111365604	ING1	-0.71	-10.02	-0.52	2.95e-20	Coronary artery disease;
CESC	cis	rs6582630	0.519	rs11181294	chr12:38312787	C/T	cg13010199	chr12:38710504	ALG10B	0.45	5.65	0.33	4.06e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs4253772	1.000	rs4253766	chr22:46623905	C/T	cg18190219	chr22:46762943	CELSR1	-0.62	-6.69	-0.38	1.3e-10	LDL cholesterol;Cholesterol, total;
CESC	cis	rs853679	0.517	rs4713152	chr6:28137454	G/A	cg26335602	chr6:28129616	ZNF389	0.52	6.84	0.39	5.58e-11	Depression;
CESC	cis	rs3796619	1.000	rs12647929	chr4:1092019	G/T	cg27284194	chr4:1044797	NA	0.37	5.56	0.32	6.64e-8	Recombination rate (males);
CESC	cis	rs7818345	0.967	rs4546679	chr8:19283335	C/A	cg11303988	chr8:19266685	CSGALNACT1	0.35	6.42	0.37	6.42e-10	Language performance in older adults (adjusted for episodic memory);
CESC	cis	rs1062177	0.906	rs2964573	chr5:151160122	A/T	cg12924095	chr5:151150029	G3BP1	0.5	6.47	0.37	4.81e-10	Preschool internalizing problems;
CESC	cis	rs10791323	0.660	rs2156681	chr11:133731644	G/T	cg15485101	chr11:133734466	NA	0.38	6.48	0.37	4.51e-10	Childhood ear infection;
CESC	cis	rs9916302	0.851	rs11868029	chr17:37650304	A/G	cg15445000	chr17:37608096	MED1	0.4	6.37	0.36	8.09e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs62229266	0.771	rs7277791	chr21:37383227	C/A	cg12218747	chr21:37451666	NA	-0.39	-5.48	-0.32	9.87e-8	Mitral valve prolapse;
CESC	cis	rs36051895	0.659	rs10121491	chr9:5046935	T/C	cg02405213	chr9:5042618	JAK2	-0.42	-5.23	-0.31	3.42e-7	Pediatric autoimmune diseases;
CESC	cis	rs2880765	0.835	rs11074276	chr15:86030363	C/A	cg10818794	chr15:86012489	AKAP13	-0.35	-5.39	-0.31	1.6e-7	Coronary artery disease;
CESC	cis	rs7811142	0.830	rs77861211	chr7:99962096	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.01	10.43	0.54	1.4e-21	Platelet count;
CESC	cis	rs733592	0.507	rs3825403	chr12:48457159	G/A	cg04545296	chr12:48745243	ZNF641	-0.29	-5.34	-0.31	2e-7	Plateletcrit;
CESC	cis	rs2637266	0.749	rs4979830	chr10:78457484	C/T	cg18941641	chr10:78392320	NA	0.4	7.33	0.41	2.74e-12	Pulmonary function;
CESC	cis	rs11122272	0.668	rs2790874	chr1:231537988	A/G	cg06096015	chr1:231504339	EGLN1	0.42	6.05	0.35	4.97e-9	Hemoglobin concentration;
CESC	cis	rs4589502	1.000	rs4589502	chr15:67155069	C/T	cg12317470	chr15:67143691	NA	0.68	6.61	0.38	2.07e-10	Lung cancer (smoking interaction);
CESC	cis	rs763121	0.853	rs5995610	chr22:39064681	C/T	cg06544989	chr22:39130855	UNC84B	0.48	8.4	0.46	2.69e-15	Menopause (age at onset);
CESC	cis	rs3785574	0.962	rs16947051	chr17:61790917	G/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.58	7.19	0.4	6.71e-12	Height;
CESC	cis	rs10504229	0.639	rs11781834	chr8:58133422	C/T	cg02725872	chr8:58115012	NA	-0.45	-6.94	-0.39	2.93e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs8070128	0.534	rs2955350	chr17:17953548	G/A	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.5	-6.33	-0.36	1.03e-9	Total body bone mineral density;
CESC	cis	rs9914988	0.943	rs9893782	chr17:27108132	C/T	cg20469991	chr17:27169893	C17orf63	-0.48	-5.25	-0.31	3.18e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CESC	cis	rs763121	0.785	rs5757199	chr22:39040617	T/G	cg06544989	chr22:39130855	UNC84B	0.5	8.66	0.47	4.63e-16	Menopause (age at onset);
CESC	cis	rs3105593	0.932	rs2414073	chr15:50850558	A/C	cg08437265	chr15:50716283	USP8	0.41	5.29	0.31	2.54e-7	QT interval;
CESC	cis	rs9818941	0.826	rs11714264	chr3:157655018	A/G	cg08654915	chr3:157813417	NA	0.49	7.89	0.44	8.07e-14	Height;
CESC	cis	rs9487051	0.872	rs9487034	chr6:109605899	A/G	cg12927641	chr6:109611667	NA	-0.43	-6.54	-0.37	3.2e-10	Reticulocyte fraction of red cells;
CESC	cis	rs12931792	0.682	rs12373113	chr16:30187513	C/T	cg17640201	chr16:30407289	ZNF48	0.6	8.24	0.45	8.18e-15	Tonsillectomy;
CESC	cis	rs12545109	1.000	rs12545109	chr8:57313906	A/C	cg09654669	chr8:57350985	NA	-0.57	-7.51	-0.42	9.32e-13	Obesity-related traits;
CESC	cis	rs11690935	0.959	rs76324055	chr2:172620150	T/A	cg13550731	chr2:172543902	DYNC1I2	-0.97	-14.87	-0.67	9.1e-37	Schizophrenia;
CESC	cis	rs9911578	0.935	rs420878	chr17:56709077	A/G	cg12560992	chr17:57184187	TRIM37	0.93	15.62	0.69	1.99e-39	Intelligence (multi-trait analysis);
CESC	cis	rs9487051	0.872	rs9386789	chr6:109603218	A/G	cg21918786	chr6:109611834	NA	-0.4	-6.03	-0.35	5.44e-9	Reticulocyte fraction of red cells;
CESC	cis	rs9929218	1.000	rs35069703	chr16:68789445	G/A	cg02972257	chr16:68554789	NA	0.53	5.97	0.34	7.54e-9	Colorectal cancer;
CESC	cis	rs1552244	1.000	rs9824585	chr3:10114802	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	12.09	0.6	4.37e-27	Alzheimer's disease;
CESC	cis	rs4820539	1.000	rs4822362	chr22:23482744	C/A	cg14186256	chr22:23484241	RTDR1	0.83	15.2	0.68	5.99e-38	Bone mineral density;
CESC	cis	rs1865721	0.682	rs3745081	chr18:73142923	A/G	cg26385618	chr18:73139727	C18orf62	-0.48	-7.77	-0.43	1.71e-13	Intelligence;
CESC	cis	rs5750830	0.597	rs4821889	chr22:39777254	T/C	cg05872129	chr22:39784769	NA	-0.72	-10.51	-0.54	7.81e-22	Intelligence (multi-trait analysis);
CESC	trans	rs970548	0.738	rs61854113	chr10:46004815	C/T	cg16175941	chr6:154779103	CNKSR3	0.56	6.44	0.37	5.66e-10	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
CESC	cis	rs4713118	0.586	rs9468290	chr6:28087674	C/T	cg19592336	chr6:28129416	ZNF389	0.6	7.98	0.44	4.4e-14	Parkinson's disease;
CESC	cis	rs11098499	0.954	rs11935596	chr4:120412457	G/C	cg09307838	chr4:120376055	NA	0.92	12.96	0.62	4.27e-30	Corneal astigmatism;
CESC	cis	rs1799949	1.000	rs11651341	chr17:41428061	T/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.42	5.79	0.33	2.03e-8	Menopause (age at onset);
CESC	cis	rs13191362	0.872	rs13213421	chr6:163203805	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.55	5.5	0.32	8.85e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs826838	0.967	rs11169387	chr12:39145737	C/T	cg26384229	chr12:38710491	ALG10B	0.79	13.34	0.63	2.07e-31	Heart rate;
CESC	cis	rs6426558	0.537	rs2102634	chr1:227324308	T/C	cg10327440	chr1:227177885	CDC42BPA	-0.47	-5.9	-0.34	1.13e-8	Neutrophil percentage of white cells;
CESC	cis	rs4409675	0.576	rs3766396	chr1:28221554	C/T	cg23691781	chr1:28212827	C1orf38	-0.28	-5.3	-0.31	2.46e-7	Corneal astigmatism;
CESC	cis	rs57244997	0.582	rs73030429	chr6:162438902	A/G	cg17173639	chr6:162384350	PARK2	-0.45	-5.15	-0.3	5.19e-7	Mosquito bite size;
CESC	cis	rs8072100	0.738	rs9895509	chr17:45549618	A/T	cg25173405	chr17:45401733	C17orf57	0.42	5.35	0.31	1.92e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs7666738	0.830	rs6825211	chr4:98807698	A/T	cg24818145	chr4:99064322	C4orf37	0.38	5.05	0.3	8.39e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs425277	1.000	rs12401379	chr1:2058580	G/C	cg16545954	chr1:2118288	C1orf86	0.34	5.65	0.33	4.17e-8	Height;
CESC	cis	rs7818688	1.000	rs10093594	chr8:96033236	A/G	cg16049864	chr8:95962084	TP53INP1	-0.58	-5.57	-0.32	6.35e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs11077998	0.967	rs4789790	chr17:80510789	G/A	cg10255544	chr17:80519551	FOXK2	0.53	8.59	0.47	7.47e-16	Reticulocyte fraction of red cells;
CESC	cis	rs6690583	0.623	rs2083284	chr1:85440023	C/T	cg22153463	chr1:85462885	MCOLN2	0.77	7.26	0.41	4.21e-12	Serum sulfate level;
CESC	cis	rs929354	0.772	rs2301916	chr7:156974127	G/T	cg05182265	chr7:156933206	UBE3C	-0.5	-7.2	-0.4	6.32e-12	Body mass index;
CESC	cis	rs12464559	0.649	rs4664066	chr2:152632406	T/C	cg01189475	chr2:152685088	ARL5A	0.65	5.69	0.33	3.36e-8	Response to cognitive-behavioural therapy in anxiety disorder;
CESC	cis	rs34172651	0.517	rs12927710	chr16:24790282	A/C	cg00339695	chr16:24857497	SLC5A11	0.54	6.68	0.38	1.42e-10	Intelligence (multi-trait analysis);
CESC	cis	rs561341	1.000	rs2470267	chr17:30274132	G/A	cg19193384	chr17:30244184	NA	-0.63	-6.55	-0.37	3.01e-10	Hip circumference adjusted for BMI;
CESC	cis	rs9733	0.791	rs11800059	chr1:150651175	C/T	cg18016565	chr1:150552671	MCL1	-0.35	-5.82	-0.34	1.69e-8	Tonsillectomy;
CESC	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg18402987	chr7:1209562	NA	0.75	7.52	0.42	8.71e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs5758659	0.633	rs762995	chr22:42672124	A/G	cg00645731	chr22:42541494	CYP2D7P1	-0.31	-5.42	-0.32	1.36e-7	Cognitive function;
CESC	cis	rs7178572	0.568	rs12911371	chr15:77689050	C/T	cg22256960	chr15:77711686	NA	-0.54	-6.95	-0.39	2.9e-11	Type 2 diabetes;
CESC	cis	rs6687430	0.514	rs587916	chr1:10545590	G/A	cg20482658	chr1:10539492	PEX14	-0.42	-8.71	-0.47	3.27e-16	Hand grip strength;
CESC	cis	rs965469	1.000	rs6051790	chr20:3342994	C/T	cg25506879	chr20:3388711	C20orf194	-0.56	-5.98	-0.34	7.29e-9	IFN-related cytopenia;
CESC	cis	rs2735413	0.918	rs12918959	chr16:78081719	T/C	cg04733911	chr16:78082701	NA	-0.53	-8.97	-0.48	5.54e-17	Systolic blood pressure (alcohol consumption interaction);
CESC	cis	rs77972916	0.505	rs6753197	chr2:43527962	G/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-5.92	-0.34	9.78e-9	Granulocyte percentage of myeloid white cells;
CESC	cis	rs1707322	1.000	rs11211204	chr1:46317864	A/G	cg06784218	chr1:46089804	CCDC17	0.32	5.57	0.32	6.35e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs75477785	0.590	rs12561766	chr1:209904252	T/G	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.85	5.21	0.3	3.82e-7	Cleft lip with or without cleft palate;
CESC	cis	rs1728785	1.000	rs1749792	chr16:68569440	T/G	cg02972257	chr16:68554789	NA	-0.55	-6.28	-0.36	1.36e-9	Ulcerative colitis;
CESC	cis	rs1348850	0.526	rs7588049	chr2:178390778	C/T	cg22681709	chr2:178499509	PDE11A	0.51	5.42	0.32	1.37e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs7605827	0.930	rs2277916	chr2:15494152	C/G	cg19274914	chr2:15703543	NA	0.34	6.28	0.36	1.41e-9	Educational attainment (years of education);
CESC	cis	rs62432291	0.681	rs294912	chr6:159667337	A/G	cg14500486	chr6:159655392	FNDC1	-0.61	-5.93	-0.34	9.62e-9	Joint mobility (Beighton score);
CESC	cis	rs870825	0.616	rs6834156	chr4:185639903	G/C	cg04058563	chr4:185651563	MLF1IP	0.64	7.09	0.4	1.21e-11	Blood protein levels;
CESC	cis	rs514406	0.861	rs11206026	chr1:53281708	G/A	cg08736216	chr1:53307985	ZYG11A	-0.42	-7.1	-0.4	1.16e-11	Monocyte count;
CESC	cis	rs9549367	0.789	rs9549698	chr13:113877701	A/G	cg18105134	chr13:113819100	PROZ	-0.69	-9.14	-0.49	1.72e-17	Platelet distribution width;
CESC	cis	rs270601	0.913	rs273916	chr5:131659830	C/A	cg07395648	chr5:131743802	NA	-0.45	-5.83	-0.34	1.57e-8	Acylcarnitine levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17806437	chr15:42211581	EHD4	-0.61	-7.04	-0.4	1.64e-11	Gut microbiome composition (summer);
CESC	cis	rs10771431	0.597	rs10771413	chr12:9354413	C/T	cg08997352	chr12:9597637	DDX12	-0.71	-8.82	-0.48	1.57e-16	Breast size;
CESC	cis	rs7998202	0.667	rs282587	chr13:113351662	G/A	cg02820901	chr13:113351484	ATP11A	0.63	5.85	0.34	1.41e-8	Glycated hemoglobin levels;
CESC	cis	rs3008870	1.000	rs3008873	chr1:67425770	G/A	cg02640540	chr1:67518911	SLC35D1	0.51	5.58	0.32	5.89e-8	Lymphocyte percentage of white cells;
CESC	cis	rs6430585	0.528	rs309123	chr2:136761175	C/G	cg07169764	chr2:136633963	MCM6	1.17	17.22	0.73	4.03e-45	Corneal structure;
CESC	cis	rs12995491	0.731	rs17435439	chr2:88511391	A/G	cg04169830	chr2:88471460	THNSL2	0.35	5.37	0.31	1.72e-7	Response to metformin (IC50);
CESC	cis	rs1215050	0.818	rs165238	chr4:98712138	G/T	cg05340658	chr4:99064831	C4orf37	0.48	6.03	0.35	5.52e-9	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs12477438	0.765	rs62154638	chr2:99639584	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.62	-8.67	-0.47	4.43e-16	Chronic sinus infection;
CESC	cis	rs5769765	0.632	rs13056783	chr22:50259152	A/T	cg26441486	chr22:50317300	CRELD2	-0.39	-5.44	-0.32	1.23e-7	Schizophrenia;
CESC	cis	rs2997447	0.655	rs2275947	chr1:26383875	A/G	cg19633962	chr1:26362018	EXTL1	-0.5	-5.45	-0.32	1.17e-7	QRS complex (12-leadsum);
CESC	cis	rs2243480	1.000	rs1796228	chr7:66033084	G/A	cg13147721	chr7:65941812	NA	-0.93	-8.79	-0.47	1.98e-16	Diabetic kidney disease;
CESC	cis	rs66725070	1	rs66725070	chr15:58267416	GACAT/G	cg12031962	chr15:58353849	ALDH1A2	-0.31	-5.07	-0.3	7.59e-7	Barrett's esophagus;
CESC	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.71	9.9	0.52	7.25e-20	Prudent dietary pattern;
CESC	cis	rs722599	0.683	rs8011071	chr14:75286705	T/C	cg11812906	chr14:75593930	NEK9	0.42	5.19	0.3	4.28e-7	IgG glycosylation;
CESC	cis	rs4253772	0.591	rs11704586	chr22:46685274	T/C	cg00784671	chr22:46762841	CELSR1	-0.57	-5.5	-0.32	8.75e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs9581857	0.579	rs118061689	chr13:27974499	A/T	cg01674679	chr13:27998804	GTF3A	-0.67	-5.22	-0.31	3.54e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
CESC	cis	rs1564271	0.553	rs2489583	chr10:26987698	A/G	cg13837822	chr10:26931731	LOC731789	0.45	6.78	0.38	7.6e-11	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg16866257	chr17:61905183	FTSJ3;PSMC5	0.51	6.72	0.38	1.09e-10	Systemic lupus erythematosus;
CESC	cis	rs7666738	0.830	rs1365458	chr4:98950961	C/T	cg05340658	chr4:99064831	C4orf37	0.82	12.97	0.62	3.98e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4474465	0.920	rs10793321	chr11:78237566	A/G	cg02023728	chr11:77925099	USP35	-0.41	-5.13	-0.3	5.67e-7	Alzheimer's disease (survival time);
CESC	cis	rs7223966	1.000	rs8076717	chr17:61850301	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.53	-6.21	-0.36	2.06e-9	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs6748734	1.000	rs6748734	chr2:241837452	A/G	cg04034577	chr2:241836375	C2orf54	-0.5	-8.67	-0.47	4.49e-16	Urinary metabolites;
CESC	cis	rs9399137	0.507	rs11757723	chr6:135291293	C/T	cg24558204	chr6:135376177	HBS1L	0.71	9.77	0.51	1.93e-19	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg15448726	chr12:53273497	NA	-0.43	-6.43	-0.37	5.89e-10	Gambling;
CESC	cis	rs7584330	0.554	rs10183995	chr2:238433307	G/A	cg14458575	chr2:238380390	NA	0.49	5.42	0.32	1.35e-7	Prostate cancer;
CESC	cis	rs9611565	0.729	rs2413647	chr22:41907148	G/A	cg06634786	chr22:41940651	POLR3H	-0.7	-7.13	-0.4	9.69e-12	Vitiligo;
CESC	cis	rs1879734	0.731	rs7519965	chr1:54163251	G/A	cg23596471	chr1:54105337	GLIS1	0.35	5.45	0.32	1.14e-7	Mitral valve prolapse;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08882774	chr16:28875105	SH2B1	-0.53	-6.2	-0.36	2.2e-9	Gut microbiome composition (summer);
CESC	cis	rs62432291	0.614	rs370434	chr6:159654551	C/G	cg14500486	chr6:159655392	FNDC1	-0.62	-6.21	-0.36	2.04e-9	Joint mobility (Beighton score);
CESC	cis	rs9796	0.621	rs557864	chr15:41471358	T/C	cg18705301	chr15:41695430	NDUFAF1	0.44	6.46	0.37	4.86e-10	Menopause (age at onset);
CESC	cis	rs6540559	0.673	rs17015224	chr1:209968918	G/A	cg25204440	chr1:209979598	IRF6	0.65	6.71	0.38	1.21e-10	Cleft lip with or without cleft palate;
CESC	cis	rs6674176	0.628	rs4660758	chr1:44424879	A/C	cg12908607	chr1:44402522	ARTN	-0.44	-6.37	-0.36	8.33e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs3858526	0.523	rs10838750	chr11:5886246	C/T	cg02574844	chr11:5959923	NA	0.47	7.43	0.42	1.53e-12	DNA methylation (variation);
CESC	cis	rs10754283	0.967	rs12058749	chr1:90105604	C/T	cg21401794	chr1:90099060	LRRC8C	0.65	8.71	0.47	3.24e-16	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs763121	0.853	rs5750652	chr22:39048316	A/G	cg06022373	chr22:39101656	GTPBP1	0.95	17.36	0.73	1.37e-45	Menopause (age at onset);
CESC	cis	rs9916302	0.904	rs2338755	chr17:37419317	C/T	cg20243544	chr17:37824526	PNMT	-0.47	-6.02	-0.35	5.7e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs9303401	0.612	rs2526370	chr17:56487636	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.49	6.46	0.37	4.99e-10	Cognitive test performance;
CESC	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.54	0.37	3.16e-10	Prudent dietary pattern;
CESC	cis	rs698833	0.798	rs4953082	chr2:44524064	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.44	5.51	0.32	8.31e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs854765	0.647	rs721669	chr17:18005073	A/G	cg16928487	chr17:17741425	SREBF1	-0.53	-8.57	-0.47	8.9e-16	Total body bone mineral density;
CESC	cis	rs7618501	0.538	rs9856572	chr3:50109073	A/T	cg24308560	chr3:49941425	MST1R	0.61	9.02	0.48	4e-17	Intelligence (multi-trait analysis);
CESC	cis	rs2243480	1.000	rs2961102	chr7:65424658	A/G	cg18252515	chr7:66147081	NA	-1.24	-12.07	-0.6	4.93e-27	Diabetic kidney disease;
CESC	cis	rs748404	0.697	rs493177	chr15:43543258	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.5	7.65	0.43	3.76e-13	Lung cancer;
CESC	cis	rs8072100	0.811	rs1912483	chr17:45443494	A/G	cg25173405	chr17:45401733	C17orf57	-0.44	-5.72	-0.33	2.81e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs7264396	0.635	rs6058366	chr20:34512172	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.81	-11.07	-0.56	1.13e-23	Total cholesterol levels;
CESC	cis	rs1538970	0.504	rs3790585	chr1:46023356	A/T	cg06784218	chr1:46089804	CCDC17	0.49	7.27	0.41	4.15e-12	Platelet count;
CESC	cis	rs6502050	0.835	rs4789672	chr17:80126603	T/C	cg23985595	chr17:80112537	CCDC57	-0.41	-6.57	-0.37	2.61e-10	Life satisfaction;
CESC	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg25324976	chr17:61989376	CSHL1	0.36	5.42	0.32	1.37e-7	Prudent dietary pattern;
CESC	cis	rs950169	0.922	rs62028133	chr15:84919375	A/C	cg17507749	chr15:85114479	UBE2QP1	0.57	6.32	0.36	1.09e-9	Schizophrenia;
CESC	cis	rs17376456	0.825	rs55947981	chr5:93278104	G/T	cg25358565	chr5:93447407	FAM172A	1.11	10.04	0.53	2.56e-20	Diabetic retinopathy;
CESC	trans	rs11601239	0.646	rs12790131	chr11:105567758	G/A	cg15315312	chr2:176867285	KIAA1715	0.46	6.04	0.35	5.06e-9	Refractive error;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10235275	chr10:65225544	JMJD1C;LOC84989	0.57	6.15	0.35	2.81e-9	Gut microbiome composition (summer);
CESC	cis	rs1784581	0.802	rs9365359	chr6:162423945	C/A	cg17173639	chr6:162384350	PARK2	0.61	9.56	0.51	8.61e-19	Itch intensity from mosquito bite;
CESC	cis	rs6952808	0.729	rs35797753	chr7:1954914	G/A	cg05863683	chr7:1912471	MAD1L1	0.42	6.34	0.36	1.01e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs9796	0.558	rs6492993	chr15:41526104	G/A	cg20272979	chr15:41787780	ITPKA	0.38	5.57	0.32	6.19e-8	Menopause (age at onset);
CESC	cis	rs748404	0.518	rs480108	chr15:43817406	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.56	7.19	0.4	6.82e-12	Lung cancer;
CESC	cis	rs2228479	0.850	rs11639925	chr16:89908250	C/T	cg14709524	chr16:89940631	TCF25	0.89	6.18	0.36	2.38e-9	Skin colour saturation;
CESC	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	7.36	0.41	2.34e-12	Prudent dietary pattern;
CESC	cis	rs2573652	0.723	rs4577068	chr15:100515959	T/A	cg09918751	chr15:100517450	ADAMTS17	-0.45	-8.74	-0.47	2.66e-16	Height;
CESC	cis	rs10463316	0.894	rs10476980	chr5:150764157	A/G	cg03212797	chr5:150827313	SLC36A1	-0.46	-6.02	-0.35	5.83e-9	Metabolite levels (Pyroglutamine);
CESC	cis	rs3806843	0.838	rs2262567	chr5:140132134	T/A	cg26395211	chr5:140044315	WDR55	0.39	5.09	0.3	6.79e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs1559088	0.600	rs58173463	chr19:33596749	C/T	cg27124370	chr19:33622961	WDR88	0.53	7.62	0.42	4.4e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26434548	chr7:129074607	FAM40B	0.57	6.91	0.39	3.62e-11	Gut microbiome composition (summer);
CESC	cis	rs9527	0.640	rs35195396	chr10:104928770	T/A	cg04362960	chr10:104952993	NT5C2	0.42	5.25	0.31	3.11e-7	Arsenic metabolism;
CESC	cis	rs875971	0.862	rs6958294	chr7:65794796	C/A	cg18252515	chr7:66147081	NA	0.43	5.77	0.33	2.21e-8	Aortic root size;
CESC	cis	rs17711722	0.727	rs781151	chr7:65479878	T/C	cg26939375	chr7:64535504	NA	0.71	9.75	0.51	2.13e-19	Calcium levels;
CESC	cis	rs10504229	0.679	rs2218271	chr8:58052446	T/A	cg22535103	chr8:58192502	C8orf71	-0.66	-7.26	-0.41	4.29e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg26338869	chr17:61819248	STRADA	0.69	9.1	0.49	2.19e-17	Prudent dietary pattern;
CESC	cis	rs9611519	0.780	rs2235852	chr22:41661154	G/T	cg17376030	chr22:41985996	PMM1	0.44	5.33	0.31	2.13e-7	Neuroticism;
CESC	cis	rs4803468	1.000	rs284654	chr19:41928724	G/A	cg14132834	chr19:41945861	ATP5SL	-0.64	-7.84	-0.43	1.07e-13	Height;
CESC	cis	rs61931739	0.679	rs10844831	chr12:34311245	G/T	cg19457237	chr12:34500585	NA	-0.42	-5.67	-0.33	3.77e-8	Morning vs. evening chronotype;
CESC	cis	rs78456975	1.000	rs13429866	chr2:1555211	C/A	cg01028140	chr2:1542097	TPO	-0.58	-5.9	-0.34	1.1e-8	Placebo response in major depressive disorder (% change in symptom score);
CESC	trans	rs12310956	0.532	rs11052954	chr12:33993512	C/G	cg26384229	chr12:38710491	ALG10B	0.46	6.3	0.36	1.27e-9	Morning vs. evening chronotype;
CESC	cis	rs1707322	1.000	rs11211205	chr1:46321874	C/T	cg06784218	chr1:46089804	CCDC17	0.32	5.57	0.32	6.35e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7927771	0.965	rs17788930	chr11:47752775	A/G	cg05585544	chr11:47624801	NA	-0.51	-8.07	-0.44	2.38e-14	Subjective well-being;
CESC	cis	rs10791097	0.667	rs4937584	chr11:130741761	A/G	cg12179176	chr11:130786555	SNX19	0.65	10.06	0.53	2.26e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs58688157	0.705	rs12419694	chr11:598033	C/T	cg02461776	chr11:598696	PHRF1	0.52	6.28	0.36	1.34e-9	Systemic lupus erythematosus;
CESC	cis	rs3015469	0.596	rs1547078	chr14:51210853	T/C	cg26011998	chr14:51135199	SAV1	0.55	5.85	0.34	1.43e-8	Plasma amyloid beta peptide concentrations (ABx-40);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08209184	chr20:35444560	C20orf117	-0.68	-8.27	-0.45	6.68e-15	Gut microbiome composition (summer);
CESC	cis	rs1707322	1.000	rs4660889	chr1:46297331	C/T	cg05343316	chr1:45956843	TESK2	0.44	5.47	0.32	1.05e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11792649	chr11:68664631	MRPL21	-0.57	-6.09	-0.35	3.87e-9	Gut microbiome composition (summer);
CESC	cis	rs3806843	1.000	rs12717860	chr5:140171442	C/T	cg26395211	chr5:140044315	WDR55	-0.44	-5.54	-0.32	7.4e-8	Depressive symptoms (multi-trait analysis);
CESC	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg00945038	chr17:61921165	SMARCD2	0.37	5.04	0.3	8.71e-7	Prudent dietary pattern;
CESC	cis	rs9309473	1.000	rs6546839	chr2:73680508	G/C	cg20560298	chr2:73613845	ALMS1	-0.46	-6.17	-0.35	2.53e-9	Metabolite levels;
CESC	cis	rs7927771	1.000	rs11605774	chr11:47832793	G/A	cg05585544	chr11:47624801	NA	-0.51	-7.87	-0.44	9.36e-14	Subjective well-being;
CESC	cis	rs7786808	0.741	rs11769149	chr7:158227127	A/G	cg01191920	chr7:158217561	PTPRN2	0.45	7.9	0.44	7.37e-14	Obesity-related traits;
CESC	cis	rs7809950	1.000	rs7809950	chr7:107237807	T/C	cg23024343	chr7:107201750	COG5	0.44	6.02	0.35	5.73e-9	Coronary artery disease;
CESC	cis	rs765787	0.530	rs1648286	chr15:45517386	G/C	cg24006582	chr15:45444508	DUOX1	-0.58	-7.07	-0.4	1.4e-11	Uric acid levels;
CESC	cis	rs2456568	0.867	rs1827931	chr11:93663170	T/C	cg26875233	chr11:93583750	C11orf90	-0.31	-5.51	-0.32	8.57e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
CESC	cis	rs1008375	1.000	rs3846357	chr4:17635887	A/T	cg02297831	chr4:17616191	MED28	0.54	6.85	0.39	5.05e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs28830936	1.000	rs17676742	chr15:41903048	A/G	cg11010575	chr15:42129464	JMJD7-PLA2G4B;JMJD7	-0.36	-5.1	-0.3	6.47e-7	Diastolic blood pressure;
CESC	cis	rs1348850	0.914	rs2060929	chr2:178280031	T/C	cg22681709	chr2:178499509	PDE11A	-0.42	-6.23	-0.36	1.79e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs11098499	0.863	rs3822192	chr4:120445720	A/C	cg24375607	chr4:120327624	NA	0.46	5.58	0.32	6e-8	Corneal astigmatism;
CESC	cis	rs9322193	0.926	rs3805751	chr6:150112329	G/A	cg13206674	chr6:150067644	NUP43	0.43	6.03	0.35	5.54e-9	Lung cancer;
CESC	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg22963979	chr7:1858916	MAD1L1	-0.37	-5.04	-0.3	8.63e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs4253772	0.938	rs41371446	chr22:46637272	T/C	cg18190219	chr22:46762943	CELSR1	-0.61	-5.84	-0.34	1.52e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs2204008	0.720	rs11180923	chr12:38255172	A/T	cg13010199	chr12:38710504	ALG10B	0.48	6.04	0.35	5.23e-9	Bladder cancer;
CESC	cis	rs992157	0.798	rs4674284	chr2:219161241	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.66	-8.66	-0.47	4.76e-16	Colorectal cancer;
CESC	cis	rs13191362	1.000	rs35017019	chr6:162982581	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.86	9.01	0.48	4.24e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs9902453	0.872	rs34698290	chr17:28500465	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	7.74	0.43	2.08e-13	Coffee consumption (cups per day);
CESC	cis	rs877282	0.629	rs78997110	chr10:764388	A/G	cg17470449	chr10:769945	NA	0.47	5.14	0.3	5.33e-7	Uric acid levels;
CESC	cis	rs2576037	0.583	rs2571028	chr18:44561100	C/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.33	-5.16	-0.3	4.84e-7	Personality dimensions;
CESC	cis	rs80130819	0.748	rs2258342	chr12:48690363	T/C	cg05342945	chr12:48394962	COL2A1	-0.48	-5.16	-0.3	4.82e-7	Prostate cancer;
CESC	cis	rs3862030	0.694	rs12781742	chr10:104227469	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.37	-5.17	-0.3	4.71e-7	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
CESC	cis	rs13256369	0.901	rs12679831	chr8:8566411	T/G	cg00074818	chr8:8560427	CLDN23	0.36	5.29	0.31	2.51e-7	Obesity-related traits;
CESC	cis	rs7666738	0.578	rs1989109	chr4:98881246	T/A	cg03467027	chr4:99064603	C4orf37	0.42	5.25	0.31	3.05e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs929596	0.556	rs4477910	chr2:234643737	A/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.63	-8.46	-0.46	1.79e-15	Total bilirubin levels in HIV-1 infection;
CESC	cis	rs12220238	0.730	rs10740421	chr10:75941002	T/G	cg19889307	chr10:75911429	ADK;AP3M1	0.59	5.35	0.31	1.94e-7	Soluble interleukin-2 receptor subunit alpha;
CESC	cis	rs778371	0.522	rs6704768	chr2:233592501	C/T	cg08000102	chr2:233561755	GIGYF2	0.8	13.57	0.64	3.29e-32	Schizophrenia;
CESC	cis	rs7666738	0.791	rs10856933	chr4:98958542	C/A	cg03467027	chr4:99064603	C4orf37	0.45	5.61	0.33	4.97e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7726839	0.540	rs4957081	chr5:646418	G/C	cg16447950	chr5:562315	NA	-0.58	-6.53	-0.37	3.38e-10	Obesity-related traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20776722	chr5:130970743	RAPGEF6	-0.6	-7.09	-0.4	1.22e-11	Gut microbiome composition (summer);
CESC	cis	rs1538970	1.000	rs7417107	chr1:45831915	G/C	cg05343316	chr1:45956843	TESK2	0.76	10.54	0.54	6.54e-22	Platelet count;
CESC	cis	rs11864453	0.679	rs2303285	chr16:72124495	A/C	cg01557791	chr16:72042693	DHODH	-0.43	-5.57	-0.32	6.39e-8	Fibrinogen levels;
CESC	cis	rs9403521	1.000	rs6901659	chr6:143985106	T/C	cg18240653	chr6:144019428	PHACTR2	-0.5	-5.57	-0.32	6.28e-8	Obesity-related traits;
CESC	cis	rs11264213	0.681	rs72659670	chr1:36236750	G/C	cg27506609	chr1:36549197	TEKT2	0.65	5.34	0.31	1.97e-7	Schizophrenia;
CESC	cis	rs7937682	0.883	rs490492	chr11:111465150	C/T	cg22437258	chr11:111473054	SIK2	0.71	9.19	0.49	1.16e-17	Primary sclerosing cholangitis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27600766	chr18:21594250	TTC39C	0.58	6.15	0.35	2.8e-9	Gut microbiome composition (summer);
CESC	cis	rs3540	0.574	rs2526000	chr15:90962626	C/T	cg10434728	chr15:90938212	IQGAP1	0.4	6.97	0.39	2.46e-11	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg18591801	chr3:52553433	STAB1	-0.29	-5.61	-0.33	5.18e-8	Electroencephalogram traits;
CESC	cis	rs10493773	0.502	rs12066742	chr1:86081149	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.44	-5.74	-0.33	2.58e-8	Urate levels in overweight individuals;
CESC	cis	rs9322193	0.884	rs62439837	chr6:149991516	G/T	cg07701084	chr6:150067640	NUP43	0.41	5.42	0.32	1.33e-7	Lung cancer;
CESC	cis	rs514406	0.861	rs7524476	chr1:53240212	C/T	cg24675658	chr1:53192096	ZYG11B	0.53	6.73	0.38	1.04e-10	Monocyte count;
CESC	cis	rs4722166	0.630	rs13311199	chr7:22789793	A/C	cg05265849	chr7:22767390	IL6	0.58	7.39	0.41	1.9e-12	Lung cancer;
CESC	cis	rs1218582	0.711	rs4845677	chr1:154838050	C/T	cg16680214	chr1:154839983	KCNN3	-0.52	-8.16	-0.45	1.36e-14	Prostate cancer;
CESC	cis	rs2980439	0.846	rs2980437	chr8:8094763	C/T	cg06636001	chr8:8085503	FLJ10661	-0.59	-7.55	-0.42	7.07e-13	Neuroticism;
CESC	cis	rs16866061	1.000	rs17480230	chr2:225399864	G/A	cg12698349	chr2:225449008	CUL3	0.76	11.25	0.57	2.89e-24	Acute graft versus host disease in bone marrow transplantation (recipient effect);
CESC	cis	rs875971	0.895	rs6460278	chr7:65662736	T/C	cg11764359	chr7:65958608	NA	-0.78	-11.07	-0.56	1.19e-23	Aortic root size;
CESC	cis	rs7267979	1.000	rs4815406	chr20:25341316	C/G	cg08601574	chr20:25228251	PYGB	-0.38	-5.46	-0.32	1.12e-7	Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg03828693	chr10:63661686	ARID5B	-0.44	-6.02	-0.35	5.94e-9	Asthma;
CESC	cis	rs2625529	0.652	rs2034879	chr15:72429989	A/G	cg16672083	chr15:72433130	SENP8	-0.46	-6.84	-0.39	5.45e-11	Red blood cell count;
CESC	trans	rs61931739	0.500	rs11053280	chr12:34559297	G/T	cg26384229	chr12:38710491	ALG10B	0.72	10.84	0.55	6.43e-23	Morning vs. evening chronotype;
CESC	cis	rs2836974	0.545	rs8128901	chr21:40710419	G/A	cg11644478	chr21:40555479	PSMG1	0.61	8.24	0.45	7.75e-15	Cognitive function;
CESC	cis	rs858239	0.600	rs1468592	chr7:23140647	C/T	cg23682824	chr7:23144976	KLHL7	-0.54	-7.74	-0.43	2.08e-13	Cerebrospinal fluid biomarker levels;
CESC	cis	rs9815354	0.857	rs73830583	chr3:41996948	C/T	cg03022575	chr3:42003672	ULK4	0.68	6.03	0.35	5.51e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs597539	0.617	rs669659	chr11:68635623	G/C	cg18350739	chr11:68623251	NA	-0.46	-7.04	-0.4	1.61e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs2710642	0.888	rs13418889	chr2:63079775	T/C	cg17519650	chr2:63277830	OTX1	0.51	6.65	0.38	1.64e-10	LDL cholesterol levels;LDL cholesterol;
CESC	cis	rs8067354	0.645	rs72838857	chr17:57836767	A/G	cg02344993	chr17:57696989	CLTC	0.57	5.97	0.34	7.53e-9	Hemoglobin concentration;
CESC	cis	rs875971	0.862	rs6460282	chr7:65691246	T/C	cg18252515	chr7:66147081	NA	0.47	6.06	0.35	4.68e-9	Aortic root size;
CESC	cis	rs826838	1.000	rs34254519	chr12:39041235	G/A	cg26384229	chr12:38710491	ALG10B	0.8	13.76	0.65	7.12e-33	Heart rate;
CESC	cis	rs12618769	0.597	rs3729568	chr2:99100196	T/G	cg10123293	chr2:99228465	UNC50	0.4	5.38	0.31	1.68e-7	Bipolar disorder;
CESC	cis	rs7605827	0.930	rs2111451	chr2:15654483	T/C	cg19274914	chr2:15703543	NA	0.32	5.7	0.33	3.17e-8	Educational attainment (years of education);
CESC	cis	rs763014	0.898	rs35666389	chr16:629458	A/G	cg09263875	chr16:632152	PIGQ	0.67	11.08	0.56	1.07e-23	Height;
CESC	trans	rs7922314	0.571	rs16917977	chr10:64729208	T/A	cg06935979	chr1:232941706	KIAA1383	-0.66	-5.99	-0.35	6.67e-9	Cutaneous psoriasis;
CESC	cis	rs13242816	1.000	rs13247015	chr7:116095623	A/C	cg04696780	chr7:116139425	CAV2	-0.63	-5.66	-0.33	3.95e-8	P wave duration;
CESC	cis	rs7447927	0.950	rs13181561	chr5:138850905	A/G	cg11459648	chr5:138714337	SLC23A1	-0.46	-6.96	-0.39	2.74e-11	Esophageal squamous cell carcinoma;
CESC	cis	rs9926296	0.744	rs154656	chr16:89708003	T/A	cg01097406	chr16:89675127	NA	0.38	5.49	0.32	9.25e-8	Vitiligo;
CESC	cis	rs6963495	0.818	rs56165465	chr7:105180384	C/T	cg19920283	chr7:105172520	RINT1	0.77	8.17	0.45	1.24e-14	Bipolar disorder (body mass index interaction);
CESC	cis	rs35306767	0.903	rs34847097	chr10:902252	A/T	cg10556349	chr10:835070	NA	0.57	5.48	0.32	9.87e-8	Eosinophil percentage of granulocytes;
CESC	cis	rs4665809	1.000	rs750451	chr2:26324241	G/A	cg04944784	chr2:26401820	FAM59B	-0.65	-7.47	-0.42	1.16e-12	Gut microbiome composition (summer);
CESC	trans	rs561341	0.883	rs2074102	chr17:30228884	G/A	cg27661571	chr11:113659931	NA	-0.64	-6.33	-0.36	1.02e-9	Hip circumference adjusted for BMI;
CESC	cis	rs898097	0.625	rs7406464	chr17:80891460	A/G	cg15664640	chr17:80829946	TBCD	-0.38	-5.64	-0.33	4.4e-8	Breast cancer;
CESC	cis	rs61931739	0.658	rs10772149	chr12:34285498	A/G	cg19457237	chr12:34500585	NA	-0.39	-5.36	-0.31	1.84e-7	Morning vs. evening chronotype;
CESC	cis	rs782590	0.935	rs2586954	chr2:55892261	A/C	cg18811423	chr2:55921094	PNPT1	0.79	12.54	0.61	1.25e-28	Metabolic syndrome;
CESC	cis	rs780096	0.526	rs1647267	chr2:27651054	A/T	cg12648201	chr2:27665141	KRTCAP3	-0.35	-6.56	-0.37	2.79e-10	Total body bone mineral density;
CESC	cis	rs7666738	0.830	rs28818180	chr4:98953625	A/G	cg03467027	chr4:99064603	C4orf37	0.45	5.61	0.33	4.97e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6964587	1.000	rs2269727	chr7:91752690	C/A	cg17063962	chr7:91808500	NA	0.59	8.13	0.45	1.69e-14	Breast cancer;
CESC	cis	rs4819052	0.851	rs9977178	chr21:46664531	G/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.49	6.11	0.35	3.61e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs7666738	0.830	rs13125930	chr4:98654695	G/A	cg03467027	chr4:99064603	C4orf37	0.44	5.39	0.31	1.52e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1799949	1.000	rs33926631	chr17:41304463	T/C	cg06001716	chr17:41278141	BRCA1;NBR2	0.38	5.23	0.31	3.5e-7	Menopause (age at onset);
CESC	cis	rs5753618	0.583	rs5753612	chr22:31821479	T/C	cg02404636	chr22:31891804	SFI1	0.39	5.37	0.31	1.71e-7	Colorectal cancer;
CESC	cis	rs7605827	0.897	rs11682528	chr2:15533183	T/C	cg19274914	chr2:15703543	NA	0.34	6.11	0.35	3.46e-9	Educational attainment (years of education);
CESC	cis	rs763121	0.853	rs4821811	chr22:39075145	C/T	cg14440974	chr22:39074834	NA	-0.42	-5.73	-0.33	2.77e-8	Menopause (age at onset);
CESC	cis	rs589448	0.900	rs588493	chr12:69751986	G/A	cg22834771	chr12:69754056	YEATS4	-0.54	-7.24	-0.41	4.92e-12	Cerebrospinal fluid biomarker levels;
CESC	cis	rs829883	0.659	rs11109522	chr12:98930964	C/T	cg25150519	chr12:98850993	NA	-0.64	-7.87	-0.44	8.8e-14	Colorectal adenoma (advanced);
CESC	cis	rs938554	0.513	rs3775946	chr4:9995256	A/G	cg11266682	chr4:10021025	SLC2A9	0.5	7.28	0.41	3.69e-12	Blood metabolite levels;
CESC	cis	rs6460942	0.915	rs17444044	chr7:12458736	A/G	cg06484146	chr7:12443880	VWDE	-0.78	-9.14	-0.49	1.68e-17	Coronary artery disease;
CESC	cis	rs2845885	0.793	rs57779243	chr11:63882363	G/T	cg05555928	chr11:63887634	MACROD1	-0.54	-5.99	-0.35	6.69e-9	Body mass index;
CESC	cis	rs6121246	0.954	rs6121245	chr20:30432060	G/A	cg13852791	chr20:30311386	BCL2L1	0.73	7.54	0.42	7.5e-13	Mean corpuscular hemoglobin;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13486387	chr9:94124044	AUH	0.56	6.18	0.35	2.43e-9	Gut microbiome composition (summer);
CESC	cis	rs514406	0.679	rs545719	chr1:53304922	T/C	cg08859206	chr1:53392774	SCP2	-0.62	-9.03	-0.49	3.65e-17	Monocyte count;
CESC	cis	rs17253792	0.822	rs76918910	chr14:56058762	T/C	cg01858014	chr14:56050164	KTN1	-0.87	-6.75	-0.38	9.11e-11	Putamen volume;
CESC	cis	rs3096299	0.642	rs12934829	chr16:89523349	T/A	cg02034447	chr16:89574710	SPG7	0.5	6.33	0.36	1.04e-9	Multiple myeloma (IgH translocation);
CESC	cis	rs1348850	0.567	rs2222711	chr2:178534110	G/T	cg23306229	chr2:178417860	TTC30B	0.52	6.11	0.35	3.47e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs897984	0.520	rs12928081	chr16:30885159	T/G	cg02466173	chr16:30829666	NA	0.45	6.56	0.37	2.82e-10	Dementia with Lewy bodies;
CESC	cis	rs9916302	0.904	rs634365	chr17:37436966	C/T	cg19468946	chr17:37922297	IKZF3	-0.39	-5.06	-0.3	7.85e-7	Glomerular filtration rate (creatinine);
CESC	trans	rs7937682	1.000	rs12363179	chr11:111568091	G/A	cg18187862	chr3:45730750	SACM1L	-0.53	-6.07	-0.35	4.52e-9	Primary sclerosing cholangitis;
CESC	cis	rs3857536	0.740	rs7745163	chr6:66889936	A/G	cg07460842	chr6:66804631	NA	-0.42	-5.39	-0.31	1.56e-7	Blood trace element (Cu levels);
CESC	cis	rs9322193	0.924	rs9322189	chr6:149909933	T/C	cg13206674	chr6:150067644	NUP43	0.44	6.3	0.36	1.24e-9	Lung cancer;
CESC	cis	rs11031096	0.621	rs12282967	chr11:4191477	A/T	cg18678763	chr11:4115507	RRM1	-0.4	-5.18	-0.3	4.46e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	trans	rs61931739	0.817	rs2636084	chr12:34130210	G/A	cg26384229	chr12:38710491	ALG10B	0.44	6.05	0.35	5.02e-9	Morning vs. evening chronotype;
CESC	trans	rs916888	0.610	rs199442	chr17:44820122	G/A	cg22433210	chr17:43662623	NA	0.62	8.04	0.44	2.96e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs17345786	0.798	rs1609159	chr3:101275902	A/C	cg12386194	chr3:101231763	SENP7	0.49	5.86	0.34	1.33e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6089584	0.888	rs6061973	chr20:60610870	C/T	cg24733560	chr20:60626293	TAF4	0.45	6.38	0.37	7.76e-10	Body mass index;
CESC	cis	rs9733	0.596	rs17606613	chr1:150683015	C/T	cg09365446	chr1:150670422	GOLPH3L	0.42	5.86	0.34	1.37e-8	Tonsillectomy;
CESC	cis	rs5753037	0.639	rs5997534	chr22:30220190	G/A	cg01021169	chr22:30184971	ASCC2	-0.47	-6.6	-0.38	2.22e-10	Type 1 diabetes;
CESC	cis	rs4665809	0.627	rs13014338	chr2:26463024	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.1	12.68	0.61	4e-29	Gut microbiome composition (summer);
CESC	cis	rs7615952	0.599	rs2279821	chr3:125734308	G/A	cg02807482	chr3:125708958	NA	-0.4	-5.25	-0.31	3.13e-7	Blood pressure (smoking interaction);
CESC	cis	rs5769765	0.542	rs5770720	chr22:50253101	A/G	cg02269571	chr22:50332266	NA	0.46	5.45	0.32	1.16e-7	Schizophrenia;
CESC	cis	rs9814567	0.896	rs13089566	chr3:134349710	G/C	cg15484384	chr3:134203672	ANAPC13;CEP63	0.32	5.11	0.3	6.06e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs4450131	0.522	rs34209544	chr10:126350452	G/C	cg20435097	chr10:126320824	FAM53B	0.29	5.14	0.3	5.35e-7	White blood cell count (basophil);
CESC	cis	rs7659604	0.539	rs7699776	chr4:122753885	A/G	cg20573242	chr4:122745356	CCNA2	0.65	8.05	0.44	2.81e-14	Type 2 diabetes;
CESC	cis	rs9796	0.870	rs3101436	chr15:41287689	A/G	cg18705301	chr15:41695430	NDUFAF1	0.43	6.36	0.36	8.58e-10	Menopause (age at onset);
CESC	cis	rs11122272	0.735	rs2808601	chr1:231536571	A/G	cg06096015	chr1:231504339	EGLN1	0.39	5.53	0.32	7.83e-8	Hemoglobin concentration;
CESC	cis	rs12220238	0.915	rs11001021	chr10:76139657	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.54	5.11	0.3	6.13e-7	Soluble interleukin-2 receptor subunit alpha;
CESC	cis	rs7666738	0.830	rs4699597	chr4:99019031	G/A	cg18180107	chr4:99064573	C4orf37	0.41	5.39	0.31	1.57e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9311474	0.607	rs4687625	chr3:52563718	C/T	cg17372223	chr3:52568218	NT5DC2	0.51	7.94	0.44	5.81e-14	Electroencephalogram traits;
CESC	cis	rs6540559	0.673	rs58637469	chr1:209971480	T/A	cg25204440	chr1:209979598	IRF6	0.65	6.71	0.38	1.21e-10	Cleft lip with or without cleft palate;
CESC	cis	rs8077577	0.708	rs4556848	chr17:18134867	C/G	cg16794390	chr17:18148240	FLII	-0.44	-6.58	-0.37	2.58e-10	Obesity-related traits;
CESC	cis	rs7811142	1.000	rs73161759	chr7:100009994	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.0	9.62	0.51	5.54e-19	Platelet count;
CESC	cis	rs4523957	0.928	rs8074850	chr17:2187931	C/A	cg16513277	chr17:2031491	SMG6	-0.56	-7.41	-0.41	1.68e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs4746818	0.892	rs2394505	chr10:70871598	A/G	cg11621586	chr10:70884670	VPS26A	-0.9	-9.91	-0.52	6.89e-20	Left atrial antero-posterior diameter;
CESC	cis	rs4141404	0.851	rs5749248	chr22:31683711	C/A	cg00478049	chr22:31556069	RNF185	0.48	5.06	0.3	8.01e-7	Paclitaxel-induced neuropathy;
CESC	cis	rs6460942	0.749	rs74834695	chr7:12464779	G/A	cg06484146	chr7:12443880	VWDE	-0.78	-9.14	-0.49	1.68e-17	Coronary artery disease;
CESC	cis	rs6032067	0.704	rs35009666	chr20:43786020	C/T	cg10761708	chr20:43804764	PI3	0.56	6.55	0.37	3.01e-10	Blood protein levels;
CESC	trans	rs61931739	1.000	rs12427391	chr12:34022891	A/G	cg26384229	chr12:38710491	ALG10B	-0.46	-6.28	-0.36	1.4e-9	Morning vs. evening chronotype;
CESC	cis	rs13191362	1.000	rs13210412	chr6:163019478	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.49	5.17	0.3	4.69e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs1729951	0.575	rs1654923	chr3:136692620	A/T	cg04103450	chr3:136751342	NA	0.4	5.31	0.31	2.32e-7	Neuroticism;
CESC	cis	rs7255436	0.931	rs7249520	chr19:8446056	G/A	cg10174797	chr19:8464628	RAB11B	0.41	5.96	0.34	8.11e-9	HDL cholesterol;
CESC	cis	rs1144333	0.655	rs76532097	chr1:76320759	G/C	cg10523679	chr1:76189770	ACADM	0.56	5.36	0.31	1.8e-7	Attention function in attention deficit hyperactive disorder;
CESC	cis	rs11997175	0.646	rs66856932	chr8:33700782	A/G	ch.8.33884649F	chr8:33765107	NA	0.57	7.56	0.42	6.61e-13	Body mass index;
CESC	cis	rs7666738	0.830	rs7662596	chr4:99019962	G/T	cg18180107	chr4:99064573	C4orf37	0.41	5.39	0.31	1.57e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9910055	0.529	rs228764	chr17:42185469	A/G	cg13607699	chr17:42295918	UBTF	-0.44	-5.51	-0.32	8.36e-8	Total body bone mineral density;
CESC	cis	rs10751667	0.643	rs6597969	chr11:928843	C/T	cg06064525	chr11:970664	AP2A2	-0.52	-10.25	-0.53	5.74e-21	Alzheimer's disease (late onset);
CESC	cis	rs854765	0.583	rs8080823	chr17:17864048	T/C	cg16928487	chr17:17741425	SREBF1	-0.6	-10.08	-0.53	1.98e-20	Total body bone mineral density;
CESC	cis	rs8114671	0.836	rs4911461	chr20:33629993	A/C	cg07148914	chr20:33460835	GGT7	-0.41	-5.31	-0.31	2.28e-7	Height;
CESC	cis	rs3747547	0.710	rs7864677	chr9:37949969	C/T	cg13774184	chr9:37916125	SHB	-0.56	-5.87	-0.34	1.32e-8	Metabolite levels (Dihydroxy docosatrienoic acid);
CESC	cis	rs9287719	0.781	rs6732671	chr2:10759149	T/G	cg00105475	chr2:10696890	NA	0.35	5.07	0.3	7.65e-7	Prostate cancer;
CESC	trans	rs916888	0.773	rs199443	chr17:44819565	C/T	cg27125505	chr17:43679177	LOC644172	0.47	6.33	0.36	1.04e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs780096	0.587	rs1049817	chr2:27550967	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.29	-5.91	-0.34	1.05e-8	Total body bone mineral density;
CESC	cis	rs854765	0.693	rs35451946	chr17:17764061	C/G	cg09796270	chr17:17721594	SREBF1	-0.42	-6.0	-0.35	6.49e-9	Total body bone mineral density;
CESC	cis	rs11785693	0.862	rs6994150	chr8:4996630	T/G	cg26367366	chr8:4980734	NA	0.75	7.3	0.41	3.44e-12	Neuroticism (multi-trait analysis);Neuroticism;
CESC	cis	rs6748734	1.000	rs4675863	chr2:241830763	A/T	cg15164180	chr2:241846931	NA	-0.35	-5.09	-0.3	6.67e-7	Urinary metabolites;
CESC	cis	rs6502050	0.871	rs6502054	chr17:80066715	G/A	cg11859384	chr17:80120422	CCDC57	0.4	5.51	0.32	8.47e-8	Life satisfaction;
CESC	trans	rs9467711	0.606	rs9379900	chr6:26603811	A/C	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.73	6.12	0.35	3.38e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs7264396	0.570	rs6060717	chr20:34544647	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.57	6.97	0.39	2.48e-11	Total cholesterol levels;
CESC	cis	rs4555082	0.834	rs2816631	chr14:105739477	G/A	cg27165867	chr14:105738592	BRF1	-0.52	-5.64	-0.33	4.33e-8	Mean platelet volume;Platelet distribution width;
CESC	cis	rs66573146	0.831	rs68111914	chr4:6986677	C/T	cg00086871	chr4:6988644	TBC1D14	1.18	7.63	0.42	4.18e-13	Granulocyte percentage of myeloid white cells;
CESC	cis	rs425277	0.606	rs2257684	chr1:2077872	A/G	cg04315214	chr1:2043799	PRKCZ	-0.44	-7.05	-0.4	1.53e-11	Height;
CESC	cis	rs1062753	0.771	rs5751245	chr22:42620940	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.38	6.2	0.36	2.18e-9	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
CESC	cis	rs35110281	0.805	rs4818843	chr21:45006607	C/T	cg01579765	chr21:45077557	HSF2BP	-0.57	-9.49	-0.5	1.43e-18	Mean corpuscular volume;
CESC	cis	rs9868809	0.881	rs6773261	chr3:48675064	A/G	cg07636037	chr3:49044803	WDR6	-0.67	-5.64	-0.33	4.29e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg03188948	chr7:1209495	NA	0.46	5.89	0.34	1.18e-8	Longevity;Endometriosis;
CESC	cis	rs8044868	0.530	rs2550870	chr16:72070129	C/T	cg16558253	chr16:72132732	DHX38	-0.37	-5.77	-0.33	2.19e-8	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CESC	trans	rs8073060	0.544	rs2626626	chr17:34026717	A/G	cg19694781	chr19:47549865	TMEM160	-0.69	-6.3	-0.36	1.22e-9	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	trans	rs9850225	0.719	rs4856616	chr3:80466481	A/C	cg04945395	chr3:111805408	C3orf52	-0.42	-6.13	-0.35	3.09e-9	Erectile dysfunction in type 1 diabetes;
CESC	cis	rs10927875	0.541	rs1048334	chr1:16340761	T/C	cg22431228	chr1:16359049	CLCNKA	-0.52	-9.96	-0.52	4.74e-20	Dilated cardiomyopathy;
CESC	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg18402987	chr7:1209562	NA	0.76	7.56	0.42	6.59e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs4474465	0.790	rs10751293	chr11:78250956	A/T	cg27205649	chr11:78285834	NARS2	0.42	5.31	0.31	2.3e-7	Alzheimer's disease (survival time);
CESC	cis	rs1023500	0.573	rs133380	chr22:42468910	C/T	cg15557168	chr22:42548783	NA	-0.43	-6.5	-0.37	3.86e-10	Schizophrenia;
CESC	cis	rs4975709	0.610	rs4975704	chr5:1859807	C/A	cg15595755	chr5:1867978	NA	0.53	8.74	0.47	2.68e-16	Cardiovascular disease risk factors;
CESC	cis	rs4604732	0.631	rs1106721	chr1:247624676	A/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.57	7.17	0.4	7.39e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg10774155	chr7:65338427	VKORC1L1	-0.52	-6.7	-0.38	1.22e-10	Asthma;
CESC	cis	rs2425143	0.818	rs7272684	chr20:34424692	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.71	-6.06	-0.35	4.71e-9	Blood protein levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10519082	chr1:245026741	HNRNPU	0.57	6.07	0.35	4.39e-9	Gut microbiome composition (summer);
CESC	cis	rs8114671	0.836	rs3746432	chr20:33592763	C/T	cg24642439	chr20:33292090	TP53INP2	-0.45	-5.43	-0.32	1.25e-7	Height;
CESC	cis	rs2274273	0.967	rs10137409	chr14:55611441	A/C	cg04306507	chr14:55594613	LGALS3	0.28	5.27	0.31	2.77e-7	Protein biomarker;
CESC	cis	rs9733	0.596	rs72702573	chr1:150689050	C/T	cg04414720	chr1:150670196	GOLPH3L	0.62	8.86	0.48	1.21e-16	Tonsillectomy;
CESC	cis	rs9322193	0.926	rs9689036	chr6:150101699	T/C	cg05861140	chr6:150128134	PCMT1	-0.35	-5.07	-0.3	7.45e-7	Lung cancer;
CESC	cis	rs1348850	0.874	rs12996447	chr2:178283592	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.72	10.1	0.53	1.7e-20	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs9858542	0.903	rs11921590	chr3:49644193	T/C	cg03060546	chr3:49711283	APEH	-0.55	-6.5	-0.37	4.04e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25968378	chr3:42544131	VIPR1	0.54	6.38	0.36	7.7e-10	Gut microbiome composition (summer);
CESC	cis	rs13191362	1.000	rs36107456	chr6:162997399	T/G	cg21926612	chr6:163149169	PACRG;PARK2	0.83	8.86	0.48	1.15e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs7772486	0.875	rs2777481	chr6:146310036	G/T	cg05347473	chr6:146136440	FBXO30	0.55	7.17	0.4	7.51e-12	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs13098911	0.540	rs78380307	chr3:46174331	T/C	cg10236987	chr1:228114221	WNT9A	0.6	6.22	0.36	1.93e-9	Celiac disease;
CESC	cis	rs2933343	0.649	rs789216	chr3:128594503	A/C	cg25356066	chr3:128598488	ACAD9	0.61	8.38	0.46	3.06e-15	IgG glycosylation;
CESC	cis	rs11792861	0.926	rs2271878	chr9:111868885	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.41	5.15	0.3	5.08e-7	Menarche (age at onset);
CESC	cis	rs3859192	0.561	rs9916158	chr17:38182229	G/T	cg17467752	chr17:38218738	THRA	-0.43	-5.87	-0.34	1.28e-8	White blood cell count;
CESC	cis	rs17253792	0.822	rs10147431	chr14:56091841	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.77	5.98	0.34	7.23e-9	Putamen volume;
CESC	cis	rs9291683	0.609	rs12500810	chr4:10031068	G/A	cg02734326	chr4:10020555	SLC2A9	0.48	6.84	0.39	5.53e-11	Bone mineral density;
CESC	cis	rs7085104	0.632	rs7096475	chr10:104609676	A/G	cg04362960	chr10:104952993	NT5C2	0.49	6.62	0.38	1.98e-10	Immature fraction of reticulocytes;Schizophrenia;
CESC	cis	rs9640161	0.830	rs17173681	chr7:150059414	A/G	cg21361702	chr7:150065534	REPIN1	-0.66	-8.15	-0.45	1.41e-14	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs2095921	1	rs2095921	chr1:11033322	C/G	cg27631724	chr1:11040367	C1orf127	0.38	6.21	0.36	2.02e-9	Male-pattern baldness;
CESC	cis	rs67460515	0.531	rs13315565	chr3:160754626	G/C	cg03342759	chr3:160939853	NMD3	-0.53	-6.84	-0.39	5.44e-11	Parkinson's disease;
CESC	cis	rs763121	0.853	rs9610993	chr22:39042818	C/A	cg14440974	chr22:39074834	NA	-0.4	-5.48	-0.32	9.77e-8	Menopause (age at onset);
CESC	cis	rs6500602	0.702	rs4786511	chr16:4571645	C/T	cg08645402	chr16:4508243	NA	0.54	8.71	0.47	3.29e-16	Schizophrenia;
CESC	cis	rs425277	0.958	rs262687	chr1:2117155	G/A	cg24578937	chr1:2090814	PRKCZ	0.53	8.94	0.48	7.03e-17	Height;
CESC	cis	rs9911578	1.000	rs6503870	chr17:56659018	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.23	0.31	3.51e-7	Intelligence (multi-trait analysis);
CESC	cis	rs1008375	1.000	rs3846357	chr4:17635887	A/T	cg16339924	chr4:17578868	LAP3	0.56	7.13	0.4	9.83e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg26338869	chr17:61819248	STRADA	0.5	6.21	0.36	2.06e-9	Prudent dietary pattern;
CESC	cis	rs926938	0.520	rs6671984	chr1:115257521	C/T	cg12756093	chr1:115239321	AMPD1	-0.54	-6.67	-0.38	1.52e-10	Autism;
CESC	cis	rs1550582	1.000	rs76091740	chr8:135514419	C/T	cg17885191	chr8:135476712	NA	0.62	7.12	0.4	1.03e-11	Educational attainment;
CESC	cis	rs1957429	0.522	rs73279816	chr14:65348375	G/A	cg23373153	chr14:65346875	NA	-0.92	-6.7	-0.38	1.21e-10	Pediatric areal bone mineral density (radius);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18163118	chr11:67250585	AIP	0.66	7.6	0.42	5.13e-13	Gut microbiome composition (summer);
CESC	cis	rs1799949	1.000	rs8070085	chr17:41341984	C/T	cg25072359	chr17:41440525	NA	-0.39	-5.29	-0.31	2.63e-7	Menopause (age at onset);
CESC	cis	rs8072100	0.512	rs9303533	chr17:45386540	A/G	cg08085267	chr17:45401833	C17orf57	-0.51	-6.82	-0.39	6.16e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs7772486	0.875	rs2748501	chr6:146312258	G/A	cg05347473	chr6:146136440	FBXO30	0.56	7.32	0.41	2.96e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs34779708	0.931	rs11010082	chr10:35351155	A/G	cg04310649	chr10:35416472	CREM	-0.54	-6.43	-0.37	5.93e-10	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs9902453	0.726	rs3115092	chr17:28036350	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.78	10.88	0.56	4.97e-23	Coffee consumption (cups per day);
CESC	cis	rs12618769	0.597	rs3754888	chr2:99090674	T/C	cg10123293	chr2:99228465	UNC50	0.4	5.38	0.31	1.64e-7	Bipolar disorder;
CESC	cis	rs11166629	1.000	rs1545240	chr8:135642632	A/C	cg27224718	chr8:135614730	ZFAT	0.49	6.02	0.35	5.93e-9	Smoking quantity;
CESC	trans	rs116095464	0.558	rs3213838	chr5:223890	G/C	cg00938859	chr5:1591904	SDHAP3	0.61	6.78	0.38	7.58e-11	Breast cancer;
CESC	cis	rs1552244	0.572	rs12107622	chr3:10171898	T/A	cg08888203	chr3:10149979	C3orf24	0.47	5.28	0.31	2.69e-7	Alzheimer's disease;
CESC	cis	rs13118159	0.767	rs2141656	chr4:1317192	C/T	cg16405210	chr4:1374714	KIAA1530	-0.6	-8.17	-0.45	1.3e-14	Longevity;
CESC	cis	rs6952808	0.692	rs12666575	chr7:2004421	C/T	cg08027265	chr7:2291960	NA	-0.39	-5.83	-0.34	1.62e-8	Bipolar disorder and schizophrenia;
CESC	trans	rs11764590	0.724	rs55789728	chr7:2107649	A/G	cg11693508	chr17:37793320	STARD3	0.53	6.04	0.35	5.25e-9	Neuroticism;
CESC	cis	rs9902453	0.619	rs2255489	chr17:28084974	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.68	-8.47	-0.46	1.76e-15	Coffee consumption (cups per day);
CESC	trans	rs208520	0.690	rs12194057	chr6:66745616	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.95	12.05	0.59	5.77e-27	Exhaled nitric oxide output;
CESC	cis	rs875971	0.522	rs4718285	chr7:65292005	A/G	cg11987759	chr7:65425863	GUSB	-0.48	-6.56	-0.37	2.82e-10	Aortic root size;
CESC	cis	rs4843747	0.749	rs13333619	chr16:88072076	C/T	cg17633681	chr16:88106987	BANP	0.69	9.07	0.49	2.69e-17	Menopause (age at onset);
CESC	cis	rs9911578	1.000	rs12952832	chr17:56906254	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.26	0.31	3.04e-7	Intelligence (multi-trait analysis);
CESC	cis	rs7666738	0.753	rs34164013	chr4:98976333	A/G	cg17366294	chr4:99064904	C4orf37	0.59	8.43	0.46	2.31e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2795502	0.882	rs3123754	chr10:43339011	G/A	cg27426351	chr10:43362370	NA	-0.45	-5.5	-0.32	8.91e-8	Blood protein levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10690677	chr1:87019175	CLCA4	-0.67	-7.65	-0.43	3.63e-13	Gut microbiome composition (summer);
CESC	cis	rs875971	0.862	rs6460307	chr7:66060871	A/G	cg11764359	chr7:65958608	NA	0.73	10.54	0.54	6.24e-22	Aortic root size;
CESC	cis	rs733592	0.507	rs7299704	chr12:48444488	A/G	cg04545296	chr12:48745243	ZNF641	0.29	5.44	0.32	1.19e-7	Plateletcrit;
CESC	cis	rs10979	1.000	rs9390104	chr6:143890978	T/C	cg25407410	chr6:143891975	LOC285740	-0.61	-9.14	-0.49	1.72e-17	Hypospadias;
CESC	cis	rs1568889	0.838	rs7131053	chr11:28143312	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.8	13.23	0.63	5.14e-31	Bipolar disorder;
CESC	cis	rs1355223	0.506	rs11032899	chr11:34870234	G/A	cg11622362	chr11:34938112	PDHX;APIP	0.44	5.14	0.3	5.23e-7	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs40363	0.729	rs6501176	chr16:3522197	A/G	cg05754148	chr16:3507555	NAT15	-0.57	-7.17	-0.4	7.62e-12	Tuberculosis;
CESC	cis	rs1124376	0.816	rs62243131	chr3:20141308	A/G	cg05072819	chr3:20081367	KAT2B	0.47	5.44	0.32	1.19e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs1218582	0.710	rs7553195	chr1:154837796	T/C	cg09359103	chr1:154839909	KCNN3	-0.68	-13.1	-0.63	1.47e-30	Prostate cancer;
CESC	cis	rs6580649	0.941	rs1859441	chr12:48423233	C/T	cg05342945	chr12:48394962	COL2A1	0.53	6.07	0.35	4.33e-9	Lung cancer;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg21512275	chr2:157198069	NA	-0.48	-6.89	-0.39	4.04e-11	Gambling;
CESC	cis	rs9814567	1.000	rs9289475	chr3:134236459	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.45	-6.08	-0.35	4.09e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs4481887	0.927	rs4603165	chr1:248473799	T/A	cg00666640	chr1:248458726	OR2T12	0.36	6.12	0.35	3.33e-9	Common traits (Other);
CESC	cis	rs12220238	1.000	rs73284257	chr10:76000710	T/G	cg19889307	chr10:75911429	ADK;AP3M1	0.63	5.75	0.33	2.5e-8	Soluble interleukin-2 receptor subunit alpha;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg05280932	chr6:88045306	C6orf162	0.44	6.31	0.36	1.16e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs1371867	0.875	rs2439456	chr8:101336874	C/T	cg11906718	chr8:101322791	RNF19A	0.47	5.95	0.34	8.49e-9	Atrioventricular conduction;
CESC	cis	rs546131	1.000	rs546131	chr11:34851760	G/C	cg11058730	chr11:34937778	PDHX;APIP	0.49	6.17	0.35	2.53e-9	Lung disease severity in cystic fibrosis;
CESC	cis	rs7091068	0.518	rs913045	chr10:95431535	C/T	cg20715218	chr10:95462985	C10orf4	0.47	6.07	0.35	4.47e-9	Urinary tract infection frequency;
CESC	cis	rs2637266	0.703	rs846577	chr10:78500277	A/G	cg18941641	chr10:78392320	NA	0.38	7.31	0.41	3.08e-12	Pulmonary function;
CESC	cis	rs7666738	0.830	rs13129479	chr4:98987860	T/C	cg05340658	chr4:99064831	C4orf37	0.8	12.42	0.61	3.31e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7927771	0.524	rs10742820	chr11:47781057	C/T	cg05585544	chr11:47624801	NA	-0.32	-5.11	-0.3	6.09e-7	Subjective well-being;
CESC	cis	rs926938	0.505	rs360629	chr1:115414733	A/G	cg12756093	chr1:115239321	AMPD1	0.45	6.01	0.35	6.15e-9	Autism;
CESC	cis	rs6060717	0.536	rs6060670	chr20:34481143	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.66	5.7	0.33	3.16e-8	Hip circumference adjusted for BMI;
CESC	cis	rs9733	0.543	rs72702558	chr1:150683251	G/A	cg22823121	chr1:150693482	HORMAD1	0.48	7.11	0.4	1.11e-11	Tonsillectomy;
CESC	cis	rs2456568	0.778	rs7944194	chr11:93682413	C/G	cg05188948	chr11:93754288	HEPHL1	-0.27	-5.23	-0.31	3.46e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
CESC	cis	rs950169	0.526	rs698620	chr15:85177208	G/A	cg11189052	chr15:85197271	WDR73	-0.48	-6.47	-0.37	4.79e-10	Schizophrenia;
CESC	cis	rs10791097	0.694	rs10894273	chr11:130742155	G/T	cg12179176	chr11:130786555	SNX19	0.65	10.06	0.53	2.26e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	trans	rs561341	1.000	rs117029332	chr17:30266085	C/G	cg20587970	chr11:113659929	NA	-1.43	-18.77	-0.76	1.45e-50	Hip circumference adjusted for BMI;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11928684	chr11:47291227	MADD	0.52	5.99	0.35	6.65e-9	Gut microbiome composition (summer);
CESC	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg07092213	chr7:1199455	ZFAND2A	-0.46	-5.48	-0.32	1.01e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7973683	0.541	rs7976319	chr12:124388511	A/G	cg00084347	chr12:124393913	DNAH10	0.27	5.53	0.32	7.67e-8	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg21581312	chr15:35529473	LOC723972	-0.48	-6.65	-0.38	1.69e-10	Gut microbiota (bacterial taxa);
CESC	trans	rs2099077	0.867	rs62365561	chr5:102795941	A/C	cg07434438	chr16:72961899	ZFHX3	0.49	6.67	0.38	1.5e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs1799949	1.000	rs34572725	chr17:41428666	G/A	cg25072359	chr17:41440525	NA	0.48	6.54	0.37	3.13e-10	Menopause (age at onset);
CESC	cis	rs7937682	0.889	rs567859	chr11:111486738	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.95	-14.6	-0.67	8.26e-36	Primary sclerosing cholangitis;
CESC	cis	rs2479106	0.591	rs913783	chr9:126434103	C/T	cg16191174	chr9:126692580	DENND1A	-0.36	-5.03	-0.3	9.02e-7	Polycystic ovary syndrome;
CESC	trans	rs28595532	0.557	rs12498329	chr4:119311524	C/T	cg26518628	chr1:97050305	NA	-0.51	-6.04	-0.35	5.25e-9	Cannabis dependence symptom count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06168166	chr11:47372949	MYBPC3	-0.49	-6.15	-0.35	2.82e-9	Gut microbiome composition (summer);
CESC	trans	rs11039798	1.000	rs6485856	chr11:48556298	G/C	cg15704280	chr7:45808275	SEPT13	0.7	6.53	0.37	3.42e-10	Axial length;
CESC	cis	rs7666738	0.830	rs1115616	chr4:99006603	A/C	cg03467027	chr4:99064603	C4orf37	0.44	5.51	0.32	8.65e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs597539	0.690	rs578791	chr11:68625809	C/T	cg18350739	chr11:68623251	NA	-0.44	-6.35	-0.36	9.53e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs5769765	0.913	rs2319462	chr22:50263370	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	0.46	5.32	0.31	2.21e-7	Schizophrenia;
CESC	cis	rs9486719	1.000	rs11152969	chr6:96908712	A/C	cg06623918	chr6:96969491	KIAA0776	-0.81	-8.3	-0.45	5.45e-15	Migraine;Coronary artery disease;
CESC	cis	rs2243480	1.000	rs709607	chr7:65449541	C/G	cg13147721	chr7:65941812	NA	0.69	6.55	0.37	2.98e-10	Diabetic kidney disease;
CESC	cis	rs1218582	0.772	rs12069356	chr1:154849771	C/T	cg24250549	chr1:154909240	PMVK	0.64	9.31	0.5	5.09e-18	Prostate cancer;
CESC	cis	rs7512552	0.839	rs1260386	chr1:150369622	G/T	cg15654264	chr1:150340011	RPRD2	0.4	5.28	0.31	2.65e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs131777	0.575	rs131760	chr22:51011936	T/C	cg25309564	chr22:51001381	C22orf41	0.6	7.54	0.42	7.64e-13	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	cis	rs7267979	1.000	rs6037121	chr20:25428311	G/A	cg08601574	chr20:25228251	PYGB	0.38	5.64	0.33	4.4e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs11122272	0.766	rs2808608	chr1:231543175	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.59	-7.97	-0.44	4.66e-14	Hemoglobin concentration;
CESC	cis	rs4654899	1.000	rs6700718	chr1:21299363	A/C	cg05370193	chr1:21551575	ECE1	-0.36	-5.28	-0.31	2.67e-7	Superior frontal gyrus grey matter volume;
CESC	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg23131131	chr22:24373011	LOC391322	-0.77	-11.18	-0.57	5.1900000000000004e-24	Liver enzyme levels (gamma-glutamyl transferase);
CESC	trans	rs61931739	0.500	rs11053167	chr12:34387092	A/C	cg13010199	chr12:38710504	ALG10B	0.46	6.03	0.35	5.51e-9	Morning vs. evening chronotype;
CESC	cis	rs4930561	0.765	rs10896304	chr11:67981714	T/G	cg16338278	chr11:67432957	ALDH3B2	0.44	5.36	0.31	1.83e-7	Breast cancer in childhood cancer survivors;IgG glycosylation;
CESC	cis	rs950776	0.518	rs11630349	chr15:78824608	C/T	cg06917634	chr15:78832804	PSMA4	0.8	12.12	0.6	3.34e-27	Sudden cardiac arrest;
CESC	cis	rs568617	0.953	rs645900	chr11:65648135	G/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.69	-7.4	-0.41	1.81e-12	Crohn's disease;
CESC	cis	rs9768139	0.935	rs6953748	chr7:158121184	G/A	cg06219351	chr7:158114137	PTPRN2	0.48	7.55	0.42	7.25e-13	Calcium levels;
CESC	cis	rs10463316	0.894	rs13357969	chr5:150751557	A/G	cg03212797	chr5:150827313	SLC36A1	-0.53	-6.76	-0.38	8.77e-11	Metabolite levels (Pyroglutamine);
CESC	cis	rs12142240	0.698	rs72677594	chr1:46824371	A/C	cg10495392	chr1:46806563	NSUN4	0.58	6.32	0.36	1.09e-9	Menopause (age at onset);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg04800682	chr3:58223165	ABHD6	0.44	6.26	0.36	1.55e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs3008870	0.755	rs10789219	chr1:67417742	A/C	cg02640540	chr1:67518911	SLC35D1	0.46	5.56	0.32	6.52e-8	Lymphocyte percentage of white cells;
CESC	cis	rs2072499	0.868	rs2758600	chr1:156195205	C/T	cg25208724	chr1:156163844	SLC25A44	0.94	14.92	0.68	6.04e-37	Testicular germ cell tumor;
CESC	cis	rs7605827	0.930	rs7577130	chr2:15527859	G/A	cg19274914	chr2:15703543	NA	0.35	6.27	0.36	1.43e-9	Educational attainment (years of education);
CESC	cis	rs7666738	0.830	rs36028444	chr4:98968635	G/T	cg03676636	chr4:99064102	C4orf37	0.34	5.2	0.3	4.04e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9894429	0.738	rs8077038	chr17:79577127	T/G	cg18240062	chr17:79603768	NPLOC4	-0.89	-13.21	-0.63	6.03e-31	Eye color traits;
CESC	cis	rs1707322	0.721	rs4330955	chr1:46217485	G/C	cg05343316	chr1:45956843	TESK2	0.51	6.2	0.36	2.19e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs875971	0.862	rs1875057	chr7:65731855	A/G	cg19163074	chr7:65112434	INTS4L2	0.4	5.08	0.3	7.16e-7	Aortic root size;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg14387153	chr12:121877053	KDM2B	0.49	6.3	0.36	1.23e-9	Fibrinogen levels;
CESC	cis	rs10504229	0.683	rs56192850	chr8:58135356	A/G	cg02725872	chr8:58115012	NA	-0.45	-7.05	-0.4	1.52e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs7808935	0.768	rs757137	chr7:27989343	T/C	cg05786569	chr7:27702416	HIBADH	0.44	5.52	0.32	8.23e-8	Prostate cancer;
CESC	trans	rs208515	0.556	rs1872309	chr6:66660432	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.75	8.67	0.47	4.26e-16	Exhaled nitric oxide levels;
CESC	cis	rs7561273	0.586	rs7580772	chr2:24357657	T/C	cg20701182	chr2:24300061	SF3B14	0.46	6.01	0.35	6.27e-9	Quantitative traits;
CESC	cis	rs2404602	0.647	rs11072626	chr15:77090826	A/G	cg23625390	chr15:77176239	SCAPER	-0.45	-6.04	-0.35	5.17e-9	Blood metabolite levels;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg25043602	chr13:113489734	ATP11A	0.54	7.08	0.4	1.29e-11	Fibrinogen levels;
CESC	cis	rs2274273	0.901	rs8011288	chr14:55735112	C/T	cg04306507	chr14:55594613	LGALS3	0.3	5.96	0.34	8.08e-9	Protein biomarker;
CESC	cis	rs7927771	0.864	rs7107726	chr11:47429245	T/A	cg05585544	chr11:47624801	NA	-0.47	-6.81	-0.39	6.45e-11	Subjective well-being;
CESC	cis	rs2243480	0.711	rs1626926	chr7:65435792	C/T	cg25894440	chr7:65020034	NA	-0.63	-5.61	-0.33	5.13e-8	Diabetic kidney disease;
CESC	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg11494091	chr17:61959527	GH2	-0.72	-11.75	-0.59	6.32e-26	Prudent dietary pattern;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04250904	chr19:12623422	ZNF709	-0.62	-7.38	-0.41	2.04e-12	Gut microbiome composition (summer);
CESC	cis	rs9487051	0.676	rs2884013	chr6:109599952	C/T	cg01475377	chr6:109611718	NA	-0.43	-6.82	-0.39	6.19e-11	Reticulocyte fraction of red cells;
CESC	cis	rs9858542	0.953	rs11715915	chr3:49455330	A/G	cg07274523	chr3:49395745	GPX1	-0.65	-7.62	-0.42	4.46e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs897984	0.721	rs2305884	chr16:30970741	G/A	cg02466173	chr16:30829666	NA	0.47	7.92	0.44	6.36e-14	Dementia with Lewy bodies;
CESC	cis	rs79057730	0.599	rs4333501	chr7:803244	C/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.86	7.51	0.42	9.05e-13	Initial pursuit acceleration;
CESC	cis	rs6570726	0.905	rs419575	chr6:145840174	A/G	cg05347473	chr6:146136440	FBXO30	0.49	6.74	0.38	1e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9916302	0.904	rs6503507	chr17:37525274	C/T	cg07936489	chr17:37558343	FBXL20	0.81	11.85	0.59	2.8e-26	Glomerular filtration rate (creatinine);
CESC	cis	rs853679	0.882	rs9380064	chr6:28143118	A/G	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.79	6.91	0.39	3.68e-11	Depression;
CESC	cis	rs12136530	0.593	rs34873850	chr1:19723310	T/C	cg01832549	chr1:19774989	CAPZB	-0.47	-6.34	-0.36	9.79e-10	Lead levels in blood;
CESC	trans	rs7178375	1.000	rs7178533	chr15:31215976	C/G	cg04373760	chr16:53404718	NA	0.53	7.03	0.4	1.76e-11	Hypertriglyceridemia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21809257	chr1:154955635	FLAD1	0.6	6.31	0.36	1.19e-9	Gut microbiome composition (summer);
CESC	cis	rs5769765	0.865	rs9616369	chr22:50304591	A/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.48	-5.44	-0.32	1.2e-7	Schizophrenia;
CESC	cis	rs3796619	1.000	rs2290409	chr4:1067249	C/T	cg27284194	chr4:1044797	NA	-0.36	-5.49	-0.32	9.61e-8	Recombination rate (males);
CESC	cis	rs7216064	0.906	rs8074644	chr17:65878217	G/C	cg07042672	chr17:66097459	LOC651250	-0.57	-6.54	-0.37	3.09e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs9859260	0.710	rs41298097	chr3:195779155	C/T	cg12923728	chr3:195709715	SDHAP1	0.54	6.96	0.39	2.68e-11	Mean corpuscular volume;
CESC	cis	rs3785574	0.962	rs13030	chr17:61908556	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.09	19.22	0.76	3.69e-52	Height;
CESC	cis	rs4665809	1.000	rs6749855	chr2:26255263	A/G	cg22920501	chr2:26401640	FAM59B	-0.68	-7.82	-0.43	1.22e-13	Gut microbiome composition (summer);
CESC	cis	rs6500602	0.647	rs1684600	chr16:4594671	C/T	cg08645402	chr16:4508243	NA	-0.42	-6.45	-0.37	5.18e-10	Schizophrenia;
CESC	cis	rs10504229	1.000	rs61212428	chr8:58173963	G/A	cg14926445	chr8:58193284	C8orf71	-0.51	-5.47	-0.32	1.03e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs7618915	0.547	rs2118540	chr3:52629386	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.47	6.56	0.37	2.76e-10	Bipolar disorder;
CESC	cis	rs9905704	0.671	rs2531733	chr17:56548811	A/G	cg12560992	chr17:57184187	TRIM37	-0.63	-5.75	-0.33	2.48e-8	Testicular germ cell tumor;
CESC	cis	rs11098499	0.954	rs17009122	chr4:120362403	G/A	cg09307838	chr4:120376055	NA	0.94	13.69	0.64	1.22e-32	Corneal astigmatism;
CESC	cis	rs2878628	0.596	rs57039206	chr3:52758570	T/A	cg07507251	chr3:52567010	NT5DC2	0.35	5.94	0.34	8.7e-9	Intelligence (multi-trait analysis);
CESC	cis	rs34779708	0.966	rs113170867	chr10:35450147	C/T	cg03585969	chr10:35415529	CREM	0.77	10.27	0.53	4.69e-21	Inflammatory bowel disease;Crohn's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05588757	chr2:95825608	ZNF514	0.55	6.57	0.37	2.65e-10	Gut microbiome composition (summer);
CESC	trans	rs7615952	0.599	rs1875683	chr3:125732481	C/G	cg07211511	chr3:129823064	LOC729375	-0.55	-6.25	-0.36	1.63e-9	Blood pressure (smoking interaction);
CESC	cis	rs524023	0.958	rs3825016	chr11:64359286	C/T	cg07220939	chr11:64358617	SLC22A12	-0.35	-5.46	-0.32	1.09e-7	Urate levels in obese individuals;
CESC	cis	rs7078219	0.523	rs4129134	chr10:101284345	C/G	cg09788492	chr10:101292477	NKX2-3	0.34	6.45	0.37	5.32e-10	Dental caries;
CESC	cis	rs9322193	0.923	rs9479094	chr6:150046219	C/T	cg07701084	chr6:150067640	NUP43	0.48	6.85	0.39	5.03e-11	Lung cancer;
CESC	cis	rs6545883	0.859	rs35760550	chr2:61603865	T/A	cg15711740	chr2:61764176	XPO1	0.4	5.1	0.3	6.53e-7	Tuberculosis;
CESC	cis	rs35110281	0.744	rs230644	chr21:44917183	C/T	cg21573476	chr21:45109991	RRP1B	0.4	5.61	0.33	5.2100000000000003e-08	Mean corpuscular volume;
CESC	cis	rs854765	0.724	rs2955371	chr17:17967397	G/A	cg16928487	chr17:17741425	SREBF1	0.58	9.93	0.52	5.95e-20	Total body bone mineral density;
CESC	cis	rs34734847	1.000	rs3021338	chr12:121162989	A/G	cg21892295	chr12:121157589	UNC119B	-0.42	-6.67	-0.38	1.46e-10	Mean corpuscular volume;
CESC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg20600338	chr14:71786811	NA	0.46	6.07	0.35	4.48e-9	Tetralogy of Fallot;
CESC	cis	rs113835537	0.529	rs4930183	chr11:66255732	C/T	cg22134325	chr11:66188745	NPAS4	0.35	5.48	0.32	1.01e-7	Airway imaging phenotypes;
CESC	cis	rs9322193	0.923	rs4869812	chr6:149990583	A/G	cg07701084	chr6:150067640	NUP43	0.45	6.27	0.36	1.45e-9	Lung cancer;
CESC	cis	rs9660180	0.837	rs915292	chr1:1792157	A/C	cg23982607	chr1:1823379	GNB1	-0.8	-13.02	-0.62	2.74e-30	Body mass index;
CESC	cis	rs7191439	0.674	rs4782429	chr16:88792097	A/G	cg27087555	chr16:88793112	FAM38A	-1.35	-12.9	-0.62	7.06e-30	Plateletcrit;
CESC	cis	rs9300255	0.569	rs1727320	chr12:123700476	T/A	cg19016782	chr12:123741754	C12orf65	-0.45	-6.5	-0.37	3.89e-10	Neutrophil percentage of white cells;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg01953119	chr2:20425340	SDC1	0.48	6.5	0.37	3.94e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs7618915	0.547	rs2118540	chr3:52629386	T/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.38	6.62	0.38	1.98e-10	Bipolar disorder;
CESC	cis	rs6089829	0.962	rs7267951	chr20:61665979	A/G	cg03213289	chr20:61660250	NA	0.39	6.16	0.35	2.7e-9	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs4756846	1.000	rs72873303	chr11:16473612	G/A	cg05579622	chr5:10618622	ANKRD33B	0.71	6.21	0.36	2.01e-9	Obesity and osteoporosis;
CESC	cis	rs7586879	0.520	rs6718511	chr2:25122324	A/G	cg01884057	chr2:25150051	NA	0.36	6.99	0.39	2.18e-11	Body mass index;
CESC	cis	rs7945705	0.967	rs10840141	chr11:8902218	T/C	cg21881798	chr11:8931708	C11orf17;ST5	0.47	7.57	0.42	6.19e-13	Hemoglobin concentration;
CESC	cis	rs7937682	1.000	rs7937682	chr11:111579939	C/G	cg09085632	chr11:111637200	PPP2R1B	-1.01	-14.47	-0.66	2.3e-35	Primary sclerosing cholangitis;
CESC	cis	rs9611565	0.918	rs7290404	chr22:41749796	C/T	cg06634786	chr22:41940651	POLR3H	-0.66	-6.94	-0.39	2.99e-11	Vitiligo;
CESC	cis	rs1790761	0.806	rs11601325	chr11:67227006	G/A	cg14500267	chr11:67383377	NA	-0.31	-5.12	-0.3	5.83e-7	Mean corpuscular volume;
CESC	cis	rs7666738	0.830	rs1534318	chr4:98965058	C/T	cg03676636	chr4:99064102	C4orf37	0.33	5.05	0.3	8.13e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6912958	0.703	rs9359748	chr6:88095500	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.33	5.39	0.31	1.57e-7	Monocyte percentage of white cells;
CESC	cis	rs4076764	0.958	rs6691127	chr1:163384831	T/C	cg24596788	chr1:163392923	NA	-0.5	-7.34	-0.41	2.55e-12	Motion sickness;
CESC	cis	rs4423214	0.840	rs1792227	chr11:71177412	A/G	cg05163923	chr11:71159392	DHCR7	-0.65	-7.55	-0.42	6.91e-13	Vitamin D levels;
CESC	cis	rs116095464	0.558	rs9312956	chr5:201812	T/C	cg16372103	chr5:203701	NA	0.51	5.7	0.33	3.12e-8	Breast cancer;
CESC	cis	rs34779708	0.931	rs13376871	chr10:35369056	A/G	cg03585969	chr10:35415529	CREM	0.76	10.13	0.53	1.37e-20	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs6582630	0.538	rs12304844	chr12:38335870	C/T	cg26384229	chr12:38710491	ALG10B	-0.41	-5.33	-0.31	2.09e-7	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs910316	0.763	rs175044	chr14:75472109	G/A	cg08847533	chr14:75593920	NEK9	-0.86	-14.16	-0.66	2.82e-34	Height;
CESC	cis	rs6732160	0.932	rs6546802	chr2:73379564	G/A	cg01422370	chr2:73384389	NA	0.51	8.77	0.47	2.15e-16	Intelligence (multi-trait analysis);
CESC	cis	rs1215050	0.791	rs783960	chr4:98893437	A/G	cg05340658	chr4:99064831	C4orf37	-0.51	-6.68	-0.38	1.41e-10	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs875971	0.862	rs801203	chr7:66023012	A/G	cg18876405	chr7:65276391	NA	-0.53	-7.22	-0.41	5.6e-12	Aortic root size;
CESC	cis	rs80130819	0.688	rs1552551	chr12:48643101	C/A	cg05342945	chr12:48394962	COL2A1	-0.48	-5.24	-0.31	3.36e-7	Prostate cancer;
CESC	trans	rs60380162	0.963	rs4561014	chr1:87725168	T/C	cg20163645	chr8:1900353	ARHGEF10	-0.43	-6.03	-0.35	5.48e-9	Loneliness (linear analysis);
CESC	cis	rs11785400	0.793	rs4567014	chr8:143737690	G/C	cg24634471	chr8:143751801	JRK	0.46	5.91	0.34	1.06e-8	Schizophrenia;
CESC	cis	rs875971	0.543	rs801191	chr7:66032955	G/A	cg11764359	chr7:65958608	NA	-0.53	-6.98	-0.39	2.34e-11	Aortic root size;
CESC	cis	rs17376456	0.809	rs12152763	chr5:93405509	T/A	cg21475434	chr5:93447410	FAM172A	0.87	7.47	0.42	1.17e-12	Diabetic retinopathy;
CESC	cis	rs34172651	0.517	rs11647120	chr16:24819806	A/G	cg04756594	chr16:24857601	SLC5A11	0.44	5.3	0.31	2.42e-7	Intelligence (multi-trait analysis);
CESC	cis	rs36051895	0.603	rs1590804	chr9:5177573	T/C	cg02405213	chr9:5042618	JAK2	-0.51	-6.62	-0.38	2.03e-10	Pediatric autoimmune diseases;
CESC	cis	rs9929218	0.953	rs12920562	chr16:68737512	C/T	cg02972257	chr16:68554789	NA	0.58	6.49	0.37	4.18e-10	Colorectal cancer;
CESC	trans	rs1545843	0.539	rs10862855	chr12:84773682	G/C	cg03015433	chr16:56623111	MT3	-0.33	-6.0	-0.35	6.34e-9	Major depressive disorder;
CESC	cis	rs11809207	0.568	rs1892494	chr1:26497626	C/G	cg00147160	chr1:26503991	CNKSR1	0.28	5.28	0.31	2.67e-7	Height;
CESC	cis	rs6933660	0.676	rs3757316	chr6:151774339	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	-0.8	-11.92	-0.59	1.66e-26	Menarche (age at onset);
CESC	cis	rs1008375	0.898	rs7670500	chr4:17586957	A/G	cg27347728	chr4:17578864	LAP3	0.46	5.49	0.32	9.24e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs2197308	0.565	rs4123923	chr12:37857684	T/C	cg13010199	chr12:38710504	ALG10B	0.52	6.63	0.38	1.86e-10	Morning vs. evening chronotype;
CESC	trans	rs4925114	0.568	rs4925109	chr17:17661802	A/G	cg21853989	chr1:45804726	MUTYH;TOE1	-0.49	-6.65	-0.38	1.71e-10	Body mass index;
CESC	cis	rs1799949	1.000	rs8176145	chr17:41249094	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.46	6.4	0.37	6.98e-10	Menopause (age at onset);
CESC	cis	rs2963155	0.518	rs2918419	chr5:142722353	T/C	cg17617527	chr5:142782415	NR3C1	0.82	7.8	0.43	1.42e-13	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21830805	chr14:91087524	TTC7B	-0.62	-7.33	-0.41	2.87e-12	Gut microbiome composition (summer);
CESC	cis	rs7633770	0.769	rs2385858	chr3:46660436	T/C	cg11219411	chr3:46661640	NA	0.48	7.86	0.43	9.51e-14	Coronary artery disease;
CESC	cis	rs9911578	1.000	rs1494977	chr17:56863064	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.12	0.3	6.02e-7	Intelligence (multi-trait analysis);
CESC	cis	rs501120	1.000	rs501120	chr10:44753867	T/C	cg09554077	chr10:44749378	NA	0.52	6.89	0.39	3.96e-11	Coronary artery disease;Coronary heart disease;
CESC	cis	rs6582630	0.555	rs11182148	chr12:38464883	A/C	cg13010199	chr12:38710504	ALG10B	0.43	5.65	0.33	4.08e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs4819052	0.851	rs13047598	chr21:46660777	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.91	13.24	0.63	4.51e-31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs12477438	0.520	rs13798	chr2:99813614	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.91	15.7	0.69	1.04e-39	Chronic sinus infection;
CESC	cis	rs9815354	1.000	rs73071329	chr3:41810539	G/A	cg03022575	chr3:42003672	ULK4	0.47	5.22	0.31	3.64e-7	Pulse pressure;Diastolic blood pressure;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg19987288	chr12:56122958	CD63	-0.5	-6.72	-0.38	1.13e-10	Fibrinogen levels;
CESC	trans	rs1814175	0.817	rs4881645	chr11:49791168	G/A	cg15704280	chr7:45808275	SEPT13	-1.02	-19.96	-0.77	1.02e-54	Height;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg02514855	chr8:100905969	COX6C	-0.42	-6.43	-0.37	5.91e-10	Gambling;
CESC	cis	rs4665809	1.000	rs10182857	chr2:26344411	C/T	cg25036284	chr2:26402008	FAM59B	-0.59	-6.88	-0.39	4.37e-11	Gut microbiome composition (summer);
CESC	cis	rs7267979	0.966	rs2145126	chr20:25263648	G/A	cg08601574	chr20:25228251	PYGB	0.39	5.65	0.33	4.08e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs2180341	1.000	rs13218061	chr6:127653758	G/A	cg27446573	chr6:127587934	RNF146	1.09	16.35	0.71	5.12e-42	Breast cancer;
CESC	cis	rs75920871	0.502	rs10790166	chr11:116779499	A/G	cg19396677	chr11:116643857	BUD13	0.41	5.17	0.3	4.59e-7	Subjective well-being;
CESC	cis	rs897080	0.515	rs2850290	chr2:44636055	A/G	cg04920474	chr2:44395004	PPM1B	0.37	5.03	0.3	9.22e-7	Height;
CESC	cis	rs34172651	0.917	rs7204281	chr16:24784475	C/T	cg06028605	chr16:24865363	SLC5A11	0.41	6.13	0.35	3.26e-9	Intelligence (multi-trait analysis);
CESC	cis	rs9611565	0.559	rs6002408	chr22:41967870	C/T	cg03806693	chr22:41940476	POLR3H	-0.98	-11.78	-0.59	4.85e-26	Vitiligo;
CESC	cis	rs599083	0.530	rs2472415	chr11:68185616	T/C	cg16797656	chr11:68205561	LRP5	-0.39	-5.18	-0.3	4.48e-7	Bone mineral density (spine);
CESC	cis	rs7412746	0.658	rs10305704	chr1:150804429	A/C	cg09365446	chr1:150670422	GOLPH3L	0.38	5.13	0.3	5.74e-7	Melanoma;
CESC	cis	rs7212590	0.581	rs8064505	chr17:57838831	G/A	cg20303301	chr17:57937339	TUBD1	-0.55	-5.18	-0.3	4.34e-7	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs7208859	0.673	rs2269915	chr17:29233344	C/T	cg19761014	chr17:28927070	LRRC37B2	0.73	5.77	0.33	2.22e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs7666738	0.861	rs5014702	chr4:99052102	C/A	cg17366294	chr4:99064904	C4orf37	0.6	8.44	0.46	2.12e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10504229	1.000	rs9650139	chr8:58190508	G/T	cg14926445	chr8:58193284	C8orf71	-0.5	-5.4	-0.31	1.49e-7	Developmental language disorder (linguistic errors);
CESC	trans	rs877282	0.700	rs816311	chr10:796490	C/A	cg22713356	chr15:30763199	NA	1.1	11.92	0.59	1.59e-26	Uric acid levels;
CESC	cis	rs634534	0.561	rs14157	chr11:65769780	T/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.75	10.97	0.56	2.48e-23	Sum eosinophil basophil counts;Eosinophil counts;
CESC	cis	rs2014572	0.967	rs10413037	chr19:57771883	A/G	cg12963866	chr19:57752005	ZNF805	-0.45	-5.93	-0.34	9.64e-9	Hyperactive-impulsive symptoms;
CESC	cis	rs6121246	0.609	rs6060955	chr20:30385071	A/G	cg13852791	chr20:30311386	BCL2L1	0.78	9.95	0.52	5.02e-20	Mean corpuscular hemoglobin;
CESC	cis	rs2440129	0.611	rs1042356	chr17:6902743	G/A	cg03762994	chr17:6899332	ALOX12	0.39	6.86	0.39	4.95e-11	Tonsillectomy;
CESC	cis	rs1559088	0.895	rs13345542	chr19:33586739	G/C	cg27124370	chr19:33622961	WDR88	0.45	6.0	0.35	6.49e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs1881797	0.932	rs41305741	chr1:247689543	A/G	cg21399703	chr1:247681439	NA	0.55	7.36	0.41	2.29e-12	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs367615	0.918	rs72797472	chr5:108881343	C/T	cg17395555	chr5:108820864	NA	0.57	8.65	0.47	5.12e-16	Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs6456156	0.583	rs7748224	chr6:167456860	C/T	cg07741184	chr6:167504864	NA	0.34	5.73	0.33	2.68e-8	Primary biliary cholangitis;
CESC	cis	rs763014	0.966	rs35642938	chr16:642249	T/C	cg09781414	chr16:715207	WDR90	-0.33	-5.03	-0.3	9.04e-7	Height;
CESC	cis	rs2074585	0.802	rs2589940	chr15:90931363	C/T	cg10434728	chr15:90938212	IQGAP1	0.42	7.69	0.43	2.9e-13	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg27051224	chr16:2113170	TSC2	0.42	6.12	0.35	3.28e-9	Fibrinogen levels;
CESC	cis	rs7833986	0.501	rs2953911	chr8:56948009	G/A	cg26371346	chr8:56986568	SNORD54;RPS20	0.57	5.16	0.3	4.9e-7	Height;
CESC	cis	rs123509	0.687	rs73077220	chr3:42842340	T/C	cg12982090	chr3:42733453	KBTBD5	-0.66	-7.52	-0.42	8.26e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs875971	0.862	rs1695820	chr7:65844563	G/A	cg18876405	chr7:65276391	NA	0.5	6.87	0.39	4.63e-11	Aortic root size;
CESC	cis	rs7216064	0.953	rs12450907	chr17:65870644	T/G	cg07042672	chr17:66097459	LOC651250	-0.54	-5.59	-0.32	5.61e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs10979	1.000	rs7774497	chr6:143889033	T/C	cg25407410	chr6:143891975	LOC285740	-0.61	-9.14	-0.49	1.72e-17	Hypospadias;
CESC	cis	rs9896052	0.572	rs4078474	chr17:73489567	C/G	cg25649188	chr17:73499917	CASKIN2	0.36	5.27	0.31	2.77e-7	Sight-threatening diabetic retinopathy in type 2 diabetes;
CESC	cis	rs6580649	0.771	rs1635535	chr12:48386241	A/G	cg05342945	chr12:48394962	COL2A1	-0.51	-6.1	-0.35	3.71e-9	Lung cancer;
CESC	cis	rs2735413	0.564	rs4324138	chr16:78101372	A/C	cg04733911	chr16:78082701	NA	0.41	5.17	0.3	4.71e-7	Systolic blood pressure (alcohol consumption interaction);
CESC	cis	rs4253772	0.530	rs11090875	chr22:46785301	C/T	cg24881330	chr22:46731750	TRMU	0.77	5.44	0.32	1.21e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs7635838	0.653	rs2606749	chr3:11373635	A/G	cg00170343	chr3:11313890	ATG7	0.54	7.79	0.43	1.5700000000000001e-13	HDL cholesterol;
CESC	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg24829409	chr8:58192753	C8orf71	-0.67	-7.99	-0.44	4.08e-14	Developmental language disorder (linguistic errors);
CESC	cis	rs7084402	0.935	rs12248958	chr10:60278255	G/A	cg07615347	chr10:60278583	BICC1	-0.59	-9.45	-0.5	1.94e-18	Refractive error;
CESC	cis	rs16854884	0.586	rs13081286	chr3:143723757	A/T	cg01302019	chr3:143689584	C3orf58	-0.33	-5.12	-0.3	5.87e-7	Economic and political preferences (feminism/equality);
CESC	cis	rs3096299	0.503	rs9940093	chr16:89558705	G/A	cg00750074	chr16:89608354	SPG7	-0.38	-5.3	-0.31	2.47e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs6912958	0.515	rs381782	chr6:88040649	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.76	11.14	0.56	6.75e-24	Monocyte percentage of white cells;
CESC	cis	rs9322193	0.962	rs9688412	chr6:150124283	A/G	cg05861140	chr6:150128134	PCMT1	0.37	5.3	0.31	2.5e-7	Lung cancer;
CESC	trans	rs7615952	0.543	rs4645102	chr3:125424441	A/G	cg21747405	chr11:67723411	NA	-0.42	-6.66	-0.38	1.53e-10	Blood pressure (smoking interaction);
CESC	trans	rs116095464	0.558	rs60251075	chr5:245292	T/C	cg00938859	chr5:1591904	SDHAP3	0.64	6.98	0.39	2.36e-11	Breast cancer;
CESC	trans	rs4332037	0.624	rs73046339	chr7:1889300	G/A	cg11693508	chr17:37793320	STARD3	0.6	6.12	0.35	3.27e-9	Bipolar disorder;
CESC	cis	rs2228479	0.850	rs2238527	chr16:89840708	C/A	cg00800038	chr16:89945340	TCF25	-0.92	-7.64	-0.42	4.02e-13	Skin colour saturation;
CESC	cis	rs6582630	0.555	rs12372536	chr12:38400864	C/G	cg13010199	chr12:38710504	ALG10B	0.48	6.21	0.36	2.03e-9	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs7607369	0.559	rs4674342	chr2:219660064	T/C	cg02176678	chr2:219576539	TTLL4	-0.4	-7.1	-0.4	1.18e-11	Red blood cell count;Amyotrophic lateral sclerosis;
CESC	cis	rs2440129	0.611	rs1042356	chr17:6902743	G/A	cg05215272	chr17:6899095	ALOX12	0.42	7.91	0.44	6.93e-14	Tonsillectomy;
CESC	cis	rs853679	0.517	rs9357061	chr6:28051772	A/G	cg22143856	chr6:28129313	ZNF389	0.49	6.3	0.36	1.2e-9	Depression;
CESC	cis	rs4481887	0.888	rs4525076	chr1:248456876	T/G	cg00666640	chr1:248458726	OR2T12	0.41	6.8	0.39	6.72e-11	Common traits (Other);
CESC	cis	rs1046896	0.627	rs7225515	chr17:80795783	C/T	cg19046167	chr17:80928561	B3GNTL1	0.46	5.51	0.32	8.54e-8	Glycated hemoglobin levels;
CESC	trans	rs2113818	0.568	rs10197989	chr2:12935982	G/A	cg25307771	chr13:91067121	NA	0.43	6.2	0.36	2.18e-9	Optic cup area;
CESC	cis	rs11190604	1.000	rs11190557	chr10:102209369	G/A	cg07080220	chr10:102295463	HIF1AN	0.55	5.51	0.32	8.5e-8	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs2635047	0.638	rs2668758	chr18:44685679	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.42	5.71	0.33	3.01e-8	Educational attainment;
CESC	cis	rs7772486	0.686	rs702314	chr6:146003510	G/A	cg05347473	chr6:146136440	FBXO30	-0.52	-6.84	-0.39	5.3e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs10752881	0.967	rs6695837	chr1:182991462	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.84	13.31	0.63	2.66e-31	Colorectal cancer;
CESC	cis	rs2011503	1.000	rs11670882	chr19:19649748	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.54	5.77	0.33	2.16e-8	Bipolar disorder;
CESC	cis	rs9388451	0.626	rs1268074	chr6:126107791	G/C	cg05901451	chr6:126070800	HEY2	-0.57	-8.24	-0.45	7.96e-15	Brugada syndrome;
CESC	cis	rs35306767	0.903	rs11253460	chr10:887382	C/G	cg26597838	chr10:835615	NA	0.87	9.13	0.49	1.86e-17	Eosinophil percentage of granulocytes;
CESC	cis	rs9611565	0.681	rs6002372	chr22:41801299	A/T	cg06481639	chr22:41940642	POLR3H	0.64	6.56	0.37	2.82e-10	Vitiligo;
CESC	cis	rs12950390	0.893	rs4239165	chr17:45847272	A/T	cg00777063	chr17:45855553	NA	-0.41	-6.14	-0.35	3.03e-9	IgG glycosylation;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23176496	chr8:67687356	SGK3	0.54	6.11	0.35	3.61e-9	Gut microbiome composition (summer);
CESC	cis	rs2985684	0.748	rs2985686	chr14:50100683	C/G	cg10008539	chr14:50087325	RPL36AL;MGAT2	-0.45	-5.06	-0.3	7.89e-7	Carotid intima media thickness;
CESC	cis	rs7772486	0.558	rs702322	chr6:146007166	G/A	cg23711669	chr6:146136114	FBXO30	-0.94	-12.0	-0.59	8.66e-27	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1218582	0.804	rs4845678	chr1:154853295	A/G	cg03351412	chr1:154909251	PMVK	0.64	8.72	0.47	3.02e-16	Prostate cancer;
CESC	cis	rs2832077	0.527	rs2832116	chr21:30228368	C/A	cg24692254	chr21:30365293	RNF160	-0.66	-9.15	-0.49	1.56e-17	Cognitive test performance;
CESC	cis	rs1878931	0.624	rs27241	chr16:3447282	C/G	cg02880119	chr16:3481970	NA	0.44	5.46	0.32	1.11e-7	Body mass index (adult);
CESC	cis	rs6502050	0.842	rs7211808	chr17:80071244	T/C	cg11859384	chr17:80120422	CCDC57	0.38	5.22	0.31	3.54e-7	Life satisfaction;
CESC	cis	rs2836974	0.605	rs2836988	chr21:40707975	A/G	cg11890956	chr21:40555474	PSMG1	-0.94	-15.27	-0.68	3.31e-38	Cognitive function;
CESC	cis	rs2841277	0.646	rs3742935	chr14:105405599	G/C	cg19901468	chr14:105411992	AHNAK2	-0.6	-8.69	-0.47	3.74e-16	Rheumatoid arthritis;
CESC	cis	rs477692	0.875	rs7091540	chr10:131420276	C/T	cg05714579	chr10:131428358	MGMT	-0.55	-7.85	-0.43	1.05e-13	Response to temozolomide;
CESC	cis	rs736801	0.569	rs12517950	chr5:131731326	A/G	cg07395648	chr5:131743802	NA	-0.42	-5.4	-0.31	1.49e-7	Breast cancer;Mosquito bite size;
CESC	cis	rs2204008	0.623	rs4882302	chr12:38415608	T/A	cg26384229	chr12:38710491	ALG10B	-0.44	-5.99	-0.35	6.77e-9	Bladder cancer;
CESC	cis	rs9926296	0.548	rs12447465	chr16:89829895	C/T	cg04287289	chr16:89883240	FANCA	0.88	15.5	0.69	5.35e-39	Vitiligo;
CESC	cis	rs7917772	0.582	rs10786698	chr10:104378750	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.38	5.23	0.31	3.38e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	trans	rs6700559	0.810	rs7521550	chr1:200592363	C/G	cg05185519	chr16:2972941	FLYWCH1	-0.48	-6.22	-0.36	1.89e-9	Coronary artery disease;
CESC	cis	rs708547	0.676	rs11133470	chr4:57864926	G/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.59	8.74	0.47	2.79e-16	Response to bleomycin (chromatid breaks);
CESC	cis	rs911555	0.723	rs11160751	chr14:103925740	T/C	cg09975044	chr14:104007538	NA	0.45	5.59	0.32	5.7e-8	Intelligence (multi-trait analysis);
CESC	cis	rs4665809	1.000	rs4665809	chr2:26251361	C/T	cg25036284	chr2:26402008	FAM59B	0.6	6.86	0.39	4.74e-11	Gut microbiome composition (summer);
CESC	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	22.44	0.81	3.19e-63	Prudent dietary pattern;
CESC	cis	rs2439831	1.000	rs2254321	chr15:43707542	T/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.86	10.53	0.54	6.86e-22	Lung cancer in ever smokers;
CESC	cis	rs853679	0.517	rs9393897	chr6:28127710	G/T	cg23281280	chr6:28129359	ZNF389	0.59	7.91	0.44	6.86e-14	Depression;
CESC	cis	rs6088590	0.582	rs6059909	chr20:33139691	C/A	cg06115741	chr20:33292138	TP53INP2	0.5	6.39	0.37	7.53e-10	Coronary artery disease;
CESC	cis	rs2075371	0.501	rs1643057	chr7:134027521	A/G	cg20476274	chr7:133979776	SLC35B4	0.42	5.36	0.31	1.8e-7	Mean platelet volume;
CESC	cis	rs11577318	0.853	rs3795684	chr1:26632781	C/T	cg00852783	chr1:26633632	UBXN11	0.51	7.16	0.4	8.01e-12	Granulocyte percentage of myeloid white cells;
CESC	cis	rs7927592	0.913	rs2236708	chr11:68378045	G/A	cg20283391	chr11:68216788	NA	-0.6	-7.23	-0.41	5.28e-12	Total body bone mineral density;
CESC	cis	rs67311347	1.000	rs4973898	chr3:40459532	A/G	cg24209194	chr3:40518798	ZNF619	-0.5	-6.69	-0.38	1.34e-10	Renal cell carcinoma;
CESC	cis	rs9325144	0.600	rs7312522	chr12:38730423	A/G	cg26384229	chr12:38710491	ALG10B	0.56	8.06	0.44	2.62e-14	Morning vs. evening chronotype;
CESC	cis	rs6831352	0.918	rs7689753	chr4:100055575	A/G	cg13256891	chr4:100009986	ADH5	-0.77	-8.45	-0.46	1.97e-15	Alcohol dependence;
CESC	cis	rs514406	0.861	rs4926932	chr1:53247495	C/T	cg16325326	chr1:53192061	ZYG11B	-0.88	-15.06	-0.68	1.8e-37	Monocyte count;
CESC	cis	rs7662987	0.517	rs2851268	chr4:100027878	A/G	cg12011299	chr4:100065546	ADH4	0.6	6.6	0.38	2.23e-10	Smoking initiation;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg05994508	chr17:78518873	RPTOR	-0.42	-6.09	-0.35	3.89e-9	Gambling;
CESC	cis	rs637571	0.607	rs589253	chr11:65693080	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.73	9.97	0.52	4.4e-20	Eosinophil percentage of white cells;
CESC	cis	rs6088590	1.000	rs6087625	chr20:33342477	A/G	cg08999081	chr20:33150536	PIGU	-0.59	-9.05	-0.49	3.07e-17	Coronary artery disease;
CESC	cis	rs7179456	0.547	rs6494036	chr15:59015961	A/T	cg05156742	chr15:59063176	FAM63B	0.59	7.44	0.42	1.43e-12	Asperger disorder;
CESC	cis	rs7666738	0.830	rs28878289	chr4:98855181	C/T	cg17366294	chr4:99064904	C4orf37	0.55	7.72	0.43	2.38e-13	Colonoscopy-negative controls vs population controls;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03205495	chr19:14640249	TECR;MIR639	0.5	6.34	0.36	9.7e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs11690935	0.589	rs2271758	chr2:172701157	T/G	cg13550731	chr2:172543902	DYNC1I2	0.52	7.02	0.4	1.83e-11	Schizophrenia;
CESC	trans	rs1728785	1.000	rs1645928	chr16:68590610	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.68	8.06	0.44	2.62e-14	Ulcerative colitis;
CESC	cis	rs8114671	0.562	rs6088621	chr20:33418740	C/T	cg24642439	chr20:33292090	TP53INP2	0.47	5.64	0.33	4.3e-8	Height;
CESC	cis	rs17376456	0.877	rs114256265	chr5:93473130	T/A	cg21475434	chr5:93447410	FAM172A	0.86	7.66	0.43	3.53e-13	Diabetic retinopathy;
CESC	cis	rs9549367	0.713	rs2476319	chr13:113836519	C/T	cg00898013	chr13:113819073	PROZ	0.46	6.9	0.39	3.73e-11	Platelet distribution width;
CESC	cis	rs2730245	0.527	rs712197	chr7:158660846	C/G	cg24397884	chr7:158709396	WDR60	0.81	8.15	0.45	1.41e-14	Height;
CESC	cis	rs4595586	0.545	rs2218762	chr12:39397762	G/A	cg26384229	chr12:38710491	ALG10B	0.54	7.64	0.42	3.96e-13	Morning vs. evening chronotype;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02205746	chr16:2732724	KCTD5	0.61	7.4	0.41	1.8e-12	Gut microbiome composition (summer);
CESC	cis	rs2415984	0.558	rs10220566	chr14:46965511	A/T	cg14871534	chr14:47121158	RPL10L	-0.35	-5.22	-0.31	3.56e-7	Number of children ever born;
CESC	cis	rs7666738	0.791	rs13125277	chr4:99009922	T/G	cg05340658	chr4:99064831	C4orf37	0.8	12.51	0.61	1.52e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs61776719	0.520	rs72661887	chr1:38416310	C/T	cg18451016	chr1:38461880	NA	0.4	5.96	0.34	8.05e-9	Coronary artery disease;
CESC	cis	rs847577	0.630	rs13221758	chr7:97719806	A/C	cg21770322	chr7:97807741	LMTK2	0.86	15.7	0.69	1e-39	Breast cancer;
CESC	trans	rs7980799	0.618	rs1482983	chr12:33690326	A/C	cg26384229	chr12:38710491	ALG10B	0.54	7.65	0.43	3.72e-13	Heart rate;Heart rate variability traits (RMSSD);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg16492828	chr12:100567203	GOLGA2L1	0.54	6.26	0.36	1.57e-9	Ulcerative colitis;
CESC	cis	rs80282103	0.618	rs56004802	chr10:1159187	C/T	cg08668510	chr10:1095578	IDI1	0.74	6.02	0.35	5.95e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs8016982	0.651	rs9806027	chr14:81668707	G/C	cg01989461	chr14:81687754	GTF2A1	0.69	10.23	0.53	6.34e-21	Schizophrenia;
CESC	cis	rs2011503	0.883	rs17216041	chr19:19366643	C/T	cg11584989	chr19:19387371	SF4	0.57	6.74	0.38	9.87e-11	Bipolar disorder;
CESC	cis	rs763121	0.853	rs8140617	chr22:38970439	A/G	cg06022373	chr22:39101656	GTPBP1	-0.76	-10.15	-0.53	1.12e-20	Menopause (age at onset);
CESC	cis	rs10504229	0.683	rs7463453	chr8:58112053	A/G	cg24829409	chr8:58192753	C8orf71	-0.59	-7.32	-0.41	2.94e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs7949030	0.588	rs2509961	chr11:62310909	T/C	cg22862634	chr11:62369728	EML3;MTA2	0.49	6.83	0.39	5.97e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20189904	chr20:35974307	SRC	0.58	7.19	0.4	6.49e-12	Gut microbiome composition (summer);
CESC	cis	rs2228479	0.541	rs9922515	chr16:89954138	G/C	cg00800038	chr16:89945340	TCF25	-0.64	-7.16	-0.4	7.77e-12	Skin colour saturation;
CESC	cis	rs3125734	0.671	rs3852406	chr10:64015162	T/C	cg09941381	chr10:64027924	RTKN2	-0.32	-5.21	-0.3	3.79e-7	Rheumatoid arthritis;
CESC	cis	rs798554	0.610	rs1182209	chr7:2808595	C/T	cg13628971	chr7:2884303	GNA12	0.4	5.21	0.3	3.81e-7	Height;
CESC	cis	rs6714710	0.603	rs13020776	chr2:98402753	T/A	cg26665480	chr2:98280029	ACTR1B	0.57	8.03	0.44	3.3e-14	Posterior cortical atrophy and Alzheimer's disease;
CESC	cis	rs910316	0.935	rs11159119	chr14:75636967	C/T	cg08847533	chr14:75593920	NEK9	-1.0	-18.49	-0.75	1.41e-49	Height;
CESC	cis	rs10504229	0.593	rs75047131	chr8:58001320	A/G	cg02725872	chr8:58115012	NA	-0.38	-5.13	-0.3	5.73e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs9733	0.596	rs12086630	chr1:150650955	T/C	cg22823121	chr1:150693482	HORMAD1	0.48	7.09	0.4	1.21e-11	Tonsillectomy;
CESC	cis	rs9512730	0.553	rs6491213	chr13:28049822	T/C	cg08193333	chr13:27998609	GTF3A	0.46	5.53	0.32	7.86e-8	Schizophrenia;
CESC	cis	rs8103278	0.507	rs4802275	chr19:46260375	C/T	cg14061069	chr19:46274453	DMPK	0.52	8.23	0.45	8.79e-15	Coronary artery disease;
CESC	cis	rs6570726	0.935	rs379164	chr6:145829093	A/T	cg05347473	chr6:146136440	FBXO30	0.49	6.69	0.38	1.3100000000000001e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1670533	0.932	rs11731289	chr4:1057773	T/G	cg04106633	chr4:1044584	NA	0.41	5.19	0.3	4.11e-7	Recombination rate (females);
CESC	cis	rs561341	0.883	rs4795661	chr17:30201774	T/A	cg19193384	chr17:30244184	NA	0.49	5.1	0.3	6.47e-7	Hip circumference adjusted for BMI;
CESC	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg25934064	chr3:52569026	NT5DC2	0.26	5.55	0.32	6.85e-8	Bipolar disorder;
CESC	cis	rs2836974	0.831	rs34592564	chr21:40516288	G/C	cg17971929	chr21:40555470	PSMG1	0.94	12.52	0.61	1.42e-28	Cognitive function;
CESC	cis	rs5167	0.504	rs7248162	chr19:45454686	T/C	cg13119609	chr19:45449297	APOC2	0.49	8.03	0.44	3.23e-14	Blood protein levels;
CESC	cis	rs6690583	0.562	rs11588919	chr1:85442813	A/T	cg22488158	chr1:85528044	WDR63	0.55	5.1	0.3	6.48e-7	Serum sulfate level;
CESC	cis	rs863345	0.604	rs11264984	chr1:158464990	C/T	cg12129480	chr1:158549410	OR10X1	-0.35	-6.97	-0.39	2.46e-11	Pneumococcal bacteremia;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg12941161	chr10:112290002	NA	0.49	7.22	0.41	5.63e-12	Systemic lupus erythematosus;
CESC	cis	rs8014204	0.544	rs2286913	chr14:75386576	G/A	cg08847533	chr14:75593920	NEK9	0.6	7.46	0.42	1.22e-12	Caffeine consumption;
CESC	cis	rs72945132	1.000	rs72945132	chr11:70113901	G/C	cg14191688	chr11:70257035	CTTN	0.43	5.15	0.3	5.06e-7	Coronary artery disease;
CESC	trans	rs7070678	0.905	rs2368394	chr10:29811059	A/G	cg06477056	chr5:175110609	HRH2	0.36	6.79	0.38	7.17e-11	Platelet thrombus formation;
CESC	cis	rs1256061	0.603	rs10148269	chr14:64736924	A/G	cg23250157	chr14:64679961	SYNE2	0.53	7.64	0.42	4.09e-13	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs295137	0.798	rs295142	chr2:201211716	C/T	cg23649088	chr2:200775458	C2orf69	-0.47	-6.19	-0.36	2.26e-9	Asthma (bronchodilator response);
CESC	cis	rs6540556	0.723	rs9430014	chr1:209905372	A/C	cg05527609	chr1:210001259	C1orf107	-0.6	-6.58	-0.37	2.49e-10	Red blood cell count;
CESC	cis	rs7301826	0.651	rs12228957	chr12:131296066	T/C	cg11011512	chr12:131303247	STX2	0.47	5.84	0.34	1.52e-8	Plasma plasminogen activator levels;
CESC	cis	rs270601	0.739	rs1979981	chr5:131601720	G/A	cg04518342	chr5:131593106	PDLIM4	0.4	5.96	0.34	7.99e-9	Acylcarnitine levels;
CESC	cis	rs1862618	0.853	rs252922	chr5:56136343	G/T	cg22800045	chr5:56110881	MAP3K1	0.81	9.96	0.52	4.75e-20	Initial pursuit acceleration;
CESC	cis	rs7666738	0.830	rs13102369	chr4:99045912	A/G	cg05340658	chr4:99064831	C4orf37	0.82	12.88	0.62	8.44e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3858526	0.584	rs10734560	chr11:5864503	G/T	cg02574844	chr11:5959923	NA	-0.48	-6.9	-0.39	3.79e-11	DNA methylation (variation);
CESC	cis	rs34779708	0.931	rs55724039	chr10:35465397	A/G	cg03585969	chr10:35415529	CREM	0.77	10.34	0.54	2.94e-21	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs3741151	0.686	rs1938777	chr11:73122340	A/G	cg17517138	chr11:73019481	ARHGEF17	0.66	5.64	0.33	4.45e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	trans	rs6780666	0.509	rs972585	chr3:136954106	G/T	cg16900796	chr19:10755136	SLC44A2	-0.43	-6.51	-0.37	3.73e-10	Intelligence (multi-trait analysis);
CESC	cis	rs10504229	1.000	rs59549824	chr8:58186205	A/C	cg24829409	chr8:58192753	C8orf71	-0.76	-9.97	-0.52	4.38e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs4664304	0.770	rs55860731	chr2:160875437	C/T	cg03641300	chr2:160917029	PLA2R1	-0.5	-7.09	-0.4	1.19e-11	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs965469	1.000	rs2236117	chr20:3302021	T/C	cg25506879	chr20:3388711	C20orf194	-0.56	-6.08	-0.35	4.16e-9	IFN-related cytopenia;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg17963944	chr7:100303258	POP7	-0.49	-6.52	-0.37	3.44e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs4919694	1.000	rs11191490	chr10:104745174	T/A	cg04362960	chr10:104952993	NT5C2	0.74	6.45	0.37	5.32e-10	Arsenic metabolism;
CESC	cis	rs35570576	0.585	rs35796193	chr17:77537418	A/G	cg05749138	chr17:77536956	NA	0.38	5.29	0.31	2.58e-7	Photic sneeze reflex;
CESC	cis	rs4713118	0.662	rs9468275	chr6:28026136	G/T	cg23281280	chr6:28129359	ZNF389	0.5	6.56	0.37	2.75e-10	Parkinson's disease;
CESC	cis	rs7412746	0.611	rs111842513	chr1:150712926	G/A	cg17724175	chr1:150552817	MCL1	0.46	7.55	0.42	6.93e-13	Melanoma;
CESC	cis	rs2243480	1.000	rs2462569	chr7:65474846	C/T	cg12463550	chr7:65579703	CRCP	-0.71	-5.96	-0.34	7.88e-9	Diabetic kidney disease;
CESC	trans	rs17685	0.753	rs6464999	chr7:75787315	T/C	cg19862616	chr7:65841803	NCRNA00174	0.85	12.42	0.61	3.15e-28	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs10089	1.000	rs10064357	chr5:127417272	A/G	cg19767477	chr5:127420684	SLC12A2	-0.41	-5.42	-0.32	1.35e-7	Ileal carcinoids;
CESC	cis	rs16866061	0.515	rs3738951	chr2:225368321	A/G	cg12698349	chr2:225449008	CUL3	0.81	14.15	0.66	3.03e-34	Acute graft versus host disease in bone marrow transplantation (recipient effect);
CESC	cis	rs1218582	0.774	rs1007170	chr1:154881461	G/A	cg09359103	chr1:154839909	KCNN3	-0.67	-12.75	-0.62	2.3e-29	Prostate cancer;
CESC	cis	rs698833	0.962	rs1065785	chr2:44660699	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.46	5.85	0.34	1.48e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24731015	chr5:70751422	BDP1	-0.56	-6.09	-0.35	4.05e-9	Gut microbiome composition (summer);
CESC	cis	rs4713118	0.662	rs9468271	chr6:28024570	A/G	cg12963246	chr6:28129442	ZNF389	0.49	6.39	0.37	7.29e-10	Parkinson's disease;
CESC	cis	rs798554	0.683	rs1636264	chr7:2864586	G/T	cg04166393	chr7:2884313	GNA12	0.64	8.43	0.46	2.27e-15	Height;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg03159329	chr2:169103514	STK39	-0.42	-6.06	-0.35	4.72e-9	Gambling;
CESC	cis	rs9905704	0.647	rs11659035	chr17:56966052	C/T	cg12560992	chr17:57184187	TRIM37	0.62	7.63	0.42	4.12e-13	Testicular germ cell tumor;
CESC	cis	rs1552244	0.872	rs6792951	chr3:10119603	C/A	cg00166722	chr3:10149974	C3orf24	0.55	7.09	0.4	1.21e-11	Alzheimer's disease;
CESC	cis	rs926938	0.543	rs360600	chr1:115388116	T/C	cg12756093	chr1:115239321	AMPD1	0.47	6.32	0.36	1.1e-9	Autism;
CESC	cis	rs3096299	0.967	rs2965935	chr16:89481274	C/T	cg02034447	chr16:89574710	SPG7	-0.4	-5.15	-0.3	4.98e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs6674176	0.660	rs6801	chr1:44396646	C/G	cg13606994	chr1:44402422	ARTN	0.43	6.67	0.38	1.53e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs1775148	1	rs1775148	chr1:205757824	C/T	cg07167872	chr1:205819463	PM20D1	0.42	6.3	0.36	1.24e-9	Prostate cancer;
CESC	cis	rs4604732	0.536	rs61184655	chr1:247651342	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.58	7.63	0.42	4.13e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs55728055	0.661	rs7285091	chr22:31996363	A/G	cg01338084	chr22:32026380	PISD	1.22	8.02	0.44	3.48e-14	Age-related hearing impairment;
CESC	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg07308232	chr7:1071921	C7orf50	-0.61	-8.77	-0.47	2.21e-16	Longevity;Endometriosis;
CESC	cis	rs7811142	1.000	rs11763414	chr7:100016844	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.01	9.83	0.52	1.21e-19	Platelet count;
CESC	cis	rs11696501	0.694	rs6124722	chr20:44263264	G/A	cg11783356	chr20:44313418	WFDC10B	-0.34	-5.29	-0.31	2.54e-7	Brain structure;
CESC	cis	rs2370759	1.000	rs11594459	chr10:32561858	A/C	cg05361325	chr10:32636312	EPC1	-0.58	-5.15	-0.3	5e-7	Sexual dysfunction (female);
CESC	cis	rs9815354	1.000	rs1717033	chr3:41910216	C/T	cg03022575	chr3:42003672	ULK4	0.44	5.13	0.3	5.55e-7	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs10489202	1.000	rs17557135	chr1:167985888	A/G	cg24449463	chr1:168025552	DCAF6	-0.46	-5.29	-0.31	2.53e-7	Schizophrenia;
CESC	cis	rs12618769	0.597	rs55934321	chr2:99099417	G/A	cg10123293	chr2:99228465	UNC50	0.39	5.14	0.3	5.22e-7	Bipolar disorder;
CESC	cis	rs8180040	0.966	rs11716763	chr3:47518266	C/T	cg27129171	chr3:47204927	SETD2	-0.63	-9.49	-0.5	1.38e-18	Colorectal cancer;
CESC	cis	rs1048238	0.506	rs10927867	chr1:16177285	A/G	cg22431228	chr1:16359049	CLCNKA	-0.36	-6.18	-0.35	2.4e-9	Systolic blood pressure;
CESC	cis	rs977987	0.931	rs11641430	chr16:75495276	T/C	cg03315344	chr16:75512273	CHST6	0.54	7.9	0.44	7.62e-14	Dupuytren's disease;
CESC	cis	rs3806843	0.735	rs801180	chr5:140092903	G/T	cg26395211	chr5:140044315	WDR55	0.46	5.97	0.34	7.77e-9	Depressive symptoms (multi-trait analysis);
CESC	cis	rs9911578	0.839	rs1871751	chr17:57190368	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.4	5.17	0.3	4.67e-7	Intelligence (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03243700	chr9:137000940	WDR5	-0.59	-6.78	-0.38	7.91e-11	Gut microbiome composition (summer);
CESC	cis	rs4835473	0.897	rs28701142	chr4:144866883	G/A	cg25736465	chr4:144833511	NA	0.39	5.99	0.35	6.86e-9	Immature fraction of reticulocytes;
CESC	cis	rs853679	0.517	rs9380055	chr6:28081629	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.58	-6.75	-0.38	9.45e-11	Depression;
CESC	cis	rs9611565	0.840	rs2234052	chr22:41777241	A/G	cg06634786	chr22:41940651	POLR3H	-0.68	-7.28	-0.41	3.87e-12	Vitiligo;
CESC	cis	rs1568889	0.877	rs1384903	chr11:28124359	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.68	6.86	0.39	4.73e-11	Bipolar disorder;
CESC	cis	rs870825	0.616	rs7680779	chr4:185652830	G/C	cg04058563	chr4:185651563	MLF1IP	-0.6	-6.93	-0.39	3.28e-11	Blood protein levels;
CESC	trans	rs10820912	0.636	rs4367687	chr9:92886193	C/T	cg23943268	chr13:33589621	KL	-0.47	-6.03	-0.35	5.55e-9	Left atrial antero-posterior diameter;
CESC	cis	rs7202877	0.572	rs8051611	chr16:75388933	C/T	cg04384234	chr16:75411784	CFDP1	-0.49	-5.89	-0.34	1.16e-8	Type 2 diabetes;Type 1 diabetes;
CESC	cis	rs9640161	0.636	rs56190213	chr7:150025720	T/C	cg10018233	chr7:150070692	REPIN1	0.39	5.38	0.31	1.67e-7	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs4803468	1.000	rs284651	chr19:41928336	T/C	cg09537434	chr19:41945824	ATP5SL	-1.11	-20.37	-0.78	3.82e-56	Height;
CESC	cis	rs950776	1.000	rs950776	chr15:78926018	A/G	cg06917634	chr15:78832804	PSMA4	0.6	6.65	0.38	1.63e-10	Sudden cardiac arrest;
CESC	cis	rs12442242	0.522	rs12901075	chr15:38359137	C/A	cg19084031	chr15:38361362	NA	1.06	6.87	0.39	4.54e-11	Total body bone mineral density;
CESC	trans	rs1814175	0.817	rs7481230	chr11:49772235	G/A	cg03929089	chr4:120376271	NA	-0.9	-14.81	-0.67	1.43e-36	Height;
CESC	cis	rs514406	0.505	rs448788	chr1:53161620	A/G	cg27535305	chr1:53392650	SCP2	0.33	5.34	0.31	2.03e-7	Monocyte count;
CESC	cis	rs2635047	0.713	rs9950812	chr18:44765943	G/A	cg24371990	chr18:44770781	NA	0.41	6.74	0.38	1e-10	Educational attainment;
CESC	cis	rs8141529	0.588	rs10222249	chr22:29257147	A/G	cg15103426	chr22:29168792	CCDC117	0.52	6.39	0.37	7.25e-10	Lymphocyte counts;
CESC	cis	rs12477438	0.798	rs4850894	chr2:99629396	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.75	-10.87	-0.56	5.17e-23	Chronic sinus infection;
CESC	cis	rs4561483	0.583	rs17236573	chr16:11994655	G/C	cg08843971	chr16:11963173	GSPT1	0.46	6.41	0.37	6.53e-10	Testicular germ cell tumor;
CESC	cis	rs2549003	1.000	rs2549007	chr5:131826875	T/C	cg02551604	chr5:131831745	NA	0.37	5.25	0.31	3.09e-7	Asthma (sex interaction);
CESC	cis	rs1707322	1.000	rs6677777	chr1:46475836	A/G	cg03146154	chr1:46216737	IPP	0.79	10.39	0.54	1.98e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs35110281	0.811	rs1122873	chr21:45044672	G/C	cg21573476	chr21:45109991	RRP1B	-0.5	-6.91	-0.39	3.62e-11	Mean corpuscular volume;
CESC	cis	rs1005277	0.522	rs289648	chr10:37971837	T/C	cg25517755	chr10:38738941	LOC399744	-0.43	-5.66	-0.33	3.99e-8	Extrinsic epigenetic age acceleration;
CESC	cis	rs7552404	1.000	rs7518038	chr1:76154430	G/A	cg10523679	chr1:76189770	ACADM	0.72	8.33	0.46	4.31e-15	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs12995491	0.569	rs6724281	chr2:88529531	T/G	cg04051697	chr2:88470813	THNSL2	0.46	6.16	0.35	2.73e-9	Response to metformin (IC50);
CESC	cis	rs4692589	0.802	rs2877501	chr4:170955277	G/T	cg19918862	chr4:170955249	NA	0.43	6.63	0.38	1.87e-10	Anxiety disorder;
CESC	trans	rs9929218	0.529	rs11640736	chr16:68738324	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.87	14.04	0.65	7.26e-34	Colorectal cancer;
CESC	cis	rs7692995	1.000	rs1876219	chr4:17961415	G/A	cg08925142	chr4:18023851	LCORL	-0.45	-5.13	-0.3	5.66e-7	Height;
CESC	cis	rs11864453	0.826	rs6499559	chr16:72132064	G/C	cg16558253	chr16:72132732	DHX38	-0.61	-9.65	-0.51	4.5e-19	Fibrinogen levels;
CESC	cis	rs3762637	1.000	rs9833415	chr3:122159840	G/A	cg24169773	chr3:122142474	KPNA1	-0.55	-6.47	-0.37	4.76e-10	LDL cholesterol levels;
CESC	cis	rs4665809	0.590	rs7606351	chr2:26292545	A/C	cg27170947	chr2:26402098	FAM59B	-0.72	-8.3	-0.45	5.54e-15	Gut microbiome composition (summer);
CESC	cis	rs8077889	0.917	rs58080788	chr17:41902909	A/G	cg26893861	chr17:41843967	DUSP3	0.74	9.39	0.5	2.82e-18	Triglycerides;
CESC	cis	rs5747327	0.874	rs3788279	chr22:18200386	G/A	cg19898043	chr22:18121309	BCL2L13	-0.4	-5.14	-0.3	5.21e-7	Myeloid white cell count;Granulocyte count;
CESC	cis	rs2816062	0.710	rs2816052	chr1:18895536	T/C	cg18795169	chr1:18902165	NA	-0.94	-19.04	-0.76	1.61e-51	Urate levels in lean individuals;
CESC	cis	rs7959452	0.901	rs1384	chr12:69747834	C/T	cg22834771	chr12:69754056	YEATS4	-0.39	-5.26	-0.31	2.94e-7	Blood protein levels;
CESC	cis	rs6901004	0.803	rs1040903	chr6:111470153	A/C	cg15721981	chr6:111408429	SLC16A10	-0.34	-5.09	-0.3	6.78e-7	Blood metabolite levels;
CESC	trans	rs12542260	0.871	rs62527884	chr8:125483344	A/G	cg09438698	chr12:133365205	GOLGA3	-0.47	-6.05	-0.35	4.83e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1707322	0.655	rs3014240	chr1:46089225	C/G	cg06784218	chr1:46089804	CCDC17	-0.4	-7.01	-0.4	1.97e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs4665809	1.000	rs4665809	chr2:26251361	C/T	cg26314531	chr2:26401878	FAM59B	0.59	6.65	0.38	1.69e-10	Gut microbiome composition (summer);
CESC	cis	rs2795502	0.938	rs3121324	chr10:43379515	C/T	cg27426351	chr10:43362370	NA	0.4	5.04	0.3	8.83e-7	Blood protein levels;
CESC	cis	rs4555082	0.957	rs2816622	chr14:105733114	T/C	cg13114125	chr14:105738426	BRF1	-0.78	-10.03	-0.52	2.81e-20	Mean platelet volume;Platelet distribution width;
CESC	cis	rs3806843	1.000	rs2240694	chr5:140183058	G/A	cg26395211	chr5:140044315	WDR55	-0.42	-5.35	-0.31	1.9e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs9487051	0.844	rs9386792	chr6:109609975	G/A	cg01475377	chr6:109611718	NA	-0.49	-8.11	-0.45	1.85e-14	Reticulocyte fraction of red cells;
CESC	cis	rs11785400	0.793	rs4736364	chr8:143742113	C/T	cg10596483	chr8:143751796	JRK	0.42	5.42	0.32	1.33e-7	Schizophrenia;
CESC	cis	rs10208940	0.920	rs10205573	chr2:68829419	A/T	cg12452813	chr2:68675892	NA	0.54	5.34	0.31	1.98e-7	Urate levels in lean individuals;
CESC	cis	rs2625529	0.730	rs2929528	chr15:72269337	C/A	cg16672083	chr15:72433130	SENP8	0.43	6.26	0.36	1.53e-9	Red blood cell count;
CESC	cis	rs853679	0.628	rs9368560	chr6:28159960	T/C	cg19592336	chr6:28129416	ZNF389	0.52	6.59	0.38	2.37e-10	Depression;
CESC	cis	rs7772486	0.754	rs702318	chr6:146005873	G/T	cg23711669	chr6:146136114	FBXO30	-1.04	-14.79	-0.67	1.66e-36	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2549003	1.000	rs2070725	chr5:131821788	C/T	cg00255919	chr5:131827918	IRF1	0.51	8.68	0.47	4.19e-16	Asthma (sex interaction);
CESC	cis	rs1153858	1.000	rs67461176	chr15:45676819	C/T	cg21132104	chr15:45694354	SPATA5L1	0.86	11.62	0.58	1.67e-25	Homoarginine levels;
CESC	cis	rs11122272	0.735	rs2491408	chr1:231519248	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.57	-7.82	-0.43	1.29e-13	Hemoglobin concentration;
CESC	cis	rs79349575	0.685	rs1124829	chr17:46967797	C/A	cg16584676	chr17:46985605	UBE2Z	0.55	6.69	0.38	1.29e-10	Type 2 diabetes;
CESC	cis	rs7666738	0.830	rs11944035	chr4:98931618	C/T	cg17366294	chr4:99064904	C4orf37	0.6	8.22	0.45	9.04e-15	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11088226	0.681	rs16989507	chr21:33939509	T/G	cg09050820	chr6:167586206	TCP10L2	0.83	7.75	0.43	2.01e-13	Gastritis;
CESC	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg04025307	chr7:1156635	C7orf50	0.5	8.22	0.45	9.39e-15	Longevity;Endometriosis;
CESC	trans	rs8073060	0.586	rs6505484	chr17:33993152	G/A	cg19694781	chr19:47549865	TMEM160	-0.75	-7.38	-0.41	2.07e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	cis	rs11583043	1.000	rs7521424	chr1:101475901	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.52	5.78	0.33	2.1e-8	Ulcerative colitis;Inflammatory bowel disease;
CESC	cis	rs17253792	0.822	rs10083493	chr14:56045411	C/T	cg01858014	chr14:56050164	KTN1	-0.96	-7.65	-0.43	3.84e-13	Putamen volume;
CESC	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	22.12	0.81	3.99e-62	Prudent dietary pattern;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg17172773	chr1:150980817	FAM63A;PRUNE	-0.48	-6.62	-0.38	1.99e-10	Ulcerative colitis;
CESC	cis	rs6860806	0.507	rs183898	chr5:131716902	C/G	cg24060327	chr5:131705240	SLC22A5	0.76	10.81	0.55	8.47e-23	Breast cancer;
CESC	cis	rs477692	0.935	rs557158	chr10:131420534	C/T	cg05714579	chr10:131428358	MGMT	0.46	6.23	0.36	1.8e-9	Response to temozolomide;
CESC	cis	rs548181	0.736	rs1941558	chr11:125425606	C/T	cg03464685	chr11:125439445	EI24	1.15	9.55	0.51	9.09e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs477692	0.669	rs12265939	chr10:131445398	A/G	cg24747557	chr10:131355152	MGMT	0.38	5.28	0.31	2.72e-7	Response to temozolomide;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11303561	chr19:1206399	STK11	0.59	6.69	0.38	1.32e-10	Gut microbiome composition (summer);
CESC	cis	rs4665809	1.000	rs6704930	chr2:26325705	G/A	cg27170947	chr2:26402098	FAM59B	-0.58	-6.92	-0.39	3.46e-11	Gut microbiome composition (summer);
CESC	cis	rs5995756	0.736	rs8140185	chr22:40010806	A/G	cg03390717	chr22:39966585	CACNA1I	0.29	5.13	0.3	5.48e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs897984	0.806	rs1458202	chr16:30953202	A/G	cg02466173	chr16:30829666	NA	-0.48	-8.06	-0.44	2.55e-14	Dementia with Lewy bodies;
CESC	cis	rs2236918	0.932	rs1776178	chr1:242011534	C/T	cg17736920	chr1:242011382	EXO1	-0.72	-9.7	-0.51	3.05e-19	Menopause (age at onset);
CESC	cis	rs12142240	1.000	rs12146051	chr1:46742952	G/C	cg00530320	chr1:46809349	NSUN4	0.55	6.63	0.38	1.87e-10	Menopause (age at onset);
CESC	cis	rs34172651	0.583	rs4787649	chr16:24700215	C/T	cg06028605	chr16:24865363	SLC5A11	-0.45	-6.69	-0.38	1.28e-10	Intelligence (multi-trait analysis);
CESC	cis	rs4722166	0.630	rs4722168	chr7:22779002	G/A	cg13104385	chr7:22767384	IL6	0.48	6.43	0.37	5.96e-10	Lung cancer;
CESC	cis	rs34779708	0.966	rs7070427	chr10:35485689	A/T	cg03585969	chr10:35415529	CREM	0.76	9.94	0.52	5.54e-20	Inflammatory bowel disease;Crohn's disease;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg27116842	chr5:66300503	MAST4	-0.49	-6.24	-0.36	1.75e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs4654899	0.758	rs1609558	chr1:21525228	C/T	cg05370193	chr1:21551575	ECE1	-0.4	-6.08	-0.35	4.11e-9	Superior frontal gyrus grey matter volume;
CESC	cis	rs4704187	0.687	rs9293650	chr5:74497084	C/T	cg03227963	chr5:74354835	NA	0.28	5.09	0.3	6.69e-7	Response to amphetamines;
CESC	cis	rs3768617	0.510	rs2296300	chr1:183099701	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.89	14.39	0.66	4.39e-35	Fuchs's corneal dystrophy;
CESC	cis	rs6540556	0.723	rs12060420	chr1:209906819	T/G	cg05527609	chr1:210001259	C1orf107	-0.62	-7.17	-0.4	7.59e-12	Red blood cell count;
CESC	cis	rs9611565	0.802	rs73176694	chr22:41786788	C/T	cg03806693	chr22:41940476	POLR3H	-1.06	-12.46	-0.61	2.35e-28	Vitiligo;
CESC	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	13.65	0.64	1.8e-32	Prudent dietary pattern;
CESC	cis	rs6674176	0.542	rs803679	chr1:44349405	G/A	cg13606994	chr1:44402422	ARTN	-0.38	-5.33	-0.31	2.11e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg07677032	chr17:61819896	STRADA	0.45	5.92	0.34	1.01e-8	Prudent dietary pattern;
CESC	cis	rs559928	0.597	rs11600667	chr11:63976183	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.62	5.28	0.31	2.7e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CESC	cis	rs9911578	1.000	rs4482353	chr17:56896834	A/G	cg05425664	chr17:57184151	TRIM37	-0.49	-6.87	-0.39	4.62e-11	Intelligence (multi-trait analysis);
CESC	cis	rs4450798	0.649	rs9855179	chr3:13790981	G/A	cg23332027	chr3:13681764	NA	0.38	5.13	0.3	5.63e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs2635047	0.967	rs2576030	chr18:44659166	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.51	7.09	0.4	1.2e-11	Educational attainment;
CESC	cis	rs7586673	0.857	rs16845580	chr2:161920884	T/C	cg21518248	chr2:162101506	NA	0.47	6.4	0.37	6.96e-10	Intelligence (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14460003	chr20:31173015	NA	0.55	6.04	0.35	5.12e-9	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06767762	chr16:70323488	AARS	-0.61	-7.57	-0.42	6.29e-13	Gut microbiome composition (summer);
CESC	cis	rs9611565	0.559	rs7290991	chr22:41964361	C/G	cg03806693	chr22:41940476	POLR3H	-0.97	-12.07	-0.6	4.96e-27	Vitiligo;
CESC	cis	rs11122272	0.732	rs999010	chr1:231495316	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.59	-8.16	-0.45	1.38e-14	Hemoglobin concentration;
CESC	cis	rs6463523	0.898	rs66892628	chr7:759374	T/A	cg14391382	chr7:866102	UNC84A	0.48	5.97	0.34	7.53e-9	Subjective well-being;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00188822	chr20:44044780	PIGT	0.58	7.17	0.4	7.52e-12	Gut microbiome composition (summer);
CESC	trans	rs916888	0.779	rs199528	chr17:44843136	C/T	cg01341218	chr17:43662625	NA	0.92	10.78	0.55	1.08e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs7949030	0.596	rs11231137	chr11:62315699	G/A	cg23462726	chr11:62437636	C11orf83;C11orf48	-0.44	-5.71	-0.33	2.98e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs35306767	0.903	rs11812523	chr10:915638	C/T	cg10556349	chr10:835070	NA	0.58	5.59	0.32	5.56e-8	Eosinophil percentage of granulocytes;
CESC	cis	rs597539	0.689	rs596874	chr11:68630874	C/T	cg04772025	chr11:68637568	NA	-0.56	-6.78	-0.38	7.57e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs1799949	0.965	rs33925201	chr17:41280682	A/G	cg06001716	chr17:41278141	BRCA1;NBR2	0.39	5.28	0.31	2.75e-7	Menopause (age at onset);
CESC	cis	rs12348691	0.503	rs7023267	chr9:100603935	G/A	cg13688889	chr9:100608707	NA	-0.87	-13.26	-0.63	4.01e-31	Alopecia areata;
CESC	cis	rs11711311	0.712	rs3773684	chr3:113334488	A/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	-0.58	-7.86	-0.43	9.74e-14	IgG glycosylation;
CESC	cis	rs5757673	1	rs5757673	chr22:39837920	T/C	cg01416388	chr22:39784598	NA	-0.66	-7.62	-0.42	4.45e-13	Post bronchodilator FEV1;
CESC	cis	rs72945132	0.882	rs3781648	chr11:70190058	T/C	cg14191688	chr11:70257035	CTTN	0.41	5.13	0.3	5.6e-7	Coronary artery disease;
CESC	cis	rs7845219	0.544	rs10956930	chr8:95919786	C/G	cg13393036	chr8:95962371	TP53INP1	-0.42	-7.77	-0.43	1.69e-13	Type 2 diabetes;
CESC	cis	rs3733585	0.578	rs6837224	chr4:9955255	G/T	cg02734326	chr4:10020555	SLC2A9	-0.4	-5.77	-0.33	2.19e-8	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs35110281	0.626	rs162388	chr21:44936032	G/A	cg01579765	chr21:45077557	HSF2BP	-0.49	-8.76	-0.47	2.41e-16	Mean corpuscular volume;
CESC	cis	rs13191362	1.000	rs73035023	chr6:163000927	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.88	9.16	0.49	1.46e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs7520050	0.966	rs4660898	chr1:46402171	A/G	cg03146154	chr1:46216737	IPP	-0.46	-5.92	-0.34	9.78e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs7523050	0.730	rs12729728	chr1:109431110	C/A	cg08274380	chr1:109419600	GPSM2	0.94	6.43	0.37	5.76e-10	Fat distribution (HIV);
CESC	cis	rs977987	0.806	rs11864102	chr16:75442360	C/T	cg03315344	chr16:75512273	CHST6	0.41	5.81	0.34	1.77e-8	Dupuytren's disease;
CESC	cis	rs798554	0.759	rs1182189	chr7:2869522	G/A	cg13628971	chr7:2884303	GNA12	0.64	8.13	0.45	1.63e-14	Height;
CESC	cis	rs3733585	0.578	rs4466042	chr4:9955367	T/C	cg00071950	chr4:10020882	SLC2A9	-0.69	-11.31	-0.57	1.83e-24	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs1218582	0.596	rs906595	chr1:154822907	C/T	cg09359103	chr1:154839909	KCNN3	-0.49	-7.75	-0.43	2.03e-13	Prostate cancer;
CESC	cis	rs11098499	0.954	rs10518331	chr4:120323595	C/T	cg24375607	chr4:120327624	NA	0.47	5.89	0.34	1.14e-8	Corneal astigmatism;
CESC	cis	rs6594499	0.872	rs10060003	chr5:110449357	A/G	cg04022379	chr5:110408740	TSLP	0.32	5.63	0.33	4.49e-8	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs7666738	0.830	rs13139024	chr4:99020700	C/T	cg18180107	chr4:99064573	C4orf37	0.41	5.39	0.31	1.57e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs12618769	0.597	rs72821943	chr2:99141640	T/C	cg10123293	chr2:99228465	UNC50	0.41	5.44	0.32	1.24e-7	Bipolar disorder;
CESC	cis	rs7666738	0.830	rs13129503	chr4:98987892	T/C	cg17366294	chr4:99064904	C4orf37	0.59	8.57	0.47	8.46e-16	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11080062	chr12:53615449	RARG	0.55	6.65	0.38	1.69e-10	Gut microbiome composition (summer);
CESC	cis	rs4843747	0.697	rs72818533	chr16:88073841	G/A	cg03395651	chr16:88107091	BANP	0.45	5.17	0.3	4.54e-7	Menopause (age at onset);
CESC	cis	rs1044826	0.647	rs4683463	chr3:139196946	T/G	cg00490450	chr3:139108681	COPB2	0.43	5.34	0.31	2e-7	Obesity-related traits;
CESC	cis	rs858239	0.601	rs10255228	chr7:23158863	G/T	cg23682824	chr7:23144976	KLHL7	0.55	7.76	0.43	1.85e-13	Cerebrospinal fluid biomarker levels;
CESC	cis	rs6500395	0.926	rs9929569	chr16:48677584	C/T	cg04672837	chr16:48644449	N4BP1	0.46	5.46	0.32	1.08e-7	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs1044826	0.692	rs169824	chr3:139235006	G/C	cg00490450	chr3:139108681	COPB2	-0.45	-5.45	-0.32	1.15e-7	Obesity-related traits;
CESC	cis	rs7412746	0.611	rs2864873	chr1:150814174	A/G	cg22823121	chr1:150693482	HORMAD1	0.45	6.35	0.36	9.19e-10	Melanoma;
CESC	cis	rs977987	0.843	rs59465235	chr16:75483810	C/G	cg03315344	chr16:75512273	CHST6	0.43	6.26	0.36	1.5e-9	Dupuytren's disease;
CESC	cis	rs7020830	0.825	rs66684257	chr9:37199087	G/T	cg14294708	chr9:37120828	ZCCHC7	1.11	20.24	0.78	1.02e-55	Schizophrenia;
CESC	trans	rs877282	0.945	rs10904555	chr10:787740	C/A	cg22713356	chr15:30763199	NA	1.32	13.44	0.64	9.25e-32	Uric acid levels;
CESC	cis	rs2735413	0.918	rs4888728	chr16:78077199	C/G	cg04733911	chr16:78082701	NA	-0.53	-9.01	-0.48	4.08e-17	Systolic blood pressure (alcohol consumption interaction);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg10949413	chr6:26158832	HIST1H2BD	-0.4	-6.32	-0.36	1.11e-9	Gambling;
CESC	cis	rs6541297	0.757	rs600845	chr1:230322708	C/T	cg20703242	chr1:230279135	GALNT2	0.4	5.31	0.31	2.36e-7	Coronary artery disease;
CESC	cis	rs67311347	1.000	rs4973994	chr3:40453024	T/C	cg24209194	chr3:40518798	ZNF619	0.49	6.23	0.36	1.78e-9	Renal cell carcinoma;
CESC	cis	rs2011503	1.000	rs6511031	chr19:19471506	T/C	cg11584989	chr19:19387371	SF4	-0.64	-7.5	-0.42	9.58e-13	Bipolar disorder;
CESC	cis	rs8177179	0.967	rs9869311	chr3:133451613	C/T	cg18769074	chr3:133464867	TF	0.31	6.04	0.35	5.17e-9	Iron status biomarkers (transferrin levels);
CESC	cis	rs10911232	0.507	rs10752891	chr1:183023283	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.87	13.5	0.64	6.03e-32	Hypertriglyceridemia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11767392	chr11:71814388	LRTOMT;C11orf59	0.55	6.77	0.38	8.34e-11	Gut microbiome composition (summer);
CESC	cis	rs6088580	0.668	rs1205337	chr20:32926041	T/A	cg08999081	chr20:33150536	PIGU	-0.64	-10.99	-0.56	2.0500000000000001e-23	Glomerular filtration rate (creatinine);
CESC	cis	rs3820068	0.581	rs16851855	chr1:15930869	G/A	cg16988262	chr1:15930761	NA	0.35	5.65	0.33	4.18e-8	Systolic blood pressure;
CESC	trans	rs1814175	0.781	rs28681334	chr11:50051177	C/T	cg03929089	chr4:120376271	NA	-0.94	-15.72	-0.69	8.37e-40	Height;
CESC	cis	rs875971	0.619	rs12533585	chr7:65984605	G/C	cg11764359	chr7:65958608	NA	0.7	9.39	0.5	2.84e-18	Aortic root size;
CESC	cis	rs938554	0.612	rs7669607	chr4:9997801	C/T	cg11266682	chr4:10021025	SLC2A9	-0.44	-6.28	-0.36	1.38e-9	Blood metabolite levels;
CESC	cis	rs12136530	0.774	rs10442642	chr1:19773818	A/G	cg01832549	chr1:19774989	CAPZB	-0.47	-6.59	-0.38	2.36e-10	Lead levels in blood;
CESC	cis	rs897984	0.542	rs35713203	chr16:31090407	G/C	cg02466173	chr16:30829666	NA	-0.45	-7.42	-0.41	1.59e-12	Dementia with Lewy bodies;
CESC	cis	rs11122272	0.735	rs2474631	chr1:231541341	T/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.55	-7.28	-0.41	3.74e-12	Hemoglobin concentration;
CESC	cis	rs2439831	0.867	rs2447211	chr15:43936351	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.81	8.46	0.46	1.81e-15	Lung cancer in ever smokers;
CESC	cis	rs1008375	1.000	rs62295634	chr4:17685346	C/A	cg16339924	chr4:17578868	LAP3	0.51	6.49	0.37	4.31e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs1371867	0.875	rs1788174	chr8:101330957	C/G	cg11906718	chr8:101322791	RNF19A	-0.49	-6.29	-0.36	1.28e-9	Atrioventricular conduction;
CESC	cis	rs6964587	0.839	rs10236107	chr7:91485461	G/A	cg17063962	chr7:91808500	NA	-0.5	-6.56	-0.37	2.77e-10	Breast cancer;
CESC	cis	rs10504229	0.679	rs11786328	chr8:58039269	A/G	cg22535103	chr8:58192502	C8orf71	-0.93	-9.27	-0.49	6.95e-18	Developmental language disorder (linguistic errors);
CESC	cis	rs875971	0.862	rs4718319	chr7:65652784	C/A	cg11764359	chr7:65958608	NA	-0.78	-11.43	-0.57	7.35e-25	Aortic root size;
CESC	cis	rs1552244	0.872	rs7646073	chr3:10097405	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	12.09	0.6	4.37e-27	Alzheimer's disease;
CESC	cis	rs7592578	0.664	rs10931461	chr2:191405280	T/A	cg27211696	chr2:191398769	TMEM194B	0.59	5.32	0.31	2.22e-7	Diastolic blood pressure;
CESC	cis	rs4727027	0.870	rs1534196	chr7:148790591	G/A	cg23158103	chr7:148848205	ZNF398	-0.42	-6.93	-0.39	3.25e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs7508	0.694	rs2410447	chr8:17923147	T/C	cg18067069	chr8:17937731	ASAH1	-0.41	-5.43	-0.32	1.28e-7	Atrial fibrillation;
CESC	cis	rs9733	0.635	rs486836	chr1:150875967	A/T	cg18016565	chr1:150552671	MCL1	-0.37	-5.94	-0.34	8.72e-9	Tonsillectomy;
CESC	cis	rs8141529	0.732	rs11556025	chr22:29168755	T/C	cg02153584	chr22:29168773	CCDC117	0.69	9.74	0.51	2.27e-19	Lymphocyte counts;
CESC	cis	rs7829975	0.688	rs13270194	chr8:8378102	T/C	cg15556689	chr8:8085844	FLJ10661	0.53	6.55	0.37	2.92e-10	Mood instability;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg00400810	chr15:42066822	MAPKBP1	-0.5	-6.19	-0.36	2.29e-9	Ulcerative colitis;
CESC	cis	rs1707322	0.506	rs2991983	chr1:46079391	T/C	cg06784218	chr1:46089804	CCDC17	-0.41	-7.2	-0.4	6.06e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg22455660	chr9:128509791	PBX3	-0.47	-6.08	-0.35	4.24e-9	Height;
CESC	cis	rs2952156	0.920	rs11078919	chr17:37835755	T/C	cg20243544	chr17:37824526	PNMT	0.63	8.42	0.46	2.43e-15	Asthma;
CESC	cis	rs4450798	0.649	rs9845991	chr3:13778031	C/A	cg05589046	chr3:13742034	LOC285375	0.34	5.09	0.3	6.68e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg12940430	chr6:43138965	SRF	-0.5	-6.42	-0.37	6.09e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs1707322	0.685	rs6690926	chr1:46134978	T/C	cg06784218	chr1:46089804	CCDC17	0.43	7.48	0.42	1.07e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00408597	chr11:9685941	SWAP70	0.59	7.04	0.4	1.63e-11	Gut microbiome composition (summer);
CESC	cis	rs12900413	0.564	rs8035800	chr15:90314790	T/C	cg24249390	chr15:90295951	MESP1	-0.41	-5.73	-0.33	2.78e-8	Coronary artery aneurysm in Kawasaki disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10450178	chr12:89920041	WDR51B	-0.63	-7.28	-0.41	3.74e-12	Gut microbiome composition (summer);
CESC	trans	rs7615952	0.546	rs2976733	chr3:125414138	T/C	cg07211511	chr3:129823064	LOC729375	-0.58	-7.37	-0.41	2.19e-12	Blood pressure (smoking interaction);
CESC	cis	rs2249694	1.000	rs4363513	chr10:135355534	A/G	cg20169779	chr10:135381914	SYCE1	0.42	5.74	0.33	2.58e-8	Obesity-related traits;
CESC	cis	rs7412746	0.634	rs12096831	chr1:150864113	T/G	cg04414720	chr1:150670196	GOLPH3L	0.52	6.8	0.39	6.72e-11	Melanoma;
CESC	cis	rs12681288	0.676	rs2701914	chr8:999935	C/T	cg15309053	chr8:964076	NA	0.39	6.61	0.38	2.11e-10	Schizophrenia;
CESC	trans	rs12356475	0.710	rs10822686	chr10:67733250	C/T	cg18346038	chr20:33264828	PIGU	-0.51	-6.22	-0.36	1.93e-9	Psoriatic arthritis;
CESC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg06347499	chr1:9599419	SLC25A33	0.43	6.0	0.35	6.6e-9	Intelligence (multi-trait analysis);
CESC	cis	rs10129255	0.536	rs6576223	chr14:107184687	C/T	cg23076370	chr14:107095027	NA	-0.66	-9.85	-0.52	1.08e-19	Kawasaki disease;
CESC	cis	rs10256972	0.524	rs6945202	chr7:1116558	T/C	cg27094323	chr7:1216898	NA	-0.39	-5.45	-0.32	1.17e-7	Longevity;Endometriosis;
CESC	cis	rs4727027	0.899	rs6944096	chr7:148870026	A/G	cg23158103	chr7:148848205	ZNF398	-0.37	-5.85	-0.34	1.44e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs9324022	0.929	rs59488041	chr14:101180041	T/A	cg18089426	chr14:101175970	NA	0.55	7.07	0.4	1.37e-11	Plateletcrit;
CESC	cis	rs8111998	0.826	rs4932778	chr19:22766971	G/A	cg19914732	chr19:22715077	NA	-0.37	-5.18	-0.3	4.45e-7	Corneal structure;
CESC	cis	rs6582630	0.615	rs11182380	chr12:38511735	G/T	cg26384229	chr12:38710491	ALG10B	-0.41	-5.41	-0.32	1.39e-7	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs1881797	0.932	rs10925071	chr1:247686521	C/T	cg21399703	chr1:247681439	NA	-0.52	-7.46	-0.42	1.22e-12	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs1808579	0.935	rs6507716	chr18:21115060	A/G	cg14672496	chr18:21087552	C18orf8	0.43	6.43	0.37	6.04e-10	Hip circumference;Body mass index;BMI (adjusted for smoking behaviour);
CESC	cis	rs10504073	0.631	rs341813	chr8:50039916	T/C	cg00325661	chr8:49890786	NA	0.5	7.28	0.41	3.89e-12	Blood metabolite ratios;
CESC	cis	rs611744	0.631	rs681963	chr8:109255032	C/A	cg21045802	chr8:109455806	TTC35	0.46	5.67	0.33	3.65e-8	Dupuytren's disease;
CESC	cis	rs6963495	0.818	rs73192144	chr7:105203535	C/T	cg19920283	chr7:105172520	RINT1	0.7	6.54	0.37	3.09e-10	Bipolar disorder (body mass index interaction);
CESC	cis	rs7246657	0.891	rs7257495	chr19:37823876	C/G	cg23950597	chr19:37808831	NA	-0.55	-6.04	-0.35	5.24e-9	Coronary artery calcification;
CESC	cis	rs694739	0.628	rs508168	chr11:64135435	G/A	cg23796481	chr11:64053134	BAD;GPR137	0.58	7.09	0.4	1.23e-11	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CESC	cis	rs7267979	1.000	rs4815409	chr20:25346697	C/A	cg08601574	chr20:25228251	PYGB	-0.38	-5.46	-0.32	1.12e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs4253772	0.591	rs6007795	chr22:46686792	C/G	cg24881330	chr22:46731750	TRMU	0.94	10.35	0.54	2.62e-21	LDL cholesterol;Cholesterol, total;
CESC	cis	rs4629710	0.592	rs9492868	chr6:131542238	A/C	cg12606694	chr6:131520996	AKAP7	0.46	5.67	0.33	3.79e-8	Multiple myeloma (IgH translocation);
CESC	cis	rs9649213	0.593	rs7803372	chr7:97992257	A/G	cg21770322	chr7:97807741	LMTK2	0.55	8.41	0.46	2.49e-15	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs2228479	1.000	rs4257207	chr16:89947861	T/A	cg04013166	chr16:89971882	TCF25	0.76	6.47	0.37	4.59e-10	Skin colour saturation;
CESC	cis	rs4955124	0.558	rs60434847	chr3:32017702	T/G	cg05935571	chr3:32023257	ZNF860;OSBPL10	1.0	8.4	0.46	2.67e-15	Schizophrenia;
CESC	cis	rs1048238	0.506	rs12039892	chr1:16167974	A/G	cg21385522	chr1:16154831	NA	0.42	5.31	0.31	2.35e-7	Systolic blood pressure;
CESC	cis	rs7586673	0.725	rs6757645	chr2:161891382	A/G	cg22496339	chr2:162101262	NA	0.41	5.17	0.3	4.63e-7	Intelligence (multi-trait analysis);
CESC	cis	rs2050392	0.624	rs2489842	chr10:30721991	T/C	cg18806716	chr10:30721971	MAP3K8	-0.64	-9.55	-0.51	9.14e-19	Inflammatory bowel disease;
CESC	cis	rs5769765	0.862	rs138897	chr22:50231067	T/C	cg02269571	chr22:50332266	NA	-0.47	-6.02	-0.35	5.66e-9	Schizophrenia;
CESC	cis	rs17253792	0.822	rs79024594	chr14:56092997	T/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.79	5.91	0.34	1.06e-8	Putamen volume;
CESC	cis	rs7666738	0.830	rs10021044	chr4:99002488	A/T	cg05340658	chr4:99064831	C4orf37	0.8	12.44	0.61	2.83e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2204008	0.545	rs1663283	chr12:38132039	G/A	cg26384229	chr12:38710491	ALG10B	-0.43	-5.92	-0.34	9.92e-9	Bladder cancer;
CESC	cis	rs66573146	0.901	rs55882710	chr4:7030704	G/A	cg00086871	chr4:6988644	TBC1D14	0.88	5.04	0.3	8.81e-7	Granulocyte percentage of myeloid white cells;
CESC	cis	rs7116495	1.000	rs10751190	chr11:71680757	C/T	cg26138937	chr11:71823887	C11orf51	-0.79	-6.51	-0.37	3.77e-10	Severe influenza A (H1N1) infection;
CESC	cis	rs769267	0.930	rs10414830	chr19:19562332	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.46	5.93	0.34	9.3e-9	Tonsillectomy;
CESC	cis	rs74181299	0.890	rs2540950	chr2:65279223	C/T	cg05010058	chr2:65284262	CEP68	0.33	5.66	0.33	3.89e-8	Pulse pressure;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg02021460	chr16:19729639	C16orf88;IQCK	0.46	6.09	0.35	3.85e-9	Systemic lupus erythematosus;
CESC	cis	rs6831352	0.918	rs2851246	chr4:100046104	A/G	cg13256891	chr4:100009986	ADH5	0.78	8.94	0.48	7.06e-17	Alcohol dependence;
CESC	cis	rs9583531	0.527	rs6492302	chr13:111352354	C/T	cg24331049	chr13:111365604	ING1	-0.7	-10.5	-0.54	8.67e-22	Coronary artery disease;
CESC	trans	rs9858542	0.953	rs10640	chr3:49454277	G/A	cg21659725	chr3:3221576	CRBN	-0.55	-6.55	-0.37	2.92e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs7615952	0.576	rs1127717	chr3:125826059	T/C	cg04553112	chr3:125709451	NA	-0.54	-5.97	-0.34	7.6e-9	Blood pressure (smoking interaction);
CESC	cis	rs2243480	1.000	rs316332	chr7:65604299	A/G	cg18252515	chr7:66147081	NA	-1.33	-13.37	-0.63	1.61e-31	Diabetic kidney disease;
CESC	cis	rs11690935	0.959	rs77280952	chr2:172620151	G/C	cg13550731	chr2:172543902	DYNC1I2	-0.97	-14.87	-0.67	9.1e-37	Schizophrenia;
CESC	cis	rs1008375	1.000	rs3815414	chr4:17606659	A/G	cg16339924	chr4:17578868	LAP3	-0.6	-7.6	-0.42	4.97e-13	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs2279817	0.743	rs3766309	chr1:17977378	C/T	cg21791023	chr1:18019539	ARHGEF10L	-0.47	-6.62	-0.38	2.03e-10	Neuroticism;
CESC	cis	rs7811142	0.830	rs6975660	chr7:99975266	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.91	9.82	0.52	1.26e-19	Platelet count;
CESC	cis	rs4282054	0.631	rs13081155	chr3:52732429	A/G	cg18337363	chr3:52569053	NT5DC2	0.31	6.0	0.35	6.63e-9	Cognitive function;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22377027	chr1:12040208	MFN2	0.57	6.04	0.35	5.32e-9	Gut microbiome composition (summer);
CESC	cis	rs9902453	0.817	rs62068625	chr17:28176581	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	8.47	0.46	1.75e-15	Coffee consumption (cups per day);
CESC	cis	rs9581857	0.579	rs76578450	chr13:27982656	C/A	cg01674679	chr13:27998804	GTF3A	-0.65	-5.19	-0.3	4.26e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
CESC	cis	rs875971	0.862	rs10950033	chr7:65739673	A/G	cg10691866	chr7:65817282	TPST1	0.31	5.37	0.31	1.75e-7	Aortic root size;
CESC	cis	rs7829975	0.511	rs2921028	chr8:8340477	T/C	cg06636001	chr8:8085503	FLJ10661	0.41	5.06	0.3	7.94e-7	Mood instability;
CESC	cis	rs7552404	0.889	rs1250874	chr1:76190978	A/G	cg22875332	chr1:76189707	ACADM	0.7	9.66	0.51	4.13e-19	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs1023500	0.551	rs133379	chr22:42468535	A/G	cg04733989	chr22:42467013	NAGA	0.8	11.49	0.58	4.5e-25	Schizophrenia;
CESC	cis	rs6991838	0.584	rs66486920	chr8:66486693	C/T	cg13398993	chr8:66546079	ARMC1	-0.46	-5.54	-0.32	7.22e-8	Intelligence (multi-trait analysis);
CESC	cis	rs2439831	1.000	rs2245790	chr15:43744457	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.8	11.71	0.58	8.62e-26	Lung cancer in ever smokers;
CESC	cis	rs11690935	0.851	rs10201430	chr2:172813241	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.72	-10.6	-0.55	4.18e-22	Schizophrenia;
CESC	trans	rs4950322	0.547	rs61838945	chr1:146583059	G/T	cg04954894	chr8:38089920	DDHD2	-0.58	-6.36	-0.36	8.8e-10	Protein quantitative trait loci;
CESC	cis	rs2414059	0.518	rs3098171	chr15:50771511	C/G	cg08437265	chr15:50716283	USP8	-0.49	-6.46	-0.37	4.98e-10	QT interval;
CESC	cis	rs5769765	0.908	rs9627800	chr22:50319351	T/C	cg02269571	chr22:50332266	NA	-0.55	-6.42	-0.37	6.1e-10	Schizophrenia;
CESC	cis	rs9815354	0.812	rs73830516	chr3:41876056	A/G	cg03022575	chr3:42003672	ULK4	0.71	6.21	0.36	1.99e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs3785574	0.962	rs56295011	chr17:61850359	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.59	7.19	0.4	6.81e-12	Height;
CESC	cis	rs6570726	0.846	rs6570698	chr6:145918635	C/G	cg23711669	chr6:146136114	FBXO30	0.83	12.25	0.6	1.19e-27	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9858542	0.953	rs9858280	chr3:49597737	T/C	cg03060546	chr3:49711283	APEH	-0.51	-5.99	-0.35	6.8e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs2832191	0.716	rs7509628	chr21:30454252	C/T	cg08807101	chr21:30365312	RNF160	0.94	14.55	0.67	1.17e-35	Dental caries;
CESC	cis	rs34381861	0.520	rs74382390	chr16:71458526	C/G	cg08717414	chr16:71523259	ZNF19	-0.81	-8.01	-0.44	3.73e-14	Post bronchodilator FEV1;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03104765	chr7:129414868	MIR183;MIR96	-0.57	-6.31	-0.36	1.2e-9	Gut microbiome composition (summer);
CESC	trans	rs673604	0.505	rs676614	chr1:36107510	G/T	cg26719024	chr10:105156444	PDCD11;USMG5	0.53	6.02	0.35	5.8e-9	Endometrial cancer;
CESC	cis	rs2839186	0.771	rs2280957	chr21:47642272	A/G	cg13126279	chr21:47581558	C21orf56	0.5	6.89	0.39	4.07e-11	Testicular germ cell tumor;
CESC	cis	rs2108225	0.872	rs4618632	chr7:107440952	T/G	cg18560240	chr7:107437656	SLC26A3	-0.43	-5.92	-0.34	9.83e-9	Ulcerative colitis;
CESC	cis	rs172166	0.637	rs1225592	chr6:28150242	G/A	cg19592336	chr6:28129416	ZNF389	0.44	6.46	0.37	4.98e-10	Cardiac Troponin-T levels;
CESC	cis	rs6142102	0.625	rs6142062	chr20:32548512	C/G	cg08999081	chr20:33150536	PIGU	0.34	5.11	0.3	6.04e-7	Skin pigmentation;
CESC	cis	rs2576037	0.526	rs10853547	chr18:44530548	A/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.55	-7.71	-0.43	2.5e-13	Personality dimensions;
CESC	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.58	7.49	0.42	1.01e-12	Prudent dietary pattern;
CESC	cis	rs798554	0.836	rs798502	chr7:2789880	G/T	cg19346786	chr7:2764209	NA	0.5	7.38	0.41	2.11e-12	Height;
CESC	cis	rs9487051	0.872	rs9487043	chr6:109610474	C/T	cg01475377	chr6:109611718	NA	-0.48	-7.82	-0.43	1.26e-13	Reticulocyte fraction of red cells;
CESC	cis	rs864537	0.622	rs1214598	chr1:167426424	C/T	cg22356347	chr1:167427500	CD247	-0.4	-8.42	-0.46	2.37e-15	Celiac disease or Rheumatoid arthritis;Celiac disease;
CESC	cis	rs16895831	0.519	rs4714614	chr6:42592183	A/G	cg10605015	chr6:42532144	UBR2	-0.47	-5.18	-0.3	4.34e-7	Granulocyte percentage of myeloid white cells;Neutrophil percentage of white cells;Eosinophil percentage of white cells;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Neutrophil count;Sum basophil neutrophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
CESC	cis	rs7191439	0.858	rs8044367	chr16:88783374	A/G	cg27087555	chr16:88793112	FAM38A	-1.22	-9.32	-0.5	4.71e-18	Plateletcrit;
CESC	cis	rs7666738	0.830	rs7679299	chr4:99057620	C/A	cg05340658	chr4:99064831	C4orf37	0.83	12.92	0.62	5.96e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6942756	0.806	rs6467237	chr7:128964831	A/G	cg02491457	chr7:128862824	NA	-0.61	-8.58	-0.47	8.27e-16	White matter hyperintensity burden;
CESC	cis	rs9611565	0.681	rs132918	chr22:41808350	C/T	cg06634786	chr22:41940651	POLR3H	0.63	6.75	0.38	9.04e-11	Vitiligo;
CESC	cis	rs1215050	0.791	rs165244	chr4:98687889	C/T	cg05340658	chr4:99064831	C4orf37	0.47	5.97	0.34	7.77e-9	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs4889855	0.530	rs12946972	chr17:78618922	A/G	cg09596252	chr17:78655493	RPTOR	0.41	5.12	0.3	5.92e-7	Fractional excretion of uric acid;
CESC	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg21782813	chr7:2030301	MAD1L1	-0.4	-5.86	-0.34	1.4e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs35306767	0.953	rs34405399	chr10:981015	G/A	cg25019033	chr10:957182	NA	-0.63	-7.83	-0.43	1.14e-13	Eosinophil percentage of granulocytes;
CESC	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg23131131	chr22:24373011	LOC391322	0.61	7.49	0.42	1.01e-12	Urinary 1,3-butadiene metabolite levels in smokers;
CESC	cis	rs56046484	0.871	rs62021230	chr15:85583952	C/T	cg08123816	chr15:85640762	PDE8A	-0.48	-5.85	-0.34	1.46e-8	Testicular germ cell tumor;
CESC	cis	rs1801251	0.896	rs79793315	chr2:233690864	C/T	cg25237894	chr2:233734115	C2orf82	-0.37	-6.71	-0.38	1.19e-10	Coronary artery disease;
CESC	cis	rs7000551	0.532	rs55726237	chr8:22252985	C/T	cg12081754	chr8:22256438	SLC39A14	0.92	12.64	0.61	5.75e-29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg09922935	chr17:34842385	ZNHIT3	0.52	6.48	0.37	4.55e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs11785400	1.000	rs13266249	chr8:143732433	A/C	cg10596483	chr8:143751796	JRK	0.43	5.58	0.32	5.95e-8	Schizophrenia;
CESC	cis	rs9311474	0.508	rs7614498	chr3:52618941	A/T	cg05564831	chr3:52568323	NT5DC2	0.48	7.55	0.42	7.01e-13	Electroencephalogram traits;
CESC	cis	rs826838	0.967	rs1352122	chr12:39130885	G/A	cg13010199	chr12:38710504	ALG10B	-0.45	-6.27	-0.36	1.48e-9	Heart rate;
CESC	cis	rs17376456	0.569	rs68122392	chr5:93077807	A/T	cg25358565	chr5:93447407	FAM172A	0.68	7.24	0.41	5.01e-12	Diabetic retinopathy;
CESC	cis	rs4666360	1.000	rs4666294	chr2:20336753	C/G	cg23291376	chr2:20336282	NA	0.37	6.18	0.35	2.46e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel);
CESC	cis	rs1552244	1.000	rs12374115	chr3:10134766	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	0.77	10.99	0.56	2.19e-23	Alzheimer's disease;
CESC	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg11494091	chr17:61959527	GH2	0.73	12.43	0.61	2.85e-28	Prudent dietary pattern;
CESC	cis	rs7772486	0.686	rs6570701	chr6:145954090	A/G	cg05347473	chr6:146136440	FBXO30	0.56	7.24	0.41	4.97e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs713587	0.520	rs839652	chr2:25334340	C/T	cg01884057	chr2:25150051	NA	-0.3	-5.21	-0.3	3.89e-7	Body mass index in non-asthmatics;
CESC	cis	rs1799949	1.000	rs36036395	chr17:41181297	T/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.39	5.12	0.3	5.88e-7	Menopause (age at onset);
CESC	cis	rs873946	0.564	rs12263364	chr10:134555548	G/T	cg06453172	chr10:134556979	INPP5A	-0.4	-5.36	-0.31	1.79e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs34779708	0.898	rs4934695	chr10:35280605	C/T	cg03585969	chr10:35415529	CREM	0.77	10.3	0.53	3.84e-21	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs9640161	0.789	rs34728606	chr7:150054694	G/A	cg21361702	chr7:150065534	REPIN1	0.6	6.45	0.37	5.33e-10	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs7116495	1.000	rs10128658	chr11:71733519	C/T	cg10381502	chr11:71823885	C11orf51	-0.64	-5.21	-0.3	3.81e-7	Severe influenza A (H1N1) infection;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25738037	chr1:168025549	DCAF6	-0.68	-7.57	-0.42	6.39e-13	Gut microbiome composition (summer);
CESC	cis	rs7412746	0.658	rs8444	chr1:150938571	G/A	cg22823121	chr1:150693482	HORMAD1	0.4	5.6	0.33	5.34e-8	Melanoma;
CESC	cis	rs853679	0.517	rs3757187	chr6:28107654	T/C	cg23161317	chr6:28129485	ZNF389	0.52	6.63	0.38	1.86e-10	Depression;
CESC	cis	rs4253772	0.551	rs9615936	chr22:46686328	C/G	cg18190219	chr22:46762943	CELSR1	-0.55	-5.47	-0.32	1.04e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs7618915	0.547	rs6768697	chr3:52703615	C/T	cg05564831	chr3:52568323	NT5DC2	0.44	6.68	0.38	1.37e-10	Bipolar disorder;
CESC	cis	rs8058578	0.832	rs35969813	chr16:30714417	T/C	cg02466173	chr16:30829666	NA	-0.48	-7.27	-0.41	3.94e-12	Multiple myeloma;
CESC	cis	rs9916302	0.851	rs4390625	chr17:37620347	A/G	cg00129232	chr17:37814104	STARD3	-0.54	-7.14	-0.4	9.08e-12	Glomerular filtration rate (creatinine);
CESC	cis	rs7017697	1.000	rs10092772	chr8:19686385	A/T	cg01411142	chr8:19674711	INTS10	-0.48	-5.72	-0.33	2.88e-8	Breast cancer;
CESC	cis	rs6912958	0.535	rs1753154	chr6:88032843	G/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.51	8.85	0.48	1.31e-16	Monocyte percentage of white cells;
CESC	cis	rs17666538	0.585	rs336444	chr8:633123	C/G	cg23958373	chr8:599963	NA	-0.67	-5.93	-0.34	9.44e-9	IgG glycosylation;
CESC	cis	rs9916302	0.706	rs8078599	chr17:37518660	C/T	cg07936489	chr17:37558343	FBXL20	0.9	9.49	0.5	1.38e-18	Glomerular filtration rate (creatinine);
CESC	cis	rs875971	0.756	rs4718328	chr7:65693337	A/G	cg12463550	chr7:65579703	CRCP	-0.49	-6.4	-0.37	6.95e-10	Aortic root size;
CESC	cis	rs7937682	0.961	rs7119563	chr11:111543916	T/A	cg22437258	chr11:111473054	SIK2	-0.65	-7.35	-0.41	2.39e-12	Primary sclerosing cholangitis;
CESC	cis	rs4843747	0.671	rs4072871	chr16:88106614	C/T	cg06374794	chr16:88002281	BANP	0.4	5.18	0.3	4.32e-7	Menopause (age at onset);
CESC	cis	rs919433	0.783	rs788011	chr2:198230771	A/G	cg20885578	chr2:198174922	NA	0.41	5.36	0.31	1.79e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs314370	0.621	rs314312	chr7:100422642	G/C	cg10426581	chr7:100472382	SRRT	0.49	5.47	0.32	1.06e-7	Resting heart rate;
CESC	cis	rs7666738	0.830	rs7691433	chr4:98968118	A/T	cg05340658	chr4:99064831	C4orf37	0.78	11.27	0.57	2.55e-24	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1904096	0.506	rs10024642	chr4:95179295	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.61	-9.28	-0.5	6.25e-18	Type 2 diabetes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16303825	chr3:10362878	SEC13	0.56	6.33	0.36	1.03e-9	Gut microbiome composition (summer);
CESC	trans	rs17764205	0.929	rs8101372	chr19:3253830	T/C	cg19548313	chr19:1065712	HMHA1	-0.49	-6.01	-0.35	6.14e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs926938	0.527	rs360670	chr1:115482386	G/A	cg12756093	chr1:115239321	AMPD1	0.45	6.18	0.35	2.44e-9	Autism;
CESC	trans	rs11191205	0.644	rs10883667	chr10:103384849	A/T	cg12418535	chr2:119607192	EN1	-0.4	-6.0	-0.35	6.56e-9	Intelligence (multi-trait analysis);
CESC	cis	rs4660306	0.884	rs7543076	chr1:45964238	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.61	-7.69	-0.43	2.86e-13	Homocysteine levels;
CESC	cis	rs72387598	1	rs72387598	chr1:45922977	CAT/C	cg05343316	chr1:45956843	TESK2	0.91	12.32	0.6	7.03e-28	Platelet distribution width;
CESC	cis	rs12824058	0.678	rs11614163	chr12:130814621	C/G	cg26677194	chr12:130822605	PIWIL1	0.53	6.64	0.38	1.82e-10	Menopause (age at onset);
CESC	cis	rs365132	0.875	rs2962844	chr5:176333748	G/T	cg16309518	chr5:176445507	NA	-0.36	-5.23	-0.31	3.41e-7	Menarche and menopause (age at onset);Menopause (age at onset);
CESC	cis	rs853679	0.517	rs1340004	chr6:28103691	C/T	cg12963246	chr6:28129442	ZNF389	0.46	5.59	0.32	5.57e-8	Depression;
CESC	cis	rs9815354	0.812	rs17216919	chr3:41888938	G/C	cg03022575	chr3:42003672	ULK4	0.71	6.23	0.36	1.84e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs6963495	0.818	rs6957192	chr7:105150255	A/C	cg02135003	chr7:105160482	PUS7	0.46	5.69	0.33	3.36e-8	Bipolar disorder (body mass index interaction);
CESC	cis	rs35110281	0.774	rs2838323	chr21:44999086	G/A	cg01579765	chr21:45077557	HSF2BP	-0.57	-9.89	-0.52	7.73e-20	Mean corpuscular volume;
CESC	trans	rs885518	0.852	rs10965131	chr9:21782230	T/A	cg07328519	chr19:4064300	ZBTB7A	0.5	6.08	0.35	4.19e-9	Lung adenocarcinoma;
CESC	cis	rs2406342	0.528	rs75536638	chr18:74499060	G/T	cg03731646	chr18:74499372	NA	0.44	5.77	0.33	2.2e-8	Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin);
CESC	cis	rs1003719	0.667	rs13050226	chr21:38457708	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.52	6.54	0.37	3.08e-10	Eye color traits;
CESC	trans	rs17685	0.712	rs56965035	chr7:75795670	G/A	cg19862616	chr7:65841803	NCRNA00174	0.84	12.03	0.59	6.77e-27	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs2204008	0.774	rs11180977	chr12:38263094	G/T	cg26384229	chr12:38710491	ALG10B	0.72	10.17	0.53	1.01e-20	Bladder cancer;
CESC	cis	rs1552244	1.000	rs4260416	chr3:10125283	C/T	cg15117754	chr3:10150083	C3orf24	0.38	5.04	0.3	8.66e-7	Alzheimer's disease;
CESC	cis	rs910316	0.692	rs7156586	chr14:75506230	A/T	cg11812906	chr14:75593930	NEK9	0.64	8.72	0.47	3.2e-16	Height;
CESC	cis	rs637571	0.522	rs1786175	chr11:65754808	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.74	10.66	0.55	2.65e-22	Eosinophil percentage of white cells;
CESC	cis	rs769267	0.930	rs6909	chr19:19619542	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	7.46	0.42	1.23e-12	Tonsillectomy;
CESC	cis	rs13095912	1.000	rs17523471	chr3:185304018	T/C	cg11274856	chr3:185301563	NA	0.37	6.09	0.35	3.89e-9	Systolic blood pressure;
CESC	cis	rs7520050	0.966	rs7556436	chr1:46363880	C/T	cg03146154	chr1:46216737	IPP	0.47	6.11	0.35	3.61e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs5769765	1.000	rs738711	chr22:50282603	A/G	cg02269571	chr22:50332266	NA	0.46	6.28	0.36	1.39e-9	Schizophrenia;
CESC	cis	rs8077889	1.000	rs2079005	chr17:41865627	T/G	cg26893861	chr17:41843967	DUSP3	0.85	9.86	0.52	1e-19	Triglycerides;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04709120	chr10:74451858	CCDC109A	0.57	6.9	0.39	3.79e-11	Gut microbiome composition (summer);
CESC	cis	rs7264396	0.623	rs761827	chr20:34207897	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.64	6.48	0.37	4.47e-10	Total cholesterol levels;
CESC	cis	rs9916302	0.904	rs4795356	chr17:37535631	C/T	cg19468946	chr17:37922297	IKZF3	0.39	5.07	0.3	7.62e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs10751667	0.600	rs10794342	chr11:924904	C/T	cg20946044	chr11:1010712	AP2A2	-0.39	-5.26	-0.31	2.98e-7	Alzheimer's disease (late onset);
CESC	cis	rs72781680	0.898	rs55761273	chr2:23957849	A/G	cg20701182	chr2:24300061	SF3B14	0.62	5.49	0.32	9.46e-8	Lymphocyte counts;
CESC	cis	rs7084402	1.000	rs7073504	chr10:60271987	C/T	cg07615347	chr10:60278583	BICC1	-0.56	-8.85	-0.48	1.27e-16	Refractive error;
CESC	cis	rs60871478	0.898	rs35928069	chr7:823067	G/C	cg05535760	chr7:792225	HEATR2	0.88	10.28	0.53	4.39e-21	Cerebrospinal P-tau181p levels;
CESC	cis	rs8133932	0.654	rs7410101	chr21:47328383	G/A	cg14185626	chr21:47401492	COL6A1	0.46	5.1	0.3	6.47e-7	Schizophrenia;
CESC	cis	rs10504229	0.953	rs59034808	chr8:58185337	T/C	cg24829409	chr8:58192753	C8orf71	-0.63	-8.73	-0.47	3e-16	Developmental language disorder (linguistic errors);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25661132	chr6:157802429	ZDHHC14	0.62	6.87	0.39	4.45e-11	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.830	rs13134819	chr4:98919885	G/C	cg17366294	chr4:99064904	C4orf37	0.57	7.96	0.44	4.98e-14	Colonoscopy-negative controls vs population controls;
CESC	cis	rs926938	0.563	rs360586	chr1:115467489	A/G	cg12756093	chr1:115239321	AMPD1	0.45	6.15	0.35	2.84e-9	Autism;
CESC	cis	rs113835537	0.529	rs57724777	chr11:66236431	G/A	cg24851651	chr11:66362959	CCS	0.53	6.17	0.35	2.49e-9	Airway imaging phenotypes;
CESC	trans	rs9987353	0.840	rs329994	chr8:9123233	A/G	cg02477354	chr7:96339276	SHFM1	-0.52	-6.59	-0.38	2.4e-10	Recombination measurement;
CESC	trans	rs116095464	0.558	rs62346526	chr5:220614	T/C	cg00938859	chr5:1591904	SDHAP3	0.6	6.66	0.38	1.55e-10	Breast cancer;
CESC	cis	rs9910055	0.659	rs227578	chr17:42210189	C/A	cg13607699	chr17:42295918	UBTF	-0.58	-7.53	-0.42	7.91e-13	Total body bone mineral density;
CESC	cis	rs7833790	0.676	rs7834555	chr8:82697625	A/G	cg27398817	chr8:82754497	SNX16	-0.42	-5.32	-0.31	2.24e-7	Diastolic blood pressure;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22438603	chr5:127418940	SLC12A2;FLJ33630	0.67	8.22	0.45	9.16e-15	Gut microbiome composition (summer);
CESC	cis	rs1395	0.778	rs11693660	chr2:27468856	T/C	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.45	5.86	0.34	1.35e-8	Blood metabolite levels;
CESC	cis	rs8060686	0.920	rs73593810	chr16:67866783	C/T	cg26727032	chr16:67993705	SLC12A4	-0.58	-6.26	-0.36	1.55e-9	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs1218582	0.772	rs4845694	chr1:154911651	C/G	cg16680214	chr1:154839983	KCNN3	-0.45	-6.95	-0.39	2.84e-11	Prostate cancer;
CESC	cis	rs17826219	0.561	rs562840	chr17:28949390	G/T	cg19761014	chr17:28927070	LRRC37B2	0.73	7.36	0.41	2.26e-12	Body mass index;
CESC	cis	rs10206020	0.885	rs6720923	chr2:1574197	T/C	cg12573674	chr2:1569213	NA	-0.46	-5.2	-0.3	3.96e-7	IgG glycosylation;
CESC	cis	rs62229266	0.804	rs56279140	chr21:37424361	C/T	cg08632701	chr21:37451849	NA	-0.37	-5.2	-0.3	3.98e-7	Mitral valve prolapse;
CESC	cis	rs4819052	0.851	rs4819043	chr21:46660078	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.45	5.58	0.32	5.81e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06557630	chr16:49889701	NA	0.49	6.08	0.35	4.14e-9	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10664184	chr19:17420304	DDA1	-0.56	-6.39	-0.37	7.56e-10	Gut microbiome composition (summer);
CESC	cis	rs3020736	0.500	rs6002618	chr22:42507859	G/C	cg15557168	chr22:42548783	NA	0.45	6.51	0.37	3.78e-10	Autism spectrum disorder or schizophrenia;
CESC	cis	rs1218582	0.772	rs6656435	chr1:154876869	G/A	cg06221963	chr1:154839813	KCNN3	-0.66	-11.39	-0.57	1.03e-24	Prostate cancer;
CESC	cis	rs2180341	0.842	rs7739679	chr6:127545428	G/A	cg24812749	chr6:127587940	RNF146	0.93	11.17	0.57	5.54e-24	Breast cancer;
CESC	cis	rs3740713	1.000	rs2643872	chr11:18450444	A/T	cg23797887	chr11:18477753	LDHAL6A	-0.52	-5.19	-0.3	4.27e-7	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs2404602	0.647	rs11629727	chr15:77009038	G/C	cg23625390	chr15:77176239	SCAPER	-0.4	-5.2	-0.3	4e-7	Blood metabolite levels;
CESC	cis	rs6546550	0.901	rs6736408	chr2:70137774	C/T	cg02498382	chr2:70120550	SNRNP27	-0.41	-7.26	-0.41	4.34e-12	Prevalent atrial fibrillation;
CESC	cis	rs7959452	0.503	rs7300266	chr12:69654187	A/G	cg14784868	chr12:69753453	YEATS4	0.7	10.09	0.53	1.74e-20	Blood protein levels;
CESC	cis	rs7635838	0.596	rs443503	chr3:11261912	A/T	cg00170343	chr3:11313890	ATG7	-0.45	-5.6	-0.33	5.35e-8	HDL cholesterol;
CESC	cis	rs4319547	0.688	rs10847415	chr12:123144293	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.46	-5.3	-0.31	2.41e-7	Body mass index;
CESC	cis	rs5769765	0.862	rs9616386	chr22:50313179	G/A	cg26441486	chr22:50317300	CRELD2	0.41	5.22	0.31	3.7e-7	Schizophrenia;
CESC	cis	rs801193	0.548	rs2109297	chr7:66122384	G/A	cg18252515	chr7:66147081	NA	0.48	6.47	0.37	4.62e-10	Aortic root size;
CESC	cis	rs2637266	1.000	rs7897061	chr10:78366776	C/T	cg18941641	chr10:78392320	NA	0.42	7.81	0.43	1.33e-13	Pulmonary function;
CESC	cis	rs9811920	0.535	rs1610509	chr3:99474327	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.33	5.51	0.32	8.64e-8	Axial length;
CESC	cis	rs864537	0.676	rs2056625	chr1:167420299	G/A	cg09179987	chr1:167433047	CD247	0.51	7.7	0.43	2.67e-13	Celiac disease or Rheumatoid arthritis;Celiac disease;
CESC	cis	rs9527	0.545	rs7095304	chr10:104954795	G/A	cg04362960	chr10:104952993	NT5C2	0.45	5.71	0.33	2.98e-8	Arsenic metabolism;
CESC	cis	rs3820068	0.603	rs927207	chr1:15990552	A/G	cg13390004	chr1:15929781	NA	0.34	5.47	0.32	1.06e-7	Systolic blood pressure;
CESC	cis	rs9611565	0.512	rs139562	chr22:42196684	G/C	cg17376030	chr22:41985996	PMM1	0.79	8.45	0.46	1.91e-15	Vitiligo;
CESC	cis	rs634534	0.591	rs688862	chr11:65733393	A/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.39	5.56	0.32	6.45e-8	Sum eosinophil basophil counts;Eosinophil counts;
CESC	cis	rs6540559	0.673	rs6540564	chr1:210019910	T/C	cg22029157	chr1:209979665	IRF6	0.7	7.88	0.44	8.64e-14	Cleft lip with or without cleft palate;
CESC	cis	rs2228479	0.702	rs12600151	chr16:89831558	C/T	cg06558623	chr16:89946397	TCF25	1.17	9.29	0.5	5.84e-18	Skin colour saturation;
CESC	cis	rs709400	1.000	rs709400	chr14:104149475	A/G	cg12935359	chr14:103987150	CKB	-0.45	-6.04	-0.35	5.3e-9	Body mass index;
CESC	trans	rs4245128	0.896	rs2197687	chr11:112796111	G/A	cg10894232	chr8:11772343	NA	0.37	6.06	0.35	4.59e-9	Life satisfaction;
CESC	cis	rs35306767	0.855	rs11253468	chr10:903261	G/A	cg20503657	chr10:835505	NA	0.78	7.75	0.43	2.03e-13	Eosinophil percentage of granulocytes;
CESC	cis	rs10504073	0.647	rs62507252	chr8:50028795	C/G	cg00325661	chr8:49890786	NA	0.58	8.33	0.46	4.34e-15	Blood metabolite ratios;
CESC	cis	rs80130819	0.688	rs4760698	chr12:48592872	C/T	cg07561017	chr12:48398056	COL2A1	0.38	5.11	0.3	6.08e-7	Prostate cancer;
CESC	cis	rs4268898	0.662	rs56006260	chr2:24409903	A/G	cg20701182	chr2:24300061	SF3B14	0.69	6.93	0.39	3.27e-11	Asthma;
CESC	cis	rs12148488	0.816	rs11854975	chr15:75363876	C/T	cg09165964	chr15:75287851	SCAMP5	0.57	7.7	0.43	2.77e-13	Caffeine consumption;
CESC	cis	rs737337	0.623	rs12974173	chr19:11333359	A/T	cg00586551	chr19:11347513	LOC55908;DOCK6	0.52	5.41	0.32	1.37e-7	HDL cholesterol;HDL cholesterol levels;
CESC	cis	rs4862750	0.872	rs6553029	chr4:187876470	G/T	cg03452623	chr4:187889614	NA	0.86	13.69	0.64	1.28e-32	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1218582	0.710	rs4845687	chr1:154878911	A/G	cg03351412	chr1:154909251	PMVK	0.69	9.38	0.5	3.14e-18	Prostate cancer;
CESC	cis	rs617791	0.669	rs4994056	chr11:65750997	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.73	10.64	0.55	2.99e-22	Breast cancer;
CESC	cis	rs2294693	0.947	rs9296351	chr6:40988102	T/C	cg14769373	chr6:40998127	UNC5CL	-0.41	-5.8	-0.34	1.92e-8	Gastric cancer;Non-cardia gastric cancer;
CESC	cis	rs35123781	0.654	rs356484	chr5:139084438	T/A	cg10513866	chr5:139070639	NA	0.43	5.68	0.33	3.58e-8	Schizophrenia;
CESC	cis	rs7618915	0.547	rs1561337	chr3:52659963	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.5	7.2	0.4	6.26e-12	Bipolar disorder;
CESC	trans	rs116095464	0.558	rs62346506	chr5:201594	T/C	cg00938859	chr5:1591904	SDHAP3	0.62	6.01	0.35	6.17e-9	Breast cancer;
CESC	trans	rs916888	0.773	rs199439	chr17:44793503	A/G	cg04282206	chr17:62833786	PLEKHM1P	0.56	6.52	0.37	3.49e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22254072	chr15:89902185	NA	0.55	6.21	0.36	2.09e-9	Gut microbiome composition (summer);
CESC	cis	rs1552244	1.000	rs6791810	chr3:10124444	A/G	cg00166722	chr3:10149974	C3orf24	-0.48	-6.41	-0.37	6.52e-10	Alzheimer's disease;
CESC	cis	rs2243480	1.000	rs34974928	chr7:65364006	T/C	cg12463550	chr7:65579703	CRCP	0.69	5.62	0.33	4.79e-8	Diabetic kidney disease;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg09428031	chr4:48782361	FRYL	0.47	6.25	0.36	1.67e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs6502050	0.835	rs8075086	chr17:80092649	A/G	cg01763666	chr17:80159506	CCDC57	-0.37	-5.1	-0.3	6.55e-7	Life satisfaction;
CESC	cis	rs9896933	0.832	rs75552659	chr17:80804630	G/A	cg20578329	chr17:80767326	TBCD	-0.76	-8.07	-0.44	2.48e-14	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
CESC	cis	rs2228479	0.702	rs11646374	chr16:89857935	G/A	cg06558623	chr16:89946397	TCF25	1.18	9.48	0.5	1.49e-18	Skin colour saturation;
CESC	cis	rs10883723	0.810	rs7079810	chr10:104243883	C/T	cg22532475	chr10:104410764	TRIM8	-0.34	-5.92	-0.34	9.93e-9	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs2576037	0.583	rs680018	chr18:44409167	T/A	cg19077165	chr18:44547161	KATNAL2	-0.6	-9.05	-0.49	3.24e-17	Personality dimensions;
CESC	cis	rs4727027	0.736	rs12704084	chr7:148915050	C/G	cg23583168	chr7:148888333	NA	-0.93	-15.89	-0.7	2.13e-40	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs1552244	0.938	rs7647987	chr3:10140696	A/G	cg00149659	chr3:10157352	C3orf10	0.72	9.04	0.49	3.45e-17	Alzheimer's disease;
CESC	cis	rs7605827	0.930	rs9287663	chr2:15596076	T/G	cg19274914	chr2:15703543	NA	0.32	5.69	0.33	3.38e-8	Educational attainment (years of education);
CESC	cis	rs6693567	0.565	rs1260398	chr1:150279876	T/C	cg09579323	chr1:150459698	TARS2	-0.47	-5.99	-0.35	6.72e-9	Migraine;
CESC	cis	rs2651899	0.867	rs2742675	chr1:3079905	A/G	cg22674798	chr1:3096360	PRDM16	0.38	7.51	0.42	9.09e-13	Migraine;
CESC	cis	rs7762018	1.000	rs6459657	chr6:170136454	A/G	cg05834625	chr6:170176447	C6orf70	0.62	7.14	0.4	9.12e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs7100689	0.646	rs1340382	chr10:82096997	G/C	cg00277334	chr10:82204260	NA	-0.6	-7.96	-0.44	5.06e-14	Post bronchodilator FEV1;
CESC	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.49	-5.62	-0.33	4.81e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs9488822	0.676	rs11153593	chr6:116335131	C/A	cg05304507	chr6:116381966	FRK	0.25	6.58	0.37	2.52e-10	Cholesterol, total;LDL cholesterol;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07512676	chr17:48785330	ANKRD40	-0.54	-6.48	-0.37	4.56e-10	Gut microbiome composition (summer);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg17213946	chr1:43997516	PTPRF	-0.45	-6.23	-0.36	1.78e-9	Fibrinogen levels;
CESC	cis	rs881375	0.900	rs2241003	chr9:123666777	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.47	6.62	0.38	2.04e-10	Rheumatoid arthritis;
CESC	cis	rs7666738	0.791	rs10856934	chr4:99010844	A/G	cg03467027	chr4:99064603	C4orf37	-0.44	-5.6	-0.33	5.25e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11252926	0.502	rs7072510	chr10:455596	C/T	cg16386425	chr10:429943	DIP2C	-0.57	-7.4	-0.41	1.82e-12	Psychosis in Alzheimer's disease;
CESC	cis	rs9522267	0.559	rs9522300	chr13:112236668	C/G	cg10483660	chr13:112241077	NA	-0.33	-5.78	-0.33	2.14e-8	Hepatitis;
CESC	cis	rs2073300	0.609	rs1936011	chr20:23341912	G/C	cg16736954	chr20:23401023	NAPB	0.79	5.96	0.34	7.88e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs7100689	0.646	rs10788562	chr10:82072310	C/T	cg00277334	chr10:82204260	NA	0.6	8.02	0.44	3.53e-14	Post bronchodilator FEV1;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg15241786	chr6:33547978	BAK1	-0.42	-6.47	-0.37	4.79e-10	Fibrinogen levels;
CESC	cis	rs4141404	0.604	rs2103853	chr22:31855475	T/C	cg02404636	chr22:31891804	SFI1	0.36	5.06	0.3	7.7e-7	Paclitaxel-induced neuropathy;
CESC	cis	rs61776719	0.520	rs72661887	chr1:38416310	C/T	cg04673462	chr1:38461896	NA	0.38	5.85	0.34	1.45e-8	Coronary artery disease;
CESC	cis	rs10504229	1.000	rs55944282	chr8:58180821	A/G	cg24829409	chr8:58192753	C8orf71	-0.76	-10.0	-0.52	3.53e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs9300255	0.596	rs7304782	chr12:123719444	A/G	cg05973401	chr12:123451056	ABCB9	-0.46	-5.61	-0.33	5.05e-8	Neutrophil percentage of white cells;
CESC	cis	rs761746	0.960	rs7289075	chr22:32013745	T/C	cg25791279	chr22:32026902	PISD	0.57	6.69	0.38	1.33e-10	Intelligence;
CESC	cis	rs36051895	0.623	rs11506293	chr9:5257430	A/G	cg02405213	chr9:5042618	JAK2	-0.49	-5.58	-0.32	6.02e-8	Pediatric autoimmune diseases;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg23359706	chr19:11491839	EPOR	0.47	6.11	0.35	3.55e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs6800768	0.593	rs11129139	chr3:24146298	C/G	cg10674438	chr3:24145617	LOC152024	-0.46	-6.29	-0.36	1.34e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs11677416	0.961	rs3783557	chr2:113530712	C/T	cg27083787	chr2:113543245	IL1A	0.66	7.51	0.42	9.29e-13	Response to antipsychotic treatment in schizophrenia (working memory);
CESC	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg07157834	chr1:205819609	PM20D1	0.44	6.46	0.37	5.07e-10	Menarche (age at onset);
CESC	cis	rs7429990	0.930	rs7374516	chr3:48002640	T/C	cg11946769	chr3:48343235	NME6	0.44	5.28	0.31	2.7e-7	Educational attainment (years of education);
CESC	cis	rs854765	0.547	rs2955384	chr17:17939573	C/T	cg16928487	chr17:17741425	SREBF1	-0.5	-8.45	-0.46	2e-15	Total body bone mineral density;
CESC	cis	rs7264396	0.623	rs2590984	chr20:34597031	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-8.73	-0.47	2.94e-16	Total cholesterol levels;
CESC	cis	rs4713118	0.597	rs172166	chr6:28020820	C/G	cg19592336	chr6:28129416	ZNF389	0.53	6.78	0.38	7.77e-11	Parkinson's disease;
CESC	cis	rs7296418	0.961	rs949143	chr12:123595163	G/A	cg00376283	chr12:123451042	ABCB9	0.74	10.87	0.56	5.16e-23	Platelet count;
CESC	cis	rs9322193	0.923	rs9689716	chr6:149976798	G/A	cg07701084	chr6:150067640	NUP43	0.47	6.62	0.38	1.97e-10	Lung cancer;
CESC	cis	rs477692	0.544	rs7894836	chr10:131442595	T/A	cg05714579	chr10:131428358	MGMT	-0.68	-9.61	-0.51	6.06e-19	Response to temozolomide;
CESC	cis	rs7216064	1.000	rs7209675	chr17:65831258	A/T	cg12091567	chr17:66097778	LOC651250	-0.78	-8.84	-0.48	1.33e-16	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs7512552	0.809	rs9436112	chr1:150406449	A/C	cg15654264	chr1:150340011	RPRD2	0.4	5.3	0.31	2.4e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs6088580	0.634	rs4911422	chr20:32999345	T/C	cg06115741	chr20:33292138	TP53INP2	-0.46	-5.98	-0.34	7.28e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.54	-6.68	-0.38	1.42e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs11249608	0.789	rs1969025	chr5:178425192	A/G	cg01312482	chr5:178451176	ZNF879	-0.39	-5.2	-0.3	3.94e-7	Pubertal anthropometrics;
CESC	cis	rs853679	0.517	rs9368554	chr6:28082711	T/C	cg20151795	chr6:28129481	ZNF389	0.45	5.87	0.34	1.29e-8	Depression;
CESC	cis	rs12291225	0.585	rs11023197	chr11:14380998	G/A	cg19336497	chr11:14380999	RRAS2	-0.44	-6.56	-0.37	2.85e-10	Sense of smell;
CESC	cis	rs9868809	0.772	rs9811318	chr3:48702606	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.62	-5.36	-0.31	1.82e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CESC	trans	rs9951602	0.833	rs9953548	chr18:76640601	C/T	cg02800362	chr5:177631904	HNRNPAB	0.6	6.48	0.37	4.49e-10	Obesity-related traits;
CESC	cis	rs1801251	0.644	rs283473	chr2:233654847	A/G	cg25237894	chr2:233734115	C2orf82	0.36	6.16	0.35	2.74e-9	Coronary artery disease;
CESC	cis	rs5769765	0.865	rs9616369	chr22:50304591	A/C	cg26441486	chr22:50317300	CRELD2	0.4	5.38	0.31	1.64e-7	Schizophrenia;
CESC	cis	rs1670533	0.932	rs9992925	chr4:1050909	A/T	cg04106633	chr4:1044584	NA	0.4	5.09	0.3	6.77e-7	Recombination rate (females);
CESC	cis	rs9322193	0.847	rs12191643	chr6:149950048	C/T	cg02462569	chr6:150064036	NUP43	-0.34	-5.06	-0.3	7.74e-7	Lung cancer;
CESC	cis	rs854765	0.663	rs1108648	chr17:17750558	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.5	-6.88	-0.39	4.36e-11	Total body bone mineral density;
CESC	cis	rs1009170	0.794	rs61988399	chr14:92581494	T/C	cg10324096	chr14:92587714	CPSF2;NDUFB1	0.54	5.07	0.3	7.38e-7	Dialysis-related mortality;
CESC	cis	rs1153858	1.000	rs8032904	chr15:45651309	C/T	cg14582100	chr15:45693742	SPATA5L1	0.42	6.08	0.35	4.27e-9	Homoarginine levels;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg05537210	chr4:110650914	PLA2G12A	-0.46	-6.69	-0.38	1.34e-10	Fibrinogen levels;
CESC	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.89	13.59	0.64	2.72e-32	Prudent dietary pattern;
CESC	cis	rs4629180	1.000	rs4851457	chr2:102091220	C/T	cg04415270	chr2:102091202	RFX8	0.46	7.33	0.41	2.73e-12	Chronic rhinosinusitis with nasal polyps;
CESC	cis	rs62458065	0.513	rs7805536	chr7:32573570	T/C	cg20159608	chr7:32802032	NA	-0.55	-6.16	-0.35	2.74e-9	Metabolite levels (HVA/MHPG ratio);
CESC	cis	rs1878931	0.501	rs9921169	chr16:3421261	A/T	cg26668626	chr16:3451006	ZNF174;ZNF434	0.72	9.58	0.51	7.24e-19	Body mass index (adult);
CESC	cis	rs6121246	0.909	rs6089071	chr20:30378384	C/G	cg13852791	chr20:30311386	BCL2L1	0.84	9.06	0.49	2.91e-17	Mean corpuscular hemoglobin;
CESC	cis	rs3785574	0.962	rs2597632	chr17:61894739	A/T	cg07677032	chr17:61819896	STRADA	0.42	5.36	0.31	1.78e-7	Height;
CESC	trans	rs916888	0.773	rs199443	chr17:44819565	C/T	cg07870213	chr5:140052090	DND1	0.61	6.65	0.38	1.67e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs738322	0.967	rs132985	chr22:38563471	C/T	cg17652424	chr22:38574118	PLA2G6	-0.32	-5.65	-0.33	4.22e-8	Cutaneous nevi;
CESC	cis	rs1552244	1.000	rs68067759	chr3:10150535	T/C	cg00149659	chr3:10157352	C3orf10	0.73	8.83	0.48	1.44e-16	Alzheimer's disease;
CESC	cis	rs2228479	0.850	rs2238531	chr16:89856217	C/G	cg04013166	chr16:89971882	TCF25	0.78	6.67	0.38	1.44e-10	Skin colour saturation;
CESC	cis	rs60871478	0.947	rs62432862	chr7:807719	G/C	cg05535760	chr7:792225	HEATR2	0.88	11.01	0.56	1.78e-23	Cerebrospinal P-tau181p levels;
CESC	cis	rs13118159	0.742	rs34947293	chr4:1335034	T/C	cg19318889	chr4:1322082	MAEA	0.46	6.33	0.36	1.04e-9	Longevity;
CESC	cis	rs3733585	0.699	rs4515163	chr4:9959603	C/T	cg02734326	chr4:10020555	SLC2A9	-0.43	-6.01	-0.35	6.1e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs60871478	0.636	rs10245785	chr7:894422	T/C	cg05535760	chr7:792225	HEATR2	-0.77	-8.08	-0.44	2.33e-14	Cerebrospinal P-tau181p levels;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg01698708	chr1:28100000	STX12	0.51	6.65	0.38	1.64e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs2361718	0.500	rs4889970	chr17:78096086	C/T	cg27427491	chr17:78079615	GAA	0.4	5.75	0.33	2.52e-8	Yeast infection;
CESC	cis	rs7666738	0.830	rs34412187	chr4:99010454	A/G	cg03467027	chr4:99064603	C4orf37	0.44	5.63	0.33	4.57e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs34779708	0.966	rs2045918	chr10:35418517	T/G	cg04310649	chr10:35416472	CREM	-0.5	-6.04	-0.35	5.26e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs6502050	0.835	rs66932937	chr17:80116803	G/A	cg11859384	chr17:80120422	CCDC57	-0.38	-5.17	-0.3	4.51e-7	Life satisfaction;
CESC	cis	rs6951245	0.832	rs79808627	chr7:1092519	C/G	cg18402987	chr7:1209562	NA	0.65	6.69	0.38	1.36e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs1707322	0.785	rs10890348	chr1:46242423	G/T	cg03146154	chr1:46216737	IPP	0.81	11.14	0.56	6.92e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg27402845	chr11:1000533	AP2A2	0.52	7.29	0.41	3.61e-12	Fibrinogen levels;
CESC	cis	rs3096299	0.719	rs2911262	chr16:89515041	C/T	cg16743903	chr16:89593216	SPG7	-0.42	-5.4	-0.32	1.45e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs9549260	0.755	rs7986407	chr13:41179798	A/G	cg21288729	chr13:41239152	FOXO1	0.61	7.5	0.42	9.83e-13	Red blood cell count;
CESC	cis	rs9322193	0.639	rs4869756	chr6:150207496	G/A	cg01145232	chr6:150245071	RAET1G	0.5	6.24	0.36	1.75e-9	Lung cancer;
CESC	trans	rs2727020	0.521	rs4980445	chr11:49570183	C/T	cg15704280	chr7:45808275	SEPT13	-0.85	-10.47	-0.54	1.08e-21	Coronary artery disease;
CESC	cis	rs672059	0.513	rs627064	chr1:183165716	C/T	cg05929019	chr1:183155154	LAMC2	-0.29	-5.37	-0.31	1.71e-7	Hypertriglyceridemia;
CESC	cis	rs4665809	0.818	rs35413760	chr2:26267137	C/A	cg08470875	chr2:26401718	FAM59B	0.58	6.07	0.35	4.29e-9	Gut microbiome composition (summer);
CESC	trans	rs208520	0.690	rs12209753	chr6:66703951	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.95	12.6	0.61	7.7e-29	Exhaled nitric oxide output;
CESC	cis	rs4819052	0.851	rs9754134	chr21:46661751	T/C	cg11663144	chr21:46675770	NA	-0.63	-10.02	-0.52	3.12e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg14893161	chr1:205819251	PM20D1	-0.74	-12.94	-0.62	5.19e-30	Monocyte percentage of white cells;
CESC	cis	rs6121246	0.529	rs6058196	chr20:30194714	A/T	cg13852791	chr20:30311386	BCL2L1	0.58	5.56	0.32	6.65e-8	Mean corpuscular hemoglobin;
CESC	trans	rs1814175	0.559	rs1818892	chr11:49863084	C/A	cg03929089	chr4:120376271	NA	-0.9	-14.75	-0.67	2.44e-36	Height;
CESC	cis	rs4654899	0.833	rs10916919	chr1:21317524	A/G	cg05370193	chr1:21551575	ECE1	-0.42	-6.46	-0.37	5.05e-10	Superior frontal gyrus grey matter volume;
CESC	cis	rs1348850	0.526	rs6433672	chr2:178378175	G/T	cg23306229	chr2:178417860	TTC30B	0.75	6.84	0.39	5.47e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs9457247	1.000	rs386548	chr6:167385533	A/T	cg25258033	chr6:167368657	RNASET2	-0.38	-5.69	-0.33	3.39e-8	Crohn's disease;
CESC	cis	rs9311474	0.508	rs3796353	chr3:52593230	C/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.3	5.43	0.32	1.25e-7	Electroencephalogram traits;
CESC	cis	rs3796352	1.000	rs71301809	chr3:53090312	C/T	cg07884673	chr3:53033167	SFMBT1	0.68	5.79	0.34	1.99e-8	Immune reponse to smallpox (secreted IL-2);
CESC	cis	rs6582630	0.593	rs7134006	chr12:38596245	A/C	cg13010199	chr12:38710504	ALG10B	0.53	6.8	0.39	6.93e-11	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs2985684	1.000	rs1952012	chr14:50098896	T/A	cg15316458	chr14:50087796	RPL36AL;MGAT2	0.45	5.15	0.3	4.99e-7	Carotid intima media thickness;
CESC	cis	rs12956009	0.583	rs11082575	chr18:44905068	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.48	-5.85	-0.34	1.46e-8	Educational attainment (years of education);
CESC	cis	rs11958404	0.932	rs6870420	chr5:157437166	T/C	cg05962755	chr5:157440814	NA	0.62	6.66	0.38	1.57e-10	IgG glycosylation;
CESC	cis	rs55871839	0.708	rs1448541	chr8:59812938	G/A	cg07426533	chr8:59803705	TOX	-0.47	-7.01	-0.4	1.95e-11	Pneumonia;
CESC	cis	rs2842992	0.724	rs2273827	chr6:160211339	C/A	cg26839252	chr6:160211577	TCP1;MRPL18	0.49	6.15	0.35	2.83e-9	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs6570726	0.935	rs376991	chr6:145828073	G/C	cg23711669	chr6:146136114	FBXO30	0.8	12.02	0.59	7.3e-27	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1799949	1.000	rs8176120	chr17:41261233	C/T	cg06001716	chr17:41278141	BRCA1;NBR2	0.38	5.3	0.31	2.39e-7	Menopause (age at onset);
CESC	cis	rs6088580	0.634	rs4911153	chr20:32961547	C/T	cg24642439	chr20:33292090	TP53INP2	-0.52	-6.78	-0.38	7.87e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs7903847	0.642	rs4635018	chr10:99137839	C/G	cg20016023	chr10:99160130	RRP12	0.32	5.17	0.3	4.61e-7	Granulocyte percentage of myeloid white cells;
CESC	trans	rs8073060	0.544	rs225287	chr17:33929487	G/T	cg19694781	chr19:47549865	TMEM160	-0.72	-6.86	-0.39	4.73e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	cis	rs7605827	0.930	rs722327	chr2:15657263	T/A	cg19274914	chr2:15703543	NA	0.37	6.65	0.38	1.65e-10	Educational attainment (years of education);
CESC	cis	rs7107174	1.000	rs4944198	chr11:78032605	T/A	cg03754400	chr11:77348600	CLNS1A	0.45	5.15	0.3	5.15e-7	Testicular germ cell tumor;
CESC	cis	rs1008375	0.932	rs6841784	chr4:17626418	G/A	cg15017067	chr4:17643749	FAM184B	0.37	5.18	0.3	4.34e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs7208859	0.623	rs7223404	chr17:29107363	C/T	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.91e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs10883723	0.810	rs7912901	chr10:104277440	T/C	cg22532475	chr10:104410764	TRIM8	-0.33	-5.67	-0.33	3.77e-8	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs7246657	0.943	rs7248733	chr19:37996361	A/C	cg23950597	chr19:37808831	NA	-0.51	-5.73	-0.33	2.73e-8	Coronary artery calcification;
CESC	cis	rs4665809	1.000	rs6546736	chr2:26293878	C/T	cg04944784	chr2:26401820	FAM59B	0.61	7.12	0.4	1.01e-11	Gut microbiome composition (summer);
CESC	cis	rs9902453	0.904	rs4567782	chr17:28268800	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	9.16	0.49	1.49e-17	Coffee consumption (cups per day);
CESC	cis	rs875971	0.825	rs6951503	chr7:65718936	T/G	cg10691866	chr7:65817282	TPST1	0.33	5.52	0.32	8.14e-8	Aortic root size;
CESC	cis	rs7520050	0.898	rs4660885	chr1:46243756	C/T	cg03146154	chr1:46216737	IPP	-0.51	-6.64	-0.38	1.76e-10	Red blood cell count;Reticulocyte count;
CESC	cis	rs3091242	0.867	rs602052	chr1:25722206	T/C	cg12412775	chr1:25698385	RHCE	-0.31	-5.59	-0.32	5.76e-8	Erythrocyte sedimentation rate;
CESC	trans	rs17307778	1.000	rs1425830	chr11:25356679	G/A	cg22888484	chr20:37075185	SNHG11	-0.64	-6.22	-0.36	1.97e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs9487051	0.872	rs4601178	chr6:109611246	C/T	cg21918786	chr6:109611834	NA	-0.4	-6.07	-0.35	4.46e-9	Reticulocyte fraction of red cells;
CESC	cis	rs10504229	0.953	rs67886764	chr8:58187117	T/C	cg05313129	chr8:58192883	C8orf71	-0.55	-6.29	-0.36	1.34e-9	Developmental language disorder (linguistic errors);
CESC	trans	rs60843830	1.000	rs114976176	chr2:264621	A/C	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.66	8.22	0.45	9.37e-15	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs7659604	0.540	rs9995322	chr4:122675642	G/A	cg19671926	chr4:122722719	EXOSC9	0.53	6.7	0.38	1.21e-10	Type 2 diabetes;
CESC	cis	rs7666738	0.716	rs28792413	chr4:99083707	G/A	cg24818145	chr4:99064322	C4orf37	0.4	5.05	0.3	8.16e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7659604	0.628	rs3828485	chr4:122722368	G/A	cg06713675	chr4:122721982	EXOSC9	-0.51	-7.07	-0.4	1.37e-11	Type 2 diabetes;
CESC	cis	rs79349575	0.783	rs12602933	chr17:47029280	G/C	cg16584676	chr17:46985605	UBE2Z	0.54	6.67	0.38	1.46e-10	Type 2 diabetes;
CESC	trans	rs10463316	0.744	rs6579869	chr5:150763621	G/A	cg24389359	chr12:111284228	CCDC63	-0.33	-6.02	-0.35	5.68e-9	Metabolite levels (Pyroglutamine);
CESC	cis	rs514406	0.708	rs536621	chr1:53309097	A/G	cg08736216	chr1:53307985	ZYG11A	-0.4	-7.14	-0.4	8.92e-12	Monocyte count;
CESC	cis	rs7666738	0.830	rs3911282	chr4:99037602	T/A	cg03467027	chr4:99064603	C4orf37	0.47	5.97	0.34	7.51e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs12497850	1.000	rs4858831	chr3:48735558	C/T	cg07636037	chr3:49044803	WDR6	0.9	15.33	0.69	2.12e-38	Parkinson's disease;
CESC	cis	rs2637266	0.935	rs2579727	chr10:78395497	A/C	cg18941641	chr10:78392320	NA	0.45	8.6	0.47	7.12e-16	Pulmonary function;
CESC	cis	rs11642862	1.000	rs11641321	chr16:30880319	G/A	cg02466173	chr16:30829666	NA	-0.58	-5.67	-0.33	3.72e-8	Tonsillectomy;
CESC	cis	rs1552244	0.882	rs17081288	chr3:10042113	A/G	cg00149659	chr3:10157352	C3orf10	0.69	8.2	0.45	1.02e-14	Alzheimer's disease;
CESC	cis	rs12136530	0.625	rs4912090	chr1:19749402	C/T	cg01832549	chr1:19774989	CAPZB	0.43	6.3	0.36	1.21e-9	Lead levels in blood;
CESC	trans	rs4349753	0.617	rs10061660	chr5:144090021	A/G	cg22407458	chr6:35109121	TCP11	0.51	6.45	0.37	5.37e-10	Photic sneeze reflex;
CESC	cis	rs2952156	0.920	rs9675194	chr17:37833805	A/G	cg19468946	chr17:37922297	IKZF3	-0.44	-5.88	-0.34	1.24e-8	Asthma;
CESC	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg26338869	chr17:61819248	STRADA	-0.7	-9.29	-0.5	5.69e-18	Prudent dietary pattern;
CESC	cis	rs7072216	0.726	rs4474372	chr10:100164571	C/T	cg26618903	chr10:100175079	PYROXD2	-0.35	-5.33	-0.31	2.1e-7	Metabolite levels;
CESC	trans	rs884127	0.744	rs13374441	chr1:220073531	C/G	cg18635631	chr12:718175	NINJ2	0.49	6.08	0.35	4.07e-9	Urinary electrolytes (magnesium/calcium ratio);
CESC	cis	rs2011503	1.000	rs45556231	chr19:19654189	G/A	cg11584989	chr19:19387371	SF4	0.58	6.67	0.38	1.52e-10	Bipolar disorder;
CESC	cis	rs9287719	0.781	rs12472807	chr2:10781605	G/A	cg02196655	chr2:10830764	NOL10	-0.37	-5.66	-0.33	3.93e-8	Prostate cancer;
CESC	cis	rs4253772	0.591	rs739165	chr22:46684528	C/T	cg10541313	chr22:46663664	TTC38	0.76	5.66	0.33	3.95e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs7914558	1.000	rs7071373	chr10:104771922	A/G	cg15744005	chr10:104629667	AS3MT	-0.33	-5.5	-0.32	9.16e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs1799949	0.501	rs9675035	chr17:41415016	A/T	cg06001716	chr17:41278141	BRCA1;NBR2	0.38	5.13	0.3	5.72e-7	Menopause (age at onset);
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg14640751	chr11:111636595	PPP2R1B	0.47	6.28	0.36	1.38e-9	Systemic lupus erythematosus;
CESC	cis	rs854765	0.647	rs854763	chr17:18010095	C/G	cg04398451	chr17:18023971	MYO15A	-0.77	-11.15	-0.57	6.08e-24	Total body bone mineral density;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg26057283	chr7:73082469	VPS37D	-0.44	-6.23	-0.36	1.83e-9	Fibrinogen levels;
CESC	cis	rs9584850	0.834	rs12463	chr13:99105302	G/A	cg22223119	chr13:99095684	FARP1	-0.36	-5.21	-0.31	3.73e-7	Neuroticism;
CESC	cis	rs2228479	0.850	rs11647174	chr16:89958538	G/A	cg14709524	chr16:89940631	TCF25	0.87	6.44	0.37	5.45e-10	Skin colour saturation;
CESC	cis	rs144345632	1	rs144345632	chr6:96886894	T/TA	cg06623918	chr6:96969491	KIAA0776	-0.81	-8.29	-0.45	5.61e-15	Facial morphology (factor 17, height of vermillion upper lip);
CESC	cis	rs3096299	0.658	rs4291902	chr16:89560315	G/C	cg02187348	chr16:89574699	SPG7	0.65	9.14	0.49	1.67e-17	Multiple myeloma (IgH translocation);
CESC	cis	rs10992471	0.598	rs2025389	chr9:95157674	A/G	cg13798575	chr9:95087839	CENPP;NOL8	0.4	5.04	0.3	8.5e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CESC	cis	rs894344	0.584	rs2028556	chr8:135648040	T/C	cg27224718	chr8:135614730	ZFAT	0.42	5.48	0.32	9.71e-8	Systolic blood pressure;
CESC	cis	rs6460942	0.908	rs73677573	chr7:12283598	G/A	cg06484146	chr7:12443880	VWDE	-0.57	-6.01	-0.35	6.03e-9	Coronary artery disease;
CESC	cis	rs2228479	0.850	rs62054640	chr16:89823157	C/T	cg04013166	chr16:89971882	TCF25	0.77	6.66	0.38	1.58e-10	Skin colour saturation;
CESC	cis	rs12476592	0.543	rs262470	chr2:63830559	C/T	cg17519650	chr2:63277830	OTX1	-0.45	-5.12	-0.3	5.75e-7	Childhood ear infection;
CESC	cis	rs3785574	0.743	rs2727334	chr17:61969063	A/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.75	9.58	0.51	7.43e-19	Height;
CESC	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg22535103	chr8:58192502	C8orf71	-0.92	-10.16	-0.53	1.04e-20	Developmental language disorder (linguistic errors);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg02729269	chr16:127772	MPG	0.4	6.0	0.35	6.46e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs2302190	0.882	rs8073754	chr17:56618030	C/T	cg25885038	chr17:56607967	SEPT4	-0.42	-5.68	-0.33	3.52e-8	Vitamin D levels;
CESC	cis	rs7811142	1.000	rs7811142	chr7:100065443	A/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.07	10.37	0.54	2.23e-21	Platelet count;
CESC	cis	rs4727027	0.901	rs12671341	chr7:148805282	T/C	cg23583168	chr7:148888333	NA	-0.74	-10.71	-0.55	1.73e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07784212	chr3:47554384	C3orf75	-0.58	-6.52	-0.37	3.52e-10	Gut microbiome composition (summer);
CESC	cis	rs6539267	0.748	rs1921953	chr12:106721012	C/T	cg00173435	chr12:106696525	TCP11L2	0.51	6.0	0.35	6.6e-9	Tourette syndrome;
CESC	cis	rs1799949	1.000	rs11653460	chr17:41331306	C/T	cg23758822	chr17:41437982	NA	1.03	15.5	0.69	5.3e-39	Menopause (age at onset);
CESC	cis	rs1862618	0.756	rs13356762	chr5:56110992	G/T	cg24549020	chr5:56110836	MAP3K1	0.65	7.53	0.42	7.9e-13	Initial pursuit acceleration;
CESC	cis	rs9929218	0.953	rs34909703	chr16:68740097	T/C	cg02972257	chr16:68554789	NA	0.56	6.47	0.37	4.69e-10	Colorectal cancer;
CESC	cis	rs933688	1.000	rs2052553	chr5:90729906	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.01	13.73	0.64	8.84e-33	Smoking behavior;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg00884529	chr7:16685823	BZW2;ANKMY2	-0.45	-6.78	-0.38	7.64e-11	Gambling;
CESC	cis	rs9487051	0.676	rs1521905	chr6:109594515	T/C	cg21918786	chr6:109611834	NA	-0.37	-5.41	-0.32	1.39e-7	Reticulocyte fraction of red cells;
CESC	cis	rs7618915	0.547	rs34173654	chr3:52634605	T/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.56	0.37	2.79e-10	Bipolar disorder;
CESC	cis	rs2481665	1.000	rs2481665	chr1:62594677	T/C	cg18591186	chr1:62594603	INADL	-0.6	-7.1	-0.4	1.13e-11	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs10504229	0.679	rs11783444	chr8:58131267	A/G	cg24829409	chr8:58192753	C8orf71	-0.58	-7.2	-0.4	6.31e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs8072100	0.840	rs11079774	chr17:45479706	C/G	cg08085267	chr17:45401833	C17orf57	-0.53	-7.1	-0.4	1.13e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs10504229	0.639	rs67002486	chr8:58117218	A/G	cg21724239	chr8:58056113	NA	0.58	5.95	0.34	8.29e-9	Developmental language disorder (linguistic errors);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg20459655	chr2:135675569	CCNT2	-0.41	-6.03	-0.35	5.56e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs853679	0.517	rs4713145	chr6:28106827	T/C	cg19592336	chr6:28129416	ZNF389	0.61	8.25	0.45	7.45e-15	Depression;
CESC	cis	rs12541635	0.677	rs1817939	chr8:107029820	A/G	cg10147462	chr8:107024639	NA	0.47	7.14	0.4	8.95e-12	Age of smoking initiation;
CESC	cis	rs9300255	0.602	rs1790095	chr12:123681222	G/A	cg00376283	chr12:123451042	ABCB9	0.71	8.76	0.47	2.39e-16	Neutrophil percentage of white cells;
CESC	cis	rs2267137	0.776	rs2267145	chr22:29805407	C/T	cg07256473	chr22:29710276	RASL10A	-0.38	-5.53	-0.32	7.55e-8	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	cis	rs9916302	0.904	rs8065963	chr17:37681332	C/T	cg20243544	chr17:37824526	PNMT	0.52	6.58	0.37	2.56e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs7250872	0.647	rs2304612	chr19:1817866	A/G	cg05970437	chr19:1864622	KLF16	-0.47	-5.57	-0.32	6.26e-8	Bipolar disorder;
CESC	cis	rs28830936	1.000	rs17734856	chr15:42045160	T/C	cg11010575	chr15:42129464	JMJD7-PLA2G4B;JMJD7	-0.42	-5.86	-0.34	1.39e-8	Diastolic blood pressure;
CESC	cis	rs17253792	0.822	rs118027213	chr14:56039076	T/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.84	5.73	0.33	2.76e-8	Putamen volume;
CESC	cis	rs6541297	1.000	rs11122405	chr1:230282997	C/A	cg20703242	chr1:230279135	GALNT2	0.73	11.17	0.57	5.58e-24	Coronary artery disease;
CESC	cis	rs7412746	0.634	rs3754212	chr1:150738200	A/G	cg04414720	chr1:150670196	GOLPH3L	0.58	7.57	0.42	6.07e-13	Melanoma;
CESC	cis	rs9911578	1.000	rs9901181	chr17:56964271	C/T	cg12560992	chr17:57184187	TRIM37	0.94	15.62	0.69	1.92e-39	Intelligence (multi-trait analysis);
CESC	cis	rs12541635	0.677	rs10086055	chr8:107024129	C/T	cg10147462	chr8:107024639	NA	0.43	6.45	0.37	5.42e-10	Age of smoking initiation;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg27405321	chr20:34359917	PHF20	-0.42	-6.08	-0.35	4.23e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs2576037	0.526	rs605487	chr18:44444778	G/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.41	6.74	0.38	9.73e-11	Personality dimensions;
CESC	cis	rs1018836	0.851	rs6986359	chr8:91643162	A/G	cg16814680	chr8:91681699	NA	-0.71	-10.7	-0.55	1.89e-22	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs921968	0.643	rs711191	chr2:219386084	T/A	cg02176678	chr2:219576539	TTLL4	0.43	7.74	0.43	2.13e-13	Mean corpuscular hemoglobin concentration;
CESC	trans	rs9693444	0.898	rs4732697	chr8:29519861	A/G	cg23709988	chr14:23772096	PPP1R3E	-0.42	-6.34	-0.36	9.84e-10	Breast cancer;
CESC	trans	rs6089829	0.926	rs1060489	chr20:61665921	C/T	cg23505145	chr19:12996616	KLF1	0.52	6.82	0.39	6.11e-11	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs748404	0.578	rs507178	chr15:43610135	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.55	8.75	0.47	2.5e-16	Lung cancer;
CESC	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg02071572	chr4:1403502	NA	0.38	5.51	0.32	8.58e-8	Longevity;
CESC	cis	rs2522056	0.808	rs7704457	chr5:131744790	C/T	cg24060327	chr5:131705240	SLC22A5	-0.62	-6.84	-0.39	5.55e-11	Lymphocyte counts;Fibrinogen;
CESC	cis	rs7666738	0.830	rs969049	chr4:98988857	C/T	cg18180107	chr4:99064573	C4orf37	0.4	5.2	0.3	3.92e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs57221529	0.766	rs72703070	chr5:590458	T/C	cg16447950	chr5:562315	NA	-0.58	-6.05	-0.35	4.93e-9	Lung disease severity in cystic fibrosis;
CESC	cis	rs3857067	0.806	rs2865343	chr4:95103005	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.61	-9.07	-0.49	2.67e-17	QT interval;
CESC	cis	rs2635047	0.904	rs2635046	chr18:44728429	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.44	6.06	0.35	4.58e-9	Educational attainment;
CESC	cis	rs5758659	0.652	rs133314	chr22:42401841	G/A	cg15557168	chr22:42548783	NA	-0.42	-6.17	-0.35	2.52e-9	Cognitive function;
CESC	cis	rs7666738	0.830	rs11097582	chr4:98772201	G/A	cg05340658	chr4:99064831	C4orf37	0.77	11.6	0.58	2.01e-25	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9549367	0.756	rs2302756	chr13:113900197	G/A	cg00898013	chr13:113819073	PROZ	0.54	7.48	0.42	1.09e-12	Platelet distribution width;
CESC	cis	rs763014	0.966	rs15564	chr16:677854	G/T	cg00802000	chr16:706648	WDR90	-0.4	-6.15	-0.35	2.8e-9	Height;
CESC	cis	rs4601790	0.601	rs12801636	chr11:65391317	C/T	cg21033440	chr11:65409861	SIPA1	-0.41	-5.37	-0.31	1.74e-7	Blood pressure (age interaction);
CESC	cis	rs3126085	0.935	rs2338430	chr1:152214420	C/T	cg03465714	chr1:152285911	FLG	0.42	5.09	0.3	6.89e-7	Atopic dermatitis;
CESC	trans	rs3942852	0.622	rs6485806	chr11:48102806	A/G	cg15704280	chr7:45808275	SEPT13	0.63	7.54	0.42	7.59e-13	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs7927771	0.832	rs10838704	chr11:47424717	T/C	cg20307385	chr11:47447363	PSMC3	-0.65	-7.78	-0.43	1.67e-13	Subjective well-being;
CESC	cis	rs12497850	0.829	rs12636030	chr3:49182237	A/G	cg06212747	chr3:49208901	KLHDC8B	0.74	9.74	0.51	2.27e-19	Parkinson's disease;
CESC	cis	rs9487051	0.872	rs1320612	chr6:109611990	C/A	cg01475377	chr6:109611718	NA	-0.52	-8.68	-0.47	4.14e-16	Reticulocyte fraction of red cells;
CESC	cis	rs9929218	0.954	rs7186333	chr16:68815838	T/A	cg02972257	chr16:68554789	NA	0.47	5.85	0.34	1.42e-8	Colorectal cancer;
CESC	cis	rs6087771	0.662	rs6058298	chr20:30247916	C/T	cg13852791	chr20:30311386	BCL2L1	0.77	9.79	0.52	1.66e-19	Subcortical brain region volumes;Putamen volume;
CESC	cis	rs6582630	0.576	rs2387837	chr12:38403164	G/T	cg26384229	chr12:38710491	ALG10B	-0.46	-6.2	-0.36	2.14e-9	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs936229	0.651	rs12908814	chr15:75132490	C/G	cg14664628	chr15:75095509	CSK	-0.55	-7.24	-0.41	5.01e-12	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CESC	cis	rs7666738	0.830	rs28444709	chr4:99028496	A/T	cg17366294	chr4:99064904	C4orf37	0.62	8.95	0.48	6.32e-17	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9611565	0.659	rs4822036	chr22:41936019	A/G	cg06481639	chr22:41940642	POLR3H	-0.61	-6.46	-0.37	4.88e-10	Vitiligo;
CESC	cis	rs11077998	0.967	rs7350963	chr17:80491067	G/A	cg10255544	chr17:80519551	FOXK2	0.55	8.94	0.48	6.67e-17	Reticulocyte fraction of red cells;
CESC	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.88	13.32	0.63	2.41e-31	Prudent dietary pattern;
CESC	cis	rs1536827	0.841	rs10857733	chr10:135332803	G/A	cg18984983	chr10:135342936	CYP2E1	0.54	5.43	0.32	1.3e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CESC	cis	rs6942756	0.876	rs822040	chr7:129065922	C/G	cg02491457	chr7:128862824	NA	0.51	6.93	0.39	3.16e-11	White matter hyperintensity burden;
CESC	cis	rs10504073	0.669	rs341801	chr8:50037784	A/G	cg00325661	chr8:49890786	NA	0.5	7.28	0.41	3.89e-12	Blood metabolite ratios;
CESC	cis	rs17125944	0.505	rs76219229	chr14:53178346	G/A	cg13660082	chr14:53194042	PSMC6	-0.64	-5.97	-0.34	7.46e-9	Alzheimer's disease (late onset);
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg07080049	chr9:96214194	FAM120A;FAM120AOS	0.52	6.85	0.39	5.22e-11	Systemic lupus erythematosus;
CESC	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg07519011	chr13:76056421	TBC1D4	0.46	6.14	0.35	3.06e-9	Myopia (pathological);
CESC	cis	rs72781680	0.752	rs72796110	chr2:23905658	T/A	cg20701182	chr2:24300061	SF3B14	0.79	6.83	0.39	5.68e-11	Lymphocyte counts;
CESC	cis	rs1799949	1.000	rs4793191	chr17:41204377	A/G	cg23758822	chr17:41437982	NA	1.0	14.95	0.68	4.7e-37	Menopause (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12508534	chr6:34855789	TAF11;ANKS1A	0.67	7.94	0.44	5.62e-14	Gut microbiome composition (summer);
CESC	cis	rs10751667	0.666	rs10902239	chr11:946484	A/G	cg06064525	chr11:970664	AP2A2	0.48	9.46	0.5	1.78e-18	Alzheimer's disease (late onset);
CESC	cis	rs9322193	0.962	rs1889473	chr6:150146621	C/G	cg07701084	chr6:150067640	NUP43	0.42	5.88	0.34	1.21e-8	Lung cancer;
CESC	cis	rs7666738	0.830	rs6532724	chr4:99060993	C/T	cg03467027	chr4:99064603	C4orf37	0.48	5.98	0.35	7.05e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1483890	0.723	rs13075664	chr3:69411365	G/A	cg22125112	chr3:69402811	FRMD4B	0.39	5.24	0.31	3.3e-7	Resting heart rate;
CESC	cis	rs11122272	0.735	rs11122280	chr1:231519816	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.54	-7.21	-0.4	5.96e-12	Hemoglobin concentration;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18960028	chr11:75526075	UVRAG	0.55	6.47	0.37	4.59e-10	Gut microbiome composition (summer);
CESC	cis	rs35110281	0.748	rs2838324	chr21:44999820	T/C	cg21573476	chr21:45109991	RRP1B	-0.45	-6.28	-0.36	1.34e-9	Mean corpuscular volume;
CESC	cis	rs9611565	0.559	rs1006407	chr22:41972032	T/C	cg06481639	chr22:41940642	POLR3H	-0.68	-6.74	-0.38	9.96e-11	Vitiligo;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08369870	chr16:70323412	AARS	-0.54	-6.57	-0.37	2.63e-10	Gut microbiome composition (summer);
CESC	trans	rs875971	0.638	rs7793569	chr7:66116633	T/G	cg26939375	chr7:64535504	NA	-0.64	-8.57	-0.47	8.53e-16	Aortic root size;
CESC	cis	rs1832871	0.672	rs6933928	chr6:158747071	C/T	cg07165851	chr6:158734300	TULP4	0.59	6.41	0.37	6.63e-10	Height;
CESC	cis	rs11608355	0.515	rs11613718	chr12:109912332	C/T	cg05360138	chr12:110035743	NA	0.81	8.75	0.47	2.52e-16	Neuroticism;
CESC	cis	rs7833986	0.501	rs17814658	chr8:56989130	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.62	7.54	0.42	7.58e-13	Height;
CESC	cis	rs4409675	0.576	rs7535816	chr1:28234054	A/G	cg23691781	chr1:28212827	C1orf38	0.28	5.45	0.32	1.17e-7	Corneal astigmatism;
CESC	cis	rs763121	0.853	rs5750630	chr22:38985818	A/C	cg06544989	chr22:39130855	UNC84B	0.5	8.31	0.45	5.07e-15	Menopause (age at onset);
CESC	cis	rs4665809	0.887	rs2384324	chr2:26354239	A/G	cg27170947	chr2:26402098	FAM59B	-0.7	-8.2	-0.45	1.05e-14	Gut microbiome composition (summer);
CESC	cis	rs6060717	0.536	rs6058356	chr20:34491530	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-6.2	-0.36	2.13e-9	Hip circumference adjusted for BMI;
CESC	cis	rs2302190	0.769	rs8082396	chr17:56632193	C/T	cg25885038	chr17:56607967	SEPT4	-0.41	-5.38	-0.31	1.63e-7	Vitamin D levels;
CESC	cis	rs6519955	0.860	rs8136098	chr22:46425646	A/G	cg05468064	chr22:46423449	NA	0.44	7.07	0.4	1.34e-11	Dupuytren's disease;
CESC	cis	rs1878931	0.501	rs17136359	chr16:3420814	C/T	cg22508957	chr16:3507546	NAT15	0.39	5.66	0.33	3.92e-8	Body mass index (adult);
CESC	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg03188948	chr7:1209495	NA	0.71	7.06	0.4	1.5e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.63	7.17	0.4	7.57e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs11822910	0.737	rs2581924	chr11:57208468	C/T	cg00522883	chr11:57194120	SLC43A3	0.54	6.93	0.39	3.28e-11	Platelet distribution width;
CESC	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	7.7	0.43	2.77e-13	Prudent dietary pattern;
CESC	cis	rs4132509	1.000	rs4132509	chr1:243943084	A/C	cg21452805	chr1:244014465	NA	-0.54	-6.7	-0.38	1.26e-10	RR interval (heart rate);
CESC	trans	rs561341	1.000	rs55978022	chr17:30275937	T/C	cg27661571	chr11:113659931	NA	-0.88	-8.06	-0.44	2.59e-14	Hip circumference adjusted for BMI;
CESC	cis	rs4862750	0.872	rs7664463	chr4:187876686	A/C	cg03647317	chr4:187891568	NA	-0.44	-6.55	-0.37	3.01e-10	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg03217964	chr16:75182191	ZFP1	-0.45	-6.57	-0.37	2.6200000000000003e-10	Gambling;
CESC	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.93	14.13	0.66	3.66e-34	Prudent dietary pattern;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg02238950	chr17:1505303	SLC43A2	0.46	6.25	0.36	1.65e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs763014	0.931	rs7192508	chr16:630367	C/T	cg07256732	chr16:621771	PIGQ	-0.3	-5.13	-0.3	5.63e-7	Height;
CESC	cis	rs656900	0.874	rs584055	chr15:80126521	A/T	cg02196730	chr15:80188777	MTHFS	-0.42	-5.44	-0.32	1.19e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs6912958	0.512	rs910563	chr6:88058885	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.72	10.81	0.55	8.16e-23	Monocyte percentage of white cells;
CESC	cis	rs782590	0.774	rs782630	chr2:55899425	T/C	cg18811423	chr2:55921094	PNPT1	0.78	12.9	0.62	7e-30	Metabolic syndrome;
CESC	cis	rs9640161	0.789	rs3735172	chr7:150028958	C/T	cg13722127	chr7:150037890	RARRES2	-0.36	-5.46	-0.32	1.09e-7	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs7631605	0.905	rs7622170	chr3:37016576	T/C	cg22985146	chr3:37219077	LRRFIP2	-0.33	-5.09	-0.3	6.91e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs10752881	1.000	rs12035773	chr1:182985716	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.84	13.3	0.63	2.79e-31	Colorectal cancer;
CESC	cis	rs6540556	0.954	rs654984	chr1:209937382	C/T	cg05527609	chr1:210001259	C1orf107	0.51	6.44	0.37	5.46e-10	Red blood cell count;
CESC	cis	rs4969178	0.965	rs938350	chr17:76399552	C/T	cg20026190	chr17:76395443	PGS1	0.47	7.44	0.42	1.45e-12	HDL cholesterol levels;
CESC	cis	rs3820068	0.705	rs57440988	chr1:15879034	T/C	cg18192808	chr1:15853278	DNAJC16	0.44	5.34	0.31	2.03e-7	Systolic blood pressure;
CESC	cis	rs7107174	1.000	rs2512547	chr11:77960888	T/C	cg02023728	chr11:77925099	USP35	0.43	5.97	0.34	7.44e-9	Testicular germ cell tumor;
CESC	cis	rs514406	0.505	rs6703127	chr1:53180565	C/T	cg08859206	chr1:53392774	SCP2	-0.54	-7.25	-0.41	4.66e-12	Monocyte count;
CESC	cis	rs7772486	0.701	rs697056	chr6:146003897	C/T	cg23711669	chr6:146136114	FBXO30	-1.03	-15.36	-0.69	1.63e-38	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7208859	0.673	rs9895815	chr17:29138033	A/G	cg14008862	chr17:28927542	LRRC37B2	0.65	5.14	0.3	5.34e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs920590	0.758	rs7011322	chr8:19661937	C/T	cg03894339	chr8:19674705	INTS10	0.63	7.26	0.41	4.24e-12	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs1005277	0.579	rs2472183	chr10:38392495	T/G	cg25517755	chr10:38738941	LOC399744	-0.47	-6.04	-0.35	5.12e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs7666738	0.618	rs10856932	chr4:98819992	C/T	cg05340658	chr4:99064831	C4orf37	0.73	10.49	0.54	9.13e-22	Colonoscopy-negative controls vs population controls;
CESC	cis	rs514406	0.505	rs12726160	chr1:53175099	A/G	cg27535305	chr1:53392650	SCP2	-0.33	-5.57	-0.32	6.32e-8	Monocyte count;
CESC	cis	rs7811142	1.000	rs11766752	chr7:100073292	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.83	8.32	0.46	4.56e-15	Platelet count;
CESC	cis	rs4132509	1.000	rs10927078	chr1:243983830	C/T	cg21452805	chr1:244014465	NA	0.5	5.65	0.33	4.07e-8	RR interval (heart rate);
CESC	cis	rs7666738	0.716	rs2865982	chr4:99031661	T/G	cg18180107	chr4:99064573	C4orf37	0.42	5.43	0.32	1.29e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs722599	0.748	rs61978948	chr14:75363369	G/A	cg00095594	chr1:236228625	NID1	-0.4	-6.14	-0.35	2.93e-9	IgG glycosylation;
CESC	cis	rs8028182	0.636	rs8028277	chr15:75684085	A/G	cg20655648	chr15:75932815	IMP3	0.46	5.85	0.34	1.41e-8	Sudden cardiac arrest;
CESC	trans	rs11191205	0.644	rs3095791	chr10:103383836	T/C	cg12418535	chr2:119607192	EN1	-0.4	-6.0	-0.35	6.56e-9	Intelligence (multi-trait analysis);
CESC	cis	rs7666738	0.512	rs6532704	chr4:98777562	C/T	cg05340658	chr4:99064831	C4orf37	0.52	6.88	0.39	4.36e-11	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9911578	1.000	rs2531729	chr17:56539890	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.41	5.41	0.32	1.38e-7	Intelligence (multi-trait analysis);
CESC	cis	rs7615952	0.932	rs13321217	chr3:125631771	G/A	cg05084668	chr3:125655381	ALG1L	-0.42	-5.13	-0.3	5.73e-7	Blood pressure (smoking interaction);
CESC	cis	rs10504229	0.953	rs2270610	chr8:58194669	A/G	cg22535103	chr8:58192502	C8orf71	-1.08	-13.7	-0.64	1.19e-32	Developmental language disorder (linguistic errors);
CESC	cis	rs12477438	0.501	rs6708878	chr2:99801564	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.75	12.51	0.61	1.6e-28	Chronic sinus infection;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg06876404	chr16:30941527	FBXL19	0.5	6.51	0.37	3.66e-10	Fibrinogen levels;
CESC	cis	rs9583531	0.600	rs4773240	chr13:111360585	G/A	cg24331049	chr13:111365604	ING1	0.75	10.98	0.56	2.28e-23	Coronary artery disease;
CESC	cis	rs2932538	0.922	rs2932535	chr1:113201412	G/C	cg22162597	chr1:113214053	CAPZA1	-0.58	-7.44	-0.42	1.39e-12	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CESC	cis	rs6087990	0.735	rs6119946	chr20:31329704	A/G	cg13636640	chr20:31349939	DNMT3B	-0.76	-12.2	-0.6	1.75e-27	Ulcerative colitis;
CESC	cis	rs6461049	0.765	rs4719431	chr7:2140312	T/C	cg21782813	chr7:2030301	MAD1L1	0.4	5.72	0.33	2.89e-8	Schizophrenia;
CESC	cis	rs9902453	0.967	rs3813034	chr17:28524804	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	7.85	0.43	1.01e-13	Coffee consumption (cups per day);
CESC	trans	rs62103177	0.810	rs62103191	chr18:77628769	C/G	cg05926928	chr17:57297772	GDPD1	1.18	10.14	0.53	1.27e-20	Opioid sensitivity;
CESC	cis	rs7666738	0.830	rs7687315	chr4:98900613	A/G	cg05340658	chr4:99064831	C4orf37	0.76	11.12	0.56	7.61e-24	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2932538	0.922	rs6537745	chr1:113154080	T/C	cg22162597	chr1:113214053	CAPZA1	0.5	6.58	0.37	2.52e-10	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CESC	cis	rs8058578	1.000	rs8048448	chr16:30692208	T/C	cg00531865	chr16:30841666	NA	-0.44	-5.97	-0.34	7.41e-9	Multiple myeloma;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19429466	chr4:87515395	PTPN13	0.56	6.62	0.38	1.94e-10	Gut microbiome composition (summer);
CESC	cis	rs12824058	0.831	rs12322456	chr12:130813594	A/G	cg24838063	chr12:130822603	PIWIL1	0.64	8.76	0.47	2.33e-16	Menopause (age at onset);
CESC	cis	rs2645694	0.911	rs2703147	chr4:77831307	C/T	cg18351406	chr4:77819688	ANKRD56	0.49	5.92	0.34	1e-8	Emphysema distribution in smoking;
CESC	cis	rs12824058	0.831	rs7299065	chr12:130809661	A/T	cg24838063	chr12:130822603	PIWIL1	0.62	8.55	0.47	9.78e-16	Menopause (age at onset);
CESC	cis	rs10465746	0.714	rs12730621	chr1:84433745	C/G	cg10977910	chr1:84465055	TTLL7	0.52	7.13	0.4	9.46e-12	Obesity-related traits;
CESC	cis	rs9287719	0.967	rs12464817	chr2:10707212	A/G	cg00105475	chr2:10696890	NA	0.39	5.71	0.33	3.1e-8	Prostate cancer;
CESC	cis	rs1506636	1.000	rs2896332	chr7:123297223	A/T	cg03229431	chr7:123269106	ASB15	-0.53	-6.87	-0.39	4.64e-11	Plateletcrit;Platelet count;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg17928916	chr17:80041824	FASN	0.51	7.22	0.41	5.46e-12	Fibrinogen levels;
CESC	cis	rs2839186	0.814	rs12482209	chr21:47664275	C/G	cg11766577	chr21:47581405	C21orf56	0.45	6.07	0.35	4.4e-9	Testicular germ cell tumor;
CESC	cis	rs13191362	1.000	rs13204439	chr6:163015358	A/C	cg21926612	chr6:163149169	PACRG;PARK2	-0.81	-8.93	-0.48	7.22e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs12541335	0.639	rs35068739	chr8:22201719	T/C	cg18135555	chr8:22132992	PIWIL2	0.24	5.3	0.31	2.47e-7	Hypertriglyceridemia;
CESC	cis	rs57221529	0.766	rs4527146	chr5:555236	A/G	cg09021430	chr5:549028	NA	-0.43	-5.43	-0.32	1.25e-7	Lung disease severity in cystic fibrosis;
CESC	cis	rs4253772	0.591	rs11703848	chr22:46685131	A/G	cg00784671	chr22:46762841	CELSR1	-0.57	-5.5	-0.32	8.75e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg26338869	chr17:61819248	STRADA	0.71	9.3	0.5	5.44e-18	Prudent dietary pattern;
CESC	cis	rs12497850	0.931	rs9867373	chr3:48960938	A/T	cg02487422	chr3:49467188	NICN1	0.4	5.2	0.3	4.08e-7	Parkinson's disease;
CESC	cis	rs7264396	0.563	rs6060566	chr20:34288226	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.64	6.87	0.39	4.47e-11	Total cholesterol levels;
CESC	cis	rs1879734	0.773	rs6658469	chr1:54133345	C/A	cg23596471	chr1:54105337	GLIS1	0.38	6.01	0.35	6.05e-9	Mitral valve prolapse;
CESC	cis	rs6831352	0.734	rs2851259	chr4:100033986	C/T	cg12011299	chr4:100065546	ADH4	0.57	6.88	0.39	4.34e-11	Alcohol dependence;
CESC	cis	rs6991838	0.556	rs7846527	chr8:66498757	A/G	cg13398993	chr8:66546079	ARMC1	-0.48	-5.76	-0.33	2.37e-8	Intelligence (multi-trait analysis);
CESC	cis	rs863345	0.604	rs2873595	chr1:158508382	G/T	cg12129480	chr1:158549410	OR10X1	-0.35	-7.03	-0.4	1.78e-11	Pneumococcal bacteremia;
CESC	cis	rs858239	0.537	rs10279691	chr7:23228387	A/G	cg23682824	chr7:23144976	KLHL7	0.45	5.85	0.34	1.46e-8	Cerebrospinal fluid biomarker levels;
CESC	cis	rs7917772	0.636	rs4919674	chr10:104522226	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.45	-5.28	-0.31	2.64e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs1018836	0.892	rs10103198	chr8:91579436	A/T	cg16814680	chr8:91681699	NA	-0.59	-8.33	-0.46	4.42e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs13108904	0.901	rs2293634	chr4:1291711	T/G	cg16405210	chr4:1374714	KIAA1530	-0.5	-6.29	-0.36	1.33e-9	Obesity-related traits;
CESC	cis	rs7618501	0.699	rs2681781	chr3:49898273	A/G	cg24308560	chr3:49941425	MST1R	-0.69	-10.31	-0.54	3.58e-21	Intelligence (multi-trait analysis);
CESC	cis	rs6502050	0.835	rs7503189	chr17:80099486	C/A	cg11859384	chr17:80120422	CCDC57	-0.38	-5.11	-0.3	6.21e-7	Life satisfaction;
CESC	cis	rs7866350	0.604	rs1935389	chr9:100994470	A/G	cg24393316	chr9:100616469	FOXE1	-0.38	-5.53	-0.32	7.66e-8	Post-traumatic stress disorder;
CESC	cis	rs9902453	0.791	rs55655651	chr17:28244286	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.65	8.2	0.45	1.05e-14	Coffee consumption (cups per day);
CESC	cis	rs72781680	0.611	rs55868657	chr2:24295385	G/A	cg06627628	chr2:24431161	ITSN2	-0.67	-6.48	-0.37	4.54e-10	Lymphocyte counts;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26770385	chr8:125486821	RNF139	0.61	6.82	0.39	6.31e-11	Gut microbiome composition (summer);
CESC	cis	rs9399135	0.967	rs10872427	chr6:135353452	T/C	cg24558204	chr6:135376177	HBS1L	0.52	7.2	0.4	6.25e-12	Red blood cell count;
CESC	cis	rs4665809	1.000	rs10202478	chr2:26276049	T/C	cg04944784	chr2:26401820	FAM59B	-0.74	-8.28	-0.45	6.01e-15	Gut microbiome composition (summer);
CESC	cis	rs11190604	1.000	rs7079756	chr10:102302105	G/A	cg07080220	chr10:102295463	HIF1AN	0.56	5.42	0.32	1.35e-7	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs6572548	0.504	rs1956082	chr14:49665496	A/C	cg16537350	chr14:50329699	NA	-0.55	-6.08	-0.35	4.26e-9	Subjective well-being;
CESC	cis	rs826838	0.967	rs1684415	chr12:39130099	T/C	cg13010199	chr12:38710504	ALG10B	-0.45	-6.26	-0.36	1.51e-9	Heart rate;
CESC	cis	rs4253772	0.530	rs55653327	chr22:46682976	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.67	5.3	0.31	2.43e-7	LDL cholesterol;Cholesterol, total;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg23365392	chr7:99970074	PILRA	0.36	6.41	0.37	6.78e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs9768139	0.708	rs896782	chr7:158114115	G/A	cg24154853	chr7:158122151	PTPRN2	0.41	6.43	0.37	5.97e-10	Calcium levels;
CESC	cis	rs875971	0.862	rs6964437	chr7:65686444	A/G	cg19163074	chr7:65112434	INTS4L2	0.44	5.53	0.32	7.83e-8	Aortic root size;
CESC	cis	rs597539	0.690	rs497149	chr11:68626639	A/T	cg21963583	chr11:68658836	MRPL21	0.42	5.72	0.33	2.89e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs4835473	0.932	rs13121861	chr4:144735160	C/T	cg25736465	chr4:144833511	NA	-0.33	-5.35	-0.31	1.92e-7	Immature fraction of reticulocytes;
CESC	cis	rs17376456	0.877	rs17316137	chr5:93456577	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.6	5.23	0.31	3.51e-7	Diabetic retinopathy;
CESC	cis	rs36051895	0.623	rs3780383	chr9:5232409	G/C	cg02405213	chr9:5042618	JAK2	-0.58	-6.32	-0.36	1.12e-9	Pediatric autoimmune diseases;
CESC	cis	rs4253772	0.688	rs113928699	chr22:46649344	G/A	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.59	5.16	0.3	4.74e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs8180040	0.966	rs6792461	chr3:47473168	C/T	cg27129171	chr3:47204927	SETD2	-0.63	-9.64	-0.51	4.95e-19	Colorectal cancer;
CESC	cis	rs4665809	0.877	rs34536218	chr2:26287376	T/A	cg26314531	chr2:26401878	FAM59B	0.7	7.44	0.42	1.42e-12	Gut microbiome composition (summer);
CESC	cis	rs62408225	0.963	rs55885254	chr6:90976234	T/C	cg06866423	chr6:90926672	BACH2	0.43	5.18	0.3	4.38e-7	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs3026101	0.624	rs1058400	chr17:5288794	G/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.39	5.29	0.31	2.51e-7	Body mass index;
CESC	cis	rs863345	0.604	rs1342953	chr1:158464499	T/C	cg12129480	chr1:158549410	OR10X1	-0.35	-6.95	-0.39	2.86e-11	Pneumococcal bacteremia;
CESC	cis	rs4835473	0.868	rs11737787	chr4:144747651	T/C	cg25736465	chr4:144833511	NA	-0.35	-5.4	-0.32	1.46e-7	Immature fraction of reticulocytes;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg00560722	chr10:101989177	CHUK	0.53	7.06	0.4	1.45e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	trans	rs561341	0.623	rs4795665	chr17:30233657	C/T	cg20587970	chr11:113659929	NA	-0.64	-8.12	-0.45	1.74e-14	Hip circumference adjusted for BMI;
CESC	cis	rs7084402	0.935	rs893370	chr10:60360834	A/T	cg07615347	chr10:60278583	BICC1	0.54	8.25	0.45	7.48e-15	Refractive error;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg12043807	chr9:99180432	ZNF367	0.46	6.07	0.35	4.52e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs951366	0.966	rs11240565	chr1:205722958	C/T	cg17178900	chr1:205818956	PM20D1	-0.53	-7.48	-0.42	1.07e-12	Menarche (age at onset);
CESC	cis	rs2760061	0.626	rs634106	chr1:228121548	C/T	cg01973587	chr1:228161476	NA	0.36	5.68	0.33	3.54e-8	Diastolic blood pressure;
CESC	cis	rs1707322	1.000	rs785470	chr1:46519622	C/A	cg06784218	chr1:46089804	CCDC17	-0.33	-5.65	-0.33	4.08e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2635047	0.638	rs2571006	chr18:44718515	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.4	5.41	0.32	1.38e-7	Educational attainment;
CESC	cis	rs4665809	1.000	rs6750681	chr2:26329677	C/T	cg26314531	chr2:26401878	FAM59B	-0.61	-6.86	-0.39	4.88e-11	Gut microbiome composition (summer);
CESC	cis	rs5750830	0.645	rs756640	chr22:39779300	G/A	cg11247378	chr22:39784982	NA	-0.52	-8.03	-0.44	3.15e-14	Intelligence (multi-trait analysis);
CESC	cis	rs752010	0.967	rs6675999	chr1:42099024	T/G	cg06885757	chr1:42089581	HIVEP3	0.5	8.18	0.45	1.2e-14	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs8103278	0.507	rs16939	chr19:46276056	C/A	cg14061069	chr19:46274453	DMPK	0.53	8.29	0.45	5.9e-15	Coronary artery disease;
CESC	cis	rs801193	0.844	rs7779971	chr7:66161790	T/C	cg11764359	chr7:65958608	NA	0.69	9.1	0.49	2.27e-17	Aortic root size;
CESC	cis	rs425277	0.565	rs3128293	chr1:2065339	A/G	cg24578937	chr1:2090814	PRKCZ	-0.36	-6.11	-0.35	3.46e-9	Height;
CESC	cis	rs6754459	0.502	rs34759180	chr2:3707394	C/T	cg10645314	chr2:3704589	ALLC	-0.7	-7.33	-0.41	2.85e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CESC	cis	rs854765	0.552	rs6502624	chr17:17847936	G/A	cg09796270	chr17:17721594	SREBF1	0.45	6.15	0.35	2.87e-9	Total body bone mineral density;
CESC	cis	rs116095464	0.558	rs10475136	chr5:232796	A/G	cg10591111	chr5:226296	SDHA	-0.53	-6.37	-0.36	8.13e-10	Breast cancer;
CESC	cis	rs748404	0.697	rs492743	chr15:43560945	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	7.8	0.43	1.47e-13	Lung cancer;
CESC	cis	rs2204008	0.528	rs11503820	chr12:38395379	G/A	cg26384229	chr12:38710491	ALG10B	-0.46	-6.04	-0.35	5.17e-9	Bladder cancer;
CESC	cis	rs2836974	0.965	rs2836967	chr21:40639102	T/G	cg17971929	chr21:40555470	PSMG1	1.07	16.32	0.71	6.47e-42	Cognitive function;
CESC	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg07167872	chr1:205819463	PM20D1	0.85	15.13	0.68	1.07e-37	Menarche (age at onset);
CESC	cis	rs909002	0.789	rs2139539	chr1:32117779	C/T	cg13919466	chr1:32135498	COL16A1	-0.47	-8.51	-0.46	1.27e-15	Intelligence (multi-trait analysis);
CESC	cis	rs12472274	0.646	rs11688732	chr2:239096622	G/T	cg17459225	chr2:239074497	NA	0.51	6.02	0.35	5.77e-9	Phospholipid levels (plasma);
CESC	cis	rs76878669	0.561	rs7115577	chr11:66172258	G/T	cg18002602	chr11:66138449	SLC29A2	-0.36	-5.86	-0.34	1.38e-8	Educational attainment (years of education);
CESC	cis	rs12477438	0.798	rs6716913	chr2:99580641	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-10.51	-0.54	7.92e-22	Chronic sinus infection;
CESC	cis	rs2070488	0.775	rs6794397	chr3:38559307	A/G	cg24069376	chr3:38537580	EXOG	0.32	5.43	0.32	1.26e-7	Electrocardiographic conduction measures;
CESC	cis	rs3808502	0.585	rs4549730	chr8:11239078	T/G	cg21775007	chr8:11205619	TDH	-0.52	-7.89	-0.44	7.81e-14	Neuroticism;
CESC	cis	rs11098499	0.955	rs35916640	chr4:120155852	T/C	cg24375607	chr4:120327624	NA	0.42	5.05	0.3	8.26e-7	Corneal astigmatism;
CESC	cis	rs7089973	0.872	rs7918388	chr10:116614563	T/C	cg25233709	chr10:116636983	FAM160B1	0.35	5.08	0.3	7.02e-7	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs74181299	0.684	rs60136636	chr2:65338422	G/A	cg05010058	chr2:65284262	CEP68	-0.32	-5.29	-0.31	2.63e-7	Pulse pressure;
CESC	cis	rs116095464	0.614	rs4371799	chr5:268192	C/A	cg22496380	chr5:211416	CCDC127	-0.73	-8.43	-0.46	2.18e-15	Breast cancer;
CESC	cis	rs2836974	0.796	rs77153312	chr21:40695499	G/A	cg17971929	chr21:40555470	PSMG1	1.03	15.24	0.68	4.35e-38	Cognitive function;
CESC	cis	rs9549367	0.713	rs1755690	chr13:113824266	T/C	cg18105134	chr13:113819100	PROZ	0.56	7.33	0.41	2.74e-12	Platelet distribution width;
CESC	cis	rs62408225	0.894	rs4707609	chr6:90946479	T/C	cg06866423	chr6:90926672	BACH2	0.43	5.31	0.31	2.28e-7	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs7552404	1.000	rs4949875	chr1:76173080	G/A	cg10523679	chr1:76189770	ACADM	0.68	7.81	0.43	1.32e-13	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs7927771	0.965	rs35184771	chr11:47475189	G/T	cg20135002	chr11:47629003	NA	-0.41	-5.11	-0.3	6.14e-7	Subjective well-being;
CESC	cis	rs2576037	0.796	rs2571030	chr18:44573854	G/A	cg19077165	chr18:44547161	KATNAL2	0.53	7.49	0.42	1.03e-12	Personality dimensions;
CESC	cis	rs7666738	0.512	rs1648536	chr4:99019881	G/T	cg17366294	chr4:99064904	C4orf37	-0.41	-5.33	-0.31	2.14e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs561341	0.882	rs111484028	chr17:30287701	G/A	cg20587970	chr11:113659929	NA	-1.12	-14.24	-0.66	1.49e-34	Hip circumference adjusted for BMI;
CESC	cis	rs2836974	0.931	rs13625	chr21:40669083	G/T	cg11644478	chr21:40555479	PSMG1	1.02	16.18	0.7	1.98e-41	Cognitive function;
CESC	cis	rs4843747	0.636	rs11864872	chr16:88105966	A/G	cg03395651	chr16:88107091	BANP	0.45	5.31	0.31	2.35e-7	Menopause (age at onset);
CESC	trans	rs11098499	0.863	rs1383533	chr4:120434576	G/A	cg25214090	chr10:38739885	LOC399744	0.69	9.45	0.5	1.84e-18	Corneal astigmatism;
CESC	cis	rs6011002	1.000	rs3848668	chr20:62293272	A/G	cg15212369	chr20:62274085	STMN3	-0.58	-5.04	-0.3	8.58e-7	Dental caries;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg12728516	chr1:155197152	GBAP1	0.46	6.66	0.38	1.54e-10	Fibrinogen levels;
CESC	cis	rs35306767	0.716	rs34487581	chr10:897201	G/A	cg10556349	chr10:835070	NA	0.75	6.28	0.36	1.34e-9	Eosinophil percentage of granulocytes;
CESC	cis	rs6495122	0.699	rs12905199	chr15:75070196	A/G	cg14664628	chr15:75095509	CSK	-0.68	-9.39	-0.5	2.81e-18	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
CESC	cis	rs7772486	0.712	rs1292335	chr6:145967877	G/T	cg05347473	chr6:146136440	FBXO30	0.41	5.81	0.34	1.83e-8	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs67311347	1.000	rs73080138	chr3:40516417	A/G	cg09455208	chr3:40491958	NA	0.48	8.35	0.46	3.77e-15	Renal cell carcinoma;
CESC	cis	rs4665809	0.531	rs10199898	chr2:26445485	T/G	cg27170947	chr2:26402098	FAM59B	-0.87	-9.89	-0.52	7.6e-20	Gut microbiome composition (summer);
CESC	cis	rs7914558	0.966	rs10786719	chr10:104637992	C/T	cg08650961	chr10:104748594	CNNM2	-0.36	-5.64	-0.33	4.39e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs116095464	0.558	rs10056628	chr5:279512	G/A	cg22857025	chr5:266934	NA	-1.32	-14.23	-0.66	1.56e-34	Breast cancer;
CESC	cis	rs2180341	1.000	rs2326567	chr6:127606160	G/A	cg24812749	chr6:127587940	RNF146	1.06	15.35	0.69	1.74e-38	Breast cancer;
CESC	trans	rs3780486	0.505	rs10813958	chr9:33165985	A/G	cg20290983	chr6:43655470	MRPS18A	0.72	11.21	0.57	4.09e-24	IgG glycosylation;
CESC	cis	rs2882667	0.858	rs13176497	chr5:138446074	T/C	cg04439458	chr5:138467593	SIL1	-0.39	-6.04	-0.35	5.21e-9	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs763121	0.925	rs5757165	chr22:38994577	C/T	cg21395723	chr22:39101663	GTPBP1	0.45	5.94	0.34	8.82e-9	Menopause (age at onset);
CESC	cis	rs9790314	0.875	rs462514	chr3:161092809	C/T	cg03342759	chr3:160939853	NMD3	-0.41	-5.39	-0.31	1.59e-7	Morning vs. evening chronotype;
CESC	cis	rs7824557	0.524	rs7835318	chr8:10953874	G/A	cg21775007	chr8:11205619	TDH	-0.38	-5.42	-0.32	1.32e-7	Retinal vascular caliber;
CESC	cis	rs8060686	0.545	rs11043	chr16:68262958	G/A	cg26727032	chr16:67993705	SLC12A4	-0.48	-5.62	-0.33	4.92e-8	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs17125944	0.542	rs75723366	chr14:53256882	T/C	cg13660082	chr14:53194042	PSMC6	-0.61	-5.51	-0.32	8.66e-8	Alzheimer's disease (late onset);
CESC	cis	rs5753037	0.585	rs249396	chr22:30213972	T/G	cg01021169	chr22:30184971	ASCC2	-0.57	-8.57	-0.47	8.55e-16	Type 1 diabetes;
CESC	cis	rs916888	0.821	rs199509	chr17:44858728	G/A	cg14517863	chr17:44321492	NA	-0.4	-5.16	-0.3	4.82e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs919433	0.963	rs1896854	chr2:198147776	G/T	cg03934865	chr2:198174659	NA	-0.46	-6.96	-0.39	2.67e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs4718428	0.705	rs4718424	chr7:66376095	G/A	cg12165864	chr7:66369176	NA	-0.67	-7.8	-0.43	1.41e-13	Corneal structure;
CESC	cis	rs7666738	0.830	rs7664305	chr4:99037691	G/A	cg24818145	chr4:99064322	C4orf37	0.38	5.04	0.3	8.81e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs1814175	0.591	rs11040589	chr11:49862449	A/G	cg03929089	chr4:120376271	NA	-0.9	-14.75	-0.67	2.44e-36	Height;
CESC	trans	rs11039798	0.588	rs10838979	chr11:48626810	T/G	cg15704280	chr7:45808275	SEPT13	0.61	6.29	0.36	1.32e-9	Axial length;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg26300613	chr20:42839365	C20orf111	-0.48	-7.11	-0.4	1.11e-11	Gambling;
CESC	cis	rs2070488	0.775	rs1132064	chr3:38566519	T/C	cg24069376	chr3:38537580	EXOG	-0.32	-5.54	-0.32	7.32e-8	Electrocardiographic conduction measures;
CESC	cis	rs875971	0.545	rs6460298	chr7:65907770	T/C	cg25405998	chr7:65216604	CCT6P1	0.46	5.21	0.3	3.87e-7	Aortic root size;
CESC	trans	rs9325144	0.600	rs2171405	chr12:38741030	G/T	cg23762105	chr12:34175262	ALG10	0.48	6.24	0.36	1.68e-9	Morning vs. evening chronotype;
CESC	cis	rs597539	0.654	rs655816	chr11:68626405	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.81	9.95	0.52	4.95e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs4450798	0.593	rs4552329	chr3:13785609	T/C	cg23332027	chr3:13681764	NA	0.39	5.3	0.31	2.47e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs875971	0.862	rs7786892	chr7:65628876	G/A	cg11764359	chr7:65958608	NA	-0.79	-11.61	-0.58	1.83e-25	Aortic root size;
CESC	cis	rs3806843	1.000	rs10066278	chr5:140156318	A/C	cg26395211	chr5:140044315	WDR55	-0.43	-5.32	-0.31	2.18e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs11227306	0.934	rs7940691	chr11:65640906	C/T	cg00576331	chr11:65640516	EFEMP2	0.43	5.66	0.33	3.95e-8	DNA methylation (variation);
CESC	cis	rs875971	0.862	rs778680	chr7:65840414	G/A	cg18876405	chr7:65276391	NA	0.5	6.84	0.39	5.47e-11	Aortic root size;
CESC	cis	rs7165102	1.000	rs11071846	chr15:65792839	C/T	cg11441148	chr15:65824328	PTPLAD1	-0.31	-5.23	-0.31	3.38e-7	Mean corpuscular hemoglobin;
CESC	cis	rs959260	0.688	rs9302990	chr17:73359446	T/C	cg20590849	chr17:73267439	MIF4GD	-0.56	-6.11	-0.35	3.51e-9	Systemic lupus erythematosus;
CESC	cis	rs13631	1.000	rs13631	chr9:140006202	G/A	cg14289826	chr9:140003911	NA	0.39	7.28	0.41	3.83e-12	Cerebrospinal fluid biomarker levels;
CESC	cis	rs2243480	1.000	rs78803505	chr7:65382572	A/T	cg12463550	chr7:65579703	CRCP	0.7	5.7	0.33	3.21e-8	Diabetic kidney disease;
CESC	cis	rs6540559	1.000	rs742214	chr1:209960925	T/C	cg23283495	chr1:209979779	IRF6	0.51	7.28	0.41	3.91e-12	Cleft lip with or without cleft palate;
CESC	cis	rs7927771	1.000	rs11039426	chr11:47863119	G/A	cg05585544	chr11:47624801	NA	-0.49	-7.61	-0.42	4.89e-13	Subjective well-being;
CESC	cis	rs854765	0.964	rs12950562	chr17:17995166	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.41	-5.39	-0.31	1.52e-7	Total body bone mineral density;
CESC	cis	rs7927592	0.701	rs12226585	chr11:68257861	A/T	cg01657329	chr11:68192670	LRP5	0.47	6.35	0.36	9.16e-10	Total body bone mineral density;
CESC	cis	rs6831352	0.918	rs13127153	chr4:100058121	C/T	cg12011299	chr4:100065546	ADH4	-0.59	-6.49	-0.37	4.3e-10	Alcohol dependence;
CESC	cis	rs7216064	1.000	rs7209675	chr17:65831258	A/T	cg07042672	chr17:66097459	LOC651250	-0.54	-6.35	-0.36	9.38e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs478304	0.651	rs11604462	chr11:65551648	G/A	cg10518572	chr11:65560635	OVOL1	-0.3	-5.71	-0.33	2.98e-8	Acne (severe);
CESC	cis	rs2952156	1.000	rs2088126	chr17:37879030	A/G	cg00129232	chr17:37814104	STARD3	-0.68	-8.59	-0.47	7.68e-16	Asthma;
CESC	cis	rs7937682	0.921	rs34584980	chr11:111441537	G/A	cg09085632	chr11:111637200	PPP2R1B	0.9	9.9	0.52	7.36e-20	Primary sclerosing cholangitis;
CESC	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg07677032	chr17:61819896	STRADA	0.44	5.88	0.34	1.21e-8	Prudent dietary pattern;
CESC	cis	rs7267979	1.000	rs4815417	chr20:25379526	C/T	cg08601574	chr20:25228251	PYGB	-0.35	-5.07	-0.3	7.52e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs2204008	0.837	rs4432085	chr12:38181146	C/T	cg13010199	chr12:38710504	ALG10B	0.54	6.69	0.38	1.28e-10	Bladder cancer;
CESC	cis	rs7223966	1.000	rs72848797	chr17:61934664	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.51	5.85	0.34	1.45e-8	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs977987	0.806	rs35787595	chr16:75466847	G/C	cg03315344	chr16:75512273	CHST6	0.42	5.97	0.34	7.63e-9	Dupuytren's disease;
CESC	cis	rs11122272	0.525	rs61835222	chr1:231537917	C/A	cg06096015	chr1:231504339	EGLN1	0.4	5.7	0.33	3.21e-8	Hemoglobin concentration;
CESC	cis	rs1707322	1.000	rs11211200	chr1:46288352	A/G	cg03146154	chr1:46216737	IPP	0.71	9.84	0.52	1.16e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs6952808	0.531	rs3778991	chr7:2172455	G/A	cg21782813	chr7:2030301	MAD1L1	0.51	7.29	0.41	3.48e-12	Bipolar disorder and schizophrenia;
CESC	cis	rs56046484	0.871	rs34978449	chr15:85580148	A/G	cg08123816	chr15:85640762	PDE8A	-0.49	-6.25	-0.36	1.63e-9	Testicular germ cell tumor;
CESC	cis	rs734999	0.545	rs12730932	chr1:2559589	T/G	cg20673091	chr1:2541236	MMEL1	-0.48	-8.03	-0.44	3.11e-14	Ulcerative colitis;
CESC	cis	rs736408	0.609	rs2336545	chr3:52787603	C/T	cg17372223	chr3:52568218	NT5DC2	-0.44	-6.6	-0.38	2.28e-10	Bipolar disorder;
CESC	cis	rs9311474	0.508	rs17052259	chr3:52593138	A/G	cg05564831	chr3:52568323	NT5DC2	0.47	7.33	0.41	2.81e-12	Electroencephalogram traits;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg02513141	chr8:19614776	NA	-0.41	-6.49	-0.37	4.22e-10	Gambling;
CESC	cis	rs854765	0.647	rs6826	chr17:18011140	C/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.5	6.3	0.36	1.21e-9	Total body bone mineral density;
CESC	cis	rs9733	0.519	rs2184833	chr1:150675483	C/T	cg04414720	chr1:150670196	GOLPH3L	0.62	9.0	0.48	4.44e-17	Tonsillectomy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14020326	chr14:105821532	PACS2	-0.55	-6.28	-0.36	1.38e-9	Gut microbiome composition (summer);
CESC	cis	rs7617773	0.539	rs13094496	chr3:48387050	G/C	cg11946769	chr3:48343235	NME6	0.64	8.1	0.45	2.09e-14	Coronary artery disease;
CESC	cis	rs9322193	0.543	rs9371533	chr6:150210681	G/A	cg09699651	chr6:150184138	LRP11	0.48	6.46	0.37	4.87e-10	Lung cancer;
CESC	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg26338869	chr17:61819248	STRADA	0.68	8.87	0.48	1.08e-16	Prudent dietary pattern;
CESC	cis	rs2404602	0.735	rs1607015	chr15:76702429	C/T	cg00316803	chr15:76480434	C15orf27	0.37	5.05	0.3	8.33e-7	Blood metabolite levels;
CESC	cis	rs9399401	0.710	rs6900087	chr6:142717303	A/T	cg04461802	chr6:142623433	GPR126	0.42	6.04	0.35	5.13e-9	Chronic obstructive pulmonary disease;
CESC	cis	rs6754311	0.773	rs666407	chr2:136640233	A/G	cg07169764	chr2:136633963	MCM6	0.69	8.58	0.47	8.32e-16	Mosquito bite size;
CESC	cis	rs6831352	0.918	rs1042365	chr4:100045500	G/T	cg13256891	chr4:100009986	ADH5	-0.72	-8.09	-0.45	2.13e-14	Alcohol dependence;
CESC	cis	rs77106637	1.000	rs11600585	chr11:72727840	A/G	cg03713592	chr11:72463424	ARAP1	1.12	10.28	0.53	4.3e-21	Type 2 diabetes;
CESC	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg15147215	chr3:52552868	STAB1	-0.4	-7.45	-0.42	1.35e-12	Electroencephalogram traits;
CESC	cis	rs6860806	0.631	rs6863548	chr5:131575920	G/A	cg14196790	chr5:131705035	SLC22A5	0.32	5.15	0.3	5.04e-7	Breast cancer;
CESC	cis	rs3126085	0.935	rs3126056	chr1:152266503	G/A	cg03465714	chr1:152285911	FLG	0.47	5.86	0.34	1.34e-8	Atopic dermatitis;
CESC	cis	rs12142240	0.660	rs7520497	chr1:46824919	C/A	cg10495392	chr1:46806563	NSUN4	0.58	6.32	0.36	1.09e-9	Menopause (age at onset);
CESC	cis	rs992157	0.560	rs4674275	chr2:219097738	G/A	cg00012203	chr2:219082015	ARPC2	-0.74	-9.9	-0.52	7.06e-20	Colorectal cancer;
CESC	cis	rs3091242	0.866	rs11249249	chr1:25758134	A/G	cg03538708	chr1:25844672	NA	-0.43	-6.5	-0.37	3.97e-10	Erythrocyte sedimentation rate;
CESC	cis	rs7666738	0.830	rs11097600	chr4:98959564	T/G	cg03676636	chr4:99064102	C4orf37	0.33	5.04	0.3	8.71e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6580649	0.883	rs879242	chr12:48503301	T/C	cg05342945	chr12:48394962	COL2A1	0.55	6.32	0.36	1.13e-9	Lung cancer;
CESC	cis	rs12477438	0.501	rs12995473	chr2:99764884	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.91	15.68	0.69	1.18e-39	Chronic sinus infection;
CESC	cis	rs6952808	0.531	rs3800922	chr7:2184505	A/G	cg02951883	chr7:2050386	MAD1L1	-0.51	-6.63	-0.38	1.88e-10	Bipolar disorder and schizophrenia;
CESC	cis	rs7267979	0.966	rs454723	chr20:25438928	G/C	cg08601574	chr20:25228251	PYGB	0.37	5.27	0.31	2.82e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs801193	0.660	rs4610622	chr7:66224497	T/C	cg18876405	chr7:65276391	NA	0.47	6.26	0.36	1.53e-9	Aortic root size;
CESC	cis	rs5750830	0.649	rs5750818	chr22:39820885	A/G	cg11247378	chr22:39784982	NA	-0.66	-9.78	-0.51	1.76e-19	Intelligence (multi-trait analysis);
CESC	trans	rs6089829	0.962	rs4809456	chr20:61660849	C/A	cg23505145	chr19:12996616	KLF1	0.52	6.71	0.38	1.21e-10	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7789940	0.904	rs12531348	chr7:75937191	G/C	cg10167463	chr7:75959203	YWHAG	-0.51	-6.04	-0.35	5.31e-9	Multiple sclerosis;
CESC	cis	rs7618501	1.000	rs7648987	chr3:49868455	A/G	cg24308560	chr3:49941425	MST1R	-0.5	-6.75	-0.38	9.41e-11	Intelligence (multi-trait analysis);
CESC	cis	rs35160687	0.509	rs13024436	chr2:86534521	G/A	cg01119172	chr2:86362222	SNORD94;PTCD3	-0.43	-5.71	-0.33	3.02e-8	Night sleep phenotypes;
CESC	cis	rs4523957	0.819	rs12450354	chr17:2159982	C/T	cg16513277	chr17:2031491	SMG6	0.6	8.18	0.45	1.22e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs1218582	0.740	rs1977879	chr1:154879743	G/A	cg24250549	chr1:154909240	PMVK	0.74	11.08	0.56	1.06e-23	Prostate cancer;
CESC	cis	rs13191362	0.872	rs36069443	chr6:163248701	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.66	6.4	0.37	7.05e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs4253772	0.637	rs8139035	chr22:46651367	A/G	cg09491104	chr22:46646882	C22orf40	-0.59	-9.15	-0.49	1.58e-17	LDL cholesterol;Cholesterol, total;
CESC	cis	rs4927850	0.881	rs7630489	chr3:195753401	T/C	cg01181863	chr3:195395398	SDHAP2	-0.48	-5.71	-0.33	3.03e-8	Pancreatic cancer;
CESC	cis	rs7635838	0.819	rs6776159	chr3:11519324	A/G	cg00170343	chr3:11313890	ATG7	0.43	5.8	0.34	1.93e-8	HDL cholesterol;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14065121	chr9:77643271	C9orf41	0.5	7.04	0.4	1.63e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs3540	0.554	rs4244879	chr15:91066915	C/T	cg10434728	chr15:90938212	IQGAP1	-0.4	-7.02	-0.4	1.85e-11	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs6831352	0.589	rs2924584	chr4:99988208	A/G	cg13256891	chr4:100009986	ADH5	0.69	9.66	0.51	4.06e-19	Alcohol dependence;
CESC	cis	rs7772486	0.754	rs10872580	chr6:146140281	C/T	cg23711669	chr6:146136114	FBXO30	-0.96	-14.96	-0.68	4.17e-37	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg26291698	chr6:43445274	TJAP1	-0.46	-6.16	-0.35	2.75e-9	Fibrinogen levels;
CESC	cis	rs12048904	0.505	rs11166511	chr1:101240686	G/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.68	-8.25	-0.45	7.29e-15	Multiple sclerosis;
CESC	cis	rs1018836	0.923	rs9643298	chr8:91552502	G/A	cg16814680	chr8:91681699	NA	-0.71	-10.3	-0.53	3.78e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs4808199	0.947	rs7250658	chr19:19571100	A/G	cg03709012	chr19:19516395	GATAD2A	1.17	13.3	0.63	2.85e-31	Nonalcoholic fatty liver disease;
CESC	cis	rs2050392	0.590	rs685319	chr10:30719331	G/A	cg02070205	chr10:30722105	MAP3K8	-0.46	-5.39	-0.31	1.59e-7	Inflammatory bowel disease;
CESC	cis	rs9322193	0.923	rs11155677	chr6:150078089	C/G	cg04369109	chr6:150039330	LATS1	-0.44	-6.07	-0.35	4.43e-9	Lung cancer;
CESC	cis	rs6089829	0.962	rs6011548	chr20:61666063	C/T	cg03213289	chr20:61660250	NA	0.39	6.16	0.35	2.7e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs2797160	1.000	rs1418642	chr6:125999768	G/A	cg05901451	chr6:126070800	HEY2	-0.46	-6.7	-0.38	1.28e-10	Endometrial cancer;
CESC	cis	rs4722166	0.630	rs4722169	chr7:22785419	C/T	cg26061582	chr7:22766209	IL6	0.5	5.48	0.32	9.97e-8	Lung cancer;
CESC	cis	rs7666738	0.830	rs13140676	chr4:98804978	C/T	cg05340658	chr4:99064831	C4orf37	0.77	11.6	0.58	2.01e-25	Colonoscopy-negative controls vs population controls;
CESC	cis	rs8078723	1.000	rs3826331	chr17:38150492	T/C	cg17467752	chr17:38218738	THRA	-0.65	-9.52	-0.5	1.13e-18	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CESC	cis	rs7666738	0.830	rs35276471	chr4:99068691	A/T	cg03467027	chr4:99064603	C4orf37	0.48	5.96	0.34	7.81e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9302635	0.513	rs7184169	chr16:72152933	C/T	cg01557791	chr16:72042693	DHODH	-0.59	-6.84	-0.39	5.42e-11	Blood protein levels;
CESC	cis	rs35110281	0.627	rs7282704	chr21:44966253	A/G	cg21573476	chr21:45109991	RRP1B	-0.37	-5.04	-0.3	8.67e-7	Mean corpuscular volume;
CESC	cis	rs3733585	0.699	rs28610447	chr4:9971517	T/C	cg02734326	chr4:10020555	SLC2A9	-0.39	-5.52	-0.32	8.08e-8	Cleft plate (environmental tobacco smoke interaction);
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg03424826	chr18:59561551	RNF152	0.56	7.17	0.4	7.25e-12	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg06873352	chr17:61820015	STRADA	0.72	12.91	0.62	6.74e-30	Prudent dietary pattern;
CESC	cis	rs2742234	0.541	rs7096500	chr10:43712095	C/T	cg07801480	chr10:43725741	RASGEF1A	-0.4	-5.25	-0.31	3.2e-7	Hirschsprung disease;
CESC	cis	rs9837602	1.000	rs1688771	chr3:99503359	T/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.52	-7.18	-0.4	6.88e-12	Breast cancer;
CESC	cis	rs10883723	0.847	rs3808934	chr10:104264280	C/T	cg22532475	chr10:104410764	TRIM8	-0.34	-5.73	-0.33	2.77e-8	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs763014	0.931	rs11643039	chr16:634260	G/A	cg07343612	chr16:622815	PIGQ	-0.55	-8.03	-0.44	3.16e-14	Height;
CESC	cis	rs992157	1.000	rs2168704	chr2:219142492	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.76	10.57	0.54	5.27e-22	Colorectal cancer;
CESC	cis	rs9467711	0.559	rs12176129	chr6:26514940	C/T	cg12826209	chr6:26865740	GUSBL1	0.58	5.09	0.3	6.93e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs7312933	0.645	rs12049942	chr12:42587052	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.49	6.37	0.36	8.18e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs11249608	0.548	rs6867208	chr5:178455575	G/A	cg21905437	chr5:178450457	ZNF879	0.6	8.74	0.47	2.75e-16	Pubertal anthropometrics;
CESC	cis	rs77956314	0.515	rs10850741	chr12:117432004	A/G	cg16111737	chr12:117408163	FBXW8	-0.49	-6.13	-0.35	3.22e-9	Subcortical brain region volumes;Hippocampal volume;
CESC	cis	rs9325144	0.671	rs7306605	chr12:38730471	C/T	cg26384229	chr12:38710491	ALG10B	0.55	7.82	0.43	1.26e-13	Morning vs. evening chronotype;
CESC	trans	rs8073060	0.586	rs4796098	chr17:33913436	T/C	cg19694781	chr19:47549865	TMEM160	0.73	7.01	0.4	1.96e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg25485084	chr12:118809325	TAOK3	0.41	6.38	0.36	7.96e-10	Systemic lupus erythematosus;
CESC	cis	rs2976388	0.566	rs13250661	chr8:143804134	C/T	cg10596483	chr8:143751796	JRK	-0.43	-5.26	-0.31	3.05e-7	Urinary tract infection frequency;
CESC	cis	rs9457247	0.534	rs9366078	chr6:167399512	A/G	cg25258033	chr6:167368657	RNASET2	-0.38	-5.54	-0.32	7.36e-8	Crohn's disease;
CESC	cis	rs734999	0.545	rs6666430	chr1:2698950	G/A	cg20673091	chr1:2541236	MMEL1	0.48	7.77	0.43	1.73e-13	Ulcerative colitis;
CESC	cis	rs992157	0.710	rs12612347	chr2:219057338	C/T	cg00012203	chr2:219082015	ARPC2	-0.83	-12.17	-0.6	2.28e-27	Colorectal cancer;
CESC	trans	rs9987353	0.840	rs329994	chr8:9123233	A/G	cg16075951	chr14:24899050	CBLN3;KHNYN	-0.46	-6.1	-0.35	3.84e-9	Recombination measurement;
CESC	cis	rs7084402	0.967	rs1649042	chr10:60328663	T/C	cg07615347	chr10:60278583	BICC1	0.59	9.18	0.49	1.26e-17	Refractive error;
CESC	cis	rs11048434	0.736	rs1476911	chr12:9090859	C/T	cg23795048	chr12:9217529	LOC144571	0.36	5.75	0.33	2.46e-8	Sjögren's syndrome;
CESC	cis	rs7560272	0.723	rs7609249	chr2:73813820	G/A	cg20560298	chr2:73613845	ALMS1	-0.51	-7.26	-0.41	4.35e-12	Schizophrenia;
CESC	cis	rs7762018	0.769	rs74838157	chr6:170077323	G/A	cg19338460	chr6:170058176	WDR27	-0.76	-7.24	-0.41	4.97e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg18402987	chr7:1209562	NA	0.75	7.52	0.42	8.71e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7208859	0.623	rs170051	chr17:28914153	G/A	cg13385521	chr17:29058706	SUZ12P	0.75	5.52	0.32	7.98e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs909674	0.524	rs5757670	chr22:39829736	G/A	cg05872129	chr22:39784769	NA	-0.81	-10.84	-0.55	6.6e-23	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs7666738	1.000	rs1426673	chr4:98924024	G/A	cg05340658	chr4:99064831	C4orf37	0.65	8.54	0.46	1.04e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs801193	1.000	rs2286684	chr7:66129830	G/T	cg18876405	chr7:65276391	NA	-0.54	-7.06	-0.4	1.46e-11	Aortic root size;
CESC	cis	rs861020	0.630	rs656566	chr1:210006603	C/T	cg05527609	chr1:210001259	C1orf107	0.74	9.67	0.51	3.97e-19	Orofacial clefts;
CESC	cis	rs2463822	1.000	rs2246920	chr11:62104937	T/G	cg06239285	chr11:62104954	ASRGL1	0.85	8.6	0.47	7.06e-16	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs2797160	1.000	rs6910933	chr6:126017155	C/G	cg05901451	chr6:126070800	HEY2	0.46	6.52	0.37	3.52e-10	Endometrial cancer;
CESC	cis	rs853679	0.517	rs4713143	chr6:28106759	A/C	cg18032046	chr6:28092343	ZSCAN16	-0.55	-6.39	-0.37	7.41e-10	Depression;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg17495092	chr1:39456765	AKIRIN1	-0.48	-6.08	-0.35	4.1e-9	Ulcerative colitis;
CESC	cis	rs12048904	0.619	rs10875346	chr1:101328083	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.84	11.38	0.57	1.04e-24	Multiple sclerosis;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg10548669	chr15:37782940	NA	-0.43	-6.07	-0.35	4.46e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs4835473	0.864	rs12507633	chr4:144883883	A/T	cg25736465	chr4:144833511	NA	0.39	5.75	0.33	2.4e-8	Immature fraction of reticulocytes;
CESC	cis	rs1799949	1.000	rs35956818	chr17:41422985	T/C	cg05368731	chr17:41323189	NBR1	0.79	10.84	0.55	6.44e-23	Menopause (age at onset);
CESC	cis	rs875971	0.545	rs73142265	chr7:65699497	G/A	cg18527119	chr7:66119851	NA	-0.47	-5.21	-0.31	3.71e-7	Aortic root size;
CESC	trans	rs1814175	0.616	rs10839388	chr11:49842603	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.42	-6.24	-0.36	1.75e-9	Height;
CESC	cis	rs7267979	1.000	rs2387880	chr20:25377787	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.88	-18.14	-0.74	2.4e-48	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs1707322	1.000	rs11211223	chr1:46380605	C/T	cg05343316	chr1:45956843	TESK2	0.44	5.41	0.32	1.41e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2073300	0.609	rs56094936	chr20:23401586	G/A	cg12062639	chr20:23401060	NAPB	1.07	8.16	0.45	1.39e-14	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	trans	rs7656342	0.808	rs10003216	chr4:9766749	A/G	cg04926556	chr7:48128294	UPP1	-0.51	-6.05	-0.35	4.87e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs2066819	1.000	rs11575232	chr12:56744422	G/A	cg26714650	chr12:56694279	CS	-1.39	-9.17	-0.49	1.37e-17	Psoriasis vulgaris;
CESC	cis	rs3008870	0.585	rs2815382	chr1:67515228	G/A	cg02640540	chr1:67518911	SLC35D1	0.66	8.72	0.47	3.05e-16	Lymphocyte percentage of white cells;
CESC	cis	rs514406	0.505	rs146750	chr1:53183447	C/G	cg27535305	chr1:53392650	SCP2	-0.33	-5.48	-0.32	1.01e-7	Monocyte count;
CESC	cis	rs2625529	0.526	rs7183810	chr15:72560458	A/T	cg16672083	chr15:72433130	SENP8	0.4	5.97	0.34	7.7e-9	Red blood cell count;
CESC	cis	rs6952808	0.531	rs3779002	chr7:2183219	C/T	cg05863683	chr7:1912471	MAD1L1	0.4	5.7	0.33	3.12e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs6089829	0.890	rs6062775	chr20:61663650	T/C	cg03213289	chr20:61660250	NA	0.39	6.07	0.35	4.42e-9	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs9929218	0.906	rs9933844	chr16:68747001	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.77	-9.6	-0.51	6.29e-19	Colorectal cancer;
CESC	cis	rs9943753	0.525	rs6606708	chr12:109833146	T/C	cg19025524	chr12:109796872	NA	-0.47	-6.66	-0.38	1.61e-10	HDL cholesterol;
CESC	trans	rs9929218	0.551	rs3785134	chr16:68728938	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.88	14.56	0.67	1.14e-35	Colorectal cancer;
CESC	cis	rs35306767	0.761	rs11253560	chr10:1047226	T/G	cg20503657	chr10:835505	NA	0.69	6.31	0.36	1.19e-9	Eosinophil percentage of granulocytes;
CESC	cis	rs4253772	0.591	rs6008545	chr22:46686375	C/T	cg10541313	chr22:46663664	TTC38	0.55	5.16	0.3	4.96e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs4523957	0.583	rs2760744	chr17:2017029	T/C	cg16513277	chr17:2031491	SMG6	-0.71	-10.1	-0.53	1.62e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs62244186	0.545	rs9284880	chr3:44759389	C/T	cg15225532	chr3:44803084	KIF15;KIAA1143	0.48	6.3	0.36	1.22e-9	Depressive symptoms;
CESC	cis	rs155076	0.711	rs4770129	chr13:21882059	T/G	cg11317459	chr13:21872234	NA	1.2	15.33	0.69	2.11e-38	White matter hyperintensity burden;
CESC	cis	rs7267979	0.966	rs2261785	chr20:25262403	C/T	cg08601574	chr20:25228251	PYGB	0.39	5.65	0.33	4.17e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs9443645	0.901	rs10943612	chr6:79698380	C/T	cg05283184	chr6:79620031	NA	-0.42	-6.52	-0.37	3.58e-10	Intelligence (multi-trait analysis);
CESC	cis	rs57083693	0.518	rs4764646	chr12:101737886	T/C	cg22051763	chr12:101673672	UTP20	-0.45	-5.67	-0.33	3.81e-8	Alcohol dependence (age at onset);
CESC	cis	rs11122272	0.735	rs2572249	chr1:231514829	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.54	-7.28	-0.41	3.86e-12	Hemoglobin concentration;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg10433104	chr11:18417767	LDHA	-0.45	-6.1	-0.35	3.75e-9	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs877282	0.583	rs11253429	chr10:823234	A/C	cg22713356	chr15:30763199	NA	1.03	9.37	0.5	3.32e-18	Uric acid levels;
CESC	cis	rs9611519	0.639	rs7289989	chr22:41476799	A/C	cg03806693	chr22:41940476	POLR3H	-0.44	-5.24	-0.31	3.27e-7	Neuroticism;
CESC	cis	rs11098499	0.909	rs35165976	chr4:120325630	G/A	cg09307838	chr4:120376055	NA	0.94	13.7	0.64	1.18e-32	Corneal astigmatism;
CESC	cis	rs7412746	0.658	rs897815	chr1:150879101	C/T	cg18016565	chr1:150552671	MCL1	-0.34	-5.11	-0.3	6.11e-7	Melanoma;
CESC	cis	rs796364	1.000	rs281760	chr2:200787804	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.86	8.24	0.45	8e-15	Schizophrenia;
CESC	cis	rs2439831	0.681	rs478104	chr15:43594900	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.93	11.1	0.56	8.93e-24	Lung cancer in ever smokers;
CESC	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg21724239	chr8:58056113	NA	0.6	5.45	0.32	1.17e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs6540556	0.723	rs3765240	chr1:209918151	G/A	cg05527609	chr1:210001259	C1orf107	-0.48	-5.98	-0.34	7.38e-9	Red blood cell count;
CESC	cis	rs875971	0.862	rs6460290	chr7:65809106	G/A	cg18876405	chr7:65276391	NA	-0.51	-7.13	-0.4	9.62e-12	Aortic root size;
CESC	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg24642844	chr7:1081250	C7orf50	-0.75	-8.99	-0.48	4.94e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs3749237	0.595	rs6797765	chr3:49423976	A/G	cg03060546	chr3:49711283	APEH	0.75	11.32	0.57	1.68e-24	Resting heart rate;
CESC	cis	rs2718058	0.613	rs2597272	chr7:37759710	C/G	cg15028436	chr7:37888078	TXNDC3	-0.42	-5.98	-0.34	7.08e-9	Alzheimer's disease (late onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11328403	chr17:16120890	PIGL	0.59	6.9	0.39	3.83e-11	Gut microbiome composition (summer);
CESC	cis	rs7412746	0.611	rs3768018	chr1:150723747	T/C	cg22823121	chr1:150693482	HORMAD1	0.46	6.26	0.36	1.56e-9	Melanoma;
CESC	cis	rs2425143	0.908	rs6088889	chr20:34175417	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	0.52	5.33	0.31	2.11e-7	Blood protein levels;
CESC	cis	rs2354432	0.607	rs4950310	chr1:146659964	A/G	cg25205988	chr1:146714368	CHD1L	1.34	9.5	0.5	1.29e-18	Mitochondrial DNA levels;
CESC	cis	rs1568889	0.938	rs12795971	chr11:28355104	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.76	9.64	0.51	4.7e-19	Bipolar disorder;
CESC	cis	rs2235642	0.893	rs2076442	chr16:1591112	G/T	cg07639376	chr16:1584516	IFT140;TMEM204	-0.36	-5.88	-0.34	1.25e-8	Coronary artery disease;
CESC	cis	rs2066819	1.000	rs76151170	chr12:56659320	C/T	cg26714650	chr12:56694279	CS	-1.43	-10.45	-0.54	1.24e-21	Psoriasis vulgaris;
CESC	cis	rs6500395	1.000	rs904818	chr16:48622582	T/C	cg04672837	chr16:48644449	N4BP1	0.52	6.51	0.37	3.83e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs1348850	0.914	rs4893957	chr2:178380409	A/G	cg22681709	chr2:178499509	PDE11A	-0.41	-5.82	-0.34	1.66e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs7618915	0.571	rs6798246	chr3:52599922	G/A	cg18099408	chr3:52552593	STAB1	-0.33	-5.45	-0.32	1.17e-7	Bipolar disorder;
CESC	cis	rs7937682	0.855	rs539693	chr11:111477387	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.95	-14.73	-0.67	2.71e-36	Primary sclerosing cholangitis;
CESC	cis	rs11785693	0.862	rs11778306	chr8:4988269	A/C	cg26367366	chr8:4980734	NA	0.67	6.51	0.37	3.78e-10	Neuroticism (multi-trait analysis);Neuroticism;
CESC	cis	rs7666738	0.830	rs11931166	chr4:99054187	A/T	cg18180107	chr4:99064573	C4orf37	0.41	5.29	0.31	2.51e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6933660	0.800	rs6930557	chr6:151755806	G/A	cg02564969	chr6:151773285	C6orf211;RMND1	0.61	8.41	0.46	2.51e-15	Menarche (age at onset);
CESC	cis	rs6691722	0.543	rs12034846	chr1:24699589	G/A	cg18323236	chr1:24743029	NIPAL3	0.36	5.32	0.31	2.2e-7	Response to interferon beta in multiple sclerosis;
CESC	cis	rs12995849	0.905	rs6712210	chr2:106449251	G/A	cg16077055	chr2:106428750	NCK2	0.39	6.18	0.35	2.45e-9	Addiction;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20963020	chr17:77081760	ENGASE	-0.52	-6.45	-0.37	5.23e-10	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22975723	chr15:93258103	NA	0.59	6.19	0.36	2.31e-9	Gut microbiome composition (summer);
CESC	cis	rs12478296	1.000	rs73007129	chr2:243000555	T/C	cg06360820	chr2:242988706	NA	-0.99	-10.05	-0.53	2.35e-20	Obesity-related traits;
CESC	cis	rs1552244	0.882	rs55840655	chr3:10042690	C/T	cg08888203	chr3:10149979	C3orf24	0.48	6.0	0.35	6.52e-9	Alzheimer's disease;
CESC	cis	rs6828523	0.640	rs74589934	chr4:175868757	G/A	cg14561282	chr4:175839468	ADAM29	0.46	5.26	0.31	2.92e-7	Breast cancer;
CESC	cis	rs7212590	0.748	rs8073489	chr17:57861794	A/C	cg20303301	chr17:57937339	TUBD1	-0.57	-5.36	-0.31	1.81e-7	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs9682041	1.000	rs6444920	chr3:170090374	A/G	cg11886554	chr3:170076028	SKIL	1.05	8.52	0.46	1.25e-15	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CESC	cis	rs6062302	0.522	rs6089929	chr20:62219679	C/T	cg09650180	chr20:62225654	GMEB2	-0.79	-8.81	-0.48	1.7e-16	Glioblastoma;
CESC	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg24829409	chr8:58192753	C8orf71	-0.69	-7.68	-0.43	3.13e-13	Developmental language disorder (linguistic errors);
CESC	cis	rs757110	0.740	rs10832776	chr11:17385224	C/A	cg15432903	chr11:17409602	KCNJ11	0.58	8.15	0.45	1.44e-14	Type 2 diabetes;
CESC	cis	rs4253772	0.530	rs79354880	chr22:46746419	C/A	cg24881330	chr22:46731750	TRMU	0.79	5.6	0.33	5.34e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs9733	0.519	rs1336900	chr1:150679033	C/T	cg22823121	chr1:150693482	HORMAD1	0.49	7.42	0.41	1.56e-12	Tonsillectomy;
CESC	cis	rs9300255	0.722	rs12298826	chr12:123829028	A/G	cg19016782	chr12:123741754	C12orf65	0.44	6.2	0.36	2.22e-9	Neutrophil percentage of white cells;
CESC	cis	rs6963495	0.818	rs73190163	chr7:105157294	G/T	cg13798780	chr7:105162888	PUS7	0.78	8.04	0.44	2.99e-14	Bipolar disorder (body mass index interaction);
CESC	cis	rs909002	0.962	rs1474181	chr1:32136610	C/G	cg13919466	chr1:32135498	COL16A1	-0.52	-9.89	-0.52	7.57e-20	Intelligence (multi-trait analysis);
CESC	cis	rs896854	0.625	rs4735335	chr8:95973327	G/C	cg26343298	chr8:95960752	TP53INP1	0.36	5.96	0.34	7.8e-9	Type 2 diabetes;
CESC	cis	rs1538970	0.851	rs2055145	chr1:45926495	C/G	cg03146154	chr1:46216737	IPP	0.47	5.43	0.32	1.29e-7	Platelet count;
CESC	cis	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	-0.5	-6.73	-0.38	1.02e-10	Bipolar disorder;
CESC	trans	rs62103177	0.714	rs12607447	chr18:77605212	A/G	cg05926928	chr17:57297772	GDPD1	0.75	7.99	0.44	4.26e-14	Opioid sensitivity;
CESC	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	-0.89	-13.82	-0.65	4.34e-33	Prudent dietary pattern;
CESC	cis	rs7107174	1.000	rs4245459	chr11:78065959	T/G	cg02023728	chr11:77925099	USP35	0.48	6.28	0.36	1.37e-9	Testicular germ cell tumor;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26662261	chr17:71228709	C17orf80;FAM104A	0.64	7.68	0.43	3.04e-13	Gut microbiome composition (summer);
CESC	cis	rs7772486	0.536	rs9373467	chr6:145955605	C/T	cg05347473	chr6:146136440	FBXO30	0.71	8.91	0.48	8.14e-17	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs916888	0.610	rs199446	chr17:44813169	G/A	cg22968622	chr17:43663579	NA	-0.75	-10.19	-0.53	8.41e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs3857536	0.813	rs6455090	chr6:66948909	G/A	cg07460842	chr6:66804631	NA	-0.42	-5.29	-0.31	2.55e-7	Blood trace element (Cu levels);
CESC	cis	rs2276314	0.802	rs4799838	chr18:33597530	T/C	cg05985134	chr18:33552581	C18orf21	0.61	7.12	0.4	1.01e-11	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs6951245	0.744	rs10275401	chr7:1213943	A/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.49	-5.81	-0.34	1.8e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs6121246	0.559	rs6060716	chr20:30274847	C/G	cg13852791	chr20:30311386	BCL2L1	0.78	10.0	0.52	3.44e-20	Mean corpuscular hemoglobin;
CESC	cis	rs11969893	0.737	rs1358758	chr6:101411891	T/C	cg12253828	chr6:101329408	ASCC3	0.72	5.95	0.34	8.27e-9	Economic and political preferences (immigration/crime);
CESC	cis	rs7829975	0.714	rs7823757	chr8:8670177	T/A	cg06636001	chr8:8085503	FLJ10661	0.42	5.5	0.32	9.04e-8	Mood instability;
CESC	cis	rs1874326	0.524	rs6467772	chr7:138113643	A/G	cg18008034	chr7:138118925	NA	-0.41	-5.22	-0.31	3.67e-7	Quantitative traits;
CESC	cis	rs9487051	0.735	rs380774	chr6:109519623	C/T	cg01475377	chr6:109611718	NA	-0.37	-5.44	-0.32	1.23e-7	Reticulocyte fraction of red cells;
CESC	cis	rs597539	0.690	rs552517	chr11:68625286	T/G	cg06028808	chr11:68637592	NA	0.48	5.71	0.33	3.08e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs10905065	0.895	rs1858447	chr10:5852230	A/G	cg11519256	chr10:5708881	ASB13	-0.4	-5.22	-0.31	3.61e-7	Menopause (age at onset);
CESC	cis	rs854765	0.583	rs8078583	chr17:17811465	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.53	7.31	0.41	3.21e-12	Total body bone mineral density;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09777416	chr17:7225013	NEURL4	-0.6	-6.77	-0.38	8.42e-11	Gut microbiome composition (summer);
CESC	cis	rs7845219	0.544	rs4570121	chr8:95917088	C/T	cg16049864	chr8:95962084	TP53INP1	-0.49	-7.22	-0.41	5.61e-12	Type 2 diabetes;
CESC	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	7.83	0.43	1.17e-13	Prudent dietary pattern;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg10754697	chr17:1504809	SLC43A2	-0.55	-7.26	-0.41	4.34e-12	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs1538970	1.000	rs4520450	chr1:45834773	A/G	cg05343316	chr1:45956843	TESK2	0.82	11.11	0.56	8.85e-24	Platelet count;
CESC	cis	rs703842	1.000	rs10747783	chr12:58176614	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.73	9.5	0.5	1.32e-18	Multiple sclerosis;
CESC	cis	rs10861342	1.000	rs10861354	chr12:105524294	T/C	cg23923672	chr12:105501055	KIAA1033	0.64	5.41	0.32	1.39e-7	IgG glycosylation;
CESC	cis	rs7666738	0.888	rs13110683	chr4:98983368	G/C	cg17366294	chr4:99064904	C4orf37	0.56	7.52	0.42	8.37e-13	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11240074	0.570	rs7535821	chr1:146953450	G/A	cg25205988	chr1:146714368	CHD1L	-0.62	-5.03	-0.3	9.05e-7	Type 2 diabetes;
CESC	cis	rs875971	0.862	rs13536	chr7:66019190	G/A	cg18252515	chr7:66147081	NA	0.46	5.96	0.34	8.08e-9	Aortic root size;
CESC	cis	rs875971	0.893	rs62465470	chr7:65601218	T/C	cg10691866	chr7:65817282	TPST1	0.31	5.17	0.3	4.57e-7	Aortic root size;
CESC	cis	rs13191362	1.000	rs35044651	chr6:163004142	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.82	8.34	0.46	4.23e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs6963495	0.745	rs73192152	chr7:105212258	A/C	cg19920283	chr7:105172520	RINT1	0.7	6.36	0.36	8.94e-10	Bipolar disorder (body mass index interaction);
CESC	cis	rs6028335	0.502	rs6028235	chr20:37608550	A/G	cg27552599	chr20:37590471	DHX35	0.39	5.81	0.34	1.81e-8	Alcohol and nicotine co-dependence;
CESC	cis	rs6952808	1.000	rs10233560	chr7:1885415	T/C	cg05863683	chr7:1912471	MAD1L1	0.37	5.52	0.32	8.19e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs2842992	0.724	rs1128670	chr6:160211636	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.85	12.01	0.59	8.38e-27	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs4132509	0.793	rs74379351	chr1:243779604	T/C	cg21452805	chr1:244014465	NA	0.61	6.31	0.36	1.18e-9	RR interval (heart rate);
CESC	trans	rs17428076	0.793	rs7584258	chr2:172659836	A/G	cg14287618	chr9:37440492	ZBTB5	0.48	6.02	0.35	5.67e-9	Myopia;
CESC	cis	rs7811142	0.830	rs11761253	chr7:99939321	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.05	10.62	0.55	3.47e-22	Platelet count;
CESC	cis	rs9911578	1.000	rs7216680	chr17:56988243	G/C	cg12560992	chr17:57184187	TRIM37	0.94	15.36	0.69	1.67e-38	Intelligence (multi-trait analysis);
CESC	cis	rs6121246	0.909	rs6060821	chr20:30294034	C/T	cg13852791	chr20:30311386	BCL2L1	0.79	8.23	0.45	8.64e-15	Mean corpuscular hemoglobin;
CESC	cis	rs7255436	0.965	rs7351098	chr19:8451671	G/C	cg16745616	chr19:8428856	ANGPTL4	-0.36	-5.49	-0.32	9.22e-8	HDL cholesterol;
CESC	cis	rs10504229	0.683	rs55881798	chr8:58106406	T/C	cg24829409	chr8:58192753	C8orf71	-0.56	-7.01	-0.4	1.97e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs7071206	0.853	rs66786803	chr10:79429941	A/G	cg07817648	chr10:79422355	NA	-0.8	-10.41	-0.54	1.65e-21	Bone mineral density;
CESC	cis	rs11792861	0.888	rs57314245	chr9:111813832	G/A	cg05043794	chr9:111880884	C9orf5	-0.37	-6.31	-0.36	1.2e-9	Menarche (age at onset);
CESC	cis	rs7267979	0.789	rs4815400	chr20:25292560	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.79	-14.56	-0.67	1.07e-35	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs3749237	0.615	rs55957735	chr3:49438158	G/A	cg07636037	chr3:49044803	WDR6	0.62	8.97	0.48	5.41e-17	Resting heart rate;
CESC	cis	rs1670533	1.000	rs13135215	chr4:1054364	A/G	cg04106633	chr4:1044584	NA	0.41	5.23	0.31	3.36e-7	Recombination rate (females);
CESC	cis	rs4819052	0.851	rs7276828	chr21:46695039	T/G	cg11663144	chr21:46675770	NA	-0.62	-9.76	-0.51	2.06e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs651907	0.557	rs13066768	chr3:101486920	A/T	cg12386194	chr3:101231763	SENP7	-0.4	-5.21	-0.3	3.82e-7	Colorectal cancer;
CESC	cis	rs9611565	0.572	rs139569	chr22:42211141	A/G	cg03806693	chr22:41940476	POLR3H	-0.74	-8.91	-0.48	8.22e-17	Vitiligo;
CESC	cis	rs2439831	0.571	rs689883	chr15:43812596	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.73	9.44	0.5	1.96e-18	Lung cancer in ever smokers;
CESC	trans	rs7824557	0.564	rs2572392	chr8:11235605	T/G	cg06636001	chr8:8085503	FLJ10661	-0.49	-6.11	-0.35	3.64e-9	Retinal vascular caliber;
CESC	trans	rs360798	0.512	rs12691187	chr2:62804436	T/A	cg07814414	chr15:31774773	NA	-0.43	-6.2	-0.36	2.15e-9	Coronary artery disease;
CESC	cis	rs11048434	0.636	rs11614970	chr12:9060053	G/A	cg23795048	chr12:9217529	LOC144571	0.34	5.3	0.31	2.45e-7	Sjögren's syndrome;
CESC	cis	rs9303401	0.527	rs7224468	chr17:56749943	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.04	12.96	0.62	4.32e-30	Cognitive test performance;
CESC	cis	rs9912789	0.744	rs9893755	chr17:79187432	C/T	cg14413466	chr17:79170920	AZI1	0.46	6.54	0.37	3.07e-10	Frontotemporal dementia;
CESC	cis	rs10751667	0.666	rs7394958	chr11:965944	C/G	cg20946044	chr11:1010712	AP2A2	-0.4	-5.46	-0.32	1.12e-7	Alzheimer's disease (late onset);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg11967563	chr10:3186147	PITRM1	0.49	6.79	0.38	7.19e-11	Fibrinogen levels;
CESC	cis	rs1799949	1.000	rs11657835	chr17:41291953	C/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.42	5.76	0.33	2.3e-8	Menopause (age at onset);
CESC	cis	rs9834373	0.853	rs3923272	chr3:78488245	A/G	cg06138941	chr3:78371609	NA	-0.42	-5.14	-0.3	5.43e-7	Protein quantitative trait loci;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg04592204	chr7:43965870	URGCP;UBE2D4	-0.5	-6.6	-0.38	2.25e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs7656342	0.808	rs10003216	chr4:9766749	A/G	cg24607948	chr9:100459097	XPA	-0.54	-6.24	-0.36	1.73e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs7799006	0.527	rs2159045	chr7:2207401	T/C	cg21782813	chr7:2030301	MAD1L1	0.48	6.71	0.38	1.17e-10	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs1577917	1.000	rs955227	chr6:86651032	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.5	-6.44	-0.37	5.73e-10	Response to antipsychotic treatment;
CESC	cis	rs4665809	0.556	rs1560869	chr2:26417095	T/C	cg22920501	chr2:26401640	FAM59B	-0.85	-10.05	-0.53	2.5e-20	Gut microbiome composition (summer);
CESC	cis	rs7520050	0.807	rs6429576	chr1:46216575	T/C	cg06784218	chr1:46089804	CCDC17	0.33	5.94	0.34	9.01e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs9902453	0.817	rs55974138	chr17:28215546	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.65	8.12	0.45	1.77e-14	Coffee consumption (cups per day);
CESC	cis	rs708547	0.647	rs1718830	chr4:57888510	T/C	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.42	-5.52	-0.32	7.99e-8	Response to bleomycin (chromatid breaks);
CESC	cis	rs514406	0.792	rs481440	chr1:53344976	C/T	cg08859206	chr1:53392774	SCP2	-0.65	-9.41	-0.5	2.54e-18	Monocyte count;
CESC	cis	rs6784615	0.744	rs1541495	chr3:52492707	T/C	cg12962167	chr3:53033115	SFMBT1	-0.74	-5.05	-0.3	8.32e-7	Waist-hip ratio;
CESC	cis	rs10504229	0.636	rs115738451	chr8:58055133	A/T	cg24829409	chr8:58192753	C8orf71	-0.59	-6.7	-0.38	1.22e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs10540	1.000	rs61876339	chr11:495283	T/C	cg21784768	chr11:537496	LRRC56	-0.55	-5.11	-0.3	6.14e-7	Body mass index;
CESC	cis	rs7523050	0.643	rs35662800	chr1:109400816	C/A	cg08274380	chr1:109419600	GPSM2	0.85	5.61	0.33	5.08e-8	Fat distribution (HIV);
CESC	cis	rs1218582	0.772	rs4845694	chr1:154911651	C/G	cg03351412	chr1:154909251	PMVK	0.68	9.09	0.49	2.32e-17	Prostate cancer;
CESC	trans	rs1545843	0.593	rs4570627	chr12:84796004	A/G	cg03015433	chr16:56623111	MT3	-0.34	-6.14	-0.35	3.04e-9	Major depressive disorder;
CESC	cis	rs950776	0.518	rs8025429	chr15:78836362	G/A	cg24631222	chr15:78858424	CHRNA5	0.39	5.12	0.3	5.79e-7	Sudden cardiac arrest;
CESC	cis	rs796364	0.806	rs11689664	chr2:201099961	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.77	-6.38	-0.36	7.86e-10	Schizophrenia;
CESC	cis	rs2404602	0.692	rs34287706	chr15:76942402	A/C	cg26408565	chr15:76604113	ETFA	-0.4	-5.68	-0.33	3.45e-8	Blood metabolite levels;
CESC	cis	rs769267	0.965	rs10419245	chr19:19383755	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	7.33	0.41	2.71e-12	Tonsillectomy;
CESC	cis	rs2342371	0.848	rs5016648	chr3:196207989	A/G	cg15048948	chr3:196158458	UBXN7	-0.42	-5.34	-0.31	1.97e-7	Fat distribution (HIV);
CESC	cis	rs4665809	1.000	rs2891490	chr2:26325927	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.66	-7.47	-0.42	1.15e-12	Gut microbiome composition (summer);
CESC	cis	rs1552244	0.626	rs2886396	chr3:10037670	C/T	cg00149659	chr3:10157352	C3orf10	0.71	8.45	0.46	2.01e-15	Alzheimer's disease;
CESC	cis	rs8060686	0.641	rs28508024	chr16:68126606	T/C	cg26727032	chr16:67993705	SLC12A4	-0.52	-6.3	-0.36	1.24e-9	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs7618501	0.633	rs2526748	chr3:50080439	A/G	cg24308560	chr3:49941425	MST1R	0.63	9.56	0.51	8.69e-19	Intelligence (multi-trait analysis);
CESC	cis	rs7772486	0.790	rs6923545	chr6:146244743	A/G	cg23711669	chr6:146136114	FBXO30	-0.94	-13.73	-0.64	9.31e-33	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2180341	0.883	rs6904630	chr6:127696869	A/G	cg27446573	chr6:127587934	RNF146	1.05	15.31	0.69	2.37e-38	Breast cancer;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03577460	chr14:24836084	NFATC4	-0.46	-6.29	-0.36	1.34e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs13191362	0.938	rs28360532	chr6:162997477	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.5	5.17	0.3	4.64e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs524281	0.817	rs10791849	chr11:65890597	T/A	cg14036092	chr11:66035641	RAB1B	-0.61	-6.08	-0.35	4.09e-9	Electroencephalogram traits;
CESC	cis	rs7937682	0.632	rs4936834	chr11:111764017	T/A	cg09085632	chr11:111637200	PPP2R1B	0.87	11.02	0.56	1.67e-23	Primary sclerosing cholangitis;
CESC	cis	rs2011503	1.000	rs76790018	chr19:19652157	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.52	5.09	0.3	6.68e-7	Bipolar disorder;
CESC	cis	rs4930103	0.935	rs4929987	chr11:2028591	C/G	cg23202291	chr11:1979235	NA	0.37	5.17	0.3	4.7e-7	DNA methylation (parent-of-origin);DNA methylation (variation);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14258078	chr17:62051773	SCN4A	-0.44	-7.07	-0.4	1.35e-11	Gut microbiome composition (summer);
CESC	cis	rs10256972	0.869	rs1007766	chr7:1034903	G/A	cg07308232	chr7:1071921	C7orf50	-0.45	-6.03	-0.35	5.41e-9	Longevity;Endometriosis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24367431	chr1:24828968	RCAN3	0.59	6.09	0.35	3.86e-9	Gut microbiome composition (summer);
CESC	cis	rs8078723	0.802	rs9303283	chr17:38192633	A/G	cg17467752	chr17:38218738	THRA	0.67	10.88	0.56	5.07e-23	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CESC	cis	rs72781680	0.582	rs72783611	chr2:24291445	C/T	cg20701182	chr2:24300061	SF3B14	0.93	10.58	0.54	4.83e-22	Lymphocyte counts;
CESC	cis	rs4727963	0.846	rs1357948	chr7:122695727	T/C	cg03640110	chr7:122635026	TAS2R16	-0.37	-5.88	-0.34	1.24e-8	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
CESC	cis	rs6733011	0.518	rs12712033	chr2:99457973	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.43	-5.31	-0.31	2.3e-7	Bipolar disorder;
CESC	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.5	-7.27	-0.41	3.93e-12	Longevity;Endometriosis;
CESC	cis	rs208520	0.560	rs2351880	chr6:66863707	G/A	cg07460842	chr6:66804631	NA	-1.02	-13.47	-0.64	7.41e-32	Exhaled nitric oxide output;
CESC	cis	rs1538970	0.748	rs11211137	chr1:46013892	T/A	cg24296786	chr1:45957014	TESK2	-0.48	-5.2	-0.3	3.99e-7	Platelet count;
CESC	cis	rs977987	0.586	rs12920883	chr16:75432681	T/C	cg03315344	chr16:75512273	CHST6	0.4	5.74	0.33	2.61e-8	Dupuytren's disease;
CESC	cis	rs1215050	0.755	rs811479	chr4:98727398	A/T	cg05340658	chr4:99064831	C4orf37	0.51	6.55	0.37	3.04e-10	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs1048238	0.846	rs945417	chr1:16344625	C/G	cg21214613	chr1:16344536	HSPB7	0.33	5.4	0.31	1.47e-7	Systolic blood pressure;
CESC	cis	rs11792861	0.816	rs28361111	chr9:111761012	A/C	cg05043794	chr9:111880884	C9orf5	-0.36	-5.81	-0.34	1.76e-8	Menarche (age at onset);
CESC	cis	rs1707322	1.000	rs11211232	chr1:46411146	C/T	cg05343316	chr1:45956843	TESK2	0.49	5.96	0.34	7.82e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01325958	chr17:37793326	STARD3	0.57	6.37	0.36	8.48e-10	Gut microbiome composition (summer);
CESC	cis	rs4566357	0.615	rs10178260	chr2:227914458	G/T	cg05526886	chr2:227700861	RHBDD1	-0.45	-5.93	-0.34	9.37e-9	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18224556	chr11:65101075	DPF2	0.57	6.92	0.39	3.47e-11	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22501760	chr22:29137527	CHEK2;HSCB	-0.65	-7.63	-0.42	4.18e-13	Gut microbiome composition (summer);
CESC	cis	rs9733	0.744	rs11204725	chr1:150742700	T/C	cg13175981	chr1:150552382	MCL1	0.52	7.24	0.41	4.94e-12	Tonsillectomy;
CESC	cis	rs1008375	0.966	rs28750296	chr4:17685826	A/T	cg02297831	chr4:17616191	MED28	0.42	5.42	0.32	1.33e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs7712401	0.601	rs34126945	chr5:122329729	A/G	cg19412675	chr5:122181750	SNX24	-0.41	-5.34	-0.31	2e-7	Mean platelet volume;
CESC	cis	rs113835537	0.935	rs79496339	chr11:66467769	T/A	cg22134325	chr11:66188745	NPAS4	0.52	5.94	0.34	8.91e-9	Airway imaging phenotypes;
CESC	cis	rs2276314	0.748	rs4799839	chr18:33597531	T/C	cg05985134	chr18:33552581	C18orf21	0.61	7.12	0.4	1.01e-11	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs9815354	0.812	rs60796012	chr3:41908668	T/C	cg03022575	chr3:42003672	ULK4	0.7	6.18	0.36	2.38e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs7084402	0.967	rs1649043	chr10:60328209	C/T	cg07615347	chr10:60278583	BICC1	0.59	9.18	0.49	1.26e-17	Refractive error;
CESC	cis	rs56399783	0.901	rs73049380	chr7:2832845	C/T	cg19731401	chr7:2775893	GNA12	0.66	5.95	0.34	8.54e-9	Childhood ear infection;
CESC	cis	rs61935443	0.720	rs11107776	chr12:95294283	T/G	cg21533806	chr12:95267307	NA	0.53	6.48	0.37	4.54e-10	Schizophrenia;
CESC	cis	rs7586673	0.930	rs6432667	chr2:161905001	T/C	cg22496339	chr2:162101262	NA	0.53	6.78	0.38	7.61e-11	Intelligence (multi-trait analysis);
CESC	trans	rs35110281	0.720	rs162394	chr21:44943550	C/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.53	-7.17	-0.4	7.59e-12	Mean corpuscular volume;
CESC	cis	rs4332037	0.624	rs11764337	chr7:1892309	A/G	cg13880726	chr7:1868755	MAD1L1	0.46	5.04	0.3	8.56e-7	Bipolar disorder;
CESC	cis	rs2797160	0.967	rs2797159	chr6:126009557	G/A	cg05901451	chr6:126070800	HEY2	0.45	6.59	0.38	2.39e-10	Endometrial cancer;
CESC	cis	rs4713118	0.662	rs9468277	chr6:28028390	C/A	cg12963246	chr6:28129442	ZNF389	0.5	6.4	0.37	6.93e-10	Parkinson's disease;
CESC	cis	rs734999	0.545	rs6698817	chr1:2564183	T/C	cg20673091	chr1:2541236	MMEL1	-0.47	-7.84	-0.43	1.11e-13	Ulcerative colitis;
CESC	cis	rs57506017	0.585	rs5011431	chr7:12268551	G/A	cg23422036	chr7:12250390	TMEM106B	0.38	5.13	0.3	5.64e-7	Neuroticism;
CESC	cis	rs892961	0.836	rs35077273	chr17:75412415	T/C	cg05865280	chr17:75406074	SEPT9	0.62	12.67	0.61	4.57e-29	Airflow obstruction;
CESC	cis	rs1008375	0.931	rs10019482	chr4:17578079	G/A	cg27347728	chr4:17578864	LAP3	0.43	5.12	0.3	5.92e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs8114671	0.562	rs6088621	chr20:33418740	C/T	cg07148914	chr20:33460835	GGT7	0.42	5.39	0.31	1.52e-7	Height;
CESC	cis	rs1215050	0.755	rs7696354	chr4:98820330	T/C	cg05340658	chr4:99064831	C4orf37	0.47	6.06	0.35	4.59e-9	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs4450131	0.522	rs3781451	chr10:126355477	G/A	cg20435097	chr10:126320824	FAM53B	0.29	5.31	0.31	2.34e-7	White blood cell count (basophil);
CESC	cis	rs926938	0.618	rs360587	chr1:115467553	A/G	cg12756093	chr1:115239321	AMPD1	0.51	7.3	0.41	3.31e-12	Autism;
CESC	cis	rs896854	0.654	rs6982393	chr8:95980708	T/C	cg13393036	chr8:95962371	TP53INP1	-0.48	-10.16	-0.53	1.04e-20	Type 2 diabetes;
CESC	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg06873352	chr17:61820015	STRADA	-0.72	-12.95	-0.62	4.69e-30	Prudent dietary pattern;
CESC	cis	rs9486719	1.000	rs28623445	chr6:96899116	G/T	cg18709589	chr6:96969512	KIAA0776	-0.54	-5.87	-0.34	1.3e-8	Migraine;Coronary artery disease;
CESC	cis	rs736408	0.522	rs6445535	chr3:52771468	T/C	cg17372223	chr3:52568218	NT5DC2	0.43	6.51	0.37	3.75e-10	Bipolar disorder;
CESC	cis	rs2439831	0.850	rs3862142	chr15:44064806	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.68	7.88	0.44	8.75e-14	Lung cancer in ever smokers;
CESC	cis	rs597539	0.615	rs583182	chr11:68678634	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.79	10.34	0.54	2.86e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs4665809	0.838	rs6546780	chr2:26352857	T/C	cg04944784	chr2:26401820	FAM59B	-0.66	-7.49	-0.42	1.03e-12	Gut microbiome composition (summer);
CESC	cis	rs1799949	0.965	rs33988650	chr17:41287880	A/G	cg25072359	chr17:41440525	NA	0.43	5.83	0.34	1.61e-8	Menopause (age at onset);
CESC	cis	rs2637266	1.000	rs2395394	chr10:78360679	G/C	cg18941641	chr10:78392320	NA	0.42	7.87	0.44	9.23e-14	Pulmonary function;
CESC	cis	rs10411936	1.000	rs1870071	chr19:16505106	A/G	cg10248733	chr19:16607483	C19orf44;CALR3	-0.49	-5.91	-0.34	1.04e-8	White blood cell count;Multiple sclerosis;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg16554516	chr1:206680868	RASSF5	-0.44	-6.3	-0.36	1.26e-9	Fibrinogen levels;
CESC	cis	rs9467773	1.000	rs9467779	chr6:26536687	A/T	cg26531700	chr6:26746687	NA	0.33	5.12	0.3	5.92e-7	Intelligence (multi-trait analysis);
CESC	cis	rs1665050	0.534	rs11855896	chr15:59234646	G/C	cg05156742	chr15:59063176	FAM63B	0.5	6.42	0.37	6.18e-10	Atopic dermatitis;
CESC	cis	rs7223966	0.515	rs2727315	chr17:61961458	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	7.1	0.4	1.15e-11	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs1801251	1.000	rs2012221	chr2:233566848	T/C	cg25237894	chr2:233734115	C2orf82	0.5	8.64	0.47	5.54e-16	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11642829	chr17:4607740	PELP1	0.56	6.61	0.38	2.07e-10	Gut microbiome composition (summer);
CESC	cis	rs13256369	0.802	rs12680019	chr8:8561698	A/G	cg00074818	chr8:8560427	CLDN23	0.36	5.17	0.3	4.63e-7	Obesity-related traits;
CESC	cis	rs477895	0.653	rs7102327	chr11:63908720	C/T	cg18225595	chr11:63971243	STIP1	0.52	5.13	0.3	5.55e-7	Mean platelet volume;
CESC	cis	rs6484504	0.576	rs158139	chr11:31216076	C/T	cg14844989	chr11:31128820	NA	-0.41	-5.86	-0.34	1.34e-8	Red blood cell count;
CESC	cis	rs748404	0.650	rs518261	chr15:43573429	A/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.59	7.76	0.43	1.84e-13	Lung cancer;
CESC	cis	rs7267979	0.966	rs4815425	chr20:25398876	G/C	cg08601574	chr20:25228251	PYGB	-0.38	-5.46	-0.32	1.08e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs11195062	0.521	rs4918485	chr10:111949323	A/T	cg00817464	chr10:111662876	XPNPEP1	0.52	7.13	0.4	9.27e-12	Multiple myeloma;
CESC	cis	rs4722166	0.630	rs12700390	chr7:22777129	G/T	cg13104385	chr7:22767384	IL6	0.48	6.43	0.37	5.96e-10	Lung cancer;
CESC	cis	rs9611565	0.659	rs4822034	chr22:41931010	T/C	cg06634786	chr22:41940651	POLR3H	-0.64	-6.69	-0.38	1.3e-10	Vitiligo;
CESC	cis	rs17270561	0.779	rs1165200	chr6:25875212	C/T	cg17691542	chr6:26056736	HIST1H1C	-0.69	-8.37	-0.46	3.47e-15	Iron status biomarkers;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg11680442	chr3:127309618	TPRA1	-0.47	-6.24	-0.36	1.77e-9	Asthma;
CESC	cis	rs7072216	0.763	rs7914401	chr10:100163928	A/G	cg26618903	chr10:100175079	PYROXD2	-0.35	-5.41	-0.32	1.41e-7	Metabolite levels;
CESC	trans	rs35110281	0.805	rs4818843	chr21:45006607	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.58	7.63	0.42	4.31e-13	Mean corpuscular volume;
CESC	cis	rs7678296	0.649	rs4585313	chr4:37240236	C/T	cg06805348	chr4:37245195	KIAA1239	-0.53	-5.59	-0.32	5.73e-8	3-hydroxypropylmercapturic acid levels in smokers;
CESC	trans	rs61931739	0.500	rs3934517	chr12:34451396	T/C	cg26384229	chr12:38710491	ALG10B	0.54	7.5	0.42	9.79e-13	Morning vs. evening chronotype;
CESC	cis	rs2730245	0.505	rs1188956	chr7:158690576	G/A	cg24397884	chr7:158709396	WDR60	0.81	12.73	0.62	2.72e-29	Height;
CESC	cis	rs2033711	0.870	rs7408188	chr19:58939389	T/G	cg13877915	chr19:58951672	ZNF132	0.39	5.8	0.34	1.93e-8	Uric acid clearance;
CESC	cis	rs875971	0.862	rs1875057	chr7:65731855	A/G	cg11764359	chr7:65958608	NA	-0.79	-11.55	-0.58	2.79e-25	Aortic root size;
CESC	cis	rs2997447	0.792	rs61775432	chr1:26416376	A/G	cg24596570	chr1:26146463	FAM54B;LOC646471	0.66	5.53	0.32	7.83e-8	QRS complex (12-leadsum);
CESC	cis	rs7927592	0.913	rs59056571	chr11:68272973	T/G	cg20283391	chr11:68216788	NA	-0.62	-7.54	-0.42	7.45e-13	Total body bone mineral density;
CESC	cis	rs1957429	0.808	rs1570296	chr14:65332294	T/A	cg23373153	chr14:65346875	NA	0.88	9.2	0.49	1.13e-17	Pediatric areal bone mineral density (radius);
CESC	cis	rs7927771	1.000	rs10838757	chr11:47763016	T/C	cg20307385	chr11:47447363	PSMC3	-0.5	-6.13	-0.35	3.18e-9	Subjective well-being;
CESC	cis	rs514406	0.505	rs405208	chr1:53176674	C/T	cg16325326	chr1:53192061	ZYG11B	0.93	16.14	0.7	2.85e-41	Monocyte count;
CESC	cis	rs2842992	0.747	rs733319	chr6:160221475	A/G	cg11366901	chr6:160182831	ACAT2	0.77	9.47	0.5	1.65e-18	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs72945132	0.882	rs7128969	chr11:70205017	C/A	cg14191688	chr11:70257035	CTTN	0.42	5.19	0.3	4.1e-7	Coronary artery disease;
CESC	cis	rs651907	0.557	rs11924013	chr3:101366698	G/A	cg12386194	chr3:101231763	SENP7	0.44	5.57	0.32	6.2e-8	Colorectal cancer;
CESC	cis	rs2637266	0.703	rs1099884	chr10:78513301	G/T	cg18941641	chr10:78392320	NA	0.38	7.5	0.42	9.82e-13	Pulmonary function;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21220614	chr22:43266108	NA	-0.52	-6.06	-0.35	4.67e-9	Gut microbiome composition (summer);
CESC	cis	rs2075371	0.501	rs1421469	chr7:134028260	C/G	cg20476274	chr7:133979776	SLC35B4	0.4	5.17	0.3	4.64e-7	Mean platelet volume;
CESC	cis	rs7107174	1.000	rs10899481	chr11:78058721	A/T	cg02023728	chr11:77925099	USP35	-0.38	-5.22	-0.31	3.53e-7	Testicular germ cell tumor;
CESC	cis	rs12477438	0.520	rs13031919	chr2:99848932	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.69	10.2	0.53	8.06e-21	Chronic sinus infection;
CESC	cis	rs734999	0.545	rs4474198	chr1:2553758	C/T	cg20673091	chr1:2541236	MMEL1	0.46	8.05	0.44	2.81e-14	Ulcerative colitis;
CESC	cis	rs7412746	0.611	rs11204726	chr1:150743492	T/C	cg04414720	chr1:150670196	GOLPH3L	0.58	7.55	0.42	7.07e-13	Melanoma;
CESC	cis	rs67460515	0.892	rs73026976	chr3:160964271	G/A	cg03342759	chr3:160939853	NMD3	-0.55	-7.79	-0.43	1.5e-13	Parkinson's disease;
CESC	cis	rs1018836	0.884	rs9643307	chr8:91625257	A/C	cg16814680	chr8:91681699	NA	-0.72	-9.98	-0.52	3.92e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs34779708	0.966	rs4934730	chr10:35415555	A/G	cg03585969	chr10:35415529	CREM	0.76	10.01	0.52	3.26e-20	Inflammatory bowel disease;Crohn's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13755614	chr9:131710194	DOLK;NUP188	0.54	6.47	0.37	4.69e-10	Gut microbiome composition (summer);
CESC	cis	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg21782813	chr7:2030301	MAD1L1	0.37	5.2	0.3	3.9e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs4689388	0.791	rs1046317	chr4:6304242	T/C	cg00701064	chr4:6280414	WFS1	0.6	8.85	0.48	1.25e-16	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs875971	0.502	rs2465121	chr7:65621004	A/G	cg25405998	chr7:65216604	CCT6P1	-0.51	-5.53	-0.32	7.66e-8	Aortic root size;
CESC	cis	rs853679	0.517	rs9368558	chr6:28133306	A/G	cg17949981	chr6:28129498	ZNF389	0.45	5.57	0.32	6.26e-8	Depression;
CESC	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg03188948	chr7:1209495	NA	0.71	6.87	0.39	4.6e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs6582630	0.519	rs1851121	chr12:38389467	T/C	cg13010199	chr12:38710504	ALG10B	0.49	6.25	0.36	1.67e-9	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs6685188	0.920	rs6676110	chr1:205662977	G/A	cg17178900	chr1:205818956	PM20D1	-0.38	-5.09	-0.3	6.94e-7	White blood cell count (basophil);Basophil percentage of white cells;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06192289	chr12:102513805	NUP37;C12orf48	0.52	6.03	0.35	5.6e-9	Gut microbiome composition (summer);
CESC	cis	rs9733	0.687	rs12410050	chr1:150857141	A/G	cg18016565	chr1:150552671	MCL1	-0.37	-5.91	-0.34	1.03e-8	Tonsillectomy;
CESC	cis	rs2842992	0.915	rs2842985	chr6:160085434	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.66	7.9	0.44	7.34e-14	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs1008375	0.932	rs2302394	chr4:17641188	A/G	cg16339924	chr4:17578868	LAP3	0.75	9.36	0.5	3.65e-18	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs796364	0.616	rs2103094	chr2:200687954	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	0.57	5.23	0.31	3.39e-7	Schizophrenia;
CESC	cis	rs875971	0.545	rs75577046	chr7:65958716	A/G	cg11764359	chr7:65958608	NA	0.8	9.57	0.51	7.82e-19	Aortic root size;
CESC	cis	rs4713118	0.586	rs6905522	chr6:28086479	A/C	cg22143856	chr6:28129313	ZNF389	0.52	6.71	0.38	1.21e-10	Parkinson's disease;
CESC	cis	rs7216064	1.000	rs7223813	chr17:65945840	A/G	cg12091567	chr17:66097778	LOC651250	-0.7	-7.14	-0.4	9.02e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs13256369	0.851	rs13255061	chr8:8563834	G/A	cg00074818	chr8:8560427	CLDN23	0.38	5.46	0.32	1.1e-7	Obesity-related traits;
CESC	cis	rs12410462	0.681	rs75876430	chr1:227661157	A/G	cg04117972	chr1:227635322	NA	0.76	6.64	0.38	1.73e-10	Major depressive disorder;
CESC	cis	rs4604732	0.527	rs12031949	chr1:247624463	G/T	cg12754571	chr1:247694271	LOC148824;OR2C3	0.44	5.49	0.32	9.6e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs854765	0.647	rs712267	chr17:18021607	G/A	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.5	6.25	0.36	1.6e-9	Total body bone mineral density;
CESC	cis	rs1062177	1.000	rs2964584	chr5:151142878	T/C	cg12924095	chr5:151150029	G3BP1	0.47	6.04	0.35	5.22e-9	Preschool internalizing problems;
CESC	cis	rs12291225	0.535	rs12806025	chr11:14413817	G/A	cg19336497	chr11:14380999	RRAS2	-0.35	-5.16	-0.3	4.82e-7	Sense of smell;
CESC	cis	rs1478897	0.804	rs9329246	chr8:11392880	A/G	cg09528494	chr8:11338675	NA	0.31	5.72	0.33	2.93e-8	Systemic lupus erythematosus;
CESC	trans	rs11098499	0.909	rs6842762	chr4:120398236	A/T	cg25214090	chr10:38739885	LOC399744	0.72	10.31	0.54	3.55e-21	Corneal astigmatism;
CESC	cis	rs2708240	0.577	rs1186173	chr7:147546603	T/C	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.34	-5.49	-0.32	9.48e-8	QT interval (drug interaction);
CESC	trans	rs4335177	0.762	rs4461961	chr9:109321818	C/T	cg00697916	chr3:65342644	MAGI1	0.32	6.0	0.35	6.5e-9	Response to paliperidone in schizophrenia (positive Marder score);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg18247339	chr14:35183597	CFL2	-0.47	-6.05	-0.35	4.98e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14536777	chr8:145665811	NFKBIL2	-0.57	-7.04	-0.4	1.67e-11	Gut microbiome composition (summer);
CESC	trans	rs1814175	0.645	rs7395438	chr11:49877379	G/T	cg15704280	chr7:45808275	SEPT13	-0.98	-18.2	-0.75	1.48e-48	Height;
CESC	cis	rs7659604	0.582	rs3217780	chr4:122737278	T/C	cg06713675	chr4:122721982	EXOSC9	-0.51	-7.02	-0.4	1.9e-11	Type 2 diabetes;
CESC	cis	rs10504229	1.000	rs17216711	chr8:58170856	T/C	cg14926445	chr8:58193284	C8orf71	-0.51	-5.47	-0.32	1.03e-7	Developmental language disorder (linguistic errors);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg16424519	chr16:21531031	SLC7A5P2	0.48	6.12	0.35	3.44e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs9640161	0.789	rs34495356	chr7:150057791	A/G	cg27494647	chr7:150038898	RARRES2	0.42	5.12	0.3	5.75e-7	Blood protein levels;Circulating chemerin levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07766779	chr6:149887504	C6orf72	0.53	6.37	0.36	8.53e-10	Gut microbiome composition (summer);
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg03532253	chr12:56399235	SUOX	0.42	6.82	0.39	6.09e-11	Thyroid stimulating hormone;
CESC	cis	rs9733	0.565	rs7524620	chr1:150616699	C/T	cg22823121	chr1:150693482	HORMAD1	-0.49	-7.33	-0.41	2.86e-12	Tonsillectomy;
CESC	cis	rs2839186	0.967	rs4819222	chr21:47707778	G/A	cg10351095	chr21:47802916	PCNT	-0.51	-6.85	-0.39	5.26e-11	Testicular germ cell tumor;
CESC	cis	rs2836974	0.897	rs2836973	chr21:40654928	A/G	cg17971929	chr21:40555470	PSMG1	1.09	16.94	0.72	3.91e-44	Cognitive function;
CESC	cis	rs4450131	0.522	rs3781453	chr10:126348761	T/C	cg20435097	chr10:126320824	FAM53B	0.28	5.15	0.3	5.07e-7	White blood cell count (basophil);
CESC	cis	rs477895	0.568	rs34838337	chr11:63870892	T/C	cg04317338	chr11:64019027	PLCB3	0.84	8.71	0.47	3.34e-16	Mean platelet volume;
CESC	cis	rs17041941	1.000	rs35718992	chr2:111998256	A/C	cg23466623	chr2:111982296	NA	0.48	5.43	0.32	1.3e-7	Cognitive function;
CESC	cis	rs7188697	0.848	rs37062	chr16:58567238	A/G	cg02549819	chr16:58548995	SETD6	-0.42	-5.25	-0.31	3.1e-7	QT interval;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg17092583	chr11:735575	NA	0.39	6.09	0.35	4.04e-9	Fibrinogen levels;
CESC	cis	rs17125944	0.505	rs2295827	chr14:53174981	C/T	cg13660082	chr14:53194042	PSMC6	-0.66	-5.92	-0.34	1.01e-8	Alzheimer's disease (late onset);
CESC	trans	rs6073597	1.000	rs6031980	chr20:43714384	C/T	cg07823935	chr2:183902842	NCKAP1	0.44	6.14	0.35	3.06e-9	Positive affect;
CESC	cis	rs10927875	0.757	rs4661679	chr1:16321010	C/T	cg21385522	chr1:16154831	NA	0.47	5.91	0.34	1.05e-8	Dilated cardiomyopathy;
CESC	cis	rs113835537	0.529	rs79798028	chr11:66199362	T/G	cg24851651	chr11:66362959	CCS	0.46	5.99	0.35	6.96e-9	Airway imaging phenotypes;
CESC	cis	rs6570726	0.846	rs6914304	chr6:145921017	T/C	cg05347473	chr6:146136440	FBXO30	0.47	6.22	0.36	1.97e-9	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs10504229	0.683	rs7460059	chr8:58111561	C/T	cg02725872	chr8:58115012	NA	-0.45	-7.04	-0.4	1.66e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs910316	1.000	rs175442	chr14:75603564	T/C	cg08847533	chr14:75593920	NEK9	-0.98	-18.77	-0.76	1.37e-50	Height;
CESC	cis	rs919433	0.926	rs787996	chr2:198216805	A/G	cg03934865	chr2:198174659	NA	0.44	6.47	0.37	4.71e-10	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs9814567	1.000	rs4974484	chr3:134219019	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.44	-5.98	-0.35	7.05e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs4665809	1.000	rs2053367	chr2:26293413	T/C	cg04944784	chr2:26401820	FAM59B	-0.66	-7.57	-0.42	6.39e-13	Gut microbiome composition (summer);
CESC	cis	rs2839186	0.708	rs17183123	chr21:47671961	G/C	cg05896524	chr21:47604654	C21orf56	0.44	5.78	0.33	2.1e-8	Testicular germ cell tumor;
CESC	cis	rs3820928	0.605	rs13410141	chr2:227805529	A/G	cg05526886	chr2:227700861	RHBDD1	-0.54	-7.41	-0.41	1.73e-12	Pulmonary function;
CESC	cis	rs1799949	0.930	rs3765640	chr17:41276247	A/G	cg25072359	chr17:41440525	NA	0.43	5.78	0.33	2.04e-8	Menopause (age at onset);
CESC	cis	rs9311474	0.502	rs4687624	chr3:52563572	C/T	cg15147215	chr3:52552868	STAB1	-0.32	-5.33	-0.31	2.1e-7	Electroencephalogram traits;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg22194305	chr4:2264032	MXD4	-0.46	-6.61	-0.38	2.11e-10	Gambling;
CESC	cis	rs2721195	0.626	rs59464125	chr8:145857786	G/A	cg26752003	chr8:145688521	CYHR1	0.47	6.43	0.37	6e-10	Age at first birth;
CESC	cis	rs2839186	0.771	rs2280959	chr21:47641996	C/G	cg13012494	chr21:47604986	C21orf56	0.44	5.86	0.34	1.39e-8	Testicular germ cell tumor;
CESC	cis	rs561341	1.000	rs117979353	chr17:30272866	A/G	cg23018236	chr17:30244563	NA	-0.58	-5.59	-0.32	5.77e-8	Hip circumference adjusted for BMI;
CESC	cis	rs7666738	0.925	rs2865952	chr4:99040305	C/T	cg03676636	chr4:99064102	C4orf37	0.37	5.35	0.31	1.87e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs651907	0.557	rs3094296	chr3:101400167	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.47	6.09	0.35	3.91e-9	Colorectal cancer;
CESC	cis	rs10129255	0.957	rs6576228	chr14:107186640	A/G	cg23076370	chr14:107095027	NA	-0.49	-6.35	-0.36	9.11e-10	Kawasaki disease;
CESC	trans	rs427691	0.625	rs370575	chr5:109011288	A/G	cg00054525	chr16:88717587	CYBA	-0.6	-6.47	-0.37	4.7e-10	Autism spectrum disorder or schizophrenia;
CESC	cis	rs9733	0.596	rs12077833	chr1:150674333	C/T	cg18016565	chr1:150552671	MCL1	0.33	5.16	0.3	4.96e-7	Tonsillectomy;
CESC	cis	rs7264396	0.790	rs6060530	chr20:34227663	C/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.6	6.51	0.37	3.84e-10	Total cholesterol levels;
CESC	trans	rs11098499	0.739	rs951570	chr4:120150467	T/C	cg25214090	chr10:38739885	LOC399744	-0.57	-7.56	-0.42	6.59e-13	Corneal astigmatism;
CESC	cis	rs1348850	0.831	rs1345139	chr2:178449791	G/T	cg23306229	chr2:178417860	TTC30B	0.45	5.71	0.33	3.01e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs7917772	0.582	rs7091252	chr10:104328859	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.41	5.61	0.33	5.05e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs7552404	0.924	rs1313071	chr1:76195542	C/G	cg10523679	chr1:76189770	ACADM	0.75	10.07	0.53	2.05e-20	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs12142240	0.698	rs17357628	chr1:46808462	A/G	cg10495392	chr1:46806563	NSUN4	0.59	6.34	0.36	9.65e-10	Menopause (age at onset);
CESC	cis	rs501120	0.636	rs920172	chr10:44782724	T/C	cg09554077	chr10:44749378	NA	0.65	5.39	0.31	1.53e-7	Coronary artery disease;Coronary heart disease;
CESC	cis	rs10504229	0.679	rs7813252	chr8:58136389	C/G	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs1707322	1.000	rs11211205	chr1:46321874	C/T	cg03146154	chr1:46216737	IPP	0.71	9.86	0.52	9.69e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs4803468	0.967	rs11670583	chr19:41920440	A/T	cg14132834	chr19:41945861	ATP5SL	-0.67	-8.23	-0.45	8.57e-15	Height;
CESC	cis	rs7615952	0.599	rs2279821	chr3:125734308	G/A	cg15145296	chr3:125709740	NA	-0.5	-5.35	-0.31	1.86e-7	Blood pressure (smoking interaction);
CESC	cis	rs7107174	1.000	rs10793300	chr11:78019582	T/A	cg02023728	chr11:77925099	USP35	0.48	6.27	0.36	1.46e-9	Testicular germ cell tumor;
CESC	cis	rs9527	0.567	rs11191573	chr10:104896816	T/C	cg04362960	chr10:104952993	NT5C2	0.44	5.54	0.32	7.12e-8	Arsenic metabolism;
CESC	cis	rs2070488	0.965	rs7372849	chr3:38524328	G/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.93	16.67	0.72	3.66e-43	Electrocardiographic conduction measures;
CESC	cis	rs9649465	0.561	rs2429620	chr7:123430012	A/G	cg03229431	chr7:123269106	ASB15	0.4	5.46	0.32	1.1e-7	Migraine;
CESC	cis	rs4689388	0.926	rs10012946	chr4:6293350	C/T	cg00701064	chr4:6280414	WFS1	-0.78	-11.23	-0.57	3.33e-24	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs116095464	0.558	rs6555055	chr5:226160	A/C	cg22857025	chr5:266934	NA	-1.27	-18.8	-0.76	1.13e-50	Breast cancer;
CESC	cis	rs568617	1.000	rs693824	chr11:65654783	A/G	cg00576331	chr11:65640516	EFEMP2	-0.45	-5.35	-0.31	1.95e-7	Crohn's disease;
CESC	trans	rs7618501	1.000	rs7374277	chr3:49784777	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.59	-8.4	-0.46	2.72e-15	Intelligence (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07719772	chr16:32360419	NA	-0.62	-6.69	-0.38	1.32e-10	Gut microbiome composition (summer);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg23181591	chr8:123793873	ZHX2	-0.44	-6.26	-0.36	1.56e-9	Gambling;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26526983	chr16:12136938	RUNDC2A	-0.59	-7.05	-0.4	1.52e-11	Gut microbiome composition (summer);
CESC	cis	rs6460942	0.908	rs3887296	chr7:12257966	A/G	cg20607287	chr7:12443886	VWDE	-0.55	-5.69	-0.33	3.34e-8	Coronary artery disease;
CESC	cis	rs10927875	0.541	rs1739840	chr1:16342237	A/G	cg22431228	chr1:16359049	CLCNKA	-0.52	-9.9	-0.52	7.22e-20	Dilated cardiomyopathy;
CESC	cis	rs727505	0.564	rs67745021	chr7:124868018	T/C	cg23710748	chr7:124431027	NA	-0.34	-5.19	-0.3	4.19e-7	Lewy body disease;
CESC	cis	rs7098414	0.511	rs10466236	chr10:82149717	C/T	cg00277334	chr10:82204260	NA	0.5	7.55	0.42	7.11e-13	Post bronchodilator FEV1;
CESC	cis	rs9894429	0.716	rs7405578	chr17:79588306	C/A	cg13777783	chr17:79615861	NA	-0.32	-5.09	-0.3	6.76e-7	Eye color traits;
CESC	cis	rs7267979	0.868	rs6138550	chr20:25223430	C/T	cg08601574	chr20:25228251	PYGB	0.44	6.36	0.36	8.57e-10	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs796364	0.715	rs1106399	chr2:201003837	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.64	-6.04	-0.35	5.26e-9	Schizophrenia;
CESC	cis	rs709400	0.633	rs10143247	chr14:103920927	G/A	cg12935359	chr14:103987150	CKB	-0.51	-7.46	-0.42	1.24e-12	Body mass index;
CESC	cis	rs4665809	1.000	rs10048648	chr2:26320315	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.68	-7.7	-0.43	2.76e-13	Gut microbiome composition (summer);
CESC	cis	rs2836974	0.965	rs7354783	chr21:40652992	G/A	cg27266027	chr21:40555129	PSMG1	0.45	5.34	0.31	2.05e-7	Cognitive function;
CESC	cis	rs6912958	0.712	rs4706294	chr6:88317675	G/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.5	-6.83	-0.39	5.9e-11	Monocyte percentage of white cells;
CESC	cis	rs4925325	0.956	rs1776263	chr20:60515820	A/G	cg13770153	chr20:60521292	NA	-0.81	-11.62	-0.58	1.65e-25	Obesity-related traits;
CESC	cis	rs1215050	0.740	rs783932	chr4:98973936	C/G	cg17366294	chr4:99064904	C4orf37	-0.38	-5.04	-0.3	8.72e-7	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs8017423	0.647	rs12589952	chr14:90821364	T/C	cg14092571	chr14:90743983	NA	0.44	6.66	0.38	1.55e-10	Mortality in heart failure;
CESC	cis	rs13191362	1.000	rs35723993	chr6:163008197	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.87	9.04	0.49	3.35e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs7666738	0.830	rs13125432	chr4:98961253	G/A	cg18180107	chr4:99064573	C4orf37	0.4	5.14	0.3	5.26e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs769267	0.965	rs12977937	chr19:19429975	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.61	7.76	0.43	1.82e-13	Tonsillectomy;
CESC	cis	rs6952808	0.609	rs6950151	chr7:1953521	T/C	cg04267008	chr7:1944627	MAD1L1	-0.59	-7.47	-0.42	1.16e-12	Bipolar disorder and schizophrenia;
CESC	cis	rs9815354	0.680	rs73073290	chr3:42027684	T/G	cg03022575	chr3:42003672	ULK4	0.75	6.64	0.38	1.72e-10	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs4664308	0.967	rs17241792	chr2:160915205	C/T	cg03641300	chr2:160917029	PLA2R1	-0.67	-10.13	-0.53	1.34e-20	Idiopathic membranous nephropathy;
CESC	trans	rs7866350	0.604	rs1935389	chr9:100994470	A/G	cg22929808	chr12:58027113	B4GALNT1	0.4	6.04	0.35	5.3300000000000004e-09	Post-traumatic stress disorder;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg19734257	chr20:56064117	HMGB1L1	-0.44	-6.73	-0.38	1.04e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.6	0.38	2.17e-10	Prudent dietary pattern;
CESC	cis	rs4853012	0.838	rs4429500	chr2:74345336	A/G	cg01017244	chr2:74357527	NA	0.65	9.29	0.5	5.92e-18	Gestational age at birth (maternal effect);
CESC	trans	rs2727020	0.638	rs1164668	chr11:49330627	A/C	cg15704280	chr7:45808275	SEPT13	0.89	14.5	0.67	1.84e-35	Coronary artery disease;
CESC	cis	rs7129220	0.588	rs61878631	chr11:10134832	C/T	cg01453529	chr11:10209919	SBF2	-0.48	-5.5	-0.32	8.85e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CESC	cis	rs12638540	0.543	rs12487678	chr3:32603358	A/C	cg11605617	chr3:32612461	DYNC1LI1	0.63	5.45	0.32	1.14e-7	Mortality in heart failure;
CESC	cis	rs12586317	0.547	rs74243586	chr14:35477325	C/T	cg16230307	chr14:35515116	FAM177A1	0.98	10.57	0.54	5.04e-22	Psoriasis;
CESC	cis	rs11098499	0.909	rs28581362	chr4:120283548	T/A	cg24375607	chr4:120327624	NA	0.42	5.19	0.3	4.19e-7	Corneal astigmatism;
CESC	cis	rs10504229	0.683	rs113492050	chr8:58130046	A/G	cg24829409	chr8:58192753	C8orf71	-0.58	-7.2	-0.4	6.31e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs2066819	1.000	rs2291361	chr12:56717805	G/A	cg26714650	chr12:56694279	CS	-1.48	-9.9	-0.52	7.03e-20	Psoriasis vulgaris;
CESC	cis	rs514406	0.505	rs431427	chr1:53179094	C/A	cg27535305	chr1:53392650	SCP2	-0.32	-5.33	-0.31	2.13e-7	Monocyte count;
CESC	cis	rs9513627	0.512	rs9517759	chr13:100180108	T/G	cg25919922	chr13:100150906	NA	0.78	9.02	0.48	3.9e-17	Obesity-related traits;
CESC	cis	rs9926296	0.656	rs2376882	chr16:89827002	T/C	cg04287289	chr16:89883240	FANCA	0.57	7.62	0.42	4.55e-13	Vitiligo;
CESC	cis	rs9467773	1.000	rs9467791	chr6:26562486	A/G	cg11502198	chr6:26597334	ABT1	-0.41	-5.8	-0.34	1.92e-8	Intelligence (multi-trait analysis);
CESC	trans	rs9906155	0.748	rs11872015	chr17:75669846	G/C	cg14889768	chr6:146864529	RAB32	0.86	6.24	0.36	1.77e-9	Body mass index;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg16370856	chr5:56470520	GPBP1	0.53	7.21	0.4	5.8e-12	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs9611565	0.921	rs2281332	chr22:41746212	T/C	cg06634786	chr22:41940651	POLR3H	-0.44	-5.03	-0.3	9.12e-7	Vitiligo;
CESC	cis	rs6430585	0.528	rs78274583	chr2:136734569	C/T	cg07169764	chr2:136633963	MCM6	1.28	17.47	0.73	5.26e-46	Corneal structure;
CESC	cis	rs7216064	1.000	rs6504555	chr17:65940727	A/G	cg07042672	chr17:66097459	LOC651250	0.63	7.69	0.43	2.97e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs1878047	0.665	rs12972888	chr19:51775714	C/G	cg14884932	chr19:51774451	NA	-0.37	-5.16	-0.3	4.87e-7	Body mass index;
CESC	cis	rs7666738	0.830	rs6853266	chr4:99047528	G/T	cg17366294	chr4:99064904	C4orf37	0.64	9.1	0.49	2.3e-17	Colonoscopy-negative controls vs population controls;
CESC	cis	rs727563	0.520	rs132773	chr22:42031768	T/A	cg06481639	chr22:41940642	POLR3H	0.57	5.97	0.34	7.74e-9	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs7666738	0.962	rs17550217	chr4:98999699	T/A	cg03676636	chr4:99064102	C4orf37	0.36	5.37	0.31	1.69e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs208520	1.000	rs208520	chr6:66952828	G/T	cg07460842	chr6:66804631	NA	-0.8	-9.18	-0.49	1.3e-17	Exhaled nitric oxide output;
CESC	cis	rs2243480	1.000	rs316307	chr7:65570171	C/T	cg18252515	chr7:66147081	NA	-1.37	-13.56	-0.64	3.47e-32	Diabetic kidney disease;
CESC	cis	rs4919087	0.715	rs1253387	chr10:99032968	G/A	cg25902810	chr10:99078978	FRAT1	-0.46	-5.15	-0.3	5.08e-7	Monocyte count;
CESC	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.53	7.12	0.4	1.04e-11	Lymphocyte counts;
CESC	cis	rs7666738	0.830	rs6840766	chr4:99016260	C/G	cg17366294	chr4:99064904	C4orf37	0.6	8.62	0.47	6.37e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1552244	1.000	rs6793396	chr3:10110927	T/C	cg00166722	chr3:10149974	C3orf24	0.53	6.65	0.38	1.64e-10	Alzheimer's disease;
CESC	cis	rs9649213	0.593	rs62478177	chr7:97964611	G/A	cg21770322	chr7:97807741	LMTK2	0.55	8.27	0.45	6.54e-15	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs6445797	0.662	rs17056878	chr3:56583072	C/T	cg13792233	chr3:56591045	CCDC66	0.4	5.2	0.3	4.06e-7	Gastritis;
CESC	cis	rs7772486	0.754	rs702324	chr6:146008793	A/G	cg23711669	chr6:146136114	FBXO30	-0.87	-12.3	-0.6	8.07e-28	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4563143	0.592	rs12151001	chr19:29283386	C/G	cg04546413	chr19:29218101	NA	0.52	6.75	0.38	9.46e-11	Methadone dose in opioid dependence;
CESC	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg01238044	chr22:24384105	GSTT1	-0.65	-8.76	-0.47	2.33e-16	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs1348850	0.914	rs12612857	chr2:178467144	A/G	cg23306229	chr2:178417860	TTC30B	0.61	7.79	0.43	1.55e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs1949733	0.585	rs2631768	chr4:8473050	A/G	cg11789530	chr4:8429930	ACOX3	-0.57	-7.06	-0.4	1.44e-11	Response to antineoplastic agents;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg11184091	chr9:131843633	DOLPP1	0.46	6.49	0.37	4.3e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs6933660	0.745	rs3800272	chr6:151744283	A/G	cg14416726	chr6:151773293	C6orf211;RMND1	0.52	6.63	0.38	1.82e-10	Menarche (age at onset);
CESC	cis	rs7786877	0.626	rs11983745	chr7:100223678	T/C	cg27028030	chr7:100209634	MOSPD3	0.58	5.51	0.32	8.71e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs7762018	0.891	rs1981069	chr6:170148837	G/A	cg13891659	chr6:170190454	C6orf122;C6orf208	0.67	6.53	0.37	3.28e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs8031584	1.000	rs35811129	chr15:31241346	G/A	cg08704250	chr15:31115839	NA	-0.68	-8.45	-0.46	1.92e-15	Huntington's disease progression;
CESC	cis	rs9399135	0.935	rs9376086	chr6:135371329	T/C	cg24558204	chr6:135376177	HBS1L	0.51	6.99	0.39	2.27e-11	Red blood cell count;
CESC	cis	rs11785400	0.793	rs4371985	chr8:143737279	C/T	cg10596483	chr8:143751796	JRK	0.42	5.17	0.3	4.51e-7	Schizophrenia;
CESC	cis	rs10911251	0.546	rs20560	chr1:183105534	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.85	13.19	0.63	6.92e-31	Colorectal cancer;
CESC	cis	rs9322193	0.962	rs9397357	chr6:150133601	G/A	cg05861140	chr6:150128134	PCMT1	-0.34	-5.04	-0.3	8.49e-7	Lung cancer;
CESC	cis	rs9611565	0.512	rs5996063	chr22:42168767	G/A	cg06481639	chr22:41940642	POLR3H	0.6	5.92	0.34	9.88e-9	Vitiligo;
CESC	cis	rs60843830	1.000	rs7595075	chr2:264019	C/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.8	10.45	0.54	1.25e-21	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs2637266	0.703	rs846575	chr10:78500483	G/A	cg18941641	chr10:78392320	NA	0.38	7.52	0.42	8.55e-13	Pulmonary function;
CESC	trans	rs61931739	0.534	rs2667447	chr12:34133468	C/A	cg26384229	chr12:38710491	ALG10B	0.51	6.8	0.39	6.9e-11	Morning vs. evening chronotype;
CESC	trans	rs7246760	0.618	rs73008113	chr19:9738196	C/T	cg02900749	chr2:68251473	NA	-0.8	-6.18	-0.35	2.43e-9	Pursuit maintenance gain;
CESC	cis	rs10883723	0.518	rs10786679	chr10:104315667	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.45	5.98	0.34	7.21e-9	Allergic disease (asthma, hay fever or eczema);
CESC	trans	rs12599106	0.707	rs2163977	chr16:34916134	A/G	cg26668828	chr6:292823	DUSP22	-0.7	-9.05	-0.49	3.09e-17	Menopause (age at onset);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg07508942	chr7:5267994	WIPI2	0.47	6.22	0.36	1.93e-9	Fibrinogen levels;
CESC	cis	rs55882075	0.750	rs13184690	chr5:179146993	T/C	cg14593053	chr5:179126677	CANX	0.6	8.88	0.48	1.05e-16	Monocyte percentage of white cells;
CESC	trans	rs877282	0.842	rs7092986	chr10:756373	G/A	cg22713356	chr15:30763199	NA	0.93	8.39	0.46	3e-15	Uric acid levels;
CESC	cis	rs1267303	0.682	rs1886117	chr1:46964909	T/A	cg25110126	chr1:46999211	NA	-0.54	-6.23	-0.36	1.78e-9	Monobrow;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg00975115	chr16:30958403	FBXL19	0.48	6.03	0.35	5.37e-9	Fibrinogen levels;
CESC	trans	rs1945213	0.694	rs9888298	chr11:55865704	T/C	cg03929089	chr4:120376271	NA	0.78	7.5	0.42	9.59e-13	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs4466137	0.953	rs974023	chr5:83014848	T/C	cg16102102	chr5:83017553	HAPLN1	-0.51	-7.24	-0.41	4.94e-12	Prostate cancer;
CESC	cis	rs3771570	1.000	rs62193197	chr2:242294301	G/A	cg21155796	chr2:242212141	HDLBP	0.6	5.18	0.3	4.5e-7	Prostate cancer;
CESC	trans	rs916888	0.697	rs199516	chr17:44856485	C/T	cg07870213	chr5:140052090	DND1	-0.62	-7.03	-0.4	1.8e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	trans	rs7615952	0.512	rs2922175	chr3:125361360	T/C	cg07211511	chr3:129823064	LOC729375	-0.59	-7.28	-0.41	3.84e-12	Blood pressure (smoking interaction);
CESC	cis	rs854765	0.647	rs7406744	chr17:17981938	C/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.64	9.07	0.49	2.69e-17	Total body bone mineral density;
CESC	cis	rs7582720	1.000	rs72932566	chr2:203855342	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.36	0.41	2.34e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs4704187	0.687	rs10058460	chr5:74498715	C/T	cg03227963	chr5:74354835	NA	0.29	5.27	0.31	2.77e-7	Response to amphetamines;
CESC	cis	rs7843479	1.000	rs13248727	chr8:21842063	T/C	cg17168535	chr8:21777572	XPO7	0.49	6.81	0.39	6.44e-11	Mean corpuscular volume;
CESC	cis	rs939658	0.805	rs35484723	chr15:79441032	A/G	cg17916960	chr15:79447300	NA	-0.35	-5.98	-0.34	7.25e-9	Refractive error;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09467020	chr12:125398629	UBC	-0.59	-6.92	-0.39	3.33e-11	Gut microbiome composition (summer);
CESC	cis	rs6582630	0.519	rs9738104	chr12:38338459	A/C	cg26384229	chr12:38710491	ALG10B	0.74	10.66	0.55	2.58e-22	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs875971	0.830	rs28714531	chr7:65968237	G/A	cg11764359	chr7:65958608	NA	0.79	11.17	0.57	5.2e-24	Aortic root size;
CESC	trans	rs61931739	0.500	rs11524949	chr12:34435551	C/T	cg13010199	chr12:38710504	ALG10B	0.49	6.16	0.35	2.66e-9	Morning vs. evening chronotype;
CESC	cis	rs854765	0.583	rs7207043	chr17:17819188	A/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.55	7.34	0.41	2.67e-12	Total body bone mineral density;
CESC	cis	rs11209002	0.545	rs2093332	chr1:67531974	G/A	cg02640540	chr1:67518911	SLC35D1	0.48	5.47	0.32	1.04e-7	Crohn's disease;
CESC	cis	rs11696501	0.694	rs6094184	chr20:44256575	G/A	cg11783356	chr20:44313418	WFDC10B	-0.35	-5.4	-0.31	1.49e-7	Brain structure;
CESC	cis	rs8092503	1.000	rs7243785	chr18:52475162	C/T	cg12377874	chr18:52495404	RAB27B	-0.38	-6.37	-0.36	8.48e-10	Childhood body mass index;
CESC	cis	rs7264396	0.635	rs6088971	chr20:34535373	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.59	7.07	0.4	1.4e-11	Total cholesterol levels;
CESC	cis	rs9815354	0.904	rs73073235	chr3:42012693	C/A	cg03022575	chr3:42003672	ULK4	0.68	6.13	0.35	3.21e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs4699052	0.928	rs2126473	chr4:104141533	G/C	cg16532752	chr4:104119610	CENPE	-0.39	-5.35	-0.31	1.9e-7	Testicular germ cell tumor;
CESC	cis	rs74781061	1.000	rs4887166	chr15:74897598	C/G	cg17294928	chr15:75287854	SCAMP5	-0.51	-5.46	-0.32	1.11e-7	Endometriosis;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg15835091	chr22:16468340	NA	-0.47	-6.79	-0.38	7.3e-11	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs8027181	0.839	rs8033073	chr15:73051093	G/A	cg25632853	chr15:73088954	NA	0.31	5.63	0.33	4.59e-8	Triglyceride levels;
CESC	cis	rs12822507	0.868	rs12830917	chr12:12792516	C/A	cg04607235	chr12:12878440	APOLD1	-0.51	-6.62	-0.38	2.04e-10	Systemic lupus erythematosus;
CESC	cis	rs614226	0.935	rs588132	chr12:121024066	A/G	cg01236616	chr12:121019343	POP5	1.49	18.26	0.75	8.44e-49	Type 1 diabetes nephropathy;
CESC	cis	rs16858210	0.648	rs57604063	chr3:183578689	A/T	cg25686905	chr3:183603175	PARL	-0.32	-5.6	-0.33	5.31e-8	Menopause (age at onset);
CESC	cis	rs7726839	0.540	rs74553517	chr5:665671	C/T	cg16447950	chr5:562315	NA	-0.62	-6.54	-0.37	3.09e-10	Obesity-related traits;
CESC	cis	rs13191362	0.810	rs66921603	chr6:162996982	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.83	8.39	0.46	3.02e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs5758659	0.714	rs2284087	chr22:42485671	T/C	cg15557168	chr22:42548783	NA	0.42	6.54	0.37	3.15e-10	Cognitive function;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08113639	chr17:17061915	MPRIP	-0.55	-6.57	-0.37	2.61e-10	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18163227	chr17:74554350	SNORD1C	-0.54	-6.02	-0.35	5.84e-9	Gut microbiome composition (summer);
CESC	cis	rs2576037	0.526	rs4258717	chr18:44456954	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.56	-7.82	-0.43	1.27e-13	Personality dimensions;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24545466	chr11:33891541	LMO2	-0.57	-6.49	-0.37	4.29e-10	Gut microbiome composition (summer);
CESC	trans	rs6964833	0.935	rs35735900	chr7:74066227	T/C	cg07504079	chr7:72649617	NCF1B	-0.55	-6.23	-0.36	1.79e-9	Menarche (age at onset);
CESC	cis	rs6866344	0.570	rs59259518	chr5:178142628	C/T	cg03877680	chr5:178157825	ZNF354A	0.84	10.06	0.53	2.24e-20	Neutrophil percentage of white cells;
CESC	cis	rs6060717	0.536	rs11697851	chr20:34524494	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.65	5.58	0.32	5.82e-8	Hip circumference adjusted for BMI;
CESC	cis	rs12893668	0.703	rs34896432	chr14:104027995	C/T	cg24130564	chr14:104152367	KLC1	-0.46	-5.74	-0.33	2.63e-8	Reticulocyte count;
CESC	cis	rs10504229	0.595	rs77615399	chr8:58117394	C/G	cg02725872	chr8:58115012	NA	-0.45	-7.05	-0.4	1.52e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs753778	1.000	rs4961257	chr8:142232704	A/G	cg23750338	chr8:142222470	SLC45A4	-0.39	-5.5	-0.32	8.91e-8	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	cis	rs7605827	0.930	rs11689686	chr2:15527659	C/T	cg19274914	chr2:15703543	NA	0.35	6.27	0.36	1.43e-9	Educational attainment (years of education);
CESC	cis	rs9287719	0.934	rs4622695	chr2:10744327	C/T	cg02196655	chr2:10830764	NOL10	-0.38	-5.83	-0.34	1.61e-8	Prostate cancer;
CESC	cis	rs208520	0.754	rs1100989	chr6:66880532	G/A	cg07460842	chr6:66804631	NA	-1.0	-12.97	-0.62	3.95e-30	Exhaled nitric oxide output;
CESC	cis	rs2718058	0.519	rs2598071	chr7:37875347	G/A	cg24998770	chr7:37888106	TXNDC3	0.37	5.67	0.33	3.82e-8	Alzheimer's disease (late onset);
CESC	cis	rs12142240	0.698	rs17361819	chr1:46828109	A/G	cg10495392	chr1:46806563	NSUN4	0.58	6.32	0.36	1.12e-9	Menopause (age at onset);
CESC	cis	rs2243480	0.666	rs1880311	chr7:65276752	G/C	cg25894440	chr7:65020034	NA	0.66	5.55	0.32	6.86e-8	Diabetic kidney disease;
CESC	cis	rs2204008	0.744	rs11181635	chr12:38378420	C/T	cg13010199	chr12:38710504	ALG10B	0.54	6.82	0.39	6e-11	Bladder cancer;
CESC	cis	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg23048001	chr7:2026167	MAD1L1	0.47	6.16	0.35	2.62e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs9790314	0.967	rs10804790	chr3:161039300	T/A	cg04691961	chr3:161091175	C3orf57	-0.43	-5.56	-0.32	6.47e-8	Morning vs. evening chronotype;
CESC	cis	rs12541635	0.966	rs2132471	chr8:107000963	G/A	cg10147462	chr8:107024639	NA	0.4	5.71	0.33	2.99e-8	Age of smoking initiation;
CESC	cis	rs7568458	0.660	rs2289972	chr2:85766545	C/T	cg02493740	chr2:85810744	VAMP5	-0.57	-8.37	-0.46	3.28e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg15130565	chr3:61546275	PTPRG	-0.46	-6.18	-0.35	2.43e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs1862618	0.853	rs11739344	chr5:56111087	A/C	cg12311346	chr5:56204834	C5orf35	-0.71	-8.52	-0.46	1.21e-15	Initial pursuit acceleration;
CESC	cis	rs5753037	0.586	rs140120	chr22:30138548	T/C	cg01021169	chr22:30184971	ASCC2	-0.47	-6.56	-0.37	2.85e-10	Type 1 diabetes;
CESC	cis	rs6460942	0.915	rs62448594	chr7:12442229	C/G	cg20607287	chr7:12443886	VWDE	-0.77	-9.04	-0.49	3.38e-17	Coronary artery disease;
CESC	cis	rs4332037	0.576	rs62434668	chr7:1866901	G/A	cg13880726	chr7:1868755	MAD1L1	-0.51	-5.09	-0.3	6.93e-7	Bipolar disorder;
CESC	cis	rs36051895	0.664	rs12344629	chr9:5109208	C/T	cg02405213	chr9:5042618	JAK2	-0.51	-6.09	-0.35	3.86e-9	Pediatric autoimmune diseases;
CESC	cis	rs2228479	0.850	rs62052711	chr16:89855100	C/A	cg19635926	chr16:89946313	TCF25	0.67	5.08	0.3	7.19e-7	Skin colour saturation;
CESC	cis	rs977987	0.806	rs4888389	chr16:75395228	T/C	cg03315344	chr16:75512273	CHST6	0.39	5.64	0.33	4.3e-8	Dupuytren's disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg27373220	chr10:465035	DIP2C	0.51	6.66	0.38	1.57e-10	Fibrinogen levels;
CESC	cis	rs2721195	0.719	rs4925811	chr8:145802447	G/T	cg11211951	chr8:145729740	GPT	-0.41	-7.13	-0.4	9.28e-12	Age at first birth;
CESC	cis	rs7918232	0.574	rs10458708	chr10:27455605	C/T	cg14442939	chr10:27389572	ANKRD26	0.79	11.75	0.59	5.91e-26	Breast cancer;
CESC	cis	rs10504229	0.683	rs7817188	chr8:58129549	C/T	cg24829409	chr8:58192753	C8orf71	-0.58	-7.2	-0.4	6.31e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs7582720	1.000	rs72936348	chr2:204064839	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.84	7.17	0.4	7.7e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs2795502	1.000	rs3121323	chr10:43377166	A/G	cg27426351	chr10:43362370	NA	-0.45	-5.8	-0.34	1.92e-8	Blood protein levels;
CESC	cis	rs597539	0.652	rs584108	chr11:68630282	A/T	cg01988459	chr11:68622903	NA	0.46	6.33	0.36	1.02e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs7618915	0.533	rs35107891	chr3:52613656	G/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	6.76	0.38	8.85e-11	Bipolar disorder;
CESC	cis	rs12926788	0.546	rs200537	chr16:24747787	G/C	cg06505273	chr16:24850292	NA	-0.53	-6.45	-0.37	5.32e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs4474465	0.850	rs7127028	chr11:78262324	A/G	cg27205649	chr11:78285834	NARS2	0.41	5.12	0.3	6.01e-7	Alzheimer's disease (survival time);
CESC	cis	rs9325144	0.650	rs6582631	chr12:38744135	T/C	cg26384229	chr12:38710491	ALG10B	0.56	7.9	0.44	7.59e-14	Morning vs. evening chronotype;
CESC	cis	rs7552404	0.727	rs11161626	chr1:76260837	C/T	cg10523679	chr1:76189770	ACADM	0.69	6.83	0.39	5.86e-11	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs9325144	0.957	rs1995419	chr12:38950726	C/G	cg26384229	chr12:38710491	ALG10B	0.51	5.89	0.34	1.19e-8	Morning vs. evening chronotype;
CESC	cis	rs34330	0.562	rs10492235	chr12:12851339	T/G	cg09462578	chr12:12878428	APOLD1	-0.8	-8.44	-0.46	2.07e-15	Systemic lupus erythematosus;
CESC	cis	rs13118159	0.836	rs2293630	chr4:1342521	G/A	cg05025164	chr4:1340916	KIAA1530	0.63	8.74	0.47	2.81e-16	Longevity;
CESC	cis	rs6502050	0.635	rs9889327	chr17:80087839	G/A	cg11859384	chr17:80120422	CCDC57	-0.38	-5.14	-0.3	5.31e-7	Life satisfaction;
CESC	cis	rs1862618	0.713	rs832550	chr5:56182589	C/T	cg03609598	chr5:56110824	MAP3K1	-0.51	-5.32	-0.31	2.22e-7	Initial pursuit acceleration;
CESC	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.44	5.41	0.32	1.39e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs13191362	1.000	rs55822577	chr6:163069710	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.53	5.03	0.3	8.86e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs10504229	0.953	rs75585481	chr8:58192202	T/C	cg14926445	chr8:58193284	C8orf71	-0.51	-5.52	-0.32	8.28e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs2204008	0.837	rs12370891	chr12:37984531	A/G	cg13010199	chr12:38710504	ALG10B	0.53	6.61	0.38	2.1e-10	Bladder cancer;
CESC	cis	rs4319547	0.656	rs10846664	chr12:122823777	C/T	cg05707623	chr12:122985044	ZCCHC8	0.49	5.72	0.33	2.82e-8	Body mass index;
CESC	cis	rs6740322	0.748	rs13420649	chr2:43463637	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.69	-8.09	-0.45	2.16e-14	Coronary artery disease;
CESC	cis	rs10752881	1.000	rs10737235	chr1:182971816	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.84	13.37	0.63	1.69e-31	Colorectal cancer;
CESC	cis	rs17021463	0.872	rs10856909	chr4:95268748	C/G	cg11021082	chr4:95130006	SMARCAD1	0.51	7.56	0.42	6.78e-13	Testicular germ cell tumor;
CESC	cis	rs9926296	0.607	rs11076629	chr16:89875259	T/C	cg04287289	chr16:89883240	FANCA	0.64	8.57	0.47	8.48e-16	Vitiligo;
CESC	cis	rs3126085	0.935	rs7540844	chr1:152230586	A/T	cg03465714	chr1:152285911	FLG	-0.44	-5.52	-0.32	8.23e-8	Atopic dermatitis;
CESC	cis	rs7917772	0.582	rs4917975	chr10:104358407	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.41	5.63	0.33	4.48e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs12136530	0.593	rs4911988	chr1:19724480	C/T	cg01832549	chr1:19774989	CAPZB	-0.45	-6.37	-0.36	8.21e-10	Lead levels in blood;
CESC	cis	rs9611519	0.732	rs1883826	chr22:41703428	G/A	cg03806693	chr22:41940476	POLR3H	-0.76	-8.65	-0.47	5.19e-16	Neuroticism;
CESC	cis	rs2011503	0.941	rs76944848	chr19:19417512	C/T	cg11584989	chr19:19387371	SF4	0.67	7.3	0.41	3.31e-12	Bipolar disorder;
CESC	cis	rs35110281	0.805	rs8131005	chr21:45041954	T/C	cg04455712	chr21:45112962	RRP1B	0.41	6.5	0.37	3.86e-10	Mean corpuscular volume;
CESC	cis	rs2204008	0.715	rs12368462	chr12:38336116	C/G	cg26384229	chr12:38710491	ALG10B	0.72	10.68	0.55	2.23e-22	Bladder cancer;
CESC	cis	rs7726839	0.540	rs3792720	chr5:643028	T/G	cg16447950	chr5:562315	NA	-0.57	-6.22	-0.36	1.92e-9	Obesity-related traits;
CESC	cis	rs7927771	0.542	rs6485775	chr11:47773518	A/G	cg18512352	chr11:47633146	NA	-0.34	-5.37	-0.31	1.74e-7	Subjective well-being;
CESC	cis	rs72945132	0.882	rs7114200	chr11:70186099	C/A	cg00319359	chr11:70116639	PPFIA1	0.79	7.45	0.42	1.3e-12	Coronary artery disease;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg02070114	chr5:139555300	C5orf32	-0.47	-6.57	-0.37	2.67e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs3785574	0.927	rs2727313	chr17:61961914	A/G	cg06873352	chr17:61820015	STRADA	0.49	7.15	0.4	8.68e-12	Height;
CESC	cis	rs7552404	1.000	rs7516226	chr1:76234257	G/A	cg22875332	chr1:76189707	ACADM	0.58	6.54	0.37	3.21e-10	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs67311347	0.568	rs57287242	chr3:40335538	T/C	cg24209194	chr3:40518798	ZNF619	0.37	5.06	0.3	7.68e-7	Renal cell carcinoma;
CESC	cis	rs9649213	0.593	rs3801256	chr7:97992095	C/G	cg21770322	chr7:97807741	LMTK2	0.57	8.84	0.48	1.39e-16	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs208520	0.909	rs9453672	chr6:66991431	A/G	cg07460842	chr6:66804631	NA	0.78	8.94	0.48	6.96e-17	Exhaled nitric oxide output;
CESC	cis	rs1707322	1.000	rs785506	chr1:46540652	C/T	cg06784218	chr1:46089804	CCDC17	-0.33	-5.55	-0.32	7e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9916302	0.904	rs8079355	chr17:37473018	G/A	cg00129232	chr17:37814104	STARD3	0.56	7.28	0.41	3.73e-12	Glomerular filtration rate (creatinine);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23486179	chr3:49466665	NICN1	0.56	6.04	0.35	5.21e-9	Gut microbiome composition (summer);
CESC	cis	rs896854	0.516	rs12679044	chr8:95891356	C/A	cg16049864	chr8:95962084	TP53INP1	-0.56	-8.46	-0.46	1.84e-15	Type 2 diabetes;
CESC	cis	rs6466055	0.669	rs6948885	chr7:104664879	C/T	cg04380332	chr7:105027541	SRPK2	-0.37	-5.26	-0.31	3e-7	Schizophrenia;
CESC	cis	rs11122272	0.735	rs2790889	chr1:231520240	C/A	cg06096015	chr1:231504339	EGLN1	0.43	6.13	0.35	3.23e-9	Hemoglobin concentration;
CESC	cis	rs727563	0.580	rs202626	chr22:41847190	C/A	cg06634786	chr22:41940651	POLR3H	0.58	6.21	0.36	2.04e-9	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs703842	1.000	rs11172344	chr12:58193448	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.69	8.87	0.48	1.09e-16	Multiple sclerosis;
CESC	cis	rs514406	0.621	rs1930306	chr1:53195686	C/G	cg16325326	chr1:53192061	ZYG11B	-0.94	-16.1	-0.7	3.83e-41	Monocyte count;
CESC	cis	rs9916302	0.904	rs620686	chr17:37453617	A/G	cg07936489	chr17:37558343	FBXL20	0.76	10.71	0.55	1.83e-22	Glomerular filtration rate (creatinine);
CESC	cis	rs4665809	0.590	rs6730317	chr2:26419482	C/T	cg26314531	chr2:26401878	FAM59B	-0.82	-9.28	-0.5	6.29e-18	Gut microbiome composition (summer);
CESC	cis	rs561341	1.000	rs4795667	chr17:30244443	T/C	cg19193384	chr17:30244184	NA	-0.66	-6.92	-0.39	3.33e-11	Hip circumference adjusted for BMI;
CESC	trans	rs561341	1.000	rs72823787	chr17:30283809	A/T	cg20587970	chr11:113659929	NA	-1.48	-19.42	-0.77	7.47e-53	Hip circumference adjusted for BMI;
CESC	cis	rs79349575	0.749	rs2270574	chr17:47022270	C/T	cg16584676	chr17:46985605	UBE2Z	0.54	6.67	0.38	1.46e-10	Type 2 diabetes;
CESC	cis	rs13256369	0.865	rs13282523	chr8:8577293	C/G	cg17143192	chr8:8559678	CLDN23	0.71	8.52	0.46	1.23e-15	Obesity-related traits;
CESC	cis	rs2075371	0.829	rs10954442	chr7:134007587	A/G	cg11752832	chr7:134001865	SLC35B4	-0.54	-6.96	-0.39	2.67e-11	Mean platelet volume;
CESC	cis	rs4969178	0.600	rs2376583	chr17:76402105	A/T	cg05887092	chr17:76393375	PGS1	0.7	11.95	0.59	1.31e-26	HDL cholesterol levels;
CESC	cis	rs1552244	0.938	rs9873794	chr3:10074153	T/G	cg08888203	chr3:10149979	C3orf24	0.46	5.94	0.34	9.15e-9	Alzheimer's disease;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg21767135	chr3:3169141	TRNT1	-0.49	-6.6	-0.38	2.22e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs7474896	0.537	rs2749588	chr10:38269457	C/G	cg25427524	chr10:38739819	LOC399744	-0.49	-5.53	-0.32	7.61e-8	Obesity (extreme);
CESC	cis	rs1023500	0.573	rs8135801	chr22:42475568	A/G	cg04733989	chr22:42467013	NAGA	-0.78	-11.89	-0.59	2.08e-26	Schizophrenia;
CESC	cis	rs7618915	0.547	rs2590846	chr3:52692359	C/G	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.31	5.61	0.33	5.12e-8	Bipolar disorder;
CESC	trans	rs9987353	0.840	rs329994	chr8:9123233	A/G	cg00959118	chr1:169455055	SLC19A2	-0.44	-6.08	-0.35	4.15e-9	Recombination measurement;
CESC	cis	rs7811142	1.000	rs7783159	chr7:100017454	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.89	9.05	0.49	3.09e-17	Platelet count;
CESC	cis	rs9896933	0.832	rs75552659	chr17:80804630	G/A	cg19500275	chr17:80737654	TBCD	0.63	6.09	0.35	3.89e-9	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg00081347	chr17:78188837	SGSH	0.48	6.68	0.38	1.37e-10	Fibrinogen levels;
CESC	cis	rs2439831	1.000	rs565007	chr15:43716641	A/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.88	10.61	0.55	3.7e-22	Lung cancer in ever smokers;
CESC	cis	rs7618915	0.501	rs1866268	chr3:52719398	C/A	cg18337363	chr3:52569053	NT5DC2	0.29	5.36	0.31	1.85e-7	Bipolar disorder;
CESC	cis	rs8067354	0.507	rs72840511	chr17:57806011	G/T	cg02344993	chr17:57696989	CLTC	0.58	6.07	0.35	4.5e-9	Hemoglobin concentration;
CESC	cis	rs798554	0.757	rs1182185	chr7:2872233	A/G	cg19346786	chr7:2764209	NA	-0.41	-6.01	-0.35	6e-9	Height;
CESC	cis	rs7084402	0.967	rs1649076	chr10:60294061	A/T	cg07615347	chr10:60278583	BICC1	0.6	9.42	0.5	2.35e-18	Refractive error;
CESC	cis	rs644799	0.664	rs603625	chr11:95554283	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.76	10.55	0.54	5.85e-22	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs7264396	0.790	rs2295355	chr20:34252654	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.87	-11.83	-0.59	3.29e-26	Total cholesterol levels;
CESC	cis	rs9300255	0.679	rs58809476	chr12:123724880	C/T	cg00376283	chr12:123451042	ABCB9	-0.6	-6.32	-0.36	1.12e-9	Neutrophil percentage of white cells;
CESC	cis	rs7520050	0.966	rs785494	chr1:46586626	C/A	cg24296786	chr1:45957014	TESK2	0.4	5.06	0.3	8.02e-7	Red blood cell count;Reticulocyte count;
CESC	cis	rs7937682	0.889	rs493810	chr11:111491888	G/T	cg22437258	chr11:111473054	SIK2	0.72	9.66	0.51	4.24e-19	Primary sclerosing cholangitis;
CESC	cis	rs801193	1.000	rs2659912	chr7:66157999	G/C	cg06456125	chr7:65229604	NA	0.4	5.25	0.31	3.1e-7	Aortic root size;
CESC	cis	rs4434138	0.568	rs6414569	chr3:52708075	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	8.06	0.44	2.67e-14	Intelligence (multi-trait analysis);
CESC	cis	rs2637266	0.783	rs860167	chr10:78532936	A/G	cg18941641	chr10:78392320	NA	0.39	7.45	0.42	1.36e-12	Pulmonary function;
CESC	cis	rs910316	0.763	rs6574205	chr14:75453039	G/C	cg08847533	chr14:75593920	NEK9	0.92	16.13	0.7	2.98e-41	Height;
CESC	cis	rs7589728	0.563	rs80324973	chr2:88447264	T/G	cg04511125	chr2:88470314	THNSL2	0.68	6.66	0.38	1.61e-10	Plasma clusterin levels;
CESC	cis	rs11638352	1.000	rs4924727	chr15:44280609	T/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.63	-5.44	-0.32	1.23e-7	Lipoprotein phospholipase A2 activity in cardiovascular disease;
CESC	cis	rs4727027	0.625	rs75129390	chr7:148846775	T/A	cg23583168	chr7:148888333	NA	-0.74	-10.73	-0.55	1.51e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs2070433	1.000	rs2070433	chr21:47961386	G/A	cg12379764	chr21:47803548	PCNT	0.61	7.25	0.41	4.56e-12	Lymphocyte counts;
CESC	cis	rs1552244	0.572	rs6442154	chr3:10168785	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.77	8.57	0.47	8.66e-16	Alzheimer's disease;
CESC	cis	rs10504229	0.683	rs72650849	chr8:58140323	A/G	cg21724239	chr8:58056113	NA	0.58	5.95	0.34	8.37e-9	Developmental language disorder (linguistic errors);
CESC	trans	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg13565492	chr6:43139072	SRF	-0.65	-6.73	-0.38	1.05e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs3762318	0.853	rs6666144	chr1:67603825	A/T	cg17031739	chr1:67600172	NA	0.53	5.11	0.3	6.16e-7	Leprosy;
CESC	cis	rs10256972	0.967	rs4723338	chr7:1036241	A/G	cg02099474	chr7:1027990	CYP2W1	-0.34	-5.06	-0.3	7.67e-7	Longevity;Endometriosis;
CESC	cis	rs244293	1.000	rs244295	chr17:53242899	T/A	cg19360675	chr17:53046073	COX11;STXBP4	-0.39	-5.09	-0.3	6.8e-7	Menarche (age at onset);
CESC	cis	rs7635838	0.587	rs347591	chr3:11290122	G/T	cg00170343	chr3:11313890	ATG7	0.56	8.02	0.44	3.45e-14	HDL cholesterol;
CESC	cis	rs11077998	0.935	rs9893826	chr17:80511128	C/T	cg10255544	chr17:80519551	FOXK2	0.53	8.6	0.47	7.31e-16	Reticulocyte fraction of red cells;
CESC	cis	rs258892	0.895	rs266437	chr5:72167441	G/C	cg21869765	chr5:72125136	TNPO1	0.48	6.0	0.35	6.61e-9	Small cell lung carcinoma;
CESC	trans	rs7819412	0.521	rs4451268	chr8:11034859	A/G	cg06636001	chr8:8085503	FLJ10661	-0.51	-6.09	-0.35	3.87e-9	Triglycerides;
CESC	cis	rs4862750	0.872	rs13101380	chr4:187894744	G/A	cg11301795	chr4:187892539	NA	-0.81	-14.21	-0.66	1.94e-34	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1559088	0.600	rs7255229	chr19:33562807	A/G	cg17764715	chr19:33622953	WDR88	0.6	8.48	0.46	1.65e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs963731	0.579	rs2060987	chr2:39282079	A/G	cg04010122	chr2:39346883	SOS1	-0.7	-5.54	-0.32	7.3e-8	Corticobasal degeneration;
CESC	cis	rs7851660	0.967	rs3758251	chr9:100613700	G/C	cg13688889	chr9:100608707	NA	-0.68	-10.54	-0.54	6.55e-22	Strep throat;
CESC	cis	rs2637266	0.703	rs7920374	chr10:78455861	T/C	cg18941641	chr10:78392320	NA	0.4	7.32	0.41	2.91e-12	Pulmonary function;
CESC	cis	rs62229266	0.773	rs878606	chr21:37406692	G/A	cg08632701	chr21:37451849	NA	-0.38	-5.16	-0.3	4.93e-7	Mitral valve prolapse;
CESC	cis	rs172166	0.637	rs1233708	chr6:28173219	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.43	-5.5	-0.32	8.75e-8	Cardiac Troponin-T levels;
CESC	cis	rs4665809	0.589	rs4665842	chr2:26448954	A/G	cg08470875	chr2:26401718	FAM59B	-0.74	-7.65	-0.43	3.83e-13	Gut microbiome composition (summer);
CESC	cis	rs116095464	0.558	rs10057299	chr5:242135	C/T	cg22857025	chr5:266934	NA	-1.27	-18.37	-0.75	3.49e-49	Breast cancer;
CESC	cis	rs6754311	0.509	rs12616520	chr2:136516748	A/T	cg15123519	chr2:136567270	LCT	0.31	5.33	0.31	2.14e-7	Mosquito bite size;
CESC	cis	rs796364	0.774	rs112564437	chr2:201074048	G/C	cg23649088	chr2:200775458	C2orf69	-0.49	-5.6	-0.33	5.24e-8	Schizophrenia;
CESC	cis	rs67311347	0.955	rs6764102	chr3:40378153	C/G	cg09455208	chr3:40491958	NA	0.49	8.42	0.46	2.41e-15	Renal cell carcinoma;
CESC	cis	rs7208859	0.623	rs73269945	chr17:29108759	G/A	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.17e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs10504229	0.953	rs116564484	chr8:58172818	T/C	cg05313129	chr8:58192883	C8orf71	-0.54	-6.22	-0.36	1.94e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs4834770	0.746	rs2389747	chr4:120236102	C/T	cg09307838	chr4:120376055	NA	0.51	6.46	0.37	4.87e-10	Blood protein levels;
CESC	cis	rs4727027	0.704	rs13221837	chr7:148903597	C/T	cg23583168	chr7:148888333	NA	-0.92	-16.79	-0.72	1.42e-43	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs7618915	0.571	rs33964154	chr3:52596914	A/G	cg18099408	chr3:52552593	STAB1	-0.32	-5.19	-0.3	4.18e-7	Bipolar disorder;
CESC	cis	rs2637266	0.967	rs12244619	chr10:78352502	C/T	cg18941641	chr10:78392320	NA	0.41	7.59	0.42	5.38e-13	Pulmonary function;
CESC	cis	rs3820928	0.874	rs7421491	chr2:227839278	C/A	cg05526886	chr2:227700861	RHBDD1	-0.43	-5.3	-0.31	2.4e-7	Pulmonary function;
CESC	cis	rs826838	1.000	rs11514441	chr12:38775190	C/T	cg13010199	chr12:38710504	ALG10B	0.6	8.56	0.47	9.34e-16	Heart rate;
CESC	cis	rs7727544	0.735	rs4705933	chr5:131678412	G/A	cg07395648	chr5:131743802	NA	-0.45	-6.02	-0.35	5.83e-9	Blood metabolite levels;
CESC	cis	rs916888	0.773	rs199534	chr17:44824213	T/G	cg17911788	chr17:44343683	NA	-0.6	-7.67	-0.43	3.31e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	trans	rs2018683	0.624	rs6462119	chr7:29003725	G/C	cg19402173	chr7:128379420	CALU	-0.54	-6.71	-0.38	1.15e-10	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CESC	cis	rs12497850	0.931	rs7626445	chr3:49114544	C/T	cg03060546	chr3:49711283	APEH	0.49	6.04	0.35	5.08e-9	Parkinson's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05433637	chr1:1510598	SSU72	-0.64	-7.66	-0.43	3.51e-13	Gut microbiome composition (summer);
CESC	trans	rs7615952	0.800	rs12489350	chr3:125644116	T/C	cg07211511	chr3:129823064	LOC729375	-1.12	-15.9	-0.7	1.92e-40	Blood pressure (smoking interaction);
CESC	cis	rs7945705	0.935	rs10769971	chr11:8925276	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.53	8.36	0.46	3.52e-15	Hemoglobin concentration;
CESC	cis	rs11648796	0.757	rs66649828	chr16:766078	A/G	cg27144592	chr16:783916	NARFL	0.44	6.14	0.35	2.98e-9	Height;
CESC	cis	rs3106136	0.609	rs11097407	chr4:95146135	C/G	cg11021082	chr4:95130006	SMARCAD1	-0.46	-6.32	-0.36	1.13e-9	Capecitabine sensitivity;
CESC	cis	rs2228479	0.850	rs2239358	chr16:89827330	C/G	cg14709524	chr16:89940631	TCF25	0.91	6.75	0.38	9.26e-11	Skin colour saturation;
CESC	cis	rs7833986	0.501	rs2719257	chr8:56940173	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.6	7.52	0.42	8.41e-13	Height;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg01989157	chr22:40742702	ADSL	0.46	6.36	0.36	8.63e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs10465746	0.967	rs12407641	chr1:84368115	T/C	cg10977910	chr1:84465055	TTLL7	0.47	6.36	0.36	8.7e-10	Obesity-related traits;
CESC	cis	rs4862750	0.914	rs9995391	chr4:187873749	A/T	cg22105103	chr4:187893119	NA	-0.46	-6.56	-0.37	2.81e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9733	0.596	rs12089989	chr1:150715782	G/A	cg09365446	chr1:150670422	GOLPH3L	0.36	5.03	0.3	9.08e-7	Tonsillectomy;
CESC	cis	rs939658	0.805	rs8024813	chr15:79427260	A/G	cg17916960	chr15:79447300	NA	-0.38	-6.22	-0.36	1.94e-9	Refractive error;
CESC	cis	rs10876993	0.890	rs4760165	chr12:58063801	C/T	cg18357645	chr12:58087776	OS9	0.64	10.34	0.54	2.75e-21	Celiac disease or Rheumatoid arthritis;
CESC	trans	rs7786808	0.552	rs896762	chr7:158182029	A/G	cg03441993	chr4:55093323	NA	-0.41	-6.28	-0.36	1.37e-9	Obesity-related traits;
CESC	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg24101359	chr6:42928495	GNMT	0.62	9.51	0.5	1.22e-18	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs4862750	0.872	rs6830828	chr4:187897472	T/G	cg03452623	chr4:187889614	NA	-0.88	-16.15	-0.7	2.59e-41	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1957429	0.808	rs763346	chr14:65330386	A/G	cg23373153	chr14:65346875	NA	-0.85	-9.23	-0.49	8.96e-18	Pediatric areal bone mineral density (radius);
CESC	trans	rs7246657	0.943	rs10406177	chr19:37907947	G/A	cg24637308	chr11:6592297	DNHD1	0.54	6.29	0.36	1.27e-9	Coronary artery calcification;
CESC	cis	rs9640161	0.636	rs56190213	chr7:150025720	T/C	cg27494647	chr7:150038898	RARRES2	0.42	5.04	0.3	8.8e-7	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs477692	0.905	rs544217	chr10:131420584	A/G	cg05714579	chr10:131428358	MGMT	0.55	7.86	0.43	9.83e-14	Response to temozolomide;
CESC	trans	rs9325144	0.555	rs4550281	chr12:38689937	A/G	cg23762105	chr12:34175262	ALG10	-0.48	-6.51	-0.37	3.66e-10	Morning vs. evening chronotype;
CESC	cis	rs7301826	0.627	rs10773823	chr12:131294501	C/T	cg11011512	chr12:131303247	STX2	0.47	5.84	0.34	1.52e-8	Plasma plasminogen activator levels;
CESC	cis	rs10489525	1.000	rs10489525	chr1:115263685	A/G	cg12756093	chr1:115239321	AMPD1	0.47	5.73	0.33	2.7e-8	Autism;
CESC	cis	rs2708240	0.936	rs2710099	chr7:147574666	G/A	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.35	-5.77	-0.33	2.23e-8	QT interval (drug interaction);
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg09408520	chr2:157188965	NR4A2	-0.47	-6.73	-0.38	1.02e-10	Vertical cup-disc ratio;
CESC	cis	rs1008375	0.898	rs61047804	chr4:17593965	G/A	cg02297831	chr4:17616191	MED28	0.51	6.27	0.36	1.43e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	trans	rs11098499	0.874	rs12502503	chr4:120116255	C/T	cg25214090	chr10:38739885	LOC399744	0.61	8.05	0.44	2.83e-14	Corneal astigmatism;
CESC	cis	rs2841277	0.708	rs10083374	chr14:105402994	T/C	cg17340268	chr14:105411764	AHNAK2	-0.52	-6.93	-0.39	3.19e-11	Rheumatoid arthritis;
CESC	cis	rs873946	0.564	rs12242672	chr10:134555609	A/T	cg27286337	chr10:134555280	INPP5A	0.59	6.98	0.39	2.4e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs4664308	1.000	rs4664308	chr2:160917497	A/G	cg03641300	chr2:160917029	PLA2R1	-0.67	-10.08	-0.53	1.88e-20	Idiopathic membranous nephropathy;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg03618215	chr12:133365750	GOLGA3	0.5	6.59	0.38	2.36e-10	Fibrinogen levels;
CESC	cis	rs8177253	0.763	rs12769	chr3:133474328	G/A	cg11941060	chr3:133502564	NA	-0.44	-5.66	-0.33	3.93e-8	Iron status biomarkers;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg11814422	chr18:47018265	SNORD58A;RPL17;SNORD58B	0.5	6.88	0.39	4.21e-11	Systemic lupus erythematosus;
CESC	cis	rs7177699	0.525	rs7402376	chr15:79113570	A/G	cg04896959	chr15:78267971	NA	0.32	5.13	0.3	5.72e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
CESC	cis	rs9311474	0.508	rs1570	chr3:52586682	T/A	cg07507251	chr3:52567010	NT5DC2	0.34	5.82	0.34	1.73e-8	Electroencephalogram traits;
CESC	cis	rs10752881	1.000	rs4304541	chr1:182970238	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.86	13.7	0.64	1.17e-32	Colorectal cancer;
CESC	cis	rs7208859	0.623	rs383436	chr17:28959179	A/G	cg19761014	chr17:28927070	LRRC37B2	0.86	6.49	0.37	4.09e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs6964587	1.000	rs9785013	chr7:91674302	G/A	cg17063962	chr7:91808500	NA	0.55	7.49	0.42	1.01e-12	Breast cancer;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg27556566	chr18:29671984	RNF138	0.53	7.27	0.41	3.94e-12	Systemic lupus erythematosus;
CESC	trans	rs7572644	0.640	rs6547820	chr2:28281545	G/A	cg07673866	chr10:94351376	KIF11	0.51	6.02	0.35	5.73e-9	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
CESC	cis	rs727505	0.954	rs59379598	chr7:124596903	C/G	cg23710748	chr7:124431027	NA	-0.45	-7.08	-0.4	1.27e-11	Lewy body disease;
CESC	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg22535103	chr8:58192502	C8orf71	-0.92	-10.19	-0.53	8.81e-21	Developmental language disorder (linguistic errors);
CESC	cis	rs208520	0.874	rs208470	chr6:66916402	G/A	cg07460842	chr6:66804631	NA	-0.87	-10.57	-0.54	5.25e-22	Exhaled nitric oxide output;
CESC	cis	rs3105593	0.933	rs3131595	chr15:50877583	C/T	cg08437265	chr15:50716283	USP8	0.41	5.28	0.31	2.68e-7	QT interval;
CESC	cis	rs1552244	0.882	rs13099507	chr3:10031603	G/A	cg00149659	chr3:10157352	C3orf10	0.61	6.61	0.38	2.1e-10	Alzheimer's disease;
CESC	cis	rs4689388	0.926	rs4688986	chr4:6285797	C/A	cg00701064	chr4:6280414	WFS1	0.77	14.09	0.65	5.09e-34	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs4132509	1.000	rs2881275	chr1:243918313	G/C	cg21452805	chr1:244014465	NA	0.49	6.13	0.35	3.2e-9	RR interval (heart rate);
CESC	cis	rs11842874	1.000	rs118021693	chr13:113688746	C/G	cg00053927	chr13:113699014	MCF2L	-0.65	-5.08	-0.3	7.3e-7	Osteoarthritis;
CESC	cis	rs7264396	0.836	rs6120995	chr20:34185726	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.6	-7.1	-0.4	1.15e-11	Total cholesterol levels;
CESC	cis	rs10028773	0.556	rs4473640	chr4:120260437	G/A	cg09307838	chr4:120376055	NA	0.76	10.33	0.54	3.09e-21	Educational attainment;
CESC	trans	rs877282	1.000	rs877281	chr10:771557	T/G	cg22713356	chr15:30763199	NA	1.26	12.75	0.62	2.39e-29	Uric acid levels;
CESC	cis	rs9815354	0.812	rs17280952	chr3:41810834	T/C	cg03022575	chr3:42003672	ULK4	0.68	6.06	0.35	4.7e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs6087990	0.842	rs6119279	chr20:31330612	A/G	cg13636640	chr20:31349939	DNMT3B	0.82	14.5	0.67	1.72e-35	Ulcerative colitis;
CESC	cis	rs6545883	0.894	rs7602859	chr2:61458206	A/T	cg15711740	chr2:61764176	XPO1	0.4	5.12	0.3	5.86e-7	Tuberculosis;
CESC	cis	rs6089584	0.888	rs2892060	chr20:60617955	G/T	cg06108461	chr20:60628389	TAF4	-0.92	-14.55	-0.67	1.22e-35	Body mass index;
CESC	cis	rs4604732	0.642	rs6426252	chr1:247639887	G/T	cg12758973	chr1:247694275	LOC148824;OR2C3	0.36	5.4	0.31	1.48e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs7520050	0.966	rs4073846	chr1:46462881	C/T	cg24296786	chr1:45957014	TESK2	-0.44	-5.59	-0.32	5.53e-8	Red blood cell count;Reticulocyte count;
CESC	cis	rs7666738	0.753	rs28390295	chr4:99028497	C/A	cg03467027	chr4:99064603	C4orf37	0.49	6.18	0.35	2.44e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9322193	0.962	rs35031906	chr6:149998574	T/C	cg13206674	chr6:150067644	NUP43	0.4	5.53	0.32	7.84e-8	Lung cancer;
CESC	trans	rs4711350	0.862	rs597723	chr6:33694079	C/T	cg09350274	chr5:137610396	GFRA3	-0.41	-6.14	-0.35	3.06e-9	Schizophrenia;
CESC	trans	rs7618501	1.000	rs7618501	chr3:49772647	A/G	cg21659725	chr3:3221576	CRBN	-0.83	-13.61	-0.64	2.43e-32	Intelligence (multi-trait analysis);
CESC	trans	rs12599106	0.584	rs12929704	chr16:34898258	C/A	cg11235426	chr6:292522	DUSP22	-0.72	-9.39	-0.5	2.88e-18	Menopause (age at onset);
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg25225632	chr5:1324090	CLPTM1L	0.44	6.21	0.36	1.98e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs9912789	0.807	rs9896850	chr17:79191726	C/T	cg11345693	chr17:79170810	AZI1	-0.33	-5.31	-0.31	2.36e-7	Frontotemporal dementia;
CESC	cis	rs4900538	0.855	rs12586378	chr14:102853150	T/C	cg18135206	chr14:102964638	TECPR2	-0.7	-8.72	-0.47	3.17e-16	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	cis	rs4604732	0.578	rs12040725	chr1:247644697	T/A	cg12754571	chr1:247694271	LOC148824;OR2C3	0.41	5.27	0.31	2.79e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs113835537	0.935	rs76228630	chr11:66458676	T/C	cg24851651	chr11:66362959	CCS	0.66	5.87	0.34	1.27e-8	Airway imaging phenotypes;
CESC	cis	rs1559088	1.000	rs28840147	chr19:33561976	A/G	cg17764715	chr19:33622953	WDR88	0.47	5.82	0.34	1.67e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.5	-5.43	-0.32	1.24e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs1799949	0.602	rs4600503	chr17:41414324	C/G	cg25072359	chr17:41440525	NA	0.47	6.36	0.36	8.86e-10	Menopause (age at onset);
CESC	cis	rs13064411	0.696	rs7624994	chr3:113228009	T/C	cg18753928	chr3:113234510	CCDC52	-0.5	-6.13	-0.35	3.23e-9	Response to simvastatin treatment (PCSK9 protein level change);
CESC	cis	rs2228479	0.850	rs11641147	chr16:89813589	C/T	cg14709524	chr16:89940631	TCF25	0.95	7.1	0.4	1.18e-11	Skin colour saturation;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14084056	chr12:48744539	ZNF641	0.6	6.74	0.38	9.57e-11	Gut microbiome composition (summer);
CESC	cis	rs8067354	0.645	rs16943838	chr17:57839604	C/T	cg02344993	chr17:57696989	CLTC	0.57	5.97	0.34	7.53e-9	Hemoglobin concentration;
CESC	cis	rs7582720	0.943	rs115827549	chr2:203725678	A/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.32	0.41	3.04e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs10791323	0.569	rs2156679	chr11:133742304	C/T	cg15485101	chr11:133734466	NA	0.3	5.22	0.31	3.56e-7	Childhood ear infection;
CESC	cis	rs6964587	0.839	rs2049314	chr7:91464134	C/T	cg17063962	chr7:91808500	NA	0.5	6.34	0.36	1.01e-9	Breast cancer;
CESC	cis	rs1062177	0.724	rs2964590	chr5:151118146	C/G	cg12924095	chr5:151150029	G3BP1	-0.42	-5.15	-0.3	5.06e-7	Preschool internalizing problems;
CESC	cis	rs896854	0.846	rs13254283	chr8:95914103	G/T	cg13393036	chr8:95962371	TP53INP1	-0.51	-11.07	-0.56	1.14e-23	Type 2 diabetes;
CESC	cis	rs6952808	0.743	rs4719308	chr7:1877502	T/G	cg13880726	chr7:1868755	MAD1L1	0.53	7.14	0.4	8.82e-12	Bipolar disorder and schizophrenia;
CESC	cis	rs34172651	0.517	rs11642954	chr16:24824248	G/A	cg06505273	chr16:24850292	NA	0.51	6.16	0.35	2.69e-9	Intelligence (multi-trait analysis);
CESC	cis	rs4268898	0.679	rs2551181	chr2:24437548	C/T	cg06627628	chr2:24431161	ITSN2	0.88	10.16	0.53	1.08e-20	Asthma;
CESC	cis	rs9583531	0.689	rs2165418	chr13:111379365	G/T	cg24331049	chr13:111365604	ING1	-0.69	-9.73	-0.51	2.41e-19	Coronary artery disease;
CESC	cis	rs2204008	0.621	rs7302846	chr12:38072979	A/C	cg26384229	chr12:38710491	ALG10B	0.44	5.93	0.34	9.45e-9	Bladder cancer;
CESC	cis	rs6964587	0.597	rs975707	chr7:91874527	C/G	cg17063962	chr7:91808500	NA	0.47	6.45	0.37	5.22e-10	Breast cancer;
CESC	cis	rs2842992	0.692	rs9347342	chr6:160193129	T/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.77	10.96	0.56	2.68e-23	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs6740322	0.895	rs10166994	chr2:43557977	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.69	-7.35	-0.41	2.54e-12	Coronary artery disease;
CESC	cis	rs644799	0.710	rs56384142	chr11:95502075	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	11.78	0.59	4.74e-26	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs172166	0.694	rs1631552	chr6:28089699	C/A	cg20151795	chr6:28129481	ZNF389	0.36	5.25	0.31	3.14e-7	Cardiac Troponin-T levels;
CESC	cis	rs17125944	0.505	rs74620173	chr14:53194068	G/T	cg13660082	chr14:53194042	PSMC6	-0.67	-6.02	-0.35	5.92e-9	Alzheimer's disease (late onset);
CESC	cis	rs734999	0.545	rs7364820	chr1:2556709	G/A	cg20673091	chr1:2541236	MMEL1	0.47	7.84	0.43	1.11e-13	Ulcerative colitis;
CESC	cis	rs3857536	0.813	rs1029400	chr6:66952385	A/G	cg07460842	chr6:66804631	NA	-0.42	-5.11	-0.3	6.32e-7	Blood trace element (Cu levels);
CESC	cis	rs1862618	0.802	rs42769	chr5:56144152	G/A	cg12311346	chr5:56204834	C5orf35	-0.72	-8.75	-0.47	2.48e-16	Initial pursuit acceleration;
CESC	cis	rs3806843	0.966	rs1030166	chr5:140185473	G/A	cg26395211	chr5:140044315	WDR55	-0.42	-5.26	-0.31	2.96e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs9300255	0.602	rs2682431	chr12:123703226	T/A	cg19016782	chr12:123741754	C12orf65	-0.45	-6.55	-0.37	2.97e-10	Neutrophil percentage of white cells;
CESC	cis	rs9611565	0.546	rs5758430	chr22:42109844	G/T	cg03806693	chr22:41940476	POLR3H	1.05	11.94	0.59	1.39e-26	Vitiligo;
CESC	cis	rs473651	0.935	rs520765	chr2:239354712	C/T	cg18131467	chr2:239335373	ASB1	1.01	20.64	0.79	4.24e-57	Multiple system atrophy;
CESC	cis	rs9611565	0.694	rs202617	chr22:41822793	C/T	cg06634786	chr22:41940651	POLR3H	0.7	7.11	0.4	1.07e-11	Vitiligo;
CESC	cis	rs6060717	0.536	rs6058364	chr20:34507890	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.77	-6.96	-0.39	2.63e-11	Hip circumference adjusted for BMI;
CESC	cis	rs752010	0.695	rs12134166	chr1:42105867	C/T	cg06885757	chr1:42089581	HIVEP3	0.48	7.77	0.43	1.73e-13	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs875971	0.862	rs2909688	chr7:65841612	C/A	cg19163074	chr7:65112434	INTS4L2	-0.41	-5.12	-0.3	6.01e-7	Aortic root size;
CESC	cis	rs739401	0.588	rs10219272	chr11:3020789	G/A	cg25174290	chr11:3078921	CARS	0.56	7.59	0.42	5.55e-13	Longevity;
CESC	cis	rs7809950	0.678	rs7803151	chr7:106934246	G/A	cg23024343	chr7:107201750	COG5	-0.55	-7.0	-0.4	2.05e-11	Coronary artery disease;
CESC	cis	rs7274811	0.652	rs291694	chr20:32000351	A/G	cg21523528	chr20:32077966	CBFA2T2	-0.57	-6.59	-0.38	2.3e-10	Height;
CESC	cis	rs4148883	0.689	rs2602861	chr4:100030896	C/T	cg13256891	chr4:100009986	ADH5	0.54	7.11	0.4	1.07e-11	Alcohol dependence;
CESC	cis	rs7247513	0.964	rs12979795	chr19:12717847	C/T	cg01871581	chr19:12707946	ZNF490	0.85	14.06	0.65	6.27e-34	Bipolar disorder;
CESC	cis	rs4268898	0.760	rs11125535	chr2:24528114	T/C	cg06627628	chr2:24431161	ITSN2	0.58	7.34	0.41	2.59e-12	Asthma;
CESC	cis	rs60843830	1.000	rs17713729	chr2:249092	A/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.87	11.76	0.59	5.66e-26	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs1728785	1.000	rs1170428	chr16:68603988	C/A	cg02972257	chr16:68554789	NA	-0.68	-7.59	-0.42	5.63e-13	Ulcerative colitis;
CESC	cis	rs6430585	0.528	rs115469964	chr2:136696608	A/C	cg07169764	chr2:136633963	MCM6	1.29	20.09	0.78	3.63e-55	Corneal structure;
CESC	cis	rs34172651	0.537	rs8049014	chr16:24698903	A/G	cg00339695	chr16:24857497	SLC5A11	0.45	5.98	0.34	7.15e-9	Intelligence (multi-trait analysis);
CESC	cis	rs56104184	0.775	rs73061695	chr19:49399988	T/C	cg21252483	chr19:49399788	TULP2	-0.52	-5.69	-0.33	3.36e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	cis	rs7100689	0.646	rs1340376	chr10:82128963	A/G	cg00277334	chr10:82204260	NA	-0.58	-7.76	-0.43	1.84e-13	Post bronchodilator FEV1;
CESC	cis	rs8092503	0.536	rs12606833	chr18:52436115	C/T	cg12377874	chr18:52495404	RAB27B	0.35	5.21	0.3	3.82e-7	Childhood body mass index;
CESC	cis	rs1707322	0.721	rs4660314	chr1:46229885	T/C	cg06784218	chr1:46089804	CCDC17	0.41	7.23	0.41	5.3e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs4803468	1.000	rs1473248	chr19:41923314	C/T	cg09537434	chr19:41945824	ATP5SL	1.1	20.39	0.78	3.13e-56	Height;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg00851154	chr1:26690578	ZNF683	-0.4	-6.06	-0.35	4.54e-9	Gambling;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12105361	chr19:10216875	PPAN-P2RY11;SNORD105;PPAN	-0.64	-7.25	-0.41	4.62e-12	Gut microbiome composition (summer);
CESC	cis	rs116095464	0.764	rs10069197	chr5:230822	G/C	cg20965017	chr5:231967	SDHA	-0.45	-5.08	-0.3	7.29e-7	Breast cancer;
CESC	cis	rs7107174	1.000	rs731600	chr11:77963133	A/G	cg02023728	chr11:77925099	USP35	0.43	6.33	0.36	1.03e-9	Testicular germ cell tumor;
CESC	cis	rs7618915	0.501	rs2336146	chr3:52626646	A/G	cg18404041	chr3:52824283	ITIH1	-0.38	-6.52	-0.37	3.57e-10	Bipolar disorder;
CESC	cis	rs6952808	0.689	rs871924	chr7:2047845	A/G	cg05863683	chr7:1912471	MAD1L1	0.47	7.07	0.4	1.37e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs863345	0.904	rs954677	chr1:158543277	G/T	cg12129480	chr1:158549410	OR10X1	-0.32	-6.46	-0.37	5.08e-10	Pneumococcal bacteremia;
CESC	trans	rs9329221	0.935	rs3750311	chr8:10283602	C/A	cg15556689	chr8:8085844	FLJ10661	-0.58	-6.62	-0.38	2e-10	Neuroticism;
CESC	cis	rs12682352	0.602	rs635594	chr8:8613387	C/T	cg06636001	chr8:8085503	FLJ10661	-0.43	-5.29	-0.31	2.55e-7	Neuroticism;
CESC	cis	rs9322193	0.923	rs17745062	chr6:150042215	T/A	cg07701084	chr6:150067640	NUP43	0.48	6.69	0.38	1.36e-10	Lung cancer;
CESC	cis	rs11203032	0.831	rs10509567	chr10:90945756	G/A	cg16672925	chr10:90967113	CH25H	0.68	6.99	0.39	2.24e-11	Heart failure;
CESC	cis	rs763121	0.853	rs5750673	chr22:39110124	G/A	cg21395723	chr22:39101663	GTPBP1	0.45	5.64	0.33	4.3e-8	Menopause (age at onset);
CESC	cis	rs6461049	0.800	rs1860831	chr7:2160931	T/C	cg05863683	chr7:1912471	MAD1L1	0.4	5.91	0.34	1.04e-8	Schizophrenia;
CESC	cis	rs1008375	0.966	rs4698638	chr4:17632988	G/C	cg15017067	chr4:17643749	FAM184B	0.36	5.19	0.3	4.25e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	trans	rs3942852	0.688	rs10742834	chr11:48169717	G/A	cg03929089	chr4:120376271	NA	-0.65	-7.03	-0.4	1.7e-11	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs270601	0.770	rs1007602	chr5:131602166	T/C	cg18301423	chr5:131593218	PDLIM4	0.38	5.5	0.32	8.83e-8	Acylcarnitine levels;
CESC	cis	rs2243480	1.000	rs35396113	chr7:65495461	C/T	cg13147721	chr7:65941812	NA	-0.9	-8.73	-0.47	2.9e-16	Diabetic kidney disease;
CESC	cis	rs3796352	1.000	rs13072457	chr3:53102389	G/A	cg07884673	chr3:53033167	SFMBT1	0.67	5.67	0.33	3.66e-8	Immune reponse to smallpox (secreted IL-2);
CESC	cis	rs1499972	0.590	rs62264770	chr3:117645883	C/T	cg07612923	chr3:117604196	NA	0.69	6.15	0.35	2.83e-9	Schizophrenia;
CESC	cis	rs7301826	1.000	rs7301826	chr12:131291101	C/T	cg11011512	chr12:131303247	STX2	0.4	5.05	0.3	8.11e-7	Plasma plasminogen activator levels;
CESC	trans	rs2537594	0.936	rs1404418	chr7:17814085	A/T	cg18737971	chr15:43941642	CATSPER2	0.49	6.63	0.38	1.86e-10	Mean corpuscular hemoglobin;
CESC	cis	rs7666738	0.830	rs2114426	chr4:98933130	C/T	cg05340658	chr4:99064831	C4orf37	0.82	12.17	0.6	2.24e-27	Colonoscopy-negative controls vs population controls;
CESC	cis	rs208520	1.000	rs9453663	chr6:66976077	A/G	cg07460842	chr6:66804631	NA	0.74	8.71	0.47	3.42e-16	Exhaled nitric oxide output;
CESC	cis	rs709400	1.000	rs7150141	chr14:104129352	G/A	cg24130564	chr14:104152367	KLC1	-0.44	-5.77	-0.33	2.26e-8	Body mass index;
CESC	cis	rs854765	0.547	rs9896837	chr17:17924868	A/G	cg09796270	chr17:17721594	SREBF1	0.39	5.35	0.31	1.89e-7	Total body bone mineral density;
CESC	cis	rs7833790	0.963	rs2400473	chr8:82703403	C/T	cg27398817	chr8:82754497	SNX16	-0.53	-6.3	-0.36	1.24e-9	Diastolic blood pressure;
CESC	cis	rs4588572	0.644	rs11742212	chr5:77779033	G/A	cg11547950	chr5:77652471	NA	-0.42	-5.77	-0.33	2.21e-8	Triglycerides;
CESC	cis	rs2635047	1.000	rs2684818	chr18:44712965	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.51	7.09	0.4	1.23e-11	Educational attainment;
CESC	cis	rs9790314	1.000	rs336589	chr3:161080358	C/T	cg04691961	chr3:161091175	C3orf57	-0.42	-5.42	-0.32	1.33e-7	Morning vs. evening chronotype;
CESC	cis	rs2415984	0.562	rs12895104	chr14:46972736	G/A	cg14871534	chr14:47121158	RPL10L	0.4	5.59	0.32	5.71e-8	Number of children ever born;
CESC	cis	rs1552244	0.882	rs112621205	chr3:10017916	G/A	cg00166722	chr3:10149974	C3orf24	0.49	5.98	0.34	7.37e-9	Alzheimer's disease;
CESC	cis	rs8180040	0.764	rs11718795	chr3:47218727	G/A	cg27129171	chr3:47204927	SETD2	0.69	10.44	0.54	1.33e-21	Colorectal cancer;
CESC	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg06873352	chr17:61820015	STRADA	0.73	12.96	0.62	4.25e-30	Prudent dietary pattern;
CESC	cis	rs12586317	0.547	rs10142667	chr14:35445090	A/G	cg05294307	chr14:35346193	BAZ1A	-0.48	-5.44	-0.32	1.21e-7	Psoriasis;
CESC	cis	rs910316	0.935	rs175076	chr14:75505486	A/G	cg08847533	chr14:75593920	NEK9	-0.95	-17.1	-0.72	1.09e-44	Height;
CESC	cis	rs875971	0.862	rs1083554	chr7:65852341	T/C	cg18252515	chr7:66147081	NA	-0.46	-6.05	-0.35	5e-9	Aortic root size;
CESC	cis	rs7432375	0.580	rs4678441	chr3:136532828	T/C	cg15507776	chr3:136538369	TMEM22	0.61	7.9	0.44	7.49e-14	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26105702	chr2:209120195	IDH1	0.64	7.35	0.41	2.51e-12	Gut microbiome composition (summer);
CESC	cis	rs765787	0.530	rs28897155	chr15:45533974	T/C	cg24006582	chr15:45444508	DUOX1	-0.59	-7.12	-0.4	9.93e-12	Uric acid levels;
CESC	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.48	-5.2	-0.3	4.05e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20284698	chr3:48956327	C3orf71;ARIH2	0.59	6.89	0.39	4.01e-11	Gut microbiome composition (summer);
CESC	cis	rs7044106	0.718	rs1960421	chr9:123394894	C/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.33	5.11	0.3	6.22e-7	Hip circumference adjusted for BMI;
CESC	cis	rs514406	0.858	rs574853	chr1:53310959	A/T	cg08736216	chr1:53307985	ZYG11A	-0.41	-6.91	-0.39	3.5e-11	Monocyte count;
CESC	cis	rs4474465	0.850	rs10793324	chr11:78251485	C/T	cg27205649	chr11:78285834	NARS2	-0.45	-5.53	-0.32	7.72e-8	Alzheimer's disease (survival time);
CESC	cis	rs7561273	0.586	rs6545264	chr2:24310105	A/G	cg06627628	chr2:24431161	ITSN2	-0.46	-5.48	-0.32	9.77e-8	Quantitative traits;
CESC	cis	rs7412746	0.611	rs4509581	chr1:150774465	A/G	cg17724175	chr1:150552817	MCL1	0.4	6.1	0.35	3.65e-9	Melanoma;
CESC	cis	rs4862750	0.872	rs13101408	chr4:187894777	G/A	cg03452623	chr4:187889614	NA	-0.86	-14.74	-0.67	2.46e-36	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs739401	0.611	rs7109088	chr11:3027485	G/T	cg25174290	chr11:3078921	CARS	0.56	7.57	0.42	6.35e-13	Longevity;
CESC	cis	rs10751667	0.666	rs11246358	chr11:967349	G/A	cg20946044	chr11:1010712	AP2A2	-0.42	-5.74	-0.33	2.6e-8	Alzheimer's disease (late onset);
CESC	cis	rs9788682	0.747	rs2568488	chr15:78736593	T/A	cg24631222	chr15:78858424	CHRNA5	-0.64	-7.61	-0.42	4.83e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs9488822	0.597	rs12214881	chr6:116342187	G/T	cg18764771	chr6:116381957	FRK	0.22	5.44	0.32	1.23e-7	Cholesterol, total;LDL cholesterol;
CESC	cis	rs1552244	1.000	rs67852463	chr3:10157205	G/C	cg08888203	chr3:10149979	C3orf24	0.47	6.14	0.35	3.07e-9	Alzheimer's disease;
CESC	cis	rs10504229	0.906	rs114627636	chr8:58173732	C/T	cg05313129	chr8:58192883	C8orf71	-0.53	-5.49	-0.32	9.43e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs7264396	0.690	rs17093156	chr20:34438583	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.85	-11.51	-0.58	3.81e-25	Total cholesterol levels;
CESC	cis	rs11792861	0.926	rs1333344	chr9:111776224	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.51	6.52	0.37	3.53e-10	Menarche (age at onset);
CESC	cis	rs854765	0.520	rs7219324	chr17:17909775	C/T	cg16928487	chr17:17741425	SREBF1	0.45	7.31	0.41	3.13e-12	Total body bone mineral density;
CESC	cis	rs1018697	0.518	rs2250301	chr10:104548393	G/A	cg04362960	chr10:104952993	NT5C2	-0.57	-6.33	-0.36	1.01e-9	Colorectal adenoma (advanced);
CESC	cis	rs8031584	0.678	rs798125	chr15:31116800	C/T	cg08109568	chr15:31115862	NA	0.73	10.07	0.53	2.13e-20	Huntington's disease progression;
CESC	cis	rs1355223	0.867	rs1869360	chr11:34698590	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.46	-6.1	-0.35	3.83e-9	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs7618501	0.521	rs3796386	chr3:49899795	G/A	cg24110177	chr3:50126178	RBM5	-0.53	-7.16	-0.4	8.05e-12	Intelligence (multi-trait analysis);
CESC	cis	rs8060686	0.641	rs3785109	chr16:68118311	G/A	cg26727032	chr16:67993705	SLC12A4	-0.54	-6.05	-0.35	4.92e-9	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.89	13.54	0.64	4.19e-32	Prudent dietary pattern;
CESC	cis	rs28374715	0.783	rs11630656	chr15:41570909	T/G	cg02330683	chr15:41787940	ITPKA	0.45	5.38	0.31	1.67e-7	Ulcerative colitis;
CESC	cis	rs12050794	0.671	rs2052713	chr15:72520392	G/C	cg16672083	chr15:72433130	SENP8	0.47	7.03	0.4	1.79e-11	Metabolite levels (HVA/MHPG ratio);
CESC	cis	rs7618915	0.501	rs3733039	chr3:52719088	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.81	0.39	6.64e-11	Bipolar disorder;
CESC	cis	rs10870270	0.913	rs4550	chr10:133781798	C/T	cg26149184	chr10:133730230	NA	0.38	5.14	0.3	5.32e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs1218582	0.772	rs6686873	chr1:154913404	C/G	cg16680214	chr1:154839983	KCNN3	-0.45	-6.88	-0.39	4.23e-11	Prostate cancer;
CESC	trans	rs7977237	0.556	rs7960952	chr12:43926132	C/T	cg12022049	chr14:65570008	MAX	0.5	6.22	0.36	1.91e-9	Intraocular pressure;
CESC	cis	rs4713118	0.527	rs4713151	chr6:28136356	G/A	cg23161317	chr6:28129485	ZNF389	0.47	5.89	0.34	1.18e-8	Parkinson's disease;
CESC	cis	rs2204008	0.775	rs8186812	chr12:38305055	C/T	cg26384229	chr12:38710491	ALG10B	0.67	9.87	0.52	9.34e-20	Bladder cancer;
CESC	cis	rs7523050	0.643	rs34096625	chr1:109401101	G/A	cg08274380	chr1:109419600	GPSM2	0.86	5.69	0.33	3.36e-8	Fat distribution (HIV);
CESC	cis	rs7980687	0.527	rs1626703	chr12:123710835	A/C	cg00376283	chr12:123451042	ABCB9	0.73	9.95	0.52	5.21e-20	Height;Educational attainment;Head circumference (infant);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg02798621	chr6:82462430	FAM46A	0.43	6.01	0.35	6.28e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs7666738	0.830	rs28444709	chr4:99028496	A/T	cg18180107	chr4:99064573	C4orf37	0.42	5.43	0.32	1.29e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2573652	0.722	rs11630930	chr15:100544145	G/T	cg00587665	chr15:100533223	ADAMTS17	-0.43	-6.94	-0.39	3e-11	Height;
CESC	cis	rs703842	0.616	rs870392	chr12:58219173	C/A	cg00677455	chr12:58241039	CTDSP2	0.74	9.95	0.52	4.9e-20	Multiple sclerosis;
CESC	cis	rs10504229	0.953	rs75545548	chr8:58172816	T/C	cg22535103	chr8:58192502	C8orf71	-1.05	-13.27	-0.63	3.63e-31	Developmental language disorder (linguistic errors);
CESC	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg18402987	chr7:1209562	NA	0.76	7.79	0.43	1.5e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs12142240	0.698	rs17361833	chr1:46828700	A/G	cg10495392	chr1:46806563	NSUN4	0.58	6.32	0.36	1.12e-9	Menopause (age at onset);
CESC	cis	rs1348850	0.668	rs13010396	chr2:178492934	T/C	cg22681709	chr2:178499509	PDE11A	-0.49	-7.1	-0.4	1.15e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs9811920	0.965	rs9837131	chr3:99854514	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.42	5.46	0.32	1.07e-7	Axial length;
CESC	cis	rs6921919	0.583	rs2041230	chr6:28365515	A/G	cg21251018	chr6:28226885	NKAPL	0.32	5.47	0.32	1.06e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs11252926	0.583	rs2066317	chr10:520309	C/T	cg16386425	chr10:429943	DIP2C	-0.47	-5.98	-0.35	7.02e-9	Psychosis in Alzheimer's disease;
CESC	cis	rs2180341	1.000	rs6569479	chr6:127606588	A/G	cg27446573	chr6:127587934	RNF146	1.07	15.97	0.7	1.09e-40	Breast cancer;
CESC	cis	rs270601	0.710	rs371709	chr5:131583240	A/G	cg18301423	chr5:131593218	PDLIM4	0.39	5.47	0.32	1.03e-7	Acylcarnitine levels;
CESC	trans	rs11039798	0.764	rs76882342	chr11:48939091	A/T	cg15704280	chr7:45808275	SEPT13	0.69	6.44	0.37	5.66e-10	Axial length;
CESC	cis	rs1799949	0.965	rs9897425	chr17:41430179	C/G	cg25072359	chr17:41440525	NA	0.52	7.68	0.43	3.18e-13	Menopause (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10511669	chr16:68271177	ESRP2	0.66	7.46	0.42	1.24e-12	Gut microbiome composition (summer);
CESC	cis	rs7829975	0.774	rs13259216	chr8:8673601	A/C	cg15556689	chr8:8085844	FLJ10661	0.47	6.0	0.35	6.42e-9	Mood instability;
CESC	cis	rs6582630	0.502	rs11614397	chr12:38328163	C/T	cg26384229	chr12:38710491	ALG10B	0.72	10.82	0.55	7.48e-23	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs853679	0.517	rs1947863	chr6:28099344	G/A	cg23161317	chr6:28129485	ZNF389	0.51	6.63	0.38	1.85e-10	Depression;
CESC	cis	rs3733585	0.673	rs9994266	chr4:9954450	C/T	cg00071950	chr4:10020882	SLC2A9	-0.7	-11.57	-0.58	2.45e-25	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs35306767	0.953	rs10904583	chr10:983498	T/C	cg26597838	chr10:835615	NA	0.72	8.29	0.45	5.56e-15	Eosinophil percentage of granulocytes;
CESC	cis	rs4268898	0.552	rs35331966	chr2:24367828	C/T	cg20701182	chr2:24300061	SF3B14	-0.39	-5.46	-0.32	1.07e-7	Asthma;
CESC	cis	rs595982	0.702	rs638050	chr19:49375676	A/G	cg03707168	chr19:49379127	PPP1R15A	0.32	5.1	0.3	6.54e-7	Red cell distribution width;
CESC	cis	rs11658309	1	rs11658309	chr17:17762247	T/G	cg16928487	chr17:17741425	SREBF1	0.59	10.67	0.55	2.43e-22	Strep throat;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg16663073	chr1:2240324	SKI	0.47	6.46	0.37	5.05e-10	Fibrinogen levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20308189	chr12:122261415	SETD1B	-0.55	-6.0	-0.35	6.28e-9	Gut microbiome composition (summer);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg07881228	chr7:30068068	PLEKHA8	-0.45	-6.03	-0.35	5.63e-9	Ulcerative colitis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22826239	chr7:23510123	IGF2BP3	-0.52	-6.02	-0.35	5.87e-9	Gut microbiome composition (summer);
CESC	cis	rs9911578	1.000	rs304292	chr17:56824123	G/A	cg12560992	chr17:57184187	TRIM37	0.92	15.09	0.68	1.43e-37	Intelligence (multi-trait analysis);
CESC	cis	rs5769765	0.865	rs4824108	chr22:50271428	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.46	5.32	0.31	2.21e-7	Schizophrenia;
CESC	cis	rs1552244	0.751	rs12715665	chr3:10021601	C/T	cg08888203	chr3:10149979	C3orf24	0.51	6.33	0.36	1.02e-9	Alzheimer's disease;
CESC	cis	rs12464559	0.522	rs4664498	chr2:152575417	A/G	cg01189475	chr2:152685088	ARL5A	0.58	5.28	0.31	2.72e-7	Response to cognitive-behavioural therapy in anxiety disorder;
CESC	cis	rs2011503	1.000	rs756999	chr19:19448200	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.51	-5.13	-0.3	5.64e-7	Bipolar disorder;
CESC	trans	rs8099014	0.911	rs4940702	chr18:56110620	T/C	cg06677321	chr17:67603831	NA	0.43	6.04	0.35	5.3300000000000004e-09	Platelet count;
CESC	cis	rs34779708	0.931	rs2384289	chr10:35343525	G/A	cg04310649	chr10:35416472	CREM	-0.54	-6.44	-0.37	5.73e-10	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs713587	0.713	rs12618252	chr2:25207950	G/A	cg01884057	chr2:25150051	NA	-0.38	-7.14	-0.4	9.11e-12	Body mass index in non-asthmatics;
CESC	cis	rs9611565	0.694	rs202665	chr22:41814401	A/G	cg17376030	chr22:41985996	PMM1	-0.62	-6.64	-0.38	1.79e-10	Vitiligo;
CESC	trans	rs6600671	0.934	rs12060031	chr1:121243450	A/G	cg17023122	chr1:144479586	NA	-0.46	-6.14	-0.35	3.04e-9	Hip geometry;
CESC	cis	rs9443645	0.868	rs9443643	chr6:79798838	A/G	cg05283184	chr6:79620031	NA	-0.43	-6.65	-0.38	1.68e-10	Intelligence (multi-trait analysis);
CESC	cis	rs826838	1.000	rs1719848	chr12:39085586	A/G	cg26384229	chr12:38710491	ALG10B	-0.62	-9.95	-0.52	5e-20	Heart rate;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg00547444	chr16:2587590	PDPK1	-0.46	-6.06	-0.35	4.56e-9	Asthma;
CESC	cis	rs763121	0.853	rs2072795	chr22:39064209	A/G	cg21395723	chr22:39101663	GTPBP1	-0.43	-5.51	-0.32	8.4e-8	Menopause (age at onset);
CESC	cis	rs34172651	0.876	rs2112785	chr16:24781176	C/T	cg06028605	chr16:24865363	SLC5A11	0.35	5.5	0.32	8.72e-8	Intelligence (multi-trait analysis);
CESC	cis	rs506597	0.920	rs221778	chr7:100298024	A/G	cg10426581	chr7:100472382	SRRT	-0.67	-5.16	-0.3	4.81e-7	Pursuit maintenance gain in psychotic disorders;
CESC	cis	rs875971	0.862	rs6945775	chr7:65968974	G/A	cg18876405	chr7:65276391	NA	0.49	6.55	0.37	3e-10	Aortic root size;
CESC	cis	rs2625529	0.730	rs2929527	chr15:72282270	T/G	cg16672083	chr15:72433130	SENP8	0.41	6.32	0.36	1.1e-9	Red blood cell count;
CESC	trans	rs9467711	0.606	rs2393667	chr6:26421345	T/C	cg06606381	chr12:133084897	FBRSL1	-0.82	-6.98	-0.39	2.4e-11	Autism spectrum disorder or schizophrenia;
CESC	cis	rs7932354	0.666	rs6485696	chr11:46842045	C/T	cg25783544	chr11:47291846	MADD	-0.39	-5.1	-0.3	6.39e-7	Bone mineral density (hip);Bone mineral density;
CESC	cis	rs6570726	0.791	rs9403729	chr6:145907007	C/T	cg05347473	chr6:146136440	FBXO30	0.58	7.38	0.41	2.1e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6582630	0.576	rs11504369	chr12:38274566	C/T	cg26384229	chr12:38710491	ALG10B	-0.43	-5.77	-0.33	2.22e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs2732480	0.577	rs1489108	chr12:48738781	G/A	cg24011408	chr12:48396354	COL2A1	0.44	5.99	0.35	6.63e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs6831352	0.725	rs2602846	chr4:100025151	T/A	cg12011299	chr4:100065546	ADH4	0.6	6.6	0.38	2.23e-10	Alcohol dependence;
CESC	cis	rs7605827	0.897	rs6431697	chr2:15540034	G/C	cg19274914	chr2:15703543	NA	0.34	6.12	0.35	3.44e-9	Educational attainment (years of education);
CESC	cis	rs9910055	0.529	rs575798	chr17:42181796	A/C	cg08499158	chr17:42289980	UBTF	0.43	5.13	0.3	5.72e-7	Total body bone mineral density;
CESC	cis	rs875971	1.000	rs6958277	chr7:65979349	A/G	cg12463550	chr7:65579703	CRCP	0.56	6.94	0.39	3.07e-11	Aortic root size;
CESC	cis	rs9457247	0.565	rs55873403	chr6:167511800	C/T	cg07741184	chr6:167504864	NA	0.43	7.69	0.43	2.96e-13	Crohn's disease;
CESC	cis	rs35110281	0.712	rs162345	chr21:44954155	T/G	cg21573476	chr21:45109991	RRP1B	-0.41	-5.8	-0.34	1.85e-8	Mean corpuscular volume;
CESC	cis	rs10848704	0.525	rs4765709	chr12:2883637	C/T	cg19995117	chr12:2880862	NA	0.5	7.77	0.43	1.77e-13	Quantitative traits;
CESC	cis	rs6460942	1.000	rs2053378	chr7:12405564	C/G	cg02935154	chr7:12443704	VWDE	-0.57	-5.8	-0.34	1.89e-8	Coronary artery disease;
CESC	cis	rs2262909	0.962	rs55735642	chr19:22241176	C/T	cg11619707	chr19:22235551	ZNF257	0.33	5.17	0.3	4.65e-7	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
CESC	cis	rs951366	0.677	rs1775140	chr1:205672107	C/A	cg23034840	chr1:205782522	SLC41A1	0.6	6.8	0.39	7.03e-11	Menarche (age at onset);
CESC	cis	rs12142240	0.659	rs67547686	chr1:46832229	G/C	cg00530320	chr1:46809349	NSUN4	0.6	8.08	0.44	2.37e-14	Menopause (age at onset);
CESC	cis	rs897080	0.515	rs698815	chr2:44706974	G/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.49	5.52	0.32	8.26e-8	Height;
CESC	cis	rs4665809	0.941	rs7602922	chr2:26265782	C/T	cg26314531	chr2:26401878	FAM59B	-0.77	-8.58	-0.47	7.92e-16	Gut microbiome composition (summer);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg09664812	chr18:9475361	RALBP1	0.42	6.4	0.37	7.19e-10	Gambling;
CESC	cis	rs2243480	1.000	rs2462569	chr7:65474846	C/T	cg13147721	chr7:65941812	NA	0.84	8.29	0.45	5.55e-15	Diabetic kidney disease;
CESC	cis	rs2354432	0.607	rs10900350	chr1:146828017	T/G	cg25205988	chr1:146714368	CHD1L	0.99	9.12	0.49	1.88e-17	Mitochondrial DNA levels;
CESC	cis	rs7824557	0.713	rs6601575	chr8:11097804	A/C	cg21775007	chr8:11205619	TDH	0.41	6.12	0.35	3.35e-9	Retinal vascular caliber;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg23009962	chr19:18572435	ELL	0.49	6.64	0.38	1.76e-10	Fibrinogen levels;
CESC	cis	rs4308124	0.708	rs6749633	chr2:111988016	A/G	cg04571233	chr2:111982156	NA	0.61	6.81	0.39	6.43e-11	Vitiligo;
CESC	cis	rs2836974	0.897	rs3945	chr21:40566067	A/G	cg11890956	chr21:40555474	PSMG1	1.14	18.57	0.75	7.34e-50	Cognitive function;
CESC	cis	rs4906332	1.000	rs3783400	chr14:103967045	G/A	cg09975044	chr14:104007538	NA	0.48	6.37	0.36	8.11e-10	Coronary artery disease;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05290695	chr8:119634602	SAMD12	-0.43	-6.1	-0.35	3.82e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs4665809	1.000	rs17040322	chr2:26351274	G/C	cg27170947	chr2:26402098	FAM59B	-0.59	-7.07	-0.4	1.36e-11	Gut microbiome composition (summer);
CESC	cis	rs941408	1.000	rs1640271	chr19:2799979	C/T	cg00079169	chr19:2811669	THOP1	0.47	6.98	0.39	2.42e-11	Total cholesterol levels;
CESC	cis	rs2204008	0.744	rs11514073	chr12:38399553	A/C	cg13010199	chr12:38710504	ALG10B	0.52	6.5	0.37	4.01e-10	Bladder cancer;
CESC	trans	rs561341	0.710	rs9900031	chr17:30199537	T/C	cg20587970	chr11:113659929	NA	0.82	9.2	0.49	1.07e-17	Hip circumference adjusted for BMI;
CESC	cis	rs270601	0.690	rs162904	chr5:131595784	C/T	cg18758796	chr5:131593413	PDLIM4	-0.47	-6.32	-0.36	1.12e-9	Acylcarnitine levels;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg07254608	chr8:41997973	NA	0.49	6.58	0.37	2.55e-10	Systemic lupus erythematosus;
CESC	trans	rs76096589	0.557	rs78173809	chr14:51145578	C/G	cg04353483	chr4:26493496	CCKAR	0.8	5.99	0.35	6.7e-9	Diisocyanate-induced asthma;
CESC	cis	rs963731	0.579	rs3796038	chr2:39239572	G/C	cg04010122	chr2:39346883	SOS1	-0.6	-5.43	-0.32	1.26e-7	Corticobasal degeneration;
CESC	cis	rs1448094	0.511	rs10779207	chr12:86152913	A/G	cg02569458	chr12:86230093	RASSF9	-0.46	-7.15	-0.4	8.28e-12	Major depressive disorder;
CESC	cis	rs9902453	0.765	rs3115087	chr17:28030267	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.7	9.06	0.49	2.98e-17	Coffee consumption (cups per day);
CESC	cis	rs2075371	0.829	rs727202	chr7:133947942	A/G	cg11752832	chr7:134001865	SLC35B4	0.52	6.77	0.38	8.12e-11	Mean platelet volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13921000	chr7:54827064	SEC61G	0.58	6.54	0.37	3.22e-10	Gut microbiome composition (summer);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg06592170	chr5:57755298	PLK2	-0.38	-6.02	-0.35	5.8e-9	Gambling;
CESC	cis	rs6500395	1.000	rs2883475	chr16:48560315	C/T	cg04672837	chr16:48644449	N4BP1	0.46	5.3	0.31	2.42e-7	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs12497850	0.797	rs61583136	chr3:49189195	C/T	cg07636037	chr3:49044803	WDR6	1.05	18.71	0.75	2.31e-50	Parkinson's disease;
CESC	cis	rs208520	1.000	rs208527	chr6:66957209	A/C	cg07460842	chr6:66804631	NA	-0.9	-10.34	-0.54	2.79e-21	Exhaled nitric oxide output;
CESC	cis	rs1799949	0.965	rs799917	chr17:41244936	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.48	6.96	0.39	2.63e-11	Menopause (age at onset);
CESC	cis	rs7607369	0.719	rs690882	chr2:219640620	T/C	cg02176678	chr2:219576539	TTLL4	-0.39	-6.74	-0.38	9.72e-11	Red blood cell count;Amyotrophic lateral sclerosis;
CESC	cis	rs2645694	0.626	rs2645684	chr4:77819892	A/C	cg10057126	chr4:77819792	ANKRD56	0.59	8.66	0.47	4.84e-16	Emphysema distribution in smoking;
CESC	cis	rs10504229	1.000	rs56255635	chr8:58178264	T/C	cg14926445	chr8:58193284	C8orf71	-0.51	-5.47	-0.32	1.03e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs10504229	1.000	rs57378064	chr8:58169844	C/G	cg05313129	chr8:58192883	C8orf71	-0.45	-5.51	-0.32	8.3e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs7580658	0.724	rs4662711	chr2:127990840	G/A	cg10021288	chr2:128175891	PROC	-0.39	-6.14	-0.35	3.05e-9	Protein C levels;
CESC	cis	rs1008375	0.966	rs6832387	chr4:17697546	G/T	cg16339924	chr4:17578868	LAP3	0.59	7.4	0.41	1.83e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07905888	chr1:36023245	NCDN;KIAA0319L	0.59	6.85	0.39	5.12e-11	Gut microbiome composition (summer);
CESC	cis	rs9894429	0.646	rs8080391	chr17:79566319	A/T	cg21984481	chr17:79567631	NPLOC4	0.57	9.34	0.5	4e-18	Eye color traits;
CESC	cis	rs1218582	0.774	rs11264284	chr1:154875793	C/T	cg24250549	chr1:154909240	PMVK	0.62	8.69	0.47	3.86e-16	Prostate cancer;
CESC	cis	rs9858542	0.537	rs4410472	chr3:49329090	A/T	cg00383909	chr3:49044727	WDR6	0.55	5.49	0.32	9.33e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs4298948	0.590	rs11043250	chr12:122372815	A/C	cg01765077	chr12:122356316	WDR66	0.49	5.14	0.3	5.43e-7	Obesity-related traits;
CESC	cis	rs7917772	0.503	rs7078435	chr10:104304766	T/C	ch.10.2196322F	chr10:104248062	ACTR1A	0.42	5.07	0.3	7.42e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs477895	0.653	rs12797120	chr11:63906819	C/T	cg04317338	chr11:64019027	PLCB3	0.87	9.06	0.49	3.04e-17	Mean platelet volume;
CESC	cis	rs9581857	0.579	rs3759433	chr13:27997999	C/T	cg22138327	chr13:27999177	GTF3A	0.76	8.48	0.46	1.58e-15	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
CESC	cis	rs1874326	0.545	rs2353348	chr7:138111275	T/C	cg18008034	chr7:138118925	NA	-0.41	-5.12	-0.3	5.89e-7	Quantitative traits;
CESC	cis	rs17826219	0.706	rs61643715	chr17:29057762	A/G	cg19761014	chr17:28927070	LRRC37B2	0.76	6.25	0.36	1.66e-9	Body mass index;
CESC	cis	rs1506636	0.646	rs805778	chr7:123214655	C/T	cg03229431	chr7:123269106	ASB15	-0.39	-5.24	-0.31	3.21e-7	Plateletcrit;Platelet count;
CESC	cis	rs11098499	0.954	rs28572238	chr4:120316686	T/G	cg24375607	chr4:120327624	NA	0.47	5.62	0.33	4.74e-8	Corneal astigmatism;
CESC	cis	rs12477438	0.798	rs10202452	chr2:99569409	T/C	cg08885076	chr2:99613938	TSGA10	-0.37	-5.04	-0.3	8.69e-7	Chronic sinus infection;
CESC	trans	rs10411161	0.640	rs7252303	chr19:52389357	G/A	cg22319618	chr22:45562946	NUP50	-0.75	-7.55	-0.42	7.24e-13	Breast cancer;
CESC	cis	rs1538970	0.781	rs713358	chr1:45988267	C/G	cg05343316	chr1:45956843	TESK2	0.87	11.83	0.59	3.22e-26	Platelet count;
CESC	cis	rs916888	0.531	rs183211	chr17:44788310	G/A	cg17911788	chr17:44343683	NA	-0.44	-6.73	-0.38	1.03e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs13191362	1.000	rs60719662	chr6:163006643	A/C	cg21926612	chr6:163149169	PACRG;PARK2	0.82	8.75	0.47	2.56e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs9859260	0.744	rs492349	chr3:195784192	G/A	cg12923728	chr3:195709715	SDHAP1	0.54	6.96	0.39	2.68e-11	Mean corpuscular volume;
CESC	cis	rs7833986	0.501	rs2719257	chr8:56940173	A/G	cg26371346	chr8:56986568	SNORD54;RPS20	0.56	5.12	0.3	5.87e-7	Height;
CESC	cis	rs477692	0.544	rs7894836	chr10:131442595	T/A	cg24747557	chr10:131355152	MGMT	0.47	6.5	0.37	4.03e-10	Response to temozolomide;
CESC	trans	rs7943203	0.962	rs116201292	chr11:108313599	T/C	cg24643211	chr18:11851603	GNAL;CHMP1B	-0.48	-6.14	-0.35	3.01e-9	Red blood cell count;Mean corpuscular volume;
CESC	cis	rs2204008	0.627	rs10878486	chr12:38148601	T/G	cg13010199	chr12:38710504	ALG10B	0.54	6.67	0.38	1.48e-10	Bladder cancer;
CESC	cis	rs10851478	0.872	rs12232355	chr15:49832378	C/T	cg08060515	chr15:49448048	GALK2;COPS2	0.41	5.05	0.3	8.06e-7	Oral cavity cancer;
CESC	cis	rs7618915	0.501	rs3733045	chr3:52643307	A/G	cg05564831	chr3:52568323	NT5DC2	0.48	7.6	0.42	5.08e-13	Bipolar disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26342398	chr1:85156326	SSX2IP	0.62	7.34	0.41	2.59e-12	Gut microbiome composition (summer);
CESC	cis	rs7552404	0.727	rs1144336	chr1:76277421	C/A	cg22875332	chr1:76189707	ACADM	0.63	6.94	0.39	3.02e-11	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs2303759	0.918	rs4802597	chr19:49872085	C/T	cg22590775	chr19:49891494	CCDC155	0.43	5.12	0.3	5.77e-7	Multiple sclerosis;
CESC	cis	rs4713118	0.616	rs9348789	chr6:28025486	C/T	cg23281280	chr6:28129359	ZNF389	0.5	6.56	0.37	2.75e-10	Parkinson's disease;
CESC	cis	rs2075371	0.966	rs2544214	chr7:133985736	G/A	cg20476274	chr7:133979776	SLC35B4	0.67	9.79	0.52	1.65e-19	Mean platelet volume;
CESC	cis	rs933688	1.000	rs6452953	chr5:90723034	T/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.08	13.54	0.64	4.18e-32	Smoking behavior;
CESC	cis	rs9354308	0.933	rs2022856	chr6:66568235	G/T	cg07460842	chr6:66804631	NA	0.68	7.68	0.43	3.08e-13	Metabolite levels;
CESC	trans	rs11098499	0.780	rs12504773	chr4:120562149	G/C	cg25214090	chr10:38739885	LOC399744	0.68	9.41	0.5	2.57e-18	Corneal astigmatism;
CESC	cis	rs56011263	0.687	rs4690293	chr4:706101	A/G	cg14024328	chr4:719362	PCGF3	-0.66	-9.47	-0.5	1.59e-18	White blood cell count;
CESC	cis	rs3768617	0.510	rs12086466	chr1:183075778	C/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.83	-13.15	-0.63	9.69e-31	Fuchs's corneal dystrophy;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	ch.15.979660F	chr15:65855109	PTPLAD1	0.45	6.17	0.35	2.59e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg16333535	chr22:24093440	ZNF70	-0.48	-6.88	-0.39	4.25e-11	Gambling;
CESC	cis	rs11249608	0.548	rs7709054	chr5:178462757	C/T	cg21905437	chr5:178450457	ZNF879	0.58	8.14	0.45	1.56e-14	Pubertal anthropometrics;
CESC	cis	rs597539	0.652	rs1249474	chr11:68654774	C/T	cg04772025	chr11:68637568	NA	0.5	6.06	0.35	4.78e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs4665809	0.590	rs2303892	chr2:26461733	C/G	cg26119090	chr2:26468346	HADHA;HADHB	1.1	12.71	0.62	3.31e-29	Gut microbiome composition (summer);
CESC	cis	rs7662987	0.517	rs2851256	chr4:100039549	G/A	cg12011299	chr4:100065546	ADH4	0.6	6.56	0.37	2.83e-10	Smoking initiation;
CESC	cis	rs1475911	0.708	rs8129075	chr21:43523430	G/T	cg09849774	chr21:43526787	UMODL1;C21orf128	-0.42	-5.13	-0.3	5.53e-7	IgG glycosylation;
CESC	cis	rs72781680	1.000	rs61739076	chr2:24149439	G/A	cg20701182	chr2:24300061	SF3B14	0.78	6.73	0.38	1.07e-10	Lymphocyte counts;
CESC	cis	rs921968	0.643	rs589967	chr2:219445165	T/C	cg02176678	chr2:219576539	TTLL4	0.42	7.28	0.41	3.73e-12	Mean corpuscular hemoglobin concentration;
CESC	trans	rs1973993	0.689	rs17131755	chr1:96886167	G/A	cg10631902	chr5:14652156	NA	-0.49	-6.39	-0.37	7.58e-10	Weight;
CESC	trans	rs208520	0.690	rs851464	chr6:66839802	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.99	-13.08	-0.63	1.69e-30	Exhaled nitric oxide output;
CESC	cis	rs6736093	0.966	rs11685190	chr2:112748704	T/C	cg12686935	chr2:112915763	FBLN7	-0.42	-5.45	-0.32	1.17e-7	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22825979	chr13:50571203	TRIM13;DLEU2	0.61	7.31	0.41	3.21e-12	Gut microbiome composition (summer);
CESC	cis	rs6540556	0.954	rs611861	chr1:209937251	C/G	cg05527609	chr1:210001259	C1orf107	-0.5	-6.55	-0.37	2.94e-10	Red blood cell count;
CESC	cis	rs17376456	1.000	rs12187701	chr5:93522290	A/G	cg25358565	chr5:93447407	FAM172A	1.18	11.23	0.57	3.38e-24	Diabetic retinopathy;
CESC	cis	rs9611565	0.918	rs9611566	chr22:41768625	A/G	cg17376030	chr22:41985996	PMM1	-0.61	-6.41	-0.37	6.79e-10	Vitiligo;
CESC	cis	rs2204008	0.774	rs12810027	chr12:38212165	A/G	cg13010199	chr12:38710504	ALG10B	0.54	6.69	0.38	1.28e-10	Bladder cancer;
CESC	cis	rs5769765	0.955	rs61136468	chr22:50312679	A/G	cg26441486	chr22:50317300	CRELD2	0.39	5.32	0.31	2.23e-7	Schizophrenia;
CESC	cis	rs2011503	0.882	rs1064395	chr19:19361735	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.53	5.58	0.32	6.04e-8	Bipolar disorder;
CESC	cis	rs1707322	0.721	rs28641748	chr1:46212836	A/G	cg06784218	chr1:46089804	CCDC17	0.43	7.58	0.42	5.65e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs875971	0.522	rs9530	chr7:65425894	A/G	cg11987759	chr7:65425863	GUSB	-0.46	-6.06	-0.35	4.61e-9	Aortic root size;
CESC	cis	rs10540	1.000	rs12788729	chr11:502371	G/A	cg03352830	chr11:487213	PTDSS2	0.74	7.21	0.4	5.99e-12	Body mass index;
CESC	cis	rs2733201	1.000	rs2706472	chr15:44433292	T/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.56	-5.29	-0.31	2.59e-7	Lipoprotein phospholipase A2 activity in cardiovascular disease;
CESC	cis	rs6540559	1.000	rs17015259	chr1:209982923	G/A	cg09509183	chr1:209979624	IRF6	0.5	6.35	0.36	9.56e-10	Cleft lip with or without cleft palate;
CESC	cis	rs9393777	0.623	rs9366658	chr6:26469866	G/A	cg14345882	chr6:26364793	BTN3A2	0.43	5.39	0.31	1.54e-7	Intelligence (multi-trait analysis);
CESC	cis	rs9790314	1.000	rs4370045	chr3:160943865	A/G	cg03342759	chr3:160939853	NMD3	-0.52	-6.84	-0.39	5.32e-11	Morning vs. evening chronotype;
CESC	cis	rs10504229	0.906	rs114627636	chr8:58173732	C/T	cg24829409	chr8:58192753	C8orf71	-0.74	-8.62	-0.47	6.24e-16	Developmental language disorder (linguistic errors);
CESC	cis	rs769267	0.965	rs2074303	chr19:19381755	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.42	5.34	0.31	1.99e-7	Tonsillectomy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11528995	chr1:117210575	IGSF3	0.57	6.82	0.39	6.21e-11	Gut microbiome composition (summer);
CESC	cis	rs2836950	0.565	rs8131132	chr21:40538256	T/C	cg17971929	chr21:40555470	PSMG1	-0.55	-7.22	-0.41	5.4e-12	Menarche (age at onset);
CESC	cis	rs8014204	0.806	rs11159105	chr14:75298052	C/T	cg08847533	chr14:75593920	NEK9	0.47	6.01	0.35	6.18e-9	Caffeine consumption;
CESC	cis	rs6500395	0.962	rs7199625	chr16:48650217	G/C	cg04672837	chr16:48644449	N4BP1	0.47	5.57	0.32	6.4e-8	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs780096	0.506	rs2288155	chr2:27714526	T/C	cg12648201	chr2:27665141	KRTCAP3	-0.31	-5.63	-0.33	4.6e-8	Total body bone mineral density;
CESC	cis	rs477895	0.838	rs35090903	chr11:64000598	C/T	cg18225595	chr11:63971243	STIP1	0.53	5.57	0.32	6.17e-8	Mean platelet volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24826392	chr2:73964445	TPRKB	0.64	7.64	0.42	3.88e-13	Gut microbiome composition (summer);
CESC	cis	rs7107174	1.000	rs1017908	chr11:77948095	A/G	cg02023728	chr11:77925099	USP35	0.56	7.06	0.4	1.43e-11	Testicular germ cell tumor;
CESC	cis	rs35306767	0.855	rs61830931	chr10:932497	T/C	cg20503657	chr10:835505	NA	1.06	9.85	0.52	1.07e-19	Eosinophil percentage of granulocytes;
CESC	cis	rs4919694	1.000	rs17727044	chr10:104821256	A/T	cg04362960	chr10:104952993	NT5C2	0.77	6.13	0.35	3.21e-9	Arsenic metabolism;
CESC	cis	rs1775715	0.737	rs12256714	chr10:32216262	A/G	cg26784012	chr10:32216390	ARHGAP12	-0.38	-5.09	-0.3	6.76e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs9467711	0.659	rs3734542	chr6:26468326	G/A	cg14345882	chr6:26364793	BTN3A2	0.62	5.49	0.32	9.43e-8	Autism spectrum disorder or schizophrenia;
CESC	cis	rs8040855	0.627	rs1532776	chr15:85624614	C/T	cg08123816	chr15:85640762	PDE8A	-0.39	-5.8	-0.34	1.85e-8	Bulimia nervosa;
CESC	cis	rs17209837	1.000	rs2302386	chr7:87091944	A/G	cg00919237	chr7:87102261	ABCB4	-0.53	-6.03	-0.35	5.36e-9	Gallbladder cancer;
CESC	cis	rs9814567	1.000	rs1814336	chr3:134200823	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.47	-6.34	-0.36	9.66e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg21236379	chr12:132328596	MMP17	0.42	6.17	0.35	2.51e-9	Fibrinogen levels;
CESC	cis	rs904092	0.720	rs1229977	chr4:100202414	A/G	cg12011299	chr4:100065546	ADH4	-0.54	-6.19	-0.36	2.28e-9	Alcohol dependence;
CESC	cis	rs4253772	0.591	rs6008384	chr22:46655948	T/C	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.69	8.14	0.45	1.54e-14	LDL cholesterol;Cholesterol, total;
CESC	cis	rs6582630	0.519	rs11181526	chr12:38360230	A/G	cg26384229	chr12:38710491	ALG10B	0.69	10.42	0.54	1.6e-21	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs780096	0.587	rs10205219	chr2:27568565	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.32	-6.03	-0.35	5.59e-9	Total body bone mineral density;
CESC	cis	rs1348850	0.872	rs13004955	chr2:178398923	A/T	cg22681709	chr2:178499509	PDE11A	0.41	5.68	0.33	3.63e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs17376456	0.877	rs9314101	chr5:93461593	A/T	cg25358565	chr5:93447407	FAM172A	1.15	11.8	0.59	4.11e-26	Diabetic retinopathy;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg00650762	chr1:23037368	EPHB2	-0.51	-7.11	-0.4	1.1e-11	Asthma;
CESC	cis	rs7107174	1.000	rs2510035	chr11:77953175	A/C	cg02023728	chr11:77925099	USP35	0.52	6.78	0.38	7.87e-11	Testicular germ cell tumor;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01813761	chr14:20812041	PARP2;RPPH1	-0.58	-6.6	-0.38	2.23e-10	Gut microbiome composition (summer);
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg25927219	chr12:112123710	ACAD10;BRAP	-0.5	-6.22	-0.36	1.91e-9	Asthma;
CESC	cis	rs3806843	1.000	rs3822346	chr5:140187322	C/T	cg16179182	chr5:140090404	VTRNA1-1	-0.41	-5.26	-0.31	2.95e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs459571	0.920	rs455073	chr9:136909141	G/C	cg13789015	chr9:136890014	NCRNA00094	0.56	8.07	0.44	2.54e-14	Platelet distribution width;
CESC	cis	rs2070488	0.775	rs7374458	chr3:38531211	T/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.82	13.35	0.63	1.93e-31	Electrocardiographic conduction measures;
CESC	cis	rs12477438	0.765	rs62156363	chr2:99693324	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.62	-8.67	-0.47	4.43e-16	Chronic sinus infection;
CESC	cis	rs2295359	1.000	rs12043240	chr1:67624304	C/T	cg03340356	chr1:67600835	NA	0.33	5.42	0.32	1.37e-7	Psoriasis;
CESC	cis	rs9916302	0.706	rs1877030	chr17:37740161	T/C	cg07936489	chr17:37558343	FBXL20	-0.96	-9.84	-0.52	1.12e-19	Glomerular filtration rate (creatinine);
CESC	cis	rs116095464	0.558	rs7356561	chr5:284381	G/C	cg22496380	chr5:211416	CCDC127	-0.74	-8.46	-0.46	1.77e-15	Breast cancer;
CESC	cis	rs4253772	0.530	rs6008662	chr22:46713917	G/A	cg09491104	chr22:46646882	C22orf40	-0.58	-8.42	-0.46	2.37e-15	LDL cholesterol;Cholesterol, total;
CESC	cis	rs7259376	0.875	rs2116919	chr19:22491706	C/G	cg02657401	chr19:22469223	NA	-0.27	-5.41	-0.32	1.44e-7	Menopause (age at onset);
CESC	cis	rs2637266	0.935	rs2583049	chr10:78403962	T/C	cg18941641	chr10:78392320	NA	0.45	8.65	0.47	4.9e-16	Pulmonary function;
CESC	cis	rs5750830	0.649	rs5757659	chr22:39812409	A/C	cg05872129	chr22:39784769	NA	-0.77	-9.75	-0.51	2.13e-19	Intelligence (multi-trait analysis);
CESC	cis	rs10256972	0.528	rs7784607	chr7:1178694	A/G	cg15112475	chr7:1198522	ZFAND2A	-0.38	-6.02	-0.35	5.95e-9	Longevity;Endometriosis;
CESC	cis	rs10504229	0.683	rs2318143	chr8:58114660	C/T	cg02725872	chr8:58115012	NA	-0.45	-7.05	-0.4	1.52e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs28374715	0.662	rs8038983	chr15:41473316	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.79	-10.26	-0.53	5.16e-21	Ulcerative colitis;
CESC	cis	rs2730245	0.527	rs2709858	chr7:158675266	C/G	cg24397884	chr7:158709396	WDR60	0.85	8.81	0.48	1.67e-16	Height;
CESC	cis	rs13191362	1.000	rs13209100	chr6:163159350	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.71	7.66	0.43	3.47e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs9796	0.689	rs6492983	chr15:41436049	T/G	cg18705301	chr15:41695430	NDUFAF1	-0.46	-6.74	-0.38	9.74e-11	Menopause (age at onset);
CESC	cis	rs7178572	0.568	rs7175674	chr15:77670910	C/T	cg22256960	chr15:77711686	NA	-0.53	-6.79	-0.38	7.5e-11	Type 2 diabetes;
CESC	cis	rs6963495	0.818	rs6956234	chr7:105149707	A/G	cg02135003	chr7:105160482	PUS7	-0.47	-5.61	-0.33	5.12e-8	Bipolar disorder (body mass index interaction);
CESC	cis	rs1729951	0.546	rs835634	chr3:136676303	C/T	cg03617693	chr3:136751559	NA	0.37	5.17	0.3	4.6e-7	Neuroticism;
CESC	cis	rs3026101	0.671	rs1806239	chr17:5295528	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.43	5.68	0.33	3.57e-8	Body mass index;
CESC	cis	rs71403859	0.730	rs12923781	chr16:71653464	G/A	cg08717414	chr16:71523259	ZNF19	-0.74	-6.38	-0.36	7.77e-10	Post bronchodilator FEV1;
CESC	cis	rs854765	0.822	rs1889014	chr17:17767165	C/T	cg09796270	chr17:17721594	SREBF1	-0.42	-5.76	-0.33	2.35e-8	Total body bone mineral density;
CESC	cis	rs568617	1.000	rs693824	chr11:65654783	A/G	cg04055107	chr11:65626734	MUS81;CFL1	0.69	7.43	0.42	1.47e-12	Crohn's disease;
CESC	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg11494091	chr17:61959527	GH2	0.73	12.52	0.61	1.41e-28	Prudent dietary pattern;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12152867	chr6:56708725	DST	0.61	6.86	0.39	4.94e-11	Gut microbiome composition (summer);
CESC	cis	rs13118159	0.801	rs13147602	chr4:1332175	A/G	cg19318889	chr4:1322082	MAEA	0.47	6.04	0.35	5.1e-9	Longevity;
CESC	cis	rs4243830	0.850	rs4908912	chr1:6599558	A/C	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.85	-7.39	-0.41	1.89e-12	Body mass index;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg05144345	chr4:1686368	FAM53A	-0.39	-6.13	-0.35	3.2e-9	Gambling;
CESC	cis	rs8180040	0.593	rs12715421	chr3:47084859	A/G	cg27129171	chr3:47204927	SETD2	0.66	9.9	0.52	7.19e-20	Colorectal cancer;
CESC	cis	rs1862618	0.853	rs832551	chr5:56180112	T/G	cg24549020	chr5:56110836	MAP3K1	0.66	7.45	0.42	1.29e-12	Initial pursuit acceleration;
CESC	trans	rs3780486	1.000	rs12342831	chr9:33124872	A/G	cg20290983	chr6:43655470	MRPS18A	0.85	12.42	0.61	3.21e-28	IgG glycosylation;
CESC	cis	rs9311474	0.597	rs13303	chr3:52558008	T/C	cg25934064	chr3:52569026	NT5DC2	0.27	5.56	0.32	6.56e-8	Electroencephalogram traits;
CESC	cis	rs7666738	0.570	rs11097612	chr4:99079772	T/C	cg05340658	chr4:99064831	C4orf37	0.65	9.03	0.49	3.66e-17	Colonoscopy-negative controls vs population controls;
CESC	cis	rs12477438	0.798	rs6761570	chr2:99577276	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-10.51	-0.54	7.92e-22	Chronic sinus infection;
CESC	cis	rs40363	0.523	rs757270	chr16:3534451	C/T	cg01073479	chr16:3509474	NAT15	-0.33	-5.09	-0.3	6.74e-7	Tuberculosis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10800280	chr6:36646508	CDKN1A	0.53	6.19	0.36	2.27e-9	Gut microbiome composition (summer);
CESC	cis	rs10504229	0.906	rs113823909	chr8:58170635	A/G	cg05313129	chr8:58192883	C8orf71	-0.56	-6.45	-0.37	5.31e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs5753618	0.561	rs715510	chr22:31690528	T/A	cg00478049	chr22:31556069	RNF185	0.44	5.03	0.3	9.11e-7	Colorectal cancer;
CESC	cis	rs939574	1.000	rs3817424	chr2:220096903	A/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.84	7.61	0.42	4.85e-13	Platelet distribution width;
CESC	cis	rs9291683	0.588	rs13113730	chr4:10017628	C/T	cg00071950	chr4:10020882	SLC2A9	0.91	17.5	0.73	4.14e-46	Bone mineral density;
CESC	cis	rs7772486	0.817	rs9386145	chr6:146363519	A/T	cg23711669	chr6:146136114	FBXO30	0.83	12.12	0.6	3.46e-27	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs117623576	0.887	rs211411	chr10:32394992	T/C	cg03047570	chr10:32398778	NA	0.79	8.24	0.45	8.13e-15	Anti-saccade response;
CESC	cis	rs9311474	0.508	rs4687629	chr3:52615227	G/C	cg18337363	chr3:52569053	NT5DC2	0.3	5.58	0.32	6.01e-8	Electroencephalogram traits;
CESC	cis	rs17253792	0.731	rs8008528	chr14:56062052	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.84	5.62	0.33	4.81e-8	Putamen volume;
CESC	cis	rs2243480	1.000	rs67536397	chr7:65947917	G/A	cg12463550	chr7:65579703	CRCP	0.71	5.46	0.32	1.08e-7	Diabetic kidney disease;
CESC	cis	rs2230307	0.536	rs631977	chr1:100544564	C/G	cg24955406	chr1:100503596	HIAT1	0.53	5.41	0.32	1.38e-7	Carotid intima media thickness;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg01737828	chr15:75230659	COX5A	0.46	6.45	0.37	5.41e-10	Systemic lupus erythematosus;
CESC	cis	rs7647973	0.769	rs7434187	chr3:49032967	C/T	cg06212747	chr3:49208901	KLHDC8B	0.5	5.47	0.32	1.06e-7	Menarche (age at onset);
CESC	cis	rs1046896	0.561	rs8076476	chr17:80861017	A/C	cg19046167	chr17:80928561	B3GNTL1	0.49	5.96	0.34	7.95e-9	Glycated hemoglobin levels;
CESC	cis	rs17376456	0.825	rs13155452	chr5:93164449	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.58	-5.1	-0.3	6.48e-7	Diabetic retinopathy;
CESC	cis	rs17711722	1.000	rs17711722	chr7:65271197	C/T	cg06456125	chr7:65229604	NA	-0.44	-5.77	-0.33	2.23e-8	Calcium levels;
CESC	cis	rs6032067	0.777	rs62208385	chr20:43789823	A/T	cg11264863	chr20:43835661	SEMG1	0.5	5.35	0.31	1.86e-7	Blood protein levels;
CESC	cis	rs72781680	1.000	rs7581107	chr2:24173565	C/T	cg08917208	chr2:24149416	ATAD2B	0.94	8.58	0.47	7.87e-16	Lymphocyte counts;
CESC	cis	rs7586879	0.616	rs6545809	chr2:25126715	C/T	cg01884057	chr2:25150051	NA	0.36	7.01	0.4	2.02e-11	Body mass index;
CESC	cis	rs3820928	0.874	rs13413235	chr2:227893863	C/T	cg05526886	chr2:227700861	RHBDD1	-0.45	-5.72	-0.33	2.82e-8	Pulmonary function;
CESC	cis	rs11078597	0.731	rs4790285	chr17:1651697	C/T	cg18436246	chr17:1640651	WDR81	-0.58	-7.18	-0.4	7.12e-12	Serum albumin level;
CESC	cis	rs1443512	0.755	rs1373160	chr12:54340383	A/G	cg17410650	chr12:54324560	NA	-0.47	-7.65	-0.43	3.85e-13	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
CESC	cis	rs2841277	0.708	rs11623422	chr14:105407031	A/G	cg19901468	chr14:105411992	AHNAK2	-0.6	-8.69	-0.47	3.79e-16	Rheumatoid arthritis;
CESC	cis	rs4604732	0.631	rs10802509	chr1:247627158	C/T	cg12754571	chr1:247694271	LOC148824;OR2C3	0.44	5.44	0.32	1.21e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	trans	rs1814175	0.817	rs12290508	chr11:49621037	C/T	cg03929089	chr4:120376271	NA	-0.9	-14.83	-0.67	1.19e-36	Height;
CESC	cis	rs4727963	0.846	rs66681308	chr7:122738236	T/G	cg03640110	chr7:122635026	TAS2R16	-0.36	-5.42	-0.32	1.32e-7	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
CESC	cis	rs7243790	0.905	rs1523871	chr18:51950877	C/G	cg04730925	chr18:51795821	POLI	-0.41	-5.49	-0.32	9.19e-8	Diastolic blood pressure;
CESC	cis	rs4664308	0.618	rs35771982	chr2:160885418	G/C	cg03641300	chr2:160917029	PLA2R1	-0.59	-8.54	-0.46	1.07e-15	Idiopathic membranous nephropathy;
CESC	cis	rs7589728	0.563	rs4972044	chr2:88466196	T/C	cg18490616	chr2:88469792	THNSL2	0.56	5.41	0.32	1.38e-7	Plasma clusterin levels;
CESC	cis	rs875971	1.000	rs3981131	chr7:65951677	A/G	cg10691866	chr7:65817282	TPST1	-0.32	-5.17	-0.3	4.71e-7	Aortic root size;
CESC	cis	rs1729951	0.546	rs12054408	chr3:136677645	T/C	cg25687071	chr3:136751404	NA	0.39	5.17	0.3	4.65e-7	Neuroticism;
CESC	cis	rs2732480	0.500	rs7297824	chr12:48598650	T/C	cg04545296	chr12:48745243	ZNF641	0.4	6.74	0.38	9.66e-11	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs9894429	0.789	rs6565611	chr17:79598319	T/C	cg21984481	chr17:79567631	NPLOC4	-0.56	-8.97	-0.48	5.52e-17	Eye color traits;
CESC	cis	rs4665809	1.000	rs7599132	chr2:26279810	A/T	cg22920501	chr2:26401640	FAM59B	0.78	9.53	0.51	1.06e-18	Gut microbiome composition (summer);
CESC	cis	rs524281	0.773	rs11227413	chr11:65883696	G/A	cg14036092	chr11:66035641	RAB1B	-0.62	-6.3	-0.36	1.25e-9	Electroencephalogram traits;
CESC	cis	rs73206853	0.563	rs7960761	chr12:111164415	T/C	cg12870014	chr12:110450643	ANKRD13A	0.73	5.36	0.31	1.78e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs3091242	0.728	rs706845	chr1:25730713	G/A	cg27572855	chr1:25598939	RHD	0.43	7.03	0.4	1.79e-11	Erythrocyte sedimentation rate;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg12148919	chr6:128841705	PTPRK	0.45	6.02	0.35	5.64e-9	Systemic lupus erythematosus;
CESC	cis	rs11098499	0.955	rs56386062	chr4:120155135	T/C	cg09307838	chr4:120376055	NA	0.87	11.39	0.57	1.02e-24	Corneal astigmatism;
CESC	cis	rs1552244	0.882	rs13100734	chr3:10022878	A/G	cg00166722	chr3:10149974	C3orf24	0.49	6.04	0.35	5.21e-9	Alzheimer's disease;
CESC	cis	rs4975709	0.589	rs4975745	chr5:1861058	G/C	cg07747251	chr5:1868357	NA	0.31	5.12	0.3	5.88e-7	Cardiovascular disease risk factors;
CESC	cis	rs6540559	0.673	rs58637469	chr1:209971480	T/A	cg22029157	chr1:209979665	IRF6	0.76	8.93	0.48	7.36e-17	Cleft lip with or without cleft palate;
CESC	cis	rs8077577	0.836	rs11652964	chr17:18040404	C/T	cg16794390	chr17:18148240	FLII	0.47	5.79	0.34	1.94e-8	Obesity-related traits;
CESC	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg11965913	chr1:205819406	PM20D1	0.83	13.73	0.64	8.9e-33	Menarche (age at onset);
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg10962336	chr13:48807050	ITM2B	-0.48	-6.42	-0.37	6.34e-10	Asthma;
CESC	cis	rs10504229	0.861	rs57942497	chr8:58171239	G/T	cg22535103	chr8:58192502	C8orf71	-1.05	-13.27	-0.63	3.63e-31	Developmental language disorder (linguistic errors);
CESC	cis	rs7937682	0.587	rs611607	chr11:111349765	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.62	-8.22	-0.45	8.93e-15	Primary sclerosing cholangitis;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg05310071	chr17:16120569	PIGL	-0.42	-6.1	-0.35	3.67e-9	Height;
CESC	cis	rs7527798	0.592	rs11118281	chr1:207832102	C/T	cg21110645	chr1:207815933	NA	-0.31	-5.41	-0.32	1.43e-7	Erythrocyte sedimentation rate;
CESC	cis	rs597539	0.652	rs553875	chr11:68695144	T/G	cg18350739	chr11:68623251	NA	-0.46	-6.81	-0.39	6.51e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs853679	0.517	rs9380055	chr6:28081629	A/G	cg23161317	chr6:28129485	ZNF389	0.51	6.53	0.37	3.44e-10	Depression;
CESC	trans	rs722599	0.748	rs55707505	chr14:75362552	T/C	cg00095594	chr1:236228625	NID1	-0.4	-6.28	-0.36	1.39e-9	IgG glycosylation;
CESC	cis	rs367943	0.556	rs7709820	chr5:112991327	G/A	cg12552261	chr5:112820674	MCC	0.39	5.06	0.3	7.7e-7	Type 2 diabetes;
CESC	trans	rs2109514	0.505	rs1633714	chr7:116022538	C/T	cg19728485	chr2:11295717	PQLC3	-0.47	-6.01	-0.35	6.26e-9	Prevalent atrial fibrillation;
CESC	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg24829409	chr8:58192753	C8orf71	-0.67	-8.18	-0.45	1.19e-14	Developmental language disorder (linguistic errors);
CESC	cis	rs4665809	0.590	rs7604564	chr2:26501953	C/A	cg04944784	chr2:26401820	FAM59B	0.93	10.1	0.53	1.71e-20	Gut microbiome composition (summer);
CESC	cis	rs561341	0.769	rs559228	chr17:30294527	T/C	cg00745463	chr17:30367425	LRRC37B	-0.81	-7.35	-0.41	2.5e-12	Hip circumference adjusted for BMI;
CESC	cis	rs9300255	0.544	rs1716157	chr12:123670473	T/C	cg19016782	chr12:123741754	C12orf65	-0.45	-6.21	-0.36	2.01e-9	Neutrophil percentage of white cells;
CESC	cis	rs11958404	0.932	rs72816592	chr5:157435246	A/G	cg05962755	chr5:157440814	NA	0.62	6.56	0.37	2.74e-10	IgG glycosylation;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg23594427	chr12:56367798	RAB5B	-0.44	-6.14	-0.35	2.99e-9	Asthma;
CESC	cis	rs2072732	0.821	rs10909868	chr1:2962207	A/C	cg03976712	chr1:2946727	NA	0.32	5.6	0.33	5.4e-8	Plateletcrit;
CESC	cis	rs7980687	0.628	rs2851443	chr12:123694250	C/T	cg05973401	chr12:123451056	ABCB9	0.46	5.67	0.33	3.65e-8	Height;Educational attainment;Head circumference (infant);
CESC	cis	rs4665809	1.000	rs6546736	chr2:26293878	C/T	cg26119090	chr2:26468346	HADHA;HADHB	0.64	7.43	0.42	1.47e-12	Gut microbiome composition (summer);
CESC	cis	rs1862618	0.671	rs72644088	chr5:56241019	G/A	cg18230493	chr5:56204884	C5orf35	0.62	8.02	0.44	3.32e-14	Initial pursuit acceleration;
CESC	cis	rs6714710	0.603	rs17489454	chr2:98407350	C/T	cg26665480	chr2:98280029	ACTR1B	0.56	7.94	0.44	5.93e-14	Posterior cortical atrophy and Alzheimer's disease;
CESC	cis	rs2976388	0.556	rs4736300	chr8:143829269	C/T	cg10596483	chr8:143751796	JRK	-0.47	-5.26	-0.31	2.99e-7	Urinary tract infection frequency;
CESC	cis	rs801193	0.548	rs7805152	chr7:66209253	C/T	cg18252515	chr7:66147081	NA	-0.48	-6.45	-0.37	5.25e-10	Aortic root size;
CESC	cis	rs7208859	0.673	rs11654331	chr17:29165017	A/G	cg19761014	chr17:28927070	LRRC37B2	0.63	5.24	0.31	3.23e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	trans	rs4665809	1.000	rs6704930	chr2:26325705	G/A	cg09258813	chr8:37823409	ADRB3	-0.37	-6.08	-0.35	4.08e-9	Gut microbiome composition (summer);
CESC	cis	rs9733	0.596	rs2867300	chr1:150666990	C/G	cg09365446	chr1:150670422	GOLPH3L	0.43	5.96	0.34	7.93e-9	Tonsillectomy;
CESC	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg03188948	chr7:1209495	NA	0.72	6.93	0.39	3.15e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs4144743	1.000	rs72823473	chr17:45321775	A/T	cg18085866	chr17:45331354	ITGB3	-0.64	-7.03	-0.4	1.78e-11	Body mass index;
CESC	cis	rs9894429	0.608	rs7406219	chr17:79609410	G/T	cg13777783	chr17:79615861	NA	-0.37	-6.2	-0.36	2.14e-9	Eye color traits;
CESC	cis	rs992157	0.560	rs6436048	chr2:219109033	C/T	cg00012203	chr2:219082015	ARPC2	0.76	9.75	0.51	2.2e-19	Colorectal cancer;
CESC	cis	rs9393777	0.588	rs6456727	chr6:26471155	T/C	cg12826209	chr6:26865740	GUSBL1	0.59	7.13	0.4	9.69e-12	Intelligence (multi-trait analysis);
CESC	cis	rs4665809	0.590	rs1049987	chr2:26413817	C/T	cg27170947	chr2:26402098	FAM59B	0.85	9.92	0.52	6.06e-20	Gut microbiome composition (summer);
CESC	cis	rs61931739	0.534	rs11053047	chr12:34161084	C/T	cg19457237	chr12:34500585	NA	-0.39	-5.34	-0.31	1.99e-7	Morning vs. evening chronotype;
CESC	cis	rs1045529	0.524	rs34251783	chr8:8891376	T/C	cg15556689	chr8:8085844	FLJ10661	-0.5	-6.28	-0.36	1.41e-9	Myopia;Myopia (pathological);
CESC	cis	rs35110281	0.591	rs189094	chr21:44932017	A/G	cg21573476	chr21:45109991	RRP1B	-0.41	-5.57	-0.32	6.4e-8	Mean corpuscular volume;
CESC	cis	rs116095464	0.558	rs11959126	chr5:283880	T/G	cg10591111	chr5:226296	SDHA	-0.53	-6.43	-0.37	6.03e-10	Breast cancer;
CESC	cis	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg15921436	chr17:44337874	NA	0.74	7.76	0.43	1.82e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs9487051	0.803	rs410449	chr6:109539853	C/T	cg01475377	chr6:109611718	NA	-0.37	-5.29	-0.31	2.62e-7	Reticulocyte fraction of red cells;
CESC	cis	rs7412746	0.611	rs10888398	chr1:150886782	A/G	cg22823121	chr1:150693482	HORMAD1	-0.36	-5.1	-0.3	6.39e-7	Melanoma;
CESC	cis	rs727563	0.580	rs202626	chr22:41847190	C/A	cg17376030	chr22:41985996	PMM1	-0.56	-6.2	-0.36	2.14e-9	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs7129220	0.588	rs77092969	chr11:10116298	G/A	cg01453529	chr11:10209919	SBF2	-0.48	-5.48	-0.32	9.85e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CESC	cis	rs72615157	0.539	rs12673441	chr7:99670328	A/T	cg22004693	chr7:99632812	ZKSCAN1	0.44	5.75	0.33	2.47e-8	Lung function (FEV1/FVC);
CESC	cis	rs7927771	0.756	rs10742803	chr11:47439938	A/G	cg18512352	chr11:47633146	NA	0.44	6.31	0.36	1.18e-9	Subjective well-being;
CESC	cis	rs9303280	0.806	rs13380815	chr17:38027583	A/G	cg19468946	chr17:37922297	IKZF3	-0.41	-5.45	-0.32	1.16e-7	Self-reported allergy;
CESC	cis	rs61996546	0.622	rs34886387	chr15:26862107	A/T	cg15066197	chr15:26874202	GABRB3	-0.34	-5.05	-0.3	8.19e-7	Response to methotrexate in juvenile idiopathic arthritis;
CESC	trans	rs8073060	0.586	rs17638867	chr17:34052513	C/T	cg19694781	chr19:47549865	TMEM160	0.68	6.31	0.36	1.15e-9	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	trans	rs11722228	0.508	rs61335146	chr4:10130793	G/C	cg26043149	chr18:55253948	FECH	0.91	11.52	0.58	3.54e-25	Gout;Urate levels;Serum uric acid levels;
CESC	cis	rs6502050	0.835	rs8065210	chr17:80090960	G/A	cg11859384	chr17:80120422	CCDC57	-0.38	-5.14	-0.3	5.31e-7	Life satisfaction;
CESC	cis	rs1200821	0.529	rs2475206	chr10:37802532	A/G	cg25427524	chr10:38739819	LOC399744	0.49	6.36	0.36	8.87e-10	Hemostatic factors and hematological phenotypes;
CESC	cis	rs6460942	0.915	rs6968695	chr7:12443878	G/C	cg17427002	chr7:12443146	VWDE	-0.56	-5.85	-0.34	1.42e-8	Coronary artery disease;
CESC	cis	rs6582630	0.537	rs11520294	chr12:38402705	C/A	cg26384229	chr12:38710491	ALG10B	0.73	10.79	0.55	9.99e-23	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs9311474	1.000	rs1060330	chr3:52288945	T/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.36	6.72	0.38	1.1e-10	Electroencephalogram traits;
CESC	cis	rs13242816	1.000	rs62468973	chr7:116125834	G/T	cg04696780	chr7:116139425	CAV2	-0.62	-5.68	-0.33	3.58e-8	P wave duration;
CESC	cis	rs10752881	1.000	rs10737236	chr1:182988608	C/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.83	-13.49	-0.64	6.39e-32	Colorectal cancer;
CESC	cis	rs13256369	0.851	rs11249890	chr8:8565245	G/T	cg17143192	chr8:8559678	CLDN23	0.77	8.76	0.47	2.37e-16	Obesity-related traits;
CESC	cis	rs6772849	1.000	rs2734037	chr3:128308884	C/T	cg16766828	chr3:128327626	NA	-0.32	-5.08	-0.3	7.08e-7	Monocyte percentage of white cells;Monocyte count;
CESC	cis	rs2380220	0.808	rs2386669	chr6:95902121	C/T	cg15832292	chr6:96025679	MANEA	-0.65	-5.95	-0.34	8.46e-9	Behavioural disinhibition (generation interaction);
CESC	cis	rs9486719	1.000	rs10872018	chr6:97026429	G/A	cg06623918	chr6:96969491	KIAA0776	-0.81	-8.37	-0.46	3.4e-15	Migraine;Coronary artery disease;
CESC	cis	rs2439831	1.000	rs101094	chr15:43787322	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.83	12.17	0.6	2.26e-27	Lung cancer in ever smokers;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08522065	chr12:46384600	SFRS2IP	0.59	6.99	0.39	2.24e-11	Gut microbiome composition (summer);
CESC	cis	rs10504229	0.610	rs7011877	chr8:58147181	C/T	cg24829409	chr8:58192753	C8orf71	-0.53	-6.91	-0.39	3.49e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs6723226	0.732	rs390480	chr2:32510072	A/C	cg02381751	chr2:32503542	YIPF4	-0.81	-11.64	-0.58	1.46e-25	Intelligence (multi-trait analysis);
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg17260383	chr8:22298246	PPP3CC	0.49	6.14	0.35	2.96e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs9311474	0.659	rs1133415	chr3:52575831	G/A	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.79	0.38	7.32e-11	Electroencephalogram traits;
CESC	cis	rs3762637	1.000	rs9842736	chr3:122161101	C/T	cg24169773	chr3:122142474	KPNA1	-0.54	-6.31	-0.36	1.2e-9	LDL cholesterol levels;
CESC	trans	rs3942852	0.806	rs4752808	chr11:48141252	G/A	cg03929089	chr4:120376271	NA	-0.57	-6.33	-0.36	1.04e-9	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs1008375	1.000	rs4698198	chr4:17656536	G/A	cg16339924	chr4:17578868	LAP3	0.56	7.01	0.4	1.96e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs684232	0.623	rs2543779	chr17:576362	C/A	cg15660573	chr17:549704	VPS53	-0.66	-9.03	-0.48	3.71e-17	Prostate cancer;
CESC	cis	rs9457247	0.905	rs444210	chr6:167390242	A/G	cg25258033	chr6:167368657	RNASET2	0.41	6.16	0.35	2.68e-9	Crohn's disease;
CESC	cis	rs7666738	0.753	rs35194639	chr4:99053819	G/C	cg03676636	chr4:99064102	C4orf37	0.33	5.12	0.3	5.93e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs875971	0.862	rs6460290	chr7:65809106	G/A	cg18252515	chr7:66147081	NA	0.4	5.2	0.3	4.06e-7	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06148997	chr2:107084783	RGPD3	-0.59	-6.98	-0.39	2.39e-11	Gut microbiome composition (summer);
CESC	cis	rs9733	0.569	rs11588404	chr1:150688529	C/A	cg09365446	chr1:150670422	GOLPH3L	0.42	5.86	0.34	1.37e-8	Tonsillectomy;
CESC	cis	rs1707322	1.000	rs4390216	chr1:46266456	C/T	cg06784218	chr1:46089804	CCDC17	0.33	5.75	0.33	2.42e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs6089829	0.962	rs11086151	chr20:61664644	C/T	cg03213289	chr20:61660250	NA	0.39	6.07	0.35	4.42e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs4523957	0.890	rs62069332	chr17:2112720	A/G	cg16513277	chr17:2031491	SMG6	-0.65	-9.02	-0.48	4.04e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs1552244	0.572	rs59074548	chr3:10164347	G/C	cg00149659	chr3:10157352	C3orf10	1.0	11.96	0.59	1.22e-26	Alzheimer's disease;
CESC	trans	rs7107217	1.000	rs1873872	chr11:129473993	A/T	cg23508591	chr15:75871807	PTPN9	0.47	6.09	0.35	4.05e-9	Breast cancer;Type 2 diabetes;
CESC	cis	rs736408	0.677	rs678	chr3:52820981	A/T	cg18404041	chr3:52824283	ITIH1	-0.45	-7.3	-0.41	3.44e-12	Bipolar disorder;
CESC	cis	rs1506636	1.000	rs641491	chr7:123399726	C/A	cg03229431	chr7:123269106	ASB15	0.53	6.95	0.39	2.89e-11	Plateletcrit;Platelet count;
CESC	cis	rs3820068	0.580	rs7512308	chr1:16006604	C/A	cg13390004	chr1:15929781	NA	0.35	5.22	0.31	3.58e-7	Systolic blood pressure;
CESC	cis	rs769267	0.965	rs2074303	chr19:19381755	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.44	5.4	0.31	1.51e-7	Tonsillectomy;
CESC	cis	rs9322193	0.923	rs9322214	chr6:150025122	C/T	cg04369109	chr6:150039330	LATS1	-0.44	-6.0	-0.35	6.58e-9	Lung cancer;
CESC	cis	rs798554	0.757	rs2533878	chr7:2878707	A/G	cg13628971	chr7:2884303	GNA12	-0.59	-7.72	-0.43	2.34e-13	Height;
CESC	cis	rs4629180	0.586	rs10206804	chr2:102132431	C/T	cg04415270	chr2:102091202	RFX8	0.3	5.23	0.31	3.46e-7	Chronic rhinosinusitis with nasal polyps;
CESC	cis	rs9733	0.536	rs10888385	chr1:150574302	T/C	cg22823121	chr1:150693482	HORMAD1	-0.35	-5.06	-0.3	7.82e-7	Tonsillectomy;
CESC	cis	rs9894429	0.646	rs7406825	chr17:79619188	C/T	cg18240062	chr17:79603768	NPLOC4	0.46	5.97	0.34	7.39e-9	Eye color traits;
CESC	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg05313129	chr8:58192883	C8orf71	-0.49	-5.32	-0.31	2.23e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs7432375	0.610	rs60574021	chr3:136520281	C/G	cg15507776	chr3:136538369	TMEM22	0.61	8.0	0.44	3.98e-14	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
CESC	cis	rs4665809	0.590	rs13019536	chr2:26526978	C/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.63	-7.04	-0.4	1.69e-11	Gut microbiome composition (summer);
CESC	cis	rs3733585	0.805	rs882222	chr4:9981294	G/A	cg11266682	chr4:10021025	SLC2A9	0.62	12.69	0.61	3.76e-29	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs4891159	0.548	rs11150952	chr18:74128188	T/C	cg24786174	chr18:74118243	ZNF516	0.84	15.96	0.7	1.24e-40	Longevity;
CESC	cis	rs9443645	0.901	rs10455356	chr6:79664748	T/C	cg05283184	chr6:79620031	NA	-0.41	-6.27	-0.36	1.48e-9	Intelligence (multi-trait analysis);
CESC	cis	rs2795502	0.938	rs3121281	chr10:43400753	A/G	cg20628663	chr10:43360327	NA	0.54	6.08	0.35	4.28e-9	Blood protein levels;
CESC	cis	rs10256972	1.000	rs10256972	chr7:1039003	G/T	cg23978390	chr7:1156363	C7orf50	-0.45	-6.07	-0.35	4.4e-9	Longevity;Endometriosis;
CESC	trans	rs61931739	0.534	rs12372557	chr12:34363843	C/T	cg13010199	chr12:38710504	ALG10B	0.48	6.2	0.36	2.16e-9	Morning vs. evening chronotype;
CESC	cis	rs6987853	0.901	rs2974344	chr8:42400732	T/G	cg09913449	chr8:42400586	C8orf40	0.4	6.34	0.36	9.76e-10	Mean corpuscular hemoglobin concentration;
CESC	cis	rs2425143	1.000	rs2425149	chr20:34359587	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.8	-7.82	-0.43	1.22e-13	Blood protein levels;
CESC	cis	rs7927771	0.965	rs11039416	chr11:47846711	G/A	cg05585544	chr11:47624801	NA	-0.49	-7.71	-0.43	2.62e-13	Subjective well-being;
CESC	cis	rs11264213	0.901	rs72661628	chr1:36406547	A/G	cg27506609	chr1:36549197	TEKT2	0.66	5.59	0.32	5.62e-8	Schizophrenia;
CESC	cis	rs17376456	0.877	rs10057814	chr5:93399092	C/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.63	5.47	0.32	1.04e-7	Diabetic retinopathy;
CESC	cis	rs2180341	0.782	rs6924274	chr6:127721556	T/A	cg27446573	chr6:127587934	RNF146	0.79	11.35	0.57	1.36e-24	Breast cancer;
CESC	cis	rs6089584	1.000	rs6089584	chr20:60564086	G/C	cg24733560	chr20:60626293	TAF4	0.4	5.76	0.33	2.38e-8	Body mass index;
CESC	cis	rs11945232	1.000	rs28372775	chr4:88343704	G/A	cg23841344	chr4:88312519	HSD17B11	-0.66	-8.22	-0.45	9.16e-15	Intelligence (multi-trait analysis);
CESC	cis	rs17655565	0.553	rs1945287	chr12:52733218	C/G	cg00777198	chr12:52828273	KRT75	0.38	5.62	0.33	4.9e-8	Plasma amyloid beta peptide concentrations (ABx-42);
CESC	cis	rs9549367	0.713	rs3024776	chr13:113827075	A/G	cg18105134	chr13:113819100	PROZ	0.7	8.54	0.46	1.05e-15	Platelet distribution width;
CESC	cis	rs921968	0.541	rs2710246	chr2:219533894	C/T	cg02176678	chr2:219576539	TTLL4	0.33	5.41	0.32	1.39e-7	Mean corpuscular hemoglobin concentration;
CESC	cis	rs6732160	0.691	rs10197935	chr2:73412362	A/T	cg01422370	chr2:73384389	NA	0.39	6.58	0.37	2.55e-10	Intelligence (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06187344	chr10:3151576	PFKP	-0.53	-6.36	-0.36	8.63e-10	Gut microbiome composition (summer);
CESC	cis	rs561341	0.654	rs6505265	chr17:30172580	C/T	cg12193833	chr17:30244370	NA	0.58	5.49	0.32	9.28e-8	Hip circumference adjusted for BMI;
CESC	cis	rs7937682	0.632	rs4441050	chr11:111772506	C/T	cg09085632	chr11:111637200	PPP2R1B	0.88	11.26	0.57	2.77e-24	Primary sclerosing cholangitis;
CESC	cis	rs875971	0.825	rs7384021	chr7:66077904	A/G	cg11764359	chr7:65958608	NA	-0.78	-11.32	-0.57	1.76e-24	Aortic root size;
CESC	cis	rs1023500	0.551	rs133355	chr22:42440285	G/A	cg15557168	chr22:42548783	NA	-0.45	-6.35	-0.36	9.27e-10	Schizophrenia;
CESC	cis	rs11792861	0.926	rs72607171	chr9:111837776	T/C	cg13535736	chr9:111863775	C9orf5	-0.51	-6.76	-0.38	8.77e-11	Menarche (age at onset);
CESC	cis	rs9796	0.653	rs28516683	chr15:41446645	A/G	cg12426344	chr15:41135900	SPINT1	-0.25	-5.51	-0.32	8.63e-8	Menopause (age at onset);
CESC	cis	rs6963495	0.818	rs73190186	chr7:105164368	G/C	cg19920283	chr7:105172520	RINT1	0.7	6.66	0.38	1.58e-10	Bipolar disorder (body mass index interaction);
CESC	cis	rs7223966	1.000	rs9912904	chr17:61763534	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.54	6.44	0.37	5.7e-10	Hip circumference adjusted for BMI;Body mass index;
CESC	trans	rs9329221	0.512	rs7843924	chr8:9976540	C/T	cg15556689	chr8:8085844	FLJ10661	0.49	6.28	0.36	1.4e-9	Neuroticism;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg17499729	chr21:37504755	NA	-0.45	-6.1	-0.35	3.71e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs7589728	0.563	rs4972044	chr2:88466196	T/C	cg07952391	chr2:88470173	THNSL2	0.64	6.21	0.36	2.05e-9	Plasma clusterin levels;
CESC	cis	rs7665939	1.000	rs72727637	chr4:190106678	G/T	cg14840187	chr4:190284988	NA	-0.84	-6.95	-0.39	2.9100000000000002e-11	Amyotrophic lateral sclerosis;
CESC	cis	rs1538970	0.924	rs3790582	chr1:45887288	T/C	cg06784218	chr1:46089804	CCDC17	0.32	5.21	0.3	3.89e-7	Platelet count;
CESC	cis	rs7659604	0.521	rs4833234	chr4:122694799	T/C	cg19671926	chr4:122722719	EXOSC9	0.64	8.56	0.47	9.28e-16	Type 2 diabetes;
CESC	cis	rs116988415	0.584	rs4899145	chr14:65241867	G/A	cg25083366	chr14:65239357	SPTB	0.69	5.05	0.3	8.08e-7	Daytime sleep phenotypes;
CESC	cis	rs1008375	0.933	rs6847966	chr4:17634255	G/A	cg04450456	chr4:17643702	FAM184B	0.37	5.18	0.3	4.46e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs6831352	0.918	rs13127582	chr4:100058194	G/A	cg13256891	chr4:100009986	ADH5	-0.77	-8.45	-0.46	1.97e-15	Alcohol dependence;
CESC	cis	rs34779708	0.966	rs17500582	chr10:35498788	T/A	cg03585969	chr10:35415529	CREM	0.75	9.88	0.52	8.37e-20	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs763014	0.833	rs3743904	chr16:632767	A/G	cg07256732	chr16:621771	PIGQ	-0.31	-5.3	-0.31	2.4e-7	Height;
CESC	trans	rs6572548	0.504	rs1956082	chr14:49665496	A/C	cg18689148	chr7:157738329	PTPRN2	0.5	6.08	0.35	4.1e-9	Subjective well-being;
CESC	cis	rs9913156	0.748	rs72835619	chr17:4557285	G/A	cg00122941	chr17:4613640	ARRB2	0.84	9.91	0.52	6.58e-20	Lymphocyte counts;
CESC	cis	rs9733	0.565	rs11804276	chr1:150685761	T/A	cg04414720	chr1:150670196	GOLPH3L	0.62	8.86	0.48	1.21e-16	Tonsillectomy;
CESC	cis	rs4862750	0.872	rs6852907	chr4:187897094	A/C	cg06074448	chr4:187884817	NA	-0.37	-5.44	-0.32	1.21e-7	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02750954	chr17:40847780	CNTNAP1	-0.43	-6.07	-0.35	4.43e-9	Gut microbiome composition (summer);
CESC	cis	rs7772486	0.875	rs1331644	chr6:146398660	T/C	cg05347473	chr6:146136440	FBXO30	0.48	6.57	0.37	2.58e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2290159	0.800	rs6766666	chr3:12690855	A/C	cg23032965	chr3:12705835	RAF1	-0.5	-5.4	-0.31	1.47e-7	Cholesterol, total;
CESC	cis	rs2842992	0.724	rs9365097	chr6:160211259	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.84	11.79	0.59	4.52e-26	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs4704187	0.687	rs6872475	chr5:74419793	G/A	cg03227963	chr5:74354835	NA	0.31	5.7	0.33	3.22e-8	Response to amphetamines;
CESC	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg06877462	chr1:205807181	PM20D1	0.42	6.35	0.36	9.46e-10	Menarche (age at onset);
CESC	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.51	-6.36	-0.36	8.83e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs8170	0.603	rs3745187	chr19:17414126	C/T	cg04749549	chr19:17459798	NA	-0.33	-5.33	-0.31	2.15e-7	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
CESC	cis	rs11577318	0.853	rs1071849	chr1:26646726	A/G	cg18121669	chr1:26560928	CCDC21	0.42	5.07	0.3	7.54e-7	Granulocyte percentage of myeloid white cells;
CESC	cis	rs9611565	0.659	rs12484694	chr22:41919330	A/G	cg06634786	chr22:41940651	POLR3H	-0.64	-6.62	-0.38	2.01e-10	Vitiligo;
CESC	cis	rs16854884	0.584	rs34372603	chr3:143738249	T/C	cg06585982	chr3:143692056	C3orf58	0.5	6.7	0.38	1.26e-10	Economic and political preferences (feminism/equality);
CESC	cis	rs1707322	1.000	rs4660334	chr1:46462126	A/C	cg03146154	chr1:46216737	IPP	0.71	9.58	0.51	7.4e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7447593	0.626	rs3812036	chr5:176813404	C/T	cg17509989	chr5:176798049	RGS14	0.6	6.35	0.36	9.46e-10	Urinary electrolytes (magnesium/calcium ratio);
CESC	cis	rs853679	0.517	rs56310871	chr6:28044482	A/G	cg12963246	chr6:28129442	ZNF389	0.55	7.35	0.41	2.46e-12	Depression;
CESC	cis	rs10197940	0.710	rs4500942	chr2:152334580	A/G	cg06191203	chr2:152266755	RIF1	-0.44	-5.53	-0.32	7.84e-8	Lung cancer;
CESC	cis	rs1790761	0.505	rs7938563	chr11:67304131	A/G	cg24690094	chr11:67383802	NA	-0.33	-5.67	-0.33	3.72e-8	Mean corpuscular volume;
CESC	cis	rs3008870	0.916	rs2025608	chr1:67422550	C/T	cg02640540	chr1:67518911	SLC35D1	0.51	5.58	0.32	5.89e-8	Lymphocyte percentage of white cells;
CESC	cis	rs933688	0.941	rs2887007	chr5:90740531	A/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.09	14.69	0.67	3.85e-36	Smoking behavior;
CESC	cis	rs7116495	0.609	rs7113520	chr11:71691946	G/A	cg26138937	chr11:71823887	C11orf51	-1.32	-8.29	-0.45	5.9e-15	Severe influenza A (H1N1) infection;
CESC	trans	rs35952432	1	rs35952432	chr6:28074901	C/T	cg06606381	chr12:133084897	FBRSL1	-1.08	-8.08	-0.44	2.26e-14	Lung cancer;
CESC	cis	rs6938	0.534	rs8025447	chr15:75192222	T/G	cg10253484	chr15:75165896	SCAMP2	-0.54	-7.12	-0.4	1.01e-11	Breast cancer;
CESC	cis	rs5850	0.557	rs10270788	chr7:23189000	T/C	cg23682824	chr7:23144976	KLHL7	0.51	6.83	0.39	5.81e-11	Blood protein levels;
CESC	cis	rs2370759	1.000	rs2225152	chr10:32574759	T/C	cg05361325	chr10:32636312	EPC1	-0.54	-5.12	-0.3	6e-7	Sexual dysfunction (female);
CESC	cis	rs6088590	1.000	rs6058111	chr20:33310999	T/C	cg08999081	chr20:33150536	PIGU	0.58	9.0	0.48	4.6e-17	Coronary artery disease;
CESC	cis	rs1847202	0.859	rs13096870	chr3:72948172	G/A	cg25664220	chr3:72788482	NA	-0.38	-5.49	-0.32	9.25e-8	Motion sickness;
CESC	cis	rs4076764	0.914	rs6704467	chr1:163364512	A/G	cg24596788	chr1:163392923	NA	-0.5	-7.56	-0.42	6.74e-13	Motion sickness;
CESC	cis	rs7589342	1.000	rs7589342	chr2:106433478	C/T	cg16077055	chr2:106428750	NCK2	0.53	7.56	0.42	6.6e-13	Addiction;
CESC	cis	rs7818688	1.000	rs10113545	chr8:96029707	A/T	cg16049864	chr8:95962084	TP53INP1	0.6	5.77	0.33	2.25e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs9916302	0.904	rs7208274	chr17:37513796	C/T	cg19468946	chr17:37922297	IKZF3	0.39	5.03	0.3	8.9e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs9894429	0.546	rs9906979	chr17:79608765	A/G	cg21984481	chr17:79567631	NPLOC4	-0.4	-6.04	-0.35	5.26e-9	Eye color traits;
CESC	cis	rs6831352	0.918	rs35662508	chr4:100050974	C/G	cg13256891	chr4:100009986	ADH5	-0.77	-8.43	-0.46	2.27e-15	Alcohol dependence;
CESC	cis	rs611744	0.816	rs626211	chr8:109189448	A/C	cg21045802	chr8:109455806	TTC35	0.46	5.51	0.32	8.7e-8	Dupuytren's disease;
CESC	cis	rs36051895	0.587	rs16922785	chr9:5200409	C/G	cg02405213	chr9:5042618	JAK2	-0.49	-5.52	-0.32	8.03e-8	Pediatric autoimmune diseases;
CESC	cis	rs9868809	0.881	rs2276852	chr3:48666923	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.6	-5.34	-0.31	1.96e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs4148883	0.675	rs10015824	chr4:100074544	C/G	cg12011299	chr4:100065546	ADH4	0.67	9.97	0.52	4.3e-20	Alcohol dependence;
CESC	cis	rs77956314	0.515	rs4767473	chr12:117365506	C/T	cg25972092	chr12:117363249	FBXW8	0.52	5.85	0.34	1.43e-8	Subcortical brain region volumes;Hippocampal volume;
CESC	cis	rs16854884	0.657	rs7637912	chr3:143749777	G/A	cg06585982	chr3:143692056	C3orf58	0.5	6.71	0.38	1.18e-10	Economic and political preferences (feminism/equality);
CESC	cis	rs2228479	0.717	rs9282682	chr16:89805794	A/G	cg04013166	chr16:89971882	TCF25	0.72	7.9	0.44	7.6e-14	Skin colour saturation;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02884024	chr20:58515388	C20orf177;PPP1R3D	0.59	6.48	0.37	4.47e-10	Gut microbiome composition (summer);
CESC	cis	rs77861329	0.748	rs731684	chr3:52109841	T/C	cg08692210	chr3:52188851	WDR51A	0.5	6.08	0.35	4.12e-9	Macrophage inflammatory protein 1b levels;
CESC	cis	rs8170	0.603	rs8109328	chr19:17417955	C/T	cg04749549	chr19:17459798	NA	-0.34	-5.34	-0.31	2.01e-7	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
CESC	cis	rs13343954	0.518	rs7252086	chr19:33534929	T/C	cg03563238	chr19:33554763	RHPN2	-0.31	-5.56	-0.32	6.65e-8	Colorectal cancer;
CESC	cis	rs9911578	0.904	rs7209253	chr17:56908987	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.26	0.31	3.04e-7	Intelligence (multi-trait analysis);
CESC	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg24503407	chr1:205819492	PM20D1	0.9	16.55	0.71	9.63e-43	Menarche (age at onset);
CESC	cis	rs61776719	0.520	rs12569027	chr1:38449163	C/T	cg12658694	chr1:38397304	INPP5B	0.65	9.39	0.5	2.82e-18	Coronary artery disease;
CESC	cis	rs9902453	1.000	rs7207021	chr17:28400516	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.63	-8.05	-0.44	2.78e-14	Coffee consumption (cups per day);
CESC	trans	rs1973993	0.544	rs2800427	chr1:97002766	A/C	cg10631902	chr5:14652156	NA	0.46	6.89	0.39	4.05e-11	Weight;
CESC	cis	rs1499972	0.648	rs62264764	chr3:117639575	G/A	cg07612923	chr3:117604196	NA	0.66	5.98	0.34	7.1e-9	Schizophrenia;
CESC	cis	rs7927771	0.560	rs4752858	chr11:47685829	C/T	cg20307385	chr11:47447363	PSMC3	-0.58	-8.03	-0.44	3.19e-14	Subjective well-being;
CESC	cis	rs7131987	0.903	rs2194518	chr12:29419460	C/T	cg09582351	chr12:29534625	ERGIC2	-0.33	-5.1	-0.3	6.36e-7	QT interval;
CESC	cis	rs854765	0.547	rs6502633	chr17:17941037	G/C	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.5	6.36	0.36	8.59e-10	Total body bone mineral density;
CESC	cis	rs2842992	0.830	rs2842966	chr6:160141592	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.67	8.7	0.47	3.62e-16	Age-related macular degeneration (geographic atrophy);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05527336	chr4:83956057	COPS4	-0.56	-6.14	-0.35	2.98e-9	Gut microbiome composition (summer);
CESC	cis	rs4555082	0.834	rs2816651	chr14:105708470	A/G	cg10792982	chr14:105748885	BRF1	0.42	5.52	0.32	7.89e-8	Mean platelet volume;Platelet distribution width;
CESC	cis	rs2242663	0.529	rs1785640	chr11:66223158	C/T	cg04006266	chr11:66300458	BBS1	0.33	5.08	0.3	7.12e-7	Bipolar disorder;
CESC	cis	rs3091242	0.933	rs61775174	chr1:25787313	G/A	cg27572855	chr1:25598939	RHD	-0.43	-6.95	-0.39	2.79e-11	Erythrocyte sedimentation rate;
CESC	cis	rs7589728	1.000	rs7589728	chr2:88518440	G/A	cg04511125	chr2:88470314	THNSL2	0.59	5.73	0.33	2.68e-8	Plasma clusterin levels;
CESC	cis	rs6570726	0.791	rs11155432	chr6:145898761	T/C	cg05347473	chr6:146136440	FBXO30	0.59	7.78	0.43	1.59e-13	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2120019	1.000	rs12324912	chr15:75361006	G/A	cg17294928	chr15:75287854	SCAMP5	-0.68	-7.51	-0.42	8.84e-13	Blood trace element (Zn levels);
CESC	cis	rs2204008	0.506	rs11495470	chr12:38026904	C/T	cg13010199	chr12:38710504	ALG10B	0.47	5.83	0.34	1.62e-8	Bladder cancer;
CESC	cis	rs875971	0.638	rs6960778	chr7:66071597	C/T	cg06456125	chr7:65229604	NA	-0.41	-5.36	-0.31	1.79e-7	Aortic root size;
CESC	cis	rs10504229	1.000	rs58382845	chr8:58169851	A/C	cg05313129	chr8:58192883	C8orf71	-0.53	-6.09	-0.35	3.95e-9	Developmental language disorder (linguistic errors);
CESC	trans	rs61931739	0.963	rs12307606	chr12:34016365	C/T	cg26384229	chr12:38710491	ALG10B	-0.46	-6.31	-0.36	1.16e-9	Morning vs. evening chronotype;
CESC	trans	rs11637445	0.627	rs4776988	chr15:68124151	C/T	cg14583481	chr3:118865028	C3orf30;IGSF11	0.43	6.19	0.36	2.22e-9	Posterior cortical atrophy and Alzheimer's disease;
CESC	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg01238044	chr22:24384105	GSTT1	0.65	7.85	0.43	1.04e-13	Urinary 1,3-butadiene metabolite levels in smokers;
CESC	cis	rs9393777	0.513	rs7754159	chr6:26620312	G/A	cg11502198	chr6:26597334	ABT1	0.52	5.31	0.31	2.35e-7	Intelligence (multi-trait analysis);
CESC	cis	rs4819052	0.851	rs2838843	chr21:46669284	T/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.44	5.37	0.31	1.7e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs8177253	0.898	rs8177258	chr3:133480387	C/A	cg01448562	chr3:133502909	NA	-0.44	-6.09	-0.35	4.06e-9	Iron status biomarkers;
CESC	cis	rs11264213	0.901	rs72661632	chr1:36420715	G/A	cg27506609	chr1:36549197	TEKT2	0.67	5.55	0.32	6.97e-8	Schizophrenia;
CESC	cis	rs12476592	0.516	rs6706123	chr2:63801522	G/A	cg17519650	chr2:63277830	OTX1	-0.48	-5.82	-0.34	1.66e-8	Childhood ear infection;
CESC	cis	rs7666738	0.830	rs3857217	chr4:99034347	T/C	cg03676636	chr4:99064102	C4orf37	0.34	5.14	0.3	5.47e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs36051895	0.626	rs3780368	chr9:5093188	G/C	cg02405213	chr9:5042618	JAK2	-0.54	-6.57	-0.37	2.58e-10	Pediatric autoimmune diseases;
CESC	cis	rs920590	0.721	rs67989257	chr8:19660278	G/A	cg17834443	chr8:19674713	INTS10	0.59	6.6	0.38	2.2e-10	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs965469	0.895	rs6037592	chr20:3392950	T/G	cg25506879	chr20:3388711	C20orf194	-0.63	-6.63	-0.38	1.92e-10	IFN-related cytopenia;
CESC	cis	rs807669	0.807	rs712948	chr22:19206499	A/G	cg02655711	chr22:19163373	SLC25A1	0.9	13.11	0.63	1.31e-30	Metabolite levels;
CESC	cis	rs7267979	1.000	rs3761117	chr20:25388070	G/A	cg08601574	chr20:25228251	PYGB	-0.37	-5.32	-0.31	2.18e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs6963495	0.818	rs73192149	chr7:105210910	A/G	cg02135003	chr7:105160482	PUS7	-0.48	-5.62	-0.33	4.83e-8	Bipolar disorder (body mass index interaction);
CESC	cis	rs35110281	0.715	rs8129601	chr21:45119104	A/G	cg04455712	chr21:45112962	RRP1B	0.5	7.81	0.43	1.38e-13	Mean corpuscular volume;
CESC	cis	rs8077577	0.747	rs57490980	chr17:18160753	T/A	cg16794390	chr17:18148240	FLII	0.41	6.33	0.36	1.05e-9	Obesity-related traits;
CESC	trans	rs61931739	0.500	rs11053246	chr12:34516620	C/T	cg26384229	chr12:38710491	ALG10B	0.71	10.63	0.55	3.31e-22	Morning vs. evening chronotype;
CESC	cis	rs2985684	0.894	rs6572586	chr14:50021941	A/C	cg02151108	chr14:50098012	C14orf104	-0.4	-5.35	-0.31	1.92e-7	Carotid intima media thickness;
CESC	cis	rs2635047	0.967	rs1119005	chr18:44725605	A/G	cg24371990	chr18:44770781	NA	0.33	5.3	0.31	2.48e-7	Educational attainment;
CESC	cis	rs7615952	0.641	rs61048217	chr3:125807905	G/T	cg15145296	chr3:125709740	NA	-0.56	-5.97	-0.34	7.65e-9	Blood pressure (smoking interaction);
CESC	cis	rs9388451	0.807	rs1269175	chr6:126040435	A/G	cg05901451	chr6:126070800	HEY2	0.61	8.99	0.48	4.68e-17	Brugada syndrome;
CESC	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.57	0.37	2.69e-10	Prudent dietary pattern;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16341945	chr7:111846878	ZNF277;DOCK4	-0.57	-6.53	-0.37	3.38e-10	Gut microbiome composition (summer);
CESC	cis	rs172166	0.637	rs1225595	chr6:28151340	A/T	cg19592336	chr6:28129416	ZNF389	0.44	6.46	0.37	4.98e-10	Cardiac Troponin-T levels;
CESC	cis	rs801193	0.591	rs2707839	chr7:66193084	A/G	cg10691866	chr7:65817282	TPST1	-0.35	-5.91	-0.34	1.06e-8	Aortic root size;
CESC	cis	rs116095464	0.558	rs10075018	chr5:239175	G/A	cg10591111	chr5:226296	SDHA	-0.51	-6.22	-0.36	1.95e-9	Breast cancer;
CESC	cis	rs651907	0.557	rs3864012	chr3:101397623	T/C	cg12386194	chr3:101231763	SENP7	0.45	5.74	0.33	2.63e-8	Colorectal cancer;
CESC	cis	rs10392	0.543	rs6028208	chr20:37556075	T/A	cg27552599	chr20:37590471	DHX35	0.38	5.79	0.34	1.94e-8	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
CESC	cis	rs7312933	0.669	rs7974476	chr12:42542484	C/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.42	5.47	0.32	1.02e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs6429637	0.542	rs12760274	chr1:44249344	C/T	cg19743044	chr1:44115203	KDM4A	-0.42	-5.04	-0.3	8.55e-7	Intelligence (multi-trait analysis);
CESC	cis	rs4077515	0.967	rs11794847	chr9:139271747	G/A	cg14169450	chr9:139327907	INPP5E	0.37	5.42	0.32	1.31e-7	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs12822507	0.868	rs12580006	chr12:12789646	C/T	cg04607235	chr12:12878440	APOLD1	-0.51	-6.57	-0.37	2.6200000000000003e-10	Systemic lupus erythematosus;
CESC	cis	rs10883723	0.810	rs61873733	chr10:104251458	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.54	7.44	0.42	1.43e-12	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs10463316	0.709	rs3857426	chr5:150789831	C/A	cg03212797	chr5:150827313	SLC36A1	-0.49	-6.46	-0.37	4.89e-10	Metabolite levels (Pyroglutamine);
CESC	trans	rs61931739	0.534	rs1843733	chr12:34047626	T/C	cg26384229	chr12:38710491	ALG10B	0.51	6.94	0.39	2.97e-11	Morning vs. evening chronotype;
CESC	cis	rs4819052	0.765	rs2838827	chr21:46656146	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.46	5.54	0.32	7.25e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs9905704	0.874	rs2643126	chr17:56737765	A/G	cg12560992	chr17:57184187	TRIM37	0.59	7.03	0.4	1.72e-11	Testicular germ cell tumor;
CESC	cis	rs7264396	0.690	rs2425171	chr20:34443173	G/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.62	7.35	0.41	2.49e-12	Total cholesterol levels;
CESC	cis	rs7666738	0.830	rs1124253	chr4:98949682	C/T	cg03676636	chr4:99064102	C4orf37	0.33	5.09	0.3	6.71e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25449970	chr10:5550506	NA	-0.57	-6.67	-0.38	1.47e-10	Gut microbiome composition (summer);
CESC	cis	rs5769765	0.779	rs12170530	chr22:50318422	T/G	cg26441486	chr22:50317300	CRELD2	0.48	5.78	0.33	2.08e-8	Schizophrenia;
CESC	cis	rs10465746	0.780	rs2147392	chr1:84404154	C/A	cg10977910	chr1:84465055	TTLL7	0.53	7.22	0.41	5.43e-12	Obesity-related traits;
CESC	cis	rs2645424	0.686	rs2294140	chr8:11705677	C/G	cg21281001	chr8:11725306	CTSB	-0.42	-5.42	-0.32	1.31e-7	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);
CESC	cis	rs703842	0.964	rs2014886	chr12:58177437	C/T	cg18357645	chr12:58087776	OS9	-0.43	-5.94	-0.34	9.06e-9	Multiple sclerosis;
CESC	cis	rs2732480	0.500	rs2450989	chr12:48653408	A/G	cg24011408	chr12:48396354	COL2A1	-0.43	-6.11	-0.35	3.52e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs2180341	0.596	rs12215298	chr6:127676833	C/T	cg27446573	chr6:127587934	RNF146	0.78	10.47	0.54	1.11e-21	Breast cancer;
CESC	cis	rs2228479	0.850	rs17226498	chr16:89840631	T/C	cg14709524	chr16:89940631	TCF25	0.91	6.74	0.38	1e-10	Skin colour saturation;
CESC	cis	rs4665809	0.590	rs35656275	chr2:26494695	G/C	cg08470875	chr2:26401718	FAM59B	0.7	7.18	0.4	6.92e-12	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08492205	chr10:103879827	LDB1	-0.66	-7.88	-0.44	8.47e-14	Gut microbiome composition (summer);
CESC	cis	rs7618915	0.501	rs55678971	chr3:52717229	T/A	cg17372223	chr3:52568218	NT5DC2	0.48	7.27	0.41	4.02e-12	Bipolar disorder;
CESC	cis	rs3733585	0.673	rs6840802	chr4:9965633	C/G	cg02734326	chr4:10020555	SLC2A9	0.43	5.82	0.34	1.73e-8	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs4689388	0.926	rs5018647	chr4:6292799	A/C	cg25554036	chr4:6271136	WFS1	0.51	8.48	0.46	1.65e-15	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs6426558	0.515	rs7543579	chr1:227377699	A/T	cg10327440	chr1:227177885	CDC42BPA	-0.5	-6.17	-0.35	2.56e-9	Neutrophil percentage of white cells;
CESC	cis	rs96067	0.652	rs274764	chr1:36574912	T/C	cg27506609	chr1:36549197	TEKT2	-0.44	-5.34	-0.31	1.97e-7	Corneal structure;
CESC	cis	rs763121	0.925	rs1056661	chr22:39080245	A/G	cg06022373	chr22:39101656	GTPBP1	0.79	12.97	0.62	4.12e-30	Menopause (age at onset);
CESC	cis	rs10857712	0.904	rs7083614	chr10:135226236	G/A	cg01444801	chr10:135216882	MTG1	-0.45	-5.3	-0.31	2.49e-7	Systemic lupus erythematosus;
CESC	cis	rs453301	0.592	rs4841084	chr8:8883905	C/T	cg06636001	chr8:8085503	FLJ10661	0.46	5.93	0.34	9.51e-9	Joint mobility (Beighton score);
CESC	cis	rs6460942	0.630	rs17670901	chr7:12386622	G/A	cg02935154	chr7:12443704	VWDE	-0.5	-5.17	-0.3	4.6e-7	Coronary artery disease;
CESC	cis	rs9522267	0.535	rs9522284	chr13:112229343	C/T	cg10483660	chr13:112241077	NA	-0.33	-5.82	-0.34	1.67e-8	Hepatitis;
CESC	cis	rs2708240	1.000	rs759178	chr7:147575112	A/C	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.35	-5.77	-0.33	2.23e-8	QT interval (drug interaction);
CESC	cis	rs66823261	0.778	rs2906332	chr8:194943	C/T	cg27532244	chr8:182981	ZNF596;RPL23AP53	-0.57	-6.65	-0.38	1.64e-10	Breast cancer (estrogen-receptor negative);Breast cancer;
CESC	cis	rs7937682	0.889	rs2850247	chr11:111637202	C/A	cg22437258	chr11:111473054	SIK2	-0.64	-7.72	-0.43	2.43e-13	Primary sclerosing cholangitis;
CESC	trans	rs1829883	0.733	rs28521637	chr5:98725123	A/C	cg23861655	chr4:57411219	NA	0.38	6.25	0.36	1.68e-9	Hemostatic factors and hematological phenotypes;
CESC	cis	rs4722166	0.573	rs35436671	chr7:22775508	G/A	cg26061582	chr7:22766209	IL6	0.52	5.64	0.33	4.41e-8	Lung cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22513511	chr1:151162618	VPS72	0.59	6.29	0.36	1.29e-9	Gut microbiome composition (summer);
CESC	trans	rs62103177	0.810	rs62103192	chr18:77629050	A/T	cg05926928	chr17:57297772	GDPD1	1.18	10.14	0.53	1.27e-20	Opioid sensitivity;
CESC	cis	rs9896933	0.778	rs80112422	chr17:80827719	G/T	cg19500275	chr17:80737654	TBCD	0.62	5.88	0.34	1.23e-8	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
CESC	cis	rs4253772	0.637	rs6008357	chr22:46652104	T/G	cg24881330	chr22:46731750	TRMU	0.89	10.09	0.53	1.86e-20	LDL cholesterol;Cholesterol, total;
CESC	cis	rs2066819	1.000	rs116535779	chr12:56739261	A/G	cg26734620	chr12:56694298	CS	0.88	8.75	0.47	2.56e-16	Psoriasis vulgaris;
CESC	cis	rs2439831	1.000	rs689826	chr15:43749916	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.82	12.06	0.6	5.55e-27	Lung cancer in ever smokers;
CESC	cis	rs6087990	0.806	rs1474738	chr20:31380309	G/A	cg13636640	chr20:31349939	DNMT3B	0.77	11.88	0.59	2.17e-26	Ulcerative colitis;
CESC	cis	rs12422267	0.609	rs11246940	chr12:132623473	A/G	cg09764611	chr12:132620959	NA	-0.52	-6.52	-0.37	3.52e-10	Plasma amyloid beta peptide concentrations (ABx-40);
CESC	cis	rs4953076	0.533	rs1551315	chr2:44407618	G/A	cg04920474	chr2:44395004	PPM1B	0.54	6.83	0.39	5.76e-11	Height;
CESC	cis	rs853679	0.517	rs9380055	chr6:28081629	A/G	cg20151795	chr6:28129481	ZNF389	0.45	5.87	0.34	1.29e-8	Depression;
CESC	cis	rs4805272	0.512	rs11879141	chr19:29320335	G/A	cg12756686	chr19:29218302	NA	0.5	6.28	0.36	1.39e-9	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
CESC	cis	rs2228479	0.850	rs76075456	chr16:89834270	T/C	cg14709524	chr16:89940631	TCF25	0.91	6.74	0.38	1e-10	Skin colour saturation;
CESC	cis	rs11098499	0.708	rs11732686	chr4:120252330	C/A	cg09307838	chr4:120376055	NA	0.77	10.49	0.54	9.15e-22	Corneal astigmatism;
CESC	cis	rs10752881	1.000	rs8179262	chr1:182973186	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.84	13.44	0.64	9.35e-32	Colorectal cancer;
CESC	cis	rs12618769	0.597	rs4851142	chr2:99133611	A/C	cg10123293	chr2:99228465	UNC50	0.39	5.13	0.3	5.6e-7	Bipolar disorder;
CESC	cis	rs12410462	0.581	rs73102371	chr1:227554880	G/A	cg04117972	chr1:227635322	NA	0.62	5.3	0.31	2.42e-7	Major depressive disorder;
CESC	cis	rs9894429	1.000	rs35435780	chr17:79579602	G/T	cg13777783	chr17:79615861	NA	-0.35	-5.79	-0.34	1.99e-8	Eye color traits;
CESC	cis	rs10876993	0.890	rs1689597	chr12:58051886	G/A	cg18357645	chr12:58087776	OS9	0.61	9.4	0.5	2.71e-18	Celiac disease or Rheumatoid arthritis;
CESC	cis	rs317689	0.513	rs317678	chr12:69692166	C/G	cg20891283	chr12:69753455	YEATS4	0.56	7.09	0.4	1.21e-11	Response to diuretic therapy;
CESC	cis	rs11155671	0.530	rs7757984	chr6:150208651	A/G	cg09699651	chr6:150184138	LRP11	0.54	7.48	0.42	1.07e-12	Testicular germ cell tumor;
CESC	cis	rs801193	0.548	rs2109297	chr7:66122384	G/A	cg18876405	chr7:65276391	NA	-0.45	-6.18	-0.35	2.43e-9	Aortic root size;
CESC	cis	rs703842	1.000	rs11172342	chr12:58187758	G/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.71	8.96	0.48	5.78e-17	Multiple sclerosis;
CESC	cis	rs60154123	0.730	rs652256	chr1:210465017	T/C	cg25204440	chr1:209979598	IRF6	0.45	5.05	0.3	8.23e-7	Coronary artery disease;
CESC	trans	rs2727020	0.894	rs10839265	chr11:49369733	C/T	cg15704280	chr7:45808275	SEPT13	-0.76	-9.47	-0.5	1.61e-18	Coronary artery disease;
CESC	cis	rs9457247	1.000	rs10946199	chr6:167404492	G/A	cg23791538	chr6:167370224	RNASET2	-0.58	-8.28	-0.45	6.28e-15	Crohn's disease;
CESC	cis	rs9486715	0.867	rs3860243	chr6:96905303	T/G	cg18709589	chr6:96969512	KIAA0776	0.46	6.47	0.37	4.68e-10	Headache;
CESC	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg03395511	chr6:291903	DUSP22	-0.72	-9.41	-0.5	2.54e-18	Menopause (age at onset);
CESC	cis	rs9314323	0.767	rs10866848	chr8:26208209	G/C	cg11498726	chr8:26250323	BNIP3L	-0.47	-6.71	-0.38	1.19e-10	Red cell distribution width;
CESC	cis	rs7599312	0.532	rs1531788	chr2:213394320	C/T	cg16329650	chr2:213403929	ERBB4	0.4	5.32	0.31	2.17e-7	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs863345	0.526	rs857723	chr1:158604000	C/T	cg12129480	chr1:158549410	OR10X1	-0.3	-5.6	-0.33	5.4e-8	Pneumococcal bacteremia;
CESC	cis	rs2033711	0.902	rs4801589	chr19:58953398	C/G	cg26874164	chr19:58962979	ZNF324B	0.54	7.66	0.43	3.55e-13	Uric acid clearance;
CESC	cis	rs3862030	0.694	rs1984795	chr10:104226830	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.37	-5.17	-0.3	4.71e-7	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
CESC	cis	rs7615952	0.576	rs4646763	chr3:125822129	G/A	cg06494592	chr3:125709126	NA	-0.51	-5.44	-0.32	1.22e-7	Blood pressure (smoking interaction);
CESC	cis	rs7561273	0.561	rs35268318	chr2:24352824	A/T	cg20701182	chr2:24300061	SF3B14	0.46	6.01	0.35	6.27e-9	Quantitative traits;
CESC	cis	rs8067354	0.574	rs9789060	chr17:58018570	A/G	cg02344993	chr17:57696989	CLTC	0.53	5.56	0.32	6.6e-8	Hemoglobin concentration;
CESC	cis	rs2204008	0.837	rs12366727	chr12:38365748	A/C	cg26384229	chr12:38710491	ALG10B	0.73	10.65	0.55	2.87e-22	Bladder cancer;
CESC	cis	rs6032067	0.777	rs80323300	chr20:43785287	T/C	cg11264863	chr20:43835661	SEMG1	0.5	5.35	0.31	1.86e-7	Blood protein levels;
CESC	cis	rs10088262	0.629	rs7827665	chr8:124804190	G/A	cg20713898	chr8:124780851	FAM91A1	-0.66	-8.96	-0.48	6.13e-17	Pancreatic cancer;
CESC	cis	rs7918232	0.941	rs10829195	chr10:27431564	G/A	cg14240646	chr10:27532245	ACBD5	-0.66	-6.43	-0.37	5.89e-10	Breast cancer;
CESC	cis	rs8177253	0.965	rs4854760	chr3:133498741	C/T	cg01448562	chr3:133502909	NA	0.39	5.47	0.32	1.03e-7	Iron status biomarkers;
CESC	cis	rs9311474	0.508	rs11720159	chr3:52617802	T/G	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.38	6.91	0.39	3.67e-11	Electroencephalogram traits;
CESC	cis	rs853679	0.550	rs1150689	chr6:28165099	T/C	cg23281280	chr6:28129359	ZNF389	0.49	6.85	0.39	5.22e-11	Depression;
CESC	cis	rs963731	0.649	rs6713281	chr2:39235330	G/T	cg04010122	chr2:39346883	SOS1	-0.72	-5.65	-0.33	4.12e-8	Corticobasal degeneration;
CESC	cis	rs782590	0.837	rs809732	chr2:55914621	T/C	cg18811423	chr2:55921094	PNPT1	0.8	12.8	0.62	1.6e-29	Metabolic syndrome;
CESC	cis	rs7089973	0.584	rs7908665	chr10:116611337	G/A	cg23260525	chr10:116636907	FAM160B1	0.43	8.28	0.45	6.14e-15	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs6066835	1.000	rs742645	chr20:47323655	G/A	cg18078177	chr20:47281410	PREX1	0.72	5.1	0.3	6.38e-7	Multiple myeloma;
CESC	cis	rs3785574	0.962	rs57553639	chr17:61848499	C/T	cg07677032	chr17:61819896	STRADA	0.42	5.25	0.31	3.15e-7	Height;
CESC	cis	rs6461049	0.765	rs1476887	chr7:2151633	T/C	cg04267008	chr7:1944627	MAD1L1	-0.48	-5.52	-0.32	8.09e-8	Schizophrenia;
CESC	cis	rs17125944	0.615	rs8019585	chr14:53374843	G/A	cg00686598	chr14:53173677	PSMC6	0.64	5.31	0.31	2.3e-7	Alzheimer's disease (late onset);
CESC	cis	rs4604732	0.631	rs74154675	chr1:247625836	G/A	cg12754571	chr1:247694271	LOC148824;OR2C3	0.44	5.44	0.32	1.21e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs12765878	1.000	rs3850671	chr10:105659387	T/C	cg24587175	chr10:105670608	OBFC1	0.34	5.57	0.32	6.31e-8	Coronary artery disease;
CESC	cis	rs7666738	0.830	rs13112037	chr4:98976986	A/T	cg17366294	chr4:99064904	C4orf37	0.59	8.43	0.46	2.31e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6500395	1.000	rs6500402	chr16:48687354	C/T	cg04672837	chr16:48644449	N4BP1	0.51	6.4	0.37	6.98e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	trans	rs637571	0.565	rs570387	chr11:65637076	T/C	cg17712092	chr4:129076599	LARP1B	-0.74	-9.4	-0.5	2.64e-18	Eosinophil percentage of white cells;
CESC	cis	rs896854	0.738	rs527234	chr8:95963798	C/G	cg13393036	chr8:95962371	TP53INP1	0.47	9.07	0.49	2.78e-17	Type 2 diabetes;
CESC	cis	rs6860806	0.507	rs156322	chr5:131653925	C/T	cg07395648	chr5:131743802	NA	-0.47	-6.13	-0.35	3.15e-9	Breast cancer;
CESC	cis	rs7666738	0.830	rs1456208	chr4:98678563	C/T	cg03467027	chr4:99064603	C4orf37	0.43	5.27	0.31	2.89e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs801193	0.591	rs4506088	chr7:66135457	G/A	cg18252515	chr7:66147081	NA	0.48	6.46	0.37	5.06e-10	Aortic root size;
CESC	cis	rs2228479	0.850	rs17226428	chr16:89842884	T/A	cg04013166	chr16:89971882	TCF25	0.78	6.67	0.38	1.51e-10	Skin colour saturation;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg14787260	chr17:40428794	STAT5B	-0.48	-6.66	-0.38	1.53e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs7208859	0.623	rs1061343	chr17:29114276	G/A	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.79e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	trans	rs7246657	0.891	rs7253114	chr19:37988725	G/A	cg24637308	chr11:6592297	DNHD1	0.52	6.16	0.35	2.66e-9	Coronary artery calcification;
CESC	trans	rs11098499	0.913	rs13126596	chr4:120140729	A/G	cg25214090	chr10:38739885	LOC399744	0.63	8.33	0.46	4.44e-15	Corneal astigmatism;
CESC	cis	rs1005277	0.579	rs9418322	chr10:38377296	G/T	cg00409905	chr10:38381863	ZNF37A	-0.45	-6.04	-0.35	5.25e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs2243480	1.000	rs431318	chr7:65511597	G/A	cg13147721	chr7:65941812	NA	-0.95	-9.04	-0.49	3.39e-17	Diabetic kidney disease;
CESC	cis	rs9399401	0.667	rs11759653	chr6:142720354	G/A	cg03128060	chr6:142623767	GPR126	0.38	6.4	0.37	7.02e-10	Chronic obstructive pulmonary disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01439366	chr20:388553	RBCK1	0.55	6.05	0.35	5.03e-9	Gut microbiome composition (summer);
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg23104823	chr14:45553408	PRPF39	-0.45	-6.14	-0.35	2.94e-9	Height;
CESC	cis	rs9611565	0.918	rs12484074	chr22:41752747	G/A	cg06634786	chr22:41940651	POLR3H	-0.65	-6.52	-0.37	3.51e-10	Vitiligo;
CESC	cis	rs7959452	0.684	rs11177615	chr12:69754189	G/A	cg22834771	chr12:69754056	YEATS4	-0.43	-5.55	-0.32	6.87e-8	Blood protein levels;
CESC	cis	rs67311347	0.869	rs9832311	chr3:40381322	A/T	cg24209194	chr3:40518798	ZNF619	0.43	5.49	0.32	9.27e-8	Renal cell carcinoma;
CESC	cis	rs1395	0.744	rs3739092	chr2:27462076	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.45	5.85	0.34	1.46e-8	Blood metabolite levels;
CESC	cis	rs72945132	0.882	rs7935969	chr11:70194175	G/A	cg00319359	chr11:70116639	PPFIA1	0.72	6.84	0.39	5.42e-11	Coronary artery disease;
CESC	cis	rs4642101	0.561	rs9831765	chr3:12805934	A/T	cg24848339	chr3:12840334	CAND2	0.34	5.2	0.3	4.03e-7	QRS complex (12-leadsum);
CESC	cis	rs1153858	1.000	rs11070453	chr15:45645154	C/G	cg21132104	chr15:45694354	SPATA5L1	0.84	11.4	0.57	9.5e-25	Homoarginine levels;
CESC	cis	rs1371867	0.875	rs962451	chr8:101331010	C/T	cg11906718	chr8:101322791	RNF19A	0.53	6.77	0.38	8.21e-11	Atrioventricular conduction;
CESC	cis	rs1707322	0.964	rs6675259	chr1:46502295	G/A	cg03146154	chr1:46216737	IPP	-0.76	-9.79	-0.52	1.66e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs4665809	0.887	rs6546716	chr2:26263836	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.7	-7.86	-0.43	9.43e-14	Gut microbiome composition (summer);
CESC	cis	rs6991838	0.584	rs1053085	chr8:66515988	C/T	cg13398993	chr8:66546079	ARMC1	-0.46	-5.45	-0.32	1.14e-7	Intelligence (multi-trait analysis);
CESC	cis	rs9894429	1.000	rs9674872	chr17:79581931	T/A	cg13777783	chr17:79615861	NA	-0.35	-5.79	-0.34	1.99e-8	Eye color traits;
CESC	cis	rs4822044	0.568	rs1883370	chr22:42143740	C/A	cg03806693	chr22:41940476	POLR3H	1.18	13.78	0.65	6.21e-33	Cannabis dependence symptom count;
CESC	cis	rs734999	0.572	rs3748816	chr1:2526746	A/G	cg20673091	chr1:2541236	MMEL1	0.44	7.44	0.42	1.39e-12	Ulcerative colitis;
CESC	cis	rs5769707	0.837	rs5770599	chr22:50019981	C/G	cg05373962	chr22:49881684	NA	-0.37	-6.14	-0.35	3.04e-9	Monocyte count;Monocyte percentage of white cells;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg10900715	chr6:41034675	C6orf130	0.46	6.26	0.36	1.57e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs12356475	0.710	rs10822686	chr10:67733250	C/T	cg16652648	chr2:197791396	PGAP1	0.48	5.99	0.35	6.64e-9	Psoriatic arthritis;
CESC	cis	rs80282103	0.717	rs41299206	chr10:1120236	T/C	cg08668510	chr10:1095578	IDI1	0.73	5.86	0.34	1.39e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs7618915	0.547	rs62255371	chr3:52747321	A/G	cg18404041	chr3:52824283	ITIH1	-0.4	-6.72	-0.38	1.1e-10	Bipolar disorder;
CESC	cis	rs17209837	1.000	rs45447097	chr7:87086144	G/A	cg00919237	chr7:87102261	ABCB4	-0.49	-5.77	-0.33	2.23e-8	Gallbladder cancer;
CESC	trans	rs7746199	0.736	rs34573979	chr6:27480526	C/T	cg06606381	chr12:133084897	FBRSL1	-1.07	-8.9	-0.48	9.12e-17	Gait speed in old age;Autism spectrum disorder or schizophrenia;
CESC	cis	rs7223966	1.000	rs6504169	chr17:61709145	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.45	-5.15	-0.3	5.14e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs7772486	0.686	rs9497395	chr6:146013592	A/G	cg05347473	chr6:146136440	FBXO30	-0.53	-6.67	-0.38	1.48e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg17178900	chr1:205818956	PM20D1	0.78	12.1	0.6	3.85e-27	Menarche (age at onset);
CESC	cis	rs7246657	1.000	rs1823061	chr19:37800626	G/A	cg23950597	chr19:37808831	NA	-0.58	-6.21	-0.36	2.08e-9	Coronary artery calcification;
CESC	cis	rs1371867	0.810	rs2919470	chr8:101233301	C/A	cg11906718	chr8:101322791	RNF19A	-0.49	-6.18	-0.36	2.36e-9	Atrioventricular conduction;
CESC	cis	rs2777491	0.789	rs316617	chr15:41795900	C/T	cg02330683	chr15:41787940	ITPKA	-0.52	-7.55	-0.42	7.25e-13	Ulcerative colitis;
CESC	cis	rs10129255	0.500	rs1974468	chr14:107142166	A/G	cg23076370	chr14:107095027	NA	-0.67	-10.15	-0.53	1.18e-20	Kawasaki disease;
CESC	cis	rs9611565	0.921	rs5751081	chr22:41742788	A/T	cg03806693	chr22:41940476	POLR3H	-0.71	-8.47	-0.46	1.76e-15	Vitiligo;
CESC	cis	rs1552244	0.935	rs6805869	chr3:10119917	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.85	-11.68	-0.58	1.06e-25	Alzheimer's disease;
CESC	cis	rs2635047	1.000	rs2684818	chr18:44712965	C/T	cg19077165	chr18:44547161	KATNAL2	-0.43	-5.88	-0.34	1.22e-8	Educational attainment;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02718464	chr13:41384019	SUGT1L1;SLC25A15;MIR621	-0.57	-6.1	-0.35	3.68e-9	Gut microbiome composition (summer);
CESC	cis	rs6762	0.748	rs5030780	chr11:838110	C/T	cg23754390	chr11:835074	CD151	0.33	5.96	0.34	8.14e-9	Mean platelet volume;
CESC	trans	rs561341	0.505	rs28708703	chr17:30386845	C/G	cg20587970	chr11:113659929	NA	-1.06	-12.78	-0.62	1.92e-29	Hip circumference adjusted for BMI;
CESC	cis	rs1692580	0.870	rs262680	chr1:2167149	C/T	cg04315214	chr1:2043799	PRKCZ	-0.39	-5.82	-0.34	1.68e-8	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03056341	chr11:64546100	SF1	0.65	7.64	0.42	4.08e-13	Gut microbiome composition (summer);
CESC	cis	rs644799	0.965	rs545342	chr11:95545369	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	9.15	0.49	1.61e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs3892630	0.588	rs8106748	chr19:33282797	G/A	cg13157960	chr19:33183277	NUDT19	0.56	5.65	0.33	4.13e-8	Red blood cell traits;
CESC	cis	rs1729951	0.575	rs35289288	chr3:136680568	C/T	cg03617693	chr3:136751559	NA	0.38	5.31	0.31	2.3e-7	Neuroticism;
CESC	cis	rs1153858	1.000	rs67461176	chr15:45676819	C/T	cg14582100	chr15:45693742	SPATA5L1	0.42	5.95	0.34	8.38e-9	Homoarginine levels;
CESC	cis	rs2952156	0.684	rs881844	chr17:37810218	C/G	cg20243544	chr17:37824526	PNMT	0.67	8.99	0.48	4.65e-17	Asthma;
CESC	cis	rs11098499	0.955	rs4145951	chr4:120155817	A/G	cg09307838	chr4:120376055	NA	0.87	11.39	0.57	1.02e-24	Corneal astigmatism;
CESC	cis	rs367943	0.635	rs2222144	chr5:112712208	G/T	cg12552261	chr5:112820674	MCC	0.38	5.07	0.3	7.31e-7	Type 2 diabetes;
CESC	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg02725872	chr8:58115012	NA	-0.42	-5.72	-0.33	2.88e-8	Developmental language disorder (linguistic errors);
CESC	trans	rs163030	0.902	rs335600	chr5:76752546	A/C	cg26150533	chr8:82396069	FABP4	-0.39	-6.06	-0.35	4.57e-9	Caudate nucleus volume;
CESC	cis	rs9916302	0.904	rs11078897	chr17:37415870	C/T	cg00129232	chr17:37814104	STARD3	-0.55	-7.11	-0.4	1.11e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs4713118	0.527	rs9461433	chr6:28095172	C/T	cg12963246	chr6:28129442	ZNF389	0.56	7.62	0.42	4.43e-13	Parkinson's disease;
CESC	cis	rs7666738	0.800	rs13107586	chr4:99028788	G/C	cg17366294	chr4:99064904	C4orf37	0.62	8.95	0.48	6.32e-17	Colonoscopy-negative controls vs population controls;
CESC	cis	rs8114671	0.527	rs2253484	chr20:33405263	A/T	cg24642439	chr20:33292090	TP53INP2	-0.42	-5.04	-0.3	8.49e-7	Height;
CESC	cis	rs936229	0.656	rs12898397	chr15:75130093	T/C	cg14664628	chr15:75095509	CSK	-0.59	-7.96	-0.44	5.14e-14	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CESC	cis	rs34375054	0.525	rs10846829	chr12:125595058	G/C	cg25124228	chr12:125621409	AACS	-0.57	-7.18	-0.4	7.17e-12	Post bronchodilator FEV1/FVC ratio;
CESC	trans	rs916888	0.821	rs199507	chr17:44858855	A/G	cg10053473	chr17:62856997	LRRC37A3	0.65	7.33	0.41	2.74e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs28489187	0.706	rs2268667	chr1:85793746	A/G	cg16011679	chr1:85725395	C1orf52	-0.53	-6.14	-0.35	3.05e-9	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	cis	rs8103278	0.507	rs8112282	chr19:46265029	C/T	cg14061069	chr19:46274453	DMPK	0.52	8.23	0.45	8.39e-15	Coronary artery disease;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg12112058	chr1:224622605	WDR26	0.47	6.1	0.35	3.75e-9	Gut microbiota (bacterial taxa);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18632102	chr5:154238496	CNOT8	-0.65	-7.19	-0.4	6.44e-12	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03812994	chr10:81205453	ZCCHC24	-0.64	-7.14	-0.4	8.98e-12	Gut microbiome composition (summer);
CESC	cis	rs4654899	0.714	rs12133972	chr1:21091338	A/T	cg05370193	chr1:21551575	ECE1	0.34	5.05	0.3	8.26e-7	Superior frontal gyrus grey matter volume;
CESC	cis	rs853679	0.542	rs2295594	chr6:28053097	G/A	cg22143856	chr6:28129313	ZNF389	0.49	6.3	0.36	1.2e-9	Depression;
CESC	cis	rs4819052	1.000	rs28628220	chr21:46663741	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.82	10.45	0.54	1.22e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs1008375	0.932	rs964012	chr4:17619184	A/G	cg02297831	chr4:17616191	MED28	0.62	7.77	0.43	1.73e-13	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	trans	rs3780486	0.834	rs75443249	chr9:33149207	A/G	cg20290983	chr6:43655470	MRPS18A	0.85	12.21	0.6	1.64e-27	IgG glycosylation;
CESC	cis	rs6540559	1.000	rs2073485	chr1:209962794	G/A	cg22029157	chr1:209979665	IRF6	0.71	10.16	0.53	1.11e-20	Cleft lip with or without cleft palate;
CESC	trans	rs11098499	0.863	rs13149407	chr4:120437825	A/G	cg25214090	chr10:38739885	LOC399744	0.7	9.5	0.5	1.34e-18	Corneal astigmatism;
CESC	cis	rs9815354	0.812	rs766286	chr3:41838329	G/A	cg03022575	chr3:42003672	ULK4	0.7	6.04	0.35	5.26e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs10504229	0.679	rs17800895	chr8:58050085	A/G	cg22535103	chr8:58192502	C8orf71	-0.94	-9.38	-0.5	2.99e-18	Developmental language disorder (linguistic errors);
CESC	cis	rs1957429	0.808	rs4902325	chr14:65330843	A/G	cg23373153	chr14:65346875	NA	-0.87	-9.05	-0.49	3.09e-17	Pediatric areal bone mineral density (radius);
CESC	trans	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg13565492	chr6:43139072	SRF	-0.61	-6.54	-0.37	3.24e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg03650474	chr10:98592837	LCOR	-0.49	-6.02	-0.35	5.79e-9	Ulcerative colitis;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg11886286	chr6:27114864	HIST1H2BK;HIST1H2AH	0.46	6.14	0.35	3.07e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs1538970	1.000	rs2492840	chr1:45849792	C/A	cg06784218	chr1:46089804	CCDC17	0.3	5.13	0.3	5.71e-7	Platelet count;
CESC	trans	rs7615952	0.641	rs7618515	chr3:125790578	C/T	cg07211511	chr3:129823064	LOC729375	-0.57	-6.39	-0.37	7.57e-10	Blood pressure (smoking interaction);
CESC	cis	rs1799949	1.000	rs12942277	chr17:41187974	G/C	cg05368731	chr17:41323189	NBR1	0.77	10.06	0.53	2.31e-20	Menopause (age at onset);
CESC	cis	rs2594989	0.943	rs2454499	chr3:11500531	T/C	cg00170343	chr3:11313890	ATG7	0.56	5.1	0.3	6.55e-7	Circulating chemerin levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02343720	chr2:241516354	RNPEPL1	-0.54	-6.51	-0.37	3.77e-10	Gut microbiome composition (summer);
CESC	cis	rs870825	0.616	rs7683537	chr4:185631998	T/C	cg04058563	chr4:185651563	MLF1IP	0.63	6.89	0.39	3.95e-11	Blood protein levels;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg05890826	chr6:12008908	NA	-0.54	-6.35	-0.36	9.29e-10	Ulcerative colitis;
CESC	cis	rs754466	0.605	rs10824578	chr10:79578244	G/C	cg17075019	chr10:79541650	NA	-0.87	-14.42	-0.66	3.39e-35	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs7264396	0.563	rs1970577	chr20:34336737	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.63	6.72	0.38	1.08e-10	Total cholesterol levels;
CESC	cis	rs116095464	1.000	rs2015774	chr5:312958	G/T	cg22857025	chr5:266934	NA	-1.18	-10.37	-0.54	2.29e-21	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05970768	chr5:171682616	UBTD2	-0.67	-8.24	-0.45	8.05e-15	Gut microbiome composition (summer);
CESC	cis	rs59918340	0.728	rs35257077	chr8:142235049	C/T	cg23750338	chr8:142222470	SLC45A4	-0.6	-9.16	-0.49	1.48e-17	Immature fraction of reticulocytes;
CESC	cis	rs425277	0.538	rs169037	chr1:2095582	G/T	cg04315214	chr1:2043799	PRKCZ	-0.44	-7.26	-0.41	4.29e-12	Height;
CESC	cis	rs67311347	1.000	rs7628247	chr3:40512682	G/T	cg01475735	chr3:40494733	NA	0.41	5.17	0.3	4.71e-7	Renal cell carcinoma;
CESC	cis	rs4803455	0.565	rs11670143	chr19:41864971	A/G	cg08477640	chr19:41863820	B9D2	0.49	6.78	0.38	7.72e-11	Migraine;Coronary artery disease;
CESC	cis	rs11871801	0.918	rs4633765	chr17:40682341	T/A	cg21433558	chr17:40837037	CNTNAP1	-0.46	-5.3	-0.31	2.43e-7	Crohn's disease;
CESC	cis	rs12545109	0.836	rs2196586	chr8:57347126	C/T	cg09654669	chr8:57350985	NA	0.56	7.03	0.4	1.74e-11	Obesity-related traits;
CESC	cis	rs4253772	0.550	rs6008729	chr22:46727428	C/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	-0.59	-6.64	-0.38	1.81e-10	LDL cholesterol;Cholesterol, total;
CESC	cis	rs1707322	1.000	rs7519181	chr1:46387829	G/C	cg05343316	chr1:45956843	TESK2	0.44	5.42	0.32	1.36e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs17253792	0.545	rs3742570	chr14:56016434	A/C	cg01858014	chr14:56050164	KTN1	-0.87	-6.37	-0.36	8.34e-10	Putamen volume;
CESC	cis	rs875971	0.964	rs12668936	chr7:65914404	C/T	cg10691866	chr7:65817282	TPST1	-0.34	-5.62	-0.33	4.93e-8	Aortic root size;
CESC	trans	rs2235573	0.527	rs139865	chr22:38353932	C/G	cg19894588	chr14:64061835	NA	0.59	7.85	0.43	1.04e-13	Glioblastoma;Glioma;
CESC	cis	rs10949834	0.618	rs810551	chr7:73492093	C/G	cg07137043	chr7:73588983	EIF4H	-0.62	-7.33	-0.41	2.74e-12	Verbal memory performance (residualized delayed recall change);
CESC	cis	rs2439831	0.850	rs56909447	chr15:44137618	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.67	7.46	0.42	1.21e-12	Lung cancer in ever smokers;
CESC	trans	rs3942852	0.806	rs10734562	chr11:48128189	A/T	cg03929089	chr4:120376271	NA	0.54	6.02	0.35	5.72e-9	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs1348850	0.793	rs6734528	chr2:178493731	G/A	cg22681709	chr2:178499509	PDE11A	-0.43	-6.41	-0.37	6.61e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14329673	chr8:95732141	DPY19L4	0.6	6.73	0.38	1.03e-10	Gut microbiome composition (summer);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg14634336	chr6:111804804	REV3L	-0.43	-6.01	-0.35	6.15e-9	Gambling;
CESC	cis	rs7799006	0.755	rs2256545	chr7:2291943	G/A	cg12823233	chr7:2316876	SNX8	-0.31	-5.17	-0.3	4.73e-7	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs72781680	1.000	rs72796327	chr2:24140372	T/C	cg20701182	chr2:24300061	SF3B14	0.7	6.16	0.35	2.65e-9	Lymphocyte counts;
CESC	cis	rs4253772	0.513	rs6008612	chr22:46707907	G/A	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.78	9.13	0.49	1.85e-17	LDL cholesterol;Cholesterol, total;
CESC	cis	rs6088580	0.634	rs6088471	chr20:32932643	C/A	cg08999081	chr20:33150536	PIGU	-0.65	-11.2	-0.57	4.14e-24	Glomerular filtration rate (creatinine);
CESC	cis	rs7412746	0.658	rs12410394	chr1:150860186	G/A	cg22823121	chr1:150693482	HORMAD1	0.42	5.86	0.34	1.35e-8	Melanoma;
CESC	cis	rs1005277	0.579	rs1740737	chr10:38499365	G/T	cg25427524	chr10:38739819	LOC399744	-0.71	-10.41	-0.54	1.67e-21	Extrinsic epigenetic age acceleration;
CESC	cis	rs4835473	0.830	rs7692672	chr4:144892201	C/T	cg25736465	chr4:144833511	NA	0.39	6.0	0.35	6.45e-9	Immature fraction of reticulocytes;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg27510503	chr22:22012035	NA	0.45	6.51	0.37	3.65e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs4665809	1.000	rs17040322	chr2:26351274	G/C	cg04944784	chr2:26401820	FAM59B	-0.66	-7.62	-0.42	4.62e-13	Gut microbiome composition (summer);
CESC	cis	rs7589728	0.563	rs12479338	chr2:88444513	C/T	cg04511125	chr2:88470314	THNSL2	0.68	6.68	0.38	1.44e-10	Plasma clusterin levels;
CESC	cis	rs10208940	0.841	rs10172125	chr2:68787191	T/G	cg12452813	chr2:68675892	NA	0.52	5.25	0.31	3.12e-7	Urate levels in lean individuals;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg01143375	chr3:191670642	NA	-0.45	-6.04	-0.35	5.24e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs875971	0.545	rs801212	chr7:66015630	C/G	cg25405998	chr7:65216604	CCT6P1	-0.46	-5.22	-0.31	3.71e-7	Aortic root size;
CESC	cis	rs896854	0.875	rs4735333	chr8:95955074	G/A	cg16049864	chr8:95962084	TP53INP1	-0.67	-12.02	-0.59	7.73e-27	Type 2 diabetes;
CESC	cis	rs826838	0.933	rs1906263	chr12:38653362	T/C	cg13010199	chr12:38710504	ALG10B	0.59	8.31	0.45	4.93e-15	Heart rate;
CESC	cis	rs9300255	0.596	rs10773002	chr12:123746961	A/T	cg19016782	chr12:123741754	C12orf65	0.38	5.76	0.33	2.27e-8	Neutrophil percentage of white cells;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16326998	chr7:5553266	FBXL18	0.6	6.53	0.37	3.29e-10	Gut microbiome composition (summer);
CESC	cis	rs11148252	0.500	rs342768	chr13:53208882	C/T	cg00495681	chr13:53174319	NA	0.53	7.38	0.41	2.02e-12	Lewy body disease;
CESC	cis	rs4332037	0.538	rs4721164	chr7:1932629	C/G	cg23422044	chr7:1970798	MAD1L1	-0.45	-5.89	-0.34	1.14e-8	Bipolar disorder;
CESC	cis	rs67460515	0.563	rs13085336	chr3:160880599	G/A	cg03342759	chr3:160939853	NMD3	-0.48	-6.27	-0.36	1.49e-9	Parkinson's disease;
CESC	cis	rs3820068	0.603	rs998032	chr1:15989918	T/C	cg17385448	chr1:15911702	AGMAT	0.44	7.29	0.41	3.48e-12	Systolic blood pressure;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14417711	chr11:6478126	TRIM3	-0.55	-6.0	-0.35	6.51e-9	Gut microbiome composition (summer);
CESC	cis	rs1499614	1.000	rs1882655	chr7:66147057	T/C	cg13147721	chr7:65941812	NA	0.96	9.03	0.49	3.53e-17	Gout;
CESC	cis	rs11864453	0.826	rs2074627	chr16:72136769	C/T	cg16558253	chr16:72132732	DHX38	-0.6	-9.43	-0.5	2.21e-18	Fibrinogen levels;
CESC	cis	rs8062405	0.722	rs3785354	chr16:28550667	C/T	cg07382826	chr16:28625726	SULT1A1	0.39	6.49	0.37	4.32e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs17401966	0.898	rs12117635	chr1:10317445	C/T	cg15208524	chr1:10270712	KIF1B	0.41	5.31	0.31	2.36e-7	Hepatocellular carcinoma;
CESC	cis	rs7116495	0.737	rs6592456	chr11:71737663	G/A	cg07596299	chr11:71824057	C11orf51	-0.84	-5.06	-0.3	8e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs17376456	0.877	rs10476596	chr5:93367074	C/T	cg25358565	chr5:93447407	FAM172A	-1.13	-10.45	-0.54	1.29e-21	Diabetic retinopathy;
CESC	cis	rs12477438	0.520	rs11678456	chr2:99708237	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.88	15.55	0.69	3.41e-39	Chronic sinus infection;
CESC	cis	rs9905704	0.647	rs12944274	chr17:57041293	C/G	cg12560992	chr17:57184187	TRIM37	-0.59	-7.45	-0.42	1.32e-12	Testicular germ cell tumor;
CESC	cis	rs36051895	0.632	rs62541944	chr9:5159318	G/T	cg02405213	chr9:5042618	JAK2	-0.52	-6.24	-0.36	1.71e-9	Pediatric autoimmune diseases;
CESC	cis	rs7259376	0.902	rs10408428	chr19:22578023	G/T	cg02657401	chr19:22469223	NA	0.26	5.14	0.3	5.27e-7	Menopause (age at onset);
CESC	cis	rs1018836	0.669	rs6471243	chr8:91656967	C/T	cg16814680	chr8:91681699	NA	0.94	17.21	0.73	4.63e-45	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs3733585	0.673	rs7378340	chr4:9955198	C/T	cg00071950	chr4:10020882	SLC2A9	-0.7	-11.52	-0.58	3.62e-25	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs9487051	0.768	rs461487	chr6:109525504	A/G	cg01475377	chr6:109611718	NA	-0.46	-6.94	-0.39	2.94e-11	Reticulocyte fraction of red cells;
CESC	cis	rs7084402	0.967	rs1649023	chr10:60285820	C/T	cg07615347	chr10:60278583	BICC1	0.59	9.54	0.51	9.81e-19	Refractive error;
CESC	trans	rs2727020	0.729	rs10839268	chr11:49380328	G/A	cg03929089	chr4:120376271	NA	-0.79	-11.94	-0.59	1.39e-26	Coronary artery disease;
CESC	cis	rs1552244	0.882	rs3755782	chr3:10029305	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.87	11.29	0.57	2.21e-24	Alzheimer's disease;
CESC	cis	rs4141404	0.816	rs5749227	chr22:31581166	A/G	cg13145458	chr22:31556086	RNF185	0.55	5.84	0.34	1.49e-8	Paclitaxel-induced neuropathy;
CESC	cis	rs2242116	0.796	rs4683296	chr3:46973820	G/C	cg27129171	chr3:47204927	SETD2	-0.55	-7.04	-0.4	1.64e-11	Birth weight;
CESC	cis	rs2637266	0.967	rs12246430	chr10:78352879	C/T	cg18941641	chr10:78392320	NA	0.43	7.97	0.44	4.67e-14	Pulmonary function;
CESC	cis	rs61931739	0.500	rs11053278	chr12:34555955	T/C	cg06521331	chr12:34319734	NA	-0.36	-5.03	-0.3	9.01e-7	Morning vs. evening chronotype;
CESC	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg26338869	chr17:61819248	STRADA	0.68	8.87	0.48	1.08e-16	Prudent dietary pattern;
CESC	cis	rs10178094	0.669	rs7595982	chr2:161332385	T/G	cg03641300	chr2:160917029	PLA2R1	-0.48	-6.32	-0.36	1.09e-9	White blood cell count;
CESC	cis	rs736408	0.609	rs13061423	chr3:52790213	T/C	cg05564831	chr3:52568323	NT5DC2	0.43	6.39	0.37	7.44e-10	Bipolar disorder;
CESC	cis	rs853679	0.517	rs7755442	chr6:28039015	T/C	cg17949981	chr6:28129498	ZNF389	0.45	5.62	0.33	4.9e-8	Depression;
CESC	cis	rs6662572	0.906	rs11590549	chr1:46086329	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.43	5.19	0.3	4.1e-7	Blood protein levels;
CESC	cis	rs7605827	0.897	rs11885852	chr2:15515371	A/C	cg19274914	chr2:15703543	NA	0.31	5.39	0.31	1.55e-7	Educational attainment (years of education);
CESC	cis	rs10411936	0.720	rs7252649	chr19:16582785	G/T	cg10248733	chr19:16607483	C19orf44;CALR3	0.53	6.64	0.38	1.82e-10	White blood cell count;Multiple sclerosis;
CESC	cis	rs4975709	0.610	rs4975706	chr5:1860365	G/T	cg14773178	chr5:1868261	NA	0.32	5.78	0.33	2.06e-8	Cardiovascular disease risk factors;
CESC	cis	rs13102973	0.965	rs7656209	chr4:135875550	G/A	cg14419869	chr4:135874104	NA	0.36	5.67	0.33	3.64e-8	Subjective well-being;
CESC	cis	rs1552244	1.000	rs6442150	chr3:10122575	T/C	cg16606324	chr3:10149918	C3orf24	0.42	5.16	0.3	4.9e-7	Alzheimer's disease;
CESC	cis	rs3785574	0.962	rs114027117	chr17:61939935	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.58	7.5	0.42	9.37e-13	Height;
CESC	cis	rs7666738	0.830	rs13102652	chr4:99006737	T/G	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.62e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4595586	0.545	rs7967931	chr12:39375162	A/C	cg26384229	chr12:38710491	ALG10B	0.54	7.53	0.42	7.85e-13	Morning vs. evening chronotype;
CESC	cis	rs863345	0.604	rs11264985	chr1:158465166	C/T	cg12129480	chr1:158549410	OR10X1	-0.35	-6.97	-0.39	2.46e-11	Pneumococcal bacteremia;
CESC	trans	rs7618501	0.602	rs2240326	chr3:50128386	G/A	cg21659725	chr3:3221576	CRBN	-0.53	-7.36	-0.41	2.33e-12	Intelligence (multi-trait analysis);
CESC	cis	rs2718058	0.519	rs2598047	chr7:37888488	G/T	cg15028436	chr7:37888078	TXNDC3	0.5	7.26	0.41	4.24e-12	Alzheimer's disease (late onset);
CESC	cis	rs9911578	1.000	rs1631237	chr17:56734695	A/G	cg05425664	chr17:57184151	TRIM37	-0.51	-7.21	-0.4	6.03e-12	Intelligence (multi-trait analysis);
CESC	trans	rs208520	0.526	rs7775830	chr6:66755249	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.99	19.21	0.76	4.13e-52	Exhaled nitric oxide output;
CESC	cis	rs10492096	0.947	rs10849483	chr12:6635374	G/A	cg13857086	chr12:6580257	VAMP1	0.56	5.44	0.32	1.23e-7	Hip geometry;
CESC	cis	rs7586879	1.000	rs10207698	chr2:25117672	C/T	cg01884057	chr2:25150051	NA	0.28	5.1	0.3	6.54e-7	Body mass index;
CESC	cis	rs73019876	0.720	rs1989118	chr19:22205679	A/G	cg11619707	chr19:22235551	ZNF257	-0.27	-5.21	-0.3	3.75e-7	Testicular germ cell tumor;
CESC	cis	rs9611565	0.546	rs34077262	chr22:42061639	A/G	cg17376030	chr22:41985996	PMM1	-0.67	-7.63	-0.42	4.29e-13	Vitiligo;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg04197904	chr22:46318272	WNT7B	-0.4	-6.08	-0.35	4.15e-9	Ulcerative colitis;
CESC	cis	rs7953249	0.656	rs6489786	chr12:121397875	A/G	cg25281562	chr12:121454272	C12orf43	-0.46	-5.7	-0.33	3.12e-8	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
CESC	cis	rs34779708	0.966	rs12782948	chr10:35450607	G/A	cg03585969	chr10:35415529	CREM	0.78	10.59	0.55	4.34e-22	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs5769765	0.819	rs9616377	chr22:50310880	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.57	-5.99	-0.35	6.82e-9	Schizophrenia;
CESC	trans	rs208515	0.525	rs4145045	chr6:66678949	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.88	10.9	0.56	4.24e-23	Exhaled nitric oxide levels;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg01496715	chr11:252450	PSMD13	0.47	6.48	0.37	4.41e-10	Fibrinogen levels;
CESC	cis	rs9660992	0.649	rs12128229	chr1:205268014	C/A	cg21643547	chr1:205240462	TMCC2	-0.47	-6.19	-0.36	2.23e-9	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs17711722	0.727	rs1880555	chr7:65432567	T/C	cg18876405	chr7:65276391	NA	0.69	9.57	0.51	8.21e-19	Calcium levels;
CESC	cis	rs7412746	0.611	rs10788794	chr1:150728676	T/C	cg22823121	chr1:150693482	HORMAD1	0.46	6.33	0.36	1.07e-9	Melanoma;
CESC	trans	rs4824093	0.610	rs3761496	chr22:50246466	T/C	cg09872104	chr7:134855509	C7orf49	-0.95	-6.67	-0.38	1.52e-10	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs9911578	0.967	rs3826353	chr17:57075299	C/T	cg05425664	chr17:57184151	TRIM37	-0.52	-7.26	-0.41	4.28e-12	Intelligence (multi-trait analysis);
CESC	cis	rs12410462	0.581	rs75219436	chr1:227546617	C/T	cg04117972	chr1:227635322	NA	0.62	5.31	0.31	2.27e-7	Major depressive disorder;
CESC	cis	rs1552244	1.000	rs58275763	chr3:10143274	C/T	cg00166722	chr3:10149974	C3orf24	0.47	5.97	0.34	7.77e-9	Alzheimer's disease;
CESC	cis	rs7107174	1.000	rs2373009	chr11:77945815	T/A	cg02023728	chr11:77925099	USP35	0.55	6.86	0.39	4.93e-11	Testicular germ cell tumor;
CESC	cis	rs10479542	0.642	rs6879665	chr5:178974581	T/A	cg14820908	chr5:178986412	RUFY1	0.44	6.16	0.35	2.69e-9	Lung cancer;
CESC	cis	rs10504229	0.953	rs72650891	chr8:58179697	T/G	cg05313129	chr8:58192883	C8orf71	-0.55	-6.37	-0.36	8.42e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs5769765	1.000	rs5769760	chr22:50259696	A/G	cg02269571	chr22:50332266	NA	0.46	6.25	0.36	1.62e-9	Schizophrenia;
CESC	cis	rs2303759	0.918	rs7251704	chr19:49890873	T/G	cg22590775	chr19:49891494	CCDC155	0.62	7.31	0.41	3.16e-12	Multiple sclerosis;
CESC	cis	rs67311347	1.000	rs9332450	chr3:40458041	C/T	cg09455208	chr3:40491958	NA	-0.44	-7.45	-0.42	1.36e-12	Renal cell carcinoma;
CESC	cis	rs1862618	0.715	rs6866779	chr5:56090000	G/A	cg24549020	chr5:56110836	MAP3K1	0.68	7.56	0.42	6.74e-13	Initial pursuit acceleration;
CESC	cis	rs7552404	0.727	rs1146653	chr1:76280438	A/G	cg10523679	chr1:76189770	ACADM	0.66	7.01	0.4	1.92e-11	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs10504229	0.654	rs903705	chr8:58128185	T/A	cg24829409	chr8:58192753	C8orf71	-0.58	-7.2	-0.4	6.31e-12	Developmental language disorder (linguistic errors);
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg07960162	chr16:68577389	ZFP90	0.42	6.17	0.35	2.61e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	trans	rs7922314	0.571	rs61865723	chr10:64757951	T/A	cg06935979	chr1:232941706	KIAA1383	-0.64	-6.14	-0.35	2.95e-9	Cutaneous psoriasis;
CESC	cis	rs637571	0.512	rs660118	chr11:65735174	G/C	cg02427764	chr11:65769310	BANF1;EIF1AD	0.7	9.7	0.51	3.1400000000000002e-19	Eosinophil percentage of white cells;
CESC	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg06873352	chr17:61820015	STRADA	0.73	12.89	0.62	7.87e-30	Prudent dietary pattern;
CESC	cis	rs1003719	0.680	rs7276569	chr21:38578207	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.61	-8.29	-0.45	5.58e-15	Eye color traits;
CESC	cis	rs9287719	0.934	rs6432115	chr2:10748343	G/T	cg02196655	chr2:10830764	NOL10	-0.38	-5.79	-0.34	1.96e-8	Prostate cancer;
CESC	cis	rs17125944	0.505	rs3783447	chr14:53191647	G/A	cg00686598	chr14:53173677	PSMC6	1.33	11.24	0.57	3.2e-24	Alzheimer's disease (late onset);
CESC	trans	rs1814175	0.616	rs10839388	chr11:49842603	C/T	cg03929089	chr4:120376271	NA	-0.87	-13.78	-0.65	6.24e-33	Height;
CESC	cis	rs55794721	0.509	rs12027110	chr1:25775682	A/T	cg27572855	chr1:25598939	RHD	0.49	8.32	0.46	4.54e-15	Plateletcrit;Mean corpuscular volume;
CESC	cis	rs12541335	0.639	rs11135995	chr8:22200148	C/T	cg27266060	chr8:22091797	NA	-0.38	-7.76	-0.43	1.87e-13	Hypertriglyceridemia;
CESC	cis	rs4713118	0.662	rs9468276	chr6:28027688	A/C	cg18032046	chr6:28092343	ZSCAN16	-0.54	-6.2	-0.36	2.21e-9	Parkinson's disease;
CESC	cis	rs8014204	0.967	rs1319171	chr14:75334096	G/T	cg11812906	chr14:75593930	NEK9	-0.41	-5.1	-0.3	6.63e-7	Caffeine consumption;
CESC	cis	rs2635047	0.682	rs4534948	chr18:44793419	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.39	5.09	0.3	6.89e-7	Educational attainment;
CESC	cis	rs13191362	1.000	rs7764785	chr6:163009967	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.82	8.22	0.45	9.12e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs10089	0.953	rs10463839	chr5:127519675	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.76	9.49	0.5	1.37e-18	Ileal carcinoids;
CESC	cis	rs9512730	0.527	rs11619784	chr13:27999643	A/G	cg08193333	chr13:27998609	GTF3A	0.55	6.39	0.37	7.3e-10	Schizophrenia;
CESC	cis	rs6540559	1.000	rs2073485	chr1:209962794	G/A	cg22442454	chr1:209979470	IRF6	0.47	5.65	0.33	4.13e-8	Cleft lip with or without cleft palate;
CESC	trans	rs629535	0.814	rs674429	chr8:70069942	G/A	cg21567404	chr3:27674614	NA	0.88	10.34	0.54	2.74e-21	Dupuytren's disease;
CESC	cis	rs7542091	0.813	rs2049999	chr1:210031331	A/G	cg22029157	chr1:209979665	IRF6	0.49	7.64	0.43	3.88e-13	Monobrow;
CESC	cis	rs116988415	0.584	rs4902310	chr14:65241906	T/C	cg25083366	chr14:65239357	SPTB	0.69	5.03	0.3	8.89e-7	Daytime sleep phenotypes;
CESC	cis	rs7666738	0.830	rs28522896	chr4:99008243	C/T	cg05340658	chr4:99064831	C4orf37	0.8	12.44	0.61	2.83e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3820928	1.000	rs4675115	chr2:227769123	C/G	cg11843606	chr2:227700838	RHBDD1	-0.4	-5.2	-0.3	3.93e-7	Pulmonary function;
CESC	cis	rs1862618	0.853	rs9283717	chr5:56078659	G/A	cg22800045	chr5:56110881	MAP3K1	0.82	10.05	0.53	2.45e-20	Initial pursuit acceleration;
CESC	cis	rs7208859	0.673	rs60020217	chr17:29185054	G/A	cg19761014	chr17:28927070	LRRC37B2	0.72	5.71	0.33	3.06e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs6933660	0.745	rs9371517	chr6:151739810	G/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.86	14.48	0.66	2.19e-35	Menarche (age at onset);
CESC	cis	rs2991971	1.000	rs9147	chr1:46016687	T/C	cg24296786	chr1:45957014	TESK2	0.63	8.21	0.45	9.97e-15	High light scatter reticulocyte count;
CESC	cis	rs6570726	0.791	rs9403734	chr6:145931459	C/G	cg05347473	chr6:146136440	FBXO30	0.58	7.43	0.42	1.48e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs3106136	0.967	rs13132963	chr4:95219780	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.46	-6.87	-0.39	4.53e-11	Capecitabine sensitivity;
CESC	cis	rs2282802	0.685	rs12717951	chr5:139589309	A/G	cg26211634	chr5:139558579	C5orf32	0.49	7.23	0.41	5.22e-12	Intelligence (multi-trait analysis);
CESC	cis	rs9910055	0.762	rs2631299	chr17:42219773	G/T	cg10896456	chr17:42255109	ASB16;C17orf65	0.44	6.52	0.37	3.58e-10	Total body bone mineral density;
CESC	cis	rs709400	0.770	rs7142883	chr14:104066645	G/A	cg12935359	chr14:103987150	CKB	-0.47	-5.96	-0.34	8.22e-9	Body mass index;
CESC	cis	rs7927771	0.896	rs12794570	chr11:47658314	C/T	cg05585544	chr11:47624801	NA	-0.53	-8.35	-0.46	3.82e-15	Subjective well-being;
CESC	cis	rs4523957	0.583	rs7503141	chr17:2044645	T/C	cg16513277	chr17:2031491	SMG6	-0.79	-11.73	-0.58	6.95e-26	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs7149337	0.809	rs10134478	chr14:51693708	G/C	cg23942311	chr14:51606299	NA	0.46	7.57	0.42	6.3e-13	Cancer;
CESC	cis	rs2629540	0.889	rs10901815	chr10:126435598	G/A	cg08799069	chr10:126477246	METTL10	-0.66	-9.2	-0.49	1.13e-17	Cocaine dependence;
CESC	cis	rs7666738	0.830	rs34273190	chr4:99004568	C/T	cg05340658	chr4:99064831	C4orf37	0.8	12.44	0.61	2.83e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7914558	0.966	rs10883817	chr10:104755431	C/T	cg08650961	chr10:104748594	CNNM2	0.34	5.7	0.33	3.21e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.55	-6.17	-0.35	2.48e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs875971	0.540	rs4717275	chr7:65265180	C/T	cg11764359	chr7:65958608	NA	-0.67	-8.64	-0.47	5.38e-16	Aortic root size;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg24179850	chr19:56154938	ZNF581	-0.46	-6.23	-0.36	1.85e-9	Ulcerative colitis;
CESC	cis	rs2075371	0.932	rs2598290	chr7:133987736	C/G	cg20476274	chr7:133979776	SLC35B4	0.67	9.79	0.52	1.65e-19	Mean platelet volume;
CESC	cis	rs9322193	0.886	rs10872652	chr6:150096439	C/T	cg07701084	chr6:150067640	NUP43	0.43	5.8	0.34	1.91e-8	Lung cancer;
CESC	cis	rs798554	0.759	rs2644291	chr7:2890456	T/C	cg19717773	chr7:2847554	GNA12	-0.47	-6.67	-0.38	1.51e-10	Height;
CESC	cis	rs7246657	0.943	rs10414904	chr19:37830088	G/A	cg23950597	chr19:37808831	NA	-0.55	-6.09	-0.35	3.96e-9	Coronary artery calcification;
CESC	cis	rs9768139	1.000	rs9768139	chr7:158120731	G/A	cg06219351	chr7:158114137	PTPRN2	0.48	7.48	0.42	1.09e-12	Calcium levels;
CESC	cis	rs2204008	0.774	rs7959048	chr12:37948276	T/A	cg26384229	chr12:38710491	ALG10B	0.71	10.61	0.55	3.71e-22	Bladder cancer;
CESC	cis	rs5753618	0.555	rs9609304	chr22:31897795	T/C	cg00478049	chr22:31556069	RNF185	-0.44	-5.17	-0.3	4.68e-7	Colorectal cancer;
CESC	cis	rs9487051	0.652	rs13210424	chr6:109598737	G/A	cg12927641	chr6:109611667	NA	-0.37	-5.52	-0.32	7.95e-8	Reticulocyte fraction of red cells;
CESC	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg23034840	chr1:205782522	SLC41A1	0.6	6.83	0.39	5.92e-11	Menarche (age at onset);
CESC	cis	rs950169	0.614	rs12903883	chr15:84680553	A/G	cg17507749	chr15:85114479	UBE2QP1	0.61	6.14	0.35	3.05e-9	Schizophrenia;
CESC	cis	rs9322193	0.962	rs2151912	chr6:150152908	A/G	cg07701084	chr6:150067640	NUP43	0.43	5.71	0.33	2.97e-8	Lung cancer;
CESC	cis	rs1008375	0.966	rs4235389	chr4:17696280	A/G	cg15017067	chr4:17643749	FAM184B	0.35	5.15	0.3	5.11e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	trans	rs7618501	0.602	rs6780731	chr3:50017478	A/G	cg21659725	chr3:3221576	CRBN	0.54	7.51	0.42	9.17e-13	Intelligence (multi-trait analysis);
CESC	cis	rs2075371	0.863	rs1421479	chr7:133949345	T/G	cg20476274	chr7:133979776	SLC35B4	0.62	8.89	0.48	9.92e-17	Mean platelet volume;
CESC	cis	rs4835473	0.897	rs924234	chr4:144627952	C/A	cg25736465	chr4:144833511	NA	0.39	5.94	0.34	8.8e-9	Immature fraction of reticulocytes;
CESC	cis	rs7914558	1.000	rs4917996	chr10:104925829	A/C	cg15744005	chr10:104629667	AS3MT	-0.31	-5.04	-0.3	8.62e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	trans	rs916888	0.773	rs199443	chr17:44819565	C/T	cg10053473	chr17:62856997	LRRC37A3	-0.72	-7.88	-0.44	8.47e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs1564271	0.528	rs2209350	chr10:26987779	A/G	cg13837822	chr10:26931731	LOC731789	0.43	6.75	0.38	9.17e-11	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;
CESC	cis	rs9815354	0.812	rs73071208	chr3:41978738	A/T	cg03022575	chr3:42003672	ULK4	0.67	5.95	0.34	8.63e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs2070488	0.775	rs2051213	chr3:38560254	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.8	12.93	0.62	5.64e-30	Electrocardiographic conduction measures;
CESC	cis	rs3749237	0.576	rs4241406	chr3:49600426	C/T	cg02487422	chr3:49467188	NICN1	0.58	8.48	0.46	1.56e-15	Resting heart rate;
CESC	cis	rs10924309	0.889	rs10802248	chr1:245858554	A/C	cg00036263	chr1:245852353	KIF26B	-0.4	-5.05	-0.3	8.1e-7	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
CESC	cis	rs9916302	0.904	rs11078910	chr17:37671269	G/T	cg00129232	chr17:37814104	STARD3	-0.54	-7.09	-0.4	1.19e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs4728302	0.838	rs10225454	chr7:133591535	G/C	cg10665199	chr7:133106180	EXOC4	0.39	5.39	0.31	1.55e-7	Intelligence;Intelligence (multi-trait analysis);
CESC	cis	rs10256972	0.521	rs871019	chr7:1105230	A/G	cg04025307	chr7:1156635	C7orf50	0.41	6.51	0.37	3.77e-10	Longevity;Endometriosis;
CESC	cis	rs7914558	0.966	rs7096269	chr10:104736721	A/G	cg08650961	chr10:104748594	CNNM2	0.32	5.11	0.3	6.16e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs3740540	0.507	rs10794161	chr10:126291327	C/A	cg04949429	chr10:126290192	LHPP	0.4	5.61	0.33	5.04e-8	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
CESC	cis	rs2832191	1.000	rs9984793	chr21:30486471	T/C	cg24692254	chr21:30365293	RNF160	-0.73	-10.87	-0.56	5.11e-23	Dental caries;
CESC	cis	rs3857067	1.000	rs899134	chr4:95019675	C/G	cg11021082	chr4:95130006	SMARCAD1	-0.52	-8.04	-0.44	3.04e-14	QT interval;
CESC	cis	rs864745	0.600	rs849335	chr7:28223990	T/C	cg23620719	chr7:28220237	JAZF1	-0.44	-5.2	-0.3	3.91e-7	Crohn's disease;Type 2 diabetes;
CESC	cis	rs875971	0.862	rs28491091	chr7:65669064	G/T	cg12463550	chr7:65579703	CRCP	-0.51	-6.48	-0.37	4.51e-10	Aortic root size;
CESC	cis	rs3105593	1.000	rs2011064	chr15:50957625	C/G	cg08437265	chr15:50716283	USP8	0.43	5.64	0.33	4.35e-8	QT interval;
CESC	cis	rs9322193	0.923	rs9688938	chr6:150110077	G/A	cg05861140	chr6:150128134	PCMT1	-0.36	-5.14	-0.3	5.22e-7	Lung cancer;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg17823829	chr1:202765754	KDM5B	0.46	6.88	0.39	4.33e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs10492096	1.000	rs11064210	chr12:6576721	C/T	cg13857086	chr12:6580257	VAMP1	0.64	6.69	0.38	1.33e-10	Hip geometry;
CESC	trans	rs1728785	0.901	rs821169	chr16:68630184	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	7.69	0.43	2.91e-13	Ulcerative colitis;
CESC	cis	rs6499255	0.951	rs1437136	chr16:69672675	G/C	cg15192750	chr16:69999425	NA	0.5	5.77	0.33	2.19e-8	IgE levels;
CESC	cis	rs9309473	0.539	rs6745560	chr2:73827117	C/T	cg20560298	chr2:73613845	ALMS1	-0.48	-6.84	-0.39	5.52e-11	Metabolite levels;
CESC	trans	rs9987353	0.840	rs329994	chr8:9123233	A/G	cg20317272	chr18:60383672	PHLPP1	-0.45	-6.1	-0.35	3.64e-9	Recombination measurement;
CESC	cis	rs2075371	1.000	rs2058976	chr7:133981379	G/T	cg20476274	chr7:133979776	SLC35B4	0.66	9.8	0.52	1.5e-19	Mean platelet volume;
CESC	trans	rs11098499	0.954	rs11935596	chr4:120412457	G/C	cg25214090	chr10:38739885	LOC399744	0.72	10.08	0.53	1.97e-20	Corneal astigmatism;
CESC	cis	rs6693567	0.565	rs11205373	chr1:150404708	A/G	cg09579323	chr1:150459698	TARS2	0.46	5.97	0.34	7.46e-9	Migraine;
CESC	cis	rs9457247	0.967	rs1590257	chr6:167377782	G/T	cg25258033	chr6:167368657	RNASET2	-0.42	-6.25	-0.36	1.63e-9	Crohn's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26201011	chr10:101874558	NA	-0.55	-6.79	-0.38	7.31e-11	Gut microbiome composition (summer);
CESC	cis	rs72945132	0.882	rs7122057	chr11:70201430	T/C	cg00319359	chr11:70116639	PPFIA1	0.72	6.98	0.39	2.33e-11	Coronary artery disease;
CESC	cis	rs4835473	0.897	rs35515006	chr4:144655858	T/A	cg25736465	chr4:144833511	NA	-0.33	-5.22	-0.31	3.68e-7	Immature fraction of reticulocytes;
CESC	cis	rs6860806	0.661	rs2171247	chr5:131580234	G/T	cg18301423	chr5:131593218	PDLIM4	0.38	5.38	0.31	1.61e-7	Breast cancer;
CESC	cis	rs1355223	0.902	rs286861	chr11:34718424	A/T	cg11058730	chr11:34937778	PDHX;APIP	-0.51	-6.89	-0.39	4.1e-11	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs5758659	0.569	rs133293	chr22:42382797	G/A	cg15557168	chr22:42548783	NA	-0.44	-6.34	-0.36	9.58e-10	Cognitive function;
CESC	cis	rs72781680	0.821	rs72796369	chr2:24162663	G/T	cg08917208	chr2:24149416	ATAD2B	0.63	6.24	0.36	1.73e-9	Lymphocyte counts;
CESC	cis	rs694739	0.595	rs11542299	chr11:64138805	T/C	cg02228329	chr11:64053129	BAD;GPR137	0.61	7.51	0.42	9.02e-13	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CESC	cis	rs9905704	0.709	rs758378	chr17:56607746	G/C	cg12560992	chr17:57184187	TRIM37	-0.6	-6.28	-0.36	1.36e-9	Testicular germ cell tumor;
CESC	trans	rs875971	1.000	rs778699	chr7:65868290	G/A	cg26939375	chr7:64535504	NA	0.47	6.06	0.35	4.77e-9	Aortic root size;
CESC	cis	rs5769765	0.955	rs9616366	chr22:50301178	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.49	-5.53	-0.32	7.82e-8	Schizophrenia;
CESC	cis	rs1707322	1.000	rs11211232	chr1:46411146	C/T	cg06784218	chr1:46089804	CCDC17	0.35	5.96	0.34	8.17e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs10504229	0.775	rs56082079	chr8:58163732	T/C	cg22535103	chr8:58192502	C8orf71	-0.95	-10.54	-0.54	6.39e-22	Developmental language disorder (linguistic errors);
CESC	cis	rs7834588	0.526	rs9298070	chr8:63870658	A/C	cg20602954	chr8:63776762	NKAIN3	-0.33	-5.26	-0.31	2.98e-7	Response to Vitamin E supplementation;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12931157	chr6:41040265	C6orf130;NFYA	0.59	7.06	0.4	1.43e-11	Gut microbiome composition (summer);
CESC	cis	rs5769765	0.908	rs138864	chr22:50204712	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.48	-5.48	-0.32	9.95e-8	Schizophrenia;
CESC	cis	rs12142240	0.698	rs17357683	chr1:46815378	C/T	cg00530320	chr1:46809349	NSUN4	0.58	7.89	0.44	8.17e-14	Menopause (age at onset);
CESC	cis	rs6570726	0.935	rs392014	chr6:145843691	A/C	cg05347473	chr6:146136440	FBXO30	0.43	5.83	0.34	1.58e-8	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6674176	0.628	rs3828146	chr1:44428715	C/T	cg13606994	chr1:44402422	ARTN	-0.37	-5.58	-0.32	6.03e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	trans	rs561341	0.556	rs542244	chr17:30307242	T/C	cg20587970	chr11:113659929	NA	-1.41	-18.1	-0.74	3.08e-48	Hip circumference adjusted for BMI;
CESC	cis	rs4563143	0.647	rs117442062	chr19:29256823	A/T	cg04546413	chr19:29218101	NA	0.56	7.77	0.43	1.76e-13	Methadone dose in opioid dependence;
CESC	cis	rs78456975	0.506	rs13384333	chr2:1555531	A/C	cg26248373	chr2:1572462	NA	-0.58	-6.89	-0.39	3.97e-11	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs35955747	0.902	rs12167361	chr22:31696278	G/C	cg25791279	chr22:32026902	PISD	-0.49	-5.86	-0.34	1.38e-8	Neutrophil count;Sum basophil neutrophil counts;
CESC	cis	rs1799949	0.965	rs11658499	chr17:41334749	C/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.38	5.04	0.3	8.73e-7	Menopause (age at onset);
CESC	cis	rs4332037	0.950	rs10267593	chr7:1937261	G/A	cg23422044	chr7:1970798	MAD1L1	-0.57	-6.89	-0.39	3.99e-11	Bipolar disorder;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg20706599	chr15:90777202	CIB1;C15orf58	-0.46	-6.52	-0.37	3.52e-10	Fibrinogen levels;
CESC	cis	rs7811142	0.779	rs77370288	chr7:99947897	A/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.1	11.29	0.57	2.15e-24	Platelet count;
CESC	cis	rs875971	0.660	rs801217	chr7:66010577	C/T	cg25985355	chr7:65971099	NA	0.32	5.27	0.31	2.86e-7	Aortic root size;
CESC	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.59	-7.67	-0.43	3.19e-13	Prudent dietary pattern;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg19973604	chr17:73914282	FBF1	0.44	6.32	0.36	1.12e-9	Fibrinogen levels;
CESC	cis	rs7512552	0.839	rs11205357	chr1:150267798	T/C	cg15654264	chr1:150340011	RPRD2	-0.41	-5.32	-0.31	2.19e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CESC	trans	rs7980799	0.935	rs7294492	chr12:33548530	C/T	cg26384229	chr12:38710491	ALG10B	-0.49	-6.74	-0.38	9.61e-11	Heart rate;Heart rate variability traits (RMSSD);
CESC	cis	rs6502050	0.835	rs7501527	chr17:80099355	A/C	cg23985595	chr17:80112537	CCDC57	-0.41	-6.22	-0.36	1.88e-9	Life satisfaction;
CESC	trans	rs4716602	0.596	rs10266659	chr7:156159278	A/G	cg07175507	chr18:77160758	NFATC1	-0.44	-6.08	-0.35	4.18e-9	Anti-saccade response;
CESC	cis	rs8020095	0.571	rs8009087	chr14:67564210	C/T	cg19548862	chr14:67692701	FAM71D	0.5	6.35	0.36	9.13e-10	Depression (quantitative trait);
CESC	cis	rs4888262	0.526	rs6564145	chr16:74621129	G/A	cg01733217	chr16:74700730	RFWD3	0.85	11.41	0.57	8.81e-25	Testicular germ cell tumor;
CESC	cis	rs6951245	0.580	rs10257426	chr7:1213694	G/A	cg03188948	chr7:1209495	NA	0.66	7.35	0.41	2.45e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2425143	0.730	rs7263640	chr20:34314725	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.82	-7.53	-0.42	7.76e-13	Blood protein levels;
CESC	trans	rs10506458	1.000	rs10506458	chr12:63445092	G/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.32	-17.48	-0.73	4.95e-46	Hemostatic factors and hematological phenotypes;
CESC	cis	rs11166927	0.703	rs2126127	chr8:140788362	G/A	cg16909799	chr8:140841666	TRAPPC9	0.48	6.7	0.38	1.26e-10	Pediatric non-alcoholic fatty liver disease activity score;
CESC	cis	rs1552244	0.935	rs41520445	chr3:10153141	A/C	cg16606324	chr3:10149918	C3orf24	-0.4	-5.09	-0.3	6.66e-7	Alzheimer's disease;
CESC	cis	rs909002	0.745	rs4949458	chr1:32142332	G/T	cg13919466	chr1:32135498	COL16A1	0.35	5.9	0.34	1.12e-8	Intelligence (multi-trait analysis);
CESC	cis	rs651907	0.557	rs12629954	chr3:101360623	C/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.45	5.82	0.34	1.73e-8	Colorectal cancer;
CESC	cis	rs858239	0.539	rs10279194	chr7:23191083	T/C	cg23682824	chr7:23144976	KLHL7	0.51	6.77	0.38	8.05e-11	Cerebrospinal fluid biomarker levels;
CESC	cis	rs9309473	0.797	rs6723247	chr2:73846749	A/G	cg20560298	chr2:73613845	ALMS1	-0.43	-5.74	-0.33	2.55e-8	Metabolite levels;
CESC	cis	rs34779708	0.966	rs998658	chr10:35408654	A/G	cg03585969	chr10:35415529	CREM	0.79	10.48	0.54	1.04e-21	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs2282802	0.685	rs62385161	chr5:139635747	T/C	cg26211634	chr5:139558579	C5orf32	0.52	7.65	0.43	3.74e-13	Intelligence (multi-trait analysis);
CESC	cis	rs9311474	0.507	rs4687644	chr3:52746541	T/G	cg07507251	chr3:52567010	NT5DC2	0.35	5.94	0.34	8.88e-9	Electroencephalogram traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14588896	chr20:2505177	NA	0.56	6.13	0.35	3.16e-9	Gut microbiome composition (summer);
CESC	cis	rs62408225	1.000	rs2875584	chr6:90950628	C/T	cg06866423	chr6:90926672	BACH2	0.5	6.11	0.35	3.52e-9	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs9486715	0.867	rs9372106	chr6:96875058	T/C	cg18709589	chr6:96969512	KIAA0776	0.46	6.63	0.38	1.88e-10	Headache;
CESC	cis	rs7666738	0.546	rs28444809	chr4:98916934	C/T	cg17366294	chr4:99064904	C4orf37	0.47	5.66	0.33	3.94e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9733	0.596	rs72702504	chr1:150635374	G/C	cg04414720	chr1:150670196	GOLPH3L	0.63	9.02	0.48	3.86e-17	Tonsillectomy;
CESC	cis	rs7264396	0.733	rs2425105	chr20:34312834	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.86	-11.83	-0.59	3.3e-26	Total cholesterol levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27079446	chr18:3449844	TGIF1	0.54	6.71	0.38	1.17e-10	Gut microbiome composition (summer);
CESC	cis	rs228437	0.913	rs4896078	chr6:134910571	A/T	cg24504307	chr6:134963096	NA	0.49	5.79	0.33	2.03e-8	Melanoma;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09850442	chr2:25896287	DTNB	0.57	6.37	0.36	8.37e-10	Gut microbiome composition (summer);
CESC	cis	rs4561483	0.603	rs11075033	chr16:12006338	C/T	cg08843971	chr16:11963173	GSPT1	0.46	6.45	0.37	5.14e-10	Testicular germ cell tumor;
CESC	cis	rs5747327	0.874	rs5746451	chr22:18126020	T/C	cg19898043	chr22:18121309	BCL2L13	-0.45	-5.62	-0.33	4.77e-8	Myeloid white cell count;Granulocyte count;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg12277888	chr11:35723985	TRIM44	-0.5	-6.93	-0.39	3.17e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs7542091	0.704	rs7537294	chr1:210043777	A/G	cg25204440	chr1:209979598	IRF6	0.37	5.1	0.3	6.55e-7	Monobrow;
CESC	cis	rs1799949	0.965	rs799912	chr17:41257134	T/C	cg25072359	chr17:41440525	NA	0.49	7.48	0.42	1.12e-12	Menopause (age at onset);
CESC	cis	rs9926296	0.548	rs6500439	chr16:89808275	A/C	cg07648498	chr16:89883185	FANCA	0.47	5.85	0.34	1.44e-8	Vitiligo;
CESC	cis	rs55871839	0.643	rs7004274	chr8:59810378	T/A	cg07426533	chr8:59803705	TOX	-0.44	-6.39	-0.37	7.37e-10	Pneumonia;
CESC	cis	rs7914558	0.966	rs2065977	chr10:104729415	C/T	cg04362960	chr10:104952993	NT5C2	0.45	5.76	0.33	2.33e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs2408955	0.521	rs11168437	chr12:48566156	C/T	cg24011408	chr12:48396354	COL2A1	0.49	7.23	0.41	5.3e-12	Glycated hemoglobin levels;
CESC	cis	rs12497850	0.897	rs9850134	chr3:48957147	A/G	cg07636037	chr3:49044803	WDR6	1.03	19.55	0.77	2.54e-53	Parkinson's disease;
CESC	cis	rs4665809	0.590	rs1049987	chr2:26413817	C/T	cg22920501	chr2:26401640	FAM59B	0.86	9.99	0.52	3.79e-20	Gut microbiome composition (summer);
CESC	cis	rs7772486	0.701	rs11155438	chr6:145950112	C/G	cg23711669	chr6:146136114	FBXO30	1.01	15.49	0.69	5.86e-39	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs11155671	0.530	rs7774787	chr6:150209432	G/A	cg09699651	chr6:150184138	LRP11	0.56	7.76	0.43	1.81e-13	Testicular germ cell tumor;
CESC	cis	rs2549003	0.966	rs2070730	chr5:131819800	G/A	cg21138405	chr5:131827807	IRF1	0.54	9.24	0.49	8.12e-18	Asthma (sex interaction);
CESC	cis	rs2075371	0.611	rs1862045	chr7:134023412	A/G	cg20476274	chr7:133979776	SLC35B4	0.54	7.26	0.41	4.38e-12	Mean platelet volume;
CESC	cis	rs7103648	0.897	rs11606287	chr11:47407439	C/A	cg03711944	chr11:47377212	SPI1	-0.36	-5.74	-0.33	2.62e-8	Diastolic blood pressure;Systolic blood pressure;
CESC	cis	rs703842	1.000	rs10783848	chr12:58196528	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.69	8.87	0.48	1.09e-16	Multiple sclerosis;
CESC	cis	rs12824058	0.831	rs7485200	chr12:130811641	C/T	cg23887609	chr12:130822674	PIWIL1	0.47	6.01	0.35	6.22e-9	Menopause (age at onset);
CESC	cis	rs2228479	0.850	rs11648433	chr16:89965055	G/A	cg04013166	chr16:89971882	TCF25	0.75	6.27	0.36	1.47e-9	Skin colour saturation;
CESC	cis	rs13256369	0.951	rs13270852	chr8:8566853	A/G	cg17143192	chr8:8559678	CLDN23	0.71	8.24	0.45	8.06e-15	Obesity-related traits;
CESC	cis	rs6987853	0.527	rs3935700	chr8:42364121	T/C	cg09913449	chr8:42400586	C8orf40	-0.36	-5.66	-0.33	3.99e-8	Mean corpuscular hemoglobin concentration;
CESC	cis	rs992157	0.764	rs13020391	chr2:219184436	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.57	-7.3	-0.41	3.26e-12	Colorectal cancer;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg04309227	chr1:26561027	CCDC21	0.51	6.75	0.38	9.38e-11	Systemic lupus erythematosus;
CESC	cis	rs6502050	0.835	rs8073645	chr17:80110957	C/T	cg11859384	chr17:80120422	CCDC57	-0.39	-5.37	-0.31	1.76e-7	Life satisfaction;
CESC	cis	rs597539	0.652	rs668576	chr11:68668208	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.8	10.35	0.54	2.68e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13116174	chr6:80816309	BCKDHB	0.59	6.26	0.36	1.56e-9	Gut microbiome composition (summer);
CESC	cis	rs7618915	1.000	rs3852063	chr3:52349204	A/G	cg05564831	chr3:52568323	NT5DC2	0.41	5.43	0.32	1.25e-7	Bipolar disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06545038	chr1:201868886	LMOD1	-0.57	-6.12	-0.35	3.4e-9	Gut microbiome composition (summer);
CESC	cis	rs4654899	1.000	rs3767248	chr1:21276854	A/G	cg05370193	chr1:21551575	ECE1	0.39	5.83	0.34	1.61e-8	Superior frontal gyrus grey matter volume;
CESC	cis	rs6088580	0.634	rs2184836	chr20:32963369	A/G	cg08999081	chr20:33150536	PIGU	-0.66	-11.72	-0.58	8.03e-26	Glomerular filtration rate (creatinine);
CESC	cis	rs7584330	0.737	rs12465714	chr2:238365637	C/T	cg14458575	chr2:238380390	NA	0.62	8.39	0.46	3.03e-15	Prostate cancer;
CESC	cis	rs3733585	0.699	rs7658170	chr4:9966593	C/T	cg11266682	chr4:10021025	SLC2A9	0.57	10.68	0.55	2.24e-22	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs57502260	0.704	rs12286536	chr11:68290234	C/G	cg20283391	chr11:68216788	NA	-0.65	-5.45	-0.32	1.12e-7	Total body bone mineral density (age 45-60);
CESC	cis	rs8180040	1.000	rs2159400	chr3:47375890	T/C	cg27129171	chr3:47204927	SETD2	-0.69	-10.73	-0.55	1.5e-22	Colorectal cancer;
CESC	cis	rs3749237	1.000	rs1317140	chr3:49878652	G/A	cg03060546	chr3:49711283	APEH	0.59	6.73	0.38	1.07e-10	Resting heart rate;
CESC	cis	rs7267979	1.000	rs6050566	chr20:25351071	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.84	-16.5	-0.71	1.44e-42	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs5753037	0.809	rs713657	chr22:30211876	A/G	cg01021169	chr22:30184971	ASCC2	-0.39	-5.1	-0.3	6.39e-7	Type 1 diabetes;
CESC	cis	rs7552404	0.924	rs2275378	chr1:76198436	T/C	cg10523679	chr1:76189770	ACADM	0.79	10.7	0.55	1.91e-22	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs6860806	0.661	rs28472559	chr5:131581611	G/A	cg18301423	chr5:131593218	PDLIM4	0.39	5.49	0.32	9.57e-8	Breast cancer;
CESC	cis	rs6087990	1.000	rs6087990	chr20:31349908	T/C	cg13636640	chr20:31349939	DNMT3B	0.93	17.19	0.73	5.14e-45	Ulcerative colitis;
CESC	cis	rs7584330	0.554	rs7587496	chr2:238387632	A/G	cg14458575	chr2:238380390	NA	0.72	6.09	0.35	3.86e-9	Prostate cancer;
CESC	cis	rs7503807	1.000	rs7503807	chr17:78591111	G/T	cg09596252	chr17:78655493	RPTOR	-0.47	-6.93	-0.39	3.17e-11	Obesity;
CESC	cis	rs1775715	0.870	rs1775735	chr10:32255846	A/G	cg18675610	chr10:32216311	ARHGAP12	0.33	5.14	0.3	5.37e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07617175	chr5:99871683	FAM174A	-0.54	-6.25	-0.36	1.64e-9	Gut microbiome composition (summer);
CESC	cis	rs7833790	0.636	rs12544174	chr8:82731477	G/A	cg07697082	chr8:82753677	SNX16	0.39	6.08	0.35	4.26e-9	Diastolic blood pressure;
CESC	trans	rs55704346	0.534	rs6814162	chr4:25389501	A/G	cg01822600	chr1:245751692	KIF26B	0.42	6.17	0.35	2.58e-9	Tonsillectomy;
CESC	cis	rs2072499	0.750	rs57056972	chr1:156159064	C/A	cg25208724	chr1:156163844	SLC25A44	1.01	12.84	0.62	1.13e-29	Testicular germ cell tumor;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg09397319	chr2:64250606	NA	0.41	6.27	0.36	1.46e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs62458065	0.713	rs921406	chr7:32486205	G/C	cg20159608	chr7:32802032	NA	-0.53	-5.08	-0.3	7.29e-7	Metabolite levels (HVA/MHPG ratio);
CESC	cis	rs35306767	0.903	rs12769873	chr10:936526	G/T	cg20503657	chr10:835505	NA	0.8	8.24	0.45	7.81e-15	Eosinophil percentage of granulocytes;
CESC	cis	rs6912958	0.667	rs7746545	chr6:88090225	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	0.37	5.84	0.34	1.56e-8	Monocyte percentage of white cells;
CESC	cis	rs1005277	0.579	rs2474584	chr10:38416389	C/T	cg25427524	chr10:38739819	LOC399744	-0.67	-9.72	-0.51	2.65e-19	Extrinsic epigenetic age acceleration;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21881364	chr11:72438004	ARAP1	-0.6	-6.6	-0.38	2.25e-10	Gut microbiome composition (summer);
CESC	cis	rs460214	0.553	rs9976546	chr21:40028193	C/G	cg05519781	chr21:40033154	ERG	-0.44	-5.45	-0.32	1.17e-7	Response to cognitive-behavioural therapy in anxiety disorder;
CESC	cis	rs4664304	0.714	rs66496937	chr2:160738509	A/G	cg03641300	chr2:160917029	PLA2R1	-0.41	-5.34	-0.31	1.97e-7	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs11098499	0.863	rs3775845	chr4:120432447	T/C	cg09307838	chr4:120376055	NA	0.94	12.8	0.62	1.53e-29	Corneal astigmatism;
CESC	cis	rs854765	0.623	rs9893690	chr17:17753846	A/T	cg16928487	chr17:17741425	SREBF1	0.58	10.45	0.54	1.28e-21	Total body bone mineral density;
CESC	cis	rs7959452	0.590	rs10878974	chr12:69781528	C/G	cg22834771	chr12:69754056	YEATS4	-0.48	-6.46	-0.37	4.87e-10	Blood protein levels;
CESC	cis	rs12971120	0.783	rs7229256	chr18:72169129	T/A	cg25817165	chr18:72167213	CNDP2	-0.56	-7.72	-0.43	2.31e-13	Refractive error;
CESC	cis	rs9322193	0.886	rs4870055	chr6:150169569	C/T	cg07701084	chr6:150067640	NUP43	0.46	5.96	0.34	8.16e-9	Lung cancer;
CESC	cis	rs727505	0.721	rs67817822	chr7:124769572	A/G	cg23710748	chr7:124431027	NA	-0.37	-6.18	-0.35	2.43e-9	Lewy body disease;
CESC	cis	rs2842992	0.915	rs1322427	chr6:160075454	C/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.63	7.67	0.43	3.39e-13	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs1267303	0.675	rs1267308	chr1:46987718	A/G	cg25110126	chr1:46999211	NA	-0.92	-9.91	-0.52	6.55e-20	Monobrow;
CESC	cis	rs9303401	0.625	rs34963822	chr17:56988424	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.99	12.31	0.6	7.4e-28	Cognitive test performance;
CESC	trans	rs5417	0.689	rs55868524	chr17:7170665	G/A	cg15655154	chr3:113604241	GRAMD1C	-0.51	-6.8	-0.39	6.96e-11	Diastolic blood pressure;
CESC	cis	rs826838	0.935	rs11169547	chr12:39185625	C/A	cg13010199	chr12:38710504	ALG10B	0.58	8.05	0.44	2.77e-14	Heart rate;
CESC	cis	rs4144027	0.935	rs10139856	chr14:104354505	T/C	cg08213375	chr14:104286397	PPP1R13B	-0.29	-5.03	-0.3	8.94e-7	Blood metabolite levels;
CESC	cis	rs9309473	0.898	rs10197755	chr2:73797623	T/A	cg20560298	chr2:73613845	ALMS1	-0.54	-7.03	-0.4	1.7e-11	Metabolite levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25922239	chr6:33757077	LEMD2	-0.6	-6.54	-0.37	3.2e-10	Gut microbiome composition (summer);
CESC	cis	rs514406	0.929	rs12145105	chr1:53340564	T/C	cg16325326	chr1:53192061	ZYG11B	0.89	14.42	0.66	3.56e-35	Monocyte count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16357477	chr17:79633857	C17orf90;CCDC137	0.66	7.7	0.43	2.67e-13	Gut microbiome composition (summer);
CESC	cis	rs898097	0.691	rs7222773	chr17:80907283	A/G	cg15369054	chr17:80825471	TBCD	-0.36	-5.12	-0.3	5.81e-7	Breast cancer;
CESC	cis	rs6089829	0.962	rs7273930	chr20:61666017	G/A	cg16240275	chr20:61666158	NCRNA00029	0.5	8.96	0.48	5.97e-17	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs2832077	0.527	rs11088095	chr21:30223188	A/T	cg14791747	chr16:20752902	THUMPD1	0.53	7.48	0.42	1.12e-12	Cognitive test performance;
CESC	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg24829409	chr8:58192753	C8orf71	-0.7	-7.82	-0.43	1.29e-13	Developmental language disorder (linguistic errors);
CESC	cis	rs6061231	0.793	rs2427320	chr20:60976723	A/G	cg22633769	chr20:60982531	CABLES2	0.5	5.05	0.3	8.42e-7	Colorectal cancer;
CESC	cis	rs9649213	0.593	rs2158553	chr7:97951131	G/A	cg08684580	chr7:98029266	BAIAP2L1	-0.35	-5.69	-0.33	3.38e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs4665809	1.000	rs2384323	chr2:26306473	C/T	cg04944784	chr2:26401820	FAM59B	-0.65	-7.41	-0.41	1.7e-12	Gut microbiome composition (summer);
CESC	cis	rs72615157	0.539	rs72615159	chr7:99674286	G/A	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.41	5.05	0.3	8.06e-7	Lung function (FEV1/FVC);
CESC	cis	rs11122272	0.735	rs2024878	chr1:231528415	A/C	cg06096015	chr1:231504339	EGLN1	-0.39	-5.72	-0.33	2.86e-8	Hemoglobin concentration;
CESC	cis	rs4975709	0.569	rs2077269	chr5:1863506	C/T	cg07747251	chr5:1868357	NA	0.33	5.46	0.32	1.08e-7	Cardiovascular disease risk factors;
CESC	cis	rs2228479	0.557	rs57071566	chr16:89889327	T/G	cg14709524	chr16:89940631	TCF25	0.84	6.02	0.35	5.74e-9	Skin colour saturation;
CESC	cis	rs113835537	0.529	rs11227495	chr11:66263243	C/T	cg24851651	chr11:66362959	CCS	0.42	5.2	0.3	3.91e-7	Airway imaging phenotypes;
CESC	cis	rs2479724	0.755	rs4318867	chr6:41753670	G/T	cg08135965	chr6:41755394	TOMM6	-0.4	-5.25	-0.31	3.19e-7	Menarche (age at onset);
CESC	cis	rs1006703	0.544	rs7220897	chr17:3837643	A/G	cg06463185	chr17:3833770	ATP2A3	-0.55	-5.91	-0.34	1.05e-8	Glucose homeostasis traits;
CESC	cis	rs6541297	0.703	rs678578	chr1:230320600	G/A	cg20703242	chr1:230279135	GALNT2	-0.41	-5.38	-0.31	1.65e-7	Coronary artery disease;
CESC	trans	rs3780486	0.846	rs2209948	chr9:33138247	G/A	cg20290983	chr6:43655470	MRPS18A	0.99	17.84	0.74	2.65e-47	IgG glycosylation;
CESC	cis	rs854765	0.547	rs2955356	chr17:17964717	G/A	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.54	-7.02	-0.4	1.86e-11	Total body bone mineral density;
CESC	cis	rs7546094	1.000	rs3013440	chr1:113195789	G/A	cg22162597	chr1:113214053	CAPZA1	-0.39	-6.01	-0.35	6.17e-9	Platelet distribution width;
CESC	cis	rs4906332	1.000	rs2065017	chr14:103879579	T/C	cg09975044	chr14:104007538	NA	0.46	6.34	0.36	9.68e-10	Coronary artery disease;
CESC	cis	rs634534	0.591	rs688862	chr11:65733393	A/G	cg04055107	chr11:65626734	MUS81;CFL1	0.45	5.5	0.32	9.11e-8	Sum eosinophil basophil counts;Eosinophil counts;
CESC	cis	rs7943191	0.810	rs7942991	chr11:62337203	A/G	cg11742103	chr11:62369870	EML3;MTA2	-0.55	-8.27	-0.45	6.36e-15	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
CESC	cis	rs6964587	1.000	rs2157747	chr7:91750578	A/G	cg17063962	chr7:91808500	NA	0.57	7.87	0.44	9.34e-14	Breast cancer;
CESC	cis	rs853679	0.517	rs3757187	chr6:28107654	T/C	cg17949981	chr6:28129498	ZNF389	0.46	5.76	0.33	2.3e-8	Depression;
CESC	cis	rs7666738	0.830	rs28618180	chr4:98912184	A/C	cg17366294	chr4:99064904	C4orf37	0.57	7.92	0.44	6.7e-14	Colonoscopy-negative controls vs population controls;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg04360491	chr11:47600569	NDUFS3;KBTBD4	0.51	6.71	0.38	1.17e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs4803468	1.000	rs10413735	chr19:41921071	C/T	cg09537434	chr19:41945824	ATP5SL	-1.11	-20.39	-0.78	3.11e-56	Height;
CESC	cis	rs763121	0.889	rs6001209	chr22:39121252	C/T	cg06022373	chr22:39101656	GTPBP1	-0.82	-11.98	-0.59	1.02e-26	Menopause (age at onset);
CESC	trans	rs1814175	0.817	rs11518158	chr11:49985633	G/T	cg03929089	chr4:120376271	NA	-0.93	-15.76	-0.7	6.39e-40	Height;
CESC	cis	rs10791097	0.694	rs4370948	chr11:130755700	A/C	cg09137382	chr11:130731461	NA	0.37	5.48	0.32	9.83e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs10504229	0.906	rs7003276	chr8:58173089	A/T	cg05313129	chr8:58192883	C8orf71	-0.54	-6.27	-0.36	1.47e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs10461617	0.617	rs79742142	chr5:56104377	A/G	cg18230493	chr5:56204884	C5orf35	-0.72	-8.5	-0.46	1.41e-15	Type 2 diabetes;
CESC	trans	rs1814175	0.591	rs11040589	chr11:49862449	A/G	cg15704280	chr7:45808275	SEPT13	-1.0	-18.78	-0.76	1.35e-50	Height;
CESC	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg12419862	chr22:24373484	LOC391322	-0.71	-10.05	-0.53	2.42e-20	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs909674	0.541	rs5750816	chr22:39810379	A/G	cg24399712	chr22:39784796	NA	0.79	10.93	0.56	3.24e-23	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs7613875	0.620	rs17657664	chr3:50032008	T/G	cg24308560	chr3:49941425	MST1R	-0.56	-7.83	-0.43	1.21e-13	Body mass index;
CESC	trans	rs4942242	0.659	rs1105586	chr13:44232633	C/T	cg19169023	chr15:41853346	TYRO3	0.54	7.36	0.41	2.28e-12	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs13095912	1.000	rs34965813	chr3:185333012	T/C	cg11274856	chr3:185301563	NA	0.35	5.66	0.33	3.93e-8	Systolic blood pressure;
CESC	cis	rs748404	0.534	rs489509	chr15:43586907	T/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.55	8.4	0.46	2.82e-15	Lung cancer;
CESC	cis	rs9814567	0.929	rs9838834	chr3:134207077	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.41	-5.66	-0.33	3.95e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs2576037	0.583	rs478820	chr18:44397782	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.52	-7.13	-0.4	9.42e-12	Personality dimensions;
CESC	cis	rs35110281	0.805	rs162402	chr21:44963418	G/C	cg01579765	chr21:45077557	HSF2BP	-0.57	-9.82	-0.52	1.31e-19	Mean corpuscular volume;
CESC	trans	rs11098499	0.954	rs10006877	chr4:120242793	C/T	cg25214090	chr10:38739885	LOC399744	0.69	9.63	0.51	5.18e-19	Corneal astigmatism;
CESC	cis	rs9487051	0.872	rs9386793	chr6:109610002	C/A	cg12927641	chr6:109611667	NA	-0.43	-6.7	-0.38	1.22e-10	Reticulocyte fraction of red cells;
CESC	cis	rs798554	0.718	rs1636247	chr7:2881917	A/G	cg19717773	chr7:2847554	GNA12	-0.51	-7.26	-0.41	4.26e-12	Height;
CESC	cis	rs2790457	0.958	rs2532742	chr10:28867220	C/G	cg04045419	chr10:28823091	WAC	-0.42	-5.04	-0.3	8.49e-7	Multiple myeloma;
CESC	cis	rs4665809	0.652	rs12611790	chr2:26404221	C/T	cg26314531	chr2:26401878	FAM59B	-0.82	-8.88	-0.48	1.07e-16	Gut microbiome composition (summer);
CESC	cis	rs660498	0.507	rs2020155	chr10:27740194	C/T	cg08398567	chr10:27609333	NA	0.38	5.18	0.3	4.5e-7	Asthma (childhood onset);
CESC	cis	rs801193	1.000	rs7788576	chr7:66148302	G/A	cg06456125	chr7:65229604	NA	-0.4	-5.16	-0.3	4.88e-7	Aortic root size;
CESC	cis	rs6741892	0.536	rs6761563	chr2:38891406	A/T	cg00359181	chr2:38893519	GALM	-0.64	-9.09	-0.49	2.43e-17	5-HTT brain serotonin transporter levels;
CESC	cis	rs875971	0.862	rs1875057	chr7:65731855	A/G	cg12463550	chr7:65579703	CRCP	-0.48	-6.01	-0.35	6.25e-9	Aortic root size;
CESC	cis	rs2075371	0.644	rs1643041	chr7:134012211	C/T	cg00033643	chr7:134001901	SLC35B4	0.42	5.16	0.3	4.74e-7	Mean platelet volume;
CESC	cis	rs763014	0.898	rs916416	chr16:632198	T/A	cg00802000	chr16:706648	WDR90	-0.41	-6.12	-0.35	3.33e-9	Height;
CESC	cis	rs1003719	0.788	rs59637309	chr21:38475398	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.63	8.77	0.47	2.14e-16	Eye color traits;
CESC	cis	rs7605827	0.930	rs10168299	chr2:15615063	A/G	cg19274914	chr2:15703543	NA	0.35	6.13	0.35	3.19e-9	Educational attainment (years of education);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04774194	chr6:127664674	ECHDC1	0.62	7.26	0.41	4.31e-12	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.962	rs11932892	chr4:99072967	C/T	cg17366294	chr4:99064904	C4orf37	0.6	7.63	0.42	4.3e-13	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9303401	0.661	rs9902820	chr17:56637545	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.52	6.8	0.39	6.98e-11	Cognitive test performance;
CESC	cis	rs2050392	0.630	rs303428	chr10:30739058	C/T	cg25182066	chr10:30743637	MAP3K8	0.43	5.92	0.34	9.88e-9	Inflammatory bowel disease;
CESC	cis	rs8031584	0.918	rs61997140	chr15:31277312	A/G	cg08109568	chr15:31115862	NA	-0.71	-9.43	-0.5	2.19e-18	Huntington's disease progression;
CESC	cis	rs6460942	0.915	rs62448596	chr7:12446869	C/T	cg19099843	chr7:12443191	VWDE	-0.5	-5.26	-0.31	2.97e-7	Coronary artery disease;
CESC	cis	rs8040855	0.627	rs11632658	chr15:85606213	C/T	cg08123816	chr15:85640762	PDE8A	0.4	5.94	0.34	8.98e-9	Bulimia nervosa;
CESC	trans	rs9467711	0.606	rs9379851	chr6:26354780	A/C	cg06606381	chr12:133084897	FBRSL1	-0.78	-7.22	-0.41	5.4e-12	Autism spectrum disorder or schizophrenia;
CESC	cis	rs9916302	0.904	rs11869109	chr17:37518205	G/T	cg15445000	chr17:37608096	MED1	-0.41	-6.74	-0.38	9.82e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs6963495	0.818	rs1355614	chr7:105179176	A/G	cg19920283	chr7:105172520	RINT1	0.71	8.05	0.44	2.89e-14	Bipolar disorder (body mass index interaction);
CESC	cis	rs9399135	0.527	rs61738492	chr6:135282771	G/A	cg24558204	chr6:135376177	HBS1L	0.7	9.47	0.5	1.6e-18	Red blood cell count;
CESC	cis	rs7656342	0.686	rs1401440	chr4:9832512	C/T	cg00071950	chr4:10020882	SLC2A9	0.41	5.54	0.32	7.34e-8	Gut microbiota (bacterial taxa);
CESC	cis	rs897984	0.572	rs112906665	chr16:31040139	T/C	cg02466173	chr16:30829666	NA	-0.39	-6.68	-0.38	1.43e-10	Dementia with Lewy bodies;
CESC	cis	rs965469	1.000	rs6051827	chr20:3372007	C/T	cg25506879	chr20:3388711	C20orf194	-0.57	-6.12	-0.35	3.38e-9	IFN-related cytopenia;
CESC	cis	rs735860	0.718	rs209488	chr6:53177540	A/T	cg10236188	chr6:53219634	NA	0.35	5.23	0.31	3.43e-7	Glaucoma;
CESC	cis	rs6062302	0.534	rs1556456	chr20:62216289	T/C	cg09650180	chr20:62225654	GMEB2	-0.79	-8.81	-0.48	1.7e-16	Glioblastoma;
CESC	cis	rs262150	0.659	rs2527237	chr7:158798494	A/G	cg09640425	chr7:158790006	NA	0.37	5.67	0.33	3.64e-8	Facial morphology (factor 20);
CESC	cis	rs9611565	0.592	rs1811113	chr22:42073134	C/T	cg06481639	chr22:41940642	POLR3H	0.57	5.74	0.33	2.58e-8	Vitiligo;
CESC	cis	rs933688	0.938	rs10063683	chr5:90714595	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.18	14.23	0.66	1.63e-34	Smoking behavior;
CESC	cis	rs7916697	0.593	rs10762198	chr10:70023053	A/G	cg06988349	chr10:69991859	ATOH7	-0.32	-5.18	-0.3	4.34e-7	Optic disc area;
CESC	trans	rs1814175	0.645	rs10444311	chr11:49986906	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.43	-6.26	-0.36	1.53e-9	Height;
CESC	cis	rs11098499	0.535	rs10005542	chr4:120268302	T/C	cg09307838	chr4:120376055	NA	0.76	10.03	0.52	2.87e-20	Corneal astigmatism;
CESC	cis	rs12477438	0.765	rs6740054	chr2:99576631	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.66	-8.88	-0.48	1.01e-16	Chronic sinus infection;
CESC	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg11301795	chr4:187892539	NA	-0.75	-12.3	-0.6	8.03e-28	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1448094	0.791	rs10863114	chr12:86332325	T/C	cg02569458	chr12:86230093	RASSF9	0.46	6.54	0.37	3.19e-10	Major depressive disorder;
CESC	cis	rs7666738	0.830	rs9998803	chr4:99002519	C/T	cg17366294	chr4:99064904	C4orf37	0.6	8.61	0.47	6.47e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1594829	0.553	rs17055108	chr8:26160739	G/A	cg11498726	chr8:26250323	BNIP3L	-0.4	-6.06	-0.35	4.68e-9	Height;
CESC	cis	rs7267979	0.873	rs6132822	chr20:25228695	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.72	11.88	0.59	2.28e-26	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg10295955	chr4:187884368	NA	-1.05	-19.34	-0.77	1.43e-52	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4604732	0.504	rs4634945	chr1:247636015	G/T	cg02104434	chr1:247694406	LOC148824;OR2C3	-0.38	-5.92	-0.34	9.68e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	trans	rs9975691	1	rs9975691	chr21:14928355	G/T	cg18786515	chr8:10207915	MSRA	-0.5	-6.3	-0.36	1.24e-9	Neurofibrillary tangles;
CESC	cis	rs8067354	0.872	rs7224006	chr17:57896338	C/T	cg13753209	chr17:57696993	CLTC	-0.52	-7.03	-0.4	1.71e-11	Hemoglobin concentration;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg14817024	chr10:70939976	SUPV3L1	-0.44	-6.09	-0.35	4e-9	Gambling;
CESC	trans	rs74054849	0.850	rs72878883	chr1:16012493	C/A	cg06826283	chr7:600452	PRKAR1B	0.7	6.25	0.36	1.66e-9	Alcoholic chronic pancreatitis;
CESC	cis	rs4803468	1.000	rs9304593	chr19:41942875	A/C	cg14132834	chr19:41945861	ATP5SL	0.6	7.54	0.42	7.5e-13	Height;
CESC	cis	rs7660520	0.557	rs76004373	chr4:183731011	C/G	cg12524338	chr4:183729343	NA	0.54	5.19	0.3	4.28e-7	Pediatric autoimmune diseases;
CESC	cis	rs6088580	0.634	rs13041646	chr20:33082881	T/A	cg08999081	chr20:33150536	PIGU	0.66	11.62	0.58	1.7e-25	Glomerular filtration rate (creatinine);
CESC	cis	rs644799	0.965	rs687529	chr11:95545587	T/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	9.15	0.49	1.61e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs9790314	1.000	rs336569	chr3:161072346	T/G	cg04691961	chr3:161091175	C3orf57	-0.4	-5.29	-0.31	2.52e-7	Morning vs. evening chronotype;
CESC	cis	rs10504229	0.683	rs67048677	chr8:58140023	C/G	cg02725872	chr8:58115012	NA	-0.45	-7.12	-0.4	1.02e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs7666738	0.830	rs1593572	chr4:98979322	A/G	cg18180107	chr4:99064573	C4orf37	-0.4	-5.18	-0.3	4.33e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs916888	0.531	rs183211	chr17:44788310	G/A	cg01341218	chr17:43662625	NA	0.51	6.64	0.38	1.81e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs9916302	0.904	rs8076546	chr17:37555403	G/A	cg15445000	chr17:37608096	MED1	-0.39	-6.44	-0.37	5.69e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs7666738	0.830	rs7682991	chr4:98982595	C/A	cg18180107	chr4:99064573	C4orf37	0.4	5.19	0.3	4.29e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2742417	0.603	rs2742372	chr3:45783472	T/C	cg04837898	chr3:45731254	SACM1L	-0.46	-6.04	-0.35	5.16e-9	Response to anti-depressant treatment in major depressive disorder;
CESC	cis	rs7829975	0.593	rs2921077	chr8:8304502	C/T	cg06636001	chr8:8085503	FLJ10661	0.58	8.02	0.44	3.5e-14	Mood instability;
CESC	cis	rs2243480	0.908	rs55876148	chr7:65379800	G/A	cg13147721	chr7:65941812	NA	-0.88	-8.15	-0.45	1.47e-14	Diabetic kidney disease;
CESC	cis	rs6502050	0.835	rs62078306	chr17:80085341	A/G	cg11859384	chr17:80120422	CCDC57	0.38	5.08	0.3	7.27e-7	Life satisfaction;
CESC	cis	rs6582630	0.537	rs1949611	chr12:38373092	C/T	cg13010199	chr12:38710504	ALG10B	-0.44	-5.66	-0.33	3.94e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs17401966	1.000	rs58053556	chr1:10442903	A/G	cg15208524	chr1:10270712	KIF1B	0.49	6.15	0.35	2.87e-9	Hepatocellular carcinoma;
CESC	cis	rs71277158	0.688	rs76336713	chr3:169911957	G/T	cg04067573	chr3:169899625	PHC3	0.67	6.4	0.37	7.18e-10	Prostate cancer;
CESC	cis	rs780096	0.526	rs13472	chr2:27600239	G/A	cg21248554	chr2:27665150	KRTCAP3	-0.32	-6.38	-0.36	7.82e-10	Total body bone mineral density;
CESC	cis	rs798554	0.616	rs1636251	chr7:2884720	T/C	cg19717773	chr7:2847554	GNA12	-0.49	-7.43	-0.42	1.5e-12	Height;
CESC	cis	rs10861342	1.000	rs11112374	chr12:105510285	G/T	cg23923672	chr12:105501055	KIAA1033	0.67	5.46	0.32	1.1e-7	IgG glycosylation;
CESC	cis	rs7927771	0.524	rs7114813	chr11:47801101	A/G	cg20307385	chr11:47447363	PSMC3	0.61	8.64	0.47	5.45e-16	Subjective well-being;
CESC	cis	rs6582630	0.512	rs11182667	chr12:38588392	C/A	cg26384229	chr12:38710491	ALG10B	-0.42	-5.55	-0.32	7e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs60871478	1.000	rs7795258	chr7:795227	A/G	cg27478167	chr7:817139	HEATR2	-0.49	-5.84	-0.34	1.48e-8	Cerebrospinal P-tau181p levels;
CESC	cis	rs9733	0.596	rs72702523	chr1:150650425	G/T	cg09365446	chr1:150670422	GOLPH3L	0.42	5.9	0.34	1.09e-8	Tonsillectomy;
CESC	cis	rs7539624	0.588	rs10916598	chr1:223895559	G/A	cg10100437	chr1:223903862	CAPN2	0.42	5.5	0.32	9.02e-8	Schizophrenia;
CESC	cis	rs933688	1.000	rs1035477	chr5:90743325	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.95	11.04	0.56	1.47e-23	Smoking behavior;
CESC	cis	rs6541297	0.757	rs2760537	chr1:230326412	C/T	cg20703242	chr1:230279135	GALNT2	-0.4	-5.32	-0.31	2.26e-7	Coronary artery disease;
CESC	cis	rs425277	0.959	rs77665022	chr1:2065958	C/T	cg23803603	chr1:2058230	PRKCZ	0.33	5.07	0.3	7.41e-7	Height;
CESC	cis	rs909674	0.690	rs5750823	chr22:39829973	C/T	cg01416388	chr22:39784598	NA	-0.55	-7.04	-0.4	1.67e-11	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs1401999	1.000	rs10937158	chr3:183708439	T/C	cg01324343	chr3:183735012	ABCC5	0.64	13.58	0.64	3.13e-32	Anterior chamber depth;
CESC	cis	rs643506	0.874	rs640651	chr11:111728911	A/G	cg17089665	chr11:111648010	NA	-0.37	-5.49	-0.32	9.27e-8	Breast cancer;
CESC	cis	rs6460942	0.591	rs7800823	chr7:12378697	G/T	cg06484146	chr7:12443880	VWDE	-0.41	-6.25	-0.36	1.67e-9	Coronary artery disease;
CESC	cis	rs6963495	0.592	rs114793754	chr7:105152162	G/C	cg19920283	chr7:105172520	RINT1	0.67	6.36	0.36	8.79e-10	Bipolar disorder (body mass index interaction);
CESC	cis	rs2425143	1.000	rs2425093	chr20:34306875	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.89	-10.65	-0.55	2.79e-22	Blood protein levels;
CESC	cis	rs2180341	0.855	rs9385422	chr6:127716457	C/T	cg27446573	chr6:127587934	RNF146	0.83	11.88	0.59	2.22e-26	Breast cancer;
CESC	cis	rs8051149	0.688	rs16943320	chr16:87870379	A/G	cg01829163	chr16:87871160	SLC7A5	-0.55	-6.84	-0.39	5.44e-11	Blood metabolite levels;
CESC	cis	rs2075371	0.829	rs1993058	chr7:133930361	G/A	cg11752832	chr7:134001865	SLC35B4	0.53	6.87	0.39	4.5e-11	Mean platelet volume;
CESC	cis	rs9814567	1.000	rs9884031	chr3:134256500	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.45	-6.15	-0.35	2.87e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs62064224	0.589	rs756785	chr17:30812845	T/C	cg18200150	chr17:30822561	MYO1D	0.41	5.27	0.31	2.83e-7	Schizophrenia;
CESC	cis	rs9549260	0.709	rs9549247	chr13:41220777	G/C	cg21288729	chr13:41239152	FOXO1	0.67	8.72	0.47	3.11e-16	Red blood cell count;
CESC	cis	rs9322193	0.962	rs9505974	chr6:150100430	C/T	cg04369109	chr6:150039330	LATS1	-0.42	-5.95	-0.34	8.52e-9	Lung cancer;
CESC	cis	rs16854884	0.657	rs4611822	chr3:143735544	C/T	cg06585982	chr3:143692056	C3orf58	0.5	6.56	0.37	2.84e-10	Economic and political preferences (feminism/equality);
CESC	cis	rs10242455	1.000	rs17161692	chr7:98953863	A/G	cg05403484	chr7:98973169	ARPC1B	0.6	5.47	0.32	1.07e-7	Blood metabolite levels;
CESC	cis	rs11098499	0.909	rs10002083	chr4:120311152	C/T	cg24375607	chr4:120327624	NA	0.46	5.55	0.32	6.98e-8	Corneal astigmatism;
CESC	cis	rs561341	1.000	rs72823785	chr17:30273784	C/T	cg12193833	chr17:30244370	NA	-0.75	-6.94	-0.39	3.07e-11	Hip circumference adjusted for BMI;
CESC	cis	rs35110281	0.632	rs9306160	chr21:45107562	T/C	cg21573476	chr21:45109991	RRP1B	-0.57	-8.15	-0.45	1.49e-14	Mean corpuscular volume;
CESC	cis	rs6831352	0.879	rs1984362	chr4:100070973	G/A	cg13256891	chr4:100009986	ADH5	-0.76	-8.02	-0.44	3.44e-14	Alcohol dependence;
CESC	cis	rs35306767	0.855	rs55708963	chr10:925712	C/A	cg10556349	chr10:835070	NA	0.72	6.21	0.36	2.06e-9	Eosinophil percentage of granulocytes;
CESC	cis	rs950169	0.800	rs4099846	chr15:84956894	C/G	cg17507749	chr15:85114479	UBE2QP1	0.59	6.54	0.37	3.11e-10	Schizophrenia;
CESC	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg03188948	chr7:1209495	NA	0.73	7.17	0.4	7.66e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs10504229	0.683	rs67077711	chr8:58139769	G/T	cg21724239	chr8:58056113	NA	0.58	5.95	0.34	8.37e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs12142240	0.667	rs55887761	chr1:46826587	C/A	cg10495392	chr1:46806563	NSUN4	0.58	6.32	0.36	1.09e-9	Menopause (age at onset);
CESC	cis	rs9560113	0.509	rs4773390	chr13:112208904	G/A	cg10483660	chr13:112241077	NA	0.43	7.19	0.4	6.66e-12	Menarche (age at onset);
CESC	cis	rs853679	0.517	rs2275508	chr6:28094731	T/C	cg22143856	chr6:28129313	ZNF389	0.5	6.59	0.38	2.34e-10	Depression;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23237418	chr14:23790594	PABPN1	-0.59	-6.95	-0.39	2.76e-11	Gut microbiome composition (summer);
CESC	cis	rs919433	1.000	rs112572902	chr2:198175179	G/C	cg10820045	chr2:198174542	NA	-0.44	-6.93	-0.39	3.21e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs741677	0.702	rs9893847	chr17:489043	C/G	cg15660573	chr17:549704	VPS53	-0.42	-5.46	-0.32	1.09e-7	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
CESC	cis	rs765787	0.530	rs1648287	chr15:45516956	T/C	cg24006582	chr15:45444508	DUOX1	-0.53	-6.64	-0.38	1.75e-10	Uric acid levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04558166	chr1:210001279	C1orf107	0.51	6.05	0.35	4.85e-9	Gut microbiome composition (summer);
CESC	cis	rs7914558	0.966	rs10786719	chr10:104637992	C/T	cg15744005	chr10:104629667	AS3MT	0.33	5.09	0.3	6.72e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs722599	0.683	rs7160852	chr14:75239424	T/C	cg11812906	chr14:75593930	NEK9	0.48	5.8	0.34	1.92e-8	IgG glycosylation;
CESC	cis	rs9322193	0.926	rs952166	chr6:150119910	A/T	cg07701084	chr6:150067640	NUP43	0.42	5.78	0.33	2.07e-8	Lung cancer;
CESC	trans	rs2727020	0.729	rs685789	chr11:49241228	G/A	cg03929089	chr4:120376271	NA	0.78	11.69	0.58	1e-25	Coronary artery disease;
CESC	trans	rs17685	0.753	rs6953665	chr7:75769049	C/T	cg19862616	chr7:65841803	NCRNA00174	0.85	12.41	0.61	3.51e-28	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs7552167	0.925	rs3932666	chr1:24511566	G/A	cg01960748	chr1:24522592	NA	-0.42	-5.25	-0.31	3.09e-7	Psoriasis vulgaris;
CESC	cis	rs1799949	1.000	rs12944430	chr17:41330820	C/G	cg25072359	chr17:41440525	NA	0.5	6.77	0.38	8.41e-11	Menopause (age at onset);
CESC	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg07092213	chr7:1199455	ZFAND2A	-0.45	-5.2	-0.3	3.98e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17825070	chr15:79614659	TMED3	-0.5	-6.03	-0.35	5.59e-9	Gut microbiome composition (summer);
CESC	cis	rs7615952	0.641	rs12488180	chr3:125782236	C/T	cg04553112	chr3:125709451	NA	-0.5	-5.61	-0.33	5e-8	Blood pressure (smoking interaction);
CESC	cis	rs875971	0.545	rs221986	chr7:65570310	T/C	cg25405998	chr7:65216604	CCT6P1	-0.49	-5.24	-0.31	3.28e-7	Aortic root size;
CESC	cis	rs1799949	1.000	rs34572725	chr17:41428666	G/A	cg06001716	chr17:41278141	BRCA1;NBR2	0.41	5.62	0.33	4.72e-8	Menopause (age at onset);
CESC	cis	rs2180341	0.804	rs6902233	chr6:127555963	A/G	cg27446573	chr6:127587934	RNF146	0.96	11.81	0.59	3.97e-26	Breast cancer;
CESC	cis	rs634534	0.622	rs552130	chr11:65732800	T/C	cg02427764	chr11:65769310	BANF1;EIF1AD	0.63	8.73	0.47	2.85e-16	Sum eosinophil basophil counts;Eosinophil counts;
CESC	cis	rs2243480	1.000	rs160652	chr7:65538431	A/G	cg12463550	chr7:65579703	CRCP	0.67	5.1	0.3	6.38e-7	Diabetic kidney disease;
CESC	cis	rs1670533	1.000	rs676561	chr4:1083112	C/T	cg27284194	chr4:1044797	NA	0.48	6.07	0.35	4.52e-9	Recombination rate (females);
CESC	cis	rs12134245	0.742	rs17501381	chr1:92003919	A/G	cg25838465	chr1:92012736	NA	-0.61	-8.93	-0.48	7.5e-17	Breast cancer;
CESC	cis	rs9910055	0.550	rs113844752	chr17:42297631	C/A	cg09913183	chr17:42254507	C17orf65;ASB16	0.42	5.06	0.3	7.72e-7	Total body bone mineral density;
CESC	cis	rs7647973	0.626	rs1586827	chr3:49671224	T/C	cg07636037	chr3:49044803	WDR6	0.53	6.3	0.36	1.22e-9	Menarche (age at onset);
CESC	cis	rs1215050	0.660	rs3864229	chr4:98714323	A/G	cg05340658	chr4:99064831	C4orf37	0.47	5.27	0.31	2.81e-7	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs9443645	1.000	rs9443645	chr6:79822924	C/T	cg05283184	chr6:79620031	NA	-0.38	-5.84	-0.34	1.54e-8	Intelligence (multi-trait analysis);
CESC	trans	rs1268083	0.546	rs9398785	chr6:126057748	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.56	-7.56	-0.42	6.58e-13	Migraine;
CESC	cis	rs72772090	0.634	rs17401901	chr5:96091925	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.61	-5.58	-0.32	5.79e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs5769765	0.837	rs8142737	chr22:50291889	T/C	cg26441486	chr22:50317300	CRELD2	0.39	5.39	0.31	1.56e-7	Schizophrenia;
CESC	cis	rs7811142	0.943	rs67196635	chr7:100025564	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.12	12.99	0.62	3.48e-30	Platelet count;
CESC	cis	rs7084402	0.967	rs1649057	chr10:60318114	C/T	cg07615347	chr10:60278583	BICC1	0.64	10.18	0.53	9.13e-21	Refractive error;
CESC	cis	rs9900497	0.783	rs758426	chr17:19620624	A/T	cg27231068	chr17:19620291	SLC47A2	-0.37	-5.14	-0.3	5.43e-7	Response to paliperidone in schizophrenia (CGI-S score);
CESC	cis	rs9457247	0.663	rs2237274	chr6:167442995	C/G	cg07741184	chr6:167504864	NA	0.33	5.77	0.33	2.18e-8	Crohn's disease;
CESC	cis	rs17345786	1.000	rs73863360	chr3:101316837	G/A	cg12386194	chr3:101231763	SENP7	0.57	6.56	0.37	2.81e-10	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6439153	0.967	rs12695512	chr3:128722082	T/G	cg24203234	chr3:128598194	ACAD9	0.4	5.29	0.31	2.56e-7	Pneumococcal bacteremia;
CESC	cis	rs875971	0.508	rs6947808	chr7:66045082	A/G	cg11764359	chr7:65958608	NA	-0.53	-6.98	-0.39	2.34e-11	Aortic root size;
CESC	cis	rs4713118	0.513	rs149951	chr6:28033087	T/C	cg23281280	chr6:28129359	ZNF389	0.37	5.47	0.32	1.06e-7	Parkinson's disease;
CESC	cis	rs40363	1.000	rs1635393	chr16:3520493	C/T	cg00484396	chr16:3507460	NAT15	0.57	7.32	0.41	2.94e-12	Tuberculosis;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg00297737	chr8:97273749	MTERFD1;PTDSS1	0.49	6.43	0.37	5.82e-10	Thyroid stimulating hormone;
CESC	cis	rs8044868	0.512	rs4788461	chr16:72156000	C/A	cg16558253	chr16:72132732	DHX38	-0.38	-5.9	-0.34	1.1e-8	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CESC	cis	rs6580649	0.941	rs11612970	chr12:48451009	T/C	cg05342945	chr12:48394962	COL2A1	0.5	5.85	0.34	1.47e-8	Lung cancer;
CESC	cis	rs10504229	1.000	rs111915672	chr8:58191665	T/C	cg05313129	chr8:58192883	C8orf71	-0.56	-6.38	-0.37	7.65e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs12477438	0.501	rs11683188	chr2:99724512	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.78	12.8	0.62	1.54e-29	Chronic sinus infection;
CESC	cis	rs9916302	0.904	rs8079355	chr17:37473018	G/A	cg15445000	chr17:37608096	MED1	-0.4	-6.61	-0.38	2.1e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs1008375	0.898	rs2079892	chr4:17577163	G/A	cg27347728	chr4:17578864	LAP3	0.43	5.12	0.3	5.92e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs61869271	0.871	rs12098332	chr10:116728074	A/T	cg23260525	chr10:116636907	FAM160B1	0.29	5.07	0.3	7.41e-7	Tonsillectomy;
CESC	cis	rs35306767	0.903	rs11253493	chr10:936931	T/C	cg25019033	chr10:957182	NA	-0.56	-6.07	-0.35	4.4e-9	Eosinophil percentage of granulocytes;
CESC	cis	rs763121	0.853	rs6519124	chr22:39045099	T/C	cg06544989	chr22:39130855	UNC84B	0.5	9.27	0.49	6.78e-18	Menopause (age at onset);
CESC	cis	rs11792861	0.926	rs7855282	chr9:111802614	T/A	cg14384093	chr9:111878565	C9orf5	-0.42	-5.18	-0.3	4.36e-7	Menarche (age at onset);
CESC	cis	rs7618915	0.547	rs13085895	chr3:52678270	G/C	cg05564831	chr3:52568323	NT5DC2	0.45	6.91	0.39	3.55e-11	Bipolar disorder;
CESC	cis	rs9549367	0.707	rs9549353	chr13:113843427	G/A	cg18105134	chr13:113819100	PROZ	-0.7	-8.26	-0.45	6.89e-15	Platelet distribution width;
CESC	cis	rs61996546	0.622	rs56031087	chr15:26847834	A/C	cg14859324	chr15:26874363	GABRB3	-0.37	-5.06	-0.3	7.97e-7	Response to methotrexate in juvenile idiopathic arthritis;
CESC	cis	rs5769765	0.955	rs8135816	chr22:50291976	G/C	cg02269571	chr22:50332266	NA	-0.45	-6.05	-0.35	4.98e-9	Schizophrenia;
CESC	cis	rs8077889	0.750	rs231533	chr17:41945588	A/G	cg26893861	chr17:41843967	DUSP3	-0.79	-7.63	-0.42	4.21e-13	Triglycerides;
CESC	cis	rs2295359	0.892	rs11209005	chr1:67618678	A/G	cg17031739	chr1:67600172	NA	0.39	5.2	0.3	3.91e-7	Psoriasis;
CESC	cis	rs30380	1.000	rs30379	chr5:96122260	T/G	cg16492584	chr5:96139282	ERAP1	-0.35	-5.35	-0.31	1.89e-7	Cerebrospinal fluid biomarker levels;
CESC	cis	rs425277	0.916	rs414777	chr1:2101687	G/A	cg24578937	chr1:2090814	PRKCZ	0.55	9.62	0.51	5.7e-19	Height;
CESC	cis	rs2836974	0.897	rs8133146	chr21:40614298	T/C	cg17971929	chr21:40555470	PSMG1	1.05	15.94	0.7	1.48e-40	Cognitive function;
CESC	cis	rs9649213	0.593	rs6465673	chr7:97968887	C/T	cg24562669	chr7:97807699	LMTK2	0.49	7.18	0.4	7.18e-12	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs780096	0.526	rs2010087	chr2:27637235	C/T	cg22903471	chr2:27725779	GCKR	-0.58	-8.33	-0.46	4.42e-15	Total body bone mineral density;
CESC	cis	rs10752881	1.000	rs4454510	chr1:182982303	A/G	ch.1.3577855R	chr1:183094577	LAMC1	-0.82	-12.84	-0.62	1.14e-29	Colorectal cancer;
CESC	trans	rs9467711	0.606	rs2073527	chr6:26374978	T/C	cg06606381	chr12:133084897	FBRSL1	-0.77	-6.78	-0.38	7.69e-11	Autism spectrum disorder or schizophrenia;
CESC	cis	rs1218582	0.772	rs11264282	chr1:154867370	G/A	cg03351412	chr1:154909251	PMVK	0.67	9.01	0.48	4.07e-17	Prostate cancer;
CESC	cis	rs1005277	0.579	rs2749616	chr10:38510993	A/T	cg25517755	chr10:38738941	LOC399744	-0.49	-6.36	-0.36	8.84e-10	Extrinsic epigenetic age acceleration;
CESC	cis	rs8177253	0.665	rs11921527	chr3:133441167	G/A	cg24879335	chr3:133465180	TF	0.37	6.5	0.37	3.93e-10	Iron status biomarkers;
CESC	cis	rs6089584	0.888	rs6061982	chr20:60620673	C/T	cg24733560	chr20:60626293	TAF4	0.45	6.44	0.37	5.45e-10	Body mass index;
CESC	cis	rs7811142	1.000	rs68116612	chr7:100006493	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.1	13.23	0.63	4.99e-31	Platelet count;
CESC	cis	rs9837602	0.529	rs1087198	chr3:99524381	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.52	-6.21	-0.36	2.05e-9	Breast cancer;
CESC	cis	rs12079745	0.623	rs115415855	chr1:169322993	G/A	cg09363564	chr1:169337483	NME7;BLZF1	-1.18	-6.79	-0.39	7.13e-11	QT interval;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg15272186	chr6:29709610	LOC285830	-0.44	-6.5	-0.37	3.86e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs4727027	0.901	rs1137432	chr7:148801658	C/T	cg23583168	chr7:148888333	NA	-0.78	-11.97	-0.59	1.14e-26	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs55823223	0.648	rs936394	chr17:73852008	C/A	cg06969265	chr17:73775802	H3F3B	0.63	6.82	0.39	6.03e-11	Psoriasis;
CESC	trans	rs11039798	0.614	rs116427493	chr11:48776141	C/T	cg15704280	chr7:45808275	SEPT13	0.72	6.56	0.37	2.79e-10	Axial length;
CESC	cis	rs6540556	0.723	rs9430016	chr1:209916884	A/G	cg05527609	chr1:210001259	C1orf107	-0.45	-5.59	-0.32	5.66e-8	Red blood cell count;
CESC	cis	rs67311347	1.000	rs12488805	chr3:40422869	C/T	cg24209194	chr3:40518798	ZNF619	0.5	6.05	0.35	4.91e-9	Renal cell carcinoma;
CESC	cis	rs7580658	0.637	rs12463909	chr2:127971738	C/G	cg10021288	chr2:128175891	PROC	0.33	5.07	0.3	7.31e-7	Protein C levels;
CESC	cis	rs4819052	0.851	rs2838848	chr21:46671017	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.45	5.6	0.33	5.33e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs2742234	0.541	rs10793424	chr10:43717116	G/T	cg07801480	chr10:43725741	RASGEF1A	-0.4	-5.24	-0.31	3.22e-7	Hirschsprung disease;
CESC	cis	rs367943	0.712	rs9326884	chr5:112697520	C/A	cg12552261	chr5:112820674	MCC	0.43	5.58	0.32	6.06e-8	Type 2 diabetes;
CESC	cis	rs2228479	0.618	rs62052174	chr16:89950901	G/A	cg00800038	chr16:89945340	TCF25	-0.88	-7.85	-0.43	1.01e-13	Skin colour saturation;
CESC	cis	rs3008870	0.629	rs12742428	chr1:67426487	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.63	8.34	0.46	4.16e-15	Lymphocyte percentage of white cells;
CESC	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-6.07	-0.35	4.4e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs992157	0.710	rs13026485	chr2:219057984	C/T	cg00012203	chr2:219082015	ARPC2	-0.83	-11.41	-0.57	8.64e-25	Colorectal cancer;
CESC	cis	rs7264396	0.635	rs6058366	chr20:34512172	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.58	7.06	0.4	1.44e-11	Total cholesterol levels;
CESC	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg23978390	chr7:1156363	C7orf50	0.62	8.9	0.48	9.25e-17	Longevity;Endometriosis;
CESC	cis	rs116095464	0.614	rs78905930	chr5:246560	G/A	cg20965017	chr5:231967	SDHA	-0.47	-5.23	-0.31	3.53e-7	Breast cancer;
CESC	cis	rs9549367	0.789	rs71446679	chr13:113894821	C/T	cg00898013	chr13:113819073	PROZ	-0.51	-6.94	-0.39	3.06e-11	Platelet distribution width;
CESC	cis	rs2204008	0.837	rs8189467	chr12:38241956	T/C	cg26384229	chr12:38710491	ALG10B	0.64	8.89	0.48	9.98e-17	Bladder cancer;
CESC	cis	rs11098499	0.779	rs10011097	chr4:120310359	T/G	cg24375607	chr4:120327624	NA	0.46	5.55	0.32	6.98e-8	Corneal astigmatism;
CESC	cis	rs9291683	0.620	rs11722946	chr4:10125990	A/G	cg00071950	chr4:10020882	SLC2A9	-0.56	-8.45	-0.46	1.97e-15	Bone mineral density;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20376421	chr12:56546193	MYL6B	0.61	7.34	0.41	2.57e-12	Gut microbiome composition (summer);
CESC	cis	rs782590	0.967	rs1084522	chr2:55843294	A/G	cg18811423	chr2:55921094	PNPT1	0.81	13.24	0.63	4.56e-31	Metabolic syndrome;
CESC	cis	rs959260	1.000	rs4788892	chr17:73391277	A/G	cg20590849	chr17:73267439	MIF4GD	-0.55	-6.35	-0.36	9.37e-10	Systemic lupus erythematosus;
CESC	cis	rs11098499	0.754	rs2036857	chr4:120249240	T/C	cg09307838	chr4:120376055	NA	0.77	10.35	0.54	2.54e-21	Corneal astigmatism;
CESC	cis	rs9814567	1.000	rs7429866	chr3:134236306	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.45	6.08	0.35	4.15e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs1670533	1.000	rs2290408	chr4:1067267	A/C	cg04106633	chr4:1044584	NA	-0.4	-5.25	-0.31	3.14e-7	Recombination rate (females);
CESC	cis	rs3857536	0.813	rs62415859	chr6:66934278	G/A	cg07460842	chr6:66804631	NA	-0.42	-5.34	-0.31	1.96e-7	Blood trace element (Cu levels);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg06934023	chr16:587828	SOLH	0.44	6.19	0.36	2.28e-9	Fibrinogen levels;
CESC	cis	rs896854	0.812	rs12546365	chr8:95911477	T/C	cg09323728	chr8:95962352	TP53INP1	-0.41	-8.97	-0.48	5.73e-17	Type 2 diabetes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25790695	chr6:155635567	TFB1M	0.61	7.09	0.4	1.2e-11	Gut microbiome composition (summer);
CESC	cis	rs6061231	0.740	rs11698650	chr20:60958374	A/T	cg22633769	chr20:60982531	CABLES2	0.54	7.01	0.4	2e-11	Colorectal cancer;
CESC	cis	rs4853012	0.838	rs6707729	chr2:74344685	G/A	cg19729930	chr2:74357872	NA	0.86	12.98	0.62	3.73e-30	Gestational age at birth (maternal effect);
CESC	cis	rs6121246	0.529	rs112367115	chr20:30178627	G/A	cg13852791	chr20:30311386	BCL2L1	0.61	5.83	0.34	1.62e-8	Mean corpuscular hemoglobin;
CESC	trans	rs4843747	0.671	rs8053377	chr16:88106465	A/G	cg26811252	chr16:29126840	RRN3P2	0.67	9.25	0.49	7.99e-18	Menopause (age at onset);
CESC	cis	rs6912958	0.559	rs242280	chr6:88048714	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.72	10.99	0.56	2.06e-23	Monocyte percentage of white cells;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16298152	chr14:70234662	SFRS5;LOC100289511	-0.61	-6.57	-0.37	2.6200000000000003e-10	Gut microbiome composition (summer);
CESC	cis	rs1552244	0.510	rs13075308	chr3:10034925	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.73	-9.22	-0.49	9.33e-18	Alzheimer's disease;
CESC	cis	rs3617	0.625	rs2240915	chr3:52859526	T/A	cg07507251	chr3:52567010	NT5DC2	0.32	5.54	0.32	7.14e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
CESC	cis	rs6893300	0.826	rs7734102	chr5:179153797	A/G	cg14593053	chr5:179126677	CANX	0.47	5.18	0.3	4.4e-7	Resting heart rate;
CESC	cis	rs2594989	0.945	rs2594969	chr3:11353399	C/G	cg00170343	chr3:11313890	ATG7	0.54	5.48	0.32	9.97e-8	Circulating chemerin levels;
CESC	cis	rs7116495	0.609	rs949324	chr11:71714526	G/C	cg10381502	chr11:71823885	C11orf51	-1.13	-7.93	-0.44	6.3e-14	Severe influenza A (H1N1) infection;
CESC	cis	rs4853012	0.941	rs2421752	chr2:74341615	A/G	cg01017244	chr2:74357527	NA	0.63	8.34	0.46	4.1e-15	Gestational age at birth (maternal effect);
CESC	cis	rs9457247	0.967	rs1794694	chr6:167404751	T/C	cg23791538	chr6:167370224	RNASET2	-0.59	-8.42	-0.46	2.44e-15	Crohn's disease;
CESC	cis	rs1862618	0.853	rs861283	chr5:56184610	C/T	cg22800045	chr5:56110881	MAP3K1	0.81	9.66	0.51	4.1e-19	Initial pursuit acceleration;
CESC	cis	rs847577	0.588	rs6946915	chr7:97711340	C/G	cg24562669	chr7:97807699	LMTK2	0.78	13.35	0.63	1.91e-31	Breast cancer;
CESC	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	22.0	0.8	9.67e-62	Prudent dietary pattern;
CESC	cis	rs453301	0.658	rs3855900	chr8:8901921	A/G	cg06636001	chr8:8085503	FLJ10661	-0.43	-5.25	-0.31	3.08e-7	Joint mobility (Beighton score);
CESC	cis	rs708547	0.581	rs6554400	chr4:57805306	A/C	cg25525207	chr4:57843836	C4orf14;POLR2B	0.44	5.56	0.32	6.69e-8	Response to bleomycin (chromatid breaks);
CESC	cis	rs2932538	0.961	rs2932534	chr1:113200797	A/G	cg22162597	chr1:113214053	CAPZA1	0.57	7.33	0.41	2.88e-12	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CESC	cis	rs7617773	0.539	rs2017859	chr3:48382261	G/A	cg11946769	chr3:48343235	NME6	0.66	8.34	0.46	4.12e-15	Coronary artery disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg05609414	chr7:39873832	NA	0.39	6.26	0.36	1.58e-9	Fibrinogen levels;
CESC	cis	rs9322193	0.923	rs9688517	chr6:150061791	T/C	cg07701084	chr6:150067640	NUP43	0.47	6.61	0.38	2.15e-10	Lung cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23227285	chr7:7676611	RPA3	-0.58	-6.7	-0.38	1.22e-10	Gut microbiome composition (summer);
CESC	cis	rs9308731	0.591	rs7565473	chr2:111943790	G/A	cg04202892	chr2:111875749	ACOXL	0.37	5.17	0.3	4.61e-7	Chronic lymphocytic leukemia;
CESC	cis	rs7771547	0.573	rs547026	chr6:36398616	G/A	cg04289385	chr6:36355825	ETV7	0.38	5.57	0.32	6.36e-8	Platelet distribution width;
CESC	cis	rs67478160	0.643	rs3818085	chr14:104215985	C/T	cg08213375	chr14:104286397	PPP1R13B	0.54	10.89	0.56	4.58e-23	Schizophrenia;
CESC	cis	rs60843830	1.000	rs3791220	chr2:227066	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.79	10.38	0.54	2.05e-21	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs597539	0.652	rs513615	chr11:68705504	G/T	cg01988459	chr11:68622903	NA	-0.48	-6.39	-0.37	7.37e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs7107174	1.000	rs10899489	chr11:78095373	G/T	cg02023728	chr11:77925099	USP35	0.38	5.22	0.31	3.66e-7	Testicular germ cell tumor;
CESC	cis	rs921968	0.529	rs6729341	chr2:219611434	T/G	cg02176678	chr2:219576539	TTLL4	-0.47	-8.43	-0.46	2.28e-15	Mean corpuscular hemoglobin concentration;
CESC	cis	rs7959452	0.535	rs1350166	chr12:69636314	G/T	cg20891283	chr12:69753455	YEATS4	0.75	11.04	0.56	1.42e-23	Blood protein levels;
CESC	cis	rs7980687	0.657	rs2851447	chr12:123665113	G/C	cg05973401	chr12:123451056	ABCB9	0.46	5.75	0.33	2.41e-8	Height;Educational attainment;Head circumference (infant);
CESC	cis	rs9488822	0.676	rs12524249	chr6:116368813	G/A	cg26893134	chr6:116381904	FRK	0.25	6.08	0.35	4.07e-9	Cholesterol, total;LDL cholesterol;
CESC	cis	rs2072499	0.750	rs7534339	chr1:156156219	A/G	cg24450063	chr1:156163899	SLC25A44	0.99	12.16	0.6	2.49e-27	Testicular germ cell tumor;
CESC	cis	rs801193	0.967	rs3800823	chr7:66147110	C/A	cg18876405	chr7:65276391	NA	-0.6	-7.97	-0.44	4.77e-14	Aortic root size;
CESC	trans	rs4332037	0.539	rs34809719	chr7:2028968	G/T	cg11693508	chr17:37793320	STARD3	0.65	6.46	0.37	4.89e-10	Bipolar disorder;
CESC	cis	rs10504229	0.635	rs72649130	chr8:58053810	G/T	cg14926445	chr8:58193284	C8orf71	-0.54	-5.14	-0.3	5.39e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs2732480	0.577	rs1489108	chr12:48738781	G/A	cg04545296	chr12:48745243	ZNF641	0.44	7.29	0.41	3.69e-12	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs1707322	1.000	rs3922887	chr1:46473802	A/G	cg05343316	chr1:45956843	TESK2	0.44	5.35	0.31	1.9e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs709400	1.000	rs6593	chr14:104163282	G/A	cg24130564	chr14:104152367	KLC1	-0.43	-5.41	-0.32	1.4e-7	Body mass index;
CESC	cis	rs17209837	0.646	rs11532733	chr7:87117982	A/G	cg00919237	chr7:87102261	ABCB4	-0.45	-5.66	-0.33	3.9e-8	Gallbladder cancer;
CESC	cis	rs4665809	0.938	rs4665822	chr2:26312555	C/G	cg22920501	chr2:26401640	FAM59B	-0.66	-7.89	-0.44	8.09e-14	Gut microbiome composition (summer);
CESC	cis	rs7539542	0.536	rs12091234	chr1:202855508	C/T	cg19681188	chr1:202830198	LOC148709	0.4	5.12	0.3	5.96e-7	Mean platelet volume;
CESC	cis	rs40363	0.723	rs2736	chr16:3536872	G/A	cg22508957	chr16:3507546	NAT15	-0.68	-7.23	-0.41	5.11e-12	Tuberculosis;
CESC	cis	rs1005277	0.579	rs2505196	chr10:38393563	G/A	cg25517755	chr10:38738941	LOC399744	-0.47	-6.04	-0.35	5.12e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs2842992	0.724	rs2273823	chr6:160211485	T/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.77	11.06	0.56	1.26e-23	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs1799949	0.965	rs11657883	chr17:41330024	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.6	7.84	0.43	1.07e-13	Menopause (age at onset);
CESC	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.71	9.86	0.52	9.92e-20	Prudent dietary pattern;
CESC	cis	rs10504229	1.000	rs3814486	chr8:58191226	A/T	cg14926445	chr8:58193284	C8orf71	-0.51	-5.52	-0.32	8.28e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs3785574	0.962	rs8066463	chr17:61818390	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.58	7.23	0.41	5.1e-12	Height;
CESC	cis	rs4629710	0.592	rs13206776	chr6:131576679	T/G	cg12606694	chr6:131520996	AKAP7	0.48	5.84	0.34	1.51e-8	Multiple myeloma (IgH translocation);
CESC	cis	rs965469	0.779	rs6037546	chr20:3298697	G/T	cg25506879	chr20:3388711	C20orf194	-0.49	-5.39	-0.31	1.59e-7	IFN-related cytopenia;
CESC	cis	rs72781680	1.000	rs72781665	chr2:24223086	G/A	cg08917208	chr2:24149416	ATAD2B	0.94	8.36	0.46	3.58e-15	Lymphocyte counts;
CESC	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg26338869	chr17:61819248	STRADA	0.69	9.15	0.49	1.59e-17	Prudent dietary pattern;
CESC	cis	rs1552244	0.882	rs66559400	chr3:10012551	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.74	-9.37	-0.5	3.35e-18	Alzheimer's disease;
CESC	cis	rs8044868	0.586	rs3844425	chr16:72194325	T/C	cg16558253	chr16:72132732	DHX38	-0.4	-6.12	-0.35	3.31e-9	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CESC	cis	rs9549367	0.789	rs9549365	chr13:113907391	C/T	cg00898013	chr13:113819073	PROZ	0.52	7.42	0.41	1.59e-12	Platelet distribution width;
CESC	cis	rs2797160	0.651	rs9491503	chr6:126031682	G/A	cg05901451	chr6:126070800	HEY2	0.5	7.28	0.41	3.86e-12	Endometrial cancer;
CESC	cis	rs6120849	0.518	rs11696652	chr20:33637060	T/G	cg24642439	chr20:33292090	TP53INP2	0.68	6.77	0.38	8.46e-11	Protein C levels;
CESC	cis	rs2295359	0.892	rs12029362	chr1:67624231	G/A	cg17031739	chr1:67600172	NA	0.4	5.24	0.31	3.23e-7	Psoriasis;
CESC	cis	rs6815814	0.950	rs5743563	chr4:38806019	A/G	cg02016764	chr4:38805732	TLR1	-0.63	-7.26	-0.41	4.22e-12	Breast cancer;
CESC	cis	rs2404602	0.647	rs11072612	chr15:76960984	A/T	cg23625390	chr15:77176239	SCAPER	-0.41	-5.59	-0.32	5.64e-8	Blood metabolite levels;
CESC	cis	rs9291683	0.530	rs998675	chr4:9948829	A/G	cg11266682	chr4:10021025	SLC2A9	0.6	12.13	0.6	3.18e-27	Bone mineral density;
CESC	cis	rs7188697	0.922	rs9924805	chr16:58615659	T/C	cg02549819	chr16:58548995	SETD6	0.44	5.43	0.32	1.26e-7	QT interval;
CESC	cis	rs920590	0.758	rs7012358	chr8:19662498	C/T	cg01411142	chr8:19674711	INTS10	0.52	5.8	0.34	1.91e-8	Acute lymphoblastic leukemia (childhood);
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg26734912	chr5:128430241	ISOC1	-0.51	-6.53	-0.37	3.35e-10	Asthma;
CESC	cis	rs2708240	1.000	rs7806512	chr7:147574555	C/T	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.37	-6.13	-0.35	3.19e-9	QT interval (drug interaction);
CESC	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg03188948	chr7:1209495	NA	0.7	7.76	0.43	1.82e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04486506	chr20:62577863	UCKL1	-0.54	-6.26	-0.36	1.52e-9	Gut microbiome composition (summer);
CESC	cis	rs11608355	0.597	rs12579285	chr12:109832712	T/C	cg19025524	chr12:109796872	NA	-0.55	-7.83	-0.43	1.17e-13	Neuroticism;
CESC	cis	rs1799949	0.965	rs6503726	chr17:41284742	T/C	cg23758822	chr17:41437982	NA	0.96	16.37	0.71	4.19e-42	Menopause (age at onset);
CESC	cis	rs9457247	0.967	rs425039	chr6:167410527	C/T	cg23791538	chr6:167370224	RNASET2	-0.61	-8.81	-0.48	1.71e-16	Crohn's disease;
CESC	cis	rs425277	1.000	rs427811	chr1:2075560	T/G	cg04315214	chr1:2043799	PRKCZ	-0.39	-5.47	-0.32	1.04e-7	Height;
CESC	cis	rs7552404	0.731	rs5745445	chr1:76344332	G/A	cg22875332	chr1:76189707	ACADM	0.6	5.89	0.34	1.19e-8	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs2576037	0.545	rs9948405	chr18:44494527	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.78	12.92	0.62	6.22e-30	Personality dimensions;
CESC	cis	rs4665809	0.590	rs35727620	chr2:26458364	G/A	cg22920501	chr2:26401640	FAM59B	0.91	10.33	0.54	3.07e-21	Gut microbiome composition (summer);
CESC	cis	rs3857067	1.000	rs1588381	chr4:95017558	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.52	-8.04	-0.44	3.05e-14	QT interval;
CESC	cis	rs4595586	0.545	rs925829	chr12:39364167	A/G	cg26384229	chr12:38710491	ALG10B	0.54	7.54	0.42	7.28e-13	Morning vs. evening chronotype;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10657806	chr12:117348826	FBXW8	0.53	6.25	0.36	1.61e-9	Gut microbiome composition (summer);
CESC	cis	rs13108904	0.557	rs1250097	chr4:1238338	C/T	cg19318889	chr4:1322082	MAEA	-0.46	-6.0	-0.35	6.58e-9	Obesity-related traits;
CESC	cis	rs7618915	0.547	rs11130313	chr3:52676190	A/C	cg17372223	chr3:52568218	NT5DC2	0.43	6.51	0.37	3.76e-10	Bipolar disorder;
CESC	cis	rs1707322	0.685	rs56177313	chr1:46225806	A/C	cg06784218	chr1:46089804	CCDC17	0.41	7.22	0.41	5.64e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7772486	0.712	rs6570726	chr6:146159460	T/C	cg23711669	chr6:146136114	FBXO30	0.7	10.39	0.54	1.98e-21	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6775745	0.654	rs9289414	chr3:131785226	C/T	cg12213930	chr3:131751605	CPNE4	0.46	5.19	0.3	4.09e-7	Neutrophil count;
CESC	cis	rs2549003	1.000	rs2070723	chr5:131823187	A/G	cg02551604	chr5:131831745	NA	-0.38	-5.39	-0.31	1.6e-7	Asthma (sex interaction);
CESC	cis	rs6088590	0.931	rs6088617	chr20:33408036	G/A	cg08999081	chr20:33150536	PIGU	0.59	8.94	0.48	6.65e-17	Coronary artery disease;
CESC	cis	rs6598163	0.712	rs10751695	chr12:132291061	A/C	cg04876069	chr12:132293656	NA	-0.41	-5.65	-0.33	4.12e-8	Migraine;
CESC	cis	rs4660306	0.677	rs781059	chr1:45934562	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.48	-5.27	-0.31	2.84e-7	Homocysteine levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22794378	chr14:89029563	ZC3H14	0.54	6.02	0.35	5.88e-9	Gut microbiome composition (summer);
CESC	cis	rs7772486	0.790	rs9497427	chr6:146238302	T/A	cg05347473	chr6:146136440	FBXO30	-0.53	-6.92	-0.39	3.46e-11	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs116095464	0.558	rs6882584	chr5:223411	A/C	cg00938859	chr5:1591904	SDHAP3	0.6	6.66	0.38	1.55e-10	Breast cancer;
CESC	cis	rs634534	0.622	rs531612	chr11:65705432	C/T	cg04055107	chr11:65626734	MUS81;CFL1	-0.55	-6.75	-0.38	9.5e-11	Sum eosinophil basophil counts;Eosinophil counts;
CESC	cis	rs10788264	0.504	rs7090214	chr10:124036494	T/C	cg09507567	chr10:124027408	NA	0.38	5.29	0.31	2.52e-7	Total body bone mineral density;
CESC	cis	rs2635047	1.000	rs2635045	chr18:44668417	T/C	cg19077165	chr18:44547161	KATNAL2	-0.42	-5.67	-0.33	3.8e-8	Educational attainment;
CESC	cis	rs7666738	0.830	rs6532721	chr4:99048015	G/A	cg24818145	chr4:99064322	C4orf37	0.38	5.04	0.3	8.49e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1538970	0.961	rs7543428	chr1:45839643	A/G	cg06784218	chr1:46089804	CCDC17	0.36	6.12	0.35	3.44e-9	Platelet count;
CESC	cis	rs2249625	0.523	rs2463702	chr6:72853778	A/G	cg18830697	chr6:72922368	RIMS1	0.41	6.2	0.36	2.15e-9	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CESC	cis	rs9311474	0.508	rs7652191	chr3:52610415	T/C	cg17372223	chr3:52568218	NT5DC2	0.41	6.27	0.36	1.43e-9	Electroencephalogram traits;
CESC	cis	rs9399135	0.933	rs7755680	chr6:135294259	A/G	cg22676075	chr6:135203613	NA	0.52	7.21	0.4	5.94e-12	Red blood cell count;
CESC	cis	rs4132509	0.947	rs10927041	chr1:243731890	T/C	cg21452805	chr1:244014465	NA	0.45	5.37	0.31	1.7e-7	RR interval (heart rate);
CESC	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.48	-5.2	-0.3	4.05e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs4253772	0.637	rs56017104	chr22:46651982	A/G	cg24881330	chr22:46731750	TRMU	0.77	6.19	0.36	2.26e-9	LDL cholesterol;Cholesterol, total;
CESC	cis	rs56011263	0.687	rs4690293	chr4:706101	A/G	cg20735989	chr4:730612	PCGF3	-0.59	-7.13	-0.4	9.63e-12	White blood cell count;
CESC	cis	rs4665809	0.525	rs10865402	chr2:26535383	A/G	cg22920501	chr2:26401640	FAM59B	-0.44	-5.38	-0.31	1.61e-7	Gut microbiome composition (summer);
CESC	cis	rs9611565	0.625	rs9607819	chr22:41958862	C/G	cg06481639	chr22:41940642	POLR3H	-0.55	-6.01	-0.35	6.05e-9	Vitiligo;
CESC	cis	rs11098499	0.909	rs17046118	chr4:120387496	T/G	cg09307838	chr4:120376055	NA	0.95	13.96	0.65	1.42e-33	Corneal astigmatism;
CESC	cis	rs2439831	0.850	rs2439832	chr15:43779686	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.82	11.58	0.58	2.38e-25	Lung cancer in ever smokers;
CESC	cis	rs9623117	0.915	rs11704416	chr22:40436973	G/C	cg05033341	chr22:40419857	FAM83F	-0.49	-5.4	-0.31	1.5e-7	Prostate cancer (SNP x SNP interaction);Prostate cancer;
CESC	cis	rs4268898	0.662	rs56006260	chr2:24409903	A/G	cg08917208	chr2:24149416	ATAD2B	0.58	5.39	0.31	1.58e-7	Asthma;
CESC	cis	rs7618915	0.524	rs12488461	chr3:52698417	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.49	7.11	0.4	1.05e-11	Bipolar disorder;
CESC	cis	rs2282802	0.685	rs7737543	chr5:139646026	A/G	cg26211634	chr5:139558579	C5orf32	0.51	7.45	0.42	1.3e-12	Intelligence (multi-trait analysis);
CESC	cis	rs17253792	0.822	rs17685053	chr14:56125771	T/A	cg01858014	chr14:56050164	KTN1	-0.71	-6.21	-0.36	2.02e-9	Putamen volume;
CESC	cis	rs1475911	0.708	rs11701371	chr21:43523972	C/G	cg19766460	chr21:43528205	UMODL1;C21orf128	0.98	13.93	0.65	1.84e-33	IgG glycosylation;
CESC	cis	rs5769765	0.908	rs138864	chr22:50204712	G/A	cg02269571	chr22:50332266	NA	-0.42	-5.35	-0.31	1.92e-7	Schizophrenia;
CESC	cis	rs853679	0.517	rs6941992	chr6:28106141	T/C	cg12963246	chr6:28129442	ZNF389	0.57	7.78	0.43	1.65e-13	Depression;
CESC	cis	rs6460942	0.556	rs2287067	chr7:12370533	T/C	cg06484146	chr7:12443880	VWDE	-0.51	-7.22	-0.41	5.49e-12	Coronary artery disease;
CESC	cis	rs9787249	0.874	rs12094291	chr1:40226046	G/A	cg02773041	chr1:40204384	PPIE	0.53	7.37	0.41	2.13e-12	Blood protein levels;
CESC	trans	rs11039798	1.000	rs7928243	chr11:48589192	A/T	cg15704280	chr7:45808275	SEPT13	0.7	6.57	0.37	2.68e-10	Axial length;
CESC	cis	rs7017914	0.935	rs56289931	chr8:71837754	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.43	-5.46	-0.32	1.09e-7	Bone mineral density;
CESC	cis	rs2832191	0.720	rs2832200	chr21:30499165	G/A	cg24692254	chr21:30365293	RNF160	-0.79	-12.11	-0.6	3.71e-27	Dental caries;
CESC	cis	rs7615952	0.599	rs2279821	chr3:125734308	G/A	cg04553112	chr3:125709451	NA	-0.49	-5.27	-0.31	2.77e-7	Blood pressure (smoking interaction);
CESC	cis	rs6840360	0.967	rs7695162	chr4:152510541	G/A	cg22705602	chr4:152727874	NA	-0.35	-5.2	-0.3	4.01e-7	Intelligence (multi-trait analysis);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg24701985	chr7:149535383	ZNF862	0.5	6.48	0.37	4.52e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs55692468	0.606	rs1878632	chr2:153323158	A/C	cg04681845	chr2:153283485	FMNL2	-0.28	-5.73	-0.33	2.76e-8	Intraocular pressure;
CESC	cis	rs7662987	0.793	rs28730632	chr4:99995703	G/A	cg13256891	chr4:100009986	ADH5	-0.59	-5.12	-0.3	5.89e-7	Smoking initiation;
CESC	cis	rs7772486	0.686	rs10872579	chr6:145966012	C/G	cg23711669	chr6:146136114	FBXO30	0.8	11.21	0.57	4.03e-24	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs11190604	1.000	rs9420785	chr10:102240451	C/G	cg07080220	chr10:102295463	HIF1AN	0.56	5.54	0.32	7.32e-8	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs7914558	0.966	rs12569617	chr10:104729996	T/C	cg15744005	chr10:104629667	AS3MT	-0.34	-5.31	-0.31	2.32e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs2839186	0.609	rs2839189	chr21:47694357	C/T	cg09417038	chr21:47716443	C21orf57	0.44	6.22	0.36	1.94e-9	Testicular germ cell tumor;
CESC	cis	rs977987	0.800	rs11645329	chr16:75336679	C/G	cg03315344	chr16:75512273	CHST6	0.39	5.48	0.32	1.01e-7	Dupuytren's disease;
CESC	cis	rs1799949	1.000	rs4793197	chr17:41231902	C/T	cg25072359	chr17:41440525	NA	0.47	6.18	0.36	2.36e-9	Menopause (age at onset);
CESC	cis	rs11030122	0.702	rs12281293	chr11:3963814	C/T	cg18678763	chr11:4115507	RRM1	-0.5	-6.64	-0.38	1.78e-10	Mean platelet volume;Platelet distribution width;
CESC	trans	rs7246657	0.943	rs8106839	chr19:37958475	C/G	cg01833234	chr11:6592585	DNHD1	0.53	6.03	0.35	5.61e-9	Coronary artery calcification;
CESC	cis	rs4969178	0.622	rs4129767	chr17:76403984	G/A	cg05887092	chr17:76393375	PGS1	0.7	11.6	0.58	1.94e-25	HDL cholesterol levels;
CESC	cis	rs8067545	0.717	rs34401389	chr17:19989436	A/T	cg13482628	chr17:19912719	NA	0.39	5.34	0.31	1.97e-7	Schizophrenia;
CESC	cis	rs6120849	0.901	rs6060266	chr20:33733078	T/C	cg24642439	chr20:33292090	TP53INP2	0.62	6.56	0.37	2.84e-10	Protein C levels;
CESC	cis	rs7178572	0.568	rs7167794	chr15:77635875	T/C	cg22256960	chr15:77711686	NA	-0.54	-6.86	-0.39	4.9e-11	Type 2 diabetes;
CESC	cis	rs853679	0.574	rs1233705	chr6:28166447	C/G	cg23281280	chr6:28129359	ZNF389	0.5	6.98	0.39	2.39e-11	Depression;
CESC	cis	rs16867321	0.951	rs13413574	chr2:181364491	A/G	cg23363182	chr2:181467187	NA	-0.41	-5.13	-0.3	5.65e-7	Obesity;
CESC	trans	rs6572548	0.504	rs1956082	chr14:49665496	A/C	cg08448040	chr3:13521693	HDAC11	-0.56	-6.29	-0.36	1.28e-9	Subjective well-being;
CESC	cis	rs7208859	0.573	rs8078182	chr17:29149664	C/T	cg19761014	chr17:28927070	LRRC37B2	0.63	6.26	0.36	1.52e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14309501	chr19:17445715	ANO8	0.58	6.68	0.38	1.44e-10	Gut microbiome composition (summer);
CESC	cis	rs826838	0.967	rs6580726	chr12:39108623	T/C	cg13010199	chr12:38710504	ALG10B	-0.42	-5.9	-0.34	1.13e-8	Heart rate;
CESC	cis	rs6831352	0.760	rs2602859	chr4:100030583	G/A	cg13256891	chr4:100009986	ADH5	0.75	8.03	0.44	3.29e-14	Alcohol dependence;
CESC	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg07157834	chr1:205819609	PM20D1	-0.55	-8.38	-0.46	3.13e-15	Monocyte percentage of white cells;
CESC	cis	rs4253772	0.591	rs11703848	chr22:46685131	A/G	cg10541313	chr22:46663664	TTC38	0.72	5.15	0.3	5.01e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs13191362	0.507	rs2849525	chr6:163126652	A/C	cg21926612	chr6:163149169	PACRG;PARK2	-0.56	-6.67	-0.38	1.47e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs7560272	0.538	rs12053242	chr2:73937168	G/A	cg20560298	chr2:73613845	ALMS1	0.42	5.8	0.34	1.87e-8	Schizophrenia;
CESC	cis	rs763014	0.966	rs7185390	chr16:666382	A/G	cg09263875	chr16:632152	PIGQ	0.67	11.4	0.57	9.36e-25	Height;
CESC	cis	rs9486715	0.867	rs2475025	chr6:96988696	A/T	cg18709589	chr6:96969512	KIAA0776	-0.46	-6.43	-0.37	5.85e-10	Headache;
CESC	cis	rs977987	0.806	rs11862095	chr16:75385418	T/A	cg03315344	chr16:75512273	CHST6	0.42	6.12	0.35	3.44e-9	Dupuytren's disease;
CESC	cis	rs317689	0.680	rs315140	chr12:69790780	A/T	cg20891283	chr12:69753455	YEATS4	0.61	7.06	0.4	1.47e-11	Response to diuretic therapy;
CESC	cis	rs6500395	0.963	rs4785248	chr16:48687947	A/G	cg04672837	chr16:48644449	N4BP1	-0.51	-6.36	-0.36	8.64e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs854765	0.547	rs4643387	chr17:17972973	C/T	cg04398451	chr17:18023971	MYO15A	-0.69	-9.75	-0.51	2.14e-19	Total body bone mineral density;
CESC	cis	rs1865760	0.566	rs4529296	chr6:26083135	C/G	cg17691542	chr6:26056736	HIST1H1C	0.42	5.57	0.32	6.13e-8	Height;
CESC	cis	rs60871478	0.947	rs62432862	chr7:807719	G/C	cg27478167	chr7:817139	HEATR2	-0.47	-5.61	-0.33	5.18e-8	Cerebrospinal P-tau181p levels;
CESC	cis	rs6540559	0.543	rs650728	chr1:210433351	C/T	cg25204440	chr1:209979598	IRF6	0.49	5.14	0.3	5.28e-7	Cleft lip with or without cleft palate;
CESC	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.44	-5.56	-0.32	6.47e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs870825	0.616	rs7683799	chr4:185632164	T/C	cg04058563	chr4:185651563	MLF1IP	0.63	6.91	0.39	3.51e-11	Blood protein levels;
CESC	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg21280719	chr6:42927975	GNMT	-0.32	-7.33	-0.41	2.81e-12	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs2842992	0.789	rs3818300	chr6:160201677	G/A	cg11366901	chr6:160182831	ACAT2	0.8	10.07	0.53	2.14e-20	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs1348850	0.632	rs4470372	chr2:178505857	G/A	cg23306229	chr2:178417860	TTC30B	0.59	7.38	0.41	2.07e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg11143796	chr4:178363279	AGA	-0.48	-6.23	-0.36	1.8e-9	Ulcerative colitis;
CESC	cis	rs17376456	0.569	rs6881815	chr5:93105666	A/G	cg21475434	chr5:93447410	FAM172A	0.49	5.04	0.3	8.6e-7	Diabetic retinopathy;
CESC	cis	rs6499255	0.903	rs1800566	chr16:69745145	C/T	cg15192750	chr16:69999425	NA	0.53	6.21	0.36	2.03e-9	IgE levels;
CESC	cis	rs7772486	0.790	rs2253768	chr6:146199922	A/G	cg05347473	chr6:146136440	FBXO30	0.58	7.36	0.41	2.25e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs875971	0.862	rs6958294	chr7:65794796	C/A	cg11764359	chr7:65958608	NA	-0.78	-11.56	-0.58	2.78e-25	Aortic root size;
CESC	cis	rs34779708	0.766	rs35308730	chr10:35549796	C/T	cg03585969	chr10:35415529	CREM	0.54	6.14	0.35	2.97e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs1218582	0.741	rs4339857	chr1:154888962	A/G	cg24250549	chr1:154909240	PMVK	0.75	11.18	0.57	5.12e-24	Prostate cancer;
CESC	cis	rs9549260	0.617	rs9549266	chr13:41278409	C/G	cg21288729	chr13:41239152	FOXO1	0.58	5.06	0.3	8e-7	Red blood cell count;
CESC	cis	rs12477438	0.539	rs12999417	chr2:99865548	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.78	-12.75	-0.62	2.32e-29	Chronic sinus infection;
CESC	trans	rs2018683	0.707	rs2057957	chr7:28974626	A/C	cg19402173	chr7:128379420	CALU	0.51	6.66	0.38	1.55e-10	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CESC	cis	rs9311474	0.507	rs4687644	chr3:52746541	T/G	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	5.81	0.34	1.79e-8	Electroencephalogram traits;
CESC	cis	rs11048434	0.736	rs1805724	chr12:9104609	T/C	cg04155231	chr12:9217510	LOC144571	0.32	5.06	0.3	7.88e-7	Sjögren's syndrome;
CESC	cis	rs2797160	1.000	rs1739362	chr6:126020703	A/T	cg05901451	chr6:126070800	HEY2	0.45	6.5	0.37	3.9e-10	Endometrial cancer;
CESC	trans	rs916888	0.610	rs199529	chr17:44837217	A/C	cg01341218	chr17:43662625	NA	0.68	8.74	0.47	2.68e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs5750830	0.649	rs5750814	chr22:39797987	T/C	cg02038168	chr22:39784481	NA	-0.64	-8.25	-0.45	7.52e-15	Intelligence (multi-trait analysis);
CESC	cis	rs7116495	1.000	rs675185	chr11:71775572	T/G	cg26138937	chr11:71823887	C11orf51	-0.83	-6.95	-0.39	2.81e-11	Severe influenza A (H1N1) infection;
CESC	cis	rs4728302	0.838	rs10225115	chr7:133591435	C/T	cg10665199	chr7:133106180	EXOC4	0.38	5.32	0.31	2.16e-7	Intelligence;Intelligence (multi-trait analysis);
CESC	cis	rs11758351	0.660	rs16891443	chr6:26221937	A/C	cg23601095	chr6:26197514	HIST1H3D	0.91	9.96	0.52	4.64e-20	Gout;Renal underexcretion gout;
CESC	trans	rs4824093	0.545	rs58876234	chr22:50258868	G/A	cg09872104	chr7:134855509	C7orf49	-0.97	-6.92	-0.39	3.45e-11	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs12586317	0.508	rs8015350	chr14:35635230	A/T	cg16230307	chr14:35515116	FAM177A1	0.4	5.04	0.3	8.74e-7	Psoriasis;
CESC	cis	rs35110281	0.641	rs9978858	chr21:45085552	A/G	cg04455712	chr21:45112962	RRP1B	0.49	7.11	0.4	1.06e-11	Mean corpuscular volume;
CESC	cis	rs12136530	0.774	rs10442634	chr1:19775246	C/T	cg01832549	chr1:19774989	CAPZB	-0.47	-6.84	-0.39	5.52e-11	Lead levels in blood;
CESC	cis	rs56104184	0.775	rs73061699	chr19:49400511	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.6	-5.99	-0.35	6.95e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	cis	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg02951883	chr7:2050386	MAD1L1	-0.55	-7.16	-0.4	8.05e-12	Bipolar disorder and schizophrenia;
CESC	cis	rs9487051	0.837	rs6568561	chr6:109592909	A/G	cg01475377	chr6:109611718	NA	-0.51	-8.56	-0.47	9.09e-16	Reticulocyte fraction of red cells;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22137448	chr16:2318988	RNPS1	0.57	6.65	0.38	1.68e-10	Gut microbiome composition (summer);
CESC	cis	rs2835872	0.733	rs1787393	chr21:39035934	G/A	cg06728970	chr21:39037746	KCNJ6	0.3	5.57	0.32	6.13e-8	Electroencephalographic traits in alcoholism;
CESC	cis	rs6463523	0.933	rs4724821	chr7:762544	C/T	cg11064039	chr7:766100	PRKAR1B;HEATR2	1.02	16.49	0.71	1.54e-42	Subjective well-being;
CESC	cis	rs9322193	0.923	rs12176034	chr6:150121693	C/T	cg13206674	chr6:150067644	NUP43	0.41	5.68	0.33	3.52e-8	Lung cancer;
CESC	cis	rs2549003	1.000	rs2070728	chr5:131819977	C/T	cg02551604	chr5:131831745	NA	-0.37	-5.22	-0.31	3.53e-7	Asthma (sex interaction);
CESC	cis	rs10791097	0.694	rs7106684	chr11:130758153	A/T	cg12179176	chr11:130786555	SNX19	0.65	10.09	0.53	1.76e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs225245	0.817	rs225302	chr17:33922396	C/T	cg05299278	chr17:33885742	SLFN14	0.38	5.39	0.31	1.57e-7	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
CESC	cis	rs644799	1.000	rs474252	chr11:95619292	G/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	12.04	0.59	6.53e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs9929218	1.000	rs67359183	chr16:68814204	T/C	cg02972257	chr16:68554789	NA	0.48	5.71	0.33	2.96e-8	Colorectal cancer;
CESC	cis	rs7208859	0.673	rs216410	chr17:28903831	C/G	cg19761014	chr17:28927070	LRRC37B2	-0.7	-7.07	-0.4	1.35e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg25781121	chr3:48282641	ZNF589	-0.52	-6.55	-0.37	3.03e-10	Fibrinogen levels;
CESC	cis	rs2842992	0.724	rs1128670	chr6:160211636	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.77	11.06	0.56	1.26e-23	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs4594175	0.926	rs10138269	chr14:51615360	T/C	cg23942311	chr14:51606299	NA	0.39	5.95	0.34	8.64e-9	Cancer;
CESC	cis	rs79387448	0.655	rs77763678	chr2:102916749	G/A	cg09003973	chr2:102972529	NA	1.06	7.88	0.44	8.27e-14	Gut microbiota (bacterial taxa);
CESC	cis	rs656900	0.647	rs600671	chr15:80117232	A/G	cg02196730	chr15:80188777	MTHFS	0.4	5.21	0.3	3.75e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs9399137	0.507	rs35571217	chr6:135290355	T/C	cg22676075	chr6:135203613	NA	0.53	7.0	0.39	2.14e-11	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	cis	rs6963495	0.649	rs1706888	chr7:105149176	A/G	cg19920283	chr7:105172520	RINT1	0.53	6.19	0.36	2.3e-9	Bipolar disorder (body mass index interaction);
CESC	cis	rs17253792	0.732	rs79014965	chr14:56117551	T/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.8	5.65	0.33	4.2e-8	Putamen volume;
CESC	cis	rs6502050	0.835	rs4789665	chr17:80168097	A/C	cg23985595	chr17:80112537	CCDC57	-0.4	-6.27	-0.36	1.45e-9	Life satisfaction;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03330302	chr2:26468406	HADHA;HADHB	-0.55	-6.56	-0.37	2.88e-10	Gut microbiome composition (summer);
CESC	trans	rs3780486	0.881	rs10738906	chr9:33135634	T/C	cg04842962	chr6:43655489	MRPS18A	1.0	19.15	0.76	6.75e-52	IgG glycosylation;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03603505	chr12:122839920	CLIP1	-0.52	-6.04	-0.35	5.22e-9	Gut microbiome composition (summer);
CESC	cis	rs863345	0.604	rs879635	chr1:158462908	C/T	cg12129480	chr1:158549410	OR10X1	-0.35	-6.97	-0.39	2.53e-11	Pneumococcal bacteremia;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg00524296	chr16:88928681	PABPN1L	0.43	6.52	0.37	3.47e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs17253792	0.822	rs77555779	chr14:56078430	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.76	5.39	0.31	1.56e-7	Putamen volume;
CESC	cis	rs736408	0.812	rs9324	chr3:52825585	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.43	5.76	0.33	2.28e-8	Bipolar disorder;
CESC	cis	rs4589502	0.841	rs55855162	chr15:67140523	C/A	cg12317470	chr15:67143691	NA	0.75	6.84	0.39	5.53e-11	Lung cancer (smoking interaction);
CESC	cis	rs11785400	0.928	rs2280878	chr8:143722366	G/A	cg24634471	chr8:143751801	JRK	0.45	5.83	0.34	1.6e-8	Schizophrenia;
CESC	cis	rs10256972	0.524	rs6945202	chr7:1116558	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.33	-5.06	-0.3	7.93e-7	Longevity;Endometriosis;
CESC	cis	rs873946	0.504	rs12775990	chr10:134575836	C/T	cg27286337	chr10:134555280	INPP5A	0.71	8.26	0.45	6.86e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs9911578	1.000	rs9901114	chr17:56575208	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	-0.4	-5.35	-0.31	1.88e-7	Intelligence (multi-trait analysis);
CESC	cis	rs965469	0.779	rs6051740	chr20:3301165	T/C	cg25506879	chr20:3388711	C20orf194	-0.49	-5.41	-0.32	1.44e-7	IFN-related cytopenia;
CESC	cis	rs10256972	0.967	rs1881122	chr7:1040946	A/T	cg00431813	chr7:1051703	C7orf50	-0.35	-5.46	-0.32	1.09e-7	Longevity;Endometriosis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02372056	chr11:64684731	ATG2A	-0.61	-6.63	-0.38	1.88e-10	Gut microbiome composition (summer);
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg06714086	chr11:33182787	CSTF3	-0.47	-6.17	-0.35	2.6e-9	Height;
CESC	trans	rs6035275	1.000	rs7267420	chr20:19320392	A/G	cg17643624	chr13:111281037	CARKD	0.75	6.0	0.35	6.52e-9	QT interval (sulfonylurea treatment interaction);
CESC	cis	rs7552404	1.000	rs28602663	chr1:76235355	C/T	cg22875332	chr1:76189707	ACADM	0.48	5.56	0.32	6.54e-8	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs2032447	0.714	rs129129	chr6:25961029	A/G	cg18357526	chr6:26021779	HIST1H4A	0.6	8.28	0.45	6.17e-15	Intelligence (multi-trait analysis);
CESC	cis	rs6460942	0.597	rs4721108	chr7:12535247	C/T	cg20607287	chr7:12443886	VWDE	-0.72	-7.71	-0.43	2.51e-13	Coronary artery disease;
CESC	cis	rs17666538	0.591	rs2878547	chr8:603416	G/A	cg26554054	chr8:600488	NA	0.6	5.14	0.3	5.37e-7	IgG glycosylation;
CESC	cis	rs9649213	0.614	rs3944111	chr7:98005766	C/T	cg09267113	chr7:98030324	BAIAP2L1	-0.44	-6.06	-0.35	4.75e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs2243480	0.901	rs35087093	chr7:65405208	C/T	cg12463550	chr7:65579703	CRCP	0.7	5.58	0.32	5.87e-8	Diabetic kidney disease;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03560797	chr7:106301641	FLJ36031	0.48	6.42	0.37	6.13e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs1005277	0.579	rs116912400	chr10:38479207	G/T	cg00409905	chr10:38381863	ZNF37A	-0.47	-6.33	-0.36	1.04e-9	Extrinsic epigenetic age acceleration;
CESC	trans	rs9951602	0.512	rs9946115	chr18:76654531	A/C	cg02800362	chr5:177631904	HNRNPAB	0.66	8.63	0.47	5.9e-16	Obesity-related traits;
CESC	cis	rs7208859	0.673	rs216409	chr17:28906269	C/T	cg17105886	chr17:28927953	LRRC37B2	-0.58	-5.22	-0.31	3.55e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	trans	rs1977584	0.573	rs1325161	chr10:45396569	G/T	cg09262100	chr14:103416268	CDC42BPB	0.61	6.14	0.35	3.02e-9	Selective IgA deficiency;
CESC	cis	rs1448094	0.510	rs11117016	chr12:86141602	T/C	cg02569458	chr12:86230093	RASSF9	-0.42	-6.43	-0.37	5.94e-10	Major depressive disorder;
CESC	cis	rs9300255	0.602	rs1716164	chr12:123663660	G/A	cg19016782	chr12:123741754	C12orf65	-0.45	-6.4	-0.37	6.92e-10	Neutrophil percentage of white cells;
CESC	cis	rs644799	0.710	rs12273579	chr11:95524421	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.76	11.03	0.56	1.55e-23	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs3740713	1.000	rs12289603	chr11:18471370	T/C	cg23797887	chr11:18477753	LDHAL6A	-0.56	-5.93	-0.34	9.58e-9	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs9916302	0.904	rs620686	chr17:37453617	A/G	cg00129232	chr17:37814104	STARD3	0.54	7.03	0.4	1.75e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs9512730	0.553	rs9507904	chr13:28049506	C/T	cg08193333	chr13:27998609	GTF3A	0.44	5.3	0.31	2.42e-7	Schizophrenia;
CESC	cis	rs7680126	0.632	rs78030862	chr4:10150412	G/A	cg11266682	chr4:10021025	SLC2A9	-0.52	-6.51	-0.37	3.81e-10	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg25346720	chr7:73184981	CLDN3	-0.46	-6.97	-0.39	2.48e-11	Gambling;
CESC	cis	rs2276314	0.857	rs28435069	chr18:33628475	A/G	cg19628046	chr18:33552617	C18orf21	0.53	5.97	0.34	7.5e-9	Endometriosis;Drug-induced torsades de pointes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22967283	chr7:4815538	KIAA0415	0.6	6.75	0.38	9.11e-11	Gut microbiome composition (summer);
CESC	cis	rs524281	0.861	rs10750779	chr11:65974591	C/G	cg14036092	chr11:66035641	RAB1B	-0.59	-6.05	-0.35	4.86e-9	Electroencephalogram traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02182185	chr11:47600575	NDUFS3;KBTBD4	0.61	7.1	0.4	1.15e-11	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13964393	chr15:45003702	B2M	-0.57	-6.85	-0.39	5.07e-11	Gut microbiome composition (summer);
CESC	cis	rs9303280	0.806	rs36095411	chr17:38031865	T/G	cg20243544	chr17:37824526	PNMT	0.53	6.97	0.39	2.46e-11	Self-reported allergy;
CESC	cis	rs736408	0.609	rs13082208	chr3:52781539	T/G	cg05564831	chr3:52568323	NT5DC2	0.44	6.72	0.38	1.13e-10	Bipolar disorder;
CESC	cis	rs13191362	1.000	rs34725898	chr6:163127302	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.66	6.56	0.37	2.8e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg04234412	chr22:24373322	LOC391322	0.73	11.44	0.57	6.79e-25	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs7818688	0.556	rs2678823	chr8:96046094	G/A	cg16049864	chr8:95962084	TP53INP1	-0.46	-5.27	-0.31	2.77e-7	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs896854	0.517	rs896851	chr8:95950251	T/C	cg16049864	chr8:95962084	TP53INP1	-0.52	-7.28	-0.41	3.87e-12	Type 2 diabetes;
CESC	cis	rs4930103	0.619	rs10769945	chr11:1985127	C/T	cg23202291	chr11:1979235	NA	0.38	5.4	0.31	1.47e-7	DNA methylation (parent-of-origin);DNA methylation (variation);
CESC	cis	rs563538	1	rs563538	chr13:37433721	A/G	cg08717751	chr13:37881008	NA	-0.68	-5.47	-0.32	1.06e-7	Spontaneous preterm birth (preterm birth);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12939298	chr14:75643618	TMED10	-0.62	-6.88	-0.39	4.31e-11	Gut microbiome composition (summer);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg15320925	chr11:207681	BET1L;RIC8A	-0.46	-6.01	-0.35	5.97e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs763014	0.833	rs3743904	chr16:632767	A/G	cg07343612	chr16:622815	PIGQ	-0.58	-8.42	-0.46	2.38e-15	Height;
CESC	cis	rs6582630	0.502	rs12815350	chr12:38439921	A/T	cg13010199	chr12:38710504	ALG10B	0.46	5.9	0.34	1.1e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs2075371	0.863	rs2075370	chr7:133967812	A/G	cg00033643	chr7:134001901	SLC35B4	0.41	5.26	0.31	2.93e-7	Mean platelet volume;
CESC	cis	rs1218582	0.772	rs4845690	chr1:154886817	C/T	cg09359103	chr1:154839909	KCNN3	0.66	12.35	0.6	5.55e-28	Prostate cancer;
CESC	cis	rs7552404	0.889	rs2211080	chr1:76243438	G/A	cg03433033	chr1:76189801	ACADM	0.62	7.21	0.4	5.97e-12	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs62005083	1.000	rs72725960	chr14:74582154	A/T	cg05179529	chr14:74551516	LIN52;ALDH6A1	0.7	5.25	0.31	3.08e-7	Mean corpuscular volume;
CESC	cis	rs7843479	0.601	rs4872204	chr8:21841396	T/C	cg17168535	chr8:21777572	XPO7	0.72	11.6	0.58	1.99e-25	Mean corpuscular volume;
CESC	cis	rs12477438	1.000	rs12466388	chr2:99916538	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.61	-7.15	-0.4	8.59e-12	Chronic sinus infection;
CESC	cis	rs79839061	0.610	rs34006051	chr4:847445	C/T	cg07828340	chr4:882639	GAK	1.07	8.16	0.45	1.38e-14	Intelligence (multi-trait analysis);
CESC	cis	rs5758511	0.680	rs5758651	chr22:42609148	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.59	8.71	0.47	3.36e-16	Birth weight;
CESC	cis	rs10465746	0.780	rs11163865	chr1:84366917	C/T	cg10977910	chr1:84465055	TTLL7	0.52	7.06	0.4	1.46e-11	Obesity-related traits;
CESC	cis	rs9921222	0.632	rs11649268	chr16:398643	A/C	cg00101154	chr16:420108	MRPL28	-0.54	-7.13	-0.4	9.75e-12	Bone mineral density (spine);Bone mineral density;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg23358871	chr17:78121069	EIF4A3	0.46	6.27	0.36	1.5e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs4664304	0.658	rs2667008	chr2:160865095	C/T	cg03641300	chr2:160917029	PLA2R1	-0.48	-6.84	-0.39	5.58e-11	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs28386778	0.704	rs1051688	chr17:62006433	G/C	cg22520471	chr17:61851767	DDX42;CCDC47	-0.81	-11.35	-0.57	1.34e-24	Prudent dietary pattern;
CESC	cis	rs9916302	0.904	rs620686	chr17:37453617	A/G	cg20243544	chr17:37824526	PNMT	-0.45	-5.48	-0.32	9.91e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs1552244	0.882	rs67762674	chr3:10014485	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.88	11.52	0.58	3.61e-25	Alzheimer's disease;
CESC	cis	rs3733585	0.673	rs4495037	chr4:9954050	C/G	cg11266682	chr4:10021025	SLC2A9	-0.58	-11.0	-0.56	2.04e-23	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs875971	0.895	rs12531677	chr7:65769086	G/A	cg11764359	chr7:65958608	NA	-0.78	-11.61	-0.58	1.78e-25	Aortic root size;
CESC	cis	rs1595825	0.891	rs6707521	chr2:198713231	A/G	cg00982548	chr2:198649783	BOLL	0.48	5.09	0.3	6.92e-7	Ulcerative colitis;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg22094802	chr19:45946652	NA	-0.48	-6.3	-0.36	1.26e-9	Fibrinogen levels;
CESC	cis	rs7811142	1.000	rs28490152	chr7:100020982	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.81	8.21	0.45	9.45e-15	Platelet count;
CESC	cis	rs4819052	1.000	rs9984901	chr21:46663952	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.87	11.11	0.56	8.67e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs8072100	0.840	rs9912311	chr17:45547132	T/C	cg08085267	chr17:45401833	C17orf57	-0.55	-7.47	-0.42	1.13e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs4561483	0.831	rs33621	chr16:12008513	G/A	cg08843971	chr16:11963173	GSPT1	-0.42	-5.75	-0.33	2.48e-8	Testicular germ cell tumor;
CESC	cis	rs780096	0.506	rs56076827	chr2:27676287	A/T	cg02592271	chr2:27665507	KRTCAP3	-0.27	-5.32	-0.31	2.21e-7	Total body bone mineral density;
CESC	cis	rs2559856	1.000	rs2559857	chr12:102089399	A/C	cg12213457	chr12:102090980	CHPT1	-0.37	-5.48	-0.32	9.79e-8	Blood protein levels;
CESC	cis	rs2243480	1.000	rs781156	chr7:65479141	C/A	cg12463550	chr7:65579703	CRCP	0.72	5.81	0.34	1.8e-8	Diabetic kidney disease;
CESC	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg18337363	chr3:52569053	NT5DC2	0.35	6.91	0.39	3.54e-11	Electroencephalogram traits;
CESC	cis	rs798554	0.600	rs2679259	chr7:2885322	C/G	cg19717773	chr7:2847554	GNA12	-0.49	-7.43	-0.42	1.5e-12	Height;
CESC	cis	rs56104184	0.775	rs55981795	chr19:49401952	A/C	cg15549821	chr19:49342101	PLEKHA4	-0.6	-5.99	-0.35	6.95e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	cis	rs10479542	0.544	rs10056863	chr5:179005100	G/A	cg09060608	chr5:178986726	RUFY1	0.5	7.38	0.41	1.99e-12	Lung cancer;
CESC	cis	rs561341	0.623	rs4795665	chr17:30233657	C/T	cg13647721	chr17:30228624	UTP6	0.8	9.63	0.51	5.09e-19	Hip circumference adjusted for BMI;
CESC	cis	rs3015497	0.603	rs2934686	chr14:51029713	A/G	cg26011998	chr14:51135199	SAV1	0.47	5.36	0.31	1.8e-7	Mean platelet volume;
CESC	cis	rs35110281	0.667	rs2838354	chr21:45119857	T/C	cg01579765	chr21:45077557	HSF2BP	-0.52	-8.54	-0.46	1.05e-15	Mean corpuscular volume;
CESC	cis	rs736408	0.609	rs2230535	chr3:52800284	T/C	cg05564831	chr3:52568323	NT5DC2	0.42	6.14	0.35	3.08e-9	Bipolar disorder;
CESC	cis	rs7666738	0.830	rs9998803	chr4:99002519	C/T	cg18180107	chr4:99064573	C4orf37	0.4	5.23	0.31	3.41e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2228479	0.850	rs17233455	chr16:89816407	A/G	cg19635926	chr16:89946313	TCF25	0.67	5.09	0.3	6.82e-7	Skin colour saturation;
CESC	cis	rs28655083	0.843	rs1502433	chr16:77087101	C/T	cg01753188	chr16:77233325	SYCE1L;MON1B	0.42	5.5	0.32	8.89e-8	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6456156	0.586	rs2017338	chr6:167471714	G/A	cg23791538	chr6:167370224	RNASET2	-0.5	-6.44	-0.37	5.46e-10	Primary biliary cholangitis;
CESC	cis	rs1799949	1.000	rs8074136	chr17:41342313	A/C	cg23758822	chr17:41437982	NA	1.02	15.29	0.68	2.9e-38	Menopause (age at onset);
CESC	cis	rs7208859	0.562	rs11650923	chr17:29008167	G/A	cg13385521	chr17:29058706	SUZ12P	0.72	5.62	0.33	4.72e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs35306767	0.903	rs4522091	chr10:874116	G/T	cg26597838	chr10:835615	NA	0.9	9.35	0.5	3.76e-18	Eosinophil percentage of granulocytes;
CESC	cis	rs6952809	0.532	rs6461361	chr7:2432167	A/G	cg05083358	chr7:2394359	EIF3B	-0.6	-5.08	-0.3	7.24e-7	Multiple sclerosis;
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg12609600	chr11:1595974	HCCA2;LOC338651	0.38	6.32	0.36	1.11e-9	Vertical cup-disc ratio;
CESC	cis	rs7666738	0.830	rs28417716	chr4:98864859	C/T	cg05340658	chr4:99064831	C4orf37	0.75	11.16	0.57	5.89e-24	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7605827	0.930	rs11681044	chr2:15717058	G/A	cg19274914	chr2:15703543	NA	0.31	5.58	0.32	6.03e-8	Educational attainment (years of education);
CESC	cis	rs950169	0.887	rs71395453	chr15:85113490	G/C	cg17507749	chr15:85114479	UBE2QP1	0.54	6.11	0.35	3.61e-9	Schizophrenia;
CESC	cis	rs7617773	0.563	rs13082269	chr3:48392274	G/A	cg11946769	chr3:48343235	NME6	0.64	8.04	0.44	2.93e-14	Coronary artery disease;
CESC	cis	rs11690935	0.632	rs1607254	chr2:172626552	A/G	cg13550731	chr2:172543902	DYNC1I2	0.6	8.29	0.45	5.76e-15	Schizophrenia;
CESC	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg07414643	chr4:187882934	NA	0.48	6.92	0.39	3.35e-11	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs12599106	0.679	rs34584967	chr16:34475725	T/G	cg01516881	chr6:292596	DUSP22	-0.53	-6.83	-0.39	5.71e-11	Menopause (age at onset);
CESC	cis	rs7412746	0.611	rs2256355	chr1:150811794	A/G	cg04414720	chr1:150670196	GOLPH3L	0.46	6.26	0.36	1.57e-9	Melanoma;
CESC	trans	rs2455012	1.000	rs9436757	chr1:66528892	C/T	cg23678594	chr1:1712021	NA	0.83	6.24	0.36	1.72e-9	Staphylococcus aureus infection;
CESC	cis	rs7811142	0.830	rs28495773	chr7:99943583	A/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.71	6.25	0.36	1.59e-9	Platelet count;
CESC	cis	rs1348850	0.526	rs10497504	chr2:178370040	T/C	cg23306229	chr2:178417860	TTC30B	0.78	6.92	0.39	3.32e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs798554	0.634	rs1182180	chr7:2873279	G/T	cg04166393	chr7:2884313	GNA12	0.37	5.07	0.3	7.44e-7	Height;
CESC	cis	rs17376456	0.825	rs6865441	chr5:93284746	G/A	cg25358565	chr5:93447407	FAM172A	1.14	9.72	0.51	2.6e-19	Diabetic retinopathy;
CESC	cis	rs904251	0.737	rs914347	chr6:37484970	A/C	cg01843034	chr6:37503916	NA	-0.28	-5.03	-0.3	9.16e-7	Cognitive performance;
CESC	cis	rs78456975	1.000	rs10192959	chr2:1553393	G/T	cg01028140	chr2:1542097	TPO	-0.59	-5.77	-0.33	2.23e-8	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs34779708	0.931	rs7908573	chr10:35309513	T/C	cg03585969	chr10:35415529	CREM	0.74	9.69	0.51	3.4e-19	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs10911251	0.546	rs2027081	chr1:183074576	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.88	14.2	0.66	2.09e-34	Colorectal cancer;
CESC	cis	rs4568518	0.530	rs12699921	chr7:17994494	G/A	cg03009463	chr7:17980271	SNX13	0.41	5.39	0.31	1.56e-7	Measles;
CESC	cis	rs1348850	0.519	rs1527406	chr2:178525655	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.57	7.05	0.4	1.57e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs939574	0.512	rs10194278	chr2:220138408	C/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.45	5.37	0.31	1.75e-7	Platelet distribution width;
CESC	cis	rs4523957	0.890	rs12941836	chr17:2194874	C/G	cg16513277	chr17:2031491	SMG6	0.6	8.18	0.45	1.15e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs12900413	0.687	rs12908343	chr15:90319095	C/T	cg24249390	chr15:90295951	MESP1	-0.42	-5.81	-0.34	1.78e-8	Coronary artery aneurysm in Kawasaki disease;
CESC	cis	rs6563842	0.528	rs56340348	chr13:41296371	C/T	cg21288729	chr13:41239152	FOXO1	0.58	7.47	0.42	1.13e-12	Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;
CESC	cis	rs2243480	0.901	rs73148097	chr7:65431787	A/C	cg25894440	chr7:65020034	NA	-0.68	-5.88	-0.34	1.23e-8	Diabetic kidney disease;
CESC	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg11965913	chr1:205819406	PM20D1	-0.8	-13.64	-0.64	1.83e-32	Menarche (age at onset);
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg05993306	chr5:137090649	HNRNPA0	-0.45	-6.01	-0.35	6.07e-9	Asthma;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg05712507	chr12:110905729	GPN3;C12orf24	0.43	6.09	0.35	3.94e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs7615952	0.599	rs6438955	chr3:125730333	C/A	cg04553112	chr3:125709451	NA	-0.47	-5.31	-0.31	2.28e-7	Blood pressure (smoking interaction);
CESC	cis	rs7618915	0.501	rs11714030	chr3:52765882	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.38	6.69	0.38	1.3e-10	Bipolar disorder;
CESC	cis	rs7666738	0.830	rs2015828	chr4:98984594	A/G	cg05340658	chr4:99064831	C4orf37	0.79	12.38	0.61	4.36e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1316952	0.831	rs78985577	chr12:124393117	G/A	cg00084347	chr12:124393913	DNAH10	0.42	6.67	0.38	1.49e-10	Visceral adipose tissue adjusted for BMI;Visceral adipose tissue/subcutaneous adipose tissue ratio;
CESC	cis	rs2795502	1.000	rs1581702	chr10:43344246	G/A	cg20628663	chr10:43360327	NA	0.61	7.22	0.41	5.62e-12	Blood protein levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22333733	chr11:31391482	DNAJC24;DCDC1	-0.51	-6.31	-0.36	1.19e-9	Gut microbiome composition (summer);
CESC	cis	rs6570726	0.791	rs383841	chr6:145888329	G/T	cg05347473	chr6:146136440	FBXO30	-0.59	-7.65	-0.43	3.71e-13	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs34779708	0.966	rs11010122	chr10:35493518	A/C	cg04310649	chr10:35416472	CREM	-0.52	-6.26	-0.36	1.54e-9	Inflammatory bowel disease;Crohn's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22805491	chr14:51172404	NA	-0.53	-6.45	-0.37	5.42e-10	Gut microbiome composition (summer);
CESC	cis	rs28829049	0.508	rs4578242	chr1:19391565	G/C	cg13387374	chr1:19411106	UBR4	0.42	5.14	0.3	5.46e-7	QRS duration in Tripanosoma cruzi seropositivity;
CESC	cis	rs1862618	0.853	rs10051747	chr5:56083289	C/A	cg24549020	chr5:56110836	MAP3K1	0.67	7.46	0.42	1.23e-12	Initial pursuit acceleration;
CESC	cis	rs12681366	0.708	rs3019154	chr8:95446508	C/T	cg13257157	chr8:95487014	RAD54B	0.38	5.14	0.3	5.25e-7	Nonsyndromic cleft lip with cleft palate;
CESC	trans	rs7839040	0.648	rs4341126	chr8:82922335	T/C	cg14472086	chr9:107730925	NA	-0.47	-6.33	-0.36	1.02e-9	Response to methotrexate in juvenile idiopathic arthritis;
CESC	cis	rs832540	0.866	rs832579	chr5:56164943	A/G	cg14703610	chr5:56206110	C5orf35	0.48	6.24	0.36	1.71e-9	Coronary artery disease;
CESC	cis	rs3825932	0.961	rs2870085	chr15:79234268	T/C	cg25744700	chr15:79237217	CTSH	0.48	6.52	0.37	3.62e-10	Type 1 diabetes;
CESC	cis	rs2836974	0.627	rs7278985	chr21:40653767	C/T	cg17971929	chr21:40555470	PSMG1	-0.87	-12.61	-0.61	6.96e-29	Cognitive function;
CESC	trans	rs3099143	1.000	rs7178759	chr15:77143513	A/G	cg18509435	chr18:59157879	CDH20	-0.52	-6.22	-0.36	1.98e-9	Recalcitrant atopic dermatitis;
CESC	cis	rs2242073	0.660	rs11678616	chr2:209004548	C/T	cg10392614	chr2:208977121	NA	-0.37	-5.07	-0.3	7.43e-7	Attention deficit hyperactivity disorder;
CESC	cis	rs2842992	0.724	rs9347340	chr6:160188891	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	-0.71	-10.26	-0.53	5.27e-21	Age-related macular degeneration (geographic atrophy);
CESC	trans	rs948562	0.744	rs11229468	chr11:58218773	C/A	cg24637035	chr12:120445227	CCDC64	-0.5	-6.06	-0.35	4.67e-9	Lymphoma;
CESC	cis	rs2708240	1.000	rs2538992	chr7:147579075	T/C	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.35	-5.78	-0.33	2.12e-8	QT interval (drug interaction);
CESC	cis	rs36051895	0.664	rs10974963	chr9:5101305	G/A	cg02405213	chr9:5042618	JAK2	-0.54	-6.57	-0.37	2.58e-10	Pediatric autoimmune diseases;
CESC	cis	rs9311474	0.659	rs7638808	chr3:52572056	C/T	cg18337363	chr3:52569053	NT5DC2	-0.31	-6.05	-0.35	5.05e-9	Electroencephalogram traits;
CESC	cis	rs12135062	0.901	rs2651928	chr1:3101722	C/T	cg00254258	chr1:3105189	PRDM16	-0.35	-5.22	-0.31	3.69e-7	Migraine;
CESC	cis	rs11166927	0.562	rs4736095	chr8:140802744	T/C	cg16909799	chr8:140841666	TRAPPC9	0.4	5.41	0.32	1.41e-7	Pediatric non-alcoholic fatty liver disease activity score;
CESC	cis	rs736801	0.808	rs2706396	chr5:131796809	A/C	cg21138405	chr5:131827807	IRF1	0.36	5.37	0.31	1.73e-7	Breast cancer;Mosquito bite size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12256311	chr17:685750	GLOD4;RNMTL1	0.53	6.43	0.37	5.84e-10	Gut microbiome composition (summer);
CESC	cis	rs3820928	1.000	rs1835158	chr2:227763993	C/A	cg05526886	chr2:227700861	RHBDD1	-0.43	-5.57	-0.32	6.14e-8	Pulmonary function;
CESC	cis	rs7223966	1.000	rs752621	chr17:61901880	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.45	-5.09	-0.3	6.87e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs2625529	0.713	rs16956634	chr15:72552243	C/G	cg16672083	chr15:72433130	SENP8	0.4	5.19	0.3	4.29e-7	Red blood cell count;
CESC	cis	rs2624839	0.629	rs2526397	chr3:50187790	A/C	cg24308560	chr3:49941425	MST1R	0.45	5.85	0.34	1.43e-8	Intelligence (multi-trait analysis);
CESC	cis	rs9916302	0.904	rs68178216	chr17:37526241	A/C	cg20243544	chr17:37824526	PNMT	-0.48	-5.79	-0.34	1.96e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs4423214	1.000	rs12419334	chr11:71139472	T/C	cg05163923	chr11:71159392	DHCR7	0.78	10.6	0.55	3.92e-22	Vitamin D levels;
CESC	trans	rs1973993	0.691	rs553785	chr1:96895325	G/A	cg10631902	chr5:14652156	NA	0.61	9.43	0.5	2.18e-18	Weight;
CESC	cis	rs897080	0.516	rs1067393	chr2:44638832	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.51	5.97	0.34	7.74e-9	Height;
CESC	cis	rs6987853	0.931	rs2923431	chr8:42394425	G/C	cg09913449	chr8:42400586	C8orf40	0.38	5.8	0.34	1.89e-8	Mean corpuscular hemoglobin concentration;
CESC	cis	rs7267979	1.000	rs4815412	chr20:25350325	A/G	cg08601574	chr20:25228251	PYGB	0.38	5.55	0.32	6.88e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7615952	0.534	rs1503072	chr3:125754691	C/T	cg15145296	chr3:125709740	NA	-0.51	-5.35	-0.31	1.92e-7	Blood pressure (smoking interaction);
CESC	cis	rs3820928	0.874	rs10439363	chr2:227815065	C/T	cg11843606	chr2:227700838	RHBDD1	-0.49	-6.42	-0.37	6.29e-10	Pulmonary function;
CESC	cis	rs1577917	0.771	rs2842607	chr6:86345039	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.53	-7.03	-0.4	1.71e-11	Response to antipsychotic treatment;
CESC	cis	rs7523050	0.643	rs35860016	chr1:109404639	C/T	cg08274380	chr1:109419600	GPSM2	0.85	5.82	0.34	1.74e-8	Fat distribution (HIV);
CESC	cis	rs875971	0.929	rs12535036	chr7:65964063	G/T	cg10691866	chr7:65817282	TPST1	-0.34	-5.59	-0.32	5.57e-8	Aortic root size;
CESC	cis	rs367615	0.918	rs4270746	chr5:108876839	T/C	cg17395555	chr5:108820864	NA	0.56	8.33	0.46	4.38e-15	Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs13392177	0.684	rs6720449	chr2:219080978	G/A	cg00012203	chr2:219082015	ARPC2	-0.66	-8.18	-0.45	1.17e-14	Pyoderma gangrenosum in inflammatory bowel disease;
CESC	cis	rs6963495	0.818	rs73190151	chr7:105152887	C/T	cg02135003	chr7:105160482	PUS7	-0.46	-5.5	-0.32	9.08e-8	Bipolar disorder (body mass index interaction);
CESC	cis	rs4332037	0.539	rs34571717	chr7:2106855	T/C	cg21782813	chr7:2030301	MAD1L1	-0.4	-5.2	-0.3	4.07e-7	Bipolar disorder;
CESC	cis	rs875971	0.862	rs801204	chr7:66022921	T/C	cg18876405	chr7:65276391	NA	-0.53	-7.22	-0.41	5.6e-12	Aortic root size;
CESC	cis	rs5769765	1.000	rs2319458	chr22:50236306	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.47	-5.26	-0.31	2.9e-7	Schizophrenia;
CESC	cis	rs1568889	0.838	rs3812738	chr11:28129982	C/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.82	13.65	0.64	1.7e-32	Bipolar disorder;
CESC	cis	rs1801251	0.964	rs7589201	chr2:233724536	A/G	cg25237894	chr2:233734115	C2orf82	-0.47	-8.29	-0.45	5.78e-15	Coronary artery disease;
CESC	cis	rs798554	0.679	rs1636249	chr7:2884283	T/G	cg18446336	chr7:2847575	GNA12	-0.34	-5.46	-0.32	1.1e-7	Height;
CESC	cis	rs7412746	0.658	rs10305711	chr1:150802996	T/C	cg22823121	chr1:150693482	HORMAD1	0.45	6.31	0.36	1.17e-9	Melanoma;
CESC	cis	rs561341	0.709	rs11542477	chr17:30185892	A/G	cg19193384	chr17:30244184	NA	0.58	5.71	0.33	2.96e-8	Hip circumference adjusted for BMI;
CESC	cis	rs853679	0.517	rs9368557	chr6:28131537	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.57	-6.49	-0.37	4.32e-10	Depression;
CESC	cis	rs9549260	0.755	rs7988604	chr13:41215802	G/T	cg21288729	chr13:41239152	FOXO1	0.65	8.62	0.47	6.27e-16	Red blood cell count;
CESC	cis	rs7188697	0.922	rs1549607	chr16:58583975	A/G	cg02549819	chr16:58548995	SETD6	0.42	5.32	0.31	2.17e-7	QT interval;
CESC	cis	rs1799949	1.000	rs11656097	chr17:41290613	G/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.45	6.31	0.36	1.17e-9	Menopause (age at onset);
CESC	cis	rs9443645	0.901	rs1354831	chr6:79613576	T/C	cg05283184	chr6:79620031	NA	-0.43	-6.51	-0.37	3.72e-10	Intelligence (multi-trait analysis);
CESC	cis	rs1878931	0.520	rs2015640	chr16:3465018	G/C	cg02880119	chr16:3481970	NA	0.47	5.77	0.33	2.16e-8	Body mass index (adult);
CESC	cis	rs7799006	0.606	rs12535174	chr7:2310974	C/T	cg08027265	chr7:2291960	NA	-0.58	-9.74	-0.51	2.4e-19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs477692	1.000	rs580745	chr10:131414401	G/A	cg05714579	chr10:131428358	MGMT	0.46	6.21	0.36	2.02e-9	Response to temozolomide;
CESC	cis	rs9916302	0.904	rs8076546	chr17:37555403	G/A	cg00129232	chr17:37814104	STARD3	0.59	7.96	0.44	5.17e-14	Glomerular filtration rate (creatinine);
CESC	cis	rs9929218	1.000	rs11865026	chr16:68774283	A/G	cg02972257	chr16:68554789	NA	0.55	6.41	0.37	6.78e-10	Colorectal cancer;
CESC	cis	rs7631605	0.905	rs72866099	chr3:37259646	C/A	cg22985146	chr3:37219077	LRRFIP2	-0.35	-5.44	-0.32	1.22e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs6540559	0.611	rs926347	chr1:209965193	T/C	cg10074409	chr1:209979377	IRF6	0.42	5.39	0.31	1.52e-7	Cleft lip with or without cleft palate;
CESC	cis	rs4665809	0.590	rs34728554	chr2:26481959	C/G	cg26314531	chr2:26401878	FAM59B	0.85	9.04	0.49	3.46e-17	Gut microbiome composition (summer);
CESC	cis	rs6952808	0.531	rs3800922	chr7:2184505	A/G	cg08027265	chr7:2291960	NA	-0.47	-7.23	-0.41	5.26e-12	Bipolar disorder and schizophrenia;
CESC	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg16132339	chr22:24313637	DDTL;DDT	0.4	6.18	0.35	2.43e-9	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs55728055	0.661	rs62237833	chr22:32012141	G/A	cg01338084	chr22:32026380	PISD	1.22	8.02	0.44	3.48e-14	Age-related hearing impairment;
CESC	cis	rs7927771	0.931	rs12361256	chr11:47910823	A/C	cg18512352	chr11:47633146	NA	-0.54	-8.84	-0.48	1.35e-16	Subjective well-being;
CESC	cis	rs2070488	1.000	rs2070488	chr3:38442490	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.93	-17.4	-0.73	9.19e-46	Electrocardiographic conduction measures;
CESC	cis	rs6060717	0.536	rs3787173	chr20:34472105	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.66	5.7	0.33	3.16e-8	Hip circumference adjusted for BMI;
CESC	cis	rs9787249	0.915	rs6664570	chr1:40206298	G/A	cg24920358	chr1:40204285	PPIE	0.43	6.51	0.37	3.85e-10	Blood protein levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19864416	chr19:42498173	ATP1A3	0.49	6.08	0.35	4.22e-9	Gut microbiome composition (summer);
CESC	cis	rs4969178	0.896	rs1976704	chr17:76401318	C/T	cg20026190	chr17:76395443	PGS1	0.46	7.35	0.41	2.41e-12	HDL cholesterol levels;
CESC	cis	rs7772486	0.902	rs1125462	chr6:146417832	A/G	cg05347473	chr6:146136440	FBXO30	0.47	6.51	0.37	3.85e-10	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg06474082	chr19:45579580	ZNF296	-0.41	-6.14	-0.35	2.94e-9	Gambling;
CESC	cis	rs561341	0.883	rs1034627	chr17:30219569	C/T	cg00745463	chr17:30367425	LRRC37B	-0.59	-6.19	-0.36	2.27e-9	Hip circumference adjusted for BMI;
CESC	cis	rs6693567	0.565	rs1260408	chr1:150307270	T/G	cg09579323	chr1:150459698	TARS2	0.48	6.1	0.35	3.84e-9	Migraine;
CESC	cis	rs853679	0.517	rs9348793	chr6:28084189	G/A	cg23161317	chr6:28129485	ZNF389	0.51	6.53	0.37	3.44e-10	Depression;
CESC	cis	rs8002861	0.905	rs6561149	chr13:44456782	T/G	cg14210620	chr13:44453864	C13orf31;CCDC122	-0.44	-5.58	-0.32	5.88e-8	Leprosy;
CESC	trans	rs116095464	0.558	rs62347683	chr5:230331	C/T	cg00938859	chr5:1591904	SDHAP3	0.61	6.74	0.38	9.82e-11	Breast cancer;
CESC	cis	rs6831352	0.959	rs6532796	chr4:100042242	C/T	cg21548116	chr4:100009993	ADH5	-0.5	-5.2	-0.3	4e-7	Alcohol dependence;
CESC	cis	rs4555082	0.874	rs2816613	chr14:105726367	C/T	cg06808227	chr14:105710500	BRF1	-0.58	-6.77	-0.38	8.26e-11	Mean platelet volume;Platelet distribution width;
CESC	cis	rs6456156	0.586	rs10946209	chr6:167480991	G/A	cg07741184	chr6:167504864	NA	0.36	6.15	0.35	2.85e-9	Primary biliary cholangitis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22583711	chr7:154795321	PAXIP1;LOC202781	0.54	6.66	0.38	1.57e-10	Gut microbiome composition (summer);
CESC	cis	rs6942407	0.546	rs7810647	chr7:86805961	C/A	cg02420886	chr7:86849541	C7orf23	0.52	5.04	0.3	8.76e-7	Food allergy;
CESC	cis	rs1475911	0.708	rs66994219	chr21:43521647	G/A	cg03240473	chr21:43526662	UMODL1;C21orf128	-0.54	-7.15	-0.4	8.52e-12	IgG glycosylation;
CESC	cis	rs61931739	0.500	rs9795938	chr12:34587739	C/T	cg23762105	chr12:34175262	ALG10	0.4	5.17	0.3	4.62e-7	Morning vs. evening chronotype;
CESC	cis	rs6496667	0.510	rs7495784	chr15:91068882	T/C	cg22089800	chr15:90895588	ZNF774	-0.46	-5.46	-0.32	1.07e-7	Rheumatoid arthritis;
CESC	cis	rs2228479	0.702	rs12600047	chr16:89831630	G/A	cg14709524	chr16:89940631	TCF25	0.92	6.68	0.38	1.39e-10	Skin colour saturation;
CESC	cis	rs3733585	0.604	rs73215003	chr4:10126317	C/G	cg05927159	chr4:10118984	WDR1	0.35	5.16	0.3	4.85e-7	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs67257959	0.708	rs10412843	chr19:17198287	A/G	cg16202187	chr19:17186497	HAUS8;MYO9B	0.45	5.39	0.31	1.56e-7	Selective IgA deficiency;
CESC	cis	rs10883723	0.810	rs3781289	chr10:104244991	G/T	cg22532475	chr10:104410764	TRIM8	-0.33	-5.61	-0.33	5.22e-8	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg17372223	chr3:52568218	NT5DC2	0.44	7.19	0.4	6.44e-12	Bipolar disorder;
CESC	cis	rs10883723	0.810	rs7917525	chr10:104246755	C/G	ch.10.2196322F	chr10:104248062	ACTR1A	0.42	5.18	0.3	4.35e-7	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs9828933	0.832	rs2292662	chr3:63897215	C/T	cg16258503	chr3:63850278	ATXN7;THOC7	-0.76	-8.19	-0.45	1.11e-14	Type 2 diabetes;
CESC	cis	rs6502050	0.871	rs6502051	chr17:80059332	A/C	cg23985595	chr17:80112537	CCDC57	0.4	6.28	0.36	1.35e-9	Life satisfaction;
CESC	cis	rs524023	0.914	rs80841	chr11:64437490	T/C	cg07220939	chr11:64358617	SLC22A12	-0.34	-5.27	-0.31	2.86e-7	Urate levels in obese individuals;
CESC	cis	rs2228479	0.867	rs11645970	chr16:89958118	G/A	cg14709524	chr16:89940631	TCF25	0.73	5.64	0.33	4.36e-8	Skin colour saturation;
CESC	cis	rs10129255	0.500	rs10143385	chr14:107190796	G/A	cg07958169	chr14:107095056	NA	-0.54	-8.29	-0.45	5.63e-15	Kawasaki disease;
CESC	trans	rs9354308	0.933	rs10455586	chr6:66571498	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.71	7.96	0.44	5.21e-14	Metabolite levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07484403	chr19:19249270	TMEM161A	0.59	6.49	0.37	4.19e-10	Gut microbiome composition (summer);
CESC	cis	rs6460942	0.597	rs35317839	chr7:12524397	C/A	cg20607287	chr7:12443886	VWDE	-0.71	-7.67	-0.43	3.19e-13	Coronary artery disease;
CESC	cis	rs72627123	0.867	rs80083802	chr14:74456996	C/G	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.8	5.37	0.31	1.71e-7	Morning vs. evening chronotype;
CESC	cis	rs2243480	1.000	rs313798	chr7:65493031	A/G	cg25894440	chr7:65020034	NA	-0.68	-5.84	-0.34	1.51e-8	Diabetic kidney disease;
CESC	cis	rs7945705	0.692	rs11042149	chr11:9010737	T/C	cg12365402	chr11:9010492	NRIP3	-0.4	-6.95	-0.39	2.92e-11	Hemoglobin concentration;
CESC	cis	rs2635047	0.967	rs2571001	chr18:44665083	C/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.47	6.3	0.36	1.21e-9	Educational attainment;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24689196	chr5:65893165	MAST4	-0.55	-6.4	-0.37	7.11e-10	Gut microbiome composition (summer);
CESC	cis	rs6032067	0.704	rs62208390	chr20:43794844	A/C	cg11264863	chr20:43835661	SEMG1	0.5	5.35	0.31	1.86e-7	Blood protein levels;
CESC	cis	rs7666738	0.830	rs4492007	chr4:98959848	A/T	cg03676636	chr4:99064102	C4orf37	0.34	5.14	0.3	5.46e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9329289	0.590	rs11251295	chr10:2563183	C/T	cg15501526	chr10:2543763	NA	0.44	7.04	0.4	1.64e-11	Age-related hearing impairment;
CESC	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg18099408	chr3:52552593	STAB1	-0.34	-6.23	-0.36	1.84e-9	Bipolar disorder;
CESC	cis	rs1670533	1.000	rs6812596	chr4:1069866	A/G	cg04106633	chr4:1044584	NA	0.4	5.11	0.3	6.07e-7	Recombination rate (females);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg26003818	chr1:231474059	C1orf124;EXOC8	-0.5	-6.04	-0.35	5.2e-9	Ulcerative colitis;
CESC	cis	rs60871478	0.578	rs62432900	chr7:826794	G/C	cg05535760	chr7:792225	HEATR2	0.97	11.19	0.57	4.78e-24	Cerebrospinal P-tau181p levels;
CESC	cis	rs12220238	1.000	rs7907801	chr10:75976638	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.6	5.44	0.32	1.24e-7	Soluble interleukin-2 receptor subunit alpha;
CESC	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg24642844	chr7:1081250	C7orf50	-0.74	-8.82	-0.48	1.53e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2637266	0.655	rs2588335	chr10:78510229	C/G	cg18941641	chr10:78392320	NA	0.42	7.88	0.44	8.65e-14	Pulmonary function;
CESC	cis	rs769267	0.930	rs751856	chr19:19602945	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.59	7.48	0.42	1.06e-12	Tonsillectomy;
CESC	cis	rs11785400	0.612	rs10110864	chr8:143750072	A/G	cg24634471	chr8:143751801	JRK	0.44	5.46	0.32	1.07e-7	Schizophrenia;
CESC	cis	rs780096	0.506	rs2288155	chr2:27714526	T/C	cg22903471	chr2:27725779	GCKR	-0.54	-7.55	-0.42	6.95e-13	Total body bone mineral density;
CESC	cis	rs950776	0.518	rs12906846	chr15:78825295	G/A	cg06917634	chr15:78832804	PSMA4	0.8	12.12	0.6	3.34e-27	Sudden cardiac arrest;
CESC	cis	rs798554	0.724	rs798498	chr7:2795882	T/G	cg18446336	chr7:2847575	GNA12	-0.38	-5.78	-0.33	2.14e-8	Height;
CESC	cis	rs11098499	0.908	rs2017057	chr4:120257711	A/G	cg09307838	chr4:120376055	NA	0.91	12.84	0.62	1.14e-29	Corneal astigmatism;
CESC	trans	rs9467711	0.606	rs9348712	chr6:26366511	T/A	cg06606381	chr12:133084897	FBRSL1	-0.76	-6.82	-0.39	6.01e-11	Autism spectrum disorder or schizophrenia;
CESC	cis	rs3617	0.598	rs56214994	chr3:52878600	G/C	cg11645453	chr3:52864694	ITIH4	-0.25	-5.11	-0.3	6.2e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
CESC	cis	rs763014	0.865	rs8909	chr16:633851	T/C	cg07343612	chr16:622815	PIGQ	-0.54	-7.75	-0.43	1.96e-13	Height;
CESC	cis	rs3820068	0.655	rs72645826	chr1:15889741	A/G	cg18192808	chr1:15853278	DNAJC16	0.43	5.17	0.3	4.6e-7	Systolic blood pressure;
CESC	cis	rs8070624	0.502	rs12951376	chr17:17752809	C/T	cg16928487	chr17:17741425	SREBF1	-0.47	-7.38	-0.41	2e-12	Total body bone mineral density;
CESC	cis	rs853679	0.517	rs55747925	chr6:28044337	T/C	cg26335602	chr6:28129616	ZNF389	0.53	7.05	0.4	1.55e-11	Depression;
CESC	cis	rs7267979	0.934	rs113469203	chr20:25343258	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.87	-17.05	-0.72	1.69e-44	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs501120	0.564	rs10899999	chr10:44690185	A/G	cg09554077	chr10:44749378	NA	0.39	5.14	0.3	5.38e-7	Coronary artery disease;Coronary heart disease;
CESC	cis	rs40363	0.645	rs4786421	chr16:3522303	A/G	cg00484396	chr16:3507460	NAT15	-0.51	-9.07	-0.49	2.84e-17	Tuberculosis;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg03426840	chr11:118661678	DDX6	-0.46	-6.66	-0.38	1.57e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg05663655	chr7:107532014	DLD	-0.45	-6.63	-0.38	1.86e-10	Gambling;
CESC	cis	rs1799949	0.864	rs60309406	chr17:41435665	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	8.51	0.46	1.29e-15	Menopause (age at onset);
CESC	cis	rs2806561	0.606	rs218341	chr1:23294153	G/C	cg12483005	chr1:23474871	LUZP1	0.34	5.16	0.3	4.86e-7	Height;
CESC	cis	rs920590	0.721	rs920587	chr8:19663339	C/A	cg03894339	chr8:19674705	INTS10	0.62	7.15	0.4	8.58e-12	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs6429082	0.818	rs61836206	chr1:235638754	C/G	cg26050004	chr1:235667680	B3GALNT2	0.62	7.86	0.43	9.85e-14	Adiposity;
CESC	cis	rs7618915	0.524	rs2028216	chr3:52680823	C/T	cg07507251	chr3:52567010	NT5DC2	0.41	7.18	0.4	7.2e-12	Bipolar disorder;
CESC	trans	rs17613427	1.000	rs72989081	chr2:142246292	C/T	cg16810031	chr17:38024146	ZPBP2	-0.9	-6.25	-0.36	1.65e-9	Left  ventricle systolic dysfunction;
CESC	cis	rs2932538	0.885	rs3762335	chr1:113100548	C/T	cg22162597	chr1:113214053	CAPZA1	0.57	7.11	0.4	1.1e-11	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CESC	cis	rs8038465	0.594	rs55816897	chr15:73869767	G/T	cg15420318	chr15:73925796	NPTN	0.47	6.64	0.38	1.76e-10	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs7044106	0.708	rs1324472	chr9:123375110	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.7	9.96	0.52	4.74e-20	Hip circumference adjusted for BMI;
CESC	cis	rs9325144	0.555	rs6582576	chr12:38701230	C/T	cg26384229	chr12:38710491	ALG10B	-0.55	-8.11	-0.45	1.95e-14	Morning vs. evening chronotype;
CESC	cis	rs2228479	0.850	rs62054611	chr16:89817017	T/C	cg19635926	chr16:89946313	TCF25	0.67	5.09	0.3	6.82e-7	Skin colour saturation;
CESC	cis	rs11098499	0.691	rs2136911	chr4:120265859	G/A	cg09307838	chr4:120376055	NA	0.76	10.03	0.52	2.87e-20	Corneal astigmatism;
CESC	cis	rs501120	1.000	rs670056	chr10:44753375	C/T	cg09554077	chr10:44749378	NA	0.52	6.89	0.39	3.96e-11	Coronary artery disease;Coronary heart disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15062189	chr2:32264818	DPY30	-0.59	-7.16	-0.4	7.92e-12	Gut microbiome composition (summer);
CESC	cis	rs2073300	0.609	rs77908916	chr20:23405626	C/G	cg16736954	chr20:23401023	NAPB	0.77	5.54	0.32	7.3e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs6032067	0.929	rs17424578	chr20:43806321	A/G	cg10761708	chr20:43804764	PI3	0.52	6.3	0.36	1.24e-9	Blood protein levels;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg27388036	chr4:104239655	NA	0.44	6.44	0.37	5.71e-10	Thyroid stimulating hormone;
CESC	cis	rs5769707	0.904	rs7288869	chr22:50015327	C/T	cg05373962	chr22:49881684	NA	-0.38	-6.7	-0.38	1.24e-10	Monocyte count;Monocyte percentage of white cells;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg18638867	chr19:42784593	NA	-0.42	-6.27	-0.36	1.45e-9	Fibrinogen levels;
CESC	cis	rs9811920	0.809	rs923472	chr3:99758029	A/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.45	-7.39	-0.41	1.96e-12	Axial length;
CESC	cis	rs3862030	0.839	rs2274351	chr10:104264107	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.37	-5.22	-0.31	3.54e-7	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
CESC	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	7.62	0.42	4.42e-13	Prudent dietary pattern;
CESC	cis	rs4925325	0.741	rs6142886	chr20:60511190	A/G	cg18761221	chr20:60518478	NA	-0.56	-8.4	-0.46	2.71e-15	Obesity-related traits;
CESC	cis	rs12477438	0.520	rs13022329	chr2:99731189	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.88	15.61	0.69	2.15e-39	Chronic sinus infection;
CESC	cis	rs7177699	0.525	rs56076311	chr15:79115120	A/G	cg04896959	chr15:78267971	NA	0.32	5.08	0.3	7.14e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
CESC	cis	rs10463316	0.817	rs1508772	chr5:150816561	A/C	cg03212797	chr5:150827313	SLC36A1	-0.51	-6.69	-0.38	1.32e-10	Metabolite levels (Pyroglutamine);
CESC	cis	rs4474465	0.920	rs10899535	chr11:78216237	G/A	cg27205649	chr11:78285834	NARS2	0.44	5.31	0.31	2.33e-7	Alzheimer's disease (survival time);
CESC	cis	rs7618915	0.501	rs11130308	chr3:52639257	G/C	cg18404041	chr3:52824283	ITIH1	-0.38	-6.52	-0.37	3.57e-10	Bipolar disorder;
CESC	cis	rs6460942	0.915	rs17541464	chr7:12462675	A/G	cg20607287	chr7:12443886	VWDE	-0.77	-10.72	-0.55	1.7e-22	Coronary artery disease;
CESC	cis	rs791888	0.767	rs2255684	chr10:89419971	C/T	cg13926569	chr10:89418898	PAPSS2	-0.53	-7.45	-0.42	1.34e-12	Magnesium levels;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg23885512	chr19:45515293	RELB	0.42	6.24	0.36	1.7e-9	Fibrinogen levels;
CESC	cis	rs6591182	0.503	rs11227241	chr11:65389890	G/C	cg27068330	chr11:65405492	SIPA1	-0.47	-5.6	-0.33	5.34e-8	Non-alcoholic fatty liver disease histology (lobular);
CESC	cis	rs477895	0.653	rs34089806	chr11:63887987	C/T	cg18225595	chr11:63971243	STIP1	0.53	5.26	0.31	3e-7	Mean platelet volume;
CESC	cis	rs4713118	0.662	rs149970	chr6:27980220	C/T	cg17949981	chr6:28129498	ZNF389	0.39	5.21	0.3	3.83e-7	Parkinson's disease;
CESC	trans	rs208520	0.661	rs7747492	chr6:66857788	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.0	-12.93	-0.62	5.39e-30	Exhaled nitric oxide output;
CESC	cis	rs1215050	0.791	rs592053	chr4:98732220	C/T	cg05340658	chr4:99064831	C4orf37	0.51	6.56	0.37	2.89e-10	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs1552244	0.938	rs9873794	chr3:10074153	T/G	cg00166722	chr3:10149974	C3orf24	0.47	6.02	0.35	5.95e-9	Alzheimer's disease;
CESC	cis	rs9910055	0.529	rs615070	chr17:42176591	A/G	cg13607699	chr17:42295918	UBTF	0.43	5.28	0.31	2.66e-7	Total body bone mineral density;
CESC	cis	rs12618769	0.597	rs12622341	chr2:99074680	A/T	cg10123293	chr2:99228465	UNC50	0.39	5.07	0.3	7.32e-7	Bipolar disorder;
CESC	cis	rs7666738	0.830	rs11947027	chr4:99005941	T/C	cg18180107	chr4:99064573	C4orf37	0.4	5.23	0.31	3.41e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4803468	1.000	rs10422956	chr19:41901261	C/T	cg14132834	chr19:41945861	ATP5SL	-0.63	-7.84	-0.43	1.12e-13	Height;
CESC	cis	rs780096	0.526	rs780107	chr2:27684734	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.36	-7.38	-0.41	2.02e-12	Total body bone mineral density;
CESC	cis	rs7811142	0.830	rs118119933	chr7:99939050	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.69	5.71	0.33	2.96e-8	Platelet count;
CESC	cis	rs3824867	0.920	rs7126210	chr11:47460306	A/G	cg20307385	chr11:47447363	PSMC3	0.5	5.96	0.34	7.83e-9	Mean corpuscular hemoglobin;
CESC	cis	rs7811142	0.720	rs112622797	chr7:99917416	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.97	8.03	0.44	3.21e-14	Platelet count;
CESC	cis	rs9287719	0.967	rs715246	chr2:10736355	G/A	cg00105475	chr2:10696890	NA	0.39	5.61	0.33	4.96e-8	Prostate cancer;
CESC	cis	rs12612435	0.554	rs35820061	chr2:137064885	C/T	cg23554286	chr2:137951070	THSD7B	0.63	5.13	0.3	5.59e-7	Takotsubo syndrome;
CESC	trans	rs650950	0.528	rs646660	chr11:35528452	C/T	cg24816464	chr3:86061715	CADM2	-0.45	-6.03	-0.35	5.59e-9	Bronchopulmonary dysplasia;
CESC	cis	rs514406	0.825	rs7523761	chr1:53250915	T/C	cg25767906	chr1:53392781	SCP2	0.43	6.02	0.35	5.86e-9	Monocyte count;
CESC	cis	rs9929218	1.000	rs12448448	chr16:68802516	T/G	cg02972257	chr16:68554789	NA	0.43	5.22	0.31	3.65e-7	Colorectal cancer;
CESC	trans	rs11098499	0.754	rs1511017	chr4:120250805	G/A	cg25214090	chr10:38739885	LOC399744	0.62	8.7	0.47	3.58e-16	Corneal astigmatism;
CESC	cis	rs1801251	0.752	rs2675966	chr2:233735543	T/C	cg25237894	chr2:233734115	C2orf82	-0.5	-8.72	-0.47	3.06e-16	Coronary artery disease;
CESC	cis	rs12497850	0.931	rs9311433	chr3:48863835	T/C	cg06212747	chr3:49208901	KLHDC8B	0.66	8.99	0.48	4.84e-17	Parkinson's disease;
CESC	cis	rs6964587	0.869	rs10250014	chr7:91490208	T/C	cg17063962	chr7:91808500	NA	-0.53	-7.23	-0.41	5.28e-12	Breast cancer;
CESC	cis	rs7772486	0.686	rs9373473	chr6:146082282	A/G	cg23711669	chr6:146136114	FBXO30	0.79	11.4	0.57	8.94e-25	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs938554	0.513	rs10939650	chr4:9998440	C/T	cg02734326	chr4:10020555	SLC2A9	0.42	5.29	0.31	2.58e-7	Blood metabolite levels;
CESC	cis	rs1799949	1.000	rs4340367	chr17:41307772	G/A	cg06001716	chr17:41278141	BRCA1;NBR2	0.37	5.07	0.3	7.62e-7	Menopause (age at onset);
CESC	cis	rs9611565	0.659	rs12484228	chr22:41939739	A/G	cg03806693	chr22:41940476	POLR3H	-1.23	-16.62	-0.71	5.48e-43	Vitiligo;
CESC	cis	rs28374715	0.635	rs112547435	chr15:41648737	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.92	-14.13	-0.66	3.48e-34	Ulcerative colitis;
CESC	cis	rs17711722	0.522	rs62469933	chr7:65265639	G/A	cg04775059	chr7:64541387	NA	0.45	5.7	0.33	3.17e-8	Calcium levels;
CESC	cis	rs7084402	0.967	rs1649062	chr10:60309326	G/A	cg07615347	chr10:60278583	BICC1	0.59	9.34	0.5	4.21e-18	Refractive error;
CESC	cis	rs875971	0.929	rs778692	chr7:65872449	A/G	cg12463550	chr7:65579703	CRCP	0.58	7.41	0.41	1.67e-12	Aortic root size;
CESC	cis	rs861020	0.630	rs627069	chr1:210004613	C/G	cg05527609	chr1:210001259	C1orf107	0.74	9.67	0.51	3.97e-19	Orofacial clefts;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg17967728	chr15:52263786	LEO1	-0.52	-6.26	-0.36	1.53e-9	Ulcerative colitis;
CESC	cis	rs9611565	0.921	rs761366	chr22:41744022	C/G	cg03806693	chr22:41940476	POLR3H	-0.97	-10.9	-0.56	4.3e-23	Vitiligo;
CESC	cis	rs2243480	1.000	rs316318	chr7:65612904	A/G	cg13147721	chr7:65941812	NA	-0.97	-9.14	-0.49	1.7e-17	Diabetic kidney disease;
CESC	cis	rs9487051	0.737	rs1260593	chr6:109521400	C/T	cg01475377	chr6:109611718	NA	-0.46	-6.93	-0.39	3.18e-11	Reticulocyte fraction of red cells;
CESC	cis	rs4629180	0.675	rs4851459	chr2:102109006	T/A	cg21388029	chr2:102003306	CREG2	0.31	5.21	0.3	3.84e-7	Chronic rhinosinusitis with nasal polyps;
CESC	cis	rs796364	1.000	rs281759	chr2:200787719	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	0.86	8.24	0.45	8e-15	Schizophrenia;
CESC	cis	rs780096	0.587	rs10205219	chr2:27568565	T/C	cg21248554	chr2:27665150	KRTCAP3	-0.35	-7.43	-0.42	1.45e-12	Total body bone mineral density;
CESC	cis	rs10911232	0.507	rs4652762	chr1:182993960	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.84	13.19	0.63	6.74e-31	Hypertriglyceridemia;
CESC	cis	rs7412746	0.611	rs11204726	chr1:150743492	T/C	cg09365446	chr1:150670422	GOLPH3L	0.4	5.26	0.31	3.03e-7	Melanoma;
CESC	cis	rs61841072	0.961	rs10803104	chr1:243126037	T/C	cg02356786	chr1:243265016	LOC731275	0.4	5.04	0.3	8.48e-7	Schizophrenia;
CESC	cis	rs28647808	1.000	rs2285484	chr9:136271841	C/A	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.9	5.73	0.33	2.75e-8	Blood protein levels;
CESC	cis	rs933688	0.759	rs1423593	chr5:90752351	T/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.89	9.76	0.51	2.08e-19	Smoking behavior;
CESC	cis	rs6831352	0.918	rs29001216	chr4:100051556	A/T	cg13256891	chr4:100009986	ADH5	-0.77	-8.43	-0.46	2.27e-15	Alcohol dependence;
CESC	cis	rs7264396	0.563	rs11698796	chr20:34248134	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.89	-9.76	-0.51	2.07e-19	Total cholesterol levels;
CESC	cis	rs9811920	0.732	rs7613864	chr3:99602470	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.46	7.72	0.43	2.44e-13	Axial length;
CESC	cis	rs787274	0.867	rs1711744	chr9:115453484	A/T	cg13803584	chr9:115635662	SNX30	-0.53	-5.37	-0.31	1.72e-7	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs9733	0.596	rs7538493	chr1:150655421	T/C	cg22823121	chr1:150693482	HORMAD1	0.48	7.09	0.4	1.21e-11	Tonsillectomy;
CESC	cis	rs12142240	0.698	rs55670684	chr1:46835139	C/T	cg00530320	chr1:46809349	NSUN4	0.63	8.16	0.45	1.33e-14	Menopause (age at onset);
CESC	cis	rs752010	0.619	rs10736421	chr1:42106230	G/A	cg06885757	chr1:42089581	HIVEP3	0.65	10.26	0.53	5.33e-21	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs5769765	0.862	rs138870	chr22:50209737	C/T	cg02269571	chr22:50332266	NA	-0.46	-5.89	-0.34	1.17e-8	Schizophrenia;
CESC	cis	rs11792861	0.926	rs11788825	chr9:111829757	T/G	cg13535736	chr9:111863775	C9orf5	-0.46	-6.32	-0.36	1.1e-9	Menarche (age at onset);
CESC	cis	rs10911232	0.507	rs10797833	chr1:183044067	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.86	13.3	0.63	2.92e-31	Hypertriglyceridemia;
CESC	cis	rs9322193	0.923	rs62439842	chr6:149996983	G/A	cg04369109	chr6:150039330	LATS1	-0.4	-5.51	-0.32	8.53e-8	Lung cancer;
CESC	cis	rs7666738	0.830	rs13106434	chr4:98991651	T/A	cg18180107	chr4:99064573	C4orf37	0.4	5.23	0.31	3.41e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs17655565	0.904	rs3809172	chr12:52695198	G/C	cg08257133	chr12:52711352	KRT83	0.51	5.74	0.33	2.65e-8	Plasma amyloid beta peptide concentrations (ABx-42);
CESC	cis	rs7833986	0.501	rs17815934	chr8:57038395	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.61	7.55	0.42	7e-13	Height;
CESC	cis	rs9549367	0.577	rs3024718	chr13:113813853	C/T	cg00898013	chr13:113819073	PROZ	0.45	6.12	0.35	3.33e-9	Platelet distribution width;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19556901	chr15:25414769	SNORD115-1	-0.52	-6.64	-0.38	1.74e-10	Gut microbiome composition (summer);
CESC	cis	rs2841277	0.645	rs28380382	chr14:105410827	C/T	cg21017887	chr14:105400489	NA	0.42	6.83	0.39	5.93e-11	Rheumatoid arthritis;
CESC	cis	rs7084402	0.967	rs7094882	chr10:60276829	C/T	cg07615347	chr10:60278583	BICC1	-0.59	-9.45	-0.5	1.9e-18	Refractive error;
CESC	cis	rs2425143	1.000	rs2425078	chr20:34298163	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.82	-8.05	-0.44	2.8e-14	Blood protein levels;
CESC	cis	rs3768617	0.510	rs12061219	chr1:183101471	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.89	14.39	0.66	4.39e-35	Fuchs's corneal dystrophy;
CESC	cis	rs9291683	0.546	rs13139055	chr4:10038924	G/T	cg11266682	chr4:10021025	SLC2A9	0.66	12.46	0.61	2.27e-28	Bone mineral density;
CESC	cis	rs244293	0.831	rs11079147	chr17:53094754	G/A	cg19360675	chr17:53046073	COX11;STXBP4	0.4	5.11	0.3	6.18e-7	Menarche (age at onset);
CESC	cis	rs7107174	0.681	rs3102742	chr11:77949334	G/T	cg02023728	chr11:77925099	USP35	0.54	6.82	0.39	6.19e-11	Testicular germ cell tumor;
CESC	cis	rs2952156	0.920	rs2517951	chr17:37853097	C/T	cg19468946	chr17:37922297	IKZF3	-0.42	-5.31	-0.31	2.3e-7	Asthma;
CESC	trans	rs453301	0.571	rs330057	chr8:9089793	C/T	cg06636001	chr8:8085503	FLJ10661	-0.53	-6.79	-0.38	7.49e-11	Joint mobility (Beighton score);
CESC	cis	rs6088580	0.634	rs6059897	chr20:33113224	A/G	cg06115741	chr20:33292138	TP53INP2	0.44	5.59	0.32	5.74e-8	Glomerular filtration rate (creatinine);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg25355645	chr19:42873746	MEGF8	0.44	6.37	0.36	8.39e-10	Fibrinogen levels;
CESC	cis	rs1218582	0.710	rs4845687	chr1:154878911	A/G	cg24250549	chr1:154909240	PMVK	0.74	11.08	0.56	1.06e-23	Prostate cancer;
CESC	cis	rs6674970	0.518	rs15740	chr1:151040435	G/A	cg04469105	chr1:151031679	CDC42SE1;MLLT11	-0.44	-5.18	-0.3	4.31e-7	Childhood ear infection;
CESC	trans	rs11992162	0.967	rs7836456	chr8:11829175	T/G	cg15556689	chr8:8085844	FLJ10661	0.55	6.53	0.37	3.39e-10	Monocyte count;
CESC	cis	rs67478160	0.643	rs2295141	chr14:104212949	T/C	cg08213375	chr14:104286397	PPP1R13B	0.54	10.89	0.56	4.58e-23	Schizophrenia;
CESC	cis	rs2836974	0.666	rs12626405	chr21:40663121	G/T	cg11890956	chr21:40555474	PSMG1	-0.95	-15.5	-0.69	5.28e-39	Cognitive function;
CESC	cis	rs1218582	0.772	rs877343	chr1:154910012	A/G	cg16680214	chr1:154839983	KCNN3	-0.45	-6.88	-0.39	4.19e-11	Prostate cancer;
CESC	cis	rs1808579	0.935	rs7239575	chr18:21120035	C/T	cg14672496	chr18:21087552	C18orf8	-0.42	-6.39	-0.37	7.32e-10	Hip circumference;Body mass index;BMI (adjusted for smoking behaviour);
CESC	cis	rs3096299	0.719	rs12934708	chr16:89523790	C/T	cg00750074	chr16:89608354	SPG7	-0.43	-6.26	-0.36	1.54e-9	Multiple myeloma (IgH translocation);
CESC	cis	rs13191362	0.507	rs2023015	chr6:163060528	A/T	cg21926612	chr6:163149169	PACRG;PARK2	-0.55	-6.74	-0.38	1.01e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	trans	rs2727020	0.595	rs10839281	chr11:49483373	A/C	cg15704280	chr7:45808275	SEPT13	-0.94	-16.68	-0.72	3.31e-43	Coronary artery disease;
CESC	cis	rs10208940	0.920	rs7576303	chr2:68838019	G/A	cg12452813	chr2:68675892	NA	0.52	5.18	0.3	4.48e-7	Urate levels in lean individuals;
CESC	cis	rs3096299	0.754	rs2965816	chr16:89514183	G/T	cg02034447	chr16:89574710	SPG7	-0.47	-6.04	-0.35	5.27e-9	Multiple myeloma (IgH translocation);
CESC	cis	rs7219021	1.000	rs68012338	chr17:46856405	G/A	cg16584676	chr17:46985605	UBE2Z	-0.56	-6.32	-0.36	1.08e-9	Schizophrenia or bipolar disorder;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg23962285	chr1:108743536	SLC25A24	0.46	6.38	0.36	7.79e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs4253772	0.530	rs9615989	chr22:46803774	A/T	cg00784671	chr22:46762841	CELSR1	-0.77	-6.06	-0.35	4.76e-9	LDL cholesterol;Cholesterol, total;
CESC	cis	rs7659604	0.537	rs6823818	chr4:122731699	G/C	cg06713675	chr4:122721982	EXOSC9	-0.51	-6.99	-0.39	2.2e-11	Type 2 diabetes;
CESC	cis	rs3733585	0.664	rs28602527	chr4:9958327	G/A	cg02734326	chr4:10020555	SLC2A9	-0.43	-6.01	-0.35	6.1e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs801193	0.591	rs2707839	chr7:66193084	A/G	cg18876405	chr7:65276391	NA	0.45	6.08	0.35	4.15e-9	Aortic root size;
CESC	cis	rs1215050	0.791	rs2695472	chr4:98855127	T/C	cg05340658	chr4:99064831	C4orf37	-0.5	-6.59	-0.38	2.32e-10	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs6939532	0.522	rs4712980	chr6:26355758	G/T	cg14345882	chr6:26364793	BTN3A2	-0.38	-5.87	-0.34	1.27e-8	Autism spectrum disorder or schizophrenia;
CESC	cis	rs17376456	0.825	rs10054903	chr5:93281491	C/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.67	5.51	0.32	8.46e-8	Diabetic retinopathy;
CESC	cis	rs8177253	0.665	rs7646118	chr3:133450039	C/T	cg18769074	chr3:133464867	TF	0.32	5.93	0.34	9.22e-9	Iron status biomarkers;
CESC	cis	rs853679	0.517	rs4711164	chr6:28115156	C/T	cg23161317	chr6:28129485	ZNF389	0.52	6.48	0.37	4.48e-10	Depression;
CESC	cis	rs2070997	0.667	rs12156431	chr9:133719540	A/G	cg11464064	chr9:133710261	ABL1	0.66	7.42	0.41	1.62e-12	Response to amphetamines;
CESC	cis	rs617791	0.569	rs11227370	chr11:65747693	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.38	-5.15	-0.3	5.05e-7	Breast cancer;
CESC	cis	rs17854409	0.803	rs1063246	chr20:61472116	G/A	cg07645718	chr20:61493192	TCFL5	0.79	5.2	0.3	4.02e-7	Obesity-related traits;
CESC	cis	rs12497850	0.805	rs6446198	chr3:49007638	T/A	cg07636037	chr3:49044803	WDR6	1.08	19.66	0.77	1.06e-53	Parkinson's disease;
CESC	cis	rs1799949	0.965	rs2236762	chr17:41226675	A/T	cg25072359	chr17:41440525	NA	0.49	7.18	0.4	7.06e-12	Menopause (age at onset);
CESC	cis	rs6582630	0.555	rs2090785	chr12:38424342	G/A	cg26384229	chr12:38710491	ALG10B	0.69	10.55	0.54	5.83e-22	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs7726839	0.540	rs12517638	chr5:645484	C/T	cg16447950	chr5:562315	NA	-0.58	-6.53	-0.37	3.38e-10	Obesity-related traits;
CESC	trans	rs10506458	0.834	rs73125186	chr12:63373400	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.3	-17.22	-0.73	4.04e-45	Hemostatic factors and hematological phenotypes;
CESC	cis	rs7474896	0.583	rs7071147	chr10:38003376	T/C	cg00409905	chr10:38381863	ZNF37A	-0.48	-5.59	-0.32	5.65e-8	Obesity (extreme);
CESC	cis	rs4654899	0.865	rs10916951	chr1:21528835	A/G	cg05370193	chr1:21551575	ECE1	-0.45	-7.0	-0.4	2.06e-11	Superior frontal gyrus grey matter volume;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg06886078	chr10:126480477	METTL10	-0.46	-6.25	-0.36	1.6e-9	Fibrinogen levels;
CESC	cis	rs1862618	0.853	rs832568	chr5:56153776	G/A	cg12311346	chr5:56204834	C5orf35	-0.74	-8.75	-0.47	2.61e-16	Initial pursuit acceleration;
CESC	cis	rs933688	0.583	rs6882172	chr5:90576958	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.48	-5.38	-0.31	1.64e-7	Smoking behavior;
CESC	cis	rs79349575	0.783	rs59270107	chr17:47026185	A/T	cg16584676	chr17:46985605	UBE2Z	0.54	6.67	0.38	1.46e-10	Type 2 diabetes;
CESC	cis	rs962856	1.000	rs11888062	chr2:67605358	C/A	cg09028215	chr2:67624308	ETAA1	-0.42	-5.52	-0.32	8.03e-8	Pancreatic cancer;
CESC	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg06873352	chr17:61820015	STRADA	0.74	13.03	0.62	2.6e-30	Prudent dietary pattern;
CESC	cis	rs9513627	0.512	rs9517759	chr13:100180108	T/G	cg15490075	chr13:100150979	NA	0.48	5.22	0.31	3.59e-7	Obesity-related traits;
CESC	cis	rs7949030	0.588	rs2428549	chr11:62312394	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.48	6.74	0.38	9.6e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs3820068	0.603	rs7531396	chr1:15969870	G/C	cg18133145	chr1:16060689	PLEKHM2	-0.4	-5.07	-0.3	7.37e-7	Systolic blood pressure;
CESC	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	22.27	0.81	1.17e-62	Prudent dietary pattern;
CESC	cis	rs7089973	0.872	rs36036948	chr10:116631649	A/G	cg25233709	chr10:116636983	FAM160B1	0.34	5.03	0.3	8.89e-7	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs4450798	0.649	rs6806000	chr3:13779211	C/T	cg23332027	chr3:13681764	NA	0.4	5.59	0.32	5.77e-8	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs16854884	0.632	rs60505453	chr3:143643864	C/G	cg06585982	chr3:143692056	C3orf58	0.54	7.1	0.4	1.15e-11	Economic and political preferences (feminism/equality);
CESC	cis	rs9300255	0.770	rs12299125	chr12:123862447	C/T	cg19016782	chr12:123741754	C12orf65	0.46	6.33	0.36	1.04e-9	Neutrophil percentage of white cells;
CESC	cis	rs9649213	0.537	rs6971825	chr7:97979548	C/T	cg21770322	chr7:97807741	LMTK2	0.57	8.84	0.48	1.39e-16	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs9649213	0.593	rs7807555	chr7:97957517	G/A	cg00277769	chr7:97922759	BAIAP2L1	-0.33	-5.42	-0.32	1.31e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs6545883	0.868	rs778755	chr2:61781037	A/G	cg15711740	chr2:61764176	XPO1	0.39	5.1	0.3	6.63e-7	Tuberculosis;
CESC	cis	rs4737010	0.570	rs10112594	chr8:41645565	C/T	cg08923054	chr8:41654455	ANK1	0.53	6.67	0.38	1.51e-10	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
CESC	cis	rs367615	0.506	rs246102	chr5:108699695	C/G	cg17395555	chr5:108820864	NA	-0.44	-7.13	-0.4	9.39e-12	Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs9399135	0.967	rs6910530	chr6:135332770	C/T	cg24558204	chr6:135376177	HBS1L	0.54	7.47	0.42	1.19e-12	Red blood cell count;
CESC	cis	rs644799	0.735	rs10831432	chr11:95516040	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	11.8	0.59	4.17e-26	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs4746818	1.000	rs4746817	chr10:70882515	T/C	cg11621586	chr10:70884670	VPS26A	0.86	8.53	0.46	1.15e-15	Left atrial antero-posterior diameter;
CESC	cis	rs9916302	0.861	rs12150493	chr17:37586154	T/C	cg00129232	chr17:37814104	STARD3	-0.56	-7.35	-0.41	2.4e-12	Glomerular filtration rate (creatinine);
CESC	cis	rs16866061	0.515	rs11695326	chr2:225415134	A/G	cg12698349	chr2:225449008	CUL3	0.84	15.12	0.68	1.11e-37	Acute graft versus host disease in bone marrow transplantation (recipient effect);
CESC	cis	rs1862618	0.853	rs2113079	chr5:56157951	A/G	cg12311346	chr5:56204834	C5orf35	-0.74	-8.94	-0.48	6.7e-17	Initial pursuit acceleration;
CESC	cis	rs11098499	0.909	rs35111518	chr4:120440682	A/G	cg09307838	chr4:120376055	NA	0.92	12.5	0.61	1.73e-28	Corneal astigmatism;
CESC	cis	rs3845702	0.736	rs16867131	chr2:180848651	A/G	cg01881094	chr2:180872142	CWC22	-1.05	-9.02	-0.48	3.86e-17	Schizophrenia;
CESC	trans	rs10772915	0.739	rs1799497	chr12:16399551	T/C	cg26946092	chr2:236139863	NA	-0.37	-6.01	-0.35	6.15e-9	Visceral fat;
CESC	cis	rs2075371	0.796	rs12672752	chr7:134007382	C/T	cg20476274	chr7:133979776	SLC35B4	0.61	8.39	0.46	2.93e-15	Mean platelet volume;
CESC	cis	rs9388451	0.839	rs980014	chr6:126068001	T/G	cg05901451	chr6:126070800	HEY2	-0.64	-9.03	-0.48	3.73e-17	Brugada syndrome;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10719100	chr8:146078187	COMMD5	0.61	7.29	0.41	3.61e-12	Gut microbiome composition (summer);
CESC	cis	rs17253792	0.822	rs75936910	chr14:56149351	T/C	cg01858014	chr14:56050164	KTN1	-0.97	-7.54	-0.42	7.36e-13	Putamen volume;
CESC	cis	rs7772486	0.754	rs9497401	chr6:146051271	T/C	cg23711669	chr6:146136114	FBXO30	-1.0	-15.4	-0.69	1.15e-38	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06339974	chr13:20437949	ZMYM5	0.59	6.49	0.37	4.3e-10	Gut microbiome composition (summer);
CESC	cis	rs4319547	0.915	rs10734924	chr12:123018894	T/G	cg23029597	chr12:123009494	RSRC2	-0.5	-5.5	-0.32	8.83e-8	Body mass index;
CESC	cis	rs12142240	0.698	rs68191463	chr1:46808695	T/C	cg00530320	chr1:46809349	NSUN4	0.6	7.98	0.44	4.48e-14	Menopause (age at onset);
CESC	cis	rs116988415	0.584	rs4902313	chr14:65242164	T/C	cg25083366	chr14:65239357	SPTB	0.69	5.05	0.3	8.39e-7	Daytime sleep phenotypes;
CESC	cis	rs875971	0.862	rs778736	chr7:65813848	C/T	cg18252515	chr7:66147081	NA	-0.45	-5.88	-0.34	1.22e-8	Aortic root size;
CESC	cis	rs4812048	0.895	rs236691	chr20:57583536	G/C	cg14073986	chr20:57617431	SLMO2	0.62	5.87	0.34	1.32e-8	Mean platelet volume;
CESC	trans	rs7246657	0.943	rs6508733	chr19:38000548	A/T	cg01833234	chr11:6592585	DNHD1	0.51	6.18	0.35	2.37e-9	Coronary artery calcification;
CESC	cis	rs1799949	1.000	rs4534897	chr17:41431808	A/G	cg06001716	chr17:41278141	BRCA1;NBR2	0.41	5.62	0.33	4.72e-8	Menopause (age at onset);
CESC	trans	rs9467711	0.584	rs34244947	chr6:26761745	T/C	cg01620082	chr3:125678407	NA	-0.74	-6.32	-0.36	1.11e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs9910055	0.762	rs2240226	chr17:42266218	C/T	cg08499158	chr17:42289980	UBTF	-0.5	-6.36	-0.36	8.78e-10	Total body bone mineral density;
CESC	trans	rs1493916	0.905	rs10460051	chr18:31413679	C/T	cg27147174	chr7:100797783	AP1S1	-0.53	-6.83	-0.39	5.73e-11	Life satisfaction;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20476274	chr7:133979776	SLC35B4	-0.56	-6.03	-0.35	5.39e-9	Gut microbiome composition (summer);
CESC	cis	rs896854	0.812	rs4582532	chr8:95969257	G/A	cg16049864	chr8:95962084	TP53INP1	-0.67	-12.13	-0.6	3.13e-27	Type 2 diabetes;
CESC	cis	rs3126085	0.935	rs7550106	chr1:152197202	C/T	cg03465714	chr1:152285911	FLG	0.43	5.48	0.32	9.96e-8	Atopic dermatitis;
CESC	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg05564831	chr3:52568323	NT5DC2	0.48	8.11	0.45	1.83e-14	Bipolar disorder;
CESC	cis	rs1552244	1.000	rs61052895	chr3:10147516	G/A	cg08888203	chr3:10149979	C3orf24	0.46	5.84	0.34	1.5e-8	Alzheimer's disease;
CESC	cis	rs4889855	0.556	rs9911795	chr17:78626115	T/C	cg09596252	chr17:78655493	RPTOR	0.42	5.09	0.3	6.68e-7	Fractional excretion of uric acid;
CESC	trans	rs11098499	0.754	rs10006259	chr4:120242145	C/T	cg25214090	chr10:38739885	LOC399744	0.61	8.47	0.46	1.73e-15	Corneal astigmatism;
CESC	cis	rs1413885	0.516	rs716592	chr1:65843982	C/T	cg14976592	chr1:65886160	LEPROT;LEPR	-0.51	-6.58	-0.37	2.47e-10	Anticoagulant levels;
CESC	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg11494091	chr17:61959527	GH2	0.73	12.49	0.61	1.88e-28	Prudent dietary pattern;
CESC	cis	rs7084402	1.000	rs11006169	chr10:60269326	T/A	cg07615347	chr10:60278583	BICC1	-0.57	-8.71	-0.47	3.43e-16	Refractive error;
CESC	cis	rs9916302	0.904	rs11654018	chr17:37703740	C/T	cg07936489	chr17:37558343	FBXL20	0.8	11.58	0.58	2.37e-25	Glomerular filtration rate (creatinine);
CESC	cis	rs873946	0.504	rs12775990	chr10:134575836	C/T	cg26818010	chr10:134567672	INPP5A	-0.91	-11.18	-0.57	5.13e-24	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs7481584	0.517	rs80872	chr11:3049984	G/T	cg25174290	chr11:3078921	CARS	-0.45	-6.28	-0.36	1.36e-9	Calcium levels;
CESC	cis	rs12477438	0.501	rs11688004	chr2:99735052	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.79	13.0	0.62	3.21e-30	Chronic sinus infection;
CESC	cis	rs7777484	0.500	rs2533885	chr7:2835655	C/T	cg19717773	chr7:2847554	GNA12	-0.66	-11.58	-0.58	2.34e-25	Height;
CESC	cis	rs36051895	0.659	rs7036476	chr9:5063664	T/C	cg02405213	chr9:5042618	JAK2	-0.46	-5.75	-0.33	2.45e-8	Pediatric autoimmune diseases;
CESC	cis	rs7618915	0.547	rs62255371	chr3:52747321	A/G	cg05564831	chr3:52568323	NT5DC2	0.44	6.63	0.38	1.92e-10	Bipolar disorder;
CESC	cis	rs2243480	1.000	rs431076	chr7:65600320	A/C	cg12463550	chr7:65579703	CRCP	0.74	5.75	0.33	2.4e-8	Diabetic kidney disease;
CESC	cis	rs6460942	1.000	rs2053378	chr7:12405564	C/G	cg20607287	chr7:12443886	VWDE	-0.79	-8.72	-0.47	3.1e-16	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00500481	chr6:36562387	SFRS3	0.62	7.07	0.4	1.39e-11	Gut microbiome composition (summer);
CESC	cis	rs11958404	0.932	rs72816566	chr5:157427613	G/A	cg05962755	chr5:157440814	NA	0.59	6.45	0.37	5.28e-10	IgG glycosylation;
CESC	cis	rs7107174	1.000	rs10899483	chr11:78061057	G/C	cg02023728	chr11:77925099	USP35	0.38	5.4	0.31	1.47e-7	Testicular germ cell tumor;
CESC	cis	rs6951245	0.507	rs11976805	chr7:1138716	C/T	cg03188948	chr7:1209495	NA	0.49	5.81	0.34	1.8e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs6460942	0.915	rs6965564	chr7:12306013	C/T	cg06484146	chr7:12443880	VWDE	-0.41	-5.68	-0.33	3.61e-8	Coronary artery disease;
CESC	cis	rs7103648	0.643	rs12365079	chr11:47696596	A/T	cg20307385	chr11:47447363	PSMC3	0.82	12.41	0.61	3.41e-28	Diastolic blood pressure;Systolic blood pressure;
CESC	cis	rs7772486	0.754	rs9390356	chr6:146118983	A/T	cg23711669	chr6:146136114	FBXO30	-1.01	-15.6	-0.69	2.22e-39	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs875971	0.862	rs9791712	chr7:66105163	C/G	cg11764359	chr7:65958608	NA	-0.74	-10.23	-0.53	6.36e-21	Aortic root size;
CESC	cis	rs6690583	0.524	rs12029690	chr1:85452867	C/G	cg22153463	chr1:85462885	MCOLN2	0.71	7.12	0.4	1.01e-11	Serum sulfate level;
CESC	cis	rs13242816	1.000	rs35800921	chr7:116124041	G/A	cg04696780	chr7:116139425	CAV2	-0.58	-5.21	-0.3	3.79e-7	P wave duration;
CESC	cis	rs13191362	0.507	rs2849520	chr6:163132038	T/C	cg06582575	chr6:163149167	PACRG;PARK2	-0.66	-7.64	-0.42	3.99e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs2404602	0.692	rs35195096	chr15:76938447	C/T	cg26408565	chr15:76604113	ETFA	-0.4	-5.68	-0.33	3.45e-8	Blood metabolite levels;
CESC	cis	rs9612	0.950	rs346546	chr19:44256910	T/C	cg08581076	chr19:44259116	C19orf61	0.52	6.19	0.36	2.33e-9	Exhaled nitric oxide output;
CESC	cis	rs9435341	0.965	rs61798468	chr1:107569316	T/G	cg09367891	chr1:107599246	PRMT6	0.72	8.38	0.46	3.06e-15	Facial morphology (factor 21, depth of nasal alae);
CESC	cis	rs2576037	0.526	rs649076	chr18:44414614	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.56	-7.89	-0.44	8.05e-14	Personality dimensions;
CESC	cis	rs600231	0.706	rs10896016	chr11:65335705	C/T	cg21890820	chr11:65308645	LTBP3	-0.41	-5.19	-0.3	4.14e-7	Bone mineral density;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg04827747	chr7:134855666	C7orf49	-0.48	-6.22	-0.36	1.95e-9	Asthma;
CESC	cis	rs1862618	0.573	rs2591962	chr5:56237155	G/A	cg22800045	chr5:56110881	MAP3K1	-0.76	-8.67	-0.47	4.42e-16	Initial pursuit acceleration;
CESC	cis	rs7618915	0.532	rs13060675	chr3:52674300	T/G	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.36	6.46	0.37	4.98e-10	Bipolar disorder;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg12095067	chr19:9929835	FBXL12	-0.41	-6.02	-0.35	5.81e-9	Gambling;
CESC	cis	rs6087990	0.835	rs4911106	chr20:31331330	A/G	cg13636640	chr20:31349939	DNMT3B	0.84	14.79	0.67	1.67e-36	Ulcerative colitis;
CESC	cis	rs71403859	0.502	rs8053720	chr16:71456142	C/G	cg08717414	chr16:71523259	ZNF19	-0.81	-8.02	-0.44	3.47e-14	Post bronchodilator FEV1;
CESC	cis	rs1707322	1.000	rs785484	chr1:46574015	T/C	cg05343316	chr1:45956843	TESK2	-0.47	-5.52	-0.32	7.97e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs10776614	0.799	rs1838568	chr10:49763690	G/C	cg19218067	chr2:181235115	NA	0.5	6.1	0.35	3.7e-9	Self-employment;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02615117	chr20:36034986	NA	-0.55	-6.86	-0.39	4.88e-11	Gut microbiome composition (summer);
CESC	cis	rs611744	0.647	rs1609472	chr8:109269232	T/G	cg21045802	chr8:109455806	TTC35	0.5	6.25	0.36	1.62e-9	Dupuytren's disease;
CESC	cis	rs113601626	1	rs113601626	chr2:24239189	T/TCCTGGC	cg20701182	chr2:24300061	SF3B14	0.82	6.96	0.39	2.66e-11	Lymphocyte percentage of white cells;
CESC	trans	rs9987353	0.840	rs329994	chr8:9123233	A/G	cg27277367	chr15:100106179	MEF2A	-0.46	-6.0	-0.35	6.36e-9	Recombination measurement;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00026230	chr16:30064606	ALDOA	0.71	8.32	0.46	4.67e-15	Gut microbiome composition (summer);
CESC	cis	rs514406	0.584	rs11205997	chr1:53195271	G/C	cg16325326	chr1:53192061	ZYG11B	-1.01	-17.88	-0.74	1.89e-47	Monocyte count;
CESC	cis	rs58785573	1.000	rs58785573	chr4:38653773	A/T	cg18361445	chr4:38666374	KLF3;FLJ13197	0.49	6.27	0.36	1.48e-9	Lymphocyte percentage of white cells;
CESC	cis	rs12142240	0.698	rs79490411	chr1:46813568	G/A	cg10495392	chr1:46806563	NSUN4	0.56	5.83	0.34	1.64e-8	Menopause (age at onset);
CESC	cis	rs8020095	0.571	rs3784078	chr14:67559710	G/C	cg19548862	chr14:67692701	FAM71D	-0.48	-5.84	-0.34	1.5e-8	Depression (quantitative trait);
CESC	cis	rs41298997	1	rs41298997	chr1:206655331	C/T	cg11166312	chr1:206654246	IKBKE	0.54	7.35	0.41	2.49e-12	Psoriasis;
CESC	cis	rs172166	0.694	rs1150666	chr6:28123928	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.48	-6.04	-0.35	5.19e-9	Cardiac Troponin-T levels;
CESC	cis	rs7957207	0.571	rs1169076	chr12:122429484	G/A	cg22168489	chr12:122356033	WDR66	-0.38	-5.12	-0.3	5.94e-7	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
CESC	cis	rs60871478	1.000	rs6460801	chr7:810506	T/C	cg27478167	chr7:817139	HEATR2	-0.48	-5.25	-0.31	3.11e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs514406	0.861	rs12038438	chr1:53230581	A/T	cg08859206	chr1:53392774	SCP2	0.52	6.88	0.39	4.34e-11	Monocyte count;
CESC	trans	rs6572548	0.504	rs1956082	chr14:49665496	A/C	cg13118410	chr11:49839281	NA	0.52	6.46	0.37	5.01e-10	Subjective well-being;
CESC	cis	rs2839186	0.609	rs2839189	chr21:47694357	C/T	cg12379764	chr21:47803548	PCNT	0.52	6.36	0.36	8.99e-10	Testicular germ cell tumor;
CESC	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg01238044	chr22:24384105	GSTT1	0.5	6.11	0.35	3.47e-9	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs11792861	0.962	rs72607161	chr9:111792640	T/C	cg14384093	chr9:111878565	C9orf5	-0.41	-5.09	-0.3	6.73e-7	Menarche (age at onset);
CESC	cis	rs116095464	1.000	rs6873902	chr5:313337	C/G	cg10591111	chr5:226296	SDHA	-0.63	-5.89	-0.34	1.16e-8	Breast cancer;
CESC	cis	rs1707322	1.000	rs12077974	chr1:46384141	G/A	cg06784218	chr1:46089804	CCDC17	0.33	5.44	0.32	1.22e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs1569419	1.000	rs1569419	chr1:2996602	C/T	cg00806481	chr1:2996650	PRDM16	0.38	5.9	0.34	1.13e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;Plateletcrit;Platelet distribution width;Mean platelet volume;Red blood cell count;
CESC	cis	rs929354	1.000	rs1182452	chr7:157053618	G/A	cg05182265	chr7:156933206	UBE3C	0.44	6.05	0.35	4.99e-9	Body mass index;
CESC	cis	rs26868	0.742	rs26848	chr16:2263516	A/G	cg07587117	chr16:2239488	CASKIN1	0.42	7.16	0.4	8.17e-12	Height;
CESC	trans	rs3780486	0.713	rs3780489	chr9:33129844	G/T	cg04842962	chr6:43655489	MRPS18A	1.01	19.68	0.77	9.13e-54	IgG glycosylation;
CESC	cis	rs4843747	0.519	rs12599755	chr16:88107006	A/G	cg06915872	chr16:87998081	BANP	0.44	5.27	0.31	2.78e-7	Menopause (age at onset);
CESC	cis	rs4722166	0.630	rs7781534	chr7:22778592	A/C	cg05265849	chr7:22767390	IL6	0.57	7.11	0.4	1.06e-11	Lung cancer;
CESC	cis	rs2243480	1.000	rs316331	chr7:65604622	A/G	cg18252515	chr7:66147081	NA	1.38	14.16	0.66	2.93e-34	Diabetic kidney disease;
CESC	cis	rs17818399	0.684	rs62134759	chr2:46791849	G/A	cg26688816	chr2:46740690	ATP6V1E2	-0.55	-5.92	-0.34	1e-8	Height;
CESC	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.54	0.37	3.07e-10	Prudent dietary pattern;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg19853194	chr18:9913725	VAPA	0.47	6.67	0.38	1.45e-10	Systemic lupus erythematosus;
CESC	cis	rs7084402	0.935	rs11006192	chr10:60343638	T/C	cg07615347	chr10:60278583	BICC1	0.55	8.35	0.46	3.86e-15	Refractive error;
CESC	cis	rs9303280	0.901	rs2313430	chr17:37929816	T/C	cg20243544	chr17:37824526	PNMT	-0.49	-6.74	-0.38	1.01e-10	Self-reported allergy;
CESC	cis	rs3091242	0.933	rs28633797	chr1:25741629	C/A	cg27572855	chr1:25598939	RHD	0.43	7.14	0.4	8.75e-12	Erythrocyte sedimentation rate;
CESC	cis	rs561341	0.883	rs4450460	chr17:30201309	C/T	cg00745463	chr17:30367425	LRRC37B	0.57	5.64	0.33	4.28e-8	Hip circumference adjusted for BMI;
CESC	cis	rs477895	0.653	rs7939784	chr11:63910153	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.93	10.18	0.53	9.01e-21	Mean platelet volume;
CESC	trans	rs4596713	0.538	rs11145460	chr9:71766091	T/G	cg16512924	chr15:28394682	HERC2	0.5	6.38	0.36	7.96e-10	Headache;
CESC	cis	rs10791097	0.653	rs11222362	chr11:130731425	T/C	cg12179176	chr11:130786555	SNX19	0.56	8.16	0.45	1.36e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs1707322	0.752	rs4660313	chr1:46110841	A/G	cg05343316	chr1:45956843	TESK2	-0.49	-6.11	-0.35	3.55e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7666738	0.830	rs10009206	chr4:99056900	A/C	cg05340658	chr4:99064831	C4orf37	-0.6	-8.55	-0.46	1.01e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7107174	1.000	rs10899456	chr11:78000155	C/G	cg02023728	chr11:77925099	USP35	0.44	6.09	0.35	3.93e-9	Testicular germ cell tumor;
CESC	cis	rs7107174	0.892	rs2090095	chr11:78034020	G/A	cg02023728	chr11:77925099	USP35	0.41	5.9	0.34	1.09e-8	Testicular germ cell tumor;
CESC	trans	rs7618501	0.602	rs2071207	chr3:50159844	T/C	cg21659725	chr3:3221576	CRBN	-0.48	-6.58	-0.37	2.5e-10	Intelligence (multi-trait analysis);
CESC	cis	rs13191362	1.000	rs13204439	chr6:163015358	A/C	cg14584255	chr6:163149320	PACRG;PARK2	-0.51	-5.76	-0.33	2.31e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs4242434	0.854	rs11782130	chr8:22452357	G/T	cg03733263	chr8:22462867	KIAA1967	0.88	13.83	0.65	4.23e-33	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CESC	cis	rs9911578	1.000	rs302854	chr17:56683612	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.27	0.31	2.87e-7	Intelligence (multi-trait analysis);
CESC	trans	rs17635075	0.590	rs57971645	chr4:167156182	G/A	cg11354629	chr13:28366598	GSX1	-0.56	-6.13	-0.35	3.2e-9	Obesity-related traits;
CESC	cis	rs10791097	0.667	rs1893019	chr11:130756664	C/G	cg09137382	chr11:130731461	NA	0.36	5.33	0.31	2.12e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs4927850	0.958	rs1975582	chr3:195751439	G/T	cg00031303	chr3:195681400	NA	0.47	5.89	0.34	1.19e-8	Pancreatic cancer;
CESC	cis	rs5750830	0.594	rs5757650	chr22:39778419	A/G	cg11247378	chr22:39784982	NA	-0.52	-7.97	-0.44	4.7e-14	Intelligence (multi-trait analysis);
CESC	cis	rs4927850	1.000	rs7627868	chr3:195753473	A/T	cg00031303	chr3:195681400	NA	0.45	5.65	0.33	4.21e-8	Pancreatic cancer;
CESC	cis	rs17826219	0.636	rs2449770	chr17:29101064	G/T	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.17e-10	Body mass index;
CESC	cis	rs875971	0.964	rs6978429	chr7:65959876	T/G	cg11764359	chr7:65958608	NA	0.96	15.25	0.68	3.95e-38	Aortic root size;
CESC	cis	rs9322193	0.884	rs7450246	chr6:150023653	C/T	cg07701084	chr6:150067640	NUP43	0.47	6.63	0.38	1.87e-10	Lung cancer;
CESC	cis	rs651907	0.535	rs2290859	chr3:101525625	C/T	cg12386194	chr3:101231763	SENP7	0.42	5.28	0.31	2.72e-7	Colorectal cancer;
CESC	cis	rs7246657	0.943	rs8109632	chr19:37931125	A/T	cg23950597	chr19:37808831	NA	-0.55	-5.99	-0.35	6.69e-9	Coronary artery calcification;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg27507545	chr10:103880405	LDB1	-0.43	-6.14	-0.35	3.01e-9	Gambling;
CESC	cis	rs28829049	0.861	rs28631243	chr1:19350083	T/C	cg13387374	chr1:19411106	UBR4	0.41	5.07	0.3	7.41e-7	QRS duration in Tripanosoma cruzi seropositivity;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09224523	chr1:206808529	DYRK3	-0.52	-6.1	-0.35	3.65e-9	Gut microbiome composition (summer);
CESC	trans	rs916888	0.779	rs199528	chr17:44843136	C/T	cg22968622	chr17:43663579	NA	1.32	17.92	0.74	1.34e-47	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs763121	0.819	rs5757237	chr22:39073835	G/C	cg06022373	chr22:39101656	GTPBP1	0.89	14.32	0.66	7.5e-35	Menopause (age at onset);
CESC	cis	rs7843479	0.965	rs733544	chr8:21835628	A/G	cg17168535	chr8:21777572	XPO7	0.51	7.2	0.4	6.27e-12	Mean corpuscular volume;
CESC	cis	rs7692995	1.000	rs13105471	chr4:17959776	C/T	cg08925142	chr4:18023851	LCORL	-0.45	-5.13	-0.3	5.66e-7	Height;
CESC	cis	rs1008375	0.966	rs758483	chr4:17703614	G/T	cg27347728	chr4:17578864	LAP3	-0.46	-5.35	-0.31	1.94e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs10540	1.000	rs61876341	chr11:495892	C/G	cg03352830	chr11:487213	PTDSS2	0.74	7.23	0.41	5.31e-12	Body mass index;
CESC	cis	rs11252926	0.565	rs60553947	chr10:474284	T/C	cg16386425	chr10:429943	DIP2C	0.48	5.99	0.35	6.99e-9	Psychosis in Alzheimer's disease;
CESC	cis	rs6952808	0.929	rs12667688	chr7:1931030	C/T	cg05863683	chr7:1912471	MAD1L1	0.5	7.71	0.43	2.52e-13	Bipolar disorder and schizophrenia;
CESC	cis	rs921968	0.565	rs6708192	chr2:219592227	A/G	cg02176678	chr2:219576539	TTLL4	-0.42	-7.45	-0.42	1.32e-12	Mean corpuscular hemoglobin concentration;
CESC	cis	rs6439153	0.933	rs6769662	chr3:128721310	A/C	cg24203234	chr3:128598194	ACAD9	0.4	5.29	0.31	2.56e-7	Pneumococcal bacteremia;
CESC	cis	rs7520050	0.966	rs946529	chr1:46485548	G/T	cg24296786	chr1:45957014	TESK2	0.44	5.5	0.32	8.98e-8	Red blood cell count;Reticulocyte count;
CESC	cis	rs684232	0.644	rs870183	chr17:599811	A/G	cg15660573	chr17:549704	VPS53	-0.62	-8.57	-0.47	8.81e-16	Prostate cancer;
CESC	cis	rs1005277	0.579	rs2474569	chr10:38383491	C/G	cg25517755	chr10:38738941	LOC399744	-0.48	-6.22	-0.36	1.95e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs7249921	0.833	rs73044054	chr19:35666661	C/A	cg15419183	chr19:35660584	FXYD5	0.55	8.48	0.46	1.57e-15	Platelet count;
CESC	cis	rs4481887	0.604	rs4642918	chr1:248411057	A/C	cg02052265	chr1:247712110	C1orf150	-0.31	-5.12	-0.3	5.88e-7	Common traits (Other);
CESC	cis	rs1568889	1.000	rs12797712	chr11:28290890	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.77	9.75	0.51	2.09e-19	Bipolar disorder;
CESC	cis	rs67311347	1.000	rs56303661	chr3:40520778	C/G	cg24209194	chr3:40518798	ZNF619	0.5	6.13	0.35	3.09e-9	Renal cell carcinoma;
CESC	cis	rs2952156	1.000	rs2643195	chr17:37853118	A/G	cg20243544	chr17:37824526	PNMT	0.55	6.71	0.38	1.15e-10	Asthma;
CESC	cis	rs7178572	1.000	rs12910361	chr15:77782335	A/G	cg22256960	chr15:77711686	NA	-0.6	-8.09	-0.44	2.19e-14	Type 2 diabetes;
CESC	cis	rs6540556	0.517	rs11807619	chr1:209881373	G/T	cg05527609	chr1:210001259	C1orf107	-0.59	-5.91	-0.34	1.05e-8	Red blood cell count;
CESC	cis	rs57506017	0.606	rs2302634	chr7:12270770	T/A	cg23422036	chr7:12250390	TMEM106B	0.39	5.17	0.3	4.57e-7	Neuroticism;
CESC	cis	rs9287719	1.000	rs9679122	chr2:10751710	T/C	cg00105475	chr2:10696890	NA	0.38	5.57	0.32	6.34e-8	Prostate cancer;
CESC	cis	rs3126085	0.935	rs1496049	chr1:152161949	C/T	cg03465714	chr1:152285911	FLG	0.48	5.73	0.33	2.68e-8	Atopic dermatitis;
CESC	cis	rs910316	0.836	rs6574212	chr14:75671659	G/A	cg11812906	chr14:75593930	NEK9	-0.81	-12.5	-0.61	1.66e-28	Height;
CESC	cis	rs1707322	1.000	rs34446427	chr1:46417655	A/C	cg06784218	chr1:46089804	CCDC17	0.33	5.63	0.33	4.7e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs708547	0.647	rs2293175	chr4:57861358	C/T	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.5	-6.7	-0.38	1.21e-10	Response to bleomycin (chromatid breaks);
CESC	cis	rs727505	1.000	rs10265763	chr7:124451514	G/A	cg23710748	chr7:124431027	NA	-0.44	-6.97	-0.39	2.46e-11	Lewy body disease;
CESC	cis	rs2075371	0.673	rs35290398	chr7:134011773	C/T	cg20476274	chr7:133979776	SLC35B4	0.58	7.49	0.42	1.03e-12	Mean platelet volume;
CESC	cis	rs2239547	0.657	rs12488303	chr3:52862003	G/A	cg11645453	chr3:52864694	ITIH4	0.32	5.89	0.34	1.15e-8	Schizophrenia;
CESC	cis	rs7552404	0.731	rs7523573	chr1:76372020	G/T	cg03433033	chr1:76189801	ACADM	0.58	5.57	0.32	6.2e-8	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs6951245	0.572	rs73264010	chr7:1040477	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.65	-6.07	-0.35	4.33e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2302729	0.578	rs2302728	chr12:2774668	A/C	cg19945202	chr12:2788847	CACNA1C	0.46	6.67	0.38	1.5e-10	Sleep quality;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg18664336	chr17:57970265	TUBD1;RPS6KB1	0.48	6.82	0.39	6.16e-11	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs2249625	0.816	rs2496499	chr6:72884414	T/A	cg18830697	chr6:72922368	RIMS1	-0.39	-5.5	-0.32	8.88e-8	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CESC	cis	rs1062177	1.000	rs2964612	chr5:151198750	G/A	cg00977110	chr5:151150581	G3BP1	0.62	6.59	0.38	2.37e-10	Preschool internalizing problems;
CESC	cis	rs3733585	0.534	rs7375642	chr4:9955236	A/G	cg02734326	chr4:10020555	SLC2A9	-0.4	-5.77	-0.33	2.19e-8	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs34734847	1.000	rs35360964	chr12:121156290	T/C	cg21892295	chr12:121157589	UNC119B	-0.42	-6.65	-0.38	1.66e-10	Mean corpuscular volume;
CESC	cis	rs1218582	0.772	rs12069356	chr1:154849771	C/T	cg09359103	chr1:154839909	KCNN3	-0.68	-13.25	-0.63	4.21e-31	Prostate cancer;
CESC	cis	rs208520	1.000	rs9453671	chr6:66991208	A/G	cg07460842	chr6:66804631	NA	0.78	8.94	0.48	6.96e-17	Exhaled nitric oxide output;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08809979	chr16:69373666	COG8;NIP7	0.57	6.03	0.35	5.37e-9	Gut microbiome composition (summer);
CESC	cis	rs2952156	0.920	rs907090	chr17:37833632	T/C	cg20243544	chr17:37824526	PNMT	0.63	8.32	0.45	4.82e-15	Asthma;
CESC	cis	rs1030877	0.960	rs3792050	chr2:105902255	T/C	cg02079111	chr2:105885981	TGFBRAP1	-0.65	-10.1	-0.53	1.67e-20	Obesity-related traits;
CESC	cis	rs10779751	1.000	rs2253213	chr1:11265785	A/G	cg08854313	chr1:11322531	MTOR	0.77	9.78	0.52	1.72e-19	Body mass index;
CESC	cis	rs4803468	1.000	rs878083	chr19:41897688	G/A	cg09537434	chr19:41945824	ATP5SL	-1.03	-18.58	-0.75	6.55e-50	Height;
CESC	trans	rs35883536	0.935	rs1106347	chr1:101149059	A/T	cg16931499	chr17:42786676	DBF4B	0.42	6.24	0.36	1.7e-9	Monocyte count;
CESC	cis	rs60154123	0.730	rs587203	chr1:210463786	C/T	cg21951975	chr1:209979733	IRF6	0.4	5.52	0.32	8.13e-8	Coronary artery disease;
CESC	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg03188948	chr7:1209495	NA	0.7	6.71	0.38	1.2e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs3820928	0.839	rs4675123	chr2:227800205	T/C	cg05526886	chr2:227700861	RHBDD1	-0.39	-5.07	-0.3	7.46e-7	Pulmonary function;
CESC	cis	rs2455799	0.552	rs1472697	chr3:15750268	G/A	cg16303742	chr3:15540471	COLQ	-0.4	-6.11	-0.35	3.45e-9	Mean platelet volume;
CESC	cis	rs722599	0.748	rs2537824	chr14:75367349	T/C	cg11812906	chr14:75593930	NEK9	-0.47	-5.63	-0.33	4.59e-8	IgG glycosylation;
CESC	cis	rs7615952	0.512	rs4646765	chr3:125820707	G/A	cg15145296	chr3:125709740	NA	-0.56	-5.91	-0.34	1.06e-8	Blood pressure (smoking interaction);
CESC	trans	rs7615952	0.512	rs2979334	chr3:125358824	G/A	cg21747405	chr11:67723411	NA	-0.44	-6.69	-0.38	1.3100000000000001e-10	Blood pressure (smoking interaction);
CESC	trans	rs116095464	0.558	rs9312977	chr5:221916	G/C	cg00938859	chr5:1591904	SDHAP3	0.6	6.66	0.38	1.55e-10	Breast cancer;
CESC	cis	rs796364	1.000	rs281794	chr2:200846666	C/T	cg23649088	chr2:200775458	C2orf69	0.55	5.16	0.3	4.74e-7	Schizophrenia;
CESC	cis	rs35417517	1	rs35417517	chr7:91772730	CG/C	cg17063962	chr7:91808500	NA	0.59	8.22	0.45	8.94e-15	Breast cancer;
CESC	cis	rs559928	0.593	rs112275221	chr11:63936994	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.66	5.44	0.32	1.2e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CESC	cis	rs8051149	0.688	rs12444533	chr16:87869711	C/T	cg01829163	chr16:87871160	SLC7A5	-0.56	-6.97	-0.39	2.55e-11	Blood metabolite levels;
CESC	cis	rs7666738	0.791	rs7658177	chr4:99035192	T/C	cg18180107	chr4:99064573	C4orf37	0.42	5.4	0.31	1.48e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs2018683	0.621	rs10261556	chr7:28976636	G/T	cg19402173	chr7:128379420	CALU	-0.56	-7.37	-0.41	2.19e-12	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CESC	cis	rs7647973	0.626	rs9824435	chr3:49674343	A/G	cg07636037	chr3:49044803	WDR6	-0.55	-6.08	-0.35	4.26e-9	Menarche (age at onset);
CESC	cis	rs854765	0.663	rs1052299	chr17:17750419	A/G	cg16928487	chr17:17741425	SREBF1	0.58	10.26	0.53	5.21e-21	Total body bone mineral density;
CESC	cis	rs35306767	0.903	rs765867	chr10:869901	G/T	cg25019033	chr10:957182	NA	-0.58	-6.13	-0.35	3.11e-9	Eosinophil percentage of granulocytes;
CESC	cis	rs894734	0.535	rs2366143	chr12:54323256	G/A	cg17410650	chr12:54324560	NA	-0.5	-9.21	-0.49	1.06e-17	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10092158	chr1:151584907	SNX27	0.66	8.04	0.44	2.92e-14	Gut microbiome composition (summer);
CESC	trans	rs1557351	0.723	rs2027702	chr18:54725272	A/G	cg11433624	chr6:7146702	RREB1	-0.36	-6.0	-0.35	6.52e-9	Multiple sclerosis (age of onset);
CESC	cis	rs6733011	0.508	rs12712041	chr2:99522059	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.41	-5.11	-0.3	6.13e-7	Bipolar disorder;
CESC	cis	rs1865760	0.566	rs1539183	chr6:26075051	G/C	cg16482183	chr6:26056742	HIST1H1C	0.39	5.31	0.31	2.35e-7	Height;
CESC	cis	rs7666738	0.830	rs7679961	chr4:99000202	C/T	cg18180107	chr4:99064573	C4orf37	0.4	5.23	0.31	3.41e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9815354	1.000	rs6783001	chr3:41862232	C/A	cg03022575	chr3:42003672	ULK4	0.45	5.15	0.3	5.19e-7	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs7666738	0.830	rs62321570	chr4:98984276	G/A	cg17366294	chr4:99064904	C4orf37	0.59	8.57	0.47	8.46e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9899728	0.539	rs35928207	chr17:73033629	T/G	cg27626185	chr17:73056755	KCTD2	-1.06	-9.13	-0.49	1.84e-17	Alzheimer's disease or small vessel stroke;
CESC	cis	rs2228479	0.850	rs74251568	chr16:89903416	A/C	cg00800038	chr16:89945340	TCF25	-0.89	-6.89	-0.39	4.13e-11	Skin colour saturation;
CESC	cis	rs10504229	0.861	rs116923397	chr8:58185162	T/G	cg24829409	chr8:58192753	C8orf71	-0.76	-9.93	-0.52	5.87e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs7086627	0.515	rs7907969	chr10:82153005	T/A	cg00277334	chr10:82204260	NA	-0.5	-7.37	-0.41	2.23e-12	Post bronchodilator FEV1;
CESC	cis	rs7998202	0.667	rs282578	chr13:113358584	A/G	cg02820901	chr13:113351484	ATP11A	0.62	5.83	0.34	1.58e-8	Glycated hemoglobin levels;
CESC	cis	rs6460942	1.000	rs112794590	chr7:12319426	G/A	cg06484146	chr7:12443880	VWDE	-0.81	-8.78	-0.47	2.13e-16	Coronary artery disease;
CESC	cis	rs1005277	0.683	rs7923868	chr10:37989766	T/C	cg00409905	chr10:38381863	ZNF37A	-0.48	-6.43	-0.37	5.87e-10	Extrinsic epigenetic age acceleration;
CESC	cis	rs2732480	0.500	rs2932093	chr12:48648271	G/T	cg24011408	chr12:48396354	COL2A1	0.44	6.18	0.35	2.41e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs644148	0.872	rs2686780	chr19:44974126	G/C	cg15540054	chr19:45004280	ZNF180	-0.6	-6.48	-0.37	4.45e-10	Personality dimensions;
CESC	trans	rs11098499	1.000	rs13435802	chr4:120177960	A/T	cg25214090	chr10:38739885	LOC399744	-0.64	-8.68	-0.47	4.09e-16	Corneal astigmatism;
CESC	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg11494091	chr17:61959527	GH2	0.73	12.52	0.61	1.41e-28	Prudent dietary pattern;
CESC	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.64	7.26	0.41	4.24e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs372883	0.600	rs2832298	chr21:30743863	C/G	cg24692254	chr21:30365293	RNF160	0.53	6.7	0.38	1.22e-10	Pancreatic cancer;
CESC	cis	rs2463822	0.688	rs7121684	chr11:62162389	T/C	cg06239285	chr11:62104954	ASRGL1	-1.07	-9.18	-0.49	1.23e-17	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs9583531	0.509	rs12184676	chr13:111396484	A/G	cg24331049	chr13:111365604	ING1	-0.78	-7.72	-0.43	2.43e-13	Coronary artery disease;
CESC	cis	rs926938	0.527	rs360666	chr1:115481290	C/T	cg12756093	chr1:115239321	AMPD1	0.46	6.37	0.36	8.39e-10	Autism;
CESC	cis	rs668210	0.793	rs1204011	chr11:65741086	G/A	cg02202077	chr11:65769826	EIF1AD;BANF1	-0.63	-5.89	-0.34	1.19e-8	Cerebrospinal fluid biomarker levels;
CESC	cis	rs11760633	0.672	rs11763500	chr7:1826385	T/A	cg23422044	chr7:1970798	MAD1L1	-0.43	-5.17	-0.3	4.54e-7	Coronary artery disease;
CESC	cis	rs2985684	1.000	rs11157696	chr14:50105746	C/G	cg10008539	chr14:50087325	RPL36AL;MGAT2	0.44	5.13	0.3	5.62e-7	Carotid intima media thickness;
CESC	cis	rs4332037	0.539	rs34809719	chr7:2028968	G/T	cg23422044	chr7:1970798	MAD1L1	-0.5	-5.35	-0.31	1.9e-7	Bipolar disorder;
CESC	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.92	14.12	0.66	3.86e-34	Prudent dietary pattern;
CESC	trans	rs7672847	0.547	rs4379028	chr4:170450913	C/A	cg19308436	chr1:237949471	RYR2	0.64	6.72	0.38	1.08e-10	Subjective well-being;
CESC	cis	rs2742417	1.000	rs2742447	chr3:45763977	C/T	cg10512202	chr3:45649293	LIMD1	0.36	5.21	0.3	3.78e-7	Response to anti-depressant treatment in major depressive disorder;
CESC	cis	rs7914558	1.000	rs10786740	chr10:104935593	G/C	cg04362960	chr10:104952993	NT5C2	0.46	6.17	0.35	2.6e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs1799949	0.965	rs4793237	chr17:41436595	A/T	cg25072359	chr17:41440525	NA	0.49	7.24	0.41	4.92e-12	Menopause (age at onset);
CESC	cis	rs9325144	0.624	rs10783330	chr12:39114084	A/G	cg26384229	chr12:38710491	ALG10B	-0.53	-7.43	-0.42	1.52e-12	Morning vs. evening chronotype;
CESC	cis	rs6866344	0.570	rs1132338	chr5:178139442	T/G	cg03877680	chr5:178157825	ZNF354A	0.81	9.91	0.52	6.58e-20	Neutrophil percentage of white cells;
CESC	trans	rs1814175	0.791	rs1722023	chr11:49908136	G/C	cg15704280	chr7:45808275	SEPT13	-1.03	-21.21	-0.79	4.77e-59	Height;
CESC	cis	rs4523957	0.552	rs2760742	chr17:2019037	A/G	cg16513277	chr17:2031491	SMG6	-0.71	-10.1	-0.53	1.62e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs208520	1.000	rs208537	chr6:66963544	A/G	cg07460842	chr6:66804631	NA	-0.9	-10.34	-0.54	2.79e-21	Exhaled nitric oxide output;
CESC	cis	rs7552404	1.000	rs11161515	chr1:76212559	C/T	cg03433033	chr1:76189801	ACADM	0.64	7.52	0.42	8.69e-13	Blood metabolite levels;Acylcarnitine levels;
CESC	trans	rs7615952	0.800	rs2062773	chr3:125639648	T/C	cg07211511	chr3:129823064	LOC729375	-1.13	-16.52	-0.71	1.28e-42	Blood pressure (smoking interaction);
CESC	trans	rs3942852	0.712	rs10742828	chr11:48104555	A/G	cg15704280	chr7:45808275	SEPT13	-0.72	-8.62	-0.47	6.39e-16	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs6598955	0.572	rs6598951	chr1:26592714	G/T	cg19743891	chr1:26644573	UBXN11;CD52	0.37	5.05	0.3	8.16e-7	Obesity-related traits;
CESC	cis	rs9291683	0.655	rs55941493	chr4:10100341	G/A	cg11266682	chr4:10021025	SLC2A9	-0.48	-8.73	-0.47	2.86e-16	Bone mineral density;
CESC	cis	rs1448094	0.556	rs11611968	chr12:86168022	G/A	cg02569458	chr12:86230093	RASSF9	0.57	8.34	0.46	4.13e-15	Major depressive disorder;
CESC	cis	rs11674184	0.714	rs16857668	chr2:11723110	G/A	cg07314298	chr2:11723111	GREB1	-0.66	-10.21	-0.53	7.63e-21	Endometriosis;
CESC	cis	rs17711722	0.522	rs4642526	chr7:65216742	G/T	cg02869306	chr7:64672164	INTS4L1	-0.32	-5.2	-0.3	4.04e-7	Calcium levels;
CESC	cis	rs7246865	0.724	rs10424674	chr19:17183185	G/A	cg19418318	chr19:17219073	MYO9B	0.33	5.34	0.31	2.04e-7	Reticulocyte fraction of red cells;
CESC	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg25934064	chr3:52569026	NT5DC2	0.26	5.27	0.31	2.83e-7	Electroencephalogram traits;
CESC	cis	rs4481887	1.000	rs4589143	chr1:248470446	A/G	cg00666640	chr1:248458726	OR2T12	0.41	6.65	0.38	1.71e-10	Common traits (Other);
CESC	cis	rs2072499	0.767	rs3001789	chr1:156197614	T/G	cg24450063	chr1:156163899	SLC25A44	0.83	12.72	0.62	2.9e-29	Testicular germ cell tumor;
CESC	cis	rs1008375	1.000	rs6849704	chr4:17652031	G/C	cg15017067	chr4:17643749	FAM184B	0.35	5.07	0.3	7.59e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs791888	0.965	rs791873	chr10:89405558	C/T	cg13926569	chr10:89418898	PAPSS2	-0.39	-5.41	-0.32	1.38e-7	Magnesium levels;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg15331837	chr8:142232772	SLC45A4	0.54	7.49	0.42	1.06e-12	Fibrinogen levels;
CESC	cis	rs17253792	0.822	rs8007065	chr14:56081272	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.76	5.39	0.31	1.56e-7	Putamen volume;
CESC	cis	rs11112613	0.713	rs4015312	chr12:105948757	A/G	cg03607813	chr12:105948248	NA	0.62	7.04	0.4	1.64e-11	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CESC	cis	rs2559856	1.000	rs10860771	chr12:102087242	A/G	cg15068132	chr12:102092402	CHPT1	-0.39	-5.18	-0.3	4.38e-7	Blood protein levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04703227	chr1:19923504	C1orf151	0.57	6.18	0.35	2.42e-9	Gut microbiome composition (summer);
CESC	cis	rs1788820	0.917	rs1788762	chr18:21132571	G/C	cg14672496	chr18:21087552	C18orf8	0.56	7.57	0.42	6.08e-13	Body mass index;
CESC	cis	rs2243480	1.000	rs1618893	chr7:66096119	C/T	cg13147721	chr7:65941812	NA	-0.59	-6.02	-0.35	5.87e-9	Diabetic kidney disease;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg06387028	chr7:72395397	POM121	-0.48	-6.07	-0.35	4.34e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs7552404	0.696	rs1417405	chr1:76457797	T/C	cg22875332	chr1:76189707	ACADM	0.58	5.66	0.33	3.97e-8	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs698813	0.604	rs2340813	chr2:44487398	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.51	5.8	0.34	1.93e-8	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
CESC	cis	rs9487051	0.872	rs1521908	chr6:109613986	T/C	cg21918786	chr6:109611834	NA	-0.38	-5.82	-0.34	1.67e-8	Reticulocyte fraction of red cells;
CESC	cis	rs12410462	1.000	rs16847833	chr1:227626662	G/A	cg23173402	chr1:227635558	NA	0.57	5.92	0.34	9.9e-9	Major depressive disorder;
CESC	cis	rs2573652	0.722	rs11858932	chr15:100542763	G/A	cg00587665	chr15:100533223	ADAMTS17	-0.4	-6.41	-0.37	6.5e-10	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10054262	chr7:856283	UNC84A	0.61	7.08	0.4	1.32e-11	Gut microbiome composition (summer);
CESC	trans	rs61931739	0.500	rs11053166	chr12:34385898	A/C	cg26384229	chr12:38710491	ALG10B	-0.76	-10.69	-0.55	2.14e-22	Morning vs. evening chronotype;
CESC	cis	rs10504229	0.906	rs7006539	chr8:58178799	A/T	cg05313129	chr8:58192883	C8orf71	-0.57	-6.61	-0.38	2.05e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs950169	1.000	rs11638297	chr15:84782417	A/C	cg03959625	chr15:84868606	LOC388152	0.36	5.13	0.3	5.64e-7	Schizophrenia;
CESC	trans	rs829883	1.000	rs249837	chr12:98876535	A/G	cg04550079	chr16:67212681	KIAA0895L	-0.37	-6.07	-0.35	4.34e-9	Colorectal adenoma (advanced);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07364676	chr22:29137974	CHEK2;HSCB	0.58	7.01	0.4	1.97e-11	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24035104	chr1:44445524	B4GALT2	0.6	7.5	0.42	9.81e-13	Gut microbiome composition (summer);
CESC	cis	rs9303401	0.527	rs12946522	chr17:56768103	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.97	11.3	0.57	2.06e-24	Cognitive test performance;
CESC	cis	rs798554	0.757	rs1182198	chr7:2862906	C/T	cg18446336	chr7:2847575	GNA12	-0.36	-5.3	-0.31	2.49e-7	Height;
CESC	cis	rs7927592	0.956	rs11228258	chr11:68254328	A/C	cg16797656	chr11:68205561	LRP5	-0.38	-5.45	-0.32	1.18e-7	Total body bone mineral density;
CESC	cis	rs9611565	0.918	rs4822024	chr22:41757647	G/A	cg06481639	chr22:41940642	POLR3H	-0.68	-7.3	-0.41	3.37e-12	Vitiligo;
CESC	cis	rs1707322	1.000	rs4460583	chr1:46449918	C/G	cg03146154	chr1:46216737	IPP	0.72	9.82	0.52	1.31e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs853679	0.550	rs1225598	chr6:28160799	T/G	cg26335602	chr6:28129616	ZNF389	0.46	6.24	0.36	1.75e-9	Depression;
CESC	cis	rs71403859	0.730	rs17356206	chr16:71736359	G/C	cg08717414	chr16:71523259	ZNF19	-0.69	-5.79	-0.33	2.02e-8	Post bronchodilator FEV1;
CESC	cis	rs897080	0.552	rs1067375	chr2:44650118	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	-0.47	-5.77	-0.33	2.24e-8	Height;
CESC	cis	rs425277	0.583	rs12059660	chr1:2041461	C/T	cg23803603	chr1:2058230	PRKCZ	-0.38	-6.7	-0.38	1.23e-10	Height;
CESC	cis	rs72781680	0.611	rs72781699	chr2:24277709	G/A	cg08917208	chr2:24149416	ATAD2B	0.61	5.95	0.34	8.56e-9	Lymphocyte counts;
CESC	cis	rs11122272	0.735	rs2437150	chr1:231488524	A/G	cg06096015	chr1:231504339	EGLN1	-0.38	-5.69	-0.33	3.37e-8	Hemoglobin concentration;
CESC	cis	rs7714584	1.000	rs59531858	chr5:150247063	T/G	cg22134413	chr5:150180641	NA	0.61	5.92	0.34	9.83e-9	Crohn's disease;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg01745522	chr6:26217416	HIST1H2BG;HIST1H2AE	-0.51	-6.68	-0.38	1.4e-10	Ulcerative colitis;
CESC	cis	rs13108904	0.934	rs13128045	chr4:1305309	C/T	cg00684032	chr4:1343700	KIAA1530	0.41	5.72	0.33	2.95e-8	Obesity-related traits;
CESC	cis	rs2576037	0.526	rs2571026	chr18:44561795	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.55	7.6	0.42	5.28e-13	Personality dimensions;
CESC	cis	rs9916302	0.904	rs6503506	chr17:37524653	C/A	cg15445000	chr17:37608096	MED1	-0.38	-6.32	-0.36	1.13e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs17750015	0.733	rs12454362	chr18:54396186	G/A	cg18434998	chr18:54306185	TXNL1	-0.44	-5.65	-0.33	4.12e-8	Depression and alcohol dependence;
CESC	cis	rs6503525	0.701	rs28618095	chr17:38109075	T/C	cg17467752	chr17:38218738	THRA	0.41	5.04	0.3	8.56e-7	Asthma;
CESC	cis	rs7202877	0.706	rs8046184	chr16:75411725	T/C	cg04384234	chr16:75411784	CFDP1	-0.49	-5.89	-0.34	1.16e-8	Type 2 diabetes;Type 1 diabetes;
CESC	cis	rs4727027	0.727	rs3801980	chr7:148878620	T/A	cg23583168	chr7:148888333	NA	-0.76	-10.27	-0.53	4.85e-21	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs11792861	0.926	rs11788825	chr9:111829757	T/G	cg05043794	chr9:111880884	C9orf5	-0.37	-6.38	-0.36	7.79e-10	Menarche (age at onset);
CESC	cis	rs4665809	0.556	rs4665322	chr2:26434605	C/G	cg25036284	chr2:26402008	FAM59B	-0.9	-10.49	-0.54	8.96e-22	Gut microbiome composition (summer);
CESC	cis	rs1799949	1.000	rs35330014	chr17:41212547	C/T	cg06001716	chr17:41278141	BRCA1;NBR2	0.38	5.08	0.3	7.26e-7	Menopause (age at onset);
CESC	trans	rs1814175	0.645	rs10839382	chr11:49823172	C/T	cg15704280	chr7:45808275	SEPT13	-1.0	-17.86	-0.74	2.18e-47	Height;
CESC	cis	rs1797081	0.901	rs703059	chr10:16876402	G/A	cg23933602	chr10:16859644	RSU1	1.12	23.87	0.83	5.36e-68	Platelet distribution width;
CESC	cis	rs34779708	0.733	rs7083266	chr10:35541632	C/A	cg04310649	chr10:35416472	CREM	-0.47	-5.39	-0.31	1.59e-7	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs10504229	1.000	rs72650899	chr8:58180525	G/T	cg14926445	chr8:58193284	C8orf71	-0.51	-5.47	-0.32	1.03e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs10479542	0.721	rs6894113	chr5:178974789	G/C	cg22764044	chr5:178986830	RUFY1	0.41	5.78	0.33	2.04e-8	Lung cancer;
CESC	cis	rs270601	0.770	rs10463891	chr5:131597392	C/T	cg18301423	chr5:131593218	PDLIM4	-0.41	-5.92	-0.34	9.8e-9	Acylcarnitine levels;
CESC	cis	rs2404602	0.692	rs58973160	chr15:77000342	T/C	cg22467129	chr15:76604101	ETFA	-0.35	-5.12	-0.3	6e-7	Blood metabolite levels;
CESC	cis	rs7044106	0.791	rs10984997	chr9:123481206	T/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.75	10.88	0.56	5.02e-23	Hip circumference adjusted for BMI;
CESC	cis	rs80282103	0.867	rs13377037	chr10:1068639	C/T	cg08668510	chr10:1095578	IDI1	0.68	5.56	0.32	6.57e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs1552244	1.000	rs7611218	chr3:10063960	T/C	cg00149659	chr3:10157352	C3orf10	0.75	9.05	0.49	3.07e-17	Alzheimer's disease;
CESC	cis	rs4243830	0.850	rs11122043	chr1:6580429	C/T	cg05709478	chr1:6581295	PLEKHG5	-0.44	-5.06	-0.3	8.02e-7	Body mass index;
CESC	cis	rs2404602	0.716	rs12592171	chr15:76755133	G/C	cg22467129	chr15:76604101	ETFA	-0.38	-5.81	-0.34	1.81e-8	Blood metabolite levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25586305	chr2:234281690	DGKD	-0.61	-6.73	-0.38	1.02e-10	Gut microbiome composition (summer);
CESC	cis	rs12681288	0.676	rs4565481	chr8:1001944	C/T	cg04851639	chr8:1020857	NA	-0.33	-6.93	-0.39	3.23e-11	Schizophrenia;
CESC	cis	rs7772486	0.875	rs2748483	chr6:146335560	A/T	cg23711669	chr6:146136114	FBXO30	-0.84	-11.66	-0.58	1.21e-25	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs45535039	1.000	rs7121752	chr11:119140173	C/T	cg16724696	chr11:118992527	HINFP	0.44	5.32	0.31	2.2e-7	Plateletcrit;
CESC	cis	rs2456568	0.802	rs1574515	chr11:93629643	T/C	cg26875233	chr11:93583750	C11orf90	-0.3	-5.35	-0.31	1.92e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
CESC	cis	rs3096299	0.933	rs2965939	chr16:89493043	G/A	cg02187348	chr16:89574699	SPG7	0.59	7.99	0.44	4.03e-14	Multiple myeloma (IgH translocation);
CESC	cis	rs2481665	0.608	rs2457815	chr1:62596679	C/T	cg18591186	chr1:62594603	INADL	-0.72	-10.23	-0.53	6.22e-21	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg18402987	chr7:1209562	NA	0.73	7.25	0.41	4.54e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs300703	0.542	rs415660	chr2:189972	C/T	cg21211680	chr2:198530	NA	0.89	10.11	0.53	1.56e-20	Blood protein levels;
CESC	cis	rs12188164	0.543	rs7728027	chr5:459943	T/C	cg16584290	chr5:462447	EXOC3	0.47	7.09	0.4	1.19e-11	Cystic fibrosis severity;
CESC	cis	rs2046867	0.862	rs6766747	chr3:72856551	T/C	cg25664220	chr3:72788482	NA	-0.48	-7.03	-0.4	1.73e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CESC	cis	rs7666738	0.830	rs11725095	chr4:99009711	T/A	cg18180107	chr4:99064573	C4orf37	0.4	5.3	0.31	2.48e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6540556	0.723	rs11487867	chr1:209892070	G/T	cg05527609	chr1:210001259	C1orf107	-0.78	-7.84	-0.43	1.13e-13	Red blood cell count;
CESC	trans	rs9650657	0.589	rs6985109	chr8:10761585	A/G	cg06636001	chr8:8085503	FLJ10661	0.51	6.28	0.36	1.4e-9	Neuroticism;
CESC	cis	rs9611565	0.608	rs202652	chr22:41838792	A/G	cg17376030	chr22:41985996	PMM1	-0.56	-6.22	-0.36	1.92e-9	Vitiligo;
CESC	cis	rs2070488	1.000	rs2268753	chr3:38500189	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.95	17.87	0.74	2.14e-47	Electrocardiographic conduction measures;
CESC	cis	rs4568518	0.616	rs4721675	chr7:18004702	T/C	cg03009463	chr7:17980271	SNX13	0.41	5.49	0.32	9.25e-8	Measles;
CESC	cis	rs12477438	0.520	rs6717729	chr2:99756941	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.86	15.7	0.69	1.05e-39	Chronic sinus infection;
CESC	cis	rs4925386	0.759	rs2427293	chr20:60925859	A/G	cg22307297	chr20:60903441	LAMA5	-0.38	-5.33	-0.31	2.1e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs4664304	0.739	rs66814375	chr2:160716059	C/T	cg03641300	chr2:160917029	PLA2R1	-0.39	-5.1	-0.3	6.45e-7	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs959260	1.000	rs8081927	chr17:73379085	C/T	cg20590849	chr17:73267439	MIF4GD	-0.59	-6.78	-0.38	7.58e-11	Systemic lupus erythematosus;
CESC	cis	rs13256369	0.802	rs13256404	chr8:8562974	T/C	cg18904891	chr8:8559673	CLDN23	0.73	8.12	0.45	1.74e-14	Obesity-related traits;
CESC	cis	rs752010	0.714	rs2148635	chr1:42082452	C/T	cg12614395	chr1:42085415	HIVEP3	-0.3	-5.32	-0.31	2.21e-7	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs7520050	0.966	rs6668284	chr1:46354510	G/A	cg03146154	chr1:46216737	IPP	-0.48	-6.22	-0.36	1.94e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs2180341	0.920	rs9401951	chr6:127671632	A/C	cg27446573	chr6:127587934	RNF146	1.07	15.44	0.69	8.48e-39	Breast cancer;
CESC	cis	rs11098499	0.865	rs2389809	chr4:120377399	T/C	cg24375607	chr4:120327624	NA	0.44	5.51	0.32	8.65e-8	Corneal astigmatism;
CESC	cis	rs17711722	0.701	rs781145	chr7:65440370	A/C	cg18876405	chr7:65276391	NA	0.7	9.67	0.51	3.76e-19	Calcium levels;
CESC	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg27094323	chr7:1216898	NA	-0.43	-6.03	-0.35	5.61e-9	Longevity;Endometriosis;
CESC	cis	rs68170813	0.559	rs77185844	chr7:106812916	A/C	cg02696742	chr7:106810147	HBP1	-0.54	-5.13	-0.3	5.7e-7	Coronary artery disease;
CESC	cis	rs4862750	0.832	rs6836426	chr4:187897837	T/G	cg06074448	chr4:187884817	NA	-0.38	-5.35	-0.31	1.91e-7	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9309473	0.718	rs10175529	chr2:73606093	A/G	cg20560298	chr2:73613845	ALMS1	-0.51	-7.1	-0.4	1.18e-11	Metabolite levels;
CESC	cis	rs7811142	0.830	rs6975660	chr7:99975266	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.74	7.36	0.41	2.29e-12	Platelet count;
CESC	cis	rs832540	0.656	rs6893754	chr5:56100006	G/A	cg22800045	chr5:56110881	MAP3K1	0.44	5.35	0.31	1.9e-7	Coronary artery disease;
CESC	cis	rs7618915	0.501	rs3852066	chr3:52621839	C/T	cg07507251	chr3:52567010	NT5DC2	0.32	5.5	0.32	8.74e-8	Bipolar disorder;
CESC	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.71	9.97	0.52	4.3e-20	Prudent dietary pattern;
CESC	cis	rs7605827	0.930	rs10201564	chr2:15623608	C/G	cg19274914	chr2:15703543	NA	0.36	6.46	0.37	5.1e-10	Educational attainment (years of education);
CESC	cis	rs1005277	0.579	rs1780137	chr10:38501475	C/G	cg25517755	chr10:38738941	LOC399744	-0.49	-6.36	-0.36	8.84e-10	Extrinsic epigenetic age acceleration;
CESC	cis	rs1348850	0.526	rs2141157	chr2:178374112	C/T	cg22681709	chr2:178499509	PDE11A	-0.5	-5.26	-0.31	2.97e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs12477438	0.765	rs1115757	chr2:99660146	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.64	-8.73	-0.47	2.94e-16	Chronic sinus infection;
CESC	cis	rs7267979	1.000	rs397119	chr20:25440187	C/A	cg08601574	chr20:25228251	PYGB	0.37	5.28	0.31	2.73e-7	Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg24865495	chr11:63912769	MACROD1	0.47	6.04	0.35	5.3e-9	Fibrinogen levels;
CESC	trans	rs7615952	0.599	rs6779141	chr3:125709995	A/T	cg07211511	chr3:129823064	LOC729375	-0.56	-6.39	-0.37	7.25e-10	Blood pressure (smoking interaction);
CESC	cis	rs9911578	1.000	rs4372750	chr17:57013803	A/C	cg12560992	chr17:57184187	TRIM37	-0.92	-15.13	-0.68	1.08e-37	Intelligence (multi-trait analysis);
CESC	cis	rs2836974	0.932	rs11910151	chr21:40560262	T/C	cg27266027	chr21:40555129	PSMG1	0.45	5.48	0.32	1.01e-7	Cognitive function;
CESC	cis	rs9733	0.519	rs6700022	chr1:150670484	G/T	cg09365446	chr1:150670422	GOLPH3L	-0.4	-5.59	-0.33	5.51e-8	Tonsillectomy;
CESC	cis	rs854765	0.616	rs8076747	chr17:17853595	C/T	cg09796270	chr17:17721594	SREBF1	0.41	5.57	0.32	6.41e-8	Total body bone mineral density;
CESC	cis	rs514406	0.505	rs374849	chr1:53185631	G/A	cg08736216	chr1:53307985	ZYG11A	-0.38	-6.26	-0.36	1.52e-9	Monocyte count;
CESC	cis	rs7552404	0.924	rs1498317	chr1:76171984	A/C	cg03433033	chr1:76189801	ACADM	0.7	9.43	0.5	2.18e-18	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs896854	0.517	rs9643353	chr8:95957063	A/G	cg23172400	chr8:95962367	TP53INP1	0.44	8.27	0.45	6.65e-15	Type 2 diabetes;
CESC	cis	rs4819052	0.959	rs9976074	chr21:46655638	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.87	10.85	0.55	5.96e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs3785574	0.962	rs114027117	chr17:61939935	T/A	cg07677032	chr17:61819896	STRADA	0.43	5.68	0.33	3.62e-8	Height;
CESC	cis	rs7582720	0.943	rs114372659	chr2:203715514	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.32	0.41	3.04e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs7714584	1.000	rs1428555	chr5:150257391	A/G	cg22134413	chr5:150180641	NA	-0.52	-5.89	-0.34	1.17e-8	Crohn's disease;
CESC	cis	rs2370759	1.000	rs77165999	chr10:32577131	T/C	cg18270830	chr10:32634957	EPC1	0.73	7.22	0.41	5.35e-12	Sexual dysfunction (female);
CESC	cis	rs7726839	0.540	rs72707016	chr5:665148	A/G	cg09021430	chr5:549028	NA	-0.42	-5.16	-0.3	4.75e-7	Obesity-related traits;
CESC	cis	rs2228479	0.850	rs12597296	chr16:89822331	C/T	cg19635926	chr16:89946313	TCF25	0.67	5.09	0.3	6.82e-7	Skin colour saturation;
CESC	cis	rs7553864	0.667	rs7512650	chr1:87609076	T/C	cg17420885	chr1:87600446	LOC339524	-0.46	-6.28	-0.36	1.36e-9	Smoking behavior;
CESC	cis	rs2279817	0.775	rs35493100	chr1:17993120	C/T	cg21791023	chr1:18019539	ARHGEF10L	-0.66	-8.15	-0.45	1.42e-14	Neuroticism;
CESC	cis	rs854765	0.583	rs9912895	chr17:17826020	C/T	cg09796270	chr17:17721594	SREBF1	-0.43	-6.12	-0.35	3.4e-9	Total body bone mineral density;
CESC	cis	rs17253792	0.545	rs35418987	chr14:56017407	T/G	cg01858014	chr14:56050164	KTN1	-0.87	-6.37	-0.36	8.34e-10	Putamen volume;
CESC	cis	rs4665809	1.000	rs11678157	chr2:26321526	T/C	cg22920501	chr2:26401640	FAM59B	-0.64	-7.75	-0.43	2.03e-13	Gut microbiome composition (summer);
CESC	cis	rs6732160	0.574	rs12465780	chr2:73472012	A/G	cg01422370	chr2:73384389	NA	-0.44	-7.61	-0.42	4.75e-13	Intelligence (multi-trait analysis);
CESC	cis	rs7267979	1.000	rs398036	chr20:25439850	C/T	cg08601574	chr20:25228251	PYGB	0.37	5.28	0.31	2.73e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7809950	1.000	rs67982599	chr7:107100104	T/G	cg23024343	chr7:107201750	COG5	-0.4	-5.65	-0.33	4.11e-8	Coronary artery disease;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg26294578	chr17:79319535	NA	-0.42	-6.07	-0.35	4.47e-9	Gambling;
CESC	cis	rs7618915	0.524	rs10433615	chr3:52638482	C/T	cg05564831	chr3:52568323	NT5DC2	0.45	6.97	0.39	2.55e-11	Bipolar disorder;
CESC	cis	rs6690583	0.697	rs2012369	chr1:85520845	T/C	cg11262906	chr1:85462892	MCOLN2	-0.43	-5.16	-0.3	4.86e-7	Serum sulfate level;
CESC	cis	rs909674	0.690	rs1972280	chr22:39831986	T/A	cg01416388	chr22:39784598	NA	-0.58	-7.43	-0.42	1.5e-12	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs870825	0.860	rs72703525	chr4:185605154	T/C	cg04058563	chr4:185651563	MLF1IP	0.54	5.24	0.31	3.27e-7	Blood protein levels;
CESC	cis	rs7605827	0.930	rs2380652	chr2:15594926	T/C	cg19274914	chr2:15703543	NA	0.33	5.97	0.34	7.72e-9	Educational attainment (years of education);
CESC	cis	rs9611519	0.780	rs1535048	chr22:41684093	C/T	cg06481639	chr22:41940642	POLR3H	-0.48	-5.28	-0.31	2.76e-7	Neuroticism;
CESC	cis	rs868036	0.609	rs2127163	chr15:68090842	C/T	cg24579218	chr15:68104479	NA	-0.37	-5.13	-0.3	5.6e-7	Restless legs syndrome;
CESC	cis	rs35306767	0.903	rs12250936	chr10:870109	C/T	cg20503657	chr10:835505	NA	0.82	8.27	0.45	6.52e-15	Eosinophil percentage of granulocytes;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg03143742	chr22:20792143	SCARF2	-0.4	-6.25	-0.36	1.6e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7811142	0.720	rs7795656	chr7:99950297	A/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.72	6.44	0.37	5.73e-10	Platelet count;
CESC	cis	rs7945705	0.520	rs1984791	chr11:9035027	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.45	6.92	0.39	3.33e-11	Hemoglobin concentration;
CESC	cis	rs3857067	0.967	rs1841925	chr4:95035175	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.51	-7.78	-0.43	1.65e-13	QT interval;
CESC	cis	rs796364	1.000	rs166845	chr2:200823360	T/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.85	8.43	0.46	2.18e-15	Schizophrenia;
CESC	cis	rs1670533	0.932	rs10902753	chr4:1056223	G/A	cg27284194	chr4:1044797	NA	0.47	5.99	0.35	6.72e-9	Recombination rate (females);
CESC	cis	rs2243480	0.803	rs13224048	chr7:65993766	G/A	cg13147721	chr7:65941812	NA	-0.95	-8.91	-0.48	8.34e-17	Diabetic kidney disease;
CESC	cis	rs6142102	0.625	rs2050208	chr20:32543573	A/G	cg08999081	chr20:33150536	PIGU	0.34	5.12	0.3	5.93e-7	Skin pigmentation;
CESC	cis	rs4660261	0.526	rs2485996	chr1:44354661	C/T	cg13606994	chr1:44402422	ARTN	-0.38	-5.81	-0.34	1.81e-8	Intelligence (multi-trait analysis);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg19828298	chr1:3713105	LRRC47	-0.4	-6.12	-0.35	3.43e-9	Gambling;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg02262025	chr16:75657287	ADAT1	-0.45	-6.36	-0.36	8.67e-10	Fibrinogen levels;
CESC	cis	rs67311347	1.000	rs9833430	chr3:40459043	C/T	cg24209194	chr3:40518798	ZNF619	0.51	6.49	0.37	4.29e-10	Renal cell carcinoma;
CESC	cis	rs9322193	0.884	rs9689702	chr6:150061856	G/A	cg07701084	chr6:150067640	NUP43	0.46	6.47	0.37	4.62e-10	Lung cancer;
CESC	cis	rs2549003	1.000	rs7735073	chr5:131815357	G/A	cg21138405	chr5:131827807	IRF1	0.54	9.38	0.5	3.2e-18	Asthma (sex interaction);
CESC	cis	rs3768617	0.740	rs28533496	chr1:183019885	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.65	8.84	0.48	1.33e-16	Fuchs's corneal dystrophy;
CESC	cis	rs854765	0.547	rs8069811	chr17:17922280	G/A	cg09796270	chr17:17721594	SREBF1	0.38	5.26	0.31	2.92e-7	Total body bone mineral density;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg22864355	chr14:105225861	SIVA1	0.42	6.1	0.35	3.8e-9	Fibrinogen levels;
CESC	cis	rs10267417	0.544	rs2072185	chr7:19748700	G/A	cg05791153	chr7:19748676	TWISTNB	0.94	10.71	0.55	1.81e-22	Night sleep phenotypes;
CESC	cis	rs4077515	0.874	rs10781505	chr9:139271355	C/T	cg14169450	chr9:139327907	INPP5E	-0.4	-5.78	-0.33	2.07e-8	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs2839186	0.900	rs2839196	chr21:47708037	G/A	cg00815214	chr21:47717953	NA	-0.34	-5.14	-0.3	5.37e-7	Testicular germ cell tumor;
CESC	cis	rs55788414	0.932	rs2317122	chr16:81182819	A/G	cg06400318	chr16:81190750	PKD1L2	-0.59	-6.97	-0.39	2.49e-11	Left ventricular obstructive tract defect (maternal effect);
CESC	cis	rs12497850	0.864	rs12493001	chr3:49181885	A/G	cg06212747	chr3:49208901	KLHDC8B	0.74	9.74	0.51	2.27e-19	Parkinson's disease;
CESC	cis	rs2120019	1.000	rs12903201	chr15:75370776	A/C	cg17294928	chr15:75287854	SCAMP5	-0.59	-6.65	-0.38	1.64e-10	Blood trace element (Zn levels);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19244826	chr22:19466934	UFD1L;CDC45L	-0.71	-8.84	-0.48	1.39e-16	Gut microbiome composition (summer);
CESC	cis	rs10207060	0.778	rs6543581	chr2:240702308	C/T	cg20333904	chr2:240724165	NA	0.37	5.63	0.33	4.65e-8	Obesity-related traits;
CESC	trans	rs9858542	1.000	rs11709525	chr3:49690496	C/T	cg21659725	chr3:3221576	CRBN	-0.54	-6.56	-0.37	2.84e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs514406	0.861	rs562182	chr1:53270010	C/T	cg24675658	chr1:53192096	ZYG11B	-0.58	-7.37	-0.41	2.22e-12	Monocyte count;
CESC	cis	rs35740288	0.571	rs11629608	chr15:86330124	C/G	cg20737812	chr15:86336631	KLHL25	-0.42	-5.2	-0.3	3.96e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
CESC	cis	rs728616	0.867	rs61860421	chr10:81743399	C/T	cg05935833	chr10:81318306	SFTPA2	-0.52	-5.06	-0.3	7.72e-7	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs11608355	0.532	rs7968387	chr12:109788019	A/C	cg19025524	chr12:109796872	NA	-0.47	-6.59	-0.38	2.32e-10	Neuroticism;
CESC	trans	rs9858542	0.953	rs1801143	chr3:49570200	C/T	cg21659725	chr3:3221576	CRBN	-0.51	-6.06	-0.35	4.6e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg07477109	chr7:99006266	BUD31;PDAP1	-0.49	-6.31	-0.36	1.2e-9	Ulcerative colitis;
CESC	cis	rs798554	0.679	rs2527677	chr7:2882621	A/G	cg19346786	chr7:2764209	NA	-0.36	-5.17	-0.3	4.71e-7	Height;
CESC	cis	rs9488822	0.597	rs12214881	chr6:116342187	G/T	cg05304507	chr6:116381966	FRK	0.25	6.58	0.37	2.49e-10	Cholesterol, total;LDL cholesterol;
CESC	cis	rs36051895	0.632	rs10974984	chr9:5150427	T/C	cg02405213	chr9:5042618	JAK2	-0.54	-6.92	-0.39	3.39e-11	Pediatric autoimmune diseases;
CESC	cis	rs4901869	0.932	rs12878445	chr14:59339361	A/G	cg02291164	chr14:59296302	NA	0.45	7.81	0.43	1.3e-13	Panic disorder;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg12269905	chr21:38574668	TTC3	0.49	6.08	0.35	4.09e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs365132	0.875	rs3923879	chr5:176355312	C/T	cg16309518	chr5:176445507	NA	-0.37	-5.38	-0.31	1.6e-7	Menarche and menopause (age at onset);Menopause (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10158133	chr10:75488242	BMS1P4	-0.55	-6.4	-0.37	6.92e-10	Gut microbiome composition (summer);
CESC	cis	rs9649465	0.967	rs3779261	chr7:123315174	A/G	cg04330084	chr7:123175371	IQUB	-0.39	-5.36	-0.31	1.82e-7	Migraine;
CESC	cis	rs7560272	0.501	rs12713790	chr2:73945611	C/T	cg20560298	chr2:73613845	ALMS1	0.41	5.69	0.33	3.43e-8	Schizophrenia;
CESC	cis	rs11203032	0.634	rs3802658	chr10:90965691	C/T	cg16672925	chr10:90967113	CH25H	-0.65	-6.35	-0.36	9.25e-10	Heart failure;
CESC	cis	rs752010	0.746	rs11210499	chr1:42089703	C/T	cg06885757	chr1:42089581	HIVEP3	-0.54	-9.35	-0.5	3.81e-18	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs3768617	0.510	rs10911242	chr1:183072147	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.88	14.27	0.66	1.19e-34	Fuchs's corneal dystrophy;
CESC	cis	rs6499129	0.867	rs7196853	chr16:67560613	T/C	cg26727032	chr16:67993705	SLC12A4	-0.51	-5.4	-0.31	1.49e-7	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs1568889	0.592	rs7110074	chr11:28469325	G/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.55	5.49	0.32	9.37e-8	Bipolar disorder;
CESC	cis	rs2439831	1.000	rs2467736	chr15:43784917	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.88	10.25	0.53	5.49e-21	Lung cancer in ever smokers;
CESC	cis	rs6736093	0.901	rs11675946	chr2:112743033	C/T	cg12686935	chr2:112915763	FBLN7	0.41	5.64	0.33	4.35e-8	Coronary artery disease;
CESC	cis	rs9910055	0.659	rs3826412	chr17:42255097	A/G	cg19774624	chr17:42201019	HDAC5	-0.89	-13.91	-0.65	2.12e-33	Total body bone mineral density;
CESC	cis	rs3931020	0.548	rs969435	chr1:75273866	A/G	cg21535942	chr1:75199100	CRYZ;TYW3	-0.43	-5.63	-0.33	4.55e-8	Resistin levels;
CESC	cis	rs4595586	0.525	rs2892450	chr12:39363678	G/A	cg26384229	chr12:38710491	ALG10B	0.54	7.54	0.42	7.28e-13	Morning vs. evening chronotype;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg23702897	chr4:2263850	MXD4	-0.54	-7.41	-0.41	1.71e-12	Fibrinogen levels;
CESC	cis	rs7264396	0.635	rs6060703	chr20:34529906	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.81	-11.1	-0.56	9.32e-24	Total cholesterol levels;
CESC	cis	rs2836974	1.000	rs12710454	chr21:40656919	A/G	cg11644478	chr21:40555479	PSMG1	0.98	14.21	0.66	1.87e-34	Cognitive function;
CESC	cis	rs6788895	1.000	rs79709238	chr3:150488477	A/C	cg09723797	chr3:150481914	SIAH2	0.68	5.09	0.3	6.7e-7	Breast cancer;
CESC	cis	rs12190007	0.547	rs1018559	chr6:169854176	A/G	cg15038512	chr6:170123185	PHF10	-0.56	-8.01	-0.44	3.59e-14	Obesity-related traits;
CESC	cis	rs9300255	0.739	rs1402275	chr12:123750895	A/G	cg00376283	chr12:123451042	ABCB9	0.74	9.37	0.5	3.36e-18	Neutrophil percentage of white cells;
CESC	cis	rs847577	0.630	rs13221758	chr7:97719806	A/C	cg24562669	chr7:97807699	LMTK2	0.83	14.61	0.67	7.49e-36	Breast cancer;
CESC	cis	rs514406	0.698	rs567880	chr1:53348564	T/G	cg25767906	chr1:53392781	SCP2	-0.56	-7.83	-0.43	1.18e-13	Monocyte count;
CESC	cis	rs12130219	1.000	rs1552994	chr1:152171461	A/G	cg17718321	chr1:152188247	HRNR	0.41	5.4	0.32	1.46e-7	Inflammatory skin disease;
CESC	cis	rs3740713	1.000	rs78549183	chr11:18459715	A/G	cg23797887	chr11:18477753	LDHAL6A	-0.53	-5.27	-0.31	2.89e-7	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs4727027	0.933	rs12540094	chr7:148847178	A/G	cg23158103	chr7:148848205	ZNF398	0.39	6.33	0.36	1.04e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg22595711	chr4:83351836	ENOPH1;HNRPDL	-0.43	-6.48	-0.37	4.56e-10	Gambling;
CESC	cis	rs2228479	0.681	rs3212346	chr16:89982358	G/A	cg06558623	chr16:89946397	TCF25	0.66	6.29	0.36	1.3e-9	Skin colour saturation;
CESC	cis	rs6860806	0.507	rs273915	chr5:131660119	G/C	cg18758796	chr5:131593413	PDLIM4	0.39	5.31	0.31	2.37e-7	Breast cancer;
CESC	cis	rs6952808	0.862	rs4721167	chr7:1933224	C/T	cg00106254	chr7:1943704	MAD1L1	-0.51	-6.48	-0.37	4.52e-10	Bipolar disorder and schizophrenia;
CESC	cis	rs977987	0.872	rs1542864	chr16:75471378	G/A	cg03315344	chr16:75512273	CHST6	0.42	6.19	0.36	2.34e-9	Dupuytren's disease;
CESC	cis	rs4950322	0.570	rs72691032	chr1:146732774	G/A	cg16700924	chr1:146552102	NA	-0.41	-5.12	-0.3	5.98e-7	Protein quantitative trait loci;
CESC	cis	rs4971059	0.608	rs7366138	chr1:155088350	G/A	cg22049894	chr1:155113146	DPM3	0.42	5.25	0.31	3.16e-7	Breast cancer;
CESC	cis	rs2625529	0.652	rs2929532	chr15:72345110	C/T	cg16672083	chr15:72433130	SENP8	0.46	7.08	0.4	1.26e-11	Red blood cell count;
CESC	cis	rs7772486	0.686	rs7739735	chr6:146123536	G/A	cg23711669	chr6:146136114	FBXO30	0.87	13.02	0.62	2.64e-30	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs12048904	0.512	rs932798	chr1:101249355	G/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.76	-9.75	-0.51	2.23e-19	Multiple sclerosis;
CESC	cis	rs12142240	0.698	rs17413701	chr1:46818452	A/G	cg00530320	chr1:46809349	NSUN4	0.58	7.89	0.44	8.15e-14	Menopause (age at onset);
CESC	cis	rs2288073	0.965	rs10199334	chr2:24392618	T/C	cg06627628	chr2:24431161	ITSN2	-0.78	-8.98	-0.48	5.26e-17	Venous thromboembolism (SNP x SNP interaction);
CESC	cis	rs2836974	0.932	rs2836953	chr21:40617483	G/A	cg11890956	chr21:40555474	PSMG1	1.18	22.6	0.81	9.51e-64	Cognitive function;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03770877	chr3:73046015	PPP4R2	0.43	6.57	0.37	2.68e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs9906944	0.707	rs12942084	chr17:47114392	A/G	cg09029085	chr17:47094198	IGF2BP1	0.25	5.06	0.3	7.94e-7	Intelligence (multi-trait analysis);Body fat percentage;
CESC	cis	rs875971	0.522	rs4718285	chr7:65292005	A/G	cg26939375	chr7:64535504	NA	0.76	10.85	0.55	6.19e-23	Aortic root size;
CESC	cis	rs7635838	0.892	rs9874535	chr3:11463730	A/G	cg00170343	chr3:11313890	ATG7	0.43	5.6	0.33	5.24e-8	HDL cholesterol;
CESC	cis	rs9916302	0.904	rs12450559	chr17:37694709	G/A	cg20243544	chr17:37824526	PNMT	0.52	6.61	0.38	2.14e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs11677370	0.574	rs10209122	chr2:3871186	C/A	cg17052675	chr2:3827356	NA	-0.47	-5.86	-0.34	1.35e-8	Type 2 diabetes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15673029	chr19:46234190	FBXO46	0.57	6.27	0.36	1.44e-9	Gut microbiome composition (summer);
CESC	cis	rs8028182	0.636	rs6495182	chr15:75814388	C/T	cg20655648	chr15:75932815	IMP3	0.48	5.91	0.34	1.05e-8	Sudden cardiac arrest;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16520737	chr19:1021368	C19orf6	-0.65	-7.59	-0.42	5.36e-13	Gut microbiome composition (summer);
CESC	trans	rs2727020	0.576	rs61885308	chr11:49343363	G/A	cg00717180	chr2:96193071	NA	-0.44	-6.07	-0.35	4.41e-9	Coronary artery disease;
CESC	cis	rs1729951	0.575	rs1654925	chr3:136690391	C/T	cg04103450	chr3:136751342	NA	-0.38	-5.05	-0.3	8.18e-7	Neuroticism;
CESC	cis	rs1005277	0.579	rs2474580	chr10:38398713	G/A	cg00409905	chr10:38381863	ZNF37A	-0.47	-6.3	-0.36	1.24e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs990171	0.506	rs2041748	chr2:102756295	A/G	cg22835712	chr2:102737379	NA	0.44	6.25	0.36	1.65e-9	Lymphocyte counts;
CESC	cis	rs6088590	0.965	rs6119534	chr20:33441257	C/T	cg24642439	chr20:33292090	TP53INP2	0.82	11.44	0.57	6.84e-25	Coronary artery disease;
CESC	cis	rs10751667	0.643	rs7479473	chr11:929111	C/T	cg20946044	chr11:1010712	AP2A2	-0.39	-5.26	-0.31	2.96e-7	Alzheimer's disease (late onset);
CESC	cis	rs7666738	0.830	rs7697315	chr4:98938764	T/C	cg03467027	chr4:99064603	C4orf37	0.46	5.69	0.33	3.36e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4665809	1.000	rs6546728	chr2:26276531	G/C	cg22920501	chr2:26401640	FAM59B	-0.79	-9.3	-0.5	5.61e-18	Gut microbiome composition (summer);
CESC	cis	rs780096	0.546	rs715325	chr2:27725572	C/A	cg21248554	chr2:27665150	KRTCAP3	-0.42	-8.7	-0.47	3.67e-16	Total body bone mineral density;
CESC	cis	rs9733	0.650	rs11204684	chr1:150608894	A/G	cg22823121	chr1:150693482	HORMAD1	-0.41	-6.09	-0.35	3.95e-9	Tonsillectomy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27510503	chr22:22012035	NA	0.52	6.3	0.36	1.27e-9	Gut microbiome composition (summer);
CESC	cis	rs2303745	0.589	rs11086065	chr19:17395003	A/G	cg04248312	chr19:17393744	ANKLE1	-0.93	-15.26	-0.68	3.79e-38	Systemic lupus erythematosus;
CESC	cis	rs9858542	0.953	rs11926781	chr3:49603289	C/T	cg03060546	chr3:49711283	APEH	-0.51	-5.94	-0.34	8.9e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs2635047	0.811	rs17723754	chr18:44771481	C/T	cg19077165	chr18:44547161	KATNAL2	-0.39	-5.08	-0.3	7.06e-7	Educational attainment;
CESC	cis	rs11190604	1.000	rs2273695	chr10:102259568	A/G	cg07080220	chr10:102295463	HIF1AN	0.55	5.4	0.31	1.49e-7	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs642858	1.000	rs6933684	chr6:140300384	C/T	cg27524944	chr6:140295369	NA	0.36	5.57	0.32	6.19e-8	Type 2 diabetes;
CESC	cis	rs9818758	0.607	rs35108630	chr3:49088356	T/A	cg00383909	chr3:49044727	WDR6	0.92	6.59	0.38	2.35e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CESC	cis	rs6430585	0.941	rs12469551	chr2:136510012	T/G	cg07169764	chr2:136633963	MCM6	-0.95	-12.91	-0.62	6.41e-30	Corneal structure;
CESC	cis	rs2985684	0.740	rs2883438	chr14:50044392	T/C	cg10008539	chr14:50087325	RPL36AL;MGAT2	-0.44	-5.24	-0.31	3.24e-7	Carotid intima media thickness;
CESC	cis	rs875971	0.862	rs6947339	chr7:65888470	T/C	cg18876405	chr7:65276391	NA	0.53	7.32	0.41	3.01e-12	Aortic root size;
CESC	trans	rs1493916	0.967	rs9953768	chr18:31399468	A/G	cg27147174	chr7:100797783	AP1S1	-0.52	-7.1	-0.4	1.14e-11	Life satisfaction;
CESC	cis	rs1153858	1.000	rs4534782	chr15:45652933	G/A	cg14582100	chr15:45693742	SPATA5L1	0.42	5.97	0.34	7.62e-9	Homoarginine levels;
CESC	cis	rs72781680	0.611	rs72781696	chr2:24267014	C/T	cg08917208	chr2:24149416	ATAD2B	0.63	6.09	0.35	3.87e-9	Lymphocyte counts;
CESC	cis	rs826838	0.904	rs10880981	chr12:38763911	G/A	cg26384229	chr12:38710491	ALG10B	0.84	14.74	0.67	2.59e-36	Heart rate;
CESC	cis	rs7178572	0.568	rs1446312	chr15:77412189	G/C	cg22256960	chr15:77711686	NA	-0.53	-6.73	-0.38	1.05e-10	Type 2 diabetes;
CESC	cis	rs57221529	0.766	rs12521988	chr5:556421	C/T	cg16447950	chr5:562315	NA	-0.7	-7.76	-0.43	1.9e-13	Lung disease severity in cystic fibrosis;
CESC	cis	rs1348850	0.632	rs11682717	chr2:178499240	C/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.59	7.54	0.42	7.5e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs727563	0.594	rs132807	chr22:42071584	T/C	cg06634786	chr22:41940651	POLR3H	0.62	6.25	0.36	1.67e-9	Crohn's disease;Inflammatory bowel disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25155766	chr12:34317569	NA	-0.52	-6.68	-0.38	1.42e-10	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07588614	chr3:113604183	GRAMD1C	-0.69	-8.41	-0.46	2.51e-15	Gut microbiome composition (summer);
CESC	cis	rs897080	0.552	rs1067389	chr2:44642290	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	5.89	0.34	1.14e-8	Height;
CESC	cis	rs7553864	0.835	rs4415539	chr1:87604245	C/T	cg17420885	chr1:87600446	LOC339524	0.37	5.26	0.31	2.91e-7	Smoking behavior;
CESC	cis	rs875971	0.862	rs11773628	chr7:65982631	G/T	cg10691866	chr7:65817282	TPST1	0.32	5.25	0.31	3.06e-7	Aortic root size;
CESC	cis	rs7542091	0.748	rs2357231	chr1:210028454	A/C	cg05527609	chr1:210001259	C1orf107	0.38	5.08	0.3	7.11e-7	Monobrow;
CESC	cis	rs13382862	0.823	rs12710743	chr2:20880714	T/C	cg14780466	chr2:20870812	GDF7	-0.46	-7.43	-0.42	1.46e-12	Abdominal aortic aneurysm;
CESC	cis	rs6546550	0.901	rs12232914	chr2:70117176	C/T	cg02498382	chr2:70120550	SNRNP27	-0.42	-7.37	-0.41	2.12e-12	Prevalent atrial fibrillation;
CESC	cis	rs9905704	0.801	rs302847	chr17:56687481	C/T	cg12560992	chr17:57184187	TRIM37	0.62	7.73	0.43	2.17e-13	Testicular germ cell tumor;
CESC	cis	rs853679	0.546	rs200981	chr6:27833174	A/G	cg02228804	chr6:27775720	HIST1H2AI;HIST1H2BL	0.64	5.54	0.32	7.29e-8	Depression;
CESC	cis	rs12042052	0.793	rs10910624	chr1:232940291	T/A	cg00951395	chr1:232941775	KIAA1383	0.53	5.4	0.32	1.46e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CESC	cis	rs962856	0.756	rs4671799	chr2:67622243	A/G	cg09028215	chr2:67624308	ETAA1	-0.44	-5.64	-0.33	4.26e-8	Pancreatic cancer;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg13309628	chr20:3801056	C20orf29	0.48	6.14	0.35	3.07e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs6688613	0.545	rs10800270	chr1:166827602	A/T	ch.1.3259774R	chr1:166827647	TADA1	0.6	6.19	0.36	2.27e-9	Refractive astigmatism;
CESC	cis	rs763121	0.853	rs1013338	chr22:38974154	C/A	cg21395723	chr22:39101663	GTPBP1	0.48	6.34	0.36	9.72e-10	Menopause (age at onset);
CESC	trans	rs61931739	0.500	rs7489270	chr12:34432062	C/T	cg26384229	chr12:38710491	ALG10B	0.69	10.37	0.54	2.3e-21	Morning vs. evening chronotype;
CESC	cis	rs1030268	0.620	rs2160746	chr7:133478204	G/C	cg10665199	chr7:133106180	EXOC4	0.56	5.61	0.33	5.03e-8	Intelligence (multi-trait analysis);
CESC	cis	rs7044106	0.791	rs10985009	chr9:123493039	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.75	-11.04	-0.56	1.49e-23	Hip circumference adjusted for BMI;
CESC	cis	rs10504229	0.596	rs6991216	chr8:58115586	T/C	cg24829409	chr8:58192753	C8orf71	-0.58	-7.2	-0.4	6.31e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs1552244	1.000	rs76041173	chr3:10078695	G/T	cg00149659	chr3:10157352	C3orf10	0.75	9.56	0.51	8.47e-19	Alzheimer's disease;
CESC	cis	rs7095944	0.614	rs61872084	chr10:126439062	C/T	cg08799069	chr10:126477246	METTL10	-0.37	-5.29	-0.31	2.58e-7	Asthma;
CESC	cis	rs1843834	0.574	rs6436499	chr2:225456551	A/T	cg22509189	chr2:225307070	NA	-0.41	-5.65	-0.33	4.19e-8	IgE levels in asthmatics (D.p. specific);
CESC	cis	rs910316	0.967	rs4899551	chr14:75660246	C/G	cg08847533	chr14:75593920	NEK9	-0.91	-15.9	-0.7	1.93e-40	Height;
CESC	cis	rs6963495	0.818	rs117845382	chr7:105152040	T/C	cg02135003	chr7:105160482	PUS7	-0.46	-5.46	-0.32	1.08e-7	Bipolar disorder (body mass index interaction);
CESC	cis	rs798766	1.000	rs798755	chr4:1720824	A/G	cg10756475	chr4:1757242	NA	0.47	6.56	0.37	2.84e-10	Bladder cancer;Urinary bladder cancer;
CESC	cis	rs826838	1.000	rs826892	chr12:39100790	T/C	cg13010199	chr12:38710504	ALG10B	-0.4	-5.54	-0.32	7.42e-8	Heart rate;
CESC	cis	rs9916302	0.904	rs2338800	chr17:37498149	C/G	cg07936489	chr17:37558343	FBXL20	0.77	11.05	0.56	1.34e-23	Glomerular filtration rate (creatinine);
CESC	cis	rs722599	0.715	rs8008785	chr14:75307600	G/A	cg11812906	chr14:75593930	NEK9	-0.43	-5.48	-0.32	9.81e-8	IgG glycosylation;
CESC	trans	rs208520	0.690	rs3846808	chr6:66818604	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.94	-12.35	-0.6	5.52e-28	Exhaled nitric oxide output;
CESC	cis	rs9815354	0.680	rs7649989	chr3:41865843	A/C	cg03022575	chr3:42003672	ULK4	0.46	5.29	0.31	2.57e-7	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs6087990	0.899	rs1883729	chr20:31363193	G/A	cg13636640	chr20:31349939	DNMT3B	0.92	16.43	0.71	2.65e-42	Ulcerative colitis;
CESC	cis	rs2354432	0.607	rs6683243	chr1:146733422	A/T	cg25205988	chr1:146714368	CHD1L	-0.95	-7.6	-0.42	5.06e-13	Mitochondrial DNA levels;
CESC	cis	rs1005277	1.000	rs1005277	chr10:38218259	A/C	cg25427524	chr10:38739819	LOC399744	0.52	6.44	0.37	5.52e-10	Extrinsic epigenetic age acceleration;
CESC	cis	rs1538970	0.962	rs2487442	chr1:45857176	C/G	cg05343316	chr1:45956843	TESK2	-0.76	-10.59	-0.55	4.53e-22	Platelet count;
CESC	cis	rs66887589	0.777	rs2017058	chr4:120257739	T/C	cg09307838	chr4:120376055	NA	0.55	7.48	0.42	1.11e-12	Diastolic blood pressure;
CESC	cis	rs7618915	0.508	rs12498066	chr3:52627660	G/A	cg18099408	chr3:52552593	STAB1	-0.31	-5.09	-0.3	6.68e-7	Bipolar disorder;
CESC	trans	rs2085496	0.764	rs1596751	chr2:193807860	A/G	cg27069263	chr2:55278118	RTN4	0.45	5.99	0.35	6.64e-9	Neuroticism;
CESC	cis	rs4332037	0.624	rs11766944	chr7:1888051	G/A	cg23422044	chr7:1970798	MAD1L1	-0.54	-5.79	-0.34	1.99e-8	Bipolar disorder;
CESC	cis	rs13256369	0.802	rs1060106	chr8:8561452	A/G	cg00074818	chr8:8560427	CLDN23	0.36	5.24	0.31	3.32e-7	Obesity-related traits;
CESC	cis	rs6963495	0.818	rs116457537	chr7:105152072	A/G	cg02135003	chr7:105160482	PUS7	-0.46	-5.46	-0.32	1.08e-7	Bipolar disorder (body mass index interaction);
CESC	cis	rs2033711	0.870	rs3764534	chr19:58929136	G/A	cg00825309	chr19:58991885	ZNF446	-0.54	-7.71	-0.43	2.62e-13	Uric acid clearance;
CESC	cis	rs936229	0.813	rs4886619	chr15:75106138	C/T	cg14664628	chr15:75095509	CSK	-0.98	-15.61	-0.69	2.13e-39	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CESC	cis	rs7843479	1.000	rs727694	chr8:21849962	T/C	cg17168535	chr8:21777572	XPO7	0.48	6.7	0.38	1.26e-10	Mean corpuscular volume;
CESC	cis	rs9660180	0.967	rs6603803	chr1:1812688	A/G	cg05132306	chr1:1846340	CALML6	-0.29	-6.01	-0.35	6.22e-9	Body mass index;
CESC	cis	rs7584330	0.737	rs1390985	chr2:238367420	G/A	cg14458575	chr2:238380390	NA	0.6	8.14	0.45	1.56e-14	Prostate cancer;
CESC	cis	rs2637266	1.000	rs2579761	chr10:78321040	C/T	cg18941641	chr10:78392320	NA	0.38	7.06	0.4	1.46e-11	Pulmonary function;
CESC	cis	rs919433	0.963	rs10166569	chr2:198183439	G/A	cg03934865	chr2:198174659	NA	-0.4	-5.4	-0.31	1.48e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs7072216	0.763	rs10736129	chr10:100171571	C/T	cg26618903	chr10:100175079	PYROXD2	0.4	6.2	0.36	2.1e-9	Metabolite levels;
CESC	cis	rs561341	1.000	rs7214017	chr17:30332220	T/C	cg00745463	chr17:30367425	LRRC37B	-0.69	-6.99	-0.39	2.25e-11	Hip circumference adjusted for BMI;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00338229	chr19:46088275	OPA3	0.63	7.32	0.41	3.03e-12	Gut microbiome composition (summer);
CESC	cis	rs736408	0.736	rs4687550	chr3:52823430	T/G	cg17372223	chr3:52568218	NT5DC2	0.37	5.2	0.3	3.97e-7	Bipolar disorder;
CESC	cis	rs1371867	0.846	rs2453624	chr8:101230523	A/G	cg11906718	chr8:101322791	RNF19A	-0.5	-6.19	-0.36	2.22e-9	Atrioventricular conduction;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04073819	chr3:133293165	CDV3	0.66	7.2	0.4	6.38e-12	Gut microbiome composition (summer);
CESC	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg24101359	chr6:42928495	GNMT	0.56	7.98	0.44	4.36e-14	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs853679	0.517	rs6941992	chr6:28106141	T/C	cg26335602	chr6:28129616	ZNF389	0.54	7.3	0.41	3.37e-12	Depression;
CESC	cis	rs9910055	0.530	rs2269905	chr17:42294462	A/G	cg13607699	chr17:42295918	UBTF	0.81	12.25	0.6	1.22e-27	Total body bone mineral density;
CESC	cis	rs2073300	0.609	rs6137936	chr20:23385232	C/T	cg12062639	chr20:23401060	NAPB	1.07	8.85	0.48	1.29e-16	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs2191566	0.960	rs2270196	chr19:44506623	A/G	cg20607764	chr19:44506953	ZNF230	0.55	7.13	0.4	9.83e-12	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs6570726	0.967	rs439017	chr6:145806123	T/C	cg23711669	chr6:146136114	FBXO30	0.77	11.23	0.57	3.42e-24	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7666738	0.830	rs13138051	chr4:99050367	C/T	cg17366294	chr4:99064904	C4orf37	0.61	8.78	0.47	2.13e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs910316	0.967	rs4899550	chr14:75647666	C/T	cg11812906	chr14:75593930	NEK9	-0.84	-13.44	-0.64	9.06e-32	Height;
CESC	cis	rs1729951	0.575	rs361242	chr3:136698330	C/G	cg04103450	chr3:136751342	NA	0.4	5.36	0.31	1.78e-7	Neuroticism;
CESC	cis	rs2075371	0.933	rs1421481	chr7:133964380	A/C	cg00033643	chr7:134001901	SLC35B4	0.41	5.28	0.31	2.67e-7	Mean platelet volume;
CESC	cis	rs9303401	0.659	rs35539277	chr17:56853833	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.02	11.44	0.57	6.89e-25	Cognitive test performance;
CESC	cis	rs7412746	0.621	rs72704656	chr1:150828307	A/G	cg09365446	chr1:150670422	GOLPH3L	0.4	5.37	0.31	1.69e-7	Melanoma;
CESC	cis	rs6582630	0.537	rs6582500	chr12:38534206	G/A	cg13010199	chr12:38710504	ALG10B	0.53	6.84	0.39	5.44e-11	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs7223966	1.000	rs9912201	chr17:61763208	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.52	6.12	0.35	3.43e-9	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs769267	0.965	rs8103496	chr19:19386015	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	7.34	0.41	2.56e-12	Tonsillectomy;
CESC	cis	rs873946	0.648	rs1543593	chr10:134553185	A/T	cg06453172	chr10:134556979	INPP5A	-0.42	-5.42	-0.32	1.35e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs2415984	0.579	rs2254846	chr14:46973394	G/A	cg14871534	chr14:47121158	RPL10L	0.35	5.32	0.31	2.24e-7	Number of children ever born;
CESC	cis	rs9467711	0.606	rs34550936	chr6:26361985	A/G	cg12826209	chr6:26865740	GUSBL1	0.62	5.4	0.32	1.45e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs1348850	0.574	rs12988366	chr2:178417945	A/C	cg23306229	chr2:178417860	TTC30B	-0.74	-6.8	-0.39	6.9e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	trans	rs687914	0.710	rs938662	chr2:45864578	A/G	cg14875093	chr19:38398164	WDR87;SIPA1L3	0.61	6.34	0.36	9.77e-10	Diastolic blood pressure;
CESC	cis	rs9322193	0.923	rs9689723	chr6:149977071	C/A	cg07701084	chr6:150067640	NUP43	0.47	6.61	0.38	2.06e-10	Lung cancer;
CESC	cis	rs7408868	1.000	rs7247835	chr19:15262844	A/G	cg14696996	chr19:15285081	NOTCH3	1.12	11.59	0.58	2.09e-25	Pulse pressure;
CESC	cis	rs9916302	0.904	rs600010	chr17:37433517	T/C	cg20243544	chr17:37824526	PNMT	0.45	5.64	0.33	4.28e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs2455799	0.573	rs2455833	chr3:15752830	T/C	cg16303742	chr3:15540471	COLQ	-0.39	-6.19	-0.36	2.31e-9	Mean platelet volume;
CESC	trans	rs12356475	0.710	rs10822686	chr10:67733250	C/T	cg00670742	chr2:87034831	CD8A	0.5	6.25	0.36	1.66e-9	Psoriatic arthritis;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg06594919	chr10:102827590	NA	0.46	6.09	0.35	3.85e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs3785574	0.962	rs2584633	chr17:61879501	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	1.1	19.47	0.77	5.16e-53	Height;
CESC	cis	rs76917914	0.820	rs2281732	chr9:100845007	A/G	cg03040243	chr9:100819229	NANS	0.49	5.48	0.32	9.69e-8	Immature fraction of reticulocytes;
CESC	cis	rs4862750	0.872	rs13101380	chr4:187894744	G/A	cg03452623	chr4:187889614	NA	-0.94	-18.94	-0.76	3.59e-51	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2243480	0.614	rs34032527	chr7:65565141	C/G	cg12463550	chr7:65579703	CRCP	0.74	5.71	0.33	3.02e-8	Diabetic kidney disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23262030	chr17:45918702	SCRN2	0.59	6.7	0.38	1.25e-10	Gut microbiome composition (summer);
CESC	cis	rs910316	0.763	rs175044	chr14:75472109	G/A	cg16144293	chr14:75469539	EIF2B2	0.41	5.36	0.31	1.81e-7	Height;
CESC	cis	rs826838	0.616	rs10880738	chr12:38617762	C/T	cg26384229	chr12:38710491	ALG10B	-0.43	-5.65	-0.33	4.09e-8	Heart rate;
CESC	cis	rs6541297	0.703	rs1264081	chr1:230311176	A/G	cg20703242	chr1:230279135	GALNT2	-0.42	-5.45	-0.32	1.12e-7	Coronary artery disease;
CESC	cis	rs28829049	0.566	rs59681755	chr1:19528985	G/A	cg13387374	chr1:19411106	UBR4	0.44	5.61	0.33	5.16e-8	QRS duration in Tripanosoma cruzi seropositivity;
CESC	cis	rs5750830	0.649	rs4821893	chr22:39797779	G/A	cg24399712	chr22:39784796	NA	-0.83	-11.46	-0.58	5.61e-25	Intelligence (multi-trait analysis);
CESC	cis	rs61996546	0.622	rs34660647	chr15:26841524	T/C	cg15066197	chr15:26874202	GABRB3	-0.35	-5.15	-0.3	5.06e-7	Response to methotrexate in juvenile idiopathic arthritis;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg12037538	chr1:25664880	TMEM50A	-0.49	-6.44	-0.37	5.68e-10	Asthma;
CESC	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.55	-6.1	-0.35	3.69e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs72781680	0.898	rs12622290	chr2:23979894	C/G	cg20701182	chr2:24300061	SF3B14	0.63	5.54	0.32	7.13e-8	Lymphocyte counts;
CESC	cis	rs12900413	0.687	rs11629590	chr15:90304644	A/G	cg24249390	chr15:90295951	MESP1	0.43	6.2	0.36	2.15e-9	Coronary artery aneurysm in Kawasaki disease;
CESC	cis	rs6728642	1.000	rs80303184	chr2:98024633	G/A	cg26665480	chr2:98280029	ACTR1B	-0.93	-6.33	-0.36	1.04e-9	Bipolar disorder lithium response (continuous) or schizophrenia;
CESC	cis	rs748404	0.660	rs690512	chr15:43717678	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	8.13	0.45	1.61e-14	Lung cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26187342	chr17:65713858	NOL11	0.64	7.41	0.41	1.68e-12	Gut microbiome composition (summer);
CESC	cis	rs3749237	0.595	rs4855859	chr3:49526300	C/T	cg06212747	chr3:49208901	KLHDC8B	0.49	6.55	0.37	3.02e-10	Resting heart rate;
CESC	cis	rs2425143	1.000	rs60646509	chr20:34303409	T/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.6	5.14	0.3	5.33e-7	Blood protein levels;
CESC	cis	rs7520050	0.966	rs61783220	chr1:46335312	G/A	cg03146154	chr1:46216737	IPP	-0.49	-6.37	-0.36	8.44e-10	Red blood cell count;Reticulocyte count;
CESC	cis	rs11785400	0.793	rs4736367	chr8:143742477	G/A	cg24634471	chr8:143751801	JRK	0.45	5.75	0.33	2.41e-8	Schizophrenia;
CESC	cis	rs6032067	1.000	rs6032066	chr20:43857700	C/T	cg10761708	chr20:43804764	PI3	0.52	6.29	0.36	1.34e-9	Blood protein levels;
CESC	cis	rs2404602	0.647	rs8025991	chr15:77155268	C/T	cg23625390	chr15:77176239	SCAPER	-0.43	-5.94	-0.34	9.08e-9	Blood metabolite levels;
CESC	cis	rs17818399	0.716	rs62134741	chr2:46782189	G/A	cg06386533	chr2:46925753	SOCS5	0.46	5.04	0.3	8.74e-7	Height;
CESC	cis	rs7777754	0.512	rs3757472	chr7:50537983	A/C	cg14593290	chr7:50529359	DDC	-0.38	-5.5	-0.32	8.78e-8	Response to zileuton treatment in asthma (FEV1 change interaction);
CESC	cis	rs514406	0.505	rs437954	chr1:53173321	C/G	cg27535305	chr1:53392650	SCP2	-0.34	-5.59	-0.32	5.68e-8	Monocyte count;
CESC	cis	rs7412746	0.622	rs72704654	chr1:150826410	G/A	cg09365446	chr1:150670422	GOLPH3L	0.39	5.23	0.31	3.44e-7	Melanoma;
CESC	cis	rs4888262	0.526	rs7191754	chr16:74610850	G/T	cg01733217	chr16:74700730	RFWD3	0.82	11.28	0.57	2.33e-24	Testicular germ cell tumor;
CESC	cis	rs7666738	0.830	rs2098934	chr4:98992403	A/G	cg03467027	chr4:99064603	C4orf37	0.44	5.51	0.32	8.65e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs514406	0.505	rs425520	chr1:53179805	C/G	cg24675658	chr1:53192096	ZYG11B	-0.46	-5.68	-0.33	3.55e-8	Monocyte count;
CESC	cis	rs780096	0.546	rs1260320	chr2:27722416	A/G	cg02592271	chr2:27665507	KRTCAP3	0.33	6.89	0.39	3.98e-11	Total body bone mineral density;
CESC	cis	rs7811142	0.887	rs35111986	chr7:100000274	C/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.73	6.38	0.36	7.86e-10	Platelet count;
CESC	cis	rs9911578	0.934	rs58092632	chr17:57111101	T/C	cg05425664	chr17:57184151	TRIM37	0.52	7.19	0.4	6.63e-12	Intelligence (multi-trait analysis);
CESC	cis	rs72634258	0.503	rs697674	chr1:7837878	C/G	cg26816564	chr1:7831052	VAMP3	0.64	6.61	0.38	2.13e-10	Inflammatory bowel disease;
CESC	cis	rs820218	0.607	rs820168	chr17:73721365	G/C	cg01592526	chr17:73663357	RECQL5;SAP30BP	0.41	5.03	0.3	8.89e-7	Rotator cuff tears;
CESC	cis	rs13108904	0.967	rs4642180	chr4:1278914	T/C	cg00684032	chr4:1343700	KIAA1530	0.4	5.56	0.32	6.51e-8	Obesity-related traits;
CESC	cis	rs1005277	0.522	rs7072977	chr10:37940440	C/A	cg25517755	chr10:38738941	LOC399744	-0.42	-5.52	-0.32	8.28e-8	Extrinsic epigenetic age acceleration;
CESC	cis	rs2011503	1.000	rs11670882	chr19:19649748	C/G	cg03709012	chr19:19516395	GATAD2A	0.52	5.39	0.31	1.54e-7	Bipolar disorder;
CESC	cis	rs2952156	0.920	rs2517958	chr17:37838751	G/A	cg20243544	chr17:37824526	PNMT	0.62	8.16	0.45	1.36e-14	Asthma;
CESC	cis	rs9398803	0.865	rs2184968	chr6:126760994	A/G	cg19875578	chr6:126661172	C6orf173	0.48	6.88	0.39	4.37e-11	Male-pattern baldness;
CESC	cis	rs4665809	0.941	rs41285975	chr2:26351144	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.67	-7.53	-0.42	7.92e-13	Gut microbiome composition (summer);
CESC	cis	rs12530845	1.000	rs73721606	chr7:135335678	C/T	cg23117316	chr7:135346802	PL-5283	-0.41	-5.24	-0.31	3.35e-7	Red blood cell traits;
CESC	cis	rs4481887	0.772	rs4916127	chr1:248466615	A/G	cg00666640	chr1:248458726	OR2T12	0.39	6.37	0.36	8.47e-10	Common traits (Other);
CESC	cis	rs977987	0.806	rs11640473	chr16:75403289	C/A	cg03315344	chr16:75512273	CHST6	0.4	5.74	0.33	2.59e-8	Dupuytren's disease;
CESC	cis	rs7212590	0.581	rs28539312	chr17:57834602	A/C	cg20303301	chr17:57937339	TUBD1	-0.55	-5.18	-0.3	4.34e-7	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs10504229	0.953	rs2270610	chr8:58194669	A/G	cg24829409	chr8:58192753	C8orf71	-0.75	-9.74	-0.51	2.37e-19	Developmental language disorder (linguistic errors);
CESC	cis	rs4835473	0.900	rs11100810	chr4:144708671	C/T	cg25736465	chr4:144833511	NA	-0.33	-5.43	-0.32	1.28e-7	Immature fraction of reticulocytes;
CESC	cis	rs881375	0.902	rs2900180	chr9:123706382	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.4	5.43	0.32	1.25e-7	Rheumatoid arthritis;
CESC	cis	rs13191362	1.000	rs35383933	chr6:163002869	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.83	8.39	0.46	3.02e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs372883	0.600	rs2832294	chr21:30739671	A/C	cg08807101	chr21:30365312	RNF160	0.46	5.31	0.31	2.28e-7	Pancreatic cancer;
CESC	cis	rs2295499	0.610	rs2239726	chr4:2697089	A/C	cg08330972	chr4:2403930	ZFYVE28	-0.32	-5.18	-0.3	4.41e-7	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
CESC	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.66	-8.75	-0.47	2.57e-16	Prudent dietary pattern;
CESC	cis	rs9929218	1.000	rs8044058	chr16:68807088	G/A	cg02972257	chr16:68554789	NA	0.48	5.73	0.33	2.71e-8	Colorectal cancer;
CESC	cis	rs17253792	0.822	rs112418863	chr14:56114079	G/A	cg01858014	chr14:56050164	KTN1	-0.96	-7.52	-0.42	8.3e-13	Putamen volume;
CESC	cis	rs8058578	1.000	rs13338946	chr16:30700858	T/C	cg02466173	chr16:30829666	NA	-0.45	-7.19	-0.4	6.43e-12	Multiple myeloma;
CESC	cis	rs3857067	0.934	rs1509941	chr4:95018784	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.5	-7.53	-0.42	8.12e-13	QT interval;
CESC	cis	rs2235642	0.928	rs56289115	chr16:1608934	A/G	cg07639376	chr16:1584516	IFT140;TMEM204	-0.32	-5.29	-0.31	2.61e-7	Coronary artery disease;
CESC	trans	rs1814175	0.817	rs4881658	chr11:49941123	G/A	cg03929089	chr4:120376271	NA	-0.93	-15.62	-0.69	1.93e-39	Height;
CESC	cis	rs9733	0.687	rs11204735	chr1:150841667	T/C	cg22823121	chr1:150693482	HORMAD1	-0.37	-5.45	-0.32	1.15e-7	Tonsillectomy;
CESC	cis	rs7824557	0.701	rs2060465	chr8:11162609	T/C	cg21775007	chr8:11205619	TDH	0.5	7.29	0.41	3.6e-12	Retinal vascular caliber;
CESC	trans	rs561341	0.714	rs75861674	chr17:30304317	A/G	cg20587970	chr11:113659929	NA	-1.09	-13.78	-0.65	5.92e-33	Hip circumference adjusted for BMI;
CESC	cis	rs7223966	1.000	rs9747164	chr17:61864787	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.53	6.16	0.35	2.69e-9	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs2795502	1.000	rs2185717	chr10:43343875	G/A	cg27426351	chr10:43362370	NA	0.48	6.09	0.35	3.85e-9	Blood protein levels;
CESC	cis	rs9443645	0.505	rs9359364	chr6:79795992	G/A	cg05283184	chr6:79620031	NA	-0.37	-5.38	-0.31	1.61e-7	Intelligence (multi-trait analysis);
CESC	cis	rs7552404	0.727	rs7521344	chr1:76318325	C/T	cg03433033	chr1:76189801	ACADM	-0.62	-6.54	-0.37	3.12e-10	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs9768139	0.733	rs12698209	chr7:158117595	A/G	cg24154853	chr7:158122151	PTPRN2	-0.43	-7.01	-0.4	1.96e-11	Calcium levels;
CESC	cis	rs637571	0.522	rs7105628	chr11:65763067	C/T	cg02202077	chr11:65769826	EIF1AD;BANF1	0.45	5.97	0.34	7.63e-9	Eosinophil percentage of white cells;
CESC	cis	rs1552244	0.882	rs17050660	chr3:10001772	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.8	-10.99	-0.56	2.18e-23	Alzheimer's disease;
CESC	cis	rs66887589	0.934	rs7681980	chr4:120533223	G/A	cg09307838	chr4:120376055	NA	-0.48	-6.52	-0.37	3.53e-10	Diastolic blood pressure;
CESC	trans	rs17181170	0.536	rs13064285	chr3:87208121	A/T	ch.2.199792288R	chr2:200084043	NA	-0.46	-6.1	-0.35	3.78e-9	Prostate cancer;
CESC	cis	rs6570726	0.905	rs377143	chr6:145834220	C/T	cg05347473	chr6:146136440	FBXO30	0.44	5.96	0.34	8.05e-9	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs514406	0.644	rs4926928	chr1:53210163	G/T	cg24675658	chr1:53192096	ZYG11B	-0.6	-7.7	-0.43	2.64e-13	Monocyte count;
CESC	cis	rs7618915	0.547	rs11130311	chr3:52675005	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.48	6.9	0.39	3.79e-11	Bipolar disorder;
CESC	cis	rs2952156	0.920	rs9675194	chr17:37833805	A/G	cg07936489	chr17:37558343	FBXL20	-0.6	-8.1	-0.45	1.97e-14	Asthma;
CESC	cis	rs72781680	1.000	rs115861480	chr2:24129464	T/A	cg08917208	chr2:24149416	ATAD2B	1.1	9.84	0.52	1.09e-19	Lymphocyte counts;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00503587	chr20:18118441	PET117	0.6	6.58	0.37	2.53e-10	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04843851	chr14:71067415	MED6	0.63	6.83	0.39	5.9e-11	Gut microbiome composition (summer);
CESC	cis	rs12701220	0.655	rs34344742	chr7:1149288	C/G	cg26769984	chr7:1090371	C7orf50	0.54	6.33	0.36	1.02e-9	Bronchopulmonary dysplasia;
CESC	cis	rs2721195	0.967	rs10108150	chr8:145687475	A/G	cg26752003	chr8:145688521	CYHR1	0.46	6.49	0.37	4.11e-10	Age at first birth;
CESC	cis	rs12477438	0.520	rs2516827	chr2:99772565	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	15.46	0.69	7.45e-39	Chronic sinus infection;
CESC	cis	rs9322193	0.884	rs7769115	chr6:150169932	C/T	cg07701084	chr6:150067640	NUP43	0.39	5.1	0.3	6.36e-7	Lung cancer;
CESC	cis	rs8077577	0.708	rs59366579	chr17:18161744	C/T	cg16794390	chr17:18148240	FLII	0.38	5.94	0.34	9.03e-9	Obesity-related traits;
CESC	cis	rs7605827	0.930	rs6745731	chr2:15537915	C/T	cg19274914	chr2:15703543	NA	0.35	6.3	0.36	1.25e-9	Educational attainment (years of education);
CESC	cis	rs11098499	0.954	rs3733519	chr4:120423448	A/G	cg09307838	chr4:120376055	NA	0.92	13.01	0.62	3.03e-30	Corneal astigmatism;
CESC	trans	rs10028773	0.515	rs9994488	chr4:120587781	C/T	cg25214090	chr10:38739885	LOC399744	0.57	7.94	0.44	5.8e-14	Educational attainment;
CESC	cis	rs9910055	0.659	rs227580	chr17:42223068	C/T	cg08499158	chr17:42289980	UBTF	0.48	5.98	0.34	7.14e-9	Total body bone mineral density;
CESC	cis	rs9733	0.596	rs1136808	chr1:150702717	G/C	cg04414720	chr1:150670196	GOLPH3L	0.62	8.8	0.48	1.76e-16	Tonsillectomy;
CESC	cis	rs2425143	0.687	rs6119649	chr20:34369596	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	0.8	7.75	0.43	1.96e-13	Blood protein levels;
CESC	cis	rs2742234	0.541	rs10793426	chr10:43745280	G/A	cg15436174	chr10:43711423	RASGEF1A	0.46	5.33	0.31	2.14e-7	Hirschsprung disease;
CESC	cis	rs9899728	0.539	rs113775187	chr17:73047290	A/G	cg27626185	chr17:73056755	KCTD2	-0.89	-8.01	-0.44	3.55e-14	Alzheimer's disease or small vessel stroke;
CESC	cis	rs208520	0.690	rs3843513	chr6:66836797	A/G	cg07460842	chr6:66804631	NA	-0.98	-13.27	-0.63	3.6e-31	Exhaled nitric oxide output;
CESC	cis	rs9300255	0.506	rs61388686	chr12:123810873	G/A	cg00376283	chr12:123451042	ABCB9	0.56	7.64	0.42	3.92e-13	Neutrophil percentage of white cells;
CESC	trans	rs11098499	0.818	rs55825515	chr4:120486402	A/G	cg25214090	chr10:38739885	LOC399744	0.65	8.78	0.47	2e-16	Corneal astigmatism;
CESC	cis	rs7666738	0.830	rs4699588	chr4:98973789	A/G	cg05340658	chr4:99064831	C4orf37	0.79	12.26	0.6	1.12e-27	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7224314	1.000	rs7226214	chr17:65383323	C/T	cg01507342	chr17:65387096	PITPNC1	-0.48	-5.68	-0.33	3.45e-8	Diisocyanate-induced asthma;
CESC	cis	rs6860806	0.507	rs2631371	chr5:131703691	G/A	cg18758796	chr5:131593413	PDLIM4	-0.42	-5.82	-0.34	1.72e-8	Breast cancer;
CESC	cis	rs7666738	0.830	rs11097605	chr4:98985167	T/C	cg03467027	chr4:99064603	C4orf37	0.43	5.44	0.32	1.24e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1568889	0.838	rs1483858	chr11:28189639	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.79	12.87	0.62	8.97e-30	Bipolar disorder;
CESC	cis	rs7659604	0.539	rs3217753	chr4:122746325	A/G	cg06713675	chr4:122721982	EXOSC9	-0.46	-6.59	-0.38	2.37e-10	Type 2 diabetes;
CESC	cis	rs523522	0.962	rs4767903	chr12:120930046	G/A	cg27279351	chr12:120934652	DYNLL1	0.69	8.87	0.48	1.1e-16	High light scatter reticulocyte count;
CESC	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg06873352	chr17:61820015	STRADA	0.72	12.8	0.62	1.61e-29	Prudent dietary pattern;
CESC	trans	rs17685	0.753	rs11972240	chr7:75694079	A/C	cg19862616	chr7:65841803	NCRNA00174	0.82	12.16	0.6	2.58e-27	Coffee consumption;Coffee consumption (cups per day);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23713156	chr17:80606235	WDR45L	0.56	6.68	0.38	1.37e-10	Gut microbiome composition (summer);
CESC	cis	rs2576037	0.526	rs642897	chr18:44396917	T/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.7	11.14	0.56	7.03e-24	Personality dimensions;
CESC	cis	rs10088262	0.540	rs6988602	chr8:124788502	C/T	cg15047889	chr8:124780837	FAM91A1	0.48	5.63	0.33	4.63e-8	Pancreatic cancer;
CESC	cis	rs1707322	0.752	rs12024590	chr1:46127496	A/C	cg03146154	chr1:46216737	IPP	0.82	11.51	0.58	3.87e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7940866	0.874	rs1433979	chr11:130871617	G/A	cg12179176	chr11:130786555	SNX19	0.64	8.94	0.48	7.05e-17	Schizophrenia;
CESC	cis	rs6732160	0.588	rs72841902	chr2:73372212	T/A	cg01422370	chr2:73384389	NA	0.56	8.95	0.48	6.23e-17	Intelligence (multi-trait analysis);
CESC	trans	rs7246657	0.943	rs7252346	chr19:37914682	G/A	cg01833234	chr11:6592585	DNHD1	0.52	6.0	0.35	6.5e-9	Coronary artery calcification;
CESC	cis	rs7666738	0.830	rs17548431	chr4:98923768	C/G	cg17366294	chr4:99064904	C4orf37	0.6	8.23	0.45	8.65e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2204008	0.576	rs11519979	chr12:37999413	C/T	cg13010199	chr12:38710504	ALG10B	0.54	6.71	0.38	1.15e-10	Bladder cancer;
CESC	cis	rs9291683	0.609	rs3796836	chr4:10011345	A/G	cg11266682	chr4:10021025	SLC2A9	0.7	14.61	0.67	7.23e-36	Bone mineral density;
CESC	cis	rs7666738	0.830	rs10012271	chr4:99065154	A/C	cg18180107	chr4:99064573	C4orf37	0.4	5.14	0.3	5.21e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3740540	0.507	rs942014	chr10:126290070	C/T	cg04949429	chr10:126290192	LHPP	0.4	5.49	0.32	9.52e-8	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
CESC	cis	rs7259376	0.902	rs7248242	chr19:22575994	A/G	cg02657401	chr19:22469223	NA	0.26	5.16	0.3	4.86e-7	Menopause (age at onset);
CESC	cis	rs7618915	0.547	rs2164884	chr3:52629633	C/T	cg05564831	chr3:52568323	NT5DC2	0.45	6.97	0.39	2.55e-11	Bipolar disorder;
CESC	cis	rs8067545	0.586	rs8080649	chr17:20069677	G/C	cg13482628	chr17:19912719	NA	0.44	5.89	0.34	1.17e-8	Schizophrenia;
CESC	cis	rs11235843	0.602	rs7106773	chr11:73383174	C/G	cg18195628	chr11:73498948	MRPL48	-0.5	-5.38	-0.31	1.67e-7	Hand grip strength;
CESC	cis	rs367615	0.731	rs58241713	chr5:108853664	G/A	cg17395555	chr5:108820864	NA	0.55	9.01	0.48	4.09e-17	Colorectal cancer (SNP x SNP interaction);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg00366814	chr2:75061219	HK2	-0.49	-6.25	-0.36	1.61e-9	Ulcerative colitis;
CESC	cis	rs4253772	0.591	rs6008546	chr22:46686377	T/G	cg24881330	chr22:46731750	TRMU	0.82	7.66	0.43	3.61e-13	LDL cholesterol;Cholesterol, total;
CESC	trans	rs7945705	0.818	rs1988708	chr11:8882893	C/A	cg10637292	chr12:52960529	KRT74	0.36	6.26	0.36	1.54e-9	Hemoglobin concentration;
CESC	cis	rs9311474	0.713	rs352170	chr3:52236077	A/G	cg05564831	chr3:52568323	NT5DC2	0.38	5.95	0.34	8.32e-9	Electroencephalogram traits;
CESC	cis	rs1044826	0.642	rs9826544	chr3:139162831	A/G	cg00490450	chr3:139108681	COPB2	0.41	5.04	0.3	8.84e-7	Obesity-related traits;
CESC	cis	rs17818399	0.890	rs34544165	chr2:46836906	A/G	cg06386533	chr2:46925753	SOCS5	0.45	5.19	0.3	4.21e-7	Height;
CESC	cis	rs1008375	0.898	rs4698620	chr4:17587361	C/T	cg27347728	chr4:17578864	LAP3	0.46	5.49	0.32	9.24e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs11864453	0.927	rs1035560	chr16:72032730	T/C	cg16558253	chr16:72132732	DHX38	-0.46	-6.63	-0.38	1.83e-10	Fibrinogen levels;
CESC	cis	rs2901656	0.544	rs6658843	chr1:172399082	G/C	cg03748243	chr1:172413542	C1orf105;PIGC	0.47	6.66	0.38	1.53e-10	Red cell distribution width;Platelet distribution width;
CESC	cis	rs2361718	0.967	rs2361719	chr17:78103403	A/G	cg20811857	chr17:78079795	GAA	0.37	5.91	0.34	1.06e-8	Yeast infection;
CESC	trans	rs629535	0.551	rs62513429	chr8:70149995	A/C	cg21567404	chr3:27674614	NA	-0.83	-9.14	-0.49	1.69e-17	Dupuytren's disease;
CESC	cis	rs2836950	0.520	rs11911087	chr21:40665192	G/A	cg11890956	chr21:40555474	PSMG1	-0.63	-8.56	-0.47	9.12e-16	Menarche (age at onset);
CESC	cis	rs10779751	0.770	rs1148480	chr1:11172006	A/G	cg08854313	chr1:11322531	MTOR	0.85	12.23	0.6	1.46e-27	Body mass index;
CESC	cis	rs13266463	0.830	rs7014552	chr8:143410423	A/G	cg16886403	chr8:143471632	TSNARE1	0.44	5.5	0.32	8.78e-8	Schizophrenia;
CESC	cis	rs7666738	0.830	rs1967977	chr4:98966141	A/G	cg18180107	chr4:99064573	C4orf37	0.4	5.14	0.3	5.26e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs77741769	0.571	rs869781	chr12:121340246	T/C	cg02419362	chr12:121203948	SPPL3	0.35	5.6	0.33	5.35e-8	Mean corpuscular volume;
CESC	cis	rs798554	0.644	rs1639040	chr7:2884116	G/T	cg04166393	chr7:2884313	GNA12	0.61	8.24	0.45	8.02e-15	Height;
CESC	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg02725872	chr8:58115012	NA	-0.42	-5.88	-0.34	1.25e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs11098499	0.588	rs6534149	chr4:120559292	T/G	cg09307838	chr4:120376055	NA	-0.62	-8.1	-0.45	2.02e-14	Corneal astigmatism;
CESC	cis	rs1971256	0.500	rs17081325	chr6:151817992	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.63	6.01	0.35	6.14e-9	Endometriosis;
CESC	cis	rs10924309	0.737	rs1122734	chr1:245853336	A/T	cg00036263	chr1:245852353	KIF26B	-0.53	-6.87	-0.39	4.45e-11	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
CESC	cis	rs7216064	1.000	rs62084251	chr17:65878736	G/A	cg12091567	chr17:66097778	LOC651250	-0.86	-8.82	-0.48	1.55e-16	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs2011503	0.941	rs72999068	chr19:19380685	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.5	5.04	0.3	8.44e-7	Bipolar disorder;
CESC	cis	rs10751667	0.643	rs10794352	chr11:946294	T/C	cg20946044	chr11:1010712	AP2A2	-0.38	-5.29	-0.31	2.63e-7	Alzheimer's disease (late onset);
CESC	cis	rs63406760	1	rs63406760	chr12:123742692	TG/T	cg05973401	chr12:123451056	ABCB9	0.49	5.52	0.32	8.03e-8	Allergic disease (asthma, hay fever or eczema);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg17535283	chr2:26541115	GPR113	0.47	6.79	0.38	7.28e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs2859741	0.967	rs522481	chr1:37488337	C/T	cg09363841	chr1:37513479	NA	-0.66	-10.52	-0.54	7.37e-22	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	ch.2.195648145F	chr2:195939902	NA	-0.51	-6.47	-0.37	4.59e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs728616	0.681	rs55855057	chr10:82034729	G/A	cg27171509	chr10:82033454	MAT1A	-0.41	-5.08	-0.3	7.16e-7	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs4780401	0.609	rs12927966	chr16:11814562	C/T	cg01061890	chr16:11836724	TXNDC11	-0.56	-7.52	-0.42	8.36e-13	Rheumatoid arthritis;
CESC	cis	rs1862618	0.853	rs1423621	chr5:56101035	G/T	cg24549020	chr5:56110836	MAP3K1	0.6	7.0	0.39	2.12e-11	Initial pursuit acceleration;
CESC	cis	rs17253792	0.822	rs111467375	chr14:56046159	T/G	cg01858014	chr14:56050164	KTN1	-0.99	-7.44	-0.42	1.43e-12	Putamen volume;
CESC	trans	rs561341	0.609	rs9906443	chr17:30185565	C/T	cg20587970	chr11:113659929	NA	0.6	7.28	0.41	3.78e-12	Hip circumference adjusted for BMI;
CESC	cis	rs7843479	0.562	rs11774629	chr8:21859315	C/T	cg17168535	chr8:21777572	XPO7	0.73	11.55	0.58	2.81e-25	Mean corpuscular volume;
CESC	cis	rs929596	0.785	rs34352510	chr2:234650562	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.69	-8.69	-0.47	3.81e-16	Total bilirubin levels in HIV-1 infection;
CESC	cis	rs6032067	0.929	rs62208428	chr20:43827578	A/C	cg11264863	chr20:43835661	SEMG1	0.48	5.29	0.31	2.53e-7	Blood protein levels;
CESC	cis	rs62432291	0.681	rs2501177	chr6:159655593	C/T	cg14500486	chr6:159655392	FNDC1	-0.62	-6.21	-0.36	2.04e-9	Joint mobility (Beighton score);
CESC	cis	rs1044826	0.642	rs295478	chr3:139223135	G/A	cg00490450	chr3:139108681	COPB2	0.45	5.53	0.32	7.8e-8	Obesity-related traits;
CESC	cis	rs7116495	0.881	rs7930544	chr11:71737354	C/T	cg26138937	chr11:71823887	C11orf51	-0.77	-6.19	-0.36	2.3e-9	Severe influenza A (H1N1) infection;
CESC	cis	rs2795502	1.000	rs1852959	chr10:43359636	T/C	cg20628663	chr10:43360327	NA	0.59	6.89	0.39	4.13e-11	Blood protein levels;
CESC	cis	rs9815354	1.000	rs56207540	chr3:41976627	G/C	cg03022575	chr3:42003672	ULK4	0.67	5.96	0.34	7.91e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs16854884	0.632	rs62267390	chr3:143644067	A/T	cg06585982	chr3:143692056	C3orf58	0.54	7.1	0.4	1.15e-11	Economic and political preferences (feminism/equality);
CESC	cis	rs62408225	1.000	rs2021716	chr6:90941289	C/T	cg06866423	chr6:90926672	BACH2	0.47	5.82	0.34	1.71e-8	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs1552244	1.000	rs17032299	chr3:10087638	C/T	cg00149659	chr3:10157352	C3orf10	0.75	9.08	0.49	2.62e-17	Alzheimer's disease;
CESC	cis	rs2832191	0.716	rs9983051	chr21:30371890	C/T	cg08807101	chr21:30365312	RNF160	0.96	14.87	0.67	8.67e-37	Dental caries;
CESC	cis	rs2251381	0.606	rs8129515	chr21:30520167	C/G	cg24692254	chr21:30365293	RNF160	0.74	10.28	0.53	4.57e-21	Selective IgA deficiency;
CESC	trans	rs13098911	0.540	rs34000569	chr3:45999209	A/G	cg10236987	chr1:228114221	WNT9A	0.57	6.07	0.35	4.38e-9	Celiac disease;
CESC	cis	rs4665809	0.590	rs6716858	chr2:26423414	G/A	cg22920501	chr2:26401640	FAM59B	-0.78	-9.87	-0.52	9.31e-20	Gut microbiome composition (summer);
CESC	cis	rs875971	0.755	rs10228885	chr7:65780529	C/G	cg12463550	chr7:65579703	CRCP	-0.47	-5.99	-0.35	6.85e-9	Aortic root size;
CESC	trans	rs5758511	0.689	rs11913578	chr22:42347391	A/C	cg15080870	chr19:47770746	CCDC9	0.5	6.27	0.36	1.42e-9	Birth weight;
CESC	cis	rs7223966	1.000	rs8070650	chr17:61744040	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.54	6.44	0.37	5.7e-10	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs12534701	0.904	rs3800577	chr7:154673469	G/T	cg24255201	chr7:154684926	DPP6	0.5	6.67	0.38	1.5e-10	Colorectal cancer (diet interaction);
CESC	cis	rs10979	1.000	rs9386034	chr6:143890572	T/G	cg25407410	chr6:143891975	LOC285740	-0.61	-9.14	-0.49	1.72e-17	Hypospadias;
CESC	cis	rs4595586	0.525	rs11611705	chr12:39426828	C/T	cg26384229	chr12:38710491	ALG10B	0.59	7.99	0.44	4.27e-14	Morning vs. evening chronotype;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23879496	chr6:43749477	VEGFA	-0.57	-6.6	-0.38	2.17e-10	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.546	rs28590002	chr4:98722642	C/T	cg17366294	chr4:99064904	C4orf37	0.53	6.66	0.38	1.61e-10	Colonoscopy-negative controls vs population controls;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg00205436	chr2:132766767	NA	-0.41	-6.82	-0.39	6.02e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs4566357	0.615	rs4675140	chr2:227908665	C/T	cg11843606	chr2:227700838	RHBDD1	-0.49	-6.49	-0.37	4.28e-10	Coronary artery disease;
CESC	cis	rs611744	0.506	rs13280454	chr8:109263240	A/G	cg21045802	chr8:109455806	TTC35	0.49	6.09	0.35	3.98e-9	Dupuytren's disease;
CESC	cis	rs832540	0.806	rs10039322	chr5:56260259	A/C	cg24531977	chr5:56204891	C5orf35	-0.4	-5.13	-0.3	5.72e-7	Coronary artery disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg16256065	chr11:68216328	LRP5	0.49	6.98	0.39	2.43e-11	Fibrinogen levels;
CESC	cis	rs501120	1.000	rs1746047	chr10:44774086	T/G	cg09554077	chr10:44749378	NA	0.52	6.94	0.39	3.05e-11	Coronary artery disease;Coronary heart disease;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg24005950	chr16:2012498	SNORA10;RPS2	0.42	6.15	0.35	2.77e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs12681366	0.663	rs2043987	chr8:95469693	G/C	cg13257157	chr8:95487014	RAD54B	0.39	5.34	0.31	2.04e-7	Nonsyndromic cleft lip with cleft palate;
CESC	cis	rs4975616	0.804	rs459961	chr5:1337106	T/A	cg07493874	chr5:1342172	CLPTM1L	-0.41	-7.73	-0.43	2.26e-13	Lung cancer;
CESC	cis	rs6570726	0.791	rs401331	chr6:145831408	A/G	cg23711669	chr6:146136114	FBXO30	1.02	15.94	0.7	1.48e-40	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs3749237	0.595	rs3870337	chr3:49557095	G/T	cg06212747	chr3:49208901	KLHDC8B	0.49	6.63	0.38	1.92e-10	Resting heart rate;
CESC	cis	rs3749237	0.595	rs17595772	chr3:49409704	G/A	cg03060546	chr3:49711283	APEH	0.75	11.29	0.57	2.23e-24	Resting heart rate;
CESC	cis	rs12477438	0.765	rs62156363	chr2:99693324	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.64	-8.73	-0.47	2.94e-16	Chronic sinus infection;
CESC	cis	rs9649213	0.593	rs7781916	chr7:97929738	A/G	cg21770322	chr7:97807741	LMTK2	0.54	8.13	0.45	1.67e-14	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7618915	0.501	rs1468638	chr3:52748058	T/C	cg18337363	chr3:52569053	NT5DC2	0.29	5.32	0.31	2.23e-7	Bipolar disorder;
CESC	cis	rs7772486	0.686	rs9403746	chr6:146103768	C/A	cg23711669	chr6:146136114	FBXO30	-0.9	-13.54	-0.64	4.32e-32	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2072499	0.932	rs3001790	chr1:156165290	T/G	cg24450063	chr1:156163899	SLC25A44	1.11	23.35	0.82	2.92e-66	Testicular germ cell tumor;
CESC	cis	rs7017914	0.967	rs7000647	chr8:71688408	C/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.2	-0.3	3.94e-7	Bone mineral density;
CESC	cis	rs7927771	0.524	rs10838739	chr11:47672743	A/G	cg20307385	chr11:47447363	PSMC3	-0.6	-8.52	-0.46	1.24e-15	Subjective well-being;
CESC	cis	rs6502050	0.805	rs56020943	chr17:80105248	C/A	cg11859384	chr17:80120422	CCDC57	-0.38	-5.11	-0.3	6.21e-7	Life satisfaction;
CESC	trans	rs17536732	0.605	rs466478	chr4:162900278	A/G	cg11413039	chr11:125774447	PUS3;DDX25	-0.59	-6.47	-0.37	4.74e-10	Risky sexual behaviors (alcohol dependence interaction);
CESC	cis	rs3126085	0.735	rs35061954	chr1:152240583	G/T	cg03465714	chr1:152285911	FLG	-0.44	-5.49	-0.32	9.57e-8	Atopic dermatitis;
CESC	cis	rs71403859	0.502	rs34766979	chr16:71475511	G/A	cg08717414	chr16:71523259	ZNF19	-1.01	-9.45	-0.5	1.9e-18	Post bronchodilator FEV1;
CESC	cis	rs17345786	0.602	rs11923273	chr3:101337863	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.44	5.5	0.32	9.05e-8	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21733363	chr11:62623427	SNORD27;SLC3A2;SNORD28;SNORD25;SNORD26;SNHG1	0.57	6.33	0.36	1.05e-9	Gut microbiome composition (summer);
CESC	cis	rs4660306	1.000	rs882803	chr1:45976147	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.51	-6.61	-0.38	2.04e-10	Homocysteine levels;
CESC	cis	rs55883249	0.957	rs62119432	chr2:9753939	C/T	cg23886495	chr2:9695866	ADAM17	0.66	5.94	0.34	9.11e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
CESC	trans	rs61931739	1.000	rs11052967	chr12:34020030	T/G	cg26384229	chr12:38710491	ALG10B	-0.46	-6.29	-0.36	1.3e-9	Morning vs. evening chronotype;
CESC	cis	rs959260	1.000	rs6501786	chr17:73378775	A/T	cg12999837	chr17:73267436	MIF4GD	0.45	5.32	0.31	2.18e-7	Systemic lupus erythematosus;
CESC	cis	rs11098499	0.954	rs10031483	chr4:120422636	T/C	cg24375607	chr4:120327624	NA	0.46	5.66	0.33	3.87e-8	Corneal astigmatism;
CESC	cis	rs11227306	0.934	rs2234458	chr11:65639374	C/T	cg00576331	chr11:65640516	EFEMP2	0.44	5.8	0.34	1.85e-8	DNA methylation (variation);
CESC	cis	rs9322193	0.962	rs9505974	chr6:150100430	C/T	cg07701084	chr6:150067640	NUP43	0.4	5.48	0.32	9.87e-8	Lung cancer;
CESC	cis	rs9929218	1.000	rs9928847	chr16:68797893	C/T	cg02972257	chr16:68554789	NA	0.44	5.33	0.31	2.08e-7	Colorectal cancer;
CESC	trans	rs2030746	0.899	rs11686154	chr2:121310937	G/A	cg15455772	chr8:33269701	FUT10	0.43	6.09	0.35	3.86e-9	LDL cholesterol;Total cholesterol levels;LDL cholesterol levels;
CESC	cis	rs6748734	1.000	rs6724662	chr2:241831560	A/G	cg15164180	chr2:241846931	NA	-0.35	-5.03	-0.3	9.01e-7	Urinary metabolites;
CESC	cis	rs10857712	0.784	rs2265639	chr10:135221576	C/G	cg01444801	chr10:135216882	MTG1	0.47	5.66	0.33	3.99e-8	Systemic lupus erythematosus;
CESC	cis	rs3820068	0.603	rs6668726	chr1:15962614	G/A	cg17385448	chr1:15911702	AGMAT	0.41	6.69	0.38	1.3100000000000001e-10	Systolic blood pressure;
CESC	cis	rs1008375	1.000	rs1121090	chr4:17676437	C/G	cg02297831	chr4:17616191	MED28	0.45	5.64	0.33	4.42e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs7618915	0.501	rs13085775	chr3:52678370	C/T	cg05564831	chr3:52568323	NT5DC2	0.47	7.53	0.42	7.94e-13	Bipolar disorder;
CESC	cis	rs9733	0.519	rs72704603	chr1:150707992	C/T	cg04414720	chr1:150670196	GOLPH3L	0.57	7.94	0.44	5.86e-14	Tonsillectomy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21165122	chr7:149321434	ZNF767	0.61	7.12	0.4	1.03e-11	Gut microbiome composition (summer);
CESC	cis	rs7116495	0.609	rs1894004	chr11:71759817	G/A	cg07596299	chr11:71824057	C11orf51	-0.88	-5.65	-0.33	4.21e-8	Severe influenza A (H1N1) infection;
CESC	cis	rs6088580	0.505	rs6058106	chr20:33278255	T/C	cg24642439	chr20:33292090	TP53INP2	-0.43	-5.12	-0.3	6e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg16405210	chr4:1374714	KIAA1530	-0.97	-12.84	-0.62	1.19e-29	Longevity;
CESC	cis	rs2832191	0.791	rs57721945	chr21:30498744	T/C	cg24692254	chr21:30365293	RNF160	-0.79	-12.11	-0.6	3.71e-27	Dental caries;
CESC	cis	rs57221529	0.766	rs72703065	chr5:588123	C/A	cg16447950	chr5:562315	NA	-0.62	-6.52	-0.37	3.51e-10	Lung disease severity in cystic fibrosis;
CESC	cis	rs6905628	1	rs6905628	chr6:90344869	C/G	cg23505970	chr6:90529759	MDN1	0.56	7.23	0.41	5.22e-12	Coronary artery disease;
CESC	cis	rs17826219	0.706	rs61643715	chr17:29057762	A/G	cg13385521	chr17:29058706	SUZ12P	0.81	6.53	0.37	3.28e-10	Body mass index;
CESC	trans	rs3942852	0.774	rs2270990	chr11:48184983	G/T	cg03929089	chr4:120376271	NA	-0.66	-7.24	-0.41	4.83e-12	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs67311347	1.000	rs977652	chr3:40479169	A/G	cg24209194	chr3:40518798	ZNF619	0.49	6.51	0.37	3.81e-10	Renal cell carcinoma;
CESC	cis	rs7615952	0.576	rs1127717	chr3:125826059	T/C	cg02807482	chr3:125708958	NA	-0.42	-5.62	-0.33	4.74e-8	Blood pressure (smoking interaction);
CESC	cis	rs7605827	0.964	rs10929367	chr2:15564718	T/C	cg19274914	chr2:15703543	NA	0.35	6.27	0.36	1.45e-9	Educational attainment (years of education);
CESC	cis	rs735396	1.000	rs2259852	chr12:121434833	G/A	cg02403541	chr12:121454288	C12orf43	0.63	9.13	0.49	1.82e-17	N-glycan levels;
CESC	cis	rs9473147	0.543	rs4711880	chr6:47480676	A/G	cg20196966	chr6:47445060	CD2AP	0.41	5.33	0.31	2.13e-7	Platelet distribution width;Mean platelet volume;
CESC	cis	rs35306767	0.855	rs11253459	chr10:886402	C/T	cg20503657	chr10:835505	NA	0.76	7.6	0.42	5.02e-13	Eosinophil percentage of granulocytes;
CESC	cis	rs7580658	0.857	rs11890187	chr2:128083738	T/C	cg10021288	chr2:128175891	PROC	-0.41	-6.48	-0.37	4.43e-10	Protein C levels;
CESC	cis	rs7843479	0.601	rs4872207	chr8:21842751	C/G	cg17168535	chr8:21777572	XPO7	-0.69	-10.17	-0.53	9.97e-21	Mean corpuscular volume;
CESC	cis	rs4253772	0.591	rs6519994	chr22:46656805	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	-0.69	-8.25	-0.45	7.49e-15	LDL cholesterol;Cholesterol, total;
CESC	cis	rs11078597	0.731	rs1317708	chr17:1639965	G/A	cg18436246	chr17:1640651	WDR81	0.62	7.54	0.42	7.44e-13	Serum albumin level;
CESC	cis	rs9733	0.596	rs72702557	chr1:150680130	A/G	cg04414720	chr1:150670196	GOLPH3L	0.62	8.86	0.48	1.21e-16	Tonsillectomy;
CESC	cis	rs11098499	0.866	rs10518329	chr4:120401835	A/G	cg24375607	chr4:120327624	NA	0.4	5.23	0.31	3.41e-7	Corneal astigmatism;
CESC	cis	rs7071206	0.947	rs4979902	chr10:79399946	C/T	cg23888215	chr10:79422304	NA	0.57	6.26	0.36	1.57e-9	Bone mineral density;
CESC	cis	rs847577	0.677	rs1495525	chr7:97826232	G/A	cg24562669	chr7:97807699	LMTK2	-0.58	-8.6	-0.47	7.16e-16	Breast cancer;
CESC	cis	rs950027	0.596	rs2467865	chr15:45638307	T/C	cg21132104	chr15:45694354	SPATA5L1	0.67	8.55	0.46	1.01e-15	Response to fenofibrate (adiponectin levels);
CESC	cis	rs2274273	1.000	rs4644	chr14:55604935	C/A	cg04306507	chr14:55594613	LGALS3	0.28	5.19	0.3	4.11e-7	Protein biomarker;
CESC	cis	rs6547741	0.967	rs4665986	chr2:27755168	G/A	cg21248554	chr2:27665150	KRTCAP3	0.25	5.09	0.3	6.82e-7	Oral cavity cancer;
CESC	cis	rs151234	0.676	rs508022	chr16:28573963	C/T	cg01378222	chr16:28622494	SULT1A1	-0.56	-7.12	-0.4	1e-11	Platelet distribution width;
CESC	cis	rs9325144	0.671	rs7485963	chr12:38768254	C/G	cg26384229	chr12:38710491	ALG10B	-0.56	-7.9	-0.44	7.48e-14	Morning vs. evening chronotype;
CESC	cis	rs875971	0.545	rs12670811	chr7:65823019	C/A	cg25405998	chr7:65216604	CCT6P1	0.46	5.2	0.3	4.02e-7	Aortic root size;
CESC	cis	rs35306767	0.953	rs10904581	chr10:964685	A/T	cg20503657	chr10:835505	NA	0.7	7.87	0.44	9.02e-14	Eosinophil percentage of granulocytes;
CESC	cis	rs7666738	0.753	rs11932536	chr4:98930105	A/G	cg17366294	chr4:99064904	C4orf37	0.6	8.22	0.45	9.04e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs75804782	0.581	rs3191996	chr2:239344412	A/G	cg18131467	chr2:239335373	ASB1	0.66	5.44	0.32	1.23e-7	Morning vs. evening chronotype;Chronotype;
CESC	cis	rs13191362	0.935	rs35537826	chr6:163145867	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.67	6.97	0.39	2.47e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs8014204	0.570	rs7147721	chr14:75186010	A/G	cg11812906	chr14:75593930	NEK9	0.42	5.14	0.3	5.46e-7	Caffeine consumption;
CESC	cis	rs3733585	0.673	rs9993410	chr4:9951264	C/T	cg00071950	chr4:10020882	SLC2A9	-0.7	-11.41	-0.57	8.64e-25	Cleft plate (environmental tobacco smoke interaction);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg06972998	chr10:76585851	MYST4	-0.45	-6.15	-0.35	2.86e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs2952156	0.920	rs12150298	chr17:37834541	T/C	cg07936489	chr17:37558343	FBXL20	-0.58	-7.68	-0.43	3.12e-13	Asthma;
CESC	cis	rs4253772	0.637	rs8135997	chr22:46651366	G/A	cg10231785	chr22:46692440	CN5H6.4;GTSE1	0.48	5.11	0.3	6.16e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs4594175	0.926	rs12432356	chr14:51631223	T/G	cg23942311	chr14:51606299	NA	0.41	6.22	0.36	1.95e-9	Cancer;
CESC	cis	rs3008870	1.000	rs58680688	chr1:67443751	C/G	cg08660285	chr1:67390436	MIER1;WDR78	-1.02	-14.14	-0.66	3.43e-34	Lymphocyte percentage of white cells;
CESC	cis	rs7666738	0.830	rs28515641	chr4:98726419	G/A	cg17366294	chr4:99064904	C4orf37	0.57	7.94	0.44	5.7e-14	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7666738	0.830	rs1896154	chr4:99021161	T/C	cg05340658	chr4:99064831	C4orf37	0.83	13.12	0.63	1.19e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7249142	0.549	rs539	chr19:19287802	A/G	cg27384695	chr19:19271486	LOC729991-MEF2B;MEF2B	0.29	5.21	0.3	3.76e-7	IgG glycosylation;
CESC	cis	rs473651	0.935	rs541013	chr2:239336492	G/A	cg18131467	chr2:239335373	ASB1	1.06	21.61	0.8	2.13e-60	Multiple system atrophy;
CESC	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg05025164	chr4:1340916	KIAA1530	0.92	12.39	0.61	4.22e-28	Longevity;
CESC	trans	rs4906172	1.000	rs4906172	chr14:102454933	C/A	cg17920195	chr4:129149383	NA	0.31	6.1	0.35	3.81e-9	Menopause (age at onset);
CESC	cis	rs7818345	1.000	rs7818345	chr8:19306618	T/C	cg11303988	chr8:19266685	CSGALNACT1	0.36	6.38	0.37	7.66e-10	Language performance in older adults (adjusted for episodic memory);
CESC	cis	rs6424115	1.000	rs4237	chr1:24114129	C/T	cg10978503	chr1:24200527	CNR2	0.27	5.37	0.31	1.7e-7	Immature fraction of reticulocytes;
CESC	cis	rs10465746	0.573	rs12121175	chr1:84468961	T/G	cg10977910	chr1:84465055	TTLL7	0.44	5.58	0.32	5.93e-8	Obesity-related traits;
CESC	cis	rs11122272	0.735	rs2474633	chr1:231486989	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.48	-6.38	-0.36	7.95e-10	Hemoglobin concentration;
CESC	cis	rs10392	0.500	rs8118646	chr20:37600887	A/G	cg27552599	chr20:37590471	DHX35	0.37	5.48	0.32	9.82e-8	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
CESC	cis	rs593982	1.000	rs56257941	chr11:65505641	C/T	cg08755490	chr11:65554678	OVOL1	-1.26	-10.56	-0.54	5.65e-22	Atopic dermatitis;
CESC	cis	rs4927850	0.709	rs6783079	chr3:195652708	T/C	cg00031303	chr3:195681400	NA	0.76	9.54	0.51	9.8e-19	Pancreatic cancer;
CESC	cis	rs67460515	0.531	rs1585483	chr3:160843111	G/A	cg03342759	chr3:160939853	NMD3	-0.52	-6.55	-0.37	2.99e-10	Parkinson's disease;
CESC	trans	rs9467711	0.659	rs13195509	chr6:26463660	C/T	cg01620082	chr3:125678407	NA	-0.78	-6.8	-0.39	6.73e-11	Autism spectrum disorder or schizophrenia;
CESC	cis	rs7680126	0.633	rs11728093	chr4:10296407	A/C	cg00071950	chr4:10020882	SLC2A9	-0.54	-6.08	-0.35	4.12e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	cis	rs514406	0.722	rs7552139	chr1:53387379	G/C	cg08736216	chr1:53307985	ZYG11A	-0.37	-6.14	-0.35	2.98e-9	Monocyte count;
CESC	cis	rs854765	0.647	rs7406744	chr17:17981938	C/G	cg16928487	chr17:17741425	SREBF1	-0.53	-8.74	-0.47	2.72e-16	Total body bone mineral density;
CESC	cis	rs72781680	0.611	rs72797824	chr2:24356456	T/G	cg08917208	chr2:24149416	ATAD2B	0.57	5.57	0.32	6.1e-8	Lymphocyte counts;
CESC	cis	rs4664304	0.934	rs72957586	chr2:160762687	G/A	cg03641300	chr2:160917029	PLA2R1	-0.48	-6.78	-0.38	8.02e-11	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs8177179	0.967	rs4443173	chr3:133439378	A/G	cg24879335	chr3:133465180	TF	0.45	8.41	0.46	2.63e-15	Iron status biomarkers (transferrin levels);
CESC	cis	rs3008870	0.585	rs2815382	chr1:67515228	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.46	5.74	0.33	2.61e-8	Lymphocyte percentage of white cells;
CESC	cis	rs1799949	0.965	rs8176323	chr17:41195711	G/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.41	5.61	0.33	5.17e-8	Menopause (age at onset);
CESC	trans	rs931812	0.825	rs35472498	chr8:101894167	G/A	cg20993868	chr7:22813445	NA	0.54	7.46	0.42	1.26e-12	Attention deficit hyperactivity disorder and conduct disorder;
CESC	cis	rs7618915	0.501	rs12635140	chr3:52738165	C/T	cg05564831	chr3:52568323	NT5DC2	-0.47	-7.43	-0.42	1.49e-12	Bipolar disorder;
CESC	cis	rs6831352	0.918	rs17218141	chr4:100055908	T/C	cg13256891	chr4:100009986	ADH5	-0.77	-8.45	-0.46	1.97e-15	Alcohol dependence;
CESC	cis	rs11763147	1	rs11763147	chr7:65326821	C/T	cg18876405	chr7:65276391	NA	-0.71	-10.0	-0.52	3.48e-20	Corneal structure;
CESC	cis	rs6831352	0.879	rs17218003	chr4:100054723	G/C	cg12011299	chr4:100065546	ADH4	-0.6	-6.62	-0.38	2.04e-10	Alcohol dependence;
CESC	cis	rs12458462	0.851	rs3859317	chr18:77443093	A/C	cg23301140	chr18:77439876	CTDP1	0.55	7.41	0.41	1.72e-12	Monocyte count;
CESC	cis	rs1018836	0.544	rs2063978	chr8:91459525	C/T	cg16814680	chr8:91681699	NA	-0.45	-6.0	-0.35	6.43e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs2204008	0.641	rs2387810	chr12:38368875	G/T	cg13010199	chr12:38710504	ALG10B	0.48	6.06	0.35	4.77e-9	Bladder cancer;
CESC	cis	rs4253772	0.591	rs11703848	chr22:46685131	A/G	cg18190219	chr22:46762943	CELSR1	-0.59	-5.46	-0.32	1.09e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs7551222	0.721	rs4252717	chr1:204512100	T/C	cg20240347	chr1:204465584	NA	-0.28	-5.74	-0.33	2.59e-8	Schizophrenia;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg22094205	chr11:74109076	PGM2L1	-0.44	-6.05	-0.35	4.85e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg01419670	chr5:115696151	NA	0.43	6.19	0.36	2.29e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs2228479	1.000	rs12596492	chr16:89957169	T/G	cg14709524	chr16:89940631	TCF25	0.87	6.44	0.37	5.45e-10	Skin colour saturation;
CESC	cis	rs7662987	0.517	rs2602873	chr4:100039032	G/C	cg12011299	chr4:100065546	ADH4	0.6	6.56	0.37	2.83e-10	Smoking initiation;
CESC	cis	rs2625529	0.689	rs12161990	chr15:72202440	T/C	cg16672083	chr15:72433130	SENP8	0.42	6.15	0.35	2.78e-9	Red blood cell count;
CESC	cis	rs7582720	0.832	rs114139737	chr2:203721733	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.32	0.41	3.04e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs736801	0.808	rs2522057	chr5:131801947	C/G	cg00255919	chr5:131827918	IRF1	-0.34	-5.12	-0.3	5.78e-7	Breast cancer;Mosquito bite size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07153501	chr2:172864976	MAP1D	0.57	6.34	0.36	1.01e-9	Gut microbiome composition (summer);
CESC	cis	rs12765878	1.000	rs11191849	chr10:105650880	T/A	cg24587175	chr10:105670608	OBFC1	0.33	5.43	0.32	1.28e-7	Coronary artery disease;
CESC	trans	rs9850225	0.665	rs6795503	chr3:80478208	A/T	cg27138204	chr12:54446100	HOXC4	0.39	6.23	0.36	1.84e-9	Erectile dysfunction in type 1 diabetes;
CESC	cis	rs9291683	0.588	rs12507330	chr4:10002195	G/A	cg02734326	chr4:10020555	SLC2A9	0.44	6.38	0.36	7.84e-10	Bone mineral density;
CESC	cis	rs873946	0.586	rs3793686	chr10:134569559	A/G	cg27297192	chr10:134578999	INPP5A	0.41	5.47	0.32	1.05e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs425277	0.561	rs925906	chr1:2044054	A/C	cg16545954	chr1:2118288	C1orf86	-0.32	-5.83	-0.34	1.61e-8	Height;
CESC	cis	rs875971	0.638	rs3898855	chr7:66036398	G/C	cg06456125	chr7:65229604	NA	-0.39	-5.1	-0.3	6.54e-7	Aortic root size;
CESC	cis	rs4665809	0.941	rs6735145	chr2:26270302	T/C	cg25036284	chr2:26402008	FAM59B	-0.61	-6.98	-0.39	2.3e-11	Gut microbiome composition (summer);
CESC	cis	rs2836633	0.894	rs55955614	chr21:40037330	T/G	cg05519781	chr21:40033154	ERG	0.78	13.52	0.64	5.12e-32	Coronary artery disease;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg01487461	chr9:2017199	SMARCA2	0.46	6.04	0.35	5.08e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs9733	0.628	rs7540874	chr1:150702663	A/C	cg04414720	chr1:150670196	GOLPH3L	0.62	8.8	0.48	1.76e-16	Tonsillectomy;
CESC	cis	rs6088580	0.634	rs1205344	chr20:32918298	G/A	cg08999081	chr20:33150536	PIGU	-0.64	-11.04	-0.56	1.46e-23	Glomerular filtration rate (creatinine);
CESC	cis	rs9323205	0.954	rs4898682	chr14:51639577	C/T	cg23942311	chr14:51606299	NA	-0.42	-5.75	-0.33	2.4e-8	Cancer;
CESC	cis	rs2769264	1.000	rs6684085	chr1:151357333	C/T	cg18801370	chr1:151430492	POGZ	-0.53	-7.01	-0.4	2.01e-11	Blood trace element (Cu levels);
CESC	cis	rs7618915	0.547	rs7642198	chr3:52677960	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.48	6.9	0.39	3.79e-11	Bipolar disorder;
CESC	trans	rs916888	0.610	rs199446	chr17:44813169	G/A	cg01341218	chr17:43662625	NA	-0.55	-7.48	-0.42	1.12e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs1799949	1.000	rs3092988	chr17:41201702	C/T	cg05368731	chr17:41323189	NBR1	0.74	9.86	0.52	9.55e-20	Menopause (age at onset);
CESC	cis	rs6120849	0.707	rs6120799	chr20:33614955	T/C	cg06115741	chr20:33292138	TP53INP2	0.53	5.05	0.3	8.15e-7	Protein C levels;
CESC	trans	rs916888	0.647	rs199523	chr17:44848517	C/A	cg10053473	chr17:62856997	LRRC37A3	0.6	8.01	0.44	3.68e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs3093024	0.595	rs4458654	chr6:167476068	A/C	cg23791538	chr6:167370224	RNASET2	-0.52	-6.9	-0.39	3.81e-11	Rheumatoid arthritis;
CESC	cis	rs9287719	0.967	rs6751398	chr2:10738972	T/C	cg02196655	chr2:10830764	NOL10	-0.37	-5.72	-0.33	2.87e-8	Prostate cancer;
CESC	trans	rs7582180	0.700	rs1437971	chr2:100986964	A/C	cg09773150	chr17:3796596	CAMKK1	0.65	6.41	0.37	6.6e-10	Intelligence (multi-trait analysis);
CESC	cis	rs67311347	1.000	rs34762643	chr3:40475433	C/T	cg01475735	chr3:40494733	NA	-0.4	-5.08	-0.3	7.14e-7	Renal cell carcinoma;
CESC	cis	rs2439831	0.681	rs484846	chr15:43600803	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.93	11.23	0.57	3.35e-24	Lung cancer in ever smokers;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg16089233	chr7:129461722	NA	0.41	6.02	0.35	5.82e-9	Thyroid stimulating hormone;
CESC	cis	rs9486719	1.000	rs11152951	chr6:96894135	C/G	cg18709589	chr6:96969512	KIAA0776	-0.53	-5.81	-0.34	1.75e-8	Migraine;Coronary artery disease;
CESC	cis	rs2836974	0.897	rs2836933	chr21:40564202	C/G	cg17971929	chr21:40555470	PSMG1	1.05	15.96	0.7	1.17e-40	Cognitive function;
CESC	cis	rs6089829	0.962	rs2277769	chr20:61666805	C/T	cg03213289	chr20:61660250	NA	0.43	6.97	0.39	2.55e-11	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs3091242	0.900	rs669063	chr1:25721154	A/G	cg12412775	chr1:25698385	RHCE	-0.31	-5.63	-0.33	4.59e-8	Erythrocyte sedimentation rate;
CESC	cis	rs478304	0.934	rs574483	chr11:65515277	A/G	cg08755490	chr11:65554678	OVOL1	0.5	6.6	0.38	2.2e-10	Acne (severe);
CESC	cis	rs6695640	0.854	rs2762889	chr1:17733147	A/C	cg01904812	chr1:17746340	RCC2	0.35	5.17	0.3	4.64e-7	Mean platelet volume;
CESC	cis	rs11122272	0.705	rs1416914	chr1:231533196	C/T	cg06096015	chr1:231504339	EGLN1	0.41	5.81	0.34	1.74e-8	Hemoglobin concentration;
CESC	trans	rs3885907	0.542	rs11147439	chr13:31325643	C/A	cg22352122	chr11:453757	PTDSS2	-0.38	-6.05	-0.35	4.8e-9	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+epirubicin+/-5FU);
CESC	cis	rs9611565	0.525	rs1883827	chr22:41703579	A/G	cg03806693	chr22:41940476	POLR3H	-0.73	-8.54	-0.46	1.06e-15	Vitiligo;
CESC	trans	rs11264799	0.765	rs67070092	chr1:157622973	T/A	cg22691776	chr3:15032403	NR2C2	0.34	6.22	0.36	1.93e-9	IgA nephropathy;
CESC	cis	rs4835473	0.639	rs28674022	chr4:144887562	C/T	cg25736465	chr4:144833511	NA	0.41	6.37	0.36	8.26e-10	Immature fraction of reticulocytes;
CESC	trans	rs7618501	1.000	rs695238	chr3:49869158	A/C	cg21659725	chr3:3221576	CRBN	0.84	13.68	0.64	1.39e-32	Intelligence (multi-trait analysis);
CESC	cis	rs9768139	0.935	rs10949715	chr7:158117246	G/T	cg24154853	chr7:158122151	PTPRN2	0.38	6.17	0.35	2.5e-9	Calcium levels;
CESC	cis	rs9811920	0.638	rs1688782	chr3:99630527	C/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.54	-8.66	-0.47	4.74e-16	Axial length;
CESC	cis	rs2439831	0.867	rs7170489	chr15:43636651	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.84	12.26	0.6	1.11e-27	Lung cancer in ever smokers;
CESC	cis	rs2836974	0.897	rs1984022	chr21:40596085	G/A	cg27266027	chr21:40555129	PSMG1	0.45	5.37	0.31	1.72e-7	Cognitive function;
CESC	cis	rs4268898	0.662	rs72793208	chr2:24510284	C/T	cg20701182	chr2:24300061	SF3B14	0.63	6.86	0.39	4.75e-11	Asthma;
CESC	cis	rs9399137	0.507	rs61738647	chr6:135282735	T/C	cg24558204	chr6:135376177	HBS1L	0.7	9.47	0.5	1.6e-18	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	cis	rs7772486	0.790	rs2253307	chr6:146196181	T/G	cg23711669	chr6:146136114	FBXO30	1.01	15.47	0.69	6.84e-39	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs113835537	0.529	rs11227511	chr11:66281244	A/C	cg22134325	chr11:66188745	NPAS4	0.36	5.66	0.33	3.93e-8	Airway imaging phenotypes;
CESC	cis	rs74181299	0.892	rs2540945	chr2:65289825	A/G	cg05010058	chr2:65284262	CEP68	0.35	6.07	0.35	4.52e-9	Pulse pressure;
CESC	cis	rs7769051	0.522	rs3736725	chr6:133095172	A/G	cg07930552	chr6:133119739	C6orf192	0.82	7.54	0.42	7.55e-13	Type 2 diabetes nephropathy;
CESC	cis	rs17431357	1.000	rs17584461	chr12:121004236	A/C	cg25045489	chr12:120971538	RNF10	-0.92	-5.43	-0.32	1.27e-7	Insulin resistance/response;
CESC	cis	rs6088590	0.561	rs6059932	chr20:33175466	C/T	cg08999081	chr20:33150536	PIGU	0.7	12.43	0.61	3.03e-28	Coronary artery disease;
CESC	cis	rs5750830	0.594	rs5757650	chr22:39778419	A/G	cg05872129	chr22:39784769	NA	-0.73	-10.36	-0.54	2.43e-21	Intelligence (multi-trait analysis);
CESC	cis	rs11677370	0.603	rs10198219	chr2:3854600	T/C	cg17052675	chr2:3827356	NA	-0.45	-5.7	-0.33	3.2e-8	Type 2 diabetes;
CESC	cis	rs9660992	0.967	rs1172135	chr1:205247160	G/C	cg21643547	chr1:205240462	TMCC2	-0.43	-6.37	-0.36	8.3e-10	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs9487051	0.735	rs1260596	chr6:109519847	T/C	cg01475377	chr6:109611718	NA	-0.37	-5.55	-0.32	6.99e-8	Reticulocyte fraction of red cells;
CESC	cis	rs7666738	0.830	rs62318906	chr4:99037110	C/T	cg03676636	chr4:99064102	C4orf37	0.33	5.12	0.3	6.01e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10887741	0.532	rs791885	chr10:89410546	A/T	cg24243914	chr10:89418206	PAPSS2	0.33	5.52	0.32	8e-8	Exercise (leisure time);
CESC	cis	rs2380220	0.872	rs67846436	chr6:95951521	G/T	cg15832292	chr6:96025679	MANEA	-0.64	-5.77	-0.33	2.17e-8	Behavioural disinhibition (generation interaction);
CESC	cis	rs9768139	0.708	rs896782	chr7:158114115	G/A	cg25566285	chr7:158114605	PTPRN2	0.54	9.06	0.49	2.86e-17	Calcium levels;
CESC	cis	rs4862750	0.832	rs6836426	chr4:187897837	T/G	cg11301795	chr4:187892539	NA	-0.77	-12.15	-0.6	2.73e-27	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs78707713	0.560	rs61848397	chr10:71225584	C/A	cg12610070	chr10:71211762	TSPAN15	-0.34	-7.07	-0.4	1.4e-11	Venous thromboembolism;
CESC	cis	rs228437	0.913	rs11154779	chr6:134909194	T/C	cg24504307	chr6:134963096	NA	0.51	5.89	0.34	1.16e-8	Melanoma;
CESC	cis	rs10504229	0.679	rs1442125	chr8:58036258	A/C	cg22535103	chr8:58192502	C8orf71	0.59	6.77	0.38	8.45e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs898097	0.805	rs60233158	chr17:80896612	A/G	cg15664640	chr17:80829946	TBCD	0.62	9.28	0.5	6.35e-18	Breast cancer;
CESC	cis	rs7660520	0.524	rs12643521	chr4:183728242	C/G	cg04526738	chr4:183727387	NA	0.72	6.98	0.39	2.31e-11	Pediatric autoimmune diseases;
CESC	cis	rs35110281	0.508	rs2838351	chr21:45110784	A/G	cg04455712	chr21:45112962	RRP1B	0.47	7.11	0.4	1.1e-11	Mean corpuscular volume;
CESC	cis	rs2294693	0.945	rs10947944	chr6:41004657	T/C	cg14418226	chr6:40996092	UNC5CL	0.53	6.26	0.36	1.54e-9	Gastric cancer;Non-cardia gastric cancer;
CESC	cis	rs6424115	0.679	rs2076345	chr1:24083494	C/T	cg15997130	chr1:24165203	NA	-0.4	-5.08	-0.3	7.2e-7	Immature fraction of reticulocytes;
CESC	cis	rs10857712	0.754	rs2297033	chr10:135234848	C/T	cg22671611	chr10:135291010	NA	-0.34	-5.09	-0.3	6.67e-7	Systemic lupus erythematosus;
CESC	cis	rs2839186	0.558	rs2968	chr21:47608580	C/T	cg00815214	chr21:47717953	NA	0.42	6.15	0.35	2.78e-9	Testicular germ cell tumor;
CESC	cis	rs10504229	1.000	rs73607874	chr8:58173433	G/C	cg05313129	chr8:58192883	C8orf71	-0.55	-6.37	-0.36	8.42e-10	Developmental language disorder (linguistic errors);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16954204	chr6:20212978	MBOAT1	-0.73	-8.94	-0.48	7.03e-17	Gut microbiome composition (summer);
CESC	cis	rs3096299	0.685	rs4785676	chr16:89553624	T/C	cg16743903	chr16:89593216	SPG7	-0.47	-6.03	-0.35	5.44e-9	Multiple myeloma (IgH translocation);
CESC	cis	rs12677618	1.000	rs12677618	chr8:142302024	C/T	cg27411547	chr8:142287226	NA	-0.47	-5.69	-0.33	3.37e-8	Plateletcrit;
CESC	cis	rs9287719	0.967	rs12467642	chr2:10761484	G/A	cg00105475	chr2:10696890	NA	0.38	5.37	0.31	1.7e-7	Prostate cancer;
CESC	cis	rs6540559	0.546	rs75308488	chr1:210030639	T/C	cg21951975	chr1:209979733	IRF6	0.57	6.09	0.35	3.96e-9	Cleft lip with or without cleft palate;
CESC	cis	rs12451471	0.500	rs8077056	chr17:78076006	C/T	cg06718696	chr17:78121285	EIF4A3	0.8	9.28	0.5	6.39e-18	Plateletcrit;Mean corpuscular hemoglobin concentration;
CESC	cis	rs17376456	0.877	rs13169675	chr5:93331284	A/G	cg21475434	chr5:93447410	FAM172A	0.8	6.77	0.38	8.23e-11	Diabetic retinopathy;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg08478283	chr1:117076803	CD58	0.46	6.17	0.35	2.6e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs6502050	0.799	rs7502524	chr17:80107261	C/T	cg23985595	chr17:80112537	CCDC57	-0.42	-6.57	-0.37	2.72e-10	Life satisfaction;
CESC	cis	rs950169	0.686	rs12906474	chr15:85109237	A/G	cg17507749	chr15:85114479	UBE2QP1	0.55	6.15	0.35	2.9e-9	Schizophrenia;
CESC	cis	rs8062405	0.824	rs62034324	chr16:28536762	T/C	cg07382826	chr16:28625726	SULT1A1	0.31	5.05	0.3	8.32e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs17345786	0.906	rs72944107	chr3:101197190	C/T	cg12386194	chr3:101231763	SENP7	0.61	6.62	0.38	2.02e-10	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4434138	0.594	rs7653028	chr3:52763000	A/T	cg17372223	chr3:52568218	NT5DC2	0.44	6.59	0.38	2.35e-10	Intelligence (multi-trait analysis);
CESC	cis	rs2274273	1.000	rs8011834	chr14:55625977	A/C	cg04306507	chr14:55594613	LGALS3	0.31	6.1	0.35	3.79e-9	Protein biomarker;
CESC	cis	rs2050392	0.624	rs303450	chr10:30725337	C/A	cg02070205	chr10:30722105	MAP3K8	-0.45	-5.37	-0.31	1.73e-7	Inflammatory bowel disease;
CESC	cis	rs763121	0.819	rs5757169	chr22:39003495	G/A	cg21395723	chr22:39101663	GTPBP1	0.5	6.72	0.38	1.12e-10	Menopause (age at onset);
CESC	cis	rs12477438	0.798	rs6759354	chr2:99632195	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.72	-10.74	-0.55	1.4e-22	Chronic sinus infection;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg19151263	chr18:48724096	MEX3C	-0.49	-6.73	-0.38	1.05e-10	Asthma;
CESC	cis	rs17001868	0.568	rs3788578	chr22:40742921	C/T	cg07138101	chr22:40742427	ADSL	0.57	5.42	0.32	1.37e-7	Mammographic density (dense area);
CESC	cis	rs1775715	0.870	rs1755080	chr10:32255195	G/A	cg18675610	chr10:32216311	ARHGAP12	0.33	5.14	0.3	5.37e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs11098499	0.909	rs28571712	chr4:120375980	G/A	cg24375607	chr4:120327624	NA	0.48	5.9	0.34	1.12e-8	Corneal astigmatism;
CESC	cis	rs9948	0.655	rs2314399	chr2:97442390	G/A	cg01990225	chr2:97406019	LMAN2L	-1.0	-7.83	-0.43	1.21e-13	Erectile dysfunction and prostate cancer treatment;
CESC	cis	rs9649213	0.593	rs11766808	chr7:97915376	A/G	cg08684580	chr7:98029266	BAIAP2L1	-0.33	-5.26	-0.31	2.92e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7085104	0.700	rs10883785	chr10:104603588	A/G	cg15744005	chr10:104629667	AS3MT	-0.36	-5.59	-0.32	5.6e-8	Immature fraction of reticulocytes;Schizophrenia;
CESC	cis	rs6968419	0.788	rs4276607	chr7:115821608	G/T	cg02561103	chr7:115862891	TES	-0.39	-5.24	-0.31	3.31e-7	Intraocular pressure;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18394496	chr11:62554881	TMEM179B	0.67	8.15	0.45	1.44e-14	Gut microbiome composition (summer);
CESC	cis	rs9287719	0.601	rs1861300	chr2:10763961	A/G	cg00105475	chr2:10696890	NA	0.37	5.03	0.3	9.03e-7	Prostate cancer;
CESC	cis	rs7843479	0.965	rs11785657	chr8:21859485	G/A	cg17168535	chr8:21777572	XPO7	0.48	6.58	0.37	2.51e-10	Mean corpuscular volume;
CESC	cis	rs6543140	0.964	rs1035126	chr2:103019981	C/T	cg04239558	chr2:103089729	SLC9A4	0.49	6.21	0.36	2e-9	Blood protein levels;
CESC	cis	rs6662572	1.000	rs11585275	chr1:46095989	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.52	5.67	0.33	3.69e-8	Blood protein levels;
CESC	cis	rs7917772	0.503	rs7904955	chr10:104367092	C/T	cg22532475	chr10:104410764	TRIM8	-0.4	-6.63	-0.38	1.83e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs13191362	0.935	rs116735807	chr6:163010615	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.82	8.22	0.45	9.12e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs9649213	0.574	rs6961790	chr7:98007993	C/G	cg21770322	chr7:97807741	LMTK2	0.54	8.22	0.45	8.9e-15	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7592578	0.771	rs12053190	chr2:191383348	A/G	cg10560079	chr2:191398806	TMEM194B	-0.69	-6.12	-0.35	3.37e-9	Diastolic blood pressure;
CESC	cis	rs6866344	0.561	rs55974982	chr5:178141421	G/A	cg10224037	chr5:178157518	ZNF354A	0.74	8.73	0.47	2.99e-16	Neutrophil percentage of white cells;
CESC	trans	rs9951602	0.512	rs9949512	chr18:76641845	T/C	cg02800362	chr5:177631904	HNRNPAB	0.62	8.1	0.45	1.96e-14	Obesity-related traits;
CESC	cis	rs9611565	0.921	rs2235846	chr22:41741042	G/C	cg06481639	chr22:41940642	POLR3H	-0.47	-5.44	-0.32	1.19e-7	Vitiligo;
CESC	cis	rs8038465	0.874	rs11574488	chr15:73999379	T/A	cg15420318	chr15:73925796	NPTN	0.4	5.63	0.33	4.52e-8	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs7264396	0.676	rs6060723	chr20:34549947	G/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.52	6.1	0.35	3.72e-9	Total cholesterol levels;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg12126796	chr10:123687380	ATE1	-0.47	-6.15	-0.35	2.78e-9	Fibrinogen levels;
CESC	cis	rs72634258	0.796	rs10746475	chr1:8168261	T/A	cg00042356	chr1:8021962	PARK7	-0.48	-5.27	-0.31	2.88e-7	Inflammatory bowel disease;
CESC	cis	rs9649213	0.555	rs67132564	chr7:98014900	T/A	cg00277769	chr7:97922759	BAIAP2L1	-0.31	-5.09	-0.3	6.92e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7618501	1.000	rs6446295	chr3:49809063	G/T	cg24308560	chr3:49941425	MST1R	-0.49	-6.74	-0.38	9.66e-11	Intelligence (multi-trait analysis);
CESC	cis	rs9322193	0.962	rs9322206	chr6:149962617	T/C	cg13206674	chr6:150067644	NUP43	0.4	5.64	0.33	4.45e-8	Lung cancer;
CESC	cis	rs2282802	0.685	rs6893253	chr5:139661279	T/C	cg26211634	chr5:139558579	C5orf32	0.51	7.42	0.41	1.55e-12	Intelligence (multi-trait analysis);
CESC	cis	rs11098499	0.863	rs12508173	chr4:120318526	T/C	cg09307838	chr4:120376055	NA	0.92	12.53	0.61	1.29e-28	Corneal astigmatism;
CESC	cis	rs7618915	0.547	rs4687638	chr3:52651966	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.48	6.77	0.38	8.42e-11	Bipolar disorder;
CESC	cis	rs9394931	1.000	rs9394931	chr6:42873245	C/T	cg10862848	chr6:42927986	GNMT	0.25	5.88	0.34	1.2e-8	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid);
CESC	cis	rs4665809	0.590	rs35746418	chr2:26455002	C/G	cg26119090	chr2:26468346	HADHA;HADHB	1.1	12.68	0.61	4e-29	Gut microbiome composition (summer);
CESC	cis	rs16854884	0.526	rs7643341	chr3:143726980	C/T	cg06585982	chr3:143692056	C3orf58	0.56	7.56	0.42	6.42e-13	Economic and political preferences (feminism/equality);
CESC	cis	rs2075371	0.796	rs1978504	chr7:134006933	C/T	cg00033643	chr7:134001901	SLC35B4	-0.42	-5.3	-0.31	2.43e-7	Mean platelet volume;
CESC	cis	rs7772486	0.743	rs2092262	chr6:146037105	C/T	cg23711669	chr6:146136114	FBXO30	-0.82	-12.04	-0.59	6.45e-27	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6952808	0.792	rs2056481	chr7:1955435	A/G	cg00106254	chr7:1943704	MAD1L1	-0.47	-6.0	-0.35	6.34e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs1790761	0.520	rs4930461	chr11:67394895	A/G	cg14500267	chr11:67383377	NA	0.36	5.72	0.33	2.91e-8	Mean corpuscular volume;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg01172785	chr16:50092553	NA	0.53	6.97	0.39	2.56e-11	Fibrinogen levels;
CESC	cis	rs9902453	0.904	rs55866125	chr17:28312993	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.7	9.3	0.5	5.37e-18	Coffee consumption (cups per day);
CESC	cis	rs7833986	0.501	rs72653941	chr8:56942247	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.58	7.24	0.41	4.87e-12	Height;
CESC	cis	rs6460942	1.000	rs111761262	chr7:12415916	T/C	cg02935154	chr7:12443704	VWDE	-0.59	-6.17	-0.35	2.53e-9	Coronary artery disease;
CESC	cis	rs61759167	1.000	rs11587518	chr1:3096925	T/A	cg01961086	chr1:3086487	PRDM16	-0.34	-5.08	-0.3	6.97e-7	Motion sickness;
CESC	cis	rs7666738	0.830	rs1967979	chr4:98966201	G/T	cg18180107	chr4:99064573	C4orf37	0.4	5.14	0.3	5.26e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs60154123	0.764	rs1418257	chr1:210452846	G/A	cg22029157	chr1:209979665	IRF6	0.49	5.6	0.33	5.33e-8	Coronary artery disease;
CESC	cis	rs8180040	0.932	rs11711265	chr3:47558448	T/C	cg27129171	chr3:47204927	SETD2	0.6	8.5	0.46	1.4e-15	Colorectal cancer;
CESC	cis	rs763014	0.833	rs3743903	chr16:632736	T/C	cg09263875	chr16:632152	PIGQ	0.67	11.24	0.57	3.15e-24	Height;
CESC	cis	rs7762018	1.000	rs60253563	chr6:170083019	T/C	cg13891659	chr6:170190454	C6orf122;C6orf208	0.53	5.52	0.32	8.28e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs9549260	0.592	rs9315783	chr13:41289164	T/C	cg21288729	chr13:41239152	FOXO1	0.58	7.04	0.4	1.63e-11	Red blood cell count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20181420	chr10:60028918	CISD1;IPMK	0.49	6.12	0.35	3.32e-9	Gut microbiome composition (summer);
CESC	cis	rs35306767	0.903	rs765867	chr10:869901	G/T	cg10556349	chr10:835070	NA	0.6	5.71	0.33	3.1e-8	Eosinophil percentage of granulocytes;
CESC	cis	rs7044106	0.791	rs10984995	chr9:123479210	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.36	5.94	0.34	8.83e-9	Hip circumference adjusted for BMI;
CESC	cis	rs17376456	0.825	rs10058331	chr5:93279115	T/G	cg21475434	chr5:93447410	FAM172A	0.81	6.44	0.37	5.45e-10	Diabetic retinopathy;
CESC	cis	rs6460942	0.591	rs7804805	chr7:12332066	C/G	cg06484146	chr7:12443880	VWDE	-0.66	-7.27	-0.41	4.01e-12	Coronary artery disease;
CESC	cis	rs698833	0.852	rs698768	chr2:44576549	C/T	cg04920474	chr2:44395004	PPM1B	0.36	5.06	0.3	7.96e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs9649213	0.593	rs7807455	chr7:97957622	C/A	cg00277769	chr7:97922759	BAIAP2L1	-0.33	-5.42	-0.32	1.31e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7590368	0.673	rs56147885	chr2:10937095	T/A	cg15705551	chr2:10952987	PDIA6	0.54	5.17	0.3	4.51e-7	Educational attainment (years of education);
CESC	cis	rs791888	0.688	rs1980649	chr10:89422375	T/C	cg13926569	chr10:89418898	PAPSS2	0.52	7.22	0.41	5.67e-12	Magnesium levels;
CESC	cis	rs7666738	0.830	rs11932887	chr4:99072965	C/G	cg05340658	chr4:99064831	C4orf37	0.85	12.97	0.62	4.01e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7618915	0.547	rs11177	chr3:52721305	G/A	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.68	0.38	1.41e-10	Bipolar disorder;
CESC	cis	rs950776	0.518	rs4887062	chr15:78837801	G/A	cg24631222	chr15:78858424	CHRNA5	0.41	5.2	0.3	3.98e-7	Sudden cardiac arrest;
CESC	cis	rs1862618	0.853	rs832569	chr5:56154584	T/A	cg24531977	chr5:56204891	C5orf35	-0.88	-10.96	-0.56	2.74e-23	Initial pursuit acceleration;
CESC	cis	rs9733	0.570	rs951281	chr1:150691122	A/C	cg22823121	chr1:150693482	HORMAD1	0.48	7.11	0.4	1.11e-11	Tonsillectomy;
CESC	cis	rs7044106	0.762	rs1547268	chr9:123408688	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.76	11.04	0.56	1.44e-23	Hip circumference adjusted for BMI;
CESC	cis	rs7044106	0.791	rs735110	chr9:123488940	T/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.36	5.69	0.33	3.44e-8	Hip circumference adjusted for BMI;
CESC	cis	rs35110281	0.782	rs6518302	chr21:45018478	A/G	cg21573476	chr21:45109991	RRP1B	-0.48	-6.78	-0.38	7.96e-11	Mean corpuscular volume;
CESC	cis	rs9611565	0.694	rs19573	chr22:41865809	C/A	cg06634786	chr22:41940651	POLR3H	0.62	6.81	0.39	6.63e-11	Vitiligo;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23411981	chr14:105940377	CRIP2	-0.54	-6.24	-0.36	1.75e-9	Gut microbiome composition (summer);
CESC	cis	rs12541335	0.639	rs13257108	chr8:22165043	T/C	cg27266060	chr8:22091797	NA	0.37	7.36	0.41	2.33e-12	Hypertriglyceridemia;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14654587	chr19:1880126	FAM108A1	-0.51	-6.87	-0.39	4.63e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs4665809	0.549	rs72809635	chr2:26411674	G/A	cg04944784	chr2:26401820	FAM59B	0.85	9.2	0.49	1.14e-17	Gut microbiome composition (summer);
CESC	cis	rs4975709	0.838	rs4975752	chr5:1880588	A/C	cg15595755	chr5:1867978	NA	0.47	7.43	0.42	1.5e-12	Cardiovascular disease risk factors;
CESC	cis	rs2985684	0.841	rs12894785	chr14:50049755	G/C	cg10008539	chr14:50087325	RPL36AL;MGAT2	-0.44	-5.28	-0.31	2.63e-7	Carotid intima media thickness;
CESC	cis	rs73001065	0.636	rs56241616	chr19:19506092	C/T	cg03709012	chr19:19516395	GATAD2A	0.93	7.68	0.43	3.03e-13	LDL cholesterol;
CESC	cis	rs6570726	0.905	rs388728	chr6:145816419	T/C	cg23711669	chr6:146136114	FBXO30	0.82	12.29	0.6	8.74e-28	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7635838	0.751	rs9811658	chr3:11395833	A/G	cg00170343	chr3:11313890	ATG7	0.47	6.56	0.37	2.88e-10	HDL cholesterol;
CESC	cis	rs854765	0.647	rs6826	chr17:18011140	C/T	cg16928487	chr17:17741425	SREBF1	-0.54	-8.7	-0.47	3.67e-16	Total body bone mineral density;
CESC	cis	rs6842047	1.000	rs6842047	chr4:187133576	A/C	cg09526685	chr4:187126073	CYP4V2	0.6	5.3	0.31	2.43e-7	Blood protein levels;
CESC	cis	rs9733	0.596	rs12077833	chr1:150674333	C/T	cg22823121	chr1:150693482	HORMAD1	0.48	7.1	0.4	1.14e-11	Tonsillectomy;
CESC	cis	rs2980439	0.818	rs2945249	chr8:8094726	G/A	cg08975724	chr8:8085496	FLJ10661	0.42	5.07	0.3	7.59e-7	Neuroticism;
CESC	cis	rs561341	1.000	rs501312	chr17:30329066	A/G	cg19193384	chr17:30244184	NA	-0.7	-6.62	-0.38	2e-10	Hip circumference adjusted for BMI;
CESC	cis	rs6500395	0.962	rs868792	chr16:48640632	T/C	cg04672837	chr16:48644449	N4BP1	0.51	6.21	0.36	2.08e-9	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs2228479	0.850	rs12596934	chr16:89841605	T/G	cg04013166	chr16:89971882	TCF25	0.78	6.69	0.38	1.3e-10	Skin colour saturation;
CESC	cis	rs80282103	0.618	rs74117849	chr10:1165425	A/G	cg08668510	chr10:1095578	IDI1	0.74	5.92	0.34	9.9e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs472402	0.580	rs10076470	chr5:6632875	G/A	cg10789808	chr5:6633262	NSUN2;SRD5A1	-0.52	-6.83	-0.39	5.74e-11	Response to amphetamines;
CESC	cis	rs10883723	0.962	rs1056738	chr10:104236481	G/A	cg22532475	chr10:104410764	TRIM8	-0.34	-5.67	-0.33	3.77e-8	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs3820928	0.839	rs13398103	chr2:227859693	T/G	cg05526886	chr2:227700861	RHBDD1	-0.5	-5.91	-0.34	1.05e-8	Pulmonary function;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg18510056	chr10:77163383	C10orf41	-0.45	-6.49	-0.37	4.19e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs1185460	0.967	rs1177563	chr11:118949083	C/T	cg23280166	chr11:118938394	VPS11	0.56	7.86	0.43	9.86e-14	Coronary artery disease;
CESC	cis	rs7264396	0.563	rs2425084	chr20:34301871	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.62	6.94	0.39	3.03e-11	Total cholesterol levels;
CESC	cis	rs116095464	0.558	rs10057299	chr5:242135	C/T	cg22496380	chr5:211416	CCDC127	-0.74	-8.63	-0.47	5.66e-16	Breast cancer;
CESC	cis	rs7107174	1.000	rs2510046	chr11:77988817	T/C	cg02023728	chr11:77925099	USP35	0.5	6.77	0.38	8.03e-11	Testicular germ cell tumor;
CESC	cis	rs7811142	1.000	rs28490152	chr7:100020982	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.03	11.78	0.59	4.88e-26	Platelet count;
CESC	cis	rs7119	0.717	rs16968835	chr15:77734261	G/A	cg17802220	chr15:77601643	NA	-0.5	-7.0	-0.39	2.12e-11	Type 2 diabetes;
CESC	cis	rs6963495	0.818	rs118134111	chr7:105161229	A/C	cg02135003	chr7:105160482	PUS7	-0.46	-5.55	-0.32	6.92e-8	Bipolar disorder (body mass index interaction);
CESC	cis	rs7084402	0.967	rs1649049	chr10:60324095	G/A	cg07615347	chr10:60278583	BICC1	0.6	9.48	0.5	1.54e-18	Refractive error;
CESC	cis	rs8177253	0.665	rs9831392	chr3:133451473	A/T	cg18769074	chr3:133464867	TF	0.32	5.89	0.34	1.19e-8	Iron status biomarkers;
CESC	cis	rs7811142	0.887	rs35111986	chr7:100000274	C/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.04	10.31	0.54	3.52e-21	Platelet count;
CESC	cis	rs2404602	0.647	rs3812908	chr15:77176158	C/T	cg23625390	chr15:77176239	SCAPER	0.44	6.23	0.36	1.87e-9	Blood metabolite levels;
CESC	cis	rs7589728	1.000	rs11893832	chr2:88507537	G/C	cg04511125	chr2:88470314	THNSL2	0.54	5.19	0.3	4.25e-7	Plasma clusterin levels;
CESC	cis	rs644799	1.000	rs488246	chr11:95560473	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	14.27	0.66	1.19e-34	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs17021463	0.643	rs17311521	chr4:95298060	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.5	-6.97	-0.39	2.46e-11	Testicular germ cell tumor;
CESC	trans	rs9354352	0.935	rs9354354	chr6:66699333	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.7	-10.31	-0.54	3.42e-21	Initial pursuit acceleration in psychotic disorders;
CESC	cis	rs8040855	0.627	rs4843019	chr15:85644459	G/T	cg08123816	chr15:85640762	PDE8A	0.38	5.69	0.33	3.32e-8	Bulimia nervosa;
CESC	cis	rs4665809	0.627	rs35461456	chr2:26482361	C/G	cg26314531	chr2:26401878	FAM59B	0.85	9.04	0.49	3.46e-17	Gut microbiome composition (summer);
CESC	cis	rs6430585	0.528	rs3099429	chr2:136655582	T/A	cg07169764	chr2:136633963	MCM6	1.11	15.14	0.68	9.79e-38	Corneal structure;
CESC	cis	rs9287719	0.967	rs6432120	chr2:10753771	C/T	cg00105475	chr2:10696890	NA	0.38	5.42	0.32	1.34e-7	Prostate cancer;
CESC	cis	rs736408	0.545	rs6445529	chr3:52662722	T/A	cg17372223	chr3:52568218	NT5DC2	0.42	6.44	0.37	5.71e-10	Bipolar disorder;
CESC	cis	rs1355223	0.902	rs12802323	chr11:34747739	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.47	-6.24	-0.36	1.76e-9	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs854765	0.583	rs7214002	chr17:17852104	G/C	cg09796270	chr17:17721594	SREBF1	0.41	5.64	0.33	4.34e-8	Total body bone mineral density;
CESC	cis	rs2120019	1.000	rs34237279	chr15:75361121	A/G	cg17294928	chr15:75287854	SCAMP5	-0.68	-7.51	-0.42	8.84e-13	Blood trace element (Zn levels);
CESC	cis	rs11155671	0.530	rs6935829	chr6:150217811	C/T	cg09699651	chr6:150184138	LRP11	0.54	7.49	0.42	1.05e-12	Testicular germ cell tumor;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17378273	chr11:45169082	PRDM11	-0.59	-7.01	-0.4	2.01e-11	Gut microbiome composition (summer);
CESC	cis	rs1801251	1.000	rs2592113	chr2:233669553	C/T	cg08000102	chr2:233561755	GIGYF2	0.66	9.59	0.51	6.85e-19	Coronary artery disease;
CESC	cis	rs7824557	0.606	rs2736273	chr8:11199938	C/A	cg21775007	chr8:11205619	TDH	0.53	7.77	0.43	1.68e-13	Retinal vascular caliber;
CESC	trans	rs1814175	0.645	rs1851850	chr11:50012168	G/A	cg15704280	chr7:45808275	SEPT13	-1.0	-18.47	-0.75	1.54e-49	Height;
CESC	cis	rs4237845	0.537	rs4237844	chr12:58267987	A/G	cg00677455	chr12:58241039	CTDSP2	-0.77	-10.07	-0.53	2.05e-20	Intelligence (multi-trait analysis);
CESC	cis	rs7914558	0.966	rs10748836	chr10:104693917	G/A	cg15744005	chr10:104629667	AS3MT	-0.35	-5.48	-0.32	9.76e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs6938	0.534	rs1133322	chr15:75212357	A/G	cg13906792	chr15:75199810	C15orf17	-0.35	-5.21	-0.3	3.79e-7	Breast cancer;
CESC	cis	rs9910055	0.659	rs7212573	chr17:42254281	A/G	cg13607699	chr17:42295918	UBTF	0.54	6.8	0.39	6.85e-11	Total body bone mineral density;
CESC	cis	rs3087591	0.922	rs9892839	chr17:29618990	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.43	-5.53	-0.32	7.6e-8	Hip circumference;
CESC	cis	rs9910055	0.530	rs2269907	chr17:42294215	G/A	cg08499158	chr17:42289980	UBTF	-0.41	-5.26	-0.31	3e-7	Total body bone mineral density;
CESC	cis	rs74181299	0.750	rs2723067	chr2:65277951	A/G	cg05010058	chr2:65284262	CEP68	0.3	5.03	0.3	8.87e-7	Pulse pressure;
CESC	cis	rs2710642	0.777	rs2539987	chr2:63142864	A/G	cg17519650	chr2:63277830	OTX1	0.54	7.04	0.4	1.66e-11	LDL cholesterol levels;LDL cholesterol;
CESC	cis	rs7267979	0.873	rs7453	chr20:25207074	A/G	cg08601574	chr20:25228251	PYGB	0.38	5.62	0.33	4.93e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7264396	0.563	rs2425071	chr20:34292961	A/C	cg23207816	chr20:34252616	CPNE1;RBM12	-0.65	-7.04	-0.4	1.63e-11	Total cholesterol levels;
CESC	cis	rs1862618	0.853	rs1862619	chr5:56098256	T/A	cg24531977	chr5:56204891	C5orf35	-0.83	-11.11	-0.56	8.79e-24	Initial pursuit acceleration;
CESC	cis	rs3126085	0.935	rs12144058	chr1:152170216	C/T	cg03465714	chr1:152285911	FLG	-0.45	-5.53	-0.32	7.5e-8	Atopic dermatitis;
CESC	cis	rs2070488	0.775	rs13072731	chr3:38533335	A/C	cg24069376	chr3:38537580	EXOG	0.37	6.39	0.37	7.25e-10	Electrocardiographic conduction measures;
CESC	cis	rs3857536	0.813	rs2040594	chr6:66943966	A/G	cg07460842	chr6:66804631	NA	-0.41	-5.22	-0.31	3.67e-7	Blood trace element (Cu levels);
CESC	cis	rs4144743	0.941	rs7211563	chr17:45324061	T/C	cg18085866	chr17:45331354	ITGB3	-0.66	-7.64	-0.43	3.87e-13	Body mass index;
CESC	trans	rs5758511	0.773	rs62240997	chr22:42354567	T/G	cg15080870	chr19:47770746	CCDC9	0.5	6.2	0.36	2.15e-9	Birth weight;
CESC	cis	rs7618915	0.570	rs11130319	chr3:52755592	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	6.81	0.39	6.65e-11	Bipolar disorder;
CESC	cis	rs4803468	1.000	rs4803465	chr19:41918158	A/G	cg09537434	chr19:41945824	ATP5SL	1.01	18.34	0.75	4.71e-49	Height;
CESC	cis	rs9309473	1.000	rs6546836	chr2:73677833	A/G	cg20560298	chr2:73613845	ALMS1	-0.47	-6.32	-0.36	1.07e-9	Metabolite levels;
CESC	cis	rs3091242	0.933	rs34006994	chr1:25780668	C/T	cg02931644	chr1:25747376	RHCE	-0.39	-6.56	-0.37	2.88e-10	Erythrocyte sedimentation rate;
CESC	cis	rs9549367	0.789	rs9549361	chr13:113898329	C/T	cg00898013	chr13:113819073	PROZ	0.51	6.86	0.39	4.78e-11	Platelet distribution width;
CESC	cis	rs514406	0.505	rs436363	chr1:53172163	T/C	cg27535305	chr1:53392650	SCP2	-0.34	-5.55	-0.32	7.05e-8	Monocyte count;
CESC	cis	rs798554	0.757	rs1182187	chr7:2870454	T/G	cg13628971	chr7:2884303	GNA12	0.64	8.31	0.45	4.97e-15	Height;
CESC	cis	rs11169225	0.724	rs7305290	chr12:50341465	A/G	cg04450003	chr12:50355995	AQP5	0.46	6.21	0.36	1.98e-9	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs3092073	0.669	rs11697323	chr20:44551579	C/T	cg00981651	chr20:44574847	PCIF1	0.4	6.0	0.35	6.31e-9	Intelligence (multi-trait analysis);
CESC	cis	rs2842992	0.789	rs9365093	chr6:160175819	C/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.71	9.29	0.5	5.98e-18	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs7845219	0.525	rs3019175	chr8:95949013	G/A	cg13393036	chr8:95962371	TP53INP1	-0.4	-7.42	-0.41	1.64e-12	Type 2 diabetes;
CESC	cis	rs9715521	0.775	rs11723682	chr4:59851969	C/T	cg11281224	chr4:60001000	NA	-0.51	-6.73	-0.38	1.02e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs12142240	0.583	rs5013330	chr1:46815154	G/A	cg00530320	chr1:46809349	NSUN4	0.58	7.89	0.44	8.17e-14	Menopause (age at onset);
CESC	cis	rs769267	0.896	rs2315610	chr19:19597240	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.46	5.95	0.34	8.41e-9	Tonsillectomy;
CESC	cis	rs472402	0.623	rs8192131	chr5:6636465	C/T	cg10789808	chr5:6633262	NSUN2;SRD5A1	-0.46	-6.12	-0.35	3.29e-9	Response to amphetamines;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg20696752	chr17:42143797	LSM12	-0.45	-6.64	-0.38	1.8e-10	Gambling;
CESC	cis	rs6736093	1.000	rs17779482	chr2:112665677	C/T	cg12686935	chr2:112915763	FBLN7	-0.39	-5.1	-0.3	6.51e-7	Coronary artery disease;
CESC	cis	rs801193	1.000	rs62466793	chr7:66191517	G/A	cg11764359	chr7:65958608	NA	0.69	9.1	0.49	2.27e-17	Aortic root size;
CESC	cis	rs9311474	0.508	rs6788887	chr3:52605005	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.49	7.18	0.4	6.94e-12	Electroencephalogram traits;
CESC	cis	rs9916302	0.706	rs667193	chr17:37448835	T/C	cg07936489	chr17:37558343	FBXL20	0.92	10.37	0.54	2.23e-21	Glomerular filtration rate (creatinine);
CESC	cis	rs3780486	1.000	rs10813951	chr9:33128021	C/T	cg13443165	chr9:33130375	B4GALT1	-0.42	-5.63	-0.33	4.47e-8	IgG glycosylation;
CESC	cis	rs6496667	0.533	rs2074584	chr15:91009381	C/T	cg10434728	chr15:90938212	IQGAP1	0.3	5.17	0.3	4.58e-7	Rheumatoid arthritis;
CESC	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	-1.07	-19.75	-0.77	5.44e-54	Prudent dietary pattern;
CESC	cis	rs684232	0.602	rs416662	chr17:535699	A/G	cg15660573	chr17:549704	VPS53	-0.8	-11.72	-0.58	7.73e-26	Prostate cancer;
CESC	cis	rs2463822	1.000	rs2463820	chr11:62112290	A/T	cg06239285	chr11:62104954	ASRGL1	0.98	8.69	0.47	3.89e-16	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs7124681	0.585	rs10838773	chr11:47834346	G/A	cg18512352	chr11:47633146	NA	0.35	5.35	0.31	1.92e-7	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
CESC	cis	rs13118159	0.836	rs12647145	chr4:1338618	C/A	cg16405210	chr4:1374714	KIAA1530	-0.54	-7.4	-0.41	1.85e-12	Longevity;
CESC	cis	rs9611565	0.512	rs5996063	chr22:42168767	G/A	cg03806693	chr22:41940476	POLR3H	1.18	13.88	0.65	2.76e-33	Vitiligo;
CESC	cis	rs6674176	0.593	rs6675620	chr1:44417630	C/T	cg13606994	chr1:44402422	ARTN	-0.36	-5.43	-0.32	1.29e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs2976388	0.566	rs6998746	chr8:143802456	A/C	cg24634471	chr8:143751801	JRK	0.44	5.31	0.31	2.3e-7	Urinary tract infection frequency;
CESC	cis	rs651907	0.535	rs58658478	chr3:101511667	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.45	5.87	0.34	1.29e-8	Colorectal cancer;
CESC	cis	rs6502050	0.835	rs6502067	chr17:80111205	A/G	cg11859384	chr17:80120422	CCDC57	-0.39	-5.37	-0.31	1.76e-7	Life satisfaction;
CESC	cis	rs9733	0.596	rs12063547	chr1:150674053	G/T	cg04414720	chr1:150670196	GOLPH3L	-0.61	-8.67	-0.47	4.29e-16	Tonsillectomy;
CESC	cis	rs798554	0.567	rs1182191	chr7:2869364	A/T	cg04166393	chr7:2884313	GNA12	0.39	5.15	0.3	5.11e-7	Height;
CESC	cis	rs514406	0.893	rs1242315	chr1:53417181	A/G	cg08859206	chr1:53392774	SCP2	-0.57	-7.35	-0.41	2.54e-12	Monocyte count;
CESC	cis	rs4862750	0.872	rs6830828	chr4:187897472	T/G	cg10295955	chr4:187884368	NA	-1.08	-22.82	-0.81	1.67e-64	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6964587	1.000	rs417	chr7:91581121	C/A	cg17063962	chr7:91808500	NA	-0.57	-7.69	-0.43	2.84e-13	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26879945	chr16:57318890	PLLP	0.53	6.12	0.35	3.26e-9	Gut microbiome composition (summer);
CESC	cis	rs11098499	0.663	rs28369503	chr4:120238925	G/A	cg09307838	chr4:120376055	NA	0.78	10.39	0.54	1.94e-21	Corneal astigmatism;
CESC	cis	rs4919694	1.000	rs10509760	chr10:104634107	A/G	cg04362960	chr10:104952993	NT5C2	0.79	6.67	0.38	1.48e-10	Arsenic metabolism;
CESC	cis	rs6860806	0.661	rs28472559	chr5:131581611	G/A	cg12564285	chr5:131593104	PDLIM4	0.39	5.86	0.34	1.4e-8	Breast cancer;
CESC	cis	rs8044995	0.517	rs2863973	chr16:68409435	A/C	cg26727032	chr16:67993705	SLC12A4	-0.55	-6.43	-0.37	5.93e-10	Schizophrenia;
CESC	cis	rs4629180	0.586	rs1159902	chr2:102133641	G/A	cg04415270	chr2:102091202	RFX8	-0.32	-5.36	-0.31	1.77e-7	Chronic rhinosinusitis with nasal polyps;
CESC	cis	rs7267979	0.789	rs1983974	chr20:25530619	A/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.78	-14.62	-0.67	6.61e-36	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7824557	0.602	rs11781375	chr8:11204532	A/G	cg21775007	chr8:11205619	TDH	0.58	8.98	0.48	5.08e-17	Retinal vascular caliber;
CESC	cis	rs780096	0.526	rs75855890	chr2:27625005	G/T	cg21248554	chr2:27665150	KRTCAP3	-0.32	-6.37	-0.36	8.51e-10	Total body bone mineral density;
CESC	cis	rs9611565	0.512	rs9607841	chr22:42186838	G/A	cg17376030	chr22:41985996	PMM1	0.8	8.44	0.46	2.16e-15	Vitiligo;
CESC	cis	rs9611519	0.780	rs9611542	chr22:41677317	C/T	cg06481639	chr22:41940642	POLR3H	-0.48	-5.27	-0.31	2.77e-7	Neuroticism;
CESC	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg26338869	chr17:61819248	STRADA	0.69	9.11	0.49	2.15e-17	Prudent dietary pattern;
CESC	cis	rs2935183	1	rs2935183	chr17:45607572	T/G	cg08085267	chr17:45401833	C17orf57	0.45	5.98	0.34	7.11e-9	Multiple sclerosis or amyotrophic lateral sclerosis;
CESC	cis	rs910316	1.000	rs10873275	chr14:75531460	A/T	cg08847533	chr14:75593920	NEK9	0.99	18.25	0.75	9.34e-49	Height;
CESC	cis	rs727563	0.636	rs2413653	chr22:42106996	T/C	cg03806693	chr22:41940476	POLR3H	1.15	13.6	0.64	2.54e-32	Crohn's disease;Inflammatory bowel disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00176896	chr8:1185355	NA	-0.48	-6.26	-0.36	1.53e-9	Gut microbiome composition (summer);
CESC	cis	rs2228479	0.850	rs45524643	chr16:89815824	G/A	cg00800038	chr16:89945340	TCF25	-0.91	-7.54	-0.42	7.39e-13	Skin colour saturation;
CESC	cis	rs916888	0.610	rs199438	chr17:44791643	G/A	cg15921436	chr17:44337874	NA	0.43	5.27	0.31	2.78e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs1862618	0.853	rs252915	chr5:56121754	C/T	cg24531977	chr5:56204891	C5orf35	0.87	11.07	0.56	1.16e-23	Initial pursuit acceleration;
CESC	cis	rs2108622	0.727	rs62107763	chr19:15982598	T/C	cg13772218	chr19:15982569	NA	0.29	5.8	0.34	1.85e-8	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CESC	cis	rs9640161	0.673	rs11773351	chr7:150030963	T/C	cg27494647	chr7:150038898	RARRES2	0.43	5.09	0.3	6.77e-7	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs898097	0.805	rs60233158	chr17:80896612	A/G	cg10494973	chr17:80897199	TBCD	-0.47	-5.5	-0.32	9.06e-8	Breast cancer;
CESC	trans	rs7980799	0.682	rs1447873	chr12:33615236	A/G	cg26384229	chr12:38710491	ALG10B	-0.55	-7.81	-0.43	1.32e-13	Heart rate;Heart rate variability traits (RMSSD);
CESC	cis	rs11252926	0.550	rs11252134	chr10:442599	G/A	cg18196295	chr10:418757	DIP2C	0.52	7.0	0.4	2.07e-11	Psychosis in Alzheimer's disease;
CESC	cis	rs875971	1.000	rs697970	chr7:65560052	G/C	cg12463550	chr7:65579703	CRCP	-0.62	-7.69	-0.43	2.98e-13	Aortic root size;
CESC	cis	rs4975709	0.569	rs1684965	chr5:1865248	A/G	cg15595755	chr5:1867978	NA	0.55	9.21	0.49	1.03e-17	Cardiovascular disease risk factors;
CESC	cis	rs6032067	0.929	rs13043503	chr20:43805835	T/C	cg10761708	chr20:43804764	PI3	0.53	6.33	0.36	1.04e-9	Blood protein levels;
CESC	cis	rs9649213	0.574	rs62479853	chr7:97917158	G/T	cg21770322	chr7:97807741	LMTK2	0.58	8.64	0.47	5.26e-16	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs9443189	1.000	rs1280048	chr6:76529583	C/T	cg01950844	chr6:76311363	SENP6	0.64	6.66	0.38	1.61e-10	Prostate cancer;
CESC	cis	rs9467773	0.620	rs9467810	chr6:26608261	A/C	cg24633756	chr6:26577808	NA	0.38	5.76	0.33	2.28e-8	Intelligence (multi-trait analysis);
CESC	cis	rs10504229	0.911	rs77203035	chr8:58175458	C/A	cg22535103	chr8:58192502	C8orf71	-1.05	-13.27	-0.63	3.63e-31	Developmental language disorder (linguistic errors);
CESC	cis	rs1322639	0.614	rs7751131	chr6:169578710	G/A	cg04662567	chr6:169592167	NA	-0.49	-5.11	-0.3	6.06e-7	Pulse pressure;
CESC	cis	rs7560272	0.501	rs2272178	chr2:73977609	C/T	cg20560298	chr2:73613845	ALMS1	0.45	6.06	0.35	4.78e-9	Schizophrenia;
CESC	cis	rs9287719	0.967	rs4284804	chr2:10722124	C/T	cg02196655	chr2:10830764	NOL10	-0.36	-5.57	-0.32	6.1e-8	Prostate cancer;
CESC	cis	rs7336332	0.598	rs74183666	chr13:28007765	A/T	cg22138327	chr13:27999177	GTF3A	0.64	5.92	0.34	9.69e-9	Weight;
CESC	cis	rs3818285	0.655	rs623980	chr10:111646147	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.43	-6.69	-0.38	1.35e-10	Superior crus of antihelix expression;
CESC	cis	rs9649213	0.593	rs10953257	chr7:97960664	A/G	cg24562669	chr7:97807699	LMTK2	-0.48	-7.04	-0.4	1.67e-11	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs6866344	0.697	rs62392833	chr5:178135452	T/A	cg03877680	chr5:178157825	ZNF354A	0.78	9.0	0.48	4.56e-17	Neutrophil percentage of white cells;
CESC	cis	rs1878931	0.624	rs37810	chr16:3451881	C/T	cg02880119	chr16:3481970	NA	0.45	5.53	0.32	7.84e-8	Body mass index (adult);
CESC	cis	rs9815354	0.812	rs56183581	chr3:41848492	C/T	cg03022575	chr3:42003672	ULK4	0.7	6.04	0.35	5.26e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs2797160	1.000	rs1739349	chr6:126014984	G/C	cg05901451	chr6:126070800	HEY2	0.46	6.55	0.37	2.89e-10	Endometrial cancer;
CESC	cis	rs7264396	0.635	rs6060710	chr20:34536055	A/G	cg17201900	chr20:34330562	RBM39	0.5	5.25	0.31	3.16e-7	Total cholesterol levels;
CESC	cis	rs4604732	0.631	rs60311891	chr1:247623127	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.57	7.17	0.4	7.64e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs7927771	0.864	rs755555	chr11:47431966	C/T	cg05585544	chr11:47624801	NA	-0.49	-7.0	-0.4	2.05e-11	Subjective well-being;
CESC	cis	rs2637266	0.783	rs846647	chr10:78515508	C/G	cg18941641	chr10:78392320	NA	0.43	8.42	0.46	2.39e-15	Pulmonary function;
CESC	cis	rs10416265	0.527	rs7508599	chr19:33546512	A/T	cg27124370	chr19:33622961	WDR88	0.55	7.59	0.42	5.3e-13	Bone properties (heel);
CESC	cis	rs3747547	0.892	rs74755693	chr9:37951859	A/G	cg13774184	chr9:37916125	SHB	-0.64	-5.47	-0.32	1.05e-7	Metabolite levels (Dihydroxy docosatrienoic acid);
CESC	cis	rs17401966	0.931	rs912961	chr1:10356848	A/G	cg15208524	chr1:10270712	KIF1B	0.43	5.44	0.32	1.18e-7	Hepatocellular carcinoma;
CESC	cis	rs1008375	0.868	rs6816286	chr4:17698088	A/G	cg16339924	chr4:17578868	LAP3	0.59	7.3	0.41	3.41e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00409521	chr11:89956229	CHORDC1	0.56	6.34	0.36	9.99e-10	Gut microbiome composition (summer);
CESC	cis	rs7107174	1.000	rs11237471	chr11:78082604	C/T	cg02023728	chr11:77925099	USP35	0.38	5.21	0.31	3.73e-7	Testicular germ cell tumor;
CESC	cis	rs11122272	0.735	rs2808611	chr1:231548480	A/G	cg06096015	chr1:231504339	EGLN1	-0.42	-5.94	-0.34	8.93e-9	Hemoglobin concentration;
CESC	cis	rs67311347	1.000	rs13095055	chr3:40505666	G/T	cg01475735	chr3:40494733	NA	0.44	5.68	0.33	3.47e-8	Renal cell carcinoma;
CESC	cis	rs4974559	0.739	rs59810282	chr4:1320968	A/G	cg02980000	chr4:1222292	CTBP1	0.7	6.35	0.36	9.11e-10	Systolic blood pressure;
CESC	cis	rs8062405	1.000	rs4788099	chr16:28855727	A/G	cg08761264	chr16:28874980	SH2B1	-0.47	-5.85	-0.34	1.42e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs2228479	0.850	rs57267516	chr16:89903552	G/A	cg04013166	chr16:89971882	TCF25	0.66	5.52	0.32	8.21e-8	Skin colour saturation;
CESC	cis	rs4589502	0.528	rs8039656	chr15:67208848	G/A	cg12317470	chr15:67143691	NA	-0.46	-5.53	-0.32	7.86e-8	Lung cancer (smoking interaction);
CESC	cis	rs7769051	0.522	rs57176306	chr6:133142168	C/T	cg07930552	chr6:133119739	C6orf192	0.9	6.45	0.37	5.19e-10	Type 2 diabetes nephropathy;
CESC	cis	rs761746	0.960	rs4820979	chr22:31914399	A/G	cg25791279	chr22:32026902	PISD	-0.53	-6.1	-0.35	3.84e-9	Intelligence;
CESC	cis	rs36051895	0.623	rs7859286	chr9:5260940	G/T	cg02405213	chr9:5042618	JAK2	-0.52	-6.43	-0.37	5.85e-10	Pediatric autoimmune diseases;
CESC	cis	rs7829975	0.902	rs777707	chr8:8584344	A/G	cg17143192	chr8:8559678	CLDN23	0.43	5.37	0.31	1.75e-7	Mood instability;
CESC	cis	rs11122272	0.735	rs10489610	chr1:231517765	C/A	cg06096015	chr1:231504339	EGLN1	0.43	6.18	0.35	2.46e-9	Hemoglobin concentration;
CESC	cis	rs35110281	0.776	rs62226866	chr21:45024186	T/C	cg01579765	chr21:45077557	HSF2BP	-0.55	-9.18	-0.49	1.24e-17	Mean corpuscular volume;
CESC	cis	rs769267	0.864	rs7245983	chr19:19657632	A/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.52	6.51	0.37	3.82e-10	Tonsillectomy;
CESC	cis	rs1707322	0.691	rs12031182	chr1:46220999	C/T	cg03146154	chr1:46216737	IPP	0.82	11.54	0.58	3.18e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs35110281	0.714	rs2282526	chr21:45080552	A/T	cg01579765	chr21:45077557	HSF2BP	-0.57	-9.45	-0.5	1.85e-18	Mean corpuscular volume;
CESC	cis	rs4835473	0.864	rs5015761	chr4:144658944	A/C	cg25736465	chr4:144833511	NA	-0.33	-5.18	-0.3	4.3e-7	Immature fraction of reticulocytes;
CESC	cis	rs12325245	0.536	rs71389028	chr16:58663260	G/A	cg05725404	chr16:58534157	NDRG4	-0.63	-5.32	-0.31	2.21e-7	Schizophrenia;
CESC	cis	rs992157	0.798	rs7557709	chr2:219167529	G/A	cg00012203	chr2:219082015	ARPC2	0.77	10.3	0.53	3.82e-21	Colorectal cancer;
CESC	cis	rs7589342	0.839	rs7589790	chr2:106433909	C/G	cg16077055	chr2:106428750	NCK2	-0.5	-6.95	-0.39	2.86e-11	Addiction;
CESC	cis	rs9733	0.565	rs11804276	chr1:150685761	T/A	cg22823121	chr1:150693482	HORMAD1	0.48	7.11	0.4	1.11e-11	Tonsillectomy;
CESC	cis	rs7520050	0.966	rs6680380	chr1:46300189	T/G	cg24296786	chr1:45957014	TESK2	0.43	5.42	0.32	1.32e-7	Red blood cell count;Reticulocyte count;
CESC	cis	rs4481887	0.927	rs4244185	chr1:248486913	A/G	cg00666640	chr1:248458726	OR2T12	0.35	5.98	0.35	7.04e-9	Common traits (Other);
CESC	cis	rs12477438	0.765	rs10181422	chr2:99558970	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.65	-8.83	-0.48	1.43e-16	Chronic sinus infection;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04065065	chr9:35096250	PIGO	0.6	6.58	0.37	2.55e-10	Gut microbiome composition (summer);
CESC	cis	rs78456975	1.000	rs72776252	chr2:1525599	G/A	cg01028140	chr2:1542097	TPO	-0.62	-5.88	-0.34	1.2e-8	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs9649213	0.593	rs12672092	chr7:97986557	C/A	cg21770322	chr7:97807741	LMTK2	0.57	8.84	0.48	1.39e-16	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs72781680	0.611	rs72783605	chr2:24287864	A/G	cg20701182	chr2:24300061	SF3B14	0.93	10.61	0.55	3.77e-22	Lymphocyte counts;
CESC	cis	rs763014	0.931	rs62030903	chr16:638323	T/A	cg07256732	chr16:621771	PIGQ	-0.32	-5.26	-0.31	3.03e-7	Height;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg08876899	chr1:35545196	ZMYM1	0.45	6.05	0.35	4.79e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs4474465	0.833	rs10899540	chr11:78245549	T/A	cg27205649	chr11:78285834	NARS2	0.44	5.34	0.31	1.96e-7	Alzheimer's disease (survival time);
CESC	cis	rs7116495	1.000	rs7949480	chr11:71697588	T/C	cg10381502	chr11:71823885	C11orf51	-0.69	-5.75	-0.33	2.45e-8	Severe influenza A (H1N1) infection;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21056458	chr19:12817517	SNORD41;TNPO2	-0.62	-7.17	-0.4	7.7e-12	Gut microbiome composition (summer);
CESC	cis	rs2204008	0.660	rs2320745	chr12:38239101	T/C	cg26384229	chr12:38710491	ALG10B	0.66	9.15	0.49	1.52e-17	Bladder cancer;
CESC	cis	rs636291	0.517	rs2781233	chr1:10529194	T/C	cg20482658	chr1:10539492	PEX14	-0.29	-5.97	-0.34	7.76e-9	Prostate cancer;
CESC	cis	rs7819412	0.775	rs2001329	chr8:10986859	C/T	cg21775007	chr8:11205619	TDH	-0.46	-6.61	-0.38	2.12e-10	Triglycerides;
CESC	cis	rs3749237	0.595	rs4855839	chr3:49507847	G/A	cg07636037	chr3:49044803	WDR6	0.64	9.17	0.49	1.34e-17	Resting heart rate;
CESC	cis	rs7666738	0.830	rs6840766	chr4:99016260	C/G	cg03467027	chr4:99064603	C4orf37	0.44	5.63	0.33	4.57e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg18538332	chr22:24372958	LOC391322	-0.68	-9.67	-0.51	3.97e-19	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs10504229	0.679	rs7840100	chr8:58036662	T/G	cg22535103	chr8:58192502	C8orf71	-0.6	-6.79	-0.38	7.43e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs9287719	0.935	rs61424402	chr2:10758371	T/A	cg02196655	chr2:10830764	NOL10	-0.37	-5.57	-0.32	6.22e-8	Prostate cancer;
CESC	cis	rs453301	0.653	rs1562211	chr8:8902424	A/G	cg15556689	chr8:8085844	FLJ10661	-0.53	-7.04	-0.4	1.64e-11	Joint mobility (Beighton score);
CESC	cis	rs34172651	0.917	rs200529	chr16:24758502	T/C	cg06028605	chr16:24865363	SLC5A11	-0.35	-5.49	-0.32	9.48e-8	Intelligence (multi-trait analysis);
CESC	trans	rs13360092	1.000	rs10058621	chr5:50555169	T/C	cg03200537	chr16:87022121	NA	0.69	6.01	0.35	6.12e-9	Verbal declarative memory;
CESC	cis	rs6598955	0.670	rs3795688	chr1:26560481	C/A	cg04990556	chr1:26633338	UBXN11	-0.79	-11.53	-0.58	3.46e-25	Obesity-related traits;
CESC	cis	rs12478296	1.000	rs56292923	chr2:243039986	C/T	cg06360820	chr2:242988706	NA	-0.71	-8.08	-0.44	2.26e-14	Obesity-related traits;
CESC	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg18402987	chr7:1209562	NA	0.76	7.57	0.42	6.04e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs910316	1.000	rs4903279	chr14:75546583	C/T	cg11812906	chr14:75593930	NEK9	0.89	15.23	0.68	4.57e-38	Height;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg18876457	chr1:160071037	NA	-0.52	-7.24	-0.41	5.02e-12	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs801193	0.591	rs2707839	chr7:66193084	A/G	cg11764359	chr7:65958608	NA	0.89	13.89	0.65	2.56e-33	Aortic root size;
CESC	cis	rs6088580	0.634	rs6088512	chr20:33095891	G/A	cg06115741	chr20:33292138	TP53INP2	0.45	5.74	0.33	2.53e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs986417	1.000	rs1254303	chr14:60886301	A/G	cg00859478	chr14:60978094	SIX6	-0.47	-5.18	-0.3	4.36e-7	Gut microbiota (bacterial taxa);
CESC	cis	rs36051895	0.664	rs7857081	chr9:5096728	G/A	cg02405213	chr9:5042618	JAK2	-0.54	-6.77	-0.38	8.31e-11	Pediatric autoimmune diseases;
CESC	cis	rs12142240	0.621	rs13374968	chr1:46843908	T/G	cg10495392	chr1:46806563	NSUN4	0.55	6.11	0.35	3.47e-9	Menopause (age at onset);
CESC	cis	rs7552404	0.961	rs1767458	chr1:76219155	A/G	cg10523679	chr1:76189770	ACADM	0.75	10.09	0.53	1.8e-20	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs7618501	0.602	rs2240327	chr3:50113034	C/T	cg24308560	chr3:49941425	MST1R	-0.59	-8.68	-0.47	4.06e-16	Intelligence (multi-trait analysis);
CESC	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg24101359	chr6:42928495	GNMT	0.55	8.05	0.44	2.83e-14	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs7267979	0.789	rs4815429	chr20:25521611	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.78	-14.55	-0.67	1.24e-35	Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs66573146	0.831	rs56081162	chr4:6989718	C/T	cg07817883	chr1:32538562	TMEM39B	1.09	6.98	0.39	2.4e-11	Granulocyte percentage of myeloid white cells;
CESC	cis	rs7084402	0.967	rs12261597	chr10:60297662	T/C	cg07615347	chr10:60278583	BICC1	-0.57	-8.56	-0.47	9.58e-16	Refractive error;
CESC	cis	rs4629180	0.586	rs1509497	chr2:102138184	C/T	cg04415270	chr2:102091202	RFX8	-0.3	-5.25	-0.31	3.19e-7	Chronic rhinosinusitis with nasal polyps;
CESC	cis	rs6460942	1.000	rs6944134	chr7:12418036	T/C	cg10578991	chr7:12443926	VWDE	-0.49	-5.5	-0.32	8.87e-8	Coronary artery disease;
CESC	cis	rs7845219	0.525	rs6471501	chr8:95922491	A/G	cg23172400	chr8:95962367	TP53INP1	-0.4	-7.41	-0.41	1.7e-12	Type 2 diabetes;
CESC	cis	rs6938	0.618	rs2044157	chr15:75225808	G/C	cg14664628	chr15:75095509	CSK	-0.51	-6.6	-0.38	2.2e-10	Breast cancer;
CESC	cis	rs2243480	1.000	rs2462569	chr7:65474846	C/T	cg18252515	chr7:66147081	NA	1.1	10.76	0.55	1.23e-22	Diabetic kidney disease;
CESC	cis	rs4665809	0.590	rs3806515	chr2:26466975	C/T	cg26314531	chr2:26401878	FAM59B	0.85	9.04	0.49	3.44e-17	Gut microbiome composition (summer);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04688917	chr3:179040469	ZNF639	0.52	6.86	0.39	4.92e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs2860975	0.620	rs1891072	chr10:96804978	G/A	cg09036531	chr10:96991505	NA	-0.37	-5.29	-0.31	2.52e-7	Immune response to smallpox vaccine (IL-6);
CESC	cis	rs61931739	0.500	rs9669027	chr12:34583528	C/T	cg23762105	chr12:34175262	ALG10	0.4	5.17	0.3	4.62e-7	Morning vs. evening chronotype;
CESC	cis	rs7666738	0.791	rs6532725	chr4:99061479	T/C	cg05340658	chr4:99064831	C4orf37	0.83	12.91	0.62	6.52e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6539267	0.847	rs12831519	chr12:106682917	A/G	cg00173435	chr12:106696525	TCP11L2	0.66	6.51	0.37	3.69e-10	Tourette syndrome;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg15055922	chr19:53193944	ZNF83	0.48	6.52	0.37	3.61e-10	Asthma;
CESC	cis	rs1823874	0.581	rs12905599	chr15:100339938	C/T	cg16400843	chr15:100339927	C15orf51	0.32	5.06	0.3	7.87e-7	IgG glycosylation;
CESC	cis	rs6860806	0.661	rs2171247	chr5:131580234	G/T	cg12564285	chr5:131593104	PDLIM4	0.39	5.98	0.34	7.12e-9	Breast cancer;
CESC	cis	rs1729951	0.575	rs16844325	chr3:136678161	C/G	cg04103450	chr3:136751342	NA	0.39	5.17	0.3	4.59e-7	Neuroticism;
CESC	cis	rs7602441	0.521	rs12052706	chr2:14765777	A/G	cg06545361	chr2:14773388	FAM84A	0.66	6.47	0.37	4.66e-10	Visceral adipose tissue adjusted for BMI;
CESC	cis	rs644799	0.526	rs534973	chr11:95633624	A/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.5	6.67	0.38	1.45e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs929596	0.517	rs1875263	chr2:234625622	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.55	-7.09	-0.4	1.24e-11	Total bilirubin levels in HIV-1 infection;
CESC	cis	rs7621025	0.500	rs71630059	chr3:136581611	G/A	cg15507776	chr3:136538369	TMEM22	-0.76	-8.65	-0.47	4.94e-16	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
CESC	cis	rs2249625	0.967	rs2056756	chr6:72916638	G/A	cg18830697	chr6:72922368	RIMS1	-0.45	-6.44	-0.37	5.67e-10	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CESC	cis	rs1018836	0.923	rs4734269	chr8:91635474	G/C	cg16814680	chr8:91681699	NA	-0.74	-10.61	-0.55	3.89e-22	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs951366	0.649	rs7522056	chr1:205735891	A/G	cg24503407	chr1:205819492	PM20D1	0.45	6.14	0.35	3.01e-9	Menarche (age at onset);
CESC	cis	rs7772486	0.875	rs10457795	chr6:146415665	A/G	cg05347473	chr6:146136440	FBXO30	0.49	6.58	0.37	2.45e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4665809	0.590	rs10197494	chr2:26445550	A/G	cg27170947	chr2:26402098	FAM59B	-0.87	-9.89	-0.52	7.6e-20	Gut microbiome composition (summer);
CESC	cis	rs7772486	0.790	rs6570723	chr6:146151230	A/T	cg05347473	chr6:146136440	FBXO30	0.55	7.26	0.41	4.4e-12	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg27086442	chr16:15149995	NTAN1	0.5	6.47	0.37	4.61e-10	Thyroid stimulating hormone;
CESC	cis	rs6062302	0.548	rs4809310	chr20:62228745	G/A	cg09650180	chr20:62225654	GMEB2	-0.82	-9.28	-0.5	6.11e-18	Glioblastoma;
CESC	cis	rs7264396	0.561	rs2064725	chr20:34569142	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-7.14	-0.4	9e-12	Total cholesterol levels;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg16092991	chr4:15004611	CPEB2	-0.47	-6.75	-0.38	9.55e-11	Gambling;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg13196216	chr6:34231128	NA	0.54	7.33	0.41	2.83e-12	Fibrinogen levels;
CESC	cis	rs2273669	0.667	rs2003315	chr6:109367169	C/T	cg05315195	chr6:109294784	ARMC2	-0.67	-6.32	-0.36	1.13e-9	Prostate cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27274463	chr12:110338238	TCHP	0.59	6.92	0.39	3.41e-11	Gut microbiome composition (summer);
CESC	cis	rs1371867	0.846	rs1788189	chr8:101249762	G/T	cg06002616	chr8:101225028	SPAG1	0.33	5.3	0.31	2.43e-7	Atrioventricular conduction;
CESC	cis	rs736408	0.812	rs1076425	chr3:52825462	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	6.61	0.38	2.05e-10	Bipolar disorder;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg07035298	chr11:76168949	C11orf30	0.4	6.13	0.35	3.22e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs2073300	0.609	rs79250740	chr20:23417165	G/A	cg12062639	chr20:23401060	NAPB	1.04	8.1	0.45	1.97e-14	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs7666738	0.830	rs4292341	chr4:98959724	C/T	cg24818145	chr4:99064322	C4orf37	0.37	5.32	0.31	2.16e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7208859	0.524	rs11653098	chr17:29122501	C/T	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.79e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs2404602	0.716	rs17363713	chr15:76746128	G/C	cg26408565	chr15:76604113	ETFA	-0.44	-6.39	-0.37	7.23e-10	Blood metabolite levels;
CESC	cis	rs7811142	0.943	rs66958101	chr7:100074020	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.05	10.31	0.54	3.54e-21	Platelet count;
CESC	cis	rs898097	0.841	rs12453162	chr17:80859971	C/T	cg10494973	chr17:80897199	TBCD	0.52	5.87	0.34	1.3e-8	Breast cancer;
CESC	cis	rs2070488	0.804	rs13094715	chr3:38504430	G/A	cg24069376	chr3:38537580	EXOG	0.35	5.99	0.35	6.71e-9	Electrocardiographic conduction measures;
CESC	cis	rs9916302	0.904	rs801420	chr17:37466103	C/G	cg20243544	chr17:37824526	PNMT	-0.45	-5.48	-0.32	9.91e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs7772486	0.875	rs6909827	chr6:146365738	A/G	cg05347473	chr6:146136440	FBXO30	0.48	6.51	0.37	3.73e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7512552	0.724	rs7002	chr1:150445819	A/G	cg15654264	chr1:150340011	RPRD2	0.4	5.23	0.31	3.5e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs9640161	0.830	rs6722	chr7:150068933	T/C	cg27494647	chr7:150038898	RARRES2	0.35	5.28	0.31	2.76e-7	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs9549367	0.789	rs9549715	chr13:113908240	G/C	cg00898013	chr13:113819073	PROZ	-0.56	-7.74	-0.43	2.08e-13	Platelet distribution width;
CESC	cis	rs7799006	0.606	rs34262822	chr7:2304275	C/T	cg12745145	chr7:2261452	MAD1L1	-0.35	-5.45	-0.32	1.16e-7	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs477692	0.625	rs4751104	chr10:131405358	G/A	cg24747557	chr10:131355152	MGMT	0.44	6.12	0.35	3.28e-9	Response to temozolomide;
CESC	cis	rs9457247	0.663	rs9459845	chr6:167440501	C/G	cg23791538	chr6:167370224	RNASET2	-0.57	-7.71	-0.43	2.6e-13	Crohn's disease;
CESC	trans	rs61931739	0.929	rs7955240	chr12:34066388	G/A	cg26384229	chr12:38710491	ALG10B	-0.46	-6.6	-0.38	2.21e-10	Morning vs. evening chronotype;
CESC	cis	rs8028182	0.577	rs28693593	chr15:75849776	A/C	cg20655648	chr15:75932815	IMP3	0.49	6.04	0.35	5.32e-9	Sudden cardiac arrest;
CESC	cis	rs75920871	0.502	rs10790166	chr11:116779499	A/G	cg03020885	chr11:116643423	BUD13	0.47	5.55	0.32	7.08e-8	Subjective well-being;
CESC	cis	rs1375194	0.558	rs13418410	chr2:33800899	C/A	cg04131969	chr2:33951647	MYADML	-0.51	-6.36	-0.36	8.87e-10	Response to antidepressants in depression;
CESC	cis	rs2033711	0.902	rs4801589	chr19:58953398	C/G	cg00825309	chr19:58991885	ZNF446	-0.57	-8.3	-0.45	5.3e-15	Uric acid clearance;
CESC	cis	rs7647973	0.667	rs4241405	chr3:49642027	C/T	cg06212747	chr3:49208901	KLHDC8B	0.68	7.95	0.44	5.47e-14	Menarche (age at onset);
CESC	cis	rs9911578	0.967	rs8182277	chr17:57144367	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.4	5.09	0.3	6.83e-7	Intelligence (multi-trait analysis);
CESC	cis	rs9303401	1.000	rs9904677	chr17:56873025	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.74	9.58	0.51	7.58e-19	Cognitive test performance;
CESC	cis	rs4604732	0.589	rs78689516	chr1:247626274	C/T	cg12758973	chr1:247694275	LOC148824;OR2C3	0.51	6.36	0.36	8.65e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs3820928	0.874	rs3752895	chr2:227886773	A/G	cg11843606	chr2:227700838	RHBDD1	-0.48	-6.33	-0.36	1.04e-9	Pulmonary function;
CESC	cis	rs116095464	0.558	rs10060089	chr5:205565	G/A	cg22496380	chr5:211416	CCDC127	-0.95	-10.05	-0.53	2.34e-20	Breast cancer;
CESC	cis	rs9910055	0.762	rs4239142	chr17:42205876	A/G	cg08499158	chr17:42289980	UBTF	0.57	7.36	0.41	2.25e-12	Total body bone mineral density;
CESC	cis	rs950776	0.593	rs481134	chr15:78877563	C/T	cg06917634	chr15:78832804	PSMA4	0.61	8.33	0.46	4.49e-15	Sudden cardiac arrest;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26631144	chr8:30670260	PPP2CB	0.49	6.04	0.35	5.26e-9	Gut microbiome composition (summer);
CESC	trans	rs916888	0.647	rs199449	chr17:44808902	G/A	cg10053473	chr17:62856997	LRRC37A3	-0.65	-9.03	-0.49	3.52e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs9467711	0.606	rs71557334	chr6:26365913	G/T	cg14345882	chr6:26364793	BTN3A2	0.6	6.17	0.35	2.57e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg02725872	chr8:58115012	NA	-0.42	-5.72	-0.33	2.88e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs9322193	0.607	rs4869755	chr6:150207483	G/A	cg01145232	chr6:150245071	RAET1G	0.5	6.24	0.36	1.75e-9	Lung cancer;
CESC	trans	rs1728785	0.901	rs11865339	chr16:68565296	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.61	7.42	0.41	1.57e-12	Ulcerative colitis;
CESC	cis	rs9733	0.526	rs6587542	chr1:150907701	G/T	cg04414720	chr1:150670196	GOLPH3L	0.45	5.96	0.34	8.13e-9	Tonsillectomy;
CESC	cis	rs60871478	0.636	rs4721600	chr7:871728	C/T	cg13798912	chr7:905769	UNC84A	-0.6	-6.07	-0.35	4.4e-9	Cerebrospinal P-tau181p levels;
CESC	cis	rs8112211	1.000	rs12609247	chr19:38821697	C/T	cg14299480	chr19:38876666	GGN	-0.42	-5.63	-0.33	4.51e-8	Blood protein levels;
CESC	cis	rs12545109	0.917	rs10098993	chr8:57323116	T/C	cg09654669	chr8:57350985	NA	-0.59	-6.93	-0.39	3.28e-11	Obesity-related traits;
CESC	cis	rs7542091	0.666	rs7537070	chr1:210043565	A/G	cg23283495	chr1:209979779	IRF6	0.35	5.8	0.34	1.84e-8	Monobrow;
CESC	trans	rs55704346	0.534	rs28609470	chr4:25397054	G/A	cg01822600	chr1:245751692	KIF26B	0.42	6.1	0.35	3.65e-9	Tonsillectomy;
CESC	cis	rs7666738	0.791	rs10033211	chr4:98995624	T/A	cg18180107	chr4:99064573	C4orf37	0.4	5.23	0.31	3.41e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1023500	0.505	rs134901	chr22:42683520	C/T	cg05082376	chr22:42548792	NA	-0.35	-5.13	-0.3	5.53e-7	Schizophrenia;
CESC	cis	rs1801251	1.000	rs6724117	chr2:233593660	T/G	cg25237894	chr2:233734115	C2orf82	0.45	7.79	0.43	1.53e-13	Coronary artery disease;
CESC	cis	rs4974559	0.739	rs28412861	chr4:1320092	A/G	cg02980000	chr4:1222292	CTBP1	0.76	6.74	0.38	9.88e-11	Systolic blood pressure;
CESC	cis	rs116095464	0.558	rs28729548	chr5:229025	C/T	cg22857025	chr5:266934	NA	-1.28	-18.8	-0.76	1.06e-50	Breast cancer;
CESC	cis	rs1912483	0.505	rs11079772	chr17:45393739	A/C	cg08085267	chr17:45401833	C17orf57	0.6	7.31	0.41	3.13e-12	Coronary artery disease;
CESC	cis	rs2637266	0.678	rs846626	chr10:78540372	T/G	cg18941641	chr10:78392320	NA	0.4	7.74	0.43	2.04e-13	Pulmonary function;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19137606	chr10:38146164	ZNF248	-0.56	-6.66	-0.38	1.59e-10	Gut microbiome composition (summer);
CESC	trans	rs7656342	0.808	rs10003216	chr4:9766749	A/G	cg05780616	chr12:96252764	SNRPF	-0.53	-6.29	-0.36	1.33e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs116095464	1.000	rs55671190	chr5:287422	G/A	cg10591111	chr5:226296	SDHA	-0.7	-5.87	-0.34	1.29e-8	Breast cancer;
CESC	cis	rs7914558	1.000	rs2275271	chr10:104814162	T/C	cg08650961	chr10:104748594	CNNM2	0.31	5.19	0.3	4.18e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs17376456	0.569	rs6879620	chr5:93119893	G/A	cg25358565	chr5:93447407	FAM172A	-0.72	-7.72	-0.43	2.33e-13	Diabetic retinopathy;
CESC	cis	rs28647808	0.881	rs4549850	chr9:136265239	T/C	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.84	5.73	0.33	2.7e-8	Blood protein levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04843900	chr20:16710618	SNRPB2	0.64	7.04	0.4	1.67e-11	Gut microbiome composition (summer);
CESC	cis	rs4819052	0.851	rs28622522	chr21:46676599	G/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.47	5.88	0.34	1.23e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg07274194	chr6:43423442	DLK2	-0.38	-6.12	-0.35	3.36e-9	Gambling;
CESC	trans	rs4662834	0.765	rs12616669	chr2:129489014	A/G	cg12497543	chr10:97515377	ENTPD1	0.38	6.13	0.35	3.18e-9	Response to bleomycin (chromatid breaks);
CESC	cis	rs2806561	0.734	rs1952527	chr1:23400969	T/C	cg12483005	chr1:23474871	LUZP1	0.37	5.72	0.33	2.87e-8	Height;
CESC	cis	rs13385	0.769	rs59443048	chr5:139602802	C/A	cg26211634	chr5:139558579	C5orf32	0.47	5.08	0.3	6.98e-7	Atrial fibrillation;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27138088	chr11:842605	TSPAN4;POLR2L	0.68	7.57	0.42	6.12e-13	Gut microbiome composition (summer);
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg19494004	chr6:79788446	PHIP	-0.51	-6.99	-0.39	2.22e-11	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs9611565	0.802	rs9611571	chr22:41784867	G/A	cg03806693	chr22:41940476	POLR3H	-1.08	-13.61	-0.64	2.32e-32	Vitiligo;
CESC	trans	rs561341	0.709	rs11542477	chr17:30185892	A/G	cg27661571	chr11:113659931	NA	0.65	6.16	0.35	2.73e-9	Hip circumference adjusted for BMI;
CESC	cis	rs34779708	0.931	rs12773169	chr10:35366462	G/C	cg03585969	chr10:35415529	CREM	0.75	9.92	0.52	6.26e-20	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs7674212	0.541	rs4699051	chr4:104114394	T/C	cg16532752	chr4:104119610	CENPE	-0.44	-6.0	-0.35	6.29e-9	Type 2 diabetes;
CESC	cis	rs4908760	0.757	rs301807	chr1:8484823	A/G	cg00120948	chr1:8484417	RERE	-0.38	-6.02	-0.35	5.82e-9	Vitiligo;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg04571369	chr19:19749068	GMIP	0.46	6.35	0.36	9.44e-10	Fibrinogen levels;
CESC	cis	rs7191700	0.712	rs7187741	chr16:11433103	C/G	cg00044050	chr16:11439710	C16orf75	-0.41	-5.22	-0.31	3.67e-7	Multiple sclerosis;
CESC	cis	rs3806843	0.766	rs702397	chr5:140050265	A/G	cg26395211	chr5:140044315	WDR55	0.45	6.06	0.35	4.77e-9	Depressive symptoms (multi-trait analysis);
CESC	cis	rs7666738	0.791	rs62318907	chr4:99037120	C/T	cg03467027	chr4:99064603	C4orf37	0.47	5.99	0.35	6.7e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7208859	0.673	rs9912122	chr17:29140716	C/A	cg04154034	chr17:28927549	LRRC37B2	0.55	5.24	0.31	3.25e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs8060686	0.545	rs74629553	chr16:68176415	C/A	cg26727032	chr16:67993705	SLC12A4	-0.5	-5.45	-0.32	1.16e-7	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs9322193	0.923	rs9371207	chr6:150179223	A/G	cg09699651	chr6:150184138	LRP11	0.52	6.56	0.37	2.83e-10	Lung cancer;
CESC	cis	rs801193	1.000	rs62466793	chr7:66191517	G/A	cg18876405	chr7:65276391	NA	0.54	7.28	0.41	3.88e-12	Aortic root size;
CESC	cis	rs4780401	0.728	rs7188511	chr16:11773743	G/T	cg01061890	chr16:11836724	TXNDC11	-0.51	-6.82	-0.39	5.98e-11	Rheumatoid arthritis;
CESC	cis	rs7945705	0.747	rs1980429	chr11:9010474	C/A	cg09997546	chr11:8931473	C11orf17;ST5	-0.3	-5.07	-0.3	7.5e-7	Hemoglobin concentration;
CESC	cis	rs4332037	0.624	rs58169303	chr7:1883274	T/C	cg23422044	chr7:1970798	MAD1L1	-0.53	-5.71	-0.33	3.02e-8	Bipolar disorder;
CESC	cis	rs9596863	0.898	rs9316668	chr13:54400431	C/T	ch.13.53330881F	chr13:54432880	NA	0.66	5.28	0.31	2.7e-7	Epilepsy and lamotrigine-induced maculopapular eruptions;
CESC	cis	rs2836974	0.897	rs35123057	chr21:40711689	C/T	cg17971929	chr21:40555470	PSMG1	0.94	12.96	0.62	4.46e-30	Cognitive function;
CESC	cis	rs6460942	1.000	rs79964328	chr7:12319392	A/C	cg10578991	chr7:12443926	VWDE	-0.61	-6.41	-0.37	6.66e-10	Coronary artery disease;
CESC	trans	rs11039798	0.512	rs1988465	chr11:49011303	C/T	cg15704280	chr7:45808275	SEPT13	0.65	6.57	0.37	2.63e-10	Axial length;
CESC	cis	rs425277	0.917	rs78395918	chr1:2045876	G/A	cg24578937	chr1:2090814	PRKCZ	0.55	9.07	0.49	2.75e-17	Height;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg23348582	chr14:82000250	SEL1L	-0.47	-6.09	-0.35	4.05e-9	Ulcerative colitis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24425829	chr1:59250882	JUN	0.6	7.19	0.4	6.59e-12	Gut microbiome composition (summer);
CESC	cis	rs2576037	0.523	rs1539881	chr18:44477897	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.35	5.74	0.33	2.65e-8	Personality dimensions;
CESC	cis	rs710216	0.912	rs11537640	chr1:43424519	T/G	cg03128534	chr1:43423976	SLC2A1	0.54	6.25	0.36	1.62e-9	Red cell distribution width;
CESC	cis	rs2832077	0.527	rs2832116	chr21:30228368	C/A	cg08807101	chr21:30365312	RNF160	-0.66	-8.57	-0.47	8.73e-16	Cognitive test performance;
CESC	cis	rs2108622	1.000	rs2108622	chr19:15990431	C/T	cg13772218	chr19:15982569	NA	0.38	6.98	0.39	2.37e-11	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CESC	cis	rs1729951	0.575	rs361244	chr3:136697506	C/T	cg03617693	chr3:136751559	NA	0.39	5.42	0.32	1.33e-7	Neuroticism;
CESC	cis	rs477895	0.653	rs11601577	chr11:63928574	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.92	10.13	0.53	1.38e-20	Mean platelet volume;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg18538297	chr19:58892579	ZNF837	-0.39	-6.19	-0.36	2.29e-9	Gambling;
CESC	cis	rs9596863	0.750	rs1971924	chr13:54432432	T/G	ch.13.53330881F	chr13:54432880	NA	-0.63	-5.37	-0.31	1.74e-7	Epilepsy and lamotrigine-induced maculopapular eruptions;
CESC	cis	rs2274273	1.000	rs7142704	chr14:55630603	C/A	cg04306507	chr14:55594613	LGALS3	0.31	6.15	0.35	2.77e-9	Protein biomarker;
CESC	cis	rs9359856	0.564	rs34766278	chr6:90397132	G/C	cg13799429	chr6:90582589	CASP8AP2	-0.64	-6.19	-0.36	2.24e-9	Bipolar disorder;
CESC	cis	rs4713118	0.662	rs9468277	chr6:28028390	C/A	cg26335602	chr6:28129616	ZNF389	0.44	5.61	0.33	5.19e-8	Parkinson's disease;
CESC	trans	rs9987353	0.840	rs329994	chr8:9123233	A/G	cg05897255	chr7:149535402	ZNF862	-0.48	-6.47	-0.37	4.67e-10	Recombination measurement;
CESC	cis	rs1799949	0.859	rs11657004	chr17:41442751	A/G	cg07153921	chr17:41440717	NA	-0.38	-5.19	-0.3	4.11e-7	Menopause (age at onset);
CESC	cis	rs4665809	0.590	rs4665318	chr2:26424517	C/T	cg04944784	chr2:26401820	FAM59B	0.87	9.59	0.51	6.83e-19	Gut microbiome composition (summer);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg01032946	chr16:30991033	SETD1A	0.54	6.88	0.39	4.21e-11	Fibrinogen levels;
CESC	cis	rs2439831	1.000	rs2444032	chr15:43755346	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.87	10.12	0.53	1.44e-20	Lung cancer in ever smokers;
CESC	cis	rs62064224	0.658	rs62065460	chr17:30715007	A/G	cg12855166	chr17:30846586	MYO1D	0.4	5.17	0.3	4.62e-7	Schizophrenia;
CESC	cis	rs875971	0.862	rs1643375	chr7:65872677	T/C	cg18252515	chr7:66147081	NA	-0.43	-5.59	-0.32	5.73e-8	Aortic root size;
CESC	cis	rs9611565	0.559	rs5758397	chr22:42019251	C/T	cg06634786	chr22:41940651	POLR3H	0.61	6.15	0.35	2.88e-9	Vitiligo;
CESC	cis	rs873946	0.557	rs4880427	chr10:134591389	T/C	cg27286337	chr10:134555280	INPP5A	0.68	7.66	0.43	3.54e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs6066835	1.000	rs3817991	chr20:47296365	G/C	cg18078177	chr20:47281410	PREX1	0.72	5.1	0.3	6.38e-7	Multiple myeloma;
CESC	cis	rs10463316	0.817	rs13359941	chr5:150802118	C/T	cg03212797	chr5:150827313	SLC36A1	-0.48	-6.2	-0.36	2.1e-9	Metabolite levels (Pyroglutamine);
CESC	cis	rs10504229	0.683	rs67492041	chr8:58140077	G/A	cg22535103	chr8:58192502	C8orf71	-0.8	-9.09	-0.49	2.46e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs7089973	0.668	rs10885622	chr10:116643844	C/T	cg23260525	chr10:116636907	FAM160B1	0.35	6.05	0.35	4.97e-9	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs6964587	1.000	rs9691325	chr7:91731047	G/A	cg17063962	chr7:91808500	NA	0.56	7.73	0.43	2.3e-13	Breast cancer;
CESC	cis	rs703842	0.616	rs10877023	chr12:58224199	C/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.57	6.65	0.38	1.67e-10	Multiple sclerosis;
CESC	cis	rs7944584	0.879	rs11039182	chr11:47346723	T/C	cg20307385	chr11:47447363	PSMC3	0.7	8.18	0.45	1.21e-14	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CESC	cis	rs2477686	0.526	rs1998759	chr1:2397174	C/T	cg07700843	chr1:2391317	NA	-0.41	-6.94	-0.39	2.95e-11	Non-obstructive azoospermia;
CESC	cis	rs12681288	0.578	rs56702775	chr8:968860	G/A	cg15309053	chr8:964076	NA	0.55	9.18	0.49	1.24e-17	Schizophrenia;
CESC	cis	rs875971	0.862	rs778720	chr7:65846275	A/C	cg10691866	chr7:65817282	TPST1	0.32	5.38	0.31	1.66e-7	Aortic root size;
CESC	cis	rs9303401	0.659	rs66514313	chr17:56714057	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.03	13.13	0.63	1.12e-30	Cognitive test performance;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17859048	chr1:151170906	PIP5K1A	0.55	6.2	0.36	2.19e-9	Gut microbiome composition (summer);
CESC	cis	rs644799	0.526	rs530914	chr11:95632156	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.52	6.85	0.39	5.24e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs4979906	1.000	rs11002246	chr10:79446777	T/A	cg07817648	chr10:79422355	NA	-0.6	-6.39	-0.37	7.58e-10	Mortality in heart failure;
CESC	cis	rs2842992	0.830	rs1998365	chr6:160179535	A/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.69	8.81	0.48	1.69e-16	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs1562975	0.609	rs11932691	chr4:109431283	C/G	cg16022748	chr4:109541635	LOC285456;RPL34	0.43	5.5	0.32	9.04e-8	Height;
CESC	cis	rs28489187	0.706	rs72724606	chr1:85850246	T/C	cg16011679	chr1:85725395	C1orf52	0.47	5.62	0.33	4.9e-8	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	cis	rs3820068	0.581	rs78175477	chr1:15948091	C/G	cg13390004	chr1:15929781	NA	0.37	5.95	0.34	8.6e-9	Systolic blood pressure;
CESC	cis	rs7647973	1.000	rs11928090	chr3:49604904	G/A	cg02487422	chr3:49467188	NICN1	0.4	5.05	0.3	8.11e-7	Menarche (age at onset);
CESC	cis	rs896854	0.967	rs10808671	chr8:95967372	A/G	cg13393036	chr8:95962371	TP53INP1	-0.52	-11.41	-0.57	8.68e-25	Type 2 diabetes;
CESC	cis	rs12313068	0.709	rs11829777	chr12:110503770	T/C	cg12870014	chr12:110450643	ANKRD13A	0.83	9.29	0.5	5.79e-18	Intelligence (multi-trait analysis);
CESC	cis	rs4595586	0.545	rs3858553	chr12:39381291	A/C	cg13010199	chr12:38710504	ALG10B	0.44	5.51	0.32	8.37e-8	Morning vs. evening chronotype;
CESC	cis	rs6088580	0.634	rs6058052	chr20:33047084	A/G	cg06115741	chr20:33292138	TP53INP2	0.46	5.97	0.34	7.6e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs9467711	0.606	rs67509210	chr6:26354100	G/T	cg14345882	chr6:26364793	BTN3A2	0.6	6.29	0.36	1.33e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs2651899	0.902	rs1736522	chr1:3080940	C/G	cg22674798	chr1:3096360	PRDM16	0.36	6.98	0.39	2.36e-11	Migraine;
CESC	cis	rs738322	1.000	rs133009	chr22:38569653	G/C	cg17652424	chr22:38574118	PLA2G6	-0.34	-6.03	-0.35	5.53e-9	Cutaneous nevi;
CESC	cis	rs7123876	0.553	rs12099027	chr11:72433920	A/G	cg04827223	chr11:72435913	ARAP1	-0.65	-11.51	-0.58	4.09e-25	Body mass index;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg11993436	chr7:155437098	RBM33	-0.44	-7.03	-0.4	1.73e-11	Gambling;
CESC	cis	rs79349575	0.783	rs4794000	chr17:47022755	C/G	cg16584676	chr17:46985605	UBE2Z	0.54	6.67	0.38	1.46e-10	Type 2 diabetes;
CESC	trans	rs6073597	1.000	rs6031980	chr20:43714384	C/T	cg07128330	chr12:2921958	ITFG2	0.46	6.56	0.37	2.8e-10	Positive affect;
CESC	cis	rs7829975	0.511	rs1543238	chr8:8134809	A/G	cg15556689	chr8:8085844	FLJ10661	0.54	6.4	0.37	6.89e-10	Mood instability;
CESC	cis	rs61008539	0.893	rs4721502	chr7:862186	A/G	cg00475322	chr7:917719	C7orf20	0.46	6.8	0.39	6.86e-11	Perceived unattractiveness to mosquitoes;
CESC	cis	rs763014	0.838	rs4984670	chr16:641044	A/G	cg07343612	chr16:622815	PIGQ	-0.5	-6.9	-0.39	3.76e-11	Height;
CESC	cis	rs397969	0.569	rs62066351	chr17:19900994	A/G	cg12073167	chr17:19770448	ULK2	-0.46	-5.28	-0.31	2.63e-7	Platelet count;
CESC	cis	rs7618915	0.547	rs12487591	chr3:52642936	A/T	cg17372223	chr3:52568218	NT5DC2	0.43	6.11	0.35	3.61e-9	Bipolar disorder;
CESC	cis	rs875971	0.862	rs4718319	chr7:65652784	C/A	cg18876405	chr7:65276391	NA	-0.53	-7.38	-0.41	2.09e-12	Aortic root size;
CESC	cis	rs7546094	0.530	rs2999158	chr1:113239478	T/C	cg22162597	chr1:113214053	CAPZA1	-0.39	-5.04	-0.3	8.59e-7	Platelet distribution width;
CESC	cis	rs761746	0.846	rs2295251	chr22:32013265	C/T	cg25791279	chr22:32026902	PISD	-0.5	-5.79	-0.34	1.93e-8	Intelligence;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10963511	chr15:25460583	SNORD115-15;SNORD115-21;SNORD115-25	-0.46	-6.07	-0.35	4.32e-9	Gut microbiome composition (summer);
CESC	cis	rs9309473	0.607	rs2421488	chr2:73590625	C/T	cg20560298	chr2:73613845	ALMS1	-0.44	-5.63	-0.33	4.52e-8	Metabolite levels;
CESC	cis	rs7959452	1.000	rs2168029	chr12:69734641	A/C	cg20891283	chr12:69753455	YEATS4	0.57	7.64	0.42	4.03e-13	Blood protein levels;
CESC	cis	rs9300255	0.722	rs12322888	chr12:123825559	A/G	cg19016782	chr12:123741754	C12orf65	-0.44	-6.17	-0.35	2.61e-9	Neutrophil percentage of white cells;
CESC	cis	rs7264396	0.790	rs6121018	chr20:34249060	C/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.64	7.77	0.43	1.78e-13	Total cholesterol levels;
CESC	cis	rs6456156	0.742	rs1331299	chr6:167533467	A/G	cg07741184	chr6:167504864	NA	0.31	5.17	0.3	4.65e-7	Primary biliary cholangitis;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg11522767	chr6:157342961	ARID1B	0.5	6.51	0.37	3.74e-10	Gut microbiota (bacterial taxa);
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg12947103	chr5:68392786	SLC30A5	-0.4	-6.45	-0.37	5.27e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs8017423	0.967	rs7155315	chr14:90700787	G/A	cg14092571	chr14:90743983	NA	-0.58	-8.43	-0.46	2.31e-15	Mortality in heart failure;
CESC	cis	rs75477785	1.000	rs12069187	chr1:209985952	G/T	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.92	6.04	0.35	5.06e-9	Cleft lip with or without cleft palate;
CESC	cis	rs1983891	0.955	rs4714479	chr6:41518807	A/G	cg20194872	chr6:41519635	FOXP4	0.54	7.74	0.43	2.14e-13	Prostate cancer;
CESC	cis	rs6987853	0.931	rs2923399	chr8:42439509	G/A	cg09913449	chr8:42400586	C8orf40	0.41	6.41	0.37	6.54e-10	Mean corpuscular hemoglobin concentration;
CESC	cis	rs4720575	1.000	rs1859522	chr7:47096901	G/A	cg00036614	chr7:47093842	NA	-0.43	-6.74	-0.38	9.73e-11	Angiotensin-converting enzyme inhibitor intolerance;
CESC	cis	rs12701220	0.655	rs12702117	chr7:1148702	T/C	cg00990874	chr7:1149470	C7orf50	-0.46	-5.07	-0.3	7.54e-7	Bronchopulmonary dysplasia;
CESC	cis	rs72781680	0.846	rs72780108	chr2:23986780	G/A	cg20701182	chr2:24300061	SF3B14	0.63	5.65	0.33	4.21e-8	Lymphocyte counts;
CESC	cis	rs12188164	0.965	rs11745789	chr5:450777	T/C	cg15813090	chr5:442598	EXOC3;C5orf55	0.42	6.26	0.36	1.51e-9	Cystic fibrosis severity;
CESC	cis	rs258892	0.841	rs34665	chr5:72158396	T/C	cg21869765	chr5:72125136	TNPO1	0.44	5.6	0.33	5.41e-8	Small cell lung carcinoma;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg05703344	chr12:111051745	TCTN1	0.46	6.58	0.37	2.44e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs501120	1.000	rs559580	chr10:44752078	C/T	cg09554077	chr10:44749378	NA	-0.49	-6.1	-0.35	3.67e-9	Coronary artery disease;Coronary heart disease;
CESC	cis	rs7250872	0.619	rs2396359	chr19:1819125	T/C	cg10370574	chr19:1840461	REXO1	-0.44	-6.12	-0.35	3.42e-9	Bipolar disorder;
CESC	cis	rs11098499	0.955	rs1397608	chr4:120161744	A/G	cg09307838	chr4:120376055	NA	0.86	11.44	0.58	6.63e-25	Corneal astigmatism;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04402633	chr11:2907113	CDKN1C	0.59	6.94	0.39	3.02e-11	Gut microbiome composition (summer);
CESC	cis	rs12973672	0.904	rs12974791	chr19:35767218	A/G	cg12095397	chr19:35769544	USF2	0.54	7.33	0.41	2.81e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs9291683	0.588	rs2240724	chr4:10021290	G/C	cg02734326	chr4:10020555	SLC2A9	0.48	6.97	0.39	2.56e-11	Bone mineral density;
CESC	cis	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg05863683	chr7:1912471	MAD1L1	-0.47	-7.48	-0.42	1.12e-12	Bipolar disorder and schizophrenia;
CESC	cis	rs7666738	0.830	rs921522	chr4:98841608	C/T	cg03467027	chr4:99064603	C4orf37	0.42	5.3	0.31	2.41e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9583531	0.600	rs9521909	chr13:111362170	A/G	cg15841412	chr13:111365552	ING1	0.52	6.74	0.38	1.01e-10	Coronary artery disease;
CESC	trans	rs1814175	0.647	rs10769646	chr11:49992204	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.43	-6.26	-0.36	1.53e-9	Height;
CESC	cis	rs1790761	0.587	rs7934075	chr11:67295949	T/C	cg14500267	chr11:67383377	NA	-0.31	-5.15	-0.3	4.98e-7	Mean corpuscular volume;
CESC	cis	rs9457247	0.508	rs9459874	chr6:167504127	A/G	cg07741184	chr6:167504864	NA	-0.32	-5.69	-0.33	3.37e-8	Crohn's disease;
CESC	cis	rs7811142	1.000	rs7783550	chr7:99987805	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	-1.08	-11.79	-0.59	4.48e-26	Platelet count;
CESC	cis	rs11122272	0.735	rs2486730	chr1:231534987	T/G	cg06096015	chr1:231504339	EGLN1	0.43	6.15	0.35	2.9e-9	Hemoglobin concentration;
CESC	cis	rs7552404	0.727	rs2172508	chr1:76320215	A/G	cg22875332	chr1:76189707	ACADM	0.63	6.2	0.36	2.17e-9	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs651907	0.535	rs34648996	chr3:101511202	A/G	cg12386194	chr3:101231763	SENP7	0.42	5.24	0.31	3.3e-7	Colorectal cancer;
CESC	cis	rs8180040	0.726	rs6774733	chr3:46991241	G/A	cg27129171	chr3:47204927	SETD2	0.65	9.42	0.5	2.28e-18	Colorectal cancer;
CESC	cis	rs7809950	1.000	rs2520268	chr7:107191161	T/A	cg23024343	chr7:107201750	COG5	-0.46	-6.2	-0.36	2.11e-9	Coronary artery disease;
CESC	cis	rs11030122	0.702	rs10767702	chr11:3934132	T/C	cg18678763	chr11:4115507	RRM1	-0.48	-6.35	-0.36	9.37e-10	Mean platelet volume;Platelet distribution width;
CESC	cis	rs11792861	0.926	rs76689835	chr9:111833792	G/A	cg05043794	chr9:111880884	C9orf5	-0.4	-6.53	-0.37	3.36e-10	Menarche (age at onset);
CESC	cis	rs13191362	1.000	rs34138336	chr6:163144929	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.66	6.56	0.37	2.8e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs3815700	0.920	rs10426856	chr19:33096406	A/G	cg02997394	chr19:33096574	ANKRD27	0.71	7.16	0.4	7.91e-12	Eosinophilic esophagitis;
CESC	trans	rs648516	0.765	rs9532193	chr13:38835243	C/T	cg14728235	chr20:57415177	GNASAS;GNAS	-0.35	-6.21	-0.36	2.05e-9	Schizophrenia;
CESC	cis	rs6690583	0.562	rs6665436	chr1:85532894	T/C	cg22488158	chr1:85528044	WDR63	0.58	5.6	0.33	5.43e-8	Serum sulfate level;
CESC	cis	rs6546550	0.901	rs6716937	chr2:70127229	G/A	cg02498382	chr2:70120550	SNRNP27	-0.41	-7.26	-0.41	4.34e-12	Prevalent atrial fibrillation;
CESC	cis	rs7617773	0.779	rs9833309	chr3:48327450	C/T	cg11946769	chr3:48343235	NME6	0.8	10.89	0.56	4.71e-23	Coronary artery disease;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg14107975	chr11:96076498	MAML2	0.44	6.15	0.35	2.79e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs2204008	0.774	rs3910796	chr12:38230660	G/T	cg26384229	chr12:38710491	ALG10B	0.74	10.7	0.55	1.96e-22	Bladder cancer;
CESC	cis	rs2991971	0.810	rs2356413	chr1:45914048	A/T	cg15605315	chr1:45957053	TESK2	-0.39	-5.31	-0.31	2.27e-7	High light scatter reticulocyte count;
CESC	cis	rs3768617	0.811	rs12043805	chr1:183008150	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.65	8.89	0.48	9.94e-17	Fuchs's corneal dystrophy;
CESC	cis	rs769267	0.930	rs6511038	chr19:19607564	A/C	cg03709012	chr19:19516395	GATAD2A	1.01	15.71	0.69	9.73e-40	Tonsillectomy;
CESC	cis	rs6582630	0.555	rs10880421	chr12:38423015	C/T	cg13010199	chr12:38710504	ALG10B	0.52	6.63	0.38	1.88e-10	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs3008870	0.755	rs2755243	chr1:67482783	T/C	cg02640540	chr1:67518911	SLC35D1	0.45	5.43	0.32	1.25e-7	Lymphocyte percentage of white cells;
CESC	cis	rs12791968	1.000	rs11038237	chr11:45001880	C/T	cg11846598	chr11:44996168	LOC221122	-0.55	-7.37	-0.41	2.23e-12	Inhibitory control;
CESC	cis	rs1499614	1.000	rs2707840	chr7:66158015	C/T	cg18252515	chr7:66147081	NA	-1.43	-14.62	-0.67	6.65e-36	Gout;
CESC	cis	rs8072100	0.570	rs9905073	chr17:45468296	G/A	cg08085267	chr17:45401833	C17orf57	-0.52	-6.67	-0.38	1.49e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs1670533	1.000	rs6852558	chr4:1059944	C/T	cg04106633	chr4:1044584	NA	0.4	5.19	0.3	4.15e-7	Recombination rate (females);
CESC	cis	rs9611565	0.592	rs4822040	chr22:41963553	C/G	cg06481639	chr22:41940642	POLR3H	-0.58	-6.38	-0.36	7.93e-10	Vitiligo;
CESC	cis	rs4481887	1.000	rs4244180	chr1:248471033	A/G	cg00666640	chr1:248458726	OR2T12	0.4	6.57	0.37	2.7e-10	Common traits (Other);
CESC	cis	rs2439831	0.850	rs28590651	chr15:44113016	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.7	6.71	0.38	1.15e-10	Lung cancer in ever smokers;
CESC	cis	rs7208859	0.623	rs3752020	chr17:29111125	T/G	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.91e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs1050631	1.000	rs1539822	chr18:33695943	C/T	cg25426722	chr18:33708991	SLC39A6;ELP2	0.44	5.67	0.33	3.75e-8	Esophageal squamous cell cancer (length of survival);
CESC	cis	rs9910055	0.676	rs11079983	chr17:42198170	C/T	cg08499158	chr17:42289980	UBTF	-0.57	-7.58	-0.42	5.78e-13	Total body bone mineral density;
CESC	cis	rs9916302	0.904	rs650106	chr17:37451559	A/G	cg07936489	chr17:37558343	FBXL20	0.76	10.71	0.55	1.83e-22	Glomerular filtration rate (creatinine);
CESC	cis	rs9914988	0.943	rs4794839	chr17:27131393	G/A	cg20469991	chr17:27169893	C17orf63	-0.49	-5.29	-0.31	2.58e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CESC	trans	rs9987353	0.840	rs329994	chr8:9123233	A/G	cg06499344	chr4:36245396	ARAP2	0.45	6.13	0.35	3.2e-9	Recombination measurement;
CESC	cis	rs57709857	0.957	rs58279725	chr8:38212611	T/C	cg01506891	chr8:38243824	LETM2	0.48	5.06	0.3	8.02e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs7811142	1.000	rs67163493	chr7:100023838	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.78	6.87	0.39	4.46e-11	Platelet count;
CESC	trans	rs2018683	0.707	rs2391717	chr7:28971162	G/C	cg19402173	chr7:128379420	CALU	-0.54	-7.12	-0.4	1.01e-11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CESC	cis	rs367615	0.506	rs2963013	chr5:108775811	C/T	cg17395555	chr5:108820864	NA	-0.57	-9.84	-0.52	1.1e-19	Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs4253772	0.591	rs12167567	chr22:46659942	G/C	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.68	8.01	0.44	3.66e-14	LDL cholesterol;Cholesterol, total;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg00169633	chr3:134093551	AMOTL2	-0.5	-6.02	-0.35	5.75e-9	Ulcerative colitis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01938359	chr5:1335135	CLPTM1L	-0.57	-6.56	-0.37	2.76e-10	Gut microbiome composition (summer);
CESC	cis	rs6570726	0.764	rs9403733	chr6:145912311	A/C	cg23711669	chr6:146136114	FBXO30	0.97	14.47	0.66	2.25e-35	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs3540	0.512	rs8033595	chr15:91083353	G/A	cg22089800	chr15:90895588	ZNF774	-0.61	-8.27	-0.45	6.47e-15	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs9399135	0.935	rs4273704	chr6:135297520	G/T	cg22676075	chr6:135203613	NA	0.52	7.21	0.4	5.94e-12	Red blood cell count;
CESC	cis	rs3617	0.591	rs11918800	chr3:52868145	G/A	cg07507251	chr3:52567010	NT5DC2	-0.32	-5.43	-0.32	1.27e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
CESC	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg03188948	chr7:1209495	NA	0.71	7.06	0.4	1.5e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs9814567	1.000	rs12490835	chr3:134223730	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.44	-6.02	-0.35	5.65e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs7084402	0.555	rs7069916	chr10:60271824	A/G	cg07615347	chr10:60278583	BICC1	0.58	8.85	0.48	1.23e-16	Refractive error;
CESC	cis	rs4900538	0.819	rs72698595	chr14:102863099	G/A	cg18135206	chr14:102964638	TECPR2	-0.69	-8.65	-0.47	4.88e-16	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	cis	rs9303401	0.614	rs12947982	chr17:57140301	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.87	10.82	0.55	7.81e-23	Cognitive test performance;
CESC	cis	rs4654899	0.865	rs61779073	chr1:21398740	C/A	cg05370193	chr1:21551575	ECE1	0.43	6.6	0.38	2.2e-10	Superior frontal gyrus grey matter volume;
CESC	trans	rs7178375	1.000	rs12907055	chr15:31204294	C/G	cg04373760	chr16:53404718	NA	0.55	7.36	0.41	2.26e-12	Hypertriglyceridemia;
CESC	cis	rs7223966	1.000	rs8076717	chr17:61850301	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.44	5.13	0.3	5.71e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs11229555	0.645	rs36002376	chr11:58204809	C/G	cg15696309	chr11:58395628	NA	-0.42	-5.05	-0.3	8.13e-7	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs2070488	0.965	rs35553573	chr3:38441439	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.94	17.41	0.73	8.52e-46	Electrocardiographic conduction measures;
CESC	cis	rs16910800	0.731	rs56067480	chr11:23190184	C/T	cg20040320	chr11:23191996	NA	-0.67	-6.66	-0.38	1.53e-10	Cancer;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg21774377	chr6:34760070	UHRF1BP1	-0.43	-6.02	-0.35	5.74e-9	Gambling;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg14899547	chr2:113521923	CKAP2L	-0.42	-6.22	-0.36	1.91e-9	Gambling;
CESC	cis	rs11048434	0.736	rs933462	chr12:9103665	T/G	cg23795048	chr12:9217529	LOC144571	0.36	5.54	0.32	7.22e-8	Sjögren's syndrome;
CESC	cis	rs1799949	0.930	rs4584865	chr17:41424919	C/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.4	5.32	0.31	2.24e-7	Menopause (age at onset);
CESC	cis	rs7851660	0.839	rs10818213	chr9:100648631	T/C	cg13688889	chr9:100608707	NA	-0.63	-8.79	-0.47	1.99e-16	Strep throat;
CESC	cis	rs2273669	0.667	rs1424479	chr6:109355790	G/T	cg05315195	chr6:109294784	ARMC2	-0.67	-6.32	-0.36	1.13e-9	Prostate cancer;
CESC	cis	rs9831754	0.906	rs4680929	chr3:78387591	T/A	cg06138941	chr3:78371609	NA	-0.66	-7.84	-0.43	1.12e-13	Calcium levels;
CESC	cis	rs6121246	0.567	rs2811	chr20:30194248	A/G	cg13852791	chr20:30311386	BCL2L1	0.58	5.56	0.32	6.65e-8	Mean corpuscular hemoglobin;
CESC	cis	rs909674	0.541	rs5750812	chr22:39793079	G/A	cg01416388	chr22:39784598	NA	-0.58	-7.42	-0.41	1.58e-12	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs9815354	0.812	rs73069292	chr3:41973963	T/C	cg03022575	chr3:42003672	ULK4	0.67	5.96	0.34	7.91e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs9323205	0.953	rs7141012	chr14:51600948	C/G	cg23942311	chr14:51606299	NA	-0.46	-5.46	-0.32	1.07e-7	Cancer;
CESC	cis	rs7208859	0.623	rs55811708	chr17:29104731	G/T	cg13385521	chr17:29058706	SUZ12P	0.77	6.15	0.35	2.81e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs9912789	0.807	rs9896850	chr17:79191726	C/T	cg25342872	chr17:79175132	AZI1	-0.49	-6.42	-0.37	6.41e-10	Frontotemporal dementia;
CESC	cis	rs55728055	0.661	rs56411340	chr22:31984476	G/T	cg01338084	chr22:32026380	PISD	1.26	8.55	0.47	9.7e-16	Age-related hearing impairment;
CESC	cis	rs951366	1.000	rs951366	chr1:205685352	C/T	cg11965913	chr1:205819406	PM20D1	0.42	6.04	0.35	5.12e-9	Menarche (age at onset);
CESC	cis	rs2228479	0.850	rs11640209	chr16:89807828	C/A	cg04013166	chr16:89971882	TCF25	0.77	6.63	0.38	1.9e-10	Skin colour saturation;
CESC	cis	rs7267979	1.000	rs1046073	chr20:25281333	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	18.72	0.75	2.09e-50	Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg11817910	chr12:31944836	H3F3C	-0.46	-6.37	-0.36	8.44e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs7512552	0.839	rs834236	chr1:150362968	C/T	cg15654264	chr1:150340011	RPRD2	0.4	5.28	0.31	2.65e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs9831754	0.906	rs2102601	chr3:78410536	G/A	cg06138941	chr3:78371609	NA	-0.62	-7.66	-0.43	3.55e-13	Calcium levels;
CESC	cis	rs2463822	0.748	rs2513053	chr11:62109473	T/A	cg06239285	chr11:62104954	ASRGL1	0.87	8.78	0.47	2.03e-16	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs7618915	0.547	rs2164884	chr3:52629633	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.48	6.8	0.39	6.78e-11	Bipolar disorder;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg12870750	chr17:7791882	CHD3	-0.43	-6.51	-0.37	3.67e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs8044995	0.925	rs9928653	chr16:68252079	T/C	cg26727032	chr16:67993705	SLC12A4	-0.59	-8.47	-0.46	1.68e-15	Schizophrenia;
CESC	cis	rs2180341	1.000	rs3798853	chr6:127636823	C/T	cg24812749	chr6:127587940	RNF146	-1.04	-14.09	-0.65	4.99e-34	Breast cancer;
CESC	cis	rs881375	0.678	rs10760125	chr9:123662590	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.52	7.66	0.43	3.56e-13	Rheumatoid arthritis;
CESC	cis	rs1799949	0.965	rs8176140	chr17:41251646	T/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.46	6.4	0.37	6.98e-10	Menopause (age at onset);
CESC	cis	rs9322193	0.962	rs7818	chr6:150132092	A/G	cg05861140	chr6:150128134	PCMT1	-0.35	-5.18	-0.3	4.37e-7	Lung cancer;
CESC	cis	rs801193	0.773	rs801207	chr7:66020590	T/C	cg19163074	chr7:65112434	INTS4L2	0.43	5.51	0.32	8.54e-8	Aortic root size;
CESC	cis	rs2878628	0.596	rs57039206	chr3:52758570	T/A	cg05564831	chr3:52568323	NT5DC2	0.46	7.19	0.4	6.63e-12	Intelligence (multi-trait analysis);
CESC	cis	rs3820928	0.874	rs1917125	chr2:227798981	G/A	cg05526886	chr2:227700861	RHBDD1	-0.4	-5.1	-0.3	6.49e-7	Pulmonary function;
CESC	cis	rs13191362	1.000	rs68144677	chr6:163149024	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.05	10.4	0.54	1.77e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs2599510	0.840	rs466146	chr2:32539236	A/C	cg02381751	chr2:32503542	YIPF4	0.5	6.6	0.38	2.25e-10	Interleukin-18 levels;
CESC	trans	rs61931739	0.500	rs11053213	chr12:34466395	G/T	cg13010199	chr12:38710504	ALG10B	0.49	6.29	0.36	1.3e-9	Morning vs. evening chronotype;
CESC	cis	rs8133932	0.654	rs369245	chr21:47337821	G/A	cg14185626	chr21:47401492	COL6A1	-0.45	-5.09	-0.3	6.84e-7	Schizophrenia;
CESC	cis	rs1559088	0.948	rs3760893	chr19:33597930	C/A	cg17764715	chr19:33622953	WDR88	0.49	6.5	0.37	4.04e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs72781680	0.898	rs72796166	chr2:23939311	G/C	cg20701182	chr2:24300061	SF3B14	0.78	6.91	0.39	3.5e-11	Lymphocyte counts;
CESC	cis	rs1949733	0.701	rs940136	chr4:8448992	G/A	cg11789530	chr4:8429930	ACOX3	0.76	11.1	0.56	9.27e-24	Response to antineoplastic agents;
CESC	cis	rs3096299	0.967	rs28689480	chr16:89460093	T/C	cg02187348	chr16:89574699	SPG7	0.57	7.44	0.42	1.41e-12	Multiple myeloma (IgH translocation);
CESC	cis	rs933688	1.000	rs10045280	chr5:90717675	T/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.11	15.83	0.7	3.48e-40	Smoking behavior;
CESC	cis	rs801193	1.000	rs2420824	chr7:66131116	G/A	cg18876405	chr7:65276391	NA	-0.57	-7.4	-0.41	1.78e-12	Aortic root size;
CESC	trans	rs9646096	0.681	rs1853325	chr13:38001186	A/G	cg01311313	chr8:35252359	UNC5D	0.51	6.04	0.35	5.22e-9	Age-related macular degeneration;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg12402495	chr1:154192844	C1orf43;UBAP2L	-0.41	-6.04	-0.35	5.08e-9	Gambling;
CESC	cis	rs11792861	0.890	rs3087979	chr9:111781779	T/C	cg13535736	chr9:111863775	C9orf5	-0.51	-6.69	-0.38	1.35e-10	Menarche (age at onset);
CESC	cis	rs6496667	0.821	rs13329289	chr15:90897454	C/T	cg22089800	chr15:90895588	ZNF774	0.57	5.76	0.33	2.27e-8	Rheumatoid arthritis;
CESC	cis	rs6728642	0.803	rs11891458	chr2:97632450	G/T	cg26665480	chr2:98280029	ACTR1B	-0.72	-7.76	-0.43	1.9e-13	Bipolar disorder lithium response (continuous) or schizophrenia;
CESC	cis	rs6570726	0.846	rs6570700	chr6:145931552	A/G	cg05347473	chr6:146136440	FBXO30	0.5	6.57	0.37	2.6e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs896854	0.548	rs574183	chr8:95973816	A/G	cg23172400	chr8:95962367	TP53INP1	0.38	6.73	0.38	1.06e-10	Type 2 diabetes;
CESC	trans	rs61931739	0.500	rs7977194	chr12:34408459	G/A	cg26384229	chr12:38710491	ALG10B	0.71	10.54	0.54	6.55e-22	Morning vs. evening chronotype;
CESC	trans	rs916888	0.773	rs169201	chr17:44790203	A/G	cg01341218	chr17:43662625	NA	0.92	10.51	0.54	8.08e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs1062177	0.774	rs2964574	chr5:151155711	G/A	cg12924095	chr5:151150029	G3BP1	0.46	6.04	0.35	5.19e-9	Preschool internalizing problems;
CESC	cis	rs10791097	0.547	rs10791101	chr11:130739133	C/T	cg12179176	chr11:130786555	SNX19	0.69	10.31	0.53	3.6e-21	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg11494091	chr17:61959527	GH2	0.76	13.11	0.63	1.31e-30	Prudent dietary pattern;
CESC	cis	rs2948294	0.588	rs12544596	chr8:8116346	A/T	cg15556689	chr8:8085844	FLJ10661	0.52	6.12	0.35	3.28e-9	Red cell distribution width;
CESC	cis	rs7959452	0.640	rs10878957	chr12:69699638	G/C	cg20891283	chr12:69753455	YEATS4	0.77	11.22	0.57	3.75e-24	Blood protein levels;
CESC	cis	rs1799949	0.965	rs4793204	chr17:41279298	A/G	cg23758822	chr17:41437982	NA	1.02	15.6	0.69	2.35e-39	Menopause (age at onset);
CESC	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg18538332	chr22:24372958	LOC391322	-0.77	-11.07	-0.56	1.2e-23	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs11190604	1.000	rs57025426	chr10:102205868	A/G	cg07080220	chr10:102295463	HIF1AN	0.55	5.51	0.32	8.5e-8	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs9790314	0.846	rs4470535	chr3:160974468	G/A	cg03342759	chr3:160939853	NMD3	-0.46	-6.33	-0.36	1.06e-9	Morning vs. evening chronotype;
CESC	cis	rs6499255	1.000	rs60231938	chr16:69830415	G/A	cg15192750	chr16:69999425	NA	0.43	5.35	0.31	1.91e-7	IgE levels;
CESC	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg18402987	chr7:1209562	NA	0.75	7.49	0.42	1.04e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs1552244	1.000	rs1552244	chr3:10135577	A/G	cg00166722	chr3:10149974	C3orf24	0.45	5.91	0.34	1.07e-8	Alzheimer's disease;
CESC	cis	rs116095464	0.558	rs7356561	chr5:284381	G/C	cg22857025	chr5:266934	NA	-1.29	-18.38	-0.75	3.21e-49	Breast cancer;
CESC	cis	rs875971	0.660	rs62465434	chr7:66005152	A/C	cg18876405	chr7:65276391	NA	0.57	7.64	0.42	4.04e-13	Aortic root size;
CESC	cis	rs6493487	0.512	rs28642856	chr15:51245680	T/C	cg02338191	chr15:51200825	AP4E1	0.63	5.86	0.34	1.39e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs4132509	0.744	rs320305	chr1:243859909	G/T	cg21452805	chr1:244014465	NA	0.51	5.95	0.34	8.47e-9	RR interval (heart rate);
CESC	cis	rs2204008	0.527	rs1315367	chr12:38177487	G/T	cg26384229	chr12:38710491	ALG10B	-0.41	-5.63	-0.33	4.55e-8	Bladder cancer;
CESC	cis	rs7086627	0.515	rs11202959	chr10:82209672	A/G	cg00277334	chr10:82204260	NA	-0.91	-15.92	-0.7	1.67e-40	Post bronchodilator FEV1;
CESC	cis	rs13385	0.813	rs57294361	chr5:139665761	C/T	cg26211634	chr5:139558579	C5orf32	0.48	5.08	0.3	7.13e-7	Atrial fibrillation;
CESC	cis	rs6951245	0.872	rs11768895	chr7:1063691	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.49	-5.71	-0.33	3.05e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs6500395	1.000	rs7185899	chr16:48714101	A/G	cg04672837	chr16:48644449	N4BP1	-0.51	-6.53	-0.37	3.33e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs617791	0.530	rs10791835	chr11:65750924	C/A	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.43	-5.07	-0.3	7.34e-7	Breast cancer;
CESC	cis	rs854765	0.929	rs2955360	chr17:17974887	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.42	-5.66	-0.33	3.87e-8	Total body bone mineral density;
CESC	cis	rs4481887	0.597	rs11488132	chr1:248542353	A/G	cg00666640	chr1:248458726	OR2T12	0.38	5.48	0.32	1e-7	Common traits (Other);
CESC	cis	rs1799949	1.000	rs4792981	chr17:41308274	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.45	6.24	0.36	1.77e-9	Menopause (age at onset);
CESC	cis	rs274567	0.602	rs272853	chr5:131688561	A/G	cg07395648	chr5:131743802	NA	-0.39	-5.13	-0.3	5.7e-7	Blood metabolite levels;
CESC	cis	rs2576037	0.526	rs4890699	chr18:44541029	T/C	cg19077165	chr18:44547161	KATNAL2	-0.54	-7.98	-0.44	4.51e-14	Personality dimensions;
CESC	cis	rs898097	0.812	rs56405605	chr17:80843663	T/C	cg10494973	chr17:80897199	TBCD	0.5	5.72	0.33	2.94e-8	Breast cancer;
CESC	cis	rs6991838	0.584	rs6994213	chr8:66513732	A/G	cg13398993	chr8:66546079	ARMC1	-0.47	-5.71	-0.33	2.95e-8	Intelligence (multi-trait analysis);
CESC	cis	rs35110281	0.666	rs9977076	chr21:45085829	G/A	cg04455712	chr21:45112962	RRP1B	0.49	7.53	0.42	8.22e-13	Mean corpuscular volume;
CESC	cis	rs854765	0.583	rs7214002	chr17:17852104	G/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.65	9.42	0.5	2.29e-18	Total body bone mineral density;
CESC	cis	rs8067545	0.611	rs6587219	chr17:20034531	T/G	cg13482628	chr17:19912719	NA	0.39	5.12	0.3	5.84e-7	Schizophrenia;
CESC	cis	rs9916302	0.706	rs1054488	chr17:37687968	A/G	cg07936489	chr17:37558343	FBXL20	-0.98	-11.47	-0.58	5.54e-25	Glomerular filtration rate (creatinine);
CESC	cis	rs959260	1.000	rs930299	chr17:73404668	A/C	cg12999837	chr17:73267436	MIF4GD	-0.49	-5.53	-0.32	7.69e-8	Systemic lupus erythematosus;
CESC	cis	rs3857536	0.776	rs6941904	chr6:66931042	A/G	cg07460842	chr6:66804631	NA	-0.42	-5.36	-0.31	1.8e-7	Blood trace element (Cu levels);
CESC	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg07677032	chr17:61819896	STRADA	0.45	6.05	0.35	4.97e-9	Prudent dietary pattern;
CESC	cis	rs2191566	0.691	rs62115513	chr19:44587192	T/C	cg20607764	chr19:44506953	ZNF230	-0.4	-5.18	-0.3	4.33e-7	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs16921914	0.565	rs286650	chr11:31230207	T/C	cg14844989	chr11:31128820	NA	-0.42	-5.94	-0.34	8.79e-9	Bone mineral density (spine);
CESC	cis	rs7680126	0.596	rs17198547	chr4:10141419	A/G	cg00071950	chr4:10020882	SLC2A9	0.48	5.97	0.34	7.51e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	cis	rs35952432	1	rs35952432	chr6:28074901	C/T	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.84	5.42	0.32	1.35e-7	Lung cancer;
CESC	cis	rs13191362	0.935	rs34540135	chr6:162934351	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.73	6.4	0.37	6.88e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs4665809	1.000	rs6729757	chr2:26285102	A/G	cg26314531	chr2:26401878	FAM59B	-0.59	-6.67	-0.38	1.5e-10	Gut microbiome composition (summer);
CESC	cis	rs7845219	0.525	rs6471501	chr8:95922491	A/G	cg09323728	chr8:95962352	TP53INP1	-0.35	-6.75	-0.38	9.36e-11	Type 2 diabetes;
CESC	cis	rs3020736	0.500	rs2413672	chr22:42513261	C/T	cg15557168	chr22:42548783	NA	0.45	6.51	0.37	3.78e-10	Autism spectrum disorder or schizophrenia;
CESC	cis	rs920590	0.510	rs4922101	chr8:19648895	A/G	cg01411142	chr8:19674711	INTS10	0.59	5.93	0.34	9.53e-9	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs7618915	0.547	rs2268026	chr3:52778347	T/C	cg17372223	chr3:52568218	NT5DC2	0.45	6.61	0.38	2.14e-10	Bipolar disorder;
CESC	trans	rs7726839	0.561	rs3915384	chr5:573395	G/T	cg25482853	chr8:67687455	SGK3	0.85	8.71	0.47	3.29e-16	Obesity-related traits;
CESC	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg26304593	chr6:42947056	PEX6	-0.45	-5.8	-0.34	1.9e-8	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs853679	0.517	rs9380056	chr6:28104476	C/T	cg08968635	chr6:28129556	ZNF389	0.42	5.72	0.33	2.82e-8	Depression;
CESC	cis	rs8020095	0.528	rs8007696	chr14:67822459	T/C	cg19548862	chr14:67692701	FAM71D	-0.45	-5.34	-0.31	2.04e-7	Depression (quantitative trait);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg27051171	chr2:7005923	CMPK2	-0.49	-6.69	-0.38	1.36e-10	Fibrinogen levels;
CESC	cis	rs2455799	0.613	rs7617039	chr3:15800740	A/G	cg16303742	chr3:15540471	COLQ	0.35	5.24	0.31	3.21e-7	Mean platelet volume;
CESC	cis	rs830124	0.602	rs1184893	chr12:122403811	G/A	cg22168489	chr12:122356033	WDR66	-0.39	-5.07	-0.3	7.4e-7	Urinary metabolites;
CESC	cis	rs3806843	0.735	rs702394	chr5:140086786	A/G	cg16179182	chr5:140090404	VTRNA1-1	0.42	5.51	0.32	8.71e-8	Depressive symptoms (multi-trait analysis);
CESC	trans	rs877282	0.891	rs10904557	chr10:797490	C/T	cg22713356	chr15:30763199	NA	-1.29	-13.34	-0.63	2.03e-31	Uric acid levels;
CESC	cis	rs4727027	0.933	rs13225884	chr7:148857795	A/G	cg23583168	chr7:148888333	NA	-0.79	-12.2	-0.6	1.82e-27	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01362762	chr13:114805400	RASA3	-0.52	-6.24	-0.36	1.75e-9	Gut microbiome composition (summer);
CESC	cis	rs2072499	0.966	rs2244144	chr1:156184598	G/A	cg25208724	chr1:156163844	SLC25A44	0.95	15.35	0.69	1.82e-38	Testicular germ cell tumor;
CESC	cis	rs151234	0.741	rs151229	chr16:28584937	G/A	cg01378222	chr16:28622494	SULT1A1	-0.57	-7.2	-0.4	6.37e-12	Platelet distribution width;
CESC	cis	rs7312774	0.748	rs7966019	chr12:107297502	G/T	cg16260113	chr12:107380972	MTERFD3	0.62	5.73	0.33	2.73e-8	Severe influenza A (H1N1) infection;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22236469	chr5:149111272	PPARGC1B	-0.59	-6.44	-0.37	5.65e-10	Gut microbiome composition (summer);
CESC	cis	rs10463316	0.894	rs13361316	chr5:150765593	T/C	cg03212797	chr5:150827313	SLC36A1	-0.46	-5.96	-0.34	8.11e-9	Metabolite levels (Pyroglutamine);
CESC	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg10862848	chr6:42927986	GNMT	-0.26	-6.54	-0.37	3.18e-10	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs6060717	0.553	rs2590958	chr20:34616590	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.49	6.22	0.36	1.96e-9	Hip circumference adjusted for BMI;
CESC	cis	rs7949030	0.626	rs11231141	chr11:62326265	T/C	cg22862634	chr11:62369728	EML3;MTA2	0.6	8.51	0.46	1.33e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	trans	rs35110281	0.837	rs2838336	chr21:45071741	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.5	-6.6	-0.38	2.23e-10	Mean corpuscular volume;
CESC	cis	rs9660992	0.573	rs1172161	chr1:205206495	C/T	cg00857998	chr1:205179979	DSTYK	0.56	6.88	0.39	4.29e-11	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs6714710	0.580	rs11680018	chr2:98479581	C/A	cg26665480	chr2:98280029	ACTR1B	0.6	8.2	0.45	1.01e-14	Posterior cortical atrophy and Alzheimer's disease;
CESC	cis	rs950169	0.881	rs4081123	chr15:84956235	A/G	cg17507749	chr15:85114479	UBE2QP1	0.59	6.54	0.37	3.11e-10	Schizophrenia;
CESC	cis	rs4323050	0.514	rs28647406	chr4:144905590	A/T	cg25736465	chr4:144833511	NA	0.41	6.25	0.36	1.65e-9	High light scatter reticulocyte percentage of red cells;
CESC	cis	rs950776	0.518	rs12907169	chr15:78825498	G/C	cg24631222	chr15:78858424	CHRNA5	-0.42	-5.33	-0.31	2.09e-7	Sudden cardiac arrest;
CESC	cis	rs6061231	0.624	rs8668	chr20:60964064	C/T	cg22601191	chr20:60968625	CABLES2	-0.41	-5.76	-0.33	2.28e-8	Colorectal cancer;
CESC	cis	rs3096299	0.933	rs889576	chr16:89429653	A/G	cg00750074	chr16:89608354	SPG7	0.4	5.73	0.33	2.72e-8	Multiple myeloma (IgH translocation);
CESC	cis	rs13191362	0.688	rs73035006	chr6:162997083	G/T	cg06582575	chr6:163149167	PACRG;PARK2	0.83	8.39	0.46	3.02e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs7219021	0.886	rs8068884	chr17:46869898	G/C	cg16584676	chr17:46985605	UBE2Z	-0.55	-6.3	-0.36	1.25e-9	Schizophrenia or bipolar disorder;
CESC	cis	rs8072100	0.570	rs9905073	chr17:45468296	G/A	cg25173405	chr17:45401733	C17orf57	-0.44	-5.65	-0.33	4.14e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs5995756	0.761	rs6001639	chr22:40003309	C/A	cg03390717	chr22:39966585	CACNA1I	-0.29	-5.07	-0.3	7.57e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs896854	0.654	rs4735339	chr8:95974373	C/T	cg23172400	chr8:95962367	TP53INP1	-0.45	-9.25	-0.49	8.02e-18	Type 2 diabetes;
CESC	cis	rs4664293	1.000	rs4665083	chr2:160430127	C/T	cg08347373	chr2:160653686	CD302	0.34	5.56	0.32	6.65e-8	Monocyte percentage of white cells;
CESC	cis	rs6754311	0.773	rs632632	chr2:136638216	A/G	cg07169764	chr2:136633963	MCM6	0.67	8.17	0.45	1.23e-14	Mosquito bite size;
CESC	trans	rs7937682	1.000	rs7121011	chr11:111568681	C/T	cg18187862	chr3:45730750	SACM1L	-0.53	-6.07	-0.35	4.52e-9	Primary sclerosing cholangitis;
CESC	cis	rs10479542	0.544	rs10056863	chr5:179005100	G/A	cg00080972	chr5:178986291	RUFY1	0.44	6.84	0.39	5.46e-11	Lung cancer;
CESC	cis	rs6088590	1.000	rs3787222	chr20:33333040	T/A	cg08999081	chr20:33150536	PIGU	0.6	9.27	0.49	6.6e-18	Coronary artery disease;
CESC	cis	rs863345	0.625	rs950487	chr1:158460130	A/T	cg12129480	chr1:158549410	OR10X1	-0.36	-7.14	-0.4	8.93e-12	Pneumococcal bacteremia;
CESC	cis	rs9926296	0.609	rs4785714	chr16:89798404	G/T	cg04287289	chr16:89883240	FANCA	-0.65	-8.79	-0.48	1.88e-16	Vitiligo;
CESC	cis	rs4298948	0.590	rs11043250	chr12:122372815	A/C	cg13699009	chr12:122356056	WDR66	0.46	5.43	0.32	1.31e-7	Obesity-related traits;
CESC	cis	rs1448094	0.512	rs4540904	chr12:86235472	A/G	cg19622623	chr12:86230825	RASSF9	-0.47	-5.95	-0.34	8.28e-9	Major depressive disorder;
CESC	cis	rs9303401	0.614	rs3887355	chr17:56538639	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.98	11.87	0.59	2.46e-26	Cognitive test performance;
CESC	cis	rs1865760	0.566	rs1800702	chr6:26086463	C/G	cg17691542	chr6:26056736	HIST1H1C	0.42	5.57	0.32	6.13e-8	Height;
CESC	cis	rs1322639	0.657	rs9355135	chr6:169573006	C/T	cg03254818	chr6:169586852	NA	0.55	5.91	0.34	1.02e-8	Pulse pressure;
CESC	cis	rs7666738	0.753	rs17483788	chr4:98985623	G/A	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.67e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs9467711	0.606	rs9393710	chr6:26367833	A/G	cg06606381	chr12:133084897	FBRSL1	-0.76	-6.86	-0.39	4.71e-11	Autism spectrum disorder or schizophrenia;
CESC	cis	rs4481887	0.962	rs5009868	chr1:248474495	A/G	cg00666640	chr1:248458726	OR2T12	0.41	6.71	0.38	1.15e-10	Common traits (Other);
CESC	cis	rs8031584	0.706	rs798084	chr15:31126935	C/T	cg14829155	chr15:31115871	NA	-0.72	-9.92	-0.52	6.44e-20	Huntington's disease progression;
CESC	cis	rs6933660	0.646	rs3736176	chr6:151773320	T/A	cg14262678	chr6:151773367	RMND1;C6orf211	0.67	9.92	0.52	6.22e-20	Menarche (age at onset);
CESC	cis	rs4819052	0.851	rs2838836	chr21:46665875	G/T	cg11663144	chr21:46675770	NA	-0.62	-9.68	-0.51	3.65e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs7542091	0.648	rs688464	chr1:209992539	C/T	cg09509183	chr1:209979624	IRF6	-0.4	-5.42	-0.32	1.31e-7	Monobrow;
CESC	trans	rs11159647	0.636	rs34944551	chr14:84735341	T/C	cg19838074	chr2:242149865	ANO7	0.41	6.04	0.35	5.21e-9	Alzheimer's disease;
CESC	cis	rs9929218	1.000	rs28450087	chr16:68803726	T/G	cg02972257	chr16:68554789	NA	0.43	5.18	0.3	4.44e-7	Colorectal cancer;
CESC	cis	rs6032067	0.636	rs6032095	chr20:43913255	A/T	cg10761708	chr20:43804764	PI3	-0.37	-5.26	-0.31	3.02e-7	Blood protein levels;
CESC	cis	rs4953318	0.704	rs10495927	chr2:46352499	A/G	cg12428440	chr2:46370979	PRKCE	0.46	6.55	0.37	2.96e-10	Red blood cell count;Hematocrit;Red blood cell traits;
CESC	cis	rs9399137	0.507	rs11759062	chr6:135381248	A/C	cg22676075	chr6:135203613	NA	0.53	7.01	0.4	1.95e-11	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	cis	rs7923609	1.000	rs10761727	chr10:64995493	C/T	cg01631684	chr10:65280961	REEP3	-0.45	-5.56	-0.32	6.57e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs561341	1.000	rs506766	chr17:30289659	T/C	cg19193384	chr17:30244184	NA	-0.7	-6.24	-0.36	1.7e-9	Hip circumference adjusted for BMI;
CESC	cis	rs875971	0.862	rs778724	chr7:65829291	T/C	cg12463550	chr7:65579703	CRCP	0.5	6.36	0.36	8.85e-10	Aortic root size;
CESC	cis	rs10242455	0.571	rs80045298	chr7:99307453	T/A	cg25640893	chr7:99214727	ZNF498	0.85	5.73	0.33	2.69e-8	Blood metabolite levels;
CESC	cis	rs11249608	0.548	rs7704565	chr5:178473923	G/C	cg21905437	chr5:178450457	ZNF879	0.57	7.81	0.43	1.34e-13	Pubertal anthropometrics;
CESC	cis	rs7811142	0.943	rs111493473	chr7:100049742	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.03	11.71	0.58	8.13e-26	Platelet count;
CESC	cis	rs6089584	0.893	rs6089305	chr20:60571817	T/C	cg06108461	chr20:60628389	TAF4	-0.8	-11.87	-0.59	2.44e-26	Body mass index;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg22185043	chr18:12947723	SEH1L	-0.45	-6.25	-0.36	1.59e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs7246657	0.943	rs2081096	chr19:37964700	G/A	cg24637308	chr11:6592297	DNHD1	0.53	6.22	0.36	1.9e-9	Coronary artery calcification;
CESC	cis	rs6424115	0.729	rs1737362	chr1:24054800	T/C	cg15997130	chr1:24165203	NA	0.41	5.48	0.32	1.01e-7	Immature fraction of reticulocytes;
CESC	cis	rs3008870	0.792	rs72673729	chr1:67441673	T/TG	cg02640540	chr1:67518911	SLC35D1	-0.53	-5.73	-0.33	2.71e-8	Lymphocyte percentage of white cells;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27021056	chr17:76837047	USP36	0.56	6.49	0.37	4.1e-10	Gut microbiome composition (summer);
CESC	cis	rs651907	0.557	rs56291106	chr3:101377474	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.48	6.2	0.36	2.21e-9	Colorectal cancer;
CESC	cis	rs6570726	0.846	rs6919684	chr6:145883801	A/G	cg23711669	chr6:146136114	FBXO30	0.92	13.86	0.65	3.11e-33	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2204008	0.774	rs11616004	chr12:38278822	G/A	cg13010199	chr12:38710504	ALG10B	0.52	6.38	0.36	8.04e-10	Bladder cancer;
CESC	cis	rs9322193	0.923	rs9479810	chr6:150072495	C/T	cg05861140	chr6:150128134	PCMT1	-0.35	-5.11	-0.3	6.19e-7	Lung cancer;
CESC	cis	rs11690935	0.632	rs62184165	chr2:172558328	A/G	cg13550731	chr2:172543902	DYNC1I2	0.59	8.33	0.46	4.51e-15	Schizophrenia;
CESC	cis	rs4648845	0.777	rs2477686	chr1:2392648	C/G	cg02275930	chr1:2372054	NA	-0.48	-8.31	-0.45	5.05e-15	Schizophrenia;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg13464876	chr9:111881992	C9orf5	-0.48	-6.41	-0.37	6.71e-10	Fibrinogen levels;
CESC	cis	rs9811920	0.683	rs16841874	chr3:99720564	A/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.4	-6.51	-0.37	3.68e-10	Axial length;
CESC	cis	rs3091242	1.000	rs3091242	chr1:25674785	C/T	cg27572855	chr1:25598939	RHD	0.5	8.45	0.46	1.99e-15	Erythrocyte sedimentation rate;
CESC	trans	rs3741489	1.000	rs75810241	chr12:133365186	G/A	cg24132527	chr5:140019269	TMCO6	1.16	7.05	0.4	1.55e-11	Cognitive function;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02842627	chr3:49967264	MON1A	0.57	6.3	0.36	1.24e-9	Gut microbiome composition (summer);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg16430402	chr1:5947386	NPHP4	0.45	6.06	0.35	4.57e-9	Fibrinogen levels;
CESC	cis	rs208346	1.000	rs208346	chr7:2799686	G/T	cg09658497	chr7:2847517	GNA12	0.38	6.03	0.35	5.38e-9	Loneliness (linear analysis);
CESC	cis	rs2637266	0.846	rs2583045	chr10:78412385	C/G	cg18941641	chr10:78392320	NA	-0.43	-7.94	-0.44	5.6e-14	Pulmonary function;
CESC	cis	rs782590	0.837	rs782573	chr2:55912961	T/C	cg18811423	chr2:55921094	PNPT1	0.8	12.8	0.62	1.6e-29	Metabolic syndrome;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18470468	chr7:98985742	ARPC1B	-0.57	-6.24	-0.36	1.69e-9	Gut microbiome composition (summer);
CESC	cis	rs2242663	0.798	rs1791679	chr11:66337874	C/A	cg24851651	chr11:66362959	CCS	0.4	5.11	0.3	6.21e-7	Bipolar disorder;
CESC	cis	rs7100689	0.598	rs35353819	chr10:82135737	A/G	cg00277334	chr10:82204260	NA	-0.57	-7.51	-0.42	9.08e-13	Post bronchodilator FEV1;
CESC	cis	rs7811142	1.000	rs2406255	chr7:100053690	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.1	10.3	0.53	3.89e-21	Platelet count;
CESC	cis	rs72945132	0.882	rs3133179	chr11:70187574	T/G	cg00319359	chr11:70116639	PPFIA1	0.71	6.92	0.39	3.49e-11	Coronary artery disease;
CESC	cis	rs72627123	0.867	rs73301493	chr14:74472197	C/A	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.8	5.77	0.33	2.2e-8	Morning vs. evening chronotype;
CESC	cis	rs2933343	0.630	rs75824035	chr3:128652985	T/C	cg24203234	chr3:128598194	ACAD9	0.45	6.07	0.35	4.37e-9	IgG glycosylation;
CESC	cis	rs73058052	1.000	rs2288920	chr19:50091798	G/T	cg09250473	chr19:50168907	IRF3;BCL2L12	0.59	5.74	0.33	2.55e-8	Fibrinogen levels;
CESC	cis	rs950776	0.531	rs12915652	chr15:78831928	G/A	cg24631222	chr15:78858424	CHRNA5	-0.42	-5.35	-0.31	1.95e-7	Sudden cardiac arrest;
CESC	trans	rs10435719	0.678	rs74724594	chr8:11790576	C/A	cg15556689	chr8:8085844	FLJ10661	0.52	6.36	0.36	8.63e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
CESC	cis	rs2070677	0.736	rs4529856	chr10:135414020	C/G	cg20169779	chr10:135381914	SYCE1	-0.8	-8.86	-0.48	1.23e-16	Gout;
CESC	cis	rs7552404	0.889	rs380075	chr1:76106961	T/A	cg03433033	chr1:76189801	ACADM	-0.67	-7.91	-0.44	7.05e-14	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs8017423	0.647	rs4904677	chr14:90819245	C/T	cg14092571	chr14:90743983	NA	0.44	6.62	0.38	1.93e-10	Mortality in heart failure;
CESC	cis	rs10504229	0.683	rs11786043	chr8:58133174	T/C	cg24829409	chr8:58192753	C8orf71	-0.58	-7.2	-0.4	6.31e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs72945132	0.882	rs7935969	chr11:70194175	G/A	cg14191688	chr11:70257035	CTTN	0.41	5.13	0.3	5.6e-7	Coronary artery disease;
CESC	cis	rs6088580	0.634	rs4911420	chr20:32998654	A/G	cg06115741	chr20:33292138	TP53INP2	-0.42	-5.52	-0.32	7.92e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs4660261	0.526	rs2906458	chr1:44336389	A/G	cg12908607	chr1:44402522	ARTN	0.48	7.07	0.4	1.4e-11	Intelligence (multi-trait analysis);
CESC	cis	rs1144333	1.000	rs5745343	chr1:76273805	A/G	cg10523679	chr1:76189770	ACADM	-0.57	-5.84	-0.34	1.55e-8	Attention function in attention deficit hyperactive disorder;
CESC	cis	rs787274	0.718	rs2185768	chr9:115462645	C/T	cg13803584	chr9:115635662	SNX30	0.51	5.05	0.3	8.34e-7	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs963731	0.579	rs6544195	chr2:39288486	A/G	cg04010122	chr2:39346883	SOS1	-0.72	-5.63	-0.33	4.52e-8	Corticobasal degeneration;
CESC	cis	rs7084402	0.967	rs1619284	chr10:60302515	C/T	cg07615347	chr10:60278583	BICC1	0.63	10.02	0.52	2.94e-20	Refractive error;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02262786	chr10:103816019	C10orf76	-0.55	-6.21	-0.36	1.99e-9	Gut microbiome composition (summer);
CESC	cis	rs1185460	1.000	rs1614264	chr11:118942638	A/C	cg01677386	chr11:118938358	VPS11	-0.44	-5.48	-0.32	9.86e-8	Coronary artery disease;
CESC	cis	rs11249608	0.548	rs7732719	chr5:178463054	A/G	cg21905437	chr5:178450457	ZNF879	0.58	8.14	0.45	1.56e-14	Pubertal anthropometrics;
CESC	cis	rs9611565	0.802	rs9611571	chr22:41784867	G/A	cg17376030	chr22:41985996	PMM1	0.57	6.26	0.36	1.56e-9	Vitiligo;
CESC	cis	rs11583043	0.708	rs3861736	chr1:101532657	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.51	5.43	0.32	1.27e-7	Ulcerative colitis;Inflammatory bowel disease;
CESC	cis	rs5417	0.636	rs222851	chr17:7139238	G/A	cg25256661	chr17:7137939	DVL2	0.56	7.51	0.42	9.25e-13	Diastolic blood pressure;
CESC	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.51	6.17	0.35	2.58e-9	Prudent dietary pattern;
CESC	cis	rs854765	0.583	rs12452254	chr17:17829434	G/A	cg16928487	chr17:17741425	SREBF1	-0.58	-9.9	-0.52	7.25e-20	Total body bone mineral density;
CESC	cis	rs4595586	0.545	rs2218761	chr12:39393593	A/G	cg26384229	chr12:38710491	ALG10B	0.54	7.64	0.42	3.96e-13	Morning vs. evening chronotype;
CESC	cis	rs2576037	0.583	rs1970668	chr18:44523220	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.36	5.72	0.33	2.9e-8	Personality dimensions;
CESC	cis	rs7762018	0.769	rs4716385	chr6:170127608	G/T	cg13891659	chr6:170190454	C6orf122;C6orf208	0.61	5.89	0.34	1.18e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs2249694	0.960	rs8192776	chr10:135348187	T/C	cg20169779	chr10:135381914	SYCE1	0.38	5.22	0.31	3.55e-7	Obesity-related traits;
CESC	cis	rs654950	0.806	rs1815257	chr1:42041479	A/C	cg06885757	chr1:42089581	HIVEP3	-0.64	-10.14	-0.53	1.22e-20	Airway imaging phenotypes;
CESC	cis	rs12410462	0.579	rs78343168	chr1:227621090	G/A	cg04117972	chr1:227635322	NA	0.82	7.37	0.41	2.22e-12	Major depressive disorder;
CESC	trans	rs916888	0.773	rs199535	chr17:44822662	A/G	cg23590916	chr17:43697445	MGC57346	0.64	6.77	0.38	8.3e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs6598955	0.724	rs7526545	chr1:26569990	C/A	cg04990556	chr1:26633338	UBXN11	-0.78	-11.35	-0.57	1.35e-24	Obesity-related traits;
CESC	cis	rs35306767	0.855	rs61830932	chr10:934183	T/C	cg26597838	chr10:835615	NA	0.9	9.8	0.52	1.49e-19	Eosinophil percentage of granulocytes;
CESC	cis	rs9814567	1.000	rs2370578	chr3:134199612	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.45	-6.07	-0.35	4.34e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs8112211	0.911	rs60071299	chr19:38850246	G/A	cg14299480	chr19:38876666	GGN	-0.44	-6.03	-0.35	5.48e-9	Blood protein levels;
CESC	cis	rs7914558	0.966	rs1971589	chr10:104744406	A/G	cg15744005	chr10:104629667	AS3MT	-0.33	-5.16	-0.3	4.81e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs7662987	0.793	rs7669660	chr4:99992602	T/C	cg13256891	chr4:100009986	ADH5	-0.59	-5.12	-0.3	5.89e-7	Smoking initiation;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19355881	chr6:34759549	UHRF1BP1	0.55	6.97	0.39	2.44e-11	Gut microbiome composition (summer);
CESC	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg07157834	chr1:205819609	PM20D1	0.71	10.43	0.54	1.49e-21	Menarche (age at onset);
CESC	cis	rs35306767	0.761	rs12770910	chr10:1050318	A/G	cg26597838	chr10:835615	NA	0.7	6.53	0.37	3.31e-10	Eosinophil percentage of granulocytes;
CESC	cis	rs6570726	0.935	rs399169	chr6:145836353	C/A	cg05347473	chr6:146136440	FBXO30	0.49	6.69	0.38	1.3100000000000001e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6933660	0.666	rs9371516	chr6:151739642	G/A	cg10883421	chr6:151773342	RMND1;C6orf211	0.86	14.27	0.66	1.2e-34	Menarche (age at onset);
CESC	cis	rs10504229	0.679	rs17800895	chr8:58050085	A/G	cg02725872	chr8:58115012	NA	-0.4	-5.28	-0.31	2.65e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs7772486	0.790	rs2253654	chr6:146199445	T/C	cg23711669	chr6:146136114	FBXO30	1.03	16.03	0.7	6.85e-41	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg17181325	chr17:1613831	TLCD2	0.46	6.37	0.36	8.11e-10	Gut microbiota (bacterial taxa);
CESC	trans	rs3942852	0.774	rs10838813	chr11:48186969	C/A	cg03929089	chr4:120376271	NA	-0.65	-7.1	-0.4	1.15e-11	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs6582630	0.577	rs12312748	chr12:38343326	T/C	cg26384229	chr12:38710491	ALG10B	-0.42	-5.48	-0.32	1.01e-7	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs763121	0.853	rs5750673	chr22:39110124	G/A	cg14440974	chr22:39074834	NA	-0.41	-5.67	-0.33	3.72e-8	Menopause (age at onset);
CESC	cis	rs1292059	1	rs1292059	chr17:57957888	T/A	cg02344993	chr17:57696989	CLTC	0.52	5.44	0.32	1.19e-7	Eosinophil percentage of granulocytes;
CESC	cis	rs2204008	0.548	rs2320740	chr12:38166421	G/A	cg13010199	chr12:38710504	ALG10B	0.52	6.6	0.38	2.18e-10	Bladder cancer;
CESC	cis	rs13191362	1.000	rs35911566	chr6:162994154	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.82	8.34	0.46	4.2e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs7666738	0.830	rs1967980	chr4:98966426	C/G	cg03467027	chr4:99064603	C4orf37	0.44	5.48	0.32	9.97e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4604732	0.631	rs34443739	chr1:247626913	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.56	6.94	0.39	2.97e-11	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs875971	0.545	rs2173571	chr7:65770379	G/A	cg18876405	chr7:65276391	NA	0.46	5.24	0.31	3.3e-7	Aortic root size;
CESC	cis	rs4819052	0.851	rs2838857	chr21:46681000	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.89	13.45	0.64	8.72e-32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs2011503	1.000	rs75582668	chr19:19569023	C/T	cg11584989	chr19:19387371	SF4	0.62	7.22	0.41	5.54e-12	Bipolar disorder;
CESC	cis	rs9611565	0.659	rs1810461	chr22:41927820	G/A	cg06481639	chr22:41940642	POLR3H	-0.6	-6.28	-0.36	1.35e-9	Vitiligo;
CESC	cis	rs7561273	0.586	rs6545264	chr2:24310105	A/G	cg01493198	chr2:24299560	SF3B14	0.42	5.16	0.3	4.85e-7	Quantitative traits;
CESC	cis	rs9522267	0.535	rs11069899	chr13:112231553	T/C	cg10483660	chr13:112241077	NA	-0.32	-5.69	-0.33	3.28e-8	Hepatitis;
CESC	cis	rs9611565	0.659	rs17367716	chr22:41913844	A/G	cg03806693	chr22:41940476	POLR3H	-1.18	-14.45	-0.66	2.78e-35	Vitiligo;
CESC	cis	rs9916302	0.904	rs4795356	chr17:37535631	C/T	cg07936489	chr17:37558343	FBXL20	0.81	11.93	0.59	1.5e-26	Glomerular filtration rate (creatinine);
CESC	cis	rs748404	0.697	rs574065	chr15:43550655	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.62	-8.01	-0.44	3.68e-14	Lung cancer;
CESC	trans	rs17508449	0.819	rs78874053	chr1:114242873	A/T	cg23028848	chr11:57092561	TNKS1BP1	-0.81	-6.4	-0.37	6.98e-10	Leprosy;
CESC	cis	rs7607369	0.559	rs4674340	chr2:219659799	A/G	cg02176678	chr2:219576539	TTLL4	-0.4	-7.23	-0.41	5.21e-12	Red blood cell count;Amyotrophic lateral sclerosis;
CESC	cis	rs6580649	0.843	rs3803184	chr12:48398002	G/C	cg24011408	chr12:48396354	COL2A1	0.4	5.28	0.31	2.7e-7	Lung cancer;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg19463885	chr2:242626846	DTYMK	-0.43	-6.21	-0.36	2.02e-9	Gambling;
CESC	cis	rs3617	0.625	rs2071042	chr3:52864584	A/G	cg11645453	chr3:52864694	ITIH4	0.26	5.18	0.3	4.39e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
CESC	cis	rs12220238	1.000	rs12355771	chr10:75894404	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.65	6.13	0.35	3.23e-9	Soluble interleukin-2 receptor subunit alpha;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02442526	chr22:46973514	NA	0.66	7.26	0.41	4.36e-12	Gut microbiome composition (summer);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg18946802	chr3:14220310	LSM3;XPC	-0.48	-6.15	-0.35	2.81e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs17854409	1.000	rs66956644	chr20:61484499	T/C	cg05147244	chr20:61493195	TCFL5	0.99	6.48	0.37	4.57e-10	Obesity-related traits;
CESC	cis	rs7666738	0.800	rs7683737	chr4:99070880	A/T	cg05340658	chr4:99064831	C4orf37	0.84	12.86	0.62	9.41e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs61931739	0.500	rs10844864	chr12:34532468	A/G	cg06521331	chr12:34319734	NA	-0.37	-5.15	-0.3	5.19e-7	Morning vs. evening chronotype;
CESC	cis	rs12477438	0.501	rs11123770	chr2:99825102	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.71	10.86	0.55	5.89e-23	Chronic sinus infection;
CESC	cis	rs12618769	0.625	rs76362434	chr2:99118005	C/T	cg10123293	chr2:99228465	UNC50	0.4	5.06	0.3	7.7e-7	Bipolar disorder;
CESC	cis	rs35146811	0.771	rs1060544	chr7:99613476	C/T	cg13334819	chr7:99746414	C7orf59	-0.45	-5.24	-0.31	3.34e-7	Coronary artery disease;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg11412766	chr2:55276306	RTN4	-0.51	-6.86	-0.39	4.9e-11	Ulcerative colitis;
CESC	cis	rs425277	0.917	rs78395918	chr1:2045876	G/A	cg16545954	chr1:2118288	C1orf86	0.33	5.4	0.31	1.48e-7	Height;
CESC	cis	rs7100689	0.516	rs10788546	chr10:82034854	T/C	cg00277334	chr10:82204260	NA	-0.46	-5.76	-0.33	2.28e-8	Post bronchodilator FEV1;
CESC	cis	rs7116495	0.609	rs17161751	chr11:71688347	G/A	cg26138937	chr11:71823887	C11orf51	1.32	8.19	0.45	1.11e-14	Severe influenza A (H1N1) infection;
CESC	cis	rs10504229	0.815	rs72650879	chr8:58164648	A/G	cg22535103	chr8:58192502	C8orf71	-0.95	-10.54	-0.54	6.39e-22	Developmental language disorder (linguistic errors);
CESC	cis	rs3820068	0.544	rs7551750	chr1:16035008	T/C	cg17385448	chr1:15911702	AGMAT	0.38	6.08	0.35	4.28e-9	Systolic blood pressure;
CESC	cis	rs4727027	0.899	rs11768971	chr7:148825826	C/G	cg23158103	chr7:148848205	ZNF398	-0.41	-6.74	-0.38	9.65e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	trans	rs7618501	1.000	rs3749240	chr3:49750188	T/A	cg21659725	chr3:3221576	CRBN	-0.82	-13.49	-0.64	6.48e-32	Intelligence (multi-trait analysis);
CESC	cis	rs6500602	0.701	rs6500614	chr16:4573938	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.37	5.17	0.3	4.64e-7	Schizophrenia;
CESC	cis	rs4253772	0.637	rs6008339	chr22:46650846	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.69	8.18	0.45	1.16e-14	LDL cholesterol;Cholesterol, total;
CESC	cis	rs875971	0.522	rs1701760	chr7:65473688	A/G	cg11987759	chr7:65425863	GUSB	-0.48	-6.62	-0.38	2.03e-10	Aortic root size;
CESC	cis	rs478304	0.651	rs11227299	chr11:65549570	C/G	cg10518572	chr11:65560635	OVOL1	-0.31	-5.85	-0.34	1.43e-8	Acne (severe);
CESC	cis	rs3768617	0.528	rs10737242	chr1:183098249	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.89	14.39	0.66	4.39e-35	Fuchs's corneal dystrophy;
CESC	cis	rs1799949	1.000	rs4793190	chr17:41200109	T/C	cg05368731	chr17:41323189	NBR1	0.75	10.35	0.54	2.72e-21	Menopause (age at onset);
CESC	cis	rs9457247	0.534	rs7750593	chr6:167387359	C/G	cg25258033	chr6:167368657	RNASET2	-0.38	-5.44	-0.32	1.2e-7	Crohn's disease;
CESC	cis	rs4268898	0.931	rs34504814	chr2:24503766	C/T	cg20701182	chr2:24300061	SF3B14	0.47	5.65	0.33	4.1e-8	Asthma;
CESC	cis	rs7412746	0.622	rs72704654	chr1:150826410	G/A	cg17724175	chr1:150552817	MCL1	0.41	6.3	0.36	1.24e-9	Melanoma;
CESC	trans	rs208520	0.690	rs12213928	chr6:66762978	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.95	12.43	0.61	2.98e-28	Exhaled nitric oxide output;
CESC	cis	rs2836974	0.799	rs13047550	chr21:40515495	T/C	cg11890956	chr21:40555474	PSMG1	1.07	16.6	0.71	6.4e-43	Cognitive function;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26419957	chr12:122252518	SETD1B	-0.69	-7.61	-0.42	4.73e-13	Gut microbiome composition (summer);
CESC	cis	rs12822507	0.831	rs34975957	chr12:12786190	G/A	cg09462578	chr12:12878428	APOLD1	-0.46	-5.71	-0.33	3.06e-8	Systemic lupus erythematosus;
CESC	cis	rs11792861	0.962	rs72607161	chr9:111792640	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.46	5.76	0.33	2.35e-8	Menarche (age at onset);
CESC	cis	rs7618915	0.501	rs10865974	chr3:52718280	A/C	cg05564831	chr3:52568323	NT5DC2	-0.45	-7.28	-0.41	3.73e-12	Bipolar disorder;
CESC	cis	rs4253772	0.872	rs4253776	chr22:46629479	C/T	cg18190219	chr22:46762943	CELSR1	0.51	6.25	0.36	1.65e-9	LDL cholesterol;Cholesterol, total;
CESC	trans	rs916888	0.821	rs70600	chr17:44860021	C/T	cg04282206	chr17:62833786	PLEKHM1P	0.54	6.22	0.36	1.93e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs7520050	0.966	rs6701614	chr1:46309420	G/C	cg03146154	chr1:46216737	IPP	-0.48	-6.3	-0.36	1.25e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs344364	0.511	rs2906912	chr16:1953151	G/A	cg26617929	chr16:1858877	NA	-0.5	-5.22	-0.31	3.63e-7	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs1552244	1.000	rs113522867	chr3:10154503	T/C	cg08888203	chr3:10149979	C3orf24	0.44	5.71	0.33	3.09e-8	Alzheimer's disease;
CESC	cis	rs992157	0.560	rs4674274	chr2:219089131	A/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.57	-7.45	-0.42	1.29e-12	Colorectal cancer;
CESC	cis	rs7809950	1.000	rs17154077	chr7:107077941	C/T	cg23024343	chr7:107201750	COG5	0.39	5.54	0.32	7.4e-8	Coronary artery disease;
CESC	trans	rs164368	0.568	rs163944	chr5:160633896	C/T	cg04183933	chr2:198363868	HSPD1;HSPE1	-0.61	-6.52	-0.37	3.63e-10	Yu-Zhi constitution type in type 2 diabetes;
CESC	cis	rs736408	0.812	rs9324	chr3:52825585	T/C	cg05564831	chr3:52568323	NT5DC2	0.46	6.57	0.37	2.67e-10	Bipolar disorder;
CESC	cis	rs7223966	1.000	rs8074771	chr17:61735865	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.54	6.44	0.37	5.7e-10	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs7107174	1.000	rs729354	chr11:77962453	T/A	cg02023728	chr11:77925099	USP35	0.46	6.49	0.37	4.25e-10	Testicular germ cell tumor;
CESC	cis	rs10751667	0.666	rs7396059	chr11:970490	C/A	cg20946044	chr11:1010712	AP2A2	-0.39	-5.4	-0.31	1.49e-7	Alzheimer's disease (late onset);
CESC	cis	rs9393777	0.582	rs6936561	chr6:26640895	C/T	cg14345882	chr6:26364793	BTN3A2	0.41	5.38	0.31	1.68e-7	Intelligence (multi-trait analysis);
CESC	cis	rs4975616	0.836	rs421629	chr5:1320136	G/A	cg26373071	chr5:1325741	CLPTM1L	0.41	6.45	0.37	5.29e-10	Lung cancer;
CESC	cis	rs57221529	0.766	rs4957053	chr5:575927	T/C	cg16447950	chr5:562315	NA	-0.64	-6.81	-0.39	6.59e-11	Lung disease severity in cystic fibrosis;
CESC	cis	rs7845219	0.544	rs34293080	chr8:95908078	G/T	cg16049864	chr8:95962084	TP53INP1	-0.51	-7.59	-0.42	5.59e-13	Type 2 diabetes;
CESC	cis	rs34172651	0.517	rs11647120	chr16:24819806	A/G	cg06028605	chr16:24865363	SLC5A11	0.53	7.71	0.43	2.47e-13	Intelligence (multi-trait analysis);
CESC	cis	rs736801	0.808	rs72797306	chr5:131800750	G/C	cg00255919	chr5:131827918	IRF1	-0.37	-5.4	-0.31	1.5e-7	Breast cancer;Mosquito bite size;
CESC	cis	rs7659604	1.000	rs7689722	chr4:122665955	T/C	cg19671926	chr4:122722719	EXOSC9	-0.49	-5.92	-0.34	9.92e-9	Type 2 diabetes;
CESC	cis	rs1552244	1.000	rs28684871	chr3:10072635	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.86	11.55	0.58	2.8e-25	Alzheimer's disease;
CESC	cis	rs7116495	1.000	rs548961	chr11:71793887	G/A	cg26138937	chr11:71823887	C11orf51	-0.86	-7.03	-0.4	1.75e-11	Severe influenza A (H1N1) infection;
CESC	cis	rs2455799	0.613	rs4685258	chr3:15792315	G/A	cg16303742	chr3:15540471	COLQ	-0.39	-6.14	-0.35	3.01e-9	Mean platelet volume;
CESC	cis	rs9790314	0.521	rs2122527	chr3:161091636	G/A	cg03342759	chr3:160939853	NMD3	-0.45	-6.25	-0.36	1.6e-9	Morning vs. evening chronotype;
CESC	cis	rs2777491	1.000	rs11631770	chr15:41737059	T/C	cg20272979	chr15:41787780	ITPKA	0.43	6.18	0.36	2.34e-9	Ulcerative colitis;
CESC	cis	rs67460515	0.892	rs13059340	chr3:161062631	T/C	cg03342759	chr3:160939853	NMD3	-0.54	-7.86	-0.44	9.41e-14	Parkinson's disease;
CESC	cis	rs6714710	0.603	rs35424768	chr2:98395653	A/C	cg26665480	chr2:98280029	ACTR1B	0.57	8.03	0.44	3.3e-14	Posterior cortical atrophy and Alzheimer's disease;
CESC	cis	rs858239	1.000	rs858239	chr7:23286315	G/A	cg23682824	chr7:23144976	KLHL7	0.41	5.44	0.32	1.2e-7	Cerebrospinal fluid biomarker levels;
CESC	cis	rs929596	0.755	rs4148324	chr2:234672722	T/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.67	-8.89	-0.48	9.89e-17	Total bilirubin levels in HIV-1 infection;
CESC	cis	rs72781680	0.560	rs72781698	chr2:24271506	C/T	cg08917208	chr2:24149416	ATAD2B	0.66	6.32	0.36	1.09e-9	Lymphocyte counts;
CESC	cis	rs769267	0.965	rs4808938	chr19:19401218	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.43	5.27	0.31	2.88e-7	Tonsillectomy;
CESC	cis	rs780096	0.546	rs12473776	chr2:27636474	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.32	-5.96	-0.34	8.13e-9	Total body bone mineral density;
CESC	cis	rs7927771	0.965	rs12787112	chr11:47687147	A/G	cg05585544	chr11:47624801	NA	-0.5	-7.88	-0.44	8.28e-14	Subjective well-being;
CESC	cis	rs1059312	1.000	rs7135987	chr12:129280117	G/A	cg09035930	chr12:129282057	SLC15A4	0.78	11.03	0.56	1.54e-23	Systemic lupus erythematosus;
CESC	cis	rs965469	0.948	rs6051769	chr20:3326438	G/A	cg25506879	chr20:3388711	C20orf194	-0.55	-5.72	-0.33	2.93e-8	IFN-related cytopenia;
CESC	cis	rs17376456	0.877	rs10064520	chr5:93427358	T/C	cg21475434	chr5:93447410	FAM172A	0.88	7.67	0.43	3.29e-13	Diabetic retinopathy;
CESC	cis	rs926392	0.640	rs2867899	chr20:37694622	C/A	cg16355469	chr20:37678765	NA	0.52	5.72	0.33	2.81e-8	Dialysis-related mortality;
CESC	cis	rs9915657	0.870	rs35271702	chr17:70140516	G/A	cg09344028	chr17:70110421	NA	0.34	6.01	0.35	6.13e-9	Thyroid hormone levels;
CESC	cis	rs9393777	0.513	rs13215020	chr6:26656073	G/A	cg12292205	chr6:26970375	C6orf41	-0.53	-5.76	-0.33	2.33e-8	Intelligence (multi-trait analysis);
CESC	cis	rs17376456	0.877	rs7701011	chr5:93311456	G/A	cg25358565	chr5:93447407	FAM172A	1.07	10.61	0.55	3.7e-22	Diabetic retinopathy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04105453	chr2:27440337	CAD	0.57	6.85	0.39	5.21e-11	Gut microbiome composition (summer);
CESC	cis	rs7937682	0.855	rs539553	chr11:111477333	C/T	cg22437258	chr11:111473054	SIK2	0.71	9.43	0.5	2.2e-18	Primary sclerosing cholangitis;
CESC	cis	rs7692995	1.000	rs7670435	chr4:17962260	G/A	cg08925142	chr4:18023851	LCORL	-0.45	-5.13	-0.3	5.66e-7	Height;
CESC	cis	rs2637266	0.600	rs10824427	chr10:78344387	A/G	cg18941641	chr10:78392320	NA	-0.34	-5.3	-0.31	2.42e-7	Pulmonary function;
CESC	cis	rs8141529	0.764	rs5762824	chr22:29222930	C/T	cg02153584	chr22:29168773	CCDC117	0.65	9.21	0.49	1.03e-17	Lymphocyte counts;
CESC	cis	rs2859741	0.608	rs532719	chr1:37477380	C/T	cg09363841	chr1:37513479	NA	0.53	7.44	0.42	1.4e-12	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18070621	chr17:79869449	PCYT2	0.6	6.71	0.38	1.19e-10	Gut microbiome composition (summer);
CESC	cis	rs3015497	0.537	rs2934664	chr14:51155485	C/A	cg26011998	chr14:51135199	SAV1	-0.54	-6.13	-0.35	3.13e-9	Mean platelet volume;
CESC	cis	rs1552244	0.882	rs34706481	chr3:10004123	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.63	-7.23	-0.41	5.3e-12	Alzheimer's disease;
CESC	cis	rs9322193	0.607	rs915140	chr6:150220810	C/T	cg01145232	chr6:150245071	RAET1G	0.52	6.57	0.37	2.72e-10	Lung cancer;
CESC	cis	rs56046484	0.956	rs34105012	chr15:85591686	C/G	cg08123816	chr15:85640762	PDE8A	-0.5	-6.21	-0.36	2.05e-9	Testicular germ cell tumor;
CESC	cis	rs1552244	0.572	rs17032426	chr3:10167112	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.78	8.92	0.48	7.63e-17	Alzheimer's disease;
CESC	cis	rs17125944	0.615	rs2357944	chr14:53305573	T/G	cg00686598	chr14:53173677	PSMC6	-0.65	-5.6	-0.33	5.48e-8	Alzheimer's disease (late onset);
CESC	cis	rs9790314	0.905	rs6789388	chr3:160970437	G/A	cg03342759	chr3:160939853	NMD3	-0.47	-6.29	-0.36	1.29e-9	Morning vs. evening chronotype;
CESC	cis	rs13191362	0.935	rs34540135	chr6:162934351	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.69	5.97	0.34	7.56e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs12900413	0.687	rs72754547	chr15:90308166	A/C	cg24249390	chr15:90295951	MESP1	-0.39	-5.47	-0.32	1.03e-7	Coronary artery aneurysm in Kawasaki disease;
CESC	cis	rs10870270	1.000	rs10781564	chr10:133757922	A/G	cg17892150	chr10:133769511	PPP2R2D	-0.84	-12.45	-0.61	2.47e-28	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs2404602	0.583	rs4381566	chr15:76589262	A/G	cg26408565	chr15:76604113	ETFA	-0.4	-5.96	-0.34	8.16e-9	Blood metabolite levels;
CESC	cis	rs9733	0.818	rs11204695	chr1:150657011	T/G	cg18016565	chr1:150552671	MCL1	-0.35	-5.82	-0.34	1.69e-8	Tonsillectomy;
CESC	cis	rs3093024	0.967	rs1571878	chr6:167540842	C/T	cg23791538	chr6:167370224	RNASET2	0.42	5.19	0.3	4.27e-7	Rheumatoid arthritis;
CESC	cis	rs6982240	0.514	rs10095322	chr8:142262327	A/G	cg00131261	chr8:142287264	NA	-0.53	-7.26	-0.41	4.25e-12	Tonsillectomy;
CESC	cis	rs3015497	0.594	rs35637875	chr14:51132533	T/G	cg09863266	chr14:51125203	SAV1	-0.36	-5.61	-0.33	5.1e-8	Mean platelet volume;
CESC	cis	rs3204270	0.639	rs6565620	chr17:79658100	C/T	cg18367735	chr17:79674897	NA	0.66	5.7	0.33	3.22e-8	Dental caries;
CESC	cis	rs6424115	0.830	rs6672157	chr1:24198840	C/G	cg10978503	chr1:24200527	CNR2	0.33	6.63	0.38	1.85e-10	Immature fraction of reticulocytes;
CESC	cis	rs56046484	0.956	rs34919315	chr15:85631906	C/A	cg08123816	chr15:85640762	PDE8A	-0.5	-6.02	-0.35	5.81e-9	Testicular germ cell tumor;
CESC	cis	rs1983891	1.000	rs2104506	chr6:41533579	C/A	cg20194872	chr6:41519635	FOXP4	0.55	7.85	0.43	1.05e-13	Prostate cancer;
CESC	cis	rs2439831	1.000	rs1814538	chr15:43759774	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.82	-11.94	-0.59	1.43e-26	Lung cancer in ever smokers;
CESC	cis	rs8114671	0.967	rs2065978	chr20:33767291	C/T	cg24642439	chr20:33292090	TP53INP2	0.44	5.26	0.31	2.95e-7	Height;
CESC	cis	rs6963495	0.818	rs73190163	chr7:105157294	G/T	cg19920283	chr7:105172520	RINT1	0.69	6.56	0.37	2.85e-10	Bipolar disorder (body mass index interaction);
CESC	trans	rs61931739	0.534	rs2087128	chr12:34000173	T/C	cg26384229	chr12:38710491	ALG10B	0.47	6.51	0.37	3.8e-10	Morning vs. evening chronotype;
CESC	cis	rs7412746	0.634	rs12096831	chr1:150864113	T/G	cg22823121	chr1:150693482	HORMAD1	0.42	5.81	0.34	1.81e-8	Melanoma;
CESC	cis	rs4906332	0.834	rs12882130	chr14:103878774	C/G	cg09975044	chr14:104007538	NA	0.38	5.12	0.3	5.93e-7	Coronary artery disease;
CESC	cis	rs9581857	0.556	rs9581861	chr13:28039991	C/T	cg22138327	chr13:27999177	GTF3A	0.64	7.1	0.4	1.16e-11	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
CESC	cis	rs8060686	0.641	rs7199588	chr16:68224582	C/T	cg26727032	chr16:67993705	SLC12A4	-0.5	-6.03	-0.35	5.36e-9	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs7824557	0.527	rs4631425	chr8:11239054	C/T	cg21775007	chr8:11205619	TDH	-0.52	-7.89	-0.44	7.81e-14	Retinal vascular caliber;
CESC	cis	rs7605827	0.897	rs763355	chr2:15518838	A/G	cg19274914	chr2:15703543	NA	0.35	6.11	0.35	3.61e-9	Educational attainment (years of education);
CESC	cis	rs7552404	1.000	rs7548962	chr1:76139266	G/A	cg22875332	chr1:76189707	ACADM	0.66	7.84	0.43	1.1e-13	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs2228479	0.702	rs2074963	chr16:89877269	T/C	cg00800038	chr16:89945340	TCF25	-0.89	-6.88	-0.39	4.22e-11	Skin colour saturation;
CESC	cis	rs6502050	0.835	rs8066284	chr17:80127825	C/T	cg23985595	chr17:80112537	CCDC57	-0.41	-6.57	-0.37	2.61e-10	Life satisfaction;
CESC	cis	rs5750830	0.649	rs4821894	chr22:39809820	G/C	cg02038168	chr22:39784481	NA	-0.62	-7.66	-0.43	3.4e-13	Intelligence (multi-trait analysis);
CESC	cis	rs76419734	0.510	rs28391170	chr4:106629246	A/C	cg24545054	chr4:106630052	GSTCD;INTS12	0.69	8.38	0.46	3.15e-15	Post bronchodilator FEV1;
CESC	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg26354017	chr1:205819088	PM20D1	-0.71	-11.53	-0.58	3.5e-25	Monocyte percentage of white cells;
CESC	cis	rs17376456	0.825	rs35496867	chr5:93220400	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.61	5.08	0.3	7.29e-7	Diabetic retinopathy;
CESC	cis	rs807669	0.548	rs5748028	chr22:19172281	G/A	cg02655711	chr22:19163373	SLC25A1	0.76	11.75	0.59	6.14e-26	Metabolite levels;
CESC	trans	rs208520	0.909	rs9453672	chr6:66991431	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.77	8.51	0.46	1.34e-15	Exhaled nitric oxide output;
CESC	cis	rs9858542	0.953	rs12330269	chr3:49513910	G/A	cg03060546	chr3:49711283	APEH	-0.54	-6.12	-0.35	3.44e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs67478160	0.619	rs10083367	chr14:104314183	C/G	cg01849466	chr14:104193079	ZFYVE21	0.5	6.84	0.39	5.43e-11	Schizophrenia;
CESC	cis	rs3741404	0.825	rs2845597	chr11:63954370	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.87	12.81	0.62	1.44e-29	Platelet count;
CESC	cis	rs8044868	0.530	rs2288002	chr16:72057282	A/G	cg01557791	chr16:72042693	DHODH	-0.46	-6.39	-0.37	7.31e-10	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CESC	cis	rs7703051	0.901	rs4704221	chr5:74759183	A/T	cg03227963	chr5:74354835	NA	-0.29	-5.26	-0.31	2.92e-7	LDL cholesterol;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
CESC	cis	rs7618501	1.000	rs7649348	chr3:49772375	G/A	cg24308560	chr3:49941425	MST1R	0.5	6.81	0.39	6.38e-11	Intelligence (multi-trait analysis);
CESC	cis	rs10504229	1.000	rs67039591	chr8:58174553	T/A	cg14926445	chr8:58193284	C8orf71	-0.51	-5.47	-0.32	1.03e-7	Developmental language disorder (linguistic errors);
CESC	trans	rs3102460	0.618	rs3102461	chr1:244577289	C/T	cg01977209	chr2:236293433	NA	0.47	6.18	0.35	2.38e-9	Obesity-related traits;
CESC	cis	rs11098499	0.954	rs59866101	chr4:120296591	T/G	cg09307838	chr4:120376055	NA	0.92	12.66	0.61	4.96e-29	Corneal astigmatism;
CESC	cis	rs2299587	0.527	rs7843715	chr8:17733526	C/A	cg08627089	chr8:17753878	FGL1	-0.39	-5.63	-0.33	4.53e-8	Economic and political preferences;
CESC	cis	rs9611565	0.569	rs188057	chr22:41822305	T/G	cg06481639	chr22:41940642	POLR3H	0.64	6.41	0.37	6.73e-10	Vitiligo;
CESC	cis	rs6540556	0.954	rs10489342	chr1:209935778	A/G	cg05527609	chr1:210001259	C1orf107	-0.44	-5.55	-0.32	6.87e-8	Red blood cell count;
CESC	cis	rs17253792	0.915	rs28537145	chr14:56179119	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.73	5.13	0.3	5.7e-7	Putamen volume;
CESC	trans	rs7000551	0.725	rs2469756	chr8:22360423	G/A	cg24804145	chr7:158144409	PTPRN2	-0.32	-6.07	-0.35	4.42e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CESC	cis	rs72781680	0.898	rs12612492	chr2:24093756	C/T	cg20701182	chr2:24300061	SF3B14	0.63	5.83	0.34	1.58e-8	Lymphocyte counts;
CESC	cis	rs7605827	0.930	rs4668900	chr2:15511740	T/C	cg19274914	chr2:15703543	NA	0.32	5.58	0.32	5.95e-8	Educational attainment (years of education);
CESC	cis	rs6964587	1.000	rs13231578	chr7:91663266	C/T	cg17063962	chr7:91808500	NA	0.55	7.35	0.41	2.47e-12	Breast cancer;
CESC	cis	rs10504229	0.610	rs7011877	chr8:58147181	C/T	cg02725872	chr8:58115012	NA	-0.37	-5.91	-0.34	1.06e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs9649213	0.593	rs1468340	chr7:97987676	T/G	cg24562669	chr7:97807699	LMTK2	0.51	7.63	0.42	4.29e-13	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7264396	0.667	rs224368	chr20:34070380	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.44	-5.26	-0.31	2.97e-7	Total cholesterol levels;
CESC	trans	rs629535	0.767	rs62513418	chr8:70114376	G/T	cg21567404	chr3:27674614	NA	-0.88	-10.26	-0.53	5.22e-21	Dupuytren's disease;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg13846682	chr14:34931391	C14orf147	-0.47	-6.69	-0.38	1.3100000000000001e-10	Ulcerative colitis;
CESC	cis	rs8103278	1.000	rs9807819	chr19:46239598	C/T	cg14061069	chr19:46274453	DMPK	-0.38	-5.44	-0.32	1.23e-7	Coronary artery disease;
CESC	cis	rs7116495	0.609	rs7111379	chr11:71826319	C/T	cg07596299	chr11:71824057	C11orf51	0.79	5.03	0.3	9.06e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs9303401	0.612	rs2526370	chr17:56487636	G/C	cg12560992	chr17:57184187	TRIM37	0.6	7.93	0.44	6.07e-14	Cognitive test performance;
CESC	cis	rs8017423	0.967	rs11624725	chr14:90713609	G/T	cg14092571	chr14:90743983	NA	0.58	8.73	0.47	2.84e-16	Mortality in heart failure;
CESC	cis	rs1005277	0.540	rs1814077	chr10:37992018	G/C	cg25517755	chr10:38738941	LOC399744	-0.41	-5.24	-0.31	3.25e-7	Extrinsic epigenetic age acceleration;
CESC	cis	rs34734847	0.842	rs7308648	chr12:121144144	C/G	cg26008908	chr12:120799332	MSI1	0.36	5.5	0.32	8.79e-8	Mean corpuscular volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03353863	chr19:52618714	ZNF616	-0.74	-8.15	-0.45	1.43e-14	Gut microbiome composition (summer);
CESC	cis	rs11112613	0.713	rs73184083	chr12:105952593	T/A	cg03607813	chr12:105948248	NA	0.59	7.41	0.41	1.75e-12	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CESC	trans	rs9858542	0.953	rs9824092	chr3:49674147	C/G	cg21659725	chr3:3221576	CRBN	-0.52	-6.3	-0.36	1.21e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs2302190	0.882	rs2270098	chr17:56572081	C/T	cg25885038	chr17:56607967	SEPT4	-0.41	-5.58	-0.32	5.79e-8	Vitamin D levels;
CESC	trans	rs4716602	0.596	rs10244786	chr7:156157989	C/T	cg07175507	chr18:77160758	NFATC1	-0.45	-6.17	-0.35	2.52e-9	Anti-saccade response;
CESC	cis	rs1784581	0.588	rs1784583	chr6:162410132	C/T	cg17173639	chr6:162384350	PARK2	-0.54	-8.2	-0.45	1.04e-14	Itch intensity from mosquito bite;
CESC	cis	rs1178968	1.000	rs1178959	chr7:72777093	T/C	cg25889504	chr7:72793014	NA	0.51	5.42	0.32	1.36e-7	Triglyceride levels;
CESC	cis	rs7412746	0.658	rs2089082	chr1:150800090	T/G	cg09365446	chr1:150670422	GOLPH3L	0.38	5.13	0.3	5.52e-7	Melanoma;
CESC	cis	rs9916302	0.706	rs11655972	chr17:37407072	C/T	cg07936489	chr17:37558343	FBXL20	-0.95	-11.1	-0.56	9.49e-24	Glomerular filtration rate (creatinine);
CESC	cis	rs7647973	0.506	rs11920251	chr3:49356671	C/T	cg03060546	chr3:49711283	APEH	0.54	7.46	0.42	1.23e-12	Menarche (age at onset);
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg23731836	chr8:29120779	KIF13B	-0.42	-6.33	-0.36	1.01e-9	Vertical cup-disc ratio;
CESC	cis	rs9487051	0.700	rs7773815	chr6:109602343	A/C	cg21918786	chr6:109611834	NA	-0.39	-5.7	-0.33	3.22e-8	Reticulocyte fraction of red cells;
CESC	trans	rs7922314	0.571	rs16918001	chr10:64749870	G/A	cg06935979	chr1:232941706	KIAA1383	-0.62	-6.01	-0.35	5.98e-9	Cutaneous psoriasis;
CESC	cis	rs8180040	0.545	rs9311403	chr3:47138878	T/C	cg27129171	chr3:47204927	SETD2	0.66	9.84	0.52	1.1e-19	Colorectal cancer;
CESC	cis	rs6088590	1.000	rs6087623	chr20:33317662	C/G	cg08999081	chr20:33150536	PIGU	0.58	8.85	0.48	1.24e-16	Coronary artery disease;
CESC	cis	rs1881797	1.000	rs12071797	chr1:247686871	A/G	cg18198730	chr1:247681584	NA	0.59	7.76	0.43	1.84e-13	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs561341	0.831	rs11658469	chr17:30206426	T/C	cg12193833	chr17:30244370	NA	0.54	5.46	0.32	1.09e-7	Hip circumference adjusted for BMI;
CESC	cis	rs561341	0.941	rs4795664	chr17:30233467	C/T	cg00745463	chr17:30367425	LRRC37B	-0.63	-6.18	-0.36	2.36e-9	Hip circumference adjusted for BMI;
CESC	cis	rs12188164	1.000	rs34847072	chr5:437862	G/C	cg21144161	chr5:423903	AHRR	0.37	6.09	0.35	3.9e-9	Cystic fibrosis severity;
CESC	cis	rs2282802	0.685	rs11748023	chr5:139558584	C/T	cg26211634	chr5:139558579	C5orf32	-0.49	-7.05	-0.4	1.55e-11	Intelligence (multi-trait analysis);
CESC	trans	rs7618501	1.000	rs7618501	chr3:49772647	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.58	-8.39	-0.46	2.99e-15	Intelligence (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24780086	chr5:14713043	ANKH	-0.53	-6.3	-0.36	1.26e-9	Gut microbiome composition (summer);
CESC	cis	rs7520050	0.778	rs3014218	chr1:46026328	A/C	cg03146154	chr1:46216737	IPP	-0.5	-6.49	-0.37	4.16e-10	Red blood cell count;Reticulocyte count;
CESC	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	13.67	0.64	1.44e-32	Prudent dietary pattern;
CESC	cis	rs9815354	0.951	rs73830511	chr3:41864643	G/T	cg03022575	chr3:42003672	ULK4	0.49	5.52	0.32	7.99e-8	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg04234412	chr22:24373322	LOC391322	0.53	7.67	0.43	3.29e-13	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs66887589	0.934	rs2389873	chr4:120554714	A/G	cg09307838	chr4:120376055	NA	-0.44	-5.85	-0.34	1.42e-8	Diastolic blood pressure;
CESC	cis	rs35306767	0.903	rs10508208	chr10:910983	C/T	cg25019033	chr10:957182	NA	-0.56	-6.27	-0.36	1.43e-9	Eosinophil percentage of granulocytes;
CESC	cis	rs9768139	0.708	rs921616	chr7:158117960	A/G	cg25566285	chr7:158114605	PTPRN2	0.49	8.13	0.45	1.64e-14	Calcium levels;
CESC	trans	rs1814175	0.645	rs1721996	chr11:49915527	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.43	-6.36	-0.36	8.98e-10	Height;
CESC	cis	rs11122272	0.735	rs2486735	chr1:231521778	C/T	cg06096015	chr1:231504339	EGLN1	0.43	6.18	0.35	2.46e-9	Hemoglobin concentration;
CESC	cis	rs4654899	0.865	rs10916910	chr1:21283192	G/T	cg05370193	chr1:21551575	ECE1	0.43	6.36	0.36	8.92e-10	Superior frontal gyrus grey matter volume;
CESC	cis	rs9549367	0.713	rs2476328	chr13:113829350	C/T	cg00898013	chr13:113819073	PROZ	0.5	7.22	0.41	5.61e-12	Platelet distribution width;
CESC	cis	rs9488822	0.702	rs10872141	chr6:116323246	C/A	cg15226275	chr6:116381976	FRK	0.25	6.22	0.36	1.94e-9	Cholesterol, total;LDL cholesterol;
CESC	cis	rs798766	1.000	rs798767	chr4:1734281	A/G	cg10756475	chr4:1757242	NA	0.45	5.81	0.34	1.82e-8	Bladder cancer;Urinary bladder cancer;
CESC	cis	rs7572263	0.724	rs6710543	chr2:209050447	G/A	cg23998903	chr2:209048830	C2orf80	-0.39	-5.14	-0.3	5.4e-7	Glioma;Non-glioblastoma glioma;
CESC	trans	rs1003719	0.715	rs762139	chr21:38568475	A/T	cg00630453	chr20:2821369	FAM113A;VPS16	-0.44	-6.18	-0.35	2.45e-9	Eye color traits;
CESC	cis	rs9902453	0.845	rs7222842	chr17:28246943	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.65	8.2	0.45	1.04e-14	Coffee consumption (cups per day);
CESC	cis	rs10191773	0.589	rs11691239	chr2:112950600	A/C	cg24977338	chr2:113188963	RGPD8;RGPD5	0.65	6.77	0.38	8.03e-11	Yeast infection;
CESC	cis	rs9322193	0.884	rs10782312	chr6:149943805	G/T	cg13206674	chr6:150067644	NUP43	0.43	6.27	0.36	1.44e-9	Lung cancer;
CESC	cis	rs11098499	0.955	rs7684942	chr4:120162201	C/T	cg09307838	chr4:120376055	NA	0.86	11.44	0.58	6.63e-25	Corneal astigmatism;
CESC	cis	rs4665809	0.590	rs6749046	chr2:26429451	C/G	cg26314531	chr2:26401878	FAM59B	0.83	9.05	0.49	3.21e-17	Gut microbiome composition (summer);
CESC	cis	rs801193	0.904	rs4718403	chr7:66242729	C/G	cg25985355	chr7:65971099	NA	-0.31	-5.14	-0.3	5.25e-7	Aortic root size;
CESC	cis	rs3750965	1.000	rs7937006	chr11:68843932	C/T	cg01403660	chr11:68851641	TPCN2	0.42	5.49	0.32	9.39e-8	Hair color;
CESC	cis	rs9796	0.689	rs9888718	chr15:41446254	T/G	cg12426344	chr15:41135900	SPINT1	-0.24	-5.31	-0.31	2.32e-7	Menopause (age at onset);
CESC	trans	rs2727020	0.521	rs7930855	chr11:49521660	C/T	cg15704280	chr7:45808275	SEPT13	0.82	9.96	0.52	4.58e-20	Coronary artery disease;
CESC	cis	rs79976124	0.800	rs10944857	chr6:66637078	C/T	cg07460842	chr6:66804631	NA	0.68	7.86	0.44	9.39e-14	Type 2 diabetes;
CESC	cis	rs8072100	0.817	rs9912101	chr17:45547078	A/G	cg08085267	chr17:45401833	C17orf57	-0.58	-7.72	-0.43	2.36e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs9583531	0.600	rs4773240	chr13:111360585	G/A	cg15841412	chr13:111365552	ING1	0.52	6.74	0.38	1.01e-10	Coronary artery disease;
CESC	cis	rs4972806	0.849	rs1542180	chr2:177028767	C/T	cg13092806	chr2:177043255	NA	0.47	7.05	0.4	1.55e-11	IgG glycosylation;
CESC	cis	rs933688	1.000	rs12188467	chr5:90765632	A/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.04	13.57	0.64	3.29e-32	Smoking behavior;
CESC	cis	rs9583531	0.657	rs9521915	chr13:111384528	C/T	cg24331049	chr13:111365604	ING1	0.72	10.24	0.53	5.77e-21	Coronary artery disease;
CESC	cis	rs514406	0.825	rs6588441	chr1:53223494	G/A	cg08736216	chr1:53307985	ZYG11A	0.42	7.11	0.4	1.06e-11	Monocyte count;
CESC	cis	rs916888	0.773	rs199448	chr17:44809001	A/G	cg17911788	chr17:44343683	NA	-0.6	-8.07	-0.44	2.39e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs4642101	0.765	rs9872103	chr3:12827452	G/T	cg24848339	chr3:12840334	CAND2	0.35	5.37	0.31	1.73e-7	QRS complex (12-leadsum);
CESC	cis	rs7208859	0.673	rs12949860	chr17:29223032	A/G	cg19761014	chr17:28927070	LRRC37B2	0.63	5.29	0.31	2.56e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs10504229	1.000	rs67243305	chr8:58174958	G/A	cg05313129	chr8:58192883	C8orf71	-0.55	-6.33	-0.36	1.04e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs875971	0.522	rs1880556	chr7:65432544	T/C	cg18876405	chr7:65276391	NA	0.72	9.87	0.52	9.33e-20	Aortic root size;
CESC	cis	rs3733585	0.605	rs4697926	chr4:10124567	G/T	cg05927159	chr4:10118984	WDR1	-0.36	-5.25	-0.31	3.1e-7	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs597539	0.654	rs619727	chr11:68627535	A/G	cg01988459	chr11:68622903	NA	-0.41	-5.34	-0.31	2.05e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs898097	0.627	rs3785514	chr17:80888905	A/G	cg05255149	chr17:80675120	FN3KRP	0.47	5.46	0.32	1.09e-7	Breast cancer;
CESC	cis	rs3020736	0.500	rs6002623	chr22:42513761	G/A	cg15557168	chr22:42548783	NA	0.45	6.51	0.37	3.78e-10	Autism spectrum disorder or schizophrenia;
CESC	cis	rs4888262	0.545	rs8050624	chr16:74686690	A/G	cg01733217	chr16:74700730	RFWD3	-0.92	-12.53	-0.61	1.35e-28	Testicular germ cell tumor;
CESC	cis	rs10256972	0.900	rs7812072	chr7:1053862	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.43	-5.38	-0.31	1.67e-7	Longevity;Endometriosis;
CESC	cis	rs977987	0.778	rs7203157	chr16:75417920	T/C	cg03315344	chr16:75512273	CHST6	0.4	5.72	0.33	2.93e-8	Dupuytren's disease;
CESC	cis	rs910316	0.967	rs175451	chr14:75589729	C/T	cg08847533	chr14:75593920	NEK9	-0.95	-17.75	-0.74	5.29e-47	Height;
CESC	cis	rs7640424	0.721	rs326356	chr3:107824563	C/T	cg09227934	chr3:107805635	CD47	-0.38	-5.35	-0.31	1.87e-7	Body mass index;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg08128925	chr19:11141458	SMARCA4	0.43	6.29	0.36	1.33e-9	Fibrinogen levels;
CESC	cis	rs3741404	0.609	rs641430	chr11:63869531	C/T	cg18225595	chr11:63971243	STIP1	-0.5	-6.59	-0.38	2.31e-10	Platelet count;
CESC	cis	rs9399137	0.507	rs13209780	chr6:135344795	G/C	cg22676075	chr6:135203613	NA	0.53	7.22	0.41	5.6e-12	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	cis	rs780096	0.526	rs7602534	chr2:27592423	C/T	cg12648201	chr2:27665141	KRTCAP3	-0.35	-6.39	-0.37	7.54e-10	Total body bone mineral density;
CESC	cis	rs4629710	0.592	rs1885641	chr6:131553986	A/G	cg12606694	chr6:131520996	AKAP7	0.49	6.04	0.35	5.19e-9	Multiple myeloma (IgH translocation);
CESC	cis	rs7945705	0.783	rs11042125	chr11:8938049	A/T	cg09997546	chr11:8931473	C11orf17;ST5	-0.39	-6.41	-0.37	6.76e-10	Hemoglobin concentration;
CESC	trans	rs2755237	0.519	rs80070740	chr13:41137784	G/A	cg02923264	chr22:30901647	SEC14L4	0.75	6.16	0.35	2.66e-9	Central corneal thickness;
CESC	cis	rs4835473	0.897	rs35599924	chr4:144901755	T/C	cg25736465	chr4:144833511	NA	0.41	6.2	0.36	2.14e-9	Immature fraction of reticulocytes;
CESC	cis	rs7107174	1.000	rs58235466	chr11:78030886	T/C	cg02023728	chr11:77925099	USP35	0.38	5.52	0.32	8.09e-8	Testicular germ cell tumor;
CESC	cis	rs2115536	0.640	rs934134	chr15:80168218	T/C	cg11839771	chr15:80205821	ST20	-0.39	-5.65	-0.33	4.16e-8	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CESC	cis	rs1670533	0.932	rs4690214	chr4:1054636	T/C	cg27284194	chr4:1044797	NA	0.46	5.85	0.34	1.42e-8	Recombination rate (females);
CESC	cis	rs7246657	1.000	rs8110011	chr19:37745813	G/T	cg23950597	chr19:37808831	NA	-0.61	-6.37	-0.36	8.38e-10	Coronary artery calcification;
CESC	cis	rs1568889	0.838	rs10767708	chr11:28294847	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.79	13.65	0.64	1.68e-32	Bipolar disorder;
CESC	cis	rs1499972	0.887	rs1499970	chr3:117692767	G/A	cg07612923	chr3:117604196	NA	-0.86	-7.23	-0.41	5.17e-12	Schizophrenia;
CESC	cis	rs10504229	0.593	rs17794451	chr8:58019217	C/T	cg24829409	chr8:58192753	C8orf71	-0.67	-7.32	-0.41	3e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs6912958	0.500	rs4707352	chr6:87929705	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.5	-8.41	-0.46	2.54e-15	Monocyte percentage of white cells;
CESC	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg24503407	chr1:205819492	PM20D1	0.47	6.9	0.39	3.81e-11	Menarche (age at onset);
CESC	cis	rs9916302	0.904	rs2338755	chr17:37419317	C/T	cg15445000	chr17:37608096	MED1	-0.4	-6.69	-0.38	1.3e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs854765	0.583	rs9913724	chr17:17819101	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.56	7.99	0.44	4.08e-14	Total body bone mineral density;
CESC	cis	rs8031584	0.781	rs4779498	chr15:31177476	C/T	cg08109568	chr15:31115862	NA	-0.6	-8.04	-0.44	3.01e-14	Huntington's disease progression;
CESC	cis	rs60843830	1.000	rs3791223	chr2:222336	T/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.87	11.47	0.58	5.31e-25	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs67478160	0.595	rs8022783	chr14:104245573	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.52	-7.18	-0.4	7.16e-12	Schizophrenia;
CESC	cis	rs10927875	1.000	rs4307563	chr1:16313788	C/T	cg22431228	chr1:16359049	CLCNKA	0.37	5.73	0.33	2.68e-8	Dilated cardiomyopathy;
CESC	cis	rs7635838	0.523	rs9873503	chr3:11396100	T/C	cg00170343	chr3:11313890	ATG7	0.47	6.56	0.37	2.77e-10	HDL cholesterol;
CESC	cis	rs17431357	1.000	rs73230306	chr12:120985336	A/G	cg25045489	chr12:120971538	RNF10	-0.93	-5.46	-0.32	1.1e-7	Insulin resistance/response;
CESC	cis	rs2075371	0.966	rs2244690	chr7:133987039	A/G	cg00033643	chr7:134001901	SLC35B4	0.44	5.6	0.33	5.4e-8	Mean platelet volume;
CESC	cis	rs9796	0.576	rs13329511	chr15:41299121	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.59	-8.23	-0.45	8.42e-15	Menopause (age at onset);
CESC	cis	rs736408	0.634	rs11717836	chr3:52807736	A/G	cg07507251	chr3:52567010	NT5DC2	0.44	7.42	0.41	1.62e-12	Bipolar disorder;
CESC	cis	rs35306767	0.903	rs7914758	chr10:891702	T/C	cg26597838	chr10:835615	NA	1.18	11.37	0.57	1.12e-24	Eosinophil percentage of granulocytes;
CESC	cis	rs7089973	0.604	rs1924034	chr10:116578539	C/T	cg23260525	chr10:116636907	FAM160B1	0.39	7.37	0.41	2.14e-12	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs76878669	0.519	rs10791869	chr11:66117113	C/T	cg18002602	chr11:66138449	SLC29A2	-0.42	-6.96	-0.39	2.67e-11	Educational attainment (years of education);
CESC	cis	rs12479064	0.724	rs10496336	chr2:99996165	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.66	-7.81	-0.43	1.3e-13	Chronic sinus infection;
CESC	cis	rs875971	0.660	rs10281080	chr7:66042441	T/C	cg18876405	chr7:65276391	NA	-0.59	-7.9	-0.44	7.25e-14	Aortic root size;
CESC	cis	rs910316	0.967	rs119076	chr14:75572419	G/T	cg08847533	chr14:75593920	NEK9	-0.95	-17.87	-0.74	2.07e-47	Height;
CESC	cis	rs950776	0.714	rs660652	chr15:78887832	A/G	cg06917634	chr15:78832804	PSMA4	-0.52	-6.21	-0.36	2.09e-9	Sudden cardiac arrest;
CESC	cis	rs909002	0.925	rs4949455	chr1:32114793	C/T	cg13919466	chr1:32135498	COL16A1	-0.47	-8.34	-0.46	4e-15	Intelligence (multi-trait analysis);
CESC	cis	rs4076764	1.000	rs7525643	chr1:163426283	G/A	cg24596788	chr1:163392923	NA	-0.47	-6.87	-0.39	4.47e-11	Motion sickness;
CESC	cis	rs9323205	1.000	rs12589519	chr14:51596684	C/G	cg23942311	chr14:51606299	NA	-0.47	-5.97	-0.34	7.59e-9	Cancer;
CESC	cis	rs4843747	0.671	rs13334603	chr16:88116016	T/C	cg17633681	chr16:88106987	BANP	0.74	9.91	0.52	7e-20	Menopause (age at onset);
CESC	cis	rs2932538	0.961	rs4838960	chr1:113163632	G/T	cg22162597	chr1:113214053	CAPZA1	-0.49	-6.48	-0.37	4.57e-10	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CESC	trans	rs7615952	0.641	rs12488180	chr3:125782236	C/T	cg07211511	chr3:129823064	LOC729375	-0.57	-6.73	-0.38	1.03e-10	Blood pressure (smoking interaction);
CESC	cis	rs12497850	0.931	rs7621015	chr3:49016056	A/G	cg06212747	chr3:49208901	KLHDC8B	0.73	9.9	0.52	7e-20	Parkinson's disease;
CESC	cis	rs12911832	1.000	rs4774310	chr15:58985164	T/G	cg05156742	chr15:59063176	FAM63B	0.5	6.02	0.35	5.84e-9	Schizophrenia;
CESC	cis	rs7605827	0.866	rs2287275	chr2:15658828	C/T	cg19274914	chr2:15703543	NA	0.37	6.65	0.38	1.65e-10	Educational attainment (years of education);
CESC	cis	rs2066819	1.000	rs117779516	chr12:56750872	G/C	cg26734620	chr12:56694298	CS	0.98	5.68	0.33	3.49e-8	Psoriasis vulgaris;
CESC	trans	rs11039798	0.588	rs11039782	chr11:48524785	A/G	cg15704280	chr7:45808275	SEPT13	0.65	6.56	0.37	2.84e-10	Axial length;
CESC	cis	rs11209002	0.524	rs982131	chr1:67542360	T/C	cg02640540	chr1:67518911	SLC35D1	0.47	5.31	0.31	2.28e-7	Crohn's disease;
CESC	cis	rs4665809	0.878	rs892448	chr2:26366205	A/G	cg25036284	chr2:26402008	FAM59B	-0.64	-7.54	-0.42	7.71e-13	Gut microbiome composition (summer);
CESC	cis	rs6546550	0.901	rs6729760	chr2:70161032	C/T	cg02498382	chr2:70120550	SNRNP27	-0.42	-7.29	-0.41	3.58e-12	Prevalent atrial fibrillation;
CESC	cis	rs2836974	0.555	rs35909862	chr21:40621158	G/A	cg11890956	chr21:40555474	PSMG1	-0.98	-16.19	-0.71	1.87e-41	Cognitive function;
CESC	cis	rs736408	0.609	rs13082208	chr3:52781539	T/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	6.81	0.39	6.36e-11	Bipolar disorder;
CESC	cis	rs2479724	0.818	rs9357369	chr6:41818202	A/C	cg17623882	chr6:41773611	USP49	-0.41	-6.04	-0.35	5.2e-9	Menarche (age at onset);
CESC	cis	rs6484504	0.532	rs11031330	chr11:31275073	G/A	cg14844989	chr11:31128820	NA	-0.37	-5.27	-0.31	2.89e-7	Red blood cell count;
CESC	cis	rs6813479	0.523	rs2926564	chr4:137744172	C/T	cg16185213	chr4:137733633	NA	0.37	5.05	0.3	8.19e-7	Longevity;
CESC	cis	rs12900413	0.687	rs62023459	chr15:90308231	A/T	cg24249390	chr15:90295951	MESP1	-0.39	-5.47	-0.32	1.03e-7	Coronary artery aneurysm in Kawasaki disease;
CESC	cis	rs5743618	0.537	rs11096957	chr4:38776491	A/C	cg02016764	chr4:38805732	TLR1	-0.33	-5.11	-0.3	6.31e-7	Asthma;Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs1008375	1.000	rs6846238	chr4:17629939	A/G	cg04450456	chr4:17643702	FAM184B	0.4	5.78	0.33	2.13e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs67311347	0.544	rs13062243	chr3:40336789	G/A	cg09455208	chr3:40491958	NA	0.37	6.51	0.37	3.82e-10	Renal cell carcinoma;
CESC	cis	rs9300255	0.602	rs1727294	chr12:123616514	A/G	cg19016782	chr12:123741754	C12orf65	-0.4	-5.6	-0.33	5.32e-8	Neutrophil percentage of white cells;
CESC	cis	rs10779751	0.770	rs1057079	chr1:11205058	A/G	cg08854313	chr1:11322531	MTOR	-0.82	-11.67	-0.58	1.18e-25	Body mass index;
CESC	cis	rs12575642	0.660	rs58632573	chr11:63896299	C/T	cg04317338	chr11:64019027	PLCB3	0.86	8.93	0.48	7.13e-17	Attention deficit hyperactivity disorder;
CESC	cis	rs1546924	0.669	rs197439	chr1:112280990	A/G	cg23955903	chr1:112298873	DDX20;C1orf183	0.39	5.11	0.3	6.04e-7	Body mass index;
CESC	cis	rs2836974	0.796	rs77153312	chr21:40695499	G/A	cg11890956	chr21:40555474	PSMG1	1.13	19.51	0.77	3.69e-53	Cognitive function;
CESC	cis	rs2836974	0.644	rs2410123	chr21:40700093	C/T	cg22974920	chr21:40686053	BRWD1	-0.42	-5.21	-0.3	3.84e-7	Cognitive function;
CESC	cis	rs7845219	0.525	rs3019175	chr8:95949013	G/A	cg09323728	chr8:95962352	TP53INP1	-0.3	-5.7	-0.33	3.21e-8	Type 2 diabetes;
CESC	cis	rs2425143	0.915	rs6060597	chr20:34370100	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	-0.72	-6.67	-0.38	1.52e-10	Blood protein levels;
CESC	cis	rs6754311	0.509	rs12616520	chr2:136516748	A/T	cg07169764	chr2:136633963	MCM6	-0.73	-9.25	-0.49	7.59e-18	Mosquito bite size;
CESC	cis	rs10479542	1.000	rs10479542	chr5:178981241	T/A	cg05457628	chr5:178986728	RUFY1	0.51	7.68	0.43	3.09e-13	Lung cancer;
CESC	cis	rs1163251	0.869	rs629735	chr1:120206932	G/T	cg19096424	chr1:120255104	PHGDH	-0.42	-5.05	-0.3	8.42e-7	Blood metabolite levels;
CESC	cis	rs10129255	1.000	rs10134517	chr14:107173745	T/C	cg23076370	chr14:107095027	NA	-0.43	-5.28	-0.31	2.64e-7	Kawasaki disease;
CESC	cis	rs17376456	0.825	rs10078941	chr5:93279029	C/T	cg21475434	chr5:93447410	FAM172A	0.74	6.16	0.35	2.7e-9	Diabetic retinopathy;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg25345767	chr1:226070210	TMEM63A	-0.4	-6.0	-0.35	6.38e-9	Gambling;
CESC	cis	rs4253772	0.592	rs1807600	chr22:46644640	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.58	6.81	0.39	6.68e-11	LDL cholesterol;Cholesterol, total;
CESC	cis	rs208520	0.955	rs28684412	chr6:66979430	A/C	cg07460842	chr6:66804631	NA	0.88	10.14	0.53	1.22e-20	Exhaled nitric oxide output;
CESC	cis	rs10949834	0.824	rs13236108	chr7:73521113	A/G	cg07137043	chr7:73588983	EIF4H	-0.65	-5.72	-0.33	2.92e-8	Verbal memory performance (residualized delayed recall change);
CESC	cis	rs3741404	0.757	rs2282492	chr11:63918589	A/G	cg18225595	chr11:63971243	STIP1	0.67	9.15	0.49	1.57e-17	Platelet count;
CESC	cis	rs57221529	0.766	rs12522140	chr5:587261	C/A	cg16447950	chr5:562315	NA	-0.62	-6.52	-0.37	3.51e-10	Lung disease severity in cystic fibrosis;
CESC	cis	rs1862618	0.802	rs42769	chr5:56144152	G/A	cg03609598	chr5:56110824	MAP3K1	-0.51	-5.54	-0.32	7.13e-8	Initial pursuit acceleration;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03990588	chr2:85826175	TMEM150A	-0.51	-6.03	-0.35	5.56e-9	Gut microbiome composition (summer);
CESC	cis	rs3892630	0.878	rs1559177	chr19:33210646	A/G	cg13157960	chr19:33183277	NUDT19	0.55	5.03	0.3	9e-7	Red blood cell traits;
CESC	cis	rs4654899	0.865	rs12410467	chr1:21356055	G/A	cg05370193	chr1:21551575	ECE1	0.43	6.22	0.36	1.97e-9	Superior frontal gyrus grey matter volume;
CESC	cis	rs7845219	0.525	rs10956931	chr8:95930301	A/G	cg13393036	chr8:95962371	TP53INP1	-0.38	-6.99	-0.39	2.28e-11	Type 2 diabetes;
CESC	cis	rs769267	0.929	rs2965180	chr19:19491973	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	-0.49	-6.19	-0.36	2.33e-9	Tonsillectomy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07705912	chr1:154155363	TPM3	0.59	6.61	0.38	2.13e-10	Gut microbiome composition (summer);
CESC	trans	rs1728785	1.000	rs864741	chr16:68576577	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.61	7.49	0.42	1.04e-12	Ulcerative colitis;
CESC	cis	rs8018808	0.875	rs176781	chr14:77887681	C/T	cg20045696	chr14:77926864	AHSA1	0.42	5.84	0.34	1.56e-8	Myeloid white cell count;
CESC	cis	rs3785574	0.962	rs2584614	chr17:61929445	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.79	10.48	0.54	1.01e-21	Height;
CESC	cis	rs3015497	0.646	rs3015492	chr14:51124743	G/A	cg26011998	chr14:51135199	SAV1	-0.59	-6.86	-0.39	4.75e-11	Mean platelet volume;
CESC	trans	rs10411161	0.702	rs10424202	chr19:52387297	G/A	cg22319618	chr22:45562946	NUP50	-0.73	-7.14	-0.4	8.9e-12	Breast cancer;
CESC	cis	rs12618769	0.597	rs4851133	chr2:99050519	T/C	cg10123293	chr2:99228465	UNC50	0.41	5.42	0.32	1.31e-7	Bipolar disorder;
CESC	cis	rs3738443	0.645	rs55768801	chr1:247362990	G/A	cg07706540	chr1:247373924	NA	-0.46	-5.45	-0.32	1.15e-7	Alcohol dependence;
CESC	cis	rs4819052	0.851	rs35064782	chr21:46674360	G/A	cg11663144	chr21:46675770	NA	-0.62	-9.59	-0.51	6.96e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs7666738	0.830	rs6811940	chr4:98777898	G/A	cg05340658	chr4:99064831	C4orf37	0.77	11.6	0.58	2.01e-25	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6432018	0.964	rs3791748	chr2:9729815	C/G	cg23886495	chr2:9695866	ADAM17	0.43	5.08	0.3	7.05e-7	Heart rate variability traits;
CESC	cis	rs12079745	0.793	rs12074492	chr1:169215363	C/G	cg09363564	chr1:169337483	NME7;BLZF1	-1.01	-6.28	-0.36	1.36e-9	QT interval;
CESC	cis	rs798554	0.836	rs2260230	chr7:2822986	T/A	cg13628971	chr7:2884303	GNA12	0.61	7.71	0.43	2.56e-13	Height;
CESC	trans	rs1814175	0.781	rs1851872	chr11:50009770	A/G	cg15704280	chr7:45808275	SEPT13	-1.04	-21.07	-0.79	1.43e-58	Height;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg23434193	chr8:74884752	TCEB1	-0.43	-6.14	-0.35	3.03e-9	Gambling;
CESC	cis	rs7680126	0.633	rs2868937	chr4:10303081	C/T	cg11266682	chr4:10021025	SLC2A9	-0.45	-5.92	-0.34	9.91e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	cis	rs6860806	0.507	rs272878	chr5:131671769	C/T	cg18758796	chr5:131593413	PDLIM4	-0.38	-5.11	-0.3	6.09e-7	Breast cancer;
CESC	cis	rs6429082	0.521	rs291390	chr1:235649678	T/C	cg26050004	chr1:235667680	B3GALNT2	0.82	12.75	0.62	2.28e-29	Adiposity;
CESC	cis	rs6912958	0.712	rs9444526	chr6:88326402	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.5	-6.74	-0.38	1e-10	Monocyte percentage of white cells;
CESC	cis	rs922692	0.773	rs2869861	chr15:79076744	A/G	cg04896959	chr15:78267971	NA	0.35	5.1	0.3	6.61e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
CESC	cis	rs60843830	1.000	rs2126129	chr2:212548	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.74	9.31	0.5	5.15e-18	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs9311474	1.000	rs7614727	chr3:52295895	C/T	cg17372223	chr3:52568218	NT5DC2	0.37	5.78	0.33	2.09e-8	Electroencephalogram traits;
CESC	cis	rs155076	1.000	rs261369	chr13:21868420	C/A	cg11317459	chr13:21872234	NA	-1.09	-12.3	-0.6	8.03e-28	White matter hyperintensity burden;
CESC	cis	rs524023	0.914	rs2360873	chr11:64391157	G/C	cg07220939	chr11:64358617	SLC22A12	-0.36	-5.45	-0.32	1.17e-7	Urate levels in obese individuals;
CESC	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg06873352	chr17:61820015	STRADA	0.72	12.74	0.62	2.58e-29	Prudent dietary pattern;
CESC	cis	rs9948	1.000	rs62152790	chr2:97478579	G/A	cg01990225	chr2:97406019	LMAN2L	-0.82	-5.83	-0.34	1.61e-8	Erectile dysfunction and prostate cancer treatment;
CESC	cis	rs3820928	0.605	rs4675124	chr2:227802354	G/A	cg11843606	chr2:227700838	RHBDD1	-0.55	-7.81	-0.43	1.34e-13	Pulmonary function;
CESC	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg04025307	chr7:1156635	C7orf50	0.48	7.76	0.43	1.89e-13	Longevity;Endometriosis;
CESC	cis	rs12477438	0.520	rs7572660	chr2:99788582	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.85	15.72	0.69	8.39e-40	Chronic sinus infection;
CESC	cis	rs3126085	0.515	rs11204984	chr1:152331987	T/C	cg03465714	chr1:152285911	FLG	0.4	5.2	0.3	3.93e-7	Atopic dermatitis;
CESC	cis	rs2952156	0.876	rs903501	chr17:37839493	T/C	cg00129232	chr17:37814104	STARD3	-0.76	-10.17	-0.53	9.96e-21	Asthma;
CESC	cis	rs7385804	0.796	rs10277087	chr7:100307538	C/G	cg16850897	chr7:100343110	ZAN	0.5	6.95	0.39	2.8e-11	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
CESC	cis	rs10870270	1.000	rs10430617	chr10:133748889	T/C	cg17892150	chr10:133769511	PPP2R2D	-0.86	-12.58	-0.61	9.08e-29	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs9926296	0.533	rs7190823	chr16:89866043	A/G	cg21285383	chr16:89894308	SPIRE2	0.29	5.27	0.31	2.87e-7	Vitiligo;
CESC	cis	rs6540559	0.546	rs735693	chr1:210033988	A/C	cg25204440	chr1:209979598	IRF6	0.58	5.67	0.33	3.77e-8	Cleft lip with or without cleft palate;
CESC	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	7.64	0.42	4.1e-13	Prudent dietary pattern;
CESC	cis	rs6088813	0.890	rs6088817	chr20:33984976	T/C	cg14752227	chr20:34000481	UQCC	-0.4	-5.09	-0.3	6.76e-7	Height;
CESC	cis	rs2228479	0.850	rs11644213	chr16:89837367	C/T	cg06558623	chr16:89946397	TCF25	-1.07	-9.01	-0.48	4.32e-17	Skin colour saturation;
CESC	cis	rs6598955	0.671	rs11247884	chr1:26577338	C/T	cg19743891	chr1:26644573	UBXN11;CD52	0.37	5.19	0.3	4.16e-7	Obesity-related traits;
CESC	cis	rs3820068	0.608	rs10927836	chr1:16034368	G/C	cg13390004	chr1:15929781	NA	0.33	5.13	0.3	5.64e-7	Systolic blood pressure;
CESC	cis	rs67311347	0.544	rs6599088	chr3:40329288	T/C	cg09455208	chr3:40491958	NA	0.35	6.24	0.36	1.68e-9	Renal cell carcinoma;
CESC	trans	rs7824557	0.583	rs2263511	chr8:11233318	A/C	cg06636001	chr8:8085503	FLJ10661	-0.49	-6.15	-0.35	2.78e-9	Retinal vascular caliber;
CESC	cis	rs2040771	0.804	rs2073754	chr22:19221406	G/T	cg17887427	chr22:19166691	SLC25A1	0.41	5.36	0.31	1.8e-7	Metabolite levels (small molecules and protein measures);
CESC	cis	rs2842992	0.724	rs9347340	chr6:160188891	C/T	cg11366901	chr6:160182831	ACAT2	-0.59	-7.71	-0.43	2.53e-13	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs2191566	0.576	rs402785	chr19:44492236	T/G	cg20607764	chr19:44506953	ZNF230	0.44	5.57	0.32	6.29e-8	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs9916302	0.904	rs9892055	chr17:37510402	C/T	cg07936489	chr17:37558343	FBXL20	0.81	11.81	0.59	3.83e-26	Glomerular filtration rate (creatinine);
CESC	cis	rs9926296	0.581	rs2108838	chr16:89904426	A/G	cg04287289	chr16:89883240	FANCA	0.69	9.04	0.49	3.44e-17	Vitiligo;
CESC	cis	rs5753618	0.539	rs737888	chr22:31611549	A/G	cg13145458	chr22:31556086	RNF185	0.48	5.4	0.31	1.51e-7	Colorectal cancer;
CESC	cis	rs6594499	0.542	rs4530809	chr5:110462230	A/G	cg04022379	chr5:110408740	TSLP	0.42	6.9	0.39	3.76e-11	Allergic disease (asthma, hay fever or eczema);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18800192	chr19:42388471	ARHGEF1	0.5	6.21	0.36	2.01e-9	Gut microbiome composition (summer);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg26678852	chr1:68297929	GNG12	-0.51	-6.38	-0.36	7.72e-10	Ulcerative colitis;
CESC	cis	rs7666738	0.830	rs7687315	chr4:98900613	A/G	cg03676636	chr4:99064102	C4orf37	0.34	5.09	0.3	6.9e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs10242455	0.702	rs17854665	chr7:99050039	G/A	cg09045935	chr12:6379348	NA	0.91	7.3	0.41	3.34e-12	Blood metabolite levels;
CESC	cis	rs4713118	0.586	rs9468290	chr6:28087674	C/T	cg23281280	chr6:28129359	ZNF389	0.58	7.93	0.44	6.31e-14	Parkinson's disease;
CESC	cis	rs7395581	0.918	rs10501321	chr11:47294626	A/G	cg25783544	chr11:47291846	MADD	0.58	7.58	0.42	5.8e-13	HDL cholesterol;
CESC	cis	rs780096	0.565	rs8179252	chr2:27746832	A/C	cg24768116	chr2:27665128	KRTCAP3	-0.31	-5.9	-0.34	1.12e-8	Total body bone mineral density;
CESC	cis	rs896854	0.654	rs4735340	chr8:95976251	A/T	cg09323728	chr8:95962352	TP53INP1	-0.4	-8.68	-0.47	4.05e-16	Type 2 diabetes;
CESC	cis	rs4948102	0.667	rs7811270	chr7:56139990	A/G	cg09872392	chr7:56161020	PHKG1	-0.44	-7.22	-0.41	5.57e-12	Plasma homocysteine levels (post-methionine load test);
CESC	cis	rs2637266	0.597	rs846622	chr10:78543005	G/A	cg18941641	chr10:78392320	NA	0.41	7.76	0.43	1.81e-13	Pulmonary function;
CESC	cis	rs34779708	0.931	rs7084196	chr10:35367161	T/C	cg04310649	chr10:35416472	CREM	-0.52	-6.4	-0.37	7.03e-10	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs1451375	0.756	rs11761683	chr7:50542879	C/T	cg14593290	chr7:50529359	DDC	-0.4	-5.25	-0.31	3.15e-7	Malaria;
CESC	cis	rs9393777	0.588	rs6456728	chr6:26477779	G/A	cg12826209	chr6:26865740	GUSBL1	0.56	6.5	0.37	3.92e-10	Intelligence (multi-trait analysis);
CESC	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg06873352	chr17:61820015	STRADA	0.72	12.51	0.61	1.53e-28	Prudent dietary pattern;
CESC	cis	rs2380220	0.810	rs66524640	chr6:95956566	T/C	cg15832292	chr6:96025679	MANEA	-0.64	-5.66	-0.33	3.83e-8	Behavioural disinhibition (generation interaction);
CESC	cis	rs4268898	0.722	rs10445893	chr2:24407128	A/G	cg06627628	chr2:24431161	ITSN2	0.54	7.29	0.41	3.54e-12	Asthma;
CESC	cis	rs8018808	0.870	rs11159264	chr14:77937017	T/C	cg20045696	chr14:77926864	AHSA1	0.47	6.65	0.38	1.7e-10	Myeloid white cell count;
CESC	cis	rs72627123	0.867	rs8018226	chr14:74471377	C/T	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.8	5.77	0.33	2.2e-8	Morning vs. evening chronotype;
CESC	cis	rs7223966	1.000	rs55868506	chr17:61851686	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.73	0.38	1.06e-10	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs854765	0.583	rs8065563	chr17:17782404	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.55	7.51	0.42	9.05e-13	Total body bone mineral density;
CESC	cis	rs6835098	0.509	rs2332655	chr4:174093002	A/G	cg08422745	chr4:174089978	GALNT7	0.55	7.36	0.41	2.26e-12	Dementia and core Alzheimer's disease neuropathologic changes;
CESC	cis	rs61776719	0.875	rs10890238	chr1:38445654	A/T	cg12658694	chr1:38397304	INPP5B	0.79	12.32	0.6	6.98e-28	Coronary artery disease;
CESC	cis	rs736408	0.609	rs13087772	chr3:52782274	T/G	cg18099408	chr3:52552593	STAB1	-0.32	-5.24	-0.31	3.23e-7	Bipolar disorder;
CESC	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg09177884	chr7:1199841	ZFAND2A	-0.51	-6.6	-0.38	2.17e-10	Longevity;Endometriosis;
CESC	cis	rs1707322	1.000	rs4660903	chr1:46457601	A/G	cg06784218	chr1:46089804	CCDC17	0.33	5.63	0.33	4.7e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2276314	1.000	rs1789513	chr18:33545630	A/G	cg19628046	chr18:33552617	C18orf21	-0.59	-6.64	-0.38	1.8e-10	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs2777491	1.000	rs2777491	chr15:41735710	T/G	cg20272979	chr15:41787780	ITPKA	0.45	6.71	0.38	1.15e-10	Ulcerative colitis;
CESC	cis	rs7208859	0.623	rs73271869	chr17:29152221	G/A	cg19761014	chr17:28927070	LRRC37B2	0.74	6.03	0.35	5.43e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs9916302	0.808	rs6503515	chr17:37606433	G/T	cg07936489	chr17:37558343	FBXL20	-0.81	-11.96	-0.59	1.17e-26	Glomerular filtration rate (creatinine);
CESC	trans	rs12356475	0.710	rs10822686	chr10:67733250	C/T	cg10361922	chr17:40925790	VPS25	0.51	6.44	0.37	5.71e-10	Psoriatic arthritis;
CESC	cis	rs1950626	0.623	rs61991083	chr14:101436435	T/C	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.69	9.23	0.49	8.76e-18	Pelvic organ prolapse (moderate/severe);
CESC	cis	rs11853189	0.882	rs79052265	chr15:78556258	A/T	cg22935921	chr15:78556834	DNAJA4	0.61	5.1	0.3	6.35e-7	Red cell distribution width;
CESC	cis	rs514406	0.668	rs520281	chr1:53365235	G/C	cg06600287	chr1:53387719	ECHDC2	-0.31	-5.74	-0.33	2.64e-8	Monocyte count;
CESC	cis	rs709400	0.628	rs2273700	chr14:103923414	A/G	cg12935359	chr14:103987150	CKB	-0.57	-8.42	-0.46	2.46e-15	Body mass index;
CESC	cis	rs7666738	0.830	rs7679299	chr4:99057620	C/A	cg17366294	chr4:99064904	C4orf37	0.62	8.88	0.48	1.03e-16	Colonoscopy-negative controls vs population controls;
CESC	trans	rs916888	0.738	rs199515	chr17:44856641	C/G	cg22968622	chr17:43663579	NA	-1.16	-16.1	-0.7	3.81e-41	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs722599	0.748	rs741096	chr14:75351487	A/G	cg11812906	chr14:75593930	NEK9	-0.47	-5.68	-0.33	3.49e-8	IgG glycosylation;
CESC	cis	rs35110281	0.506	rs13051661	chr21:45111518	A/T	cg21573476	chr21:45109991	RRP1B	-0.59	-8.71	-0.47	3.25e-16	Mean corpuscular volume;
CESC	cis	rs7824557	0.602	rs35807737	chr8:11204411	C/G	cg21775007	chr8:11205619	TDH	0.58	8.94	0.48	6.84e-17	Retinal vascular caliber;
CESC	cis	rs11122272	0.735	rs2572263	chr1:231509408	C/T	cg06096015	chr1:231504339	EGLN1	0.43	6.18	0.35	2.46e-9	Hemoglobin concentration;
CESC	cis	rs4704187	0.687	rs6864485	chr5:74497984	T/C	cg03227963	chr5:74354835	NA	0.28	5.18	0.3	4.33e-7	Response to amphetamines;
CESC	cis	rs6912958	0.712	rs4587138	chr6:88356915	G/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-6.71	-0.38	1.19e-10	Monocyte percentage of white cells;
CESC	cis	rs709400	0.663	rs2273703	chr14:103918029	C/G	cg12935359	chr14:103987150	CKB	-0.51	-7.51	-0.42	9.15e-13	Body mass index;
CESC	cis	rs7666738	0.830	rs7696715	chr4:98938486	T/C	cg05340658	chr4:99064831	C4orf37	0.82	12.54	0.61	1.29e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4700695	0.719	rs36923	chr5:65464783	G/C	cg21114390	chr5:65439923	SFRS12	-0.49	-5.92	-0.34	9.86e-9	Facial morphology (factor 19);
CESC	cis	rs35110281	0.659	rs11702544	chr21:45091861	C/T	cg21573476	chr21:45109991	RRP1B	-0.54	-8.01	-0.44	3.73e-14	Mean corpuscular volume;
CESC	cis	rs12142240	0.698	rs6703374	chr1:46862332	C/G	cg00530320	chr1:46809349	NSUN4	0.6	8.27	0.45	6.54e-15	Menopause (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03008165	chr11:77024667	NA	-0.62	-7.31	-0.41	3.2e-12	Gut microbiome composition (summer);
CESC	cis	rs3820068	0.581	rs6692461	chr1:15928449	A/G	cg13390004	chr1:15929781	NA	0.34	5.45	0.32	1.13e-7	Systolic blood pressure;
CESC	cis	rs881375	0.678	rs2269060	chr9:123683569	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.46	6.7	0.38	1.24e-10	Rheumatoid arthritis;
CESC	cis	rs4665809	1.000	rs6546727	chr2:26275282	C/T	cg27170947	chr2:26402098	FAM59B	-0.59	-6.88	-0.39	4.18e-11	Gut microbiome composition (summer);
CESC	cis	rs367943	1.000	rs168365	chr5:112817984	G/A	cg12552261	chr5:112820674	MCC	-0.62	-7.78	-0.43	1.58e-13	Type 2 diabetes;
CESC	cis	rs524281	0.773	rs7925123	chr11:65993213	G/C	cg14036092	chr11:66035641	RAB1B	-0.53	-5.31	-0.31	2.38e-7	Electroencephalogram traits;
CESC	cis	rs1801251	1.000	rs778166	chr2:233664097	A/T	cg25237894	chr2:233734115	C2orf82	0.46	8.17	0.45	1.27e-14	Coronary artery disease;
CESC	cis	rs7937682	0.889	rs490199	chr11:111487890	A/G	cg22437258	chr11:111473054	SIK2	0.71	9.48	0.5	1.47e-18	Primary sclerosing cholangitis;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg08974500	chr6:170863287	PSMB1;TBP	0.48	6.74	0.38	9.75e-11	Systemic lupus erythematosus;
CESC	cis	rs4472734	1.000	rs4072973	chr1:214628635	A/C	cg00063699	chr1:214624242	PTPN14	-0.33	-5.08	-0.3	7.25e-7	Height;
CESC	cis	rs11871801	0.918	rs36005199	chr17:40597555	A/G	cg21433558	chr17:40837037	CNTNAP1	0.42	5.15	0.3	5.12e-7	Crohn's disease;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg24720361	chr12:57882021	MARS	-0.52	-7.25	-0.41	4.66e-12	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs1881797	1.000	rs12063141	chr1:247688343	G/A	cg05639522	chr1:247681581	NA	0.5	6.34	0.36	9.98e-10	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs6690583	0.697	rs4907126	chr1:85523453	C/T	cg22153463	chr1:85462885	MCOLN2	0.64	7.96	0.44	4.97e-14	Serum sulfate level;
CESC	cis	rs7264396	0.790	rs6060539	chr20:34239382	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.64	7.77	0.43	1.78e-13	Total cholesterol levels;
CESC	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	22.02	0.8	8.6e-62	Prudent dietary pattern;
CESC	cis	rs12824058	0.831	rs11060826	chr12:130809931	G/C	cg24838063	chr12:130822603	PIWIL1	0.62	8.55	0.47	9.78e-16	Menopause (age at onset);
CESC	cis	rs524281	0.861	rs7941431	chr11:65960157	C/T	cg14036092	chr11:66035641	RAB1B	-0.59	-6.18	-0.35	2.45e-9	Electroencephalogram traits;
CESC	cis	rs8141529	0.719	rs6005916	chr22:29233342	T/C	cg15103426	chr22:29168792	CCDC117	0.7	9.85	0.52	1.06e-19	Lymphocyte counts;
CESC	cis	rs710216	0.536	rs710221	chr1:43414200	G/A	cg03128534	chr1:43423976	SLC2A1	0.75	11.41	0.57	8.38e-25	Red cell distribution width;
CESC	cis	rs6951245	0.542	rs28460147	chr7:1217192	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.46	5.3	0.31	2.48e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs9611565	0.765	rs132920	chr22:41810170	T/C	cg06481639	chr22:41940642	POLR3H	0.62	6.52	0.37	3.49e-10	Vitiligo;
CESC	cis	rs736408	0.562	rs12497998	chr3:52793602	C/T	cg17372223	chr3:52568218	NT5DC2	0.41	6.07	0.35	4.45e-9	Bipolar disorder;
CESC	cis	rs2735413	0.750	rs60659587	chr16:78071554	G/T	cg04733911	chr16:78082701	NA	0.4	5.09	0.3	6.69e-7	Systolic blood pressure (alcohol consumption interaction);
CESC	cis	rs4642101	0.618	rs7612317	chr3:12820558	C/T	cg24848339	chr3:12840334	CAND2	0.38	6.02	0.35	5.8e-9	QRS complex (12-leadsum);
CESC	cis	rs2797160	1.000	rs1739354	chr6:126017808	G/C	cg05901451	chr6:126070800	HEY2	0.45	6.46	0.37	5e-10	Endometrial cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11559952	chr10:112064744	SMNDC1	0.54	6.38	0.36	8.02e-10	Gut microbiome composition (summer);
CESC	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg03452623	chr4:187889614	NA	-0.94	-18.76	-0.76	1.57e-50	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs9987353	0.840	rs329994	chr8:9123233	A/G	cg00214165	chr5:7869652	MTRR;FASTKD3	-0.48	-6.03	-0.35	5.51e-9	Recombination measurement;
CESC	cis	rs9457247	0.663	rs2237277	chr6:167442107	G/A	cg23791538	chr6:167370224	RNASET2	-0.57	-7.7	-0.43	2.7e-13	Crohn's disease;
CESC	cis	rs7267979	1.000	rs4815412	chr20:25350325	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.88	18.14	0.74	2.23e-48	Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04585227	chr7:158671570	WDR60	-0.58	-6.27	-0.36	1.49e-9	Gut microbiome composition (summer);
CESC	cis	rs919433	0.963	rs4850428	chr2:198169772	G/A	cg03934865	chr2:198174659	NA	-0.41	-5.65	-0.33	4.09e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs6456156	0.766	rs150112	chr6:167509878	C/T	cg07741184	chr6:167504864	NA	-0.35	-6.26	-0.36	1.55e-9	Primary biliary cholangitis;
CESC	cis	rs11690935	0.569	rs62183770	chr2:172838117	C/G	cg13550731	chr2:172543902	DYNC1I2	0.5	6.86	0.39	4.72e-11	Schizophrenia;
CESC	cis	rs9660992	0.573	rs7368327	chr1:205214792	C/T	cg21643547	chr1:205240462	TMCC2	-0.37	-5.12	-0.3	5.9e-7	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs28829049	0.508	rs4578242	chr1:19391565	G/C	cg22333259	chr1:19394757	NA	0.33	5.25	0.31	3.12e-7	QRS duration in Tripanosoma cruzi seropositivity;
CESC	cis	rs4076764	0.914	rs6704467	chr1:163364512	A/G	cg06092702	chr1:163392909	NA	-0.41	-6.1	-0.35	3.84e-9	Motion sickness;
CESC	cis	rs6860806	0.507	rs635619	chr5:131720265	G/A	cg24060327	chr5:131705240	SLC22A5	0.76	10.91	0.56	3.9699999999999997e-23	Breast cancer;
CESC	cis	rs7208859	0.573	rs73277960	chr17:29177441	T/C	cg19761014	chr17:28927070	LRRC37B2	0.62	5.24	0.31	3.29e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs9911578	1.000	rs1971659	chr17:57004787	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.13	0.3	5.67e-7	Intelligence (multi-trait analysis);
CESC	cis	rs798554	0.567	rs2527695	chr7:2858267	T/G	cg04166393	chr7:2884313	GNA12	0.39	5.15	0.3	5.07e-7	Height;
CESC	cis	rs10411936	0.682	rs6512113	chr19:16598269	C/T	cg10248733	chr19:16607483	C19orf44;CALR3	0.58	6.9	0.39	3.75e-11	White blood cell count;Multiple sclerosis;
CESC	cis	rs9649465	1.000	rs3958047	chr7:123327936	G/C	cg04330084	chr7:123175371	IQUB	-0.38	-5.22	-0.31	3.69e-7	Migraine;
CESC	cis	rs9660180	0.783	rs1107910	chr1:1692321	C/T	cg17747265	chr1:1875780	NA	-0.38	-6.05	-0.35	4.93e-9	Body mass index;
CESC	trans	rs35110281	0.807	rs9976441	chr21:45046591	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.51	6.71	0.38	1.2e-10	Mean corpuscular volume;
CESC	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg22105103	chr4:187893119	NA	-0.5	-7.28	-0.41	3.75e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs875971	0.862	rs11760844	chr7:65739883	C/G	cg11764359	chr7:65958608	NA	-0.79	-12.0	-0.59	9.01e-27	Aortic root size;
CESC	cis	rs1185460	1.000	rs1784305	chr11:118942048	G/A	cg01677386	chr11:118938358	VPS11	-0.45	-5.71	-0.33	3e-8	Coronary artery disease;
CESC	cis	rs425277	0.606	rs3128339	chr1:2046938	G/T	cg04315214	chr1:2043799	PRKCZ	0.65	11.4	0.57	9.18e-25	Height;
CESC	cis	rs875971	0.502	rs1796227	chr7:66087019	G/C	cg11764359	chr7:65958608	NA	-0.82	-9.58	-0.51	7.32e-19	Aortic root size;
CESC	cis	rs2880765	0.835	rs7180923	chr15:86050890	A/T	cg19183879	chr15:85880815	NA	-0.25	-5.23	-0.31	3.48e-7	Coronary artery disease;
CESC	cis	rs4654899	0.758	rs9426652	chr1:21458151	G/A	cg05370193	chr1:21551575	ECE1	0.37	5.51	0.32	8.41e-8	Superior frontal gyrus grey matter volume;
CESC	trans	rs10506458	0.915	rs17738485	chr12:63394932	T/C	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.34	-18.45	-0.75	1.83e-49	Hemostatic factors and hematological phenotypes;
CESC	cis	rs79057730	0.599	rs35928068	chr7:805363	G/C	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.88	7.42	0.41	1.6e-12	Initial pursuit acceleration;
CESC	cis	rs6546550	0.935	rs4241261	chr2:70063660	A/G	cg02498382	chr2:70120550	SNRNP27	-0.38	-6.62	-0.38	1.97e-10	Prevalent atrial fibrillation;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00735591	chr19:10828665	DNM2;MIR638	-0.63	-7.01	-0.4	1.97e-11	Gut microbiome composition (summer);
CESC	cis	rs425277	1.000	rs262672	chr1:2080813	G/T	cg24578937	chr1:2090814	PRKCZ	0.55	9.54	0.51	9.57e-19	Height;
CESC	cis	rs561341	1.000	rs510264	chr17:30323414	A/G	cg00745463	chr17:30367425	LRRC37B	-0.86	-7.76	-0.43	1.8e-13	Hip circumference adjusted for BMI;
CESC	trans	rs9987353	0.840	rs329994	chr8:9123233	A/G	cg25131247	chr11:118660965	DDX6	0.45	6.09	0.35	4.03e-9	Recombination measurement;
CESC	cis	rs12973672	1.000	rs10414846	chr19:35772471	A/G	cg12095397	chr19:35769544	USF2	-0.54	-7.34	-0.41	2.6e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs2439831	0.681	rs825739	chr15:43592428	T/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.92	10.9	0.56	4.16e-23	Lung cancer in ever smokers;
CESC	cis	rs9470366	0.883	rs9462210	chr6:36628953	G/A	cg08179530	chr6:36648295	CDKN1A	0.5	6.05	0.35	4.94e-9	QRS duration;
CESC	cis	rs1448094	0.533	rs10863078	chr12:86152672	C/T	cg02569458	chr12:86230093	RASSF9	-0.46	-7.15	-0.4	8.28e-12	Major depressive disorder;
CESC	cis	rs3105593	1.000	rs62017210	chr15:50960620	T/C	cg08437265	chr15:50716283	USP8	0.45	5.92	0.34	1e-8	QT interval;
CESC	cis	rs7267979	1.000	rs6050617	chr20:25421648	C/T	cg08601574	chr20:25228251	PYGB	0.38	5.64	0.33	4.4e-8	Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs7618501	1.000	rs2234391	chr3:49842625	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.56	7.84	0.43	1.07e-13	Intelligence (multi-trait analysis);
CESC	cis	rs17125944	0.686	rs2296495	chr14:53379878	G/A	cg00686598	chr14:53173677	PSMC6	0.96	7.22	0.41	5.39e-12	Alzheimer's disease (late onset);
CESC	cis	rs425277	0.628	rs262662	chr1:2085033	A/G	cg16545954	chr1:2118288	C1orf86	0.34	6.44	0.37	5.68e-10	Height;
CESC	cis	rs12464559	0.649	rs9287998	chr2:152621356	C/T	cg01189475	chr2:152685088	ARL5A	0.65	5.72	0.33	2.94e-8	Response to cognitive-behavioural therapy in anxiety disorder;
CESC	cis	rs3820928	0.904	rs2396432	chr2:227765891	C/T	cg11843606	chr2:227700838	RHBDD1	-0.45	-5.87	-0.34	1.27e-8	Pulmonary function;
CESC	cis	rs7188697	0.922	rs246258	chr16:58579274	A/G	cg21335942	chr16:58549945	SETD6	-0.47	-5.64	-0.33	4.31e-8	QT interval;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg27266822	chr1:16073415	TMEM82	-0.4	-5.99	-0.35	6.64e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs7772486	0.790	rs2265918	chr6:146219164	A/G	cg05347473	chr6:146136440	FBXO30	0.55	7.05	0.4	1.57e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg26338869	chr17:61819248	STRADA	0.69	9.21	0.49	1.06e-17	Prudent dietary pattern;
CESC	cis	rs1267303	0.642	rs114746843	chr1:46999239	C/A	cg25110126	chr1:46999211	NA	1.07	12.0	0.59	8.98e-27	Monobrow;
CESC	cis	rs1448094	0.717	rs7298614	chr12:86296513	C/T	cg02569458	chr12:86230093	RASSF9	0.36	5.07	0.3	7.55e-7	Major depressive disorder;
CESC	cis	rs2576037	0.796	rs2571031	chr18:44577063	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.6	-8.71	-0.47	3.35e-16	Personality dimensions;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04306007	chr2:161350288	RBMS1	-0.52	-6.0	-0.35	6.59e-9	Gut microbiome composition (summer);
CESC	cis	rs3892630	0.878	rs6510277	chr19:33183669	C/A	cg13157960	chr19:33183277	NUDT19	0.53	5.2	0.3	4.04e-7	Red blood cell traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02500917	chr7:100080970	C7orf51	0.62	6.72	0.38	1.12e-10	Gut microbiome composition (summer);
CESC	cis	rs6089584	0.507	rs6061989	chr20:60627893	C/T	cg24733560	chr20:60626293	TAF4	0.48	7.12	0.4	1e-11	Body mass index;
CESC	cis	rs9322193	0.884	rs9688699	chr6:150054816	A/G	cg13206674	chr6:150067644	NUP43	0.43	6.09	0.35	4e-9	Lung cancer;
CESC	cis	rs11122272	0.735	rs910823	chr1:231498766	G/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.55	-7.61	-0.42	4.76e-13	Hemoglobin concentration;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg10165071	chr2:217557160	IGFBP5	0.43	6.33	0.36	1.02e-9	Fibrinogen levels;
CESC	cis	rs6429082	0.523	rs704718	chr1:235666159	A/T	cg26050004	chr1:235667680	B3GALNT2	0.82	12.98	0.62	3.8e-30	Adiposity;
CESC	cis	rs9325144	0.534	rs4882283	chr12:38710249	C/T	cg13010199	chr12:38710504	ALG10B	0.41	5.5	0.32	8.96e-8	Morning vs. evening chronotype;
CESC	cis	rs909674	0.818	rs8137426	chr22:39844350	T/G	cg05872129	chr22:39784769	NA	-0.82	-10.06	-0.53	2.22e-20	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs9910055	0.639	rs11656871	chr17:42269141	G/C	cg08499158	chr17:42289980	UBTF	-0.51	-6.3	-0.36	1.21e-9	Total body bone mineral density;
CESC	cis	rs208520	0.802	rs208496	chr6:66930786	G/C	cg07460842	chr6:66804631	NA	-0.9	-10.86	-0.55	5.7e-23	Exhaled nitric oxide output;
CESC	cis	rs6429082	0.667	rs10802800	chr1:235706283	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.47	-5.12	-0.3	5.77e-7	Adiposity;
CESC	cis	rs2806561	0.704	rs588387	chr1:23523689	A/G	cg12483005	chr1:23474871	LUZP1	0.43	6.55	0.37	3.06e-10	Height;
CESC	cis	rs769267	1.000	rs1009136	chr19:19440428	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.61	-7.86	-0.44	9.39e-14	Tonsillectomy;
CESC	cis	rs8078723	0.668	rs3859192	chr17:38128648	C/T	cg17467752	chr17:38218738	THRA	0.54	7.8	0.43	1.38e-13	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CESC	cis	rs6500395	0.962	rs9921741	chr16:48589896	G/A	cg04672837	chr16:48644449	N4BP1	0.46	5.61	0.33	5.16e-8	Response to tocilizumab in rheumatoid arthritis;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg07189025	chr1:235671652	NA	0.41	6.29	0.36	1.27e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	trans	rs709082	0.624	rs709093	chr3:191462300	T/C	cg25305879	chr2:106814630	NA	0.41	6.4	0.37	7.05e-10	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7666738	0.716	rs35195511	chr4:98859660	G/A	cg05340658	chr4:99064831	C4orf37	0.75	11.17	0.57	5.26e-24	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2228479	0.702	rs17226841	chr16:89828484	C/T	cg14709524	chr16:89940631	TCF25	0.91	6.75	0.38	9.26e-11	Skin colour saturation;
CESC	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg18402987	chr7:1209562	NA	0.77	7.88	0.44	8.56e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs8058578	1.000	rs67456513	chr16:30714828	A/T	cg00531865	chr16:30841666	NA	-0.44	-5.77	-0.33	2.15e-8	Multiple myeloma;
CESC	cis	rs3820068	0.581	rs16851848	chr1:15927698	G/A	cg13390004	chr1:15929781	NA	0.35	5.58	0.32	5.83e-8	Systolic blood pressure;
CESC	cis	rs3617	0.625	rs11922961	chr3:52868610	T/C	cg07507251	chr3:52567010	NT5DC2	-0.31	-5.34	-0.31	2.03e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
CESC	cis	rs67311347	0.910	rs7617361	chr3:40373259	G/T	cg01475735	chr3:40494733	NA	-0.4	-5.2	-0.3	4.05e-7	Renal cell carcinoma;
CESC	trans	rs2727020	0.729	rs34647977	chr11:49195543	G/A	cg03929089	chr4:120376271	NA	-0.78	-11.91	-0.59	1.72e-26	Coronary artery disease;
CESC	cis	rs4555082	0.874	rs2816625	chr14:105734565	G/A	cg13114125	chr14:105738426	BRF1	-0.9	-11.3	-0.57	1.99e-24	Mean platelet volume;Platelet distribution width;
CESC	cis	rs9916302	0.904	rs8076546	chr17:37555403	G/A	cg20243544	chr17:37824526	PNMT	-0.49	-6.22	-0.36	1.94e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs5758659	0.714	rs5751220	chr22:42516205	A/C	cg04733989	chr22:42467013	NAGA	-0.4	-5.41	-0.32	1.39e-7	Cognitive function;
CESC	cis	rs2370759	1.000	rs11597888	chr10:32635834	G/A	cg01819863	chr10:32635814	EPC1	1.16	12.73	0.62	2.71e-29	Sexual dysfunction (female);
CESC	cis	rs6952808	0.760	rs11764960	chr7:1950532	G/A	cg00106254	chr7:1943704	MAD1L1	-0.48	-5.95	-0.34	8.35e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs9916302	0.904	rs4511574	chr17:37532916	A/G	cg20243544	chr17:37824526	PNMT	0.45	5.53	0.32	7.59e-8	Glomerular filtration rate (creatinine);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04081153	chr1:27021879	ARID1A	0.59	6.44	0.37	5.44e-10	Gut microbiome composition (summer);
CESC	trans	rs11764590	0.756	rs17132130	chr7:2108036	G/C	cg11693508	chr17:37793320	STARD3	0.54	6.1	0.35	3.77e-9	Neuroticism;
CESC	cis	rs11252926	0.502	rs7072510	chr10:455596	C/T	cg18196295	chr10:418757	DIP2C	0.51	6.9	0.39	3.93e-11	Psychosis in Alzheimer's disease;
CESC	cis	rs7772697	0.632	rs7742644	chr6:149426296	C/T	cg02561343	chr6:149291652	UST	0.31	5.03	0.3	9.06e-7	Diabetic retinopathy;
CESC	cis	rs651907	0.557	rs7612283	chr3:101434919	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.45	5.88	0.34	1.22e-8	Colorectal cancer;
CESC	cis	rs3087591	0.960	rs9303642	chr17:29578360	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.42	-5.25	-0.31	3.18e-7	Hip circumference;
CESC	cis	rs7631605	0.905	rs6773752	chr3:37225837	C/T	cg22985146	chr3:37219077	LRRFIP2	-0.32	-5.18	-0.3	4.37e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs6736093	0.966	rs3811633	chr2:112754880	G/A	cg12686935	chr2:112915763	FBLN7	-0.43	-5.66	-0.33	3.94e-8	Coronary artery disease;
CESC	cis	rs11792861	0.926	rs7046725	chr9:111882729	T/G	cg05043794	chr9:111880884	C9orf5	-0.38	-6.27	-0.36	1.49e-9	Menarche (age at onset);
CESC	cis	rs7666738	0.830	rs7657179	chr4:98948569	G/A	cg03676636	chr4:99064102	C4orf37	0.34	5.11	0.3	6.21e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4665809	0.627	rs35461456	chr2:26482361	C/G	cg27170947	chr2:26402098	FAM59B	0.87	9.85	0.52	1.01e-19	Gut microbiome composition (summer);
CESC	cis	rs290268	0.874	rs290990	chr9:93561695	A/G	cg02608019	chr9:93564028	SYK	-0.47	-6.93	-0.39	3.13e-11	Platelet count;
CESC	cis	rs4901869	0.966	rs9972208	chr14:59336116	C/T	cg02291164	chr14:59296302	NA	0.45	7.73	0.43	2.21e-13	Panic disorder;
CESC	cis	rs854765	0.693	rs12941039	chr17:17765655	C/T	cg09796270	chr17:17721594	SREBF1	-0.46	-6.47	-0.37	4.84e-10	Total body bone mineral density;
CESC	cis	rs1062177	0.826	rs1549920	chr5:151140844	A/T	cg12924095	chr5:151150029	G3BP1	0.42	5.67	0.33	3.79e-8	Preschool internalizing problems;
CESC	cis	rs7726839	0.555	rs4541696	chr5:581053	A/G	cg09021430	chr5:549028	NA	-0.6	-12.23	-0.6	1.42e-27	Obesity-related traits;
CESC	cis	rs7666738	0.962	rs11728816	chr4:98951767	C/T	cg17366294	chr4:99064904	C4orf37	0.54	7.16	0.4	8.11e-12	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2014572	0.967	rs11667407	chr19:57763122	C/T	cg12963866	chr19:57752005	ZNF805	-0.47	-6.35	-0.36	9.56e-10	Hyperactive-impulsive symptoms;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06659073	chr6:158589307	SERAC1;GTF2H5	0.56	6.09	0.35	3.98e-9	Gut microbiome composition (summer);
CESC	cis	rs9611565	0.512	rs139561	chr22:42195410	C/T	cg03806693	chr22:41940476	POLR3H	1.11	13.31	0.63	2.67e-31	Vitiligo;
CESC	cis	rs76878669	0.561	rs3177514	chr11:66130358	T/G	cg18002602	chr11:66138449	SLC29A2	0.39	6.48	0.37	4.49e-10	Educational attainment (years of education);
CESC	cis	rs7264396	0.790	rs10211771	chr20:34219994	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.88	-12.04	-0.59	6.24e-27	Total cholesterol levels;
CESC	cis	rs7131987	0.903	rs67517901	chr12:29421346	A/G	cg09582351	chr12:29534625	ERGIC2	-0.35	-5.52	-0.32	8.08e-8	QT interval;
CESC	cis	rs853679	0.517	rs3757185	chr6:28107776	T/A	cg23161317	chr6:28129485	ZNF389	0.52	6.63	0.38	1.86e-10	Depression;
CESC	cis	rs1801251	0.963	rs13011298	chr2:233612996	A/G	cg25237894	chr2:233734115	C2orf82	0.45	7.91	0.44	6.96e-14	Coronary artery disease;
CESC	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg11965913	chr1:205819406	PM20D1	-0.76	-10.93	-0.56	3.42e-23	Menarche (age at onset);
CESC	cis	rs9595066	0.712	rs4391951	chr13:44755071	C/T	cg04068111	chr13:44716778	NA	0.41	5.46	0.32	1.1e-7	Schizophrenia;
CESC	trans	rs10986105	1.000	rs7859011	chr9:126678431	C/T	cg01909245	chr11:1873757	LSP1	0.53	6.28	0.36	1.38e-9	Polycystic ovary syndrome;
CESC	cis	rs13064411	0.735	rs7631138	chr3:113231925	A/T	cg18753928	chr3:113234510	CCDC52	-0.49	-5.94	-0.34	8.7e-9	Response to simvastatin treatment (PCSK9 protein level change);
CESC	cis	rs3096299	0.685	rs3803681	chr16:89544756	C/T	cg02187348	chr16:89574699	SPG7	0.61	8.55	0.47	9.83e-16	Multiple myeloma (IgH translocation);
CESC	trans	rs7072793	0.591	rs3118470	chr10:6101713	A/G	cg09000804	chr14:104682988	NA	-0.38	-6.32	-0.36	1.12e-9	Plasma t-tau levels;
CESC	cis	rs4642101	0.640	rs7629354	chr3:12827746	T/G	cg24848339	chr3:12840334	CAND2	0.38	5.8	0.34	1.89e-8	QRS complex (12-leadsum);
CESC	cis	rs4555082	0.957	rs2816622	chr14:105733114	T/C	cg10792982	chr14:105748885	BRF1	0.4	5.38	0.31	1.64e-7	Mean platelet volume;Platelet distribution width;
CESC	cis	rs1799949	0.501	rs9675035	chr17:41415016	A/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	8.6	0.47	6.99e-16	Menopause (age at onset);
CESC	cis	rs847577	0.722	rs1013886	chr7:97709861	A/G	cg21770322	chr7:97807741	LMTK2	-0.65	-10.7	-0.55	1.85e-22	Breast cancer;
CESC	cis	rs79149102	0.649	rs1531163	chr15:75113083	A/G	cg17294928	chr15:75287854	SCAMP5	-0.69	-5.1	-0.3	6.55e-7	Lung cancer;
CESC	cis	rs2243480	1.000	rs2460422	chr7:65601505	C/T	cg18252515	chr7:66147081	NA	-1.42	-14.5	-0.67	1.8e-35	Diabetic kidney disease;
CESC	cis	rs637571	0.544	rs56239996	chr11:65730003	A/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.43	6.22	0.36	1.92e-9	Eosinophil percentage of white cells;
CESC	cis	rs4665809	0.941	rs6735145	chr2:26270302	T/C	cg26314531	chr2:26401878	FAM59B	-0.62	-6.85	-0.39	5.1e-11	Gut microbiome composition (summer);
CESC	cis	rs1256061	0.603	rs1269056	chr14:64743890	T/C	cg21174375	chr14:64681225	SYNE2	0.51	6.77	0.38	8.31e-11	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs7666738	0.791	rs6828752	chr4:99063382	C/T	cg05340658	chr4:99064831	C4orf37	0.84	13.04	0.63	2.35e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2108622	1.000	rs62107762	chr19:15982538	C/G	cg13772218	chr19:15982569	NA	0.37	6.95	0.39	2.87e-11	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CESC	cis	rs933688	1.000	rs11959525	chr5:90703840	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.86	10.24	0.53	5.93e-21	Smoking behavior;
CESC	cis	rs7223966	1.000	rs8070650	chr17:61744040	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.44	-5.16	-0.3	4.73e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs9916302	0.847	rs7218670	chr17:37500424	G/A	cg20243544	chr17:37824526	PNMT	-0.47	-5.94	-0.34	9.04e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs72634258	0.519	rs35197830	chr1:7930983	A/G	cg00042356	chr1:8021962	PARK7	0.51	5.66	0.33	3.91e-8	Inflammatory bowel disease;
CESC	cis	rs10078	1.000	rs10078	chr5:438102	G/T	cg15813090	chr5:442598	EXOC3;C5orf55	0.36	5.34	0.31	2e-7	Fat distribution (HIV);
CESC	cis	rs9733	0.593	rs10888384	chr1:150574256	C/T	cg18016565	chr1:150552671	MCL1	-0.42	-6.86	-0.39	4.98e-11	Tonsillectomy;
CESC	cis	rs9457247	1.000	rs448060	chr6:167382622	A/G	cg25258033	chr6:167368657	RNASET2	0.39	5.87	0.34	1.27e-8	Crohn's disease;
CESC	cis	rs4843747	0.671	rs72818577	chr16:88111181	G/A	cg06915872	chr16:87998081	BANP	0.44	5.2	0.3	3.95e-7	Menopause (age at onset);
CESC	cis	rs2380220	0.720	rs9374178	chr6:95979974	G/T	cg15832292	chr6:96025679	MANEA	0.62	6.87	0.39	4.62e-11	Behavioural disinhibition (generation interaction);
CESC	cis	rs2288912	0.807	rs7251501	chr19:45455706	C/T	cg20090143	chr19:45452003	APOC2	0.37	6.39	0.37	7.51e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs7777484	0.517	rs2644306	chr7:2831602	A/G	cg18446336	chr7:2847575	GNA12	-0.37	-6.24	-0.36	1.73e-9	Height;
CESC	cis	rs1832871	0.711	rs9459826	chr6:158680396	C/G	cg07165851	chr6:158734300	TULP4	-0.52	-5.63	-0.33	4.65e-8	Height;
CESC	cis	rs9291683	0.530	rs11723591	chr4:9985398	T/A	cg00071950	chr4:10020882	SLC2A9	0.76	13.25	0.63	4.21e-31	Bone mineral density;
CESC	cis	rs13256369	0.802	rs12681925	chr8:8561649	G/A	cg17143192	chr8:8559678	CLDN23	0.77	8.74	0.47	2.64e-16	Obesity-related traits;
CESC	cis	rs2836974	0.897	rs13047678	chr21:40708853	C/T	cg11644478	chr21:40555479	PSMG1	0.89	12.26	0.6	1.15e-27	Cognitive function;
CESC	cis	rs7640424	0.620	rs7637244	chr3:107815763	T/A	cg09227934	chr3:107805635	CD47	-0.45	-5.58	-0.32	5.86e-8	Body mass index;
CESC	cis	rs116095464	0.558	rs55664502	chr5:270485	T/C	cg22857025	chr5:266934	NA	-1.29	-18.61	-0.75	5.33e-50	Breast cancer;
CESC	cis	rs9733	0.688	rs12725667	chr1:150766070	A/T	cg18016565	chr1:150552671	MCL1	-0.36	-5.89	-0.34	1.19e-8	Tonsillectomy;
CESC	trans	rs875971	0.929	rs778682	chr7:65837934	A/G	cg26939375	chr7:64535504	NA	0.47	6.06	0.35	4.66e-9	Aortic root size;
CESC	cis	rs10751667	0.666	rs7123912	chr11:963936	T/C	cg20946044	chr11:1010712	AP2A2	-0.38	-5.35	-0.31	1.92e-7	Alzheimer's disease (late onset);
CESC	cis	rs1448094	0.621	rs10863091	chr12:86282240	T/C	cg02569458	chr12:86230093	RASSF9	0.42	6.15	0.35	2.81e-9	Major depressive disorder;
CESC	cis	rs27434	0.583	rs34756	chr5:96152383	C/T	cg16492584	chr5:96139282	ERAP1	0.38	5.56	0.32	6.71e-8	Ankylosing spondylitis;
CESC	cis	rs6991838	0.584	rs7823840	chr8:66519001	A/G	cg13398993	chr8:66546079	ARMC1	-0.45	-5.41	-0.32	1.38e-7	Intelligence (multi-trait analysis);
CESC	cis	rs4588572	0.688	rs11743511	chr5:77692819	C/T	cg11547950	chr5:77652471	NA	-0.41	-5.69	-0.33	3.27e-8	Triglycerides;
CESC	cis	rs9583531	0.891	rs7999536	chr13:111382199	G/A	cg24331049	chr13:111365604	ING1	0.76	8.03	0.44	3.24e-14	Coronary artery disease;
CESC	cis	rs7894051	1.000	rs7074435	chr10:135190570	G/T	cg20534287	chr10:135191450	PAOX	0.57	5.57	0.32	6.28e-8	Lifespan;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg06426436	chr5:133339613	VDAC1	0.49	6.21	0.36	2.02e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs10461617	0.541	rs7715822	chr5:56043600	G/T	cg22800045	chr5:56110881	MAP3K1	0.7	6.42	0.37	6.29e-10	Type 2 diabetes;
CESC	cis	rs3796619	1.000	rs4045481	chr4:1090625	C/T	cg27284194	chr4:1044797	NA	0.38	5.69	0.33	3.4e-8	Recombination rate (males);
CESC	cis	rs6964587	0.935	rs28412174	chr7:91577245	T/G	cg17063962	chr7:91808500	NA	-0.57	-7.61	-0.42	4.66e-13	Breast cancer;
CESC	cis	rs9916302	0.784	rs4795382	chr17:37700860	A/G	cg20243544	chr17:37824526	PNMT	0.51	6.5	0.37	3.89e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs17376456	0.877	rs9314100	chr5:93447394	T/C	cg25358565	chr5:93447407	FAM172A	1.19	11.28	0.57	2.31e-24	Diabetic retinopathy;
CESC	cis	rs2072732	0.821	rs7412983	chr1:2943183	A/C	cg03976712	chr1:2946727	NA	0.34	5.35	0.31	1.9e-7	Plateletcrit;
CESC	cis	rs7618915	0.524	rs2028216	chr3:52680823	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	6.98	0.39	2.35e-11	Bipolar disorder;
CESC	cis	rs2576037	0.526	rs649076	chr18:44414614	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.41	6.84	0.39	5.54e-11	Personality dimensions;
CESC	cis	rs12586317	0.508	rs10134914	chr14:35425012	T/G	cg16230307	chr14:35515116	FAM177A1	0.83	10.08	0.53	1.91e-20	Psoriasis;
CESC	cis	rs7177699	0.534	rs7403708	chr15:79123885	T/C	cg04896959	chr15:78267971	NA	0.32	5.03	0.3	8.89e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
CESC	cis	rs75229567	0.541	rs775443	chr12:70122623	C/T	cg10114359	chr12:70132523	RAB3IP	-0.75	-5.91	-0.34	1.04e-8	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
CESC	cis	rs1728785	1.000	rs1069288	chr16:68585285	C/G	cg02972257	chr16:68554789	NA	-0.55	-6.28	-0.36	1.37e-9	Ulcerative colitis;
CESC	cis	rs854765	0.647	rs4365346	chr17:17989373	G/T	cg04398451	chr17:18023971	MYO15A	-0.75	-11.07	-0.56	1.18e-23	Total body bone mineral density;
CESC	cis	rs7843479	0.562	rs4872191	chr8:21824547	A/G	cg17168535	chr8:21777572	XPO7	0.75	11.94	0.59	1.41e-26	Mean corpuscular volume;
CESC	cis	rs6952808	0.609	rs12699453	chr7:1953056	C/T	cg05863683	chr7:1912471	MAD1L1	0.38	5.89	0.34	1.19e-8	Bipolar disorder and schizophrenia;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg00289125	chr2:20251812	LAPTM4A	0.43	6.06	0.35	4.7e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg22105103	chr4:187893119	NA	0.46	6.84	0.39	5.33e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6831352	0.842	rs1230156	chr4:99989626	C/T	cg12011299	chr4:100065546	ADH4	0.67	7.93	0.44	6.27e-14	Alcohol dependence;
CESC	cis	rs796364	0.951	rs72932280	chr2:200996851	G/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.71	-6.86	-0.39	4.78e-11	Schizophrenia;
CESC	cis	rs801193	0.967	rs2707849	chr7:66152712	T/C	cg11764359	chr7:65958608	NA	0.69	9.1	0.49	2.27e-17	Aortic root size;
CESC	cis	rs13118159	0.767	rs2141656	chr4:1317192	C/T	cg02018176	chr4:1364513	KIAA1530	0.43	6.07	0.35	4.53e-9	Longevity;
CESC	cis	rs7666738	0.830	rs10034619	chr4:98970067	G/C	cg17366294	chr4:99064904	C4orf37	0.58	8.26	0.45	7.11e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1008375	0.966	rs6449330	chr4:17703949	C/T	cg16339924	chr4:17578868	LAP3	-0.58	-7.27	-0.41	4.04e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs1707322	0.752	rs10789467	chr1:46118745	C/G	cg03146154	chr1:46216737	IPP	0.82	11.52	0.58	3.64e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs10028773	0.515	rs9994488	chr4:120587781	C/T	cg09307838	chr4:120376055	NA	0.69	9.05	0.49	3.22e-17	Educational attainment;
CESC	cis	rs8067545	0.611	rs2189709	chr17:20083226	T/A	cg13482628	chr17:19912719	NA	-0.43	-5.74	-0.33	2.65e-8	Schizophrenia;
CESC	cis	rs2440129	0.611	rs1126667	chr17:6902760	C/T	cg08946332	chr17:6899888	ALOX12	-0.41	-5.98	-0.35	7.04e-9	Tonsillectomy;
CESC	cis	rs9311474	0.569	rs7614981	chr3:52566914	G/T	cg18099408	chr3:52552593	STAB1	-0.4	-7.43	-0.42	1.52e-12	Electroencephalogram traits;
CESC	cis	rs28829049	0.597	rs12563386	chr1:19455205	T/C	cg13387374	chr1:19411106	UBR4	0.43	5.39	0.31	1.54e-7	QRS duration in Tripanosoma cruzi seropositivity;
CESC	cis	rs7814319	0.933	rs7002575	chr8:97242124	G/A	cg20787634	chr8:97240163	UQCRB	-0.63	-8.2	-0.45	1.03e-14	Lung function (FVC);
CESC	cis	rs858239	0.537	rs6942981	chr7:23231548	C/T	cg23682824	chr7:23144976	KLHL7	0.45	5.79	0.34	1.98e-8	Cerebrospinal fluid biomarker levels;
CESC	trans	rs637571	0.607	rs574586	chr11:65697083	G/A	cg17712092	chr4:129076599	LARP1B	0.78	10.5	0.54	8.89e-22	Eosinophil percentage of white cells;
CESC	cis	rs12618769	0.597	rs72819996	chr2:99059983	G/A	cg10123293	chr2:99228465	UNC50	0.39	5.18	0.3	4.49e-7	Bipolar disorder;
CESC	cis	rs7188697	0.922	rs37036	chr16:58553348	T/C	cg21335942	chr16:58549945	SETD6	0.46	5.41	0.32	1.44e-7	QT interval;
CESC	cis	rs7727544	0.684	rs272893	chr5:131663062	T/C	cg07395648	chr5:131743802	NA	-0.44	-5.81	-0.34	1.79e-8	Blood metabolite levels;
CESC	cis	rs7937682	0.575	rs7930208	chr11:111741463	T/C	cg09085632	chr11:111637200	PPP2R1B	0.9	11.72	0.58	8.02e-26	Primary sclerosing cholangitis;
CESC	cis	rs6502050	0.871	rs9916649	chr17:80075739	G/A	cg11859384	chr17:80120422	CCDC57	0.4	5.5	0.32	8.88e-8	Life satisfaction;
CESC	cis	rs2180341	0.883	rs7760748	chr6:127690062	C/T	cg27446573	chr6:127587934	RNF146	1.05	15.58	0.69	2.65e-39	Breast cancer;
CESC	cis	rs5750830	0.649	rs5750811	chr22:39793066	G/T	cg24399712	chr22:39784796	NA	0.82	10.93	0.56	3.32e-23	Intelligence (multi-trait analysis);
CESC	cis	rs17401966	0.838	rs1013953	chr1:10319459	T/A	cg15208524	chr1:10270712	KIF1B	0.39	5.14	0.3	5.37e-7	Hepatocellular carcinoma;
CESC	trans	rs2657294	0.620	rs4746261	chr10:76845632	C/T	ch.2.195648145F	chr2:195939902	NA	0.5	6.32	0.36	1.07e-9	Pneumonia;
CESC	cis	rs7551222	0.634	rs11801289	chr1:204528969	G/C	cg20240347	chr1:204465584	NA	-0.28	-5.65	-0.33	4.12e-8	Schizophrenia;
CESC	cis	rs10504229	0.683	rs77548248	chr8:58117542	G/A	cg24829409	chr8:58192753	C8orf71	-0.58	-7.21	-0.41	5.76e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs2710642	0.721	rs6727888	chr2:62887884	T/C	cg17519650	chr2:63277830	OTX1	0.5	6.08	0.35	4.28e-9	LDL cholesterol levels;LDL cholesterol;
CESC	cis	rs9300255	0.602	rs1790131	chr12:123701010	G/T	cg19016782	chr12:123741754	C12orf65	-0.45	-6.5	-0.37	3.89e-10	Neutrophil percentage of white cells;
CESC	cis	rs12451471	0.637	rs12950757	chr17:78096800	T/G	cg24585782	chr17:78113791	EIF4A3	-0.6	-8.06	-0.44	2.7e-14	Plateletcrit;Mean corpuscular hemoglobin concentration;
CESC	cis	rs57506017	0.585	rs4721057	chr7:12267221	A/G	cg23422036	chr7:12250390	TMEM106B	0.38	5.17	0.3	4.7e-7	Neuroticism;
CESC	cis	rs6456156	0.524	rs6934043	chr6:167466449	C/T	cg07741184	chr6:167504864	NA	0.35	6.08	0.35	4.1e-9	Primary biliary cholangitis;
CESC	cis	rs7561273	0.609	rs1056122	chr2:24342505	C/T	cg20701182	chr2:24300061	SF3B14	-0.46	-5.99	-0.35	6.81e-9	Quantitative traits;
CESC	cis	rs853679	0.517	rs9393886	chr6:28050039	T/G	cg23281280	chr6:28129359	ZNF389	0.57	7.78	0.43	1.61e-13	Depression;
CESC	cis	rs2251381	0.750	rs2251186	chr21:30528880	G/A	cg24692254	chr21:30365293	RNF160	0.78	10.55	0.54	5.89e-22	Selective IgA deficiency;
CESC	cis	rs7811142	0.830	rs11769057	chr7:99964661	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.01	10.43	0.54	1.4e-21	Platelet count;
CESC	cis	rs9486719	1.000	rs11153067	chr6:97039421	A/T	cg18709589	chr6:96969512	KIAA0776	0.51	5.58	0.32	5.99e-8	Migraine;Coronary artery disease;
CESC	cis	rs909002	0.800	rs7529064	chr1:32105192	C/A	cg13919466	chr1:32135498	COL16A1	-0.46	-8.21	-0.45	1e-14	Intelligence (multi-trait analysis);
CESC	cis	rs3749237	0.595	rs6797765	chr3:49423976	A/G	cg02487422	chr3:49467188	NICN1	0.53	7.7	0.43	2.74e-13	Resting heart rate;
CESC	cis	rs3858526	0.874	rs10838879	chr11:5950169	C/T	cg05234568	chr11:5960015	NA	-0.63	-7.53	-0.42	8.12e-13	DNA methylation (variation);
CESC	cis	rs4665809	0.531	rs10199898	chr2:26445485	T/G	cg25036284	chr2:26402008	FAM59B	-0.86	-9.4	-0.5	2.74e-18	Gut microbiome composition (summer);
CESC	cis	rs3008870	1.000	rs2985817	chr1:67398607	G/C	cg02640540	chr1:67518911	SLC35D1	0.51	5.58	0.32	5.89e-8	Lymphocyte percentage of white cells;
CESC	cis	rs55788414	0.932	rs9921748	chr16:81181783	T/C	cg06400318	chr16:81190750	PKD1L2	-0.59	-7.04	-0.4	1.62e-11	Left ventricular obstructive tract defect (maternal effect);
CESC	cis	rs7666738	0.830	rs6839277	chr4:99015563	C/T	cg17366294	chr4:99064904	C4orf37	0.6	8.62	0.47	6.37e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs847577	0.588	rs6946915	chr7:97711340	C/G	cg21770322	chr7:97807741	LMTK2	0.82	14.54	0.67	1.25e-35	Breast cancer;
CESC	cis	rs1538970	1.000	rs4660853	chr1:45849090	C/T	cg03146154	chr1:46216737	IPP	0.44	5.31	0.31	2.29e-7	Platelet count;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg00746083	chr14:21905454	CHD8	-0.47	-6.04	-0.35	5.14e-9	Asthma;
CESC	cis	rs3617	0.573	rs2336668	chr3:52919096	G/T	cg07507251	chr3:52567010	NT5DC2	-0.33	-5.46	-0.32	1.07e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
CESC	trans	rs7824557	0.545	rs2572380	chr8:11237477	A/G	cg06636001	chr8:8085503	FLJ10661	-0.49	-6.13	-0.35	3.17e-9	Retinal vascular caliber;
CESC	cis	rs523522	0.962	rs655530	chr12:121022275	T/C	cg12219531	chr12:120966889	COQ5	0.76	10.07	0.53	2.15e-20	High light scatter reticulocyte count;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg09133386	chr6:20404188	E2F3	-0.51	-7.6	-0.42	5.08e-13	Gambling;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg09698166	chr20:21106763	PLK1S1	0.48	6.79	0.38	7.32e-11	Systemic lupus erythematosus;
CESC	cis	rs2439831	0.850	rs28509275	chr15:44098105	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.71	7.07	0.4	1.37e-11	Lung cancer in ever smokers;
CESC	cis	rs17253792	0.822	rs8006705	chr14:56171283	C/T	cg01858014	chr14:56050164	KTN1	-0.75	-6.5	-0.37	3.96e-10	Putamen volume;
CESC	cis	rs7618915	0.524	rs12488461	chr3:52698417	T/C	cg18099408	chr3:52552593	STAB1	-0.31	-5.18	-0.3	4.49e-7	Bipolar disorder;
CESC	cis	rs7264396	0.677	rs6060553	chr20:34267386	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.63	6.84	0.39	5.52e-11	Total cholesterol levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20440414	chr17:46178346	CBX1	0.66	7.43	0.42	1.46e-12	Gut microbiome composition (summer);
CESC	cis	rs7264396	0.635	rs6060656	chr20:34466382	G/A	cg17201900	chr20:34330562	RBM39	0.5	5.07	0.3	7.37e-7	Total cholesterol levels;
CESC	cis	rs897984	0.683	rs13337900	chr16:30822409	G/A	cg00531865	chr16:30841666	NA	-0.55	-8.34	-0.46	4.24e-15	Dementia with Lewy bodies;
CESC	cis	rs2243480	0.803	rs423187	chr7:65509499	G/C	cg25894440	chr7:65020034	NA	-0.64	-5.28	-0.31	2.67e-7	Diabetic kidney disease;
CESC	trans	rs9987353	0.840	rs329994	chr8:9123233	A/G	cg07274998	chr10:126107781	OAT	-0.44	-6.15	-0.35	2.87e-9	Recombination measurement;
CESC	cis	rs17376456	1.000	rs56046246	chr5:93531545	T/G	cg25358565	chr5:93447407	FAM172A	1.18	11.23	0.57	3.38e-24	Diabetic retinopathy;
CESC	cis	rs12900413	0.687	rs28653538	chr15:90304964	T/C	cg24249390	chr15:90295951	MESP1	-0.4	-5.59	-0.32	5.74e-8	Coronary artery aneurysm in Kawasaki disease;
CESC	cis	rs1050631	1.000	rs719147	chr18:33698192	T/G	cg25426722	chr18:33708991	SLC39A6;ELP2	0.43	5.57	0.32	6.17e-8	Esophageal squamous cell cancer (length of survival);
CESC	cis	rs7084402	0.967	rs1896243	chr10:60276291	C/T	cg07615347	chr10:60278583	BICC1	-0.58	-9.21	-0.49	1.01e-17	Refractive error;
CESC	cis	rs801193	0.569	rs2013908	chr7:66121069	A/T	cg12463550	chr7:65579703	CRCP	-0.5	-6.43	-0.37	5.9e-10	Aortic root size;
CESC	cis	rs10911232	0.507	rs10911206	chr1:183012423	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.87	13.67	0.64	1.52e-32	Hypertriglyceridemia;
CESC	cis	rs561341	0.700	rs79272796	chr17:30226974	T/C	cg13647721	chr17:30228624	UTP6	0.82	10.61	0.55	3.73e-22	Hip circumference adjusted for BMI;
CESC	cis	rs1451375	0.527	rs6950777	chr7:50597056	G/A	cg14593290	chr7:50529359	DDC	0.51	6.45	0.37	5.26e-10	Malaria;
CESC	cis	rs2243480	1.000	rs6460274	chr7:65628484	T/A	cg13147721	chr7:65941812	NA	0.97	9.19	0.49	1.2e-17	Diabetic kidney disease;
CESC	cis	rs9640161	0.750	rs3800780	chr7:150027284	C/A	cg10018233	chr7:150070692	REPIN1	0.43	6.35	0.36	9.1e-10	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs11711311	0.955	rs2124105	chr3:113406003	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.67	8.6	0.47	7.08e-16	IgG glycosylation;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg19502932	chr11:6640663	TPP1	-0.45	-6.12	-0.35	3.33e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs16895831	0.519	rs12196290	chr6:42552548	G/A	cg10605015	chr6:42532144	UBR2	-0.52	-5.81	-0.34	1.75e-8	Granulocyte percentage of myeloid white cells;Neutrophil percentage of white cells;Eosinophil percentage of white cells;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Neutrophil count;Sum basophil neutrophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
CESC	cis	rs1538970	0.962	rs2185549	chr1:45814103	C/T	cg03146154	chr1:46216737	IPP	-0.46	-5.47	-0.32	1.04e-7	Platelet count;
CESC	cis	rs6964587	0.967	rs1978061	chr7:91779242	G/A	cg17063962	chr7:91808500	NA	0.59	8.22	0.45	8.94e-15	Breast cancer;
CESC	cis	rs7089973	0.604	rs7915943	chr10:116618077	G/A	cg23260525	chr10:116636907	FAM160B1	0.41	7.43	0.42	1.53e-12	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	trans	rs11098499	0.954	rs13113483	chr4:120309039	C/T	cg25214090	chr10:38739885	LOC399744	0.68	9.2	0.49	1.14e-17	Corneal astigmatism;
CESC	cis	rs7481584	0.624	rs2106229	chr11:3041195	G/A	cg25174290	chr11:3078921	CARS	-0.43	-5.86	-0.34	1.38e-8	Calcium levels;
CESC	cis	rs3820928	0.874	rs13423046	chr2:227901805	G/T	cg05526886	chr2:227700861	RHBDD1	-0.45	-5.7	-0.33	3.18e-8	Pulmonary function;
CESC	cis	rs72781680	0.611	rs72783619	chr2:24311607	G/A	cg20701182	chr2:24300061	SF3B14	0.93	10.58	0.54	4.83e-22	Lymphocyte counts;
CESC	cis	rs801193	1.000	rs7782320	chr7:66177098	C/T	cg11764359	chr7:65958608	NA	0.71	9.47	0.5	1.62e-18	Aortic root size;
CESC	cis	rs1879734	0.731	rs10888804	chr1:54160570	C/T	cg23596471	chr1:54105337	GLIS1	0.35	5.66	0.33	3.96e-8	Mitral valve prolapse;
CESC	cis	rs11148252	0.595	rs4884522	chr13:53053768	C/A	cg00495681	chr13:53174319	NA	0.61	8.32	0.46	4.58e-15	Lewy body disease;
CESC	cis	rs11920090	0.800	rs11917504	chr3:170736708	A/T	cg09710316	chr3:170744871	SLC2A2	0.41	5.08	0.3	7.3e-7	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
CESC	cis	rs13118159	0.767	rs2141656	chr4:1317192	C/T	cg19318889	chr4:1322082	MAEA	0.43	5.74	0.33	2.57e-8	Longevity;
CESC	cis	rs56104184	0.775	rs73061695	chr19:49399988	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.6	-5.99	-0.35	6.95e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	cis	rs17376456	0.877	rs7701974	chr5:93311417	C/T	cg21475434	chr5:93447410	FAM172A	0.76	6.88	0.39	4.31e-11	Diabetic retinopathy;
CESC	cis	rs2795502	1.000	rs2142991	chr10:43341105	C/T	cg20628663	chr10:43360327	NA	-0.61	-7.24	-0.41	4.87e-12	Blood protein levels;
CESC	cis	rs2651899	0.872	rs207199	chr1:3076857	T/G	cg07622451	chr1:3079886	PRDM16	0.31	5.6	0.33	5.47e-8	Migraine;
CESC	cis	rs8141529	0.664	rs5762862	chr22:29252732	C/T	cg15103426	chr22:29168792	CCDC117	0.54	6.65	0.38	1.62e-10	Lymphocyte counts;
CESC	cis	rs7771547	0.573	rs664370	chr6:36393816	A/G	cg07856975	chr6:36356162	ETV7	0.37	5.55	0.32	6.87e-8	Platelet distribution width;
CESC	cis	rs8014204	0.604	rs2159906	chr14:75390912	G/T	cg08847533	chr14:75593920	NEK9	0.6	7.78	0.43	1.62e-13	Caffeine consumption;
CESC	cis	rs8070128	0.600	rs8071238	chr17:17900990	T/C	cg04398451	chr17:18023971	MYO15A	-0.68	-9.48	-0.5	1.54e-18	Total body bone mineral density;
CESC	cis	rs9419702	0.568	rs7920966	chr10:133555185	G/T	cg04492858	chr10:133558786	NA	0.43	6.37	0.36	8.39e-10	Survival in rectal cancer;
CESC	cis	rs763121	0.853	rs9607566	chr22:39075434	C/G	cg06022373	chr22:39101656	GTPBP1	0.9	14.15	0.66	2.99e-34	Menopause (age at onset);
CESC	cis	rs7666738	0.546	rs1863602	chr4:98909304	T/C	cg05340658	chr4:99064831	C4orf37	0.6	7.48	0.42	1.06e-12	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6484504	0.600	rs208063	chr11:31159777	C/T	cg14844989	chr11:31128820	NA	-0.41	-5.85	-0.34	1.47e-8	Red blood cell count;
CESC	cis	rs9487051	0.676	rs6568568	chr6:109597048	C/T	cg21918786	chr6:109611834	NA	-0.38	-5.52	-0.32	8.19e-8	Reticulocyte fraction of red cells;
CESC	cis	rs9486719	0.843	rs2499787	chr6:96841762	G/C	cg18709589	chr6:96969512	KIAA0776	0.57	5.66	0.33	3.94e-8	Migraine;Coronary artery disease;
CESC	cis	rs7208859	0.623	rs35916850	chr17:29011173	G/A	cg19761014	chr17:28927070	LRRC37B2	0.81	6.67	0.38	1.49e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs6570726	0.935	rs585292	chr6:145862228	T/C	cg05347473	chr6:146136440	FBXO30	0.48	6.45	0.37	5.27e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs478304	0.651	rs78412025	chr11:65495696	T/C	cg10518572	chr11:65560635	OVOL1	-0.33	-6.61	-0.38	2.09e-10	Acne (severe);
CESC	cis	rs736408	0.736	rs4687550	chr3:52823430	T/G	cg05564831	chr3:52568323	NT5DC2	0.43	6.21	0.36	2.06e-9	Bipolar disorder;
CESC	cis	rs7851660	0.874	rs13299924	chr9:100627562	C/T	cg13688889	chr9:100608707	NA	-0.63	-8.87	-0.48	1.09e-16	Strep throat;
CESC	trans	rs1814175	0.817	rs10839358	chr11:49770972	G/A	cg03929089	chr4:120376271	NA	-0.9	-14.97	-0.68	4.06e-37	Height;
CESC	cis	rs62005083	0.748	rs72725911	chr14:74500621	G/A	cg05179529	chr14:74551516	LIN52;ALDH6A1	0.7	5.22	0.31	3.68e-7	Mean corpuscular volume;
CESC	cis	rs11122272	0.735	rs2808597	chr1:231532351	T/C	cg06096015	chr1:231504339	EGLN1	0.43	6.15	0.35	2.9e-9	Hemoglobin concentration;
CESC	cis	rs6701037	1.000	rs6683533	chr1:175125440	G/A	cg00321850	chr1:175162397	KIAA0040	-0.42	-5.88	-0.34	1.22e-8	Alcohol dependence;
CESC	cis	rs258892	0.793	rs6452682	chr5:72082390	T/G	cg21869765	chr5:72125136	TNPO1	-0.42	-5.42	-0.32	1.36e-7	Small cell lung carcinoma;
CESC	cis	rs16910800	0.638	rs12273883	chr11:23164569	C/G	cg20040320	chr11:23191996	NA	0.64	6.34	0.36	1e-9	Cancer;
CESC	cis	rs9815354	1.000	rs9848754	chr3:41753647	C/T	cg03022575	chr3:42003672	ULK4	0.51	5.06	0.3	7.69e-7	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs79387448	0.935	rs7567133	chr2:103253128	C/A	cg09003973	chr2:102972529	NA	0.57	5.15	0.3	5.01e-7	Gut microbiota (bacterial taxa);
CESC	cis	rs11969893	0.850	rs9404055	chr6:101302260	C/T	cg12253828	chr6:101329408	ASCC3	1.11	9.79	0.52	1.5700000000000001e-19	Economic and political preferences (immigration/crime);
CESC	cis	rs10504229	1.000	rs72650885	chr8:58175131	G/A	cg22535103	chr8:58192502	C8orf71	-1.05	-13.27	-0.63	3.63e-31	Developmental language disorder (linguistic errors);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15422734	chr19:49206777	FUT2	-0.56	-6.44	-0.37	5.54e-10	Gut microbiome composition (summer);
CESC	cis	rs7613875	0.620	rs17657688	chr3:50033228	C/T	cg24308560	chr3:49941425	MST1R	0.6	8.46	0.46	1.85e-15	Body mass index;
CESC	cis	rs965469	1.000	rs2236108	chr20:3286331	A/C	cg25506879	chr20:3388711	C20orf194	-0.54	-5.88	-0.34	1.24e-8	IFN-related cytopenia;
CESC	cis	rs17826219	0.706	rs2322197	chr17:29105805	T/C	cg13385521	chr17:29058706	SUZ12P	0.74	6.04	0.35	5.1e-9	Body mass index;
CESC	cis	rs9487051	0.802	rs6910696	chr6:109592329	A/T	cg01475377	chr6:109611718	NA	-0.52	-8.83	-0.48	1.41e-16	Reticulocyte fraction of red cells;
CESC	cis	rs7267979	0.966	rs2482918	chr20:25412135	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.85	-16.55	-0.71	9.69e-43	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs6500395	0.963	rs12444902	chr16:48667126	G/T	cg04672837	chr16:48644449	N4BP1	0.49	6.26	0.36	1.54e-9	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs7584330	0.737	rs12469894	chr2:238365528	T/C	cg14458575	chr2:238380390	NA	0.62	8.39	0.46	3.03e-15	Prostate cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05617452	chr16:1877333	HAGH;FAHD1	0.59	6.93	0.39	3.24e-11	Gut microbiome composition (summer);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg07272677	chr4:186741447	SORBS2	0.45	6.35	0.36	9.55e-10	Fibrinogen levels;
CESC	cis	rs72781680	1.000	rs17712391	chr2:24245659	C/T	cg20701182	chr2:24300061	SF3B14	0.83	7.16	0.4	8.12e-12	Lymphocyte counts;
CESC	cis	rs9788721	0.630	rs77681598	chr15:78906103	C/A	cg24631222	chr15:78858424	CHRNA5	0.42	5.44	0.32	1.24e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23409613	chr14:53196849	STYX	0.64	7.99	0.44	4.08e-14	Gut microbiome composition (summer);
CESC	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.57	-7.38	-0.41	1.99e-12	Longevity;Endometriosis;
CESC	cis	rs11997175	0.646	rs6993892	chr8:33729200	T/C	ch.8.33884649F	chr8:33765107	NA	0.56	7.32	0.41	3.02e-12	Body mass index;
CESC	cis	rs7605378	0.528	rs281791	chr2:200850402	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.48	-5.43	-0.32	1.26e-7	Osteoporosis;
CESC	cis	rs6570726	0.533	rs1832374	chr6:145717752	A/G	cg23711669	chr6:146136114	FBXO30	0.48	5.72	0.33	2.91e-8	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1499614	0.522	rs13247442	chr7:66188858	T/C	cg18252515	chr7:66147081	NA	-1.28	-9.23	-0.49	9.02e-18	Gout;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg10735211	chr4:4310922	ZNF509	0.44	6.3	0.36	1.24e-9	Fibrinogen levels;
CESC	cis	rs62458065	0.513	rs10265319	chr7:32571564	A/C	cg20159608	chr7:32802032	NA	-0.55	-6.16	-0.35	2.74e-9	Metabolite levels (HVA/MHPG ratio);
CESC	cis	rs748404	0.697	rs501884	chr15:43553982	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.51	7.98	0.44	4.38e-14	Lung cancer;
CESC	cis	rs4665809	1.000	rs6546727	chr2:26275282	C/T	cg26314531	chr2:26401878	FAM59B	-0.62	-6.91	-0.39	3.66e-11	Gut microbiome composition (summer);
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg08413153	chr17:46185283	SNX11	-0.51	-6.69	-0.38	1.3100000000000001e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs2073300	0.609	rs6137948	chr20:23416845	G/A	cg16736954	chr20:23401023	NAPB	0.78	5.79	0.34	2e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs2576037	0.526	rs9962523	chr18:44486414	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.69	10.57	0.54	5.17e-22	Personality dimensions;
CESC	cis	rs17209837	0.607	rs117917293	chr7:87114824	G/C	cg00919237	chr7:87102261	ABCB4	-0.46	-5.88	-0.34	1.21e-8	Gallbladder cancer;
CESC	cis	rs7208859	0.623	rs73269974	chr17:29112384	C/T	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.17e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs3824867	0.920	rs9919526	chr11:47451623	C/T	cg20307385	chr11:47447363	PSMC3	-0.47	-5.48	-0.32	9.68e-8	Mean corpuscular hemoglobin;
CESC	cis	rs5997397	0.934	rs6005864	chr22:29157487	A/G	cg02153584	chr22:29168773	CCDC117	-0.56	-7.45	-0.42	1.29e-12	Red cell distribution width;
CESC	cis	rs7762018	0.891	rs7764839	chr6:170146351	C/A	cg05834625	chr6:170176447	C6orf70	0.65	7.17	0.4	7.57e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs1348850	0.874	rs12996447	chr2:178283592	C/T	cg22681709	chr2:178499509	PDE11A	-0.4	-5.95	-0.34	8.31e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs1218582	0.804	rs869506	chr1:154859581	A/C	cg24250549	chr1:154909240	PMVK	0.72	10.85	0.55	6.34e-23	Prostate cancer;
CESC	cis	rs2033711	0.755	rs4801587	chr19:58936679	C/A	cg13877915	chr19:58951672	ZNF132	0.39	5.62	0.33	4.74e-8	Uric acid clearance;
CESC	trans	rs11098499	0.954	rs1022145	chr4:120230979	A/G	cg25214090	chr10:38739885	LOC399744	0.7	9.65	0.51	4.55e-19	Corneal astigmatism;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg13736585	chr7:43909721	MRPS24	0.47	6.19	0.36	2.23e-9	Thyroid stimulating hormone;
CESC	cis	rs1707322	0.752	rs6703748	chr1:46095976	G/A	cg05343316	chr1:45956843	TESK2	0.51	6.35	0.36	9.45e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs1814175	0.654	rs7482446	chr11:49779020	A/G	cg15704280	chr7:45808275	SEPT13	-1.01	-19.33	-0.76	1.48e-52	Height;
CESC	cis	rs3733585	0.699	rs4339211	chr4:9947658	C/T	cg11266682	chr4:10021025	SLC2A9	-0.59	-11.16	-0.57	5.99e-24	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs10871290	0.881	rs11649338	chr16:74471420	C/T	cg01733217	chr16:74700730	RFWD3	-0.61	-8.19	-0.45	1.09e-14	Breast cancer;
CESC	cis	rs9814567	1.000	rs55913793	chr3:134285968	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.45	-6.05	-0.35	4.79e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs2637266	1.000	rs7081214	chr10:78361134	G/A	cg18941641	chr10:78392320	NA	0.41	7.73	0.43	2.17e-13	Pulmonary function;
CESC	cis	rs12586317	0.620	rs12588810	chr14:35554484	C/T	cg05294307	chr14:35346193	BAZ1A	-0.48	-5.17	-0.3	4.71e-7	Psoriasis;
CESC	cis	rs72945132	1.000	rs72945129	chr11:70110808	C/T	cg00319359	chr11:70116639	PPFIA1	0.84	7.84	0.43	1.11e-13	Coronary artery disease;
CESC	cis	rs2427308	0.643	rs477859	chr20:60937597	A/G	cg24112000	chr20:60950667	NA	0.45	5.39	0.31	1.57e-7	Colorectal cancer;
CESC	cis	rs854765	0.547	rs7212167	chr17:17913504	G/A	cg16928487	chr17:17741425	SREBF1	-0.57	-9.89	-0.52	7.74e-20	Total body bone mineral density;
CESC	cis	rs1215050	0.740	rs1214997	chr4:99041533	A/T	cg05340658	chr4:99064831	C4orf37	0.57	7.55	0.42	7.11e-13	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs4555082	0.874	rs78923231	chr14:105754033	C/T	cg13114125	chr14:105738426	BRF1	-0.91	-10.96	-0.56	2.65e-23	Mean platelet volume;Platelet distribution width;
CESC	cis	rs847577	0.550	rs12670686	chr7:97708397	A/G	cg24562669	chr7:97807699	LMTK2	0.78	13.16	0.63	8.64e-31	Breast cancer;
CESC	cis	rs4450798	0.744	rs4611801	chr3:13763808	A/G	cg05589046	chr3:13742034	LOC285375	0.35	5.28	0.31	2.71e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs2836974	0.899	rs35774464	chr21:40580169	G/A	cg11890956	chr21:40555474	PSMG1	1.11	17.72	0.74	6.83e-47	Cognitive function;
CESC	cis	rs7267979	0.866	rs437635	chr20:25456888	A/G	cg08601574	chr20:25228251	PYGB	0.37	5.36	0.31	1.77e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs1707322	1.000	rs11211243	chr1:46455433	G/C	cg03146154	chr1:46216737	IPP	0.72	9.82	0.52	1.31e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7918232	0.941	rs1753413	chr10:27397112	T/C	cg14240646	chr10:27532245	ACBD5	-0.68	-6.37	-0.36	8.36e-10	Breast cancer;
CESC	cis	rs96067	0.772	rs6700737	chr1:36598214	A/G	cg24686825	chr1:36642396	MAP7D1	-0.53	-5.88	-0.34	1.23e-8	Corneal structure;
CESC	cis	rs2228479	0.541	rs62052173	chr16:89950739	T/C	cg06558623	chr16:89946397	TCF25	0.59	5.83	0.34	1.59e-8	Skin colour saturation;
CESC	cis	rs4523957	0.583	rs6503302	chr17:2052704	C/T	cg16513277	chr17:2031491	SMG6	-0.79	-11.67	-0.58	1.14e-25	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs8017423	0.845	rs80167706	chr14:90727629	G/C	cg14092571	chr14:90743983	NA	-0.55	-8.17	-0.45	1.24e-14	Mortality in heart failure;
CESC	cis	rs13385	0.769	rs36050010	chr5:139569859	C/A	cg26211634	chr5:139558579	C5orf32	0.47	5.28	0.31	2.75e-7	Atrial fibrillation;
CESC	cis	rs712039	0.617	rs36081240	chr17:35785054	G/A	cg16670864	chr17:35848621	DUSP14	0.43	5.32	0.31	2.24e-7	Tuberculosis;
CESC	cis	rs227584	0.663	rs2040810	chr17:42243771	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	-0.4	-5.98	-0.34	7.24e-9	Bone mineral density (hip);Bone mineral density;
CESC	cis	rs801193	0.935	rs2659916	chr7:66151352	C/G	cg11764359	chr7:65958608	NA	0.69	9.06	0.49	2.98e-17	Aortic root size;
CESC	cis	rs3767633	0.925	rs1553444	chr1:161813515	C/T	cg09175582	chr1:161736000	ATF6	0.85	7.18	0.4	6.84e-12	IgG glycosylation;
CESC	cis	rs854765	0.583	rs4925125	chr17:17794444	T/C	cg16928487	chr17:17741425	SREBF1	0.53	9.01	0.48	4.08e-17	Total body bone mineral density;
CESC	cis	rs9649465	0.967	rs12534834	chr7:123307079	T/C	cg04330084	chr7:123175371	IQUB	-0.37	-5.05	-0.3	8.09e-7	Migraine;
CESC	trans	rs1814175	0.538	rs1684260	chr11:49224231	G/A	cg03929089	chr4:120376271	NA	0.78	11.75	0.59	5.9e-26	Height;
CESC	cis	rs7666738	0.830	rs28761309	chr4:98867393	C/T	cg17366294	chr4:99064904	C4orf37	0.54	7.48	0.42	1.1e-12	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9318086	0.648	rs7331047	chr13:24467342	T/C	cg25267304	chr13:24462978	PCOTH;MIPEP	0.49	6.96	0.39	2.6e-11	Myopia (pathological);
CESC	cis	rs4689388	0.926	rs4689394	chr4:6291003	C/G	cg25554036	chr4:6271136	WFS1	-0.52	-8.47	-0.46	1.66e-15	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg14893161	chr1:205819251	PM20D1	0.92	17.05	0.72	1.66e-44	Menarche (age at onset);
CESC	cis	rs2230307	0.536	rs580678	chr1:100483009	C/A	cg24955406	chr1:100503596	HIAT1	0.54	5.44	0.32	1.19e-7	Carotid intima media thickness;
CESC	cis	rs7582720	1.000	rs114079739	chr2:203825106	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.36	0.41	2.34e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs2235642	0.893	rs2076442	chr16:1591112	G/T	cg03771183	chr16:1608904	IFT140	0.41	5.9	0.34	1.1e-8	Coronary artery disease;
CESC	cis	rs920590	0.527	rs79929516	chr8:19650050	G/C	cg03894339	chr8:19674705	INTS10	0.74	7.74	0.43	2.11e-13	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs9488822	0.597	rs12214881	chr6:116342187	G/T	cg15226275	chr6:116381976	FRK	0.24	6.2	0.36	2.17e-9	Cholesterol, total;LDL cholesterol;
CESC	cis	rs9894429	1.000	rs9894429	chr17:79596811	C/T	cg13777783	chr17:79615861	NA	-0.34	-5.65	-0.33	4.22e-8	Eye color traits;
CESC	cis	rs7927771	0.864	rs55927797	chr11:47446292	A/T	cg18512352	chr11:47633146	NA	-0.51	-7.31	-0.41	3.18e-12	Subjective well-being;
CESC	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg03647317	chr4:187891568	NA	-0.37	-5.37	-0.31	1.69e-7	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg04742047	chr19:14544036	PKN1	-0.45	-6.0	-0.35	6.53e-9	Fibrinogen levels;
CESC	cis	rs9318086	0.624	rs9510909	chr13:24436760	C/T	cg25267304	chr13:24462978	PCOTH;MIPEP	0.43	5.75	0.33	2.5e-8	Myopia (pathological);
CESC	cis	rs2839186	0.739	rs7282763	chr21:47696800	C/T	cg10351095	chr21:47802916	PCNT	-0.51	-6.98	-0.39	2.36e-11	Testicular germ cell tumor;
CESC	cis	rs4975616	0.804	rs31489	chr5:1342714	C/A	cg07493874	chr5:1342172	CLPTM1L	-0.42	-7.79	-0.43	1.56e-13	Lung cancer;
CESC	cis	rs13191362	0.935	rs34603926	chr6:163266793	A/T	cg14584255	chr6:163149320	PACRG;PARK2	0.53	5.41	0.32	1.41e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs3617	0.625	rs7617468	chr3:52849549	T/C	cg07507251	chr3:52567010	NT5DC2	0.33	5.74	0.33	2.53e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
CESC	cis	rs7631605	0.967	rs4678949	chr3:37253277	C/T	cg22985146	chr3:37219077	LRRFIP2	-0.33	-5.11	-0.3	6.25e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs1538970	0.924	rs12037201	chr1:45941349	G/T	cg06784218	chr1:46089804	CCDC17	0.35	5.64	0.33	4.32e-8	Platelet count;
CESC	cis	rs709400	1.000	rs10135248	chr14:104122310	T/C	cg12935359	chr14:103987150	CKB	-0.42	-5.74	-0.33	2.6e-8	Body mass index;
CESC	cis	rs7927771	0.965	rs4752881	chr11:47898535	A/G	cg05585544	chr11:47624801	NA	-0.49	-7.45	-0.42	1.34e-12	Subjective well-being;
CESC	cis	rs8114671	0.562	rs2378292	chr20:33485178	T/C	cg07148914	chr20:33460835	GGT7	0.52	6.8	0.39	6.88e-11	Height;
CESC	trans	rs13398848	1.000	rs10496302	chr2:84210195	C/T	cg23262351	chr6:79576851	IRAK1BP1	-0.69	-6.08	-0.35	4.1e-9	Conduct disorder (symptom count);Conduct disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10056854	chr16:22019337	C16orf52	0.55	6.27	0.36	1.49e-9	Gut microbiome composition (summer);
CESC	cis	rs11638352	1.000	rs2615295	chr15:44412598	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.61	-5.62	-0.33	4.75e-8	Lipoprotein phospholipase A2 activity in cardiovascular disease;
CESC	cis	rs6964587	1.000	rs2299240	chr7:91654618	A/G	cg17063962	chr7:91808500	NA	0.56	7.69	0.43	2.84e-13	Breast cancer;
CESC	cis	rs1215050	0.740	rs783941	chr4:99008235	T/C	cg17366294	chr4:99064904	C4orf37	-0.4	-5.23	-0.31	3.42e-7	Waist-to-hip ratio adjusted for body mass index;
CESC	trans	rs916888	0.773	rs199439	chr17:44793503	A/G	cg23590916	chr17:43697445	MGC57346	0.65	6.69	0.38	1.33e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs2072732	0.821	rs58265521	chr1:2943398	C/A	cg15211996	chr1:2936768	ACTRT2	0.35	5.74	0.33	2.65e-8	Plateletcrit;
CESC	trans	rs1116547	0.602	rs6878001	chr5:112813100	T/C	cg10115368	chr14:100435663	NA	0.5	6.1	0.35	3.68e-9	Cerebral amyloid angiopathy;
CESC	cis	rs7091068	0.550	rs7079013	chr10:95487878	A/C	cg20715218	chr10:95462985	C10orf4	0.49	6.48	0.37	4.46e-10	Urinary tract infection frequency;
CESC	cis	rs736408	0.609	rs13082208	chr3:52781539	T/G	cg07507251	chr3:52567010	NT5DC2	0.42	7.3	0.41	3.4e-12	Bipolar disorder;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg11328405	chr15:49170157	SHC4;EID1	0.53	7.36	0.41	2.29e-12	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs9916302	0.808	rs6503515	chr17:37606433	G/T	cg20243544	chr17:37824526	PNMT	0.51	6.5	0.37	3.97e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs782590	0.517	rs13013133	chr2:55889466	G/A	cg18811423	chr2:55921094	PNPT1	-0.58	-7.65	-0.43	3.67e-13	Metabolic syndrome;
CESC	cis	rs1008375	0.898	rs4698620	chr4:17587361	C/T	cg16339924	chr4:17578868	LAP3	0.73	9.53	0.51	1.03e-18	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs4704187	0.649	rs7717415	chr5:74558893	A/G	cg03227963	chr5:74354835	NA	0.29	5.24	0.31	3.31e-7	Response to amphetamines;
CESC	cis	rs6963495	0.769	rs117986187	chr7:105167311	G/A	cg19920283	chr7:105172520	RINT1	0.7	6.68	0.38	1.39e-10	Bipolar disorder (body mass index interaction);
CESC	cis	rs7666738	0.822	rs6815312	chr4:99058220	T/C	cg18180107	chr4:99064573	C4orf37	0.41	5.24	0.31	3.24e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1552244	0.882	rs3732966	chr3:10015740	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.75	-9.49	-0.5	1.38e-18	Alzheimer's disease;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg16221875	chr6:21588597	NA	0.48	6.01	0.35	6.19e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs7202877	0.706	rs37599	chr16:75502132	C/T	cg04384234	chr16:75411784	CFDP1	0.44	5.29	0.31	2.56e-7	Type 2 diabetes;Type 1 diabetes;
CESC	cis	rs11252926	0.501	rs2050971	chr10:525530	T/G	cg16386425	chr10:429943	DIP2C	0.41	5.04	0.3	8.76e-7	Psychosis in Alzheimer's disease;
CESC	cis	rs9329289	0.851	rs61835719	chr10:2543390	A/G	cg15501526	chr10:2543763	NA	0.64	11.38	0.57	1.1e-24	Age-related hearing impairment;
CESC	cis	rs1784581	0.588	rs7758559	chr6:162438635	G/T	cg17173639	chr6:162384350	PARK2	0.55	8.25	0.45	7.24e-15	Itch intensity from mosquito bite;
CESC	cis	rs728616	0.614	rs12411833	chr10:82103230	T/C	cg05935833	chr10:81318306	SFTPA2	-0.37	-5.31	-0.31	2.3e-7	Chronic obstructive pulmonary disease-related biomarkers;
CESC	trans	rs7902708	0.920	rs12258467	chr10:54423900	C/T	cg26219051	chr22:43739629	SCUBE1	-0.48	-6.19	-0.36	2.25e-9	Bone properties (heel);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04482943	chr17:26684713	TMEM199;POLDIP2	0.63	7.02	0.4	1.87e-11	Gut microbiome composition (summer);
CESC	cis	rs7811142	0.720	rs112622797	chr7:99917416	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.07	9.09	0.49	2.43e-17	Platelet count;
CESC	cis	rs798766	1.000	rs1665366	chr4:1728381	A/G	cg05874882	chr4:1763078	NA	0.6	7.67	0.43	3.35e-13	Bladder cancer;Urinary bladder cancer;
CESC	cis	rs2976388	0.566	rs13250661	chr8:143804134	C/T	cg24634471	chr8:143751801	JRK	-0.44	-5.29	-0.31	2.6e-7	Urinary tract infection frequency;
CESC	cis	rs1552244	0.935	rs35148833	chr3:10116937	C/A	cg08888203	chr3:10149979	C3orf24	0.53	6.67	0.38	1.51e-10	Alzheimer's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09071838	chr13:25497213	CENPJ	0.6	7.14	0.4	8.79e-12	Gut microbiome composition (summer);
CESC	cis	rs796364	1.000	rs281794	chr2:200846666	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.89	8.77	0.47	2.23e-16	Schizophrenia;
CESC	cis	rs7412746	0.658	rs11581757	chr1:150892244	A/G	cg17724175	chr1:150552817	MCL1	0.39	5.96	0.34	8.12e-9	Melanoma;
CESC	cis	rs2228479	0.702	rs62053701	chr16:89860584	G/A	cg04013166	chr16:89971882	TCF25	0.77	6.61	0.38	2.05e-10	Skin colour saturation;
CESC	cis	rs35995292	0.500	rs8180877	chr7:38931258	G/A	cg19327137	chr7:38886074	VPS41	0.67	11.01	0.56	1.76e-23	Subjective well-being (multi-trait analysis);
CESC	cis	rs11098499	0.954	rs10008392	chr4:120318839	G/A	cg24375607	chr4:120327624	NA	0.48	5.81	0.34	1.8e-8	Corneal astigmatism;
CESC	cis	rs7089973	0.604	rs17663387	chr10:116588060	C/G	cg23260525	chr10:116636907	FAM160B1	0.38	7.08	0.4	1.29e-11	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17676428	chr11:1314042	TOLLIP	-0.55	-6.06	-0.35	4.71e-9	Gut microbiome composition (summer);
CESC	cis	rs2274273	0.638	rs9919921	chr14:55695505	A/G	cg04306507	chr14:55594613	LGALS3	0.31	5.25	0.31	3.2e-7	Protein biomarker;
CESC	cis	rs820218	0.743	rs820233	chr17:73697391	C/T	cg01592526	chr17:73663357	RECQL5;SAP30BP	0.41	5.6	0.33	5.26e-8	Rotator cuff tears;
CESC	cis	rs854765	0.505	rs4506969	chr17:17899839	A/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.5	6.45	0.37	5.32e-10	Total body bone mineral density;
CESC	cis	rs881375	0.715	rs11794516	chr9:123640230	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.5	7.12	0.4	1.01e-11	Rheumatoid arthritis;
CESC	cis	rs34779708	0.702	rs7087150	chr10:35542138	A/T	cg04310649	chr10:35416472	CREM	-0.47	-5.39	-0.31	1.59e-7	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs514406	0.755	rs11206015	chr1:53242187	T/C	cg27535305	chr1:53392650	SCP2	0.31	5.51	0.32	8.35e-8	Monocyte count;
CESC	cis	rs36051895	0.560	rs10975009	chr9:5220397	T/G	cg02405213	chr9:5042618	JAK2	-0.5	-6.09	-0.35	4.01e-9	Pediatric autoimmune diseases;
CESC	cis	rs8044868	0.530	rs4788464	chr16:72223899	T/C	cg16558253	chr16:72132732	DHX38	-0.43	-6.68	-0.38	1.37e-10	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CESC	cis	rs1552244	0.572	rs73117481	chr3:10160132	C/T	cg00149659	chr3:10157352	C3orf10	1.0	11.96	0.59	1.22e-26	Alzheimer's disease;
CESC	cis	rs10979	1.000	rs9399447	chr6:143896163	T/A	cg25407410	chr6:143891975	LOC285740	-0.61	-9.14	-0.49	1.66e-17	Hypospadias;
CESC	cis	rs9796	0.870	rs3900905	chr15:41260801	G/A	cg18705301	chr15:41695430	NDUFAF1	0.42	6.24	0.36	1.74e-9	Menopause (age at onset);
CESC	cis	rs780096	0.526	rs7602534	chr2:27592423	C/T	cg02592271	chr2:27665507	KRTCAP3	-0.29	-5.81	-0.34	1.77e-8	Total body bone mineral density;
CESC	cis	rs2033711	0.870	rs11669741	chr19:58960481	C/T	cg11952622	chr19:58962976	ZNF324B	-0.47	-6.56	-0.37	2.83e-10	Uric acid clearance;
CESC	cis	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.61	6.87	0.39	4.67e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7249142	0.597	rs7250650	chr19:19285989	A/T	cg27384695	chr19:19271486	LOC729991-MEF2B;MEF2B	0.29	5.21	0.3	3.75e-7	IgG glycosylation;
CESC	cis	rs6952808	0.756	rs12537348	chr7:1948172	C/G	cg04267008	chr7:1944627	MAD1L1	-0.74	-9.86	-0.52	1.01e-19	Bipolar disorder and schizophrenia;
CESC	cis	rs514406	0.644	rs4926928	chr1:53210163	G/T	cg08859206	chr1:53392774	SCP2	-0.54	-6.98	-0.39	2.34e-11	Monocyte count;
CESC	cis	rs8062405	0.755	rs12447461	chr16:28582941	C/A	cg01378222	chr16:28622494	SULT1A1	0.31	5.3	0.31	2.49e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs6463523	0.898	rs66892628	chr7:759374	T/A	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.97	14.68	0.67	4.26e-36	Subjective well-being;
CESC	cis	rs875971	0.545	rs3936065	chr7:65790564	C/T	cg11764359	chr7:65958608	NA	0.82	9.61	0.51	6.13e-19	Aortic root size;
CESC	cis	rs2115536	0.720	rs12916091	chr15:80222572	T/G	cg00225070	chr15:80189496	MTHFS	0.42	5.56	0.32	6.65e-8	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CESC	cis	rs4268898	0.552	rs12620938	chr2:24367122	C/A	cg06627628	chr2:24431161	ITSN2	0.59	8.19	0.45	1.12e-14	Asthma;
CESC	cis	rs10028773	0.700	rs7671797	chr4:120248157	A/G	cg09307838	chr4:120376055	NA	0.78	10.54	0.54	6.4e-22	Educational attainment;
CESC	cis	rs7927771	0.770	rs11039203	chr11:47384597	A/G	cg18512352	chr11:47633146	NA	-0.52	-7.51	-0.42	9.24e-13	Subjective well-being;
CESC	cis	rs7116495	1.000	rs2511079	chr11:71804154	C/T	cg26138937	chr11:71823887	C11orf51	-0.86	-7.72	-0.43	2.38e-13	Severe influenza A (H1N1) infection;
CESC	cis	rs13191362	1.000	rs34697913	chr6:163000187	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.5	5.17	0.3	4.64e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs7833790	0.926	rs72686467	chr8:82758929	T/G	cg17211192	chr8:82754475	SNX16	0.7	8.32	0.46	4.71e-15	Diastolic blood pressure;
CESC	cis	rs4243830	0.522	rs10157142	chr1:6618785	A/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.87	-8.13	-0.45	1.61e-14	Body mass index;
CESC	cis	rs3767633	0.925	rs2298019	chr1:161736035	A/G	cg09175582	chr1:161736000	ATF6	0.83	6.17	0.35	2.53e-9	IgG glycosylation;
CESC	cis	rs1580019	0.587	rs7806941	chr7:32553319	G/T	cg07520158	chr7:32535189	LSM5;AVL9	0.52	6.69	0.38	1.33e-10	Cognitive ability;
CESC	cis	rs7811142	0.562	rs7786844	chr7:99934008	T/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.95	10.92	0.56	3.71e-23	Platelet count;
CESC	cis	rs6714710	0.603	rs2044458	chr2:98377512	A/T	cg26665480	chr2:98280029	ACTR1B	0.53	7.58	0.42	5.78e-13	Posterior cortical atrophy and Alzheimer's disease;
CESC	cis	rs8031584	0.958	rs11293	chr15:31234981	G/A	cg14829155	chr15:31115871	NA	-0.72	-9.68	-0.51	3.49e-19	Huntington's disease progression;
CESC	cis	rs13191362	1.000	rs13201023	chr6:162981381	C/G	cg14584255	chr6:163149320	PACRG;PARK2	0.49	5.23	0.31	3.42e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs6580649	0.771	rs1034762	chr12:48389643	G/T	cg05342945	chr12:48394962	COL2A1	0.53	6.34	0.36	9.69e-10	Lung cancer;
CESC	cis	rs11098499	0.644	rs34835603	chr4:120553428	C/T	cg09307838	chr4:120376055	NA	0.78	10.46	0.54	1.13e-21	Corneal astigmatism;
CESC	cis	rs5743618	0.537	rs10020220	chr4:38765867	A/G	cg02016764	chr4:38805732	TLR1	-0.34	-5.21	-0.3	3.84e-7	Asthma;Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs1800795	0.652	rs7802307	chr7:22766433	T/A	cg05472934	chr7:22766657	IL6	0.78	10.14	0.53	1.27e-20	Cerebrospinal fluid clusterin levels in APOEe4- carriers;
CESC	cis	rs4555082	0.750	rs2816650	chr14:105708343	C/T	cg13114125	chr14:105738426	BRF1	-0.81	-9.76	-0.51	1.95e-19	Mean platelet volume;Platelet distribution width;
CESC	cis	rs933688	0.532	rs2973477	chr5:90553722	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.44	-5.11	-0.3	6.1e-7	Smoking behavior;
CESC	cis	rs1799949	1.000	rs8176296	chr17:41203591	T/C	cg05368731	chr17:41323189	NBR1	0.75	10.35	0.54	2.72e-21	Menopause (age at onset);
CESC	trans	rs9325144	0.560	rs11183150	chr12:38674698	A/G	cg23762105	chr12:34175262	ALG10	0.48	6.29	0.36	1.32e-9	Morning vs. evening chronotype;
CESC	cis	rs763121	0.853	rs2235230	chr22:39124467	A/G	cg06022373	chr22:39101656	GTPBP1	-0.86	-12.72	-0.62	3.04e-29	Menopause (age at onset);
CESC	cis	rs17818399	0.788	rs17818315	chr2:46818992	C/T	cg06386533	chr2:46925753	SOCS5	0.48	5.46	0.32	1.08e-7	Height;
CESC	cis	rs9811920	0.609	rs4928232	chr3:99694217	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.61	-7.37	-0.41	2.19e-12	Axial length;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg17847749	chr12:116355168	NA	0.46	6.27	0.36	1.49e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs6952808	0.564	rs73038441	chr7:2139286	T/C	cg02951883	chr7:2050386	MAD1L1	-0.47	-6.01	-0.35	6.14e-9	Bipolar disorder and schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09574498	chr17:48944758	NA	-0.67	-7.63	-0.42	4.14e-13	Gut microbiome composition (summer);
CESC	cis	rs7772486	0.790	rs7753696	chr6:146279098	G/T	cg05347473	chr6:146136440	FBXO30	-0.58	-7.35	-0.41	2.39e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs8072100	0.744	rs34537623	chr17:45530203	A/G	cg08085267	chr17:45401833	C17orf57	-0.54	-7.28	-0.41	3.75e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs10927875	0.541	rs1763607	chr1:16337509	G/A	cg22431228	chr1:16359049	CLCNKA	-0.52	-9.99	-0.52	3.63e-20	Dilated cardiomyopathy;
CESC	cis	rs1862618	0.671	rs2591956	chr5:56244604	G/A	cg22800045	chr5:56110881	MAP3K1	-0.59	-7.58	-0.42	5.95e-13	Initial pursuit acceleration;
CESC	cis	rs9487051	0.768	rs371960	chr6:109525082	A/G	cg01475377	chr6:109611718	NA	-0.48	-7.45	-0.42	1.34e-12	Reticulocyte fraction of red cells;
CESC	cis	rs1707322	0.963	rs4660900	chr1:46419605	T/C	cg06784218	chr1:46089804	CCDC17	0.33	5.63	0.33	4.7e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs875971	0.895	rs1833495	chr7:65921595	T/C	cg26939375	chr7:64535504	NA	0.46	6.0	0.35	6.4e-9	Aortic root size;
CESC	cis	rs5769765	0.865	rs3788730	chr22:50244695	C/T	cg26441486	chr22:50317300	CRELD2	-0.4	-5.52	-0.32	8.04e-8	Schizophrenia;
CESC	trans	rs7618501	0.633	rs4688690	chr3:50022292	G/A	cg21659725	chr3:3221576	CRBN	0.54	7.55	0.42	7.09e-13	Intelligence (multi-trait analysis);
CESC	cis	rs9682041	0.808	rs9880558	chr3:170067771	A/G	cg11886554	chr3:170076028	SKIL	-0.57	-5.47	-0.32	1.05e-7	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CESC	cis	rs7191868	1	rs7191868	chr16:536090	G/C	cg00676925	chr16:540266	RAB11FIP3	-0.64	-7.34	-0.41	2.55e-12	Platelet distribution width;
CESC	cis	rs7219021	0.739	rs1973404	chr17:46967892	G/T	cg16584676	chr17:46985605	UBE2Z	-0.65	-7.82	-0.43	1.24e-13	Schizophrenia or bipolar disorder;
CESC	cis	rs4969178	0.965	rs8071889	chr17:76398101	A/G	cg05887092	chr17:76393375	PGS1	0.58	9.08	0.49	2.62e-17	HDL cholesterol levels;
CESC	trans	rs61931739	0.534	rs4931772	chr12:34044590	G/A	cg26384229	chr12:38710491	ALG10B	0.53	7.22	0.41	5.44e-12	Morning vs. evening chronotype;
CESC	cis	rs3824867	0.920	rs7130693	chr11:47452321	T/C	cg20307385	chr11:47447363	PSMC3	-0.49	-5.94	-0.34	9.16e-9	Mean corpuscular hemoglobin;
CESC	cis	rs763014	0.898	rs1981484	chr16:630710	A/G	cg07343612	chr16:622815	PIGQ	-0.58	-8.49	-0.46	1.53e-15	Height;
CESC	cis	rs6088590	1.000	rs2076668	chr20:33437621	G/A	cg24642439	chr20:33292090	TP53INP2	0.82	11.56	0.58	2.76e-25	Coronary artery disease;
CESC	cis	rs9910055	0.659	rs227584	chr17:42225547	A/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.68	9.08	0.49	2.61e-17	Total body bone mineral density;
CESC	cis	rs7666738	0.830	rs13110498	chr4:98959150	G/A	cg05340658	chr4:99064831	C4orf37	0.8	12.33	0.6	6.31e-28	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04104609	chr2:219523980	ZNF142;BCS1L	0.52	6.18	0.35	2.45e-9	Gut microbiome composition (summer);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg12317515	chr5:74063363	GFM2;NSA2	0.5	6.93	0.39	3.29e-11	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	10.56	0.54	5.51e-22	Prudent dietary pattern;
CESC	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.53	0.37	3.4e-10	Prudent dietary pattern;
CESC	cis	rs854765	0.583	rs4534911	chr17:17852330	A/G	cg09796270	chr17:17721594	SREBF1	0.49	6.66	0.38	1.56e-10	Total body bone mineral density;
CESC	cis	rs9911578	0.967	rs2643124	chr17:56741672	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.24	0.31	3.23e-7	Intelligence (multi-trait analysis);
CESC	cis	rs250677	0.958	rs36078	chr5:148430567	G/A	cg18129178	chr5:148520854	ABLIM3	-0.52	-5.46	-0.32	1.1e-7	Breast cancer;
CESC	cis	rs6991838	0.584	rs7812446	chr8:66505988	G/T	cg13398993	chr8:66546079	ARMC1	-0.47	-5.59	-0.32	5.56e-8	Intelligence (multi-trait analysis);
CESC	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg07332563	chr6:291687	DUSP22	-0.7	-9.24	-0.49	8.36e-18	Menopause (age at onset);
CESC	cis	rs2842992	0.830	rs2025190	chr6:160138241	C/T	cg11366901	chr6:160182831	ACAT2	0.84	10.74	0.55	1.47e-22	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs208520	0.909	rs60604603	chr6:67022955	T/C	cg07460842	chr6:66804631	NA	0.84	8.13	0.45	1.67e-14	Exhaled nitric oxide output;
CESC	trans	rs11039798	0.614	rs2174703	chr11:48788242	G/A	cg15704280	chr7:45808275	SEPT13	0.71	6.22	0.36	1.92e-9	Axial length;
CESC	cis	rs3768617	0.565	rs2027080	chr1:183074415	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.83	13.29	0.63	3.24e-31	Fuchs's corneal dystrophy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11179286	chr13:115047994	UPF3A	0.59	7.31	0.41	3.16e-12	Gut microbiome composition (summer);
CESC	cis	rs2191566	1.000	rs10418363	chr19:44525463	A/G	cg20607764	chr19:44506953	ZNF230	-0.57	-7.45	-0.42	1.3e-12	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs67460515	0.506	rs935497	chr3:160600563	A/G	cg03342759	chr3:160939853	NMD3	-0.48	-6.32	-0.36	1.09e-9	Parkinson's disease;
CESC	cis	rs6867032	1.000	rs4246753	chr5:2014721	G/A	cg26168224	chr5:2018326	NA	0.95	19.19	0.76	4.89e-52	Gut microbiome composition (winter);
CESC	cis	rs10504229	1.000	rs67895971	chr8:58177994	A/G	cg05313129	chr8:58192883	C8orf71	-0.55	-6.37	-0.36	8.42e-10	Developmental language disorder (linguistic errors);
CESC	trans	rs11055612	0.776	rs1075010	chr12:13918341	T/C	cg23361084	chr11:73309262	FAM168A	-0.47	-6.02	-0.35	5.92e-9	Brain structure (temporal lobe volume);
CESC	cis	rs1799949	0.930	rs3092987	chr17:41222723	T/C	cg23758822	chr17:41437982	NA	1.04	15.41	0.69	1.12e-38	Menopause (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27536708	chr12:21654836	RECQL;GOLT1B	-0.55	-6.11	-0.35	3.52e-9	Gut microbiome composition (summer);
CESC	cis	rs1799949	0.965	rs33961729	chr17:41287924	C/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.64	8.64	0.47	5.5e-16	Menopause (age at onset);
CESC	cis	rs965469	0.901	rs6037563	chr20:3326568	G/A	cg25506879	chr20:3388711	C20orf194	-0.54	-5.78	-0.33	2.14e-8	IFN-related cytopenia;
CESC	cis	rs8060686	0.920	rs73591961	chr16:67801309	G/A	cg26727032	chr16:67993705	SLC12A4	-0.57	-6.06	-0.35	4.61e-9	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs12477438	1.000	rs11897712	chr2:99735697	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-8.6	-0.47	6.98e-16	Chronic sinus infection;
CESC	cis	rs7551222	0.752	rs1380576	chr1:204488278	G/C	cg20240347	chr1:204465584	NA	-0.28	-5.66	-0.33	3.95e-8	Schizophrenia;
CESC	cis	rs1801251	1.000	rs2592102	chr2:233726772	G/T	cg25237894	chr2:233734115	C2orf82	-0.47	-8.1	-0.45	1.98e-14	Coronary artery disease;
CESC	cis	rs2412819	0.542	rs62018894	chr15:43912987	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.52	6.68	0.38	1.41e-10	Lung cancer;
CESC	cis	rs875971	0.861	rs801215	chr7:66011938	A/T	cg10691866	chr7:65817282	TPST1	0.33	5.39	0.31	1.58e-7	Aortic root size;
CESC	cis	rs7762018	0.941	rs4716387	chr6:170136777	G/C	cg05834625	chr6:170176447	C6orf70	0.62	7.13	0.4	9.56e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs1707322	0.826	rs10890349	chr1:46249955	T/C	cg03146154	chr1:46216737	IPP	0.81	11.3	0.57	1.99e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg18538332	chr22:24372958	LOC391322	0.69	9.99	0.52	3.71e-20	Liver enzyme levels (gamma-glutamyl transferase);
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg07115559	chr11:122932847	HSPA8	0.43	6.48	0.37	4.4e-10	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs2985684	0.789	rs7161649	chr14:50064028	A/G	cg02151108	chr14:50098012	C14orf104	-0.38	-5.03	-0.3	8.89e-7	Carotid intima media thickness;
CESC	cis	rs12995491	0.731	rs56188884	chr2:88508657	G/A	cg04169830	chr2:88471460	THNSL2	0.33	5.13	0.3	5.52e-7	Response to metformin (IC50);
CESC	cis	rs3105593	0.575	rs3098174	chr15:50778853	C/T	cg05456662	chr15:50716270	USP8	0.45	6.05	0.35	5.04e-9	QT interval;
CESC	cis	rs7613875	0.620	rs3774734	chr3:50108792	C/A	cg24308560	chr3:49941425	MST1R	0.58	8.38	0.46	3.11e-15	Body mass index;
CESC	cis	rs7927771	0.832	rs55677087	chr11:47397714	C/G	cg18512352	chr11:47633146	NA	-0.52	-7.58	-0.42	5.86e-13	Subjective well-being;
CESC	cis	rs9611565	0.579	rs73178621	chr22:41921665	A/G	cg17376030	chr22:41985996	PMM1	0.76	8.22	0.45	9.05e-15	Vitiligo;
CESC	cis	rs4474465	0.850	rs10899549	chr11:78255389	T/C	cg27205649	chr11:78285834	NARS2	0.42	5.32	0.31	2.16e-7	Alzheimer's disease (survival time);
CESC	cis	rs6582630	0.502	rs10880092	chr12:38262965	A/T	cg13010199	chr12:38710504	ALG10B	0.51	6.29	0.36	1.29e-9	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs7927771	0.757	rs1057233	chr11:47376448	G/A	cg18512352	chr11:47633146	NA	0.51	7.17	0.4	7.32e-12	Subjective well-being;
CESC	cis	rs1448094	0.512	rs7137596	chr12:86239884	C/G	cg00310523	chr12:86230176	RASSF9	0.35	5.49	0.32	9.32e-8	Major depressive disorder;
CESC	cis	rs559555	0.812	rs3754835	chr2:32206029	T/G	cg02381751	chr2:32503542	YIPF4	0.42	5.34	0.31	1.96e-7	Blood metabolite ratios;Blood metabolite levels;
CESC	cis	rs950776	0.518	rs4886572	chr15:78837452	A/G	cg24631222	chr15:78858424	CHRNA5	0.39	5.12	0.3	6.02e-7	Sudden cardiac arrest;
CESC	cis	rs12701220	0.744	rs2030958	chr7:1076010	G/T	cg26769984	chr7:1090371	C7orf50	0.68	7.72	0.43	2.34e-13	Bronchopulmonary dysplasia;
CESC	cis	rs514406	0.861	rs2448792	chr1:53268313	T/C	cg16325326	chr1:53192061	ZYG11B	-0.9	-15.33	-0.69	2.02e-38	Monocyte count;
CESC	cis	rs6963495	0.818	rs117907809	chr7:105168472	C/A	cg13798780	chr7:105162888	PUS7	0.76	7.72	0.43	2.36e-13	Bipolar disorder (body mass index interaction);
CESC	cis	rs4819052	0.851	rs4819039	chr21:46659458	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.75	9.98	0.52	4.1e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs35146811	0.844	rs34031156	chr7:99677917	T/A	cg22906224	chr7:99728672	NA	0.42	5.19	0.3	4.12e-7	Coronary artery disease;
CESC	cis	rs3091242	0.933	rs909833	chr1:25754140	C/G	cg02931644	chr1:25747376	RHCE	0.38	6.37	0.36	8.43e-10	Erythrocyte sedimentation rate;
CESC	cis	rs6121246	0.909	rs6060960	chr20:30394517	G/T	cg13852791	chr20:30311386	BCL2L1	-0.75	-8.41	-0.46	2.48e-15	Mean corpuscular hemoglobin;
CESC	cis	rs796364	0.951	rs7586284	chr2:201068002	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.61	5.71	0.33	3.07e-8	Schizophrenia;
CESC	cis	rs10191773	0.535	rs72833432	chr2:113102746	T/C	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.61	-6.37	-0.36	8.21e-10	Yeast infection;
CESC	trans	rs1814175	0.791	rs10769625	chr11:49869887	G/A	cg15704280	chr7:45808275	SEPT13	-1.03	-20.77	-0.79	1.6e-57	Height;
CESC	cis	rs8014204	0.604	rs11625594	chr14:75389833	G/A	cg11812906	chr14:75593930	NEK9	0.54	6.67	0.38	1.48e-10	Caffeine consumption;
CESC	cis	rs875971	0.862	rs6460302	chr7:65960257	C/G	cg12463550	chr7:65579703	CRCP	0.47	5.79	0.34	1.99e-8	Aortic root size;
CESC	cis	rs2637266	0.783	rs846633	chr10:78535744	A/C	cg18941641	chr10:78392320	NA	-0.38	-7.33	-0.41	2.81e-12	Pulmonary function;
CESC	cis	rs7918232	0.943	rs4747584	chr10:27373333	G/A	cg14240646	chr10:27532245	ACBD5	-0.67	-6.24	-0.36	1.75e-9	Breast cancer;
CESC	cis	rs11871801	1.000	rs57307201	chr17:40572793	G/A	cg21433558	chr17:40837037	CNTNAP1	0.45	5.04	0.3	8.46e-7	Crohn's disease;
CESC	cis	rs9916302	0.718	rs7219909	chr17:37706243	C/T	cg20243544	chr17:37824526	PNMT	0.51	6.5	0.37	3.97e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs3824867	0.920	rs7105907	chr11:47450318	A/T	cg20307385	chr11:47447363	PSMC3	-0.47	-5.48	-0.32	9.68e-8	Mean corpuscular hemoglobin;
CESC	cis	rs735860	0.687	rs2294852	chr6:53157214	C/G	cg10236188	chr6:53219634	NA	-0.35	-5.04	-0.3	8.74e-7	Glaucoma;
CESC	cis	rs13191362	0.935	rs7769048	chr6:163010040	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.87	8.98	0.48	5.33e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs1046896	1.000	rs9909940	chr17:80689036	C/T	cg02711726	chr17:80685570	FN3KRP	-0.56	-8.27	-0.45	6.53e-15	Glycated hemoglobin levels;
CESC	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg06873352	chr17:61820015	STRADA	0.73	12.96	0.62	4.39e-30	Prudent dietary pattern;
CESC	cis	rs950027	0.787	rs1153845	chr15:45724729	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.48	-5.81	-0.34	1.82e-8	Response to fenofibrate (adiponectin levels);
CESC	cis	rs2115536	0.730	rs4573897	chr15:80187225	G/A	cg00225070	chr15:80189496	MTHFS	0.48	6.49	0.37	4.22e-10	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CESC	trans	rs4843747	0.641	rs11117353	chr16:88090895	A/G	cg26811252	chr16:29126840	RRN3P2	0.7	9.85	0.52	1.02e-19	Menopause (age at onset);
CESC	cis	rs56235845	0.694	rs6875461	chr5:176754665	C/T	cg06060754	chr5:176797920	RGS14	-0.44	-5.6	-0.33	5.28e-8	Hemoglobin concentration;Hematocrit;
CESC	cis	rs11264213	0.901	rs683622	chr1:36443569	C/T	cg27506609	chr1:36549197	TEKT2	-0.43	-5.03	-0.3	8.9e-7	Schizophrenia;
CESC	cis	rs4604732	0.588	rs7552461	chr1:247628644	G/A	cg12758973	chr1:247694275	LOC148824;OR2C3	0.48	6.01	0.35	6.07e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs769267	0.930	rs892021	chr19:19613480	T/C	cg03709012	chr19:19516395	GATAD2A	1.01	15.9	0.7	1.97e-40	Tonsillectomy;
CESC	trans	rs10448044	1.000	rs7820287	chr8:80100004	G/C	cg08211306	chr6:46097784	ENPP4	0.42	6.02	0.35	5.87e-9	Suicide in bipolar disorder;
CESC	cis	rs854765	0.583	rs12603148	chr17:17865257	C/T	cg04398451	chr17:18023971	MYO15A	-0.72	-10.46	-0.54	1.13e-21	Total body bone mineral density;
CESC	cis	rs6570726	0.755	rs2092297	chr6:145893765	A/G	cg05347473	chr6:146136440	FBXO30	0.59	7.63	0.42	4.24e-13	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs11077998	0.933	rs4239021	chr17:80531826	T/C	cg10255544	chr17:80519551	FOXK2	0.55	8.73	0.47	2.83e-16	Reticulocyte fraction of red cells;
CESC	cis	rs9911578	0.967	rs2333410	chr17:57137129	G/A	cg05425664	chr17:57184151	TRIM37	0.51	7.03	0.4	1.77e-11	Intelligence (multi-trait analysis);
CESC	cis	rs9303280	0.868	rs11650661	chr17:38026286	A/T	cg20243544	chr17:37824526	PNMT	0.53	7.05	0.4	1.57e-11	Self-reported allergy;
CESC	trans	rs9858542	0.953	rs6997	chr3:49453834	C/T	cg21659725	chr3:3221576	CRBN	-0.53	-6.74	-0.38	9.95e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs3008870	0.755	rs2755242	chr1:67479598	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.62	8.04	0.44	3.01e-14	Lymphocyte percentage of white cells;
CESC	cis	rs524281	0.861	rs10896077	chr11:65851733	C/G	cg14036092	chr11:66035641	RAB1B	-0.62	-6.39	-0.37	7.55e-10	Electroencephalogram traits;
CESC	cis	rs2011503	1.000	rs4808206	chr19:19645645	C/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.52	5.12	0.3	5.77e-7	Bipolar disorder;
CESC	cis	rs7084402	1.000	rs36097682	chr10:60269738	G/A	cg07615347	chr10:60278583	BICC1	-0.57	-8.71	-0.47	3.43e-16	Refractive error;
CESC	cis	rs72945132	0.882	rs56368190	chr11:70204328	T/G	cg14191688	chr11:70257035	CTTN	0.41	5.12	0.3	6.02e-7	Coronary artery disease;
CESC	cis	rs6732160	0.774	rs1367291	chr2:73374865	A/T	cg01422370	chr2:73384389	NA	0.43	7.47	0.42	1.16e-12	Intelligence (multi-trait analysis);
CESC	cis	rs748404	0.587	rs690276	chr15:43704558	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.59	7.78	0.43	1.67e-13	Lung cancer;
CESC	cis	rs5753618	0.583	rs5749268	chr22:31809152	G/A	cg13145458	chr22:31556086	RNF185	-0.5	-5.96	-0.34	7.96e-9	Colorectal cancer;
CESC	cis	rs1003719	0.762	rs3787786	chr21:38463436	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.63	8.77	0.47	2.14e-16	Eye color traits;
CESC	trans	rs17685	0.753	rs7804598	chr7:75702578	C/T	cg19862616	chr7:65841803	NCRNA00174	0.83	11.96	0.59	1.23e-26	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs6991838	0.584	rs6472218	chr8:66547737	G/C	cg13398993	chr8:66546079	ARMC1	0.46	5.65	0.33	4.19e-8	Intelligence (multi-trait analysis);
CESC	cis	rs793571	0.590	rs618684	chr15:59115922	A/G	cg05156742	chr15:59063176	FAM63B	0.6	7.81	0.43	1.3e-13	Schizophrenia;
CESC	cis	rs2370759	0.891	rs11592754	chr10:32619572	A/C	cg01819863	chr10:32635814	EPC1	1.12	10.05	0.53	2.45e-20	Sexual dysfunction (female);
CESC	cis	rs3768617	0.510	rs1886500	chr1:183095048	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.89	14.39	0.66	4.39e-35	Fuchs's corneal dystrophy;
CESC	cis	rs1499972	0.941	rs1456182	chr3:117659680	C/T	cg07612923	chr3:117604196	NA	0.91	7.88	0.44	8.41e-14	Schizophrenia;
CESC	cis	rs3818285	0.679	rs612155	chr10:111630731	C/G	cg00817464	chr10:111662876	XPNPEP1	0.48	7.53	0.42	7.85e-13	Superior crus of antihelix expression;
CESC	cis	rs10504229	0.679	rs16920056	chr8:58106218	C/A	cg21724239	chr8:58056113	NA	0.57	5.9	0.34	1.08e-8	Developmental language disorder (linguistic errors);
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg03705947	chr1:68152081	GADD45A	-0.45	-6.22	-0.36	1.89e-9	Height;
CESC	cis	rs116095464	0.558	rs55776650	chr5:273826	G/A	cg22496380	chr5:211416	CCDC127	-0.75	-8.59	-0.47	7.5e-16	Breast cancer;
CESC	cis	rs854765	0.647	rs6502637	chr17:17986098	A/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.47	6.01	0.35	6.26e-9	Total body bone mineral density;
CESC	cis	rs9733	0.596	rs2867304	chr1:150630995	G/A	cg04414720	chr1:150670196	GOLPH3L	0.63	9.04	0.49	3.47e-17	Tonsillectomy;
CESC	cis	rs2191566	0.576	rs381628	chr19:44494333	T/C	cg20607764	chr19:44506953	ZNF230	0.45	5.74	0.33	2.57e-8	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs17407555	0.601	rs73229828	chr4:10026833	A/G	cg11266682	chr4:10021025	SLC2A9	-0.5	-5.94	-0.34	8.82e-9	Schizophrenia (age at onset);
CESC	cis	rs938554	0.779	rs9998811	chr4:9966477	G/A	cg00071950	chr4:10020882	SLC2A9	-0.45	-5.24	-0.31	3.36e-7	Blood metabolite levels;
CESC	cis	rs400736	0.930	rs226251	chr1:8024690	T/C	cg25007680	chr1:8021821	PARK7	0.72	10.17	0.53	1.02e-20	Response to antidepressants and depression;
CESC	cis	rs1568889	0.838	rs10835276	chr11:28167147	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.8	13.45	0.64	8.35e-32	Bipolar disorder;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg10078639	chr10:116286586	ABLIM1	-0.46	-6.12	-0.35	3.31e-9	Ulcerative colitis;
CESC	cis	rs763121	0.853	rs4821812	chr22:39075235	G/C	cg21395723	chr22:39101663	GTPBP1	0.43	5.28	0.31	2.76e-7	Menopause (age at onset);
CESC	cis	rs858239	0.636	rs28706766	chr7:23169834	T/A	cg27449745	chr7:23145252	KLHL7	-0.49	-6.38	-0.36	7.81e-10	Cerebrospinal fluid biomarker levels;
CESC	cis	rs9814567	1.000	rs4309773	chr3:134277301	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.45	-6.08	-0.35	4.19e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	trans	rs3942852	0.568	rs10769314	chr11:48097620	C/T	cg03929089	chr4:120376271	NA	-0.63	-7.77	-0.43	1.78e-13	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs270601	0.710	rs4705852	chr5:131602807	A/G	cg24060327	chr5:131705240	SLC22A5	-0.47	-6.08	-0.35	4.12e-9	Acylcarnitine levels;
CESC	cis	rs4727963	0.792	rs12665913	chr7:122741302	T/C	cg03640110	chr7:122635026	TAS2R16	0.4	6.14	0.35	3.08e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
CESC	cis	rs4665809	1.000	rs1550382	chr2:26266877	T/G	cg04944784	chr2:26401820	FAM59B	-0.67	-7.53	-0.42	8.08e-13	Gut microbiome composition (summer);
CESC	cis	rs17209837	0.915	rs17149660	chr7:87089524	T/C	cg00919237	chr7:87102261	ABCB4	-0.5	-5.83	-0.34	1.6e-8	Gallbladder cancer;
CESC	cis	rs778371	0.788	rs4973569	chr2:233767037	A/G	cg08000102	chr2:233561755	GIGYF2	-0.81	-11.03	-0.56	1.53e-23	Schizophrenia;
CESC	cis	rs172166	0.694	rs1225716	chr6:28113746	A/C	cg12963246	chr6:28129442	ZNF389	0.43	6.25	0.36	1.59e-9	Cardiac Troponin-T levels;
CESC	cis	rs712039	0.652	rs853222	chr17:35790022	G/T	cg16670864	chr17:35848621	DUSP14	0.44	5.38	0.31	1.63e-7	Tuberculosis;
CESC	cis	rs17376456	0.866	rs13356088	chr5:93423479	C/T	cg25358565	chr5:93447407	FAM172A	1.22	10.91	0.56	3.85e-23	Diabetic retinopathy;
CESC	cis	rs7553864	0.667	rs10873820	chr1:87605973	C/G	cg17420885	chr1:87600446	LOC339524	0.41	5.5	0.32	9.08e-8	Smoking behavior;
CESC	cis	rs360798	0.532	rs360799	chr2:62953166	G/A	cg17519650	chr2:63277830	OTX1	-0.6	-7.71	-0.43	2.6e-13	Coronary artery disease;
CESC	cis	rs1062177	1.000	rs6890099	chr5:151151962	A/G	cg00977110	chr5:151150581	G3BP1	0.67	7.07	0.4	1.4e-11	Preschool internalizing problems;
CESC	cis	rs7937682	0.883	rs542831	chr11:111471392	T/A	cg22437258	chr11:111473054	SIK2	0.73	9.56	0.51	8.27e-19	Primary sclerosing cholangitis;
CESC	cis	rs7772486	0.686	rs10872579	chr6:145966012	C/G	cg05347473	chr6:146136440	FBXO30	0.46	5.96	0.34	8.21e-9	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2933343	0.700	rs789233	chr3:128603150	G/T	cg24203234	chr3:128598194	ACAD9	0.45	6.16	0.35	2.63e-9	IgG glycosylation;
CESC	cis	rs1797885	0.836	rs74280679	chr3:12570986	T/C	cg26432171	chr3:12704882	RAF1	-0.47	-5.94	-0.34	9.04e-9	Immature fraction of reticulocytes;
CESC	cis	rs992157	0.732	rs10932771	chr2:219170236	A/T	cg00012203	chr2:219082015	ARPC2	0.74	9.93	0.52	5.65e-20	Colorectal cancer;
CESC	trans	rs11098499	0.913	rs10010696	chr4:120164303	T/C	cg25214090	chr10:38739885	LOC399744	0.63	8.26	0.45	7.19e-15	Corneal astigmatism;
CESC	cis	rs77106637	0.929	rs74333814	chr11:72457487	C/T	cg03713592	chr11:72463424	ARAP1	1.3	11.05	0.56	1.39e-23	Type 2 diabetes;
CESC	trans	rs1814175	0.669	rs12416837	chr11:49669761	G/T	cg03929089	chr4:120376271	NA	-0.73	-9.66	-0.51	4.28e-19	Height;
CESC	cis	rs10876993	0.928	rs1689594	chr12:58057156	T/C	cg18357645	chr12:58087776	OS9	0.63	10.22	0.53	7.1e-21	Celiac disease or Rheumatoid arthritis;
CESC	cis	rs6952808	0.692	rs56727870	chr7:2029940	T/C	cg05863683	chr7:1912471	MAD1L1	0.43	6.35	0.36	9.24e-10	Bipolar disorder and schizophrenia;
CESC	cis	rs9814567	1.000	rs4974493	chr3:134219993	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.46	-6.28	-0.36	1.37e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs2737618	0.674	rs2737684	chr1:200092951	C/T	cg21825944	chr1:200113062	NR5A2	-0.43	-6.43	-0.37	5.84e-10	Uric acid levels;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg25201980	chr8:146127417	ZNF250	-0.47	-7.13	-0.4	9.83e-12	Gambling;
CESC	cis	rs3740540	0.530	rs10751598	chr10:126290951	A/G	cg04949429	chr10:126290192	LHPP	-0.4	-5.56	-0.32	6.62e-8	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
CESC	cis	rs1355223	0.583	rs2915178	chr11:34878051	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.82	12.56	0.61	1.07e-28	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs9527	0.590	rs7087040	chr10:104799668	G/A	cg04362960	chr10:104952993	NT5C2	0.43	5.56	0.32	6.7e-8	Arsenic metabolism;
CESC	cis	rs875971	0.522	rs4502988	chr7:65297746	A/G	cg06456125	chr7:65229604	NA	0.44	5.75	0.33	2.47e-8	Aortic root size;
CESC	cis	rs12200560	0.505	rs9400167	chr6:97077192	G/T	cg06623918	chr6:96969491	KIAA0776	0.5	6.42	0.37	6.42e-10	Coronary heart disease;
CESC	cis	rs9649213	0.593	rs7778015	chr7:97920270	T/C	cg24562669	chr7:97807699	LMTK2	0.48	6.8	0.39	6.74e-11	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18955698	chr17:43025023	KIF18B	-0.59	-6.95	-0.39	2.9100000000000002e-11	Gut microbiome composition (summer);
CESC	cis	rs10504229	0.636	rs117439064	chr8:58055279	A/G	cg21724239	chr8:58056113	NA	0.64	5.91	0.34	1.05e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs7618915	0.571	rs6762457	chr3:52609157	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	6.87	0.39	4.56e-11	Bipolar disorder;
CESC	cis	rs6783573	0.965	rs7650998	chr3:46607255	C/T	cg27371741	chr3:46619158	LRRC2;TDGF1	0.31	5.25	0.31	3.17e-7	Cerebrospinal fluid biomarker levels;
CESC	cis	rs12291225	0.645	rs3763950	chr11:14278049	T/A	cg19336497	chr11:14380999	RRAS2	-0.4	-5.74	-0.33	2.64e-8	Sense of smell;
CESC	cis	rs3733585	0.753	rs1122141	chr4:9947278	T/C	cg11266682	chr4:10021025	SLC2A9	-0.6	-12.03	-0.59	7.11e-27	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs8072100	1.000	rs11650372	chr17:45721795	G/A	cg08085267	chr17:45401833	C17orf57	-0.43	-5.67	-0.33	3.64e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs2295499	0.754	rs1828803	chr4:2689449	C/A	cg27239842	chr4:2403781	ZFYVE28	-0.31	-5.04	-0.3	8.74e-7	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg12721145	chr4:109571876	OSTC	0.51	7.23	0.41	5.15e-12	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	trans	rs6780666	0.509	rs9838168	chr3:136963967	C/T	cg16900796	chr19:10755136	SLC44A2	-0.4	-6.14	-0.35	3.05e-9	Intelligence (multi-trait analysis);
CESC	cis	rs9788682	0.747	rs2938671	chr15:78732754	A/G	cg24631222	chr15:78858424	CHRNA5	-0.63	-7.44	-0.42	1.44e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs1355223	0.902	rs860712	chr11:34743494	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.48	-6.44	-0.37	5.45e-10	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs6867032	0.958	rs4505990	chr5:2015811	A/G	cg26168224	chr5:2018326	NA	0.96	19.55	0.77	2.72e-53	Gut microbiome composition (winter);
CESC	cis	rs12142240	0.698	rs6429599	chr1:46827871	G/A	cg10495392	chr1:46806563	NSUN4	0.58	6.32	0.36	1.12e-9	Menopause (age at onset);
CESC	cis	rs2953145	0.568	rs1133354	chr2:241522450	A/G	cg07929629	chr2:241523174	NA	0.67	9.46	0.5	1.8e-18	Bipolar disorder;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg05934196	chr8:22925766	TNFRSF10B	-0.38	-6.07	-0.35	4.49e-9	Gambling;
CESC	cis	rs5747327	0.839	rs1470341	chr22:18198109	G/A	cg19898043	chr22:18121309	BCL2L13	-0.4	-5.14	-0.3	5.21e-7	Myeloid white cell count;Granulocyte count;
CESC	cis	rs6582630	0.519	rs11181998	chr12:38439970	C/A	cg26384229	chr12:38710491	ALG10B	0.69	10.55	0.54	5.83e-22	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs853679	0.517	rs9380052	chr6:28064623	A/G	cg19592336	chr6:28129416	ZNF389	0.55	7.11	0.4	1.06e-11	Depression;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26494424	chr12:124118326	EIF2B1;GTF2H3	0.61	6.99	0.39	2.19e-11	Gut microbiome composition (summer);
CESC	cis	rs13191362	1.000	rs67646369	chr6:163003233	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.5	5.17	0.3	4.64e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg07677032	chr17:61819896	STRADA	0.45	5.93	0.34	9.64e-9	Prudent dietary pattern;
CESC	cis	rs10791323	0.604	rs2853116	chr11:133707063	A/G	cg15485101	chr11:133734466	NA	0.41	6.57	0.37	2.66e-10	Childhood ear infection;
CESC	cis	rs12438659	1	rs12438659	chr15:78824924	G/A	cg06917634	chr15:78832804	PSMA4	-0.59	-6.98	-0.39	2.32e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs875971	0.505	rs2462573	chr7:65507392	C/T	cg05332525	chr7:65337924	VKORC1L1	-0.49	-6.05	-0.35	5.03e-9	Aortic root size;
CESC	cis	rs897984	0.683	rs12447534	chr16:30804257	C/T	cg02466173	chr16:30829666	NA	0.59	11.13	0.56	7.43e-24	Dementia with Lewy bodies;
CESC	cis	rs951366	0.649	rs7522056	chr1:205735891	A/G	cg26354017	chr1:205819088	PM20D1	0.52	6.84	0.39	5.6e-11	Menarche (age at onset);
CESC	cis	rs7809950	1.000	rs7782057	chr7:107098877	T/A	cg23024343	chr7:107201750	COG5	-0.41	-5.78	-0.33	2.12e-8	Coronary artery disease;
CESC	cis	rs2839186	0.585	rs2839154	chr21:47637760	C/T	cg10351095	chr21:47802916	PCNT	0.41	5.32	0.31	2.26e-7	Testicular germ cell tumor;
CESC	cis	rs2576037	0.526	rs607780	chr18:44417456	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.56	-7.89	-0.44	8.05e-14	Personality dimensions;
CESC	cis	rs597539	0.652	rs1249474	chr11:68654774	C/T	cg01988459	chr11:68622903	NA	-0.41	-5.74	-0.33	2.57e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	trans	rs57221529	0.709	rs72703090	chr5:598314	C/T	cg25482853	chr8:67687455	SGK3	1.04	10.08	0.53	1.87e-20	Lung disease severity in cystic fibrosis;
CESC	trans	rs7246760	0.867	rs1820114	chr19:9805692	G/A	cg02900749	chr2:68251473	NA	-0.82	-7.26	-0.41	4.38e-12	Pursuit maintenance gain;
CESC	cis	rs1983170	1.000	rs1983170	chr1:91986482	G/A	cg25838465	chr1:92012736	NA	0.45	5.44	0.32	1.22e-7	Eosinophil percentage of white cells;
CESC	cis	rs898097	0.841	rs8074284	chr17:80909967	G/A	cg15664640	chr17:80829946	TBCD	0.58	8.22	0.45	9.37e-15	Breast cancer;
CESC	cis	rs4819052	0.851	rs8131143	chr21:46671646	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.91	-13.45	-0.64	8.56e-32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs12136530	0.744	rs877012	chr1:19772660	G/A	cg01832549	chr1:19774989	CAPZB	-0.48	-6.85	-0.39	5.28e-11	Lead levels in blood;
CESC	cis	rs2835872	0.758	rs1787398	chr21:39037504	A/C	cg06728970	chr21:39037746	KCNJ6	0.3	5.53	0.32	7.57e-8	Electroencephalographic traits in alcoholism;
CESC	cis	rs6540559	0.673	rs6540564	chr1:210019910	T/C	cg25204440	chr1:209979598	IRF6	0.59	5.92	0.34	9.82e-9	Cleft lip with or without cleft palate;
CESC	cis	rs10089	0.953	rs72794400	chr5:127516028	C/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.75	10.11	0.53	1.58e-20	Ileal carcinoids;
CESC	cis	rs2073300	1.000	rs6137980	chr20:23466726	G/T	cg12062639	chr20:23401060	NAPB	0.93	5.89	0.34	1.15e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs4665809	1.000	rs12469163	chr2:26283587	T/C	cg04944784	chr2:26401820	FAM59B	-0.65	-7.53	-0.42	7.97e-13	Gut microbiome composition (summer);
CESC	cis	rs67311347	1.000	rs28491638	chr3:40496263	T/C	cg24209194	chr3:40518798	ZNF619	0.5	6.11	0.35	3.59e-9	Renal cell carcinoma;
CESC	cis	rs939574	1.000	rs79013471	chr2:220096122	C/A	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.84	7.61	0.42	4.85e-13	Platelet distribution width;
CESC	cis	rs7666738	0.830	rs3852122	chr4:98697400	T/C	cg24818145	chr4:99064322	C4orf37	0.39	5.08	0.3	7.03e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs1814175	0.817	rs1794162	chr11:49899506	A/C	cg03929089	chr4:120376271	NA	-0.93	-16.26	-0.71	1.03e-41	Height;
CESC	cis	rs9457247	0.935	rs1187530	chr6:167376812	C/T	cg25258033	chr6:167368657	RNASET2	-0.42	-6.25	-0.36	1.63e-9	Crohn's disease;
CESC	cis	rs2506889	0.553	rs17035189	chr1:10597024	A/G	cg20482658	chr1:10539492	PEX14	-0.26	-5.25	-0.31	3.07e-7	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01044692	chr2:208490024	FAM119A	0.65	7.54	0.42	7.63e-13	Gut microbiome composition (summer);
CESC	cis	rs6089584	0.854	rs6061407	chr20:60622048	A/C	cg13770153	chr20:60521292	NA	-0.44	-5.7	-0.33	3.2e-8	Body mass index;
CESC	cis	rs4689388	0.889	rs13128674	chr4:6294517	C/T	cg25554036	chr4:6271136	WFS1	0.51	8.37	0.46	3.31e-15	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs6860806	0.661	rs4705929	chr5:131584178	G/T	cg18301423	chr5:131593218	PDLIM4	0.39	5.5	0.32	9.06e-8	Breast cancer;
CESC	cis	rs1348850	0.914	rs2121430	chr2:178318375	A/G	cg22681709	chr2:178499509	PDE11A	-0.37	-5.41	-0.32	1.43e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs11792861	0.926	rs72607166	chr9:111821530	A/C	cg13535736	chr9:111863775	C9orf5	-0.51	-6.81	-0.39	6.45e-11	Menarche (age at onset);
CESC	cis	rs1801251	1.000	rs7606090	chr2:233606740	T/C	cg08000102	chr2:233561755	GIGYF2	0.64	9.09	0.49	2.47e-17	Coronary artery disease;
CESC	cis	rs2228479	0.867	rs12919804	chr16:89945369	G/A	cg00800038	chr16:89945340	TCF25	-0.88	-7.85	-0.43	1.01e-13	Skin colour saturation;
CESC	cis	rs7520050	0.778	rs2088102	chr1:46032974	T/C	cg03146154	chr1:46216737	IPP	-0.51	-6.54	-0.37	3.24e-10	Red blood cell count;Reticulocyte count;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg15213689	chr11:47202094	PACSIN3	0.49	6.31	0.36	1.18e-9	Fibrinogen levels;
CESC	cis	rs3806843	0.864	rs2531343	chr5:140129346	A/G	cg26395211	chr5:140044315	WDR55	0.39	5.09	0.3	6.79e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs9473147	0.516	rs7767350	chr6:47485126	C/T	cg20196966	chr6:47445060	CD2AP	0.41	5.33	0.31	2.13e-7	Platelet distribution width;Mean platelet volume;
CESC	cis	rs7666738	0.830	rs6831219	chr4:98993576	C/A	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.62e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3096299	1.000	rs3096299	chr16:89448663	G/A	cg00750074	chr16:89608354	SPG7	-0.36	-5.09	-0.3	6.83e-7	Multiple myeloma (IgH translocation);
CESC	trans	rs274437	0.739	rs10457998	chr6:104790542	C/A	cg24439334	chr1:2345374	PEX10	0.55	6.0	0.35	6.49e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3736485	0.816	rs11070851	chr15:51763249	C/G	cg08986416	chr15:51914746	DMXL2	0.41	5.21	0.31	3.72e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs6545883	0.929	rs2121660	chr2:61653058	T/C	cg15711740	chr2:61764176	XPO1	0.4	5.13	0.3	5.47e-7	Tuberculosis;
CESC	cis	rs4888262	0.526	rs7205992	chr16:74590578	T/A	cg01733217	chr16:74700730	RFWD3	0.81	11.35	0.57	1.39e-24	Testicular germ cell tumor;
CESC	cis	rs2180341	0.814	rs6569488	chr6:127726256	C/T	cg27446573	chr6:127587934	RNF146	0.83	12.03	0.59	6.99e-27	Breast cancer;
CESC	cis	rs763121	0.853	rs2072798	chr22:39148483	G/A	cg21395723	chr22:39101663	GTPBP1	0.46	5.97	0.34	7.51e-9	Menopause (age at onset);
CESC	cis	rs2361718	0.564	rs2304844	chr17:78084507	G/C	cg27427491	chr17:78079615	GAA	-0.41	-6.07	-0.35	4.53e-9	Yeast infection;
CESC	cis	rs6598955	0.724	rs12132137	chr1:26631243	C/T	cg04990556	chr1:26633338	UBXN11	-0.75	-10.39	-0.54	2.01e-21	Obesity-related traits;
CESC	cis	rs4713118	0.662	rs13218430	chr6:28029837	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.54	-6.2	-0.36	2.21e-9	Parkinson's disease;
CESC	cis	rs17539620	0.519	rs12665532	chr6:154835182	C/G	cg20019720	chr6:154832845	CNKSR3	0.43	6.37	0.36	8.33e-10	Lipoprotein (a) levels;
CESC	cis	rs5769765	0.955	rs9616394	chr22:50314927	G/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.59	-5.99	-0.35	6.64e-9	Schizophrenia;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg11258043	chr6:73972820	KHDC1	-0.5	-6.09	-0.35	3.87e-9	Ulcerative colitis;
CESC	cis	rs4665809	0.838	rs6546749	chr2:26306288	T/C	cg08470875	chr2:26401718	FAM59B	-0.62	-6.71	-0.38	1.2e-10	Gut microbiome composition (summer);
CESC	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg21280719	chr6:42927975	GNMT	-0.3	-7.02	-0.4	1.85e-11	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs80130819	0.591	rs17122651	chr12:48496660	C/T	cg24011408	chr12:48396354	COL2A1	-0.41	-5.18	-0.3	4.47e-7	Prostate cancer;
CESC	cis	rs6430585	0.528	rs7606267	chr2:136668123	T/C	cg07169764	chr2:136633963	MCM6	1.28	19.05	0.76	1.45e-51	Corneal structure;
CESC	cis	rs9611565	0.802	rs132916	chr22:41806768	C/G	cg06481639	chr22:41940642	POLR3H	0.48	5.55	0.32	7.02e-8	Vitiligo;
CESC	cis	rs36051895	0.575	rs7035251	chr9:5133665	T/A	cg02405213	chr9:5042618	JAK2	-0.47	-5.99	-0.35	6.78e-9	Pediatric autoimmune diseases;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg11296937	chr11:64084966	PRDX5;TRMT112	0.44	6.23	0.36	1.82e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs9649213	0.593	rs7776638	chr7:97993506	C/T	cg00277769	chr7:97922759	BAIAP2L1	-0.33	-5.41	-0.32	1.41e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs6598955	0.671	rs12141563	chr1:26589636	A/G	cg19743891	chr1:26644573	UBXN11;CD52	0.37	5.19	0.3	4.16e-7	Obesity-related traits;
CESC	cis	rs2380220	0.541	rs72928273	chr6:96079360	C/T	cg15832292	chr6:96025679	MANEA	-0.77	-8.1	-0.45	2.07e-14	Behavioural disinhibition (generation interaction);
CESC	cis	rs597539	0.652	rs686390	chr11:68656077	T/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.78	9.71	0.51	2.97e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs9896933	0.832	rs79103992	chr17:80855483	G/A	cg19500275	chr17:80737654	TBCD	0.66	6.11	0.35	3.63e-9	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
CESC	cis	rs3741151	0.686	rs11544310	chr11:73107592	A/G	cg17517138	chr11:73019481	ARHGEF17	0.82	6.54	0.37	3.07e-10	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs9311474	0.607	rs34005367	chr3:52558904	A/T	cg07507251	chr3:52567010	NT5DC2	0.47	8.71	0.47	3.42e-16	Electroencephalogram traits;
CESC	cis	rs9611565	0.592	rs4822038	chr22:41958495	G/A	cg17376030	chr22:41985996	PMM1	0.73	7.55	0.42	7.23e-13	Vitiligo;
CESC	cis	rs796364	0.760	rs56285751	chr2:200919836	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.85	-7.93	-0.44	6.07e-14	Schizophrenia;
CESC	cis	rs1728785	1.000	rs1170433	chr16:68606081	A/G	cg02972257	chr16:68554789	NA	-0.59	-6.71	-0.38	1.2e-10	Ulcerative colitis;
CESC	cis	rs6439153	0.933	rs11711812	chr3:128708554	G/A	cg24203234	chr3:128598194	ACAD9	0.43	5.59	0.32	5.56e-8	Pneumococcal bacteremia;
CESC	cis	rs6540556	0.517	rs61820570	chr1:209884953	C/T	cg05527609	chr1:210001259	C1orf107	-0.73	-7.15	-0.4	8.66e-12	Red blood cell count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23375783	chr17:73008576	ICT1	0.53	6.38	0.36	7.66e-10	Gut microbiome composition (summer);
CESC	cis	rs11098499	0.722	rs1814814	chr4:120258124	C/G	cg09307838	chr4:120376055	NA	0.81	11.35	0.57	1.39e-24	Corneal astigmatism;
CESC	cis	rs9303401	0.614	rs66480139	chr17:57101538	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.9	11.27	0.57	2.59e-24	Cognitive test performance;
CESC	cis	rs7219021	1.000	rs11868085	chr17:46847575	C/T	cg16584676	chr17:46985605	UBE2Z	-0.64	-7.23	-0.41	5.13e-12	Schizophrenia or bipolar disorder;
CESC	cis	rs13266463	0.898	rs13267784	chr8:143394915	C/T	cg16886403	chr8:143471632	TSNARE1	0.46	5.55	0.32	7.03e-8	Schizophrenia;
CESC	cis	rs9457247	0.935	rs1044059	chr6:167369897	C/A	cg25258033	chr6:167368657	RNASET2	-0.41	-6.2	-0.36	2.1e-9	Crohn's disease;
CESC	cis	rs7639513	0.590	rs3729931	chr3:12626516	A/G	cg23032965	chr3:12705835	RAF1	-0.62	-8.72	-0.47	3.13e-16	Itch intensity from mosquito bite;
CESC	trans	rs12599106	0.680	rs34728702	chr16:34896584	A/G	cg07332563	chr6:291687	DUSP22	-0.66	-8.42	-0.46	2.47e-15	Menopause (age at onset);
CESC	cis	rs875971	1.000	rs1544549	chr7:66090663	T/A	cg18876405	chr7:65276391	NA	-0.5	-6.6	-0.38	2.29e-10	Aortic root size;
CESC	cis	rs2011503	1.000	rs2965179	chr19:19512755	G/A	cg11584989	chr19:19387371	SF4	0.63	7.42	0.41	1.63e-12	Bipolar disorder;
CESC	cis	rs2933343	0.729	rs1683780	chr3:128640239	C/T	cg24203234	chr3:128598194	ACAD9	0.44	5.79	0.33	2.01e-8	IgG glycosylation;
CESC	cis	rs965469	1.000	rs2236092	chr20:3258188	G/C	cg25506879	chr20:3388711	C20orf194	-0.57	-6.14	-0.35	2.97e-9	IFN-related cytopenia;
CESC	cis	rs7872515	0.887	rs28727560	chr9:94864754	A/C	cg01248375	chr9:94877805	SPTLC1	0.55	5.83	0.34	1.64e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs9635726	0.638	rs2952155	chr17:37861718	T/C	cg00129232	chr17:37814104	STARD3	-0.75	-8.46	-0.46	1.82e-15	Primary biliary cholangitis;
CESC	cis	rs6545883	0.929	rs1186711	chr2:61688505	T/C	cg15711740	chr2:61764176	XPO1	-0.4	-5.06	-0.3	7.95e-7	Tuberculosis;
CESC	cis	rs3857067	1.000	rs1585652	chr4:95014313	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.52	-8.04	-0.44	3.04e-14	QT interval;
CESC	cis	rs10949834	0.878	rs2269083	chr7:73519661	G/A	cg07137043	chr7:73588983	EIF4H	-0.66	-5.7	-0.33	3.2e-8	Verbal memory performance (residualized delayed recall change);
CESC	cis	rs1799949	0.628	rs4474733	chr17:41433660	G/T	cg23758822	chr17:41437982	NA	1.02	12.83	0.62	1.27e-29	Menopause (age at onset);
CESC	cis	rs7845219	0.544	rs4735330	chr8:95917770	A/C	cg23172400	chr8:95962367	TP53INP1	-0.37	-6.78	-0.38	7.89e-11	Type 2 diabetes;
CESC	trans	rs9951602	0.512	rs7241419	chr18:76640778	C/G	cg02800362	chr5:177631904	HNRNPAB	0.62	8.1	0.45	1.96e-14	Obesity-related traits;
CESC	cis	rs6570726	0.935	rs371744	chr6:145841024	C/T	cg23711669	chr6:146136114	FBXO30	0.77	11.63	0.58	1.61e-25	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7666738	0.791	rs2081622	chr4:98927369	T/C	cg03467027	chr4:99064603	C4orf37	0.46	5.59	0.32	5.78e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7100689	0.577	rs10788545	chr10:82034675	A/G	cg09936400	chr10:82049201	MAT1A	0.4	5.85	0.34	1.43e-8	Post bronchodilator FEV1;
CESC	cis	rs7116495	0.609	rs73543643	chr11:71835596	C/T	cg10381502	chr11:71823885	C11orf51	1.06	6.77	0.38	8.27e-11	Severe influenza A (H1N1) infection;
CESC	cis	rs3096299	0.967	rs28689480	chr16:89460093	T/C	cg08822215	chr16:89438651	ANKRD11	-0.39	-5.84	-0.34	1.51e-8	Multiple myeloma (IgH translocation);
CESC	trans	rs561341	0.941	rs2428336	chr17:30290577	T/C	cg27661571	chr11:113659931	NA	-0.71	-7.11	-0.4	1.1e-11	Hip circumference adjusted for BMI;
CESC	cis	rs425277	0.539	rs3128338	chr1:2046786	G/A	cg16545954	chr1:2118288	C1orf86	-0.31	-5.7	-0.33	3.13e-8	Height;
CESC	cis	rs743757	1.000	rs2236971	chr3:50473349	G/A	cg10928302	chr3:50126174	RBM5	0.53	5.08	0.3	7.24e-7	Diastolic blood pressure;
CESC	cis	rs7680126	0.596	rs11731652	chr4:10292984	T/C	cg11266682	chr4:10021025	SLC2A9	-0.43	-5.72	-0.33	2.9e-8	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	cis	rs3760982	0.585	rs10422108	chr19:44294868	C/T	cg11993925	chr19:44307056	LYPD5	0.33	5.61	0.33	5.11e-8	Breast cancer (estrogen-receptor negative);Breast cancer;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg18170098	chr16:71880032	ATXN1L	-0.46	-6.37	-0.36	8.48e-10	Asthma;
CESC	cis	rs898097	0.841	rs8074284	chr17:80909967	G/A	cg15369054	chr17:80825471	TBCD	-0.46	-6.2	-0.36	2.13e-9	Breast cancer;
CESC	cis	rs11098499	0.826	rs12511640	chr4:120251248	T/C	cg09307838	chr4:120376055	NA	0.77	10.49	0.54	9.15e-22	Corneal astigmatism;
CESC	cis	rs9287719	0.967	rs6744854	chr2:10747246	C/G	cg00105475	chr2:10696890	NA	0.38	5.57	0.32	6.34e-8	Prostate cancer;
CESC	trans	rs7246657	0.943	rs7252346	chr19:37914682	G/A	cg24637308	chr11:6592297	DNHD1	0.54	6.34	0.36	1.01e-9	Coronary artery calcification;
CESC	cis	rs7615952	0.641	rs7632497	chr3:125783086	A/C	cg15145296	chr3:125709740	NA	-0.53	-5.65	-0.33	4.05e-8	Blood pressure (smoking interaction);
CESC	trans	rs4843747	0.803	rs72818522	chr16:88059144	C/T	cg26811252	chr16:29126840	RRN3P2	0.71	9.8	0.52	1.51e-19	Menopause (age at onset);
CESC	cis	rs2380220	0.574	rs9400526	chr6:95998441	T/C	cg23517279	chr6:96025343	MANEA	0.54	5.8	0.34	1.85e-8	Behavioural disinhibition (generation interaction);
CESC	cis	rs736408	0.608	rs6445534	chr3:52743384	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	8.08	0.44	2.26e-14	Bipolar disorder;
CESC	cis	rs425277	0.539	rs3107142	chr1:2044542	T/C	cg16545954	chr1:2118288	C1orf86	-0.31	-5.67	-0.33	3.74e-8	Height;
CESC	cis	rs9916302	0.904	rs2168785	chr17:37407135	C/T	cg07936489	chr17:37558343	FBXL20	-0.79	-11.22	-0.57	3.68e-24	Glomerular filtration rate (creatinine);
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg24086158	chr2:47169120	MCFD2;TTC7A	-0.42	-6.05	-0.35	4.89e-9	Vertical cup-disc ratio;
CESC	cis	rs1018836	0.632	rs1028255	chr8:91485578	A/T	cg16814680	chr8:91681699	NA	-0.62	-8.57	-0.47	8.89e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs6500395	0.962	rs9924483	chr16:48646258	C/T	cg04672837	chr16:48644449	N4BP1	0.47	5.57	0.32	6.4e-8	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs6570726	0.935	rs1883406	chr6:145823205	A/G	cg23711669	chr6:146136114	FBXO30	0.81	12.04	0.59	6.44e-27	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs7615952	0.512	rs2922175	chr3:125361360	T/C	cg21747405	chr11:67723411	NA	-0.44	-6.69	-0.38	1.3100000000000001e-10	Blood pressure (smoking interaction);
CESC	cis	rs1975974	0.872	rs17052344	chr17:21717543	A/G	cg18423549	chr17:21743878	NA	0.49	6.92	0.39	3.43e-11	Psoriasis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19210712	chr3:44903163	MIR564;TMEM42	0.58	6.58	0.37	2.51e-10	Gut microbiome composition (summer);
CESC	cis	rs7089973	0.966	rs55711292	chr10:116604870	T/G	cg23260525	chr10:116636907	FAM160B1	0.38	6.12	0.35	3.43e-9	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg17267720	chr15:34396248	PGBD4	-0.43	-6.27	-0.36	1.42e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs72945132	0.882	rs56368270	chr11:70162590	A/G	cg14191688	chr11:70257035	CTTN	0.45	5.52	0.32	7.96e-8	Coronary artery disease;
CESC	cis	rs155076	0.666	rs2015241	chr13:21888254	A/G	cg06138931	chr13:21896616	NA	0.54	5.62	0.33	4.82e-8	White matter hyperintensity burden;
CESC	cis	rs2836974	0.666	rs2836975	chr21:40663620	A/G	cg11644478	chr21:40555479	PSMG1	-0.82	-12.24	-0.6	1.34e-27	Cognitive function;
CESC	cis	rs11122272	0.735	rs2739506	chr1:231529183	T/G	cg06096015	chr1:231504339	EGLN1	0.43	6.15	0.35	2.9e-9	Hemoglobin concentration;
CESC	cis	rs6433857	0.594	rs11894486	chr2:181520678	C/T	cg23363182	chr2:181467187	NA	-0.46	-6.35	-0.36	9.29e-10	Body mass index;
CESC	cis	rs9457247	1.000	rs364283	chr6:167383750	C/T	cg07741184	chr6:167504864	NA	0.31	5.53	0.32	7.76e-8	Crohn's disease;
CESC	cis	rs17376456	0.825	rs10476590	chr5:93244884	A/T	cg21475434	chr5:93447410	FAM172A	0.76	6.2	0.36	2.16e-9	Diabetic retinopathy;
CESC	cis	rs7412746	0.658	rs7521719	chr1:150913134	G/A	cg22823121	chr1:150693482	HORMAD1	0.4	5.7	0.33	3.2e-8	Melanoma;
CESC	cis	rs11078597	0.708	rs7503952	chr17:1649259	G/C	cg18436246	chr17:1640651	WDR81	0.62	7.63	0.42	4.25e-13	Serum albumin level;
CESC	cis	rs643506	0.874	rs609007	chr11:111719593	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.4	-5.11	-0.3	6.05e-7	Breast cancer;
CESC	trans	rs1814175	0.645	rs4411280	chr11:49962750	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.43	-6.24	-0.36	1.75e-9	Height;
CESC	cis	rs10876993	0.890	rs810204	chr12:58075733	T/C	cg18357645	chr12:58087776	OS9	0.65	10.63	0.55	3.37e-22	Celiac disease or Rheumatoid arthritis;
CESC	cis	rs10461617	0.541	rs860581	chr5:56150537	A/G	cg22800045	chr5:56110881	MAP3K1	0.83	8.07	0.44	2.47e-14	Type 2 diabetes;
CESC	cis	rs56046484	0.956	rs12904410	chr15:85609788	C/T	cg08123816	chr15:85640762	PDE8A	-0.46	-5.83	-0.34	1.62e-8	Testicular germ cell tumor;
CESC	cis	rs62432291	0.681	rs397476	chr6:159639284	A/G	cg14500486	chr6:159655392	FNDC1	-0.52	-5.91	-0.34	1.07e-8	Joint mobility (Beighton score);
CESC	cis	rs858239	0.601	rs6962526	chr7:23158233	G/A	cg23682824	chr7:23144976	KLHL7	0.54	7.4	0.41	1.79e-12	Cerebrospinal fluid biomarker levels;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg02477126	chr22:24988729	C22orf36;GGT1	-0.47	-6.02	-0.35	5.79e-9	Asthma;
CESC	cis	rs798554	0.610	rs2248390	chr7:2855594	T/C	cg19717773	chr7:2847554	GNA12	-0.54	-8.47	-0.46	1.68e-15	Height;
CESC	cis	rs873946	0.517	rs2803990	chr10:134560340	A/G	cg27286337	chr10:134555280	INPP5A	0.68	8.68	0.47	4.08e-16	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs11997175	0.625	rs4268088	chr8:33599343	A/T	ch.8.33884649F	chr8:33765107	NA	0.51	6.29	0.36	1.34e-9	Body mass index;
CESC	cis	rs7666738	0.830	rs3907020	chr4:99038583	T/C	cg05340658	chr4:99064831	C4orf37	0.8	12.39	0.61	3.91e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3105593	0.933	rs3131576	chr15:50863658	T/C	cg08437265	chr15:50716283	USP8	0.42	5.49	0.32	9.2e-8	QT interval;
CESC	cis	rs2820292	0.804	rs2644120	chr1:201882277	C/G	cg11586189	chr1:201857591	SHISA4	0.38	6.46	0.37	5.09e-10	Waist circumference;Body mass index (joint analysis main effects and smoking interaction);Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);
CESC	cis	rs875971	1.000	rs2420591	chr7:65912381	T/C	cg18876405	chr7:65276391	NA	0.51	6.83	0.39	5.69e-11	Aortic root size;
CESC	cis	rs4665809	1.000	rs4665819	chr2:26309073	A/G	cg08470875	chr2:26401718	FAM59B	-0.48	-5.27	-0.31	2.79e-7	Gut microbiome composition (summer);
CESC	cis	rs796364	0.951	rs6722092	chr2:201059371	G/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.6	6.17	0.35	2.5e-9	Schizophrenia;
CESC	cis	rs1728785	1.000	rs1645976	chr16:68563509	T/C	cg02972257	chr16:68554789	NA	-0.55	-6.37	-0.36	8.21e-10	Ulcerative colitis;
CESC	cis	rs10504229	1.000	rs112284078	chr8:58191640	A/G	cg05313129	chr8:58192883	C8orf71	-0.58	-6.61	-0.38	2.12e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs3096299	0.606	rs4785573	chr16:89565403	A/G	cg02187348	chr16:89574699	SPG7	0.5	6.16	0.35	2.71e-9	Multiple myeloma (IgH translocation);
CESC	cis	rs3820928	0.810	rs10175929	chr2:227858609	T/C	cg11843606	chr2:227700838	RHBDD1	-0.43	-5.53	-0.32	7.7e-8	Pulmonary function;
CESC	cis	rs10256972	0.527	rs2949170	chr7:1216438	A/G	cg15112475	chr7:1198522	ZFAND2A	-0.42	-6.44	-0.37	5.66e-10	Longevity;Endometriosis;
CESC	cis	rs3091242	0.933	rs11249251	chr1:25770188	C/G	cg27572855	chr1:25598939	RHD	0.43	7.22	0.41	5.47e-12	Erythrocyte sedimentation rate;
CESC	trans	rs10506458	0.915	rs60094497	chr12:63394838	T/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.34	-18.45	-0.75	1.83e-49	Hemostatic factors and hematological phenotypes;
CESC	cis	rs4132509	0.948	rs1458023	chr1:243886673	A/G	cg21452805	chr1:244014465	NA	0.51	6.52	0.37	3.45e-10	RR interval (heart rate);
CESC	cis	rs1707322	0.721	rs28501477	chr1:46199084	A/G	cg05343316	chr1:45956843	TESK2	0.51	6.2	0.36	2.19e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs11039798	0.688	rs8188953	chr11:48749201	A/T	cg15704280	chr7:45808275	SEPT13	0.7	6.31	0.36	1.14e-9	Axial length;
CESC	cis	rs5753618	0.504	rs5753669	chr22:31905819	T/G	cg00478049	chr22:31556069	RNF185	-0.46	-5.52	-0.32	8.25e-8	Colorectal cancer;
CESC	cis	rs875971	0.660	rs10215132	chr7:66054406	C/A	cg25985355	chr7:65971099	NA	0.32	5.24	0.31	3.24e-7	Aortic root size;
CESC	cis	rs3785574	0.927	rs2854183	chr17:61968002	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.04	16.56	0.71	9.03e-43	Height;
CESC	cis	rs926938	0.765	rs12407408	chr1:115234275	A/G	cg12756093	chr1:115239321	AMPD1	0.65	10.11	0.53	1.58e-20	Autism;
CESC	cis	rs11122272	0.735	rs2808580	chr1:231509259	A/G	cg06096015	chr1:231504339	EGLN1	0.43	6.18	0.35	2.46e-9	Hemoglobin concentration;
CESC	cis	rs2249625	0.545	rs55681410	chr6:72877859	G/A	cg18830697	chr6:72922368	RIMS1	0.42	5.94	0.34	8.7e-9	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CESC	cis	rs2361718	0.967	rs2361719	chr17:78103403	A/G	cg21238619	chr17:78079768	GAA	0.34	5.58	0.32	6.02e-8	Yeast infection;
CESC	cis	rs9430161	0.579	rs7542354	chr1:11040385	G/A	cg02454025	chr1:11042201	C1orf127	0.87	13.72	0.64	9.82e-33	Ewing sarcoma;
CESC	cis	rs868036	1.000	rs9972436	chr15:68098027	G/C	cg08079166	chr15:68083412	MAP2K5	0.44	6.94	0.39	2.94e-11	Restless legs syndrome;
CESC	cis	rs10823500	0.777	rs2184335	chr10:72006891	C/T	cg04118878	chr10:71993077	PPA1	0.5	5.72	0.33	2.81e-8	Blood protein levels;
CESC	cis	rs7618915	0.501	rs34157897	chr3:52716937	T/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.81	0.39	6.64e-11	Bipolar disorder;
CESC	cis	rs12348691	0.503	rs1867279	chr9:100616041	T/C	cg13688889	chr9:100608707	NA	-0.9	-13.65	-0.64	1.78e-32	Alopecia areata;
CESC	cis	rs6121246	0.529	rs73235789	chr20:30196148	T/C	cg13852791	chr20:30311386	BCL2L1	0.67	6.71	0.38	1.2e-10	Mean corpuscular hemoglobin;
CESC	cis	rs3026101	0.671	rs3026125	chr17:5293627	T/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.43	5.68	0.33	3.57e-8	Body mass index;
CESC	cis	rs798554	0.724	rs798498	chr7:2795882	T/G	cg19717773	chr7:2847554	GNA12	-0.56	-8.15	-0.45	1.46e-14	Height;
CESC	cis	rs769267	0.965	rs2965191	chr19:19453521	T/G	cg17414380	chr19:19431394	KIAA0892;SF4	-0.49	-6.06	-0.35	4.66e-9	Tonsillectomy;
CESC	cis	rs1348850	0.561	rs4893956	chr2:178373452	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.68	6.17	0.35	2.52e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs4523957	0.651	rs9910413	chr17:2081419	G/A	cg16513277	chr17:2031491	SMG6	-0.71	-10.17	-0.53	1.04e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02565297	chr12:133144810	FBRSL1	-0.53	-6.31	-0.36	1.16e-9	Gut microbiome composition (summer);
CESC	cis	rs9291683	0.632	rs12508991	chr4:10041104	C/T	cg02734326	chr4:10020555	SLC2A9	0.47	6.53	0.37	3.29e-10	Bone mineral density;
CESC	cis	rs34638657	0.872	rs2967355	chr16:82200103	G/T	cg09439754	chr16:82129088	HSD17B2	0.37	5.33	0.31	2.06e-7	Lung adenocarcinoma;
CESC	cis	rs8014204	0.836	rs11159099	chr14:75235397	A/G	cg11812906	chr14:75593930	NEK9	0.42	5.22	0.31	3.66e-7	Caffeine consumption;
CESC	cis	rs10789491	1.000	rs4097354	chr1:47187073	T/G	cg03812309	chr1:46938281	NA	0.35	5.04	0.3	8.59e-7	Response to hepatitis C treatment;
CESC	cis	rs8177253	0.530	rs8177177	chr3:133463195	A/G	cg16262614	chr3:133464971	TF	0.28	5.28	0.31	2.63e-7	Iron status biomarkers;
CESC	cis	rs734999	0.545	rs6666788	chr1:2567500	A/G	cg18854424	chr1:2615690	NA	-0.3	-5.95	-0.34	8.47e-9	Ulcerative colitis;
CESC	cis	rs60594510	1	rs60594510	chr12:110594503	C/T	cg12870014	chr12:110450643	ANKRD13A	0.65	5.59	0.32	5.76e-8	Intelligence (multi-trait analysis);
CESC	cis	rs3008870	1.000	rs2985797	chr1:67431499	C/T	cg02640540	chr1:67518911	SLC35D1	-0.53	-5.59	-0.32	5.68e-8	Lymphocyte percentage of white cells;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18313106	chr1:229694614	ABCB10	0.52	6.31	0.36	1.14e-9	Gut microbiome composition (summer);
CESC	cis	rs9790314	0.846	rs899275	chr3:161042104	T/C	cg03342759	chr3:160939853	NMD3	-0.54	-7.78	-0.43	1.65e-13	Morning vs. evening chronotype;
CESC	cis	rs7662987	0.517	rs3018047	chr4:100014510	C/T	cg13256891	chr4:100009986	ADH5	-0.67	-7.48	-0.42	1.1e-12	Smoking initiation;
CESC	cis	rs875971	0.619	rs2302918	chr7:66000932	A/G	cg18876405	chr7:65276391	NA	0.58	7.78	0.43	1.59e-13	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22586474	chr7:931148	C7orf20	-0.6	-6.85	-0.39	5.29e-11	Gut microbiome composition (summer);
CESC	cis	rs2576037	0.796	rs2571030	chr18:44573854	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.59	-8.49	-0.46	1.47e-15	Personality dimensions;
CESC	trans	rs208520	0.837	rs208486	chr6:66926255	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.85	-9.88	-0.52	8.61e-20	Exhaled nitric oxide output;
CESC	cis	rs262150	0.501	rs2730206	chr7:158815173	G/C	cg19418458	chr7:158789849	NA	-0.41	-6.22	-0.36	1.95e-9	Facial morphology (factor 20);
CESC	cis	rs12912251	1.000	rs12916379	chr15:38991520	A/G	cg01338139	chr15:38987640	C15orf53	-0.53	-6.16	-0.35	2.63e-9	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
CESC	cis	rs4660306	1.000	rs2356559	chr1:45981512	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.55	-6.97	-0.39	2.45e-11	Homocysteine levels;
CESC	cis	rs6860806	0.661	rs2171247	chr5:131580234	G/T	cg11843238	chr5:131593191	PDLIM4	0.36	5.25	0.31	3.12e-7	Breast cancer;
CESC	cis	rs9640161	0.789	rs34495356	chr7:150057791	A/G	cg17279839	chr7:150038598	RARRES2	0.46	5.43	0.32	1.28e-7	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs10504073	0.584	rs1511365	chr8:49975321	A/T	cg00325661	chr8:49890786	NA	0.61	9.21	0.49	1.03e-17	Blood metabolite ratios;
CESC	cis	rs7091068	0.566	rs1326220	chr10:95486155	G/A	cg20715218	chr10:95462985	C10orf4	0.56	5.38	0.31	1.65e-7	Urinary tract infection frequency;
CESC	cis	rs7267979	0.934	rs2257464	chr20:25265872	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	18.61	0.75	5.02e-50	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7923452	0.938	rs34560372	chr10:30773831	G/A	cg18806716	chr10:30721971	MAP3K8	0.48	5.67	0.33	3.81e-8	Itch intensity from mosquito bite;
CESC	cis	rs6088580	0.505	rs6141503	chr20:33274469	G/A	cg06115741	chr20:33292138	TP53INP2	-0.43	-5.08	-0.3	7.14e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs6570726	0.791	rs621382	chr6:145799144	T/C	cg23711669	chr6:146136114	FBXO30	1.0	15.7	0.69	1.01e-39	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05537210	chr4:110650914	PLA2G12A	0.49	6.99	0.39	2.2e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs7818688	0.614	rs59265059	chr8:95832816	G/A	cg16049864	chr8:95962084	TP53INP1	0.55	5.62	0.33	4.81e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs11122272	0.603	rs2998427	chr1:231528112	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.56	-7.69	-0.43	2.92e-13	Hemoglobin concentration;
CESC	cis	rs3105593	1.000	rs2414060	chr15:50873262	A/G	cg08437265	chr15:50716283	USP8	0.4	5.26	0.31	2.92e-7	QT interval;
CESC	cis	rs9300255	0.664	rs28636834	chr12:123871070	A/C	cg19016782	chr12:123741754	C12orf65	0.47	6.39	0.37	7.59e-10	Neutrophil percentage of white cells;
CESC	cis	rs2836974	0.931	rs2989330	chr21:40716209	A/G	cg11644478	chr21:40555479	PSMG1	0.89	11.51	0.58	3.98e-25	Cognitive function;
CESC	cis	rs1580019	0.961	rs1868776	chr7:32494435	G/T	cg06627557	chr7:32535165	LSM5;AVL9	-0.72	-10.09	-0.53	1.86e-20	Cognitive ability;
CESC	cis	rs2228479	0.850	rs11645240	chr16:89837326	T/C	cg04013166	chr16:89971882	TCF25	0.78	6.69	0.38	1.3e-10	Skin colour saturation;
CESC	cis	rs853679	0.517	rs9368550	chr6:28051803	T/A	cg20151795	chr6:28129481	ZNF389	0.44	5.59	0.33	5.5e-8	Depression;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05809890	chr11:1491432	HCCA2	-0.57	-6.63	-0.38	1.89e-10	Gut microbiome composition (summer);
CESC	cis	rs4481887	0.962	rs10749653	chr1:248481384	C/G	cg00666640	chr1:248458726	OR2T12	0.41	6.56	0.37	2.84e-10	Common traits (Other);
CESC	cis	rs2075371	1.000	rs378358	chr7:133970628	A/G	cg00033643	chr7:134001901	SLC35B4	0.41	5.28	0.31	2.7e-7	Mean platelet volume;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg11028091	chr15:72522207	PKM2	0.44	6.08	0.35	4.19e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs7819412	0.645	rs10156356	chr8:11046209	T/C	cg21775007	chr8:11205619	TDH	-0.4	-5.28	-0.31	2.7e-7	Triglycerides;
CESC	cis	rs3812762	0.826	rs2292045	chr11:8806709	G/T	cg03980550	chr11:8754370	ST5	-0.38	-5.21	-0.3	3.88e-7	Hypospadias;
CESC	cis	rs12497850	0.897	rs9681717	chr3:48872998	A/G	cg06212747	chr3:49208901	KLHDC8B	0.65	8.37	0.46	3.37e-15	Parkinson's disease;
CESC	cis	rs10504229	0.679	rs11781858	chr8:58038406	C/T	cg21724239	chr8:58056113	NA	0.57	5.09	0.3	6.73e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs1153858	1.000	rs12593230	chr15:45646968	A/T	cg21132104	chr15:45694354	SPATA5L1	0.84	11.4	0.57	9.5e-25	Homoarginine levels;
CESC	cis	rs79839061	0.732	rs73207773	chr4:827249	G/A	cg07828340	chr4:882639	GAK	0.93	6.39	0.37	7.58e-10	Intelligence (multi-trait analysis);
CESC	trans	rs650950	0.528	rs646660	chr11:35528452	C/T	cg05897255	chr7:149535402	ZNF862	0.47	6.38	0.36	7.8e-10	Bronchopulmonary dysplasia;
CESC	cis	rs4764487	0.687	rs10744702	chr12:6349127	G/A	cg08284733	chr12:6341482	CD9	0.43	6.34	0.36	1.01e-9	Mean platelet volume;
CESC	cis	rs1950626	0.750	rs35820579	chr14:101435515	T/C	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.82	10.42	0.54	1.59e-21	Pelvic organ prolapse (moderate/severe);
CESC	cis	rs13096760	1	rs13096760	chr3:49476806	T/C	cg03060546	chr3:49711283	APEH	0.76	11.69	0.58	9.45e-26	Intelligence (multi-trait analysis);
CESC	cis	rs2933343	0.729	rs1680785	chr3:128644816	C/T	cg24203234	chr3:128598194	ACAD9	0.43	5.8	0.34	1.93e-8	IgG glycosylation;
CESC	cis	rs453301	0.653	rs2956244	chr8:8885166	A/G	cg06636001	chr8:8085503	FLJ10661	0.45	5.88	0.34	1.23e-8	Joint mobility (Beighton score);
CESC	cis	rs6460942	0.591	rs6942551	chr7:12338356	C/T	cg06484146	chr7:12443880	VWDE	-0.63	-7.0	-0.39	2.16e-11	Coronary artery disease;
CESC	cis	rs1983891	0.955	rs6917029	chr6:41548540	C/G	cg20194872	chr6:41519635	FOXP4	0.54	7.72	0.43	2.38e-13	Prostate cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14539990	chr9:140728301	EHMT1	-0.53	-6.1	-0.35	3.81e-9	Gut microbiome composition (summer);
CESC	cis	rs9300255	0.544	rs1790100	chr12:123656725	G/T	cg19016782	chr12:123741754	C12orf65	-0.43	-6.15	-0.35	2.78e-9	Neutrophil percentage of white cells;
CESC	cis	rs7618915	0.547	rs34215106	chr3:52659124	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.48	6.9	0.39	3.85e-11	Bipolar disorder;
CESC	cis	rs225245	0.791	rs4796103	chr17:34025182	A/G	cg05299278	chr17:33885742	SLFN14	0.38	5.51	0.32	8.62e-8	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
CESC	cis	rs7945705	0.869	rs2742471	chr11:9003953	C/T	cg12365402	chr11:9010492	NRIP3	-0.44	-7.41	-0.41	1.65e-12	Hemoglobin concentration;
CESC	cis	rs3862030	0.500	rs11191327	chr10:104303883	T/C	ch.10.2196322F	chr10:104248062	ACTR1A	0.43	5.24	0.31	3.28e-7	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
CESC	cis	rs4268898	0.662	rs55661701	chr2:24400769	A/C	cg20701182	chr2:24300061	SF3B14	0.72	7.23	0.41	5.21e-12	Asthma;
CESC	cis	rs1862618	0.853	rs33325	chr5:56142547	G/C	cg22800045	chr5:56110881	MAP3K1	0.81	9.96	0.52	4.58e-20	Initial pursuit acceleration;
CESC	cis	rs1005277	0.540	rs4934907	chr10:38015230	A/C	cg25517755	chr10:38738941	LOC399744	-0.4	-5.14	-0.3	5.34e-7	Extrinsic epigenetic age acceleration;
CESC	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	21.62	0.8	1.91e-60	Prudent dietary pattern;
CESC	cis	rs12136530	0.593	rs881247	chr1:19733320	A/G	cg01832549	chr1:19774989	CAPZB	-0.44	-6.25	-0.36	1.59e-9	Lead levels in blood;
CESC	cis	rs10911251	0.528	rs2147584	chr1:183074764	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.88	14.2	0.66	2.05e-34	Colorectal cancer;
CESC	cis	rs7584330	0.780	rs12474519	chr2:238377012	G/A	cg14458575	chr2:238380390	NA	0.71	9.92	0.52	6.45e-20	Prostate cancer;
CESC	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg18402987	chr7:1209562	NA	0.49	6.68	0.38	1.4e-10	Longevity;Endometriosis;
CESC	cis	rs4555082	0.874	rs2816606	chr14:105716034	C/T	cg13114125	chr14:105738426	BRF1	-0.8	-9.72	-0.51	2.64e-19	Mean platelet volume;Platelet distribution width;
CESC	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg22535103	chr8:58192502	C8orf71	-0.92	-10.19	-0.53	8.81e-21	Developmental language disorder (linguistic errors);
CESC	cis	rs1799949	0.526	rs4352088	chr17:41414679	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.38	5.06	0.3	7.85e-7	Menopause (age at onset);
CESC	cis	rs7072216	0.727	rs3750603	chr10:100175536	A/T	cg26618903	chr10:100175079	PYROXD2	-0.38	-5.96	-0.34	8.02e-9	Metabolite levels;
CESC	cis	rs10197940	0.686	rs12616688	chr2:152242099	C/G	cg06191203	chr2:152266755	RIF1	-0.45	-5.36	-0.31	1.77e-7	Lung cancer;
CESC	cis	rs8031584	0.918	rs34693097	chr15:31253984	A/G	cg14298792	chr15:30685198	CHRFAM7A	-0.46	-5.54	-0.32	7.38e-8	Huntington's disease progression;
CESC	cis	rs7666738	1.000	rs35066600	chr4:98991066	C/A	cg17366294	chr4:99064904	C4orf37	0.53	7.06	0.4	1.42e-11	Colonoscopy-negative controls vs population controls;
CESC	trans	rs1945213	0.694	rs11227181	chr11:55856053	C/T	cg15704280	chr7:45808275	SEPT13	0.76	7.34	0.41	2.57e-12	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs514406	0.861	rs2477741	chr1:53265278	A/G	cg08736216	chr1:53307985	ZYG11A	0.43	7.13	0.4	9.53e-12	Monocyte count;
CESC	cis	rs2073300	0.609	rs3827085	chr20:23356985	A/T	cg16736954	chr20:23401023	NAPB	0.81	6.09	0.35	4.02e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs4319547	0.656	rs1553179	chr12:122831073	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.5	-5.81	-0.34	1.78e-8	Body mass index;
CESC	cis	rs6732160	0.691	rs11886257	chr2:73416873	C/T	cg01422370	chr2:73384389	NA	0.44	7.54	0.42	7.45e-13	Intelligence (multi-trait analysis);
CESC	cis	rs2836974	0.932	rs73221193	chr21:40554693	C/T	cg11644478	chr21:40555479	PSMG1	1.01	16.18	0.7	2.08e-41	Cognitive function;
CESC	cis	rs2204008	0.630	rs1283300	chr12:38150227	C/T	cg26384229	chr12:38710491	ALG10B	-0.44	-5.99	-0.35	6.87e-9	Bladder cancer;
CESC	cis	rs644799	0.931	rs496305	chr11:95567035	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.68	8.6	0.47	6.86e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs875971	0.545	rs7811204	chr7:65852200	G/A	cg11764359	chr7:65958608	NA	0.82	9.37	0.5	3.25e-18	Aortic root size;
CESC	cis	rs9929218	0.954	rs7198799	chr16:68818390	C/T	cg02972257	chr16:68554789	NA	0.49	5.82	0.34	1.7e-8	Colorectal cancer;
CESC	cis	rs854765	0.654	rs9911281	chr17:17762457	G/C	cg09796270	chr17:17721594	SREBF1	-0.4	-5.75	-0.33	2.43e-8	Total body bone mineral density;
CESC	cis	rs208520	0.837	rs208498	chr6:66931560	G/A	cg07460842	chr6:66804631	NA	-0.82	-10.01	-0.52	3.23e-20	Exhaled nitric oxide output;
CESC	cis	rs7618915	0.571	rs12487445	chr3:52618319	A/C	cg05564831	chr3:52568323	NT5DC2	0.46	6.85	0.39	5.24e-11	Bipolar disorder;
CESC	cis	rs875971	0.792	rs6971752	chr7:65737986	G/A	cg18876405	chr7:65276391	NA	-0.49	-6.75	-0.38	9.38e-11	Aortic root size;
CESC	cis	rs929354	0.772	rs1182432	chr7:157029176	A/G	cg05182265	chr7:156933206	UBE3C	-0.45	-6.66	-0.38	1.59e-10	Body mass index;
CESC	cis	rs7712401	0.645	rs154497	chr5:122221420	T/C	cg19412675	chr5:122181750	SNX24	0.4	5.05	0.3	8.3e-7	Mean platelet volume;
CESC	cis	rs4535700	0.501	rs2135116	chr7:55991144	A/G	cg09872392	chr7:56161020	PHKG1	0.41	5.81	0.34	1.8e-8	Macular telangiectasia type 2;
CESC	cis	rs9596863	1.000	rs9596856	chr13:54409401	C/T	ch.13.53330881F	chr13:54432880	NA	0.66	5.25	0.31	3.08e-7	Epilepsy and lamotrigine-induced maculopapular eruptions;
CESC	cis	rs561341	1.000	rs72823785	chr17:30273784	C/T	cg00745463	chr17:30367425	LRRC37B	-0.82	-7.48	-0.42	1.08e-12	Hip circumference adjusted for BMI;
CESC	cis	rs798554	0.757	rs1182171	chr7:2878510	A/G	cg13628971	chr7:2884303	GNA12	0.63	8.09	0.45	2.17e-14	Height;
CESC	cis	rs5750830	0.649	rs2413590	chr22:39790191	G/C	cg24399712	chr22:39784796	NA	-0.84	-11.77	-0.59	5.08e-26	Intelligence (multi-trait analysis);
CESC	cis	rs6089829	0.962	rs6062778	chr20:61663959	A/G	cg08564027	chr20:61660810	NA	0.9	15.42	0.69	9.97e-39	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs597539	0.690	rs635529	chr11:68626294	C/T	cg06028808	chr11:68637592	NA	0.44	5.05	0.3	8.33e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs35306767	0.807	rs11253513	chr10:968450	C/T	cg25019033	chr10:957182	NA	-0.65	-8.25	-0.45	7.58e-15	Eosinophil percentage of granulocytes;
CESC	cis	rs6860806	0.695	rs11952099	chr5:131576772	A/G	cg14196790	chr5:131705035	SLC22A5	0.33	5.31	0.31	2.3e-7	Breast cancer;
CESC	cis	rs6489785	0.509	rs4767937	chr12:121223244	G/C	cg02419362	chr12:121203948	SPPL3	0.35	5.72	0.33	2.87e-8	Longevity;Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs977987	0.806	rs12051136	chr16:75435731	G/T	cg03315344	chr16:75512273	CHST6	0.41	5.85	0.34	1.43e-8	Dupuytren's disease;
CESC	cis	rs748404	0.578	rs510108	chr15:43605439	T/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.54	8.57	0.47	8.63e-16	Lung cancer;
CESC	trans	rs1814175	0.935	rs28586931	chr11:49693872	G/A	cg15704280	chr7:45808275	SEPT13	-1.0	-17.88	-0.74	1.87e-47	Height;
CESC	cis	rs4919087	0.892	rs2065861	chr10:99004608	C/T	cg25902810	chr10:99078978	FRAT1	0.65	9.33	0.5	4.53e-18	Monocyte count;
CESC	cis	rs4713118	0.662	rs149948	chr6:27974817	C/G	cg26335602	chr6:28129616	ZNF389	0.41	5.54	0.32	7.32e-8	Parkinson's disease;
CESC	cis	rs1728785	1.000	rs4783657	chr16:68586322	G/T	cg02972257	chr16:68554789	NA	-0.56	-6.35	-0.36	9.09e-10	Ulcerative colitis;
CESC	cis	rs6076065	0.707	rs12349	chr20:23352480	A/G	cg11657817	chr20:23433608	CST11	0.41	6.12	0.35	3.37e-9	Facial morphology (factor 15, philtrum width);
CESC	cis	rs1552244	1.000	rs35198334	chr3:10104553	G/C	cg00166722	chr3:10149974	C3orf24	0.52	6.43	0.37	5.93e-10	Alzheimer's disease;
CESC	cis	rs6951245	1.000	rs884977	chr7:1066410	T/C	cg18402987	chr7:1209562	NA	0.48	5.19	0.3	4.13e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs9311474	0.508	rs7614498	chr3:52618941	A/T	cg18337363	chr3:52569053	NT5DC2	0.3	5.5	0.32	8.74e-8	Electroencephalogram traits;
CESC	cis	rs6977660	0.652	rs12673842	chr7:19747437	T/C	cg07541023	chr7:19748670	TWISTNB	0.79	6.77	0.38	8.08e-11	Thyroid stimulating hormone;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg00160902	chr4:16944285	NA	-0.43	-6.2	-0.36	2.1e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs7605827	0.791	rs7604881	chr2:15476735	T/A	cg19274914	chr2:15703543	NA	0.3	5.38	0.31	1.64e-7	Educational attainment (years of education);
CESC	trans	rs2727020	0.755	rs652655	chr11:49251293	G/A	cg15704280	chr7:45808275	SEPT13	0.86	14.21	0.66	1.88e-34	Coronary artery disease;
CESC	cis	rs4629180	0.917	rs34217240	chr2:102136682	G/A	cg04415270	chr2:102091202	RFX8	0.43	6.72	0.38	1.08e-10	Chronic rhinosinusitis with nasal polyps;
CESC	cis	rs875971	0.577	rs34888281	chr7:65585771	C/T	cg18876405	chr7:65276391	NA	-0.7	-9.71	-0.51	2.97e-19	Aortic root size;
CESC	cis	rs7605827	0.930	rs2111458	chr2:15598039	T/A	cg19274914	chr2:15703543	NA	0.33	5.82	0.34	1.73e-8	Educational attainment (years of education);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14634842	chr2:232574012	PTMA	-0.59	-6.58	-0.37	2.43e-10	Gut microbiome composition (summer);
CESC	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg06074448	chr4:187884817	NA	-0.37	-5.43	-0.32	1.27e-7	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19886179	chr2:162164993	PSMD14	0.55	6.36	0.36	8.58e-10	Gut microbiome composition (summer);
CESC	cis	rs7474896	0.537	rs598857	chr10:38302926	A/G	cg00409905	chr10:38381863	ZNF37A	0.46	5.15	0.3	5.05e-7	Obesity (extreme);
CESC	trans	rs9354308	1.000	rs9360161	chr6:66565457	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.53	6.31	0.36	1.16e-9	Metabolite levels;
CESC	cis	rs826838	0.967	rs1719854	chr12:39127707	G/A	cg26384229	chr12:38710491	ALG10B	-0.67	-11.01	-0.56	1.82e-23	Heart rate;
CESC	cis	rs8020095	0.571	rs8006371	chr14:67375341	T/G	cg19548862	chr14:67692701	FAM71D	-0.5	-6.1	-0.35	3.83e-9	Depression (quantitative trait);
CESC	cis	rs7666738	0.830	rs6832568	chr4:98994061	G/A	cg05340658	chr4:99064831	C4orf37	0.8	12.44	0.61	2.83e-28	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03149719	chr17:1358724	CRK	-0.57	-6.2	-0.36	2.12e-9	Gut microbiome composition (summer);
CESC	cis	rs4665809	0.838	rs6546749	chr2:26306288	T/C	cg25036284	chr2:26402008	FAM59B	-0.74	-8.4	-0.46	2.72e-15	Gut microbiome composition (summer);
CESC	cis	rs7927592	0.731	rs643609	chr11:68241833	A/G	cg16797656	chr11:68205561	LRP5	0.5	7.75	0.43	1.98e-13	Total body bone mineral density;
CESC	cis	rs9611565	0.608	rs202652	chr22:41838792	A/G	cg06634786	chr22:41940651	POLR3H	0.58	6.31	0.36	1.14e-9	Vitiligo;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13823003	chr17:72856049	GRIN2C	0.46	6.1	0.35	3.74e-9	Gut microbiome composition (summer);
CESC	cis	rs4803468	1.000	rs17318666	chr19:41940342	T/G	cg09537434	chr19:41945824	ATP5SL	1.13	21.82	0.8	4.09e-61	Height;
CESC	cis	rs8112211	0.834	rs3843754	chr19:38807184	G/A	cg14299480	chr19:38876666	GGN	-0.42	-5.73	-0.33	2.79e-8	Blood protein levels;
CESC	cis	rs1881797	1.000	rs12061460	chr1:247686787	G/A	cg21399703	chr1:247681439	NA	0.55	7.37	0.41	2.13e-12	Acute lymphoblastic leukemia (childhood);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg16725865	chr1:92546135	BTBD8	0.44	6.03	0.35	5.46e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs7647973	0.600	rs11920267	chr3:49275964	G/A	cg06212747	chr3:49208901	KLHDC8B	0.7	10.38	0.54	2.04e-21	Menarche (age at onset);
CESC	cis	rs72772090	0.539	rs11747179	chr5:96112969	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.6	-5.04	-0.3	8.7e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg20706599	chr15:90777202	CIB1;C15orf58	-0.48	-6.32	-0.36	1.11e-9	Ulcerative colitis;
CESC	cis	rs708547	0.624	rs1277284	chr4:57855361	T/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.6	8.92	0.48	7.94e-17	Response to bleomycin (chromatid breaks);
CESC	cis	rs2243480	1.000	rs778704	chr7:65863467	T/C	cg13147721	chr7:65941812	NA	-0.95	-8.95	-0.48	6.27e-17	Diabetic kidney disease;
CESC	cis	rs798766	1.000	rs798754	chr4:1720757	A/G	cg07041428	chr4:1763019	NA	-0.37	-5.44	-0.32	1.19e-7	Bladder cancer;Urinary bladder cancer;
CESC	cis	rs11153306	0.515	rs3213575	chr6:111919271	C/T	cg22127309	chr6:111907043	TRAF3IP2	-0.4	-5.78	-0.33	2.13e-8	Tonsillectomy;
CESC	cis	rs3820068	0.705	rs2145397	chr1:15896199	G/A	cg18192808	chr1:15853278	DNAJC16	0.45	5.48	0.32	9.95e-8	Systolic blood pressure;
CESC	cis	rs7216064	1.000	rs8081517	chr17:65845697	A/T	cg07042672	chr17:66097459	LOC651250	-0.57	-6.64	-0.38	1.72e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs9811920	0.569	rs793445	chr3:99576644	T/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.63	-10.21	-0.53	7.53e-21	Axial length;
CESC	cis	rs12765878	0.967	rs10883940	chr10:105650598	G/A	cg24587175	chr10:105670608	OBFC1	0.33	5.43	0.32	1.28e-7	Coronary artery disease;
CESC	trans	rs3942852	0.545	rs10838798	chr11:48091303	T/G	cg03929089	chr4:120376271	NA	-0.64	-7.91	-0.44	6.85e-14	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs1178968	0.818	rs2528709	chr7:72788457	C/A	cg25889504	chr7:72793014	NA	0.44	5.13	0.3	5.52e-7	Triglyceride levels;
CESC	cis	rs597539	0.652	rs686390	chr11:68656077	T/C	cg18350739	chr11:68623251	NA	-0.46	-6.94	-0.39	3.09e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs10504229	0.724	rs72650827	chr8:58126884	A/T	cg02725872	chr8:58115012	NA	-0.45	-6.84	-0.39	5.31e-11	Developmental language disorder (linguistic errors);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12810189	chr7:107220588	BCAP29	0.56	6.03	0.35	5.62e-9	Gut microbiome composition (summer);
CESC	cis	rs2576037	0.521	rs4986227	chr18:44595031	G/C	cg19077165	chr18:44547161	KATNAL2	-0.43	-5.66	-0.33	4.02e-8	Personality dimensions;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg03416154	chr22:21336337	LZTR1	-0.45	-6.19	-0.36	2.33e-9	Fibrinogen levels;
CESC	cis	rs7044106	0.791	rs10984998	chr9:123481516	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.84	13.61	0.64	2.4e-32	Hip circumference adjusted for BMI;
CESC	cis	rs1538970	0.962	rs2185549	chr1:45814103	C/T	cg06784218	chr1:46089804	CCDC17	-0.32	-5.24	-0.31	3.2e-7	Platelet count;
CESC	cis	rs66887589	0.616	rs6822808	chr4:120217365	C/A	cg09307838	chr4:120376055	NA	0.66	8.95	0.48	6.29e-17	Diastolic blood pressure;
CESC	cis	rs1552244	1.000	rs6764168	chr3:10123805	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	11.97	0.59	1.11e-26	Alzheimer's disease;
CESC	cis	rs72781680	0.898	rs116113042	chr2:23960194	G/T	cg08917208	chr2:24149416	ATAD2B	0.96	8.67	0.47	4.28e-16	Lymphocyte counts;
CESC	cis	rs1030268	0.651	rs12707118	chr7:133474900	C/T	cg10665199	chr7:133106180	EXOC4	-0.57	-6.22	-0.36	1.88e-9	Intelligence (multi-trait analysis);
CESC	cis	rs4450798	0.500	rs73139918	chr3:13789096	T/G	cg23332027	chr3:13681764	NA	0.41	5.72	0.33	2.83e-8	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs262150	0.659	rs2730275	chr7:158793397	A/G	cg09640425	chr7:158790006	NA	-0.38	-5.79	-0.33	2.02e-8	Facial morphology (factor 20);
CESC	cis	rs4819052	0.819	rs7279136	chr21:46692287	C/T	cg11663144	chr21:46675770	NA	-0.62	-9.76	-0.51	2.06e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg09664812	chr18:9475361	RALBP1	0.45	6.21	0.36	2.08e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs2742234	0.590	rs1254965	chr10:43689853	C/T	cg15436174	chr10:43711423	RASGEF1A	0.5	5.84	0.34	1.5e-8	Hirschsprung disease;
CESC	cis	rs35146811	0.807	rs10228764	chr7:99608029	A/G	cg22906224	chr7:99728672	NA	0.45	5.37	0.31	1.75e-7	Coronary artery disease;
CESC	cis	rs7474896	0.609	rs11011336	chr10:37985316	A/G	cg25427524	chr10:38739819	LOC399744	-0.46	-5.38	-0.31	1.6e-7	Obesity (extreme);
CESC	cis	rs963731	0.649	rs10201980	chr2:39204820	C/T	cg04010122	chr2:39346883	SOS1	0.68	5.1	0.3	6.48e-7	Corticobasal degeneration;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07889337	chr17:38257022	NR1D1	0.63	7.75	0.43	1.91e-13	Gut microbiome composition (summer);
CESC	cis	rs4654899	1.000	rs7554997	chr1:21400139	C/T	cg05370193	chr1:21551575	ECE1	0.4	5.97	0.34	7.48e-9	Superior frontal gyrus grey matter volume;
CESC	cis	rs12295403	0.691	rs9705036	chr11:18686916	A/G	cg20219074	chr11:18656078	SPTY2D1	-0.48	-5.25	-0.31	3.2e-7	Ovarian reserve;
CESC	trans	rs916888	0.773	rs199448	chr17:44809001	A/G	cg22968622	chr17:43663579	NA	1.3	18.48	0.75	1.45e-49	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs514406	0.861	rs7513052	chr1:53241360	C/T	cg08736216	chr1:53307985	ZYG11A	0.32	5.74	0.33	2.59e-8	Monocyte count;
CESC	cis	rs2243480	1.000	rs316304	chr7:65616894	T/C	cg18252515	chr7:66147081	NA	-1.42	-14.5	-0.67	1.72e-35	Diabetic kidney disease;
CESC	cis	rs9486719	1.000	rs2472890	chr6:96867646	C/T	cg18709589	chr6:96969512	KIAA0776	0.53	5.81	0.34	1.75e-8	Migraine;Coronary artery disease;
CESC	cis	rs9488822	0.676	rs12190737	chr6:116328128	C/A	cg18764771	chr6:116381957	FRK	0.22	5.39	0.31	1.57e-7	Cholesterol, total;LDL cholesterol;
CESC	cis	rs2576037	0.523	rs4890705	chr18:44509758	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.5	-6.75	-0.38	9.09e-11	Personality dimensions;
CESC	cis	rs11792861	0.926	rs7855282	chr9:111802614	T/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.47	5.9	0.34	1.11e-8	Menarche (age at onset);
CESC	cis	rs8067354	0.872	rs1295925	chr17:57910263	T/C	cg02344993	chr17:57696989	CLTC	-0.48	-6.15	-0.35	2.86e-9	Hemoglobin concentration;
CESC	cis	rs2180341	0.694	rs2875972	chr6:127585522	T/C	cg27446573	chr6:127587934	RNF146	0.88	12.43	0.61	2.93e-28	Breast cancer;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg20796294	chr1:220219430	EPRS	-0.48	-6.1	-0.35	3.65e-9	Ulcerative colitis;
CESC	cis	rs1218582	0.772	rs877343	chr1:154910012	A/G	cg09359103	chr1:154839909	KCNN3	-0.66	-12.33	-0.6	6.5e-28	Prostate cancer;
CESC	trans	rs7672847	0.547	rs56076741	chr4:170456047	A/G	cg19308436	chr1:237949471	RYR2	0.63	6.82	0.39	6.26e-11	Subjective well-being;
CESC	cis	rs644799	1.000	rs546809	chr11:95579938	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.56	6.72	0.38	1.11e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03592283	chr3:44666723	ZNF197	0.65	7.77	0.43	1.75e-13	Gut microbiome composition (summer);
CESC	cis	rs35306767	0.903	rs12769002	chr10:927666	C/G	cg26597838	chr10:835615	NA	-1.12	-11.05	-0.56	1.32e-23	Eosinophil percentage of granulocytes;
CESC	cis	rs1790761	0.692	rs10896179	chr11:67316928	C/A	cg00290607	chr11:67383545	NA	0.4	5.81	0.34	1.83e-8	Mean corpuscular volume;
CESC	cis	rs9300255	0.510	rs1790109	chr12:123637752	C/G	cg05973401	chr12:123451056	ABCB9	0.5	5.77	0.33	2.18e-8	Neutrophil percentage of white cells;
CESC	cis	rs5747327	0.770	rs5746460	chr22:18178393	A/T	cg19898043	chr22:18121309	BCL2L13	-0.4	-5.16	-0.3	4.95e-7	Myeloid white cell count;Granulocyte count;
CESC	cis	rs11711311	1.000	rs1043132	chr3:113528689	A/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.71	10.25	0.53	5.62e-21	IgG glycosylation;
CESC	cis	rs12995491	0.731	rs34991383	chr2:88500337	T/G	cg07952391	chr2:88470173	THNSL2	-0.54	-8.13	-0.45	1.62e-14	Response to metformin (IC50);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg14733031	chr19:17904427	B3GNT3	-0.36	-6.07	-0.35	4.38e-9	Gambling;
CESC	cis	rs2839186	0.770	rs2839984	chr21:47671690	A/G	cg13126279	chr21:47581558	C21orf56	-0.49	-6.62	-0.38	1.96e-10	Testicular germ cell tumor;
CESC	cis	rs1799949	1.000	rs12936816	chr17:41301709	C/T	cg05368731	chr17:41323189	NBR1	0.8	11.27	0.57	2.51e-24	Menopause (age at onset);
CESC	cis	rs8018808	0.935	rs2242619	chr14:77895119	C/T	cg20045696	chr14:77926864	AHSA1	-0.43	-6.04	-0.35	5.18e-9	Myeloid white cell count;
CESC	trans	rs1814175	0.817	rs6486046	chr11:49997017	T/C	cg15704280	chr7:45808275	SEPT13	-1.05	-20.9	-0.79	5.74e-58	Height;
CESC	cis	rs9287719	0.967	rs10195802	chr2:10754532	C/T	cg02196655	chr2:10830764	NOL10	-0.37	-5.69	-0.33	3.39e-8	Prostate cancer;
CESC	cis	rs2050392	0.929	rs10826798	chr10:30700904	G/A	cg25182066	chr10:30743637	MAP3K8	0.38	5.04	0.3	8.52e-7	Inflammatory bowel disease;
CESC	cis	rs66573146	0.572	rs66819208	chr4:6946128	A/G	cg00086871	chr4:6988644	TBC1D14	1.05	6.92	0.39	3.44e-11	Granulocyte percentage of myeloid white cells;
CESC	cis	rs3784262	1.000	rs4646629	chr15:58255215	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.31	-5.13	-0.3	5.51e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
CESC	cis	rs2115630	0.905	rs1975277	chr15:85329558	C/T	cg09876464	chr15:85330779	ZNF592	0.37	5.8	0.34	1.88e-8	P wave terminal force;
CESC	cis	rs875971	0.756	rs4718328	chr7:65693337	A/G	cg18876405	chr7:65276391	NA	-0.51	-7.07	-0.4	1.34e-11	Aortic root size;
CESC	cis	rs7666738	0.830	rs35213297	chr4:98984049	T/C	cg03467027	chr4:99064603	C4orf37	0.42	5.3	0.31	2.5e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs8114671	0.836	rs13042358	chr20:33634479	G/A	cg06115741	chr20:33292138	TP53INP2	-0.44	-5.29	-0.31	2.53e-7	Height;
CESC	cis	rs1707322	1.000	rs1707337	chr1:46508769	A/G	cg06784218	chr1:46089804	CCDC17	-0.33	-5.65	-0.33	4.08e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs4253772	0.530	rs113258957	chr22:46663678	G/C	cg00784671	chr22:46762841	CELSR1	-0.5	-5.37	-0.31	1.73e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs7193541	0.646	rs7188880	chr16:74664810	A/T	cg05580060	chr16:74700937	RFWD3	-0.48	-6.21	-0.36	1.99e-9	Multiple myeloma;
CESC	cis	rs3749237	0.615	rs11130202	chr3:49566715	C/T	cg03060546	chr3:49711283	APEH	0.76	11.64	0.58	1.48e-25	Resting heart rate;
CESC	cis	rs4665809	1.000	rs2384323	chr2:26306473	C/T	cg27170947	chr2:26402098	FAM59B	-0.58	-6.84	-0.39	5.56e-11	Gut microbiome composition (summer);
CESC	cis	rs7647973	0.600	rs12631989	chr3:49273996	C/T	cg03060546	chr3:49711283	APEH	0.51	6.82	0.39	6.1e-11	Menarche (age at onset);
CESC	cis	rs1506636	0.525	rs7812023	chr7:123260228	C/T	cg03229431	chr7:123269106	ASB15	-0.48	-5.79	-0.34	1.96e-8	Plateletcrit;Platelet count;
CESC	cis	rs4629180	0.727	rs10188564	chr2:102101064	C/A	cg04415270	chr2:102091202	RFX8	-0.46	-7.52	-0.42	8.59e-13	Chronic rhinosinusitis with nasal polyps;
CESC	cis	rs7210086	0.808	rs4331375	chr17:70640082	A/G	cg04206342	chr17:70636940	NA	-0.35	-6.36	-0.36	8.76e-10	Ulcerative colitis;
CESC	cis	rs11997175	0.597	rs6988880	chr8:33594504	C/T	ch.8.33884649F	chr8:33765107	NA	0.51	6.29	0.36	1.34e-9	Body mass index;
CESC	cis	rs7208859	0.573	rs216442	chr17:28931197	T/G	cg14008862	chr17:28927542	LRRC37B2	0.73	5.52	0.32	8.23e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs4665809	0.549	rs7577896	chr2:26524493	C/T	cg27170947	chr2:26402098	FAM59B	0.68	6.75	0.38	9.19e-11	Gut microbiome composition (summer);
CESC	cis	rs10883723	0.641	rs80146619	chr10:104405850	G/A	cg22532475	chr10:104410764	TRIM8	-0.42	-5.65	-0.33	4.18e-8	Allergic disease (asthma, hay fever or eczema);
CESC	trans	rs561341	1.000	rs72825740	chr17:30338356	A/G	cg20587970	chr11:113659929	NA	-1.5	-18.68	-0.75	2.92e-50	Hip circumference adjusted for BMI;
CESC	cis	rs11190604	1.000	rs11190604	chr10:102302457	A/G	cg07080220	chr10:102295463	HIF1AN	0.63	5.73	0.33	2.74e-8	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs3008870	1.000	rs2985811	chr1:67377722	G/T	cg02640540	chr1:67518911	SLC35D1	0.49	5.21	0.3	3.81e-7	Lymphocyte percentage of white cells;
CESC	cis	rs992157	0.735	rs2271541	chr2:219082119	G/T	cg00012203	chr2:219082015	ARPC2	0.85	12.32	0.6	7.16e-28	Colorectal cancer;
CESC	cis	rs2243480	1.000	rs1964692	chr7:65454183	G/A	cg12463550	chr7:65579703	CRCP	0.72	5.81	0.34	1.8e-8	Diabetic kidney disease;
CESC	trans	rs116095464	0.558	rs10059907	chr5:205360	G/C	cg00938859	chr5:1591904	SDHAP3	0.66	6.26	0.36	1.55e-9	Breast cancer;
CESC	cis	rs7666738	0.645	rs10013290	chr4:99082799	G/A	cg17366294	chr4:99064904	C4orf37	0.55	7.46	0.42	1.21e-12	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9314323	0.862	rs3808580	chr8:26250296	C/T	cg13160058	chr8:26243215	BNIP3L	0.31	5.08	0.3	7.01e-7	Red cell distribution width;
CESC	cis	rs4450131	0.500	rs2362515	chr10:126336158	C/T	cg20435097	chr10:126320824	FAM53B	0.28	5.03	0.3	8.99e-7	White blood cell count (basophil);
CESC	cis	rs6964587	0.692	rs6970629	chr7:91846599	T/C	cg17063962	chr7:91808500	NA	0.46	6.56	0.37	2.8e-10	Breast cancer;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg07207053	chr12:132601934	EP400NL	0.51	6.58	0.37	2.45e-10	Fibrinogen levels;
CESC	cis	rs2228479	0.717	rs17233678	chr16:89809962	T/C	cg04013166	chr16:89971882	TCF25	0.77	6.69	0.38	1.32e-10	Skin colour saturation;
CESC	cis	rs9611565	0.659	rs1810461	chr22:41927820	G/A	cg17376030	chr22:41985996	PMM1	0.72	7.9	0.44	7.33e-14	Vitiligo;
CESC	cis	rs8044868	0.548	rs3909541	chr16:72201119	C/T	cg16558253	chr16:72132732	DHX38	0.39	5.86	0.34	1.35e-8	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CESC	cis	rs12142240	0.698	rs17361936	chr1:46862893	C/T	cg10495392	chr1:46806563	NSUN4	0.56	6.14	0.35	2.98e-9	Menopause (age at onset);
CESC	cis	rs875971	0.793	rs460678	chr7:65527200	C/G	cg11764359	chr7:65958608	NA	0.89	13.09	0.63	1.58e-30	Aortic root size;
CESC	cis	rs1425132	0.905	rs10234231	chr7:37563810	C/T	cg15028436	chr7:37888078	TXNDC3	-0.32	-5.41	-0.32	1.42e-7	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
CESC	cis	rs10504229	0.679	rs17801003	chr8:58050930	A/G	cg22535103	chr8:58192502	C8orf71	-0.94	-9.37	-0.5	3.38e-18	Developmental language disorder (linguistic errors);
CESC	cis	rs2841277	0.708	rs10083374	chr14:105402994	T/C	cg14403583	chr14:105418241	AHNAK2	-0.57	-7.9	-0.44	7.61e-14	Rheumatoid arthritis;
CESC	cis	rs72781680	0.611	rs72797818	chr2:24351107	G/A	cg20701182	chr2:24300061	SF3B14	0.91	10.23	0.53	6.45e-21	Lymphocyte counts;
CESC	cis	rs1008375	1.000	rs1974624	chr4:17650281	A/G	cg02297831	chr4:17616191	MED28	0.6	7.51	0.42	9.14e-13	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs67311347	1.000	rs12488805	chr3:40422869	C/T	cg09455208	chr3:40491958	NA	0.52	8.38	0.46	3.16e-15	Renal cell carcinoma;
CESC	trans	rs7615952	0.673	rs35001498	chr3:125628644	A/G	cg07211511	chr3:129823064	LOC729375	-0.88	-8.25	-0.45	7.56e-15	Blood pressure (smoking interaction);
CESC	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.37	5.46	0.32	1.08e-7	Electroencephalogram traits;
CESC	cis	rs9311474	0.508	rs6786043	chr3:52604861	A/G	cg17372223	chr3:52568218	NT5DC2	0.41	6.34	0.36	9.92e-10	Electroencephalogram traits;
CESC	cis	rs1904096	0.506	rs2865350	chr4:95212813	A/T	cg11021082	chr4:95130006	SMARCAD1	0.64	9.38	0.5	3.19e-18	Type 2 diabetes;
CESC	cis	rs4664293	0.715	rs13002625	chr2:160504625	T/C	cg08347373	chr2:160653686	CD302	0.3	5.15	0.3	5.08e-7	Monocyte percentage of white cells;
CESC	cis	rs2204008	0.837	rs11168341	chr12:37961951	C/T	cg13010199	chr12:38710504	ALG10B	0.53	6.76	0.38	8.67e-11	Bladder cancer;
CESC	cis	rs9649213	0.593	rs6968144	chr7:97915697	G/A	cg08684580	chr7:98029266	BAIAP2L1	-0.33	-5.13	-0.3	5.56e-7	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10883266	chr13:100741297	PCCA	0.59	6.92	0.39	3.42e-11	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.830	rs10516426	chr4:99035827	A/G	cg05340658	chr4:99064831	C4orf37	0.82	12.88	0.62	8.27e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2842992	0.958	rs2758318	chr6:160069637	C/G	cg11366901	chr6:160182831	ACAT2	0.71	8.49	0.46	1.47e-15	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg18402987	chr7:1209562	NA	0.75	7.52	0.42	8.71e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs710216	0.917	rs3754223	chr1:43419091	A/T	cg07803811	chr1:43423981	SLC2A1	0.47	5.05	0.3	8.41e-7	Red cell distribution width;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg08602689	chr13:103452535	BIVM;KDELC1	0.51	6.9	0.39	3.84e-11	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs801193	0.548	rs6975044	chr7:66227482	C/T	cg18252515	chr7:66147081	NA	-0.47	-6.2	-0.36	2.17e-9	Aortic root size;
CESC	cis	rs11997175	0.715	rs7012923	chr8:33630937	A/C	ch.8.33884649F	chr8:33765107	NA	0.53	6.24	0.36	1.74e-9	Body mass index;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11280390	chr19:8478043	MARCH2	0.54	6.32	0.36	1.1e-9	Gut microbiome composition (summer);
CESC	cis	rs2882667	0.931	rs7706391	chr5:138349164	G/A	cg04439458	chr5:138467593	SIL1	-0.33	-5.68	-0.33	3.5e-8	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs6860806	0.661	rs6890009	chr5:131580033	G/T	cg18301423	chr5:131593218	PDLIM4	0.39	5.5	0.32	8.95e-8	Breast cancer;
CESC	cis	rs12956009	0.558	rs12960592	chr18:44857203	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.45	5.73	0.33	2.78e-8	Educational attainment (years of education);
CESC	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg10150615	chr22:24372951	LOC391322	-0.59	-8.05	-0.44	2.79e-14	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs10883723	0.773	rs7917402	chr10:104246690	C/T	cg22532475	chr10:104410764	TRIM8	-0.33	-5.69	-0.33	3.44e-8	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs72781680	0.752	rs72796110	chr2:23905658	T/A	cg08917208	chr2:24149416	ATAD2B	1.16	10.42	0.54	1.59e-21	Lymphocyte counts;
CESC	cis	rs9322193	0.923	rs56397000	chr6:150060483	C/T	cg13206674	chr6:150067644	NUP43	0.44	6.52	0.37	3.54e-10	Lung cancer;
CESC	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg04025307	chr7:1156635	C7orf50	0.57	9.67	0.51	3.9e-19	Longevity;Endometriosis;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg07193667	chr4:48501509	FRYL	0.44	6.33	0.36	1.05e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs10504229	0.815	rs55855654	chr8:58164299	T/G	cg22535103	chr8:58192502	C8orf71	-0.95	-10.54	-0.54	6.39e-22	Developmental language disorder (linguistic errors);
CESC	cis	rs10078	0.848	rs890985	chr5:479746	C/G	cg15813090	chr5:442598	EXOC3;C5orf55	0.34	5.08	0.3	7.14e-7	Fat distribution (HIV);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg02407659	chr6:105628063	POPDC3	0.41	6.43	0.37	5.83e-10	Gambling;
CESC	cis	rs3820068	0.705	rs4646063	chr1:15829813	G/A	cg17385448	chr1:15911702	AGMAT	0.42	6.23	0.36	1.86e-9	Systolic blood pressure;
CESC	cis	rs4268898	0.965	rs13033241	chr2:24476118	G/C	cg06627628	chr2:24431161	ITSN2	0.67	8.1	0.45	1.96e-14	Asthma;
CESC	cis	rs6484504	0.532	rs10835757	chr11:31281902	C/T	cg14844989	chr11:31128820	NA	-0.39	-5.45	-0.32	1.14e-7	Red blood cell count;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg24132523	chr1:145827062	GPR89A	-0.47	-6.54	-0.37	3.16e-10	Asthma;
CESC	trans	rs2727020	0.634	rs11040331	chr11:49345726	T/C	cg15704280	chr7:45808275	SEPT13	-0.78	-8.94	-0.48	6.63e-17	Coronary artery disease;
CESC	cis	rs9905704	0.645	rs831952	chr17:56669583	T/C	cg12560992	chr17:57184187	TRIM37	0.64	5.96	0.34	8.03e-9	Testicular germ cell tumor;
CESC	cis	rs7666738	0.830	rs9998803	chr4:99002519	C/T	cg05340658	chr4:99064831	C4orf37	0.8	12.44	0.61	2.83e-28	Colonoscopy-negative controls vs population controls;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg09603710	chr16:716055	WDR90	0.45	6.42	0.37	6.21e-10	Fibrinogen levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21594567	chr8:146228379	ZNF252;C8orf77	0.53	6.1	0.35	3.8e-9	Gut microbiome composition (summer);
CESC	trans	rs561341	0.654	rs6505265	chr17:30172580	C/T	cg27661571	chr11:113659931	NA	0.64	6.02	0.35	5.77e-9	Hip circumference adjusted for BMI;
CESC	cis	rs875971	0.658	rs432667	chr7:65514633	A/G	cg12463550	chr7:65579703	CRCP	0.59	7.47	0.42	1.16e-12	Aortic root size;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg05518842	chr16:1823291	MRPS34;EME2	-0.49	-6.18	-0.35	2.42e-9	Ulcerative colitis;
CESC	cis	rs7666738	0.830	rs4699601	chr4:99034429	G/A	cg17366294	chr4:99064904	C4orf37	0.62	8.86	0.48	1.22e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6728642	1.000	rs59178801	chr2:97604455	C/T	cg26665480	chr2:98280029	ACTR1B	-0.69	-6.92	-0.39	3.46e-11	Bipolar disorder lithium response (continuous) or schizophrenia;
CESC	cis	rs72781680	0.660	rs72780104	chr2:23983715	A/G	cg08917208	chr2:24149416	ATAD2B	0.96	8.7	0.47	3.55e-16	Lymphocyte counts;
CESC	trans	rs1223629	1.000	rs57695785	chr10:95943813	C/T	cg16346422	chr11:2920819	SLC22A18;SLC22A18AS	0.67	6.04	0.35	5.08e-9	Glucose homeostasis traits;
CESC	trans	rs9325144	0.560	rs10785586	chr12:38676197	G/A	cg23762105	chr12:34175262	ALG10	0.49	6.33	0.36	1.04e-9	Morning vs. evening chronotype;
CESC	cis	rs4790333	1.000	rs4790333	chr17:2262703	A/G	cg02569219	chr17:2266849	SGSM2	-0.48	-6.32	-0.36	1.09e-9	Proinsulin levels;
CESC	cis	rs787274	0.543	rs10114623	chr9:115631360	G/A	cg13803584	chr9:115635662	SNX30	-0.63	-5.93	-0.34	9.35e-9	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs7116495	0.737	rs6592456	chr11:71737663	G/A	cg26138937	chr11:71823887	C11orf51	-1.28	-7.54	-0.42	7.59e-13	Severe influenza A (H1N1) infection;
CESC	cis	rs617791	0.530	rs7934543	chr11:65752508	G/T	cg09783858	chr11:65769428	EIF1AD;BANF1	0.53	6.37	0.36	8.31e-10	Breast cancer;
CESC	cis	rs921968	0.643	rs612874	chr2:219492924	T/C	cg02176678	chr2:219576539	TTLL4	0.39	6.63	0.38	1.84e-10	Mean corpuscular hemoglobin concentration;
CESC	trans	rs9486715	0.838	rs7770889	chr6:96858453	C/T	cg16678718	chr17:76497959	DNAH17	-0.44	-6.07	-0.35	4.41e-9	Headache;
CESC	cis	rs962856	0.964	rs6546303	chr2:67613118	G/A	cg09028215	chr2:67624308	ETAA1	-0.41	-5.47	-0.32	1.02e-7	Pancreatic cancer;
CESC	cis	rs2262909	0.962	rs12610034	chr19:22314528	G/A	cg11619707	chr19:22235551	ZNF257	0.32	5.15	0.3	5.21e-7	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
CESC	cis	rs9911578	1.000	rs6503866	chr17:56619581	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.39	-5.16	-0.3	4.83e-7	Intelligence (multi-trait analysis);
CESC	cis	rs7647973	0.588	rs9883000	chr3:49667691	A/G	cg03060546	chr3:49711283	APEH	0.7	8.41	0.46	2.49e-15	Menarche (age at onset);
CESC	cis	rs4835473	0.932	rs28377887	chr4:144898228	G/A	cg25736465	chr4:144833511	NA	0.39	6.08	0.35	4.07e-9	Immature fraction of reticulocytes;
CESC	cis	rs2070488	0.965	rs3762788	chr3:38493852	C/A	cg24069376	chr3:38537580	EXOG	0.48	8.73	0.47	2.97e-16	Electrocardiographic conduction measures;
CESC	cis	rs3126085	0.935	rs6666382	chr1:152217226	C/G	cg03465714	chr1:152285911	FLG	0.45	5.37	0.31	1.73e-7	Atopic dermatitis;
CESC	cis	rs7129220	0.588	rs7105321	chr11:10111339	T/C	cg01453529	chr11:10209919	SBF2	-0.49	-5.57	-0.32	6.31e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CESC	cis	rs13108904	0.557	rs1250086	chr4:1248051	G/A	cg05025164	chr4:1340916	KIAA1530	-0.7	-9.6	-0.51	6.38e-19	Obesity-related traits;
CESC	cis	rs3087591	0.960	rs2952984	chr17:29469614	T/C	cg24425628	chr17:29625626	OMG;NF1	0.41	5.06	0.3	8e-7	Hip circumference;
CESC	cis	rs7618915	0.531	rs77146033	chr3:52701501	G/T	cg17372223	chr3:52568218	NT5DC2	0.44	6.63	0.38	1.86e-10	Bipolar disorder;
CESC	trans	rs11165623	0.765	rs12749081	chr1:96970371	A/C	cg10631902	chr5:14652156	NA	-0.46	-6.77	-0.38	8.47e-11	Hip circumference;Waist circumference;
CESC	cis	rs7940866	0.834	rs7939417	chr11:130853832	T/A	cg12179176	chr11:130786555	SNX19	0.69	10.53	0.54	6.76e-22	Schizophrenia;
CESC	cis	rs12500824	0.564	rs1511818	chr4:77263775	A/C	cg20311846	chr4:77356250	SHROOM3	0.4	7.74	0.43	2.07e-13	Coronary artery disease;
CESC	cis	rs897080	0.552	rs1067397	chr2:44679285	A/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.47	5.42	0.32	1.32e-7	Height;
CESC	cis	rs10791323	0.569	rs10750542	chr11:133713436	T/C	cg14349672	chr11:133703707	NA	-0.37	-5.19	-0.3	4.28e-7	Childhood ear infection;
CESC	cis	rs9322193	0.884	rs9383864	chr6:150173105	T/C	cg09699651	chr6:150184138	LRP11	0.51	6.43	0.37	5.91e-10	Lung cancer;
CESC	trans	rs1437396	0.657	rs3111413	chr2:55592247	T/C	cg07921503	chr7:2445843	CHST12	-0.24	-6.19	-0.36	2.29e-9	Alcohol dependence;
CESC	cis	rs780096	0.526	rs7594812	chr2:27611469	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.32	-5.95	-0.34	8.33e-9	Total body bone mineral density;
CESC	cis	rs9400271	0.632	rs9374069	chr6:109586334	A/G	cg01475377	chr6:109611718	NA	-0.46	-7.12	-0.4	9.98e-12	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
CESC	cis	rs11758351	0.660	rs11757754	chr6:26219744	A/C	cg01420254	chr6:26195488	NA	0.77	8.49	0.46	1.48e-15	Gout;Renal underexcretion gout;
CESC	cis	rs2249625	0.874	rs2496534	chr6:72922550	C/T	cg18830697	chr6:72922368	RIMS1	-0.41	-5.74	-0.33	2.54e-8	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CESC	cis	rs1538970	0.924	rs7531253	chr1:45890183	T/C	cg03146154	chr1:46216737	IPP	0.44	5.09	0.3	6.74e-7	Platelet count;
CESC	cis	rs736408	0.677	rs678	chr3:52820981	A/T	cg05564831	chr3:52568323	NT5DC2	0.43	6.19	0.36	2.25e-9	Bipolar disorder;
CESC	trans	rs7615952	0.866	rs11922276	chr3:125631326	G/T	cg07211511	chr3:129823064	LOC729375	-1.07	-14.34	-0.66	6.43e-35	Blood pressure (smoking interaction);
CESC	cis	rs6831352	0.918	rs34936974	chr4:100052384	A/G	cg13256891	chr4:100009986	ADH5	0.62	7.15	0.4	8.48e-12	Alcohol dependence;
CESC	cis	rs2439831	0.571	rs2470121	chr15:43937618	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.69	8.5	0.46	1.35e-15	Lung cancer in ever smokers;
CESC	cis	rs6952808	0.862	rs4721167	chr7:1933224	C/T	cg21782813	chr7:2030301	MAD1L1	0.39	5.56	0.32	6.68e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs13191362	1.000	rs34773528	chr6:163088796	G/C	cg21926612	chr6:163149169	PACRG;PARK2	1.03	10.9	0.56	4.11e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	trans	rs10506458	1.000	rs73128794	chr12:63445313	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.32	-17.38	-0.73	1.15e-45	Hemostatic factors and hematological phenotypes;
CESC	cis	rs644799	0.965	rs607039	chr11:95547086	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.92	13.87	0.65	2.93e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs875971	0.862	rs801203	chr7:66023012	A/G	cg19163074	chr7:65112434	INTS4L2	0.42	5.25	0.31	3.18e-7	Aortic root size;
CESC	cis	rs875971	0.964	rs1643388	chr7:65844562	T/C	cg10691866	chr7:65817282	TPST1	-0.34	-5.46	-0.32	1.12e-7	Aortic root size;
CESC	cis	rs6565180	0.962	rs6565183	chr16:30382755	T/C	cg17640201	chr16:30407289	ZNF48	-0.94	-15.9	-0.7	2e-40	Tonsillectomy;
CESC	cis	rs4819052	0.851	rs1056099	chr21:46678892	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.47	6.01	0.35	6.19e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs9875589	0.509	rs6770928	chr3:14077189	G/C	cg19554555	chr3:13937349	NA	-0.44	-5.62	-0.33	4.74e-8	Ovarian reserve;
CESC	cis	rs9322193	0.923	rs10782314	chr6:150056663	C/T	cg07701084	chr6:150067640	NUP43	0.46	6.25	0.36	1.64e-9	Lung cancer;
CESC	cis	rs9733	0.596	rs11807058	chr1:150640475	G/A	cg04414720	chr1:150670196	GOLPH3L	0.63	9.02	0.48	3.86e-17	Tonsillectomy;
CESC	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg27532560	chr4:187881888	NA	-0.4	-6.08	-0.35	4.1e-9	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs651907	0.535	rs35810977	chr3:101531380	G/A	cg12386194	chr3:101231763	SENP7	0.42	5.28	0.31	2.7e-7	Colorectal cancer;
CESC	cis	rs28830936	0.510	rs11070349	chr15:42085017	A/C	cg11010575	chr15:42129464	JMJD7-PLA2G4B;JMJD7	-0.33	-5.16	-0.3	4.79e-7	Diastolic blood pressure;
CESC	cis	rs7917772	0.582	rs10786687	chr10:104336994	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.41	5.61	0.33	5.05e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs853679	0.882	rs4713140	chr6:28097193	C/T	cg23281280	chr6:28129359	ZNF389	0.52	5.32	0.31	2.23e-7	Depression;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg16194746	chr8:8341955	NA	-0.36	-6.12	-0.35	3.41e-9	Gambling;
CESC	cis	rs4727963	0.792	rs1525468	chr7:122716911	A/C	cg03640110	chr7:122635026	TAS2R16	0.41	6.65	0.38	1.62e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
CESC	cis	rs2717559	0.542	rs2717586	chr8:143897882	C/T	cg17252645	chr8:143867129	LY6D	0.35	5.98	0.34	7.38e-9	Urinary tract infection frequency;
CESC	cis	rs3733585	0.699	rs7437120	chr4:9967683	T/A	cg02734326	chr4:10020555	SLC2A9	-0.4	-5.7	-0.33	3.16e-8	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs6964587	0.626	rs10225241	chr7:91524940	A/G	cg17063962	chr7:91808500	NA	-0.46	-6.48	-0.37	4.55e-10	Breast cancer;
CESC	cis	rs10791097	0.642	rs7107568	chr11:130779668	T/C	cg12179176	chr11:130786555	SNX19	0.84	14.53	0.67	1.39e-35	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs875971	0.545	rs11770063	chr7:65783016	G/A	cg11764359	chr7:65958608	NA	0.82	9.61	0.51	6.13e-19	Aortic root size;
CESC	cis	rs35306767	0.903	rs12244253	chr10:889320	G/T	cg25019033	chr10:957182	NA	-0.57	-6.13	-0.35	3.19e-9	Eosinophil percentage of granulocytes;
CESC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg01363902	chr12:121022439	NA	-0.5	-6.46	-0.37	4.88e-10	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs77956314	0.515	rs4767473	chr12:117365506	C/T	cg02017074	chr12:117425053	FBXW8	0.75	8.23	0.45	8.72e-15	Subcortical brain region volumes;Hippocampal volume;
CESC	cis	rs2228479	0.850	rs17226973	chr16:89825248	T/C	cg14709524	chr16:89940631	TCF25	0.91	6.75	0.38	9.34e-11	Skin colour saturation;
CESC	cis	rs9815354	0.904	rs62258655	chr3:41932330	G/A	cg03022575	chr3:42003672	ULK4	-0.48	-5.57	-0.32	6.22e-8	Pulse pressure;Diastolic blood pressure;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg06551418	chr8:145111391	OPLAH	0.39	6.13	0.35	3.17e-9	Gambling;
CESC	cis	rs80282103	0.618	rs11250264	chr10:1151723	A/C	cg08668510	chr10:1095578	IDI1	0.77	6.35	0.36	9.51e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs7336332	0.598	rs77055070	chr13:28010516	C/G	cg01674679	chr13:27998804	GTF3A	-0.58	-5.34	-0.31	2.04e-7	Weight;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13649242	chr6:170893854	PDCD2	0.59	6.53	0.37	3.26e-10	Gut microbiome composition (summer);
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg22577136	chr1:206644165	IKBKE	-0.42	-6.27	-0.36	1.46e-9	Vertical cup-disc ratio;
CESC	cis	rs4764124	0.646	rs10744078	chr12:14978535	T/G	cg19759883	chr12:14956454	WBP11;C12orf60	-0.59	-8.46	-0.46	1.82e-15	Pubertal anthropometrics;
CESC	cis	rs7208859	0.673	rs9915139	chr17:29158515	A/G	cg13385521	chr17:29058706	SUZ12P	0.75	5.84	0.34	1.55e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs9814567	1.000	rs2370642	chr3:134222136	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.46	-6.28	-0.36	1.37e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs6815814	0.950	rs45588337	chr4:38807328	A/G	cg02016764	chr4:38805732	TLR1	-0.63	-7.26	-0.41	4.22e-12	Breast cancer;
CESC	cis	rs6502050	0.698	rs6502076	chr17:80121978	A/G	cg23985595	chr17:80112537	CCDC57	-0.41	-6.57	-0.37	2.6200000000000003e-10	Life satisfaction;
CESC	cis	rs597539	0.652	rs604524	chr11:68629929	G/A	cg06028808	chr11:68637592	NA	0.45	5.38	0.31	1.64e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs6063312	1.000	rs6063312	chr20:47343059	G/T	cg18078177	chr20:47281410	PREX1	0.55	5.53	0.32	7.54e-8	Tonometry;
CESC	cis	rs7666738	0.830	rs28444709	chr4:99028496	A/T	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.58e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1109430	0.661	rs11119403	chr1:210249847	G/A	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.92	6.23	0.36	1.82e-9	Orofacial clefts;
CESC	cis	rs4727027	0.635	rs12111923	chr7:148885877	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.45	5.25	0.31	3.17e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs6674176	0.660	rs12726706	chr1:44399942	G/A	cg15962314	chr1:44399869	ARTN	0.28	5.14	0.3	5.46e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg14977279	chr14:105609411	JAG2	0.52	6.78	0.38	7.67e-11	Fibrinogen levels;
CESC	cis	rs12477438	0.798	rs4850891	chr2:99574642	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.7	-10.22	-0.53	6.79e-21	Chronic sinus infection;
CESC	cis	rs2576037	0.526	rs2576051	chr18:44557884	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.42	-6.88	-0.39	4.31e-11	Personality dimensions;
CESC	cis	rs61759167	1.000	rs61759167	chr1:3091587	C/T	cg01961086	chr1:3086487	PRDM16	-0.34	-5.06	-0.3	8.02e-7	Motion sickness;
CESC	cis	rs6582630	0.555	rs1906260	chr12:38601013	T/G	cg13010199	chr12:38710504	ALG10B	0.53	6.86	0.39	4.71e-11	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs6089584	0.927	rs2296083	chr20:60574216	C/T	cg24733560	chr20:60626293	TAF4	0.38	5.41	0.32	1.44e-7	Body mass index;
CESC	cis	rs4654899	1.000	rs6426656	chr1:21343245	G/C	cg05370193	chr1:21551575	ECE1	0.41	6.16	0.35	2.64e-9	Superior frontal gyrus grey matter volume;
CESC	cis	rs9287719	0.967	rs6706542	chr2:10742491	A/C	cg00105475	chr2:10696890	NA	0.39	5.64	0.33	4.44e-8	Prostate cancer;
CESC	cis	rs559928	0.606	rs55942618	chr11:63936005	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.66	5.84	0.34	1.55e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CESC	cis	rs2204008	0.614	rs4578492	chr12:38036350	T/C	cg26384229	chr12:38710491	ALG10B	0.75	10.72	0.55	1.61e-22	Bladder cancer;
CESC	cis	rs9322193	0.962	rs10214845	chr6:150104260	A/G	cg07701084	chr6:150067640	NUP43	0.43	5.85	0.34	1.45e-8	Lung cancer;
CESC	cis	rs10540	0.908	rs35608427	chr11:498976	T/C	cg21784768	chr11:537496	LRRC56	-0.54	-5.07	-0.3	7.31e-7	Body mass index;
CESC	cis	rs763014	0.865	rs710924	chr16:633353	T/C	cg07256732	chr16:621771	PIGQ	-0.3	-5.14	-0.3	5.22e-7	Height;
CESC	cis	rs7216064	1.000	rs4318247	chr17:65882172	A/G	cg12091567	chr17:66097778	LOC651250	-0.86	-8.82	-0.48	1.55e-16	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs1775715	0.707	rs2778669	chr10:32161541	C/T	cg18675610	chr10:32216311	ARHGAP12	0.35	5.38	0.31	1.6e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs12142240	0.698	rs6696777	chr1:46810970	A/G	cg00530320	chr1:46809349	NSUN4	0.58	7.85	0.43	1.05e-13	Menopause (age at onset);
CESC	cis	rs8022179	0.580	rs8013228	chr14:103842650	A/G	cg12935359	chr14:103987150	CKB	-0.48	-6.22	-0.36	1.95e-9	Monocyte count;
CESC	cis	rs601339	0.877	rs2649991	chr12:123179461	A/G	cg11919336	chr12:123188078	GPR109A	0.48	6.44	0.37	5.44e-10	Adiponectin levels;
CESC	cis	rs7202877	0.656	rs4888394	chr16:75413709	T/C	cg04384234	chr16:75411784	CFDP1	-0.49	-5.89	-0.34	1.16e-8	Type 2 diabetes;Type 1 diabetes;
CESC	cis	rs2549003	0.966	rs10072571	chr5:131816711	A/C	cg02551604	chr5:131831745	NA	-0.37	-5.22	-0.31	3.53e-7	Asthma (sex interaction);
CESC	cis	rs2456568	0.867	rs7114457	chr11:93657817	C/T	cg26875233	chr11:93583750	C11orf90	-0.3	-5.16	-0.3	4.77e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
CESC	cis	rs11190604	1.000	rs4919466	chr10:102241213	T/C	cg07080220	chr10:102295463	HIF1AN	0.56	5.54	0.32	7.32e-8	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs1048238	0.506	rs848212	chr1:16263452	A/G	cg22431228	chr1:16359049	CLCNKA	0.37	6.59	0.38	2.43e-10	Systolic blood pressure;
CESC	cis	rs9818758	0.545	rs9853352	chr3:49813258	C/T	cg00383909	chr3:49044727	WDR6	-0.83	-5.69	-0.33	3.42e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CESC	cis	rs6860806	0.661	rs1588263	chr5:131577158	T/C	cg22638593	chr5:131593259	PDLIM4	0.39	5.07	0.3	7.6e-7	Breast cancer;
CESC	cis	rs736408	0.511	rs12637632	chr3:52708073	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	7.55	0.42	6.86e-13	Bipolar disorder;
CESC	cis	rs3925075	0.966	rs7195915	chr16:31344455	A/G	cg02846316	chr16:31340340	ITGAM	0.42	6.76	0.38	8.91e-11	IgA nephropathy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21638323	chr11:47600536	KBTBD4;NDUFS3	0.54	6.05	0.35	4.79e-9	Gut microbiome composition (summer);
CESC	cis	rs9532580	0.619	rs2755211	chr13:41142223	C/T	cg21288729	chr13:41239152	FOXO1	0.67	7.94	0.44	5.69e-14	Mean corpuscular hemoglobin;
CESC	cis	rs9549260	0.522	rs4245401	chr13:41277736	G/T	cg21288729	chr13:41239152	FOXO1	0.57	7.59	0.42	5.49e-13	Red blood cell count;
CESC	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg03188948	chr7:1209495	NA	0.7	6.71	0.38	1.2e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2952156	0.920	rs2517953	chr17:37841211	G/C	cg00129232	chr17:37814104	STARD3	-0.81	-11.91	-0.59	1.71e-26	Asthma;
CESC	cis	rs10504229	0.861	rs6990796	chr8:58183097	G/C	cg05313129	chr8:58192883	C8orf71	-0.55	-6.29	-0.36	1.34e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs9527	0.590	rs12414232	chr10:104914491	A/T	cg04362960	chr10:104952993	NT5C2	0.43	5.33	0.31	2.12e-7	Arsenic metabolism;
CESC	cis	rs2836974	0.932	rs8129416	chr21:40617145	C/T	cg11644478	chr21:40555479	PSMG1	1.01	15.97	0.7	1.12e-40	Cognitive function;
CESC	cis	rs514406	0.861	rs11206011	chr1:53235910	T/C	cg16325326	chr1:53192061	ZYG11B	-0.71	-11.84	-0.59	3e-26	Monocyte count;
CESC	cis	rs761746	0.921	rs7291918	chr22:32008039	A/G	cg25791279	chr22:32026902	PISD	0.58	6.83	0.39	5.84e-11	Intelligence;
CESC	cis	rs6461049	0.800	rs3800909	chr7:2159594	C/G	cg08027265	chr7:2291960	NA	-0.41	-6.39	-0.37	7.45e-10	Schizophrenia;
CESC	cis	rs6120849	0.754	rs6088682	chr20:33615702	A/C	cg24642439	chr20:33292090	TP53INP2	0.68	6.77	0.38	8.46e-11	Protein C levels;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg15464363	chr22:32149800	DEPDC5	-0.4	-6.47	-0.37	4.79e-10	Gambling;
CESC	cis	rs2230307	0.572	rs512999	chr1:100563330	A/G	cg24955406	chr1:100503596	HIAT1	0.53	5.25	0.31	3.18e-7	Carotid intima media thickness;
CESC	cis	rs2243480	1.000	rs6959002	chr7:65650496	A/G	cg18252515	chr7:66147081	NA	1.36	13.62	0.64	2.24e-32	Diabetic kidney disease;
CESC	cis	rs4072980	0.524	rs28442147	chr1:38395410	T/A	cg17077180	chr1:38461687	NA	0.43	6.14	0.35	3e-9	Coronary artery disease;
CESC	cis	rs870825	0.616	rs7678849	chr4:185648868	T/C	cg04058563	chr4:185651563	MLF1IP	0.63	6.96	0.39	2.59e-11	Blood protein levels;
CESC	cis	rs1971256	0.500	rs75278317	chr6:151821271	G/A	cg10883421	chr6:151773342	RMND1;C6orf211	0.64	5.89	0.34	1.14e-8	Endometriosis;
CESC	cis	rs2952156	0.920	rs8078228	chr17:37834998	C/T	cg19468946	chr17:37922297	IKZF3	-0.39	-5.1	-0.3	6.37e-7	Asthma;
CESC	cis	rs9473147	0.516	rs2171089	chr6:47515811	A/G	cg20196966	chr6:47445060	CD2AP	0.4	5.18	0.3	4.45e-7	Platelet distribution width;Mean platelet volume;
CESC	cis	rs4862750	0.872	rs7664463	chr4:187876686	A/C	cg06074448	chr4:187884817	NA	-0.46	-6.87	-0.39	4.56e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs13064411	0.735	rs6438157	chr3:113207316	G/T	cg18753928	chr3:113234510	CCDC52	-0.52	-6.31	-0.36	1.17e-9	Response to simvastatin treatment (PCSK9 protein level change);
CESC	cis	rs9039	1.000	rs56193985	chr16:9207199	C/A	cg08831531	chr16:9218945	NA	-0.52	-7.11	-0.4	1.07e-11	Menopause (age at onset);
CESC	trans	rs2823962	0.759	rs2823933	chr21:18022418	G/T	cg06419850	chr17:4688683	VMO1	-0.44	-6.23	-0.36	1.83e-9	Amyotrophic lateral sclerosis;
CESC	cis	rs9318086	0.712	rs3794339	chr13:24434065	A/C	cg25267304	chr13:24462978	PCOTH;MIPEP	0.41	5.34	0.31	1.98e-7	Myopia (pathological);
CESC	cis	rs7412746	0.634	rs7521592	chr1:150821691	A/C	cg04414720	chr1:150670196	GOLPH3L	0.54	7.13	0.4	9.67e-12	Melanoma;
CESC	cis	rs4969178	0.965	rs11653305	chr17:76386918	T/C	cg20026190	chr17:76395443	PGS1	0.44	6.83	0.39	5.8e-11	HDL cholesterol levels;
CESC	cis	rs13191362	1.000	rs13212608	chr6:163032128	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.86	9.12	0.49	1.91e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs1005277	0.540	rs2224248	chr10:38451886	A/G	cg00409905	chr10:38381863	ZNF37A	-0.45	-5.96	-0.34	7.89e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs3087591	1.000	rs9904169	chr17:29572518	C/T	cg24425628	chr17:29625626	OMG;NF1	-0.42	-5.03	-0.3	9.19e-7	Hip circumference;
CESC	trans	rs4132509	0.793	rs10927047	chr1:243803677	A/T	cg11709150	chr1:2440438	PANK4	0.62	6.47	0.37	4.67e-10	RR interval (heart rate);
CESC	cis	rs71403859	0.667	rs12149264	chr16:71720921	T/G	cg08717414	chr16:71523259	ZNF19	-0.71	-6.24	-0.36	1.73e-9	Post bronchodilator FEV1;
CESC	trans	rs7615952	0.515	rs7630575	chr3:125682330	A/G	cg07211511	chr3:129823064	LOC729375	-0.62	-6.44	-0.37	5.46e-10	Blood pressure (smoking interaction);
CESC	cis	rs963731	0.522	rs1454222	chr2:39215895	C/A	cg04010122	chr2:39346883	SOS1	-0.7	-5.22	-0.31	3.64e-7	Corticobasal degeneration;
CESC	cis	rs34779708	0.931	rs12771399	chr10:35452377	C/T	cg04310649	chr10:35416472	CREM	-0.54	-6.53	-0.37	3.25e-10	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs425277	1.000	rs262641	chr1:2104981	C/T	cg24578937	chr1:2090814	PRKCZ	-0.5	-8.83	-0.48	1.48e-16	Height;
CESC	cis	rs4237845	0.514	rs4760339	chr12:58268149	G/T	cg00677455	chr12:58241039	CTDSP2	0.8	10.71	0.55	1.76e-22	Intelligence (multi-trait analysis);
CESC	cis	rs17818399	1.000	rs62136864	chr2:46829124	G/A	cg06386533	chr2:46925753	SOCS5	0.5	5.77	0.33	2.24e-8	Height;
CESC	cis	rs4975709	0.610	rs4975706	chr5:1860365	G/T	cg20790798	chr5:1857306	NA	-0.38	-5.11	-0.3	6.21e-7	Cardiovascular disease risk factors;
CESC	cis	rs514406	0.679	rs12563825	chr1:53238324	G/T	cg08859206	chr1:53392774	SCP2	0.67	10.45	0.54	1.28e-21	Monocyte count;
CESC	cis	rs10046574	0.831	rs10239457	chr7:135116926	A/G	cg27474649	chr7:135195673	CNOT4	-0.68	-5.34	-0.31	2e-7	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs7208859	0.623	rs11658022	chr17:29085359	A/T	cg14008862	chr17:28927542	LRRC37B2	0.68	5.3	0.31	2.47e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs9611519	0.780	rs5751071	chr22:41656332	G/A	cg03806693	chr22:41940476	POLR3H	-0.55	-6.27	-0.36	1.46e-9	Neuroticism;
CESC	cis	rs7937682	0.632	rs11603779	chr11:111781047	A/C	cg09085632	chr11:111637200	PPP2R1B	0.88	11.23	0.57	3.51e-24	Primary sclerosing cholangitis;
CESC	cis	rs76878669	0.606	rs1785639	chr11:66100430	G/A	cg18002602	chr11:66138449	SLC29A2	0.41	6.73	0.38	1.08e-10	Educational attainment (years of education);
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg15926737	chr12:57853737	GLI1	-0.5	-6.47	-0.37	4.71e-10	Height;
CESC	cis	rs853679	0.505	rs200992	chr6:27814677	A/G	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.8	6.51	0.37	3.8e-10	Depression;
CESC	cis	rs6964587	0.773	rs59242586	chr7:91918145	A/G	cg17063962	chr7:91808500	NA	0.53	6.78	0.38	7.95e-11	Breast cancer;
CESC	cis	rs1728785	0.901	rs7194664	chr16:68643313	T/C	cg02972257	chr16:68554789	NA	-0.63	-7.0	-0.39	2.14e-11	Ulcerative colitis;
CESC	cis	rs1355223	0.902	rs1453380	chr11:34703682	C/G	cg11058730	chr11:34937778	PDHX;APIP	-0.46	-6.15	-0.35	2.82e-9	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs1023500	0.529	rs133375	chr22:42466509	C/G	cg15557168	chr22:42548783	NA	-0.45	-6.5	-0.37	3.87e-10	Schizophrenia;
CESC	cis	rs6688363	0.943	rs1016732	chr1:160086968	A/G	cg01023271	chr1:160068607	IGSF8	0.55	5.4	0.31	1.48e-7	Response to antipsychotic treatment;
CESC	cis	rs769267	0.501	rs2965187	chr19:19522970	T/A	cg11584989	chr19:19387371	SF4	0.54	6.77	0.38	8.41e-11	Tonsillectomy;
CESC	cis	rs472402	0.580	rs10060745	chr5:6658003	T/C	cg10789808	chr5:6633262	NSUN2;SRD5A1	-0.54	-7.01	-0.4	2e-11	Response to amphetamines;
CESC	cis	rs599083	0.530	rs2508834	chr11:68175354	C/T	cg16797656	chr11:68205561	LRP5	-0.4	-5.33	-0.31	2.1e-7	Bone mineral density (spine);
CESC	cis	rs7772486	0.875	rs9373483	chr6:146364194	A/G	cg05347473	chr6:146136440	FBXO30	0.47	6.16	0.35	2.66e-9	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9291683	0.588	rs2240722	chr4:10020757	A/G	cg00071950	chr4:10020882	SLC2A9	0.92	17.72	0.74	6.98e-47	Bone mineral density;
CESC	cis	rs3096299	0.685	rs8050512	chr16:89552320	C/G	cg02187348	chr16:89574699	SPG7	0.64	8.99	0.48	4.91e-17	Multiple myeloma (IgH translocation);
CESC	cis	rs4563143	0.675	rs56407818	chr19:29279379	G/A	cg12667521	chr19:29218732	NA	0.5	6.39	0.37	7.47e-10	Methadone dose in opioid dependence;
CESC	cis	rs2625529	0.652	rs9302260	chr15:72174611	T/C	cg16672083	chr15:72433130	SENP8	0.45	6.72	0.38	1.09e-10	Red blood cell count;
CESC	cis	rs751837	0.591	rs10138056	chr14:103424854	A/G	cg10087771	chr14:103399429	CDC42BPB	0.7	6.09	0.35	4.01e-9	Large B-cell lymphoma;
CESC	cis	rs7666738	0.830	rs36047842	chr4:99004902	C/A	cg03467027	chr4:99064603	C4orf37	0.44	5.51	0.32	8.65e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1003719	0.762	rs8130846	chr21:38480242	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.63	8.77	0.47	2.14e-16	Eye color traits;
CESC	cis	rs6952808	0.501	rs4721429	chr7:2171704	T/C	cg21782813	chr7:2030301	MAD1L1	0.5	7.24	0.41	4.74e-12	Bipolar disorder and schizophrenia;
CESC	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg18591801	chr3:52553433	STAB1	-0.3	-5.76	-0.33	2.27e-8	Electroencephalogram traits;
CESC	cis	rs7666738	0.830	rs17027225	chr4:99028564	C/T	cg05340658	chr4:99064831	C4orf37	0.83	13.1	0.63	1.43e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs854765	0.583	rs7207043	chr17:17819188	A/G	cg09796270	chr17:17721594	SREBF1	0.42	5.95	0.34	8.29e-9	Total body bone mineral density;
CESC	trans	rs877282	0.891	rs12767062	chr10:797961	C/T	cg22713356	chr15:30763199	NA	1.35	13.42	0.64	1.08e-31	Uric acid levels;
CESC	cis	rs2933343	0.649	rs789216	chr3:128594503	A/C	cg24203234	chr3:128598194	ACAD9	0.4	5.34	0.31	2.05e-7	IgG glycosylation;
CESC	cis	rs13256369	1.000	rs13267501	chr8:8574058	G/A	cg18904891	chr8:8559673	CLDN23	0.7	8.19	0.45	1.14e-14	Obesity-related traits;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg22332891	chr1:178995082	FAM20B	-0.5	-6.19	-0.36	2.32e-9	Ulcerative colitis;
CESC	cis	rs1552244	0.882	rs6443276	chr3:10008905	C/A	cg08888203	chr3:10149979	C3orf24	0.48	6.0	0.35	6.49e-9	Alzheimer's disease;
CESC	cis	rs7808935	0.958	rs17156041	chr7:27975745	C/T	cg05786569	chr7:27702416	HIBADH	0.46	5.08	0.3	7.17e-7	Prostate cancer;
CESC	cis	rs1862618	0.573	rs2034245	chr5:56243685	T/C	cg12311346	chr5:56204834	C5orf35	0.87	10.66	0.55	2.52e-22	Initial pursuit acceleration;
CESC	cis	rs662064	0.962	rs2506902	chr1:10563681	C/T	cg20482658	chr1:10539492	PEX14	0.37	7.15	0.4	8.25e-12	Asthma;
CESC	cis	rs1983891	0.955	rs6917270	chr6:41548755	A/G	cg20194872	chr6:41519635	FOXP4	0.53	7.46	0.42	1.21e-12	Prostate cancer;
CESC	cis	rs9596863	1.000	rs9596859	chr13:54431200	T/A	ch.13.53330881F	chr13:54432880	NA	0.66	5.25	0.31	3.08e-7	Epilepsy and lamotrigine-induced maculopapular eruptions;
CESC	cis	rs2440129	0.611	rs1126667	chr17:6902760	C/T	cg09737314	chr17:6899359	ALOX12	-0.47	-8.29	-0.45	5.81e-15	Tonsillectomy;
CESC	cis	rs12477438	0.501	rs7608938	chr2:99782226	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.79	12.62	0.61	6.6e-29	Chronic sinus infection;
CESC	cis	rs5747327	0.874	rs5747333	chr22:18180567	G/C	cg19898043	chr22:18121309	BCL2L13	-0.4	-5.19	-0.3	4.18e-7	Myeloid white cell count;Granulocyte count;
CESC	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg23131131	chr22:24373011	LOC391322	0.72	10.04	0.52	2.65e-20	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs151234	0.676	rs554206	chr16:28576369	G/A	cg01378222	chr16:28622494	SULT1A1	-0.57	-7.19	-0.4	6.79e-12	Platelet distribution width;
CESC	cis	rs7666738	0.830	rs11935078	chr4:99010476	T/A	cg17366294	chr4:99064904	C4orf37	0.6	8.62	0.47	6.37e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1799949	0.965	rs2236762	chr17:41226675	A/T	cg05368731	chr17:41323189	NBR1	0.59	8.21	0.45	9.98e-15	Menopause (age at onset);
CESC	cis	rs4819052	0.851	rs10470258	chr21:46658989	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.91	13.24	0.63	4.51e-31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs2795502	0.882	rs2744091	chr10:43339441	A/G	cg20628663	chr10:43360327	NA	-0.62	-7.39	-0.41	1.9e-12	Blood protein levels;
CESC	cis	rs7666738	0.800	rs13107147	chr4:99028753	C/T	cg03676636	chr4:99064102	C4orf37	0.34	5.18	0.3	4.4e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11098499	0.954	rs10518328	chr4:120401779	G/A	cg24375607	chr4:120327624	NA	0.45	5.49	0.32	9.3e-8	Corneal astigmatism;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg18330637	chr20:18548049	LOC388789	-0.45	-6.0	-0.35	6.41e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs2710642	0.611	rs1534420	chr2:62884053	C/T	cg17519650	chr2:63277830	OTX1	-0.46	-5.44	-0.32	1.23e-7	LDL cholesterol levels;LDL cholesterol;
CESC	cis	rs7077164	1.000	rs1227769	chr10:71586296	C/T	cg07630274	chr10:71583235	COL13A1	-0.38	-6.99	-0.39	2.27e-11	Non-alcoholic fatty liver disease histology (lobular);
CESC	cis	rs11711311	1.000	rs9848993	chr3:113497914	T/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.73	10.32	0.54	3.29e-21	IgG glycosylation;
CESC	cis	rs853679	0.517	rs1947863	chr6:28099344	G/A	cg08968635	chr6:28129556	ZNF389	0.42	5.72	0.33	2.82e-8	Depression;
CESC	cis	rs7589342	0.929	rs2060036	chr2:106436101	G/A	cg16077055	chr2:106428750	NCK2	0.54	7.64	0.42	4.08e-13	Addiction;
CESC	trans	rs4942242	0.626	rs7986998	chr13:44209916	G/A	cg19169023	chr15:41853346	TYRO3	0.56	7.1	0.4	1.18e-11	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs28647808	1.000	rs28591209	chr9:136259668	T/C	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.85	5.74	0.33	2.59e-8	Blood protein levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21951679	chr5:178977648	RUFY1	0.47	6.19	0.36	2.23e-9	Gut microbiome composition (summer);
CESC	cis	rs1552244	0.572	rs6785976	chr3:10168647	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.7	-8.04	-0.44	2.93e-14	Alzheimer's disease;
CESC	cis	rs3806843	0.676	rs2563304	chr5:140072057	C/T	cg26395211	chr5:140044315	WDR55	0.47	5.95	0.34	8.29e-9	Depressive symptoms (multi-trait analysis);
CESC	cis	rs77741769	0.571	rs3861797	chr12:121255334	T/C	cg02419362	chr12:121203948	SPPL3	0.35	5.69	0.33	3.37e-8	Mean corpuscular volume;
CESC	cis	rs7618501	0.516	rs2856236	chr3:50161717	A/C	cg24110177	chr3:50126178	RBM5	0.5	6.71	0.38	1.2e-10	Intelligence (multi-trait analysis);
CESC	cis	rs6430585	0.583	rs79633114	chr2:136586825	C/T	cg07169764	chr2:136633963	MCM6	1.34	19.5	0.77	3.91e-53	Corneal structure;
CESC	cis	rs9467711	0.606	rs9379900	chr6:26603811	A/C	cg21479132	chr6:26055353	NA	0.65	5.69	0.33	3.29e-8	Autism spectrum disorder or schizophrenia;
CESC	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg05313129	chr8:58192883	C8orf71	-0.49	-5.32	-0.31	2.23e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs1912483	0.545	rs35161461	chr17:45401757	A/G	cg25173405	chr17:45401733	C17orf57	-0.49	-5.72	-0.33	2.85e-8	Coronary artery disease;
CESC	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg14159672	chr1:205819179	PM20D1	0.81	12.95	0.62	4.67e-30	Menarche (age at onset);
CESC	cis	rs74181299	0.964	rs2540951	chr2:65276736	A/G	cg05010058	chr2:65284262	CEP68	0.31	5.56	0.32	6.63e-8	Pulse pressure;
CESC	cis	rs3091242	0.781	rs71652378	chr1:25721457	G/C	cg12412775	chr1:25698385	RHCE	-0.31	-5.62	-0.33	4.72e-8	Erythrocyte sedimentation rate;
CESC	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	13.8	0.65	5.28e-33	Prudent dietary pattern;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg07588614	chr3:113604183	GRAMD1C	0.45	6.38	0.36	8.08e-10	Fibrinogen levels;
CESC	trans	rs4332037	0.539	rs11772627	chr7:2109821	G/C	cg11693508	chr17:37793320	STARD3	0.68	6.92	0.39	3.42e-11	Bipolar disorder;
CESC	cis	rs4253772	0.678	rs1055659	chr22:46638298	C/T	cg09491104	chr22:46646882	C22orf40	-0.44	-5.83	-0.34	1.59e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs12458462	0.892	rs3786228	chr18:77464170	C/T	cg23301140	chr18:77439876	CTDP1	-0.58	-8.07	-0.44	2.47e-14	Monocyte count;
CESC	cis	rs8022179	0.580	rs6575977	chr14:103823348	G/T	cg12935359	chr14:103987150	CKB	0.53	6.46	0.37	5.11e-10	Monocyte count;
CESC	cis	rs3858526	0.959	rs4559671	chr11:5923419	C/T	cg13902645	chr11:5959945	NA	-0.6	-7.38	-0.41	2.03e-12	DNA methylation (variation);
CESC	cis	rs77956314	0.515	rs4238051	chr12:117366299	A/G	cg25972092	chr12:117363249	FBXW8	0.53	5.69	0.33	3.36e-8	Subcortical brain region volumes;Hippocampal volume;
CESC	cis	rs6543140	0.964	rs4851593	chr2:103089227	C/T	cg04239558	chr2:103089729	SLC9A4	-0.48	-6.21	-0.36	2.09e-9	Blood protein levels;
CESC	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg03647317	chr4:187891568	NA	0.41	6.05	0.35	4.83e-9	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7085104	0.572	rs284860	chr10:104572963	T/C	cg04362960	chr10:104952993	NT5C2	-0.47	-6.37	-0.36	8.35e-10	Immature fraction of reticulocytes;Schizophrenia;
CESC	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.09	21.08	0.79	1.38e-58	Prudent dietary pattern;
CESC	cis	rs6032067	0.852	rs6032046	chr20:43823679	A/G	cg10761708	chr20:43804764	PI3	0.53	6.36	0.36	8.83e-10	Blood protein levels;
CESC	cis	rs9796	0.689	rs13329537	chr15:41449211	C/G	cg09898695	chr15:41135793	SPINT1	0.21	5.04	0.3	8.66e-7	Menopause (age at onset);
CESC	cis	rs34779708	0.931	rs2001893	chr10:35300623	G/A	cg03585969	chr10:35415529	CREM	0.75	9.89	0.52	7.5599999999999994e-20	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs7312774	0.618	rs3759317	chr12:107370252	T/C	cg16260113	chr12:107380972	MTERFD3	0.81	7.18	0.4	7.13e-12	Severe influenza A (H1N1) infection;
CESC	cis	rs4727963	0.846	rs1464875	chr7:122729085	G/A	cg03640110	chr7:122635026	TAS2R16	-0.37	-5.55	-0.32	6.79e-8	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
CESC	cis	rs4713118	0.515	rs9368549	chr6:28050047	T/A	cg20151795	chr6:28129481	ZNF389	0.44	5.59	0.33	5.5e-8	Parkinson's disease;
CESC	cis	rs244293	0.965	rs244357	chr17:53193181	A/G	cg19360675	chr17:53046073	COX11;STXBP4	-0.39	-5.03	-0.3	9.21e-7	Menarche (age at onset);
CESC	cis	rs2479106	0.791	rs2670139	chr9:126634255	T/C	cg16191174	chr9:126692580	DENND1A	0.49	6.62	0.38	2.02e-10	Polycystic ovary syndrome;
CESC	cis	rs2075371	0.863	rs12672691	chr7:133954431	C/T	cg20476274	chr7:133979776	SLC35B4	0.63	9.08	0.49	2.53e-17	Mean platelet volume;
CESC	cis	rs1153858	1.000	rs1980288	chr15:45620612	T/C	cg14582100	chr15:45693742	SPATA5L1	0.41	5.71	0.33	3.08e-8	Homoarginine levels;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg23411981	chr14:105940377	CRIP2	0.45	6.21	0.36	2.09e-9	Fibrinogen levels;
CESC	cis	rs875971	1.000	rs1981798	chr7:65954903	G/T	cg11764359	chr7:65958608	NA	0.96	15.21	0.68	5.68e-38	Aortic root size;
CESC	cis	rs2040771	0.711	rs361639	chr22:19268024	A/G	cg17887427	chr22:19166691	SLC25A1	-0.39	-5.13	-0.3	5.55e-7	Metabolite levels (small molecules and protein measures);
CESC	cis	rs12477438	0.765	rs2309454	chr2:99595418	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.64	-8.73	-0.47	2.94e-16	Chronic sinus infection;
CESC	cis	rs7618915	0.501	rs7624716	chr3:52751534	T/C	cg05564831	chr3:52568323	NT5DC2	0.46	7.19	0.4	6.64e-12	Bipolar disorder;
CESC	cis	rs7223966	1.000	rs7222060	chr17:61868279	C/T	cg11494091	chr17:61959527	GH2	0.38	5.17	0.3	4.56e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs3820068	0.581	rs72645861	chr1:15920314	A/G	cg13390004	chr1:15929781	NA	0.33	5.04	0.3	8.45e-7	Systolic blood pressure;
CESC	trans	rs2727020	0.553	rs11040400	chr11:49518296	C/A	cg03929089	chr4:120376271	NA	-0.8	-11.78	-0.59	5.03e-26	Coronary artery disease;
CESC	trans	rs11098499	0.954	rs10031665	chr4:120422852	T/C	cg25214090	chr10:38739885	LOC399744	0.7	9.78	0.51	1.7e-19	Corneal astigmatism;
CESC	cis	rs3858526	0.920	rs11039548	chr11:5930283	G/A	cg05234568	chr11:5960015	NA	-0.56	-6.42	-0.37	6.24e-10	DNA methylation (variation);
CESC	cis	rs6502050	0.835	rs4789732	chr17:80131382	A/G	cg11859384	chr17:80120422	CCDC57	-0.39	-5.34	-0.31	1.97e-7	Life satisfaction;
CESC	cis	rs8180040	0.620	rs6767907	chr3:47162661	C/T	cg27129171	chr3:47204927	SETD2	-0.64	-9.54	-0.51	9.72e-19	Colorectal cancer;
CESC	cis	rs897080	0.518	rs1067330	chr2:44627822	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.49	5.82	0.34	1.67e-8	Height;
CESC	cis	rs17253792	0.731	rs8008528	chr14:56062052	C/T	cg01858014	chr14:56050164	KTN1	-0.96	-7.13	-0.4	9.72e-12	Putamen volume;
CESC	trans	rs9929218	0.911	rs4783685	chr16:68834107	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.64	-8.06	-0.44	2.61e-14	Colorectal cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18898693	chr10:80829147	ZMIZ1	-0.6	-6.34	-0.36	9.75e-10	Gut microbiome composition (summer);
CESC	cis	rs820218	0.926	rs820205	chr17:73641052	A/T	cg01592526	chr17:73663357	RECQL5;SAP30BP	0.44	6.15	0.35	2.9e-9	Rotator cuff tears;
CESC	cis	rs796364	0.901	rs4673762	chr2:201065171	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.6	5.61	0.33	5e-8	Schizophrenia;
CESC	cis	rs16854884	0.657	rs1867608	chr3:143752938	G/A	cg06585982	chr3:143692056	C3orf58	0.5	6.64	0.38	1.78e-10	Economic and political preferences (feminism/equality);
CESC	cis	rs2046867	0.862	rs57396880	chr3:72844785	G/A	cg25664220	chr3:72788482	NA	-0.47	-6.77	-0.38	8.26e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CESC	cis	rs2836974	0.623	rs7280326	chr21:40700408	A/G	cg22974920	chr21:40686053	BRWD1	-0.45	-5.57	-0.32	6.21e-8	Cognitive function;
CESC	cis	rs6963495	0.649	rs1706888	chr7:105149176	A/G	cg13798780	chr7:105162888	PUS7	0.5	6.09	0.35	4.04e-9	Bipolar disorder (body mass index interaction);
CESC	cis	rs2073300	0.609	rs6137945	chr20:23406136	C/T	cg16736954	chr20:23401023	NAPB	0.78	5.69	0.33	3.37e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	trans	rs11098499	0.863	rs1010740	chr4:120463409	C/T	cg25214090	chr10:38739885	LOC399744	-0.69	-9.33	-0.5	4.5e-18	Corneal astigmatism;
CESC	cis	rs9326248	0.530	rs2000614	chr11:116915742	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.56	5.18	0.3	4.38e-7	Blood protein levels;
CESC	cis	rs12142240	0.698	rs72679807	chr1:46846490	G/A	cg10495392	chr1:46806563	NSUN4	0.56	6.15	0.35	2.86e-9	Menopause (age at onset);
CESC	cis	rs2404602	0.669	rs1875885	chr15:76638081	G/A	cg26408565	chr15:76604113	ETFA	-0.42	-5.98	-0.34	7.26e-9	Blood metabolite levels;
CESC	cis	rs2820292	0.678	rs4309038	chr1:201884647	C/G	cg06775570	chr1:201857621	SHISA4	-0.31	-5.15	-0.3	5.1e-7	Waist circumference;Body mass index (joint analysis main effects and smoking interaction);Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);
CESC	cis	rs1799949	1.000	rs2175957	chr17:41286822	T/G	cg05368731	chr17:41323189	NBR1	0.8	11.35	0.57	1.34e-24	Menopause (age at onset);
CESC	cis	rs2276314	0.857	rs28791905	chr18:33602213	G/A	cg05985134	chr18:33552581	C18orf21	0.58	6.69	0.38	1.35e-10	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs7116495	0.609	rs1541304	chr11:71714078	T/C	cg10381502	chr11:71823885	C11orf51	-1.16	-7.72	-0.43	2.32e-13	Severe influenza A (H1N1) infection;
CESC	cis	rs12541635	0.966	rs2059943	chr8:107071607	G/T	cg10147462	chr8:107024639	NA	0.38	5.33	0.31	2.14e-7	Age of smoking initiation;
CESC	cis	rs826838	0.935	rs7301104	chr12:39182821	C/T	cg13010199	chr12:38710504	ALG10B	0.58	8.05	0.44	2.77e-14	Heart rate;
CESC	cis	rs17270561	1.000	rs17270561	chr6:25820439	A/C	cg17691542	chr6:26056736	HIST1H1C	-0.62	-7.26	-0.41	4.29e-12	Iron status biomarkers;
CESC	cis	rs644799	0.965	rs565771	chr11:95644179	T/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.61	7.98	0.44	4.42e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs9916302	0.605	rs2879258	chr17:37399379	G/T	cg07936489	chr17:37558343	FBXL20	-0.88	-8.84	-0.48	1.34e-16	Glomerular filtration rate (creatinine);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01062786	chr14:20929651	TMEM55B	0.55	6.69	0.38	1.29e-10	Gut microbiome composition (summer);
CESC	cis	rs826838	1.000	rs826886	chr12:39095797	A/G	cg26384229	chr12:38710491	ALG10B	0.62	10.11	0.53	1.55e-20	Heart rate;
CESC	cis	rs2710642	0.576	rs1872789	chr2:62883470	A/C	cg17519650	chr2:63277830	OTX1	0.44	5.26	0.31	2.91e-7	LDL cholesterol levels;LDL cholesterol;
CESC	trans	rs526821	0.595	rs551665	chr11:55343268	G/A	cg15704280	chr7:45808275	SEPT13	-0.54	-6.69	-0.38	1.32e-10	Pediatric bone mineral density (spine);
CESC	cis	rs11190604	1.000	rs2489053	chr10:102353341	A/G	cg07080220	chr10:102295463	HIF1AN	0.55	5.64	0.33	4.39e-8	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs11785693	0.909	rs62489556	chr8:4968149	G/A	cg26367366	chr8:4980734	NA	0.86	7.35	0.41	2.48e-12	Neuroticism (multi-trait analysis);Neuroticism;
CESC	cis	rs5760092	0.755	rs4585126	chr22:24270005	T/C	cg12419862	chr22:24373484	LOC391322	0.75	9.8	0.52	1.49e-19	Urinary 1,3-butadiene metabolite levels in smokers;
CESC	cis	rs3008870	0.920	rs2755253	chr1:67470843	C/T	cg02640540	chr1:67518911	SLC35D1	0.47	5.7	0.33	3.26e-8	Lymphocyte percentage of white cells;
CESC	cis	rs9287719	0.967	rs6727768	chr2:10757479	T/C	cg02196655	chr2:10830764	NOL10	-0.37	-5.67	-0.33	3.73e-8	Prostate cancer;
CESC	cis	rs35110281	0.666	rs9977076	chr21:45085829	G/A	cg01579765	chr21:45077557	HSF2BP	-0.54	-9.12	-0.49	1.95e-17	Mean corpuscular volume;
CESC	cis	rs1034435	0.755	rs713923	chr22:48891519	C/T	cg05992904	chr22:48892994	FAM19A5	0.52	8.28	0.45	6.13e-15	Late-onset Alzheimer's disease;
CESC	cis	rs1552244	0.882	rs3755782	chr3:10029305	T/C	cg08888203	chr3:10149979	C3orf24	0.49	6.17	0.35	2.49e-9	Alzheimer's disease;
CESC	trans	rs7395662	0.517	rs11039885	chr11:48647107	A/G	cg00717180	chr2:96193071	NA	-0.46	-6.19	-0.36	2.23e-9	HDL cholesterol;
CESC	cis	rs7107174	1.000	rs12270434	chr11:78103300	G/A	cg02023728	chr11:77925099	USP35	0.39	5.45	0.32	1.14e-7	Testicular germ cell tumor;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg11646757	chr7:128095699	C7orf68	-0.48	-6.42	-0.37	6.33e-10	Height;
CESC	cis	rs7666738	0.830	rs10470951	chr4:99037051	G/A	cg03467027	chr4:99064603	C4orf37	0.47	5.97	0.34	7.51e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1799949	1.000	rs1545764	chr17:41424565	G/A	cg05368731	chr17:41323189	NBR1	0.78	10.53	0.54	6.98e-22	Menopause (age at onset);
CESC	cis	rs2777491	0.915	rs8036498	chr15:41603276	A/G	cg02330683	chr15:41787940	ITPKA	0.46	6.76	0.38	8.67e-11	Ulcerative colitis;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg03200734	chr16:67235732	ELMO3	0.5	7.28	0.41	3.7e-12	Fibrinogen levels;
CESC	cis	rs611744	0.604	rs13248461	chr8:109285833	C/T	cg21045802	chr8:109455806	TTC35	0.52	6.46	0.37	5.03e-10	Dupuytren's disease;
CESC	cis	rs10540	0.730	rs61876338	chr11:493730	A/G	cg21784768	chr11:537496	LRRC56	-0.55	-5.12	-0.3	5.99e-7	Body mass index;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg21528620	chr1:110753221	KCNC4	-0.43	-6.3	-0.36	1.2e-9	Fibrinogen levels;
CESC	cis	rs4665809	0.652	rs6727974	chr2:26524639	A/G	cg25036284	chr2:26402008	FAM59B	0.64	7.22	0.41	5.55e-12	Gut microbiome composition (summer);
CESC	cis	rs9916302	0.904	rs7223438	chr17:37521355	T/C	cg20243544	chr17:37824526	PNMT	-0.48	-5.79	-0.34	1.96e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs10131894	0.611	rs174994	chr14:75434102	A/G	cg08847533	chr14:75593920	NEK9	-0.75	-11.77	-0.59	5.43e-26	Coronary artery disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg07154754	chr12:132514292	SNORA49;EP400	0.5	7.36	0.41	2.37e-12	Fibrinogen levels;
CESC	cis	rs780096	0.526	rs780106	chr2:27681598	A/C	cg24768116	chr2:27665128	KRTCAP3	-0.3	-5.57	-0.32	6.2e-8	Total body bone mineral density;
CESC	cis	rs4718428	0.705	rs2901311	chr7:66415069	T/C	cg12165864	chr7:66369176	NA	-0.67	-7.64	-0.42	3.91e-13	Corneal structure;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg23226134	chr1:11866389	CLCN6;MTHFR	-0.48	-6.76	-0.38	8.95e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs7937682	0.632	rs10891294	chr11:111699224	C/T	cg09085632	chr11:111637200	PPP2R1B	0.85	10.37	0.54	2.32e-21	Primary sclerosing cholangitis;
CESC	trans	rs2115172	0.836	rs4835799	chr5:122762229	A/G	cg01172656	chr10:64893120	NRBF2	0.45	6.07	0.35	4.46e-9	Weight;
CESC	cis	rs35110281	0.776	rs1073522	chr21:45009219	T/A	cg01579765	chr21:45077557	HSF2BP	-0.55	-9.27	-0.49	6.73e-18	Mean corpuscular volume;
CESC	cis	rs17376456	0.877	rs35075119	chr5:93385457	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.62	5.36	0.31	1.8e-7	Diabetic retinopathy;
CESC	trans	rs3942852	0.759	rs905475	chr11:48149755	C/T	cg03929089	chr4:120376271	NA	-0.57	-6.31	-0.36	1.15e-9	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs9811920	0.965	rs6767441	chr3:99863183	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.43	5.58	0.32	5.99e-8	Axial length;
CESC	cis	rs7223966	0.921	rs67018565	chr17:61928055	C/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.44	-5.14	-0.3	5.24e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs644799	1.000	rs651445	chr11:95539122	T/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	9.15	0.49	1.61e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs4835473	0.932	rs3872	chr4:144889941	C/T	cg25736465	chr4:144833511	NA	0.38	5.77	0.33	2.2e-8	Immature fraction of reticulocytes;
CESC	trans	rs2727020	0.729	rs2866328	chr11:49282421	A/G	cg15704280	chr7:45808275	SEPT13	0.87	14.38	0.66	4.84e-35	Coronary artery disease;
CESC	cis	rs7264396	0.676	rs1341603	chr20:34556216	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.52	6.09	0.35	4.04e-9	Total cholesterol levels;
CESC	cis	rs863345	0.967	rs863359	chr1:158544733	A/C	cg12129480	chr1:158549410	OR10X1	-0.31	-6.29	-0.36	1.31e-9	Pneumococcal bacteremia;
CESC	cis	rs10242455	0.702	rs73397499	chr7:99039627	T/C	cg25640893	chr7:99214727	ZNF498	0.72	5.11	0.3	6.25e-7	Blood metabolite levels;
CESC	cis	rs9487051	0.676	rs9400267	chr6:109600164	T/C	cg21918786	chr6:109611834	NA	-0.39	-5.67	-0.33	3.79e-8	Reticulocyte fraction of red cells;
CESC	cis	rs270601	0.909	rs2569265	chr5:131704519	T/C	cg04518342	chr5:131593106	PDLIM4	-0.36	-5.07	-0.3	7.31e-7	Acylcarnitine levels;
CESC	cis	rs1707322	0.721	rs10890343	chr1:46157922	C/T	cg05343316	chr1:45956843	TESK2	0.5	6.28	0.36	1.38e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs6026584	1.000	rs6026584	chr20:57469073	C/T	cg11480267	chr20:57463503	GNAS	-0.48	-5.94	-0.34	8.96e-9	Renal function-related traits (BUN);
CESC	cis	rs9611565	0.571	rs2050032	chr22:42152429	C/T	cg06634786	chr22:41940651	POLR3H	0.48	5.42	0.32	1.32e-7	Vitiligo;
CESC	cis	rs769267	0.930	rs6909	chr19:19619542	A/G	cg03709012	chr19:19516395	GATAD2A	1.01	15.89	0.7	2.1e-40	Tonsillectomy;
CESC	cis	rs9905704	0.846	rs302863	chr17:56698827	A/G	cg12560992	chr17:57184187	TRIM37	-0.58	-7.15	-0.4	8.63e-12	Testicular germ cell tumor;
CESC	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	10.25	0.53	5.63e-21	Prudent dietary pattern;
CESC	cis	rs7666738	0.830	rs13136930	chr4:98937933	A/T	cg03467027	chr4:99064603	C4orf37	0.48	5.91	0.34	1.03e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs360798	0.512	rs2215870	chr2:63132342	C/G	cg17519650	chr2:63277830	OTX1	0.52	6.58	0.37	2.55e-10	Coronary artery disease;
CESC	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.4	5.08	0.3	6.98e-7	Lymphocyte counts;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg20021244	chr5:139944115	APBB3;SLC35A4	-0.47	-6.35	-0.36	9.13e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs651907	0.557	rs17411983	chr3:101399126	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.47	-6.11	-0.35	3.46e-9	Colorectal cancer;
CESC	cis	rs7618915	0.547	rs34215106	chr3:52659124	T/C	cg18404041	chr3:52824283	ITIH1	-0.38	-6.34	-0.36	9.62e-10	Bipolar disorder;
CESC	cis	rs1800469	1.000	rs2241714	chr19:41869392	C/T	cg08477640	chr19:41863820	B9D2	-0.67	-9.4	-0.5	2.63e-18	Colorectal cancer;
CESC	cis	rs2832077	0.527	rs11088095	chr21:30223188	A/T	cg08807101	chr21:30365312	RNF160	-0.66	-8.57	-0.47	8.73e-16	Cognitive test performance;
CESC	cis	rs2735413	0.881	rs12921945	chr16:78080133	G/T	cg04733911	chr16:78082701	NA	-0.53	-9.05	-0.49	3.11e-17	Systolic blood pressure (alcohol consumption interaction);
CESC	cis	rs4268898	0.636	rs76172309	chr2:24458911	G/C	cg06627628	chr2:24431161	ITSN2	-0.98	-11.2	-0.57	4.39e-24	Asthma;
CESC	cis	rs11123610	0.520	rs11682697	chr2:3721127	A/G	cg10645314	chr2:3704589	ALLC	-0.46	-5.09	-0.3	6.83e-7	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CESC	cis	rs11785693	0.862	rs73183618	chr8:4988340	T/C	cg26367366	chr8:4980734	NA	0.62	6.3	0.36	1.25e-9	Neuroticism (multi-trait analysis);Neuroticism;
CESC	cis	rs524281	0.861	rs7935336	chr11:65865325	C/T	cg14036092	chr11:66035641	RAB1B	-0.62	-6.29	-0.36	1.27e-9	Electroencephalogram traits;
CESC	trans	rs5756813	0.661	rs2285178	chr22:38205989	T/C	cg19894588	chr14:64061835	NA	-0.67	-8.32	-0.46	4.72e-15	Optic cup area;Vertical cup-disc ratio;
CESC	cis	rs992157	0.560	rs6436047	chr2:219108913	A/C	cg20019365	chr2:219134978	PNKD;AAMP	0.62	8.25	0.45	7.67e-15	Colorectal cancer;
CESC	cis	rs12497850	0.797	rs61583136	chr3:49189195	C/T	cg03060546	chr3:49711283	APEH	0.55	6.8	0.39	7.11e-11	Parkinson's disease;
CESC	cis	rs637571	0.565	rs633800	chr11:65638719	G/A	cg26695010	chr11:65641043	EFEMP2	0.61	7.75	0.43	1.99e-13	Eosinophil percentage of white cells;
CESC	cis	rs35306767	0.953	rs7908138	chr10:962978	C/T	cg26597838	chr10:835615	NA	0.82	9.53	0.51	1.07e-18	Eosinophil percentage of granulocytes;
CESC	cis	rs4704187	0.663	rs28539749	chr5:74533902	G/A	cg03227963	chr5:74354835	NA	0.27	5.04	0.3	8.67e-7	Response to amphetamines;
CESC	cis	rs1707322	1.000	rs7531911	chr1:46330423	A/G	cg03146154	chr1:46216737	IPP	0.74	10.16	0.53	1.08e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs2727020	0.595	rs10466496	chr11:49501514	C/T	cg15704280	chr7:45808275	SEPT13	-0.95	-16.98	-0.72	2.94e-44	Coronary artery disease;
CESC	cis	rs4523957	0.891	rs216200	chr17:2199846	C/T	cg16513277	chr17:2031491	SMG6	0.61	8.3	0.45	5.2e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs1348850	0.958	rs1545364	chr2:178462882	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.64	8.95	0.48	6.21e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs769267	0.895	rs2965189	chr19:19519518	G/T	cg03709012	chr19:19516395	GATAD2A	0.98	15.74	0.7	7.55e-40	Tonsillectomy;
CESC	trans	rs73198271	0.710	rs7837843	chr8:8656485	A/G	cg23754772	chr18:12253859	CIDEA	-0.34	-6.26	-0.36	1.55e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs2860975	0.620	rs7095531	chr10:96811841	A/G	cg09036531	chr10:96991505	NA	-0.36	-5.24	-0.31	3.25e-7	Immune response to smallpox vaccine (IL-6);
CESC	cis	rs2991971	0.716	rs7532573	chr1:45915892	A/T	cg24296786	chr1:45957014	TESK2	-0.62	-8.77	-0.47	2.19e-16	High light scatter reticulocyte count;
CESC	cis	rs9300255	0.739	rs1879380	chr12:123739111	G/A	cg00376283	chr12:123451042	ABCB9	-0.62	-6.4	-0.37	6.86e-10	Neutrophil percentage of white cells;
CESC	cis	rs7937682	0.855	rs539693	chr11:111477387	A/G	cg22437258	chr11:111473054	SIK2	0.72	9.63	0.51	5.14e-19	Primary sclerosing cholangitis;
CESC	cis	rs11122272	0.735	rs2808584	chr1:231512925	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.57	-7.82	-0.43	1.29e-13	Hemoglobin concentration;
CESC	cis	rs9814567	1.000	rs3846056	chr3:134227292	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.42	-5.76	-0.33	2.38e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs2836950	0.561	rs34705151	chr21:40553344	G/A	cg11644478	chr21:40555479	PSMG1	-0.54	-7.36	-0.41	2.32e-12	Menarche (age at onset);
CESC	cis	rs12887734	0.524	rs4900599	chr14:104283444	G/T	cg08213375	chr14:104286397	PPP1R13B	0.41	6.91	0.39	3.66e-11	Schizophrenia;Autism spectrum disorder or schizophrenia;
CESC	cis	rs56104184	0.775	rs17272700	chr19:49391770	G/A	cg21252483	chr19:49399788	TULP2	-0.52	-5.65	-0.33	4.21e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	cis	rs9611565	0.512	rs9607841	chr22:42186838	G/A	cg06634786	chr22:41940651	POLR3H	-0.67	-6.55	-0.37	3.02e-10	Vitiligo;
CESC	cis	rs17854409	0.803	rs1048100	chr20:61472073	C/A	cg07645718	chr20:61493192	TCFL5	0.76	5.47	0.32	1.04e-7	Obesity-related traits;
CESC	cis	rs3793683	0.597	rs12783367	chr10:134587334	T/C	cg26818010	chr10:134567672	INPP5A	-0.91	-11.2	-0.57	4.4e-24	Migraine;
CESC	cis	rs6997458	0.813	rs3758078	chr8:86374664	A/G	cg21346043	chr8:86351067	CA3	-0.34	-5.04	-0.3	8.56e-7	Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	cis	rs1799949	1.000	rs12516	chr17:41196408	G/A	cg23758822	chr17:41437982	NA	1.01	15.25	0.68	3.94e-38	Menopause (age at onset);
CESC	cis	rs12765878	0.967	rs10883941	chr10:105650782	C/T	cg11005552	chr10:105648138	OBFC1	0.34	5.05	0.3	8.35e-7	Coronary artery disease;
CESC	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg10819733	chr22:24237672	NA	-0.39	-5.57	-0.32	6.38e-8	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs736408	0.521	rs13074853	chr3:52779801	T/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.36	6.52	0.37	3.48e-10	Bipolar disorder;
CESC	cis	rs2439831	0.681	rs526450	chr15:43599325	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.93	11.09	0.56	9.8e-24	Lung cancer in ever smokers;
CESC	cis	rs7666738	0.830	rs17550630	chr4:99008332	G/T	cg05340658	chr4:99064831	C4orf37	0.8	12.44	0.61	2.83e-28	Colonoscopy-negative controls vs population controls;
CESC	trans	rs5756813	0.635	rs6000899	chr22:38203796	C/T	cg19894588	chr14:64061835	NA	-0.68	-8.42	-0.46	2.36e-15	Optic cup area;Vertical cup-disc ratio;
CESC	cis	rs17601876	0.807	rs10519299	chr15:51551346	C/G	cg19946085	chr15:51559439	CYP19A1	-0.34	-5.21	-0.3	3.85e-7	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
CESC	cis	rs4975616	0.869	rs466502	chr5:1325767	C/T	cg26373071	chr5:1325741	CLPTM1L	-0.41	-6.69	-0.38	1.3100000000000001e-10	Lung cancer;
CESC	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg07308232	chr7:1071921	C7orf50	-0.4	-5.47	-0.32	1.06e-7	Longevity;Endometriosis;
CESC	cis	rs7084402	0.967	rs10826199	chr10:60274213	T/C	cg07615347	chr10:60278583	BICC1	-0.57	-8.96	-0.48	6.01e-17	Refractive error;
CESC	cis	rs9583531	0.527	rs3818496	chr13:111358488	G/A	cg15841412	chr13:111365552	ING1	0.47	6.31	0.36	1.17e-9	Coronary artery disease;
CESC	cis	rs5769765	0.908	rs9616388	chr22:50313438	T/C	cg02269571	chr22:50332266	NA	-0.57	-7.1	-0.4	1.14e-11	Schizophrenia;
CESC	cis	rs9522267	0.535	rs7339347	chr13:112237920	C/T	cg10483660	chr13:112241077	NA	-0.32	-5.74	-0.33	2.52e-8	Hepatitis;
CESC	cis	rs7666738	0.791	rs10010438	chr4:99022177	C/T	cg05340658	chr4:99064831	C4orf37	0.82	12.99	0.62	3.34e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2228479	0.850	rs34033205	chr16:89922959	G/T	cg04013166	chr16:89971882	TCF25	0.75	6.07	0.35	4.46e-9	Skin colour saturation;
CESC	cis	rs875971	0.522	rs34973832	chr7:65396204	A/G	cg06456125	chr7:65229604	NA	0.45	5.91	0.34	1.07e-8	Aortic root size;
CESC	cis	rs9322193	0.884	rs9322210	chr6:150016576	G/A	cg04369109	chr6:150039330	LATS1	-0.41	-5.75	-0.33	2.42e-8	Lung cancer;
CESC	cis	rs1008375	1.000	rs10939749	chr4:17692319	A/C	cg16339924	chr4:17578868	LAP3	0.6	7.37	0.41	2.19e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs514406	0.861	rs1412706	chr1:53237721	G/A	cg08859206	chr1:53392774	SCP2	0.54	7.13	0.4	9.6e-12	Monocyte count;
CESC	cis	rs2841277	0.708	rs28600075	chr14:105408315	T/C	cg14403583	chr14:105418241	AHNAK2	-0.58	-8.07	-0.44	2.5e-14	Rheumatoid arthritis;
CESC	cis	rs962856	0.866	rs13387185	chr2:67628649	G/T	cg09028215	chr2:67624308	ETAA1	-0.39	-5.26	-0.31	2.9e-7	Pancreatic cancer;
CESC	cis	rs1552244	1.000	rs7628448	chr3:10146828	G/A	cg00166722	chr3:10149974	C3orf24	0.45	5.38	0.31	1.68e-7	Alzheimer's disease;
CESC	cis	rs1670533	1.000	rs34956924	chr4:1047270	T/C	cg27284194	chr4:1044797	NA	0.47	5.74	0.33	2.62e-8	Recombination rate (females);
CESC	cis	rs11792861	0.926	rs10512391	chr9:111809530	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.45	5.39	0.31	1.57e-7	Menarche (age at onset);
CESC	cis	rs1577917	1.000	rs12663651	chr6:86701655	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.45	-5.82	-0.34	1.67e-8	Response to antipsychotic treatment;
CESC	cis	rs8177253	0.931	rs8177256	chr3:133480276	G/T	cg12373951	chr3:133503437	NA	0.43	6.3	0.36	1.24e-9	Iron status biomarkers;
CESC	cis	rs1448094	0.512	rs7970842	chr12:86243258	C/T	cg00310523	chr12:86230176	RASSF9	0.35	5.38	0.31	1.6e-7	Major depressive disorder;
CESC	cis	rs2239547	0.522	rs2581805	chr3:52979050	T/C	cg11645453	chr3:52864694	ITIH4	-0.31	-5.22	-0.31	3.67e-7	Schizophrenia;
CESC	cis	rs938554	0.736	rs4697699	chr4:9945722	T/C	cg00071950	chr4:10020882	SLC2A9	-0.51	-6.01	-0.35	6.04e-9	Blood metabolite levels;
CESC	cis	rs7647973	0.580	rs7652746	chr3:49262307	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.67	-9.72	-0.51	2.75e-19	Menarche (age at onset);
CESC	cis	rs514406	0.679	rs545719	chr1:53304922	T/C	cg25767906	chr1:53392781	SCP2	-0.47	-6.62	-0.38	1.97e-10	Monocyte count;
CESC	trans	rs7251275	0.744	rs2270075	chr19:44132306	G/A	cg12052658	chr17:14212064	HS3ST3B1	0.5	6.21	0.36	1.99e-9	Macrophage inflammatory protein 1b levels;
CESC	cis	rs2304069	0.545	rs7445660	chr5:149413610	A/C	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.48	6.63	0.38	1.86e-10	HIV-1 control;
CESC	cis	rs7953249	0.618	rs7954039	chr12:121398654	A/C	cg02403541	chr12:121454288	C12orf43	-0.53	-6.9	-0.39	3.77e-11	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
CESC	cis	rs798554	1.000	rs798536	chr7:2766383	G/A	cg19717773	chr7:2847554	GNA12	-0.59	-8.53	-0.46	1.13e-15	Height;
CESC	cis	rs6577655	0.517	rs4909294	chr8:135588020	C/T	cg17885191	chr8:135476712	NA	0.46	5.17	0.3	4.61e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CESC	cis	rs9486719	1.000	rs11153064	chr6:97021959	A/G	cg18709589	chr6:96969512	KIAA0776	-0.52	-5.7	-0.33	3.16e-8	Migraine;Coronary artery disease;
CESC	cis	rs13256369	0.851	rs13267036	chr8:8566685	G/A	cg18904891	chr8:8559673	CLDN23	0.69	7.51	0.42	9.04e-13	Obesity-related traits;
CESC	cis	rs9788333	0.707	rs12584557	chr13:21886171	C/A	cg25811766	chr13:21894605	NA	0.79	11.97	0.59	1.1e-26	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22487624	chr1:115212681	DENND2C	0.51	6.19	0.36	2.34e-9	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27629023	chr11:62648823	SLC3A2	0.56	6.5	0.37	4.01e-10	Gut microbiome composition (summer);
CESC	cis	rs56775891	0.959	rs11663602	chr18:77578191	G/T	cg24058013	chr18:77568902	NA	-0.38	-5.34	-0.31	1.97e-7	Schizophrenia;
CESC	cis	rs6502050	0.805	rs6502061	chr17:80086158	C/T	cg23985595	chr17:80112537	CCDC57	0.42	6.53	0.37	3.27e-10	Life satisfaction;
CESC	cis	rs6088580	0.634	rs6088498	chr20:33020446	A/G	cg08999081	chr20:33150536	PIGU	0.62	11.17	0.57	5.58e-24	Glomerular filtration rate (creatinine);
CESC	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg07157834	chr1:205819609	PM20D1	0.78	12.52	0.61	1.49e-28	Menarche (age at onset);
CESC	cis	rs7582720	0.725	rs72934725	chr2:203725983	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.32	0.41	3.04e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs7843479	0.601	rs2306645	chr8:21845428	C/T	cg17168535	chr8:21777572	XPO7	-0.7	-10.71	-0.55	1.79e-22	Mean corpuscular volume;
CESC	cis	rs873946	0.586	rs3829130	chr10:134563122	C/T	cg27297192	chr10:134578999	INPP5A	0.4	5.27	0.31	2.77e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs7927771	0.965	rs34958982	chr11:47547046	T/C	cg05585544	chr11:47624801	NA	-0.53	-8.07	-0.44	2.41e-14	Subjective well-being;
CESC	cis	rs7692995	1.000	rs2125654	chr4:18025368	A/T	cg08925142	chr4:18023851	LCORL	-0.44	-5.21	-0.3	3.83e-7	Height;
CESC	cis	rs3741151	1.000	rs79038783	chr11:73038746	C/G	cg17517138	chr11:73019481	ARHGEF17	1.09	7.65	0.43	3.64e-13	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs1950626	0.833	rs12897114	chr14:101395140	A/G	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.8	10.74	0.55	1.4e-22	Pelvic organ prolapse (moderate/severe);
CESC	cis	rs2749592	0.611	rs176888	chr10:38406161	C/A	cg00409905	chr10:38381863	ZNF37A	-0.55	-7.03	-0.4	1.73e-11	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs853679	0.517	rs4711165	chr6:28115184	T/G	cg08968635	chr6:28129556	ZNF389	0.41	5.28	0.31	2.68e-7	Depression;
CESC	cis	rs3809863	0.602	rs11650072	chr17:45393665	A/G	cg08085267	chr17:45401833	C17orf57	-0.69	-9.36	-0.5	3.48e-18	Glaucoma (primary open-angle);
CESC	cis	rs4919694	1.000	rs12245343	chr10:104774050	A/G	cg04362960	chr10:104952993	NT5C2	0.74	6.38	0.37	7.75e-10	Arsenic metabolism;
CESC	cis	rs11864453	0.680	rs8047377	chr16:72148339	T/C	cg01557791	chr16:72042693	DHODH	-0.47	-6.34	-0.36	9.86e-10	Fibrinogen levels;
CESC	cis	rs2046867	0.818	rs62249861	chr3:72867779	A/G	cg25664220	chr3:72788482	NA	-0.45	-6.52	-0.37	3.55e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CESC	cis	rs8044995	0.636	rs117761434	chr16:68254196	G/A	cg26727032	chr16:67993705	SLC12A4	-0.48	-5.18	-0.3	4.5e-7	Schizophrenia;
CESC	cis	rs9926296	0.744	rs154656	chr16:89708003	T/A	cg04287289	chr16:89883240	FANCA	-0.46	-5.83	-0.34	1.64e-8	Vitiligo;
CESC	cis	rs4654899	0.931	rs4654887	chr1:21234923	A/G	cg05370193	chr1:21551575	ECE1	-0.36	-5.34	-0.31	2e-7	Superior frontal gyrus grey matter volume;
CESC	cis	rs7618915	0.547	rs12487591	chr3:52642936	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.47	6.27	0.36	1.46e-9	Bipolar disorder;
CESC	cis	rs4853012	0.775	rs12465641	chr2:74337715	A/G	cg05776053	chr2:74358815	NA	-0.4	-5.17	-0.3	4.69e-7	Gestational age at birth (maternal effect);
CESC	cis	rs250677	0.687	rs10040624	chr5:148437579	A/G	cg18129178	chr5:148520854	ABLIM3	-0.47	-5.3	-0.31	2.42e-7	Breast cancer;
CESC	cis	rs13191362	1.000	rs67025553	chr6:163011552	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.82	8.22	0.45	9.12e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs4819052	0.851	rs2236446	chr21:46678985	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.76	10.4	0.54	1.76e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs4665809	0.590	rs13016300	chr2:26468365	G/C	cg26119090	chr2:26468346	HADHA;HADHB	1.1	12.68	0.61	4e-29	Gut microbiome composition (summer);
CESC	cis	rs910316	0.737	rs175499	chr14:75535927	G/A	cg16144293	chr14:75469539	EIF2B2	0.4	5.27	0.31	2.83e-7	Height;
CESC	cis	rs2353275	0.655	rs7068651	chr10:88160039	A/G	cg07322936	chr10:88137208	NA	0.92	5.58	0.32	5.92e-8	Asthma (childhood onset);Asthma;
CESC	cis	rs9888739	0.591	rs4632147	chr16:31363381	C/T	cg15817542	chr16:31343056	ITGAM	-0.49	-6.89	-0.39	4.17e-11	Systemic lupus erythematosus;
CESC	cis	rs3812049	0.784	rs2568928	chr5:127487603	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.82	-10.2	-0.53	7.78e-21	Lymphocyte counts;Red cell distribution width;
CESC	cis	rs4808199	0.895	rs7252888	chr19:19628037	C/T	cg03709012	chr19:19516395	GATAD2A	1.04	12.86	0.62	9.68e-30	Nonalcoholic fatty liver disease;
CESC	cis	rs2576037	0.566	rs2437854	chr18:44557613	T/C	cg19077165	chr18:44547161	KATNAL2	0.65	9.86	0.52	9.48e-20	Personality dimensions;
CESC	cis	rs35955747	0.869	rs5997909	chr22:31591228	G/A	cg25791279	chr22:32026902	PISD	-0.45	-5.36	-0.31	1.81e-7	Neutrophil count;Sum basophil neutrophil counts;
CESC	cis	rs1799949	0.930	rs1554063	chr17:41287145	T/C	cg07153921	chr17:41440717	NA	-0.38	-5.03	-0.3	9.22e-7	Menopause (age at onset);
CESC	cis	rs10791323	0.582	rs2723613	chr11:133706696	G/A	cg15485101	chr11:133734466	NA	0.4	6.56	0.37	2.88e-10	Childhood ear infection;
CESC	cis	rs7666738	0.830	rs3896704	chr4:99034252	C/T	cg17366294	chr4:99064904	C4orf37	0.62	8.86	0.48	1.22e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9487051	0.676	rs1829694	chr6:109593860	G/T	cg01475377	chr6:109611718	NA	-0.44	-6.99	-0.39	2.19e-11	Reticulocyte fraction of red cells;
CESC	cis	rs910316	1.000	rs7156328	chr14:75532941	T/C	cg11812906	chr14:75593930	NEK9	0.89	15.17	0.68	7.72e-38	Height;
CESC	trans	rs7849782	0.935	rs2485534	chr9:104451338	A/T	cg09047884	chr22:43484984	TTLL1	-0.44	-6.07	-0.35	4.3e-9	Coronary artery aneurysm in Kawasaki disease;
CESC	cis	rs73110464	0.609	rs727266	chr12:53356411	C/T	cg14581129	chr12:53358946	NA	-0.57	-7.87	-0.44	9.29e-14	Cancer (pleiotropy);
CESC	cis	rs11792861	0.781	rs17729408	chr9:111740860	A/G	cg05043794	chr9:111880884	C9orf5	0.4	6.55	0.37	3.06e-10	Menarche (age at onset);
CESC	trans	rs7107217	1.000	rs1873872	chr11:129473993	A/T	cg03574882	chr7:151574332	PRKAG2	0.43	6.0	0.35	6.51e-9	Breast cancer;Type 2 diabetes;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg09149896	chr17:48624438	SPATA20	-0.4	-6.11	-0.35	3.52e-9	Gambling;
CESC	cis	rs62064224	0.589	rs8069673	chr17:30661250	C/T	cg18200150	chr17:30822561	MYO1D	-0.39	-5.12	-0.3	5.97e-7	Schizophrenia;
CESC	cis	rs875971	0.830	rs6967708	chr7:65657313	A/T	cg18876405	chr7:65276391	NA	-0.53	-7.38	-0.41	2.09e-12	Aortic root size;
CESC	cis	rs2404602	0.684	rs62026898	chr15:76944371	C/A	cg23625390	chr15:77176239	SCAPER	-0.45	-6.21	-0.36	2.04e-9	Blood metabolite levels;
CESC	cis	rs4819052	0.851	rs2838849	chr21:46671027	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.93	13.67	0.64	1.54e-32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs11204677	1	rs11204677	chr1:150574695	C/G	cg18016565	chr1:150552671	MCL1	-0.42	-6.89	-0.39	4.03e-11	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
CESC	cis	rs1355223	0.506	rs1509660	chr11:34865017	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.54	-6.72	-0.38	1.12e-10	Systemic lupus erythematosus and Systemic sclerosis;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg19429466	chr4:87515395	PTPN13	-0.48	-6.3	-0.36	1.23e-9	Ulcerative colitis;
CESC	cis	rs1552244	0.882	rs2130813	chr3:10038706	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.87	11.4	0.57	9.22e-25	Alzheimer's disease;
CESC	cis	rs910316	1.000	rs175443	chr14:75601963	C/T	cg16144293	chr14:75469539	EIF2B2	0.38	5.03	0.3	9.15e-7	Height;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg12393716	chr11:62495049	TTC9C;HNRNPUL2	0.49	6.49	0.37	4.25e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs9549367	0.789	rs9549708	chr13:113891887	A/G	cg00898013	chr13:113819073	PROZ	-0.51	-6.95	-0.39	2.78e-11	Platelet distribution width;
CESC	cis	rs514406	0.929	rs2607095	chr1:53325639	T/C	cg08736216	chr1:53307985	ZYG11A	-0.42	-7.0	-0.4	2.05e-11	Monocyte count;
CESC	cis	rs7793919	0.726	rs10232008	chr7:4783206	T/G	cg09789173	chr7:4769017	FOXK1	0.76	11.45	0.58	6.14e-25	Mosquito bite size;
CESC	cis	rs9311474	0.659	rs7638808	chr3:52572056	C/T	cg15147215	chr3:52552868	STAB1	0.29	5.11	0.3	6.3e-7	Electroencephalogram traits;
CESC	cis	rs4704187	0.687	rs2335136	chr5:74407994	T/C	cg03227963	chr5:74354835	NA	0.32	5.94	0.34	8.7e-9	Response to amphetamines;
CESC	cis	rs2479724	0.935	rs1887718	chr6:41857691	C/T	cg08135965	chr6:41755394	TOMM6	0.43	5.98	0.34	7.34e-9	Menarche (age at onset);
CESC	cis	rs7086627	0.515	rs1870147	chr10:82212541	A/T	cg03267442	chr10:82210566	NA	-0.32	-5.14	-0.3	5.28e-7	Post bronchodilator FEV1;
CESC	cis	rs28595532	0.800	rs67686161	chr4:119336720	C/T	cg21605333	chr4:119757512	SEC24D	0.93	5.92	0.34	1.02e-8	Cannabis dependence symptom count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12754671	chr1:161171876	NDUFS2	0.57	6.64	0.38	1.78e-10	Gut microbiome composition (summer);
CESC	cis	rs6088580	0.543	rs13042351	chr20:33238573	G/A	cg24642439	chr20:33292090	TP53INP2	-0.45	-5.29	-0.31	2.6e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs3741151	0.686	rs12288753	chr11:73136261	A/T	cg17517138	chr11:73019481	ARHGEF17	0.64	5.5	0.32	8.83e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs8114671	0.562	rs6120739	chr20:33405227	A/G	cg24642439	chr20:33292090	TP53INP2	0.43	5.18	0.3	4.31e-7	Height;
CESC	cis	rs2075371	0.829	rs35897242	chr7:134004041	G/A	cg00033643	chr7:134001901	SLC35B4	0.41	5.17	0.3	4.67e-7	Mean platelet volume;
CESC	cis	rs7017914	0.967	rs35207116	chr8:71708971	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.43	-5.5	-0.32	8.84e-8	Bone mineral density;
CESC	cis	rs4722166	0.541	rs1800795	chr7:22766645	C/G	cg05472934	chr7:22766657	IL6	0.86	11.55	0.58	2.89e-25	Lung cancer;
CESC	cis	rs17039065	1.000	rs719786	chr4:109396732	G/A	cg16022748	chr4:109541635	LOC285456;RPL34	0.61	5.16	0.3	4.75e-7	Gut microbiome composition (summer);
CESC	cis	rs7618501	0.665	rs7621352	chr3:50070763	A/C	cg24110177	chr3:50126178	RBM5	0.52	7.16	0.4	7.81e-12	Intelligence (multi-trait analysis);
CESC	cis	rs11792861	0.926	rs1044905	chr9:111781495	G/A	cg05043794	chr9:111880884	C9orf5	-0.41	-6.82	-0.39	6.13e-11	Menarche (age at onset);
CESC	cis	rs7296418	0.675	rs1879379	chr12:123727443	G/A	cg00376283	chr12:123451042	ABCB9	0.63	8.74	0.47	2.77e-16	Platelet count;
CESC	cis	rs75477785	0.590	rs12078802	chr1:210143601	G/A	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.91	6.32	0.36	1.09e-9	Cleft lip with or without cleft palate;
CESC	cis	rs7264396	0.563	rs2425121	chr20:34326186	A/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.63	6.86	0.39	4.77e-11	Total cholesterol levels;
CESC	cis	rs10129255	0.957	rs8014696	chr14:107177994	A/C	cg23076370	chr14:107095027	NA	0.43	5.48	0.32	1.01e-7	Kawasaki disease;
CESC	cis	rs61008539	0.893	rs7783487	chr7:860160	A/C	cg15782153	chr7:917662	C7orf20	0.49	7.01	0.4	1.95e-11	Perceived unattractiveness to mosquitoes;
CESC	cis	rs71277158	0.688	rs73879173	chr3:169845604	T/G	cg04067573	chr3:169899625	PHC3	0.71	7.11	0.4	1.06e-11	Prostate cancer;
CESC	cis	rs11098499	0.954	rs10008459	chr4:120394231	T/C	cg24375607	chr4:120327624	NA	0.45	5.74	0.33	2.61e-8	Corneal astigmatism;
CESC	cis	rs4132509	0.895	rs12138168	chr1:244009113	A/G	cg21452805	chr1:244014465	NA	0.53	6.41	0.37	6.49e-10	RR interval (heart rate);
CESC	trans	rs1814175	0.591	rs11040589	chr11:49862449	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.43	-6.26	-0.36	1.51e-9	Height;
CESC	cis	rs4700695	0.719	rs27077	chr5:65445342	C/T	cg21114390	chr5:65439923	SFRS12	0.45	5.58	0.32	6.01e-8	Facial morphology (factor 19);
CESC	cis	rs7084402	0.967	rs1649092	chr10:60289389	A/T	cg07615347	chr10:60278583	BICC1	0.63	10.13	0.53	1.3e-20	Refractive error;
CESC	cis	rs722599	0.748	rs731165	chr14:75352555	T/C	cg11812906	chr14:75593930	NEK9	-0.47	-5.68	-0.33	3.49e-8	IgG glycosylation;
CESC	cis	rs7208859	0.623	rs9895785	chr17:29107708	C/T	cg13385521	chr17:29058706	SUZ12P	-0.79	-6.36	-0.36	8.73e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs67311347	0.866	rs1454491	chr3:40352647	C/G	cg09455208	chr3:40491958	NA	0.41	6.93	0.39	3.2e-11	Renal cell carcinoma;
CESC	cis	rs769267	0.895	rs2965189	chr19:19519518	G/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.43	5.76	0.33	2.27e-8	Tonsillectomy;
CESC	cis	rs1799949	1.000	rs8176103	chr17:41267050	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.68	9.48	0.5	1.49e-18	Menopause (age at onset);
CESC	cis	rs9858542	0.953	rs9859556	chr3:49455986	G/T	cg03060546	chr3:49711283	APEH	-0.53	-6.01	-0.35	6.14e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs7605827	0.860	rs6760297	chr2:15632472	T/C	cg19274914	chr2:15703543	NA	0.36	6.42	0.37	6.32e-10	Educational attainment (years of education);
CESC	cis	rs2180341	0.782	rs6924274	chr6:127721556	T/A	cg24812749	chr6:127587940	RNF146	0.82	11.71	0.58	8.13e-26	Breast cancer;
CESC	cis	rs7809950	1.000	rs2712191	chr7:107182724	C/G	cg23024343	chr7:107201750	COG5	-0.41	-5.78	-0.33	2.1e-8	Coronary artery disease;
CESC	cis	rs1799949	0.965	rs11656945	chr17:41330265	A/G	cg23758822	chr17:41437982	NA	1.04	15.64	0.69	1.61e-39	Menopause (age at onset);
CESC	cis	rs4665809	0.590	rs17528653	chr2:26507724	T/C	cg25036284	chr2:26402008	FAM59B	0.84	8.75	0.47	2.61e-16	Gut microbiome composition (summer);
CESC	cis	rs7945705	0.967	rs10769970	chr11:8917937	A/G	cg09997546	chr11:8931473	C11orf17;ST5	0.37	5.95	0.34	8.38e-9	Hemoglobin concentration;
CESC	cis	rs7927592	0.731	rs11228288	chr11:68353550	A/G	cg20283391	chr11:68216788	NA	-0.42	-5.16	-0.3	4.82e-7	Total body bone mineral density;
CESC	cis	rs7659604	1.000	rs35249024	chr4:122664538	C/A	cg19671926	chr4:122722719	EXOSC9	-0.45	-5.26	-0.31	2.96e-7	Type 2 diabetes;
CESC	cis	rs1949733	0.701	rs2631735	chr4:8476118	A/G	cg11789530	chr4:8429930	ACOX3	0.67	7.63	0.42	4.17e-13	Response to antineoplastic agents;
CESC	trans	rs208520	0.690	rs207077	chr6:66769855	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.94	-12.03	-0.59	6.99e-27	Exhaled nitric oxide output;
CESC	cis	rs1552244	0.816	rs56387520	chr3:10042782	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.85	11.01	0.56	1.86e-23	Alzheimer's disease;
CESC	cis	rs9611565	0.559	rs1006407	chr22:41972032	T/C	cg17376030	chr22:41985996	PMM1	0.78	7.98	0.44	4.51e-14	Vitiligo;
CESC	cis	rs7613875	0.641	rs6446194	chr3:50067298	T/A	cg24110177	chr3:50126178	RBM5	0.59	8.32	0.45	4.85e-15	Body mass index;
CESC	cis	rs7829975	0.714	rs4840362	chr8:8670082	C/G	cg15556689	chr8:8085844	FLJ10661	-0.43	-5.57	-0.32	6.36e-8	Mood instability;
CESC	cis	rs561341	0.941	rs2428341	chr17:30317295	C/T	cg00745463	chr17:30367425	LRRC37B	-0.48	-5.29	-0.31	2.55e-7	Hip circumference adjusted for BMI;
CESC	cis	rs12541635	0.966	rs2029881	chr8:107002226	A/G	cg10147462	chr8:107024639	NA	0.4	5.69	0.33	3.32e-8	Age of smoking initiation;
CESC	cis	rs9287719	0.967	rs728281	chr2:10750355	T/C	cg00105475	chr2:10696890	NA	0.38	5.57	0.32	6.34e-8	Prostate cancer;
CESC	cis	rs5769765	1.000	rs764813	chr22:50286172	T/C	cg26441486	chr22:50317300	CRELD2	0.38	5.37	0.31	1.77e-7	Schizophrenia;
CESC	cis	rs1008375	0.966	rs2098152	chr4:17684392	G/T	cg15017067	chr4:17643749	FAM184B	0.34	5.05	0.3	8.24e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs12136530	0.593	rs9287047	chr1:19736534	T/C	cg01832549	chr1:19774989	CAPZB	-0.44	-6.23	-0.36	1.85e-9	Lead levels in blood;
CESC	cis	rs6963495	0.745	rs818620	chr7:105172685	G/C	cg19920283	chr7:105172520	RINT1	0.71	7.92	0.44	6.76e-14	Bipolar disorder (body mass index interaction);
CESC	cis	rs9287719	0.934	rs6432111	chr2:10744620	A/C	cg00105475	chr2:10696890	NA	0.39	5.64	0.33	4.44e-8	Prostate cancer;
CESC	cis	rs6460942	1.000	rs6460942	chr7:12420989	T/C	cg17427002	chr7:12443146	VWDE	-0.53	-5.31	-0.31	2.38e-7	Coronary artery disease;
CESC	cis	rs7412746	0.658	rs4970986	chr1:150907955	A/G	cg22823121	chr1:150693482	HORMAD1	0.4	5.7	0.33	3.2e-8	Melanoma;
CESC	cis	rs875971	0.545	rs73148639	chr7:65855329	A/T	cg11764359	chr7:65958608	NA	0.81	9.9	0.52	7.51e-20	Aortic root size;
CESC	cis	rs989128	0.600	rs739924	chr17:48631607	T/C	cg24438145	chr17:48624694	SPATA20	0.44	5.17	0.3	4.57e-7	Type 2 diabetes;
CESC	cis	rs727563	0.555	rs5751136	chr22:42075581	T/A	cg06481639	chr22:41940642	POLR3H	0.5	5.3	0.31	2.49e-7	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs10463316	0.823	rs7700342	chr5:150776323	C/T	cg03212797	chr5:150827313	SLC36A1	-0.51	-6.81	-0.39	6.65e-11	Metabolite levels (Pyroglutamine);
CESC	cis	rs9488822	0.636	rs12201275	chr6:116314563	C/G	cg15226275	chr6:116381976	FRK	0.25	6.24	0.36	1.72e-9	Cholesterol, total;LDL cholesterol;
CESC	cis	rs6543140	0.964	rs2160200	chr2:103033963	G/T	cg04239558	chr2:103089729	SLC9A4	0.45	5.76	0.33	2.28e-8	Blood protein levels;
CESC	cis	rs1847202	0.859	rs4274693	chr3:72949375	A/G	cg25664220	chr3:72788482	NA	-0.37	-5.68	-0.33	3.51e-8	Motion sickness;
CESC	cis	rs1448094	0.549	rs4919770	chr12:86238050	G/T	cg19622623	chr12:86230825	RASSF9	-0.41	-5.04	-0.3	8.46e-7	Major depressive disorder;
CESC	cis	rs6545883	0.931	rs12713437	chr2:61722904	C/T	cg15711740	chr2:61764176	XPO1	-0.42	-5.32	-0.31	2.25e-7	Tuberculosis;
CESC	cis	rs35306767	0.903	rs11253488	chr10:922482	G/C	cg25019033	chr10:957182	NA	-0.6	-6.41	-0.37	6.76e-10	Eosinophil percentage of granulocytes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09301086	chr2:3691534	COLEC11	-0.54	-6.47	-0.37	4.82e-10	Gut microbiome composition (summer);
CESC	cis	rs67311347	0.577	rs2887951	chr3:40282104	C/G	cg09455208	chr3:40491958	NA	0.35	5.62	0.33	4.82e-8	Renal cell carcinoma;
CESC	cis	rs514406	0.767	rs551591	chr1:53301876	A/G	cg16325326	chr1:53192061	ZYG11B	0.73	11.05	0.56	1.33e-23	Monocyte count;
CESC	cis	rs1799949	1.000	rs1545764	chr17:41424565	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.6	7.87	0.44	9.16e-14	Menopause (age at onset);
CESC	cis	rs853679	0.574	rs1233705	chr6:28166447	C/G	cg26335602	chr6:28129616	ZNF389	0.48	6.54	0.37	3.07e-10	Depression;
CESC	cis	rs12681288	0.963	rs7822955	chr8:1029090	C/T	cg04851639	chr8:1020857	NA	0.34	7.17	0.4	7.35e-12	Schizophrenia;
CESC	cis	rs9379850	0.730	rs9393738	chr6:26620658	G/A	cg14345882	chr6:26364793	BTN3A2	0.42	5.3	0.31	2.41e-7	Intelligence (multi-trait analysis);
CESC	cis	rs11190604	1.000	rs75063298	chr10:102213600	C/A	cg07080220	chr10:102295463	HIF1AN	0.55	5.51	0.32	8.5e-8	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs7520050	0.966	rs12564541	chr1:46380237	G/A	cg03146154	chr1:46216737	IPP	-0.48	-6.21	-0.36	2.08e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg12419862	chr22:24373484	LOC391322	-0.73	-10.26	-0.53	5.15e-21	Liver enzyme levels (gamma-glutamyl transferase);
CESC	trans	rs16867579	1.000	rs16867579	chr8:102375267	A/C	cg17311587	chr7:1250088	NA	0.62	6.08	0.35	4.08e-9	Smooth-surface caries;
CESC	trans	rs208520	0.690	rs12198745	chr6:66722598	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.9	11.51	0.58	3.9e-25	Exhaled nitric oxide output;
CESC	cis	rs7188697	0.922	rs11862156	chr16:58596753	C/T	cg02549819	chr16:58548995	SETD6	0.43	5.4	0.31	1.51e-7	QT interval;
CESC	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.34	6.64	0.38	1.73e-10	Bipolar disorder;
CESC	trans	rs5763662	0.661	rs12484740	chr22:30606927	C/T	cg03005062	chr1:38680057	NA	-0.69	-6.01	-0.35	5.97e-9	LDL cholesterol levels;LDL cholesterol;
CESC	cis	rs11190604	1.000	rs10786597	chr10:102291287	C/T	cg07080220	chr10:102295463	HIF1AN	0.7	6.48	0.37	4.34e-10	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs780096	0.565	rs780104	chr2:27677691	G/A	cg12648201	chr2:27665141	KRTCAP3	-0.35	-6.56	-0.37	2.79e-10	Total body bone mineral density;
CESC	cis	rs7561273	0.586	rs4149372	chr2:24305512	T/G	cg01493198	chr2:24299560	SF3B14	0.41	5.07	0.3	7.53e-7	Quantitative traits;
CESC	cis	rs12586317	0.547	rs115019197	chr14:35503764	G/A	cg05294307	chr14:35346193	BAZ1A	-0.51	-5.4	-0.31	1.49e-7	Psoriasis;
CESC	trans	rs6073597	1.000	rs6031980	chr20:43714384	C/T	cg00635299	chr1:220219163	EPRS	0.42	6.39	0.37	7.31e-10	Positive affect;
CESC	cis	rs3820068	0.581	rs72645879	chr1:15928199	A/G	cg13390004	chr1:15929781	NA	0.35	5.58	0.32	5.83e-8	Systolic blood pressure;
CESC	cis	rs2734839	0.537	rs1554929	chr11:113278764	C/T	cg14159747	chr11:113255604	NA	0.37	6.75	0.38	9.24e-11	Information processing speed;
CESC	cis	rs2439831	0.850	rs12440573	chr15:44108997	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.66	5.97	0.34	7.71e-9	Lung cancer in ever smokers;
CESC	cis	rs7666738	0.546	rs62320963	chr4:98839297	A/G	cg17366294	chr4:99064904	C4orf37	0.5	6.03	0.35	5.49e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6732160	0.588	rs13394018	chr2:73372605	C/T	cg01422370	chr2:73384389	NA	0.56	9.17	0.49	1.38e-17	Intelligence (multi-trait analysis);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg09352908	chr3:37017749	NA	0.49	6.87	0.39	4.44e-11	Fibrinogen levels;
CESC	cis	rs2415984	0.562	rs1389605	chr14:46964784	T/C	cg14871534	chr14:47121158	RPL10L	0.39	5.49	0.32	9.54e-8	Number of children ever born;
CESC	cis	rs7786808	0.741	rs7789415	chr7:158227617	C/T	cg09998033	chr7:158218633	PTPRN2	-0.38	-5.66	-0.33	3.87e-8	Obesity-related traits;
CESC	cis	rs734999	0.545	rs6666430	chr1:2698950	G/A	cg18854424	chr1:2615690	NA	0.3	5.75	0.33	2.44e-8	Ulcerative colitis;
CESC	cis	rs3540	0.576	rs10152871	chr15:91047469	G/A	cg10434728	chr15:90938212	IQGAP1	-0.43	-7.77	-0.43	1.72e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs9314323	0.964	rs3808579	chr8:26250682	C/T	cg11498726	chr8:26250323	BNIP3L	-0.45	-6.62	-0.38	2.02e-10	Red cell distribution width;
CESC	cis	rs9660992	0.674	rs1151785	chr1:205232299	C/T	cg00857998	chr1:205179979	DSTYK	0.47	5.35	0.31	1.87e-7	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs7666738	0.791	rs60028147	chr4:99046618	G/A	cg17366294	chr4:99064904	C4orf37	0.6	8.51	0.46	1.33e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9916302	0.800	rs8081220	chr17:37473157	A/C	cg20243544	chr17:37824526	PNMT	-0.44	-5.29	-0.31	2.51e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs4911259	0.513	rs6057665	chr20:31463460	A/G	cg13636640	chr20:31349939	DNMT3B	-0.53	-7.41	-0.41	1.66e-12	Inflammatory bowel disease;
CESC	cis	rs11203032	0.831	rs12219735	chr10:90922890	C/T	cg16672925	chr10:90967113	CH25H	0.74	7.05	0.4	1.56e-11	Heart failure;
CESC	cis	rs7649275	0.938	rs1809282	chr3:53781957	A/G	cg21503701	chr3:53781065	CACNA1D	-0.38	-5.11	-0.3	6.12e-7	Trans fatty acid levels;
CESC	cis	rs6570726	0.791	rs422099	chr6:145806936	C/T	cg05347473	chr6:146136440	FBXO30	0.57	7.33	0.41	2.79e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1045714	0.895	rs61729413	chr7:2646796	G/A	cg20813462	chr7:2646259	IQCE	0.63	5.44	0.32	1.19e-7	Urate levels in lean individuals;
CESC	cis	rs13006833	0.634	rs1876877	chr2:191145274	G/A	cg25963032	chr2:191064776	C2orf88	0.37	5.05	0.3	8.21e-7	Urinary metabolites;
CESC	cis	rs9937943	0.667	rs12934000	chr16:74623420	T/G	cg01733217	chr16:74700730	RFWD3	0.58	5.27	0.31	2.79e-7	Neutrophil percentage of white cells;
CESC	cis	rs910316	1.000	rs13099	chr14:75599155	G/A	cg16144293	chr14:75469539	EIF2B2	0.4	5.25	0.31	3.14e-7	Height;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg24908708	chr8:95835570	INTS8	-0.44	-6.15	-0.35	2.79e-9	Fibrinogen levels;
CESC	cis	rs7100689	0.577	rs1143694	chr10:82040052	C/T	cg00277334	chr10:82204260	NA	0.51	6.59	0.38	2.41e-10	Post bronchodilator FEV1;
CESC	cis	rs909002	0.759	rs10914454	chr1:32078940	G/A	cg13919466	chr1:32135498	COL16A1	-0.47	-8.4	-0.46	2.72e-15	Intelligence (multi-trait analysis);
CESC	cis	rs12155623	0.803	rs7011862	chr8:49817333	C/G	cg00325661	chr8:49890786	NA	0.39	5.22	0.31	3.63e-7	Sudden cardiac arrest;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg19188060	chr3:184017239	PSMD2	-0.47	-6.41	-0.37	6.57e-10	Fibrinogen levels;
CESC	cis	rs1862618	0.802	rs832547	chr5:56183941	C/G	cg18230493	chr5:56204884	C5orf35	-0.73	-8.57	-0.47	8.93e-16	Initial pursuit acceleration;
CESC	cis	rs4076764	0.914	rs10753614	chr1:163365903	C/T	cg06092702	chr1:163392909	NA	0.43	6.27	0.36	1.48e-9	Motion sickness;
CESC	cis	rs7264396	0.563	rs73902913	chr20:34432784	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.84	-9.34	-0.5	4.01e-18	Total cholesterol levels;
CESC	cis	rs3741404	0.609	rs687581	chr11:63871533	G/T	cg18225595	chr11:63971243	STIP1	-0.52	-6.8	-0.39	7.07e-11	Platelet count;
CESC	cis	rs2204008	0.701	rs3898237	chr12:38219714	A/G	cg13010199	chr12:38710504	ALG10B	0.53	6.65	0.38	1.69e-10	Bladder cancer;
CESC	cis	rs7208859	0.673	rs9915963	chr17:29019643	C/T	cg19761014	chr17:28927070	LRRC37B2	0.67	5.99	0.35	6.81e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs4727027	0.866	rs12666477	chr7:148812322	A/G	cg23158103	chr7:148848205	ZNF398	-0.4	-6.4	-0.37	7.03e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs7714584	1.000	rs7709650	chr5:150246685	C/T	cg22134413	chr5:150180641	NA	0.55	6.08	0.35	4.25e-9	Crohn's disease;
CESC	cis	rs2842992	0.830	rs2025189	chr6:160137518	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.69	9.01	0.48	4.25e-17	Age-related macular degeneration (geographic atrophy);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17021988	chr4:40428050	RBM47	-0.62	-7.46	-0.42	1.24e-12	Gut microbiome composition (summer);
CESC	cis	rs4642101	0.824	rs11717013	chr3:12843862	A/C	cg05775895	chr3:12838266	CAND2	0.39	5.78	0.33	2.1e-8	QRS complex (12-leadsum);
CESC	cis	rs9457247	0.663	rs7749278	chr6:167435325	C/T	cg25258033	chr6:167368657	RNASET2	-0.35	-5.05	-0.3	8.36e-7	Crohn's disease;
CESC	cis	rs703842	1.000	rs10877015	chr12:58167788	A/G	cg18357645	chr12:58087776	OS9	-0.41	-5.77	-0.33	2.24e-8	Multiple sclerosis;
CESC	cis	rs295140	0.605	rs34693942	chr2:201184348	T/C	cg23649088	chr2:200775458	C2orf69	-0.43	-5.73	-0.33	2.79e-8	QT interval;
CESC	trans	rs7819412	0.522	rs10088853	chr8:10987967	G/A	cg11875060	chr3:155571743	SLC33A1	-0.51	-6.19	-0.36	2.24e-9	Triglycerides;
CESC	cis	rs7044106	0.762	rs1470307	chr9:123433039	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.72	10.68	0.55	2.28e-22	Hip circumference adjusted for BMI;
CESC	cis	rs11997175	0.600	rs4739590	chr8:33802686	A/G	ch.8.33884649F	chr8:33765107	NA	0.55	7.21	0.4	5.86e-12	Body mass index;
CESC	cis	rs3096299	0.719	rs2911262	chr16:89515041	C/T	cg00750074	chr16:89608354	SPG7	-0.41	-5.97	-0.34	7.57e-9	Multiple myeloma (IgH translocation);
CESC	cis	rs7267979	1.000	rs6083862	chr20:25411086	A/T	cg08601574	chr20:25228251	PYGB	-0.34	-5.23	-0.31	3.5e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs2522056	0.935	rs1981524	chr5:131756506	C/T	cg24060327	chr5:131705240	SLC22A5	0.68	7.78	0.43	1.66e-13	Lymphocyte counts;Fibrinogen;
CESC	cis	rs1050631	0.592	rs1785927	chr18:33726447	C/G	cg25426722	chr18:33708991	SLC39A6;ELP2	0.53	7.16	0.4	7.87e-12	Esophageal squamous cell cancer (length of survival);
CESC	cis	rs35110281	0.714	rs7277539	chr21:45053011	A/G	cg01579765	chr21:45077557	HSF2BP	-0.54	-8.9	-0.48	8.97e-17	Mean corpuscular volume;
CESC	cis	rs11098499	0.697	rs11941899	chr4:120382758	C/A	cg09307838	chr4:120376055	NA	0.95	13.79	0.65	5.71e-33	Corneal astigmatism;
CESC	trans	rs8073060	0.544	rs8072676	chr17:33999517	C/T	cg19694781	chr19:47549865	TMEM160	-0.72	-6.84	-0.39	5.32e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	cis	rs6752107	1.000	rs6738490	chr2:234161583	T/C	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.38	5.85	0.34	1.45e-8	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs748404	0.660	rs2439845	chr15:43722610	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	8.3	0.45	5.47e-15	Lung cancer;
CESC	cis	rs826838	0.967	rs4768329	chr12:39129394	T/C	cg13010199	chr12:38710504	ALG10B	-0.45	-6.26	-0.36	1.51e-9	Heart rate;
CESC	cis	rs8060686	0.641	rs55725810	chr16:68189636	C/T	cg26727032	chr16:67993705	SLC12A4	-0.53	-6.02	-0.35	5.67e-9	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs2463822	0.920	rs7924998	chr11:62073980	C/G	cg06239285	chr11:62104954	ASRGL1	-1.13	-9.93	-0.52	5.78e-20	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs3540	0.512	rs7176518	chr15:91079637	C/T	cg22089800	chr15:90895588	ZNF774	-0.62	-8.44	-0.46	2.05e-15	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs7927771	0.524	rs10838769	chr11:47825333	A/G	cg20307385	chr11:47447363	PSMC3	-0.58	-8.03	-0.44	3.12e-14	Subjective well-being;
CESC	cis	rs7412746	0.634	rs72704658	chr1:150833010	T/C	cg17724175	chr1:150552817	MCL1	0.41	6.26	0.36	1.55e-9	Melanoma;
CESC	cis	rs12541635	0.677	rs61002083	chr8:106982132	A/G	cg10147462	chr8:107024639	NA	0.45	6.53	0.37	3.37e-10	Age of smoking initiation;
CESC	cis	rs4727027	0.933	rs757738	chr7:148872351	T/G	cg23158103	chr7:148848205	ZNF398	-0.42	-6.8	-0.39	6.87e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs6089829	0.851	rs4809460	chr20:61661355	T/C	cg03213289	chr20:61660250	NA	0.39	6.06	0.35	4.64e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs5753618	0.583	rs5749279	chr22:31854209	A/G	cg13145458	chr22:31556086	RNF185	-0.43	-5.34	-0.31	2.01e-7	Colorectal cancer;
CESC	cis	rs769267	0.930	rs4808967	chr19:19640524	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.43	5.42	0.32	1.34e-7	Tonsillectomy;
CESC	trans	rs6700559	0.810	rs2808250	chr1:200592547	A/T	cg13401811	chr12:52345646	ACVR1B	0.47	6.03	0.35	5.59e-9	Coronary artery disease;
CESC	cis	rs9916302	0.904	rs7216086	chr17:37709422	G/A	cg20243544	chr17:37824526	PNMT	0.48	6.04	0.35	5.29e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs3791406	0.654	rs3752804	chr2:240029490	C/T	cg13090969	chr2:240043331	HDAC4	-0.52	-6.29	-0.36	1.29e-9	Skin aging (microtopography measurement);
CESC	cis	rs274567	0.501	rs581968	chr5:131710202	G/A	cg18758796	chr5:131593413	PDLIM4	-0.43	-5.96	-0.34	8.15e-9	Blood metabolite levels;
CESC	cis	rs1538970	0.924	rs11211118	chr1:45930270	A/C	cg05343316	chr1:45956843	TESK2	0.89	12.12	0.6	3.27e-27	Platelet count;
CESC	cis	rs2952156	0.834	rs903503	chr17:37829571	C/A	cg20243544	chr17:37824526	PNMT	0.63	8.15	0.45	1.47e-14	Asthma;
CESC	cis	rs11229555	0.645	rs34794607	chr11:58188401	A/T	cg15696309	chr11:58395628	NA	-0.42	-5.05	-0.3	8.13e-7	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs10752881	0.875	rs10797825	chr1:183024581	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.87	13.5	0.64	5.97e-32	Colorectal cancer;
CESC	cis	rs514406	0.505	rs374849	chr1:53185631	G/A	cg27535305	chr1:53392650	SCP2	-0.33	-5.38	-0.31	1.66e-7	Monocyte count;
CESC	cis	rs2120019	0.938	rs8040169	chr15:75370958	C/A	cg17294928	chr15:75287854	SCAMP5	-0.59	-6.65	-0.38	1.64e-10	Blood trace element (Zn levels);
CESC	cis	rs67311347	1.000	rs73078164	chr3:40480289	G/A	cg09455208	chr3:40491958	NA	0.49	8.07	0.44	2.53e-14	Renal cell carcinoma;
CESC	trans	rs2727020	0.894	rs1880438	chr11:49370698	A/G	cg15704280	chr7:45808275	SEPT13	-0.76	-9.47	-0.5	1.61e-18	Coronary artery disease;
CESC	cis	rs12142240	0.698	rs6684274	chr1:46810842	A/G	cg10495392	chr1:46806563	NSUN4	-0.57	-6.28	-0.36	1.38e-9	Menopause (age at onset);
CESC	cis	rs35306767	0.903	rs11253485	chr10:919362	C/T	cg20503657	chr10:835505	NA	0.78	7.74	0.43	2.08e-13	Eosinophil percentage of granulocytes;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg21864845	chr1:1208426	UBE2J2	0.46	6.11	0.35	3.5e-9	Gut microbiota (bacterial taxa);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg07421368	chr2:67624930	ETAA1	0.47	6.01	0.35	6.2e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs2997447	0.655	rs2275949	chr1:26385150	C/G	cg19633962	chr1:26362018	EXTL1	-0.55	-5.5	-0.32	9.06e-8	QRS complex (12-leadsum);
CESC	trans	rs1973993	0.967	rs6679458	chr1:96946253	G/T	cg10631902	chr5:14652156	NA	0.46	6.22	0.36	1.95e-9	Weight;
CESC	cis	rs7116495	0.609	rs674319	chr11:71775391	T/C	cg07596299	chr11:71824057	C11orf51	-0.93	-5.87	-0.34	1.32e-8	Severe influenza A (H1N1) infection;
CESC	cis	rs13191362	0.507	rs2849518	chr6:163134248	T/C	cg06582575	chr6:163149167	PACRG;PARK2	-0.55	-6.43	-0.37	5.93e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs2204008	0.818	rs1589389	chr12:38416041	G/A	cg13010199	chr12:38710504	ALG10B	-0.41	-5.4	-0.31	1.49e-7	Bladder cancer;
CESC	cis	rs244293	0.965	rs244287	chr17:53232036	C/T	cg19360675	chr17:53046073	COX11;STXBP4	0.39	5.09	0.3	6.7e-7	Menarche (age at onset);
CESC	cis	rs10129255	0.556	rs6576222	chr14:107184681	G/A	cg23076370	chr14:107095027	NA	-0.65	-9.81	-0.52	1.35e-19	Kawasaki disease;
CESC	cis	rs8077889	0.750	rs80053172	chr17:41936843	C/T	cg26893861	chr17:41843967	DUSP3	0.86	8.51	0.46	1.31e-15	Triglycerides;
CESC	cis	rs732765	0.602	rs2359192	chr14:75410523	A/C	cg21190982	chr14:75180524	FCF1;KIAA0317	0.36	5.17	0.3	4.6e-7	Non-small cell lung cancer;
CESC	cis	rs875971	0.964	rs778723	chr7:65829497	T/C	cg12463550	chr7:65579703	CRCP	0.59	7.56	0.42	6.49e-13	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09235050	chr20:57599210	TUBB1	-0.59	-7.11	-0.4	1.07e-11	Gut microbiome composition (summer);
CESC	cis	rs1799949	0.965	rs4239149	chr17:41328095	A/G	cg05368731	chr17:41323189	NBR1	-0.55	-7.52	-0.42	8.38e-13	Menopause (age at onset);
CESC	cis	rs4888262	0.514	rs8048239	chr16:74578317	A/T	cg01733217	chr16:74700730	RFWD3	0.82	11.54	0.58	3.04e-25	Testicular germ cell tumor;
CESC	cis	rs1707322	1.000	rs10890372	chr1:46391020	T/G	cg03146154	chr1:46216737	IPP	0.72	9.82	0.52	1.31e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs35110281	0.811	rs2838339	chr21:45075750	A/G	cg04455712	chr21:45112962	RRP1B	-0.39	-5.75	-0.33	2.48e-8	Mean corpuscular volume;
CESC	cis	rs9549367	0.789	rs35569628	chr13:113872712	T/C	cg00898013	chr13:113819073	PROZ	-0.5	-7.29	-0.41	3.65e-12	Platelet distribution width;
CESC	cis	rs9894429	0.646	rs7405870	chr17:79617284	G/A	cg18240062	chr17:79603768	NPLOC4	0.51	6.58	0.37	2.48e-10	Eye color traits;
CESC	cis	rs55788414	0.527	rs2873368	chr16:81184208	C/G	cg06400318	chr16:81190750	PKD1L2	-0.6	-6.77	-0.38	8.45e-11	Left ventricular obstructive tract defect (maternal effect);
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg18543035	chr10:8374526	NA	0.44	6.12	0.35	3.28e-9	Systemic lupus erythematosus;
CESC	cis	rs16854884	0.657	rs35788195	chr3:143739311	C/T	cg06585982	chr3:143692056	C3orf58	0.49	6.14	0.35	2.96e-9	Economic and political preferences (feminism/equality);
CESC	cis	rs7666738	0.716	rs2865982	chr4:99031661	T/G	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.58e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs67311347	1.000	rs1123019	chr3:40488280	C/T	cg24209194	chr3:40518798	ZNF619	0.5	6.26	0.36	1.54e-9	Renal cell carcinoma;
CESC	cis	rs7408868	1.000	rs10410514	chr19:15277610	C/T	cg14696996	chr19:15285081	NOTCH3	1.11	11.94	0.59	1.43e-26	Pulse pressure;
CESC	cis	rs60154123	0.505	rs7540237	chr1:210053325	C/T	cg21951975	chr1:209979733	IRF6	0.59	6.43	0.37	5.96e-10	Coronary artery disease;
CESC	cis	rs6815814	0.768	rs6835514	chr4:38894380	C/T	cg02016764	chr4:38805732	TLR1	0.42	6.19	0.36	2.31e-9	Breast cancer;
CESC	cis	rs9894429	0.546	rs55917554	chr17:79608776	T/C	cg18240062	chr17:79603768	NPLOC4	0.67	8.9	0.48	8.9e-17	Eye color traits;
CESC	cis	rs909002	0.849	rs7546297	chr1:32106494	A/G	cg13919466	chr1:32135498	COL16A1	-0.48	-8.27	-0.45	6.34e-15	Intelligence (multi-trait analysis);
CESC	cis	rs17376456	0.877	rs28633397	chr5:93447048	A/G	cg25358565	chr5:93447407	FAM172A	1.15	11.8	0.59	4.11e-26	Diabetic retinopathy;
CESC	cis	rs9596863	1.000	rs9596866	chr13:54459385	A/T	ch.13.53330881F	chr13:54432880	NA	0.65	5.22	0.31	3.58e-7	Epilepsy and lamotrigine-induced maculopapular eruptions;
CESC	cis	rs4889855	0.614	rs7221663	chr17:78484166	T/C	cg00066239	chr17:78472159	NA	-0.38	-5.22	-0.31	3.55e-7	Fractional excretion of uric acid;
CESC	cis	rs8114671	0.551	rs4911162	chr20:33411425	G/C	cg06115741	chr20:33292138	TP53INP2	0.49	5.81	0.34	1.76e-8	Height;
CESC	cis	rs2932538	0.961	rs12126494	chr1:113228623	G/A	cg22162597	chr1:113214053	CAPZA1	0.6	7.25	0.41	4.6e-12	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CESC	cis	rs4819052	0.851	rs8131143	chr21:46671646	C/G	cg20896738	chr21:46707857	POFUT2;LOC642852	-0.44	-5.47	-0.32	1.05e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs35955747	0.869	rs28715	chr22:31730169	C/T	cg25791279	chr22:32026902	PISD	0.5	6.05	0.35	4.98e-9	Neutrophil count;Sum basophil neutrophil counts;
CESC	cis	rs2836974	0.931	rs2836968	chr21:40642386	A/G	cg17971929	chr21:40555470	PSMG1	1.08	16.28	0.71	9.03e-42	Cognitive function;
CESC	cis	rs801193	1.000	rs2659906	chr7:66165310	T/C	cg06456125	chr7:65229604	NA	0.4	5.23	0.31	3.51e-7	Aortic root size;
CESC	cis	rs9322193	0.926	rs9689036	chr6:150101699	T/C	cg09699651	chr6:150184138	LRP11	0.4	5.1	0.3	6.34e-7	Lung cancer;
CESC	cis	rs5769765	0.862	rs9616386	chr22:50313179	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.58	-6.23	-0.36	1.86e-9	Schizophrenia;
CESC	cis	rs2576037	0.526	rs2576051	chr18:44557884	G/A	cg19077165	chr18:44547161	KATNAL2	0.53	7.56	0.42	6.54e-13	Personality dimensions;
CESC	cis	rs10779751	1.000	rs12120734	chr1:11262020	A/G	cg08854313	chr1:11322531	MTOR	0.91	14.25	0.66	1.35e-34	Body mass index;
CESC	cis	rs10504229	0.610	rs6993531	chr8:58147283	A/G	cg24829409	chr8:58192753	C8orf71	-0.54	-7.08	-0.4	1.3e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs6558174	0.802	rs6558170	chr8:22487388	C/G	cg03733263	chr8:22462867	KIAA1967	0.43	5.2	0.3	3.95e-7	Breast cancer;
CESC	cis	rs2839186	0.706	rs2839188	chr21:47692798	C/T	cg10351095	chr21:47802916	PCNT	-0.44	-5.56	-0.32	6.53e-8	Testicular germ cell tumor;
CESC	cis	rs921968	0.541	rs561570	chr2:219379348	T/A	cg02176678	chr2:219576539	TTLL4	0.5	9.03	0.48	3.72e-17	Mean corpuscular hemoglobin concentration;
CESC	cis	rs1348850	0.567	rs3770009	chr2:178536544	C/T	cg22681709	chr2:178499509	PDE11A	-0.51	-7.47	-0.42	1.15e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs36051895	0.664	rs7847141	chr9:5097171	A/T	cg02405213	chr9:5042618	JAK2	-0.5	-6.18	-0.35	2.44e-9	Pediatric autoimmune diseases;
CESC	cis	rs9902453	0.967	rs4429345	chr17:28458105	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.61	-7.72	-0.43	2.44e-13	Coffee consumption (cups per day);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05076971	chr7:117824189	NAA38	0.54	6.61	0.38	2.12e-10	Gut microbiome composition (summer);
CESC	cis	rs2354432	0.607	rs6593751	chr1:146726023	A/G	cg25205988	chr1:146714368	CHD1L	-1.02	-8.47	-0.46	1.66e-15	Mitochondrial DNA levels;
CESC	cis	rs8177253	1.000	rs8177240	chr3:133477701	T/G	cg01448562	chr3:133502909	NA	-0.44	-6.1	-0.35	3.69e-9	Iron status biomarkers;
CESC	cis	rs796364	0.951	rs11680258	chr2:200996976	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.65	-6.48	-0.37	4.56e-10	Schizophrenia;
CESC	cis	rs10504229	0.953	rs72650891	chr8:58179697	T/G	cg24829409	chr8:58192753	C8orf71	-0.76	-10.0	-0.52	3.53e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs11098499	0.955	rs7684942	chr4:120162201	C/T	cg24375607	chr4:120327624	NA	0.43	5.24	0.31	3.34e-7	Corneal astigmatism;
CESC	cis	rs7666738	0.830	rs60391193	chr4:98933912	T/G	cg05340658	chr4:99064831	C4orf37	0.82	12.54	0.61	1.29e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4919694	1.000	rs12252500	chr10:104794984	G/C	cg04362960	chr10:104952993	NT5C2	0.77	6.69	0.38	1.34e-10	Arsenic metabolism;
CESC	cis	rs7208859	0.673	rs1347359	chr17:28914529	T/C	cg14008862	chr17:28927542	LRRC37B2	0.66	5.75	0.33	2.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs6942756	0.531	rs7800983	chr7:128971130	C/T	cg02491457	chr7:128862824	NA	0.44	6.21	0.36	2.02e-9	White matter hyperintensity burden;
CESC	cis	rs2463822	0.669	rs72919480	chr11:62043133	G/A	cg06239285	chr11:62104954	ASRGL1	-1.13	-9.21	-0.49	1.05e-17	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs2303759	0.626	rs12982246	chr19:49801169	A/G	cg22307029	chr19:49891270	CCDC155	0.49	5.35	0.31	1.86e-7	Multiple sclerosis;
CESC	cis	rs12928939	0.517	rs12149325	chr16:71968147	G/C	cg03805757	chr16:71968109	PKD1L3	-0.59	-6.62	-0.38	2.01e-10	Post bronchodilator FEV1;
CESC	cis	rs782590	0.935	rs2627776	chr2:55873301	T/A	cg18811423	chr2:55921094	PNPT1	0.81	13.07	0.63	1.89e-30	Metabolic syndrome;
CESC	cis	rs601339	1.000	rs7969523	chr12:123168636	T/G	cg11919336	chr12:123188078	GPR109A	0.45	5.86	0.34	1.36e-8	Adiponectin levels;
CESC	cis	rs1862618	0.525	rs2662021	chr5:56261691	C/T	cg22800045	chr5:56110881	MAP3K1	-0.64	-7.54	-0.42	7.64e-13	Initial pursuit acceleration;
CESC	trans	rs916888	0.779	rs430685	chr17:44859148	T/C	cg07870213	chr5:140052090	DND1	-0.61	-6.89	-0.39	4.01e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs13102973	0.931	rs116199858	chr4:135847256	G/C	cg14419869	chr4:135874104	NA	0.33	5.19	0.3	4.29e-7	Subjective well-being;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg08687137	chr11:62389499	B3GAT3	-0.49	-6.63	-0.38	1.83e-10	Fibrinogen levels;
CESC	cis	rs798554	0.757	rs960273	chr7:2857876	T/C	cg04166393	chr7:2884313	GNA12	0.62	7.7	0.43	2.71e-13	Height;
CESC	cis	rs10465746	0.658	rs980418	chr1:84365653	T/G	cg10977910	chr1:84465055	TTLL7	0.56	7.78	0.43	1.62e-13	Obesity-related traits;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg26558919	chr17:66508512	PRKAR1A	-0.49	-6.15	-0.35	2.86e-9	Asthma;
CESC	cis	rs2839186	0.934	rs4819221	chr21:47695417	G/T	cg10351095	chr21:47802916	PCNT	0.48	6.57	0.37	2.67e-10	Testicular germ cell tumor;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg07911682	chr1:51425659	FAF1	0.43	6.09	0.35	3.92e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs6032067	0.777	rs17423897	chr20:43780307	T/C	cg10761708	chr20:43804764	PI3	0.53	6.27	0.36	1.48e-9	Blood protein levels;
CESC	cis	rs875971	0.545	rs221986	chr7:65570310	T/C	cg11764359	chr7:65958608	NA	-0.8	-8.94	-0.48	6.67e-17	Aortic root size;
CESC	cis	rs9916302	0.904	rs620686	chr17:37453617	A/G	cg19468946	chr17:37922297	IKZF3	0.41	5.22	0.31	3.59e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs67311347	1.000	rs9827461	chr3:40489351	T/A	cg24209194	chr3:40518798	ZNF619	0.5	6.18	0.35	2.46e-9	Renal cell carcinoma;
CESC	cis	rs1843834	0.574	rs6436499	chr2:225456551	A/T	cg22455342	chr2:225449267	CUL3	0.65	8.93	0.48	7.35e-17	IgE levels in asthmatics (D.p. specific);
CESC	cis	rs262150	1.000	rs262150	chr7:158777934	G/A	cg09640425	chr7:158790006	NA	-0.35	-5.3	-0.31	2.48e-7	Facial morphology (factor 20);
CESC	cis	rs514406	0.505	rs146750	chr1:53183447	C/G	cg08736216	chr1:53307985	ZYG11A	-0.38	-6.35	-0.36	9.15e-10	Monocyte count;
CESC	cis	rs7615952	0.576	rs12497295	chr3:125818650	G/A	cg02807482	chr3:125708958	NA	-0.39	-5.11	-0.3	6.29e-7	Blood pressure (smoking interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20201475	chr3:168867307	MECOM	0.57	7.03	0.4	1.71e-11	Gut microbiome composition (summer);
CESC	cis	rs367943	0.933	rs451453	chr5:112808970	G/C	cg12552261	chr5:112820674	MCC	-0.62	-7.85	-0.43	1.05e-13	Type 2 diabetes;
CESC	trans	rs1728785	1.000	rs1615609	chr16:68596401	C/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.65	7.83	0.43	1.18e-13	Ulcerative colitis;
CESC	cis	rs1799949	0.965	rs11651623	chr17:41329847	G/A	cg05368731	chr17:41323189	NBR1	0.78	10.64	0.55	2.97e-22	Menopause (age at onset);
CESC	cis	rs965469	1.000	rs6051736	chr20:3296898	T/C	cg25506879	chr20:3388711	C20orf194	-0.56	-6.08	-0.35	4.16e-9	IFN-related cytopenia;
CESC	cis	rs9948	0.655	rs61742095	chr2:97366088	T/C	cg01990225	chr2:97406019	LMAN2L	-0.89	-6.97	-0.39	2.48e-11	Erectile dysfunction and prostate cancer treatment;
CESC	cis	rs514406	0.861	rs4926932	chr1:53247495	C/T	cg08736216	chr1:53307985	ZYG11A	0.43	7.25	0.41	4.64e-12	Monocyte count;
CESC	cis	rs875971	0.522	rs2949690	chr7:65483242	C/T	cg25985355	chr7:65971099	NA	0.32	5.35	0.31	1.9e-7	Aortic root size;
CESC	cis	rs854765	0.547	rs2955359	chr17:17946730	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.62	-8.81	-0.48	1.7e-16	Total body bone mineral density;
CESC	cis	rs11098499	0.874	rs13139045	chr4:120168588	T/C	cg09307838	chr4:120376055	NA	0.8	10.35	0.54	2.58e-21	Corneal astigmatism;
CESC	cis	rs8067354	0.645	rs9901606	chr17:57811407	A/C	cg13753209	chr17:57696993	CLTC	0.65	7.95	0.44	5.28e-14	Hemoglobin concentration;
CESC	cis	rs9457247	0.663	rs9459845	chr6:167440501	C/G	cg25258033	chr6:167368657	RNASET2	0.36	5.16	0.3	4.88e-7	Crohn's disease;
CESC	cis	rs2228479	0.702	rs3819574	chr16:89826630	G/A	cg04013166	chr16:89971882	TCF25	0.78	6.69	0.38	1.33e-10	Skin colour saturation;
CESC	cis	rs1862618	0.853	rs252916	chr5:56121788	G/C	cg03609598	chr5:56110824	MAP3K1	-0.51	-5.5	-0.32	9.11e-8	Initial pursuit acceleration;
CESC	cis	rs12142240	0.698	rs67200518	chr1:46835777	T/C	cg10495392	chr1:46806563	NSUN4	0.58	6.32	0.36	1.1e-9	Menopause (age at onset);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg00615915	chr18:61637299	SERPINB8	-0.44	-6.61	-0.38	2.12e-10	Gambling;
CESC	cis	rs11098499	0.863	rs3775844	chr4:120428033	G/A	cg09307838	chr4:120376055	NA	0.95	13.11	0.63	1.3e-30	Corneal astigmatism;
CESC	cis	rs7312933	0.865	rs1920687	chr12:42398275	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.4	5.14	0.3	5.34e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs1401999	0.510	rs12634398	chr3:183708405	A/G	cg01324343	chr3:183735012	ABCC5	0.39	6.76	0.38	8.51e-11	Anterior chamber depth;
CESC	cis	rs10504229	0.906	rs56130194	chr8:58197061	C/A	cg24829409	chr8:58192753	C8orf71	-0.74	-8.44	-0.46	2.09e-15	Developmental language disorder (linguistic errors);
CESC	cis	rs1865721	1.000	rs3813080	chr18:73186227	C/T	cg26385618	chr18:73139727	C18orf62	-0.52	-7.77	-0.43	1.68e-13	Intelligence;
CESC	cis	rs17376456	0.825	rs56108532	chr5:93276342	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.67	5.72	0.33	2.86e-8	Diabetic retinopathy;
CESC	cis	rs6893300	0.961	rs1469020	chr5:179214024	G/A	cg14593053	chr5:179126677	CANX	-0.51	-5.57	-0.32	6.16e-8	Resting heart rate;
CESC	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.51	-5.7	-0.33	3.21e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs898097	0.578	rs9906163	chr17:80908174	T/C	cg15664640	chr17:80829946	TBCD	0.42	6.07	0.35	4.3e-9	Breast cancer;
CESC	cis	rs79349575	0.783	rs62078372	chr17:47028989	T/C	cg16584676	chr17:46985605	UBE2Z	0.54	6.67	0.38	1.46e-10	Type 2 diabetes;
CESC	cis	rs826838	0.967	rs11169142	chr12:39085773	A/T	cg26384229	chr12:38710491	ALG10B	-0.62	-9.95	-0.52	5e-20	Heart rate;
CESC	cis	rs7914558	0.966	rs3902934	chr10:104746649	A/G	cg08650961	chr10:104748594	CNNM2	0.32	5.14	0.3	5.23e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23957188	chr1:115124358	BCAS2	-0.56	-6.56	-0.37	2.79e-10	Gut microbiome composition (summer);
CESC	cis	rs11098499	0.604	rs34278750	chr4:120571136	G/A	cg24375607	chr4:120327624	NA	0.44	5.35	0.31	1.87e-7	Corneal astigmatism;
CESC	cis	rs9910055	0.636	rs7089	chr17:42269017	T/C	cg13607699	chr17:42295918	UBTF	0.57	7.31	0.41	3.2e-12	Total body bone mineral density;
CESC	cis	rs1552244	0.882	rs13088350	chr3:10044626	T/C	cg00149659	chr3:10157352	C3orf10	0.71	8.4	0.46	2.71e-15	Alzheimer's disease;
CESC	cis	rs8180040	1.000	rs295449	chr3:47375955	G/A	cg27129171	chr3:47204927	SETD2	0.67	10.1	0.53	1.72e-20	Colorectal cancer;
CESC	cis	rs941408	1.000	rs1736176	chr19:2790394	G/A	cg06609049	chr19:2785107	THOP1	0.73	10.6	0.55	4.06e-22	Total cholesterol levels;
CESC	cis	rs2204008	0.905	rs7294297	chr12:38442573	T/C	cg26384229	chr12:38710491	ALG10B	0.64	9.46	0.5	1.69e-18	Bladder cancer;
CESC	cis	rs72945132	1.000	rs7938912	chr11:70114885	C/T	cg00319359	chr11:70116639	PPFIA1	0.84	8.25	0.45	7.56e-15	Coronary artery disease;
CESC	cis	rs9733	0.519	rs1134067	chr1:150721175	G/T	cg18016565	chr1:150552671	MCL1	0.35	5.11	0.3	6.05e-7	Tonsillectomy;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg11582133	chr15:41576691	LOC729082	-0.43	-6.11	-0.35	3.47e-9	Gambling;
CESC	cis	rs875971	0.520	rs12666485	chr7:65625122	T/C	cg19163074	chr7:65112434	INTS4L2	-0.46	-5.05	-0.3	8.07e-7	Aortic root size;
CESC	cis	rs714031	0.872	rs3788576	chr22:40071894	G/A	cg21377881	chr22:40064566	CACNA1I	-0.36	-5.92	-0.34	9.97e-9	Schizophrenia;
CESC	cis	rs262150	0.851	rs2730249	chr7:158767628	A/G	cg19418458	chr7:158789849	NA	0.5	7.94	0.44	5.61e-14	Facial morphology (factor 20);
CESC	trans	rs673604	0.505	rs676614	chr1:36107510	G/T	cg10678486	chr18:48494218	ELAC1	0.53	6.03	0.35	5.46e-9	Endometrial cancer;
CESC	cis	rs2204008	0.806	rs11525001	chr12:38234397	A/G	cg26384229	chr12:38710491	ALG10B	0.64	8.91	0.48	8.24e-17	Bladder cancer;
CESC	cis	rs2979489	0.945	rs13250272	chr8:30294942	A/G	cg26383811	chr8:30366931	RBPMS	0.83	9.69	0.51	3.31e-19	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CESC	cis	rs7953508	0.506	rs768775	chr12:93968197	T/C	cg18151635	chr12:93972918	NA	-0.44	-5.89	-0.34	1.19e-8	Pubertal anthropometrics;
CESC	cis	rs9733	0.596	rs6669369	chr1:150695892	C/T	cg04414720	chr1:150670196	GOLPH3L	0.62	8.8	0.48	1.76e-16	Tonsillectomy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21906083	chr1:160772137	LY9	-0.59	-7.0	-0.4	2.05e-11	Gut microbiome composition (summer);
CESC	cis	rs3796352	1.000	rs4478072	chr3:53106125	G/T	cg12962167	chr3:53033115	SFMBT1	0.56	5.82	0.34	1.72e-8	Immune reponse to smallpox (secreted IL-2);
CESC	cis	rs1552244	1.000	rs7637888	chr3:10080722	T/C	cg00149659	chr3:10157352	C3orf10	0.77	9.66	0.51	4.22e-19	Alzheimer's disease;
CESC	cis	rs941408	0.515	rs1005556	chr19:2778543	G/T	cg06609049	chr19:2785107	THOP1	0.85	13.07	0.63	1.76e-30	Total cholesterol levels;
CESC	cis	rs34172651	0.876	rs1862451	chr16:24803620	A/G	cg06028605	chr16:24865363	SLC5A11	0.41	6.22	0.36	1.94e-9	Intelligence (multi-trait analysis);
CESC	cis	rs1559088	1.000	rs12979164	chr19:33553228	G/C	cg17764715	chr19:33622953	WDR88	0.45	5.68	0.33	3.6e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs4588572	0.686	rs2362823	chr5:77693623	A/G	cg11547950	chr5:77652471	NA	0.46	5.98	0.34	7.29e-9	Triglycerides;
CESC	cis	rs7666738	0.830	rs6854902	chr4:99033416	T/G	cg05340658	chr4:99064831	C4orf37	0.83	13.1	0.63	1.43e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs60871478	0.947	rs4074610	chr7:791755	G/A	cg00934597	chr7:893267	UNC84A	0.47	5.17	0.3	4.72e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs2286492	0.881	rs78433057	chr7:22930238	A/G	cg05472934	chr7:22766657	IL6	-0.69	-5.13	-0.3	5.59e-7	Bipolar disorder;
CESC	cis	rs10992471	0.565	rs12552866	chr9:95110549	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.4	-5.04	-0.3	8.5e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CESC	cis	rs35079168	0.735	rs1887309	chr9:137308242	A/G	cg00753924	chr9:137298813	RXRA	0.4	6.38	0.36	7.98e-10	Intelligence;
CESC	cis	rs5753037	0.653	rs131282	chr22:30156608	A/C	cg01021169	chr22:30184971	ASCC2	-0.44	-6.01	-0.35	6.28e-9	Type 1 diabetes;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg06239170	chr6:657134	HUS1B;EXOC2	0.53	7.16	0.4	7.95e-12	Fibrinogen levels;
CESC	cis	rs7044106	0.762	rs4837789	chr9:123426256	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.33	5.04	0.3	8.5e-7	Hip circumference adjusted for BMI;
CESC	cis	rs1215050	0.791	rs1648546	chr4:98899294	T/C	cg05340658	chr4:99064831	C4orf37	-0.53	-7.0	-0.39	2.14e-11	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs3733585	0.699	rs7694997	chr4:9947811	A/G	cg11266682	chr4:10021025	SLC2A9	-0.58	-10.78	-0.55	1.08e-22	Cleft plate (environmental tobacco smoke interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02921634	chr21:43109546	NCRNA00111	-0.57	-6.31	-0.36	1.16e-9	Gut microbiome composition (summer);
CESC	trans	rs1493916	0.721	rs4799723	chr18:31367050	T/G	cg27147174	chr7:100797783	AP1S1	-0.49	-6.43	-0.37	5.75e-10	Life satisfaction;
CESC	cis	rs41308713	0.786	rs8116471	chr20:37034694	A/C	cg09132763	chr20:37064059	LOC388796;SNORA71D	1.13	6.51	0.37	3.77e-10	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
CESC	trans	rs11098499	0.874	rs6832670	chr4:120118792	A/G	cg25214090	chr10:38739885	LOC399744	0.61	8.1	0.45	2.06e-14	Corneal astigmatism;
CESC	cis	rs13108904	0.935	rs1680072	chr4:1281695	T/G	cg16405210	chr4:1374714	KIAA1530	0.45	5.58	0.32	5.89e-8	Obesity-related traits;
CESC	cis	rs2522056	1.000	rs2706381	chr5:131810619	C/T	cg07395648	chr5:131743802	NA	0.43	5.06	0.3	8.01e-7	Lymphocyte counts;Fibrinogen;
CESC	cis	rs7617773	1.000	rs6442106	chr3:48190815	G/A	cg11946769	chr3:48343235	NME6	-0.62	-8.23	-0.45	8.76e-15	Coronary artery disease;
CESC	cis	rs2342371	0.756	rs3973	chr3:196124278	A/G	cg09821211	chr3:195954098	OSTalpha	-0.37	-5.3	-0.31	2.46e-7	Fat distribution (HIV);
CESC	trans	rs916888	0.610	rs199436	chr17:44789285	C/T	cg22433210	chr17:43662623	NA	-0.58	-7.27	-0.41	4.13e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs2487048	0.761	rs1800976	chr9:107690709	C/G	cg14470647	chr9:107690075	ABCA1	-0.58	-7.29	-0.41	3.6e-12	Intraocular pressure;
CESC	cis	rs9888739	0.858	rs60312440	chr16:31340086	C/T	cg15817542	chr16:31343056	ITGAM	-0.49	-6.64	-0.38	1.76e-10	Systemic lupus erythematosus;
CESC	cis	rs853679	0.542	rs9380063	chr6:28137853	A/G	cg19592336	chr6:28129416	ZNF389	0.58	7.65	0.43	3.83e-13	Depression;
CESC	cis	rs6570726	0.967	rs418662	chr6:145848832	A/C	cg23711669	chr6:146136114	FBXO30	0.74	10.72	0.55	1.65e-22	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs8072100	0.738	rs9915222	chr17:45448615	G/T	cg08085267	chr17:45401833	C17orf57	-0.51	-6.35	-0.36	9.29e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs6089584	0.888	rs6142927	chr20:60605848	A/G	cg06108461	chr20:60628389	TAF4	-0.83	-11.36	-0.57	1.24e-24	Body mass index;
CESC	cis	rs7264396	0.580	rs2064511	chr20:34448810	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	-0.62	-6.38	-0.36	7.83e-10	Total cholesterol levels;
CESC	cis	rs7666738	0.830	rs9998582	chr4:98938949	T/C	cg05340658	chr4:99064831	C4orf37	0.82	12.54	0.61	1.29e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs250677	0.652	rs250680	chr5:148436024	T/C	cg18129178	chr5:148520854	ABLIM3	-0.48	-5.48	-0.32	1e-7	Breast cancer;
CESC	cis	rs9322193	0.884	rs10782312	chr6:149943805	G/T	cg07701084	chr6:150067640	NUP43	0.46	6.45	0.37	5.26e-10	Lung cancer;
CESC	cis	rs875971	0.545	rs3735147	chr7:65970528	A/C	cg11764359	chr7:65958608	NA	0.81	9.69	0.51	3.42e-19	Aortic root size;
CESC	cis	rs736408	0.546	rs3733046	chr3:52621627	C/T	cg05564831	chr3:52568323	NT5DC2	0.48	7.64	0.42	3.95e-13	Bipolar disorder;
CESC	cis	rs8177179	1.000	rs8177179	chr3:133463457	G/A	cg17775713	chr3:133465469	TF	0.32	5.71	0.33	3.1e-8	Iron status biomarkers (transferrin levels);
CESC	trans	rs35110281	0.782	rs9981790	chr21:45045052	G/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.49	6.46	0.37	4.98e-10	Mean corpuscular volume;
CESC	cis	rs10089	0.951	rs56066100	chr5:127460571	G/C	cg19767477	chr5:127420684	SLC12A2	-0.4	-5.32	-0.31	2.18e-7	Ileal carcinoids;
CESC	cis	rs11997175	0.624	rs17778980	chr8:33700926	T/C	ch.8.33884649F	chr8:33765107	NA	0.56	7.34	0.41	2.56e-12	Body mass index;
CESC	cis	rs6502050	0.835	rs8078950	chr17:80122327	T/G	cg23985595	chr17:80112537	CCDC57	-0.41	-6.57	-0.37	2.6200000000000003e-10	Life satisfaction;
CESC	trans	rs2727020	0.894	rs2866361	chr11:49372481	A/G	cg03929089	chr4:120376271	NA	-0.65	-7.61	-0.42	4.67e-13	Coronary artery disease;
CESC	cis	rs875971	0.830	rs427973	chr7:65526648	C/A	cg11764359	chr7:65958608	NA	0.9	13.28	0.63	3.47e-31	Aortic root size;
CESC	cis	rs4642101	0.793	rs12714880	chr3:12832101	G/A	cg24848339	chr3:12840334	CAND2	0.35	5.4	0.31	1.48e-7	QRS complex (12-leadsum);
CESC	cis	rs863345	0.933	rs863354	chr1:158542460	A/G	cg12129480	chr1:158549410	OR10X1	-0.32	-6.38	-0.36	7.87e-10	Pneumococcal bacteremia;
CESC	cis	rs6430585	0.527	rs1438303	chr2:136429857	C/T	cg07169764	chr2:136633963	MCM6	1.06	12.0	0.59	9.01e-27	Corneal structure;
CESC	cis	rs2108622	0.727	rs7253873	chr19:15980900	A/G	cg13772218	chr19:15982569	NA	0.3	5.87	0.34	1.27e-8	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CESC	cis	rs1506636	0.962	rs629474	chr7:123399684	C/T	cg03229431	chr7:123269106	ASB15	0.53	6.95	0.39	2.89e-11	Plateletcrit;Platelet count;
CESC	cis	rs10489202	0.632	rs203781	chr1:167880518	A/C	cg24449463	chr1:168025552	DCAF6	-0.43	-5.61	-0.33	5.03e-8	Schizophrenia;
CESC	cis	rs2239547	0.522	rs9865094	chr3:52985319	G/C	cg11645453	chr3:52864694	ITIH4	-0.32	-5.39	-0.31	1.53e-7	Schizophrenia;
CESC	trans	rs10435719	0.718	rs7813935	chr8:11795636	A/G	cg15556689	chr8:8085844	FLJ10661	0.53	6.47	0.37	4.63e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
CESC	cis	rs12497850	0.865	rs13072911	chr3:48962128	T/G	cg02487422	chr3:49467188	NICN1	0.4	5.22	0.31	3.6e-7	Parkinson's disease;
CESC	cis	rs10504229	0.683	rs2318143	chr8:58114660	C/T	cg24829409	chr8:58192753	C8orf71	-0.58	-7.2	-0.4	6.31e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs1372520	0.745	rs2736994	chr4:90784528	A/G	cg15133208	chr4:90757351	SNCA	-0.42	-5.46	-0.32	1.07e-7	Neuroticism;
CESC	cis	rs11920090	0.789	rs73169742	chr3:170756779	C/T	cg09710316	chr3:170744871	SLC2A2	0.51	5.43	0.32	1.28e-7	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22185043	chr18:12947723	SEH1L	0.61	7.17	0.4	7.51e-12	Gut microbiome composition (summer);
CESC	cis	rs2832077	0.527	rs2142375	chr21:30223742	G/A	cg08807101	chr21:30365312	RNF160	-0.66	-8.57	-0.47	8.73e-16	Cognitive test performance;
CESC	cis	rs9399135	0.967	rs7773126	chr6:135318390	A/G	cg24558204	chr6:135376177	HBS1L	0.5	6.77	0.38	8.49e-11	Red blood cell count;
CESC	cis	rs1483890	0.723	rs1843046	chr3:69410614	C/A	cg22125112	chr3:69402811	FRMD4B	0.41	5.53	0.32	7.56e-8	Resting heart rate;
CESC	cis	rs4665809	0.878	rs6748745	chr2:26364190	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.75	-8.81	-0.48	1.68e-16	Gut microbiome composition (summer);
CESC	cis	rs7274811	0.779	rs34145153	chr20:32159067	C/T	cg21523528	chr20:32077966	CBFA2T2	0.61	7.14	0.4	8.96e-12	Height;
CESC	cis	rs265548	0.646	rs36689	chr19:17910639	A/G	cg16744531	chr19:17905626	B3GNT3	0.58	8.09	0.45	2.16e-14	Tumor biomarkers;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18865566	chr20:32274387	E2F1	0.59	6.18	0.35	2.45e-9	Gut microbiome composition (summer);
CESC	cis	rs7640424	0.819	rs179046	chr3:107840773	A/C	cg09227934	chr3:107805635	CD47	-0.47	-6.03	-0.35	5.57e-9	Body mass index;
CESC	cis	rs34779708	0.897	rs34481177	chr10:35380913	C/T	cg04310649	chr10:35416472	CREM	-0.51	-6.06	-0.35	4.62e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs11825685	0.790	rs80204957	chr11:134545553	A/T	cg06603561	chr11:134479413	NA	-0.61	-5.35	-0.31	1.89e-7	IgG glycosylation;
CESC	cis	rs2836950	0.520	rs59916147	chr21:40634702	T/G	cg11644478	chr21:40555479	PSMG1	-0.55	-7.36	-0.41	2.39e-12	Menarche (age at onset);
CESC	cis	rs11650494	0.710	rs76651802	chr17:47473785	A/G	cg08112188	chr17:47440006	ZNF652	0.83	6.31	0.36	1.17e-9	Prostate cancer;
CESC	trans	rs11098499	0.863	rs11933966	chr4:120476715	G/A	cg25214090	chr10:38739885	LOC399744	0.66	8.96	0.48	5.92e-17	Corneal astigmatism;
CESC	cis	rs806215	1.000	rs806216	chr7:127237862	C/A	cg25922125	chr7:127225783	GCC1	-0.45	-5.23	-0.31	3.51e-7	Type 2 diabetes;
CESC	trans	rs17685	0.712	rs10271413	chr7:75754858	G/A	cg19862616	chr7:65841803	NCRNA00174	0.85	12.55	0.61	1.13e-28	Coffee consumption;Coffee consumption (cups per day);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00635599	chr16:14165630	MKL2	0.63	6.74	0.38	9.6e-11	Gut microbiome composition (summer);
CESC	cis	rs7551222	0.663	rs1563828	chr1:204516577	A/G	cg20240347	chr1:204465584	NA	-0.29	-5.93	-0.34	9.39e-9	Schizophrenia;
CESC	cis	rs1862618	0.853	rs860580	chr5:56149429	G/T	cg22800045	chr5:56110881	MAP3K1	-0.75	-9.47	-0.5	1.61e-18	Initial pursuit acceleration;
CESC	cis	rs17253792	0.822	rs113649689	chr14:56088065	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.76	5.39	0.31	1.56e-7	Putamen volume;
CESC	cis	rs2228479	0.702	rs11646374	chr16:89857935	G/A	cg04013166	chr16:89971882	TCF25	0.77	6.64	0.38	1.81e-10	Skin colour saturation;
CESC	cis	rs12410462	0.581	rs7541809	chr1:227547299	G/A	cg04117972	chr1:227635322	NA	0.62	5.31	0.31	2.27e-7	Major depressive disorder;
CESC	cis	rs8067545	0.611	rs8071274	chr17:20216928	T/C	cg13482628	chr17:19912719	NA	-0.41	-5.35	-0.31	1.94e-7	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24729577	chr1:1447567	ATAD3A	0.67	8.2	0.45	1.05e-14	Gut microbiome composition (summer);
CESC	cis	rs2380220	0.510	rs9387562	chr6:96057006	G/T	cg23517279	chr6:96025343	MANEA	0.54	5.23	0.31	3.5e-7	Behavioural disinhibition (generation interaction);
CESC	cis	rs921968	0.541	rs549026	chr2:219339283	T/C	cg02176678	chr2:219576539	TTLL4	0.5	8.97	0.48	5.67e-17	Mean corpuscular hemoglobin concentration;
CESC	cis	rs4319547	0.656	rs10734918	chr12:122921512	A/C	cg05707623	chr12:122985044	ZCCHC8	-0.53	-6.08	-0.35	4.2e-9	Body mass index;
CESC	cis	rs3008870	1.000	rs2815352	chr1:67482104	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.0	13.5	0.64	5.92e-32	Lymphocyte percentage of white cells;
CESC	cis	rs10751667	0.666	rs7950967	chr11:955638	G/A	cg01483505	chr11:975446	AP2A2	0.37	5.05	0.3	8.3e-7	Alzheimer's disease (late onset);
CESC	cis	rs757081	0.867	rs2521999	chr11:17333183	G/A	cg15432903	chr11:17409602	KCNJ11	-0.48	-6.03	-0.35	5.49e-9	Systolic blood pressure;
CESC	cis	rs7524258	0.867	rs35399313	chr1:7277293	T/C	cg07173049	chr1:7289937	CAMTA1	0.37	5.6	0.33	5.26e-8	Tourette's syndrome or obsessive-compulsive disorder;
CESC	cis	rs992157	0.687	rs35271699	chr2:219117482	G/A	cg00012203	chr2:219082015	ARPC2	0.83	11.63	0.58	1.52e-25	Colorectal cancer;
CESC	cis	rs1975974	0.511	rs56935892	chr17:21754089	A/G	cg18423549	chr17:21743878	NA	-0.67	-10.06	-0.53	2.2e-20	Psoriasis;
CESC	cis	rs17345786	1.000	rs11715368	chr3:101336380	G/A	cg12386194	chr3:101231763	SENP7	0.57	6.58	0.37	2.48e-10	Colonoscopy-negative controls vs population controls;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg22187246	chr11:71849870	FOLR3	0.44	6.05	0.35	4.99e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs3785574	0.962	rs7219920	chr17:61811642	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.1	19.45	0.77	5.95e-53	Height;
CESC	cis	rs9894429	0.789	rs7219915	chr17:79591813	C/T	cg13777783	chr17:79615861	NA	-0.33	-5.23	-0.31	3.45e-7	Eye color traits;
CESC	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	13.63	0.64	2.03e-32	Prudent dietary pattern;
CESC	cis	rs875971	0.508	rs10950045	chr7:66066373	T/C	cg19163074	chr7:65112434	INTS4L2	0.43	5.48	0.32	9.93e-8	Aortic root size;
CESC	cis	rs9910055	0.529	rs368328	chr17:42170289	G/A	cg19774624	chr17:42201019	HDAC5	0.57	7.45	0.42	1.3e-12	Total body bone mineral density;
CESC	cis	rs10504229	0.683	rs113492050	chr8:58130046	A/G	cg21724239	chr8:58056113	NA	0.58	5.95	0.34	8.29e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs763121	0.719	rs9610995	chr22:39057763	C/T	cg21395723	chr22:39101663	GTPBP1	0.43	5.37	0.31	1.74e-7	Menopause (age at onset);
CESC	cis	rs9467711	0.659	rs3823158	chr6:26463271	T/A	cg21479132	chr6:26055353	NA	0.72	5.14	0.3	5.22e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs4319547	1.000	rs9705654	chr12:123083508	T/C	cg23029597	chr12:123009494	RSRC2	-0.46	-5.26	-0.31	3.04e-7	Body mass index;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg21647170	chr7:56119546	CCT6A;PSPH	-0.44	-6.25	-0.36	1.66e-9	Gambling;
CESC	cis	rs9814567	0.929	rs13088413	chr3:134309977	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.45	6.03	0.35	5.55e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs6121246	0.559	rs6060857	chr20:30300222	A/G	cg13852791	chr20:30311386	BCL2L1	0.86	11.25	0.57	2.93e-24	Mean corpuscular hemoglobin;
CESC	cis	rs9291683	0.588	rs2240721	chr4:10020564	G/A	cg00071950	chr4:10020882	SLC2A9	0.92	17.67	0.74	1.1e-46	Bone mineral density;
CESC	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	13.8	0.65	5.22e-33	Prudent dietary pattern;
CESC	cis	rs72781680	0.846	rs55707417	chr2:24029928	G/A	cg08917208	chr2:24149416	ATAD2B	1.13	10.18	0.53	9.42e-21	Lymphocyte counts;
CESC	cis	rs10851478	0.872	rs12595692	chr15:49757108	C/T	cg08060515	chr15:49448048	GALK2;COPS2	0.42	5.16	0.3	4.79e-7	Oral cavity cancer;
CESC	cis	rs6500395	0.962	rs1872652	chr16:48642928	C/A	cg04672837	chr16:48644449	N4BP1	0.47	5.58	0.32	6.09e-8	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs2730245	0.661	rs842696	chr7:158662698	T/C	cg24397884	chr7:158709396	WDR60	0.69	10.14	0.53	1.23e-20	Height;
CESC	cis	rs1448094	0.621	rs7315084	chr12:86283817	A/G	cg02569458	chr12:86230093	RASSF9	0.41	6.12	0.35	3.43e-9	Major depressive disorder;
CESC	cis	rs977987	0.778	rs1109341	chr16:75445605	G/A	cg03315344	chr16:75512273	CHST6	0.4	5.73	0.33	2.66e-8	Dupuytren's disease;
CESC	cis	rs2576037	0.523	rs590923	chr18:44404259	G/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.33	5.26	0.31	2.99e-7	Personality dimensions;
CESC	cis	rs68170813	0.559	rs74745121	chr7:106958037	T/C	cg02696742	chr7:106810147	HBP1	-0.53	-5.04	-0.3	8.64e-7	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08249556	chr21:30365104	RNF160	0.57	6.18	0.35	2.47e-9	Gut microbiome composition (summer);
CESC	cis	rs9457247	0.508	rs2285147	chr6:167505548	G/A	cg07741184	chr6:167504864	NA	0.32	5.49	0.32	9.4e-8	Crohn's disease;
CESC	cis	rs769267	0.930	rs1054930	chr19:19648346	G/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.47	5.86	0.34	1.33e-8	Tonsillectomy;
CESC	cis	rs2282526	0.615	rs463738	chr21:44921166	G/A	cg01579765	chr21:45077557	HSF2BP	0.41	6.17	0.35	2.57e-9	Mean corpuscular hemoglobin;
CESC	cis	rs9868809	0.772	rs12107252	chr3:48691316	T/C	cg06212747	chr3:49208901	KLHDC8B	-0.64	-5.63	-0.33	4.55e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs2075371	0.897	rs1646702	chr7:134000177	C/G	cg11752832	chr7:134001865	SLC35B4	0.54	7.0	0.4	2.04e-11	Mean platelet volume;
CESC	cis	rs9768139	0.733	rs10156158	chr7:158122287	G/T	cg06219351	chr7:158114137	PTPRN2	-0.52	-8.13	-0.45	1.63e-14	Calcium levels;
CESC	cis	rs4665809	0.941	rs1434079	chr2:26284670	C/G	cg08470875	chr2:26401718	FAM59B	-0.46	-5.14	-0.3	5.45e-7	Gut microbiome composition (summer);
CESC	cis	rs1218582	0.628	rs12130132	chr1:154880386	C/T	cg16680214	chr1:154839983	KCNN3	-0.41	-6.13	-0.35	3.11e-9	Prostate cancer;
CESC	cis	rs7635838	0.859	rs9869977	chr3:11480081	C/A	cg00170343	chr3:11313890	ATG7	0.42	5.6	0.33	5.25e-8	HDL cholesterol;
CESC	cis	rs965469	1.000	rs6051702	chr20:3251924	A/C	cg25506879	chr20:3388711	C20orf194	-0.59	-6.27	-0.36	1.48e-9	IFN-related cytopenia;
CESC	cis	rs861020	0.527	rs614662	chr1:209962419	C/T	cg09509183	chr1:209979624	IRF6	-0.37	-5.08	-0.3	6.98e-7	Orofacial clefts;
CESC	cis	rs59918340	0.728	rs2304279	chr8:142229891	A/G	cg23750338	chr8:142222470	SLC45A4	0.61	9.17	0.49	1.41e-17	Immature fraction of reticulocytes;
CESC	cis	rs9815354	0.767	rs73073342	chr3:41839455	A/C	cg03022575	chr3:42003672	ULK4	0.7	6.04	0.35	5.26e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs1670533	1.000	rs2290411	chr4:1051077	T/C	cg27284194	chr4:1044797	NA	0.45	5.54	0.32	7.32e-8	Recombination rate (females);
CESC	cis	rs4835473	0.900	rs36083417	chr4:144655406	T/A	cg25736465	chr4:144833511	NA	-0.32	-5.04	-0.3	8.48e-7	Immature fraction of reticulocytes;
CESC	cis	rs3820068	0.581	rs72645879	chr1:15928199	A/G	cg17385448	chr1:15911702	AGMAT	0.41	6.69	0.38	1.33e-10	Systolic blood pressure;
CESC	cis	rs4073405	0.552	rs2289448	chr11:45305195	C/T	cg27235148	chr11:45376932	NA	0.29	5.04	0.3	8.55e-7	Schizophrenia;
CESC	cis	rs7267979	1.000	rs6076336	chr20:25319212	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.89	-18.7	-0.75	2.48e-50	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs1670533	1.000	rs1010342	chr4:1068819	C/T	cg27284194	chr4:1044797	NA	0.45	5.98	0.34	7.06e-9	Recombination rate (females);
CESC	cis	rs1552244	1.000	rs56270432	chr3:10087517	G/C	cg00149659	chr3:10157352	C3orf10	0.72	8.53	0.46	1.14e-15	Alzheimer's disease;
CESC	cis	rs782590	1.000	rs782594	chr2:55844445	T/C	cg18811423	chr2:55921094	PNPT1	0.81	13.08	0.63	1.7e-30	Metabolic syndrome;
CESC	cis	rs6540559	0.546	rs634601	chr1:210421594	C/T	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.55	6.15	0.35	2.87e-9	Cleft lip with or without cleft palate;
CESC	cis	rs870825	0.616	rs12512839	chr4:185610347	G/A	cg04058563	chr4:185651563	MLF1IP	0.64	6.46	0.37	5e-10	Blood protein levels;
CESC	cis	rs9314323	0.862	rs3808580	chr8:26250296	C/T	cg11498726	chr8:26250323	BNIP3L	0.45	6.74	0.38	9.87e-11	Red cell distribution width;
CESC	cis	rs2228479	0.702	rs12600151	chr16:89831558	C/T	cg00800038	chr16:89945340	TCF25	-0.92	-7.64	-0.42	4.02e-13	Skin colour saturation;
CESC	cis	rs9393777	0.623	rs9366658	chr6:26469866	G/A	cg12826209	chr6:26865740	GUSBL1	0.68	7.35	0.41	2.43e-12	Intelligence (multi-trait analysis);
CESC	cis	rs11098499	0.779	rs72918579	chr4:120333222	G/C	cg09307838	chr4:120376055	NA	0.95	13.42	0.64	1.07e-31	Corneal astigmatism;
CESC	cis	rs11577318	0.853	rs12728971	chr1:26626612	C/T	cg00813993	chr1:26644493	UBXN11;CD52	-0.4	-6.46	-0.37	5.05e-10	Granulocyte percentage of myeloid white cells;
CESC	cis	rs7618915	0.547	rs62253700	chr3:52625019	T/A	cg17372223	chr3:52568218	NT5DC2	0.44	6.53	0.37	3.36e-10	Bipolar disorder;
CESC	cis	rs4665809	1.000	rs3910272	chr2:26287842	T/A	cg25036284	chr2:26402008	FAM59B	-0.74	-8.4	-0.46	2.72e-15	Gut microbiome composition (summer);
CESC	cis	rs6598955	0.543	rs79778574	chr1:26538482	A/G	cg04990556	chr1:26633338	UBXN11	0.82	9.33	0.5	4.37e-18	Obesity-related traits;
CESC	cis	rs1801251	1.000	rs2100053	chr2:233719516	G/T	cg08000102	chr2:233561755	GIGYF2	-0.71	-10.22	-0.53	6.85e-21	Coronary artery disease;
CESC	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg23708337	chr7:1209742	NA	0.5	5.57	0.32	6.3e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs4478858	0.735	rs11436	chr1:31837320	T/C	cg00250761	chr1:31883323	NA	-0.26	-5.07	-0.3	7.56e-7	Alcohol dependence;
CESC	cis	rs8028182	0.666	rs4886708	chr15:75762608	C/T	cg20655648	chr15:75932815	IMP3	0.48	6.07	0.35	4.41e-9	Sudden cardiac arrest;
CESC	cis	rs2075371	1.000	rs8134	chr7:133974519	A/G	cg11752832	chr7:134001865	SLC35B4	0.54	7.09	0.4	1.19e-11	Mean platelet volume;
CESC	cis	rs2243480	0.831	rs57294491	chr7:65684901	T/A	cg18252515	chr7:66147081	NA	1.37	13.59	0.64	2.8e-32	Diabetic kidney disease;
CESC	trans	rs1814175	0.616	rs28417656	chr11:50040152	C/T	cg03929089	chr4:120376271	NA	-0.91	-14.82	-0.67	1.29e-36	Height;
CESC	cis	rs12701220	0.503	rs12702047	chr7:1132720	G/A	cg26769984	chr7:1090371	C7orf50	0.57	5.69	0.33	3.38e-8	Bronchopulmonary dysplasia;
CESC	cis	rs2777491	0.872	rs7176588	chr15:41588872	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.59	-8.9	-0.48	8.93e-17	Ulcerative colitis;
CESC	cis	rs8177253	0.507	rs4241357	chr3:133475563	A/C	cg12373951	chr3:133503437	NA	-0.36	-5.52	-0.32	8.2e-8	Iron status biomarkers;
CESC	cis	rs111326718	1	rs111326718	chr10:104771211	A/AAAAAT	cg15744005	chr10:104629667	AS3MT	-0.34	-5.51	-0.32	8.56e-8	Reticulocyte count;
CESC	cis	rs9287719	0.967	rs7600728	chr2:10739999	A/G	cg00105475	chr2:10696890	NA	0.39	5.61	0.33	4.96e-8	Prostate cancer;
CESC	cis	rs425277	0.606	rs451061	chr1:2075068	C/G	cg04315214	chr1:2043799	PRKCZ	-0.46	-7.58	-0.42	5.86e-13	Height;
CESC	cis	rs4665809	1.000	rs4665823	chr2:26312723	A/G	cg26314531	chr2:26401878	FAM59B	-0.62	-7.09	-0.4	1.25e-11	Gut microbiome composition (summer);
CESC	cis	rs875971	0.545	rs316323	chr7:65610989	C/T	cg19163074	chr7:65112434	INTS4L2	0.46	5.05	0.3	8.07e-7	Aortic root size;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg22913584	chr5:81046758	SSBP2	-0.44	-6.19	-0.36	2.3e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs7927771	0.524	rs1563821	chr11:47756568	C/T	cg18512352	chr11:47633146	NA	0.35	5.51	0.32	8.36e-8	Subjective well-being;
CESC	cis	rs4589502	0.800	rs2035150	chr15:67201794	A/C	cg09911534	chr15:67153556	NA	0.38	5.06	0.3	7.76e-7	Lung cancer (smoking interaction);
CESC	cis	rs9894429	1.000	rs7223613	chr17:79574803	C/T	cg13777783	chr17:79615861	NA	0.35	5.79	0.34	1.99e-8	Eye color traits;
CESC	cis	rs8020095	0.528	rs10144122	chr14:67856690	A/G	cg19548862	chr14:67692701	FAM71D	-0.45	-5.26	-0.31	2.98e-7	Depression (quantitative trait);
CESC	cis	rs9916302	0.904	rs4795359	chr17:37573146	C/T	cg07936489	chr17:37558343	FBXL20	-0.8	-11.5	-0.58	4.2e-25	Glomerular filtration rate (creatinine);
CESC	cis	rs6912958	0.631	rs9450704	chr6:88182704	G/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-5.15	-0.3	5.1e-7	Monocyte percentage of white cells;
CESC	cis	rs9894429	0.789	rs9747336	chr17:79584189	C/T	cg18240062	chr17:79603768	NPLOC4	0.89	13.21	0.63	6.03e-31	Eye color traits;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05840127	chr12:3181055	NA	-0.38	-6.26	-0.36	1.56e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs6429082	0.764	rs291369	chr1:235691913	T/C	cg26050004	chr1:235667680	B3GALNT2	0.6	7.29	0.41	3.49e-12	Adiposity;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03956243	chr12:54059090	ATP5G2	-0.46	-6.44	-0.37	5.51e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs9549260	0.564	rs9315784	chr13:41289166	G/A	cg21288729	chr13:41239152	FOXO1	0.58	7.04	0.4	1.63e-11	Red blood cell count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26450010	chr19:17412054	ABHD8	-0.6	-6.94	-0.39	2.94e-11	Gut microbiome composition (summer);
CESC	cis	rs4909189	1.000	rs71547530	chr7:158135503	A/G	cg06219351	chr7:158114137	PTPRN2	-0.58	-7.2	-0.4	6.3e-12	Response to amphetamines;
CESC	cis	rs7851660	0.967	rs7860598	chr9:100600702	G/A	cg13688889	chr9:100608707	NA	-0.68	-10.61	-0.55	3.8e-22	Strep throat;
CESC	cis	rs9322193	0.923	rs9479810	chr6:150072495	C/T	cg07701084	chr6:150067640	NUP43	0.43	5.81	0.34	1.79e-8	Lung cancer;
CESC	cis	rs2439831	0.850	rs61390361	chr15:44159842	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.68	7.43	0.42	1.45e-12	Lung cancer in ever smokers;
CESC	cis	rs597539	0.652	rs627731	chr11:68698663	A/C	cg18350739	chr11:68623251	NA	-0.46	-6.98	-0.39	2.41e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs1551570	0.766	rs55752217	chr19:10218434	C/T	cg00593900	chr19:10206746	ANGPTL6	0.33	5.53	0.32	7.57e-8	Narcolepsy;
CESC	cis	rs3126085	0.935	rs12746239	chr1:152246726	G/A	cg03465714	chr1:152285911	FLG	0.5	5.98	0.34	7.27e-9	Atopic dermatitis;
CESC	cis	rs2243480	1.000	rs1979823	chr7:65704613	G/A	cg18252515	chr7:66147081	NA	1.41	14.3	0.66	9.43e-35	Diabetic kidney disease;
CESC	cis	rs2235642	0.750	rs2974845	chr16:1648162	T/C	cg03771183	chr16:1608904	IFT140	0.38	5.43	0.32	1.3e-7	Coronary artery disease;
CESC	cis	rs34172651	0.606	rs7194189	chr16:24703484	G/T	cg00339695	chr16:24857497	SLC5A11	-0.45	-6.02	-0.35	5.88e-9	Intelligence (multi-trait analysis);
CESC	cis	rs853679	0.517	rs67878650	chr6:28142587	G/C	cg17949981	chr6:28129498	ZNF389	0.42	5.23	0.31	3.39e-7	Depression;
CESC	cis	rs1577917	0.958	rs12205492	chr6:86475976	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.52	-6.82	-0.39	5.97e-11	Response to antipsychotic treatment;
CESC	cis	rs7267979	0.966	rs2387882	chr20:25378802	C/T	cg08601574	chr20:25228251	PYGB	-0.38	-5.55	-0.32	6.92e-8	Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs11098499	0.697	rs11941899	chr4:120382758	C/A	cg25214090	chr10:38739885	LOC399744	0.69	9.79	0.52	1.58e-19	Corneal astigmatism;
CESC	cis	rs2286503	0.780	rs1304431	chr7:22865412	T/C	cg11367502	chr7:22862612	TOMM7	0.42	5.61	0.33	5e-8	Fibrinogen;
CESC	cis	rs4474465	0.688	rs10899553	chr11:78265210	A/G	cg27205649	chr11:78285834	NARS2	0.45	5.55	0.32	6.77e-8	Alzheimer's disease (survival time);
CESC	cis	rs6964587	0.626	rs2106745	chr7:91506635	C/T	cg17063962	chr7:91808500	NA	-0.45	-6.28	-0.36	1.38e-9	Breast cancer;
CESC	cis	rs35110281	0.641	rs9983670	chr21:45083425	A/G	cg04455712	chr21:45112962	RRP1B	0.5	7.86	0.43	9.82e-14	Mean corpuscular volume;
CESC	cis	rs7524258	0.903	rs4908450	chr1:7292756	T/C	cg07173049	chr1:7289937	CAMTA1	0.47	7.15	0.4	8.5e-12	Tourette's syndrome or obsessive-compulsive disorder;
CESC	cis	rs4953076	0.573	rs6734443	chr2:44408282	G/C	cg04920474	chr2:44395004	PPM1B	0.56	7.07	0.4	1.37e-11	Height;
CESC	cis	rs1799949	1.000	rs12950607	chr17:41299928	G/C	cg23758822	chr17:41437982	NA	1.02	15.64	0.69	1.65e-39	Menopause (age at onset);
CESC	cis	rs854765	0.575	rs2955357	chr17:17946401	T/C	cg04398451	chr17:18023971	MYO15A	0.72	10.46	0.54	1.15e-21	Total body bone mineral density;
CESC	cis	rs7666738	0.893	rs11729640	chr4:99052699	C/T	cg17366294	chr4:99064904	C4orf37	0.61	8.78	0.47	2.13e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11098499	0.955	rs1551	chr4:120158500	T/G	cg24375607	chr4:120327624	NA	0.43	5.17	0.3	4.57e-7	Corneal astigmatism;
CESC	cis	rs11871801	0.517	rs665268	chr17:40722029	A/G	cg21433558	chr17:40837037	CNTNAP1	0.48	5.9	0.34	1.11e-8	Crohn's disease;
CESC	cis	rs10838687	0.800	rs7928073	chr11:47361857	C/T	cg25783544	chr11:47291846	MADD	0.56	6.27	0.36	1.43e-9	Proinsulin levels;
CESC	cis	rs116095464	0.558	rs62344300	chr5:246336	A/G	cg10591111	chr5:226296	SDHA	-0.52	-6.38	-0.36	7.94e-10	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09915983	chr20:2844691	VPS16;PTPRA	-0.54	-6.59	-0.38	2.31e-10	Gut microbiome composition (summer);
CESC	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	10.07	0.53	2.14e-20	Prudent dietary pattern;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05407442	chr14:68161980	RDH11	-0.61	-7.29	-0.41	3.63e-12	Gut microbiome composition (summer);
CESC	cis	rs703842	0.616	rs10877023	chr12:58224199	C/A	cg00677455	chr12:58241039	CTDSP2	0.76	10.4	0.54	1.75e-21	Multiple sclerosis;
CESC	cis	rs68092024	0.704	rs792832	chr3:99474862	C/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.43	-6.77	-0.38	8.4e-11	Cleft lip with or without cleft palate;
CESC	cis	rs12545109	0.571	rs4314648	chr8:57276937	G/A	cg09654669	chr8:57350985	NA	-0.56	-6.21	-0.36	2.05e-9	Obesity-related traits;
CESC	trans	rs12339966	0.689	rs2252360	chr9:11677175	C/G	cg03904639	chr13:37677730	CSNK1A1L	-0.39	-6.1	-0.35	3.74e-9	Systolic blood pressure;
CESC	cis	rs780096	0.526	rs7594812	chr2:27611469	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.29	-5.38	-0.31	1.61e-7	Total body bone mineral density;
CESC	cis	rs11792861	0.890	rs3087979	chr9:111781779	T/C	cg14384093	chr9:111878565	C9orf5	-0.41	-5.05	-0.3	8.32e-7	Menarche (age at onset);
CESC	cis	rs8103278	0.507	rs4802276	chr19:46260748	T/C	cg14061069	chr19:46274453	DMPK	0.56	8.73	0.47	2.97e-16	Coronary artery disease;
CESC	cis	rs2243480	1.000	rs466983	chr7:65520496	T/G	cg13147721	chr7:65941812	NA	-0.89	-8.5	-0.46	1.43e-15	Diabetic kidney disease;
CESC	cis	rs2290159	0.800	rs28462331	chr3:12660466	G/C	cg23032965	chr3:12705835	RAF1	0.53	5.68	0.33	3.58e-8	Cholesterol, total;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg06128920	chr1:1447374	ATAD3A	-0.43	-6.09	-0.35	3.95e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs644799	0.710	rs3748253	chr11:95519506	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.75	11.15	0.57	6.1e-24	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs67311347	1.000	rs56291770	chr3:40515370	T/C	cg09455208	chr3:40491958	NA	0.51	8.34	0.46	4.1e-15	Renal cell carcinoma;
CESC	cis	rs7772486	0.597	rs2246132	chr6:146182515	C/G	cg05347473	chr6:146136440	FBXO30	0.73	9.58	0.51	7.28e-19	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7818345	1.000	rs11780343	chr8:19290963	C/T	cg11303988	chr8:19266685	CSGALNACT1	0.36	6.63	0.38	1.9e-10	Language performance in older adults (adjusted for episodic memory);
CESC	cis	rs4721295	0.573	rs3779000	chr7:2181628	G/A	cg23048001	chr7:2026167	MAD1L1	0.41	5.24	0.31	3.25e-7	Schizophrenia, schizoaffective disorder or bipolar disorder;
CESC	cis	rs12681366	0.734	rs3019146	chr8:95414106	C/T	cg13257157	chr8:95487014	RAD54B	0.37	5.04	0.3	8.46e-7	Nonsyndromic cleft lip with cleft palate;
CESC	cis	rs6493487	0.512	rs71471522	chr15:51153797	G/A	cg02338191	chr15:51200825	AP4E1	0.51	5.12	0.3	5.98e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs6570726	0.791	rs398408	chr6:145801020	G/A	cg23711669	chr6:146136114	FBXO30	0.99	15.28	0.68	3.17e-38	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs873946	0.590	rs7071777	chr10:134559976	T/A	cg18305652	chr10:134549665	INPP5A	0.46	6.48	0.37	4.44e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs477895	0.713	rs11607165	chr11:63963947	T/G	cg04317338	chr11:64019027	PLCB3	0.9	9.39	0.5	2.86e-18	Mean platelet volume;
CESC	cis	rs10979	0.782	rs9390108	chr6:143892722	A/T	cg25407410	chr6:143891975	LOC285740	-0.6	-8.92	-0.48	7.73e-17	Hypospadias;
CESC	cis	rs7107174	0.892	rs12281104	chr11:78046940	T/C	cg02023728	chr11:77925099	USP35	0.39	5.51	0.32	8.54e-8	Testicular germ cell tumor;
CESC	cis	rs453301	0.686	rs4840389	chr8:8884503	G/C	cg15556689	chr8:8085844	FLJ10661	-0.5	-6.12	-0.35	3.31e-9	Joint mobility (Beighton score);
CESC	cis	rs6540559	0.673	rs17015361	chr1:210018901	C/G	cg25204440	chr1:209979598	IRF6	0.53	5.27	0.31	2.8e-7	Cleft lip with or without cleft palate;
CESC	cis	rs12155623	0.834	rs16939055	chr8:49824013	T/G	cg00325661	chr8:49890786	NA	0.38	5.13	0.3	5.73e-7	Sudden cardiac arrest;
CESC	cis	rs3747547	0.642	rs55836506	chr9:38071741	C/G	cg13774184	chr9:37916125	SHB	-0.68	-5.75	-0.33	2.43e-8	Metabolite levels (Dihydroxy docosatrienoic acid);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg26979339	chr12:107168153	RIC8B	-0.51	-6.7	-0.38	1.23e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs7666738	0.830	rs1834645	chr4:98979593	T/A	cg17366294	chr4:99064904	C4orf37	0.59	8.41	0.46	2.53e-15	Colonoscopy-negative controls vs population controls;
CESC	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg00928393	chr15:28358388	HERC2	0.52	6.08	0.35	4.06e-9	Response to antipsychotic treatment;
CESC	cis	rs951366	0.966	rs11240565	chr1:205722958	C/T	cg26354017	chr1:205819088	PM20D1	-0.51	-6.87	-0.39	4.67e-11	Menarche (age at onset);
CESC	cis	rs3749237	1.000	rs2307021	chr3:49765483	C/G	cg03060546	chr3:49711283	APEH	0.66	7.84	0.43	1.09e-13	Resting heart rate;
CESC	cis	rs1728785	1.000	rs4783653	chr16:68562815	C/T	cg02972257	chr16:68554789	NA	-0.55	-6.45	-0.37	5.28e-10	Ulcerative colitis;
CESC	cis	rs8067354	0.574	rs1295923	chr17:57960436	A/G	cg02344993	chr17:57696989	CLTC	0.54	5.6	0.33	5.31e-8	Hemoglobin concentration;
CESC	cis	rs6952808	0.500	rs3778996	chr7:2177190	G/A	cg02951883	chr7:2050386	MAD1L1	-0.49	-6.43	-0.37	5.78e-10	Bipolar disorder and schizophrenia;
CESC	cis	rs897080	0.515	rs1067366	chr2:44655094	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.47	5.55	0.32	6.87e-8	Height;
CESC	cis	rs11676348	0.846	rs7594532	chr2:219008000	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.45	-5.92	-0.34	9.68e-9	Ulcerative colitis;
CESC	cis	rs3008870	0.755	rs2755271	chr1:67474977	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.62	8.14	0.45	1.57e-14	Lymphocyte percentage of white cells;
CESC	cis	rs2625529	0.526	rs6494997	chr15:72560642	C/T	cg16672083	chr15:72433130	SENP8	0.43	6.46	0.37	4.88e-10	Red blood cell count;
CESC	cis	rs7651736	1.000	rs7651736	chr3:136760598	A/G	cg04103450	chr3:136751342	NA	0.36	5.41	0.32	1.38e-7	Neuroticism;
CESC	cis	rs1215050	0.740	rs783924	chr4:98969234	C/T	cg05340658	chr4:99064831	C4orf37	-0.54	-7.32	-0.41	2.98e-12	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs7020830	0.898	rs308523	chr9:37338785	C/T	cg14294708	chr9:37120828	ZCCHC7	1.11	19.69	0.77	8.52e-54	Schizophrenia;
CESC	cis	rs9814567	1.000	rs4955485	chr3:134295843	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.4	-5.44	-0.32	1.23e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs67072384	0.818	rs2291292	chr11:72467013	C/T	cg04827223	chr11:72435913	ARAP1	-0.72	-7.41	-0.41	1.65e-12	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
CESC	cis	rs6540559	0.673	rs7550857	chr1:209956542	C/A	cg09509183	chr1:209979624	IRF6	0.55	5.67	0.33	3.74e-8	Cleft lip with or without cleft palate;
CESC	cis	rs77956314	0.515	rs9804817	chr12:117440220	G/A	cg25972092	chr12:117363249	FBXW8	-0.54	-5.89	-0.34	1.18e-8	Subcortical brain region volumes;Hippocampal volume;
CESC	cis	rs7666738	0.830	rs13130923	chr4:99046281	T/C	cg24818145	chr4:99064322	C4orf37	0.38	5.04	0.3	8.49e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6502050	0.736	rs12150322	chr17:80061582	T/G	cg23985595	chr17:80112537	CCDC57	0.41	6.28	0.36	1.38e-9	Life satisfaction;
CESC	cis	rs72945132	0.882	rs7929271	chr11:70165749	A/G	cg14191688	chr11:70257035	CTTN	0.43	5.46	0.32	1.08e-7	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15260365	chr11:67771606	UNC93B1	0.57	6.92	0.39	3.31e-11	Gut microbiome composition (summer);
CESC	cis	rs7667	0.960	rs10917437	chr1:19710373	T/C	cg15026089	chr1:19640712	PQLC2	-0.31	-5.18	-0.3	4.43e-7	Crohn's disease and psoriasis;
CESC	cis	rs2180341	1.000	rs7756336	chr6:127650299	T/C	cg27446573	chr6:127587934	RNF146	1.09	16.35	0.71	5.12e-42	Breast cancer;
CESC	cis	rs1799949	0.965	rs799908	chr17:41278916	A/G	cg25072359	chr17:41440525	NA	0.48	7.1	0.4	1.15e-11	Menopause (age at onset);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg01737507	chr5:122372093	PPIC	-0.46	-6.22	-0.36	1.89e-9	Ulcerative colitis;
CESC	cis	rs7772486	0.790	rs11760	chr6:146205973	G/T	cg05347473	chr6:146136440	FBXO30	0.55	7.05	0.4	1.52e-11	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs7132746	0.620	rs61928910	chr12:86195948	A/G	cg06215984	chr1:203258903	NA	-0.56	-6.16	-0.35	2.64e-9	Lewy body disease;
CESC	cis	rs9733	0.596	rs6690725	chr1:150632322	T/C	cg18016565	chr1:150552671	MCL1	0.33	5.13	0.3	5.67e-7	Tonsillectomy;
CESC	cis	rs2841277	0.676	rs10438246	chr14:105410183	T/C	cg19901468	chr14:105411992	AHNAK2	-0.6	-8.78	-0.47	2.07e-16	Rheumatoid arthritis;
CESC	cis	rs9649213	0.555	rs6948346	chr7:97959956	A/G	cg00277769	chr7:97922759	BAIAP2L1	-0.34	-5.57	-0.32	6.25e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs12497850	0.931	rs4974080	chr3:49030828	A/C	cg06212747	chr3:49208901	KLHDC8B	0.73	9.61	0.51	5.84e-19	Parkinson's disease;
CESC	cis	rs7666738	0.830	rs2865979	chr4:99027137	T/C	cg03467027	chr4:99064603	C4orf37	0.49	6.18	0.35	2.44e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs57221529	0.766	rs72703042	chr5:579269	C/T	cg16447950	chr5:562315	NA	-0.62	-6.54	-0.37	3.2e-10	Lung disease severity in cystic fibrosis;
CESC	cis	rs3741151	0.773	rs79994237	chr11:73147974	T/C	cg17517138	chr11:73019481	ARHGEF17	1.0	7.39	0.41	1.91e-12	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs7811142	0.830	rs6948685	chr7:99970188	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.01	10.03	0.52	2.83e-20	Platelet count;
CESC	cis	rs1499614	1.000	rs60326618	chr7:66166358	G/A	cg18252515	chr7:66147081	NA	-1.42	-14.62	-0.67	6.69e-36	Gout;
CESC	cis	rs662064	0.889	rs1188526	chr1:10549848	G/C	cg20482658	chr1:10539492	PEX14	-0.39	-8.0	-0.44	3.93e-14	Asthma;
CESC	trans	rs8073060	0.586	rs225298	chr17:33923946	T/G	cg19694781	chr19:47549865	TMEM160	-0.71	-6.97	-0.39	2.49e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	cis	rs919433	0.963	rs4850787	chr2:198181750	G/A	cg10820045	chr2:198174542	NA	-0.4	-5.64	-0.33	4.39e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs12956009	0.559	rs1893787	chr18:44856030	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.45	5.86	0.34	1.37e-8	Educational attainment (years of education);
CESC	trans	rs3780486	0.957	rs10971434	chr9:33168891	C/A	cg04842962	chr6:43655489	MRPS18A	0.86	12.59	0.61	8.51e-29	IgG glycosylation;
CESC	cis	rs9487051	0.676	rs6568567	chr6:109596993	A/G	cg12927641	chr6:109611667	NA	-0.37	-5.5	-0.32	8.91e-8	Reticulocyte fraction of red cells;
CESC	cis	rs1348850	0.526	rs4893829	chr2:178399810	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.65	-6.01	-0.35	6.12e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs1059312	1.000	rs7970815	chr12:129288366	G/A	cg09035930	chr12:129282057	SLC15A4	0.79	11.2	0.57	4.35e-24	Systemic lupus erythematosus;
CESC	cis	rs477692	1.000	rs473073	chr10:131429646	G/T	cg05714579	chr10:131428358	MGMT	0.51	6.92	0.39	3.31e-11	Response to temozolomide;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg03705947	chr1:68152081	GADD45A	0.5	6.94	0.39	3.09e-11	Systemic lupus erythematosus;
CESC	cis	rs1799949	0.602	rs8176257	chr17:41216205	G/T	cg05368731	chr17:41323189	NBR1	0.72	8.21	0.45	9.49e-15	Menopause (age at onset);
CESC	cis	rs644148	0.803	rs2686771	chr19:44999494	T/C	cg15540054	chr19:45004280	ZNF180	-0.72	-8.44	-0.46	2.12e-15	Personality dimensions;
CESC	cis	rs7592578	0.679	rs4287794	chr2:191327147	T/C	cg27211696	chr2:191398769	TMEM194B	-0.53	-5.38	-0.31	1.63e-7	Diastolic blood pressure;
CESC	trans	rs9858542	0.951	rs1800668	chr3:49395757	G/A	cg21659725	chr3:3221576	CRBN	-0.55	-6.53	-0.37	3.38e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	trans	rs61931739	0.500	rs11513287	chr12:34584351	G/A	cg26384229	chr12:38710491	ALG10B	0.73	10.92	0.56	3.54e-23	Morning vs. evening chronotype;
CESC	cis	rs3015497	0.646	rs2934693	chr14:51101641	C/T	cg26011998	chr14:51135199	SAV1	-0.58	-6.46	-0.37	5.06e-10	Mean platelet volume;
CESC	cis	rs2404602	0.692	rs72738889	chr15:76992063	G/A	cg26408565	chr15:76604113	ETFA	-0.39	-5.58	-0.32	6.05e-8	Blood metabolite levels;
CESC	cis	rs9325144	0.556	rs34565156	chr12:39028239	G/A	cg26384229	chr12:38710491	ALG10B	-0.56	-7.83	-0.43	1.16e-13	Morning vs. evening chronotype;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22461615	chr4:83821917	THAP9	0.61	7.48	0.42	1.11e-12	Gut microbiome composition (summer);
CESC	cis	rs12765878	1.000	rs2067832	chr10:105643134	G/A	cg24587175	chr10:105670608	OBFC1	0.31	5.07	0.3	7.48e-7	Coronary artery disease;
CESC	cis	rs3105593	0.965	rs12442721	chr15:50910813	C/T	cg08437265	chr15:50716283	USP8	0.4	5.13	0.3	5.69e-7	QT interval;
CESC	trans	rs9329221	0.537	rs6983332	chr8:9977918	A/G	cg06636001	chr8:8085503	FLJ10661	-0.46	-6.03	-0.35	5.58e-9	Neuroticism;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg02438591	chr16:2205559	TRAF7;SNORD60	-0.47	-6.03	-0.35	5.37e-9	Ulcerative colitis;
CESC	cis	rs1799949	1.000	rs8176289	chr17:41206056	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.64	8.65	0.47	4.88e-16	Menopause (age at onset);
CESC	cis	rs2645694	0.626	rs2703116	chr4:77824289	C/T	cg18351406	chr4:77819688	ANKRD56	-0.49	-6.09	-0.35	3.98e-9	Emphysema distribution in smoking;
CESC	trans	rs11098499	0.739	rs6534130	chr4:120131339	A/T	cg25214090	chr10:38739885	LOC399744	-0.55	-7.2	-0.4	6.35e-12	Corneal astigmatism;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12867853	chr22:44351301	SAMM50	0.56	6.42	0.37	6.18e-10	Gut microbiome composition (summer);
CESC	trans	rs1814175	0.817	rs10769617	chr11:49810421	G/A	cg03929089	chr4:120376271	NA	-0.91	-15.29	-0.68	2.8900000000000003e-38	Height;
CESC	cis	rs6424115	0.708	rs12748109	chr1:24181177	C/T	cg15997130	chr1:24165203	NA	-0.4	-5.04	-0.3	8.83e-7	Immature fraction of reticulocytes;
CESC	cis	rs6461049	0.765	rs10224497	chr7:2149967	A/G	cg02951883	chr7:2050386	MAD1L1	-0.4	-5.13	-0.3	5.68e-7	Schizophrenia;
CESC	cis	rs9790314	1.000	rs1478565	chr3:161027464	C/T	cg03342759	chr3:160939853	NMD3	-0.45	-5.85	-0.34	1.41e-8	Morning vs. evening chronotype;
CESC	cis	rs1862618	0.713	rs832550	chr5:56182589	C/T	cg24531977	chr5:56204891	C5orf35	-0.87	-10.87	-0.56	5.43e-23	Initial pursuit acceleration;
CESC	cis	rs1448094	0.547	rs7954472	chr12:86166258	T/C	cg00310523	chr12:86230176	RASSF9	0.35	5.71	0.33	3.01e-8	Major depressive disorder;
CESC	cis	rs6062302	0.522	rs13038448	chr20:62218453	C/T	cg06363034	chr20:62225388	GMEB2	-0.52	-6.54	-0.37	3.07e-10	Glioblastoma;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg03000844	chr2:242641386	ING5	-0.4	-6.04	-0.35	5.1e-9	Gambling;
CESC	cis	rs977987	0.806	rs4993970	chr16:75411619	G/A	cg03315344	chr16:75512273	CHST6	0.4	5.74	0.33	2.65e-8	Dupuytren's disease;
CESC	cis	rs2297440	0.530	rs34533955	chr20:62233020	A/C	cg06363034	chr20:62225388	GMEB2	-0.51	-6.58	-0.37	2.52e-10	Glioma;Non-glioblastoma glioma;Glioblastoma;
CESC	cis	rs7666738	0.791	rs6833691	chr4:98951508	A/G	cg03676636	chr4:99064102	C4orf37	0.33	5.12	0.3	5.97e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7937682	0.632	rs14133	chr11:111782697	C/G	cg22437258	chr11:111473054	SIK2	-0.49	-5.51	-0.32	8.46e-8	Primary sclerosing cholangitis;
CESC	cis	rs5758659	0.623	rs133328	chr22:42408079	T/C	cg15557168	chr22:42548783	NA	-0.45	-6.69	-0.38	1.33e-10	Cognitive function;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg24110768	chr12:58159478	CYP27B1	-0.48	-6.29	-0.36	1.28e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs172166	0.694	rs1631552	chr6:28089699	C/A	cg17221315	chr6:27791827	HIST1H4J	0.44	5.84	0.34	1.51e-8	Cardiac Troponin-T levels;
CESC	cis	rs875971	0.660	rs10950044	chr7:66042976	A/G	cg14393609	chr7:65229607	NA	-0.47	-6.31	-0.36	1.16e-9	Aortic root size;
CESC	trans	rs2764766	0.755	rs245314	chr5:127164455	C/T	cg15764593	chr10:829463	NA	0.39	6.15	0.35	2.82e-9	Schizophrenia;
CESC	cis	rs12155623	0.603	rs2203065	chr8:49881987	A/G	cg22283653	chr8:49824208	NA	-0.34	-5.14	-0.3	5.46e-7	Sudden cardiac arrest;
CESC	cis	rs11077998	0.967	rs4789796	chr17:80521135	T/C	cg10255544	chr17:80519551	FOXK2	0.54	8.68	0.47	4.11e-16	Reticulocyte fraction of red cells;
CESC	cis	rs7918232	0.941	rs1775350	chr10:27441973	C/T	cg14442939	chr10:27389572	ANKRD26	-0.67	-6.45	-0.37	5.34e-10	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16786661	chr2:234160315	ATG16L1	0.62	7.34	0.41	2.69e-12	Gut microbiome composition (summer);
CESC	cis	rs13108904	0.967	rs13150571	chr4:1278636	C/G	cg00684032	chr4:1343700	KIAA1530	0.4	5.56	0.32	6.51e-8	Obesity-related traits;
CESC	cis	rs7959452	0.901	rs1384	chr12:69747834	C/T	cg14784868	chr12:69753453	YEATS4	0.6	8.56	0.47	9.5e-16	Blood protein levels;
CESC	cis	rs1552244	0.872	rs6803517	chr3:10065426	C/T	cg08888203	chr3:10149979	C3orf24	0.5	6.33	0.36	1.05e-9	Alzheimer's disease;
CESC	cis	rs4665809	0.877	rs34536218	chr2:26287376	T/A	cg26119090	chr2:26468346	HADHA;HADHB	0.8	8.59	0.47	7.61e-16	Gut microbiome composition (summer);
CESC	trans	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg01341218	chr17:43662625	NA	0.92	10.51	0.54	8.08e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs6570726	0.791	rs387376	chr6:145822565	T/C	cg05347473	chr6:146136440	FBXO30	0.59	7.59	0.42	5.36e-13	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1499614	1.000	rs2707840	chr7:66158015	C/T	cg13147721	chr7:65941812	NA	-0.94	-8.81	-0.48	1.69e-16	Gout;
CESC	cis	rs8018808	1.000	rs12432247	chr14:77856321	T/C	cg20045696	chr14:77926864	AHSA1	-0.38	-5.18	-0.3	4.46e-7	Myeloid white cell count;
CESC	cis	rs4253772	0.550	rs738444	chr22:46721088	C/T	cg18190219	chr22:46762943	CELSR1	-0.44	-5.6	-0.33	5.38e-8	LDL cholesterol;Cholesterol, total;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg09338170	chr1:100436032	SLC35A3	0.45	6.44	0.37	5.68e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs4319547	0.774	rs7307233	chr12:123124301	C/G	cg05707623	chr12:122985044	ZCCHC8	-0.51	-6.12	-0.35	3.43e-9	Body mass index;
CESC	cis	rs10504229	0.953	rs2270610	chr8:58194669	A/G	cg02725872	chr8:58115012	NA	-0.35	-5.12	-0.3	5.93e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs10779751	1.000	rs4845856	chr1:11274547	T/C	cg08854313	chr1:11322531	MTOR	0.91	14.23	0.66	1.61e-34	Body mass index;
CESC	cis	rs7666738	0.830	rs11938686	chr4:98964470	A/G	cg18180107	chr4:99064573	C4orf37	0.39	5.09	0.3	6.72e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9916302	0.904	rs10852933	chr17:37698194	G/T	cg07936489	chr17:37558343	FBXL20	-0.8	-11.62	-0.58	1.73e-25	Glomerular filtration rate (creatinine);
CESC	cis	rs910316	0.967	rs4384542	chr14:75658013	A/C	cg11812906	chr14:75593930	NEK9	-0.86	-14.17	-0.66	2.67e-34	Height;
CESC	cis	rs1862618	0.853	rs2432195	chr5:56120413	C/T	cg12311346	chr5:56204834	C5orf35	-0.72	-8.86	-0.48	1.15e-16	Initial pursuit acceleration;
CESC	cis	rs798554	0.757	rs1182188	chr7:2869985	T/C	cg04166393	chr7:2884313	GNA12	0.6	7.83	0.43	1.14e-13	Height;
CESC	cis	rs6540559	0.673	rs7525951	chr1:210018306	C/T	cg21951975	chr1:209979733	IRF6	-0.55	-6.65	-0.38	1.64e-10	Cleft lip with or without cleft palate;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg17959943	chr7:135194977	CNOT4	-0.44	-6.31	-0.36	1.14e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs854765	0.583	rs8065563	chr17:17782404	A/G	cg09796270	chr17:17721594	SREBF1	0.47	6.5	0.37	3.87e-10	Total body bone mineral density;
CESC	cis	rs870825	0.655	rs12502771	chr4:185635834	T/C	cg04058563	chr4:185651563	MLF1IP	0.62	6.86	0.39	4.91e-11	Blood protein levels;
CESC	cis	rs1023500	0.505	rs134888	chr22:42674281	C/T	cg15557168	chr22:42548783	NA	-0.45	-7.01	-0.4	1.96e-11	Schizophrenia;
CESC	cis	rs4665809	1.000	rs2891490	chr2:26325927	T/C	cg04944784	chr2:26401820	FAM59B	-0.65	-7.4	-0.41	1.8e-12	Gut microbiome composition (summer);
CESC	cis	rs7692995	1.000	rs11936915	chr4:17948497	T/C	cg08925142	chr4:18023851	LCORL	-0.44	-5.1	-0.3	6.36e-7	Height;
CESC	cis	rs1729951	0.575	rs1682356	chr3:136692037	T/C	cg25687071	chr3:136751404	NA	0.4	5.26	0.31	2.93e-7	Neuroticism;
CESC	cis	rs2204008	0.599	rs2320526	chr12:38220405	T/A	cg13010199	chr12:38710504	ALG10B	0.48	5.88	0.34	1.25e-8	Bladder cancer;
CESC	cis	rs6061231	0.798	rs2427308	chr20:60969451	C/T	cg24112000	chr20:60950667	NA	-0.6	-7.28	-0.41	3.89e-12	Colorectal cancer;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg16965475	chr1:52870119	ORC1L;PRPF38A	-0.53	-6.3	-0.36	1.2e-9	Ulcerative colitis;
CESC	cis	rs35306767	0.953	rs10904583	chr10:983498	T/C	cg25019033	chr10:957182	NA	-0.64	-7.9	-0.44	7.56e-14	Eosinophil percentage of granulocytes;
CESC	cis	rs1799949	0.501	rs35399157	chr17:41411602	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	8.6	0.47	6.99e-16	Menopause (age at onset);
CESC	cis	rs796364	0.715	rs11688872	chr2:201052418	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.77	-6.51	-0.37	3.76e-10	Schizophrenia;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg07116015	chr17:27046591	RAB34;SNORD42B;RPL23A	-0.52	-6.51	-0.37	3.72e-10	Ulcerative colitis;
CESC	cis	rs2576037	0.583	rs641366	chr18:44430326	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.52	-7.19	-0.4	6.61e-12	Personality dimensions;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg07339812	chr16:25268887	ZKSCAN2	-0.51	-6.42	-0.37	6.26e-10	Asthma;
CESC	cis	rs10479542	0.784	rs7703730	chr5:178986632	C/A	cg09060608	chr5:178986726	RUFY1	-0.51	-7.52	-0.42	8.3e-13	Lung cancer;
CESC	cis	rs78456975	0.527	rs10206020	chr2:1557927	A/G	cg26248373	chr2:1572462	NA	-0.55	-6.54	-0.37	3.24e-10	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs6933660	0.745	rs6912830	chr6:151743629	A/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.53	-6.98	-0.39	2.35e-11	Menarche (age at onset);
CESC	cis	rs698833	0.926	rs1065786	chr2:44660616	G/T	cg18685995	chr2:44588913	PREPL;C2orf34	-0.45	-5.89	-0.34	1.18e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs651907	0.557	rs11914318	chr3:101453858	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.45	5.88	0.34	1.22e-8	Colorectal cancer;
CESC	cis	rs2795502	1.000	rs2744092	chr10:43339343	T/C	cg27426351	chr10:43362370	NA	-0.45	-5.5	-0.32	8.91e-8	Blood protein levels;
CESC	cis	rs61931739	0.749	rs11053093	chr12:34231095	A/G	cg19457237	chr12:34500585	NA	-0.38	-5.45	-0.32	1.15e-7	Morning vs. evening chronotype;
CESC	cis	rs6500602	1.000	rs6500602	chr16:4497451	T/C	cg08645402	chr16:4508243	NA	0.44	6.65	0.38	1.71e-10	Schizophrenia;
CESC	cis	rs3126085	0.935	rs7533529	chr1:152176871	T/C	cg03465714	chr1:152285911	FLG	-0.46	-5.59	-0.32	5.7e-8	Atopic dermatitis;
CESC	cis	rs7107174	0.792	rs10899488	chr11:78088754	A/G	cg02023728	chr11:77925099	USP35	0.44	5.85	0.34	1.48e-8	Testicular germ cell tumor;
CESC	trans	rs17685	0.712	rs4732578	chr7:75721532	A/G	cg19862616	chr7:65841803	NCRNA00174	0.85	12.47	0.61	2.13e-28	Coffee consumption;Coffee consumption (cups per day);
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg09665691	chr3:47563885	NA	0.49	6.13	0.35	3.26e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs62103177	0.810	rs62103192	chr18:77629050	A/T	cg12964065	chr18:77638022	KCNG2	0.58	5.46	0.32	1.07e-7	Opioid sensitivity;
CESC	cis	rs12188164	0.610	rs6555242	chr5:416546	A/C	cg15813090	chr5:442598	EXOC3;C5orf55	0.36	5.74	0.33	2.53e-8	Cystic fibrosis severity;
CESC	cis	rs10504229	1.000	rs75037501	chr8:58170136	T/G	cg05313129	chr8:58192883	C8orf71	-0.55	-6.29	-0.36	1.31e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs10461617	0.592	rs6450403	chr5:56062737	A/C	cg22800045	chr5:56110881	MAP3K1	0.63	7.94	0.44	5.83e-14	Type 2 diabetes;
CESC	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg02353165	chr6:42928485	GNMT	0.86	14.79	0.67	1.73e-36	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg11965913	chr1:205819406	PM20D1	0.64	10.52	0.54	7.26e-22	Monocyte percentage of white cells;
CESC	cis	rs8016982	0.962	rs8007841	chr14:81647878	C/T	cg01989461	chr14:81687754	GTF2A1	-0.48	-6.15	-0.35	2.9e-9	Schizophrenia;
CESC	cis	rs4713118	0.587	rs9393899	chr6:28133528	G/C	cg18032046	chr6:28092343	ZSCAN16	-0.57	-6.49	-0.37	4.32e-10	Parkinson's disease;
CESC	cis	rs3793683	0.556	rs2803989	chr10:134560596	C/T	cg18305652	chr10:134549665	INPP5A	0.48	7.57	0.42	6.08e-13	Migraine;
CESC	cis	rs10208940	0.920	rs13400155	chr2:68723636	G/A	cg12452813	chr2:68675892	NA	0.52	5.24	0.31	3.26e-7	Urate levels in lean individuals;
CESC	trans	rs9929218	0.953	rs12930910	chr16:68762520	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.75	-9.88	-0.52	8.58e-20	Colorectal cancer;
CESC	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg06877462	chr1:205807181	PM20D1	0.39	5.84	0.34	1.51e-8	Menarche (age at onset);
CESC	cis	rs10484885	0.763	rs56401039	chr6:90522486	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.75	-7.12	-0.4	1.04e-11	QRS interval (sulfonylurea treatment interaction);
CESC	cis	rs12983728	1.000	rs12983728	chr19:58671267	G/A	cg24884572	chr19:58661833	ZNF329	0.55	5.26	0.31	2.92e-7	Cholesterol, total;
CESC	cis	rs7296418	0.754	rs1619283	chr12:123717362	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.32	-5.05	-0.3	8.18e-7	Platelet count;
CESC	cis	rs3087591	0.960	rs4795587	chr17:29587917	A/C	cg24425628	chr17:29625626	OMG;NF1	-0.47	-5.73	-0.33	2.66e-8	Hip circumference;
CESC	cis	rs698833	0.506	rs4952705	chr2:44499867	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.46	5.13	0.3	5.66e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs791888	0.965	rs791875	chr10:89406088	C/T	cg13926569	chr10:89418898	PAPSS2	-0.4	-5.43	-0.32	1.3e-7	Magnesium levels;
CESC	cis	rs6860806	0.632	rs4330455	chr5:131586349	T/C	cg04518342	chr5:131593106	PDLIM4	0.4	6.01	0.35	6.19e-9	Breast cancer;
CESC	cis	rs77216612	0.835	rs10845621	chr12:12887977	C/T	cg09462578	chr12:12878428	APOLD1	-0.98	-14.75	-0.67	2.29e-36	Lymphocyte counts;
CESC	cis	rs11122272	0.735	rs2572253	chr1:231512768	C/A	cg06096015	chr1:231504339	EGLN1	0.43	6.18	0.35	2.46e-9	Hemoglobin concentration;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg13078969	chr12:1799970	ADIPOR2	0.39	6.04	0.35	5.06e-9	Gambling;
CESC	cis	rs916888	0.773	rs199443	chr17:44819565	C/T	cg15921436	chr17:44337874	NA	0.74	8.12	0.45	1.79e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs6499255	0.951	rs689455	chr16:69761661	T/G	cg15192750	chr16:69999425	NA	0.51	5.91	0.34	1.07e-8	IgE levels;
CESC	cis	rs7246657	0.943	rs7259968	chr19:37811854	T/C	cg23950597	chr19:37808831	NA	-0.57	-6.33	-0.36	1.06e-9	Coronary artery calcification;
CESC	cis	rs4835473	0.897	rs1553070	chr4:144637134	C/T	cg25736465	chr4:144833511	NA	0.39	6.12	0.35	3.39e-9	Immature fraction of reticulocytes;
CESC	cis	rs6912958	0.559	rs1201409	chr6:88055264	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.48	8.36	0.46	3.54e-15	Monocyte percentage of white cells;
CESC	cis	rs1124376	1.000	rs17006623	chr3:20161043	G/T	cg05072819	chr3:20081367	KAT2B	0.49	5.35	0.31	1.93e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs921968	0.508	rs72965103	chr2:219312469	T/C	cg02176678	chr2:219576539	TTLL4	-0.52	-9.12	-0.49	1.96e-17	Mean corpuscular hemoglobin concentration;
CESC	cis	rs4654899	0.743	rs61781069	chr1:21130735	T/C	cg05370193	chr1:21551575	ECE1	0.41	5.87	0.34	1.28e-8	Superior frontal gyrus grey matter volume;
CESC	cis	rs9611565	0.802	rs73176692	chr22:41785735	G/A	cg17376030	chr22:41985996	PMM1	0.67	7.19	0.4	6.44e-12	Vitiligo;
CESC	cis	rs9837602	1.000	rs9851645	chr3:99767409	G/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.54	7.56	0.42	6.43e-13	Breast cancer;
CESC	cis	rs4835473	0.864	rs7681559	chr4:144616401	T/C	cg25736465	chr4:144833511	NA	-0.42	-6.22	-0.36	1.95e-9	Immature fraction of reticulocytes;
CESC	cis	rs7666738	0.830	rs7663661	chr4:99014761	A/G	cg03676636	chr4:99064102	C4orf37	0.33	5.16	0.3	4.86e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs35110281	0.626	rs162389	chr21:44936227	T/C	cg01579765	chr21:45077557	HSF2BP	-0.49	-8.76	-0.47	2.41e-16	Mean corpuscular volume;
CESC	cis	rs7666738	0.830	rs79075162	chr4:98960674	A/T	cg18180107	chr4:99064573	C4orf37	0.4	5.14	0.3	5.26e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs17376456	0.825	rs74825443	chr5:93254973	T/C	cg25358565	chr5:93447407	FAM172A	1.13	10.44	0.54	1.31e-21	Diabetic retinopathy;
CESC	cis	rs6540559	1.000	rs742214	chr1:209960925	T/C	cg22442454	chr1:209979470	IRF6	0.45	5.34	0.31	2.02e-7	Cleft lip with or without cleft palate;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg14344315	chr15:31733445	NA	0.43	6.01	0.35	6.11e-9	Thyroid stimulating hormone;
CESC	cis	rs2576037	0.526	rs605487	chr18:44444778	G/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.57	-7.94	-0.44	5.73e-14	Personality dimensions;
CESC	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg16145915	chr7:1198662	ZFAND2A	-0.49	-7.1	-0.4	1.17e-11	Longevity;Endometriosis;
CESC	cis	rs7618915	0.547	rs34537256	chr3:52657472	A/G	cg18099408	chr3:52552593	STAB1	-0.32	-5.19	-0.3	4.2e-7	Bipolar disorder;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg12525736	chr1:228269915	ARF1	-0.49	-6.04	-0.35	5.16e-9	Ulcerative colitis;
CESC	cis	rs4474465	0.850	rs10793328	chr11:78256868	A/G	cg02023728	chr11:77925099	USP35	-0.38	-5.04	-0.3	8.62e-7	Alzheimer's disease (survival time);
CESC	cis	rs780096	0.526	rs780117	chr2:27698343	C/G	cg02592271	chr2:27665507	KRTCAP3	-0.29	-5.82	-0.34	1.68e-8	Total body bone mineral density;
CESC	cis	rs35306767	0.953	rs10904581	chr10:964685	A/T	cg25019033	chr10:957182	NA	-0.65	-8.19	-0.45	1.08e-14	Eosinophil percentage of granulocytes;
CESC	trans	rs1814175	0.754	rs28593359	chr11:50042357	C/T	cg03929089	chr4:120376271	NA	-0.94	-15.73	-0.69	7.69e-40	Height;
CESC	cis	rs796364	0.806	rs79156935	chr2:200913822	T/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.84	-7.75	-0.43	1.94e-13	Schizophrenia;
CESC	cis	rs7959452	0.558	rs1478464	chr12:69779789	G/C	cg20891283	chr12:69753455	YEATS4	0.87	14.05	0.65	6.94e-34	Blood protein levels;
CESC	trans	rs11039798	0.588	rs11039781	chr11:48523085	T/G	cg15704280	chr7:45808275	SEPT13	0.65	6.56	0.37	2.84e-10	Axial length;
CESC	cis	rs2050392	0.687	rs608693	chr10:30734971	G/A	cg25182066	chr10:30743637	MAP3K8	-0.48	-6.44	-0.37	5.64e-10	Inflammatory bowel disease;
CESC	cis	rs2760061	0.659	rs708107	chr1:228189495	C/T	cg18477163	chr1:228402036	OBSCN	0.3	5.19	0.3	4.25e-7	Diastolic blood pressure;
CESC	cis	rs9303401	0.538	rs12603174	chr17:56489279	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.9	11.03	0.56	1.6e-23	Cognitive test performance;
CESC	cis	rs7762018	1.000	rs73242910	chr6:170114670	A/G	cg13891659	chr6:170190454	C6orf122;C6orf208	0.52	5.27	0.31	2.86e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs7264396	0.790	rs6060530	chr20:34227663	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.85	-10.31	-0.54	3.47e-21	Total cholesterol levels;
CESC	cis	rs7666738	0.830	rs991168	chr4:98928293	T/C	cg05340658	chr4:99064831	C4orf37	0.82	12.2	0.6	1.81e-27	Colonoscopy-negative controls vs population controls;
CESC	cis	rs73206853	0.841	rs73191819	chr12:110920182	C/T	cg12870014	chr12:110450643	ANKRD13A	0.63	5.22	0.31	3.56e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs477692	0.569	rs1762418	chr10:131303353	G/A	cg05714579	chr10:131428358	MGMT	0.39	5.26	0.31	2.9e-7	Response to temozolomide;
CESC	trans	rs3780486	0.522	rs10217770	chr9:33146393	C/A	cg04842962	chr6:43655489	MRPS18A	0.66	9.82	0.52	1.33e-19	IgG glycosylation;
CESC	trans	rs804280	0.542	rs35647515	chr8:11791629	C/T	cg15556689	chr8:8085844	FLJ10661	0.51	6.36	0.36	8.66e-10	Myopia (pathological);
CESC	cis	rs208520	0.690	rs12189780	chr6:66759619	G/A	cg07460842	chr6:66804631	NA	0.96	12.78	0.62	1.92e-29	Exhaled nitric oxide output;
CESC	cis	rs11122272	0.735	rs2011357	chr1:231480208	A/G	cg06096015	chr1:231504339	EGLN1	0.44	6.29	0.36	1.31e-9	Hemoglobin concentration;
CESC	cis	rs6061231	0.837	rs6121558	chr20:60961365	A/G	cg22633769	chr20:60982531	CABLES2	0.5	5.12	0.3	5.95e-7	Colorectal cancer;
CESC	cis	rs116095464	0.510	rs73016876	chr5:244475	T/C	cg22857025	chr5:266934	NA	-1.26	-17.43	-0.73	7.56e-46	Breast cancer;
CESC	cis	rs3820068	0.603	rs7529759	chr1:15977877	A/G	cg13390004	chr1:15929781	NA	0.36	5.68	0.33	3.52e-8	Systolic blood pressure;
CESC	cis	rs1799949	1.000	rs34942571	chr17:41273379	G/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.44	5.89	0.34	1.16e-8	Menopause (age at onset);
CESC	cis	rs1552244	0.935	rs7652190	chr3:10105150	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	11.78	0.59	4.93e-26	Alzheimer's disease;
CESC	cis	rs1799949	0.894	rs71367985	chr17:41374463	G/A	cg05368731	chr17:41323189	NBR1	0.61	8.28	0.45	6.11e-15	Menopause (age at onset);
CESC	cis	rs1552244	1.000	rs6764168	chr3:10123805	A/G	cg08888203	chr3:10149979	C3orf24	0.52	6.65	0.38	1.63e-10	Alzheimer's disease;
CESC	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg05552183	chr6:42928497	GNMT	0.78	12.94	0.62	5.31e-30	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs727505	1.000	rs12111865	chr7:124498035	G/A	cg23710748	chr7:124431027	NA	-0.4	-6.47	-0.37	4.6e-10	Lewy body disease;
CESC	cis	rs4819052	0.851	rs2838856	chr21:46680766	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.86	12.44	0.61	2.65e-28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs9527	0.615	rs11191489	chr10:104740568	C/A	cg08650961	chr10:104748594	CNNM2	0.32	5.08	0.3	6.98e-7	Arsenic metabolism;
CESC	cis	rs11264213	0.901	rs72661641	chr1:36448130	A/G	cg27506609	chr1:36549197	TEKT2	0.67	5.56	0.32	6.59e-8	Schizophrenia;
CESC	cis	rs7107174	1.000	rs1485483	chr11:77930138	T/C	cg02023728	chr11:77925099	USP35	0.5	6.18	0.36	2.38e-9	Testicular germ cell tumor;
CESC	cis	rs3936840	0.861	rs1044502	chr14:102965897	G/A	cg18135206	chr14:102964638	TECPR2	0.41	5.46	0.32	1.11e-7	Plateletcrit;
CESC	cis	rs6460942	0.778	rs76030612	chr7:12462937	C/A	cg10578991	chr7:12443926	VWDE	-0.43	-5.55	-0.32	6.81e-8	Coronary artery disease;
CESC	cis	rs7542091	0.669	rs7540534	chr1:210044824	A/T	cg23283495	chr1:209979779	IRF6	0.35	5.8	0.34	1.84e-8	Monobrow;
CESC	cis	rs1153858	1.000	rs4775906	chr15:45638294	C/T	cg14582100	chr15:45693742	SPATA5L1	0.42	6.08	0.35	4.2e-9	Homoarginine levels;
CESC	cis	rs2228479	0.681	rs11642428	chr16:89971909	A/T	cg00800038	chr16:89945340	TCF25	-0.58	-6.27	-0.36	1.44e-9	Skin colour saturation;
CESC	cis	rs13118159	0.651	rs4974599	chr4:1314430	A/C	cg05025164	chr4:1340916	KIAA1530	0.58	7.94	0.44	5.63e-14	Longevity;
CESC	cis	rs9902453	0.845	rs3115099	chr17:28019293	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	8.53	0.46	1.15e-15	Coffee consumption (cups per day);
CESC	cis	rs870825	0.616	rs6817521	chr4:185649827	A/G	cg04058563	chr4:185651563	MLF1IP	-0.67	-7.14	-0.4	8.9e-12	Blood protein levels;
CESC	cis	rs1577917	1.000	rs12201880	chr6:86627007	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.44	-5.78	-0.33	2.14e-8	Response to antipsychotic treatment;
CESC	cis	rs3540	0.533	rs2601197	chr15:90940059	C/A	cg22089800	chr15:90895588	ZNF774	0.63	8.72	0.47	3.02e-16	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs9287719	0.967	rs12995159	chr2:10753323	C/T	cg00105475	chr2:10696890	NA	0.38	5.42	0.32	1.34e-7	Prostate cancer;
CESC	cis	rs12780046	0.536	rs7914788	chr10:101063589	C/T	cg27143070	chr10:101087766	CNNM1	-0.37	-5.44	-0.32	1.21e-7	Non-glioblastoma glioma;
CESC	cis	rs17376456	0.542	rs2084916	chr5:93194961	A/T	cg25358565	chr5:93447407	FAM172A	-0.7	-7.43	-0.42	1.45e-12	Diabetic retinopathy;
CESC	cis	rs7666738	0.830	rs13111977	chr4:98953813	G/A	cg17366294	chr4:99064904	C4orf37	0.6	8.47	0.46	1.72e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6977660	0.652	rs58559474	chr7:19751569	C/T	cg07541023	chr7:19748670	TWISTNB	0.82	7.27	0.41	4.17e-12	Thyroid stimulating hormone;
CESC	cis	rs10129255	0.957	rs8022165	chr14:107189919	C/G	cg07958169	chr14:107095056	NA	-0.4	-5.54	-0.32	7.3e-8	Kawasaki disease;
CESC	cis	rs2297440	0.527	rs4809318	chr20:62264760	G/A	cg09650180	chr20:62225654	GMEB2	-0.81	-9.1	-0.49	2.31e-17	Glioma;Non-glioblastoma glioma;Glioblastoma;
CESC	cis	rs703842	1.000	rs10877013	chr12:58165085	C/T	cg18357645	chr12:58087776	OS9	-0.38	-5.42	-0.32	1.34e-7	Multiple sclerosis;
CESC	trans	rs4927850	1.000	rs7630875	chr3:195753766	A/G	cg16724585	chr3:197361211	NA	-0.55	-6.97	-0.39	2.54e-11	Pancreatic cancer;
CESC	cis	rs13382862	0.862	rs340595	chr2:20889714	A/G	cg09074113	chr2:20870087	GDF7	-0.42	-6.87	-0.39	4.56e-11	Abdominal aortic aneurysm;
CESC	cis	rs1983891	0.706	rs9381084	chr6:41570350	C/T	cg20194872	chr6:41519635	FOXP4	0.46	6.56	0.37	2.75e-10	Prostate cancer;
CESC	cis	rs6570726	0.738	rs7746330	chr6:145899257	A/C	cg05347473	chr6:146136440	FBXO30	0.58	7.57	0.42	6.18e-13	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4665809	0.818	rs35413760	chr2:26267137	C/A	cg26314531	chr2:26401878	FAM59B	0.69	7.36	0.41	2.27e-12	Gut microbiome composition (summer);
CESC	cis	rs10751667	0.666	rs10902248	chr11:957742	A/G	cg06064525	chr11:970664	AP2A2	-0.48	-9.52	-0.5	1.15e-18	Alzheimer's disease (late onset);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg19818298	chr14:21905552	CHD8	-0.43	-6.23	-0.36	1.8e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs524281	0.648	rs4565902	chr11:65810045	T/G	cg14036092	chr11:66035641	RAB1B	-0.57	-5.42	-0.32	1.37e-7	Electroencephalogram traits;
CESC	cis	rs11203032	0.831	rs10887929	chr10:90948864	T/C	cg16672925	chr10:90967113	CH25H	0.72	7.16	0.4	7.78e-12	Heart failure;
CESC	cis	rs6693567	0.516	rs3850844	chr1:150413940	G/T	cg09579323	chr1:150459698	TARS2	0.48	6.0	0.35	6.34e-9	Migraine;
CESC	cis	rs12956009	0.583	rs16952069	chr18:44904220	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.48	6.11	0.35	3.5e-9	Educational attainment (years of education);
CESC	cis	rs4901869	0.902	rs2162491	chr14:59296247	C/T	cg02291164	chr14:59296302	NA	0.46	8.07	0.44	2.41e-14	Panic disorder;
CESC	cis	rs7592578	0.723	rs4371384	chr2:191430741	A/G	cg27211696	chr2:191398769	TMEM194B	0.64	5.81	0.34	1.81e-8	Diastolic blood pressure;
CESC	cis	rs2439831	0.867	rs2278860	chr15:43659046	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.85	-12.75	-0.62	2.26e-29	Lung cancer in ever smokers;
CESC	cis	rs2629540	0.731	rs11245341	chr10:126408777	G/C	cg08799069	chr10:126477246	METTL10	0.6	7.51	0.42	8.93e-13	Cocaine dependence;
CESC	cis	rs57221529	0.766	rs12522303	chr5:555564	A/C	cg16447950	chr5:562315	NA	-0.7	-7.76	-0.43	1.9e-13	Lung disease severity in cystic fibrosis;
CESC	cis	rs2845885	0.793	rs56241103	chr11:63882364	C/T	cg26318627	chr11:63887540	MACROD1	-0.46	-5.46	-0.32	1.1e-7	Body mass index;
CESC	cis	rs10504229	0.645	rs6995814	chr8:58114159	C/T	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs4466137	0.951	rs336958	chr5:82973396	A/G	cg16102102	chr5:83017553	HAPLN1	-0.4	-5.44	-0.32	1.18e-7	Prostate cancer;
CESC	cis	rs4820539	0.902	rs9612237	chr22:23472954	T/C	cg14186256	chr22:23484241	RTDR1	0.81	14.46	0.66	2.43e-35	Bone mineral density;
CESC	cis	rs9325144	0.600	rs61931871	chr12:38829889	G/A	cg26384229	chr12:38710491	ALG10B	-0.57	-7.94	-0.44	5.9e-14	Morning vs. evening chronotype;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg08426800	chr19:1229184	NA	0.46	6.07	0.35	4.49e-9	Fibrinogen levels;
CESC	cis	rs896854	0.517	rs896851	chr8:95950251	T/C	cg13393036	chr8:95962371	TP53INP1	-0.44	-7.83	-0.43	1.21e-13	Type 2 diabetes;
CESC	cis	rs7100689	0.646	rs1572819	chr10:82112488	A/G	cg00277334	chr10:82204260	NA	-0.61	-8.01	-0.44	3.56e-14	Post bronchodilator FEV1;
CESC	cis	rs6460942	0.597	rs35317839	chr7:12524397	C/A	cg10578991	chr7:12443926	VWDE	-0.49	-5.13	-0.3	5.63e-7	Coronary artery disease;
CESC	cis	rs1316952	0.831	rs77732168	chr12:124392120	G/C	cg00084347	chr12:124393913	DNAH10	0.41	5.68	0.33	3.56e-8	Visceral adipose tissue adjusted for BMI;Visceral adipose tissue/subcutaneous adipose tissue ratio;
CESC	cis	rs711245	0.573	rs3770796	chr2:36799515	T/C	cg09467607	chr2:36825704	FEZ2	0.57	9.98	0.52	3.98e-20	Height;
CESC	cis	rs9300255	0.544	rs1716157	chr12:123670473	T/C	cg00376283	chr12:123451042	ABCB9	0.71	8.71	0.47	3.27e-16	Neutrophil percentage of white cells;
CESC	cis	rs11696501	0.739	rs6104257	chr20:44262100	G/T	cg11783356	chr20:44313418	WFDC10B	-0.34	-5.29	-0.31	2.54e-7	Brain structure;
CESC	cis	rs77106637	0.932	rs17244499	chr11:72629946	C/T	cg04827223	chr11:72435913	ARAP1	0.52	5.49	0.32	9.64e-8	Type 2 diabetes;
CESC	cis	rs7618915	0.547	rs8906	chr3:52739520	T/C	cg18099408	chr3:52552593	STAB1	-0.32	-5.2	-0.3	4.03e-7	Bipolar disorder;
CESC	cis	rs922182	0.633	rs4776698	chr15:64267534	C/A	cg24729988	chr15:64271149	DAPK2	-0.48	-6.82	-0.39	6.32e-11	Blood protein levels;
CESC	cis	rs2404602	0.536	rs11072599	chr15:76774508	T/C	cg22467129	chr15:76604101	ETFA	-0.38	-5.82	-0.34	1.69e-8	Blood metabolite levels;
CESC	cis	rs780096	0.546	rs35073769	chr2:27731376	C/T	cg24768116	chr2:27665128	KRTCAP3	-0.33	-5.89	-0.34	1.18e-8	Total body bone mineral density;
CESC	cis	rs2730245	0.592	rs2657385	chr7:158649373	A/G	cg24397884	chr7:158709396	WDR60	0.67	9.71	0.51	2.83e-19	Height;
CESC	cis	rs6543140	1.000	rs6543140	chr2:103074274	G/T	cg04239558	chr2:103089729	SLC9A4	0.47	6.16	0.35	2.64e-9	Blood protein levels;
CESC	cis	rs6502050	0.799	rs7212023	chr17:80170354	G/A	cg23985595	chr17:80112537	CCDC57	-0.42	-6.67	-0.38	1.48e-10	Life satisfaction;
CESC	cis	rs4665809	0.590	rs17528653	chr2:26507724	T/C	cg08470875	chr2:26401718	FAM59B	0.69	6.74	0.38	1.01e-10	Gut microbiome composition (summer);
CESC	cis	rs2439831	0.850	rs3825783	chr15:44102309	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.64	5.81	0.34	1.77e-8	Lung cancer in ever smokers;
CESC	cis	rs4820294	0.926	rs62236671	chr22:38069305	G/A	cg21798802	chr22:38057573	PDXP	0.46	7.89	0.44	8.23e-14	Fat distribution (HIV);
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg02357389	chr12:82752162	CCDC59;C12orf26	-0.45	-6.12	-0.35	3.39e-9	Thyroid stimulating hormone;
CESC	cis	rs6547741	0.874	rs28381983	chr2:27804432	T/C	cg27432699	chr2:27873401	GPN1	0.49	6.63	0.38	1.89e-10	Oral cavity cancer;
CESC	cis	rs892961	0.932	rs11657725	chr17:75405501	G/C	cg05865280	chr17:75406074	SEPT9	0.59	10.95	0.56	2.82e-23	Airflow obstruction;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13656025	chr17:7744978	KDM6B	0.63	7.48	0.42	1.1e-12	Gut microbiome composition (summer);
CESC	trans	rs7107217	1.000	rs1873872	chr11:129473993	A/T	cg26085966	chr14:64319812	SYNE2	0.53	6.73	0.38	1.06e-10	Breast cancer;Type 2 diabetes;
CESC	cis	rs72945132	0.882	rs6592522	chr11:70128271	G/A	cg00319359	chr11:70116639	PPFIA1	0.79	7.55	0.42	6.95e-13	Coronary artery disease;
CESC	trans	rs12659622	0.790	rs10454921	chr5:15676169	C/T	cg22457238	chr19:58570995	ZNF135	-0.51	-6.01	-0.35	6.11e-9	Obesity-related traits;
CESC	cis	rs12220238	1.000	rs11000894	chr10:75906598	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.64	6.23	0.36	1.87e-9	Soluble interleukin-2 receptor subunit alpha;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg22234897	chr17:7826291	KCNAB3	0.44	6.1	0.35	3.84e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs208520	0.770	rs2224422	chr6:66883993	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.92	-11.49	-0.58	4.62e-25	Exhaled nitric oxide output;
CESC	cis	rs10504229	1.000	rs58371676	chr8:58189382	G/A	cg22535103	chr8:58192502	C8orf71	-1.05	-13.08	-0.63	1.71e-30	Developmental language disorder (linguistic errors);
CESC	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg03188948	chr7:1209495	NA	0.57	6.45	0.37	5.21e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs11048434	0.736	rs933462	chr12:9103665	T/G	cg04155231	chr12:9217510	LOC144571	0.32	5.06	0.3	7.79e-7	Sjögren's syndrome;
CESC	cis	rs6570726	0.846	rs973856	chr6:145781916	C/T	cg05347473	chr6:146136440	FBXO30	-0.45	-6.02	-0.35	5.81e-9	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7666738	0.830	rs13110903	chr4:98946373	A/G	cg03467027	chr4:99064603	C4orf37	0.46	5.82	0.34	1.74e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10733682	0.659	rs867560	chr9:129465233	C/G	cg00232160	chr9:129468157	NA	-0.37	-5.81	-0.34	1.78e-8	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.49	-5.2	-0.3	4.06e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs1881797	1.000	rs12061460	chr1:247686787	G/A	cg18198730	chr1:247681584	NA	0.59	7.76	0.43	1.84e-13	Acute lymphoblastic leukemia (childhood);
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg20685215	chr8:10696571	PINX1	-0.45	-6.04	-0.35	5.12e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs6940638	0.688	rs1028308	chr6:27129757	G/A	cg12292205	chr6:26970375	C6orf41	-0.4	-5.43	-0.32	1.3e-7	Intelligence (multi-trait analysis);
CESC	cis	rs4588572	0.644	rs10805920	chr5:77698222	G/A	cg11547950	chr5:77652471	NA	-0.4	-5.69	-0.33	3.33e-8	Triglycerides;
CESC	cis	rs8177253	0.965	rs8177245	chr3:133479230	A/G	cg12373951	chr3:133503437	NA	0.42	6.09	0.35	4.03e-9	Iron status biomarkers;
CESC	cis	rs2070433	0.851	rs10854484	chr21:47926702	T/C	cg12379764	chr21:47803548	PCNT	0.5	6.08	0.35	4.26e-9	Lymphocyte counts;
CESC	cis	rs9733	0.566	rs112967224	chr1:150677263	G/A	cg09365446	chr1:150670422	GOLPH3L	0.42	5.9	0.34	1.09e-8	Tonsillectomy;
CESC	cis	rs131777	0.575	rs963980	chr22:51022117	C/A	cg25309564	chr22:51001381	C22orf41	0.62	7.96	0.44	5.08e-14	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	cis	rs10479542	0.642	rs6879665	chr5:178974581	T/A	cg05457628	chr5:178986728	RUFY1	0.45	6.11	0.35	3.46e-9	Lung cancer;
CESC	cis	rs9311474	0.508	rs12629701	chr3:52619836	T/C	cg05564831	chr3:52568323	NT5DC2	0.47	7.24	0.41	4.73e-12	Electroencephalogram traits;
CESC	cis	rs894344	0.584	rs11985416	chr8:135634005	A/G	cg27224718	chr8:135614730	ZFAT	0.38	5.07	0.3	7.37e-7	Systolic blood pressure;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg27139841	chr20:44718745	NCOA5	-0.44	-6.37	-0.36	8.47e-10	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs12155623	0.803	rs7011862	chr8:49817333	C/G	cg22283653	chr8:49824208	NA	0.37	5.36	0.31	1.83e-7	Sudden cardiac arrest;
CESC	cis	rs7202877	0.656	rs977986	chr16:75506696	T/G	cg03315344	chr16:75512273	CHST6	0.53	5.08	0.3	7.03e-7	Type 2 diabetes;Type 1 diabetes;
CESC	cis	rs7666738	0.791	rs62318907	chr4:99037120	C/T	cg03676636	chr4:99064102	C4orf37	0.33	5.09	0.3	6.71e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs611744	0.647	rs631775	chr8:109252746	T/C	cg21045802	chr8:109455806	TTC35	0.46	5.66	0.33	3.95e-8	Dupuytren's disease;
CESC	cis	rs11190604	1.000	rs4919464	chr10:102221195	A/G	cg07080220	chr10:102295463	HIF1AN	0.55	5.51	0.32	8.5e-8	Palmitoleic acid (16:1n-7) levels;
CESC	trans	rs116095464	0.558	rs10080225	chr5:232175	A/G	cg00938859	chr5:1591904	SDHAP3	0.63	6.87	0.39	4.6e-11	Breast cancer;
CESC	cis	rs2243480	1.000	rs73150014	chr7:65450919	A/C	cg12463550	chr7:65579703	CRCP	0.68	5.46	0.32	1.09e-7	Diabetic kidney disease;
CESC	cis	rs4253772	0.938	rs41355347	chr22:46637511	G/A	cg00784671	chr22:46762841	CELSR1	-0.57	-5.63	-0.33	4.54e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs367615	0.680	rs1103198	chr5:108973583	G/T	cg17395555	chr5:108820864	NA	0.4	5.46	0.32	1.09e-7	Colorectal cancer (SNP x SNP interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04567173	chr4:25379221	ANAPC4	0.66	7.18	0.4	6.82e-12	Gut microbiome composition (summer);
CESC	cis	rs9715521	1.000	rs9715521	chr4:59824487	G/A	cg11281224	chr4:60001000	NA	-0.51	-6.67	-0.38	1.45e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs801193	0.569	rs881285	chr7:66119420	A/G	cg18252515	chr7:66147081	NA	0.48	6.43	0.37	5.77e-10	Aortic root size;
CESC	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg23131131	chr22:24373011	LOC391322	-0.73	-10.2	-0.53	7.73e-21	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs6580649	0.769	rs60629297	chr12:48438290	T/A	cg24011408	chr12:48396354	COL2A1	-0.43	-5.37	-0.31	1.71e-7	Lung cancer;
CESC	cis	rs9303401	0.703	rs9910629	chr17:57210301	C/G	cg12560992	chr17:57184187	TRIM37	0.48	5.74	0.33	2.52e-8	Cognitive test performance;
CESC	cis	rs28647808	0.881	rs7029256	chr9:136263655	T/C	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.84	5.73	0.33	2.7e-8	Blood protein levels;
CESC	cis	rs897984	0.770	rs12930657	chr16:30931968	C/T	cg00531865	chr16:30841666	NA	0.51	7.12	0.4	1.01e-11	Dementia with Lewy bodies;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27367093	chr11:72145746	CLPB	0.64	8.05	0.44	2.73e-14	Gut microbiome composition (summer);
CESC	cis	rs637571	0.557	rs1204649	chr11:65702776	A/C	cg02202077	chr11:65769826	EIF1AD;BANF1	0.46	6.05	0.35	4.92e-9	Eosinophil percentage of white cells;
CESC	cis	rs12701220	0.857	rs1057558	chr7:1062366	A/G	cg26769984	chr7:1090371	C7orf50	0.61	6.92	0.39	3.3e-11	Bronchopulmonary dysplasia;
CESC	cis	rs34779708	0.966	rs113170867	chr10:35450147	C/T	cg04310649	chr10:35416472	CREM	-0.51	-6.25	-0.36	1.62e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs35110281	0.807	rs9984002	chr21:45061501	T/C	cg01579765	chr21:45077557	HSF2BP	-0.56	-9.21	-0.49	1.04e-17	Mean corpuscular volume;
CESC	cis	rs1355223	0.902	rs11605785	chr11:34751387	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.46	-5.94	-0.34	8.84e-9	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs9649213	0.593	rs3779194	chr7:98010277	A/G	cg24562669	chr7:97807699	LMTK2	0.51	7.53	0.42	7.86e-13	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs801193	0.839	rs6968619	chr7:66068867	T/C	cg26939375	chr7:64535504	NA	-0.54	-7.43	-0.42	1.53e-12	Aortic root size;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg25433490	chr11:72504708	STARD10	-0.45	-6.16	-0.35	2.62e-9	Asthma;
CESC	cis	rs853679	0.517	rs12332979	chr6:28141548	T/G	cg20151795	chr6:28129481	ZNF389	0.41	5.28	0.31	2.69e-7	Depression;
CESC	cis	rs9902453	0.967	rs4533341	chr17:28495672	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	7.9	0.44	7.44e-14	Coffee consumption (cups per day);
CESC	cis	rs9287719	0.967	rs2010080	chr2:10736552	A/T	cg00105475	chr2:10696890	NA	0.39	5.61	0.33	4.96e-8	Prostate cancer;
CESC	cis	rs6502050	0.605	rs35158616	chr17:80094480	A/G	cg11859384	chr17:80120422	CCDC57	-0.38	-5.04	-0.3	8.69e-7	Life satisfaction;
CESC	cis	rs6714710	0.603	rs11678591	chr2:98541001	T/C	cg26665480	chr2:98280029	ACTR1B	0.56	7.85	0.43	1.04e-13	Posterior cortical atrophy and Alzheimer's disease;
CESC	cis	rs6032067	0.704	rs2223901	chr20:43789924	C/G	cg10761708	chr20:43804764	PI3	0.56	6.55	0.37	3.01e-10	Blood protein levels;
CESC	cis	rs9325144	0.752	rs12300353	chr12:39154492	G/C	cg26384229	chr12:38710491	ALG10B	-0.52	-6.97	-0.39	2.47e-11	Morning vs. evening chronotype;
CESC	cis	rs17711722	0.701	rs781145	chr7:65440370	A/C	cg05332525	chr7:65337924	VKORC1L1	0.51	6.21	0.36	1.99e-9	Calcium levels;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg18528640	chr1:155579964	MSTO1	-0.48	-6.45	-0.37	5.32e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs713587	0.520	rs483428	chr2:25305136	A/G	cg01884057	chr2:25150051	NA	0.31	5.34	0.31	2.04e-7	Body mass index in non-asthmatics;
CESC	trans	rs7615952	0.641	rs12495947	chr3:125771698	C/T	cg07211511	chr3:129823064	LOC729375	-0.59	-6.53	-0.37	3.37e-10	Blood pressure (smoking interaction);
CESC	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.65	7.41	0.41	1.72e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs9329221	0.512	rs7843924	chr8:9976540	C/T	cg06636001	chr8:8085503	FLJ10661	0.49	6.46	0.37	4.99e-10	Neuroticism;
CESC	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg07677032	chr17:61819896	STRADA	0.45	6.05	0.35	5.02e-9	Prudent dietary pattern;
CESC	cis	rs7542091	0.635	rs7550733	chr1:210044968	G/A	cg23283495	chr1:209979779	IRF6	0.35	5.8	0.34	1.84e-8	Monobrow;
CESC	cis	rs897080	0.515	rs1067325	chr2:44628997	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	5.91	0.34	1.07e-8	Height;
CESC	cis	rs7927771	1.000	rs12418852	chr11:47868853	C/G	cg05585544	chr11:47624801	NA	-0.49	-7.61	-0.42	4.89e-13	Subjective well-being;
CESC	cis	rs262150	0.579	rs73167299	chr7:158784367	C/T	cg23096020	chr7:158799433	NA	0.46	5.1	0.3	6.48e-7	Facial morphology (factor 20);
CESC	cis	rs7481584	0.962	rs2071110	chr11:2991219	C/G	cg25174290	chr11:3078921	CARS	-0.46	-5.55	-0.32	7.03e-8	Calcium levels;
CESC	cis	rs4523957	0.928	rs216206	chr17:2196088	C/T	cg16513277	chr17:2031491	SMG6	0.59	8.08	0.44	2.29e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs9300255	0.620	rs7313483	chr12:123726834	C/T	cg19016782	chr12:123741754	C12orf65	-0.48	-6.72	-0.38	1.09e-10	Neutrophil percentage of white cells;
CESC	cis	rs10256972	0.528	rs7784607	chr7:1178694	A/G	cg23978390	chr7:1156363	C7orf50	0.64	9.16	0.49	1.49e-17	Longevity;Endometriosis;
CESC	cis	rs503341	0.756	rs10897450	chr11:63593219	G/C	cg04362095	chr11:63592001	C11orf84	-0.58	-8.17	-0.45	1.26e-14	Pulse pressure;
CESC	cis	rs651907	0.557	rs56291106	chr3:101377474	C/T	cg12386194	chr3:101231763	SENP7	0.44	5.38	0.31	1.64e-7	Colorectal cancer;
CESC	cis	rs9309473	0.950	rs6546849	chr2:73831037	A/G	cg20560298	chr2:73613845	ALMS1	-0.45	-6.03	-0.35	5.44e-9	Metabolite levels;
CESC	cis	rs1577917	1.000	rs12201741	chr6:86602619	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.42	-5.41	-0.32	1.39e-7	Response to antipsychotic treatment;
CESC	cis	rs13191362	0.935	rs35049401	chr6:162968464	T/G	cg06582575	chr6:163149167	PACRG;PARK2	0.78	7.01	0.4	1.93e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg07573057	chr8:82754234	SNX16	-0.47	-6.7	-0.38	1.25e-10	Gambling;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27106230	chr13:99229068	STK24	0.57	6.33	0.36	1.04e-9	Gut microbiome composition (summer);
CESC	cis	rs6502050	0.799	rs4789667	chr17:80162143	C/T	cg23985595	chr17:80112537	CCDC57	-0.39	-6.29	-0.36	1.34e-9	Life satisfaction;
CESC	cis	rs7264396	0.836	rs6058275	chr20:34186331	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-7.89	-0.44	7.84e-14	Total cholesterol levels;
CESC	cis	rs7429990	0.932	rs7630685	chr3:48131170	G/C	cg11946769	chr3:48343235	NME6	-0.51	-6.32	-0.36	1.11e-9	Educational attainment (years of education);
CESC	cis	rs3741151	0.773	rs73544767	chr11:73204619	C/T	cg17517138	chr11:73019481	ARHGEF17	0.98	7.17	0.4	7.42e-12	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs1799949	0.965	rs11080034	chr17:41443014	T/C	cg25072359	chr17:41440525	NA	0.49	7.34	0.41	2.66e-12	Menopause (age at onset);
CESC	cis	rs2839186	0.616	rs4819213	chr21:47619300	G/A	cg12516959	chr21:47718080	NA	0.41	5.97	0.34	7.7e-9	Testicular germ cell tumor;
CESC	cis	rs3820068	0.581	rs72645877	chr1:15928106	G/T	cg17385448	chr1:15911702	AGMAT	0.41	6.69	0.38	1.33e-10	Systolic blood pressure;
CESC	cis	rs2274273	0.905	rs8007944	chr14:55576816	A/C	cg04306507	chr14:55594613	LGALS3	0.3	5.93	0.34	9.34e-9	Protein biomarker;
CESC	cis	rs6860806	0.507	rs272854	chr5:131688017	C/T	cg07395648	chr5:131743802	NA	-0.41	-5.28	-0.31	2.65e-7	Breast cancer;
CESC	cis	rs9300255	0.722	rs10773008	chr12:123800820	A/G	cg00376283	chr12:123451042	ABCB9	0.59	6.86	0.39	4.85e-11	Neutrophil percentage of white cells;
CESC	cis	rs2235642	0.750	rs2859310	chr16:1656765	C/T	cg03715980	chr16:1756201	MAPK8IP3	-0.4	-5.27	-0.31	2.87e-7	Coronary artery disease;
CESC	cis	rs7618915	0.547	rs34173654	chr3:52634605	T/C	cg07507251	chr3:52567010	NT5DC2	0.41	7.21	0.4	5.94e-12	Bipolar disorder;
CESC	cis	rs28386778	0.863	rs3760252	chr17:61852186	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	21.26	0.79	3.33e-59	Prudent dietary pattern;
CESC	cis	rs847577	0.715	rs4729402	chr7:97707731	A/G	cg24562669	chr7:97807699	LMTK2	0.46	6.9	0.39	3.9e-11	Breast cancer;
CESC	trans	rs801193	1.000	rs7782320	chr7:66177098	C/T	cg26939375	chr7:64535504	NA	0.63	8.66	0.47	4.62e-16	Aortic root size;
CESC	cis	rs7412746	0.658	rs6658066	chr1:150918937	T/G	cg17724175	chr1:150552817	MCL1	0.34	5.2	0.3	3.95e-7	Melanoma;
CESC	cis	rs8077889	0.719	rs4793033	chr17:41879627	C/T	cg26893861	chr17:41843967	DUSP3	0.94	14.98	0.68	3.69e-37	Triglycerides;
CESC	cis	rs7044106	0.762	rs10984974	chr9:123421556	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.69	10.03	0.52	2.79e-20	Hip circumference adjusted for BMI;
CESC	cis	rs3091242	0.933	rs3093584	chr1:25668714	T/C	cg03538708	chr1:25844672	NA	0.37	5.45	0.32	1.17e-7	Erythrocyte sedimentation rate;
CESC	cis	rs514406	0.929	rs1672908	chr1:53340885	A/G	cg08859206	chr1:53392774	SCP2	-0.66	-8.92	-0.48	7.96e-17	Monocyte count;
CESC	cis	rs11969893	0.737	rs9498439	chr6:101404768	A/T	cg12253828	chr6:101329408	ASCC3	0.86	7.03	0.4	1.79e-11	Economic and political preferences (immigration/crime);
CESC	cis	rs3741404	0.620	rs12787945	chr11:63977546	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.71	10.11	0.53	1.55e-20	Platelet count;
CESC	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg07157834	chr1:205819609	PM20D1	0.68	10.03	0.52	2.87e-20	Menarche (age at onset);
CESC	cis	rs9322193	0.923	rs14314	chr6:150141531	A/C	cg04369109	chr6:150039330	LATS1	-0.42	-5.62	-0.33	4.88e-8	Lung cancer;
CESC	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg26516362	chr5:178986906	RUFY1	-0.48	-7.63	-0.42	4.15e-13	Lung cancer;
CESC	cis	rs10129255	0.500	rs2027902	chr14:107215393	T/C	cg07958169	chr14:107095056	NA	-0.51	-7.65	-0.43	3.66e-13	Kawasaki disease;
CESC	cis	rs1552244	0.938	rs7647987	chr3:10140696	A/G	cg08888203	chr3:10149979	C3orf24	0.46	6.01	0.35	6.24e-9	Alzheimer's disease;
CESC	cis	rs7666738	0.830	rs62318472	chr4:98926030	G/A	cg05340658	chr4:99064831	C4orf37	0.78	11.47	0.58	5.56e-25	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4144743	1.000	rs61312893	chr17:45325023	C/G	cg18085866	chr17:45331354	ITGB3	-0.64	-6.99	-0.39	2.25e-11	Body mass index;
CESC	cis	rs67257959	0.708	rs1979260	chr19:17193551	C/T	cg16202187	chr19:17186497	HAUS8;MYO9B	-0.42	-5.15	-0.3	5.06e-7	Selective IgA deficiency;
CESC	cis	rs3857536	0.813	rs7757647	chr6:66947207	A/G	cg07460842	chr6:66804631	NA	-0.42	-5.29	-0.31	2.55e-7	Blood trace element (Cu levels);
CESC	cis	rs12142240	0.698	rs1053627	chr1:46827728	A/C	cg00530320	chr1:46809349	NSUN4	0.6	8.04	0.44	2.96e-14	Menopause (age at onset);
CESC	cis	rs17401966	1.000	rs2229687	chr1:10473196	C/T	cg15208524	chr1:10270712	KIF1B	0.4	5.11	0.3	6.19e-7	Hepatocellular carcinoma;
CESC	cis	rs6982240	0.514	rs10481414	chr8:142275326	T/C	cg27411547	chr8:142287226	NA	-0.53	-7.4	-0.41	1.76e-12	Tonsillectomy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17941572	chr1:63784454	NA	-0.37	-6.37	-0.36	8.45e-10	Gut microbiome composition (summer);
CESC	cis	rs3796352	1.000	rs11714876	chr3:53101640	C/G	cg07884673	chr3:53033167	SFMBT1	-0.62	-5.58	-0.32	5.96e-8	Immune reponse to smallpox (secreted IL-2);
CESC	cis	rs8014204	1.000	rs8014374	chr14:75322914	G/A	cg08847533	chr14:75593920	NEK9	-0.48	-6.07	-0.35	4.35e-9	Caffeine consumption;
CESC	cis	rs17039065	0.920	rs56988845	chr4:109458114	T/C	cg16022748	chr4:109541635	LOC285456;RPL34	0.64	6.02	0.35	5.84e-9	Gut microbiome composition (summer);
CESC	cis	rs6120849	0.754	rs6087667	chr20:33651887	A/G	cg24642439	chr20:33292090	TP53INP2	0.67	6.62	0.38	1.94e-10	Protein C levels;
CESC	trans	rs17039065	0.920	rs73838435	chr4:109445261	A/G	cg27151770	chr16:49620536	ZNF423	-0.51	-6.14	-0.35	3.03e-9	Gut microbiome composition (summer);
CESC	trans	rs561341	0.700	rs79272796	chr17:30226974	T/C	cg20587970	chr11:113659929	NA	-0.61	-8.09	-0.45	2.19e-14	Hip circumference adjusted for BMI;
CESC	cis	rs11583043	0.918	rs3850453	chr1:101408933	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.55	6.32	0.36	1.08e-9	Ulcerative colitis;Inflammatory bowel disease;
CESC	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg04025307	chr7:1156635	C7orf50	0.42	6.89	0.39	4.16e-11	Longevity;Endometriosis;
CESC	cis	rs9916302	0.861	rs9903363	chr17:37499604	C/G	cg20243544	chr17:37824526	PNMT	-0.47	-5.96	-0.34	7.99e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs654950	0.775	rs28972757	chr1:41993013	T/C	cg06885757	chr1:42089581	HIVEP3	-0.44	-6.88	-0.39	4.38e-11	Airway imaging phenotypes;
CESC	cis	rs9311474	0.508	rs6805156	chr3:52609362	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.6	8.64	0.47	5.42e-16	Electroencephalogram traits;
CESC	cis	rs17125944	0.572	rs79312783	chr14:53250296	A/T	cg00686598	chr14:53173677	PSMC6	1.37	11.76	0.59	5.78e-26	Alzheimer's disease (late onset);
CESC	cis	rs11098499	0.955	rs1511019	chr4:120166007	T/G	cg09307838	chr4:120376055	NA	0.87	11.42	0.57	7.94e-25	Corneal astigmatism;
CESC	trans	rs1945213	0.694	rs7129022	chr11:55876132	A/G	cg15704280	chr7:45808275	SEPT13	0.75	7.28	0.41	3.87e-12	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs4665809	0.887	rs4665814	chr2:26273687	G/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.7	-7.85	-0.43	1.06e-13	Gut microbiome composition (summer);
CESC	cis	rs7618501	0.521	rs6774354	chr3:49961780	G/A	cg24308560	chr3:49941425	MST1R	-0.6	-8.77	-0.47	2.17e-16	Intelligence (multi-trait analysis);
CESC	cis	rs61935443	0.832	rs10859778	chr12:95268010	C/G	cg21533806	chr12:95267307	NA	0.56	6.87	0.39	4.56e-11	Schizophrenia;
CESC	cis	rs8078723	1.000	rs1042658	chr17:38173902	C/T	cg17467752	chr17:38218738	THRA	0.66	9.91	0.52	6.68e-20	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CESC	cis	rs9309473	1.000	rs7584575	chr2:73666402	C/T	cg20560298	chr2:73613845	ALMS1	-0.51	-6.76	-0.38	8.64e-11	Metabolite levels;
CESC	cis	rs853679	0.517	rs9380062	chr6:28137569	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.57	-6.59	-0.38	2.36e-10	Depression;
CESC	cis	rs796364	0.951	rs12613687	chr2:200999256	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.7	-6.78	-0.38	7.71e-11	Schizophrenia;
CESC	cis	rs67311347	1.000	rs2168111	chr3:40395325	T/G	cg01475735	chr3:40494733	NA	-0.42	-5.39	-0.31	1.55e-7	Renal cell carcinoma;
CESC	cis	rs193541	0.632	rs246279	chr5:122241263	C/G	cg19412675	chr5:122181750	SNX24	-0.6	-5.35	-0.31	1.95e-7	Glucose homeostasis traits;
CESC	cis	rs6570726	1.000	rs951143	chr6:145932576	C/T	cg05347473	chr6:146136440	FBXO30	0.45	6.26	0.36	1.56e-9	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs763121	0.962	rs6001193	chr22:39074737	A/G	cg06544989	chr22:39130855	UNC84B	0.47	8.98	0.48	5.09e-17	Menopause (age at onset);
CESC	cis	rs2197308	0.606	rs12314897	chr12:38392293	C/T	cg26384229	chr12:38710491	ALG10B	-0.46	-6.11	-0.35	3.48e-9	Morning vs. evening chronotype;
CESC	cis	rs798554	0.757	rs1182176	chr7:2874601	A/G	cg13628971	chr7:2884303	GNA12	0.6	8.09	0.44	2.17e-14	Height;
CESC	cis	rs6542838	0.641	rs10192266	chr2:99521837	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.47	-5.98	-0.34	7.17e-9	Fear of minor pain;
CESC	cis	rs9916302	0.653	rs4239223	chr17:37717004	T/C	cg07936489	chr17:37558343	FBXL20	-0.98	-11.47	-0.58	5.54e-25	Glomerular filtration rate (creatinine);
CESC	cis	rs473651	0.935	rs35080527	chr2:239351387	T/C	cg18131467	chr2:239335373	ASB1	1.01	20.6	0.78	6.03e-57	Multiple system atrophy;
CESC	cis	rs7618915	0.571	rs6798246	chr3:52599922	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.47	6.59	0.38	2.33e-10	Bipolar disorder;
CESC	cis	rs3540	0.512	rs8033818	chr15:91075535	C/T	cg22089800	chr15:90895588	ZNF774	-0.63	-8.16	-0.45	1.34e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs73058052	0.935	rs3745474	chr19:50086806	C/T	cg09250473	chr19:50168907	IRF3;BCL2L12	0.56	5.26	0.31	2.94e-7	Fibrinogen levels;
CESC	cis	rs12586317	0.534	rs28384418	chr14:35452126	C/A	cg16230307	chr14:35515116	FAM177A1	0.84	10.26	0.53	5.07e-21	Psoriasis;
CESC	cis	rs9733	0.596	rs6587518	chr1:150661787	T/C	cg18016565	chr1:150552671	MCL1	0.34	5.16	0.3	4.95e-7	Tonsillectomy;
CESC	cis	rs453301	0.631	rs7843369	chr8:8797786	T/G	cg15556689	chr8:8085844	FLJ10661	-0.46	-5.09	-0.3	6.94e-7	Joint mobility (Beighton score);
CESC	cis	rs1008375	0.863	rs7680984	chr4:17600884	A/G	cg27347728	chr4:17578864	LAP3	0.45	5.44	0.32	1.21e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs7208859	0.524	rs11653605	chr17:29088385	T/G	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.91e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs7666738	0.830	rs13125537	chr4:98978428	A/G	cg03467027	chr4:99064603	C4orf37	0.43	5.4	0.31	1.49e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs8020095	0.571	rs9323484	chr14:67239632	C/T	cg19548862	chr14:67692701	FAM71D	-0.5	-6.25	-0.36	1.67e-9	Depression (quantitative trait);
CESC	cis	rs4474465	0.920	rs10751291	chr11:78217687	T/C	cg27205649	chr11:78285834	NARS2	0.43	5.47	0.32	1.05e-7	Alzheimer's disease (survival time);
CESC	cis	rs597539	0.652	rs513615	chr11:68705504	G/T	cg18350739	chr11:68623251	NA	-0.47	-6.92	-0.39	3.32e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs708547	0.697	rs67479587	chr4:57878884	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.47	6.61	0.38	2.11e-10	Response to bleomycin (chromatid breaks);
CESC	cis	rs4953076	0.573	rs7593987	chr2:44393532	C/T	cg04920474	chr2:44395004	PPM1B	-0.57	-7.31	-0.41	3.1e-12	Height;
CESC	cis	rs3858526	0.514	rs1530973	chr11:5861449	C/T	cg05234568	chr11:5960015	NA	-0.64	-8.75	-0.47	2.46e-16	DNA methylation (variation);
CESC	cis	rs977987	0.806	rs11862582	chr16:75431295	T/C	cg03315344	chr16:75512273	CHST6	0.4	5.72	0.33	2.85e-8	Dupuytren's disease;
CESC	cis	rs2976388	0.578	rs34956412	chr8:143822028	C/T	cg24634471	chr8:143751801	JRK	-0.46	-5.06	-0.3	7.87e-7	Urinary tract infection frequency;
CESC	cis	rs3793683	0.965	rs3829131	chr10:134564627	A/G	cg27286337	chr10:134555280	INPP5A	-0.91	-14.24	-0.66	1.5e-34	Migraine;
CESC	cis	rs881375	0.900	rs1008383	chr9:123683579	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.39	5.24	0.31	3.22e-7	Rheumatoid arthritis;
CESC	cis	rs524281	0.861	rs12226649	chr11:65842047	T/C	cg14036092	chr11:66035641	RAB1B	-0.59	-6.01	-0.35	6.21e-9	Electroencephalogram traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00695560	chr13:100153670	TM9SF2	0.57	6.61	0.38	2.09e-10	Gut microbiome composition (summer);
CESC	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg23708337	chr7:1209742	NA	0.52	5.16	0.3	4.88e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs4665809	0.590	rs7606351	chr2:26292545	A/C	cg26314531	chr2:26401878	FAM59B	-0.78	-8.62	-0.47	6.3e-16	Gut microbiome composition (summer);
CESC	cis	rs2760061	0.626	rs672977	chr1:228120288	A/C	cg02753203	chr1:228287806	NA	-0.51	-7.43	-0.42	1.5e-12	Diastolic blood pressure;
CESC	cis	rs1003719	0.751	rs56268364	chr21:38542765	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.57	-7.66	-0.43	3.53e-13	Eye color traits;
CESC	cis	rs11711311	0.955	rs9851812	chr3:113412362	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.59	7.8	0.43	1.41e-13	IgG glycosylation;
CESC	cis	rs2617583	0.967	rs2652510	chr5:1447860	C/T	cg07151155	chr5:1473589	LPCAT1	-0.36	-5.53	-0.32	7.81e-8	Breast cancer;
CESC	cis	rs875971	0.825	rs801202	chr7:66023929	C/T	cg12463550	chr7:65579703	CRCP	-0.5	-6.32	-0.36	1.08e-9	Aortic root size;
CESC	cis	rs875971	0.825	rs28480509	chr7:66099224	A/G	cg12463550	chr7:65579703	CRCP	-0.48	-6.0	-0.35	6.63e-9	Aortic root size;
CESC	cis	rs35146811	0.883	rs4134903	chr7:99711040	G/A	cg22906224	chr7:99728672	NA	0.44	5.18	0.3	4.45e-7	Coronary artery disease;
CESC	cis	rs524281	0.731	rs476551	chr11:66006323	G/C	cg14036092	chr11:66035641	RAB1B	-0.51	-5.31	-0.31	2.35e-7	Electroencephalogram traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05428912	chr6:42989345	C6orf153	0.61	7.08	0.4	1.26e-11	Gut microbiome composition (summer);
CESC	cis	rs10754283	0.967	rs2002883	chr1:90105838	A/G	cg21401794	chr1:90099060	LRRC8C	0.69	9.34	0.5	4.06e-18	Amyotrophic lateral sclerosis (sporadic);
CESC	trans	rs9975691	1	rs9975691	chr21:14928355	G/T	cg08835464	chr7:142569053	TRPV6	-0.38	-6.08	-0.35	4.2e-9	Neurofibrillary tangles;
CESC	cis	rs919433	0.750	rs788012	chr2:198229856	A/T	cg10820045	chr2:198174542	NA	0.4	5.83	0.34	1.57e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs3096299	0.967	rs2911256	chr16:89485096	G/C	cg02187348	chr16:89574699	SPG7	0.6	8.22	0.45	9.44e-15	Multiple myeloma (IgH translocation);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26291698	chr6:43445274	TJAP1	0.57	6.23	0.36	1.85e-9	Gut microbiome composition (summer);
CESC	cis	rs7762018	1.000	rs6904601	chr6:170131905	T/G	cg05834625	chr6:170176447	C6orf70	0.66	7.82	0.43	1.29e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs10504229	0.683	rs2291765	chr8:58142874	C/T	cg21724239	chr8:58056113	NA	0.55	6.39	0.37	7.47e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs2637266	0.678	rs1660918	chr10:78511674	T/A	cg18941641	chr10:78392320	NA	0.39	7.43	0.42	1.46e-12	Pulmonary function;
CESC	trans	rs7618501	0.633	rs7621026	chr3:49975334	A/G	cg21659725	chr3:3221576	CRBN	0.49	6.81	0.39	6.69e-11	Intelligence (multi-trait analysis);
CESC	cis	rs6942756	1.000	rs67520056	chr7:128982075	A/G	cg02491457	chr7:128862824	NA	-0.67	-9.08	-0.49	2.54e-17	White matter hyperintensity burden;
CESC	cis	rs2439831	1.000	rs2467740	chr15:43746792	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.89	10.68	0.55	2.22e-22	Lung cancer in ever smokers;
CESC	cis	rs7618915	0.547	rs62253700	chr3:52625019	T/A	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	5.66	0.33	3.97e-8	Bipolar disorder;
CESC	cis	rs7772486	0.875	rs10872582	chr6:146373061	G/A	cg23711669	chr6:146136114	FBXO30	0.76	11.07	0.56	1.13e-23	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08434152	chr2:74405770	MOBKL1B	-0.6	-6.38	-0.36	7.83e-10	Gut microbiome composition (summer);
CESC	cis	rs709400	0.628	rs1951392	chr14:103853367	T/G	cg12935359	chr14:103987150	CKB	-0.52	-7.36	-0.41	2.34e-12	Body mass index;
CESC	cis	rs6540559	0.611	rs17015226	chr1:209970096	C/G	cg22029157	chr1:209979665	IRF6	0.69	8.04	0.44	3.04e-14	Cleft lip with or without cleft palate;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg10432265	chr11:94800316	SFRS2B	-0.37	-6.16	-0.35	2.67e-9	Gambling;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18064852	chr5:36690457	NA	0.61	7.15	0.4	8.37e-12	Gut microbiome composition (summer);
CESC	cis	rs2455799	0.552	rs2470516	chr3:15759050	T/G	cg09340198	chr3:15902540	ANKRD28	-0.33	-5.1	-0.3	6.39e-7	Mean platelet volume;
CESC	cis	rs2933343	0.951	rs789251	chr3:128576770	G/A	cg25356066	chr3:128598488	ACAD9	0.59	7.53	0.42	8.02e-13	IgG glycosylation;
CESC	cis	rs921968	0.541	rs4674314	chr2:219423520	A/G	cg02176678	chr2:219576539	TTLL4	-0.48	-8.44	-0.46	2.08e-15	Mean corpuscular hemoglobin concentration;
CESC	cis	rs9549367	0.789	rs2302757	chr13:113909339	A/G	cg18105134	chr13:113819100	PROZ	-0.72	-8.87	-0.48	1.09e-16	Platelet distribution width;
CESC	cis	rs9815354	1.000	rs7622259	chr3:41881351	A/T	cg03022575	chr3:42003672	ULK4	0.45	5.29	0.31	2.59e-7	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs9640161	0.830	rs7800196	chr7:150061534	C/G	cg13722127	chr7:150037890	RARRES2	0.33	5.12	0.3	5.77e-7	Blood protein levels;Circulating chemerin levels;
CESC	trans	rs877282	0.755	rs2486578	chr10:785227	C/T	cg22713356	chr15:30763199	NA	-1.0	-11.0	-0.56	2.04e-23	Uric acid levels;
CESC	cis	rs634534	0.562	rs642293	chr11:65730217	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.45	6.65	0.38	1.68e-10	Sum eosinophil basophil counts;Eosinophil counts;
CESC	cis	rs8002861	0.626	rs9533634	chr13:44397815	T/C	cg19180546	chr13:44453867	C13orf31;CCDC122	-0.41	-5.26	-0.31	3e-7	Leprosy;
CESC	cis	rs10870270	0.956	rs10430618	chr10:133748996	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.87	-12.74	-0.62	2.55e-29	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg11301795	chr4:187892539	NA	0.76	12.39	0.61	4.09e-28	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4243830	0.737	rs4908926	chr1:6617041	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.84	-8.41	-0.46	2.58e-15	Body mass index;
CESC	cis	rs11123406	0.651	rs11123407	chr2:111950594	A/C	cg04202892	chr2:111875749	ACOXL	0.36	5.09	0.3	6.79e-7	Type 2 diabetes;
CESC	cis	rs523522	0.962	rs4767914	chr12:120993817	C/T	cg27279351	chr12:120934652	DYNLL1	0.68	8.7	0.47	3.47e-16	High light scatter reticulocyte count;
CESC	trans	rs61931739	0.500	rs7306053	chr12:34510848	T/G	cg26384229	chr12:38710491	ALG10B	0.54	7.55	0.42	7.05e-13	Morning vs. evening chronotype;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg02767759	chr16:30366751	CD2BP2	-0.45	-6.6	-0.38	2.28e-10	Gambling;
CESC	cis	rs12497850	0.931	rs11924597	chr3:48937790	T/C	cg02487422	chr3:49467188	NICN1	0.39	5.1	0.3	6.42e-7	Parkinson's disease;
CESC	cis	rs17376456	0.569	rs6879620	chr5:93119893	G/A	cg21475434	chr5:93447410	FAM172A	-0.51	-5.16	-0.3	4.88e-7	Diabetic retinopathy;
CESC	cis	rs524281	0.861	rs535395	chr11:65906534	A/G	cg14036092	chr11:66035641	RAB1B	0.54	5.91	0.34	1.06e-8	Electroencephalogram traits;
CESC	trans	rs561341	1.000	rs7216102	chr17:30259450	A/G	cg20587970	chr11:113659929	NA	-0.79	-10.26	-0.53	5.01e-21	Hip circumference adjusted for BMI;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg15708219	chr10:22621481	NA	0.44	6.03	0.35	5.52e-9	Thyroid stimulating hormone;
CESC	cis	rs2635047	0.542	rs11082567	chr18:44769820	C/T	cg24371990	chr18:44770781	NA	0.36	5.95	0.34	8.29e-9	Educational attainment;
CESC	cis	rs9644630	0.930	rs6586839	chr8:19365543	A/T	cg01280390	chr8:19363452	CSGALNACT1	-0.33	-5.1	-0.3	6.54e-7	Oropharynx cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13149330	chr1:174968980	CACYBP	0.58	6.02	0.35	5.82e-9	Gut microbiome composition (summer);
CESC	cis	rs896854	0.654	rs13248607	chr8:95986637	T/G	cg13393036	chr8:95962371	TP53INP1	-0.49	-10.7	-0.55	1.94e-22	Type 2 diabetes;
CESC	cis	rs4664308	1.000	rs17831161	chr2:160909360	A/G	cg03641300	chr2:160917029	PLA2R1	-0.68	-10.17	-0.53	9.82e-21	Idiopathic membranous nephropathy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22162225	chr2:62932835	EHBP1	0.63	8.02	0.44	3.49e-14	Gut microbiome composition (summer);
CESC	cis	rs3806843	0.735	rs801189	chr5:140063091	A/G	cg26395211	chr5:140044315	WDR55	0.47	6.03	0.35	5.51e-9	Depressive symptoms (multi-trait analysis);
CESC	cis	rs12586317	0.547	rs45531432	chr14:35484423	C/T	cg16230307	chr14:35515116	FAM177A1	0.98	10.57	0.54	5.22e-22	Psoriasis;
CESC	cis	rs2070488	0.775	rs961179	chr3:38509618	G/A	cg24069376	chr3:38537580	EXOG	0.35	6.0	0.35	6.43e-9	Electrocardiographic conduction measures;
CESC	cis	rs9640161	0.789	rs66688634	chr7:150053806	G/A	cg21361702	chr7:150065534	REPIN1	0.61	6.61	0.38	2.09e-10	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs34172651	0.517	rs2287783	chr16:24831727	C/T	cg04756594	chr16:24857601	SLC5A11	0.45	5.35	0.31	1.91e-7	Intelligence (multi-trait analysis);
CESC	cis	rs9486715	0.838	rs9386473	chr6:96873341	C/A	cg18709589	chr6:96969512	KIAA0776	0.45	6.51	0.37	3.65e-10	Headache;
CESC	cis	rs155076	0.666	rs4638420	chr13:21872348	A/G	cg11317459	chr13:21872234	NA	1.21	14.76	0.67	2.21e-36	White matter hyperintensity burden;
CESC	trans	rs2207136	0.868	rs3843525	chr6:50837217	C/G	cg06522515	chr3:184090630	THPO	0.39	6.78	0.38	7.81e-11	Myopia;
CESC	cis	rs9300255	0.602	rs2682431	chr12:123703226	T/A	cg00376283	chr12:123451042	ABCB9	0.7	8.89	0.48	9.66e-17	Neutrophil percentage of white cells;
CESC	trans	rs3942852	0.774	rs924715	chr11:48181060	G/A	cg03929089	chr4:120376271	NA	-0.65	-7.08	-0.4	1.3e-11	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs40363	0.723	rs4785936	chr16:3535116	A/G	cg05754148	chr16:3507555	NAT15	-0.58	-5.62	-0.33	4.77e-8	Tuberculosis;
CESC	cis	rs4692589	1.000	rs1871683	chr4:170937348	T/C	cg19918862	chr4:170955249	NA	0.36	5.65	0.33	4.07e-8	Anxiety disorder;
CESC	cis	rs763121	0.853	rs138712	chr22:39141600	C/T	cg06544989	chr22:39130855	UNC84B	0.5	9.06	0.49	2.94e-17	Menopause (age at onset);
CESC	cis	rs8114671	0.562	rs2424999	chr20:33386430	G/A	cg08999081	chr20:33150536	PIGU	0.37	5.08	0.3	7.17e-7	Height;
CESC	cis	rs79349575	0.783	rs903567	chr17:46980318	C/T	cg16584676	chr17:46985605	UBE2Z	0.53	6.6	0.38	2.25e-10	Type 2 diabetes;
CESC	cis	rs9303280	0.901	rs1008723	chr17:38066267	G/T	cg19468946	chr17:37922297	IKZF3	-0.41	-5.47	-0.32	1.06e-7	Self-reported allergy;
CESC	cis	rs1707322	0.928	rs7527244	chr1:46368772	A/G	cg03146154	chr1:46216737	IPP	0.74	10.16	0.53	1.08e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs1862618	0.853	rs1559282	chr5:56099375	T/A	cg24549020	chr5:56110836	MAP3K1	0.59	6.95	0.39	2.75e-11	Initial pursuit acceleration;
CESC	cis	rs3126085	0.935	rs10888467	chr1:152171707	C/T	cg03465714	chr1:152285911	FLG	-0.42	-5.37	-0.31	1.73e-7	Atopic dermatitis;
CESC	cis	rs137603	0.623	rs470075	chr22:39686806	G/A	cg01093212	chr22:39715156	SNORD43;RPL3	-0.41	-5.04	-0.3	8.65e-7	Primary biliary cholangitis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18426487	chr10:35379348	CUL2	0.61	7.05	0.4	1.56e-11	Gut microbiome composition (summer);
CESC	cis	rs4713118	0.513	rs9368547	chr6:28028067	A/G	cg17221315	chr6:27791827	HIST1H4J	0.42	5.34	0.31	1.98e-7	Parkinson's disease;
CESC	cis	rs1552244	1.000	rs34179822	chr3:10140017	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	12.72	0.62	2.88e-29	Alzheimer's disease;
CESC	cis	rs3812762	0.871	rs11042068	chr11:8815599	C/G	cg03980550	chr11:8754370	ST5	-0.38	-5.12	-0.3	5.96e-7	Hypospadias;
CESC	cis	rs818427	0.593	rs351768	chr5:112200028	T/A	cg07820702	chr5:112228657	REEP5	0.39	5.27	0.31	2.82e-7	Total body bone mineral density;
CESC	cis	rs2576037	0.583	rs9916891	chr18:44493521	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.5	-6.71	-0.38	1.14e-10	Personality dimensions;
CESC	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg00080972	chr5:178986291	RUFY1	-0.48	-7.8	-0.43	1.47e-13	Lung cancer;
CESC	cis	rs4665809	1.000	rs10048648	chr2:26320315	T/C	cg04944784	chr2:26401820	FAM59B	-0.63	-7.23	-0.41	5.29e-12	Gut microbiome composition (summer);
CESC	cis	rs1371867	0.810	rs1618528	chr8:101259134	T/C	cg11906718	chr8:101322791	RNF19A	-0.48	-6.04	-0.35	5.21e-9	Atrioventricular conduction;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg26399201	chr5:132149404	ANKRD43	0.49	6.09	0.35	3.99e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs1153858	0.723	rs4580098	chr15:45596909	T/A	cg14582100	chr15:45693742	SPATA5L1	0.38	5.28	0.31	2.76e-7	Homoarginine levels;
CESC	cis	rs875971	0.862	rs6962717	chr7:65883735	G/A	cg18252515	chr7:66147081	NA	-0.43	-5.59	-0.32	5.73e-8	Aortic root size;
CESC	cis	rs2070677	0.935	rs11101887	chr10:135418062	G/A	cg20169779	chr10:135381914	SYCE1	-0.74	-9.71	-0.51	2.99e-19	Gout;
CESC	cis	rs3008870	1.000	rs2065000	chr1:67468124	G/C	cg08660285	chr1:67390436	MIER1;WDR78	-1.02	-14.35	-0.66	6.26e-35	Lymphocyte percentage of white cells;
CESC	cis	rs2836974	0.932	rs2836955	chr21:40619887	G/A	cg27266027	chr21:40555129	PSMG1	0.45	5.15	0.3	4.98e-7	Cognitive function;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg05360402	chr5:110848191	STARD4	0.48	6.48	0.37	4.45e-10	Systemic lupus erythematosus;
CESC	cis	rs66573146	1.000	rs56074877	chr4:6990374	C/T	cg00086871	chr4:6988644	TBC1D14	1.18	7.59	0.42	5.45e-13	Granulocyte percentage of myeloid white cells;
CESC	cis	rs12930096	1.000	rs12921437	chr16:11680148	T/C	cg07439791	chr16:11680400	LITAF	0.62	5.5	0.32	8.93e-8	QT interval;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg05610740	chr12:96794311	CDK17	-0.49	-6.32	-0.36	1.11e-9	Fibrinogen levels;
CESC	cis	rs921968	0.509	rs655441	chr2:219357545	C/T	cg02176678	chr2:219576539	TTLL4	0.5	8.98	0.48	5.22e-17	Mean corpuscular hemoglobin concentration;
CESC	cis	rs3733585	0.699	rs6449171	chr4:9965998	C/T	cg00071950	chr4:10020882	SLC2A9	0.72	11.29	0.57	2.15e-24	Cleft plate (environmental tobacco smoke interaction);
CESC	trans	rs875971	1.000	rs1363055	chr7:65943275	A/G	cg26939375	chr7:64535504	NA	0.46	6.0	0.35	6.4e-9	Aortic root size;
CESC	cis	rs9894429	0.671	rs6565616	chr17:79612161	C/T	cg18240062	chr17:79603768	NPLOC4	0.53	7.0	0.4	2.07e-11	Eye color traits;
CESC	cis	rs9733	0.596	rs2275236	chr1:150669952	A/G	cg04414720	chr1:150670196	GOLPH3L	-0.6	-8.42	-0.46	2.42e-15	Tonsillectomy;
CESC	cis	rs67311347	0.956	rs7640228	chr3:40516190	G/A	cg09455208	chr3:40491958	NA	-0.5	-8.39	-0.46	3.02e-15	Renal cell carcinoma;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15302530	chr7:108210038	THAP5;DNAJB9	0.53	6.38	0.36	7.68e-10	Gut microbiome composition (summer);
CESC	cis	rs1865721	0.771	rs7228890	chr18:73137492	C/A	cg26385618	chr18:73139727	C18orf62	-0.48	-7.92	-0.44	6.58e-14	Intelligence;
CESC	cis	rs8114671	0.869	rs1544047	chr20:33670753	T/C	cg24642439	chr20:33292090	TP53INP2	-0.47	-5.7	-0.33	3.19e-8	Height;
CESC	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg04025307	chr7:1156635	C7orf50	0.42	5.85	0.34	1.47e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg11494091	chr17:61959527	GH2	0.73	12.69	0.61	3.72e-29	Prudent dietary pattern;
CESC	cis	rs506597	0.920	rs221800	chr7:100288552	T/C	cg10426581	chr7:100472382	SRRT	-0.69	-5.39	-0.31	1.57e-7	Pursuit maintenance gain in psychotic disorders;
CESC	cis	rs875971	1.000	rs10257427	chr7:65743208	T/C	cg18876405	chr7:65276391	NA	-0.51	-7.0	-0.4	2.05e-11	Aortic root size;
CESC	cis	rs1862618	0.853	rs11739344	chr5:56111087	A/C	cg24531977	chr5:56204891	C5orf35	-0.87	-10.95	-0.56	2.88e-23	Initial pursuit acceleration;
CESC	cis	rs7131987	0.934	rs7316004	chr12:29411698	C/T	cg09582351	chr12:29534625	ERGIC2	-0.35	-5.72	-0.33	2.9e-8	QT interval;
CESC	cis	rs838147	0.563	rs281379	chr19:49214274	C/T	cg21064579	chr19:49206444	FUT2	0.4	5.49	0.32	9.5e-8	Dietary macronutrient intake;
CESC	cis	rs10832963	1.000	rs10128711	chr11:18632984	A/G	cg20219074	chr11:18656078	SPTY2D1	0.79	11.73	0.58	7.39e-26	Breast cancer;
CESC	cis	rs1059312	0.966	rs12370194	chr12:129277250	A/T	cg09035930	chr12:129282057	SLC15A4	0.75	10.45	0.54	1.28e-21	Systemic lupus erythematosus;
CESC	trans	rs7937682	0.921	rs688354	chr11:111438762	A/G	cg18187862	chr3:45730750	SACM1L	0.49	6.04	0.35	5.29e-9	Primary sclerosing cholangitis;
CESC	cis	rs7795096	0.743	rs9648729	chr7:151537759	G/C	cg17008978	chr7:151542804	PRKAG2	0.4	7.39	0.41	1.97e-12	Bipolar disorder (age of onset and psychotic symptoms);
CESC	cis	rs7618501	0.633	rs2008877	chr3:50162291	T/G	cg24110177	chr3:50126178	RBM5	0.52	7.02	0.4	1.91e-11	Intelligence (multi-trait analysis);
CESC	cis	rs8103278	0.507	rs10401971	chr19:46261982	C/T	cg14061069	chr19:46274453	DMPK	0.52	8.23	0.45	8.37e-15	Coronary artery disease;
CESC	cis	rs7605827	0.930	rs765432	chr2:15561440	C/T	cg19274914	chr2:15703543	NA	-0.32	-5.7	-0.33	3.16e-8	Educational attainment (years of education);
CESC	cis	rs6723226	0.721	rs10172510	chr2:32620888	A/G	cg02381751	chr2:32503542	YIPF4	0.54	6.89	0.39	4.14e-11	Intelligence (multi-trait analysis);
CESC	cis	rs4819052	0.851	rs2838866	chr21:46713014	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.69	8.97	0.48	5.5e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs10465746	0.935	rs6687372	chr1:84447634	C/T	cg10977910	chr1:84465055	TTLL7	0.46	6.31	0.36	1.14e-9	Obesity-related traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06273413	chr7:92157551	PEX1;C7orf64	0.62	6.72	0.38	1.11e-10	Gut microbiome composition (summer);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03112782	chr1:37979729	MEAF6	0.53	6.79	0.38	7.55e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs4665809	1.000	rs6749855	chr2:26255263	A/G	cg08470875	chr2:26401718	FAM59B	-0.57	-6.09	-0.35	3.95e-9	Gut microbiome composition (summer);
CESC	cis	rs4891159	0.790	rs35516239	chr18:74129942	C/T	cg24786174	chr18:74118243	ZNF516	-0.73	-11.51	-0.58	3.96e-25	Longevity;
CESC	cis	rs7666738	0.753	rs10033138	chr4:98981922	A/C	cg18180107	chr4:99064573	C4orf37	0.4	5.19	0.3	4.29e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4919694	1.000	rs35159404	chr10:104805610	C/A	cg04362960	chr10:104952993	NT5C2	0.8	6.89	0.39	4.13e-11	Arsenic metabolism;
CESC	cis	rs9488822	0.676	rs1556857	chr6:116325559	T/C	cg05304507	chr6:116381966	FRK	0.26	6.56	0.37	2.82e-10	Cholesterol, total;LDL cholesterol;
CESC	cis	rs1707322	0.721	rs4431884	chr1:46101323	C/T	cg06784218	chr1:46089804	CCDC17	0.41	7.31	0.41	3.1e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9443645	0.901	rs9352666	chr6:79572184	C/G	cg05283184	chr6:79620031	NA	-0.44	-6.84	-0.39	5.6e-11	Intelligence (multi-trait analysis);
CESC	trans	rs9850225	0.666	rs2372669	chr3:81029234	T/G	cg27138204	chr12:54446100	HOXC4	-0.37	-6.06	-0.35	4.76e-9	Erectile dysfunction in type 1 diabetes;
CESC	cis	rs12142240	0.698	rs66847432	chr1:46832013	G/A	cg00530320	chr1:46809349	NSUN4	0.6	8.08	0.44	2.37e-14	Menopause (age at onset);
CESC	cis	rs6499255	0.951	rs8054096	chr16:69695886	G/A	cg15192750	chr16:69999425	NA	0.46	5.34	0.31	2.04e-7	IgE levels;
CESC	cis	rs459571	0.920	rs417142	chr9:136891370	G/T	cg13789015	chr9:136890014	NCRNA00094	0.55	7.9	0.44	7.61e-14	Platelet distribution width;
CESC	cis	rs6463523	0.864	rs73047957	chr7:759373	A/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.96	14.73	0.67	2.83e-36	Subjective well-being;
CESC	cis	rs524281	1.000	rs547087	chr11:65846264	A/G	cg14036092	chr11:66035641	RAB1B	0.53	5.88	0.34	1.21e-8	Electroencephalogram traits;
CESC	cis	rs35146811	0.586	rs6946168	chr7:99598286	C/T	cg22531904	chr7:99595276	NA	-0.4	-5.21	-0.3	3.79e-7	Coronary artery disease;
CESC	cis	rs7618915	0.501	rs55678971	chr3:52717229	T/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.59	8.06	0.44	2.58e-14	Bipolar disorder;
CESC	cis	rs7666738	0.830	rs115279324	chr4:99042114	T/C	cg03676636	chr4:99064102	C4orf37	0.33	5.08	0.3	7.13e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg18402987	chr7:1209562	NA	0.4	5.1	0.3	6.61e-7	Longevity;Endometriosis;
CESC	cis	rs1707322	0.721	rs11211178	chr1:46227566	G/T	cg03146154	chr1:46216737	IPP	0.81	11.44	0.58	6.59e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7264396	0.563	rs2425071	chr20:34292961	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	0.88	10.58	0.55	4.63e-22	Total cholesterol levels;
CESC	cis	rs853679	0.607	rs13203816	chr6:28079598	T/C	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.85	5.58	0.32	6.04e-8	Depression;
CESC	cis	rs748404	0.646	rs2253268	chr15:43800968	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.51	7.72	0.43	2.32e-13	Lung cancer;
CESC	cis	rs9921222	0.585	rs7195617	chr16:376781	A/G	cg26944245	chr16:421049	TMEM8A;MRPL28	-0.44	-7.12	-0.4	9.88e-12	Bone mineral density (spine);Bone mineral density;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg17173397	chr1:20539594	NA	-0.48	-6.51	-0.37	3.68e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg20887711	chr4:1340912	KIAA1530	0.7	9.7	0.51	3.15e-19	Longevity;
CESC	cis	rs858239	0.511	rs10256996	chr7:23145295	G/T	cg23682824	chr7:23144976	KLHL7	-0.47	-6.33	-0.36	1.05e-9	Cerebrospinal fluid biomarker levels;
CESC	cis	rs4523957	0.671	rs4790070	chr17:2158094	C/G	cg16513277	chr17:2031491	SMG6	0.48	5.49	0.32	9.45e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs9910055	0.762	rs6503489	chr17:42246289	G/A	cg10896456	chr17:42255109	ASB16;C17orf65	0.47	7.03	0.4	1.77e-11	Total body bone mineral density;
CESC	cis	rs10504229	0.639	rs11781834	chr8:58133422	C/T	cg24829409	chr8:58192753	C8orf71	-0.58	-7.05	-0.4	1.52e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs10479542	0.784	rs7702303	chr5:178986436	G/A	cg26516362	chr5:178986906	RUFY1	0.47	7.52	0.42	8.62e-13	Lung cancer;
CESC	cis	rs7552404	0.731	rs10873808	chr1:76406767	T/C	cg10523679	chr1:76189770	ACADM	0.71	6.85	0.39	5e-11	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs9341808	0.667	rs1408292	chr6:80883906	G/T	cg08355045	chr6:80787529	NA	0.32	5.05	0.3	8.21e-7	Sitting height ratio;
CESC	cis	rs798554	0.797	rs1182183	chr7:2873136	C/T	cg13628971	chr7:2884303	GNA12	0.62	8.28	0.45	6.17e-15	Height;
CESC	cis	rs79839061	0.636	rs76839318	chr4:837810	T/A	cg07828340	chr4:882639	GAK	0.86	5.9	0.34	1.09e-8	Intelligence (multi-trait analysis);
CESC	trans	rs9858542	0.953	rs9814873	chr3:49454112	A/G	cg21659725	chr3:3221576	CRBN	-0.5	-6.23	-0.36	1.82e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs7584330	0.657	rs10190310	chr2:238352282	C/T	cg14458575	chr2:238380390	NA	0.64	8.9	0.48	9.09e-17	Prostate cancer;
CESC	cis	rs17001868	0.568	rs9611318	chr22:40739414	C/G	cg07138101	chr22:40742427	ADSL	0.57	5.38	0.31	1.66e-7	Mammographic density (dense area);
CESC	cis	rs644799	0.965	rs566877	chr11:95528045	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	9.15	0.49	1.61e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs12900413	0.687	rs13343254	chr15:90311283	G/A	cg24249390	chr15:90295951	MESP1	-0.4	-5.5	-0.32	9.05e-8	Coronary artery aneurysm in Kawasaki disease;
CESC	cis	rs11676348	0.772	rs11687200	chr2:218944615	A/G	cg00012203	chr2:219082015	ARPC2	-0.44	-5.54	-0.32	7.45e-8	Ulcerative colitis;
CESC	cis	rs796364	0.806	rs112305133	chr2:201010380	A/G	cg23649088	chr2:200775458	C2orf69	-0.58	-5.71	-0.33	3.07e-8	Schizophrenia;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg12349571	chr15:70364359	TLE3	0.45	6.33	0.36	1.05e-9	Fibrinogen levels;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg22182611	chr19:1503537	NA	-0.45	-6.08	-0.35	4.23e-9	Fibrinogen levels;
CESC	cis	rs12545109	0.765	rs2438063	chr8:57384360	A/G	cg09654669	chr8:57350985	NA	0.59	6.93	0.39	3.19e-11	Obesity-related traits;
CESC	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	10.28	0.53	4.4e-21	Prudent dietary pattern;
CESC	cis	rs9916302	0.784	rs4795361	chr17:37573446	G/A	cg15445000	chr17:37608096	MED1	0.41	6.81	0.39	6.45e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs9487051	0.872	rs9480922	chr6:109607211	G/A	cg21918786	chr6:109611834	NA	-0.41	-6.13	-0.35	3.24e-9	Reticulocyte fraction of red cells;
CESC	trans	rs61931739	0.500	rs11053249	chr12:34518834	A/T	cg26384229	chr12:38710491	ALG10B	0.7	10.48	0.54	1e-21	Morning vs. evening chronotype;
CESC	cis	rs1218582	0.772	rs4845693	chr1:154911257	A/G	cg03351412	chr1:154909251	PMVK	-0.58	-7.41	-0.41	1.66e-12	Prostate cancer;
CESC	cis	rs4713118	0.586	rs9468290	chr6:28087674	C/T	cg12963246	chr6:28129442	ZNF389	0.56	7.63	0.42	4.26e-13	Parkinson's disease;
CESC	cis	rs9910055	0.762	rs2526021	chr17:42213347	G/A	cg10896456	chr17:42255109	ASB16;C17orf65	0.44	6.52	0.37	3.58e-10	Total body bone mineral density;
CESC	cis	rs425277	1.000	rs436045	chr1:2071556	A/G	cg04315214	chr1:2043799	PRKCZ	0.4	5.65	0.33	4.14e-8	Height;
CESC	cis	rs736408	0.716	rs2239550	chr3:52822509	G/C	cg05564831	chr3:52568323	NT5DC2	0.44	6.38	0.36	7.86e-10	Bipolar disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01728682	chr2:25057480	ADCY3	-0.58	-6.84	-0.39	5.42e-11	Gut microbiome composition (summer);
CESC	cis	rs12200560	0.505	rs211167	chr6:97069087	T/A	cg06623918	chr6:96969491	KIAA0776	0.46	5.81	0.34	1.82e-8	Coronary heart disease;
CESC	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg02071572	chr4:1403502	NA	0.37	5.48	0.32	9.71e-8	Longevity;
CESC	trans	rs208520	1.000	rs208529	chr6:66957549	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.78	-8.63	-0.47	5.64e-16	Exhaled nitric oxide output;
CESC	cis	rs711830	1.000	rs1318778	chr2:177037831	C/G	cg13092806	chr2:177043255	NA	0.88	12.03	0.59	6.83e-27	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
CESC	cis	rs9814567	0.712	rs9838889	chr3:134332311	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.4	-5.1	-0.3	6.38e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs853679	0.517	rs9468297	chr6:28118874	G/T	cg17949981	chr6:28129498	ZNF389	0.45	5.49	0.32	9.35e-8	Depression;
CESC	cis	rs10504229	0.610	rs6993531	chr8:58147283	A/G	cg02725872	chr8:58115012	NA	-0.37	-5.94	-0.34	8.87e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs875971	0.862	rs2901152	chr7:65765004	G/A	cg10691866	chr7:65817282	TPST1	0.33	5.55	0.32	6.96e-8	Aortic root size;
CESC	cis	rs6430585	0.583	rs3769008	chr2:136586183	C/T	cg07169764	chr2:136633963	MCM6	1.28	18.11	0.74	3.06e-48	Corneal structure;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg24568548	chr11:43544500	NA	0.46	6.55	0.37	2.97e-10	Fibrinogen levels;
CESC	cis	rs1577917	1.000	rs34106666	chr6:86676258	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.43	-5.67	-0.33	3.66e-8	Response to antipsychotic treatment;
CESC	cis	rs853679	0.517	rs4713144	chr6:28106790	C/G	cg17949981	chr6:28129498	ZNF389	0.45	5.71	0.33	3.07e-8	Depression;
CESC	cis	rs6088590	1.000	rs10048849	chr20:33419680	C/T	cg08999081	chr20:33150536	PIGU	0.59	8.93	0.48	7.21e-17	Coronary artery disease;
CESC	cis	rs2721195	0.874	rs2721173	chr8:145744429	C/T	cg22382021	chr8:145755756	MGC70857;KIAA1688	-0.31	-5.28	-0.31	2.75e-7	Age at first birth;
CESC	cis	rs611744	0.647	rs1448151	chr8:109276283	C/A	cg21045802	chr8:109455806	TTC35	0.49	6.08	0.35	4.24e-9	Dupuytren's disease;
CESC	cis	rs10911232	0.507	rs4596846	chr1:182976034	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.83	13.29	0.63	3.24e-31	Hypertriglyceridemia;
CESC	cis	rs1003719	0.788	rs2835595	chr21:38466203	G/T	cg10648535	chr21:38446584	PIGP;TTC3	0.63	8.77	0.47	2.14e-16	Eye color traits;
CESC	cis	rs116095464	1.000	rs28416084	chr5:217640	G/A	cg16372103	chr5:203701	NA	0.49	5.29	0.31	2.58e-7	Breast cancer;
CESC	cis	rs7584330	0.518	rs7561919	chr2:238435241	A/G	cg14458575	chr2:238380390	NA	0.68	6.47	0.37	4.76e-10	Prostate cancer;
CESC	cis	rs9790314	0.846	rs7636941	chr3:160993928	A/G	cg03342759	chr3:160939853	NMD3	-0.51	-7.37	-0.41	2.23e-12	Morning vs. evening chronotype;
CESC	cis	rs1461503	0.780	rs75981430	chr11:122842469	A/C	cg27398637	chr11:122830231	C11orf63	-0.54	-8.02	-0.44	3.32e-14	Menarche (age at onset);
CESC	cis	rs68170813	0.559	rs75932578	chr7:106844694	C/T	cg02696742	chr7:106810147	HBP1	-0.53	-5.09	-0.3	6.93e-7	Coronary artery disease;
CESC	cis	rs1003719	0.737	rs2835587	chr21:38461795	A/T	cg10648535	chr21:38446584	PIGP;TTC3	0.63	8.77	0.47	2.21e-16	Eye color traits;
CESC	cis	rs2901656	0.677	rs2301455	chr1:172418268	C/T	cg03748243	chr1:172413542	C1orf105;PIGC	0.52	7.91	0.44	7.02e-14	Red cell distribution width;Platelet distribution width;
CESC	cis	rs832540	0.931	rs832535	chr5:56213334	C/T	cg24531977	chr5:56204891	C5orf35	-0.44	-5.56	-0.32	6.56e-8	Coronary artery disease;
CESC	cis	rs9611565	0.802	rs9611577	chr22:41793090	T/G	cg03806693	chr22:41940476	POLR3H	-1.01	-12.06	-0.6	5.63e-27	Vitiligo;
CESC	cis	rs4835473	0.897	rs12649594	chr4:144910460	T/C	cg25736465	chr4:144833511	NA	0.42	6.43	0.37	6.02e-10	Immature fraction of reticulocytes;
CESC	cis	rs1005277	0.579	rs2505197	chr10:38393310	T/C	cg00409905	chr10:38381863	ZNF37A	-0.47	-6.3	-0.36	1.24e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs2342371	0.816	rs11707744	chr3:196213855	C/G	cg15048948	chr3:196158458	UBXN7	-0.4	-5.03	-0.3	9.04e-7	Fat distribution (HIV);
CESC	cis	rs8067354	0.872	rs1295925	chr17:57910263	T/C	cg13753209	chr17:57696993	CLTC	-0.52	-7.03	-0.4	1.71e-11	Hemoglobin concentration;
CESC	cis	rs3820068	0.581	rs6692489	chr1:15928517	A/G	cg17385448	chr1:15911702	AGMAT	0.44	7.16	0.4	7.97e-12	Systolic blood pressure;
CESC	cis	rs4819052	0.851	rs2838865	chr21:46712299	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.74	9.81	0.52	1.44e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs7044106	0.762	rs7024046	chr9:123419178	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.77	11.23	0.57	3.37e-24	Hip circumference adjusted for BMI;
CESC	trans	rs61931739	0.534	rs11053016	chr12:34104372	C/T	cg26384229	chr12:38710491	ALG10B	0.59	8.18	0.45	1.17e-14	Morning vs. evening chronotype;
CESC	cis	rs4862750	0.794	rs7672272	chr4:187896774	T/G	cg11301795	chr4:187892539	NA	-0.75	-12.39	-0.61	3.91e-28	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4243830	0.649	rs11579888	chr1:6609896	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.85	-8.42	-0.46	2.37e-15	Body mass index;
CESC	cis	rs4523957	0.928	rs12943566	chr17:2157774	A/G	cg16513277	chr17:2031491	SMG6	0.59	7.92	0.44	6.65e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	trans	rs35110281	0.782	rs4818856	chr21:45043495	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.53	6.9	0.39	3.75e-11	Mean corpuscular volume;
CESC	cis	rs9486719	0.948	rs2472881	chr6:96862562	C/T	cg06623918	chr6:96969491	KIAA0776	0.82	8.4	0.46	2.72e-15	Migraine;Coronary artery disease;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg18842717	chr11:3400387	ZNF195	-0.46	-6.24	-0.36	1.73e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs1801251	1.000	rs283480	chr2:233648742	G/A	cg08000102	chr2:233561755	GIGYF2	0.67	9.28	0.5	6.17e-18	Coronary artery disease;
CESC	cis	rs72781680	1.000	rs6731001	chr2:24192952	A/G	cg08917208	chr2:24149416	ATAD2B	0.94	8.54	0.46	1.09e-15	Lymphocyte counts;
CESC	cis	rs727505	1.000	rs55964341	chr7:124517280	A/G	cg23710748	chr7:124431027	NA	-0.48	-7.52	-0.42	8.73e-13	Lewy body disease;
CESC	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg10862848	chr6:42927986	GNMT	-0.29	-7.24	-0.41	4.79e-12	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs12950390	0.776	rs4793646	chr17:45853966	A/C	cg00777063	chr17:45855553	NA	-0.39	-5.74	-0.33	2.62e-8	IgG glycosylation;
CESC	cis	rs7044106	0.762	rs4837789	chr9:123426256	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.77	11.29	0.57	2.2e-24	Hip circumference adjusted for BMI;
CESC	cis	rs9322193	1.000	rs9767077	chr6:150109615	T/A	cg07701084	chr6:150067640	NUP43	0.43	5.85	0.34	1.45e-8	Lung cancer;
CESC	cis	rs7520050	1.000	rs12410070	chr1:46358882	T/C	cg24296786	chr1:45957014	TESK2	0.42	5.23	0.31	3.53e-7	Red blood cell count;Reticulocyte count;
CESC	cis	rs9875589	0.509	rs1488379	chr3:14014719	A/G	cg19554555	chr3:13937349	NA	-0.44	-5.61	-0.33	5.2e-8	Ovarian reserve;
CESC	cis	rs6032067	0.925	rs35751129	chr20:43847658	C/A	cg11264863	chr20:43835661	SEMG1	0.48	5.13	0.3	5.65e-7	Blood protein levels;
CESC	cis	rs13191362	1.000	rs13207239	chr6:163008772	A/C	cg21926612	chr6:163149169	PACRG;PARK2	0.87	8.94	0.48	6.87e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs11958404	0.929	rs60700182	chr5:157438376	A/G	cg05962755	chr5:157440814	NA	0.59	6.52	0.37	3.45e-10	IgG glycosylation;
CESC	cis	rs11920090	0.722	rs5404	chr3:170724955	A/G	cg09710316	chr3:170744871	SLC2A2	-0.54	-6.2	-0.36	2.17e-9	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
CESC	cis	rs875971	0.862	rs6945775	chr7:65968974	G/A	cg12463550	chr7:65579703	CRCP	0.49	6.11	0.35	3.61e-9	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23610820	chr19:43774921	PSG9	-0.5	-6.24	-0.36	1.68e-9	Gut microbiome composition (summer);
CESC	cis	rs614226	0.935	rs17431717	chr12:120912210	G/A	cg01236616	chr12:121019343	POP5	-1.43	-15.07	-0.68	1.72e-37	Type 1 diabetes nephropathy;
CESC	cis	rs9911578	1.000	rs11870671	chr17:56605360	A/G	cg05425664	chr17:57184151	TRIM37	0.5	7.06	0.4	1.5e-11	Intelligence (multi-trait analysis);
CESC	cis	rs9640161	0.750	rs3735173	chr7:150020526	C/T	cg21361702	chr7:150065534	REPIN1	0.52	6.08	0.35	4.06e-9	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs10504229	1.000	rs117231141	chr8:58185465	A/G	cg14926445	chr8:58193284	C8orf71	-0.51	-5.52	-0.32	8.28e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs875971	0.862	rs6460279	chr7:65662761	T/C	cg18876405	chr7:65276391	NA	-0.55	-7.48	-0.42	1.12e-12	Aortic root size;
CESC	cis	rs2074585	0.647	rs2601188	chr15:90929563	A/G	cg10434728	chr15:90938212	IQGAP1	-0.41	-7.48	-0.42	1.08e-12	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
CESC	cis	rs3824867	0.920	rs4752836	chr11:47465095	T/C	cg20307385	chr11:47447363	PSMC3	0.51	6.09	0.35	3.96e-9	Mean corpuscular hemoglobin;
CESC	cis	rs2066819	1.000	rs79824801	chr12:56728137	T/C	cg26734620	chr12:56694298	CS	0.98	5.95	0.34	8.45e-9	Psoriasis vulgaris;
CESC	cis	rs2576037	0.583	rs2156049	chr18:44455717	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.79	13.27	0.63	3.82e-31	Personality dimensions;
CESC	cis	rs875971	0.638	rs6460305	chr7:66060408	G/A	cg18876405	chr7:65276391	NA	-0.59	-7.87	-0.44	9.35e-14	Aortic root size;
CESC	cis	rs8031584	0.678	rs4779497	chr15:31151365	T/A	cg08704250	chr15:31115839	NA	-0.68	-9.12	-0.49	1.97e-17	Huntington's disease progression;
CESC	cis	rs1707322	0.928	rs10732844	chr1:46372688	T/C	cg05343316	chr1:45956843	TESK2	0.44	5.55	0.32	7.05e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7116495	0.867	rs510925	chr11:71809500	C/T	cg10381502	chr11:71823885	C11orf51	0.97	6.26	0.36	1.54e-9	Severe influenza A (H1N1) infection;
CESC	trans	rs561341	1.000	rs498391	chr17:30328704	G/A	cg20587970	chr11:113659929	NA	-1.34	-17.07	-0.72	1.45e-44	Hip circumference adjusted for BMI;
CESC	cis	rs80130819	0.748	rs987986	chr12:48645427	C/G	cg05342945	chr12:48394962	COL2A1	-0.54	-5.65	-0.33	4.16e-8	Prostate cancer;
CESC	cis	rs514406	0.644	rs6661196	chr1:53203664	A/G	cg08859206	chr1:53392774	SCP2	0.64	9.27	0.49	6.88e-18	Monocyte count;
CESC	cis	rs17376456	1.000	rs9968691	chr5:93509756	C/G	cg25358565	chr5:93447407	FAM172A	1.18	11.54	0.58	3.22e-25	Diabetic retinopathy;
CESC	cis	rs910316	1.000	rs175512	chr14:75523382	T/C	cg11812906	chr14:75593930	NEK9	-0.91	-15.62	-0.69	1.87e-39	Height;
CESC	cis	rs3733585	0.699	rs17245723	chr4:9962218	A/T	cg00071950	chr4:10020882	SLC2A9	-0.73	-11.83	-0.59	3.28e-26	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs656900	0.647	rs898436	chr15:80117132	C/T	cg02196730	chr15:80188777	MTHFS	-0.39	-5.05	-0.3	8.31e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs1862618	0.802	rs33327	chr5:56142693	T/G	cg12311346	chr5:56204834	C5orf35	-0.74	-8.76	-0.47	2.43e-16	Initial pursuit acceleration;
CESC	cis	rs2072499	0.966	rs6427304	chr1:156156789	A/G	cg25208724	chr1:156163844	SLC25A44	0.98	17.44	0.73	6.76e-46	Testicular germ cell tumor;
CESC	cis	rs4665809	0.938	rs6742226	chr2:26342537	A/G	cg25036284	chr2:26402008	FAM59B	-0.58	-6.64	-0.38	1.8e-10	Gut microbiome composition (summer);
CESC	cis	rs7598759	0.588	rs6737291	chr2:232329559	T/C	cg19187155	chr2:232395269	NMUR1	0.4	6.27	0.36	1.49e-9	Noise-induced hearing loss;
CESC	cis	rs7666738	0.830	rs72882693	chr4:98960804	T/A	cg05340658	chr4:99064831	C4orf37	0.8	12.39	0.61	3.96e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6460942	1.000	rs111761262	chr7:12415916	T/C	cg10578991	chr7:12443926	VWDE	-0.56	-6.0	-0.35	6.36e-9	Coronary artery disease;
CESC	cis	rs8062405	1.000	rs55830740	chr16:28847149	G/C	cg08761264	chr16:28874980	SH2B1	-0.46	-5.77	-0.33	2.26e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs6754311	0.681	rs4954493	chr2:136609975	T/C	cg15123519	chr2:136567270	LCT	0.31	5.16	0.3	4.81e-7	Mosquito bite size;
CESC	cis	rs7666738	0.830	rs28456179	chr4:98991439	A/G	cg03676636	chr4:99064102	C4orf37	0.34	5.3	0.31	2.38e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs539096	0.500	rs2906457	chr1:44338575	A/C	cg23954153	chr1:44402353	ARTN	-0.35	-5.53	-0.32	7.68e-8	Intelligence (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05797001	chr16:75681577	KARS;TERF2IP	-0.54	-6.11	-0.35	3.56e-9	Gut microbiome composition (summer);
CESC	cis	rs9325144	0.505	rs1906262	chr12:38653605	A/G	cg26384229	chr12:38710491	ALG10B	0.68	10.94	0.56	3.21e-23	Morning vs. evening chronotype;
CESC	cis	rs8092503	0.536	rs12962378	chr18:52431095	T/C	cg12377874	chr18:52495404	RAB27B	0.35	5.15	0.3	4.97e-7	Childhood body mass index;
CESC	cis	rs4919687	0.550	rs10748828	chr10:104456794	C/T	cg04362960	chr10:104952993	NT5C2	-0.42	-5.06	-0.3	8.01e-7	Colorectal cancer;
CESC	cis	rs2625529	0.526	rs11634622	chr15:72562327	G/A	cg16672083	chr15:72433130	SENP8	0.43	6.46	0.37	4.88e-10	Red blood cell count;
CESC	cis	rs6580649	0.941	rs17122611	chr12:48458149	C/T	cg24011408	chr12:48396354	COL2A1	-0.42	-5.28	-0.31	2.67e-7	Lung cancer;
CESC	cis	rs3741798	1.000	rs3741798	chr12:12496086	C/T	cg08615371	chr12:12503544	MANSC1	0.79	5.65	0.33	4.22e-8	Cerebrospinal fluid biomarker levels;
CESC	cis	rs853679	0.550	rs1233699	chr6:28169158	A/T	cg23161317	chr6:28129485	ZNF389	0.45	6.04	0.35	5.1e-9	Depression;
CESC	cis	rs3747547	0.642	rs7018923	chr9:38088027	C/T	cg13774184	chr9:37916125	SHB	-0.61	-5.27	-0.31	2.8e-7	Metabolite levels (Dihydroxy docosatrienoic acid);
CESC	cis	rs6951245	0.882	rs10256720	chr7:1210825	C/G	cg23708337	chr7:1209742	NA	0.55	5.58	0.32	5.91e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg22314900	chr2:109150331	NA	-0.42	-6.01	-0.35	5.96e-9	Gambling;
CESC	cis	rs1707322	1.000	rs1588663	chr1:46548825	G/A	cg06784218	chr1:46089804	CCDC17	-0.33	-5.57	-0.32	6.35e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs875971	0.825	rs1000464	chr7:65777909	G/C	cg12463550	chr7:65579703	CRCP	-0.45	-5.83	-0.34	1.63e-8	Aortic root size;
CESC	cis	rs4927850	1.000	rs4927850	chr3:195751630	C/T	cg01181863	chr3:195395398	SDHAP2	0.51	6.15	0.35	2.86e-9	Pancreatic cancer;
CESC	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.56	-7.25	-0.41	4.61e-12	Longevity;Endometriosis;
CESC	cis	rs8008758	1.000	rs8013718	chr14:101689506	C/T	cg26224664	chr14:101693935	NA	-0.36	-5.3	-0.31	2.45e-7	Body mass index (alcohol intake interaction);
CESC	cis	rs2742417	0.624	rs2742394	chr3:45757591	C/T	cg04837898	chr3:45731254	SACM1L	-0.48	-6.55	-0.37	2.96e-10	Response to anti-depressant treatment in major depressive disorder;
CESC	cis	rs4665809	0.525	rs4665324	chr2:26447147	A/C	cg26314531	chr2:26401878	FAM59B	-0.85	-9.04	-0.49	3.46e-17	Gut microbiome composition (summer);
CESC	cis	rs7811142	1.000	rs113738841	chr7:100081306	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.13	13.1	0.63	1.4e-30	Platelet count;
CESC	cis	rs4713118	0.621	rs4713132	chr6:28034035	A/G	cg17949981	chr6:28129498	ZNF389	0.42	5.2	0.3	3.96e-7	Parkinson's disease;
CESC	cis	rs7927771	0.832	rs67116452	chr11:47385194	G/A	cg18512352	chr11:47633146	NA	-0.52	-7.51	-0.42	9.24e-13	Subjective well-being;
CESC	cis	rs6456156	0.774	rs6931530	chr6:167527200	A/C	cg07741184	chr6:167504864	NA	-0.31	-5.21	-0.31	3.71e-7	Primary biliary cholangitis;
CESC	cis	rs698833	0.509	rs1946932	chr2:44543125	C/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.53	5.26	0.31	2.97e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs897984	0.762	rs897986	chr16:30980902	T/C	cg02466173	chr16:30829666	NA	0.47	7.79	0.43	1.48e-13	Dementia with Lewy bodies;
CESC	cis	rs2075371	0.829	rs11770764	chr7:134003308	T/C	cg20476274	chr7:133979776	SLC35B4	0.58	8.1	0.45	1.98e-14	Mean platelet volume;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg15774864	chr2:63272214	LOC100132215;EHBP1	0.46	6.07	0.35	4.37e-9	Fibrinogen levels;
CESC	cis	rs4969178	0.965	rs3817294	chr17:76396963	A/G	cg05887092	chr17:76393375	PGS1	0.58	9.22	0.49	9.9e-18	HDL cholesterol levels;
CESC	cis	rs72781680	1.000	rs11553491	chr2:24225901	G/C	cg08917208	chr2:24149416	ATAD2B	1.02	8.9	0.48	9.29e-17	Lymphocyte counts;
CESC	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg06873352	chr17:61820015	STRADA	0.72	12.95	0.62	4.84e-30	Prudent dietary pattern;
CESC	cis	rs3126085	0.935	rs41267154	chr1:152286367	C/A	cg03465714	chr1:152285911	FLG	0.5	5.71	0.33	2.96e-8	Atopic dermatitis;
CESC	cis	rs9308433	0.529	rs9430133	chr1:214496313	C/T	cg06198575	chr1:214491504	SMYD2	0.49	5.98	0.34	7.22e-9	IgG glycosylation;
CESC	cis	rs10504229	0.512	rs117968470	chr8:58014651	C/G	cg02725872	chr8:58115012	NA	-0.38	-5.1	-0.3	6.54e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs17376456	0.597	rs1031423	chr5:93276883	A/G	cg25358565	chr5:93447407	FAM172A	-0.44	-5.15	-0.3	4.97e-7	Diabetic retinopathy;
CESC	cis	rs17102884	0.506	rs4899541	chr14:75403437	T/G	cg08847533	chr14:75593920	NEK9	-0.44	-5.49	-0.32	9.41e-8	Neuroticism;
CESC	cis	rs2243480	0.803	rs36004293	chr7:65416512	T/C	cg18252515	chr7:66147081	NA	-1.05	-10.01	-0.52	3.2e-20	Diabetic kidney disease;
CESC	cis	rs4713118	0.587	rs9393899	chr6:28133528	G/C	cg20151795	chr6:28129481	ZNF389	0.44	5.55	0.32	6.85e-8	Parkinson's disease;
CESC	cis	rs7264396	0.635	rs6058365	chr20:34508092	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.59	7.06	0.4	1.46e-11	Total cholesterol levels;
CESC	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.05	19.14	0.76	7.08e-52	Prudent dietary pattern;
CESC	cis	rs832540	0.931	rs832529	chr5:56229288	C/T	cg12311346	chr5:56204834	C5orf35	-0.42	-5.28	-0.31	2.64e-7	Coronary artery disease;
CESC	cis	rs7772486	0.875	rs2474356	chr6:146296798	G/A	cg23711669	chr6:146136114	FBXO30	0.89	13.0	0.62	3.19e-30	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs12348691	0.503	rs7848950	chr9:100612774	T/C	cg13688889	chr9:100608707	NA	-0.89	-13.65	-0.64	1.79e-32	Alopecia areata;
CESC	cis	rs6088590	0.648	rs6059991	chr20:33280836	C/T	cg08999081	chr20:33150536	PIGU	0.66	10.69	0.55	2.02e-22	Coronary artery disease;
CESC	cis	rs4268898	0.662	rs72793208	chr2:24510284	C/T	cg06627628	chr2:24431161	ITSN2	-0.97	-11.12	-0.56	7.81e-24	Asthma;
CESC	cis	rs9611565	0.694	rs106860	chr22:41840407	C/T	cg06634786	chr22:41940651	POLR3H	-0.68	-6.84	-0.39	5.59e-11	Vitiligo;
CESC	cis	rs12479064	0.724	rs3087403	chr2:100058870	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.6	-7.48	-0.42	1.07e-12	Chronic sinus infection;
CESC	cis	rs4704187	0.687	rs10214239	chr5:74357475	G/A	cg03227963	chr5:74354835	NA	0.29	5.31	0.31	2.34e-7	Response to amphetamines;
CESC	cis	rs9814567	1.000	rs2177601	chr3:134245434	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.45	6.08	0.35	4.21e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs16866061	1.000	rs4674916	chr2:225365635	C/A	cg12698349	chr2:225449008	CUL3	0.74	11.27	0.57	2.5e-24	Acute graft versus host disease in bone marrow transplantation (recipient effect);
CESC	cis	rs3815700	0.844	rs444089	chr19:33106991	G/C	cg24916020	chr19:33096688	ANKRD27	0.59	5.72	0.33	2.86e-8	Eosinophilic esophagitis;
CESC	cis	rs7212590	0.748	rs55794618	chr17:57934337	G/C	cg20303301	chr17:57937339	TUBD1	-0.58	-5.68	-0.33	3.47e-8	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs9309473	1.000	rs11899902	chr2:73631564	G/A	cg20560298	chr2:73613845	ALMS1	-0.5	-6.65	-0.38	1.69e-10	Metabolite levels;
CESC	cis	rs6088580	0.602	rs6058064	chr20:33086622	A/G	cg08999081	chr20:33150536	PIGU	0.65	11.38	0.57	1.04e-24	Glomerular filtration rate (creatinine);
CESC	cis	rs9790314	0.967	rs336541	chr3:161056698	A/C	cg04691961	chr3:161091175	C3orf57	-0.4	-5.11	-0.3	6.05e-7	Morning vs. evening chronotype;
CESC	cis	rs2230307	0.536	rs526128	chr1:100473427	T/A	cg24955406	chr1:100503596	HIAT1	0.55	5.48	0.32	9.85e-8	Carotid intima media thickness;
CESC	cis	rs6938	0.575	rs12909335	chr15:75214789	T/G	cg17294928	chr15:75287854	SCAMP5	0.51	6.71	0.38	1.2e-10	Breast cancer;
CESC	cis	rs9355610	0.609	rs7772112	chr6:167408896	G/A	cg23791538	chr6:167370224	RNASET2	0.54	6.37	0.36	8.26e-10	Graves' disease;
CESC	cis	rs7542091	0.704	rs4133950	chr1:210044393	C/G	cg22029157	chr1:209979665	IRF6	0.5	7.86	0.43	9.93e-14	Monobrow;
CESC	cis	rs7223966	1.000	rs11870797	chr17:61804622	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.68	0.38	1.4e-10	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs514406	0.893	rs1242330	chr1:53396842	T/G	cg08859206	chr1:53392774	SCP2	-0.58	-7.44	-0.42	1.45e-12	Monocyte count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13064004	chr8:38854350	ADAM9;TM2D2	0.63	7.37	0.41	2.22e-12	Gut microbiome composition (summer);
CESC	cis	rs7044106	0.734	rs10491784	chr9:123432289	A/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.81	12.82	0.62	1.3e-29	Hip circumference adjusted for BMI;
CESC	cis	rs11622475	1.000	rs11622475	chr14:104509076	C/T	cg12183467	chr14:104352244	NA	-0.39	-5.53	-0.32	7.8e-8	Bipolar disorder;
CESC	cis	rs10504229	0.679	rs7813252	chr8:58136389	C/G	cg02725872	chr8:58115012	NA	-0.45	-7.05	-0.4	1.52e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs67311347	0.955	rs12487955	chr3:40412853	T/C	cg24209194	chr3:40518798	ZNF619	0.42	5.25	0.31	3.15e-7	Renal cell carcinoma;
CESC	cis	rs7772486	0.654	rs6928007	chr6:146074941	G/A	cg05347473	chr6:146136440	FBXO30	-0.52	-6.94	-0.39	3.01e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs738322	0.967	rs133017	chr22:38572637	A/C	cg17652424	chr22:38574118	PLA2G6	-0.34	-6.04	-0.35	5.08e-9	Cutaneous nevi;
CESC	cis	rs1552244	1.000	rs2160869	chr3:10079255	G/A	cg00149659	chr3:10157352	C3orf10	0.75	9.42	0.5	2.25e-18	Alzheimer's disease;
CESC	cis	rs2303759	0.874	rs8108669	chr19:49845895	C/T	cg22307029	chr19:49891270	CCDC155	0.62	7.3	0.41	3.29e-12	Multiple sclerosis;
CESC	cis	rs16867321	0.950	rs2887180	chr2:181449305	C/A	cg23363182	chr2:181467187	NA	-0.43	-5.29	-0.31	2.61e-7	Obesity;
CESC	cis	rs17431357	1.000	rs73230322	chr12:121010885	G/A	cg25045489	chr12:120971538	RNF10	-0.92	-5.43	-0.32	1.27e-7	Insulin resistance/response;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13305165	chr3:25831802	NGLY1;OXSM	-0.55	-6.55	-0.37	3.03e-10	Gut microbiome composition (summer);
CESC	cis	rs9733	0.596	rs7412396	chr1:150666797	C/T	cg22823121	chr1:150693482	HORMAD1	0.46	6.39	0.37	7.43e-10	Tonsillectomy;
CESC	cis	rs60154123	0.554	rs1338290	chr1:210465467	G/A	cg23283495	chr1:209979779	IRF6	0.42	5.41	0.32	1.41e-7	Coronary artery disease;
CESC	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg06873352	chr17:61820015	STRADA	0.73	12.89	0.62	7.87e-30	Prudent dietary pattern;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg26069066	chr20:44044698	PIGT	-0.46	-6.11	-0.35	3.45e-9	Ulcerative colitis;
CESC	cis	rs11828289	0.660	rs12099049	chr11:23219311	A/G	cg20040320	chr11:23191996	NA	-0.71	-5.95	-0.34	8.63e-9	Cancer;
CESC	cis	rs7851660	0.809	rs10984253	chr9:100664474	A/G	cg13688889	chr9:100608707	NA	-0.63	-8.95	-0.48	6.33e-17	Strep throat;
CESC	cis	rs11997175	0.646	rs4593495	chr8:33692649	C/T	ch.8.33884649F	chr8:33765107	NA	0.56	7.33	0.41	2.73e-12	Body mass index;
CESC	cis	rs12325245	0.536	rs35432891	chr16:58561966	G/A	cg02549819	chr16:58548995	SETD6	0.96	6.42	0.37	6.42e-10	Schizophrenia;
CESC	cis	rs7542091	0.704	rs4133950	chr1:210044393	C/G	cg23283495	chr1:209979779	IRF6	0.35	5.69	0.33	3.41e-8	Monobrow;
CESC	cis	rs6582630	0.519	rs11514372	chr12:38308613	T/G	cg26384229	chr12:38710491	ALG10B	0.71	10.63	0.55	3.23e-22	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs6460942	0.597	rs7811374	chr7:12517437	T/C	cg02935154	chr7:12443704	VWDE	-0.54	-5.44	-0.32	1.23e-7	Coronary artery disease;
CESC	cis	rs4660306	0.614	rs1765711	chr1:45936285	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.47	5.2	0.3	3.91e-7	Homocysteine levels;
CESC	cis	rs1707322	0.721	rs10890341	chr1:46147240	C/A	cg05343316	chr1:45956843	TESK2	0.51	6.32	0.36	1.09e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs8058578	1.000	rs67128646	chr16:30672097	A/C	cg02466173	chr16:30829666	NA	-0.48	-7.34	-0.41	2.56e-12	Multiple myeloma;
CESC	cis	rs854765	0.583	rs7222480	chr17:17818817	G/T	cg16928487	chr17:17741425	SREBF1	-0.59	-10.25	-0.53	5.56e-21	Total body bone mineral density;
CESC	cis	rs644799	1.000	rs525404	chr11:95566520	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.53	6.37	0.36	8.52e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	trans	rs916888	0.821	rs70600	chr17:44860021	C/T	cg27125505	chr17:43679177	LOC644172	0.53	7.03	0.4	1.75e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs4950928	0.823	rs4950929	chr1:203160126	A/C	cg14085262	chr1:203155938	CHI3L1	0.47	5.27	0.31	2.83e-7	YKL-40 levels;
CESC	trans	rs2963826	0.589	rs298091	chr5:58996603	A/T	cg22129074	chr11:74204105	LIPT2	0.49	6.5	0.37	3.97e-10	Obesity-related traits;
CESC	cis	rs6940638	0.662	rs7759694	chr6:27240956	C/T	cg12292205	chr6:26970375	C6orf41	-0.38	-5.23	-0.31	3.45e-7	Intelligence (multi-trait analysis);
CESC	cis	rs634534	0.622	rs552130	chr11:65732800	T/C	cg04055107	chr11:65626734	MUS81;CFL1	0.43	5.37	0.31	1.75e-7	Sum eosinophil basophil counts;Eosinophil counts;
CESC	cis	rs7811142	0.775	rs1636980	chr7:99938864	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	-0.73	-6.69	-0.38	1.32e-10	Platelet count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17331554	chr14:105167820	INF2	-0.61	-7.35	-0.41	2.51e-12	Gut microbiome composition (summer);
CESC	cis	rs8067545	0.532	rs12943904	chr17:20007567	G/C	cg12073167	chr17:19770448	ULK2	-0.44	-5.28	-0.31	2.71e-7	Schizophrenia;
CESC	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg07157834	chr1:205819609	PM20D1	0.72	10.41	0.54	1.66e-21	Menarche (age at onset);
CESC	cis	rs7937682	0.924	rs7924683	chr11:111555796	C/A	cg09085632	chr11:111637200	PPP2R1B	-1.02	-16.9	-0.72	5.47e-44	Primary sclerosing cholangitis;
CESC	cis	rs9847710	0.733	rs2581790	chr3:53101780	A/G	cg13284614	chr3:52569169	NT5DC2;LOC440957	-0.32	-5.14	-0.3	5.32e-7	Ulcerative colitis;
CESC	cis	rs10876993	0.855	rs1689604	chr12:58048304	T/C	cg18357645	chr12:58087776	OS9	0.58	9.0	0.48	4.49e-17	Celiac disease or Rheumatoid arthritis;
CESC	cis	rs854765	0.583	rs7222480	chr17:17818817	G/T	cg09796270	chr17:17721594	SREBF1	0.46	6.39	0.37	7.35e-10	Total body bone mineral density;
CESC	cis	rs75804782	0.580	rs72987332	chr2:239362529	G/T	cg18131467	chr2:239335373	ASB1	-0.7	-5.56	-0.32	6.56e-8	Morning vs. evening chronotype;Chronotype;
CESC	cis	rs7551222	0.691	rs11240760	chr1:204547268	A/G	cg20240347	chr1:204465584	NA	-0.28	-5.66	-0.33	3.84e-8	Schizophrenia;
CESC	cis	rs2404602	0.716	rs17460201	chr15:76673627	C/T	cg22467129	chr15:76604101	ETFA	0.38	5.77	0.33	2.15e-8	Blood metabolite levels;
CESC	cis	rs35110281	0.659	rs2236667	chr21:45112939	A/G	cg01579765	chr21:45077557	HSF2BP	-0.53	-9.19	-0.49	1.17e-17	Mean corpuscular volume;
CESC	cis	rs1044826	0.642	rs2071388	chr3:139236683	C/T	cg00490450	chr3:139108681	COPB2	-0.44	-5.35	-0.31	1.95e-7	Obesity-related traits;
CESC	cis	rs7829975	0.714	rs4841040	chr8:8654527	T/C	cg15556689	chr8:8085844	FLJ10661	0.5	6.37	0.36	8.51e-10	Mood instability;
CESC	cis	rs7666738	0.830	rs7691864	chr4:98971376	G/C	cg03676636	chr4:99064102	C4orf37	0.33	5.11	0.3	6.08e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg03188948	chr7:1209495	NA	0.7	6.71	0.38	1.17e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs1008375	0.966	rs3775923	chr4:17585625	T/C	cg16339924	chr4:17578868	LAP3	0.83	10.64	0.55	2.91e-22	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs7666738	0.830	rs7679961	chr4:99000202	C/T	cg03467027	chr4:99064603	C4orf37	0.44	5.51	0.32	8.65e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2243480	1.000	rs3885839	chr7:65290403	G/T	cg12463550	chr7:65579703	CRCP	0.69	5.53	0.32	7.48e-8	Diabetic kidney disease;
CESC	cis	rs6502050	0.835	rs34287733	chr17:80078236	C/T	cg11859384	chr17:80120422	CCDC57	0.38	5.15	0.3	5.1e-7	Life satisfaction;
CESC	cis	rs3785574	0.962	rs2955235	chr17:61966950	A/C	cg01411255	chr17:61851458	DDX42;CCDC47	1.01	15.49	0.69	5.85e-39	Height;
CESC	cis	rs8114671	0.869	rs6060199	chr20:33654773	A/G	cg24642439	chr20:33292090	TP53INP2	-0.47	-5.7	-0.33	3.19e-8	Height;
CESC	cis	rs1218582	0.741	rs10908447	chr1:154869742	C/T	cg24250549	chr1:154909240	PMVK	0.58	7.82	0.43	1.26e-13	Prostate cancer;
CESC	cis	rs2576037	0.583	rs12386118	chr18:44540376	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.49	-6.56	-0.37	2.79e-10	Personality dimensions;
CESC	cis	rs7618915	0.571	rs2251219	chr3:52584787	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	-0.38	-6.3	-0.36	1.23e-9	Bipolar disorder;
CESC	cis	rs17209837	0.527	rs45479991	chr7:87083339	A/T	cg00919237	chr7:87102261	ABCB4	-0.51	-6.58	-0.37	2.45e-10	Gallbladder cancer;
CESC	cis	rs863345	0.604	rs4276920	chr1:158504972	G/C	cg12129480	chr1:158549410	OR10X1	-0.35	-7.06	-0.4	1.45e-11	Pneumococcal bacteremia;
CESC	cis	rs875971	0.964	rs160635	chr7:65528918	T/C	cg18876405	chr7:65276391	NA	0.56	7.49	0.42	1.03e-12	Aortic root size;
CESC	cis	rs8077577	0.945	rs62073611	chr17:18071961	C/G	cg16794390	chr17:18148240	FLII	0.44	5.47	0.32	1.06e-7	Obesity-related traits;
CESC	cis	rs7772486	0.686	rs2179323	chr6:145982786	T/G	cg23711669	chr6:146136114	FBXO30	-0.88	-13.1	-0.63	1.44e-30	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2439831	0.867	rs2255051	chr15:43846161	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.8	8.65	0.47	5.16e-16	Lung cancer in ever smokers;
CESC	cis	rs7845219	0.525	rs3019175	chr8:95949013	G/A	cg23172400	chr8:95962367	TP53INP1	-0.34	-6.12	-0.35	3.28e-9	Type 2 diabetes;
CESC	cis	rs295140	0.585	rs4233996	chr2:201131228	A/T	cg23649088	chr2:200775458	C2orf69	-0.44	-6.0	-0.35	6.56e-9	QT interval;
CESC	cis	rs1348850	0.554	rs7595576	chr2:178371921	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.69	6.19	0.36	2.22e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs8031584	0.918	rs61997140	chr15:31277312	A/G	cg08704250	chr15:31115839	NA	-0.63	-8.12	-0.45	1.82e-14	Huntington's disease progression;
CESC	cis	rs965469	0.779	rs6037534	chr20:3269832	G/A	cg25506879	chr20:3388711	C20orf194	-0.48	-5.29	-0.31	2.52e-7	IFN-related cytopenia;
CESC	cis	rs2842992	0.830	rs2758352	chr6:160122921	A/G	cg11366901	chr6:160182831	ACAT2	0.82	10.3	0.53	3.96e-21	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs9314614	0.934	rs2980955	chr8:6694434	A/G	cg27319216	chr8:6693540	XKR5	-0.35	-5.12	-0.3	5.96e-7	IgA nephropathy;White blood cell count (basophil);
CESC	cis	rs10751667	0.643	rs11246362	chr11:969818	C/T	cg06064525	chr11:970664	AP2A2	-0.47	-9.23	-0.49	8.83e-18	Alzheimer's disease (late onset);
CESC	cis	rs116095464	0.558	rs10055354	chr5:243794	G/A	cg22496380	chr5:211416	CCDC127	-0.74	-8.63	-0.47	5.66e-16	Breast cancer;
CESC	cis	rs3740713	1.000	rs74663287	chr11:18460300	T/C	cg23797887	chr11:18477753	LDHAL6A	-0.53	-5.11	-0.3	6.1e-7	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs514406	0.893	rs499195	chr1:53344907	C/T	cg24675658	chr1:53192096	ZYG11B	-0.48	-5.89	-0.34	1.16e-8	Monocyte count;
CESC	cis	rs10479542	0.630	rs6879664	chr5:178974576	T/G	cg22764044	chr5:178986830	RUFY1	0.41	5.61	0.33	4.96e-8	Lung cancer;
CESC	cis	rs367943	0.712	rs26964	chr5:112738532	T/C	cg12552261	chr5:112820674	MCC	0.41	5.43	0.32	1.28e-7	Type 2 diabetes;
CESC	cis	rs7605827	0.930	rs6740183	chr2:15692583	T/C	cg19274914	chr2:15703543	NA	0.37	6.7	0.38	1.22e-10	Educational attainment (years of education);
CESC	cis	rs9916302	0.851	rs4390625	chr17:37620347	A/G	cg07936489	chr17:37558343	FBXL20	-0.81	-11.96	-0.59	1.17e-26	Glomerular filtration rate (creatinine);
CESC	cis	rs7818688	0.578	rs11786451	chr8:95897031	T/G	cg16049864	chr8:95962084	TP53INP1	0.49	5.06	0.3	7.8e-7	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs919433	1.000	rs1429414	chr2:198162430	C/T	cg10820045	chr2:198174542	NA	-0.39	-5.73	-0.33	2.68e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs9894429	0.789	rs9747336	chr17:79584189	C/T	cg21984481	chr17:79567631	NPLOC4	-0.58	-9.48	-0.5	1.5e-18	Eye color traits;
CESC	cis	rs875971	0.825	rs1129531	chr7:65619104	C/T	cg10691866	chr7:65817282	TPST1	0.32	5.31	0.31	2.28e-7	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18113596	chr7:57247912	LOC642006	-0.51	-7.42	-0.41	1.62e-12	Gut microbiome composition (summer);
CESC	cis	rs12136530	0.744	rs34929465	chr1:19777950	G/A	cg01832549	chr1:19774989	CAPZB	-0.46	-6.78	-0.38	8e-11	Lead levels in blood;
CESC	cis	rs734999	0.505	rs10910107	chr1:2539181	C/T	cg20673091	chr1:2541236	MMEL1	0.45	7.79	0.43	1.5e-13	Ulcerative colitis;
CESC	cis	rs7666738	0.830	rs17484966	chr4:99014432	T/C	cg17366294	chr4:99064904	C4orf37	0.6	8.62	0.47	6.37e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6893300	0.776	rs55868831	chr5:179157296	T/C	cg14593053	chr5:179126677	CANX	-0.47	-5.15	-0.3	5.1e-7	Resting heart rate;
CESC	cis	rs514406	0.893	rs512723	chr1:53343880	C/T	cg08736216	chr1:53307985	ZYG11A	0.43	7.23	0.41	5.32e-12	Monocyte count;
CESC	trans	rs2417940	0.741	rs7313981	chr12:21012430	T/C	cg19502417	chr1:21930336	RAP1GAP	-0.46	-6.1	-0.35	3.71e-9	Bilirubin levels;
CESC	cis	rs7833790	1.000	rs7833790	chr8:82731157	T/C	cg07697082	chr8:82753677	SNX16	0.39	5.48	0.32	9.84e-8	Diastolic blood pressure;
CESC	cis	rs9910055	0.529	rs425038	chr17:42182028	T/C	cg13607699	chr17:42295918	UBTF	-0.56	-7.15	-0.4	8.38e-12	Total body bone mineral density;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23567369	chr14:24036565	AP1G2	0.57	6.18	0.35	2.41e-9	Gut microbiome composition (summer);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg09172752	chr15:77197536	NA	-0.53	-6.45	-0.37	5.14e-10	Ulcerative colitis;
CESC	cis	rs3858526	0.584	rs10769276	chr11:5868020	G/T	cg02574844	chr11:5959923	NA	-0.44	-6.6	-0.38	2.21e-10	DNA methylation (variation);
CESC	cis	rs208520	1.000	rs12200490	chr6:66976084	G/A	cg07460842	chr6:66804631	NA	0.89	10.27	0.53	4.85e-21	Exhaled nitric oxide output;
CESC	cis	rs7615952	0.599	rs12485717	chr3:125707075	C/T	cg06494592	chr3:125709126	NA	0.46	5.03	0.3	8.94e-7	Blood pressure (smoking interaction);
CESC	cis	rs7824557	0.564	rs2437152	chr8:11235497	G/A	cg21775007	chr8:11205619	TDH	-0.54	-8.1	-0.45	1.98e-14	Retinal vascular caliber;
CESC	cis	rs9859260	0.710	rs419068	chr3:195782176	C/T	cg12923728	chr3:195709715	SDHAP1	0.53	6.93	0.39	3.14e-11	Mean corpuscular volume;
CESC	cis	rs1595825	0.891	rs73054825	chr2:198636355	G/C	cg00982548	chr2:198649783	BOLL	-0.47	-5.08	-0.3	7.12e-7	Ulcerative colitis;
CESC	cis	rs9814567	1.000	rs7611828	chr3:134250325	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.45	-6.15	-0.35	2.87e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs8067354	0.609	rs1292066	chr17:57932314	T/A	cg13753209	chr17:57696993	CLTC	0.68	8.63	0.47	5.94e-16	Hemoglobin concentration;
CESC	cis	rs7659604	0.676	rs6534323	chr4:122695888	G/A	cg19748678	chr4:122722346	EXOSC9	0.72	9.42	0.5	2.39e-18	Type 2 diabetes;
CESC	trans	rs61931739	0.500	rs11053199	chr12:34450534	C/T	cg26384229	chr12:38710491	ALG10B	-0.55	-7.76	-0.43	1.87e-13	Morning vs. evening chronotype;
CESC	cis	rs4481887	0.927	rs6671702	chr1:248482851	G/A	cg00666640	chr1:248458726	OR2T12	0.35	5.88	0.34	1.23e-8	Common traits (Other);
CESC	cis	rs4423214	1.000	rs3794060	chr11:71187679	C/T	cg05163923	chr11:71159392	DHCR7	0.8	10.72	0.55	1.69e-22	Vitamin D levels;
CESC	cis	rs7666738	0.830	rs11721726	chr4:98996314	T/C	cg05340658	chr4:99064831	C4orf37	0.8	12.44	0.61	2.83e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs34779708	0.897	rs4934529	chr10:35302376	T/A	cg04310649	chr10:35416472	CREM	-0.5	-5.98	-0.34	7.34e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs9611565	0.659	rs17367849	chr22:41923644	G/A	cg06634786	chr22:41940651	POLR3H	-0.7	-7.47	-0.42	1.19e-12	Vitiligo;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09473867	chr1:8763372	RERE	0.56	6.32	0.36	1.09e-9	Gut microbiome composition (summer);
CESC	cis	rs1878931	0.580	rs4578649	chr16:3407258	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.92	-14.21	-0.66	1.82e-34	Body mass index (adult);
CESC	cis	rs1620921	0.505	rs1344729	chr6:161204841	C/T	cg01280913	chr6:161186852	NA	-0.36	-5.27	-0.31	2.81e-7	Lipoprotein (a) - cholesterol levels;
CESC	cis	rs909674	0.865	rs5757682	chr22:39848259	T/G	cg05872129	chr22:39784769	NA	-0.81	-9.88	-0.52	8.3e-20	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs10927875	0.722	rs1763606	chr1:16338282	A/G	cg21385522	chr1:16154831	NA	0.62	7.52	0.42	8.52e-13	Dilated cardiomyopathy;
CESC	trans	rs1973993	0.689	rs17115225	chr1:96884330	C/T	cg10631902	chr5:14652156	NA	-0.49	-6.39	-0.37	7.58e-10	Weight;
CESC	cis	rs2652822	0.525	rs8037296	chr15:63516759	A/G	cg02713581	chr15:63449717	RPS27L	0.49	6.34	0.36	1e-9	Metabolic traits;
CESC	cis	rs1878931	0.535	rs7188903	chr16:3412861	A/G	cg02880119	chr16:3481970	NA	-0.42	-5.34	-0.31	1.98e-7	Body mass index (adult);
CESC	cis	rs4665809	0.838	rs2243834	chr2:26357748	A/C	cg25036284	chr2:26402008	FAM59B	0.56	6.68	0.38	1.43e-10	Gut microbiome composition (summer);
CESC	trans	rs8073060	0.586	rs11080356	chr17:33895309	T/C	cg19694781	chr19:47549865	TMEM160	0.69	6.76	0.38	8.98e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	cis	rs826838	0.967	rs826879	chr12:39088999	A/C	cg13010199	chr12:38710504	ALG10B	-0.42	-5.95	-0.34	8.63e-9	Heart rate;
CESC	cis	rs3096299	0.933	rs2965939	chr16:89493043	G/A	cg00750074	chr16:89608354	SPG7	-0.4	-5.73	-0.33	2.71e-8	Multiple myeloma (IgH translocation);
CESC	cis	rs1008375	0.966	rs4698638	chr4:17632988	G/C	cg02297831	chr4:17616191	MED28	0.54	6.85	0.39	5.05e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs853679	0.517	rs9393895	chr6:28127621	T/C	cg23161317	chr6:28129485	ZNF389	0.52	6.48	0.37	4.37e-10	Depression;
CESC	trans	rs35160687	0.644	rs11127024	chr2:86505453	C/T	ch.2.2367852R	chr2:113497768	CKAP2L	0.48	6.0	0.35	6.48e-9	Night sleep phenotypes;
CESC	cis	rs11864453	1.000	rs7185407	chr16:72034957	A/T	cg01557791	chr16:72042693	DHODH	0.63	8.45	0.46	2.02e-15	Fibrinogen levels;
CESC	cis	rs7666738	0.570	rs1869351	chr4:99077286	T/C	cg05340658	chr4:99064831	C4orf37	0.65	9.19	0.49	1.17e-17	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6582630	0.563	rs923281	chr12:38590241	G/A	cg26384229	chr12:38710491	ALG10B	-0.42	-5.55	-0.32	7e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs10751667	1.000	rs7927156	chr11:970607	A/G	cg06064525	chr11:970664	AP2A2	-0.33	-5.82	-0.34	1.71e-8	Alzheimer's disease (late onset);
CESC	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg15112475	chr7:1198522	ZFAND2A	-0.37	-5.92	-0.34	1.02e-8	Longevity;Endometriosis;
CESC	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg23708337	chr7:1209742	NA	0.55	5.41	0.32	1.44e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs3780486	0.846	rs10971438	chr9:33180308	A/G	cg04842962	chr6:43655489	MRPS18A	0.85	12.49	0.61	1.81e-28	IgG glycosylation;
CESC	cis	rs4665809	1.000	rs12469163	chr2:26283587	T/C	cg26314531	chr2:26401878	FAM59B	-0.58	-6.54	-0.37	3.18e-10	Gut microbiome composition (summer);
CESC	cis	rs4423214	1.000	rs11546509	chr11:71162785	A/G	cg05163923	chr11:71159392	DHCR7	0.76	10.38	0.54	2.13e-21	Vitamin D levels;
CESC	cis	rs796364	0.951	rs281769	chr2:200809709	T/C	cg23649088	chr2:200775458	C2orf69	0.54	5.33	0.31	2.13e-7	Schizophrenia;
CESC	cis	rs16866061	0.515	rs114968850	chr2:225352461	C/G	cg12698349	chr2:225449008	CUL3	0.83	14.59	0.67	8.47e-36	Acute graft versus host disease in bone marrow transplantation (recipient effect);
CESC	cis	rs3858526	0.834	rs7129481	chr11:5991114	G/T	cg13902645	chr11:5959945	NA	-0.49	-5.74	-0.33	2.52e-8	DNA methylation (variation);
CESC	trans	rs1814175	0.817	rs7483795	chr11:49704930	G/A	cg15704280	chr7:45808275	SEPT13	-1.04	-19.78	-0.77	4.33e-54	Height;
CESC	cis	rs12541635	0.639	rs1032545	chr8:107005825	C/T	cg10147462	chr8:107024639	NA	0.45	6.72	0.38	1.13e-10	Age of smoking initiation;
CESC	cis	rs853679	0.542	rs2295594	chr6:28053097	G/A	cg08968635	chr6:28129556	ZNF389	0.39	5.22	0.31	3.64e-7	Depression;
CESC	cis	rs11214589	0.905	rs10891539	chr11:113236492	G/C	cg14159747	chr11:113255604	NA	0.28	5.04	0.3	8.51e-7	Neuroticism;
CESC	cis	rs1514687	0.534	rs73908736	chr2:1465401	C/T	cg13703866	chr2:1479523	TPO	-0.85	-5.58	-0.32	6e-8	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);
CESC	cis	rs597539	0.652	rs482172	chr11:68668437	C/A	cg04772025	chr11:68637568	NA	0.5	5.99	0.35	6.85e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs7937682	1.000	rs10502147	chr11:111569931	G/A	cg22437258	chr11:111473054	SIK2	-0.68	-7.83	-0.43	1.19e-13	Primary sclerosing cholangitis;
CESC	cis	rs2996428	0.536	rs12126653	chr1:3773815	C/G	cg13057898	chr1:3703894	LRRC47	0.45	6.09	0.35	4e-9	Red cell distribution width;
CESC	trans	rs507080	0.922	rs654792	chr11:118552996	A/C	cg02280908	chr2:28615925	FOSL2	0.44	6.02	0.35	5.8e-9	Serum metabolite levels;
CESC	cis	rs2070997	0.756	rs2987903	chr9:133711263	G/A	cg11464064	chr9:133710261	ABL1	0.59	5.82	0.34	1.65e-8	Response to amphetamines;
CESC	cis	rs7666738	0.791	rs11097601	chr4:98960103	C/T	cg05340658	chr4:99064831	C4orf37	0.8	12.39	0.61	3.96e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs875971	1.000	rs9986696	chr7:65704576	C/A	cg10691866	chr7:65817282	TPST1	0.33	5.52	0.32	8.13e-8	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12241299	chr14:20929705	TMEM55B	-0.62	-7.34	-0.41	2.64e-12	Gut microbiome composition (summer);
CESC	cis	rs734999	0.588	rs3748819	chr1:2524966	C/T	cg18854424	chr1:2615690	NA	0.27	5.14	0.3	5.31e-7	Ulcerative colitis;
CESC	cis	rs8072100	0.790	rs3760371	chr17:45695914	T/C	cg08085267	chr17:45401833	C17orf57	0.47	5.8	0.34	1.89e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs2243480	1.000	rs313824	chr7:65581207	C/T	cg13147721	chr7:65941812	NA	-0.99	-9.36	-0.5	3.5e-18	Diabetic kidney disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20299458	chr4:62383146	LPHN3	-0.61	-7.49	-0.42	1.04e-12	Gut microbiome composition (summer);
CESC	cis	rs6674176	0.561	rs12127226	chr1:44395309	C/T	cg12908607	chr1:44402522	ARTN	-0.51	-7.54	-0.42	7.68e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs7208859	0.524	rs57670615	chr17:29069498	A/G	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.1e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs8177253	0.666	rs8177197	chr3:133469530	G/A	cg11941060	chr3:133502564	NA	-0.48	-6.21	-0.36	2.02e-9	Iron status biomarkers;
CESC	cis	rs2243480	0.522	rs73150635	chr7:65972490	C/T	cg18252515	chr7:66147081	NA	-1.29	-9.61	-0.51	5.87e-19	Diabetic kidney disease;
CESC	cis	rs1018836	0.923	rs7013893	chr8:91563137	G/A	cg16814680	chr8:91681699	NA	-0.69	-9.68	-0.51	3.67e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg00176896	chr8:1185355	NA	0.39	6.79	0.38	7.43e-11	Gambling;
CESC	cis	rs875971	0.862	rs1860469	chr7:66106875	A/G	cg19163074	chr7:65112434	INTS4L2	0.43	5.44	0.32	1.24e-7	Aortic root size;
CESC	cis	rs6426558	0.537	rs12139758	chr1:227260519	A/G	cg10327440	chr1:227177885	CDC42BPA	0.46	5.68	0.33	3.52e-8	Neutrophil percentage of white cells;
CESC	cis	rs8111998	0.826	rs7247524	chr19:22764213	C/A	cg19914732	chr19:22715077	NA	-0.37	-5.09	-0.3	6.68e-7	Corneal structure;
CESC	cis	rs11098499	0.909	rs7681214	chr4:120385320	C/A	cg24375607	chr4:120327624	NA	0.44	5.48	0.32	9.91e-8	Corneal astigmatism;
CESC	cis	rs7666738	0.752	rs62318905	chr4:99036103	T/G	cg03676636	chr4:99064102	C4orf37	0.33	5.12	0.3	6.01e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9916302	0.904	rs7208274	chr17:37513796	C/T	cg20243544	chr17:37824526	PNMT	-0.49	-6.09	-0.35	3.9e-9	Glomerular filtration rate (creatinine);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27199523	chr6:139094722	CCDC28A	-0.66	-7.24	-0.41	5e-12	Gut microbiome composition (summer);
CESC	cis	rs35110281	0.591	rs189094	chr21:44932017	A/G	cg01579765	chr21:45077557	HSF2BP	-0.5	-8.14	-0.45	1.6e-14	Mean corpuscular volume;
CESC	cis	rs6084875	0.733	rs4143674	chr20:4741304	T/C	cg05143360	chr20:4741328	NA	0.56	7.56	0.42	6.51e-13	Systemic lupus erythematosus;
CESC	cis	rs7615952	0.576	rs1127717	chr3:125826059	T/C	cg18479299	chr3:125709523	NA	-0.48	-5.29	-0.31	2.61e-7	Blood pressure (smoking interaction);
CESC	trans	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg27125505	chr17:43679177	LOC644172	0.49	6.75	0.38	9.18e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs1881797	0.872	rs12404733	chr1:247690417	A/C	cg05639522	chr1:247681581	NA	0.42	5.77	0.33	2.18e-8	Acute lymphoblastic leukemia (childhood);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg17497049	chr19:56110871	FIZ1;ZNF524	-0.48	-6.18	-0.35	2.42e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs1018836	0.828	rs7816023	chr8:91567398	T/C	cg16814680	chr8:91681699	NA	-0.63	-9.25	-0.49	7.74e-18	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs61931739	0.534	rs11053049	chr12:34164537	T/C	cg19457237	chr12:34500585	NA	-0.39	-5.33	-0.31	2.08e-7	Morning vs. evening chronotype;
CESC	cis	rs734999	0.545	rs28532547	chr1:2561286	T/G	cg18854424	chr1:2615690	NA	-0.3	-5.83	-0.34	1.62e-8	Ulcerative colitis;
CESC	cis	rs1448094	0.813	rs6539942	chr12:86452969	T/C	cg02569458	chr12:86230093	RASSF9	-0.34	-5.1	-0.3	6.54e-7	Major depressive disorder;
CESC	cis	rs11785400	0.928	rs10100287	chr8:143734836	C/T	cg10596483	chr8:143751796	JRK	0.42	5.4	0.31	1.49e-7	Schizophrenia;
CESC	cis	rs1062753	0.961	rs9620007	chr22:42405657	C/G	cg22189786	chr22:42395067	WBP2NL	0.43	5.43	0.32	1.26e-7	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
CESC	cis	rs58785573	0.504	rs13151185	chr4:38609196	G/T	cg18361445	chr4:38666374	KLF3;FLJ13197	0.53	7.34	0.41	2.65e-12	Lymphocyte percentage of white cells;
CESC	cis	rs7772486	0.754	rs702304	chr6:145990797	A/G	cg23711669	chr6:146136114	FBXO30	-0.96	-14.81	-0.67	1.49e-36	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2836974	0.863	rs1065242	chr21:40567716	C/G	cg11890956	chr21:40555474	PSMG1	1.19	22.43	0.81	3.59e-63	Cognitive function;
CESC	cis	rs9457247	0.510	rs6456151	chr6:167471851	A/C	cg23791538	chr6:167370224	RNASET2	-0.5	-6.44	-0.37	5.46e-10	Crohn's disease;
CESC	cis	rs10791097	0.547	rs3829271	chr11:130753912	T/A	cg12179176	chr11:130786555	SNX19	0.66	10.15	0.53	1.12e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs9311474	0.508	rs7614498	chr3:52618941	A/T	cg18404041	chr3:52824283	ITIH1	-0.39	-6.63	-0.38	1.92e-10	Electroencephalogram traits;
CESC	cis	rs9311474	1.000	rs1060330	chr3:52288945	T/C	cg17372223	chr3:52568218	NT5DC2	0.41	6.26	0.36	1.59e-9	Electroencephalogram traits;
CESC	cis	rs875971	0.862	rs4718330	chr7:65715243	G/A	cg18876405	chr7:65276391	NA	-0.51	-7.19	-0.4	6.66e-12	Aortic root size;
CESC	cis	rs769267	0.929	rs2905431	chr19:19482882	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.44	-5.7	-0.33	3.24e-8	Tonsillectomy;
CESC	cis	rs8060686	0.925	rs1134760	chr16:67964203	T/C	cg26727032	chr16:67993705	SLC12A4	-0.58	-8.07	-0.44	2.39e-14	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs12973672	1.000	rs8101606	chr19:35774556	A/C	cg12095397	chr19:35769544	USF2	0.52	7.13	0.4	9.38e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14903832	chr2:198318098	COQ10B	0.64	7.25	0.41	4.49e-12	Gut microbiome composition (summer);
CESC	cis	rs4834770	1.000	rs4834770	chr4:120241849	A/G	cg09307838	chr4:120376055	NA	0.45	5.37	0.31	1.74e-7	Blood protein levels;
CESC	cis	rs6570726	0.905	rs406799	chr6:145821837	G/C	cg23711669	chr6:146136114	FBXO30	0.81	12.04	0.59	6.44e-27	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs637571	0.726	rs689274	chr11:65665988	A/G	cg17712092	chr4:129076599	LARP1B	-0.75	-10.22	-0.53	6.83e-21	Eosinophil percentage of white cells;
CESC	trans	rs2321882	0.958	rs1413030	chr13:59395182	G/A	cg20914879	chr14:56566808	NA	-0.43	-6.17	-0.35	2.51e-9	Body mass index;
CESC	cis	rs7412746	0.611	rs1889740	chr1:150799755	C/T	cg17724175	chr1:150552817	MCL1	0.33	5.23	0.31	3.49e-7	Melanoma;
CESC	cis	rs7336332	0.598	rs1885989	chr13:28010117	G/A	cg01674679	chr13:27998804	GTF3A	-0.59	-5.36	-0.31	1.82e-7	Weight;
CESC	cis	rs4253772	0.513	rs12171124	chr22:46710693	A/C	cg18190219	chr22:46762943	CELSR1	-0.58	-6.66	-0.38	1.57e-10	LDL cholesterol;Cholesterol, total;
CESC	cis	rs9640161	0.750	rs73170185	chr7:150030191	C/A	cg27494647	chr7:150038898	RARRES2	0.42	5.17	0.3	4.62e-7	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs2991971	0.810	rs6657237	chr1:45920108	A/T	cg24296786	chr1:45957014	TESK2	-0.6	-8.56	-0.47	9.12e-16	High light scatter reticulocyte count;
CESC	cis	rs78456975	0.739	rs72776248	chr2:1521314	A/G	cg01028140	chr2:1542097	TPO	-0.54	-5.34	-0.31	2e-7	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs7772486	0.790	rs9376968	chr6:146180364	T/C	cg23711669	chr6:146136114	FBXO30	0.89	13.12	0.63	1.21e-30	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs916888	0.697	rs199516	chr17:44856485	C/T	cg10053473	chr17:62856997	LRRC37A3	0.68	7.69	0.43	2.94e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs113835537	0.529	rs3816492	chr11:66297363	C/T	cg24851651	chr11:66362959	CCS	0.52	6.05	0.35	4.92e-9	Airway imaging phenotypes;
CESC	cis	rs1538970	0.816	rs868351	chr1:46009818	G/T	cg05343316	chr1:45956843	TESK2	0.84	11.82	0.59	3.45e-26	Platelet count;
CESC	cis	rs6493487	0.512	rs12911270	chr15:51166326	C/T	cg02338191	chr15:51200825	AP4E1	0.6	5.49	0.32	9.32e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs2243480	1.000	rs160655	chr7:65533214	T/C	cg13147721	chr7:65941812	NA	-0.93	-8.87	-0.48	1.1e-16	Diabetic kidney disease;
CESC	cis	rs61931739	0.500	rs11053177	chr12:34412829	G/A	cg06521331	chr12:34319734	NA	-0.37	-5.12	-0.3	5.75e-7	Morning vs. evening chronotype;
CESC	cis	rs910316	1.000	rs10146482	chr14:75574087	C/T	cg11812906	chr14:75593930	NEK9	0.91	16.22	0.71	1.43e-41	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03241323	chr2:187454863	ITGAV	0.68	7.46	0.42	1.21e-12	Gut microbiome composition (summer);
CESC	cis	rs10504073	0.647	rs55920380	chr8:50026353	G/A	cg00325661	chr8:49890786	NA	0.59	8.45	0.46	2e-15	Blood metabolite ratios;
CESC	cis	rs5753618	0.583	rs5753628	chr22:31860322	A/G	cg02404636	chr22:31891804	SFI1	0.39	5.34	0.31	1.97e-7	Colorectal cancer;
CESC	cis	rs1005277	0.522	rs289648	chr10:37971837	T/C	cg25427524	chr10:38739819	LOC399744	-0.62	-9.03	-0.49	3.53e-17	Extrinsic epigenetic age acceleration;
CESC	trans	rs10435719	0.867	rs62493601	chr8:11788307	C/T	cg15556689	chr8:8085844	FLJ10661	0.51	6.32	0.36	1.09e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
CESC	cis	rs6938	0.534	rs1127796	chr15:75193004	C/T	cg13906792	chr15:75199810	C15orf17	0.35	5.31	0.31	2.33e-7	Breast cancer;
CESC	cis	rs17001868	0.568	rs12484697	chr22:40736472	A/G	cg07138101	chr22:40742427	ADSL	-0.54	-5.12	-0.3	5.93e-7	Mammographic density (dense area);
CESC	trans	rs61931739	0.500	rs7965421	chr12:34523624	G/T	cg26384229	chr12:38710491	ALG10B	0.71	10.63	0.55	3.31e-22	Morning vs. evening chronotype;
CESC	cis	rs17376456	0.569	rs1026279	chr5:93209581	C/A	cg21475434	chr5:93447410	FAM172A	-0.5	-5.04	-0.3	8.56e-7	Diabetic retinopathy;
CESC	cis	rs6076065	0.963	rs2424543	chr20:23389955	G/T	cg11657817	chr20:23433608	CST11	0.34	5.24	0.31	3.24e-7	Facial morphology (factor 15, philtrum width);
CESC	cis	rs34172651	0.917	rs200539	chr16:24735178	T/C	cg06028605	chr16:24865363	SLC5A11	-0.43	-6.48	-0.37	4.38e-10	Intelligence (multi-trait analysis);
CESC	cis	rs4819052	0.851	rs2330011	chr21:46658498	G/A	cg11663144	chr21:46675770	NA	-0.55	-8.56	-0.47	9.52e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs2066819	1.000	rs11171803	chr12:56718422	T/C	cg26804944	chr12:56660921	COQ10A	-0.85	-5.14	-0.3	5.39e-7	Psoriasis vulgaris;
CESC	cis	rs4237845	0.788	rs1962047	chr12:58292707	G/A	cg02175503	chr12:58329896	NA	0.63	7.83	0.43	1.14e-13	Intelligence (multi-trait analysis);
CESC	cis	rs9322193	0.923	rs12176034	chr6:150121693	C/T	cg04369109	chr6:150039330	LATS1	-0.47	-6.42	-0.37	6.11e-10	Lung cancer;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg26792749	chr19:41816040	CCDC97	-0.48	-6.39	-0.37	7.47e-10	Fibrinogen levels;
CESC	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg07677032	chr17:61819896	STRADA	0.45	6.05	0.35	4.97e-9	Prudent dietary pattern;
CESC	cis	rs9660180	0.875	rs4648727	chr1:1776269	C/A	cg17747265	chr1:1875780	NA	0.43	6.8	0.39	7.1e-11	Body mass index;
CESC	cis	rs1005224	1.000	rs1981898	chr14:76175565	C/A	cg25116370	chr14:76127843	TTLL5;C14orf1	-0.42	-5.79	-0.34	1.97e-8	Large artery stroke;
CESC	cis	rs2439831	0.764	rs2447193	chr15:43929733	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.7	8.59	0.47	7.81e-16	Lung cancer in ever smokers;
CESC	cis	rs601339	1.000	rs2454722	chr12:123171218	A/G	cg11919336	chr12:123188078	GPR109A	0.47	6.38	0.36	8.07e-10	Adiponectin levels;
CESC	cis	rs4409675	0.576	rs6660899	chr1:28214281	G/C	cg23691781	chr1:28212827	C1orf38	0.28	5.74	0.33	2.59e-8	Corneal astigmatism;
CESC	cis	rs7833790	0.724	rs6473311	chr8:82726682	G/A	cg07697082	chr8:82753677	SNX16	0.41	6.25	0.36	1.67e-9	Diastolic blood pressure;
CESC	cis	rs77956314	0.515	rs4238051	chr12:117366299	A/G	cg16111737	chr12:117408163	FBXW8	-0.48	-5.74	-0.33	2.61e-8	Subcortical brain region volumes;Hippocampal volume;
CESC	cis	rs2637266	0.739	rs2439580	chr10:78423214	T/G	cg18941641	chr10:78392320	NA	0.39	7.28	0.41	3.87e-12	Pulmonary function;
CESC	cis	rs9349203	1	rs9349203	chr6:41893323	G/A	cg08135965	chr6:41755394	TOMM6	0.37	5.07	0.3	7.6e-7	Menarche (age at onset);
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg09192333	chr22:38142150	TRIOBP	0.45	6.0	0.35	6.54e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	trans	rs17508449	0.865	rs75296543	chr1:114138286	C/A	cg23028848	chr11:57092561	TNKS1BP1	-0.79	-6.26	-0.36	1.54e-9	Leprosy;
CESC	cis	rs3820068	0.705	rs4646077	chr1:15827136	C/T	cg17385448	chr1:15911702	AGMAT	0.39	6.18	0.35	2.44e-9	Systolic blood pressure;
CESC	cis	rs10789491	1.000	rs7547522	chr1:47179918	C/G	cg15501359	chr1:47185051	KIAA0494	0.77	8.56	0.47	9.21e-16	Response to hepatitis C treatment;
CESC	cis	rs2228479	0.850	rs62054257	chr16:89900195	G/A	cg06558623	chr16:89946397	TCF25	1.12	8.22	0.45	9.28e-15	Skin colour saturation;
CESC	cis	rs12188164	0.686	rs72711367	chr5:418494	A/G	cg26850624	chr5:429559	AHRR	-0.5	-6.8	-0.39	6.97e-11	Cystic fibrosis severity;
CESC	cis	rs4664308	0.692	rs4233681	chr2:160960058	T/C	cg03641300	chr2:160917029	PLA2R1	-0.44	-6.23	-0.36	1.86e-9	Idiopathic membranous nephropathy;
CESC	cis	rs7267979	0.868	rs6138546	chr20:25216534	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.82	15.42	0.69	1.02e-38	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs4268898	0.662	rs58971404	chr2:24403753	G/A	cg20701182	chr2:24300061	SF3B14	0.73	7.32	0.41	3.02e-12	Asthma;
CESC	cis	rs71403859	1.000	rs71403859	chr16:71640207	C/T	cg08717414	chr16:71523259	ZNF19	-0.79	-6.93	-0.39	3.19e-11	Post bronchodilator FEV1;
CESC	trans	rs9329221	0.521	rs4841294	chr8:10105068	G/T	cg15556689	chr8:8085844	FLJ10661	-0.5	-6.11	-0.35	3.54e-9	Neuroticism;
CESC	cis	rs6545883	0.965	rs778752	chr2:61776902	C/G	cg15711740	chr2:61764176	XPO1	-0.45	-5.7	-0.33	3.17e-8	Tuberculosis;
CESC	cis	rs703842	1.000	rs10431505	chr12:58178589	A/G	cg00677455	chr12:58241039	CTDSP2	0.53	6.97	0.39	2.55e-11	Multiple sclerosis;
CESC	cis	rs17253792	0.822	rs58569951	chr14:56152245	T/C	cg01858014	chr14:56050164	KTN1	-0.78	-6.61	-0.38	2.06e-10	Putamen volume;
CESC	cis	rs7833986	0.534	rs2667980	chr8:56896541	A/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.58	7.16	0.4	8.04e-12	Height;
CESC	cis	rs1044826	0.642	rs4683464	chr3:139196961	C/T	cg00490450	chr3:139108681	COPB2	0.4	5.05	0.3	8.16e-7	Obesity-related traits;
CESC	cis	rs11864453	0.611	rs1050361	chr16:72130203	C/G	cg16558253	chr16:72132732	DHX38	-0.54	-8.44	-0.46	2.03e-15	Fibrinogen levels;
CESC	cis	rs4594175	0.926	rs10873044	chr14:51615856	T/C	cg23942311	chr14:51606299	NA	0.39	5.95	0.34	8.64e-9	Cancer;
CESC	cis	rs9309711	0.666	rs4321399	chr2:3481659	G/A	cg10845886	chr2:3471009	TTC15	-0.67	-9.24	-0.49	8.22e-18	Neurofibrillary tangles;
CESC	cis	rs10504229	0.683	rs16921817	chr8:58107563	A/T	cg02725872	chr8:58115012	NA	-0.43	-6.81	-0.39	6.53e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg22105103	chr4:187893119	NA	0.51	7.69	0.43	2.88e-13	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2408955	0.521	rs10875749	chr12:48531917	T/A	cg04545296	chr12:48745243	ZNF641	-0.33	-5.72	-0.33	2.85e-8	Glycated hemoglobin levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18395393	chr17:8339079	NDEL1	0.59	6.47	0.37	4.62e-10	Gut microbiome composition (summer);
CESC	cis	rs7927771	0.542	rs10769300	chr11:47865560	C/T	cg20307385	chr11:47447363	PSMC3	0.63	8.77	0.47	2.17e-16	Subjective well-being;
CESC	cis	rs6474412	1.000	rs6997909	chr8:42560249	A/G	cg25026480	chr8:42547641	NA	0.32	5.09	0.3	6.85e-7	Smoking behavior;
CESC	trans	rs9929218	0.954	rs12596834	chr16:68823199	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.62	-8.13	-0.45	1.69e-14	Colorectal cancer;
CESC	cis	rs796364	0.789	rs1653297	chr2:201075483	C/T	cg23649088	chr2:200775458	C2orf69	0.49	5.65	0.33	4.21e-8	Schizophrenia;
CESC	cis	rs8077577	0.895	rs11655797	chr17:18107850	C/T	cg16794390	chr17:18148240	FLII	0.41	5.54	0.32	7.2e-8	Obesity-related traits;
CESC	cis	rs782590	0.935	rs782649	chr2:55860308	T/C	cg18811423	chr2:55921094	PNPT1	0.79	12.63	0.61	5.98e-29	Metabolic syndrome;
CESC	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg27094323	chr7:1216898	NA	-0.42	-5.97	-0.34	7.59e-9	Longevity;Endometriosis;
CESC	cis	rs1799949	1.000	rs3950989	chr17:41237953	G/A	cg06001716	chr17:41278141	BRCA1;NBR2	0.38	5.32	0.31	2.2e-7	Menopause (age at onset);
CESC	cis	rs28374715	0.681	rs28687846	chr15:41599902	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.0	-14.25	-0.66	1.3600000000000001e-34	Ulcerative colitis;
CESC	cis	rs61776719	0.520	rs12569027	chr1:38449163	C/T	cg18451016	chr1:38461880	NA	0.42	6.33	0.36	1.04e-9	Coronary artery disease;
CESC	cis	rs950169	0.920	rs11637666	chr15:84703874	A/G	cg17507749	chr15:85114479	UBE2QP1	0.64	6.66	0.38	1.53e-10	Schizophrenia;
CESC	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.71	-11.4	-0.57	9.16e-25	Longevity;Endometriosis;
CESC	trans	rs2898290	0.540	rs35005793	chr8:11450472	G/A	cg15556689	chr8:8085844	FLJ10661	0.57	7.04	0.4	1.62e-11	Systolic blood pressure;
CESC	cis	rs672059	1.000	rs522372	chr1:183157449	C/G	ch.1.3577855R	chr1:183094577	LAMC1	-0.54	-6.93	-0.39	3.12e-11	Hypertriglyceridemia;
CESC	cis	rs6991838	0.584	rs10089708	chr8:66555162	T/C	cg13398993	chr8:66546079	ARMC1	0.49	5.89	0.34	1.18e-8	Intelligence (multi-trait analysis);
CESC	cis	rs7186908	0.711	rs9923344	chr16:72190653	T/C	cg01557791	chr16:72042693	DHODH	-0.64	-7.15	-0.4	8.33e-12	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs4891159	0.790	rs11150953	chr18:74145491	G/A	cg24786174	chr18:74118243	ZNF516	-0.72	-10.87	-0.56	5.42e-23	Longevity;
CESC	cis	rs999943	0.846	rs2274200	chr6:33625696	T/C	cg14003231	chr6:33640908	ITPR3	0.71	12.4	0.61	3.68e-28	Obesity (extreme);
CESC	cis	rs9457247	0.765	rs1060404	chr6:167429467	A/G	cg07741184	chr6:167504864	NA	0.36	6.54	0.37	3.11e-10	Crohn's disease;
CESC	cis	rs6952808	0.689	rs12670737	chr7:2046830	C/T	cg04267008	chr7:1944627	MAD1L1	-0.58	-7.02	-0.4	1.89e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs4629180	1.000	rs908133	chr2:102092374	A/C	cg04415270	chr2:102091202	RFX8	-0.41	-6.67	-0.38	1.5e-10	Chronic rhinosinusitis with nasal polyps;
CESC	cis	rs2985684	0.841	rs12894785	chr14:50049755	G/C	cg04989706	chr14:50066350	PPIL5	-0.46	-5.15	-0.3	5.04e-7	Carotid intima media thickness;
CESC	cis	rs7927771	0.542	rs7122217	chr11:47777920	G/C	cg18512352	chr11:47633146	NA	-0.35	-5.47	-0.32	1.03e-7	Subjective well-being;
CESC	trans	rs35110281	0.811	rs2838339	chr21:45075750	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.54	-7.09	-0.4	1.25e-11	Mean corpuscular volume;
CESC	cis	rs3092073	0.624	rs7275164	chr20:44604822	G/A	cg00981651	chr20:44574847	PCIF1	0.37	5.37	0.31	1.75e-7	Intelligence (multi-trait analysis);
CESC	cis	rs853679	0.546	rs200950	chr6:27835772	A/G	cg26587870	chr6:27730563	NA	-0.6	-5.29	-0.31	2.58e-7	Depression;
CESC	cis	rs7666738	0.791	rs13128640	chr4:99003918	A/C	cg17366294	chr4:99064904	C4orf37	0.6	8.61	0.47	6.47e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs733175	0.855	rs9291641	chr4:10007259	C/T	cg00071950	chr4:10020882	SLC2A9	0.55	6.62	0.38	1.95e-10	Psychosis and Alzheimer's disease;
CESC	cis	rs2011503	1.000	rs74950305	chr19:19639448	C/T	cg11584989	chr19:19387371	SF4	0.61	7.03	0.4	1.79e-11	Bipolar disorder;
CESC	cis	rs4689388	0.750	rs10001190	chr4:6284633	C/T	cg14416269	chr4:6271139	WFS1	-0.42	-6.61	-0.38	2.08e-10	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs80130819	0.515	rs72644846	chr12:48508283	A/G	cg05342945	chr12:48394962	COL2A1	0.55	6.32	0.36	1.13e-9	Prostate cancer;
CESC	cis	rs7811142	0.830	rs11769057	chr7:99964661	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.1	11.77	0.59	5.44e-26	Platelet count;
CESC	cis	rs7762018	1.000	rs6942332	chr6:170131934	A/G	cg13891659	chr6:170190454	C6orf122;C6orf208	0.55	5.56	0.32	6.5e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs7772486	0.790	rs9497435	chr6:146265340	C/A	cg23711669	chr6:146136114	FBXO30	-0.81	-11.61	-0.58	1.87e-25	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6987853	0.787	rs2923427	chr8:42385748	A/C	cg09913449	chr8:42400586	C8orf40	0.45	7.62	0.42	4.55e-13	Mean corpuscular hemoglobin concentration;
CESC	cis	rs1514687	0.534	rs11211654	chr2:1474131	C/T	cg13703866	chr2:1479523	TPO	-0.8	-6.32	-0.36	1.09e-9	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);
CESC	cis	rs7903847	0.642	rs11189196	chr10:99155079	A/G	cg20016023	chr10:99160130	RRP12	-0.3	-5.16	-0.3	4.77e-7	Granulocyte percentage of myeloid white cells;
CESC	cis	rs7116495	0.609	rs949323	chr11:71714528	T/G	cg10381502	chr11:71823885	C11orf51	-1.13	-7.93	-0.44	6.3e-14	Severe influenza A (H1N1) infection;
CESC	cis	rs2708240	0.577	rs1177007	chr7:147546371	G/A	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.38	-5.76	-0.33	2.36e-8	QT interval (drug interaction);
CESC	cis	rs933688	1.000	rs6452951	chr5:90653868	T/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.97	13.31	0.63	2.75e-31	Smoking behavior;
CESC	cis	rs2243480	0.706	rs6460257	chr7:65196780	C/T	cg25985355	chr7:65971099	NA	-0.43	-5.58	-0.32	6.06e-8	Diabetic kidney disease;
CESC	cis	rs12765878	1.000	rs2273698	chr10:105649158	G/A	cg24587175	chr10:105670608	OBFC1	0.32	5.22	0.31	3.58e-7	Coronary artery disease;
CESC	cis	rs7084402	0.967	rs1658423	chr10:60331627	T/G	cg07615347	chr10:60278583	BICC1	0.56	8.39	0.46	2.91e-15	Refractive error;
CESC	cis	rs9543976	1.000	rs2328964	chr13:76138830	G/T	cg01531495	chr13:76123901	UCHL3	0.56	5.65	0.33	4.21e-8	Diabetic retinopathy;
CESC	cis	rs10504229	0.683	rs66730544	chr8:58127280	A/T	cg22535103	chr8:58192502	C8orf71	-0.84	-9.44	-0.5	2.04e-18	Developmental language disorder (linguistic errors);
CESC	cis	rs13191362	1.000	rs34443622	chr6:163208214	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.04	9.88	0.52	8.25e-20	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs6089584	1.000	rs6089585	chr20:60564395	G/A	cg24733560	chr20:60626293	TAF4	0.4	5.77	0.33	2.15e-8	Body mass index;
CESC	cis	rs17711722	0.523	rs313812	chr7:65505043	T/C	cg05332525	chr7:65337924	VKORC1L1	-0.48	-6.05	-0.35	4.86e-9	Calcium levels;
CESC	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.64	7.2	0.4	6.35e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7927592	0.956	rs12365160	chr11:68250419	A/G	cg16797656	chr11:68205561	LRP5	0.39	5.47	0.32	1.06e-7	Total body bone mineral density;
CESC	cis	rs798502	0.541	rs2644307	chr7:2832973	G/A	cg19717773	chr7:2847554	GNA12	-0.63	-10.29	-0.53	3.97e-21	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Inflammatory bowel disease;Waist circumference adjusted for BMI in non-smokers;Ulcerative colitis;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
CESC	cis	rs9513627	0.573	rs4771336	chr13:100210610	T/G	cg15490075	chr13:100150979	NA	0.48	5.38	0.31	1.66e-7	Obesity-related traits;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg26548542	chr16:89177266	ACSF3	0.42	6.16	0.35	2.7e-9	Fibrinogen levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12392475	chr5:140537692	PCDHB17	-0.49	-6.05	-0.35	4.84e-9	Gut microbiome composition (summer);
CESC	trans	rs4108601	0.590	rs17868255	chr2:52030913	C/T	cg02531768	chr10:521758	DIP2C	-0.72	-6.14	-0.35	2.95e-9	Facial morphology (factor 19);
CESC	cis	rs909674	0.818	rs5750830	chr22:39840828	C/A	cg11247378	chr22:39784982	NA	-0.63	-8.64	-0.47	5.22e-16	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs7680126	0.595	rs17251963	chr4:10142561	A/G	cg00071950	chr4:10020882	SLC2A9	-0.49	-5.32	-0.31	2.23e-7	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	cis	rs72781680	0.611	rs72797810	chr2:24336469	G/A	cg06627628	chr2:24431161	ITSN2	-0.67	-6.51	-0.37	3.7e-10	Lymphocyte counts;
CESC	trans	rs35110281	0.591	rs162369	chr21:44931965	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.49	6.68	0.38	1.41e-10	Mean corpuscular volume;
CESC	cis	rs6967385	0.704	rs17149929	chr7:12406080	A/T	cg02935154	chr7:12443704	VWDE	0.32	5.05	0.3	8.25e-7	Response to taxane treatment (placlitaxel);
CESC	cis	rs748404	0.560	rs570933	chr15:43824030	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.55	7.05	0.4	1.52e-11	Lung cancer;
CESC	cis	rs950169	0.545	rs4842841	chr15:84641125	G/A	cg17507749	chr15:85114479	UBE2QP1	0.62	5.98	0.34	7.21e-9	Schizophrenia;
CESC	cis	rs853679	0.517	rs6922063	chr6:28094366	G/A	cg17221315	chr6:27791827	HIST1H4J	0.43	5.03	0.3	9.18e-7	Depression;
CESC	trans	rs11098499	0.657	rs4463052	chr4:120313258	T/C	cg25214090	chr10:38739885	LOC399744	0.68	9.2	0.49	1.14e-17	Corneal astigmatism;
CESC	cis	rs8177253	0.665	rs9869257	chr3:133451412	G/T	cg16262614	chr3:133464971	TF	0.3	5.46	0.32	1.11e-7	Iron status biomarkers;
CESC	cis	rs12048904	0.619	rs10783153	chr1:101328230	T/C	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.64	7.51	0.42	9.22e-13	Multiple sclerosis;
CESC	cis	rs3820068	0.603	rs72645900	chr1:15931980	A/T	cg17385448	chr1:15911702	AGMAT	0.44	7.16	0.4	7.97e-12	Systolic blood pressure;
CESC	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg18402987	chr7:1209562	NA	0.73	7.13	0.4	9.84e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7811142	1.000	rs7811142	chr7:100065443	A/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.14	11.37	0.57	1.12e-24	Platelet count;
CESC	cis	rs6752107	0.967	rs6431661	chr2:234167421	C/T	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.4	6.04	0.35	5.16e-9	Crohn's disease;Inflammatory bowel disease;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg25215298	chr1:860022	SAMD11	-0.38	-6.08	-0.35	4.12e-9	Gambling;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00602371	chr16:77233247	SYCE1L;MON1B	-0.53	-6.09	-0.35	4.02e-9	Gut microbiome composition (summer);
CESC	cis	rs9876781	0.559	rs11130167	chr3:48400060	A/G	cg11946769	chr3:48343235	NME6	0.4	5.07	0.3	7.31e-7	Longevity;
CESC	cis	rs2294693	0.891	rs9369256	chr6:40998344	G/C	cg14418226	chr6:40996092	UNC5CL	0.55	6.8	0.39	6.93e-11	Gastric cancer;Non-cardia gastric cancer;
CESC	cis	rs9649213	0.593	rs3801263	chr7:97965016	A/G	cg21770322	chr7:97807741	LMTK2	0.55	8.27	0.45	6.54e-15	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs6987853	0.933	rs2974352	chr8:42408483	C/T	cg09913449	chr8:42400586	C8orf40	0.4	6.38	0.37	7.72e-10	Mean corpuscular hemoglobin concentration;
CESC	cis	rs67311347	0.826	rs9863679	chr3:40439614	G/A	cg09455208	chr3:40491958	NA	0.5	8.24	0.45	8.07e-15	Renal cell carcinoma;
CESC	cis	rs9815354	0.812	rs17283929	chr3:41941898	C/G	cg03022575	chr3:42003672	ULK4	-0.7	-6.71	-0.38	1.16e-10	Pulse pressure;Diastolic blood pressure;
CESC	trans	rs6445797	0.788	rs6445805	chr3:56670281	G/C	cg15444621	chr13:113611794	NA	0.32	6.01	0.35	6.11e-9	Gastritis;
CESC	cis	rs2721195	0.967	rs748195	chr8:145682514	T/C	cg26752003	chr8:145688521	CYHR1	-0.59	-7.75	-0.43	1.93e-13	Age at first birth;
CESC	cis	rs896854	0.624	rs9297949	chr8:95969445	A/C	cg09323728	chr8:95962352	TP53INP1	-0.37	-7.92	-0.44	6.51e-14	Type 2 diabetes;
CESC	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg14338887	chr6:42928500	GNMT	0.35	5.08	0.3	7.25e-7	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs7223966	1.000	rs8068603	chr17:61755211	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.58	7.42	0.41	1.55e-12	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs6952808	0.582	rs871925	chr7:2047875	G/A	cg23048001	chr7:2026167	MAD1L1	-0.49	-6.39	-0.37	7.43e-10	Bipolar disorder and schizophrenia;
CESC	cis	rs7412746	0.587	rs11204722	chr1:150730184	A/C	cg17724175	chr1:150552817	MCL1	-0.37	-5.66	-0.33	3.91e-8	Melanoma;
CESC	cis	rs1003719	0.613	rs9978998	chr21:38535848	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.59	-8.06	-0.44	2.72e-14	Eye color traits;
CESC	cis	rs780096	0.527	rs12471703	chr2:27738854	C/T	cg02592271	chr2:27665507	KRTCAP3	-0.33	-6.41	-0.37	6.76e-10	Total body bone mineral density;
CESC	cis	rs73058052	1.000	rs73057994	chr19:50091273	C/A	cg09250473	chr19:50168907	IRF3;BCL2L12	0.59	5.74	0.33	2.55e-8	Fibrinogen levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12753558	chr1:247464072	ZNF496	-0.59	-6.21	-0.36	2e-9	Gut microbiome composition (summer);
CESC	trans	rs916888	0.773	rs199445	chr17:44817408	C/T	cg23590916	chr17:43697445	MGC57346	0.65	6.68	0.38	1.38e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs9660180	0.967	rs6664664	chr1:1751264	G/A	cg13866156	chr1:1669148	SLC35E2	-0.51	-6.82	-0.39	6.21e-11	Body mass index;
CESC	cis	rs7937682	0.924	rs10891288	chr11:111552053	G/T	cg09085632	chr11:111637200	PPP2R1B	1.02	17.0	0.72	2.54e-44	Primary sclerosing cholangitis;
CESC	cis	rs7647973	0.848	rs4955411	chr3:49145304	A/G	cg06212747	chr3:49208901	KLHDC8B	0.55	6.36	0.36	8.72e-10	Menarche (age at onset);
CESC	cis	rs9325144	0.505	rs7138977	chr12:38642109	G/A	cg26384229	chr12:38710491	ALG10B	0.67	10.81	0.55	8.39e-23	Morning vs. evening chronotype;
CESC	cis	rs6504663	0.558	rs11871603	chr17:48559037	T/G	cg03611598	chr17:48586076	MYCBPAP	0.53	6.21	0.36	2.06e-9	Visceral fat;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg03909886	chr10:42606808	NA	0.42	6.36	0.36	8.57e-10	Fibrinogen levels;
CESC	cis	rs2033711	0.783	rs8113810	chr19:58932106	A/G	cg00825309	chr19:58991885	ZNF446	-0.54	-7.71	-0.43	2.57e-13	Uric acid clearance;
CESC	cis	rs7843479	0.582	rs7818254	chr8:21798316	C/T	cg17168535	chr8:21777572	XPO7	0.74	12.35	0.6	5.77e-28	Mean corpuscular volume;
CESC	cis	rs3947	0.950	rs1692811	chr8:11703048	C/G	cg00262122	chr8:11665843	FDFT1	-0.5	-5.06	-0.3	7.67e-7	Blood protein levels;
CESC	trans	rs11039798	0.588	rs7108164	chr11:48626363	A/C	cg15704280	chr7:45808275	SEPT13	0.61	6.29	0.36	1.32e-9	Axial length;
CESC	cis	rs7811142	0.830	rs1063945	chr7:99930447	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.69	6.12	0.35	3.41e-9	Platelet count;
CESC	cis	rs9303401	0.659	rs62081315	chr17:56781468	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.05	12.77	0.62	1.94e-29	Cognitive test performance;
CESC	cis	rs1707322	1.000	rs11211248	chr1:46476844	A/G	cg06784218	chr1:46089804	CCDC17	0.33	5.7	0.33	3.15e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7116495	0.609	rs7121080	chr11:71703935	G/A	cg26138937	chr11:71823887	C11orf51	-1.22	-8.09	-0.45	2.15e-14	Severe influenza A (H1N1) infection;
CESC	cis	rs10504229	0.593	rs78459635	chr8:58004995	G/T	cg24829409	chr8:58192753	C8orf71	-0.67	-7.32	-0.41	3e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs3793683	0.520	rs4880426	chr10:134590610	G/A	cg26818010	chr10:134567672	INPP5A	-0.9	-11.23	-0.57	3.42e-24	Migraine;
CESC	cis	rs7829975	0.593	rs2921051	chr8:8320104	C/A	cg15556689	chr8:8085844	FLJ10661	0.61	8.16	0.45	1.35e-14	Mood instability;
CESC	cis	rs2839186	0.605	rs2839173	chr21:47676711	G/A	cg10351095	chr21:47802916	PCNT	-0.48	-6.46	-0.37	5.11e-10	Testicular germ cell tumor;
CESC	cis	rs1707322	0.721	rs6697821	chr1:46216722	A/G	cg06784218	chr1:46089804	CCDC17	0.43	7.58	0.42	5.65e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs17376456	0.825	rs17374166	chr5:93238655	T/C	cg21475434	chr5:93447410	FAM172A	0.78	6.83	0.39	5.85e-11	Diabetic retinopathy;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg23192255	chr4:1309340	MAEA	0.47	6.17	0.35	2.55e-9	Fibrinogen levels;
CESC	cis	rs798554	0.836	rs798526	chr7:2775542	G/C	cg04166393	chr7:2884313	GNA12	0.59	7.48	0.42	1.12e-12	Height;
CESC	cis	rs7647973	0.626	rs2329021	chr3:49679072	G/A	cg07636037	chr3:49044803	WDR6	0.53	6.34	0.36	9.78e-10	Menarche (age at onset);
CESC	cis	rs67311347	1.000	rs9865348	chr3:40397658	A/C	cg09455208	chr3:40491958	NA	0.53	9.29	0.5	5.82e-18	Renal cell carcinoma;
CESC	cis	rs3741404	1.000	rs3741404	chr11:63999240	G/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.92	13.92	0.65	2.01e-33	Platelet count;
CESC	cis	rs6952808	0.929	rs11768206	chr7:1932151	T/G	cg04267008	chr7:1944627	MAD1L1	-0.72	-9.3	-0.5	5.53e-18	Bipolar disorder and schizophrenia;
CESC	cis	rs2013441	1.000	rs11654025	chr17:20198160	A/T	cg13482628	chr17:19912719	NA	-0.39	-5.07	-0.3	7.58e-7	Obesity-related traits;
CESC	cis	rs748404	0.631	rs12905772	chr15:43648444	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.6	7.64	0.43	3.88e-13	Lung cancer;
CESC	cis	rs3540	0.597	rs12708583	chr15:91050271	C/T	cg10434728	chr15:90938212	IQGAP1	0.41	7.61	0.42	4.69e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs250677	0.958	rs36070	chr5:148417240	T/C	cg18129178	chr5:148520854	ABLIM3	-0.52	-5.8	-0.34	1.86e-8	Breast cancer;
CESC	cis	rs9359856	0.600	rs17584763	chr6:90502088	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.65	-6.58	-0.37	2.53e-10	Bipolar disorder;
CESC	cis	rs60154123	0.505	rs76426571	chr1:210041634	C/T	cg21951975	chr1:209979733	IRF6	0.58	6.23	0.36	1.85e-9	Coronary artery disease;
CESC	cis	rs514406	0.861	rs4926577	chr1:53226788	C/A	cg16325326	chr1:53192061	ZYG11B	-0.89	-15.32	-0.69	2.26e-38	Monocyte count;
CESC	cis	rs6748734	1.000	rs4311055	chr2:241821017	T/C	cg07537917	chr2:241836409	C2orf54	-0.25	-5.35	-0.31	1.89e-7	Urinary metabolites;
CESC	cis	rs3126085	0.935	rs1390488	chr1:152199500	T/C	cg03465714	chr1:152285911	FLG	-0.43	-5.24	-0.31	3.23e-7	Atopic dermatitis;
CESC	cis	rs10870270	0.956	rs4880405	chr10:133787021	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.6	-7.68	-0.43	3.03e-13	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs11098499	0.604	rs10022185	chr4:120571765	C/G	cg09307838	chr4:120376055	NA	0.76	9.58	0.51	7.28e-19	Corneal astigmatism;
CESC	cis	rs2576037	0.583	rs8098948	chr18:44512332	C/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.79	13.24	0.63	4.57e-31	Personality dimensions;
CESC	cis	rs6502050	0.635	rs11867440	chr17:80147185	A/T	cg23985595	chr17:80112537	CCDC57	-0.42	-6.57	-0.37	2.58e-10	Life satisfaction;
CESC	cis	rs1348850	0.914	rs7587604	chr2:178309848	T/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.75	10.72	0.55	1.7e-22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs523522	0.962	rs3893104	chr12:120903936	G/A	cg27279351	chr12:120934652	DYNLL1	0.69	8.69	0.47	3.82e-16	High light scatter reticulocyte count;
CESC	cis	rs708547	0.575	rs6847086	chr4:57791864	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.49	-6.17	-0.35	2.59e-9	Response to bleomycin (chromatid breaks);
CESC	cis	rs2425143	1.000	rs73905926	chr20:34251982	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.83	-7.52	-0.42	8.7e-13	Blood protein levels;
CESC	cis	rs9487051	0.582	rs351723	chr6:109545547	G/A	cg01475377	chr6:109611718	NA	-0.38	-5.18	-0.3	4.49e-7	Reticulocyte fraction of red cells;
CESC	cis	rs11264213	0.901	rs72661608	chr1:36333850	C/G	cg27506609	chr1:36549197	TEKT2	0.69	5.49	0.32	9.42e-8	Schizophrenia;
CESC	cis	rs7224737	1.000	rs9889618	chr17:40293467	C/T	cg20291162	chr17:40259547	DHX58	-0.4	-5.48	-0.32	9.96e-8	Fibrinogen levels;
CESC	cis	rs7918232	0.943	rs6482593	chr10:27371437	A/G	cg14442939	chr10:27389572	ANKRD26	0.7	6.63	0.38	1.87e-10	Breast cancer;
CESC	cis	rs7818688	0.585	rs2678829	chr8:96028180	C/T	cg16049864	chr8:95962084	TP53INP1	-0.6	-6.5	-0.37	3.9e-10	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs769267	0.930	rs10402451	chr19:19608537	A/G	cg03709012	chr19:19516395	GATAD2A	1.01	15.71	0.69	9.73e-40	Tonsillectomy;
CESC	cis	rs9581857	0.579	rs75872792	chr13:27996064	G/T	cg01674679	chr13:27998804	GTF3A	-0.67	-5.58	-0.32	5.88e-8	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
CESC	cis	rs1552244	1.000	rs9809061	chr3:10085130	C/G	cg08888203	chr3:10149979	C3orf24	0.47	6.03	0.35	5.4e-9	Alzheimer's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05590361	chr11:68039700	C11orf24	0.59	6.26	0.36	1.58e-9	Gut microbiome composition (summer);
CESC	cis	rs5167	0.566	rs204905	chr19:45460764	G/A	cg20090143	chr19:45452003	APOC2	0.34	5.56	0.32	6.56e-8	Blood protein levels;
CESC	cis	rs66530629	0.874	rs4562565	chr1:25121874	A/G	cg22509179	chr1:25234806	RUNX3	-0.43	-5.43	-0.32	1.29e-7	Plateletcrit;
CESC	cis	rs6503863	1	rs6503863	chr17:56517034	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.49	6.58	0.37	2.53e-10	Intelligence (multi-trait analysis);
CESC	cis	rs7771547	0.573	rs629721	chr6:36398229	T/C	cg04289385	chr6:36355825	ETV7	0.38	5.57	0.32	6.41e-8	Platelet distribution width;
CESC	cis	rs6460942	0.915	rs62447638	chr7:12484667	G/A	cg02935154	chr7:12443704	VWDE	-0.56	-5.83	-0.34	1.61e-8	Coronary artery disease;
CESC	cis	rs8078723	0.714	rs9915252	chr17:38145088	C/G	cg17344932	chr17:38183730	MED24;SNORD124	0.35	5.05	0.3	8.15e-7	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CESC	cis	rs875971	0.793	rs460678	chr7:65527200	C/G	cg18876405	chr7:65276391	NA	0.56	7.51	0.42	8.81e-13	Aortic root size;
CESC	cis	rs4072980	0.545	rs7528185	chr1:38452059	C/T	cg26528311	chr1:38462546	FHL3	-0.34	-5.07	-0.3	7.4e-7	Coronary artery disease;
CESC	cis	rs1799949	0.683	rs55737636	chr17:41264739	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	7.78	0.43	1.58e-13	Menopause (age at onset);
CESC	cis	rs7904368	0.806	rs7099178	chr10:16862578	C/G	cg23933602	chr10:16859644	RSU1	0.6	5.49	0.32	9.24e-8	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
CESC	cis	rs916888	0.773	rs169201	chr17:44790203	A/G	cg01570182	chr17:44337453	NA	0.94	10.63	0.55	3.24e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs1552244	0.882	rs17050672	chr3:10025463	G/A	cg00149659	chr3:10157352	C3orf10	0.58	6.17	0.35	2.51e-9	Alzheimer's disease;
CESC	cis	rs9487051	1.000	rs9400272	chr6:109616762	A/G	cg01475377	chr6:109611718	NA	-0.4	-6.22	-0.36	1.93e-9	Reticulocyte fraction of red cells;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg01345365	chr2:12163619	NA	-0.45	-6.65	-0.38	1.66e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs1153858	1.000	rs16942000	chr15:45633003	C/T	cg14582100	chr15:45693742	SPATA5L1	0.42	6.08	0.35	4.2e-9	Homoarginine levels;
CESC	cis	rs10905065	0.898	rs2892078	chr10:5831138	A/G	cg11519256	chr10:5708881	ASB13	-0.41	-5.47	-0.32	1.04e-7	Menopause (age at onset);
CESC	cis	rs79349575	0.745	rs170319	chr17:46991531	T/C	cg16584676	chr17:46985605	UBE2Z	0.53	6.6	0.38	2.25e-10	Type 2 diabetes;
CESC	cis	rs208515	0.592	rs10944862	chr6:66674215	C/T	cg07460842	chr6:66804631	NA	0.86	10.87	0.56	5.19e-23	Exhaled nitric oxide levels;
CESC	cis	rs7666738	0.791	rs34790496	chr4:98930516	C/T	cg05340658	chr4:99064831	C4orf37	0.78	11.44	0.57	6.92e-25	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6964587	1.000	rs61244255	chr7:91751662	C/T	cg17063962	chr7:91808500	NA	0.55	7.4	0.41	1.8e-12	Breast cancer;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg18462168	chr15:22892545	CYFIP1	0.43	6.07	0.35	4.5e-9	Systemic lupus erythematosus;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg01523285	chr1:52301876	NRD1	0.42	6.76	0.38	8.9e-11	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs853679	0.517	rs9295758	chr6:28120663	C/G	cg19592336	chr6:28129416	ZNF389	0.62	8.11	0.45	1.84e-14	Depression;
CESC	cis	rs11696845	0.626	rs1111032	chr20:43378770	A/G	cg25301532	chr20:43378953	KCNK15	0.39	6.23	0.36	1.87e-9	Obesity-related traits;
CESC	cis	rs62103177	0.810	rs62103178	chr18:77624555	C/G	cg12964065	chr18:77638022	KCNG2	0.58	5.46	0.32	1.07e-7	Opioid sensitivity;
CESC	cis	rs9814567	1.000	rs13081688	chr3:134259954	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.45	6.08	0.35	4.21e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs7809950	1.000	rs1544336	chr7:107082415	G/C	cg23024343	chr7:107201750	COG5	-0.39	-5.51	-0.32	8.44e-8	Coronary artery disease;
CESC	cis	rs79976124	0.837	rs10455591	chr6:66650584	A/G	cg07460842	chr6:66804631	NA	0.75	8.81	0.48	1.64e-16	Type 2 diabetes;
CESC	cis	rs4563143	0.647	rs117946634	chr19:29256822	G/T	cg14983838	chr19:29218262	NA	0.51	6.13	0.35	3.09e-9	Methadone dose in opioid dependence;
CESC	cis	rs12579753	0.871	rs10862362	chr12:82199383	T/G	cg24719984	chr12:82153464	PPFIA2	-0.33	-5.04	-0.3	8.55e-7	Resting heart rate;
CESC	cis	rs2576037	0.796	rs2247021	chr18:44578794	A/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.33	5.25	0.31	3.13e-7	Personality dimensions;
CESC	cis	rs7833986	0.501	rs72653990	chr8:57037115	G/A	cg26371346	chr8:56986568	SNORD54;RPS20	0.56	5.04	0.3	8.57e-7	Height;
CESC	cis	rs1552244	1.000	rs3895942	chr3:10108745	G/C	cg08888203	chr3:10149979	C3orf24	0.53	6.83	0.39	5.8200000000000003e-11	Alzheimer's disease;
CESC	cis	rs965513	1.000	rs7850258	chr9:100549013	C/T	cg13688889	chr9:100608707	NA	0.57	7.94	0.44	5.82e-14	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
CESC	cis	rs2836974	0.623	rs7280326	chr21:40700408	A/G	cg11890956	chr21:40555474	PSMG1	-0.93	-15.01	-0.68	2.9e-37	Cognitive function;
CESC	cis	rs79349575	0.783	rs4255820	chr17:46996583	T/A	cg16584676	chr17:46985605	UBE2Z	0.54	6.61	0.38	2.05e-10	Type 2 diabetes;
CESC	cis	rs734999	0.545	rs28690427	chr1:2571823	A/G	cg18854424	chr1:2615690	NA	-0.3	-5.88	-0.34	1.2e-8	Ulcerative colitis;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg26771998	chr10:75490334	BMS1P4	-0.39	-6.33	-0.36	1.04e-9	Gambling;
CESC	trans	rs561341	0.843	rs4795666	chr17:30241409	A/G	cg20587970	chr11:113659929	NA	-0.76	-9.69	-0.51	3.33e-19	Hip circumference adjusted for BMI;
CESC	cis	rs17376456	0.877	rs114256265	chr5:93473130	T/A	cg25358565	chr5:93447407	FAM172A	1.17	11.51	0.58	3.92e-25	Diabetic retinopathy;
CESC	cis	rs896854	1.000	rs7003387	chr8:95961979	C/G	cg09323728	chr8:95962352	TP53INP1	-0.45	-9.86	-0.52	9.98e-20	Type 2 diabetes;
CESC	trans	rs1814175	0.558	rs5025146	chr11:49795724	C/G	cg15704280	chr7:45808275	SEPT13	-0.99	-17.52	-0.73	3.72e-46	Height;
CESC	cis	rs7134594	0.714	rs7313056	chr12:109871458	T/C	cg19025524	chr12:109796872	NA	-0.39	-5.68	-0.33	3.61e-8	HDL cholesterol;
CESC	cis	rs4253772	1.000	rs4253766	chr22:46623905	C/T	cg00784671	chr22:46762841	CELSR1	-0.48	-5.28	-0.31	2.65e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs7394190	0.748	rs78985317	chr10:75514465	C/T	cg07699608	chr10:75541558	CHCHD1	0.65	5.35	0.31	1.87e-7	Incident atrial fibrillation;
CESC	cis	rs898097	0.841	rs11656358	chr17:80853956	G/A	cg05255149	chr17:80675120	FN3KRP	-0.45	-5.15	-0.3	4.97e-7	Breast cancer;
CESC	cis	rs854765	0.547	rs4365348	chr17:17912548	C/T	cg04398451	chr17:18023971	MYO15A	-0.68	-10.13	-0.53	1.34e-20	Total body bone mineral density;
CESC	cis	rs6912958	0.559	rs242267	chr6:88061837	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.75	-11.08	-0.56	1.04e-23	Monocyte percentage of white cells;
CESC	cis	rs17376456	0.825	rs10079708	chr5:93261796	G/C	cg25358565	chr5:93447407	FAM172A	1.12	10.4	0.54	1.88e-21	Diabetic retinopathy;
CESC	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg07092213	chr7:1199455	ZFAND2A	-0.43	-5.67	-0.33	3.72e-8	Longevity;Endometriosis;
CESC	cis	rs2836974	0.829	rs34227163	chr21:40551943	A/G	cg27266027	chr21:40555129	PSMG1	0.43	5.25	0.31	3.2e-7	Cognitive function;
CESC	cis	rs2880765	0.835	rs4514633	chr15:86041017	T/G	cg19183879	chr15:85880815	NA	-0.26	-5.34	-0.31	2.01e-7	Coronary artery disease;
CESC	cis	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg17911788	chr17:44343683	NA	-0.53	-7.15	-0.4	8.49e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs36051895	0.632	rs2149552	chr9:5132838	A/G	cg02405213	chr9:5042618	JAK2	-0.48	-6.01	-0.35	6.09e-9	Pediatric autoimmune diseases;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08331513	chr11:2906981	CDKN1C	0.55	6.16	0.35	2.71e-9	Gut microbiome composition (summer);
CESC	cis	rs1670533	1.000	rs11735663	chr4:1051845	C/T	cg27284194	chr4:1044797	NA	0.44	5.5	0.32	8.83e-8	Recombination rate (females);
CESC	cis	rs35306767	0.903	rs12264711	chr10:929525	T/C	cg26597838	chr10:835615	NA	0.87	9.37	0.5	3.21e-18	Eosinophil percentage of granulocytes;
CESC	cis	rs2635047	0.615	rs2684819	chr18:44710691	C/T	cg24371990	chr18:44770781	NA	0.32	5.15	0.3	5.03e-7	Educational attainment;
CESC	cis	rs926938	0.527	rs360678	chr1:115493902	T/A	cg12756093	chr1:115239321	AMPD1	0.45	6.18	0.36	2.37e-9	Autism;
CESC	cis	rs769267	0.931	rs2965197	chr19:19470910	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.63	-8.04	-0.44	3.09e-14	Tonsillectomy;
CESC	cis	rs12220238	0.915	rs61045754	chr10:76153125	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.55	5.1	0.3	6.42e-7	Soluble interleukin-2 receptor subunit alpha;
CESC	cis	rs367943	0.712	rs9326888	chr5:112731133	A/C	cg12552261	chr5:112820674	MCC	0.39	5.25	0.31	3.18e-7	Type 2 diabetes;
CESC	cis	rs7107174	1.000	rs10793308	chr11:78086005	C/T	cg02023728	chr11:77925099	USP35	0.38	5.27	0.31	2.84e-7	Testicular germ cell tumor;
CESC	cis	rs910316	0.687	rs175059	chr14:75490667	T/C	cg16144293	chr14:75469539	EIF2B2	0.4	5.26	0.31	2.91e-7	Height;
CESC	trans	rs3942852	0.806	rs1503188	chr11:48117478	C/T	cg15704280	chr7:45808275	SEPT13	-0.64	-7.53	-0.42	7.89e-13	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs9303280	0.773	rs4795397	chr17:38023745	A/G	cg19468946	chr17:37922297	IKZF3	-0.42	-5.66	-0.33	3.94e-8	Self-reported allergy;
CESC	cis	rs698833	0.828	rs1067341	chr2:44623687	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.48	6.06	0.35	4.73e-9	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs1552244	0.872	rs115331527	chr3:10154504	G/A	cg00149659	chr3:10157352	C3orf10	0.71	8.73	0.47	2.93e-16	Alzheimer's disease;
CESC	cis	rs4450798	0.793	rs62234789	chr3:13750425	G/A	cg05589046	chr3:13742034	LOC285375	0.38	5.6	0.33	5.41e-8	Bipolar disorder with mood-incongruent psychosis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05550202	chr5:177481396	NA	-0.58	-6.91	-0.39	3.62e-11	Gut microbiome composition (summer);
CESC	cis	rs3741151	0.773	rs7110369	chr11:73160946	C/A	cg17517138	chr11:73019481	ARHGEF17	1.0	7.41	0.41	1.74e-12	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs561341	1.000	rs548957	chr17:30302411	G/A	cg00745463	chr17:30367425	LRRC37B	-0.78	-7.09	-0.4	1.2e-11	Hip circumference adjusted for BMI;
CESC	cis	rs6502050	0.805	rs6502057	chr17:80082060	A/G	cg01763666	chr17:80159506	CCDC57	0.37	5.26	0.31	2.92e-7	Life satisfaction;
CESC	trans	rs4596713	0.507	rs10115283	chr9:71801162	T/G	cg16512924	chr15:28394682	HERC2	0.48	6.11	0.35	3.47e-9	Headache;
CESC	trans	rs629535	0.679	rs62511660	chr8:70157089	G/A	cg21567404	chr3:27674614	NA	-0.83	-9.14	-0.49	1.69e-17	Dupuytren's disease;
CESC	cis	rs1862618	0.802	rs7733041	chr5:56107377	A/C	cg12311346	chr5:56204834	C5orf35	-0.68	-8.25	-0.45	7.46e-15	Initial pursuit acceleration;
CESC	cis	rs12824058	0.798	rs4759652	chr12:130808771	C/T	cg24838063	chr12:130822603	PIWIL1	0.62	8.3	0.45	5.43e-15	Menopause (age at onset);
CESC	trans	rs853679	0.882	rs4713140	chr6:28097193	C/T	cg06606381	chr12:133084897	FBRSL1	-0.61	-6.04	-0.35	5.1e-9	Depression;
CESC	cis	rs35110281	0.782	rs7282933	chr21:45046988	A/G	cg01579765	chr21:45077557	HSF2BP	-0.56	-9.42	-0.5	2.39e-18	Mean corpuscular volume;
CESC	cis	rs6449957	0.639	rs40419	chr5:67515602	T/C	cg23036683	chr5:67512108	NA	0.47	6.51	0.37	3.71e-10	Cleft lip with or without cleft palate;
CESC	cis	rs113835537	0.529	rs11227515	chr11:66287383	C/T	cg24851651	chr11:66362959	CCS	0.42	5.22	0.31	3.64e-7	Airway imaging phenotypes;
CESC	cis	rs12476592	0.543	rs4671510	chr2:63742880	A/G	cg17519650	chr2:63277830	OTX1	-0.48	-5.42	-0.32	1.34e-7	Childhood ear infection;
CESC	cis	rs1371867	0.875	rs962452	chr8:101331369	G/A	cg11906718	chr8:101322791	RNF19A	0.46	5.91	0.34	1.03e-8	Atrioventricular conduction;
CESC	cis	rs2842992	1.000	rs2842992	chr6:160071159	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.67	7.81	0.43	1.36e-13	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs10504229	1.000	rs73609760	chr8:58192170	A/G	cg24829409	chr8:58192753	C8orf71	-0.75	-9.71	-0.51	2.85e-19	Developmental language disorder (linguistic errors);
CESC	cis	rs7084402	0.934	rs1658428	chr10:60330917	T/C	cg07615347	chr10:60278583	BICC1	0.59	9.15	0.49	1.57e-17	Refractive error;
CESC	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg14820908	chr5:178986412	RUFY1	-0.5	-7.73	-0.43	2.26e-13	Lung cancer;
CESC	trans	rs7937682	1.000	rs7937682	chr11:111579939	C/G	cg18187862	chr3:45730750	SACM1L	0.53	6.28	0.36	1.41e-9	Primary sclerosing cholangitis;
CESC	cis	rs1670533	0.932	rs13108207	chr4:1054218	C/T	cg27284194	chr4:1044797	NA	0.45	5.8	0.34	1.93e-8	Recombination rate (females);
CESC	cis	rs7647973	0.592	rs6774202	chr3:49687779	T/G	cg13072238	chr3:49761600	GMPPB	-0.44	-5.41	-0.32	1.41e-7	Menarche (age at onset);
CESC	cis	rs4665809	0.652	rs11685594	chr2:26402846	A/G	cg25036284	chr2:26402008	FAM59B	-0.82	-9.33	-0.5	4.47e-18	Gut microbiome composition (summer);
CESC	cis	rs6088580	0.634	rs6059824	chr20:33014543	T/C	cg24642439	chr20:33292090	TP53INP2	0.53	6.91	0.39	3.58e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs17376456	0.877	rs17083460	chr5:93462354	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.62	5.44	0.32	1.23e-7	Diabetic retinopathy;
CESC	cis	rs7267979	0.586	rs6050445	chr20:25195394	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.69	11.45	0.58	6.22e-25	Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg07418289	chr13:92004352	MIR17HG	0.42	6.39	0.37	7.54e-10	Cleft plate (environmental tobacco smoke interaction);
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg17913451	chr14:58619030	C14orf37	0.47	6.4	0.37	6.83e-10	Systemic lupus erythematosus;
CESC	cis	rs1862618	0.525	rs2662021	chr5:56261691	C/T	cg18230493	chr5:56204884	C5orf35	0.66	7.96	0.44	5.2e-14	Initial pursuit acceleration;
CESC	cis	rs4713118	0.621	rs9368548	chr6:28034737	A/G	cg22143856	chr6:28129313	ZNF389	0.45	5.5	0.32	8.9e-8	Parkinson's disease;
CESC	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg11494091	chr17:61959527	GH2	0.72	12.16	0.6	2.58e-27	Prudent dietary pattern;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00040446	chr1:40367965	MYCL1	0.59	7.12	0.4	1.01e-11	Gut microbiome composition (summer);
CESC	cis	rs875971	0.540	rs1723268	chr7:65473080	A/C	cg05332525	chr7:65337924	VKORC1L1	0.49	6.11	0.35	3.57e-9	Aortic root size;
CESC	cis	rs1506636	0.962	rs10243279	chr7:123441262	T/A	cg03229431	chr7:123269106	ASB15	0.48	5.99	0.35	6.71e-9	Plateletcrit;Platelet count;
CESC	cis	rs2710642	0.611	rs2204655	chr2:62883786	C/T	cg17519650	chr2:63277830	OTX1	0.44	5.26	0.31	2.91e-7	LDL cholesterol levels;LDL cholesterol;
CESC	cis	rs7940866	0.803	rs1865296	chr11:130882944	C/T	cg12179176	chr11:130786555	SNX19	-0.66	-10.63	-0.55	3.21e-22	Schizophrenia;
CESC	cis	rs12476592	0.602	rs6546019	chr2:63817440	A/G	cg17519650	chr2:63277830	OTX1	-0.45	-5.12	-0.3	5.75e-7	Childhood ear infection;
CESC	cis	rs7605827	0.930	rs6733519	chr2:15525567	T/C	cg19274914	chr2:15703543	NA	0.35	6.11	0.35	3.61e-9	Educational attainment (years of education);
CESC	cis	rs9322193	0.923	rs9505982	chr6:149939601	G/A	cg07701084	chr6:150067640	NUP43	0.43	6.0	0.35	6.52e-9	Lung cancer;
CESC	cis	rs17407555	0.606	rs73229818	chr4:10019884	C/T	cg00071950	chr4:10020882	SLC2A9	-0.6	-6.16	-0.35	2.64e-9	Schizophrenia (age at onset);
CESC	cis	rs853679	0.513	rs9468296	chr6:28113730	A/G	cg12963246	chr6:28129442	ZNF389	0.58	7.56	0.42	6.4e-13	Depression;
CESC	cis	rs4141404	0.640	rs9606854	chr22:31930567	C/T	cg00478049	chr22:31556069	RNF185	-0.51	-5.53	-0.32	7.72e-8	Paclitaxel-induced neuropathy;
CESC	cis	rs7618915	0.571	rs6778844	chr3:52596398	C/T	cg07507251	chr3:52567010	NT5DC2	-0.43	-7.37	-0.41	2.2e-12	Bipolar disorder;
CESC	cis	rs9583531	0.891	rs61969072	chr13:111380701	T/G	cg24331049	chr13:111365604	ING1	-0.75	-7.82	-0.43	1.26e-13	Coronary artery disease;
CESC	cis	rs9796	0.653	rs28516683	chr15:41446645	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.46	-6.87	-0.39	4.48e-11	Menopause (age at onset);
CESC	cis	rs4665809	0.590	rs9309474	chr2:26448830	T/A	cg04944784	chr2:26401820	FAM59B	-0.96	-10.55	-0.54	5.79e-22	Gut microbiome composition (summer);
CESC	cis	rs796364	1.000	rs1658807	chr2:200767512	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.85	8.36	0.46	3.59e-15	Schizophrenia;
CESC	cis	rs909002	0.800	rs7549590	chr1:32109849	G/A	cg13919466	chr1:32135498	COL16A1	-0.47	-8.43	-0.46	2.3e-15	Intelligence (multi-trait analysis);
CESC	cis	rs10504229	0.906	rs113857287	chr8:58191683	T/C	cg14926445	chr8:58193284	C8orf71	-0.52	-5.53	-0.32	7.54e-8	Developmental language disorder (linguistic errors);
CESC	trans	rs650950	0.528	rs646660	chr11:35528452	C/T	cg10651637	chr15:45315642	SORD	0.44	6.33	0.36	1.03e-9	Bronchopulmonary dysplasia;
CESC	cis	rs7615952	0.576	rs2276729	chr3:125826214	G/A	cg15145296	chr3:125709740	NA	-0.54	-5.96	-0.34	8.2e-9	Blood pressure (smoking interaction);
CESC	trans	rs11722228	1.000	rs4697695	chr4:9915850	C/T	cg26043149	chr18:55253948	FECH	0.48	6.47	0.37	4.6e-10	Gout;Urate levels;Serum uric acid levels;
CESC	cis	rs7216064	1.000	rs56148300	chr17:65892752	T/C	cg12091567	chr17:66097778	LOC651250	-0.75	-8.7	-0.47	3.59e-16	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs738322	0.901	rs132941	chr22:38545942	T/C	cg25457927	chr22:38595422	NA	-0.3	-5.48	-0.32	9.77e-8	Cutaneous nevi;
CESC	cis	rs2051211	1.000	rs2051211	chr3:38559749	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.62	-7.35	-0.41	2.45e-12	QRS duration;
CESC	cis	rs798554	0.797	rs35957220	chr7:2812632	C/G	cg13628971	chr7:2884303	GNA12	0.62	7.84	0.43	1.11e-13	Height;
CESC	cis	rs6912958	0.781	rs985764	chr6:88215206	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.5	-6.65	-0.38	1.66e-10	Monocyte percentage of white cells;
CESC	cis	rs10883723	0.773	rs11191313	chr10:104278618	C/T	cg22532475	chr10:104410764	TRIM8	-0.41	-6.32	-0.36	1.08e-9	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs703842	0.616	rs7489290	chr12:58228588	C/G	cg02175503	chr12:58329896	NA	0.48	5.85	0.34	1.44e-8	Multiple sclerosis;
CESC	cis	rs597539	0.652	rs622082	chr11:68703959	A/G	cg18350739	chr11:68623251	NA	-0.44	-6.81	-0.39	6.64e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs4665809	0.590	rs17528653	chr2:26507724	T/C	cg26314531	chr2:26401878	FAM59B	0.81	8.1	0.45	2.06e-14	Gut microbiome composition (summer);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg16326998	chr7:5553266	FBXL18	-0.5	-6.59	-0.38	2.36e-10	Fibrinogen levels;
CESC	cis	rs9902453	0.765	rs34585141	chr17:28336432	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.67	-8.69	-0.47	3.76e-16	Coffee consumption (cups per day);
CESC	cis	rs854765	0.551	rs56886154	chr17:17831473	C/A	cg09796270	chr17:17721594	SREBF1	0.46	6.39	0.37	7.35e-10	Total body bone mineral density;
CESC	cis	rs7927592	0.913	rs11228268	chr11:68287447	A/T	cg20283391	chr11:68216788	NA	-0.63	-7.61	-0.42	4.78e-13	Total body bone mineral density;
CESC	cis	rs77741769	0.571	rs11065282	chr12:121264415	G/T	cg02419362	chr12:121203948	SPPL3	0.33	5.43	0.32	1.31e-7	Mean corpuscular volume;
CESC	cis	rs7044106	0.791	rs10985004	chr9:123484937	T/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.75	11.22	0.57	3.67e-24	Hip circumference adjusted for BMI;
CESC	cis	rs9311474	0.508	rs11720159	chr3:52617802	T/G	cg05564831	chr3:52568323	NT5DC2	0.48	7.7	0.43	2.71e-13	Electroencephalogram traits;
CESC	cis	rs10883723	0.773	rs7917402	chr10:104246690	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.55	7.56	0.42	6.43e-13	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs6952808	0.531	rs3800922	chr7:2184505	A/G	cg04267008	chr7:1944627	MAD1L1	-0.57	-6.68	-0.38	1.44e-10	Bipolar disorder and schizophrenia;
CESC	cis	rs7914558	1.000	rs10786733	chr10:104794947	G/A	cg15744005	chr10:104629667	AS3MT	-0.34	-5.53	-0.32	7.79e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs698833	0.828	rs6705951	chr2:44534012	A/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.46	5.78	0.33	2.13e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs10504229	1.000	rs72652905	chr8:58188355	A/G	cg24829409	chr8:58192753	C8orf71	-0.78	-10.18	-0.53	9.38e-21	Developmental language disorder (linguistic errors);
CESC	cis	rs16937	0.640	rs6664706	chr1:205182563	T/C	cg21643547	chr1:205240462	TMCC2	-0.33	-5.4	-0.31	1.48e-7	Schizophrenia;
CESC	cis	rs9815354	0.812	rs56290987	chr3:42004882	T/C	cg03022575	chr3:42003672	ULK4	0.65	5.73	0.33	2.75e-8	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs9902453	0.740	rs2729446	chr17:28102499	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-10.34	-0.54	2.82e-21	Coffee consumption (cups per day);
CESC	cis	rs243505	0.559	rs1558420	chr7:148480114	G/T	cg09806900	chr7:148480153	CUL1	0.44	5.27	0.31	2.83e-7	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs951366	0.903	rs708723	chr1:205739266	C/T	cg07167872	chr1:205819463	PM20D1	0.48	7.28	0.41	3.92e-12	Menarche (age at onset);
CESC	cis	rs9911578	0.934	rs8081967	chr17:57072701	T/C	cg12560992	chr17:57184187	TRIM37	1.0	17.01	0.72	2.3e-44	Intelligence (multi-trait analysis);
CESC	cis	rs67311347	1.000	rs2305521	chr3:40429183	A/G	cg09455208	chr3:40491958	NA	0.45	7.5	0.42	9.87e-13	Renal cell carcinoma;
CESC	cis	rs6831352	1.000	rs6837685	chr4:100049145	G/A	cg13256891	chr4:100009986	ADH5	0.72	8.45	0.46	1.94e-15	Alcohol dependence;
CESC	cis	rs7103648	0.735	rs3824869	chr11:47378245	T/C	cg03711944	chr11:47377212	SPI1	0.42	6.47	0.37	4.67e-10	Diastolic blood pressure;Systolic blood pressure;
CESC	cis	rs10927875	0.632	rs904911	chr1:16126932	C/T	cg18973939	chr1:16164122	FLJ37453	0.37	5.52	0.32	8.2e-8	Dilated cardiomyopathy;
CESC	cis	rs3820928	0.874	rs6728239	chr2:227856552	A/G	cg11843606	chr2:227700838	RHBDD1	-0.4	-5.07	-0.3	7.64e-7	Pulmonary function;
CESC	cis	rs6785206	0.803	rs6774512	chr3:128415868	C/T	cg16766828	chr3:128327626	NA	-0.53	-5.08	-0.3	7.02e-7	Lymphocyte percentage of white cells;
CESC	cis	rs916888	0.773	rs169201	chr17:44790203	A/G	cg17911788	chr17:44343683	NA	-0.63	-8.1	-0.45	2.09e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	trans	rs875971	0.638	rs10278816	chr7:66036987	T/C	cg26939375	chr7:64535504	NA	-0.64	-8.62	-0.47	6.05e-16	Aortic root size;
CESC	cis	rs11155671	0.530	rs2342769	chr6:150216507	T/C	cg11878867	chr6:150167359	LRP11	-0.35	-5.06	-0.3	8.01e-7	Testicular germ cell tumor;
CESC	cis	rs6860806	0.661	rs2136187	chr5:131577894	T/C	cg11843238	chr5:131593191	PDLIM4	0.35	5.21	0.3	3.8e-7	Breast cancer;
CESC	cis	rs875971	0.862	rs7803416	chr7:65954199	A/G	cg10691866	chr7:65817282	TPST1	-0.35	-5.62	-0.33	4.9e-8	Aortic root size;
CESC	cis	rs30380	0.922	rs246453	chr5:96123336	T/C	cg16492584	chr5:96139282	ERAP1	-0.35	-5.35	-0.31	1.95e-7	Cerebrospinal fluid biomarker levels;
CESC	trans	rs7615952	0.576	rs66671308	chr3:125793526	T/G	cg07211511	chr3:129823064	LOC729375	-0.57	-6.39	-0.37	7.57e-10	Blood pressure (smoking interaction);
CESC	cis	rs2231884	0.697	rs11227332	chr11:65623739	A/G	cg04055107	chr11:65626734	MUS81;CFL1	1.0	8.94	0.48	6.64e-17	Inflammatory bowel disease;
CESC	cis	rs4955124	0.643	rs17028714	chr3:32041229	T/C	cg05935571	chr3:32023257	ZNF860;OSBPL10	0.82	6.4	0.37	7.07e-10	Schizophrenia;
CESC	cis	rs7605378	0.567	rs717915	chr2:200714766	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.47	5.23	0.31	3.53e-7	Osteoporosis;
CESC	cis	rs2836974	0.831	rs6517521	chr21:40551588	A/G	cg11890956	chr21:40555474	PSMG1	1.15	22.29	0.81	1.04e-62	Cognitive function;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg10258395	chr2:240026647	HDAC4	0.47	6.16	0.35	2.72e-9	Fibrinogen levels;
CESC	cis	rs7107174	0.581	rs11237485	chr11:78126011	G/A	cg02023728	chr11:77925099	USP35	0.44	5.64	0.33	4.28e-8	Testicular germ cell tumor;
CESC	cis	rs13095912	1.000	rs6784948	chr3:185342787	C/T	cg11274856	chr3:185301563	NA	0.35	5.55	0.32	6.89e-8	Systolic blood pressure;
CESC	cis	rs57502260	0.679	rs72936524	chr11:68275898	G/A	cg20283391	chr11:68216788	NA	-0.68	-5.61	-0.33	4.99e-8	Total body bone mineral density (age 45-60);
CESC	cis	rs7412746	0.611	rs12410869	chr1:150856153	G/T	cg04414720	chr1:150670196	GOLPH3L	0.45	5.9	0.34	1.12e-8	Melanoma;
CESC	cis	rs11098499	0.644	rs7693919	chr4:120540571	G/A	cg09307838	chr4:120376055	NA	0.74	9.84	0.52	1.16e-19	Corneal astigmatism;
CESC	cis	rs8049040	0.586	rs16972663	chr16:71460564	C/T	cg08717414	chr16:71523259	ZNF19	-0.61	-6.65	-0.38	1.65e-10	Blood protein levels;
CESC	trans	rs916888	0.773	rs199535	chr17:44822662	A/G	cg07870213	chr5:140052090	DND1	0.63	7.01	0.4	2e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs6594499	0.564	rs12518884	chr5:110452223	A/G	cg04022379	chr5:110408740	TSLP	0.43	7.38	0.41	2.08e-12	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs11785400	0.793	rs4587307	chr8:143738529	G/A	cg10596483	chr8:143751796	JRK	0.43	5.41	0.32	1.37e-7	Schizophrenia;
CESC	cis	rs7589342	0.899	rs879900	chr2:106494347	A/G	cg14210321	chr2:106509881	NCK2	-0.47	-5.48	-0.32	9.71e-8	Addiction;
CESC	cis	rs10504229	1.000	rs58608483	chr8:58195269	T/G	cg05313129	chr8:58192883	C8orf71	-0.48	-5.86	-0.34	1.35e-8	Developmental language disorder (linguistic errors);
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg22015966	chr11:47198573	ARFGAP2	0.46	6.01	0.35	6.22e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs9926296	0.533	rs7190823	chr16:89866043	A/G	cg04287289	chr16:89883240	FANCA	0.9	16.31	0.71	6.93e-42	Vitiligo;
CESC	cis	rs2228479	1.000	rs62052186	chr16:89969567	A/T	cg00800038	chr16:89945340	TCF25	-0.91	-7.41	-0.41	1.71e-12	Skin colour saturation;
CESC	cis	rs2735413	0.802	rs6564504	chr16:78095419	G/T	cg04733911	chr16:78082701	NA	0.46	7.28	0.41	3.75e-12	Systolic blood pressure (alcohol consumption interaction);
CESC	cis	rs7666738	0.680	rs11097613	chr4:99079991	G/T	cg24818145	chr4:99064322	C4orf37	0.4	5.14	0.3	5.46e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9916302	0.904	rs7221875	chr17:37543328	G/A	cg15445000	chr17:37608096	MED1	-0.38	-6.28	-0.36	1.39e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs1949733	0.635	rs4358384	chr4:8536913	C/T	cg11789530	chr4:8429930	ACOX3	-0.64	-8.03	-0.44	3.14e-14	Response to antineoplastic agents;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23388371	chr19:36359516	APLP1	0.55	6.23	0.36	1.8e-9	Gut microbiome composition (summer);
CESC	cis	rs2075371	0.764	rs1643034	chr7:134006176	A/G	cg00033643	chr7:134001901	SLC35B4	0.41	5.27	0.31	2.8e-7	Mean platelet volume;
CESC	cis	rs2243480	0.901	rs2900904	chr7:65204264	C/G	cg18252515	chr7:66147081	NA	-1.26	-11.91	-0.59	1.81e-26	Diabetic kidney disease;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg11179286	chr13:115047994	UPF3A	-0.43	-6.24	-0.36	1.72e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs9790314	1.000	rs7647327	chr3:161016421	T/C	cg03342759	chr3:160939853	NMD3	-0.44	-5.77	-0.33	2.15e-8	Morning vs. evening chronotype;
CESC	cis	rs66731853	0.769	rs530104	chr1:20895721	A/G	cg04087271	chr1:20915334	CDA	-0.58	-7.01	-0.4	1.93e-11	Mean corpuscular volume;
CESC	cis	rs7623687	0.892	rs73088122	chr3:49432404	C/T	cg07274523	chr3:49395745	GPX1	0.64	5.63	0.33	4.66e-8	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;
CESC	cis	rs3820928	0.904	rs4439949	chr2:227764954	T/G	cg11843606	chr2:227700838	RHBDD1	-0.45	-5.93	-0.34	9.45e-9	Pulmonary function;
CESC	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	21.95	0.8	1.49e-61	Prudent dietary pattern;
CESC	cis	rs637571	0.544	rs55704213	chr11:65730002	C/A	cg02202077	chr11:65769826	EIF1AD;BANF1	0.48	6.28	0.36	1.39e-9	Eosinophil percentage of white cells;
CESC	cis	rs8072100	0.840	rs9900360	chr17:45491979	C/T	cg25173405	chr17:45401733	C17orf57	-0.42	-5.53	-0.32	7.75e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs765787	0.530	rs1706835	chr15:45517884	G/A	cg24006582	chr15:45444508	DUOX1	-0.57	-6.88	-0.39	4.22e-11	Uric acid levels;
CESC	cis	rs7246657	0.525	rs1667351	chr19:37478027	A/T	cg23950597	chr19:37808831	NA	-0.43	-5.05	-0.3	8.1e-7	Coronary artery calcification;
CESC	cis	rs17293817	0.617	rs55894130	chr10:1413338	G/A	cg04271617	chr10:1416546	ADARB2	0.35	5.36	0.31	1.83e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs2294693	0.786	rs12055704	chr6:40988504	C/T	cg14418226	chr6:40996092	UNC5CL	0.54	6.14	0.35	3.06e-9	Gastric cancer;Non-cardia gastric cancer;
CESC	cis	rs12142240	0.698	rs57267378	chr1:46816644	A/G	cg10495392	chr1:46806563	NSUN4	0.57	6.28	0.36	1.39e-9	Menopause (age at onset);
CESC	cis	rs17095355	1.000	rs12569906	chr10:111706856	A/T	cg00817464	chr10:111662876	XPNPEP1	-0.47	-5.48	-0.32	9.82e-8	Biliary atresia;
CESC	cis	rs9300255	0.537	rs1790101	chr12:123704844	T/C	cg00376283	chr12:123451042	ABCB9	0.7	8.89	0.48	9.66e-17	Neutrophil percentage of white cells;
CESC	cis	rs36207871	1	rs36207871	chr12:56684496	TAGGAA/T	cg26714650	chr12:56694279	CS	1.29	16.3	0.71	7.7e-42	Inflammatory skin disease;
CESC	cis	rs9611565	0.840	rs4822025	chr22:41776646	C/G	cg06481639	chr22:41940642	POLR3H	-0.61	-6.46	-0.37	5.12e-10	Vitiligo;
CESC	cis	rs16866061	0.515	rs13020268	chr2:225437923	C/T	cg12698349	chr2:225449008	CUL3	0.82	14.85	0.67	1.06e-36	Acute graft versus host disease in bone marrow transplantation (recipient effect);
CESC	cis	rs6460942	0.597	rs4721105	chr7:12534881	C/T	cg06484146	chr7:12443880	VWDE	-0.73	-7.77	-0.43	1.68e-13	Coronary artery disease;
CESC	trans	rs61931739	0.929	rs1825358	chr12:34011895	C/T	cg26384229	chr12:38710491	ALG10B	-0.45	-6.19	-0.36	2.29e-9	Morning vs. evening chronotype;
CESC	cis	rs9549367	0.724	rs7985335	chr13:113869244	G/T	cg00898013	chr13:113819073	PROZ	0.49	7.38	0.41	2.1e-12	Platelet distribution width;
CESC	cis	rs1862618	0.641	rs170733	chr5:56249251	A/G	cg20203395	chr5:56204925	C5orf35	0.4	5.15	0.3	5.15e-7	Initial pursuit acceleration;
CESC	cis	rs6728642	0.831	rs10496325	chr2:97683329	C/T	cg26665480	chr2:98280029	ACTR1B	0.67	7.33	0.41	2.75e-12	Bipolar disorder lithium response (continuous) or schizophrenia;
CESC	cis	rs7605827	0.930	rs13006997	chr2:15700872	T/C	cg19274914	chr2:15703543	NA	0.3	5.34	0.31	2.03e-7	Educational attainment (years of education);
CESC	cis	rs3820068	0.603	rs6429767	chr1:15963334	G/A	cg13390004	chr1:15929781	NA	0.37	5.9	0.34	1.11e-8	Systolic blood pressure;
CESC	cis	rs60733400	0.782	rs4648564	chr1:2562169	C/T	cg18854424	chr1:2615690	NA	-0.31	-6.19	-0.36	2.29e-9	Multiple sclerosis;
CESC	cis	rs10995240	1	rs10995240	chr10:64388631	G/C	cg03961010	chr10:64397487	ZNF365	-0.39	-6.22	-0.36	1.94e-9	Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;Eosinophil percentage of white cells;Eosinophil counts;
CESC	cis	rs155076	0.938	rs9509630	chr13:21844314	G/A	cg11317459	chr13:21872234	NA	-1.01	-11.12	-0.56	7.88e-24	White matter hyperintensity burden;
CESC	cis	rs7044106	0.734	rs12553070	chr9:123485266	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.73	10.79	0.55	9.7e-23	Hip circumference adjusted for BMI;
CESC	cis	rs826838	0.967	rs11183622	chr12:38792849	T/C	cg13010199	chr12:38710504	ALG10B	0.6	8.53	0.46	1.1e-15	Heart rate;
CESC	cis	rs7666738	0.830	rs1426664	chr4:98988264	A/C	cg17366294	chr4:99064904	C4orf37	0.6	8.59	0.47	7.62e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs12190007	0.547	rs3006217	chr6:169862878	A/G	cg15038512	chr6:170123185	PHF10	-0.54	-7.97	-0.44	4.64e-14	Obesity-related traits;
CESC	cis	rs7216064	0.861	rs73352810	chr17:65875184	G/A	cg12091567	chr17:66097778	LOC651250	-0.81	-9.2	-0.49	1.14e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs1595825	0.891	rs76637837	chr2:198529496	G/A	cg10820045	chr2:198174542	NA	0.41	5.21	0.3	3.79e-7	Ulcerative colitis;
CESC	trans	rs11088226	0.681	rs74779447	chr21:33929013	G/A	cg09050820	chr6:167586206	TCP10L2	0.84	8.07	0.44	2.46e-14	Gastritis;
CESC	cis	rs9322193	0.887	rs9505824	chr6:149954799	A/G	cg07701084	chr6:150067640	NUP43	0.45	6.39	0.37	7.37e-10	Lung cancer;
CESC	cis	rs4268898	0.931	rs34504814	chr2:24503766	C/T	cg06627628	chr2:24431161	ITSN2	-0.71	-8.66	-0.47	4.59e-16	Asthma;
CESC	cis	rs710216	0.879	rs710218	chr1:43427218	A/T	cg07803811	chr1:43423981	SLC2A1	0.46	5.26	0.31	2.99e-7	Red cell distribution width;
CESC	cis	rs9303401	0.527	rs12939313	chr17:56755616	A/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.03	11.15	0.57	6.17e-24	Cognitive test performance;
CESC	cis	rs66530629	0.874	rs10903106	chr1:25148686	G/A	cg22509179	chr1:25234806	RUNX3	-0.42	-5.38	-0.31	1.63e-7	Plateletcrit;
CESC	cis	rs56104184	0.775	rs73061692	chr19:49399676	T/C	cg21252483	chr19:49399788	TULP2	-0.52	-5.69	-0.33	3.36e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	cis	rs2295359	0.892	rs72676067	chr1:67658803	G/A	cg03340356	chr1:67600835	NA	0.32	5.27	0.31	2.76e-7	Psoriasis;
CESC	cis	rs2342371	0.545	rs4393941	chr3:196206743	A/G	cg15048948	chr3:196158458	UBXN7	-0.4	-5.66	-0.33	3.92e-8	Fat distribution (HIV);
CESC	cis	rs10504229	0.595	rs79077737	chr8:58117520	G/A	cg22535103	chr8:58192502	C8orf71	-0.8	-9.03	-0.49	3.55e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs9399135	0.967	rs9389256	chr6:135331254	A/C	cg22676075	chr6:135203613	NA	0.5	7.04	0.4	1.61e-11	Red blood cell count;
CESC	cis	rs9649213	0.593	rs3823740	chr7:97957104	T/G	cg00277769	chr7:97922759	BAIAP2L1	-0.34	-5.57	-0.32	6.38e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs6831352	0.918	rs13133647	chr4:100058727	C/T	cg12011299	chr4:100065546	ADH4	-0.6	-6.62	-0.38	2.04e-10	Alcohol dependence;
CESC	cis	rs1552244	1.000	rs55822690	chr3:10128003	A/G	cg00149659	chr3:10157352	C3orf10	0.71	8.69	0.47	3.84e-16	Alzheimer's disease;
CESC	cis	rs947211	0.898	rs1772156	chr1:205752894	T/C	cg17178900	chr1:205818956	PM20D1	0.4	5.22	0.31	3.69e-7	Parkinson's disease;
CESC	cis	rs16867321	0.666	rs7556967	chr2:181586333	C/T	cg23363182	chr2:181467187	NA	-0.43	-5.7	-0.33	3.2e-8	Obesity;
CESC	cis	rs61931739	0.500	rs10772163	chr12:34532950	T/C	cg06521331	chr12:34319734	NA	-0.37	-5.15	-0.3	5.19e-7	Morning vs. evening chronotype;
CESC	cis	rs780096	0.526	rs780102	chr2:27659491	T/C	cg22903471	chr2:27725779	GCKR	-0.52	-7.39	-0.41	1.88e-12	Total body bone mineral density;
CESC	cis	rs1451375	0.617	rs17733244	chr7:50575495	T/C	cg14593290	chr7:50529359	DDC	0.52	6.05	0.35	5.03e-9	Malaria;
CESC	cis	rs6952808	0.609	rs12699453	chr7:1953056	C/T	cg02951883	chr7:2050386	MAD1L1	-0.4	-5.31	-0.31	2.32e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs6728642	1.000	rs73959416	chr2:97604518	A/T	cg26665480	chr2:98280029	ACTR1B	-0.7	-6.92	-0.39	3.47e-11	Bipolar disorder lithium response (continuous) or schizophrenia;
CESC	cis	rs8020095	0.571	rs68178754	chr14:67383094	T/C	cg19548862	chr14:67692701	FAM71D	-0.49	-5.94	-0.34	8.86e-9	Depression (quantitative trait);
CESC	cis	rs9457247	0.967	rs424185	chr6:167410907	C/T	cg07741184	chr6:167504864	NA	0.3	5.52	0.32	8.06e-8	Crohn's disease;
CESC	cis	rs3806843	0.676	rs778594	chr5:140027304	T/C	cg26395211	chr5:140044315	WDR55	0.52	6.54	0.37	3.13e-10	Depressive symptoms (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01719780	chr1:157126054	NA	0.56	6.6	0.38	2.18e-10	Gut microbiome composition (summer);
CESC	cis	rs4853012	0.887	rs77148265	chr2:74339519	C/T	cg05776053	chr2:74358815	NA	0.44	5.27	0.31	2.78e-7	Gestational age at birth (maternal effect);
CESC	cis	rs4819052	0.851	rs4818768	chr21:46659818	T/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.46	5.79	0.34	2e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs1814175	0.817	rs1794164	chr11:49899610	T/C	cg15704280	chr7:45808275	SEPT13	-1.03	-20.27	-0.78	8.31e-56	Height;
CESC	cis	rs875971	0.830	rs427973	chr7:65526648	C/A	cg10691866	chr7:65817282	TPST1	-0.34	-5.51	-0.32	8.37e-8	Aortic root size;
CESC	cis	rs3617	0.559	rs11915546	chr3:52866845	A/C	cg07507251	chr3:52567010	NT5DC2	-0.32	-5.43	-0.32	1.27e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
CESC	cis	rs9311474	0.508	rs12637627	chr3:52619962	G/T	cg18099408	chr3:52552593	STAB1	-0.31	-5.14	-0.3	5.23e-7	Electroencephalogram traits;
CESC	cis	rs2204008	0.685	rs4556621	chr12:38187236	C/A	cg13010199	chr12:38710504	ALG10B	0.53	6.64	0.38	1.79e-10	Bladder cancer;
CESC	cis	rs3105593	1.000	rs934625	chr15:50968756	T/C	cg08437265	chr15:50716283	USP8	0.45	5.93	0.34	9.66e-9	QT interval;
CESC	cis	rs9837602	1.000	rs9837602	chr3:99824685	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.49	6.84	0.39	5.38e-11	Breast cancer;
CESC	trans	rs1728785	1.000	rs1645976	chr16:68563509	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.61	7.42	0.41	1.57e-12	Ulcerative colitis;
CESC	cis	rs4132509	0.744	rs12047209	chr1:243954407	A/C	cg21452805	chr1:244014465	NA	0.66	7.24	0.41	4.81e-12	RR interval (heart rate);
CESC	cis	rs1008375	0.966	rs6832414	chr4:17696866	C/G	cg15017067	chr4:17643749	FAM184B	0.37	5.2	0.3	3.95e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs1355223	0.902	rs836467	chr11:34737432	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.47	-6.2	-0.36	2.14e-9	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs3820928	0.874	rs2229812	chr2:227896886	C/T	cg11843606	chr2:227700838	RHBDD1	-0.49	-6.4	-0.37	6.87e-10	Pulmonary function;
CESC	cis	rs10504229	0.635	rs72649130	chr8:58053810	G/T	cg24829409	chr8:58192753	C8orf71	-0.7	-7.79	-0.43	1.49e-13	Developmental language disorder (linguistic errors);
CESC	cis	rs9611565	0.879	rs5758311	chr22:41759375	G/T	cg06481639	chr22:41940642	POLR3H	-0.44	-5.14	-0.3	5.26e-7	Vitiligo;
CESC	cis	rs559928	0.597	rs947939	chr11:63885287	C/T	cg18225595	chr11:63971243	STIP1	0.64	5.47	0.32	1.05e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CESC	cis	rs116095464	0.510	rs73016876	chr5:244475	T/C	cg22496380	chr5:211416	CCDC127	-0.79	-9.12	-0.49	1.95e-17	Breast cancer;
CESC	cis	rs425277	1.000	rs381664	chr1:2088104	A/G	cg16545954	chr1:2118288	C1orf86	0.33	5.63	0.33	4.65e-8	Height;
CESC	cis	rs7481584	0.962	rs2237905	chr11:2976584	T/C	cg25174290	chr11:3078921	CARS	-0.49	-5.88	-0.34	1.21e-8	Calcium levels;
CESC	cis	rs2836974	0.865	rs34778912	chr21:40667037	T/G	cg11644478	chr21:40555479	PSMG1	1.02	16.18	0.7	1.98e-41	Cognitive function;
CESC	cis	rs853679	0.517	rs9380055	chr6:28081629	A/G	cg17949981	chr6:28129498	ZNF389	0.45	5.63	0.33	4.71e-8	Depression;
CESC	cis	rs2439831	0.702	rs7171750	chr15:44025858	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.7	6.6	0.38	2.25e-10	Lung cancer in ever smokers;
CESC	cis	rs1023500	1.000	rs3752591	chr22:42339516	A/G	cg03806693	chr22:41940476	POLR3H	-0.52	-5.2	-0.3	4e-7	Schizophrenia;
CESC	cis	rs2032447	0.839	rs199751	chr6:26015583	T/C	cg02841227	chr6:26021843	HIST1H4A	0.44	5.35	0.31	1.91e-7	Intelligence (multi-trait analysis);
CESC	cis	rs9527	0.590	rs7917650	chr10:104937100	G/C	cg04362960	chr10:104952993	NT5C2	0.43	5.33	0.31	2.05e-7	Arsenic metabolism;
CESC	cis	rs938554	0.779	rs4639073	chr4:9973781	T/C	cg00071950	chr4:10020882	SLC2A9	-0.44	-5.11	-0.3	6.17e-7	Blood metabolite levels;
CESC	cis	rs6964587	1.000	rs34548928	chr7:91668365	G/A	cg17063962	chr7:91808500	NA	0.6	8.31	0.45	4.96e-15	Breast cancer;
CESC	cis	rs3096299	0.900	rs2911258	chr16:89480760	A/G	cg00750074	chr16:89608354	SPG7	-0.36	-5.1	-0.3	6.59e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs6732160	0.588	rs13403748	chr2:73371475	T/C	cg01422370	chr2:73384389	NA	0.56	8.95	0.48	6.23e-17	Intelligence (multi-trait analysis);
CESC	cis	rs962856	1.000	rs1032157	chr2:67601816	C/T	cg09028215	chr2:67624308	ETAA1	-0.41	-5.4	-0.31	1.48e-7	Pancreatic cancer;
CESC	cis	rs6089829	0.962	rs6062780	chr20:61666648	T/C	cg03213289	chr20:61660250	NA	0.39	6.16	0.35	2.7e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs4237845	0.967	rs4553410	chr12:58301211	G/A	cg00677455	chr12:58241039	CTDSP2	0.5	6.29	0.36	1.32e-9	Intelligence (multi-trait analysis);
CESC	cis	rs807669	0.525	rs9605955	chr22:19181557	C/T	cg02655711	chr22:19163373	SLC25A1	0.42	6.16	0.35	2.66e-9	Metabolite levels;
CESC	cis	rs2017305	0.834	rs79520726	chr10:70781956	T/C	cg01024728	chr10:70782572	NA	0.56	5.35	0.31	1.89e-7	Depression (quantitative trait);
CESC	cis	rs875971	0.964	rs2277911	chr7:65958625	T/G	cg18876405	chr7:65276391	NA	0.5	6.48	0.37	4.33e-10	Aortic root size;
CESC	cis	rs7395581	0.918	rs10838693	chr11:47350553	G/C	cg25783544	chr11:47291846	MADD	0.58	7.42	0.41	1.55e-12	HDL cholesterol;
CESC	cis	rs9612	1.000	rs346545	chr19:44256386	T/C	cg08581076	chr19:44259116	C19orf61	0.52	6.19	0.36	2.33e-9	Exhaled nitric oxide output;
CESC	cis	rs787274	1.000	rs1965335	chr9:115504483	C/T	cg13803584	chr9:115635662	SNX30	0.57	5.16	0.3	4.84e-7	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs4780401	0.642	rs7194145	chr16:11764615	T/G	cg01061890	chr16:11836724	TXNDC11	-0.39	-5.06	-0.3	7.71e-7	Rheumatoid arthritis;
CESC	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg21724239	chr8:58056113	NA	0.59	5.64	0.33	4.27e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs7666738	0.830	rs34313689	chr4:99013689	T/C	cg05340658	chr4:99064831	C4orf37	0.8	12.35	0.6	5.51e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2249694	0.922	rs4306261	chr10:135410989	A/G	cg19469447	chr10:135341870	CYP2E1	0.36	5.09	0.3	6.96e-7	Obesity-related traits;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg24657977	chr1:206859686	MAPKAPK2	-0.5	-6.01	-0.35	6.15e-9	Ulcerative colitis;
CESC	cis	rs17376456	0.877	rs10055741	chr5:93297187	C/T	cg21475434	chr5:93447410	FAM172A	0.76	6.9	0.39	3.89e-11	Diabetic retinopathy;
CESC	cis	rs7107174	1.000	rs9651769	chr11:77996166	T/C	cg02023728	chr11:77925099	USP35	0.48	6.68	0.38	1.41e-10	Testicular germ cell tumor;
CESC	cis	rs72945132	0.882	rs12278741	chr11:70135742	A/G	cg00319359	chr11:70116639	PPFIA1	0.78	7.67	0.43	3.32e-13	Coronary artery disease;
CESC	cis	rs6693567	0.565	rs834242	chr1:150379858	G/A	cg09579323	chr1:150459698	TARS2	0.45	5.85	0.34	1.41e-8	Migraine;
CESC	cis	rs2033711	0.840	rs4801590	chr19:58961813	G/C	cg26874164	chr19:58962979	ZNF324B	0.54	7.54	0.42	7.72e-13	Uric acid clearance;
CESC	cis	rs2228479	0.702	rs17233441	chr16:89817998	C/G	cg04013166	chr16:89971882	TCF25	0.77	6.66	0.38	1.58e-10	Skin colour saturation;
CESC	cis	rs7666738	0.830	rs7662199	chr4:99019766	G/A	cg17366294	chr4:99064904	C4orf37	0.6	8.57	0.47	8.74e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7666738	0.830	rs13148913	chr4:99009732	C/T	cg03676636	chr4:99064102	C4orf37	0.33	5.16	0.3	4.86e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs875971	0.964	rs778735	chr7:65814809	C/A	cg12463550	chr7:65579703	CRCP	0.55	7.03	0.4	1.76e-11	Aortic root size;
CESC	cis	rs67311347	0.869	rs9832311	chr3:40381322	A/T	cg09455208	chr3:40491958	NA	0.47	8.1	0.45	2.08e-14	Renal cell carcinoma;
CESC	cis	rs2011503	1.000	rs2011503	chr19:19443986	C/T	cg11584989	chr19:19387371	SF4	0.63	7.59	0.42	5.5e-13	Bipolar disorder;
CESC	cis	rs250677	0.687	rs36044	chr5:148441128	T/C	cg18129178	chr5:148520854	ABLIM3	-0.52	-5.94	-0.34	8.76e-9	Breast cancer;
CESC	cis	rs17666538	0.585	rs1669615	chr8:616665	T/C	cg23958373	chr8:599963	NA	0.83	6.04	0.35	5.2e-9	IgG glycosylation;
CESC	cis	rs1552244	0.882	rs17081288	chr3:10042113	A/G	cg00166722	chr3:10149974	C3orf24	0.48	5.95	0.34	8.39e-9	Alzheimer's disease;
CESC	cis	rs9291683	0.610	rs993172	chr4:10324361	G/T	cg00071950	chr4:10020882	SLC2A9	0.55	8.06	0.44	2.56e-14	Bone mineral density;
CESC	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg06877462	chr1:205807181	PM20D1	-0.34	-5.33	-0.31	2.15e-7	Monocyte percentage of white cells;
CESC	cis	rs10845606	1.000	rs10845609	chr12:12838920	T/A	cg04607235	chr12:12878440	APOLD1	-0.74	-8.24	-0.45	8.24e-15	Systemic lupus erythematosus;
CESC	cis	rs9311474	0.629	rs13081028	chr3:52555316	G/A	cg05564831	chr3:52568323	NT5DC2	0.53	9.03	0.49	3.63e-17	Electroencephalogram traits;
CESC	cis	rs2485892	0.581	rs2484032	chr1:210317225	G/A	cg22029157	chr1:209979665	IRF6	0.5	5.83	0.34	1.62e-8	Manic episodes in bipolar disorder;
CESC	cis	rs6088580	0.634	rs6142153	chr20:32968747	C/G	cg06115741	chr20:33292138	TP53INP2	-0.47	-6.02	-0.35	5.66e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs412050	0.744	rs238781	chr22:22341871	C/T	cg17089214	chr22:22089827	YPEL1	0.56	5.04	0.3	8.7e-7	Attention deficit hyperactivity disorder;
CESC	cis	rs8141529	0.636	rs5762813	chr22:29203314	C/T	cg02153584	chr22:29168773	CCDC117	0.48	5.26	0.31	3.04e-7	Lymphocyte counts;
CESC	cis	rs9788333	0.707	rs12584557	chr13:21886171	C/A	cg06138931	chr13:21896616	NA	0.56	7.91	0.44	7.18e-14	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs6502050	0.835	rs28640920	chr17:80105151	A/T	cg11859384	chr17:80120422	CCDC57	-0.38	-5.11	-0.3	6.21e-7	Life satisfaction;
CESC	cis	rs4319547	0.774	rs7295105	chr12:123124225	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.51	-5.97	-0.34	7.79e-9	Body mass index;
CESC	cis	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg09324608	chr17:30823087	MYO1D	-0.41	-6.32	-0.36	1.1e-9	Schizophrenia;
CESC	cis	rs5769765	0.908	rs4824109	chr22:50271460	T/C	cg02269571	chr22:50332266	NA	0.47	6.34	0.36	9.73e-10	Schizophrenia;
CESC	cis	rs820218	0.926	rs8074319	chr17:73652060	C/A	cg01592526	chr17:73663357	RECQL5;SAP30BP	0.4	5.26	0.31	2.95e-7	Rotator cuff tears;
CESC	cis	rs1552244	0.882	rs34706481	chr3:10004123	G/A	cg00149659	chr3:10157352	C3orf10	0.57	6.09	0.35	3.98e-9	Alzheimer's disease;
CESC	cis	rs6460942	1.000	rs2053381	chr7:12400710	C/A	cg20607287	chr7:12443886	VWDE	-0.67	-7.73	-0.43	2.26e-13	Coronary artery disease;
CESC	cis	rs8177253	1.000	rs8177248	chr3:133479626	C/T	cg12373951	chr3:133503437	NA	0.38	5.41	0.32	1.38e-7	Iron status biomarkers;
CESC	trans	rs12310956	0.532	rs11052935	chr12:33970946	C/T	cg26384229	chr12:38710491	ALG10B	0.51	6.98	0.39	2.42e-11	Morning vs. evening chronotype;
CESC	cis	rs6580649	0.941	rs58046797	chr12:48487619	T/C	cg05342945	chr12:48394962	COL2A1	0.5	5.74	0.33	2.59e-8	Lung cancer;
CESC	cis	rs7223966	1.000	rs7223966	chr17:61893398	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.71	0.38	1.15e-10	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs4253772	0.575	rs9615979	chr22:46789021	G/T	cg00784671	chr22:46762841	CELSR1	-0.61	-5.46	-0.32	1.11e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs8078723	0.763	rs4433838	chr17:38143532	C/T	cg17467752	chr17:38218738	THRA	-0.55	-8.15	-0.45	1.45e-14	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CESC	cis	rs35306767	0.903	rs34847097	chr10:902252	A/T	cg25019033	chr10:957182	NA	-0.57	-6.08	-0.35	4.24e-9	Eosinophil percentage of granulocytes;
CESC	cis	rs4665809	0.556	rs4665322	chr2:26434605	C/G	cg26314531	chr2:26401878	FAM59B	-0.85	-9.51	-0.5	1.24e-18	Gut microbiome composition (summer);
CESC	cis	rs1878931	0.531	rs9635548	chr16:3417156	G/A	cg05754148	chr16:3507555	NAT15	-0.39	-5.19	-0.3	4.24e-7	Body mass index (adult);
CESC	cis	rs2573652	0.963	rs2573649	chr15:100514040	C/G	cg09918751	chr15:100517450	ADAMTS17	-0.38	-7.36	-0.41	2.33e-12	Height;
CESC	cis	rs7923609	1.000	rs7910927	chr10:65138910	T/G	cg01631684	chr10:65280961	REEP3	-0.42	-5.17	-0.3	4.72e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs8031584	0.958	rs3512	chr15:31235005	G/C	cg08109568	chr15:31115862	NA	-0.71	-9.44	-0.5	2.02e-18	Huntington's disease progression;
CESC	cis	rs896854	0.654	rs10104909	chr8:95977973	C/T	cg16049864	chr8:95962084	TP53INP1	-0.66	-11.67	-0.58	1.13e-25	Type 2 diabetes;
CESC	cis	rs16910800	0.731	rs59845980	chr11:23191511	T/G	cg20040320	chr11:23191996	NA	-0.67	-6.66	-0.38	1.53e-10	Cancer;
CESC	cis	rs763014	0.931	rs11648728	chr16:635525	C/T	cg00802000	chr16:706648	WDR90	-0.41	-6.19	-0.36	2.26e-9	Height;
CESC	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg01516881	chr6:292596	DUSP22	0.83	11.25	0.57	3e-24	Menopause (age at onset);
CESC	cis	rs6430585	0.697	rs7607174	chr2:136513670	T/A	cg07169764	chr2:136633963	MCM6	1.27	16.82	0.72	1.04e-43	Corneal structure;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg07956857	chr9:106761676	NA	-0.44	-6.4	-0.37	7.08e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs875971	0.597	rs11763224	chr7:65983615	G/T	cg18876405	chr7:65276391	NA	0.47	5.28	0.31	2.73e-7	Aortic root size;
CESC	cis	rs875971	0.862	rs6460279	chr7:65662761	T/C	cg11764359	chr7:65958608	NA	-0.78	-11.07	-0.56	1.19e-23	Aortic root size;
CESC	cis	rs7246657	0.943	rs10420754	chr19:37959372	C/G	cg23950597	chr19:37808831	NA	-0.55	-5.99	-0.35	6.69e-9	Coronary artery calcification;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14181387	chr1:36022775	NCDN;KIAA0319L	0.57	6.05	0.35	4.8e-9	Gut microbiome composition (summer);
CESC	cis	rs1008375	0.932	rs11941874	chr4:17666416	C/T	cg02297831	chr4:17616191	MED28	-0.49	-5.69	-0.33	3.28e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs79911532	0.515	rs10226745	chr7:75843603	C/T	cg06959773	chr7:76033795	SRCRB4D;ZP3	0.56	5.21	0.3	3.83e-7	Mononucleosis;
CESC	cis	rs7089973	0.584	rs758585	chr10:116582560	C/A	cg03647239	chr10:116582469	FAM160B1	0.44	5.71	0.33	3.03e-8	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs921968	0.565	rs7586384	chr2:219582897	T/C	cg02176678	chr2:219576539	TTLL4	-0.43	-7.37	-0.41	2.24e-12	Mean corpuscular hemoglobin concentration;
CESC	trans	rs2727020	0.612	rs603672	chr11:49234566	T/A	cg15704280	chr7:45808275	SEPT13	0.84	13.52	0.64	4.91e-32	Coronary artery disease;
CESC	cis	rs3126085	0.935	rs12045496	chr1:152253910	A/G	cg03465714	chr1:152285911	FLG	-0.45	-5.56	-0.32	6.52e-8	Atopic dermatitis;
CESC	cis	rs9611565	1.000	rs5751086	chr22:41768862	C/T	cg03806693	chr22:41940476	POLR3H	-0.56	-6.67	-0.38	1.51e-10	Vitiligo;
CESC	cis	rs7937682	0.602	rs11214036	chr11:111773169	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.92	-12.74	-0.62	2.61e-29	Primary sclerosing cholangitis;
CESC	cis	rs10924309	0.889	rs10924307	chr1:245858125	C/T	cg00036263	chr1:245852353	KIF26B	-0.43	-5.26	-0.31	3.03e-7	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
CESC	cis	rs7666738	0.830	rs11938686	chr4:98964470	A/G	cg03676636	chr4:99064102	C4orf37	0.33	5.05	0.3	8.13e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs79976124	0.876	rs17511913	chr6:66644361	C/T	cg07460842	chr6:66804631	NA	0.69	8.07	0.44	2.5e-14	Type 2 diabetes;
CESC	cis	rs9399137	0.507	rs4289677	chr6:135275485	A/G	cg22676075	chr6:135203613	NA	0.54	6.98	0.39	2.38e-11	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	cis	rs4253772	0.530	rs715518	chr22:46754177	C/G	cg10541313	chr22:46663664	TTC38	0.75	5.31	0.31	2.36e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs4969178	0.930	rs7208596	chr17:76396528	C/G	cg20026190	chr17:76395443	PGS1	0.49	7.81	0.43	1.34e-13	HDL cholesterol levels;
CESC	cis	rs28489187	0.706	rs3087894	chr1:85787118	G/C	cg16011679	chr1:85725395	C1orf52	0.56	6.55	0.37	3.05e-10	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	cis	rs10789491	1.000	rs4660956	chr1:47158486	A/G	cg15501359	chr1:47185051	KIAA0494	0.76	8.05	0.44	2.87e-14	Response to hepatitis C treatment;
CESC	cis	rs4665809	1.000	rs2891490	chr2:26325927	T/C	cg08470875	chr2:26401718	FAM59B	-0.47	-5.23	-0.31	3.38e-7	Gut microbiome composition (summer);
CESC	cis	rs2637266	0.561	rs7090852	chr10:78499053	A/G	cg18941641	chr10:78392320	NA	-0.32	-5.1	-0.3	6.49e-7	Pulmonary function;
CESC	cis	rs765787	0.530	rs12913123	chr15:45516425	C/T	cg24006582	chr15:45444508	DUOX1	0.52	6.25	0.36	1.61e-9	Uric acid levels;
CESC	cis	rs28374715	0.532	rs316604	chr15:41775221	C/T	cg20272979	chr15:41787780	ITPKA	0.42	5.17	0.3	4.53e-7	Ulcerative colitis;
CESC	cis	rs3785574	0.927	rs2854160	chr17:61977248	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.58	7.35	0.41	2.43e-12	Height;
CESC	cis	rs11608355	0.545	rs35422737	chr12:109911456	A/G	cg05360138	chr12:110035743	NA	0.81	8.75	0.47	2.52e-16	Neuroticism;
CESC	cis	rs10876993	0.928	rs2640637	chr12:58077586	G/A	cg18357645	chr12:58087776	OS9	0.63	10.52	0.54	7.21e-22	Celiac disease or Rheumatoid arthritis;
CESC	cis	rs12500824	0.564	rs7681311	chr4:77318829	G/A	cg20311846	chr4:77356250	SHROOM3	0.39	7.5	0.42	9.73e-13	Coronary artery disease;
CESC	cis	rs4568518	0.710	rs6955337	chr7:18014574	A/G	cg03009463	chr7:17980271	SNX13	-0.46	-6.05	-0.35	4.98e-9	Measles;
CESC	cis	rs1799949	1.000	rs8176265	chr17:41213996	C/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.4	5.31	0.31	2.28e-7	Menopause (age at onset);
CESC	trans	rs10463316	0.894	rs7729216	chr5:150762277	A/G	cg24389359	chr12:111284228	CCDC63	-0.33	-6.02	-0.35	5.68e-9	Metabolite levels (Pyroglutamine);
CESC	cis	rs9733	0.596	rs6669369	chr1:150695892	C/T	cg18016565	chr1:150552671	MCL1	0.34	5.28	0.31	2.67e-7	Tonsillectomy;
CESC	cis	rs12497850	0.931	rs6414613	chr3:49035885	C/T	cg03060546	chr3:49711283	APEH	0.5	6.07	0.35	4.47e-9	Parkinson's disease;
CESC	cis	rs3020736	0.500	rs6002601	chr22:42489058	A/T	cg04733989	chr22:42467013	NAGA	-0.79	-12.03	-0.59	6.75e-27	Autism spectrum disorder or schizophrenia;
CESC	cis	rs11252926	0.599	rs11252213	chr10:454694	C/T	cg16386425	chr10:429943	DIP2C	-0.57	-7.25	-0.41	4.54e-12	Psychosis in Alzheimer's disease;
CESC	cis	rs6752107	1.000	rs2289474	chr2:234181848	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.49	6.7	0.38	1.25e-10	Crohn's disease;Inflammatory bowel disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22242926	chr17:73627717	RECQL5	-0.57	-6.62	-0.38	1.98e-10	Gut microbiome composition (summer);
CESC	cis	rs7264396	0.563	rs6058322	chr20:34367277	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	-0.68	-7.4	-0.41	1.83e-12	Total cholesterol levels;
CESC	cis	rs9322193	0.923	rs9480031	chr6:150080011	A/C	cg07701084	chr6:150067640	NUP43	0.49	6.77	0.38	8.5e-11	Lung cancer;
CESC	cis	rs798554	0.797	rs2107964	chr7:2863574	G/A	cg18446336	chr7:2847575	GNA12	-0.37	-5.47	-0.32	1.05e-7	Height;
CESC	trans	rs877282	0.583	rs11253424	chr10:813426	C/T	cg22713356	chr15:30763199	NA	1.04	10.34	0.54	2.86e-21	Uric acid levels;
CESC	cis	rs6466055	0.639	rs3823752	chr7:104624626	C/T	cg04380332	chr7:105027541	SRPK2	-0.38	-5.42	-0.32	1.35e-7	Schizophrenia;
CESC	cis	rs9649213	0.593	rs6963210	chr7:97944986	G/A	cg08684580	chr7:98029266	BAIAP2L1	-0.36	-5.82	-0.34	1.69e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7618915	0.547	rs7642198	chr3:52677960	T/C	cg17372223	chr3:52568218	NT5DC2	0.43	6.51	0.37	3.76e-10	Bipolar disorder;
CESC	cis	rs3820068	0.524	rs34094056	chr1:15824154	G/T	cg17385448	chr1:15911702	AGMAT	0.41	6.33	0.36	1.02e-9	Systolic blood pressure;
CESC	cis	rs6121246	0.909	rs8126355	chr20:30332660	C/T	cg13852791	chr20:30311386	BCL2L1	0.82	8.74	0.47	2.63e-16	Mean corpuscular hemoglobin;
CESC	cis	rs7084402	0.967	rs1649034	chr10:60279324	G/A	cg07615347	chr10:60278583	BICC1	-0.6	-9.67	-0.51	3.77e-19	Refractive error;
CESC	cis	rs1372520	0.873	rs983361	chr4:90761944	T/G	cg15133208	chr4:90757351	SNCA	-0.41	-5.63	-0.33	4.5e-8	Neuroticism;
CESC	cis	rs798554	0.757	rs1182185	chr7:2872233	A/G	cg09658497	chr7:2847517	GNA12	-0.39	-5.78	-0.33	2.14e-8	Height;
CESC	cis	rs4665809	1.000	rs2384323	chr2:26306473	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.67	-7.58	-0.42	5.91e-13	Gut microbiome composition (summer);
CESC	cis	rs7607369	0.719	rs7567622	chr2:219624549	A/T	cg02176678	chr2:219576539	TTLL4	-0.44	-7.77	-0.43	1.74e-13	Red blood cell count;Amyotrophic lateral sclerosis;
CESC	cis	rs11249608	0.548	rs13156530	chr5:178475017	C/T	cg01312482	chr5:178451176	ZNF879	-0.45	-6.1	-0.35	3.72e-9	Pubertal anthropometrics;
CESC	cis	rs9811920	0.638	rs793474	chr3:99544380	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.56	6.92	0.39	3.46e-11	Axial length;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg03146981	chr16:70719277	MTSS1L	-0.47	-6.79	-0.38	7.26e-11	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs6088590	0.710	rs6059992	chr20:33282275	T/C	cg08999081	chr20:33150536	PIGU	0.65	10.71	0.55	1.77e-22	Coronary artery disease;
CESC	cis	rs9649213	0.593	rs6975156	chr7:97925534	T/C	cg08684580	chr7:98029266	BAIAP2L1	-0.35	-5.68	-0.33	3.49e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs2652822	0.554	rs11635698	chr15:63478573	G/A	cg02713581	chr15:63449717	RPS27L	0.52	6.69	0.38	1.34e-10	Metabolic traits;
CESC	cis	rs1823874	0.581	rs12910401	chr15:100339897	T/C	cg16400843	chr15:100339927	C15orf51	0.32	5.03	0.3	9.21e-7	IgG glycosylation;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06197760	chr6:7585736	DSP	-0.56	-6.26	-0.36	1.5e-9	Gut microbiome composition (summer);
CESC	cis	rs6088590	1.000	rs6119516	chr20:33328024	C/T	cg08999081	chr20:33150536	PIGU	0.59	9.1	0.49	2.28e-17	Coronary artery disease;
CESC	cis	rs17253792	0.822	rs12323476	chr14:56172722	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	-0.68	-5.96	-0.34	8.09e-9	Putamen volume;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg11564601	chr22:30592435	NA	-0.4	-6.63	-0.38	1.92e-10	Gut microbiota (bacterial taxa);
CESC	trans	rs11098499	0.866	rs7665125	chr4:120402079	G/T	cg25214090	chr10:38739885	LOC399744	0.61	8.78	0.47	2.06e-16	Corneal astigmatism;
CESC	cis	rs35110281	0.633	rs2329593	chr21:45121987	T/C	cg01579765	chr21:45077557	HSF2BP	-0.55	-9.08	-0.49	2.66e-17	Mean corpuscular volume;
CESC	cis	rs6062302	0.522	rs2872810	chr20:62241931	C/T	cg06363034	chr20:62225388	GMEB2	0.5	6.35	0.36	9.49e-10	Glioblastoma;
CESC	cis	rs736408	0.546	rs3733046	chr3:52621627	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.59	8.46	0.46	1.83e-15	Bipolar disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02986938	chr1:174968958	CACYBP	0.6	6.77	0.38	8.31e-11	Gut microbiome composition (summer);
CESC	cis	rs7264396	0.563	rs6058296	chr20:34269225	G/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.6	5.83	0.34	1.58e-8	Total cholesterol levels;
CESC	cis	rs4563143	0.675	rs73029049	chr19:29275534	C/A	cg04546413	chr19:29218101	NA	0.56	7.91	0.44	6.84e-14	Methadone dose in opioid dependence;
CESC	cis	rs7772486	0.597	rs6912351	chr6:146264071	T/C	cg05347473	chr6:146136440	FBXO30	-0.75	-9.55	-0.51	8.95e-19	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs10832963	0.924	rs10832950	chr11:18635815	A/G	cg09201001	chr11:18656081	SPTY2D1	0.82	12.36	0.6	5.21e-28	Breast cancer;
CESC	cis	rs897984	0.542	rs4468641	chr16:31096876	A/C	cg02466173	chr16:30829666	NA	-0.4	-6.81	-0.39	6.65e-11	Dementia with Lewy bodies;
CESC	cis	rs763121	0.853	rs7289577	chr22:39042214	C/G	cg14440974	chr22:39074834	NA	-0.4	-5.48	-0.32	9.77e-8	Menopause (age at onset);
CESC	cis	rs8072100	0.676	rs9905308	chr17:45409386	T/A	cg08085267	chr17:45401833	C17orf57	-0.65	-8.88	-0.48	1e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs9311474	0.659	rs1133415	chr3:52575831	G/A	cg07507251	chr3:52567010	NT5DC2	0.37	6.71	0.38	1.19e-10	Electroencephalogram traits;
CESC	cis	rs2637266	0.756	rs7079818	chr10:78469935	T/A	cg18941641	chr10:78392320	NA	0.44	8.25	0.45	7.25e-15	Pulmonary function;
CESC	cis	rs35306767	0.761	rs11253558	chr10:1043983	T/C	cg26597838	chr10:835615	NA	0.7	6.39	0.37	7.54e-10	Eosinophil percentage of granulocytes;
CESC	cis	rs1552244	1.000	rs67006488	chr3:10152993	T/C	cg16606324	chr3:10149918	C3orf24	0.41	5.21	0.3	3.84e-7	Alzheimer's disease;
CESC	cis	rs7666738	0.830	rs1426663	chr4:98990092	T/G	cg05340658	chr4:99064831	C4orf37	0.8	12.43	0.61	3.04e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2836633	1.000	rs2836631	chr21:40065906	G/T	cg05519781	chr21:40033154	ERG	-0.59	-9.5	-0.5	1.28e-18	Coronary artery disease;
CESC	cis	rs4722166	0.630	rs12700390	chr7:22777129	G/T	cg05472934	chr7:22766657	IL6	0.87	10.94	0.56	3.06e-23	Lung cancer;
CESC	cis	rs9905704	0.647	rs9901655	chr17:56987142	G/A	cg12560992	chr17:57184187	TRIM37	0.58	7.05	0.4	1.52e-11	Testicular germ cell tumor;
CESC	cis	rs2228479	0.850	rs11646766	chr16:89838578	A/T	cg06558623	chr16:89946397	TCF25	1.17	9.29	0.5	5.84e-18	Skin colour saturation;
CESC	cis	rs7666738	0.606	rs28625338	chr4:99076996	A/G	cg24818145	chr4:99064322	C4orf37	0.4	5.25	0.31	3.18e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs113835537	0.529	rs57207756	chr11:66270360	C/T	cg22134325	chr11:66188745	NPAS4	0.46	7.13	0.4	9.52e-12	Airway imaging phenotypes;
CESC	cis	rs8005677	1.000	rs8016061	chr14:23375809	A/G	cg25600027	chr14:23388339	RBM23	-0.41	-5.04	-0.3	8.45e-7	Cognitive ability (multi-trait analysis);
CESC	cis	rs9733	0.596	rs6685702	chr1:150656307	A/G	cg17724175	chr1:150552817	MCL1	0.44	7.21	0.41	5.8e-12	Tonsillectomy;
CESC	cis	rs34779708	0.966	rs17591163	chr10:35465279	G/C	cg03585969	chr10:35415529	CREM	0.77	10.33	0.54	2.96e-21	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs863345	0.565	rs6679056	chr1:158450314	A/G	cg12129480	chr1:158549410	OR10X1	-0.34	-6.73	-0.38	1.06e-10	Pneumococcal bacteremia;
CESC	cis	rs8072100	0.967	rs4794058	chr17:45597098	C/T	cg08085267	chr17:45401833	C17orf57	0.42	5.47	0.32	1.03e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs12586317	0.547	rs2254990	chr14:35465565	T/C	cg16230307	chr14:35515116	FAM177A1	0.98	10.57	0.54	5.04e-22	Psoriasis;
CESC	cis	rs6964587	0.967	rs10280620	chr7:91582183	C/G	cg17063962	chr7:91808500	NA	-0.57	-7.68	-0.43	3.06e-13	Breast cancer;
CESC	cis	rs875971	0.929	rs10950041	chr7:65973875	T/C	cg10691866	chr7:65817282	TPST1	-0.34	-5.64	-0.33	4.29e-8	Aortic root size;
CESC	cis	rs270601	0.955	rs273911	chr5:131661526	C/G	cg18758796	chr5:131593413	PDLIM4	0.39	5.33	0.31	2.15e-7	Acylcarnitine levels;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg15340270	chr11:62420901	INTS5	-0.45	-6.16	-0.35	2.72e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs10504229	1.000	rs57624567	chr8:58176995	T/C	cg14926445	chr8:58193284	C8orf71	-0.51	-5.47	-0.32	1.03e-7	Developmental language disorder (linguistic errors);
CESC	trans	rs7618501	1.000	rs1491986	chr3:49739086	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.58	-8.34	-0.46	4.21e-15	Intelligence (multi-trait analysis);
CESC	cis	rs950776	0.518	rs12915428	chr15:78823368	G/A	cg06917634	chr15:78832804	PSMA4	0.8	12.12	0.6	3.34e-27	Sudden cardiac arrest;
CESC	trans	rs7922314	0.571	rs7083998	chr10:64750962	G/A	cg06935979	chr1:232941706	KIAA1383	-0.62	-6.0	-0.35	6.34e-9	Cutaneous psoriasis;
CESC	cis	rs3857067	1.000	rs2199603	chr4:95016174	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.52	-8.03	-0.44	3.2e-14	QT interval;
CESC	cis	rs796364	0.806	rs11691873	chr2:200966337	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.75	-6.49	-0.37	4.2e-10	Schizophrenia;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg23946709	chr14:23527317	CDH24	-0.49	-6.59	-0.38	2.41e-10	Fibrinogen levels;
CESC	trans	rs4950322	0.518	rs11811023	chr1:146581118	C/T	cg04954894	chr8:38089920	DDHD2	0.58	6.41	0.37	6.72e-10	Protein quantitative trait loci;
CESC	cis	rs11122272	0.735	rs2491412	chr1:231535880	A/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.5	-6.59	-0.38	2.31e-10	Hemoglobin concentration;
CESC	cis	rs9788682	0.747	rs12101809	chr15:78779801	C/T	cg24631222	chr15:78858424	CHRNA5	0.62	7.22	0.41	5.34e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs698833	0.729	rs4952708	chr2:44517072	A/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.46	5.67	0.33	3.65e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs11122272	0.735	rs2491416	chr1:231547335	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.52	6.95	0.39	2.84e-11	Hemoglobin concentration;
CESC	cis	rs4803468	0.967	rs4605279	chr19:41888131	C/G	cg14132834	chr19:41945861	ATP5SL	-0.61	-7.61	-0.42	4.85e-13	Height;
CESC	cis	rs7555523	0.887	rs7518099	chr1:165736880	C/T	cg24409356	chr1:165738333	TMCO1	0.98	8.91	0.48	8.52e-17	Intraocular pressure;Glaucoma (high intraocular pressure);
CESC	cis	rs3091242	0.935	rs3093632	chr1:25684012	C/T	cg03538708	chr1:25844672	NA	-0.36	-5.29	-0.31	2.62e-7	Erythrocyte sedimentation rate;
CESC	cis	rs7772486	0.754	rs6906258	chr6:146089356	A/G	cg05347473	chr6:146136440	FBXO30	-0.55	-6.97	-0.39	2.54e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7666738	0.830	rs1111541	chr4:99033860	A/G	cg03467027	chr4:99064603	C4orf37	-0.46	-5.76	-0.33	2.31e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2576037	0.526	rs2510444	chr18:44376849	G/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.34	5.4	0.31	1.47e-7	Personality dimensions;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15920017	chr6:90062628	UBE2J1	0.55	6.62	0.38	1.93e-10	Gut microbiome composition (summer);
CESC	cis	rs9399137	0.507	rs4580893	chr6:135297662	G/A	cg22676075	chr6:135203613	NA	0.54	7.06	0.4	1.46e-11	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	cis	rs6570726	0.791	rs443628	chr6:145883484	T/C	cg05347473	chr6:146136440	FBXO30	0.54	6.84	0.39	5.31e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1799949	1.000	rs33946455	chr17:41321846	C/T	cg25072359	chr17:41440525	NA	0.47	6.34	0.36	9.98e-10	Menopause (age at onset);
CESC	cis	rs6815814	0.950	rs5743795	chr4:38832495	C/T	cg02016764	chr4:38805732	TLR1	-0.61	-6.86	-0.39	4.8e-11	Breast cancer;
CESC	cis	rs941873	0.868	rs4980063	chr10:81105844	A/T	cg09469691	chr10:81107165	PPIF	0.57	7.89	0.44	7.81e-14	Height;
CESC	cis	rs3815700	1.000	rs10406750	chr19:33097144	C/T	cg24916020	chr19:33096688	ANKRD27	0.59	5.87	0.34	1.28e-8	Eosinophilic esophagitis;
CESC	cis	rs9837602	0.529	rs793459	chr3:99520591	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.52	-6.21	-0.36	2.05e-9	Breast cancer;
CESC	cis	rs9303401	0.592	rs66583824	chr17:56639853	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.02	12.93	0.62	5.59e-30	Cognitive test performance;
CESC	trans	rs11098499	0.913	rs10006304	chr4:120124305	A/G	cg25214090	chr10:38739885	LOC399744	0.62	8.24	0.45	7.91e-15	Corneal astigmatism;
CESC	cis	rs79976124	0.837	rs75346757	chr6:66648386	A/T	cg07460842	chr6:66804631	NA	0.75	8.76	0.47	2.33e-16	Type 2 diabetes;
CESC	cis	rs1153858	1.000	rs1820518	chr15:45694579	C/T	cg21132104	chr15:45694354	SPATA5L1	0.86	11.67	0.58	1.14e-25	Homoarginine levels;
CESC	cis	rs793571	0.590	rs474875	chr15:59086703	A/C	cg05156742	chr15:59063176	FAM63B	0.62	8.33	0.46	4.31e-15	Schizophrenia;
CESC	cis	rs7177699	0.526	rs7166764	chr15:79123509	T/G	cg04896959	chr15:78267971	NA	-0.31	-5.05	-0.3	8.13e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
CESC	cis	rs7267979	1.000	rs4813566	chr20:25386465	G/T	cg08601574	chr20:25228251	PYGB	-0.38	-5.55	-0.32	6.85e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs9733	0.688	rs12725667	chr1:150766070	A/T	cg22823121	chr1:150693482	HORMAD1	-0.38	-5.76	-0.33	2.33e-8	Tonsillectomy;
CESC	cis	rs2576037	0.562	rs13381557	chr18:44513371	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.37	5.83	0.34	1.64e-8	Personality dimensions;
CESC	trans	rs561341	1.000	rs550923	chr17:30327013	G/C	cg27661571	chr11:113659931	NA	-0.82	-7.63	-0.42	4.18e-13	Hip circumference adjusted for BMI;
CESC	cis	rs7267979	1.000	rs6050626	chr20:25428261	T/C	cg08601574	chr20:25228251	PYGB	0.38	5.64	0.33	4.42e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs4713118	0.616	rs9348789	chr6:28025486	C/T	cg23161317	chr6:28129485	ZNF389	0.49	6.19	0.36	2.28e-9	Parkinson's disease;
CESC	cis	rs6741892	0.536	rs13024840	chr2:38895920	T/A	cg00359181	chr2:38893519	GALM	-0.64	-8.99	-0.48	4.95e-17	5-HTT brain serotonin transporter levels;
CESC	cis	rs7927771	0.864	rs755555	chr11:47431966	C/T	cg18512352	chr11:47633146	NA	-0.5	-7.07	-0.4	1.37e-11	Subjective well-being;
CESC	cis	rs780096	0.506	rs1262430	chr2:27673798	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.32	-5.97	-0.34	7.47e-9	Total body bone mineral density;
CESC	cis	rs9611565	0.659	rs9611604	chr22:41916001	C/G	cg06481639	chr22:41940642	POLR3H	-0.64	-6.58	-0.37	2.43e-10	Vitiligo;
CESC	cis	rs10751667	0.666	rs7103585	chr11:971166	T/C	cg06064525	chr11:970664	AP2A2	-0.47	-9.13	-0.49	1.87e-17	Alzheimer's disease (late onset);
CESC	cis	rs10754283	0.934	rs10493829	chr1:90117833	T/C	cg21401794	chr1:90099060	LRRC8C	0.71	9.51	0.5	1.26e-18	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs35306767	0.855	rs12774985	chr10:904245	C/T	cg26597838	chr10:835615	NA	1.19	11.34	0.57	1.41e-24	Eosinophil percentage of granulocytes;
CESC	cis	rs8018808	0.935	rs2091916	chr14:77914752	A/G	cg20045696	chr14:77926864	AHSA1	0.42	5.79	0.33	2.04e-8	Myeloid white cell count;
CESC	cis	rs9467711	0.606	rs9393714	chr6:26373740	G/T	cg14345882	chr6:26364793	BTN3A2	0.61	6.45	0.37	5.32e-10	Autism spectrum disorder or schizophrenia;
CESC	cis	rs7818688	0.654	rs896848	chr8:95981810	G/A	cg16049864	chr8:95962084	TP53INP1	0.5	5.45	0.32	1.17e-7	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs17433780	0.504	rs4142706	chr1:89475230	A/C	cg09516651	chr1:89888402	LOC400759	0.4	5.63	0.33	4.67e-8	Carotid intima media thickness;
CESC	cis	rs7412746	0.634	rs7521592	chr1:150821691	A/C	cg17724175	chr1:150552817	MCL1	0.41	6.19	0.36	2.26e-9	Melanoma;
CESC	cis	rs244293	0.965	rs244352	chr17:53195478	C/T	cg19360675	chr17:53046073	COX11;STXBP4	0.4	5.22	0.31	3.56e-7	Menarche (age at onset);
CESC	cis	rs12497850	0.931	rs7616815	chr3:48779715	C/T	cg07636037	chr3:49044803	WDR6	0.94	16.47	0.71	1.91e-42	Parkinson's disease;
CESC	cis	rs7647973	0.626	rs2131108	chr3:49665390	C/T	cg13072238	chr3:49761600	GMPPB	-0.44	-5.45	-0.32	1.17e-7	Menarche (age at onset);
CESC	cis	rs2439831	0.867	rs486301	chr15:43836949	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.72	9.54	0.51	9.52e-19	Lung cancer in ever smokers;
CESC	trans	rs7839040	0.698	rs17715625	chr8:82927562	G/A	cg14472086	chr9:107730925	NA	-0.47	-6.33	-0.36	1.02e-9	Response to methotrexate in juvenile idiopathic arthritis;
CESC	cis	rs11677370	0.574	rs10190477	chr2:3862738	A/G	cg17052675	chr2:3827356	NA	0.45	5.73	0.33	2.71e-8	Type 2 diabetes;
CESC	cis	rs9322193	0.923	rs9767105	chr6:149980727	A/G	cg09699651	chr6:150184138	LRP11	0.45	5.67	0.33	3.7e-8	Lung cancer;
CESC	cis	rs7666738	0.830	rs7663924	chr4:99037679	A/G	cg05340658	chr4:99064831	C4orf37	-0.83	-12.44	-0.61	2.73e-28	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11696739	0.761	rs2254458	chr20:1551485	C/T	cg25189608	chr11:96117844	CCDC82	0.4	6.18	0.35	2.35e-9	Mean platelet volume;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg17748167	chr1:31769917	ZCCHC17;SNRNP40	0.44	6.26	0.36	1.56e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg06873352	chr17:61820015	STRADA	0.72	12.37	0.6	4.8e-28	Prudent dietary pattern;
CESC	cis	rs2124969	0.506	rs10497210	chr2:160985549	G/A	cg03641300	chr2:160917029	PLA2R1	-0.55	-5.59	-0.32	5.59e-8	Waist circumference adjusted for body mass index;
CESC	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg24503407	chr1:205819492	PM20D1	0.83	13.14	0.63	1.04e-30	Menarche (age at onset);
CESC	cis	rs77956314	0.515	rs4767473	chr12:117365506	C/T	cg16111737	chr12:117408163	FBXW8	-0.47	-5.85	-0.34	1.47e-8	Subcortical brain region volumes;Hippocampal volume;
CESC	cis	rs4689388	0.816	rs13147655	chr4:6293474	A/G	cg14416269	chr4:6271139	WFS1	0.46	7.76	0.43	1.79e-13	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs7336332	0.662	rs9581862	chr13:28039993	T/G	cg01674679	chr13:27998804	GTF3A	-0.55	-5.89	-0.34	1.17e-8	Weight;
CESC	cis	rs11249608	0.548	rs7707587	chr5:178462590	G/C	cg21905437	chr5:178450457	ZNF879	0.58	8.12	0.45	1.81e-14	Pubertal anthropometrics;
CESC	cis	rs7618915	0.547	rs2268027	chr3:52766606	G/A	cg07507251	chr3:52567010	NT5DC2	0.42	7.37	0.41	2.24e-12	Bipolar disorder;
CESC	cis	rs7917772	0.582	rs6584512	chr10:104329685	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.41	5.61	0.33	5.05e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs72945132	0.882	rs7937984	chr11:70144254	C/T	cg14191688	chr11:70257035	CTTN	0.42	5.34	0.31	1.95e-7	Coronary artery disease;
CESC	cis	rs7772486	0.790	rs2265918	chr6:146219164	A/G	cg23711669	chr6:146136114	FBXO30	0.92	13.36	0.63	1.78e-31	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs12477438	0.798	rs2309524	chr2:99659510	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.76	-10.94	-0.56	3.02e-23	Chronic sinus infection;
CESC	cis	rs12701220	0.553	rs7782024	chr7:1157502	G/T	cg26769984	chr7:1090371	C7orf50	0.55	6.32	0.36	1.13e-9	Bronchopulmonary dysplasia;
CESC	cis	rs7662987	0.517	rs3018048	chr4:100005538	C/T	cg12011299	chr4:100065546	ADH4	0.59	6.71	0.38	1.18e-10	Smoking initiation;
CESC	cis	rs7511006	1.000	rs5771109	chr22:50678571	T/C	cg16473166	chr22:50639996	SELO	0.52	6.41	0.37	6.48e-10	Obesity-related traits;
CESC	cis	rs826838	0.802	rs10785619	chr12:38742897	T/A	cg26384229	chr12:38710491	ALG10B	0.66	11.32	0.57	1.69e-24	Heart rate;
CESC	cis	rs2742234	0.541	rs10899779	chr10:43723976	C/T	cg15436174	chr10:43711423	RASGEF1A	0.47	5.5	0.32	8.97e-8	Hirschsprung disease;
CESC	cis	rs7909791	0.606	rs3814219	chr10:105647095	A/G	cg24587175	chr10:105670608	OBFC1	-0.42	-6.08	-0.35	4.13e-9	White matter hyperintensity burden;
CESC	cis	rs2425143	0.730	rs6058354	chr20:34491110	C/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.66	5.7	0.33	3.16e-8	Blood protein levels;
CESC	cis	rs10883723	0.775	rs2296579	chr10:104241375	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.56	7.66	0.43	3.52e-13	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs2243480	1.000	rs7794661	chr7:65389730	T/C	cg12463550	chr7:65579703	CRCP	0.7	5.59	0.32	5.52e-8	Diabetic kidney disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12448664	chr15:85143675	ZSCAN2	-0.61	-7.1	-0.4	1.13e-11	Gut microbiome composition (summer);
CESC	cis	rs561341	0.825	rs2008368	chr17:30347397	T/C	cg23018236	chr17:30244563	NA	-0.55	-5.16	-0.3	4.77e-7	Hip circumference adjusted for BMI;
CESC	cis	rs514406	0.861	rs12141260	chr1:53300127	C/T	cg16325326	chr1:53192061	ZYG11B	0.84	13.71	0.64	1.03e-32	Monocyte count;
CESC	cis	rs1692580	0.840	rs262679	chr1:2169792	C/T	cg04315214	chr1:2043799	PRKCZ	-0.38	-5.41	-0.32	1.41e-7	Coronary artery disease;
CESC	cis	rs1552244	1.000	rs9881859	chr3:10072814	A/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.88	11.81	0.59	3.97e-26	Alzheimer's disease;
CESC	cis	rs798766	1.000	rs798754	chr4:1720757	A/G	cg10756475	chr4:1757242	NA	0.45	6.3	0.36	1.23e-9	Bladder cancer;Urinary bladder cancer;
CESC	cis	rs11718455	0.960	rs13065591	chr3:43996585	T/C	cg08738300	chr3:44038990	NA	0.44	5.73	0.33	2.75e-8	Coronary artery disease;
CESC	cis	rs13118159	0.550	rs4974617	chr4:1373658	T/C	cg02018176	chr4:1364513	KIAA1530	0.61	7.87	0.44	9.2e-14	Longevity;
CESC	cis	rs7605827	0.930	rs13035937	chr2:15698050	C/T	cg19274914	chr2:15703543	NA	-0.35	-6.36	-0.36	9.01e-10	Educational attainment (years of education);
CESC	cis	rs7640424	0.754	rs182736	chr3:107838891	C/A	cg09227934	chr3:107805635	CD47	0.48	5.99	0.35	6.9e-9	Body mass index;
CESC	cis	rs36051895	0.632	rs11788164	chr9:5129395	A/G	cg02405213	chr9:5042618	JAK2	-0.51	-6.29	-0.36	1.31e-9	Pediatric autoimmune diseases;
CESC	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg01874867	chr7:94954059	PON1	-0.42	-6.36	-0.36	8.62e-10	Paraoxonase activity;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg16595246	chr2:48009933	MSH6	0.5	6.46	0.37	5e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs11155671	0.530	rs9969044	chr6:150209204	A/G	cg09699651	chr6:150184138	LRP11	0.55	7.44	0.42	1.41e-12	Testicular germ cell tumor;
CESC	cis	rs977987	0.778	rs4888413	chr16:75443223	C/A	cg03315344	chr16:75512273	CHST6	0.41	5.86	0.34	1.35e-8	Dupuytren's disease;
CESC	cis	rs5758659	0.714	rs6002607	chr22:42496506	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.34	5.87	0.34	1.28e-8	Cognitive function;
CESC	cis	rs7246657	0.943	rs10406177	chr19:37907947	G/A	cg23950597	chr19:37808831	NA	-0.55	-5.99	-0.35	6.81e-9	Coronary artery calcification;
CESC	cis	rs6867032	0.958	rs4246754	chr5:2014776	A/C	cg26168224	chr5:2018326	NA	0.87	15.8	0.7	4.38e-40	Gut microbiome composition (winter);
CESC	cis	rs9487051	0.714	rs7774390	chr6:109602461	C/G	cg01475377	chr6:109611718	NA	0.44	6.89	0.39	4.15e-11	Reticulocyte fraction of red cells;
CESC	cis	rs6565180	0.926	rs12446288	chr16:30388709	A/G	cg17640201	chr16:30407289	ZNF48	0.97	16.51	0.71	1.34e-42	Tonsillectomy;
CESC	cis	rs6598955	0.640	rs4233460	chr1:26633387	A/G	cg00852783	chr1:26633632	UBXN11	0.43	6.18	0.36	2.35e-9	Obesity-related traits;
CESC	cis	rs6991838	0.584	rs4737749	chr8:66539907	A/C	cg13398993	chr8:66546079	ARMC1	0.46	5.65	0.33	4.19e-8	Intelligence (multi-trait analysis);
CESC	cis	rs870825	0.616	rs28673855	chr4:185627416	T/G	cg04058563	chr4:185651563	MLF1IP	0.64	7.05	0.4	1.59e-11	Blood protein levels;
CESC	cis	rs7474896	0.583	rs11011347	chr10:38019264	G/A	cg00409905	chr10:38381863	ZNF37A	-0.49	-5.6	-0.33	5.42e-8	Obesity (extreme);
CESC	cis	rs7208859	0.623	rs7208088	chr17:29143667	C/T	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.1e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs853679	0.517	rs9380062	chr6:28137569	G/A	cg17949981	chr6:28129498	ZNF389	0.42	5.24	0.31	3.27e-7	Depression;
CESC	cis	rs7503807	0.688	rs901062	chr17:78595674	C/T	cg09596252	chr17:78655493	RPTOR	0.37	5.2	0.3	4.03e-7	Obesity;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg16216227	chr4:174293382	SAP30	0.38	6.19	0.36	2.26e-9	Gambling;
CESC	cis	rs1983170	1.000	rs597288	chr1:91999296	C/T	cg02896835	chr1:92012615	NA	0.57	6.54	0.37	3.13e-10	Eosinophil percentage of white cells;
CESC	cis	rs2228479	1.000	rs62052186	chr16:89969567	A/T	cg04013166	chr16:89971882	TCF25	0.75	6.27	0.36	1.47e-9	Skin colour saturation;
CESC	cis	rs7666738	0.800	rs13107586	chr4:99028788	G/C	cg05340658	chr4:99064831	C4orf37	0.83	13.1	0.63	1.43e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs59918340	0.728	rs10875467	chr8:142233396	A/C	cg16341495	chr8:142228727	SLC45A4	0.43	5.31	0.31	2.28e-7	Immature fraction of reticulocytes;
CESC	cis	rs7833790	0.724	rs12676336	chr8:82771008	C/T	cg02079420	chr8:82753780	SNX16	-0.54	-8.24	-0.45	8.22e-15	Diastolic blood pressure;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg19137606	chr10:38146164	ZNF248	-0.48	-6.85	-0.39	5.02e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs1348850	0.914	rs10497503	chr2:178371739	G/T	cg22681709	chr2:178499509	PDE11A	-0.42	-6.32	-0.36	1.13e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs13191362	1.000	rs35593345	chr6:163174981	G/C	cg14584255	chr6:163149320	PACRG;PARK2	0.66	6.16	0.35	2.7e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs977987	0.966	rs11643207	chr16:75498793	C/T	cg03315344	chr16:75512273	CHST6	0.54	7.92	0.44	6.39e-14	Dupuytren's disease;
CESC	cis	rs17764205	0.929	rs10401854	chr19:3256318	T/C	cg04171554	chr19:2761892	SGTA	-0.55	-5.15	-0.3	4.97e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs7508679	1.000	rs7508679	chr19:7222832	A/G	cg09779027	chr19:7224513	INSR	0.54	8.73	0.47	3e-16	Hypothyroidism;
CESC	cis	rs9649465	1.000	rs2896334	chr7:123367705	A/C	cg04330084	chr7:123175371	IQUB	-0.38	-5.13	-0.3	5.55e-7	Migraine;
CESC	cis	rs10129255	0.957	rs6576233	chr14:107195477	G/A	cg23076370	chr14:107095027	NA	-0.55	-7.06	-0.4	1.49e-11	Kawasaki disease;
CESC	cis	rs10927875	0.596	rs1806990	chr1:16129377	G/A	cg21385522	chr1:16154831	NA	-1.03	-16.9	-0.72	5.51e-44	Dilated cardiomyopathy;
CESC	cis	rs6951245	0.507	rs11976805	chr7:1138716	C/T	cg18402987	chr7:1209562	NA	0.55	6.71	0.38	1.15e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs1862618	0.853	rs252915	chr5:56121754	C/T	cg18230493	chr5:56204884	C5orf35	0.71	8.5	0.46	1.42e-15	Initial pursuit acceleration;
CESC	cis	rs62064224	0.720	rs8078837	chr17:30763537	A/G	cg09324608	chr17:30823087	MYO1D	0.53	8.2	0.45	1.08e-14	Schizophrenia;
CESC	cis	rs1256061	0.603	rs1269056	chr14:64743890	T/C	cg23250157	chr14:64679961	SYNE2	0.53	7.62	0.42	4.61e-13	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs7116495	1.000	rs493065	chr11:71796929	T/C	cg10381502	chr11:71823885	C11orf51	-0.66	-5.4	-0.31	1.51e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs9487051	0.807	rs1915835	chr6:109597483	C/T	cg12927641	chr6:109611667	NA	-0.41	-6.43	-0.37	5.98e-10	Reticulocyte fraction of red cells;
CESC	cis	rs11785400	0.753	rs9694286	chr8:143737157	G/T	cg10596483	chr8:143751796	JRK	0.43	5.45	0.32	1.14e-7	Schizophrenia;
CESC	cis	rs3806843	0.933	rs2337987	chr5:140188383	T/G	cg26395211	chr5:140044315	WDR55	-0.41	-5.19	-0.3	4.17e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs1707322	0.964	rs785496	chr1:46588006	T/C	cg05343316	chr1:45956843	TESK2	-0.47	-5.52	-0.32	7.97e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7615952	0.641	rs7640158	chr3:125808011	G/A	cg02807482	chr3:125708958	NA	-0.39	-5.07	-0.3	7.59e-7	Blood pressure (smoking interaction);
CESC	cis	rs67072384	1.000	rs72966113	chr11:72450970	C/T	cg04827223	chr11:72435913	ARAP1	-0.71	-6.85	-0.39	5e-11	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
CESC	cis	rs1448094	0.511	rs6539921	chr12:86164163	G/A	cg02569458	chr12:86230093	RASSF9	0.49	7.62	0.42	4.61e-13	Major depressive disorder;
CESC	cis	rs1552244	0.882	rs6796419	chr3:10040812	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.75	-9.64	-0.51	4.83e-19	Alzheimer's disease;
CESC	cis	rs10504229	0.906	rs116341227	chr8:58190532	G/C	cg14926445	chr8:58193284	C8orf71	-0.5	-5.4	-0.31	1.49e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs6120849	0.754	rs8501	chr20:33590584	T/C	cg24642439	chr20:33292090	TP53INP2	0.67	6.62	0.38	1.94e-10	Protein C levels;
CESC	cis	rs4319547	0.915	rs3803005	chr12:123110654	T/C	cg23029597	chr12:123009494	RSRC2	-0.46	-5.12	-0.3	5.93e-7	Body mass index;
CESC	cis	rs8114671	0.839	rs2104084	chr20:33649217	G/C	cg06115741	chr20:33292138	TP53INP2	-0.43	-5.15	-0.3	5.03e-7	Height;
CESC	cis	rs28647808	0.786	rs4962134	chr9:136256626	G/A	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.85	5.74	0.33	2.59e-8	Blood protein levels;
CESC	cis	rs2742417	0.603	rs2742453	chr3:45765858	G/A	cg04837898	chr3:45731254	SACM1L	-0.47	-6.17	-0.35	2.54e-9	Response to anti-depressant treatment in major depressive disorder;
CESC	cis	rs4713118	0.662	rs464312	chr6:27967591	T/A	cg26335602	chr6:28129616	ZNF389	0.41	5.57	0.32	6.18e-8	Parkinson's disease;
CESC	trans	rs12356475	0.710	rs10822686	chr10:67733250	C/T	cg08974656	chr2:96931567	CIAO1;TMEM127	0.55	6.53	0.37	3.33e-10	Psoriatic arthritis;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg21605566	chr1:14075549	PRDM2	-0.46	-6.11	-0.35	3.59e-9	Thyroid stimulating hormone;
CESC	cis	rs7589342	0.839	rs1465641	chr2:106438936	C/T	cg16077055	chr2:106428750	NCK2	0.48	6.88	0.39	4.33e-11	Addiction;
CESC	cis	rs4843747	0.671	rs4072871	chr16:88106614	C/T	cg06915872	chr16:87998081	BANP	0.44	5.26	0.31	3.03e-7	Menopause (age at onset);
CESC	cis	rs853679	0.517	rs1904841	chr6:28108085	C/T	cg22143856	chr6:28129313	ZNF389	0.5	6.49	0.37	4.09e-10	Depression;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg17832212	chr1:33367304	TMEM54	-0.51	-6.4	-0.37	7.07e-10	Asthma;
CESC	cis	rs477895	1.000	rs34292685	chr11:64049021	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.74	6.67	0.38	1.46e-10	Mean platelet volume;
CESC	cis	rs9896933	0.830	rs607544	chr17:80768760	C/G	cg20578329	chr17:80767326	TBCD	-0.69	-7.43	-0.42	1.51e-12	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
CESC	cis	rs7666738	0.830	rs10000573	chr4:99048785	G/C	cg03676636	chr4:99064102	C4orf37	0.33	5.12	0.3	5.93e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs7246760	0.748	rs73507210	chr19:9885891	A/G	cg02900749	chr2:68251473	NA	-0.76	-6.86	-0.39	4.73e-11	Pursuit maintenance gain;
CESC	trans	rs62103177	0.810	rs62096745	chr18:77619135	A/G	cg05926928	chr17:57297772	GDPD1	1.24	11.08	0.56	1.09e-23	Opioid sensitivity;
CESC	cis	rs35306767	0.714	rs7072554	chr10:1090988	C/T	cg26597838	chr10:835615	NA	0.49	5.19	0.3	4.16e-7	Eosinophil percentage of granulocytes;
CESC	cis	rs3858526	0.584	rs10769274	chr11:5866925	T/C	cg13902645	chr11:5959945	NA	-0.67	-9.57	-0.51	7.8e-19	DNA methylation (variation);
CESC	cis	rs1218582	0.682	rs12046459	chr1:154912017	A/C	cg06221963	chr1:154839813	KCNN3	-0.65	-10.68	-0.55	2.24e-22	Prostate cancer;
CESC	cis	rs4727027	0.870	rs62507485	chr7:148764182	C/T	cg23158103	chr7:148848205	ZNF398	-0.4	-6.44	-0.37	5.59e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs782590	0.967	rs58003472	chr2:55797507	T/C	cg18811423	chr2:55921094	PNPT1	0.78	12.54	0.61	1.22e-28	Metabolic syndrome;
CESC	cis	rs1595825	0.891	rs17520121	chr2:198898718	T/G	cg10820045	chr2:198174542	NA	0.39	5.06	0.3	7.76e-7	Ulcerative colitis;
CESC	cis	rs854765	0.583	rs6502622	chr17:17834691	A/G	cg16928487	chr17:17741425	SREBF1	-0.56	-9.74	-0.51	2.28e-19	Total body bone mineral density;
CESC	cis	rs5750830	0.649	rs5757663	chr22:39821319	T/C	cg24399712	chr22:39784796	NA	-0.82	-10.89	-0.56	4.48e-23	Intelligence (multi-trait analysis);
CESC	cis	rs7044106	0.791	rs10984997	chr9:123481206	T/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.33	5.08	0.3	7.05e-7	Hip circumference adjusted for BMI;
CESC	cis	rs2075371	0.933	rs1868785	chr7:133945855	G/C	cg20476274	chr7:133979776	SLC35B4	0.64	9.32	0.5	4.57e-18	Mean platelet volume;
CESC	cis	rs17253792	0.822	rs28478195	chr14:56047851	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.82	5.88	0.34	1.25e-8	Putamen volume;
CESC	cis	rs875971	0.862	rs801206	chr7:66021966	C/G	cg12463550	chr7:65579703	CRCP	-0.5	-6.32	-0.36	1.08e-9	Aortic root size;
CESC	cis	rs55794721	0.509	rs4649085	chr1:25778832	G/A	cg03538708	chr1:25844672	NA	-0.41	-6.27	-0.36	1.48e-9	Plateletcrit;Mean corpuscular volume;
CESC	cis	rs7618915	0.501	rs7622694	chr3:52663882	G/A	cg17372223	chr3:52568218	NT5DC2	0.42	6.47	0.37	4.63e-10	Bipolar disorder;
CESC	cis	rs2404602	0.608	rs12911035	chr15:76606591	T/C	cg22467129	chr15:76604101	ETFA	-0.41	-6.33	-0.36	1.05e-9	Blood metabolite levels;
CESC	cis	rs873946	0.586	rs3793685	chr10:134569316	G/A	cg26818010	chr10:134567672	INPP5A	-0.94	-11.42	-0.57	7.87e-25	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs7577696	0.597	rs2280968	chr2:32290040	G/T	cg02381751	chr2:32503542	YIPF4	-0.42	-5.05	-0.3	8.32e-7	Inflammatory biomarkers;
CESC	trans	rs3780486	0.629	rs10971439	chr9:33180813	C/T	cg04842962	chr6:43655489	MRPS18A	-0.59	-6.81	-0.39	6.7e-11	IgG glycosylation;
CESC	cis	rs853679	0.517	rs9468298	chr6:28122345	A/G	cg20151795	chr6:28129481	ZNF389	0.46	5.74	0.33	2.6e-8	Depression;
CESC	cis	rs9322193	0.962	rs4869731	chr6:150131208	T/C	cg05861140	chr6:150128134	PCMT1	-0.37	-5.33	-0.31	2.07e-7	Lung cancer;
CESC	cis	rs172166	0.694	rs1225716	chr6:28113746	A/C	cg22143856	chr6:28129313	ZNF389	0.37	5.26	0.31	2.97e-7	Cardiac Troponin-T levels;
CESC	cis	rs2839186	0.934	rs17182538	chr21:47705673	C/A	cg10351095	chr21:47802916	PCNT	-0.5	-6.77	-0.38	8.06e-11	Testicular germ cell tumor;
CESC	cis	rs977987	0.806	rs7188231	chr16:75436561	T/C	cg03315344	chr16:75512273	CHST6	0.4	5.82	0.34	1.66e-8	Dupuytren's disease;
CESC	cis	rs13040088	0.935	rs62200158	chr20:61557906	C/T	cg23096297	chr20:61557774	DIDO1	1.03	11.14	0.56	7.03e-24	Menopause (age at onset);
CESC	cis	rs1577917	0.958	rs2121594	chr6:86576854	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.49	-6.2	-0.36	2.18e-9	Response to antipsychotic treatment;
CESC	cis	rs2732480	0.500	rs11168464	chr12:48602115	C/T	cg24011408	chr12:48396354	COL2A1	0.43	6.11	0.35	3.5e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	trans	rs208520	1.000	rs72882100	chr6:66981495	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.84	9.35	0.5	3.7e-18	Exhaled nitric oxide output;
CESC	cis	rs2243480	1.000	rs35283677	chr7:65359233	C/T	cg13147721	chr7:65941812	NA	-0.9	-8.76	-0.47	2.35e-16	Diabetic kidney disease;
CESC	cis	rs12618769	0.597	rs17031905	chr2:99070902	A/G	cg10123293	chr2:99228465	UNC50	0.41	5.56	0.32	6.6e-8	Bipolar disorder;
CESC	cis	rs6866344	0.570	rs11740283	chr5:178136440	T/C	cg03877680	chr5:178157825	ZNF354A	0.83	10.16	0.53	1.07e-20	Neutrophil percentage of white cells;
CESC	cis	rs780096	0.505	rs12475426	chr2:27599132	G/A	cg21248554	chr2:27665150	KRTCAP3	-0.34	-7.02	-0.4	1.85e-11	Total body bone mineral density;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg07017636	chr1:165567312	NA	0.47	6.46	0.37	5.05e-10	Systemic lupus erythematosus;
CESC	cis	rs6570726	0.577	rs406868	chr6:145809983	C/T	cg05347473	chr6:146136440	FBXO30	0.73	9.27	0.49	6.59e-18	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9581857	0.685	rs78595793	chr13:28031881	C/T	cg22138327	chr13:27999177	GTF3A	0.63	5.09	0.3	6.92e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
CESC	cis	rs4888262	0.564	rs6564147	chr16:74622586	G/A	cg01733217	chr16:74700730	RFWD3	0.85	11.4	0.57	9.25e-25	Testicular germ cell tumor;
CESC	cis	rs858239	0.669	rs1006709	chr7:23140099	C/T	cg23682824	chr7:23144976	KLHL7	0.47	6.52	0.37	3.61e-10	Cerebrospinal fluid biomarker levels;
CESC	cis	rs854765	0.583	rs11871899	chr17:17826748	C/G	cg16928487	chr17:17741425	SREBF1	-0.58	-9.9	-0.52	7.25e-20	Total body bone mineral density;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg24028381	chr8:145133668	EXOSC4	-0.44	-6.4	-0.37	7.19e-10	Fibrinogen levels;
CESC	trans	rs2727020	0.576	rs11040223	chr11:49034633	G/T	cg00717180	chr2:96193071	NA	-0.53	-7.47	-0.42	1.17e-12	Coronary artery disease;
CESC	cis	rs9768139	0.611	rs12698211	chr7:158119623	G/A	cg06219351	chr7:158114137	PTPRN2	-0.5	-7.84	-0.43	1.1e-13	Calcium levels;
CESC	cis	rs1707322	1.000	rs11211237	chr1:46447329	G/C	cg05343316	chr1:45956843	TESK2	0.44	5.42	0.32	1.36e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs208520	0.955	rs9453664	chr6:66976079	A/C	cg07460842	chr6:66804631	NA	0.74	8.71	0.47	3.42e-16	Exhaled nitric oxide output;
CESC	cis	rs16854884	0.683	rs920968	chr3:143770698	C/G	cg06585982	chr3:143692056	C3orf58	0.51	6.52	0.37	3.54e-10	Economic and political preferences (feminism/equality);
CESC	cis	rs3785574	0.924	rs2727292	chr17:61893747	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.1	19.27	0.76	2.4e-52	Height;
CESC	cis	rs7618915	0.547	rs62253700	chr3:52625019	T/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	6.69	0.38	1.29e-10	Bipolar disorder;
CESC	cis	rs1538970	0.781	rs11211139	chr1:46015751	G/T	cg06784218	chr1:46089804	CCDC17	0.41	6.38	0.36	7.97e-10	Platelet count;
CESC	cis	rs1801251	1.000	rs2305137	chr2:233712049	G/A	cg08000102	chr2:233561755	GIGYF2	-0.68	-9.93	-0.52	5.99e-20	Coronary artery disease;
CESC	cis	rs78456975	0.527	rs4073862	chr2:1563433	A/G	cg26248373	chr2:1572462	NA	-0.54	-6.48	-0.37	4.55e-10	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs1144333	1.000	rs1144333	chr1:76275100	A/G	cg22875332	chr1:76189707	ACADM	-0.55	-5.32	-0.31	2.22e-7	Attention function in attention deficit hyperactive disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09513169	chr5:178287767	ZNF354B	-0.65	-7.57	-0.42	6.29e-13	Gut microbiome composition (summer);
CESC	cis	rs3820928	0.874	rs10194663	chr2:227875369	T/A	cg05526886	chr2:227700861	RHBDD1	-0.44	-5.43	-0.32	1.3e-7	Pulmonary function;
CESC	cis	rs17209837	0.646	rs4148818	chr7:87083738	T/C	cg00919237	chr7:87102261	ABCB4	-0.51	-6.58	-0.37	2.45e-10	Gallbladder cancer;
CESC	cis	rs7772486	0.623	rs9485021	chr6:146068797	A/G	cg05347473	chr6:146136440	FBXO30	-0.52	-6.94	-0.39	3.01e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs11098499	0.754	rs12509621	chr4:120249660	T/C	cg09307838	chr4:120376055	NA	0.77	10.49	0.54	9.15e-22	Corneal astigmatism;
CESC	trans	rs9693444	0.898	rs4732697	chr8:29519861	A/G	cg17561891	chr7:86849173	C7orf23	-0.44	-6.17	-0.35	2.51e-9	Breast cancer;
CESC	cis	rs9616064	0.557	rs5767318	chr22:47048792	A/G	cg05621596	chr22:47072043	GRAMD4	-0.68	-9.8	-0.52	1.45e-19	Urate levels in obese individuals;
CESC	cis	rs3008870	0.959	rs2985810	chr1:67376162	T/C	cg08660285	chr1:67390436	MIER1;WDR78	1.05	14.57	0.67	9.8e-36	Lymphocyte percentage of white cells;
CESC	cis	rs2228479	0.850	rs62054610	chr16:89816920	G/A	cg14709524	chr16:89940631	TCF25	0.93	6.94	0.39	3.03e-11	Skin colour saturation;
CESC	cis	rs7084402	0.967	rs1621811	chr10:60320664	T/C	cg07615347	chr10:60278583	BICC1	0.63	10.12	0.53	1.48e-20	Refractive error;
CESC	cis	rs4319547	1.000	rs7307735	chr12:123087442	A/G	cg23029597	chr12:123009494	RSRC2	-0.46	-5.26	-0.31	3.01e-7	Body mass index;
CESC	cis	rs1595825	0.891	rs2045244	chr2:198506466	C/T	cg00982548	chr2:198649783	BOLL	-0.48	-5.12	-0.3	5.91e-7	Ulcerative colitis;
CESC	cis	rs731174	0.959	rs12747993	chr1:38190852	T/C	cg12339802	chr1:38156545	C1orf109	-0.54	-6.29	-0.36	1.34e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs1697139	0.583	rs13186050	chr5:66528139	C/T	cg11553311	chr5:66541588	NA	0.36	5.16	0.3	4.74e-7	Breast cancer;
CESC	trans	rs208520	0.874	rs208518	chr6:66948501	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.85	9.86	0.52	9.56e-20	Exhaled nitric oxide output;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg08687137	chr11:62389499	B3GAT3	-0.51	-6.38	-0.36	8.03e-10	Ulcerative colitis;
CESC	cis	rs16854884	0.582	rs34402874	chr3:143643249	T/A	cg06585982	chr3:143692056	C3orf58	0.53	6.54	0.37	3.23e-10	Economic and political preferences (feminism/equality);
CESC	cis	rs7208859	0.623	rs58908911	chr17:29244558	C/T	cg19761014	chr17:28927070	LRRC37B2	0.69	5.48	0.32	9.65e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs2475553	0.520	rs62437129	chr6:158655757	T/G	cg07165851	chr6:158734300	TULP4	0.59	5.54	0.32	7.29e-8	Lipoprotein (a) - cholesterol levels;
CESC	cis	rs6782228	0.883	rs11712115	chr3:128404269	G/A	cg15607142	chr3:128420513	NA	-0.37	-5.08	-0.3	7.24e-7	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
CESC	cis	rs9916302	0.904	rs7501488	chr17:37576417	T/G	cg15445000	chr17:37608096	MED1	0.4	6.5	0.37	3.93e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs7666738	0.570	rs11097612	chr4:99079772	T/C	cg17366294	chr4:99064904	C4orf37	0.43	5.77	0.33	2.15e-8	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08180934	chr12:16035177	STRAP	0.57	6.31	0.36	1.19e-9	Gut microbiome composition (summer);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg14838070	chr5:150030486	SYNPO	0.48	6.8	0.39	6.83e-11	Fibrinogen levels;
CESC	cis	rs8072100	0.840	rs56952963	chr17:45493826	T/C	cg25173405	chr17:45401733	C17orf57	-0.42	-5.53	-0.32	7.75e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs9436747	0.585	rs11581702	chr1:65987659	T/C	cg14976592	chr1:65886160	LEPROT;LEPR	-0.42	-5.19	-0.3	4.21e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
CESC	trans	rs9833726	0.860	rs9877300	chr3:85962170	C/T	cg10416071	chr15:75628863	COMMD4	0.63	6.23	0.36	1.87e-9	Breast cancer;
CESC	cis	rs13191362	0.935	rs35100164	chr6:162963003	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.8	7.7	0.43	2.75e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg18402987	chr7:1209562	NA	0.76	7.57	0.42	6.04e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs514406	0.565	rs897732	chr1:53382816	A/C	cg08859206	chr1:53392774	SCP2	-0.65	-9.31	-0.5	5.23e-18	Monocyte count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22767408	chr2:230787493	TRIP12;FBXO36	0.54	6.09	0.35	3.85e-9	Gut microbiome composition (summer);
CESC	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg24642844	chr7:1081250	C7orf50	-0.77	-9.41	-0.5	2.48e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs34779708	0.931	rs12268745	chr10:35305989	C/G	cg04310649	chr10:35416472	CREM	-0.51	-6.27	-0.36	1.5e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs4819052	0.851	rs9977178	chr21:46664531	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.91	13.27	0.63	3.65e-31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs7927771	0.524	rs7107792	chr11:47669249	A/C	cg20307385	chr11:47447363	PSMC3	0.62	8.79	0.48	1.96e-16	Subjective well-being;
CESC	cis	rs10504229	0.683	rs73603874	chr8:58108340	G/A	cg21724239	chr8:58056113	NA	0.57	5.9	0.34	1.08e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs9443189	0.570	rs529383	chr6:76297847	T/G	cg01950844	chr6:76311363	SENP6	0.9	8.4	0.46	2.71e-15	Prostate cancer;
CESC	cis	rs798554	0.679	rs1614791	chr7:2888057	G/T	cg13628971	chr7:2884303	GNA12	0.64	8.49	0.46	1.5e-15	Height;
CESC	cis	rs9811920	0.598	rs793470	chr3:99548274	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.42	5.43	0.32	1.27e-7	Axial length;
CESC	cis	rs4835473	0.897	rs12505617	chr4:144644675	C/T	cg25736465	chr4:144833511	NA	0.39	5.97	0.34	7.69e-9	Immature fraction of reticulocytes;
CESC	cis	rs6762	0.692	rs7928925	chr11:839155	G/A	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.75	-9.83	-0.52	1.23e-19	Mean platelet volume;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg09464028	chr2:128744380	SAP130	-0.45	-6.04	-0.35	5.23e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs2273669	0.667	rs12214567	chr6:109317330	C/T	cg05315195	chr6:109294784	ARMC2	-0.66	-6.28	-0.36	1.36e-9	Prostate cancer;
CESC	cis	rs2070997	0.816	rs6597643	chr9:133725830	C/T	cg11464064	chr9:133710261	ABL1	-0.52	-5.75	-0.33	2.49e-8	Response to amphetamines;
CESC	cis	rs10504229	1.000	rs17805332	chr8:58169798	A/G	cg05313129	chr8:58192883	C8orf71	-0.53	-6.16	-0.35	2.66e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs7267979	0.549	rs6138537	chr20:25184466	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.57	8.52	0.46	1.24e-15	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs9787249	0.533	rs1883649	chr1:40246549	C/T	cg02773041	chr1:40204384	PPIE	0.39	5.6	0.33	5.33e-8	Blood protein levels;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg12748608	chr7:931987	C7orf20	0.49	6.87	0.39	4.54e-11	Fibrinogen levels;
CESC	cis	rs116161686	0.500	rs76610459	chr1:210050756	T/G	cg22029157	chr1:209979665	IRF6	0.68	7.09	0.4	1.19e-11	Coronary artery disease;
CESC	cis	rs75477785	0.590	rs72649912	chr1:210076950	C/T	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.96	6.81	0.39	6.53e-11	Cleft lip with or without cleft palate;
CESC	cis	rs10504229	0.683	rs6984765	chr8:58127124	T/C	cg22535103	chr8:58192502	C8orf71	-0.84	-9.44	-0.5	2.04e-18	Developmental language disorder (linguistic errors);
CESC	cis	rs72627123	0.867	rs80298117	chr14:74447383	G/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.79	5.35	0.31	1.9e-7	Morning vs. evening chronotype;
CESC	cis	rs2836974	0.932	rs8128734	chr21:40569511	G/A	cg11644478	chr21:40555479	PSMG1	1.02	16.23	0.71	1.32e-41	Cognitive function;
CESC	cis	rs7617773	0.780	rs34946886	chr3:48338487	A/G	cg11946769	chr3:48343235	NME6	0.89	12.11	0.6	3.63e-27	Coronary artery disease;
CESC	cis	rs896854	0.738	rs2515226	chr8:95965743	G/A	cg13393036	chr8:95962371	TP53INP1	0.47	9.09	0.49	2.33e-17	Type 2 diabetes;
CESC	cis	rs72781680	1.000	rs111229211	chr2:24167417	T/G	cg08917208	chr2:24149416	ATAD2B	0.87	7.18	0.4	6.86e-12	Lymphocyte counts;
CESC	cis	rs6952808	0.792	rs13224989	chr7:1953766	C/G	cg22963979	chr7:1858916	MAD1L1	-0.37	-5.23	-0.31	3.51e-7	Bipolar disorder and schizophrenia;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg14320087	chr8:74005537	C8orf84	-0.45	-6.36	-0.36	8.9e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.55	-6.17	-0.35	2.48e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7512552	0.839	rs1625468	chr1:150321486	G/A	cg15654264	chr1:150340011	RPRD2	0.39	5.12	0.3	5.94e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs4268898	0.636	rs72787371	chr2:24570073	T/A	cg20701182	chr2:24300061	SF3B14	0.62	6.67	0.38	1.48e-10	Asthma;
CESC	cis	rs4523957	0.651	rs9908373	chr17:2086534	G/A	cg16513277	chr17:2031491	SMG6	-0.68	-9.37	-0.5	3.38e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs8072100	0.576	rs12948299	chr17:45403057	T/C	cg08085267	chr17:45401833	C17orf57	-0.66	-8.04	-0.44	2.97e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs6964587	1.000	rs13231820	chr7:91663529	A/G	cg17063962	chr7:91808500	NA	0.54	7.17	0.4	7.61e-12	Breast cancer;
CESC	cis	rs9611565	0.840	rs2234059	chr22:41777913	T/C	cg03806693	chr22:41940476	POLR3H	-1.12	-13.95	-0.65	1.55e-33	Vitiligo;
CESC	cis	rs801193	0.569	rs2659893	chr7:66199993	G/A	cg11764359	chr7:65958608	NA	0.73	10.55	0.54	5.73e-22	Aortic root size;
CESC	trans	rs208520	0.661	rs207099	chr6:66796373	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.01	-12.91	-0.62	6.39e-30	Exhaled nitric oxide output;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg20285559	chr1:6688542	THAP3	0.5	7.08	0.4	1.33e-11	Fibrinogen levels;
CESC	cis	rs796364	0.951	rs7565005	chr2:201013277	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.63	-6.25	-0.36	1.59e-9	Schizophrenia;
CESC	cis	rs6582630	0.615	rs10880642	chr12:38554152	A/G	cg26384229	chr12:38710491	ALG10B	-0.45	-6.1	-0.35	3.83e-9	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs2836950	0.565	rs8130320	chr21:40580258	C/T	cg17971929	chr21:40555470	PSMG1	-0.54	-7.02	-0.4	1.86e-11	Menarche (age at onset);
CESC	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg23034840	chr1:205782522	SLC41A1	0.68	8.32	0.46	4.7e-15	Menarche (age at onset);
CESC	cis	rs4713118	0.662	rs149901	chr6:27965503	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.55	-6.76	-0.38	8.6e-11	Parkinson's disease;
CESC	cis	rs4919087	0.961	rs11189120	chr10:99069493	G/T	cg25902810	chr10:99078978	FRAT1	0.72	10.73	0.55	1.48e-22	Monocyte count;
CESC	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg22907277	chr7:1156413	C7orf50	0.4	5.78	0.33	2.13e-8	Longevity;Endometriosis;
CESC	cis	rs801193	0.569	rs6951302	chr7:66132512	T/C	cg11764359	chr7:65958608	NA	-0.73	-10.44	-0.54	1.38e-21	Aortic root size;
CESC	cis	rs8044868	0.530	rs2288000	chr16:72058881	A/G	cg16558253	chr16:72132732	DHX38	-0.37	-5.67	-0.33	3.8e-8	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CESC	cis	rs17376456	1.000	rs13163610	chr5:93548877	A/C	cg25358565	chr5:93447407	FAM172A	1.13	11.09	0.56	1e-23	Diabetic retinopathy;
CESC	cis	rs1008375	0.966	rs4698638	chr4:17632988	G/C	cg16339924	chr4:17578868	LAP3	0.56	7.13	0.4	9.83e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs7267979	1.000	rs6083813	chr20:25337671	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.88	-18.13	-0.74	2.42e-48	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs4660306	0.961	rs1494813	chr1:45957290	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.61	-7.69	-0.43	2.86e-13	Homocysteine levels;
CESC	cis	rs4728302	0.869	rs10224575	chr7:133590875	G/A	cg10665199	chr7:133106180	EXOC4	0.39	5.39	0.31	1.55e-7	Intelligence;Intelligence (multi-trait analysis);
CESC	cis	rs4642101	0.640	rs12629398	chr3:12826799	A/G	cg24848339	chr3:12840334	CAND2	0.41	6.39	0.37	7.25e-10	QRS complex (12-leadsum);
CESC	cis	rs736801	0.780	rs12521868	chr5:131784393	A/C	cg21138405	chr5:131827807	IRF1	0.36	5.23	0.31	3.43e-7	Breast cancer;Mosquito bite size;
CESC	cis	rs80282103	0.867	rs17155821	chr10:1071701	A/G	cg08668510	chr10:1095578	IDI1	0.66	5.27	0.31	2.78e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs875971	1.000	rs2420820	chr7:66091907	T/C	cg18876405	chr7:65276391	NA	-0.5	-6.58	-0.37	2.56e-10	Aortic root size;
CESC	cis	rs12476592	0.571	rs2028883	chr2:63804531	G/A	cg17519650	chr2:63277830	OTX1	-0.48	-5.42	-0.32	1.34e-7	Childhood ear infection;
CESC	cis	rs881375	0.678	rs10760129	chr9:123700183	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.46	6.55	0.37	2.92e-10	Rheumatoid arthritis;
CESC	cis	rs9837602	1.000	rs793499	chr3:99565576	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.55	-7.64	-0.42	3.94e-13	Breast cancer;
CESC	cis	rs10489202	1.000	rs67600256	chr1:167972357	T/C	cg24449463	chr1:168025552	DCAF6	-0.46	-5.3	-0.31	2.41e-7	Schizophrenia;
CESC	cis	rs17376456	0.569	rs13186432	chr5:93336940	G/A	cg25358565	chr5:93447407	FAM172A	-0.45	-5.18	-0.3	4.43e-7	Diabetic retinopathy;
CESC	cis	rs7212590	0.748	rs73315252	chr17:57854855	A/G	cg20303301	chr17:57937339	TUBD1	-0.57	-5.36	-0.31	1.81e-7	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg17178900	chr1:205818956	PM20D1	0.79	11.83	0.59	3.39e-26	Menarche (age at onset);
CESC	cis	rs651907	0.514	rs12636047	chr3:101434449	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.45	5.88	0.34	1.22e-8	Colorectal cancer;
CESC	cis	rs7116495	0.609	rs7111379	chr11:71826319	C/T	cg10381502	chr11:71823885	C11orf51	1.06	6.8	0.39	6.99e-11	Severe influenza A (H1N1) infection;
CESC	cis	rs3733585	0.631	rs4697924	chr4:10124239	A/G	cg02734326	chr4:10020555	SLC2A9	-0.38	-5.06	-0.3	7.82e-7	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs7927771	0.524	rs10838763	chr11:47794802	C/T	cg18512352	chr11:47633146	NA	0.33	5.17	0.3	4.51e-7	Subjective well-being;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25017976	chr1:154947060	CKS1B;SHC1	0.61	6.55	0.37	2.91e-10	Gut microbiome composition (summer);
CESC	cis	rs7845219	0.544	rs9643350	chr8:95917276	C/A	cg09323728	chr8:95962352	TP53INP1	-0.32	-6.22	-0.36	1.91e-9	Type 2 diabetes;
CESC	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg21226059	chr5:178986404	RUFY1	-0.52	-7.93	-0.44	6.12e-14	Lung cancer;
CESC	trans	rs916888	0.821	rs199514	chr17:44856881	G/A	cg23590916	chr17:43697445	MGC57346	-0.64	-6.67	-0.38	1.45e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs9894429	0.646	rs7220310	chr17:79606056	C/A	cg18240062	chr17:79603768	NPLOC4	0.54	7.07	0.4	1.41e-11	Eye color traits;
CESC	cis	rs2262909	1.000	rs436039	chr19:22214873	T/C	cg11619707	chr19:22235551	ZNF257	-0.35	-5.7	-0.33	3.19e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg15990800	chr14:55738852	FBXO34	-0.47	-6.12	-0.35	3.31e-9	Height;
CESC	cis	rs9814567	1.000	rs62271515	chr3:134300507	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.4	-5.44	-0.32	1.21e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs9790314	1.000	rs975323	chr3:161021322	A/G	cg04691961	chr3:161091175	C3orf57	-0.44	-5.73	-0.33	2.74e-8	Morning vs. evening chronotype;
CESC	cis	rs7762018	0.891	rs73242950	chr6:170144737	C/T	cg13891659	chr6:170190454	C6orf122;C6orf208	0.67	6.66	0.38	1.61e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs2732480	0.500	rs11168464	chr12:48602115	C/T	cg04545296	chr12:48745243	ZNF641	0.4	6.74	0.38	9.66e-11	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs1729951	0.575	rs2163896	chr3:136691177	G/A	cg04103450	chr3:136751342	NA	0.4	5.31	0.31	2.32e-7	Neuroticism;
CESC	cis	rs10256972	0.933	rs35696159	chr7:1047194	A/G	cg00431813	chr7:1051703	C7orf50	-0.35	-5.48	-0.32	9.75e-8	Longevity;Endometriosis;
CESC	cis	rs6461049	0.800	rs3778977	chr7:2159746	C/T	cg21782813	chr7:2030301	MAD1L1	0.44	6.22	0.36	1.94e-9	Schizophrenia;
CESC	cis	rs9527	0.590	rs7067663	chr10:104883650	A/G	cg04362960	chr10:104952993	NT5C2	0.45	5.64	0.33	4.38e-8	Arsenic metabolism;
CESC	cis	rs7666738	0.830	rs4699601	chr4:99034429	G/A	cg03467027	chr4:99064603	C4orf37	0.48	6.05	0.35	4.87e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1799949	1.000	rs35668327	chr17:41273095	G/A	cg23758822	chr17:41437982	NA	1.02	15.64	0.69	1.61e-39	Menopause (age at onset);
CESC	cis	rs4665809	1.000	rs4665809	chr2:26251361	C/T	cg22920501	chr2:26401640	FAM59B	0.66	7.88	0.44	8.33e-14	Gut microbiome composition (summer);
CESC	cis	rs4481887	0.927	rs12044126	chr1:248481952	T/C	cg00666640	chr1:248458726	OR2T12	0.36	6.07	0.35	4.47e-9	Common traits (Other);
CESC	cis	rs75804782	0.641	rs72987328	chr2:239360097	C/T	cg18131467	chr2:239335373	ASB1	-0.71	-5.83	-0.34	1.6e-8	Morning vs. evening chronotype;Chronotype;
CESC	cis	rs853679	0.546	rs200996	chr6:27811828	G/A	cg17221315	chr6:27791827	HIST1H4J	0.62	5.33	0.31	2.13e-7	Depression;
CESC	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg26354017	chr1:205819088	PM20D1	0.97	17.12	0.72	9.23e-45	Menarche (age at onset);
CESC	cis	rs13102973	0.965	rs13126242	chr4:135860948	T/C	cg14419869	chr4:135874104	NA	0.34	5.37	0.31	1.72e-7	Subjective well-being;
CESC	cis	rs78456975	0.607	rs73909625	chr2:1541934	A/G	cg01028140	chr2:1542097	TPO	-0.61	-5.8	-0.34	1.88e-8	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs2404602	0.679	rs12900494	chr15:76912504	A/G	cg22467129	chr15:76604101	ETFA	-0.36	-5.31	-0.31	2.34e-7	Blood metabolite levels;
CESC	cis	rs7210086	0.768	rs4395115	chr17:70640382	G/C	cg04206342	chr17:70636940	NA	-0.28	-5.15	-0.3	5.13e-7	Ulcerative colitis;
CESC	cis	rs6028335	0.674	rs16987779	chr20:37671455	C/T	cg16355469	chr20:37678765	NA	0.52	5.15	0.3	5.19e-7	Alcohol and nicotine co-dependence;
CESC	cis	rs727505	1.000	rs1541416	chr7:124450345	T/C	cg23710748	chr7:124431027	NA	-0.37	-5.9	-0.34	1.12e-8	Lewy body disease;
CESC	cis	rs10504229	0.953	rs115634610	chr8:58190533	G/A	cg14926445	chr8:58193284	C8orf71	-0.5	-5.4	-0.31	1.49e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs4689388	0.750	rs10755148	chr4:6295064	A/G	cg14416269	chr4:6271139	WFS1	0.43	6.6	0.38	2.21e-10	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs265548	0.538	rs36688	chr19:17911212	A/C	cg21960279	chr19:17905606	B3GNT3	0.48	7.03	0.4	1.77e-11	Tumor biomarkers;
CESC	cis	rs514406	0.861	rs4926577	chr1:53226788	C/A	cg24675658	chr1:53192096	ZYG11B	0.53	6.78	0.38	7.96e-11	Monocyte count;
CESC	cis	rs12681288	0.723	rs12545453	chr8:970582	C/T	cg15309053	chr8:964076	NA	0.36	5.71	0.33	3.04e-8	Schizophrenia;
CESC	trans	rs6089829	0.962	rs1060490	chr20:61665871	A/G	cg23505145	chr19:12996616	KLF1	0.52	6.8	0.39	6.85e-11	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs9399135	1.000	rs9399135	chr6:135368314	G/A	cg24558204	chr6:135376177	HBS1L	0.5	6.8	0.39	6.76e-11	Red blood cell count;
CESC	cis	rs959260	1.000	rs2117563	chr17:73368985	A/G	cg20590849	chr17:73267439	MIF4GD	-0.55	-6.44	-0.37	5.48e-10	Systemic lupus erythematosus;
CESC	cis	rs72781680	0.716	rs17045975	chr2:24099611	A/T	cg08917208	chr2:24149416	ATAD2B	-0.55	-5.56	-0.32	6.61e-8	Lymphocyte counts;
CESC	cis	rs9457247	1.000	rs430477	chr6:167389851	T/C	cg23791538	chr6:167370224	RNASET2	-0.6	-8.65	-0.47	4.96e-16	Crohn's disease;
CESC	trans	rs9319321	0.550	rs7324598	chr13:27414170	C/T	cg14332112	chr6:47277683	TNFRSF21	-0.47	-6.03	-0.35	5.63e-9	Asthma (toluene diisocyanate-induced);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03170725	chr2:27498214	DNAJC5G	-0.71	-7.76	-0.43	1.81e-13	Gut microbiome composition (summer);
CESC	cis	rs4077515	0.935	rs3812565	chr9:139272502	T/C	cg14169450	chr9:139327907	INPP5E	0.43	6.31	0.36	1.16e-9	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs9733	0.596	rs72702504	chr1:150635374	G/C	cg18016565	chr1:150552671	MCL1	0.33	5.15	0.3	5.13e-7	Tonsillectomy;
CESC	cis	rs4481887	0.893	rs1339990	chr1:248509495	C/T	cg00666640	chr1:248458726	OR2T12	-0.33	-5.86	-0.34	1.35e-8	Common traits (Other);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg04095345	chr6:34857663	ANKS1A	0.43	6.21	0.36	2.03e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs2832191	0.632	rs1984011	chr21:30337831	T/A	cg08807101	chr21:30365312	RNF160	-0.91	-14.09	-0.65	5.03e-34	Dental caries;
CESC	cis	rs7412746	0.611	rs111842513	chr1:150712926	G/A	cg18016565	chr1:150552671	MCL1	0.34	5.23	0.31	3.46e-7	Melanoma;
CESC	cis	rs6541297	0.555	rs910502	chr1:230294185	A/T	cg20703242	chr1:230279135	GALNT2	0.65	7.07	0.4	1.41e-11	Coronary artery disease;
CESC	cis	rs7945705	0.967	rs7943377	chr11:8848700	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.37	5.64	0.33	4.4e-8	Hemoglobin concentration;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03108344	chr6:150326762	RAET1K	0.56	6.67	0.38	1.47e-10	Gut microbiome composition (summer);
CESC	cis	rs72772090	0.520	rs56325109	chr5:96112295	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.6	-5.05	-0.3	8.29e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs9549367	0.789	rs7317558	chr13:113893625	G/A	cg00898013	chr13:113819073	PROZ	-0.52	-7.42	-0.41	1.59e-12	Platelet distribution width;
CESC	cis	rs4713118	0.629	rs203888	chr6:28021589	C/T	cg19592336	chr6:28129416	ZNF389	0.5	6.68	0.38	1.36e-10	Parkinson's disease;
CESC	cis	rs4665809	0.838	rs7565843	chr2:26292912	G/C	cg27170947	chr2:26402098	FAM59B	-0.6	-7.23	-0.41	5.28e-12	Gut microbiome composition (summer);
CESC	cis	rs7131987	0.903	rs11050153	chr12:29405148	T/C	cg09582351	chr12:29534625	ERGIC2	-0.33	-5.42	-0.32	1.34e-7	QT interval;
CESC	cis	rs397969	0.570	rs2108981	chr17:19878666	G/A	cg12073167	chr17:19770448	ULK2	-0.49	-5.88	-0.34	1.25e-8	Platelet count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18075073	chr11:210610	RIC8A	-0.55	-6.16	-0.35	2.67e-9	Gut microbiome composition (summer);
CESC	cis	rs561341	0.831	rs11658469	chr17:30206426	T/C	cg00745463	chr17:30367425	LRRC37B	0.57	5.68	0.33	3.63e-8	Hip circumference adjusted for BMI;
CESC	cis	rs8180040	0.966	rs62260711	chr3:47564491	G/C	cg27129171	chr3:47204927	SETD2	-0.61	-8.52	-0.46	1.23e-15	Colorectal cancer;
CESC	cis	rs7246657	0.943	rs4969487	chr19:37831039	C/T	cg23950597	chr19:37808831	NA	-0.62	-6.37	-0.36	8.15e-10	Coronary artery calcification;
CESC	cis	rs1153858	0.943	rs67045941	chr15:45677011	A/G	cg21132104	chr15:45694354	SPATA5L1	0.86	11.62	0.58	1.67e-25	Homoarginine levels;
CESC	cis	rs1874326	0.545	rs6467769	chr7:138109790	G/A	cg18008034	chr7:138118925	NA	-0.41	-5.14	-0.3	5.34e-7	Quantitative traits;
CESC	cis	rs72634258	0.519	rs4908708	chr1:7938113	G/C	cg00042356	chr1:8021962	PARK7	0.52	5.61	0.33	5.2100000000000003e-08	Inflammatory bowel disease;
CESC	cis	rs514406	0.570	rs1332776	chr1:53189816	C/T	cg08859206	chr1:53392774	SCP2	-0.57	-8.08	-0.44	2.3e-14	Monocyte count;
CESC	cis	rs1018836	0.828	rs7014967	chr8:91557843	G/T	cg16814680	chr8:91681699	NA	-0.64	-9.15	-0.49	1.58e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs12477438	0.715	rs7586608	chr2:99558017	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.65	-8.83	-0.48	1.48e-16	Chronic sinus infection;
CESC	cis	rs4660261	0.526	rs803680	chr1:44364370	G/C	cg12908607	chr1:44402522	ARTN	-0.47	-6.93	-0.39	3.17e-11	Intelligence (multi-trait analysis);
CESC	cis	rs6088580	0.634	rs2184836	chr20:32963369	A/G	cg06115741	chr20:33292138	TP53INP2	-0.46	-5.96	-0.34	7.8e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs7772486	0.875	rs932522	chr6:146374026	A/G	cg23711669	chr6:146136114	FBXO30	-0.86	-12.77	-0.62	2.02e-29	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs12497850	0.897	rs6795025	chr3:49081247	T/C	cg03060546	chr3:49711283	APEH	0.5	5.99	0.35	6.84e-9	Parkinson's disease;
CESC	cis	rs4888262	0.545	rs12716768	chr16:74556486	A/G	cg01733217	chr16:74700730	RFWD3	-0.69	-8.56	-0.47	9.29e-16	Testicular germ cell tumor;
CESC	trans	rs916888	0.773	rs199534	chr17:44824213	T/G	cg23590916	chr17:43697445	MGC57346	0.64	6.5	0.37	4.05e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs644799	1.000	rs564675	chr11:95561873	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	14.27	0.66	1.19e-34	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs7264396	0.563	rs2425120	chr20:34324456	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.88	-10.7	-0.55	1.88e-22	Total cholesterol levels;
CESC	cis	rs9303401	0.573	rs35104446	chr17:57180234	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.93	11.67	0.58	1.16e-25	Cognitive test performance;
CESC	cis	rs72945132	0.882	rs60780459	chr11:70162468	A/G	cg14191688	chr11:70257035	CTTN	0.42	5.34	0.31	1.95e-7	Coronary artery disease;
CESC	cis	rs2573652	0.928	rs2581348	chr15:100514063	C/T	cg00587665	chr15:100533223	ADAMTS17	-0.33	-5.35	-0.31	1.91e-7	Height;
CESC	cis	rs13191362	1.000	rs7769686	chr6:163199467	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.58	5.66	0.33	3.9e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs75477785	0.590	rs72649923	chr1:210130204	T/A	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.91	6.32	0.36	1.12e-9	Cleft lip with or without cleft palate;
CESC	cis	rs17253792	0.915	rs77252471	chr14:56178075	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.73	5.13	0.3	5.7e-7	Putamen volume;
CESC	cis	rs7903847	0.596	rs10882934	chr10:99170995	T/G	cg20016023	chr10:99160130	RRP12	-0.3	-5.04	-0.3	8.7e-7	Granulocyte percentage of myeloid white cells;
CESC	cis	rs1707322	0.964	rs6697830	chr1:46290477	C/A	cg05343316	chr1:45956843	TESK2	0.41	5.05	0.3	8.05e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs17293817	0.617	rs55820900	chr10:1410128	A/G	cg04271617	chr10:1416546	ADARB2	0.34	5.13	0.3	5.71e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs9948	0.529	rs62156208	chr2:97383686	A/G	cg01990225	chr2:97406019	LMAN2L	-0.99	-7.31	-0.41	3.23e-12	Erectile dysfunction and prostate cancer treatment;
CESC	cis	rs1475911	1.000	rs12482477	chr21:43517233	T/A	cg03240473	chr21:43526662	UMODL1;C21orf128	-0.41	-5.16	-0.3	4.77e-7	IgG glycosylation;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg21962918	chr5:134094454	DDX46	-0.47	-6.55	-0.37	2.95e-10	Fibrinogen levels;
CESC	cis	rs11098499	0.954	rs59866101	chr4:120296591	T/G	cg24375607	chr4:120327624	NA	0.46	5.55	0.32	6.98e-8	Corneal astigmatism;
CESC	cis	rs3741151	0.686	rs11823913	chr11:73141627	C/G	cg17517138	chr11:73019481	ARHGEF17	0.62	5.33	0.31	2.15e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs9487051	0.872	rs9374079	chr6:109609619	A/G	cg01475377	chr6:109611718	NA	-0.51	-8.36	-0.46	3.66e-15	Reticulocyte fraction of red cells;
CESC	cis	rs1728785	1.000	rs11648314	chr16:68596775	A/G	cg02972257	chr16:68554789	NA	-0.7	-8.17	-0.45	1.25e-14	Ulcerative colitis;
CESC	cis	rs6460942	1.000	rs62448568	chr7:12407445	A/G	cg10578991	chr7:12443926	VWDE	-0.55	-5.84	-0.34	1.53e-8	Coronary artery disease;
CESC	cis	rs2243480	1.000	rs316329	chr7:65608416	A/C	cg13147721	chr7:65941812	NA	-0.97	-8.88	-0.48	1.05e-16	Diabetic kidney disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg25754926	chr6:7986689	MGC26597	0.43	6.06	0.35	4.74e-9	Fibrinogen levels;
CESC	trans	rs875971	1.000	rs778685	chr7:65836176	G/T	cg26939375	chr7:64535504	NA	0.47	6.06	0.35	4.66e-9	Aortic root size;
CESC	cis	rs67311347	1.000	rs9834052	chr3:40399060	G/A	cg09455208	chr3:40491958	NA	0.47	8.19	0.45	1.11e-14	Renal cell carcinoma;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21701354	chr7:129592850	UBE2H	0.55	6.65	0.38	1.65e-10	Gut microbiome composition (summer);
CESC	cis	rs644799	0.672	rs11021307	chr11:95501407	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.8	11.91	0.59	1.72e-26	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs7089973	0.549	rs34434610	chr10:116739745	A/G	cg23260525	chr10:116636907	FAM160B1	0.3	5.24	0.31	3.21e-7	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs6662572	0.737	rs72677550	chr1:46589276	G/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.47	5.06	0.3	7.81e-7	Blood protein levels;
CESC	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg26338869	chr17:61819248	STRADA	-0.7	-9.46	-0.5	1.75e-18	Prudent dietary pattern;
CESC	cis	rs7829975	0.774	rs1039915	chr8:8679614	T/C	cg15556689	chr8:8085844	FLJ10661	0.47	5.95	0.34	8.53e-9	Mood instability;
CESC	cis	rs7635838	0.892	rs4684773	chr3:11418508	C/T	cg00170343	chr3:11313890	ATG7	0.42	5.56	0.32	6.72e-8	HDL cholesterol;
CESC	cis	rs10463316	0.832	rs246486	chr5:150727880	C/T	cg03212797	chr5:150827313	SLC36A1	0.56	7.24	0.41	4.73e-12	Metabolite levels (Pyroglutamine);
CESC	cis	rs4566357	0.576	rs3769644	chr2:227917240	C/G	cg05526886	chr2:227700861	RHBDD1	-0.52	-6.83	-0.39	5.73e-11	Coronary artery disease;
CESC	cis	rs7772486	0.727	rs4896843	chr6:146063451	T/C	cg05347473	chr6:146136440	FBXO30	-0.53	-6.74	-0.38	9.76e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2066819	1.000	rs11575229	chr12:56750737	C/T	cg26714650	chr12:56694279	CS	-1.39	-9.05	-0.49	3.19e-17	Psoriasis vulgaris;
CESC	cis	rs10256972	0.527	rs2949170	chr7:1216438	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.42	-5.32	-0.31	2.21e-7	Longevity;Endometriosis;
CESC	cis	rs8031584	0.918	rs3817498	chr15:31268781	T/C	cg08704250	chr15:31115839	NA	-0.54	-6.81	-0.39	6.41e-11	Huntington's disease progression;
CESC	cis	rs929596	0.614	rs10929302	chr2:234665782	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.66	-8.28	-0.45	6.14e-15	Total bilirubin levels in HIV-1 infection;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg10089324	chr1:51984752	EPS15	0.54	7.36	0.41	2.37e-12	Systemic lupus erythematosus;
CESC	cis	rs1670533	0.932	rs13108207	chr4:1054218	C/T	cg04106633	chr4:1044584	NA	0.39	5.1	0.3	6.45e-7	Recombination rate (females);
CESC	cis	rs75477785	0.590	rs12566152	chr1:209986747	C/T	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.92	6.04	0.35	5.06e-9	Cleft lip with or without cleft palate;
CESC	trans	rs9467711	0.606	rs13203358	chr6:26590578	A/T	cg01620082	chr3:125678407	NA	-0.62	-6.04	-0.35	5.11e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs11683229	0.777	rs2018650	chr2:63272724	T/C	cg17519650	chr2:63277830	OTX1	-0.73	-5.76	-0.33	2.36e-8	Protein quantitative trait loci;
CESC	cis	rs11252926	0.550	rs10904148	chr10:454551	G/T	cg16386425	chr10:429943	DIP2C	-0.57	-7.25	-0.41	4.54e-12	Psychosis in Alzheimer's disease;
CESC	cis	rs5769765	0.908	rs2319464	chr22:50265777	A/G	cg02269571	chr22:50332266	NA	0.46	6.25	0.36	1.62e-9	Schizophrenia;
CESC	cis	rs1107366	1.000	rs1107366	chr3:125904165	A/G	cg08481491	chr3:125900108	ALDH1L1	-0.37	-5.33	-0.31	2.14e-7	Metabolite levels;
CESC	cis	rs270601	0.690	rs162907	chr5:131580152	A/G	cg09877947	chr5:131593287	PDLIM4	-0.41	-5.11	-0.3	6.2e-7	Acylcarnitine levels;
CESC	cis	rs2952156	0.920	rs2517957	chr17:37838716	G/A	cg07936489	chr17:37558343	FBXL20	-0.6	-7.77	-0.43	1.77e-13	Asthma;
CESC	cis	rs870825	0.616	rs4416519	chr4:185639502	T/C	cg04058563	chr4:185651563	MLF1IP	0.64	7.09	0.4	1.21e-11	Blood protein levels;
CESC	trans	rs7944735	0.578	rs7949985	chr11:48062449	C/T	cg15704280	chr7:45808275	SEPT13	0.68	6.05	0.35	4.89e-9	Intraocular pressure;
CESC	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg05025164	chr4:1340916	KIAA1530	-0.83	-11.34	-0.57	1.48e-24	Longevity;
CESC	cis	rs2635047	0.565	rs2571004	chr18:44710302	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.41	5.59	0.32	5.7e-8	Educational attainment;
CESC	cis	rs1499614	0.901	rs2178742	chr7:66197799	G/A	cg12463550	chr7:65579703	CRCP	0.73	5.73	0.33	2.78e-8	Gout;
CESC	cis	rs2361718	0.500	rs12451697	chr17:78100690	T/A	cg20811857	chr17:78079795	GAA	-0.42	-6.04	-0.35	5.31e-9	Yeast infection;
CESC	cis	rs1065852	0.526	rs2413663	chr22:42402399	T/A	cg22189786	chr22:42395067	WBP2NL	0.43	5.34	0.31	2e-7	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
CESC	cis	rs875971	0.545	rs4718364	chr7:66001340	C/A	cg11764359	chr7:65958608	NA	0.82	10.05	0.53	2.44e-20	Aortic root size;
CESC	cis	rs6502050	0.799	rs4789673	chr17:80123218	T/C	cg23985595	chr17:80112537	CCDC57	-0.41	-6.57	-0.37	2.6200000000000003e-10	Life satisfaction;
CESC	cis	rs875971	0.522	rs709604	chr7:65497434	A/G	cg18876405	chr7:65276391	NA	-0.7	-9.74	-0.51	2.25e-19	Aortic root size;
CESC	cis	rs11722228	0.521	rs12501336	chr4:10137351	G/A	cg14348967	chr4:10160060	NA	-0.4	-5.3	-0.31	2.43e-7	Gout;Urate levels;Serum uric acid levels;
CESC	cis	rs2180341	0.751	rs9388553	chr6:127574044	A/G	cg27446573	chr6:127587934	RNF146	0.87	12.25	0.6	1.19e-27	Breast cancer;
CESC	cis	rs9443645	0.869	rs9443626	chr6:79629564	G/C	cg05283184	chr6:79620031	NA	-0.42	-6.43	-0.37	5.98e-10	Intelligence (multi-trait analysis);
CESC	cis	rs1178968	1.000	rs4273741	chr7:72773966	C/A	cg25889504	chr7:72793014	NA	0.47	5.03	0.3	8.91e-7	Triglyceride levels;
CESC	cis	rs7927771	0.832	rs4752994	chr11:47411065	A/T	cg25783544	chr11:47291846	MADD	0.45	5.16	0.3	4.88e-7	Subjective well-being;
CESC	trans	rs1814175	0.817	rs10769617	chr11:49810421	G/A	cg15704280	chr7:45808275	SEPT13	-1.03	-20.27	-0.78	8.26e-56	Height;
CESC	cis	rs7084402	0.967	rs1649082	chr10:60292434	A/C	cg07615347	chr10:60278583	BICC1	0.61	9.55	0.51	9.26e-19	Refractive error;
CESC	cis	rs10751667	0.643	rs12278229	chr11:946985	A/G	cg20946044	chr11:1010712	AP2A2	-0.39	-5.53	-0.32	7.73e-8	Alzheimer's disease (late onset);
CESC	trans	rs12960505	0.506	rs6508235	chr18:51053941	A/G	cg06077405	chr7:2313805	SNX8	-0.53	-7.04	-0.4	1.6e-11	Intelligence (multi-trait analysis);
CESC	cis	rs1153858	1.000	rs12593230	chr15:45646968	A/T	cg14582100	chr15:45693742	SPATA5L1	0.42	5.95	0.34	8.45e-9	Homoarginine levels;
CESC	cis	rs13108904	0.840	rs13149790	chr4:1262239	A/G	cg00684032	chr4:1343700	KIAA1530	0.41	5.83	0.34	1.58e-8	Obesity-related traits;
CESC	cis	rs7937682	0.632	rs4936800	chr11:111734097	T/A	cg09085632	chr11:111637200	PPP2R1B	0.91	11.76	0.59	5.82e-26	Primary sclerosing cholangitis;
CESC	cis	rs11122272	0.701	rs2790887	chr1:231523724	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.57	-7.82	-0.43	1.29e-13	Hemoglobin concentration;
CESC	cis	rs7605827	0.866	rs11689153	chr2:15533899	A/G	cg19274914	chr2:15703543	NA	0.35	6.39	0.37	7.22e-10	Educational attainment (years of education);
CESC	cis	rs9486719	1.000	rs67996804	chr6:96884387	C/T	cg18709589	chr6:96969512	KIAA0776	-0.53	-5.81	-0.34	1.75e-8	Migraine;Coronary artery disease;
CESC	cis	rs12325245	0.536	rs71389028	chr16:58663260	G/A	cg02549819	chr16:58548995	SETD6	0.94	6.09	0.35	4.04e-9	Schizophrenia;
CESC	cis	rs9359856	0.510	rs78649003	chr6:90454644	A/C	cg13799429	chr6:90582589	CASP8AP2	-0.68	-7.68	-0.43	3.1400000000000003e-13	Bipolar disorder;
CESC	cis	rs6964587	0.869	rs2013334	chr7:91549657	G/A	cg01689657	chr7:91764605	CYP51A1	-0.29	-5.17	-0.3	4.57e-7	Breast cancer;
CESC	cis	rs7618915	0.571	rs1961958	chr3:52585990	A/G	cg07507251	chr3:52567010	NT5DC2	0.43	7.4	0.41	1.83e-12	Bipolar disorder;
CESC	cis	rs7618915	0.524	rs35249778	chr3:52661640	G/C	cg07507251	chr3:52567010	NT5DC2	0.4	6.99	0.39	2.26e-11	Bipolar disorder;
CESC	cis	rs7945705	0.902	rs10743095	chr11:8936984	T/C	cg12365402	chr11:9010492	NRIP3	0.33	5.24	0.31	3.23e-7	Hemoglobin concentration;
CESC	cis	rs6952808	0.510	rs13227554	chr7:2048220	G/C	cg05863683	chr7:1912471	MAD1L1	-0.45	-6.67	-0.38	1.48e-10	Bipolar disorder and schizophrenia;
CESC	cis	rs926938	0.618	rs360675	chr1:115490918	T/C	cg12756093	chr1:115239321	AMPD1	0.5	7.16	0.4	7.75e-12	Autism;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13155599	chr4:120221765	C4orf3	0.63	6.85	0.39	5.25e-11	Gut microbiome composition (summer);
CESC	cis	rs853679	0.513	rs13437444	chr6:28070998	C/T	cg12963246	chr6:28129442	ZNF389	0.48	5.23	0.31	3.49e-7	Depression;
CESC	cis	rs6580649	0.657	rs57863747	chr12:48470425	G/T	cg24011408	chr12:48396354	COL2A1	-0.4	-5.04	-0.3	8.67e-7	Lung cancer;
CESC	cis	rs7618915	0.508	rs13065851	chr3:52644836	T/A	cg18404041	chr3:52824283	ITIH1	-0.4	-6.63	-0.38	1.85e-10	Bipolar disorder;
CESC	cis	rs6089829	0.962	rs9679865	chr20:61666132	C/G	cg08564027	chr20:61660810	NA	0.9	15.37	0.69	1.54e-38	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs2353275	0.677	rs2353813	chr10:88276181	T/C	cg07322936	chr10:88137208	NA	0.95	5.86	0.34	1.4e-8	Asthma (childhood onset);Asthma;
CESC	cis	rs4253772	0.938	rs75977757	chr22:46641525	G/T	cg18190219	chr22:46762943	CELSR1	-0.62	-5.89	-0.34	1.19e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs1153858	1.000	rs4775907	chr15:45638647	G/A	cg21132104	chr15:45694354	SPATA5L1	0.82	11.02	0.56	1.72e-23	Homoarginine levels;
CESC	cis	rs1570884	0.516	rs9526580	chr13:50164023	C/G	cg08779649	chr13:50194554	NA	-0.35	-6.1	-0.35	3.66e-9	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
CESC	cis	rs6963495	0.719	rs73190174	chr7:105161216	T/G	cg19920283	chr7:105172520	RINT1	0.69	6.56	0.37	2.85e-10	Bipolar disorder (body mass index interaction);
CESC	cis	rs798554	0.679	rs1636254	chr7:2885724	T/C	cg18446336	chr7:2847575	GNA12	-0.35	-5.56	-0.32	6.7e-8	Height;
CESC	cis	rs5744897	0.708	rs34504371	chr12:133279469	G/A	cg17341477	chr12:133246679	POLE	0.57	5.2	0.3	3.93e-7	Urate levels in overweight individuals;
CESC	cis	rs6662572	0.737	rs10890357	chr1:46318054	T/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.44	-5.04	-0.3	8.65e-7	Blood protein levels;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg07835289	chr1:236030215	LYST	0.49	6.31	0.36	1.2e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs7829975	0.593	rs2921051	chr8:8320104	C/A	cg06636001	chr8:8085503	FLJ10661	0.51	6.75	0.38	9.33e-11	Mood instability;
CESC	cis	rs6061231	0.561	rs67072353	chr20:60940702	G/A	cg22633769	chr20:60982531	CABLES2	0.59	5.14	0.3	5.4e-7	Colorectal cancer;
CESC	cis	rs2273669	0.667	rs11153150	chr6:109316652	C/G	cg05315195	chr6:109294784	ARMC2	-0.66	-6.28	-0.36	1.36e-9	Prostate cancer;
CESC	cis	rs7100689	0.784	rs7089058	chr10:82071263	T/C	cg09936400	chr10:82049201	MAT1A	0.36	5.23	0.31	3.51e-7	Post bronchodilator FEV1;
CESC	cis	rs9462846	0.959	rs6937172	chr6:42884375	A/T	cg05552183	chr6:42928497	GNMT	0.46	5.25	0.31	3.08e-7	Blood protein levels;
CESC	cis	rs9796	0.689	rs9888718	chr15:41446254	T/G	cg09898695	chr15:41135793	SPINT1	-0.22	-5.05	-0.3	8.12e-7	Menopause (age at onset);
CESC	cis	rs4332037	0.707	rs62435132	chr7:1891315	C/T	cg13880726	chr7:1868755	MAD1L1	-0.48	-5.08	-0.3	7.23e-7	Bipolar disorder;
CESC	cis	rs597539	0.652	rs557625	chr11:68634722	G/A	cg21963583	chr11:68658836	MRPL21	0.4	5.52	0.32	8.06e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs7949030	0.688	rs2849031	chr11:62365665	G/A	cg11742103	chr11:62369870	EML3;MTA2	-0.62	-9.32	-0.5	4.88e-18	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs72848980	0.512	rs3781362	chr10:105375601	T/C	cg00126946	chr10:105363258	SH3PXD2A	0.61	8.61	0.47	6.83e-16	White matter hyperintensity burden;
CESC	cis	rs6964587	0.621	rs39744	chr7:92043016	A/G	cg17063962	chr7:91808500	NA	0.51	7.42	0.41	1.55e-12	Breast cancer;
CESC	cis	rs2000999	0.514	rs17604676	chr16:72221984	C/T	cg04254540	chr16:71951199	KIAA0174	-0.58	-5.09	-0.3	6.93e-7	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
CESC	cis	rs1045714	0.895	rs2293405	chr7:2644607	G/T	cg20813462	chr7:2646259	IQCE	0.63	5.57	0.32	6.1e-8	Urate levels in lean individuals;
CESC	cis	rs2075371	0.863	rs12707139	chr7:133954153	A/G	cg11752832	chr7:134001865	SLC35B4	0.53	6.79	0.38	7.51e-11	Mean platelet volume;
CESC	cis	rs4665809	1.000	rs12471809	chr2:26307140	A/G	cg04944784	chr2:26401820	FAM59B	-0.67	-7.64	-0.42	3.95e-13	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23296058	chr5:86708877	CCNH	0.59	6.56	0.37	2.74e-10	Gut microbiome composition (summer);
CESC	cis	rs11997175	0.583	rs67830367	chr8:33833788	G/C	ch.8.33884649F	chr8:33765107	NA	0.48	6.07	0.35	4.49e-9	Body mass index;
CESC	cis	rs60843830	1.000	rs17714252	chr2:285471	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.78	10.2	0.53	8.1899999999999992e-21	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs910316	1.000	rs910316	chr14:75626042	A/C	cg08847533	chr14:75593920	NEK9	1.0	18.49	0.75	1.41e-49	Height;
CESC	cis	rs734999	0.545	rs28568531	chr1:2555640	T/A	cg20673091	chr1:2541236	MMEL1	0.47	7.67	0.43	3.2e-13	Ulcerative colitis;
CESC	cis	rs80130819	0.515	rs7315258	chr12:48572670	T/C	cg05342945	chr12:48394962	COL2A1	-0.54	-5.87	-0.34	1.3e-8	Prostate cancer;
CESC	cis	rs7666738	0.611	rs34982650	chr4:98819530	T/A	cg05340658	chr4:99064831	C4orf37	0.73	10.48	0.54	1.02e-21	Colonoscopy-negative controls vs population controls;
CESC	cis	rs35110281	0.748	rs2838322	chr21:44998615	G/C	cg01579765	chr21:45077557	HSF2BP	-0.54	-9.03	-0.49	3.57e-17	Mean corpuscular volume;
CESC	cis	rs9614461	0.702	rs16993867	chr22:45733199	A/G	cg01808030	chr22:45809952	RIBC2;SMC1B	0.67	7.8	0.43	1.43e-13	Tonsillectomy;
CESC	cis	rs853679	0.550	rs1233707	chr6:28172953	G/A	cg21251018	chr6:28226885	NKAPL	0.34	5.12	0.3	5.83e-7	Depression;
CESC	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg23131131	chr22:24373011	LOC391322	0.68	9.67	0.51	3.75e-19	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs2832191	0.740	rs2012645	chr21:30445961	G/A	cg08807101	chr21:30365312	RNF160	0.93	14.2	0.66	2.05e-34	Dental caries;
CESC	cis	rs1003719	0.667	rs2835606	chr21:38490851	G/C	cg10648535	chr21:38446584	PIGP;TTC3	0.53	6.62	0.38	1.99e-10	Eye color traits;
CESC	cis	rs2997447	0.706	rs17184898	chr1:26447870	A/T	cg24596570	chr1:26146463	FAM54B;LOC646471	0.59	5.17	0.3	4.68e-7	QRS complex (12-leadsum);
CESC	trans	rs3780486	0.522	rs7029897	chr9:33124042	T/C	cg04842962	chr6:43655489	MRPS18A	0.71	11.02	0.56	1.71e-23	IgG glycosylation;
CESC	cis	rs4689388	0.610	rs4328980	chr4:6281756	A/G	cg14416269	chr4:6271139	WFS1	0.43	6.1	0.35	3.66e-9	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs2204008	0.605	rs4608149	chr12:38132057	G/C	cg26384229	chr12:38710491	ALG10B	0.74	10.7	0.55	1.96e-22	Bladder cancer;
CESC	cis	rs8064299	0.967	rs7420	chr17:72765215	A/G	cg25054828	chr17:72772726	NAT9;TMEM104	-0.6	-8.62	-0.47	6.11e-16	Monocyte count;
CESC	cis	rs28647808	0.881	rs71483207	chr9:136258698	A/G	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.86	5.78	0.33	2.09e-8	Blood protein levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17767659	chr6:41888922	MED20;BYSL	0.57	7.12	0.4	1e-11	Gut microbiome composition (summer);
CESC	cis	rs2404602	0.684	rs3910756	chr15:76945369	C/T	cg00316803	chr15:76480434	C15orf27	0.4	5.67	0.33	3.76e-8	Blood metabolite levels;
CESC	cis	rs7208859	0.623	rs9897728	chr17:29108804	A/G	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.91e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs12477438	0.520	rs720229	chr2:99704273	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.79	12.88	0.62	8.35e-30	Chronic sinus infection;
CESC	cis	rs2991971	0.782	rs10789463	chr1:45927848	C/A	cg05343316	chr1:45956843	TESK2	0.58	8.41	0.46	2.59e-15	High light scatter reticulocyte count;
CESC	cis	rs10949834	0.878	rs2237501	chr7:73504359	A/G	cg07137043	chr7:73588983	EIF4H	-0.65	-5.65	-0.33	4.1e-8	Verbal memory performance (residualized delayed recall change);
CESC	trans	rs9929218	1.000	rs2113201	chr16:68815000	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.64	-8.5	-0.46	1.38e-15	Colorectal cancer;
CESC	cis	rs2072499	0.966	rs2253677	chr1:156171296	C/G	cg06970220	chr1:156163860	SLC25A44	-0.42	-5.65	-0.33	4.15e-8	Testicular germ cell tumor;
CESC	cis	rs7666738	0.822	rs28512427	chr4:98919029	G/A	cg17366294	chr4:99064904	C4orf37	0.57	7.78	0.43	1.6e-13	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11650494	0.908	rs118099826	chr17:47447836	G/T	cg08112188	chr17:47440006	ZNF652	1.16	7.85	0.43	1.03e-13	Prostate cancer;
CESC	cis	rs1552244	1.000	rs56270432	chr3:10087517	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-10.71	-0.55	1.84e-22	Alzheimer's disease;
CESC	cis	rs863345	0.967	rs10908679	chr1:158506275	T/G	cg12129480	chr1:158549410	OR10X1	-0.31	-6.28	-0.36	1.4e-9	Pneumococcal bacteremia;
CESC	cis	rs1448094	0.512	rs7953318	chr12:86245929	G/A	cg19622623	chr12:86230825	RASSF9	-0.46	-5.89	-0.34	1.14e-8	Major depressive disorder;
CESC	cis	rs4713118	0.516	rs6931858	chr6:28078411	A/T	cg12963246	chr6:28129442	ZNF389	0.49	6.17	0.35	2.57e-9	Parkinson's disease;
CESC	cis	rs34779708	0.966	rs4934539	chr10:35472199	A/G	cg04310649	chr10:35416472	CREM	-0.54	-6.78	-0.38	7.74e-11	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs611744	0.538	rs59930666	chr8:109262296	T/C	cg21045802	chr8:109455806	TTC35	0.56	7.02	0.4	1.89e-11	Dupuytren's disease;
CESC	cis	rs12681366	0.537	rs3019284	chr8:95473076	A/C	cg13257157	chr8:95487014	RAD54B	0.45	5.44	0.32	1.23e-7	Nonsyndromic cleft lip with cleft palate;
CESC	cis	rs7903847	0.642	rs11812223	chr10:99158455	T/C	cg20016023	chr10:99160130	RRP12	-0.3	-5.17	-0.3	4.61e-7	Granulocyte percentage of myeloid white cells;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg03066081	chr17:77784036	NA	-0.42	-6.09	-0.35	4e-9	Gambling;
CESC	cis	rs919433	0.927	rs7592748	chr2:198170688	G/A	cg03934865	chr2:198174659	NA	-0.42	-5.55	-0.32	6.94e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs425277	0.606	rs377283	chr1:2075570	T/C	cg12718519	chr1:2058417	PRKCZ	0.25	5.06	0.3	8.01e-7	Height;
CESC	cis	rs7772486	0.686	rs2092263	chr6:146029687	G/A	cg23711669	chr6:146136114	FBXO30	-0.87	-12.9	-0.62	7e-30	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs10924970	0.649	rs4659493	chr1:235482272	T/C	cg26050004	chr1:235667680	B3GALNT2	0.44	5.11	0.3	6.16e-7	Asthma;
CESC	trans	rs61931739	0.500	rs34703942	chr12:34583776	T/C	cg26384229	chr12:38710491	ALG10B	-0.53	-7.43	-0.42	1.46e-12	Morning vs. evening chronotype;
CESC	cis	rs9733	0.596	rs17606613	chr1:150683015	C/T	cg04414720	chr1:150670196	GOLPH3L	0.62	8.86	0.48	1.21e-16	Tonsillectomy;
CESC	cis	rs9911578	1.000	rs2079703	chr17:56603978	G/A	cg05425664	chr17:57184151	TRIM37	0.5	7.06	0.4	1.5e-11	Intelligence (multi-trait analysis);
CESC	cis	rs9486719	0.790	rs2499790	chr6:96845078	G/A	cg18709589	chr6:96969512	KIAA0776	0.55	5.64	0.33	4.26e-8	Migraine;Coronary artery disease;
CESC	cis	rs17253792	0.822	rs79538158	chr14:56051365	G/T	cg01858014	chr14:56050164	KTN1	-0.97	-7.15	-0.4	8.64e-12	Putamen volume;
CESC	cis	rs7647973	0.580	rs4955432	chr3:49266772	C/T	cg02487422	chr3:49467188	NICN1	0.4	5.49	0.32	9.35e-8	Menarche (age at onset);
CESC	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.58	7.49	0.42	1.01e-12	Prudent dietary pattern;
CESC	cis	rs5498	0.809	rs1056538	chr19:10402938	G/A	cg21994045	chr19:10403936	ICAM5	0.45	6.36	0.36	8.75e-10	Lymphocyte counts;Soluble ICAM-1;Blood protein levels;
CESC	cis	rs155076	0.711	rs4770131	chr13:21897468	A/G	cg23743428	chr13:21893420	NA	-0.43	-5.17	-0.3	4.64e-7	White matter hyperintensity burden;
CESC	cis	rs28386778	0.700	rs12449555	chr17:62003982	T/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.66	-8.79	-0.48	1.96e-16	Prudent dietary pattern;
CESC	cis	rs6495122	0.662	rs12898997	chr15:75090349	C/T	cg14664628	chr15:75095509	CSK	-0.72	-9.91	-0.52	6.94e-20	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
CESC	cis	rs10504229	0.683	rs11775506	chr8:58133639	G/T	cg21724239	chr8:58056113	NA	0.57	5.87	0.34	1.3e-8	Developmental language disorder (linguistic errors);
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg06506598	chr5:79783889	FAM151B	0.47	6.34	0.36	1.01e-9	Thyroid stimulating hormone;
CESC	cis	rs7772486	0.764	rs2265468	chr6:146218346	A/C	cg23711669	chr6:146136114	FBXO30	0.94	13.79	0.65	5.83e-33	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25697769	chr22:39097335	JOSD1	0.52	6.05	0.35	5.03e-9	Gut microbiome composition (summer);
CESC	cis	rs116095464	0.558	rs2162870	chr5:228129	G/A	cg20965017	chr5:231967	SDHA	-0.45	-5.08	-0.3	7.29e-7	Breast cancer;
CESC	cis	rs780096	0.506	rs1647265	chr2:27692261	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.3	-5.57	-0.32	6.2e-8	Total body bone mineral density;
CESC	cis	rs11809207	0.523	rs2783626	chr1:26501044	C/T	cg00147160	chr1:26503991	CNKSR1	-0.28	-5.36	-0.31	1.81e-7	Height;
CESC	cis	rs12995491	0.569	rs6724281	chr2:88529531	T/G	cg07952391	chr2:88470173	THNSL2	-0.73	-10.83	-0.55	7.24e-23	Response to metformin (IC50);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15522353	chr1:39547558	MACF1	0.56	6.12	0.35	3.41e-9	Gut microbiome composition (summer);
CESC	cis	rs965469	0.842	rs6051776	chr20:3332062	T/C	cg25506879	chr20:3388711	C20orf194	-0.51	-5.45	-0.32	1.18e-7	IFN-related cytopenia;
CESC	cis	rs6570726	0.764	rs366673	chr6:145814628	T/A	cg23711669	chr6:146136114	FBXO30	1.01	15.91	0.7	1.88e-40	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs863345	0.564	rs10908662	chr1:158489200	C/A	cg12129480	chr1:158549410	OR10X1	-0.34	-6.85	-0.39	5.17e-11	Pneumococcal bacteremia;
CESC	cis	rs4975709	0.569	rs2077269	chr5:1863506	C/T	cg11168104	chr5:1857477	NA	-0.39	-5.8	-0.34	1.85e-8	Cardiovascular disease risk factors;
CESC	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	10.3	0.53	3.96e-21	Prudent dietary pattern;
CESC	cis	rs4629180	0.630	rs10188189	chr2:102127926	A/G	cg01388757	chr2:102091195	RFX8	-0.32	-5.26	-0.31	3.02e-7	Chronic rhinosinusitis with nasal polyps;
CESC	cis	rs798554	0.616	rs1636252	chr7:2884993	A/C	cg13628971	chr7:2884303	GNA12	0.47	6.27	0.36	1.46e-9	Height;
CESC	cis	rs6089829	0.962	rs6011548	chr20:61666063	C/T	cg16240275	chr20:61666158	NCRNA00029	0.5	8.96	0.48	6.1e-17	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs10823500	0.777	rs10762348	chr10:71952322	C/A	cg04118878	chr10:71993077	PPA1	0.46	5.47	0.32	1.02e-7	Blood protein levels;
CESC	cis	rs2463822	0.925	rs2513075	chr11:62102408	C/T	cg06239285	chr11:62104954	ASRGL1	0.89	8.97	0.48	5.69e-17	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs2836974	0.897	rs34599551	chr21:40594898	C/A	cg17971929	chr21:40555470	PSMG1	1.07	16.63	0.71	4.99e-43	Cognitive function;
CESC	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg02475777	chr4:1388615	CRIPAK	0.73	9.3	0.5	5.53e-18	Longevity;
CESC	cis	rs7666738	0.753	rs10033138	chr4:98981922	A/C	cg05340658	chr4:99064831	C4orf37	0.8	12.42	0.61	3.31e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs853679	0.517	rs9380056	chr6:28104476	C/T	cg12963246	chr6:28129442	ZNF389	0.57	7.78	0.43	1.65e-13	Depression;
CESC	cis	rs561341	0.830	rs2301765	chr17:30202056	T/A	cg00745463	chr17:30367425	LRRC37B	0.58	5.72	0.33	2.86e-8	Hip circumference adjusted for BMI;
CESC	cis	rs2519796	0.564	rs2519111	chr9:136809118	C/G	cg13751417	chr9:136814406	VAV2	-0.43	-5.55	-0.32	6.8e-8	Hematocrit;Hemoglobin concentration;
CESC	cis	rs9486719	1.000	rs12197411	chr6:97039621	G/A	cg18709589	chr6:96969512	KIAA0776	-0.5	-5.42	-0.32	1.31e-7	Migraine;Coronary artery disease;
CESC	cis	rs7208859	0.673	rs2470251	chr17:29095061	T/C	cg19761014	chr17:28927070	LRRC37B2	0.68	6.7	0.38	1.26e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs7666738	0.962	rs2865991	chr4:99067369	C/A	cg17366294	chr4:99064904	C4orf37	0.54	7.1	0.4	1.11e-11	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3105593	1.000	rs2630	chr15:50849399	T/C	cg08437265	chr15:50716283	USP8	0.4	5.14	0.3	5.28e-7	QT interval;
CESC	cis	rs2836974	0.932	rs73221193	chr21:40554693	C/T	cg27266027	chr21:40555129	PSMG1	0.42	5.07	0.3	7.6e-7	Cognitive function;
CESC	cis	rs7666738	0.830	rs6834014	chr4:98951431	G/A	cg05340658	chr4:99064831	C4orf37	0.8	12.48	0.61	2e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6580649	0.941	rs757556	chr12:48502493	C/T	cg05342945	chr12:48394962	COL2A1	0.55	6.32	0.36	1.13e-9	Lung cancer;
CESC	cis	rs365132	0.875	rs2940521	chr5:176339209	A/C	cg16309518	chr5:176445507	NA	-0.37	-5.37	-0.31	1.71e-7	Menarche and menopause (age at onset);Menopause (age at onset);
CESC	cis	rs7274811	0.681	rs293733	chr20:31975976	C/T	cg21523528	chr20:32077966	CBFA2T2	-0.46	-5.44	-0.32	1.23e-7	Height;
CESC	cis	rs10791111	1	rs10791111	chr11:130856099	T/G	cg12179176	chr11:130786555	SNX19	0.7	10.99	0.56	2.12e-23	Autism spectrum disorder or schizophrenia;
CESC	cis	rs79057730	0.599	rs4720893	chr7:804434	G/A	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.87	7.42	0.41	1.64e-12	Initial pursuit acceleration;
CESC	cis	rs9611565	0.722	rs202635	chr22:41809637	C/T	cg06634786	chr22:41940651	POLR3H	0.71	7.47	0.42	1.16e-12	Vitiligo;
CESC	cis	rs60871478	0.853	rs62432864	chr7:808405	T/G	cg27478167	chr7:817139	HEATR2	-0.5	-5.6	-0.33	5.36e-8	Cerebrospinal P-tau181p levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26551211	chr6:170599713	DLL1	0.54	6.09	0.35	4.01e-9	Gut microbiome composition (summer);
CESC	cis	rs7084402	0.967	rs1658479	chr10:60289398	C/A	cg07615347	chr10:60278583	BICC1	0.61	9.68	0.51	3.68e-19	Refractive error;
CESC	cis	rs11645898	0.935	rs4788611	chr16:72175256	A/G	cg14768367	chr16:72042858	DHODH	-0.76	-6.49	-0.37	4.28e-10	Blood protein levels;
CESC	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg23131131	chr22:24373011	LOC391322	-0.56	-7.41	-0.41	1.64e-12	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs4561483	0.673	rs28279	chr16:11968555	A/C	cg08843971	chr16:11963173	GSPT1	0.53	7.75	0.43	1.95e-13	Testicular germ cell tumor;
CESC	cis	rs6542838	0.641	rs6741166	chr2:99534926	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.47	-5.84	-0.34	1.55e-8	Fear of minor pain;
CESC	cis	rs12824058	0.844	rs7956408	chr12:130807547	A/T	cg26677194	chr12:130822605	PIWIL1	-0.39	-5.39	-0.31	1.58e-7	Menopause (age at onset);
CESC	cis	rs9814567	1.000	rs9854299	chr3:134206728	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.44	-6.08	-0.35	4.26e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs546131	0.928	rs499183	chr11:34836678	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.48	5.98	0.34	7.09e-9	Lung disease severity in cystic fibrosis;
CESC	cis	rs2273669	0.667	rs12214121	chr6:109322554	A/G	cg05315195	chr6:109294784	ARMC2	0.67	6.23	0.36	1.84e-9	Prostate cancer;
CESC	cis	rs9322193	0.923	rs9767123	chr6:149981459	A/G	cg13206674	chr6:150067644	NUP43	0.43	6.17	0.35	2.52e-9	Lung cancer;
CESC	cis	rs597539	0.652	rs1249474	chr11:68654774	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.73	9.48	0.5	1.54e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs11785400	0.793	rs7007891	chr8:143749228	C/T	cg24634471	chr8:143751801	JRK	-0.45	-5.62	-0.33	4.94e-8	Schizophrenia;
CESC	trans	rs2099077	0.867	rs1864084	chr5:102791137	T/A	cg07434438	chr16:72961899	ZFHX3	0.5	6.78	0.38	7.88e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs2050392	0.858	rs306583	chr10:30710057	C/T	cg18806716	chr10:30721971	MAP3K8	0.41	6.07	0.35	4.53e-9	Inflammatory bowel disease;
CESC	cis	rs6448317	0.906	rs6448313	chr4:24905088	G/A	cg21108841	chr4:24914750	CCDC149	0.49	6.15	0.35	2.9e-9	Heschl's gyrus morphology;
CESC	cis	rs7429990	0.965	rs4858810	chr3:48043737	G/A	cg11946769	chr3:48343235	NME6	-0.49	-6.01	-0.35	6.15e-9	Educational attainment (years of education);
CESC	cis	rs7666738	0.830	rs3907021	chr4:99038668	C/T	cg03676636	chr4:99064102	C4orf37	0.33	5.12	0.3	5.93e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs875971	0.564	rs313804	chr7:65514622	A/G	cg26939375	chr7:64535504	NA	0.48	6.19	0.36	2.32e-9	Aortic root size;
CESC	cis	rs447735	0.587	rs7188458	chr16:89726484	A/G	cg03605463	chr16:89740564	NA	0.41	5.22	0.31	3.68e-7	Hemoglobin concentration;
CESC	cis	rs8017423	0.967	rs6575117	chr14:90715412	G/A	cg14092571	chr14:90743983	NA	-0.58	-8.73	-0.47	2.91e-16	Mortality in heart failure;
CESC	cis	rs9858542	0.953	rs7633271	chr3:49555963	T/C	cg03060546	chr3:49711283	APEH	-0.5	-5.79	-0.33	2.02e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs2712381	0.517	rs62273237	chr3:128310107	T/C	cg16766828	chr3:128327626	NA	-0.32	-5.47	-0.32	1.05e-7	Monocyte count;
CESC	cis	rs801193	0.660	rs1962050	chr7:66240008	C/T	cg10691866	chr7:65817282	TPST1	0.32	5.5	0.32	9.11e-8	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03520966	chr10:90751269	ACTA2;FAS	0.54	6.34	0.36	9.7e-10	Gut microbiome composition (summer);
CESC	cis	rs9733	0.744	rs11204725	chr1:150742700	T/C	cg18016565	chr1:150552671	MCL1	-0.36	-5.82	-0.34	1.71e-8	Tonsillectomy;
CESC	cis	rs9467711	0.659	rs35304979	chr6:26356347	C/A	cg12826209	chr6:26865740	GUSBL1	0.61	5.17	0.3	4.52e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs524281	1.000	rs524281	chr11:65886662	C/A	cg14036092	chr11:66035641	RAB1B	0.55	6.42	0.37	6.29e-10	Electroencephalogram traits;
CESC	cis	rs4233802	1.000	rs10209398	chr2:151151095	A/G	cg25300694	chr2:151184358	NA	-1.04	-8.8	-0.48	1.75e-16	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
CESC	cis	rs2760061	0.598	rs590657	chr1:228117581	A/C	cg02753203	chr1:228287806	NA	-0.5	-7.24	-0.41	4.85e-12	Diastolic blood pressure;
CESC	cis	rs4642101	0.855	rs9873475	chr3:12845422	A/G	cg05775895	chr3:12838266	CAND2	0.39	5.78	0.33	2.1e-8	QRS complex (12-leadsum);
CESC	cis	rs116095464	0.558	rs10055405	chr5:265666	C/T	cg12570787	chr5:219185	SDHA;CCDC127	0.52	5.41	0.32	1.42e-7	Breast cancer;
CESC	cis	rs734999	0.588	rs2985859	chr1:2532416	T/C	cg20673091	chr1:2541236	MMEL1	-0.45	-7.46	-0.42	1.2e-12	Ulcerative colitis;
CESC	cis	rs7618915	0.570	rs13068293	chr3:52672167	C/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	6.99	0.39	2.19e-11	Bipolar disorder;
CESC	cis	rs2274273	0.624	rs66551709	chr14:55791022	A/T	cg04306507	chr14:55594613	LGALS3	0.29	5.08	0.3	7.1e-7	Protein biomarker;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg19552494	chr11:60674271	PRPF19	0.53	6.83	0.39	5.71e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs6121246	0.567	rs6060247	chr20:30190720	C/G	cg13852791	chr20:30311386	BCL2L1	0.58	5.44	0.32	1.2e-7	Mean corpuscular hemoglobin;
CESC	cis	rs1707322	1.000	rs4660896	chr1:46372416	A/G	cg06784218	chr1:46089804	CCDC17	0.32	5.57	0.32	6.35e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7666738	0.830	rs7673385	chr4:99024922	T/G	cg17366294	chr4:99064904	C4orf37	0.61	8.67	0.47	4.35e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11122272	0.735	rs2572249	chr1:231514829	G/A	cg06096015	chr1:231504339	EGLN1	0.42	6.11	0.35	3.53e-9	Hemoglobin concentration;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg02471486	chr8:71016278	NA	0.45	6.28	0.36	1.36e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs644799	0.965	rs566877	chr11:95528045	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.53	6.41	0.37	6.77e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs7772486	0.875	rs13198450	chr6:146370524	C/A	cg05347473	chr6:146136440	FBXO30	0.5	6.5	0.37	3.88e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1799949	1.000	rs8070085	chr17:41341984	C/T	cg05368731	chr17:41323189	NBR1	-0.59	-7.79	-0.43	1.51e-13	Menopause (age at onset);
CESC	cis	rs17384381	1.000	rs12758237	chr1:85870783	G/A	cg16011679	chr1:85725395	C1orf52	0.8	8.1	0.45	1.98e-14	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2963155	0.518	rs853176	chr5:142636456	A/G	cg17617527	chr5:142782415	NR3C1	-0.84	-8.0	-0.44	3.82e-14	Breast cancer;
CESC	cis	rs896854	0.654	rs896847	chr8:95972551	G/A	cg09323728	chr8:95962352	TP53INP1	-0.39	-8.53	-0.46	1.11e-15	Type 2 diabetes;
CESC	cis	rs372883	0.600	rs407712	chr21:30722531	G/A	cg08807101	chr21:30365312	RNF160	-0.47	-5.44	-0.32	1.22e-7	Pancreatic cancer;
CESC	cis	rs9733	0.818	rs7520022	chr1:150659173	C/G	cg22823121	chr1:150693482	HORMAD1	-0.4	-6.24	-0.36	1.69e-9	Tonsillectomy;
CESC	cis	rs2276314	0.857	rs28375959	chr18:33601534	T/G	cg19628046	chr18:33552617	C18orf21	0.51	5.58	0.32	5.92e-8	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs875971	0.964	rs2161065	chr7:65932905	A/G	cg10691866	chr7:65817282	TPST1	-0.34	-5.67	-0.33	3.76e-8	Aortic root size;
CESC	cis	rs7216064	1.000	rs4790908	chr17:65852907	T/G	cg12091567	chr17:66097778	LOC651250	-0.8	-9.02	-0.48	3.83e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs11203032	0.831	rs10887926	chr10:90940358	G/A	cg16672925	chr10:90967113	CH25H	0.72	7.17	0.4	7.66e-12	Heart failure;
CESC	cis	rs35110281	0.667	rs7282122	chr21:45082365	G/A	cg01579765	chr21:45077557	HSF2BP	-0.52	-9.28	-0.5	6.25e-18	Mean corpuscular volume;
CESC	trans	rs208515	0.525	rs12191500	chr6:66668681	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.87	10.74	0.55	1.42e-22	Exhaled nitric oxide levels;
CESC	cis	rs7894051	1.000	rs11101721	chr10:135190358	C/G	cg24905316	chr10:135186343	ECHS1	0.64	5.59	0.32	5.6e-8	Lifespan;
CESC	cis	rs7959452	0.590	rs11177643	chr12:69785712	T/G	cg14784868	chr12:69753453	YEATS4	0.83	13.07	0.63	1.82e-30	Blood protein levels;
CESC	cis	rs11122272	0.735	rs2749706	chr1:231527170	C/A	cg06096015	chr1:231504339	EGLN1	0.43	6.15	0.35	2.79e-9	Hemoglobin concentration;
CESC	cis	rs9911578	0.835	rs9303398	chr17:56484257	T/C	cg12560992	chr17:57184187	TRIM37	-0.87	-14.46	-0.66	2.55e-35	Intelligence (multi-trait analysis);
CESC	trans	rs4596713	0.508	rs13289984	chr9:71775047	A/C	cg16512924	chr15:28394682	HERC2	0.48	6.14	0.35	2.95e-9	Headache;
CESC	cis	rs597539	0.690	rs552517	chr11:68625286	T/G	cg21963583	chr11:68658836	MRPL21	0.42	5.69	0.33	3.44e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs910316	1.000	rs11845639	chr14:75570293	C/T	cg08847533	chr14:75593920	NEK9	0.98	18.45	0.75	1.85e-49	Height;
CESC	cis	rs3540	0.533	rs2256110	chr15:90971036	T/C	cg22089800	chr15:90895588	ZNF774	0.64	8.78	0.47	2.09e-16	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	trans	rs379440	0.686	rs163622	chr5:111793954	C/T	cg14395298	chr13:23412250	NA	0.71	6.07	0.35	4.41e-9	vWF and FVIII levels;
CESC	cis	rs1385374	1.000	rs1385374	chr12:129300694	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.61	5.3	0.31	2.42e-7	Systemic lupus erythematosus;
CESC	cis	rs7552404	1.000	rs7518038	chr1:76154430	G/A	cg03433033	chr1:76189801	ACADM	0.68	8.14	0.45	1.54e-14	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs4862750	0.872	rs56389997	chr4:187894796	A/C	cg06074448	chr4:187884817	NA	-0.37	-5.43	-0.32	1.3e-7	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs3008870	0.583	rs2031495	chr1:67421714	G/T	cg08660285	chr1:67390436	MIER1;WDR78	0.99	11.11	0.56	8.58e-24	Lymphocyte percentage of white cells;
CESC	cis	rs7208859	0.623	rs11652533	chr17:29060601	A/C	cg13385521	chr17:29058706	SUZ12P	0.81	6.53	0.37	3.28e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs2842992	0.915	rs2758335	chr6:160111011	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.64	8.08	0.44	2.36e-14	Age-related macular degeneration (geographic atrophy);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg23024824	chr15:70349890	TLE3	0.49	6.32	0.36	1.11e-9	Fibrinogen levels;
CESC	trans	rs4716602	0.596	rs4997808	chr7:156158734	C/G	cg07175507	chr18:77160758	NFATC1	-0.46	-6.2	-0.36	2.14e-9	Anti-saccade response;
CESC	cis	rs1552244	0.935	rs7652190	chr3:10105150	G/A	cg08888203	chr3:10149979	C3orf24	0.51	6.39	0.37	7.29e-10	Alzheimer's disease;
CESC	cis	rs875971	1.000	rs6957199	chr7:65978519	T/C	cg11764359	chr7:65958608	NA	0.96	15.25	0.68	3.95e-38	Aortic root size;
CESC	cis	rs9488822	0.676	rs868943	chr6:116337503	G/A	cg15226275	chr6:116381976	FRK	0.24	6.2	0.36	2.17e-9	Cholesterol, total;LDL cholesterol;
CESC	cis	rs2841277	0.676	rs10438246	chr14:105410183	T/C	cg21017887	chr14:105400489	NA	0.42	6.83	0.39	5.93e-11	Rheumatoid arthritis;
CESC	cis	rs9322193	0.887	rs9767113	chr6:150039293	T/C	cg13206674	chr6:150067644	NUP43	0.41	5.8	0.34	1.9e-8	Lung cancer;
CESC	cis	rs9322193	0.923	rs57938011	chr6:149964105	T/A	cg02462569	chr6:150064036	NUP43	-0.35	-5.17	-0.3	4.52e-7	Lung cancer;
CESC	cis	rs1465370	0.682	rs2268382	chr7:130027037	A/C	cg04743876	chr7:130013617	NA	0.31	5.73	0.33	2.7e-8	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
CESC	cis	rs10504229	0.636	rs72649133	chr8:58054681	G/A	cg05313129	chr8:58192883	C8orf71	-0.52	-5.21	-0.3	3.78e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs4803468	0.905	rs284662	chr19:41932275	T/C	cg14132834	chr19:41945861	ATP5SL	-0.69	-8.39	-0.46	2.98e-15	Height;
CESC	cis	rs9399137	0.507	rs4594969	chr6:135285586	A/T	cg24558204	chr6:135376177	HBS1L	0.7	9.62	0.51	5.64e-19	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg05450629	chr15:90627448	IDH2	0.48	6.8	0.39	6.92e-11	Fibrinogen levels;
CESC	cis	rs736408	0.609	rs62255396	chr3:52782839	C/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.31	5.48	0.32	9.67e-8	Bipolar disorder;
CESC	cis	rs2019216	0.542	rs7405615	chr17:21935430	C/G	cg22648282	chr17:21454238	C17orf51	-0.39	-5.07	-0.3	7.48e-7	Pelvic organ prolapse;
CESC	cis	rs17001868	0.568	rs74424549	chr22:40736938	A/C	cg07138101	chr22:40742427	ADSL	0.57	5.38	0.31	1.66e-7	Mammographic density (dense area);
CESC	cis	rs9796	0.553	rs1869908	chr15:41257224	C/A	cg18705301	chr15:41695430	NDUFAF1	0.56	7.7	0.43	2.65e-13	Menopause (age at onset);
CESC	cis	rs8114671	0.967	rs1577924	chr20:33784288	C/G	cg06115741	chr20:33292138	TP53INP2	-0.41	-5.08	-0.3	7.22e-7	Height;
CESC	cis	rs6496667	0.557	rs2601203	chr15:90958129	T/G	cg10434728	chr15:90938212	IQGAP1	0.36	6.36	0.36	8.95e-10	Rheumatoid arthritis;
CESC	cis	rs7772486	0.686	rs702314	chr6:146003510	G/A	cg23711669	chr6:146136114	FBXO30	-0.86	-12.74	-0.62	2.59e-29	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs965469	1.000	rs6037590	chr20:3374085	G/A	cg25506879	chr20:3388711	C20orf194	-0.58	-6.11	-0.35	3.57e-9	IFN-related cytopenia;
CESC	trans	rs11098499	0.615	rs28850368	chr4:120554313	G/A	cg25214090	chr10:38739885	LOC399744	0.61	8.57	0.47	8.89e-16	Corneal astigmatism;
CESC	trans	rs2727020	0.729	rs1164685	chr11:49293660	G/A	cg15704280	chr7:45808275	SEPT13	0.87	14.55	0.67	1.22e-35	Coronary artery disease;
CESC	cis	rs7246657	0.943	rs10420722	chr19:37973774	C/G	cg23950597	chr19:37808831	NA	-0.65	-6.67	-0.38	1.5e-10	Coronary artery calcification;
CESC	cis	rs9291683	0.588	rs12506364	chr4:10023448	C/T	cg00071950	chr4:10020882	SLC2A9	0.89	17.27	0.73	2.76e-45	Bone mineral density;
CESC	cis	rs6964587	1.000	rs6952389	chr7:91657994	A/G	cg17063962	chr7:91808500	NA	0.57	7.88	0.44	8.76e-14	Breast cancer;
CESC	cis	rs7772486	0.875	rs2814873	chr6:146308932	T/C	cg23711669	chr6:146136114	FBXO30	0.9	13.1	0.63	1.45e-30	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4862750	0.872	rs4862747	chr4:187877236	A/T	cg22105103	chr4:187893119	NA	-0.49	-7.18	-0.4	7.25e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2276314	0.857	rs4799408	chr18:33588982	C/T	cg19628046	chr18:33552617	C18orf21	-0.49	-5.57	-0.32	6.31e-8	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs2066819	1.000	rs118130855	chr12:56677979	T/A	cg26734620	chr12:56694298	CS	1.07	6.58	0.37	2.56e-10	Psoriasis vulgaris;
CESC	cis	rs4808199	0.948	rs1859287	chr19:19422187	T/C	cg03709012	chr19:19516395	GATAD2A	1.04	12.12	0.6	3.38e-27	Nonalcoholic fatty liver disease;
CESC	cis	rs6541297	1.000	rs6665367	chr1:230279169	G/A	cg20703242	chr1:230279135	GALNT2	0.68	10.87	0.56	5.47e-23	Coronary artery disease;
CESC	cis	rs7520050	0.778	rs2991985	chr1:46080530	T/C	cg24296786	chr1:45957014	TESK2	0.47	6.02	0.35	5.84e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs4523957	0.620	rs9894215	chr17:2070698	G/A	cg16513277	chr17:2031491	SMG6	-0.79	-11.85	-0.59	2.89e-26	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs4819052	0.851	rs8133045	chr21:46658137	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.75	10.02	0.52	2.94e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14819942	chr15:35414228	NA	-0.56	-6.6	-0.38	2.17e-10	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.830	rs6829567	chr4:99047340	T/C	cg17366294	chr4:99064904	C4orf37	0.61	8.78	0.47	2.13e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6968419	0.755	rs4710	chr7:115897392	G/C	cg02561103	chr7:115862891	TES	-0.41	-5.33	-0.31	2.13e-7	Intraocular pressure;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17165990	chr19:19656778	CILP2	-0.6	-6.83	-0.39	5.75e-11	Gut microbiome composition (summer);
CESC	cis	rs5167	0.525	rs10402642	chr19:45453878	G/A	cg09555818	chr19:45449301	APOC2	0.41	6.54	0.37	3.08e-10	Blood protein levels;
CESC	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg07167872	chr1:205819463	PM20D1	0.75	12.35	0.6	5.62e-28	Menarche (age at onset);
CESC	cis	rs1465370	0.720	rs5011387	chr7:130017149	C/T	cg04743876	chr7:130013617	NA	0.31	5.86	0.34	1.38e-8	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
CESC	trans	rs877282	0.891	rs11253393	chr10:788824	G/T	cg22713356	chr15:30763199	NA	1.32	13.44	0.64	9.25e-32	Uric acid levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24844295	chr17:78821928	RPTOR	-0.6	-6.97	-0.39	2.5e-11	Gut microbiome composition (summer);
CESC	cis	rs7927771	0.832	rs10769262	chr11:47411581	G/A	cg25783544	chr11:47291846	MADD	0.45	5.16	0.3	4.88e-7	Subjective well-being;
CESC	cis	rs10883723	0.810	rs3740406	chr10:104272789	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.55	7.58	0.42	5.73e-13	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs1278769	0.786	rs7998551	chr13:113540649	G/T	cg00823993	chr13:113535758	ATP11A	0.58	7.56	0.42	6.46e-13	Interstitial lung disease;
CESC	cis	rs11630290	1.000	rs72750990	chr15:64005333	C/T	cg12036633	chr15:63758958	NA	-0.56	-5.24	-0.31	3.26e-7	Iris characteristics;
CESC	cis	rs3820928	0.874	rs2276593	chr2:227898434	A/G	cg05526886	chr2:227700861	RHBDD1	0.46	5.84	0.34	1.51e-8	Pulmonary function;
CESC	cis	rs708547	0.957	rs1623306	chr4:57773595	C/G	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.53	-5.28	-0.31	2.67e-7	Response to bleomycin (chromatid breaks);
CESC	cis	rs888194	0.677	rs7973253	chr12:109878115	A/G	cg19025524	chr12:109796872	NA	-0.41	-6.24	-0.36	1.73e-9	Neuroticism;
CESC	cis	rs763121	0.626	rs5757236	chr22:39073824	T/C	cg06544989	chr22:39130855	UNC84B	0.5	8.88	0.48	1.05e-16	Menopause (age at onset);
CESC	cis	rs6032067	0.641	rs17332243	chr20:43756071	T/C	cg10761708	chr20:43804764	PI3	0.5	5.25	0.31	3.12e-7	Blood protein levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13614812	chr17:21254058	NA	-0.45	-6.1	-0.35	3.81e-9	Gut microbiome composition (summer);
CESC	cis	rs6087771	0.781	rs6089067	chr20:30358894	G/C	cg13852791	chr20:30311386	BCL2L1	0.82	10.58	0.54	4.72e-22	Subcortical brain region volumes;Putamen volume;
CESC	cis	rs34779708	0.931	rs4934697	chr10:35287192	C/T	cg03585969	chr10:35415529	CREM	0.77	10.22	0.53	6.85e-21	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs9303280	0.806	rs11870965	chr17:38030205	T/A	cg19468946	chr17:37922297	IKZF3	-0.41	-5.45	-0.32	1.16e-7	Self-reported allergy;
CESC	cis	rs11809207	0.523	rs7087	chr1:26496651	T/C	cg00147160	chr1:26503991	CNKSR1	0.28	5.32	0.31	2.23e-7	Height;
CESC	cis	rs2549003	1.000	rs2548997	chr5:131835395	C/T	cg21138405	chr5:131827807	IRF1	-0.58	-9.83	-0.52	1.19e-19	Asthma (sex interaction);
CESC	cis	rs2795502	1.000	rs2473119	chr10:43339038	A/T	cg20628663	chr10:43360327	NA	-0.63	-7.47	-0.42	1.16e-12	Blood protein levels;
CESC	cis	rs6460942	0.597	rs17545416	chr7:12525944	A/T	cg06484146	chr7:12443880	VWDE	-0.71	-7.69	-0.43	2.88e-13	Coronary artery disease;
CESC	cis	rs6066835	1.000	rs6063311	chr20:47325315	C/T	cg18078177	chr20:47281410	PREX1	0.72	5.1	0.3	6.38e-7	Multiple myeloma;
CESC	cis	rs9929218	0.906	rs10852450	chr16:68749529	G/A	cg02972257	chr16:68554789	NA	0.57	6.59	0.38	2.32e-10	Colorectal cancer;
CESC	cis	rs7666738	0.830	rs6833822	chr4:98951354	G/A	cg03467027	chr4:99064603	C4orf37	0.45	5.67	0.33	3.69e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs875971	0.862	rs10276077	chr7:65728411	A/G	cg18876405	chr7:65276391	NA	-0.5	-6.98	-0.39	2.32e-11	Aortic root size;
CESC	cis	rs7267979	0.966	rs4813557	chr20:25292545	C/T	cg08601574	chr20:25228251	PYGB	-0.39	-5.58	-0.32	6.07e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7772486	0.776	rs2265467	chr6:146218339	T/A	cg23711669	chr6:146136114	FBXO30	0.77	10.91	0.56	3.81e-23	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4242434	0.819	rs6558173	chr8:22492103	A/C	cg03733263	chr8:22462867	KIAA1967	-0.88	-15.25	-0.68	4.12e-38	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11922607	chr18:21083993	C18orf8	-0.61	-7.09	-0.4	1.24e-11	Gut microbiome composition (summer);
CESC	cis	rs6062302	0.522	rs6090475	chr20:62245397	C/A	cg06363034	chr20:62225388	GMEB2	-0.5	-6.35	-0.36	9.49e-10	Glioblastoma;
CESC	cis	rs597539	0.652	rs674654	chr11:68698762	G/T	cg01988459	chr11:68622903	NA	-0.42	-5.9	-0.34	1.12e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs7665939	1.000	rs72727639	chr4:190107992	G/C	cg14840187	chr4:190284988	NA	-0.83	-6.89	-0.39	3.99e-11	Amyotrophic lateral sclerosis;
CESC	cis	rs72945132	0.882	rs113472486	chr11:70194945	C/G	cg14191688	chr11:70257035	CTTN	0.41	5.13	0.3	5.6e-7	Coronary artery disease;
CESC	cis	rs1218582	0.682	rs12144978	chr1:154850445	G/A	cg16680214	chr1:154839983	KCNN3	-0.5	-7.57	-0.42	6.23e-13	Prostate cancer;
CESC	cis	rs870825	0.587	rs28454955	chr4:185632701	C/T	cg04058563	chr4:185651563	MLF1IP	0.63	6.89	0.39	3.95e-11	Blood protein levels;
CESC	trans	rs61931739	0.500	rs7965679	chr12:34542494	T/C	cg26384229	chr12:38710491	ALG10B	0.53	7.41	0.41	1.74e-12	Morning vs. evening chronotype;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00021576	chr1:244211966	NA	0.61	7.06	0.4	1.44e-11	Gut microbiome composition (summer);
CESC	cis	rs875971	0.895	rs778700	chr7:65866450	C/T	cg10691866	chr7:65817282	TPST1	-0.34	-5.47	-0.32	1.06e-7	Aortic root size;
CESC	cis	rs6570726	0.935	rs409725	chr6:145840340	G/A	cg23711669	chr6:146136114	FBXO30	0.8	12.02	0.59	7.36e-27	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs11969893	0.649	rs12527901	chr6:101280435	G/A	cg12253828	chr6:101329408	ASCC3	0.93	8.18	0.45	1.16e-14	Economic and political preferences (immigration/crime);
CESC	cis	rs7267979	0.903	rs2500400	chr20:25354705	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.88	-17.58	-0.73	2.19e-46	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs17666538	0.535	rs1669613	chr8:617565	G/C	cg07234876	chr8:600039	NA	0.84	5.94	0.34	9.04e-9	IgG glycosylation;
CESC	cis	rs10504229	0.906	rs2270608	chr8:58194688	T/C	cg02725872	chr8:58115012	NA	-0.35	-5.17	-0.3	4.69e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs4253772	0.515	rs74766656	chr22:46662497	A/G	cg24881330	chr22:46731750	TRMU	0.8	6.6	0.38	2.24e-10	LDL cholesterol;Cholesterol, total;
CESC	cis	rs514406	0.505	rs431459	chr1:53183230	T/G	cg24675658	chr1:53192096	ZYG11B	-0.47	-5.92	-0.34	1.02e-8	Monocyte count;
CESC	cis	rs896854	0.654	rs13274945	chr8:95986626	C/T	cg16049864	chr8:95962084	TP53INP1	-0.66	-11.64	-0.58	1.46e-25	Type 2 diabetes;
CESC	cis	rs5758659	0.657	rs5758587	chr22:42517636	C/G	cg04733989	chr22:42467013	NAGA	-0.43	-6.05	-0.35	4.98e-9	Cognitive function;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26987697	chr4:47916498	NFXL1	0.54	6.24	0.36	1.68e-9	Gut microbiome composition (summer);
CESC	cis	rs911555	0.723	rs7144010	chr14:103869869	G/A	cg12935359	chr14:103987150	CKB	0.6	8.79	0.48	1.9e-16	Intelligence (multi-trait analysis);
CESC	cis	rs887829	0.507	rs10929301	chr2:234663649	C/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.48	-6.12	-0.35	3.35e-9	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CESC	cis	rs3749237	0.595	rs1050088	chr3:49570882	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.46	-6.18	-0.35	2.45e-9	Resting heart rate;
CESC	cis	rs7107174	1.000	rs2510054	chr11:77959659	A/G	cg02023728	chr11:77925099	USP35	-0.43	-6.0	-0.35	6.56e-9	Testicular germ cell tumor;
CESC	cis	rs66887589	0.967	rs13104219	chr4:120438174	G/T	cg09307838	chr4:120376055	NA	0.51	6.78	0.38	7.71e-11	Diastolic blood pressure;
CESC	cis	rs367615	0.552	rs2963023	chr5:108730070	C/T	cg17395555	chr5:108820864	NA	-0.45	-7.51	-0.42	8.87e-13	Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs7618915	0.501	rs3852066	chr3:52621839	C/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	5.83	0.34	1.59e-8	Bipolar disorder;
CESC	cis	rs5769765	0.720	rs138820	chr22:50164078	A/G	cg02269571	chr22:50332266	NA	-0.45	-5.62	-0.33	4.82e-8	Schizophrenia;
CESC	cis	rs7618915	0.501	rs6617	chr3:52740182	C/G	cg17372223	chr3:52568218	NT5DC2	0.43	6.56	0.37	2.76e-10	Bipolar disorder;
CESC	cis	rs9467773	0.620	rs9467810	chr6:26608261	A/C	cg11502198	chr6:26597334	ABT1	0.49	7.03	0.4	1.79e-11	Intelligence (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16484018	chr1:33502708	AK2	-0.65	-7.72	-0.43	2.33e-13	Gut microbiome composition (summer);
CESC	cis	rs11690935	0.877	rs13024846	chr2:172835803	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.92	-13.04	-0.63	2.35e-30	Schizophrenia;
CESC	cis	rs9443645	0.901	rs9341754	chr6:79584973	A/C	cg05283184	chr6:79620031	NA	-0.44	-6.64	-0.38	1.74e-10	Intelligence (multi-trait analysis);
CESC	cis	rs6499255	0.951	rs12595878	chr16:69628217	C/T	cg15192750	chr16:69999425	NA	0.51	5.98	0.34	7.11e-9	IgE levels;
CESC	cis	rs6540559	0.611	rs6540563	chr1:210019858	C/G	cg22029157	chr1:209979665	IRF6	0.7	7.88	0.44	8.64e-14	Cleft lip with or without cleft palate;
CESC	cis	rs17655565	0.543	rs1882122	chr12:52745616	G/A	cg00777198	chr12:52828273	KRT75	0.37	5.11	0.3	6.04e-7	Plasma amyloid beta peptide concentrations (ABx-42);
CESC	cis	rs875971	0.862	rs778684	chr7:65836403	A/T	cg11764359	chr7:65958608	NA	0.81	11.87	0.59	2.48e-26	Aortic root size;
CESC	cis	rs9733	0.519	rs1336899	chr1:150678910	T/C	cg09365446	chr1:150670422	GOLPH3L	0.41	5.73	0.33	2.74e-8	Tonsillectomy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00319449	chr10:77169139	NA	0.51	6.03	0.35	5.48e-9	Gut microbiome composition (summer);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg06831761	chr7:104885108	SRPK2	-0.46	-6.3	-0.36	1.26e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs66573146	0.831	rs67702333	chr4:6983040	C/G	cg00086871	chr4:6988644	TBC1D14	1.21	7.9	0.44	7.68e-14	Granulocyte percentage of myeloid white cells;
CESC	cis	rs13191362	1.000	rs13202339	chr6:163081812	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.99	10.24	0.53	5.84e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs561341	1.000	rs113676348	chr17:30244327	A/G	cg13647721	chr17:30228624	UTP6	0.6	5.45	0.32	1.17e-7	Hip circumference adjusted for BMI;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04005938	chr7:148334417	NA	-0.72	-8.14	-0.45	1.54e-14	Gut microbiome composition (summer);
CESC	cis	rs17253792	0.731	rs3736876	chr14:56120178	T/C	cg01858014	chr14:56050164	KTN1	-0.96	-7.52	-0.42	8.3e-13	Putamen volume;
CESC	cis	rs1348850	0.526	rs4893829	chr2:178399810	A/G	cg22681709	chr2:178499509	PDE11A	0.49	5.28	0.31	2.73e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs977987	0.843	rs11149820	chr16:75422760	G/A	cg03315344	chr16:75512273	CHST6	0.4	5.73	0.33	2.68e-8	Dupuytren's disease;
CESC	cis	rs7666738	0.830	rs6811940	chr4:98777898	G/A	cg24818145	chr4:99064322	C4orf37	0.38	5.05	0.3	8.39e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs854765	0.547	rs8069811	chr17:17922280	G/A	cg04398451	chr17:18023971	MYO15A	-0.7	-10.37	-0.54	2.28e-21	Total body bone mineral density;
CESC	cis	rs10540	1.000	rs35068485	chr11:466032	A/T	cg03576123	chr11:487126	PTDSS2	-1.06	-10.99	-0.56	2.1e-23	Body mass index;
CESC	cis	rs9486715	0.867	rs9384628	chr6:96960232	T/C	cg18709589	chr6:96969512	KIAA0776	0.46	6.48	0.37	4.41e-10	Headache;
CESC	cis	rs67460515	0.892	rs34896809	chr3:161059804	C/T	cg03342759	chr3:160939853	NMD3	-0.54	-7.83	-0.43	1.17e-13	Parkinson's disease;
CESC	cis	rs7264396	0.635	rs6058378	chr20:34546658	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.81	-11.06	-0.56	1.23e-23	Total cholesterol levels;
CESC	cis	rs6088580	0.634	rs4142007	chr20:32990050	G/T	cg08999081	chr20:33150536	PIGU	-0.64	-11.24	-0.57	3.23e-24	Glomerular filtration rate (creatinine);
CESC	cis	rs3015497	0.528	rs3015467	chr14:51158848	C/T	cg26011998	chr14:51135199	SAV1	-0.54	-5.84	-0.34	1.54e-8	Mean platelet volume;
CESC	cis	rs9388451	0.872	rs2008027	chr6:126052359	A/G	cg10911889	chr6:126070802	HEY2	0.36	5.1	0.3	6.59e-7	Brugada syndrome;
CESC	cis	rs10838687	0.736	rs830083	chr11:47254051	G/C	cg25783544	chr11:47291846	MADD	-0.56	-6.45	-0.37	5.15e-10	Proinsulin levels;
CESC	cis	rs12134245	0.776	rs12137878	chr1:91973210	G/T	cg07090678	chr1:91966139	CDC7	0.4	5.5	0.32	8.91e-8	Breast cancer;
CESC	cis	rs3762637	0.943	rs28403550	chr3:122251838	C/A	cg24169773	chr3:122142474	KPNA1	-0.59	-6.91	-0.39	3.59e-11	LDL cholesterol levels;
CESC	cis	rs514406	0.798	rs4351588	chr1:53263826	A/T	cg27535305	chr1:53392650	SCP2	0.34	5.89	0.34	1.17e-8	Monocyte count;
CESC	cis	rs4862750	0.758	rs2375915	chr4:187896255	A/C	cg22105103	chr4:187893119	NA	0.48	6.79	0.38	7.4e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7957197	0.671	rs56158042	chr12:121455589	G/A	cg02403541	chr12:121454288	C12orf43	-0.42	-5.05	-0.3	8.4e-7	Type 2 diabetes;
CESC	cis	rs4604732	0.631	rs11490200	chr1:247625915	G/T	cg12754571	chr1:247694271	LOC148824;OR2C3	0.44	5.44	0.32	1.21e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs7818688	1.000	rs11776189	chr8:96036741	T/G	cg16049864	chr8:95962084	TP53INP1	0.61	5.76	0.33	2.28e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs8044868	0.586	rs6499557	chr16:72082654	A/G	cg16558253	chr16:72132732	DHX38	-0.4	-6.32	-0.36	1.12e-9	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CESC	cis	rs7666738	0.830	rs13130923	chr4:99046281	T/C	cg18180107	chr4:99064573	C4orf37	0.41	5.29	0.31	2.51e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs72387598	1	rs72387598	chr1:45922977	CAT/C	cg24296786	chr1:45957014	TESK2	-0.46	-5.15	-0.3	5.16e-7	Platelet distribution width;
CESC	cis	rs9487051	0.872	rs1111865	chr6:109610863	A/G	cg12927641	chr6:109611667	NA	0.45	6.99	0.39	2.17e-11	Reticulocyte fraction of red cells;
CESC	cis	rs1552244	0.882	rs56224841	chr3:10044014	A/C	cg08888203	chr3:10149979	C3orf24	0.48	6.0	0.35	6.52e-9	Alzheimer's disease;
CESC	cis	rs7216064	1.000	rs2046323	chr17:65849927	T/G	cg07042672	chr17:66097459	LOC651250	-0.53	-5.57	-0.32	6.1e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs734999	0.549	rs6670198	chr1:2520527	T/C	cg18854424	chr1:2615690	NA	0.29	5.58	0.32	5.79e-8	Ulcerative colitis;
CESC	cis	rs6912958	0.559	rs373646	chr6:88056896	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.73	10.82	0.55	7.85e-23	Monocyte percentage of white cells;
CESC	cis	rs727563	0.594	rs5758408	chr22:42077737	A/C	cg03806693	chr22:41940476	POLR3H	1.09	12.68	0.61	4.09e-29	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs8114671	0.836	rs2425012	chr20:33581955	G/A	cg07148914	chr20:33460835	GGT7	-0.41	-5.28	-0.31	2.75e-7	Height;
CESC	cis	rs7561273	0.586	rs11892283	chr2:24317850	T/C	cg06627628	chr2:24431161	ITSN2	-0.48	-5.71	-0.33	3.03e-8	Quantitative traits;
CESC	cis	rs5760092	0.755	rs4585126	chr22:24270005	T/C	cg11905131	chr22:24372483	LOC391322	0.6	7.59	0.42	5.6e-13	Urinary 1,3-butadiene metabolite levels in smokers;
CESC	cis	rs6540559	1.000	rs2235373	chr1:209963803	G/A	cg09509183	chr1:209979624	IRF6	0.51	6.22	0.36	1.95e-9	Cleft lip with or without cleft palate;
CESC	cis	rs947211	0.948	rs1775143	chr1:205755550	C/T	cg14893161	chr1:205819251	PM20D1	0.4	5.23	0.31	3.42e-7	Parkinson's disease;
CESC	cis	rs7666738	0.830	rs11935078	chr4:99010476	T/A	cg05340658	chr4:99064831	C4orf37	0.8	12.51	0.61	1.52e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7845219	0.544	rs7015841	chr8:95920193	A/C	cg13393036	chr8:95962371	TP53INP1	-0.42	-8.03	-0.44	3.25e-14	Type 2 diabetes;
CESC	cis	rs6733011	0.508	rs925887	chr2:99514671	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.41	5.19	0.3	4.1e-7	Bipolar disorder;
CESC	cis	rs8070128	0.583	rs7406982	chr17:17942613	C/T	cg04398451	chr17:18023971	MYO15A	-0.73	-10.55	-0.54	5.95e-22	Total body bone mineral density;
CESC	cis	rs1728785	1.000	rs1645979	chr16:68603660	G/T	cg02972257	chr16:68554789	NA	-0.66	-7.4	-0.41	1.75e-12	Ulcerative colitis;
CESC	cis	rs9914988	0.943	rs59461345	chr17:27151852	G/T	cg20469991	chr17:27169893	C17orf63	-0.47	-5.13	-0.3	5.64e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CESC	cis	rs9311474	0.508	rs7625743	chr3:52606366	C/G	cg05564831	chr3:52568323	NT5DC2	0.48	7.76	0.43	1.85e-13	Electroencephalogram traits;
CESC	cis	rs611744	0.669	rs13251024	chr8:109258333	T/C	cg21045802	chr8:109455806	TTC35	0.46	5.67	0.33	3.65e-8	Dupuytren's disease;
CESC	cis	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg07308232	chr7:1071921	C7orf50	-0.6	-8.45	-0.46	2.02e-15	Longevity;Endometriosis;
CESC	cis	rs2991971	0.869	rs2453404	chr1:46014735	A/G	cg24296786	chr1:45957014	TESK2	0.63	8.16	0.45	1.37e-14	High light scatter reticulocyte count;
CESC	cis	rs1552244	1.000	rs7637888	chr3:10080722	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.78	-10.37	-0.54	2.25e-21	Alzheimer's disease;
CESC	cis	rs2228479	0.764	rs7184960	chr16:89961661	C/T	cg06558623	chr16:89946397	TCF25	0.68	5.99	0.35	6.63e-9	Skin colour saturation;
CESC	cis	rs9913156	0.793	rs55974786	chr17:4567564	T/C	cg19197139	chr17:4613644	ARRB2	0.93	10.68	0.55	2.2e-22	Lymphocyte counts;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08156809	chr7:74071310	GTF2I	0.59	6.98	0.39	2.34e-11	Gut microbiome composition (summer);
CESC	cis	rs4665809	1.000	rs4665298	chr2:26256378	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.69	-7.88	-0.44	8.71e-14	Gut microbiome composition (summer);
CESC	cis	rs4689592	0.513	rs3857178	chr4:7066516	G/A	cg06697600	chr4:7070879	GRPEL1	-0.49	-7.25	-0.41	4.68e-12	Monocyte percentage of white cells;
CESC	cis	rs6963495	0.818	rs818619	chr7:105172505	A/T	cg02135003	chr7:105160482	PUS7	-0.43	-5.98	-0.34	7.27e-9	Bipolar disorder (body mass index interaction);
CESC	cis	rs3096299	0.935	rs3114890	chr16:89449546	C/G	cg02187348	chr16:89574699	SPG7	0.54	7.08	0.4	1.28e-11	Multiple myeloma (IgH translocation);
CESC	trans	rs7839040	0.698	rs10091992	chr8:82932881	T/C	cg14472086	chr9:107730925	NA	-0.46	-6.24	-0.36	1.69e-9	Response to methotrexate in juvenile idiopathic arthritis;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg06581840	chr11:113644397	ZW10	-0.46	-6.0	-0.35	6.58e-9	Fibrinogen levels;
CESC	cis	rs2243480	1.000	rs313807	chr7:65499481	C/T	cg12463550	chr7:65579703	CRCP	0.72	5.92	0.34	9.68e-9	Diabetic kidney disease;
CESC	cis	rs1550582	1.000	rs62523710	chr8:135538773	T/C	cg17885191	chr8:135476712	NA	0.65	7.28	0.41	3.73e-12	Educational attainment;
CESC	cis	rs71403859	0.667	rs35538253	chr16:71677975	C/T	cg08717414	chr16:71523259	ZNF19	-0.69	-5.81	-0.34	1.76e-8	Post bronchodilator FEV1;
CESC	cis	rs116095464	0.510	rs55750776	chr5:230467	T/C	cg10591111	chr5:226296	SDHA	-0.54	-6.65	-0.38	1.72e-10	Breast cancer;
CESC	cis	rs8017423	0.935	rs12884698	chr14:90750566	G/A	cg14092571	chr14:90743983	NA	0.56	8.45	0.46	1.98e-15	Mortality in heart failure;
CESC	cis	rs1832871	0.711	rs9459946	chr6:158707957	T/C	cg07165851	chr6:158734300	TULP4	0.61	6.68	0.38	1.38e-10	Height;
CESC	cis	rs7267005	0.661	rs2425085	chr20:34302402	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.87	-5.35	-0.31	1.89e-7	Response to paliperidone in schizophrenia (Multivariate);
CESC	cis	rs2836974	0.897	rs35386515	chr21:40532047	C/T	cg11890956	chr21:40555474	PSMG1	1.17	22.39	0.81	4.79e-63	Cognitive function;
CESC	cis	rs559928	0.606	rs56311067	chr11:63931607	C/T	cg18225595	chr11:63971243	STIP1	0.69	6.22	0.36	1.88e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CESC	cis	rs2072732	0.904	rs717795	chr1:2970464	T/C	cg15211996	chr1:2936768	ACTRT2	0.29	5.24	0.31	3.25e-7	Plateletcrit;
CESC	cis	rs6484504	0.576	rs286653	chr11:31227824	C/T	cg14844989	chr11:31128820	NA	-0.41	-5.77	-0.33	2.16e-8	Red blood cell count;
CESC	cis	rs2235642	0.928	rs2076435	chr16:1607574	C/T	cg07639376	chr16:1584516	IFT140;TMEM204	-0.32	-5.28	-0.31	2.74e-7	Coronary artery disease;
CESC	cis	rs2637266	0.729	rs1099883	chr10:78516158	G/T	cg18941641	chr10:78392320	NA	0.43	8.42	0.46	2.39e-15	Pulmonary function;
CESC	cis	rs17253792	0.822	rs17683656	chr14:56053361	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	-0.83	-6.05	-0.35	4.84e-9	Putamen volume;
CESC	cis	rs56163509	1	rs56163509	chr16:28864471	A/G	cg08761264	chr16:28874980	SH2B1	-0.45	-5.49	-0.32	9.61e-8	Tonsillectomy;Mean corpuscular volume;
CESC	cis	rs1847202	0.859	rs13096870	chr3:72948172	G/A	cg10804678	chr3:72788309	NA	-0.4	-5.29	-0.31	2.62e-7	Motion sickness;
CESC	cis	rs2070997	0.607	rs7856783	chr9:133713507	T/C	cg11464064	chr9:133710261	ABL1	0.72	8.06	0.44	2.58e-14	Response to amphetamines;
CESC	cis	rs722599	0.683	rs10144860	chr14:75286426	T/C	cg11812906	chr14:75593930	NEK9	0.45	5.45	0.32	1.14e-7	IgG glycosylation;
CESC	cis	rs8031584	0.918	rs34095794	chr15:31269691	C/T	cg08704250	chr15:31115839	NA	-0.62	-7.97	-0.44	4.65e-14	Huntington's disease progression;
CESC	cis	rs3026101	0.671	rs57406064	chr17:5300183	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.42	5.6	0.33	5.31e-8	Body mass index;
CESC	cis	rs2180341	0.960	rs9401953	chr6:127687574	G/A	cg27446573	chr6:127587934	RNF146	1.05	15.58	0.69	2.65e-39	Breast cancer;
CESC	cis	rs7552404	1.000	rs1498312	chr1:76177849	C/T	cg03433033	chr1:76189801	ACADM	0.69	8.23	0.45	8.67e-15	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs8002861	0.905	rs12875768	chr13:44428305	C/T	cg19180546	chr13:44453867	C13orf31;CCDC122	-0.44	-5.49	-0.32	9.55e-8	Leprosy;
CESC	cis	rs2836974	0.568	rs7282604	chr21:40536910	C/T	cg27266027	chr21:40555129	PSMG1	-0.42	-5.45	-0.32	1.16e-7	Cognitive function;
CESC	cis	rs5769765	1.000	rs2295409	chr22:50261060	G/C	cg02269571	chr22:50332266	NA	0.46	6.2	0.36	2.13e-9	Schizophrenia;
CESC	cis	rs4481887	0.927	rs10157089	chr1:248488157	A/G	cg00666640	chr1:248458726	OR2T12	0.35	5.98	0.35	7.04e-9	Common traits (Other);
CESC	cis	rs7640424	0.589	rs78673584	chr3:107813133	A/G	cg09227934	chr3:107805635	CD47	-0.46	-5.65	-0.33	4.07e-8	Body mass index;
CESC	cis	rs829883	1.000	rs249839	chr12:98872364	T/C	cg25150519	chr12:98850993	NA	0.68	9.14	0.49	1.7e-17	Colorectal adenoma (advanced);
CESC	cis	rs13106227	0.602	rs13152154	chr4:77417756	C/T	cg20311846	chr4:77356250	SHROOM3	-0.32	-6.13	-0.35	3.21e-9	Eosinophilic esophagitis (pediatric);
CESC	cis	rs910316	0.967	rs4899545	chr14:75568138	A/G	cg08847533	chr14:75593920	NEK9	1.01	19.49	0.77	4.22e-53	Height;
CESC	cis	rs9322193	0.923	rs14314	chr6:150141531	A/C	cg13206674	chr6:150067644	NUP43	0.42	5.78	0.33	2.12e-8	Lung cancer;
CESC	cis	rs1799949	1.000	rs4793197	chr17:41231902	C/T	cg05368731	chr17:41323189	NBR1	0.78	10.62	0.55	3.57e-22	Menopause (age at onset);
CESC	cis	rs8064299	0.597	rs3785539	chr17:72775099	A/G	cg25054828	chr17:72772726	NAT9;TMEM104	0.88	14.97	0.68	3.91e-37	Monocyte count;
CESC	cis	rs8078723	0.674	rs9303284	chr17:38205793	C/T	cg17467752	chr17:38218738	THRA	-0.72	-11.25	-0.57	2.87e-24	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CESC	cis	rs67311347	1.000	rs10510708	chr3:40404770	A/G	cg24209194	chr3:40518798	ZNF619	0.44	5.71	0.33	2.98e-8	Renal cell carcinoma;
CESC	cis	rs12410462	0.681	rs115956039	chr1:227661978	G/A	cg04117972	chr1:227635322	NA	0.8	6.85	0.39	5.16e-11	Major depressive disorder;
CESC	cis	rs3747547	0.818	rs3827519	chr9:37948724	T/C	cg13774184	chr9:37916125	SHB	-0.57	-5.97	-0.34	7.8e-9	Metabolite levels (Dihydroxy docosatrienoic acid);
CESC	cis	rs2594989	1.000	rs2594993	chr3:11360744	C/T	cg00170343	chr3:11313890	ATG7	0.59	5.25	0.31	3.1e-7	Circulating chemerin levels;
CESC	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg03647317	chr4:187891568	NA	-0.44	-6.71	-0.38	1.15e-10	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs10506458	0.915	rs2013050	chr12:63394310	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.34	-18.45	-0.75	1.83e-49	Hemostatic factors and hematological phenotypes;
CESC	cis	rs2154427	0.938	rs113791275	chr21:34202806	A/C	cg03746930	chr21:34165763	C21orf62;C21orf49	-0.53	-5.32	-0.31	2.17e-7	Bilirubin levels;
CESC	cis	rs1062177	0.756	rs2915827	chr5:151119705	T/A	cg12924095	chr5:151150029	G3BP1	-0.43	-5.34	-0.31	1.95e-7	Preschool internalizing problems;
CESC	cis	rs1552244	0.748	rs9862221	chr3:10059658	G/T	cg00166722	chr3:10149974	C3orf24	0.54	6.53	0.37	3.29e-10	Alzheimer's disease;
CESC	cis	rs738322	1.000	rs133012	chr22:38570721	G/A	cg17652424	chr22:38574118	PLA2G6	-0.34	-6.04	-0.35	5.08e-9	Cutaneous nevi;
CESC	cis	rs11098499	0.865	rs11722183	chr4:120280597	A/C	cg09307838	chr4:120376055	NA	0.95	13.4	0.64	1.27e-31	Corneal astigmatism;
CESC	cis	rs16854884	0.632	rs34038325	chr3:143685097	G/A	cg06585982	chr3:143692056	C3orf58	0.48	6.01	0.35	6.11e-9	Economic and political preferences (feminism/equality);
CESC	cis	rs4588572	0.779	rs3088102	chr5:77654679	G/A	cg11547950	chr5:77652471	NA	0.49	6.47	0.37	4.74e-10	Triglycerides;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00897250	chr12:569679	B4GALNT3	-0.62	-6.85	-0.39	5.23e-11	Gut microbiome composition (summer);
CESC	cis	rs9906944	0.707	rs9912906	chr17:47104432	A/T	cg09029085	chr17:47094198	IGF2BP1	0.25	5.06	0.3	7.94e-7	Intelligence (multi-trait analysis);Body fat percentage;
CESC	cis	rs561341	0.883	rs1034626	chr17:30219500	C/G	cg00745463	chr17:30367425	LRRC37B	0.58	5.88	0.34	1.22e-8	Hip circumference adjusted for BMI;
CESC	cis	rs72945132	0.882	rs72945194	chr11:70138621	A/G	cg00319359	chr11:70116639	PPFIA1	0.81	7.38	0.41	2e-12	Coronary artery disease;
CESC	cis	rs7586879	0.681	rs6723803	chr2:25120713	G/C	cg01884057	chr2:25150051	NA	0.36	7.01	0.4	2.02e-11	Body mass index;
CESC	cis	rs11711311	1.000	rs7649590	chr3:113447267	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.57	7.57	0.42	6.15e-13	IgG glycosylation;
CESC	cis	rs780096	0.546	rs2293571	chr2:27729480	C/T	cg02592271	chr2:27665507	KRTCAP3	-0.32	-6.55	-0.37	3e-10	Total body bone mineral density;
CESC	cis	rs7191439	0.858	rs11076702	chr16:88774569	A/C	cg27087555	chr16:88793112	FAM38A	-1.4	-11.24	-0.57	3.18e-24	Plateletcrit;
CESC	cis	rs72634258	0.945	rs7539255	chr1:8133352	T/C	cg00042356	chr1:8021962	PARK7	0.82	7.73	0.43	2.19e-13	Inflammatory bowel disease;
CESC	cis	rs116095464	1.000	rs62346511	chr5:208265	C/T	cg22857025	chr5:266934	NA	-1.27	-7.32	-0.41	2.92e-12	Breast cancer;
CESC	trans	rs6137473	0.535	rs6082511	chr20:21773991	A/C	cg01401824	chr2:159902017	TANC1	0.36	6.01	0.35	6.13e-9	Adolescent idiopathic scoliosis;
CESC	cis	rs25645	0.830	rs4072639	chr17:38189049	G/A	cg17467752	chr17:38218738	THRA	-0.51	-6.61	-0.38	2.16e-10	Myeloid white cell count;
CESC	cis	rs12042107	0.740	rs10922912	chr1:91207367	A/G	cg13456504	chr1:91191583	NA	-0.33	-5.67	-0.33	3.8e-8	Educational attainment;
CESC	cis	rs7249142	0.549	rs741706	chr19:19281672	C/T	cg27384695	chr19:19271486	LOC729991-MEF2B;MEF2B	0.29	5.21	0.3	3.75e-7	IgG glycosylation;
CESC	cis	rs896854	0.625	rs4735336	chr8:95973410	A/C	cg09323728	chr8:95962352	TP53INP1	0.37	7.94	0.44	5.64e-14	Type 2 diabetes;
CESC	trans	rs35365539	1	rs35365539	chr3:49794347	A/AC	cg21665057	chr3:196295764	WDR53;FBXO45	-0.59	-8.49	-0.46	1.51e-15	Blood protein levels;
CESC	cis	rs7927771	0.524	rs10838760	chr11:47786414	A/G	cg18512352	chr11:47633146	NA	0.34	5.24	0.31	3.22e-7	Subjective well-being;
CESC	trans	rs208520	1.000	rs208535	chr6:66962286	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.85	-9.42	-0.5	2.36e-18	Exhaled nitric oxide output;
CESC	cis	rs2645694	0.626	rs2703118	chr4:77823672	A/G	cg18351406	chr4:77819688	ANKRD56	0.53	6.57	0.37	2.68e-10	Emphysema distribution in smoking;
CESC	cis	rs2735413	0.958	rs2735401	chr16:78057103	A/C	cg04733911	chr16:78082701	NA	0.46	7.14	0.4	8.82e-12	Systolic blood pressure (alcohol consumption interaction);
CESC	cis	rs17826219	0.706	rs9893922	chr17:29068425	T/C	cg14008862	chr17:28927542	LRRC37B2	0.65	5.14	0.3	5.34e-7	Body mass index;
CESC	trans	rs561341	1.000	rs473356	chr17:30321762	G/C	cg27661571	chr11:113659931	NA	-0.82	-7.63	-0.42	4.18e-13	Hip circumference adjusted for BMI;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23288008	chr1:228296932	MRPL55	0.65	7.04	0.4	1.62e-11	Gut microbiome composition (summer);
CESC	trans	rs61931739	0.500	rs7313094	chr12:34457508	T/C	cg26384229	chr12:38710491	ALG10B	0.55	7.61	0.42	4.69e-13	Morning vs. evening chronotype;
CESC	cis	rs4919694	0.611	rs76695159	chr10:105070837	C/T	cg04362960	chr10:104952993	NT5C2	0.68	5.59	0.32	5.56e-8	Arsenic metabolism;
CESC	cis	rs10464366	0.544	rs9639812	chr7:39192058	C/T	cg18850127	chr7:39170497	POU6F2	0.37	5.16	0.3	4.8e-7	IgG glycosylation;
CESC	cis	rs752092	0.925	rs8032007	chr15:101790817	C/T	cg19997662	chr15:101784653	CHSY1	0.54	7.43	0.42	1.54e-12	Corneal structure;
CESC	cis	rs7680126	0.596	rs10939835	chr4:10313750	A/G	cg00071950	chr4:10020882	SLC2A9	-0.5	-5.25	-0.31	3.06e-7	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	cis	rs7089973	0.872	rs11818114	chr10:116634878	G/C	cg23260525	chr10:116636907	FAM160B1	0.37	6.15	0.35	2.84e-9	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs9488822	0.676	rs1999929	chr6:116381994	T/C	cg18764771	chr6:116381957	FRK	0.23	5.88	0.34	1.23e-8	Cholesterol, total;LDL cholesterol;
CESC	cis	rs546131	0.928	rs552627	chr11:34826680	G/A	cg06937548	chr11:34938143	PDHX;APIP	0.5	6.15	0.35	2.86e-9	Lung disease severity in cystic fibrosis;
CESC	cis	rs916888	0.610	rs199530	chr17:44836653	C/T	cg17911788	chr17:44343683	NA	0.41	6.48	0.37	4.38e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs1801251	0.963	rs66549961	chr2:233602293	A/G	cg25237894	chr2:233734115	C2orf82	0.45	7.89	0.44	8.12e-14	Coronary artery disease;
CESC	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	22.29	0.81	1e-62	Prudent dietary pattern;
CESC	cis	rs10791097	0.582	rs2282578	chr11:130735691	A/T	cg12179176	chr11:130786555	SNX19	0.68	10.0	0.52	3.48e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs9894429	1.000	rs12948099	chr17:79600799	C/G	cg18240062	chr17:79603768	NPLOC4	0.74	10.37	0.54	2.3e-21	Eye color traits;
CESC	cis	rs7666738	0.830	rs35491210	chr4:99003364	T/C	cg03467027	chr4:99064603	C4orf37	0.43	5.4	0.31	1.49e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9487051	0.872	rs1521908	chr6:109613986	T/C	cg01475377	chr6:109611718	NA	-0.51	-8.46	-0.46	1.87e-15	Reticulocyte fraction of red cells;
CESC	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg03188948	chr7:1209495	NA	0.72	6.93	0.39	3.15e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs1915146	0.546	rs2454055	chr10:126859832	T/C	cg05090351	chr10:126851162	NA	0.61	9.36	0.5	3.44e-18	Menarche (age at onset);
CESC	cis	rs5758659	0.652	rs133323	chr22:42405922	T/C	cg15557168	chr22:42548783	NA	-0.42	-6.27	-0.36	1.48e-9	Cognitive function;
CESC	cis	rs367943	1.000	rs348944	chr5:112822925	C/T	cg12552261	chr5:112820674	MCC	-0.63	-7.96	-0.44	4.96e-14	Type 2 diabetes;
CESC	cis	rs17095355	0.792	rs61881587	chr10:111759710	A/T	cg00817464	chr10:111662876	XPNPEP1	-0.52	-5.92	-0.34	1.02e-8	Biliary atresia;
CESC	cis	rs9311474	0.581	rs4687626	chr3:52569098	G/A	cg18337363	chr3:52569053	NT5DC2	0.29	5.16	0.3	4.95e-7	Electroencephalogram traits;
CESC	cis	rs9897596	1	rs9897596	chr17:17593453	T/C	cg04398451	chr17:18023971	MYO15A	0.38	5.15	0.3	5.19e-7	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CESC	cis	rs9910055	0.573	rs228768	chr17:42191893	A/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.44	5.5	0.32	8.88e-8	Total body bone mineral density;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23649784	chr1:156105746	LMNA	-0.66	-7.31	-0.41	3.16e-12	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.830	rs12233741	chr4:98950296	C/T	cg17366294	chr4:99064904	C4orf37	0.59	8.52	0.46	1.24e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs477692	0.583	rs12415589	chr10:131428336	C/G	cg24747557	chr10:131355152	MGMT	0.38	5.38	0.31	1.62e-7	Response to temozolomide;
CESC	cis	rs7772486	0.790	rs6926657	chr6:146255794	G/A	cg05347473	chr6:146136440	FBXO30	-0.55	-7.0	-0.39	2.12e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4805272	0.512	rs765484	chr19:29344663	A/G	cg12756686	chr19:29218302	NA	0.44	5.83	0.34	1.65e-8	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
CESC	cis	rs4974559	0.790	rs7654152	chr4:1325042	G/A	cg02980000	chr4:1222292	CTBP1	0.82	7.38	0.41	2.1e-12	Systolic blood pressure;
CESC	cis	rs9300255	0.566	rs10744150	chr12:123721614	A/C	cg05973401	chr12:123451056	ABCB9	0.45	5.45	0.32	1.13e-7	Neutrophil percentage of white cells;
CESC	cis	rs3815700	1.000	rs8100168	chr19:33093084	G/A	cg02997394	chr19:33096574	ANKRD27	0.66	5.52	0.32	8.23e-8	Eosinophilic esophagitis;
CESC	cis	rs12295403	0.964	rs34364314	chr11:18691674	G/A	cg09887367	chr11:18690185	NA	-0.4	-5.81	-0.34	1.82e-8	Ovarian reserve;
CESC	cis	rs941873	0.868	rs10740497	chr10:81126380	T/C	cg08514558	chr10:81106712	PPIF	0.36	6.22	0.36	1.94e-9	Height;
CESC	cis	rs2479106	0.791	rs2536951	chr9:126646519	A/G	cg16191174	chr9:126692580	DENND1A	0.48	6.53	0.37	3.39e-10	Polycystic ovary syndrome;
CESC	cis	rs9311474	0.508	rs11714565	chr3:52606292	C/T	cg07507251	chr3:52567010	NT5DC2	0.33	5.69	0.33	3.36e-8	Electroencephalogram traits;
CESC	cis	rs4555082	0.834	rs1473672	chr14:105721981	G/T	cg27165867	chr14:105738592	BRF1	-0.52	-5.66	-0.33	3.92e-8	Mean platelet volume;Platelet distribution width;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26764764	chr17:79077412	BAIAP2	-0.56	-6.16	-0.35	2.7e-9	Gut microbiome composition (summer);
CESC	cis	rs2806561	0.734	rs11578046	chr1:23425139	G/A	cg12483005	chr1:23474871	LUZP1	0.33	5.08	0.3	7.13e-7	Height;
CESC	cis	rs9486719	1.000	rs11152951	chr6:96894135	C/G	cg06623918	chr6:96969491	KIAA0776	-0.81	-8.29	-0.45	5.61e-15	Migraine;Coronary artery disease;
CESC	cis	rs698833	0.886	rs1056865	chr2:44546741	A/G	cg04920474	chr2:44395004	PPM1B	0.36	5.16	0.3	4.92e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg01755729	chr8:146012904	ZNF34	-0.46	-6.02	-0.35	5.66e-9	Fibrinogen levels;
CESC	cis	rs1050631	0.564	rs948416	chr18:33715673	A/G	cg25426722	chr18:33708991	SLC39A6;ELP2	0.53	7.12	0.4	9.97e-12	Esophageal squamous cell cancer (length of survival);
CESC	cis	rs9303280	0.743	rs2941522	chr17:37910368	C/T	cg19468946	chr17:37922297	IKZF3	0.41	5.75	0.33	2.39e-8	Self-reported allergy;
CESC	cis	rs12701220	0.655	rs6955290	chr7:1151066	A/G	cg00990874	chr7:1149470	C7orf50	0.48	5.22	0.31	3.56e-7	Bronchopulmonary dysplasia;
CESC	cis	rs2991971	1.000	rs518365	chr1:46010652	A/G	cg24296786	chr1:45957014	TESK2	0.64	8.34	0.46	4.05e-15	High light scatter reticulocyte count;
CESC	cis	rs853679	0.517	rs4713146	chr6:28111536	A/T	cg17949981	chr6:28129498	ZNF389	0.44	5.39	0.31	1.55e-7	Depression;
CESC	cis	rs9815354	0.638	rs73069277	chr3:41967521	C/T	cg03022575	chr3:42003672	ULK4	0.67	5.96	0.34	7.91e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs4268898	0.560	rs78711174	chr2:24496531	G/A	cg06627628	chr2:24431161	ITSN2	-0.97	-10.74	-0.55	1.39e-22	Asthma;
CESC	cis	rs7122539	0.506	rs10791896	chr11:66689240	G/T	cg24851651	chr11:66362959	CCS	0.4	5.78	0.33	2.08e-8	HIV-1 susceptibility;
CESC	cis	rs13191362	1.000	rs13218900	chr6:163081638	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.95	9.59	0.51	7e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs873946	0.564	rs2803992	chr10:134550882	T/C	cg27286337	chr10:134555280	INPP5A	0.71	8.81	0.48	1.66e-16	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs55871839	0.708	rs4738731	chr8:59809840	C/G	cg07426533	chr8:59803705	TOX	-0.45	-6.74	-0.38	9.7e-11	Pneumonia;
CESC	cis	rs258892	0.895	rs34672	chr5:72165389	G/A	cg21869765	chr5:72125136	TNPO1	0.44	5.6	0.33	5.41e-8	Small cell lung carcinoma;
CESC	cis	rs10479542	0.642	rs6879665	chr5:178974581	T/A	cg19626725	chr5:178986131	RUFY1	0.35	5.17	0.3	4.57e-7	Lung cancer;
CESC	cis	rs916888	0.773	rs199457	chr17:44795469	C/T	cg27589368	chr17:43923255	LOC100128977;IMP5	-0.39	-5.24	-0.31	3.31e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs7666738	0.830	rs10049627	chr4:99025272	A/C	cg17366294	chr4:99064904	C4orf37	0.62	8.95	0.48	6.32e-17	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4964805	0.632	rs9706225	chr12:104188086	T/C	cg02344784	chr12:104178138	NT5DC3	0.46	6.57	0.37	2.73e-10	Attention deficit hyperactivity disorder;
CESC	cis	rs1008375	1.000	rs7673500	chr4:17621383	C/T	cg02297831	chr4:17616191	MED28	0.61	7.77	0.43	1.76e-13	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs1975974	0.935	rs11870387	chr17:21730236	G/C	cg18423549	chr17:21743878	NA	-0.53	-7.11	-0.4	1.07e-11	Psoriasis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07752194	chr10:126686658	CTBP2	-0.53	-6.05	-0.35	4.95e-9	Gut microbiome composition (summer);
CESC	cis	rs8062405	0.690	rs7187604	chr16:28565953	A/G	cg07382826	chr16:28625726	SULT1A1	0.4	6.56	0.37	2.87e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	trans	rs526821	0.595	rs608964	chr11:55339266	G/A	cg15704280	chr7:45808275	SEPT13	-0.51	-6.28	-0.36	1.41e-9	Pediatric bone mineral density (spine);
CESC	cis	rs796364	1.000	rs11680723	chr2:200810957	C/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-1.03	-7.96	-0.44	5.03e-14	Schizophrenia;
CESC	cis	rs7084402	0.967	rs1658440	chr10:60323933	T/A	cg07615347	chr10:60278583	BICC1	0.61	9.62	0.51	5.56e-19	Refractive error;
CESC	cis	rs2239815	0.576	rs10427628	chr22:29239766	T/C	cg02153584	chr22:29168773	CCDC117	0.45	5.06	0.3	7.89e-7	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
CESC	cis	rs9322193	0.923	rs7767622	chr6:150002902	T/C	cg13206674	chr6:150067644	NUP43	0.45	6.47	0.37	4.82e-10	Lung cancer;
CESC	cis	rs12586317	0.513	rs11156871	chr14:35481196	G/A	cg16230307	chr14:35515116	FAM177A1	0.98	10.57	0.54	5.04e-22	Psoriasis;
CESC	cis	rs1862618	0.853	rs832551	chr5:56180112	T/G	cg22800045	chr5:56110881	MAP3K1	0.81	9.66	0.51	4.1e-19	Initial pursuit acceleration;
CESC	cis	rs3087591	1.000	rs8082020	chr17:29694795	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.51	-6.4	-0.37	7.01e-10	Hip circumference;
CESC	cis	rs7208859	0.524	rs59923796	chr17:29064919	G/A	cg19761014	chr17:28927070	LRRC37B2	0.77	6.31	0.36	1.17e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22984404	chr17:30469399	RHOT1	0.56	6.17	0.35	2.52e-9	Gut microbiome composition (summer);
CESC	cis	rs61332075	0.518	rs6749508	chr2:239456243	C/T	cg18131467	chr2:239335373	ASB1	-0.58	-6.02	-0.35	5.69e-9	Lung function (FEV1/FVC);
CESC	cis	rs3749237	0.595	rs2878298	chr3:49406080	T/C	cg03060546	chr3:49711283	APEH	0.75	11.29	0.57	2.17e-24	Resting heart rate;
CESC	cis	rs2204008	0.840	rs3892363	chr12:38479487	G/A	cg13010199	chr12:38710504	ALG10B	0.47	6.11	0.35	3.63e-9	Bladder cancer;
CESC	cis	rs7193541	0.694	rs3896277	chr16:74480694	A/T	cg01733217	chr16:74700730	RFWD3	0.7	10.3	0.53	3.88e-21	Multiple myeloma;
CESC	cis	rs3733585	0.699	rs11724510	chr4:9958583	C/T	cg02734326	chr4:10020555	SLC2A9	-0.44	-6.11	-0.35	3.58e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs875971	0.545	rs73142265	chr7:65699497	G/A	cg25405998	chr7:65216604	CCT6P1	0.5	5.42	0.32	1.36e-7	Aortic root size;
CESC	cis	rs1218582	0.772	rs4845690	chr1:154886817	C/T	cg03351412	chr1:154909251	PMVK	-0.7	-9.39	-0.5	2.9e-18	Prostate cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21250466	chr4:854474	GAK	-0.65	-7.77	-0.43	1.78e-13	Gut microbiome composition (summer);
CESC	trans	rs9858542	0.953	rs7646366	chr3:49470668	G/A	cg21659725	chr3:3221576	CRBN	-0.56	-6.63	-0.38	1.83e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs1185460	1.000	rs1185460	chr11:118943433	C/T	cg01677386	chr11:118938358	VPS11	0.42	5.03	0.3	8.94e-7	Coronary artery disease;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg25722142	chr6:139695762	CITED2	-0.49	-6.58	-0.37	2.56e-10	Height;
CESC	cis	rs832540	0.669	rs832539	chr5:56199386	A/C	cg24531977	chr5:56204891	C5orf35	-0.56	-7.46	-0.42	1.25e-12	Coronary artery disease;
CESC	cis	rs5167	0.504	rs3760625	chr19:45456941	G/A	cg20090143	chr19:45452003	APOC2	0.37	6.39	0.37	7.51e-10	Blood protein levels;
CESC	cis	rs8078723	0.510	rs11655264	chr17:38138995	G/C	cg17467752	chr17:38218738	THRA	-0.48	-7.01	-0.4	2.03e-11	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CESC	cis	rs1670533	0.818	rs585735	chr4:1080391	G/C	cg04106633	chr4:1044584	NA	0.4	5.1	0.3	6.33e-7	Recombination rate (females);
CESC	cis	rs938554	0.692	rs4428284	chr4:9996392	A/T	cg00071950	chr4:10020882	SLC2A9	0.62	6.86	0.39	4.97e-11	Blood metabolite levels;
CESC	cis	rs6952808	0.594	rs3778965	chr7:2138296	G/A	cg02951883	chr7:2050386	MAD1L1	-0.46	-5.99	-0.35	6.84e-9	Bipolar disorder and schizophrenia;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg24029926	chr7:33102655	NT5C3	-0.46	-6.23	-0.36	1.82e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs3820068	0.705	rs72643701	chr1:15866219	G/A	cg18192808	chr1:15853278	DNAJC16	0.43	5.28	0.31	2.66e-7	Systolic blood pressure;
CESC	cis	rs6582630	0.560	rs12315134	chr12:38419857	T/A	cg26384229	chr12:38710491	ALG10B	-0.41	-5.49	-0.32	9.35e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs3820928	0.839	rs35068645	chr2:227844265	T/C	cg11843606	chr2:227700838	RHBDD1	-0.45	-5.78	-0.33	2.15e-8	Pulmonary function;
CESC	cis	rs875971	0.862	rs778720	chr7:65846275	A/C	cg12463550	chr7:65579703	CRCP	-0.47	-5.97	-0.34	7.71e-9	Aortic root size;
CESC	cis	rs2354432	0.505	rs7551766	chr1:146858964	A/G	cg25205988	chr1:146714368	CHD1L	-1.03	-8.43	-0.46	2.28e-15	Mitochondrial DNA levels;
CESC	cis	rs1801251	1.000	rs11555646	chr2:233599904	A/C	cg08000102	chr2:233561755	GIGYF2	0.69	9.8	0.52	1.48e-19	Coronary artery disease;
CESC	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg16103275	chr6:290800	DUSP22	-0.43	-6.09	-0.35	3.86e-9	Menopause (age at onset);
CESC	cis	rs8180040	0.764	rs6794193	chr3:47114904	T/C	cg27129171	chr3:47204927	SETD2	0.7	10.49	0.54	9.21e-22	Colorectal cancer;
CESC	cis	rs10489525	0.599	rs17033129	chr1:115611539	C/T	cg01522456	chr1:115632236	TSPAN2	0.45	5.58	0.32	6.08e-8	Autism;
CESC	cis	rs9649213	0.593	rs7807555	chr7:97957517	G/A	cg24562669	chr7:97807699	LMTK2	0.51	7.57	0.42	6.13e-13	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg10819733	chr22:24237672	NA	-0.37	-5.22	-0.31	3.59e-7	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs6800768	0.633	rs7623348	chr3:24130263	C/A	cg10674438	chr3:24145617	LOC152024	-0.42	-5.63	-0.33	4.69e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs6500602	0.653	rs3747579	chr16:4445327	A/G	cg08645402	chr16:4508243	NA	-0.39	-5.6	-0.33	5.29e-8	Schizophrenia;
CESC	cis	rs9611565	0.694	rs202656	chr22:41842203	T/A	cg06634786	chr22:41940651	POLR3H	0.71	7.13	0.4	9.54e-12	Vitiligo;
CESC	trans	rs9693444	0.898	rs4732697	chr8:29519861	A/G	cg07236798	chr8:131455818	NA	-0.41	-6.05	-0.35	4.89e-9	Breast cancer;
CESC	cis	rs9354308	0.771	rs2814100	chr6:66528107	A/G	cg07460842	chr6:66804631	NA	0.51	5.58	0.32	6.05e-8	Metabolite levels;
CESC	cis	rs362272	0.545	rs2239725	chr4:3305739	C/T	cg14583973	chr4:3374767	RGS12	0.32	5.48	0.32	9.89e-8	Serum sulfate level;
CESC	cis	rs7851660	0.809	rs10512255	chr9:100652582	C/T	cg13688889	chr9:100608707	NA	-0.66	-9.14	-0.49	1.64e-17	Strep throat;
CESC	cis	rs7589342	0.839	rs10192144	chr2:106439854	A/G	cg16077055	chr2:106428750	NCK2	0.48	6.88	0.39	4.33e-11	Addiction;
CESC	cis	rs362296	0.698	rs362282	chr4:3259671	G/A	cg08886695	chr4:3369023	RGS12	0.43	5.75	0.33	2.52e-8	Parental longevity (mother's age at death);
CESC	cis	rs9815354	1.000	rs2128835	chr3:41862873	A/G	cg03022575	chr3:42003672	ULK4	0.48	5.3	0.31	2.46e-7	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs10504229	0.654	rs903705	chr8:58128185	T/A	cg02725872	chr8:58115012	NA	-0.45	-7.05	-0.4	1.52e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs9430161	0.645	rs6675082	chr1:11033797	T/C	cg27631724	chr1:11040367	C1orf127	0.37	5.92	0.34	1.01e-8	Ewing sarcoma;
CESC	cis	rs10870270	1.000	rs11146354	chr10:133774757	A/G	cg08754478	chr10:133766260	PPP2R2D	-0.59	-7.57	-0.42	6.29e-13	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs12220238	1.000	rs7909915	chr10:75960942	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.6	5.44	0.32	1.24e-7	Soluble interleukin-2 receptor subunit alpha;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg23692589	chr11:67256716	AIP	0.46	6.84	0.39	5.35e-11	Fibrinogen levels;
CESC	cis	rs12048904	0.541	rs6699536	chr1:101276544	A/G	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.59	6.66	0.38	1.55e-10	Multiple sclerosis;
CESC	cis	rs7772486	0.686	rs9376961	chr6:146048737	C/T	cg23711669	chr6:146136114	FBXO30	0.88	12.91	0.62	6.46e-30	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs10197940	0.624	rs17270233	chr2:152372420	A/G	cg19508488	chr2:152266495	RIF1	0.51	5.39	0.31	1.56e-7	Lung cancer;
CESC	cis	rs10129255	0.957	rs8009464	chr14:107185850	C/T	cg23076370	chr14:107095027	NA	-0.48	-6.25	-0.36	1.65e-9	Kawasaki disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg16931877	chr3:32726605	CNOT10	-0.47	-6.32	-0.36	1.11e-9	Fibrinogen levels;
CESC	cis	rs1799949	1.000	rs11654452	chr17:41189383	G/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	8.22	0.45	8.86e-15	Menopause (age at onset);
CESC	cis	rs9300255	0.507	rs1727302	chr12:123632930	G/A	cg05973401	chr12:123451056	ABCB9	0.49	5.89	0.34	1.15e-8	Neutrophil percentage of white cells;
CESC	cis	rs7937682	0.737	rs542275	chr11:111431614	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.8	-11.09	-0.56	9.9e-24	Primary sclerosing cholangitis;
CESC	cis	rs11577318	0.853	rs11803933	chr1:26629465	G/C	cg00813993	chr1:26644493	UBXN11;CD52	-0.4	-6.46	-0.37	5.05e-10	Granulocyte percentage of myeloid white cells;
CESC	cis	rs10200159	1.000	rs6717574	chr2:55821846	A/G	cg13617705	chr2:55845095	SMEK2	0.68	5.13	0.3	5.68e-7	Vitiligo;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg03758918	chr6:45389877	RUNX2	-0.5	-6.2	-0.36	2.1e-9	Asthma;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09321108	chr11:47870340	NUP160	0.57	6.27	0.36	1.48e-9	Gut microbiome composition (summer);
CESC	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg26338869	chr17:61819248	STRADA	0.69	9.08	0.49	2.62e-17	Prudent dietary pattern;
CESC	cis	rs7618915	0.571	rs34954168	chr3:52612159	C/T	cg17372223	chr3:52568218	NT5DC2	0.43	6.37	0.36	8.15e-10	Bipolar disorder;
CESC	cis	rs6570726	0.935	rs421268	chr6:145845558	A/T	cg23711669	chr6:146136114	FBXO30	0.8	11.89	0.59	2e-26	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7191439	0.858	rs11076701	chr16:88774525	A/G	cg27087555	chr16:88793112	FAM38A	-1.25	-10.49	-0.54	9.1e-22	Plateletcrit;
CESC	cis	rs9487051	0.676	rs6929438	chr6:109595506	C/T	cg21918786	chr6:109611834	NA	-0.37	-5.49	-0.32	9.35e-8	Reticulocyte fraction of red cells;
CESC	cis	rs910316	1.000	rs4903284	chr14:75592483	G/C	cg08847533	chr14:75593920	NEK9	0.99	18.93	0.76	3.76e-51	Height;
CESC	cis	rs7762018	0.514	rs60671539	chr6:170165981	A/G	cg05834625	chr6:170176447	C6orf70	0.48	6.75	0.38	9.44e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs79349575	0.777	rs28517720	chr17:46976756	C/G	cg16584676	chr17:46985605	UBE2Z	0.53	6.58	0.37	2.57e-10	Type 2 diabetes;
CESC	cis	rs2243480	0.708	rs781141	chr7:65438553	A/G	cg25894440	chr7:65020034	NA	-0.6	-5.31	-0.31	2.38e-7	Diabetic kidney disease;
CESC	cis	rs9649213	0.593	rs13307593	chr7:97986146	A/G	cg21770322	chr7:97807741	LMTK2	0.57	8.84	0.48	1.39e-16	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs807669	0.525	rs9604934	chr22:19194868	C/T	cg02655711	chr22:19163373	SLC25A1	0.43	6.42	0.37	6.15e-10	Metabolite levels;
CESC	cis	rs453301	0.522	rs1964356	chr8:8853270	G/T	cg06636001	chr8:8085503	FLJ10661	0.41	5.42	0.32	1.32e-7	Joint mobility (Beighton score);
CESC	cis	rs1200821	0.535	rs1208783	chr10:37767467	A/G	cg25427524	chr10:38739819	LOC399744	-0.42	-5.48	-0.32	1e-7	Hemostatic factors and hematological phenotypes;
CESC	cis	rs3733418	0.860	rs12647419	chr4:165929153	G/A	cg10852876	chr4:165953100	TRIM60	-0.46	-5.37	-0.31	1.75e-7	Obesity-related traits;
CESC	cis	rs3105593	1.000	rs3109881	chr15:50839272	G/A	cg08437265	chr15:50716283	USP8	0.43	5.62	0.33	4.77e-8	QT interval;
CESC	cis	rs1949733	0.523	rs55977448	chr4:8542918	G/T	cg11789530	chr4:8429930	ACOX3	-0.57	-7.18	-0.4	6.97e-12	Response to antineoplastic agents;
CESC	cis	rs909341	0.710	rs6089953	chr20:62291008	C/T	cg03999872	chr20:62272968	STMN3	-0.55	-5.62	-0.33	4.95e-8	Atopic dermatitis;
CESC	cis	rs12497850	0.931	rs11920534	chr3:48937761	G/T	cg03060546	chr3:49711283	APEH	0.46	5.79	0.33	2.02e-8	Parkinson's disease;
CESC	cis	rs7296418	0.580	rs78455769	chr12:123856443	G/A	cg00376283	chr12:123451042	ABCB9	0.57	7.77	0.43	1.76e-13	Platelet count;
CESC	cis	rs7666738	0.830	rs28615340	chr4:98896922	T/C	cg05340658	chr4:99064831	C4orf37	0.75	10.89	0.56	4.51e-23	Colonoscopy-negative controls vs population controls;
CESC	cis	rs524023	0.881	rs544838	chr11:64429059	T/C	cg07220939	chr11:64358617	SLC22A12	-0.34	-5.32	-0.31	2.19e-7	Urate levels in obese individuals;
CESC	trans	rs9325144	0.555	rs12424003	chr12:38688140	C/T	cg23762105	chr12:34175262	ALG10	0.48	6.28	0.36	1.36e-9	Morning vs. evening chronotype;
CESC	cis	rs7666738	0.830	rs17027216	chr4:99009152	G/C	cg05340658	chr4:99064831	C4orf37	0.8	12.51	0.61	1.52e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs116095464	0.558	rs56127718	chr5:270273	G/T	cg22857025	chr5:266934	NA	-1.3	-18.8	-0.76	1.12e-50	Breast cancer;
CESC	trans	rs1814175	0.817	rs10839318	chr11:49657511	G/C	cg03929089	chr4:120376271	NA	-0.94	-15.58	-0.69	2.69e-39	Height;
CESC	cis	rs7772486	0.875	rs9403764	chr6:146360582	G/A	cg05347473	chr6:146136440	FBXO30	0.5	6.5	0.37	3.88e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs3762637	0.943	rs6762156	chr3:122236025	A/C	cg24169773	chr3:122142474	KPNA1	-0.59	-6.94	-0.39	3.01e-11	LDL cholesterol levels;
CESC	cis	rs17362650	0.653	rs13020173	chr2:9548651	T/G	cg12832956	chr2:9616023	IAH1	-0.57	-6.38	-0.36	7.96e-10	Alcohol dependence (age at onset);
CESC	cis	rs9640161	0.830	rs76741564	chr7:150059529	A/T	cg10018233	chr7:150070692	REPIN1	0.37	5.72	0.33	2.84e-8	Blood protein levels;Circulating chemerin levels;
CESC	trans	rs1545843	0.595	rs61929351	chr12:84793647	C/A	cg03015433	chr16:56623111	MT3	-0.34	-6.12	-0.35	3.37e-9	Major depressive disorder;
CESC	cis	rs6433857	0.657	rs2368178	chr2:181501938	T/C	cg23363182	chr2:181467187	NA	-0.45	-6.8	-0.39	6.88e-11	Body mass index;
CESC	cis	rs1475911	1.000	rs1475911	chr21:43513480	A/C	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.39	-5.72	-0.33	2.85e-8	IgG glycosylation;
CESC	cis	rs1387259	0.723	rs2732488	chr12:48771444	G/A	cg04545296	chr12:48745243	ZNF641	0.36	6.01	0.35	6.28e-9	Obstructive sleep apnea trait (apnea hypopnea index);
CESC	cis	rs7615952	0.576	rs4646759	chr3:125822946	G/C	cg04553112	chr3:125709451	NA	-0.54	-5.82	-0.34	1.71e-8	Blood pressure (smoking interaction);
CESC	cis	rs6088580	0.634	rs4911422	chr20:32999345	T/C	cg08999081	chr20:33150536	PIGU	-0.65	-11.29	-0.57	2.22e-24	Glomerular filtration rate (creatinine);
CESC	cis	rs9291683	0.620	rs717615	chr4:10104670	C/T	cg11266682	chr4:10021025	SLC2A9	0.5	9.39	0.5	2.81e-18	Bone mineral density;
CESC	cis	rs950169	1.000	rs1848093	chr15:84755527	G/C	cg17507749	chr15:85114479	UBE2QP1	0.64	7.11	0.4	1.11e-11	Schizophrenia;
CESC	cis	rs2573652	1.000	rs2727198	chr15:100513722	T/C	cg09918751	chr15:100517450	ADAMTS17	-0.38	-7.34	-0.41	2.67e-12	Height;
CESC	cis	rs801193	1.000	rs2286684	chr7:66129830	G/T	cg11764359	chr7:65958608	NA	-0.68	-8.81	-0.48	1.68e-16	Aortic root size;
CESC	cis	rs75229567	0.618	rs35394896	chr12:70188346	T/A	cg10114359	chr12:70132523	RAB3IP	0.75	5.7	0.33	3.26e-8	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg13047596	chr2:233735017	C2orf82	-0.45	-6.03	-0.35	5.54e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs3820068	0.603	rs6429753	chr1:15900537	A/G	cg17385448	chr1:15911702	AGMAT	0.36	5.56	0.32	6.55e-8	Systolic blood pressure;
CESC	cis	rs425277	0.561	rs925906	chr1:2044054	A/C	cg04315214	chr1:2043799	PRKCZ	0.61	10.47	0.54	1.08e-21	Height;
CESC	cis	rs12142240	0.660	rs72886903	chr1:46813860	C/T	cg00530320	chr1:46809349	NSUN4	0.58	7.89	0.44	8.17e-14	Menopause (age at onset);
CESC	cis	rs763014	0.931	rs1981483	chr16:630665	G/A	cg00802000	chr16:706648	WDR90	-0.41	-6.12	-0.35	3.35e-9	Height;
CESC	cis	rs8018808	0.791	rs2205190	chr14:77886723	T/G	cg20045696	chr14:77926864	AHSA1	0.43	5.84	0.34	1.52e-8	Myeloid white cell count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11142944	chr22:35653622	HMGXB4	0.59	6.6	0.38	2.2e-10	Gut microbiome composition (summer);
CESC	cis	rs6582630	0.502	rs11495393	chr12:38341194	T/C	cg26384229	chr12:38710491	ALG10B	0.68	10.14	0.53	1.29e-20	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs7819412	0.522	rs4841497	chr8:10985140	A/G	cg21775007	chr8:11205619	TDH	-0.39	-5.3	-0.31	2.41e-7	Triglycerides;
CESC	cis	rs7216064	1.000	rs56148300	chr17:65892752	T/C	cg07042672	chr17:66097459	LOC651250	-0.61	-7.5	-0.42	9.45e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs35740288	0.545	rs11637283	chr15:86316103	C/T	cg20737812	chr15:86336631	KLHL25	-0.44	-5.22	-0.31	3.61e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
CESC	cis	rs57221529	0.709	rs72707023	chr5:667620	G/A	cg16447950	chr5:562315	NA	-0.64	-6.51	-0.37	3.79e-10	Lung disease severity in cystic fibrosis;
CESC	cis	rs7584330	0.737	rs1497127	chr2:238369282	A/G	cg14458575	chr2:238380390	NA	0.54	7.82	0.43	1.27e-13	Prostate cancer;
CESC	cis	rs4965006	0.591	rs4964913	chr12:132412488	C/A	cg00588090	chr12:132412438	PUS1	-0.56	-8.36	-0.46	3.65e-15	Posterior cortical atrophy and Alzheimer's disease;
CESC	cis	rs7714584	1.000	rs2115069	chr5:150252365	G/A	cg22134413	chr5:150180641	NA	0.55	6.08	0.35	4.25e-9	Crohn's disease;
CESC	cis	rs2836974	0.899	rs8127087	chr21:40544502	C/T	cg27266027	chr21:40555129	PSMG1	0.47	5.67	0.33	3.69e-8	Cognitive function;
CESC	cis	rs7208859	0.623	rs216423	chr17:28942109	G/C	cg04154034	chr17:28927549	LRRC37B2	0.68	6.16	0.35	2.69e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs116161686	0.500	rs76610459	chr1:210050756	T/G	cg25204440	chr1:209979598	IRF6	0.64	6.07	0.35	4.36e-9	Coronary artery disease;
CESC	cis	rs10752881	1.000	rs12028732	chr1:182985525	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.84	13.3	0.63	2.79e-31	Colorectal cancer;
CESC	cis	rs6424115	0.830	rs3003335	chr1:24200052	A/G	cg10978503	chr1:24200527	CNR2	0.33	6.63	0.38	1.85e-10	Immature fraction of reticulocytes;
CESC	cis	rs11690935	0.595	rs788170	chr2:172919958	T/C	cg13550731	chr2:172543902	DYNC1I2	0.5	6.78	0.38	7.88e-11	Schizophrenia;
CESC	cis	rs1915146	0.546	rs9422857	chr10:126861278	C/G	cg05090351	chr10:126851162	NA	0.61	9.35	0.5	3.7e-18	Menarche (age at onset);
CESC	cis	rs6541297	0.941	rs6665258	chr1:230279058	G/A	cg20703242	chr1:230279135	GALNT2	0.68	10.87	0.56	5.47e-23	Coronary artery disease;
CESC	cis	rs9309711	0.506	rs9284794	chr2:3492052	G/A	cg15541040	chr2:3486749	NA	-0.44	-5.67	-0.33	3.81e-8	Neurofibrillary tangles;
CESC	cis	rs7020830	0.861	rs13289001	chr9:37311592	A/G	cg14294708	chr9:37120828	ZCCHC7	1.25	24.48	0.83	5.59e-70	Schizophrenia;
CESC	cis	rs559928	0.606	rs7941773	chr11:63952759	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.66	5.82	0.34	1.7e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CESC	cis	rs7666738	0.830	rs4492007	chr4:98959848	A/T	cg17366294	chr4:99064904	C4orf37	0.59	8.47	0.46	1.71e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1707322	0.752	rs28568986	chr1:46207743	C/T	cg06784218	chr1:46089804	CCDC17	0.41	7.21	0.41	5.75e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7605827	0.930	rs1473178	chr2:15576750	T/C	cg19274914	chr2:15703543	NA	0.34	6.07	0.35	4.38e-9	Educational attainment (years of education);
CESC	cis	rs3782089	0.744	rs11545200	chr11:65319751	G/A	cg00206168	chr11:65308501	LTBP3	0.99	6.62	0.38	2.04e-10	Height;
CESC	cis	rs4974559	0.739	rs28411197	chr4:1279781	C/T	cg02980000	chr4:1222292	CTBP1	0.81	7.39	0.41	1.88e-12	Systolic blood pressure;
CESC	trans	rs7922314	0.571	rs16918003	chr10:64751852	T/C	cg06935979	chr1:232941706	KIAA1383	-0.62	-6.02	-0.35	5.84e-9	Cutaneous psoriasis;
CESC	cis	rs9430161	0.644	rs6685766	chr1:11037051	T/C	cg02454025	chr1:11042201	C1orf127	0.93	14.49	0.66	1.93e-35	Ewing sarcoma;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg12692187	chr10:94353140	KIF11	0.48	6.04	0.35	5.32e-9	Thyroid stimulating hormone;
CESC	cis	rs896854	0.654	rs10104909	chr8:95977973	C/T	cg09323728	chr8:95962352	TP53INP1	-0.41	-8.97	-0.48	5.44e-17	Type 2 diabetes;
CESC	cis	rs2404602	0.692	rs7350777	chr15:76985441	G/A	cg26408565	chr15:76604113	ETFA	-0.39	-5.56	-0.32	6.68e-8	Blood metabolite levels;
CESC	cis	rs3820068	0.581	rs74054797	chr1:15926217	G/A	cg17385448	chr1:15911702	AGMAT	0.41	6.69	0.38	1.33e-10	Systolic blood pressure;
CESC	cis	rs6690583	0.623	rs12047435	chr1:85452927	T/G	cg22153463	chr1:85462885	MCOLN2	0.73	7.14	0.4	8.84e-12	Serum sulfate level;
CESC	cis	rs138880	0.542	rs9616215	chr22:50318834	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.66	-5.4	-0.31	1.5e-7	Schizophrenia;
CESC	cis	rs7943191	0.810	rs7942991	chr11:62337203	A/G	cg22862634	chr11:62369728	EML3;MTA2	-0.47	-6.58	-0.37	2.45e-10	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
CESC	cis	rs1665050	1.000	rs1665050	chr15:59293605	A/G	cg05156742	chr15:59063176	FAM63B	-0.46	-5.58	-0.32	6.01e-8	Atopic dermatitis;
CESC	cis	rs7188697	0.885	rs1646010	chr16:58549204	G/C	cg21335942	chr16:58549945	SETD6	0.46	5.29	0.31	2.55e-7	QT interval;
CESC	cis	rs1018836	0.608	rs6982329	chr8:91467488	A/G	cg16814680	chr8:91681699	NA	-0.51	-7.05	-0.4	1.55e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs10864907	0.614	rs12711745	chr2:113700355	T/C	cg12858261	chr2:113808755	IL1F8	0.45	5.47	0.32	1.03e-7	Pulmonary function;
CESC	cis	rs9905704	0.587	rs2003537	chr17:56611871	C/G	cg12560992	chr17:57184187	TRIM37	-0.65	-6.19	-0.36	2.29e-9	Testicular germ cell tumor;
CESC	cis	rs2439831	0.850	rs8023458	chr15:44080939	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.67	7.78	0.43	1.66e-13	Lung cancer in ever smokers;
CESC	cis	rs2108225	0.872	rs7792139	chr7:107445433	G/A	cg18560240	chr7:107437656	SLC26A3	-0.41	-5.56	-0.32	6.54e-8	Ulcerative colitis;
CESC	trans	rs11098499	0.865	rs11098513	chr4:120316075	A/G	cg25214090	chr10:38739885	LOC399744	0.66	8.84	0.48	1.32e-16	Corneal astigmatism;
CESC	cis	rs3820928	0.874	rs12467261	chr2:227888838	T/C	cg05526886	chr2:227700861	RHBDD1	-0.45	-5.75	-0.33	2.4e-8	Pulmonary function;
CESC	cis	rs1552244	1.000	rs6772315	chr3:10113644	G/A	cg16606324	chr3:10149918	C3orf24	0.43	5.22	0.31	3.71e-7	Alzheimer's disease;
CESC	cis	rs1055129	0.560	rs2305913	chr17:73922941	T/C	cg02678768	chr17:74002944	EVPL	0.41	5.77	0.33	2.17e-8	White matter hyperintensity burden;
CESC	cis	rs34172651	0.517	rs35560136	chr16:24788915	T/A	cg02428538	chr16:24856791	SLC5A11	-0.6	-6.2	-0.36	2.13e-9	Intelligence (multi-trait analysis);
CESC	trans	rs4596713	0.508	rs59620993	chr9:71771911	C/T	cg16512924	chr15:28394682	HERC2	0.5	6.29	0.36	1.33e-9	Headache;
CESC	cis	rs1874326	0.524	rs6968570	chr7:138110039	T/G	cg18008034	chr7:138118925	NA	-0.41	-5.14	-0.3	5.34e-7	Quantitative traits;
CESC	cis	rs9311474	0.597	rs13303	chr3:52558008	T/C	cg18404041	chr3:52824283	ITIH1	-0.37	-6.63	-0.38	1.83e-10	Electroencephalogram traits;
CESC	cis	rs7666738	0.830	rs11935078	chr4:99010476	T/A	cg18180107	chr4:99064573	C4orf37	0.4	5.3	0.31	2.48e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9322193	0.923	rs12205092	chr6:150082511	G/T	cg07701084	chr6:150067640	NUP43	0.43	5.8	0.34	1.85e-8	Lung cancer;
CESC	cis	rs2228479	0.702	rs62052710	chr16:89854893	C/T	cg19635926	chr16:89946313	TCF25	0.67	5.08	0.3	7.19e-7	Skin colour saturation;
CESC	cis	rs3812565	0.530	rs10781538	chr9:139320929	C/G	cg14169450	chr9:139327907	INPP5E	-0.54	-8.7	-0.47	3.65e-16	Granulocyte percentage of myeloid white cells;
CESC	trans	rs11098499	0.954	rs7654587	chr4:120388406	C/T	cg25214090	chr10:38739885	LOC399744	0.7	9.93	0.52	5.63e-20	Corneal astigmatism;
CESC	cis	rs60154123	0.686	rs227222	chr1:210191272	T/C	cg21951975	chr1:209979733	IRF6	-0.56	-5.22	-0.31	3.6e-7	Coronary artery disease;
CESC	trans	rs877282	0.853	rs11595507	chr10:756703	C/T	cg22713356	chr15:30763199	NA	0.93	8.39	0.46	3e-15	Uric acid levels;
CESC	cis	rs858239	0.539	rs57864591	chr7:23184424	T/A	cg23682824	chr7:23144976	KLHL7	0.51	6.69	0.38	1.29e-10	Cerebrospinal fluid biomarker levels;
CESC	cis	rs1552244	0.872	rs35988239	chr3:10074145	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.75	-8.42	-0.46	2.34e-15	Alzheimer's disease;
CESC	trans	rs57221529	0.709	rs72703034	chr5:577101	C/T	cg25482853	chr8:67687455	SGK3	1.01	10.17	0.53	9.74e-21	Lung disease severity in cystic fibrosis;
CESC	cis	rs11098499	0.954	rs12510138	chr4:120423935	C/G	cg09307838	chr4:120376055	NA	0.92	13.14	0.63	1.02e-30	Corneal astigmatism;
CESC	cis	rs13106227	0.550	rs1398017	chr4:77372902	T/C	cg20311846	chr4:77356250	SHROOM3	-0.31	-5.67	-0.33	3.65e-8	Eosinophilic esophagitis (pediatric);
CESC	cis	rs7666738	0.830	rs10516426	chr4:99035827	A/G	cg03676636	chr4:99064102	C4orf37	0.33	5.12	0.3	5.78e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs921968	0.565	rs2272188	chr2:219612282	C/T	cg02176678	chr2:219576539	TTLL4	0.46	8.22	0.45	9.16e-15	Mean corpuscular hemoglobin concentration;
CESC	cis	rs1008375	0.868	rs6816286	chr4:17698088	A/G	cg15017067	chr4:17643749	FAM184B	0.36	5.11	0.3	6.26e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	trans	rs62103177	0.733	rs62103193	chr18:77629217	C/T	cg05926928	chr17:57297772	GDPD1	1.18	10.14	0.53	1.27e-20	Opioid sensitivity;
CESC	cis	rs7000551	0.675	rs2443503	chr8:22381850	A/G	cg12081754	chr8:22256438	SLC39A14	0.44	5.86	0.34	1.37e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CESC	cis	rs4253772	0.591	rs739165	chr22:46684528	C/T	cg00784671	chr22:46762841	CELSR1	-0.58	-5.83	-0.34	1.57e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs3796352	1.000	rs34340609	chr3:53077276	A/G	cg07884673	chr3:53033167	SFMBT1	0.53	5.16	0.3	4.74e-7	Immune reponse to smallpox (secreted IL-2);
CESC	cis	rs7178572	0.568	rs4886856	chr15:77510585	A/G	cg22256960	chr15:77711686	NA	-0.53	-6.69	-0.38	1.33e-10	Type 2 diabetes;
CESC	cis	rs13191362	1.000	rs35575481	chr6:163007746	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.82	8.29	0.45	5.87e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg09199933	chr17:41561366	DHX8	-0.47	-6.31	-0.36	1.17e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs6741892	0.536	rs11688977	chr2:38896631	C/T	cg08308459	chr2:38893161	GALM	-0.53	-6.47	-0.37	4.75e-10	5-HTT brain serotonin transporter levels;
CESC	cis	rs6502050	0.799	rs9675196	chr17:80096655	C/T	cg23985595	chr17:80112537	CCDC57	-0.41	-6.4	-0.37	7.08e-10	Life satisfaction;
CESC	trans	rs877282	0.842	rs35117541	chr10:764683	C/T	cg22713356	chr15:30763199	NA	1.16	11.35	0.57	1.37e-24	Uric acid levels;
CESC	cis	rs17666538	0.539	rs1703925	chr8:608279	A/G	cg23958373	chr8:599963	NA	0.81	5.87	0.34	1.27e-8	IgG glycosylation;
CESC	cis	rs1448094	0.511	rs34885805	chr12:86155180	A/T	cg02569458	chr12:86230093	RASSF9	0.51	7.7	0.43	2.65e-13	Major depressive disorder;
CESC	cis	rs67311347	1.000	rs34762643	chr3:40475433	C/T	cg09455208	chr3:40491958	NA	0.44	7.53	0.42	8.04e-13	Renal cell carcinoma;
CESC	cis	rs6831352	0.691	rs2602887	chr4:100041473	A/G	cg13256891	chr4:100009986	ADH5	0.71	7.42	0.41	1.62e-12	Alcohol dependence;
CESC	cis	rs10256972	0.527	rs2949170	chr7:1216438	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.48	-6.8	-0.39	6.94e-11	Longevity;Endometriosis;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg09985698	chr21:45759020	C21orf2	-0.46	-6.02	-0.35	5.85e-9	Fibrinogen levels;
CESC	cis	rs2243480	1.000	rs4548056	chr7:65298873	A/G	cg12463550	chr7:65579703	CRCP	0.7	5.83	0.34	1.6e-8	Diabetic kidney disease;
CESC	cis	rs6754311	0.731	rs2322660	chr2:136557319	A/G	cg15123519	chr2:136567270	LCT	-0.34	-5.81	-0.34	1.76e-8	Mosquito bite size;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg05943971	chr1:151763686	TDRKH	-0.51	-6.08	-0.35	4.08e-9	Ulcerative colitis;
CESC	cis	rs9916302	0.706	rs8182252	chr17:37727950	T/C	cg15445000	chr17:37608096	MED1	-0.37	-5.15	-0.3	5.01e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs9913156	0.793	rs72835642	chr17:4573407	T/C	cg00122941	chr17:4613640	ARRB2	0.88	10.19	0.53	8.39e-21	Lymphocyte counts;
CESC	cis	rs854765	0.663	rs1108648	chr17:17750558	G/A	cg04398451	chr17:18023971	MYO15A	0.66	9.54	0.51	9.7e-19	Total body bone mineral density;
CESC	cis	rs2066819	1.000	rs17118403	chr12:56630067	C/T	cg26734620	chr12:56694298	CS	1.05	6.75	0.38	9.35e-11	Psoriasis vulgaris;
CESC	cis	rs3008870	0.755	rs2815362	chr1:67496803	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.6	7.83	0.43	1.17e-13	Lymphocyte percentage of white cells;
CESC	cis	rs1962636	1	rs1962636	chr16:22064395	A/C	cg09370801	chr16:22207107	NA	0.55	8.18	0.45	1.18e-14	Schizophrenia;
CESC	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg04025307	chr7:1156635	C7orf50	0.41	5.21	0.31	3.71e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs478304	0.651	rs4930319	chr11:65555458	G/C	cg10518572	chr11:65560635	OVOL1	-0.31	-5.8	-0.34	1.91e-8	Acne (severe);
CESC	cis	rs9611565	0.546	rs739132	chr22:42123099	A/T	cg17376030	chr22:41985996	PMM1	-0.79	-8.55	-0.46	1e-15	Vitiligo;
CESC	cis	rs820218	0.886	rs820158	chr17:73660179	A/G	cg01592526	chr17:73663357	RECQL5;SAP30BP	0.44	5.6	0.33	5.49e-8	Rotator cuff tears;
CESC	cis	rs710216	0.917	rs3754223	chr1:43419091	A/T	cg03128534	chr1:43423976	SLC2A1	0.56	6.51	0.37	3.75e-10	Red cell distribution width;
CESC	cis	rs8062405	1.000	rs72793811	chr16:28839392	G/A	cg05966235	chr16:28915196	ATP2A1	0.35	5.12	0.3	5.8e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs11750568	1.000	rs931617	chr5:178514893	A/C	cg10208897	chr5:178548229	ADAMTS2	0.38	5.34	0.31	2.02e-7	Height;
CESC	cis	rs9457247	0.602	rs4710175	chr6:167467800	A/G	cg07741184	chr6:167504864	NA	0.37	6.37	0.36	8.32e-10	Crohn's disease;
CESC	cis	rs561341	0.830	rs2301765	chr17:30202056	T/A	cg13647721	chr17:30228624	UTP6	-0.61	-5.68	-0.33	3.47e-8	Hip circumference adjusted for BMI;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg20488697	chr17:79885644	LOC92659;MAFG	0.48	6.26	0.36	1.56e-9	Systemic lupus erythematosus;
CESC	cis	rs34779708	0.931	rs7079498	chr10:35375344	C/T	cg04310649	chr10:35416472	CREM	-0.52	-6.42	-0.37	6.25e-10	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs10464366	0.544	rs4355688	chr7:39158402	C/T	cg18850127	chr7:39170497	POU6F2	0.39	5.51	0.32	8.38e-8	IgG glycosylation;
CESC	cis	rs6540556	0.723	rs11119336	chr1:209930585	G/C	cg05527609	chr1:210001259	C1orf107	-0.67	-7.91	-0.44	7.01e-14	Red blood cell count;
CESC	cis	rs736408	0.716	rs2239549	chr3:52823126	C/T	cg18337363	chr3:52569053	NT5DC2	0.3	5.17	0.3	4.59e-7	Bipolar disorder;
CESC	cis	rs1008375	1.000	rs11722037	chr4:17683811	G/A	cg02297831	chr4:17616191	MED28	0.43	5.58	0.32	5.94e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs9287719	0.870	rs728135	chr2:10745132	A/C	cg02196655	chr2:10830764	NOL10	-0.38	-5.78	-0.33	2.05e-8	Prostate cancer;
CESC	cis	rs5753618	0.504	rs8138525	chr22:32011929	T/C	cg02404636	chr22:31891804	SFI1	-0.42	-5.55	-0.32	6.77e-8	Colorectal cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08140891	chr1:154955627	FLAD1	0.61	7.45	0.42	1.35e-12	Gut microbiome composition (summer);
CESC	cis	rs9457247	1.000	rs1794693	chr6:167405670	T/C	cg25258033	chr6:167368657	RNASET2	0.39	5.89	0.34	1.15e-8	Crohn's disease;
CESC	cis	rs12142240	0.698	rs1057533	chr1:46815836	C/T	cg00530320	chr1:46809349	NSUN4	0.58	7.89	0.44	8.17e-14	Menopause (age at onset);
CESC	cis	rs1009170	0.718	rs7152335	chr14:92590839	T/C	cg10324096	chr14:92587714	CPSF2;NDUFB1	0.54	5.1	0.3	6.61e-7	Dialysis-related mortality;
CESC	cis	rs1499972	0.941	rs55958116	chr3:117672772	C/T	cg07612923	chr3:117604196	NA	0.89	7.41	0.41	1.71e-12	Schizophrenia;
CESC	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg18538332	chr22:24372958	LOC391322	-0.78	-11.51	-0.58	3.97e-25	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs7605378	0.528	rs281767	chr2:200823281	C/A	cg17644776	chr2:200775616	C2orf69	0.52	6.36	0.36	8.92e-10	Osteoporosis;
CESC	cis	rs950776	0.593	rs680244	chr15:78871288	T/C	cg24631222	chr15:78858424	CHRNA5	0.44	5.61	0.33	5.17e-8	Sudden cardiac arrest;
CESC	cis	rs7809950	0.817	rs2253833	chr7:107205669	A/G	cg23024343	chr7:107201750	COG5	0.56	7.22	0.41	5.59e-12	Coronary artery disease;
CESC	cis	rs7107174	0.901	rs11237459	chr11:78056273	A/C	cg02023728	chr11:77925099	USP35	0.4	5.79	0.34	2e-8	Testicular germ cell tumor;
CESC	cis	rs7666738	0.927	rs11736876	chr4:98987206	A/G	cg05340658	chr4:99064831	C4orf37	0.59	7.9	0.44	7.64e-14	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9311474	0.508	rs6786919	chr3:52599789	A/G	cg05564831	chr3:52568323	NT5DC2	0.47	7.43	0.42	1.48e-12	Electroencephalogram traits;
CESC	cis	rs1862618	0.853	rs832578	chr5:56164223	C/T	cg22800045	chr5:56110881	MAP3K1	0.79	9.7	0.51	3.11e-19	Initial pursuit acceleration;
CESC	cis	rs13223928	0.516	rs1872880	chr7:3148389	G/C	cg19214707	chr7:3157722	NA	-0.45	-6.15	-0.35	2.77e-9	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
CESC	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg20887711	chr4:1340912	KIAA1530	0.86	11.47	0.58	5.29e-25	Longevity;
CESC	trans	rs11098499	0.863	rs9884402	chr4:120489982	A/G	cg25214090	chr10:38739885	LOC399744	0.64	8.69	0.47	3.86e-16	Corneal astigmatism;
CESC	cis	rs11255291	0.668	rs6602265	chr10:7732939	A/G	cg26051552	chr10:7670683	ITIH5	0.37	5.24	0.31	3.28e-7	Ovarian reserve;
CESC	cis	rs2228479	0.867	rs17784386	chr16:89947457	A/G	cg06558623	chr16:89946397	TCF25	1.06	8.98	0.48	5.17e-17	Skin colour saturation;
CESC	cis	rs6460942	0.915	rs62448593	chr7:12436845	G/C	cg10578991	chr7:12443926	VWDE	-0.51	-5.67	-0.33	3.75e-8	Coronary artery disease;
CESC	cis	rs478304	0.593	rs4645927	chr11:65482827	C/T	cg27068330	chr11:65405492	SIPA1	-0.47	-5.51	-0.32	8.36e-8	Acne (severe);
CESC	cis	rs597539	0.731	rs664229	chr11:68624483	C/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.81	9.91	0.52	6.77e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	trans	rs931812	0.757	rs4734492	chr8:101901901	C/T	cg20993868	chr7:22813445	NA	-0.44	-6.85	-0.39	5.16e-11	Attention deficit hyperactivity disorder and conduct disorder;
CESC	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.52	7.1	0.4	1.17e-11	Lymphocyte counts;
CESC	cis	rs6011002	1.000	rs75451331	chr20:62316834	G/T	cg15212369	chr20:62274085	STMN3	-0.59	-5.15	-0.3	5.18e-7	Dental caries;
CESC	cis	rs6456156	0.586	rs12213683	chr6:167460718	G/A	cg23791538	chr6:167370224	RNASET2	-0.49	-6.37	-0.36	8.2e-10	Primary biliary cholangitis;
CESC	cis	rs12497850	0.931	rs3774628	chr3:48801840	C/T	cg07636037	chr3:49044803	WDR6	0.96	17.3	0.73	2.1e-45	Parkinson's disease;
CESC	cis	rs12325245	0.536	rs12925676	chr16:58625326	C/T	cg01152986	chr16:58549298	SETD6	0.86	5.07	0.3	7.48e-7	Schizophrenia;
CESC	cis	rs10927875	0.632	rs4481843	chr1:16128205	G/A	cg21385522	chr1:16154831	NA	-1.03	-16.84	-0.72	9.42e-44	Dilated cardiomyopathy;
CESC	cis	rs853679	0.517	rs9468298	chr6:28122345	A/G	cg23281280	chr6:28129359	ZNF389	0.6	7.95	0.44	5.53e-14	Depression;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg20811730	chr1:150293902	PRPF3	-0.47	-6.25	-0.36	1.59e-9	Fibrinogen levels;
CESC	cis	rs9837602	0.529	rs793458	chr3:99520169	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.62	-9.72	-0.51	2.66e-19	Breast cancer;
CESC	cis	rs9649213	0.593	rs736754	chr7:97931559	C/T	cg00277769	chr7:97922759	BAIAP2L1	-0.34	-5.62	-0.33	4.89e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs4481887	1.000	rs4360553	chr1:248467092	A/G	cg00666640	chr1:248458726	OR2T12	0.4	6.54	0.37	3.2e-10	Common traits (Other);
CESC	cis	rs17253792	0.822	rs10148122	chr14:56146694	G/T	cg01858014	chr14:56050164	KTN1	-0.94	-7.57	-0.42	6.2800000000000005e-13	Putamen volume;
CESC	cis	rs6674176	0.935	rs4314918	chr1:44377503	G/A	cg23954153	chr1:44402353	ARTN	-0.35	-5.05	-0.3	8.42e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs9325144	0.600	rs7965877	chr12:38743697	G/T	cg26384229	chr12:38710491	ALG10B	0.56	8.07	0.44	2.52e-14	Morning vs. evening chronotype;
CESC	trans	rs4332037	0.707	rs62435132	chr7:1891315	C/T	cg11693508	chr17:37793320	STARD3	0.61	6.18	0.35	2.45e-9	Bipolar disorder;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg20372048	chr12:82752172	CCDC59;C12orf26	-0.46	-6.03	-0.35	5.44e-9	Asthma;
CESC	cis	rs2228479	0.850	rs11647174	chr16:89958538	G/A	cg00800038	chr16:89945340	TCF25	-0.94	-7.87	-0.44	9.24e-14	Skin colour saturation;
CESC	cis	rs9388451	0.839	rs3966775	chr6:126067655	C/A	cg05901451	chr6:126070800	HEY2	-0.64	-9.14	-0.49	1.69e-17	Brugada syndrome;
CESC	cis	rs9486719	0.656	rs6924957	chr6:96853579	G/T	cg06623918	chr6:96969491	KIAA0776	0.76	8.91	0.48	8.52e-17	Migraine;Coronary artery disease;
CESC	cis	rs597539	0.617	rs686348	chr11:68636996	A/G	cg18350739	chr11:68623251	NA	-0.46	-7.02	-0.4	1.88e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg07216194	chr8:27182965	PTK2B	-0.48	-6.23	-0.36	1.79e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs698833	0.892	rs698796	chr2:44689669	C/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.48	6.11	0.35	3.56e-9	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs854765	0.647	rs7211714	chr17:17986955	A/G	cg16928487	chr17:17741425	SREBF1	-0.55	-8.99	-0.48	4.8e-17	Total body bone mineral density;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08844988	chr16:24741147	TNRC6A	0.54	6.62	0.38	1.98e-10	Gut microbiome composition (summer);
CESC	cis	rs7100689	0.784	rs4934083	chr10:82116501	G/C	cg00277334	chr10:82204260	NA	-0.59	-7.34	-0.41	2.65e-12	Post bronchodilator FEV1;
CESC	cis	rs9733	0.650	rs6698495	chr1:150564476	T/C	cg13175981	chr1:150552382	MCL1	0.72	10.66	0.55	2.52e-22	Tonsillectomy;
CESC	cis	rs909002	0.720	rs4949459	chr1:32142354	G/T	cg13919466	chr1:32135498	COL16A1	-0.39	-6.71	-0.38	1.17e-10	Intelligence (multi-trait analysis);
CESC	cis	rs5769765	0.862	rs56377703	chr22:50306940	C/T	cg02269571	chr22:50332266	NA	-0.54	-6.58	-0.37	2.44e-10	Schizophrenia;
CESC	cis	rs684232	0.602	rs4968057	chr17:517521	T/A	cg15660573	chr17:549704	VPS53	-0.81	-11.88	-0.59	2.24e-26	Prostate cancer;
CESC	cis	rs11166927	0.548	rs9324514	chr8:140830241	A/G	cg16909799	chr8:140841666	TRAPPC9	0.63	9.9	0.52	7.29e-20	Pediatric non-alcoholic fatty liver disease activity score;
CESC	cis	rs116095464	0.558	rs56342538	chr5:225796	T/C	cg22857025	chr5:266934	NA	-1.27	-18.88	-0.76	5.63e-51	Breast cancer;
CESC	cis	rs2836974	0.863	rs8132333	chr21:40527900	A/G	cg11890956	chr21:40555474	PSMG1	1.17	23.27	0.82	5.24e-66	Cognitive function;
CESC	cis	rs514406	0.929	rs515857	chr1:53336859	A/G	cg08859206	chr1:53392774	SCP2	-0.49	-6.31	-0.36	1.19e-9	Monocyte count;
CESC	cis	rs1003719	0.667	rs6517404	chr21:38494918	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.52	6.89	0.39	4.09e-11	Eye color traits;
CESC	cis	rs2777491	1.000	rs2730055	chr15:41735708	C/A	cg18705301	chr15:41695430	NDUFAF1	-0.65	-9.98	-0.52	4.09e-20	Ulcerative colitis;
CESC	trans	rs801193	1.000	rs2659912	chr7:66157999	G/C	cg26939375	chr7:64535504	NA	0.64	8.77	0.47	2.21e-16	Aortic root size;
CESC	cis	rs7772486	0.875	rs10872583	chr6:146396699	G/T	cg05347473	chr6:146136440	FBXO30	-0.52	-6.75	-0.38	9.11e-11	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs1005277	0.579	rs1740737	chr10:38499365	G/T	cg27523141	chr10:43048294	ZNF37B	0.46	6.04	0.35	5.31e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs3762637	1.000	rs9843165	chr3:122131111	G/C	cg24169773	chr3:122142474	KPNA1	-0.5	-6.02	-0.35	5.76e-9	LDL cholesterol levels;
CESC	cis	rs2991971	1.000	rs9147	chr1:46016687	T/C	cg03146154	chr1:46216737	IPP	-0.44	-5.5	-0.32	9.01e-8	High light scatter reticulocyte count;
CESC	cis	rs4955124	0.558	rs17028710	chr3:32037880	T/C	cg05935571	chr3:32023257	ZNF860;OSBPL10	0.96	7.02	0.4	1.91e-11	Schizophrenia;
CESC	cis	rs7208859	0.524	rs8069400	chr17:29075967	G/T	cg14008862	chr17:28927542	LRRC37B2	0.68	5.45	0.32	1.14e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs10504229	0.953	rs78089850	chr8:58171557	A/G	cg05313129	chr8:58192883	C8orf71	-0.53	-6.1	-0.35	3.81e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs7264396	0.832	rs224381	chr20:34097136	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.43	-5.05	-0.3	8.18e-7	Total cholesterol levels;
CESC	cis	rs12586317	0.511	rs113770696	chr14:35444383	C/T	cg16230307	chr14:35515116	FAM177A1	0.96	10.66	0.55	2.55e-22	Psoriasis;
CESC	cis	rs561341	1.000	rs546519	chr17:30297682	T/G	cg19193384	chr17:30244184	NA	-0.61	-6.41	-0.37	6.51e-10	Hip circumference adjusted for BMI;
CESC	cis	rs4713118	0.621	rs9295755	chr6:28033174	C/T	cg18032046	chr6:28092343	ZSCAN16	0.47	5.36	0.31	1.77e-7	Parkinson's disease;
CESC	cis	rs12618769	0.652	rs7588254	chr2:99217785	G/T	cg10123293	chr2:99228465	UNC50	0.38	5.06	0.3	7.85e-7	Bipolar disorder;
CESC	cis	rs4555082	1.000	rs7146683	chr14:105759385	A/G	cg13114125	chr14:105738426	BRF1	-0.72	-9.25	-0.49	7.83e-18	Mean platelet volume;Platelet distribution width;
CESC	cis	rs9309473	1.000	rs7576245	chr2:73829678	C/T	cg20560298	chr2:73613845	ALMS1	-0.47	-6.32	-0.36	1.11e-9	Metabolite levels;
CESC	cis	rs6922893	1.000	rs6900011	chr6:71667550	C/G	cg10766373	chr6:71666121	B3GAT2	-0.32	-5.09	-0.3	6.83e-7	Obesity-related traits;
CESC	cis	rs7843479	0.965	rs11135742	chr8:21802910	A/T	cg17168535	chr8:21777572	XPO7	0.5	6.9	0.39	3.73e-11	Mean corpuscular volume;
CESC	cis	rs7618915	0.501	rs10865974	chr3:52718280	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.58	-8.42	-0.46	2.36e-15	Bipolar disorder;
CESC	cis	rs16854884	0.558	rs6768153	chr3:143667429	C/A	cg06585982	chr3:143692056	C3orf58	0.55	7.37	0.41	2.13e-12	Economic and political preferences (feminism/equality);
CESC	cis	rs329122	0.528	rs329117	chr5:133860101	T/C	cg26284174	chr5:133860141	NA	0.47	5.49	0.32	9.57e-8	Body mass index;Type 2 diabetes;
CESC	cis	rs7834588	0.526	rs7008796	chr8:63866789	C/A	cg20602954	chr8:63776762	NKAIN3	0.32	5.03	0.3	9.22e-7	Response to Vitamin E supplementation;
CESC	trans	rs2832077	0.527	rs9980449	chr21:30224889	G/C	cg14791747	chr16:20752902	THUMPD1	0.53	7.48	0.42	1.12e-12	Cognitive test performance;
CESC	cis	rs9837602	0.551	rs1630555	chr3:99423273	A/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.38	-5.27	-0.31	2.86e-7	Breast cancer;
CESC	cis	rs6860806	0.661	rs1588263	chr5:131577158	T/C	cg18301423	chr5:131593218	PDLIM4	0.39	5.5	0.32	8.96e-8	Breast cancer;
CESC	cis	rs12458462	0.892	rs2007483	chr18:77476131	A/T	cg11879182	chr18:77439856	CTDP1	0.87	13.84	0.65	3.9e-33	Monocyte count;
CESC	cis	rs7811142	0.830	rs1063945	chr7:99930447	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.09	11.28	0.57	2.4e-24	Platelet count;
CESC	cis	rs367943	0.637	rs10039956	chr5:113010928	G/A	cg12552261	chr5:112820674	MCC	0.48	5.74	0.33	2.54e-8	Type 2 diabetes;
CESC	cis	rs2085601	0.509	rs1458558	chr4:89887620	C/T	cg17769793	chr4:89976368	FAM13A	-0.35	-5.65	-0.33	4.04e-8	Hair greying;
CESC	cis	rs34779708	0.931	rs7099036	chr10:35349574	C/T	cg04310649	chr10:35416472	CREM	-0.52	-6.25	-0.36	1.65e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs6570726	0.967	rs441364	chr6:145853662	G/C	cg05347473	chr6:146136440	FBXO30	0.4	5.2	0.3	4.08e-7	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1707322	1.000	rs785490	chr1:46577124	T/C	cg06784218	chr1:46089804	CCDC17	-0.36	-5.93	-0.34	9.35e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs11958404	0.932	rs12514557	chr5:157418954	T/C	cg05962755	chr5:157440814	NA	0.62	6.72	0.38	1.08e-10	IgG glycosylation;
CESC	trans	rs1814175	0.587	rs7937757	chr11:49978342	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.43	-6.26	-0.36	1.53e-9	Height;
CESC	cis	rs7680126	0.530	rs2903827	chr4:10175872	C/G	cg00071950	chr4:10020882	SLC2A9	-0.52	-5.94	-0.34	8.79e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	cis	rs1799949	1.000	rs4793189	chr17:41190715	G/A	cg25072359	chr17:41440525	NA	0.5	6.47	0.37	4.61e-10	Menopause (age at onset);
CESC	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg04025307	chr7:1156635	C7orf50	0.57	10.24	0.53	5.83e-21	Longevity;Endometriosis;
CESC	cis	rs853679	0.517	rs1904841	chr6:28108085	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.52	-6.05	-0.35	5.02e-9	Depression;
CESC	cis	rs11227306	0.902	rs625652	chr11:65641931	T/A	cg00576331	chr11:65640516	EFEMP2	0.47	6.04	0.35	5.18e-9	DNA methylation (variation);
CESC	cis	rs6089584	0.816	rs6061410	chr20:60625329	A/G	cg06108461	chr20:60628389	TAF4	-0.92	-14.32	-0.66	7.92e-35	Body mass index;
CESC	cis	rs847577	0.569	rs35101190	chr7:97695888	G/A	cg21770322	chr7:97807741	LMTK2	0.82	14.59	0.67	8.56e-36	Breast cancer;
CESC	cis	rs9325144	0.647	rs1875609	chr12:39018259	C/T	cg26384229	chr12:38710491	ALG10B	-0.54	-7.57	-0.42	6.4e-13	Morning vs. evening chronotype;
CESC	cis	rs9929218	0.906	rs4783565	chr16:68750190	G/A	cg02972257	chr16:68554789	NA	0.58	6.67	0.38	1.5e-10	Colorectal cancer;
CESC	cis	rs6951245	0.810	rs117800627	chr7:1081075	G/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.6	6.79	0.38	7.38e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs780096	0.526	rs72819536	chr2:27682850	G/T	cg22903471	chr2:27725779	GCKR	-0.55	-7.77	-0.43	1.69e-13	Total body bone mineral density;
CESC	cis	rs9905704	0.633	rs2632506	chr17:56467408	G/T	cg12560992	chr17:57184187	TRIM37	-0.61	-5.75	-0.33	2.49e-8	Testicular germ cell tumor;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02546072	chr22:39898416	SMCR7L	0.56	6.33	0.36	1.04e-9	Gut microbiome composition (summer);
CESC	cis	rs2191566	0.960	rs56171514	chr19:44506110	G/C	cg20607764	chr19:44506953	ZNF230	-0.51	-6.56	-0.37	2.82e-10	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg19723775	chr5:179050963	HNRNPH1	0.44	5.91	0.34	1.03e-8	Lung cancer;
CESC	cis	rs1707322	0.927	rs6690386	chr1:46253011	C/T	cg05343316	chr1:45956843	TESK2	0.49	6.05	0.35	4.99e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2842992	0.789	rs4235925	chr6:160202860	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.73	9.35	0.5	3.83e-18	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs11098499	0.754	rs1814813	chr4:120258207	G/T	cg09307838	chr4:120376055	NA	-0.77	-10.94	-0.56	3.23e-23	Corneal astigmatism;
CESC	cis	rs868036	1.000	rs1026734	chr15:68100950	T/C	cg08079166	chr15:68083412	MAP2K5	0.44	6.94	0.39	2.94e-11	Restless legs syndrome;
CESC	cis	rs7927771	1.000	rs7120333	chr11:47817441	C/T	cg18512352	chr11:47633146	NA	-0.6	-9.57	-0.51	8.16e-19	Subjective well-being;
CESC	cis	rs6502050	0.731	rs35156322	chr17:80096323	T/C	cg23985595	chr17:80112537	CCDC57	-0.42	-6.6	-0.38	2.18e-10	Life satisfaction;
CESC	cis	rs67311347	1.000	rs9882171	chr3:40518821	G/A	cg01475735	chr3:40494733	NA	-0.42	-5.41	-0.32	1.38e-7	Renal cell carcinoma;
CESC	cis	rs9457247	0.967	rs388406	chr6:167409562	A/G	cg23791538	chr6:167370224	RNASET2	-0.61	-8.81	-0.48	1.62e-16	Crohn's disease;
CESC	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg07677032	chr17:61819896	STRADA	0.46	6.21	0.36	2.06e-9	Prudent dietary pattern;
CESC	cis	rs3820068	0.626	rs61103742	chr1:15909153	A/C	cg17385448	chr1:15911702	AGMAT	0.42	6.66	0.38	1.6e-10	Systolic blood pressure;
CESC	cis	rs7949030	0.596	rs11231137	chr11:62315699	G/A	cg02375832	chr11:62437615	C11orf48	-0.39	-5.46	-0.32	1.08e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs919433	0.963	rs12693815	chr2:198168403	T/C	cg03934865	chr2:198174659	NA	-0.4	-5.54	-0.32	7.21e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs13118159	0.778	rs12650998	chr4:1338832	T/C	cg13395646	chr4:1353034	KIAA1530	-0.4	-5.26	-0.31	3.01e-7	Longevity;
CESC	cis	rs4561483	0.549	rs33659	chr16:11963361	A/G	cg08843971	chr16:11963173	GSPT1	-0.55	-7.95	-0.44	5.25e-14	Testicular germ cell tumor;
CESC	cis	rs2721195	0.967	rs748193	chr8:145682115	C/T	cg11211951	chr8:145729740	GPT	0.42	6.94	0.39	3.07e-11	Age at first birth;
CESC	cis	rs17253792	0.822	rs79747476	chr14:56160485	C/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.81	5.67	0.33	3.65e-8	Putamen volume;
CESC	trans	rs1285495	0.627	rs10912059	chr1:187354887	C/T	cg20118422	chr15:64455210	PPIB	-0.47	-6.1	-0.35	3.81e-9	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16060664	chr8:42010866	AP3M2	0.54	6.2	0.36	2.15e-9	Gut microbiome composition (summer);
CESC	cis	rs7618915	0.547	rs11130313	chr3:52676190	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	7.01	0.4	2e-11	Bipolar disorder;
CESC	cis	rs7927771	0.524	rs12421563	chr11:47780222	G/A	cg05585544	chr11:47624801	NA	-0.32	-5.11	-0.3	6.09e-7	Subjective well-being;
CESC	cis	rs7618915	0.501	rs3755798	chr3:52741160	G/A	cg07507251	chr3:52567010	NT5DC2	0.32	5.54	0.32	7.3e-8	Bipolar disorder;
CESC	cis	rs2637266	1.000	rs7478008	chr10:78355575	T/A	cg18941641	chr10:78392320	NA	0.42	7.79	0.43	1.49e-13	Pulmonary function;
CESC	cis	rs16857609	0.564	rs12624106	chr2:218290445	A/G	cg15335768	chr2:218268053	DIRC3	-0.38	-5.34	-0.31	1.96e-7	Breast cancer;Breast cancer (estrogen-receptor negative);
CESC	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg14820908	chr5:178986412	RUFY1	-0.5	-7.8	-0.43	1.43e-13	Lung cancer;
CESC	cis	rs826838	0.874	rs10880943	chr12:38734317	C/T	cg13010199	chr12:38710504	ALG10B	0.62	8.9	0.48	8.97e-17	Heart rate;
CESC	cis	rs736408	0.509	rs1108842	chr3:52720080	A/C	cg17372223	chr3:52568218	NT5DC2	0.45	7.54	0.42	7.38e-13	Bipolar disorder;
CESC	cis	rs208520	0.770	rs1342960	chr6:66883514	T/C	cg07460842	chr6:66804631	NA	-0.94	-12.15	-0.6	2.75e-27	Exhaled nitric oxide output;
CESC	cis	rs9611565	0.608	rs202652	chr22:41838792	A/G	cg06481639	chr22:41940642	POLR3H	0.52	5.68	0.33	3.48e-8	Vitiligo;
CESC	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg05863683	chr7:1912471	MAD1L1	0.38	5.64	0.33	4.43e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs2296225	0.722	rs900037	chr1:21057788	C/T	cg24673385	chr1:21051448	SH2D5	0.35	5.65	0.33	4.13e-8	Eosinophilic esophagitis;
CESC	cis	rs1448094	0.512	rs7302741	chr12:86237127	C/T	cg00310523	chr12:86230176	RASSF9	0.37	5.65	0.33	4.22e-8	Major depressive disorder;
CESC	cis	rs2033711	0.840	rs3764533	chr19:58929194	A/G	cg11952622	chr19:58962976	ZNF324B	0.52	6.93	0.39	3.12e-11	Uric acid clearance;
CESC	cis	rs514406	0.800	rs4926930	chr1:53217335	A/G	cg08859206	chr1:53392774	SCP2	0.54	7.12	0.4	1.03e-11	Monocyte count;
CESC	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-6.21	-0.36	2.01e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs10857712	0.703	rs1056521	chr10:135235890	T/C	cg01444801	chr10:135216882	MTG1	-0.46	-5.26	-0.31	2.91e-7	Systemic lupus erythematosus;
CESC	cis	rs8014204	0.935	rs4903267	chr14:75360419	G/T	cg26191576	chr14:75389716	RPS6KL1	0.36	5.17	0.3	4.61e-7	Caffeine consumption;
CESC	cis	rs875971	0.862	rs2420174	chr7:65645361	C/T	cg12463550	chr7:65579703	CRCP	-0.49	-6.21	-0.36	2.06e-9	Aortic root size;
CESC	cis	rs8177253	0.965	rs4854761	chr3:133498789	A/G	cg01448562	chr3:133502909	NA	0.4	5.56	0.32	6.52e-8	Iron status biomarkers;
CESC	cis	rs72945132	0.825	rs57871058	chr11:70192344	T/C	cg14191688	chr11:70257035	CTTN	0.4	5.05	0.3	8.13e-7	Coronary artery disease;
CESC	cis	rs12701220	0.655	rs7778968	chr7:1144622	C/G	cg26769984	chr7:1090371	C7orf50	0.53	6.37	0.36	8.49e-10	Bronchopulmonary dysplasia;
CESC	cis	rs4450798	0.793	rs79204004	chr3:13758473	G/C	cg23332027	chr3:13681764	NA	0.4	5.55	0.32	6.83e-8	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs1799949	0.930	rs33968979	chr17:41297992	G/T	cg06001716	chr17:41278141	BRCA1;NBR2	0.39	5.26	0.31	3e-7	Menopause (age at onset);
CESC	cis	rs7429990	0.965	rs28637561	chr3:48021018	G/A	cg11946769	chr3:48343235	NME6	-0.44	-5.38	-0.31	1.65e-7	Educational attainment (years of education);
CESC	cis	rs12545109	0.879	rs2609994	chr8:57365844	A/G	cg09654669	chr8:57350985	NA	-0.57	-6.67	-0.38	1.46e-10	Obesity-related traits;
CESC	cis	rs7193541	0.684	rs9931225	chr16:74699293	T/C	cg01733217	chr16:74700730	RFWD3	1.08	22.1	0.81	4.71e-62	Multiple myeloma;
CESC	cis	rs4835473	0.932	rs11725708	chr4:144696836	T/C	cg25736465	chr4:144833511	NA	-0.33	-5.18	-0.3	4.39e-7	Immature fraction of reticulocytes;
CESC	cis	rs736408	0.677	rs2286798	chr3:52821177	G/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.45	-5.76	-0.33	2.32e-8	Bipolar disorder;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg12112058	chr1:224622605	WDR26	-0.47	-6.86	-0.39	4.89e-11	Gambling;
CESC	cis	rs67311347	0.955	rs11719205	chr3:40417258	G/A	cg24209194	chr3:40518798	ZNF619	0.44	5.82	0.34	1.72e-8	Renal cell carcinoma;
CESC	cis	rs35306767	0.953	rs7908138	chr10:962978	C/T	cg25019033	chr10:957182	NA	-0.67	-8.16	-0.45	1.4e-14	Eosinophil percentage of granulocytes;
CESC	cis	rs7618915	0.570	rs11130319	chr3:52755592	A/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	5.58	0.32	5.93e-8	Bipolar disorder;
CESC	cis	rs8020095	0.528	rs28521373	chr14:67738075	T/C	cg19548862	chr14:67692701	FAM71D	-0.45	-5.44	-0.32	1.2e-7	Depression (quantitative trait);
CESC	cis	rs7811142	0.830	rs41280971	chr7:99954457	G/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.13	11.76	0.59	5.69e-26	Platelet count;
CESC	cis	rs8060686	0.623	rs6499157	chr16:68105474	A/C	cg26727032	chr16:67993705	SLC12A4	-0.6	-8.9	-0.48	8.84e-17	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs9894429	0.646	rs8079963	chr17:79603285	C/T	cg21984481	chr17:79567631	NPLOC4	-0.35	-5.34	-0.31	1.97e-7	Eye color traits;
CESC	cis	rs898097	0.841	rs2271918	chr17:80861206	A/G	cg15664640	chr17:80829946	TBCD	-0.67	-9.43	-0.5	2.15e-18	Breast cancer;
CESC	cis	rs7674212	0.570	rs2711899	chr4:104062414	T/C	cg16532752	chr4:104119610	CENPE	-0.38	-5.1	-0.3	6.54e-7	Type 2 diabetes;
CESC	cis	rs875971	0.862	rs12537823	chr7:65720884	C/T	cg10691866	chr7:65817282	TPST1	-0.3	-5.17	-0.3	4.54e-7	Aortic root size;
CESC	cis	rs763121	0.853	rs138704	chr22:39133410	A/G	cg06544989	chr22:39130855	UNC84B	0.49	9.04	0.49	3.36e-17	Menopause (age at onset);
CESC	cis	rs11711311	1.000	rs9855613	chr3:113448455	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.57	7.68	0.43	3.09e-13	IgG glycosylation;
CESC	cis	rs4722166	0.598	rs4722171	chr7:22785717	A/G	cg05265849	chr7:22767390	IL6	0.57	7.08	0.4	1.31e-11	Lung cancer;
CESC	cis	rs10791097	0.694	rs10791100	chr11:130738946	T/A	cg12179176	chr11:130786555	SNX19	0.64	10.04	0.52	2.69e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs3960554	0.808	rs111714534	chr7:75748896	C/T	cg17325771	chr7:75508891	RHBDD2	-0.36	-5.2	-0.3	3.98e-7	Eotaxin levels;
CESC	cis	rs9916302	0.904	rs8076494	chr17:37516722	A/G	cg20243544	chr17:37824526	PNMT	-0.49	-5.92	-0.34	1.01e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs769267	0.930	rs2099334	chr19:19578450	A/G	cg03709012	chr19:19516395	GATAD2A	1.01	15.7	0.69	1.01e-39	Tonsillectomy;
CESC	cis	rs7084402	0.967	rs7100474	chr10:60273121	T/C	cg07615347	chr10:60278583	BICC1	-0.57	-8.84	-0.48	1.41e-16	Refractive error;
CESC	cis	rs1008375	1.000	rs55939327	chr4:17642937	T/A	cg16339924	chr4:17578868	LAP3	0.56	7.02	0.4	1.9e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg26338869	chr17:61819248	STRADA	0.68	8.87	0.48	1.08e-16	Prudent dietary pattern;
CESC	trans	rs1814175	0.617	rs6486020	chr11:49769149	T/G	cg11707556	chr5:10655725	ANKRD33B	-0.42	-6.06	-0.35	4.69e-9	Height;
CESC	trans	rs9467711	0.659	rs3734542	chr6:26468326	G/A	cg06606381	chr12:133084897	FBRSL1	-0.95	-7.48	-0.42	1.07e-12	Autism spectrum disorder or schizophrenia;
CESC	cis	rs2576037	0.583	rs8094654	chr18:44527397	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.49	-6.44	-0.37	5.49e-10	Personality dimensions;
CESC	cis	rs7959452	0.535	rs11177577	chr12:69671791	C/T	cg20891283	chr12:69753455	YEATS4	0.75	11.2	0.57	4.14e-24	Blood protein levels;
CESC	cis	rs2228479	0.717	rs34027607	chr16:89808939	T/C	cg06558623	chr16:89946397	TCF25	0.79	7.45	0.42	1.32e-12	Skin colour saturation;
CESC	cis	rs875971	1.000	rs778699	chr7:65868290	G/A	cg12463550	chr7:65579703	CRCP	0.58	7.41	0.41	1.67e-12	Aortic root size;
CESC	cis	rs17253792	0.822	rs76205307	chr14:56166038	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.81	5.68	0.33	3.46e-8	Putamen volume;
CESC	cis	rs6691722	0.503	rs7546875	chr1:24703667	T/C	cg02336364	chr1:24764700	NIPAL3	0.33	6.82	0.39	6.06e-11	Response to interferon beta in multiple sclerosis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02438591	chr16:2205559	TRAF7;SNORD60	0.6	6.94	0.39	2.95e-11	Gut microbiome composition (summer);
CESC	cis	rs9322193	0.884	rs880245	chr6:150167398	A/G	cg09699651	chr6:150184138	LRP11	-0.45	-5.47	-0.32	1.05e-7	Lung cancer;
CESC	cis	rs7312933	0.592	rs1551210	chr12:42865874	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.48	6.17	0.35	2.61e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs12497850	0.931	rs13064784	chr3:49135961	C/G	cg02487422	chr3:49467188	NICN1	0.45	5.67	0.33	3.69e-8	Parkinson's disease;
CESC	cis	rs1538970	0.961	rs7553318	chr1:45843086	A/G	cg06784218	chr1:46089804	CCDC17	0.34	5.71	0.33	2.98e-8	Platelet count;
CESC	cis	rs3785574	0.962	rs8066463	chr17:61818390	A/G	cg06873352	chr17:61820015	STRADA	0.48	7.04	0.4	1.63e-11	Height;
CESC	cis	rs2239547	0.522	rs4519686	chr3:52997871	C/T	cg11645453	chr3:52864694	ITIH4	0.32	5.7	0.33	3.16e-8	Schizophrenia;
CESC	cis	rs9863	0.828	rs12833624	chr12:124476873	C/T	cg17562584	chr12:124393655	DNAH10	0.32	5.49	0.32	9.37e-8	White blood cell count;
CESC	cis	rs9322193	0.651	rs9322188	chr6:149909491	A/G	cg13206674	chr6:150067644	NUP43	-0.4	-5.72	-0.33	2.87e-8	Lung cancer;
CESC	cis	rs9768139	0.733	rs13221388	chr7:158119270	G/A	cg24154853	chr7:158122151	PTPRN2	0.43	6.78	0.38	7.65e-11	Calcium levels;
CESC	cis	rs11958404	0.615	rs10044900	chr5:157451580	C/T	cg05962755	chr5:157440814	NA	-0.38	-5.85	-0.34	1.43e-8	IgG glycosylation;
CESC	cis	rs514406	0.825	rs3863643	chr1:53224577	C/T	cg08859206	chr1:53392774	SCP2	0.53	7.09	0.4	1.19e-11	Monocyte count;
CESC	cis	rs3096299	0.934	rs9927904	chr16:89462847	G/A	cg02187348	chr16:89574699	SPG7	0.51	6.74	0.38	1.01e-10	Multiple myeloma (IgH translocation);
CESC	cis	rs11098499	0.863	rs13134665	chr4:120426430	T/C	cg24375607	chr4:120327624	NA	0.43	5.11	0.3	6.08e-7	Corneal astigmatism;
CESC	cis	rs3784262	1.000	rs4646619	chr15:58258342	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.31	-5.11	-0.3	6.15e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22350171	chr1:228675139	RNF187	0.57	6.38	0.36	7.71e-10	Gut microbiome composition (summer);
CESC	cis	rs4713118	0.629	rs172165	chr6:28020814	T/G	cg26335602	chr6:28129616	ZNF389	0.44	5.66	0.33	3.97e-8	Parkinson's disease;
CESC	cis	rs1799949	1.000	rs12951869	chr17:41187567	T/G	cg25072359	chr17:41440525	NA	0.5	6.46	0.37	4.89e-10	Menopause (age at onset);
CESC	cis	rs7945705	0.967	rs34842234	chr11:8891894	G/A	cg09997546	chr11:8931473	C11orf17;ST5	0.36	5.85	0.34	1.48e-8	Hemoglobin concentration;
CESC	cis	rs2635047	0.935	rs2635050	chr18:44664131	G/A	cg19077165	chr18:44547161	KATNAL2	-0.43	-5.85	-0.34	1.47e-8	Educational attainment;
CESC	cis	rs2522056	1.000	rs757105	chr5:131795663	C/T	cg24060327	chr5:131705240	SLC22A5	0.59	6.63	0.38	1.85e-10	Lymphocyte counts;Fibrinogen;
CESC	cis	rs2120019	1.000	rs12901243	chr15:75374233	C/T	cg09165964	chr15:75287851	SCAMP5	-0.67	-8.12	-0.45	1.76e-14	Blood trace element (Zn levels);
CESC	trans	rs1814175	0.715	rs1722007	chr11:49897319	T/C	cg15704280	chr7:45808275	SEPT13	-1.02	-19.96	-0.77	9.67e-55	Height;
CESC	cis	rs68170813	0.641	rs4730228	chr7:106904077	T/C	cg02696742	chr7:106810147	HBP1	-0.52	-5.09	-0.3	6.84e-7	Coronary artery disease;
CESC	cis	rs34526934	0.608	rs2857539	chr2:177024863	G/A	cg14324370	chr2:177042789	NA	-0.49	-5.9	-0.34	1.1e-8	Obstructive sleep apnea trait (apnea hypopnea index);
CESC	cis	rs453301	0.571	rs2929456	chr8:9083416	G/A	cg15556689	chr8:8085844	FLJ10661	-0.53	-6.61	-0.38	2.14e-10	Joint mobility (Beighton score);
CESC	cis	rs4253772	0.591	rs6007740	chr22:46654323	A/G	cg24881330	chr22:46731750	TRMU	-0.87	-10.17	-0.53	1.02e-20	LDL cholesterol;Cholesterol, total;
CESC	cis	rs13256369	0.826	rs7846050	chr8:8575669	A/G	cg17143192	chr8:8559678	CLDN23	0.73	8.88	0.48	1.04e-16	Obesity-related traits;
CESC	cis	rs7580658	0.963	rs12463451	chr2:128053883	C/T	cg10021288	chr2:128175891	PROC	-0.41	-6.55	-0.37	3.06e-10	Protein C levels;
CESC	cis	rs2991971	1.000	rs9147	chr1:46016687	T/C	cg15605315	chr1:45957053	TESK2	0.43	5.36	0.31	1.82e-7	High light scatter reticulocyte count;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05409038	chr2:71221890	TEX261	0.48	6.03	0.35	5.6e-9	Gut microbiota (bacterial taxa);
CESC	trans	rs9314308	0.609	rs4872343	chr8:25547166	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.47	-6.0	-0.35	6.6e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs2120019	1.000	rs12903201	chr15:75370776	A/C	cg09165964	chr15:75287851	SCAMP5	-0.67	-8.12	-0.45	1.76e-14	Blood trace element (Zn levels);
CESC	cis	rs2011503	0.882	rs10407933	chr19:19364319	A/G	cg11584989	chr19:19387371	SF4	0.53	6.41	0.37	6.52e-10	Bipolar disorder;
CESC	cis	rs6459788	0.585	rs6950818	chr7:157235364	C/G	cg03453431	chr7:157225567	NA	-0.39	-6.68	-0.38	1.44e-10	Epstein-Barr virus copy number in lymphoblastoid cell lines;
CESC	trans	rs4716602	0.596	rs10265909	chr7:156158095	T/C	cg07175507	chr18:77160758	NFATC1	-0.45	-6.14	-0.35	3e-9	Anti-saccade response;
CESC	cis	rs10504229	0.906	rs6990615	chr8:58182956	G/A	cg24829409	chr8:58192753	C8orf71	-0.76	-9.93	-0.52	5.87e-20	Developmental language disorder (linguistic errors);
CESC	trans	rs11098499	0.754	rs10213267	chr4:120239074	A/G	cg25214090	chr10:38739885	LOC399744	0.61	8.51	0.46	1.33e-15	Corneal astigmatism;
CESC	cis	rs896854	0.654	rs28591375	chr8:95973637	C/G	cg13393036	chr8:95962371	TP53INP1	-0.49	-10.52	-0.54	7.38e-22	Type 2 diabetes;
CESC	cis	rs7394190	0.748	rs16930909	chr10:75561582	T/C	cg07699608	chr10:75541558	CHCHD1	0.62	5.13	0.3	5.57e-7	Incident atrial fibrillation;
CESC	cis	rs617791	0.530	rs10791835	chr11:65750924	C/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.45	-5.1	-0.3	6.36e-7	Breast cancer;
CESC	cis	rs875971	1.000	rs4718307	chr7:65610988	A/G	cg11764359	chr7:65958608	NA	-0.92	-14.57	-0.67	9.81e-36	Aortic root size;
CESC	cis	rs12586317	0.513	rs17102962	chr14:35478782	A/T	cg16230307	chr14:35515116	FAM177A1	0.98	10.57	0.54	5.04e-22	Psoriasis;
CESC	cis	rs6912958	0.781	rs6454632	chr6:88231824	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.34	-5.62	-0.33	4.79e-8	Monocyte percentage of white cells;
CESC	cis	rs9487051	0.676	rs1829694	chr6:109593860	G/T	cg12927641	chr6:109611667	NA	-0.37	-5.56	-0.32	6.55e-8	Reticulocyte fraction of red cells;
CESC	cis	rs6831352	0.918	rs4699712	chr4:100060490	A/T	cg13256891	chr4:100009986	ADH5	-0.75	-8.21	-0.45	9.89e-15	Alcohol dependence;
CESC	cis	rs3820928	0.775	rs10179756	chr2:227897076	A/G	cg05526886	chr2:227700861	RHBDD1	-0.45	-5.68	-0.33	3.55e-8	Pulmonary function;
CESC	cis	rs62064224	0.614	rs8065246	chr17:30682274	T/C	cg18200150	chr17:30822561	MYO1D	0.39	5.17	0.3	4.71e-7	Schizophrenia;
CESC	cis	rs9894429	0.934	rs35868252	chr17:79575472	C/G	cg21984481	chr17:79567631	NPLOC4	0.49	8.04	0.44	2.97e-14	Eye color traits;
CESC	cis	rs62064224	0.714	rs16967266	chr17:30632274	G/A	cg18200150	chr17:30822561	MYO1D	0.39	5.21	0.3	3.87e-7	Schizophrenia;
CESC	cis	rs763121	0.889	rs1837988	chr22:38901094	A/G	cg06022373	chr22:39101656	GTPBP1	0.78	11.1	0.56	8.93e-24	Menopause (age at onset);
CESC	cis	rs6584283	0.846	rs11190135	chr10:101286848	A/G	cg09788492	chr10:101292477	NKX2-3	0.33	6.31	0.36	1.14e-9	Ulcerative colitis;
CESC	cis	rs896854	0.714	rs572547	chr8:95966286	A/G	cg13393036	chr8:95962371	TP53INP1	0.47	9.09	0.49	2.33e-17	Type 2 diabetes;
CESC	cis	rs8077577	0.895	rs11654741	chr17:18124470	C/A	cg16794390	chr17:18148240	FLII	0.44	5.9	0.34	1.12e-8	Obesity-related traits;
CESC	cis	rs12497850	0.543	rs6446218	chr3:49075513	A/T	cg02487422	chr3:49467188	NICN1	0.45	5.6	0.33	5.31e-8	Parkinson's disease;
CESC	cis	rs1790761	0.692	rs614080	chr11:67347287	G/A	cg08355456	chr11:67383691	NA	0.34	5.22	0.31	3.59e-7	Mean corpuscular volume;
CESC	cis	rs11696501	0.739	rs2281210	chr20:44243172	T/G	cg11783356	chr20:44313418	WFDC10B	-0.35	-5.35	-0.31	1.87e-7	Brain structure;
CESC	cis	rs6460942	0.841	rs62448597	chr7:12449110	G/C	cg10578991	chr7:12443926	VWDE	-0.45	-5.09	-0.3	6.83e-7	Coronary artery disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg13679837	chr20:21283918	XRN2	-0.47	-6.23	-0.36	1.79e-9	Fibrinogen levels;
CESC	cis	rs4713118	0.516	rs6931858	chr6:28078411	A/T	cg26335602	chr6:28129616	ZNF389	0.49	6.17	0.35	2.6e-9	Parkinson's disease;
CESC	cis	rs3126085	0.935	rs4421596	chr1:152181673	G/A	cg26876637	chr1:152193138	HRNR	0.48	5.44	0.32	1.21e-7	Atopic dermatitis;
CESC	cis	rs11148252	0.557	rs9536223	chr13:53233194	A/T	cg00495681	chr13:53174319	NA	0.6	8.22	0.45	8.91e-15	Lewy body disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg08857039	chr6:42110396	C6orf132	-0.41	-6.14	-0.35	3.09e-9	Fibrinogen levels;
CESC	cis	rs873946	0.586	rs57431984	chr10:134567697	C/T	cg26818010	chr10:134567672	INPP5A	-0.94	-11.42	-0.57	7.62e-25	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs7666738	0.830	rs7696568	chr4:99005333	A/T	cg18180107	chr4:99064573	C4orf37	0.4	5.23	0.31	3.41e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7666738	0.830	rs6843777	chr4:98866635	T/A	cg05340658	chr4:99064831	C4orf37	0.74	10.69	0.55	2.07e-22	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6582630	0.516	rs12814528	chr12:38296111	G/A	cg26384229	chr12:38710491	ALG10B	-0.44	-5.7	-0.33	3.17e-8	Drug-induced liver injury (flucloxacillin);
CESC	trans	rs1501138	0.642	rs887648	chr4:16296121	G/A	cg02999755	chr11:102963244	DCUN1D5	0.66	6.05	0.35	4.81e-9	Systemic juvenile idiopathic arthritis;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg27304813	chr3:120068385	LRRC58	0.48	6.29	0.36	1.27e-9	Systemic lupus erythematosus;
CESC	cis	rs6463523	0.864	rs73047957	chr7:759373	A/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.97	14.68	0.67	4.26e-36	Subjective well-being;
CESC	cis	rs9399135	0.967	rs7741626	chr6:135314182	C/T	cg22676075	chr6:135203613	NA	0.51	7.23	0.41	5.22e-12	Red blood cell count;
CESC	cis	rs514406	0.668	rs520281	chr1:53365235	G/C	cg16325326	chr1:53192061	ZYG11B	0.61	8.92	0.48	8.04e-17	Monocyte count;
CESC	cis	rs761746	0.960	rs1543416	chr22:31925073	A/G	cg25791279	chr22:32026902	PISD	0.44	5.38	0.31	1.64e-7	Intelligence;
CESC	cis	rs9649213	0.593	rs7796611	chr7:97908223	A/G	cg00277769	chr7:97922759	BAIAP2L1	-0.36	-5.89	-0.34	1.2e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs9486719	0.843	rs3860229	chr6:97036559	T/C	cg06623918	chr6:96969491	KIAA0776	-0.88	-10.52	-0.54	7.14e-22	Migraine;Coronary artery disease;
CESC	cis	rs12618769	0.570	rs17032866	chr2:99132415	A/G	cg10123293	chr2:99228465	UNC50	0.4	5.38	0.31	1.64e-7	Bipolar disorder;
CESC	cis	rs1669338	0.507	rs4685609	chr3:3202279	T/C	cg16797762	chr3:3221439	CRBN	-0.63	-6.69	-0.38	1.3100000000000001e-10	White matter integrity;
CESC	cis	rs7568458	0.684	rs7593969	chr2:85809670	A/G	cg02493740	chr2:85810744	VAMP5	0.56	8.26	0.45	6.78e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CESC	cis	rs13064411	0.696	rs1552432	chr3:113225660	G/C	cg18753928	chr3:113234510	CCDC52	-0.5	-6.13	-0.35	3.23e-9	Response to simvastatin treatment (PCSK9 protein level change);
CESC	cis	rs4862750	0.872	rs9997374	chr4:187877549	T/A	cg06074448	chr4:187884817	NA	-0.36	-5.12	-0.3	5.96e-7	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs13191362	0.935	rs116735807	chr6:163010615	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.87	8.98	0.48	5.33e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs9611565	0.659	rs17367849	chr22:41923644	G/A	cg17376030	chr22:41985996	PMM1	0.73	8.12	0.45	1.72e-14	Vitiligo;
CESC	cis	rs2075371	0.897	rs12667905	chr7:134000812	A/C	cg11752832	chr7:134001865	SLC35B4	0.53	6.84	0.39	5.43e-11	Mean platelet volume;
CESC	cis	rs7666738	0.791	rs1527516	chr4:98967937	A/C	cg03676636	chr4:99064102	C4orf37	0.33	5.08	0.3	7.24e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs35110281	0.622	rs9977258	chr21:44976485	G/T	cg21573476	chr21:45109991	RRP1B	-0.43	-5.91	-0.34	1.08e-8	Mean corpuscular volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03043827	chr4:128981985	LARP1B	0.56	6.16	0.35	2.72e-9	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.791	rs10033994	chr4:98969582	C/T	cg03676636	chr4:99064102	C4orf37	0.34	5.2	0.3	4.04e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9814567	0.752	rs13098546	chr3:134333161	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.43	5.56	0.32	6.5e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs9858542	0.953	rs7623659	chr3:49414791	C/T	cg03060546	chr3:49711283	APEH	-0.54	-6.16	-0.35	2.67e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs4713118	0.629	rs172165	chr6:28020814	T/G	cg23281280	chr6:28129359	ZNF389	0.48	6.32	0.36	1.1e-9	Parkinson's disease;
CESC	cis	rs60154123	0.505	rs77990373	chr1:210041111	T/C	cg22029157	chr1:209979665	IRF6	0.72	7.16	0.4	8.04e-12	Coronary artery disease;
CESC	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg16405210	chr4:1374714	KIAA1530	-0.94	-12.63	-0.61	6.31e-29	Longevity;
CESC	cis	rs6460942	0.915	rs62447642	chr7:12489147	T/C	cg02935154	chr7:12443704	VWDE	-0.57	-5.94	-0.34	9.02e-9	Coronary artery disease;
CESC	cis	rs7605827	0.897	rs1919292	chr2:15567236	A/G	cg19274914	chr2:15703543	NA	0.32	5.74	0.33	2.53e-8	Educational attainment (years of education);
CESC	cis	rs863345	0.625	rs7534112	chr1:158532065	G/A	cg12129480	chr1:158549410	OR10X1	-0.35	-7.0	-0.4	2.08e-11	Pneumococcal bacteremia;
CESC	cis	rs472109	0.967	rs360153	chr11:9762274	T/C	cg03108697	chr11:9732066	SWAP70	-0.36	-5.55	-0.32	6.75e-8	Coronary artery disease;
CESC	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg02725872	chr8:58115012	NA	0.4	5.62	0.33	4.85e-8	Developmental language disorder (linguistic errors);
CESC	trans	rs561341	1.000	rs55962687	chr17:30260369	C/T	cg20587970	chr11:113659929	NA	-1.35	-16.55	-0.71	9.41e-43	Hip circumference adjusted for BMI;
CESC	cis	rs9916302	0.904	rs585961	chr17:37444036	G/A	cg00129232	chr17:37814104	STARD3	0.52	6.68	0.38	1.43e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs7267979	0.789	rs6083820	chr20:25354178	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.71	-11.76	-0.59	5.77e-26	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	10.31	0.54	3.43e-21	Prudent dietary pattern;
CESC	cis	rs62064224	0.703	rs62065492	chr17:30822607	C/T	cg09324608	chr17:30823087	MYO1D	0.5	7.7	0.43	2.73e-13	Schizophrenia;
CESC	cis	rs9303401	0.573	rs34097494	chr17:57171917	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.92	11.49	0.58	4.47e-25	Cognitive test performance;
CESC	cis	rs6484504	0.576	rs208091	chr11:31190099	G/C	cg14844989	chr11:31128820	NA	-0.43	-6.08	-0.35	4.22e-9	Red blood cell count;
CESC	cis	rs35110281	0.774	rs1378080	chr21:45011315	T/A	cg04455712	chr21:45112962	RRP1B	0.38	5.58	0.32	5.93e-8	Mean corpuscular volume;
CESC	trans	rs9467711	0.659	rs36033628	chr6:26456074	T/G	cg06606381	chr12:133084897	FBRSL1	-0.94	-6.61	-0.38	2.08e-10	Autism spectrum disorder or schizophrenia;
CESC	cis	rs6500395	0.963	rs961951	chr16:48716720	A/G	cg04672837	chr16:48644449	N4BP1	-0.51	-6.51	-0.37	3.67e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs7786808	0.615	rs4909212	chr7:158197037	G/T	cg09998033	chr7:158218633	PTPRN2	-0.39	-5.66	-0.33	3.99e-8	Obesity-related traits;
CESC	cis	rs10089	1.000	rs4836366	chr5:127482494	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.78	10.51	0.54	8.08e-22	Ileal carcinoids;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg10756578	chr16:86589063	MTHFSD;FLJ30679	-0.44	-6.09	-0.35	3.86e-9	Gambling;
CESC	trans	rs11039798	1.000	rs34044596	chr11:48527936	T/C	cg15704280	chr7:45808275	SEPT13	0.7	6.47	0.37	4.67e-10	Axial length;
CESC	cis	rs9322193	0.923	rs9800686	chr6:149955600	A/C	cg02462569	chr6:150064036	NUP43	-0.35	-5.17	-0.3	4.52e-7	Lung cancer;
CESC	cis	rs12956009	0.559	rs12607072	chr18:44839888	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.49	6.39	0.37	7.52e-10	Educational attainment (years of education);
CESC	cis	rs7618915	0.524	rs12488461	chr3:52698417	T/C	cg07507251	chr3:52567010	NT5DC2	0.42	7.35	0.41	2.48e-12	Bipolar disorder;
CESC	cis	rs4948102	0.691	rs10435504	chr7:56059591	G/C	cg09872392	chr7:56161020	PHKG1	-0.46	-7.25	-0.41	4.59e-12	Plasma homocysteine levels (post-methionine load test);
CESC	cis	rs9916302	0.904	rs600010	chr17:37433517	T/C	cg07936489	chr17:37558343	FBXL20	-0.78	-11.11	-0.56	8.49e-24	Glomerular filtration rate (creatinine);
CESC	cis	rs4481887	1.000	rs10736378	chr1:248455769	T/G	cg00666640	chr1:248458726	OR2T12	0.38	6.35	0.36	9.44e-10	Common traits (Other);
CESC	cis	rs10461617	0.541	rs860581	chr5:56150537	A/G	cg12311346	chr5:56204834	C5orf35	-0.7	-6.77	-0.38	8.36e-11	Type 2 diabetes;
CESC	cis	rs6121246	0.609	rs6088997	chr20:30289824	A/G	cg13852791	chr20:30311386	BCL2L1	-0.77	-9.77	-0.51	1.86e-19	Mean corpuscular hemoglobin;
CESC	cis	rs875971	0.619	rs10278371	chr7:66051540	C/A	cg18876405	chr7:65276391	NA	-0.58	-7.5	-0.42	9.83e-13	Aortic root size;
CESC	cis	rs875971	0.545	rs316306	chr7:65618674	G/A	cg18876405	chr7:65276391	NA	-0.51	-5.96	-0.34	8.21e-9	Aortic root size;
CESC	cis	rs710216	0.917	rs900834	chr1:43412343	A/G	cg22176566	chr1:43424700	SLC2A1	-0.51	-5.62	-0.33	4.72e-8	Red cell distribution width;
CESC	cis	rs798554	0.634	rs1182180	chr7:2873279	G/T	cg09658497	chr7:2847517	GNA12	-0.34	-5.22	-0.31	3.53e-7	Height;
CESC	cis	rs9660180	1.000	rs9660180	chr1:1723031	G/A	cg13866156	chr1:1669148	SLC35E2	-0.51	-6.66	-0.38	1.56e-10	Body mass index;
CESC	cis	rs2576037	0.526	rs10853544	chr18:44474194	T/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.34	5.41	0.32	1.4e-7	Personality dimensions;
CESC	cis	rs13108904	0.870	rs4974543	chr4:1251222	A/G	cg00684032	chr4:1343700	KIAA1530	0.41	5.77	0.33	2.22e-8	Obesity-related traits;
CESC	cis	rs1008375	1.000	rs1121089	chr4:17676476	C/A	cg16339924	chr4:17578868	LAP3	0.51	6.44	0.37	5.73e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs6724607	1.000	rs6434402	chr2:191469322	C/T	cg10560079	chr2:191398806	TMEM194B	-0.49	-7.2	-0.4	6.13e-12	Pulse pressure;
CESC	cis	rs7683537	0.501	rs2171838	chr4:185667404	A/G	cg04058563	chr4:185651563	MLF1IP	-0.45	-5.23	-0.31	3.4e-7	Systemic lupus erythematosus;
CESC	cis	rs4975616	0.836	rs13178866	chr5:1323212	C/T	cg07493874	chr5:1342172	CLPTM1L	-0.41	-7.86	-0.43	9.75e-14	Lung cancer;
CESC	trans	rs3942852	0.910	rs10742829	chr11:48115837	C/T	cg03929089	chr4:120376271	NA	0.57	6.13	0.35	3.25e-9	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs9487051	0.646	rs11153165	chr6:109622159	G/A	cg01475377	chr6:109611718	NA	-0.39	-5.39	-0.31	1.55e-7	Reticulocyte fraction of red cells;
CESC	cis	rs9309473	0.519	rs4852950	chr2:73864670	C/T	cg20560298	chr2:73613845	ALMS1	0.49	6.86	0.39	4.9e-11	Metabolite levels;
CESC	cis	rs4654899	0.727	rs11805169	chr1:21156862	A/T	cg05370193	chr1:21551575	ECE1	-0.36	-5.46	-0.32	1.11e-7	Superior frontal gyrus grey matter volume;
CESC	cis	rs2841277	0.708	rs9671643	chr14:105408030	A/G	cg15352829	chr14:105391018	PLD4	-0.59	-10.35	-0.54	2.66e-21	Rheumatoid arthritis;
CESC	cis	rs4964805	0.657	rs11111783	chr12:104188523	A/G	cg02344784	chr12:104178138	NT5DC3	0.47	6.6	0.38	2.19e-10	Attention deficit hyperactivity disorder;
CESC	cis	rs1799949	1.000	rs8074136	chr17:41342313	A/C	cg25072359	chr17:41440525	NA	0.45	6.05	0.35	4.84e-9	Menopause (age at onset);
CESC	cis	rs35110281	0.715	rs2838353	chr21:45119228	C/T	cg01579765	chr21:45077557	HSF2BP	-0.52	-8.8	-0.48	1.82e-16	Mean corpuscular volume;
CESC	cis	rs1799949	1.000	rs2298862	chr17:41176688	T/C	cg23758822	chr17:41437982	NA	1.03	14.68	0.67	3.99e-36	Menopause (age at onset);
CESC	cis	rs473651	0.935	rs477041	chr2:239355995	C/G	cg21699342	chr2:239360505	ASB1	-0.55	-9.26	-0.49	7.29e-18	Multiple system atrophy;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg22521096	chr17:7518744	FXR2;SHBG	0.47	6.07	0.35	4.38e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs7666738	0.830	rs6532721	chr4:99048015	G/A	cg03467027	chr4:99064603	C4orf37	0.47	5.98	0.34	7.19e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1371867	0.846	rs1660351	chr8:101275034	C/T	cg11906718	chr8:101322791	RNF19A	0.49	6.41	0.37	6.59e-10	Atrioventricular conduction;
CESC	cis	rs2342371	0.509	rs9683218	chr3:196211033	C/T	cg15048948	chr3:196158458	UBXN7	-0.39	-5.49	-0.32	9.43e-8	Fat distribution (HIV);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg17404403	chr4:110737017	GAR1	0.45	6.13	0.35	3.25e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs6582630	0.598	rs12823134	chr12:38514347	T/A	cg26384229	chr12:38710491	ALG10B	-0.41	-5.41	-0.32	1.38e-7	Drug-induced liver injury (flucloxacillin);
CESC	trans	rs9325144	0.600	rs11183505	chr12:38759110	G/T	cg23762105	chr12:34175262	ALG10	0.48	6.23	0.36	1.84e-9	Morning vs. evening chronotype;
CESC	cis	rs10504229	1.000	rs949848	chr8:58169125	A/G	cg05313129	chr8:58192883	C8orf71	-0.55	-6.37	-0.36	8.42e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs7927771	0.542	rs3886262	chr11:47817010	T/G	cg18512352	chr11:47633146	NA	0.35	5.33	0.31	2.05e-7	Subjective well-being;
CESC	cis	rs7666738	0.830	rs13129503	chr4:98987892	T/C	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.67e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9457247	0.624	rs2239826	chr6:167504880	T/C	cg07741184	chr6:167504864	NA	0.4	6.82	0.39	6.22e-11	Crohn's disease;
CESC	cis	rs5750830	0.649	rs5750820	chr22:39825322	T/G	cg02038168	chr22:39784481	NA	-0.62	-7.62	-0.42	4.63e-13	Intelligence (multi-trait analysis);
CESC	cis	rs9394438	0.593	rs10947679	chr6:37543524	C/G	cg00985040	chr6:37553208	NA	0.39	6.81	0.39	6.68e-11	IgG glycosylation;
CESC	cis	rs10504229	0.683	rs882429	chr8:58129292	A/G	cg21724239	chr8:58056113	NA	0.58	5.95	0.34	8.29e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs11577318	0.812	rs3795683	chr1:26632831	C/A	cg00852783	chr1:26633632	UBXN11	0.51	7.11	0.4	1.1e-11	Granulocyte percentage of myeloid white cells;
CESC	cis	rs7914558	0.966	rs10786725	chr10:104682357	T/C	cg15744005	chr10:104629667	AS3MT	-0.35	-5.49	-0.32	9.56e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13745513	chr9:131018379	GOLGA2	-0.57	-6.8	-0.39	6.77e-11	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13973472	chr14:55032305	NA	0.53	6.09	0.35	4.02e-9	Gut microbiome composition (summer);
CESC	cis	rs5753618	0.504	rs9609297	chr22:31893731	G/T	cg02404636	chr22:31891804	SFI1	0.39	5.16	0.3	4.9e-7	Colorectal cancer;
CESC	cis	rs708547	0.647	rs6843644	chr4:57891239	G/A	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.42	-5.46	-0.32	1.1e-7	Response to bleomycin (chromatid breaks);
CESC	cis	rs7666738	0.753	rs1527520	chr4:98929164	A/G	cg17366294	chr4:99064904	C4orf37	0.6	8.23	0.45	8.65e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4144743	1.000	rs72823474	chr17:45321776	G/C	cg18085866	chr17:45331354	ITGB3	-0.64	-7.03	-0.4	1.78e-11	Body mass index;
CESC	cis	rs4889855	0.530	rs8072592	chr17:78615361	A/C	cg16591659	chr17:78472290	NA	0.33	5.46	0.32	1.09e-7	Fractional excretion of uric acid;
CESC	cis	rs9549367	0.577	rs3024713	chr13:113813321	G/A	cg18105134	chr13:113819100	PROZ	-0.75	-8.59	-0.47	7.53e-16	Platelet distribution width;
CESC	cis	rs854765	0.551	rs8070748	chr17:17859421	A/G	cg09796270	chr17:17721594	SREBF1	0.45	6.15	0.35	2.87e-9	Total body bone mineral density;
CESC	cis	rs2455799	0.573	rs2654648	chr3:15775425	T/C	cg16303742	chr3:15540471	COLQ	-0.4	-6.18	-0.35	2.4e-9	Mean platelet volume;
CESC	cis	rs6062302	0.548	rs4809310	chr20:62228745	G/A	cg06363034	chr20:62225388	GMEB2	-0.52	-6.68	-0.38	1.42e-10	Glioblastoma;
CESC	cis	rs6500395	1.000	rs9933314	chr16:48676608	T/C	cg04672837	chr16:48644449	N4BP1	0.51	6.31	0.36	1.16e-9	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs2204008	0.744	rs12099650	chr12:38317140	C/G	cg13010199	chr12:38710504	ALG10B	0.42	5.3	0.31	2.42e-7	Bladder cancer;
CESC	cis	rs2070488	0.804	rs13092473	chr3:38458958	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.81	12.98	0.62	3.7e-30	Electrocardiographic conduction measures;
CESC	cis	rs4466137	0.868	rs1975801	chr5:83022127	A/G	cg16102102	chr5:83017553	HAPLN1	-0.51	-7.22	-0.41	5.5e-12	Prostate cancer;
CESC	cis	rs1799949	1.000	rs1973646	chr17:41310495	T/C	cg05368731	chr17:41323189	NBR1	0.78	10.8	0.55	8.75e-23	Menopause (age at onset);
CESC	cis	rs1799949	1.000	rs915945	chr17:41179864	C/T	cg23758822	chr17:41437982	NA	1.03	14.56	0.67	1.1e-35	Menopause (age at onset);
CESC	cis	rs71403859	0.730	rs17355804	chr16:71717214	A/G	cg08717414	chr16:71523259	ZNF19	-0.69	-5.98	-0.34	7.38e-9	Post bronchodilator FEV1;
CESC	cis	rs3806843	1.000	rs7732179	chr5:140199039	G/A	cg26395211	chr5:140044315	WDR55	-0.42	-5.32	-0.31	2.19e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs7998202	0.667	rs282576	chr13:113358864	A/G	cg02820901	chr13:113351484	ATP11A	0.65	5.67	0.33	3.68e-8	Glycated hemoglobin levels;
CESC	cis	rs7127900	0.614	rs72853920	chr11:2206429	T/C	cg25635251	chr11:2234043	NA	-0.52	-5.81	-0.34	1.8e-8	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15331837	chr8:142232772	SLC45A4	-0.78	-9.31	-0.5	5.19e-18	Gut microbiome composition (summer);
CESC	cis	rs2228479	0.717	rs17233678	chr16:89809962	T/C	cg00800038	chr16:89945340	TCF25	-0.88	-7.36	-0.41	2.3e-12	Skin colour saturation;
CESC	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg21724239	chr8:58056113	NA	-0.58	-5.52	-0.32	8.09e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs1218582	0.774	rs4845680	chr1:154863195	A/G	cg03351412	chr1:154909251	PMVK	0.66	8.89	0.48	9.97e-17	Prostate cancer;
CESC	cis	rs2276314	0.857	rs9304155	chr18:33585710	A/C	cg19628046	chr18:33552617	C18orf21	0.53	5.98	0.34	7.14e-9	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs597539	0.690	rs608810	chr11:68624118	G/C	cg06028808	chr11:68637592	NA	0.45	5.21	0.3	3.83e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs9649213	0.593	rs7807555	chr7:97957517	G/A	cg21770322	chr7:97807741	LMTK2	0.56	8.61	0.47	6.55e-16	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs6089829	0.925	rs6122086	chr20:61664528	T/C	cg16240275	chr20:61666158	NCRNA00029	0.5	8.87	0.48	1.08e-16	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs12477438	0.765	rs6542846	chr2:99563654	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.64	-8.92	-0.48	7.83e-17	Chronic sinus infection;
CESC	cis	rs6728642	0.908	rs6576996	chr2:97623312	T/C	cg26665480	chr2:98280029	ACTR1B	-0.72	-7.82	-0.43	1.23e-13	Bipolar disorder lithium response (continuous) or schizophrenia;
CESC	cis	rs4665809	1.000	rs6546726	chr2:26275116	A/G	cg08470875	chr2:26401718	FAM59B	-0.48	-5.18	-0.3	4.45e-7	Gut microbiome composition (summer);
CESC	cis	rs9611565	0.503	rs5751156	chr22:42170025	A/G	cg06634786	chr22:41940651	POLR3H	0.69	6.84	0.39	5.39e-11	Vitiligo;
CESC	cis	rs270601	0.710	rs4705852	chr5:131602807	A/G	cg09877947	chr5:131593287	PDLIM4	0.48	6.31	0.36	1.16e-9	Acylcarnitine levels;
CESC	cis	rs1552244	0.554	rs2272120	chr3:10046703	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.62	7.99	0.44	4.24e-14	Alzheimer's disease;
CESC	cis	rs881375	0.678	rs10118357	chr9:123680068	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	6.2	0.36	2.14e-9	Rheumatoid arthritis;
CESC	cis	rs6940638	0.688	rs9379960	chr6:27121325	A/C	cg12292205	chr6:26970375	C6orf41	-0.4	-5.46	-0.32	1.1e-7	Intelligence (multi-trait analysis);
CESC	cis	rs1862618	0.853	rs190414	chr5:56116772	C/A	cg24531977	chr5:56204891	C5orf35	-0.87	-11.03	-0.56	1.58e-23	Initial pursuit acceleration;
CESC	cis	rs524281	0.861	rs12049852	chr11:65884702	T/C	cg14036092	chr11:66035641	RAB1B	-0.49	-5.39	-0.31	1.53e-7	Electroencephalogram traits;
CESC	cis	rs7617480	0.648	rs14018	chr3:48784270	G/A	cg07636037	chr3:49044803	WDR6	0.79	10.66	0.55	2.61e-22	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CESC	cis	rs3749237	0.595	rs10865955	chr3:49499829	G/A	cg07636037	chr3:49044803	WDR6	0.6	8.78	0.47	2e-16	Resting heart rate;
CESC	cis	rs9916302	0.653	rs11657058	chr17:37699378	T/G	cg07936489	chr17:37558343	FBXL20	-0.98	-11.47	-0.58	5.54e-25	Glomerular filtration rate (creatinine);
CESC	cis	rs6575793	0.553	rs12436130	chr14:101031036	C/T	cg18516195	chr14:101012996	BEGAIN	0.42	5.07	0.3	7.6e-7	Menarche (age at onset);
CESC	cis	rs1008375	1.000	rs1008374	chr4:17683219	G/A	cg02297831	chr4:17616191	MED28	0.44	5.64	0.33	4.46e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs9811920	0.609	rs2452320	chr3:99645216	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.64	10.11	0.53	1.53e-20	Axial length;
CESC	cis	rs7666738	0.791	rs10005118	chr4:99038196	A/C	cg03467027	chr4:99064603	C4orf37	0.47	5.99	0.35	6.71e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6815814	0.950	rs5743556	chr4:38806851	A/G	cg02016764	chr4:38805732	TLR1	-0.63	-7.2	-0.4	6.39e-12	Breast cancer;
CESC	cis	rs4481887	0.927	rs11204631	chr1:248479530	A/G	cg00666640	chr1:248458726	OR2T12	0.34	5.32	0.31	2.18e-7	Common traits (Other);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10633491	chr19:4066815	ZBTB7A	-0.64	-7.44	-0.42	1.37e-12	Gut microbiome composition (summer);
CESC	cis	rs17067123	0.614	rs6857116	chr4:180062542	G/A	cg26610307	chr4:180072759	NA	-0.49	-5.04	-0.3	8.45e-7	Response to hepatitis C treatment;
CESC	cis	rs5750830	0.594	rs6001587	chr22:39819008	T/C	cg05872129	chr22:39784769	NA	-0.81	-10.75	-0.55	1.29e-22	Intelligence (multi-trait analysis);
CESC	cis	rs7208859	0.673	rs73263981	chr17:28920502	A/G	cg04154034	chr17:28927549	LRRC37B2	0.66	5.85	0.34	1.42e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs782590	0.967	rs11125581	chr2:55796527	C/G	cg18811423	chr2:55921094	PNPT1	0.8	12.91	0.62	6.74e-30	Metabolic syndrome;
CESC	cis	rs2235544	0.542	rs11206272	chr1:54470035	G/C	cg25741118	chr1:54482237	LDLRAD1	0.24	5.76	0.33	2.29e-8	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
CESC	cis	rs7927771	0.698	rs34467936	chr11:47915299	A/G	cg18512352	chr11:47633146	NA	-0.61	-9.47	-0.5	1.61e-18	Subjective well-being;
CESC	trans	rs4942242	0.640	rs17460861	chr13:44230078	C/G	cg19169023	chr15:41853346	TYRO3	0.63	8.21	0.45	9.59e-15	Response to tocilizumab in rheumatoid arthritis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10828910	chr2:63850056	LOC388955	-0.69	-8.07	-0.44	2.41e-14	Gut microbiome composition (summer);
CESC	cis	rs7188697	0.922	rs1981961	chr16:58597291	A/T	cg02549819	chr16:58548995	SETD6	0.43	5.4	0.31	1.51e-7	QT interval;
CESC	cis	rs7845219	0.539	rs713113	chr8:95877787	C/T	cg23172400	chr8:95962367	TP53INP1	0.35	6.44	0.37	5.69e-10	Type 2 diabetes;
CESC	cis	rs3026101	0.624	rs1806255	chr17:5314263	G/C	cg24500398	chr17:5266808	RABEP1	-0.41	-5.7	-0.33	3.23e-8	Body mass index;
CESC	cis	rs13191362	1.000	rs35424047	chr6:163029715	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.81	8.44	0.46	2.13e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs6594713	0.717	rs9326891	chr5:112873928	C/T	cg12552261	chr5:112820674	MCC	0.61	5.61	0.33	5.12e-8	Brain cytoarchitecture;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14584092	chr19:2116709	AP3D1	-0.53	-6.46	-0.37	4.97e-10	Gut microbiome composition (summer);
CESC	cis	rs1580019	0.510	rs4723162	chr7:32543804	C/A	cg06627557	chr7:32535165	LSM5;AVL9	1.06	18.8	0.76	1.12e-50	Cognitive ability;
CESC	cis	rs6456156	0.565	rs12529238	chr6:167465576	G/A	cg07741184	chr6:167504864	NA	0.35	6.08	0.35	4.1e-9	Primary biliary cholangitis;
CESC	cis	rs2073499	1.000	rs6776145	chr3:50316119	C/T	cg05260129	chr3:50388622	TUSC4;CYB561D2	-0.75	-7.93	-0.44	6.08e-14	Schizophrenia;
CESC	trans	rs10411161	0.721	rs10401778	chr19:52384315	C/T	cg22319618	chr22:45562946	NUP50	-0.71	-7.04	-0.4	1.66e-11	Breast cancer;
CESC	cis	rs1799949	0.965	rs35521261	chr17:41313612	A/G	cg05368731	chr17:41323189	NBR1	0.8	11.19	0.57	4.64e-24	Menopause (age at onset);
CESC	cis	rs72781680	1.000	rs72781631	chr2:24195064	G/A	cg20701182	chr2:24300061	SF3B14	0.6	5.45	0.32	1.15e-7	Lymphocyte counts;
CESC	cis	rs7937682	0.883	rs11213941	chr11:111434094	T/C	cg09085632	chr11:111637200	PPP2R1B	0.97	13.15	0.63	9.55e-31	Primary sclerosing cholangitis;
CESC	cis	rs4144743	0.759	rs16941731	chr17:45317022	C/T	cg18085866	chr17:45331354	ITGB3	0.56	5.17	0.3	4.56e-7	Body mass index;
CESC	cis	rs30380	1.000	rs26510	chr5:96125910	C/T	cg16492584	chr5:96139282	ERAP1	-0.34	-5.03	-0.3	9e-7	Cerebrospinal fluid biomarker levels;
CESC	cis	rs34172651	0.617	rs9922436	chr16:24704490	C/G	cg00339695	chr16:24857497	SLC5A11	0.43	5.7	0.33	3.18e-8	Intelligence (multi-trait analysis);
CESC	cis	rs4975709	0.838	rs4975752	chr5:1880588	A/C	cg12288994	chr5:1860383	NA	0.37	5.91	0.34	1.07e-8	Cardiovascular disease risk factors;
CESC	cis	rs5753618	0.583	rs9606843	chr22:31853371	A/C	cg02404636	chr22:31891804	SFI1	0.39	5.3	0.31	2.42e-7	Colorectal cancer;
CESC	cis	rs13118159	0.550	rs10016557	chr4:1363628	C/T	cg20887711	chr4:1340912	KIAA1530	-0.68	-8.88	-0.48	1e-16	Longevity;
CESC	cis	rs11677416	1.000	rs2856841	chr2:113537339	A/G	cg27083787	chr2:113543245	IL1A	0.62	7.54	0.42	7.51e-13	Response to antipsychotic treatment in schizophrenia (working memory);
CESC	cis	rs7552404	1.000	rs7533888	chr1:76160449	A/C	cg03433033	chr1:76189801	ACADM	0.68	8.14	0.45	1.54e-14	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs1707322	1.000	rs7531911	chr1:46330423	A/G	cg06784218	chr1:46089804	CCDC17	0.32	5.52	0.32	8.1e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7923609	1.000	rs4310508	chr10:65138573	A/G	cg01631684	chr10:65280961	REEP3	-0.42	-5.18	-0.3	4.48e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs5756813	0.661	rs5995500	chr22:38204640	A/G	cg19894588	chr14:64061835	NA	-0.68	-8.45	-0.46	1.98e-15	Optic cup area;Vertical cup-disc ratio;
CESC	cis	rs9322193	0.923	rs3798761	chr6:150004779	A/G	cg07701084	chr6:150067640	NUP43	0.48	6.74	0.38	1.01e-10	Lung cancer;
CESC	cis	rs7909074	1.000	rs7909074	chr10:45395839	G/A	cg05187965	chr10:45406764	TMEM72	-0.36	-5.48	-0.32	9.69e-8	Mean corpuscular volume;
CESC	cis	rs62064224	0.765	rs62065463	chr17:30732405	G/T	cg18200150	chr17:30822561	MYO1D	0.68	10.6	0.55	4.19e-22	Schizophrenia;
CESC	trans	rs61931739	0.500	rs7311284	chr12:34478477	C/G	cg26384229	chr12:38710491	ALG10B	0.7	10.6	0.55	3.94e-22	Morning vs. evening chronotype;
CESC	cis	rs3096299	0.685	rs4238830	chr16:89540241	C/T	cg02187348	chr16:89574699	SPG7	0.65	9.11	0.49	2.08e-17	Multiple myeloma (IgH translocation);
CESC	cis	rs12479064	0.724	rs6748200	chr2:100080895	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.62	-7.34	-0.41	2.65e-12	Chronic sinus infection;
CESC	trans	rs1493916	1.000	rs4393645	chr18:31394407	C/T	cg27147174	chr7:100797783	AP1S1	-0.52	-7.03	-0.4	1.76e-11	Life satisfaction;
CESC	cis	rs769267	0.965	rs2023882	chr19:19405405	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.42	5.33	0.31	2.07e-7	Tonsillectomy;
CESC	cis	rs1799949	0.965	rs9897425	chr17:41430179	C/G	cg23758822	chr17:41437982	NA	1.01	17.05	0.72	1.68e-44	Menopause (age at onset);
CESC	cis	rs72781680	0.898	rs12614616	chr2:23996501	T/G	cg20701182	chr2:24300061	SF3B14	0.63	5.65	0.33	4.21e-8	Lymphocyte counts;
CESC	cis	rs2070488	1.000	rs2070488	chr3:38442490	A/G	cg24069376	chr3:38537580	EXOG	-0.46	-8.47	-0.46	1.75e-15	Electrocardiographic conduction measures;
CESC	cis	rs10129255	0.500	rs2105991	chr14:107138039	C/G	cg07958169	chr14:107095056	NA	-0.52	-8.32	-0.45	4.79e-15	Kawasaki disease;
CESC	cis	rs6952808	1.000	rs6952808	chr7:1886535	C/G	cg13880726	chr7:1868755	MAD1L1	0.48	6.37	0.36	8.33e-10	Bipolar disorder and schizophrenia;
CESC	cis	rs79839061	0.518	rs3755961	chr4:895059	A/G	cg07828340	chr4:882639	GAK	1.07	8.25	0.45	7.63e-15	Intelligence (multi-trait analysis);
CESC	cis	rs2836974	0.644	rs2410123	chr21:40700093	C/T	cg17971929	chr21:40555470	PSMG1	-0.87	-12.67	-0.61	4.59e-29	Cognitive function;
CESC	cis	rs1348850	0.914	rs3813259	chr2:178257214	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.89	12.87	0.62	9.15e-30	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs11098499	1.000	rs6837898	chr4:120179154	C/T	cg24375607	chr4:120327624	NA	0.43	5.23	0.31	3.41e-7	Corneal astigmatism;
CESC	cis	rs6547741	0.967	rs4665996	chr2:27814343	T/C	cg27432699	chr2:27873401	GPN1	0.49	6.85	0.39	5.03e-11	Oral cavity cancer;
CESC	cis	rs75804782	0.522	rs11889150	chr2:239324542	A/G	cg18131467	chr2:239335373	ASB1	-0.6	-7.33	-0.41	2.71e-12	Morning vs. evening chronotype;Chronotype;
CESC	trans	rs1945213	0.694	rs7106894	chr11:55877315	T/C	cg15704280	chr7:45808275	SEPT13	0.69	6.67	0.38	1.51e-10	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs1862618	0.853	rs832554	chr5:56115036	A/G	cg24549020	chr5:56110836	MAP3K1	0.65	7.45	0.42	1.3e-12	Initial pursuit acceleration;
CESC	cis	rs6460942	0.659	rs13247370	chr7:12514632	T/C	cg02935154	chr7:12443704	VWDE	-0.49	-5.15	-0.3	5.05e-7	Coronary artery disease;
CESC	trans	rs1814175	0.645	rs847632	chr11:49926097	C/T	cg15704280	chr7:45808275	SEPT13	-0.98	-18.48	-0.75	1.48e-49	Height;
CESC	cis	rs9399135	0.816	rs4134030	chr6:135354094	G/T	cg22676075	chr6:135203613	NA	0.5	7.13	0.4	9.64e-12	Red blood cell count;
CESC	cis	rs7618915	0.508	rs13065851	chr3:52644836	T/A	cg05564831	chr3:52568323	NT5DC2	0.45	6.76	0.38	8.65e-11	Bipolar disorder;
CESC	cis	rs7586673	0.578	rs6723841	chr2:161879616	G/T	cg22496339	chr2:162101262	NA	0.47	6.01	0.35	6.14e-9	Intelligence (multi-trait analysis);
CESC	cis	rs1348850	0.634	rs2293471	chr2:178487729	T/G	cg23306229	chr2:178417860	TTC30B	0.56	6.14	0.35	3.05e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs4555082	0.874	rs113291192	chr14:105738181	C/T	cg27165867	chr14:105738592	BRF1	-0.57	-6.17	-0.35	2.52e-9	Mean platelet volume;Platelet distribution width;
CESC	cis	rs4072980	0.527	rs11210825	chr1:38446986	G/A	cg17077180	chr1:38461687	NA	0.47	7.27	0.41	4.04e-12	Coronary artery disease;
CESC	trans	rs8073060	0.533	rs178736	chr17:33928158	G/T	cg19694781	chr19:47549865	TMEM160	-0.73	-7.01	-0.4	1.96e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	cis	rs769267	0.895	rs1858999	chr19:19497669	C/G	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.49	-6.33	-0.36	1.07e-9	Tonsillectomy;
CESC	cis	rs72901758	0.662	rs56326958	chr17:76250439	C/G	cg23302638	chr17:76210176	BIRC5	0.48	5.22	0.31	3.6e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
CESC	cis	rs909674	0.775	rs4821896	chr22:39833437	T/C	cg01416388	chr22:39784598	NA	-0.58	-7.27	-0.41	4.08e-12	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs2952156	0.920	rs8078228	chr17:37834998	C/T	cg20243544	chr17:37824526	PNMT	0.63	8.38	0.46	3.08e-15	Asthma;
CESC	cis	rs787274	0.619	rs1475293	chr9:115619587	C/T	cg13803584	chr9:115635662	SNX30	0.53	5.17	0.3	4.6e-7	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs4665809	0.590	rs11897162	chr2:26503654	T/C	cg26119090	chr2:26468346	HADHA;HADHB	0.97	10.77	0.55	1.12e-22	Gut microbiome composition (summer);
CESC	cis	rs9611565	0.512	rs6002474	chr22:42168181	A/G	cg06634786	chr22:41940651	POLR3H	0.68	6.78	0.38	7.6e-11	Vitiligo;
CESC	cis	rs13242816	1.000	rs12706090	chr7:116104045	A/G	cg04696780	chr7:116139425	CAV2	0.6	5.71	0.33	3.04e-8	P wave duration;
CESC	cis	rs10870270	1.000	rs4880246	chr10:133764064	C/T	cg26149184	chr10:133730230	NA	0.38	5.13	0.3	5.68e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs9640161	0.750	rs4395803	chr7:150025367	A/C	cg17279839	chr7:150038598	RARRES2	0.41	5.04	0.3	8.44e-7	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg22105103	chr4:187893119	NA	0.47	6.95	0.39	2.75e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4555082	0.874	rs28822720	chr14:105746282	T/C	cg06808227	chr14:105710500	BRF1	-0.61	-7.31	-0.41	3.21e-12	Mean platelet volume;Platelet distribution width;
CESC	cis	rs10504229	0.595	rs79077737	chr8:58117520	G/A	cg21724239	chr8:58056113	NA	0.58	5.97	0.34	7.54e-9	Developmental language disorder (linguistic errors);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg13338022	chr15:43029438	CDAN1	-0.47	-6.79	-0.38	7.4e-11	Gambling;
CESC	cis	rs910316	1.000	rs7303	chr14:75520065	T/C	cg11812906	chr14:75593930	NEK9	0.89	14.86	0.67	9.77e-37	Height;
CESC	cis	rs12701220	0.503	rs12702047	chr7:1132720	G/A	cg02733842	chr7:1102375	C7orf50	-0.4	-5.08	-0.3	7.05e-7	Bronchopulmonary dysplasia;
CESC	cis	rs2933343	0.621	rs789241	chr3:128585752	G/A	cg24203234	chr3:128598194	ACAD9	0.41	5.69	0.33	3.33e-8	IgG glycosylation;
CESC	trans	rs61931739	0.500	rs11053274	chr12:34547605	G/A	cg13010199	chr12:38710504	ALG10B	0.49	6.24	0.36	1.71e-9	Morning vs. evening chronotype;
CESC	cis	rs7737355	0.738	rs3776001	chr5:130957992	T/A	cg06307176	chr5:131281290	NA	0.38	5.04	0.3	8.68e-7	Life satisfaction;
CESC	cis	rs4727027	0.901	rs1534197	chr7:148771970	T/C	cg23583168	chr7:148888333	NA	-0.78	-11.74	-0.59	6.48e-26	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs4906332	1.000	rs55731474	chr14:103878481	G/A	cg09975044	chr14:104007538	NA	0.46	6.4	0.37	7.09e-10	Coronary artery disease;
CESC	cis	rs896854	0.738	rs2515226	chr8:95965743	G/A	cg16049864	chr8:95962084	TP53INP1	0.63	9.82	0.52	1.33e-19	Type 2 diabetes;
CESC	cis	rs6800768	0.633	rs62255804	chr3:24149034	G/A	cg10674438	chr3:24145617	LOC152024	-0.47	-6.46	-0.37	5.08e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs1448094	0.511	rs61930588	chr12:86158991	A/G	cg00310523	chr12:86230176	RASSF9	0.32	5.15	0.3	5.03e-7	Major depressive disorder;
CESC	cis	rs7945705	0.870	rs4929922	chr11:8975776	A/G	cg12365402	chr11:9010492	NRIP3	-0.37	-5.76	-0.33	2.28e-8	Hemoglobin concentration;
CESC	cis	rs61996546	0.622	rs11637029	chr15:26836107	T/A	cg15066197	chr15:26874202	GABRB3	-0.35	-5.07	-0.3	7.55e-7	Response to methotrexate in juvenile idiopathic arthritis;
CESC	cis	rs9894429	0.789	rs7502346	chr17:79603741	T/C	cg13777783	chr17:79615861	NA	-0.33	-5.24	-0.31	3.24e-7	Eye color traits;
CESC	cis	rs6502050	0.805	rs4789740	chr17:80119202	T/C	cg11859384	chr17:80120422	CCDC57	-0.39	-5.44	-0.32	1.2e-7	Life satisfaction;
CESC	cis	rs2425143	1.000	rs11696947	chr20:34312658	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.82	-7.58	-0.42	5.86e-13	Blood protein levels;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg22515636	chr2:109150313	NA	-0.52	-7.56	-0.42	6.71e-13	Gambling;
CESC	cis	rs611744	0.647	rs9969614	chr8:109260581	A/G	cg21045802	chr8:109455806	TTC35	0.45	5.65	0.33	4.03e-8	Dupuytren's disease;
CESC	cis	rs9911578	0.967	rs686425	chr17:56776730	A/G	cg12560992	chr17:57184187	TRIM37	0.92	15.44	0.69	8.18e-39	Intelligence (multi-trait analysis);
CESC	cis	rs5750830	0.649	rs5750814	chr22:39797987	T/C	cg24399712	chr22:39784796	NA	-0.83	-11.67	-0.58	1.15e-25	Intelligence (multi-trait analysis);
CESC	cis	rs7044106	0.762	rs1547267	chr9:123408736	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.64	8.63	0.47	5.83e-16	Hip circumference adjusted for BMI;
CESC	cis	rs3813567	0.759	rs12594550	chr15:78959037	C/G	cg05914723	chr15:78953907	NA	-0.47	-6.18	-0.35	2.45e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
CESC	trans	rs9951602	0.512	rs1599633	chr18:76643526	T/C	cg02800362	chr5:177631904	HNRNPAB	0.62	8.1	0.45	1.96e-14	Obesity-related traits;
CESC	cis	rs4132509	0.696	rs10927062	chr1:243889364	A/G	cg21452805	chr1:244014465	NA	0.45	5.54	0.32	7.12e-8	RR interval (heart rate);
CESC	cis	rs4728302	0.869	rs7792492	chr7:133595316	C/T	cg10665199	chr7:133106180	EXOC4	0.39	5.37	0.31	1.71e-7	Intelligence;Intelligence (multi-trait analysis);
CESC	cis	rs34779708	0.931	rs34087268	chr10:35346724	T/G	cg04310649	chr10:35416472	CREM	-0.51	-6.0	-0.35	6.31e-9	Inflammatory bowel disease;Crohn's disease;
CESC	trans	rs916888	0.821	rs199506	chr17:44859031	A/G	cg01341218	chr17:43662625	NA	-0.85	-10.21	-0.53	7.25e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs2066819	1.000	rs116535779	chr12:56739261	A/G	cg26714650	chr12:56694279	CS	-1.22	-14.6	-0.67	8.06e-36	Psoriasis vulgaris;
CESC	cis	rs12410462	0.681	rs113316536	chr1:227547033	T/G	cg10327440	chr1:227177885	CDC42BPA	-0.67	-5.69	-0.33	3.43e-8	Major depressive disorder;
CESC	cis	rs703842	0.616	rs4760332	chr12:58222672	A/C	cg02175503	chr12:58329896	NA	-0.47	-5.79	-0.33	2.01e-8	Multiple sclerosis;
CESC	cis	rs6967414	0.786	rs9639026	chr7:6746736	A/G	cg09896999	chr7:6746977	ZNF12	-0.55	-6.95	-0.39	2.79e-11	Hematocrit;Hemoglobin concentration;
CESC	cis	rs7264396	0.563	rs2425111	chr20:34319765	A/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.63	6.88	0.39	4.29e-11	Total cholesterol levels;
CESC	cis	rs9300255	0.596	rs11057207	chr12:123730891	T/G	cg05973401	chr12:123451056	ABCB9	0.45	5.45	0.32	1.13e-7	Neutrophil percentage of white cells;
CESC	cis	rs4713118	0.662	rs13218430	chr6:28029837	T/C	cg22143856	chr6:28129313	ZNF389	0.42	5.26	0.31	2.91e-7	Parkinson's disease;
CESC	cis	rs10392	0.543	rs6028200	chr20:37540615	C/T	cg27552599	chr20:37590471	DHX35	0.39	5.62	0.33	4.87e-8	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
CESC	cis	rs10504229	0.683	rs56196593	chr8:58141898	G/A	cg24829409	chr8:58192753	C8orf71	-0.6	-7.49	-0.42	1.05e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs36096196	0.891	rs12081179	chr1:2251119	A/G	cg00093522	chr1:2252019	NA	0.44	6.15	0.35	2.86e-9	Coronary artery disease;
CESC	cis	rs7100689	0.784	rs4934083	chr10:82116501	G/C	cg09936400	chr10:82049201	MAT1A	0.36	5.07	0.3	7.61e-7	Post bronchodilator FEV1;
CESC	cis	rs7666738	0.830	rs11947578	chr4:98930462	T/G	cg03467027	chr4:99064603	C4orf37	0.46	5.6	0.33	5.39e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7000551	0.689	rs2449339	chr8:22387981	G/A	cg12081754	chr8:22256438	SLC39A14	0.39	5.29	0.31	2.52e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CESC	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg17178900	chr1:205818956	PM20D1	0.49	7.2	0.4	6.27e-12	Menarche (age at onset);
CESC	cis	rs6952808	0.825	rs11761818	chr7:1935273	C/T	cg05863683	chr7:1912471	MAD1L1	0.45	6.87	0.39	4.55e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs736408	0.509	rs13083798	chr3:52649748	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.44	6.81	0.39	6.41e-11	Bipolar disorder;
CESC	trans	rs78472555	0.633	rs2570930	chr15:100214935	C/T	cg17514665	chr17:1657533	SERPINF2	0.45	6.09	0.35	3.88e-9	Post bronchodilator FEV1/FVC ratio in COPD;
CESC	cis	rs7927771	0.839	rs59360790	chr11:47669175	T/C	cg20307385	chr11:47447363	PSMC3	-0.4	-5.09	-0.3	6.73e-7	Subjective well-being;
CESC	trans	rs7618501	1.000	rs7634902	chr3:49762662	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.58	-8.39	-0.46	2.92e-15	Intelligence (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09547170	chr10:105726688	SLK	-0.61	-6.91	-0.39	3.59e-11	Gut microbiome composition (summer);
CESC	cis	rs6685188	0.920	rs6593964	chr1:205662337	G/T	cg24503407	chr1:205819492	PM20D1	0.45	6.27	0.36	1.46e-9	White blood cell count (basophil);Basophil percentage of white cells;
CESC	cis	rs17539620	0.519	rs871071	chr6:154837667	T/C	cg20019720	chr6:154832845	CNKSR3	0.43	6.31	0.36	1.18e-9	Lipoprotein (a) levels;
CESC	cis	rs42648	0.935	rs42664	chr7:89984409	A/G	cg23697855	chr7:89950296	NA	0.27	5.12	0.3	5.74e-7	Homocysteine levels;
CESC	cis	rs4803468	0.967	rs2304243	chr19:41942708	C/G	cg09537434	chr19:41945824	ATP5SL	1.06	19.76	0.77	5e-54	Height;
CESC	cis	rs2075371	1.000	rs2544213	chr7:133982867	G/C	cg00033643	chr7:134001901	SLC35B4	0.43	5.61	0.33	5.1e-8	Mean platelet volume;
CESC	cis	rs2289328	0.823	rs35565646	chr15:40660515	G/A	cg13931752	chr15:40660718	DISP2	0.47	5.81	0.34	1.81e-8	Intelligence (multi-trait analysis);Cognitive ability;Cognitive ability (multi-trait analysis);
CESC	cis	rs7605827	0.930	rs10164574	chr2:15677258	G/A	cg19274914	chr2:15703543	NA	0.36	6.4	0.37	6.95e-10	Educational attainment (years of education);
CESC	cis	rs9911578	0.757	rs8081906	chr17:56631907	A/T	cg05425664	chr17:57184151	TRIM37	0.43	5.43	0.32	1.26e-7	Intelligence (multi-trait analysis);
CESC	cis	rs6879260	1.000	rs10903252	chr5:179733934	T/C	cg23248424	chr5:179741104	GFPT2	-0.56	-7.71	-0.43	2.57e-13	Height;
CESC	cis	rs6570726	0.557	rs403956	chr6:145829956	T/C	cg23711669	chr6:146136114	FBXO30	0.94	12.46	0.61	2.26e-28	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs11098499	0.954	rs9998585	chr4:120396802	T/A	cg09307838	chr4:120376055	NA	0.92	13.12	0.63	1.21e-30	Corneal astigmatism;
CESC	cis	rs4563143	0.663	rs10417671	chr19:29235335	T/C	cg14983838	chr19:29218262	NA	0.38	5.2	0.3	3.94e-7	Methadone dose in opioid dependence;
CESC	cis	rs9487023	1	rs9487023	chr6:109590004	A/G	cg01475377	chr6:109611718	NA	-0.43	-6.7	-0.38	1.26e-10	Red blood cell count;Mean corpuscular hemoglobin concentration;Neutrophil percentage of white cells;Lymphocyte percentage of white cells;Mean corpuscular hemoglobin;High light scatter reticulocyte percentage of red cells;Mean corpuscular volume;
CESC	cis	rs4595586	0.545	rs4142846	chr12:39395140	C/T	cg26384229	chr12:38710491	ALG10B	0.43	6.14	0.35	2.95e-9	Morning vs. evening chronotype;
CESC	cis	rs6570726	0.935	rs442254	chr6:145849118	T/C	cg23711669	chr6:146136114	FBXO30	0.8	11.89	0.59	2e-26	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs10463316	0.862	rs1983171	chr5:150778691	A/G	cg03212797	chr5:150827313	SLC36A1	-0.54	-7.15	-0.4	8.64e-12	Metabolite levels (Pyroglutamine);
CESC	cis	rs2274273	0.870	rs3825616	chr14:55853288	G/C	cg04306507	chr14:55594613	LGALS3	0.3	5.91	0.34	1.07e-8	Protein biomarker;
CESC	cis	rs6089829	0.962	rs6122350	chr20:61664617	A/G	cg03213289	chr20:61660250	NA	0.39	6.07	0.35	4.42e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7666738	0.830	rs11944107	chr4:98931638	G/C	cg03467027	chr4:99064603	C4orf37	0.46	5.6	0.33	5.39e-8	Colonoscopy-negative controls vs population controls;
CESC	trans	rs10448044	1.000	rs10448044	chr8:80103432	T/C	cg08211306	chr6:46097784	ENPP4	0.42	6.08	0.35	4.2e-9	Suicide in bipolar disorder;
CESC	cis	rs9902453	0.967	rs55744550	chr17:28475729	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.62	8.02	0.44	3.43e-14	Coffee consumption (cups per day);
CESC	cis	rs950776	0.518	rs12916483	chr15:78832397	G/A	cg24631222	chr15:78858424	CHRNA5	-0.42	-5.33	-0.31	2.06e-7	Sudden cardiac arrest;
CESC	cis	rs367615	0.661	rs9326773	chr5:108833523	C/T	cg17395555	chr5:108820864	NA	0.63	11.25	0.57	2.95e-24	Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs1552244	0.882	rs67895180	chr3:10026079	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.87	11.29	0.57	2.21e-24	Alzheimer's disease;
CESC	cis	rs1728785	1.000	rs1728789	chr16:68595776	C/T	cg02972257	chr16:68554789	NA	-0.59	-6.7	-0.38	1.23e-10	Ulcerative colitis;
CESC	cis	rs1580019	0.587	rs6951955	chr7:32548761	A/T	cg06627557	chr7:32535165	LSM5;AVL9	1.06	18.8	0.76	1.12e-50	Cognitive ability;
CESC	cis	rs6951245	0.744	rs10275401	chr7:1213943	A/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.44	-5.03	-0.3	9.22e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12898849	chr1:178511736	C1orf220	0.6	6.54	0.37	3.07e-10	Gut microbiome composition (summer);
CESC	cis	rs7618915	0.501	rs6804145	chr3:52694198	C/T	cg17372223	chr3:52568218	NT5DC2	0.42	6.47	0.37	4.6e-10	Bipolar disorder;
CESC	cis	rs7949030	0.504	rs2516633	chr11:62371773	A/C	cg23462726	chr11:62437636	C11orf83;C11orf48	0.45	5.97	0.34	7.59e-9	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs9486719	1.000	rs12210146	chr6:96903962	A/G	cg18709589	chr6:96969512	KIAA0776	0.57	6.2	0.36	2.18e-9	Migraine;Coronary artery disease;
CESC	cis	rs3768617	0.510	rs2333620	chr1:183100555	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.89	14.39	0.66	4.39e-35	Fuchs's corneal dystrophy;
CESC	cis	rs11648796	0.757	rs66649828	chr16:766078	A/G	cg00802000	chr16:706648	WDR90	-0.39	-5.16	-0.3	4.74e-7	Height;
CESC	cis	rs644148	0.785	rs117048220	chr19:44965555	G/A	cg15540054	chr19:45004280	ZNF180	0.66	7.89	0.44	7.86e-14	Personality dimensions;
CESC	cis	rs875971	0.660	rs801193	chr7:66030612	A/C	cg10691866	chr7:65817282	TPST1	0.32	5.18	0.3	4.37e-7	Aortic root size;
CESC	cis	rs3096299	0.967	rs7205785	chr16:89458984	A/G	cg08392591	chr16:89556376	ANKRD11	0.43	5.45	0.32	1.13e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs780096	0.526	rs780107	chr2:27684734	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.32	-5.97	-0.34	7.45e-9	Total body bone mineral density;
CESC	cis	rs9611519	0.894	rs8136923	chr22:41470522	G/A	cg03806693	chr22:41940476	POLR3H	-0.57	-5.94	-0.34	8.97e-9	Neuroticism;
CESC	cis	rs8067354	0.957	rs9896742	chr17:57826530	T/G	cg02344993	chr17:57696989	CLTC	0.49	6.31	0.36	1.14e-9	Hemoglobin concentration;
CESC	cis	rs514406	0.698	rs576891	chr1:53364976	A/G	cg16325326	chr1:53192061	ZYG11B	0.53	7.5	0.42	9.67e-13	Monocyte count;
CESC	trans	rs10435719	0.744	rs11250175	chr8:11792758	G/T	cg15556689	chr8:8085844	FLJ10661	0.54	6.58	0.37	2.47e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
CESC	cis	rs1707322	1.000	rs6687301	chr1:46382852	T/C	cg05343316	chr1:45956843	TESK2	0.44	5.41	0.32	1.39e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	13.6	0.64	2.58e-32	Prudent dietary pattern;
CESC	cis	rs11997175	0.575	rs56942690	chr8:33820308	G/A	ch.8.33884649F	chr8:33765107	NA	0.59	7.35	0.41	2.41e-12	Body mass index;
CESC	cis	rs9916302	0.904	rs4794807	chr17:37531718	T/A	cg19468946	chr17:37922297	IKZF3	0.39	5.04	0.3	8.72e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs2479106	0.591	rs4836935	chr9:126345893	T/G	cg16191174	chr9:126692580	DENND1A	0.37	5.04	0.3	8.66e-7	Polycystic ovary syndrome;
CESC	cis	rs193541	0.632	rs30063	chr5:122295693	G/A	cg19412675	chr5:122181750	SNX24	0.46	5.42	0.32	1.37e-7	Glucose homeostasis traits;
CESC	cis	rs959260	1.000	rs4789188	chr17:73397871	A/C	cg20590849	chr17:73267439	MIF4GD	-0.52	-5.95	-0.34	8.46e-9	Systemic lupus erythematosus;
CESC	cis	rs9858213	1	rs9858213	chr3:49731861	G/T	cg03060546	chr3:49711283	APEH	-0.57	-6.8	-0.39	7.07e-11	Educational attainment;
CESC	cis	rs7474896	0.609	rs1830612	chr10:37999883	A/G	cg25427524	chr10:38739819	LOC399744	-0.45	-5.26	-0.31	3.04e-7	Obesity (extreme);
CESC	trans	rs7726839	0.540	rs72703087	chr5:598029	C/T	cg25482853	chr8:67687455	SGK3	1.04	10.14	0.53	1.27e-20	Obesity-related traits;
CESC	cis	rs2576037	0.566	rs2437854	chr18:44557613	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.77	-12.47	-0.61	2.14e-28	Personality dimensions;
CESC	trans	rs16917919	0.632	rs35712032	chr10:19106327	G/A	cg13853761	chr11:64863232	C11orf2	-0.48	-6.02	-0.35	5.87e-9	Brain structure (hippocampal volume);
CESC	cis	rs6502050	0.697	rs8078634	chr17:80126208	C/T	cg11859384	chr17:80120422	CCDC57	-0.41	-5.71	-0.33	3.03e-8	Life satisfaction;
CESC	cis	rs10896135	0.526	rs624561	chr11:66414915	C/T	cg24851651	chr11:66362959	CCS	-0.55	-7.33	-0.41	2.75e-12	Bipolar disorder;
CESC	cis	rs854765	0.583	rs11869536	chr17:17826528	T/A	cg04398451	chr17:18023971	MYO15A	-0.67	-9.6	-0.51	6.42e-19	Total body bone mineral density;
CESC	cis	rs2354432	0.607	rs3766524	chr1:146729093	A/G	cg25205988	chr1:146714368	CHD1L	-1.01	-8.37	-0.46	3.47e-15	Mitochondrial DNA levels;
CESC	cis	rs1400745	0.718	rs799681	chr14:35350579	A/G	cg16230307	chr14:35515116	FAM177A1	0.44	5.24	0.31	3.23e-7	Monocyte count;
CESC	cis	rs2997447	0.655	rs1317709	chr1:26384690	A/C	cg19633962	chr1:26362018	EXTL1	-0.48	-5.24	-0.31	3.26e-7	QRS complex (12-leadsum);
CESC	cis	rs992157	0.731	rs1399132	chr2:219159770	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.7	9.53	0.51	1.06e-18	Colorectal cancer;
CESC	cis	rs9916302	0.861	rs11078913	chr17:37671714	G/T	cg07936489	chr17:37558343	FBXL20	-0.79	-11.81	-0.59	3.91e-26	Glomerular filtration rate (creatinine);
CESC	trans	rs709082	0.680	rs709103	chr3:191471306	T/C	cg25305879	chr2:106814630	NA	0.4	6.44	0.37	5.56e-10	Colonoscopy-negative controls vs population controls;
CESC	cis	rs921968	0.643	rs585859	chr2:219383121	C/T	cg02176678	chr2:219576539	TTLL4	0.39	6.82	0.39	6.07e-11	Mean corpuscular hemoglobin concentration;
CESC	cis	rs4950322	0.634	rs4950415	chr1:146822702	G/C	cg22381352	chr1:146742008	CHD1L	-0.48	-5.15	-0.3	5.14e-7	Protein quantitative trait loci;
CESC	cis	rs916888	0.610	rs199453	chr17:44800946	C/T	cg01570182	chr17:44337453	NA	0.63	8.65	0.47	5.11e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs6545883	0.894	rs7566035	chr2:61520815	C/T	cg15711740	chr2:61764176	XPO1	0.4	5.07	0.3	7.35e-7	Tuberculosis;
CESC	cis	rs2479724	0.846	rs2254474	chr6:41843044	T/G	cg17623882	chr6:41773611	USP49	-0.41	-5.83	-0.34	1.58e-8	Menarche (age at onset);
CESC	cis	rs769267	0.930	rs10282	chr19:19619317	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.47	6.05	0.35	5.05e-9	Tonsillectomy;
CESC	cis	rs7615952	0.800	rs12489350	chr3:125644116	T/C	cg05084668	chr3:125655381	ALG1L	-0.5	-6.01	-0.35	6.17e-9	Blood pressure (smoking interaction);
CESC	cis	rs9948	0.655	rs62156232	chr2:97431161	C/A	cg01990225	chr2:97406019	LMAN2L	-0.98	-7.37	-0.41	2.17e-12	Erectile dysfunction and prostate cancer treatment;
CESC	cis	rs1788820	0.917	rs1788825	chr18:21109250	T/C	cg14672496	chr18:21087552	C18orf8	0.53	7.11	0.4	1.07e-11	Body mass index;
CESC	cis	rs11098499	0.863	rs11098531	chr4:120465001	G/A	cg24375607	chr4:120327624	NA	0.44	5.36	0.31	1.84e-7	Corneal astigmatism;
CESC	cis	rs2730245	0.615	rs2527207	chr7:158743078	A/G	cg24397884	chr7:158709396	WDR60	-0.86	-9.18	-0.49	1.24e-17	Height;
CESC	cis	rs9311474	0.502	rs4687624	chr3:52563572	C/T	cg07507251	chr3:52567010	NT5DC2	0.48	8.67	0.47	4.43e-16	Electroencephalogram traits;
CESC	cis	rs7336332	0.517	rs9581842	chr13:27978953	G/C	cg01674679	chr13:27998804	GTF3A	-0.53	-5.04	-0.3	8.81e-7	Weight;
CESC	cis	rs1395	0.778	rs1978881	chr2:27400850	C/A	cg22903471	chr2:27725779	GCKR	-0.44	-5.41	-0.32	1.38e-7	Blood metabolite levels;
CESC	cis	rs1008375	1.000	rs28501187	chr4:17643620	G/A	cg02297831	chr4:17616191	MED28	0.57	7.34	0.41	2.67e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs644799	0.526	rs506180	chr11:95623109	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.45	5.8	0.34	1.92e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg18003189	chr10:30723096	MAP3K8	-0.46	-6.48	-0.37	4.41e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs12042107	0.656	rs1342780	chr1:91198676	A/C	cg13456504	chr1:91191583	NA	0.35	6.12	0.35	3.27e-9	Educational attainment;
CESC	cis	rs853679	0.550	rs1233707	chr6:28172953	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.47	-5.61	-0.33	5.18e-8	Depression;
CESC	cis	rs6831352	0.918	rs1042364	chr4:100045574	T/C	cg12011299	chr4:100065546	ADH4	0.59	6.68	0.38	1.41e-10	Alcohol dependence;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg20432401	chr2:114252811	CBWD2	0.41	6.18	0.35	2.37e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs72945132	0.882	rs67244582	chr11:70122009	G/A	cg00319359	chr11:70116639	PPFIA1	0.78	7.78	0.43	1.6e-13	Coronary artery disease;
CESC	cis	rs12822507	0.868	rs12830917	chr12:12792516	C/A	cg09462578	chr12:12878428	APOLD1	-0.45	-5.71	-0.33	3.06e-8	Systemic lupus erythematosus;
CESC	cis	rs1129187	0.837	rs4714634	chr6:42901120	G/A	cg05552183	chr6:42928497	GNMT	0.76	11.57	0.58	2.45e-25	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs1620921	0.505	rs11756055	chr6:161210622	C/T	cg01280913	chr6:161186852	NA	-0.38	-5.43	-0.32	1.28e-7	Lipoprotein (a) - cholesterol levels;
CESC	trans	rs916888	0.821	rs199514	chr17:44856881	G/A	cg22968622	chr17:43663579	NA	-1.22	-16.23	-0.71	1.35e-41	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs1707322	0.752	rs28719889	chr1:46202283	C/T	cg03146154	chr1:46216737	IPP	0.81	11.41	0.57	8.44e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs6690583	0.524	rs12045710	chr1:85451765	T/C	cg22153463	chr1:85462885	MCOLN2	0.71	7.13	0.4	9.73e-12	Serum sulfate level;
CESC	cis	rs4835473	1.000	rs4835473	chr4:144903572	A/T	cg25736465	chr4:144833511	NA	0.41	6.19	0.36	2.33e-9	Immature fraction of reticulocytes;
CESC	cis	rs6502050	0.637	rs74765203	chr17:80118223	A/G	cg11859384	chr17:80120422	CCDC57	-0.39	-5.35	-0.31	1.95e-7	Life satisfaction;
CESC	cis	rs10540	0.908	rs35608427	chr11:498976	T/C	cg03934478	chr11:495069	RNH1	0.56	5.43	0.32	1.25e-7	Body mass index;
CESC	trans	rs2727020	0.658	rs4980442	chr11:49445016	G/T	cg15704280	chr7:45808275	SEPT13	-0.9	-15.56	-0.69	3.08e-39	Coronary artery disease;
CESC	cis	rs2721195	0.614	rs12719778	chr8:145879883	T/C	cg15320075	chr8:145703422	NA	0.49	6.5	0.37	3.86e-10	Age at first birth;
CESC	cis	rs10743315	0.557	rs77344887	chr12:19312751	C/T	cg02471346	chr12:19282374	PLEKHA5	0.75	5.66	0.33	3.91e-8	Gut microbiota (bacterial taxa);
CESC	cis	rs7134594	0.617	rs9668192	chr12:109860911	T/A	cg19025524	chr12:109796872	NA	-0.4	-5.68	-0.33	3.62e-8	HDL cholesterol;
CESC	cis	rs72781680	0.611	rs55905755	chr2:24330264	T/C	cg06627628	chr2:24431161	ITSN2	-0.67	-6.32	-0.36	1.13e-9	Lymphocyte counts;
CESC	cis	rs10504073	0.669	rs341799	chr8:50036574	A/G	cg00325661	chr8:49890786	NA	0.51	7.54	0.42	7.35e-13	Blood metabolite ratios;
CESC	cis	rs2933343	0.700	rs6787833	chr3:128656184	A/G	cg24203234	chr3:128598194	ACAD9	0.44	6.01	0.35	6e-9	IgG glycosylation;
CESC	cis	rs9905704	0.681	rs2531728	chr17:56539792	T/C	cg12560992	chr17:57184187	TRIM37	0.63	5.87	0.34	1.33e-8	Testicular germ cell tumor;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg26565884	chr16:89187106	ACSF3	0.45	6.57	0.37	2.59e-10	Fibrinogen levels;
CESC	cis	rs644799	0.931	rs496305	chr11:95567035	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.54	6.46	0.37	4.92e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs7618915	0.501	rs13079063	chr3:52744460	A/G	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	5.75	0.33	2.41e-8	Bipolar disorder;
CESC	cis	rs3096299	0.933	rs2965823	chr16:89454924	G/A	cg00750074	chr16:89608354	SPG7	-0.37	-5.23	-0.31	3.37e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs9549367	0.789	rs2316442	chr13:113877487	C/T	cg00898013	chr13:113819073	PROZ	-0.51	-6.99	-0.39	2.18e-11	Platelet distribution width;
CESC	cis	rs1976403	0.633	rs1697422	chr1:21821897	T/C	cg04349561	chr1:21808255	NBPF3	-0.41	-6.01	-0.35	6.27e-9	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs8072100	0.846	rs7214799	chr17:45702099	C/T	cg08085267	chr17:45401833	C17orf57	0.41	5.17	0.3	4.67e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs2882667	0.964	rs12055237	chr5:138307306	A/G	cg04439458	chr5:138467593	SIL1	-0.37	-5.8	-0.34	1.92e-8	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs875971	0.862	rs778707	chr7:65857027	G/A	cg18876405	chr7:65276391	NA	0.53	7.32	0.41	3.01e-12	Aortic root size;
CESC	cis	rs7772486	0.754	rs9399567	chr6:146147295	C/T	cg05347473	chr6:146136440	FBXO30	0.56	6.88	0.39	4.39e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.44	5.42	0.32	1.36e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05147328	chr17:79849438	ANAPC11;THOC4	0.48	6.24	0.36	1.71e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg23034840	chr1:205782522	SLC41A1	0.68	8.43	0.46	2.21e-15	Menarche (age at onset);
CESC	cis	rs12926788	0.542	rs11862971	chr16:24767574	C/A	cg00339695	chr16:24857497	SLC5A11	0.5	6.57	0.37	2.58e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs9733	0.519	rs1336900	chr1:150679033	C/T	cg17724175	chr1:150552817	MCL1	0.42	6.92	0.39	3.3e-11	Tonsillectomy;
CESC	cis	rs2404618	0.587	rs6994849	chr8:1492839	G/T	cg13402656	chr8:1511478	DLGAP2	0.65	9.64	0.51	4.94e-19	Lung cancer;
CESC	cis	rs514406	0.792	rs1242201	chr1:53344748	G/A	cg06600287	chr1:53387719	ECHDC2	-0.29	-5.1	-0.3	6.48e-7	Monocyte count;
CESC	cis	rs6860806	0.507	rs169256	chr5:131688533	A/G	cg24060327	chr5:131705240	SLC22A5	-0.64	-7.11	-0.4	1.11e-11	Breast cancer;
CESC	cis	rs7520050	0.966	rs6656992	chr1:46333068	C/G	cg03146154	chr1:46216737	IPP	-0.48	-6.22	-0.36	1.98e-9	Red blood cell count;Reticulocyte count;
CESC	trans	rs1814175	0.817	rs10769648	chr11:50013992	T/C	cg15704280	chr7:45808275	SEPT13	-1.05	-21.18	-0.79	6.15e-59	Height;
CESC	cis	rs1878931	0.507	rs35214904	chr16:3410017	C/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.67	-8.06	-0.44	2.68e-14	Body mass index (adult);
CESC	cis	rs9486715	0.867	rs9373907	chr6:96981189	G/A	cg06623918	chr6:96969491	KIAA0776	0.86	12.48	0.61	1.97e-28	Headache;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05028089	chr10:79793366	RPS24	-0.56	-6.34	-0.36	1.01e-9	Gut microbiome composition (summer);
CESC	cis	rs2576037	0.796	rs2571018	chr18:44585344	T/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.34	-5.27	-0.31	2.9e-7	Personality dimensions;
CESC	cis	rs9486719	0.857	rs11759769	chr6:97065212	G/A	cg18709589	chr6:96969512	KIAA0776	-0.49	-5.45	-0.32	1.14e-7	Migraine;Coronary artery disease;
CESC	cis	rs1552244	0.882	rs34706481	chr3:10004123	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.76	8.9	0.48	8.92e-17	Alzheimer's disease;
CESC	trans	rs673604	0.505	rs676614	chr1:36107510	G/T	cg05313393	chr1:249120451	SH3BP5L	0.53	6.0	0.35	6.48e-9	Endometrial cancer;
CESC	cis	rs4523957	0.928	rs12938295	chr17:2160854	A/G	cg16513277	chr17:2031491	SMG6	0.6	8.18	0.45	1.22e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs644799	1.000	rs580255	chr11:95577929	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	8.76	0.47	2.41e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	trans	rs5769765	0.862	rs9616385	chr22:50313124	C/T	cg09872104	chr7:134855509	C7orf49	-0.55	-6.31	-0.36	1.19e-9	Schizophrenia;
CESC	cis	rs11030122	0.632	rs714380	chr11:4059653	A/T	cg18678763	chr11:4115507	RRM1	-0.44	-6.03	-0.35	5.57e-9	Mean platelet volume;Platelet distribution width;
CESC	cis	rs7044106	0.791	rs4836831	chr9:123496570	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.35	5.47	0.32	1.03e-7	Hip circumference adjusted for BMI;
CESC	cis	rs12681288	0.550	rs4272405	chr8:959014	C/G	cg04851639	chr8:1020857	NA	-0.28	-5.59	-0.32	5.55e-8	Schizophrenia;
CESC	cis	rs2404602	0.692	rs3110382	chr15:77148688	G/A	cg26408565	chr15:76604113	ETFA	0.37	5.3	0.31	2.49e-7	Blood metabolite levels;
CESC	cis	rs7666738	0.830	rs10011009	chr4:98981749	G/A	cg03676636	chr4:99064102	C4orf37	0.33	5.13	0.3	5.6e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9896933	0.832	rs79103992	chr17:80855483	G/A	cg20578329	chr17:80767326	TBCD	-0.77	-7.82	-0.43	1.24e-13	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
CESC	cis	rs4689592	0.546	rs10937784	chr4:7060935	G/C	cg26116260	chr4:7069785	GRPEL1	0.97	14.9	0.68	7.15e-37	Monocyte percentage of white cells;
CESC	cis	rs9660992	0.573	rs12140703	chr1:205182865	G/C	cg21643547	chr1:205240462	TMCC2	-0.39	-5.56	-0.32	6.46e-8	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs9549367	0.713	rs9549681	chr13:113829873	T/C	cg18105134	chr13:113819100	PROZ	-0.69	-8.26	-0.45	6.8e-15	Platelet distribution width;
CESC	cis	rs72781680	0.800	rs72790306	chr2:24111311	T/G	cg20701182	chr2:24300061	SF3B14	0.78	6.91	0.39	3.59e-11	Lymphocyte counts;
CESC	cis	rs8060686	0.858	rs2271294	chr16:67902326	A/T	cg26727032	chr16:67993705	SLC12A4	-0.65	-9.58	-0.51	7.54e-19	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs2290159	0.800	rs7636754	chr3:12678725	C/G	cg23032965	chr3:12705835	RAF1	0.54	5.72	0.33	2.9e-8	Cholesterol, total;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg18570646	chr15:37391424	MEIS2	0.37	6.02	0.35	5.71e-9	Gambling;
CESC	cis	rs9527	0.590	rs1046411	chr10:104837816	G/A	cg04362960	chr10:104952993	NT5C2	0.43	5.5	0.32	9.06e-8	Arsenic metabolism;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg23667572	chr19:11170597	SMARCA4	0.45	6.5	0.37	3.9e-10	Fibrinogen levels;
CESC	cis	rs2295359	1.000	rs9729046	chr1:67607082	C/G	cg03340356	chr1:67600835	NA	0.32	5.46	0.32	1.11e-7	Psoriasis;
CESC	cis	rs17376456	0.825	rs7715562	chr5:93222034	C/T	cg21475434	chr5:93447410	FAM172A	-0.74	-6.65	-0.38	1.71e-10	Diabetic retinopathy;
CESC	cis	rs644799	0.542	rs10831417	chr11:95467262	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	-0.45	-5.8	-0.34	1.93e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07816229	chr5:154317915	GEMIN5	0.54	6.09	0.35	4.05e-9	Gut microbiome composition (summer);
CESC	cis	rs12995491	0.933	rs34366691	chr2:88537451	G/A	cg04511125	chr2:88470314	THNSL2	-0.51	-7.44	-0.42	1.38e-12	Response to metformin (IC50);
CESC	cis	rs10851478	0.872	rs7174135	chr15:49755442	T/A	cg08060515	chr15:49448048	GALK2;COPS2	0.42	5.16	0.3	4.79e-7	Oral cavity cancer;
CESC	cis	rs2228479	0.867	rs62052189	chr16:89975555	G/C	cg00800038	chr16:89945340	TCF25	-0.75	-7.05	-0.4	1.54e-11	Skin colour saturation;
CESC	cis	rs7927592	0.701	rs12226585	chr11:68257861	A/T	cg16797656	chr11:68205561	LRP5	-0.51	-8.05	-0.44	2.82e-14	Total body bone mineral density;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04674143	chr19:4831543	TICAM1	0.59	6.84	0.39	5.49e-11	Gut microbiome composition (summer);
CESC	cis	rs412050	0.895	rs2329886	chr22:22298474	G/A	cg17089214	chr22:22089827	YPEL1	0.67	6.1	0.35	3.76e-9	Attention deficit hyperactivity disorder;
CESC	cis	rs514406	0.893	rs1242317	chr1:53414766	T/C	cg16325326	chr1:53192061	ZYG11B	0.91	14.94	0.68	5.09e-37	Monocyte count;
CESC	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg24829409	chr8:58192753	C8orf71	-0.65	-7.36	-0.41	2.29e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs8017423	0.935	rs17188598	chr14:90722473	A/T	cg14092571	chr14:90743983	NA	-0.56	-8.49	-0.46	1.54e-15	Mortality in heart failure;
CESC	cis	rs2832191	0.626	rs2254796	chr21:30341891	A/G	cg08807101	chr21:30365312	RNF160	-0.85	-12.5	-0.61	1.72e-28	Dental caries;
CESC	cis	rs6500395	0.775	rs7198145	chr16:48666500	A/C	cg04672837	chr16:48644449	N4BP1	0.49	6.43	0.37	5.82e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs4253772	0.550	rs6008762	chr22:46736228	T/C	cg24881330	chr22:46731750	TRMU	0.9	7.81	0.43	1.33e-13	LDL cholesterol;Cholesterol, total;
CESC	cis	rs13191362	0.935	rs35537826	chr6:163145867	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.48	5.31	0.31	2.29e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	trans	rs35110281	0.811	rs2838337	chr21:45072621	A/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.54	7.11	0.4	1.05e-11	Mean corpuscular volume;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg09844983	chr1:28240714	RPA2	-0.45	-6.49	-0.37	4.1e-10	Gambling;
CESC	cis	rs6800768	0.633	rs826371	chr3:24163645	C/G	cg10674438	chr3:24145617	LOC152024	-0.46	-6.73	-0.38	1.03e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs1538970	0.924	rs1826691	chr1:45881262	A/G	cg24296786	chr1:45957014	TESK2	0.44	5.13	0.3	5.65e-7	Platelet count;
CESC	cis	rs4727027	0.866	rs2373438	chr7:148780287	C/A	cg23583168	chr7:148888333	NA	-0.79	-12.11	-0.6	3.74e-27	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs4555082	0.834	rs2816631	chr14:105739477	G/A	cg06808227	chr14:105710500	BRF1	-0.56	-6.38	-0.37	7.71e-10	Mean platelet volume;Platelet distribution width;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16837769	chr7:10979899	NDUFA4	-0.56	-6.48	-0.37	4.55e-10	Gut microbiome composition (summer);
CESC	cis	rs9549367	0.756	rs9603814	chr13:113900782	C/T	cg18105134	chr13:113819100	PROZ	0.61	7.87	0.44	9.23e-14	Platelet distribution width;
CESC	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg24503407	chr1:205819492	PM20D1	0.83	12.71	0.62	3.15e-29	Menarche (age at onset);
CESC	cis	rs9815354	0.516	rs115135603	chr3:42031622	T/C	cg03022575	chr3:42003672	ULK4	0.75	6.64	0.38	1.72e-10	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs17376456	0.825	rs17372725	chr5:93135588	C/A	cg25358565	chr5:93447407	FAM172A	1.1	10.84	0.55	6.88e-23	Diabetic retinopathy;
CESC	cis	rs8020095	0.571	rs1138802	chr14:67439669	C/A	cg19548862	chr14:67692701	FAM71D	-0.49	-5.89	-0.34	1.16e-8	Depression (quantitative trait);
CESC	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	7.75	0.43	1.94e-13	Prudent dietary pattern;
CESC	cis	rs6668108	1	rs6668108	chr1:165691320	A/G	cg24409356	chr1:165738333	TMCO1	0.9	8.2	0.45	1.04e-14	Intraocular pressure;
CESC	cis	rs7605827	0.836	rs4396684	chr2:15634404	C/T	cg19274914	chr2:15703543	NA	0.33	5.79	0.33	2.02e-8	Educational attainment (years of education);
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg18176887	chr7:108210328	THAP5;DNAJB9	-0.48	-6.72	-0.38	1.08e-10	Asthma;
CESC	cis	rs7618915	0.501	rs12635140	chr3:52738165	C/T	cg17372223	chr3:52568218	NT5DC2	-0.43	-6.6	-0.38	2.25e-10	Bipolar disorder;
CESC	cis	rs8044868	0.586	rs2070937	chr16:72089740	A/G	cg16558253	chr16:72132732	DHX38	-0.41	-6.49	-0.37	4.12e-10	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CESC	cis	rs9837602	1.000	rs62285478	chr3:99822135	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.49	6.83	0.39	5.64e-11	Breast cancer;
CESC	cis	rs10256972	0.527	rs2949170	chr7:1216438	A/G	cg07308232	chr7:1071921	C7orf50	-0.44	-5.73	-0.33	2.75e-8	Longevity;Endometriosis;
CESC	cis	rs34172651	0.517	rs189919	chr16:24737741	G/A	cg04756594	chr16:24857601	SLC5A11	-0.5	-5.81	-0.34	1.82e-8	Intelligence (multi-trait analysis);
CESC	cis	rs926938	0.527	rs360667	chr1:115481451	C/G	cg12756093	chr1:115239321	AMPD1	-0.46	-6.4	-0.37	6.82e-10	Autism;
CESC	cis	rs6032067	0.929	rs35869085	chr20:43805134	G/C	cg11264863	chr20:43835661	SEMG1	0.51	5.56	0.32	6.63e-8	Blood protein levels;
CESC	cis	rs2425143	0.512	rs11699653	chr20:34622916	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.57	-7.28	-0.41	3.86e-12	Blood protein levels;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg02927949	chr13:103426033	C13orf27	-0.48	-6.36	-0.36	8.75e-10	Fibrinogen levels;
CESC	cis	rs7937682	0.737	rs682239	chr11:111425105	A/G	cg22437258	chr11:111473054	SIK2	-0.61	-7.74	-0.43	2.13e-13	Primary sclerosing cholangitis;
CESC	cis	rs7635838	0.654	rs347585	chr3:11286220	C/T	cg00170343	chr3:11313890	ATG7	0.43	5.3	0.31	2.45e-7	HDL cholesterol;
CESC	cis	rs4253772	0.550	rs6008613	chr22:46707924	G/T	cg24881330	chr22:46731750	TRMU	0.81	7.31	0.41	3.09e-12	LDL cholesterol;Cholesterol, total;
CESC	cis	rs10504229	1.000	rs114312649	chr8:58182539	C/G	cg24829409	chr8:58192753	C8orf71	-0.76	-9.93	-0.52	5.87e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs7552404	0.961	rs17587071	chr1:76225083	A/C	cg03433033	chr1:76189801	ACADM	0.69	8.34	0.46	4.12e-15	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs17818399	0.926	rs1824050	chr2:46839477	T/C	cg02822958	chr2:46747628	ATP6V1E2	0.47	5.73	0.33	2.73e-8	Height;
CESC	cis	rs2573652	1.000	rs2573651	chr15:100514109	T/G	cg09918751	chr15:100517450	ADAMTS17	-0.39	-7.61	-0.42	4.66e-13	Height;
CESC	cis	rs67311347	1.000	rs7628796	chr3:40507332	G/A	cg24209194	chr3:40518798	ZNF619	-0.52	-6.85	-0.39	5.1e-11	Renal cell carcinoma;
CESC	cis	rs2841277	0.708	rs11623422	chr14:105407031	A/G	cg15352829	chr14:105391018	PLD4	-0.6	-10.51	-0.54	8.09e-22	Rheumatoid arthritis;
CESC	cis	rs2361718	0.501	rs8065486	chr17:78138196	A/G	cg23534315	chr17:78082725	GAA	-0.42	-5.67	-0.33	3.78e-8	Yeast infection;
CESC	trans	rs3780486	0.522	rs1328898	chr9:33163271	A/G	cg04842962	chr6:43655489	MRPS18A	0.68	10.35	0.54	2.56e-21	IgG glycosylation;
CESC	cis	rs6570726	0.935	rs451349	chr6:145820894	A/G	cg05347473	chr6:146136440	FBXO30	0.49	6.71	0.38	1.2e-10	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs656319	0.625	rs34427895	chr8:9875221	G/C	cg15556689	chr8:8085844	FLJ10661	-0.53	-6.36	-0.36	9.01e-10	Myopia (pathological);
CESC	cis	rs9393777	0.513	rs7754159	chr6:26620312	G/A	cg12826209	chr6:26865740	GUSBL1	0.76	8.73	0.47	2.93e-16	Intelligence (multi-trait analysis);
CESC	cis	rs1008375	0.932	rs6857678	chr4:17696964	A/T	cg15017067	chr4:17643749	FAM184B	0.37	5.2	0.3	3.95e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs4237845	0.537	rs10747787	chr12:58260657	A/G	cg00677455	chr12:58241039	CTDSP2	0.75	10.52	0.54	7.33e-22	Intelligence (multi-trait analysis);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg16256719	chr1:228613082	HIST3H3	0.52	7.12	0.4	1.02e-11	Fibrinogen levels;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg23946709	chr14:23527317	CDH24	-0.49	-6.5	-0.37	3.87e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs5750830	0.649	rs4384886	chr22:39793766	C/T	cg05872129	chr22:39784769	NA	-0.85	-12.1	-0.6	3.94e-27	Intelligence (multi-trait analysis);
CESC	cis	rs2439831	0.681	rs28578454	chr15:43603032	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.86	10.79	0.55	9.43e-23	Lung cancer in ever smokers;
CESC	cis	rs709400	0.663	rs11628213	chr14:103952453	A/C	cg12935359	chr14:103987150	CKB	-0.57	-8.39	-0.46	2.88e-15	Body mass index;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17896229	chr20:5294595	PROKR2	-0.49	-6.32	-0.36	1.13e-9	Gut microbiome composition (summer);
CESC	cis	rs7412746	0.658	rs10305711	chr1:150802996	T/C	cg04414720	chr1:150670196	GOLPH3L	0.55	7.44	0.42	1.37e-12	Melanoma;
CESC	cis	rs332507	0.830	rs3772787	chr3:124395368	G/C	cg05980111	chr3:124395277	KALRN	0.38	5.08	0.3	7.19e-7	Plateletcrit;
CESC	cis	rs9733	0.596	rs11204687	chr1:150629880	C/A	cg18016565	chr1:150552671	MCL1	0.33	5.13	0.3	5.67e-7	Tonsillectomy;
CESC	cis	rs6860806	0.507	rs272882	chr5:131669161	G/T	cg07395648	chr5:131743802	NA	-0.44	-5.72	-0.33	2.95e-8	Breast cancer;
CESC	cis	rs4689388	0.926	rs4343789	chr4:6285228	C/G	cg00701064	chr4:6280414	WFS1	0.75	13.49	0.64	6.32e-32	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs5769707	0.967	rs5770585	chr22:50007874	G/A	cg20744362	chr22:50050164	C22orf34	0.48	8.37	0.46	3.36e-15	Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.63	7.16	0.4	7.99e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2070488	0.804	rs7646429	chr3:38467713	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.82	13.14	0.63	1.09e-30	Electrocardiographic conduction measures;
CESC	cis	rs7615952	0.641	rs6805074	chr3:125772274	T/A	cg06494592	chr3:125709126	NA	-0.49	-5.2	-0.3	3.92e-7	Blood pressure (smoking interaction);
CESC	cis	rs2599510	0.811	rs2243844	chr2:32775984	G/T	cg02381751	chr2:32503542	YIPF4	0.43	5.14	0.3	5.4e-7	Interleukin-18 levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21535199	chr1:152749106	LCE1F	-0.53	-8.04	-0.44	3e-14	Gut microbiome composition (summer);
CESC	cis	rs9303401	0.659	rs7210700	chr17:56668186	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.02	12.93	0.62	5.59e-30	Cognitive test performance;
CESC	cis	rs7918232	0.830	rs9833	chr10:27400861	G/A	cg14442939	chr10:27389572	ANKRD26	0.68	6.51	0.37	3.77e-10	Breast cancer;
CESC	cis	rs36051895	0.554	rs10975027	chr9:5248827	G/A	cg02405213	chr9:5042618	JAK2	-0.55	-6.53	-0.37	3.24e-10	Pediatric autoimmune diseases;
CESC	cis	rs4319547	0.695	rs7969429	chr12:122875606	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.54	-6.14	-0.35	3.08e-9	Body mass index;
CESC	cis	rs7605827	0.930	rs11898971	chr2:15613678	C/T	cg19274914	chr2:15703543	NA	-0.36	-6.45	-0.37	5.14e-10	Educational attainment (years of education);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02671019	chr1:24829462	RCAN3	0.55	6.17	0.35	2.48e-9	Gut microbiome composition (summer);
CESC	cis	rs6032067	0.929	rs17333381	chr20:43804919	C/T	cg11264863	chr20:43835661	SEMG1	0.51	5.56	0.32	6.5e-8	Blood protein levels;
CESC	cis	rs870825	0.929	rs72689278	chr4:185593718	C/T	cg04058563	chr4:185651563	MLF1IP	0.57	5.29	0.31	2.54e-7	Blood protein levels;
CESC	cis	rs8060686	0.545	rs12444313	chr16:68254404	A/C	cg26727032	chr16:67993705	SLC12A4	-0.48	-5.18	-0.3	4.5e-7	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs12824058	0.767	rs4759654	chr12:130815559	A/G	cg24838063	chr12:130822603	PIWIL1	0.62	8.55	0.47	9.78e-16	Menopause (age at onset);
CESC	cis	rs6089829	0.962	rs6011548	chr20:61666063	C/T	cg08564027	chr20:61660810	NA	0.9	15.37	0.69	1.54e-38	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs6987853	0.933	rs2974353	chr8:42409165	A/C	cg09913449	chr8:42400586	C8orf40	0.4	6.38	0.37	7.72e-10	Mean corpuscular hemoglobin concentration;
CESC	cis	rs7618501	0.633	rs9866695	chr3:50069452	G/T	cg24308560	chr3:49941425	MST1R	0.64	9.22	0.49	9.57e-18	Intelligence (multi-trait analysis);
CESC	cis	rs72945132	0.769	rs3781644	chr11:70190375	G/A	cg00319359	chr11:70116639	PPFIA1	0.72	6.84	0.39	5.42e-11	Coronary artery disease;
CESC	cis	rs941873	0.772	rs7086293	chr10:81103247	T/C	cg09469691	chr10:81107165	PPIF	0.55	7.49	0.42	1.04e-12	Height;
CESC	cis	rs1950500	0.585	rs8003339	chr14:24817817	T/C	cg16194253	chr14:24768981	DHRS1;C14orf21	0.52	6.56	0.37	2.85e-10	Height;
CESC	cis	rs5750830	0.649	rs5757664	chr22:39821536	A/G	cg05872129	chr22:39784769	NA	-0.84	-11.4	-0.57	9.27e-25	Intelligence (multi-trait analysis);
CESC	cis	rs1059312	0.808	rs2306683	chr12:129299675	C/G	cg09035930	chr12:129282057	SLC15A4	0.67	8.84	0.48	1.4e-16	Systemic lupus erythematosus;
CESC	cis	rs477692	1.000	rs567700	chr10:131423126	C/T	cg05714579	chr10:131428358	MGMT	0.48	6.49	0.37	4.29e-10	Response to temozolomide;
CESC	cis	rs514406	0.505	rs146750	chr1:53183447	C/G	cg08859206	chr1:53392774	SCP2	-0.55	-7.38	-0.41	2.03e-12	Monocyte count;
CESC	cis	rs6460942	1.000	rs17191008	chr7:12417690	T/G	cg17427002	chr7:12443146	VWDE	-0.55	-5.24	-0.31	3.26e-7	Coronary artery disease;
CESC	cis	rs2637266	0.783	rs846640	chr10:78524293	T/C	cg18941641	chr10:78392320	NA	0.4	7.72	0.43	2.36e-13	Pulmonary function;
CESC	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg04234412	chr22:24373322	LOC391322	-0.49	-7.12	-0.4	1.02e-11	Liver enzyme levels (gamma-glutamyl transferase);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23967848	chr2:71556215	NA	-0.51	-6.72	-0.38	1.1e-10	Gut microbiome composition (summer);
CESC	cis	rs1448094	0.511	rs59668915	chr12:86197170	C/T	cg02569458	chr12:86230093	RASSF9	0.52	7.75	0.43	1.92e-13	Major depressive disorder;
CESC	cis	rs35110281	0.805	rs162402	chr21:44963418	G/C	cg04455712	chr21:45112962	RRP1B	0.37	5.5	0.32	9.14e-8	Mean corpuscular volume;
CESC	cis	rs9911578	1.000	rs9915935	chr17:56843048	A/G	cg05425664	chr17:57184151	TRIM37	-0.5	-6.9	-0.39	3.8e-11	Intelligence (multi-trait analysis);
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg10554839	chr10:27529782	ACBD5	0.48	6.08	0.35	4.08e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs7647973	0.710	rs1491983	chr3:49639803	G/T	cg07636037	chr3:49044803	WDR6	0.6	7.17	0.4	7.33e-12	Menarche (age at onset);
CESC	cis	rs7851660	0.874	rs2417576	chr9:100628707	C/T	cg13688889	chr9:100608707	NA	-0.63	-8.87	-0.48	1.09e-16	Strep throat;
CESC	cis	rs11969893	0.737	rs6930051	chr6:101406108	A/G	cg12253828	chr6:101329408	ASCC3	0.86	7.12	0.4	1e-11	Economic and political preferences (immigration/crime);
CESC	cis	rs798554	0.757	rs2533879	chr7:2859847	G/A	cg04166393	chr7:2884313	GNA12	0.62	7.72	0.43	2.35e-13	Height;
CESC	cis	rs7107174	1.000	rs1893448	chr11:77969180	G/A	cg02023728	chr11:77925099	USP35	0.42	6.15	0.35	2.85e-9	Testicular germ cell tumor;
CESC	cis	rs514406	0.627	rs485128	chr1:53344583	T/C	cg08736216	chr1:53307985	ZYG11A	-0.44	-7.35	-0.41	2.54e-12	Monocyte count;
CESC	cis	rs4969178	0.965	rs938351	chr17:76399404	C/T	cg20026190	chr17:76395443	PGS1	0.48	7.6	0.42	5.19e-13	HDL cholesterol levels;
CESC	cis	rs7605827	0.930	rs11694458	chr2:15530469	C/G	cg19274914	chr2:15703543	NA	0.37	6.74	0.38	9.98e-11	Educational attainment (years of education);
CESC	cis	rs4746818	1.000	rs4284308	chr10:70884861	C/T	cg11621586	chr10:70884670	VPS26A	0.93	12.53	0.61	1.35e-28	Left atrial antero-posterior diameter;
CESC	trans	rs7716219	0.731	rs7704138	chr5:54944262	C/T	cg15910928	chr8:17658838	MTUS1	-0.41	-6.32	-0.36	1.12e-9	Height;
CESC	cis	rs798554	0.836	rs798526	chr7:2775542	G/C	cg19346786	chr7:2764209	NA	-0.5	-7.27	-0.41	4.14e-12	Height;
CESC	cis	rs7551222	0.721	rs4951402	chr1:204539122	C/T	cg20240347	chr1:204465584	NA	-0.27	-5.52	-0.32	8.01e-8	Schizophrenia;
CESC	cis	rs873946	0.586	rs12776770	chr10:134564831	T/C	cg27297192	chr10:134578999	INPP5A	0.41	5.47	0.32	1.05e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	trans	rs12599106	0.625	rs12923277	chr16:34896261	G/A	cg07332563	chr6:291687	DUSP22	-0.66	-8.38	-0.46	3.11e-15	Menopause (age at onset);
CESC	cis	rs1448094	0.580	rs11615323	chr12:86282171	T/C	cg00310523	chr12:86230176	RASSF9	0.37	5.43	0.32	1.29e-7	Major depressive disorder;
CESC	cis	rs6681460	0.966	rs10749765	chr1:67150280	C/T	cg02459107	chr1:67143332	SGIP1	0.38	5.28	0.31	2.64e-7	Presence of antiphospholipid antibodies;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg09273779	chr9:35605990	TESK1	-0.43	-6.27	-0.36	1.49e-9	Gambling;
CESC	cis	rs2070488	0.775	rs6794397	chr3:38559307	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.77	12.43	0.61	2.92e-28	Electrocardiographic conduction measures;
CESC	cis	rs3087591	0.922	rs11867284	chr17:29597464	G/A	cg24425628	chr17:29625626	OMG;NF1	0.47	5.92	0.34	1e-8	Hip circumference;
CESC	cis	rs2072732	0.821	rs58265521	chr1:2943398	C/A	cg03976712	chr1:2946727	NA	0.34	5.35	0.31	1.9e-7	Plateletcrit;
CESC	cis	rs7618915	0.571	rs6798246	chr3:52599922	G/A	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.38	6.72	0.38	1.13e-10	Bipolar disorder;
CESC	cis	rs12472274	0.646	rs35468889	chr2:239090959	G/A	cg17459225	chr2:239074497	NA	0.49	5.85	0.34	1.41e-8	Phospholipid levels (plasma);
CESC	cis	rs4566357	0.595	rs2272203	chr2:227914655	C/G	cg11843606	chr2:227700838	RHBDD1	-0.46	-6.37	-0.36	8.35e-10	Coronary artery disease;
CESC	cis	rs796364	1.000	rs35220450	chr2:200780737	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.95	-7.49	-0.42	1.06e-12	Schizophrenia;
CESC	cis	rs8111998	0.826	rs7245541	chr19:22768771	C/T	cg19914732	chr19:22715077	NA	0.37	5.32	0.31	2.25e-7	Corneal structure;
CESC	cis	rs2576037	0.583	rs512699	chr18:44374681	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.32	-5.18	-0.3	4.45e-7	Personality dimensions;
CESC	cis	rs1707322	1.000	rs11211228	chr1:46399840	G/A	cg03146154	chr1:46216737	IPP	0.72	9.82	0.52	1.31e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs75477785	1.000	rs12064085	chr1:210050077	T/A	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.79	5.15	0.3	5.08e-7	Cleft lip with or without cleft palate;
CESC	trans	rs3942852	1.000	rs3942852	chr11:48115089	C/T	cg15704280	chr7:45808275	SEPT13	-0.57	-6.6	-0.38	2.28e-10	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs7917772	0.582	rs10786684	chr10:104323028	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.42	-5.83	-0.34	1.62e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs617791	0.508	rs2276132	chr11:65770545	G/A	cg09783858	chr11:65769428	EIF1AD;BANF1	0.51	6.04	0.35	5.07e-9	Breast cancer;
CESC	cis	rs12541335	0.639	rs11779277	chr8:22200683	C/T	cg18135555	chr8:22132992	PIWIL2	0.25	5.34	0.31	2e-7	Hypertriglyceridemia;
CESC	cis	rs12887734	0.524	rs12588797	chr14:104300020	C/T	cg08213375	chr14:104286397	PPP1R13B	-0.41	-6.95	-0.39	2.88e-11	Schizophrenia;Autism spectrum disorder or schizophrenia;
CESC	cis	rs12142240	0.667	rs41293287	chr1:46808852	C/T	cg00530320	chr1:46809349	NSUN4	0.6	7.98	0.44	4.48e-14	Menopause (age at onset);
CESC	cis	rs2303759	0.874	rs8108669	chr19:49845895	C/T	cg24324837	chr19:49891574	CCDC155	0.43	5.12	0.3	5.98e-7	Multiple sclerosis;
CESC	cis	rs897984	0.806	rs10782001	chr16:30942625	G/A	cg00531865	chr16:30841666	NA	0.51	7.12	0.4	1.01e-11	Dementia with Lewy bodies;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10998122	chr11:64008466	FKBP2	0.54	6.09	0.35	3.99e-9	Gut microbiome composition (summer);
CESC	cis	rs193541	0.632	rs6595413	chr5:122156949	G/A	cg19412675	chr5:122181750	SNX24	0.45	5.15	0.3	4.98e-7	Glucose homeostasis traits;
CESC	trans	rs12107539	0.918	rs56087525	chr3:151003677	T/G	cg05862518	chr17:40277425	RAB5C	-0.47	-6.09	-0.35	4.05e-9	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
CESC	cis	rs9894429	0.646	rs8079963	chr17:79603285	C/T	cg18240062	chr17:79603768	NPLOC4	0.54	7.11	0.4	1.06e-11	Eye color traits;
CESC	cis	rs9649213	0.593	rs35941058	chr7:97918159	T/C	cg00277769	chr7:97922759	BAIAP2L1	-0.35	-5.74	-0.33	2.55e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs10751667	0.643	rs7396951	chr11:927355	G/A	cg20946044	chr11:1010712	AP2A2	-0.39	-5.26	-0.31	2.96e-7	Alzheimer's disease (late onset);
CESC	cis	rs2414059	0.548	rs3098177	chr15:50783777	A/G	cg05456662	chr15:50716270	USP8	-0.44	-5.91	-0.34	1.04e-8	QT interval;
CESC	cis	rs933688	0.818	rs10052492	chr5:90759930	T/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.82	10.63	0.55	3.14e-22	Smoking behavior;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11523538	chr1:244013970	NA	0.58	6.49	0.37	4.31e-10	Gut microbiome composition (summer);
CESC	cis	rs7631605	0.846	rs68159333	chr3:37259739	G/A	cg22985146	chr3:37219077	LRRFIP2	-0.35	-5.44	-0.32	1.18e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs12893668	0.703	rs7140568	chr14:104041374	C/T	cg24130564	chr14:104152367	KLC1	-0.47	-5.73	-0.33	2.71e-8	Reticulocyte count;
CESC	cis	rs875971	0.862	rs801209	chr7:66019390	G/T	cg18252515	chr7:66147081	NA	0.46	5.96	0.34	8.08e-9	Aortic root size;
CESC	cis	rs897080	0.515	rs4953088	chr2:44564518	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	-0.55	-6.47	-0.37	4.82e-10	Height;
CESC	cis	rs939574	1.000	rs45488900	chr2:220116509	G/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.87	7.48	0.42	1.06e-12	Platelet distribution width;
CESC	cis	rs7089973	0.872	rs35622181	chr10:116631976	C/T	cg25233709	chr10:116636983	FAM160B1	0.34	5.03	0.3	9.07e-7	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs4523957	0.890	rs6503324	chr17:2100512	C/T	cg16513277	chr17:2031491	SMG6	-0.67	-9.25	-0.49	7.75e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs1799949	0.965	rs34616041	chr17:41188786	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.61	7.83	0.43	1.21e-13	Menopause (age at onset);
CESC	cis	rs2228479	0.850	rs17226512	chr16:89839976	T/C	cg06558623	chr16:89946397	TCF25	1.17	9.29	0.5	5.84e-18	Skin colour saturation;
CESC	trans	rs983392	0.679	rs636317	chr11:60019150	C/T	cg13921652	chr1:144931966	PDE4DIP	0.47	6.0	0.35	6.41e-9	Alzheimer's disease (late onset);
CESC	cis	rs9457247	1.000	rs413232	chr6:167400972	G/A	cg23791538	chr6:167370224	RNASET2	-0.59	-8.32	-0.46	4.54e-15	Crohn's disease;
CESC	cis	rs3845702	0.736	rs72960664	chr2:180832672	C/T	cg01881094	chr2:180872142	CWC22	1.05	8.97	0.48	5.61e-17	Schizophrenia;
CESC	cis	rs12220238	1.000	rs7076721	chr10:75996682	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.64	6.22	0.36	1.89e-9	Soluble interleukin-2 receptor subunit alpha;
CESC	cis	rs2197308	0.605	rs2387437	chr12:37919367	T/C	cg26384229	chr12:38710491	ALG10B	0.67	9.69	0.51	3.43e-19	Morning vs. evening chronotype;
CESC	cis	rs1799949	1.000	rs4793215	chr17:41318932	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.59	7.85	0.43	1.01e-13	Menopause (age at onset);
CESC	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg24642844	chr7:1081250	C7orf50	-0.75	-8.99	-0.48	4.94e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs1568889	0.838	rs10458896	chr11:28057957	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.8	13.5	0.64	5.83e-32	Bipolar disorder;
CESC	cis	rs1799949	1.000	rs4793194	chr17:41218333	G/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.45	6.21	0.36	2.01e-9	Menopause (age at onset);
CESC	cis	rs6460942	0.915	rs17324858	chr7:12305792	G/T	cg06484146	chr7:12443880	VWDE	-0.4	-5.72	-0.33	2.91e-8	Coronary artery disease;
CESC	cis	rs6088580	0.624	rs6120645	chr20:33025171	C/T	cg06115741	chr20:33292138	TP53INP2	0.48	6.14	0.35	3e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs2439831	1.000	rs2439841	chr15:43734749	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.84	11.94	0.59	1.35e-26	Lung cancer in ever smokers;
CESC	cis	rs2439831	1.000	rs1814538	chr15:43759774	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.87	-10.27	-0.53	4.95e-21	Lung cancer in ever smokers;
CESC	cis	rs826838	0.935	rs11169511	chr12:39175802	T/C	cg26384229	chr12:38710491	ALG10B	0.78	13.28	0.63	3.36e-31	Heart rate;
CESC	cis	rs9640161	0.636	rs3735171	chr7:150033882	A/G	cg17279839	chr7:150038598	RARRES2	0.45	5.4	0.32	1.45e-7	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs7772486	0.686	rs2072911	chr6:146056801	G/A	cg23711669	chr6:146136114	FBXO30	-0.86	-12.56	-0.61	1.04e-28	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7208859	0.623	rs9912440	chr17:29148772	A/G	cg19761014	chr17:28927070	LRRC37B2	0.74	6.29	0.36	1.27e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs514406	0.929	rs564273	chr1:53332445	G/C	cg25767906	chr1:53392781	SCP2	-0.43	-5.42	-0.32	1.37e-7	Monocyte count;
CESC	cis	rs11122272	0.735	rs2749705	chr1:231526696	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.56	-7.73	-0.43	2.3e-13	Hemoglobin concentration;
CESC	cis	rs1499972	0.618	rs62264771	chr3:117647197	G/T	cg07612923	chr3:117604196	NA	0.69	6.15	0.35	2.83e-9	Schizophrenia;
CESC	cis	rs9300255	0.537	rs2695482	chr12:123623174	C/T	cg05973401	chr12:123451056	ABCB9	0.52	5.82	0.34	1.74e-8	Neutrophil percentage of white cells;
CESC	cis	rs9815354	0.857	rs73073252	chr3:42016891	C/T	cg03022575	chr3:42003672	ULK4	0.62	6.55	0.37	2.97e-10	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs769267	0.930	rs4808959	chr19:19572108	T/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.57	7.24	0.41	4.72e-12	Tonsillectomy;
CESC	cis	rs7020830	0.931	rs13293916	chr9:37136359	C/G	cg14294708	chr9:37120828	ZCCHC7	1.28	25.61	0.84	1.21e-73	Schizophrenia;
CESC	cis	rs10901296	0.591	rs7862241	chr9:133669244	C/T	cg11464064	chr9:133710261	ABL1	0.63	5.38	0.31	1.64e-7	Bilirubin levels;
CESC	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg07677032	chr17:61819896	STRADA	0.49	6.64	0.38	1.75e-10	Prudent dietary pattern;
CESC	cis	rs7301826	0.651	rs4759519	chr12:131289508	G/A	cg11011512	chr12:131303247	STX2	0.47	5.82	0.34	1.71e-8	Plasma plasminogen activator levels;
CESC	trans	rs1545843	0.593	rs4573731	chr12:84796746	A/C	cg03015433	chr16:56623111	MT3	-0.34	-6.14	-0.35	3.04e-9	Major depressive disorder;
CESC	cis	rs561341	0.824	rs1978115	chr17:30220776	A/C	cg19193384	chr17:30244184	NA	-0.55	-5.87	-0.34	1.31e-8	Hip circumference adjusted for BMI;
CESC	cis	rs13191362	1.000	rs13202339	chr6:163081812	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.61	6.25	0.36	1.67e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs79839061	0.520	rs6842808	chr4:906903	C/T	cg07828340	chr4:882639	GAK	1.07	7.36	0.41	2.31e-12	Intelligence (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26678852	chr1:68297929	GNG12	0.56	6.12	0.35	3.28e-9	Gut microbiome composition (summer);
CESC	cis	rs727505	1.000	rs17246404	chr7:124462661	C/T	cg23710748	chr7:124431027	NA	-0.48	-7.61	-0.42	4.76e-13	Lewy body disease;
CESC	cis	rs17711722	0.523	rs313812	chr7:65505043	T/C	cg26939375	chr7:64535504	NA	-0.69	-9.87	-0.52	8.83e-20	Calcium levels;
CESC	cis	rs4654899	0.865	rs72988025	chr1:21351441	A/G	cg05370193	chr1:21551575	ECE1	0.41	6.17	0.35	2.48e-9	Superior frontal gyrus grey matter volume;
CESC	cis	rs3820068	0.581	rs6669417	chr1:15922371	G/T	cg17385448	chr1:15911702	AGMAT	0.43	7.0	0.4	2.1e-11	Systolic blood pressure;
CESC	cis	rs7772486	0.875	rs2748498	chr6:146319166	C/G	cg23711669	chr6:146136114	FBXO30	0.83	11.92	0.59	1.62e-26	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs854765	0.552	rs11078407	chr17:17841083	T/C	cg04398451	chr17:18023971	MYO15A	-0.7	-10.49	-0.54	9.32e-22	Total body bone mineral density;
CESC	cis	rs7074356	0.831	rs12764048	chr10:82148963	A/G	cg05935833	chr10:81318306	SFTPA2	-0.45	-5.77	-0.33	2.15e-8	Borderline personality disorder;
CESC	cis	rs7224737	1.000	rs7219220	chr17:40294280	T/C	cg20291162	chr17:40259547	DHX58	-0.4	-5.43	-0.32	1.26e-7	Fibrinogen levels;
CESC	cis	rs7542091	0.669	rs7540534	chr1:210044824	A/T	cg09509183	chr1:209979624	IRF6	0.4	5.78	0.33	2.12e-8	Monobrow;
CESC	cis	rs853679	1.000	rs7740487	chr6:28216486	C/G	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.74	7.26	0.41	4.42e-12	Depression;
CESC	cis	rs7618501	0.521	rs952594	chr3:49908023	G/A	cg24308560	chr3:49941425	MST1R	-0.65	-9.29	-0.5	5.71e-18	Intelligence (multi-trait analysis);
CESC	cis	rs34779708	0.931	rs2148482	chr10:35348910	A/G	cg03585969	chr10:35415529	CREM	0.78	10.34	0.54	2.94e-21	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs12530845	0.945	rs76298187	chr7:135334534	A/G	cg23117316	chr7:135346802	PL-5283	-0.4	-5.15	-0.3	4.98e-7	Red blood cell traits;
CESC	cis	rs7927592	0.763	rs10791982	chr11:68337664	T/G	cg16797656	chr11:68205561	LRP5	-0.49	-7.51	-0.42	8.79e-13	Total body bone mineral density;
CESC	cis	rs208520	0.526	rs9294682	chr6:66795159	G/A	cg07460842	chr6:66804631	NA	-1.09	-25.73	-0.85	5.21e-74	Exhaled nitric oxide output;
CESC	cis	rs748404	0.560	rs529611	chr15:43805988	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.58	7.37	0.41	2.18e-12	Lung cancer;
CESC	cis	rs7945705	0.692	rs2742470	chr11:9004002	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.41	-6.78	-0.38	7.63e-11	Hemoglobin concentration;
CESC	cis	rs2836974	0.644	rs2836986	chr21:40702136	A/C	cg11890956	chr21:40555474	PSMG1	-0.93	-14.92	-0.68	6.02e-37	Cognitive function;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23697400	chr5:64064613	SDCCAG10;SFRS12IP1	-0.63	-7.33	-0.41	2.85e-12	Gut microbiome composition (summer);
CESC	cis	rs7542091	0.637	rs9429826	chr1:210052146	G/A	cg23283495	chr1:209979779	IRF6	0.35	5.65	0.33	4.12e-8	Monobrow;
CESC	cis	rs9911578	0.967	rs57869245	chr17:57106630	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	-0.38	-5.09	-0.3	6.79e-7	Intelligence (multi-trait analysis);
CESC	cis	rs4900538	0.963	rs8017980	chr14:102961341	C/G	cg18135206	chr14:102964638	TECPR2	0.83	11.3	0.57	1.92e-24	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	cis	rs75804782	0.625	rs1039887	chr2:239434892	A/G	cg18131467	chr2:239335373	ASB1	-0.55	-5.73	-0.33	2.77e-8	Morning vs. evening chronotype;Chronotype;
CESC	trans	rs12105421	1.000	rs2310353	chr2:103577432	C/T	cg26738437	chr17:34308465	CCL16	0.6	6.03	0.35	5.5e-9	Psychosis (atypical);
CESC	cis	rs7267979	0.706	rs6037069	chr20:25234166	C/T	cg08601574	chr20:25228251	PYGB	0.39	5.86	0.34	1.38e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs1443512	0.812	rs2044210	chr12:54335533	C/G	cg12374095	chr12:54320830	NA	-0.43	-6.08	-0.35	4.1e-9	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
CESC	cis	rs6788895	1.000	rs75942495	chr3:150477877	G/A	cg09723797	chr3:150481914	SIAH2	0.71	5.19	0.3	4.22e-7	Breast cancer;
CESC	cis	rs4595586	0.545	rs12814188	chr12:39380853	C/T	cg26384229	chr12:38710491	ALG10B	0.54	7.53	0.42	7.85e-13	Morning vs. evening chronotype;
CESC	cis	rs7945705	0.869	rs11042154	chr11:9029700	A/G	cg12365402	chr11:9010492	NRIP3	-0.39	-6.19	-0.36	2.23e-9	Hemoglobin concentration;
CESC	cis	rs703842	0.963	rs923829	chr12:58174306	T/C	cg00599273	chr12:58146742	CDK4	0.33	5.03	0.3	9.14e-7	Multiple sclerosis;
CESC	cis	rs4919694	0.536	rs12414777	chr10:104697781	C/T	cg04362960	chr10:104952993	NT5C2	0.56	5.85	0.34	1.46e-8	Arsenic metabolism;
CESC	cis	rs763121	0.925	rs5757165	chr22:38994577	C/T	cg06022373	chr22:39101656	GTPBP1	0.89	14.97	0.68	3.9e-37	Menopause (age at onset);
CESC	cis	rs7666738	0.962	rs13147921	chr4:99069296	C/G	cg17366294	chr4:99064904	C4orf37	0.53	6.7	0.38	1.23e-10	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4975709	0.589	rs1466607	chr5:1864856	A/G	cg12288994	chr5:1860383	NA	0.41	6.7	0.38	1.21e-10	Cardiovascular disease risk factors;
CESC	cis	rs9660180	0.967	rs9660106	chr1:1797947	A/G	cg23982607	chr1:1823379	GNB1	-0.8	-12.99	-0.62	3.33e-30	Body mass index;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02007638	chr19:2785672	THOP1	0.54	6.15	0.35	2.9e-9	Gut microbiome composition (summer);
CESC	cis	rs2797160	1.000	rs1935772	chr6:125994708	T/C	cg05901451	chr6:126070800	HEY2	-0.45	-6.52	-0.37	3.47e-10	Endometrial cancer;
CESC	cis	rs711245	0.573	rs11899523	chr2:36800918	T/C	cg01206211	chr2:36825736	FEZ2	0.34	5.36	0.31	1.81e-7	Height;
CESC	cis	rs7772486	0.754	rs9386134	chr6:146145508	G/A	cg23711669	chr6:146136114	FBXO30	1.01	15.11	0.68	1.28e-37	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs13191362	0.935	rs73008456	chr6:163013697	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.82	8.22	0.45	9.12e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs10129255	0.957	rs8019272	chr14:107192946	C/A	cg23076370	chr14:107095027	NA	-0.47	-5.92	-0.34	9.93e-9	Kawasaki disease;
CESC	cis	rs4889855	0.530	rs4303599	chr17:78566700	C/T	cg16591659	chr17:78472290	NA	0.35	5.73	0.33	2.77e-8	Fractional excretion of uric acid;
CESC	trans	rs629535	0.735	rs525610	chr8:70074535	A/G	cg21567404	chr3:27674614	NA	0.88	10.34	0.54	2.74e-21	Dupuytren's disease;
CESC	cis	rs9322193	0.884	rs9480009	chr6:150079638	A/G	cg04369109	chr6:150039330	LATS1	-0.44	-6.07	-0.35	4.43e-9	Lung cancer;
CESC	cis	rs67311347	1.000	rs962847	chr3:40495156	A/G	cg24209194	chr3:40518798	ZNF619	-0.56	-7.47	-0.42	1.16e-12	Renal cell carcinoma;
CESC	cis	rs8060686	0.920	rs58588228	chr16:67802010	C/T	cg26727032	chr16:67993705	SLC12A4	-0.57	-6.06	-0.35	4.61e-9	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs9987353	0.519	rs2929465	chr8:9064002	C/G	cg06636001	chr8:8085503	FLJ10661	-0.53	-6.66	-0.38	1.6e-10	Recombination measurement;
CESC	cis	rs2070997	0.651	rs34149255	chr9:133669533	T/C	cg11464064	chr9:133710261	ABL1	0.57	6.7	0.38	1.24e-10	Response to amphetamines;
CESC	cis	rs2072499	0.900	rs2248080	chr1:156195971	T/A	cg24450063	chr1:156163899	SLC25A44	0.94	14.42	0.66	3.37e-35	Testicular germ cell tumor;
CESC	cis	rs896854	0.684	rs10099941	chr8:95987008	C/T	cg23172400	chr8:95962367	TP53INP1	-0.44	-9.22	-0.49	9.93e-18	Type 2 diabetes;
CESC	cis	rs7089973	0.604	rs7095816	chr10:116585109	T/C	cg23260525	chr10:116636907	FAM160B1	0.4	7.55	0.42	6.93e-13	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg14684917	chr11:62380363	EML3;ROM1	-0.5	-6.01	-0.35	6.18e-9	Intelligence (multi-trait analysis);
CESC	cis	rs2249694	0.620	rs9419079	chr10:135326985	G/A	cg20169779	chr10:135381914	SYCE1	0.42	5.43	0.32	1.26e-7	Obesity-related traits;
CESC	trans	rs10411161	0.702	rs7250138	chr19:52385232	G/C	cg22319618	chr22:45562946	NUP50	-0.68	-6.71	-0.38	1.2e-10	Breast cancer;
CESC	cis	rs76525880	0.619	rs2288277	chr17:46651061	T/C	cg06593406	chr17:46696139	NA	-0.59	-5.05	-0.3	8.35e-7	Colorectal or endometrial cancer;
CESC	cis	rs1670533	1.000	rs6821725	chr4:1060360	C/G	cg04106633	chr4:1044584	NA	0.4	5.19	0.3	4.15e-7	Recombination rate (females);
CESC	cis	rs2404602	0.692	rs35077207	chr15:76935306	A/G	cg22467129	chr15:76604101	ETFA	-0.36	-5.24	-0.31	3.26e-7	Blood metabolite levels;
CESC	cis	rs875971	0.965	rs697968	chr7:65535033	G/A	cg18876405	chr7:65276391	NA	-0.53	-6.89	-0.39	3.98e-11	Aortic root size;
CESC	cis	rs2070997	0.607	rs11244146	chr9:133675143	A/G	cg11464064	chr9:133710261	ABL1	-0.6	-7.25	-0.41	4.7e-12	Response to amphetamines;
CESC	cis	rs3091242	0.933	rs34006994	chr1:25780668	C/T	cg12412775	chr1:25698385	RHCE	0.28	5.08	0.3	7.05e-7	Erythrocyte sedimentation rate;
CESC	cis	rs1355223	0.934	rs11602669	chr11:34695114	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.45	-5.99	-0.35	6.67e-9	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs1790761	0.504	rs61894496	chr11:67391907	C/T	cg14500267	chr11:67383377	NA	0.34	5.54	0.32	7.16e-8	Mean corpuscular volume;
CESC	cis	rs6496667	0.533	rs2074583	chr15:91009192	T/C	cg10434728	chr15:90938212	IQGAP1	0.31	5.47	0.32	1.05e-7	Rheumatoid arthritis;
CESC	cis	rs9467711	0.606	rs9379851	chr6:26354780	A/C	cg14345882	chr6:26364793	BTN3A2	0.59	6.2	0.36	2.17e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs76419734	0.510	rs2553463	chr4:106730663	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	-0.66	-6.8	-0.39	6.8e-11	Post bronchodilator FEV1;
CESC	cis	rs1775715	0.677	rs2799034	chr10:32175896	A/G	cg18675610	chr10:32216311	ARHGAP12	0.34	5.29	0.31	2.55e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs1568889	1.000	rs7949704	chr11:28373543	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.78	10.0	0.52	3.42e-20	Bipolar disorder;
CESC	cis	rs11098499	0.738	rs28408407	chr4:120376030	C/G	cg24375607	chr4:120327624	NA	0.47	5.86	0.34	1.38e-8	Corneal astigmatism;
CESC	cis	rs514406	0.858	rs574853	chr1:53310959	A/T	cg01802117	chr1:53393560	SCP2	-0.4	-5.11	-0.3	6.26e-7	Monocyte count;
CESC	cis	rs6424115	0.767	rs11591202	chr1:24102080	A/C	cg15997130	chr1:24165203	NA	-0.42	-5.27	-0.31	2.85e-7	Immature fraction of reticulocytes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27396760	chr16:81726253	CMIP	-0.55	-6.09	-0.35	3.96e-9	Gut microbiome composition (summer);
CESC	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	22.71	0.81	4.12e-64	Prudent dietary pattern;
CESC	cis	rs7714584	1.000	rs1896709	chr5:150245032	A/G	cg22134413	chr5:150180641	NA	0.49	5.7	0.33	3.1e-8	Crohn's disease;
CESC	cis	rs1801251	0.896	rs4973561	chr2:233687337	C/G	cg25237894	chr2:233734115	C2orf82	-0.35	-6.15	-0.35	2.82e-9	Coronary artery disease;
CESC	cis	rs7666738	0.924	rs13124368	chr4:99039615	T/C	cg05340658	chr4:99064831	C4orf37	0.82	12.88	0.62	8.44e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4654899	0.865	rs72975078	chr1:21476196	A/G	cg05370193	chr1:21551575	ECE1	0.45	6.85	0.39	5e-11	Superior frontal gyrus grey matter volume;
CESC	cis	rs8072100	0.967	rs62076549	chr17:45579555	T/G	cg08085267	chr17:45401833	C17orf57	0.41	5.35	0.31	1.9e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs2011503	0.943	rs8102502	chr19:19652746	T/C	cg11584989	chr19:19387371	SF4	0.48	5.87	0.34	1.32e-8	Bipolar disorder;
CESC	trans	rs61931739	0.517	rs10844802	chr12:34231001	C/A	cg26384229	chr12:38710491	ALG10B	0.63	9.17	0.49	1.41e-17	Morning vs. evening chronotype;
CESC	cis	rs2425143	0.822	rs6060677	chr20:34499368	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	-0.67	-6.0	-0.35	6.3e-9	Blood protein levels;
CESC	cis	rs8060686	0.641	rs2285910	chr16:68104422	T/C	cg26727032	chr16:67993705	SLC12A4	-0.53	-6.04	-0.35	5.09e-9	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs666930	0.967	rs637868	chr1:120257110	A/G	cg19096424	chr1:120255104	PHGDH	0.5	6.98	0.39	2.41e-11	Breast cancer;
CESC	cis	rs4566357	0.615	rs10178098	chr2:227914425	C/T	cg11843606	chr2:227700838	RHBDD1	-0.46	-6.28	-0.36	1.38e-9	Coronary artery disease;
CESC	cis	rs13108904	0.905	rs11247983	chr4:1281951	C/G	cg00684032	chr4:1343700	KIAA1530	0.39	5.43	0.32	1.27e-7	Obesity-related traits;
CESC	cis	rs62005083	1.000	rs72725940	chr14:74553601	T/C	cg05179529	chr14:74551516	LIN52;ALDH6A1	0.7	5.22	0.31	3.68e-7	Mean corpuscular volume;
CESC	cis	rs3806843	1.000	rs4151680	chr5:140186657	A/G	cg16179182	chr5:140090404	VTRNA1-1	-0.41	-5.26	-0.31	2.95e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs7666738	0.830	rs10022331	chr4:98960392	C/A	cg05340658	chr4:99064831	C4orf37	0.8	12.39	0.61	3.96e-28	Colonoscopy-negative controls vs population controls;
CESC	trans	rs7618501	1.000	rs7618519	chr3:49772708	A/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.58	-8.39	-0.46	2.99e-15	Intelligence (multi-trait analysis);
CESC	cis	rs4803468	0.967	rs4803462	chr19:41908936	T/A	cg09537434	chr19:41945824	ATP5SL	-1.06	-19.02	-0.76	1.85e-51	Height;
CESC	cis	rs8062405	0.755	rs56209193	chr16:28585636	C/T	cg01378222	chr16:28622494	SULT1A1	0.31	5.22	0.31	3.58e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs11758351	0.660	rs16891446	chr6:26226996	A/C	cg01420254	chr6:26195488	NA	0.77	8.49	0.46	1.48e-15	Gout;Renal underexcretion gout;
CESC	trans	rs11098499	0.863	rs3775847	chr4:120447642	A/C	cg25214090	chr10:38739885	LOC399744	0.7	9.68	0.51	3.69e-19	Corneal astigmatism;
CESC	cis	rs637571	0.522	rs528736	chr11:65705108	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.7	9.76	0.51	1.97e-19	Eosinophil percentage of white cells;
CESC	cis	rs7586673	0.578	rs6723840	chr2:161879615	G/T	cg21518248	chr2:162101506	NA	0.43	5.53	0.32	7.81e-8	Intelligence (multi-trait analysis);
CESC	cis	rs9611565	0.685	rs169363	chr22:41853117	G/T	cg06481639	chr22:41940642	POLR3H	0.59	6.16	0.35	2.73e-9	Vitiligo;
CESC	trans	rs629535	0.547	rs62513420	chr8:70122597	G/A	cg21567404	chr3:27674614	NA	-0.84	-9.06	-0.49	2.88e-17	Dupuytren's disease;
CESC	cis	rs10504229	0.683	rs11785258	chr8:58132893	A/G	cg02725872	chr8:58115012	NA	-0.45	-7.05	-0.4	1.52e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs11122272	0.735	rs2739506	chr1:231529183	T/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.56	-7.66	-0.43	3.45e-13	Hemoglobin concentration;
CESC	cis	rs6088580	0.524	rs11167241	chr20:33250835	C/T	cg24642439	chr20:33292090	TP53INP2	-0.47	-5.53	-0.32	7.81e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs4478858	0.735	rs4949393	chr1:31851875	G/A	cg00250761	chr1:31883323	NA	-0.26	-5.04	-0.3	8.54e-7	Alcohol dependence;
CESC	cis	rs9488822	0.636	rs1544155	chr6:116346394	C/A	cg18764771	chr6:116381957	FRK	0.23	5.71	0.33	3.07e-8	Cholesterol, total;LDL cholesterol;
CESC	cis	rs68170813	0.559	rs7800443	chr7:106910723	G/A	cg02696742	chr7:106810147	HBP1	-0.52	-5.07	-0.3	7.42e-7	Coronary artery disease;
CESC	cis	rs4148883	0.504	rs4147544	chr4:100134514	G/T	cg12011299	chr4:100065546	ADH4	-0.5	-6.92	-0.39	3.45e-11	Alcohol dependence;
CESC	cis	rs2404602	0.692	rs12904198	chr15:77146978	G/A	cg26408565	chr15:76604113	ETFA	-0.39	-5.68	-0.33	3.63e-8	Blood metabolite levels;
CESC	cis	rs10479542	0.702	rs13183521	chr5:178975606	A/G	cg00080972	chr5:178986291	RUFY1	-0.37	-5.46	-0.32	1.12e-7	Lung cancer;
CESC	cis	rs7809950	0.817	rs3779495	chr7:107250260	G/A	cg23024343	chr7:107201750	COG5	0.58	7.59	0.42	5.43e-13	Coronary artery disease;
CESC	cis	rs7727544	0.684	rs274561	chr5:131719228	A/C	cg24060327	chr5:131705240	SLC22A5	-0.61	-8.04	-0.44	2.99e-14	Blood metabolite levels;
CESC	cis	rs7542091	0.704	rs9429825	chr1:210052133	C/G	cg25204440	chr1:209979598	IRF6	0.36	5.03	0.3	9.14e-7	Monobrow;
CESC	cis	rs875971	0.862	rs9791713	chr7:66105198	C/A	cg18252515	chr7:66147081	NA	0.5	6.53	0.37	3.31e-10	Aortic root size;
CESC	cis	rs6582630	0.519	rs10880629	chr12:38533611	T/G	cg13010199	chr12:38710504	ALG10B	0.46	5.96	0.34	7.85e-9	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs172166	0.637	rs1233691	chr6:28153897	T/G	cg19592336	chr6:28129416	ZNF389	0.42	6.28	0.36	1.37e-9	Cardiac Troponin-T levels;
CESC	cis	rs12410462	0.901	rs79626242	chr1:227650385	A/G	cg04117972	chr1:227635322	NA	0.62	6.0	0.35	6.56e-9	Major depressive disorder;
CESC	cis	rs1559088	0.948	rs12610071	chr19:33582687	A/C	cg27124370	chr19:33622961	WDR88	0.47	6.15	0.35	2.91e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs2836974	0.931	rs13047663	chr21:40708818	C/T	cg11644478	chr21:40555479	PSMG1	0.92	13.03	0.62	2.56e-30	Cognitive function;
CESC	cis	rs4835473	0.932	rs66474962	chr4:144656298	C/T	cg25736465	chr4:144833511	NA	-0.32	-5.11	-0.3	6.3e-7	Immature fraction of reticulocytes;
CESC	cis	rs4604732	0.536	rs78019731	chr1:247626430	C/T	cg12754571	chr1:247694271	LOC148824;OR2C3	0.44	5.44	0.32	1.21e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs3785574	0.962	rs56295011	chr17:61850359	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.81	10.77	0.55	1.12e-22	Height;
CESC	cis	rs736408	0.527	rs2577831	chr3:52628056	C/A	cg25934064	chr3:52569026	NT5DC2	0.25	5.26	0.31	3.02e-7	Bipolar disorder;
CESC	cis	rs6032067	0.641	rs34602589	chr20:43768734	T/A	cg10761708	chr20:43804764	PI3	0.55	6.12	0.35	3.4e-9	Blood protein levels;
CESC	cis	rs10979	1.000	rs9386037	chr6:143891950	T/C	cg25407410	chr6:143891975	LOC285740	-0.62	-9.3	-0.5	5.3e-18	Hypospadias;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07155664	chr5:149829590	RPS14	-0.67	-8.22	-0.45	9e-15	Gut microbiome composition (summer);
CESC	cis	rs35306767	0.807	rs11253513	chr10:968450	C/T	cg20503657	chr10:835505	NA	0.7	7.89	0.44	7.91e-14	Eosinophil percentage of granulocytes;
CESC	cis	rs16854884	0.657	rs35796781	chr3:143731662	T/C	cg06585982	chr3:143692056	C3orf58	0.49	6.26	0.36	1.51e-9	Economic and political preferences (feminism/equality);
CESC	trans	rs6572548	0.504	rs1956082	chr14:49665496	A/C	cg03274021	chr8:130952480	FAM49B	-0.56	-6.11	-0.35	3.58e-9	Subjective well-being;
CESC	cis	rs6120849	0.754	rs3746436	chr20:33586193	C/T	cg24642439	chr20:33292090	TP53INP2	0.66	6.52	0.37	3.59e-10	Protein C levels;
CESC	cis	rs9372253	0.678	rs9372251	chr6:110700656	A/G	cg19196401	chr6:110721138	DDO	-0.4	-5.67	-0.33	3.67e-8	Platelet distribution width;
CESC	cis	rs7208859	0.623	rs11657391	chr17:29194287	G/A	cg19761014	chr17:28927070	LRRC37B2	0.72	5.71	0.33	3.06e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs7666738	1.000	rs7666738	chr4:98968077	C/T	cg05340658	chr4:99064831	C4orf37	0.61	8.18	0.45	1.18e-14	Colonoscopy-negative controls vs population controls;
CESC	cis	rs425277	1.000	rs262651	chr1:2091397	A/G	cg16545954	chr1:2118288	C1orf86	0.33	5.59	0.32	5.57e-8	Height;
CESC	cis	rs6088580	0.608	rs1205342	chr20:32921842	C/T	cg06115741	chr20:33292138	TP53INP2	-0.44	-5.65	-0.33	4.13e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs6686643	0.762	rs9333433	chr1:165611455	G/C	cg19407955	chr1:165599744	MGST3	-0.54	-5.68	-0.33	3.55e-8	Total ventricular volume;
CESC	cis	rs9916302	0.904	rs8081338	chr17:37406139	C/T	cg07936489	chr17:37558343	FBXL20	-0.79	-11.09	-0.56	9.87e-24	Glomerular filtration rate (creatinine);
CESC	cis	rs9322193	0.923	rs3924871	chr6:149983216	G/A	cg04369109	chr6:150039330	LATS1	-0.39	-5.48	-0.32	9.78e-8	Lung cancer;
CESC	cis	rs7811142	0.830	rs61735533	chr7:99955866	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.72	6.41	0.37	6.71e-10	Platelet count;
CESC	cis	rs2228479	1.000	rs12596492	chr16:89957169	T/G	cg00800038	chr16:89945340	TCF25	-0.94	-7.87	-0.44	9.24e-14	Skin colour saturation;
CESC	cis	rs7224314	1.000	rs6504503	chr17:65386690	A/T	cg01507342	chr17:65387096	PITPNC1	-0.46	-5.65	-0.33	4.05e-8	Diisocyanate-induced asthma;
CESC	cis	rs9788682	0.747	rs2656072	chr15:78744292	A/G	cg24631222	chr15:78858424	CHRNA5	-0.61	-7.19	-0.4	6.65e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs9322193	0.962	rs9505974	chr6:150100430	C/T	cg13206674	chr6:150067644	NUP43	0.39	5.58	0.32	5.93e-8	Lung cancer;
CESC	cis	rs1577917	0.771	rs2842608	chr6:86295858	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.57	-8.02	-0.44	3.45e-14	Response to antipsychotic treatment;
CESC	cis	rs7829975	0.688	rs6995407	chr8:8384647	C/G	cg15556689	chr8:8085844	FLJ10661	0.62	7.26	0.41	4.29e-12	Mood instability;
CESC	cis	rs7107174	1.000	rs1385600	chr11:77936166	C/T	cg02023728	chr11:77925099	USP35	-0.41	-5.75	-0.33	2.41e-8	Testicular germ cell tumor;
CESC	cis	rs7927771	0.832	rs11605672	chr11:47413733	A/G	cg20307385	chr11:47447363	PSMC3	-0.58	-7.13	-0.4	9.65e-12	Subjective well-being;
CESC	cis	rs2657888	0.965	rs2657903	chr12:56933722	G/A	cg23002907	chr12:56915593	RBMS2	0.39	5.15	0.3	5.11e-7	Adiponectin levels;
CESC	cis	rs651907	0.535	rs11712309	chr3:101519097	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.46	6.05	0.35	4.95e-9	Colorectal cancer;
CESC	cis	rs909674	0.541	rs5750816	chr22:39810379	A/G	cg02038168	chr22:39784481	NA	0.61	7.86	0.43	9.8e-14	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20017464	chr17:30677219	MIR632;ZNF207	-0.52	-6.08	-0.35	4.2e-9	Gut microbiome composition (summer);
CESC	cis	rs1595825	0.891	rs76308665	chr2:198518062	C/T	cg10820045	chr2:198174542	NA	0.41	5.21	0.3	3.79e-7	Ulcerative colitis;
CESC	cis	rs7618915	0.547	rs4687548	chr3:52666650	A/T	cg18404041	chr3:52824283	ITIH1	-0.39	-6.58	-0.37	2.45e-10	Bipolar disorder;
CESC	cis	rs1348850	0.750	rs55792594	chr2:178496468	C/T	cg22681709	chr2:178499509	PDE11A	-0.43	-6.47	-0.37	4.78e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs7659604	0.702	rs61217486	chr4:122693973	T/C	cg19748678	chr4:122722346	EXOSC9	0.72	9.35	0.5	3.75e-18	Type 2 diabetes;
CESC	cis	rs7666738	0.830	rs13124127	chr4:98990729	G/A	cg18180107	chr4:99064573	C4orf37	0.4	5.18	0.3	4.42e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6582630	0.537	rs7310749	chr12:38400472	C/T	cg13010199	chr12:38710504	ALG10B	0.49	6.26	0.36	1.57e-9	Drug-induced liver injury (flucloxacillin);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06294803	chr3:184033282	EIF4G1	0.58	6.95	0.39	2.89e-11	Gut microbiome composition (summer);
CESC	trans	rs9325144	0.560	rs6582539	chr12:38630097	C/T	cg23762105	chr12:34175262	ALG10	0.47	6.43	0.37	5.85e-10	Morning vs. evening chronotype;
CESC	cis	rs3617	0.572	rs2245538	chr3:52852060	T/C	cg07507251	chr3:52567010	NT5DC2	0.33	5.72	0.33	2.81e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
CESC	cis	rs911555	0.755	rs7147664	chr14:103963420	G/A	cg24130564	chr14:104152367	KLC1	-0.5	-6.55	-0.37	2.94e-10	Intelligence (multi-trait analysis);
CESC	cis	rs7829975	0.806	rs2428	chr8:8641145	C/T	cg06636001	chr8:8085503	FLJ10661	0.47	6.22	0.36	1.93e-9	Mood instability;
CESC	cis	rs2404618	0.504	rs2906567	chr8:1494118	C/T	cg13402656	chr8:1511478	DLGAP2	-0.71	-10.68	-0.55	2.3e-22	Lung cancer;
CESC	cis	rs9322193	0.607	rs9383941	chr6:150233236	A/G	cg01145232	chr6:150245071	RAET1G	-0.53	-6.89	-0.39	3.94e-11	Lung cancer;
CESC	cis	rs10504229	0.871	rs16921952	chr8:58163317	A/T	cg24829409	chr8:58192753	C8orf71	-0.63	-8.82	-0.48	1.55e-16	Developmental language disorder (linguistic errors);
CESC	cis	rs6088580	0.634	rs6087587	chr20:33058628	G/T	cg08999081	chr20:33150536	PIGU	0.66	11.57	0.58	2.49e-25	Glomerular filtration rate (creatinine);
CESC	cis	rs60843830	0.964	rs62114538	chr2:256116	G/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.87	11.8	0.59	4.13e-26	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs765787	0.530	rs4775844	chr15:45542048	T/C	cg24006582	chr15:45444508	DUOX1	-0.59	-7.32	-0.41	3.04e-12	Uric acid levels;
CESC	cis	rs4722166	0.508	rs1474348	chr7:22767908	C/G	cg13104385	chr7:22767384	IL6	0.43	5.98	0.34	7.13e-9	Lung cancer;
CESC	cis	rs9611565	0.559	rs5751160	chr22:42175695	A/G	cg03806693	chr22:41940476	POLR3H	1.17	13.6	0.64	2.7e-32	Vitiligo;
CESC	cis	rs16854884	0.657	rs1979910	chr3:143710268	A/C	cg06585982	chr3:143692056	C3orf58	0.52	6.78	0.38	7.72e-11	Economic and political preferences (feminism/equality);
CESC	cis	rs709400	0.628	rs12889639	chr14:103860206	G/A	cg12935359	chr14:103987150	CKB	0.49	7.4	0.41	1.78e-12	Body mass index;
CESC	cis	rs9815354	0.812	rs73071239	chr3:41992610	C/A	cg03022575	chr3:42003672	ULK4	0.67	5.88	0.34	1.23e-8	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs8017423	0.935	rs11159959	chr14:90733656	C/T	cg14092571	chr14:90743983	NA	0.55	8.22	0.45	9.21e-15	Mortality in heart failure;
CESC	cis	rs9911578	1.000	rs9915935	chr17:56843048	A/G	cg12560992	chr17:57184187	TRIM37	0.92	15.34	0.69	1.88e-38	Intelligence (multi-trait analysis);
CESC	cis	rs7618915	0.508	rs13065851	chr3:52644836	T/A	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.3	5.18	0.3	4.37e-7	Bipolar disorder;
CESC	cis	rs1506636	1.000	rs689341	chr7:123403974	C/A	cg03229431	chr7:123269106	ASB15	0.5	6.73	0.38	1.03e-10	Plateletcrit;Platelet count;
CESC	cis	rs1005277	0.563	rs2505216	chr10:38482830	T/C	cg25427524	chr10:38739819	LOC399744	-0.7	-10.24	-0.53	6.01e-21	Extrinsic epigenetic age acceleration;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg07728084	chr10:21683123	NA	0.46	6.0	0.35	6.46e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs9611565	0.559	rs7290990	chr22:41964357	C/A	cg06634786	chr22:41940651	POLR3H	-0.62	-6.83	-0.39	5.85e-11	Vitiligo;
CESC	cis	rs3806843	0.706	rs2563302	chr5:140079051	T/C	cg26395211	chr5:140044315	WDR55	0.47	6.05	0.35	5.05e-9	Depressive symptoms (multi-trait analysis);
CESC	cis	rs2732480	0.577	rs2732457	chr12:48758379	A/G	cg24011408	chr12:48396354	COL2A1	-0.4	-5.51	-0.32	8.55e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs9916302	0.904	rs4795357	chr17:37569551	T/C	cg00129232	chr17:37814104	STARD3	-0.53	-6.59	-0.38	2.35e-10	Glomerular filtration rate (creatinine);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19575883	chr2:172231724	METTL8	-0.66	-7.74	-0.43	2.07e-13	Gut microbiome composition (summer);
CESC	cis	rs735396	1.000	rs735396	chr12:121438844	T/C	cg25281562	chr12:121454272	C12orf43	0.39	5.07	0.3	7.47e-7	N-glycan levels;
CESC	trans	rs208520	0.690	rs851467	chr6:66802721	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.99	-12.82	-0.62	1.32e-29	Exhaled nitric oxide output;
CESC	cis	rs854765	0.583	rs67253360	chr17:17828973	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.57	8.18	0.45	1.22e-14	Total body bone mineral density;
CESC	cis	rs1881797	1.000	rs10925062	chr1:247658978	G/C	cg11166453	chr1:247681781	NA	0.47	5.83	0.34	1.63e-8	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs72781680	0.611	rs2111884	chr2:24289472	A/T	cg08917208	chr2:24149416	ATAD2B	0.6	5.66	0.33	3.99e-8	Lymphocyte counts;
CESC	cis	rs6693567	0.565	rs3754214	chr1:150478623	T/C	cg09579323	chr1:150459698	TARS2	0.45	5.57	0.32	6.2e-8	Migraine;
CESC	cis	rs9467773	0.620	rs2451738	chr6:26618459	A/T	cg20266910	chr6:26577678	NA	-0.33	-5.5	-0.32	8.8e-8	Intelligence (multi-trait analysis);
CESC	trans	rs3749237	0.964	rs62260719	chr3:49852419	G/A	cg21659725	chr3:3221576	CRBN	0.55	6.46	0.37	4.99e-10	Resting heart rate;
CESC	cis	rs5743618	0.516	rs10024216	chr4:38764112	C/T	cg02016764	chr4:38805732	TLR1	-0.33	-5.05	-0.3	8.26e-7	Asthma;Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs7949030	0.588	rs2428548	chr11:62311462	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.49	6.83	0.39	5.97e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs1801251	1.000	rs1022330	chr2:233577330	G/A	cg08000102	chr2:233561755	GIGYF2	0.66	9.02	0.48	3.87e-17	Coronary artery disease;
CESC	trans	rs4942242	0.663	rs17460812	chr13:44215504	A/G	cg19169023	chr15:41853346	TYRO3	-0.54	-6.9	-0.39	3.92e-11	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs6540559	1.000	rs2235372	chr1:209960436	A/G	cg25204440	chr1:209979598	IRF6	-0.63	-7.81	-0.43	1.3e-13	Cleft lip with or without cleft palate;
CESC	cis	rs6696846	0.740	rs12125465	chr1:205074854	C/A	cg00857998	chr1:205179979	DSTYK	0.55	7.28	0.41	3.77e-12	Red blood cell count;
CESC	cis	rs2011503	1.000	rs75525243	chr19:19638218	G/A	cg11584989	chr19:19387371	SF4	0.61	7.03	0.4	1.79e-11	Bipolar disorder;
CESC	cis	rs10540	1.000	rs12421457	chr11:505780	T/C	cg03576123	chr11:487126	PTDSS2	-1.13	-11.14	-0.56	6.63e-24	Body mass index;
CESC	cis	rs796364	0.806	rs11688168	chr2:200916004	G/A	cg23649088	chr2:200775458	C2orf69	-0.55	-5.05	-0.3	8.29e-7	Schizophrenia;
CESC	trans	rs9850225	0.719	rs4856616	chr3:80466481	A/C	cg01092528	chr4:76861103	NAAA	0.42	6.43	0.37	5.89e-10	Erectile dysfunction in type 1 diabetes;
CESC	cis	rs9649465	0.967	rs7791183	chr7:123343719	A/G	cg04330084	chr7:123175371	IQUB	-0.38	-5.22	-0.31	3.69e-7	Migraine;
CESC	cis	rs769267	0.740	rs2965185	chr19:19525792	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.5	6.12	0.35	3.28e-9	Tonsillectomy;
CESC	cis	rs7123876	0.587	rs11604034	chr11:72364147	G/C	cg03713592	chr11:72463424	ARAP1	0.62	5.03	0.3	8.91e-7	Body mass index;
CESC	cis	rs7772486	0.754	rs9390358	chr6:146145678	C/T	cg05347473	chr6:146136440	FBXO30	0.53	6.63	0.38	1.88e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs61656020	1	rs61656020	chr16:1882221	C/G	cg07677296	chr16:1877182	HAGH;FAHD1	-0.54	-5.18	-0.3	4.4e-7	Ankle injury;
CESC	cis	rs7666738	0.861	rs10018654	chr4:99002226	A/G	cg05340658	chr4:99064831	C4orf37	0.8	12.42	0.61	3.13e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1448094	0.512	rs10863086	chr12:86244225	G/A	cg00310523	chr12:86230176	RASSF9	0.35	5.38	0.31	1.67e-7	Major depressive disorder;
CESC	cis	rs7208859	0.623	rs59447372	chr17:29057585	C/T	cg19761014	chr17:28927070	LRRC37B2	0.76	6.25	0.36	1.66e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs10791097	0.667	rs4937585	chr11:130741940	A/G	cg12179176	chr11:130786555	SNX19	0.65	10.06	0.53	2.23e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs7618915	0.547	rs34215106	chr3:52659124	T/C	cg05564831	chr3:52568323	NT5DC2	0.44	6.76	0.38	8.84e-11	Bipolar disorder;
CESC	cis	rs6736093	0.966	rs11687451	chr2:112682561	G/A	cg12686935	chr2:112915763	FBLN7	-0.44	-5.72	-0.33	2.86e-8	Coronary artery disease;
CESC	cis	rs7666738	0.830	rs11938686	chr4:98964470	A/G	cg03467027	chr4:99064603	C4orf37	0.44	5.46	0.32	1.1e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9611565	0.512	rs5751145	chr22:42133552	C/T	cg17376030	chr22:41985996	PMM1	-0.81	-8.44	-0.46	2.09e-15	Vitiligo;
CESC	cis	rs6582630	0.502	rs4379906	chr12:38295673	G/A	cg26384229	chr12:38710491	ALG10B	0.63	9.25	0.49	7.58e-18	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs7662987	0.517	rs2851263	chr4:100030354	A/G	cg13256891	chr4:100009986	ADH5	0.75	8.02	0.44	3.43e-14	Smoking initiation;
CESC	cis	rs7809950	0.953	rs1468336	chr7:107208250	T/C	cg23024343	chr7:107201750	COG5	0.44	5.74	0.33	2.62e-8	Coronary artery disease;
CESC	cis	rs10465746	0.780	rs4907190	chr1:84409168	T/C	cg10977910	chr1:84465055	TTLL7	0.52	7.14	0.4	9.05e-12	Obesity-related traits;
CESC	cis	rs8180040	0.726	rs7610636	chr3:47064436	A/C	cg27129171	chr3:47204927	SETD2	-0.67	-10.07	-0.53	2.01e-20	Colorectal cancer;
CESC	cis	rs11098499	0.908	rs7696649	chr4:120322177	G/A	cg09307838	chr4:120376055	NA	0.91	12.42	0.61	3.24e-28	Corneal astigmatism;
CESC	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg02353165	chr6:42928485	GNMT	-0.84	-13.48	-0.64	6.81e-32	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs6952808	0.510	rs13227554	chr7:2048220	G/C	cg02951883	chr7:2050386	MAD1L1	0.49	6.4	0.37	7.12e-10	Bipolar disorder and schizophrenia;
CESC	cis	rs514406	0.644	rs6662414	chr1:53198893	A/G	cg08736216	chr1:53307985	ZYG11A	0.3	5.09	0.3	6.84e-7	Monocyte count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01353464	chr3:38180116	ACAA1;MYD88	0.6	7.02	0.4	1.83e-11	Gut microbiome composition (summer);
CESC	cis	rs1005277	0.579	rs2983343	chr10:38383332	A/G	cg25427524	chr10:38739819	LOC399744	-0.65	-9.48	-0.5	1.51e-18	Extrinsic epigenetic age acceleration;
CESC	cis	rs7917772	0.636	rs2249850	chr10:104512006	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.52	6.05	0.35	4.8e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs7267979	1.000	rs11087520	chr20:25436827	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.82	15.9	0.7	1.91e-40	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs72781680	0.898	rs72788218	chr2:24090435	C/T	cg08917208	chr2:24149416	ATAD2B	0.9	8.41	0.46	2.54e-15	Lymphocyte counts;
CESC	cis	rs11078597	0.731	rs8077638	chr17:1640793	C/T	cg18436246	chr17:1640651	WDR81	0.62	7.59	0.42	5.36e-13	Serum albumin level;
CESC	cis	rs2075371	0.527	rs1862046	chr7:134023524	T/C	cg20476274	chr7:133979776	SLC35B4	0.55	7.25	0.41	4.54e-12	Mean platelet volume;
CESC	cis	rs78456975	0.941	rs28913033	chr2:1523194	T/C	cg01028140	chr2:1542097	TPO	-0.6	-5.8	-0.34	1.84e-8	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs9512730	0.553	rs9512702	chr13:28033485	A/G	cg08193333	chr13:27998609	GTF3A	0.44	5.31	0.31	2.29e-7	Schizophrenia;
CESC	cis	rs9649213	0.502	rs6465680	chr7:98005778	A/G	cg24562669	chr7:97807699	LMTK2	0.5	7.43	0.42	1.47e-12	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg02475777	chr4:1388615	CRIPAK	0.4	5.05	0.3	8.18e-7	Longevity;
CESC	trans	rs1994135	0.608	rs1482994	chr12:33713631	T/C	cg26384229	chr12:38710491	ALG10B	0.56	7.75	0.43	1.96e-13	Resting heart rate;
CESC	trans	rs11148252	0.508	rs11148260	chr13:53162643	A/C	cg18335740	chr13:41363409	SLC25A15	0.61	8.85	0.48	1.3e-16	Lewy body disease;
CESC	cis	rs79349575	0.783	rs4399576	chr17:47009835	G/A	cg26022315	chr17:47021804	SNF8	0.39	5.16	0.3	4.94e-7	Type 2 diabetes;
CESC	cis	rs6987853	0.933	rs2974339	chr8:42397529	T/C	cg09913449	chr8:42400586	C8orf40	0.39	6.13	0.35	3.15e-9	Mean corpuscular hemoglobin concentration;
CESC	cis	rs10504229	0.639	rs17331850	chr8:58113538	G/T	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs9581857	0.615	rs3759435	chr13:27996813	T/G	cg01674679	chr13:27998804	GTF3A	-0.65	-6.4	-0.37	7.16e-10	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
CESC	cis	rs12926788	0.542	rs6497759	chr16:24801737	G/A	cg02428538	chr16:24856791	SLC5A11	-0.48	-5.04	-0.3	8.68e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs6662572	0.686	rs113117837	chr1:46278158	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.46	5.11	0.3	6.26e-7	Blood protein levels;
CESC	cis	rs7091068	0.616	rs7901507	chr10:95505424	C/G	cg20715218	chr10:95462985	C10orf4	0.58	5.57	0.32	6.17e-8	Urinary tract infection frequency;
CESC	cis	rs17539620	0.624	rs871069	chr6:154837578	A/C	cg17771515	chr6:154831774	CNKSR3	0.59	5.85	0.34	1.43e-8	Lipoprotein (a) levels;
CESC	cis	rs6665290	0.835	rs7549465	chr1:227214399	A/C	cg10327440	chr1:227177885	CDC42BPA	-1.12	-21.97	-0.8	1.21e-61	Myeloid white cell count;
CESC	cis	rs6570726	0.791	rs401561	chr6:145835917	G/T	cg23711669	chr6:146136114	FBXO30	1.02	15.96	0.7	1.2e-40	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs477692	0.870	rs475250	chr10:131412558	C/G	cg05714579	chr10:131428358	MGMT	0.54	7.47	0.42	1.16e-12	Response to temozolomide;
CESC	cis	rs9911578	0.935	rs12948039	chr17:57045184	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.38	5.18	0.3	4.36e-7	Intelligence (multi-trait analysis);
CESC	cis	rs4728302	0.838	rs10225605	chr7:133591676	G/A	cg10665199	chr7:133106180	EXOC4	0.39	5.39	0.31	1.55e-7	Intelligence;Intelligence (multi-trait analysis);
CESC	cis	rs7429990	0.965	rs4858887	chr3:48092017	G/T	cg11946769	chr3:48343235	NME6	-0.5	-5.9	-0.34	1.13e-8	Educational attainment (years of education);
CESC	cis	rs11969893	0.850	rs9404058	chr6:101323078	T/C	cg12253828	chr6:101329408	ASCC3	1.11	9.64	0.51	4.95e-19	Economic and political preferences (immigration/crime);
CESC	cis	rs3096299	0.719	rs2965945	chr16:89514017	T/C	cg08392591	chr16:89556376	ANKRD11	0.55	7.48	0.42	1.08e-12	Multiple myeloma (IgH translocation);
CESC	cis	rs7647973	0.710	rs1491983	chr3:49639803	G/T	cg06212747	chr3:49208901	KLHDC8B	0.68	8.05	0.44	2.84e-14	Menarche (age at onset);
CESC	cis	rs4862750	0.872	rs4862747	chr4:187877236	A/T	cg10295955	chr4:187884368	NA	1.06	21.18	0.79	6.03e-59	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs892961	0.932	rs7222170	chr17:75413096	G/A	cg05865280	chr17:75406074	SEPT9	0.62	12.67	0.61	4.57e-29	Airflow obstruction;
CESC	cis	rs11252926	0.537	rs4881274	chr10:459940	G/A	cg03684893	chr10:554711	DIP2C	-0.35	-5.2	-0.3	4.01e-7	Psychosis in Alzheimer's disease;
CESC	cis	rs9901225	1	rs9901225	chr17:40755811	C/T	cg14558262	chr17:40713999	COASY	0.78	12.34	0.6	5.9e-28	Colorectal or endometrial cancer;
CESC	cis	rs7267979	0.668	rs2387977	chr20:25599776	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.65	-10.61	-0.55	3.66e-22	Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15883249	chr12:13028664	RPL13AP20	-0.56	-6.19	-0.36	2.24e-9	Gut microbiome composition (summer);
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg11287903	chr10:115613834	DCLRE1A;NHLRC2	0.52	7.0	0.4	2.07e-11	Systemic lupus erythematosus;
CESC	cis	rs7208859	0.673	rs999797	chr17:29159329	G/A	cg19761014	chr17:28927070	LRRC37B2	0.69	5.34	0.31	2.02e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs754466	0.606	rs7084705	chr10:79596675	A/G	cg17075019	chr10:79541650	NA	-0.77	-12.39	-0.61	4.02e-28	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs9788682	0.895	rs3813570	chr15:78832832	T/C	cg24631222	chr15:78858424	CHRNA5	0.8	10.26	0.53	5.12e-21	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs3540	0.574	rs2601205	chr15:90961813	A/G	cg22089800	chr15:90895588	ZNF774	0.6	8.03	0.44	3.28e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	trans	rs17685	0.753	rs1574107	chr7:75685047	A/C	cg19862616	chr7:65841803	NCRNA00174	0.86	12.65	0.61	5.35e-29	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs1218582	0.745	rs1580943	chr1:154865125	G/A	cg16680214	chr1:154839983	KCNN3	-0.45	-6.94	-0.39	2.95e-11	Prostate cancer;
CESC	cis	rs1801251	0.778	rs2675967	chr2:233736133	C/G	cg08000102	chr2:233561755	GIGYF2	-0.61	-7.38	-0.41	2.03e-12	Coronary artery disease;
CESC	cis	rs4523957	0.820	rs2224770	chr17:2205923	T/C	cg16513277	chr17:2031491	SMG6	0.59	7.77	0.43	1.78e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs3806843	0.619	rs2569160	chr5:140028774	T/C	cg26395211	chr5:140044315	WDR55	0.53	6.81	0.39	6.52e-11	Depressive symptoms (multi-trait analysis);
CESC	cis	rs9399401	0.667	rs6900233	chr6:142717283	C/G	cg03128060	chr6:142623767	GPR126	0.38	6.4	0.37	7.02e-10	Chronic obstructive pulmonary disease;
CESC	cis	rs9300255	0.537	rs2695482	chr12:123623174	C/T	cg19016782	chr12:123741754	C12orf65	-0.37	-5.07	-0.3	7.56e-7	Neutrophil percentage of white cells;
CESC	cis	rs6732160	0.691	rs6728147	chr2:73423490	A/G	cg01422370	chr2:73384389	NA	-0.45	-7.86	-0.43	9.68e-14	Intelligence (multi-trait analysis);
CESC	cis	rs643506	0.874	rs645411	chr11:111694490	T/C	cg09085632	chr11:111637200	PPP2R1B	0.42	5.46	0.32	1.09e-7	Breast cancer;
CESC	cis	rs7927771	0.832	rs4752993	chr11:47410951	T/C	cg18512352	chr11:47633146	NA	0.53	7.96	0.44	5e-14	Subjective well-being;
CESC	cis	rs9303401	0.659	rs66514313	chr17:56714057	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.04	13.0	0.62	3.27e-30	Cognitive test performance;
CESC	cis	rs17711722	0.701	rs4467826	chr7:65368708	A/G	cg14393609	chr7:65229607	NA	0.55	7.55	0.42	6.97e-13	Calcium levels;
CESC	trans	rs2115172	0.836	rs4835799	chr5:122762229	A/G	cg22344139	chr1:44435583	DPH2	0.48	6.25	0.36	1.65e-9	Weight;
CESC	cis	rs854765	0.693	rs8079321	chr17:17760789	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.6	8.96	0.48	5.8e-17	Total body bone mineral density;
CESC	cis	rs3008870	0.755	rs2815363	chr1:67497221	A/G	cg02640540	chr1:67518911	SLC35D1	-0.45	-5.59	-0.32	5.74e-8	Lymphocyte percentage of white cells;
CESC	cis	rs11122272	0.735	rs2486734	chr1:231531392	A/G	cg06096015	chr1:231504339	EGLN1	0.43	6.15	0.35	2.9e-9	Hemoglobin concentration;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05910615	chr19:36248877	HSPB6;C19orf55	0.62	7.72	0.43	2.42e-13	Gut microbiome composition (summer);
CESC	cis	rs897080	0.515	rs1067336	chr2:44625876	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.53	6.15	0.35	2.8e-9	Height;
CESC	cis	rs7833986	0.501	rs2953901	chr8:56981824	C/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.61	7.55	0.42	6.89e-13	Height;
CESC	cis	rs12765878	1.000	rs4918068	chr10:105644736	T/G	cg11005552	chr10:105648138	OBFC1	0.35	5.1	0.3	6.34e-7	Coronary artery disease;
CESC	trans	rs164368	0.568	rs163944	chr5:160633896	C/T	cg08125972	chr19:36705377	ZNF565;ZNF146	-0.57	-6.0	-0.35	6.32e-9	Yu-Zhi constitution type in type 2 diabetes;
CESC	cis	rs17376456	0.569	rs7721668	chr5:93290995	G/A	cg25358565	chr5:93447407	FAM172A	-0.45	-5.35	-0.31	1.92e-7	Diabetic retinopathy;
CESC	cis	rs11690935	0.959	rs12185567	chr2:172560729	A/C	cg13550731	chr2:172543902	DYNC1I2	0.96	14.64	0.67	5.9e-36	Schizophrenia;
CESC	cis	rs7542091	0.648	rs688464	chr1:209992539	C/T	cg23283495	chr1:209979779	IRF6	-0.38	-5.85	-0.34	1.42e-8	Monobrow;
CESC	cis	rs796364	1.000	rs281762	chr2:200799201	C/G	cg23649088	chr2:200775458	C2orf69	0.54	5.33	0.31	2.13e-7	Schizophrenia;
CESC	cis	rs7829975	0.777	rs560544	chr8:8637429	G/A	cg17143192	chr8:8559678	CLDN23	-0.44	-5.41	-0.32	1.41e-7	Mood instability;
CESC	cis	rs8064299	0.655	rs2305214	chr17:72768970	G/A	cg25054828	chr17:72772726	NAT9;TMEM104	0.53	6.99	0.39	2.25e-11	Monocyte count;
CESC	cis	rs9399401	0.677	rs11155241	chr6:142664439	T/A	cg03128060	chr6:142623767	GPR126	0.37	6.26	0.36	1.58e-9	Chronic obstructive pulmonary disease;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg12152867	chr6:56708725	DST	0.47	6.14	0.35	2.95e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs6565681	0.760	rs9901680	chr17:78378088	A/G	cg15383979	chr17:78362278	RNF213;LOC100294362	-0.79	-8.86	-0.48	1.19e-16	Moyamoya disease;
CESC	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	10.12	0.53	1.44e-20	Prudent dietary pattern;
CESC	cis	rs67311347	1.000	rs9874499	chr3:40441908	C/T	cg09455208	chr3:40491958	NA	0.5	8.54	0.46	1.03e-15	Renal cell carcinoma;
CESC	cis	rs7586673	0.866	rs7579662	chr2:161915810	G/A	cg08807892	chr2:162101083	NA	0.44	5.92	0.34	9.81e-9	Intelligence (multi-trait analysis);
CESC	cis	rs10791323	0.572	rs10894755	chr11:133739685	C/T	cg15485101	chr11:133734466	NA	-0.35	-5.71	-0.33	3.01e-8	Childhood ear infection;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05800758	chr8:101225800	SPAG1	0.47	6.22	0.36	1.92e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs11676348	0.772	rs7422358	chr2:218952778	C/T	cg00012203	chr2:219082015	ARPC2	-0.39	-5.07	-0.3	7.49e-7	Ulcerative colitis;
CESC	trans	rs5756813	0.688	rs12484064	chr22:38126746	C/A	cg19894588	chr14:64061835	NA	-0.65	-7.41	-0.41	1.7e-12	Optic cup area;Vertical cup-disc ratio;
CESC	cis	rs921968	0.643	rs1055816	chr2:219501328	G/A	cg02176678	chr2:219576539	TTLL4	0.4	6.93	0.39	3.18e-11	Mean corpuscular hemoglobin concentration;
CESC	cis	rs10423674	0.526	rs12462498	chr19:18832950	A/G	cg14292368	chr19:18793705	CRTC1	0.43	5.61	0.33	5.13e-8	Menarche (age at onset);
CESC	cis	rs2294693	0.947	rs736793	chr6:40997919	A/T	cg14769373	chr6:40998127	UNC5CL	-0.47	-6.58	-0.37	2.5e-10	Gastric cancer;Non-cardia gastric cancer;
CESC	cis	rs7666738	0.830	rs9994346	chr4:99037986	A/G	cg18180107	chr4:99064573	C4orf37	0.43	5.52	0.32	8.03e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9787249	0.957	rs2274949	chr1:40221067	G/A	cg02773041	chr1:40204384	PPIE	0.51	7.05	0.4	1.51e-11	Blood protein levels;
CESC	trans	rs6828577	0.819	rs366656	chr4:119634694	T/C	cg05098011	chr1:151736092	OAZ3;MRPL9	0.48	6.14	0.35	3.01e-9	Perioperative myocardial infarction in coronary artery bypass surgery;
CESC	cis	rs300703	0.542	rs67993758	chr2:179594	C/T	cg21211680	chr2:198530	NA	-0.91	-10.75	-0.55	1.31e-22	Blood protein levels;
CESC	cis	rs1008375	0.966	rs6449313	chr4:17588320	A/G	cg27347728	chr4:17578864	LAP3	0.45	5.24	0.31	3.21e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs12477438	0.798	rs6542849	chr2:99578493	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-10.51	-0.54	7.92e-22	Chronic sinus infection;
CESC	cis	rs780096	0.546	rs1647284	chr2:27608115	C/T	cg21248554	chr2:27665150	KRTCAP3	-0.34	-7.0	-0.4	2.04e-11	Total body bone mineral density;
CESC	cis	rs896854	0.654	rs6982393	chr8:95980708	T/C	cg16049864	chr8:95962084	TP53INP1	-0.64	-11.12	-0.56	7.79e-24	Type 2 diabetes;
CESC	cis	rs2637266	0.935	rs2583054	chr10:78401442	A/G	cg18941641	chr10:78392320	NA	0.45	8.65	0.47	4.9e-16	Pulmonary function;
CESC	cis	rs8031584	0.706	rs798084	chr15:31126935	C/T	cg14298792	chr15:30685198	CHRFAM7A	-0.48	-5.82	-0.34	1.68e-8	Huntington's disease progression;
CESC	cis	rs6540559	0.673	rs7550857	chr1:209956542	C/A	cg21951975	chr1:209979733	IRF6	0.62	7.66	0.43	3.46e-13	Cleft lip with or without cleft palate;
CESC	cis	rs4268898	0.662	rs9917315	chr2:24431501	C/A	cg08917208	chr2:24149416	ATAD2B	0.55	5.27	0.31	2.89e-7	Asthma;
CESC	trans	rs6073597	1.000	rs6031980	chr20:43714384	C/T	cg12792366	chr3:37217087	LRRFIP2	0.45	6.18	0.35	2.43e-9	Positive affect;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg02375201	chr1:27114675	PIGV	-0.52	-6.18	-0.35	2.43e-9	Ulcerative colitis;
CESC	cis	rs9649213	0.593	rs34534766	chr7:97920871	G/C	cg00277769	chr7:97922759	BAIAP2L1	-0.34	-5.57	-0.32	6.1e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs9948	0.655	rs6576981	chr2:97394406	G/C	cg01990225	chr2:97406019	LMAN2L	-0.87	-7.29	-0.41	3.59e-12	Erectile dysfunction and prostate cancer treatment;
CESC	cis	rs2070677	1.000	rs12263487	chr10:135403585	A/G	cg20169779	chr10:135381914	SYCE1	-0.9	-11.19	-0.57	4.67e-24	Gout;
CESC	cis	rs780096	0.546	rs4665976	chr2:27640325	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.34	-6.3	-0.36	1.2e-9	Total body bone mineral density;
CESC	cis	rs36051895	0.695	rs10124627	chr9:5025746	T/G	cg02405213	chr9:5042618	JAK2	-0.48	-5.97	-0.34	7.77e-9	Pediatric autoimmune diseases;
CESC	cis	rs28489187	0.706	rs3768227	chr1:85804087	A/G	cg16011679	chr1:85725395	C1orf52	0.55	6.37	0.36	8.25e-10	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	cis	rs6430585	0.583	rs59213715	chr2:136646582	A/C	cg07169764	chr2:136633963	MCM6	1.24	18.77	0.76	1.37e-50	Corneal structure;
CESC	cis	rs2011503	1.000	rs2965201	chr19:19478051	C/T	cg11584989	chr19:19387371	SF4	-0.63	-7.42	-0.41	1.63e-12	Bipolar disorder;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg01304440	chr3:32726769	CNOT10	-0.46	-6.07	-0.35	4.35e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs933688	1.000	rs186717	chr5:90780467	T/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.81	10.14	0.53	1.22e-20	Smoking behavior;
CESC	cis	rs13256369	1.000	rs12550762	chr8:8576535	T/A	cg17143192	chr8:8559678	CLDN23	0.7	8.24	0.45	8.14e-15	Obesity-related traits;
CESC	cis	rs9325144	0.555	rs11183215	chr12:38693127	G/A	cg26384229	chr12:38710491	ALG10B	-0.6	-8.57	-0.47	8.48e-16	Morning vs. evening chronotype;
CESC	cis	rs2762353	0.779	rs1408273	chr6:25840946	C/T	cg12310025	chr6:25882481	NA	0.37	6.15	0.35	2.92e-9	Blood metabolite levels;
CESC	cis	rs6060717	0.536	rs6060704	chr20:34530270	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.78	-6.98	-0.39	2.32e-11	Hip circumference adjusted for BMI;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg11037719	chr6:2999695	NQO2	0.5	6.23	0.36	1.82e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs2412819	0.597	rs78282429	chr15:43922003	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.48	7.25	0.41	4.7e-12	Lung cancer;
CESC	cis	rs76878669	0.561	rs7125752	chr11:66162419	C/T	cg18002602	chr11:66138449	SLC29A2	-0.44	-7.15	-0.4	8.56e-12	Educational attainment (years of education);
CESC	cis	rs8060686	0.641	rs113258243	chr16:68086656	C/T	cg26727032	chr16:67993705	SLC12A4	-0.55	-6.12	-0.35	3.34e-9	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs8077577	0.895	rs62073607	chr17:18071338	A/G	cg16794390	chr17:18148240	FLII	0.37	5.08	0.3	7.01e-7	Obesity-related traits;
CESC	cis	rs4862750	0.872	rs4862747	chr4:187877236	A/T	cg03647317	chr4:187891568	NA	0.38	5.55	0.32	6.94e-8	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6963495	0.818	rs73190149	chr7:105152793	C/T	cg13798780	chr7:105162888	PUS7	0.78	8.0	0.44	4.02e-14	Bipolar disorder (body mass index interaction);
CESC	cis	rs9787249	0.957	rs7547787	chr1:40220806	C/T	cg24920358	chr1:40204285	PPIE	0.41	6.06	0.35	4.56e-9	Blood protein levels;
CESC	cis	rs909674	0.775	rs8138462	chr22:39839670	G/C	cg11247378	chr22:39784982	NA	-0.58	-8.57	-0.47	8.52e-16	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	trans	rs9354308	1.000	rs9354308	chr6:66565353	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.53	6.37	0.36	8.27e-10	Metabolite levels;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg11530914	chr16:67281528	FHOD1;SLC9A5	0.49	6.6	0.38	2.22e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs938554	0.826	rs7376960	chr4:9970570	A/G	cg00071950	chr4:10020882	SLC2A9	-0.45	-5.19	-0.3	4.28e-7	Blood metabolite levels;
CESC	cis	rs2204008	0.774	rs8189620	chr12:38241621	A/G	cg13010199	chr12:38710504	ALG10B	0.51	6.33	0.36	1.04e-9	Bladder cancer;
CESC	cis	rs4853012	0.838	rs60705299	chr2:74345370	C/G	cg01017244	chr2:74357527	NA	0.68	9.95	0.52	5.1e-20	Gestational age at birth (maternal effect);
CESC	cis	rs4969178	0.965	rs4969186	chr17:76398404	C/G	cg05887092	chr17:76393375	PGS1	0.61	9.98	0.52	4.19e-20	HDL cholesterol levels;
CESC	cis	rs853679	0.517	rs9380062	chr6:28137569	G/A	cg26335602	chr6:28129616	ZNF389	0.52	6.84	0.39	5.58e-11	Depression;
CESC	cis	rs782590	0.643	rs13009906	chr2:55739434	A/G	cg18811423	chr2:55921094	PNPT1	-0.56	-7.82	-0.43	1.25e-13	Metabolic syndrome;
CESC	cis	rs6762	0.748	rs7936838	chr11:839093	G/C	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.68	-8.35	-0.46	3.76e-15	Mean platelet volume;
CESC	cis	rs36051895	0.589	rs16922786	chr9:5200714	A/G	cg02405213	chr9:5042618	JAK2	-0.5	-5.87	-0.34	1.31e-8	Pediatric autoimmune diseases;
CESC	cis	rs3749237	0.595	rs11130199	chr3:49538799	T/C	cg02487422	chr3:49467188	NICN1	0.59	8.52	0.46	1.2e-15	Resting heart rate;
CESC	cis	rs3093024	0.839	rs968334	chr6:167526096	T/C	cg07741184	chr6:167504864	NA	-0.36	-6.21	-0.36	2.09e-9	Rheumatoid arthritis;
CESC	cis	rs11792861	0.888	rs57314245	chr9:111813832	G/A	cg13535736	chr9:111863775	C9orf5	-0.46	-6.27	-0.36	1.43e-9	Menarche (age at onset);
CESC	cis	rs11098499	0.909	rs11723839	chr4:120299673	G/A	cg09307838	chr4:120376055	NA	0.92	12.54	0.61	1.23e-28	Corneal astigmatism;
CESC	cis	rs7044106	1.000	rs7044106	chr9:123494062	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.59	6.66	0.38	1.54e-10	Hip circumference adjusted for BMI;
CESC	cis	rs7216064	0.953	rs1599859	chr17:65837193	C/G	cg07042672	chr17:66097459	LOC651250	-0.57	-6.68	-0.38	1.38e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs8044868	0.530	rs8059437	chr16:72116467	A/G	cg16558253	chr16:72132732	DHX38	-0.38	-6.08	-0.35	4.22e-9	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CESC	cis	rs116095464	0.558	rs10055405	chr5:265666	C/T	cg20965017	chr5:231967	SDHA	-0.47	-5.3	-0.31	2.49e-7	Breast cancer;
CESC	cis	rs3780486	0.846	rs10113903	chr9:33122645	C/G	cg13443165	chr9:33130375	B4GALT1	-0.45	-6.57	-0.37	2.63e-10	IgG glycosylation;
CESC	cis	rs11252926	0.537	rs6560836	chr10:444997	C/T	cg16386425	chr10:429943	DIP2C	-0.56	-7.23	-0.41	5.02e-12	Psychosis in Alzheimer's disease;
CESC	cis	rs36051895	0.623	rs2381215	chr9:5262607	C/T	cg02405213	chr9:5042618	JAK2	-0.57	-6.95	-0.39	2.9e-11	Pediatric autoimmune diseases;
CESC	cis	rs3761218	0.668	rs6052079	chr20:3774209	G/T	cg25011176	chr20:3776985	CDC25B	-0.47	-6.22	-0.36	1.93e-9	Bipolar disorder;
CESC	cis	rs11122272	0.701	rs7414807	chr1:231476874	G/A	cg06096015	chr1:231504339	EGLN1	0.43	6.37	0.36	8.49e-10	Hemoglobin concentration;
CESC	cis	rs72781680	0.898	rs2879640	chr2:24043573	T/C	cg08917208	chr2:24149416	ATAD2B	0.95	8.71	0.47	3.45e-16	Lymphocyte counts;
CESC	cis	rs6087990	0.735	rs1040554	chr20:31380073	C/T	cg13636640	chr20:31349939	DNMT3B	0.77	12.58	0.61	8.78e-29	Ulcerative colitis;
CESC	trans	rs9329221	0.650	rs657913	chr8:9882575	G/T	cg15556689	chr8:8085844	FLJ10661	-0.55	-6.93	-0.39	3.16e-11	Neuroticism;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg13078969	chr12:1799970	ADIPOR2	-0.46	-6.53	-0.37	3.39e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs7903847	0.642	rs11189192	chr10:99149403	G/A	cg20016023	chr10:99160130	RRP12	-0.3	-5.16	-0.3	4.93e-7	Granulocyte percentage of myeloid white cells;
CESC	trans	rs73198271	0.653	rs10087633	chr8:8660444	A/G	cg23754772	chr18:12253859	CIDEA	-0.33	-6.18	-0.35	2.45e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs798766	1.000	rs798719	chr4:1698183	C/T	cg05874882	chr4:1763078	NA	-0.53	-7.05	-0.4	1.53e-11	Bladder cancer;Urinary bladder cancer;
CESC	cis	rs6500395	1.000	rs3919552	chr16:48716328	C/T	cg04672837	chr16:48644449	N4BP1	-0.51	-6.53	-0.37	3.33e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs3540	0.554	rs113942266	chr15:91072990	A/G	cg22089800	chr15:90895588	ZNF774	-0.64	-8.89	-0.48	9.92e-17	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	trans	rs61931739	0.500	rs12809868	chr12:34464905	C/T	cg13010199	chr12:38710504	ALG10B	0.49	6.28	0.36	1.39e-9	Morning vs. evening chronotype;
CESC	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg10074409	chr1:209979377	IRF6	0.43	8.41	0.46	2.49e-15	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
CESC	trans	rs7618501	1.000	rs2271960	chr3:49878078	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.57	7.91	0.44	6.81e-14	Intelligence (multi-trait analysis);
CESC	cis	rs8017423	0.967	rs1005788	chr14:90692747	C/T	cg14092571	chr14:90743983	NA	-0.57	-8.36	-0.46	3.48e-15	Mortality in heart failure;
CESC	cis	rs524281	0.692	rs10791845	chr11:65834340	C/G	cg14036092	chr11:66035641	RAB1B	0.58	6.34	0.36	1e-9	Electroencephalogram traits;
CESC	cis	rs5750830	0.649	rs5750813	chr22:39795228	G/C	cg02038168	chr22:39784481	NA	-0.59	-7.49	-0.42	1.03e-12	Intelligence (multi-trait analysis);
CESC	cis	rs4253772	0.550	rs6008601	chr22:46705326	C/G	cg09491104	chr22:46646882	C22orf40	-0.51	-6.01	-0.35	6.03e-9	LDL cholesterol;Cholesterol, total;
CESC	cis	rs7267979	0.528	rs2387976	chr20:25599560	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.7	-11.53	-0.58	3.51e-25	Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26622502	chr11:65769931	EIF1AD;BANF1	-0.59	-6.25	-0.36	1.66e-9	Gut microbiome composition (summer);
CESC	cis	rs9911578	1.000	rs6503866	chr17:56619581	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.41	-5.53	-0.32	7.63e-8	Intelligence (multi-trait analysis);
CESC	cis	rs1707322	0.721	rs28817701	chr1:46186050	C/T	cg05343316	chr1:45956843	TESK2	0.51	6.2	0.36	2.19e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs754466	0.957	rs61854183	chr10:79698077	T/C	cg17075019	chr10:79541650	NA	-0.73	-8.93	-0.48	7.24e-17	Liver enzyme levels (gamma-glutamyl transferase);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg22066304	chr19:55691730	SYT5	0.49	6.66	0.38	1.61e-10	Fibrinogen levels;
CESC	cis	rs7818345	0.967	rs35029660	chr8:19308126	T/C	cg11303988	chr8:19266685	CSGALNACT1	0.36	6.3	0.36	1.2e-9	Language performance in older adults (adjusted for episodic memory);
CESC	cis	rs9513627	0.920	rs7320057	chr13:100155586	G/A	cg25919922	chr13:100150906	NA	0.65	5.11	0.3	6.31e-7	Obesity-related traits;
CESC	cis	rs6032067	0.929	rs62205504	chr20:43867894	C/G	cg10761708	chr20:43804764	PI3	0.5	6.15	0.35	2.83e-9	Blood protein levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07552157	chr3:142720316	SR140	0.63	7.71	0.43	2.57e-13	Gut microbiome composition (summer);
CESC	cis	rs875971	0.723	rs28391294	chr7:65654315	T/C	cg11764359	chr7:65958608	NA	-0.78	-11.43	-0.57	7.35e-25	Aortic root size;
CESC	cis	rs7927771	0.524	rs10838784	chr11:47882341	G/A	cg18512352	chr11:47633146	NA	0.36	5.6	0.33	5.27e-8	Subjective well-being;
CESC	cis	rs116095464	0.558	rs59284383	chr5:284525	C/G	cg22857025	chr5:266934	NA	-1.29	-18.38	-0.75	3.21e-49	Breast cancer;
CESC	cis	rs2070488	0.804	rs2268755	chr3:38501916	A/G	cg24069376	chr3:38537580	EXOG	-0.32	-5.58	-0.32	6e-8	Electrocardiographic conduction measures;
CESC	cis	rs1862618	0.671	rs2034244	chr5:56242774	T/C	cg14703610	chr5:56206110	C5orf35	-0.41	-5.19	-0.3	4.17e-7	Initial pursuit acceleration;
CESC	cis	rs6842047	1.000	rs6842047	chr4:187133576	A/C	cg02012338	chr4:187126139	CYP4V2	0.62	5.38	0.31	1.61e-7	Blood protein levels;
CESC	cis	rs8044995	0.568	rs55675218	chr16:68323647	G/C	cg26727032	chr16:67993705	SLC12A4	-0.54	-5.21	-0.3	3.8e-7	Schizophrenia;
CESC	cis	rs10242455	0.702	rs17161700	chr7:98977067	A/G	cg25640893	chr7:99214727	ZNF498	0.91	5.66	0.33	4.01e-8	Blood metabolite levels;
CESC	cis	rs853679	0.517	rs9393893	chr6:28109262	T/C	cg19592336	chr6:28129416	ZNF389	0.61	8.17	0.45	1.28e-14	Depression;
CESC	cis	rs12995849	0.727	rs10200841	chr2:106456387	C/T	cg16077055	chr2:106428750	NCK2	0.39	6.06	0.35	4.62e-9	Addiction;
CESC	cis	rs62064224	0.703	rs62065493	chr17:30822620	C/G	cg18200150	chr17:30822561	MYO1D	0.75	12.1	0.6	3.9e-27	Schizophrenia;
CESC	cis	rs2742540	0.503	rs982273	chr11:8906862	T/G	cg14711859	chr11:8959438	ASCL3	0.38	5.79	0.34	2e-8	Hematocrit;
CESC	cis	rs7402982	0.934	rs6598539	chr15:99204483	T/C	cg03437748	chr15:99193247	IGF1R	0.71	11.03	0.56	1.55e-23	Birth weight;
CESC	cis	rs9858542	0.953	rs35261698	chr3:49537839	C/G	cg07274523	chr3:49395745	GPX1	0.66	8.05	0.44	2.82e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs72772090	0.539	rs17481759	chr5:96114695	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.57	-5.14	-0.3	5.45e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs8031584	0.697	rs798080	chr15:31122169	T/C	cg08704250	chr15:31115839	NA	0.69	9.22	0.49	9.79e-18	Huntington's disease progression;
CESC	cis	rs1448094	0.511	rs17279289	chr12:86162792	T/G	cg02569458	chr12:86230093	RASSF9	0.49	7.68	0.43	3.15e-13	Major depressive disorder;
CESC	cis	rs8005677	1.000	rs8014936	chr14:23375145	A/G	cg01529538	chr14:23388837	RBM23	0.51	6.99	0.39	2.25e-11	Cognitive ability (multi-trait analysis);
CESC	cis	rs10979	1.000	rs9403505	chr6:143885841	A/G	cg25407410	chr6:143891975	LOC285740	-0.61	-9.21	-0.49	9.97e-18	Hypospadias;
CESC	cis	rs3096299	0.685	rs4785676	chr16:89553624	T/C	cg02034447	chr16:89574710	SPG7	0.5	6.35	0.36	9.31e-10	Multiple myeloma (IgH translocation);
CESC	cis	rs9796	0.866	rs2928148	chr15:41401550	G/A	cg18705301	chr15:41695430	NDUFAF1	0.42	6.26	0.36	1.58e-9	Menopause (age at onset);
CESC	cis	rs597583	0.715	rs4938400	chr11:117399604	C/A	cg27161313	chr11:117392002	DSCAML1	-0.53	-6.03	-0.35	5.47e-9	Putamen volume;
CESC	cis	rs611744	0.583	rs1448148	chr8:109333074	T/A	cg21045802	chr8:109455806	TTC35	0.56	6.85	0.39	5.13e-11	Dupuytren's disease;
CESC	cis	rs35110281	0.666	rs2236665	chr21:45108987	C/A	cg01579765	chr21:45077557	HSF2BP	-0.52	-8.68	-0.47	4.11e-16	Mean corpuscular volume;
CESC	cis	rs4919694	1.000	rs7099987	chr10:104807926	C/T	cg04362960	chr10:104952993	NT5C2	0.79	7.08	0.4	1.27e-11	Arsenic metabolism;
CESC	cis	rs17095355	1.000	rs12570423	chr10:111690942	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.45	-5.07	-0.3	7.38e-7	Biliary atresia;
CESC	cis	rs7833986	0.501	rs72653951	chr8:56961837	G/A	cg26371346	chr8:56986568	SNORD54;RPS20	0.58	5.3	0.31	2.38e-7	Height;
CESC	cis	rs3617	0.573	rs9880978	chr3:52923251	C/G	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.32	5.59	0.32	5.74e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
CESC	cis	rs858239	0.600	rs7785842	chr7:23141706	T/A	cg23682824	chr7:23144976	KLHL7	0.54	7.7	0.43	2.68e-13	Cerebrospinal fluid biomarker levels;
CESC	cis	rs7659604	0.676	rs6534323	chr4:122695888	G/A	cg20573242	chr4:122745356	CCNA2	0.52	6.53	0.37	3.42e-10	Type 2 diabetes;
CESC	cis	rs988913	0.723	rs4490666	chr6:55000651	C/T	cg03513858	chr6:54763001	FAM83B	0.33	5.05	0.3	8.26e-7	Menarche (age at onset);
CESC	cis	rs6460942	0.597	rs13227809	chr7:12525557	G/A	cg02935154	chr7:12443704	VWDE	-0.55	-5.53	-0.32	7.71e-8	Coronary artery disease;
CESC	cis	rs780096	0.526	rs10182937	chr2:27651693	T/C	cg21248554	chr2:27665150	KRTCAP3	-0.36	-7.38	-0.41	2.02e-12	Total body bone mineral density;
CESC	cis	rs1008375	0.966	rs4235391	chr4:17696409	A/G	cg02297831	chr4:17616191	MED28	0.44	5.34	0.31	1.99e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	trans	rs1728785	0.818	rs1728769	chr16:68564186	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.61	7.42	0.41	1.57e-12	Ulcerative colitis;
CESC	cis	rs34779708	0.931	rs2384287	chr10:35340559	A/G	cg04310649	chr10:35416472	CREM	-0.51	-6.01	-0.35	6.07e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs853679	0.517	rs9380061	chr6:28132803	T/C	cg17949981	chr6:28129498	ZNF389	0.45	5.57	0.32	6.26e-8	Depression;
CESC	cis	rs7917772	0.503	rs11191342	chr10:104344450	G/A	ch.10.2196322F	chr10:104248062	ACTR1A	0.42	5.16	0.3	4.94e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	trans	rs7246760	1.000	rs2287839	chr19:9940814	C/G	cg02900749	chr2:68251473	NA	-0.76	-6.38	-0.36	7.69e-10	Pursuit maintenance gain;
CESC	cis	rs17376456	0.877	rs10062711	chr5:93348659	G/A	cg25358565	chr5:93447407	FAM172A	1.1	10.64	0.55	3.12e-22	Diabetic retinopathy;
CESC	cis	rs9487051	0.676	rs6910119	chr6:109599263	A/G	cg21918786	chr6:109611834	NA	-0.37	-5.5	-0.32	9.15e-8	Reticulocyte fraction of red cells;
CESC	cis	rs6570726	1.000	rs436066	chr6:145847127	C/T	cg05347473	chr6:146136440	FBXO30	0.44	5.92	0.34	1.02e-8	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4665809	0.652	rs2241739	chr2:26411894	C/T	cg27170947	chr2:26402098	FAM59B	-0.83	-10.42	-0.54	1.51e-21	Gut microbiome composition (summer);
CESC	cis	rs9399135	0.967	rs9389258	chr6:135361140	T/C	cg22676075	chr6:135203613	NA	0.51	7.3	0.41	3.45e-12	Red blood cell count;
CESC	cis	rs3820068	0.603	rs932602	chr1:15986087	A/G	cg13390004	chr1:15929781	NA	0.34	5.49	0.32	9.33e-8	Systolic blood pressure;
CESC	trans	rs11098499	0.908	rs7696649	chr4:120322177	G/A	cg25214090	chr10:38739885	LOC399744	0.71	9.87	0.52	9.3e-20	Corneal astigmatism;
CESC	cis	rs270601	0.633	rs733300	chr5:131572243	A/G	cg18301423	chr5:131593218	PDLIM4	0.38	5.24	0.31	3.27e-7	Acylcarnitine levels;
CESC	cis	rs1729951	0.546	rs361246	chr3:136695667	G/A	cg03617693	chr3:136751559	NA	0.39	5.4	0.31	1.47e-7	Neuroticism;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00369061	chr11:129765581	NFRKB	0.59	6.46	0.37	5.12e-10	Gut microbiome composition (summer);
CESC	cis	rs2130392	0.892	rs11728389	chr4:185622046	C/T	cg21366198	chr4:185655624	MLF1IP	0.43	6.08	0.35	4.24e-9	Kawasaki disease;
CESC	cis	rs1904096	0.506	rs17021463	chr4:95224812	T/G	cg11021082	chr4:95130006	SMARCAD1	-0.62	-9.82	-0.52	1.3e-19	Type 2 diabetes;
CESC	cis	rs7116495	0.609	rs3750907	chr11:71822560	T/C	cg10381502	chr11:71823885	C11orf51	1.16	7.22	0.41	5.55e-12	Severe influenza A (H1N1) infection;
CESC	cis	rs9914988	0.943	rs4794838	chr17:27131095	T/C	cg20469991	chr17:27169893	C17orf63	-0.48	-5.25	-0.31	3.18e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CESC	cis	rs4713118	0.621	rs4713132	chr6:28034035	A/G	cg20151795	chr6:28129481	ZNF389	0.4	5.09	0.3	6.94e-7	Parkinson's disease;
CESC	cis	rs10540	0.730	rs61876338	chr11:493730	A/G	cg03934478	chr11:495069	RNH1	0.54	5.15	0.3	4.97e-7	Body mass index;
CESC	cis	rs6500602	0.727	rs2160567	chr16:4535557	C/T	cg08645402	chr16:4508243	NA	0.53	8.53	0.46	1.18e-15	Schizophrenia;
CESC	cis	rs473651	0.904	rs501333	chr2:239336045	G/A	cg18131467	chr2:239335373	ASB1	1.03	21.68	0.8	1.23e-60	Multiple system atrophy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04367680	chr8:74005697	C8orf84	-0.56	-6.67	-0.38	1.5e-10	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23805785	chr1:32671112	IQCC	0.58	6.93	0.39	3.2e-11	Gut microbiome composition (summer);
CESC	cis	rs72945132	0.882	rs66627443	chr11:70199036	C/G	cg14191688	chr11:70257035	CTTN	0.41	5.1	0.3	6.49e-7	Coronary artery disease;
CESC	cis	rs11638352	0.661	rs2042738	chr15:44426553	T/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.56	-5.29	-0.31	2.53e-7	Lipoprotein phospholipase A2 activity in cardiovascular disease;
CESC	cis	rs72634258	0.945	rs161800	chr1:8042402	A/T	cg00042356	chr1:8021962	PARK7	0.58	6.24	0.36	1.77e-9	Inflammatory bowel disease;
CESC	trans	rs694739	0.726	rs516124	chr11:64128423	G/T	cg01888411	chr11:34378293	ABTB2	0.39	6.03	0.35	5.39e-9	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CESC	cis	rs55794721	0.509	rs873308	chr1:25758655	A/G	cg27572855	chr1:25598939	RHD	-0.5	-8.75	-0.47	2.49e-16	Plateletcrit;Mean corpuscular volume;
CESC	cis	rs2933343	0.700	rs789238	chr3:128636715	A/G	cg11901034	chr3:128598214	ACAD9	-0.39	-5.69	-0.33	3.28e-8	IgG glycosylation;
CESC	cis	rs72634258	0.945	rs225131	chr1:8095486	T/C	cg00042356	chr1:8021962	PARK7	0.53	6.01	0.35	6.21e-9	Inflammatory bowel disease;
CESC	cis	rs2204008	0.666	rs67792345	chr12:38204698	T/C	cg13010199	chr12:38710504	ALG10B	0.53	6.43	0.37	5.94e-10	Bladder cancer;
CESC	trans	rs10506458	0.915	rs79133015	chr12:63396838	G/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.35	-18.82	-0.76	9.08e-51	Hemostatic factors and hematological phenotypes;
CESC	cis	rs7208859	0.673	rs56846352	chr17:29119188	C/T	cg04154034	chr17:28927549	LRRC37B2	0.55	5.24	0.31	3.25e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs10088262	0.591	rs13270541	chr8:124794849	G/A	cg20713898	chr8:124780851	FAM91A1	-0.67	-9.11	-0.49	2.02e-17	Pancreatic cancer;
CESC	cis	rs875971	0.862	rs6460306	chr7:66060793	T/C	cg19163074	chr7:65112434	INTS4L2	0.41	5.21	0.3	3.76e-7	Aortic root size;
CESC	cis	rs875971	1.000	rs6460295	chr7:65882728	T/C	cg11764359	chr7:65958608	NA	0.98	15.79	0.7	4.71e-40	Aortic root size;
CESC	cis	rs870825	0.616	rs28563856	chr4:185635581	G/A	cg04058563	chr4:185651563	MLF1IP	0.62	6.86	0.39	4.91e-11	Blood protein levels;
CESC	cis	rs7666738	0.546	rs1863602	chr4:98909304	T/C	cg17366294	chr4:99064904	C4orf37	0.52	6.58	0.37	2.54e-10	Colonoscopy-negative controls vs population controls;
CESC	cis	rs60871478	1.000	rs9195	chr7:825786	C/T	cg27478167	chr7:817139	HEATR2	0.43	5.19	0.3	4.21e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs2361718	0.500	rs12451697	chr17:78100690	T/A	cg27427491	chr17:78079615	GAA	-0.39	-5.74	-0.33	2.59e-8	Yeast infection;
CESC	cis	rs3008870	0.816	rs1118392	chr1:67366549	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-0.7	-9.06	-0.49	2.9e-17	Lymphocyte percentage of white cells;
CESC	cis	rs2303759	0.918	rs1054770	chr19:49878115	G/A	cg24324837	chr19:49891574	CCDC155	0.51	5.99	0.35	6.76e-9	Multiple sclerosis;
CESC	cis	rs1784581	0.802	rs9365355	chr6:162414604	A/G	cg17173639	chr6:162384350	PARK2	0.61	9.42	0.5	2.25e-18	Itch intensity from mosquito bite;
CESC	cis	rs921968	0.541	rs3770216	chr2:219443717	A/G	cg02176678	chr2:219576539	TTLL4	-0.54	-9.87	-0.52	9.27e-20	Mean corpuscular hemoglobin concentration;
CESC	cis	rs10927875	0.722	rs6696912	chr1:16338474	T/C	cg22431228	chr1:16359049	CLCNKA	-0.47	-7.82	-0.43	1.22e-13	Dilated cardiomyopathy;
CESC	cis	rs425277	0.583	rs3128334	chr1:2038662	G/A	cg04315214	chr1:2043799	PRKCZ	0.45	7.32	0.41	2.99e-12	Height;
CESC	cis	rs7078219	0.524	rs6584277	chr10:101278055	A/G	cg09788492	chr10:101292477	NKX2-3	0.32	5.98	0.34	7.23e-9	Dental caries;
CESC	cis	rs992157	0.643	rs10191283	chr2:219056755	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.68	9.54	0.51	9.55e-19	Colorectal cancer;
CESC	cis	rs6088580	0.634	rs6059896	chr20:33111783	T/C	cg24642439	chr20:33292090	TP53INP2	0.5	6.55	0.37	3.05e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs2635047	0.656	rs1355594	chr18:44763994	T/G	cg24371990	chr18:44770781	NA	0.41	6.68	0.38	1.4e-10	Educational attainment;
CESC	cis	rs8002861	0.765	rs12868462	chr13:44453480	C/T	cg14210620	chr13:44453864	C13orf31;CCDC122	-0.44	-5.57	-0.32	6.27e-8	Leprosy;
CESC	cis	rs7618915	0.547	rs4687548	chr3:52666650	A/T	cg07507251	chr3:52567010	NT5DC2	0.4	7.03	0.4	1.78e-11	Bipolar disorder;
CESC	cis	rs9486719	1.000	rs28623445	chr6:96899116	G/T	cg06623918	chr6:96969491	KIAA0776	-0.81	-8.3	-0.45	5.21e-15	Migraine;Coronary artery disease;
CESC	cis	rs11792861	0.962	rs11789624	chr9:111796231	T/C	cg05043794	chr9:111880884	C9orf5	-0.42	-6.92	-0.39	3.35e-11	Menarche (age at onset);
CESC	cis	rs875971	0.830	rs427973	chr7:65526648	C/A	cg18876405	chr7:65276391	NA	0.56	7.45	0.42	1.34e-12	Aortic root size;
CESC	cis	rs10504229	0.683	rs7000349	chr8:58114569	C/A	cg21724239	chr8:58056113	NA	0.58	5.93	0.34	9.45e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs116095464	0.558	rs7708515	chr5:234989	C/G	cg22857025	chr5:266934	NA	-1.28	-18.64	-0.75	3.96e-50	Breast cancer;
CESC	cis	rs6540559	0.673	rs17015224	chr1:209968918	G/A	cg22029157	chr1:209979665	IRF6	0.76	8.93	0.48	7.36e-17	Cleft lip with or without cleft palate;
CESC	cis	rs7312933	0.703	rs10880268	chr12:42599122	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.49	6.4	0.37	6.94e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs7412746	0.634	rs3754212	chr1:150738200	A/G	cg17724175	chr1:150552817	MCL1	0.42	6.45	0.37	5.2400000000000005e-10	Melanoma;
CESC	cis	rs1595825	0.838	rs7603283	chr2:198517592	A/G	cg10820045	chr2:198174542	NA	0.41	5.21	0.3	3.79e-7	Ulcerative colitis;
CESC	cis	rs735396	0.694	rs2264750	chr12:121450165	C/T	cg25281562	chr12:121454272	C12orf43	0.5	6.2	0.36	2.18e-9	N-glycan levels;
CESC	cis	rs6952808	0.531	rs3779003	chr7:2184902	C/T	cg05863683	chr7:1912471	MAD1L1	0.36	5.17	0.3	4.65e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs3820928	0.874	rs55959848	chr2:227805426	C/A	cg05526886	chr2:227700861	RHBDD1	-0.39	-5.04	-0.3	8.54e-7	Pulmonary function;
CESC	cis	rs8058578	1.000	rs13338946	chr16:30700858	T/C	cg00531865	chr16:30841666	NA	-0.42	-5.44	-0.32	1.23e-7	Multiple myeloma;
CESC	cis	rs2235642	0.893	rs2076445	chr16:1592266	A/T	cg09080909	chr16:1797204	MAPK8IP3	-0.38	-5.27	-0.31	2.85e-7	Coronary artery disease;
CESC	cis	rs3771570	1.000	rs62193205	chr2:242316512	C/T	cg21155796	chr2:242212141	HDLBP	0.6	5.27	0.31	2.89e-7	Prostate cancer;
CESC	cis	rs769267	0.896	rs10410664	chr19:19556651	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	7.4	0.41	1.78e-12	Tonsillectomy;
CESC	cis	rs4665809	1.000	rs12475854	chr2:26267375	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.69	-7.84	-0.43	1.07e-13	Gut microbiome composition (summer);
CESC	cis	rs1799949	1.000	rs9646412	chr17:41425893	A/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.61	8.13	0.45	1.66e-14	Menopause (age at onset);
CESC	cis	rs712039	0.652	rs1829453	chr17:35809843	A/G	cg16670864	chr17:35848621	DUSP14	0.41	5.13	0.3	5.52e-7	Tuberculosis;
CESC	cis	rs12618769	0.543	rs2278211	chr2:99149946	G/A	cg10123293	chr2:99228465	UNC50	0.42	5.43	0.32	1.3e-7	Bipolar disorder;
CESC	cis	rs79057730	0.599	rs112891948	chr7:816059	C/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.87	7.3	0.41	3.39e-12	Initial pursuit acceleration;
CESC	cis	rs3820068	0.603	rs6429767	chr1:15963334	G/A	cg16988262	chr1:15930761	NA	0.34	5.45	0.32	1.16e-7	Systolic blood pressure;
CESC	cis	rs7943191	0.810	rs7942154	chr11:62337163	G/A	cg22862634	chr11:62369728	EML3;MTA2	0.47	6.35	0.36	9.12e-10	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg10573403	chr14:36003118	INSM2	0.44	6.14	0.35	2.94e-9	Systemic lupus erythematosus;
CESC	cis	rs7582720	0.945	rs72934601	chr2:204031137	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	6.87	0.39	4.55e-11	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg00526316	chr1:151043472	GABPB2	-0.44	-6.12	-0.35	3.3e-9	Height;
CESC	cis	rs7520050	0.966	rs1707335	chr1:46571921	C/T	cg03146154	chr1:46216737	IPP	-0.43	-5.52	-0.32	8.27e-8	Red blood cell count;Reticulocyte count;
CESC	cis	rs4979906	1.000	rs11002249	chr10:79447228	C/T	cg07817648	chr10:79422355	NA	-0.49	-5.52	-0.32	8.19e-8	Mortality in heart failure;
CESC	cis	rs5769765	0.646	rs9616205	chr22:50309915	A/T	cg02269571	chr22:50332266	NA	-0.61	-7.66	-0.43	3.57e-13	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05236972	chr22:46933233	CELSR1	0.57	6.88	0.39	4.34e-11	Gut microbiome composition (summer);
CESC	cis	rs12464559	0.649	rs9288006	chr2:152661831	G/A	cg01189475	chr2:152685088	ARL5A	0.65	5.88	0.34	1.26e-8	Response to cognitive-behavioural therapy in anxiety disorder;
CESC	cis	rs9926296	0.585	rs8045232	chr16:89857548	A/G	cg21285383	chr16:89894308	SPIRE2	0.32	5.76	0.33	2.32e-8	Vitiligo;
CESC	trans	rs7047415	1.000	rs7029315	chr9:98544912	A/G	cg00788170	chr1:227921688	SNAP47;LOC100130093;JMJD4	-0.45	-6.12	-0.35	3.28e-9	Alzheimer disease and age of onset;
CESC	cis	rs4689388	0.750	rs10001190	chr4:6284633	C/T	cg00701064	chr4:6280414	WFS1	-0.66	-10.31	-0.54	3.46e-21	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs6502050	0.731	rs35156322	chr17:80096323	T/C	cg01763666	chr17:80159506	CCDC57	-0.37	-5.1	-0.3	6.61e-7	Life satisfaction;
CESC	cis	rs9300255	0.699	rs11057204	chr12:123725827	T/C	cg05973401	chr12:123451056	ABCB9	0.51	5.62	0.33	4.77e-8	Neutrophil percentage of white cells;
CESC	cis	rs1008375	0.966	rs11947836	chr4:17697187	A/G	cg16339924	chr4:17578868	LAP3	-0.66	-8.07	-0.44	2.54e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs875971	1.000	rs778699	chr7:65868290	G/A	cg18876405	chr7:65276391	NA	0.5	6.68	0.38	1.43e-10	Aortic root size;
CESC	cis	rs7089973	0.624	rs11196940	chr10:116593791	T/G	cg23260525	chr10:116636907	FAM160B1	0.41	7.44	0.42	1.45e-12	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06134974	chr12:51477539	CSRNP2	0.6	6.94	0.39	2.94e-11	Gut microbiome composition (summer);
CESC	cis	rs6163	0.588	rs3818708	chr10:104503584	C/T	cg04362960	chr10:104952993	NT5C2	0.41	5.58	0.32	5.9e-8	Waist circumference;Hip circumference;
CESC	cis	rs6963495	0.818	rs6955796	chr7:105170321	T/G	cg19920283	chr7:105172520	RINT1	0.69	6.54	0.37	3.15e-10	Bipolar disorder (body mass index interaction);
CESC	cis	rs7666738	0.830	rs115279324	chr4:99042114	T/C	cg17366294	chr4:99064904	C4orf37	0.6	8.51	0.46	1.33e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs12701220	0.655	rs12702117	chr7:1148702	T/C	cg04025307	chr7:1156635	C7orf50	0.44	5.41	0.32	1.38e-7	Bronchopulmonary dysplasia;
CESC	cis	rs597539	0.652	rs604524	chr11:68629929	G/A	cg18350739	chr11:68623251	NA	-0.46	-6.84	-0.39	5.59e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs477692	0.685	rs534430	chr10:131398734	A/C	cg05714579	chr10:131428358	MGMT	0.5	6.77	0.38	8.16e-11	Response to temozolomide;
CESC	cis	rs4803468	0.967	rs13344547	chr19:41945848	G/T	cg09537434	chr19:41945824	ATP5SL	1.06	19.91	0.77	1.51e-54	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05258477	chr6:170151703	C6orf70;TCTE3	0.58	6.47	0.37	4.58e-10	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25802399	chr20:61847276	YTHDF1	0.62	7.26	0.41	4.4e-12	Gut microbiome composition (summer);
CESC	trans	rs4950322	0.580	rs17355419	chr1:146581676	T/C	cg04954894	chr8:38089920	DDHD2	-0.59	-6.42	-0.37	6.22e-10	Protein quantitative trait loci;
CESC	cis	rs7561273	0.609	rs6720226	chr2:24295853	A/G	cg20701182	chr2:24300061	SF3B14	0.46	6.14	0.35	2.93e-9	Quantitative traits;
CESC	cis	rs941873	0.868	rs10740497	chr10:81126380	T/C	cg09469691	chr10:81107165	PPIF	0.56	7.56	0.42	6.79e-13	Height;
CESC	cis	rs2712184	0.756	rs2541395	chr2:217647675	C/T	cg05032264	chr2:217675019	NA	-0.34	-5.15	-0.3	5.03e-7	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
CESC	cis	rs853679	0.517	rs9393885	chr6:28050009	A/T	cg22143856	chr6:28129313	ZNF389	0.49	6.3	0.36	1.2e-9	Depression;
CESC	cis	rs12478296	0.681	rs56357900	chr2:243033966	A/C	cg06360820	chr2:242988706	NA	-0.7	-7.82	-0.43	1.29e-13	Obesity-related traits;
CESC	trans	rs10776614	0.799	rs1838569	chr10:49763677	A/C	cg19218067	chr2:181235115	NA	0.5	6.1	0.35	3.7e-9	Self-employment;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg05463257	chr3:182782445	MCCC1	0.46	6.44	0.37	5.66e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs877282	0.853	rs7083589	chr10:754494	G/A	cg22713356	chr15:30763199	NA	0.93	8.39	0.46	3e-15	Uric acid levels;
CESC	cis	rs72945132	0.825	rs947811	chr11:70209142	A/T	cg00319359	chr11:70116639	PPFIA1	0.73	6.96	0.39	2.63e-11	Coronary artery disease;
CESC	cis	rs11608355	0.515	rs7955932	chr12:109941303	G/A	cg05360138	chr12:110035743	NA	0.82	8.85	0.48	1.27e-16	Neuroticism;
CESC	cis	rs2806561	0.765	rs652706	chr1:23514246	G/A	cg12483005	chr1:23474871	LUZP1	0.38	6.0	0.35	6.44e-9	Height;
CESC	cis	rs6546550	0.935	rs3214007	chr2:70098808	A/G	cg02498382	chr2:70120550	SNRNP27	-0.38	-6.54	-0.37	3.2e-10	Prevalent atrial fibrillation;
CESC	cis	rs1355223	0.506	rs6484738	chr11:34860858	C/T	cg06937548	chr11:34938143	PDHX;APIP	0.41	5.1	0.3	6.58e-7	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs9287719	0.967	rs9287720	chr2:10752664	C/T	cg02196655	chr2:10830764	NOL10	-0.37	-5.69	-0.33	3.39e-8	Prostate cancer;
CESC	trans	rs624896	0.661	rs163207	chr5:113725710	C/G	cg24875808	chr15:86742911	AGBL1	0.71	6.13	0.35	3.19e-9	JT interval (sulfonylurea treatment interaction);
CESC	cis	rs561341	1.000	rs4795668	chr17:30244554	G/A	cg12193833	chr17:30244370	NA	-0.72	-7.38	-0.41	2.07e-12	Hip circumference adjusted for BMI;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06227920	chr15:65477998	CLPX	0.6	6.57	0.37	2.61e-10	Gut microbiome composition (summer);
CESC	cis	rs4835473	0.800	rs1849133	chr4:144879415	C/T	cg25736465	chr4:144833511	NA	0.4	5.99	0.35	6.7e-9	Immature fraction of reticulocytes;
CESC	cis	rs3785574	0.743	rs2727334	chr17:61969063	A/T	cg07677032	chr17:61819896	STRADA	0.43	5.42	0.32	1.35e-7	Height;
CESC	cis	rs875971	1.000	rs937495	chr7:65779798	A/G	cg11764359	chr7:65958608	NA	-0.94	-15.61	-0.69	2.13e-39	Aortic root size;
CESC	cis	rs4810685	0.526	rs6018686	chr20:46410965	A/C	cg08288986	chr20:46415360	SULF2	0.51	5.81	0.34	1.75e-8	Attention deficit hyperactivity disorder (time to onset);
CESC	cis	rs11997175	0.655	rs72630922	chr8:33662401	G/A	ch.8.33884649F	chr8:33765107	NA	0.47	5.96	0.34	7.88e-9	Body mass index;
CESC	cis	rs2279817	1.000	rs10788680	chr1:18019454	A/G	cg21791023	chr1:18019539	ARHGEF10L	0.58	8.51	0.46	1.31e-15	Neuroticism;
CESC	cis	rs2243480	1.000	rs160646	chr7:65556280	C/T	cg12463550	chr7:65579703	CRCP	0.75	5.78	0.33	2.06e-8	Diabetic kidney disease;
CESC	cis	rs9324022	0.722	rs111475476	chr14:101165917	C/T	cg18089426	chr14:101175970	NA	0.55	5.64	0.33	4.41e-8	Plateletcrit;
CESC	cis	rs425277	0.916	rs414777	chr1:2101687	G/A	cg16545954	chr1:2118288	C1orf86	0.33	5.59	0.32	5.7e-8	Height;
CESC	cis	rs853679	0.517	rs9295759	chr6:28124469	C/T	cg19592336	chr6:28129416	ZNF389	0.61	7.97	0.44	4.74e-14	Depression;
CESC	cis	rs57221529	0.766	rs12519469	chr5:581772	A/G	cg16447950	chr5:562315	NA	-0.6	-6.32	-0.36	1.09e-9	Lung disease severity in cystic fibrosis;
CESC	cis	rs7927771	0.524	rs7936948	chr11:47704200	T/G	cg20307385	chr11:47447363	PSMC3	0.61	8.46	0.46	1.87e-15	Subjective well-being;
CESC	trans	rs687914	0.710	rs938662	chr2:45864578	A/G	cg24859228	chr10:12391835	CAMK1D	0.59	6.04	0.35	5.18e-9	Diastolic blood pressure;
CESC	cis	rs2075371	0.611	rs11762920	chr7:134018514	C/T	cg20476274	chr7:133979776	SLC35B4	0.59	7.81	0.43	1.36e-13	Mean platelet volume;
CESC	cis	rs2243480	1.000	rs316313	chr7:65593548	G/A	cg13147721	chr7:65941812	NA	-0.99	-9.4	-0.5	2.68e-18	Diabetic kidney disease;
CESC	cis	rs7618915	0.547	rs11130314	chr3:52697082	T/C	cg05564831	chr3:52568323	NT5DC2	0.44	6.72	0.38	1.08e-10	Bipolar disorder;
CESC	trans	rs7945404	0.548	rs10750188	chr11:121230246	A/C	cg09432902	chr12:113909932	LHX5	0.45	6.08	0.35	4.23e-9	QT interval;
CESC	cis	rs1153858	0.943	rs7402632	chr15:45701913	A/T	cg14582100	chr15:45693742	SPATA5L1	0.41	5.79	0.34	1.97e-8	Homoarginine levels;
CESC	cis	rs6466055	0.720	rs12334245	chr7:104995627	T/C	cg04380332	chr7:105027541	SRPK2	-0.42	-5.54	-0.32	7.45e-8	Schizophrenia;
CESC	cis	rs35123781	0.696	rs7703195	chr5:139071632	G/A	cg10513866	chr5:139070639	NA	0.45	6.37	0.36	8.36e-10	Schizophrenia;
CESC	cis	rs4474465	0.850	rs10899536	chr11:78216992	C/A	cg27205649	chr11:78285834	NARS2	0.44	5.35	0.31	1.94e-7	Alzheimer's disease (survival time);
CESC	trans	rs6089829	0.962	rs11086151	chr20:61664644	C/T	cg23505145	chr19:12996616	KLF1	0.52	6.74	0.38	1e-10	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs12410462	0.681	rs75876430	chr1:227661157	A/G	cg23173402	chr1:227635558	NA	0.68	5.93	0.34	9.49e-9	Major depressive disorder;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg12427896	chr2:111880694	BCL2L11	-0.45	-6.67	-0.38	1.45e-10	Gambling;
CESC	cis	rs9581857	1.000	rs9581857	chr13:28027714	A/C	cg01674679	chr13:27998804	GTF3A	-0.67	-5.29	-0.31	2.58e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
CESC	cis	rs9291683	0.546	rs7442336	chr4:10045783	G/A	cg11266682	chr4:10021025	SLC2A9	0.65	12.28	0.6	9.38e-28	Bone mineral density;
CESC	cis	rs10206020	0.885	rs11885392	chr2:1578182	C/A	cg12573674	chr2:1569213	NA	-0.45	-5.18	-0.3	4.5e-7	IgG glycosylation;
CESC	cis	rs7666738	0.830	rs4699580	chr4:98930673	T/C	cg17366294	chr4:99064904	C4orf37	0.6	8.22	0.45	9.04e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs74181299	0.684	rs6756585	chr2:65340070	G/A	cg05010058	chr2:65284262	CEP68	-0.31	-5.07	-0.3	7.51e-7	Pulse pressure;
CESC	cis	rs2273669	0.667	rs76747161	chr6:109305456	G/A	cg05315195	chr6:109294784	ARMC2	-0.65	-6.08	-0.35	4.15e-9	Prostate cancer;
CESC	cis	rs9649213	0.593	rs11766808	chr7:97915376	A/G	cg00277769	chr7:97922759	BAIAP2L1	-0.35	-5.74	-0.33	2.55e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs4979906	1.000	rs11002246	chr10:79446777	T/A	cg00983440	chr10:79422392	NA	-0.48	-5.08	-0.3	7.19e-7	Mortality in heart failure;
CESC	cis	rs6502050	0.835	rs12450189	chr17:80095128	A/C	cg11859384	chr17:80120422	CCDC57	-0.38	-5.14	-0.3	5.29e-7	Life satisfaction;
CESC	cis	rs11155671	0.530	rs9371544	chr6:150217360	A/G	cg09699651	chr6:150184138	LRP11	0.54	7.62	0.42	4.61e-13	Testicular germ cell tumor;
CESC	cis	rs12711979	0.765	rs10208316	chr2:3827630	T/C	cg17052675	chr2:3827356	NA	-0.42	-6.72	-0.38	1.12e-10	Itch intensity from mosquito bite adjusted by bite size;
CESC	cis	rs9790314	0.967	rs1382427	chr3:161032576	T/C	cg04691961	chr3:161091175	C3orf57	-0.43	-5.56	-0.32	6.47e-8	Morning vs. evening chronotype;
CESC	cis	rs7592578	0.640	rs56127319	chr2:191296429	G/A	cg27211696	chr2:191398769	TMEM194B	-0.6	-6.08	-0.35	4.21e-9	Diastolic blood pressure;
CESC	cis	rs2898681	0.618	rs7677726	chr4:53739262	A/G	cg00791764	chr4:53727839	RASL11B	-0.55	-5.34	-0.31	1.98e-7	Optic nerve measurement (cup area);
CESC	cis	rs7809950	1.000	rs2894475	chr7:107262558	A/T	cg23024343	chr7:107201750	COG5	-0.42	-5.81	-0.34	1.79e-8	Coronary artery disease;
CESC	cis	rs2072732	0.861	rs12036378	chr1:2955158	G/A	cg03976712	chr1:2946727	NA	0.33	5.53	0.32	7.83e-8	Plateletcrit;
CESC	cis	rs1050631	0.564	rs1785905	chr18:33713287	T/A	cg25426722	chr18:33708991	SLC39A6;ELP2	0.59	8.21	0.45	9.51e-15	Esophageal squamous cell cancer (length of survival);
CESC	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	10.38	0.54	2.06e-21	Prudent dietary pattern;
CESC	cis	rs736408	0.648	rs3774354	chr3:52817675	G/A	cg07507251	chr3:52567010	NT5DC2	0.37	6.1	0.35	3.82e-9	Bipolar disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19008789	chr15:55700587	CCPG1	0.58	6.14	0.35	3e-9	Gut microbiome composition (summer);
CESC	cis	rs7116495	1.000	rs656640	chr11:71781710	T/C	cg10381502	chr11:71823885	C11orf51	-0.68	-5.48	-0.32	9.68e-8	Severe influenza A (H1N1) infection;
CESC	cis	rs3733585	0.664	rs17185870	chr4:9958214	C/A	cg11266682	chr4:10021025	SLC2A9	-0.6	-11.12	-0.56	7.79e-24	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs55728055	0.661	rs55673702	chr22:32035518	G/A	cg01338084	chr22:32026380	PISD	1.22	8.7	0.47	3.47e-16	Age-related hearing impairment;
CESC	cis	rs9611565	0.765	rs202663	chr22:41812819	T/C	cg06481639	chr22:41940642	POLR3H	0.61	6.45	0.37	5.35e-10	Vitiligo;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04800682	chr3:58223165	ABHD6	-0.58	-6.9	-0.39	3.74e-11	Gut microbiome composition (summer);
CESC	cis	rs10206020	0.759	rs11903889	chr2:1576601	C/T	cg12573674	chr2:1569213	NA	-0.46	-5.2	-0.3	3.96e-7	IgG glycosylation;
CESC	cis	rs7408868	0.908	rs10416865	chr19:15277601	T/C	cg14696996	chr19:15285081	NOTCH3	1.11	11.94	0.59	1.43e-26	Pulse pressure;
CESC	cis	rs6952808	0.798	rs28970524	chr7:1927484	C/T	cg02951883	chr7:2050386	MAD1L1	-0.51	-6.76	-0.38	8.53e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs4713118	0.513	rs149950	chr6:28033039	T/G	cg12963246	chr6:28129442	ZNF389	0.39	5.6	0.33	5.36e-8	Parkinson's disease;
CESC	cis	rs763121	0.853	rs2267395	chr22:39113903	C/T	cg21395723	chr22:39101663	GTPBP1	0.51	7.08	0.4	1.33e-11	Menopause (age at onset);
CESC	cis	rs962856	0.575	rs588779	chr2:67665951	C/T	cg09028215	chr2:67624308	ETAA1	-0.44	-5.35	-0.31	1.93e-7	Pancreatic cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04662649	chr15:41191689	VPS18	-0.6	-7.19	-0.4	6.66e-12	Gut microbiome composition (summer);
CESC	cis	rs736801	0.780	rs11951091	chr5:131786595	G/A	cg21138405	chr5:131827807	IRF1	-0.4	-5.82	-0.34	1.72e-8	Breast cancer;Mosquito bite size;
CESC	cis	rs6542838	0.553	rs6739503	chr2:99537295	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.43	-5.51	-0.32	8.69e-8	Fear of minor pain;
CESC	cis	rs8058578	1.000	rs3747481	chr16:30666367	C/T	cg02466173	chr16:30829666	NA	-0.46	-7.33	-0.41	2.73e-12	Multiple myeloma;
CESC	cis	rs796364	0.901	rs35572201	chr2:201035093	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.66	-6.44	-0.37	5.65e-10	Schizophrenia;
CESC	cis	rs72634258	0.554	rs35123409	chr1:7878568	C/T	cg26816564	chr1:7831052	VAMP3	0.63	5.56	0.32	6.42e-8	Inflammatory bowel disease;
CESC	cis	rs3026101	0.624	rs7426	chr17:5288983	T/C	cg24500398	chr17:5266808	RABEP1	-0.42	-6.03	-0.35	5.43e-9	Body mass index;
CESC	trans	rs62110082	0.522	rs12459126	chr19:52332884	G/C	cg18094401	chr15:25434150	SNORD115-29;SNORD115-36;SNORD115-43;SNORD115-11	-0.58	-6.37	-0.36	8.23e-10	Bipolar disorder (body mass index interaction);
CESC	cis	rs7811142	0.887	rs4074838	chr7:100032665	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.0	9.63	0.51	5.12e-19	Platelet count;
CESC	cis	rs11098499	0.955	rs13113112	chr4:120156040	C/T	cg24375607	chr4:120327624	NA	0.42	5.09	0.3	6.73e-7	Corneal astigmatism;
CESC	cis	rs7833790	0.963	rs7836040	chr8:82698328	G/A	cg07697082	chr8:82753677	SNX16	0.37	5.16	0.3	4.74e-7	Diastolic blood pressure;
CESC	cis	rs1046896	0.586	rs9897951	chr17:80810662	T/C	cg19500275	chr17:80737654	TBCD	0.48	5.49	0.32	9.19e-8	Glycated hemoglobin levels;
CESC	cis	rs7927771	1.000	rs10838748	chr11:47716381	T/G	cg18512352	chr11:47633146	NA	-0.6	-9.5	-0.5	1.34e-18	Subjective well-being;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg04524006	chr5:111093197	C5orf13	0.46	6.1	0.35	3.82e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs2228479	0.850	rs62054638	chr16:89821131	G/C	cg00800038	chr16:89945340	TCF25	-0.91	-7.54	-0.42	7.39e-13	Skin colour saturation;
CESC	cis	rs6815814	0.768	rs6851685	chr4:38893843	G/T	cg02016764	chr4:38805732	TLR1	-0.52	-6.88	-0.39	4.41e-11	Breast cancer;
CESC	cis	rs875971	0.862	rs778697	chr7:65870426	G/A	cg12463550	chr7:65579703	CRCP	0.51	6.41	0.37	6.58e-10	Aortic root size;
CESC	cis	rs4819052	0.851	rs875621	chr21:46682295	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.75	10.07	0.53	2.16e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs4665809	1.000	rs6546736	chr2:26293878	C/T	cg08470875	chr2:26401718	FAM59B	0.45	5.07	0.3	7.49e-7	Gut microbiome composition (summer);
CESC	cis	rs9896933	0.830	rs607544	chr17:80768760	C/G	cg19500275	chr17:80737654	TBCD	0.66	6.7	0.38	1.25e-10	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
CESC	cis	rs7216064	1.000	rs9915108	chr17:65874463	T/C	cg07042672	chr17:66097459	LOC651250	-0.56	-6.5	-0.37	3.96e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	trans	rs11252926	0.674	rs11598550	chr10:504778	A/C	cg00953403	chr17:74099816	EXOC7	-0.51	-6.39	-0.37	7.44e-10	Psychosis in Alzheimer's disease;
CESC	cis	rs11676348	0.776	rs11690316	chr2:219017462	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.46	-6.0	-0.35	6.34e-9	Ulcerative colitis;
CESC	cis	rs73001065	0.818	rs12610185	chr19:19721722	G/A	cg03709012	chr19:19516395	GATAD2A	0.96	6.02	0.35	5.77e-9	LDL cholesterol;
CESC	cis	rs1218582	0.710	rs9794000	chr1:154878876	T/A	cg09359103	chr1:154839909	KCNN3	-0.65	-12.31	-0.6	7.76e-28	Prostate cancer;
CESC	cis	rs3820068	0.580	rs34426856	chr1:16006315	C/T	cg18133145	chr1:16060689	PLEKHM2	-0.42	-5.16	-0.3	4.75e-7	Systolic blood pressure;
CESC	cis	rs727563	0.593	rs132770	chr22:42017264	A/G	cg17376030	chr22:41985996	PMM1	-0.83	-9.11	-0.49	2.06e-17	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs9348721	0.673	rs9358934	chr6:26363755	G/C	cg14345882	chr6:26364793	BTN3A2	0.62	6.53	0.37	3.29e-10	Intelligence (multi-trait analysis);
CESC	cis	rs7666738	0.830	rs2865978	chr4:99017946	G/T	cg05340658	chr4:99064831	C4orf37	0.82	12.99	0.62	3.34e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1799949	1.000	rs4793229	chr17:41418334	C/T	cg25072359	chr17:41440525	NA	-0.47	-6.28	-0.36	1.35e-9	Menopause (age at onset);
CESC	cis	rs514406	0.505	rs431427	chr1:53179094	C/A	cg08859206	chr1:53392774	SCP2	-0.56	-7.35	-0.41	2.49e-12	Monocyte count;
CESC	cis	rs7845219	0.544	rs2123647	chr8:95931782	A/G	cg16049864	chr8:95962084	TP53INP1	0.48	7.16	0.4	7.86e-12	Type 2 diabetes;
CESC	cis	rs10504229	0.683	rs11786843	chr8:58133629	T/C	cg02725872	chr8:58115012	NA	-0.44	-6.89	-0.39	3.94e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs11792861	0.641	rs10979586	chr9:111647764	C/T	cg05043794	chr9:111880884	C9orf5	-0.31	-5.04	-0.3	8.79e-7	Menarche (age at onset);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg18163227	chr17:74554350	SNORD1C	0.45	6.19	0.36	2.3e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs9611519	0.929	rs11090039	chr22:41496800	G/A	cg03806693	chr22:41940476	POLR3H	-0.6	-5.92	-0.34	1.01e-8	Neuroticism;
CESC	cis	rs11098499	0.604	rs2389886	chr4:120570422	C/T	cg24375607	chr4:120327624	NA	0.42	5.16	0.3	4.78e-7	Corneal astigmatism;
CESC	cis	rs28830936	0.966	rs17678552	chr15:42066190	T/C	cg11010575	chr15:42129464	JMJD7-PLA2G4B;JMJD7	-0.41	-5.81	-0.34	1.77e-8	Diastolic blood pressure;
CESC	cis	rs1577917	0.916	rs12203358	chr6:86603224	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.44	-5.62	-0.33	4.9e-8	Response to antipsychotic treatment;
CESC	cis	rs2070488	0.965	rs7642472	chr3:38525567	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.96	17.81	0.74	3.3e-47	Electrocardiographic conduction measures;
CESC	cis	rs6060717	0.536	rs17431878	chr20:34502107	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-6.93	-0.39	3.22e-11	Hip circumference adjusted for BMI;
CESC	cis	rs704795	0.836	rs1083865	chr2:27620827	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.32	-6.07	-0.35	4.36e-9	Menopause (age at onset);
CESC	cis	rs9902453	0.933	rs4470197	chr17:28464474	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	7.59	0.42	5.29e-13	Coffee consumption (cups per day);
CESC	cis	rs17376456	0.825	rs13161885	chr5:93071242	A/C	cg25358565	chr5:93447407	FAM172A	1.15	10.72	0.55	1.63e-22	Diabetic retinopathy;
CESC	cis	rs1355223	0.934	rs5010670	chr11:34766649	A/C	cg11058730	chr11:34937778	PDHX;APIP	-0.44	-5.74	-0.33	2.62e-8	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs6088580	0.668	rs1205337	chr20:32926041	T/A	cg06115741	chr20:33292138	TP53INP2	-0.45	-5.67	-0.33	3.79e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs6736093	0.966	rs11674226	chr2:112698388	G/A	cg12686935	chr2:112915763	FBLN7	-0.43	-5.56	-0.32	6.75e-8	Coronary artery disease;
CESC	cis	rs911555	0.755	rs1138400	chr14:103956833	A/G	cg24130564	chr14:104152367	KLC1	-0.5	-6.58	-0.37	2.56e-10	Intelligence (multi-trait analysis);
CESC	cis	rs6952808	0.595	rs2398705	chr7:2164995	G/A	cg02951883	chr7:2050386	MAD1L1	-0.46	-5.92	-0.34	9.71e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs12701220	0.503	rs13222294	chr7:1172969	G/A	cg26769984	chr7:1090371	C7orf50	0.48	5.1	0.3	6.52e-7	Bronchopulmonary dysplasia;
CESC	cis	rs8062405	0.573	rs11645306	chr16:28983936	G/C	cg05966235	chr16:28915196	ATP2A1	-0.4	-5.69	-0.33	3.42e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs796364	1.000	rs71424239	chr2:200725473	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.9	-7.17	-0.4	7.55e-12	Schizophrenia;
CESC	cis	rs7020830	0.516	rs36047049	chr9:37375472	G/T	cg14294708	chr9:37120828	ZCCHC7	1.01	12.05	0.59	6.02e-27	Schizophrenia;
CESC	cis	rs5760092	0.755	rs4585126	chr22:24270005	T/C	cg23131131	chr22:24373011	LOC391322	0.6	7.48	0.42	1.13e-12	Urinary 1,3-butadiene metabolite levels in smokers;
CESC	cis	rs4819052	0.819	rs34818688	chr21:46672416	C/T	cg11663144	chr21:46675770	NA	-0.64	-10.05	-0.53	2.34e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg19318889	chr4:1322082	MAEA	0.56	6.8	0.39	6.86e-11	Longevity;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg12843872	chr7:90894352	FZD1	-0.46	-6.75	-0.38	9.22e-11	Gambling;
CESC	cis	rs854765	1.000	rs854765	chr17:18012730	T/C	cg16928487	chr17:17741425	SREBF1	0.58	9.51	0.5	1.26e-18	Total body bone mineral density;
CESC	cis	rs2120019	1.000	rs35736167	chr15:75332002	T/G	cg17294928	chr15:75287854	SCAMP5	-0.74	-8.31	-0.45	5.03e-15	Blood trace element (Zn levels);
CESC	cis	rs1218582	0.741	rs7544528	chr1:154844585	C/T	cg16680214	chr1:154839983	KCNN3	-0.54	-8.51	-0.46	1.33e-15	Prostate cancer;
CESC	cis	rs950776	0.752	rs2869546	chr15:78907345	C/T	cg06917634	chr15:78832804	PSMA4	-0.56	-6.84	-0.39	5.33e-11	Sudden cardiac arrest;
CESC	cis	rs7927771	0.524	rs4539273	chr11:47694699	C/T	cg20307385	chr11:47447363	PSMC3	-0.58	-8.03	-0.44	3.1e-14	Subjective well-being;
CESC	cis	rs4472734	0.965	rs4259615	chr1:214628959	C/G	cg00063699	chr1:214624242	PTPN14	-0.33	-5.04	-0.3	8.73e-7	Height;
CESC	cis	rs2997447	0.655	rs12059101	chr1:26384013	A/G	cg19633962	chr1:26362018	EXTL1	-0.54	-5.43	-0.32	1.27e-7	QRS complex (12-leadsum);
CESC	cis	rs7635838	0.751	rs6442260	chr3:11590751	C/T	cg00170343	chr3:11313890	ATG7	-0.46	-5.95	-0.34	8.25e-9	HDL cholesterol;
CESC	cis	rs6461049	0.800	rs2398706	chr7:2156338	A/T	cg21782813	chr7:2030301	MAD1L1	0.41	5.75	0.33	2.45e-8	Schizophrenia;
CESC	cis	rs9926296	0.656	rs7191144	chr16:89823393	C/T	cg27121462	chr16:89883253	FANCA	0.54	6.9	0.39	3.81e-11	Vitiligo;
CESC	cis	rs11711311	1.000	rs10934243	chr3:113430239	T/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.69	9.69	0.51	3.42e-19	IgG glycosylation;
CESC	cis	rs514406	0.679	rs11585495	chr1:53244331	T/C	cg24675658	chr1:53192096	ZYG11B	0.77	11.82	0.59	3.51e-26	Monocyte count;
CESC	cis	rs9291683	0.566	rs13122689	chr4:10044648	A/G	cg00071950	chr4:10020882	SLC2A9	0.81	13.65	0.64	1.7e-32	Bone mineral density;
CESC	cis	rs853679	0.517	rs17711801	chr6:28092307	C/G	cg22143856	chr6:28129313	ZNF389	0.51	6.62	0.38	2e-10	Depression;
CESC	cis	rs3126085	0.877	rs4456097	chr1:152229741	G/A	cg03465714	chr1:152285911	FLG	-0.44	-5.45	-0.32	1.15e-7	Atopic dermatitis;
CESC	cis	rs13191362	1.000	rs34619021	chr6:163029767	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.51	5.53	0.32	7.85e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	trans	rs9325144	0.600	rs1817648	chr12:38733424	C/T	cg23762105	chr12:34175262	ALG10	0.44	6.01	0.35	6.13e-9	Morning vs. evening chronotype;
CESC	cis	rs1552244	1.000	rs7622963	chr3:10139825	C/T	cg00166722	chr3:10149974	C3orf24	0.46	5.89	0.34	1.18e-8	Alzheimer's disease;
CESC	cis	rs514406	0.644	rs1855127	chr1:53199594	A/G	cg25767906	chr1:53392781	SCP2	0.44	6.07	0.35	4.34e-9	Monocyte count;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg10709532	chr8:145654026	VPS28	0.45	6.21	0.36	2e-9	Systemic lupus erythematosus;
CESC	cis	rs2109514	1.000	rs2109514	chr7:116159961	G/A	cg12739419	chr7:116140593	CAV2	-0.36	-6.55	-0.37	3.02e-10	Prevalent atrial fibrillation;
CESC	cis	rs881375	0.967	rs1930781	chr9:123687834	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.38	5.08	0.3	7.23e-7	Rheumatoid arthritis;
CESC	cis	rs9640161	0.789	rs2373751	chr7:150021599	G/C	cg27494647	chr7:150038898	RARRES2	0.44	5.19	0.3	4.17e-7	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs854765	0.647	rs9303144	chr17:17977355	T/C	cg04398451	chr17:18023971	MYO15A	-0.78	-11.51	-0.58	4.01e-25	Total body bone mineral density;
CESC	cis	rs7216064	0.953	rs4791046	chr17:65851973	G/A	cg07042672	chr17:66097459	LOC651250	-0.55	-6.23	-0.36	1.82e-9	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs858239	0.799	rs10279941	chr7:23370508	C/G	cg23682824	chr7:23144976	KLHL7	0.42	5.44	0.32	1.2e-7	Cerebrospinal fluid biomarker levels;
CESC	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg25987502	chr17:6899865	ALOX12	0.45	7.47	0.42	1.16e-12	Tonsillectomy;
CESC	trans	rs61931739	0.517	rs11513277	chr12:34074799	G/T	cg26384229	chr12:38710491	ALG10B	0.6	8.38	0.46	3.22e-15	Morning vs. evening chronotype;
CESC	cis	rs9787249	0.957	rs12239844	chr1:40217258	T/C	cg02773041	chr1:40204384	PPIE	0.53	7.52	0.42	8.54e-13	Blood protein levels;
CESC	cis	rs11785400	1.000	rs4557682	chr8:143738182	T/C	cg24634471	chr8:143751801	JRK	0.47	6.21	0.36	2e-9	Schizophrenia;
CESC	cis	rs7267979	0.903	rs6115109	chr20:25239667	G/A	cg08601574	chr20:25228251	PYGB	0.42	5.92	0.34	1.01e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs6088580	0.660	rs6059893	chr20:33105897	T/G	cg24642439	chr20:33292090	TP53INP2	0.5	6.54	0.37	3.14e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs6088580	0.634	rs6120650	chr20:33039973	G/A	cg06115741	chr20:33292138	TP53INP2	0.47	6.1	0.35	3.84e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs2250402	0.510	rs8031319	chr15:40323692	A/G	cg10636054	chr15:40330586	SRP14	1.01	7.46	0.42	1.23e-12	Corneal curvature;
CESC	cis	rs7771547	0.542	rs597153	chr6:36395997	C/T	cg07856975	chr6:36356162	ETV7	0.36	5.38	0.31	1.67e-7	Platelet distribution width;
CESC	cis	rs9322193	0.926	rs2342860	chr6:150098777	T/C	cg04369109	chr6:150039330	LATS1	-0.39	-5.28	-0.31	2.71e-7	Lung cancer;
CESC	cis	rs6690583	0.623	rs74689037	chr1:85439268	C/T	cg22153463	chr1:85462885	MCOLN2	0.77	7.26	0.41	4.31e-12	Serum sulfate level;
CESC	cis	rs11098499	0.908	rs7695996	chr4:120322033	C/T	cg24375607	chr4:120327624	NA	0.48	5.87	0.34	1.28e-8	Corneal astigmatism;
CESC	cis	rs6484504	0.600	rs7122895	chr11:31346620	G/C	cg14844989	chr11:31128820	NA	0.39	5.51	0.32	8.43e-8	Red blood cell count;
CESC	cis	rs9457247	1.000	rs398278	chr6:167388169	A/G	cg23791538	chr6:167370224	RNASET2	-0.61	-8.55	-0.47	9.66e-16	Crohn's disease;
CESC	cis	rs6540559	0.673	rs11803382	chr1:209986426	G/A	cg22029157	chr1:209979665	IRF6	0.76	8.7	0.47	3.54e-16	Cleft lip with or without cleft palate;
CESC	cis	rs2033711	0.870	rs11669741	chr19:58960481	C/T	cg26874164	chr19:58962979	ZNF324B	-0.52	-7.42	-0.41	1.61e-12	Uric acid clearance;
CESC	cis	rs2950393	0.895	rs2958123	chr12:57062225	A/G	cg05584118	chr12:57595605	LRP1	-0.36	-5.21	-0.3	3.84e-7	Platelet distribution width;
CESC	cis	rs7618915	0.547	rs13085895	chr3:52678270	G/C	cg18404041	chr3:52824283	ITIH1	-0.39	-6.55	-0.37	2.9e-10	Bipolar disorder;
CESC	cis	rs7000551	0.751	rs2443505	chr8:22375341	G/A	cg12081754	chr8:22256438	SLC39A14	0.42	5.63	0.33	4.6e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CESC	cis	rs11167764	1.000	rs6580220	chr5:141480558	G/A	cg08523384	chr5:141488047	NDFIP1	-0.38	-5.64	-0.33	4.34e-8	Crohn's disease;
CESC	cis	rs28673728	0.897	rs28391281	chr1:38408974	T/C	cg04673462	chr1:38461896	NA	0.39	5.92	0.34	9.68e-9	Red cell distribution width;
CESC	cis	rs2576037	0.583	rs10070	chr18:44388899	G/A	cg19077165	chr18:44547161	KATNAL2	-0.61	-9.16	-0.49	1.5e-17	Personality dimensions;
CESC	cis	rs10845606	1.000	rs10845606	chr12:12834894	G/T	cg04607235	chr12:12878440	APOLD1	-0.71	-8.02	-0.44	3.43e-14	Systemic lupus erythematosus;
CESC	cis	rs35306767	0.953	rs12357633	chr10:957246	C/T	cg10556349	chr10:835070	NA	0.66	6.32	0.36	1.08e-9	Eosinophil percentage of granulocytes;
CESC	trans	rs9987353	0.840	rs329994	chr8:9123233	A/G	cg02106828	chr1:236959224	MTR	-0.45	-6.03	-0.35	5.52e-9	Recombination measurement;
CESC	cis	rs2204008	0.837	rs11612397	chr12:38357455	T/C	cg13010199	chr12:38710504	ALG10B	0.48	6.06	0.35	4.62e-9	Bladder cancer;
CESC	cis	rs5769707	0.967	rs5770585	chr22:50007874	G/A	cg05373962	chr22:49881684	NA	-0.38	-6.61	-0.38	2.12e-10	Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs11690935	0.959	rs6759575	chr2:172689068	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.96	-14.52	-0.67	1.55e-35	Schizophrenia;
CESC	cis	rs6570726	0.902	rs973855	chr6:145781850	C/T	cg05347473	chr6:146136440	FBXO30	-0.41	-5.63	-0.33	4.47e-8	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1670533	0.932	rs10902753	chr4:1056223	G/A	cg04106633	chr4:1044584	NA	0.4	5.09	0.3	6.7e-7	Recombination rate (females);
CESC	trans	rs6818288	0.778	rs12512013	chr4:30077820	A/G	cg12528397	chr3:62933670	NA	0.42	6.13	0.35	3.2e-9	Obesity-related traits;
CESC	cis	rs472402	0.580	rs7706809	chr5:6635971	G/T	cg10789808	chr5:6633262	NSUN2;SRD5A1	-0.54	-7.32	-0.41	2.92e-12	Response to amphetamines;
CESC	cis	rs35306767	0.761	rs12773961	chr10:1013215	C/G	cg20503657	chr10:835505	NA	0.71	6.7	0.38	1.23e-10	Eosinophil percentage of granulocytes;
CESC	cis	rs4665809	0.652	rs2241739	chr2:26411894	C/T	cg26314531	chr2:26401878	FAM59B	-0.76	-8.68	-0.47	3.98e-16	Gut microbiome composition (summer);
CESC	trans	rs7615952	0.512	rs2979351	chr3:125363599	C/T	cg00769240	chr8:12517080	NA	-0.44	-6.02	-0.35	5.7e-9	Blood pressure (smoking interaction);
CESC	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg05552183	chr6:42928497	GNMT	0.76	11.55	0.58	2.9e-25	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs2050392	0.517	rs589980	chr10:30756385	T/A	cg18806716	chr10:30721971	MAP3K8	-0.46	-7.07	-0.4	1.34e-11	Inflammatory bowel disease;
CESC	cis	rs10851478	0.872	rs12908635	chr15:49855920	A/G	cg08060515	chr15:49448048	GALK2;COPS2	0.42	5.19	0.3	4.12e-7	Oral cavity cancer;
CESC	trans	rs61931739	0.817	rs1687002	chr12:34170263	T/C	cg26384229	chr12:38710491	ALG10B	0.47	6.5	0.37	3.94e-10	Morning vs. evening chronotype;
CESC	cis	rs1218582	0.741	rs2335407	chr1:154843347	A/G	cg03351412	chr1:154909251	PMVK	-0.61	-7.73	-0.43	2.28e-13	Prostate cancer;
CESC	cis	rs9322193	0.884	rs10872646	chr6:150067675	A/G	cg13206674	chr6:150067644	NUP43	0.45	6.44	0.37	5.65e-10	Lung cancer;
CESC	cis	rs7772486	0.846	rs9403767	chr6:146402386	G/T	cg23711669	chr6:146136114	FBXO30	0.89	13.02	0.62	2.64e-30	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1008375	0.966	rs6449330	chr4:17703949	C/T	cg02297831	chr4:17616191	MED28	-0.41	-5.04	-0.3	8.57e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs1670533	1.000	rs10084888	chr4:1053814	G/T	cg04106633	chr4:1044584	NA	0.41	5.2	0.3	3.94e-7	Recombination rate (females);
CESC	cis	rs6736093	0.932	rs17174697	chr2:112662914	A/G	cg12686935	chr2:112915763	FBLN7	-0.42	-5.17	-0.3	4.56e-7	Coronary artery disease;
CESC	cis	rs6952808	0.531	rs3778998	chr7:2180753	C/A	cg08027265	chr7:2291960	NA	-0.45	-7.1	-0.4	1.15e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.47	-5.93	-0.34	9.38e-9	Longevity;Endometriosis;
CESC	cis	rs733175	0.855	rs10023068	chr4:10004832	C/T	cg00071950	chr4:10020882	SLC2A9	-0.56	-6.45	-0.37	5.14e-10	Psychosis and Alzheimer's disease;
CESC	trans	rs561341	1.000	rs4795669	chr17:30244701	C/T	cg27661571	chr11:113659931	NA	-0.69	-6.95	-0.39	2.88e-11	Hip circumference adjusted for BMI;
CESC	cis	rs1577917	0.958	rs11756510	chr6:86699794	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.47	-5.99	-0.35	6.9e-9	Response to antipsychotic treatment;
CESC	cis	rs896854	0.738	rs509594	chr8:95967156	C/G	cg09323728	chr8:95962352	TP53INP1	0.36	6.98	0.39	2.32e-11	Type 2 diabetes;
CESC	cis	rs6912958	0.781	rs4707376	chr6:88270947	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-6.5	-0.37	3.95e-10	Monocyte percentage of white cells;
CESC	cis	rs2204008	0.639	rs7311462	chr12:38278130	G/A	cg13010199	chr12:38710504	ALG10B	0.52	6.38	0.36	8.04e-10	Bladder cancer;
CESC	cis	rs35740288	0.721	rs17637276	chr15:86243520	T/C	cg20737812	chr15:86336631	KLHL25	-0.38	-5.1	-0.3	6.57e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
CESC	cis	rs9291683	0.552	rs11736410	chr4:10017241	G/A	cg00071950	chr4:10020882	SLC2A9	0.91	17.5	0.73	4.21e-46	Bone mineral density;
CESC	cis	rs950169	1.000	rs950169	chr15:84706461	C/T	cg17507749	chr15:85114479	UBE2QP1	0.64	6.92	0.39	3.47e-11	Schizophrenia;
CESC	cis	rs6547741	1.000	rs6756238	chr2:27841305	G/A	cg27432699	chr2:27873401	GPN1	0.49	6.82	0.39	6.31e-11	Oral cavity cancer;
CESC	cis	rs2734839	0.537	rs11214603	chr11:113279922	G/A	cg14159747	chr11:113255604	NA	0.36	6.52	0.37	3.63e-10	Information processing speed;
CESC	cis	rs4555082	0.874	rs2816620	chr14:105732704	G/T	cg10792982	chr14:105748885	BRF1	0.4	5.04	0.3	8.82e-7	Mean platelet volume;Platelet distribution width;
CESC	cis	rs75804782	0.521	rs2117691	chr2:239414734	C/T	cg18131467	chr2:239335373	ASB1	-0.66	-5.29	-0.31	2.58e-7	Morning vs. evening chronotype;Chronotype;
CESC	cis	rs7191439	0.728	rs8043637	chr16:88781125	T/C	cg02389323	chr16:88786976	FAM38A	0.83	6.87	0.39	4.62e-11	Plateletcrit;
CESC	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg07308232	chr7:1071921	C7orf50	-0.41	-5.45	-0.32	1.15e-7	Longevity;Endometriosis;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg14797438	chr18:9615155	PPP4R1	-0.41	-6.03	-0.35	5.4e-9	Gambling;
CESC	cis	rs12142240	0.660	rs7520497	chr1:46824919	C/A	cg00530320	chr1:46809349	NSUN4	0.6	8.04	0.44	2.96e-14	Menopause (age at onset);
CESC	cis	rs10484885	0.824	rs72919982	chr6:90532600	C/G	cg13799429	chr6:90582589	CASP8AP2	-0.76	-6.94	-0.39	3e-11	QRS interval (sulfonylurea treatment interaction);
CESC	cis	rs12472274	0.941	rs11677230	chr2:239092054	T/C	cg17459225	chr2:239074497	NA	0.58	8.29	0.45	5.7e-15	Phospholipid levels (plasma);
CESC	cis	rs9393777	0.513	rs7759969	chr6:26663096	T/A	cg12292205	chr6:26970375	C6orf41	-0.53	-5.75	-0.33	2.45e-8	Intelligence (multi-trait analysis);
CESC	cis	rs6951245	0.542	rs28460147	chr7:1217192	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.47	-5.56	-0.32	6.51e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs116095464	0.614	rs10067482	chr5:219328	T/G	cg12570787	chr5:219185	SDHA;CCDC127	0.53	5.74	0.33	2.63e-8	Breast cancer;
CESC	cis	rs67311347	0.955	rs60554147	chr3:40472503	T/C	cg24209194	chr3:40518798	ZNF619	0.47	6.11	0.35	3.6e-9	Renal cell carcinoma;
CESC	cis	rs9399135	0.967	rs9402676	chr6:135355507	C/T	cg22676075	chr6:135203613	NA	0.51	7.3	0.41	3.39e-12	Red blood cell count;
CESC	cis	rs875971	0.505	rs2462573	chr7:65507392	C/T	cg14393609	chr7:65229607	NA	-0.52	-7.15	-0.4	8.31e-12	Aortic root size;
CESC	cis	rs3793683	0.520	rs4880426	chr10:134590610	G/A	cg27286337	chr10:134555280	INPP5A	0.64	7.34	0.41	2.55e-12	Migraine;
CESC	trans	rs62103177	0.810	rs62103178	chr18:77624555	C/G	cg05926928	chr17:57297772	GDPD1	1.18	10.14	0.53	1.27e-20	Opioid sensitivity;
CESC	cis	rs9863706	0.619	rs920289	chr3:72504422	G/A	cg22685502	chr3:72496851	RYBP	-0.26	-5.4	-0.31	1.51e-7	Height;
CESC	cis	rs738322	0.935	rs75387	chr22:38572057	C/T	cg17652424	chr22:38574118	PLA2G6	-0.34	-6.04	-0.35	5.08e-9	Cutaneous nevi;
CESC	cis	rs9788682	0.747	rs3743078	chr15:78894759	C/G	cg24631222	chr15:78858424	CHRNA5	-0.79	-9.93	-0.52	5.97e-20	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg17198369	chr8:144883931	SCRIB	0.45	6.43	0.37	6.01e-10	Fibrinogen levels;
CESC	cis	rs1552244	0.554	rs2272120	chr3:10046703	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.56	-7.26	-0.41	4.31e-12	Alzheimer's disease;
CESC	cis	rs9322193	0.884	rs10872646	chr6:150067675	A/G	cg04369109	chr6:150039330	LATS1	-0.43	-5.91	-0.34	1.05e-8	Lung cancer;
CESC	cis	rs832540	0.656	rs6893754	chr5:56100006	G/A	cg12311346	chr5:56204834	C5orf35	-0.41	-5.15	-0.3	5.08e-7	Coronary artery disease;
CESC	cis	rs17253792	0.822	rs111467375	chr14:56046159	T/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.85	5.74	0.33	2.53e-8	Putamen volume;
CESC	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg26338869	chr17:61819248	STRADA	0.68	9.16	0.49	1.42e-17	Prudent dietary pattern;
CESC	cis	rs7666738	0.791	rs13125277	chr4:99009922	T/G	cg17366294	chr4:99064904	C4orf37	0.6	8.62	0.47	6.37e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11098499	0.738	rs34965784	chr4:120361586	G/C	cg24375607	chr4:120327624	NA	0.47	5.89	0.34	1.14e-8	Corneal astigmatism;
CESC	cis	rs7208859	0.673	rs28588622	chr17:29245699	G/A	cg19761014	chr17:28927070	LRRC37B2	0.7	5.64	0.33	4.47e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs72781680	0.652	rs12618900	chr2:23910775	C/T	cg20701182	chr2:24300061	SF3B14	0.78	6.38	0.36	7.87e-10	Lymphocyte counts;
CESC	cis	rs6879260	1.000	rs729568	chr5:179732350	C/T	cg13944838	chr5:179740914	GFPT2	0.61	8.26	0.45	6.96e-15	Height;
CESC	cis	rs6597981	0.592	rs10902218	chr11:743813	C/T	cg20225915	chr11:805726	LRDD	0.3	5.1	0.3	6.39e-7	Breast cancer;
CESC	cis	rs6998277	1.000	rs35155104	chr8:103646559	G/T	cg10187029	chr8:103597600	NA	0.57	6.44	0.37	5.46e-10	Migraine;
CESC	cis	rs2440129	0.611	rs434473	chr17:6904934	A/G	cg09737314	chr17:6899359	ALOX12	-0.4	-6.48	-0.37	4.35e-10	Tonsillectomy;
CESC	cis	rs2262909	0.893	rs4244912	chr19:22203237	T/A	cg11619707	chr19:22235551	ZNF257	-0.35	-5.69	-0.33	3.31e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
CESC	cis	rs10540	0.908	rs35608427	chr11:498976	T/C	cg03352830	chr11:487213	PTDSS2	0.74	7.19	0.4	6.72e-12	Body mass index;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09779924	chr19:2755476	SGTA	-0.65	-7.59	-0.42	5.48e-13	Gut microbiome composition (summer);
CESC	cis	rs9649213	0.574	rs7791321	chr7:97944125	G/C	cg00277769	chr7:97922759	BAIAP2L1	-0.34	-5.53	-0.32	7.56e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs1843834	0.898	rs4674936	chr2:225553731	C/T	cg22455342	chr2:225449267	CUL3	0.53	6.56	0.37	2.86e-10	IgE levels in asthmatics (D.p. specific);
CESC	cis	rs1372520	1.000	rs1372520	chr4:90757505	T/C	cg15133208	chr4:90757351	SNCA	-0.38	-5.12	-0.3	5.78e-7	Neuroticism;
CESC	cis	rs9611565	0.592	rs5996037	chr22:41965292	A/G	cg06481639	chr22:41940642	POLR3H	-0.59	-6.48	-0.37	4.52e-10	Vitiligo;
CESC	cis	rs12900413	0.687	rs13343250	chr15:90311410	T/C	cg24249390	chr15:90295951	MESP1	-0.41	-5.61	-0.33	5.06e-8	Coronary artery aneurysm in Kawasaki disease;
CESC	cis	rs644799	1.000	rs564675	chr11:95561873	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.55	6.76	0.38	8.51e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs1008375	0.966	rs11722132	chr4:17697217	T/C	cg15017067	chr4:17643749	FAM184B	0.37	5.2	0.3	3.95e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs6963495	0.818	rs56055535	chr7:105163574	C/A	cg19920283	chr7:105172520	RINT1	0.7	6.66	0.38	1.58e-10	Bipolar disorder (body mass index interaction);
CESC	cis	rs1018836	0.608	rs12679836	chr8:91465287	A/G	cg16814680	chr8:91681699	NA	-0.52	-7.31	-0.41	3.08e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs12497850	0.931	rs7643368	chr3:48992855	T/G	cg02487422	chr3:49467188	NICN1	0.44	5.57	0.32	6.38e-8	Parkinson's disease;
CESC	cis	rs769267	0.896	rs2074298	chr19:19377716	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	7.22	0.41	5.44e-12	Tonsillectomy;
CESC	cis	rs12497850	0.864	rs6779394	chr3:49157771	G/A	cg03060546	chr3:49711283	APEH	0.53	6.31	0.36	1.19e-9	Parkinson's disease;
CESC	cis	rs1707322	0.721	rs4415615	chr1:46132109	C/T	cg03146154	chr1:46216737	IPP	0.82	11.51	0.58	3.87e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs1008375	1.000	rs10939756	chr4:17693867	C/T	cg02297831	chr4:17616191	MED28	0.45	5.54	0.32	7.44e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs977987	0.806	rs34021527	chr16:75474090	A/G	cg03315344	chr16:75512273	CHST6	0.43	6.12	0.35	3.35e-9	Dupuytren's disease;
CESC	cis	rs7130144	0.541	rs57632525	chr11:130463168	C/G	cg26307797	chr11:130446613	NA	-0.74	-6.5	-0.37	3.95e-10	Urate levels in lean individuals;
CESC	cis	rs9300255	0.770	rs7980687	chr12:123822711	G/A	cg19016782	chr12:123741754	C12orf65	0.43	5.4	0.31	1.51e-7	Neutrophil percentage of white cells;
CESC	cis	rs4819052	0.679	rs2255761	chr21:46683622	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.85	12.83	0.62	1.28e-29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs2228479	0.850	rs62056091	chr16:89930414	G/A	cg04013166	chr16:89971882	TCF25	0.73	5.99	0.35	6.99e-9	Skin colour saturation;
CESC	cis	rs10242455	0.702	rs28377312	chr7:98984213	G/A	cg25640893	chr7:99214727	ZNF498	1.07	6.45	0.37	5.2e-10	Blood metabolite levels;
CESC	cis	rs6460942	0.514	rs118124486	chr7:12470381	T/G	cg06484146	chr7:12443880	VWDE	-0.54	-8.42	-0.46	2.42e-15	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16079358	chr14:23340577	LRP10	-0.55	-6.0	-0.35	6.53e-9	Gut microbiome composition (summer);
CESC	cis	rs7772486	0.754	rs1415746	chr6:146077107	A/G	cg23711669	chr6:146136114	FBXO30	-1.0	-15.71	-0.69	9.49e-40	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6964587	0.967	rs2188153	chr7:91595117	G/T	cg17063962	chr7:91808500	NA	0.57	7.76	0.43	1.79e-13	Breast cancer;
CESC	cis	rs5769765	0.908	rs4058453	chr22:50250297	T/C	cg02269571	chr22:50332266	NA	0.47	5.45	0.32	1.15e-7	Schizophrenia;
CESC	cis	rs66573146	1.000	rs28384174	chr4:6961107	G/T	cg00086871	chr4:6988644	TBC1D14	1.09	6.61	0.38	2.14e-10	Granulocyte percentage of myeloid white cells;
CESC	cis	rs7666738	0.830	rs969048	chr4:98988921	T/C	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.6e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7568458	0.684	rs1048740	chr2:85764966	A/T	cg02493740	chr2:85810744	VAMP5	-0.57	-8.34	-0.46	4.23e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CESC	cis	rs7103648	0.669	rs12577383	chr11:47774238	C/T	cg20307385	chr11:47447363	PSMC3	0.8	12.17	0.6	2.22e-27	Diastolic blood pressure;Systolic blood pressure;
CESC	cis	rs7772486	0.875	rs9322043	chr6:146352690	A/G	cg05347473	chr6:146136440	FBXO30	0.49	6.36	0.36	8.75e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6582630	0.560	rs11504462	chr12:38440379	G/A	cg26384229	chr12:38710491	ALG10B	-0.41	-5.49	-0.32	9.35e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs7000551	0.508	rs11780977	chr8:22245028	G/A	cg12081754	chr8:22256438	SLC39A14	0.91	12.46	0.61	2.26e-28	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CESC	cis	rs56104184	0.775	rs56349331	chr19:49403009	T/A	cg21252483	chr19:49399788	TULP2	-0.52	-5.69	-0.33	3.36e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	cis	rs12973672	0.855	rs7256866	chr19:35771257	A/G	cg12095397	chr19:35769544	USF2	0.54	7.35	0.41	2.49e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs4654899	0.865	rs10916927	chr1:21385795	T/C	cg05370193	chr1:21551575	ECE1	0.42	6.32	0.36	1.09e-9	Superior frontal gyrus grey matter volume;
CESC	cis	rs9902453	0.765	rs9890747	chr17:28007442	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.79	10.66	0.55	2.5e-22	Coffee consumption (cups per day);
CESC	cis	rs736408	0.660	rs2019065	chr3:52809525	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.57	-7.99	-0.44	4.19e-14	Bipolar disorder;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg21721210	chr19:39574878	PAPL	-0.41	-6.02	-0.35	5.71e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs2576037	0.583	rs641366	chr18:44430326	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.34	5.51	0.32	8.53e-8	Personality dimensions;
CESC	trans	rs7088591	0.867	rs16911397	chr10:59727630	T/C	cg10559231	chr5:14188039	TRIO	0.76	6.28	0.36	1.38e-9	Blood pressure;
CESC	cis	rs875971	1.000	rs7792762	chr7:66004138	T/C	cg18876405	chr7:65276391	NA	0.52	6.91	0.39	3.66e-11	Aortic root size;
CESC	cis	rs597539	0.615	rs583182	chr11:68678634	C/T	cg21963583	chr11:68658836	MRPL21	0.42	6.05	0.35	4.92e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs901683	1.000	rs71496609	chr10:46021031	C/A	cg16031567	chr10:46195673	NA	-0.77	-5.04	-0.3	8.57e-7	Red blood cell traits;Mean corpuscular volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17219981	chr11:64490808	NRXN2	0.5	6.03	0.35	5.58e-9	Gut microbiome composition (summer);
CESC	cis	rs8062405	0.755	rs7193402	chr16:28586127	A/G	cg07382826	chr16:28625726	SULT1A1	0.4	6.63	0.38	1.91e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs9649213	0.593	rs12704982	chr7:97926053	C/T	cg24562669	chr7:97807699	LMTK2	0.48	6.92	0.39	3.3e-11	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs208520	1.000	rs12191403	chr6:66978137	C/T	cg07460842	chr6:66804631	NA	0.88	10.14	0.53	1.22e-20	Exhaled nitric oxide output;
CESC	cis	rs710216	0.917	rs710223	chr1:43411038	C/G	cg03128534	chr1:43423976	SLC2A1	0.56	6.35	0.36	9.41e-10	Red cell distribution width;
CESC	cis	rs6502050	1.000	rs6502050	chr17:80058236	C/G	cg11859384	chr17:80120422	CCDC57	0.44	6.14	0.35	3.04e-9	Life satisfaction;
CESC	trans	rs9467711	0.659	rs34605993	chr6:26454363	C/T	cg01620082	chr3:125678407	NA	-0.8	-6.16	-0.35	2.74e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg18402987	chr7:1209562	NA	0.75	7.49	0.42	1.04e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs476633	0.691	rs11858115	chr15:41542591	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.48	-7.0	-0.39	2.13e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs801193	0.660	rs2659897	chr7:66187715	A/G	cg18876405	chr7:65276391	NA	-0.48	-6.47	-0.37	4.62e-10	Aortic root size;
CESC	cis	rs1552244	1.000	rs28684871	chr3:10072635	C/A	cg00149659	chr3:10157352	C3orf10	0.75	9.21	0.49	1.05e-17	Alzheimer's disease;
CESC	cis	rs5769765	0.908	rs138889	chr22:50226673	T/C	cg02269571	chr22:50332266	NA	-0.46	-5.9	-0.34	1.09e-8	Schizophrenia;
CESC	trans	rs1814175	0.615	rs10839378	chr11:49806943	C/T	cg15704280	chr7:45808275	SEPT13	-0.97	-17.13	-0.72	8.69e-45	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12091641	chr8:145180933	NA	-0.52	-6.05	-0.35	4.83e-9	Gut microbiome composition (summer);
CESC	cis	rs929354	0.772	rs3802120	chr7:156977794	C/T	cg05182265	chr7:156933206	UBE3C	-0.51	-7.51	-0.42	9.08e-13	Body mass index;
CESC	cis	rs6580649	0.882	rs59766465	chr12:48470169	G/A	cg24011408	chr12:48396354	COL2A1	-0.4	-5.04	-0.3	8.67e-7	Lung cancer;
CESC	cis	rs875971	1.000	rs6958484	chr7:65599446	G/A	cg18876405	chr7:65276391	NA	-0.5	-6.78	-0.38	7.91e-11	Aortic root size;
CESC	cis	rs7666738	0.830	rs13125432	chr4:98961253	G/A	cg17366294	chr4:99064904	C4orf37	0.6	8.52	0.46	1.2e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7647973	0.600	rs35174559	chr3:49287759	T/C	cg06212747	chr3:49208901	KLHDC8B	0.7	10.59	0.55	4.26e-22	Menarche (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23981150	chr1:161111090	NA	-0.68	-8.26	-0.45	7.24e-15	Gut microbiome composition (summer);
CESC	trans	rs7674118	0.834	rs28826088	chr4:166845815	G/A	cg23810282	chr5:43037519	NA	0.67	6.02	0.35	5.77e-9	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs9513593	0.901	rs11069350	chr13:99780461	A/G	cg21788972	chr13:99853209	UBAC2	0.45	5.14	0.3	5.33e-7	Psoriasis;
CESC	cis	rs1558375	0.679	rs31670	chr7:87059164	C/T	cg00919237	chr7:87102261	ABCB4	0.38	5.17	0.3	4.56e-7	Gallbladder cancer;
CESC	cis	rs1847505	0.609	rs9317154	chr13:61560533	A/G	cg25164009	chr13:61490935	NA	-0.41	-5.48	-0.32	9.91e-8	Polychlorinated biphenyl levels;
CESC	cis	rs9581857	0.685	rs9579084	chr13:28028201	A/G	cg22138327	chr13:27999177	GTF3A	-0.6	-5.4	-0.31	1.47e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
CESC	cis	rs2708240	1.000	rs2708271	chr7:147574111	C/A	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.35	-5.78	-0.33	2.06e-8	QT interval (drug interaction);
CESC	cis	rs7429990	0.965	rs34750113	chr3:47986392	C/T	cg11946769	chr3:48343235	NME6	0.46	5.61	0.33	5.14e-8	Educational attainment (years of education);
CESC	cis	rs60154123	0.772	rs614167	chr1:210425895	T/C	cg25204440	chr1:209979598	IRF6	0.49	5.09	0.3	6.73e-7	Coronary artery disease;
CESC	cis	rs736408	0.545	rs6445529	chr3:52662722	T/A	cg07507251	chr3:52567010	NT5DC2	0.32	5.62	0.33	4.94e-8	Bipolar disorder;
CESC	cis	rs62064224	0.703	rs62065492	chr17:30822607	C/T	cg25809561	chr17:30822961	MYO1D	0.64	9.31	0.5	5.19e-18	Schizophrenia;
CESC	cis	rs10463316	0.817	rs10040628	chr5:150821027	T/G	cg03212797	chr5:150827313	SLC36A1	-0.49	-6.33	-0.36	1.02e-9	Metabolite levels (Pyroglutamine);
CESC	cis	rs4689388	0.890	rs11732208	chr4:6292716	G/C	cg14416269	chr4:6271139	WFS1	0.47	7.95	0.44	5.49e-14	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs2857078	0.732	rs9893756	chr17:42321109	T/C	cg19774624	chr17:42201019	HDAC5	0.45	5.68	0.33	3.52e-8	Red cell distribution width;Reticulocyte count;
CESC	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.57	7.14	0.4	9.17e-12	Prudent dietary pattern;
CESC	cis	rs3858526	0.584	rs10734559	chr11:5861788	A/C	cg05234568	chr11:5960015	NA	-0.63	-8.67	-0.47	4.35e-16	DNA methylation (variation);
CESC	cis	rs10416265	0.527	rs6510337	chr19:33545701	C/T	cg27124370	chr19:33622961	WDR88	0.54	7.5	0.42	9.5e-13	Bone properties (heel);
CESC	cis	rs1005277	0.579	rs1780137	chr10:38501475	C/G	cg25427524	chr10:38739819	LOC399744	-0.71	-10.4	-0.54	1.84e-21	Extrinsic epigenetic age acceleration;
CESC	cis	rs9311474	0.507	rs4687644	chr3:52746541	T/G	cg05564831	chr3:52568323	NT5DC2	0.46	7.19	0.4	6.64e-12	Electroencephalogram traits;
CESC	cis	rs1580019	0.563	rs13225132	chr7:32800975	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.42	5.07	0.3	7.35e-7	Cognitive ability;
CESC	cis	rs617791	0.669	rs4994056	chr11:65750997	G/A	cg02202077	chr11:65769826	EIF1AD;BANF1	0.45	6.05	0.35	4.82e-9	Breast cancer;
CESC	cis	rs6938	0.596	rs11630918	chr15:75155896	C/T	cg17294928	chr15:75287854	SCAMP5	0.53	7.12	0.4	9.86e-12	Breast cancer;
CESC	cis	rs9611519	0.579	rs8136274	chr22:41415311	T/C	cg03806693	chr22:41940476	POLR3H	-0.52	-6.06	-0.35	4.68e-9	Neuroticism;
CESC	cis	rs9611565	0.592	rs9611612	chr22:41961189	T/C	cg17376030	chr22:41985996	PMM1	0.52	5.79	0.34	1.95e-8	Vitiligo;
CESC	cis	rs644799	0.710	rs10831427	chr11:95508383	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.75	11.2	0.57	4.24e-24	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs447	1.000	rs2158566	chr7:83755276	A/C	cg22846510	chr7:83753280	SEMA3A	-0.44	-5.38	-0.31	1.64e-7	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs8114671	0.836	rs2425012	chr20:33581955	G/A	cg24642439	chr20:33292090	TP53INP2	-0.46	-5.54	-0.32	7.12e-8	Height;
CESC	cis	rs3740713	1.000	rs73440625	chr11:18470800	A/G	cg23797887	chr11:18477753	LDHAL6A	-0.54	-5.21	-0.31	3.72e-7	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs11674184	0.659	rs59129126	chr2:11728388	T/C	cg07314298	chr2:11723111	GREB1	-0.63	-9.51	-0.5	1.26e-18	Endometriosis;
CESC	cis	rs2243480	1.000	rs13237037	chr7:65997882	T/C	cg12463550	chr7:65579703	CRCP	0.72	5.55	0.32	6.96e-8	Diabetic kidney disease;
CESC	cis	rs7044106	0.762	rs4142158	chr9:123410819	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.63	8.58	0.47	8.19e-16	Hip circumference adjusted for BMI;
CESC	cis	rs7147624	1.000	rs2411821	chr14:65896914	G/T	cg03016385	chr14:66212404	NA	-0.49	-5.23	-0.31	3.49e-7	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs6831352	0.760	rs2602859	chr4:100030583	G/A	cg12011299	chr4:100065546	ADH4	0.6	6.56	0.37	2.83e-10	Alcohol dependence;
CESC	cis	rs7412746	0.611	rs4319334	chr1:150766822	G/A	cg22823121	chr1:150693482	HORMAD1	0.4	5.69	0.33	3.43e-8	Melanoma;
CESC	cis	rs4304924	0.500	rs2281856	chr13:79207644	C/T	cg07926092	chr13:79233506	RNF219	-0.52	-5.87	-0.34	1.28e-8	Large artery stroke;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14971544	chr1:54955149	NA	-0.65	-6.85	-0.39	5.13e-11	Gut microbiome composition (summer);
CESC	cis	rs6540559	0.932	rs764093	chr1:209983331	A/G	cg10074409	chr1:209979377	IRF6	0.35	5.73	0.33	2.68e-8	Cleft lip with or without cleft palate;
CESC	cis	rs6831352	0.879	rs7672728	chr4:100055173	A/G	cg13256891	chr4:100009986	ADH5	-0.77	-8.45	-0.46	1.97e-15	Alcohol dependence;
CESC	trans	rs7582180	0.700	rs1437971	chr2:100986964	A/C	cg09662051	chr2:162164883	PSMD14	0.61	6.01	0.35	5.97e-9	Intelligence (multi-trait analysis);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg08744727	chr4:206112	ZNF876P	0.51	6.51	0.37	3.74e-10	Fibrinogen levels;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg00474465	chr10:124907942	HMX2	0.45	6.18	0.35	2.36e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	22.16	0.81	2.75e-62	Prudent dietary pattern;
CESC	cis	rs1691799	0.528	rs1472314	chr12:66788838	C/G	cg16791601	chr12:66731901	HELB	-0.62	-9.43	-0.5	2.14e-18	White blood cell count (basophil);
CESC	cis	rs9287719	0.967	rs6759100	chr2:10746710	A/G	cg02196655	chr2:10830764	NOL10	-0.38	-5.78	-0.33	2.05e-8	Prostate cancer;
CESC	cis	rs854765	0.647	rs8066764	chr17:17974668	C/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.47	5.86	0.34	1.36e-8	Total body bone mineral density;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg20087917	chr14:77924039	C14orf133;AHSA1	-0.45	-6.45	-0.37	5.36e-10	Height;
CESC	cis	rs2415984	0.505	rs1389607	chr14:46957922	T/C	cg14871534	chr14:47121158	RPL10L	0.38	5.77	0.33	2.22e-8	Number of children ever born;
CESC	cis	rs868036	1.000	rs6494696	chr15:68103206	C/G	cg08079166	chr15:68083412	MAP2K5	-0.44	-7.1	-0.4	1.15e-11	Restless legs syndrome;
CESC	cis	rs4665809	0.590	rs4665837	chr2:26434022	C/A	cg27170947	chr2:26402098	FAM59B	-0.87	-9.77	-0.51	1.86e-19	Gut microbiome composition (summer);
CESC	cis	rs3126085	0.935	rs4845750	chr1:152201217	A/G	cg03465714	chr1:152285911	FLG	-0.45	-5.47	-0.32	1.02e-7	Atopic dermatitis;
CESC	trans	rs9578106	0.703	rs79792825	chr13:30155776	C/T	cg08144675	chr16:73097057	NA	-0.58	-6.05	-0.35	4.81e-9	Breast cancer;
CESC	cis	rs12136530	0.551	rs4244002	chr1:19738190	C/T	cg01832549	chr1:19774989	CAPZB	-0.36	-5.07	-0.3	7.6e-7	Lead levels in blood;
CESC	cis	rs9916302	0.904	rs8079560	chr17:37497661	C/T	cg20243544	chr17:37824526	PNMT	-0.47	-5.96	-0.34	7.99e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs16917546	1.000	rs7905030	chr10:64421600	G/C	cg03961010	chr10:64397487	ZNF365	-0.38	-6.22	-0.36	1.94e-9	Basal cell carcinoma;
CESC	cis	rs921968	0.613	rs2303566	chr2:219557738	C/T	cg02176678	chr2:219576539	TTLL4	-0.43	-7.65	-0.43	3.72e-13	Mean corpuscular hemoglobin concentration;
CESC	trans	rs11098499	0.644	rs28787668	chr4:120554687	G/A	cg25214090	chr10:38739885	LOC399744	0.62	8.65	0.47	4.98e-16	Corneal astigmatism;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07084973	chr3:49209008	KLHDC8B	0.55	6.22	0.36	1.95e-9	Gut microbiome composition (summer);
CESC	cis	rs4713118	0.662	rs9380045	chr6:28025279	A/G	cg23161317	chr6:28129485	ZNF389	0.49	6.19	0.36	2.28e-9	Parkinson's disease;
CESC	cis	rs854765	0.562	rs2955381	chr17:17945500	G/C	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.5	-6.33	-0.36	1.03e-9	Total body bone mineral density;
CESC	cis	rs35306767	0.715	rs17293580	chr10:1034895	T/C	cg25019033	chr10:957182	NA	-0.62	-6.03	-0.35	5.46e-9	Eosinophil percentage of granulocytes;
CESC	cis	rs7666738	0.570	rs1869351	chr4:99077286	T/C	cg24818145	chr4:99064322	C4orf37	0.4	5.25	0.31	3.18e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01133655	chr6:3140601	BPHL	-0.58	-6.9	-0.39	3.77e-11	Gut microbiome composition (summer);
CESC	cis	rs765787	0.530	rs28733848	chr15:45516047	C/T	cg24006582	chr15:45444508	DUOX1	-0.58	-7.12	-0.4	1.04e-11	Uric acid levels;
CESC	cis	rs6558174	0.863	rs17746902	chr8:22491980	A/C	cg03733263	chr8:22462867	KIAA1967	-0.46	-6.06	-0.35	4.55e-9	Breast cancer;
CESC	cis	rs8180040	0.966	rs59586735	chr3:47518325	C/T	cg27129171	chr3:47204927	SETD2	-0.63	-9.49	-0.5	1.44e-18	Colorectal cancer;
CESC	cis	rs546131	0.928	rs553789	chr11:34827579	G/A	cg06937548	chr11:34938143	PDHX;APIP	0.52	6.51	0.37	3.75e-10	Lung disease severity in cystic fibrosis;
CESC	cis	rs7666738	0.830	rs11097606	chr4:99011486	C/T	cg03467027	chr4:99064603	C4orf37	0.45	5.69	0.33	3.44e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7613875	0.620	rs13079006	chr3:49996924	G/T	cg24308560	chr3:49941425	MST1R	-0.56	-7.8	-0.43	1.42e-13	Body mass index;
CESC	cis	rs2625529	0.652	rs2957740	chr15:72307691	A/G	cg16672083	chr15:72433130	SENP8	0.42	6.43	0.37	5.9e-10	Red blood cell count;
CESC	cis	rs2075371	0.829	rs1993058	chr7:133930361	G/A	cg20476274	chr7:133979776	SLC35B4	0.61	8.83	0.48	1.46e-16	Mean platelet volume;
CESC	cis	rs9611565	0.527	rs2234053	chr22:41777315	G/T	cg17376030	chr22:41985996	PMM1	0.67	7.26	0.41	4.21e-12	Vitiligo;
CESC	cis	rs853679	0.517	rs1904840	chr6:28108232	C/T	cg23161317	chr6:28129485	ZNF389	0.5	6.4	0.37	7.04e-10	Depression;
CESC	cis	rs1801251	1.000	rs283476	chr2:233650168	A/G	cg08000102	chr2:233561755	GIGYF2	0.66	9.28	0.5	6.14e-18	Coronary artery disease;
CESC	cis	rs9291683	0.610	rs993173	chr4:10323935	T/C	cg00071950	chr4:10020882	SLC2A9	-0.55	-8.3	-0.45	5.41e-15	Bone mineral density;
CESC	cis	rs1316952	0.831	rs78985577	chr12:124393117	G/A	cg12597309	chr12:124393772	DNAH10	0.33	5.55	0.32	6.95e-8	Visceral adipose tissue adjusted for BMI;Visceral adipose tissue/subcutaneous adipose tissue ratio;
CESC	cis	rs9911578	1.000	rs2333332	chr17:56631054	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	-0.4	-5.28	-0.31	2.67e-7	Intelligence (multi-trait analysis);
CESC	cis	rs4523957	0.715	rs6503321	chr17:2096580	G/A	cg16513277	chr17:2031491	SMG6	-0.58	-7.87	-0.44	9.09e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs11997175	0.583	rs7009719	chr8:33834824	C/G	ch.8.33884649F	chr8:33765107	NA	0.48	6.07	0.35	4.49e-9	Body mass index;
CESC	cis	rs898097	0.841	rs55810435	chr17:80836722	G/C	cg10494973	chr17:80897199	TBCD	0.5	5.79	0.33	2.01e-8	Breast cancer;
CESC	cis	rs7772486	0.790	rs3924499	chr6:146232978	A/T	cg23711669	chr6:146136114	FBXO30	-0.94	-13.56	-0.64	3.62e-32	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs873946	0.586	rs12259688	chr10:134549628	A/G	cg06453172	chr10:134556979	INPP5A	-0.43	-5.7	-0.33	3.26e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs1215050	0.904	rs1727285	chr4:98978821	G/A	cg05340658	chr4:99064831	C4orf37	-0.54	-6.76	-0.38	8.67e-11	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs875971	0.862	rs10250544	chr7:65766561	A/G	cg18876405	chr7:65276391	NA	-0.5	-6.92	-0.39	3.36e-11	Aortic root size;
CESC	cis	rs9649213	0.574	rs6961790	chr7:98007993	C/G	cg24562669	chr7:97807699	LMTK2	0.48	7.04	0.4	1.62e-11	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs2116941	1.000	rs2033493	chr19:10340854	A/C	cg01850179	chr19:10340795	S1PR2	-0.58	-7.47	-0.42	1.15e-12	Pulse pressure;
CESC	cis	rs7615952	0.641	rs12487875	chr3:125787224	C/A	cg06494592	chr3:125709126	NA	-0.51	-5.46	-0.32	1.12e-7	Blood pressure (smoking interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10757852	chr3:141319363	RASA2	-0.73	-8.59	-0.47	7.57e-16	Gut microbiome composition (summer);
CESC	cis	rs40363	1.000	rs1635393	chr16:3520493	C/T	cg05754148	chr16:3507555	NAT15	0.64	7.2	0.4	6.33e-12	Tuberculosis;
CESC	cis	rs228437	0.770	rs376192	chr6:134904524	A/G	cg24504307	chr6:134963096	NA	-0.41	-5.08	-0.3	7.17e-7	Melanoma;
CESC	cis	rs6088580	0.601	rs6059872	chr20:33082775	C/A	cg06115741	chr20:33292138	TP53INP2	0.46	5.91	0.34	1.02e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs861020	0.563	rs61820640	chr1:210041297	G/T	cg05527609	chr1:210001259	C1orf107	-0.95	-10.65	-0.55	2.9e-22	Orofacial clefts;
CESC	cis	rs28489187	0.706	rs233071	chr1:85806005	C/T	cg16011679	chr1:85725395	C1orf52	0.47	5.48	0.32	1.01e-7	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	cis	rs9322193	0.923	rs2297930	chr6:150039496	T/C	cg07701084	chr6:150067640	NUP43	0.49	6.88	0.39	4.34e-11	Lung cancer;
CESC	cis	rs1005277	0.522	rs9418276	chr10:37940116	G/T	cg25427524	chr10:38739819	LOC399744	-0.63	-9.11	-0.49	2.03e-17	Extrinsic epigenetic age acceleration;
CESC	cis	rs8017423	0.967	rs61996919	chr14:90701803	A/C	cg14092571	chr14:90743983	NA	-0.57	-8.37	-0.46	3.28e-15	Mortality in heart failure;
CESC	trans	rs9929218	0.954	rs17715762	chr16:68828250	T/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.62	-8.05	-0.44	2.78e-14	Colorectal cancer;
CESC	cis	rs533581	0.816	rs8058234	chr16:88975447	C/G	cg16701003	chr16:89028210	CBFA2T3	0.55	8.36	0.46	3.6e-15	Social autistic-like traits;
CESC	trans	rs11250098	0.503	rs13270870	chr8:10770782	A/G	cg15556689	chr8:8085844	FLJ10661	-0.56	-6.78	-0.38	7.86e-11	Morning vs. evening chronotype;
CESC	cis	rs9733	0.596	rs6685702	chr1:150656307	A/G	cg22823121	chr1:150693482	HORMAD1	0.48	7.09	0.4	1.21e-11	Tonsillectomy;
CESC	cis	rs425277	0.585	rs3107143	chr1:2045372	G/C	cg04315214	chr1:2043799	PRKCZ	0.62	11.23	0.57	3.43e-24	Height;
CESC	cis	rs12476592	0.571	rs7584404	chr2:63794342	C/T	cg17519650	chr2:63277830	OTX1	-0.48	-5.42	-0.32	1.34e-7	Childhood ear infection;
CESC	cis	rs75477785	1.000	rs17015217	chr1:209966629	G/A	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.86	5.67	0.33	3.78e-8	Cleft lip with or without cleft palate;
CESC	cis	rs4423214	0.592	rs10898193	chr11:71197083	A/G	cg05163923	chr11:71159392	DHCR7	0.51	5.39	0.31	1.57e-7	Vitamin D levels;
CESC	cis	rs1008375	0.900	rs7658447	chr4:17579415	T/C	cg02297831	chr4:17616191	MED28	0.52	6.01	0.35	6.19e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs4237845	0.537	rs2002275	chr12:58283385	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.49	5.81	0.34	1.77e-8	Intelligence (multi-trait analysis);
CESC	cis	rs478304	0.903	rs546202	chr11:65510024	C/T	cg08755490	chr11:65554678	OVOL1	-0.45	-5.81	-0.34	1.81e-8	Acne (severe);
CESC	cis	rs2836974	0.897	rs1541102	chr21:40628765	C/T	cg27266027	chr21:40555129	PSMG1	0.46	5.36	0.31	1.77e-7	Cognitive function;
CESC	trans	rs4942242	0.763	rs7327129	chr13:44233014	T/C	cg19169023	chr15:41853346	TYRO3	-0.61	-8.56	-0.47	9.12e-16	Response to tocilizumab in rheumatoid arthritis;
CESC	trans	rs916888	0.773	rs199451	chr17:44801784	G/A	cg22968622	chr17:43663579	NA	1.35	18.5	0.75	1.23e-49	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs10791097	0.694	rs3190331	chr11:130748131	C/T	cg12179176	chr11:130786555	SNX19	-0.67	-10.54	-0.54	6.17e-22	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs7666738	0.791	rs11097610	chr4:99011795	C/G	cg17366294	chr4:99064904	C4orf37	0.58	8.26	0.45	7.23e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1270639	0.778	rs1796271	chr7:157438129	T/G	cg13357408	chr7:157437802	PTPRN2	0.59	6.85	0.39	5.2e-11	Colorectal cancer;
CESC	cis	rs5753618	0.561	rs2413047	chr22:31666026	A/G	cg00478049	chr22:31556069	RNF185	0.45	5.16	0.3	4.89e-7	Colorectal cancer;
CESC	cis	rs514406	1.000	rs514406	chr1:53330458	A/G	cg08736216	chr1:53307985	ZYG11A	-0.41	-6.6	-0.38	2.22e-10	Monocyte count;
CESC	cis	rs7937682	0.889	rs564086	chr11:111501079	C/G	cg09085632	chr11:111637200	PPP2R1B	-1.0	-16.2	-0.71	1.64e-41	Primary sclerosing cholangitis;
CESC	cis	rs644799	1.000	rs627568	chr11:95569253	A/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.94	13.69	0.64	1.29e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.44	-5.5	-0.32	9.01e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs3820068	0.705	rs72645804	chr1:15868387	A/C	cg17385448	chr1:15911702	AGMAT	0.38	5.9	0.34	1.1e-8	Systolic blood pressure;
CESC	cis	rs1552244	0.882	rs36006511	chr3:10054191	C/T	cg00166722	chr3:10149974	C3orf24	0.48	5.98	0.34	7.15e-9	Alzheimer's disease;
CESC	cis	rs7100689	0.646	rs10788586	chr10:82117435	A/G	cg00277334	chr10:82204260	NA	-0.58	-7.76	-0.43	1.84e-13	Post bronchodilator FEV1;
CESC	cis	rs1348850	0.526	rs2218575	chr2:178368997	C/A	cg22681709	chr2:178499509	PDE11A	-0.5	-5.26	-0.31	2.97e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs2204008	0.665	rs11179830	chr12:38220966	T/C	cg26384229	chr12:38710491	ALG10B	0.67	9.49	0.5	1.38e-18	Bladder cancer;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg01494614	chr11:10562837	RNF141	-0.48	-6.55	-0.37	2.89e-10	Ulcerative colitis;
CESC	cis	rs7078219	0.965	rs11190141	chr10:101292390	C/T	cg09788492	chr10:101292477	NKX2-3	0.3	5.41	0.32	1.44e-7	Dental caries;
CESC	cis	rs9902453	0.933	rs60694493	chr17:28473256	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	8.01	0.44	3.58e-14	Coffee consumption (cups per day);
CESC	cis	rs7274811	0.681	rs291705	chr20:31969658	A/G	cg21523528	chr20:32077966	CBFA2T2	0.44	5.31	0.31	2.36e-7	Height;
CESC	cis	rs704795	0.836	rs1647281	chr2:27612938	G/C	cg17158414	chr2:27665306	KRTCAP3	-0.32	-5.94	-0.34	8.84e-9	Menopause (age at onset);
CESC	cis	rs1153858	1.000	rs7494956	chr15:45668565	T/C	cg14582100	chr15:45693742	SPATA5L1	0.42	5.95	0.34	8.38e-9	Homoarginine levels;
CESC	cis	rs344364	0.511	rs62040571	chr16:1948514	C/G	cg03013636	chr16:1946785	NA	0.48	6.62	0.38	2.02e-10	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs9322193	0.962	rs4870048	chr6:150155460	A/G	cg04369109	chr6:150039330	LATS1	-0.44	-6.02	-0.35	5.81e-9	Lung cancer;
CESC	trans	rs966321	0.846	rs11586171	chr1:4328580	G/A	cg01726854	chr17:56429881	SUPT4H1	0.44	6.12	0.35	3.33e-9	Factor VII;
CESC	cis	rs2273669	0.667	rs12215614	chr6:109313629	T/C	cg05315195	chr6:109294784	ARMC2	-0.66	-6.37	-0.36	8.17e-10	Prostate cancer;
CESC	cis	rs2236918	0.710	rs2526700	chr1:242019999	C/A	cg17736920	chr1:242011382	EXO1	0.56	6.96	0.39	2.64e-11	Menopause (age at onset);
CESC	cis	rs1005224	0.889	rs12717566	chr14:76147507	C/T	cg25116370	chr14:76127843	TTLL5;C14orf1	-0.43	-5.84	-0.34	1.51e-8	Large artery stroke;
CESC	cis	rs709400	0.628	rs7150317	chr14:103921691	C/G	cg12935359	chr14:103987150	CKB	-0.51	-7.46	-0.42	1.24e-12	Body mass index;
CESC	cis	rs4654899	0.802	rs61781104	chr1:21257235	T/A	cg05370193	chr1:21551575	ECE1	0.41	5.68	0.33	3.61e-8	Superior frontal gyrus grey matter volume;
CESC	cis	rs4727027	0.870	rs11525060	chr7:148801091	G/A	cg23158103	chr7:148848205	ZNF398	-0.4	-6.38	-0.36	7.9e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs3793683	0.520	rs12769959	chr10:134579026	A/C	cg27297192	chr10:134578999	INPP5A	0.39	5.22	0.31	3.62e-7	Migraine;
CESC	cis	rs9811920	0.638	rs10936008	chr3:99686665	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.56	6.98	0.39	2.42e-11	Axial length;
CESC	cis	rs1008375	1.000	rs1974624	chr4:17650281	A/G	cg15017067	chr4:17643749	FAM184B	0.39	5.47	0.32	1.02e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg26338869	chr17:61819248	STRADA	-0.62	-8.17	-0.45	1.31e-14	Prudent dietary pattern;
CESC	cis	rs4909189	1.000	rs62493650	chr7:158135570	G/T	cg25566285	chr7:158114605	PTPRN2	0.44	5.97	0.34	7.51e-9	Response to amphetamines;
CESC	cis	rs6912958	0.667	rs7746545	chr6:88090225	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.73	10.21	0.53	7.48e-21	Monocyte percentage of white cells;
CESC	cis	rs72945132	0.769	rs11235754	chr11:70136092	C/T	cg14191688	chr11:70257035	CTTN	0.41	5.27	0.31	2.9e-7	Coronary artery disease;
CESC	cis	rs1801251	1.000	rs13003675	chr2:233584109	C/T	cg25237894	chr2:233734115	C2orf82	0.5	8.41	0.46	2.63e-15	Coronary artery disease;
CESC	cis	rs28386778	0.799	rs12450683	chr17:61984299	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.82	12.48	0.61	1.92e-28	Prudent dietary pattern;
CESC	cis	rs2120019	0.935	rs12591119	chr15:75355944	A/G	cg17294928	chr15:75287854	SCAMP5	-0.65	-6.96	-0.39	2.66e-11	Blood trace element (Zn levels);
CESC	cis	rs7618915	0.501	rs62253740	chr3:52684128	A/T	cg18337363	chr3:52569053	NT5DC2	0.28	5.24	0.31	3.22e-7	Bipolar disorder;
CESC	cis	rs9916302	0.706	rs801418	chr17:37457982	G/C	cg07936489	chr17:37558343	FBXL20	0.92	10.37	0.54	2.23e-21	Glomerular filtration rate (creatinine);
CESC	cis	rs2228479	0.867	rs34272502	chr16:89949000	G/C	cg06558623	chr16:89946397	TCF25	1.06	8.98	0.48	5.17e-17	Skin colour saturation;
CESC	trans	rs931812	0.757	rs13251801	chr8:101902629	A/T	cg20993868	chr7:22813445	NA	0.43	6.85	0.39	5.12e-11	Attention deficit hyperactivity disorder and conduct disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24334838	chr7:72298981	SBDSP;TYW1B	0.57	6.1	0.35	3.8e-9	Gut microbiome composition (summer);
CESC	cis	rs7078219	0.505	rs10883372	chr10:101292483	T/A	cg09788492	chr10:101292477	NKX2-3	0.34	6.41	0.37	6.45e-10	Dental caries;
CESC	cis	rs780096	0.527	rs11127044	chr2:27740404	C/G	cg21248554	chr2:27665150	KRTCAP3	-0.34	-6.82	-0.39	6.12e-11	Total body bone mineral density;
CESC	cis	rs798554	0.686	rs7777484	chr7:2814271	A/G	cg09658497	chr7:2847517	GNA12	-0.36	-5.42	-0.32	1.34e-7	Height;
CESC	cis	rs875971	0.660	rs801192	chr7:66031952	C/G	cg14393609	chr7:65229607	NA	-0.45	-6.13	-0.35	3.17e-9	Aortic root size;
CESC	cis	rs1552244	0.882	rs17050660	chr3:10001772	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	0.73	9.93	0.52	5.69e-20	Alzheimer's disease;
CESC	cis	rs4665809	0.652	rs2384360	chr2:26405016	C/G	cg27170947	chr2:26402098	FAM59B	-0.82	-9.69	-0.51	3.38e-19	Gut microbiome composition (summer);
CESC	cis	rs10504229	1.000	rs56740825	chr8:58175617	A/G	cg14926445	chr8:58193284	C8orf71	-0.51	-5.47	-0.32	1.03e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs9487051	0.714	rs6902892	chr6:109627601	G/T	cg01475377	chr6:109611718	NA	-0.43	-6.73	-0.38	1.03e-10	Reticulocyte fraction of red cells;
CESC	cis	rs4713118	0.621	rs9295756	chr6:28033396	G/T	cg12963246	chr6:28129442	ZNF389	0.54	6.97	0.39	2.47e-11	Parkinson's disease;
CESC	cis	rs1008375	0.931	rs6813374	chr4:17649494	T/C	cg04450456	chr4:17643702	FAM184B	0.36	5.06	0.3	7.87e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs10504229	0.595	rs76447299	chr8:58117395	A/G	cg21724239	chr8:58056113	NA	0.58	5.95	0.34	8.29e-9	Developmental language disorder (linguistic errors);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg06767762	chr16:70323488	AARS	0.43	6.31	0.36	1.14e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs2742234	0.541	rs10793427	chr10:43747443	G/A	cg15436174	chr10:43711423	RASGEF1A	0.44	5.11	0.3	6.06e-7	Hirschsprung disease;
CESC	cis	rs74181299	0.684	rs11126029	chr2:65338264	C/T	cg05010058	chr2:65284262	CEP68	-0.31	-5.08	-0.3	7.18e-7	Pulse pressure;
CESC	cis	rs6665290	0.935	rs17528667	chr1:227201770	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.2	-31.15	-0.89	1.43e-90	Myeloid white cell count;
CESC	cis	rs763014	0.931	rs7199839	chr16:636126	T/C	cg09263875	chr16:632152	PIGQ	0.68	11.61	0.58	1.81e-25	Height;
CESC	cis	rs4862307	0.836	rs4507404	chr4:185003767	C/T	cg06737308	chr4:185021514	ENPP6	-0.45	-5.98	-0.34	7.16e-9	Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	cis	rs2576037	0.526	rs1539878	chr18:44523004	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.43	7.19	0.4	6.49e-12	Personality dimensions;
CESC	cis	rs172166	0.694	rs1631552	chr6:28089699	C/A	cg12963246	chr6:28129442	ZNF389	0.43	6.38	0.36	8.03e-10	Cardiac Troponin-T levels;
CESC	cis	rs11997175	0.624	rs17700425	chr8:33691467	T/G	ch.8.33884649F	chr8:33765107	NA	0.57	7.37	0.41	2.18e-12	Body mass index;
CESC	trans	rs801193	1.000	rs6975195	chr7:66124774	T/A	cg26939375	chr7:64535504	NA	-0.64	-8.57	-0.47	8.53e-16	Aortic root size;
CESC	cis	rs4699052	0.625	rs1850321	chr4:104252765	T/C	cg16532752	chr4:104119610	CENPE	-0.39	-5.47	-0.32	1.02e-7	Testicular germ cell tumor;
CESC	cis	rs6032067	0.777	rs13038275	chr20:43780988	A/T	cg10761708	chr20:43804764	PI3	0.54	6.29	0.36	1.31e-9	Blood protein levels;
CESC	cis	rs9322193	0.772	rs7738696	chr6:150170121	A/G	cg07701084	chr6:150067640	NUP43	0.46	5.97	0.34	7.61e-9	Lung cancer;
CESC	cis	rs1448094	0.556	rs17345522	chr12:86169929	T/C	cg00310523	chr12:86230176	RASSF9	0.42	6.35	0.36	9.52e-10	Major depressive disorder;
CESC	cis	rs12220238	1.000	rs115418388	chr10:75976296	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.6	5.44	0.32	1.24e-7	Soluble interleukin-2 receptor subunit alpha;
CESC	cis	rs2228479	0.850	rs62054640	chr16:89823157	C/T	cg14709524	chr16:89940631	TCF25	0.93	6.94	0.39	3.03e-11	Skin colour saturation;
CESC	cis	rs9611565	0.840	rs2234052	chr22:41777241	A/G	cg17376030	chr22:41985996	PMM1	0.6	6.45	0.37	5.42e-10	Vitiligo;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg23538226	chr2:25016181	CENPO;C2orf79	-0.43	-6.1	-0.35	3.67e-9	Gambling;
CESC	cis	rs7666738	0.791	rs1426674	chr4:98924247	C/A	cg05340658	chr4:99064831	C4orf37	0.82	12.2	0.6	1.81e-27	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7666738	0.791	rs7684521	chr4:99071219	A/G	cg05340658	chr4:99064831	C4orf37	0.84	12.83	0.62	1.29e-29	Colonoscopy-negative controls vs population controls;
CESC	cis	rs8058578	1.000	rs7204278	chr16:30730274	A/G	cg02466173	chr16:30829666	NA	-0.42	-6.79	-0.38	7.37e-11	Multiple myeloma;
CESC	cis	rs7116495	0.881	rs676721	chr11:71770638	G/A	cg10381502	chr11:71823885	C11orf51	-0.64	-5.3	-0.31	2.5e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs634534	0.561	rs655744	chr11:65776585	G/T	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.7	-9.99	-0.52	3.64e-20	Sum eosinophil basophil counts;Eosinophil counts;
CESC	cis	rs1878931	0.545	rs28603	chr16:3449479	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.73	-8.22	-0.45	9.14e-15	Body mass index (adult);
CESC	cis	rs3733585	0.631	rs4697707	chr4:10119787	G/T	cg05927159	chr4:10118984	WDR1	0.34	5.08	0.3	7.04e-7	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs514406	0.763	rs7535088	chr1:53215042	A/G	cg08859206	chr1:53392774	SCP2	0.54	7.12	0.4	1.03e-11	Monocyte count;
CESC	trans	rs11039798	1.000	rs7123704	chr11:48580535	G/A	cg15704280	chr7:45808275	SEPT13	0.7	6.57	0.37	2.68e-10	Axial length;
CESC	cis	rs4474465	0.790	rs6592790	chr11:78262618	T/C	cg27205649	chr11:78285834	NARS2	0.42	5.23	0.31	3.39e-7	Alzheimer's disease (survival time);
CESC	cis	rs12711979	0.509	rs10195488	chr2:3824135	T/C	cg17052675	chr2:3827356	NA	-0.66	-11.02	-0.56	1.71e-23	Itch intensity from mosquito bite adjusted by bite size;
CESC	cis	rs9733	0.596	rs11586422	chr1:150679358	C/T	cg18016565	chr1:150552671	MCL1	0.35	5.36	0.31	1.86e-7	Tonsillectomy;
CESC	cis	rs4665809	0.590	rs6730310	chr2:26419470	C/G	cg26314531	chr2:26401878	FAM59B	-0.83	-9.28	-0.5	6.08e-18	Gut microbiome composition (summer);
CESC	cis	rs9399135	0.967	rs12527683	chr6:135324534	C/T	cg22676075	chr6:135203613	NA	0.52	7.31	0.41	3.25e-12	Red blood cell count;
CESC	cis	rs1801251	1.000	rs11676216	chr2:233706368	C/T	cg25237894	chr2:233734115	C2orf82	-0.46	-8.05	-0.44	2.73e-14	Coronary artery disease;
CESC	cis	rs7130144	0.541	rs7936386	chr11:130462505	T/C	cg26307797	chr11:130446613	NA	-0.76	-6.78	-0.38	7.92e-11	Urate levels in lean individuals;
CESC	cis	rs56235845	0.694	rs6875461	chr5:176754665	C/T	cg16006841	chr5:176797999	RGS14	-0.48	-6.08	-0.35	4.07e-9	Hemoglobin concentration;Hematocrit;
CESC	cis	rs7666738	0.830	rs17558151	chr4:99048699	T/C	cg17366294	chr4:99064904	C4orf37	0.6	8.51	0.46	1.33e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.65	7.41	0.41	1.72e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2882667	1.000	rs10064130	chr5:138309307	C/T	cg04439458	chr5:138467593	SIL1	-0.37	-5.85	-0.34	1.44e-8	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs2072499	0.966	rs2984615	chr1:156165317	G/C	cg24450063	chr1:156163899	SLC25A44	1.1	23.34	0.82	3.27e-66	Testicular germ cell tumor;
CESC	cis	rs4689388	0.926	rs9998835	chr4:6293237	C/G	cg25554036	chr4:6271136	WFS1	0.51	8.36	0.46	3.55e-15	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs977987	0.778	rs12445726	chr16:75465575	C/T	cg03315344	chr16:75512273	CHST6	0.41	5.91	0.34	1.07e-8	Dupuytren's disease;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg17176517	chr3:125239027	SNX4	-0.42	-6.53	-0.37	3.27e-10	Gambling;
CESC	cis	rs2952156	0.920	rs1018246	chr17:37835240	C/T	cg00129232	chr17:37814104	STARD3	-0.74	-10.75	-0.55	1.35e-22	Asthma;
CESC	cis	rs2243480	1.000	rs13247184	chr7:65358928	A/G	cg12463550	chr7:65579703	CRCP	0.69	5.53	0.32	7.85e-8	Diabetic kidney disease;
CESC	cis	rs3096299	0.582	rs12935119	chr16:89542874	A/T	cg08392591	chr16:89556376	ANKRD11	0.52	7.06	0.4	1.44e-11	Multiple myeloma (IgH translocation);
CESC	cis	rs6580649	0.657	rs57863747	chr12:48470425	G/T	cg05342945	chr12:48394962	COL2A1	0.5	5.74	0.33	2.59e-8	Lung cancer;
CESC	cis	rs11098499	0.954	rs10006525	chr4:120408931	T/G	cg24375607	chr4:120327624	NA	0.46	5.79	0.34	1.96e-8	Corneal astigmatism;
CESC	cis	rs116095464	0.558	rs28636067	chr5:199415	G/A	cg22496380	chr5:211416	CCDC127	-0.94	-9.83	-0.52	1.25e-19	Breast cancer;
CESC	cis	rs4950322	0.570	rs72692920	chr1:146780214	C/T	cg16700924	chr1:146552102	NA	-0.41	-5.1	-0.3	6.37e-7	Protein quantitative trait loci;
CESC	cis	rs11252926	0.537	rs4881255	chr10:453638	T/C	cg18196295	chr10:418757	DIP2C	0.54	7.37	0.41	2.17e-12	Psychosis in Alzheimer's disease;
CESC	cis	rs514406	0.929	rs12354395	chr1:53327663	A/G	cg08736216	chr1:53307985	ZYG11A	-0.42	-7.01	-0.4	1.93e-11	Monocyte count;
CESC	cis	rs763121	0.853	rs5750677	chr22:39147715	C/T	cg14440974	chr22:39074834	NA	-0.38	-5.25	-0.31	3.06e-7	Menopause (age at onset);
CESC	cis	rs11722228	0.522	rs73212880	chr4:10115692	T/A	cg14348967	chr4:10160060	NA	-0.4	-5.03	-0.3	9.07e-7	Gout;Urate levels;Serum uric acid levels;
CESC	cis	rs6502050	0.723	rs11650635	chr17:80083816	T/C	cg23985595	chr17:80112537	CCDC57	0.42	6.52	0.37	3.56e-10	Life satisfaction;
CESC	trans	rs916888	0.773	rs169201	chr17:44790203	A/G	cg22433210	chr17:43662623	NA	0.99	11.0	0.56	1.96e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs2730245	0.527	rs842702	chr7:158696814	C/T	cg24397884	chr7:158709396	WDR60	0.85	8.84	0.48	1.41e-16	Height;
CESC	cis	rs35110281	0.807	rs4818850	chr21:45028071	T/G	cg04455712	chr21:45112962	RRP1B	0.42	6.34	0.36	9.76e-10	Mean corpuscular volume;
CESC	cis	rs9611519	0.780	rs9611542	chr22:41677317	C/T	cg17376030	chr22:41985996	PMM1	0.51	5.72	0.33	2.91e-8	Neuroticism;
CESC	cis	rs12711979	0.740	rs6711964	chr2:3820916	A/T	cg17052675	chr2:3827356	NA	-0.41	-6.47	-0.37	4.74e-10	Itch intensity from mosquito bite adjusted by bite size;
CESC	cis	rs875971	1.000	rs1540651	chr7:65650121	C/T	cg10691866	chr7:65817282	TPST1	0.35	5.77	0.33	2.23e-8	Aortic root size;
CESC	cis	rs6540559	0.546	rs735693	chr1:210033988	A/C	cg22029157	chr1:209979665	IRF6	0.66	7.25	0.41	4.53e-12	Cleft lip with or without cleft palate;
CESC	cis	rs10411936	0.608	rs7259642	chr19:16601926	C/A	cg10248733	chr19:16607483	C19orf44;CALR3	0.52	6.28	0.36	1.35e-9	White blood cell count;Multiple sclerosis;
CESC	cis	rs34779708	0.801	rs12098720	chr10:35538683	G/A	cg03585969	chr10:35415529	CREM	0.57	6.57	0.37	2.6200000000000003e-10	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs2073300	0.609	rs6137939	chr20:23390206	C/T	cg16736954	chr20:23401023	NAPB	-0.76	-6.13	-0.35	3.22e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs9486719	1.000	rs3798289	chr6:97023632	T/C	cg18709589	chr6:96969512	KIAA0776	-0.52	-5.7	-0.33	3.16e-8	Migraine;Coronary artery disease;
CESC	cis	rs12497850	0.627	rs4974078	chr3:49009386	C/T	cg07636037	chr3:49044803	WDR6	0.66	9.82	0.52	1.28e-19	Parkinson's disease;
CESC	cis	rs2652834	0.808	rs4775614	chr15:63351687	A/G	cg05507819	chr15:63340323	TPM1	0.62	6.08	0.35	4.22e-9	HDL cholesterol;
CESC	cis	rs4253772	0.592	rs1807600	chr22:46644640	A/G	cg24881330	chr22:46731750	TRMU	0.73	7.96	0.44	5.2e-14	LDL cholesterol;Cholesterol, total;
CESC	trans	rs4335177	0.963	rs1907440	chr9:109373874	T/C	cg12580783	chr12:49362475	WNT10B	-0.34	-6.65	-0.38	1.72e-10	Response to paliperidone in schizophrenia (positive Marder score);
CESC	cis	rs9811920	0.638	rs793503	chr3:99588070	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.6	9.63	0.51	5.16e-19	Axial length;
CESC	cis	rs12142240	0.698	rs45517837	chr1:46859225	A/G	cg10495392	chr1:46806563	NSUN4	0.56	6.17	0.35	2.61e-9	Menopause (age at onset);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg08504806	chr7:2027239	MAD1L1	0.5	6.86	0.39	4.8e-11	Fibrinogen levels;
CESC	cis	rs35955747	0.838	rs7285171	chr22:31598367	C/T	cg25791279	chr22:32026902	PISD	-0.47	-5.64	-0.33	4.3e-8	Neutrophil count;Sum basophil neutrophil counts;
CESC	cis	rs12136530	0.651	rs4912081	chr1:19710002	G/T	cg01832549	chr1:19774989	CAPZB	-0.37	-5.37	-0.31	1.7e-7	Lead levels in blood;
CESC	cis	rs9487051	0.768	rs463503	chr6:109525757	T/C	cg01475377	chr6:109611718	NA	-0.46	-6.91	-0.39	3.64e-11	Reticulocyte fraction of red cells;
CESC	cis	rs875971	0.660	rs10215132	chr7:66054406	C/A	cg18876405	chr7:65276391	NA	-0.57	-7.61	-0.42	4.7e-13	Aortic root size;
CESC	cis	rs1270639	0.778	rs2530405	chr7:157446021	C/G	cg13357408	chr7:157437802	PTPRN2	0.62	7.26	0.41	4.32e-12	Colorectal cancer;
CESC	cis	rs561341	0.883	rs72821942	chr17:30234460	C/T	cg13647721	chr17:30228624	UTP6	0.6	5.49	0.32	9.34e-8	Hip circumference adjusted for BMI;
CESC	cis	rs9902453	0.845	rs2259855	chr17:28097860	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.67	-8.47	-0.46	1.67e-15	Coffee consumption (cups per day);
CESC	cis	rs1348850	0.567	rs880898	chr2:178532470	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.54	7.25	0.41	4.54e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs4713118	0.662	rs9380046	chr6:28030499	T/C	cg22143856	chr6:28129313	ZNF389	0.42	5.2	0.3	3.91e-7	Parkinson's disease;
CESC	cis	rs910316	0.663	rs175034	chr14:75463687	T/G	cg08847533	chr14:75593920	NEK9	-0.87	-14.71	-0.67	3.14e-36	Height;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg24149930	chr19:33182641	NUDT19	0.44	6.12	0.35	3.35e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs7605827	0.964	rs6748427	chr2:15564799	T/C	cg19274914	chr2:15703543	NA	0.34	6.04	0.35	5.23e-9	Educational attainment (years of education);
CESC	cis	rs668210	0.793	rs534201	chr11:65776728	A/T	cg02202077	chr11:65769826	EIF1AD;BANF1	0.65	6.89	0.39	4.14e-11	Cerebrospinal fluid biomarker levels;
CESC	cis	rs7904368	0.806	rs7899853	chr10:16857603	A/T	cg14835575	chr10:16859367	RSU1	0.51	5.25	0.31	3.19e-7	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
CESC	cis	rs2075371	1.000	rs2241336	chr7:133979578	A/G	cg00033643	chr7:134001901	SLC35B4	0.43	5.67	0.33	3.78e-8	Mean platelet volume;
CESC	cis	rs7666738	0.606	rs13108868	chr4:99083753	C/T	cg05340658	chr4:99064831	C4orf37	0.65	9.03	0.49	3.66e-17	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2315504	0.626	rs757271	chr17:39003503	A/C	cg05063374	chr17:38953512	KRT28	0.37	5.07	0.3	7.43e-7	Height;
CESC	cis	rs9300255	0.544	rs10772995	chr12:123671761	T/C	cg00376283	chr12:123451042	ABCB9	0.71	8.71	0.47	3.27e-16	Neutrophil percentage of white cells;
CESC	cis	rs4975709	0.569	rs931509	chr5:1858821	A/T	cg20790798	chr5:1857306	NA	-0.39	-5.07	-0.3	7.57e-7	Cardiovascular disease risk factors;
CESC	cis	rs2243480	1.000	rs73142162	chr7:65374296	A/T	cg12463550	chr7:65579703	CRCP	0.7	5.45	0.32	1.16e-7	Diabetic kidney disease;
CESC	cis	rs9287719	0.967	rs759403	chr2:10729897	C/T	cg00105475	chr2:10696890	NA	0.39	5.69	0.33	3.35e-8	Prostate cancer;
CESC	cis	rs909674	0.818	rs8136980	chr22:39844574	G/A	cg11247378	chr22:39784982	NA	-0.62	-8.9	-0.48	9.06e-17	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg07414643	chr4:187882934	NA	0.5	7.3	0.41	3.33e-12	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs9291683	0.668	rs2241474	chr4:10086015	T/C	cg26043149	chr18:55253948	FECH	0.46	6.17	0.35	2.51e-9	Bone mineral density;
CESC	cis	rs9837602	0.507	rs793455	chr3:99526135	C/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.4	5.34	0.31	1.96e-7	Breast cancer;
CESC	cis	rs7551222	0.752	rs12133735	chr1:204556836	G/T	cg20240347	chr1:204465584	NA	-0.3	-6.02	-0.35	5.94e-9	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17504096	chr1:205649242	SLC45A3	0.54	6.4	0.37	7.01e-10	Gut microbiome composition (summer);
CESC	cis	rs2599510	0.693	rs2754514	chr2:32788836	T/A	cg02381751	chr2:32503542	YIPF4	0.58	7.59	0.42	5.37e-13	Interleukin-18 levels;
CESC	cis	rs12893668	0.663	rs12889731	chr14:104087482	C/T	cg19000871	chr14:103996768	TRMT61A	-0.34	-5.07	-0.3	7.37e-7	Reticulocyte count;
CESC	cis	rs9322193	0.923	rs12526675	chr6:150050676	A/C	cg13206674	chr6:150067644	NUP43	-0.43	-5.98	-0.35	7.04e-9	Lung cancer;
CESC	cis	rs8180040	0.690	rs7640397	chr3:46989828	C/T	cg27129171	chr3:47204927	SETD2	0.66	9.68	0.51	3.5e-19	Colorectal cancer;
CESC	cis	rs8135665	0.600	rs8142379	chr22:38450971	G/A	cg13116946	chr22:38479732	SLC16A8	0.43	5.26	0.31	2.96e-7	Advanced age-related macular degeneration;Age-related macular degeneration;
CESC	cis	rs3820928	1.000	rs10197757	chr2:227763244	A/C	cg11843606	chr2:227700838	RHBDD1	-0.43	-5.9	-0.34	1.12e-8	Pulmonary function;
CESC	cis	rs798554	1.000	rs798544	chr7:2763102	A/G	cg09658497	chr7:2847517	GNA12	0.44	6.39	0.37	7.58e-10	Height;
CESC	cis	rs868036	0.609	rs16951304	chr15:68089618	T/C	cg08079166	chr15:68083412	MAP2K5	0.43	5.8	0.34	1.84e-8	Restless legs syndrome;
CESC	cis	rs2243480	1.000	rs427044	chr7:65508545	G/A	cg18252515	chr7:66147081	NA	-1.28	-12.44	-0.61	2.78e-28	Diabetic kidney disease;
CESC	cis	rs78456975	1.000	rs6730391	chr2:1566838	A/C	cg26248373	chr2:1572462	NA	-0.56	-5.33	-0.31	2.07e-7	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs3096299	0.967	rs753852	chr16:89446419	G/A	cg00750074	chr16:89608354	SPG7	-0.39	-5.38	-0.31	1.65e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs9790314	0.846	rs6791213	chr3:161033721	A/G	cg03342759	chr3:160939853	NMD3	-0.54	-7.78	-0.43	1.65e-13	Morning vs. evening chronotype;
CESC	cis	rs6724607	1.000	rs4853513	chr2:191479455	C/T	cg27211696	chr2:191398769	TMEM194B	-0.52	-7.77	-0.43	1.78e-13	Pulse pressure;
CESC	cis	rs4665809	1.000	rs6749855	chr2:26255263	A/G	cg25036284	chr2:26402008	FAM59B	-0.62	-6.84	-0.39	5.44e-11	Gut microbiome composition (summer);
CESC	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg24101359	chr6:42928495	GNMT	0.68	11.09	0.56	9.82e-24	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs2991971	0.810	rs12119202	chr1:45925931	A/T	cg24296786	chr1:45957014	TESK2	-0.62	-8.77	-0.47	2.21e-16	High light scatter reticulocyte count;
CESC	trans	rs916888	0.773	rs199451	chr17:44801784	G/A	cg04282206	chr17:62833786	PLEKHM1P	0.57	6.51	0.37	3.69e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs2842992	0.830	rs2758313	chr6:160154099	C/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.68	8.75	0.47	2.59e-16	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs1881797	1.000	rs12061460	chr1:247686787	G/A	cg11166453	chr1:247681781	NA	0.44	5.77	0.33	2.24e-8	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs4141404	0.673	rs1968023	chr22:31942770	A/G	cg02404636	chr22:31891804	SFI1	-0.43	-5.41	-0.32	1.42e-7	Paclitaxel-induced neuropathy;
CESC	trans	rs8012	0.537	rs11085825	chr19:13007458	A/G	cg12649340	chr1:119575837	WARS2	-0.44	-6.01	-0.35	6.26e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;Blood metabolite levels;
CESC	cis	rs6964587	0.900	rs62467794	chr7:91850578	C/T	cg17063962	chr7:91808500	NA	0.57	6.75	0.38	9.37e-11	Breast cancer;
CESC	cis	rs6594499	0.500	rs10491424	chr5:110453806	T/C	cg04022379	chr5:110408740	TSLP	0.42	7.33	0.41	2.8e-12	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs11122272	0.735	rs2572248	chr1:231514942	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.57	-7.82	-0.43	1.29e-13	Hemoglobin concentration;
CESC	cis	rs2404602	0.692	rs55864032	chr15:77122548	A/G	cg26408565	chr15:76604113	ETFA	-0.38	-5.56	-0.32	6.49e-8	Blood metabolite levels;
CESC	cis	rs763014	0.931	rs1981483	chr16:630665	G/A	cg00908189	chr16:619842	PIGQ	0.66	9.26	0.49	7.42e-18	Height;
CESC	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg24829409	chr8:58192753	C8orf71	-0.67	-8.09	-0.44	2.23e-14	Developmental language disorder (linguistic errors);
CESC	cis	rs7789940	1.000	rs17149161	chr7:75978229	C/A	cg10167463	chr7:75959203	YWHAG	-0.56	-7.09	-0.4	1.23e-11	Multiple sclerosis;
CESC	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	10.2	0.53	7.97e-21	Prudent dietary pattern;
CESC	cis	rs977987	0.806	rs1109342	chr16:75445675	A/G	cg03315344	chr16:75512273	CHST6	-0.38	-5.44	-0.32	1.24e-7	Dupuytren's disease;
CESC	cis	rs2204008	0.571	rs1117803	chr12:38281007	C/G	cg26384229	chr12:38710491	ALG10B	-0.46	-5.95	-0.34	8.45e-9	Bladder cancer;
CESC	cis	rs9914544	0.932	rs11870265	chr17:18820985	A/T	cg26378065	chr17:18585709	ZNF286B	0.47	6.15	0.35	2.86e-9	Educational attainment (years of education);
CESC	cis	rs597539	0.652	rs516425	chr11:68715675	G/A	cg18350739	chr11:68623251	NA	-0.45	-6.91	-0.39	3.7e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs1387259	0.790	rs2732445	chr12:48645533	C/T	cg24011408	chr12:48396354	COL2A1	0.44	6.15	0.35	2.82e-9	Obstructive sleep apnea trait (apnea hypopnea index);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26565884	chr16:89187106	ACSF3	-0.55	-6.63	-0.38	1.84e-10	Gut microbiome composition (summer);
CESC	cis	rs17376456	0.877	rs10052428	chr5:93476530	T/C	cg21475434	chr5:93447410	FAM172A	0.86	7.66	0.43	3.53e-13	Diabetic retinopathy;
CESC	cis	rs7223966	1.000	rs11079511	chr17:61858537	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.52	6.07	0.35	4.36e-9	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs1124376	0.935	rs67660889	chr3:20170538	G/C	cg05072819	chr3:20081367	KAT2B	0.54	5.81	0.34	1.81e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs2072732	0.861	rs67025412	chr1:2951806	T/C	cg15211996	chr1:2936768	ACTRT2	0.34	5.95	0.34	8.31e-9	Plateletcrit;
CESC	cis	rs2243480	1.000	rs4718317	chr7:65648901	A/G	cg18252515	chr7:66147081	NA	1.25	12.08	0.6	4.67e-27	Diabetic kidney disease;
CESC	cis	rs7552404	1.000	rs211718	chr1:76106675	C/T	cg10523679	chr1:76189770	ACADM	0.68	7.95	0.44	5.33e-14	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs6963495	0.556	rs818474	chr7:105155243	A/T	cg13798780	chr7:105162888	PUS7	0.51	6.2	0.36	2.18e-9	Bipolar disorder (body mass index interaction);
CESC	cis	rs11098499	0.754	rs1849457	chr4:120254355	A/G	cg09307838	chr4:120376055	NA	0.79	10.5	0.54	8.92e-22	Corneal astigmatism;
CESC	cis	rs11696501	0.739	rs6073835	chr20:44286454	C/T	cg11783356	chr20:44313418	WFDC10B	-0.33	-5.16	-0.3	4.82e-7	Brain structure;
CESC	cis	rs36051895	0.589	rs17492549	chr9:5202830	A/C	cg02405213	chr9:5042618	JAK2	-0.48	-5.59	-0.32	5.61e-8	Pediatric autoimmune diseases;
CESC	trans	rs11098499	0.739	rs7441137	chr4:120133221	G/T	cg25214090	chr10:38739885	LOC399744	-0.54	-7.16	-0.4	7.81e-12	Corneal astigmatism;
CESC	cis	rs4595586	0.525	rs1400279	chr12:39343825	T/A	cg13010199	chr12:38710504	ALG10B	0.45	5.65	0.33	4.2e-8	Morning vs. evening chronotype;
CESC	cis	rs10504229	1.000	rs67594249	chr8:58180521	T/A	cg24829409	chr8:58192753	C8orf71	-0.76	-10.0	-0.52	3.53e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs17125944	0.505	rs75194546	chr14:53212069	A/C	cg00686598	chr14:53173677	PSMC6	1.42	11.93	0.59	1.52e-26	Alzheimer's disease (late onset);
CESC	cis	rs13242816	1.000	rs35800776	chr7:116110069	C/A	cg04696780	chr7:116139425	CAV2	-0.59	-5.24	-0.31	3.3e-7	P wave duration;
CESC	cis	rs10504229	0.679	rs2218271	chr8:58052446	T/A	cg24829409	chr8:58192753	C8orf71	-0.5	-6.25	-0.36	1.62e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs11690935	0.959	rs6754817	chr2:172663394	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.94	-13.89	-0.65	2.46e-33	Schizophrenia;
CESC	cis	rs3785574	0.962	rs7219920	chr17:61811642	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.58	7.16	0.4	7.84e-12	Height;
CESC	cis	rs1569175	1.000	rs2189471	chr2:200924202	G/A	cg19045956	chr2:200819837	C2orf60;C2orf47	0.64	5.36	0.31	1.83e-7	Response to treatment for acute lymphoblastic leukemia;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg21582582	chr3:182698605	DCUN1D1	-0.47	-6.33	-0.36	1.07e-9	Asthma;
CESC	cis	rs290268	0.669	rs10993693	chr9:93557698	C/T	cg02608019	chr9:93564028	SYK	0.49	7.05	0.4	1.54e-11	Platelet count;
CESC	cis	rs3806843	1.000	rs7732179	chr5:140199039	G/A	cg16179182	chr5:140090404	VTRNA1-1	-0.41	-5.35	-0.31	1.88e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs7666738	0.888	rs13110683	chr4:98983368	G/C	cg03676636	chr4:99064102	C4orf37	0.36	5.36	0.31	1.78e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11966931	1.000	rs17528993	chr6:108114633	C/G	cg10566610	chr6:108093680	SCML4	0.32	5.62	0.33	4.89e-8	Neutrophil percentage of white cells;
CESC	cis	rs3026101	0.671	rs8066702	chr17:5310121	A/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.45	6.06	0.35	4.6e-9	Body mass index;
CESC	cis	rs4986811	0.929	rs5030180	chr11:32448239	G/A	cg27409910	chr11:32454216	WT1	0.42	5.17	0.3	4.62e-7	Rubella-specific interleukin-6 secretion;
CESC	cis	rs8103278	1.000	rs17571725	chr19:46290822	C/T	cg14061069	chr19:46274453	DMPK	-0.37	-5.16	-0.3	4.94e-7	Coronary artery disease;
CESC	cis	rs9309711	0.961	rs11678655	chr2:3476234	T/G	cg10845886	chr2:3471009	TTC15	-0.87	-12.51	-0.61	1.63e-28	Neurofibrillary tangles;
CESC	trans	rs1814175	0.502	rs12365889	chr11:49623034	G/A	cg15704280	chr7:45808275	SEPT13	-0.87	-11.16	-0.57	5.81e-24	Height;
CESC	cis	rs68170813	0.559	rs76534758	chr7:106963262	T/C	cg02696742	chr7:106810147	HBP1	-0.55	-5.17	-0.3	4.64e-7	Coronary artery disease;
CESC	cis	rs11997175	0.631	rs7826866	chr8:33665090	A/T	ch.8.33884649F	chr8:33765107	NA	0.46	5.81	0.34	1.78e-8	Body mass index;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00289125	chr2:20251812	LAPTM4A	-0.54	-6.32	-0.36	1.12e-9	Gut microbiome composition (summer);
CESC	cis	rs7772486	0.686	rs1292337	chr6:145967807	A/G	cg05347473	chr6:146136440	FBXO30	-0.53	-6.97	-0.39	2.51e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2228479	0.614	rs1137042	chr16:89975638	A/G	cg04013166	chr16:89971882	TCF25	0.71	8.54	0.46	1.1e-15	Skin colour saturation;
CESC	cis	rs6062302	0.522	rs3761126	chr20:62252044	C/T	cg06363034	chr20:62225388	GMEB2	-0.52	-6.74	-0.38	9.85e-11	Glioblastoma;
CESC	cis	rs651907	0.514	rs34301719	chr3:101417993	C/T	cg12386194	chr3:101231763	SENP7	0.48	5.87	0.34	1.3e-8	Colorectal cancer;
CESC	cis	rs9467711	0.606	rs9393708	chr6:26362643	C/T	cg12826209	chr6:26865740	GUSBL1	-0.63	-5.7	-0.33	3.24e-8	Autism spectrum disorder or schizophrenia;
CESC	cis	rs7219021	0.774	rs9909916	chr17:46961493	C/T	cg16584676	chr17:46985605	UBE2Z	-0.66	-7.42	-0.41	1.61e-12	Schizophrenia or bipolar disorder;
CESC	cis	rs3126085	0.825	rs11204933	chr1:152172185	C/T	cg03465714	chr1:152285911	FLG	-0.45	-5.54	-0.32	7.45e-8	Atopic dermatitis;
CESC	cis	rs6582630	0.519	rs11495699	chr12:38286219	G/T	cg13010199	chr12:38710504	ALG10B	0.53	6.39	0.37	7.43e-10	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs2836974	0.583	rs2776306	chr21:40713754	A/G	cg11890956	chr21:40555474	PSMG1	0.68	9.49	0.5	1.4e-18	Cognitive function;
CESC	cis	rs10089	1.000	rs1560636	chr5:127447987	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.8	11.17	0.57	5.47e-24	Ileal carcinoids;
CESC	cis	rs7945705	0.967	rs34842234	chr11:8891894	G/A	cg21881798	chr11:8931708	C11orf17;ST5	0.5	7.94	0.44	5.61e-14	Hemoglobin concentration;
CESC	cis	rs748404	0.660	rs690472	chr15:43764368	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.57	7.5	0.42	9.94e-13	Lung cancer;
CESC	trans	rs916888	0.821	rs199507	chr17:44858855	A/G	cg23590916	chr17:43697445	MGC57346	-0.61	-6.51	-0.37	3.66e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs796364	0.951	rs36086821	chr2:201067436	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.61	5.74	0.33	2.56e-8	Schizophrenia;
CESC	cis	rs1707322	0.686	rs11211179	chr1:46228082	A/C	cg05343316	chr1:45956843	TESK2	0.47	6.02	0.35	5.8e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs1045902	0.516	rs7851	chr2:73478461	A/T	cg01422370	chr2:73384389	NA	0.36	5.07	0.3	7.65e-7	Intelligence (multi-trait analysis);
CESC	trans	rs617791	0.678	rs551659	chr11:65749645	C/T	cg17712092	chr4:129076599	LARP1B	0.74	10.3	0.53	3.76e-21	Breast cancer;
CESC	cis	rs35110281	0.776	rs9983763	chr21:44990578	A/G	cg21573476	chr21:45109991	RRP1B	0.47	6.44	0.37	5.67e-10	Mean corpuscular volume;
CESC	cis	rs10504229	0.861	rs6990617	chr8:58182960	G/T	cg22535103	chr8:58192502	C8orf71	-1.05	-13.08	-0.63	1.71e-30	Developmental language disorder (linguistic errors);
CESC	cis	rs4144743	0.938	rs35069360	chr17:45321270	C/T	cg18085866	chr17:45331354	ITGB3	-0.65	-7.07	-0.4	1.39e-11	Body mass index;
CESC	cis	rs5758511	0.680	rs5758687	chr22:42656588	A/T	cg00645731	chr22:42541494	CYP2D7P1	0.56	8.58	0.47	8.05e-16	Birth weight;
CESC	cis	rs17125944	0.686	rs9646151	chr14:53354464	C/G	cg00686598	chr14:53173677	PSMC6	-0.6	-5.54	-0.32	7.42e-8	Alzheimer's disease (late onset);
CESC	cis	rs9311474	0.508	rs11720159	chr3:52617802	T/G	cg07507251	chr3:52567010	NT5DC2	0.33	5.67	0.33	3.76e-8	Electroencephalogram traits;
CESC	cis	rs28673728	0.897	rs28391281	chr1:38408974	T/C	cg26398791	chr1:38455867	SF3A3	-0.41	-5.23	-0.31	3.4e-7	Red cell distribution width;
CESC	cis	rs2404602	0.692	rs35395069	chr15:76986334	C/T	cg22467129	chr15:76604101	ETFA	-0.34	-5.12	-0.3	5.9e-7	Blood metabolite levels;
CESC	cis	rs66686620	1.000	rs6724990	chr2:69247789	C/T	cg12800200	chr2:69260302	ANTXR1	0.42	6.22	0.36	1.93e-9	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09560399	chr11:19138459	ZDHHC13	-0.57	-6.63	-0.38	1.87e-10	Gut microbiome composition (summer);
CESC	cis	rs2243480	1.000	rs160642	chr7:65558373	C/T	cg12463550	chr7:65579703	CRCP	0.74	5.71	0.33	3.02e-8	Diabetic kidney disease;
CESC	trans	rs7246760	0.737	rs57296518	chr19:9819950	A/G	cg02900749	chr2:68251473	NA	-0.77	-7.13	-0.4	9.35e-12	Pursuit maintenance gain;
CESC	cis	rs710216	0.917	rs2297977	chr1:43415288	G/T	cg07803811	chr1:43423981	SLC2A1	0.5	5.36	0.31	1.84e-7	Red cell distribution width;
CESC	cis	rs7927771	1.000	rs11039412	chr11:47841581	G/A	cg20307385	chr11:47447363	PSMC3	-0.49	-6.04	-0.35	5.24e-9	Subjective well-being;
CESC	cis	rs10883723	0.810	rs12265877	chr10:104247247	C/G	ch.10.2196322F	chr10:104248062	ACTR1A	0.42	5.16	0.3	4.93e-7	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs4919694	1.000	rs12268849	chr10:104737682	G/A	cg04362960	chr10:104952993	NT5C2	0.68	5.88	0.34	1.22e-8	Arsenic metabolism;
CESC	cis	rs9457247	0.663	rs2237274	chr6:167442995	C/G	cg25258033	chr6:167368657	RNASET2	0.35	5.07	0.3	7.41e-7	Crohn's disease;
CESC	cis	rs7605378	1.000	rs769958	chr2:200695901	G/A	cg23649088	chr2:200775458	C2orf69	0.5	6.63	0.38	1.9e-10	Osteoporosis;
CESC	cis	rs10861342	1.000	rs11112380	chr12:105526695	C/T	cg23923672	chr12:105501055	KIAA1033	0.67	5.09	0.3	6.92e-7	IgG glycosylation;
CESC	cis	rs10504229	0.683	rs61364624	chr8:58134339	T/A	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	trans	rs7090925	0.853	rs2892582	chr10:8482310	C/T	cg02275004	chr12:976007	WNK1;HSN2	-0.44	-6.0	-0.35	6.41e-9	Systemic lupus erythematosus;
CESC	cis	rs9583531	0.657	rs9521915	chr13:111384528	C/T	cg15841412	chr13:111365552	ING1	0.45	5.66	0.33	3.98e-8	Coronary artery disease;
CESC	cis	rs7618915	0.547	rs4687548	chr3:52666650	A/T	cg05564831	chr3:52568323	NT5DC2	0.45	6.89	0.39	4.03e-11	Bipolar disorder;
CESC	cis	rs5997397	0.967	rs5762777	chr22:29150044	T/C	cg15103426	chr22:29168792	CCDC117	0.47	6.07	0.35	4.42e-9	Red cell distribution width;
CESC	cis	rs651907	0.535	rs13084113	chr3:101534039	C/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.46	6.04	0.35	5.19e-9	Colorectal cancer;
CESC	cis	rs9322193	0.923	rs12526675	chr6:150050676	A/C	cg04369109	chr6:150039330	LATS1	0.47	6.64	0.38	1.81e-10	Lung cancer;
CESC	cis	rs10754283	0.967	rs7523046	chr1:90109499	G/A	cg21401794	chr1:90099060	LRRC8C	0.68	9.24	0.49	8.33e-18	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs939574	1.000	rs7574937	chr2:220099331	C/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.83	7.33	0.41	2.78e-12	Platelet distribution width;
CESC	cis	rs2885056	0.830	rs2018810	chr19:10669172	A/G	cg09936142	chr19:10668400	KRI1	-0.43	-5.08	-0.3	7.14e-7	Red cell distribution width;
CESC	cis	rs4919087	1.000	rs10786329	chr10:99074621	G/A	cg25902810	chr10:99078978	FRAT1	0.71	10.31	0.54	3.48e-21	Monocyte count;
CESC	cis	rs9768139	0.733	rs12698208	chr7:158117575	C/T	cg24154853	chr7:158122151	PTPRN2	0.45	7.34	0.41	2.65e-12	Calcium levels;
CESC	cis	rs6831352	0.918	rs7670241	chr4:100059619	G/T	cg13256891	chr4:100009986	ADH5	-0.77	-8.45	-0.46	1.97e-15	Alcohol dependence;
CESC	trans	rs60843830	1.000	rs7595075	chr2:264019	C/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.69	8.62	0.47	6.13e-16	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs854765	0.964	rs854762	chr17:18009102	G/A	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.47	-5.85	-0.34	1.48e-8	Total body bone mineral density;
CESC	trans	rs2797160	0.904	rs2326292	chr6:125999674	G/A	cg05039488	chr6:79577232	IRAK1BP1	-0.48	-6.62	-0.38	2.02e-10	Endometrial cancer;
CESC	cis	rs17253792	0.822	rs79024594	chr14:56092997	T/G	cg01858014	chr14:56050164	KTN1	-0.85	-6.99	-0.39	2.22e-11	Putamen volume;
CESC	cis	rs748404	0.587	rs690276	chr15:43704558	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.53	8.47	0.46	1.69e-15	Lung cancer;
CESC	cis	rs9649213	0.593	rs3779194	chr7:98010277	A/G	cg21770322	chr7:97807741	LMTK2	0.57	8.63	0.47	5.93e-16	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs8002861	0.875	rs12869697	chr13:44439169	T/C	cg19180546	chr13:44453867	C13orf31;CCDC122	-0.43	-5.4	-0.31	1.47e-7	Leprosy;
CESC	cis	rs4268898	0.636	rs72787383	chr2:24583861	G/A	cg06627628	chr2:24431161	ITSN2	-1.03	-11.63	-0.58	1.53e-25	Asthma;
CESC	cis	rs2836974	0.568	rs11910906	chr21:40685662	T/C	cg11644478	chr21:40555479	PSMG1	-0.8	-11.61	-0.58	1.88e-25	Cognitive function;
CESC	cis	rs1538970	1.000	rs17395553	chr1:45864761	C/T	cg05343316	chr1:45956843	TESK2	0.83	11.71	0.58	8.6e-26	Platelet count;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg20645649	chr9:127624485	RPL35	-0.53	-7.57	-0.42	6.31e-13	Gambling;
CESC	trans	rs1728785	0.901	rs11075688	chr16:68655924	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.69	-7.98	-0.44	4.42e-14	Ulcerative colitis;
CESC	cis	rs514406	0.861	rs11206026	chr1:53281708	G/A	cg24675658	chr1:53192096	ZYG11B	-0.56	-7.0	-0.4	2.05e-11	Monocyte count;
CESC	cis	rs11645898	0.748	rs72791112	chr16:72204069	T/A	cg14768367	chr16:72042858	DHODH	-0.73	-5.84	-0.34	1.49e-8	Blood protein levels;
CESC	trans	rs7726839	0.794	rs10474792	chr5:600058	G/A	cg25482853	chr8:67687455	SGK3	0.62	6.38	0.36	8.03e-10	Obesity-related traits;
CESC	cis	rs72945132	0.882	rs7937984	chr11:70144254	C/T	cg00319359	chr11:70116639	PPFIA1	0.78	7.71	0.43	2.52e-13	Coronary artery disease;
CESC	cis	rs2522056	1.000	rs2706339	chr5:131800105	G/T	cg24060327	chr5:131705240	SLC22A5	0.61	6.93	0.39	3.24e-11	Lymphocyte counts;Fibrinogen;
CESC	cis	rs7666738	0.546	rs10018080	chr4:98758436	C/A	cg17366294	chr4:99064904	C4orf37	0.49	6.1	0.35	3.68e-9	Colonoscopy-negative controls vs population controls;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg00852613	chr13:50159829	RCBTB1	0.44	6.28	0.36	1.37e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs9486719	0.948	rs2472904	chr6:96874962	T/G	cg06623918	chr6:96969491	KIAA0776	0.81	8.29	0.45	5.61e-15	Migraine;Coronary artery disease;
CESC	cis	rs1797885	0.934	rs299650	chr3:12538595	T/C	cg26432171	chr3:12704882	RAF1	-0.48	-6.0	-0.35	6.52e-9	Immature fraction of reticulocytes;
CESC	cis	rs735539	1.000	rs2290143	chr13:21280363	A/G	cg04906043	chr13:21280425	IL17D	0.39	5.92	0.34	1.01e-8	Dental caries;
CESC	trans	rs2391518	0.639	rs2968997	chr4:130784669	A/C	cg24601559	chr2:43328536	NA	0.35	6.1	0.35	3.83e-9	Body mass index;
CESC	cis	rs2115536	0.730	rs12898642	chr15:80182050	T/C	cg00225070	chr15:80189496	MTHFS	0.48	6.66	0.38	1.54e-10	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CESC	cis	rs892961	0.932	rs66886702	chr17:75412714	G/A	cg05865280	chr17:75406074	SEPT9	0.62	12.67	0.61	4.57e-29	Airflow obstruction;
CESC	cis	rs10504229	0.683	rs7820302	chr8:58142502	C/T	cg21724239	chr8:58056113	NA	0.57	6.1	0.35	3.8e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs67478160	0.643	rs3818085	chr14:104215985	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.5	-7.06	-0.4	1.45e-11	Schizophrenia;
CESC	cis	rs6540559	1.000	rs742214	chr1:209960925	T/C	cg22029157	chr1:209979665	IRF6	0.7	10.01	0.52	3.13e-20	Cleft lip with or without cleft palate;
CESC	cis	rs7216064	1.000	rs2365764	chr17:65857714	G/A	cg07042672	chr17:66097459	LOC651250	-0.54	-5.62	-0.33	4.77e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs4727027	0.716	rs4727020	chr7:148837317	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.41	5.03	0.3	8.93e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs9649213	0.593	rs62478233	chr7:98023092	T/C	cg24562669	chr7:97807699	LMTK2	0.51	7.54	0.42	7.55e-13	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg11965913	chr1:205819406	PM20D1	0.9	16.9	0.72	5.68e-44	Menarche (age at onset);
CESC	cis	rs8114671	0.836	rs734308	chr20:33572096	A/G	cg06115741	chr20:33292138	TP53INP2	-0.46	-5.52	-0.32	8.18e-8	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10635912	chr19:10305863	DNMT1	0.6	6.82	0.39	6.02e-11	Gut microbiome composition (summer);
CESC	cis	rs2839186	0.619	rs2187118	chr21:47611310	C/T	cg00815214	chr21:47717953	NA	-0.38	-5.42	-0.32	1.31e-7	Testicular germ cell tumor;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg18022496	chr3:196594351	SENP5	0.46	6.14	0.35	2.95e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.89	13.75	0.65	7.91e-33	Prudent dietary pattern;
CESC	cis	rs6598955	0.670	rs10794525	chr1:26537193	C/A	cg00852783	chr1:26633632	UBXN11	0.41	5.97	0.34	7.44e-9	Obesity-related traits;
CESC	cis	rs870825	0.860	rs28696121	chr4:185598743	G/A	cg04058563	chr4:185651563	MLF1IP	0.6	6.11	0.35	3.53e-9	Blood protein levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04400030	chr15:64387986	SNX1	0.55	6.23	0.36	1.79e-9	Gut microbiome composition (summer);
CESC	cis	rs13082711	0.596	rs683503	chr3:27348094	C/T	cg02860705	chr3:27208620	NA	0.51	6.6	0.38	2.25e-10	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CESC	cis	rs10504229	0.683	rs2318143	chr8:58114660	C/T	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs7914558	0.966	rs10786719	chr10:104637992	C/T	cg04362960	chr10:104952993	NT5C2	-0.44	-5.52	-0.32	7.92e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs2404602	0.684	rs8037847	chr15:76856551	C/T	cg23625390	chr15:77176239	SCAPER	-0.44	-6.13	-0.35	3.14e-9	Blood metabolite levels;
CESC	trans	rs35110281	0.782	rs6518302	chr21:45018478	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.54	7.1	0.4	1.16e-11	Mean corpuscular volume;
CESC	cis	rs17376456	0.877	rs10514380	chr5:93409370	C/T	cg21475434	chr5:93447410	FAM172A	0.8	7.26	0.41	4.26e-12	Diabetic retinopathy;
CESC	cis	rs10979	0.557	rs9285501	chr6:143915121	G/C	cg25407410	chr6:143891975	LOC285740	-0.46	-6.05	-0.35	4.96e-9	Hypospadias;
CESC	trans	rs11098499	0.754	rs1814813	chr4:120258207	G/T	cg25214090	chr10:38739885	LOC399744	-0.58	-8.41	-0.46	2.55e-15	Corneal astigmatism;
CESC	cis	rs17376456	0.690	rs6892055	chr5:93113023	A/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.59	5.05	0.3	8.04e-7	Diabetic retinopathy;
CESC	cis	rs9303401	0.921	rs34102441	chr17:56877414	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.73	9.6	0.51	6.34e-19	Cognitive test performance;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg07729303	chr15:22940817	CYFIP1	0.47	6.23	0.36	1.78e-9	Fibrinogen levels;
CESC	cis	rs11098499	0.648	rs2002047	chr4:120257228	A/G	cg09307838	chr4:120376055	NA	0.81	10.94	0.56	3.14e-23	Corneal astigmatism;
CESC	cis	rs73019876	0.868	rs2262908	chr19:22134800	C/T	cg11619707	chr19:22235551	ZNF257	-0.3	-5.68	-0.33	3.63e-8	Testicular germ cell tumor;
CESC	cis	rs7662987	0.517	rs2851277	chr4:100022910	G/T	cg13256891	chr4:100009986	ADH5	0.75	8.03	0.44	3.21e-14	Smoking initiation;
CESC	cis	rs253959	0.729	rs1567335	chr5:115501792	C/T	cg23108291	chr5:115420582	COMMD10	-0.42	-5.19	-0.3	4.11e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs2250402	0.510	rs8031319	chr15:40323692	A/G	cg01081584	chr15:40268610	EIF2AK4	-0.59	-5.34	-0.31	2e-7	Corneal curvature;
CESC	trans	rs931812	0.895	rs965625	chr8:101909749	T/C	cg20993868	chr7:22813445	NA	0.56	8.03	0.44	3.25e-14	Attention deficit hyperactivity disorder and conduct disorder;
CESC	cis	rs3540	0.533	rs2256097	chr15:90971331	A/T	cg10434728	chr15:90938212	IQGAP1	0.39	6.86	0.39	4.98e-11	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs514406	0.505	rs387436	chr1:53179376	C/T	cg08736216	chr1:53307985	ZYG11A	0.39	6.51	0.37	3.78e-10	Monocyte count;
CESC	cis	rs2625529	0.607	rs2912231	chr15:72567957	G/T	cg16672083	chr15:72433130	SENP8	-0.44	-5.78	-0.33	2.1e-8	Red blood cell count;
CESC	cis	rs67311347	1.000	rs7641495	chr3:40494690	T/C	cg01475735	chr3:40494733	NA	0.46	5.98	0.34	7.28e-9	Renal cell carcinoma;
CESC	cis	rs7589342	0.792	rs13426321	chr2:106500280	G/A	cg14210321	chr2:106509881	NCK2	-0.47	-5.37	-0.31	1.71e-7	Addiction;
CESC	cis	rs6460942	0.915	rs17444141	chr7:12460971	T/G	cg10578991	chr7:12443926	VWDE	-0.5	-5.52	-0.32	7.93e-8	Coronary artery disease;
CESC	cis	rs6964587	0.967	rs10953065	chr7:91808915	A/G	cg01689657	chr7:91764605	CYP51A1	-0.31	-5.62	-0.33	4.85e-8	Breast cancer;
CESC	cis	rs1976403	0.659	rs10799699	chr1:21820961	C/T	cg02390115	chr1:21767211	NBPF3	0.4	5.79	0.33	2.01e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs1499614	1.000	rs2707830	chr7:66167645	T/C	cg18252515	chr7:66147081	NA	-1.42	-14.62	-0.67	6.69e-36	Gout;
CESC	trans	rs1814175	0.588	rs1721994	chr11:49914050	G/A	cg03929089	chr4:120376271	NA	-0.92	-15.2	-0.68	6e-38	Height;
CESC	cis	rs7412746	0.611	rs10788794	chr1:150728676	T/C	cg18016565	chr1:150552671	MCL1	0.35	5.08	0.3	7.01e-7	Melanoma;
CESC	cis	rs738322	0.753	rs2267372	chr22:38598234	A/G	cg17652424	chr22:38574118	PLA2G6	0.31	5.38	0.31	1.64e-7	Cutaneous nevi;
CESC	cis	rs4803468	1.000	rs3816037	chr19:41918009	C/T	cg09537434	chr19:41945824	ATP5SL	-1.03	-18.3	-0.75	6.46e-49	Height;
CESC	trans	rs13178541	0.810	rs7378848	chr5:135087025	C/T	cg06130072	chr11:1036714	MUC6	0.33	6.09	0.35	3.89e-9	IgG glycosylation;
CESC	cis	rs919433	0.854	rs13013049	chr2:198208664	C/T	cg03934865	chr2:198174659	NA	-0.42	-5.67	-0.33	3.77e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs9322193	0.923	rs10872645	chr6:150063976	G/A	cg04369109	chr6:150039330	LATS1	-0.38	-5.19	-0.3	4.09e-7	Lung cancer;
CESC	cis	rs3540	0.512	rs3862434	chr15:91080387	C/T	cg22089800	chr15:90895588	ZNF774	0.61	8.32	0.45	4.84e-15	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs7828089	0.561	rs13266541	chr8:22266135	G/A	cg23129673	chr8:22266227	SLC39A14	0.39	5.75	0.33	2.45e-8	Verbal declarative memory;
CESC	cis	rs9733	0.526	rs11204698	chr1:150659545	G/A	cg17724175	chr1:150552817	MCL1	0.45	7.33	0.41	2.84e-12	Tonsillectomy;
CESC	cis	rs2933343	0.951	rs9871612	chr3:128570402	C/T	cg25356066	chr3:128598488	ACAD9	0.51	6.17	0.35	2.52e-9	IgG glycosylation;
CESC	cis	rs7666738	0.830	rs4323111	chr4:98952276	A/G	cg03467027	chr4:99064603	C4orf37	0.44	5.48	0.32	9.87e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs12479064	0.724	rs11885942	chr2:100004165	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.69	-8.12	-0.45	1.75e-14	Chronic sinus infection;
CESC	cis	rs7044106	0.791	rs10985000	chr9:123484115	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.34	5.55	0.32	6.77e-8	Hip circumference adjusted for BMI;
CESC	cis	rs35110281	0.641	rs4819283	chr21:45083011	T/A	cg01579765	chr21:45077557	HSF2BP	-0.53	-8.85	-0.48	1.3e-16	Mean corpuscular volume;
CESC	cis	rs6429082	0.818	rs696248	chr1:235668511	C/A	cg26050004	chr1:235667680	B3GALNT2	0.66	8.15	0.45	1.43e-14	Adiposity;
CESC	cis	rs826838	0.967	rs7963716	chr12:38876090	C/T	cg13010199	chr12:38710504	ALG10B	0.61	8.46	0.46	1.86e-15	Heart rate;
CESC	cis	rs2243480	1.000	rs1404147	chr7:65264524	C/T	cg18252515	chr7:66147081	NA	-1.15	-11.63	-0.58	1.57e-25	Diabetic kidney disease;
CESC	cis	rs10911251	0.509	rs4652780	chr1:183105923	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.84	13.34	0.63	2.05e-31	Colorectal cancer;
CESC	cis	rs7618915	0.501	rs55678971	chr3:52717229	T/A	cg05564831	chr3:52568323	NT5DC2	0.48	7.34	0.41	2.55e-12	Bipolar disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06077741	chr3:43121458	C3orf39	-0.6	-6.7	-0.38	1.23e-10	Gut microbiome composition (summer);
CESC	cis	rs12451471	0.559	rs12452263	chr17:78079310	T/C	cg06718696	chr17:78121285	EIF4A3	0.79	9.64	0.51	4.87e-19	Plateletcrit;Mean corpuscular hemoglobin concentration;
CESC	cis	rs875971	0.862	rs10261398	chr7:65750164	A/G	cg11764359	chr7:65958608	NA	-0.8	-12.02	-0.59	7.52e-27	Aortic root size;
CESC	cis	rs9814567	1.000	rs9856693	chr3:134306913	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.41	-5.55	-0.32	7.09e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	10.24	0.53	5.92e-21	Prudent dietary pattern;
CESC	cis	rs6502050	0.835	rs7222057	chr17:80087647	C/A	cg23985595	chr17:80112537	CCDC57	-0.42	-6.55	-0.37	2.99e-10	Life satisfaction;
CESC	cis	rs4909189	1.000	rs71547530	chr7:158135503	A/G	cg24154853	chr7:158122151	PTPRN2	0.51	6.43	0.37	5.99e-10	Response to amphetamines;
CESC	cis	rs514406	0.644	rs7530078	chr1:53204861	G/T	cg08859206	chr1:53392774	SCP2	0.64	9.35	0.5	3.74e-18	Monocyte count;
CESC	trans	rs1814175	0.645	rs1851849	chr11:50012164	G/A	cg15704280	chr7:45808275	SEPT13	-1.0	-18.49	-0.75	1.41e-49	Height;
CESC	cis	rs11690935	0.959	rs973889	chr2:172579954	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.96	-14.86	-0.67	9.31e-37	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08072980	chr7:50450320	IKZF1	-0.56	-6.98	-0.39	2.35e-11	Gut microbiome composition (summer);
CESC	cis	rs61931739	0.500	rs6488213	chr12:34393319	C/T	cg23762105	chr12:34175262	ALG10	-0.39	-5.14	-0.3	5.26e-7	Morning vs. evening chronotype;
CESC	cis	rs10392	0.543	rs58414555	chr20:37554152	A/C	cg27552599	chr20:37590471	DHX35	0.37	5.56	0.32	6.44e-8	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
CESC	cis	rs826838	1.000	rs11183747	chr12:38822595	A/G	cg26384229	chr12:38710491	ALG10B	-0.83	-14.5	-0.67	1.73e-35	Heart rate;
CESC	trans	rs5763662	1.000	rs5763854	chr22:30577589	A/G	cg13174343	chr10:51767556	AGAP6	0.65	6.1	0.35	3.65e-9	LDL cholesterol levels;LDL cholesterol;
CESC	cis	rs75920871	0.502	rs10790166	chr11:116779499	A/G	cg06541888	chr11:116658840	ZNF259	0.44	5.27	0.31	2.77e-7	Subjective well-being;
CESC	cis	rs35306767	0.903	rs11253494	chr10:937047	C/T	cg20503657	chr10:835505	NA	0.79	7.94	0.44	5.86e-14	Eosinophil percentage of granulocytes;
CESC	cis	rs2933343	0.729	rs789231	chr3:128602847	A/G	cg24203234	chr3:128598194	ACAD9	0.43	5.79	0.34	1.97e-8	IgG glycosylation;
CESC	cis	rs35160687	0.644	rs17738058	chr2:86513203	G/C	cg01119172	chr2:86362222	SNORD94;PTCD3	-0.38	-5.1	-0.3	6.45e-7	Night sleep phenotypes;
CESC	cis	rs9322193	0.962	rs3805752	chr6:150116626	C/T	cg13206674	chr6:150067644	NUP43	0.42	5.76	0.33	2.31e-8	Lung cancer;
CESC	cis	rs1538970	0.962	rs9429160	chr1:45827968	G/T	cg03146154	chr1:46216737	IPP	0.46	5.47	0.32	1.03e-7	Platelet count;
CESC	cis	rs7223966	1.000	rs7220821	chr17:61704147	G/A	cg11494091	chr17:61959527	GH2	0.39	5.51	0.32	8.35e-8	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs4601790	0.601	rs12801636	chr11:65391317	C/T	cg26668713	chr11:65405903	SIPA1	0.65	7.86	0.44	9.4e-14	Blood pressure (age interaction);
CESC	cis	rs1691799	0.899	rs1168310	chr12:66726355	A/G	cg16791601	chr12:66731901	HELB	0.62	10.01	0.52	3.26e-20	White blood cell count (basophil);
CESC	cis	rs6582630	0.555	rs11182217	chr12:38480030	G/A	cg13010199	chr12:38710504	ALG10B	0.49	6.37	0.36	8.46e-10	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs6028335	0.502	rs7265661	chr20:37586842	G/T	cg27552599	chr20:37590471	DHX35	0.38	5.57	0.32	6.39e-8	Alcohol and nicotine co-dependence;
CESC	cis	rs17253792	0.822	rs80328469	chr14:56067701	G/A	cg01858014	chr14:56050164	KTN1	-0.93	-7.33	-0.41	2.71e-12	Putamen volume;
CESC	trans	rs1814175	0.904	rs1846289	chr11:49620253	G/A	cg15704280	chr7:45808275	SEPT13	-1.0	-17.94	-0.74	1.14e-47	Height;
CESC	cis	rs10464366	0.746	rs17171537	chr7:39145647	C/T	cg18850127	chr7:39170497	POU6F2	0.36	5.06	0.3	7.85e-7	IgG glycosylation;
CESC	cis	rs2370759	1.000	rs16933177	chr10:32565705	G/A	cg18270830	chr10:32634957	EPC1	0.73	6.99	0.39	2.16e-11	Sexual dysfunction (female);
CESC	cis	rs9768139	0.733	rs34173461	chr7:158122175	C/G	cg27057461	chr7:158136379	PTPRN2	-0.35	-5.51	-0.32	8.6e-8	Calcium levels;
CESC	cis	rs4253772	0.591	rs6008595	chr22:46703860	A/T	cg10541313	chr22:46663664	TTC38	0.67	5.9	0.34	1.1e-8	LDL cholesterol;Cholesterol, total;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg08278194	chr3:39497860	NA	0.47	6.36	0.36	8.89e-10	Fibrinogen levels;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg22607980	chr1:89357197	GTF2B	-0.46	-6.14	-0.35	3.03e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs7666738	0.830	rs13140676	chr4:98804978	C/T	cg24818145	chr4:99064322	C4orf37	0.38	5.05	0.3	8.39e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs796364	0.951	rs35618222	chr2:201065777	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.63	5.8	0.34	1.85e-8	Schizophrenia;
CESC	cis	rs4727963	0.792	rs10953968	chr7:122716333	G/A	cg03640110	chr7:122635026	TAS2R16	0.41	6.57	0.37	2.72e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
CESC	cis	rs4665809	0.838	rs7565843	chr2:26292912	G/C	cg22920501	chr2:26401640	FAM59B	-0.69	-8.44	-0.46	2.06e-15	Gut microbiome composition (summer);
CESC	cis	rs854765	0.686	rs8065497	chr17:17782649	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.46	-6.08	-0.35	4.26e-9	Total body bone mineral density;
CESC	cis	rs7618915	0.501	rs3852066	chr3:52621839	C/T	cg05564831	chr3:52568323	NT5DC2	0.48	7.64	0.42	4.06e-13	Bipolar disorder;
CESC	cis	rs911555	0.755	rs2273702	chr14:103918182	C/G	cg09975044	chr14:104007538	NA	-0.46	-5.83	-0.34	1.59e-8	Intelligence (multi-trait analysis);
CESC	cis	rs9926296	0.656	rs2376883	chr16:89826926	A/G	cg27121462	chr16:89883253	FANCA	0.54	6.79	0.39	7.27e-11	Vitiligo;
CESC	cis	rs754466	0.651	rs56138814	chr10:79625795	T/C	cg17075019	chr10:79541650	NA	-0.85	-13.12	-0.63	1.25e-30	Liver enzyme levels (gamma-glutamyl transferase);
CESC	trans	rs916888	0.773	rs169201	chr17:44790203	A/G	cg04282206	chr17:62833786	PLEKHM1P	0.57	6.54	0.37	3.22e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs7772486	0.686	rs9390347	chr6:146044747	G/T	cg05347473	chr6:146136440	FBXO30	-0.52	-6.93	-0.39	3.22e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9583531	0.527	rs2391866	chr13:111363294	A/T	cg15841412	chr13:111365552	ING1	0.52	6.74	0.38	1.01e-10	Coronary artery disease;
CESC	cis	rs45535039	0.506	rs2511856	chr11:119144148	A/C	cg23558831	chr11:118978103	C2CD2L	-0.43	-5.23	-0.31	3.51e-7	Plateletcrit;
CESC	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg06074448	chr4:187884817	NA	-0.37	-5.4	-0.31	1.5e-7	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2243480	1.000	rs7778911	chr7:65694506	T/C	cg12463550	chr7:65579703	CRCP	-0.74	-5.73	-0.33	2.74e-8	Diabetic kidney disease;
CESC	cis	rs1448094	0.511	rs56291271	chr12:86162287	G/A	cg02569458	chr12:86230093	RASSF9	0.49	7.68	0.43	3.15e-13	Major depressive disorder;
CESC	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg18765753	chr7:1198926	ZFAND2A	-0.43	-6.4	-0.37	7.1e-10	Longevity;Endometriosis;
CESC	cis	rs9486719	1.000	rs3798295	chr6:97052164	C/T	cg06623918	chr6:96969491	KIAA0776	-0.82	-8.4	-0.46	2.7e-15	Migraine;Coronary artery disease;
CESC	cis	rs7618915	0.547	rs2268026	chr3:52778347	T/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.49	0.37	4.1e-10	Bipolar disorder;
CESC	cis	rs7666738	0.830	rs732299	chr4:98995389	C/T	cg03676636	chr4:99064102	C4orf37	0.33	5.13	0.3	5.51e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs950776	0.518	rs8053	chr15:78841220	T/C	cg24631222	chr15:78858424	CHRNA5	0.39	5.06	0.3	7.72e-7	Sudden cardiac arrest;
CESC	cis	rs6542838	0.702	rs6739176	chr2:99536846	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.42	-5.36	-0.31	1.78e-7	Fear of minor pain;
CESC	cis	rs870825	0.550	rs59051283	chr4:185646476	C/T	cg04058563	chr4:185651563	MLF1IP	0.63	6.96	0.39	2.59e-11	Blood protein levels;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg04983327	chr17:25289961	NA	-0.43	-6.3	-0.36	1.24e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs6495122	0.699	rs3784789	chr15:75082552	C/G	cg09165964	chr15:75287851	SCAMP5	0.4	5.22	0.31	3.55e-7	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
CESC	cis	rs3892630	0.588	rs2112917	chr19:33317543	C/T	cg22980127	chr19:33182716	NUDT19	1.16	14.45	0.66	2.76e-35	Red blood cell traits;
CESC	cis	rs9911578	0.835	rs58647683	chr17:56483194	T/C	cg12560992	chr17:57184187	TRIM37	-0.89	-14.85	-0.67	1.07e-36	Intelligence (multi-trait analysis);
CESC	cis	rs6754311	0.550	rs10173394	chr2:136522675	C/T	cg07169764	chr2:136633963	MCM6	-0.73	-9.13	-0.49	1.78e-17	Mosquito bite size;
CESC	cis	rs16866061	1.000	rs72972378	chr2:225372562	A/G	cg12698349	chr2:225449008	CUL3	0.73	10.85	0.55	6e-23	Acute graft versus host disease in bone marrow transplantation (recipient effect);
CESC	cis	rs9322193	0.923	rs11155671	chr6:149972132	G/A	cg13206674	chr6:150067644	NUP43	0.43	6.26	0.36	1.53e-9	Lung cancer;
CESC	cis	rs4722166	0.541	rs1800795	chr7:22766645	C/G	cg05265849	chr7:22767390	IL6	0.51	6.71	0.38	1.19e-10	Lung cancer;
CESC	cis	rs6690583	0.562	rs76839162	chr1:85530021	A/G	cg22153463	chr1:85462885	MCOLN2	0.72	6.93	0.39	3.2e-11	Serum sulfate level;
CESC	cis	rs2230307	0.536	rs11166384	chr1:100439890	C/T	cg24955406	chr1:100503596	HIAT1	0.55	5.48	0.32	9.85e-8	Carotid intima media thickness;
CESC	cis	rs4803468	1.000	rs284649	chr19:41926838	C/T	cg14132834	chr19:41945861	ATP5SL	-0.67	-8.35	-0.46	3.74e-15	Height;
CESC	trans	rs5756813	0.754	rs15691	chr22:38172380	C/A	cg19894588	chr14:64061835	NA	-0.7	-8.74	-0.47	2.75e-16	Optic cup area;Vertical cup-disc ratio;
CESC	cis	rs651907	0.535	rs35799195	chr3:101521927	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.46	6.05	0.35	4.95e-9	Colorectal cancer;
CESC	cis	rs6582630	0.576	rs4882372	chr12:38356609	C/A	cg26384229	chr12:38710491	ALG10B	-0.46	-6.06	-0.35	4.72e-9	Drug-induced liver injury (flucloxacillin);
CESC	trans	rs11098499	0.954	rs6857105	chr4:120222298	C/G	cg25214090	chr10:38739885	LOC399744	0.65	8.95	0.48	6.35e-17	Corneal astigmatism;
CESC	cis	rs17253792	0.908	rs74354306	chr14:56065778	T/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.85	6.13	0.35	3.15e-9	Putamen volume;
CESC	cis	rs12477438	0.765	rs6722164	chr2:99561527	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.63	-8.83	-0.48	1.47e-16	Chronic sinus infection;
CESC	cis	rs367943	0.901	rs348951	chr5:112822017	G/C	cg12552261	chr5:112820674	MCC	-0.63	-7.94	-0.44	5.83e-14	Type 2 diabetes;
CESC	cis	rs11750568	1.000	rs11750568	chr5:178535713	A/G	cg10208897	chr5:178548229	ADAMTS2	0.39	5.49	0.32	9.51e-8	Height;
CESC	cis	rs8067354	0.645	rs11079389	chr17:57887952	G/A	cg13753209	chr17:57696993	CLTC	0.56	6.3	0.36	1.21e-9	Hemoglobin concentration;
CESC	cis	rs12681288	0.823	rs12681230	chr8:994422	G/A	cg15309053	chr8:964076	NA	0.32	5.37	0.31	1.73e-7	Schizophrenia;
CESC	cis	rs4523957	0.651	rs9898819	chr17:2076352	G/A	cg16513277	chr17:2031491	SMG6	-0.68	-9.44	-0.5	1.94e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs1707322	1.000	rs1707337	chr1:46508769	A/G	cg03146154	chr1:46216737	IPP	-0.72	-9.73	-0.51	2.49e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs1552244	0.882	rs67895180	chr3:10026079	T/C	cg08888203	chr3:10149979	C3orf24	0.49	6.17	0.35	2.49e-9	Alzheimer's disease;
CESC	trans	rs117533700	1.000	rs10423956	chr19:13170224	C/T	cg24196017	chr15:43021976	CDAN1	-0.76	-6.03	-0.35	5.61e-9	Monocyte count;
CESC	cis	rs6952808	0.609	rs6950151	chr7:1953521	T/C	cg03354898	chr7:1950403	MAD1L1	-0.31	-5.18	-0.3	4.49e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs4901869	0.966	rs4901868	chr14:59333792	C/T	cg02291164	chr14:59296302	NA	-0.44	-7.6	-0.42	4.97e-13	Panic disorder;
CESC	cis	rs7660520	1.000	rs7660520	chr4:183745321	C/T	cg07132183	chr4:182873955	NA	0.37	5.08	0.3	7.27e-7	Pediatric autoimmune diseases;
CESC	cis	rs11608355	0.545	rs56144717	chr12:109902304	T/C	cg05360138	chr12:110035743	NA	0.82	8.92	0.48	7.93e-17	Neuroticism;
CESC	cis	rs9467711	0.606	rs66827971	chr6:26365766	T/C	cg14345882	chr6:26364793	BTN3A2	0.6	6.17	0.35	2.57e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs2230307	0.536	rs640030	chr1:100574992	C/T	cg24955406	chr1:100503596	HIAT1	-0.52	-5.13	-0.3	5.69e-7	Carotid intima media thickness;
CESC	trans	rs1908814	0.516	rs13281315	chr8:11794855	C/G	cg15556689	chr8:8085844	FLJ10661	0.51	6.33	0.36	1.02e-9	Neuroticism;
CESC	cis	rs2404602	0.716	rs12594577	chr15:76828793	A/C	cg26408565	chr15:76604113	ETFA	-0.42	-6.08	-0.35	4.29e-9	Blood metabolite levels;
CESC	cis	rs4253772	1.000	rs11705483	chr22:46630544	C/A	cg00784671	chr22:46762841	CELSR1	-0.57	-5.63	-0.33	4.54e-8	LDL cholesterol;Cholesterol, total;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13885159	chr11:62473858	BSCL2;GNG3	0.65	7.87	0.44	9.35e-14	Gut microbiome composition (summer);
CESC	cis	rs798554	0.704	rs709282	chr7:2769921	G/A	cg09658497	chr7:2847517	GNA12	-0.36	-5.43	-0.32	1.24e-7	Height;
CESC	trans	rs9858542	0.953	rs1873625	chr3:49666964	C/A	cg21659725	chr3:3221576	CRBN	-0.52	-6.31	-0.36	1.14e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs35110281	0.659	rs2236667	chr21:45112939	A/G	cg21573476	chr21:45109991	RRP1B	-0.56	-8.45	-0.46	1.97e-15	Mean corpuscular volume;
CESC	trans	rs7246760	0.609	rs12459250	chr19:9909543	C/T	cg02900749	chr2:68251473	NA	-0.73	-6.52	-0.37	3.46e-10	Pursuit maintenance gain;
CESC	trans	rs916888	0.610	rs199536	chr17:44820425	T/C	cg10053473	chr17:62856997	LRRC37A3	0.66	9.26	0.49	7.05e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs17376456	0.825	rs28610997	chr5:93248374	T/C	cg25358565	chr5:93447407	FAM172A	1.13	10.1	0.53	1.69e-20	Diabetic retinopathy;
CESC	trans	rs61931739	0.500	rs11053271	chr12:34545407	C/A	cg26384229	chr12:38710491	ALG10B	0.72	10.84	0.55	6.43e-23	Morning vs. evening chronotype;
CESC	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg26338869	chr17:61819248	STRADA	0.7	9.28	0.5	6.1e-18	Prudent dietary pattern;
CESC	cis	rs597539	0.690	rs11228383	chr11:68623228	T/G	cg18350739	chr11:68623251	NA	-0.46	-6.64	-0.38	1.73e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs11958404	1.000	rs11958404	chr5:157410278	A/T	cg05962755	chr5:157440814	NA	0.51	5.74	0.33	2.64e-8	IgG glycosylation;
CESC	cis	rs875971	0.862	rs6959268	chr7:65812966	G/A	cg11764359	chr7:65958608	NA	-0.8	-11.89	-0.59	2.01e-26	Aortic root size;
CESC	cis	rs5753618	0.539	rs5997933	chr22:31672752	A/C	cg13145458	chr22:31556086	RNF185	0.48	5.36	0.31	1.8e-7	Colorectal cancer;
CESC	cis	rs643506	1.000	rs4936675	chr11:111623088	T/A	cg09085632	chr11:111637200	PPP2R1B	0.55	7.01	0.4	1.92e-11	Breast cancer;
CESC	cis	rs1971256	0.500	rs3912290	chr6:151818297	T/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.63	6.03	0.35	5.34e-9	Endometriosis;
CESC	cis	rs4986172	0.726	rs12051846	chr17:43226887	A/G	cg10701640	chr17:43249399	NA	0.43	6.86	0.39	4.81e-11	Height;
CESC	cis	rs6963495	0.818	rs73192113	chr7:105169603	C/T	cg02135003	chr7:105160482	PUS7	-0.46	-5.5	-0.32	9.1e-8	Bipolar disorder (body mass index interaction);
CESC	cis	rs6879260	1.000	rs6874653	chr5:179730843	A/G	cg23221052	chr5:179740743	GFPT2	-0.63	-8.17	-0.45	1.31e-14	Height;
CESC	trans	rs17132261	1.000	rs17132029	chr5:109702488	A/G	cg17540356	chr11:69632220	FGF3	-0.61	-6.02	-0.35	5.82e-9	Cardiac structure and function;Left ventricle wall thickness;
CESC	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.45	5.29	0.31	2.52e-7	Renal function-related traits (BUN);
CESC	cis	rs3806843	0.705	rs2530230	chr5:140088131	G/A	cg16179182	chr5:140090404	VTRNA1-1	0.45	5.88	0.34	1.24e-8	Depressive symptoms (multi-trait analysis);
CESC	cis	rs7618501	0.633	rs9861216	chr3:50059339	A/G	cg24308560	chr3:49941425	MST1R	0.63	9.43	0.5	2.24e-18	Intelligence (multi-trait analysis);
CESC	cis	rs1707322	0.717	rs10890345	chr1:46213927	C/T	cg05343316	chr1:45956843	TESK2	0.51	6.32	0.36	1.09e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7843479	0.965	rs3816786	chr8:21860425	A/T	cg17168535	chr8:21777572	XPO7	0.44	6.08	0.35	4.17e-9	Mean corpuscular volume;
CESC	cis	rs449303	1	rs449303	chr14:60605788	A/G	cg00846580	chr14:60632234	DHRS7	0.76	7.15	0.4	8.6e-12	Age-related hearing impairment (SNP x SNP interaction);
CESC	trans	rs2018683	0.834	rs733485	chr7:29026685	C/A	cg19402173	chr7:128379420	CALU	-0.6	-7.51	-0.42	8.79e-13	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CESC	cis	rs7916410	0.512	rs1900003	chr10:70004551	A/C	cg06988349	chr10:69991859	ATOH7	0.39	6.39	0.37	7.5e-10	Optic disc area;
CESC	cis	rs539096	0.501	rs713191	chr1:44314553	A/G	cg13606994	chr1:44402422	ARTN	-0.35	-5.14	-0.3	5.31e-7	Intelligence (multi-trait analysis);
CESC	cis	rs7552404	1.000	rs2133134	chr1:76179587	G/A	cg03433033	chr1:76189801	ACADM	0.66	7.79	0.43	1.55e-13	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs7772486	0.624	rs9485018	chr6:146025731	T/C	cg23711669	chr6:146136114	FBXO30	-0.86	-12.62	-0.61	6.46e-29	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1580019	0.961	rs766657	chr7:32499510	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.73	10.11	0.53	1.51e-20	Cognitive ability;
CESC	cis	rs7660520	0.524	rs6839881	chr4:183729137	A/T	cg12524338	chr4:183729343	NA	0.51	5.3	0.31	2.4e-7	Pediatric autoimmune diseases;
CESC	cis	rs3820068	0.705	rs4646091	chr1:15822043	T/C	cg17385448	chr1:15911702	AGMAT	0.39	6.18	0.35	2.44e-9	Systolic blood pressure;
CESC	cis	rs738322	0.804	rs4821743	chr22:38514906	A/G	cg17652424	chr22:38574118	PLA2G6	-0.29	-5.1	-0.3	6.59e-7	Cutaneous nevi;
CESC	cis	rs7580658	0.613	rs12478656	chr2:128196520	G/T	cg10021288	chr2:128175891	PROC	-0.4	-5.95	-0.34	8.5e-9	Protein C levels;
CESC	cis	rs8177253	0.761	rs13079426	chr3:133522334	A/G	cg12373951	chr3:133503437	NA	0.51	7.56	0.42	6.74e-13	Iron status biomarkers;
CESC	cis	rs7552404	0.691	rs1770890	chr1:76401117	A/G	cg03433033	chr1:76189801	ACADM	-0.56	-6.06	-0.35	4.61e-9	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs3749237	0.595	rs11130196	chr3:49490149	A/C	cg07636037	chr3:49044803	WDR6	0.64	9.28	0.5	6.11e-18	Resting heart rate;
CESC	cis	rs2933343	0.700	rs1683777	chr3:128624880	T/G	cg24203234	chr3:128598194	ACAD9	0.39	5.25	0.31	3.19e-7	IgG glycosylation;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03383661	chr6:42714115	TBCC	0.52	6.74	0.38	9.91e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	22.35	0.81	6.51e-63	Prudent dietary pattern;
CESC	cis	rs727505	0.909	rs1031957	chr7:124627301	T/C	cg23710748	chr7:124431027	NA	-0.45	-7.05	-0.4	1.51e-11	Lewy body disease;
CESC	cis	rs4654899	0.758	rs4457549	chr1:21487231	A/G	cg05370193	chr1:21551575	ECE1	-0.38	-5.68	-0.33	3.47e-8	Superior frontal gyrus grey matter volume;
CESC	cis	rs55728055	0.661	rs55894054	chr22:31976299	T/C	cg01338084	chr22:32026380	PISD	1.26	8.55	0.47	9.7e-16	Age-related hearing impairment;
CESC	cis	rs9487051	0.872	rs9480922	chr6:109607211	G/A	cg01475377	chr6:109611718	NA	-0.52	-8.56	-0.47	9.05e-16	Reticulocyte fraction of red cells;
CESC	cis	rs9790314	1.000	rs336543	chr3:161061080	C/T	cg04691961	chr3:161091175	C3orf57	0.45	5.8	0.34	1.91e-8	Morning vs. evening chronotype;
CESC	cis	rs7937682	0.774	rs59921976	chr11:111473088	G/A	cg22437258	chr11:111473054	SIK2	0.74	9.81	0.52	1.38e-19	Primary sclerosing cholangitis;
CESC	cis	rs3936840	0.514	rs8007356	chr14:102975266	G/A	cg18135206	chr14:102964638	TECPR2	0.46	5.87	0.34	1.29e-8	Plateletcrit;
CESC	cis	rs1008375	1.000	rs7659718	chr4:17638020	A/C	cg16339924	chr4:17578868	LAP3	0.66	8.45	0.46	1.95e-15	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs2576037	0.899	rs12955429	chr18:44585484	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.38	-5.74	-0.33	2.59e-8	Personality dimensions;
CESC	cis	rs6963495	0.818	rs711430	chr7:105167969	A/G	cg13798780	chr7:105162888	PUS7	0.6	6.94	0.39	2.96e-11	Bipolar disorder (body mass index interaction);
CESC	cis	rs9596863	1.000	rs9596862	chr13:54432908	A/G	ch.13.53330881F	chr13:54432880	NA	0.66	5.25	0.31	3.08e-7	Epilepsy and lamotrigine-induced maculopapular eruptions;
CESC	cis	rs17711722	0.640	rs13237956	chr7:65318029	G/A	cg05332525	chr7:65337924	VKORC1L1	0.52	6.41	0.37	6.6e-10	Calcium levels;
CESC	cis	rs11098499	0.909	rs28793658	chr4:120307214	A/C	cg24375607	chr4:120327624	NA	0.46	5.55	0.32	6.98e-8	Corneal astigmatism;
CESC	cis	rs113835537	0.529	rs3741360	chr11:66300348	A/G	cg24851651	chr11:66362959	CCS	0.5	5.98	0.34	7.08e-9	Airway imaging phenotypes;
CESC	cis	rs2204008	0.782	rs117824012	chr12:38215517	T/C	cg26384229	chr12:38710491	ALG10B	0.74	10.7	0.55	1.96e-22	Bladder cancer;
CESC	cis	rs514406	0.505	rs374849	chr1:53185631	G/A	cg16325326	chr1:53192061	ZYG11B	0.9	15.22	0.68	5.29e-38	Monocyte count;
CESC	cis	rs425277	0.585	rs364677	chr1:2071765	A/G	cg23803603	chr1:2058230	PRKCZ	-0.31	-5.32	-0.31	2.26e-7	Height;
CESC	cis	rs1538970	0.924	rs1006216	chr1:45909994	A/G	cg03146154	chr1:46216737	IPP	0.46	5.34	0.31	1.97e-7	Platelet count;
CESC	cis	rs7809950	0.678	rs62483641	chr7:106901741	T/C	cg23024343	chr7:107201750	COG5	-0.54	-6.79	-0.38	7.55e-11	Coronary artery disease;
CESC	cis	rs853679	0.882	rs3757188	chr6:28107357	T/C	cg26335602	chr6:28129616	ZNF389	0.53	5.23	0.31	3.42e-7	Depression;
CESC	trans	rs2727020	0.553	rs3907576	chr11:49536639	A/C	cg15704280	chr7:45808275	SEPT13	-0.94	-16.08	-0.7	4.42e-41	Coronary artery disease;
CESC	cis	rs11122272	0.735	rs2808592	chr1:231523757	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.57	-7.82	-0.43	1.29e-13	Hemoglobin concentration;
CESC	cis	rs7927771	0.839	rs11039308	chr11:47622412	G/A	cg05585544	chr11:47624801	NA	-0.42	-6.58	-0.37	2.54e-10	Subjective well-being;
CESC	cis	rs72949976	0.966	rs6752061	chr2:214027818	C/T	cg08319019	chr2:214017104	IKZF2	-0.45	-5.76	-0.33	2.34e-8	Lung cancer;Squamous cell lung carcinoma;
CESC	cis	rs6952808	0.689	rs11771625	chr7:2050401	C/T	cg04267008	chr7:1944627	MAD1L1	-0.62	-7.46	-0.42	1.27e-12	Bipolar disorder and schizophrenia;
CESC	cis	rs2228479	0.681	rs8044906	chr16:89969603	T/C	cg04013166	chr16:89971882	TCF25	0.69	8.01	0.44	3.67e-14	Skin colour saturation;
CESC	cis	rs11718455	0.960	rs11929518	chr3:44016874	A/G	cg08738300	chr3:44038990	NA	0.47	5.98	0.35	7.01e-9	Coronary artery disease;
CESC	cis	rs9790314	0.765	rs4856768	chr3:161004392	G/A	cg03342759	chr3:160939853	NMD3	-0.46	-6.29	-0.36	1.28e-9	Morning vs. evening chronotype;
CESC	cis	rs11247915	0.600	rs3795686	chr1:26582091	G/A	cg04990556	chr1:26633338	UBXN11	-0.64	-7.08	-0.4	1.26e-11	Obesity-related traits;
CESC	cis	rs2487048	0.725	rs2246293	chr9:107690838	C/G	cg14470647	chr9:107690075	ABCA1	0.58	7.35	0.41	2.44e-12	Intraocular pressure;
CESC	cis	rs2425143	0.908	rs58448091	chr20:34325470	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.8	-7.51	-0.42	9.02e-13	Blood protein levels;
CESC	cis	rs7727544	1.000	rs7727038	chr5:131590257	C/T	cg24060327	chr5:131705240	SLC22A5	-0.41	-5.15	-0.3	5.07e-7	Blood metabolite levels;
CESC	cis	rs875971	0.862	rs1860469	chr7:66106875	A/G	cg11764359	chr7:65958608	NA	-0.7	-9.73	-0.51	2.51e-19	Aortic root size;
CESC	cis	rs643506	0.874	rs613292	chr11:111668805	C/T	cg09085632	chr11:111637200	PPP2R1B	0.39	5.12	0.3	5.9e-7	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17184704	chr10:11727286	NA	-0.59	-6.95	-0.39	2.75e-11	Gut microbiome composition (summer);
CESC	cis	rs1707322	0.929	rs785500	chr1:46593044	C/T	cg03146154	chr1:46216737	IPP	-0.69	-9.13	-0.49	1.84e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs1814175	0.645	rs1721997	chr11:49916653	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.43	-6.36	-0.36	8.98e-10	Height;
CESC	cis	rs1008375	0.931	rs979823	chr4:17700176	G/A	cg16339924	chr4:17578868	LAP3	0.62	7.63	0.42	4.31e-13	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs17376456	0.825	rs28705226	chr5:93233135	T/C	cg21475434	chr5:93447410	FAM172A	0.74	6.6	0.38	2.26e-10	Diabetic retinopathy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11649068	chr17:34136647	TAF15	0.57	6.97	0.39	2.46e-11	Gut microbiome composition (summer);
CESC	cis	rs6963495	0.818	rs117845382	chr7:105152040	T/C	cg19920283	chr7:105172520	RINT1	0.67	6.36	0.36	8.79e-10	Bipolar disorder (body mass index interaction);
CESC	cis	rs10206020	0.879	rs72778007	chr2:1573178	C/T	cg26248373	chr2:1572462	NA	-0.61	-7.13	-0.4	9.41e-12	IgG glycosylation;
CESC	cis	rs4835473	0.932	rs1473055	chr4:144918867	A/G	cg25736465	chr4:144833511	NA	0.42	6.28	0.36	1.38e-9	Immature fraction of reticulocytes;
CESC	cis	rs2075371	0.933	rs1421480	chr7:133958114	A/C	cg20476274	chr7:133979776	SLC35B4	0.68	9.88	0.52	8.59e-20	Mean platelet volume;
CESC	cis	rs3768617	1.000	rs2027077	chr1:183073453	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.66	9.34	0.5	4.21e-18	Fuchs's corneal dystrophy;
CESC	cis	rs17376456	0.877	rs12716456	chr5:93397557	A/G	cg25358565	chr5:93447407	FAM172A	1.11	11.19	0.57	4.56e-24	Diabetic retinopathy;
CESC	cis	rs6952808	0.630	rs10239050	chr7:2158390	A/G	cg23048001	chr7:2026167	MAD1L1	0.46	6.0	0.35	6.39e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs6738485	0.507	rs66569888	chr2:106886967	G/A	cg15412446	chr2:106886593	NA	-0.67	-6.4	-0.37	6.9e-10	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
CESC	cis	rs4595586	0.632	rs1356266	chr12:39403581	A/G	cg26384229	chr12:38710491	ALG10B	-0.4	-5.72	-0.33	2.86e-8	Morning vs. evening chronotype;
CESC	cis	rs2130392	0.924	rs873687	chr4:185638853	G/A	cg21366198	chr4:185655624	MLF1IP	0.42	5.86	0.34	1.37e-8	Kawasaki disease;
CESC	cis	rs4711336	1.000	rs2229642	chr6:33659472	C/G	cg14003231	chr6:33640908	ITPR3	0.32	5.42	0.32	1.34e-7	Height;
CESC	cis	rs2072499	0.966	rs2842882	chr1:156165342	T/G	cg06970220	chr1:156163860	SLC25A44	0.39	5.22	0.31	3.67e-7	Testicular germ cell tumor;
CESC	cis	rs1552244	1.000	rs9879080	chr3:10084224	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.87	11.76	0.59	5.62e-26	Alzheimer's disease;
CESC	cis	rs6582630	0.519	rs12819814	chr12:38332568	G/C	cg13010199	chr12:38710504	ALG10B	0.45	5.82	0.34	1.69e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs2243480	1.000	rs4145008	chr7:65647511	T/G	cg13147721	chr7:65941812	NA	0.97	9.16	0.49	1.47e-17	Diabetic kidney disease;
CESC	cis	rs60871478	0.636	rs56393680	chr7:885696	A/G	cg15782153	chr7:917662	C7orf20	0.53	5.6	0.33	5.47e-8	Cerebrospinal P-tau181p levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11346722	chr6:34512215	SPDEF	-0.49	-6.65	-0.38	1.67e-10	Gut microbiome composition (summer);
CESC	cis	rs1552244	0.935	rs7652190	chr3:10105150	G/A	cg00166722	chr3:10149974	C3orf24	0.52	6.38	0.36	7.91e-10	Alzheimer's disease;
CESC	cis	rs208520	0.526	rs6913344	chr6:66754285	A/C	cg07460842	chr6:66804631	NA	-1.01	-20.77	-0.79	1.56e-57	Exhaled nitric oxide output;
CESC	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.6	0.38	2.17e-10	Prudent dietary pattern;
CESC	cis	rs11112613	0.762	rs73184078	chr12:105950017	A/G	cg03607813	chr12:105948248	NA	0.67	8.31	0.45	5.16e-15	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CESC	cis	rs6674176	0.569	rs34830883	chr1:44405339	T/C	cg12908607	chr1:44402522	ARTN	-0.49	-7.48	-0.42	1.09e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg22338127	chr1:209979572	IRF6	0.56	8.78	0.47	2.05e-16	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
CESC	cis	rs7208859	0.623	rs9915566	chr17:29132158	G/A	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.1e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs896854	0.517	rs2013597	chr8:95951807	G/A	cg16049864	chr8:95962084	TP53INP1	-0.54	-7.64	-0.42	3.92e-13	Type 2 diabetes;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg08891424	chr2:190648631	ORMDL1;PMS1	-0.41	-6.21	-0.36	2.06e-9	Gambling;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg27359633	chr20:33104463	DYNLRB1	-0.38	-6.11	-0.35	3.48e-9	Gambling;
CESC	cis	rs11690935	0.959	rs2292815	chr2:172586651	C/G	cg13550731	chr2:172543902	DYNC1I2	-0.96	-14.09	-0.65	4.92e-34	Schizophrenia;
CESC	trans	rs2109514	0.505	rs1633714	chr7:116022538	C/T	cg14091419	chr15:28356810	HERC2	0.46	6.5	0.37	3.89e-10	Prevalent atrial fibrillation;
CESC	cis	rs7216064	1.000	rs62084238	chr17:65856573	T/A	cg12091567	chr17:66097778	LOC651250	-0.83	-8.3	-0.45	5.54e-15	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs11098499	0.821	rs28665282	chr4:120384186	C/T	cg24375607	chr4:120327624	NA	0.45	5.52	0.32	8.05e-8	Corneal astigmatism;
CESC	cis	rs875971	0.895	rs10755833	chr7:65913917	A/G	cg10691866	chr7:65817282	TPST1	-0.34	-5.62	-0.33	4.93e-8	Aortic root size;
CESC	cis	rs7666738	0.830	rs79075162	chr4:98960674	A/T	cg03467027	chr4:99064603	C4orf37	0.44	5.57	0.32	6.41e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9388451	0.807	rs1268070	chr6:126041164	A/G	cg05901451	chr6:126070800	HEY2	-0.6	-8.3	-0.45	5.25e-15	Brugada syndrome;
CESC	cis	rs832540	0.618	rs41106	chr5:56145057	G/T	cg22800045	chr5:56110881	MAP3K1	0.49	5.88	0.34	1.24e-8	Coronary artery disease;
CESC	cis	rs7258465	1.000	rs10164319	chr19:18569833	G/A	cg25828334	chr19:18545568	ISYNA1	-0.32	-5.16	-0.3	4.8e-7	Breast cancer;
CESC	cis	rs2235642	0.691	rs2281235	chr16:1603535	T/C	cg03771183	chr16:1608904	IFT140	0.41	5.95	0.34	8.47e-9	Coronary artery disease;
CESC	cis	rs7927771	0.965	rs4752881	chr11:47898535	A/G	cg18512352	chr11:47633146	NA	-0.62	-9.65	-0.51	4.44e-19	Subjective well-being;
CESC	cis	rs854765	0.547	rs2955385	chr17:17939247	C/T	cg16928487	chr17:17741425	SREBF1	-0.55	-9.28	-0.5	6.45e-18	Total body bone mineral density;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15652989	chr16:69222106	SNTB2	-0.54	-6.08	-0.35	4.2e-9	Gut microbiome composition (summer);
CESC	cis	rs4253772	0.591	rs113101219	chr22:46659186	C/A	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.6	5.29	0.31	2.61e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs372883	0.530	rs2832302	chr21:30749793	G/T	cg24692254	chr21:30365293	RNF160	-0.49	-6.06	-0.35	4.64e-9	Pancreatic cancer;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg19434433	chr17:44849214	WNT3	0.44	6.21	0.36	2.09e-9	Thyroid stimulating hormone;
CESC	cis	rs1552244	1.000	rs7648104	chr3:10073311	C/A	cg08888203	chr3:10149979	C3orf24	0.46	5.9	0.34	1.11e-8	Alzheimer's disease;
CESC	cis	rs8103278	0.507	rs4802275	chr19:46260375	C/T	cg11657440	chr19:46296263	DMWD	0.78	11.89	0.59	2.1e-26	Coronary artery disease;
CESC	cis	rs6933660	0.760	rs3806982	chr6:151774916	G/A	cg02564969	chr6:151773285	C6orf211;RMND1	0.62	8.49	0.46	1.49e-15	Menarche (age at onset);
CESC	cis	rs6736093	0.966	rs11679801	chr2:112712835	G/A	cg12686935	chr2:112915763	FBLN7	-0.42	-5.3	-0.31	2.49e-7	Coronary artery disease;
CESC	cis	rs10227331	1.000	rs10227331	chr7:157294938	A/T	cg04156418	chr7:157293606	NA	0.31	5.26	0.31	2.96e-7	Inattentive symptoms;
CESC	cis	rs6570726	0.791	rs6570695	chr6:145911286	C/A	cg23711669	chr6:146136114	FBXO30	0.92	13.58	0.64	3.16e-32	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs1728785	0.901	rs1170444	chr16:68573287	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.61	7.44	0.42	1.41e-12	Ulcerative colitis;
CESC	cis	rs17666538	0.636	rs10107345	chr8:603700	G/T	cg07685180	chr8:600429	NA	0.6	5.23	0.31	3.52e-7	IgG glycosylation;
CESC	cis	rs9902453	0.691	rs140701	chr17:28538532	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.51	6.19	0.36	2.29e-9	Coffee consumption (cups per day);
CESC	cis	rs400736	0.671	rs2131630	chr1:7990367	G/A	cg25007680	chr1:8021821	PARK7	-0.57	-8.16	-0.45	1.35e-14	Response to antidepressants and depression;
CESC	cis	rs2836974	0.644	rs11088471	chr21:40699313	A/G	cg11644478	chr21:40555479	PSMG1	-0.78	-11.45	-0.58	6.12e-25	Cognitive function;
CESC	cis	rs9905704	0.681	rs2680710	chr17:56552902	A/G	cg12560992	chr17:57184187	TRIM37	-0.62	-5.8	-0.34	1.86e-8	Testicular germ cell tumor;
CESC	cis	rs2050392	0.590	rs694346	chr10:30711929	C/T	cg25182066	chr10:30743637	MAP3K8	-0.46	-5.91	-0.34	1.03e-8	Inflammatory bowel disease;
CESC	cis	rs897080	0.552	rs1067326	chr2:44628605	T/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	5.91	0.34	1.07e-8	Height;
CESC	cis	rs7618915	0.547	rs11720432	chr3:52672742	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.48	6.81	0.39	6.58e-11	Bipolar disorder;
CESC	cis	rs6723226	0.765	rs12612824	chr2:32579759	C/T	cg02381751	chr2:32503542	YIPF4	-0.91	-12.8	-0.62	1.55e-29	Intelligence (multi-trait analysis);
CESC	cis	rs9788333	0.962	rs12584792	chr13:21887208	C/T	cg23743428	chr13:21893420	NA	-0.38	-6.1	-0.35	3.69e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.64	7.2	0.4	6.35e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs6570726	0.516	rs10457779	chr6:145736663	C/T	cg23711669	chr6:146136114	FBXO30	0.54	6.76	0.38	8.53e-11	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg18103236	chr10:81060645	ZMIZ1	0.46	6.19	0.36	2.23e-9	Fibrinogen levels;
CESC	cis	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg13880726	chr7:1868755	MAD1L1	0.4	5.28	0.31	2.72e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs892961	0.932	rs67415822	chr17:75412678	A/G	cg05865280	chr17:75406074	SEPT9	0.62	12.67	0.61	4.57e-29	Airflow obstruction;
CESC	cis	rs117623576	0.941	rs17488859	chr10:32386072	A/G	cg03047570	chr10:32398778	NA	0.72	6.7	0.38	1.25e-10	Anti-saccade response;
CESC	cis	rs9287719	0.967	rs10203785	chr2:10752508	T/C	cg00105475	chr2:10696890	NA	0.38	5.42	0.32	1.34e-7	Prostate cancer;
CESC	cis	rs1448094	0.512	rs1900701	chr12:86236231	T/C	cg02569458	chr12:86230093	RASSF9	0.48	7.11	0.4	1.07e-11	Major depressive disorder;
CESC	cis	rs7618915	0.571	rs6805539	chr3:52609710	T/A	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.33	5.76	0.33	2.39e-8	Bipolar disorder;
CESC	cis	rs72781680	0.752	rs72780185	chr2:24003967	G/A	cg20701182	chr2:24300061	SF3B14	0.63	5.65	0.33	4.21e-8	Lymphocyte counts;
CESC	cis	rs12477438	0.520	rs6741773	chr2:99738962	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	15.15	0.68	9.04e-38	Chronic sinus infection;
CESC	cis	rs8064299	0.967	rs878906	chr17:72769334	T/C	cg25054828	chr17:72772726	NAT9;TMEM104	0.64	9.21	0.49	9.94e-18	Monocyte count;
CESC	cis	rs10979	0.557	rs9390120	chr6:143909411	A/G	cg25407410	chr6:143891975	LOC285740	-0.49	-6.46	-0.37	4.95e-10	Hypospadias;
CESC	cis	rs9911578	1.000	rs10401050	chr17:56953786	A/C	cg05425664	chr17:57184151	TRIM37	-0.5	-6.96	-0.39	2.6e-11	Intelligence (multi-trait analysis);
CESC	cis	rs7474896	0.515	rs662928	chr10:38316216	G/T	cg25427524	chr10:38739819	LOC399744	0.48	5.48	0.32	9.76e-8	Obesity (extreme);
CESC	cis	rs3096299	0.632	rs4399533	chr16:89539382	G/C	cg02187348	chr16:89574699	SPG7	0.64	8.94	0.48	7.01e-17	Multiple myeloma (IgH translocation);
CESC	cis	rs12497850	0.866	rs6791234	chr3:48996137	A/G	cg06212747	chr3:49208901	KLHDC8B	0.71	9.36	0.5	3.59e-18	Parkinson's disease;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg16066696	chr14:77843743	C14orf174;TMED8	-0.39	-6.21	-0.36	2e-9	Gambling;
CESC	cis	rs34779708	0.966	rs2126984	chr10:35410291	A/G	cg04310649	chr10:35416472	CREM	-0.57	-6.79	-0.39	7.2e-11	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs875971	0.545	rs1267814	chr7:66044409	G/A	cg25405998	chr7:65216604	CCT6P1	-0.46	-5.22	-0.31	3.71e-7	Aortic root size;
CESC	cis	rs7829975	0.593	rs2921061	chr8:8317615	A/T	cg06636001	chr8:8085503	FLJ10661	0.49	6.34	0.36	9.85e-10	Mood instability;
CESC	trans	rs9325144	0.560	rs12424821	chr12:38649951	C/T	cg23762105	chr12:34175262	ALG10	0.48	6.23	0.36	1.81e-9	Morning vs. evening chronotype;
CESC	cis	rs11190604	0.943	rs7085261	chr10:102209811	G/A	cg07080220	chr10:102295463	HIF1AN	0.55	5.51	0.32	8.5e-8	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs2228479	0.717	rs2270460	chr16:89972416	C/A	cg04013166	chr16:89971882	TCF25	0.72	7.09	0.4	1.2e-11	Skin colour saturation;
CESC	cis	rs12681288	0.782	rs2600500	chr8:1029031	G/C	cg04851639	chr8:1020857	NA	-0.43	-9.0	-0.48	4.57e-17	Schizophrenia;
CESC	cis	rs7264396	0.563	rs2425120	chr20:34324456	A/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.63	6.86	0.39	4.77e-11	Total cholesterol levels;
CESC	cis	rs12681288	0.676	rs2701923	chr8:994605	A/G	cg04851639	chr8:1020857	NA	-0.34	-7.38	-0.41	2.01e-12	Schizophrenia;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg19508191	chr12:109124361	CORO1C	-0.45	-6.05	-0.35	5.05e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02565672	chr1:161123809	UFC1	0.58	6.24	0.36	1.76e-9	Gut microbiome composition (summer);
CESC	cis	rs7208859	0.623	rs7220289	chr17:29103762	G/T	cg19761014	chr17:28927070	LRRC37B2	0.75	6.14	0.35	2.95e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs875971	0.660	rs10950044	chr7:66042976	A/G	cg25985355	chr7:65971099	NA	0.33	5.39	0.31	1.53e-7	Aortic root size;
CESC	cis	rs9287719	0.967	rs2287061	chr2:10743153	C/T	cg02196655	chr2:10830764	NOL10	-0.38	-5.83	-0.34	1.61e-8	Prostate cancer;
CESC	cis	rs7714584	1.000	rs1428554	chr5:150257616	A/G	cg22134413	chr5:150180641	NA	0.5	5.82	0.34	1.7e-8	Crohn's disease;
CESC	cis	rs2228479	0.702	rs62052710	chr16:89854893	C/T	cg00800038	chr16:89945340	TCF25	-0.9	-7.5	-0.42	9.55e-13	Skin colour saturation;
CESC	cis	rs34779708	0.966	rs10827487	chr10:35406878	T/A	cg03585969	chr10:35415529	CREM	0.78	10.41	0.54	1.74e-21	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs7824557	0.602	rs7839053	chr8:11207431	C/T	cg21775007	chr8:11205619	TDH	0.57	8.65	0.47	5.01e-16	Retinal vascular caliber;
CESC	cis	rs56046484	1.000	rs12911330	chr15:85630334	T/G	cg08123816	chr15:85640762	PDE8A	-0.5	-6.02	-0.35	5.81e-9	Testicular germ cell tumor;
CESC	cis	rs9649465	1.000	rs10238422	chr7:123353708	G/C	cg04330084	chr7:123175371	IQUB	-0.38	-5.19	-0.3	4.21e-7	Migraine;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09325174	chr14:50154983	POLE2	0.57	6.43	0.37	6.04e-10	Gut microbiome composition (summer);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg11255513	chr11:113644528	ZW10	0.47	6.48	0.37	4.54e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs2635047	0.713	rs9950812	chr18:44765943	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.42	5.7	0.33	3.25e-8	Educational attainment;
CESC	cis	rs9467711	0.606	rs9379855	chr6:26364930	C/T	cg12826209	chr6:26865740	GUSBL1	-0.57	-5.13	-0.3	5.47e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs3857067	0.806	rs11943926	chr4:95136512	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.65	-10.22	-0.53	7.09e-21	QT interval;
CESC	trans	rs629535	0.814	rs62513381	chr8:70110991	T/C	cg21567404	chr3:27674614	NA	-0.87	-10.05	-0.53	2.43e-20	Dupuytren's disease;
CESC	cis	rs11785400	0.762	rs7017931	chr8:143726728	A/G	cg24634471	chr8:143751801	JRK	0.46	5.82	0.34	1.73e-8	Schizophrenia;
CESC	cis	rs709400	0.627	rs62007686	chr14:103899344	A/G	cg12935359	chr14:103987150	CKB	-0.55	-7.97	-0.44	4.6e-14	Body mass index;
CESC	cis	rs911555	0.755	rs9671414	chr14:103967299	C/T	cg12935359	chr14:103987150	CKB	0.58	7.8	0.43	1.43e-13	Intelligence (multi-trait analysis);
CESC	cis	rs7089973	0.624	rs11196930	chr10:116583596	C/T	cg23260525	chr10:116636907	FAM160B1	0.38	6.86	0.39	4.73e-11	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs9303401	0.659	rs62083410	chr17:56964386	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.01	12.69	0.61	3.78e-29	Cognitive test performance;
CESC	cis	rs13064447	0.874	rs13058951	chr3:12752381	C/T	cg23032965	chr3:12705835	RAF1	0.43	5.46	0.32	1.09e-7	Major depression and alcohol dependence;
CESC	cis	rs10504229	0.683	rs11775506	chr8:58133639	G/T	cg24829409	chr8:58192753	C8orf71	-0.58	-7.12	-0.4	1.02e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs4253772	0.591	rs6008595	chr22:46703860	A/T	cg09491104	chr22:46646882	C22orf40	-0.52	-6.43	-0.37	5.82e-10	LDL cholesterol;Cholesterol, total;
CESC	cis	rs854765	0.583	rs4077198	chr17:17834563	T/C	cg16928487	chr17:17741425	SREBF1	-0.57	-9.74	-0.51	2.33e-19	Total body bone mineral density;
CESC	cis	rs1790761	0.667	rs4147581	chr11:67351585	C/G	cg00290607	chr11:67383545	NA	0.45	6.35	0.36	9.21e-10	Mean corpuscular volume;
CESC	cis	rs13223928	0.565	rs10951053	chr7:3155579	C/T	cg19214707	chr7:3157722	NA	-0.46	-6.13	-0.35	3.22e-9	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
CESC	cis	rs6952808	0.656	rs73048919	chr7:2103637	C/A	cg23048001	chr7:2026167	MAD1L1	0.46	5.96	0.34	8.11e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs3096299	0.781	rs2170839	chr16:89409452	C/G	cg08822215	chr16:89438651	ANKRD11	-0.4	-5.8	-0.34	1.93e-8	Multiple myeloma (IgH translocation);
CESC	cis	rs2262909	0.889	rs61268244	chr19:22310130	C/T	cg11619707	chr19:22235551	ZNF257	0.33	5.31	0.31	2.35e-7	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
CESC	cis	rs11718455	1.000	rs11917515	chr3:44020237	A/G	cg08738300	chr3:44038990	NA	0.45	5.81	0.34	1.78e-8	Coronary artery disease;
CESC	cis	rs9902453	0.900	rs12451122	chr17:28486376	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	7.55	0.42	6.98e-13	Coffee consumption (cups per day);
CESC	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg14159672	chr1:205819179	PM20D1	0.81	12.95	0.62	4.67e-30	Menarche (age at onset);
CESC	cis	rs35306767	0.953	rs12354639	chr10:963681	G/A	cg10556349	chr10:835070	NA	0.55	5.89	0.34	1.16e-8	Eosinophil percentage of granulocytes;
CESC	cis	rs12477438	0.784	rs13407840	chr2:99569928	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.62	-8.66	-0.47	4.81e-16	Chronic sinus infection;
CESC	cis	rs7103648	0.712	rs10838703	chr11:47422861	C/G	cg20307385	chr11:47447363	PSMC3	0.87	13.32	0.63	2.44e-31	Diastolic blood pressure;Systolic blood pressure;
CESC	cis	rs3126085	0.935	rs11586114	chr1:152299767	G/A	cg03465714	chr1:152285911	FLG	0.49	5.46	0.32	1.11e-7	Atopic dermatitis;
CESC	cis	rs3806843	0.966	rs2563266	chr5:140136915	C/A	cg26395211	chr5:140044315	WDR55	0.44	5.59	0.32	5.7e-8	Depressive symptoms (multi-trait analysis);
CESC	cis	rs2836974	0.897	rs1571709	chr21:40553980	T/C	cg11644478	chr21:40555479	PSMG1	1.06	17.86	0.74	2.19e-47	Cognitive function;
CESC	cis	rs910316	1.000	rs4903284	chr14:75592483	G/C	cg11812906	chr14:75593930	NEK9	0.89	15.03	0.68	2.4e-37	Height;
CESC	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg07677032	chr17:61819896	STRADA	0.45	6.05	0.35	5.02e-9	Prudent dietary pattern;
CESC	cis	rs4566357	0.615	rs3769643	chr2:227917270	T/C	cg05526886	chr2:227700861	RHBDD1	-0.52	-6.83	-0.39	5.73e-11	Coronary artery disease;
CESC	cis	rs780096	0.565	rs813592	chr2:27721971	T/C	cg12648201	chr2:27665141	KRTCAP3	-0.36	-6.72	-0.38	1.11e-10	Total body bone mineral density;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg01956158	chr8:132916947	EFR3A	0.5	6.3	0.36	1.27e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs11030122	0.702	rs1349583	chr11:3972236	G/A	cg18678763	chr11:4115507	RRM1	-0.46	-6.12	-0.35	3.33e-9	Mean platelet volume;Platelet distribution width;
CESC	cis	rs9303401	0.659	rs7210432	chr17:56668170	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.03	12.7	0.62	3.56e-29	Cognitive test performance;
CESC	cis	rs875971	0.660	rs801190	chr7:66033033	C/T	cg06456125	chr7:65229604	NA	-0.4	-5.27	-0.31	2.8e-7	Aortic root size;
CESC	cis	rs80282103	0.618	rs76068439	chr10:1121018	T/A	cg08668510	chr10:1095578	IDI1	0.95	5.3	0.31	2.46e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs4927850	0.752	rs7624460	chr3:195748530	C/T	cg01181863	chr3:195395398	SDHAP2	-0.55	-6.55	-0.37	2.91e-10	Pancreatic cancer;
CESC	cis	rs9929218	0.954	rs112225541	chr16:68755165	C/T	cg02972257	chr16:68554789	NA	0.55	6.41	0.37	6.69e-10	Colorectal cancer;
CESC	cis	rs17021463	0.966	rs10856908	chr4:95222755	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.63	-10.45	-0.54	1.22e-21	Testicular germ cell tumor;
CESC	cis	rs6499188	0.522	rs8046299	chr16:68672346	G/A	cg02972257	chr16:68554789	NA	-0.6	-6.95	-0.39	2.86e-11	Ulcerative colitis;
CESC	cis	rs798766	1.000	rs11729657	chr4:1737585	T/C	cg10756475	chr4:1757242	NA	0.47	6.51	0.37	3.69e-10	Bladder cancer;Urinary bladder cancer;
CESC	cis	rs739401	0.611	rs12284275	chr11:3024384	T/C	cg08508325	chr11:3079039	CARS	-0.57	-10.67	-0.55	2.46e-22	Longevity;
CESC	trans	rs7618501	1.000	rs3749241	chr3:49744392	A/G	cg21659725	chr3:3221576	CRBN	-0.82	-13.49	-0.64	6.48e-32	Intelligence (multi-trait analysis);
CESC	cis	rs2380220	0.541	rs72928277	chr6:96079745	G/T	cg04719120	chr6:96025338	MANEA	-0.64	-6.74	-0.38	1.01e-10	Behavioural disinhibition (generation interaction);
CESC	cis	rs67311347	1.000	rs6795475	chr3:40489281	A/G	cg09455208	chr3:40491958	NA	0.45	7.59	0.42	5.38e-13	Renal cell carcinoma;
CESC	cis	rs2249694	0.960	rs7094588	chr10:135401586	A/G	cg19469447	chr10:135341870	CYP2E1	0.36	5.17	0.3	4.72e-7	Obesity-related traits;
CESC	cis	rs6545883	0.965	rs2305155	chr2:61729258	A/G	cg15711740	chr2:61764176	XPO1	-0.41	-5.09	-0.3	6.76e-7	Tuberculosis;
CESC	cis	rs1153858	0.895	rs12593402	chr15:45617392	G/A	cg21132104	chr15:45694354	SPATA5L1	0.82	10.84	0.55	6.43e-23	Homoarginine levels;
CESC	cis	rs1707322	0.752	rs4586014	chr1:46150443	A/G	cg06784218	chr1:46089804	CCDC17	0.41	7.21	0.41	5.75e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs208520	0.690	rs1100981	chr6:66852052	T/C	cg07460842	chr6:66804631	NA	-1.01	-13.48	-0.64	6.84e-32	Exhaled nitric oxide output;
CESC	cis	rs2842992	0.662	rs2273825	chr6:160211424	A/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.85	12.01	0.59	8.38e-27	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs7927592	0.731	rs11228275	chr11:68303980	G/A	cg20283391	chr11:68216788	NA	0.43	5.54	0.32	7.11e-8	Total body bone mineral density;
CESC	cis	rs8017423	0.967	rs28424204	chr14:90705669	G/C	cg14092571	chr14:90743983	NA	-0.58	-8.54	-0.46	1.04e-15	Mortality in heart failure;
CESC	cis	rs896854	0.654	rs6982393	chr8:95980708	T/C	cg23172400	chr8:95962367	TP53INP1	-0.44	-9.16	-0.49	1.43e-17	Type 2 diabetes;
CESC	cis	rs8060686	0.641	rs12448677	chr16:68209741	G/A	cg26727032	chr16:67993705	SLC12A4	-0.53	-6.03	-0.35	5.55e-9	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs6952808	0.601	rs3800882	chr7:2120758	G/A	cg08993922	chr7:2212490	MAD1L1	0.38	5.39	0.31	1.59e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs57221529	0.709	rs111352378	chr5:577079	G/A	cg16447950	chr5:562315	NA	-0.64	-6.81	-0.39	6.59e-11	Lung disease severity in cystic fibrosis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06473843	chr1:32757546	HDAC1	0.52	6.22	0.36	1.9e-9	Gut microbiome composition (summer);
CESC	cis	rs875971	0.862	rs10250544	chr7:65766561	A/G	cg11764359	chr7:65958608	NA	-0.78	-11.64	-0.58	1.47e-25	Aortic root size;
CESC	cis	rs863345	0.604	rs2054992	chr1:158506015	G/A	cg12129480	chr1:158549410	OR10X1	-0.33	-6.61	-0.38	2.11e-10	Pneumococcal bacteremia;
CESC	trans	rs634534	0.561	rs613924	chr11:65769295	C/T	cg17712092	chr4:129076599	LARP1B	0.73	10.25	0.53	5.63e-21	Sum eosinophil basophil counts;Eosinophil counts;
CESC	cis	rs1215050	0.874	rs17545594	chr4:98652689	A/G	cg05340658	chr4:99064831	C4orf37	-0.49	-5.96	-0.34	8.03e-9	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs2070997	0.607	rs11244140	chr9:133663058	T/C	cg11464064	chr9:133710261	ABL1	0.51	5.53	0.32	7.49e-8	Response to amphetamines;
CESC	cis	rs514406	0.505	rs269293	chr1:53187767	A/C	cg16325326	chr1:53192061	ZYG11B	0.89	15.11	0.68	1.2e-37	Monocyte count;
CESC	cis	rs60871478	0.636	rs55663559	chr7:884057	G/A	cg13798912	chr7:905769	UNC84A	-0.56	-5.65	-0.33	4.04e-8	Cerebrospinal P-tau181p levels;
CESC	cis	rs763014	0.966	rs4984903	chr16:680695	A/G	cg07343612	chr16:622815	PIGQ	-0.54	-7.98	-0.44	4.5e-14	Height;
CESC	cis	rs4555082	0.957	rs3000073	chr14:105729792	G/A	cg10792982	chr14:105748885	BRF1	0.41	5.74	0.33	2.52e-8	Mean platelet volume;Platelet distribution width;
CESC	cis	rs13118159	0.778	rs12650998	chr4:1338832	T/C	cg00684032	chr4:1343700	KIAA1530	0.42	6.45	0.37	5.29e-10	Longevity;
CESC	cis	rs1185460	0.565	rs540261	chr11:118947634	C/T	cg23280166	chr11:118938394	VPS11	-0.38	-5.24	-0.31	3.36e-7	Coronary artery disease;
CESC	cis	rs7538876	0.935	rs11577822	chr1:17754608	T/G	cg07965774	chr1:17746286	RCC2	0.31	5.05	0.3	8.15e-7	Basal cell carcinoma;
CESC	cis	rs9902453	0.845	rs3115101	chr17:28041627	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	8.53	0.46	1.15e-15	Coffee consumption (cups per day);
CESC	cis	rs9488822	0.676	rs12524249	chr6:116368813	G/A	cg15226275	chr6:116381976	FRK	0.25	6.35	0.36	9.34e-10	Cholesterol, total;LDL cholesterol;
CESC	cis	rs2075371	1.000	rs2504	chr7:133979545	A/T	cg20476274	chr7:133979776	SLC35B4	0.64	9.4	0.5	2.76e-18	Mean platelet volume;
CESC	cis	rs933688	1.000	rs10474353	chr5:90732285	A/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.01	13.73	0.64	8.84e-33	Smoking behavior;
CESC	cis	rs6733011	0.578	rs12712038	chr2:99497710	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.4	-5.03	-0.3	9.22e-7	Bipolar disorder;
CESC	cis	rs35306767	0.903	rs12778891	chr10:950130	T/A	cg25019033	chr10:957182	NA	-0.58	-6.21	-0.36	2.08e-9	Eosinophil percentage of granulocytes;
CESC	cis	rs4986172	0.690	rs11657325	chr17:43242694	C/T	cg10701640	chr17:43249399	NA	0.39	6.39	0.37	7.39e-10	Height;
CESC	cis	rs9888739	1.000	rs13338069	chr16:31299474	A/G	cg15817542	chr16:31343056	ITGAM	-0.44	-5.12	-0.3	5.84e-7	Systemic lupus erythematosus;
CESC	cis	rs10838687	0.736	rs76832686	chr11:47247287	C/T	cg25783544	chr11:47291846	MADD	0.58	6.65	0.38	1.63e-10	Proinsulin levels;
CESC	cis	rs4853012	0.838	rs59570457	chr2:74344282	T/C	cg20891558	chr2:74357851	NA	0.81	11.89	0.59	1.99e-26	Gestational age at birth (maternal effect);
CESC	cis	rs344364	0.511	rs62040569	chr16:1948137	C/T	cg03013636	chr16:1946785	NA	0.48	6.62	0.38	2.02e-10	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs10751667	0.666	rs4074233	chr11:977685	G/A	cg20946044	chr11:1010712	AP2A2	-0.39	-5.4	-0.31	1.48e-7	Alzheimer's disease (late onset);
CESC	cis	rs7659604	1.000	rs10005932	chr4:122664782	T/C	cg19671926	chr4:122722719	EXOSC9	-0.44	-5.3	-0.31	2.49e-7	Type 2 diabetes;
CESC	cis	rs6750795	0.641	rs10933375	chr2:232367296	A/T	cg19187155	chr2:232395269	NMUR1	-0.44	-6.01	-0.35	6.26e-9	Height;
CESC	cis	rs6460942	0.505	rs73055515	chr7:12328804	A/G	cg20607287	chr7:12443886	VWDE	-0.56	-5.71	-0.33	2.98e-8	Coronary artery disease;
CESC	cis	rs4665809	0.590	rs1469523	chr2:26474631	T/A	cg26314531	chr2:26401878	FAM59B	0.85	9.04	0.49	3.46e-17	Gut microbiome composition (summer);
CESC	cis	rs3733585	0.648	rs7378305	chr4:9954893	C/T	cg00071950	chr4:10020882	SLC2A9	-0.69	-11.3	-0.57	2.01e-24	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs992157	0.798	rs12053514	chr2:219167965	C/T	cg00012203	chr2:219082015	ARPC2	-0.73	-9.49	-0.5	1.37e-18	Colorectal cancer;
CESC	cis	rs2243480	1.000	rs313802	chr7:65516373	A/G	cg13147721	chr7:65941812	NA	-0.88	-8.52	-0.46	1.19e-15	Diabetic kidney disease;
CESC	cis	rs1552244	1.000	rs111392584	chr3:10075991	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.79	-10.53	-0.54	7e-22	Alzheimer's disease;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg20269352	chr1:44483206	SLC6A9	0.4	6.21	0.36	1.99e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs1620921	0.505	rs9456586	chr6:161207643	G/A	cg01280913	chr6:161186852	NA	-0.38	-5.73	-0.33	2.67e-8	Lipoprotein (a) - cholesterol levels;
CESC	cis	rs12497850	0.864	rs4513485	chr3:49139966	G/A	cg06212747	chr3:49208901	KLHDC8B	0.74	9.97	0.52	4.37e-20	Parkinson's disease;
CESC	cis	rs4268898	0.662	rs72793967	chr2:24422902	C/T	cg06627628	chr2:24431161	ITSN2	-1.03	-11.36	-0.57	1.26e-24	Asthma;
CESC	cis	rs2120019	0.938	rs59094290	chr15:75308561	G/T	cg17294928	chr15:75287854	SCAMP5	-0.74	-8.51	-0.46	1.35e-15	Blood trace element (Zn levels);
CESC	cis	rs7772486	0.754	rs6906258	chr6:146089356	A/G	cg23711669	chr6:146136114	FBXO30	-0.99	-15.26	-0.68	3.83e-38	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs3091242	0.933	rs12402120	chr1:25751632	C/T	cg03538708	chr1:25844672	NA	-0.42	-6.33	-0.36	1.04e-9	Erythrocyte sedimentation rate;
CESC	cis	rs17253792	0.822	rs78922774	chr14:56115302	T/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.8	5.65	0.33	4.2e-8	Putamen volume;
CESC	cis	rs7247513	0.759	rs8110545	chr19:12754898	C/T	cg23899408	chr19:12877188	HOOK2	0.43	5.21	0.3	3.82e-7	Bipolar disorder;
CESC	cis	rs861020	1.000	rs7555285	chr1:209970355	C/G	cg05527609	chr1:210001259	C1orf107	-0.8	-9.49	-0.5	1.45e-18	Orofacial clefts;
CESC	cis	rs11711311	1.000	rs3773682	chr3:113520576	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.59	7.86	0.44	9.41e-14	IgG glycosylation;
CESC	cis	rs7927771	0.542	rs10769300	chr11:47865560	C/T	cg18512352	chr11:47633146	NA	0.35	5.37	0.31	1.7e-7	Subjective well-being;
CESC	cis	rs172166	0.637	rs1233691	chr6:28153897	T/G	cg21251018	chr6:28226885	NKAPL	0.36	6.01	0.35	6.18e-9	Cardiac Troponin-T levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25187967	chr11:77024606	NA	-0.69	-8.26	-0.45	6.96e-15	Gut microbiome composition (summer);
CESC	cis	rs690037	0.780	rs690437	chr3:16380890	C/T	cg23474789	chr3:16306055	DPH3;OXNAD1	-0.43	-5.87	-0.34	1.33e-8	Optic nerve measurement (cup-to-disc ratio);Optic nerve measurement (cup area);
CESC	cis	rs73001065	0.688	rs59148799	chr19:19484008	A/G	cg03709012	chr19:19516395	GATAD2A	0.93	7.68	0.43	3.03e-13	LDL cholesterol;
CESC	cis	rs4332037	0.950	rs11767515	chr7:1941051	C/T	cg23422044	chr7:1970798	MAD1L1	-0.53	-5.33	-0.31	2.09e-7	Bipolar disorder;
CESC	cis	rs6502050	0.835	rs4789676	chr17:80123078	C/T	cg23985595	chr17:80112537	CCDC57	-0.41	-6.57	-0.37	2.6200000000000003e-10	Life satisfaction;
CESC	cis	rs2732480	0.500	rs11168468	chr12:48612465	C/T	cg24011408	chr12:48396354	COL2A1	0.43	5.98	0.35	7.02e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs7412746	0.658	rs1027699	chr1:150811712	T/C	cg17724175	chr1:150552817	MCL1	0.4	6.13	0.35	3.25e-9	Melanoma;
CESC	cis	rs7666738	0.830	rs4699597	chr4:99019031	G/A	cg03467027	chr4:99064603	C4orf37	0.46	5.81	0.34	1.8e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs875971	0.862	rs949930	chr7:65766822	C/G	cg10691866	chr7:65817282	TPST1	0.31	5.37	0.31	1.75e-7	Aortic root size;
CESC	cis	rs9902453	0.967	rs8072664	chr17:28333385	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.62	-7.83	-0.43	1.15e-13	Coffee consumption (cups per day);
CESC	cis	rs2070997	0.667	rs7851946	chr9:133719256	A/T	cg11464064	chr9:133710261	ABL1	-0.68	-7.94	-0.44	5.93e-14	Response to amphetamines;
CESC	cis	rs9837602	0.507	rs793448	chr3:99532949	G/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.63	-9.82	-0.52	1.35e-19	Breast cancer;
CESC	cis	rs6570726	0.791	rs10872577	chr6:145900560	G/T	cg23711669	chr6:146136114	FBXO30	0.97	14.97	0.68	4.06e-37	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs763121	0.853	rs2267393	chr22:39101619	G/C	cg06544989	chr22:39130855	UNC84B	0.51	9.58	0.51	7.49e-19	Menopause (age at onset);
CESC	cis	rs611744	0.647	rs7015513	chr8:109262570	A/C	cg21045802	chr8:109455806	TTC35	0.47	5.83	0.34	1.63e-8	Dupuytren's disease;
CESC	cis	rs4665809	0.941	rs1434079	chr2:26284670	C/G	cg26314531	chr2:26401878	FAM59B	-0.59	-6.67	-0.38	1.5e-10	Gut microbiome composition (summer);
CESC	trans	rs10242455	0.702	rs55927283	chr7:99057191	G/C	cg09045935	chr12:6379348	NA	0.89	7.65	0.43	3.65e-13	Blood metabolite levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15132647	chr1:52607948	ZFYVE9	0.59	6.53	0.37	3.26e-10	Gut microbiome composition (summer);
CESC	cis	rs9894429	0.966	rs6565605	chr17:79589359	C/T	cg13777783	chr17:79615861	NA	-0.35	-5.82	-0.34	1.66e-8	Eye color traits;
CESC	cis	rs9910055	0.676	rs11079983	chr17:42198170	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.57	7.57	0.42	6.21e-13	Total body bone mineral density;
CESC	cis	rs1023500	0.505	rs134891	chr22:42675882	T/C	cg15557168	chr22:42548783	NA	-0.44	-6.85	-0.39	5.25e-11	Schizophrenia;
CESC	cis	rs9326248	0.530	rs10750100	chr11:116917244	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.56	5.18	0.3	4.38e-7	Blood protein levels;
CESC	cis	rs9309473	1.000	rs10207220	chr2:73785046	G/C	cg20560298	chr2:73613845	ALMS1	-0.55	-7.22	-0.41	5.42e-12	Metabolite levels;
CESC	trans	rs2099077	0.867	rs75781417	chr5:102795938	G/T	cg07434438	chr16:72961899	ZFHX3	0.49	6.67	0.38	1.5e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs14057	0.792	rs78728410	chr1:6663031	G/C	cg06778853	chr1:6672620	PHF13	-0.28	-5.2	-0.3	3.96e-7	Systolic blood pressure;
CESC	cis	rs10504229	0.639	rs56825757	chr8:58106469	A/G	cg21724239	chr8:58056113	NA	0.57	5.9	0.34	1.08e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs763014	0.966	rs15564	chr16:677854	G/T	cg07343612	chr16:622815	PIGQ	-0.55	-8.26	-0.45	6.8e-15	Height;
CESC	cis	rs2749592	0.513	rs1208708	chr10:38085576	A/G	cg25427524	chr10:38739819	LOC399744	-0.65	-9.81	-0.52	1.37e-19	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs1862618	0.671	rs28397234	chr5:56248428	T/G	cg20203395	chr5:56204925	C5orf35	0.4	5.23	0.31	3.39e-7	Initial pursuit acceleration;
CESC	cis	rs796364	0.762	rs13030712	chr2:200973569	G/A	cg23649088	chr2:200775458	C2orf69	0.56	6.68	0.38	1.43e-10	Schizophrenia;
CESC	cis	rs9287719	0.967	rs10206225	chr2:10758657	A/G	cg00105475	chr2:10696890	NA	0.37	5.38	0.31	1.67e-7	Prostate cancer;
CESC	cis	rs7618915	0.621	rs6788993	chr3:52605136	T/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.64	0.38	1.77e-10	Bipolar disorder;
CESC	cis	rs28374715	0.578	rs17730589	chr15:41600878	T/C	cg18705301	chr15:41695430	NDUFAF1	-1.07	-15.33	-0.69	2.03e-38	Ulcerative colitis;
CESC	cis	rs8141529	0.748	rs7287918	chr22:29281710	G/A	cg02153584	chr22:29168773	CCDC117	0.59	7.62	0.42	4.62e-13	Lymphocyte counts;
CESC	cis	rs3026101	0.671	rs2285746	chr17:5311742	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.42	5.6	0.33	5.31e-8	Body mass index;
CESC	cis	rs501120	0.810	rs513391	chr10:44749708	A/C	cg09554077	chr10:44749378	NA	0.49	6.61	0.38	2.11e-10	Coronary artery disease;Coronary heart disease;
CESC	cis	rs4665809	0.941	rs6735145	chr2:26270302	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.71	-7.92	-0.44	6.62e-14	Gut microbiome composition (summer);
CESC	cis	rs9611565	0.512	rs6519289	chr22:42170432	A/C	cg17376030	chr22:41985996	PMM1	-0.78	-8.24	-0.45	7.79e-15	Vitiligo;
CESC	cis	rs8031584	0.958	rs11629793	chr15:31238423	G/A	cg08109568	chr15:31115862	NA	-0.7	-9.33	-0.5	4.49e-18	Huntington's disease progression;
CESC	cis	rs7116495	1.000	rs73539532	chr11:71815684	C/A	cg10381502	chr11:71823885	C11orf51	0.66	5.35	0.31	1.93e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs2011503	0.882	rs10423874	chr19:19359500	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.53	5.58	0.32	6.04e-8	Bipolar disorder;
CESC	cis	rs67311347	1.000	rs4246666	chr3:40407670	C/T	cg01475735	chr3:40494733	NA	-0.4	-5.08	-0.3	7.3e-7	Renal cell carcinoma;
CESC	cis	rs6598955	0.950	rs6700455	chr1:26545864	T/C	cg04990556	chr1:26633338	UBXN11	0.81	10.92	0.56	3.5e-23	Obesity-related traits;
CESC	cis	rs10751667	1.000	rs6597972	chr11:928402	C/T	cg06064525	chr11:970664	AP2A2	-0.41	-7.37	-0.41	2.18e-12	Alzheimer's disease (late onset);
CESC	cis	rs854765	0.856	rs2955382	chr17:17947710	C/T	cg16928487	chr17:17741425	SREBF1	0.51	8.67	0.47	4.53e-16	Total body bone mineral density;
CESC	cis	rs7666738	0.830	rs2098934	chr4:98992403	A/G	cg17366294	chr4:99064904	C4orf37	0.6	8.61	0.47	6.47e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs796364	0.715	rs77089299	chr2:201116853	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.77	-5.14	-0.3	5.37e-7	Schizophrenia;
CESC	cis	rs116095464	0.558	rs7708182	chr5:234788	C/G	cg22496380	chr5:211416	CCDC127	-0.75	-8.8	-0.48	1.82e-16	Breast cancer;
CESC	trans	rs11168187	0.528	rs2214526	chr12:47942029	A/G	cg11982293	chr2:175205387	NA	0.44	6.1	0.35	3.69e-9	Vertical cup-disc ratio;
CESC	trans	rs4332037	0.539	rs55993248	chr7:2071132	A/G	cg11693508	chr17:37793320	STARD3	0.62	6.17	0.35	2.52e-9	Bipolar disorder;
CESC	trans	rs66573146	1.000	rs55672215	chr4:6970529	T/C	cg07817883	chr1:32538562	TMEM39B	1.28	8.41	0.46	2.55e-15	Granulocyte percentage of myeloid white cells;
CESC	cis	rs7631605	0.905	rs7611106	chr3:37017024	G/A	cg22985146	chr3:37219077	LRRFIP2	-0.33	-5.09	-0.3	6.91e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg14893161	chr1:205819251	PM20D1	0.95	18.5	0.75	1.29e-49	Menarche (age at onset);
CESC	cis	rs4665809	0.590	rs13387855	chr2:26420708	T/G	cg04944784	chr2:26401820	FAM59B	-0.93	-10.74	-0.55	1.38e-22	Gut microbiome composition (summer);
CESC	trans	rs7107217	1.000	rs1873872	chr11:129473993	A/T	cg08854128	chr5:171881546	SH3PXD2B	0.43	6.05	0.35	4.84e-9	Breast cancer;Type 2 diabetes;
CESC	cis	rs10504229	1.000	rs67188507	chr8:58187492	A/T	cg22535103	chr8:58192502	C8orf71	-1.05	-13.12	-0.63	1.24e-30	Developmental language disorder (linguistic errors);
CESC	cis	rs2404602	0.692	rs36070630	chr15:76949259	T/C	cg22467129	chr15:76604101	ETFA	-0.36	-5.3	-0.31	2.43e-7	Blood metabolite levels;
CESC	cis	rs6460942	1.000	rs75333414	chr7:12303829	T/A	cg10578991	chr7:12443926	VWDE	-0.49	-5.35	-0.31	1.87e-7	Coronary artery disease;
CESC	cis	rs12134245	0.776	rs6688261	chr1:91987034	C/T	cg25838465	chr1:92012736	NA	-0.64	-10.21	-0.53	7.26e-21	Breast cancer;
CESC	cis	rs7089973	0.966	rs12775180	chr10:116639754	T/C	cg25233709	chr10:116636983	FAM160B1	0.37	5.19	0.3	4.09e-7	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs1577917	1.000	rs12215037	chr6:86727631	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.49	-6.32	-0.36	1.11e-9	Response to antipsychotic treatment;
CESC	cis	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg21782813	chr7:2030301	MAD1L1	0.44	6.16	0.35	2.7e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs644799	1.000	rs474252	chr11:95619292	G/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.47	5.66	0.33	3.97e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs9768139	0.935	rs7809076	chr7:158118438	C/T	cg06219351	chr7:158114137	PTPRN2	0.44	6.87	0.39	4.53e-11	Calcium levels;
CESC	cis	rs881375	0.702	rs3761847	chr9:123690239	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.43	6.25	0.36	1.64e-9	Rheumatoid arthritis;
CESC	cis	rs9649213	0.574	rs6979373	chr7:97961844	T/C	cg21770322	chr7:97807741	LMTK2	0.55	8.25	0.45	7.24e-15	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs6460942	0.915	rs17324858	chr7:12305792	G/T	cg20607287	chr7:12443886	VWDE	-0.42	-6.08	-0.35	4.12e-9	Coronary artery disease;
CESC	cis	rs6493487	0.512	rs7175024	chr15:51257790	A/G	cg02338191	chr15:51200825	AP4E1	0.63	5.85	0.34	1.46e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs3733585	0.604	rs73215003	chr4:10126317	C/G	cg02734326	chr4:10020555	SLC2A9	-0.38	-5.3	-0.31	2.43e-7	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs7927592	0.913	rs11228262	chr11:68274907	G/T	cg20283391	chr11:68216788	NA	-0.63	-7.61	-0.42	4.78e-13	Total body bone mineral density;
CESC	cis	rs7429990	0.965	rs6791834	chr3:48115088	C/A	cg11946769	chr3:48343235	NME6	-0.45	-5.53	-0.32	7.61e-8	Educational attainment (years of education);
CESC	cis	rs1552244	1.000	rs9827740	chr3:10120531	T/C	cg00166722	chr3:10149974	C3orf24	0.55	7.09	0.4	1.21e-11	Alzheimer's disease;
CESC	cis	rs6424115	0.679	rs2294495	chr1:24075876	C/T	cg15997130	chr1:24165203	NA	-0.45	-5.47	-0.32	1.07e-7	Immature fraction of reticulocytes;
CESC	trans	rs156299	0.798	rs156278	chr7:24202161	G/A	cg05664523	chr2:677534	TMEM18	-0.46	-6.01	-0.35	6.09e-9	Vitamin D levels;
CESC	cis	rs6088590	0.965	rs6087639	chr20:33443866	G/A	cg06115741	chr20:33292138	TP53INP2	0.63	8.0	0.44	3.94e-14	Coronary artery disease;
CESC	cis	rs9660180	0.967	rs6687065	chr1:1778469	A/G	cg23982607	chr1:1823379	GNB1	-0.77	-12.45	-0.61	2.6e-28	Body mass index;
CESC	cis	rs4862750	0.914	rs9998558	chr4:187874691	A/G	cg22105103	chr4:187893119	NA	0.46	6.66	0.38	1.61e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7605827	0.930	rs7578126	chr2:15522772	C/T	cg19274914	chr2:15703543	NA	0.33	5.83	0.34	1.65e-8	Educational attainment (years of education);
CESC	cis	rs17092148	0.636	rs2295096	chr20:33464710	A/G	cg24642439	chr20:33292090	TP53INP2	-0.5	-5.06	-0.3	7.9e-7	Neuroticism;
CESC	cis	rs7666738	0.800	rs1559858	chr4:99024075	A/G	cg05340658	chr4:99064831	C4orf37	0.81	12.3	0.6	8.1e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs72634258	0.786	rs9434993	chr1:8179744	G/C	cg00042356	chr1:8021962	PARK7	0.5	5.4	0.31	1.47e-7	Inflammatory bowel disease;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg00605358	chr12:89747739	DUSP6	-0.46	-6.63	-0.38	1.86e-10	Gambling;
CESC	cis	rs709400	0.633	rs3783395	chr14:103895020	T/C	cg12935359	chr14:103987150	CKB	-0.5	-7.29	-0.41	3.62e-12	Body mass index;
CESC	cis	rs6752107	0.936	rs1045100	chr2:234203597	T/C	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.41	6.14	0.35	2.93e-9	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs796364	1.000	rs281762	chr2:200799201	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.83	8.38	0.46	3.17e-15	Schizophrenia;
CESC	cis	rs2425143	1.000	rs11699044	chr20:34312713	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	-0.61	-5.89	-0.34	1.17e-8	Blood protein levels;
CESC	cis	rs963731	0.649	rs2888585	chr2:39246683	C/T	cg04010122	chr2:39346883	SOS1	-0.72	-5.37	-0.31	1.7e-7	Corticobasal degeneration;
CESC	cis	rs9818941	0.824	rs60410659	chr3:157811198	A/T	cg08654915	chr3:157813417	NA	0.44	7.29	0.41	3.5e-12	Height;
CESC	cis	rs6460942	0.915	rs6945067	chr7:12444731	A/C	cg10578991	chr7:12443926	VWDE	-0.45	-5.09	-0.3	6.83e-7	Coronary artery disease;
CESC	cis	rs225245	0.817	rs225290	chr17:33927904	C/G	cg05299278	chr17:33885742	SLFN14	0.38	5.48	0.32	1.01e-7	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
CESC	trans	rs916888	0.821	rs70600	chr17:44860021	C/T	cg01341218	chr17:43662625	NA	0.86	9.97	0.52	4.49e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs9649213	0.613	rs7777415	chr7:97959214	A/T	cg24562669	chr7:97807699	LMTK2	0.52	7.65	0.43	3.64e-13	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs9916302	0.904	rs11867312	chr17:37597748	C/T	cg20243544	chr17:37824526	PNMT	0.51	6.5	0.37	4.03e-10	Glomerular filtration rate (creatinine);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07155211	chr1:23695625	C1orf213;ZNF436	0.57	6.38	0.36	7.8e-10	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16169620	chr1:155827015	GON4L	0.6	6.61	0.38	2.15e-10	Gut microbiome composition (summer);
CESC	cis	rs2228479	0.717	rs1800358	chr16:89809319	T/C	cg04013166	chr16:89971882	TCF25	0.72	7.87	0.44	9.3e-14	Skin colour saturation;
CESC	cis	rs6460942	0.556	rs2287067	chr7:12370533	T/C	cg02935154	chr7:12443704	VWDE	-0.4	-5.34	-0.31	2.04e-7	Coronary artery disease;
CESC	cis	rs11252926	0.574	rs4881254	chr10:453567	C/T	cg18196295	chr10:418757	DIP2C	0.54	7.45	0.42	1.32e-12	Psychosis in Alzheimer's disease;
CESC	cis	rs919433	0.684	rs55775495	chr2:198245965	C/T	cg03934865	chr2:198174659	NA	0.37	5.35	0.31	1.89e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs597539	0.690	rs647661	chr11:68625875	T/C	cg04772025	chr11:68637568	NA	0.57	6.63	0.38	1.87e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs2842992	0.789	rs4709376	chr6:160226337	A/G	cg11366901	chr6:160182831	ACAT2	0.77	9.23	0.49	8.69e-18	Age-related macular degeneration (geographic atrophy);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04579263	chr14:91525979	RPS6KA5	-0.49	-6.25	-0.36	1.61e-9	Gut microbiome composition (summer);
CESC	cis	rs7071206	0.947	rs10509391	chr10:79422369	G/A	cg23888215	chr10:79422304	NA	-0.52	-5.53	-0.32	7.8e-8	Bone mineral density;
CESC	cis	rs7811142	0.943	rs67196635	chr7:100025564	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.03	11.56	0.58	2.62e-25	Platelet count;
CESC	cis	rs875971	0.571	rs160641	chr7:65577346	G/A	cg11764359	chr7:65958608	NA	-0.81	-9.53	-0.51	1.05e-18	Aortic root size;
CESC	cis	rs1448094	0.621	rs7133309	chr12:86284078	T/C	cg02569458	chr12:86230093	RASSF9	0.41	6.12	0.35	3.27e-9	Major depressive disorder;
CESC	cis	rs4664308	0.967	rs34248629	chr2:160902497	C/T	cg03641300	chr2:160917029	PLA2R1	-0.67	-9.8	-0.52	1.55e-19	Idiopathic membranous nephropathy;
CESC	cis	rs11229555	1.000	rs10896795	chr11:58366561	A/G	cg15696309	chr11:58395628	NA	-0.44	-5.64	-0.33	4.46e-8	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs9916302	0.706	rs1874226	chr17:37729031	C/T	cg00129232	chr17:37814104	STARD3	0.59	6.12	0.35	3.3e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.53	-6.66	-0.38	1.61e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs8014204	0.762	rs2359237	chr14:75245002	G/A	cg08847533	chr14:75593920	NEK9	0.41	5.27	0.31	2.87e-7	Caffeine consumption;
CESC	cis	rs853679	0.550	rs1225599	chr6:28165190	C/T	cg26335602	chr6:28129616	ZNF389	0.48	6.54	0.37	3.07e-10	Depression;
CESC	trans	rs11098499	0.739	rs9996382	chr4:120151012	C/T	cg25214090	chr10:38739885	LOC399744	0.54	7.3	0.41	3.27e-12	Corneal astigmatism;
CESC	cis	rs4665809	0.590	rs36064164	chr2:26502768	C/T	cg22920501	chr2:26401640	FAM59B	0.92	10.12	0.53	1.47e-20	Gut microbiome composition (summer);
CESC	cis	rs7772486	0.790	rs9403755	chr6:146231470	C/A	cg05347473	chr6:146136440	FBXO30	-0.55	-7.05	-0.4	1.57e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs228437	1.000	rs9376050	chr6:134910136	A/G	cg24504307	chr6:134963096	NA	0.61	6.4	0.37	6.87e-10	Melanoma;
CESC	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg11494091	chr17:61959527	GH2	0.73	12.48	0.61	2.02e-28	Prudent dietary pattern;
CESC	cis	rs60154123	0.614	rs646512	chr1:210453938	C/T	cg21951975	chr1:209979733	IRF6	-0.42	-6.07	-0.35	4.4e-9	Coronary artery disease;
CESC	cis	rs9443189	0.813	rs2842556	chr6:76447204	T/C	cg01950844	chr6:76311363	SENP6	-0.59	-6.53	-0.37	3.32e-10	Prostate cancer;
CESC	cis	rs6964587	1.000	rs7785095	chr7:91640773	A/T	cg17063962	chr7:91808500	NA	-0.56	-7.76	-0.43	1.9e-13	Breast cancer;
CESC	cis	rs1322639	0.614	rs9364361	chr6:169580499	C/T	cg04662567	chr6:169592167	NA	-0.56	-5.95	-0.34	8.47e-9	Pulse pressure;
CESC	cis	rs17023223	0.537	rs10923756	chr1:119674648	A/T	cg05756136	chr1:119680316	WARS2	-0.47	-5.71	-0.33	3.1e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CESC	cis	rs11122272	0.766	rs2808608	chr1:231543175	A/G	cg06096015	chr1:231504339	EGLN1	0.41	5.71	0.33	3e-8	Hemoglobin concentration;
CESC	cis	rs6032067	1.000	rs6032052	chr20:43829883	C/A	cg11264863	chr20:43835661	SEMG1	0.48	5.29	0.31	2.56e-7	Blood protein levels;
CESC	cis	rs1712517	0.503	rs72846198	chr10:105098024	G/A	cg04362960	chr10:104952993	NT5C2	-0.49	-5.85	-0.34	1.45e-8	Migraine;
CESC	cis	rs2281845	0.965	rs7516023	chr1:201085521	C/T	cg17810781	chr1:201082982	CACNA1S	0.37	5.1	0.3	6.48e-7	Permanent tooth development;
CESC	cis	rs2070997	0.607	rs4602941	chr9:133663776	C/T	cg11464064	chr9:133710261	ABL1	0.56	6.44	0.37	5.64e-10	Response to amphetamines;
CESC	cis	rs9640161	0.711	rs60268791	chr7:150023800	G/T	cg21361702	chr7:150065534	REPIN1	0.45	5.29	0.31	2.6e-7	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs926938	0.563	rs360645	chr1:115427218	A/G	cg12756093	chr1:115239321	AMPD1	0.5	7.34	0.41	2.59e-12	Autism;
CESC	cis	rs60871478	1.000	rs62432250	chr7:801792	C/G	cg05535760	chr7:792225	HEATR2	0.85	10.63	0.55	3.18e-22	Cerebrospinal P-tau181p levels;
CESC	cis	rs853679	0.517	rs56310871	chr6:28044482	A/G	cg19592336	chr6:28129416	ZNF389	0.6	7.97	0.44	4.69e-14	Depression;
CESC	cis	rs798766	0.723	rs3134865	chr4:1723279	T/C	cg07041428	chr4:1763019	NA	-0.39	-5.56	-0.32	6.66e-8	Bladder cancer;Urinary bladder cancer;
CESC	cis	rs73206853	0.764	rs6606685	chr12:110881986	C/G	cg12870014	chr12:110450643	ANKRD13A	0.65	5.85	0.34	1.45e-8	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	trans	rs7618501	1.000	rs57648519	chr3:49813169	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.59	8.5	0.46	1.41e-15	Intelligence (multi-trait analysis);
CESC	trans	rs3808502	0.549	rs4841564	chr8:11425809	T/G	cg15556689	chr8:8085844	FLJ10661	-0.58	-6.82	-0.39	6.24e-11	Neuroticism;
CESC	cis	rs2228479	0.702	rs17233176	chr16:89832751	G/C	cg14709524	chr16:89940631	TCF25	0.91	6.74	0.38	1e-10	Skin colour saturation;
CESC	cis	rs2836974	1.000	rs2836974	chr21:40663181	A/G	cg27266027	chr21:40555129	PSMG1	-0.43	-5.04	-0.3	8.76e-7	Cognitive function;
CESC	cis	rs2635047	0.638	rs2668784	chr18:44711391	A/G	cg24371990	chr18:44770781	NA	0.32	5.15	0.3	5.03e-7	Educational attainment;
CESC	cis	rs9393777	0.513	rs9393739	chr6:26646966	T/G	cg12292205	chr6:26970375	C6orf41	-0.53	-5.84	-0.34	1.53e-8	Intelligence (multi-trait analysis);
CESC	cis	rs7264396	0.790	rs6058294	chr20:34259396	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.87	-11.83	-0.59	3.29e-26	Total cholesterol levels;
CESC	cis	rs9926296	0.585	rs1800337	chr16:89845194	A/G	cg07648498	chr16:89883185	FANCA	0.47	5.88	0.34	1.24e-8	Vitiligo;
CESC	cis	rs6693567	0.545	rs1694386	chr1:150377965	C/G	cg09579323	chr1:150459698	TARS2	0.47	5.88	0.34	1.23e-8	Migraine;
CESC	cis	rs3820068	0.581	rs1547031	chr1:15918960	G/A	cg16988262	chr1:15930761	NA	0.33	5.33	0.31	2.14e-7	Systolic blood pressure;
CESC	cis	rs244293	0.672	rs9901526	chr17:53012379	G/T	cg19360675	chr17:53046073	COX11;STXBP4	-0.5	-6.64	-0.38	1.74e-10	Menarche (age at onset);
CESC	cis	rs698833	0.892	rs786618	chr2:44593929	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.47	5.97	0.34	7.41e-9	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs12579753	0.872	rs11519752	chr12:82207300	A/G	cg24719984	chr12:82153464	PPFIA2	-0.33	-5.04	-0.3	8.55e-7	Resting heart rate;
CESC	cis	rs2243480	1.000	rs781150	chr7:65480973	C/T	cg25894440	chr7:65020034	NA	-0.68	-5.84	-0.34	1.51e-8	Diabetic kidney disease;
CESC	cis	rs818427	0.896	rs712663	chr5:112223594	T/C	cg07820702	chr5:112228657	REEP5	-0.47	-6.16	-0.35	2.67e-9	Total body bone mineral density;
CESC	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.52	0.37	3.54e-10	Prudent dietary pattern;
CESC	cis	rs2066819	1.000	rs79750959	chr12:56702012	C/A	cg26804944	chr12:56660921	COQ10A	-0.85	-5.14	-0.3	5.39e-7	Psoriasis vulgaris;
CESC	cis	rs7216064	1.000	rs11079707	chr17:65835617	A/G	cg12091567	chr17:66097778	LOC651250	0.79	8.64	0.47	5.53e-16	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	trans	rs1814175	0.645	rs7103554	chr11:50027612	G/A	cg15704280	chr7:45808275	SEPT13	-1.0	-18.53	-0.75	9.55e-50	Height;
CESC	cis	rs3862435	0.572	rs2589969	chr15:90908051	T/C	cg22089800	chr15:90895588	ZNF774	0.49	5.33	0.31	2.13e-7	Response to exercise (triglyceride level interaction);
CESC	trans	rs1814175	0.645	rs11040703	chr11:50024961	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.42	-6.13	-0.35	3.1e-9	Height;
CESC	cis	rs6933660	0.800	rs9383893	chr6:151757327	T/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.5	-6.71	-0.38	1.21e-10	Menarche (age at onset);
CESC	cis	rs10504229	0.679	rs12679920	chr8:58051710	G/T	cg22535103	chr8:58192502	C8orf71	-0.68	-7.38	-0.41	2.03e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs7223966	0.691	rs9893518	chr17:62006997	A/G	cg11494091	chr17:61959527	GH2	0.41	5.5	0.32	8.88e-8	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs2235544	0.565	rs633697	chr1:54468760	A/G	cg25741118	chr1:54482237	LDLRAD1	0.24	5.77	0.33	2.2e-8	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
CESC	cis	rs66573146	0.656	rs66905212	chr4:6949508	G/C	cg00086871	chr4:6988644	TBC1D14	0.97	5.88	0.34	1.23e-8	Granulocyte percentage of myeloid white cells;
CESC	cis	rs9443645	0.509	rs12176511	chr6:79565721	G/A	cg05283184	chr6:79620031	NA	0.41	6.04	0.35	5.19e-9	Intelligence (multi-trait analysis);
CESC	cis	rs514406	0.644	rs7530078	chr1:53204861	G/T	cg24675658	chr1:53192096	ZYG11B	0.64	8.84	0.48	1.36e-16	Monocyte count;
CESC	cis	rs4253772	0.550	rs9615949	chr22:46722531	C/T	cg24881330	chr22:46731750	TRMU	0.77	6.28	0.36	1.36e-9	LDL cholesterol;Cholesterol, total;
CESC	cis	rs2408955	0.521	rs11168437	chr12:48566156	C/T	cg04545296	chr12:48745243	ZNF641	0.36	6.07	0.35	4.32e-9	Glycated hemoglobin levels;
CESC	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg07167872	chr1:205819463	PM20D1	-0.63	-10.55	-0.54	5.77e-22	Monocyte percentage of white cells;
CESC	cis	rs7927771	0.524	rs11039419	chr11:47851354	C/T	cg20307385	chr11:47447363	PSMC3	0.62	8.62	0.47	6.13e-16	Subjective well-being;
CESC	cis	rs9311474	0.508	rs12637627	chr3:52619962	G/T	cg05564831	chr3:52568323	NT5DC2	0.46	7.32	0.41	3.01e-12	Electroencephalogram traits;
CESC	trans	rs3942852	0.568	rs2904315	chr11:48109948	C/T	cg15704280	chr7:45808275	SEPT13	0.74	9.7	0.51	3.07e-19	Acute lymphoblastic leukemia (childhood);
CESC	trans	rs1814175	0.645	rs28478790	chr11:50054322	C/A	cg15704280	chr7:45808275	SEPT13	-1.0	-18.7	-0.75	2.39e-50	Height;
CESC	cis	rs425277	0.583	rs1467217	chr1:2045165	G/A	cg12718519	chr1:2058417	PRKCZ	-0.26	-5.55	-0.32	6.98e-8	Height;
CESC	cis	rs2742234	0.955	rs2075910	chr10:43614230	G/A	cg15436174	chr10:43711423	RASGEF1A	-0.4	-5.11	-0.3	6.04e-7	Hirschsprung disease;
CESC	cis	rs853679	0.513	rs9468296	chr6:28113730	A/G	cg22143856	chr6:28129313	ZNF389	0.52	6.51	0.37	3.67e-10	Depression;
CESC	cis	rs7264396	0.790	rs3746410	chr20:34190870	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-7.5	-0.42	9.55e-13	Total cholesterol levels;
CESC	cis	rs6570726	0.967	rs365515	chr6:145802833	C/T	cg05347473	chr6:146136440	FBXO30	-0.42	-5.67	-0.33	3.78e-8	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1552244	1.000	rs6442148	chr3:10078289	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.88	12.05	0.59	5.93e-27	Alzheimer's disease;
CESC	cis	rs7103648	0.742	rs34937994	chr11:47389638	C/T	cg03711944	chr11:47377212	SPI1	-0.35	-5.44	-0.32	1.22e-7	Diastolic blood pressure;Systolic blood pressure;
CESC	cis	rs35110281	0.837	rs2838341	chr21:45076443	A/G	cg21573476	chr21:45109991	RRP1B	-0.48	-6.81	-0.39	6.56e-11	Mean corpuscular volume;
CESC	cis	rs11122272	0.735	rs2474623	chr1:231513993	T/C	cg06096015	chr1:231504339	EGLN1	0.43	6.18	0.35	2.46e-9	Hemoglobin concentration;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02737517	chr20:62729726	OPRL1	-0.5	-6.06	-0.35	4.73e-9	Gut microbiome composition (summer);
CESC	cis	rs6432018	0.927	rs11674769	chr2:9734278	T/C	cg23886495	chr2:9695866	ADAM17	0.43	5.08	0.3	7.2e-7	Heart rate variability traits;
CESC	cis	rs9911578	1.000	rs1267545	chr17:56646909	A/G	cg12560992	chr17:57184187	TRIM37	0.92	15.27	0.68	3.42e-38	Intelligence (multi-trait analysis);
CESC	cis	rs10479542	0.630	rs6879664	chr5:178974576	T/G	cg00080972	chr5:178986291	RUFY1	0.39	5.69	0.33	3.32e-8	Lung cancer;
CESC	cis	rs4713118	0.616	rs9348789	chr6:28025486	C/T	cg19592336	chr6:28129416	ZNF389	0.54	6.94	0.39	3e-11	Parkinson's disease;
CESC	cis	rs1448094	0.512	rs11832992	chr12:86240790	T/C	cg00310523	chr12:86230176	RASSF9	0.36	5.71	0.33	3.02e-8	Major depressive disorder;
CESC	cis	rs2073300	0.536	rs6137947	chr20:23414630	C/A	cg12062639	chr20:23401060	NAPB	1.04	8.1	0.45	1.97e-14	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs875971	0.545	rs73146609	chr7:65767464	A/G	cg11764359	chr7:65958608	NA	0.82	9.71	0.51	2.93e-19	Aortic root size;
CESC	trans	rs11098499	0.619	rs28502463	chr4:120257023	T/C	cg25214090	chr10:38739885	LOC399744	0.64	9.08	0.49	2.59e-17	Corneal astigmatism;
CESC	cis	rs4654899	1.000	rs2271115	chr1:21295864	C/T	cg05370193	chr1:21551575	ECE1	0.39	5.9	0.34	1.12e-8	Superior frontal gyrus grey matter volume;
CESC	cis	rs470119	0.902	rs131808	chr22:50963357	G/C	cg12969734	chr22:50962224	SCO2	0.4	6.13	0.35	3.24e-9	Mean corpuscular hemoglobin;
CESC	cis	rs6456156	0.586	rs12203510	chr6:167473006	C/T	cg07741184	chr6:167504864	NA	0.35	5.84	0.34	1.49e-8	Primary biliary cholangitis;
CESC	cis	rs1005277	0.563	rs2505216	chr10:38482830	T/C	cg00409905	chr10:38381863	ZNF37A	-0.47	-6.33	-0.36	1.04e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs7799006	0.722	rs33981648	chr7:2288669	T/C	cg08027265	chr7:2291960	NA	-0.57	-9.68	-0.51	3.53e-19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	trans	rs561341	0.505	rs548298	chr17:30297494	C/A	cg20587970	chr11:113659929	NA	-1.12	-14.24	-0.66	1.49e-34	Hip circumference adjusted for BMI;
CESC	cis	rs68170813	0.523	rs10253172	chr7:106786474	C/T	cg02696742	chr7:106810147	HBP1	0.56	5.3	0.31	2.45e-7	Coronary artery disease;
CESC	cis	rs9322193	0.923	rs12660304	chr6:150060783	A/G	cg07701084	chr6:150067640	NUP43	0.46	6.64	0.38	1.81e-10	Lung cancer;
CESC	cis	rs4819052	0.851	rs1999333	chr21:46670401	C/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.43	5.39	0.31	1.54e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs3008870	0.959	rs3008852	chr1:67383416	G/A	cg02640540	chr1:67518911	SLC35D1	0.47	5.11	0.3	6.28e-7	Lymphocyte percentage of white cells;
CESC	cis	rs14403	1.000	rs111667565	chr1:243669012	T/C	cg21452805	chr1:244014465	NA	0.51	5.8	0.34	1.92e-8	Schizophrenia;
CESC	cis	rs9911578	0.933	rs2531726	chr17:56522533	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.38	-5.1	-0.3	6.41e-7	Intelligence (multi-trait analysis);
CESC	cis	rs412050	0.895	rs240065	chr22:22296119	C/T	cg17089214	chr22:22089827	YPEL1	0.73	6.94	0.39	2.93e-11	Attention deficit hyperactivity disorder;
CESC	cis	rs72945132	0.882	rs61177215	chr11:70129534	G/A	cg00319359	chr11:70116639	PPFIA1	0.78	7.78	0.43	1.6e-13	Coronary artery disease;
CESC	cis	rs6430585	0.583	rs3769012	chr2:136556480	C/T	cg07169764	chr2:136633963	MCM6	1.32	19.18	0.76	5.29e-52	Corneal structure;
CESC	cis	rs1799949	0.929	rs799906	chr17:41278116	T/C	cg07153921	chr17:41440717	NA	-0.38	-5.04	-0.3	8.65e-7	Menopause (age at onset);
CESC	cis	rs1879734	0.731	rs7555617	chr1:54158155	A/C	cg23596471	chr1:54105337	GLIS1	0.35	5.57	0.32	6.32e-8	Mitral valve prolapse;
CESC	cis	rs10504229	1.000	rs57261109	chr8:58172152	C/T	cg05313129	chr8:58192883	C8orf71	-0.55	-6.37	-0.36	8.42e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs10504229	1.000	rs17217033	chr8:58180061	G/T	cg22535103	chr8:58192502	C8orf71	-1.05	-13.27	-0.63	3.63e-31	Developmental language disorder (linguistic errors);
CESC	cis	rs853679	0.517	rs9380061	chr6:28132803	T/C	cg20151795	chr6:28129481	ZNF389	0.44	5.55	0.32	6.85e-8	Depression;
CESC	cis	rs7605827	0.930	rs2380657	chr2:15678482	T/C	cg19274914	chr2:15703543	NA	0.36	6.39	0.37	7.29e-10	Educational attainment (years of education);
CESC	cis	rs6502050	0.835	rs4789737	chr17:80123269	G/A	cg23985595	chr17:80112537	CCDC57	-0.41	-6.57	-0.37	2.6200000000000003e-10	Life satisfaction;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg17237111	chr4:114682438	CAMK2D	-0.5	-6.57	-0.37	2.7e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs4925386	0.840	rs6143036	chr20:60921721	C/A	cg24112000	chr20:60950667	NA	-0.45	-5.3	-0.31	2.39e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs17376456	0.877	rs114256265	chr5:93473130	T/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.63	5.33	0.31	2.11e-7	Diabetic retinopathy;
CESC	cis	rs9487051	0.714	rs7774377	chr6:109602443	G/A	cg21918786	chr6:109611834	NA	-0.38	-5.68	-0.33	3.54e-8	Reticulocyte fraction of red cells;
CESC	cis	rs6938	0.575	rs12902515	chr15:75160998	G/C	cg10253484	chr15:75165896	SCAMP2	-0.51	-6.94	-0.39	2.93e-11	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19458608	chr3:129830607	LOC729375	-0.62	-6.97	-0.39	2.5e-11	Gut microbiome composition (summer);
CESC	cis	rs7124681	0.584	rs10769285	chr11:47709212	C/T	cg18512352	chr11:47633146	NA	0.35	5.39	0.31	1.53e-7	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
CESC	cis	rs7809950	1.000	rs2237672	chr7:107131563	A/C	cg23024343	chr7:107201750	COG5	-0.42	-5.86	-0.34	1.37e-8	Coronary artery disease;
CESC	cis	rs2228479	0.850	rs11640209	chr16:89807828	C/A	cg06558623	chr16:89946397	TCF25	1.15	9.22	0.49	9.66e-18	Skin colour saturation;
CESC	cis	rs11711311	1.000	rs9811746	chr3:113515060	T/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.69	9.46	0.5	1.74e-18	IgG glycosylation;
CESC	cis	rs4141404	0.740	rs9609301	chr22:31895940	C/T	cg00478049	chr22:31556069	RNF185	-0.44	-5.12	-0.3	5.86e-7	Paclitaxel-induced neuropathy;
CESC	cis	rs1153858	1.000	rs2066090	chr15:45650018	T/C	cg14582100	chr15:45693742	SPATA5L1	0.43	6.15	0.35	2.82e-9	Homoarginine levels;
CESC	cis	rs17376456	0.825	rs12716454	chr5:93272279	A/C	cg25358565	chr5:93447407	FAM172A	1.16	10.12	0.53	1.48e-20	Diabetic retinopathy;
CESC	cis	rs9611565	0.649	rs202625	chr22:41827082	G/A	cg17376030	chr22:41985996	PMM1	-0.76	-8.1	-0.45	2.03e-14	Vitiligo;
CESC	cis	rs826838	0.872	rs826878	chr12:39088837	A/T	cg26384229	chr12:38710491	ALG10B	-0.6	-9.5	-0.5	1.28e-18	Heart rate;
CESC	cis	rs929596	1.000	rs929596	chr2:234674476	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.64	-7.86	-0.43	9.75e-14	Total bilirubin levels in HIV-1 infection;
CESC	cis	rs1023500	0.573	rs2269524	chr22:42475703	T/G	cg15557168	chr22:42548783	NA	0.44	6.19	0.36	2.31e-9	Schizophrenia;
CESC	cis	rs9640161	0.750	rs11764936	chr7:150025915	G/T	cg13722127	chr7:150037890	RARRES2	0.35	5.03	0.3	9.21e-7	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs2859741	0.967	rs575939	chr1:37513854	T/C	cg09363841	chr1:37513479	NA	-0.7	-11.57	-0.58	2.51e-25	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
CESC	cis	rs881375	0.654	rs10760126	chr9:123662618	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.47	6.78	0.38	7.79e-11	Rheumatoid arthritis;
CESC	trans	rs10776614	0.799	rs7088010	chr10:49767246	C/T	cg19218067	chr2:181235115	NA	0.49	6.0	0.35	6.35e-9	Self-employment;
CESC	cis	rs9311474	0.508	rs17052259	chr3:52593138	A/G	cg17372223	chr3:52568218	NT5DC2	0.4	5.94	0.34	8.99e-9	Electroencephalogram traits;
CESC	cis	rs12130219	0.500	rs4845743	chr1:152184149	A/G	cg17718321	chr1:152188247	HRNR	-0.51	-8.49	-0.46	1.47e-15	Inflammatory skin disease;
CESC	cis	rs60154123	0.505	rs77990373	chr1:210041111	T/C	cg21951975	chr1:209979733	IRF6	0.58	6.23	0.36	1.85e-9	Coronary artery disease;
CESC	cis	rs916888	0.821	rs70602	chr17:44859715	T/C	cg01570182	chr17:44337453	NA	-0.87	-10.41	-0.54	1.71e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs35306767	0.953	rs11253517	chr10:970524	A/G	cg10556349	chr10:835070	NA	-0.53	-5.44	-0.32	1.19e-7	Eosinophil percentage of granulocytes;
CESC	cis	rs826838	0.967	rs11169142	chr12:39085773	A/T	cg13010199	chr12:38710504	ALG10B	-0.41	-5.63	-0.33	4.66e-8	Heart rate;
CESC	cis	rs6500602	0.609	rs7202910	chr16:4518948	T/A	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.36	5.17	0.3	4.61e-7	Schizophrenia;
CESC	cis	rs1775715	0.707	rs2808073	chr10:32179275	A/G	cg18675610	chr10:32216311	ARHGAP12	0.35	5.33	0.31	2.07e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs9911578	0.835	rs9889419	chr17:56473259	C/T	cg05425664	chr17:57184151	TRIM37	-0.44	-6.24	-0.36	1.69e-9	Intelligence (multi-trait analysis);
CESC	cis	rs2637266	0.653	rs846590	chr10:78491609	T/C	cg18941641	chr10:78392320	NA	0.39	7.59	0.42	5.61e-13	Pulmonary function;
CESC	cis	rs6089584	1.000	rs6089584	chr20:60564086	G/C	cg13770153	chr20:60521292	NA	-0.45	-5.95	-0.34	8.68e-9	Body mass index;
CESC	cis	rs2046867	0.818	rs62249866	chr3:72878632	T/C	cg25664220	chr3:72788482	NA	-0.46	-6.44	-0.37	5.67e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CESC	cis	rs1843834	0.898	rs2015099	chr2:225519915	T/C	cg22455342	chr2:225449267	CUL3	0.53	6.66	0.38	1.55e-10	IgE levels in asthmatics (D.p. specific);
CESC	cis	rs10504229	0.593	rs75047131	chr8:58001320	A/G	cg22535103	chr8:58192502	C8orf71	-0.9	-9.02	-0.48	4e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs6831352	0.877	rs28987101	chr4:100049253	T/G	cg13256891	chr4:100009986	ADH5	-0.77	-8.43	-0.46	2.27e-15	Alcohol dependence;
CESC	cis	rs896854	0.967	rs10956933	chr8:95967688	C/G	cg13393036	chr8:95962371	TP53INP1	-0.52	-11.41	-0.57	8.68e-25	Type 2 diabetes;
CESC	cis	rs138880	0.505	rs56248708	chr22:50306969	G/A	cg02269571	chr22:50332266	NA	-0.67	-6.57	-0.37	2.6200000000000003e-10	Schizophrenia;
CESC	cis	rs11711311	1.000	rs12631232	chr3:113497386	C/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.66	8.94	0.48	6.7e-17	IgG glycosylation;
CESC	cis	rs11871801	1.000	rs72823064	chr17:40569974	T/C	cg21433558	chr17:40837037	CNTNAP1	0.46	5.12	0.3	5.77e-7	Crohn's disease;
CESC	cis	rs9733	0.596	rs11204704	chr1:150671630	T/C	cg18016565	chr1:150552671	MCL1	0.33	5.11	0.3	6.22e-7	Tonsillectomy;
CESC	cis	rs7762018	0.941	rs4716387	chr6:170136777	G/C	cg13891659	chr6:170190454	C6orf122;C6orf208	0.61	6.19	0.36	2.33e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs6665290	0.904	rs11578103	chr1:227189642	C/A	cg10327440	chr1:227177885	CDC42BPA	-1.22	-32.82	-0.9	2.35e-95	Myeloid white cell count;
CESC	cis	rs4665809	0.590	rs1122972	chr2:26418788	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.08	-13.26	-0.63	4e-31	Gut microbiome composition (summer);
CESC	cis	rs10504229	0.953	rs75545548	chr8:58172816	T/C	cg24829409	chr8:58192753	C8orf71	-0.76	-10.0	-0.52	3.53e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs2549003	1.000	rs2549004	chr5:131827825	C/G	cg02551604	chr5:131831745	NA	0.38	5.35	0.31	1.9e-7	Asthma (sex interaction);
CESC	cis	rs7833790	0.724	rs6473310	chr8:82707981	A/G	cg02079420	chr8:82753780	SNX16	0.52	7.8	0.43	1.47e-13	Diastolic blood pressure;
CESC	cis	rs2440129	0.611	rs11571335	chr17:6904263	C/T	cg12262378	chr17:6899522	ALOX12	0.39	6.69	0.38	1.35e-10	Tonsillectomy;
CESC	cis	rs5750830	0.649	rs4384886	chr22:39793766	C/T	cg01416388	chr22:39784598	NA	-0.58	-7.42	-0.41	1.58e-12	Intelligence (multi-trait analysis);
CESC	cis	rs1799949	0.896	rs35908185	chr17:41255111	A/T	cg06001716	chr17:41278141	BRCA1;NBR2	0.39	5.31	0.31	2.3e-7	Menopause (age at onset);
CESC	cis	rs977987	0.800	rs3784935	chr16:75336430	T/G	cg03315344	chr16:75512273	CHST6	0.39	5.48	0.32	1.01e-7	Dupuytren's disease;
CESC	cis	rs2721195	0.967	rs10108150	chr8:145687475	A/G	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.55	-7.91	-0.44	7.03e-14	Age at first birth;
CESC	cis	rs4523957	0.620	rs8064309	chr17:2059961	T/C	cg16513277	chr17:2031491	SMG6	-0.72	-10.2	-0.53	8.12e-21	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs12476592	0.602	rs262533	chr2:63906048	C/G	cg17519650	chr2:63277830	OTX1	-0.46	-5.11	-0.3	6.22e-7	Childhood ear infection;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg14989522	chr19:58874386	ZNF497	-0.49	-6.65	-0.38	1.68e-10	Fibrinogen levels;
CESC	cis	rs11792861	0.890	rs57387569	chr9:111920392	T/C	cg05043794	chr9:111880884	C9orf5	-0.43	-6.8	-0.39	6.77e-11	Menarche (age at onset);
CESC	cis	rs4665809	1.000	rs13030858	chr2:26315451	G/A	cg04944784	chr2:26401820	FAM59B	-0.67	-7.75	-0.43	2e-13	Gut microbiome composition (summer);
CESC	cis	rs17401966	1.000	rs1536263	chr1:10378914	T/C	cg15208524	chr1:10270712	KIF1B	0.46	5.71	0.33	3.08e-8	Hepatocellular carcinoma;
CESC	trans	rs4942242	0.663	rs7985489	chr13:44206148	T/C	cg19169023	chr15:41853346	TYRO3	0.56	7.12	0.4	1.03e-11	Response to tocilizumab in rheumatoid arthritis;
CESC	trans	rs10808739	0.588	rs10112945	chr8:65677331	C/A	cg19896198	chr1:12123262	TNFRSF8	0.36	6.02	0.35	5.91e-9	HIV-1 susceptibility;
CESC	cis	rs77956314	0.515	rs4767490	chr12:117435016	A/G	cg16111737	chr12:117408163	FBXW8	-0.43	-5.11	-0.3	6.22e-7	Subcortical brain region volumes;Hippocampal volume;
CESC	cis	rs7937682	0.587	rs571594	chr11:111359334	A/G	cg09085632	chr11:111637200	PPP2R1B	0.6	7.82	0.43	1.27e-13	Primary sclerosing cholangitis;
CESC	cis	rs7680126	0.596	rs4637402	chr4:10045430	C/T	cg00071950	chr4:10020882	SLC2A9	0.66	7.66	0.43	3.5e-13	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	cis	rs11098499	0.863	rs11098532	chr4:120490726	C/A	cg24375607	chr4:120327624	NA	0.46	5.58	0.32	5.85e-8	Corneal astigmatism;
CESC	cis	rs1448094	0.512	rs1584368	chr12:86245117	A/C	cg19622623	chr12:86230825	RASSF9	-0.46	-5.95	-0.34	8.4e-9	Major depressive disorder;
CESC	cis	rs1707322	1.000	rs12097799	chr1:46459886	C/A	cg05343316	chr1:45956843	TESK2	0.45	5.54	0.32	7.24e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10685336	chr3:149688848	PFN2	0.5	6.21	0.36	2.08e-9	Gut microbiome composition (summer);
CESC	cis	rs6800768	0.633	rs826374	chr3:24163921	A/C	cg10674438	chr3:24145617	LOC152024	-0.43	-6.34	-0.36	9.96e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs9902453	0.765	rs2467334	chr17:28135508	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-10.34	-0.54	2.82e-21	Coffee consumption (cups per day);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg25393494	chr17:17109936	PLD6	0.35	5.99	0.35	6.69e-9	Fibrinogen levels;
CESC	cis	rs6951245	0.744	rs1133122	chr7:1192572	C/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.47	5.62	0.33	4.81e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs6433857	0.594	rs1406257	chr2:181521345	A/G	cg23363182	chr2:181467187	NA	-0.46	-6.24	-0.36	1.69e-9	Body mass index;
CESC	trans	rs208520	0.560	rs2351880	chr6:66863707	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.02	-13.07	-0.63	1.82e-30	Exhaled nitric oxide output;
CESC	cis	rs9303542	0.559	rs12602539	chr17:46617459	T/A	cg04904318	chr17:46607828	HOXB1	-0.58	-5.67	-0.33	3.64e-8	Ovarian cancer;Epithelial ovarian cancer;
CESC	cis	rs6570726	0.935	rs1883406	chr6:145823205	A/G	cg05347473	chr6:146136440	FBXO30	0.49	6.71	0.38	1.2e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6545883	0.965	rs12713439	chr2:61752154	G/A	cg15711740	chr2:61764176	XPO1	-0.44	-5.38	-0.31	1.68e-7	Tuberculosis;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg01923549	chr6:41774024	USP49	0.45	6.07	0.35	4.37e-9	Fibrinogen levels;
CESC	cis	rs113835537	0.877	rs57127845	chr11:66318325	C/T	cg22134325	chr11:66188745	NPAS4	0.52	5.94	0.34	9.15e-9	Airway imaging phenotypes;
CESC	cis	rs9902453	0.967	rs60176674	chr17:28479854	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	8.09	0.44	2.2e-14	Coffee consumption (cups per day);
CESC	cis	rs4704187	0.687	rs6885887	chr5:74497842	A/C	cg03227963	chr5:74354835	NA	0.29	5.24	0.31	3.29e-7	Response to amphetamines;
CESC	cis	rs780096	0.506	rs1647285	chr2:27714511	A/C	cg21248554	chr2:27665150	KRTCAP3	-0.36	-7.42	-0.41	1.59e-12	Total body bone mineral density;
CESC	cis	rs6732160	0.706	rs1430347	chr2:73367059	G/A	cg01422370	chr2:73384389	NA	0.39	6.6	0.38	2.28e-10	Intelligence (multi-trait analysis);
CESC	cis	rs4563143	0.514	rs73029079	chr19:29294903	A/G	cg04546413	chr19:29218101	NA	0.49	6.05	0.35	4.79e-9	Methadone dose in opioid dependence;
CESC	cis	rs637571	0.544	rs617791	chr11:65702523	C/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.59	7.66	0.43	3.48e-13	Eosinophil percentage of white cells;
CESC	cis	rs7666738	0.783	rs10028584	chr4:98962404	C/T	cg17366294	chr4:99064904	C4orf37	0.6	8.48	0.46	1.55e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs17539620	0.624	rs62432737	chr6:154834772	G/A	cg20019720	chr6:154832845	CNKSR3	0.47	6.24	0.36	1.74e-9	Lipoprotein (a) levels;
CESC	trans	rs60843830	1.000	rs17713729	chr2:249092	A/C	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.65	8.09	0.45	2.18e-14	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs763121	0.853	rs4821808	chr22:39065739	A/G	cg06544989	chr22:39130855	UNC84B	0.49	8.38	0.46	3.04e-15	Menopause (age at onset);
CESC	cis	rs3105593	1.000	rs4775893	chr15:50898695	A/T	cg08437265	chr15:50716283	USP8	0.42	5.55	0.32	7.01e-8	QT interval;
CESC	cis	rs1008375	0.863	rs10003291	chr4:17600728	A/C	cg02297831	chr4:17616191	MED28	0.58	6.99	0.39	2.2e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs7772486	0.754	rs4896841	chr6:146041522	T/C	cg23711669	chr6:146136114	FBXO30	-1.0	-15.54	-0.69	3.89e-39	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg18404041	chr3:52824283	ITIH1	-0.37	-6.46	-0.37	4.87e-10	Electroencephalogram traits;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg26687565	chr4:141072046	MAML3	-0.47	-6.26	-0.36	1.53e-9	Thyroid stimulating hormone;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg18543035	chr10:8374526	NA	-0.4	-6.13	-0.35	3.18e-9	Gambling;
CESC	cis	rs7520050	0.966	rs11211234	chr1:46438787	C/A	cg03146154	chr1:46216737	IPP	-0.47	-6.03	-0.35	5.46e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs4713118	0.621	rs10484403	chr6:28033523	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.51	-5.97	-0.34	7.54e-9	Parkinson's disease;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg16265552	chr3:113667068	ZDHHC23	0.51	6.72	0.38	1.11e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs17376456	0.877	rs17316137	chr5:93456577	C/T	cg25358565	chr5:93447407	FAM172A	1.12	11.29	0.57	2.13e-24	Diabetic retinopathy;
CESC	cis	rs853679	0.517	rs3173443	chr6:28137027	T/G	cg26335602	chr6:28129616	ZNF389	0.52	6.84	0.39	5.58e-11	Depression;
CESC	cis	rs2228479	0.850	rs9282681	chr16:89805914	T/C	cg14709524	chr16:89940631	TCF25	0.87	6.45	0.37	5.39e-10	Skin colour saturation;
CESC	cis	rs7666738	0.830	rs34870112	chr4:99045815	T/G	cg17366294	chr4:99064904	C4orf37	0.61	8.78	0.47	2.13e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs34779708	0.966	rs10827492	chr10:35429825	A/G	cg03585969	chr10:35415529	CREM	-0.73	-9.66	-0.51	4.03e-19	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs6486730	0.508	rs7133440	chr12:129269244	A/C	cg09035930	chr12:129282057	SLC15A4	-0.41	-5.25	-0.31	3.14e-7	Systemic lupus erythematosus;
CESC	cis	rs2204008	0.538	rs61931093	chr12:38242911	C/T	cg26384229	chr12:38710491	ALG10B	-0.46	-5.98	-0.34	7.11e-9	Bladder cancer;
CESC	cis	rs9393777	0.623	rs56296968	chr6:26474571	C/T	cg14345882	chr6:26364793	BTN3A2	0.43	5.35	0.31	1.95e-7	Intelligence (multi-trait analysis);
CESC	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.71	-11.32	-0.57	1.65e-24	Longevity;Endometriosis;
CESC	cis	rs11122272	0.668	rs1538664	chr1:231555295	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.49	-6.64	-0.38	1.8e-10	Hemoglobin concentration;
CESC	cis	rs12368653	0.591	rs1038914	chr12:58011066	G/A	cg00700412	chr12:58011837	NA	-0.46	-7.26	-0.41	4.29e-12	Multiple sclerosis;
CESC	cis	rs4665809	1.000	rs6720314	chr2:26334852	G/A	cg04944784	chr2:26401820	FAM59B	-0.78	-8.86	-0.48	1.18e-16	Gut microbiome composition (summer);
CESC	cis	rs2013441	0.670	rs35317166	chr17:19959820	T/A	cg12073167	chr17:19770448	ULK2	-0.43	-5.11	-0.3	6.19e-7	Obesity-related traits;
CESC	cis	rs9291683	0.645	rs11557743	chr4:10118377	C/G	cg11266682	chr4:10021025	SLC2A9	-0.46	-8.38	-0.46	3.17e-15	Bone mineral density;
CESC	cis	rs73019876	0.869	rs6511306	chr19:22163848	A/G	cg11619707	chr19:22235551	ZNF257	-0.28	-5.11	-0.3	6.09e-7	Testicular germ cell tumor;
CESC	cis	rs7937682	0.558	rs7113067	chr11:111692182	G/A	cg22437258	chr11:111473054	SIK2	-0.52	-5.75	-0.33	2.48e-8	Primary sclerosing cholangitis;
CESC	cis	rs9902453	0.967	rs62070344	chr17:28476997	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.62	7.93	0.44	6.11e-14	Coffee consumption (cups per day);
CESC	cis	rs875971	0.545	rs67397473	chr7:65633305	A/G	cg18876405	chr7:65276391	NA	0.51	5.96	0.34	8.21e-9	Aortic root size;
CESC	cis	rs16854884	0.657	rs16854772	chr3:143703890	A/G	cg06585982	chr3:143692056	C3orf58	0.46	5.69	0.33	3.32e-8	Economic and political preferences (feminism/equality);
CESC	cis	rs7918232	0.941	rs10741128	chr10:27411509	G/A	cg14240646	chr10:27532245	ACBD5	-0.66	-6.43	-0.37	5.89e-10	Breast cancer;
CESC	cis	rs9322193	0.923	rs10782316	chr6:150073891	A/C	cg13206674	chr6:150067644	NUP43	0.46	6.59	0.38	2.41e-10	Lung cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08708209	chr1:221915487	DUSP10	0.58	6.55	0.37	3.04e-10	Gut microbiome composition (summer);
CESC	cis	rs6736093	0.796	rs34240639	chr2:112809951	T/A	cg12686935	chr2:112915763	FBLN7	-0.45	-5.95	-0.34	8.59e-9	Coronary artery disease;
CESC	cis	rs853679	0.517	rs4713146	chr6:28111536	A/T	cg22143856	chr6:28129313	ZNF389	0.52	6.53	0.37	3.27e-10	Depression;
CESC	cis	rs1957429	0.901	rs60979440	chr14:65390231	A/G	cg23373153	chr14:65346875	NA	-0.9	-9.7	-0.51	3.21e-19	Pediatric areal bone mineral density (radius);
CESC	cis	rs9291683	0.595	rs35501905	chr4:10053431	C/T	cg00071950	chr4:10020882	SLC2A9	0.83	14.75	0.67	2.38e-36	Bone mineral density;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27051171	chr2:7005923	CMPK2	0.66	7.6	0.42	5.2e-13	Gut microbiome composition (summer);
CESC	trans	rs9388451	0.626	rs9385383	chr6:126086290	G/T	cg05039488	chr6:79577232	IRAK1BP1	-0.62	-8.55	-0.46	9.67e-16	Brugada syndrome;
CESC	cis	rs1691799	0.867	rs1168330	chr12:66763167	C/T	cg16791601	chr12:66731901	HELB	0.67	10.81	0.55	8.23e-23	White blood cell count (basophil);
CESC	cis	rs2836950	0.545	rs4818001	chr21:40575088	T/C	cg17971929	chr21:40555470	PSMG1	-0.6	-8.06	-0.44	2.64e-14	Menarche (age at onset);
CESC	trans	rs2727020	0.521	rs11040408	chr11:49534880	A/T	cg03929089	chr4:120376271	NA	0.61	7.21	0.4	5.74e-12	Coronary artery disease;
CESC	trans	rs116095464	0.558	rs1812843	chr5:267658	A/G	cg00938859	chr5:1591904	SDHAP3	0.63	6.77	0.38	8.38e-11	Breast cancer;
CESC	cis	rs909674	0.775	rs4821896	chr22:39833437	T/C	cg02038168	chr22:39784481	NA	-0.66	-8.47	-0.46	1.72e-15	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs6460942	0.915	rs62448602	chr7:12457145	T/G	cg10578991	chr7:12443926	VWDE	-0.5	-5.52	-0.32	7.93e-8	Coronary artery disease;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg06474646	chr7:128864675	AHCYL2	-0.5	-6.27	-0.36	1.44e-9	Ulcerative colitis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13504215	chr3:30648325	TGFBR2	0.57	6.8	0.39	6.81e-11	Gut microbiome composition (summer);
CESC	cis	rs9733	0.818	rs10888388	chr1:150687296	C/T	cg18016565	chr1:150552671	MCL1	-0.35	-5.89	-0.34	1.15e-8	Tonsillectomy;
CESC	cis	rs227584	0.663	rs3180912	chr17:42259463	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.4	6.11	0.35	3.63e-9	Bone mineral density (hip);Bone mineral density;
CESC	cis	rs6831352	0.879	rs29001212	chr4:100051877	T/C	cg13256891	chr4:100009986	ADH5	-0.77	-8.43	-0.46	2.27e-15	Alcohol dependence;
CESC	cis	rs4689388	0.926	rs4688987	chr4:6287329	C/T	cg25554036	chr4:6271136	WFS1	0.55	9.01	0.48	4.27e-17	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs6728642	0.808	rs114192053	chr2:97871906	G/A	cg26665480	chr2:98280029	ACTR1B	-0.92	-6.97	-0.39	2.47e-11	Bipolar disorder lithium response (continuous) or schizophrenia;
CESC	cis	rs7618915	0.501	rs35526119	chr3:52749334	C/T	cg07507251	chr3:52567010	NT5DC2	0.34	5.92	0.34	9.68e-9	Bipolar disorder;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg25353064	chr10:96991431	NA	0.5	6.66	0.38	1.62e-10	Fibrinogen levels;
CESC	cis	rs4919087	1.000	rs7076523	chr10:99089296	T/C	cg25902810	chr10:99078978	FRAT1	-0.67	-8.9	-0.48	9.11e-17	Monocyte count;
CESC	cis	rs8067545	0.611	rs16960697	chr17:20027718	A/G	cg13482628	chr17:19912719	NA	0.41	5.49	0.32	9.21e-8	Schizophrenia;
CESC	cis	rs6087990	0.806	rs910085	chr20:31383353	T/G	cg13636640	chr20:31349939	DNMT3B	0.82	13.16	0.63	9.12e-31	Ulcerative colitis;
CESC	cis	rs3859192	0.561	rs9916158	chr17:38182229	G/T	cg17344932	chr17:38183730	MED24;SNORD124	0.62	9.57	0.51	7.92e-19	White blood cell count;
CESC	cis	rs3106136	0.564	rs60428594	chr4:95103466	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.46	-6.23	-0.36	1.8e-9	Capecitabine sensitivity;
CESC	cis	rs9733	0.596	rs2867301	chr1:150653795	C/T	cg09365446	chr1:150670422	GOLPH3L	0.42	5.9	0.34	1.09e-8	Tonsillectomy;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg10120645	chr8:125486635	RNF139	-0.44	-6.16	-0.35	2.69e-9	Fibrinogen levels;
CESC	cis	rs1348850	0.537	rs3770010	chr2:178537796	T/C	cg23306229	chr2:178417860	TTC30B	0.53	7.01	0.4	2.03e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs6831352	0.918	rs29001195	chr4:100054244	G/T	cg13256891	chr4:100009986	ADH5	-0.77	-8.45	-0.46	1.97e-15	Alcohol dependence;
CESC	cis	rs10504229	0.593	rs78459635	chr8:58004995	G/T	cg22535103	chr8:58192502	C8orf71	-0.9	-8.95	-0.48	6.29e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs7727544	0.606	rs200838	chr5:131710399	A/C	cg14196790	chr5:131705035	SLC22A5	-0.42	-6.62	-0.38	1.93e-10	Blood metabolite levels;
CESC	cis	rs910316	0.839	rs35977276	chr14:75637359	A/C	cg11812906	chr14:75593930	NEK9	-0.88	-14.52	-0.67	1.5e-35	Height;
CESC	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.52	0.37	3.63e-10	Prudent dietary pattern;
CESC	cis	rs3733585	0.673	rs9994937	chr4:9964799	G/T	cg02734326	chr4:10020555	SLC2A9	-0.45	-6.29	-0.36	1.27e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs7267979	1.000	rs6037105	chr20:25374199	C/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.88	-18.13	-0.74	2.42e-48	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs8114671	0.562	rs6088642	chr20:33483186	G/T	cg06115741	chr20:33292138	TP53INP2	0.46	5.58	0.32	6.06e-8	Height;
CESC	cis	rs2204008	0.774	rs11615665	chr12:38328162	T/A	cg26384229	chr12:38710491	ALG10B	0.72	10.82	0.55	7.48e-23	Bladder cancer;
CESC	cis	rs853679	0.517	rs9357066	chr6:28129831	T/C	cg23281280	chr6:28129359	ZNF389	0.59	7.9	0.44	7.47e-14	Depression;
CESC	cis	rs597539	0.690	rs635529	chr11:68626294	C/T	cg04772025	chr11:68637568	NA	0.54	6.02	0.35	5.87e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs1577917	0.958	rs1591438	chr6:86525214	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-6.28	-0.36	1.4e-9	Response to antipsychotic treatment;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg01941219	chr13:98795021	FARP1	-0.48	-6.46	-0.37	4.87e-10	Fibrinogen levels;
CESC	cis	rs9325144	0.510	rs6582599	chr12:38715965	T/G	cg26384229	chr12:38710491	ALG10B	0.56	7.75	0.43	1.93e-13	Morning vs. evening chronotype;
CESC	cis	rs3785574	0.962	rs2727329	chr17:61924566	C/T	cg07677032	chr17:61819896	STRADA	0.42	5.2	0.3	3.93e-7	Height;
CESC	cis	rs7666738	0.830	rs6832209	chr4:98994120	A/G	cg03467027	chr4:99064603	C4orf37	0.43	5.4	0.31	1.49e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs1038903	0.893	rs6448594	chr4:28757925	G/T	cg15651925	chr7:156259219	NA	0.48	6.11	0.35	3.51e-9	Menarche (age at onset);
CESC	cis	rs6547741	0.874	rs28381983	chr2:27804432	T/C	cg21248554	chr2:27665150	KRTCAP3	0.25	5.15	0.3	5.2e-7	Oral cavity cancer;
CESC	cis	rs4665809	0.590	rs2033317	chr2:26477650	G/A	cg08470875	chr2:26401718	FAM59B	0.76	8.06	0.44	2.69e-14	Gut microbiome composition (summer);
CESC	trans	rs12356475	0.710	rs10822686	chr10:67733250	C/T	cg06481920	chr2:132431767	NA	0.5	6.36	0.36	8.99e-10	Psoriatic arthritis;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg18005807	chr22:18506799	MICAL3	0.46	6.15	0.35	2.84e-9	Systemic lupus erythematosus;
CESC	cis	rs9443645	0.527	rs4706746	chr6:79674176	G/A	cg05283184	chr6:79620031	NA	-0.36	-5.14	-0.3	5.21e-7	Intelligence (multi-trait analysis);
CESC	cis	rs9623117	1.000	rs9611267	chr22:40506004	C/T	cg05033341	chr22:40419857	FAM83F	0.42	5.39	0.31	1.54e-7	Prostate cancer (SNP x SNP interaction);Prostate cancer;
CESC	cis	rs2836974	0.897	rs12481860	chr21:40537836	T/A	cg11890956	chr21:40555474	PSMG1	1.18	22.8	0.81	2.05e-64	Cognitive function;
CESC	cis	rs4704187	0.687	rs11950665	chr5:74423339	A/G	cg03227963	chr5:74354835	NA	0.31	5.65	0.33	4.17e-8	Response to amphetamines;
CESC	cis	rs7927592	0.956	rs7124078	chr11:68298633	G/T	cg20283391	chr11:68216788	NA	-0.5	-5.98	-0.34	7.31e-9	Total body bone mineral density;
CESC	cis	rs8078723	0.933	rs55846942	chr17:38164470	G/A	cg17467752	chr17:38218738	THRA	0.69	10.54	0.54	6.17e-22	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CESC	cis	rs12142240	0.698	rs932816	chr1:46859749	G/A	cg10495392	chr1:46806563	NSUN4	0.56	6.17	0.35	2.61e-9	Menopause (age at onset);
CESC	cis	rs780096	0.647	rs11682083	chr2:27752296	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.29	-5.13	-0.3	5.68e-7	Total body bone mineral density;
CESC	cis	rs8077889	0.917	rs1859048	chr17:41892039	A/C	cg26893861	chr17:41843967	DUSP3	-0.64	-7.75	-0.43	1.93e-13	Triglycerides;
CESC	cis	rs2836974	0.568	rs419469	chr21:40537234	C/T	cg11644478	chr21:40555479	PSMG1	0.83	12.56	0.61	1.05e-28	Cognitive function;
CESC	cis	rs4803468	0.934	rs2317131	chr19:41885151	C/T	cg14132834	chr19:41945861	ATP5SL	-0.6	-7.49	-0.42	1.02e-12	Height;
CESC	cis	rs4076764	1.000	rs7528020	chr1:163426537	G/A	cg24596788	chr1:163392923	NA	-0.47	-6.85	-0.39	5.08e-11	Motion sickness;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg15986164	chr4:901785	GAK	0.44	6.39	0.37	7.53e-10	Thyroid stimulating hormone;
CESC	cis	rs5769765	0.908	rs138867	chr22:50207703	A/G	cg02269571	chr22:50332266	NA	0.47	5.99	0.35	6.85e-9	Schizophrenia;
CESC	cis	rs9660180	0.967	rs9660106	chr1:1797947	A/G	cg20999797	chr1:1681921	NA	0.27	5.32	0.31	2.2e-7	Body mass index;
CESC	cis	rs10540	0.915	rs12419209	chr11:494510	T/C	cg03576123	chr11:487126	PTDSS2	-1.09	-10.86	-0.56	5.59e-23	Body mass index;
CESC	cis	rs2732480	0.557	rs2409004	chr12:48721451	T/C	cg04545296	chr12:48745243	ZNF641	0.36	6.27	0.36	1.49e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs2988277	0.737	rs1723015	chr1:167432894	T/C	cg22356347	chr1:167427500	CD247	-0.31	-6.34	-0.36	1e-9	Allergic disease (asthma, hay fever or eczema);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg13591497	chr9:126129566	CRB2	0.46	6.34	0.36	9.98e-10	Fibrinogen levels;
CESC	cis	rs4950928	0.823	rs2494277	chr1:203168092	A/G	cg17014757	chr1:203156097	CHI3L1	-0.54	-5.38	-0.31	1.6e-7	YKL-40 levels;
CESC	cis	rs873946	0.586	rs12783078	chr10:134569706	C/T	cg18305652	chr10:134549665	INPP5A	0.45	6.28	0.36	1.34e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs7588746	0.868	rs12104649	chr2:201128832	C/T	cg23649088	chr2:200775458	C2orf69	-0.53	-6.32	-0.36	1.12e-9	Bipolar disorder lithium response (continuous) or schizophrenia;
CESC	cis	rs11997175	0.549	rs4349945	chr8:33654323	T/C	ch.8.33884649F	chr8:33765107	NA	0.66	8.38	0.46	3.15e-15	Body mass index;
CESC	cis	rs7809950	0.723	rs62483634	chr7:106878516	G/A	cg23024343	chr7:107201750	COG5	-0.46	-5.9	-0.34	1.12e-8	Coronary artery disease;
CESC	cis	rs7552404	1.000	rs7516226	chr1:76234257	G/A	cg03433033	chr1:76189801	ACADM	0.62	7.14	0.4	8.85e-12	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs9322193	0.887	rs3777949	chr6:149917157	G/A	cg13206674	chr6:150067644	NUP43	0.42	6.16	0.35	2.7e-9	Lung cancer;
CESC	cis	rs9660180	0.967	rs2272908	chr1:1721479	A/G	cg17747265	chr1:1875780	NA	0.55	9.03	0.49	3.57e-17	Body mass index;
CESC	cis	rs1552244	0.816	rs17050701	chr3:10041554	A/G	cg08888203	chr3:10149979	C3orf24	0.48	6.1	0.35	3.84e-9	Alzheimer's disease;
CESC	trans	rs360798	0.512	rs1906200	chr2:62806598	C/T	cg07814414	chr15:31774773	NA	-0.42	-6.25	-0.36	1.67e-9	Coronary artery disease;
CESC	cis	rs4665809	1.000	rs13030858	chr2:26315451	G/A	cg08470875	chr2:26401718	FAM59B	-0.48	-5.27	-0.31	2.79e-7	Gut microbiome composition (summer);
CESC	cis	rs2070488	0.775	rs2300669	chr3:38541318	C/A	cg24069376	chr3:38537580	EXOG	-0.34	-5.83	-0.34	1.6e-8	Electrocardiographic conduction measures;
CESC	cis	rs1062177	0.756	rs2964589	chr5:151118189	G/T	cg00977110	chr5:151150581	G3BP1	-0.6	-6.22	-0.36	1.91e-9	Preschool internalizing problems;
CESC	cis	rs10479542	0.702	rs13183521	chr5:178975606	A/G	cg14820908	chr5:178986412	RUFY1	-0.38	-5.47	-0.32	1.05e-7	Lung cancer;
CESC	cis	rs7474896	0.537	rs1779068	chr10:38250785	G/A	cg25427524	chr10:38739819	LOC399744	0.49	5.46	0.32	1.1e-7	Obesity (extreme);
CESC	cis	rs35110281	0.782	rs9981291	chr21:45031458	A/G	cg04455712	chr21:45112962	RRP1B	0.4	5.82	0.34	1.67e-8	Mean corpuscular volume;
CESC	cis	rs9926296	0.744	rs164748	chr16:89708292	C/G	cg03605463	chr16:89740564	NA	0.64	7.76	0.43	1.89e-13	Vitiligo;
CESC	trans	rs17635075	1.000	rs2131247	chr4:167347496	C/T	cg14326305	chr9:107573154	ABCA1	0.6	6.23	0.36	1.84e-9	Obesity-related traits;
CESC	cis	rs40363	0.645	rs250627	chr16:3527050	G/A	cg05754148	chr16:3507555	NAT15	0.54	7.9	0.44	7.65e-14	Tuberculosis;
CESC	cis	rs9287719	0.601	rs10177062	chr2:10713698	C/T	cg00105475	chr2:10696890	NA	0.4	5.47	0.32	1.05e-7	Prostate cancer;
CESC	trans	rs6600671	0.967	rs12069545	chr1:121172203	A/G	cg17023122	chr1:144479586	NA	0.45	6.2	0.36	2.1e-9	Hip geometry;
CESC	cis	rs476633	0.691	rs2164996	chr15:41536624	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.47	-6.82	-0.39	6.1e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs4472734	0.932	rs11120327	chr1:214626397	G/A	cg00063699	chr1:214624242	PTPN14	-0.33	-5.11	-0.3	6.06e-7	Height;
CESC	cis	rs35306767	0.903	rs13377166	chr10:886259	G/A	cg10556349	chr10:835070	NA	0.58	5.59	0.32	5.63e-8	Eosinophil percentage of granulocytes;
CESC	cis	rs7666738	0.791	rs10856933	chr4:98958542	C/A	cg05340658	chr4:99064831	C4orf37	0.8	12.4	0.61	3.76e-28	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04108296	chr1:167691246	MPZL1	0.62	6.71	0.38	1.17e-10	Gut microbiome composition (summer);
CESC	cis	rs9309473	1.000	rs11674602	chr2:73723185	A/T	cg20560298	chr2:73613845	ALMS1	-0.56	-7.28	-0.41	3.91e-12	Metabolite levels;
CESC	cis	rs10479542	0.583	rs4131080	chr5:179044292	G/A	cg19626725	chr5:178986131	RUFY1	0.39	6.06	0.35	4.67e-9	Lung cancer;
CESC	cis	rs7312933	1.000	rs7312933	chr12:42503467	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.46	-6.0	-0.35	6.63e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	trans	rs61931739	0.534	rs7965503	chr12:34199349	A/G	cg13010199	chr12:38710504	ALG10B	0.48	6.0	0.35	6.54e-9	Morning vs. evening chronotype;
CESC	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg24642844	chr7:1081250	C7orf50	-0.68	-8.39	-0.46	2.9e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2721195	0.719	rs4925811	chr8:145802447	G/T	cg17328964	chr8:145687451	CYHR1	0.44	6.1	0.35	3.79e-9	Age at first birth;
CESC	cis	rs4975616	0.869	rs421284	chr5:1325590	T/C	cg26373071	chr5:1325741	CLPTM1L	0.44	7.07	0.4	1.42e-11	Lung cancer;
CESC	trans	rs1044826	1.000	rs9868544	chr3:139163154	C/T	cg05129325	chr1:215255161	KCNK2	-0.34	-6.1	-0.35	3.75e-9	Obesity-related traits;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg13629201	chr9:5111420	JAK2	0.52	6.93	0.39	3.13e-11	Fibrinogen levels;
CESC	cis	rs1448094	0.520	rs12304244	chr12:86272823	C/T	cg00310523	chr12:86230176	RASSF9	0.34	5.18	0.3	4.38e-7	Major depressive disorder;
CESC	cis	rs9733	0.596	rs72702570	chr1:150688196	C/T	cg09365446	chr1:150670422	GOLPH3L	0.42	5.86	0.34	1.37e-8	Tonsillectomy;
CESC	cis	rs34779708	0.931	rs7084196	chr10:35367161	T/C	cg03585969	chr10:35415529	CREM	0.76	10.09	0.53	1.8e-20	Inflammatory bowel disease;Crohn's disease;
CESC	trans	rs6780666	0.527	rs9877177	chr3:136957488	C/A	cg16900796	chr19:10755136	SLC44A2	-0.42	-6.41	-0.37	6.46e-10	Intelligence (multi-trait analysis);
CESC	cis	rs8111998	0.826	rs8108776	chr19:22765384	C/T	cg19914732	chr19:22715077	NA	-0.38	-5.26	-0.31	2.93e-7	Corneal structure;
CESC	cis	rs6662572	0.737	rs72677530	chr1:46529677	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.46	5.13	0.3	5.49e-7	Blood protein levels;
CESC	cis	rs910316	0.737	rs175077	chr14:75506875	G/A	cg11812906	chr14:75593930	NEK9	-0.82	-12.97	-0.62	4.02e-30	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16755220	chr16:12070685	RUNDC2A	0.59	6.92	0.39	3.45e-11	Gut microbiome composition (summer);
CESC	cis	rs9916302	0.821	rs11078916	chr17:37746307	T/C	cg20243544	chr17:37824526	PNMT	0.56	6.88	0.39	4.37e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs2243480	0.666	rs1880311	chr7:65276752	G/C	cg13147721	chr7:65941812	NA	0.86	7.92	0.44	6.53e-14	Diabetic kidney disease;
CESC	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg10819733	chr22:24237672	NA	-0.44	-6.29	-0.36	1.27e-9	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs72781680	0.848	rs56021814	chr2:24073437	T/A	cg08917208	chr2:24149416	ATAD2B	0.93	8.47	0.46	1.77e-15	Lymphocyte counts;
CESC	cis	rs6088813	1.000	rs6087704	chr20:34001058	C/T	cg14752227	chr20:34000481	UQCC	-0.39	-5.06	-0.3	7.88e-7	Height;
CESC	cis	rs7772486	0.719	rs7753770	chr6:146066161	G/A	cg05347473	chr6:146136440	FBXO30	-0.57	-7.36	-0.41	2.27e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1986734	0.619	rs13106227	chr4:77418681	G/A	cg20311846	chr4:77356250	SHROOM3	-0.26	-5.28	-0.31	2.63e-7	Eosinophilic esophagitis (pediatric);Metabolite levels (small molecules and protein measures);
CESC	cis	rs10911251	0.546	rs3359	chr1:183112041	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.82	12.32	0.6	7.25e-28	Colorectal cancer;
CESC	cis	rs2991971	0.933	rs2356553	chr1:46009313	G/C	cg15605315	chr1:45957053	TESK2	0.44	5.66	0.33	3.92e-8	High light scatter reticulocyte count;
CESC	cis	rs2708240	0.967	rs2710140	chr7:147570584	A/G	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.34	-5.53	-0.32	7.72e-8	QT interval (drug interaction);
CESC	cis	rs12973672	1.000	rs12973672	chr19:35767866	A/G	cg12095397	chr19:35769544	USF2	0.54	7.33	0.41	2.81e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs1348850	0.914	rs12104588	chr2:178253675	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.9	13.34	0.63	2.02e-31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs4849845	0.704	rs4848580	chr2:121001117	A/G	cg24070213	chr2:121070622	NA	-0.41	-5.89	-0.34	1.16e-8	Mean platelet volume;
CESC	cis	rs8072100	0.656	rs2610367	chr17:45569815	A/G	cg08085267	chr17:45401833	C17orf57	-0.51	-6.57	-0.37	2.63e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg27513886	chr16:31073034	ZNF668	0.46	6.23	0.36	1.83e-9	Fibrinogen levels;
CESC	cis	rs9291683	0.588	rs3796829	chr4:10019138	C/G	cg02734326	chr4:10020555	SLC2A9	0.52	7.43	0.42	1.51e-12	Bone mineral density;
CESC	cis	rs3833788	1	rs3833788	chr12:121151062	CTCTCTTG/C	cg21892295	chr12:121157589	UNC119B	-0.42	-6.65	-0.38	1.66e-10	Mean corpuscular hemoglobin;
CESC	cis	rs2562784	0.638	rs2585054	chr15:84273328	A/G	cg17507749	chr15:85114479	UBE2QP1	-0.52	-5.04	-0.3	8.44e-7	Height;
CESC	cis	rs7267005	0.661	rs2425110	chr20:34318815	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	0.95	5.86	0.34	1.39e-8	Response to paliperidone in schizophrenia (Multivariate);
CESC	cis	rs72781680	0.898	rs113522526	chr2:24018476	C/T	cg20701182	chr2:24300061	SF3B14	0.63	5.59	0.32	5.62e-8	Lymphocyte counts;
CESC	cis	rs27434	0.583	rs34764	chr5:96155229	A/G	cg16492584	chr5:96139282	ERAP1	-0.38	-5.47	-0.32	1.04e-7	Ankylosing spondylitis;
CESC	cis	rs13191362	0.935	rs67368176	chr6:162968436	A/T	cg21926612	chr6:163149169	PACRG;PARK2	0.83	7.54	0.42	7.47e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	trans	rs7582180	0.700	rs1437971	chr2:100986964	A/C	cg14257593	chr9:36191184	CLTA	0.61	6.35	0.36	9.13e-10	Intelligence (multi-trait analysis);
CESC	cis	rs8044868	0.530	rs2288000	chr16:72058881	A/G	cg01557791	chr16:72042693	DHODH	-0.46	-6.36	-0.36	8.8e-10	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CESC	cis	rs798502	0.541	rs2644307	chr7:2832973	G/A	cg18446336	chr7:2847575	GNA12	-0.45	-7.53	-0.42	7.78e-13	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Inflammatory bowel disease;Waist circumference adjusted for BMI in non-smokers;Ulcerative colitis;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg17481046	chr3:40547578	ZNF620	-0.42	-6.46	-0.37	4.93e-10	Gambling;
CESC	cis	rs1020064	0.636	rs2576726	chr2:105936412	A/G	cg02079111	chr2:105885981	TGFBRAP1	0.39	5.27	0.31	2.77e-7	AIDS;
CESC	cis	rs4253772	0.872	rs4253776	chr22:46629479	C/T	cg24881330	chr22:46731750	TRMU	-0.55	-5.17	-0.3	4.57e-7	LDL cholesterol;Cholesterol, total;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	ch.20.234237F	chr20:10626720	JAG1	0.38	6.12	0.35	3.32e-9	Gambling;
CESC	cis	rs2645694	0.533	rs2645681	chr4:77820949	G/A	cg10057126	chr4:77819792	ANKRD56	0.59	8.61	0.47	6.84e-16	Emphysema distribution in smoking;
CESC	cis	rs926392	0.692	rs6028259	chr20:37696977	T/A	cg16355469	chr20:37678765	NA	0.5	5.56	0.32	6.59e-8	Dialysis-related mortality;
CESC	cis	rs6484504	0.576	rs208103	chr11:31167400	A/G	cg14844989	chr11:31128820	NA	-0.43	-6.13	-0.35	3.25e-9	Red blood cell count;
CESC	cis	rs7264396	0.790	rs3787164	chr20:34228866	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.86	-11.84	-0.59	3.02e-26	Total cholesterol levels;
CESC	cis	rs35306767	0.714	rs17293608	chr10:1056252	C/T	cg25019033	chr10:957182	NA	-0.52	-5.12	-0.3	5.91e-7	Eosinophil percentage of granulocytes;
CESC	cis	rs2243480	1.000	rs1039664	chr7:65449716	T/G	cg12463550	chr7:65579703	CRCP	0.72	5.92	0.34	9.68e-9	Diabetic kidney disease;
CESC	cis	rs5769765	0.862	rs9616380	chr22:50312225	T/C	cg26441486	chr22:50317300	CRELD2	0.42	5.24	0.31	3.33e-7	Schizophrenia;
CESC	cis	rs870825	0.616	rs6552807	chr4:185640531	A/G	cg04058563	chr4:185651563	MLF1IP	0.65	7.16	0.4	8e-12	Blood protein levels;
CESC	cis	rs10876993	0.928	rs1628552	chr12:58082142	C/T	cg18357645	chr12:58087776	OS9	0.63	10.41	0.54	1.67e-21	Celiac disease or Rheumatoid arthritis;
CESC	cis	rs2204008	0.563	rs2320512	chr12:38266913	G/A	cg26384229	chr12:38710491	ALG10B	-0.44	-5.7	-0.33	3.11e-8	Bladder cancer;
CESC	cis	rs644799	1.000	rs586498	chr11:95537828	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	13.67	0.64	1.45e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs11122272	0.735	rs2474625	chr1:231519331	A/G	cg06096015	chr1:231504339	EGLN1	0.43	6.18	0.35	2.46e-9	Hemoglobin concentration;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg06611277	chr10:26987120	PDSS1	0.48	6.16	0.35	2.7e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs7666738	0.830	rs6818045	chr4:99049374	G/A	cg18180107	chr4:99064573	C4orf37	0.4	5.16	0.3	4.94e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs8060686	0.641	rs118035472	chr16:68242311	A/G	cg26727032	chr16:67993705	SLC12A4	-0.54	-6.01	-0.35	5.98e-9	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs1862618	0.853	rs33326	chr5:56142601	G/A	cg24531977	chr5:56204891	C5orf35	-0.88	-11.14	-0.56	6.81e-24	Initial pursuit acceleration;
CESC	cis	rs7811142	0.830	rs7792525	chr7:99972122	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.9	8.57	0.47	8.48e-16	Platelet count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13748577	chr7:148787770	ZNF786	0.56	6.22	0.36	1.89e-9	Gut microbiome composition (summer);
CESC	cis	rs11577318	0.796	rs4625269	chr1:26626967	C/A	cg00852783	chr1:26633632	UBXN11	0.5	6.99	0.39	2.17e-11	Granulocyte percentage of myeloid white cells;
CESC	cis	rs7107174	1.000	rs2450131	chr11:77944568	A/C	cg02023728	chr11:77925099	USP35	0.52	6.81	0.39	6.37e-11	Testicular germ cell tumor;
CESC	cis	rs66782572	1	rs66782572	chr3:52567617	A/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.39	-5.81	-0.34	1.8e-8	Hemoglobin concentration;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16889839	chr12:132547279	EP400	-0.58	-6.8	-0.39	6.87e-11	Gut microbiome composition (summer);
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg10663503	chr17:8126298	C17orf44	-0.52	-6.87	-0.39	4.69e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs651907	0.535	rs12631513	chr3:101517476	A/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.46	6.05	0.35	4.95e-9	Colorectal cancer;
CESC	cis	rs1153858	1.000	rs72623915	chr15:45647433	C/T	cg21132104	chr15:45694354	SPATA5L1	0.84	11.4	0.57	9.5e-25	Homoarginine levels;
CESC	cis	rs11098499	0.954	rs10017543	chr4:120321420	G/A	cg24375607	chr4:120327624	NA	0.49	5.97	0.34	7.73e-9	Corneal astigmatism;
CESC	cis	rs2841277	0.708	rs11851053	chr14:105407208	T/C	cg15352829	chr14:105391018	PLD4	-0.6	-10.51	-0.54	8.09e-22	Rheumatoid arthritis;
CESC	cis	rs1348850	0.526	rs6718769	chr2:178450909	T/C	cg23306229	chr2:178417860	TTC30B	0.75	7.12	0.4	1.02e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs3741798	0.901	rs61922024	chr12:12485881	C/A	cg08615371	chr12:12503544	MANSC1	0.87	6.35	0.36	9.19e-10	Cerebrospinal fluid biomarker levels;
CESC	cis	rs7072216	0.691	rs3829853	chr10:100171174	A/G	cg26618903	chr10:100175079	PYROXD2	-0.38	-5.79	-0.34	1.99e-8	Metabolite levels;
CESC	cis	rs7727544	0.684	rs274567	chr5:131714409	C/T	cg24060327	chr5:131705240	SLC22A5	0.62	8.19	0.45	1.11e-14	Blood metabolite levels;
CESC	cis	rs7666738	0.830	rs1025203	chr4:99023073	G/A	cg05340658	chr4:99064831	C4orf37	0.81	12.03	0.59	6.66e-27	Colonoscopy-negative controls vs population controls;
CESC	cis	rs77741769	0.569	rs10774572	chr12:121309561	A/G	cg02419362	chr12:121203948	SPPL3	0.34	5.59	0.32	5.6e-8	Mean corpuscular volume;
CESC	cis	rs2731664	0.792	rs335452	chr5:176879671	C/T	cg23176889	chr5:176863531	GRK6	-0.62	-11.01	-0.56	1.88e-23	Intelligence (multi-trait analysis);
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg16354296	chr10:112257617	DUSP5	0.43	6.09	0.35	3.97e-9	Vertical cup-disc ratio;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg09317403	chr14:92994936	RIN3	-0.39	-6.06	-0.35	4.65e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7249142	0.549	rs2239369	chr19:19292405	A/T	cg27384695	chr19:19271486	LOC729991-MEF2B;MEF2B	-0.29	-5.33	-0.31	2.09e-7	IgG glycosylation;
CESC	cis	rs2836974	0.568	rs7282604	chr21:40536910	C/T	cg11890956	chr21:40555474	PSMG1	-0.97	-16.67	-0.72	3.63e-43	Cognitive function;
CESC	cis	rs2180341	0.960	rs6913424	chr6:127707010	A/C	cg27446573	chr6:127587934	RNF146	1.03	14.89	0.67	7.67e-37	Breast cancer;
CESC	cis	rs826838	1.000	rs11168218	chr12:38884466	A/G	cg13010199	chr12:38710504	ALG10B	0.6	8.51	0.46	1.26e-15	Heart rate;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06867065	chr19:51871233	CLDND2	-0.52	-6.17	-0.35	2.48e-9	Gut microbiome composition (summer);
CESC	cis	rs2836974	1.000	rs12710454	chr21:40656919	A/G	cg27266027	chr21:40555129	PSMG1	0.45	5.23	0.31	3.38e-7	Cognitive function;
CESC	cis	rs8064299	0.597	rs4789097	chr17:72781208	C/T	cg25054828	chr17:72772726	NAT9;TMEM104	-0.87	-14.99	-0.68	3.29e-37	Monocyte count;
CESC	cis	rs2836974	0.583	rs9981884	chr21:40585633	G/A	cg17971929	chr21:40555470	PSMG1	0.62	8.0	0.44	3.93e-14	Cognitive function;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05315670	chr11:64037304	BAD	0.6	6.86	0.39	4.78e-11	Gut microbiome composition (summer);
CESC	cis	rs4728302	0.869	rs13231079	chr7:133604373	C/G	cg10665199	chr7:133106180	EXOC4	0.4	5.56	0.32	6.62e-8	Intelligence;Intelligence (multi-trait analysis);
CESC	cis	rs801193	0.569	rs2013908	chr7:66121069	A/T	cg11764359	chr7:65958608	NA	-0.73	-10.44	-0.54	1.38e-21	Aortic root size;
CESC	cis	rs9399135	0.636	rs4646871	chr6:135265617	A/G	cg24558204	chr6:135376177	HBS1L	-0.58	-8.23	-0.45	8.64e-15	Red blood cell count;
CESC	trans	rs1814175	0.803	rs11040451	chr11:49650639	C/T	cg03929089	chr4:120376271	NA	-0.87	-13.23	-0.63	4.97e-31	Height;
CESC	cis	rs6991838	0.584	rs34226237	chr8:66513165	A/C	cg13398993	chr8:66546079	ARMC1	-0.47	-5.79	-0.34	1.98e-8	Intelligence (multi-trait analysis);
CESC	cis	rs7666738	0.962	rs4699605	chr4:99064379	A/G	cg05340658	chr4:99064831	C4orf37	0.69	9.36	0.5	3.49e-18	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7666738	0.791	rs11729596	chr4:99045461	A/G	cg17366294	chr4:99064904	C4orf37	0.61	8.78	0.47	2.13e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2991971	1.000	rs9147	chr1:46016687	T/C	cg06784218	chr1:46089804	CCDC17	-0.3	-5.16	-0.3	4.9e-7	High light scatter reticulocyte count;
CESC	cis	rs751837	0.591	rs2896462	chr14:103434739	A/G	cg10087771	chr14:103399429	CDC42BPB	0.67	6.08	0.35	4.07e-9	Large B-cell lymphoma;
CESC	cis	rs2439831	0.681	rs498837	chr15:43608024	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.9	11.12	0.56	7.77e-24	Lung cancer in ever smokers;
CESC	cis	rs875971	0.830	rs6976714	chr7:65891461	G/A	cg11764359	chr7:65958608	NA	0.81	11.81	0.59	3.86e-26	Aortic root size;
CESC	cis	rs4141404	0.706	rs5753698	chr22:31970054	A/C	cg02404636	chr22:31891804	SFI1	0.42	5.76	0.33	2.32e-8	Paclitaxel-induced neuropathy;
CESC	cis	rs4803468	0.967	rs7259900	chr19:41889429	A/T	cg14132834	chr19:41945861	ATP5SL	-0.64	-8.0	-0.44	4.02e-14	Height;
CESC	cis	rs7623687	1.000	rs7623687	chr3:49448566	A/C	cg19401529	chr3:49056140	DALRD3	0.6	5.27	0.31	2.78e-7	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;
CESC	cis	rs9522267	0.535	rs12583489	chr13:112233455	G/A	cg10483660	chr13:112241077	NA	-0.33	-5.79	-0.33	2.04e-8	Hepatitis;
CESC	trans	rs673604	0.505	rs676614	chr1:36107510	G/T	cg23404562	chr10:115615082	NHLRC2;DCLRE1A	0.55	6.41	0.37	6.46e-10	Endometrial cancer;
CESC	cis	rs6461049	0.638	rs1859993	chr7:2183702	A/G	cg08027265	chr7:2291960	NA	-0.38	-6.01	-0.35	6.23e-9	Schizophrenia;
CESC	cis	rs9818758	0.607	rs5030795	chr3:49141116	C/T	cg00383909	chr3:49044727	WDR6	0.84	6.44	0.37	5.59e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg09157727	chr15:96873850	NR2F2	0.47	6.13	0.35	3.22e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs644799	0.687	rs11021318	chr11:95522996	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.77	11.31	0.57	1.89e-24	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs929354	0.772	rs6967764	chr7:156994964	C/T	cg05182265	chr7:156933206	UBE3C	-0.51	-7.49	-0.42	1.02e-12	Body mass index;
CESC	cis	rs7772486	0.558	rs7753273	chr6:146066039	C/T	cg05347473	chr6:146136440	FBXO30	-0.71	-9.16	-0.49	1.42e-17	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6598955	0.724	rs12757113	chr1:26597144	C/T	cg00852783	chr1:26633632	UBXN11	0.4	5.8	0.34	1.92e-8	Obesity-related traits;
CESC	cis	rs896854	0.625	rs7823886	chr8:95986459	A/T	cg23172400	chr8:95962367	TP53INP1	-0.42	-8.67	-0.47	4.42e-16	Type 2 diabetes;
CESC	cis	rs6500395	1.000	rs7188741	chr16:48607966	T/C	cg04672837	chr16:48644449	N4BP1	0.52	6.51	0.37	3.68e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs10129255	0.536	rs3944157	chr14:107138303	C/T	cg07958169	chr14:107095056	NA	-0.44	-6.51	-0.37	3.79e-10	Kawasaki disease;
CESC	cis	rs7216064	0.953	rs9890629	chr17:65871559	G/A	cg12091567	chr17:66097778	LOC651250	-0.81	-9.07	-0.49	2.67e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs7605827	0.930	rs4668905	chr2:15543776	C/A	cg19274914	chr2:15703543	NA	0.34	6.12	0.35	3.44e-9	Educational attainment (years of education);
CESC	trans	rs1814175	0.817	rs7947286	chr11:49874657	C/T	cg03929089	chr4:120376271	NA	-0.91	-15.43	-0.69	9.49e-39	Height;
CESC	cis	rs7666738	0.830	rs13137808	chr4:99047095	T/C	cg24818145	chr4:99064322	C4orf37	0.38	5.04	0.3	8.49e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2842992	0.830	rs2842966	chr6:160141592	C/T	cg11366901	chr6:160182831	ACAT2	0.82	10.7	0.55	1.96e-22	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs7811142	1.000	rs67315960	chr7:100015124	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.11	11.0	0.56	1.99e-23	Platelet count;
CESC	cis	rs73206853	0.764	rs7960705	chr12:111084540	G/A	cg12870014	chr12:110450643	ANKRD13A	0.65	5.59	0.32	5.71e-8	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs4853012	0.838	rs4563249	chr2:74354016	G/T	cg19729930	chr2:74357872	NA	0.9	13.71	0.64	1.09e-32	Gestational age at birth (maternal effect);
CESC	cis	rs7520050	0.966	rs1085243	chr1:46544768	C/T	cg03146154	chr1:46216737	IPP	-0.44	-5.69	-0.33	3.34e-8	Red blood cell count;Reticulocyte count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10295110	chr16:4524375	NMRAL1;HMOX2	0.55	6.26	0.36	1.59e-9	Gut microbiome composition (summer);
CESC	cis	rs2637266	0.626	rs724113	chr10:78557309	C/T	cg18941641	chr10:78392320	NA	0.41	7.77	0.43	1.73e-13	Pulmonary function;
CESC	trans	rs9937837	1.000	rs35466388	chr16:31314599	T/C	cg04903759	chr3:167238645	WDR49	0.53	6.63	0.38	1.89e-10	Systemic lupus erythematosus;
CESC	cis	rs10911232	0.507	rs61081633	chr1:182995608	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.84	13.19	0.63	6.74e-31	Hypertriglyceridemia;
CESC	trans	rs11098499	0.863	rs10018280	chr4:120478139	T/G	cg25214090	chr10:38739885	LOC399744	0.67	9.15	0.49	1.52e-17	Corneal astigmatism;
CESC	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg23131131	chr22:24373011	LOC391322	-0.67	-9.2	-0.49	1.09e-17	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs939658	0.805	rs11638625	chr15:79434787	T/G	cg17916960	chr15:79447300	NA	-0.38	-6.32	-0.36	1.1e-9	Refractive error;
CESC	cis	rs736408	0.522	rs11716747	chr3:52748857	C/T	cg18404041	chr3:52824283	ITIH1	-0.4	-6.81	-0.39	6.34e-11	Bipolar disorder;
CESC	cis	rs909674	0.541	rs5757655	chr22:39797178	C/G	cg24399712	chr22:39784796	NA	0.81	11.34	0.57	1.44e-24	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs314370	0.951	rs17881696	chr7:100493359	G/A	cg10426581	chr7:100472382	SRRT	0.84	8.18	0.45	1.23e-14	Resting heart rate;
CESC	cis	rs11155671	0.530	rs6939761	chr6:150210994	T/C	cg09699651	chr6:150184138	LRP11	0.55	7.7	0.43	2.78e-13	Testicular germ cell tumor;
CESC	cis	rs11608355	0.515	rs2287192	chr12:109931594	C/T	cg05360138	chr12:110035743	NA	0.8	8.55	0.46	1.02e-15	Neuroticism;
CESC	cis	rs2370759	1.000	rs16933243	chr10:32615135	T/C	cg18270830	chr10:32634957	EPC1	0.71	6.75	0.38	9.32e-11	Sexual dysfunction (female);
CESC	cis	rs826838	0.904	rs7973992	chr12:39168233	T/C	cg13010199	chr12:38710504	ALG10B	0.58	8.08	0.44	2.27e-14	Heart rate;
CESC	trans	rs1945213	0.659	rs17149979	chr11:55840862	A/G	cg03929089	chr4:120376271	NA	0.76	7.26	0.41	4.31e-12	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs28374715	0.783	rs11635269	chr15:41570710	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.98	-14.36	-0.66	5.43e-35	Ulcerative colitis;
CESC	cis	rs7107174	1.000	rs4944198	chr11:78032605	T/A	cg02023728	chr11:77925099	USP35	0.43	6.08	0.35	4.2e-9	Testicular germ cell tumor;
CESC	cis	rs780096	0.526	rs11127013	chr2:27692973	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.28	-5.07	-0.3	7.42e-7	Total body bone mineral density;
CESC	cis	rs9611565	0.681	rs6002372	chr22:41801299	A/T	cg06634786	chr22:41940651	POLR3H	0.73	7.47	0.42	1.2e-12	Vitiligo;
CESC	cis	rs7216064	1.000	rs3935969	chr17:65881959	A/G	cg12091567	chr17:66097778	LOC651250	-0.81	-9.2	-0.49	1.14e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs2073300	1.000	rs6114101	chr20:23446322	C/T	cg12062639	chr20:23401060	NAPB	0.85	6.22	0.36	1.93e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs6963495	0.818	rs73190186	chr7:105164368	G/C	cg13798780	chr7:105162888	PUS7	0.78	8.06	0.44	2.68e-14	Bipolar disorder (body mass index interaction);
CESC	cis	rs12136530	0.669	rs10917449	chr1:19756869	A/G	cg01832549	chr1:19774989	CAPZB	-0.48	-6.43	-0.37	5.97e-10	Lead levels in blood;
CESC	cis	rs7098414	0.511	rs7916349	chr10:82152638	G/A	cg00277334	chr10:82204260	NA	-0.5	-7.37	-0.41	2.23e-12	Post bronchodilator FEV1;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06041985	chr20:442822	TBC1D20	0.57	6.42	0.37	6.44e-10	Gut microbiome composition (summer);
CESC	cis	rs748404	0.697	rs572959	chr15:43550502	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	8.08	0.44	2.31e-14	Lung cancer;
CESC	cis	rs832540	0.695	rs702686	chr5:56201350	A/G	cg24549020	chr5:56110836	MAP3K1	0.49	6.06	0.35	4.56e-9	Coronary artery disease;
CESC	cis	rs7811142	0.775	rs1636980	chr7:99938864	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	-0.94	-9.45	-0.5	1.86e-18	Platelet count;
CESC	cis	rs7772486	0.790	rs6570723	chr6:146151230	A/T	cg23711669	chr6:146136114	FBXO30	0.9	13.27	0.63	3.71e-31	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1570884	0.556	rs2146146	chr13:50170368	C/T	cg03651054	chr13:50194643	NA	0.31	5.08	0.3	7.07e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
CESC	cis	rs265548	0.608	rs36690	chr19:17910483	C/T	cg16024904	chr19:17905718	B3GNT3	0.44	5.84	0.34	1.54e-8	Tumor biomarkers;
CESC	cis	rs1448094	0.512	rs11503595	chr12:86244075	T/A	cg19622623	chr12:86230825	RASSF9	-0.46	-5.92	-0.34	9.94e-9	Major depressive disorder;
CESC	cis	rs6089584	0.606	rs2296082	chr20:60573983	A/G	cg24733560	chr20:60626293	TAF4	0.44	6.41	0.37	6.64e-10	Body mass index;
CESC	cis	rs13108904	0.870	rs13132584	chr4:1251504	G/T	cg00684032	chr4:1343700	KIAA1530	0.41	5.77	0.33	2.22e-8	Obesity-related traits;
CESC	cis	rs13191362	0.872	rs13194619	chr6:163203657	C/T	cg06582575	chr6:163149167	PACRG;PARK2	1.04	9.88	0.52	8.25e-20	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg25458520	chr6:36099195	MAPK13	-0.42	-6.5	-0.37	3.86e-10	Gambling;
CESC	cis	rs1862618	0.573	rs2034245	chr5:56243685	T/C	cg24549020	chr5:56110836	MAP3K1	-0.58	-6.24	-0.36	1.73e-9	Initial pursuit acceleration;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19717193	chr7:105162577	PUS7	0.57	6.6	0.38	2.26e-10	Gut microbiome composition (summer);
CESC	cis	rs7618915	0.547	rs11130323	chr3:52770277	T/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.31	5.49	0.32	9.47e-8	Bipolar disorder;
CESC	cis	rs4665809	1.000	rs4665820	chr2:26309150	T/C	cg26314531	chr2:26401878	FAM59B	-0.62	-7.07	-0.4	1.37e-11	Gut microbiome composition (summer);
CESC	cis	rs9611565	0.694	rs5758347	chr22:41821019	G/T	cg17376030	chr22:41985996	PMM1	-0.76	-8.01	-0.44	3.71e-14	Vitiligo;
CESC	cis	rs7208859	0.623	rs34756112	chr17:29113016	A/G	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.1e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs6748734	0.843	rs6749674	chr2:241834501	G/C	cg07537917	chr2:241836409	C2orf54	-0.25	-5.51	-0.32	8.67e-8	Urinary metabolites;
CESC	cis	rs561341	1.000	rs55643307	chr17:30263074	T/C	cg12193833	chr17:30244370	NA	-0.71	-6.37	-0.36	8.43e-10	Hip circumference adjusted for BMI;
CESC	cis	rs1552244	0.554	rs17050704	chr3:10045734	T/C	cg00149659	chr3:10157352	C3orf10	0.54	6.63	0.38	1.89e-10	Alzheimer's disease;
CESC	cis	rs9322193	0.923	rs9688861	chr6:149959060	G/T	cg04369109	chr6:150039330	LATS1	-0.36	-5.03	-0.3	9.18e-7	Lung cancer;
CESC	cis	rs11078597	0.671	rs1045806	chr17:1641806	G/A	cg18436246	chr17:1640651	WDR81	0.62	7.59	0.42	5.36e-13	Serum albumin level;
CESC	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg26338869	chr17:61819248	STRADA	0.67	8.85	0.48	1.3e-16	Prudent dietary pattern;
CESC	cis	rs7267979	0.844	rs2424703	chr20:25270124	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.79	14.56	0.67	1.07e-35	Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs11088226	0.846	rs2154500	chr21:33926391	T/C	cg09050820	chr6:167586206	TCP10L2	0.63	6.81	0.39	6.42e-11	Gastritis;
CESC	cis	rs79057730	0.599	rs6944167	chr7:826274	G/C	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.69	6.47	0.37	4.72e-10	Initial pursuit acceleration;
CESC	cis	rs4253772	0.575	rs9615956	chr22:46749634	C/T	cg24881330	chr22:46731750	TRMU	0.76	5.07	0.3	7.46e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs8018808	0.935	rs17824034	chr14:77878683	A/G	cg20045696	chr14:77926864	AHSA1	0.47	6.42	0.37	6.33e-10	Myeloid white cell count;
CESC	cis	rs9733	0.818	rs4970926	chr1:150673684	T/C	cg22823121	chr1:150693482	HORMAD1	-0.41	-6.29	-0.36	1.31e-9	Tonsillectomy;
CESC	cis	rs7605827	0.930	rs7590340	chr2:15601441	C/T	cg19274914	chr2:15703543	NA	0.37	6.72	0.38	1.13e-10	Educational attainment (years of education);
CESC	cis	rs6060717	0.536	rs11167279	chr20:34509107	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.65	5.61	0.33	4.97e-8	Hip circumference adjusted for BMI;
CESC	cis	rs9908102	0.710	rs73981622	chr17:12914834	A/C	cg26162695	chr17:12921313	ELAC2	0.53	5.73	0.33	2.68e-8	Schizophrenia;
CESC	cis	rs694739	0.628	rs508168	chr11:64135435	G/A	cg02228329	chr11:64053129	BAD;GPR137	0.62	7.67	0.43	3.25e-13	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CESC	cis	rs8114671	0.528	rs6119542	chr20:33484545	G/T	cg07148914	chr20:33460835	GGT7	0.46	6.13	0.35	3.19e-9	Height;
CESC	cis	rs4970988	0.556	rs2280078	chr1:150600181	C/T	cg13175981	chr1:150552382	MCL1	0.45	5.54	0.32	7.46e-8	Urate levels;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg14039299	chr9:135251409	TTF1	-0.51	-6.88	-0.39	4.3e-11	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs11958404	0.932	rs72816600	chr5:157436349	T/C	cg05962755	chr5:157440814	NA	0.62	6.56	0.37	2.74e-10	IgG glycosylation;
CESC	cis	rs6831352	0.918	rs2851249	chr4:100044822	T/C	cg12011299	chr4:100065546	ADH4	0.59	6.66	0.38	1.56e-10	Alcohol dependence;
CESC	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg18402987	chr7:1209562	NA	0.72	7.39	0.41	1.94e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs858239	0.738	rs7807879	chr7:23260588	G/T	cg23682824	chr7:23144976	KLHL7	0.47	5.82	0.34	1.66e-8	Cerebrospinal fluid biomarker levels;
CESC	cis	rs6952808	0.729	rs35797753	chr7:1954914	G/A	cg21782813	chr7:2030301	MAD1L1	0.41	5.82	0.34	1.72e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs62064224	0.533	rs11657826	chr17:30790386	T/A	cg25809561	chr17:30822961	MYO1D	0.62	8.98	0.48	5.34e-17	Schizophrenia;
CESC	cis	rs13256369	0.901	rs12681327	chr8:8566414	G/T	cg18904891	chr8:8559673	CLDN23	0.7	8.04	0.44	3.06e-14	Obesity-related traits;
CESC	cis	rs736408	0.509	rs13083798	chr3:52649748	A/G	cg15147215	chr3:52552868	STAB1	-0.29	-5.24	-0.31	3.27e-7	Bipolar disorder;
CESC	trans	rs7615952	0.599	rs2333408	chr3:125732098	G/A	cg07211511	chr3:129823064	LOC729375	-0.58	-6.92	-0.39	3.34e-11	Blood pressure (smoking interaction);
CESC	cis	rs2732480	0.500	rs2932093	chr12:48648271	G/T	cg04545296	chr12:48745243	ZNF641	0.4	6.67	0.38	1.48e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs10208940	0.764	rs6741037	chr2:68787042	C/T	cg12452813	chr2:68675892	NA	0.52	5.25	0.31	3.12e-7	Urate levels in lean individuals;
CESC	cis	rs17253792	0.822	rs10137885	chr14:56173590	A/G	cg01858014	chr14:56050164	KTN1	-0.75	-6.77	-0.38	8.09e-11	Putamen volume;
CESC	cis	rs9381040	0.674	rs4711657	chr6:41162715	G/A	cg03526776	chr6:41159608	TREML2	0.39	6.83	0.39	5.73e-11	Alzheimer's disease (late onset);
CESC	cis	rs7552404	0.765	rs211717	chr1:76106969	G/A	cg10523679	chr1:76189770	ACADM	-0.7	-8.07	-0.44	2.39e-14	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs561341	0.883	rs7406056	chr17:30220224	C/T	cg13647721	chr17:30228624	UTP6	0.61	5.73	0.33	2.74e-8	Hip circumference adjusted for BMI;
CESC	cis	rs858239	0.669	rs1990365	chr7:23115966	T/C	cg23682824	chr7:23144976	KLHL7	0.48	6.59	0.38	2.38e-10	Cerebrospinal fluid biomarker levels;
CESC	cis	rs7264396	0.790	rs2207889	chr20:34224898	A/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.63	7.56	0.42	6.68e-13	Total cholesterol levels;
CESC	cis	rs763121	0.853	rs5750673	chr22:39110124	G/A	cg06022373	chr22:39101656	GTPBP1	0.91	14.78	0.67	1.9e-36	Menopause (age at onset);
CESC	trans	rs6089829	0.925	rs4809270	chr20:61676709	C/A	cg23505145	chr19:12996616	KLF1	0.52	6.45	0.37	5.33e-10	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs11098499	0.698	rs4422403	chr4:120258194	C/T	cg09307838	chr4:120376055	NA	0.76	10.33	0.54	3.02e-21	Corneal astigmatism;
CESC	cis	rs2832191	0.791	rs2832199	chr21:30498501	G/A	cg08807101	chr21:30365312	RNF160	-0.73	-10.05	-0.53	2.35e-20	Dental caries;
CESC	cis	rs7267979	0.966	rs6050567	chr20:25354561	C/T	cg08601574	chr20:25228251	PYGB	-0.38	-5.55	-0.32	6.85e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs2635047	0.542	rs2668772	chr18:44770621	T/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.33	5.16	0.3	4.74e-7	Educational attainment;
CESC	cis	rs35079168	0.809	rs11103483	chr9:137287874	G/A	cg00753924	chr9:137298813	RXRA	-0.36	-5.56	-0.32	6.58e-8	Intelligence;
CESC	cis	rs3806843	0.966	rs3756338	chr5:140180561	A/G	cg26395211	chr5:140044315	WDR55	-0.42	-5.36	-0.31	1.85e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs10504229	0.679	rs11786328	chr8:58039269	A/G	cg02725872	chr8:58115012	NA	-0.39	-5.09	-0.3	6.88e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs2412208	0.527	rs4436414	chr1:7120915	G/A	cg20434152	chr1:7120926	CAMTA1	-0.35	-5.7	-0.33	3.26e-8	Survival in sporadic amyotrophic lateral sclerosis;
CESC	cis	rs4588572	0.643	rs10063742	chr5:77759362	A/G	cg11547950	chr5:77652471	NA	-0.44	-5.48	-0.32	9.67e-8	Triglycerides;
CESC	cis	rs17253792	0.822	rs79022053	chr14:56071721	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.79	5.91	0.34	1.06e-8	Putamen volume;
CESC	cis	rs6088580	0.634	rs6088478	chr20:32971719	T/C	cg06115741	chr20:33292138	TP53INP2	-0.46	-5.96	-0.34	7.8e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.54	-6.96	-0.39	2.64e-11	Prudent dietary pattern;
CESC	cis	rs1448094	0.511	rs10863079	chr12:86152700	T/A	cg00310523	chr12:86230176	RASSF9	-0.31	-5.04	-0.3	8.55e-7	Major depressive disorder;
CESC	trans	rs72996113	0.702	rs11224393	chr11:100569021	A/G	cg01999051	chr6:166797738	BRP44L	0.7	6.08	0.35	4.17e-9	Reticulocyte fraction of red cells;Reticulocyte count;
CESC	cis	rs1790761	0.554	rs3758938	chr11:67402362	T/G	cg14500267	chr11:67383377	NA	-0.34	-5.14	-0.3	5.33e-7	Mean corpuscular volume;
CESC	cis	rs727563	0.565	rs132774	chr22:42031953	C/G	cg06481639	chr22:41940642	POLR3H	-0.52	-6.02	-0.35	5.66e-9	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs6495122	0.699	rs2168518	chr15:75081078	G/A	cg09165964	chr15:75287851	SCAMP5	0.4	5.23	0.31	3.46e-7	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
CESC	cis	rs7927771	0.800	rs35996350	chr11:47389223	A/G	cg05585544	chr11:47624801	NA	-0.49	-7.37	-0.41	2.16e-12	Subjective well-being;
CESC	cis	rs8114671	0.562	rs6087651	chr20:33518353	C/T	cg07148914	chr20:33460835	GGT7	0.46	6.13	0.35	3.19e-9	Height;
CESC	cis	rs11690935	0.959	rs4668412	chr2:172619770	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.97	-14.95	-0.68	4.66e-37	Schizophrenia;
CESC	cis	rs4665809	0.652	rs7585891	chr2:26403766	G/A	cg08470875	chr2:26401718	FAM59B	-0.7	-7.43	-0.41	1.54e-12	Gut microbiome composition (summer);
CESC	cis	rs2243480	0.908	rs1532573	chr7:65798802	A/G	cg18252515	chr7:66147081	NA	1.41	14.58	0.67	9.57e-36	Diabetic kidney disease;
CESC	cis	rs11051970	0.559	rs11051973	chr12:32541912	G/T	cg24626660	chr12:32551988	NA	0.38	5.12	0.3	5.82e-7	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs1862618	0.802	rs194058	chr5:56188977	G/A	cg12311346	chr5:56204834	C5orf35	-0.76	-9.27	-0.49	6.68e-18	Initial pursuit acceleration;
CESC	cis	rs12575642	0.660	rs58632573	chr11:63896299	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.92	10.16	0.53	1.05e-20	Attention deficit hyperactivity disorder;
CESC	cis	rs6088580	0.634	rs1205344	chr20:32918298	G/A	cg24642439	chr20:33292090	TP53INP2	-0.51	-6.66	-0.38	1.53e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs11864453	0.762	rs6416742	chr16:72149061	C/T	cg16558253	chr16:72132732	DHX38	-0.56	-8.87	-0.48	1.11e-16	Fibrinogen levels;
CESC	cis	rs2230307	0.536	rs629340	chr1:100538621	A/T	cg24955406	chr1:100503596	HIAT1	0.53	5.41	0.32	1.38e-7	Carotid intima media thickness;
CESC	cis	rs12145833	0.596	rs61833906	chr1:243419706	T/C	cg02356786	chr1:243265016	LOC731275	0.77	5.81	0.34	1.8e-8	Obesity (early onset extreme);
CESC	cis	rs7188697	0.922	rs6499962	chr16:58610750	A/C	cg21335942	chr16:58549945	SETD6	-0.45	-5.24	-0.31	3.34e-7	QT interval;
CESC	cis	rs17253792	0.731	rs74823888	chr14:56049800	T/C	cg01858014	chr14:56050164	KTN1	-0.99	-7.44	-0.42	1.43e-12	Putamen volume;
CESC	cis	rs4665809	0.590	rs2303892	chr2:26461733	C/G	cg26314531	chr2:26401878	FAM59B	0.85	9.04	0.49	3.46e-17	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09156115	chr16:56553898	BBS2	0.56	6.27	0.36	1.45e-9	Gut microbiome composition (summer);
CESC	cis	rs10887741	0.690	rs11202503	chr10:89440749	T/G	cg13926569	chr10:89418898	PAPSS2	0.36	5.36	0.31	1.79e-7	Exercise (leisure time);
CESC	cis	rs1008375	0.932	rs7697329	chr4:17657853	C/A	cg27347728	chr4:17578864	LAP3	0.45	5.16	0.3	4.96e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23385838	chr12:1755068	WNT5B	-0.59	-6.82	-0.39	6.02e-11	Gut microbiome composition (summer);
CESC	cis	rs13108904	0.557	rs1250095	chr4:1239312	C/T	cg05025164	chr4:1340916	KIAA1530	-0.66	-9.05	-0.49	3.22e-17	Obesity-related traits;
CESC	cis	rs9549367	0.789	rs2287248	chr13:113889226	T/C	cg00898013	chr13:113819073	PROZ	-0.5	-6.86	-0.39	4.95e-11	Platelet distribution width;
CESC	cis	rs2070488	0.699	rs13064938	chr3:38440237	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.79	12.46	0.61	2.31e-28	Electrocardiographic conduction measures;
CESC	cis	rs3820068	0.581	rs34453754	chr1:15993208	G/C	cg16988262	chr1:15930761	NA	0.33	5.24	0.31	3.32e-7	Systolic blood pressure;
CESC	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg26338869	chr17:61819248	STRADA	0.69	9.1	0.49	2.2e-17	Prudent dietary pattern;
CESC	cis	rs6904897	0.563	rs6569976	chr6:135224753	A/C	cg22676075	chr6:135203613	NA	0.65	9.46	0.5	1.77e-18	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	cis	rs7714584	0.793	rs11955174	chr5:150254391	T/G	cg22134413	chr5:150180641	NA	0.51	5.92	0.34	9.88e-9	Crohn's disease;
CESC	cis	rs7692995	1.000	rs7663818	chr4:17936443	C/T	cg08925142	chr4:18023851	LCORL	-0.46	-5.31	-0.31	2.29e-7	Height;
CESC	cis	rs9291683	0.546	rs6829727	chr4:10051672	A/C	cg11266682	chr4:10021025	SLC2A9	0.6	11.3	0.57	2.06e-24	Bone mineral density;
CESC	cis	rs11711311	1.000	rs9811353	chr3:113483979	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.73	10.31	0.54	3.51e-21	IgG glycosylation;
CESC	cis	rs3857536	0.813	rs9294688	chr6:66945904	C/T	cg07460842	chr6:66804631	NA	-0.42	-5.29	-0.31	2.55e-7	Blood trace element (Cu levels);
CESC	cis	rs9796	0.621	rs58109657	chr15:41471750	A/G	cg12386646	chr15:41787261	ITPKA	-0.34	-5.29	-0.31	2.52e-7	Menopause (age at onset);
CESC	cis	rs72901758	0.768	rs1567237	chr17:76246294	A/G	cg25512537	chr17:76250053	NA	-0.38	-5.29	-0.31	2.62e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
CESC	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg07677032	chr17:61819896	STRADA	0.45	5.92	0.34	9.86e-9	Prudent dietary pattern;
CESC	cis	rs7107174	1.000	rs72931690	chr11:78073192	G/A	cg02023728	chr11:77925099	USP35	0.47	6.18	0.35	2.45e-9	Testicular germ cell tumor;
CESC	cis	rs12474201	0.832	rs6738426	chr2:46986416	A/G	cg06386533	chr2:46925753	SOCS5	0.83	11.43	0.57	7.16e-25	Height;
CESC	cis	rs7474896	0.522	rs117157955	chr10:37984164	G/T	cg25427524	chr10:38739819	LOC399744	-0.46	-5.28	-0.31	2.75e-7	Obesity (extreme);
CESC	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg17178900	chr1:205818956	PM20D1	0.8	11.89	0.59	2.07e-26	Menarche (age at onset);
CESC	cis	rs66887589	0.934	rs12648182	chr4:120503891	T/A	cg09307838	chr4:120376055	NA	-0.52	-7.0	-0.4	2.1e-11	Diastolic blood pressure;
CESC	cis	rs7605827	0.930	rs11674824	chr2:15537429	G/A	cg19274914	chr2:15703543	NA	0.36	6.55	0.37	2.91e-10	Educational attainment (years of education);
CESC	cis	rs7552404	0.731	rs2029683	chr1:76341643	T/G	cg03433033	chr1:76189801	ACADM	-0.59	-6.13	-0.35	3.21e-9	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs6032067	0.929	rs17424723	chr20:43814520	G/T	cg11264863	chr20:43835661	SEMG1	-0.53	-5.71	-0.33	2.95e-8	Blood protein levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12115567	chr11:6255973	FAM160A2	0.58	6.41	0.37	6.55e-10	Gut microbiome composition (summer);
CESC	cis	rs1941023	0.584	rs2233252	chr11:60157107	T/G	cg08716584	chr11:60157161	MS4A7	-0.6	-10.18	-0.53	9e-21	Congenital heart disease (maternal effect);
CESC	cis	rs6540556	0.954	rs6696463	chr1:209933757	G/C	cg05527609	chr1:210001259	C1orf107	-0.45	-5.63	-0.33	4.66e-8	Red blood cell count;
CESC	cis	rs7811142	0.830	rs73401451	chr7:99981895	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.1	11.28	0.57	2.27e-24	Platelet count;
CESC	cis	rs4132509	1.000	rs6659180	chr1:243995348	C/T	cg21452805	chr1:244014465	NA	0.45	5.65	0.33	4.13e-8	RR interval (heart rate);
CESC	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg18402987	chr7:1209562	NA	0.76	7.56	0.42	6.59e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs6500395	1.000	rs12934126	chr16:48705951	C/G	cg04672837	chr16:48644449	N4BP1	-0.51	-6.53	-0.37	3.33e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs2295499	0.754	rs16843272	chr4:2717515	G/A	cg27239842	chr4:2403781	ZFYVE28	-0.31	-5.2	-0.3	4.03e-7	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
CESC	cis	rs9916302	0.595	rs4795371	chr17:37636695	T/G	cg00129232	chr17:37814104	STARD3	-0.55	-7.33	-0.41	2.87e-12	Glomerular filtration rate (creatinine);
CESC	cis	rs5167	0.504	rs4803779	chr19:45456497	T/C	cg20090143	chr19:45452003	APOC2	0.37	6.39	0.37	7.51e-10	Blood protein levels;
CESC	cis	rs875971	0.862	rs778705	chr7:65861115	G/A	cg18876405	chr7:65276391	NA	0.53	7.32	0.41	3.01e-12	Aortic root size;
CESC	cis	rs2012796	0.957	rs7151434	chr14:81819468	A/G	cg02996355	chr14:81879375	NA	0.49	5.84	0.34	1.52e-8	Night sleep phenotypes;
CESC	cis	rs3785574	0.621	rs1051684	chr17:62006497	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	-0.51	-6.43	-0.37	6e-10	Height;
CESC	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg07677032	chr17:61819896	STRADA	0.46	6.17	0.35	2.58e-9	Prudent dietary pattern;
CESC	cis	rs9916302	0.904	rs11078915	chr17:37715426	T/C	cg15445000	chr17:37608096	MED1	0.42	6.83	0.39	5.67e-11	Glomerular filtration rate (creatinine);
CESC	trans	rs1814175	0.586	rs10769603	chr11:49688837	T/C	cg03929089	chr4:120376271	NA	-0.84	-11.79	-0.59	4.67e-26	Height;
CESC	cis	rs8067545	1.000	rs1860302	chr17:19914399	T/A	cg13482628	chr17:19912719	NA	0.42	5.66	0.33	4e-8	Schizophrenia;
CESC	cis	rs2929278	0.589	rs2411284	chr15:44038899	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.53	-6.96	-0.39	2.74e-11	Schizophrenia;
CESC	cis	rs2717559	0.522	rs35816096	chr8:143884938	C/T	cg17252645	chr8:143867129	LY6D	-0.31	-5.44	-0.32	1.22e-7	Urinary tract infection frequency;
CESC	cis	rs12220238	1.000	rs11000925	chr10:75972601	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.6	5.45	0.32	1.13e-7	Soluble interleukin-2 receptor subunit alpha;
CESC	cis	rs6748734	1.000	rs7604393	chr2:241825034	T/G	cg07537917	chr2:241836409	C2orf54	-0.24	-5.05	-0.3	8.05e-7	Urinary metabolites;
CESC	cis	rs9303280	0.901	rs12936231	chr17:38029120	C/G	cg20243544	chr17:37824526	PNMT	0.51	6.87	0.39	4.62e-11	Self-reported allergy;
CESC	cis	rs8014204	1.000	rs8014374	chr14:75322914	G/A	cg11812906	chr14:75593930	NEK9	-0.41	-5.12	-0.3	5.88e-7	Caffeine consumption;
CESC	cis	rs12893668	0.542	rs12884809	chr14:104095320	G/A	cg24130564	chr14:104152367	KLC1	-0.5	-6.57	-0.37	2.6200000000000003e-10	Reticulocyte count;
CESC	cis	rs875971	1.000	rs10215948	chr7:65747786	G/A	cg18876405	chr7:65276391	NA	-0.5	-6.92	-0.39	3.49e-11	Aortic root size;
CESC	cis	rs10876993	0.784	rs7314152	chr12:58017701	T/G	cg18357645	chr12:58087776	OS9	-0.58	-8.84	-0.48	1.38e-16	Celiac disease or Rheumatoid arthritis;
CESC	cis	rs910316	1.000	rs175449	chr14:75590846	A/T	cg16144293	chr14:75469539	EIF2B2	0.39	5.18	0.3	4.44e-7	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02339682	chr6:56819432	DST;BEND6	0.53	6.43	0.37	5.96e-10	Gut microbiome composition (summer);
CESC	cis	rs9457247	0.663	rs9459839	chr6:167431829	T/C	cg23791538	chr6:167370224	RNASET2	-0.54	-7.33	-0.41	2.81e-12	Crohn's disease;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg06790275	chr15:68346669	PIAS1	0.5	6.75	0.38	9.13e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs10463316	0.894	rs6579875	chr5:150782574	C/T	cg03212797	chr5:150827313	SLC36A1	-0.42	-5.07	-0.3	7.6e-7	Metabolite levels (Pyroglutamine);
CESC	cis	rs290268	0.874	rs290997	chr9:93559351	G/A	cg02608019	chr9:93564028	SYK	0.67	10.21	0.53	7.53e-21	Platelet count;
CESC	cis	rs17807624	0.780	rs11250152	chr8:11454200	A/C	cg21775007	chr8:11205619	TDH	-0.37	-5.17	-0.3	4.52e-7	Systemic lupus erythematosus;
CESC	cis	rs3011225	0.710	rs3011224	chr1:44318483	C/T	cg12908607	chr1:44402522	ARTN	-0.46	-6.64	-0.38	1.72e-10	Amyotrophic lateral sclerosis (age of onset);
CESC	cis	rs1371867	0.555	rs2861348	chr8:101285074	A/G	cg11906718	chr8:101322791	RNF19A	0.43	5.45	0.32	1.17e-7	Atrioventricular conduction;
CESC	cis	rs2228479	0.850	rs12598316	chr16:89916600	C/A	cg00800038	chr16:89945340	TCF25	-0.9	-6.8	-0.39	6.83e-11	Skin colour saturation;
CESC	cis	rs3087591	1.000	rs9902427	chr17:29625430	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.46	-5.86	-0.34	1.34e-8	Hip circumference;
CESC	cis	rs727505	0.865	rs17325193	chr7:124648385	A/G	cg23710748	chr7:124431027	NA	-0.45	-6.98	-0.39	2.31e-11	Lewy body disease;
CESC	cis	rs6831352	0.918	rs7669636	chr4:100059312	G/A	cg13256891	chr4:100009986	ADH5	-0.77	-8.45	-0.46	1.97e-15	Alcohol dependence;
CESC	cis	rs4253772	0.591	rs6007727	chr22:46650959	G/A	cg10231785	chr22:46692440	CN5H6.4;GTSE1	0.48	5.11	0.3	6.16e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs4704187	0.663	rs1422697	chr5:74445817	G/A	cg03227963	chr5:74354835	NA	0.3	5.67	0.33	3.76e-8	Response to amphetamines;
CESC	cis	rs7918232	0.882	rs10829190	chr10:27409555	C/T	cg14442939	chr10:27389572	ANKRD26	0.67	6.77	0.38	8.28e-11	Breast cancer;
CESC	cis	rs9322193	0.923	rs12205092	chr6:150082511	G/T	cg04369109	chr6:150039330	LATS1	-0.46	-6.29	-0.36	1.29e-9	Lung cancer;
CESC	cis	rs8180040	0.764	rs11130115	chr3:47181661	C/A	cg27129171	chr3:47204927	SETD2	0.7	10.6	0.55	4.18e-22	Colorectal cancer;
CESC	trans	rs10489896	0.541	rs2065143	chr1:234568613	T/C	cg10395685	chr11:86085715	CCDC81	-0.42	-6.13	-0.35	3.19e-9	Cognitive test performance;
CESC	cis	rs1080500	1.000	rs1080500	chr3:53175017	C/T	cg07507251	chr3:52567010	NT5DC2	0.35	5.63	0.33	4.6e-8	Autism spectrum disorder or schizophrenia;
CESC	cis	rs1878931	0.597	rs37814	chr16:3455247	C/T	cg02880119	chr16:3481970	NA	0.42	5.24	0.31	3.31e-7	Body mass index (adult);
CESC	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg11905131	chr22:24372483	LOC391322	-0.79	-11.76	-0.59	5.75e-26	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs13106227	0.550	rs13146564	chr4:77376636	C/A	cg20311846	chr4:77356250	SHROOM3	-0.31	-5.67	-0.33	3.69e-8	Eosinophilic esophagitis (pediatric);
CESC	cis	rs1448094	0.791	rs11117122	chr12:86337749	A/C	cg02569458	chr12:86230093	RASSF9	0.45	6.34	0.36	9.64e-10	Major depressive disorder;
CESC	cis	rs9811920	0.809	rs4928150	chr3:99685991	A/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.43	5.71	0.33	3.06e-8	Axial length;
CESC	cis	rs472109	1.000	rs93138	chr11:9759713	A/C	cg03108697	chr11:9732066	SWAP70	-0.34	-5.17	-0.3	4.68e-7	Coronary artery disease;
CESC	cis	rs12476592	0.602	rs1356390	chr2:63669625	C/T	cg17519650	chr2:63277830	OTX1	0.46	5.18	0.3	4.36e-7	Childhood ear infection;
CESC	cis	rs7615952	0.932	rs1976458	chr3:125647512	T/G	cg05084668	chr3:125655381	ALG1L	-0.51	-5.95	-0.34	8.56e-9	Blood pressure (smoking interaction);
CESC	cis	rs12148488	0.738	rs4886417	chr15:75330159	T/G	cg09165964	chr15:75287851	SCAMP5	0.6	8.08	0.44	2.24e-14	Caffeine consumption;
CESC	cis	rs7771547	0.573	rs546353	chr6:36398597	C/A	cg04289385	chr6:36355825	ETV7	0.38	5.57	0.32	6.41e-8	Platelet distribution width;
CESC	cis	rs873946	0.586	rs3793685	chr10:134569316	G/A	cg27286337	chr10:134555280	INPP5A	0.68	7.69	0.43	2.9e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs7666738	0.830	rs13147195	chr4:98893334	G/T	cg17366294	chr4:99064904	C4orf37	0.55	7.51	0.42	9.34e-13	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9814567	1.000	rs4423809	chr3:134300107	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.44	6.0	0.35	6.44e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs9354308	0.933	rs1938068	chr6:66607807	T/C	cg07460842	chr6:66804631	NA	0.65	7.38	0.41	2.04e-12	Metabolite levels;
CESC	cis	rs116095464	0.764	rs10069197	chr5:230822	G/C	cg10591111	chr5:226296	SDHA	-0.54	-6.65	-0.38	1.72e-10	Breast cancer;
CESC	cis	rs1881797	1.000	rs67977965	chr1:247687835	G/A	cg21399703	chr1:247681439	NA	0.55	7.37	0.41	2.13e-12	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs7847628	0.765	rs7026635	chr9:123550027	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.52	-6.05	-0.35	4.95e-9	Birth weight;
CESC	cis	rs7116495	1.000	rs482013	chr11:71803962	G/A	cg26138937	chr11:71823887	C11orf51	-0.86	-7.03	-0.4	1.75e-11	Severe influenza A (H1N1) infection;
CESC	cis	rs4237845	0.537	rs12426201	chr12:58259752	C/T	cg02175503	chr12:58329896	NA	0.48	5.75	0.33	2.42e-8	Intelligence (multi-trait analysis);
CESC	cis	rs7296418	0.738	rs1568428	chr12:123738876	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	0.32	5.22	0.31	3.63e-7	Platelet count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08292968	chr12:111020671	PPTC7	0.61	7.55	0.42	7.05e-13	Gut microbiome composition (summer);
CESC	cis	rs4665809	1.000	rs6546766	chr2:26328680	T/C	cg22920501	chr2:26401640	FAM59B	-0.68	-8.22	-0.45	9.31e-15	Gut microbiome composition (summer);
CESC	cis	rs853679	0.517	rs6932109	chr6:28078303	A/G	cg12963246	chr6:28129442	ZNF389	-0.59	-8.2	-0.45	1.02e-14	Depression;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg17269277	chr4:1796142	FGFR3	0.47	6.05	0.35	5e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs9549367	0.789	rs3794422	chr13:113893729	G/A	cg18105134	chr13:113819100	PROZ	-0.69	-8.42	-0.46	2.39e-15	Platelet distribution width;
CESC	cis	rs9549367	0.713	rs4907599	chr13:113861441	C/T	cg18105134	chr13:113819100	PROZ	0.54	7.03	0.4	1.73e-11	Platelet distribution width;
CESC	cis	rs3749237	0.595	rs11130196	chr3:49490149	A/C	cg06212747	chr3:49208901	KLHDC8B	0.52	6.98	0.39	2.35e-11	Resting heart rate;
CESC	cis	rs7208859	0.524	rs57670615	chr17:29069498	A/G	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.79e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs6089829	0.925	rs4809270	chr20:61676709	C/A	cg08564027	chr20:61660810	NA	0.91	14.59	0.67	8.57e-36	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02330394	chr6:10695063	C6orf52;PAK1IP1	0.54	6.01	0.35	6.04e-9	Gut microbiome composition (summer);
CESC	cis	rs763121	0.819	rs5757161	chr22:38990662	G/A	cg06544989	chr22:39130855	UNC84B	0.52	9.51	0.5	1.23e-18	Menopause (age at onset);
CESC	cis	rs9470366	0.816	rs1321310	chr6:36623124	C/T	cg08179530	chr6:36648295	CDKN1A	-0.52	-6.16	-0.35	2.75e-9	QRS duration;
CESC	cis	rs7666738	0.830	rs7682991	chr4:98982595	C/A	cg05340658	chr4:99064831	C4orf37	0.8	12.42	0.61	3.31e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2228479	0.850	rs62056069	chr16:89912000	C/T	cg14709524	chr16:89940631	TCF25	0.88	6.1	0.35	3.82e-9	Skin colour saturation;
CESC	cis	rs72901758	0.768	rs72901762	chr17:76244926	A/G	cg25512537	chr17:76250053	NA	0.37	5.23	0.31	3.41e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
CESC	cis	rs9905704	0.918	rs369184	chr17:56709086	C/T	cg12560992	chr17:57184187	TRIM37	0.59	7.05	0.4	1.52e-11	Testicular germ cell tumor;
CESC	cis	rs4319547	0.695	rs10846746	chr12:122868696	C/T	cg05707623	chr12:122985044	ZCCHC8	0.55	6.22	0.36	1.89e-9	Body mass index;
CESC	cis	rs11098499	0.863	rs10030660	chr4:120436704	G/A	cg09307838	chr4:120376055	NA	0.93	12.69	0.61	3.78e-29	Corneal astigmatism;
CESC	cis	rs754466	0.580	rs2579176	chr10:79529350	A/G	cg17075019	chr10:79541650	NA	-0.84	-12.78	-0.62	1.79e-29	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs1784581	0.588	rs6415086	chr6:162418147	C/T	cg17173639	chr6:162384350	PARK2	0.56	8.62	0.47	6.34e-16	Itch intensity from mosquito bite;
CESC	cis	rs1707322	1.000	rs7517560	chr1:46425943	A/G	cg06784218	chr1:46089804	CCDC17	0.33	5.63	0.33	4.7e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2777491	0.915	rs7178634	chr15:41634587	A/G	cg02330683	chr15:41787940	ITPKA	0.44	6.51	0.37	3.74e-10	Ulcerative colitis;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg21638108	chr19:19431283	KIAA0892;SF4	-0.47	-6.27	-0.36	1.43e-9	Ulcerative colitis;
CESC	cis	rs2243480	1.000	rs34703416	chr7:65300642	A/G	cg25894440	chr7:65020034	NA	-0.6	-5.35	-0.31	1.86e-7	Diabetic kidney disease;
CESC	cis	rs17711722	0.675	rs6947132	chr7:65273495	G/A	cg11764359	chr7:65958608	NA	-0.67	-8.59	-0.47	7.69e-16	Calcium levels;
CESC	cis	rs12364620	1	rs12364620	chr11:68252123	T/G	cg20283391	chr11:68216788	NA	-0.64	-7.81	-0.43	1.36e-13	Total body bone mineral density (age 0-15);
CESC	cis	rs193541	0.593	rs154517	chr5:122189825	A/T	cg19412675	chr5:122181750	SNX24	0.46	5.47	0.32	1.05e-7	Glucose homeostasis traits;
CESC	cis	rs11190604	1.000	rs9419897	chr10:102246125	T/C	cg07080220	chr10:102295463	HIF1AN	0.55	5.38	0.31	1.6e-7	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs425277	0.585	rs3107157	chr1:2061969	A/G	cg19257562	chr1:2043853	PRKCZ	0.38	6.14	0.35	2.93e-9	Height;
CESC	cis	rs7666738	0.830	rs13149779	chr4:99010145	G/T	cg17366294	chr4:99064904	C4orf37	0.58	8.32	0.46	4.54e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2841277	0.676	rs10438247	chr14:105411781	G/A	cg17340268	chr14:105411764	AHNAK2	-0.52	-7.04	-0.4	1.6e-11	Rheumatoid arthritis;
CESC	cis	rs9300255	0.679	rs28583837	chr12:123863620	G/A	cg19016782	chr12:123741754	C12orf65	0.44	5.4	0.31	1.48e-7	Neutrophil percentage of white cells;
CESC	cis	rs61008539	0.853	rs10950611	chr7:861094	G/T	cg00475322	chr7:917719	C7orf20	0.47	7.04	0.4	1.67e-11	Perceived unattractiveness to mosquitoes;
CESC	trans	rs4942242	0.663	rs7332737	chr13:44215043	C/T	cg19169023	chr15:41853346	TYRO3	-0.63	-7.93	-0.44	6.13e-14	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs2576037	0.523	rs590923	chr18:44404259	G/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.35	5.5	0.32	8.74e-8	Personality dimensions;
CESC	cis	rs16867321	0.694	rs721301	chr2:181387265	A/G	cg23363182	chr2:181467187	NA	0.48	6.84	0.39	5.61e-11	Obesity;
CESC	cis	rs1005277	0.579	rs2504143	chr10:38383706	C/T	cg25427524	chr10:38739819	LOC399744	-0.66	-9.47	-0.5	1.6e-18	Extrinsic epigenetic age acceleration;
CESC	cis	rs614226	0.938	rs12857	chr12:120933946	T/G	cg01236616	chr12:121019343	POP5	1.45	17.59	0.73	2.08e-46	Type 1 diabetes nephropathy;
CESC	cis	rs7923452	0.938	rs753173	chr10:30778738	T/C	cg18806716	chr10:30721971	MAP3K8	0.49	5.88	0.34	1.22e-8	Itch intensity from mosquito bite;
CESC	cis	rs2204008	0.837	rs10876019	chr12:37985477	C/T	cg26384229	chr12:38710491	ALG10B	0.74	10.84	0.55	6.46e-23	Bladder cancer;
CESC	cis	rs6964587	0.839	rs11767135	chr7:91551245	T/G	cg01689657	chr7:91764605	CYP51A1	-0.29	-5.17	-0.3	4.57e-7	Breast cancer;
CESC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg18827097	chr2:3522506	ADI1	0.49	6.3	0.36	1.26e-9	Tetralogy of Fallot;
CESC	cis	rs6570726	0.818	rs412350	chr6:145852409	T/C	cg05347473	chr6:146136440	FBXO30	0.58	7.55	0.42	6.97e-13	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9916302	0.861	rs8081033	chr17:37506650	A/G	cg20243544	chr17:37824526	PNMT	-0.49	-6.09	-0.35	3.9e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs2228479	1.000	rs2228479	chr16:89985940	G/A	cg14709524	chr16:89940631	TCF25	0.85	6.06	0.35	4.62e-9	Skin colour saturation;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10932289	chr17:55038442	COIL	0.62	6.53	0.37	3.28e-10	Gut microbiome composition (summer);
CESC	cis	rs9943753	0.525	rs983307	chr12:109815103	T/G	cg19025524	chr12:109796872	NA	-0.47	-6.7	-0.38	1.23e-10	HDL cholesterol;
CESC	cis	rs875971	0.798	rs7789615	chr7:65878661	A/G	cg11764359	chr7:65958608	NA	0.78	11.31	0.57	1.86e-24	Aortic root size;
CESC	cis	rs9039	0.918	rs12933086	chr16:9225494	A/G	cg08831531	chr16:9218945	NA	-0.57	-7.22	-0.41	5.66e-12	Menopause (age at onset);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg24361620	chr11:45868787	CRY2	0.49	6.43	0.37	5.97e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs453301	0.682	rs2929308	chr8:9084121	T/A	cg06636001	chr8:8085503	FLJ10661	-0.55	-7.28	-0.41	3.8e-12	Joint mobility (Beighton score);
CESC	cis	rs1538970	0.816	rs4633317	chr1:45985157	T/C	cg05343316	chr1:45956843	TESK2	0.92	12.59	0.61	8.59e-29	Platelet count;
CESC	cis	rs3020736	0.500	rs764481	chr22:42518426	G/A	cg04733989	chr22:42467013	NAGA	-0.78	-11.9	-0.59	1.87e-26	Autism spectrum disorder or schizophrenia;
CESC	cis	rs1552244	1.000	rs3846177	chr3:10068572	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.88	11.96	0.59	1.2e-26	Alzheimer's disease;
CESC	cis	rs933688	1.000	rs10073657	chr5:90689749	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.18	16.88	0.72	6.87e-44	Smoking behavior;
CESC	cis	rs1843834	0.539	rs2068244	chr2:225440011	A/G	cg22455342	chr2:225449267	CUL3	-0.69	-8.31	-0.45	4.86e-15	IgE levels in asthmatics (D.p. specific);
CESC	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg06873352	chr17:61820015	STRADA	0.72	12.85	0.62	1.03e-29	Prudent dietary pattern;
CESC	trans	rs9929218	1.000	rs35069703	chr16:68789445	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.7	-8.68	-0.47	4.11e-16	Colorectal cancer;
CESC	cis	rs4849845	0.612	rs3806491	chr2:121008675	G/A	cg24070213	chr2:121070622	NA	0.44	6.39	0.37	7.34e-10	Mean platelet volume;
CESC	cis	rs881375	0.715	rs7858209	chr9:123645760	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.48	6.99	0.39	2.29e-11	Rheumatoid arthritis;
CESC	cis	rs12079745	0.793	rs12062884	chr1:169209513	G/A	cg09363564	chr1:169337483	NME7;BLZF1	-1.03	-6.33	-0.36	1.04e-9	QT interval;
CESC	cis	rs2629540	0.882	rs10901813	chr10:126429875	G/A	cg08799069	chr10:126477246	METTL10	-0.69	-9.3	-0.5	5.47e-18	Cocaine dependence;
CESC	cis	rs854765	0.583	rs7213225	chr17:17869111	T/C	cg04398451	chr17:18023971	MYO15A	-0.7	-9.85	-0.52	1.04e-19	Total body bone mineral density;
CESC	cis	rs787274	1.000	rs7868830	chr9:115577125	G/A	cg13803584	chr9:115635662	SNX30	-0.59	-5.16	-0.3	4.75e-7	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs4689388	0.926	rs4308429	chr4:6294001	A/G	cg14416269	chr4:6271139	WFS1	0.46	7.76	0.43	1.79e-13	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg04025307	chr7:1156635	C7orf50	0.46	6.29	0.36	1.3e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs10504229	0.593	rs80174614	chr8:58024631	G/A	cg22535103	chr8:58192502	C8orf71	-0.67	-7.19	-0.4	6.53e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs11252926	1.000	rs11252926	chr10:566379	C/T	cg08603382	chr10:743973	NA	-0.6	-7.68	-0.43	3.07e-13	Psychosis in Alzheimer's disease;
CESC	cis	rs4704187	0.687	rs10462512	chr5:74387317	C/G	cg03227963	chr5:74354835	NA	0.32	5.92	0.34	9.97e-9	Response to amphetamines;
CESC	cis	rs4665809	1.000	rs4665821	chr2:26309949	A/C	cg27170947	chr2:26402098	FAM59B	-0.59	-7.02	-0.4	1.84e-11	Gut microbiome composition (summer);
CESC	cis	rs2486288	0.656	rs11854325	chr15:45548959	T/C	cg21132104	chr15:45694354	SPATA5L1	-0.54	-6.54	-0.37	3.21e-10	Glomerular filtration rate;
CESC	cis	rs7193541	0.682	rs28681530	chr16:74682496	C/T	cg01733217	chr16:74700730	RFWD3	1.05	20.16	0.78	2e-55	Multiple myeloma;
CESC	trans	rs629535	0.911	rs490165	chr8:70014976	A/G	cg21567404	chr3:27674614	NA	-0.89	-10.79	-0.55	9.77e-23	Dupuytren's disease;
CESC	cis	rs910316	0.737	rs175424	chr14:75626257	T/C	cg08847533	chr14:75593920	NEK9	-0.87	-14.36	-0.66	5.69e-35	Height;
CESC	cis	rs6088580	0.634	rs4911152	chr20:32955024	T/C	cg06115741	chr20:33292138	TP53INP2	-0.45	-5.81	-0.34	1.75e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs34779708	0.897	rs4934527	chr10:35281118	T/A	cg03585969	chr10:35415529	CREM	0.77	10.32	0.54	3.18e-21	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs1018836	0.575	rs17635255	chr8:91518135	A/T	cg16814680	chr8:91681699	NA	-0.56	-6.5	-0.37	4.01e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs9916302	0.851	rs9904919	chr17:37556431	G/C	cg15445000	chr17:37608096	MED1	-0.39	-6.44	-0.37	5.69e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs7044106	0.708	rs991121	chr9:123370345	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.69	9.82	0.52	1.32e-19	Hip circumference adjusted for BMI;
CESC	cis	rs4905014	1.000	rs4905014	chr14:93412031	C/G	cg21097788	chr14:93502930	ITPK1	0.7	5.53	0.32	7.61e-8	Age-related diseases and mortality;Age-related diseases, mortality and associated endophenotypes;
CESC	cis	rs7726839	0.540	rs61731455	chr5:665295	A/G	cg09021430	chr5:549028	NA	-0.42	-5.16	-0.3	4.75e-7	Obesity-related traits;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg02322435	chr11:67815326	TCIRG1	0.55	7.58	0.42	5.77e-13	Fibrinogen levels;
CESC	cis	rs8060686	0.641	rs111227007	chr16:68093138	T/A	cg26727032	chr16:67993705	SLC12A4	-0.55	-6.15	-0.35	2.9e-9	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs35110281	0.837	rs2838336	chr21:45071741	A/G	cg04455712	chr21:45112962	RRP1B	-0.41	-6.22	-0.36	1.98e-9	Mean corpuscular volume;
CESC	cis	rs9905704	0.874	rs304265	chr17:56749298	C/T	cg12560992	chr17:57184187	TRIM37	0.58	6.94	0.39	3.01e-11	Testicular germ cell tumor;
CESC	cis	rs116095464	0.558	rs10036253	chr5:238519	A/C	cg10591111	chr5:226296	SDHA	-0.52	-6.32	-0.36	1.1e-9	Breast cancer;
CESC	cis	rs11098499	0.954	rs13113483	chr4:120309039	C/T	cg09307838	chr4:120376055	NA	0.92	12.66	0.61	4.96e-29	Corneal astigmatism;
CESC	cis	rs916888	0.821	rs70600	chr17:44860021	C/T	cg15921436	chr17:44337874	NA	0.69	7.29	0.41	3.52e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs4233802	0.708	rs7564743	chr2:151133831	A/G	cg25300694	chr2:151184358	NA	0.9	7.32	0.41	3.03e-12	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
CESC	cis	rs6499255	1.000	rs4985518	chr16:69787158	T/C	cg15192750	chr16:69999425	NA	0.44	5.36	0.31	1.84e-7	IgE levels;
CESC	cis	rs7089973	0.604	rs58587374	chr10:116597572	A/G	cg23260525	chr10:116636907	FAM160B1	0.4	7.38	0.41	2.03e-12	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs9640161	0.783	rs1132261	chr7:150059987	G/A	cg21361702	chr7:150065534	REPIN1	0.69	8.31	0.45	4.97e-15	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs2549003	0.811	rs10035166	chr5:131823927	C/T	cg21138405	chr5:131827807	IRF1	-0.42	-5.83	-0.34	1.62e-8	Asthma (sex interaction);
CESC	cis	rs9311474	0.713	rs352168	chr3:52237970	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.32	5.8	0.34	1.92e-8	Electroencephalogram traits;
CESC	cis	rs7208859	0.524	rs59923796	chr17:29064919	G/A	cg13385521	chr17:29058706	SUZ12P	0.82	6.62	0.38	2.04e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs1862618	0.525	rs2662021	chr5:56261691	C/T	cg20203395	chr5:56204925	C5orf35	0.46	5.66	0.33	3.98e-8	Initial pursuit acceleration;
CESC	cis	rs2046867	0.818	rs6792109	chr3:72867091	C/T	cg25664220	chr3:72788482	NA	-0.42	-5.95	-0.34	8.45e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CESC	cis	rs1552244	0.572	rs17032440	chr3:10169819	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	0.75	8.25	0.45	7.7e-15	Alzheimer's disease;
CESC	cis	rs1865760	0.555	rs2051541	chr6:25945211	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.38	-5.2	-0.3	4.02e-7	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07624948	chr16:28962847	NFATC2IP	-0.62	-7.18	-0.4	6.89e-12	Gut microbiome composition (summer);
CESC	trans	rs629535	0.699	rs539956	chr8:70033647	G/A	cg21567404	chr3:27674614	NA	0.93	11.14	0.56	6.62e-24	Dupuytren's disease;
CESC	cis	rs35306767	0.807	rs61831436	chr10:837882	G/A	cg10556349	chr10:835070	NA	0.7	6.0	0.35	6.41e-9	Eosinophil percentage of granulocytes;
CESC	cis	rs798554	0.642	rs2533871	chr7:2883006	C/G	cg04166393	chr7:2884313	GNA12	0.62	8.46	0.46	1.85e-15	Height;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg24511898	chr2:242576823	ATG4B;THAP4	0.47	6.55	0.37	2.97e-10	Systemic lupus erythematosus;
CESC	cis	rs7617773	0.817	rs6800492	chr3:48323890	G/A	cg11946769	chr3:48343235	NME6	0.81	10.85	0.55	6.06e-23	Coronary artery disease;
CESC	cis	rs9549260	0.755	rs55920113	chr13:41222112	C/T	cg21288729	chr13:41239152	FOXO1	0.65	8.5	0.46	1.4e-15	Red blood cell count;
CESC	cis	rs9549367	0.789	rs2287250	chr13:113889474	C/T	cg00898013	chr13:113819073	PROZ	0.48	6.9	0.39	3.72e-11	Platelet distribution width;
CESC	cis	rs7615952	0.599	rs1044215	chr3:125725559	C/G	cg15145296	chr3:125709740	NA	-0.45	-5.14	-0.3	5.34e-7	Blood pressure (smoking interaction);
CESC	trans	rs11098499	0.866	rs6824111	chr4:120285968	T/A	cg25214090	chr10:38739885	LOC399744	0.65	9.11	0.49	2.04e-17	Corneal astigmatism;
CESC	cis	rs2361718	0.568	rs1042397	chr17:78092063	G/A	cg20811857	chr17:78079795	GAA	-0.37	-5.64	-0.33	4.44e-8	Yeast infection;
CESC	cis	rs6665290	0.870	rs17600725	chr1:227204231	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.17	-25.22	-0.84	2.18e-72	Myeloid white cell count;
CESC	cis	rs7618915	0.547	rs11130323	chr3:52770277	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	6.83	0.39	5.96e-11	Bipolar disorder;
CESC	cis	rs8072100	0.656	rs2610367	chr17:45569815	A/G	cg25173405	chr17:45401733	C17orf57	-0.41	-5.31	-0.31	2.27e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs10885582	0.904	rs12357781	chr10:116343076	C/T	cg17056676	chr10:116301354	ABLIM1	0.3	5.1	0.3	6.45e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs4975709	0.589	rs1466606	chr5:1865055	C/T	cg10800226	chr5:1850261	NA	0.31	5.06	0.3	7.76e-7	Cardiovascular disease risk factors;
CESC	cis	rs2242073	0.660	rs6751246	chr2:209002331	T/C	cg10392614	chr2:208977121	NA	-0.37	-5.04	-0.3	8.79e-7	Attention deficit hyperactivity disorder;
CESC	cis	rs8031584	0.678	rs798125	chr15:31116800	C/T	cg08704250	chr15:31115839	NA	0.69	9.22	0.49	9.79e-18	Huntington's disease progression;
CESC	cis	rs9796	0.558	rs7166205	chr15:41514733	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.47	-7.09	-0.4	1.2e-11	Menopause (age at onset);
CESC	cis	rs8099014	0.859	rs11152072	chr18:56098912	A/G	cg19312305	chr18:56117016	MIR122	-0.3	-5.51	-0.32	8.34e-8	Platelet count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08090396	chr3:52805200	NEK4	-0.59	-6.87	-0.39	4.5e-11	Gut microbiome composition (summer);
CESC	cis	rs2108225	0.934	rs2283045	chr7:107440714	G/A	cg18560240	chr7:107437656	SLC26A3	-0.37	-5.08	-0.3	7.01e-7	Ulcerative colitis;
CESC	cis	rs875971	0.862	rs2088655	chr7:65795711	T/C	cg12463550	chr7:65579703	CRCP	-0.48	-6.17	-0.35	2.6e-9	Aortic root size;
CESC	cis	rs6952808	0.630	rs4719443	chr7:2161099	A/G	cg04267008	chr7:1944627	MAD1L1	-0.58	-6.9	-0.39	3.75e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs35306767	0.951	rs55742421	chr10:961037	A/C	cg25019033	chr10:957182	NA	-0.6	-6.42	-0.37	6.2e-10	Eosinophil percentage of granulocytes;
CESC	cis	rs5769765	0.837	rs4824110	chr22:50271631	T/A	cg22709217	chr22:50311962	ALG12;CRELD2	0.46	5.32	0.31	2.21e-7	Schizophrenia;
CESC	cis	rs3892630	0.824	rs2287882	chr19:33332952	C/T	cg22980127	chr19:33182716	NUDT19	0.99	11.18	0.57	5.0600000000000004e-24	Red blood cell traits;
CESC	cis	rs662064	0.890	rs1632108	chr1:10561923	C/T	cg20482658	chr1:10539492	PEX14	0.38	7.59	0.42	5.56e-13	Asthma;
CESC	cis	rs6964587	0.626	rs35849169	chr7:91507313	A/G	cg17063962	chr7:91808500	NA	0.42	5.92	0.34	9.83e-9	Breast cancer;
CESC	cis	rs17854409	1.000	rs16983290	chr20:61478894	A/G	cg05147244	chr20:61493195	TCFL5	-0.99	-7.54	-0.42	7.73e-13	Obesity-related traits;
CESC	cis	rs873946	0.648	rs12783354	chr10:134557235	T/A	cg26818010	chr10:134567672	INPP5A	-0.9	-10.88	-0.56	4.78e-23	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs7116495	0.881	rs6592449	chr11:71670222	C/T	cg10381502	chr11:71823885	C11orf51	-0.65	-5.54	-0.32	7.21e-8	Severe influenza A (H1N1) infection;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18368637	chr6:144179905	LTV1	-0.58	-6.1	-0.35	3.69e-9	Gut microbiome composition (summer);
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg08888278	chr19:13953225	NA	-0.5	-6.87	-0.39	4.63e-11	Asthma;
CESC	cis	rs61776719	0.500	rs11210866	chr1:38449565	T/C	cg26398791	chr1:38455867	SF3A3	-0.42	-5.38	-0.31	1.62e-7	Coronary artery disease;
CESC	cis	rs28673728	0.897	rs28391281	chr1:38408974	T/C	cg12658694	chr1:38397304	INPP5B	0.64	9.27	0.49	6.76e-18	Red cell distribution width;
CESC	cis	rs2204008	0.744	rs11514358	chr12:38255526	G/A	cg13010199	chr12:38710504	ALG10B	0.52	6.38	0.36	8.04e-10	Bladder cancer;
CESC	cis	rs3858526	0.883	rs10769333	chr11:5939685	A/T	cg02574844	chr11:5959923	NA	-0.41	-5.16	-0.3	4.73e-7	DNA methylation (variation);
CESC	cis	rs9549367	0.713	rs556990	chr13:113845059	T/C	cg18105134	chr13:113819100	PROZ	0.54	7.05	0.4	1.55e-11	Platelet distribution width;
CESC	cis	rs5769765	0.908	rs9616217	chr22:50318946	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.54	-5.57	-0.32	6.18e-8	Schizophrenia;
CESC	cis	rs3096299	0.685	rs3803682	chr16:89544636	C/T	cg02034447	chr16:89574710	SPG7	0.46	5.92	0.34	9.81e-9	Multiple myeloma (IgH translocation);
CESC	cis	rs2637266	0.935	rs4520537	chr10:78392978	C/T	cg18941641	chr10:78392320	NA	0.44	8.62	0.47	6.27e-16	Pulmonary function;
CESC	cis	rs10504073	0.584	rs115370638	chr8:49916452	A/G	cg00325661	chr8:49890786	NA	0.53	7.95	0.44	5.42e-14	Blood metabolite ratios;
CESC	cis	rs2797160	1.000	rs2747722	chr6:126009629	A/G	cg05901451	chr6:126070800	HEY2	0.45	6.59	0.38	2.39e-10	Endometrial cancer;
CESC	cis	rs6089829	0.889	rs6122348	chr20:61663921	C/T	cg08564027	chr20:61660810	NA	0.9	15.42	0.69	9.97e-39	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs4481887	0.927	rs4282853	chr1:248475127	A/G	cg00666640	chr1:248458726	OR2T12	0.36	6.12	0.35	3.33e-9	Common traits (Other);
CESC	cis	rs9300255	0.537	rs1619561	chr12:123620268	G/C	cg05973401	chr12:123451056	ABCB9	0.55	6.06	0.35	4.77e-9	Neutrophil percentage of white cells;
CESC	cis	rs4689592	0.554	rs3951346	chr4:7073321	C/T	cg26116260	chr4:7069785	GRPEL1	0.94	14.36	0.66	5.55e-35	Monocyte percentage of white cells;
CESC	cis	rs853679	0.517	rs9380050	chr6:28048538	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.53	-6.09	-0.35	3.91e-9	Depression;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21370986	chr7:6145114	USP42	0.58	6.82	0.39	5.98e-11	Gut microbiome composition (summer);
CESC	cis	rs11048434	0.736	rs1805732	chr12:9090892	A/G	cg04155231	chr12:9217510	LOC144571	-0.33	-5.22	-0.31	3.57e-7	Sjögren's syndrome;
CESC	cis	rs919433	0.889	rs12472355	chr2:198205840	C/A	cg10820045	chr2:198174542	NA	-0.39	-5.75	-0.33	2.45e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs17711722	0.565	rs73372653	chr7:65442795	A/T	cg05332525	chr7:65337924	VKORC1L1	0.46	5.7	0.33	3.11e-8	Calcium levels;
CESC	cis	rs853679	0.517	rs9393901	chr6:28136797	A/G	cg19592336	chr6:28129416	ZNF389	0.58	7.71	0.43	2.54e-13	Depression;
CESC	cis	rs1707322	1.000	rs4660336	chr1:46487976	T/C	cg06784218	chr1:46089804	CCDC17	-0.32	-5.5	-0.32	8.79e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs8114671	0.836	rs6142280	chr20:33622242	A/C	cg07148914	chr20:33460835	GGT7	-0.42	-5.41	-0.32	1.44e-7	Height;
CESC	cis	rs7208859	0.623	rs11657990	chr17:29124200	C/T	cg14008862	chr17:28927542	LRRC37B2	0.65	5.13	0.3	5.49e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs10504229	0.683	rs58883273	chr8:58138275	A/G	cg02725872	chr8:58115012	NA	-0.45	-7.05	-0.4	1.52e-11	Developmental language disorder (linguistic errors);
CESC	trans	rs2593957	0.503	rs9821382	chr3:108812154	A/G	cg17027945	chr15:74284732	STOML1	-0.51	-6.03	-0.35	5.54e-9	Colorectal cancer (diet interaction);
CESC	cis	rs17253792	0.749	rs74979160	chr14:56097568	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.76	5.39	0.31	1.56e-7	Putamen volume;
CESC	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg18402987	chr7:1209562	NA	0.76	7.79	0.43	1.5e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2228479	0.702	rs11076620	chr16:89831520	A/T	cg06558623	chr16:89946397	TCF25	1.17	9.29	0.5	5.84e-18	Skin colour saturation;
CESC	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg11494091	chr17:61959527	GH2	0.76	13.18	0.63	7.67e-31	Prudent dietary pattern;
CESC	cis	rs9346455	0.614	rs2273888	chr6:72006512	C/T	cg27238071	chr6:71998145	OGFRL1	-0.65	-6.35	-0.36	9.44e-10	Antipsychotic drug-induced weight gain (time interaction);Antipsychotic drug-induced weight gain;
CESC	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg06877462	chr1:205807181	PM20D1	0.39	5.51	0.32	8.43e-8	Menarche (age at onset);
CESC	cis	rs7465272	0.530	rs10103161	chr8:143738571	A/G	cg24634471	chr8:143751801	JRK	0.46	5.97	0.34	7.52e-9	Bipolar disorder and schizophrenia;
CESC	trans	rs629535	0.783	rs510632	chr8:70034570	A/G	cg21567404	chr3:27674614	NA	0.93	11.25	0.57	2.83e-24	Dupuytren's disease;
CESC	cis	rs9549367	0.789	rs2302754	chr13:113898385	C/T	cg00898013	chr13:113819073	PROZ	0.48	6.55	0.37	3.01e-10	Platelet distribution width;
CESC	cis	rs4819052	0.885	rs9980676	chr21:46665430	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.75	9.96	0.52	4.61e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs12824058	0.831	rs11608407	chr12:130805869	G/A	cg26677194	chr12:130822605	PIWIL1	0.49	6.24	0.36	1.75e-9	Menopause (age at onset);
CESC	trans	rs864643	0.773	rs11129837	chr3:39589963	A/G	cg13917004	chr19:42462874	RABAC1	0.48	6.02	0.35	5.91e-9	Attention deficit hyperactivity disorder;
CESC	cis	rs2243480	0.522	rs1638736	chr7:66092308	A/T	cg13147721	chr7:65941812	NA	-0.72	-5.92	-0.34	1.02e-8	Diabetic kidney disease;
CESC	cis	rs853679	0.517	rs35512245	chr6:28079953	T/C	cg23281280	chr6:28129359	ZNF389	0.58	7.93	0.44	6.31e-14	Depression;
CESC	cis	rs1862618	0.853	rs2548665	chr5:56131805	T/A	cg24531977	chr5:56204891	C5orf35	-0.89	-11.26	-0.57	2.62e-24	Initial pursuit acceleration;
CESC	cis	rs1030268	0.546	rs12707100	chr7:133274376	T/C	cg10665199	chr7:133106180	EXOC4	0.51	5.4	0.32	1.45e-7	Intelligence (multi-trait analysis);
CESC	cis	rs8027181	0.839	rs998021	chr15:72999825	T/C	cg25632853	chr15:73088954	NA	0.3	5.24	0.31	3.3e-7	Triglyceride levels;
CESC	cis	rs425277	1.000	rs809912	chr1:2078385	C/T	cg24578937	chr1:2090814	PRKCZ	0.55	9.54	0.51	9.57e-19	Height;
CESC	cis	rs6089584	0.927	rs6089593	chr20:60572312	G/A	cg13770153	chr20:60521292	NA	-0.48	-6.35	-0.36	9.54e-10	Body mass index;
CESC	cis	rs9905704	0.507	rs7219031	chr17:56445908	G/A	cg12560992	chr17:57184187	TRIM37	0.64	5.49	0.32	9.54e-8	Testicular germ cell tumor;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg02895995	chr19:7554069	PEX11G	-0.46	-6.92	-0.39	3.41e-11	Gambling;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04117832	chr2:152685230	ARL5A	0.44	6.19	0.36	2.23e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs1023500	0.573	rs2269524	chr22:42475703	T/G	cg12850546	chr22:42539477	CYP2D7P1	0.43	5.12	0.3	5.88e-7	Schizophrenia;
CESC	cis	rs7666738	0.546	rs13148080	chr4:98680947	A/G	cg17366294	chr4:99064904	C4orf37	0.47	5.82	0.34	1.68e-8	Colonoscopy-negative controls vs population controls;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg20646217	chr22:21356059	FLJ39582;THAP7	-0.45	-6.46	-0.37	5.13e-10	Gambling;
CESC	cis	rs6942756	0.806	rs7794622	chr7:128996268	T/C	cg02491457	chr7:128862824	NA	-0.6	-8.46	-0.46	1.78e-15	White matter hyperintensity burden;
CESC	cis	rs2228479	0.850	rs11649100	chr16:89798179	A/G	cg06558623	chr16:89946397	TCF25	1.03	7.52	0.42	8.67e-13	Skin colour saturation;
CESC	cis	rs1448094	0.838	rs11834294	chr12:86311958	C/T	cg02569458	chr12:86230093	RASSF9	0.36	5.12	0.3	6.01e-7	Major depressive disorder;
CESC	cis	rs4148883	0.689	rs1311621	chr4:100014018	T/C	cg13256891	chr4:100009986	ADH5	0.54	7.09	0.4	1.25e-11	Alcohol dependence;
CESC	cis	rs5753618	0.539	rs695438	chr22:31811876	G/C	cg13145458	chr22:31556086	RNF185	-0.44	-5.55	-0.32	6.84e-8	Colorectal cancer;
CESC	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg23708337	chr7:1209742	NA	0.55	5.41	0.32	1.44e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs17711722	0.510	rs11767457	chr7:65290615	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.37	5.04	0.3	8.54e-7	Calcium levels;
CESC	cis	rs6088590	1.000	rs12626122	chr20:33425800	A/G	cg08999081	chr20:33150536	PIGU	0.59	8.58	0.47	8.33e-16	Coronary artery disease;
CESC	cis	rs8092503	1.000	rs7231263	chr18:52493167	A/T	cg12377874	chr18:52495404	RAB27B	-0.33	-5.73	-0.33	2.66e-8	Childhood body mass index;
CESC	cis	rs7824557	0.603	rs2249804	chr8:11215617	C/G	cg21775007	chr8:11205619	TDH	0.54	7.78	0.43	1.62e-13	Retinal vascular caliber;
CESC	cis	rs7927771	0.524	rs7929725	chr11:47881740	A/G	cg20307385	chr11:47447363	PSMC3	0.62	8.76	0.47	2.32e-16	Subjective well-being;
CESC	cis	rs597539	0.652	rs673821	chr11:68678718	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.78	9.76	0.51	1.99e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs9611565	0.722	rs202635	chr22:41809637	C/T	cg03806693	chr22:41940476	POLR3H	1.04	12.37	0.61	4.76e-28	Vitiligo;
CESC	cis	rs7044106	0.762	rs10760112	chr9:123467570	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.36	5.9	0.34	1.11e-8	Hip circumference adjusted for BMI;
CESC	cis	rs5753618	0.561	rs5753609	chr22:31819212	A/G	cg02404636	chr22:31891804	SFI1	0.44	6.29	0.36	1.31e-9	Colorectal cancer;
CESC	cis	rs7927771	0.832	rs11607981	chr11:47401060	T/G	cg18512352	chr11:47633146	NA	-0.51	-7.43	-0.42	1.46e-12	Subjective well-being;
CESC	cis	rs6496667	0.509	rs2657948	chr15:90948617	G/A	cg22089800	chr15:90895588	ZNF774	0.44	5.63	0.33	4.48e-8	Rheumatoid arthritis;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg18679886	chr7:107531975	DLD	-0.49	-6.59	-0.38	2.34e-10	Height;
CESC	cis	rs13064411	0.696	rs7619913	chr3:113017503	A/G	cg18753928	chr3:113234510	CCDC52	-0.49	-5.07	-0.3	7.62e-7	Response to simvastatin treatment (PCSK9 protein level change);
CESC	cis	rs7927771	0.832	rs10838697	chr11:47384484	T/A	cg20307385	chr11:47447363	PSMC3	-0.61	-7.21	-0.41	5.76e-12	Subjective well-being;
CESC	cis	rs863345	0.584	rs1117125	chr1:158509396	T/C	cg12129480	chr1:158549410	OR10X1	-0.35	-7.04	-0.4	1.68e-11	Pneumococcal bacteremia;
CESC	cis	rs9532580	0.656	rs2721068	chr13:41139712	T/C	cg21288729	chr13:41239152	FOXO1	0.67	7.9	0.44	7.34e-14	Mean corpuscular hemoglobin;
CESC	cis	rs9322193	0.962	rs6914319	chr6:150127440	G/A	cg13206674	chr6:150067644	NUP43	0.42	5.88	0.34	1.21e-8	Lung cancer;
CESC	cis	rs2051211	1.000	rs17037804	chr3:38559215	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.57	-7.14	-0.4	8.97e-12	QRS duration;
CESC	cis	rs763121	0.719	rs9610995	chr22:39057763	C/T	cg06544989	chr22:39130855	UNC84B	0.49	8.49	0.46	1.53e-15	Menopause (age at onset);
CESC	cis	rs7843479	0.898	rs4311656	chr8:21802276	T/G	cg17168535	chr8:21777572	XPO7	0.5	6.87	0.39	4.48e-11	Mean corpuscular volume;
CESC	cis	rs13256369	0.950	rs13255655	chr8:8577736	C/T	cg00074818	chr8:8560427	CLDN23	0.42	6.01	0.35	6.24e-9	Obesity-related traits;
CESC	cis	rs6456156	0.586	rs7761977	chr6:167485678	A/G	cg07741184	chr6:167504864	NA	0.37	6.28	0.36	1.39e-9	Primary biliary cholangitis;
CESC	cis	rs6690583	1.000	rs10443172	chr1:85485768	T/C	cg22153463	chr1:85462885	MCOLN2	-0.74	-8.69	-0.47	3.76e-16	Serum sulfate level;
CESC	cis	rs34779708	0.931	rs12776390	chr10:35391535	T/G	cg03585969	chr10:35415529	CREM	0.78	10.4	0.54	1.88e-21	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs4975709	0.589	rs4975747	chr5:1862836	G/A	cg20790798	chr5:1857306	NA	-0.4	-5.42	-0.32	1.37e-7	Cardiovascular disease risk factors;
CESC	cis	rs2204008	0.693	rs12372025	chr12:38202028	G/A	cg13010199	chr12:38710504	ALG10B	0.54	6.75	0.38	9.46e-11	Bladder cancer;
CESC	cis	rs2011503	0.882	rs2060276	chr19:19522491	T/G	cg11584989	chr19:19387371	SF4	0.62	6.86	0.39	4.74e-11	Bipolar disorder;
CESC	cis	rs2070488	0.775	rs762318	chr3:38516369	C/A	cg24069376	chr3:38537580	EXOG	0.36	6.09	0.35	4.02e-9	Electrocardiographic conduction measures;
CESC	trans	rs1005277	0.579	rs1780146	chr10:38517874	C/A	cg27523141	chr10:43048294	ZNF37B	0.46	6.01	0.35	6.19e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs10791097	0.547	rs12365680	chr11:130749059	C/T	cg14779329	chr11:130786720	SNX19	0.32	5.04	0.3	8.7e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs7927771	1.000	rs4752857	chr11:47655752	C/T	cg18512352	chr11:47633146	NA	-0.61	-9.7	-0.51	3.19e-19	Subjective well-being;
CESC	cis	rs3796352	1.000	rs34244302	chr3:53102236	C/G	cg12962167	chr3:53033115	SFMBT1	0.7	6.17	0.35	2.6e-9	Immune reponse to smallpox (secreted IL-2);
CESC	cis	rs300703	0.935	rs10167992	chr2:263270	C/T	cg21211680	chr2:198530	NA	-0.77	-6.89	-0.39	4.04e-11	Blood protein levels;
CESC	cis	rs1799949	0.965	rs11657883	chr17:41330024	T/C	cg05368731	chr17:41323189	NBR1	0.78	10.62	0.55	3.59e-22	Menopause (age at onset);
CESC	cis	rs13191362	1.000	rs13220181	chr6:163004401	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.82	8.8	0.48	1.79e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs7223966	1.000	rs16947005	chr17:61702989	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.55	-6.54	-0.37	3.07e-10	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs7020830	0.898	rs13289199	chr9:37278064	A/T	cg14294708	chr9:37120828	ZCCHC7	1.12	18.93	0.76	3.96e-51	Schizophrenia;
CESC	cis	rs4727027	0.800	rs12530946	chr7:148887942	A/G	cg23583168	chr7:148888333	NA	-0.94	-17.34	-0.73	1.57e-45	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs1843834	0.505	rs2140508	chr2:225355839	G/T	cg22455342	chr2:225449267	CUL3	0.72	9.92	0.52	6.31e-20	IgE levels in asthmatics (D.p. specific);
CESC	cis	rs6460942	1.000	rs73053527	chr7:12313008	C/A	cg10578991	chr7:12443926	VWDE	-0.61	-6.41	-0.37	6.66e-10	Coronary artery disease;
CESC	cis	rs11250464	0.833	rs4554799	chr10:1407728	C/T	cg26394196	chr10:1453818	ADARB2	-0.45	-6.01	-0.35	6.13e-9	Radiation response;
CESC	cis	rs858239	0.600	rs13438179	chr7:23143851	T/C	cg23682824	chr7:23144976	KLHL7	0.54	7.7	0.43	2.68e-13	Cerebrospinal fluid biomarker levels;
CESC	cis	rs853679	0.517	rs9393886	chr6:28050039	T/G	cg08968635	chr6:28129556	ZNF389	0.39	5.22	0.31	3.64e-7	Depression;
CESC	cis	rs7267979	0.844	rs8184820	chr20:25250577	C/T	cg08601574	chr20:25228251	PYGB	-0.41	-5.81	-0.34	1.81e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs4704187	0.687	rs4324655	chr5:74373360	C/T	cg03227963	chr5:74354835	NA	0.31	5.81	0.34	1.74e-8	Response to amphetamines;
CESC	cis	rs1595825	0.891	rs4491721	chr2:198521407	C/G	cg10820045	chr2:198174542	NA	0.41	5.21	0.3	3.79e-7	Ulcerative colitis;
CESC	cis	rs1005277	0.579	rs2474567	chr10:38382492	C/T	cg00409905	chr10:38381863	ZNF37A	-0.45	-6.0	-0.35	6.61e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs35123781	0.696	rs13154510	chr5:139071301	A/C	cg10513866	chr5:139070639	NA	0.45	6.43	0.37	6e-10	Schizophrenia;
CESC	cis	rs9660992	0.573	rs12125276	chr1:205199440	C/T	cg00857998	chr1:205179979	DSTYK	0.56	6.88	0.39	4.29e-11	Mean corpuscular volume;Mean platelet volume;
CESC	trans	rs637571	0.584	rs7107912	chr11:65603252	G/A	cg17712092	chr4:129076599	LARP1B	-0.64	-8.07	-0.44	2.51e-14	Eosinophil percentage of white cells;
CESC	cis	rs11969893	0.850	rs9498418	chr6:101331838	A/T	cg12253828	chr6:101329408	ASCC3	0.91	7.44	0.42	1.39e-12	Economic and political preferences (immigration/crime);
CESC	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg04234412	chr22:24373322	LOC391322	0.65	8.91	0.48	8.33e-17	Urinary 1,3-butadiene metabolite levels in smokers;
CESC	cis	rs9649213	0.574	rs12873	chr7:97922773	T/C	cg00277769	chr7:97922759	BAIAP2L1	-0.34	-5.57	-0.32	6.2e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs6120849	0.901	rs6088735	chr20:33745676	C/T	cg24642439	chr20:33292090	TP53INP2	0.6	6.4	0.37	7.09e-10	Protein C levels;
CESC	cis	rs2072732	0.861	rs72629498	chr1:2954203	C/T	cg15211996	chr1:2936768	ACTRT2	0.35	5.63	0.33	4.51e-8	Plateletcrit;
CESC	cis	rs2070677	0.935	rs2864985	chr10:135348757	C/G	cg20169779	chr10:135381914	SYCE1	0.7	8.08	0.44	2.34e-14	Gout;
CESC	cis	rs1577917	0.917	rs35283633	chr6:86690787	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.47	-5.95	-0.34	8.41e-9	Response to antipsychotic treatment;
CESC	cis	rs6867032	1.000	rs4975794	chr5:2015330	A/G	cg26168224	chr5:2018326	NA	-0.94	-18.51	-0.75	1.13e-49	Gut microbiome composition (winter);
CESC	cis	rs7621025	0.505	rs13063893	chr3:136387638	C/T	cg15507776	chr3:136538369	TMEM22	-0.81	-7.32	-0.41	2.99e-12	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
CESC	cis	rs7248779	1.000	rs7248779	chr19:2403564	G/T	cg22729335	chr19:2427816	TIMM13	-0.5	-7.07	-0.4	1.34e-11	Cortisol levels (saliva);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08836619	chr5:139555389	C5orf32	-0.64	-6.91	-0.39	3.66e-11	Gut microbiome composition (summer);
CESC	cis	rs4889855	0.505	rs7501740	chr17:78610345	A/G	cg16591659	chr17:78472290	NA	-0.34	-5.49	-0.32	9.53e-8	Fractional excretion of uric acid;
CESC	cis	rs36051895	0.632	rs10815166	chr9:5149920	T/G	cg02405213	chr9:5042618	JAK2	-0.51	-6.4	-0.37	6.99e-10	Pediatric autoimmune diseases;
CESC	cis	rs9322193	0.962	rs9688412	chr6:150124283	A/G	cg13206674	chr6:150067644	NUP43	-0.41	-5.78	-0.33	2.07e-8	Lung cancer;
CESC	cis	rs6912958	0.712	rs2754262	chr6:88405585	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.34	-5.32	-0.31	2.17e-7	Monocyte percentage of white cells;
CESC	cis	rs1843834	0.505	rs7585047	chr2:225373897	C/T	cg22509189	chr2:225307070	NA	-0.41	-5.52	-0.32	8e-8	IgE levels in asthmatics (D.p. specific);
CESC	cis	rs7267979	0.808	rs84816	chr20:25459919	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.72	12.81	0.62	1.44e-29	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs1788820	0.917	rs1788760	chr18:21137442	A/G	cg14672496	chr18:21087552	C18orf8	0.56	7.62	0.42	4.43e-13	Body mass index;
CESC	cis	rs7666738	0.791	rs1527516	chr4:98967937	A/C	cg03467027	chr4:99064603	C4orf37	0.44	5.48	0.32	9.97e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4704187	0.687	rs1600074	chr5:74436574	C/T	cg03227963	chr5:74354835	NA	0.3	5.55	0.32	6.82e-8	Response to amphetamines;
CESC	cis	rs3820068	0.580	rs12760698	chr1:16009814	G/A	cg13390004	chr1:15929781	NA	0.33	5.13	0.3	5.5e-7	Systolic blood pressure;
CESC	cis	rs57221529	0.766	rs72706608	chr5:559203	C/T	cg09021430	chr5:549028	NA	-0.42	-5.26	-0.31	2.92e-7	Lung disease severity in cystic fibrosis;
CESC	cis	rs11098499	0.779	rs10016060	chr4:120298412	A/G	cg09307838	chr4:120376055	NA	0.92	12.66	0.61	4.96e-29	Corneal astigmatism;
CESC	cis	rs1008375	0.864	rs4698196	chr4:17574735	T/C	cg16339924	chr4:17578868	LAP3	0.82	10.38	0.54	2.06e-21	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs642803	0.933	rs644740	chr11:65561468	C/T	cg10518572	chr11:65560635	OVOL1	0.3	6.44	0.37	5.51e-10	Urate levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18632100	chr19:59028615	ZBTB45	-0.61	-6.62	-0.38	2.01e-10	Gut microbiome composition (summer);
CESC	cis	rs7618915	1.000	rs3852064	chr3:52349412	G/T	cg05315796	chr3:52349193	DNAH1	0.36	5.31	0.31	2.28e-7	Bipolar disorder;
CESC	cis	rs1670533	1.000	rs4690212	chr4:1054898	T/C	cg04106633	chr4:1044584	NA	0.41	5.19	0.3	4.11e-7	Recombination rate (females);
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg20021244	chr5:139944115	APBB3;SLC35A4	-0.46	-6.22	-0.36	1.94e-9	Asthma;
CESC	cis	rs96067	0.643	rs274133	chr1:36581792	G/A	cg27506609	chr1:36549197	TEKT2	-0.37	-5.7	-0.33	3.22e-8	Corneal structure;
CESC	cis	rs10088262	0.629	rs1367829	chr8:124797135	A/G	cg20713898	chr8:124780851	FAM91A1	-0.67	-9.11	-0.49	2.02e-17	Pancreatic cancer;
CESC	cis	rs362272	0.524	rs2857982	chr4:3358665	G/A	cg14583973	chr4:3374767	RGS12	0.32	5.58	0.32	5.85e-8	Serum sulfate level;
CESC	cis	rs9796	0.727	rs61203391	chr15:41352912	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.4	-5.83	-0.34	1.58e-8	Menopause (age at onset);
CESC	cis	rs7124681	0.584	rs1471712	chr11:47912150	G/A	cg20307385	chr11:47447363	PSMC3	-0.57	-7.98	-0.44	4.46e-14	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
CESC	cis	rs1144333	1.000	rs1340684	chr1:76471146	T/C	cg10523679	chr1:76189770	ACADM	0.58	5.36	0.31	1.8e-7	Attention function in attention deficit hyperactive disorder;
CESC	cis	rs7949030	0.626	rs11231154	chr11:62362293	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.66	9.86	0.52	9.55e-20	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs13385	0.769	rs34266577	chr5:139547797	C/T	cg26211634	chr5:139558579	C5orf32	0.47	5.16	0.3	4.77e-7	Atrial fibrillation;
CESC	cis	rs734999	0.505	rs10910107	chr1:2539181	C/T	cg18854424	chr1:2615690	NA	0.3	6.01	0.35	6.23e-9	Ulcerative colitis;
CESC	cis	rs6963495	0.818	rs73190158	chr7:105153943	T/C	cg13798780	chr7:105162888	PUS7	0.78	8.04	0.44	2.99e-14	Bipolar disorder (body mass index interaction);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg15239874	chr12:121148841	UNC119B	0.47	6.02	0.35	5.75e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs813218	0.625	rs793484	chr3:99491508	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.33	-5.44	-0.32	1.2e-7	Orofacial clefts;
CESC	cis	rs2249694	0.509	rs9419072	chr10:135310445	G/A	cg20169779	chr10:135381914	SYCE1	0.41	5.42	0.32	1.36e-7	Obesity-related traits;
CESC	cis	rs769267	1.000	rs7247309	chr19:19439631	A/T	cg03709012	chr19:19516395	GATAD2A	-0.96	-14.2	-0.66	2.12e-34	Tonsillectomy;
CESC	cis	rs72781680	1.000	rs55982282	chr2:24188128	G/A	cg20701182	chr2:24300061	SF3B14	0.71	6.25	0.36	1.59e-9	Lymphocyte counts;
CESC	cis	rs708547	0.957	rs1623306	chr4:57773595	C/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.66	7.03	0.4	1.74e-11	Response to bleomycin (chromatid breaks);
CESC	trans	rs1814175	0.592	rs1794161	chr11:49898825	A/C	cg03929089	chr4:120376271	NA	-0.9	-14.75	-0.67	2.44e-36	Height;
CESC	cis	rs4481887	0.861	rs7412034	chr1:248434150	G/C	cg00666640	chr1:248458726	OR2T12	0.34	5.89	0.34	1.17e-8	Common traits (Other);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22727761	chr1:24286270	PNRC2	0.55	6.05	0.35	4.96e-9	Gut microbiome composition (summer);
CESC	cis	rs12618769	0.597	rs4850876	chr2:99112069	C/T	cg10123293	chr2:99228465	UNC50	0.39	5.13	0.3	5.6e-7	Bipolar disorder;
CESC	cis	rs8072100	0.967	rs7221548	chr17:45582952	T/C	cg08085267	chr17:45401833	C17orf57	0.43	5.64	0.33	4.44e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs67478160	0.679	rs7156834	chr14:104211180	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.49	-6.87	-0.39	4.47e-11	Schizophrenia;
CESC	cis	rs9300255	0.544	rs1790123	chr12:123659542	C/T	cg00376283	chr12:123451042	ABCB9	0.57	6.1	0.35	3.64e-9	Neutrophil percentage of white cells;
CESC	cis	rs8031584	0.678	rs4779790	chr15:31164595	T/C	cg08109568	chr15:31115862	NA	-0.71	-9.63	-0.51	5.02e-19	Huntington's disease progression;
CESC	cis	rs7819412	0.740	rs11250119	chr8:11037034	C/T	cg21775007	chr8:11205619	TDH	-0.35	-5.11	-0.3	6.12e-7	Triglycerides;
CESC	cis	rs898097	1.000	rs898098	chr17:80904564	G/A	cg10494973	chr17:80897199	TBCD	-0.48	-5.6	-0.33	5.24e-8	Breast cancer;
CESC	cis	rs11098499	0.863	rs6858777	chr4:120475966	A/G	cg09307838	chr4:120376055	NA	0.9	12.45	0.61	2.6e-28	Corneal astigmatism;
CESC	cis	rs4689592	0.554	rs3822270	chr4:7069804	C/A	cg19539972	chr4:7069911	GRPEL1	0.77	9.72	0.51	2.71e-19	Monocyte percentage of white cells;
CESC	cis	rs10911251	0.528	rs2093982	chr1:183094191	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.89	14.39	0.66	4.39e-35	Colorectal cancer;
CESC	cis	rs11069349	0.608	rs9585056	chr13:100081766	A/G	cg25919922	chr13:100150906	NA	-0.55	-6.29	-0.36	1.34e-9	Self-reported allergy;
CESC	cis	rs12586317	0.514	rs61100068	chr14:35400232	A/T	cg05294307	chr14:35346193	BAZ1A	-0.53	-5.34	-0.31	1.99e-7	Psoriasis;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg18986451	chr3:100428869	TFG	0.44	6.08	0.35	4.14e-9	Systemic lupus erythematosus;
CESC	cis	rs2806561	0.894	rs628106	chr1:23537685	C/T	cg12483005	chr1:23474871	LUZP1	0.32	5.15	0.3	4.99e-7	Height;
CESC	trans	rs7937682	0.924	rs10891286	chr11:111532691	C/G	cg18187862	chr3:45730750	SACM1L	0.47	6.04	0.35	5.2e-9	Primary sclerosing cholangitis;
CESC	cis	rs7666738	0.830	rs7696715	chr4:98938486	T/C	cg17366294	chr4:99064904	C4orf37	0.61	8.56	0.47	9.36e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7605827	0.897	rs7590198	chr2:15536314	C/T	cg19274914	chr2:15703543	NA	0.36	6.59	0.38	2.3e-10	Educational attainment (years of education);
CESC	cis	rs400736	0.894	rs225092	chr1:8036075	G/C	cg25007680	chr1:8021821	PARK7	0.72	10.31	0.54	3.52e-21	Response to antidepressants and depression;
CESC	cis	rs7216064	1.000	rs6504543	chr17:65837659	T/C	cg07042672	chr17:66097459	LOC651250	-0.63	-7.58	-0.42	5.88e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs2732480	0.500	rs1552550	chr12:48643351	C/A	cg04545296	chr12:48745243	ZNF641	0.39	6.62	0.38	1.99e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs4481887	0.927	rs4336885	chr1:248473168	A/C	cg00666640	chr1:248458726	OR2T12	0.36	5.98	0.35	7.04e-9	Common traits (Other);
CESC	cis	rs561341	1.000	rs7216102	chr17:30259450	A/G	cg00745463	chr17:30367425	LRRC37B	-0.47	-5.24	-0.31	3.26e-7	Hip circumference adjusted for BMI;
CESC	trans	rs7819412	0.540	rs11777355	chr8:11044689	A/G	cg06636001	chr8:8085503	FLJ10661	-0.53	-6.11	-0.35	3.53e-9	Triglycerides;
CESC	trans	rs1814175	0.935	rs10839329	chr11:49694206	G/A	cg15704280	chr7:45808275	SEPT13	-1.0	-17.88	-0.74	1.87e-47	Height;
CESC	cis	rs1348850	0.526	rs10930797	chr2:178437553	C/G	cg23306229	chr2:178417860	TTC30B	0.67	5.97	0.34	7.8e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs4950322	0.515	rs12060046	chr1:146720934	T/C	cg16700924	chr1:146552102	NA	-0.39	-5.1	-0.3	6.63e-7	Protein quantitative trait loci;
CESC	cis	rs5758659	1.000	rs5758677	chr22:42643039	A/C	cg04733989	chr22:42467013	NAGA	0.42	5.82	0.34	1.67e-8	Cognitive function;
CESC	cis	rs9916302	0.904	rs7223331	chr17:37482930	A/G	cg19468946	chr17:37922297	IKZF3	0.4	5.22	0.31	3.56e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs2228479	1.000	rs4257207	chr16:89947861	T/A	cg00800038	chr16:89945340	TCF25	-0.95	-8.0	-0.44	3.92e-14	Skin colour saturation;
CESC	cis	rs12477438	0.520	rs2171359	chr2:99795360	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.84	15.36	0.69	1.63e-38	Chronic sinus infection;
CESC	cis	rs12586317	0.547	rs28569331	chr14:35473584	T/C	cg05294307	chr14:35346193	BAZ1A	-0.51	-5.45	-0.32	1.16e-7	Psoriasis;
CESC	cis	rs7945705	0.869	rs11042154	chr11:9029700	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.45	-7.02	-0.4	1.9e-11	Hemoglobin concentration;
CESC	cis	rs60871478	1.000	rs9195	chr7:825786	C/T	cg05535760	chr7:792225	HEATR2	-0.83	-10.54	-0.54	6.23e-22	Cerebrospinal P-tau181p levels;
CESC	cis	rs453301	0.653	rs7016139	chr8:8895470	A/G	cg06636001	chr8:8085503	FLJ10661	-0.45	-5.79	-0.34	2e-8	Joint mobility (Beighton score);
CESC	cis	rs67311347	1.000	rs7625736	chr3:40441345	C/G	cg01475735	chr3:40494733	NA	0.46	6.09	0.35	4.05e-9	Renal cell carcinoma;
CESC	cis	rs4563143	0.675	rs17498203	chr19:29279734	G/T	cg14983838	chr19:29218262	NA	0.48	5.62	0.33	4.73e-8	Methadone dose in opioid dependence;
CESC	cis	rs9399135	0.967	rs45544135	chr6:135324051	T/C	cg22676075	chr6:135203613	NA	0.52	7.32	0.41	2.99e-12	Red blood cell count;
CESC	cis	rs10838687	0.825	rs12222581	chr11:47342019	A/T	cg25783544	chr11:47291846	MADD	0.59	7.26	0.41	4.24e-12	Proinsulin levels;
CESC	cis	rs9325144	0.560	rs10785573	chr12:38654166	G/A	cg26384229	chr12:38710491	ALG10B	-0.6	-8.49	-0.46	1.45e-15	Morning vs. evening chronotype;
CESC	cis	rs1801251	1.000	rs283471	chr2:233656627	G/A	cg25237894	chr2:233734115	C2orf82	0.46	7.88	0.44	8.69e-14	Coronary artery disease;
CESC	trans	rs9467711	0.606	rs68072215	chr6:26377927	T/C	cg06606381	chr12:133084897	FBRSL1	-0.73	-6.26	-0.36	1.53e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs9309473	0.583	rs11899517	chr2:73573261	A/G	cg20560298	chr2:73613845	ALMS1	-0.48	-6.51	-0.37	3.79e-10	Metabolite levels;
CESC	cis	rs35110281	0.743	rs230640	chr21:44914815	A/T	cg21573476	chr21:45109991	RRP1B	0.44	6.22	0.36	1.95e-9	Mean corpuscular volume;
CESC	cis	rs4665809	0.549	rs34075014	chr2:26520842	T/C	cg26119090	chr2:26468346	HADHA;HADHB	1.02	10.52	0.54	7.59e-22	Gut microbiome composition (summer);
CESC	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg26354017	chr1:205819088	PM20D1	0.85	13.02	0.62	2.82e-30	Menarche (age at onset);
CESC	cis	rs362272	0.545	rs3135146	chr4:3307638	C/G	cg14583973	chr4:3374767	RGS12	-0.31	-5.31	-0.31	2.27e-7	Serum sulfate level;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19306474	chr10:6243561	PFKFB3	0.54	6.04	0.35	5.06e-9	Gut microbiome composition (summer);
CESC	cis	rs738322	0.967	rs132971	chr22:38561911	T/G	cg25457927	chr22:38595422	NA	-0.3	-5.6	-0.33	5.25e-8	Cutaneous nevi;
CESC	cis	rs10870270	0.956	rs11146325	chr10:133767529	A/G	cg17892150	chr10:133769511	PPP2R2D	-0.87	-12.67	-0.61	4.28e-29	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs718433	0.584	rs7142784	chr14:22213799	C/T	cg02257791	chr14:22217085	NA	-0.33	-5.14	-0.3	5.32e-7	Intraocular pressure;
CESC	cis	rs9875589	0.509	rs4684174	chr3:14048375	C/T	cg19554555	chr3:13937349	NA	-0.44	-5.65	-0.33	4.16e-8	Ovarian reserve;
CESC	cis	rs10979	1.000	rs9390113	chr6:143896205	G/A	cg25407410	chr6:143891975	LOC285740	-0.61	-9.2	-0.49	1.13e-17	Hypospadias;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06168319	chr4:84205972	COQ2	0.63	7.43	0.42	1.49e-12	Gut microbiome composition (summer);
CESC	cis	rs709400	0.859	rs7693	chr14:104023704	C/T	cg12935359	chr14:103987150	CKB	-0.51	-6.71	-0.38	1.2e-10	Body mass index;
CESC	cis	rs5769765	0.955	rs6520066	chr22:50294988	C/T	cg26441486	chr22:50317300	CRELD2	0.4	5.55	0.32	6.82e-8	Schizophrenia;
CESC	cis	rs854765	0.583	rs11078406	chr17:17840823	G/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.63	9.35	0.5	3.76e-18	Total body bone mineral density;
CESC	cis	rs8040855	0.627	rs11637512	chr15:85648759	T/C	cg08123816	chr15:85640762	PDE8A	-0.39	-5.74	-0.33	2.6e-8	Bulimia nervosa;
CESC	cis	rs941873	0.803	rs2105461	chr10:81101679	A/G	cg08514558	chr10:81106712	PPIF	-0.35	-6.08	-0.35	4.21e-9	Height;
CESC	cis	rs9790314	1.000	rs336579	chr3:161086610	G/A	cg04691961	chr3:161091175	C3orf57	-0.44	-5.64	-0.33	4.39e-8	Morning vs. evening chronotype;
CESC	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.48	-5.2	-0.3	4.05e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs12356475	0.710	rs10822686	chr10:67733250	C/T	cg15572086	chr1:116961459	C1orf203	0.55	6.23	0.36	1.84e-9	Psoriatic arthritis;
CESC	cis	rs13108904	0.967	rs2293635	chr4:1291791	A/G	cg00684032	chr4:1343700	KIAA1530	0.4	5.51	0.32	8.35e-8	Obesity-related traits;
CESC	cis	rs7123876	0.830	rs59311588	chr11:72435996	A/G	cg03713592	chr11:72463424	ARAP1	0.6	6.77	0.38	8.21e-11	Body mass index;
CESC	cis	rs10870270	0.957	rs9971084	chr10:133788747	G/C	cg17892150	chr10:133769511	PPP2R2D	-0.85	-12.42	-0.61	3.3e-28	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	trans	rs916888	0.821	rs199514	chr17:44856881	G/A	cg22433210	chr17:43662623	NA	-0.93	-10.69	-0.55	2.14e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08925066	chr14:39572669	SEC23A	0.64	7.35	0.41	2.42e-12	Gut microbiome composition (summer);
CESC	cis	rs4969178	0.932	rs3744219	chr17:76400236	G/A	cg05887092	chr17:76393375	PGS1	0.58	9.26	0.49	7e-18	HDL cholesterol levels;
CESC	cis	rs9818758	0.607	rs56306491	chr3:49314960	G/A	cg00383909	chr3:49044727	WDR6	0.89	5.94	0.34	8.93e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CESC	cis	rs262150	1.000	rs262154	chr7:158773936	G/A	cg19418458	chr7:158789849	NA	-0.49	-7.69	-0.43	2.97e-13	Facial morphology (factor 20);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05993306	chr5:137090649	HNRNPA0	-0.52	-7.11	-0.4	1.11e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs9611519	0.780	rs9611528	chr22:41648502	T/C	cg03806693	chr22:41940476	POLR3H	-0.57	-6.52	-0.37	3.59e-10	Neuroticism;
CESC	cis	rs1008375	0.902	rs7654332	chr4:17691778	A/T	cg02297831	chr4:17616191	MED28	0.5	5.95	0.34	8.38e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs12410462	0.579	rs77529417	chr1:227547895	T/C	cg04117972	chr1:227635322	NA	0.63	5.35	0.31	1.9e-7	Major depressive disorder;
CESC	cis	rs6032067	0.673	rs13042474	chr20:43893068	G/T	cg10761708	chr20:43804764	PI3	0.41	5.14	0.3	5.43e-7	Blood protein levels;
CESC	cis	rs10504229	0.683	rs67035623	chr8:58139963	G/T	cg21724239	chr8:58056113	NA	0.58	5.95	0.34	8.37e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs7943191	0.810	rs7942154	chr11:62337163	G/A	cg23462726	chr11:62437636	C11orf83;C11orf48	-0.44	-5.84	-0.34	1.56e-8	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
CESC	cis	rs7580658	0.676	rs4150407	chr2:128049631	C/T	cg10021288	chr2:128175891	PROC	0.34	5.6	0.33	5.33e-8	Protein C levels;
CESC	cis	rs11122272	0.766	rs2739511	chr1:231526490	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.59	-8.22	-0.45	9.37e-15	Hemoglobin concentration;
CESC	cis	rs2204008	0.805	rs3863360	chr12:37966432	C/T	cg26384229	chr12:38710491	ALG10B	0.67	9.51	0.5	1.2e-18	Bladder cancer;
CESC	cis	rs5769765	0.955	rs5769761	chr22:50263641	G/T	cg26441486	chr22:50317300	CRELD2	-0.39	-5.5	-0.32	8.72e-8	Schizophrenia;
CESC	cis	rs17666538	0.585	rs4333567	chr8:636611	C/T	cg23958373	chr8:599963	NA	0.81	5.1	0.3	6.6e-7	IgG glycosylation;
CESC	cis	rs9611565	0.592	rs5758427	chr22:42099688	A/G	cg06481639	chr22:41940642	POLR3H	0.64	6.55	0.37	2.94e-10	Vitiligo;
CESC	cis	rs4595586	0.525	rs73096109	chr12:39355720	C/A	cg13010199	chr12:38710504	ALG10B	0.45	5.65	0.33	4.09e-8	Morning vs. evening chronotype;
CESC	trans	rs4904167	0.841	rs12436650	chr14:84679067	A/G	cg06870609	chr15:89787223	FANCI	0.46	6.01	0.35	6.03e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs7412746	0.658	rs4970982	chr1:150865084	G/C	cg04414720	chr1:150670196	GOLPH3L	0.51	6.78	0.38	7.88e-11	Melanoma;
CESC	cis	rs2276314	1.000	rs9304153	chr18:33562150	T/C	cg19628046	chr18:33552617	C18orf21	0.53	5.72	0.33	2.83e-8	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs3752962	0.588	rs903164	chr17:1939502	G/A	cg24156229	chr17:1948635	NA	-0.65	-9.81	-0.52	1.38e-19	Itch intensity from mosquito bite;
CESC	cis	rs2070433	0.706	rs2268524	chr21:47838700	C/T	cg12379764	chr21:47803548	PCNT	0.67	7.31	0.41	3.08e-12	Lymphocyte counts;
CESC	cis	rs597539	0.552	rs6591361	chr11:68719284	T/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.71	8.51	0.46	1.3e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs9815354	0.680	rs73073294	chr3:42028053	A/G	cg03022575	chr3:42003672	ULK4	0.75	6.64	0.38	1.72e-10	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs2228479	0.702	rs17177891	chr16:89799950	C/T	cg04013166	chr16:89971882	TCF25	0.74	6.37	0.36	8.27e-10	Skin colour saturation;
CESC	trans	rs2727020	0.718	rs1404366	chr11:49415899	T/A	cg15704280	chr7:45808275	SEPT13	-0.8	-10.1	-0.53	1.66e-20	Coronary artery disease;
CESC	cis	rs6089584	0.816	rs744778	chr20:60631365	A/G	cg13770153	chr20:60521292	NA	-0.5	-6.48	-0.37	4.33e-10	Body mass index;
CESC	cis	rs8058578	1.000	rs56656810	chr16:30788759	C/A	cg02466173	chr16:30829666	NA	-0.45	-7.23	-0.41	5.16e-12	Multiple myeloma;
CESC	trans	rs1728785	0.901	rs1170420	chr16:68635877	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	7.69	0.43	2.91e-13	Ulcerative colitis;
CESC	cis	rs3733585	0.699	rs6449176	chr4:9967843	G/A	cg00071950	chr4:10020882	SLC2A9	-0.7	-11.44	-0.58	6.69e-25	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs798554	0.610	rs1182209	chr7:2808595	C/T	cg09658497	chr7:2847517	GNA12	-0.36	-5.41	-0.32	1.39e-7	Height;
CESC	cis	rs7618915	0.501	rs2159644	chr3:52774530	C/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	5.72	0.33	2.89e-8	Bipolar disorder;
CESC	cis	rs919433	0.783	rs788007	chr2:198233676	T/G	cg03934865	chr2:198174659	NA	0.43	6.21	0.36	2.01e-9	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs2599510	0.811	rs2710615	chr2:32791222	A/T	cg02381751	chr2:32503542	YIPF4	0.52	6.54	0.37	3.24e-10	Interleukin-18 levels;
CESC	cis	rs875971	0.737	rs7803424	chr7:65880605	T/C	cg12463550	chr7:65579703	CRCP	0.59	7.52	0.42	8.29e-13	Aortic root size;
CESC	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg22105103	chr4:187893119	NA	0.47	7.01	0.4	1.94e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs713587	0.525	rs1541984	chr2:25082414	G/A	cg01884057	chr2:25150051	NA	0.35	6.58	0.37	2.53e-10	Body mass index in non-asthmatics;
CESC	cis	rs4746818	0.793	rs2805913	chr10:70858062	A/G	cg11621586	chr10:70884670	VPS26A	0.71	8.09	0.45	2.13e-14	Left atrial antero-posterior diameter;
CESC	cis	rs7412746	0.611	rs11204748	chr1:150927369	G/T	cg22823121	chr1:150693482	HORMAD1	0.37	5.26	0.31	3.01e-7	Melanoma;
CESC	cis	rs6032067	0.929	rs2233883	chr20:43835822	T/C	cg10761708	chr20:43804764	PI3	0.5	5.94	0.34	8.83e-9	Blood protein levels;
CESC	cis	rs1062177	0.855	rs919263	chr5:151265853	A/G	cg00977110	chr5:151150581	G3BP1	0.52	5.82	0.34	1.66e-8	Preschool internalizing problems;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg20095338	chr12:76478402	NAP1L1	0.46	6.25	0.36	1.59e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs1552244	1.000	rs68045038	chr3:10151828	A/G	cg00166722	chr3:10149974	C3orf24	0.45	5.63	0.33	4.62e-8	Alzheimer's disease;
CESC	cis	rs7666738	0.830	rs113999196	chr4:99041961	C/T	cg03467027	chr4:99064603	C4orf37	0.47	5.98	0.34	7.19e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs13242816	1.000	rs35364754	chr7:116109716	T/G	cg04696780	chr7:116139425	CAV2	-0.63	-5.71	-0.33	2.98e-8	P wave duration;
CESC	cis	rs933688	1.000	rs332531	chr5:90790451	G/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.89	10.36	0.54	2.38e-21	Smoking behavior;
CESC	cis	rs858239	0.600	rs10237755	chr7:23131564	A/G	cg23682824	chr7:23144976	KLHL7	0.55	7.67	0.43	3.39e-13	Cerebrospinal fluid biomarker levels;
CESC	cis	rs875971	0.520	rs2420597	chr7:65915986	A/G	cg18876405	chr7:65276391	NA	0.52	7.09	0.4	1.24e-11	Aortic root size;
CESC	cis	rs1008375	0.966	rs11737844	chr4:17697421	A/C	cg02297831	chr4:17616191	MED28	0.44	5.4	0.32	1.45e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	trans	rs11098499	0.954	rs9998585	chr4:120396802	T/A	cg25214090	chr10:38739885	LOC399744	0.72	10.31	0.54	3.55e-21	Corneal astigmatism;
CESC	cis	rs9399135	0.904	rs4895438	chr6:135317665	G/T	cg22676075	chr6:135203613	NA	0.51	7.19	0.4	6.51e-12	Red blood cell count;
CESC	cis	rs13256369	0.851	rs13254997	chr8:8563753	G/C	cg18904891	chr8:8559673	CLDN23	0.71	8.07	0.44	2.44e-14	Obesity-related traits;
CESC	cis	rs4253772	0.550	rs6008601	chr22:46705326	C/G	cg00784671	chr22:46762841	CELSR1	-0.51	-5.8	-0.34	1.92e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs11871801	0.517	rs60929812	chr17:40759448	G/A	cg14558262	chr17:40713999	COASY	0.5	5.83	0.34	1.58e-8	Crohn's disease;
CESC	cis	rs826838	0.620	rs11614695	chr12:39331847	C/T	cg26384229	chr12:38710491	ALG10B	0.74	11.1	0.56	9.41e-24	Heart rate;
CESC	cis	rs4594175	0.926	rs60234748	chr14:51630102	T/C	cg23942311	chr14:51606299	NA	0.4	6.21	0.36	2.01e-9	Cancer;
CESC	cis	rs1552244	1.000	rs68067759	chr3:10150535	T/C	cg00166722	chr3:10149974	C3orf24	0.45	5.67	0.33	3.82e-8	Alzheimer's disease;
CESC	trans	rs2018683	0.683	rs12538606	chr7:28969408	T/C	cg19402173	chr7:128379420	CALU	-0.5	-6.78	-0.38	7.59e-11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CESC	cis	rs6582630	0.555	rs2387598	chr12:38510472	G/A	cg13010199	chr12:38710504	ALG10B	-0.43	-5.44	-0.32	1.19e-7	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs1008375	0.800	rs28754811	chr4:17612312	C/T	cg02297831	chr4:17616191	MED28	0.57	7.0	0.4	2.05e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs9916302	0.706	rs7208252	chr17:37584368	A/G	cg07936489	chr17:37558343	FBXL20	-0.91	-9.93	-0.52	5.62e-20	Glomerular filtration rate (creatinine);
CESC	cis	rs6088580	0.634	rs6059779	chr20:32950325	C/T	cg08999081	chr20:33150536	PIGU	-0.65	-11.53	-0.58	3.34e-25	Glomerular filtration rate (creatinine);
CESC	cis	rs941873	0.835	rs10762859	chr10:81103370	T/A	cg11057378	chr10:81107060	PPIF	0.32	5.17	0.3	4.72e-7	Height;
CESC	cis	rs9359856	0.564	rs34732313	chr6:90368380	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.65	-6.35	-0.36	9.29e-10	Bipolar disorder;
CESC	cis	rs910316	0.967	rs12890371	chr14:75593839	T/C	cg11812906	chr14:75593930	NEK9	0.9	15.44	0.69	8.28e-39	Height;
CESC	cis	rs5758659	0.716	rs86669	chr22:42680800	C/T	cg00645731	chr22:42541494	CYP2D7P1	-0.31	-5.55	-0.32	6.98e-8	Cognitive function;
CESC	cis	rs1144333	1.000	rs1144333	chr1:76275100	A/G	cg03433033	chr1:76189801	ACADM	-0.52	-5.06	-0.3	8.01e-7	Attention function in attention deficit hyperactive disorder;
CESC	cis	rs67460515	0.892	rs11711413	chr3:160998910	C/G	cg03342759	chr3:160939853	NMD3	-0.53	-7.59	-0.42	5.43e-13	Parkinson's disease;
CESC	cis	rs10883723	0.810	rs6584508	chr10:104258567	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.54	7.42	0.41	1.55e-12	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs6540556	0.724	rs6679631	chr1:209935491	C/A	cg05527609	chr1:210001259	C1orf107	-0.44	-5.55	-0.32	6.87e-8	Red blood cell count;
CESC	cis	rs1178968	1.000	rs12534600	chr7:72762721	C/T	cg25889504	chr7:72793014	NA	-0.49	-5.18	-0.3	4.38e-7	Triglyceride levels;
CESC	cis	rs13385	0.769	rs4913078	chr5:139626680	A/T	cg26211634	chr5:139558579	C5orf32	0.47	5.18	0.3	4.33e-7	Atrial fibrillation;
CESC	cis	rs9532580	0.778	rs34373380	chr13:41244217	T/A	cg21288729	chr13:41239152	FOXO1	0.68	8.46	0.46	1.82e-15	Mean corpuscular hemoglobin;
CESC	cis	rs7116495	0.609	rs4245463	chr11:71743213	C/A	cg18441811	chr11:71824068	C11orf51	-0.87	-5.33	-0.31	2.07e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs2228479	0.850	rs12597299	chr16:89822364	C/A	cg06558623	chr16:89946397	TCF25	1.16	9.28	0.5	6.08e-18	Skin colour saturation;
CESC	cis	rs35110281	0.805	rs8131005	chr21:45041954	T/C	cg21573476	chr21:45109991	RRP1B	-0.4	-5.77	-0.33	2.2e-8	Mean corpuscular volume;
CESC	cis	rs4906332	0.966	rs17679729	chr14:103924312	A/G	cg09975044	chr14:104007538	NA	0.47	6.39	0.37	7.34e-10	Coronary artery disease;
CESC	cis	rs820218	0.926	rs1661744	chr17:73647138	C/T	cg01592526	chr17:73663357	RECQL5;SAP30BP	0.41	5.47	0.32	1.03e-7	Rotator cuff tears;
CESC	cis	rs55871839	0.708	rs10112089	chr8:59813429	C/T	cg07426533	chr8:59803705	TOX	-0.47	-7.01	-0.4	1.95e-11	Pneumonia;
CESC	cis	rs2439831	0.764	rs12324584	chr15:43683446	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.86	12.81	0.62	1.51e-29	Lung cancer in ever smokers;
CESC	cis	rs4835473	0.900	rs4835303	chr4:144742686	T/C	cg25736465	chr4:144833511	NA	-0.32	-5.07	-0.3	7.42e-7	Immature fraction of reticulocytes;
CESC	cis	rs778371	0.723	rs6710294	chr2:233579634	T/C	cg08000102	chr2:233561755	GIGYF2	0.84	14.38	0.66	4.81e-35	Schizophrenia;
CESC	cis	rs10504073	0.584	rs4873307	chr8:49950417	C/T	cg00325661	chr8:49890786	NA	0.55	8.21	0.45	9.72e-15	Blood metabolite ratios;
CESC	cis	rs2742234	0.590	rs2435337	chr10:43661836	G/C	cg07801480	chr10:43725741	RASGEF1A	0.46	5.76	0.33	2.3e-8	Hirschsprung disease;
CESC	cis	rs8014204	1.000	rs4553560	chr14:75334199	T/C	cg08847533	chr14:75593920	NEK9	-0.47	-5.88	-0.34	1.25e-8	Caffeine consumption;
CESC	cis	rs4834770	0.717	rs1022146	chr4:120236103	A/G	cg09307838	chr4:120376055	NA	0.51	6.46	0.37	4.87e-10	Blood protein levels;
CESC	cis	rs9611565	0.694	rs5758389	chr22:41941749	T/C	cg17376030	chr22:41985996	PMM1	0.46	5.36	0.31	1.79e-7	Vitiligo;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01936430	chr1:204380496	PPP1R15B	0.62	7.37	0.41	2.11e-12	Gut microbiome composition (summer);
CESC	cis	rs736408	0.507	rs6445531	chr3:52717282	T/C	cg07507251	chr3:52567010	NT5DC2	0.32	5.61	0.33	5.12e-8	Bipolar disorder;
CESC	cis	rs6987853	0.787	rs2974354	chr8:42413943	A/G	cg09913449	chr8:42400586	C8orf40	0.44	7.24	0.41	4.99e-12	Mean corpuscular hemoglobin concentration;
CESC	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg23708337	chr7:1209742	NA	0.54	5.4	0.31	1.48e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs13108904	0.934	rs13128045	chr4:1305309	C/T	cg22903657	chr4:1355424	KIAA1530	-0.37	-5.13	-0.3	5.63e-7	Obesity-related traits;
CESC	cis	rs2836974	0.568	rs7282604	chr21:40536910	C/T	cg11644478	chr21:40555479	PSMG1	-0.83	-12.92	-0.62	5.85e-30	Cognitive function;
CESC	cis	rs6429082	0.818	rs291383	chr1:235643100	G/A	cg26050004	chr1:235667680	B3GALNT2	0.62	7.83	0.43	1.19e-13	Adiposity;
CESC	cis	rs950776	0.616	rs6495307	chr15:78890321	C/T	cg24631222	chr15:78858424	CHRNA5	-0.43	-5.43	-0.32	1.25e-7	Sudden cardiac arrest;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18947032	chr10:70748274	KIAA1279	-0.51	-6.26	-0.36	1.53e-9	Gut microbiome composition (summer);
CESC	cis	rs7944584	0.511	rs10838725	chr11:47557871	T/C	cg20307385	chr11:47447363	PSMC3	0.83	12.3	0.6	8.59e-28	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CESC	cis	rs2625529	0.526	rs8040828	chr15:72492779	C/A	cg16672083	chr15:72433130	SENP8	0.47	7.05	0.4	1.57e-11	Red blood cell count;
CESC	cis	rs7833790	0.724	rs72603871	chr8:82754460	C/G	cg17211192	chr8:82754475	SNX16	0.5	6.41	0.37	6.74e-10	Diastolic blood pressure;
CESC	cis	rs4481887	0.927	rs10888343	chr1:248446642	A/G	cg00666640	chr1:248458726	OR2T12	0.41	6.79	0.39	7.3e-11	Common traits (Other);
CESC	trans	rs607987	0.836	rs1222203	chr11:30336334	A/G	cg25993608	chr18:76621396	NA	-0.42	-6.0	-0.35	6.63e-9	Body mass index;
CESC	cis	rs7659604	0.539	rs11098646	chr4:122729301	T/C	cg06713675	chr4:122721982	EXOSC9	-0.51	-7.01	-0.4	1.94e-11	Type 2 diabetes;
CESC	cis	rs1799949	1.000	rs8176242	chr17:41217874	C/T	cg05368731	chr17:41323189	NBR1	0.77	10.41	0.54	1.7e-21	Menopause (age at onset);
CESC	cis	rs7481584	0.847	rs1468102	chr11:3004526	C/G	cg25174290	chr11:3078921	CARS	-0.48	-5.88	-0.34	1.22e-8	Calcium levels;
CESC	cis	rs2762353	0.779	rs1408273	chr6:25840946	C/T	cg03264133	chr6:25882463	NA	0.37	6.13	0.35	3.21e-9	Blood metabolite levels;
CESC	cis	rs35110281	0.659	rs2236667	chr21:45112939	A/G	cg04455712	chr21:45112962	RRP1B	0.49	7.87	0.44	8.94e-14	Mean corpuscular volume;
CESC	cis	rs9522267	0.535	rs9522301	chr13:112236726	A/T	cg10483660	chr13:112241077	NA	-0.32	-5.74	-0.33	2.64e-8	Hepatitis;
CESC	cis	rs2576037	0.583	rs9947131	chr18:44534769	G/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.35	5.54	0.32	7.25e-8	Personality dimensions;
CESC	cis	rs1348850	0.651	rs4893821	chr2:178229352	A/G	cg22681709	chr2:178499509	PDE11A	0.37	5.57	0.32	6.29e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs7429990	0.965	rs9846062	chr3:47998966	A/G	cg11946769	chr3:48343235	NME6	0.45	5.34	0.31	2.01e-7	Educational attainment (years of education);
CESC	cis	rs6088580	0.634	rs6120669	chr20:33105028	T/C	cg08999081	chr20:33150536	PIGU	0.65	11.47	0.58	5.24e-25	Glomerular filtration rate (creatinine);
CESC	cis	rs6815814	0.799	rs11466640	chr4:38778903	A/G	cg02016764	chr4:38805732	TLR1	0.68	7.9	0.44	7.55e-14	Breast cancer;
CESC	cis	rs62103177	0.564	rs2115996	chr18:77701007	C/G	cg12964065	chr18:77638022	KCNG2	0.53	5.98	0.34	7.25e-9	Opioid sensitivity;
CESC	trans	rs4716602	0.596	rs10261230	chr7:156159632	C/T	cg07175507	chr18:77160758	NFATC1	-0.44	-6.04	-0.35	5.07e-9	Anti-saccade response;
CESC	cis	rs12451471	0.559	rs34746710	chr17:78079224	G/A	cg24585782	chr17:78113791	EIF4A3	-0.57	-7.48	-0.42	1.08e-12	Plateletcrit;Mean corpuscular hemoglobin concentration;
CESC	cis	rs12497850	0.897	rs6795025	chr3:49081247	T/C	cg06212747	chr3:49208901	KLHDC8B	0.69	9.08	0.49	2.64e-17	Parkinson's disease;
CESC	cis	rs4665809	1.000	rs4665305	chr2:26313524	C/T	cg27170947	chr2:26402098	FAM59B	-0.59	-6.9	-0.39	3.83e-11	Gut microbiome composition (summer);
CESC	trans	rs2727020	0.521	rs10839299	chr11:49573981	C/T	cg15704280	chr7:45808275	SEPT13	-0.84	-10.3	-0.53	3.95e-21	Coronary artery disease;
CESC	cis	rs9902453	0.934	rs4427857	chr17:28457989	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.65	8.29	0.45	5.57e-15	Coffee consumption (cups per day);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05719672	chr15:91446576	MAN2A2	0.46	6.46	0.37	5.11e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs13256369	1.000	rs9329165	chr8:8576642	C/T	cg18904891	chr8:8559673	CLDN23	-0.68	-8.21	-0.45	9.79e-15	Obesity-related traits;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg03574882	chr7:151574332	PRKAG2	-0.45	-6.45	-0.37	5.14e-10	Fibrinogen levels;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg00552226	chr2:70475288	TIA1	-0.45	-6.02	-0.35	5.82e-9	Height;
CESC	cis	rs1448094	0.511	rs59858864	chr12:86166404	G/A	cg02569458	chr12:86230093	RASSF9	0.56	8.07	0.44	2.43e-14	Major depressive disorder;
CESC	cis	rs2075371	0.897	rs1643033	chr7:134004662	T/C	cg11752832	chr7:134001865	SLC35B4	0.53	6.89	0.39	3.99e-11	Mean platelet volume;
CESC	cis	rs1008375	0.898	rs7678654	chr4:17575376	T/G	cg16339924	chr4:17578868	LAP3	0.74	9.56	0.51	8.75e-19	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12129596	chr19:55770037	SAPS1	0.5	6.04	0.35	5.1e-9	Gut microbiome composition (summer);
CESC	cis	rs1448094	0.512	rs4362214	chr12:86245145	C/T	cg19622623	chr12:86230825	RASSF9	-0.46	-5.89	-0.34	1.14e-8	Major depressive disorder;
CESC	cis	rs6088590	0.687	rs73106933	chr20:33287425	T/C	cg06115741	chr20:33292138	TP53INP2	0.52	6.45	0.37	5.37e-10	Coronary artery disease;
CESC	cis	rs2603127	0.768	rs9873564	chr3:108496627	G/T	cg03329597	chr3:108125523	MYH15	0.57	5.35	0.31	1.95e-7	Hemostatic factors and hematological phenotypes;
CESC	cis	rs7552404	0.690	rs7549863	chr1:76327923	T/C	cg10523679	chr1:76189770	ACADM	-0.65	-6.61	-0.38	2.12e-10	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs736801	0.780	rs11951091	chr5:131786595	G/A	cg00255919	chr5:131827918	IRF1	-0.36	-5.16	-0.3	4.8e-7	Breast cancer;Mosquito bite size;
CESC	cis	rs4268898	0.662	rs72793213	chr2:24524725	A/G	cg08917208	chr2:24149416	ATAD2B	0.52	5.2	0.3	4.02e-7	Asthma;
CESC	cis	rs9325144	0.560	rs10785586	chr12:38676197	G/A	cg26384229	chr12:38710491	ALG10B	-0.6	-8.45	-0.46	1.97e-15	Morning vs. evening chronotype;
CESC	cis	rs7666738	0.830	rs11727653	chr4:99001774	T/C	cg18180107	chr4:99064573	C4orf37	0.4	5.23	0.31	3.41e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2404602	0.692	rs8037005	chr15:76951109	C/T	cg26408565	chr15:76604113	ETFA	-0.4	-5.69	-0.33	3.3e-8	Blood metabolite levels;
CESC	cis	rs911555	0.539	rs4374097	chr14:104072766	A/C	cg24130564	chr14:104152367	KLC1	-0.79	-13.02	-0.62	2.7e-30	Intelligence (multi-trait analysis);
CESC	cis	rs875971	0.505	rs1167386	chr7:65513096	G/A	cg26939375	chr7:64535504	NA	-0.74	-10.62	-0.55	3.37e-22	Aortic root size;
CESC	cis	rs939574	0.790	rs2385397	chr2:220087796	G/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-0.88	-7.91	-0.44	6.98e-14	Platelet distribution width;
CESC	cis	rs10791097	0.967	rs1944142	chr11:130717440	C/T	cg12179176	chr11:130786555	SNX19	0.54	7.78	0.43	1.6e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs9902453	0.967	rs7222685	chr17:28496430	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	7.84	0.43	1.08e-13	Coffee consumption (cups per day);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09508119	chr19:506588	C19orf20	0.59	6.61	0.38	2.16e-10	Gut microbiome composition (summer);
CESC	cis	rs853679	0.517	rs9348797	chr6:28137533	G/C	cg18032046	chr6:28092343	ZSCAN16	-0.57	-6.59	-0.38	2.36e-10	Depression;
CESC	cis	rs11764590	0.651	rs12673687	chr7:2081873	C/T	cg21782813	chr7:2030301	MAD1L1	-0.4	-5.23	-0.31	3.45e-7	Neuroticism;
CESC	cis	rs8020095	0.571	rs7142669	chr14:67250392	A/C	cg19548862	chr14:67692701	FAM71D	-0.5	-6.2	-0.36	2.13e-9	Depression (quantitative trait);
CESC	cis	rs9649213	0.593	rs10953255	chr7:97923198	A/G	cg24562669	chr7:97807699	LMTK2	0.5	7.26	0.41	4.26e-12	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs1348850	0.837	rs4243388	chr2:178284604	T/G	cg22681709	chr2:178499509	PDE11A	-0.42	-6.23	-0.36	1.79e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs9863	0.861	rs11833002	chr12:124446616	G/A	cg00084347	chr12:124393913	DNAH10	0.27	5.28	0.31	2.71e-7	White blood cell count;
CESC	cis	rs9341808	0.628	rs1892475	chr6:80862213	T/C	cg08355045	chr6:80787529	NA	0.32	5.03	0.3	8.88e-7	Sitting height ratio;
CESC	cis	rs3126085	0.935	rs3126046	chr1:152256925	G/A	cg03465714	chr1:152285911	FLG	0.46	5.74	0.33	2.61e-8	Atopic dermatitis;
CESC	cis	rs6952808	0.792	rs11771973	chr7:1950440	C/G	cg22963979	chr7:1858916	MAD1L1	-0.37	-5.11	-0.3	6.25e-7	Bipolar disorder and schizophrenia;
CESC	trans	rs1814175	0.817	rs80244685	chr11:49763292	C/A	cg15704280	chr7:45808275	SEPT13	-1.0	-17.46	-0.73	5.98e-46	Height;
CESC	cis	rs1707322	1.000	rs4660334	chr1:46462126	A/C	cg05343316	chr1:45956843	TESK2	0.45	5.46	0.32	1.09e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs10927875	0.864	rs12135073	chr1:16167799	C/T	cg21385522	chr1:16154831	NA	0.89	12.39	0.61	3.95e-28	Dilated cardiomyopathy;
CESC	cis	rs1790761	0.667	rs4147581	chr11:67351585	C/G	cg14500267	chr11:67383377	NA	0.36	5.72	0.33	2.93e-8	Mean corpuscular volume;
CESC	cis	rs7264396	0.779	rs2425162	chr20:34429974	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.6	7.04	0.4	1.67e-11	Total cholesterol levels;
CESC	cis	rs1799949	0.930	rs33968979	chr17:41297992	G/T	cg23758822	chr17:41437982	NA	1.02	15.64	0.69	1.65e-39	Menopause (age at onset);
CESC	cis	rs9308731	0.644	rs3789068	chr2:111909247	A/G	cg04202892	chr2:111875749	ACOXL	0.43	6.13	0.35	3.18e-9	Chronic lymphocytic leukemia;
CESC	cis	rs6685188	0.920	rs6593964	chr1:205662337	G/T	cg07157834	chr1:205819609	PM20D1	0.39	5.2	0.3	4.06e-7	White blood cell count (basophil);Basophil percentage of white cells;
CESC	cis	rs1552244	1.000	rs7637888	chr3:10080722	T/C	cg08888203	chr3:10149979	C3orf24	0.46	5.9	0.34	1.11e-8	Alzheimer's disease;
CESC	cis	rs4689388	0.926	rs4458523	chr4:6289986	G/T	cg14416269	chr4:6271139	WFS1	-0.44	-7.37	-0.41	2.23e-12	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs72781680	0.611	rs78861366	chr2:24354428	A/G	cg06627628	chr2:24431161	ITSN2	-0.68	-6.51	-0.37	3.81e-10	Lymphocyte counts;
CESC	cis	rs11190604	1.000	rs7099965	chr10:102301165	A/G	cg07080220	chr10:102295463	HIF1AN	0.66	6.04	0.35	5.08e-9	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs5769765	0.955	rs61136468	chr22:50312679	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.48	-5.43	-0.32	1.25e-7	Schizophrenia;
CESC	cis	rs7336332	0.569	rs57724994	chr13:28010389	T/C	cg22138327	chr13:27999177	GTF3A	0.49	5.12	0.3	5.78e-7	Weight;
CESC	cis	rs72945132	0.882	rs3133179	chr11:70187574	T/G	cg14191688	chr11:70257035	CTTN	0.43	5.51	0.32	8.64e-8	Coronary artery disease;
CESC	cis	rs35306767	0.903	rs35637113	chr10:874149	G/C	cg25019033	chr10:957182	NA	-0.59	-6.29	-0.36	1.32e-9	Eosinophil percentage of granulocytes;
CESC	cis	rs2204008	0.905	rs7294297	chr12:38442573	T/C	cg13010199	chr12:38710504	ALG10B	0.42	5.43	0.32	1.28e-7	Bladder cancer;
CESC	cis	rs2282802	0.685	rs7730245	chr5:139628163	C/A	cg26211634	chr5:139558579	C5orf32	0.51	7.29	0.41	3.55e-12	Intelligence (multi-trait analysis);
CESC	cis	rs7107174	0.792	rs2888465	chr11:77945807	T/C	cg02023728	chr11:77925099	USP35	0.55	7.2	0.4	6.14e-12	Testicular germ cell tumor;
CESC	cis	rs7077164	1.000	rs1227764	chr10:71583223	G/A	cg20696214	chr10:71583771	COL13A1	-0.46	-6.31	-0.36	1.2e-9	Non-alcoholic fatty liver disease histology (lobular);
CESC	cis	rs9649213	0.593	rs6973775	chr7:98004685	G/A	cg08684580	chr7:98029266	BAIAP2L1	-0.37	-5.95	-0.34	8.5e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7927771	0.832	rs55677087	chr11:47397714	C/G	cg20307385	chr11:47447363	PSMC3	-0.58	-6.95	-0.39	2.81e-11	Subjective well-being;
CESC	cis	rs62408225	1.000	rs62408222	chr6:90948476	A/G	cg06866423	chr6:90926672	BACH2	0.51	6.21	0.36	2e-9	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg25441200	chr7:156742235	NOM1	0.44	6.08	0.35	4.17e-9	Systemic lupus erythematosus;
CESC	cis	rs1707322	1.000	rs785478	chr1:46491635	C/T	cg06784218	chr1:46089804	CCDC17	-0.34	-5.96	-0.34	7.95e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs60871478	0.636	rs4721600	chr7:871728	C/T	cg05535760	chr7:792225	HEATR2	-0.74	-7.7	-0.43	2.64e-13	Cerebrospinal P-tau181p levels;
CESC	cis	rs8114671	0.647	rs945959	chr20:33734905	G/C	cg24642439	chr20:33292090	TP53INP2	0.51	6.5	0.37	3.86e-10	Height;
CESC	cis	rs72781680	0.644	rs72783627	chr2:24315685	A/C	cg06627628	chr2:24431161	ITSN2	-0.68	-6.58	-0.37	2.44e-10	Lymphocyte counts;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03362689	chr3:49044465	P4HTM;WDR6	-0.54	-6.25	-0.36	1.62e-9	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09148975	chr1:38274245	C1orf122;YRDC	0.57	6.18	0.35	2.42e-9	Gut microbiome composition (summer);
CESC	cis	rs727563	0.635	rs2899348	chr22:42164516	C/G	cg03806693	chr22:41940476	POLR3H	1.18	13.88	0.65	2.76e-33	Crohn's disease;Inflammatory bowel disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27402845	chr11:1000533	AP2A2	-0.55	-6.2	-0.36	2.21e-9	Gut microbiome composition (summer);
CESC	cis	rs270601	0.837	rs367805	chr5:131701279	T/C	cg24060327	chr5:131705240	SLC22A5	-0.74	-9.94	-0.52	5.55e-20	Acylcarnitine levels;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg21242684	chr2:98262069	COX5B	-0.44	-6.2	-0.36	2.19e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs611744	0.647	rs1584373	chr8:109263399	C/A	cg21045802	chr8:109455806	TTC35	0.46	5.7	0.33	3.13e-8	Dupuytren's disease;
CESC	cis	rs3096299	0.679	rs3102338	chr16:89442250	C/G	cg08392591	chr16:89556376	ANKRD11	0.41	5.22	0.31	3.55e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs11098499	0.954	rs35063680	chr4:120387102	T/C	cg24375607	chr4:120327624	NA	0.44	5.48	0.32	9.91e-8	Corneal astigmatism;
CESC	cis	rs1336900	0.637	rs35967040	chr1:150555588	A/C	cg18016565	chr1:150552671	MCL1	-0.37	-5.4	-0.31	1.51e-7	Blood protein levels;
CESC	cis	rs34779708	0.966	rs878264	chr10:35440581	T/C	cg04310649	chr10:35416472	CREM	-0.54	-6.69	-0.38	1.35e-10	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs10992471	0.756	rs7027595	chr9:95131553	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.45	-5.68	-0.33	3.52e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CESC	cis	rs2730245	0.636	rs2657382	chr7:158650941	G/A	cg24397884	chr7:158709396	WDR60	0.72	10.29	0.53	4.05e-21	Height;
CESC	cis	rs763121	0.962	rs909564	chr22:39126508	A/G	cg21395723	chr22:39101663	GTPBP1	0.39	5.22	0.31	3.6e-7	Menopause (age at onset);
CESC	cis	rs6460942	1.000	rs7808819	chr7:12297440	C/T	cg02935154	chr7:12443704	VWDE	-0.59	-5.82	-0.34	1.69e-8	Coronary artery disease;
CESC	cis	rs4713118	0.629	rs203889	chr6:28021775	T/G	cg12963246	chr6:28129442	ZNF389	0.48	6.3	0.36	1.2e-9	Parkinson's disease;
CESC	cis	rs8067545	0.750	rs9915758	chr17:19964775	A/G	cg13482628	chr17:19912719	NA	0.38	5.07	0.3	7.57e-7	Schizophrenia;
CESC	cis	rs1865721	0.804	rs72977818	chr18:73146852	T/C	cg26385618	chr18:73139727	C18orf62	-0.52	-8.21	-0.45	1e-14	Intelligence;
CESC	cis	rs938554	0.612	rs28592748	chr4:9998605	T/C	cg11266682	chr4:10021025	SLC2A9	0.47	6.54	0.37	3.22e-10	Blood metabolite levels;
CESC	cis	rs3015497	0.967	rs3015483	chr14:51137474	C/G	cg26011998	chr14:51135199	SAV1	-0.41	-5.18	-0.3	4.4e-7	Mean platelet volume;
CESC	cis	rs4683142	0.518	rs6802312	chr3:46025941	T/C	cg18004856	chr3:46029278	FYCO1	0.4	5.52	0.32	8.01e-8	Methadone dose in opioid dependence;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22120017	chr8:101964390	YWHAZ	0.6	6.53	0.37	3.41e-10	Gut microbiome composition (summer);
CESC	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg14159672	chr1:205819179	PM20D1	0.93	16.31	0.71	6.74e-42	Menarche (age at onset);
CESC	cis	rs763014	0.932	rs2269560	chr16:682442	A/C	cg09263875	chr16:632152	PIGQ	0.67	11.29	0.57	2.08e-24	Height;
CESC	cis	rs67478160	0.619	rs55824307	chr14:104271207	C/T	cg08213375	chr14:104286397	PPP1R13B	0.54	10.79	0.55	9.69e-23	Schizophrenia;
CESC	cis	rs6963495	0.818	rs117887993	chr7:105193837	T/G	cg02135003	chr7:105160482	PUS7	-0.48	-5.66	-0.33	3.95e-8	Bipolar disorder (body mass index interaction);
CESC	cis	rs9733	0.596	rs7418501	chr1:150711896	A/T	cg22823121	chr1:150693482	HORMAD1	0.46	6.75	0.38	9.54e-11	Tonsillectomy;
CESC	cis	rs5769765	1.000	rs5770742	chr22:50270309	T/C	cg02269571	chr22:50332266	NA	0.46	6.28	0.36	1.39e-9	Schizophrenia;
CESC	cis	rs1552244	0.882	rs28366039	chr3:10028988	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.7	-7.96	-0.44	5.16e-14	Alzheimer's disease;
CESC	cis	rs8067545	0.750	rs4925081	chr17:19991993	A/G	cg13482628	chr17:19912719	NA	-0.37	-5.13	-0.3	5.6e-7	Schizophrenia;
CESC	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.09	20.61	0.78	5.5e-57	Prudent dietary pattern;
CESC	cis	rs17376456	0.825	rs17372615	chr5:93124768	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.61	5.26	0.31	3.01e-7	Diabetic retinopathy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25149927	chr12:109250901	SSH1	-0.59	-6.94	-0.39	3e-11	Gut microbiome composition (summer);
CESC	cis	rs709400	0.930	rs61996717	chr14:104048571	T/C	cg12935359	chr14:103987150	CKB	-0.5	-6.31	-0.36	1.16e-9	Body mass index;
CESC	trans	rs877282	0.945	rs11253397	chr10:789774	A/G	cg22713356	chr15:30763199	NA	1.32	13.44	0.64	9.25e-32	Uric acid levels;
CESC	cis	rs10242455	0.571	rs28365067	chr7:99272310	G/A	cg25640893	chr7:99214727	ZNF498	0.96	6.17	0.35	2.53e-9	Blood metabolite levels;
CESC	cis	rs7666738	0.800	rs10028921	chr4:98962630	G/T	cg03676636	chr4:99064102	C4orf37	0.33	5.13	0.3	5.58e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2777491	0.915	rs7178777	chr15:41634588	C/A	cg20272979	chr15:41787780	ITPKA	0.36	5.33	0.31	2.09e-7	Ulcerative colitis;
CESC	cis	rs6963495	0.818	rs6955796	chr7:105170321	T/G	cg13798780	chr7:105162888	PUS7	0.77	7.88	0.44	8.3e-14	Bipolar disorder (body mass index interaction);
CESC	cis	rs17125944	0.686	rs11621275	chr14:53363316	C/G	cg00686598	chr14:53173677	PSMC6	-0.57	-5.16	-0.3	4.78e-7	Alzheimer's disease (late onset);
CESC	cis	rs11792861	0.926	rs76689835	chr9:111833792	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.43	5.31	0.31	2.29e-7	Menarche (age at onset);
CESC	trans	rs6467710	1.000	rs6467710	chr7:137203819	C/G	cg14964336	chr4:1523275	NA	0.96	6.05	0.35	4.91e-9	AIDS progression;
CESC	cis	rs9911578	0.933	rs11868348	chr17:57179238	C/T	cg12560992	chr17:57184187	TRIM37	1.01	17.89	0.74	1.77e-47	Intelligence (multi-trait analysis);
CESC	cis	rs2204008	0.550	rs11495600	chr12:38126654	C/T	cg13010199	chr12:38710504	ALG10B	0.54	6.69	0.38	1.28e-10	Bladder cancer;
CESC	cis	rs11146838	1	rs11146838	chr10:39149977	A/T	cg25427524	chr10:38739819	LOC399744	-0.78	-12.07	-0.6	4.98e-27	Breast cancer;
CESC	cis	rs4654899	1.000	rs6703227	chr1:21374810	A/G	cg05370193	chr1:21551575	ECE1	0.4	6.13	0.35	3.18e-9	Superior frontal gyrus grey matter volume;
CESC	cis	rs6775745	0.541	rs16838395	chr3:131755693	A/G	cg12213930	chr3:131751605	CPNE4	-0.48	-5.38	-0.31	1.66e-7	Neutrophil count;
CESC	cis	rs13256369	1.000	rs13282915	chr8:8570891	T/G	cg17143192	chr8:8559678	CLDN23	0.74	8.83	0.48	1.5e-16	Obesity-related traits;
CESC	cis	rs2576037	0.899	rs12955429	chr18:44585484	C/T	cg19077165	chr18:44547161	KATNAL2	0.48	6.54	0.37	3.09e-10	Personality dimensions;
CESC	cis	rs67478160	0.643	rs11626377	chr14:104234357	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.5	-6.89	-0.39	4.13e-11	Schizophrenia;
CESC	cis	rs9303401	0.659	rs34275691	chr17:56736640	A/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.03	13.13	0.63	1.12e-30	Cognitive test performance;
CESC	cis	rs7116495	0.609	rs4944243	chr11:71674354	T/C	cg10381502	chr11:71823885	C11orf51	-1.18	-7.71	-0.43	2.53e-13	Severe influenza A (H1N1) infection;
CESC	cis	rs9322193	0.923	rs10872649	chr6:150080590	T/G	cg04369109	chr6:150039330	LATS1	-0.43	-5.99	-0.35	6.69e-9	Lung cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07862083	chr17:21187823	MAP2K3	0.56	6.74	0.38	9.69e-11	Gut microbiome composition (summer);
CESC	cis	rs6860806	0.661	rs334902	chr5:131586559	C/G	cg12564285	chr5:131593104	PDLIM4	0.38	5.85	0.34	1.43e-8	Breast cancer;
CESC	cis	rs854765	0.619	rs6502636	chr17:17983817	A/T	cg04398451	chr17:18023971	MYO15A	-0.77	-11.34	-0.57	1.48e-24	Total body bone mineral density;
CESC	cis	rs6580649	0.941	rs4760683	chr12:48516296	T/C	cg05342945	chr12:48394962	COL2A1	0.5	5.87	0.34	1.28e-8	Lung cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07744562	chr6:90539506	CASP8AP2	0.55	6.25	0.36	1.61e-9	Gut microbiome composition (summer);
CESC	cis	rs888194	0.568	rs10850137	chr12:109874794	C/G	cg19025524	chr12:109796872	NA	-0.37	-5.07	-0.3	7.64e-7	Neuroticism;
CESC	trans	rs637571	0.522	rs1151512	chr11:65757533	G/A	cg17712092	chr4:129076599	LARP1B	0.75	10.57	0.54	5.01e-22	Eosinophil percentage of white cells;
CESC	cis	rs34172651	0.517	rs36113933	chr16:24838862	A/G	cg06028605	chr16:24865363	SLC5A11	0.55	8.24	0.45	7.88e-15	Intelligence (multi-trait analysis);
CESC	cis	rs2109514	0.569	rs926200	chr7:116170195	T/A	cg04696780	chr7:116139425	CAV2	-0.3	-5.22	-0.31	3.55e-7	Prevalent atrial fibrillation;
CESC	cis	rs801193	0.527	rs2707837	chr7:66181073	G/C	cg10691866	chr7:65817282	TPST1	-0.32	-5.44	-0.32	1.19e-7	Aortic root size;
CESC	cis	rs911555	0.755	rs7147664	chr14:103963420	G/A	cg12935359	chr14:103987150	CKB	-0.59	-8.46	-0.46	1.8e-15	Intelligence (multi-trait analysis);
CESC	cis	rs17711722	0.503	rs453835	chr7:65511159	T/A	cg19163074	chr7:65112434	INTS4L2	0.46	5.66	0.33	3.89e-8	Calcium levels;
CESC	cis	rs4780401	0.609	rs9924522	chr16:11816852	C/A	cg01061890	chr16:11836724	TXNDC11	-0.56	-7.52	-0.42	8.36e-13	Rheumatoid arthritis;
CESC	cis	rs1799949	0.965	rs12950779	chr17:41306523	C/T	cg06001716	chr17:41278141	BRCA1;NBR2	0.37	5.08	0.3	7.17e-7	Menopause (age at onset);
CESC	cis	rs2295499	0.754	rs16843272	chr4:2717515	G/A	cg08330972	chr4:2403930	ZFYVE28	-0.33	-5.42	-0.32	1.35e-7	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg06494227	chr22:30752758	CCDC157;SF3A1	-0.51	-6.66	-0.38	1.55e-10	Fibrinogen levels;
CESC	cis	rs9640161	0.789	rs2098053	chr7:150043205	G/A	cg21361702	chr7:150065534	REPIN1	0.57	6.01	0.35	6.25e-9	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs11696501	0.688	rs6104291	chr20:44323368	C/G	cg11783356	chr20:44313418	WFDC10B	-0.31	-5.08	-0.3	7.02e-7	Brain structure;
CESC	cis	rs2243480	1.000	rs34702770	chr7:65344823	T/C	cg12463550	chr7:65579703	CRCP	0.68	5.61	0.33	5.08e-8	Diabetic kidney disease;
CESC	cis	rs4423214	0.625	rs78685409	chr11:71137383	T/C	cg05163923	chr11:71159392	DHCR7	-0.66	-7.65	-0.43	3.63e-13	Vitamin D levels;
CESC	cis	rs7605827	0.897	rs6745621	chr2:15537866	C/A	cg19274914	chr2:15703543	NA	0.36	6.4	0.37	7.05e-10	Educational attainment (years of education);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20835789	chr3:15469053	METTL6;EAF1	0.58	6.7	0.38	1.23e-10	Gut microbiome composition (summer);
CESC	trans	rs208520	1.000	rs12191598	chr6:66983962	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.84	9.33	0.5	4.5e-18	Exhaled nitric oxide output;
CESC	cis	rs910316	0.763	rs175036	chr14:75464295	C/T	cg08847533	chr14:75593920	NEK9	-0.9	-15.84	-0.7	3.34e-40	Height;
CESC	trans	rs9858542	0.953	rs11926781	chr3:49603289	C/T	cg21659725	chr3:3221576	CRBN	-0.53	-6.52	-0.37	3.49e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs2836974	0.565	rs34304022	chr21:40579619	G/A	cg11890956	chr21:40555474	PSMG1	0.9	9.61	0.51	5.85e-19	Cognitive function;
CESC	cis	rs6674176	0.597	rs6671164	chr1:44403489	G/T	cg13606994	chr1:44402422	ARTN	-0.39	-6.09	-0.35	3.99e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs258892	0.947	rs62360681	chr5:72187013	T/G	cg21869765	chr5:72125136	TNPO1	0.45	5.62	0.33	4.9e-8	Small cell lung carcinoma;
CESC	cis	rs853679	0.517	rs17711801	chr6:28092307	C/G	cg08968635	chr6:28129556	ZNF389	0.41	5.51	0.32	8.4e-8	Depression;
CESC	cis	rs11864453	0.826	rs2074627	chr16:72136769	C/T	cg01557791	chr16:72042693	DHODH	-0.51	-6.66	-0.38	1.54e-10	Fibrinogen levels;
CESC	cis	rs6912958	0.559	rs107690	chr6:88069352	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.35	-5.8	-0.34	1.84e-8	Monocyte percentage of white cells;
CESC	cis	rs1707322	0.685	rs28617418	chr1:46189526	T/A	cg06784218	chr1:46089804	CCDC17	0.43	7.58	0.42	5.65e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs72781680	0.898	rs72798049	chr2:23958002	C/G	cg20701182	chr2:24300061	SF3B14	0.62	5.49	0.32	9.46e-8	Lymphocyte counts;
CESC	cis	rs3812762	0.879	rs10743088	chr11:8787620	A/C	cg03980550	chr11:8754370	ST5	0.36	5.15	0.3	5.15e-7	Hypospadias;
CESC	cis	rs897984	0.542	rs4468641	chr16:31096876	A/C	cg00531865	chr16:30841666	NA	-0.39	-5.47	-0.32	1.06e-7	Dementia with Lewy bodies;
CESC	cis	rs35110281	0.591	rs162390	chr21:44936826	C/T	cg21573476	chr21:45109991	RRP1B	-0.39	-5.6	-0.33	5.44e-8	Mean corpuscular volume;
CESC	cis	rs193541	0.545	rs12518979	chr5:122181787	G/T	cg19412675	chr5:122181750	SNX24	-0.42	-5.08	-0.3	7.02e-7	Glucose homeostasis traits;
CESC	cis	rs1256061	0.603	rs960069	chr14:64745002	C/T	cg21174375	chr14:64681225	SYNE2	0.53	7.15	0.4	8.45e-12	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs3785574	0.924	rs2584641	chr17:61862889	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.58	7.1	0.4	1.15e-11	Height;
CESC	cis	rs344364	0.511	rs1742395	chr16:1955965	G/A	cg03013636	chr16:1946785	NA	0.44	6.1	0.35	3.76e-9	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs10463316	0.862	rs11740475	chr5:150777997	A/G	cg03212797	chr5:150827313	SLC36A1	-0.43	-5.61	-0.33	5.12e-8	Metabolite levels (Pyroglutamine);
CESC	cis	rs1799949	1.000	rs11079056	chr17:41300799	C/A	cg06001716	chr17:41278141	BRCA1;NBR2	0.39	5.26	0.31	3e-7	Menopause (age at onset);
CESC	cis	rs147649347	1	rs147649347	chr2:24210076	GATAA/G	cg20701182	chr2:24300061	SF3B14	0.69	6.07	0.35	4.35e-9	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	cis	rs10479542	0.892	rs7723230	chr5:178980474	T/C	cg19626725	chr5:178986131	RUFY1	0.39	6.37	0.36	8.51e-10	Lung cancer;
CESC	cis	rs854765	0.534	rs7207461	chr17:17949789	T/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.62	-8.73	-0.47	2.97e-16	Total body bone mineral density;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg27556566	chr18:29671984	RNF138	0.54	7.25	0.41	4.51e-12	Gut microbiota (bacterial taxa);
CESC	cis	rs9309711	0.736	rs9309717	chr2:3495078	C/T	cg10845886	chr2:3471009	TTC15	0.66	8.89	0.48	9.47e-17	Neurofibrillary tangles;
CESC	cis	rs875971	0.862	rs7783779	chr7:65796626	A/G	cg18876405	chr7:65276391	NA	-0.53	-7.3	-0.41	3.28e-12	Aortic root size;
CESC	cis	rs992157	0.764	rs4672886	chr2:219185545	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.59	-7.86	-0.43	9.93e-14	Colorectal cancer;
CESC	cis	rs6502050	0.835	rs56232956	chr17:80078929	C/T	cg11859384	chr17:80120422	CCDC57	0.37	5.04	0.3	8.57e-7	Life satisfaction;
CESC	cis	rs875971	0.545	rs10950025	chr7:65623933	G/A	cg19163074	chr7:65112434	INTS4L2	-0.46	-5.05	-0.3	8.07e-7	Aortic root size;
CESC	cis	rs11792861	0.525	rs2417975	chr9:111860185	A/C	cg05043794	chr9:111880884	C9orf5	-0.28	-5.07	-0.3	7.57e-7	Menarche (age at onset);
CESC	cis	rs3820928	0.967	rs12622456	chr2:227768868	G/A	cg05526886	chr2:227700861	RHBDD1	-0.44	-5.61	-0.33	4.97e-8	Pulmonary function;
CESC	cis	rs7605827	0.897	rs10166702	chr2:15528454	T/C	cg19274914	chr2:15703543	NA	0.35	6.27	0.36	1.43e-9	Educational attainment (years of education);
CESC	cis	rs2286503	0.752	rs6461669	chr7:22858066	T/G	cg11367502	chr7:22862612	TOMM7	0.41	5.45	0.32	1.16e-7	Fibrinogen;
CESC	cis	rs9911578	1.000	rs4398153	chr17:56968181	T/C	cg12560992	chr17:57184187	TRIM37	-0.92	-15.0	-0.68	3.02e-37	Intelligence (multi-trait analysis);
CESC	cis	rs1799949	1.000	rs11653460	chr17:41331306	C/T	cg05368731	chr17:41323189	NBR1	0.76	10.35	0.54	2.73e-21	Menopause (age at onset);
CESC	cis	rs1278769	1.000	rs1278769	chr13:113536627	C/T	cg00823993	chr13:113535758	ATP11A	0.47	6.27	0.36	1.49e-9	Interstitial lung disease;
CESC	cis	rs172166	0.694	rs203876	chr6:28046673	T/C	cg19592336	chr6:28129416	ZNF389	0.47	6.86	0.39	4.78e-11	Cardiac Troponin-T levels;
CESC	cis	rs1448094	0.511	rs17279133	chr12:86162353	G/A	cg00310523	chr12:86230176	RASSF9	0.35	5.59	0.32	5.75e-8	Major depressive disorder;
CESC	cis	rs4819052	0.851	rs8130285	chr21:46671701	G/C	cg11663144	chr21:46675770	NA	-0.63	-9.96	-0.52	4.67e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs2731664	0.792	rs2630765	chr5:176876825	T/C	cg23176889	chr5:176863531	GRK6	-0.64	-11.06	-0.56	1.22e-23	Intelligence (multi-trait analysis);
CESC	cis	rs2795502	0.873	rs3121327	chr10:43388285	G/A	cg27426351	chr10:43362370	NA	0.49	6.0	0.35	6.55e-9	Blood protein levels;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg15236340	chr19:52838590	ZNF610	0.48	6.44	0.37	5.48e-10	Fibrinogen levels;
CESC	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg14893161	chr1:205819251	PM20D1	0.87	15.34	0.69	1.9e-38	Menarche (age at onset);
CESC	cis	rs6088590	1.000	rs6088607	chr20:33378733	C/T	cg08999081	chr20:33150536	PIGU	0.58	8.9	0.48	9.32e-17	Coronary artery disease;
CESC	cis	rs62103177	0.713	rs62103186	chr18:77627574	G/C	cg12964065	chr18:77638022	KCNG2	0.58	5.46	0.32	1.07e-7	Opioid sensitivity;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg24582500	chr10:131934763	GLRX3	0.43	6.01	0.35	6.19e-9	Gut microbiota (bacterial taxa);
CESC	trans	rs75107833	0.580	rs6433464	chr2:175008772	C/T	cg22524735	chr8:144779094	BREA2	-0.44	-6.13	-0.35	3.2e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs9522267	0.535	rs9515453	chr13:112234612	T/C	cg10483660	chr13:112241077	NA	-0.33	-5.79	-0.33	2.04e-8	Hepatitis;
CESC	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.56	0.37	2.89e-10	Prudent dietary pattern;
CESC	cis	rs1670533	1.000	rs7685541	chr4:1058501	G/A	cg27284194	chr4:1044797	NA	0.48	6.1	0.35	3.7e-9	Recombination rate (females);
CESC	cis	rs3750965	1.000	rs731974	chr11:68847156	C/T	cg01403660	chr11:68851641	TPCN2	0.39	5.11	0.3	6.25e-7	Hair color;
CESC	cis	rs748404	0.631	rs2412781	chr15:43667900	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.59	-7.63	-0.42	4.32e-13	Lung cancer;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg11649068	chr17:34136647	TAF15	-0.47	-6.3	-0.36	1.25e-9	Ulcerative colitis;
CESC	cis	rs921968	0.541	rs7583449	chr2:219403022	A/C	cg02176678	chr2:219576539	TTLL4	-0.53	-9.38	-0.5	3.15e-18	Mean corpuscular hemoglobin concentration;
CESC	cis	rs2404602	0.583	rs12438741	chr15:76542114	C/A	cg26408565	chr15:76604113	ETFA	-0.42	-6.25	-0.36	1.61e-9	Blood metabolite levels;
CESC	trans	rs2235573	0.527	rs139878	chr22:38361559	C/T	cg19894588	chr14:64061835	NA	0.63	8.28	0.45	6.09e-15	Glioblastoma;Glioma;
CESC	cis	rs10751667	0.666	rs7944815	chr11:959776	C/T	cg06064525	chr11:970664	AP2A2	-0.47	-9.44	-0.5	2.07e-18	Alzheimer's disease (late onset);
CESC	cis	rs12464559	0.649	rs12693116	chr2:152623917	A/G	cg01189475	chr2:152685088	ARL5A	0.68	5.87	0.34	1.31e-8	Response to cognitive-behavioural therapy in anxiety disorder;
CESC	cis	rs9303401	0.614	rs56284918	chr17:57178838	A/G	cg12560992	chr17:57184187	TRIM37	0.5	5.21	0.3	3.78e-7	Cognitive test performance;
CESC	cis	rs910316	1.000	rs12435391	chr14:75601737	A/G	cg08847533	chr14:75593920	NEK9	0.99	19.05	0.76	1.47e-51	Height;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03662217	chr21:35747882	FAM165B	0.51	6.62	0.38	1.98e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs7937682	1.000	rs505372	chr11:111507189	A/C	cg09085632	chr11:111637200	PPP2R1B	-0.98	-15.55	-0.69	3.35e-39	Primary sclerosing cholangitis;
CESC	cis	rs6495122	0.699	rs1378941	chr15:75080150	C/A	cg14664628	chr15:75095509	CSK	-0.68	-9.37	-0.5	3.23e-18	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
CESC	cis	rs2204008	0.659	rs4002655	chr12:38169881	T/G	cg26384229	chr12:38710491	ALG10B	0.72	10.46	0.54	1.18e-21	Bladder cancer;
CESC	cis	rs1005277	0.579	rs2103938	chr10:38493998	T/G	cg25427524	chr10:38739819	LOC399744	-0.72	-10.76	-0.55	1.23e-22	Extrinsic epigenetic age acceleration;
CESC	cis	rs1355223	0.583	rs1553757	chr11:34867089	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.84	12.68	0.61	4.2e-29	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs2072438	0.503	rs10739590	chr9:123871481	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.37	5.27	0.31	2.84e-7	Rheumatoid arthritis;
CESC	cis	rs35110281	0.774	rs2838321	chr21:44995488	A/T	cg01579765	chr21:45077557	HSF2BP	-0.56	-9.75	-0.51	2.11e-19	Mean corpuscular volume;
CESC	cis	rs17253792	0.818	rs78393484	chr14:56065802	T/C	cg01858014	chr14:56050164	KTN1	-0.96	-7.13	-0.4	9.72e-12	Putamen volume;
CESC	cis	rs7084402	0.967	rs1621227	chr10:60327734	C/G	cg07615347	chr10:60278583	BICC1	0.59	9.18	0.49	1.26e-17	Refractive error;
CESC	cis	rs10791323	0.569	rs10791328	chr11:133713730	A/G	cg15485101	chr11:133734466	NA	0.41	6.61	0.38	2.16e-10	Childhood ear infection;
CESC	cis	rs6500602	0.561	rs62039231	chr16:4519548	A/G	cg08645402	chr16:4508243	NA	0.57	8.97	0.48	5.57e-17	Schizophrenia;
CESC	cis	rs12701220	0.894	rs8591	chr7:1036799	C/T	cg26769984	chr7:1090371	C7orf50	0.64	7.59	0.42	5.55e-13	Bronchopulmonary dysplasia;
CESC	cis	rs2066819	1.000	rs76466034	chr12:56719450	G/A	cg26714650	chr12:56694279	CS	-1.48	-9.9	-0.52	7.03e-20	Psoriasis vulgaris;
CESC	cis	rs7219021	0.705	rs7207087	chr17:46917953	C/G	cg16584676	chr17:46985605	UBE2Z	0.57	6.98	0.39	2.32e-11	Schizophrenia or bipolar disorder;
CESC	cis	rs951366	1.000	rs951366	chr1:205685352	C/T	cg07157834	chr1:205819609	PM20D1	0.4	5.62	0.33	4.72e-8	Menarche (age at onset);
CESC	trans	rs3942852	0.568	rs6485807	chr11:48102867	G/A	cg15704280	chr7:45808275	SEPT13	-0.72	-9.41	-0.5	2.58e-18	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs35306767	0.668	rs12356612	chr10:1055055	C/T	cg25019033	chr10:957182	NA	-0.52	-5.21	-0.3	3.81e-7	Eosinophil percentage of granulocytes;
CESC	cis	rs9311474	0.607	rs4687625	chr3:52563718	C/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.29	5.2	0.3	4.08e-7	Electroencephalogram traits;
CESC	cis	rs9910055	0.659	rs8079310	chr17:42270291	A/G	cg13607699	chr17:42295918	UBTF	0.59	7.57	0.42	6.13e-13	Total body bone mineral density;
CESC	cis	rs9300255	0.509	rs641760	chr12:123518866	T/C	cg00376283	chr12:123451042	ABCB9	0.75	8.92	0.48	8.09e-17	Neutrophil percentage of white cells;
CESC	cis	rs62432291	0.681	rs429339	chr6:159660148	C/T	cg14500486	chr6:159655392	FNDC1	-0.62	-6.34	-0.36	9.83e-10	Joint mobility (Beighton score);
CESC	cis	rs17401966	1.000	rs7530167	chr1:10453374	A/G	cg15208524	chr1:10270712	KIF1B	0.46	5.8	0.34	1.86e-8	Hepatocellular carcinoma;
CESC	cis	rs6693567	0.545	rs11205375	chr1:150412474	C/T	cg09579323	chr1:150459698	TARS2	0.48	6.08	0.35	4.13e-9	Migraine;
CESC	cis	rs2204008	0.616	rs1607852	chr12:38398125	G/A	cg26384229	chr12:38710491	ALG10B	0.73	10.41	0.54	1.74e-21	Bladder cancer;
CESC	cis	rs1020064	0.636	rs2679876	chr2:105938107	T/C	cg02079111	chr2:105885981	TGFBRAP1	0.37	5.12	0.3	5.88e-7	AIDS;
CESC	cis	rs12142240	0.698	rs9661240	chr1:46827050	G/A	cg10495392	chr1:46806563	NSUN4	0.58	6.32	0.36	1.09e-9	Menopause (age at onset);
CESC	trans	rs3960554	1.000	rs2097947	chr7:75836382	A/T	cg19862616	chr7:65841803	NCRNA00174	0.52	6.05	0.35	4.89e-9	Eotaxin levels;
CESC	cis	rs6088590	0.561	rs6059926	chr20:33164804	C/T	cg06115741	chr20:33292138	TP53INP2	0.51	6.51	0.37	3.74e-10	Coronary artery disease;
CESC	cis	rs9457247	0.663	rs2282860	chr6:167440244	T/C	cg07741184	chr6:167504864	NA	0.34	6.09	0.35	3.9e-9	Crohn's disease;
CESC	cis	rs12079745	0.793	rs3766052	chr1:169126031	A/T	cg09363564	chr1:169337483	NME7;BLZF1	-1.18	-6.95	-0.39	2.85e-11	QT interval;
CESC	cis	rs11098499	0.909	rs10026736	chr4:120384322	G/C	cg24375607	chr4:120327624	NA	0.48	5.87	0.34	1.33e-8	Corneal astigmatism;
CESC	cis	rs9905704	0.647	rs6503892	chr17:57067086	G/A	cg12560992	chr17:57184187	TRIM37	0.65	8.05	0.44	2.8e-14	Testicular germ cell tumor;
CESC	cis	rs2180341	0.961	rs3798857	chr6:127659473	A/T	cg24812749	chr6:127587940	RNF146	1.07	15.4	0.69	1.16e-38	Breast cancer;
CESC	cis	rs829661	0.532	rs12621663	chr2:30784540	G/A	cg12454169	chr2:30669597	LCLAT1	-0.4	-5.03	-0.3	9.16e-7	Midgestational circulating levels of PBDEs (fetal genetic effect);
CESC	cis	rs6964587	1.000	rs7784248	chr7:91758111	A/G	cg17063962	chr7:91808500	NA	0.58	7.97	0.44	4.71e-14	Breast cancer;
CESC	cis	rs10256972	0.527	rs2949170	chr7:1216438	A/G	cg04025307	chr7:1156635	C7orf50	0.57	9.29	0.5	5.65e-18	Longevity;Endometriosis;
CESC	cis	rs524281	0.861	rs6591207	chr11:65949674	A/T	cg14036092	chr11:66035641	RAB1B	-0.56	-5.85	-0.34	1.45e-8	Electroencephalogram traits;
CESC	cis	rs7666738	0.753	rs13120995	chr4:98972762	A/G	cg05340658	chr4:99064831	C4orf37	0.79	12.26	0.6	1.12e-27	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9660992	0.736	rs72745207	chr1:205251991	C/G	cg21643547	chr1:205240462	TMCC2	-0.46	-6.14	-0.35	3e-9	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs4919694	1.000	rs4917379	chr10:104752831	A/T	cg04362960	chr10:104952993	NT5C2	0.74	6.44	0.37	5.71e-10	Arsenic metabolism;
CESC	cis	rs30380	0.632	rs27045	chr5:96138861	C/T	cg16492584	chr5:96139282	ERAP1	-0.49	-6.76	-0.38	8.56e-11	Cerebrospinal fluid biomarker levels;
CESC	cis	rs3733585	0.563	rs881971	chr4:9930962	A/G	cg00071950	chr4:10020882	SLC2A9	-0.65	-10.59	-0.55	4.47e-22	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs8067545	1.000	rs4925065	chr17:19914546	C/T	cg13482628	chr17:19912719	NA	0.46	6.17	0.35	2.55e-9	Schizophrenia;
CESC	cis	rs17376456	0.778	rs10476604	chr5:93461838	C/T	cg25358565	chr5:93447407	FAM172A	0.53	6.22	0.36	1.98e-9	Diabetic retinopathy;
CESC	cis	rs6496667	0.533	rs886491	chr15:90993215	G/A	cg10434728	chr15:90938212	IQGAP1	0.31	5.45	0.32	1.13e-7	Rheumatoid arthritis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17114847	chr11:47736795	AGBL2	0.53	6.25	0.36	1.63e-9	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.800	rs2865987	chr4:99067852	A/C	cg03467027	chr4:99064603	C4orf37	0.49	6.06	0.35	4.55e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs910316	1.000	rs876402	chr14:75601862	C/T	cg16144293	chr14:75469539	EIF2B2	0.41	5.31	0.31	2.32e-7	Height;
CESC	cis	rs6761276	0.649	rs3811057	chr2:113831188	C/A	cg12858261	chr2:113808755	IL1F8	0.46	5.68	0.33	3.63e-8	Protein quantitative trait loci;
CESC	cis	rs14403	0.913	rs12042298	chr1:243651806	C/T	cg21452805	chr1:244014465	NA	0.45	5.09	0.3	6.88e-7	Schizophrenia;
CESC	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.56	-6.25	-0.36	1.67e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs12824058	0.831	rs4759658	chr12:130815872	C/T	cg23887609	chr12:130822674	PIWIL1	0.45	5.86	0.34	1.38e-8	Menopause (age at onset);
CESC	cis	rs7617480	0.558	rs12715430	chr3:48942855	A/C	cg07636037	chr3:49044803	WDR6	0.85	11.57	0.58	2.46e-25	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CESC	cis	rs1023500	0.505	rs134888	chr22:42674281	C/T	cg04733989	chr22:42467013	NAGA	0.64	9.8	0.52	1.53e-19	Schizophrenia;
CESC	cis	rs11122272	0.735	rs2486728	chr1:231535883	T/G	cg06096015	chr1:231504339	EGLN1	0.43	6.08	0.35	4.22e-9	Hemoglobin concentration;
CESC	cis	rs6539267	0.847	rs17217845	chr12:106697802	C/T	cg00173435	chr12:106696525	TCP11L2	-0.62	-6.36	-0.36	9.01e-10	Tourette syndrome;
CESC	cis	rs9322193	0.884	rs10872647	chr6:150079823	T/C	cg02462569	chr6:150064036	NUP43	-0.38	-5.46	-0.32	1.11e-7	Lung cancer;
CESC	cis	rs9581857	0.685	rs9581856	chr13:28025615	G/C	cg22138327	chr13:27999177	GTF3A	0.64	5.14	0.3	5.37e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22215202	chr19:50321460	MED25	-0.54	-6.03	-0.35	5.36e-9	Gut microbiome composition (summer);
CESC	cis	rs6893300	0.776	rs56396231	chr5:179157298	T/G	cg14593053	chr5:179126677	CANX	-0.47	-5.15	-0.3	5.1e-7	Resting heart rate;
CESC	cis	rs10504229	1.000	rs73609747	chr8:58189104	G/C	cg05313129	chr8:58192883	C8orf71	-0.55	-6.29	-0.36	1.34e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs34172651	0.917	rs6497760	chr16:24806535	G/A	cg06028605	chr16:24865363	SLC5A11	0.41	6.22	0.36	1.94e-9	Intelligence (multi-trait analysis);
CESC	cis	rs3087591	0.922	rs2341348	chr17:29534867	C/T	cg24425628	chr17:29625626	OMG;NF1	0.42	5.03	0.3	9.22e-7	Hip circumference;
CESC	cis	rs4253772	0.637	rs41279831	chr22:46651623	T/C	cg00784671	chr22:46762841	CELSR1	-0.52	-5.49	-0.32	9.2e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs3741404	0.825	rs11603384	chr11:63949095	G/A	cg04317338	chr11:64019027	PLCB3	0.54	6.47	0.37	4.65e-10	Platelet count;
CESC	cis	rs7666738	0.830	rs4699603	chr4:99056172	T/C	cg18180107	chr4:99064573	C4orf37	0.42	5.36	0.31	1.79e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7666738	1.000	rs880473	chr4:98922596	C/T	cg17366294	chr4:99064904	C4orf37	0.55	7.14	0.4	9.06e-12	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7178572	0.568	rs8030074	chr15:77654232	C/T	cg22256960	chr15:77711686	NA	-0.53	-6.79	-0.38	7.53e-11	Type 2 diabetes;
CESC	cis	rs17376456	0.825	rs13165400	chr5:93091427	G/A	cg25358565	chr5:93447407	FAM172A	1.1	10.54	0.54	6.5e-22	Diabetic retinopathy;
CESC	cis	rs35110281	0.501	rs162378	chr21:44925905	A/G	cg01579765	chr21:45077557	HSF2BP	0.38	6.19	0.36	2.27e-9	Mean corpuscular volume;
CESC	cis	rs1847202	0.793	rs13088835	chr3:72949861	A/T	cg25664220	chr3:72788482	NA	-0.38	-5.52	-0.32	8.08e-8	Motion sickness;
CESC	cis	rs11792861	0.888	rs75543406	chr9:111816903	A/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.45	5.62	0.33	4.83e-8	Menarche (age at onset);
CESC	cis	rs9325144	0.560	rs6582561	chr12:38666821	G/A	cg26384229	chr12:38710491	ALG10B	-0.6	-8.49	-0.46	1.45e-15	Morning vs. evening chronotype;
CESC	cis	rs7845219	0.525	rs7820818	chr8:95919231	G/A	cg13393036	chr8:95962371	TP53INP1	-0.43	-7.98	-0.44	4.45e-14	Type 2 diabetes;
CESC	cis	rs780096	0.526	rs1260342	chr2:27663416	G/T	cg12648201	chr2:27665141	KRTCAP3	-0.35	-6.56	-0.37	2.79e-10	Total body bone mineral density;
CESC	cis	rs9913156	0.670	rs4470203	chr17:4567798	G/A	cg19197139	chr17:4613644	ARRB2	-0.72	-8.78	-0.47	2.03e-16	Lymphocyte counts;
CESC	trans	rs61931739	0.571	rs4001689	chr12:34243271	C/T	cg26384229	chr12:38710491	ALG10B	0.63	9.2	0.49	1.11e-17	Morning vs. evening chronotype;
CESC	cis	rs10504229	0.683	rs73603877	chr8:58108428	C/T	cg21724239	chr8:58056113	NA	0.57	5.9	0.34	1.08e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs7605827	0.897	rs6708187	chr2:15684964	T/A	cg19274914	chr2:15703543	NA	0.36	6.39	0.37	7.29e-10	Educational attainment (years of education);
CESC	cis	rs7089973	0.604	rs11196952	chr10:116607592	G/A	cg25233709	chr10:116636983	FAM160B1	0.38	6.08	0.35	4.13e-9	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs1153858	0.887	rs28569043	chr15:45730926	A/T	cg14582100	chr15:45693742	SPATA5L1	0.37	5.04	0.3	8.53e-7	Homoarginine levels;
CESC	cis	rs3749237	0.595	rs4855873	chr3:49459114	A/C	cg02487422	chr3:49467188	NICN1	0.57	8.34	0.46	4.01e-15	Resting heart rate;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg19458608	chr3:129830607	LOC729375	-0.48	-6.31	-0.36	1.14e-9	Asthma;
CESC	cis	rs34779708	0.931	rs12767414	chr10:35390193	C/T	cg03585969	chr10:35415529	CREM	0.77	10.11	0.53	1.53e-20	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs72781680	0.898	rs72786288	chr2:24075416	G/T	cg08917208	chr2:24149416	ATAD2B	0.93	8.48	0.46	1.57e-15	Lymphocyte counts;
CESC	cis	rs6963495	0.818	rs116845562	chr7:105217038	T/C	cg19920283	chr7:105172520	RINT1	0.65	6.0	0.35	6.53e-9	Bipolar disorder (body mass index interaction);
CESC	cis	rs787274	0.867	rs786981	chr9:115457856	T/G	cg13803584	chr9:115635662	SNX30	0.54	5.21	0.3	3.83e-7	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs9512730	0.527	rs11619722	chr13:27998600	T/C	cg04070771	chr13:27998621	GTF3A	0.51	5.5	0.32	9.11e-8	Schizophrenia;
CESC	cis	rs10883723	0.703	rs7898410	chr10:104245858	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.54	7.56	0.42	6.77e-13	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs1153858	0.943	rs28605551	chr15:45641720	C/T	cg14582100	chr15:45693742	SPATA5L1	0.42	6.08	0.35	4.2e-9	Homoarginine levels;
CESC	cis	rs7666738	0.791	rs2865958	chr4:99040732	G/T	cg05340658	chr4:99064831	C4orf37	0.82	12.88	0.62	8.44e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7799006	0.964	rs3757440	chr7:2272936	A/G	cg12745145	chr7:2261452	MAD1L1	-0.34	-5.31	-0.31	2.34e-7	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs6456156	0.586	rs1358882	chr6:167467101	G/A	cg07741184	chr6:167504864	NA	0.35	6.08	0.35	4.1e-9	Primary biliary cholangitis;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg27254601	chr16:29817104	MAZ	-0.49	-6.64	-0.38	1.79e-10	Asthma;
CESC	cis	rs10129255	0.957	rs10150241	chr14:107184184	A/T	cg23076370	chr14:107095027	NA	0.44	5.83	0.34	1.62e-8	Kawasaki disease;
CESC	cis	rs617791	0.530	rs55947178	chr11:65754230	G/A	cg09783858	chr11:65769428	EIF1AD;BANF1	0.53	6.37	0.36	8.31e-10	Breast cancer;
CESC	cis	rs208520	0.690	rs12194057	chr6:66745616	A/G	cg07460842	chr6:66804631	NA	0.96	12.69	0.61	3.81e-29	Exhaled nitric oxide output;
CESC	trans	rs7246657	0.943	rs3745765	chr19:37854235	G/T	cg24637308	chr11:6592297	DNHD1	0.52	6.08	0.35	4.27e-9	Coronary artery calcification;
CESC	cis	rs2075371	0.933	rs1868785	chr7:133945855	G/C	cg11752832	chr7:134001865	SLC35B4	0.52	6.71	0.38	1.2e-10	Mean platelet volume;
CESC	cis	rs7666738	0.830	rs62321597	chr4:99014221	C/A	cg03467027	chr4:99064603	C4orf37	0.44	5.63	0.33	4.57e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11711311	1.000	rs2603792	chr3:113509187	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.56	7.39	0.41	1.92e-12	IgG glycosylation;
CESC	cis	rs11148252	0.595	rs9526968	chr13:53240183	T/C	cg00495681	chr13:53174319	NA	0.6	8.21	0.45	9.62e-15	Lewy body disease;
CESC	cis	rs6942756	0.915	rs6946938	chr7:129004662	A/C	cg02491457	chr7:128862824	NA	-0.6	-8.39	-0.46	2.99e-15	White matter hyperintensity burden;
CESC	cis	rs4555082	0.874	rs2816613	chr14:105726367	C/T	cg27165867	chr14:105738592	BRF1	-0.52	-5.66	-0.33	3.92e-8	Mean platelet volume;Platelet distribution width;
CESC	cis	rs2635047	0.713	rs17723389	chr18:44762307	C/T	cg24371990	chr18:44770781	NA	0.41	6.68	0.38	1.38e-10	Educational attainment;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09692677	chr20:34359756	PHF20	-0.52	-6.32	-0.36	1.12e-9	Gut microbiome composition (summer);
CESC	cis	rs57221529	0.713	rs12522724	chr5:590742	T/C	cg16447950	chr5:562315	NA	-0.58	-6.05	-0.35	4.93e-9	Lung disease severity in cystic fibrosis;
CESC	cis	rs6942756	0.668	rs644723	chr7:129107881	C/T	cg02491457	chr7:128862824	NA	-0.58	-8.07	-0.44	2.53e-14	White matter hyperintensity burden;
CESC	cis	rs9905704	0.708	rs304263	chr17:56749941	C/T	cg12560992	chr17:57184187	TRIM37	0.61	7.69	0.43	2.92e-13	Testicular germ cell tumor;
CESC	cis	rs17666538	0.710	rs12716640	chr8:645376	A/C	cg02524346	chr8:600233	NA	0.84	7.22	0.41	5.49e-12	IgG glycosylation;
CESC	cis	rs6912958	0.525	rs242262	chr6:88018057	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.52	8.88	0.48	1.06e-16	Monocyte percentage of white cells;
CESC	cis	rs3806843	1.000	rs13157397	chr5:140184442	G/A	cg16179182	chr5:140090404	VTRNA1-1	-0.4	-5.1	-0.3	6.55e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs1003719	0.788	rs2835579	chr21:38457965	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.62	8.67	0.47	4.41e-16	Eye color traits;
CESC	cis	rs1003719	0.843	rs1003721	chr21:38492657	T/G	cg10648535	chr21:38446584	PIGP;TTC3	0.6	7.94	0.44	5.87e-14	Eye color traits;
CESC	cis	rs6693567	0.545	rs1260385	chr1:150316385	G/A	cg09579323	chr1:150459698	TARS2	0.5	6.24	0.36	1.75e-9	Migraine;
CESC	cis	rs7980687	0.527	rs1727295	chr12:123616861	G/A	cg05973401	chr12:123451056	ABCB9	0.56	7.04	0.4	1.65e-11	Height;Educational attainment;Head circumference (infant);
CESC	cis	rs16854884	0.657	rs6778627	chr3:143720869	G/T	cg06585982	chr3:143692056	C3orf58	0.45	5.82	0.34	1.71e-8	Economic and political preferences (feminism/equality);
CESC	cis	rs1707322	0.963	rs10890371	chr1:46390897	T/G	cg05343316	chr1:45956843	TESK2	0.44	5.42	0.32	1.36e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs6499255	0.951	rs12596823	chr16:69634757	A/C	cg15192750	chr16:69999425	NA	0.5	5.77	0.33	2.22e-8	IgE levels;
CESC	cis	rs34638657	0.687	rs2303265	chr16:82203705	A/C	cg09439754	chr16:82129088	HSD17B2	-0.36	-6.36	-0.36	8.85e-10	Lung adenocarcinoma;
CESC	cis	rs2625529	0.824	rs4777475	chr15:72218206	C/T	cg16672083	chr15:72433130	SENP8	-0.4	-5.26	-0.31	3.04e-7	Red blood cell count;
CESC	cis	rs1707322	0.686	rs2230659	chr1:46078884	C/T	cg05343316	chr1:45956843	TESK2	-0.53	-6.45	-0.37	5.42e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7937682	0.632	rs14133	chr11:111782697	C/G	cg09085632	chr11:111637200	PPP2R1B	0.87	11.25	0.57	2.88e-24	Primary sclerosing cholangitis;
CESC	cis	rs2108622	0.727	rs8104311	chr19:15982760	T/C	cg13772218	chr19:15982569	NA	0.29	5.67	0.33	3.8e-8	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg26774059	chr17:26684261	POLDIP2;TMEM199	-0.45	-6.01	-0.35	6.24e-9	Fibrinogen levels;
CESC	cis	rs77741769	0.571	rs35905305	chr12:121328082	T/G	cg02419362	chr12:121203948	SPPL3	0.34	5.53	0.32	7.55e-8	Mean corpuscular volume;
CESC	cis	rs854765	0.547	rs2955383	chr17:17941364	A/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.55	7.27	0.41	4.15e-12	Total body bone mineral density;
CESC	cis	rs5750830	0.621	rs5757665	chr22:39821641	A/G	cg24399712	chr22:39784796	NA	-0.81	-10.81	-0.55	8.51e-23	Intelligence (multi-trait analysis);
CESC	cis	rs796364	0.806	rs6435040	chr2:200861161	T/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.85	7.7	0.43	2.79e-13	Schizophrenia;
CESC	cis	rs9291683	0.507	rs6845554	chr4:10013173	T/G	cg02734326	chr4:10020555	SLC2A9	0.42	5.77	0.33	2.27e-8	Bone mineral density;
CESC	cis	rs35306767	0.903	rs11253475	chr10:907262	C/A	cg10556349	chr10:835070	NA	0.58	5.48	0.32	9.7e-8	Eosinophil percentage of granulocytes;
CESC	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.58	7.49	0.42	1.01e-12	Prudent dietary pattern;
CESC	cis	rs1729951	0.575	rs16844326	chr3:136678385	G/C	cg04103450	chr3:136751342	NA	0.4	5.28	0.31	2.66e-7	Neuroticism;
CESC	cis	rs17376456	0.569	rs11135397	chr5:93214975	G/T	cg25358565	chr5:93447407	FAM172A	0.66	7.24	0.41	4.82e-12	Diabetic retinopathy;
CESC	cis	rs896854	0.818	rs13262110	chr8:95926890	C/T	cg26343298	chr8:95960752	TP53INP1	0.32	5.28	0.31	2.74e-7	Type 2 diabetes;
CESC	cis	rs77972916	0.611	rs61552842	chr2:43584036	G/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.57	-5.21	-0.3	3.89e-7	Granulocyte percentage of myeloid white cells;
CESC	cis	rs561341	1.000	rs693116	chr17:30246124	C/T	cg19193384	chr17:30244184	NA	-0.7	-6.41	-0.37	6.77e-10	Hip circumference adjusted for BMI;
CESC	cis	rs11690935	0.549	rs2129475	chr2:172916772	A/G	cg13550731	chr2:172543902	DYNC1I2	0.5	6.77	0.38	8.32e-11	Schizophrenia;
CESC	cis	rs1348850	1.000	rs1348850	chr2:178418575	A/G	cg23306229	chr2:178417860	TTC30B	0.6	7.67	0.43	3.37e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs763014	0.932	rs2384974	chr16:651279	C/G	cg07343612	chr16:622815	PIGQ	-0.55	-8.12	-0.45	1.81e-14	Height;
CESC	cis	rs7666738	0.791	rs13120773	chr4:98972589	C/T	cg17366294	chr4:99064904	C4orf37	0.59	8.43	0.46	2.31e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2204008	0.720	rs11180923	chr12:38255172	A/T	cg26384229	chr12:38710491	ALG10B	0.68	9.7	0.51	3.2e-19	Bladder cancer;
CESC	cis	rs2777491	0.957	rs16971798	chr15:41657144	A/T	cg02330683	chr15:41787940	ITPKA	-0.44	-6.57	-0.37	2.69e-10	Ulcerative colitis;
CESC	cis	rs6499755	0.712	rs31087	chr16:55363238	G/A	cg02859129	chr16:55357253	IRX6	0.32	5.04	0.3	8.43e-7	Hypospadias;
CESC	cis	rs9649465	1.000	rs9649465	chr7:123376560	G/A	cg04330084	chr7:123175371	IQUB	-0.38	-5.18	-0.3	4.46e-7	Migraine;
CESC	cis	rs941408	0.515	rs1736188	chr19:2782368	A/G	cg02580895	chr19:2754563	NA	-0.48	-6.7	-0.38	1.25e-10	Total cholesterol levels;
CESC	cis	rs2635047	0.875	rs2251948	chr18:44681356	A/T	cg19077165	chr18:44547161	KATNAL2	-0.44	-5.93	-0.34	9.55e-9	Educational attainment;
CESC	cis	rs7666738	0.962	rs1527515	chr4:99025733	C/A	cg18180107	chr4:99064573	C4orf37	0.46	5.7	0.33	3.18e-8	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13444131	chr19:40322546	DYRK1B	-0.67	-7.68	-0.43	3.13e-13	Gut microbiome composition (summer);
CESC	cis	rs2250402	0.510	rs7535	chr15:40328575	G/C	cg20255370	chr15:40268687	EIF2AK4	-0.58	-5.22	-0.31	3.54e-7	Corneal curvature;
CESC	cis	rs514406	0.763	rs6685599	chr1:53213172	G/A	cg16325326	chr1:53192061	ZYG11B	-0.89	-15.22	-0.68	5.28e-38	Monocyte count;
CESC	cis	rs1348850	0.597	rs4893964	chr2:178447658	G/T	cg23306229	chr2:178417860	TTC30B	0.68	7.48	0.42	1.1e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs911555	0.574	rs34251103	chr14:103860063	A/G	cg12935359	chr14:103987150	CKB	0.61	8.74	0.47	2.75e-16	Intelligence (multi-trait analysis);
CESC	trans	rs61931739	0.500	rs9705909	chr12:34576419	G/C	cg26384229	chr12:38710491	ALG10B	0.73	10.92	0.56	3.54e-23	Morning vs. evening chronotype;
CESC	cis	rs2933343	0.621	rs789241	chr3:128585752	G/A	cg25356066	chr3:128598488	ACAD9	0.59	8.35	0.46	3.8e-15	IgG glycosylation;
CESC	cis	rs1044826	0.619	rs57357132	chr3:139118358	A/T	cg00490450	chr3:139108681	COPB2	-0.42	-5.2	-0.3	4.03e-7	Obesity-related traits;
CESC	cis	rs12497850	0.931	rs6791542	chr3:48787219	A/G	cg02487422	chr3:49467188	NICN1	0.41	5.39	0.31	1.55e-7	Parkinson's disease;
CESC	cis	rs7542091	0.704	rs9429825	chr1:210052133	C/G	cg22029157	chr1:209979665	IRF6	0.5	7.91	0.44	6.88e-14	Monobrow;
CESC	cis	rs4664304	0.754	rs67504285	chr2:160821211	C/T	cg03641300	chr2:160917029	PLA2R1	-0.41	-5.59	-0.33	5.5e-8	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs769267	0.930	rs7254927	chr19:19404786	C/G	cg03709012	chr19:19516395	GATAD2A	0.95	13.98	0.65	1.22e-33	Tonsillectomy;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg00387107	chr7:101845057	CUX1	0.5	6.46	0.37	4.85e-10	Fibrinogen levels;
CESC	trans	rs11148252	0.553	rs9536236	chr13:53255012	T/A	cg18335740	chr13:41363409	SLC25A15	0.5	6.74	0.38	9.72e-11	Lewy body disease;
CESC	cis	rs8049634	0.528	rs3785017	chr16:84093931	A/G	cg06572904	chr16:84086012	NA	-0.47	-5.13	-0.3	5.65e-7	Small cell lung carcinoma;
CESC	cis	rs4819052	0.851	rs3673	chr21:46681775	C/T	cg11663144	chr21:46675770	NA	-0.48	-7.32	-0.41	3e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs72634258	0.554	rs12741937	chr1:7897622	A/T	cg26816564	chr1:7831052	VAMP3	0.61	5.31	0.31	2.35e-7	Inflammatory bowel disease;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg03108344	chr6:150326762	RAET1K	-0.47	-6.2	-0.36	2.14e-9	Ulcerative colitis;
CESC	cis	rs10465746	0.740	rs1536165	chr1:84465073	C/A	cg10977910	chr1:84465055	TTLL7	0.41	5.08	0.3	6.98e-7	Obesity-related traits;
CESC	cis	rs595982	0.527	rs73061658	chr19:49372376	G/C	cg15549821	chr19:49342101	PLEKHA4	-0.65	-6.96	-0.39	2.63e-11	Red cell distribution width;
CESC	cis	rs9362426	0.943	rs7744338	chr6:88101999	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.52	5.94	0.34	8.78e-9	Depressive episodes in bipolar disorder;
CESC	cis	rs10504229	0.683	rs2291765	chr8:58142874	C/T	cg24829409	chr8:58192753	C8orf71	-0.5	-6.89	-0.39	4.16e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs9911578	1.000	rs172565	chr17:56808996	A/T	cg12560992	chr17:57184187	TRIM37	0.93	15.6	0.69	2.28e-39	Intelligence (multi-trait analysis);
CESC	cis	rs6835098	1.000	rs10027708	chr4:174083116	T/C	cg08422745	chr4:174089978	GALNT7	-0.83	-11.79	-0.59	4.45e-26	Dementia and core Alzheimer's disease neuropathologic changes;
CESC	cis	rs6430585	0.528	rs309162	chr2:136690783	T/A	cg07169764	chr2:136633963	MCM6	1.16	17.03	0.72	1.95e-44	Corneal structure;
CESC	cis	rs2732480	0.500	rs11168468	chr12:48612465	C/T	cg04545296	chr12:48745243	ZNF641	0.39	6.46	0.37	5.05e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs2228479	0.702	rs17233176	chr16:89832751	G/C	cg00800038	chr16:89945340	TCF25	-0.92	-7.64	-0.42	4.02e-13	Skin colour saturation;
CESC	cis	rs2115536	0.967	rs4778734	chr15:80210851	A/G	cg11839771	chr15:80205821	ST20	-0.37	-5.37	-0.31	1.69e-7	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CESC	cis	rs7666738	0.830	rs4699600	chr4:99019429	C/G	cg05340658	chr4:99064831	C4orf37	0.82	12.99	0.62	3.34e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs514406	0.729	rs534070	chr1:53308858	T/G	cg16325326	chr1:53192061	ZYG11B	0.61	9.29	0.5	6.05e-18	Monocyte count;
CESC	cis	rs4474465	0.688	rs10501429	chr11:78279790	T/G	cg27205649	chr11:78285834	NARS2	0.48	6.08	0.35	4.1e-9	Alzheimer's disease (survival time);
CESC	cis	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg13379408	chr18:11909052	MPPE1	0.4	5.31	0.31	2.32e-7	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	13.21	0.63	5.81e-31	Prudent dietary pattern;
CESC	cis	rs77956314	0.901	rs12310299	chr12:117335487	C/G	cg02017074	chr12:117425053	FBXW8	-0.54	-5.14	-0.3	5.44e-7	Subcortical brain region volumes;Hippocampal volume;
CESC	trans	rs916888	0.779	rs430685	chr17:44859148	T/C	cg10053473	chr17:62856997	LRRC37A3	0.65	7.26	0.41	4.26e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs10870270	1.000	rs7898755	chr10:133777122	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.86	-12.56	-0.61	1.08e-28	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs3767633	0.925	rs2055539	chr1:161807866	T/C	cg09175582	chr1:161736000	ATF6	0.86	6.88	0.39	4.23e-11	IgG glycosylation;
CESC	cis	rs9926296	0.643	rs12596429	chr16:89841374	T/C	cg04287289	chr16:89883240	FANCA	0.59	7.87	0.44	9.24e-14	Vitiligo;
CESC	cis	rs2836974	0.602	rs8130854	chr21:40707041	G/A	cg17971929	chr21:40555470	PSMG1	-0.86	-12.63	-0.61	6.28e-29	Cognitive function;
CESC	cis	rs875971	0.862	rs10261398	chr7:65750164	A/G	cg10691866	chr7:65817282	TPST1	0.31	5.32	0.31	2.25e-7	Aortic root size;
CESC	cis	rs6582630	0.502	rs10880450	chr12:38440294	G/C	cg26384229	chr12:38710491	ALG10B	0.65	9.69	0.51	3.43e-19	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs7746199	0.736	rs6904596	chr6:27491299	G/A	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.82	6.1	0.35	3.77e-9	Gait speed in old age;Autism spectrum disorder or schizophrenia;
CESC	cis	rs9355610	0.892	rs2247314	chr6:167370230	T/C	cg23791538	chr6:167370224	RNASET2	0.68	9.7	0.51	3.05e-19	Graves' disease;
CESC	cis	rs7927592	0.763	rs3740628	chr11:68381415	A/G	cg16797656	chr11:68205561	LRP5	0.47	7.02	0.4	1.82e-11	Total body bone mineral density;
CESC	cis	rs863345	0.625	rs10752626	chr1:158528118	G/A	cg12129480	chr1:158549410	OR10X1	-0.34	-6.89	-0.39	4.1e-11	Pneumococcal bacteremia;
CESC	cis	rs36051895	0.632	rs7030853	chr9:5179002	C/T	cg02405213	chr9:5042618	JAK2	-0.51	-6.56	-0.37	2.84e-10	Pediatric autoimmune diseases;
CESC	cis	rs10129255	0.957	rs8019272	chr14:107192946	C/A	cg07958169	chr14:107095056	NA	-0.4	-5.5	-0.32	8.83e-8	Kawasaki disease;
CESC	cis	rs11252926	0.931	rs4881399	chr10:567325	A/G	cg08603382	chr10:743973	NA	0.56	7.27	0.41	3.95e-12	Psychosis in Alzheimer's disease;
CESC	cis	rs6570726	0.967	rs1396648	chr6:145785248	C/A	cg23711669	chr6:146136114	FBXO30	-0.72	-10.54	-0.54	6.39e-22	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs11098499	0.779	rs80242894	chr4:120375752	G/A	cg25214090	chr10:38739885	LOC399744	0.69	9.79	0.52	1.64e-19	Corneal astigmatism;
CESC	cis	rs1577917	0.958	rs11758508	chr6:86506878	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.43	5.68	0.33	3.47e-8	Response to antipsychotic treatment;
CESC	cis	rs6502050	0.777	rs4625783	chr17:80086395	T/C	cg11859384	chr17:80120422	CCDC57	0.38	5.12	0.3	6.01e-7	Life satisfaction;
CESC	cis	rs2991971	0.903	rs2991973	chr1:46020632	G/A	cg15605315	chr1:45957053	TESK2	0.43	5.45	0.32	1.15e-7	High light scatter reticulocyte count;
CESC	cis	rs2228479	0.717	rs12917681	chr16:89810941	C/A	cg00800038	chr16:89945340	TCF25	-0.72	-7.37	-0.41	2.14e-12	Skin colour saturation;
CESC	cis	rs6032067	0.929	rs6032049	chr20:43825556	C/T	cg10761708	chr20:43804764	PI3	0.53	6.39	0.37	7.37e-10	Blood protein levels;
CESC	cis	rs7762018	0.655	rs11966349	chr6:170162537	A/G	cg05834625	chr6:170176447	C6orf70	-0.49	-5.92	-0.34	9.71e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs7605827	0.930	rs6431707	chr2:15638165	A/T	cg19274914	chr2:15703543	NA	0.35	6.11	0.35	3.58e-9	Educational attainment (years of education);
CESC	cis	rs7527798	0.592	rs11118360	chr1:207858586	G/A	cg21110645	chr1:207815933	NA	-0.31	-5.26	-0.31	2.95e-7	Erythrocyte sedimentation rate;
CESC	cis	rs11785400	0.762	rs9694556	chr8:143727841	A/G	cg24634471	chr8:143751801	JRK	0.45	5.68	0.33	3.52e-8	Schizophrenia;
CESC	cis	rs9814567	0.762	rs13093893	chr3:134292131	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.49	6.1	0.35	3.68e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs2472297	1.000	rs2472297	chr15:75027880	A/G	cg09165964	chr15:75287851	SCAMP5	-0.48	-5.05	-0.3	8.21e-7	Caffeine metabolism (plasma 1,3,7-trimethylxanthine (caffeine) level);Coffee consumption (cups per day);Coffee consumption;Caffeine metabolism (plasma 1,3-dimethylxanthine (theophylline) level);Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) to 1,3,7-trimethylxanthine (caffeine) ratio);
CESC	cis	rs60871478	0.636	rs12534606	chr7:895928	A/G	cg13798912	chr7:905769	UNC84A	-0.56	-5.53	-0.32	7.82e-8	Cerebrospinal P-tau181p levels;
CESC	cis	rs9915657	0.660	rs975772	chr17:70067810	T/G	cg09344028	chr17:70110421	NA	0.39	7.2	0.4	6.15e-12	Thyroid hormone levels;
CESC	cis	rs7223966	1.000	rs7223412	chr17:61808172	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.68	0.38	1.4e-10	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs1465370	0.682	rs6972781	chr7:130023179	A/G	cg04743876	chr7:130013617	NA	0.3	5.62	0.33	4.94e-8	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
CESC	cis	rs8060686	0.545	rs78229587	chr16:68165243	T/C	cg26727032	chr16:67993705	SLC12A4	-0.49	-5.41	-0.32	1.43e-7	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs13108904	0.967	rs11247986	chr4:1294347	G/A	cg00684032	chr4:1343700	KIAA1530	0.39	5.34	0.31	2e-7	Obesity-related traits;
CESC	cis	rs4819052	0.808	rs2246697	chr21:46689999	G/A	cg11663144	chr21:46675770	NA	-0.62	-9.82	-0.52	1.27e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs1577917	0.876	rs12190735	chr6:86686467	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.45	-5.86	-0.34	1.39e-8	Response to antipsychotic treatment;
CESC	trans	rs1814175	0.587	rs847628	chr11:49927064	A/T	cg03929089	chr4:120376271	NA	-0.92	-15.2	-0.68	6e-38	Height;
CESC	cis	rs9287719	0.935	rs7600495	chr2:10739800	A/G	cg02196655	chr2:10830764	NOL10	-0.37	-5.72	-0.33	2.87e-8	Prostate cancer;
CESC	trans	rs2207136	0.835	rs2746651	chr6:50839832	G/A	cg06522515	chr3:184090630	THPO	-0.35	-6.18	-0.35	2.43e-9	Myopia;
CESC	cis	rs2204008	0.805	rs11180825	chr12:38242916	G/T	cg26384229	chr12:38710491	ALG10B	0.71	10.11	0.53	1.52e-20	Bladder cancer;
CESC	cis	rs3096299	0.658	rs3934737	chr16:89560209	G/A	cg02187348	chr16:89574699	SPG7	0.7	9.96	0.52	4.69e-20	Multiple myeloma (IgH translocation);
CESC	cis	rs8031584	0.678	rs798125	chr15:31116800	C/T	cg14829155	chr15:31115871	NA	0.76	10.65	0.55	2.8e-22	Huntington's disease progression;
CESC	cis	rs1552244	1.000	rs6414438	chr3:10073824	G/C	cg00166722	chr3:10149974	C3orf24	0.48	6.1	0.35	3.66e-9	Alzheimer's disease;
CESC	cis	rs172166	0.611	rs203882	chr6:28078502	G/A	cg12963246	chr6:28129442	ZNF389	0.43	6.31	0.36	1.15e-9	Cardiac Troponin-T levels;
CESC	cis	rs2880765	0.835	rs11074276	chr15:86030363	C/A	cg19183879	chr15:85880815	NA	-0.25	-5.18	-0.3	4.49e-7	Coronary artery disease;
CESC	cis	rs55882075	0.967	rs12656648	chr5:179152106	C/A	cg14593053	chr5:179126677	CANX	0.46	5.99	0.35	6.83e-9	Monocyte percentage of white cells;
CESC	cis	rs9875589	0.509	rs4685062	chr3:14066409	T/C	cg19554555	chr3:13937349	NA	-0.44	-5.6	-0.33	5.43e-8	Ovarian reserve;
CESC	cis	rs10876993	0.890	rs2619441	chr12:58083015	C/A	cg18357645	chr12:58087776	OS9	0.63	10.64	0.55	2.98e-22	Celiac disease or Rheumatoid arthritis;
CESC	cis	rs909674	0.865	rs5757683	chr22:39850174	G/A	cg11247378	chr22:39784982	NA	-0.62	-8.78	-0.47	2.13e-16	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	trans	rs561341	1.000	rs8073186	chr17:30244956	T/C	cg20587970	chr11:113659929	NA	-0.97	-11.82	-0.59	3.47e-26	Hip circumference adjusted for BMI;
CESC	cis	rs11123610	0.520	rs59726279	chr2:3718655	A/G	cg10645314	chr2:3704589	ALLC	-0.46	-5.18	-0.3	4.35e-7	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CESC	cis	rs35110281	0.744	rs162398	chr21:44949285	T/C	cg04455712	chr21:45112962	RRP1B	0.34	5.16	0.3	4.93e-7	Mean corpuscular volume;
CESC	cis	rs4282054	0.631	rs13081155	chr3:52732429	A/G	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.34	6.76	0.38	9.02e-11	Cognitive function;
CESC	cis	rs7851660	0.874	rs7847010	chr9:100630439	T/C	cg13688889	chr9:100608707	NA	-0.63	-8.8	-0.48	1.83e-16	Strep throat;
CESC	cis	rs2797160	1.000	rs1954361	chr6:126001423	C/G	cg05901451	chr6:126070800	HEY2	-0.45	-6.62	-0.38	1.97e-10	Endometrial cancer;
CESC	cis	rs798554	0.610	rs2248390	chr7:2855594	T/C	cg09658497	chr7:2847517	GNA12	-0.33	-5.08	-0.3	7.14e-7	Height;
CESC	cis	rs1215050	0.527	rs1214998	chr4:99042878	T/G	cg17366294	chr4:99064904	C4orf37	0.45	5.86	0.34	1.38e-8	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs477895	0.838	rs11605738	chr11:64013406	G/A	cg04317338	chr11:64019027	PLCB3	0.92	10.01	0.52	3.13e-20	Mean platelet volume;
CESC	cis	rs7666738	0.830	rs62321564	chr4:98976496	C/G	cg05340658	chr4:99064831	C4orf37	0.79	12.26	0.6	1.12e-27	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7666738	0.830	rs17027058	chr4:98864671	G/A	cg03467027	chr4:99064603	C4orf37	0.42	5.17	0.3	4.61e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4722166	0.630	rs1829927	chr7:22779918	G/A	cg05472934	chr7:22766657	IL6	0.87	10.94	0.56	3.06e-23	Lung cancer;
CESC	cis	rs10129255	0.957	rs10150241	chr14:107184184	A/T	cg07958169	chr14:107095056	NA	0.39	5.64	0.33	4.41e-8	Kawasaki disease;
CESC	cis	rs2075371	0.611	rs62462979	chr7:134019379	G/T	cg20476274	chr7:133979776	SLC35B4	0.53	7.3	0.41	3.4e-12	Mean platelet volume;
CESC	cis	rs7772486	0.686	rs2142983	chr6:146069701	G/C	cg23711669	chr6:146136114	FBXO30	-0.88	-13.21	-0.63	5.93e-31	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs798554	0.679	rs1614791	chr7:2888057	G/T	cg18446336	chr7:2847575	GNA12	-0.35	-5.38	-0.31	1.67e-7	Height;
CESC	cis	rs7851660	0.935	rs10818124	chr9:100603008	C/T	cg13688889	chr9:100608707	NA	-0.68	-10.61	-0.55	3.8e-22	Strep throat;
CESC	cis	rs8072100	0.807	rs2175290	chr17:45479917	C/A	cg08085267	chr17:45401833	C17orf57	-0.54	-7.23	-0.41	5.13e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg16504641	chr6:137143711	PEX7	-0.5	-6.31	-0.36	1.19e-9	Ulcerative colitis;
CESC	cis	rs748404	0.660	rs2444251	chr15:43788595	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.57	7.5	0.42	9.94e-13	Lung cancer;
CESC	trans	rs7746199	0.673	rs35501037	chr6:27739566	T/A	cg06606381	chr12:133084897	FBRSL1	-1.05	-8.23	-0.45	8.53e-15	Gait speed in old age;Autism spectrum disorder or schizophrenia;
CESC	cis	rs787274	0.718	rs4979170	chr9:115626918	C/G	cg13803584	chr9:115635662	SNX30	0.56	5.04	0.3	8.55e-7	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs1790761	0.587	rs4930430	chr11:67294198	A/G	cg08355456	chr11:67383691	NA	0.32	5.19	0.3	4.15e-7	Mean corpuscular volume;
CESC	cis	rs896854	0.654	rs10429443	chr8:95971164	A/G	cg09323728	chr8:95962352	TP53INP1	-0.38	-8.15	-0.45	1.49e-14	Type 2 diabetes;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg07791997	chr11:73882526	PPME1;C2CD3	-0.47	-6.38	-0.36	7.84e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs2249694	0.960	rs9630033	chr10:135418505	G/T	cg20169779	chr10:135381914	SYCE1	-0.4	-5.71	-0.33	3.1e-8	Obesity-related traits;
CESC	cis	rs3739821	0.841	rs943392	chr9:130725441	A/G	cg09665592	chr9:130699885	DPM2	0.48	5.08	0.3	6.97e-7	Glaucoma (primary angle closure);
CESC	cis	rs2354432	0.607	rs894469	chr1:146672906	C/T	cg25205988	chr1:146714368	CHD1L	1.19	9.08	0.49	2.58e-17	Mitochondrial DNA levels;
CESC	cis	rs2075371	0.611	rs11762920	chr7:134018514	C/T	cg11752832	chr7:134001865	SLC35B4	0.43	5.09	0.3	6.9e-7	Mean platelet volume;
CESC	cis	rs6570726	0.791	rs6570695	chr6:145911286	C/A	cg05347473	chr6:146136440	FBXO30	0.57	7.44	0.42	1.37e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2439831	1.000	rs689596	chr15:43761717	A/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.89	10.58	0.54	4.72e-22	Lung cancer in ever smokers;
CESC	cis	rs854765	0.929	rs2955360	chr17:17974887	G/A	cg04398451	chr17:18023971	MYO15A	0.67	9.65	0.51	4.44e-19	Total body bone mineral density;
CESC	cis	rs2046867	0.818	rs17010215	chr3:72886965	A/G	cg25664220	chr3:72788482	NA	-0.46	-6.4	-0.37	7.09e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CESC	cis	rs6912958	0.967	rs9450688	chr6:88159276	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.55	-7.58	-0.42	5.88e-13	Monocyte percentage of white cells;
CESC	cis	rs7216064	1.000	rs55896768	chr17:65913358	T/C	cg12091567	chr17:66097778	LOC651250	-0.7	-8.06	-0.44	2.55e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs28647808	0.881	rs4962047	chr9:136262916	T/C	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.84	5.72	0.33	2.87e-8	Blood protein levels;
CESC	cis	rs2243480	1.000	rs73142166	chr7:65375832	A/G	cg25894440	chr7:65020034	NA	-0.64	-5.31	-0.31	2.33e-7	Diabetic kidney disease;
CESC	trans	rs10463316	0.894	rs6891272	chr5:150762842	G/T	cg24389359	chr12:111284228	CCDC63	-0.33	-6.02	-0.35	5.68e-9	Metabolite levels (Pyroglutamine);
CESC	cis	rs60154123	0.730	rs590380	chr1:210463071	C/T	cg22029157	chr1:209979665	IRF6	0.44	5.19	0.3	4.17e-7	Coronary artery disease;
CESC	cis	rs7107174	1.000	rs2450129	chr11:77940385	T/C	cg02023728	chr11:77925099	USP35	0.48	6.81	0.39	6.61e-11	Testicular germ cell tumor;
CESC	cis	rs17666538	0.585	rs10090260	chr8:608034	T/C	cg26554054	chr8:600488	NA	0.65	5.2	0.3	3.96e-7	IgG glycosylation;
CESC	cis	rs73206853	0.764	rs76142162	chr12:110884307	C/G	cg12870014	chr12:110450643	ANKRD13A	0.63	5.18	0.3	4.34e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs3815700	1.000	rs7248845	chr19:33096718	T/C	cg24916020	chr19:33096688	ANKRD27	0.6	6.04	0.35	5.09e-9	Eosinophilic esophagitis;
CESC	cis	rs1843834	0.539	rs6739735	chr2:225405253	A/G	cg22455342	chr2:225449267	CUL3	-0.71	-9.83	-0.52	1.19e-19	IgE levels in asthmatics (D.p. specific);
CESC	cis	rs11098499	0.954	rs6849171	chr4:120409549	G/A	cg09160332	chr4:120329925	NA	-0.38	-5.12	-0.3	5.84e-7	Corneal astigmatism;
CESC	cis	rs8028182	0.636	rs11634863	chr15:75766672	C/A	cg20655648	chr15:75932815	IMP3	0.48	5.98	0.34	7.2e-9	Sudden cardiac arrest;
CESC	cis	rs9399137	0.507	rs6940878	chr6:135366309	G/A	cg24558204	chr6:135376177	HBS1L	0.66	8.97	0.48	5.56e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	cis	rs1062177	0.826	rs2915873	chr5:151156658	G/A	cg12924095	chr5:151150029	G3BP1	0.46	6.04	0.35	5.19e-9	Preschool internalizing problems;
CESC	cis	rs35110281	0.693	rs11089093	chr21:45121161	C/T	cg01579765	chr21:45077557	HSF2BP	-0.55	-9.11	-0.49	2.15e-17	Mean corpuscular volume;
CESC	cis	rs12142240	0.698	rs7515284	chr1:46809419	A/G	cg00530320	chr1:46809349	NSUN4	0.6	7.98	0.44	4.48e-14	Menopause (age at onset);
CESC	cis	rs1577917	0.958	rs13219504	chr6:86556917	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.51	-6.48	-0.37	4.42e-10	Response to antipsychotic treatment;
CESC	cis	rs763014	0.898	rs8050792	chr16:656033	T/C	cg09263875	chr16:632152	PIGQ	0.67	11.42	0.57	7.69e-25	Height;
CESC	cis	rs962856	0.619	rs7592026	chr2:67595139	A/G	cg09028215	chr2:67624308	ETAA1	0.42	5.19	0.3	4.22e-7	Pancreatic cancer;
CESC	cis	rs6429082	1.000	rs2055127	chr1:235598973	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.42	-5.46	-0.32	1.11e-7	Adiposity;
CESC	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg26354017	chr1:205819088	PM20D1	0.85	12.72	0.62	3e-29	Menarche (age at onset);
CESC	cis	rs1003719	0.667	rs3753073	chr21:38466615	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.53	6.61	0.38	2.08e-10	Eye color traits;
CESC	cis	rs8040855	0.547	rs17611171	chr15:85572699	T/A	cg08123816	chr15:85640762	PDE8A	-0.39	-5.85	-0.34	1.42e-8	Bulimia nervosa;
CESC	cis	rs34779708	0.966	rs12775759	chr10:35400183	G/T	cg03585969	chr10:35415529	CREM	0.77	10.1	0.53	1.71e-20	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs17407555	0.647	rs55811736	chr4:10014221	G/A	cg00071950	chr4:10020882	SLC2A9	-0.6	-6.13	-0.35	3.09e-9	Schizophrenia (age at onset);
CESC	cis	rs72781680	0.898	rs72780111	chr2:23991146	G/A	cg20701182	chr2:24300061	SF3B14	0.63	5.65	0.33	4.21e-8	Lymphocyte counts;
CESC	cis	rs9733	0.596	rs34140753	chr1:150642583	T/C	cg22823121	chr1:150693482	HORMAD1	0.48	7.1	0.4	1.14e-11	Tonsillectomy;
CESC	cis	rs2380220	0.808	rs2716069	chr6:95912976	C/G	cg15832292	chr6:96025679	MANEA	-0.65	-5.95	-0.34	8.46e-9	Behavioural disinhibition (generation interaction);
CESC	cis	rs9419702	0.568	rs7093241	chr10:133556596	G/A	cg04492858	chr10:133558786	NA	0.44	6.54	0.37	3.2e-10	Survival in rectal cancer;
CESC	cis	rs12136530	0.806	rs7522676	chr1:19762660	T/C	cg01832549	chr1:19774989	CAPZB	-0.47	-6.46	-0.37	4.86e-10	Lead levels in blood;
CESC	cis	rs400736	0.526	rs10864329	chr1:8164460	G/A	cg25007680	chr1:8021821	PARK7	-0.45	-5.89	-0.34	1.15e-8	Response to antidepressants and depression;
CESC	cis	rs2070433	0.539	rs2070432	chr21:47957332	G/A	cg12379764	chr21:47803548	PCNT	0.62	8.06	0.44	2.7e-14	Lymphocyte counts;
CESC	cis	rs2742234	0.590	rs2565201	chr10:43618484	T/C	cg07801480	chr10:43725741	RASGEF1A	0.4	5.26	0.31	3.04e-7	Hirschsprung disease;
CESC	cis	rs2228479	0.850	rs62054224	chr16:89892071	C/T	cg04013166	chr16:89971882	TCF25	0.67	5.49	0.32	9.55e-8	Skin colour saturation;
CESC	cis	rs6502050	0.769	rs9898292	chr17:80100345	A/T	cg11859384	chr17:80120422	CCDC57	-0.38	-5.11	-0.3	6.21e-7	Life satisfaction;
CESC	cis	rs10979	1.000	rs9376760	chr6:143886969	C/T	cg25407410	chr6:143891975	LOC285740	-0.59	-8.73	-0.47	2.93e-16	Hypospadias;
CESC	cis	rs524023	0.957	rs561193	chr11:64353029	A/G	cg07220939	chr11:64358617	SLC22A12	0.35	5.19	0.3	4.29e-7	Urate levels in obese individuals;
CESC	cis	rs10504229	1.000	rs114486414	chr8:58185103	G/A	cg24829409	chr8:58192753	C8orf71	-0.76	-9.93	-0.52	5.87e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs1348850	0.567	rs3770011	chr2:178537890	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.55	6.84	0.39	5.43e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs11098499	0.955	rs56386062	chr4:120155135	T/C	cg24375607	chr4:120327624	NA	0.42	5.05	0.3	8.26e-7	Corneal astigmatism;
CESC	cis	rs6429082	0.755	rs291370	chr1:235693041	A/G	cg26050004	chr1:235667680	B3GALNT2	0.65	8.6	0.47	7.22e-16	Adiposity;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg04090027	chr2:97760622	FAHD2B	0.46	6.38	0.36	8.05e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs7424096	0.582	rs12105781	chr2:37221567	T/C	cg14987922	chr2:37194071	STRN	0.5	5.46	0.32	1.1e-7	High light scatter reticulocyte percentage of red cells;
CESC	cis	rs7937682	0.889	rs1789361	chr11:111485334	T/C	cg22437258	chr11:111473054	SIK2	0.71	9.56	0.51	8.68e-19	Primary sclerosing cholangitis;
CESC	cis	rs1707322	0.752	rs11211173	chr1:46219376	C/T	cg05343316	chr1:45956843	TESK2	0.51	6.32	0.36	1.09e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs6120849	0.754	rs6119560	chr20:33606977	G/C	cg06115741	chr20:33292138	TP53INP2	0.53	5.05	0.3	8.15e-7	Protein C levels;
CESC	cis	rs6860806	0.631	rs4705931	chr5:131588345	T/C	cg18301423	chr5:131593218	PDLIM4	0.38	5.46	0.32	1.12e-7	Breast cancer;
CESC	cis	rs3796352	1.000	rs13078971	chr3:53103645	G/C	cg12962167	chr3:53033115	SFMBT1	0.71	6.22	0.36	1.92e-9	Immune reponse to smallpox (secreted IL-2);
CESC	cis	rs12681366	0.564	rs10808669	chr8:95481061	A/C	cg13257157	chr8:95487014	RAD54B	0.45	5.44	0.32	1.22e-7	Nonsyndromic cleft lip with cleft palate;
CESC	cis	rs6089584	0.853	rs1746280	chr20:60577821	C/G	cg24733560	chr20:60626293	TAF4	0.42	5.7	0.33	3.17e-8	Body mass index;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00504756	chr16:74330795	PSMD7	0.58	6.63	0.38	1.88e-10	Gut microbiome composition (summer);
CESC	trans	rs4498364	0.541	rs760829	chr6:97550414	G/A	cg09636063	chr6:158957850	TMEM181	0.44	6.31	0.36	1.2e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
CESC	cis	rs123509	0.913	rs339682	chr3:42791123	A/G	cg12982090	chr3:42733453	KBTBD5	0.74	8.94	0.48	6.82e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs875971	0.545	rs2460427	chr7:65619205	T/C	cg18876405	chr7:65276391	NA	-0.51	-5.96	-0.34	8.21e-9	Aortic root size;
CESC	cis	rs5167	0.566	rs204905	chr19:45460764	G/A	cg09555818	chr19:45449301	APOC2	0.47	7.22	0.41	5.6e-12	Blood protein levels;
CESC	cis	rs317689	0.581	rs315132	chr12:69761996	G/C	cg14784868	chr12:69753453	YEATS4	0.72	9.53	0.51	1.06e-18	Response to diuretic therapy;
CESC	cis	rs11638352	1.000	rs890465	chr15:44356463	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.62	6.0	0.35	6.51e-9	Lipoprotein phospholipase A2 activity in cardiovascular disease;
CESC	cis	rs2404602	0.631	rs9646213	chr15:76807672	G/C	cg26408565	chr15:76604113	ETFA	-0.41	-5.99	-0.35	6.8e-9	Blood metabolite levels;
CESC	cis	rs67460515	0.563	rs35914913	chr3:160826561	A/G	cg03342759	chr3:160939853	NMD3	-0.51	-6.55	-0.37	3.06e-10	Parkinson's disease;
CESC	cis	rs6952809	0.532	rs6953297	chr7:2440874	C/G	cg23289794	chr7:2394357	EIF3B	-0.71	-6.72	-0.38	1.09e-10	Multiple sclerosis;
CESC	cis	rs13108904	0.935	rs4974575	chr4:1252028	A/G	cg00684032	chr4:1343700	KIAA1530	0.35	5.45	0.32	1.15e-7	Obesity-related traits;
CESC	cis	rs7771547	0.573	rs10440841	chr6:36399086	G/A	cg04289385	chr6:36355825	ETV7	-0.38	-5.57	-0.32	6.41e-8	Platelet distribution width;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg24963443	chr5:180673122	NA	-0.44	-7.02	-0.4	1.9e-11	Gambling;
CESC	cis	rs7520050	0.966	rs6701614	chr1:46309420	G/C	cg24296786	chr1:45957014	TESK2	0.42	5.39	0.31	1.6e-7	Red blood cell count;Reticulocyte count;
CESC	cis	rs4481887	1.000	rs6663817	chr1:248495613	A/G	cg00666640	chr1:248458726	OR2T12	0.41	6.57	0.37	2.64e-10	Common traits (Other);
CESC	cis	rs17711722	0.565	rs73372653	chr7:65442795	A/T	cg04775059	chr7:64541387	NA	0.44	5.31	0.31	2.38e-7	Calcium levels;
CESC	cis	rs6964587	1.000	rs6974607	chr7:91750116	G/A	cg17063962	chr7:91808500	NA	0.53	7.14	0.4	9.24e-12	Breast cancer;
CESC	cis	rs67460515	0.892	rs11711695	chr3:161057593	A/G	cg03342759	chr3:160939853	NMD3	-0.54	-8.13	-0.45	1.68e-14	Parkinson's disease;
CESC	cis	rs12118280	0.581	rs545593	chr1:108720242	G/A	cg11967332	chr1:108735228	SLC25A24	-0.6	-6.71	-0.38	1.15e-10	Myeloid white cell count;
CESC	cis	rs709400	0.663	rs9671911	chr14:103967343	T/C	cg12935359	chr14:103987150	CKB	-0.52	-7.51	-0.42	8.84e-13	Body mass index;
CESC	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.81	-14.46	-0.66	2.47e-35	Longevity;Endometriosis;
CESC	cis	rs4665809	0.590	rs35656275	chr2:26494695	G/C	cg26119090	chr2:26468346	HADHA;HADHB	1.1	12.85	0.62	1.08e-29	Gut microbiome composition (summer);
CESC	cis	rs7937682	0.889	rs1784785	chr11:111483306	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.95	-14.72	-0.67	3.09e-36	Primary sclerosing cholangitis;
CESC	cis	rs9916302	0.904	rs6503503	chr17:37514373	G/A	cg20243544	chr17:37824526	PNMT	-0.47	-5.74	-0.33	2.54e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs1550582	1.000	rs16905157	chr8:135519964	C/T	cg17885191	chr8:135476712	NA	0.64	7.41	0.41	1.74e-12	Educational attainment;
CESC	cis	rs7666738	0.830	rs13138920	chr4:99020786	A/G	cg17366294	chr4:99064904	C4orf37	0.61	8.76	0.47	2.35e-16	Colonoscopy-negative controls vs population controls;
CESC	trans	rs2975734	0.709	rs6988826	chr8:10109625	T/C	cg15556689	chr8:8085844	FLJ10661	-0.54	-6.11	-0.35	3.47e-9	Morning vs. evening chronotype;Chronotype;
CESC	cis	rs10504229	0.906	rs6990615	chr8:58182956	G/A	cg05313129	chr8:58192883	C8orf71	-0.55	-6.29	-0.36	1.34e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs6912958	0.781	rs2273129	chr6:88182439	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.43	-5.83	-0.34	1.58e-8	Monocyte percentage of white cells;
CESC	cis	rs10242455	0.702	rs78080383	chr7:99064465	C/T	cg25640893	chr7:99214727	ZNF498	1.16	7.09	0.4	1.22e-11	Blood metabolite levels;
CESC	cis	rs1153858	1.000	rs2066090	chr15:45650018	T/C	cg21132104	chr15:45694354	SPATA5L1	0.84	11.41	0.57	8.8e-25	Homoarginine levels;
CESC	trans	rs2727020	0.576	rs10839305	chr11:49598733	T/C	cg03929089	chr4:120376271	NA	-0.86	-13.52	-0.64	4.87e-32	Coronary artery disease;
CESC	cis	rs7680126	0.672	rs4697957	chr4:10182254	A/G	cg11266682	chr4:10021025	SLC2A9	-0.41	-5.2	-0.3	3.94e-7	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	cis	rs875971	0.895	rs1974769	chr7:65950614	G/A	cg10691866	chr7:65817282	TPST1	-0.35	-5.6	-0.33	5.33e-8	Aortic root size;
CESC	cis	rs67311347	1.000	rs9822909	chr3:40457084	G/T	cg09455208	chr3:40491958	NA	0.47	7.07	0.4	1.38e-11	Renal cell carcinoma;
CESC	cis	rs4555082	0.874	rs4677	chr14:105717279	T/C	cg10792982	chr14:105748885	BRF1	0.42	5.57	0.32	6.39e-8	Mean platelet volume;Platelet distribution width;
CESC	cis	rs10751667	0.643	rs7394436	chr11:970373	G/C	cg20946044	chr11:1010712	AP2A2	-0.39	-5.4	-0.31	1.49e-7	Alzheimer's disease (late onset);
CESC	cis	rs561341	1.000	rs693116	chr17:30246124	C/T	cg12193833	chr17:30244370	NA	-0.76	-6.85	-0.39	5.14e-11	Hip circumference adjusted for BMI;
CESC	cis	rs17253792	0.545	rs34719936	chr14:56015134	G/A	cg01858014	chr14:56050164	KTN1	-0.81	-5.71	-0.33	3.08e-8	Putamen volume;
CESC	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.6	0.38	2.17e-10	Prudent dietary pattern;
CESC	cis	rs35110281	0.667	rs2250773	chr21:45087786	T/C	cg01579765	chr21:45077557	HSF2BP	-0.52	-9.17	-0.49	1.39e-17	Mean corpuscular volume;
CESC	cis	rs4665809	0.652	rs11685594	chr2:26402846	A/G	cg04944784	chr2:26401820	FAM59B	-0.91	-10.4	-0.54	1.82e-21	Gut microbiome composition (summer);
CESC	cis	rs3096299	0.933	rs3114848	chr16:89452771	G/A	cg00750074	chr16:89608354	SPG7	-0.37	-5.24	-0.31	3.3e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs875971	0.522	rs7784623	chr7:65395034	T/G	cg11987759	chr7:65425863	GUSB	-0.47	-6.49	-0.37	4.32e-10	Aortic root size;
CESC	cis	rs7666738	0.761	rs13136913	chr4:98998031	C/T	cg03467027	chr4:99064603	C4orf37	0.44	5.51	0.32	8.65e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs561341	0.941	rs4525554	chr17:30312819	T/C	cg23018236	chr17:30244563	NA	-0.52	-5.1	-0.3	6.39e-7	Hip circumference adjusted for BMI;
CESC	cis	rs6835098	0.962	rs4419455	chr4:174083622	C/T	cg08422745	chr4:174089978	GALNT7	0.75	9.77	0.51	1.83e-19	Dementia and core Alzheimer's disease neuropathologic changes;
CESC	cis	rs10751667	1.000	rs10751667	chr11:941941	A/T	cg06064525	chr11:970664	AP2A2	-0.42	-7.62	-0.42	4.56e-13	Alzheimer's disease (late onset);
CESC	cis	rs9815354	1.000	rs1716993	chr3:41974556	G/C	cg03022575	chr3:42003672	ULK4	-0.46	-5.34	-0.31	1.99e-7	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs4654899	0.758	rs12078457	chr1:21397071	C/T	cg05370193	chr1:21551575	ECE1	0.36	5.41	0.32	1.39e-7	Superior frontal gyrus grey matter volume;
CESC	cis	rs2997447	0.761	rs61776576	chr1:26429898	G/A	cg24596570	chr1:26146463	FAM54B;LOC646471	0.6	5.14	0.3	5.43e-7	QRS complex (12-leadsum);
CESC	cis	rs4713118	0.513	rs149950	chr6:28033039	T/G	cg19592336	chr6:28129416	ZNF389	0.44	6.39	0.37	7.51e-10	Parkinson's disease;
CESC	cis	rs2730245	0.593	rs842699	chr7:158663404	T/A	cg01943577	chr7:158741284	NA	-0.46	-6.07	-0.35	4.5e-9	Height;
CESC	cis	rs17376456	0.825	rs56108532	chr5:93276342	C/T	cg25358565	chr5:93447407	FAM172A	1.11	10.56	0.54	5.4e-22	Diabetic retinopathy;
CESC	cis	rs4665809	0.590	rs5001914	chr2:26415429	A/G	cg27170947	chr2:26402098	FAM59B	-0.84	-9.99	-0.52	3.83e-20	Gut microbiome composition (summer);
CESC	cis	rs2304069	0.733	rs216138	chr5:149437190	C/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.77	9.35	0.5	3.95e-18	HIV-1 control;
CESC	cis	rs11098499	0.754	rs7672594	chr4:120248543	A/C	cg09307838	chr4:120376055	NA	0.78	10.55	0.54	5.92e-22	Corneal astigmatism;
CESC	cis	rs7044106	0.762	rs10984972	chr9:123409864	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.84	13.77	0.65	6.71e-33	Hip circumference adjusted for BMI;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21161649	chr21:45284362	AGPAT3	0.58	6.34	0.36	9.61e-10	Gut microbiome composition (summer);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg21789044	chr6:5085404	PPP1R3G	-0.47	-6.49	-0.37	4.25e-10	Fibrinogen levels;
CESC	cis	rs10504229	0.775	rs55734109	chr8:58162322	G/A	cg05313129	chr8:58192883	C8orf71	-0.48	-5.14	-0.3	5.46e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs7666738	0.830	rs113999196	chr4:99041961	C/T	cg03676636	chr4:99064102	C4orf37	0.33	5.12	0.3	5.93e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2425143	1.000	rs6060557	chr20:34270266	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.61	5.16	0.3	4.75e-7	Blood protein levels;
CESC	cis	rs763121	0.853	rs1569716	chr22:38998519	C/A	cg21395723	chr22:39101663	GTPBP1	0.48	6.39	0.37	7.43e-10	Menopause (age at onset);
CESC	cis	rs7618915	0.571	rs1961959	chr3:52585760	G/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.31	5.36	0.31	1.8e-7	Bipolar disorder;
CESC	cis	rs9611565	0.729	rs132902	chr22:41797758	A/G	cg17376030	chr22:41985996	PMM1	0.55	6.07	0.35	4.32e-9	Vitiligo;
CESC	cis	rs1878931	0.580	rs7204571	chr16:3402444	T/C	cg22508957	chr16:3507546	NAT15	-0.36	-5.08	-0.3	7.05e-7	Body mass index (adult);
CESC	cis	rs4689388	0.853	rs13103357	chr4:6294544	A/G	cg00701064	chr4:6280414	WFS1	0.68	11.71	0.58	8.68e-26	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs1707322	0.717	rs1135850	chr1:46093692	G/A	cg05343316	chr1:45956843	TESK2	0.52	6.53	0.37	3.41e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9341808	0.558	rs2490234	chr6:80816966	G/C	cg08355045	chr6:80787529	NA	0.34	5.19	0.3	4.13e-7	Sitting height ratio;
CESC	cis	rs9300255	0.568	rs1790090	chr12:123633424	G/A	cg19016782	chr12:123741754	C12orf65	-0.37	-5.04	-0.3	8.55e-7	Neutrophil percentage of white cells;
CESC	cis	rs9303280	0.806	rs36095411	chr17:38031865	T/G	cg19468946	chr17:37922297	IKZF3	-0.42	-5.57	-0.32	6.19e-8	Self-reported allergy;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg17174230	chr11:65337779	SSSCA1	-0.47	-6.11	-0.35	3.57e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs896854	0.654	rs1453377	chr8:95969947	C/T	cg09323728	chr8:95962352	TP53INP1	-0.38	-8.2	-0.45	1.06e-14	Type 2 diabetes;
CESC	cis	rs11676348	0.818	rs1126579	chr2:219000734	T/C	cg00012203	chr2:219082015	ARPC2	-0.58	-7.62	-0.42	4.43e-13	Ulcerative colitis;
CESC	cis	rs1552244	1.000	rs28684871	chr3:10072635	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.79	-10.5	-0.54	8.34e-22	Alzheimer's disease;
CESC	trans	rs2727020	0.636	rs10839275	chr11:49438962	T/A	cg15704280	chr7:45808275	SEPT13	-0.9	-15.53	-0.69	3.95e-39	Coronary artery disease;
CESC	cis	rs7412746	0.552	rs4970980	chr1:150864992	A/C	cg04414720	chr1:150670196	GOLPH3L	0.44	5.83	0.34	1.6e-8	Melanoma;
CESC	cis	rs614226	0.872	rs12307148	chr12:120903179	T/C	cg01236616	chr12:121019343	POP5	-1.39	-15.84	-0.7	3.24e-40	Type 1 diabetes nephropathy;
CESC	cis	rs2836974	0.897	rs2836924	chr21:40525639	C/T	cg27266027	chr21:40555129	PSMG1	0.49	6.01	0.35	6.14e-9	Cognitive function;
CESC	cis	rs875971	0.825	rs7384021	chr7:66077904	A/G	cg12463550	chr7:65579703	CRCP	-0.53	-6.77	-0.38	8.05e-11	Aortic root size;
CESC	cis	rs911555	0.755	rs55742283	chr14:103942965	A/G	cg24130564	chr14:104152367	KLC1	0.48	6.21	0.36	2.09e-9	Intelligence (multi-trait analysis);
CESC	cis	rs2204008	0.641	rs2387810	chr12:38368875	G/T	cg26384229	chr12:38710491	ALG10B	0.73	10.96	0.56	2.65e-23	Bladder cancer;
CESC	cis	rs67311347	1.000	rs9875245	chr3:40442280	G/T	cg09455208	chr3:40491958	NA	0.5	8.28	0.45	6.1e-15	Renal cell carcinoma;
CESC	cis	rs9611565	0.879	rs2235845	chr22:41729294	T/G	cg03806693	chr22:41940476	POLR3H	-0.71	-8.51	-0.46	1.32e-15	Vitiligo;
CESC	cis	rs5750830	0.649	rs5757664	chr22:39821536	A/G	cg02038168	chr22:39784481	NA	-0.66	-8.29	-0.45	5.63e-15	Intelligence (multi-trait analysis);
CESC	cis	rs7264396	0.790	rs11697903	chr20:34272224	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.86	-11.84	-0.59	2.93e-26	Total cholesterol levels;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg24182333	chr10:73610570	PSAP	0.45	6.33	0.36	1.04e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs13095912	0.889	rs35917986	chr3:185310041	G/A	cg11274856	chr3:185301563	NA	0.37	6.05	0.35	5.02e-9	Systolic blood pressure;
CESC	cis	rs7927592	0.956	rs10896343	chr11:68317860	G/C	cg16797656	chr11:68205561	LRP5	0.4	5.51	0.32	8.62e-8	Total body bone mineral density;
CESC	cis	rs7772486	0.837	rs2474354	chr6:146323795	T/A	cg05347473	chr6:146136440	FBXO30	0.48	6.51	0.37	3.83e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs8062405	1.000	rs62036626	chr16:28844284	A/G	cg08761264	chr16:28874980	SH2B1	-0.46	-5.72	-0.33	2.9e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs738322	0.967	rs2092180	chr22:38571563	A/G	cg25457927	chr22:38595422	NA	-0.3	-5.46	-0.32	1.1e-7	Cutaneous nevi;
CESC	cis	rs4332037	0.615	rs62435127	chr7:1884937	A/G	cg13880726	chr7:1868755	MAD1L1	-0.51	-5.35	-0.31	1.9e-7	Bipolar disorder;
CESC	cis	rs7666738	0.830	rs10014284	chr4:98681951	G/C	cg17366294	chr4:99064904	C4orf37	0.56	7.61	0.42	4.87e-13	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2404602	0.622	rs11637296	chr15:77207885	C/A	cg23625390	chr15:77176239	SCAPER	-0.39	-5.18	-0.3	4.39e-7	Blood metabolite levels;
CESC	cis	rs735396	0.595	rs2258287	chr12:121454313	G/T	cg15155738	chr12:121454335	C12orf43	0.43	5.1	0.3	6.55e-7	N-glycan levels;
CESC	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg06877462	chr1:205807181	PM20D1	0.37	5.38	0.31	1.64e-7	Menarche (age at onset);
CESC	cis	rs7666738	0.822	rs9992360	chr4:98937123	T/C	cg05340658	chr4:99064831	C4orf37	0.82	12.54	0.61	1.29e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7225537	0.559	rs3744137	chr17:17046024	C/A	cg20098446	chr17:17120238	FLCN	0.33	5.13	0.3	5.68e-7	Mean platelet volume;
CESC	cis	rs10411936	0.750	rs8112401	chr19:16593012	C/T	cg10248733	chr19:16607483	C19orf44;CALR3	0.53	6.59	0.38	2.36e-10	White blood cell count;Multiple sclerosis;
CESC	cis	rs7264396	0.635	rs6060685	chr20:34512023	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.81	-11.07	-0.56	1.13e-23	Total cholesterol levels;
CESC	cis	rs514406	0.929	rs562178	chr1:53319562	T/C	cg16325326	chr1:53192061	ZYG11B	0.82	13.08	0.63	1.64e-30	Monocyte count;
CESC	cis	rs8040855	0.576	rs62022527	chr15:85531253	A/G	cg08123816	chr15:85640762	PDE8A	-0.39	-5.69	-0.33	3.36e-8	Bulimia nervosa;
CESC	cis	rs2276314	1.000	rs9956938	chr18:33567061	A/G	cg05985134	chr18:33552581	C18orf21	0.62	6.94	0.39	2.94e-11	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs9303401	0.659	rs2072316	chr17:56604813	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.02	12.92	0.62	6.16e-30	Cognitive test performance;
CESC	cis	rs2115630	0.645	rs3825878	chr15:85174755	C/T	cg12501888	chr15:85177176	SCAND2	-0.48	-6.34	-0.36	9.89e-10	P wave terminal force;
CESC	cis	rs6570726	0.935	rs432086	chr6:145841593	C/T	cg23711669	chr6:146136114	FBXO30	-0.79	-11.63	-0.58	1.56e-25	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9902453	0.967	rs34323226	chr17:28517454	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	7.85	0.43	1.01e-13	Coffee consumption (cups per day);
CESC	cis	rs3091242	0.804	rs631133	chr1:25724146	T/C	cg12412775	chr1:25698385	RHCE	-0.32	-5.8	-0.34	1.84e-8	Erythrocyte sedimentation rate;
CESC	cis	rs9911578	0.967	rs11079354	chr17:56594460	G/A	cg12560992	chr17:57184187	TRIM37	-0.93	-15.59	-0.69	2.43e-39	Intelligence (multi-trait analysis);
CESC	cis	rs8114671	0.552	rs2024635	chr20:33422614	G/A	cg07148914	chr20:33460835	GGT7	0.42	5.38	0.31	1.63e-7	Height;
CESC	cis	rs1552244	0.748	rs9862221	chr3:10059658	G/T	cg16606324	chr3:10149918	C3orf24	0.44	5.24	0.31	3.21e-7	Alzheimer's disease;
CESC	cis	rs4253772	0.550	rs6007761	chr22:46670394	C/T	cg24881330	chr22:46731750	TRMU	-0.78	-8.73	-0.47	2.9e-16	LDL cholesterol;Cholesterol, total;
CESC	cis	rs5750830	0.649	rs6001588	chr22:39819049	G/C	cg02038168	chr22:39784481	NA	-0.62	-7.66	-0.43	3.51e-13	Intelligence (multi-trait analysis);
CESC	cis	rs4253772	0.515	rs74766656	chr22:46662497	A/G	cg00784671	chr22:46762841	CELSR1	-0.51	-5.48	-0.32	9.94e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs17345786	0.954	rs17508319	chr3:101318903	G/A	cg12386194	chr3:101231763	SENP7	0.57	6.55	0.37	3e-10	Colonoscopy-negative controls vs population controls;
CESC	cis	rs13118159	0.801	rs7664474	chr4:1329116	T/A	cg20887711	chr4:1340912	KIAA1530	0.53	7.46	0.42	1.23e-12	Longevity;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg10978402	chr15:90931990	IQGAP1	-0.52	-6.38	-0.36	8.03e-10	Ulcerative colitis;
CESC	cis	rs7520050	0.966	rs1707304	chr1:46598269	C/A	cg03146154	chr1:46216737	IPP	-0.42	-5.35	-0.31	1.88e-7	Red blood cell count;Reticulocyte count;
CESC	cis	rs6062302	0.534	rs1556456	chr20:62216289	T/C	cg06363034	chr20:62225388	GMEB2	-0.52	-6.58	-0.37	2.53e-10	Glioblastoma;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg11586605	chr11:108535779	DDX10	-0.46	-6.15	-0.35	2.79e-9	Ulcerative colitis;
CESC	cis	rs863345	0.604	rs2157687	chr1:158493000	C/T	cg12129480	chr1:158549410	OR10X1	-0.35	-6.86	-0.39	4.84e-11	Pneumococcal bacteremia;
CESC	cis	rs9811920	0.965	rs10222474	chr3:99862551	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.45	5.83	0.34	1.62e-8	Axial length;
CESC	cis	rs5753618	0.504	rs5753659	chr22:31893613	A/G	cg13145458	chr22:31556086	RNF185	-0.5	-5.42	-0.32	1.37e-7	Colorectal cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03342113	chr11:61197477	CPSF7;SDHAF2	0.63	7.63	0.42	4.19e-13	Gut microbiome composition (summer);
CESC	cis	rs12586317	0.547	rs3759548	chr14:35450333	C/T	cg05294307	chr14:35346193	BAZ1A	-0.51	-5.44	-0.32	1.23e-7	Psoriasis;
CESC	cis	rs4803455	0.586	rs4803457	chr19:41861359	T/C	cg09537434	chr19:41945824	ATP5SL	-0.71	-9.68	-0.51	3.49e-19	Migraine;Coronary artery disease;
CESC	cis	rs637571	0.522	rs12797319	chr11:65735672	G/A	cg04055107	chr11:65626734	MUS81;CFL1	0.42	5.1	0.3	6.53e-7	Eosinophil percentage of white cells;
CESC	cis	rs13082711	0.871	rs13061912	chr3:27495586	A/G	cg02860705	chr3:27208620	NA	0.51	6.33	0.36	1.06e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CESC	cis	rs3106136	0.527	rs4693376	chr4:95157240	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.63	-9.7	-0.51	3.19e-19	Capecitabine sensitivity;
CESC	cis	rs6952808	0.825	rs11761818	chr7:1935273	C/T	cg04267008	chr7:1944627	MAD1L1	-0.71	-9.11	-0.49	2.06e-17	Bipolar disorder and schizophrenia;
CESC	cis	rs17854409	0.881	rs6011430	chr20:61497014	C/T	cg05147244	chr20:61493195	TCFL5	-0.85	-6.82	-0.39	6.03e-11	Obesity-related traits;
CESC	cis	rs7084402	0.967	rs1649037	chr10:60331135	C/T	cg07615347	chr10:60278583	BICC1	0.6	9.27	0.5	6.55e-18	Refractive error;
CESC	cis	rs2839186	0.934	rs13049797	chr21:47707582	T/C	cg10351095	chr21:47802916	PCNT	-0.5	-6.8	-0.39	7.02e-11	Testicular germ cell tumor;
CESC	cis	rs763121	0.853	rs2413545	chr22:39092524	C/T	cg06022373	chr22:39101656	GTPBP1	0.85	12.34	0.6	6.24e-28	Menopause (age at onset);
CESC	cis	rs7809950	1.000	rs2520260	chr7:107172794	A/G	cg23024343	chr7:107201750	COG5	-0.41	-5.71	-0.33	3.03e-8	Coronary artery disease;
CESC	cis	rs875971	1.000	rs6460292	chr7:65810075	G/A	cg12463550	chr7:65579703	CRCP	-0.55	-7.02	-0.4	1.82e-11	Aortic root size;
CESC	cis	rs10465746	0.780	rs6703493	chr1:84435812	G/A	cg10977910	chr1:84465055	TTLL7	0.53	7.33	0.41	2.77e-12	Obesity-related traits;
CESC	cis	rs11864453	0.713	rs2241412	chr16:72144284	A/G	cg16558253	chr16:72132732	DHX38	-0.55	-8.77	-0.47	2.24e-16	Fibrinogen levels;
CESC	cis	rs7914558	0.966	rs3758543	chr10:104944744	C/G	cg04362960	chr10:104952993	NT5C2	0.46	6.16	0.35	2.74e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs6951245	0.882	rs10256720	chr7:1210825	C/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.51	-5.7	-0.33	3.21e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs78456975	1.000	rs111935361	chr2:1554192	C/A	cg01028140	chr2:1542097	TPO	-0.58	-5.9	-0.34	1.1e-8	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs2425143	1.000	rs1056196	chr20:34327159	T/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.6	5.3	0.31	2.46e-7	Blood protein levels;
CESC	cis	rs5769765	0.773	rs58375955	chr22:50312630	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.58	-6.21	-0.36	2.01e-9	Schizophrenia;
CESC	cis	rs2228479	0.850	rs62056065	chr16:89905115	C/G	cg04013166	chr16:89971882	TCF25	0.72	5.75	0.33	2.41e-8	Skin colour saturation;
CESC	cis	rs9611565	0.569	rs6002328	chr22:41710034	T/C	cg03806693	chr22:41940476	POLR3H	-0.7	-8.29	-0.45	5.91e-15	Vitiligo;
CESC	trans	rs9929218	0.551	rs8051095	chr16:68722049	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.98	17.14	0.73	8.09e-45	Colorectal cancer;
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg22068822	chr5:171682568	UBTD2	-0.43	-6.3	-0.36	1.25e-9	Vertical cup-disc ratio;
CESC	cis	rs10504229	0.683	rs949856	chr8:58144496	G/A	cg24829409	chr8:58192753	C8orf71	-0.54	-6.79	-0.39	7.19e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs2295359	0.892	rs17375018	chr1:67655147	A/G	cg03340356	chr1:67600835	NA	-0.31	-5.25	-0.31	3.06e-7	Psoriasis;
CESC	cis	rs2576037	0.544	rs629097	chr18:44378097	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.36	5.78	0.33	2.15e-8	Personality dimensions;
CESC	cis	rs7223966	0.921	rs2854207	chr17:61947107	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.54	6.46	0.37	5.06e-10	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs7520050	0.966	rs6680380	chr1:46300189	T/G	cg03146154	chr1:46216737	IPP	-0.47	-6.15	-0.35	2.87e-9	Red blood cell count;Reticulocyte count;
CESC	trans	rs35110281	0.712	rs162345	chr21:44954155	T/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.49	6.69	0.38	1.35e-10	Mean corpuscular volume;
CESC	cis	rs9796	0.804	rs28688742	chr15:41403638	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.47	-6.94	-0.39	3.09e-11	Menopause (age at onset);
CESC	cis	rs8070624	0.543	rs8068175	chr17:17874486	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.6	8.13	0.45	1.68e-14	Total body bone mineral density;
CESC	cis	rs9287719	0.967	rs6432116	chr2:10748615	T/C	cg02196655	chr2:10830764	NOL10	-0.38	-5.79	-0.34	1.96e-8	Prostate cancer;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg23074011	chr10:75545361	KIAA0913	0.43	6.13	0.35	3.17e-9	Systemic lupus erythematosus;
CESC	cis	rs7786808	0.741	rs4909222	chr7:158228095	C/T	cg09998033	chr7:158218633	PTPRN2	0.43	6.41	0.37	6.54e-10	Obesity-related traits;
CESC	cis	rs10492096	1.000	rs11064218	chr12:6586261	C/T	cg13857086	chr12:6580257	VAMP1	0.65	6.17	0.35	2.59e-9	Hip geometry;
CESC	cis	rs892961	0.899	rs8071024	chr17:75414067	T/C	cg05865280	chr17:75406074	SEPT9	0.63	12.76	0.62	2.1e-29	Airflow obstruction;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg02685901	chr6:43597772	MAD2L1BP;GTPBP2	-0.43	-6.22	-0.36	1.89e-9	Gambling;
CESC	cis	rs72945132	0.882	rs11235967	chr11:70191691	T/C	cg14191688	chr11:70257035	CTTN	0.43	5.5	0.32	8.9e-8	Coronary artery disease;
CESC	cis	rs4604732	0.631	rs74154675	chr1:247625836	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.57	7.17	0.4	7.39e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs10504229	0.593	rs76118562	chr8:57988110	G/C	cg22535103	chr8:58192502	C8orf71	-0.92	-9.07	-0.49	2.85e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs3815700	1.000	rs7260624	chr19:33096562	A/G	cg02997394	chr19:33096574	ANKRD27	0.71	7.32	0.41	2.93e-12	Eosinophilic esophagitis;
CESC	cis	rs1153858	0.723	rs4580098	chr15:45596909	T/A	cg21132104	chr15:45694354	SPATA5L1	0.8	10.19	0.53	8.67e-21	Homoarginine levels;
CESC	cis	rs1538970	0.924	rs10890327	chr1:45891458	C/T	cg24296786	chr1:45957014	TESK2	-0.46	-5.3	-0.31	2.41e-7	Platelet count;
CESC	cis	rs6963495	0.769	rs117986187	chr7:105167311	G/A	cg02135003	chr7:105160482	PUS7	-0.46	-5.51	-0.32	8.38e-8	Bipolar disorder (body mass index interaction);
CESC	cis	rs4665809	1.000	rs6546767	chr2:26328746	A/G	cg26314531	chr2:26401878	FAM59B	-0.61	-6.87	-0.39	4.62e-11	Gut microbiome composition (summer);
CESC	cis	rs3749237	0.595	rs11130196	chr3:49490149	A/C	cg03060546	chr3:49711283	APEH	0.77	11.69	0.58	9.65e-26	Resting heart rate;
CESC	cis	rs9911578	1.000	rs12602346	chr17:56901713	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.26	0.31	3.04e-7	Intelligence (multi-trait analysis);
CESC	cis	rs12136530	0.577	rs12120180	chr1:19791441	C/T	cg01832549	chr1:19774989	CAPZB	-0.39	-5.45	-0.32	1.15e-7	Lead levels in blood;
CESC	cis	rs2732480	0.500	rs2450991	chr12:48651621	A/G	cg04545296	chr12:48745243	ZNF641	0.39	6.62	0.38	1.99e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs1577917	0.958	rs12192546	chr6:86476484	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.49	6.18	0.35	2.45e-9	Response to antipsychotic treatment;
CESC	cis	rs7927592	0.913	rs7115374	chr11:68300076	G/T	cg20283391	chr11:68216788	NA	-0.62	-7.44	-0.42	1.42e-12	Total body bone mineral density;
CESC	cis	rs4820803	1.000	rs4820803	chr22:29669648	C/G	cg07256473	chr22:29710276	RASL10A	-0.43	-5.15	-0.3	5.1e-7	Breast cancer;
CESC	cis	rs8114671	0.967	rs2069945	chr20:33761837	C/G	cg24642439	chr20:33292090	TP53INP2	0.45	5.61	0.33	5.1e-8	Height;
CESC	cis	rs7605827	0.930	rs10179754	chr2:15541214	C/T	cg19274914	chr2:15703543	NA	0.36	6.55	0.37	2.91e-10	Educational attainment (years of education);
CESC	cis	rs7264396	0.563	rs2425132	chr20:34338390	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.59	6.62	0.38	2.03e-10	Total cholesterol levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05062148	chr1:25757186	TMEM57	-0.55	-6.09	-0.35	3.91e-9	Gut microbiome composition (summer);
CESC	cis	rs4242434	0.672	rs4615566	chr8:22520682	T/C	cg03733263	chr8:22462867	KIAA1967	-0.74	-11.16	-0.57	5.77e-24	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CESC	cis	rs2243480	1.000	rs313809	chr7:65499983	G/A	cg12463550	chr7:65579703	CRCP	0.69	5.5	0.32	9.17e-8	Diabetic kidney disease;
CESC	cis	rs780096	0.546	rs4425043	chr2:27733452	G/A	cg02592271	chr2:27665507	KRTCAP3	-0.33	-6.5	-0.37	3.97e-10	Total body bone mineral density;
CESC	cis	rs9818758	0.607	rs34326553	chr3:49134429	A/G	cg00383909	chr3:49044727	WDR6	0.91	6.46	0.37	5.08e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CESC	cis	rs736408	0.688	rs2239551	chr3:52818579	A/G	cg07507251	chr3:52567010	NT5DC2	-0.37	-6.29	-0.36	1.33e-9	Bipolar disorder;
CESC	cis	rs4975709	0.569	rs2077269	chr5:1863506	C/T	cg17650747	chr5:1873721	NA	0.43	5.93	0.34	9.42e-9	Cardiovascular disease risk factors;
CESC	cis	rs2842992	0.915	rs1322427	chr6:160075454	C/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.64	7.46	0.42	1.27e-12	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs1005277	0.579	rs1740732	chr10:38491385	C/T	cg00409905	chr10:38381863	ZNF37A	-0.5	-6.71	-0.38	1.15e-10	Extrinsic epigenetic age acceleration;
CESC	cis	rs6696846	0.691	rs11240370	chr1:205118336	T/G	cg00857998	chr1:205179979	DSTYK	0.57	7.45	0.42	1.28e-12	Red blood cell count;
CESC	cis	rs9304742	0.962	rs12461778	chr19:53454963	T/A	cg09915433	chr19:53449742	NA	-0.37	-5.04	-0.3	8.59e-7	Psoriasis;
CESC	cis	rs2204008	0.605	rs4608149	chr12:38132057	G/C	cg13010199	chr12:38710504	ALG10B	0.54	6.69	0.38	1.28e-10	Bladder cancer;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg22541143	chr4:84377292	HELQ;MRPS18C	-0.47	-6.21	-0.36	2.02e-9	Ulcerative colitis;
CESC	cis	rs4974559	0.790	rs5019560	chr4:1324793	G/A	cg02980000	chr4:1222292	CTBP1	0.68	7.68	0.43	3.07e-13	Systolic blood pressure;
CESC	cis	rs1580019	0.537	rs7804609	chr7:32558094	A/C	cg07520158	chr7:32535189	LSM5;AVL9	0.53	6.74	0.38	1.01e-10	Cognitive ability;
CESC	cis	rs1005277	0.579	rs2505257	chr10:38372664	A/G	cg25517755	chr10:38738941	LOC399744	-0.48	-6.22	-0.36	1.94e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs10911232	0.524	rs4652773	chr1:183054827	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.84	13.44	0.64	9.64e-32	Hypertriglyceridemia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12753895	chr1:46216422	IPP	0.64	7.05	0.4	1.59e-11	Gut microbiome composition (summer);
CESC	cis	rs7799006	0.606	rs34262822	chr7:2304275	C/T	cg08027265	chr7:2291960	NA	-0.57	-9.64	-0.51	4.77e-19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs6502050	0.731	rs35156322	chr17:80096323	T/C	cg11859384	chr17:80120422	CCDC57	-0.38	-5.14	-0.3	5.29e-7	Life satisfaction;
CESC	cis	rs34638657	0.732	rs2911425	chr16:82203026	T/C	cg09439754	chr16:82129088	HSD17B2	-0.37	-6.4	-0.37	7.17e-10	Lung adenocarcinoma;
CESC	cis	rs35146811	1.000	rs35146811	chr7:99720994	A/C	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.45	5.52	0.32	8.15e-8	Coronary artery disease;
CESC	cis	rs597539	0.652	rs602364	chr11:68662167	C/T	cg01988459	chr11:68622903	NA	-0.39	-5.4	-0.31	1.49e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs4481887	0.741	rs28444488	chr1:248531776	C/A	cg26353448	chr1:248524236	OR2T4	-0.38	-5.31	-0.31	2.3e-7	Common traits (Other);
CESC	trans	rs801193	1.000	rs3778909	chr7:66255646	G/C	cg26939375	chr7:64535504	NA	0.66	9.12	0.49	1.89e-17	Aortic root size;
CESC	cis	rs67311347	1.000	rs56303661	chr3:40520778	C/G	cg09455208	chr3:40491958	NA	0.51	8.42	0.46	2.37e-15	Renal cell carcinoma;
CESC	cis	rs8028182	0.636	rs12909863	chr15:75825822	G/C	cg20655648	chr15:75932815	IMP3	0.48	6.02	0.35	5.64e-9	Sudden cardiac arrest;
CESC	cis	rs13191362	1.000	rs34637087	chr6:163004064	T/G	cg14584255	chr6:163149320	PACRG;PARK2	0.5	5.17	0.3	4.64e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs116095464	0.558	rs9312979	chr5:222057	A/C	cg16372103	chr5:203701	NA	0.49	5.29	0.31	2.58e-7	Breast cancer;
CESC	cis	rs4604732	0.578	rs112449432	chr1:247624180	T/C	cg12758973	chr1:247694275	LOC148824;OR2C3	0.51	6.34	0.36	1e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs3857536	0.813	rs6455084	chr6:66935658	A/T	cg07460842	chr6:66804631	NA	-0.42	-5.34	-0.31	1.96e-7	Blood trace element (Cu levels);
CESC	trans	rs17685	0.784	rs1613890	chr7:75735037	T/C	cg19862616	chr7:65841803	NCRNA00174	0.85	12.47	0.61	2.13e-28	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs1552244	0.935	rs35586456	chr3:10116938	A/G	cg00149659	chr3:10157352	C3orf10	0.74	8.79	0.48	1.96e-16	Alzheimer's disease;
CESC	cis	rs1881797	1.000	rs68059491	chr1:247683070	C/T	cg11166453	chr1:247681781	NA	0.45	5.65	0.33	4.03e-8	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs56399783	0.901	rs73033407	chr7:2878857	G/C	cg19731401	chr7:2775893	GNA12	0.62	5.3	0.31	2.38e-7	Childhood ear infection;
CESC	cis	rs2267137	0.903	rs2072051	chr22:29755888	C/T	cg07256473	chr22:29710276	RASL10A	-0.41	-6.17	-0.35	2.54e-9	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	cis	rs6424115	0.793	rs2502998	chr1:24198327	T/A	cg10978503	chr1:24200527	CNR2	0.34	6.72	0.38	1.11e-10	Immature fraction of reticulocytes;
CESC	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg06873352	chr17:61820015	STRADA	0.73	12.96	0.62	4.24e-30	Prudent dietary pattern;
CESC	cis	rs7937682	0.632	rs1045282	chr11:111754574	A/C	cg09085632	chr11:111637200	PPP2R1B	0.87	10.93	0.56	3.49e-23	Primary sclerosing cholangitis;
CESC	cis	rs73206853	0.764	rs7966591	chr12:110644045	G/A	cg12870014	chr12:110450643	ANKRD13A	0.69	5.97	0.34	7.55e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs7551222	0.681	rs2045623	chr1:204497413	A/G	cg20240347	chr1:204465584	NA	-0.28	-5.59	-0.32	5.78e-8	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00280548	chr10:70587131	STOX1	0.62	7.14	0.4	8.76e-12	Gut microbiome composition (summer);
CESC	cis	rs6714710	0.603	rs2305143	chr2:98413781	C/T	cg26665480	chr2:98280029	ACTR1B	0.56	7.92	0.44	6.75e-14	Posterior cortical atrophy and Alzheimer's disease;
CESC	cis	rs11166927	0.934	rs7015426	chr8:140802688	C/G	cg16909799	chr8:140841666	TRAPPC9	0.57	8.46	0.46	1.85e-15	Pediatric non-alcoholic fatty liver disease activity score;
CESC	cis	rs175714	0.845	rs175702	chr14:75971133	G/T	cg01624173	chr14:75981868	NA	-0.55	-7.96	-0.44	4.91e-14	Lymphocyte counts;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20631654	chr20:56285704	PMEPA1	-0.6	-6.82	-0.39	6.25e-11	Gut microbiome composition (summer);
CESC	cis	rs4835473	0.932	rs4835279	chr4:144710070	G/C	cg25736465	chr4:144833511	NA	-0.33	-5.43	-0.32	1.28e-7	Immature fraction of reticulocytes;
CESC	cis	rs67460515	0.926	rs13062740	chr3:161024208	G/A	cg03342759	chr3:160939853	NMD3	-0.52	-7.26	-0.41	4.28e-12	Parkinson's disease;
CESC	cis	rs769267	1.000	rs1009136	chr19:19440428	A/G	cg03709012	chr19:19516395	GATAD2A	-0.94	-13.72	-0.64	1.01e-32	Tonsillectomy;
CESC	cis	rs933688	0.818	rs10052492	chr5:90759930	T/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.0	12.68	0.61	3.98e-29	Smoking behavior;
CESC	cis	rs1153858	1.000	rs3759899	chr15:45655903	T/C	cg21132104	chr15:45694354	SPATA5L1	0.86	11.64	0.58	1.46e-25	Homoarginine levels;
CESC	cis	rs7714584	0.793	rs11949375	chr5:150202980	T/C	cg22134413	chr5:150180641	NA	0.5	5.33	0.31	2.15e-7	Crohn's disease;
CESC	cis	rs7666738	0.546	rs13141117	chr4:98892798	G/A	cg17366294	chr4:99064904	C4orf37	0.48	5.93	0.34	9.25e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4665809	0.941	rs2289021	chr2:26362515	A/C	cg26119090	chr2:26468346	HADHA;HADHB	0.63	7.55	0.42	6.93e-13	Gut microbiome composition (summer);
CESC	cis	rs6942756	1.000	rs11979476	chr7:128993756	G/T	cg02491457	chr7:128862824	NA	0.65	8.63	0.47	5.89e-16	White matter hyperintensity burden;
CESC	cis	rs8016982	0.611	rs8008870	chr14:81709374	C/T	cg01989461	chr14:81687754	GTF2A1	0.71	10.82	0.55	7.97e-23	Schizophrenia;
CESC	cis	rs5753618	0.583	rs5753615	chr22:31828027	T/C	cg02404636	chr22:31891804	SFI1	0.4	5.4	0.31	1.49e-7	Colorectal cancer;
CESC	cis	rs11690935	0.959	rs10206062	chr2:172577276	A/T	cg13550731	chr2:172543902	DYNC1I2	-0.96	-14.72	-0.67	2.89e-36	Schizophrenia;
CESC	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg24642844	chr7:1081250	C7orf50	-0.39	-5.12	-0.3	5.99e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09000510	chr9:35605352	TESK1	0.64	7.44	0.42	1.37e-12	Gut microbiome composition (summer);
CESC	cis	rs78456975	0.622	rs11896517	chr2:1518112	A/G	cg01028140	chr2:1542097	TPO	-0.47	-5.39	-0.31	1.55e-7	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs13031619	0.650	rs6542617	chr2:3694932	C/T	cg19052272	chr2:3704530	ALLC	0.54	6.84	0.39	5.34e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CESC	cis	rs3820068	0.603	rs7531396	chr1:15969870	G/C	cg13390004	chr1:15929781	NA	0.37	5.84	0.34	1.51e-8	Systolic blood pressure;
CESC	cis	rs11051970	0.592	rs12227991	chr12:32540045	C/G	cg24626660	chr12:32551988	NA	0.38	5.12	0.3	5.82e-7	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs11098499	0.691	rs12510133	chr4:120271344	A/C	cg09307838	chr4:120376055	NA	0.77	10.19	0.53	8.72e-21	Corneal astigmatism;
CESC	cis	rs501120	0.657	rs617542	chr10:44743636	G/A	cg09554077	chr10:44749378	NA	0.43	5.19	0.3	4.27e-7	Coronary artery disease;Coronary heart disease;
CESC	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg09033563	chr22:24373618	LOC391322	-0.43	-5.54	-0.32	7.14e-8	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs12325245	0.536	rs35832551	chr16:58591444	G/T	cg05725404	chr16:58534157	NDRG4	-0.61	-5.24	-0.31	3.21e-7	Schizophrenia;
CESC	cis	rs4853012	0.887	rs2280644	chr2:74358411	G/A	cg05890377	chr2:74357713	NA	0.71	8.95	0.48	6.36e-17	Gestational age at birth (maternal effect);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26875902	chr16:2223324	TRAF7	-0.59	-6.78	-0.38	7.71e-11	Gut microbiome composition (summer);
CESC	cis	rs765787	0.530	rs2413784	chr15:45530516	A/C	cg24006582	chr15:45444508	DUOX1	-0.59	-7.23	-0.41	5.15e-12	Uric acid levels;
CESC	cis	rs17270561	0.779	rs1165200	chr6:25875212	C/T	cg16482183	chr6:26056742	HIST1H1C	-0.58	-6.89	-0.39	4.13e-11	Iron status biomarkers;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14320633	chr8:86157573	CA13	-0.53	-6.32	-0.36	1.11e-9	Gut microbiome composition (summer);
CESC	cis	rs1218582	0.711	rs4845677	chr1:154838050	C/T	cg03351412	chr1:154909251	PMVK	0.61	7.84	0.43	1.12e-13	Prostate cancer;
CESC	cis	rs7726839	0.574	rs72707007	chr5:661856	T/C	cg16447950	chr5:562315	NA	-0.61	-6.43	-0.37	5.93e-10	Obesity-related traits;
CESC	cis	rs28489187	0.660	rs2207368	chr1:85847683	A/G	cg16011679	chr1:85725395	C1orf52	0.49	5.8	0.34	1.84e-8	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	cis	rs10129255	0.536	rs17113249	chr14:107134290	A/G	cg07958169	chr14:107095056	NA	-0.54	-8.8	-0.48	1.85e-16	Kawasaki disease;
CESC	cis	rs7927771	0.832	rs10838699	chr11:47386073	T/C	cg20307385	chr11:47447363	PSMC3	0.59	7.02	0.4	1.91e-11	Subjective well-being;
CESC	cis	rs12931792	0.712	rs56399904	chr16:30166183	C/T	cg17640201	chr16:30407289	ZNF48	0.58	8.01	0.44	3.63e-14	Tonsillectomy;
CESC	cis	rs916888	0.610	rs199442	chr17:44820122	G/A	cg15921436	chr17:44337874	NA	0.44	5.51	0.32	8.59e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs1050631	0.564	rs684890	chr18:33744677	T/C	cg25426722	chr18:33708991	SLC39A6;ELP2	0.6	8.4	0.46	2.72e-15	Esophageal squamous cell cancer (length of survival);
CESC	cis	rs6456156	0.774	rs2021999	chr6:167529766	G/C	cg07741184	chr6:167504864	NA	-0.31	-5.12	-0.3	5.75e-7	Primary biliary cholangitis;
CESC	cis	rs10504073	0.584	rs62507182	chr8:49942500	C/A	cg00325661	chr8:49890786	NA	0.56	8.3	0.45	5.47e-15	Blood metabolite ratios;
CESC	trans	rs6991952	0.845	rs7822766	chr8:25742279	A/T	cg05977900	chr3:182512126	ATP11B	-0.52	-6.5	-0.37	3.87e-10	Inguinal hernia;
CESC	cis	rs8077577	0.895	rs62072468	chr17:18118179	A/G	cg16794390	chr17:18148240	FLII	0.41	5.63	0.33	4.55e-8	Obesity-related traits;
CESC	cis	rs7680126	0.632	rs11731464	chr4:10148376	G/A	cg00071950	chr4:10020882	SLC2A9	-0.53	-5.53	-0.32	7.73e-8	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	cis	rs4689388	0.926	rs9998519	chr4:6292909	C/T	cg14416269	chr4:6271139	WFS1	0.48	8.11	0.45	1.86e-14	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs477692	0.789	rs568166	chr10:131400088	G/A	cg05714579	chr10:131428358	MGMT	0.48	6.37	0.36	8.44e-10	Response to temozolomide;
CESC	cis	rs853679	0.517	rs4711164	chr6:28115156	C/T	cg08968635	chr6:28129556	ZNF389	0.41	5.28	0.31	2.68e-7	Depression;
CESC	cis	rs7091068	0.616	rs7920366	chr10:95497178	A/T	cg20715218	chr10:95462985	C10orf4	0.57	5.36	0.31	1.79e-7	Urinary tract infection frequency;
CESC	cis	rs3806843	0.735	rs2530242	chr5:140053351	G/C	cg16179182	chr5:140090404	VTRNA1-1	0.41	5.41	0.32	1.42e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs11098499	0.775	rs67281037	chr4:120281157	G/C	cg24375607	chr4:120327624	NA	0.42	5.19	0.3	4.19e-7	Corneal astigmatism;
CESC	cis	rs7605827	0.930	rs3805106	chr2:15535863	C/G	cg19274914	chr2:15703543	NA	0.39	6.82	0.39	6e-11	Educational attainment (years of education);
CESC	cis	rs6594499	0.872	rs1379300	chr5:110441439	A/G	cg04022379	chr5:110408740	TSLP	0.34	6.17	0.35	2.57e-9	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs77697190	1.000	rs74392582	chr14:103847760	C/T	cg09975044	chr14:104007538	NA	-0.85	-5.27	-0.31	2.8e-7	Mean corpuscular hemoglobin;
CESC	cis	rs782590	0.967	rs11125579	chr2:55739804	T/C	cg18811423	chr2:55921094	PNPT1	0.71	10.88	0.56	4.95e-23	Metabolic syndrome;
CESC	cis	rs17401966	1.000	rs1339458	chr1:10328338	C/T	cg15208524	chr1:10270712	KIF1B	0.47	5.97	0.34	7.56e-9	Hepatocellular carcinoma;
CESC	cis	rs2637266	0.703	rs846630	chr10:78536950	G/A	cg18941641	chr10:78392320	NA	0.4	7.64	0.42	4.04e-13	Pulmonary function;
CESC	cis	rs2836974	0.899	rs34433511	chr21:40618883	A/C	cg11890956	chr21:40555474	PSMG1	1.17	21.63	0.8	1.74e-60	Cognitive function;
CESC	cis	rs3617	0.573	rs6795646	chr3:52922621	C/T	cg05564831	chr3:52568323	NT5DC2	-0.35	-5.15	-0.3	5.12e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
CESC	cis	rs651907	0.557	rs11711079	chr3:101386918	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.47	6.08	0.35	4.17e-9	Colorectal cancer;
CESC	cis	rs72945132	0.882	rs11235953	chr11:70184937	C/T	cg14191688	chr11:70257035	CTTN	0.43	5.51	0.32	8.64e-8	Coronary artery disease;
CESC	cis	rs910316	0.687	rs175059	chr14:75490667	T/C	cg08847533	chr14:75593920	NEK9	-0.91	-16.11	-0.7	3.63e-41	Height;
CESC	trans	rs9467711	0.659	rs35555795	chr6:26509382	C/T	cg01620082	chr3:125678407	NA	-0.8	-6.23	-0.36	1.86e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs1670533	1.000	rs7685541	chr4:1058501	G/A	cg04106633	chr4:1044584	NA	0.41	5.17	0.3	4.51e-7	Recombination rate (females);
CESC	cis	rs7615952	0.599	rs6438955	chr3:125730333	C/A	cg06494592	chr3:125709126	NA	-0.45	-5.13	-0.3	5.71e-7	Blood pressure (smoking interaction);
CESC	cis	rs3820928	1.000	rs4675120	chr2:227774888	C/T	cg11843606	chr2:227700838	RHBDD1	-0.43	-5.81	-0.34	1.74e-8	Pulmonary function;
CESC	cis	rs35110281	0.693	rs4819290	chr21:45122713	C/T	cg01579765	chr21:45077557	HSF2BP	-0.54	-9.0	-0.48	4.61e-17	Mean corpuscular volume;
CESC	cis	rs7927592	0.956	rs11228278	chr11:68308530	G/A	cg16797656	chr11:68205561	LRP5	0.42	6.28	0.36	1.39e-9	Total body bone mineral density;
CESC	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg23708337	chr7:1209742	NA	0.5	5.32	0.31	2.25e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7666738	0.830	rs35939134	chr4:98980311	A/G	cg03676636	chr4:99064102	C4orf37	0.33	5.18	0.3	4.43e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs12188164	0.515	rs11742006	chr5:408529	C/T	cg26850624	chr5:429559	AHRR	-0.43	-5.46	-0.32	1.08e-7	Cystic fibrosis severity;
CESC	cis	rs7811142	0.666	rs28401739	chr7:99905684	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.93	9.54	0.51	9.58e-19	Platelet count;
CESC	cis	rs1018836	0.851	rs10808620	chr8:91622940	T/C	cg16814680	chr8:91681699	NA	-0.77	-11.99	-0.59	9.5e-27	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs9733	0.519	rs6700022	chr1:150670484	G/T	cg18016565	chr1:150552671	MCL1	-0.34	-5.3	-0.31	2.48e-7	Tonsillectomy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09071690	chr1:59012457	OMA1	0.54	6.03	0.35	5.55e-9	Gut microbiome composition (summer);
CESC	cis	rs9287719	0.967	rs6721514	chr2:10751062	T/C	cg02196655	chr2:10830764	NOL10	-0.38	-5.79	-0.34	1.96e-8	Prostate cancer;
CESC	cis	rs6964587	1.000	rs7800582	chr7:91701346	G/A	cg17063962	chr7:91808500	NA	0.6	8.37	0.46	3.45e-15	Breast cancer;
CESC	cis	rs7666738	0.819	rs62318904	chr4:99036101	A/T	cg05340658	chr4:99064831	C4orf37	0.82	12.42	0.61	3.27e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7937682	0.889	rs479667	chr11:111484034	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.95	-14.79	-0.67	1.76e-36	Primary sclerosing cholangitis;
CESC	cis	rs875971	1.000	rs6460296	chr7:65895139	C/T	cg11764359	chr7:65958608	NA	0.94	14.96	0.68	4.3e-37	Aortic root size;
CESC	cis	rs7666738	0.830	rs10470951	chr4:99037051	G/A	cg17366294	chr4:99064904	C4orf37	0.61	8.77	0.47	2.27e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2204008	0.744	rs11519905	chr12:38222959	G/A	cg26384229	chr12:38710491	ALG10B	0.74	10.63	0.55	3.35e-22	Bladder cancer;
CESC	trans	rs55704346	0.534	rs2271389	chr4:25392728	G/A	cg01822600	chr1:245751692	KIF26B	0.42	6.17	0.35	2.58e-9	Tonsillectomy;
CESC	cis	rs875971	0.505	rs6955582	chr7:65431686	A/G	cg11987759	chr7:65425863	GUSB	-0.46	-6.36	-0.36	9e-10	Aortic root size;
CESC	cis	rs4253772	0.550	rs6008600	chr22:46704676	A/G	cg18190219	chr22:46762943	CELSR1	-0.56	-6.44	-0.37	5.69e-10	LDL cholesterol;Cholesterol, total;
CESC	cis	rs4474465	0.688	rs7937225	chr11:78278126	T/A	cg01578073	chr11:78285783	NARS2	-0.45	-5.15	-0.3	5.15e-7	Alzheimer's disease (survival time);
CESC	cis	rs7223966	1.000	rs11079508	chr17:61750066	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.54	6.44	0.37	5.7e-10	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs9611565	0.512	rs5751153	chr22:42156561	T/C	cg17376030	chr22:41985996	PMM1	-0.77	-8.07	-0.44	2.39e-14	Vitiligo;
CESC	cis	rs798554	0.757	rs1182177	chr7:2874540	C/T	cg19717773	chr7:2847554	GNA12	-0.57	-8.12	-0.45	1.78e-14	Height;
CESC	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg15112475	chr7:1198522	ZFAND2A	-0.33	-5.26	-0.31	2.9e-7	Longevity;Endometriosis;
CESC	cis	rs3026101	0.671	rs3026145	chr17:5316742	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.4	5.17	0.3	4.63e-7	Body mass index;
CESC	cis	rs1799949	1.000	rs35070007	chr17:41316747	C/G	cg19454999	chr17:41278357	BRCA1;NBR2	-0.53	-7.36	-0.41	2.29e-12	Menopause (age at onset);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg15470736	chr7:157056012	UBE3C	0.45	6.28	0.36	1.41e-9	Fibrinogen levels;
CESC	cis	rs7071206	1.000	rs7071206	chr10:79401316	C/T	cg07817648	chr10:79422355	NA	0.82	10.99	0.56	2.14e-23	Bone mineral density;
CESC	cis	rs1348850	0.668	rs6734426	chr2:178493770	C/T	cg22681709	chr2:178499509	PDE11A	-0.46	-6.34	-0.36	9.62e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs524281	0.817	rs10896097	chr11:65967953	A/C	cg14036092	chr11:66035641	RAB1B	-0.5	-5.44	-0.32	1.2e-7	Electroencephalogram traits;
CESC	cis	rs2204008	0.713	rs11173567	chr12:38089375	T/C	cg13010199	chr12:38710504	ALG10B	0.46	5.62	0.33	4.73e-8	Bladder cancer;
CESC	cis	rs6460942	0.915	rs17541464	chr7:12462675	A/G	cg10578991	chr7:12443926	VWDE	-0.49	-6.28	-0.36	1.39e-9	Coronary artery disease;
CESC	cis	rs7927771	0.524	rs7129797	chr11:47667167	G/C	cg20307385	chr11:47447363	PSMC3	0.62	8.66	0.47	4.63e-16	Subjective well-being;
CESC	cis	rs662064	0.748	rs2480777	chr1:10597551	C/T	cg20482658	chr1:10539492	PEX14	0.41	8.41	0.46	2.64e-15	Asthma;
CESC	cis	rs1552244	1.000	rs9881859	chr3:10072814	A/T	cg00149659	chr3:10157352	C3orf10	0.74	9.07	0.49	2.81e-17	Alzheimer's disease;
CESC	cis	rs7914558	1.000	rs7911789	chr10:104756374	T/C	cg08650961	chr10:104748594	CNNM2	0.33	5.52	0.32	7.89e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs17376456	0.877	rs13165147	chr5:93422214	G/A	cg25358565	chr5:93447407	FAM172A	1.14	11.29	0.57	2.12e-24	Diabetic retinopathy;
CESC	cis	rs796364	0.806	rs11674293	chr2:201026743	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.74	-6.24	-0.36	1.76e-9	Schizophrenia;
CESC	trans	rs8135828	0.770	rs5763301	chr22:29929627	G/A	cg17961835	chr3:126195582	ZXDC	-0.45	-6.03	-0.35	5.5e-9	Lipid traits;
CESC	cis	rs17039065	0.920	rs7671977	chr4:109435999	T/C	cg16022748	chr4:109541635	LOC285456;RPL34	0.67	6.4	0.37	7.14e-10	Gut microbiome composition (summer);
CESC	cis	rs9611565	0.605	rs202638	chr22:41855458	A/G	cg06634786	chr22:41940651	POLR3H	0.53	5.9	0.34	1.11e-8	Vitiligo;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg14293102	chr19:2232170	DOT1L	0.46	6.45	0.37	5.23e-10	Thyroid stimulating hormone;
CESC	cis	rs2235642	0.505	rs56359342	chr16:1654948	G/A	cg09080909	chr16:1797204	MAPK8IP3	-0.45	-6.08	-0.35	4.08e-9	Coronary artery disease;
CESC	cis	rs2832077	0.506	rs2832085	chr21:30155258	G/T	cg08807101	chr21:30365312	RNF160	-0.45	-5.09	-0.3	6.75e-7	Cognitive test performance;
CESC	cis	rs4604732	0.631	rs12091081	chr1:247623064	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	7.52	0.42	8.38e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs9487051	0.714	rs7774390	chr6:109602461	C/G	cg21918786	chr6:109611834	NA	0.38	5.65	0.33	4.18e-8	Reticulocyte fraction of red cells;
CESC	cis	rs6736093	1.000	rs6755101	chr2:112658964	T/C	cg12686935	chr2:112915763	FBLN7	-0.42	-5.17	-0.3	4.56e-7	Coronary artery disease;
CESC	cis	rs3741404	0.895	rs2429455	chr11:63995302	C/G	cg04317338	chr11:64019027	PLCB3	0.55	6.96	0.39	2.68e-11	Platelet count;
CESC	cis	rs965469	1.000	rs2281497	chr20:3258874	G/A	cg25506879	chr20:3388711	C20orf194	-0.57	-6.14	-0.35	2.97e-9	IFN-related cytopenia;
CESC	cis	rs7927592	0.672	rs10501398	chr11:68331715	C/G	cg20283391	chr11:68216788	NA	0.43	5.55	0.32	6.94e-8	Total body bone mineral density;
CESC	cis	rs870825	0.616	rs67641203	chr4:185623845	A/C	cg04058563	chr4:185651563	MLF1IP	0.64	7.05	0.4	1.59e-11	Blood protein levels;
CESC	cis	rs9399401	0.601	rs9321870	chr6:142800758	A/T	cg03128060	chr6:142623767	GPR126	0.31	5.41	0.32	1.4e-7	Chronic obstructive pulmonary disease;
CESC	cis	rs9322193	0.923	rs55849538	chr6:149956466	T/C	cg02462569	chr6:150064036	NUP43	-0.35	-5.17	-0.3	4.61e-7	Lung cancer;
CESC	cis	rs10911232	0.524	rs10911229	chr1:183050368	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.85	13.7	0.64	1.21e-32	Hypertriglyceridemia;
CESC	cis	rs798554	0.797	rs798491	chr7:2800521	A/G	cg18446336	chr7:2847575	GNA12	-0.39	-5.8	-0.34	1.86e-8	Height;
CESC	cis	rs6558174	0.965	rs1564595	chr8:22488939	A/G	cg03733263	chr8:22462867	KIAA1967	0.46	6.2	0.36	2.16e-9	Breast cancer;
CESC	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.46	6.19	0.36	2.25e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs4253772	0.591	rs8135363	chr22:46651713	T/C	cg10231785	chr22:46692440	CN5H6.4;GTSE1	0.48	5.11	0.3	6.16e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs4253772	0.550	rs9615951	chr22:46728056	C/A	cg00784671	chr22:46762841	CELSR1	-0.53	-5.69	-0.33	3.35e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs875971	0.862	rs35378740	chr7:65987712	C/A	cg19163074	chr7:65112434	INTS4L2	-0.43	-5.34	-0.31	2e-7	Aortic root size;
CESC	cis	rs225245	0.791	rs720774	chr17:34017453	T/G	cg05299278	chr17:33885742	SLFN14	0.39	5.51	0.32	8.44e-8	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
CESC	cis	rs9308433	0.529	rs11800749	chr1:214499754	A/G	cg06198575	chr1:214491504	SMYD2	-0.47	-5.77	-0.33	2.19e-8	IgG glycosylation;
CESC	cis	rs7246657	1.000	rs10426297	chr19:37798373	A/G	cg23950597	chr19:37808831	NA	-0.58	-6.21	-0.36	2.08e-9	Coronary artery calcification;
CESC	cis	rs9583531	0.600	rs6492303	chr13:111356800	G/A	cg15841412	chr13:111365552	ING1	0.5	6.51	0.37	3.78e-10	Coronary artery disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg08853494	chr4:76439657	RCHY1;THAP6	-0.46	-6.06	-0.35	4.74e-9	Fibrinogen levels;
CESC	cis	rs644799	0.526	rs693792	chr11:95622200	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.45	5.75	0.33	2.46e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs12497850	0.931	rs6414613	chr3:49035885	C/T	cg06212747	chr3:49208901	KLHDC8B	0.73	9.83	0.52	1.19e-19	Parkinson's disease;
CESC	cis	rs5758659	0.904	rs5758653	chr22:42613485	G/T	cg05082376	chr22:42548792	NA	-0.37	-5.5	-0.32	8.91e-8	Cognitive function;
CESC	cis	rs2204008	0.749	rs4579984	chr12:38166266	A/G	cg26384229	chr12:38710491	ALG10B	0.68	9.69	0.51	3.26e-19	Bladder cancer;
CESC	cis	rs662064	0.926	rs589400	chr1:10561282	A/G	cg20482658	chr1:10539492	PEX14	0.39	7.72	0.43	2.4e-13	Asthma;
CESC	cis	rs1707322	1.000	rs4660335	chr1:46474718	C/T	cg03146154	chr1:46216737	IPP	0.77	10.4	0.54	1.75e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs62244186	0.541	rs9859879	chr3:44840166	G/A	cg15225532	chr3:44803084	KIF15;KIAA1143	0.48	6.24	0.36	1.7e-9	Depressive symptoms;
CESC	cis	rs79349575	0.783	rs56046215	chr17:47008757	A/T	cg26022315	chr17:47021804	SNF8	0.39	5.15	0.3	5.04e-7	Type 2 diabetes;
CESC	cis	rs9814567	1.000	rs13090969	chr3:134307257	C/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.45	6.06	0.35	4.58e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs6500395	1.000	rs11643264	chr16:48558462	A/G	cg04672837	chr16:48644449	N4BP1	0.45	5.21	0.3	3.83e-7	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs3862030	0.503	rs6584505	chr10:104254412	C/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.53	7.26	0.41	4.27e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24030037	chr8:27457282	CLU	-0.52	-6.05	-0.35	4.98e-9	Gut microbiome composition (summer);
CESC	cis	rs7243790	1.000	rs55756660	chr18:51962984	A/G	cg04730925	chr18:51795821	POLI	-0.42	-5.54	-0.32	7.12e-8	Diastolic blood pressure;
CESC	cis	rs11583043	0.918	rs3850453	chr1:101408933	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.46	5.14	0.3	5.35e-7	Ulcerative colitis;Inflammatory bowel disease;
CESC	cis	rs1878931	0.501	rs4785934	chr16:3419934	G/T	cg05754148	chr16:3507555	NAT15	-0.38	-5.1	-0.3	6.33e-7	Body mass index (adult);
CESC	cis	rs7017914	0.967	rs6998786	chr8:71694630	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.42	-5.3	-0.31	2.38e-7	Bone mineral density;
CESC	cis	rs34779708	0.931	rs7079205	chr10:35324619	C/T	cg03585969	chr10:35415529	CREM	0.79	10.23	0.53	6.42e-21	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs116095464	0.558	rs59284383	chr5:284525	C/G	cg22496380	chr5:211416	CCDC127	-0.74	-8.46	-0.46	1.77e-15	Breast cancer;
CESC	cis	rs2204008	0.837	rs1589395	chr12:38420405	C/T	cg26384229	chr12:38710491	ALG10B	0.7	10.71	0.55	1.83e-22	Bladder cancer;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg14802355	chr4:103683140	MANBA	0.47	7.01	0.4	1.97e-11	Thyroid stimulating hormone;
CESC	cis	rs1865721	0.761	rs62089540	chr18:73218332	G/A	cg26385618	chr18:73139727	C18orf62	-0.53	-7.75	-0.43	1.94e-13	Intelligence;
CESC	cis	rs763512	0.532	rs3094499	chr17:35891336	A/G	cg16670864	chr17:35848621	DUSP14	0.42	5.04	0.3	8.81e-7	3-hydroxypropylmercapturic acid levels in smokers;
CESC	cis	rs929354	1.000	rs1182385	chr7:157040583	C/T	cg05182265	chr7:156933206	UBE3C	0.42	5.92	0.34	1.01e-8	Body mass index;
CESC	trans	rs6445797	0.632	rs6802051	chr3:56670924	G/A	cg15444621	chr13:113611794	NA	0.34	6.08	0.35	4.13e-9	Gastritis;
CESC	cis	rs1552244	0.882	rs13062917	chr3:10017032	T/A	cg00166722	chr3:10149974	C3orf24	0.49	6.04	0.35	5.3e-9	Alzheimer's disease;
CESC	cis	rs9815354	1.000	rs2625668	chr3:41905930	T/C	cg03022575	chr3:42003672	ULK4	0.44	5.16	0.3	4.85e-7	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs9733	0.818	rs6694531	chr1:150683512	C/A	cg18016565	chr1:150552671	MCL1	-0.35	-5.89	-0.34	1.15e-8	Tonsillectomy;
CESC	cis	rs8002861	0.870	rs12865116	chr13:44440441	C/G	cg14210620	chr13:44453864	C13orf31;CCDC122	-0.46	-5.82	-0.34	1.67e-8	Leprosy;
CESC	cis	rs2625529	0.556	rs8038007	chr15:72568043	C/G	cg16672083	chr15:72433130	SENP8	0.42	6.26	0.36	1.5e-9	Red blood cell count;
CESC	cis	rs12822507	0.732	rs10492241	chr12:12750509	C/T	cg11838227	chr12:12764436	CREBL2	0.41	5.68	0.33	3.46e-8	Systemic lupus erythematosus;
CESC	cis	rs4819052	0.851	rs13047598	chr21:46660777	G/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.46	5.79	0.34	2e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs950169	0.959	rs12902070	chr15:84793558	T/C	cg17507749	chr15:85114479	UBE2QP1	0.62	6.82	0.39	6.29e-11	Schizophrenia;
CESC	cis	rs9916302	0.904	rs9894500	chr17:37515735	G/C	cg00129232	chr17:37814104	STARD3	0.52	6.49	0.37	4.13e-10	Glomerular filtration rate (creatinine);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00049973	chr17:58603597	APPBP2	0.59	6.31	0.36	1.15e-9	Gut microbiome composition (summer);
CESC	cis	rs6987853	0.787	rs2974351	chr8:42407047	A/T	cg09913449	chr8:42400586	C8orf40	0.45	7.6	0.42	5.18e-13	Mean corpuscular hemoglobin concentration;
CESC	cis	rs6736093	0.966	rs11683694	chr2:112702647	C/T	cg12686935	chr2:112915763	FBLN7	-0.42	-5.46	-0.32	1.1e-7	Coronary artery disease;
CESC	cis	rs2075371	0.932	rs2241333	chr7:133970750	C/T	cg11752832	chr7:134001865	SLC35B4	0.49	6.27	0.36	1.43e-9	Mean platelet volume;
CESC	cis	rs6032067	1.000	rs6032059	chr20:43852443	A/T	cg10761708	chr20:43804764	PI3	0.52	6.26	0.36	1.57e-9	Blood protein levels;
CESC	cis	rs62408225	1.000	rs56106243	chr6:90975990	C/T	cg06866423	chr6:90926672	BACH2	0.44	5.36	0.31	1.8e-7	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs644799	0.932	rs480079	chr11:95643777	A/T	cg25478527	chr11:95522999	CEP57;FAM76B	-0.48	-6.19	-0.36	2.23e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs4660306	0.677	rs781061	chr1:45932887	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.47	5.17	0.3	4.57e-7	Homocysteine levels;
CESC	cis	rs3857067	0.836	rs12501138	chr4:95098444	T/A	cg11021082	chr4:95130006	SMARCAD1	-0.6	-9.01	-0.48	4.22e-17	QT interval;
CESC	cis	rs13242816	1.000	rs17138714	chr7:116114274	C/T	cg04696780	chr7:116139425	CAV2	-0.6	-5.36	-0.31	1.78e-7	P wave duration;
CESC	cis	rs11716531	0.512	rs7612312	chr3:27230230	C/A	cg02860705	chr3:27208620	NA	0.44	5.91	0.34	1.05e-8	Diastolic blood pressure;
CESC	cis	rs9311474	0.607	rs4475032	chr3:52560021	C/T	cg07507251	chr3:52567010	NT5DC2	0.47	8.71	0.47	3.29e-16	Electroencephalogram traits;
CESC	cis	rs7084402	0.967	rs1649069	chr10:60303695	A/G	cg07615347	chr10:60278583	BICC1	-0.59	-9.27	-0.49	6.78e-18	Refractive error;
CESC	cis	rs2836950	0.501	rs2836983	chr21:40689336	G/A	cg11644478	chr21:40555479	PSMG1	-0.55	-7.49	-0.42	1.03e-12	Menarche (age at onset);
CESC	cis	rs6502050	0.835	rs35555954	chr17:80122438	T/C	cg11859384	chr17:80120422	CCDC57	-0.38	-5.25	-0.31	3.18e-7	Life satisfaction;
CESC	cis	rs4253772	0.513	rs6008700	chr22:46722560	C/T	cg24881330	chr22:46731750	TRMU	0.92	10.16	0.53	1.06e-20	LDL cholesterol;Cholesterol, total;
CESC	cis	rs250677	0.687	rs250674	chr5:148438597	A/G	cg18129178	chr5:148520854	ABLIM3	0.49	5.63	0.33	4.71e-8	Breast cancer;
CESC	cis	rs4523957	0.583	rs2984940	chr17:2023825	A/G	cg16513277	chr17:2031491	SMG6	-0.71	-10.1	-0.53	1.62e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs7584330	0.518	rs13420503	chr2:238437623	G/A	cg14458575	chr2:238380390	NA	0.5	5.45	0.32	1.15e-7	Prostate cancer;
CESC	cis	rs875971	1.000	rs12698523	chr7:65968113	C/G	cg10691866	chr7:65817282	TPST1	-0.34	-5.59	-0.32	5.57e-8	Aortic root size;
CESC	cis	rs12530845	0.887	rs78641973	chr7:135324311	C/T	cg23117316	chr7:135346802	PL-5283	-0.47	-5.75	-0.33	2.4e-8	Red blood cell traits;
CESC	cis	rs7618915	0.547	rs33967311	chr3:52683864	G/T	cg17372223	chr3:52568218	NT5DC2	0.41	6.36	0.36	8.74e-10	Bipolar disorder;
CESC	cis	rs2304069	0.507	rs4705407	chr5:149404983	G/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.41	5.79	0.34	1.95e-8	HIV-1 control;
CESC	cis	rs9894429	0.934	rs35868252	chr17:79575472	C/G	cg18240062	chr17:79603768	NPLOC4	-0.72	-10.27	-0.53	4.71e-21	Eye color traits;
CESC	cis	rs7772486	0.875	rs2814869	chr6:146315509	G/A	cg23711669	chr6:146136114	FBXO30	0.83	12.06	0.6	5.63e-27	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs477692	0.905	rs489966	chr10:131422115	C/G	cg05714579	chr10:131428358	MGMT	-0.55	-7.93	-0.44	6.05e-14	Response to temozolomide;
CESC	cis	rs2576037	0.583	rs9947131	chr18:44534769	G/T	cg19077165	chr18:44547161	KATNAL2	-0.65	-9.86	-0.52	9.61e-20	Personality dimensions;
CESC	cis	rs3008870	1.000	rs1137656	chr1:67451602	A/C	cg02640540	chr1:67518911	SLC35D1	-0.51	-5.58	-0.32	5.89e-8	Lymphocyte percentage of white cells;
CESC	cis	rs7589728	0.563	rs75606549	chr2:88466069	T/C	cg07952391	chr2:88470173	THNSL2	0.64	6.21	0.36	2.05e-9	Plasma clusterin levels;
CESC	cis	rs10899021	0.920	rs12287097	chr11:74332664	A/G	cg25880958	chr11:74394337	NA	-0.74	-7.86	-0.43	9.71e-14	Response to metformin (IC50);
CESC	cis	rs2439831	0.850	rs7168158	chr15:44050376	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.7	7.95	0.44	5.33e-14	Lung cancer in ever smokers;
CESC	cis	rs7833790	0.724	rs6473310	chr8:82707981	A/G	cg07697082	chr8:82753677	SNX16	0.35	5.39	0.31	1.53e-7	Diastolic blood pressure;
CESC	cis	rs3761218	1.000	rs3761218	chr20:3776175	A/G	cg25011176	chr20:3776985	CDC25B	0.47	5.99	0.35	6.87e-9	Bipolar disorder;
CESC	cis	rs4974559	0.790	rs2293631	chr4:1315917	C/A	cg02980000	chr4:1222292	CTBP1	0.63	7.18	0.4	7.17e-12	Systolic blood pressure;
CESC	cis	rs12220238	1.000	rs10824110	chr10:75968098	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.6	5.44	0.32	1.24e-7	Soluble interleukin-2 receptor subunit alpha;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg05573287	chr3:12983221	IQSEC1	0.47	6.67	0.38	1.46e-10	Fibrinogen levels;
CESC	cis	rs16867321	0.614	rs12693245	chr2:181445110	T/C	cg23363182	chr2:181467187	NA	0.5	7.38	0.41	2.06e-12	Obesity;
CESC	cis	rs258892	0.895	rs266430	chr5:72125176	A/G	cg21869765	chr5:72125136	TNPO1	-0.44	-5.65	-0.33	4.05e-8	Small cell lung carcinoma;
CESC	cis	rs60871478	1.000	rs34086011	chr7:805430	C/T	cg27478167	chr7:817139	HEATR2	-0.47	-5.61	-0.33	5.18e-8	Cerebrospinal P-tau181p levels;
CESC	cis	rs5769765	0.908	rs9616390	chr22:50314289	G/C	cg02269571	chr22:50332266	NA	-0.57	-6.49	-0.37	4.14e-10	Schizophrenia;
CESC	cis	rs4268898	0.527	rs72789910	chr2:24388609	T/G	cg20701182	chr2:24300061	SF3B14	0.75	7.4	0.41	1.79e-12	Asthma;
CESC	cis	rs854765	0.647	rs854808	chr17:18006634	C/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.52	6.58	0.37	2.53e-10	Total body bone mineral density;
CESC	cis	rs4689592	0.503	rs2292461	chr4:7058473	C/T	cg19539972	chr4:7069911	GRPEL1	0.63	7.2	0.4	6.25e-12	Monocyte percentage of white cells;
CESC	trans	rs1994135	0.617	rs1384590	chr12:33734271	C/T	cg26384229	chr12:38710491	ALG10B	0.46	6.66	0.38	1.57e-10	Resting heart rate;
CESC	cis	rs2439831	0.681	rs1549525	chr15:43627855	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	13.22	0.63	5.55e-31	Lung cancer in ever smokers;
CESC	cis	rs501120	0.810	rs607592	chr10:44750215	A/G	cg09554077	chr10:44749378	NA	0.5	6.65	0.38	1.71e-10	Coronary artery disease;Coronary heart disease;
CESC	cis	rs6121246	0.909	rs1994249	chr20:30287593	C/T	cg13852791	chr20:30311386	BCL2L1	0.79	8.3	0.45	5.47e-15	Mean corpuscular hemoglobin;
CESC	cis	rs1348850	0.914	rs1975544	chr2:178465423	G/A	cg22681709	chr2:178499509	PDE11A	-0.36	-5.05	-0.3	8.05e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs2228479	0.850	rs62054610	chr16:89816920	G/A	cg19635926	chr16:89946313	TCF25	0.67	5.09	0.3	6.82e-7	Skin colour saturation;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg20250722	chr6:26522136	HCG11	-0.39	-6.31	-0.36	1.19e-9	Gambling;
CESC	cis	rs3008870	0.755	rs1925409	chr1:67365089	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.62	-8.17	-0.45	1.29e-14	Lymphocyte percentage of white cells;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg15030636	chr1:246768697	CNST	-0.42	-6.42	-0.37	6.32e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs17826219	0.706	rs8075107	chr17:29106649	C/A	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.17e-10	Body mass index;
CESC	cis	rs10504229	1.000	rs59383954	chr8:58189689	G/A	cg22535103	chr8:58192502	C8orf71	-1.05	-13.08	-0.63	1.71e-30	Developmental language disorder (linguistic errors);
CESC	cis	rs6964587	1.000	rs13239875	chr7:91716104	G/A	cg17063962	chr7:91808500	NA	0.57	7.92	0.44	6.54e-14	Breast cancer;
CESC	cis	rs2836974	0.602	rs2836987	chr21:40706594	C/T	cg22974920	chr21:40686053	BRWD1	-0.45	-5.59	-0.32	5.71e-8	Cognitive function;
CESC	cis	rs6460942	0.630	rs62448731	chr7:12341174	G/A	cg20607287	chr7:12443886	VWDE	-0.58	-6.29	-0.36	1.28e-9	Coronary artery disease;
CESC	cis	rs6088580	0.634	rs6120669	chr20:33105028	T/C	cg06115741	chr20:33292138	TP53INP2	0.46	5.97	0.34	7.75e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs9513593	1.000	rs1927724	chr13:99992312	A/C	cg21788972	chr13:99853209	UBAC2	0.62	7.04	0.4	1.66e-11	Psoriasis;
CESC	cis	rs11677370	0.603	rs10171309	chr2:3851690	C/T	cg17052675	chr2:3827356	NA	-0.44	-5.7	-0.33	3.21e-8	Type 2 diabetes;
CESC	cis	rs7116495	1.000	rs610041	chr11:71797968	A/G	cg26138937	chr11:71823887	C11orf51	-0.86	-7.03	-0.4	1.75e-11	Severe influenza A (H1N1) infection;
CESC	cis	rs72781680	0.611	rs6720131	chr2:24364736	C/T	cg06627628	chr2:24431161	ITSN2	-0.69	-6.54	-0.37	3.23e-10	Lymphocyte counts;
CESC	cis	rs1552244	0.882	rs3732967	chr3:10015437	T/C	cg00166722	chr3:10149974	C3orf24	0.49	6.04	0.35	5.3e-9	Alzheimer's disease;
CESC	trans	rs1285495	0.627	rs10912059	chr1:187354887	C/T	cg07931792	chr19:12707809	ZNF490	0.54	6.47	0.37	4.8e-10	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
CESC	cis	rs4746818	1.000	rs4284308	chr10:70884861	C/T	cg04149295	chr10:70884716	VPS26A	0.63	7.0	0.4	2.06e-11	Left atrial antero-posterior diameter;
CESC	cis	rs7071206	0.891	rs10824559	chr10:79409222	A/G	cg00983440	chr10:79422392	NA	-0.64	-7.31	-0.41	3.08e-12	Bone mineral density;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10274682	chr19:6496041	TUBB4;MIR220B	-0.54	-6.46	-0.37	4.88e-10	Gut microbiome composition (summer);
CESC	cis	rs9303401	0.659	rs11079358	chr17:56920949	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.01	12.45	0.61	2.57e-28	Cognitive test performance;
CESC	cis	rs9322193	0.962	rs3763162	chr6:150140810	A/G	cg04369109	chr6:150039330	LATS1	0.4	5.44	0.32	1.23e-7	Lung cancer;
CESC	cis	rs6493487	0.512	rs17599974	chr15:51237349	C/T	cg02338191	chr15:51200825	AP4E1	-0.6	-5.6	-0.33	5.47e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg05707844	chr2:37383994	EIF2AK2	-0.45	-6.17	-0.35	2.5e-9	Fibrinogen levels;
CESC	trans	rs7824557	0.564	rs2572379	chr8:11237480	A/G	cg06636001	chr8:8085503	FLJ10661	-0.5	-6.28	-0.36	1.39e-9	Retinal vascular caliber;
CESC	cis	rs9303401	0.538	rs2240259	chr17:56458129	A/C	cg25039879	chr17:56429692	SUPT4H1	0.69	6.9	0.39	3.82e-11	Cognitive test performance;
CESC	cis	rs6942756	0.747	rs598412	chr7:129127736	C/T	cg02491457	chr7:128862824	NA	0.55	7.46	0.42	1.24e-12	White matter hyperintensity burden;
CESC	cis	rs4862750	0.872	rs6553030	chr4:187899234	T/C	cg11301795	chr4:187892539	NA	-0.75	-12.53	-0.61	1.39e-28	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2075371	0.611	rs12531769	chr7:134016899	C/G	cg11752832	chr7:134001865	SLC35B4	0.43	5.15	0.3	5.2e-7	Mean platelet volume;
CESC	cis	rs72780191	0.574	rs55836224	chr2:23895597	T/C	cg20701182	chr2:24300061	SF3B14	0.66	6.94	0.39	3.07e-11	White blood cell count;
CESC	cis	rs7618915	0.547	rs13085331	chr3:52627486	G/C	cg07507251	chr3:52567010	NT5DC2	0.4	6.96	0.39	2.7e-11	Bipolar disorder;
CESC	cis	rs8103278	0.507	rs522769	chr19:46284520	G/A	cg11657440	chr19:46296263	DMWD	0.81	12.52	0.61	1.45e-28	Coronary artery disease;
CESC	cis	rs2228479	0.867	rs57940434	chr16:89975496	G/A	cg06558623	chr16:89946397	TCF25	0.9	7.89	0.44	7.95e-14	Skin colour saturation;
CESC	cis	rs10751667	0.643	rs10751666	chr11:941933	C/T	cg01483505	chr11:975446	AP2A2	0.38	5.18	0.3	4.33e-7	Alzheimer's disease (late onset);
CESC	cis	rs2294693	0.947	rs742492	chr6:40996381	G/A	cg14418226	chr6:40996092	UNC5CL	0.53	6.66	0.38	1.59e-10	Gastric cancer;Non-cardia gastric cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16702520	chr1:28157047	PPP1R8	0.58	6.26	0.36	1.56e-9	Gut microbiome composition (summer);
CESC	cis	rs58785573	0.624	rs337605	chr4:38647753	C/T	cg18361445	chr4:38666374	KLF3;FLJ13197	0.51	6.64	0.38	1.8e-10	Lymphocyte percentage of white cells;
CESC	cis	rs9291683	0.588	rs17247314	chr4:10004743	C/G	cg11266682	chr4:10021025	SLC2A9	0.64	12.76	0.62	2.09e-29	Bone mineral density;
CESC	cis	rs2952156	0.920	rs8078228	chr17:37834998	C/T	cg00129232	chr17:37814104	STARD3	-0.73	-10.6	-0.55	4.07e-22	Asthma;
CESC	cis	rs1552244	1.000	rs28684871	chr3:10072635	C/A	cg08888203	chr3:10149979	C3orf24	0.48	6.2	0.36	2.15e-9	Alzheimer's disease;
CESC	cis	rs3741404	0.665	rs12418535	chr11:63910980	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.9	13.31	0.63	2.68e-31	Platelet count;
CESC	trans	rs459571	0.920	rs433402	chr9:136898627	A/G	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.6	-7.57	-0.42	6.18e-13	Platelet distribution width;
CESC	cis	rs10751667	0.643	rs12278229	chr11:946985	A/G	cg06064525	chr11:970664	AP2A2	-0.49	-9.97	-0.52	4.34e-20	Alzheimer's disease (late onset);
CESC	cis	rs926938	0.520	rs6663115	chr1:115272254	G/A	cg12756093	chr1:115239321	AMPD1	-0.54	-6.6	-0.38	2.17e-10	Autism;
CESC	cis	rs4803468	1.000	rs284656	chr19:41929251	T/C	cg09537434	chr19:41945824	ATP5SL	-1.11	-20.58	-0.78	6.86e-57	Height;
CESC	cis	rs875971	0.793	rs460678	chr7:65527200	C/G	cg12463550	chr7:65579703	CRCP	0.57	7.05	0.4	1.52e-11	Aortic root size;
CESC	cis	rs9486715	0.867	rs9372106	chr6:96875058	T/C	cg06623918	chr6:96969491	KIAA0776	0.77	11.0	0.56	1.94e-23	Headache;
CESC	cis	rs1580019	0.563	rs13225132	chr7:32800975	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.99	15.33	0.69	2.02e-38	Cognitive ability;
CESC	cis	rs9488822	0.676	rs10456902	chr6:116333742	C/G	cg26893134	chr6:116381904	FRK	-0.25	-6.23	-0.36	1.78e-9	Cholesterol, total;LDL cholesterol;
CESC	cis	rs6691722	0.503	rs12086212	chr1:24708740	C/T	cg18323236	chr1:24743029	NIPAL3	0.42	6.12	0.35	3.44e-9	Response to interferon beta in multiple sclerosis;
CESC	cis	rs2243480	1.000	rs4548056	chr7:65298873	A/G	cg13147721	chr7:65941812	NA	-0.84	-8.34	-0.46	4.04e-15	Diabetic kidney disease;
CESC	cis	rs870825	0.616	rs7659201	chr4:185632013	G/A	cg04058563	chr4:185651563	MLF1IP	0.63	6.89	0.39	3.95e-11	Blood protein levels;
CESC	cis	rs1799949	0.930	rs35292991	chr17:41334016	C/A	cg05368731	chr17:41323189	NBR1	0.76	10.35	0.54	2.73e-21	Menopause (age at onset);
CESC	cis	rs4423214	1.000	rs12797951	chr11:71143266	G/T	cg05163923	chr11:71159392	DHCR7	-0.76	-10.52	-0.54	7.5e-22	Vitamin D levels;
CESC	cis	rs1729951	0.575	rs1654904	chr3:136681149	T/C	cg03617693	chr3:136751559	NA	0.38	5.31	0.31	2.3e-7	Neuroticism;
CESC	cis	rs9768139	0.935	rs10949715	chr7:158117246	G/T	cg25566285	chr7:158114605	PTPRN2	0.54	9.63	0.51	5.14e-19	Calcium levels;
CESC	cis	rs8180040	0.627	rs9821119	chr3:47198437	C/G	cg27129171	chr3:47204927	SETD2	0.67	9.81	0.52	1.36e-19	Colorectal cancer;
CESC	trans	rs17536732	0.748	rs1440603	chr4:162816560	T/C	cg14364212	chr10:15760690	ITGA8	0.58	6.01	0.35	5.99e-9	Risky sexual behaviors (alcohol dependence interaction);
CESC	cis	rs4819052	0.851	rs4819040	chr21:46659762	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.71	9.96	0.52	4.68e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs6860806	0.661	rs4705929	chr5:131584178	G/T	cg04518342	chr5:131593106	PDLIM4	0.41	6.04	0.35	5.13e-9	Breast cancer;
CESC	cis	rs3026101	0.671	rs8081480	chr17:5282761	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.41	5.48	0.32	9.98e-8	Body mass index;
CESC	cis	rs873946	0.586	rs3829130	chr10:134563122	C/T	cg26818010	chr10:134567672	INPP5A	-0.92	-11.19	-0.57	4.64e-24	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs4253772	0.832	rs6008259	chr22:46633782	G/A	cg09491104	chr22:46646882	C22orf40	-0.56	-8.56	-0.47	9.61e-16	LDL cholesterol;Cholesterol, total;
CESC	cis	rs910316	0.763	rs175450	chr14:75590340	G/A	cg08847533	chr14:75593920	NEK9	-0.91	-15.67	-0.69	1.28e-39	Height;
CESC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg13837895	chr19:50145301	SCAF1	-0.54	-6.2	-0.36	2.16e-9	Lung cancer in ever smokers;
CESC	cis	rs4975709	0.589	rs1684967	chr5:1863055	G/C	cg20790798	chr5:1857306	NA	-0.4	-5.43	-0.32	1.29e-7	Cardiovascular disease risk factors;
CESC	cis	rs7618501	1.000	rs9859153	chr3:49807085	G/T	cg24308560	chr3:49941425	MST1R	-0.52	-7.18	-0.4	7.15e-12	Intelligence (multi-trait analysis);
CESC	cis	rs60154123	0.730	rs689248	chr1:210463122	A/G	cg23283495	chr1:209979779	IRF6	-0.41	-5.32	-0.31	2.18e-7	Coronary artery disease;
CESC	cis	rs483180	0.531	rs539708	chr1:120208503	G/T	cg19096424	chr1:120255104	PHGDH	-0.43	-5.24	-0.31	3.26e-7	Macular telangiectasia type 2;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg01159149	chr11:10830970	EIF4G2	-0.47	-6.44	-0.37	5.5e-10	Height;
CESC	cis	rs61776719	0.875	rs10890238	chr1:38445654	A/T	cg17077180	chr1:38461687	NA	0.56	8.82	0.48	1.6e-16	Coronary artery disease;
CESC	cis	rs9291683	0.526	rs6827785	chr4:10018205	C/T	cg11266682	chr4:10021025	SLC2A9	0.68	13.13	0.63	1.13e-30	Bone mineral density;
CESC	trans	rs9858542	0.953	rs9841110	chr3:49492481	C/G	cg21659725	chr3:3221576	CRBN	-0.55	-6.49	-0.37	4.26e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs3096299	0.933	rs2965939	chr16:89493043	G/A	cg08822215	chr16:89438651	ANKRD11	-0.37	-5.57	-0.32	6.17e-8	Multiple myeloma (IgH translocation);
CESC	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.48	-5.08	-0.3	7.1e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02698600	chr1:201450009	NA	0.57	6.45	0.37	5.4e-10	Gut microbiome composition (summer);
CESC	cis	rs6460942	1.000	rs17274870	chr7:12406221	G/T	cg06484146	chr7:12443880	VWDE	-0.8	-9.01	-0.48	4.07e-17	Coronary artery disease;
CESC	cis	rs2180341	0.920	rs6906717	chr6:127596782	C/A	cg27446573	chr6:127587934	RNF146	1.07	15.98	0.7	1e-40	Breast cancer;
CESC	cis	rs2832191	1.000	rs6516891	chr21:30483070	C/T	cg08807101	chr21:30365312	RNF160	-0.67	-9.26	-0.49	7.29e-18	Dental caries;
CESC	trans	rs6600671	0.899	rs2319971	chr1:121226982	A/C	cg17023122	chr1:144479586	NA	0.48	6.69	0.38	1.29e-10	Hip geometry;
CESC	cis	rs62229266	0.557	rs4817760	chr21:37395301	T/C	cg12218747	chr21:37451666	NA	-0.38	-5.27	-0.31	2.8e-7	Mitral valve prolapse;
CESC	cis	rs2072732	0.756	rs12041634	chr1:2951034	A/T	cg15211996	chr1:2936768	ACTRT2	0.34	5.95	0.34	8.31e-9	Plateletcrit;
CESC	cis	rs9790314	1.000	rs9850455	chr3:161017192	G/A	cg03342759	chr3:160939853	NMD3	-0.5	-6.9	-0.39	3.8e-11	Morning vs. evening chronotype;
CESC	cis	rs4699052	0.507	rs6533085	chr4:104281586	A/T	cg16532752	chr4:104119610	CENPE	-0.53	-7.04	-0.4	1.62e-11	Testicular germ cell tumor;
CESC	cis	rs858239	0.600	rs28499396	chr7:23124098	A/G	cg23682824	chr7:23144976	KLHL7	0.54	7.54	0.42	7.42e-13	Cerebrospinal fluid biomarker levels;
CESC	cis	rs10779751	0.690	rs28729193	chr1:11180151	T/C	cg08854313	chr1:11322531	MTOR	-0.72	-8.77	-0.47	2.16e-16	Body mass index;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02902800	chr4:6784175	KIAA0232	0.58	6.95	0.39	2.82e-11	Gut microbiome composition (summer);
CESC	cis	rs7216064	1.000	rs8082512	chr17:65837059	T/C	cg07042672	chr17:66097459	LOC651250	-0.54	-5.67	-0.33	3.73e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs34779708	0.966	rs12775799	chr10:35488264	C/T	cg03585969	chr10:35415529	CREM	0.75	9.89	0.52	7.86e-20	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs9814567	1.000	rs1880377	chr3:134270468	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.45	6.08	0.35	4.21e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg19319069	chr7:129593010	UBE2H	-0.47	-6.46	-0.37	4.99e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs2404602	0.532	rs206205	chr15:76736091	T/G	cg23625390	chr15:77176239	SCAPER	0.35	5.05	0.3	8.18e-7	Blood metabolite levels;
CESC	cis	rs1799949	0.550	rs2343818	chr17:41409774	G/A	cg25072359	chr17:41440525	NA	0.5	6.68	0.38	1.41e-10	Menopause (age at onset);
CESC	cis	rs3749237	0.595	rs2878298	chr3:49406080	T/C	cg02487422	chr3:49467188	NICN1	0.55	7.97	0.44	4.74e-14	Resting heart rate;
CESC	cis	rs881375	0.631	rs10739577	chr9:123668854	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.52	7.66	0.43	3.56e-13	Rheumatoid arthritis;
CESC	cis	rs11098499	0.908	rs7696649	chr4:120322177	G/A	cg24375607	chr4:120327624	NA	0.48	5.83	0.34	1.64e-8	Corneal astigmatism;
CESC	cis	rs7107174	1.000	rs11237438	chr11:77998488	T/C	cg02023728	chr11:77925099	USP35	0.48	6.75	0.38	9.5e-11	Testicular germ cell tumor;
CESC	cis	rs2050392	1.000	rs2265185	chr10:30691777	A/C	cg18806716	chr10:30721971	MAP3K8	-0.4	-5.8	-0.34	1.87e-8	Inflammatory bowel disease;
CESC	cis	rs4595586	0.655	rs7958206	chr12:39329294	G/A	cg26384229	chr12:38710491	ALG10B	0.43	6.31	0.36	1.2e-9	Morning vs. evening chronotype;
CESC	trans	rs2727020	0.617	rs7102702	chr11:49401125	T/G	cg03929089	chr4:120376271	NA	-0.69	-8.35	-0.46	3.92e-15	Coronary artery disease;
CESC	cis	rs5760092	0.618	rs4461358	chr22:24260106	T/C	cg01238044	chr22:24384105	GSTT1	0.66	7.89	0.44	7.87e-14	Urinary 1,3-butadiene metabolite levels in smokers;
CESC	cis	rs35306767	0.953	rs12259338	chr10:969377	C/T	cg25019033	chr10:957182	NA	-0.65	-8.25	-0.45	7.58e-15	Eosinophil percentage of granulocytes;
CESC	cis	rs959260	1.000	rs930298	chr17:73404666	T/G	cg12999837	chr17:73267436	MIF4GD	-0.49	-5.53	-0.32	7.69e-8	Systemic lupus erythematosus;
CESC	cis	rs8062405	0.755	rs4788078	chr16:28559981	G/A	cg01378222	chr16:28622494	SULT1A1	0.3	5.14	0.3	5.27e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs854765	0.583	rs7207395	chr17:17819335	C/T	cg04398451	chr17:18023971	MYO15A	-0.66	-9.24	-0.49	8.32e-18	Total body bone mineral density;
CESC	trans	rs74054849	0.850	rs72876771	chr1:15999623	C/G	cg06826283	chr7:600452	PRKAR1B	0.73	6.06	0.35	4.77e-9	Alcoholic chronic pancreatitis;
CESC	cis	rs2304069	0.779	rs245081	chr5:149356075	G/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.69	9.09	0.49	2.34e-17	HIV-1 control;
CESC	cis	rs17023223	0.509	rs61806978	chr1:119713215	A/G	cg05756136	chr1:119680316	WARS2	-0.47	-5.69	-0.33	3.34e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CESC	cis	rs17253792	0.822	rs78522049	chr14:56071203	A/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.79	5.91	0.34	1.06e-8	Putamen volume;
CESC	cis	rs7666738	0.830	rs35491210	chr4:99003364	T/C	cg03676636	chr4:99064102	C4orf37	0.33	5.13	0.3	5.51e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9291683	0.530	rs35908990	chr4:9976105	G/A	cg02734326	chr4:10020555	SLC2A9	0.45	6.77	0.38	8.46e-11	Bone mineral density;
CESC	cis	rs7085104	0.572	rs284856	chr10:104574329	A/T	cg23093090	chr10:104574429	C10orf26	0.34	5.41	0.32	1.42e-7	Immature fraction of reticulocytes;Schizophrenia;
CESC	cis	rs12477438	0.520	rs11123766	chr2:99780915	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.85	15.73	0.69	8.16e-40	Chronic sinus infection;
CESC	cis	rs7631605	0.905	rs4678920	chr3:37020649	T/C	cg22985146	chr3:37219077	LRRFIP2	-0.34	-5.22	-0.31	3.61e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs12497850	0.966	rs6792510	chr3:48723302	G/C	cg07636037	chr3:49044803	WDR6	0.92	14.61	0.67	7.14e-36	Parkinson's disease;
CESC	cis	rs854765	0.583	rs67253360	chr17:17828973	T/C	cg16928487	chr17:17741425	SREBF1	-0.57	-9.74	-0.51	2.41e-19	Total body bone mineral density;
CESC	cis	rs2294693	0.947	rs9381025	chr6:40986623	C/T	cg14418226	chr6:40996092	UNC5CL	0.43	5.47	0.32	1.07e-7	Gastric cancer;Non-cardia gastric cancer;
CESC	trans	rs7980799	0.682	rs7138529	chr12:33634855	T/C	cg26384229	chr12:38710491	ALG10B	-0.59	-8.62	-0.47	6.34e-16	Heart rate;Heart rate variability traits (RMSSD);
CESC	cis	rs853679	0.517	rs2275508	chr6:28094731	T/C	cg17221315	chr6:27791827	HIST1H4J	0.43	5.03	0.3	9.18e-7	Depression;
CESC	cis	rs1862618	0.853	rs2548664	chr5:56133555	G/A	cg18230493	chr5:56204884	C5orf35	-0.75	-8.9	-0.48	9.02e-17	Initial pursuit acceleration;
CESC	cis	rs597539	0.652	rs513359	chr11:68669496	A/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	-0.77	-10.18	-0.53	9.33e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs11608355	0.521	rs6606703	chr12:109813665	C/T	cg19025524	chr12:109796872	NA	-0.53	-7.76	-0.43	1.83e-13	Neuroticism;
CESC	cis	rs11945232	1.000	rs11945232	chr4:88342369	A/G	cg23841344	chr4:88312519	HSD17B11	-0.47	-6.01	-0.35	6.2e-9	Intelligence (multi-trait analysis);
CESC	cis	rs7605827	0.930	rs12692275	chr2:15716781	C/T	cg19274914	chr2:15703543	NA	0.37	6.62	0.38	1.96e-10	Educational attainment (years of education);
CESC	cis	rs12681288	0.712	rs2600488	chr8:1021266	A/C	cg04851639	chr8:1020857	NA	-0.32	-7.17	-0.4	7.38e-12	Schizophrenia;
CESC	cis	rs72781680	0.898	rs12620558	chr2:23936022	G/A	cg20701182	chr2:24300061	SF3B14	0.78	6.91	0.39	3.5e-11	Lymphocyte counts;
CESC	cis	rs10979	0.964	rs35826562	chr6:143898672	G/A	cg25407410	chr6:143891975	LOC285740	-0.61	-9.12	-0.49	1.91e-17	Hypospadias;
CESC	cis	rs7811142	0.830	rs75636500	chr7:99947657	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.11	10.55	0.54	5.87e-22	Platelet count;
CESC	cis	rs4253772	0.530	rs113258957	chr22:46663678	G/C	cg24881330	chr22:46731750	TRMU	0.79	6.42	0.37	6.34e-10	LDL cholesterol;Cholesterol, total;
CESC	cis	rs6426558	0.537	rs6692080	chr1:227390162	C/T	cg10327440	chr1:227177885	CDC42BPA	-0.48	-5.91	-0.34	1.07e-8	Neutrophil percentage of white cells;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg20304750	chr12:124821387	NCOR2	0.48	6.11	0.35	3.49e-9	Fibrinogen levels;
CESC	cis	rs113835537	0.559	rs57045447	chr11:66339683	A/G	cg24851651	chr11:66362959	CCS	0.5	5.96	0.34	7.95e-9	Airway imaging phenotypes;
CESC	cis	rs938554	0.570	rs7696983	chr4:9995829	A/C	cg11266682	chr4:10021025	SLC2A9	0.52	6.87	0.39	4.48e-11	Blood metabolite levels;
CESC	cis	rs1799949	0.628	rs4474733	chr17:41433660	G/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.59	6.95	0.39	2.9100000000000002e-11	Menopause (age at onset);
CESC	cis	rs7044106	0.512	rs7873848	chr9:123354222	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.76	11.72	0.58	7.93e-26	Hip circumference adjusted for BMI;
CESC	cis	rs1003719	0.788	rs2006941	chr21:38467616	C/A	cg10648535	chr21:38446584	PIGP;TTC3	0.63	8.77	0.47	2.14e-16	Eye color traits;
CESC	cis	rs2576037	0.526	rs538221	chr18:44375111	G/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.33	5.42	0.32	1.37e-7	Personality dimensions;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg09174674	chr1:9884042	CLSTN1	-0.47	-6.18	-0.35	2.4e-9	Fibrinogen levels;
CESC	cis	rs1538970	0.774	rs67683090	chr1:45977803	T/G	cg05343316	chr1:45956843	TESK2	0.93	12.78	0.62	1.91e-29	Platelet count;
CESC	cis	rs7666738	0.830	rs17026973	chr4:98680041	T/A	cg03467027	chr4:99064603	C4orf37	0.44	5.39	0.31	1.52e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9322193	0.923	rs9383812	chr6:150033491	C/T	cg07701084	chr6:150067640	NUP43	0.47	6.77	0.38	8.49e-11	Lung cancer;
CESC	trans	rs62103177	0.810	rs3902996	chr18:77630571	A/G	cg05926928	chr17:57297772	GDPD1	1.14	9.88	0.52	8.43e-20	Opioid sensitivity;
CESC	cis	rs7116495	0.609	rs4945378	chr11:71668866	G/A	cg10381502	chr11:71823885	C11orf51	-1.1	-7.6	-0.42	5.21e-13	Severe influenza A (H1N1) infection;
CESC	cis	rs58688157	0.705	rs12419618	chr11:611531	G/A	cg17005319	chr11:655579	DEAF1	0.53	5.16	0.3	4.76e-7	Systemic lupus erythematosus;
CESC	cis	rs60871478	0.636	rs56393680	chr7:885696	A/G	cg13798912	chr7:905769	UNC84A	-0.55	-5.28	-0.31	2.64e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs28489187	0.706	rs233069	chr1:85805466	C/T	cg16011679	chr1:85725395	C1orf52	0.48	5.6	0.33	5.29e-8	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	cis	rs17292804	0.506	rs71417868	chr14:104046592	A/T	cg24130564	chr14:104152367	KLC1	-0.5	-6.38	-0.36	7.92e-10	Autism spectrum disorder or schizophrenia;
CESC	cis	rs6938	0.596	rs11072511	chr15:75159433	A/G	cg10253484	chr15:75165896	SCAMP2	-0.51	-6.94	-0.39	2.93e-11	Breast cancer;
CESC	cis	rs514406	0.861	rs1571979	chr1:53237526	G/A	cg24675658	chr1:53192096	ZYG11B	0.53	6.69	0.38	1.29e-10	Monocyte count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00226754	chr12:124068984	TMED2	0.55	6.49	0.37	4.1e-10	Gut microbiome composition (summer);
CESC	cis	rs684232	0.543	rs4968095	chr17:507539	A/G	cg12384639	chr17:618140	VPS53	0.4	5.14	0.3	5.42e-7	Prostate cancer;
CESC	trans	rs11098499	0.739	rs4833612	chr4:120147596	A/C	cg25214090	chr10:38739885	LOC399744	-0.56	-7.5	-0.42	9.44e-13	Corneal astigmatism;
CESC	cis	rs6963495	0.818	rs55922564	chr7:105155890	G/A	cg13798780	chr7:105162888	PUS7	0.78	8.04	0.44	2.99e-14	Bipolar disorder (body mass index interaction);
CESC	cis	rs367943	1.000	rs348952	chr5:112821990	G/T	cg12552261	chr5:112820674	MCC	-0.63	-7.96	-0.44	4.96e-14	Type 2 diabetes;
CESC	cis	rs9858542	0.953	rs11922013	chr3:49458355	G/C	cg07274523	chr3:49395745	GPX1	0.67	8.23	0.45	8.41e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs873946	0.590	rs7071777	chr10:134559976	T/A	cg27297192	chr10:134578999	INPP5A	0.39	5.08	0.3	7.26e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	trans	rs10838798	0.517	rs1967210	chr11:48096692	G/T	cg15704280	chr7:45808275	SEPT13	-0.57	-6.02	-0.35	5.72e-9	Height;
CESC	cis	rs524023	1.000	rs3825018	chr11:64358809	G/A	cg07220939	chr11:64358617	SLC22A12	-0.35	-5.46	-0.32	1.09e-7	Urate levels in obese individuals;
CESC	cis	rs1348850	0.526	rs10497504	chr2:178370040	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.69	6.19	0.36	2.22e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs13191362	0.935	rs34934114	chr6:163082480	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.0	10.3	0.53	3.82e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs6732160	0.574	rs7557055	chr2:73472670	G/A	cg01422370	chr2:73384389	NA	0.43	7.25	0.41	4.71e-12	Intelligence (multi-trait analysis);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg02375201	chr1:27114675	PIGV	-0.47	-6.09	-0.35	3.87e-9	Fibrinogen levels;
CESC	cis	rs1348850	0.872	rs4893959	chr2:178400204	G/A	cg22681709	chr2:178499509	PDE11A	-0.46	-6.69	-0.38	1.34e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs854765	0.856	rs2955382	chr17:17947710	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.42	-5.76	-0.33	2.28e-8	Total body bone mineral density;
CESC	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg26338869	chr17:61819248	STRADA	0.67	8.77	0.47	2.24e-16	Prudent dietary pattern;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01274715	chr10:92618033	HTR7	-0.48	-6.19	-0.36	2.29e-9	Gut microbiome composition (summer);
CESC	cis	rs9788682	0.642	rs2568483	chr15:78752343	A/G	cg24631222	chr15:78858424	CHRNA5	0.6	6.97	0.39	2.47e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs36051895	0.623	rs7035456	chr9:5261440	G/A	cg02405213	chr9:5042618	JAK2	-0.54	-6.66	-0.38	1.57e-10	Pediatric autoimmune diseases;
CESC	cis	rs35110281	0.693	rs4819290	chr21:45122713	C/T	cg04455712	chr21:45112962	RRP1B	0.49	7.37	0.41	2.13e-12	Mean corpuscular volume;
CESC	cis	rs806215	0.950	rs3735644	chr7:127222157	G/A	cg25922125	chr7:127225783	GCC1	-0.45	-5.04	-0.3	8.61e-7	Type 2 diabetes;
CESC	cis	rs62103177	0.810	rs3902996	chr18:77630571	A/G	cg12964065	chr18:77638022	KCNG2	0.56	5.45	0.32	1.12e-7	Opioid sensitivity;
CESC	cis	rs854765	0.583	rs8073001	chr17:17831716	A/C	cg04398451	chr17:18023971	MYO15A	0.65	9.41	0.5	2.56e-18	Total body bone mineral density;
CESC	cis	rs10504229	1.000	rs67344620	chr8:58187537	C/A	cg05313129	chr8:58192883	C8orf71	-0.55	-6.29	-0.36	1.34e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs9549260	0.755	rs2721067	chr13:41156708	C/T	cg21288729	chr13:41239152	FOXO1	0.61	7.57	0.42	6.17e-13	Red blood cell count;
CESC	cis	rs6575793	0.967	rs11845605	chr14:101037726	C/T	cg18516195	chr14:101012996	BEGAIN	-0.45	-6.27	-0.36	1.47e-9	Menarche (age at onset);
CESC	cis	rs4969178	0.965	rs938351	chr17:76399404	C/T	cg05887092	chr17:76393375	PGS1	0.59	9.4	0.5	2.73e-18	HDL cholesterol levels;
CESC	cis	rs2204008	0.775	rs8186812	chr12:38305055	C/T	cg13010199	chr12:38710504	ALG10B	0.42	5.39	0.31	1.58e-7	Bladder cancer;
CESC	cis	rs1707322	1.000	rs785480	chr1:46492164	C/G	cg03146154	chr1:46216737	IPP	0.71	9.64	0.51	4.73e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs778371	0.723	rs737027	chr2:233641083	G/C	cg08000102	chr2:233561755	GIGYF2	0.83	14.42	0.66	3.32e-35	Schizophrenia;
CESC	cis	rs1552244	0.882	rs56224841	chr3:10044014	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.85	11.01	0.56	1.86e-23	Alzheimer's disease;
CESC	cis	rs7829975	0.871	rs777709	chr8:8583872	T/C	cg18904891	chr8:8559673	CLDN23	-0.44	-5.41	-0.32	1.44e-7	Mood instability;
CESC	cis	rs644799	1.000	rs611020	chr11:95567905	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.68	8.53	0.46	1.18e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs4481887	0.893	rs10788763	chr1:248429070	A/T	cg00666640	chr1:248458726	OR2T12	-0.31	-5.83	-0.34	1.59e-8	Common traits (Other);
CESC	cis	rs1728785	1.000	rs864741	chr16:68576577	C/T	cg02972257	chr16:68554789	NA	-0.55	-6.31	-0.36	1.17e-9	Ulcerative colitis;
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg04342999	chr5:138629163	MATR3	-0.41	-6.05	-0.35	4.92e-9	Vertical cup-disc ratio;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg25978167	chr4:57301353	PAICS;PPAT	-0.43	-6.04	-0.35	5.08e-9	Gambling;
CESC	cis	rs1008375	1.000	rs13119927	chr4:17691640	G/A	cg16339924	chr4:17578868	LAP3	-0.66	-7.92	-0.44	6.43e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs7100689	0.697	rs4934084	chr10:82116960	T/C	cg00277334	chr10:82204260	NA	-0.59	-7.35	-0.41	2.39e-12	Post bronchodilator FEV1;
CESC	cis	rs1862618	0.802	rs986049	chr5:56110233	G/A	cg24549020	chr5:56110836	MAP3K1	0.64	7.46	0.42	1.26e-12	Initial pursuit acceleration;
CESC	cis	rs7615952	0.599	rs16834938	chr3:125706046	C/T	cg04553112	chr3:125709451	NA	-0.5	-5.81	-0.34	1.78e-8	Blood pressure (smoking interaction);
CESC	cis	rs2425143	0.908	rs6060625	chr20:34414318	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.7	-6.18	-0.35	2.41e-9	Blood protein levels;
CESC	trans	rs7980799	0.935	rs1905408	chr12:33516963	G/A	cg26384229	chr12:38710491	ALG10B	-0.47	-6.44	-0.37	5.7e-10	Heart rate;Heart rate variability traits (RMSSD);
CESC	cis	rs12701220	0.553	rs7782024	chr7:1157502	G/T	cg01324507	chr7:1177794	C7orf50	0.53	5.09	0.3	6.72e-7	Bronchopulmonary dysplasia;
CESC	cis	rs2274273	0.686	rs57033289	chr14:55623317	C/A	cg04306507	chr14:55594613	LGALS3	0.31	5.26	0.31	2.99e-7	Protein biomarker;
CESC	cis	rs950169	0.922	rs11638445	chr15:85137694	C/A	cg17507749	chr15:85114479	UBE2QP1	0.54	6.18	0.35	2.45e-9	Schizophrenia;
CESC	cis	rs2455799	0.613	rs4684261	chr3:15796505	G/A	cg16303742	chr3:15540471	COLQ	-0.39	-6.14	-0.35	3.01e-9	Mean platelet volume;
CESC	cis	rs2191566	0.960	rs8105571	chr19:44510341	C/T	cg20607764	chr19:44506953	ZNF230	-0.59	-7.6	-0.42	5.2e-13	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs11690935	0.959	rs6705200	chr2:172637600	A/G	cg13550731	chr2:172543902	DYNC1I2	-1.02	-16.98	-0.72	2.91e-44	Schizophrenia;
CESC	cis	rs4728302	0.559	rs7779409	chr7:133158475	A/G	cg10665199	chr7:133106180	EXOC4	0.54	7.47	0.42	1.17e-12	Intelligence;Intelligence (multi-trait analysis);
CESC	cis	rs1348850	0.914	rs4893938	chr2:178250095	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.83	12.0	0.59	8.46e-27	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs7584330	0.518	rs11903073	chr2:238432766	C/T	cg14458575	chr2:238380390	NA	0.48	5.31	0.31	2.37e-7	Prostate cancer;
CESC	cis	rs6460942	1.000	rs2053378	chr7:12405564	C/G	cg10578991	chr7:12443926	VWDE	-0.55	-5.86	-0.34	1.36e-8	Coronary artery disease;
CESC	cis	rs853679	0.517	rs9393896	chr6:28127703	C/T	cg19592336	chr6:28129416	ZNF389	0.61	7.98	0.44	4.44e-14	Depression;
CESC	cis	rs6502050	0.787	rs7222326	chr17:80057272	T/C	cg11859384	chr17:80120422	CCDC57	0.39	5.05	0.3	8.31e-7	Life satisfaction;
CESC	cis	rs7605827	0.930	rs2052439	chr2:15702029	C/G	cg19274914	chr2:15703543	NA	0.36	6.44	0.37	5.68e-10	Educational attainment (years of education);
CESC	cis	rs4665809	0.549	rs7577896	chr2:26524493	C/T	cg22920501	chr2:26401640	FAM59B	0.71	7.02	0.4	1.83e-11	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25195100	chr20:61903949	ARFGAP1	0.63	7.46	0.42	1.24e-12	Gut microbiome composition (summer);
CESC	cis	rs10791323	0.569	rs2282601	chr11:133712594	C/G	cg15485101	chr11:133734466	NA	0.4	6.51	0.37	3.65e-10	Childhood ear infection;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25004679	chr17:74722398	C17orf95;JMJD6	0.59	6.86	0.39	4.76e-11	Gut microbiome composition (summer);
CESC	cis	rs6484504	0.600	rs942272	chr11:31364368	C/T	cg14844989	chr11:31128820	NA	0.39	5.25	0.31	3.13e-7	Red blood cell count;
CESC	cis	rs3820068	0.581	rs1547031	chr1:15918960	G/A	cg17385448	chr1:15911702	AGMAT	0.44	7.11	0.4	1.08e-11	Systolic blood pressure;
CESC	cis	rs950169	0.922	rs4842939	chr15:84827966	C/T	cg17507749	chr15:85114479	UBE2QP1	-0.49	-5.81	-0.34	1.81e-8	Schizophrenia;
CESC	cis	rs585510	1	rs585510	chr12:121000133	A/G	cg12219531	chr12:120966889	COQ5	0.75	9.92	0.52	6.36e-20	Reticulocyte fraction of red cells;
CESC	cis	rs3806843	0.966	rs2563255	chr5:140142547	T/C	cg26395211	chr5:140044315	WDR55	0.39	5.17	0.3	4.51e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs4535700	0.501	rs9642405	chr7:55978166	C/T	cg09872392	chr7:56161020	PHKG1	0.41	6.03	0.35	5.59e-9	Macular telangiectasia type 2;
CESC	cis	rs9926296	0.568	rs886950	chr16:89836872	T/C	cg27121462	chr16:89883253	FANCA	0.75	10.66	0.55	2.66e-22	Vitiligo;
CESC	trans	rs4332037	0.539	rs57148375	chr7:2025001	G/C	cg11693508	chr17:37793320	STARD3	0.67	6.73	0.38	1.07e-10	Bipolar disorder;
CESC	cis	rs782590	0.764	rs935177	chr2:55826761	C/G	cg18811423	chr2:55921094	PNPT1	0.77	12.1	0.6	4.01e-27	Metabolic syndrome;
CESC	trans	rs2727020	0.729	rs34647977	chr11:49195543	G/A	cg15704280	chr7:45808275	SEPT13	-0.84	-13.72	-0.64	9.55e-33	Coronary artery disease;
CESC	cis	rs9811920	0.683	rs7650727	chr3:99688976	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.38	-6.29	-0.36	1.3e-9	Axial length;
CESC	cis	rs7000551	0.556	rs6998780	chr8:22254639	C/T	cg12081754	chr8:22256438	SLC39A14	0.89	12.19	0.6	1.95e-27	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CESC	cis	rs244293	0.760	rs4794547	chr17:53011172	A/G	cg19360675	chr17:53046073	COX11;STXBP4	-0.48	-6.57	-0.37	2.63e-10	Menarche (age at onset);
CESC	trans	rs3808502	0.549	rs7831039	chr8:11427637	A/T	cg15556689	chr8:8085844	FLJ10661	-0.57	-6.81	-0.39	6.66e-11	Neuroticism;
CESC	cis	rs274567	0.501	rs272856	chr5:131687081	G/C	cg07395648	chr5:131743802	NA	-0.41	-5.23	-0.31	3.51e-7	Blood metabolite levels;
CESC	cis	rs10392	0.543	rs4812333	chr20:37536119	T/A	cg27552599	chr20:37590471	DHX35	0.38	5.38	0.31	1.61e-7	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
CESC	cis	rs172166	0.694	rs1150666	chr6:28123928	T/C	cg23161317	chr6:28129485	ZNF389	0.41	5.59	0.32	5.75e-8	Cardiac Troponin-T levels;
CESC	cis	rs4689388	0.853	rs13103357	chr4:6294544	A/G	cg25554036	chr4:6271136	WFS1	0.51	8.37	0.46	3.31e-15	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg04234412	chr22:24373322	LOC391322	-0.73	-11.52	-0.58	3.52e-25	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs4604732	0.536	rs7528219	chr1:247628307	C/T	cg12754571	chr1:247694271	LOC148824;OR2C3	0.41	5.09	0.3	6.91e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs2540647	0.908	rs2023634	chr22:18972450	C/T	cg12798833	chr22:18958832	DGCR5	-0.63	-7.65	-0.43	3.73e-13	Blood metabolite ratios;
CESC	cis	rs3125734	0.633	rs1864836	chr10:64028538	C/G	cg09941381	chr10:64027924	RTKN2	-0.31	-5.11	-0.3	6.26e-7	Rheumatoid arthritis;
CESC	cis	rs7208859	0.623	rs9914242	chr17:29216245	G/T	cg19761014	chr17:28927070	LRRC37B2	0.66	5.51	0.32	8.42e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg10227393	chr19:3721525	NA	-0.49	-6.62	-0.38	1.97e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs7580658	0.724	rs6712551	chr2:127998485	G/A	cg10021288	chr2:128175891	PROC	-0.39	-6.1	-0.35	3.69e-9	Protein C levels;
CESC	cis	rs614226	0.744	rs787832	chr12:120986801	A/G	cg01236616	chr12:121019343	POP5	1.55	19.98	0.78	8.29e-55	Type 1 diabetes nephropathy;
CESC	cis	rs3916	0.911	rs2239758	chr12:121162637	A/G	cg21892295	chr12:121157589	UNC119B	-0.36	-5.33	-0.31	2.1e-7	Urinary metabolites (H-NMR features);
CESC	cis	rs8077577	0.895	rs62072498	chr17:18125951	C/G	cg16794390	chr17:18148240	FLII	0.43	5.85	0.34	1.44e-8	Obesity-related traits;
CESC	cis	rs6762477	0.505	rs17304079	chr3:50085153	A/G	cg03060546	chr3:49711283	APEH	-0.44	-5.06	-0.3	7.7300000000000005e-07	Menarche (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03657549	chr7:128116813	METTL2B	0.51	6.05	0.35	4.8e-9	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26257210	chr1:6305348	HES3	0.55	6.49	0.37	4.29e-10	Gut microbiome composition (summer);
CESC	cis	rs6860806	0.531	rs272887	chr5:131665713	A/G	cg24060327	chr5:131705240	SLC22A5	-0.78	-10.95	-0.56	2.89e-23	Breast cancer;
CESC	cis	rs801193	0.967	rs2707849	chr7:66152712	T/C	cg14393609	chr7:65229607	NA	0.47	6.31	0.36	1.17e-9	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07881228	chr7:30068068	PLEKHA8	0.57	6.86	0.39	4.93e-11	Gut microbiome composition (summer);
CESC	cis	rs7178909	0.872	rs17241560	chr15:90429202	T/A	cg19708238	chr15:90437601	AP3S2	0.36	5.03	0.3	9.01e-7	Common traits (Other);
CESC	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	22.12	0.81	3.99e-62	Prudent dietary pattern;
CESC	trans	rs10411161	0.702	rs16983200	chr19:52386723	G/A	cg22319618	chr22:45562946	NUP50	-0.73	-7.14	-0.4	8.9e-12	Breast cancer;
CESC	cis	rs9640161	0.750	rs11538922	chr7:150035183	C/T	cg10018233	chr7:150070692	REPIN1	0.47	6.82	0.39	6.1e-11	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs6987853	0.736	rs2923446	chr8:42404177	G/A	cg09913449	chr8:42400586	C8orf40	0.45	7.63	0.42	4.28e-13	Mean corpuscular hemoglobin concentration;
CESC	cis	rs360798	0.532	rs1022110	chr2:63046039	T/G	cg17519650	chr2:63277830	OTX1	-0.47	-5.59	-0.32	5.52e-8	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21640038	chr17:65362901	PSMD12	-0.61	-6.67	-0.38	1.48e-10	Gut microbiome composition (summer);
CESC	cis	rs6456156	0.792	rs10946212	chr6:167515947	C/G	cg23791538	chr6:167370224	RNASET2	-0.41	-5.35	-0.31	1.87e-7	Primary biliary cholangitis;
CESC	cis	rs7000551	0.505	rs13258195	chr8:22227271	A/G	cg02463440	chr8:22132932	PIWIL2	-0.41	-5.03	-0.3	9.07e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CESC	cis	rs875971	0.545	rs6460281	chr7:65681115	A/C	cg18876405	chr7:65276391	NA	0.51	5.88	0.34	1.25e-8	Aortic root size;
CESC	cis	rs9787249	0.915	rs58589165	chr1:40213670	A/T	cg02773041	chr1:40204384	PPIE	0.53	7.56	0.42	6.49e-13	Blood protein levels;
CESC	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg22105103	chr4:187893119	NA	-0.48	-6.74	-0.38	9.77e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs17826219	0.568	rs2626985	chr17:29077437	A/G	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.1e-10	Body mass index;
CESC	cis	rs453301	0.653	rs7853	chr8:8890814	A/G	cg06636001	chr8:8085503	FLJ10661	0.48	6.06	0.35	4.7e-9	Joint mobility (Beighton score);
CESC	cis	rs9322193	0.923	rs1984111	chr6:150152856	G/A	cg09699651	chr6:150184138	LRP11	0.4	5.18	0.3	4.32e-7	Lung cancer;
CESC	cis	rs2439831	0.850	rs28696802	chr15:44140395	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.66	6.03	0.35	5.4e-9	Lung cancer in ever smokers;
CESC	cis	rs2050392	0.590	rs694346	chr10:30711929	C/T	cg02070205	chr10:30722105	MAP3K8	-0.45	-5.24	-0.31	3.32e-7	Inflammatory bowel disease;
CESC	cis	rs7666738	0.515	rs10015315	chr4:98700137	A/G	cg05340658	chr4:99064831	C4orf37	0.58	7.23	0.41	5.32e-12	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7542091	0.704	rs1883331	chr1:210043483	A/G	cg09509183	chr1:209979624	IRF6	0.4	5.78	0.33	2.12e-8	Monobrow;
CESC	cis	rs55728055	0.661	rs61561528	chr22:31983071	A/G	cg01338084	chr22:32026380	PISD	1.22	8.02	0.44	3.48e-14	Age-related hearing impairment;
CESC	cis	rs1775715	0.835	rs113450267	chr10:32223728	G/A	cg18675610	chr10:32216311	ARHGAP12	0.33	5.06	0.3	7.93e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs826838	0.935	rs1684407	chr12:39127270	C/T	cg13010199	chr12:38710504	ALG10B	-0.45	-6.26	-0.36	1.53e-9	Heart rate;
CESC	cis	rs7829975	0.711	rs4841051	chr8:8685646	C/T	cg17143192	chr8:8559678	CLDN23	-0.47	-5.89	-0.34	1.19e-8	Mood instability;
CESC	cis	rs2204008	0.806	rs1589382	chr12:38408565	T/A	cg26384229	chr12:38710491	ALG10B	0.69	10.57	0.54	4.96e-22	Bladder cancer;
CESC	trans	rs9951602	0.512	rs9955812	chr18:76650954	T/A	cg02800362	chr5:177631904	HNRNPAB	0.66	8.66	0.47	4.55e-16	Obesity-related traits;
CESC	cis	rs7178572	0.568	rs12905951	chr15:77649431	G/A	cg22256960	chr15:77711686	NA	-0.54	-6.83	-0.39	5.83e-11	Type 2 diabetes;
CESC	cis	rs2228479	0.702	rs62052710	chr16:89854893	C/T	cg06558623	chr16:89946397	TCF25	1.18	9.44	0.5	1.97e-18	Skin colour saturation;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22508203	chr13:97762289	NA	0.59	6.58	0.37	2.54e-10	Gut microbiome composition (summer);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg13081381	chr13:82264192	NA	-0.47	-6.53	-0.37	3.43e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs938554	0.737	rs11723439	chr4:9951819	C/T	cg11266682	chr4:10021025	SLC2A9	-0.5	-6.13	-0.35	3.13e-9	Blood metabolite levels;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg08496016	chr9:99181722	ZNF367	-0.44	-6.09	-0.35	4.01e-9	Height;
CESC	cis	rs2243480	0.803	rs36004293	chr7:65416512	T/C	cg12463550	chr7:65579703	CRCP	0.69	5.72	0.33	2.85e-8	Diabetic kidney disease;
CESC	cis	rs896854	0.967	rs10808671	chr8:95967372	A/G	cg26343298	chr8:95960752	TP53INP1	0.36	5.91	0.34	1.06e-8	Type 2 diabetes;
CESC	cis	rs9649213	0.593	rs6465677	chr7:98003552	C/T	cg24562669	chr7:97807699	LMTK2	0.48	7.05	0.4	1.52e-11	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs1707322	0.721	rs28817701	chr1:46186050	C/T	cg03146154	chr1:46216737	IPP	0.82	11.54	0.58	3.18e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs561341	1.000	rs117979353	chr17:30272866	A/G	cg20587970	chr11:113659929	NA	-1.48	-19.43	-0.77	7.1e-53	Hip circumference adjusted for BMI;
CESC	cis	rs4819052	0.819	rs7279136	chr21:46692287	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.46	5.69	0.33	3.35e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs4665809	0.877	rs34536218	chr2:26287376	T/A	cg08470875	chr2:26401718	FAM59B	0.59	6.11	0.35	3.53e-9	Gut microbiome composition (summer);
CESC	cis	rs2243480	0.808	rs12698508	chr7:65411958	A/T	cg18252515	chr7:66147081	NA	-1.23	-11.49	-0.58	4.61e-25	Diabetic kidney disease;
CESC	cis	rs3091242	0.933	rs3093584	chr1:25668714	T/C	cg27572855	chr1:25598939	RHD	-0.44	-7.23	-0.41	5.25e-12	Erythrocyte sedimentation rate;
CESC	cis	rs8016982	0.674	rs11159494	chr14:81667611	G/C	cg01989461	chr14:81687754	GTF2A1	0.75	11.83	0.59	3.33e-26	Schizophrenia;
CESC	cis	rs899997	1.000	rs11634628	chr15:79005579	G/A	cg04896959	chr15:78267971	NA	0.42	6.32	0.36	1.09e-9	Coronary artery disease or large artery stroke;
CESC	cis	rs7520050	0.807	rs28647556	chr1:46206399	G/A	cg24296786	chr1:45957014	TESK2	-0.46	-5.98	-0.34	7.23e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs12893668	0.608	rs12889721	chr14:104034863	C/T	cg24130564	chr14:104152367	KLC1	-0.52	-6.62	-0.38	1.98e-10	Reticulocyte count;
CESC	cis	rs1941023	0.584	rs2241920	chr11:60164204	A/G	cg08716584	chr11:60157161	MS4A7	0.57	9.45	0.5	1.94e-18	Congenital heart disease (maternal effect);
CESC	cis	rs10883723	0.810	rs2296590	chr10:104262628	G/A	ch.10.2196322F	chr10:104248062	ACTR1A	0.42	5.08	0.3	6.99e-7	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs4450798	0.649	rs9310430	chr3:13781682	A/G	cg05589046	chr3:13742034	LOC285375	0.34	5.09	0.3	6.68e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs1862618	0.853	rs33326	chr5:56142601	G/A	cg18230493	chr5:56204884	C5orf35	-0.74	-8.84	-0.48	1.37e-16	Initial pursuit acceleration;
CESC	cis	rs10504229	0.593	rs77607045	chr8:58010464	T/C	cg02725872	chr8:58115012	NA	-0.38	-5.1	-0.3	6.54e-7	Developmental language disorder (linguistic errors);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07555597	chr2:62423100	B3GNT2	0.65	8.15	0.45	1.43e-14	Gut microbiome composition (summer);
CESC	cis	rs9916302	0.904	rs650106	chr17:37451559	A/G	cg19468946	chr17:37922297	IKZF3	0.41	5.22	0.31	3.59e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs1728785	1.000	rs1170426	chr16:68603798	C/T	cg02972257	chr16:68554789	NA	-0.59	-6.71	-0.38	1.2e-10	Ulcerative colitis;
CESC	cis	rs7223966	1.000	rs11871767	chr17:61698723	A/G	cg11494091	chr17:61959527	GH2	0.38	5.06	0.3	7.99e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs7274811	0.744	rs6120309	chr20:32169600	A/G	cg21523528	chr20:32077966	CBFA2T2	0.44	5.37	0.31	1.73e-7	Height;
CESC	cis	rs7071206	0.853	rs114936111	chr10:79430143	G/A	cg23888215	chr10:79422304	NA	-0.5	-5.71	-0.33	2.99e-8	Bone mineral density;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27634258	chr15:51058042	SPPL2A	0.65	7.68	0.43	3.06e-13	Gut microbiome composition (summer);
CESC	cis	rs9733	0.596	rs6669369	chr1:150695892	C/T	cg17724175	chr1:150552817	MCL1	0.45	7.31	0.41	3.17e-12	Tonsillectomy;
CESC	cis	rs7618501	0.699	rs2681780	chr3:49897830	C/T	cg24308560	chr3:49941425	MST1R	-0.69	-10.26	-0.53	5.27e-21	Intelligence (multi-trait analysis);
CESC	cis	rs4665809	0.567	rs12999875	chr2:26414847	A/C	cg26314531	chr2:26401878	FAM59B	0.84	9.25	0.49	7.65e-18	Gut microbiome composition (summer);
CESC	cis	rs10479542	0.503	rs12719865	chr5:178993566	C/T	cg05457628	chr5:178986728	RUFY1	0.51	7.51	0.42	8.99e-13	Lung cancer;
CESC	cis	rs7044106	0.762	rs1158553	chr9:123400974	C/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.33	5.1	0.3	6.43e-7	Hip circumference adjusted for BMI;
CESC	cis	rs2404602	0.716	rs17461634	chr15:76764107	G/A	cg22467129	chr15:76604101	ETFA	-0.38	-5.78	-0.33	2.11e-8	Blood metabolite levels;
CESC	trans	rs17039212	0.522	rs12620068	chr2:49905093	A/C	cg10837625	chr15:45428812	DUOX1	0.89	7.19	0.4	6.76e-12	Systemic lupus erythematosus;
CESC	cis	rs2276314	0.857	rs56230698	chr18:33628885	A/G	cg05985134	chr18:33552581	C18orf21	0.62	7.21	0.4	5.98e-12	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs854765	0.505	rs2955358	chr17:17946623	A/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.54	-7.2	-0.4	6.22e-12	Total body bone mineral density;
CESC	cis	rs5753618	0.504	rs9609329	chr22:31966313	A/C	cg13145458	chr22:31556086	RNF185	-0.5	-5.82	-0.34	1.7e-8	Colorectal cancer;
CESC	cis	rs17601876	0.814	rs11632903	chr15:51564341	C/T	cg19946085	chr15:51559439	CYP19A1	-0.32	-5.13	-0.3	5.67e-7	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
CESC	cis	rs644799	0.710	rs10831433	chr11:95519787	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.77	11.72	0.58	7.56e-26	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs921968	0.541	rs664514	chr2:219329819	A/G	cg02176678	chr2:219576539	TTLL4	0.5	8.91	0.48	8.53e-17	Mean corpuscular hemoglobin concentration;
CESC	cis	rs4132509	0.843	rs12034588	chr1:243784392	T/A	cg21452805	chr1:244014465	NA	0.46	5.07	0.3	7.49e-7	RR interval (heart rate);
CESC	cis	rs3820068	0.705	rs4645992	chr1:15849742	G/T	cg17385448	chr1:15911702	AGMAT	0.41	6.13	0.35	3.19e-9	Systolic blood pressure;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg18113596	chr7:57247912	LOC642006	0.39	6.83	0.39	5.92e-11	Fibrinogen levels;
CESC	cis	rs2439831	0.850	rs12442297	chr15:44168470	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.65	6.65	0.38	1.62e-10	Lung cancer in ever smokers;
CESC	cis	rs3748682	0.861	rs2291297	chr1:38272660	G/A	cg12658694	chr1:38397304	INPP5B	0.5	5.04	0.3	8.66e-7	Hypothyroidism;
CESC	cis	rs7267979	1.000	rs884613	chr20:25288505	C/T	cg08601574	chr20:25228251	PYGB	-0.36	-5.09	-0.3	6.75e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs9611565	0.559	rs132761	chr22:42004371	C/T	cg17376030	chr22:41985996	PMM1	-0.8	-8.91	-0.48	8.68e-17	Vitiligo;
CESC	cis	rs6860806	0.507	rs635620	chr5:131720263	A/G	cg18758796	chr5:131593413	PDLIM4	-0.41	-5.74	-0.33	2.61e-8	Breast cancer;
CESC	cis	rs8072100	0.713	rs4968228	chr17:45497548	T/C	cg08085267	chr17:45401833	C17orf57	-0.52	-6.6	-0.38	2.28e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs1003719	0.715	rs35199609	chr21:38510262	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-8.56	-0.47	9.46e-16	Eye color traits;
CESC	cis	rs514406	0.679	rs11585495	chr1:53244331	T/C	cg25767906	chr1:53392781	SCP2	0.53	7.72	0.43	2.46e-13	Monocyte count;
CESC	trans	rs10435719	0.805	rs13269417	chr8:11791962	C/T	cg15556689	chr8:8085844	FLJ10661	0.53	6.57	0.37	2.72e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
CESC	cis	rs9488822	0.676	rs13194714	chr6:116394819	T/A	cg18764771	chr6:116381957	FRK	0.23	5.67	0.33	3.77e-8	Cholesterol, total;LDL cholesterol;
CESC	cis	rs459571	0.834	rs379417	chr9:136890704	G/A	cg13789015	chr9:136890014	NCRNA00094	0.56	7.96	0.44	5.15e-14	Platelet distribution width;
CESC	cis	rs28498503	1.000	rs7238497	chr18:76660481	G/C	cg00806245	chr18:76673096	NA	-0.74	-6.15	-0.35	2.78e-9	Attention function in attention deficit hyperactive disorder;
CESC	trans	rs208520	0.690	rs2126120	chr6:66742754	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.96	12.2	0.6	1.84e-27	Exhaled nitric oxide output;
CESC	cis	rs9399137	0.507	rs7768278	chr6:135274957	T/C	cg24558204	chr6:135376177	HBS1L	0.72	9.69	0.51	3.35e-19	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	cis	rs3858526	0.584	rs10742809	chr11:5862532	G/T	cg05234568	chr11:5960015	NA	0.54	7.43	0.42	1.49e-12	DNA methylation (variation);
CESC	cis	rs17407555	0.518	rs16891234	chr4:9946163	A/G	cg11266682	chr4:10021025	SLC2A9	-0.58	-7.2	-0.4	6.41e-12	Schizophrenia (age at onset);
CESC	cis	rs1395	0.744	rs11679220	chr2:27476378	G/A	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.43	5.64	0.33	4.38e-8	Blood metabolite levels;
CESC	cis	rs1707322	0.721	rs10890337	chr1:46124527	C/T	cg05343316	chr1:45956843	TESK2	0.5	6.12	0.35	3.43e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs3126085	0.935	rs2291770	chr1:152179792	G/C	cg03465714	chr1:152285911	FLG	-0.43	-5.16	-0.3	4.81e-7	Atopic dermatitis;
CESC	trans	rs9391997	0.568	rs9328192	chr6:434364	C/T	cg18341491	chr13:38174258	POSTN	0.32	6.14	0.35	2.99e-9	Chronic lymphocytic leukemia;
CESC	cis	rs916888	0.610	rs199438	chr17:44791643	G/A	cg01570182	chr17:44337453	NA	0.66	8.94	0.48	6.86e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs7267979	1.000	rs6076345	chr20:25381895	T/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.88	-18.07	-0.74	4.03e-48	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs2455799	0.613	rs13080234	chr3:15852492	C/T	cg16303742	chr3:15540471	COLQ	-0.37	-5.72	-0.33	2.8e-8	Mean platelet volume;
CESC	cis	rs1691799	0.867	rs1168341	chr12:66759080	G/C	cg16791601	chr12:66731901	HELB	-0.79	-14.11	-0.65	4.25e-34	White blood cell count (basophil);
CESC	cis	rs9389248	0.690	rs1028314	chr6:135255710	A/C	cg24558204	chr6:135376177	HBS1L	-0.63	-8.81	-0.48	1.65e-16	High light scatter reticulocyte percentage of red cells;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg09914029	chr8:117859175	RAD21	0.41	6.16	0.35	2.67e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs1051424	0.642	rs115869798	chr17:57892829	T/A	cg02344993	chr17:57696989	CLTC	0.68	8.37	0.46	3.31e-15	Obesity-related traits;
CESC	cis	rs1728785	0.901	rs2862781	chr16:68639234	A/T	cg02972257	chr16:68554789	NA	-0.63	-7.01	-0.4	1.94e-11	Ulcerative colitis;
CESC	cis	rs704	0.585	rs1007398	chr17:26665648	A/G	cg10342447	chr17:26645325	TMEM97	-0.45	-6.29	-0.36	1.32e-9	Osteoprotegerin levels;
CESC	cis	rs12579753	0.719	rs4384447	chr12:82268069	G/C	cg21193143	chr12:82153300	PPFIA2	-0.34	-5.12	-0.3	5.77e-7	Resting heart rate;
CESC	cis	rs1348850	0.526	rs59972556	chr2:178399561	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.67	6.13	0.35	3.22e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs7615952	0.641	rs6805074	chr3:125772274	T/A	cg04553112	chr3:125709451	NA	-0.52	-5.47	-0.32	1.05e-7	Blood pressure (smoking interaction);
CESC	cis	rs17125944	0.615	rs7146179	chr14:53298853	A/G	cg00686598	chr14:53173677	PSMC6	-0.69	-6.02	-0.35	5.64e-9	Alzheimer's disease (late onset);
CESC	cis	rs300703	0.872	rs300752	chr2:209292	A/G	cg21211680	chr2:198530	NA	0.99	8.63	0.47	5.63e-16	Blood protein levels;
CESC	cis	rs9831754	0.704	rs9882111	chr3:78470746	A/G	cg06138941	chr3:78371609	NA	-0.51	-6.44	-0.37	5.69e-10	Calcium levels;
CESC	cis	rs12048904	0.619	rs10875347	chr1:101333737	T/C	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.64	7.49	0.42	1.03e-12	Multiple sclerosis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13852536	chr9:32567045	NDUFB6	-0.66	-7.66	-0.43	3.58e-13	Gut microbiome composition (summer);
CESC	cis	rs7618501	0.669	rs7634084	chr3:49949834	A/T	cg24110177	chr3:50126178	RBM5	-0.5	-7.08	-0.4	1.26e-11	Intelligence (multi-trait analysis);
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg08496016	chr9:99181722	ZNF367	0.49	6.92	0.39	3.38e-11	Systemic lupus erythematosus;
CESC	cis	rs2228479	0.681	rs11642428	chr16:89971909	A/T	cg06558623	chr16:89946397	TCF25	0.52	5.07	0.3	7.57e-7	Skin colour saturation;
CESC	cis	rs8072100	0.905	rs11651766	chr17:45574931	G/T	cg08085267	chr17:45401833	C17orf57	-0.47	-6.22	-0.36	1.94e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg25164226	chr22:47158357	TBC1D22A	-0.44	-6.43	-0.37	5.94e-10	Gambling;
CESC	cis	rs36051895	0.664	rs3780381	chr9:5114523	A/C	cg02405213	chr9:5042618	JAK2	-0.53	-6.33	-0.36	1.06e-9	Pediatric autoimmune diseases;
CESC	cis	rs727563	0.608	rs2076200	chr22:41985956	G/T	cg03806693	chr22:41940476	POLR3H	-1.16	-13.06	-0.63	1.99e-30	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs9311474	0.508	rs11720159	chr3:52617802	T/G	cg18337363	chr3:52569053	NT5DC2	0.3	5.58	0.32	6.09e-8	Electroencephalogram traits;
CESC	cis	rs4253772	0.551	rs9615936	chr22:46686328	C/G	cg24881330	chr22:46731750	TRMU	0.84	6.65	0.38	1.66e-10	LDL cholesterol;Cholesterol, total;
CESC	cis	rs701145	0.529	rs355759	chr3:154008078	G/C	cg16511985	chr3:153974050	SGEF	0.43	6.01	0.35	6.01e-9	Coronary artery disease;
CESC	cis	rs12142240	0.698	rs72677592	chr1:46818288	A/G	cg00530320	chr1:46809349	NSUN4	0.58	7.89	0.44	8.15e-14	Menopause (age at onset);
CESC	cis	rs6088580	0.634	rs11700221	chr20:32940320	T/C	cg06115741	chr20:33292138	TP53INP2	-0.44	-5.54	-0.32	7.16e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs7208859	0.573	rs73267872	chr17:29067207	T/C	cg14008862	chr17:28927542	LRRC37B2	0.65	5.21	0.3	3.78e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs853679	0.517	rs4713137	chr6:28083521	C/G	cg22143856	chr6:28129313	ZNF389	0.52	6.71	0.38	1.21e-10	Depression;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg01324437	chr2:98206175	ANKRD36B	-0.47	-6.32	-0.36	1.07e-9	Thyroid stimulating hormone;
CESC	cis	rs7998202	0.567	rs914019	chr13:113352911	A/G	cg02820901	chr13:113351484	ATP11A	0.54	5.38	0.31	1.64e-7	Glycated hemoglobin levels;
CESC	cis	rs4665809	1.000	rs6546728	chr2:26276531	G/C	cg04944784	chr2:26401820	FAM59B	-0.8	-8.93	-0.48	7.17e-17	Gut microbiome composition (summer);
CESC	cis	rs9549260	0.564	rs9577110	chr13:41271878	T/G	cg21288729	chr13:41239152	FOXO1	0.6	7.72	0.43	2.36e-13	Red blood cell count;
CESC	cis	rs8070740	0.947	rs3809842	chr17:5329199	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.54	6.53	0.37	3.32e-10	Menopause (age at onset);
CESC	cis	rs6460942	0.749	rs62448592	chr7:12435985	A/T	cg16278512	chr7:12443529	VWDE	-0.5	-5.08	-0.3	7.3e-7	Coronary artery disease;
CESC	cis	rs727505	0.954	rs2054586	chr7:124708414	C/T	cg23710748	chr7:124431027	NA	-0.39	-6.1	-0.35	3.77e-9	Lewy body disease;
CESC	cis	rs736408	0.774	rs4687551	chr3:52823448	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.42	-5.68	-0.33	3.59e-8	Bipolar disorder;
CESC	cis	rs4819052	0.851	rs7275874	chr21:46671223	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.75	9.92	0.52	6.18e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs11690935	0.921	rs7355523	chr2:172744421	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.96	-14.21	-0.66	1.81e-34	Schizophrenia;
CESC	cis	rs67311347	1.000	rs17078916	chr3:40445438	C/T	cg24209194	chr3:40518798	ZNF619	0.51	6.24	0.36	1.75e-9	Renal cell carcinoma;
CESC	cis	rs3126085	0.935	rs55942250	chr1:152251914	G/A	cg03465714	chr1:152285911	FLG	0.5	5.7	0.33	3.11e-8	Atopic dermatitis;
CESC	cis	rs873946	0.648	rs12782123	chr10:134554662	G/A	cg18305652	chr10:134549665	INPP5A	0.49	6.95	0.39	2.89e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs57506017	0.565	rs2043539	chr7:12253880	G/A	cg23422036	chr7:12250390	TMEM106B	0.39	5.21	0.3	3.77e-7	Neuroticism;
CESC	cis	rs35306767	0.855	rs11253499	chr10:944090	A/C	cg26597838	chr10:835615	NA	0.95	10.15	0.53	1.19e-20	Eosinophil percentage of granulocytes;
CESC	cis	rs2573652	1.000	rs12441080	chr15:100516968	A/G	cg09918751	chr15:100517450	ADAMTS17	0.41	7.93	0.44	6.13e-14	Height;
CESC	cis	rs9611565	0.546	rs2092274	chr22:42123737	A/G	cg06481639	chr22:41940642	POLR3H	0.63	6.51	0.37	3.68e-10	Vitiligo;
CESC	cis	rs6912958	0.781	rs9444512	chr6:88223397	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.55	-7.43	-0.42	1.46e-12	Monocyte percentage of white cells;
CESC	cis	rs10416265	0.527	rs7508599	chr19:33546512	A/T	cg17764715	chr19:33622953	WDR88	0.61	8.35	0.46	3.88e-15	Bone properties (heel);
CESC	cis	rs148387471	1	rs148387471	chr3:127057551	ATAG/A	cg27326032	chr3:127006922	NA	-0.45	-5.52	-0.32	8.19e-8	Interleukin-10 levels;Interleukin-13 levels;
CESC	cis	rs72781680	1.000	rs72796316	chr2:24132272	T/C	cg20701182	chr2:24300061	SF3B14	0.63	5.67	0.33	3.79e-8	Lymphocyte counts;
CESC	cis	rs4665809	0.793	rs6546715	chr2:26261520	G/A	cg04944784	chr2:26401820	FAM59B	-0.63	-7.17	-0.4	7.54e-12	Gut microbiome composition (summer);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg16321116	chr14:59655311	DAAM1	-0.47	-6.12	-0.35	3.31e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs2295499	0.754	rs35679952	chr4:2619709	G/A	cg08330972	chr4:2403930	ZFYVE28	0.34	5.46	0.32	1.1e-7	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
CESC	trans	rs7618501	0.602	rs2624816	chr3:50117312	T/G	cg21659725	chr3:3221576	CRBN	-0.51	-7.03	-0.4	1.7e-11	Intelligence (multi-trait analysis);
CESC	cis	rs72634258	0.945	rs12740409	chr1:8027830	A/C	cg00042356	chr1:8021962	PARK7	0.92	8.2	0.45	1.01e-14	Inflammatory bowel disease;
CESC	cis	rs3008870	1.000	rs2985795	chr1:67426223	A/G	cg02640540	chr1:67518911	SLC35D1	0.52	5.59	0.33	5.5e-8	Lymphocyte percentage of white cells;
CESC	cis	rs9788682	1.000	rs35212593	chr15:78831826	G/A	cg06917634	chr15:78832804	PSMA4	-0.55	-6.49	-0.37	4.15e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs965469	1.000	rs6051716	chr20:3267736	C/T	cg25506879	chr20:3388711	C20orf194	-0.58	-6.04	-0.35	5.18e-9	IFN-related cytopenia;
CESC	cis	rs9649213	0.593	rs1132971	chr7:97921533	A/G	cg08684580	chr7:98029266	BAIAP2L1	-0.34	-5.41	-0.32	1.44e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7412746	0.658	rs11589458	chr1:150792616	A/G	cg17724175	chr1:150552817	MCL1	0.42	6.33	0.36	1.06e-9	Melanoma;
CESC	cis	rs698833	0.828	rs6748528	chr2:44517752	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.44	5.5	0.32	8.85e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs7552404	0.924	rs1146581	chr1:76213024	T/G	cg03433033	chr1:76189801	ACADM	0.7	9.56	0.51	8.27e-19	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs9914988	0.943	rs2874253	chr17:27157863	A/T	cg20469991	chr17:27169893	C17orf63	-0.48	-5.25	-0.31	3.18e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CESC	cis	rs116095464	0.558	rs7708515	chr5:234989	C/G	cg22496380	chr5:211416	CCDC127	-0.75	-8.76	-0.47	2.36e-16	Breast cancer;
CESC	cis	rs4253772	0.530	rs9615980	chr22:46791143	A/T	cg00784671	chr22:46762841	CELSR1	-0.53	-5.07	-0.3	7.34e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs796364	0.512	rs1653290	chr2:201078165	A/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.53	5.37	0.31	1.74e-7	Schizophrenia;
CESC	cis	rs13095912	1.000	rs13072061	chr3:185326023	G/T	cg11274856	chr3:185301563	NA	0.36	5.81	0.34	1.83e-8	Systolic blood pressure;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11599612	chr6:151187337	MTHFD1L	-0.62	-7.18	-0.4	7.12e-12	Gut microbiome composition (summer);
CESC	cis	rs6582630	0.519	rs80226845	chr12:38528231	C/A	cg13010199	chr12:38710504	ALG10B	0.46	5.96	0.34	7.85e-9	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs597539	0.652	rs488363	chr11:68658298	C/G	cg18350739	chr11:68623251	NA	-0.43	-6.73	-0.38	1.05e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs763014	0.898	rs8050792	chr16:656033	T/C	cg07597022	chr16:675116	RAB40C	-0.3	-5.09	-0.3	6.85e-7	Height;
CESC	cis	rs8067545	0.611	rs2703788	chr17:20159686	T/C	cg13482628	chr17:19912719	NA	-0.43	-5.63	-0.33	4.59e-8	Schizophrenia;
CESC	cis	rs7507204	0.767	rs62125962	chr19:3410852	A/G	cg08380311	chr19:3435252	NFIC	0.63	6.72	0.38	1.1e-10	Height;
CESC	cis	rs748404	0.660	rs2467741	chr15:43742626	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.57	7.61	0.42	4.92e-13	Lung cancer;
CESC	cis	rs6032067	0.852	rs2868240	chr20:43874039	A/G	cg10761708	chr20:43804764	PI3	-0.45	-5.41	-0.32	1.41e-7	Blood protein levels;
CESC	cis	rs9611565	0.659	rs4822036	chr22:41936019	A/G	cg03806693	chr22:41940476	POLR3H	-1.23	-16.62	-0.71	5.48e-43	Vitiligo;
CESC	cis	rs2239547	0.657	rs3755803	chr3:52866157	C/G	cg11645453	chr3:52864694	ITIH4	0.36	6.5	0.37	3.98e-10	Schizophrenia;
CESC	cis	rs896854	0.812	rs12546365	chr8:95911477	T/C	cg16049864	chr8:95962084	TP53INP1	-0.68	-12.13	-0.6	3.08e-27	Type 2 diabetes;
CESC	cis	rs116988415	0.584	rs2269308	chr14:65244950	G/A	cg25083366	chr14:65239357	SPTB	0.71	5.23	0.31	3.44e-7	Daytime sleep phenotypes;
CESC	cis	rs1552244	1.000	rs6772315	chr3:10113644	G/A	cg08888203	chr3:10149979	C3orf24	0.53	6.72	0.38	1.11e-10	Alzheimer's disease;
CESC	cis	rs2836950	0.520	rs2836966	chr21:40637521	A/G	cg17971929	chr21:40555470	PSMG1	-0.54	-6.93	-0.39	3.25e-11	Menarche (age at onset);
CESC	cis	rs8072100	0.790	rs7222225	chr17:45693497	A/G	cg08085267	chr17:45401833	C17orf57	0.47	5.8	0.34	1.89e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs7077164	1.000	rs1227776	chr10:71580893	G/A	cg20696214	chr10:71583771	COL13A1	-0.46	-6.56	-0.37	2.74e-10	Non-alcoholic fatty liver disease histology (lobular);
CESC	cis	rs7605827	0.930	rs4668912	chr2:15610882	C/T	cg19274914	chr2:15703543	NA	0.35	6.13	0.35	3.19e-9	Educational attainment (years of education);
CESC	cis	rs7103648	0.669	rs10437655	chr11:47391948	G/A	cg20307385	chr11:47447363	PSMC3	0.84	12.4	0.61	3.62e-28	Diastolic blood pressure;Systolic blood pressure;
CESC	cis	rs2243480	0.803	rs55700941	chr7:65389800	T/A	cg18252515	chr7:66147081	NA	-1.18	-10.78	-0.55	1.08e-22	Diabetic kidney disease;
CESC	cis	rs4547160	1.000	rs4547160	chr12:63503650	A/C	cg26727693	chr12:63544175	AVPR1A	0.33	5.15	0.3	4.98e-7	Morning vs. evening chronotype;
CESC	cis	rs631288	0.557	rs6697092	chr1:146659277	C/G	cg25205988	chr1:146714368	CHD1L	1.04	6.66	0.38	1.58e-10	PR interval in Tripanosoma cruzi seropositivity;
CESC	cis	rs10504229	1.000	rs57378064	chr8:58169844	C/G	cg24829409	chr8:58192753	C8orf71	-0.62	-8.5	-0.46	1.41e-15	Developmental language disorder (linguistic errors);
CESC	cis	rs8112211	1.000	rs12611255	chr19:38815483	T/C	cg14299480	chr19:38876666	GGN	-0.42	-5.71	-0.33	2.98e-8	Blood protein levels;
CESC	cis	rs1801251	1.000	rs7587309	chr2:233705702	G/T	cg25237894	chr2:233734115	C2orf82	-0.46	-8.15	-0.45	1.43e-14	Coronary artery disease;
CESC	cis	rs703842	0.642	rs10876994	chr12:58064737	A/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.49	5.29	0.31	2.56e-7	Multiple sclerosis;
CESC	trans	rs9467711	0.523	rs9379853	chr6:26357635	A/G	cg06606381	chr12:133084897	FBRSL1	-0.76	-6.87	-0.39	4.66e-11	Autism spectrum disorder or schizophrenia;
CESC	cis	rs614367	1.000	rs614367	chr11:69328764	A/G	cg08353955	chr11:69289746	NA	0.49	5.39	0.31	1.58e-7	Breast cancer;Breast cancer (early onset);
CESC	cis	rs12819124	0.502	rs10875718	chr12:48411102	G/T	cg24011408	chr12:48396354	COL2A1	0.53	8.09	0.45	2.16e-14	Glycated hemoglobin levels;
CESC	cis	rs7615952	0.688	rs12485622	chr3:125710739	T/C	cg04553112	chr3:125709451	NA	-0.51	-5.59	-0.33	5.51e-8	Blood pressure (smoking interaction);
CESC	cis	rs926938	0.520	rs6660624	chr1:115272163	G/A	cg12756093	chr1:115239321	AMPD1	-0.52	-6.36	-0.36	8.77e-10	Autism;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14929913	chr10:1147979	WDR37	-0.65	-7.23	-0.41	5.21e-12	Gut microbiome composition (summer);
CESC	cis	rs6120849	0.754	rs6088682	chr20:33615702	A/C	cg06115741	chr20:33292138	TP53INP2	0.53	5.05	0.3	8.15e-7	Protein C levels;
CESC	cis	rs728616	0.558	rs7097080	chr10:82166700	A/G	cg05935833	chr10:81318306	SFTPA2	-0.37	-5.14	-0.3	5.39e-7	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs4950322	0.634	rs7542951	chr1:146812058	C/T	cg22381352	chr1:146742008	CHD1L	-0.47	-5.05	-0.3	8.2e-7	Protein quantitative trait loci;
CESC	cis	rs4604732	0.631	rs74154673	chr1:247625629	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.57	7.17	0.4	7.39e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs7618915	0.547	rs3774365	chr3:52642487	T/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.3	5.26	0.31	3e-7	Bipolar disorder;
CESC	cis	rs2842992	0.513	rs7759086	chr6:160193853	A/G	cg26839252	chr6:160211577	TCP1;MRPL18	0.49	6.14	0.35	2.95e-9	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs704795	0.902	rs11887784	chr2:27679919	A/G	cg22903471	chr2:27725779	GCKR	-0.55	-7.77	-0.43	1.69e-13	Menopause (age at onset);
CESC	cis	rs1552244	0.751	rs12715665	chr3:10021601	C/T	cg00149659	chr3:10157352	C3orf10	0.71	8.29	0.45	5.85e-15	Alzheimer's disease;
CESC	cis	rs780096	0.526	rs780112	chr2:27665361	C/G	cg22903471	chr2:27725779	GCKR	-0.52	-7.39	-0.41	1.88e-12	Total body bone mineral density;
CESC	cis	rs921968	0.541	rs1863704	chr2:219562675	C/T	cg02176678	chr2:219576539	TTLL4	-0.52	-8.75	-0.47	2.57e-16	Mean corpuscular hemoglobin concentration;
CESC	cis	rs9926296	0.605	rs12709094	chr16:89853017	A/G	cg07648498	chr16:89883185	FANCA	0.43	5.31	0.31	2.38e-7	Vitiligo;
CESC	cis	rs9549260	0.534	rs4943809	chr13:41297404	T/A	cg21288729	chr13:41239152	FOXO1	0.57	5.15	0.3	5.1e-7	Red blood cell count;
CESC	cis	rs4268898	0.965	rs4665673	chr2:24459737	A/T	cg20701182	chr2:24300061	SF3B14	-0.42	-5.15	-0.3	5.21e-7	Asthma;
CESC	cis	rs12681288	0.550	rs4410933	chr8:959581	A/G	cg15309053	chr8:964076	NA	0.51	8.94	0.48	6.89e-17	Schizophrenia;
CESC	cis	rs4835473	0.897	rs7682128	chr4:144630103	A/G	cg25736465	chr4:144833511	NA	0.4	6.17	0.35	2.59e-9	Immature fraction of reticulocytes;
CESC	cis	rs7945705	0.747	rs11042150	chr11:9010819	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.39	-6.53	-0.37	3.3e-10	Hemoglobin concentration;
CESC	cis	rs9926296	0.605	rs12709094	chr16:89853017	A/G	cg04287289	chr16:89883240	FANCA	0.89	15.03	0.68	2.34e-37	Vitiligo;
CESC	cis	rs9362426	1.000	rs406900	chr6:88085447	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.47	5.93	0.34	9.21e-9	Depressive episodes in bipolar disorder;
CESC	trans	rs11072089	0.892	rs11072093	chr15:69669978	C/T	cg10917153	chr15:42448786	PLA2G4F	0.42	6.05	0.35	4.79e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs7666738	0.830	rs7657490	chr4:99043973	C/T	cg03676636	chr4:99064102	C4orf37	0.33	5.12	0.3	5.93e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1691799	0.899	rs1060724	chr12:66740444	T/C	cg16791601	chr12:66731901	HELB	-0.75	-12.95	-0.62	4.83e-30	White blood cell count (basophil);
CESC	cis	rs4689388	0.926	rs6446480	chr4:6295565	C/T	cg25554036	chr4:6271136	WFS1	0.5	8.13	0.45	1.66e-14	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs35110281	0.744	rs8131027	chr21:45104908	G/C	cg04455712	chr21:45112962	RRP1B	0.46	7.28	0.41	3.69e-12	Mean corpuscular volume;
CESC	cis	rs9916302	0.904	rs2024073	chr17:37471330	T/G	cg19468946	chr17:37922297	IKZF3	0.4	5.27	0.31	2.83e-7	Glomerular filtration rate (creatinine);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20471045	chr19:49568214	NTF4	0.61	7.01	0.4	2.01e-11	Gut microbiome composition (summer);
CESC	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.46	-6.14	-0.35	2.93e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7618915	0.547	rs3755806	chr3:52643685	C/T	cg17372223	chr3:52568218	NT5DC2	-0.41	-6.02	-0.35	5.76e-9	Bipolar disorder;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg21484680	chr2:27593328	EIF2B4;SNX17	-0.5	-6.6	-0.38	2.19e-10	Fibrinogen levels;
CESC	cis	rs7845219	0.544	rs4735332	chr8:95923660	C/T	cg09323728	chr8:95962352	TP53INP1	-0.34	-6.77	-0.38	8.44e-11	Type 2 diabetes;
CESC	cis	rs2806561	0.765	rs682766	chr1:23516397	C/G	cg12483005	chr1:23474871	LUZP1	0.38	6.0	0.35	6.44e-9	Height;
CESC	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg03188948	chr7:1209495	NA	0.72	6.95	0.39	2.83e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2191566	0.664	rs62115482	chr19:44554083	C/A	cg20607764	chr19:44506953	ZNF230	-0.44	-5.64	-0.33	4.34e-8	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs8141529	0.732	rs5762784	chr22:29171298	C/T	cg02153584	chr22:29168773	CCDC117	0.7	10.05	0.53	2.43e-20	Lymphocyte counts;
CESC	cis	rs2836974	0.897	rs35123057	chr21:40711689	C/T	cg11644478	chr21:40555479	PSMG1	0.95	14.26	0.66	1.25e-34	Cognitive function;
CESC	cis	rs7662987	0.517	rs1311617	chr4:100012425	T/G	cg12011299	chr4:100065546	ADH4	0.61	6.71	0.38	1.17e-10	Smoking initiation;
CESC	cis	rs9715521	0.589	rs11726451	chr4:59852381	A/C	cg11281224	chr4:60001000	NA	-0.4	-5.35	-0.31	1.9e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs2735413	0.802	rs5008070	chr16:78096404	T/C	cg04733911	chr16:78082701	NA	0.47	7.32	0.41	3.01e-12	Systolic blood pressure (alcohol consumption interaction);
CESC	cis	rs59918340	0.764	rs4961338	chr8:142230192	C/T	cg16341495	chr8:142228727	SLC45A4	0.45	5.5	0.32	8.72e-8	Immature fraction of reticulocytes;
CESC	cis	rs7178572	0.568	rs12907847	chr15:77493174	C/T	cg22256960	chr15:77711686	NA	-0.53	-6.69	-0.38	1.33e-10	Type 2 diabetes;
CESC	trans	rs1814175	0.527	rs7128827	chr11:49665644	C/T	cg15704280	chr7:45808275	SEPT13	0.88	11.18	0.57	5.18e-24	Height;
CESC	cis	rs35110281	0.565	rs7278003	chr21:44966069	T/C	cg21573476	chr21:45109991	RRP1B	-0.4	-5.44	-0.32	1.2e-7	Mean corpuscular volume;
CESC	cis	rs2836633	0.895	rs2836598	chr21:40024758	C/G	cg12884169	chr21:40033163	ERG	0.35	5.44	0.32	1.22e-7	Coronary artery disease;
CESC	cis	rs2625529	0.730	rs2957368	chr15:72329906	C/T	cg16672083	chr15:72433130	SENP8	-0.43	-6.6	-0.38	2.24e-10	Red blood cell count;
CESC	cis	rs7666738	0.830	rs13112037	chr4:98976986	A/T	cg03676636	chr4:99064102	C4orf37	0.34	5.2	0.3	3.93e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10887741	0.690	rs12772633	chr10:89442492	G/A	cg13926569	chr10:89418898	PAPSS2	0.36	5.43	0.32	1.29e-7	Exercise (leisure time);
CESC	cis	rs1008375	1.000	rs2058337	chr4:17678649	C/T	cg02297831	chr4:17616191	MED28	0.45	5.84	0.34	1.51e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs2842992	0.789	rs2475566	chr6:160148741	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.74	9.21	0.49	1.03e-17	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs559928	0.606	rs78038516	chr11:63978067	C/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.62	5.61	0.33	5.1e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CESC	cis	rs2832191	0.791	rs57721945	chr21:30498744	T/C	cg08807101	chr21:30365312	RNF160	-0.72	-9.88	-0.52	8.5e-20	Dental caries;
CESC	cis	rs9549367	0.789	rs12584813	chr13:113895443	C/G	cg18105134	chr13:113819100	PROZ	-0.67	-8.06	-0.44	2.71e-14	Platelet distribution width;
CESC	cis	rs1008375	0.966	rs2315553	chr4:17627332	T/C	cg02297831	chr4:17616191	MED28	0.6	7.75	0.43	1.93e-13	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs959260	1.000	rs2117562	chr17:73369000	C/T	cg12999837	chr17:73267436	MIF4GD	-0.47	-5.45	-0.32	1.17e-7	Systemic lupus erythematosus;
CESC	cis	rs13108904	0.557	rs1250098	chr4:1238256	A/T	cg02475777	chr4:1388615	CRIPAK	-0.47	-6.15	-0.35	2.9e-9	Obesity-related traits;
CESC	trans	rs11098499	0.863	rs10030660	chr4:120436704	G/A	cg25214090	chr10:38739885	LOC399744	0.7	9.5	0.5	1.34e-18	Corneal astigmatism;
CESC	cis	rs1018836	0.851	rs2023624	chr8:91618874	T/C	cg16814680	chr8:91681699	NA	-0.77	-11.99	-0.59	9.6e-27	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs6502050	0.835	rs7212441	chr17:80080047	T/G	cg11859384	chr17:80120422	CCDC57	0.38	5.15	0.3	5.1e-7	Life satisfaction;
CESC	cis	rs7552404	0.765	rs211717	chr1:76106969	G/A	cg03433033	chr1:76189801	ACADM	-0.67	-7.91	-0.44	7.05e-14	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs832540	0.512	rs33320	chr5:56206529	C/T	cg12311346	chr5:56204834	C5orf35	-0.5	-6.2	-0.36	2.11e-9	Coronary artery disease;
CESC	cis	rs6582630	0.638	rs35864536	chr12:38472255	T/A	cg26384229	chr12:38710491	ALG10B	-0.42	-5.52	-0.32	8.27e-8	Drug-induced liver injury (flucloxacillin);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18851521	chr18:268131	THOC1	0.59	7.21	0.4	5.69e-12	Gut microbiome composition (summer);
CESC	cis	rs56399783	0.901	rs17132741	chr7:2868997	C/T	cg19731401	chr7:2775893	GNA12	-0.59	-5.52	-0.32	7.9e-8	Childhood ear infection;
CESC	cis	rs1499972	0.941	rs62264816	chr3:117666232	C/G	cg07612923	chr3:117604196	NA	0.89	7.41	0.41	1.71e-12	Schizophrenia;
CESC	cis	rs71403859	0.502	rs34380814	chr16:71488175	C/T	cg08717414	chr16:71523259	ZNF19	-0.78	-8.36	-0.46	3.54e-15	Post bronchodilator FEV1;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg14094447	chr9:74383399	TMEM2	-0.46	-6.19	-0.36	2.31e-9	Fibrinogen levels;
CESC	cis	rs3008870	0.785	rs10889651	chr1:67463513	A/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.65	-8.58	-0.47	7.92e-16	Lymphocyte percentage of white cells;
CESC	cis	rs2637266	0.655	rs10824436	chr10:78457848	T/C	cg18941641	chr10:78392320	NA	0.39	6.88	0.39	4.26e-11	Pulmonary function;
CESC	cis	rs9976767	0.608	rs11909987	chr21:43822402	C/A	cg23042151	chr21:43824109	UBASH3A	-0.32	-6.01	-0.35	5.98e-9	Type 1 diabetes;
CESC	cis	rs9660180	1.000	rs9660180	chr1:1723031	G/A	cg17747265	chr1:1875780	NA	-0.58	-9.33	-0.5	4.41e-18	Body mass index;
CESC	cis	rs3785574	0.962	rs2584621	chr17:61912436	G/A	cg06873352	chr17:61820015	STRADA	0.47	6.81	0.39	6.42e-11	Height;
CESC	cis	rs17711722	0.522	rs6957759	chr7:65271785	A/G	cg04775059	chr7:64541387	NA	0.44	5.52	0.32	8.23e-8	Calcium levels;
CESC	cis	rs4713118	0.621	rs9368548	chr6:28034737	A/G	cg20151795	chr6:28129481	ZNF389	0.43	5.36	0.31	1.85e-7	Parkinson's disease;
CESC	cis	rs7666738	0.830	rs28867388	chr4:98962794	A/T	cg03676636	chr4:99064102	C4orf37	0.33	5.14	0.3	5.39e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs826838	0.935	rs11183940	chr12:38851642	A/G	cg26384229	chr12:38710491	ALG10B	0.83	14.57	0.67	1.05e-35	Heart rate;
CESC	cis	rs9457247	0.765	rs3752520	chr6:167436159	T/C	cg07741184	chr6:167504864	NA	0.35	6.29	0.36	1.31e-9	Crohn's disease;
CESC	cis	rs2625529	0.652	rs2899775	chr15:72268354	C/T	cg16672083	chr15:72433130	SENP8	0.46	6.81	0.39	6.7e-11	Red blood cell count;
CESC	cis	rs1862618	0.671	rs72644088	chr5:56241019	G/A	cg22800045	chr5:56110881	MAP3K1	-0.59	-7.41	-0.41	1.65e-12	Initial pursuit acceleration;
CESC	cis	rs2625529	0.526	rs10851850	chr15:72486509	A/G	cg16672083	chr15:72433130	SENP8	0.41	6.3	0.36	1.23e-9	Red blood cell count;
CESC	cis	rs12950390	0.893	rs72831644	chr17:45824391	T/C	cg00777063	chr17:45855553	NA	-0.42	-6.16	-0.35	2.64e-9	IgG glycosylation;
CESC	cis	rs3981351	0.797	rs61866462	chr10:115464690	C/T	cg24846397	chr10:115438155	CASP7	-0.34	-5.09	-0.3	6.93e-7	Obesity-related traits;
CESC	cis	rs75064307	0.834	rs4588370	chr3:108114050	G/A	cg03329597	chr3:108125523	MYH15	0.51	5.77	0.33	2.17e-8	Intelligence (multi-trait analysis);
CESC	cis	rs11122272	0.735	rs2808603	chr1:231537738	T/C	cg06096015	chr1:231504339	EGLN1	0.43	6.08	0.35	4.07e-9	Hemoglobin concentration;
CESC	cis	rs11958404	1.000	rs72816523	chr5:157403168	G/C	cg05962755	chr5:157440814	NA	0.58	6.39	0.37	7.58e-10	IgG glycosylation;
CESC	cis	rs9300255	0.663	rs7953929	chr12:123758235	C/G	cg00376283	chr12:123451042	ABCB9	0.62	6.82	0.39	6.1e-11	Neutrophil percentage of white cells;
CESC	cis	rs34330	0.562	rs17212236	chr12:12855483	G/C	cg04607235	chr12:12878440	APOLD1	-0.84	-9.03	-0.49	3.59e-17	Systemic lupus erythematosus;
CESC	cis	rs11098499	0.754	rs10212775	chr4:120239244	G/C	cg09307838	chr4:120376055	NA	0.79	10.77	0.55	1.17e-22	Corneal astigmatism;
CESC	cis	rs62408225	1.000	rs55771973	chr6:90981319	T/G	cg06866423	chr6:90926672	BACH2	0.43	5.15	0.3	5.08e-7	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs2742234	0.541	rs10899786	chr10:43744583	G/A	cg07801480	chr10:43725741	RASGEF1A	-0.41	-5.22	-0.31	3.61e-7	Hirschsprung disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.56	-6.22	-0.36	1.97e-9	Gut microbiome composition (summer);
CESC	cis	rs8060686	0.641	rs78537727	chr16:68120606	A/G	cg26727032	chr16:67993705	SLC12A4	-0.54	-6.05	-0.35	4.92e-9	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs6460942	0.915	rs17541242	chr7:12459068	A/G	cg02935154	chr7:12443704	VWDE	-0.58	-6.25	-0.36	1.67e-9	Coronary artery disease;
CESC	cis	rs1881797	1.000	rs68059491	chr1:247683070	C/T	cg05639522	chr1:247681581	NA	0.5	6.36	0.36	8.64e-10	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs2637266	0.875	rs2395409	chr10:78381004	A/G	cg18941641	chr10:78392320	NA	0.4	7.49	0.42	1.03e-12	Pulmonary function;
CESC	cis	rs919433	0.783	rs788014	chr2:198228997	G/A	cg10820045	chr2:198174542	NA	0.4	5.83	0.34	1.57e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs733175	0.855	rs10018666	chr4:10004805	C/T	cg00071950	chr4:10020882	SLC2A9	0.57	6.75	0.38	9.47e-11	Psychosis and Alzheimer's disease;
CESC	cis	rs9621305	0.502	rs2295242	chr22:31957752	G/A	cg25791279	chr22:32026902	PISD	0.55	5.55	0.32	6.84e-8	Intelligence;
CESC	cis	rs11155671	0.530	rs9371223	chr6:150214806	T/C	cg09699651	chr6:150184138	LRP11	0.54	7.44	0.42	1.38e-12	Testicular germ cell tumor;
CESC	cis	rs7552404	0.696	rs67487205	chr1:76373756	T/C	cg22875332	chr1:76189707	ACADM	0.59	5.73	0.33	2.74e-8	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs7394190	0.748	rs12572278	chr10:75504513	C/A	cg07699608	chr10:75541558	CHCHD1	0.64	5.21	0.3	3.8e-7	Incident atrial fibrillation;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg21518056	chr19:33183187	NUDT19	-0.57	-7.05	-0.4	1.54e-11	Ulcerative colitis;
CESC	cis	rs365132	1.000	rs2055619	chr5:176415964	A/G	cg16309518	chr5:176445507	NA	-0.37	-5.35	-0.31	1.9e-7	Menarche and menopause (age at onset);Menopause (age at onset);
CESC	cis	rs1559088	0.573	rs1270591	chr19:33622942	C/T	cg03563238	chr19:33554763	RHPN2	0.29	5.28	0.31	2.67e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs870825	0.616	rs55685500	chr4:185614810	G/A	cg04058563	chr4:185651563	MLF1IP	0.64	6.48	0.37	4.51e-10	Blood protein levels;
CESC	cis	rs8067354	0.645	rs9901606	chr17:57811407	A/C	cg02344993	chr17:57696989	CLTC	0.68	8.08	0.44	2.34e-14	Hemoglobin concentration;
CESC	cis	rs11098499	0.697	rs4373140	chr4:120307698	A/G	cg09307838	chr4:120376055	NA	0.92	12.66	0.61	4.96e-29	Corneal astigmatism;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23868848	chr8:128806661	PVT1	0.56	6.01	0.35	5.97e-9	Gut microbiome composition (summer);
CESC	cis	rs7301826	0.651	rs10773824	chr12:131298851	G/A	cg11011512	chr12:131303247	STX2	0.46	5.57	0.32	6.37e-8	Plasma plasminogen activator levels;
CESC	cis	rs4148883	0.651	rs4147547	chr4:100127311	G/T	cg13256891	chr4:100009986	ADH5	0.5	6.47	0.37	4.68e-10	Alcohol dependence;
CESC	cis	rs4642101	0.662	rs9874893	chr3:12833079	C/G	cg24848339	chr3:12840334	CAND2	0.38	5.75	0.33	2.52e-8	QRS complex (12-leadsum);
CESC	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg12419862	chr22:24373484	LOC391322	0.61	8.22	0.45	9.07e-15	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs10832963	1.000	rs10832956	chr11:18645668	A/G	cg09201001	chr11:18656081	SPTY2D1	0.83	12.89	0.62	7.9e-30	Breast cancer;
CESC	cis	rs1862618	0.671	rs906631	chr5:56245803	C/G	cg24531977	chr5:56204891	C5orf35	0.7	9.44	0.5	2.05e-18	Initial pursuit acceleration;
CESC	cis	rs3733585	0.648	rs28513781	chr4:9959334	G/C	cg02734326	chr4:10020555	SLC2A9	-0.43	-6.01	-0.35	6.1e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs2066819	1.000	rs41423244	chr12:56693520	A/C	cg26714650	chr12:56694279	CS	1.52	10.3	0.53	3.81e-21	Psoriasis vulgaris;
CESC	cis	rs7666738	0.830	rs17550735	chr4:99014076	T/G	cg18180107	chr4:99064573	C4orf37	0.4	5.3	0.31	2.48e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10504229	0.679	rs1596142	chr8:58032406	G/A	cg22535103	chr8:58192502	C8orf71	-0.61	-6.86	-0.39	4.87e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs6570726	0.791	rs441290	chr6:145883183	A/G	cg23711669	chr6:146136114	FBXO30	0.87	12.82	0.62	1.32e-29	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4555082	0.957	rs2816622	chr14:105733114	T/C	cg06808227	chr14:105710500	BRF1	-0.58	-7.07	-0.4	1.35e-11	Mean platelet volume;Platelet distribution width;
CESC	cis	rs9549367	0.826	rs1885688	chr13:113894236	G/T	cg00898013	chr13:113819073	PROZ	-0.53	-7.52	-0.42	8.66e-13	Platelet distribution width;
CESC	trans	rs4942242	0.663	rs1390371	chr13:44211727	A/G	cg19169023	chr15:41853346	TYRO3	0.58	7.38	0.41	1.99e-12	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs4780401	0.609	rs4781143	chr16:11809721	T/G	cg01061890	chr16:11836724	TXNDC11	-0.56	-7.59	-0.42	5.37e-13	Rheumatoid arthritis;
CESC	cis	rs13191362	0.935	rs66635391	chr6:162964577	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.81	7.71	0.43	2.49e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs1218582	0.804	rs4845398	chr1:154859038	G/C	cg06221963	chr1:154839813	KCNN3	-0.66	-11.44	-0.58	6.67e-25	Prostate cancer;
CESC	cis	rs807669	0.903	rs2800974	chr22:19168087	C/T	cg02655711	chr22:19163373	SLC25A1	0.96	14.87	0.67	9.02e-37	Metabolite levels;
CESC	trans	rs11098499	0.954	rs71614438	chr4:120371252	G/A	cg25214090	chr10:38739885	LOC399744	0.7	9.92	0.52	6.5e-20	Corneal astigmatism;
CESC	cis	rs9611565	0.659	rs116959331	chr22:41932774	A/G	cg06634786	chr22:41940651	POLR3H	-0.64	-6.69	-0.38	1.3e-10	Vitiligo;
CESC	cis	rs78889164	1.000	rs60463402	chr19:33855841	C/T	cg02272751	chr19:33882848	PEPD	-0.51	-6.62	-0.38	2.02e-10	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg17101226	chr11:64794859	SNX15	-0.47	-6.26	-0.36	1.53e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs875971	0.862	rs778697	chr7:65870426	G/A	cg19163074	chr7:65112434	INTS4L2	-0.41	-5.11	-0.3	6.29e-7	Aortic root size;
CESC	cis	rs8028182	0.636	rs8023815	chr15:75814704	G/A	cg20655648	chr15:75932815	IMP3	0.48	5.9	0.34	1.08e-8	Sudden cardiac arrest;
CESC	trans	rs7246657	0.891	rs7257495	chr19:37823876	C/G	cg24637308	chr11:6592297	DNHD1	0.53	6.24	0.36	1.74e-9	Coronary artery calcification;
CESC	cis	rs10256972	0.900	rs4388364	chr7:1033045	T/G	cg23978390	chr7:1156363	C7orf50	0.44	5.81	0.34	1.77e-8	Longevity;Endometriosis;
CESC	cis	rs826838	0.967	rs826870	chr12:39120250	G/A	cg26384229	chr12:38710491	ALG10B	-0.67	-11.02	-0.56	1.72e-23	Heart rate;
CESC	cis	rs763014	0.931	rs59476302	chr16:629006	C/T	cg00908189	chr16:619842	PIGQ	0.67	9.39	0.5	2.78e-18	Height;
CESC	cis	rs12478296	1.000	rs55814222	chr2:243041166	C/T	cg06360820	chr2:242988706	NA	-0.66	-7.52	-0.42	8.51e-13	Obesity-related traits;
CESC	cis	rs9815354	0.767	rs17281609	chr3:41833432	G/A	cg03022575	chr3:42003672	ULK4	0.7	6.04	0.35	5.26e-9	Pulse pressure;Diastolic blood pressure;
CESC	trans	rs17057718	1.000	rs12486855	chr3:57125864	A/G	cg04869497	chr17:20059225	CYTSB	-0.56	-5.99	-0.35	6.63e-9	Cerebrospinal fluid biomarker levels;
CESC	cis	rs1552244	1.000	rs9820598	chr3:10117912	C/G	cg00149659	chr3:10157352	C3orf10	0.73	8.89	0.48	9.97e-17	Alzheimer's disease;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg24489237	chr1:164529170	PBX1	-0.42	-6.23	-0.36	1.78e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs9811920	0.609	rs7636447	chr3:99612677	G/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.64	10.11	0.53	1.53e-20	Axial length;
CESC	cis	rs736408	0.505	rs2083180	chr3:52668119	G/T	cg18404041	chr3:52824283	ITIH1	-0.38	-6.55	-0.37	2.95e-10	Bipolar disorder;
CESC	cis	rs8114671	0.527	rs2295352	chr20:33320055	C/G	cg08999081	chr20:33150536	PIGU	-0.38	-5.33	-0.31	2.05e-7	Height;
CESC	cis	rs2243480	0.708	rs781141	chr7:65438553	A/G	cg18252515	chr7:66147081	NA	-1.06	-10.21	-0.53	7.51e-21	Diabetic kidney disease;
CESC	cis	rs6964587	1.000	rs13231238	chr7:91653851	T/G	cg17063962	chr7:91808500	NA	0.58	8.02	0.44	3.36e-14	Breast cancer;
CESC	cis	rs57786342	0.539	rs4902652	chr14:69280309	A/G	cg03189333	chr14:69283534	NA	0.45	5.17	0.3	4.53e-7	Macrophage inflammatory protein 1a levels;
CESC	cis	rs367615	0.552	rs3828603	chr5:108712068	G/C	cg17395555	chr5:108820864	NA	-0.45	-7.5	-0.42	9.87e-13	Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs4713118	0.662	rs9357060	chr6:28024486	C/G	cg18032046	chr6:28092343	ZSCAN16	-0.52	-6.03	-0.35	5.5e-9	Parkinson's disease;
CESC	cis	rs7208859	0.623	rs9894709	chr17:29078454	G/A	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.91e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs10504229	1.000	rs77120900	chr8:58170368	C/T	cg24829409	chr8:58192753	C8orf71	-0.76	-9.92	-0.52	6.14e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs11098499	0.954	rs10006706	chr4:120409152	A/G	cg09160332	chr4:120329925	NA	-0.39	-5.18	-0.3	4.35e-7	Corneal astigmatism;
CESC	cis	rs7786877	0.582	rs2075674	chr7:100225031	G/A	cg20848291	chr7:100343083	ZAN	-0.67	-7.01	-0.4	1.96e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs8177253	1.000	rs8177271	chr3:133482230	G/A	cg01448562	chr3:133502909	NA	-0.43	-5.94	-0.34	8.79e-9	Iron status biomarkers;
CESC	cis	rs4713675	0.584	rs3818527	chr6:33661035	A/G	cg14003231	chr6:33640908	ITPR3	-0.32	-5.55	-0.32	6.98e-8	Plateletcrit;
CESC	trans	rs116095464	0.558	rs56081398	chr5:247318	C/T	cg00938859	chr5:1591904	SDHAP3	0.71	6.69	0.38	1.29e-10	Breast cancer;
CESC	cis	rs17384381	0.953	rs12120551	chr1:85810903	T/C	cg16011679	chr1:85725395	C1orf52	0.8	8.2	0.45	1.03e-14	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4713118	0.662	rs149900	chr6:28014597	C/T	cg23161317	chr6:28129485	ZNF389	0.49	5.88	0.34	1.26e-8	Parkinson's disease;
CESC	cis	rs7635838	0.892	rs2880897	chr3:11494544	A/G	cg00170343	chr3:11313890	ATG7	0.46	6.18	0.35	2.46e-9	HDL cholesterol;
CESC	cis	rs722599	0.683	rs7142898	chr14:75254310	A/T	cg11812906	chr14:75593930	NEK9	0.45	5.45	0.32	1.17e-7	IgG glycosylation;
CESC	cis	rs9649213	0.574	rs3801257	chr7:97991792	A/G	cg00277769	chr7:97922759	BAIAP2L1	-0.33	-5.55	-0.32	7.08e-8	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18265147	chr1:9256671	NA	0.59	6.2	0.36	2.17e-9	Gut microbiome composition (summer);
CESC	cis	rs7811142	0.830	rs73401451	chr7:99981895	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.7	6.19	0.36	2.33e-9	Platelet count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07967114	chr12:94915694	NA	-0.56	-6.63	-0.38	1.91e-10	Gut microbiome composition (summer);
CESC	cis	rs595982	0.559	rs17272680	chr19:49364511	A/G	cg15549821	chr19:49342101	PLEKHA4	0.68	8.1	0.45	2.04e-14	Red cell distribution width;
CESC	cis	rs8002861	0.875	rs12869697	chr13:44439169	T/C	cg14210620	chr13:44453864	C13orf31;CCDC122	-0.45	-5.62	-0.33	4.93e-8	Leprosy;
CESC	cis	rs688020	1.000	rs673500	chr7:4229445	C/G	cg02004499	chr7:4244250	SDK1	-0.39	-5.43	-0.32	1.24e-7	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg04441191	chr3:48130393	MAP4	-0.46	-6.22	-0.36	1.91e-9	Fibrinogen levels;
CESC	cis	rs2734839	0.964	rs2734838	chr11:113286501	A/G	cg14159747	chr11:113255604	NA	0.29	5.13	0.3	5.48e-7	Information processing speed;
CESC	cis	rs9649213	0.593	rs34776142	chr7:97899873	C/T	cg21770322	chr7:97807741	LMTK2	0.58	8.5	0.46	1.36e-15	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs1799949	0.896	rs35908185	chr17:41255111	A/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.45	6.3	0.36	1.21e-9	Menopause (age at onset);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg16754643	chr12:133518353	ZNF605	0.6	8.03	0.44	3.1e-14	Fibrinogen levels;
CESC	cis	rs6582630	0.555	rs6582503	chr12:38557886	A/C	cg26384229	chr12:38710491	ALG10B	0.76	11.63	0.58	1.62e-25	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs8031584	0.958	rs34294266	chr15:31246840	A/G	cg14829155	chr15:31115871	NA	-0.72	-9.67	-0.51	3.76e-19	Huntington's disease progression;
CESC	cis	rs3105593	0.605	rs3131562	chr15:50772479	C/T	cg08437265	chr15:50716283	USP8	0.48	6.34	0.36	9.58e-10	QT interval;
CESC	cis	rs72945132	0.678	rs12786421	chr11:70235314	G/C	cg00319359	chr11:70116639	PPFIA1	0.71	6.66	0.38	1.6e-10	Coronary artery disease;
CESC	cis	rs7568498	0.517	rs197261	chr2:161904823	A/G	cg08807892	chr2:162101083	NA	-0.54	-5.79	-0.33	2.03e-8	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);
CESC	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg09664259	chr3:156544070	LEKR1	0.49	6.05	0.35	4.82e-9	Myopia (pathological);
CESC	cis	rs7412746	0.611	rs4970984	chr1:150887377	T/C	cg04414720	chr1:150670196	GOLPH3L	0.45	5.96	0.34	8.13e-9	Melanoma;
CESC	cis	rs1559088	0.803	rs10405770	chr19:33616549	C/T	cg17764715	chr19:33622953	WDR88	0.45	5.85	0.34	1.45e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs6460942	0.514	rs118124486	chr7:12470381	T/G	cg02935154	chr7:12443704	VWDE	-0.5	-7.52	-0.42	8.35e-13	Coronary artery disease;
CESC	cis	rs11642862	0.901	rs76345698	chr16:30946165	G/A	cg02466173	chr16:30829666	NA	-0.57	-5.21	-0.3	3.81e-7	Tonsillectomy;
CESC	cis	rs6541297	0.938	rs1555289	chr1:230292499	C/T	cg05784532	chr1:230284198	GALNT2	-0.49	-5.51	-0.32	8.4e-8	Coronary artery disease;
CESC	cis	rs7666738	1.000	rs35066600	chr4:98991066	C/A	cg05340658	chr4:99064831	C4orf37	0.66	9.01	0.48	4.1e-17	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1050631	1.000	rs3110564	chr18:33701589	C/T	cg25426722	chr18:33708991	SLC39A6;ELP2	-0.43	-5.74	-0.33	2.54e-8	Esophageal squamous cell cancer (length of survival);
CESC	trans	rs1667255	0.830	rs2034404	chr18:29156302	A/G	cg16010370	chr3:53290200	TKT	0.43	5.99	0.35	6.67e-9	Retinol levels;
CESC	cis	rs4979906	1.000	rs4979907	chr10:79451969	C/A	cg07817648	chr10:79422355	NA	-0.59	-6.29	-0.36	1.28e-9	Mortality in heart failure;
CESC	cis	rs863345	0.604	rs10908651	chr1:158451272	A/C	cg12129480	chr1:158549410	OR10X1	0.34	6.79	0.38	7.4e-11	Pneumococcal bacteremia;
CESC	cis	rs11098499	0.909	rs79026312	chr4:120440677	C/A	cg09307838	chr4:120376055	NA	0.92	12.5	0.61	1.73e-28	Corneal astigmatism;
CESC	cis	rs853679	0.550	rs1237875	chr6:28173010	A/G	cg22143856	chr6:28129313	ZNF389	-0.42	-5.33	-0.31	2.09e-7	Depression;
CESC	cis	rs55871839	0.708	rs12115074	chr8:59817473	C/T	cg07426533	chr8:59803705	TOX	-0.41	-5.89	-0.34	1.19e-8	Pneumonia;
CESC	cis	rs6987853	0.712	rs56220385	chr8:42428862	A/T	cg09913449	chr8:42400586	C8orf40	0.47	7.85	0.43	1.04e-13	Mean corpuscular hemoglobin concentration;
CESC	cis	rs6540559	0.546	rs75308488	chr1:210030639	T/C	cg22029157	chr1:209979665	IRF6	0.72	7.12	0.4	1.04e-11	Cleft lip with or without cleft palate;
CESC	cis	rs704795	0.805	rs1728926	chr2:27612937	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.34	-6.26	-0.36	1.55e-9	Menopause (age at onset);
CESC	cis	rs7107174	1.000	rs10899470	chr11:78020052	C/T	cg02023728	chr11:77925099	USP35	0.48	6.27	0.36	1.46e-9	Testicular germ cell tumor;
CESC	cis	rs9487051	0.676	rs7753705	chr6:109593302	A/C	cg12927641	chr6:109611667	NA	-0.37	-5.56	-0.32	6.55e-8	Reticulocyte fraction of red cells;
CESC	cis	rs7202877	0.706	rs1540	chr16:75481185	G/C	cg04384234	chr16:75411784	CFDP1	0.52	5.84	0.34	1.56e-8	Type 2 diabetes;Type 1 diabetes;
CESC	cis	rs1008375	1.000	rs10939749	chr4:17692319	A/C	cg02297831	chr4:17616191	MED28	0.47	5.7	0.33	3.11e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs7264396	0.563	rs6060592	chr20:34352414	C/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.68	7.4	0.41	1.83e-12	Total cholesterol levels;
CESC	cis	rs965469	1.000	rs6051705	chr20:3253143	G/A	cg25506879	chr20:3388711	C20orf194	-0.58	-6.24	-0.36	1.7e-9	IFN-related cytopenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05874913	chr2:160569340	MARCH7	0.6	6.53	0.37	3.27e-10	Gut microbiome composition (summer);
CESC	cis	rs9549260	0.753	rs9549243	chr13:41217205	G/A	cg21288729	chr13:41239152	FOXO1	0.58	5.86	0.34	1.38e-8	Red blood cell count;
CESC	cis	rs6088580	0.524	rs6088564	chr20:33249444	A/G	cg08999081	chr20:33150536	PIGU	-0.46	-6.42	-0.37	6.23e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs4919087	0.926	rs953097	chr10:98981914	T/C	cg25902810	chr10:99078978	FRAT1	0.71	10.32	0.54	3.25e-21	Monocyte count;
CESC	cis	rs76878669	0.561	rs6591217	chr11:66174653	G/A	cg18002602	chr11:66138449	SLC29A2	-0.36	-5.82	-0.34	1.7e-8	Educational attainment (years of education);
CESC	cis	rs4665809	1.000	rs2384323	chr2:26306473	C/T	cg25036284	chr2:26402008	FAM59B	-0.57	-6.57	-0.37	2.61e-10	Gut microbiome composition (summer);
CESC	cis	rs4713118	0.662	rs13218430	chr6:28029837	T/C	cg19592336	chr6:28129416	ZNF389	0.54	6.94	0.39	3e-11	Parkinson's disease;
CESC	cis	rs1005277	0.579	rs2505248	chr10:38459097	A/G	cg25427524	chr10:38739819	LOC399744	-0.66	-9.62	-0.51	5.71e-19	Extrinsic epigenetic age acceleration;
CESC	cis	rs9649213	0.593	rs6969731	chr7:97924571	T/G	cg21770322	chr7:97807741	LMTK2	0.54	8.13	0.45	1.67e-14	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs67478160	0.619	rs11160759	chr14:104231542	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.5	-6.89	-0.39	4.13e-11	Schizophrenia;
CESC	trans	rs1728785	0.901	rs1183956	chr16:68606726	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.65	7.93	0.44	6e-14	Ulcerative colitis;
CESC	cis	rs1448094	0.842	rs10779231	chr12:86462237	T/C	cg02569458	chr12:86230093	RASSF9	-0.35	-5.24	-0.31	3.23e-7	Major depressive disorder;
CESC	cis	rs798554	0.757	rs1182171	chr7:2878510	A/G	cg19346786	chr7:2764209	NA	-0.46	-6.56	-0.37	2.82e-10	Height;
CESC	cis	rs2243480	1.000	rs6949812	chr7:65387101	G/A	cg12463550	chr7:65579703	CRCP	0.7	5.58	0.32	5.94e-8	Diabetic kidney disease;
CESC	trans	rs561341	1.000	rs473356	chr17:30321762	G/C	cg20587970	chr11:113659929	NA	-1.44	-18.71	-0.75	2.25e-50	Hip circumference adjusted for BMI;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg04284535	chr17:41624145	ETV4	0.39	6.17	0.35	2.58e-9	Gambling;
CESC	cis	rs3733585	0.673	rs4292332	chr4:9953830	C/A	cg00071950	chr4:10020882	SLC2A9	-0.69	-11.34	-0.57	1.42e-24	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs10463316	0.963	rs4958450	chr5:150739932	A/C	cg03212797	chr5:150827313	SLC36A1	-0.45	-5.29	-0.31	2.57e-7	Metabolite levels (Pyroglutamine);
CESC	cis	rs4819052	0.851	rs7275874	chr21:46671223	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.45	5.62	0.33	4.81e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs7666738	0.830	rs62321570	chr4:98984276	G/A	cg18180107	chr4:99064573	C4orf37	0.4	5.19	0.3	4.29e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10504229	1.000	rs1390411	chr8:58194146	C/A	cg22535103	chr8:58192502	C8orf71	-1.07	-13.57	-0.64	3.2e-32	Developmental language disorder (linguistic errors);
CESC	cis	rs12410462	0.681	rs4131980	chr1:227572123	A/G	cg23173402	chr1:227635558	NA	0.68	5.72	0.33	2.88e-8	Major depressive disorder;
CESC	trans	rs4824093	0.610	rs73443906	chr22:50274293	A/G	cg09872104	chr7:134855509	C7orf49	-0.97	-6.92	-0.39	3.45e-11	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs910316	0.763	rs1548807	chr14:75479582	T/G	cg16144293	chr14:75469539	EIF2B2	-0.39	-5.24	-0.31	3.34e-7	Height;
CESC	cis	rs826838	1.000	rs11183941	chr12:38851692	G/C	cg13010199	chr12:38710504	ALG10B	0.6	8.53	0.46	1.18e-15	Heart rate;
CESC	cis	rs2228479	0.541	rs12918575	chr16:89811151	A/G	cg04013166	chr16:89971882	TCF25	0.72	7.87	0.44	9.3e-14	Skin colour saturation;
CESC	cis	rs4423214	1.000	rs12806844	chr11:71170770	G/A	cg05163923	chr11:71159392	DHCR7	0.78	10.34	0.54	2.91e-21	Vitamin D levels;
CESC	trans	rs4906172	0.716	rs8019874	chr14:102521309	T/C	cg17920195	chr4:129149383	NA	0.32	6.24	0.36	1.76e-9	Menopause (age at onset);
CESC	cis	rs7072216	0.770	rs1737	chr10:100176366	T/C	cg26618903	chr10:100175079	PYROXD2	-0.33	-5.11	-0.3	6.12e-7	Metabolite levels;
CESC	cis	rs10504229	1.000	rs67384205	chr8:58180348	C/G	cg05313129	chr8:58192883	C8orf71	-0.55	-6.37	-0.36	8.42e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs7666738	0.791	rs13127542	chr4:98949159	C/T	cg05340658	chr4:99064831	C4orf37	0.81	12.65	0.61	5.22e-29	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16755598	chr14:50100815	C14orf104	0.56	6.71	0.38	1.19e-10	Gut microbiome composition (summer);
CESC	cis	rs2835872	0.758	rs1709833	chr21:39037805	C/T	cg06728970	chr21:39037746	KCNJ6	-0.29	-5.25	-0.31	3.09e-7	Electroencephalographic traits in alcoholism;
CESC	trans	rs2391518	0.639	rs2968999	chr4:130784545	G/A	cg04981619	chr2:43328122	NA	0.38	6.0	0.35	6.3e-9	Body mass index;
CESC	cis	rs896854	0.654	rs4735339	chr8:95974373	C/T	cg09323728	chr8:95962352	TP53INP1	-0.4	-8.68	-0.47	4.05e-16	Type 2 diabetes;
CESC	cis	rs10256972	0.869	rs4720158	chr7:1040325	A/G	cg02099474	chr7:1027990	CYP2W1	-0.34	-5.03	-0.3	8.89e-7	Longevity;Endometriosis;
CESC	cis	rs11098499	0.866	rs12374244	chr4:120281972	A/T	cg24375607	chr4:120327624	NA	0.42	5.19	0.3	4.19e-7	Corneal astigmatism;
CESC	cis	rs17376456	0.825	rs12716454	chr5:93272279	A/C	cg21475434	chr5:93447410	FAM172A	0.81	6.49	0.37	4.2e-10	Diabetic retinopathy;
CESC	cis	rs2204008	0.604	rs11172718	chr12:38069819	T/C	cg13010199	chr12:38710504	ALG10B	0.47	5.83	0.34	1.62e-8	Bladder cancer;
CESC	cis	rs858239	0.669	rs6461687	chr7:23116580	A/G	cg23682824	chr7:23144976	KLHL7	0.46	6.21	0.36	2.03e-9	Cerebrospinal fluid biomarker levels;
CESC	cis	rs7116495	0.609	rs73543640	chr11:71834374	G/T	cg07596299	chr11:71824057	C11orf51	0.79	5.03	0.3	9.07e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs933688	0.877	rs10474352	chr5:90732225	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.17	14.3	0.66	9.03e-35	Smoking behavior;
CESC	cis	rs4901847	0.562	rs3829765	chr14:58605790	G/A	cg15908186	chr14:58618357	C14orf37	0.34	5.12	0.3	5.97e-7	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs9291683	0.679	rs3756225	chr4:10094133	G/C	cg11266682	chr4:10021025	SLC2A9	-0.49	-9.29	-0.5	5.72e-18	Bone mineral density;
CESC	cis	rs5769765	0.728	rs6520064	chr22:50294469	A/G	cg26441486	chr22:50317300	CRELD2	0.39	5.41	0.32	1.4e-7	Schizophrenia;
CESC	cis	rs11264213	0.786	rs115087102	chr1:36258854	G/A	cg27506609	chr1:36549197	TEKT2	0.65	5.34	0.31	1.97e-7	Schizophrenia;
CESC	trans	rs7246760	0.748	rs61604825	chr19:9726998	C/A	cg02900749	chr2:68251473	NA	-0.79	-6.02	-0.35	5.78e-9	Pursuit maintenance gain;
CESC	cis	rs9640161	0.789	rs66688634	chr7:150053806	G/A	cg27494647	chr7:150038898	RARRES2	0.42	5.09	0.3	6.75e-7	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs2637266	0.935	rs7477361	chr10:78393586	G/A	cg18941641	chr10:78392320	NA	0.45	8.59	0.47	7.52e-16	Pulmonary function;
CESC	cis	rs9487051	0.872	rs9487034	chr6:109605899	A/G	cg21918786	chr6:109611834	NA	-0.4	-5.87	-0.34	1.32e-8	Reticulocyte fraction of red cells;
CESC	cis	rs7656342	0.636	rs4697902	chr4:9863936	T/C	cg00071950	chr4:10020882	SLC2A9	-0.4	-5.28	-0.31	2.72e-7	Gut microbiota (bacterial taxa);
CESC	cis	rs79057730	0.528	rs6965219	chr7:821807	C/G	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.7	6.46	0.37	5.11e-10	Initial pursuit acceleration;
CESC	cis	rs4728302	0.869	rs6943986	chr7:133616965	G/A	cg10665199	chr7:133106180	EXOC4	0.41	5.42	0.32	1.36e-7	Intelligence;Intelligence (multi-trait analysis);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05323904	chr16:691677	FAM195A	0.53	6.8	0.39	7.11e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs9457247	1.000	rs402749	chr6:167386104	C/T	cg07741184	chr6:167504864	NA	0.31	5.53	0.32	7.87e-8	Crohn's disease;
CESC	cis	rs514406	0.893	rs476108	chr1:53317351	C/T	cg24675658	chr1:53192096	ZYG11B	-0.6	-7.68	-0.43	3.1e-13	Monocyte count;
CESC	cis	rs8070128	0.601	rs8080602	chr17:17954728	G/C	cg09796270	chr17:17721594	SREBF1	-0.38	-5.07	-0.3	7.66e-7	Total body bone mineral density;
CESC	cis	rs7208859	0.623	rs77009951	chr17:29080650	T/C	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.17e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs79247733	0.786	rs2286442	chr22:30772686	C/T	cg03868770	chr22:30783737	RNF215	-0.58	-5.88	-0.34	1.25e-8	Tonsillectomy;
CESC	cis	rs9549367	0.789	rs2287247	chr13:113889212	A/G	cg00898013	chr13:113819073	PROZ	-0.52	-7.2	-0.4	6.09e-12	Platelet distribution width;
CESC	cis	rs977987	0.835	rs8046109	chr16:75360096	A/G	cg03315344	chr16:75512273	CHST6	0.38	5.45	0.32	1.18e-7	Dupuytren's disease;
CESC	trans	rs724568	0.643	rs6710930	chr2:67923789	T/C	cg19718508	chr5:176831858	F12	-0.46	-6.4	-0.37	6.96e-10	Major depressive disorder (broad);
CESC	cis	rs17666538	0.535	rs168062	chr8:632444	T/A	cg23958373	chr8:599963	NA	0.77	5.91	0.34	1.07e-8	IgG glycosylation;
CESC	cis	rs533123	0.668	rs414491	chr1:29170159	C/G	cg08366446	chr1:29138936	OPRD1	0.55	5.62	0.33	4.93e-8	Schizophrenia;
CESC	trans	rs61931739	0.500	rs6488211	chr12:34375620	A/T	cg26384229	chr12:38710491	ALG10B	-0.58	-8.42	-0.46	2.33e-15	Morning vs. evening chronotype;
CESC	cis	rs10992471	0.756	rs7848055	chr9:95115492	A/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.44	-5.58	-0.32	5.98e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CESC	cis	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg02951883	chr7:2050386	MAD1L1	-0.58	-7.89	-0.44	7.75e-14	Bipolar disorder and schizophrenia;
CESC	cis	rs2730245	0.593	rs842699	chr7:158663404	T/A	cg14689365	chr7:158441557	NCAPG2	0.42	5.26	0.31	2.98e-7	Height;
CESC	cis	rs9911578	1.000	rs7215808	chr17:56940742	G/C	cg12560992	chr17:57184187	TRIM37	0.93	15.42	0.69	9.91e-39	Intelligence (multi-trait analysis);
CESC	cis	rs9322193	0.923	rs1984111	chr6:150152856	G/A	cg13206674	chr6:150067644	NUP43	0.42	5.93	0.34	9.66e-9	Lung cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21828898	chr3:132379245	UBA5;ACAD11	-0.58	-6.42	-0.37	6.26e-10	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22428023	chr1:36851581	STK40	0.59	6.6	0.38	2.29e-10	Gut microbiome composition (summer);
CESC	cis	rs9287719	0.934	rs12692416	chr2:10745627	A/G	cg02196655	chr2:10830764	NOL10	-0.38	-5.78	-0.33	2.05e-8	Prostate cancer;
CESC	cis	rs5758659	1.000	rs134869	chr22:42652074	G/A	cg15557168	chr22:42548783	NA	-0.5	-8.12	-0.45	1.77e-14	Cognitive function;
CESC	cis	rs9863	0.861	rs11833002	chr12:124446616	G/A	cg17562584	chr12:124393655	DNAH10	0.32	5.48	0.32	9.77e-8	White blood cell count;
CESC	cis	rs12042052	0.590	rs16858252	chr1:232949224	A/C	cg00951395	chr1:232941775	KIAA1383	0.79	6.77	0.38	8.1e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CESC	cis	rs4835473	0.932	rs4305468	chr4:144908468	C/G	cg25736465	chr4:144833511	NA	-0.4	-6.0	-0.35	6.45e-9	Immature fraction of reticulocytes;
CESC	cis	rs9916302	0.904	rs2168785	chr17:37407135	C/T	cg20243544	chr17:37824526	PNMT	0.48	5.96	0.34	7.8e-9	Glomerular filtration rate (creatinine);
CESC	trans	rs9467711	0.606	rs9393712	chr6:26371000	G/C	cg06606381	chr12:133084897	FBRSL1	-0.76	-6.86	-0.39	4.71e-11	Autism spectrum disorder or schizophrenia;
CESC	cis	rs708547	0.915	rs28605409	chr4:57766261	A/G	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.53	-5.35	-0.31	1.88e-7	Response to bleomycin (chromatid breaks);
CESC	cis	rs2733201	1.000	rs1426658	chr15:44338919	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.53	-5.11	-0.3	6.12e-7	Lipoprotein phospholipase A2 activity in cardiovascular disease;
CESC	cis	rs2191566	0.691	rs8105315	chr19:44588786	T/G	cg20607764	chr19:44506953	ZNF230	-0.4	-5.31	-0.31	2.3e-7	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs4665809	1.000	rs7588802	chr2:26277789	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.77	-8.64	-0.47	5.4e-16	Gut microbiome composition (summer);
CESC	cis	rs9325144	0.560	rs6582539	chr12:38630097	C/T	cg26384229	chr12:38710491	ALG10B	-0.59	-8.72	-0.47	3.03e-16	Morning vs. evening chronotype;
CESC	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg23708337	chr7:1209742	NA	0.52	5.16	0.3	4.88e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2011503	0.943	rs8100927	chr19:19643636	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.52	5.09	0.3	6.68e-7	Bipolar disorder;
CESC	cis	rs6547741	1.000	rs11127071	chr2:27838058	C/A	cg21248554	chr2:27665150	KRTCAP3	0.24	5.09	0.3	6.94e-7	Oral cavity cancer;
CESC	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg06873352	chr17:61820015	STRADA	0.73	12.98	0.62	3.9e-30	Prudent dietary pattern;
CESC	cis	rs7772486	0.641	rs2777485	chr6:146334377	G/A	cg05347473	chr6:146136440	FBXO30	0.65	8.16	0.45	1.32e-14	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs35110281	0.720	rs162394	chr21:44943550	C/G	cg21573476	chr21:45109991	RRP1B	0.42	5.87	0.34	1.3e-8	Mean corpuscular volume;
CESC	cis	rs10256972	0.967	rs4723338	chr7:1036241	A/G	cg23978390	chr7:1156363	C7orf50	0.44	5.9	0.34	1.08e-8	Longevity;Endometriosis;
CESC	cis	rs7811142	1.000	rs7809801	chr7:100072031	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.13	13.32	0.63	2.4e-31	Platelet count;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg18035301	chr10:30722695	MAP3K8	0.49	6.2	0.36	2.18e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg04025307	chr7:1156635	C7orf50	0.56	9.49	0.5	1.43e-18	Longevity;Endometriosis;
CESC	cis	rs6691722	0.503	rs3765432	chr1:24706461	A/G	cg02336364	chr1:24764700	NIPAL3	0.33	6.65	0.38	1.68e-10	Response to interferon beta in multiple sclerosis;
CESC	cis	rs921968	0.643	rs526134	chr2:219402371	G/A	cg02176678	chr2:219576539	TTLL4	0.42	7.44	0.42	1.43e-12	Mean corpuscular hemoglobin concentration;
CESC	cis	rs61931739	0.534	rs10844828	chr12:34303109	C/T	cg06521331	chr12:34319734	NA	-0.4	-5.48	-0.32	9.85e-8	Morning vs. evening chronotype;
CESC	cis	rs9527	0.590	rs7912517	chr10:104905529	G/A	cg04362960	chr10:104952993	NT5C2	0.42	5.28	0.31	2.71e-7	Arsenic metabolism;
CESC	cis	rs887829	0.694	rs869283	chr2:234626287	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.44	-5.35	-0.31	1.88e-7	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CESC	cis	rs9303401	0.632	rs7222087	chr17:57221619	A/T	cg12560992	chr17:57184187	TRIM37	0.44	5.32	0.31	2.22e-7	Cognitive test performance;
CESC	cis	rs9910055	0.552	rs12937114	chr17:42325073	A/G	cg19774624	chr17:42201019	HDAC5	-0.48	-6.15	-0.35	2.78e-9	Total body bone mineral density;
CESC	cis	rs7618915	0.501	rs2109634	chr3:52752075	T/G	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.72	0.38	1.12e-10	Bipolar disorder;
CESC	cis	rs7584330	0.737	rs7584314	chr2:238361089	C/T	cg14458575	chr2:238380390	NA	0.6	8.32	0.46	4.61e-15	Prostate cancer;
CESC	cis	rs7909074	0.898	rs10793565	chr10:45388231	G/C	cg05187965	chr10:45406764	TMEM72	-0.35	-5.54	-0.32	7.41e-8	Mean corpuscular volume;
CESC	cis	rs2456568	0.548	rs10501809	chr11:93666263	C/G	cg26875233	chr11:93583750	C11orf90	-0.32	-5.65	-0.33	4.09e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
CESC	cis	rs9902453	0.933	rs1532042	chr17:28504389	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	7.48	0.42	1.11e-12	Coffee consumption (cups per day);
CESC	cis	rs763014	0.932	rs4984898	chr16:641164	G/T	cg07343612	chr16:622815	PIGQ	-0.5	-6.91	-0.39	3.5e-11	Height;
CESC	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	10.38	0.54	2.06e-21	Prudent dietary pattern;
CESC	cis	rs28374715	0.578	rs7169543	chr15:41620405	T/C	cg02330683	chr15:41787940	ITPKA	0.49	5.77	0.33	2.23e-8	Ulcerative colitis;
CESC	cis	rs10504229	0.683	rs55881798	chr8:58106406	T/C	cg22535103	chr8:58192502	C8orf71	-0.77	-8.76	-0.47	2.37e-16	Developmental language disorder (linguistic errors);
CESC	cis	rs10504229	0.775	rs17805110	chr8:58161439	C/G	cg22535103	chr8:58192502	C8orf71	0.92	10.08	0.53	1.9e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs4665809	0.590	rs9309474	chr2:26448830	T/A	cg08470875	chr2:26401718	FAM59B	-0.75	-7.79	-0.43	1.49e-13	Gut microbiome composition (summer);
CESC	cis	rs12497850	1.000	rs12497850	chr3:48748989	G/T	cg03060546	chr3:49711283	APEH	0.43	5.31	0.31	2.31e-7	Parkinson's disease;
CESC	cis	rs920590	0.684	rs7461774	chr8:19666645	G/A	cg01411142	chr8:19674711	INTS10	0.58	6.32	0.36	1.08e-9	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs1552244	1.000	rs66797209	chr3:10078526	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.78	-10.37	-0.54	2.25e-21	Alzheimer's disease;
CESC	cis	rs701145	0.617	rs355775	chr3:154036129	A/G	cg16511985	chr3:153974050	SGEF	0.41	5.57	0.32	6.13e-8	Coronary artery disease;
CESC	cis	rs7208859	0.623	rs7219712	chr17:29080570	G/T	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.17e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs7539624	0.541	rs10916601	chr1:223897416	G/A	cg10100437	chr1:223903862	CAPN2	0.43	5.44	0.32	1.22e-7	Schizophrenia;
CESC	cis	rs7267979	0.844	rs35735333	chr20:25337205	T/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.79	-14.75	-0.67	2.44e-36	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7945705	0.935	rs2653593	chr11:8877317	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.46	-7.76	-0.43	1.9e-13	Hemoglobin concentration;
CESC	cis	rs72781680	0.716	rs2712050	chr2:24059408	A/C	cg08917208	chr2:24149416	ATAD2B	0.65	6.43	0.37	6e-10	Lymphocyte counts;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02222454	chr3:141762828	NA	-0.64	-6.98	-0.39	2.33e-11	Gut microbiome composition (summer);
CESC	cis	rs7940866	0.770	rs10791104	chr11:130814893	A/T	cg12179176	chr11:130786555	SNX19	0.65	9.73	0.51	2.5e-19	Schizophrenia;
CESC	cis	rs10883723	0.810	rs10786669	chr10:104256094	C/G	ch.10.2196322F	chr10:104248062	ACTR1A	0.42	5.08	0.3	6.99e-7	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs10242455	0.702	rs73397481	chr7:99030108	C/T	cg25640893	chr7:99214727	ZNF498	1.0	6.34	0.36	9.64e-10	Blood metabolite levels;
CESC	trans	rs17536732	0.786	rs17536842	chr4:162841102	A/T	cg06571387	chr2:176964101	HOXD12	-0.49	-6.64	-0.38	1.78e-10	Risky sexual behaviors (alcohol dependence interaction);
CESC	cis	rs3785574	0.962	rs2584623	chr17:61906679	G/A	cg07677032	chr17:61819896	STRADA	0.42	5.33	0.31	2.08e-7	Height;
CESC	cis	rs3020736	0.500	rs764481	chr22:42518426	G/A	cg15557168	chr22:42548783	NA	0.45	6.51	0.37	3.78e-10	Autism spectrum disorder or schizophrenia;
CESC	cis	rs6083	0.571	rs17190678	chr15:58847372	C/G	cg05156742	chr15:59063176	FAM63B	-0.69	-9.75	-0.51	2.17e-19	Schizophrenia;
CESC	cis	rs60154123	0.772	rs701942	chr1:210429392	C/G	cg21951975	chr1:209979733	IRF6	0.47	6.08	0.35	4.09e-9	Coronary artery disease;
CESC	cis	rs875971	0.638	rs801216	chr7:66011667	T/C	cg18876405	chr7:65276391	NA	-0.57	-7.63	-0.42	4.14e-13	Aortic root size;
CESC	cis	rs6499255	1.000	rs4985523	chr16:69797192	T/A	cg15192750	chr16:69999425	NA	0.48	5.94	0.34	8.91e-9	IgE levels;
CESC	cis	rs7267979	0.966	rs4815414	chr20:25361701	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.88	-18.14	-0.74	2.23e-48	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs11931598	0.514	rs10937779	chr4:7039326	G/A	cg26116260	chr4:7069785	GRPEL1	0.44	6.4	0.37	7.1e-10	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
CESC	cis	rs2228479	0.681	rs11641790	chr16:89961957	A/G	cg04013166	chr16:89971882	TCF25	-0.72	-8.87	-0.48	1.1e-16	Skin colour saturation;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14898140	chr17:66031871	KPNA2	0.68	7.93	0.44	6.04e-14	Gut microbiome composition (summer);
CESC	cis	rs11122272	0.735	rs973254	chr1:231521149	T/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.59	-8.22	-0.45	9.37e-15	Hemoglobin concentration;
CESC	cis	rs7577696	0.597	rs375050	chr2:32413765	C/T	cg02381751	chr2:32503542	YIPF4	0.46	5.38	0.31	1.67e-7	Inflammatory biomarkers;
CESC	cis	rs2404602	0.647	rs116505114	chr15:77074794	T/C	cg23625390	chr15:77176239	SCAPER	-0.47	-6.57	-0.37	2.7e-10	Blood metabolite levels;
CESC	cis	rs7618915	0.547	rs4687636	chr3:52633929	G/A	cg05564831	chr3:52568323	NT5DC2	0.46	6.96	0.39	2.61e-11	Bipolar disorder;
CESC	cis	rs10461617	0.592	rs6450403	chr5:56062737	A/C	cg24549020	chr5:56110836	MAP3K1	0.46	5.5	0.32	8.91e-8	Type 2 diabetes;
CESC	cis	rs875971	0.540	rs4717275	chr7:65265180	C/T	cg26939375	chr7:64535504	NA	-0.76	-10.7	-0.55	1.91e-22	Aortic root size;
CESC	cis	rs6747952	0.899	rs12731	chr2:239087912	G/A	cg17459225	chr2:239074497	NA	0.33	5.32	0.31	2.18e-7	Mean corpuscular hemoglobin concentration;
CESC	cis	rs7618915	1.000	rs3852063	chr3:52349204	A/G	cg07507251	chr3:52567010	NT5DC2	0.41	6.13	0.35	3.13e-9	Bipolar disorder;
CESC	cis	rs1728785	1.000	rs1728785	chr16:68591230	G/T	cg02972257	chr16:68554789	NA	0.66	7.56	0.42	6.48e-13	Ulcerative colitis;
CESC	cis	rs9325144	0.555	rs4882284	chr12:38710459	C/T	cg26384229	chr12:38710491	ALG10B	-0.58	-8.36	-0.46	3.54e-15	Morning vs. evening chronotype;
CESC	cis	rs7216064	1.000	rs7224923	chr17:65842265	T/G	cg12091567	chr17:66097778	LOC651250	-0.86	-8.83	-0.48	1.49e-16	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs637571	0.522	rs503524	chr11:65751764	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.75	10.84	0.55	6.84e-23	Eosinophil percentage of white cells;
CESC	cis	rs7727544	0.735	rs274558	chr5:131721174	A/G	cg24060327	chr5:131705240	SLC22A5	0.68	9.31	0.5	5.12e-18	Blood metabolite levels;
CESC	trans	rs11039798	0.588	rs589834	chr11:48419382	C/G	cg15704280	chr7:45808275	SEPT13	-0.62	-6.25	-0.36	1.63e-9	Axial length;
CESC	cis	rs727563	0.638	rs5996058	chr22:42141452	A/G	cg03806693	chr22:41940476	POLR3H	1.18	13.87	0.65	2.9e-33	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs818427	0.783	rs57721139	chr5:112223870	G/A	cg07820702	chr5:112228657	REEP5	-0.42	-5.23	-0.31	3.48e-7	Total body bone mineral density;
CESC	cis	rs801193	0.569	rs2707847	chr7:66202871	C/G	cg18252515	chr7:66147081	NA	-0.47	-6.41	-0.37	6.57e-10	Aortic root size;
CESC	cis	rs6964587	0.933	rs6465350	chr7:91768615	G/A	cg17063962	chr7:91808500	NA	0.59	8.28	0.45	6.05e-15	Breast cancer;
CESC	cis	rs2228479	0.850	rs1800331	chr16:89858417	C/A	cg14709524	chr16:89940631	TCF25	0.93	6.97	0.39	2.5e-11	Skin colour saturation;
CESC	cis	rs2281845	0.507	rs7547762	chr1:201088245	A/G	cg06714761	chr1:201096289	NA	0.43	6.73	0.38	1.04e-10	Permanent tooth development;
CESC	cis	rs801193	0.569	rs13226966	chr7:66233623	A/G	cg12463550	chr7:65579703	CRCP	0.49	6.32	0.36	1.1e-9	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07331747	chr5:172410821	ATP6V0E1	0.63	7.21	0.4	5.87e-12	Gut microbiome composition (summer);
CESC	trans	rs1814175	0.754	rs10839453	chr11:49955815	A/T	cg15704280	chr7:45808275	SEPT13	-1.03	-21.33	-0.79	1.95e-59	Height;
CESC	cis	rs1218582	0.774	rs12036859	chr1:154859940	A/C	cg06221963	chr1:154839813	KCNN3	0.69	11.72	0.58	7.99e-26	Prostate cancer;
CESC	cis	rs875971	0.862	rs4718377	chr7:66049678	C/T	cg18876405	chr7:65276391	NA	-0.53	-7.25	-0.41	4.64e-12	Aortic root size;
CESC	cis	rs35306767	0.903	rs12762228	chr10:880854	G/A	cg26597838	chr10:835615	NA	1.18	11.37	0.57	1.12e-24	Eosinophil percentage of granulocytes;
CESC	cis	rs568617	0.953	rs1151519	chr11:65645831	G/C	cg00576331	chr11:65640516	EFEMP2	0.45	5.3	0.31	2.48e-7	Crohn's disease;
CESC	cis	rs1008375	1.000	rs28480159	chr4:17685707	A/C	cg16339924	chr4:17578868	LAP3	0.51	6.55	0.37	2.98e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs3617	0.573	rs3821873	chr3:52913006	C/T	cg11645453	chr3:52864694	ITIH4	-0.27	-5.39	-0.31	1.57e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
CESC	cis	rs12497850	0.864	rs4513485	chr3:49139966	G/A	cg07636037	chr3:49044803	WDR6	1.01	17.62	0.73	1.54e-46	Parkinson's disease;
CESC	cis	rs7208859	0.673	rs11080135	chr17:29176481	A/G	cg19761014	chr17:28927070	LRRC37B2	0.72	5.71	0.33	3.06e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg12498409	chr7:40174463	C7orf10;C7orf11	-0.4	-6.18	-0.35	2.44e-9	Gambling;
CESC	cis	rs12541635	0.677	rs1496183	chr8:107024445	C/T	cg10147462	chr8:107024639	NA	0.48	7.39	0.41	1.94e-12	Age of smoking initiation;
CESC	cis	rs11191205	0.865	rs11191161	chr10:103726528	C/T	cg15320455	chr10:103880129	LDB1	-0.76	-6.82	-0.39	6.22e-11	Intelligence (multi-trait analysis);
CESC	cis	rs2130392	0.926	rs1107907	chr4:185620108	G/T	cg21366198	chr4:185655624	MLF1IP	-0.5	-6.95	-0.39	2.76e-11	Kawasaki disease;
CESC	cis	rs6964587	1.000	rs11981461	chr7:91692662	A/G	cg17063962	chr7:91808500	NA	0.6	8.37	0.46	3.45e-15	Breast cancer;
CESC	cis	rs7666738	0.830	rs13119995	chr4:99026790	T/C	cg18180107	chr4:99064573	C4orf37	0.42	5.43	0.32	1.29e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs694739	0.595	rs11542299	chr11:64138805	T/C	cg01888411	chr11:34378293	ABTB2	0.41	6.17	0.35	2.57e-9	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CESC	cis	rs1322639	0.574	rs9364360	chr6:169580174	G/A	cg03254818	chr6:169586852	NA	0.55	5.95	0.34	8.28e-9	Pulse pressure;
CESC	cis	rs7264396	0.790	rs2425097	chr20:34308926	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.86	-11.41	-0.57	8.82e-25	Total cholesterol levels;
CESC	cis	rs9914578	1.000	rs62067978	chr17:2013058	G/A	cg16513277	chr17:2031491	SMG6	-0.62	-7.04	-0.4	1.67e-11	Body mass index;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg12642705	chr10:135124069	ZNF511;TUBGCP2	0.52	7.54	0.42	7.7e-13	Gut microbiota (bacterial taxa);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg19495351	chr2:210675091	UNC80	0.36	6.11	0.35	3.53e-9	Gambling;
CESC	cis	rs1395	0.778	rs62128747	chr2:27412605	T/C	cg22903471	chr2:27725779	GCKR	-0.42	-5.21	-0.3	3.81e-7	Blood metabolite levels;
CESC	cis	rs3741798	1.000	rs77559638	chr12:12499909	T/A	cg08615371	chr12:12503544	MANSC1	0.86	6.1	0.35	3.73e-9	Cerebrospinal fluid biomarker levels;
CESC	cis	rs9488822	0.636	rs10872142	chr6:116369052	C/A	cg18764771	chr6:116381957	FRK	0.23	5.72	0.33	2.83e-8	Cholesterol, total;LDL cholesterol;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13876481	chr6:147124881	C6orf103;LOC729176	-0.65	-7.66	-0.43	3.42e-13	Gut microbiome composition (summer);
CESC	cis	rs2985684	0.789	rs7161649	chr14:50064028	A/G	cg04989706	chr14:50066350	PPIL5	-0.46	-5.15	-0.3	5.08e-7	Carotid intima media thickness;
CESC	cis	rs2370759	1.000	rs11599522	chr10:32568434	G/C	cg18270830	chr10:32634957	EPC1	0.72	7.18	0.4	6.85e-12	Sexual dysfunction (female);
CESC	cis	rs13191362	0.935	rs34709632	chr6:163048380	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.86	8.39	0.46	2.99e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs875971	0.502	rs2946580	chr7:65531842	G/A	cg19163074	chr7:65112434	INTS4L2	0.5	5.21	0.31	3.72e-7	Aortic root size;
CESC	cis	rs858239	0.720	rs10227559	chr7:23272144	G/A	cg23682824	chr7:23144976	KLHL7	0.42	5.22	0.31	3.65e-7	Cerebrospinal fluid biomarker levels;
CESC	cis	rs1865721	0.771	rs4410169	chr18:73138840	A/G	cg26385618	chr18:73139727	C18orf62	-0.49	-8.0	-0.44	3.82e-14	Intelligence;
CESC	cis	rs7814319	0.933	rs13261690	chr8:97238661	C/A	cg20787634	chr8:97240163	UQCRB	-0.63	-8.18	-0.45	1.2e-14	Lung function (FVC);
CESC	cis	rs5760092	0.755	rs915589	chr22:24261004	C/T	cg04234412	chr22:24373322	LOC391322	0.74	9.58	0.51	7.26e-19	Urinary 1,3-butadiene metabolite levels in smokers;
CESC	cis	rs3008870	0.755	rs2755254	chr1:67470855	C/T	cg02640540	chr1:67518911	SLC35D1	0.45	5.49	0.32	9.28e-8	Lymphocyte percentage of white cells;
CESC	cis	rs6964587	0.633	rs13231620	chr7:91507859	G/A	cg17063962	chr7:91808500	NA	-0.45	-5.31	-0.31	2.36e-7	Breast cancer;
CESC	cis	rs763121	0.819	rs8137829	chr22:39061030	G/A	cg06544989	chr22:39130855	UNC84B	0.49	8.49	0.46	1.53e-15	Menopause (age at onset);
CESC	trans	rs12542260	0.871	rs72713049	chr8:125484088	T/G	cg09438698	chr12:133365205	GOLGA3	-0.47	-6.05	-0.35	4.83e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs826838	0.967	rs1352123	chr12:39130992	T/C	cg13010199	chr12:38710504	ALG10B	-0.45	-6.27	-0.36	1.48e-9	Heart rate;
CESC	cis	rs7618915	0.501	rs1468638	chr3:52748058	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.53	7.88	0.44	8.44e-14	Bipolar disorder;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg02070114	chr5:139555300	C5orf32	0.47	6.1	0.35	3.79e-9	Thyroid stimulating hormone;
CESC	cis	rs1799949	0.965	rs8176130	chr17:41258043	C/T	cg05368731	chr17:41323189	NBR1	0.79	11.2	0.57	4.19e-24	Menopause (age at onset);
CESC	cis	rs6460942	0.591	rs62451461	chr7:12355480	G/A	cg06484146	chr7:12443880	VWDE	-0.62	-6.6	-0.38	2.28e-10	Coronary artery disease;
CESC	cis	rs7824557	0.620	rs6996368	chr8:11182704	G/A	cg21775007	chr8:11205619	TDH	0.53	8.21	0.45	9.83e-15	Retinal vascular caliber;
CESC	cis	rs2033562	0.505	rs9297327	chr8:103540181	A/C	cg09916692	chr8:103549622	NA	-0.36	-6.89	-0.39	4.04e-11	IgA nephropathy;
CESC	cis	rs72901758	0.661	rs56683270	chr17:76247827	T/C	cg26068271	chr17:76253126	NA	0.44	6.6	0.38	2.22e-10	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
CESC	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg11494091	chr17:61959527	GH2	0.73	12.56	0.61	1.07e-28	Prudent dietary pattern;
CESC	cis	rs6076065	0.962	rs2424529	chr20:23369317	A/G	cg11657817	chr20:23433608	CST11	0.35	5.2	0.3	3.92e-7	Facial morphology (factor 15, philtrum width);
CESC	cis	rs4900538	0.927	rs1190547	chr14:102905087	G/C	cg18135206	chr14:102964638	TECPR2	-0.78	-10.3	-0.53	3.94e-21	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	cis	rs7103648	0.669	rs11039332	chr11:47695840	G/A	cg10504702	chr11:47789108	FNBP4	0.44	5.5	0.32	8.74e-8	Diastolic blood pressure;Systolic blood pressure;
CESC	cis	rs12142240	0.698	rs72677585	chr1:46812374	T/C	cg10495392	chr1:46806563	NSUN4	0.57	6.29	0.36	1.33e-9	Menopause (age at onset);
CESC	cis	rs58688157	0.542	rs7926440	chr11:589819	C/T	cg02461776	chr11:598696	PHRF1	0.53	5.95	0.34	8.61e-9	Systemic lupus erythematosus;
CESC	cis	rs6665290	0.935	rs6670924	chr1:227196048	A/C	cg10327440	chr1:227177885	CDC42BPA	-1.22	-32.88	-0.9	1.62e-95	Myeloid white cell count;
CESC	cis	rs889312	0.500	rs252905	chr5:56118875	C/T	cg14703610	chr5:56206110	C5orf35	0.48	6.44	0.37	5.59e-10	Breast cancer;Breast cancer (early onset);
CESC	cis	rs1862618	0.853	rs3099459	chr5:56137170	G/C	cg18230493	chr5:56204884	C5orf35	-0.75	-8.9	-0.48	9.02e-17	Initial pursuit acceleration;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg05160409	chr11:60681264	TMEM109	0.43	6.24	0.36	1.68e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs2072732	0.898	rs2981856	chr1:2972524	T/C	cg15211996	chr1:2936768	ACTRT2	0.33	5.91	0.34	1.02e-8	Plateletcrit;
CESC	cis	rs4268898	0.662	rs2303296	chr2:24432839	A/G	cg20701182	chr2:24300061	SF3B14	0.68	7.16	0.4	7.75e-12	Asthma;
CESC	cis	rs10751667	0.643	rs7396767	chr11:938808	G/A	cg06064525	chr11:970664	AP2A2	-0.52	-10.43	-0.54	1.43e-21	Alzheimer's disease (late onset);
CESC	cis	rs1707322	0.752	rs11211152	chr1:46114157	C/T	cg03146154	chr1:46216737	IPP	0.82	11.51	0.58	3.87e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10000825	chr7:131012516	MKLN1	0.72	8.38	0.46	3.24e-15	Gut microbiome composition (summer);
CESC	cis	rs4664293	0.967	rs3940435	chr2:160494783	G/A	cg08347373	chr2:160653686	CD302	-0.32	-5.12	-0.3	5.87e-7	Monocyte percentage of white cells;
CESC	cis	rs2228479	0.850	rs117285117	chr16:89910250	T/G	cg14709524	chr16:89940631	TCF25	0.88	6.1	0.35	3.82e-9	Skin colour saturation;
CESC	cis	rs7917772	0.503	rs56219824	chr10:104302337	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.53	7.33	0.41	2.81e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs7552404	0.656	rs11161792	chr1:76336746	C/T	cg10523679	chr1:76189770	ACADM	0.68	6.56	0.37	2.76e-10	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs72627509	0.857	rs56155140	chr4:57824451	G/A	cg26694713	chr4:57773883	REST	0.55	5.36	0.31	1.79e-7	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CESC	cis	rs9291683	0.609	rs34709913	chr4:10028955	T/C	cg02734326	chr4:10020555	SLC2A9	0.48	6.72	0.38	1.1e-10	Bone mineral density;
CESC	cis	rs9399135	0.967	rs6923827	chr6:135335382	C/T	cg24558204	chr6:135376177	HBS1L	0.48	6.6	0.38	2.21e-10	Red blood cell count;
CESC	cis	rs2070488	0.775	rs6599204	chr3:38525734	C/T	cg24069376	chr3:38537580	EXOG	0.32	5.27	0.31	2.87e-7	Electrocardiographic conduction measures;
CESC	cis	rs6963495	0.818	rs73190158	chr7:105153943	T/C	cg19920283	chr7:105172520	RINT1	0.69	6.56	0.37	2.85e-10	Bipolar disorder (body mass index interaction);
CESC	cis	rs888194	0.587	rs6606711	chr12:109849297	A/G	cg19025524	chr12:109796872	NA	-0.47	-6.83	-0.39	5.64e-11	Neuroticism;
CESC	cis	rs708547	0.676	rs11133470	chr4:57864926	G/T	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.5	-6.71	-0.38	1.17e-10	Response to bleomycin (chromatid breaks);
CESC	cis	rs1355223	0.583	rs2915177	chr11:34880266	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.84	12.93	0.62	5.8e-30	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs597539	0.690	rs615644	chr11:68621806	G/C	cg04772025	chr11:68637568	NA	0.52	5.79	0.34	1.98e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs17711722	0.675	rs6947132	chr7:65273495	G/A	cg18876405	chr7:65276391	NA	-0.7	-9.84	-0.52	1.15e-19	Calcium levels;
CESC	cis	rs1465370	0.720	rs7811462	chr7:130017487	G/A	cg04743876	chr7:130013617	NA	0.31	5.86	0.34	1.38e-8	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
CESC	trans	rs11039798	0.588	rs12294395	chr11:48476860	C/T	cg03929089	chr4:120376271	NA	0.6	6.01	0.35	5.97e-9	Axial length;
CESC	cis	rs977987	0.835	rs3851733	chr16:75370263	G/C	cg03315344	chr16:75512273	CHST6	0.38	5.38	0.31	1.63e-7	Dupuytren's disease;
CESC	cis	rs2243480	0.711	rs2460426	chr7:65623129	A/G	cg18252515	chr7:66147081	NA	1.36	13.62	0.64	2.25e-32	Diabetic kidney disease;
CESC	trans	rs274437	0.739	rs10457998	chr6:104790542	C/A	cg23629166	chr1:2345368	PEX10	0.56	6.04	0.35	5.16e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10883723	0.810	rs3740406	chr10:104272789	C/T	cg22532475	chr10:104410764	TRIM8	-0.33	-5.68	-0.33	3.5e-8	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs2976388	0.566	rs2585141	chr8:143806343	G/A	cg24634471	chr8:143751801	JRK	-0.43	-5.15	-0.3	5.14e-7	Urinary tract infection frequency;
CESC	cis	rs11785693	0.862	rs62491189	chr8:4991309	T/C	cg26367366	chr8:4980734	NA	0.88	8.07	0.44	2.52e-14	Neuroticism (multi-trait analysis);Neuroticism;
CESC	cis	rs8141529	0.732	rs6005872	chr22:29172898	T/G	cg15103426	chr22:29168792	CCDC117	0.72	10.07	0.53	2.05e-20	Lymphocyte counts;
CESC	cis	rs6120849	0.901	rs6060270	chr20:33736814	G/T	cg24642439	chr20:33292090	TP53INP2	0.63	6.68	0.38	1.37e-10	Protein C levels;
CESC	cis	rs8014204	0.935	rs3742786	chr14:75373011	A/G	cg26191576	chr14:75389716	RPS6KL1	0.36	5.22	0.31	3.57e-7	Caffeine consumption;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13357752	chr19:4639397	TNFAIP8L1	0.63	6.95	0.39	2.88e-11	Gut microbiome composition (summer);
CESC	cis	rs11048434	0.673	rs11611106	chr12:9060204	A/C	cg04155231	chr12:9217510	LOC144571	-0.32	-5.17	-0.3	4.53e-7	Sjögren's syndrome;
CESC	cis	rs9522267	1.000	rs9522266	chr13:112195456	C/T	cg10483660	chr13:112241077	NA	-0.3	-5.04	-0.3	8.69e-7	Hepatitis;
CESC	cis	rs735396	0.770	rs1169314	chr12:121443116	A/G	cg02403541	chr12:121454288	C12orf43	0.75	10.51	0.54	8.26e-22	N-glycan levels;
CESC	cis	rs1153858	1.000	rs56806728	chr15:45637814	A/G	cg14582100	chr15:45693742	SPATA5L1	0.42	6.08	0.35	4.2e-9	Homoarginine levels;
CESC	cis	rs9291683	0.530	rs882223	chr4:9981625	A/C	cg02734326	chr4:10020555	SLC2A9	0.46	6.9	0.39	3.73e-11	Bone mineral density;
CESC	cis	rs12765878	1.000	rs9325507	chr10:105645622	C/T	cg11005552	chr10:105648138	OBFC1	0.36	5.18	0.3	4.42e-7	Coronary artery disease;
CESC	cis	rs11155671	0.546	rs1999633	chr6:150187712	C/T	cg01145232	chr6:150245071	RAET1G	0.44	5.89	0.34	1.16e-8	Testicular germ cell tumor;
CESC	cis	rs559928	0.606	rs56207008	chr11:63883215	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.65	5.82	0.34	1.71e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CESC	cis	rs6499255	0.951	rs1437135	chr16:69757828	A/G	cg15192750	chr16:69999425	NA	0.47	5.47	0.32	1.06e-7	IgE levels;
CESC	cis	rs4803468	0.967	rs3786553	chr19:41902746	T/G	cg09537434	chr19:41945824	ATP5SL	-1.01	-18.06	-0.74	4.5e-48	Height;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg06710522	chr17:45908972	MRPL10;LRRC46	0.42	6.04	0.35	5.14e-9	Systemic lupus erythematosus;
CESC	cis	rs9790314	0.967	rs7623206	chr3:160971518	G/A	cg03342759	chr3:160939853	NMD3	-0.47	-6.21	-0.36	2.05e-9	Morning vs. evening chronotype;
CESC	cis	rs4973397	0.810	rs12694890	chr2:232276553	A/T	cg09339159	chr2:232260559	B3GNT7	-0.59	-6.14	-0.35	2.97e-9	Anti-saccade response;
CESC	cis	rs9611519	0.780	rs9611542	chr22:41677317	C/T	cg03806693	chr22:41940476	POLR3H	-0.73	-8.3	-0.45	5.44e-15	Neuroticism;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg07216194	chr8:27182965	PTK2B	0.53	7.27	0.41	3.94e-12	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs172166	0.694	rs1225716	chr6:28113746	A/C	cg17221315	chr6:27791827	HIST1H4J	0.45	5.8	0.34	1.85e-8	Cardiac Troponin-T levels;
CESC	cis	rs2242194	0.816	rs11264296	chr1:154994750	T/C	cg12436631	chr1:155007014	DCST1;DCST2	0.46	8.12	0.45	1.83e-14	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23954629	chr11:120895111	TBCEL	0.6	6.45	0.37	5.39e-10	Gut microbiome composition (summer);
CESC	cis	rs7937682	0.640	rs587010	chr11:111425658	C/A	cg22437258	chr11:111473054	SIK2	0.61	7.58	0.42	5.87e-13	Primary sclerosing cholangitis;
CESC	cis	rs13256369	0.760	rs7816171	chr8:8575835	T/C	cg18904891	chr8:8559673	CLDN23	0.69	8.06	0.44	2.63e-14	Obesity-related traits;
CESC	cis	rs643506	0.790	rs688095	chr11:111678771	T/C	cg09085632	chr11:111637200	PPP2R1B	0.4	5.31	0.31	2.32e-7	Breast cancer;
CESC	cis	rs9322193	0.924	rs9498382	chr6:149932118	A/G	cg13206674	chr6:150067644	NUP43	0.42	6.1	0.35	3.66e-9	Lung cancer;
CESC	cis	rs780096	0.565	rs780104	chr2:27677691	G/A	cg21248554	chr2:27665150	KRTCAP3	-0.36	-7.38	-0.41	2.02e-12	Total body bone mineral density;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25120284	chr17:46894671	TTLL6	0.53	6.07	0.35	4.52e-9	Gut microbiome composition (summer);
CESC	cis	rs1865721	0.728	rs67357037	chr18:73219024	G/T	cg26385618	chr18:73139727	C18orf62	-0.53	-7.75	-0.43	2.02e-13	Intelligence;
CESC	cis	rs736801	0.504	rs2070721	chr5:131825842	T/G	cg00255919	chr5:131827918	IRF1	0.38	6.4	0.37	7.09e-10	Breast cancer;Mosquito bite size;
CESC	cis	rs12824058	0.831	rs7485200	chr12:130811641	C/T	cg26677194	chr12:130822605	PIWIL1	0.54	7.1	0.4	1.14e-11	Menopause (age at onset);
CESC	cis	rs4664308	1.000	rs1511218	chr2:160906390	T/C	cg03641300	chr2:160917029	PLA2R1	-0.67	-10.16	-0.53	1.08e-20	Idiopathic membranous nephropathy;
CESC	cis	rs7615952	1.000	rs7616044	chr3:125649354	G/C	cg05084668	chr3:125655381	ALG1L	-0.5	-6.1	-0.35	3.71e-9	Blood pressure (smoking interaction);
CESC	cis	rs853679	0.517	rs3757185	chr6:28107776	T/A	cg17949981	chr6:28129498	ZNF389	0.46	5.76	0.33	2.3e-8	Depression;
CESC	cis	rs11098499	0.865	rs9996417	chr4:120295862	T/C	cg09307838	chr4:120376055	NA	0.94	12.84	0.62	1.16e-29	Corneal astigmatism;
CESC	cis	rs9303280	0.901	rs2305479	chr17:38062217	C/T	cg19468946	chr17:37922297	IKZF3	-0.42	-5.7	-0.33	3.27e-8	Self-reported allergy;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg26887379	chr1:12677936	DHRS3	-0.46	-6.05	-0.35	4.89e-9	Height;
CESC	cis	rs9902453	0.817	rs12051834	chr17:28192785	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.65	8.21	0.45	9.9e-15	Coffee consumption (cups per day);
CESC	cis	rs514406	0.607	rs11206000	chr1:53205923	A/C	cg25767906	chr1:53392781	SCP2	0.43	5.86	0.34	1.37e-8	Monocyte count;
CESC	trans	rs17536732	0.786	rs17458754	chr4:162844633	A/T	cg12177677	chr2:158300475	CYTIP	-0.62	-6.12	-0.35	3.41e-9	Risky sexual behaviors (alcohol dependence interaction);
CESC	cis	rs854765	0.583	rs8070128	chr17:17804725	C/T	cg16928487	chr17:17741425	SREBF1	0.58	9.93	0.52	5.75e-20	Total body bone mineral density;
CESC	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.54	-6.11	-0.35	3.61e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs40363	0.723	rs2379831	chr16:3538927	T/C	cg21433313	chr16:3507492	NAT15	-0.61	-6.63	-0.38	1.84e-10	Tuberculosis;
CESC	cis	rs3806843	1.000	rs1548699	chr5:140164918	T/C	cg26395211	chr5:140044315	WDR55	-0.42	-5.31	-0.31	2.31e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs2235642	0.893	rs2143285	chr16:1593171	A/G	cg09080909	chr16:1797204	MAPK8IP3	-0.38	-5.17	-0.3	4.68e-7	Coronary artery disease;
CESC	cis	rs35306767	0.714	rs12777800	chr10:1070361	G/A	cg20503657	chr10:835505	NA	0.57	5.17	0.3	4.53e-7	Eosinophil percentage of granulocytes;
CESC	cis	rs9322193	0.961	rs9767713	chr6:149909377	T/G	cg07701084	chr6:150067640	NUP43	0.4	5.44	0.32	1.2e-7	Lung cancer;
CESC	cis	rs7799006	0.723	rs2270052	chr7:2291399	C/T	cg12745145	chr7:2261452	MAD1L1	-0.32	-5.13	-0.3	5.67e-7	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs10504229	0.679	rs12679941	chr8:58051812	G/T	cg02725872	chr8:58115012	NA	-0.34	-5.29	-0.31	2.51e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs1218582	0.772	rs6669791	chr1:154845484	G/T	cg09359103	chr1:154839909	KCNN3	-0.69	-13.47	-0.64	7.53e-32	Prostate cancer;
CESC	cis	rs9649213	0.614	rs62479858	chr7:97924226	C/T	cg09267113	chr7:98030324	BAIAP2L1	-0.46	-5.99	-0.35	6.93e-9	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs9987353	0.840	rs329994	chr8:9123233	A/G	cg23203755	chr3:149182974	NA	0.45	6.14	0.35	3.02e-9	Recombination measurement;
CESC	cis	rs7474896	0.559	rs2753880	chr10:38173338	G/A	cg25427524	chr10:38739819	LOC399744	0.51	5.8	0.34	1.85e-8	Obesity (extreme);
CESC	cis	rs1153858	0.943	rs11070454	chr15:45680252	C/T	cg14582100	chr15:45693742	SPATA5L1	0.42	5.95	0.34	8.38e-9	Homoarginine levels;
CESC	cis	rs11098499	1.000	rs7659194	chr4:120207147	T/G	cg24375607	chr4:120327624	NA	0.41	5.03	0.3	9e-7	Corneal astigmatism;
CESC	cis	rs11587400	0.679	rs6537836	chr1:115108923	T/C	cg12756093	chr1:115239321	AMPD1	0.43	5.76	0.33	2.27e-8	Autism;
CESC	cis	rs9488822	0.636	rs12201275	chr6:116314563	C/G	cg26893134	chr6:116381904	FRK	0.25	6.14	0.35	3.05e-9	Cholesterol, total;LDL cholesterol;
CESC	trans	rs650950	0.528	rs646660	chr11:35528452	C/T	cg00187635	chr16:83986795	OSGIN1	-0.45	-6.12	-0.35	3.44e-9	Bronchopulmonary dysplasia;
CESC	cis	rs6714710	0.603	rs7583868	chr2:98588372	C/A	cg26665480	chr2:98280029	ACTR1B	0.56	7.87	0.44	8.96e-14	Posterior cortical atrophy and Alzheimer's disease;
CESC	cis	rs6460942	1.000	rs7808819	chr7:12297440	C/T	cg20607287	chr7:12443886	VWDE	-0.74	-7.84	-0.43	1.08e-13	Coronary artery disease;
CESC	cis	rs6964587	0.773	rs13223564	chr7:91932666	A/G	cg17063962	chr7:91808500	NA	0.54	6.76	0.38	8.76e-11	Breast cancer;
CESC	cis	rs9467711	0.606	rs68112369	chr6:26365759	T/C	cg12826209	chr6:26865740	GUSBL1	0.61	5.13	0.3	5.57e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs4665809	0.590	rs4665319	chr2:26424583	A/C	cg22920501	chr2:26401640	FAM59B	-0.75	-9.07	-0.49	2.83e-17	Gut microbiome composition (summer);
CESC	cis	rs6942756	0.806	rs2566886	chr7:128917866	G/A	cg02491457	chr7:128862824	NA	0.65	9.41	0.5	2.51e-18	White matter hyperintensity burden;
CESC	cis	rs225245	0.791	rs3890901	chr17:34011322	A/C	cg05299278	chr17:33885742	SLFN14	0.37	5.35	0.31	1.9e-7	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
CESC	trans	rs6073597	1.000	rs6031980	chr20:43714384	C/T	cg01840591	chr16:19179931	SYT17	0.45	6.57	0.37	2.67e-10	Positive affect;
CESC	cis	rs939574	0.790	rs72955439	chr2:220090804	T/C	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.88	7.38	0.41	2e-12	Platelet distribution width;
CESC	cis	rs13382862	0.895	rs2289082	chr2:20881958	A/T	cg12334488	chr2:20871173	GDF7	0.37	6.11	0.35	3.55e-9	Abdominal aortic aneurysm;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg03642513	chr4:71859104	DCK	0.5	6.61	0.38	2.14e-10	Systemic lupus erythematosus;
CESC	cis	rs2404602	0.716	rs117129193	chr15:76656803	A/G	cg26408565	chr15:76604113	ETFA	-0.41	-6.01	-0.35	6.01e-9	Blood metabolite levels;
CESC	cis	rs8060686	0.591	rs255054	chr16:68017356	A/G	cg26727032	chr16:67993705	SLC12A4	-0.5	-5.73	-0.33	2.68e-8	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs911555	0.706	rs10129426	chr14:104018455	C/T	cg24130564	chr14:104152367	KLC1	-0.56	-8.12	-0.45	1.8e-14	Intelligence (multi-trait analysis);
CESC	cis	rs9902453	1.000	rs4581755	chr17:28427898	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	7.95	0.44	5.29e-14	Coffee consumption (cups per day);
CESC	cis	rs7662987	0.517	rs4235436	chr4:100039620	G/A	cg13256891	chr4:100009986	ADH5	0.75	8.03	0.44	3.29e-14	Smoking initiation;
CESC	cis	rs4555082	0.957	rs2816627	chr14:105736109	A/G	cg13114125	chr14:105738426	BRF1	-0.71	-9.13	-0.49	1.82e-17	Mean platelet volume;Platelet distribution width;
CESC	cis	rs9291683	0.588	rs3756238	chr4:10013202	C/T	cg02734326	chr4:10020555	SLC2A9	0.52	7.43	0.42	1.5e-12	Bone mineral density;
CESC	cis	rs10479542	0.642	rs6879665	chr5:178974581	T/A	cg00080972	chr5:178986291	RUFY1	0.39	5.69	0.33	3.32e-8	Lung cancer;
CESC	cis	rs616402	0.527	rs10779737	chr1:10580275	C/G	cg20482658	chr1:10539492	PEX14	-0.28	-6.04	-0.35	5.19e-9	Breast size;
CESC	cis	rs8067545	0.611	rs733794	chr17:20157957	T/C	cg13482628	chr17:19912719	NA	-0.42	-5.61	-0.33	5.03e-8	Schizophrenia;
CESC	cis	rs875971	0.862	rs778686	chr7:65835910	C/T	cg10691866	chr7:65817282	TPST1	-0.31	-5.22	-0.31	3.56e-7	Aortic root size;
CESC	cis	rs9902453	0.868	rs8066602	chr17:28523085	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	8.09	0.45	2.15e-14	Coffee consumption (cups per day);
CESC	cis	rs3931020	0.508	rs11485298	chr1:75217752	C/T	cg10128416	chr1:75198403	TYW3;CRYZ	0.44	5.34	0.31	1.97e-7	Resistin levels;
CESC	cis	rs9926296	0.715	rs2115401	chr16:89740609	A/G	cg04287289	chr16:89883240	FANCA	0.4	5.2	0.3	3.96e-7	Vitiligo;
CESC	cis	rs55788414	0.932	rs729265	chr16:81183600	G/A	cg06400318	chr16:81190750	PKD1L2	-0.6	-7.09	-0.4	1.22e-11	Left ventricular obstructive tract defect (maternal effect);
CESC	cis	rs6088590	0.931	rs6088617	chr20:33408036	G/A	cg06115741	chr20:33292138	TP53INP2	0.61	7.59	0.42	5.47e-13	Coronary artery disease;
CESC	cis	rs703842	0.616	rs10783851	chr12:58231155	A/G	cg00677455	chr12:58241039	CTDSP2	-0.7	-9.22	-0.49	9.76e-18	Multiple sclerosis;
CESC	cis	rs17001868	0.568	rs9611329	chr22:40792038	G/T	cg07138101	chr22:40742427	ADSL	0.52	5.32	0.31	2.17e-7	Mammographic density (dense area);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg05332869	chr20:39658073	TOP1	-0.5	-7.17	-0.4	7.65e-12	Gambling;
CESC	cis	rs12477438	0.572	rs10170063	chr2:99655639	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.64	-8.73	-0.47	2.94e-16	Chronic sinus infection;
CESC	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg06873352	chr17:61820015	STRADA	0.72	12.67	0.61	4.43e-29	Prudent dietary pattern;
CESC	cis	rs7520050	0.807	rs4468203	chr1:46113272	T/C	cg03146154	chr1:46216737	IPP	0.52	6.88	0.39	4.28e-11	Red blood cell count;Reticulocyte count;
CESC	cis	rs28386778	0.830	rs7209321	chr17:61855668	A/C	cg07677032	chr17:61819896	STRADA	0.45	5.89	0.34	1.14e-8	Prudent dietary pattern;
CESC	cis	rs875971	1.000	rs4718344	chr7:65874381	C/A	cg11764359	chr7:65958608	NA	0.96	15.23	0.68	4.78e-38	Aortic root size;
CESC	cis	rs2243480	1.000	rs34193460	chr7:65393110	A/G	cg13147721	chr7:65941812	NA	-0.88	-8.09	-0.45	2.17e-14	Diabetic kidney disease;
CESC	cis	rs6690583	0.623	rs12042910	chr1:85452580	G/A	cg22153463	chr1:85462885	MCOLN2	0.71	7.12	0.4	1.01e-11	Serum sulfate level;
CESC	cis	rs9916302	0.808	rs12948906	chr17:37644854	C/T	cg19468946	chr17:37922297	IKZF3	-0.39	-5.13	-0.3	5.47e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs55794721	0.509	rs6699113	chr1:25777743	C/T	cg27572855	chr1:25598939	RHD	0.49	8.31	0.45	4.97e-15	Plateletcrit;Mean corpuscular volume;
CESC	cis	rs9322193	1.000	rs9322193	chr6:149919143	T/G	cg13206674	chr6:150067644	NUP43	0.38	5.42	0.32	1.31e-7	Lung cancer;
CESC	cis	rs9309473	0.607	rs4641966	chr2:73590806	G/A	cg20560298	chr2:73613845	ALMS1	-0.43	-5.78	-0.33	2.13e-8	Metabolite levels;
CESC	cis	rs2576037	0.583	rs578451	chr18:44404525	T/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.53	-7.33	-0.41	2.85e-12	Personality dimensions;
CESC	cis	rs11920090	0.932	rs2292620	chr3:170724036	T/C	cg09710316	chr3:170744871	SLC2A2	0.52	5.89	0.34	1.17e-8	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
CESC	cis	rs2228479	0.850	rs62054609	chr16:89816569	C/A	cg19635926	chr16:89946313	TCF25	0.67	5.09	0.3	6.82e-7	Skin colour saturation;
CESC	cis	rs3026101	0.624	rs17635627	chr17:5296059	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.49	6.5	0.37	3.94e-10	Body mass index;
CESC	cis	rs9399137	0.507	rs4896118	chr6:135276065	A/G	cg24558204	chr6:135376177	HBS1L	-0.65	-8.84	-0.48	1.4e-16	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	cis	rs5750830	0.569	rs5750809	chr22:39791491	T/G	cg11247378	chr22:39784982	NA	-0.65	-9.63	-0.51	5e-19	Intelligence (multi-trait analysis);
CESC	trans	rs61931739	0.500	rs7137392	chr12:34447074	T/C	cg26384229	chr12:38710491	ALG10B	0.54	7.5	0.42	9.79e-13	Morning vs. evening chronotype;
CESC	cis	rs847577	0.651	rs10464490	chr7:97715319	T/G	cg21770322	chr7:97807741	LMTK2	0.64	10.52	0.54	7.29e-22	Breast cancer;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg27013360	chr6:41040518	NFYA;C6orf130	-0.48	-7.95	-0.44	5.54e-14	Gambling;
CESC	cis	rs1552244	0.572	rs67439440	chr3:10169503	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.68	-7.65	-0.43	3.85e-13	Alzheimer's disease;
CESC	trans	rs61931739	0.500	rs7489132	chr12:34539712	C/T	cg13010199	chr12:38710504	ALG10B	0.51	6.58	0.37	2.47e-10	Morning vs. evening chronotype;
CESC	cis	rs1008375	1.000	rs4698200	chr4:17657051	G/A	cg16339924	chr4:17578868	LAP3	0.57	7.13	0.4	9.66e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs244293	0.730	rs11079142	chr17:53021955	A/G	cg19360675	chr17:53046073	COX11;STXBP4	-0.42	-5.6	-0.33	5.29e-8	Menarche (age at onset);
CESC	cis	rs5750830	0.645	rs756640	chr22:39779300	G/A	cg01416388	chr22:39784598	NA	-0.5	-6.68	-0.38	1.43e-10	Intelligence (multi-trait analysis);
CESC	cis	rs1707322	0.717	rs1135850	chr1:46093692	G/A	cg06784218	chr1:46089804	CCDC17	0.4	7.01	0.4	1.97e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7605827	0.930	rs1015837	chr2:15665847	C/T	cg19274914	chr2:15703543	NA	0.33	5.76	0.33	2.28e-8	Educational attainment (years of education);
CESC	cis	rs1707322	0.752	rs12047629	chr1:46162802	G/A	cg05343316	chr1:45956843	TESK2	0.51	6.32	0.36	1.09e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs6088580	0.634	rs4911421	chr20:32998948	T/C	cg08999081	chr20:33150536	PIGU	-0.65	-11.29	-0.57	2.22e-24	Glomerular filtration rate (creatinine);
CESC	cis	rs2832191	1.000	rs2832183	chr21:30482150	G/A	cg24692254	chr21:30365293	RNF160	-0.74	-11.14	-0.56	6.55e-24	Dental caries;
CESC	cis	rs4660306	0.744	rs11211113	chr1:45923668	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.46	5.03	0.3	9.16e-7	Homocysteine levels;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg14431266	chr11:67057003	ANKRD13D	-0.42	-6.31	-0.36	1.2e-9	Gambling;
CESC	cis	rs1665050	0.534	rs10444841	chr15:59234048	C/G	cg05156742	chr15:59063176	FAM63B	0.5	6.42	0.37	6.18e-10	Atopic dermatitis;
CESC	cis	rs4665809	0.590	rs6730317	chr2:26419482	C/T	cg22920501	chr2:26401640	FAM59B	-0.87	-10.52	-0.54	7.59e-22	Gut microbiome composition (summer);
CESC	cis	rs7647973	1.000	rs4241407	chr3:49600319	C/T	cg02487422	chr3:49467188	NICN1	0.39	5.11	0.3	6.09e-7	Menarche (age at onset);
CESC	cis	rs3858526	0.752	rs11040173	chr11:6009378	A/G	cg13902645	chr11:5959945	NA	0.49	5.58	0.32	5.97e-8	DNA methylation (variation);
CESC	cis	rs7412746	0.658	rs57818453	chr1:150763139	G/A	cg04414720	chr1:150670196	GOLPH3L	0.57	7.49	0.42	1.06e-12	Melanoma;
CESC	cis	rs1832871	0.711	rs9456266	chr6:158714422	A/G	cg07165851	chr6:158734300	TULP4	0.6	6.59	0.38	2.33e-10	Height;
CESC	trans	rs61931739	0.534	rs10844767	chr12:34152368	C/G	cg26384229	chr12:38710491	ALG10B	0.64	9.06	0.49	2.9e-17	Morning vs. evening chronotype;
CESC	cis	rs35110281	0.811	rs2838337	chr21:45072621	A/C	cg01579765	chr21:45077557	HSF2BP	-0.56	-9.39	-0.5	2.85e-18	Mean corpuscular volume;
CESC	trans	rs6054906	0.710	rs6117744	chr20:7265038	A/C	cg15387272	chr1:36863509	LSM10	-0.42	-6.1	-0.35	3.67e-9	Response to amphetamines;
CESC	cis	rs2274273	0.714	rs7154889	chr14:55806885	G/A	cg04306507	chr14:55594613	LGALS3	0.32	6.38	0.36	7.9e-10	Protein biomarker;
CESC	cis	rs5769765	1.000	rs768619	chr22:50287266	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.45	-5.2	-0.3	4.05e-7	Schizophrenia;
CESC	cis	rs736408	0.562	rs2072390	chr3:52780509	A/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.33	6.03	0.35	5.4e-9	Bipolar disorder;
CESC	cis	rs796364	0.806	rs115717210	chr2:201006247	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.72	-6.48	-0.37	4.47e-10	Schizophrenia;
CESC	trans	rs11098499	0.754	rs17049949	chr4:120255290	A/G	cg25214090	chr10:38739885	LOC399744	0.64	9.04	0.49	3.46e-17	Corneal astigmatism;
CESC	cis	rs13102973	0.931	rs4561977	chr4:135848936	T/C	cg14419869	chr4:135874104	NA	0.33	5.19	0.3	4.29e-7	Subjective well-being;
CESC	cis	rs2745967	0.791	rs12095883	chr1:208109185	G/A	cg09788693	chr1:208063733	CD34	0.32	5.1	0.3	6.37e-7	Resting heart rate;
CESC	cis	rs9549260	0.709	rs9549240	chr13:41186644	T/G	cg21288729	chr13:41239152	FOXO1	0.63	8.0	0.44	3.79e-14	Red blood cell count;
CESC	cis	rs10504229	0.953	rs6991035	chr8:58183374	C/T	cg14926445	chr8:58193284	C8orf71	-0.51	-5.52	-0.32	8.28e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs7255374	0.566	rs7255904	chr19:41529020	C/T	cg20630647	chr19:41531805	NA	0.41	6.38	0.36	8.08e-10	DDT metabolite (p,p'-DDE levels);
CESC	cis	rs2243480	0.522	rs778717	chr7:65848151	G/C	cg18252515	chr7:66147081	NA	-1.29	-9.65	-0.51	4.59e-19	Diabetic kidney disease;
CESC	cis	rs9911578	1.000	rs12940681	chr17:56933622	T/C	cg05425664	chr17:57184151	TRIM37	-0.46	-6.39	-0.37	7.49e-10	Intelligence (multi-trait analysis);
CESC	cis	rs35955747	0.869	rs34873968	chr22:31581773	C/T	cg25791279	chr22:32026902	PISD	-0.48	-5.75	-0.33	2.42e-8	Neutrophil count;Sum basophil neutrophil counts;
CESC	cis	rs9908102	0.740	rs7216235	chr17:12900383	C/T	cg26162695	chr17:12921313	ELAC2	-0.52	-5.68	-0.33	3.46e-8	Schizophrenia;
CESC	cis	rs274567	0.501	rs581968	chr5:131710202	G/A	cg04518342	chr5:131593106	PDLIM4	-0.36	-5.21	-0.3	3.8e-7	Blood metabolite levels;
CESC	cis	rs3015497	0.527	rs2934671	chr14:51153081	C/T	cg26011998	chr14:51135199	SAV1	-0.6	-6.7	-0.38	1.26e-10	Mean platelet volume;
CESC	cis	rs4233802	1.000	rs4366927	chr2:151138525	T/C	cg25300694	chr2:151184358	NA	0.9	7.86	0.43	9.73e-14	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
CESC	cis	rs9487051	0.676	rs6568560	chr6:109592851	G/A	cg21918786	chr6:109611834	NA	-0.37	-5.41	-0.32	1.39e-7	Reticulocyte fraction of red cells;
CESC	cis	rs875971	0.862	rs709609	chr7:65560561	A/G	cg18876405	chr7:65276391	NA	-0.56	-7.36	-0.41	2.32e-12	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14527942	chr3:10276383	IRAK2	-0.49	-6.04	-0.35	5.16e-9	Gut microbiome composition (summer);
CESC	cis	rs1878931	0.501	rs37800	chr16:3423648	T/G	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.78	-10.32	-0.54	3.24e-21	Body mass index (adult);
CESC	cis	rs2011503	0.882	rs56144632	chr19:19368310	G/A	cg11584989	chr19:19387371	SF4	0.63	7.56	0.42	6.77e-13	Bipolar disorder;
CESC	cis	rs1008375	0.966	rs6837664	chr4:17697835	G/C	cg16339924	chr4:17578868	LAP3	0.59	7.32	0.41	2.99e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs8141529	1.000	rs132534	chr22:29299806	T/C	cg02153584	chr22:29168773	CCDC117	-0.47	-5.63	-0.33	4.64e-8	Lymphocyte counts;
CESC	cis	rs6580649	0.943	rs3803183	chr12:48398080	T/A	cg05342945	chr12:48394962	COL2A1	-0.54	-6.51	-0.37	3.81e-10	Lung cancer;
CESC	cis	rs910316	1.000	rs8017642	chr14:75590822	G/A	cg08847533	chr14:75593920	NEK9	0.99	19.04	0.76	1.58e-51	Height;
CESC	cis	rs3785574	0.962	rs2584628	chr17:61894578	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.58	7.23	0.41	5.04e-12	Height;
CESC	cis	rs4148883	0.629	rs2602899	chr4:100010128	C/T	cg13256891	chr4:100009986	ADH5	0.53	6.87	0.39	4.44e-11	Alcohol dependence;
CESC	cis	rs4711336	1.000	rs11759396	chr6:33656654	C/G	cg15676125	chr6:33679581	C6orf125	0.34	5.06	0.3	7.91e-7	Height;
CESC	cis	rs10242455	0.571	rs41258334	chr7:99271808	T/C	cg25640893	chr7:99214727	ZNF498	0.96	6.17	0.35	2.53e-9	Blood metabolite levels;
CESC	cis	rs858239	0.539	rs10225608	chr7:23188908	A/G	cg23682824	chr7:23144976	KLHL7	0.51	6.83	0.39	5.81e-11	Cerebrospinal fluid biomarker levels;
CESC	cis	rs514406	0.893	rs522287	chr1:53365493	C/T	cg08736216	chr1:53307985	ZYG11A	-0.38	-6.16	-0.35	2.68e-9	Monocyte count;
CESC	cis	rs7546094	1.000	rs2932532	chr1:113234456	G/A	cg22162597	chr1:113214053	CAPZA1	-0.38	-5.88	-0.34	1.22e-8	Platelet distribution width;
CESC	cis	rs965469	1.000	rs2281494	chr20:3235494	A/G	cg25506879	chr20:3388711	C20orf194	-0.57	-6.18	-0.36	2.37e-9	IFN-related cytopenia;
CESC	cis	rs10885582	0.781	rs10787535	chr10:116301436	G/A	cg17056676	chr10:116301354	ABLIM1	-0.3	-5.38	-0.31	1.61e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs9815354	0.812	rs12186050	chr3:41836879	G/C	cg03022575	chr3:42003672	ULK4	0.7	6.04	0.35	5.26e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs9325144	0.555	rs7955128	chr12:38684121	A/T	cg13010199	chr12:38710504	ALG10B	0.43	5.83	0.34	1.64e-8	Morning vs. evening chronotype;
CESC	cis	rs4925386	0.681	rs2427295	chr20:60927431	G/A	cg24112000	chr20:60950667	NA	-0.47	-5.89	-0.34	1.14e-8	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs10504229	0.593	rs2317990	chr8:58024168	G/T	cg22535103	chr8:58192502	C8orf71	-0.67	-7.19	-0.4	6.53e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs6032067	0.777	rs13038342	chr20:43800232	C/T	cg11264863	chr20:43835661	SEMG1	0.5	5.43	0.32	1.27e-7	Blood protein levels;
CESC	cis	rs9733	0.596	rs12089731	chr1:150647798	T/C	cg09365446	chr1:150670422	GOLPH3L	0.42	5.91	0.34	1.03e-8	Tonsillectomy;
CESC	cis	rs9303401	0.614	rs34941454	chr17:57102742	T/G	cg12560992	chr17:57184187	TRIM37	0.5	5.26	0.31	2.91e-7	Cognitive test performance;
CESC	cis	rs7100689	0.646	rs1538819	chr10:82122523	A/G	cg00277334	chr10:82204260	NA	-0.58	-7.76	-0.43	1.84e-13	Post bronchodilator FEV1;
CESC	cis	rs2732480	0.557	rs2732441	chr12:48723324	C/G	cg24011408	chr12:48396354	COL2A1	0.43	5.97	0.34	7.7e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg06191203	chr2:152266755	RIF1	-0.41	-6.19	-0.36	2.27e-9	Gambling;
CESC	cis	rs741677	0.713	rs516382	chr17:486431	A/G	cg15660573	chr17:549704	VPS53	0.41	5.39	0.31	1.58e-7	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
CESC	cis	rs10242455	0.702	rs6976017	chr7:99249999	G/A	cg25640893	chr7:99214727	ZNF498	0.78	5.24	0.31	3.31e-7	Blood metabolite levels;
CESC	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg14159672	chr1:205819179	PM20D1	-0.69	-11.22	-0.57	3.59e-24	Monocyte percentage of white cells;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg00873937	chr10:69991564	ATOH7	-0.41	-6.29	-0.36	1.34e-9	Gambling;
CESC	cis	rs4595586	0.545	rs2388174	chr12:39389237	G/A	cg26384229	chr12:38710491	ALG10B	0.49	7.01	0.4	1.94e-11	Morning vs. evening chronotype;
CESC	cis	rs9910055	0.659	rs7207464	chr17:42245033	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	0.49	7.33	0.41	2.77e-12	Total body bone mineral density;
CESC	cis	rs17666538	0.636	rs10107345	chr8:603700	G/T	cg26554054	chr8:600488	NA	0.58	5.06	0.3	7.9e-7	IgG glycosylation;
CESC	trans	rs877282	0.853	rs11596346	chr10:756673	A/T	cg22713356	chr15:30763199	NA	0.93	8.39	0.46	3e-15	Uric acid levels;
CESC	cis	rs1355223	0.902	rs1578622	chr11:34725915	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.48	-6.24	-0.36	1.68e-9	Systemic lupus erythematosus and Systemic sclerosis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10566763	chr6:106773518	ATG5	0.54	6.44	0.37	5.74e-10	Gut microbiome composition (summer);
CESC	cis	rs7216064	1.000	rs7214758	chr17:65880538	T/C	cg07042672	chr17:66097459	LOC651250	-0.59	-6.27	-0.36	1.49e-9	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs1707322	0.963	rs6690652	chr1:46376692	G/T	cg05343316	chr1:45956843	TESK2	0.44	5.55	0.32	7.05e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7666738	0.830	rs11931166	chr4:99054187	A/T	cg17366294	chr4:99064904	C4orf37	0.61	8.78	0.47	2.13e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1008375	0.646	rs13103430	chr4:17567355	A/C	cg16339924	chr4:17578868	LAP3	-0.54	-6.37	-0.36	8.09e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs10924309	0.737	rs4378245	chr1:245852727	G/A	cg00036263	chr1:245852353	KIF26B	-0.53	-6.94	-0.39	3.05e-11	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
CESC	cis	rs7178572	0.633	rs4886876	chr15:77838491	C/T	cg22256960	chr15:77711686	NA	-0.53	-6.95	-0.39	2.89e-11	Type 2 diabetes;
CESC	cis	rs1008375	1.000	rs13119927	chr4:17691640	G/A	cg27347728	chr4:17578864	LAP3	-0.45	-5.16	-0.3	4.93e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs35306767	0.951	rs12777021	chr10:967270	T/C	cg20503657	chr10:835505	NA	0.87	9.03	0.49	3.67e-17	Eosinophil percentage of granulocytes;
CESC	trans	rs60843830	1.000	rs57542652	chr2:228088	G/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.68	8.23	0.45	8.83e-15	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs561341	1.000	rs55736640	chr17:30333848	G/A	cg23018236	chr17:30244563	NA	-0.54	-5.08	-0.3	7.08e-7	Hip circumference adjusted for BMI;
CESC	cis	rs12681288	0.645	rs2600509	chr8:989022	C/G	cg04851639	chr8:1020857	NA	0.32	6.8	0.39	7.03e-11	Schizophrenia;
CESC	cis	rs9611565	0.765	rs132914	chr22:41805749	T/C	cg06481639	chr22:41940642	POLR3H	0.62	6.52	0.37	3.49e-10	Vitiligo;
CESC	cis	rs7945705	0.747	rs1123936	chr11:9003306	A/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.3	-5.11	-0.3	6.27e-7	Hemoglobin concentration;
CESC	cis	rs6582630	0.537	rs1949611	chr12:38373092	C/T	cg26384229	chr12:38710491	ALG10B	-0.66	-10.0	-0.52	3.39e-20	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs6893300	0.542	rs7736300	chr5:179196898	G/A	cg14593053	chr5:179126677	CANX	0.55	8.17	0.45	1.24e-14	Resting heart rate;
CESC	cis	rs6582630	0.519	rs10880576	chr12:38497693	T/C	cg13010199	chr12:38710504	ALG10B	0.42	5.49	0.32	9.17e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs9858542	1.000	rs6770670	chr3:49686682	T/C	cg03060546	chr3:49711283	APEH	-0.59	-6.94	-0.39	2.96e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs6582630	0.502	rs11182760	chr12:38606273	A/T	cg13010199	chr12:38710504	ALG10B	0.53	6.88	0.39	4.41e-11	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs4975616	0.869	rs452932	chr5:1330253	T/C	cg07493874	chr5:1342172	CLPTM1L	-0.41	-7.93	-0.44	6.2e-14	Lung cancer;
CESC	cis	rs12618769	0.597	rs2309390	chr2:99114310	T/C	cg10123293	chr2:99228465	UNC50	0.41	5.44	0.32	1.24e-7	Bipolar disorder;
CESC	trans	rs877282	1.000	rs12775643	chr10:773242	G/A	cg22713356	chr15:30763199	NA	1.12	11.31	0.57	1.87e-24	Uric acid levels;
CESC	cis	rs2243480	1.000	rs313820	chr7:65574466	A/C	cg18252515	chr7:66147081	NA	-1.39	-13.92	-0.65	1.93e-33	Diabetic kidney disease;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg18803079	chr1:64014643	EFCAB7;DLEU2L	-0.47	-6.07	-0.35	4.36e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg22535103	chr8:58192502	C8orf71	-0.92	-10.16	-0.53	1.04e-20	Developmental language disorder (linguistic errors);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg10265472	chr16:20753215	THUMPD1	-0.49	-6.31	-0.36	1.16e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs5747327	0.874	rs34891900	chr22:18163158	C/T	cg19898043	chr22:18121309	BCL2L13	-0.41	-5.28	-0.31	2.74e-7	Myeloid white cell count;Granulocyte count;
CESC	cis	rs7512552	0.839	rs2794684	chr1:150320571	C/T	cg15654264	chr1:150340011	RPRD2	0.39	5.16	0.3	4.81e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs2832191	0.720	rs4643617	chr21:30485278	T/C	cg24692254	chr21:30365293	RNF160	-0.8	-12.74	-0.62	2.64e-29	Dental caries;
CESC	cis	rs3771570	1.000	rs62186411	chr2:242236667	A/C	cg21155796	chr2:242212141	HDLBP	0.61	5.16	0.3	4.88e-7	Prostate cancer;
CESC	cis	rs7666738	0.830	rs7663438	chr4:99014582	C/T	cg03676636	chr4:99064102	C4orf37	0.35	5.49	0.32	9.33e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7927771	0.864	rs755553	chr11:47432303	G/A	cg05585544	chr11:47624801	NA	0.42	6.19	0.36	2.3e-9	Subjective well-being;
CESC	cis	rs6762	0.642	rs28692469	chr11:839675	T/C	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.74	-9.81	-0.52	1.39e-19	Mean platelet volume;
CESC	cis	rs6499255	0.951	rs8045705	chr16:69581672	A/G	cg15192750	chr16:69999425	NA	0.47	5.51	0.32	8.71e-8	IgE levels;
CESC	cis	rs314370	0.951	rs3757868	chr7:100482720	G/A	cg10426581	chr7:100472382	SRRT	0.85	8.22	0.45	9.27e-15	Resting heart rate;
CESC	cis	rs9649213	0.555	rs6956686	chr7:97997945	T/C	cg24562669	chr7:97807699	LMTK2	0.5	7.47	0.42	1.2e-12	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs870825	0.616	rs35533356	chr4:185639134	A/G	cg04058563	chr4:185651563	MLF1IP	0.65	7.13	0.4	9.78e-12	Blood protein levels;
CESC	cis	rs8114671	0.967	rs9574	chr20:33764632	C/G	cg24642439	chr20:33292090	TP53INP2	0.43	5.31	0.31	2.32e-7	Height;
CESC	cis	rs8031584	0.541	rs2959037	chr15:31218164	T/C	cg08109568	chr15:31115862	NA	0.68	9.54	0.51	1.01e-18	Huntington's disease progression;
CESC	cis	rs9355610	0.727	rs2247315	chr6:167370211	A/C	cg25258033	chr6:167368657	RNASET2	-0.39	-5.55	-0.32	6.9e-8	Graves' disease;
CESC	cis	rs9911578	0.785	rs10853008	chr17:56993407	T/C	cg05425664	chr17:57184151	TRIM37	0.48	5.8	0.34	1.91e-8	Intelligence (multi-trait analysis);
CESC	cis	rs853679	0.517	rs9393896	chr6:28127703	C/T	cg26335602	chr6:28129616	ZNF389	0.52	6.78	0.38	7.92e-11	Depression;
CESC	cis	rs8180040	1.000	rs807936	chr3:47322496	C/T	cg27129171	chr3:47204927	SETD2	0.66	10.09	0.53	1.82e-20	Colorectal cancer;
CESC	cis	rs6424115	1.000	rs2256179	chr1:24132305	A/G	cg10978503	chr1:24200527	CNR2	-0.28	-5.59	-0.32	5.66e-8	Immature fraction of reticulocytes;
CESC	cis	rs9287719	0.601	rs62128635	chr2:10725334	G/C	cg00105475	chr2:10696890	NA	0.4	5.35	0.31	1.94e-7	Prostate cancer;
CESC	cis	rs4523957	0.928	rs8077545	chr17:2184555	A/G	cg16513277	chr17:2031491	SMG6	-0.6	-8.21	-0.45	9.51e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs514406	0.661	rs550561	chr1:53375134	C/T	cg25767906	chr1:53392781	SCP2	-0.54	-7.54	-0.42	7.6e-13	Monocyte count;
CESC	cis	rs875971	0.895	rs1833495	chr7:65921595	T/C	cg11764359	chr7:65958608	NA	0.97	15.5	0.69	5.25e-39	Aortic root size;
CESC	trans	rs9467711	0.606	rs9379852	chr6:26357278	A/G	cg06606381	chr12:133084897	FBRSL1	-0.76	-6.87	-0.39	4.66e-11	Autism spectrum disorder or schizophrenia;
CESC	cis	rs2243480	1.000	rs1404147	chr7:65264524	C/T	cg25894440	chr7:65020034	NA	-0.56	-5.03	-0.3	9.23e-7	Diabetic kidney disease;
CESC	cis	rs7259376	0.807	rs11669254	chr19:22544805	A/G	cg02657401	chr19:22469223	NA	-0.26	-5.13	-0.3	5.53e-7	Menopause (age at onset);
CESC	cis	rs559928	0.606	rs17773078	chr11:63906224	G/A	cg18225595	chr11:63971243	STIP1	0.64	5.82	0.34	1.73e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CESC	cis	rs6570726	0.935	rs434298	chr6:145846873	G/A	cg23711669	chr6:146136114	FBXO30	0.79	11.73	0.58	7.06e-26	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs911555	0.574	rs34251103	chr14:103860063	A/G	cg24130564	chr14:104152367	KLC1	0.47	6.11	0.35	3.54e-9	Intelligence (multi-trait analysis);
CESC	cis	rs863345	0.565	rs2220633	chr1:158445272	A/G	cg12129480	chr1:158549410	OR10X1	-0.36	-7.17	-0.4	7.34e-12	Pneumococcal bacteremia;
CESC	cis	rs6690583	0.623	rs61769366	chr1:85534062	G/A	cg22488158	chr1:85528044	WDR63	0.54	5.04	0.3	8.49e-7	Serum sulfate level;
CESC	cis	rs6942756	0.876	rs822038	chr7:129065477	A/G	cg02491457	chr7:128862824	NA	-0.52	-7.07	-0.4	1.4e-11	White matter hyperintensity burden;
CESC	cis	rs7615952	0.599	rs16834938	chr3:125706046	C/T	cg15145296	chr3:125709740	NA	-0.48	-5.44	-0.32	1.21e-7	Blood pressure (smoking interaction);
CESC	cis	rs10504229	0.906	rs56138544	chr8:58184558	A/C	cg22535103	chr8:58192502	C8orf71	-1.05	-13.08	-0.63	1.71e-30	Developmental language disorder (linguistic errors);
CESC	cis	rs7107174	0.892	rs2510031	chr11:77969956	T/C	cg02023728	chr11:77925099	USP35	0.41	6.06	0.35	4.7e-9	Testicular germ cell tumor;
CESC	cis	rs734999	0.588	rs78506337	chr1:2537095	G/A	cg20673091	chr1:2541236	MMEL1	0.46	7.78	0.43	1.67e-13	Ulcerative colitis;
CESC	cis	rs668210	0.793	rs677350	chr11:65761967	G/A	cg02202077	chr11:65769826	EIF1AD;BANF1	0.69	7.56	0.42	6.56e-13	Cerebrospinal fluid biomarker levels;
CESC	cis	rs1941023	0.567	rs955019	chr11:60174250	C/T	cg08716584	chr11:60157161	MS4A7	-0.41	-6.22	-0.36	1.95e-9	Congenital heart disease (maternal effect);
CESC	cis	rs7589728	0.563	rs80324973	chr2:88447264	T/G	cg07952391	chr2:88470173	THNSL2	0.62	6.03	0.35	5.61e-9	Plasma clusterin levels;
CESC	cis	rs2243480	0.711	rs1626926	chr7:65435792	C/T	cg13147721	chr7:65941812	NA	-0.87	-8.63	-0.47	5.76e-16	Diabetic kidney disease;
CESC	cis	rs2404618	0.534	rs2214861	chr8:1490604	A/G	cg02903104	chr8:1507517	DLGAP2	0.28	5.58	0.32	5.86e-8	Lung cancer;
CESC	cis	rs7264396	0.790	rs6060565	chr20:34285442	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.65	7.82	0.43	1.25e-13	Total cholesterol levels;
CESC	cis	rs2836974	0.863	rs12483216	chr21:40539614	T/C	cg17971929	chr21:40555470	PSMG1	1.04	15.93	0.7	1.5e-40	Cognitive function;
CESC	cis	rs6032067	0.641	rs34811768	chr20:43765800	T/C	cg10761708	chr20:43804764	PI3	0.55	6.05	0.35	4.95e-9	Blood protein levels;
CESC	cis	rs137603	0.644	rs137620	chr22:39709776	T/C	cg01093212	chr22:39715156	SNORD43;RPL3	-0.41	-5.31	-0.31	2.28e-7	Primary biliary cholangitis;
CESC	cis	rs35123781	1.000	rs2336880	chr5:139063728	A/G	cg10513866	chr5:139070639	NA	-0.38	-5.78	-0.33	2.08e-8	Schizophrenia;
CESC	cis	rs1707322	0.752	rs6662164	chr1:46146230	T/A	cg06784218	chr1:46089804	CCDC17	0.37	6.41	0.37	6.57e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9926296	0.715	rs467035	chr16:89740285	C/G	cg04287289	chr16:89883240	FANCA	0.41	5.39	0.31	1.57e-7	Vitiligo;
CESC	cis	rs854765	0.583	rs8065416	chr17:17851162	C/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.54	7.08	0.4	1.28e-11	Total body bone mineral density;
CESC	cis	rs7786877	0.626	rs11983745	chr7:100223678	T/C	cg20848291	chr7:100343083	ZAN	-0.67	-6.98	-0.39	2.34e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs7107174	0.892	rs11237463	chr11:78060464	A/G	cg02023728	chr11:77925099	USP35	0.48	6.35	0.36	9.33e-10	Testicular germ cell tumor;
CESC	cis	rs7582720	1.000	rs6722332	chr2:203745327	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.39	0.41	1.96e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg00144180	chr2:240294362	HDAC4	0.51	7.14	0.4	9.09e-12	Fibrinogen levels;
CESC	cis	rs5750830	0.594	rs5757648	chr22:39775156	G/A	cg01416388	chr22:39784598	NA	-0.54	-7.15	-0.4	8.7e-12	Intelligence (multi-trait analysis);
CESC	cis	rs1799949	1.000	rs2037075	chr17:41305826	G/T	cg05368731	chr17:41323189	NBR1	0.79	10.86	0.55	5.86e-23	Menopause (age at onset);
CESC	cis	rs473651	0.935	rs540636	chr2:239358341	T/C	cg18131467	chr2:239335373	ASB1	1.01	20.41	0.78	2.63e-56	Multiple system atrophy;
CESC	cis	rs4665809	0.590	rs2891496	chr2:26452605	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.12	13.0	0.62	3.12e-30	Gut microbiome composition (summer);
CESC	cis	rs9790314	0.663	rs778648	chr3:160708943	A/G	cg04691961	chr3:161091175	C3orf57	-0.38	-5.04	-0.3	8.73e-7	Morning vs. evening chronotype;
CESC	cis	rs11690935	0.959	rs6722757	chr2:172591963	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.97	-14.72	-0.67	3.01e-36	Schizophrenia;
CESC	cis	rs6061231	0.556	rs6121571	chr20:60977323	T/G	cg22541963	chr20:60982533	CABLES2	0.5	6.18	0.36	2.35e-9	Colorectal cancer;
CESC	cis	rs6540559	0.673	rs41305104	chr1:209950848	G/A	cg22029157	chr1:209979665	IRF6	0.65	6.99	0.39	2.28e-11	Cleft lip with or without cleft palate;
CESC	cis	rs35306767	0.953	rs11253509	chr10:964306	C/T	cg20503657	chr10:835505	NA	0.7	7.83	0.43	1.21e-13	Eosinophil percentage of granulocytes;
CESC	cis	rs3617	0.539	rs4687687	chr3:52948332	A/G	cg13284614	chr3:52569169	NT5DC2;LOC440957	-0.32	-5.48	-0.32	1e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
CESC	cis	rs858239	0.601	rs1558313	chr7:23156079	G/A	cg23682824	chr7:23144976	KLHL7	0.54	7.47	0.42	1.18e-12	Cerebrospinal fluid biomarker levels;
CESC	cis	rs4689592	0.554	rs66925245	chr4:7071999	C/T	cg19539972	chr4:7069911	GRPEL1	-0.71	-7.3	-0.41	3.33e-12	Monocyte percentage of white cells;
CESC	cis	rs5758659	0.714	rs133373	chr22:42465788	G/A	cg04733989	chr22:42467013	NAGA	0.45	6.24	0.36	1.73e-9	Cognitive function;
CESC	cis	rs4450798	0.649	rs4684154	chr3:13787411	A/G	cg23332027	chr3:13681764	NA	0.39	5.44	0.32	1.23e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18722557	chr10:123734694	NSMCE4A	0.55	6.09	0.35	3.85e-9	Gut microbiome composition (summer);
CESC	cis	rs4713118	0.621	rs9368548	chr6:28034737	A/G	cg08968635	chr6:28129556	ZNF389	0.4	5.17	0.3	4.65e-7	Parkinson's disease;
CESC	cis	rs7917772	0.503	rs2031602	chr10:104307955	G/C	cg22532475	chr10:104410764	TRIM8	-0.33	-5.74	-0.33	2.65e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs9733	0.596	rs12085275	chr1:150650265	T/C	cg18016565	chr1:150552671	MCL1	0.33	5.14	0.3	5.34e-7	Tonsillectomy;
CESC	cis	rs12618769	0.597	rs4850874	chr2:99069799	G/A	cg10123293	chr2:99228465	UNC50	0.41	5.51	0.32	8.7e-8	Bipolar disorder;
CESC	cis	rs801193	1.000	rs2659915	chr7:66153101	A/G	cg11764359	chr7:65958608	NA	0.72	9.66	0.51	4.29e-19	Aortic root size;
CESC	cis	rs11718455	0.960	rs34019365	chr3:44004735	G/A	cg08738300	chr3:44038990	NA	0.46	6.12	0.35	3.34e-9	Coronary artery disease;
CESC	cis	rs9660992	0.710	rs4951184	chr1:205240659	A/T	cg21643547	chr1:205240462	TMCC2	-0.48	-6.8	-0.39	7.12e-11	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs4665809	0.680	rs3955310	chr2:26290828	T/G	cg27170947	chr2:26402098	FAM59B	-0.6	-7.23	-0.41	5.28e-12	Gut microbiome composition (summer);
CESC	cis	rs9311474	0.967	rs11717383	chr3:52287468	G/T	cg18337363	chr3:52569053	NT5DC2	0.32	6.06	0.35	4.6e-9	Electroencephalogram traits;
CESC	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg18402987	chr7:1209562	NA	0.75	7.49	0.42	1.04e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2204008	0.774	rs11520273	chr12:38354075	A/T	cg13010199	chr12:38710504	ALG10B	0.45	5.77	0.33	2.24e-8	Bladder cancer;
CESC	cis	rs10751667	0.600	rs7394783	chr11:1005108	C/T	cg06064525	chr11:970664	AP2A2	0.34	5.94	0.34	8.69e-9	Alzheimer's disease (late onset);
CESC	cis	rs875971	0.862	rs17747530	chr7:65994729	G/C	cg11764359	chr7:65958608	NA	0.79	11.32	0.57	1.67e-24	Aortic root size;
CESC	cis	rs7084402	0.935	rs717453	chr10:60268398	C/T	cg07615347	chr10:60278583	BICC1	-0.59	-8.98	-0.48	5.19e-17	Refractive error;
CESC	cis	rs1316952	0.831	rs78985577	chr12:124393117	G/A	cg17562584	chr12:124393655	DNAH10	0.4	5.45	0.32	1.15e-7	Visceral adipose tissue adjusted for BMI;Visceral adipose tissue/subcutaneous adipose tissue ratio;
CESC	cis	rs1950626	0.796	rs7152870	chr14:101389987	T/A	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	-0.79	-10.32	-0.54	3.37e-21	Pelvic organ prolapse (moderate/severe);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22754179	chr19:42901115	NA	-0.61	-7.24	-0.41	4.84e-12	Gut microbiome composition (summer);
CESC	cis	rs597539	0.552	rs6591361	chr11:68719284	T/C	cg21963583	chr11:68658836	MRPL21	0.41	5.73	0.33	2.75e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs4819052	0.851	rs2877018	chr21:46658306	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.46	5.79	0.34	2e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs4665809	0.556	rs1560869	chr2:26417095	T/C	cg08470875	chr2:26401718	FAM59B	-0.73	-7.98	-0.44	4.43e-14	Gut microbiome composition (summer);
CESC	cis	rs12497850	0.897	rs7432989	chr3:49105136	A/G	cg02487422	chr3:49467188	NICN1	0.44	5.54	0.32	7.23e-8	Parkinson's disease;
CESC	cis	rs3091242	0.933	rs10903130	chr1:25769221	A/T	cg03538708	chr1:25844672	NA	-0.38	-5.69	-0.33	3.37e-8	Erythrocyte sedimentation rate;
CESC	cis	rs7552404	0.924	rs1146579	chr1:76209792	C/T	cg03433033	chr1:76189801	ACADM	-0.73	-10.34	-0.54	2.78e-21	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs6088580	0.634	rs6059851	chr20:33047945	G/A	cg06115741	chr20:33292138	TP53INP2	0.46	5.97	0.34	7.61e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs2836974	0.653	rs8130556	chr21:40516872	C/T	cg11644478	chr21:40555479	PSMG1	0.97	14.67	0.67	4.59e-36	Cognitive function;
CESC	cis	rs1348850	0.554	rs7595576	chr2:178371921	C/T	cg22681709	chr2:178499509	PDE11A	-0.5	-5.16	-0.3	4.97e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs7089973	0.966	rs17721283	chr10:116644141	A/G	cg23260525	chr10:116636907	FAM160B1	0.34	5.35	0.31	1.92e-7	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs832540	0.898	rs252890	chr5:56226410	T/C	cg24531977	chr5:56204891	C5orf35	-0.42	-5.36	-0.31	1.84e-7	Coronary artery disease;
CESC	cis	rs7666738	0.830	rs34412187	chr4:99010454	A/G	cg03676636	chr4:99064102	C4orf37	0.33	5.16	0.3	4.86e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs9951602	0.512	rs8097996	chr18:76648035	A/G	cg02800362	chr5:177631904	HNRNPAB	0.64	8.28	0.45	5.96e-15	Obesity-related traits;
CESC	cis	rs12545109	0.765	rs1960726	chr8:57411733	T/C	cg09654669	chr8:57350985	NA	-0.46	-6.28	-0.36	1.4e-9	Obesity-related traits;
CESC	cis	rs1862618	0.526	rs2591963	chr5:56237135	T/A	cg24549020	chr5:56110836	MAP3K1	-0.59	-6.42	-0.37	6.32e-10	Initial pursuit acceleration;
CESC	cis	rs1552244	1.000	rs6804473	chr3:10060425	C/T	cg00149659	chr3:10157352	C3orf10	0.75	9.05	0.49	3.07e-17	Alzheimer's disease;
CESC	cis	rs1538970	0.924	rs1826691	chr1:45881262	A/G	cg05343316	chr1:45956843	TESK2	-0.84	-11.74	-0.58	6.88e-26	Platelet count;
CESC	cis	rs8067545	0.750	rs7208635	chr17:19990990	T/C	cg13482628	chr17:19912719	NA	0.37	5.09	0.3	6.81e-7	Schizophrenia;
CESC	trans	rs1814175	0.817	rs7924619	chr11:49620632	G/A	cg03929089	chr4:120376271	NA	-0.91	-14.98	-0.68	3.52e-37	Height;
CESC	cis	rs66887589	0.807	rs13134517	chr4:120405262	G/A	cg09307838	chr4:120376055	NA	0.53	7.12	0.4	1.04e-11	Diastolic blood pressure;
CESC	cis	rs4665809	1.000	rs6709595	chr2:26259885	A/G	cg04944784	chr2:26401820	FAM59B	-0.63	-7.17	-0.4	7.54e-12	Gut microbiome composition (summer);
CESC	cis	rs67311347	1.000	rs9827461	chr3:40489351	T/A	cg09455208	chr3:40491958	NA	0.49	7.98	0.44	4.53e-14	Renal cell carcinoma;
CESC	cis	rs965469	0.947	rs4611719	chr20:3228423	G/A	cg25506879	chr20:3388711	C20orf194	-0.65	-6.87	-0.39	4.52e-11	IFN-related cytopenia;
CESC	cis	rs2797160	0.904	rs1418637	chr6:125992553	A/G	cg05901451	chr6:126070800	HEY2	-0.46	-6.74	-0.38	9.78e-11	Endometrial cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14405528	chr22:47372700	TBC1D22A	-0.65	-7.26	-0.41	4.34e-12	Gut microbiome composition (summer);
CESC	cis	rs2841277	0.676	rs10438246	chr14:105410183	T/C	cg15352829	chr14:105391018	PLD4	-0.59	-10.4	-0.54	1.75e-21	Rheumatoid arthritis;
CESC	cis	rs4713118	0.629	rs149899	chr6:28019979	C/T	cg19592336	chr6:28129416	ZNF389	0.52	6.71	0.38	1.18e-10	Parkinson's disease;
CESC	cis	rs35110281	0.776	rs9983763	chr21:44990578	A/G	cg01579765	chr21:45077557	HSF2BP	0.53	8.54	0.46	1.07e-15	Mean corpuscular volume;
CESC	cis	rs477895	1.000	rs2286614	chr11:64068310	C/T	cg04317338	chr11:64019027	PLCB3	0.71	5.91	0.34	1.07e-8	Mean platelet volume;
CESC	cis	rs72945132	0.825	rs58532402	chr11:70189491	C/T	cg00319359	chr11:70116639	PPFIA1	0.72	6.84	0.39	5.42e-11	Coronary artery disease;
CESC	cis	rs1878931	0.580	rs3848355	chr16:3407489	A/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.98	15.26	0.68	3.53e-38	Body mass index (adult);
CESC	cis	rs5760092	0.755	rs4585126	chr22:24270005	T/C	cg01238044	chr22:24384105	GSTT1	0.6	7.26	0.41	4.22e-12	Urinary 1,3-butadiene metabolite levels in smokers;
CESC	trans	rs7246657	0.943	rs1559229	chr19:37876197	T/C	cg24637308	chr11:6592297	DNHD1	0.53	6.18	0.35	2.37e-9	Coronary artery calcification;
CESC	cis	rs1865721	0.804	rs4510115	chr18:73209635	G/A	cg26385618	chr18:73139727	C18orf62	-0.52	-7.57	-0.42	6.2800000000000005e-13	Intelligence;
CESC	cis	rs10870270	0.956	rs10870281	chr10:133762642	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.6	-7.68	-0.43	3.1400000000000003e-13	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs854765	0.647	rs741782	chr17:18019712	T/C	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.48	6.05	0.35	4.83e-9	Total body bone mineral density;
CESC	trans	rs12356475	0.710	rs10822686	chr10:67733250	C/T	cg18395189	chr1:152189015	HRNR	-0.43	-6.23	-0.36	1.81e-9	Psoriatic arthritis;
CESC	cis	rs7084402	0.967	rs1658432	chr10:60329069	C/G	cg07615347	chr10:60278583	BICC1	0.59	9.18	0.49	1.26e-17	Refractive error;
CESC	cis	rs1008375	0.966	rs4515155	chr4:17696477	G/T	cg02297831	chr4:17616191	MED28	0.44	5.34	0.31	1.99e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs3540	0.618	rs2301832	chr15:91040725	A/T	cg22089800	chr15:90895588	ZNF774	-0.62	-8.17	-0.45	1.26e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs4466137	0.953	rs1420654	chr5:82975793	G/A	cg16102102	chr5:83017553	HAPLN1	-0.42	-6.27	-0.36	1.49e-9	Prostate cancer;
CESC	cis	rs514406	0.861	rs551435	chr1:53260537	G/T	cg24675658	chr1:53192096	ZYG11B	0.53	6.69	0.38	1.29e-10	Monocyte count;
CESC	cis	rs6541297	0.757	rs642235	chr1:230325027	C/G	cg20703242	chr1:230279135	GALNT2	-0.38	-5.12	-0.3	5.99e-7	Coronary artery disease;
CESC	cis	rs4665809	0.590	rs7579504	chr2:26439995	T/C	cg08470875	chr2:26401718	FAM59B	-0.75	-7.79	-0.43	1.49e-13	Gut microbiome composition (summer);
CESC	cis	rs6912958	0.500	rs4707352	chr6:87929705	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.73	-10.31	-0.54	3.55e-21	Monocyte percentage of white cells;
CESC	cis	rs7659604	0.676	rs7691955	chr4:122700462	A/T	cg06713675	chr4:122721982	EXOSC9	-0.45	-6.38	-0.36	7.86e-10	Type 2 diabetes;
CESC	cis	rs12545109	0.917	rs1370304	chr8:57322822	G/C	cg09654669	chr8:57350985	NA	-0.53	-6.62	-0.38	1.99e-10	Obesity-related traits;
CESC	cis	rs2842992	0.830	rs1475123	chr6:160178007	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.68	7.74	0.43	2.14e-13	Age-related macular degeneration (geographic atrophy);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01806965	chr8:144378397	ZNF696	-0.61	-6.53	-0.37	3.3e-10	Gut microbiome composition (summer);
CESC	cis	rs6754311	0.731	rs3769005	chr2:136603366	C/G	cg15123519	chr2:136567270	LCT	0.3	5.16	0.3	4.73e-7	Mosquito bite size;
CESC	cis	rs7923609	0.934	rs10761771	chr10:65230164	T/C	cg01631684	chr10:65280961	REEP3	-0.44	-5.44	-0.32	1.2e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs12971120	0.891	rs2278158	chr18:72178300	G/T	cg26446133	chr18:72167187	CNDP2	-0.74	-9.14	-0.49	1.69e-17	Refractive error;
CESC	trans	rs3780486	0.541	rs10738909	chr9:33148834	T/C	cg04842962	chr6:43655489	MRPS18A	0.68	10.26	0.53	5.21e-21	IgG glycosylation;
CESC	cis	rs7666738	0.830	rs11941961	chr4:99065654	G/T	cg05340658	chr4:99064831	C4orf37	0.82	12.54	0.61	1.23e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs12458462	0.859	rs2242177	chr18:77477379	G/A	cg11879182	chr18:77439856	CTDP1	0.87	13.46	0.64	8.32e-32	Monocyte count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19905802	chr11:62554200	TMEM179B;TAF6L	0.63	7.3	0.41	3.41e-12	Gut microbiome composition (summer);
CESC	cis	rs2180341	0.521	rs12203812	chr6:127617816	A/T	cg27446573	chr6:127587934	RNF146	0.52	6.82	0.39	6.12e-11	Breast cancer;
CESC	cis	rs10896135	0.526	rs12795774	chr11:66381517	T/C	cg15964523	chr11:66469143	SPTBN2	0.41	5.33	0.31	2.15e-7	Bipolar disorder;
CESC	cis	rs2239908	0.718	rs241776	chr17:26644308	C/T	cg10342447	chr17:26645325	TMEM97	0.4	5.51	0.32	8.62e-8	Blood protein levels;
CESC	cis	rs854765	0.583	rs8065416	chr17:17851162	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.59	8.26	0.45	7.24e-15	Total body bone mineral density;
CESC	cis	rs5417	0.662	rs8067500	chr17:7172631	A/G	cg14660024	chr17:7154518	C17orf81;DULLARD	-0.47	-6.31	-0.36	1.17e-9	Diastolic blood pressure;
CESC	cis	rs1153858	1.000	rs7171577	chr15:45627979	G/A	cg14582100	chr15:45693742	SPATA5L1	0.41	5.89	0.34	1.18e-8	Homoarginine levels;
CESC	cis	rs7481584	0.886	rs4758621	chr11:3009640	C/T	cg25174290	chr11:3078921	CARS	0.48	5.96	0.34	7.91e-9	Calcium levels;
CESC	cis	rs7674212	0.539	rs6850461	chr4:104120041	C/T	cg16532752	chr4:104119610	CENPE	-0.4	-5.46	-0.32	1.09e-7	Type 2 diabetes;
CESC	cis	rs798554	0.610	rs2644304	chr7:2878779	T/C	cg19717773	chr7:2847554	GNA12	-0.51	-8.05	-0.44	2.72e-14	Height;
CESC	cis	rs6500395	0.963	rs12919278	chr16:48692537	A/G	cg04672837	chr16:48644449	N4BP1	-0.51	-6.36	-0.36	8.64e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs1580019	0.885	rs4460269	chr7:32496445	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.72	9.97	0.52	4.3e-20	Cognitive ability;
CESC	cis	rs9303401	0.659	rs12150536	chr17:56640834	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.03	12.7	0.62	3.56e-29	Cognitive test performance;
CESC	cis	rs7017914	0.902	rs1373480	chr8:71686967	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.2	-0.3	3.94e-7	Bone mineral density;
CESC	cis	rs4253772	0.550	rs6008729	chr22:46727428	C/G	cg24881330	chr22:46731750	TRMU	-0.82	-8.82	-0.48	1.52e-16	LDL cholesterol;Cholesterol, total;
CESC	cis	rs7178572	0.568	rs11072653	chr15:77693934	C/T	cg22256960	chr15:77711686	NA	-0.54	-6.95	-0.39	2.9e-11	Type 2 diabetes;
CESC	cis	rs858239	0.698	rs858295	chr7:23245569	A/G	cg23682824	chr7:23144976	KLHL7	0.43	5.79	0.34	1.95e-8	Cerebrospinal fluid biomarker levels;
CESC	cis	rs7829975	0.540	rs2976909	chr8:8346690	C/T	cg15556689	chr8:8085844	FLJ10661	-0.48	-5.89	-0.34	1.15e-8	Mood instability;
CESC	cis	rs4588572	0.643	rs6861678	chr5:77764613	G/C	cg11547950	chr5:77652471	NA	-0.44	-5.48	-0.32	9.67e-8	Triglycerides;
CESC	cis	rs2011503	0.943	rs10406278	chr19:19494725	A/C	cg11584989	chr19:19387371	SF4	-0.63	-7.42	-0.41	1.63e-12	Bipolar disorder;
CESC	cis	rs7605827	0.930	rs1125534	chr2:15618339	G/A	cg19274914	chr2:15703543	NA	0.36	6.41	0.37	6.6e-10	Educational attainment (years of education);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12245206	chr19:59070421	UBE2M;LOC100131691	0.62	6.8	0.39	7.12e-11	Gut microbiome composition (summer);
CESC	cis	rs853679	0.517	rs9348796	chr6:28126202	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.57	-6.49	-0.37	4.32e-10	Depression;
CESC	cis	rs4319547	0.585	rs7953007	chr12:122816977	A/C	cg05707623	chr12:122985044	ZCCHC8	-0.48	-5.6	-0.33	5.34e-8	Body mass index;
CESC	cis	rs6582630	0.615	rs12821226	chr12:38546406	C/T	cg26384229	chr12:38710491	ALG10B	-0.39	-5.19	-0.3	4.22e-7	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs9902453	0.780	rs10445384	chr17:28182685	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.58	7.32	0.41	2.99e-12	Coffee consumption (cups per day);
CESC	cis	rs870825	0.616	rs2130394	chr4:185642577	C/A	cg04058563	chr4:185651563	MLF1IP	0.64	7.1	0.4	1.15e-11	Blood protein levels;
CESC	cis	rs6545883	0.929	rs10193666	chr2:61629408	C/T	cg15711740	chr2:61764176	XPO1	0.41	5.21	0.3	3.79e-7	Tuberculosis;
CESC	cis	rs6866344	0.697	rs17184302	chr5:178127676	C/T	cg10224037	chr5:178157518	ZNF354A	0.67	7.37	0.41	2.13e-12	Neutrophil percentage of white cells;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg23087020	chr1:167190262	POU2F1	-0.48	-6.79	-0.38	7.22e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs9811920	0.732	rs7613864	chr3:99602470	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.44	5.82	0.34	1.7e-8	Axial length;
CESC	cis	rs13118159	0.742	rs7679860	chr4:1333987	C/T	cg19318889	chr4:1322082	MAEA	0.46	6.03	0.35	5.51e-9	Longevity;
CESC	cis	rs7666738	0.791	rs34088022	chr4:99001508	G/T	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.62e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9926296	0.568	rs886950	chr16:89836872	T/C	cg04287289	chr16:89883240	FANCA	0.9	15.35	0.69	1.76e-38	Vitiligo;
CESC	cis	rs875971	0.545	rs801199	chr7:66025273	A/G	cg18876405	chr7:65276391	NA	-0.5	-5.91	-0.34	1.05e-8	Aortic root size;
CESC	cis	rs6087990	0.806	rs4911258	chr20:31369479	G/A	cg13636640	chr20:31349939	DNMT3B	0.81	12.5	0.61	1.67e-28	Ulcerative colitis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26852651	chr1:151584651	SNX27	0.55	6.67	0.38	1.48e-10	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03767357	chr7:130353742	COPG2;TSGA13	0.54	6.15	0.35	2.84e-9	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00822591	chr3:16306489	DPH3;OXNAD1	0.56	6.03	0.35	5.36e-9	Gut microbiome composition (summer);
CESC	cis	rs9625935	0.518	rs713718	chr22:30314092	A/C	cg01021169	chr22:30184971	ASCC2	0.43	6.78	0.38	7.64e-11	Tonsillectomy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14489327	chr19:1021257	C19orf6	-0.6	-6.9	-0.39	3.81e-11	Gut microbiome composition (summer);
CESC	cis	rs4713118	0.621	rs9295755	chr6:28033174	C/T	cg23281280	chr6:28129359	ZNF389	-0.56	-7.56	-0.42	6.63e-13	Parkinson's disease;
CESC	cis	rs1278769	0.735	rs9577395	chr13:113534984	C/G	cg00823993	chr13:113535758	ATP11A	0.59	7.68	0.43	3e-13	Interstitial lung disease;
CESC	cis	rs631288	0.557	rs894467	chr1:146662018	C/T	cg25205988	chr1:146714368	CHD1L	1.04	6.66	0.38	1.58e-10	PR interval in Tripanosoma cruzi seropositivity;
CESC	cis	rs8141529	0.764	rs5752812	chr22:29225603	T/A	cg02153584	chr22:29168773	CCDC117	0.64	9.16	0.49	1.46e-17	Lymphocyte counts;
CESC	cis	rs12541635	0.966	rs56352125	chr8:107041831	G/T	cg10147462	chr8:107024639	NA	0.43	6.11	0.35	3.49e-9	Age of smoking initiation;
CESC	cis	rs873946	0.689	rs2803993	chr10:134550606	T/C	cg18305652	chr10:134549665	INPP5A	0.49	7.43	0.42	1.52e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs7903847	0.642	rs10786341	chr10:99158607	G/A	cg20016023	chr10:99160130	RRP12	-0.3	-5.19	-0.3	4.18e-7	Granulocyte percentage of myeloid white cells;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05040584	chr10:121411475	BAG3	0.54	6.71	0.38	1.17e-10	Gut microbiome composition (summer);
CESC	trans	rs916888	0.610	rs199529	chr17:44837217	A/C	cg22968622	chr17:43663579	NA	0.97	13.11	0.63	1.35e-30	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs11235843	1.000	rs11235843	chr11:73373996	A/G	cg03538470	chr11:73498718	MRPL48	0.55	5.15	0.3	5.16e-7	Hand grip strength;
CESC	trans	rs7615952	0.736	rs13063122	chr3:125643860	G/A	cg07211511	chr3:129823064	LOC729375	-1.11	-15.27	-0.68	3.39e-38	Blood pressure (smoking interaction);
CESC	cis	rs514406	0.505	rs7543239	chr1:53162416	A/G	cg08859206	chr1:53392774	SCP2	-0.6	-8.05	-0.44	2.89e-14	Monocyte count;
CESC	cis	rs9457247	0.534	rs7750593	chr6:167387359	C/G	cg23791538	chr6:167370224	RNASET2	0.7	9.88	0.52	8.62e-20	Crohn's disease;
CESC	cis	rs12368653	0.616	rs1027315	chr12:58034192	T/C	cg18357645	chr12:58087776	OS9	0.4	5.75	0.33	2.49e-8	Multiple sclerosis;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg20299458	chr4:62383146	LPHN3	-0.43	-6.12	-0.35	3.42e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs2228479	0.850	rs17226512	chr16:89839976	T/C	cg14709524	chr16:89940631	TCF25	0.91	6.74	0.38	1e-10	Skin colour saturation;
CESC	cis	rs6502050	0.799	rs9911129	chr17:80087819	C/T	cg01763666	chr17:80159506	CCDC57	-0.37	-5.1	-0.3	6.55e-7	Life satisfaction;
CESC	cis	rs7107770	0.663	rs7111751	chr11:125075288	A/T	cg27629782	chr11:125073726	PKNOX2	-0.32	-5.32	-0.31	2.24e-7	Photic sneeze reflex;
CESC	cis	rs7412746	0.658	rs57818453	chr1:150763139	G/A	cg18016565	chr1:150552671	MCL1	0.34	5.03	0.3	9.21e-7	Melanoma;
CESC	cis	rs7264396	0.563	rs56941405	chr20:34313426	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.64	6.86	0.39	4.8e-11	Total cholesterol levels;
CESC	cis	rs7615952	0.576	rs2276729	chr3:125826214	G/A	cg02772935	chr3:125709198	NA	-0.48	-5.52	-0.32	8.11e-8	Blood pressure (smoking interaction);
CESC	cis	rs2439831	0.850	rs7181039	chr15:44179112	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.64	6.57	0.37	2.63e-10	Lung cancer in ever smokers;
CESC	cis	rs12893668	0.667	rs71417869	chr14:104077434	A/G	cg24130564	chr14:104152367	KLC1	-0.54	-6.87	-0.39	4.5e-11	Reticulocyte count;
CESC	cis	rs35110281	0.667	rs2070533	chr21:45122753	G/A	cg01579765	chr21:45077557	HSF2BP	-0.53	-8.85	-0.48	1.25e-16	Mean corpuscular volume;
CESC	cis	rs11509880	0.543	rs10950393	chr7:12263546	T/C	cg23422036	chr7:12250390	TMEM106B	0.39	5.23	0.31	3.51e-7	Coronary artery disease;
CESC	cis	rs2797160	1.000	rs4897153	chr6:126003403	A/G	cg05901451	chr6:126070800	HEY2	-0.46	-6.62	-0.38	1.94e-10	Endometrial cancer;
CESC	cis	rs1862618	0.641	rs170733	chr5:56249251	A/G	cg24531977	chr5:56204891	C5orf35	0.72	9.6	0.51	6.52e-19	Initial pursuit acceleration;
CESC	trans	rs9467711	0.606	rs2073531	chr6:26375256	A/G	cg06606381	chr12:133084897	FBRSL1	-0.77	-6.78	-0.38	7.69e-11	Autism spectrum disorder or schizophrenia;
CESC	cis	rs3820068	0.705	rs4646096	chr1:15820758	A/G	cg18192808	chr1:15853278	DNAJC16	0.47	5.78	0.33	2.05e-8	Systolic blood pressure;
CESC	cis	rs6951245	0.872	rs57068908	chr7:1060084	A/C	cg18402987	chr7:1209562	NA	0.61	6.46	0.37	4.86e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs9287719	0.967	rs4669593	chr2:10701908	C/T	cg02196655	chr2:10830764	NOL10	-0.36	-5.42	-0.32	1.31e-7	Prostate cancer;
CESC	cis	rs1475911	0.708	rs56185023	chr21:43521538	T/C	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.53	-8.21	-0.45	9.85e-15	IgG glycosylation;
CESC	trans	rs61869271	0.871	rs6585309	chr10:116730337	A/G	cg17463145	chr7:79084011	MAGI2	-0.31	-6.24	-0.36	1.72e-9	Tonsillectomy;
CESC	cis	rs10504229	0.728	rs72650852	chr8:58150463	G/A	cg05313129	chr8:58192883	C8orf71	-0.49	-5.32	-0.31	2.22e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs559928	0.692	rs915987	chr11:64027888	G/A	cg18225595	chr11:63971243	STIP1	0.61	5.14	0.3	5.41e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg22215202	chr19:50321460	MED25	0.45	6.14	0.35	2.97e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs7666738	0.830	rs6852015	chr4:99054373	C/A	cg17366294	chr4:99064904	C4orf37	0.61	8.78	0.47	2.13e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs360798	0.512	rs2539978	chr2:63195179	T/C	cg17519650	chr2:63277830	OTX1	0.57	7.44	0.42	1.38e-12	Coronary artery disease;
CESC	cis	rs3540	0.597	rs3743409	chr15:91045539	T/A	cg10434728	chr15:90938212	IQGAP1	-0.42	-7.71	-0.43	2.56e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs2842992	0.747	rs9365095	chr6:160192928	T/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.77	9.93	0.52	5.92e-20	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs17253792	0.822	rs77408754	chr14:56082047	C/T	cg01858014	chr14:56050164	KTN1	-0.93	-7.54	-0.42	7.5e-13	Putamen volume;
CESC	cis	rs5753618	0.561	rs1858821	chr22:31676454	T/C	cg13145458	chr22:31556086	RNF185	0.51	5.68	0.33	3.46e-8	Colorectal cancer;
CESC	cis	rs9443645	0.869	rs9343863	chr6:79752792	T/C	cg05283184	chr6:79620031	NA	-0.43	-6.68	-0.38	1.36e-10	Intelligence (multi-trait analysis);
CESC	cis	rs7786808	0.544	rs6971888	chr7:158193835	G/A	cg09998033	chr7:158218633	PTPRN2	0.34	5.18	0.3	4.38e-7	Obesity-related traits;
CESC	cis	rs698833	0.926	rs786624	chr2:44604941	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	-0.43	-5.49	-0.32	9.54e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs7829975	0.711	rs12682352	chr8:8646246	A/G	cg06636001	chr8:8085503	FLJ10661	0.51	6.56	0.37	2.8e-10	Mood instability;
CESC	cis	rs9311474	0.508	rs6786919	chr3:52599789	A/G	cg18337363	chr3:52569053	NT5DC2	0.29	5.24	0.31	3.31e-7	Electroencephalogram traits;
CESC	cis	rs7618501	0.966	rs13063621	chr3:49821625	T/C	cg24308560	chr3:49941425	MST1R	-0.5	-6.8	-0.39	7.06e-11	Intelligence (multi-trait analysis);
CESC	cis	rs3617	0.573	rs12492391	chr3:52912296	C/A	cg07507251	chr3:52567010	NT5DC2	0.36	5.93	0.34	9.45e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22638185	chr17:42385946	RUNDC3A	0.57	6.42	0.37	6.29e-10	Gut microbiome composition (summer);
CESC	cis	rs4820294	1.000	rs62236667	chr22:38061520	C/G	cg21798802	chr22:38057573	PDXP	0.46	7.99	0.44	4.16e-14	Fat distribution (HIV);
CESC	cis	rs7520050	0.966	rs7522601	chr1:46419021	G/A	cg03146154	chr1:46216737	IPP	-0.47	-6.1	-0.35	3.74e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs854572	0.870	rs757158	chr7:94955528	C/T	cg19678392	chr7:94953810	PON1	-0.57	-8.41	-0.46	2.55e-15	Paraoxonase activity;
CESC	cis	rs910316	0.663	rs175034	chr14:75463687	T/G	cg11812906	chr14:75593930	NEK9	-0.8	-12.71	-0.62	3.25e-29	Height;
CESC	cis	rs1799949	0.965	rs8176140	chr17:41251646	T/A	cg23758822	chr17:41437982	NA	1.0	15.37	0.69	1.56e-38	Menopause (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09409496	chr21:38738374	DYRK1A	0.59	7.05	0.4	1.59e-11	Gut microbiome composition (summer);
CESC	cis	rs4692589	1.000	rs17546378	chr4:170935854	G/A	cg19918862	chr4:170955249	NA	0.36	5.65	0.33	4.07e-8	Anxiety disorder;
CESC	cis	rs9733	0.596	rs11204704	chr1:150671630	T/C	cg04414720	chr1:150670196	GOLPH3L	0.63	9.02	0.48	3.87e-17	Tonsillectomy;
CESC	cis	rs1003719	0.680	rs3737540	chr21:38523266	C/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.5	-6.63	-0.38	1.89e-10	Eye color traits;
CESC	cis	rs763121	0.853	rs1062687	chr22:39134715	T/C	cg14440974	chr22:39074834	NA	-0.37	-5.3	-0.31	2.44e-7	Menopause (age at onset);
CESC	cis	rs4689388	0.856	rs10016157	chr4:6294414	T/C	cg25554036	chr4:6271136	WFS1	0.51	8.37	0.46	3.31e-15	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs2243480	1.000	rs4548056	chr7:65298873	A/G	cg18252515	chr7:66147081	NA	-1.01	-9.63	-0.51	5.21e-19	Diabetic kidney disease;
CESC	cis	rs2011503	1.000	rs17684164	chr19:19626769	C/T	cg11584989	chr19:19387371	SF4	0.61	7.06	0.4	1.45e-11	Bipolar disorder;
CESC	cis	rs798554	0.759	rs2644291	chr7:2890456	T/C	cg18446336	chr7:2847575	GNA12	-0.36	-5.56	-0.32	6.61e-8	Height;
CESC	cis	rs7520050	0.808	rs11211195	chr1:46282295	T/C	cg24296786	chr1:45957014	TESK2	0.43	5.41	0.32	1.38e-7	Red blood cell count;Reticulocyte count;
CESC	cis	rs3087591	0.922	rs12939969	chr17:29463577	A/G	cg24425628	chr17:29625626	OMG;NF1	0.41	5.06	0.3	7.7300000000000005e-07	Hip circumference;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18927317	chr7:75987610	YWHAG	0.59	6.48	0.37	4.5e-10	Gut microbiome composition (summer);
CESC	cis	rs7772486	0.754	rs697054	chr6:146003770	C/T	cg23711669	chr6:146136114	FBXO30	1.01	15.22	0.68	4.99e-38	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs60871478	0.786	rs62432898	chr7:826102	G/A	cg13798912	chr7:905769	UNC84A	0.56	5.63	0.33	4.52e-8	Cerebrospinal P-tau181p levels;
CESC	cis	rs17253792	0.915	rs76952651	chr14:56188994	G/A	cg01858014	chr14:56050164	KTN1	-0.94	-7.35	-0.41	2.5e-12	Putamen volume;
CESC	cis	rs561341	0.714	rs75861674	chr17:30304317	A/G	cg12193833	chr17:30244370	NA	-0.56	-5.78	-0.33	2.15e-8	Hip circumference adjusted for BMI;
CESC	cis	rs11640533	0.901	rs11862250	chr16:53415038	C/A	cg02380802	chr16:53407808	NA	0.43	5.59	0.32	5.71e-8	Intelligence (multi-trait analysis);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg08269949	chr6:26538502	HMGN4	-0.45	-6.51	-0.37	3.75e-10	Gambling;
CESC	cis	rs9733	0.596	rs6681990	chr1:150695929	A/G	cg22823121	chr1:150693482	HORMAD1	0.47	6.96	0.39	2.6e-11	Tonsillectomy;
CESC	cis	rs881375	0.678	rs3761846	chr9:123689597	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.43	6.33	0.36	1.06e-9	Rheumatoid arthritis;
CESC	cis	rs7605827	0.930	rs7590458	chr2:15601574	A/G	cg19274914	chr2:15703543	NA	-0.36	-6.52	-0.37	3.56e-10	Educational attainment (years of education);
CESC	cis	rs875971	0.862	rs1968126	chr7:66057004	A/G	cg11764359	chr7:65958608	NA	-0.78	-11.24	-0.57	3.14e-24	Aortic root size;
CESC	cis	rs9788682	1.000	rs12441354	chr15:78821016	G/A	cg24631222	chr15:78858424	CHRNA5	0.77	9.92	0.52	6.29e-20	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs765787	0.530	rs1631533	chr15:45518628	C/T	cg24006582	chr15:45444508	DUOX1	-0.57	-6.88	-0.39	4.23e-11	Uric acid levels;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg04709120	chr10:74451858	CCDC109A	-0.47	-6.33	-0.36	1.02e-9	Ulcerative colitis;
CESC	cis	rs28374715	0.528	rs7178360	chr15:41631175	T/A	cg18705301	chr15:41695430	NDUFAF1	-1.06	-15.64	-0.69	1.7e-39	Ulcerative colitis;
CESC	cis	rs10178094	0.933	rs10172311	chr2:161329365	C/T	cg03641300	chr2:160917029	PLA2R1	0.37	5.35	0.31	1.86e-7	White blood cell count;
CESC	cis	rs3806843	0.766	rs801176	chr5:140087010	A/G	cg26395211	chr5:140044315	WDR55	-0.47	-6.09	-0.35	4.03e-9	Depressive symptoms (multi-trait analysis);
CESC	cis	rs6952808	0.931	rs12537479	chr7:1868995	A/G	cg13880726	chr7:1868755	MAD1L1	-0.52	-7.03	-0.4	1.77e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs7219021	1.000	rs2032843	chr17:46847524	T/A	cg16584676	chr17:46985605	UBE2Z	-0.7	-7.81	-0.43	1.37e-13	Schizophrenia or bipolar disorder;
CESC	cis	rs752010	0.806	rs943375	chr1:42092152	A/G	cg06885757	chr1:42089581	HIVEP3	0.5	8.31	0.45	5.03e-15	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs807669	0.548	rs9605957	chr22:19187375	G/A	cg17887427	chr22:19166691	SLC25A1	-0.44	-5.66	-0.33	4.01e-8	Metabolite levels;
CESC	cis	rs2070488	0.965	rs13097628	chr3:38521156	T/C	cg24069376	chr3:38537580	EXOG	0.48	8.8	0.48	1.81e-16	Electrocardiographic conduction measures;
CESC	cis	rs11055008	0.935	rs10845601	chr12:12820134	A/G	cg04607235	chr12:12878440	APOLD1	0.71	9.36	0.5	3.59e-18	Pulse pressure;
CESC	cis	rs4665809	0.652	rs4665832	chr2:26404775	A/G	cg25036284	chr2:26402008	FAM59B	-0.82	-9.33	-0.5	4.31e-18	Gut microbiome composition (summer);
CESC	cis	rs873946	0.648	rs3750578	chr10:134563366	A/G	cg26818010	chr10:134567672	INPP5A	-0.91	-11.09	-0.56	1e-23	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs7116495	0.786	rs1573501	chr11:71735693	C/T	cg26138937	chr11:71823887	C11orf51	-1.33	-7.85	-0.43	1.06e-13	Severe influenza A (H1N1) infection;
CESC	cis	rs7084402	0.967	rs1649055	chr10:60320045	T/A	cg07615347	chr10:60278583	BICC1	0.63	10.12	0.53	1.48e-20	Refractive error;
CESC	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg24101359	chr6:42928495	GNMT	0.55	7.88	0.44	8.68e-14	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs7618915	0.547	rs13064064	chr3:52657002	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.48	6.9	0.39	3.85e-11	Bipolar disorder;
CESC	cis	rs7267979	0.966	rs2261784	chr20:25262396	G/C	cg08601574	chr20:25228251	PYGB	0.39	5.65	0.33	4.13e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs477692	0.648	rs10829599	chr10:131321881	C/T	cg05714579	chr10:131428358	MGMT	0.41	5.28	0.31	2.71e-7	Response to temozolomide;
CESC	cis	rs6761276	0.674	rs3811056	chr2:113831183	T/C	cg12858261	chr2:113808755	IL1F8	0.46	5.68	0.33	3.63e-8	Protein quantitative trait loci;
CESC	cis	rs7605827	0.836	rs1549016	chr2:15616859	G/A	cg19274914	chr2:15703543	NA	0.36	6.42	0.37	6.17e-10	Educational attainment (years of education);
CESC	cis	rs7618915	0.547	rs11714419	chr3:52628816	A/G	cg18404041	chr3:52824283	ITIH1	-0.37	-6.06	-0.35	4.58e-9	Bipolar disorder;
CESC	cis	rs9910055	0.659	rs227578	chr17:42210189	C/A	cg16434002	chr17:42200994	HDAC5	0.37	5.03	0.3	9.18e-7	Total body bone mineral density;
CESC	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg03188948	chr7:1209495	NA	0.7	6.71	0.38	1.2e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs763121	0.853	rs5750677	chr22:39147715	C/T	cg06022373	chr22:39101656	GTPBP1	0.93	15.87	0.7	2.44e-40	Menopause (age at onset);
CESC	cis	rs2243480	1.000	rs36033484	chr7:65390558	T/G	cg25894440	chr7:65020034	NA	-0.62	-5.16	-0.3	4.73e-7	Diabetic kidney disease;
CESC	cis	rs4713118	0.513	rs9368547	chr6:28028067	A/G	cg12963246	chr6:28129442	ZNF389	0.38	5.55	0.32	6.82e-8	Parkinson's disease;
CESC	cis	rs55788414	0.932	rs35424543	chr16:81181983	G/A	cg06400318	chr16:81190750	PKD1L2	-0.61	-5.46	-0.32	1.1e-7	Left ventricular obstructive tract defect (maternal effect);
CESC	cis	rs9346455	1.000	rs9346455	chr6:71991816	A/C	cg27238071	chr6:71998145	OGFRL1	0.59	5.44	0.32	1.19e-7	Antipsychotic drug-induced weight gain (time interaction);Antipsychotic drug-induced weight gain;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22783180	chr10:8091753	NA	0.57	6.56	0.37	2.81e-10	Gut microbiome composition (summer);
CESC	cis	rs1670533	1.000	rs6839931	chr4:1053172	A/G	cg27284194	chr4:1044797	NA	0.45	5.71	0.33	3.1e-8	Recombination rate (females);
CESC	cis	rs3091242	0.900	rs4649086	chr1:25778967	T/A	cg27572855	chr1:25598939	RHD	0.43	7.24	0.41	4.99e-12	Erythrocyte sedimentation rate;
CESC	cis	rs6783573	0.535	rs12637699	chr3:46628443	C/T	cg27371741	chr3:46619158	LRRC2;TDGF1	-0.32	-5.03	-0.3	9.02e-7	Cerebrospinal fluid biomarker levels;
CESC	cis	rs2303745	0.589	rs8103523	chr19:17398269	A/G	cg22549504	chr19:17448937	GTPBP3	0.49	5.44	0.32	1.24e-7	Systemic lupus erythematosus;
CESC	cis	rs67311347	1.000	rs962847	chr3:40495156	A/G	cg09455208	chr3:40491958	NA	-0.48	-8.1	-0.45	2.05e-14	Renal cell carcinoma;
CESC	cis	rs7267979	1.000	rs10966	chr20:25282944	A/G	cg08601574	chr20:25228251	PYGB	0.39	5.59	0.32	5.56e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs780096	0.526	rs2010087	chr2:27637235	C/T	cg12648201	chr2:27665141	KRTCAP3	-0.35	-6.37	-0.36	8.27e-10	Total body bone mineral density;
CESC	cis	rs9911578	1.000	rs2567905	chr17:56782297	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.19	0.3	4.29e-7	Intelligence (multi-trait analysis);
CESC	cis	rs9322193	0.962	rs1112730	chr6:150087519	G/A	cg04369109	chr6:150039330	LATS1	-0.39	-5.27	-0.31	2.82e-7	Lung cancer;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg16704476	chr12:107350911	C12orf23	-0.55	-7.74	-0.43	2.05e-13	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs35883536	1.000	rs1832123	chr1:101168196	A/G	cg16931499	chr17:42786676	DBF4B	0.42	6.14	0.35	3e-9	Monocyte count;
CESC	cis	rs3091242	0.934	rs666686	chr1:25719511	A/G	cg03538708	chr1:25844672	NA	-0.36	-5.47	-0.32	1.03e-7	Erythrocyte sedimentation rate;
CESC	cis	rs1577917	0.958	rs13213551	chr6:86608701	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.42	-5.5	-0.32	9.03e-8	Response to antipsychotic treatment;
CESC	cis	rs4689388	0.890	rs4342257	chr4:6290037	G/C	cg00701064	chr4:6280414	WFS1	0.72	12.78	0.62	1.92e-29	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs11864453	0.713	rs9926156	chr16:72142895	G/C	cg01557791	chr16:72042693	DHODH	-0.48	-6.29	-0.36	1.27e-9	Fibrinogen levels;
CESC	cis	rs1475911	0.708	rs66994219	chr21:43521647	G/A	cg09849774	chr21:43526787	UMODL1;C21orf128	-0.43	-5.11	-0.3	6.15e-7	IgG glycosylation;
CESC	trans	rs163030	0.902	rs448293	chr5:76738927	A/C	cg26150533	chr8:82396069	FABP4	-0.39	-6.01	-0.35	6.12e-9	Caudate nucleus volume;
CESC	cis	rs7945705	0.935	rs11042102	chr11:8882164	C/T	cg09997546	chr11:8931473	C11orf17;ST5	0.35	5.64	0.33	4.29e-8	Hemoglobin concentration;
CESC	cis	rs709400	0.628	rs11622356	chr14:103912195	C/T	cg12935359	chr14:103987150	CKB	-0.57	-8.42	-0.46	2.43e-15	Body mass index;
CESC	cis	rs1799949	0.931	rs34410138	chr17:41279770	A/G	cg05368731	chr17:41323189	NBR1	0.79	11.25	0.57	3.01e-24	Menopause (age at onset);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg22395253	chr7:104941898	SRPK2	0.5	6.4	0.37	7.05e-10	Fibrinogen levels;
CESC	cis	rs11676348	0.846	rs7607437	chr2:219008392	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.45	-5.77	-0.33	2.26e-8	Ulcerative colitis;
CESC	cis	rs11227306	0.934	rs2303385	chr11:65640562	G/A	cg00576331	chr11:65640516	EFEMP2	0.47	6.08	0.35	4.1e-9	DNA methylation (variation);
CESC	cis	rs7607369	0.782	rs639913	chr2:219365971	A/C	cg02176678	chr2:219576539	TTLL4	0.5	9.05	0.49	3.15e-17	Red blood cell count;Amyotrophic lateral sclerosis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08579753	chr1:39174525	NA	-0.64	-8.02	-0.44	3.36e-14	Gut microbiome composition (summer);
CESC	cis	rs8067342	0.611	rs7213842	chr17:21175537	C/T	cg03858720	chr17:21194718	MAP2K3	-0.38	-5.2	-0.3	3.89e-7	Immature fraction of reticulocytes;Red cell distribution width;
CESC	cis	rs116095464	0.558	rs12173015	chr5:269967	A/C	cg22857025	chr5:266934	NA	1.01	12.12	0.6	3.48e-27	Breast cancer;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg05182418	chr14:104176381	XRCC3	0.46	6.24	0.36	1.7e-9	Fibrinogen levels;
CESC	cis	rs1218582	0.772	rs6699043	chr1:154913021	T/C	cg06221963	chr1:154839813	KCNN3	-0.66	-11.17	-0.57	5.33e-24	Prostate cancer;
CESC	cis	rs1348850	0.668	rs13034886	chr2:178493301	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.44	5.08	0.3	7.12e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs477895	0.639	rs35858916	chr11:63950529	T/G	cg18225595	chr11:63971243	STIP1	0.52	5.16	0.3	4.77e-7	Mean platelet volume;
CESC	cis	rs6484504	0.532	rs11031342	chr11:31309818	G/A	cg14844989	chr11:31128820	NA	-0.4	-5.49	-0.32	9.59e-8	Red blood cell count;
CESC	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg17178900	chr1:205818956	PM20D1	0.87	15.49	0.69	5.76e-39	Menarche (age at onset);
CESC	cis	rs9611565	0.694	rs5758324	chr22:41787950	G/T	cg17376030	chr22:41985996	PMM1	0.43	5.16	0.3	4.84e-7	Vitiligo;
CESC	cis	rs2228479	0.867	rs2270459	chr16:89979851	A/C	cg04013166	chr16:89971882	TCF25	-0.68	-6.99	-0.39	2.24e-11	Skin colour saturation;
CESC	cis	rs6866344	0.570	rs6896799	chr5:178147014	G/C	cg10224037	chr5:178157518	ZNF354A	0.73	8.49	0.46	1.53e-15	Neutrophil percentage of white cells;
CESC	cis	rs2625529	0.526	rs55763892	chr15:72540180	C/T	cg16672083	chr15:72433130	SENP8	0.4	5.89	0.34	1.14e-8	Red blood cell count;
CESC	cis	rs1707322	0.896	rs946528	chr1:46485562	C/T	cg05343316	chr1:45956843	TESK2	-0.41	-5.05	-0.3	8.14e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14308291	chr1:36396265	EIF2C3	-0.49	-6.62	-0.38	1.95e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs2836974	0.568	rs8130795	chr21:40549983	T/A	cg11644478	chr21:40555479	PSMG1	0.82	12.48	0.61	1.94e-28	Cognitive function;
CESC	trans	rs7937682	0.774	rs59921976	chr11:111473088	G/A	cg18187862	chr3:45730750	SACM1L	0.48	6.01	0.35	5.97e-9	Primary sclerosing cholangitis;
CESC	cis	rs12220238	0.908	rs10824077	chr10:75887038	C/T	cg19889307	chr10:75911429	ADK;AP3M1	-0.63	-6.29	-0.36	1.33e-9	Soluble interleukin-2 receptor subunit alpha;
CESC	cis	rs7680126	0.671	rs7663044	chr4:10023939	C/G	cg00071950	chr4:10020882	SLC2A9	0.54	5.15	0.3	5.07e-7	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	cis	rs1218582	0.741	rs10908447	chr1:154869742	C/T	cg06221963	chr1:154839813	KCNN3	-0.67	-11.23	-0.57	3.35e-24	Prostate cancer;
CESC	cis	rs763121	0.853	rs5757208	chr22:39049230	A/C	cg06544989	chr22:39130855	UNC84B	0.49	8.52	0.46	1.22e-15	Menopause (age at onset);
CESC	cis	rs9831754	1.000	rs112170848	chr3:78359996	G/A	cg06138941	chr3:78371609	NA	-0.75	-8.54	-0.46	1.09e-15	Calcium levels;
CESC	cis	rs644799	1.000	rs543530	chr11:95545170	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	9.15	0.49	1.61e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs7100689	0.784	rs3120977	chr10:82075324	C/G	cg09936400	chr10:82049201	MAT1A	0.37	5.26	0.31	2.93e-7	Post bronchodilator FEV1;
CESC	cis	rs875971	0.862	rs6460302	chr7:65960257	C/G	cg10691866	chr7:65817282	TPST1	-0.32	-5.25	-0.31	3.14e-7	Aortic root size;
CESC	cis	rs6540559	1.000	rs6659367	chr1:209982408	G/T	cg25204440	chr1:209979598	IRF6	0.62	8.03	0.44	3.12e-14	Cleft lip with or without cleft palate;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg15344021	chr17:2240169	TSR1;SGSM2	0.49	6.19	0.36	2.3e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs7178572	0.568	rs1389436	chr15:77665848	G/T	cg22256960	chr15:77711686	NA	-0.53	-6.77	-0.38	8.05e-11	Type 2 diabetes;
CESC	cis	rs9303401	0.659	rs35828828	chr17:56718205	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.03	13.07	0.63	1.81e-30	Cognitive test performance;
CESC	cis	rs1552244	1.000	rs4269070	chr3:10126083	C/G	cg00149659	chr3:10157352	C3orf10	0.71	8.76	0.47	2.39e-16	Alzheimer's disease;
CESC	cis	rs9910055	0.659	rs2246287	chr17:42232442	C/G	cg13607699	chr17:42295918	UBTF	0.58	7.54	0.42	7.45e-13	Total body bone mineral density;
CESC	cis	rs12579753	0.917	rs10862361	chr12:82197946	T/C	cg24719984	chr12:82153464	PPFIA2	-0.33	-5.04	-0.3	8.55e-7	Resting heart rate;
CESC	cis	rs798554	0.610	rs2644304	chr7:2878779	T/C	cg13628971	chr7:2884303	GNA12	0.4	5.34	0.31	2.01e-7	Height;
CESC	cis	rs8114671	0.869	rs1544047	chr20:33670753	T/C	cg06115741	chr20:33292138	TP53INP2	-0.44	-5.31	-0.31	2.27e-7	Height;
CESC	cis	rs7267979	1.000	rs2257809	chr20:25266476	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	18.61	0.75	5.02e-50	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs13191362	0.935	rs13212137	chr6:163010261	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.87	8.98	0.48	5.33e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs9399135	0.935	rs11754504	chr6:135321509	C/T	cg24558204	chr6:135376177	HBS1L	0.53	7.28	0.41	3.85e-12	Red blood cell count;
CESC	cis	rs965469	0.652	rs6051837	chr20:3388994	G/T	cg25506879	chr20:3388711	C20orf194	-0.53	-6.17	-0.35	2.56e-9	IFN-related cytopenia;
CESC	cis	rs9926296	0.565	rs8055825	chr16:89832848	C/T	cg07648498	chr16:89883185	FANCA	0.43	5.18	0.3	4.37e-7	Vitiligo;
CESC	cis	rs4764487	0.760	rs733700	chr12:6337974	A/G	cg08284733	chr12:6341482	CD9	0.37	5.47	0.32	1.02e-7	Mean platelet volume;
CESC	cis	rs1799949	0.965	rs4793237	chr17:41436595	A/T	cg05368731	chr17:41323189	NBR1	0.54	7.3	0.41	3.3e-12	Menopause (age at onset);
CESC	trans	rs4919087	1.000	rs7067835	chr10:99074649	T/C	cg09150807	chr12:131568764	GPR133	-0.37	-6.07	-0.35	4.41e-9	Monocyte count;
CESC	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg14159672	chr1:205819179	PM20D1	0.79	12.21	0.6	1.62e-27	Menarche (age at onset);
CESC	cis	rs6570726	1.000	rs404229	chr6:145868200	G/A	cg05347473	chr6:146136440	FBXO30	0.43	5.79	0.34	2e-8	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1448094	0.817	rs10863111	chr12:86330615	T/C	cg02569458	chr12:86230093	RASSF9	0.45	6.43	0.37	5.79e-10	Major depressive disorder;
CESC	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg10862848	chr6:42927986	GNMT	-0.29	-7.4	-0.41	1.78e-12	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs3733585	0.775	rs13124007	chr4:10043931	G/C	cg11266682	chr4:10021025	SLC2A9	0.65	12.28	0.6	9.55e-28	Cleft plate (environmental tobacco smoke interaction);
CESC	trans	rs62103177	0.810	rs62103175	chr18:77622467	C/T	cg05926928	chr17:57297772	GDPD1	1.19	10.32	0.54	3.18e-21	Opioid sensitivity;
CESC	cis	rs1371867	0.846	rs1660324	chr8:101281271	C/T	cg11906718	chr8:101322791	RNF19A	0.5	6.43	0.37	5.77e-10	Atrioventricular conduction;
CESC	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg16405210	chr4:1374714	KIAA1530	-0.95	-12.51	-0.61	1.51e-28	Longevity;
CESC	cis	rs68170813	0.559	rs77727587	chr7:106815754	C/G	cg02696742	chr7:106810147	HBP1	-0.55	-5.32	-0.31	2.24e-7	Coronary artery disease;
CESC	cis	rs9324022	0.860	rs72698720	chr14:101178715	C/G	cg18089426	chr14:101175970	NA	0.61	7.68	0.43	3.05e-13	Plateletcrit;
CESC	cis	rs9291683	0.546	rs13129453	chr4:10044784	T/C	cg11266682	chr4:10021025	SLC2A9	0.65	12.28	0.6	9.55e-28	Bone mineral density;
CESC	cis	rs116095464	0.558	rs2162870	chr5:228129	G/A	cg12570787	chr5:219185	SDHA;CCDC127	0.53	5.69	0.33	3.34e-8	Breast cancer;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg09662431	chr10:73975914	ASCC1;C10orf104	-0.51	-7.6	-0.42	5.19e-13	Gambling;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg25759457	chr1:172502420	C1orf9	0.45	6.24	0.36	1.7e-9	Systemic lupus erythematosus;
CESC	cis	rs7647973	0.925	rs6446257	chr3:49253492	A/G	cg13072238	chr3:49761600	GMPPB	0.41	5.1	0.3	6.35e-7	Menarche (age at onset);
CESC	cis	rs6540556	0.723	rs1000283	chr1:209894661	A/G	cg05527609	chr1:210001259	C1orf107	0.63	7.01	0.4	1.97e-11	Red blood cell count;
CESC	cis	rs2412208	0.545	rs7414485	chr1:7121397	G/A	cg20434152	chr1:7120926	CAMTA1	-0.36	-5.73	-0.33	2.7e-8	Survival in sporadic amyotrophic lateral sclerosis;
CESC	cis	rs6424115	0.830	rs2503000	chr1:24197898	C/G	cg15997130	chr1:24165203	NA	0.38	5.11	0.3	6.3e-7	Immature fraction of reticulocytes;
CESC	cis	rs7927771	0.864	rs3781627	chr11:47441472	T/A	cg05585544	chr11:47624801	NA	0.44	6.3	0.36	1.22e-9	Subjective well-being;
CESC	cis	rs4975616	0.869	rs421284	chr5:1325590	T/C	cg07493874	chr5:1342172	CLPTM1L	-0.42	-7.98	-0.44	4.32e-14	Lung cancer;
CESC	cis	rs2361718	0.500	rs8068856	chr17:78100731	A/G	cg23534315	chr17:78082725	GAA	0.37	5.21	0.3	3.75e-7	Yeast infection;
CESC	cis	rs10838687	0.800	rs2290146	chr11:47353498	G/A	cg25783544	chr11:47291846	MADD	0.56	6.45	0.37	5.33e-10	Proinsulin levels;
CESC	cis	rs6519955	0.866	rs9626920	chr22:46428993	A/G	cg05468064	chr22:46423449	NA	-0.4	-6.44	-0.37	5.68e-10	Dupuytren's disease;
CESC	cis	rs10504229	0.906	rs114627636	chr8:58173732	C/T	cg14926445	chr8:58193284	C8orf71	-0.54	-5.28	-0.31	2.75e-7	Developmental language disorder (linguistic errors);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg05893876	chr8:120428507	NOV	-0.45	-6.24	-0.36	1.71e-9	Fibrinogen levels;
CESC	cis	rs1971256	0.500	rs17081284	chr6:151800796	C/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.62	5.67	0.33	3.82e-8	Endometriosis;
CESC	cis	rs7927592	0.956	rs7102273	chr11:68385579	T/C	cg20283391	chr11:68216788	NA	-0.48	-5.8	-0.34	1.88e-8	Total body bone mineral density;
CESC	cis	rs1499614	0.901	rs2178742	chr7:66197799	G/A	cg18252515	chr7:66147081	NA	-1.42	-14.62	-0.67	6.69e-36	Gout;
CESC	cis	rs854765	0.618	rs9908017	chr17:17774422	C/T	cg09796270	chr17:17721594	SREBF1	-0.42	-5.97	-0.34	7.74e-9	Total body bone mineral density;
CESC	cis	rs736408	0.812	rs2240920	chr3:52831009	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	-0.4	-5.1	-0.3	6.52e-7	Bipolar disorder;
CESC	cis	rs7017914	0.967	rs10089583	chr8:71849484	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.18	-0.3	4.4e-7	Bone mineral density;
CESC	cis	rs1799949	1.000	rs8077486	chr17:41212805	C/T	cg05368731	chr17:41323189	NBR1	0.57	7.82	0.43	1.24e-13	Menopause (age at onset);
CESC	cis	rs2295499	0.639	rs7681728	chr4:2680515	A/G	cg27239842	chr4:2403781	ZFYVE28	-0.32	-5.27	-0.31	2.85e-7	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
CESC	cis	rs2760061	0.599	rs849903	chr1:228137659	T/C	cg02753203	chr1:228287806	NA	-0.47	-6.68	-0.38	1.38e-10	Diastolic blood pressure;
CESC	cis	rs1348850	0.526	rs10930797	chr2:178437553	C/G	cg22681709	chr2:178499509	PDE11A	-0.49	-5.12	-0.3	6.02e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs17095355	0.901	rs7069128	chr10:111760075	C/T	cg00817464	chr10:111662876	XPNPEP1	0.51	5.98	0.34	7.22e-9	Biliary atresia;
CESC	cis	rs909674	0.818	rs7364148	chr22:39842165	T/C	cg02038168	chr22:39784481	NA	-0.64	-7.49	-0.42	1e-12	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs7615952	0.641	rs61048217	chr3:125807905	G/T	cg06494592	chr3:125709126	NA	-0.51	-5.51	-0.32	8.32e-8	Blood pressure (smoking interaction);
CESC	cis	rs40363	0.671	rs4786425	chr16:3537650	A/G	cg22508957	chr16:3507546	NAT15	-0.68	-7.23	-0.41	5.11e-12	Tuberculosis;
CESC	cis	rs722599	0.748	rs7145173	chr14:75351647	G/A	cg08847533	chr14:75593920	NEK9	-0.45	-5.51	-0.32	8.52e-8	IgG glycosylation;
CESC	cis	rs208520	0.690	rs1318604	chr6:66825278	A/C	cg07460842	chr6:66804631	NA	-1.01	-13.46	-0.64	8.19e-32	Exhaled nitric oxide output;
CESC	cis	rs9611565	0.559	rs4822049	chr22:41993496	G/A	cg06481639	chr22:41940642	POLR3H	-0.65	-6.38	-0.37	7.65e-10	Vitiligo;
CESC	cis	rs921968	0.565	rs6761437	chr2:219598092	G/A	cg02176678	chr2:219576539	TTLL4	-0.45	-8.04	-0.44	2.97e-14	Mean corpuscular hemoglobin concentration;
CESC	cis	rs10129255	0.500	rs11628999	chr14:107208446	C/T	cg07958169	chr14:107095056	NA	-0.53	-8.17	-0.45	1.23e-14	Kawasaki disease;
CESC	cis	rs10089	0.953	rs6879970	chr5:127387178	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.77	10.06	0.53	2.19e-20	Ileal carcinoids;
CESC	cis	rs5769707	0.933	rs2157444	chr22:49994292	A/G	cg20744362	chr22:50050164	C22orf34	0.42	6.96	0.39	2.75e-11	Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs9309473	0.519	rs2421586	chr2:73899719	C/T	cg20560298	chr2:73613845	ALMS1	0.53	7.32	0.41	3.04e-12	Metabolite levels;
CESC	trans	rs9329221	0.537	rs6601414	chr8:9976748	G/A	cg06636001	chr8:8085503	FLJ10661	0.49	6.29	0.36	1.28e-9	Neuroticism;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg17774058	chr20:6748719	BMP2	0.42	6.2	0.36	2.14e-9	Systemic lupus erythematosus;
CESC	cis	rs7957197	0.938	rs34565150	chr12:121429901	A/G	cg12635120	chr12:121345228	NA	-0.36	-5.15	-0.3	5.03e-7	Type 2 diabetes;
CESC	cis	rs2549003	1.000	rs3846732	chr5:131816087	T/C	cg21138405	chr5:131827807	IRF1	0.54	9.24	0.49	8.61e-18	Asthma (sex interaction);
CESC	cis	rs853679	0.517	rs56364346	chr6:28050762	T/G	cg26335602	chr6:28129616	ZNF389	0.53	7.05	0.4	1.55e-11	Depression;
CESC	cis	rs868036	1.000	rs1026735	chr15:68101700	A/G	cg08079166	chr15:68083412	MAP2K5	0.44	6.94	0.39	2.94e-11	Restless legs syndrome;
CESC	cis	rs8040855	0.575	rs12912860	chr15:85573498	T/C	cg08123816	chr15:85640762	PDE8A	-0.39	-5.81	-0.34	1.79e-8	Bulimia nervosa;
CESC	cis	rs8077889	0.672	rs15359	chr17:41843979	C/G	cg26893861	chr17:41843967	DUSP3	-1.08	-22.44	-0.81	3.23e-63	Triglycerides;
CESC	cis	rs763014	0.898	rs8050792	chr16:656033	T/C	cg07343612	chr16:622815	PIGQ	-0.54	-8.05	-0.44	2.86e-14	Height;
CESC	cis	rs7666738	0.830	rs4619898	chr4:98959646	G/A	cg05340658	chr4:99064831	C4orf37	0.8	12.36	0.6	5.29e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs8141529	0.719	rs132561	chr22:29351179	C/T	cg02153584	chr22:29168773	CCDC117	-0.46	-5.73	-0.33	2.7e-8	Lymphocyte counts;
CESC	cis	rs26868	0.766	rs30995	chr16:2248017	C/T	cg02248941	chr16:2239361	CASKIN1	-0.38	-6.21	-0.36	2.04e-9	Height;
CESC	cis	rs9467711	0.606	rs9393711	chr6:26370659	C/T	cg14345882	chr6:26364793	BTN3A2	0.6	6.21	0.36	2.06e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs736408	0.507	rs6445531	chr3:52717282	T/C	cg05564831	chr3:52568323	NT5DC2	0.46	7.33	0.41	2.88e-12	Bipolar disorder;
CESC	cis	rs67311347	1.000	rs17078941	chr3:40450888	A/G	cg09455208	chr3:40491958	NA	-0.49	-8.01	-0.44	3.57e-14	Renal cell carcinoma;
CESC	cis	rs807669	0.505	rs2236759	chr22:19187427	C/G	cg17887427	chr22:19166691	SLC25A1	-0.39	-5.24	-0.31	3.29e-7	Metabolite levels;
CESC	trans	rs117004340	0.687	rs73203975	chr8:13213016	C/T	cg13468214	chr4:1046988	NA	0.66	6.52	0.37	3.6e-10	Obstructive sleep apnea trait (apnea hypopnea index);
CESC	cis	rs7927592	0.763	rs10896326	chr11:68234571	T/C	cg16797656	chr11:68205561	LRP5	0.48	7.29	0.41	3.63e-12	Total body bone mineral density;
CESC	cis	rs4141404	0.818	rs5997897	chr22:31570436	G/A	cg02404636	chr22:31891804	SFI1	-0.38	-5.47	-0.32	1.03e-7	Paclitaxel-induced neuropathy;
CESC	cis	rs6952808	0.723	rs60995052	chr7:2030007	G/C	cg22963979	chr7:1858916	MAD1L1	-0.38	-5.14	-0.3	5.29e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs738322	0.967	rs4385	chr22:38573229	T/C	cg17652424	chr22:38574118	PLA2G6	-0.34	-6.07	-0.35	4.35e-9	Cutaneous nevi;
CESC	cis	rs9487051	0.872	rs1111864	chr6:109611138	A/G	cg01475377	chr6:109611718	NA	-0.51	-8.38	-0.46	3.06e-15	Reticulocyte fraction of red cells;
CESC	cis	rs875971	0.964	rs6978721	chr7:65883204	A/G	cg11764359	chr7:65958608	NA	0.98	15.79	0.7	4.71e-40	Aortic root size;
CESC	cis	rs7264396	0.790	rs6579255	chr20:34219496	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.65	7.78	0.43	1.59e-13	Total cholesterol levels;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg08240007	chr2:220407822	CHPF;TMEM198	-0.45	-6.0	-0.35	6.54e-9	Ulcerative colitis;
CESC	trans	rs875971	1.000	rs6963646	chr7:65685767	T/C	cg26939375	chr7:64535504	NA	-0.46	-6.1	-0.35	3.8e-9	Aortic root size;
CESC	cis	rs35110281	0.806	rs1454649	chr21:45032982	C/T	cg01579765	chr21:45077557	HSF2BP	-0.56	-9.35	-0.5	3.95e-18	Mean corpuscular volume;
CESC	cis	rs9527	0.590	rs11191513	chr10:104772984	T/G	cg08650961	chr10:104748594	CNNM2	0.31	5.03	0.3	9.04e-7	Arsenic metabolism;
CESC	trans	rs4332037	0.539	rs4470910	chr7:2071723	C/T	cg11693508	chr17:37793320	STARD3	0.66	6.68	0.38	1.43e-10	Bipolar disorder;
CESC	cis	rs9894429	0.752	rs6565610	chr17:79592652	A/G	cg21984481	chr17:79567631	NPLOC4	-0.56	-8.99	-0.48	4.98e-17	Eye color traits;
CESC	cis	rs7296418	0.738	rs10846489	chr12:123743927	A/G	cg00376283	chr12:123451042	ABCB9	-0.62	-8.59	-0.47	7.33e-16	Platelet count;
CESC	trans	rs9951602	0.512	rs4798995	chr18:76654344	T/G	cg02800362	chr5:177631904	HNRNPAB	0.66	8.63	0.47	5.9e-16	Obesity-related traits;
CESC	cis	rs651907	0.535	rs36060163	chr3:101360963	C/T	cg12386194	chr3:101231763	SENP7	0.43	5.35	0.31	1.92e-7	Colorectal cancer;
CESC	cis	rs1801251	0.727	rs13029336	chr2:233569935	A/G	cg25237894	chr2:233734115	C2orf82	-0.38	-6.64	-0.38	1.76e-10	Coronary artery disease;
CESC	cis	rs963731	0.579	rs6739807	chr2:39287668	G/A	cg04010122	chr2:39346883	SOS1	-0.64	-5.46	-0.32	1.07e-7	Corticobasal degeneration;
CESC	cis	rs10479542	0.549	rs4376229	chr5:179042971	A/G	cg00080972	chr5:178986291	RUFY1	0.38	5.72	0.33	2.89e-8	Lung cancer;
CESC	cis	rs35110281	0.627	rs7283362	chr21:44973667	C/G	cg04455712	chr21:45112962	RRP1B	0.38	5.66	0.33	4.03e-8	Mean corpuscular volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16664859	chr1:226309452	NA	0.59	6.74	0.38	9.93e-11	Gut microbiome composition (summer);
CESC	cis	rs6952808	0.792	rs13224989	chr7:1953766	C/G	cg00106254	chr7:1943704	MAD1L1	-0.45	-5.64	-0.33	4.46e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs7084402	0.967	rs1658495	chr10:60280153	C/A	cg07615347	chr10:60278583	BICC1	-0.6	-9.67	-0.51	3.99e-19	Refractive error;
CESC	cis	rs7267979	0.903	rs6132819	chr20:25218618	C/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.83	15.02	0.68	2.71e-37	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7624766	0.555	rs718757	chr3:160534225	A/G	cg22637730	chr3:160473554	PPM1L	-0.39	-5.09	-0.3	6.64e-7	Response to methotrexate in rheumatoid arthritis;
CESC	cis	rs12701220	0.541	rs12535516	chr7:1114440	C/G	cg26769984	chr7:1090371	C7orf50	0.54	5.72	0.33	2.85e-8	Bronchopulmonary dysplasia;
CESC	cis	rs7618915	0.570	rs4687633	chr3:52630548	G/A	cg17372223	chr3:52568218	NT5DC2	0.44	6.53	0.37	3.36e-10	Bipolar disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23954953	chr1:97187154	PTBP2	0.54	6.0	0.35	6.33e-9	Gut microbiome composition (summer);
CESC	cis	rs911555	0.723	rs7149767	chr14:103863545	G/A	cg24130564	chr14:104152367	KLC1	0.45	5.91	0.34	1.03e-8	Intelligence (multi-trait analysis);
CESC	cis	rs9796	0.689	rs692511	chr15:41446252	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.43	-6.33	-0.36	1.05e-9	Menopause (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26998856	chr6:35227515	ZNF76	0.64	7.47	0.42	1.16e-12	Gut microbiome composition (summer);
CESC	cis	rs4665809	0.878	rs6720312	chr2:26364934	A/G	cg25036284	chr2:26402008	FAM59B	0.65	7.73	0.43	2.24e-13	Gut microbiome composition (summer);
CESC	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg07677032	chr17:61819896	STRADA	0.45	6.05	0.35	5.02e-9	Prudent dietary pattern;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg26820199	chr1:151372228	PSMB4	-0.54	-6.34	-0.36	1.01e-9	Ulcerative colitis;
CESC	cis	rs7618501	0.669	rs7634084	chr3:49949834	A/T	cg24308560	chr3:49941425	MST1R	-0.64	-9.83	-0.52	1.17e-19	Intelligence (multi-trait analysis);
CESC	cis	rs6762	0.748	rs28735718	chr11:839629	A/G	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.67	-8.45	-0.46	1.96e-15	Mean platelet volume;
CESC	cis	rs116095464	1.000	rs56700778	chr5:313186	A/T	cg22857025	chr5:266934	NA	-1.24	-7.67	-0.43	3.29e-13	Breast cancer;
CESC	cis	rs7542091	0.666	rs7537070	chr1:210043565	A/G	cg21951975	chr1:209979733	IRF6	0.47	8.25	0.45	7.51e-15	Monobrow;
CESC	cis	rs1790761	0.505	rs7945035	chr11:67348162	A/G	cg14500267	chr11:67383377	NA	-0.31	-5.12	-0.3	5.81e-7	Mean corpuscular volume;
CESC	cis	rs3096299	0.658	rs12443705	chr16:89547054	C/G	cg08392591	chr16:89556376	ANKRD11	0.6	8.13	0.45	1.64e-14	Multiple myeloma (IgH translocation);
CESC	cis	rs5769765	0.773	rs9616383	chr22:50313014	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.58	-6.23	-0.36	1.86e-9	Schizophrenia;
CESC	cis	rs1062177	0.694	rs2915816	chr5:151115857	G/A	cg00977110	chr5:151150581	G3BP1	-0.53	-5.81	-0.34	1.74e-8	Preschool internalizing problems;
CESC	cis	rs6714710	0.580	rs57681139	chr2:98454473	C/T	cg26665480	chr2:98280029	ACTR1B	0.57	8.02	0.44	3.49e-14	Posterior cortical atrophy and Alzheimer's disease;
CESC	cis	rs933688	0.938	rs10063683	chr5:90714595	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.11	12.45	0.61	2.47e-28	Smoking behavior;
CESC	cis	rs4665809	0.590	rs13019536	chr2:26526978	C/A	cg04944784	chr2:26401820	FAM59B	-0.56	-6.25	-0.36	1.61e-9	Gut microbiome composition (summer);
CESC	cis	rs7772486	0.790	rs2265474	chr6:146182092	G/A	cg05347473	chr6:146136440	FBXO30	0.59	7.5	0.42	9.88e-13	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1707322	0.721	rs4660883	chr1:46236098	C/T	cg06784218	chr1:46089804	CCDC17	0.43	7.5	0.42	9.83e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs12545109	0.800	rs1992122	chr8:57409467	A/G	cg09654669	chr8:57350985	NA	-0.47	-6.48	-0.37	4.37e-10	Obesity-related traits;
CESC	cis	rs2228479	0.850	rs62054640	chr16:89823157	C/T	cg19635926	chr16:89946313	TCF25	0.67	5.09	0.3	6.82e-7	Skin colour saturation;
CESC	cis	rs6032067	0.632	rs62208389	chr20:43794783	A/T	cg11264863	chr20:43835661	SEMG1	0.5	5.35	0.31	1.86e-7	Blood protein levels;
CESC	cis	rs11690935	0.959	rs12692974	chr2:172663256	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.96	-14.68	-0.67	4.14e-36	Schizophrenia;
CESC	trans	rs9467711	0.524	rs13216484	chr6:26762087	C/T	cg06606381	chr12:133084897	FBRSL1	-0.94	-7.65	-0.43	3.72e-13	Autism spectrum disorder or schizophrenia;
CESC	cis	rs765787	0.530	rs11854689	chr15:45516052	A/G	cg24006582	chr15:45444508	DUOX1	-0.58	-7.12	-0.4	1.04e-11	Uric acid levels;
CESC	cis	rs854765	0.618	rs8068820	chr17:17834119	A/G	cg16928487	chr17:17741425	SREBF1	-0.57	-9.74	-0.51	2.33e-19	Total body bone mineral density;
CESC	cis	rs6121246	0.954	rs6060978	chr20:30416893	G/A	cg13852791	chr20:30311386	BCL2L1	0.76	7.78	0.43	1.6e-13	Mean corpuscular hemoglobin;
CESC	trans	rs2207136	0.804	rs1178066	chr6:50895795	G/A	cg06522515	chr3:184090630	THPO	-0.35	-6.06	-0.35	4.68e-9	Myopia;
CESC	cis	rs4975616	0.869	rs467095	chr5:1336221	T/C	cg06550200	chr5:1325588	CLPTM1L	-0.68	-10.29	-0.53	4.22e-21	Lung cancer;
CESC	cis	rs7726839	0.540	rs72703080	chr5:595238	A/G	cg16447950	chr5:562315	NA	-0.55	-5.16	-0.3	4.75e-7	Obesity-related traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26877198	chr19:9938416	UBL5	0.59	7.0	0.4	2.1e-11	Gut microbiome composition (summer);
CESC	cis	rs644799	0.735	rs10831432	chr11:95516040	C/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.75	11.15	0.57	6.1e-24	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	trans	rs17039065	0.920	rs7672020	chr4:109436064	T/C	cg27151770	chr16:49620536	ZNF423	-0.51	-6.21	-0.36	2.09e-9	Gut microbiome composition (summer);
CESC	cis	rs12893668	0.644	rs12890820	chr14:104034849	T/C	cg24130564	chr14:104152367	KLC1	-0.5	-6.22	-0.36	1.93e-9	Reticulocyte count;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg05699592	chr3:48885332	PRKAR2A	0.45	6.17	0.35	2.5e-9	Thyroid stimulating hormone;
CESC	cis	rs1348850	0.567	rs880897	chr2:178532503	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.55	6.95	0.39	2.92e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs7666738	0.830	rs4699593	chr4:98980628	A/G	cg18180107	chr4:99064573	C4orf37	0.39	5.07	0.3	7.39e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs17401966	1.000	rs12402052	chr1:10318652	C/G	cg15208524	chr1:10270712	KIF1B	0.5	6.47	0.37	4.65e-10	Hepatocellular carcinoma;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17235505	chr3:9439402	SETD5;LOC440944	-0.56	-6.26	-0.36	1.57e-9	Gut microbiome composition (summer);
CESC	cis	rs8072100	0.790	rs6505048	chr17:45674998	G/A	cg08085267	chr17:45401833	C17orf57	0.49	6.04	0.35	5.17e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs1448094	0.556	rs11610789	chr12:86169541	A/G	cg02569458	chr12:86230093	RASSF9	0.57	8.38	0.46	3.07e-15	Major depressive disorder;
CESC	cis	rs5769707	0.681	rs9616329	chr22:50026314	G/A	cg20744362	chr22:50050164	C22orf34	0.39	5.93	0.34	9.58e-9	Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs7584330	0.740	rs12471291	chr2:238441751	T/G	cg14458575	chr2:238380390	NA	0.5	7.14	0.4	8.85e-12	Prostate cancer;
CESC	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.61	7.68	0.43	3.08e-13	Prudent dietary pattern;
CESC	cis	rs916888	0.773	rs538628	chr17:44787313	G/C	cg01570182	chr17:44337453	NA	0.9	10.23	0.53	6.61e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05808815	chr1:54666250	CYB5RL;MRPL37	0.49	6.11	0.35	3.49e-9	Gut microbiome composition (summer);
CESC	cis	rs1707322	1.000	rs4660906	chr1:46470860	C/T	cg03146154	chr1:46216737	IPP	0.69	9.24	0.49	8.15e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs10242455	0.867	rs1879859	chr7:99294762	C/T	cg07715041	chr7:99302981	CYP3A7	-0.44	-5.56	-0.32	6.73e-8	Blood metabolite levels;
CESC	cis	rs17039065	0.920	rs17039063	chr4:109381134	A/G	cg16022748	chr4:109541635	LOC285456;RPL34	0.6	5.06	0.3	8.01e-7	Gut microbiome composition (summer);
CESC	cis	rs9611565	0.506	rs2024566	chr22:41697338	A/G	cg03806693	chr22:41940476	POLR3H	-0.76	-8.65	-0.47	5.19e-16	Vitiligo;
CESC	cis	rs10751667	0.643	rs7395613	chr11:933873	C/T	cg06064525	chr11:970664	AP2A2	-0.52	-10.37	-0.54	2.34e-21	Alzheimer's disease (late onset);
CESC	cis	rs67311347	1.000	rs12634013	chr3:40452388	T/C	cg09455208	chr3:40491958	NA	0.53	8.72	0.47	3.11e-16	Renal cell carcinoma;
CESC	cis	rs3862260	0.509	rs3862262	chr1:120161841	G/T	cg11530693	chr1:120165357	ZNF697	0.7	10.91	0.56	4.03e-23	Systemic lupus erythematosus;
CESC	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg11905131	chr22:24372483	LOC391322	-0.7	-10.04	-0.52	2.62e-20	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs6430585	0.528	rs10496738	chr2:136751488	C/T	cg07169764	chr2:136633963	MCM6	1.27	17.1	0.72	1.1e-44	Corneal structure;
CESC	cis	rs7523050	0.643	rs12741359	chr1:109400489	T/C	cg08274380	chr1:109419600	GPSM2	0.83	5.58	0.32	5.89e-8	Fat distribution (HIV);
CESC	cis	rs2573652	1.000	rs2581345	chr15:100514291	A/G	cg09918751	chr15:100517450	ADAMTS17	-0.4	-7.86	-0.43	9.74e-14	Height;
CESC	cis	rs1691799	0.899	rs1168322	chr12:66743769	C/T	cg16791601	chr12:66731901	HELB	-0.79	-14.55	-0.67	1.18e-35	White blood cell count (basophil);
CESC	trans	rs7947523	0.813	rs4999940	chr11:80942337	C/T	cg21800906	chr11:32914818	QSER1	0.46	6.07	0.35	4.48e-9	Emphysema imaging phenotypes;
CESC	cis	rs911555	0.723	rs4906320	chr14:103876925	T/C	cg24130564	chr14:104152367	KLC1	0.46	5.96	0.34	8.04e-9	Intelligence (multi-trait analysis);
CESC	cis	rs7795096	0.532	rs7812239	chr7:151546806	C/G	cg17008978	chr7:151542804	PRKAG2	0.35	5.53	0.32	7.66e-8	Bipolar disorder (age of onset and psychotic symptoms);
CESC	cis	rs1801251	1.000	rs283471	chr2:233656627	G/A	cg08000102	chr2:233561755	GIGYF2	0.69	9.79	0.52	1.58e-19	Coronary artery disease;
CESC	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg11494091	chr17:61959527	GH2	0.73	12.56	0.61	1.09e-28	Prudent dietary pattern;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13725913	chr9:140675929	EHMT1	-0.51	-6.02	-0.35	5.87e-9	Gut microbiome composition (summer);
CESC	cis	rs1008375	0.900	rs13144986	chr4:17675019	C/A	cg02297831	chr4:17616191	MED28	-0.56	-6.3	-0.36	1.21e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs1552244	0.872	rs6771931	chr3:10113408	C/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-11.04	-0.56	1.41e-23	Alzheimer's disease;
CESC	cis	rs6912958	0.712	rs2814712	chr6:88396322	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.36	5.77	0.33	2.19e-8	Monocyte percentage of white cells;
CESC	cis	rs9457247	0.663	rs10946205	chr6:167451311	A/G	cg23791538	chr6:167370224	RNASET2	-0.58	-7.85	-0.43	1e-13	Crohn's disease;
CESC	cis	rs12477438	0.501	rs11685756	chr2:99766215	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.91	15.68	0.69	1.18e-39	Chronic sinus infection;
CESC	cis	rs67311347	1.000	rs1454497	chr3:40496326	C/T	cg24209194	chr3:40518798	ZNF619	-0.56	-7.45	-0.42	1.35e-12	Renal cell carcinoma;
CESC	cis	rs992157	0.798	rs10206064	chr2:219157959	T/C	cg20019365	chr2:219134978	PNKD;AAMP	0.68	9.02	0.48	3.81e-17	Colorectal cancer;
CESC	cis	rs17376456	0.877	rs10476526	chr5:93461916	G/A	cg21475434	chr5:93447410	FAM172A	0.82	7.56	0.42	6.81e-13	Diabetic retinopathy;
CESC	cis	rs7772486	0.790	rs9403750	chr6:146167762	G/A	cg05347473	chr6:146136440	FBXO30	0.55	7.26	0.41	4.4e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4665809	0.652	rs6728090	chr2:26524726	C/T	cg22920501	chr2:26401640	FAM59B	-0.71	-7.87	-0.44	9.22e-14	Gut microbiome composition (summer);
CESC	cis	rs2880765	0.835	rs730372	chr15:86038193	G/T	cg10818794	chr15:86012489	AKAP13	0.34	5.29	0.31	2.6e-7	Coronary artery disease;
CESC	cis	rs738322	0.967	rs4380	chr22:38569529	T/C	cg17652424	chr22:38574118	PLA2G6	-0.33	-5.93	-0.34	9.22e-9	Cutaneous nevi;
CESC	cis	rs6860806	0.661	rs4705929	chr5:131584178	G/T	cg09877947	chr5:131593287	PDLIM4	0.47	6.13	0.35	3.2e-9	Breast cancer;
CESC	cis	rs2797160	0.651	rs6569436	chr6:126032104	A/G	cg05901451	chr6:126070800	HEY2	0.5	7.25	0.41	4.61e-12	Endometrial cancer;
CESC	cis	rs2075371	0.966	rs2244690	chr7:133987039	A/G	cg11752832	chr7:134001865	SLC35B4	0.54	7.02	0.4	1.88e-11	Mean platelet volume;
CESC	cis	rs6952808	0.895	rs12669518	chr7:1921429	G/C	cg23048001	chr7:2026167	MAD1L1	0.43	5.57	0.32	6.1e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs4547160	0.962	rs7308703	chr12:63494993	C/T	cg26727693	chr12:63544175	AVPR1A	-0.42	-6.3	-0.36	1.21e-9	Morning vs. evening chronotype;
CESC	trans	rs877282	0.583	rs12358255	chr10:828626	C/T	cg22713356	chr15:30763199	NA	0.97	9.25	0.49	7.82e-18	Uric acid levels;
CESC	cis	rs13256369	0.901	rs12681298	chr8:8566235	A/G	cg18904891	chr8:8559673	CLDN23	-0.73	-8.61	-0.47	6.67e-16	Obesity-related traits;
CESC	cis	rs8114671	0.967	rs6142322	chr20:33788538	C/A	cg06115741	chr20:33292138	TP53INP2	-0.42	-5.16	-0.3	4.74e-7	Height;
CESC	cis	rs1808579	0.904	rs1788781	chr18:21165080	A/C	cg14672496	chr18:21087552	C18orf8	-0.36	-5.32	-0.31	2.23e-7	Hip circumference;Body mass index;BMI (adjusted for smoking behaviour);
CESC	cis	rs8053891	0.756	rs9930930	chr16:72001971	A/G	cg04254540	chr16:71951199	KIAA0174	-0.42	-5.4	-0.32	1.45e-7	Coronary artery disease;
CESC	cis	rs3806843	1.000	rs10072015	chr5:140170655	A/T	cg16179182	chr5:140090404	VTRNA1-1	0.4	5.15	0.3	5.05e-7	Depressive symptoms (multi-trait analysis);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg13920768	chr9:133557644	PRDM12	-0.39	-6.29	-0.36	1.31e-9	Gambling;
CESC	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg04234412	chr22:24373322	LOC391322	-0.5	-7.19	-0.4	6.66e-12	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs9916302	0.784	rs34473775	chr17:37396201	G/T	cg00129232	chr17:37814104	STARD3	-0.57	-7.49	-0.42	1.02e-12	Glomerular filtration rate (creatinine);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg27275677	chr13:115047248	UPF3A	-0.44	-6.08	-0.35	4.26e-9	Fibrinogen levels;
CESC	cis	rs2549003	1.000	rs2070726	chr5:131821738	C/A	cg00255919	chr5:131827918	IRF1	0.51	8.68	0.47	4.19e-16	Asthma (sex interaction);
CESC	cis	rs1862618	0.853	rs252898	chr5:56188931	T/C	cg03609598	chr5:56110824	MAP3K1	-0.51	-5.42	-0.32	1.36e-7	Initial pursuit acceleration;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg07645736	chr6:137243249	SLC35D3	-0.52	-7.38	-0.41	2.02e-12	Gut microbiota (bacterial taxa);
CESC	cis	rs4604732	0.536	rs4433437	chr1:247636580	A/T	cg12758973	chr1:247694275	LOC148824;OR2C3	0.45	5.71	0.33	3.08e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs7811142	0.943	rs67483801	chr7:100031758	G/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.85	8.83	0.48	1.5e-16	Platelet count;
CESC	cis	rs12497850	0.931	rs9311432	chr3:48850443	T/A	cg06212747	chr3:49208901	KLHDC8B	0.67	8.99	0.48	4.66e-17	Parkinson's disease;
CESC	cis	rs875971	0.862	rs4149461	chr7:65744732	T/C	cg12463550	chr7:65579703	CRCP	-0.46	-5.86	-0.34	1.34e-8	Aortic root size;
CESC	cis	rs344364	0.511	rs1657133	chr16:1950300	A/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.55	-6.2	-0.36	2.15e-9	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs1799949	0.896	rs8176086	chr17:41274778	G/A	cg06001716	chr17:41278141	BRCA1;NBR2	0.39	5.28	0.31	2.75e-7	Menopause (age at onset);
CESC	cis	rs9914988	0.943	rs9894335	chr17:27138483	C/A	cg20469991	chr17:27169893	C17orf63	-0.47	-5.13	-0.3	5.5e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CESC	cis	rs2295359	0.892	rs11209004	chr1:67613932	G/A	cg17031739	chr1:67600172	NA	0.4	5.27	0.31	2.88e-7	Psoriasis;
CESC	cis	rs13034020	0.522	rs62150978	chr2:61256222	T/C	cg18625361	chr2:61244694	PEX13;PUS10	0.66	6.41	0.37	6.45e-10	Hodgkin's lymphoma;
CESC	cis	rs6964587	0.839	rs11767135	chr7:91551245	T/G	cg17063962	chr7:91808500	NA	-0.53	-7.09	-0.4	1.21e-11	Breast cancer;
CESC	cis	rs6762	0.719	rs28620453	chr11:836971	G/C	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.69	-8.91	-0.48	8.69e-17	Mean platelet volume;
CESC	cis	rs9393777	0.513	rs13210025	chr6:26654817	A/C	cg12292205	chr6:26970375	C6orf41	-0.51	-5.49	-0.32	9.37e-8	Intelligence (multi-trait analysis);
CESC	cis	rs7078219	0.505	rs41290504	chr10:101293035	C/A	cg09788492	chr10:101292477	NKX2-3	0.32	5.99	0.35	6.65e-9	Dental caries;
CESC	cis	rs7618915	0.547	rs11130311	chr3:52675005	T/C	cg17372223	chr3:52568218	NT5DC2	0.43	6.51	0.37	3.76e-10	Bipolar disorder;
CESC	trans	rs2727020	0.514	rs4980444	chr11:49550764	T/A	cg03929089	chr4:120376271	NA	-0.81	-12.24	-0.6	1.37e-27	Coronary artery disease;
CESC	cis	rs926938	0.541	rs360623	chr1:115407268	G/C	cg12756093	chr1:115239321	AMPD1	0.43	5.84	0.34	1.54e-8	Autism;
CESC	cis	rs3820068	0.603	rs7537618	chr1:15977682	G/A	cg13390004	chr1:15929781	NA	0.36	5.68	0.33	3.52e-8	Systolic blood pressure;
CESC	cis	rs123509	0.687	rs73077208	chr3:42835205	G/A	cg12982090	chr3:42733453	KBTBD5	-0.66	-7.52	-0.42	8.26e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs1878931	0.582	rs9635562	chr16:3416689	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.73	9.25	0.49	7.99e-18	Body mass index (adult);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01830674	chr2:219433148	RQCD1;USP37	0.69	8.17	0.45	1.27e-14	Gut microbiome composition (summer);
CESC	cis	rs74781061	0.929	rs6495118	chr15:74912012	T/G	cg17294928	chr15:75287854	SCAMP5	-0.49	-5.2	-0.3	3.92e-7	Endometriosis;
CESC	cis	rs28489187	0.683	rs6657817	chr1:85874614	C/T	cg16011679	chr1:85725395	C1orf52	-0.46	-5.53	-0.32	7.8e-8	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	cis	rs2235642	0.893	rs2076442	chr16:1591112	G/T	cg09080909	chr16:1797204	MAPK8IP3	-0.39	-5.26	-0.31	3.03e-7	Coronary artery disease;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg19936194	chr3:141595256	ATP1B3	-0.5	-6.39	-0.37	7.53e-10	Ulcerative colitis;
CESC	trans	rs7937682	0.924	rs11213968	chr11:111527629	G/C	cg18187862	chr3:45730750	SACM1L	0.5	6.36	0.36	8.96e-10	Primary sclerosing cholangitis;
CESC	cis	rs6694270	0.529	rs11261065	chr1:19106254	A/C	cg19637330	chr1:19110922	NA	-0.48	-5.91	-0.34	1.05e-8	Drug-induced liver injury (nitrofurantoin);
CESC	cis	rs2204008	0.775	rs2387809	chr12:38363338	T/A	cg26384229	chr12:38710491	ALG10B	0.73	10.95	0.56	2.81e-23	Bladder cancer;
CESC	cis	rs9291683	0.632	rs10939669	chr4:10045827	A/G	cg02734326	chr4:10020555	SLC2A9	0.47	6.6	0.38	2.23e-10	Bone mineral density;
CESC	cis	rs9486715	0.867	rs4839834	chr6:96882109	C/A	cg18709589	chr6:96969512	KIAA0776	0.45	6.29	0.36	1.31e-9	Headache;
CESC	cis	rs11997175	0.846	rs6999445	chr8:33732693	G/A	ch.8.33884649F	chr8:33765107	NA	0.78	10.44	0.54	1.35e-21	Body mass index;
CESC	cis	rs66569888	0.632	rs6728600	chr2:106898653	G/T	cg16099169	chr2:106886729	NA	-0.51	-5.42	-0.32	1.31e-7	Facial morphology (factor 23);
CESC	cis	rs10883723	0.810	rs2296585	chr10:104245549	C/T	cg22532475	chr10:104410764	TRIM8	-0.34	-5.83	-0.34	1.57e-8	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs637571	0.726	rs669371	chr11:65674153	G/T	cg04055107	chr11:65626734	MUS81;CFL1	-0.67	-8.32	-0.46	4.59e-15	Eosinophil percentage of white cells;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03831054	chr5:140768999	PCDHGB4;PCDHGA4;PCDHGA6;PCDHGA1;PCDHGA5;PCDHGB1;PCDHGA3;PCDHGA2;PCDHGA7;PCDHGB2;PCDHGB3	-0.54	-6.29	-0.36	1.33e-9	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20697630	chr1:20960374	PINK1	0.55	6.17	0.35	2.59e-9	Gut microbiome composition (summer);
CESC	cis	rs9311474	1.000	rs7614727	chr3:52295895	C/T	cg07507251	chr3:52567010	NT5DC2	0.32	5.73	0.33	2.66e-8	Electroencephalogram traits;
CESC	cis	rs9733	0.596	rs11807058	chr1:150640475	G/A	cg22823121	chr1:150693482	HORMAD1	0.48	7.12	0.4	1.02e-11	Tonsillectomy;
CESC	cis	rs35306767	0.903	rs35637113	chr10:874149	G/C	cg20503657	chr10:835505	NA	0.82	8.12	0.45	1.71e-14	Eosinophil percentage of granulocytes;
CESC	cis	rs78456975	0.739	rs28913003	chr2:1519620	A/T	cg01028140	chr2:1542097	TPO	-0.47	-5.29	-0.31	2.56e-7	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs9303401	0.614	rs35057477	chr17:57097064	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.97	12.0	0.59	8.95e-27	Cognitive test performance;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg01213651	chr5:165085761	NA	-0.38	-6.29	-0.36	1.31e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs7666738	0.830	rs2098934	chr4:98992403	A/G	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.62e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11785400	1.000	rs6988393	chr8:143740596	A/G	cg10596483	chr8:143751796	JRK	0.43	5.65	0.33	4.1e-8	Schizophrenia;
CESC	cis	rs16854884	0.657	rs35085196	chr3:143712210	C/T	cg06585982	chr3:143692056	C3orf58	0.52	6.71	0.38	1.15e-10	Economic and political preferences (feminism/equality);
CESC	cis	rs9913156	0.793	rs4346260	chr17:4567215	A/G	cg00122941	chr17:4613640	ARRB2	-0.82	-9.66	-0.51	4.06e-19	Lymphocyte counts;
CESC	cis	rs7666738	0.830	rs10516426	chr4:99035827	A/G	cg18180107	chr4:99064573	C4orf37	0.41	5.27	0.31	2.76e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7927771	0.832	rs11607981	chr11:47401060	T/G	cg05585544	chr11:47624801	NA	-0.48	-7.04	-0.4	1.67e-11	Subjective well-being;
CESC	cis	rs9322193	0.962	rs4816	chr6:150114745	G/A	cg05861140	chr6:150128134	PCMT1	-0.37	-5.3	-0.31	2.42e-7	Lung cancer;
CESC	cis	rs35306767	0.714	rs10508206	chr10:1075777	A/C	cg26597838	chr10:835615	NA	0.57	6.0	0.35	6.44e-9	Eosinophil percentage of granulocytes;
CESC	cis	rs1451375	0.617	rs10277662	chr7:50594836	C/T	cg14593290	chr7:50529359	DDC	0.49	5.99	0.35	6.77e-9	Malaria;
CESC	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg07677032	chr17:61819896	STRADA	0.44	5.81	0.34	1.78e-8	Prudent dietary pattern;
CESC	cis	rs6750795	0.569	rs1797387	chr2:232414692	A/G	cg19187155	chr2:232395269	NMUR1	0.66	11.53	0.58	3.27e-25	Height;
CESC	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg19318889	chr4:1322082	MAEA	0.56	6.79	0.39	7.23e-11	Longevity;
CESC	cis	rs35123781	1.000	rs599946	chr5:139057461	A/G	cg10513866	chr5:139070639	NA	0.37	5.37	0.31	1.75e-7	Schizophrenia;
CESC	cis	rs4268898	1.000	rs10195436	chr2:24436112	C/T	cg06627628	chr2:24431161	ITSN2	0.62	7.32	0.41	2.89e-12	Asthma;
CESC	cis	rs9399137	0.507	rs61738647	chr6:135282735	T/C	cg22676075	chr6:135203613	NA	0.51	6.61	0.38	2.1e-10	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	cis	rs6987853	0.933	rs1343875	chr8:42424749	C/T	cg09913449	chr8:42400586	C8orf40	0.41	6.53	0.37	3.25e-10	Mean corpuscular hemoglobin concentration;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20703731	chr5:55237351	IL6ST	-0.55	-6.66	-0.38	1.61e-10	Gut microbiome composition (summer);
CESC	cis	rs6547741	0.874	rs58737572	chr2:27852118	A/C	cg27432699	chr2:27873401	GPN1	0.5	7.03	0.4	1.74e-11	Oral cavity cancer;
CESC	cis	rs2637266	0.846	rs2579773	chr10:78402847	A/C	cg18941641	chr10:78392320	NA	0.41	7.52	0.42	8.34e-13	Pulmonary function;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg13114696	chr21:47808953	PCNT	0.44	6.14	0.35	3.03e-9	Fibrinogen levels;
CESC	cis	rs2249625	0.523	rs2496501	chr6:72885364	A/G	cg18830697	chr6:72922368	RIMS1	-0.47	-6.88	-0.39	4.4e-11	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CESC	trans	rs459571	0.715	rs401826	chr9:136890591	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.65	-8.31	-0.45	5.09e-15	Platelet distribution width;
CESC	cis	rs1799949	0.965	rs33961729	chr17:41287924	C/A	cg23758822	chr17:41437982	NA	1.01	15.2	0.68	5.81e-38	Menopause (age at onset);
CESC	cis	rs62064224	0.593	rs916663	chr17:30835833	A/C	cg24550644	chr17:30846204	MYO1D	0.43	6.53	0.37	3.3e-10	Schizophrenia;
CESC	cis	rs62103177	0.535	rs4799109	chr18:77675188	A/T	cg12964065	chr18:77638022	KCNG2	0.51	5.33	0.31	2.08e-7	Opioid sensitivity;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16480132	chr7:149571111	LOC401431;ATP6V0E2	0.53	6.04	0.35	5.25e-9	Gut microbiome composition (summer);
CESC	cis	rs2797160	0.967	rs2747718	chr6:126009109	C/A	cg05901451	chr6:126070800	HEY2	0.45	6.59	0.38	2.39e-10	Endometrial cancer;
CESC	cis	rs10504229	0.683	rs62621195	chr8:58133964	G/A	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs6732160	0.549	rs6744529	chr2:73480869	A/G	cg01422370	chr2:73384389	NA	0.42	7.12	0.4	1.03e-11	Intelligence (multi-trait analysis);
CESC	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg14159672	chr1:205819179	PM20D1	0.87	14.81	0.67	1.42e-36	Menarche (age at onset);
CESC	cis	rs9649213	0.593	rs62478177	chr7:97964611	G/A	cg00277769	chr7:97922759	BAIAP2L1	-0.34	-5.62	-0.33	4.84e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs9926296	0.585	rs8045232	chr16:89857548	A/G	cg01097406	chr16:89675127	NA	-0.33	-5.09	-0.3	6.91e-7	Vitiligo;
CESC	trans	rs3942852	0.806	rs11039515	chr11:48119474	A/G	cg15704280	chr7:45808275	SEPT13	0.63	7.37	0.41	2.12e-12	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs7618501	1.000	rs6775384	chr3:49853073	G/A	cg24308560	chr3:49941425	MST1R	-0.52	-7.12	-0.4	1e-11	Intelligence (multi-trait analysis);
CESC	cis	rs9787249	0.957	rs7548120	chr1:40204424	A/T	cg19912559	chr1:40204330	PPIE	0.43	6.59	0.38	2.3e-10	Blood protein levels;
CESC	cis	rs35110281	0.744	rs8131027	chr21:45104908	G/C	cg01579765	chr21:45077557	HSF2BP	-0.49	-8.26	-0.45	7.19e-15	Mean corpuscular volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03789152	chr12:72233372	TBC1D15	0.65	7.56	0.42	6.69e-13	Gut microbiome composition (summer);
CESC	cis	rs1801251	0.778	rs709933	chr2:233733144	G/A	cg08000102	chr2:233561755	GIGYF2	-0.6	-8.17	-0.45	1.26e-14	Coronary artery disease;
CESC	cis	rs1950626	0.577	rs35097045	chr14:101454403	G/C	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.67	8.97	0.48	5.38e-17	Pelvic organ prolapse (moderate/severe);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08523029	chr5:130500466	HINT1	0.61	6.84	0.39	5.54e-11	Gut microbiome composition (summer);
CESC	cis	rs9611565	0.592	rs12484254	chr22:41962003	T/A	cg06634786	chr22:41940651	POLR3H	-0.62	-6.83	-0.39	5.85e-11	Vitiligo;
CESC	cis	rs926938	0.520	rs2007231	chr1:115266306	C/T	cg12756093	chr1:115239321	AMPD1	-0.54	-6.89	-0.39	4.02e-11	Autism;
CESC	cis	rs1799949	1.000	rs72829113	chr17:41181835	C/T	cg25072359	chr17:41440525	NA	0.49	6.42	0.37	6.13e-10	Menopause (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01831166	chr2:198570100	MARS2	0.59	6.24	0.36	1.74e-9	Gut microbiome composition (summer);
CESC	cis	rs3820928	0.874	rs4675134	chr2:227843489	C/T	cg11843606	chr2:227700838	RHBDD1	-0.5	-6.49	-0.37	4.27e-10	Pulmonary function;
CESC	cis	rs3785574	0.924	rs2727292	chr17:61893747	A/G	cg06873352	chr17:61820015	STRADA	0.47	6.86	0.39	4.85e-11	Height;
CESC	cis	rs1395	0.778	rs11693001	chr2:27412744	C/T	cg22903471	chr2:27725779	GCKR	-0.42	-5.21	-0.3	3.81e-7	Blood metabolite levels;
CESC	cis	rs7811142	1.000	rs11773661	chr7:100073069	G/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.0	9.6	0.51	6.43e-19	Platelet count;
CESC	cis	rs6500602	0.727	rs8051389	chr16:4570570	C/T	cg08645402	chr16:4508243	NA	0.54	8.81	0.48	1.7e-16	Schizophrenia;
CESC	cis	rs116095464	0.614	rs56299325	chr5:220594	C/T	cg22857025	chr5:266934	NA	-1.27	-18.89	-0.76	5.51e-51	Breast cancer;
CESC	cis	rs7772486	0.686	rs9390357	chr6:146129347	A/G	cg05347473	chr6:146136440	FBXO30	0.51	6.75	0.38	9.17e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs11864453	0.647	rs9932062	chr16:72136055	T/C	cg16558253	chr16:72132732	DHX38	-0.54	-8.44	-0.46	2.04e-15	Fibrinogen levels;
CESC	cis	rs1048257	0.553	rs2819421	chr14:105408811	A/G	cg21017887	chr14:105400489	NA	0.42	6.79	0.38	7.31e-11	Systemic lupus erythematosus;
CESC	cis	rs7395581	0.918	rs10742799	chr11:47293702	T/C	cg25783544	chr11:47291846	MADD	0.62	8.26	0.45	6.99e-15	HDL cholesterol;
CESC	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	10.26	0.53	5.01e-21	Prudent dietary pattern;
CESC	cis	rs8103278	0.507	rs62111759	chr19:46296230	A/T	cg14061069	chr19:46274453	DMPK	0.55	8.65	0.47	4.93e-16	Coronary artery disease;
CESC	cis	rs4253772	0.551	rs9615936	chr22:46686328	C/G	cg09491104	chr22:46646882	C22orf40	-0.51	-5.43	-0.32	1.25e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs10504229	0.953	rs59265461	chr8:58189701	A/T	cg22535103	chr8:58192502	C8orf71	-1.05	-13.08	-0.63	1.71e-30	Developmental language disorder (linguistic errors);
CESC	cis	rs4862750	0.872	rs1991254	chr4:187875375	T/G	cg03452623	chr4:187889614	NA	-0.85	-13.57	-0.64	3.32e-32	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9287719	0.934	rs12692418	chr2:10745870	T/C	cg00105475	chr2:10696890	NA	0.38	5.55	0.32	6.76e-8	Prostate cancer;
CESC	cis	rs7267979	0.816	rs6115094	chr20:25210827	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.73	12.63	0.61	5.88e-29	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs2228479	0.850	rs62052714	chr16:89857180	T/C	cg00800038	chr16:89945340	TCF25	-0.9	-7.5	-0.42	9.55e-13	Skin colour saturation;
CESC	cis	rs10191773	0.522	rs6747639	chr2:112967458	C/T	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.69	-6.9	-0.39	3.75e-11	Yeast infection;
CESC	cis	rs7923609	0.846	rs7098181	chr10:65027143	G/T	cg01631684	chr10:65280961	REEP3	-0.44	-5.4	-0.31	1.51e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs9733	0.565	rs11804276	chr1:150685761	T/A	cg09365446	chr1:150670422	GOLPH3L	0.42	5.86	0.34	1.37e-8	Tonsillectomy;
CESC	cis	rs9790314	0.502	rs7647118	chr3:161016165	T/C	cg03342759	chr3:160939853	NMD3	-0.52	-7.4	-0.41	1.76e-12	Morning vs. evening chronotype;
CESC	cis	rs7833790	1.000	rs7834808	chr8:82704996	A/G	cg02079420	chr8:82753780	SNX16	0.56	7.51	0.42	9.17e-13	Diastolic blood pressure;
CESC	cis	rs2425143	1.000	rs11696947	chr20:34312658	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.61	5.29	0.31	2.61e-7	Blood protein levels;
CESC	cis	rs7772486	0.875	rs10457792	chr6:146412415	T/C	cg05347473	chr6:146136440	FBXO30	0.48	6.51	0.37	3.83e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7143963	0.666	rs2092973	chr14:103320961	G/A	cg24154132	chr14:103367632	TRAF3	0.36	6.54	0.37	3.23e-10	Body mass index;
CESC	cis	rs4481887	0.790	rs4453078	chr1:248411889	A/G	cg00666640	chr1:248458726	OR2T12	-0.3	-5.4	-0.31	1.49e-7	Common traits (Other);
CESC	trans	rs875971	0.660	rs12698534	chr7:65986845	C/T	cg26939375	chr7:64535504	NA	0.64	8.68	0.47	4.14e-16	Aortic root size;
CESC	cis	rs2228479	0.557	rs2293584	chr16:89888686	C/G	cg06558623	chr16:89946397	TCF25	1.12	8.24	0.45	7.86e-15	Skin colour saturation;
CESC	cis	rs7927771	1.000	rs12361031	chr11:47783076	G/A	cg18512352	chr11:47633146	NA	-0.61	-9.64	-0.51	4.87e-19	Subjective well-being;
CESC	cis	rs2197308	0.692	rs67352173	chr12:37906912	A/T	cg13010199	chr12:38710504	ALG10B	0.46	5.78	0.33	2.05e-8	Morning vs. evening chronotype;
CESC	cis	rs2243480	1.000	rs1796220	chr7:66062100	C/T	cg18252515	chr7:66147081	NA	-1.39	-14.25	-0.66	1.31e-34	Diabetic kidney disease;
CESC	cis	rs9486719	1.000	rs11152969	chr6:96908712	A/C	cg18709589	chr6:96969512	KIAA0776	-0.54	-5.97	-0.34	7.42e-9	Migraine;Coronary artery disease;
CESC	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	22.13	0.81	3.58e-62	Prudent dietary pattern;
CESC	cis	rs2932538	0.922	rs999923	chr1:113110548	T/C	cg22162597	chr1:113214053	CAPZA1	0.55	6.96	0.39	2.59e-11	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CESC	cis	rs9322193	0.923	rs2184369	chr6:150097817	G/A	cg04369109	chr6:150039330	LATS1	-0.39	-5.34	-0.31	2.01e-7	Lung cancer;
CESC	cis	rs6940638	0.688	rs9379960	chr6:27121325	A/C	cg12826209	chr6:26865740	GUSBL1	0.41	5.41	0.32	1.39e-7	Intelligence (multi-trait analysis);
CESC	cis	rs10088262	0.527	rs3911939	chr8:124793744	T/G	cg20713898	chr8:124780851	FAM91A1	-0.67	-8.54	-0.46	1.06e-15	Pancreatic cancer;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03705947	chr1:68152081	GADD45A	0.51	6.89	0.39	4.09e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs2836950	0.520	rs1980407	chr21:40543961	T/C	cg11890956	chr21:40555474	PSMG1	-0.69	-9.97	-0.52	4.48e-20	Menarche (age at onset);
CESC	cis	rs703842	0.892	rs1021469	chr12:58208164	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.65	8.06	0.44	2.6e-14	Multiple sclerosis;
CESC	cis	rs35306767	0.855	rs11253459	chr10:886402	C/T	cg10556349	chr10:835070	NA	0.54	5.16	0.3	4.75e-7	Eosinophil percentage of granulocytes;
CESC	cis	rs7666738	0.678	rs7670805	chr4:99008763	A/G	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.62e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05485520	chr3:45883628	LZTFL1	0.53	7.05	0.4	1.54e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs10504229	1.000	rs72650887	chr8:58177343	G/A	cg24829409	chr8:58192753	C8orf71	-0.76	-10.0	-0.52	3.53e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs1728785	0.901	rs8050289	chr16:68566976	T/A	cg02972257	chr16:68554789	NA	-0.55	-6.37	-0.36	8.21e-10	Ulcerative colitis;
CESC	cis	rs7618915	0.547	rs11130323	chr3:52770277	T/C	cg17372223	chr3:52568218	NT5DC2	0.45	6.61	0.38	2.14e-10	Bipolar disorder;
CESC	cis	rs55871839	0.684	rs7829715	chr8:59803836	C/T	cg07426533	chr8:59803705	TOX	0.5	7.14	0.4	9.01e-12	Pneumonia;
CESC	cis	rs6463523	0.898	rs66892628	chr7:759374	T/A	cg11064039	chr7:766100	PRKAR1B;HEATR2	1.0	15.85	0.7	3.03e-40	Subjective well-being;
CESC	cis	rs17376456	0.877	rs9314095	chr5:93425495	T/C	cg21475434	chr5:93447410	FAM172A	0.83	7.47	0.42	1.17e-12	Diabetic retinopathy;
CESC	cis	rs938554	0.571	rs4144	chr4:10016322	T/C	cg02734326	chr4:10020555	SLC2A9	0.51	5.71	0.33	2.97e-8	Blood metabolite levels;
CESC	cis	rs2880765	0.835	rs6497202	chr15:86021375	T/C	cg10818794	chr15:86012489	AKAP13	-0.34	-5.24	-0.31	3.32e-7	Coronary artery disease;
CESC	cis	rs4727027	0.933	rs34578816	chr7:148847606	G/A	cg23583168	chr7:148888333	NA	-0.81	-12.62	-0.61	6.75e-29	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs7949030	0.588	rs2428549	chr11:62312394	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.57	8.57	0.47	8.49e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs66887589	0.870	rs2389875	chr4:120557014	G/T	cg09307838	chr4:120376055	NA	-0.47	-6.4	-0.37	6.86e-10	Diastolic blood pressure;
CESC	cis	rs6570726	0.791	rs6570694	chr6:145911204	C/G	cg05347473	chr6:146136440	FBXO30	0.57	7.44	0.42	1.37e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7520050	0.966	rs1707335	chr1:46571921	C/T	cg24296786	chr1:45957014	TESK2	0.41	5.17	0.3	4.63e-7	Red blood cell count;Reticulocyte count;
CESC	cis	rs921968	0.541	rs634590	chr2:219372768	C/A	cg02176678	chr2:219576539	TTLL4	0.5	9.05	0.49	3.15e-17	Mean corpuscular hemoglobin concentration;
CESC	cis	rs3947	0.906	rs1692821	chr8:11699988	C/T	cg00262122	chr8:11665843	FDFT1	-0.49	-5.67	-0.33	3.79e-8	Blood protein levels;
CESC	cis	rs6089584	0.545	rs6089578	chr20:60554636	G/T	cg06108461	chr20:60628389	TAF4	-0.53	-6.91	-0.39	3.65e-11	Body mass index;
CESC	trans	rs9914544	0.591	rs9900052	chr17:18699398	G/A	cg04702396	chr17:15466718	FAM18B2	0.53	6.61	0.38	2.06e-10	Educational attainment (years of education);
CESC	cis	rs4561483	0.603	rs11544193	chr16:12009304	C/A	cg08843971	chr16:11963173	GSPT1	0.46	6.45	0.37	5.14e-10	Testicular germ cell tumor;
CESC	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg22535103	chr8:58192502	C8orf71	-0.92	-10.19	-0.53	8.81e-21	Developmental language disorder (linguistic errors);
CESC	cis	rs9486715	1.000	rs6905568	chr6:97066382	T/C	cg18709589	chr6:96969512	KIAA0776	-0.46	-6.48	-0.37	4.56e-10	Headache;
CESC	cis	rs7772486	0.875	rs9390377	chr6:146386932	G/A	cg05347473	chr6:146136440	FBXO30	0.51	6.76	0.38	8.56e-11	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00377757	chr17:76921538	TIMP2	0.56	6.52	0.37	3.52e-10	Gut microbiome composition (summer);
CESC	cis	rs79349575	0.783	rs4793996	chr17:47019597	T/C	cg26022315	chr17:47021804	SNF8	0.39	5.16	0.3	4.94e-7	Type 2 diabetes;
CESC	cis	rs4132509	1.000	rs6660534	chr1:243791642	A/C	cg21452805	chr1:244014465	NA	0.44	5.34	0.31	1.99e-7	RR interval (heart rate);
CESC	cis	rs12048904	0.619	rs12239082	chr1:101330077	G/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.85	-11.41	-0.57	8.26e-25	Multiple sclerosis;
CESC	cis	rs13191362	1.000	rs73035021	chr6:163000716	C/A	cg14584255	chr6:163149320	PACRG;PARK2	0.5	5.17	0.3	4.64e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs10504229	1.000	rs56168206	chr8:58184485	G/A	cg22535103	chr8:58192502	C8orf71	-1.05	-13.08	-0.63	1.71e-30	Developmental language disorder (linguistic errors);
CESC	cis	rs7666738	0.830	rs1025204	chr4:99023441	G/A	cg05340658	chr4:99064831	C4orf37	0.83	13.01	0.62	3e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs875971	0.830	rs778711	chr7:65851657	G/A	cg11764359	chr7:65958608	NA	0.78	11.31	0.57	1.86e-24	Aortic root size;
CESC	cis	rs875971	0.862	rs4718383	chr7:66108409	T/C	cg19163074	chr7:65112434	INTS4L2	0.43	5.44	0.32	1.24e-7	Aortic root size;
CESC	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg26338869	chr17:61819248	STRADA	0.7	9.28	0.5	6.1e-18	Prudent dietary pattern;
CESC	trans	rs61931739	0.500	rs11053248	chr12:34518011	G/A	cg26384229	chr12:38710491	ALG10B	0.71	10.63	0.55	3.31e-22	Morning vs. evening chronotype;
CESC	cis	rs11711311	0.824	rs35341324	chr3:113351719	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.61	7.74	0.43	2.07e-13	IgG glycosylation;
CESC	trans	rs7107217	1.000	rs1873872	chr11:129473993	A/T	cg06745955	chr17:27038470	PROCA1	0.45	6.04	0.35	5.14e-9	Breast cancer;Type 2 diabetes;
CESC	cis	rs2625529	0.617	rs7175373	chr15:72203517	G/T	cg16672083	chr15:72433130	SENP8	0.42	6.47	0.37	4.69e-10	Red blood cell count;
CESC	cis	rs896854	0.967	rs1320164	chr8:95960767	G/A	cg26343298	chr8:95960752	TP53INP1	0.37	5.94	0.34	8.73e-9	Type 2 diabetes;
CESC	cis	rs9916302	0.851	rs7220650	chr17:37487168	A/G	cg00129232	chr17:37814104	STARD3	0.54	7.08	0.4	1.33e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs9486719	1.000	rs12190507	chr6:96898265	T/G	cg18709589	chr6:96969512	KIAA0776	-0.54	-5.87	-0.34	1.3e-8	Migraine;Coronary artery disease;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg11319265	chr21:37258822	NA	0.4	6.28	0.36	1.38e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs7512552	0.839	rs1097070	chr1:150332955	A/T	cg15654264	chr1:150340011	RPRD2	0.39	5.24	0.31	3.25e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs10504073	0.647	rs4873317	chr8:50021111	C/T	cg00325661	chr8:49890786	NA	0.57	8.6	0.47	7.15e-16	Blood metabolite ratios;
CESC	cis	rs4665809	1.000	rs4665308	chr2:26330514	C/A	cg22920501	chr2:26401640	FAM59B	-0.67	-8.09	-0.44	2.22e-14	Gut microbiome composition (summer);
CESC	cis	rs3617	0.625	rs2336558	chr3:52886240	C/T	cg07507251	chr3:52567010	NT5DC2	-0.32	-5.49	-0.32	9.52e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
CESC	cis	rs10493773	0.609	rs2389972	chr1:86190666	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.41	-6.1	-0.35	3.74e-9	Urate levels in overweight individuals;
CESC	cis	rs12142240	0.698	rs72677589	chr1:46817770	T/C	cg00530320	chr1:46809349	NSUN4	0.58	7.89	0.44	8.17e-14	Menopause (age at onset);
CESC	cis	rs8017423	0.608	rs12588149	chr14:90822676	G/A	cg14092571	chr14:90743983	NA	0.44	6.77	0.38	8.12e-11	Mortality in heart failure;
CESC	cis	rs4909189	0.957	rs71547529	chr7:158135469	G/T	cg06219351	chr7:158114137	PTPRN2	-0.61	-8.04	-0.44	3.09e-14	Response to amphetamines;
CESC	cis	rs902774	0.554	rs4503623	chr12:53353759	T/C	cg16329197	chr12:53359506	NA	-0.55	-7.85	-0.43	1e-13	Prostate cancer;
CESC	cis	rs79387448	0.745	rs78136548	chr2:103103740	T/G	cg09003973	chr2:102972529	NA	0.85	6.24	0.36	1.68e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs2243480	0.615	rs34363376	chr7:65939536	T/C	cg18252515	chr7:66147081	NA	-1.39	-13.86	-0.65	3.27e-33	Diabetic kidney disease;
CESC	trans	rs4295623	0.553	rs34962960	chr8:11594597	G/A	cg15556689	chr8:8085844	FLJ10661	-0.54	-6.2	-0.36	2.14e-9	Morning vs. evening chronotype;
CESC	cis	rs6951245	0.744	rs10275401	chr7:1213943	A/C	cg03188948	chr7:1209495	NA	0.74	7.92	0.44	6.39e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs561341	1.000	rs550923	chr17:30327013	G/C	cg12193833	chr17:30244370	NA	-0.72	-6.68	-0.38	1.42e-10	Hip circumference adjusted for BMI;
CESC	cis	rs736408	0.660	rs2019065	chr3:52809525	C/T	cg05564831	chr3:52568323	NT5DC2	-0.41	-6.18	-0.35	2.41e-9	Bipolar disorder;
CESC	cis	rs597539	0.652	rs10792001	chr11:68637737	G/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.77	9.59	0.51	6.99e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs2991971	0.934	rs11211129	chr1:45983080	C/T	cg15605315	chr1:45957053	TESK2	0.49	6.43	0.37	5.98e-10	High light scatter reticulocyte count;
CESC	cis	rs10791323	0.593	rs2282604	chr11:133714672	A/G	cg06766960	chr11:133703094	NA	-0.36	-5.3	-0.31	2.4e-7	Childhood ear infection;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23233234	chr2:70528859	FAM136A	0.63	7.19	0.4	6.59e-12	Gut microbiome composition (summer);
CESC	cis	rs6089829	0.962	rs7267951	chr20:61665979	A/G	cg16240275	chr20:61666158	NCRNA00029	0.5	8.96	0.48	6.1e-17	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs2274273	0.870	rs8018110	chr14:55641714	C/T	cg04306507	chr14:55594613	LGALS3	0.3	5.97	0.34	7.68e-9	Protein biomarker;
CESC	cis	rs7267979	0.932	rs4280527	chr20:25544014	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.74	13.18	0.63	7.58e-31	Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs60843830	1.000	rs6709534	chr2:217334	G/C	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.65	7.91	0.44	6.93e-14	Spherical equivalent (joint analysis main effects and education interaction);
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg26035463	chr12:117627651	FBXO21	-0.47	-6.05	-0.35	5.02e-9	Height;
CESC	cis	rs4604732	0.578	rs79203328	chr1:247626581	C/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.57	7.17	0.4	7.39e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs9658691	0.607	rs9658750	chr10:90766596	A/G	cg03111039	chr10:90751583	FAS;ACTA2	-0.6	-5.24	-0.31	3.33e-7	Mosquito bite size;
CESC	cis	rs11098499	0.954	rs6857105	chr4:120222298	C/G	cg09307838	chr4:120376055	NA	0.89	12.42	0.61	3.14e-28	Corneal astigmatism;
CESC	cis	rs4268898	0.529	rs4426488	chr2:24372815	A/G	cg20701182	chr2:24300061	SF3B14	-0.38	-5.28	-0.31	2.72e-7	Asthma;
CESC	cis	rs1475911	0.708	rs8129075	chr21:43523430	G/T	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.48	-7.49	-0.42	1.03e-12	IgG glycosylation;
CESC	cis	rs854765	0.583	rs4925123	chr17:17784374	A/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.5	-6.46	-0.37	5.05e-10	Total body bone mineral density;
CESC	cis	rs523522	0.962	rs4767912	chr12:120981202	A/G	cg12219531	chr12:120966889	COQ5	0.75	9.99	0.52	3.7e-20	High light scatter reticulocyte count;
CESC	cis	rs561341	0.882	rs16967101	chr17:30377162	A/G	cg19193384	chr17:30244184	NA	-0.51	-5.24	-0.31	3.3e-7	Hip circumference adjusted for BMI;
CESC	cis	rs7208859	0.573	rs73267865	chr17:29064204	C/G	cg13385521	chr17:29058706	SUZ12P	0.81	6.53	0.37	3.28e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs12971120	1.000	rs3829640	chr18:72174980	A/G	cg25817165	chr18:72167213	CNDP2	-0.64	-8.22	-0.45	9.01e-15	Refractive error;
CESC	cis	rs644799	1.000	rs488246	chr11:95560473	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	9.15	0.49	1.57e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs4713118	0.621	rs4713134	chr6:28034121	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.53	-6.06	-0.35	4.65e-9	Parkinson's disease;
CESC	cis	rs1348850	0.574	rs10195917	chr2:178443121	C/T	cg23306229	chr2:178417860	TTC30B	0.59	6.19	0.36	2.27e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs6964587	0.967	rs6980247	chr7:91594228	T/A	cg17063962	chr7:91808500	NA	0.56	7.68	0.43	3.04e-13	Breast cancer;
CESC	cis	rs7666738	0.791	rs10033211	chr4:98995624	T/A	cg17366294	chr4:99064904	C4orf37	0.6	8.61	0.47	6.47e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2239547	0.522	rs6768844	chr3:53004620	A/G	cg11645453	chr3:52864694	ITIH4	-0.32	-5.37	-0.31	1.7e-7	Schizophrenia;
CESC	cis	rs35110281	0.782	rs2246602	chr21:45064296	C/A	cg04455712	chr21:45112962	RRP1B	0.39	5.75	0.33	2.46e-8	Mean corpuscular volume;
CESC	trans	rs55872338	0.588	rs79671379	chr10:44536443	A/G	cg04664161	chr19:1876758	NA	0.63	6.13	0.35	3.16e-9	Facial morphology (factor 20);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17055371	chr11:3078785	CARS	0.6	7.09	0.4	1.21e-11	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11725182	chr1:5968678	NPHP4	-0.71	-7.75	-0.43	2.02e-13	Gut microbiome composition (summer);
CESC	cis	rs7937682	0.889	rs2850247	chr11:111637202	C/A	cg09085632	chr11:111637200	PPP2R1B	1.15	19.47	0.77	5.1e-53	Primary sclerosing cholangitis;
CESC	cis	rs2066819	1.000	rs59295315	chr12:56708576	G/A	cg26804944	chr12:56660921	COQ10A	-0.85	-5.14	-0.3	5.39e-7	Psoriasis vulgaris;
CESC	cis	rs4819052	0.808	rs11909411	chr21:46676556	A/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.47	5.84	0.34	1.49e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs2404618	0.534	rs2214861	chr8:1490604	A/G	cg13402656	chr8:1511478	DLGAP2	-0.62	-9.69	-0.51	3.3e-19	Lung cancer;
CESC	cis	rs9910055	0.502	rs1684662	chr17:42180822	T/A	cg13607699	chr17:42295918	UBTF	-0.44	-5.52	-0.32	8.02e-8	Total body bone mineral density;
CESC	cis	rs6860806	0.531	rs272888	chr5:131665423	T/C	cg18758796	chr5:131593413	PDLIM4	0.38	5.15	0.3	5.13e-7	Breast cancer;
CESC	cis	rs72627123	0.531	rs3742806	chr14:74532523	A/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.78	5.36	0.31	1.81e-7	Morning vs. evening chronotype;
CESC	cis	rs798554	0.724	rs798498	chr7:2795882	T/G	cg13628971	chr7:2884303	GNA12	0.65	8.5	0.46	1.43e-15	Height;
CESC	cis	rs989128	0.600	rs9913677	chr17:48628581	T/A	cg24438145	chr17:48624694	SPATA20	0.44	5.25	0.31	3.14e-7	Type 2 diabetes;
CESC	cis	rs17376456	0.825	rs10054790	chr5:93272520	A/G	cg21475434	chr5:93447410	FAM172A	0.81	6.49	0.37	4.2e-10	Diabetic retinopathy;
CESC	cis	rs2836974	0.897	rs8132419	chr21:40527827	C/T	cg11890956	chr21:40555474	PSMG1	1.19	23.83	0.83	7.74e-68	Cognitive function;
CESC	cis	rs6089584	0.888	rs6061405	chr20:60617033	A/G	cg06108461	chr20:60628389	TAF4	-0.89	-13.47	-0.64	7.2e-32	Body mass index;
CESC	cis	rs4906332	1.000	rs11625172	chr14:103944912	G/A	cg09975044	chr14:104007538	NA	0.47	6.39	0.37	7.49e-10	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21119375	chr2:44393385	NA	-0.66	-7.28	-0.41	3.92e-12	Gut microbiome composition (summer);
CESC	trans	rs72681920	0.881	rs12512110	chr4:100195815	A/C	cg22948791	chr15:71404101	CT62	0.56	6.2	0.36	2.13e-9	Alcohol dependence;
CESC	trans	rs916888	0.773	rs199445	chr17:44817408	C/T	cg10053473	chr17:62856997	LRRC37A3	-0.72	-7.9	-0.44	7.4e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs12497850	0.865	rs7649458	chr3:48920127	C/T	cg03060546	chr3:49711283	APEH	0.42	5.28	0.31	2.7e-7	Parkinson's disease;
CESC	cis	rs1218582	0.772	rs6686873	chr1:154913404	C/G	cg06221963	chr1:154839813	KCNN3	-0.66	-11.11	-0.56	8.55e-24	Prostate cancer;
CESC	cis	rs703842	1.000	rs10877013	chr12:58165085	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.71	9.23	0.49	8.87e-18	Multiple sclerosis;
CESC	trans	rs9693444	0.898	rs4732697	chr8:29519861	A/G	cg25798026	chr22:32149910	DEPDC5	-0.41	-6.18	-0.35	2.42e-9	Breast cancer;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg24780086	chr5:14713043	ANKH	-0.44	-6.15	-0.35	2.78e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs757110	0.803	rs7928810	chr11:17372443	G/T	cg15432903	chr11:17409602	KCNJ11	0.57	8.11	0.45	1.88e-14	Type 2 diabetes;
CESC	cis	rs748404	0.516	rs523156	chr15:43811843	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.49	-7.0	-0.39	2.13e-11	Lung cancer;
CESC	trans	rs7618501	1.000	rs35261599	chr3:49773236	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.59	-8.48	-0.46	1.65e-15	Intelligence (multi-trait analysis);
CESC	cis	rs1506636	0.886	rs4731112	chr7:123269118	C/G	cg03229431	chr7:123269106	ASB15	-0.51	-6.93	-0.39	3.2e-11	Plateletcrit;Platelet count;
CESC	cis	rs9486719	1.000	rs12213426	chr6:96896035	T/C	cg06623918	chr6:96969491	KIAA0776	-0.81	-8.3	-0.45	5.21e-15	Migraine;Coronary artery disease;
CESC	cis	rs6963495	0.818	rs73190166	chr7:105159955	G/A	cg19920283	chr7:105172520	RINT1	0.68	6.34	0.36	9.71e-10	Bipolar disorder (body mass index interaction);
CESC	cis	rs10504229	0.683	rs61241336	chr8:58106585	A/G	cg22535103	chr8:58192502	C8orf71	-0.77	-8.76	-0.47	2.37e-16	Developmental language disorder (linguistic errors);
CESC	cis	rs7917772	0.582	rs10786689	chr10:104356359	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.41	5.63	0.33	4.48e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs270601	0.770	rs1007602	chr5:131602166	T/C	cg12564285	chr5:131593104	PDLIM4	0.38	5.8	0.34	1.92e-8	Acylcarnitine levels;
CESC	cis	rs6598163	0.712	rs10751695	chr12:132291061	A/C	cg04063615	chr12:132293388	NA	-0.4	-5.23	-0.31	3.51e-7	Migraine;
CESC	cis	rs597539	0.652	rs514833	chr11:68657734	C/T	cg18350739	chr11:68623251	NA	-0.43	-6.73	-0.38	1.05e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs6540559	1.000	rs17015259	chr1:209982923	G/A	cg22029157	chr1:209979665	IRF6	0.69	10.11	0.53	1.57e-20	Cleft lip with or without cleft palate;
CESC	cis	rs854765	0.547	rs7212167	chr17:17913504	G/A	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.54	7.17	0.4	7.52e-12	Total body bone mineral density;
CESC	cis	rs7618501	0.699	rs1317154	chr3:49910084	T/C	cg24308560	chr3:49941425	MST1R	-0.67	-9.89	-0.52	7.66e-20	Intelligence (multi-trait analysis);
CESC	cis	rs2070677	0.935	rs11812637	chr10:135413418	A/G	cg20169779	chr10:135381914	SYCE1	-0.75	-9.88	-0.52	8.57e-20	Gout;
CESC	cis	rs35110281	0.667	rs4819286	chr21:45120121	G/A	cg04455712	chr21:45112962	RRP1B	0.53	8.19	0.45	1.09e-14	Mean corpuscular volume;
CESC	cis	rs2573652	1.000	rs2573625	chr15:100513158	A/G	cg00587665	chr15:100533223	ADAMTS17	0.33	5.11	0.3	6.14e-7	Height;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg26571942	chr2:30455099	LBH	-0.47	-6.0	-0.35	6.4e-9	Ulcerative colitis;
CESC	cis	rs7666738	0.715	rs3857216	chr4:99032129	G/T	cg05340658	chr4:99064831	C4orf37	0.83	13.1	0.63	1.43e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs875971	1.000	rs7781698	chr7:65896312	A/T	cg10691866	chr7:65817282	TPST1	-0.35	-5.71	-0.33	3.1e-8	Aortic root size;
CESC	cis	rs2243480	1.000	rs10247526	chr7:65780696	T/G	cg18252515	chr7:66147081	NA	1.42	14.53	0.67	1.39e-35	Diabetic kidney disease;
CESC	cis	rs3820068	0.603	rs7529759	chr1:15977877	A/G	cg17385448	chr1:15911702	AGMAT	0.43	7.04	0.4	1.66e-11	Systolic blood pressure;
CESC	cis	rs1799949	0.896	rs8176098	chr17:41268206	A/C	cg06001716	chr17:41278141	BRCA1;NBR2	0.39	5.35	0.31	1.89e-7	Menopause (age at onset);
CESC	cis	rs898097	0.783	rs11650335	chr17:80835111	A/G	cg15664640	chr17:80829946	TBCD	-0.65	-9.29	-0.5	5.91e-18	Breast cancer;
CESC	cis	rs910316	0.935	rs175448	chr14:75591071	G/A	cg08847533	chr14:75593920	NEK9	-0.98	-18.75	-0.76	1.61e-50	Height;
CESC	cis	rs4722166	0.630	rs12700391	chr7:22777327	C/A	cg26061582	chr7:22766209	IL6	0.51	5.55	0.32	6.82e-8	Lung cancer;
CESC	cis	rs9888739	1.000	rs36001237	chr16:31318257	A/T	cg15817542	chr16:31343056	ITGAM	-0.41	-5.05	-0.3	8.33e-7	Systemic lupus erythematosus;
CESC	cis	rs11792861	0.564	rs3816237	chr9:111718348	T/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.63	9.71	0.51	2.87e-19	Menarche (age at onset);
CESC	cis	rs6952808	0.723	rs60995052	chr7:2030007	G/C	cg21782813	chr7:2030301	MAD1L1	0.5	7.17	0.4	7.6e-12	Bipolar disorder and schizophrenia;
CESC	cis	rs208515	0.525	rs12204452	chr6:66680325	C/T	cg07460842	chr6:66804631	NA	0.86	10.87	0.56	5.19e-23	Exhaled nitric oxide levels;
CESC	cis	rs56046484	0.913	rs17611290	chr15:85574419	A/G	cg08123816	chr15:85640762	PDE8A	-0.49	-6.25	-0.36	1.63e-9	Testicular germ cell tumor;
CESC	cis	rs7131987	0.903	rs918873	chr12:29390501	G/T	cg09582351	chr12:29534625	ERGIC2	-0.34	-5.34	-0.31	1.97e-7	QT interval;
CESC	trans	rs9354308	0.899	rs2802058	chr6:66550787	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.62	6.89	0.39	4.03e-11	Metabolite levels;
CESC	cis	rs7684253	0.565	rs7680140	chr4:57823457	A/G	cg21154227	chr4:57904332	IGFBP7	0.37	5.33	0.31	2.13e-7	Migraine;
CESC	cis	rs1218582	0.774	rs12036859	chr1:154859940	A/C	cg16680214	chr1:154839983	KCNN3	0.51	8.03	0.44	3.1e-14	Prostate cancer;
CESC	cis	rs6493487	0.512	rs58661036	chr15:51201780	A/C	cg02338191	chr15:51200825	AP4E1	0.6	5.58	0.32	5.79e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs7208859	0.524	rs77498725	chr17:29063986	C/T	cg14008862	chr17:28927542	LRRC37B2	0.65	5.12	0.3	5.86e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs4555082	0.830	rs2816648	chr14:105708289	C/T	cg13114125	chr14:105738426	BRF1	-0.87	-10.52	-0.54	7.51e-22	Mean platelet volume;Platelet distribution width;
CESC	cis	rs2836633	0.929	rs11701577	chr21:40028906	C/T	cg12884169	chr21:40033163	ERG	0.38	5.97	0.34	7.52e-9	Coronary artery disease;
CESC	cis	rs7274811	0.681	rs186026	chr20:31951993	G/T	cg21523528	chr20:32077966	CBFA2T2	-0.44	-5.31	-0.31	2.29e-7	Height;
CESC	cis	rs826838	0.967	rs1719853	chr12:39128515	A/G	cg26384229	chr12:38710491	ALG10B	-0.66	-10.31	-0.54	3.42e-21	Heart rate;
CESC	trans	rs1545843	0.593	rs11116362	chr12:84796506	T/C	cg03015433	chr16:56623111	MT3	-0.34	-6.15	-0.35	2.82e-9	Major depressive disorder;
CESC	cis	rs2576037	0.583	rs593340	chr18:44418346	C/T	cg19077165	chr18:44547161	KATNAL2	-0.6	-9.11	-0.49	2.13e-17	Personality dimensions;
CESC	cis	rs947211	1.000	rs823144	chr1:205744546	C/A	cg26354017	chr1:205819088	PM20D1	0.4	5.13	0.3	5.48e-7	Parkinson's disease;
CESC	cis	rs57506017	0.540	rs1435527	chr7:12262571	C/T	cg23422036	chr7:12250390	TMEM106B	0.39	5.23	0.31	3.51e-7	Neuroticism;
CESC	cis	rs4665809	1.000	rs4233708	chr2:26291345	C/T	cg26314531	chr2:26401878	FAM59B	-0.59	-6.67	-0.38	1.5e-10	Gut microbiome composition (summer);
CESC	cis	rs12188164	0.965	rs72717438	chr5:448663	C/T	cg17553881	chr5:443987	EXOC3;C5orf55	-0.38	-6.14	-0.35	2.97e-9	Cystic fibrosis severity;
CESC	cis	rs4862750	0.872	rs7679956	chr4:187900229	C/T	cg03452623	chr4:187889614	NA	-0.94	-19.24	-0.76	3.13e-52	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4323050	0.510	rs4254715	chr4:144914293	T/G	cg25736465	chr4:144833511	NA	0.43	6.44	0.37	5.61e-10	High light scatter reticulocyte percentage of red cells;
CESC	cis	rs2120019	1.000	rs1867146	chr15:75354971	C/G	cg09165964	chr15:75287851	SCAMP5	-0.73	-8.47	-0.46	1.7e-15	Blood trace element (Zn levels);
CESC	cis	rs5758511	0.680	rs1107553	chr22:42667473	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.56	8.49	0.46	1.46e-15	Birth weight;
CESC	cis	rs11792861	0.505	rs12377869	chr9:111907803	C/A	cg13535736	chr9:111863775	C9orf5	-0.41	-5.8	-0.34	1.92e-8	Menarche (age at onset);
CESC	cis	rs76878669	0.561	rs7110944	chr11:66118217	C/T	cg18002602	chr11:66138449	SLC29A2	-0.42	-6.96	-0.39	2.67e-11	Educational attainment (years of education);
CESC	cis	rs7647973	0.580	rs11716334	chr3:49230096	G/A	cg03060546	chr3:49711283	APEH	0.5	6.84	0.39	5.55e-11	Menarche (age at onset);
CESC	cis	rs763121	0.853	rs138716	chr22:39146527	C/T	cg14440974	chr22:39074834	NA	-0.38	-5.13	-0.3	5.6e-7	Menopause (age at onset);
CESC	trans	rs9354308	0.899	rs2814153	chr6:66557611	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.63	6.99	0.39	2.27e-11	Metabolite levels;
CESC	cis	rs9916302	0.904	rs8065879	chr17:37515978	G/A	cg15445000	chr17:37608096	MED1	-0.41	-6.81	-0.39	6.37e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs2228479	0.850	rs12600051	chr16:89992072	G/T	cg04013166	chr16:89971882	TCF25	0.79	6.58	0.37	2.57e-10	Skin colour saturation;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03625676	chr5:156887393	NIPAL4	0.44	6.08	0.35	4.06e-9	Gut microbiome composition (summer);
CESC	cis	rs35306767	0.904	rs10904584	chr10:983747	A/T	cg10556349	chr10:835070	NA	0.51	5.47	0.32	1.04e-7	Eosinophil percentage of granulocytes;
CESC	cis	rs6665290	0.669	rs6426558	chr1:227175367	G/T	cg10327440	chr1:227177885	CDC42BPA	-1.14	-23.96	-0.83	2.82e-68	Myeloid white cell count;
CESC	cis	rs317689	0.690	rs7969559	chr12:69655167	A/G	cg14784868	chr12:69753453	YEATS4	0.51	5.78	0.33	2.12e-8	Response to diuretic therapy;
CESC	cis	rs55986470	0.817	rs72993054	chr2:239404244	C/T	cg18131467	chr2:239335373	ASB1	-0.7	-5.75	-0.33	2.42e-8	Chronotype;
CESC	cis	rs7615952	0.641	rs7640158	chr3:125808011	G/A	cg04553112	chr3:125709451	NA	-0.55	-5.82	-0.34	1.71e-8	Blood pressure (smoking interaction);
CESC	cis	rs4862750	0.872	rs7664463	chr4:187876686	A/C	cg03452623	chr4:187889614	NA	-0.89	-16.49	-0.71	1.6e-42	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7301826	0.571	rs4759788	chr12:131296314	T/C	cg11011512	chr12:131303247	STX2	0.46	5.57	0.32	6.21e-8	Plasma plasminogen activator levels;
CESC	cis	rs2243480	1.000	rs1638734	chr7:66097539	A/C	cg08632164	chr7:65971372	NA	-0.49	-5.15	-0.3	5.03e-7	Diabetic kidney disease;
CESC	trans	rs61931739	0.500	rs11053211	chr12:34464334	T/C	cg26384229	chr12:38710491	ALG10B	0.54	7.49	0.42	1.02e-12	Morning vs. evening chronotype;
CESC	cis	rs6987853	0.933	rs2923401	chr8:42442208	T/C	cg09913449	chr8:42400586	C8orf40	0.4	6.27	0.36	1.46e-9	Mean corpuscular hemoglobin concentration;
CESC	cis	rs10191773	0.589	rs72831634	chr2:112946796	A/G	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.71	-6.9	-0.39	3.9e-11	Yeast infection;
CESC	cis	rs2842992	0.872	rs2758330	chr6:160104844	G/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.67	8.05	0.44	2.87e-14	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs6982240	0.514	rs10481391	chr8:142277149	A/G	cg00131261	chr8:142287264	NA	-0.54	-7.53	-0.42	8e-13	Tonsillectomy;
CESC	cis	rs7666738	0.716	rs28792413	chr4:99083707	G/A	cg05340658	chr4:99064831	C4orf37	0.73	10.38	0.54	2.13e-21	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7618915	0.547	rs62255362	chr3:52699741	C/G	cg07507251	chr3:52567010	NT5DC2	0.4	7.1	0.4	1.15e-11	Bipolar disorder;
CESC	cis	rs7618915	0.547	rs11714419	chr3:52628816	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	6.64	0.38	1.74e-10	Bipolar disorder;
CESC	cis	rs4563143	0.675	rs55976444	chr19:29265214	G/C	cg12667521	chr19:29218732	NA	0.48	6.4	0.37	6.97e-10	Methadone dose in opioid dependence;
CESC	cis	rs858239	0.601	rs11984129	chr7:23152677	A/G	cg23682824	chr7:23144976	KLHL7	0.54	7.36	0.41	2.31e-12	Cerebrospinal fluid biomarker levels;
CESC	cis	rs14403	1.000	rs14403	chr1:243663893	A/G	cg21452805	chr1:244014465	NA	-0.52	-5.93	-0.34	9.54e-9	Schizophrenia;
CESC	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg11301795	chr4:187892539	NA	-0.75	-11.49	-0.58	4.49e-25	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs3747547	0.642	rs11792197	chr9:38086999	C/T	cg13774184	chr9:37916125	SHB	-0.62	-5.3	-0.31	2.38e-7	Metabolite levels (Dihydroxy docosatrienoic acid);
CESC	cis	rs597539	0.652	rs482172	chr11:68668437	C/A	cg01988459	chr11:68622903	NA	-0.42	-5.79	-0.34	1.99e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01399255	chr7:100271274	GNB2	0.64	7.78	0.43	1.63e-13	Gut microbiome composition (summer);
CESC	trans	rs17181170	0.574	rs34610470	chr3:87208044	G/A	ch.2.199792288R	chr2:200084043	NA	-0.46	-6.1	-0.35	3.78e-9	Prostate cancer;
CESC	cis	rs6568686	0.553	rs9372301	chr6:111903329	T/C	cg22127309	chr6:111907043	TRAF3IP2	-0.52	-5.17	-0.3	4.65e-7	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
CESC	cis	rs7927771	0.542	rs7108479	chr11:47781460	G/T	cg20307385	chr11:47447363	PSMC3	0.61	8.59	0.47	7.41e-16	Subjective well-being;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg17816495	chr19:19030203	DDX49;COPE	-0.52	-7.18	-0.4	7.25e-12	Fibrinogen levels;
CESC	cis	rs17376456	0.825	rs17372057	chr5:93071916	C/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.61	5.34	0.31	2e-7	Diabetic retinopathy;
CESC	cis	rs7100689	0.646	rs2050824	chr10:82123563	G/A	cg00277334	chr10:82204260	NA	-0.58	-7.76	-0.43	1.84e-13	Post bronchodilator FEV1;
CESC	cis	rs17854409	0.764	rs16983293	chr20:61479056	A/G	cg05147244	chr20:61493195	TCFL5	0.99	5.52	0.32	8.1e-8	Obesity-related traits;
CESC	cis	rs56046484	0.871	rs7177110	chr15:85671755	A/G	cg08123816	chr15:85640762	PDE8A	-0.44	-5.57	-0.32	6.33e-8	Testicular germ cell tumor;
CESC	cis	rs9287719	0.639	rs2357650	chr2:10696877	C/T	cg00105475	chr2:10696890	NA	0.44	6.56	0.37	2.88e-10	Prostate cancer;
CESC	cis	rs1801251	0.963	rs66549961	chr2:233602293	A/G	cg08000102	chr2:233561755	GIGYF2	0.66	9.34	0.5	4.2e-18	Coronary artery disease;
CESC	cis	rs9916302	0.904	rs634365	chr17:37436966	C/T	cg20243544	chr17:37824526	PNMT	0.44	5.38	0.31	1.61e-7	Glomerular filtration rate (creatinine);
CESC	trans	rs853679	0.882	rs9461432	chr6:28086883	T/C	cg06606381	chr12:133084897	FBRSL1	-0.65	-6.43	-0.37	5.96e-10	Depression;
CESC	cis	rs2439831	0.681	rs540388	chr15:43606494	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	12.92	0.62	5.83e-30	Lung cancer in ever smokers;
CESC	cis	rs36051895	0.626	rs12349785	chr9:5076613	G/C	cg02405213	chr9:5042618	JAK2	-0.51	-6.17	-0.35	2.59e-9	Pediatric autoimmune diseases;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16031872	chr3:142297641	ATR	0.58	6.18	0.35	2.37e-9	Gut microbiome composition (summer);
CESC	cis	rs7917772	0.503	rs11191342	chr10:104344450	G/A	cg22532475	chr10:104410764	TRIM8	-0.36	-6.33	-0.36	1.07e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs9649213	0.593	rs6465666	chr7:97937258	C/T	cg21770322	chr7:97807741	LMTK2	-0.57	-8.59	-0.47	7.75e-16	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs2777491	0.915	rs8036498	chr15:41603276	A/G	cg20272979	chr15:41787780	ITPKA	0.36	5.19	0.3	4.25e-7	Ulcerative colitis;
CESC	cis	rs75477785	0.590	rs7528642	chr1:209916598	G/A	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.76	5.09	0.3	6.66e-7	Cleft lip with or without cleft palate;
CESC	cis	rs11203032	0.831	rs11203018	chr10:90948783	T/C	cg16672925	chr10:90967113	CH25H	0.72	7.16	0.4	7.78e-12	Heart failure;
CESC	cis	rs2625529	0.652	rs8027164	chr15:72407733	A/T	cg16672083	chr15:72433130	SENP8	0.45	7.06	0.4	1.49e-11	Red blood cell count;
CESC	cis	rs2898681	0.521	rs115874483	chr4:53728272	G/A	cg00791764	chr4:53727839	RASL11B	0.44	5.26	0.31	3.03e-7	Optic nerve measurement (cup area);
CESC	cis	rs9457247	1.000	rs406095	chr6:167409087	C/T	cg23791538	chr6:167370224	RNASET2	-0.61	-8.81	-0.48	1.71e-16	Crohn's disease;
CESC	trans	rs10463316	0.894	rs6579866	chr5:150762524	A/G	cg24389359	chr12:111284228	CCDC63	-0.33	-6.02	-0.35	5.68e-9	Metabolite levels (Pyroglutamine);
CESC	cis	rs60154123	0.554	rs1338290	chr1:210465467	G/A	cg21951975	chr1:209979733	IRF6	0.46	5.99	0.35	6.98e-9	Coronary artery disease;
CESC	cis	rs2952156	0.959	rs2517956	chr17:37843859	G/A	cg07936489	chr17:37558343	FBXL20	-0.52	-6.17	-0.35	2.49e-9	Asthma;
CESC	cis	rs3796619	0.503	rs1466216	chr4:1071907	C/T	cg27284194	chr4:1044797	NA	-0.56	-9.01	-0.48	4.1e-17	Recombination rate (males);
CESC	cis	rs9818941	0.824	rs2686541	chr3:157788184	G/C	cg08654915	chr3:157813417	NA	-0.43	-7.1	-0.4	1.13e-11	Height;
CESC	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	7.72	0.43	2.43e-13	Prudent dietary pattern;
CESC	trans	rs877282	0.853	rs10904544	chr10:756966	A/G	cg22713356	chr15:30763199	NA	0.95	8.36	0.46	3.67e-15	Uric acid levels;
CESC	cis	rs911555	0.755	rs11627446	chr14:103946450	G/C	cg09975044	chr14:104007538	NA	0.43	5.31	0.31	2.33e-7	Intelligence (multi-trait analysis);
CESC	cis	rs1048238	0.506	rs7547314	chr1:16186722	G/A	cg21385522	chr1:16154831	NA	0.45	5.82	0.34	1.7e-8	Systolic blood pressure;
CESC	cis	rs459571	0.959	rs2073818	chr9:136918662	C/A	cg13789015	chr9:136890014	NCRNA00094	0.57	8.07	0.44	2.49e-14	Platelet distribution width;
CESC	cis	rs17376456	0.542	rs10476588	chr5:93208330	C/T	cg25358565	chr5:93447407	FAM172A	-0.71	-7.46	-0.42	1.23e-12	Diabetic retinopathy;
CESC	cis	rs16857609	0.564	rs3732009	chr2:218291393	G/A	cg15335768	chr2:218268053	DIRC3	-0.37	-5.19	-0.3	4.18e-7	Breast cancer;Breast cancer (estrogen-receptor negative);
CESC	cis	rs7621025	0.617	rs12637102	chr3:136211960	A/G	cg15507776	chr3:136538369	TMEM22	0.44	5.11	0.3	6.3e-7	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
CESC	trans	rs7839040	0.698	rs12549223	chr8:82932601	A/G	cg14472086	chr9:107730925	NA	-0.46	-6.24	-0.36	1.69e-9	Response to methotrexate in juvenile idiopathic arthritis;
CESC	cis	rs4665809	0.627	rs7562192	chr2:26469457	C/G	cg26314531	chr2:26401878	FAM59B	0.85	9.23	0.49	8.65e-18	Gut microbiome composition (summer);
CESC	cis	rs11191270	0.554	rs11191253	chr10:104066507	A/T	cg15320455	chr10:103880129	LDB1	0.61	5.68	0.33	3.54e-8	Intelligence (multi-trait analysis);
CESC	cis	rs4853012	0.941	rs4852329	chr2:74354544	A/G	cg01017244	chr2:74357527	NA	0.8	10.39	0.54	1.99e-21	Gestational age at birth (maternal effect);
CESC	cis	rs6546550	0.803	rs10165883	chr2:70117015	C/T	cg02498382	chr2:70120550	SNRNP27	-0.41	-7.02	-0.4	1.87e-11	Prevalent atrial fibrillation;
CESC	cis	rs7937682	0.883	rs568506	chr11:111466429	C/T	cg22437258	chr11:111473054	SIK2	0.71	9.19	0.49	1.16e-17	Primary sclerosing cholangitis;
CESC	cis	rs2404602	0.647	rs12910820	chr15:77022825	T/C	cg23625390	chr15:77176239	SCAPER	-0.46	-6.38	-0.36	8.06e-10	Blood metabolite levels;
CESC	cis	rs9894429	0.608	rs7406382	chr17:79597786	T/C	cg21984481	chr17:79567631	NPLOC4	-0.34	-5.2	-0.3	4.08e-7	Eye color traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26465743	chr13:77901232	MYCBP2	-0.61	-7.11	-0.4	1.05e-11	Gut microbiome composition (summer);
CESC	cis	rs9611565	0.559	rs7290990	chr22:41964357	C/A	cg17376030	chr22:41985996	PMM1	0.53	5.88	0.34	1.25e-8	Vitiligo;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07391756	chr12:132568647	EP400NL	0.65	7.36	0.41	2.28e-12	Gut microbiome composition (summer);
CESC	cis	rs7811142	1.000	rs7783159	chr7:100017454	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.03	10.86	0.55	5.83e-23	Platelet count;
CESC	cis	rs4849845	0.637	rs62168279	chr2:121026771	T/C	cg24070213	chr2:121070622	NA	0.45	6.51	0.37	3.82e-10	Mean platelet volume;
CESC	cis	rs752010	0.841	rs7519983	chr1:42083369	C/T	cg06885757	chr1:42089581	HIVEP3	0.47	7.71	0.43	2.5e-13	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs3785574	0.962	rs114027117	chr17:61939935	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.08	19.81	0.77	3.37e-54	Height;
CESC	cis	rs478304	0.934	rs610037	chr11:65546857	A/C	cg08755490	chr11:65554678	OVOL1	0.52	6.85	0.39	5.28e-11	Acne (severe);
CESC	cis	rs916888	0.773	rs199534	chr17:44824213	T/G	cg15921436	chr17:44337874	NA	0.72	7.62	0.42	4.52e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs9611565	0.512	rs132767	chr22:42009520	C/T	cg06481639	chr22:41940642	POLR3H	-0.54	-5.6	-0.33	5.29e-8	Vitiligo;
CESC	cis	rs6987853	0.623	rs10109400	chr8:42455353	T/C	cg09913449	chr8:42400586	C8orf40	0.42	7.02	0.4	1.88e-11	Mean corpuscular hemoglobin concentration;
CESC	cis	rs796364	0.951	rs1105964	chr2:201000776	T/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.63	-6.23	-0.36	1.87e-9	Schizophrenia;
CESC	cis	rs7845219	0.544	rs4570121	chr8:95917088	C/T	cg13393036	chr8:95962371	TP53INP1	-0.43	-8.01	-0.44	3.67e-14	Type 2 diabetes;
CESC	cis	rs763121	0.853	rs926299	chr22:39095698	C/G	cg06022373	chr22:39101656	GTPBP1	0.94	17.4	0.73	9.39e-46	Menopause (age at onset);
CESC	cis	rs1552244	1.000	rs9811771	chr3:10133949	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.82	-11.01	-0.56	1.81e-23	Alzheimer's disease;
CESC	cis	rs941873	0.835	rs4246944	chr10:81105684	C/T	cg08514558	chr10:81106712	PPIF	0.33	5.66	0.33	4.01e-8	Height;
CESC	trans	rs2727020	0.635	rs7124266	chr11:49280857	T/G	cg15704280	chr7:45808275	SEPT13	0.81	10.93	0.56	3.32e-23	Coronary artery disease;
CESC	cis	rs75804782	0.521	rs72993074	chr2:239413582	T/G	cg18131467	chr2:239335373	ASB1	-0.73	-5.44	-0.32	1.19e-7	Morning vs. evening chronotype;Chronotype;
CESC	cis	rs17655565	0.581	rs2298794	chr12:52760732	G/A	cg00777198	chr12:52828273	KRT75	0.37	5.09	0.3	6.7e-7	Plasma amyloid beta peptide concentrations (ABx-42);
CESC	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.4	-5.87	-0.34	1.31e-8	Longevity;Endometriosis;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg14539990	chr9:140728301	EHMT1	0.47	6.54	0.37	3.13e-10	Fibrinogen levels;
CESC	trans	rs853679	0.556	rs45509595	chr6:27840926	T/C	cg21479132	chr6:26055353	NA	0.83	6.03	0.35	5.51e-9	Depression;
CESC	cis	rs524023	0.914	rs7932437	chr11:64373504	T/C	cg07220939	chr11:64358617	SLC22A12	-0.34	-5.18	-0.3	4.35e-7	Urate levels in obese individuals;
CESC	cis	rs2243480	1.000	rs6959002	chr7:65650496	A/G	cg12463550	chr7:65579703	CRCP	-0.73	-5.66	-0.33	4.03e-8	Diabetic kidney disease;
CESC	cis	rs7264396	0.836	rs6058276	chr20:34187728	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.6	-7.07	-0.4	1.38e-11	Total cholesterol levels;
CESC	cis	rs2197308	0.594	rs9705810	chr12:37895003	G/A	cg26384229	chr12:38710491	ALG10B	-0.52	-7.12	-0.4	1.01e-11	Morning vs. evening chronotype;
CESC	cis	rs4819052	0.851	rs4819044	chr21:46660118	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.74	9.89	0.52	7.86e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs8078723	0.630	rs60137005	chr17:38129996	A/T	cg17467752	chr17:38218738	THRA	0.57	8.36	0.46	3.52e-15	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CESC	cis	rs1864400	0.645	rs2249005	chr10:43627280	A/G	cg07801480	chr10:43725741	RASGEF1A	0.43	5.44	0.32	1.2e-7	Hirschsprung disease;
CESC	cis	rs1448094	0.511	rs10779210	chr12:86162432	T/C	cg00310523	chr12:86230176	RASSF9	-0.32	-5.03	-0.3	8.9e-7	Major depressive disorder;
CESC	cis	rs963731	0.649	rs2924714	chr2:39333288	A/G	cg04010122	chr2:39346883	SOS1	-0.76	-5.65	-0.33	4.05e-8	Corticobasal degeneration;
CESC	cis	rs1707322	1.000	rs9793167	chr1:46446800	G/A	cg06784218	chr1:46089804	CCDC17	0.33	5.63	0.33	4.7e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs3762318	0.951	rs12095536	chr1:67600142	T/C	cg17031739	chr1:67600172	NA	0.5	5.29	0.31	2.57e-7	Leprosy;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg15806038	chr2:3601756	RNASEH1	0.42	6.71	0.38	1.16e-10	Gambling;
CESC	cis	rs4727027	0.933	rs6464940	chr7:148826309	G/T	cg23158103	chr7:148848205	ZNF398	-0.4	-6.34	-0.36	9.68e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs55883249	0.958	rs113937820	chr2:9746668	A/G	cg23886495	chr2:9695866	ADAM17	0.66	5.87	0.34	1.29e-8	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
CESC	trans	rs61931739	0.500	rs7955933	chr12:34473608	A/G	cg26384229	chr12:38710491	ALG10B	0.53	7.41	0.41	1.67e-12	Morning vs. evening chronotype;
CESC	cis	rs7412746	0.658	rs6657388	chr1:150748786	A/G	cg09365446	chr1:150670422	GOLPH3L	0.39	5.11	0.3	6.18e-7	Melanoma;
CESC	cis	rs10479542	0.630	rs6879664	chr5:178974576	T/G	cg21226059	chr5:178986404	RUFY1	0.45	6.32	0.36	1.09e-9	Lung cancer;
CESC	cis	rs9303280	0.901	rs2952140	chr17:37928059	C/T	cg20243544	chr17:37824526	PNMT	-0.53	-7.32	-0.41	3.05e-12	Self-reported allergy;
CESC	cis	rs7551222	0.749	rs6594018	chr1:204568152	A/G	cg20240347	chr1:204465584	NA	-0.26	-5.38	-0.31	1.65e-7	Schizophrenia;
CESC	cis	rs1538970	0.851	rs2055145	chr1:45926495	C/G	cg06784218	chr1:46089804	CCDC17	0.37	6.02	0.35	5.78e-9	Platelet count;
CESC	cis	rs599083	0.530	rs667126	chr11:68177728	C/T	cg01657329	chr11:68192670	LRP5	0.44	5.24	0.31	3.32e-7	Bone mineral density (spine);
CESC	cis	rs1865721	1.000	rs72977888	chr18:73195250	C/T	cg26385618	chr18:73139727	C18orf62	-0.51	-7.6	-0.42	5.1e-13	Intelligence;
CESC	trans	rs1728785	0.892	rs4783562	chr16:68562963	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.62	7.2	0.4	6.15e-12	Ulcerative colitis;
CESC	cis	rs7809950	0.678	rs2237665	chr7:106906998	T/C	cg23024343	chr7:107201750	COG5	-0.54	-6.79	-0.38	7.55e-11	Coronary artery disease;
CESC	cis	rs3806843	0.741	rs2563293	chr5:140110536	T/C	cg26395211	chr5:140044315	WDR55	0.47	6.08	0.35	4.27e-9	Depressive symptoms (multi-trait analysis);
CESC	cis	rs8133932	0.654	rs371587	chr21:47348512	G/A	cg14185626	chr21:47401492	COL6A1	-0.48	-5.36	-0.31	1.78e-7	Schizophrenia;
CESC	cis	rs10484885	0.793	rs9359862	chr6:90474508	A/G	cg13799429	chr6:90582589	CASP8AP2	0.7	7.94	0.44	5.6e-14	QRS interval (sulfonylurea treatment interaction);
CESC	cis	rs7412746	0.566	rs2864871	chr1:150766964	T/C	cg09365446	chr1:150670422	GOLPH3L	0.38	5.06	0.3	7.7300000000000005e-07	Melanoma;
CESC	cis	rs933688	0.652	rs4916856	chr5:90596403	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.56	-7.12	-0.4	1e-11	Smoking behavior;
CESC	cis	rs875971	1.000	rs1968225	chr7:65874773	T/C	cg11764359	chr7:65958608	NA	0.98	15.79	0.7	4.71e-40	Aortic root size;
CESC	cis	rs12497850	1.000	rs4858798	chr3:48727112	C/T	cg07636037	chr3:49044803	WDR6	0.91	16.19	0.71	1.89e-41	Parkinson's disease;
CESC	cis	rs2635047	0.875	rs2635040	chr18:44640972	G/T	cg19077165	chr18:44547161	KATNAL2	-0.54	-7.31	-0.41	3.11e-12	Educational attainment;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26147668	chr7:130081239	TSGA14	-0.54	-6.37	-0.36	8.45e-10	Gut microbiome composition (summer);
CESC	cis	rs1008375	1.000	rs28693609	chr4:17645233	C/T	cg02297831	chr4:17616191	MED28	0.53	6.64	0.38	1.76e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs11711311	1.000	rs9828449	chr3:113518602	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.74	10.44	0.54	1.33e-21	IgG glycosylation;
CESC	cis	rs9911578	0.967	rs8072712	chr17:57162464	A/T	cg05425664	chr17:57184151	TRIM37	-0.53	-7.31	-0.41	3.23e-12	Intelligence (multi-trait analysis);
CESC	cis	rs4642101	0.640	rs3901666	chr3:12824363	G/T	cg05775895	chr3:12838266	CAND2	-0.36	-5.51	-0.32	8.64e-8	QRS complex (12-leadsum);
CESC	cis	rs902774	0.597	rs7299694	chr12:53352572	A/C	cg05393297	chr12:53359155	NA	-0.6	-8.46	-0.46	1.88e-15	Prostate cancer;
CESC	cis	rs801193	0.660	rs1016265	chr7:66214567	C/T	cg10691866	chr7:65817282	TPST1	-0.36	-6.13	-0.35	3.09e-9	Aortic root size;
CESC	cis	rs514406	0.708	rs514881	chr1:53336737	A/G	cg08859206	chr1:53392774	SCP2	0.63	9.32	0.5	4.63e-18	Monocyte count;
CESC	trans	rs17716202	0.702	rs67311922	chr5:55892488	T/C	cg14306956	chr9:37027384	PAX5	-0.55	-6.01	-0.35	6.15e-9	Psychosis in Alzheimer's disease;
CESC	cis	rs754466	0.580	rs12357670	chr10:79558180	T/C	cg17075019	chr10:79541650	NA	-0.89	-14.04	-0.65	7.43e-34	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs889398	0.802	rs2937121	chr16:69870409	T/G	cg09409435	chr16:70099608	PDXDC2	-0.42	-5.26	-0.31	2.92e-7	Body mass index;
CESC	cis	rs6089829	0.855	rs4809459	chr20:61661345	C/T	cg08564027	chr20:61660810	NA	0.9	15.36	0.69	1.69e-38	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs9611565	0.659	rs202653	chr22:41840158	C/T	cg03806693	chr22:41940476	POLR3H	1.13	15.27	0.68	3.52e-38	Vitiligo;
CESC	cis	rs2014572	0.901	rs35658377	chr19:57755627	T/G	cg12963866	chr19:57752005	ZNF805	-0.48	-6.47	-0.37	4.63e-10	Hyperactive-impulsive symptoms;
CESC	cis	rs7584330	0.666	rs72620819	chr2:238354982	C/T	cg14458575	chr2:238380390	NA	0.86	10.89	0.56	4.57e-23	Prostate cancer;
CESC	cis	rs4664308	0.935	rs6731260	chr2:160977769	A/G	cg03641300	chr2:160917029	PLA2R1	-0.66	-9.69	-0.51	3.34e-19	Idiopathic membranous nephropathy;
CESC	cis	rs6032067	0.641	rs62206437	chr20:43759316	T/C	cg10761708	chr20:43804764	PI3	0.48	5.18	0.3	4.44e-7	Blood protein levels;
CESC	cis	rs3733585	0.631	rs7699671	chr4:10125874	C/T	cg11266682	chr4:10021025	SLC2A9	-0.57	-10.49	-0.54	9.49e-22	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs1577917	0.771	rs4441928	chr6:86241894	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.52	7.33	0.41	2.86e-12	Response to antipsychotic treatment;
CESC	cis	rs2228479	0.867	rs11642451	chr16:89958127	T/C	cg06558623	chr16:89946397	TCF25	1.08	9.18	0.49	1.3e-17	Skin colour saturation;
CESC	trans	rs3794271	0.706	rs9971816	chr12:20826911	C/T	cg09976981	chr22:43564007	TTLL12	0.47	7.0	0.4	2.09e-11	Response to TNF-alpha inhibitors in rheumatoid arthritis;
CESC	cis	rs9623117	1.000	rs9611257	chr22:40455378	T/A	cg05033341	chr22:40419857	FAM83F	-0.43	-5.21	-0.3	3.8e-7	Prostate cancer (SNP x SNP interaction);Prostate cancer;
CESC	cis	rs4919044	0.740	rs73319304	chr10:94777045	A/G	cg00487187	chr10:94451625	HHEX	-0.45	-5.05	-0.3	8.21e-7	Coronary artery disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg07849438	chr12:19593035	AEBP2	-0.47	-6.58	-0.37	2.49e-10	Fibrinogen levels;
CESC	cis	rs62005083	0.500	rs10135300	chr14:74574561	G/T	cg05179529	chr14:74551516	LIN52;ALDH6A1	0.53	5.77	0.33	2.16e-8	Mean corpuscular volume;
CESC	trans	rs11039798	0.841	rs11039783	chr11:48526828	G/C	cg15704280	chr7:45808275	SEPT13	0.7	6.47	0.37	4.71e-10	Axial length;
CESC	cis	rs7267979	0.934	rs2261115	chr20:25259807	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.86	16.87	0.72	7.12e-44	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs875971	0.638	rs801216	chr7:66011667	T/C	cg25985355	chr7:65971099	NA	0.32	5.27	0.31	2.86e-7	Aortic root size;
CESC	cis	rs35306767	0.855	rs61830932	chr10:934183	T/C	cg25019033	chr10:957182	NA	-0.58	-6.28	-0.36	1.37e-9	Eosinophil percentage of granulocytes;
CESC	cis	rs7666738	0.830	rs6830124	chr4:99054872	C/T	cg18180107	chr4:99064573	C4orf37	-0.4	-5.2	-0.3	3.98e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs847577	0.569	rs2394817	chr7:97690438	C/T	cg24562669	chr7:97807699	LMTK2	0.77	13.04	0.63	2.29e-30	Breast cancer;
CESC	cis	rs7542091	0.666	rs7537070	chr1:210043565	A/G	cg09509183	chr1:209979624	IRF6	0.4	5.78	0.33	2.12e-8	Monobrow;
CESC	cis	rs929354	0.806	rs28446734	chr7:156996775	T/C	cg05182265	chr7:156933206	UBE3C	-0.5	-7.2	-0.4	6.35e-12	Body mass index;
CESC	cis	rs12476592	0.602	rs2305157	chr2:63822785	T/C	cg17519650	chr2:63277830	OTX1	-0.46	-5.14	-0.3	5.28e-7	Childhood ear infection;
CESC	cis	rs2842992	0.789	rs10945635	chr6:160214487	C/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.78	9.65	0.51	4.6e-19	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs6460942	0.749	rs74834695	chr7:12464779	G/A	cg02935154	chr7:12443704	VWDE	-0.58	-6.16	-0.35	2.73e-9	Coronary artery disease;
CESC	cis	rs9790314	0.967	rs6762645	chr3:160948349	T/G	cg04691961	chr3:161091175	C3orf57	-0.4	-5.07	-0.3	7.61e-7	Morning vs. evening chronotype;
CESC	cis	rs477692	0.699	rs471390	chr10:131382825	A/G	cg24747557	chr10:131355152	MGMT	0.37	5.1	0.3	6.41e-7	Response to temozolomide;
CESC	cis	rs7666738	0.830	rs3896704	chr4:99034252	C/T	cg18180107	chr4:99064573	C4orf37	0.42	5.4	0.31	1.48e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9649213	0.593	rs6949718	chr7:97924483	G/A	cg08684580	chr7:98029266	BAIAP2L1	-0.34	-5.42	-0.32	1.31e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs17253792	0.822	rs78820104	chr14:56068854	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.79	5.91	0.34	1.06e-8	Putamen volume;
CESC	cis	rs75477785	0.590	rs4844941	chr1:210220118	T/C	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.91	6.32	0.36	1.09e-9	Cleft lip with or without cleft palate;
CESC	cis	rs9487051	0.676	rs6928622	chr6:109595112	C/T	cg01475377	chr6:109611718	NA	-0.44	-7.02	-0.4	1.84e-11	Reticulocyte fraction of red cells;
CESC	cis	rs3096299	0.933	rs889576	chr16:89429653	A/G	cg02187348	chr16:89574699	SPG7	-0.54	-7.24	-0.41	4.82e-12	Multiple myeloma (IgH translocation);
CESC	trans	rs7819412	0.775	rs2001329	chr8:10986859	C/T	cg06636001	chr8:8085503	FLJ10661	-0.49	-6.13	-0.35	3.12e-9	Triglycerides;
CESC	cis	rs2279817	1.000	rs2279816	chr1:18021867	T/C	cg21791023	chr1:18019539	ARHGEF10L	0.57	8.09	0.45	2.1e-14	Neuroticism;
CESC	cis	rs10504229	1.000	rs117231141	chr8:58185465	A/G	cg24829409	chr8:58192753	C8orf71	-0.76	-9.93	-0.52	5.87e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs798554	1.000	rs798540	chr7:2764130	G/A	cg09658497	chr7:2847517	GNA12	-0.44	-6.25	-0.36	1.64e-9	Height;
CESC	cis	rs6541297	1.000	rs4846836	chr1:230281316	G/A	cg20703242	chr1:230279135	GALNT2	0.68	10.88	0.56	4.75e-23	Coronary artery disease;
CESC	cis	rs910316	0.664	rs2098252	chr14:75492732	T/C	cg08847533	chr14:75593920	NEK9	0.92	16.29	0.71	8.22e-42	Height;
CESC	cis	rs228769	0.543	rs170634	chr17:42175821	C/A	cg19774624	chr17:42201019	HDAC5	0.62	8.74	0.47	2.71e-16	Bone mineral density (hip);Bone mineral density (spine);
CESC	cis	rs1008375	0.900	rs6851783	chr4:17578469	A/G	cg16339924	chr4:17578868	LAP3	0.83	10.53	0.54	6.69e-22	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs397969	0.573	rs203475	chr17:19850975	A/G	cg12073167	chr17:19770448	ULK2	-0.45	-5.28	-0.31	2.72e-7	Platelet count;
CESC	cis	rs8062405	0.755	rs4788074	chr16:28593597	A/G	cg01378222	chr16:28622494	SULT1A1	-0.32	-5.53	-0.32	7.72e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	trans	rs650950	0.528	rs646660	chr11:35528452	C/T	cg21679509	chr7:28219613	JAZF1	0.44	6.4	0.37	7.03e-10	Bronchopulmonary dysplasia;
CESC	cis	rs9811920	0.732	rs793446	chr3:99578114	A/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.48	-7.99	-0.44	4.14e-14	Axial length;
CESC	cis	rs9322193	0.962	rs3763163	chr6:150140906	G/T	cg04369109	chr6:150039330	LATS1	-0.43	-6.0	-0.35	6.34e-9	Lung cancer;
CESC	cis	rs1355223	0.506	rs12294339	chr11:34860199	C/T	cg06937548	chr11:34938143	PDHX;APIP	0.42	5.06	0.3	7.87e-7	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs6547741	0.844	rs9941696	chr2:27920064	C/T	cg27432699	chr2:27873401	GPN1	-0.61	-9.02	-0.48	3.99e-17	Oral cavity cancer;
CESC	trans	rs35110281	0.720	rs162376	chr21:44926759	G/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.53	-7.09	-0.4	1.2e-11	Mean corpuscular volume;
CESC	cis	rs9649213	0.593	rs6945554	chr7:97972946	T/C	cg24562669	chr7:97807699	LMTK2	0.51	7.63	0.42	4.29e-13	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs2243480	0.901	rs35087093	chr7:65405208	C/T	cg25894440	chr7:65020034	NA	-0.59	-5.07	-0.3	7.57e-7	Diabetic kidney disease;
CESC	cis	rs7666738	0.830	rs13328005	chr4:99055480	T/C	cg17366294	chr4:99064904	C4orf37	0.6	8.52	0.46	1.23e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4253772	0.591	rs6007748	chr22:46657798	A/G	cg09491104	chr22:46646882	C22orf40	-0.6	-8.98	-0.48	5.18e-17	LDL cholesterol;Cholesterol, total;
CESC	cis	rs2075371	0.933	rs431306	chr7:133955974	A/T	cg20476274	chr7:133979776	SLC35B4	0.68	9.92	0.52	6.24e-20	Mean platelet volume;
CESC	cis	rs76793172	0.623	rs8107744	chr19:46300848	C/A	cg12641515	chr19:46296257	DMWD	0.62	5.17	0.3	4.65e-7	Eosinophil counts;
CESC	trans	rs57221529	0.766	rs56216231	chr5:581193	G/A	cg25482853	chr8:67687455	SGK3	1.0	10.02	0.52	2.96e-20	Lung disease severity in cystic fibrosis;
CESC	cis	rs12477438	0.520	rs7604557	chr2:99747829	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.86	16.02	0.7	7.14e-41	Chronic sinus infection;
CESC	cis	rs9611565	0.649	rs738422	chr22:42123399	C/T	cg06481639	chr22:41940642	POLR3H	0.48	5.56	0.32	6.63e-8	Vitiligo;
CESC	cis	rs113835537	0.529	rs3741360	chr11:66300348	A/G	cg22134325	chr11:66188745	NPAS4	0.39	5.84	0.34	1.51e-8	Airway imaging phenotypes;
CESC	cis	rs5758659	0.519	rs133307	chr22:42396568	C/A	cg15557168	chr22:42548783	NA	-0.43	-6.34	-0.36	9.93e-10	Cognitive function;
CESC	cis	rs6032067	0.777	rs34163611	chr20:43778990	T/C	cg11264863	chr20:43835661	SEMG1	0.5	5.37	0.31	1.75e-7	Blood protein levels;
CESC	cis	rs2997447	0.846	rs72886619	chr1:26452604	G/A	cg24596570	chr1:26146463	FAM54B;LOC646471	0.59	5.16	0.3	4.74e-7	QRS complex (12-leadsum);
CESC	cis	rs875971	0.789	rs7808013	chr7:66071196	A/G	cg10691866	chr7:65817282	TPST1	0.33	5.53	0.32	7.81e-8	Aortic root size;
CESC	cis	rs2242116	0.761	rs6780601	chr3:46965856	A/G	cg27129171	chr3:47204927	SETD2	0.53	6.76	0.38	8.94e-11	Birth weight;
CESC	cis	rs769267	0.895	rs2315279	chr19:19479936	C/A	cg03709012	chr19:19516395	GATAD2A	-0.99	-15.52	-0.69	4.48e-39	Tonsillectomy;
CESC	cis	rs597539	0.615	rs583182	chr11:68678634	C/T	cg06028808	chr11:68637592	NA	0.42	5.19	0.3	4.21e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg17896229	chr20:5294595	PROKR2	0.39	6.16	0.35	2.65e-9	Fibrinogen levels;
CESC	cis	rs4072980	0.524	rs28442147	chr1:38395410	T/A	cg18451016	chr1:38461880	NA	0.42	6.03	0.35	5.45e-9	Coronary artery disease;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg15019617	chr10:91152447	IFIT1	0.47	6.01	0.35	5.96e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs13191362	1.000	rs13201023	chr6:162981381	C/G	cg06582575	chr6:163149167	PACRG;PARK2	0.83	8.73	0.47	2.92e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs7927771	1.000	rs10838748	chr11:47716381	T/G	cg20307385	chr11:47447363	PSMC3	-0.48	-5.87	-0.34	1.27e-8	Subjective well-being;
CESC	cis	rs7618501	0.633	rs4688757	chr3:50035323	T/C	cg24110177	chr3:50126178	RBM5	-0.53	-7.26	-0.41	4.23e-12	Intelligence (multi-trait analysis);
CESC	cis	rs9322193	0.923	rs2297932	chr6:150039361	C/G	cg13206674	chr6:150067644	NUP43	0.46	6.59	0.38	2.43e-10	Lung cancer;
CESC	cis	rs6500602	0.855	rs2304631	chr16:4475868	A/T	cg08645402	chr16:4508243	NA	0.38	5.2	0.3	3.96e-7	Schizophrenia;
CESC	cis	rs875971	0.862	rs1167399	chr7:65561877	G/A	cg19163074	chr7:65112434	INTS4L2	0.46	5.57	0.32	6.37e-8	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07237882	chr5:137090689	HNRNPA0	0.6	7.06	0.4	1.5e-11	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.830	rs2865949	chr4:99039967	A/G	cg18180107	chr4:99064573	C4orf37	0.41	5.29	0.31	2.51e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4665809	0.590	rs7588328	chr2:26469788	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.1	12.71	0.62	3.31e-29	Gut microbiome composition (summer);
CESC	cis	rs1874326	0.545	rs4574789	chr7:138109427	C/A	cg18008034	chr7:138118925	NA	-0.41	-5.14	-0.3	5.34e-7	Quantitative traits;
CESC	trans	rs62103177	0.564	rs7228971	chr18:77738025	C/T	cg05926928	chr17:57297772	GDPD1	-0.7	-6.34	-0.36	9.91e-10	Opioid sensitivity;
CESC	cis	rs2191566	0.691	rs55812285	chr19:44587930	T/C	cg20607764	chr19:44506953	ZNF230	-0.4	-5.2	-0.3	4.04e-7	Acute lymphoblastic leukemia (childhood);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg05614267	chr16:69373129	NIP7;COG8	-0.37	-6.02	-0.35	5.72e-9	Gambling;
CESC	cis	rs9787249	0.874	rs7520588	chr1:40214525	T/A	cg24920358	chr1:40204285	PPIE	0.43	6.4	0.37	7.07e-10	Blood protein levels;
CESC	cis	rs870825	0.616	rs12502860	chr4:185636105	T/C	cg04058563	chr4:185651563	MLF1IP	0.62	6.86	0.39	4.91e-11	Blood protein levels;
CESC	cis	rs17826219	0.561	rs562840	chr17:28949390	G/T	cg04154034	chr17:28927549	LRRC37B2	0.62	6.01	0.35	6e-9	Body mass index;
CESC	cis	rs854765	0.583	rs8075965	chr17:17853180	A/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.55	7.14	0.4	8.73e-12	Total body bone mineral density;
CESC	cis	rs7618915	0.547	rs2336542	chr3:52710636	A/G	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.64	0.38	1.82e-10	Bipolar disorder;
CESC	cis	rs9911578	0.867	rs72628394	chr17:57121313	C/T	cg05425664	chr17:57184151	TRIM37	0.51	7.07	0.4	1.34e-11	Intelligence (multi-trait analysis);
CESC	cis	rs9611565	0.512	rs2899349	chr22:42164660	T/C	cg03806693	chr22:41940476	POLR3H	1.18	13.88	0.65	2.76e-33	Vitiligo;
CESC	cis	rs2249625	0.545	rs60835713	chr6:72880349	T/C	cg18830697	chr6:72922368	RIMS1	0.42	5.94	0.34	8.7e-9	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CESC	cis	rs11031096	0.782	rs10767845	chr11:4156922	C/T	cg18678763	chr11:4115507	RRM1	-0.46	-6.31	-0.36	1.19e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	cis	rs17711722	0.523	rs365896	chr7:65510697	A/G	cg02869306	chr7:64672164	INTS4L1	0.33	5.21	0.3	3.87e-7	Calcium levels;
CESC	trans	rs11720469	0.967	rs7430936	chr3:166500933	G/A	cg03163944	chr19:37663716	ZNF585A	-0.41	-6.06	-0.35	4.65e-9	Fast beta electroencephalogram;
CESC	cis	rs2279817	0.818	rs71644062	chr1:17980530	C/T	cg21791023	chr1:18019539	ARHGEF10L	-0.67	-7.92	-0.44	6.76e-14	Neuroticism;
CESC	cis	rs854765	0.583	rs9635697	chr17:17870394	T/A	cg16928487	chr17:17741425	SREBF1	-0.57	-9.55	-0.51	9.29e-19	Total body bone mineral density;
CESC	cis	rs12325245	0.536	rs12931051	chr16:58626534	C/T	cg02549819	chr16:58548995	SETD6	0.95	6.11	0.35	3.54e-9	Schizophrenia;
CESC	cis	rs4665809	0.590	rs10495756	chr2:26485586	A/G	cg08470875	chr2:26401718	FAM59B	0.75	7.76	0.43	1.81e-13	Gut microbiome composition (summer);
CESC	cis	rs10504229	0.906	rs56138544	chr8:58184558	A/C	cg14926445	chr8:58193284	C8orf71	-0.51	-5.52	-0.32	8.28e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs763121	0.813	rs2179143	chr22:39037984	A/G	cg21395723	chr22:39101663	GTPBP1	0.39	5.1	0.3	6.63e-7	Menopause (age at onset);
CESC	cis	rs798554	0.567	rs1182191	chr7:2869364	A/T	cg19717773	chr7:2847554	GNA12	-0.49	-7.39	-0.41	1.94e-12	Height;
CESC	cis	rs56873913	0.904	rs7251295	chr19:50096859	G/C	cg09250473	chr19:50168907	IRF3;BCL2L12	0.46	5.04	0.3	8.57e-7	Schizophrenia;
CESC	cis	rs9457247	1.000	rs404222	chr6:167402150	G/A	cg25258033	chr6:167368657	RNASET2	0.38	5.84	0.34	1.54e-8	Crohn's disease;
CESC	cis	rs875971	1.000	rs6963646	chr7:65685767	T/C	cg12463550	chr7:65579703	CRCP	-0.57	-7.38	-0.41	2.04e-12	Aortic root size;
CESC	cis	rs9929218	0.817	rs3114404	chr16:68722096	C/T	cg02972257	chr16:68554789	NA	0.6	6.53	0.37	3.34e-10	Colorectal cancer;
CESC	cis	rs9910055	1.000	rs9895423	chr17:42285740	T/C	cg19774624	chr17:42201019	HDAC5	-0.64	-7.83	-0.43	1.19e-13	Total body bone mineral density;
CESC	cis	rs27434	0.583	rs151909	chr5:96156888	T/C	cg16492584	chr5:96139282	ERAP1	-0.36	-5.09	-0.3	6.81e-7	Ankylosing spondylitis;
CESC	cis	rs10779751	1.000	rs1064261	chr1:11288758	C/T	cg08854313	chr1:11322531	MTOR	0.77	10.66	0.55	2.65e-22	Body mass index;
CESC	cis	rs7116495	0.609	rs11235444	chr11:71831859	G/A	cg10381502	chr11:71823885	C11orf51	1.16	7.33	0.41	2.77e-12	Severe influenza A (H1N1) infection;
CESC	cis	rs3096299	0.632	rs8051537	chr16:89544384	T/A	cg02187348	chr16:89574699	SPG7	0.61	8.51	0.46	1.3e-15	Multiple myeloma (IgH translocation);
CESC	cis	rs7949030	0.626	rs7930896	chr11:62325272	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.62	9.13	0.49	1.81e-17	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs116095464	0.558	rs55776650	chr5:273826	G/A	cg22857025	chr5:266934	NA	-1.3	-18.75	-0.76	1.71e-50	Breast cancer;
CESC	cis	rs17401966	0.931	rs12131441	chr1:10428952	G/A	cg15208524	chr1:10270712	KIF1B	0.4	5.14	0.3	5.37e-7	Hepatocellular carcinoma;
CESC	cis	rs67460515	0.892	rs13073147	chr3:161045237	T/C	cg03342759	chr3:160939853	NMD3	-0.54	-7.73	-0.43	2.27e-13	Parkinson's disease;
CESC	cis	rs6499255	0.951	rs74026882	chr16:69635059	A/G	cg15192750	chr16:69999425	NA	0.51	5.98	0.34	7.11e-9	IgE levels;
CESC	cis	rs6456156	0.565	rs12529238	chr6:167465576	G/A	cg23791538	chr6:167370224	RNASET2	-0.49	-6.37	-0.36	8.13e-10	Primary biliary cholangitis;
CESC	cis	rs938554	0.571	rs12509955	chr4:10024303	C/T	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.83	-0.43	1.19e-13	Blood metabolite levels;
CESC	cis	rs6500602	0.702	rs4786493	chr16:4500122	C/T	cg08645402	chr16:4508243	NA	0.5	8.42	0.46	2.44e-15	Schizophrenia;
CESC	cis	rs3106136	0.967	rs61514245	chr4:95165053	C/G	cg11021082	chr4:95130006	SMARCAD1	-0.45	-6.81	-0.39	6.69e-11	Capecitabine sensitivity;
CESC	cis	rs3749237	0.576	rs4241406	chr3:49600426	C/T	cg06212747	chr3:49208901	KLHDC8B	0.48	6.46	0.37	4.88e-10	Resting heart rate;
CESC	cis	rs2249694	0.960	rs4351776	chr10:135415572	G/T	cg20169779	chr10:135381914	SYCE1	-0.39	-5.58	-0.32	5.82e-8	Obesity-related traits;
CESC	cis	rs7666738	0.606	rs6839946	chr4:99076132	A/C	cg24818145	chr4:99064322	C4orf37	0.4	5.2	0.3	3.98e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1799949	0.930	rs3092987	chr17:41222723	T/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.43	5.75	0.33	2.41e-8	Menopause (age at onset);
CESC	cis	rs9911578	0.874	rs302874	chr17:56767996	A/G	cg05425664	chr17:57184151	TRIM37	-0.52	-7.08	-0.4	1.29e-11	Intelligence (multi-trait analysis);
CESC	cis	rs9811920	0.609	rs17174947	chr3:99598884	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.64	10.11	0.53	1.53e-20	Axial length;
CESC	cis	rs4853012	0.838	rs60964317	chr2:74343423	A/T	cg01017244	chr2:74357527	NA	0.66	9.58	0.51	7.55e-19	Gestational age at birth (maternal effect);
CESC	cis	rs11645898	0.935	rs72787091	chr16:72190184	C/T	cg14768367	chr16:72042858	DHODH	-0.79	-6.58	-0.37	2.51e-10	Blood protein levels;
CESC	cis	rs7296418	0.699	rs11608297	chr12:123826642	T/C	cg05973401	chr12:123451056	ABCB9	0.42	5.35	0.31	1.91e-7	Platelet count;
CESC	cis	rs643506	0.874	rs687152	chr11:111721673	T/C	cg17089665	chr11:111648010	NA	-0.36	-5.2	-0.3	4.07e-7	Breast cancer;
CESC	trans	rs5769765	0.819	rs9616379	chr22:50312035	C/T	cg09872104	chr7:134855509	C7orf49	-0.55	-6.27	-0.36	1.47e-9	Schizophrenia;
CESC	cis	rs10870270	0.957	rs10870307	chr10:133780610	T/C	cg17892150	chr10:133769511	PPP2R2D	-0.85	-12.37	-0.61	4.7e-28	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs7605827	0.930	rs4410258	chr2:15594984	A/C	cg19274914	chr2:15703543	NA	0.32	5.69	0.33	3.38e-8	Educational attainment (years of education);
CESC	cis	rs1799949	0.965	rs8067269	chr17:41235799	C/T	cg05368731	chr17:41323189	NBR1	0.53	7.4	0.41	1.86e-12	Menopause (age at onset);
CESC	cis	rs7671266	0.616	rs4320137	chr4:10072969	C/T	cg00071950	chr4:10020882	SLC2A9	0.58	5.71	0.33	2.95e-8	Cardiovascular disease risk factors;
CESC	cis	rs3796352	1.000	rs11710292	chr3:53117798	T/C	cg12962167	chr3:53033115	SFMBT1	0.68	5.89	0.34	1.18e-8	Immune reponse to smallpox (secreted IL-2);
CESC	trans	rs60843830	0.928	rs2306060	chr2:230912	A/C	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.68	8.53	0.46	1.11e-15	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs873946	0.517	rs7071784	chr10:134559980	T/C	cg27286337	chr10:134555280	INPP5A	0.58	6.83	0.39	5.92e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs4074961	0.669	rs4652964	chr1:38078300	A/G	cg13401533	chr1:37979913	MEAF6	0.52	7.04	0.4	1.61e-11	Axial length;
CESC	cis	rs1448094	0.511	rs4469976	chr12:86146723	T/C	cg02569458	chr12:86230093	RASSF9	-0.42	-6.44	-0.37	5.67e-10	Major depressive disorder;
CESC	cis	rs13191362	0.938	rs28360532	chr6:162997477	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.88	9.16	0.49	1.46e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs1729951	0.575	rs1682356	chr3:136692037	T/C	cg04103450	chr3:136751342	NA	0.41	5.48	0.32	9.91e-8	Neuroticism;
CESC	cis	rs9311474	0.508	rs11718420	chr3:52611413	T/C	cg17372223	chr3:52568218	NT5DC2	0.39	5.91	0.34	1.02e-8	Electroencephalogram traits;
CESC	cis	rs711245	0.518	rs11886145	chr2:36825716	C/G	cg01206211	chr2:36825736	FEZ2	0.34	5.77	0.33	2.2e-8	Height;
CESC	cis	rs9581857	0.556	rs1885990	chr13:28040502	C/T	cg22138327	chr13:27999177	GTF3A	0.6	6.69	0.38	1.33e-10	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
CESC	cis	rs60871478	0.947	rs62432866	chr7:809281	T/G	cg27478167	chr7:817139	HEATR2	-0.47	-5.34	-0.31	1.98e-7	Cerebrospinal P-tau181p levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23037648	chr3:101568246	NFKBIZ	0.57	6.22	0.36	1.92e-9	Gut microbiome composition (summer);
CESC	cis	rs11676348	0.818	rs7423433	chr2:218985084	G/A	cg00012203	chr2:219082015	ARPC2	-0.56	-7.31	-0.41	3.18e-12	Ulcerative colitis;
CESC	cis	rs7592578	0.679	rs62181019	chr2:191325414	A/G	cg10560079	chr2:191398806	TMEM194B	-0.54	-5.35	-0.31	1.95e-7	Diastolic blood pressure;
CESC	cis	rs965469	0.895	rs6051844	chr20:3402674	G/T	cg25506879	chr20:3388711	C20orf194	0.55	6.1	0.35	3.65e-9	IFN-related cytopenia;
CESC	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg07092213	chr7:1199455	ZFAND2A	-0.54	-6.26	-0.36	1.5e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg10381409	chr21:37692231	MORC3	0.47	6.13	0.35	3.2e-9	Systemic lupus erythematosus;
CESC	cis	rs3857067	1.000	rs6532462	chr4:95026833	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.53	-8.12	-0.45	1.77e-14	QT interval;
CESC	cis	rs6540559	1.000	rs2235372	chr1:209960436	A/G	cg22029157	chr1:209979665	IRF6	-0.69	-9.77	-0.51	1.91e-19	Cleft lip with or without cleft palate;
CESC	cis	rs6137287	0.643	rs6047259	chr20:21098319	A/G	cg13880779	chr20:21376337	NKX2-4	-0.34	-5.51	-0.32	8.6e-8	Height;
CESC	cis	rs1799949	1.000	rs11079056	chr17:41300799	C/A	cg23758822	chr17:41437982	NA	1.02	15.64	0.69	1.65e-39	Menopause (age at onset);
CESC	cis	rs11997175	1.000	rs6468201	chr8:33746854	G/C	ch.8.33884649F	chr8:33765107	NA	0.64	8.39	0.46	3.03e-15	Body mass index;
CESC	cis	rs4604732	0.588	rs6677477	chr1:247629411	C/T	cg12758973	chr1:247694275	LOC148824;OR2C3	0.47	5.82	0.34	1.73e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs7809950	1.000	rs3801954	chr7:107117048	C/T	cg23024343	chr7:107201750	COG5	-0.43	-6.04	-0.35	5.27e-9	Coronary artery disease;
CESC	trans	rs916888	0.610	rs199452	chr17:44801340	C/T	cg10053473	chr17:62856997	LRRC37A3	-0.67	-9.43	-0.5	2.21e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	trans	rs2018683	0.834	rs2012754	chr7:29026257	G/A	cg19402173	chr7:128379420	CALU	-0.63	-7.85	-0.43	1e-13	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CESC	cis	rs9443645	0.527	rs9343861	chr6:79744868	C/A	cg05283184	chr6:79620031	NA	-0.38	-5.42	-0.32	1.35e-7	Intelligence (multi-trait analysis);
CESC	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg07308232	chr7:1071921	C7orf50	-0.48	-6.83	-0.39	5.66e-11	Longevity;Endometriosis;
CESC	cis	rs4253772	0.744	rs9627278	chr22:46643432	C/G	cg09491104	chr22:46646882	C22orf40	-0.43	-5.8	-0.34	1.9e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs2295359	0.892	rs72676069	chr1:67658954	T/C	cg17031739	chr1:67600172	NA	0.4	5.19	0.3	4.15e-7	Psoriasis;
CESC	cis	rs7474896	0.559	rs1208560	chr10:38221618	A/T	cg00409905	chr10:38381863	ZNF37A	0.45	5.08	0.3	7.06e-7	Obesity (extreme);
CESC	trans	rs61931739	0.517	rs11052964	chr12:34010996	G/C	cg26384229	chr12:38710491	ALG10B	0.58	8.06	0.44	2.68e-14	Morning vs. evening chronotype;
CESC	cis	rs11583043	0.958	rs12746722	chr1:101464789	G/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.53	5.89	0.34	1.17e-8	Ulcerative colitis;Inflammatory bowel disease;
CESC	cis	rs10751667	0.666	rs7395267	chr11:962326	C/A	cg20946044	chr11:1010712	AP2A2	-0.38	-5.35	-0.31	1.92e-7	Alzheimer's disease (late onset);
CESC	cis	rs7412746	0.658	rs10305711	chr1:150802996	T/C	cg09365446	chr1:150670422	GOLPH3L	0.38	5.13	0.3	5.74e-7	Melanoma;
CESC	cis	rs7927771	0.800	rs55876153	chr11:47416636	G/A	cg20307385	chr11:47447363	PSMC3	-0.62	-7.67	-0.43	3.34e-13	Subjective well-being;
CESC	cis	rs7412746	0.611	rs66847267	chr1:150875173	C/A	cg17724175	chr1:150552817	MCL1	0.33	5.15	0.3	5.17e-7	Melanoma;
CESC	cis	rs2243480	1.000	rs2257790	chr7:65600450	C/T	cg12463550	chr7:65579703	CRCP	0.74	5.87	0.34	1.29e-8	Diabetic kidney disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03416154	chr22:21336337	LZTR1	0.61	7.05	0.4	1.58e-11	Gut microbiome composition (summer);
CESC	cis	rs6089584	0.606	rs2273989	chr20:60579138	G/A	cg06108461	chr20:60628389	TAF4	-0.56	-7.3	-0.41	3.27e-12	Body mass index;
CESC	cis	rs13256369	0.951	rs13270852	chr8:8566853	A/G	cg00074818	chr8:8560427	CLDN23	0.34	5.05	0.3	8.3e-7	Obesity-related traits;
CESC	cis	rs11642862	1.000	rs11645175	chr16:30803299	C/T	cg02466173	chr16:30829666	NA	-0.59	-5.92	-0.34	9.76e-9	Tonsillectomy;
CESC	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg18538332	chr22:24372958	LOC391322	0.77	11.26	0.57	2.6e-24	Liver enzyme levels (gamma-glutamyl transferase);
CESC	trans	rs2207136	0.868	rs1157986	chr6:50843329	C/T	cg06522515	chr3:184090630	THPO	-0.38	-6.64	-0.38	1.77e-10	Myopia;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg17461271	chr1:172717683	NA	0.45	6.02	0.35	5.77e-9	Fibrinogen levels;
CESC	cis	rs9910055	0.529	rs228766	chr17:42186813	A/G	cg19774624	chr17:42201019	HDAC5	0.58	7.7	0.43	2.63e-13	Total body bone mineral density;
CESC	trans	rs13360092	1.000	rs13358049	chr5:50542459	C/T	cg03200537	chr16:87022121	NA	0.69	6.01	0.35	6.12e-9	Verbal declarative memory;
CESC	cis	rs6912958	0.754	rs6918909	chr6:88247251	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.5	-6.7	-0.38	1.24e-10	Monocyte percentage of white cells;
CESC	cis	rs4308124	0.708	rs6747657	chr2:112003163	C/T	cg04571233	chr2:111982156	NA	-0.56	-6.31	-0.36	1.16e-9	Vitiligo;
CESC	cis	rs7512552	0.839	rs1103115	chr1:150332304	G/A	cg15654264	chr1:150340011	RPRD2	0.39	5.24	0.31	3.25e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs7927771	0.800	rs35996350	chr11:47389223	A/G	cg18512352	chr11:47633146	NA	-0.5	-7.28	-0.41	3.85e-12	Subjective well-being;
CESC	trans	rs10820912	0.673	rs4743861	chr9:92885650	T/A	cg23943268	chr13:33589621	KL	-0.47	-6.03	-0.35	5.55e-9	Left atrial antero-posterior diameter;
CESC	cis	rs12956009	0.518	rs1560902	chr18:44898765	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.5	6.49	0.37	4.11e-10	Educational attainment (years of education);
CESC	cis	rs7254114	0.568	rs8111456	chr19:11301147	A/G	cg02815516	chr19:11306319	KANK2	-0.34	-5.46	-0.32	1.12e-7	Immature fraction of reticulocytes;
CESC	cis	rs6461049	0.800	rs3778977	chr7:2159746	C/T	cg08027265	chr7:2291960	NA	-0.42	-6.49	-0.37	4.13e-10	Schizophrenia;
CESC	cis	rs7264396	0.790	rs3787168	chr20:34233278	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.86	-11.94	-0.59	1.44e-26	Total cholesterol levels;
CESC	cis	rs9913156	0.793	rs72835644	chr17:4573667	G/A	cg00122941	chr17:4613640	ARRB2	0.88	10.3	0.53	3.7e-21	Lymphocyte counts;
CESC	cis	rs8044868	0.548	rs3909541	chr16:72201119	C/T	cg01557791	chr16:72042693	DHODH	0.39	5.21	0.3	3.81e-7	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CESC	cis	rs1348850	0.874	rs952746	chr2:178306584	A/G	cg23306229	chr2:178417860	TTC30B	0.62	7.91	0.44	6.82e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs7249921	0.833	rs59975720	chr19:35660954	G/A	cg15419183	chr19:35660584	FXYD5	0.56	8.36	0.46	3.57e-15	Platelet count;
CESC	cis	rs3812831	0.669	rs382913	chr13:114928255	G/T	cg08824895	chr13:115047677	UPF3A	0.39	5.17	0.3	4.53e-7	Schizophrenia;
CESC	trans	rs728996	0.560	rs2094260	chr6:51644687	G/A	cg15101985	chr10:85961501	PCDH21	-0.46	-6.0	-0.35	6.4e-9	Weight loss (gastric bypass surgery);
CESC	cis	rs11249608	0.548	rs6601007	chr5:178455796	G/C	cg21905437	chr5:178450457	ZNF879	0.6	8.73	0.47	2.84e-16	Pubertal anthropometrics;
CESC	cis	rs9916302	0.808	rs12947281	chr17:37652210	G/T	cg19468946	chr17:37922297	IKZF3	-0.39	-5.08	-0.3	7.08e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs1707322	0.650	rs4553239	chr1:46150486	C/A	cg06784218	chr1:46089804	CCDC17	0.43	7.6	0.42	5.22e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs1667255	0.830	rs2034404	chr18:29156302	A/G	cg18084450	chr1:235530719	TBCE	0.49	6.05	0.35	5.05e-9	Retinol levels;
CESC	cis	rs6429082	0.818	rs834198	chr1:235671987	A/G	cg26050004	chr1:235667680	B3GALNT2	0.66	8.09	0.44	2.18e-14	Adiposity;
CESC	cis	rs6987853	0.787	rs2974346	chr8:42401205	T/C	cg09913449	chr8:42400586	C8orf40	0.45	7.63	0.42	4.28e-13	Mean corpuscular hemoglobin concentration;
CESC	cis	rs7772486	0.790	rs9376971	chr6:146259505	C/T	cg23711669	chr6:146136114	FBXO30	-0.92	-13.3	-0.63	2.94e-31	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg04125625	chr1:29564120	PTPRU	-0.45	-6.0	-0.35	6.38e-9	Asthma;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg21302562	chr1:44497012	SLC6A9	-0.44	-6.34	-0.36	9.81e-10	Gambling;
CESC	cis	rs9322193	0.851	rs9322194	chr6:149920249	C/T	cg13206674	chr6:150067644	NUP43	0.4	5.72	0.33	2.83e-8	Lung cancer;
CESC	cis	rs34779708	0.931	rs11010132	chr10:35517265	C/G	cg04310649	chr10:35416472	CREM	-0.5	-6.05	-0.35	5e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs5167	0.504	rs7258345	chr19:45453151	T/G	cg09555818	chr19:45449301	APOC2	0.41	6.55	0.37	3.05e-10	Blood protein levels;
CESC	cis	rs9611565	0.512	rs132767	chr22:42009520	C/T	cg06634786	chr22:41940651	POLR3H	-0.57	-5.84	-0.34	1.49e-8	Vitiligo;
CESC	cis	rs4595586	0.545	rs12823721	chr12:39386461	G/A	cg26384229	chr12:38710491	ALG10B	0.54	7.53	0.42	7.85e-13	Morning vs. evening chronotype;
CESC	cis	rs9325144	0.602	rs11169100	chr12:39077861	G/T	cg26384229	chr12:38710491	ALG10B	-0.51	-6.98	-0.39	2.34e-11	Morning vs. evening chronotype;
CESC	cis	rs7336332	0.598	rs10220056	chr13:28003781	T/G	cg01674679	chr13:27998804	GTF3A	-0.59	-5.34	-0.31	1.98e-7	Weight;
CESC	cis	rs6500395	0.928	rs7199206	chr16:48702538	A/G	cg04672837	chr16:48644449	N4BP1	-0.5	-6.2	-0.36	2.19e-9	Response to tocilizumab in rheumatoid arthritis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12768767	chr1:47779966	STIL	0.61	6.61	0.38	2.05e-10	Gut microbiome composition (summer);
CESC	cis	rs1552244	1.000	rs6414438	chr3:10073824	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.79	-10.7	-0.55	1.91e-22	Alzheimer's disease;
CESC	cis	rs1808579	0.874	rs1367083	chr18:21100240	C/T	cg14672496	chr18:21087552	C18orf8	0.45	6.56	0.37	2.82e-10	Hip circumference;Body mass index;BMI (adjusted for smoking behaviour);
CESC	cis	rs7662987	0.517	rs2602865	chr4:100034841	T/C	cg12011299	chr4:100065546	ADH4	0.6	6.56	0.37	2.83e-10	Smoking initiation;
CESC	trans	rs7618501	0.633	rs4688758	chr3:50028385	G/A	cg21659725	chr3:3221576	CRBN	0.54	7.55	0.42	7.09e-13	Intelligence (multi-trait analysis);
CESC	cis	rs12900413	0.562	rs28450767	chr15:90298228	A/G	cg24249390	chr15:90295951	MESP1	-0.38	-5.14	-0.3	5.46e-7	Coronary artery aneurysm in Kawasaki disease;
CESC	cis	rs1008375	1.000	rs56308330	chr4:17643050	G/A	cg16339924	chr4:17578868	LAP3	0.57	7.13	0.4	9.66e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs2228479	0.702	rs62053701	chr16:89860584	G/A	cg14709524	chr16:89940631	TCF25	0.93	6.97	0.39	2.5e-11	Skin colour saturation;
CESC	cis	rs4699052	0.963	rs2061646	chr4:104183894	T/C	cg16532752	chr4:104119610	CENPE	-0.44	-5.98	-0.34	7.17e-9	Testicular germ cell tumor;
CESC	cis	rs11098499	1.000	rs10029750	chr4:120172543	A/G	cg24375607	chr4:120327624	NA	0.43	5.24	0.31	3.34e-7	Corneal astigmatism;
CESC	cis	rs4689388	0.727	rs1801213	chr4:6293696	C/G	cg14416269	chr4:6271139	WFS1	0.42	6.5	0.37	4e-10	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs1008375	0.931	rs3796814	chr4:17602033	G/C	cg16339924	chr4:17578868	LAP3	0.64	8.12	0.45	1.73e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	7.81	0.43	1.33e-13	Prudent dietary pattern;
CESC	cis	rs6121246	0.580	rs6121016	chr20:30245239	C/T	cg13852791	chr20:30311386	BCL2L1	0.81	8.59	0.47	7.37e-16	Mean corpuscular hemoglobin;
CESC	cis	rs10200159	1.000	rs10200159	chr2:55845109	T/C	cg13617705	chr2:55845095	SMEK2	0.74	5.34	0.31	2e-7	Vitiligo;
CESC	cis	rs11078597	0.731	rs34962442	chr17:1640529	C/T	cg18436246	chr17:1640651	WDR81	0.63	7.63	0.42	4.3e-13	Serum albumin level;
CESC	cis	rs9291683	0.588	rs35866697	chr4:10018604	C/A	cg00071950	chr4:10020882	SLC2A9	0.9	16.87	0.72	7.08e-44	Bone mineral density;
CESC	cis	rs7552404	1.000	rs1498316	chr1:76159198	G/A	cg10523679	chr1:76189770	ACADM	0.68	7.81	0.43	1.32e-13	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs2836950	0.565	rs2836930	chr21:40545656	A/G	cg17971929	chr21:40555470	PSMG1	-0.6	-8.02	-0.44	3.31e-14	Menarche (age at onset);
CESC	cis	rs208515	0.525	rs9453538	chr6:66668508	G/A	cg07460842	chr6:66804631	NA	0.83	10.33	0.54	3.09e-21	Exhaled nitric oxide levels;
CESC	cis	rs820218	0.847	rs1661745	chr17:73647139	A/G	cg01592526	chr17:73663357	RECQL5;SAP30BP	0.43	5.79	0.33	2.02e-8	Rotator cuff tears;
CESC	cis	rs7589728	0.563	rs78168096	chr2:88473575	G/A	cg07952391	chr2:88470173	THNSL2	0.63	6.02	0.35	5.73e-9	Plasma clusterin levels;
CESC	cis	rs10256972	0.869	rs1007766	chr7:1034903	G/A	cg02099474	chr7:1027990	CYP2W1	-0.38	-5.63	-0.33	4.51e-8	Longevity;Endometriosis;
CESC	cis	rs6502050	0.799	rs34448080	chr17:80121275	A/G	cg11859384	chr17:80120422	CCDC57	-0.39	-5.34	-0.31	1.98e-7	Life satisfaction;
CESC	cis	rs2243480	1.000	rs6966322	chr7:65646754	A/G	cg18252515	chr7:66147081	NA	1.36	13.62	0.64	2.24e-32	Diabetic kidney disease;
CESC	cis	rs854765	0.654	rs9911281	chr17:17762457	G/C	cg16928487	chr17:17741425	SREBF1	0.55	9.61	0.51	6.15e-19	Total body bone mineral density;
CESC	cis	rs4319547	0.615	rs2341439	chr12:122848096	C/G	cg05707623	chr12:122985044	ZCCHC8	-0.53	-6.15	-0.35	2.77e-9	Body mass index;
CESC	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg05025164	chr4:1340916	KIAA1530	0.7	9.56	0.51	8.45e-19	Longevity;
CESC	cis	rs27434	0.605	rs12659825	chr5:96188083	T/C	cg16492584	chr5:96139282	ERAP1	0.53	6.35	0.36	9.22e-10	Ankylosing spondylitis;
CESC	cis	rs4555082	0.874	rs1882846	chr14:105717448	G/C	cg06808227	chr14:105710500	BRF1	-0.57	-6.58	-0.37	2.49e-10	Mean platelet volume;Platelet distribution width;
CESC	cis	rs2479724	0.875	rs2253961	chr6:41827011	A/G	cg08135965	chr6:41755394	TOMM6	0.41	5.5	0.32	8.74e-8	Menarche (age at onset);
CESC	cis	rs1218582	0.741	rs6656494	chr1:154839799	A/G	cg09359103	chr1:154839909	KCNN3	-0.69	-13.25	-0.63	4.3e-31	Prostate cancer;
CESC	cis	rs2294693	0.945	rs9381023	chr6:40983281	C/T	cg14769373	chr6:40998127	UNC5CL	0.46	6.07	0.35	4.32e-9	Gastric cancer;Non-cardia gastric cancer;
CESC	cis	rs9858542	0.953	rs9841110	chr3:49492481	C/G	cg03060546	chr3:49711283	APEH	-0.53	-6.04	-0.35	5.21e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs12142240	0.659	rs72677602	chr1:46837487	G/A	cg00530320	chr1:46809349	NSUN4	0.62	7.96	0.44	4.98e-14	Menopause (age at onset);
CESC	cis	rs7249142	0.562	rs10417796	chr19:19287072	A/G	cg27384695	chr19:19271486	LOC729991-MEF2B;MEF2B	0.28	5.12	0.3	5.98e-7	IgG glycosylation;
CESC	cis	rs1799949	0.526	rs4352088	chr17:41414679	A/G	cg23758822	chr17:41437982	NA	1.04	15.72	0.69	8.63e-40	Menopause (age at onset);
CESC	cis	rs17826219	0.706	rs57698184	chr17:29064918	T/C	cg13385521	chr17:29058706	SUZ12P	0.82	6.62	0.38	2.04e-10	Body mass index;
CESC	cis	rs1008375	0.931	rs2109519	chr4:17695453	A/G	cg15017067	chr4:17643749	FAM184B	0.38	5.4	0.31	1.49e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs2842992	0.789	rs2295901	chr6:160201295	C/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.77	9.4	0.5	2.67e-18	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs8177253	0.798	rs9871148	chr3:133507509	T/C	cg11941060	chr3:133502564	NA	-0.51	-6.62	-0.38	1.96e-10	Iron status biomarkers;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16401850	chr14:106445160	NA	-0.49	-6.1	-0.35	3.82e-9	Gut microbiome composition (summer);
CESC	cis	rs7264396	0.747	rs6058291	chr20:34247769	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.86	-11.84	-0.59	3.14e-26	Total cholesterol levels;
CESC	cis	rs2952156	0.920	rs9303274	chr17:37836353	T/C	cg19468946	chr17:37922297	IKZF3	-0.39	-5.03	-0.3	8.93e-7	Asthma;
CESC	trans	rs2832077	0.527	rs9981922	chr21:30212718	A/G	cg14791747	chr16:20752902	THUMPD1	0.53	7.51	0.42	8.86e-13	Cognitive test performance;
CESC	cis	rs7116495	1.000	rs116781589	chr11:71825006	G/T	cg26138937	chr11:71823887	C11orf51	0.85	6.86	0.39	4.92e-11	Severe influenza A (H1N1) infection;
CESC	cis	rs6952808	0.792	rs4721184	chr7:1950784	T/C	cg22963979	chr7:1858916	MAD1L1	-0.37	-5.1	-0.3	6.41e-7	Bipolar disorder and schizophrenia;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg15759889	chr19:17420039	DDA1	-0.49	-6.5	-0.37	3.92e-10	Thyroid stimulating hormone;
CESC	cis	rs6662572	0.737	rs4557909	chr1:46316949	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.44	-5.04	-0.3	8.65e-7	Blood protein levels;
CESC	cis	rs4891159	0.790	rs10514217	chr18:74144939	A/G	cg24786174	chr18:74118243	ZNF516	-0.51	-6.38	-0.36	7.99e-10	Longevity;
CESC	cis	rs6499255	0.951	rs8046314	chr16:69697922	T/A	cg15192750	chr16:69999425	NA	0.46	5.34	0.31	2.04e-7	IgE levels;
CESC	cis	rs6964587	0.626	rs409	chr7:91556355	C/T	cg17063962	chr7:91808500	NA	0.45	6.33	0.36	1.07e-9	Breast cancer;
CESC	cis	rs6952808	0.691	rs2398709	chr7:2112548	C/T	cg23048001	chr7:2026167	MAD1L1	0.4	5.22	0.31	3.68e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs6500395	0.963	rs2883642	chr16:48685146	C/T	cg04672837	chr16:48644449	N4BP1	-0.51	-6.36	-0.36	8.64e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs8017423	0.536	rs11625794	chr14:90811229	C/T	cg14092571	chr14:90743983	NA	-0.4	-5.87	-0.34	1.31e-8	Mortality in heart failure;
CESC	cis	rs7914558	1.000	rs7094843	chr10:104806654	A/C	cg04362960	chr10:104952993	NT5C2	0.47	6.32	0.36	1.11e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs854765	0.547	rs2955378	chr17:17930253	G/A	cg04398451	chr17:18023971	MYO15A	-0.71	-10.32	-0.54	3.19e-21	Total body bone mineral density;
CESC	cis	rs1707322	1.000	rs785478	chr1:46491635	C/T	cg03146154	chr1:46216737	IPP	-0.72	-9.87	-0.52	8.94e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs1552244	0.554	rs17050705	chr3:10046398	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.62	7.99	0.44	4.24e-14	Alzheimer's disease;
CESC	cis	rs2228479	0.850	rs11648433	chr16:89965055	G/A	cg14709524	chr16:89940631	TCF25	0.86	6.25	0.36	1.66e-9	Skin colour saturation;
CESC	cis	rs7666738	0.887	rs34509663	chr4:98982531	C/T	cg17366294	chr4:99064904	C4orf37	0.56	7.52	0.42	8.37e-13	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9916302	0.707	rs11078903	chr17:37631924	G/A	cg20243544	chr17:37824526	PNMT	0.51	6.44	0.37	5.65e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs6565681	0.943	rs6565683	chr17:78362300	A/T	cg15383979	chr17:78362278	RNF213;LOC100294362	-0.77	-8.66	-0.47	4.67e-16	Moyamoya disease;
CESC	cis	rs1448094	0.547	rs7954472	chr12:86166258	T/C	cg02569458	chr12:86230093	RASSF9	0.49	7.68	0.43	3.04e-13	Major depressive disorder;
CESC	cis	rs10979	1.000	rs9321923	chr6:143897206	A/G	cg25407410	chr6:143891975	LOC285740	-0.6	-9.13	-0.49	1.8e-17	Hypospadias;
CESC	cis	rs1681630	0.545	rs1228001	chr11:47986994	A/T	cg18512352	chr11:47633146	NA	-0.33	-5.22	-0.31	3.55e-7	Height;
CESC	cis	rs2439831	1.000	rs2444250	chr15:43785051	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.88	10.25	0.53	5.49e-21	Lung cancer in ever smokers;
CESC	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg26338869	chr17:61819248	STRADA	0.67	8.66	0.47	4.55e-16	Prudent dietary pattern;
CESC	trans	rs1606974	0.649	rs1028145	chr2:51928042	G/T	cg21066735	chr11:15671806	NA	-0.74	-6.14	-0.35	3.07e-9	Educational attainment (years of education);Educational attainment;
CESC	cis	rs4450798	0.649	rs7631252	chr3:13803506	C/T	cg23332027	chr3:13681764	NA	0.4	5.75	0.33	2.45e-8	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs3733585	0.699	rs6449178	chr4:9968684	A/G	cg00071950	chr4:10020882	SLC2A9	0.67	10.82	0.55	7.57e-23	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs7186908	1.000	rs7186908	chr16:72220373	G/C	cg01557791	chr16:72042693	DHODH	-0.69	-7.16	-0.4	7.73e-12	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs1448094	0.512	rs12313775	chr12:86241197	G/A	cg00310523	chr12:86230176	RASSF9	0.36	5.63	0.33	4.6e-8	Major depressive disorder;
CESC	cis	rs7917772	0.565	rs61869210	chr10:104437175	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.52	5.91	0.34	1.07e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs6456156	0.586	rs7742305	chr6:167485723	C/T	cg07741184	chr6:167504864	NA	0.37	6.28	0.36	1.39e-9	Primary biliary cholangitis;
CESC	cis	rs854765	0.583	rs9904163	chr17:17830553	C/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.55	7.28	0.41	3.9e-12	Total body bone mineral density;
CESC	cis	rs2997447	0.846	rs3008414	chr1:26404747	G/A	cg24596570	chr1:26146463	FAM54B;LOC646471	0.59	5.06	0.3	7.88e-7	QRS complex (12-leadsum);
CESC	cis	rs796364	0.951	rs7608668	chr2:201000017	T/C	cg23649088	chr2:200775458	C2orf69	-0.56	-5.79	-0.34	2.01e-8	Schizophrenia;
CESC	cis	rs1178968	1.000	rs1178969	chr7:72759114	A/G	cg25889504	chr7:72793014	NA	0.52	5.47	0.32	1.03e-7	Triglyceride levels;
CESC	cis	rs1957429	0.808	rs1467573	chr14:65347583	T/C	cg23373153	chr14:65346875	NA	0.96	11.49	0.58	4.43e-25	Pediatric areal bone mineral density (radius);
CESC	cis	rs8008758	1.000	rs12435364	chr14:101690209	G/A	cg26224664	chr14:101693935	NA	-0.35	-5.33	-0.31	2.07e-7	Body mass index (alcohol intake interaction);
CESC	cis	rs4862750	0.872	rs56389997	chr4:187894796	A/C	cg07414643	chr4:187882934	NA	0.54	7.67	0.43	3.32e-13	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg12189382	chr17:79077463	BAIAP2	0.44	6.49	0.37	4.3e-10	Fibrinogen levels;
CESC	cis	rs2075371	0.611	rs12707154	chr7:134015832	C/T	cg11752832	chr7:134001865	SLC35B4	0.43	5.22	0.31	3.58e-7	Mean platelet volume;
CESC	trans	rs7937682	0.889	rs516263	chr11:111484719	A/C	cg18187862	chr3:45730750	SACM1L	0.48	6.05	0.35	4.86e-9	Primary sclerosing cholangitis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13057098	chr11:49873813	NA	-0.49	-6.05	-0.35	4.95e-9	Gut microbiome composition (summer);
CESC	cis	rs6693567	0.565	rs1260457	chr1:150347374	G/A	cg09579323	chr1:150459698	TARS2	0.48	6.12	0.35	3.27e-9	Migraine;
CESC	cis	rs9400271	0.609	rs9386783	chr6:109588644	G/T	cg01475377	chr6:109611718	NA	-0.46	-7.18	-0.4	7.24e-12	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
CESC	cis	rs7264396	0.790	rs6060541	chr20:34248066	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.64	7.77	0.43	1.78e-13	Total cholesterol levels;
CESC	cis	rs769267	1.000	rs3764567	chr19:19440066	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	-0.42	-5.13	-0.3	5.7e-7	Tonsillectomy;
CESC	cis	rs9660180	1.000	rs3737628	chr1:1722932	C/T	cg03396347	chr1:1875803	NA	-0.44	-6.79	-0.39	7.14e-11	Body mass index;
CESC	cis	rs9916302	0.851	rs612209	chr17:37442713	G/C	cg19468946	chr17:37922297	IKZF3	0.42	5.48	0.32	9.97e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs6088590	0.648	rs6058105	chr20:33271719	C/T	cg24642439	chr20:33292090	TP53INP2	0.71	9.39	0.5	2.91e-18	Coronary artery disease;
CESC	cis	rs5758659	0.652	rs5758537	chr22:42397042	G/T	cg04733989	chr22:42467013	NAGA	0.44	5.82	0.34	1.71e-8	Cognitive function;
CESC	cis	rs7927592	0.913	rs7118897	chr11:68360680	G/A	cg16797656	chr11:68205561	LRP5	0.38	5.42	0.32	1.35e-7	Total body bone mineral density;
CESC	cis	rs2832191	0.511	rs7278227	chr21:30482707	C/T	cg08807101	chr21:30365312	RNF160	-0.53	-6.8	-0.39	6.89e-11	Dental caries;
CESC	cis	rs727505	1.000	rs113394869	chr7:124518172	G/C	cg23710748	chr7:124431027	NA	-0.48	-7.52	-0.42	8.73e-13	Lewy body disease;
CESC	cis	rs1218582	0.688	rs58629129	chr1:154910930	T/C	cg16680214	chr1:154839983	KCNN3	-0.45	-6.77	-0.38	8.23e-11	Prostate cancer;
CESC	cis	rs3820068	0.603	rs59558854	chr1:15971399	T/G	cg16988262	chr1:15930761	NA	0.33	5.41	0.32	1.44e-7	Systolic blood pressure;
CESC	cis	rs9894429	1.000	rs9674872	chr17:79581931	T/A	cg18240062	chr17:79603768	NPLOC4	0.72	10.27	0.53	4.71e-21	Eye color traits;
CESC	cis	rs854765	0.547	rs2955353	chr17:17948979	T/C	cg16928487	chr17:17741425	SREBF1	0.55	9.13	0.49	1.86e-17	Total body bone mineral density;
CESC	trans	rs17685	0.712	rs10235738	chr7:75773460	G/A	cg19862616	chr7:65841803	NCRNA00174	0.8	11.44	0.57	6.89e-25	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs929596	0.755	rs887829	chr2:234668570	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.65	8.45	0.46	1.9e-15	Total bilirubin levels in HIV-1 infection;
CESC	trans	rs60843830	1.000	rs2290911	chr2:224919	A/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.67	8.25	0.45	7.47e-15	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs559928	0.597	rs2096706	chr11:63924446	T/G	cg18225595	chr11:63971243	STIP1	0.67	5.9	0.34	1.1e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CESC	cis	rs4728302	0.869	rs7805864	chr7:133610390	G/A	cg10665199	chr7:133106180	EXOC4	0.4	5.61	0.33	4.98e-8	Intelligence;Intelligence (multi-trait analysis);
CESC	cis	rs7208859	0.673	rs216410	chr17:28903831	C/G	cg14008862	chr17:28927542	LRRC37B2	-0.54	-5.29	-0.31	2.59e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs9929218	0.953	rs2902323	chr16:68736292	C/T	cg02972257	chr16:68554789	NA	0.58	6.47	0.37	4.74e-10	Colorectal cancer;
CESC	trans	rs459571	0.959	rs2073818	chr9:136918662	C/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.65	-8.5	-0.46	1.43e-15	Platelet distribution width;
CESC	cis	rs2066819	1.000	rs58852079	chr12:56706922	A/C	cg26804944	chr12:56660921	COQ10A	-0.85	-5.14	-0.3	5.39e-7	Psoriasis vulgaris;
CESC	cis	rs2777491	0.957	rs16971798	chr15:41657144	A/T	cg20272979	chr15:41787780	ITPKA	-0.36	-5.28	-0.31	2.73e-7	Ulcerative colitis;
CESC	cis	rs2115630	0.645	rs6496284	chr15:85178270	A/G	cg12501888	chr15:85177176	SCAND2	-0.5	-6.48	-0.37	4.53e-10	P wave terminal force;
CESC	cis	rs12142240	0.698	rs72677593	chr1:46824363	T/C	cg10495392	chr1:46806563	NSUN4	0.58	6.32	0.36	1.09e-9	Menopause (age at onset);
CESC	cis	rs6088580	0.634	rs6087580	chr20:32992592	A/G	cg24642439	chr20:33292090	TP53INP2	-0.55	-7.36	-0.41	2.32e-12	Glomerular filtration rate (creatinine);
CESC	cis	rs2836974	0.583	rs2735307	chr21:40713358	C/T	cg17971929	chr21:40555470	PSMG1	0.59	7.61	0.42	4.8e-13	Cognitive function;
CESC	cis	rs2455799	0.573	rs2455829	chr3:15746937	G/A	cg16303742	chr3:15540471	COLQ	-0.36	-5.42	-0.32	1.33e-7	Mean platelet volume;
CESC	cis	rs9788721	0.592	rs28564957	chr15:78906107	C/A	cg06917634	chr15:78832804	PSMA4	-0.55	-7.31	-0.41	3.14e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
CESC	cis	rs736408	0.677	rs678	chr3:52820981	A/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.3	5.03	0.3	8.98e-7	Bipolar disorder;
CESC	cis	rs7208859	0.725	rs9897673	chr17:29243366	T/C	cg19761014	chr17:28927070	LRRC37B2	0.66	6.17	0.35	2.57e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs561341	1.000	rs548957	chr17:30302411	G/A	cg19193384	chr17:30244184	NA	-0.67	-6.36	-0.36	8.74e-10	Hip circumference adjusted for BMI;
CESC	cis	rs2760061	0.626	rs2313118	chr1:228118084	T/C	cg01973587	chr1:228161476	NA	0.35	5.31	0.31	2.3e-7	Diastolic blood pressure;
CESC	cis	rs96067	0.740	rs10752586	chr1:36614713	C/G	cg24686825	chr1:36642396	MAP7D1	-0.49	-5.59	-0.32	5.73e-8	Corneal structure;
CESC	cis	rs6963495	0.818	rs818619	chr7:105172505	A/T	cg13798780	chr7:105162888	PUS7	0.6	6.94	0.39	2.96e-11	Bipolar disorder (body mass index interaction);
CESC	cis	rs10848704	0.525	rs4073984	chr12:2885780	G/A	cg19995117	chr12:2880862	NA	0.5	7.7	0.43	2.72e-13	Quantitative traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11539992	chr17:74497631	RHBDF2	0.59	6.77	0.38	8.25e-11	Gut microbiome composition (summer);
CESC	cis	rs9399135	0.967	rs2327580	chr6:135364417	A/C	cg22676075	chr6:135203613	NA	0.51	7.29	0.41	3.64e-12	Red blood cell count;
CESC	cis	rs3749237	1.000	rs11920900	chr3:49823024	G/C	cg03060546	chr3:49711283	APEH	0.66	7.88	0.44	8.24e-14	Resting heart rate;
CESC	cis	rs2836974	0.563	rs6517522	chr21:40553845	T/C	cg11644478	chr21:40555479	PSMG1	0.7	10.21	0.53	7.41e-21	Cognitive function;
CESC	cis	rs1697139	0.935	rs1625369	chr5:66513022	C/T	cg11553311	chr5:66541588	NA	0.33	5.05	0.3	8.4e-7	Breast cancer;
CESC	cis	rs748404	0.631	rs7167882	chr15:43678663	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.62	7.96	0.44	4.91e-14	Lung cancer;
CESC	cis	rs2228479	0.850	rs62054638	chr16:89821131	G/C	cg06558623	chr16:89946397	TCF25	1.16	9.28	0.5	6.08e-18	Skin colour saturation;
CESC	cis	rs2576037	1.000	rs2576037	chr18:44585420	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.49	6.37	0.36	8.43e-10	Personality dimensions;
CESC	cis	rs847577	0.722	rs7790120	chr7:97712831	C/A	cg21770322	chr7:97807741	LMTK2	0.64	10.58	0.55	4.59e-22	Breast cancer;
CESC	cis	rs861020	0.630	rs616544	chr1:210007368	T/C	cg05527609	chr1:210001259	C1orf107	0.74	9.67	0.51	3.97e-19	Orofacial clefts;
CESC	cis	rs67311347	1.000	rs11715214	chr3:40403004	C/A	cg09455208	chr3:40491958	NA	0.52	8.86	0.48	1.19e-16	Renal cell carcinoma;
CESC	cis	rs3091242	0.900	rs1883427	chr1:25744468	C/T	cg03538708	chr1:25844672	NA	-0.41	-6.18	-0.36	2.39e-9	Erythrocyte sedimentation rate;
CESC	cis	rs9443645	0.870	rs9350799	chr6:79723651	C/A	cg05283184	chr6:79620031	NA	-0.4	-6.25	-0.36	1.68e-9	Intelligence (multi-trait analysis);
CESC	cis	rs6570726	1.000	rs444564	chr6:145859795	G/C	cg05347473	chr6:146136440	FBXO30	0.43	5.78	0.33	2.1e-8	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs112591243	0.685	rs73379602	chr21:48027317	G/A	cg21286782	chr1:113265602	FAM19A3	-0.61	-6.19	-0.36	2.31e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
CESC	cis	rs3820068	0.705	rs58424111	chr1:15868470	A/C	cg17385448	chr1:15911702	AGMAT	0.36	5.66	0.33	3.96e-8	Systolic blood pressure;
CESC	cis	rs9393692	0.620	rs9379844	chr6:26291527	A/G	cg13736514	chr6:26305472	NA	0.36	5.93	0.34	9.57e-9	Educational attainment;
CESC	cis	rs77956314	0.515	rs7302025	chr12:117442902	C/T	cg25972092	chr12:117363249	FBXW8	0.54	6.07	0.35	4.37e-9	Subcortical brain region volumes;Hippocampal volume;
CESC	cis	rs3096299	0.606	rs4785674	chr16:89536613	A/G	cg02034447	chr16:89574710	SPG7	0.43	5.04	0.3	8.68e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs10463316	0.894	rs6880137	chr5:150755232	A/G	cg03212797	chr5:150827313	SLC36A1	-0.44	-5.75	-0.33	2.49e-8	Metabolite levels (Pyroglutamine);
CESC	cis	rs7666738	1.000	rs13124102	chr4:98990696	G/A	cg17366294	chr4:99064904	C4orf37	0.53	7.06	0.4	1.42e-11	Colonoscopy-negative controls vs population controls;
CESC	trans	rs6934970	0.860	rs4515421	chr6:112980969	A/G	cg05146922	chr2:10634174	NA	-0.38	-6.18	-0.35	2.35e-9	Bipolar disorder (body mass index interaction);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg05826458	chr2:111875031	ACOXL	-0.35	-6.05	-0.35	4.98e-9	Gambling;
CESC	cis	rs9322193	0.923	rs9285524	chr6:150015258	G/A	cg04369109	chr6:150039330	LATS1	-0.37	-5.07	-0.3	7.56e-7	Lung cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00917603	chr5:140209956	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.46	-6.07	-0.35	4.36e-9	Gut microbiome composition (summer);
CESC	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	22.35	0.81	6.51e-63	Prudent dietary pattern;
CESC	cis	rs57221529	0.766	rs4245972	chr5:578572	A/G	cg16447950	chr5:562315	NA	-0.64	-6.81	-0.39	6.59e-11	Lung disease severity in cystic fibrosis;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg26350446	chr7:111202682	IMMP2L	-0.46	-6.38	-0.36	7.67e-10	Asthma;
CESC	cis	rs763121	0.853	rs5757200	chr22:39043491	T/G	cg06544989	chr22:39130855	UNC84B	0.5	8.66	0.47	4.63e-16	Menopause (age at onset);
CESC	cis	rs854765	0.551	rs6502626	chr17:17849450	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.65	9.29	0.5	5.8e-18	Total body bone mineral density;
CESC	cis	rs11650494	0.908	rs9891264	chr17:47407342	T/A	cg08112188	chr17:47440006	ZNF652	0.83	6.16	0.35	2.75e-9	Prostate cancer;
CESC	cis	rs3096299	0.935	rs3102387	chr16:89432276	A/C	cg16743903	chr16:89593216	SPG7	-0.41	-5.18	-0.3	4.33e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs1506636	0.927	rs11983604	chr7:123329754	T/G	cg03229431	chr7:123269106	ASB15	-0.51	-6.79	-0.38	7.53e-11	Plateletcrit;Platelet count;
CESC	cis	rs13266463	1.000	rs13266463	chr8:143403693	A/G	cg06454464	chr8:143427921	TSNARE1	-0.38	-5.09	-0.3	6.9e-7	Schizophrenia;
CESC	cis	rs9902453	0.934	rs4343336	chr17:28488236	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.62	8.08	0.44	2.37e-14	Coffee consumption (cups per day);
CESC	cis	rs782590	0.935	rs6739513	chr2:55749902	G/A	cg18811423	chr2:55921094	PNPT1	0.79	12.42	0.61	3.19e-28	Metabolic syndrome;
CESC	cis	rs9560113	0.573	rs9560130	chr13:112229460	G/A	cg10483660	chr13:112241077	NA	0.44	7.17	0.4	7.32e-12	Menarche (age at onset);
CESC	cis	rs9329289	0.926	rs10903784	chr10:2541943	G/T	cg18171855	chr10:2543474	NA	-0.38	-5.84	-0.34	1.51e-8	Age-related hearing impairment;
CESC	cis	rs561341	0.941	rs17780086	chr17:30343282	G/A	cg12193833	chr17:30244370	NA	-0.75	-6.57	-0.37	2.6e-10	Hip circumference adjusted for BMI;
CESC	cis	rs72781680	0.898	rs12614616	chr2:23996501	T/G	cg08917208	chr2:24149416	ATAD2B	0.95	8.71	0.47	3.45e-16	Lymphocyte counts;
CESC	cis	rs17376456	0.877	rs10055340	chr5:93317644	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.64	5.63	0.33	4.56e-8	Diabetic retinopathy;
CESC	cis	rs798554	0.759	rs798495	chr7:2797267	T/C	cg09658497	chr7:2847517	GNA12	-0.42	-5.89	-0.34	1.17e-8	Height;
CESC	cis	rs3008870	0.755	rs2815349	chr1:67472280	G/A	cg02640540	chr1:67518911	SLC35D1	0.45	5.43	0.32	1.25e-7	Lymphocyte percentage of white cells;
CESC	cis	rs76525880	0.538	rs7405452	chr17:46674670	A/G	cg06593406	chr17:46696139	NA	-0.62	-5.98	-0.34	7.22e-9	Colorectal or endometrial cancer;
CESC	cis	rs763121	0.752	rs6001190	chr22:39073811	T/C	cg06022373	chr22:39101656	GTPBP1	0.88	13.88	0.65	2.67e-33	Menopause (age at onset);
CESC	cis	rs977987	0.836	rs34673655	chr16:75323559	T/C	cg03315344	chr16:75512273	CHST6	0.37	5.35	0.31	1.94e-7	Dupuytren's disease;
CESC	cis	rs7818345	0.935	rs4333618	chr8:19283442	G/C	cg11303988	chr8:19266685	CSGALNACT1	0.35	6.42	0.37	6.42e-10	Language performance in older adults (adjusted for episodic memory);
CESC	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg04025307	chr7:1156635	C7orf50	0.55	9.69	0.51	3.39e-19	Longevity;Endometriosis;
CESC	cis	rs1552244	0.872	rs115331527	chr3:10154504	G/A	cg16606324	chr3:10149918	C3orf24	0.42	5.2	0.3	4.02e-7	Alzheimer's disease;
CESC	cis	rs854765	0.929	rs854766	chr17:18012775	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.44	5.74	0.33	2.54e-8	Total body bone mineral density;
CESC	cis	rs561341	1.000	rs530209	chr17:30315287	A/G	cg23018236	chr17:30244563	NA	-0.52	-5.1	-0.3	6.39e-7	Hip circumference adjusted for BMI;
CESC	trans	rs7618501	1.000	rs9859153	chr3:49807085	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.59	8.5	0.46	1.36e-15	Intelligence (multi-trait analysis);
CESC	cis	rs9910055	1.000	rs9895423	chr17:42285740	T/C	cg08499158	chr17:42289980	UBTF	-0.62	-7.11	-0.4	1.07e-11	Total body bone mineral density;
CESC	cis	rs11122272	0.735	rs2808603	chr1:231537738	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.55	-7.47	-0.42	1.15e-12	Hemoglobin concentration;
CESC	cis	rs1153858	0.848	rs9806699	chr15:45740392	G/A	cg21132104	chr15:45694354	SPATA5L1	0.62	7.53	0.42	8.23e-13	Homoarginine levels;
CESC	cis	rs9768139	0.733	rs10156158	chr7:158122287	G/T	cg25566285	chr7:158114605	PTPRN2	0.51	8.46	0.46	1.77e-15	Calcium levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11557382	chr7:153446256	NA	-0.44	-6.44	-0.37	5.63e-10	Gut microbiome composition (summer);
CESC	cis	rs9916302	0.660	rs4795367	chr17:37608843	G/C	cg07936489	chr17:37558343	FBXL20	-0.91	-9.97	-0.52	4.37e-20	Glomerular filtration rate (creatinine);
CESC	trans	rs561341	0.883	rs4450460	chr17:30201309	C/T	cg20587970	chr11:113659929	NA	0.99	11.7	0.58	9.14e-26	Hip circumference adjusted for BMI;
CESC	cis	rs1552244	1.000	rs9875081	chr3:10083935	G/A	cg00149659	chr3:10157352	C3orf10	0.75	9.44	0.5	2.06e-18	Alzheimer's disease;
CESC	cis	rs2637266	0.703	rs1866889	chr10:78486389	A/G	cg18941641	chr10:78392320	NA	0.4	7.67	0.43	3.3e-13	Pulmonary function;
CESC	cis	rs3096299	0.632	rs4399533	chr16:89539382	G/C	cg02034447	chr16:89574710	SPG7	0.49	6.34	0.36	9.76e-10	Multiple myeloma (IgH translocation);
CESC	cis	rs7267979	0.789	rs2260197	chr20:25284343	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.71	11.64	0.58	1.46e-25	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs524023	0.914	rs2360872	chr11:64353405	T/C	cg07220939	chr11:64358617	SLC22A12	-0.33	-5.14	-0.3	5.25e-7	Urate levels in obese individuals;
CESC	cis	rs2735413	1.000	rs2735413	chr16:78053643	A/T	cg04733911	chr16:78082701	NA	-0.42	-6.24	-0.36	1.74e-9	Systolic blood pressure (alcohol consumption interaction);
CESC	cis	rs2243480	1.000	rs316312	chr7:65596491	T/G	cg12463550	chr7:65579703	CRCP	0.73	5.68	0.33	3.5e-8	Diabetic kidney disease;
CESC	cis	rs727563	0.593	rs132770	chr22:42017264	A/G	cg03806693	chr22:41940476	POLR3H	1.11	12.69	0.61	3.65e-29	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs899997	1.000	rs4887078	chr15:79011073	C/T	cg04896959	chr15:78267971	NA	0.42	6.38	0.36	7.95e-10	Coronary artery disease or large artery stroke;
CESC	cis	rs7811142	0.667	rs3873746	chr7:99935097	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.84	9.13	0.49	1.82e-17	Platelet count;
CESC	cis	rs3020736	0.500	rs6002604	chr22:42493081	A/T	cg04733989	chr22:42467013	NAGA	-0.79	-12.03	-0.59	6.75e-27	Autism spectrum disorder or schizophrenia;
CESC	cis	rs4727963	0.740	rs1404834	chr7:122715112	A/T	cg03640110	chr7:122635026	TAS2R16	0.4	6.43	0.37	6.01e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
CESC	trans	rs1557351	0.723	rs9945715	chr18:54720377	T/C	cg11433624	chr6:7146702	RREB1	0.38	6.12	0.35	3.34e-9	Multiple sclerosis (age of onset);
CESC	cis	rs1348850	0.558	rs4337505	chr2:178529714	A/T	cg23306229	chr2:178417860	TTC30B	0.47	5.56	0.32	6.7e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs7845219	0.544	rs4735330	chr8:95917770	A/C	cg09323728	chr8:95962352	TP53INP1	-0.32	-6.23	-0.36	1.8e-9	Type 2 diabetes;
CESC	cis	rs7819412	0.594	rs7460507	chr8:10969075	C/T	cg21775007	chr8:11205619	TDH	-0.39	-5.6	-0.33	5.38e-8	Triglycerides;
CESC	cis	rs7520050	0.807	rs6671802	chr1:46124663	A/G	cg24296786	chr1:45957014	TESK2	-0.46	-5.96	-0.34	8.19e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs8016982	0.632	rs8010219	chr14:81696982	A/G	cg01989461	chr14:81687754	GTF2A1	0.47	5.33	0.31	2.11e-7	Schizophrenia;
CESC	cis	rs28386778	0.863	rs3760252	chr17:61852186	G/C	cg06873352	chr17:61820015	STRADA	0.73	12.78	0.62	1.83e-29	Prudent dietary pattern;
CESC	cis	rs9287719	0.967	rs3814388	chr2:10702099	A/T	cg00105475	chr2:10696890	NA	0.39	5.71	0.33	3.1e-8	Prostate cancer;
CESC	cis	rs6665290	0.669	rs3768421	chr1:227177193	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.13	-24.36	-0.83	1.41e-69	Myeloid white cell count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26056348	chr7:75932317	HSPB1	0.54	6.63	0.38	1.91e-10	Gut microbiome composition (summer);
CESC	cis	rs3087591	1.000	rs2057769	chr17:29691368	C/A	cg24425628	chr17:29625626	OMG;NF1	-0.46	-5.75	-0.33	2.49e-8	Hip circumference;
CESC	cis	rs1799949	0.931	rs34474989	chr17:41445410	A/T	cg07153921	chr17:41440717	NA	-0.38	-5.15	-0.3	5.13e-7	Menopause (age at onset);
CESC	cis	rs703842	0.616	rs1875125	chr12:58227241	T/G	cg00677455	chr12:58241039	CTDSP2	0.73	9.87	0.52	9.2e-20	Multiple sclerosis;
CESC	trans	rs916888	0.773	rs199535	chr17:44822662	A/G	cg22433210	chr17:43662623	NA	0.98	11.57	0.58	2.54e-25	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs10504229	0.593	rs17192845	chr8:58053339	C/T	cg22535103	chr8:58192502	C8orf71	-0.94	-9.38	-0.5	3.05e-18	Developmental language disorder (linguistic errors);
CESC	cis	rs6952808	0.862	rs4721135	chr7:1912222	A/G	cg23048001	chr7:2026167	MAD1L1	0.4	5.44	0.32	1.21e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs684232	0.602	rs35206514	chr17:519859	T/C	cg12384639	chr17:618140	VPS53	0.43	5.51	0.32	8.37e-8	Prostate cancer;
CESC	cis	rs6540556	0.954	rs6696463	chr1:209933757	G/C	cg23920097	chr1:209922102	NA	-0.37	-5.54	-0.32	7.2e-8	Red blood cell count;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg07136949	chr6:7986672	MGC26597	0.47	6.93	0.39	3.26e-11	Fibrinogen levels;
CESC	cis	rs72781680	1.000	rs72781689	chr2:24256349	C/T	cg20701182	chr2:24300061	SF3B14	0.99	8.48	0.46	1.64e-15	Lymphocyte counts;
CESC	cis	rs533581	0.816	rs533406	chr16:88974860	A/G	cg16701003	chr16:89028210	CBFA2T3	0.55	8.27	0.45	6.73e-15	Social autistic-like traits;
CESC	cis	rs7927771	1.000	rs12419692	chr11:47624714	A/C	cg18512352	chr11:47633146	NA	0.57	8.95	0.48	6.16e-17	Subjective well-being;
CESC	cis	rs8103278	0.864	rs2070737	chr19:46282890	A/T	cg12641515	chr19:46296257	DMWD	-0.52	-5.88	-0.34	1.24e-8	Coronary artery disease;
CESC	cis	rs4665809	0.590	rs4665315	chr2:26416036	T/G	cg26314531	chr2:26401878	FAM59B	-0.83	-9.26	-0.49	7.29e-18	Gut microbiome composition (summer);
CESC	cis	rs8060686	0.641	rs75297764	chr16:68212820	C/T	cg26727032	chr16:67993705	SLC12A4	-0.53	-6.03	-0.35	5.55e-9	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs10504229	1.000	rs67236942	chr8:58176525	T/C	cg22535103	chr8:58192502	C8orf71	-1.05	-13.27	-0.63	3.63e-31	Developmental language disorder (linguistic errors);
CESC	cis	rs397969	0.596	rs12450857	chr17:19895248	C/T	cg12073167	chr17:19770448	ULK2	-0.46	-5.53	-0.32	7.6e-8	Platelet count;
CESC	cis	rs4604732	0.631	rs1106721	chr1:247624676	A/C	cg12754571	chr1:247694271	LOC148824;OR2C3	0.44	5.44	0.32	1.21e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs12579753	0.719	rs4418885	chr12:82275845	A/T	cg23701643	chr12:82153290	PPFIA2	-0.37	-5.4	-0.31	1.48e-7	Resting heart rate;
CESC	cis	rs9473147	0.543	rs4715019	chr6:47447041	T/A	cg20196966	chr6:47445060	CD2AP	0.4	5.15	0.3	5.07e-7	Platelet distribution width;Mean platelet volume;
CESC	cis	rs12791968	1.000	rs12791968	chr11:45001490	C/T	cg11846598	chr11:44996168	LOC221122	0.54	7.17	0.4	7.54e-12	Inhibitory control;
CESC	cis	rs9902453	0.933	rs9303628	chr17:28527228	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.64	8.2	0.45	1.03e-14	Coffee consumption (cups per day);
CESC	cis	rs909674	0.514	rs7423	chr22:39781429	C/T	cg02038168	chr22:39784481	NA	-0.56	-7.46	-0.42	1.24e-12	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs7178572	0.568	rs11636554	chr15:77608747	C/T	cg22256960	chr15:77711686	NA	-0.53	-6.78	-0.38	7.59e-11	Type 2 diabetes;
CESC	cis	rs7917772	0.503	rs7078435	chr10:104304766	T/C	cg22532475	chr10:104410764	TRIM8	-0.34	-5.85	-0.34	1.43e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs2380220	0.808	rs2613547	chr6:95910311	C/T	cg15832292	chr6:96025679	MANEA	-0.65	-5.95	-0.34	8.46e-9	Behavioural disinhibition (generation interaction);
CESC	cis	rs8072100	0.745	rs7214410	chr17:45422628	A/G	cg25173405	chr17:45401733	C17orf57	-0.44	-5.72	-0.33	2.87e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs2154427	0.511	rs7279487	chr21:34001824	T/C	cg21871883	chr21:34145043	C21orf49;C21orf66	0.69	6.52	0.37	3.44e-10	Bilirubin levels;
CESC	cis	rs9443645	0.901	rs2174742	chr6:79610101	G/T	cg05283184	chr6:79620031	NA	-0.41	-6.38	-0.36	7.79e-10	Intelligence (multi-trait analysis);
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg02269272	chr17:17991219	DRG2	0.46	6.28	0.36	1.4e-9	Systemic lupus erythematosus;
CESC	trans	rs11722228	0.539	rs62287552	chr4:10153197	C/T	cg26043149	chr18:55253948	FECH	0.99	12.72	0.62	3.02e-29	Gout;Urate levels;Serum uric acid levels;
CESC	cis	rs11098499	0.874	rs13123591	chr4:120105990	T/G	cg09307838	chr4:120376055	NA	0.67	8.17	0.45	1.26e-14	Corneal astigmatism;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13409575	chr2:63277708	OTX1	0.59	6.52	0.37	3.59e-10	Gut microbiome composition (summer);
CESC	cis	rs7474896	0.537	rs598857	chr10:38302926	A/G	cg25427524	chr10:38739819	LOC399744	0.49	5.56	0.32	6.5e-8	Obesity (extreme);
CESC	cis	rs11997175	0.625	rs2882300	chr8:33585323	G/A	ch.8.33884649F	chr8:33765107	NA	0.55	6.97	0.39	2.55e-11	Body mass index;
CESC	cis	rs4713118	0.662	rs156744	chr6:27967274	G/A	cg19592336	chr6:28129416	ZNF389	0.54	7.17	0.4	7.59e-12	Parkinson's disease;
CESC	cis	rs6952808	0.792	rs4721184	chr7:1950784	T/C	cg08027265	chr7:2291960	NA	-0.34	-5.13	-0.3	5.68e-7	Bipolar disorder and schizophrenia;
CESC	trans	rs208515	0.525	rs10944863	chr6:66676238	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.88	10.9	0.56	4.24e-23	Exhaled nitric oxide levels;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg00762468	chr16:103568	POLR3K;SNRNP25	-0.45	-6.48	-0.37	4.37e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg13357178	chr17:41623362	ETV4	0.47	6.08	0.35	4.1e-9	Myopia (pathological);
CESC	cis	rs1799949	0.965	rs4793230	chr17:41427403	A/C	cg23758822	chr17:41437982	NA	1.03	18.09	0.74	3.44e-48	Menopause (age at onset);
CESC	cis	rs7647973	0.710	rs12637313	chr3:49645458	A/G	cg06212747	chr3:49208901	KLHDC8B	0.68	7.95	0.44	5.47e-14	Menarche (age at onset);
CESC	cis	rs11864453	0.826	rs12325142	chr16:72138112	G/T	cg16558253	chr16:72132732	DHX38	-0.61	-9.79	-0.52	1.58e-19	Fibrinogen levels;
CESC	cis	rs2835872	0.758	rs1787395	chr21:39036478	A/C	cg06728970	chr21:39037746	KCNJ6	0.3	5.57	0.32	6.36e-8	Electroencephalographic traits in alcoholism;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg18313106	chr1:229694614	ABCB10	-0.43	-6.27	-0.36	1.46e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs8062405	0.792	rs12446550	chr16:28543381	G/A	cg07382826	chr16:28625726	SULT1A1	0.31	5.1	0.3	6.35e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs2204008	0.683	rs12370288	chr12:38127740	G/A	cg13010199	chr12:38710504	ALG10B	0.54	6.6	0.38	2.21e-10	Bladder cancer;
CESC	cis	rs1670533	1.000	rs10084890	chr4:1053934	C/G	cg04106633	chr4:1044584	NA	-0.41	-5.22	-0.31	3.7e-7	Recombination rate (females);
CESC	cis	rs9910055	0.573	rs113184718	chr17:42206543	A/T	cg08499158	chr17:42289980	UBTF	0.49	6.19	0.36	2.33e-9	Total body bone mineral density;
CESC	cis	rs4835473	0.932	rs5015760	chr4:144659108	G/T	cg25736465	chr4:144833511	NA	-0.33	-5.31	-0.31	2.3e-7	Immature fraction of reticulocytes;
CESC	cis	rs77861329	1.000	rs164639	chr3:52210872	A/G	cg08692210	chr3:52188851	WDR51A	-0.62	-6.62	-0.38	2.02e-10	Macrophage inflammatory protein 1b levels;
CESC	cis	rs9322193	0.962	rs11155685	chr6:150102785	A/C	cg13206674	chr6:150067644	NUP43	0.41	5.78	0.33	2.05e-8	Lung cancer;
CESC	cis	rs780096	0.526	rs780117	chr2:27698343	C/G	cg22903471	chr2:27725779	GCKR	-0.52	-7.38	-0.41	2.05e-12	Total body bone mineral density;
CESC	cis	rs7666738	0.819	rs13120307	chr4:99036100	A/C	cg17366294	chr4:99064904	C4orf37	0.62	8.62	0.47	6.05e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1348850	0.574	rs11889488	chr2:178426793	A/G	cg22681709	chr2:178499509	PDE11A	0.49	5.04	0.3	8.66e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs7267979	1.000	rs6050629	chr20:25430680	G/A	cg08601574	chr20:25228251	PYGB	0.38	5.64	0.33	4.4e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs5769765	0.908	rs4824109	chr22:50271460	T/C	cg26441486	chr22:50317300	CRELD2	-0.39	-5.33	-0.31	2.07e-7	Schizophrenia;
CESC	cis	rs8103278	1.000	rs17571725	chr19:46290822	C/T	cg11657440	chr19:46296263	DMWD	-0.61	-7.75	-0.43	1.99e-13	Coronary artery disease;
CESC	cis	rs8114671	0.836	rs2038504	chr20:33648187	T/C	cg24642439	chr20:33292090	TP53INP2	-0.47	-5.71	-0.33	3.09e-8	Height;
CESC	cis	rs1670533	1.000	rs6822863	chr4:1055606	G/A	cg27284194	chr4:1044797	NA	0.47	6.01	0.35	6.16e-9	Recombination rate (females);
CESC	cis	rs1983170	0.778	rs906241	chr1:92012154	G/T	cg02896835	chr1:92012615	NA	-0.57	-6.63	-0.38	1.93e-10	Eosinophil percentage of white cells;
CESC	cis	rs72945132	0.882	rs17160762	chr11:70134766	A/G	cg00319359	chr11:70116639	PPFIA1	-0.77	-7.39	-0.41	1.98e-12	Coronary artery disease;
CESC	cis	rs12291225	0.753	rs1431374	chr11:14303975	T/C	cg19336497	chr11:14380999	RRAS2	-0.37	-5.28	-0.31	2.65e-7	Sense of smell;
CESC	cis	rs7223966	1.000	rs8073373	chr17:61703320	T/C	cg11494091	chr17:61959527	GH2	0.39	5.43	0.32	1.26e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs11718455	0.767	rs6771202	chr3:43990087	A/T	cg08738300	chr3:44038990	NA	0.42	5.64	0.33	4.31e-8	Coronary artery disease;
CESC	cis	rs597583	0.671	rs4938401	chr11:117399605	T/G	cg27161313	chr11:117392002	DSCAML1	-0.53	-6.03	-0.35	5.47e-9	Putamen volume;
CESC	cis	rs2361710	0.668	rs2304855	chr17:78118266	T/A	cg06718696	chr17:78121285	EIF4A3	0.48	5.66	0.33	3.9e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
CESC	cis	rs826838	0.935	rs980571	chr12:39127532	C/G	cg13010199	chr12:38710504	ALG10B	-0.44	-6.1	-0.35	3.81e-9	Heart rate;
CESC	cis	rs2072499	0.966	rs2842869	chr1:156160696	A/G	cg25208724	chr1:156163844	SLC25A44	1.01	18.98	0.76	2.67e-51	Testicular germ cell tumor;
CESC	trans	rs7246657	0.882	rs8112610	chr19:37928730	C/A	cg24637308	chr11:6592297	DNHD1	0.54	6.27	0.36	1.43e-9	Coronary artery calcification;
CESC	cis	rs12541335	0.639	rs11135995	chr8:22200148	C/T	cg18135555	chr8:22132992	PIWIL2	-0.25	-5.52	-0.32	8.27e-8	Hypertriglyceridemia;
CESC	cis	rs3785574	0.962	rs16947051	chr17:61790917	G/C	cg06420487	chr17:61919686	SMARCD2	0.46	5.52	0.32	8.21e-8	Height;
CESC	cis	rs9309473	0.606	rs1589576	chr2:73738804	A/G	cg20560298	chr2:73613845	ALMS1	-0.5	-5.84	-0.34	1.5e-8	Metabolite levels;
CESC	cis	rs763014	0.966	rs4984675	chr16:670117	T/C	cg07343612	chr16:622815	PIGQ	-0.53	-7.72	-0.43	2.4e-13	Height;
CESC	cis	rs7116495	0.881	rs615000	chr11:71802952	A/C	cg26138937	chr11:71823887	C11orf51	-0.89	-7.22	-0.41	5.37e-12	Severe influenza A (H1N1) infection;
CESC	cis	rs12618769	0.625	rs3769726	chr2:99105827	G/C	cg10123293	chr2:99228465	UNC50	0.39	5.13	0.3	5.6e-7	Bipolar disorder;
CESC	cis	rs11792861	0.566	rs11792635	chr9:111848819	A/G	cg05043794	chr9:111880884	C9orf5	-0.29	-5.13	-0.3	5.62e-7	Menarche (age at onset);
CESC	cis	rs4853012	0.838	rs6707729	chr2:74344685	G/A	cg05890377	chr2:74357713	NA	0.77	10.47	0.54	1.05e-21	Gestational age at birth (maternal effect);
CESC	cis	rs7267979	1.000	rs2500443	chr20:25331442	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.85	-16.43	-0.71	2.69e-42	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7772486	0.790	rs9791313	chr6:146266172	T/C	cg23711669	chr6:146136114	FBXO30	-0.81	-11.61	-0.58	1.87e-25	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6933660	0.745	rs3800272	chr6:151744283	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	-0.87	-13.78	-0.65	6.09e-33	Menarche (age at onset);
CESC	cis	rs6952808	0.689	rs58227534	chr7:2046328	A/G	cg05863683	chr7:1912471	MAD1L1	0.47	7.08	0.4	1.28e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs4589502	1.000	rs16950284	chr15:67154184	A/G	cg09911534	chr15:67153556	NA	0.53	5.63	0.33	4.55e-8	Lung cancer (smoking interaction);
CESC	cis	rs950776	0.616	rs12901300	chr15:78892952	G/A	cg24631222	chr15:78858424	CHRNA5	-0.43	-5.43	-0.32	1.3e-7	Sudden cardiac arrest;
CESC	cis	rs4713118	0.662	rs9468275	chr6:28026136	G/T	cg26335602	chr6:28129616	ZNF389	0.44	5.61	0.33	5.19e-8	Parkinson's disease;
CESC	cis	rs2479724	0.755	rs4318867	chr6:41753670	G/T	cg17623882	chr6:41773611	USP49	0.41	5.64	0.33	4.29e-8	Menarche (age at onset);
CESC	cis	rs898097	0.841	rs4986122	chr17:80825500	C/T	cg05483915	chr17:80145575	CCDC57	0.45	5.49	0.32	9.41e-8	Breast cancer;
CESC	cis	rs6088580	0.634	rs7271970	chr20:32987666	A/G	cg24642439	chr20:33292090	TP53INP2	-0.52	-6.94	-0.39	3.04e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs4819052	0.788	rs9978857	chr21:46705155	T/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.62	7.98	0.44	4.47e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs2882667	1.000	rs2882667	chr5:138314106	C/T	cg04439458	chr5:138467593	SIL1	-0.35	-5.54	-0.32	7.22e-8	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs9911578	1.000	rs6503866	chr17:56619581	C/T	cg12560992	chr17:57184187	TRIM37	-0.93	-15.59	-0.69	2.43e-39	Intelligence (multi-trait analysis);
CESC	cis	rs10883723	0.810	rs7072351	chr10:104265047	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.53	7.25	0.41	4.46e-12	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs8141529	0.748	rs6519766	chr22:29269991	A/G	cg02153584	chr22:29168773	CCDC117	-0.56	-7.58	-0.42	5.98e-13	Lymphocyte counts;
CESC	cis	rs1062177	1.000	rs6890099	chr5:151151962	A/G	cg12924095	chr5:151150029	G3BP1	0.48	6.07	0.35	4.45e-9	Preschool internalizing problems;
CESC	cis	rs12476592	0.602	rs959195	chr2:63804125	G/A	cg17519650	chr2:63277830	OTX1	-0.48	-5.42	-0.32	1.34e-7	Childhood ear infection;
CESC	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	22.02	0.8	8.6e-62	Prudent dietary pattern;
CESC	cis	rs2120019	0.935	rs34835684	chr15:75331805	T/G	cg17294928	chr15:75287854	SCAMP5	-0.74	-8.31	-0.45	5.03e-15	Blood trace element (Zn levels);
CESC	cis	rs6088590	0.965	rs6088620	chr20:33412022	A/G	cg08999081	chr20:33150536	PIGU	0.58	8.9	0.48	9.24e-17	Coronary artery disease;
CESC	cis	rs4909189	0.915	rs11773551	chr7:158136146	C/T	cg25566285	chr7:158114605	PTPRN2	0.44	5.48	0.32	9.93e-8	Response to amphetamines;
CESC	cis	rs9430161	0.579	rs6696575	chr1:11037136	G/A	cg27631724	chr1:11040367	C1orf127	0.46	7.81	0.43	1.36e-13	Ewing sarcoma;
CESC	trans	rs802075	0.905	rs1025348	chr6:49652760	T/C	cg06254729	chr2:28550422	BRE	-0.37	-6.14	-0.35	3e-9	Bone mineral density (hip) and age at menarche;
CESC	cis	rs17376456	1.000	rs67150649	chr5:93292377	A/G	cg21475434	chr5:93447410	FAM172A	0.72	6.08	0.35	4.11e-9	Diabetic retinopathy;
CESC	cis	rs1878931	0.582	rs27239	chr16:3442140	T/C	cg02880119	chr16:3481970	NA	0.42	5.31	0.31	2.35e-7	Body mass index (adult);
CESC	cis	rs5167	0.504	rs3760625	chr19:45456941	G/A	cg09555818	chr19:45449301	APOC2	0.41	6.54	0.37	3.08e-10	Blood protein levels;
CESC	cis	rs10504229	0.683	rs16921831	chr8:58111142	G/A	cg21724239	chr8:58056113	NA	0.58	5.93	0.34	9.45e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs1577917	0.876	rs12201992	chr6:86618219	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.44	-5.75	-0.33	2.51e-8	Response to antipsychotic treatment;
CESC	cis	rs8031584	1.000	rs35239376	chr15:31290538	A/C	cg08704250	chr15:31115839	NA	-0.65	-7.85	-0.43	1.05e-13	Huntington's disease progression;
CESC	cis	rs1862618	0.853	rs33325	chr5:56142547	G/C	cg24531977	chr5:56204891	C5orf35	-0.88	-11.51	-0.58	3.94e-25	Initial pursuit acceleration;
CESC	cis	rs3008870	0.920	rs975452	chr1:67480190	A/T	cg08660285	chr1:67390436	MIER1;WDR78	1.01	13.78	0.65	5.96e-33	Lymphocyte percentage of white cells;
CESC	cis	rs7666738	0.830	rs13102369	chr4:99045912	A/G	cg24818145	chr4:99064322	C4orf37	0.38	5.04	0.3	8.49e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6073597	1.000	rs6031980	chr20:43714384	C/T	cg23740882	chr20:44098387	WFDC2	0.33	5.04	0.3	8.45e-7	Positive affect;
CESC	cis	rs2304069	0.545	rs9686746	chr5:149399968	G/A	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.46	6.17	0.35	2.51e-9	HIV-1 control;
CESC	cis	rs7927592	0.546	rs638076	chr11:68202580	A/G	cg01657329	chr11:68192670	LRP5	-0.55	-7.23	-0.41	5.33e-12	Total body bone mineral density;
CESC	cis	rs9300255	0.568	rs1047158	chr12:123644056	C/A	cg00376283	chr12:123451042	ABCB9	0.7	8.86	0.48	1.16e-16	Neutrophil percentage of white cells;
CESC	cis	rs8014204	0.839	rs6574197	chr14:75331487	A/G	cg08847533	chr14:75593920	NEK9	-0.47	-5.82	-0.34	1.72e-8	Caffeine consumption;
CESC	cis	rs4704187	0.687	rs7700965	chr5:74356857	T/C	cg03227963	chr5:74354835	NA	0.29	5.32	0.31	2.22e-7	Response to amphetamines;
CESC	cis	rs4604732	0.588	rs6677477	chr1:247629411	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.52	6.38	0.36	7.89e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs796364	0.616	rs2689762	chr2:200687204	G/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.56	5.08	0.3	7.26e-7	Schizophrenia;
CESC	cis	rs2243480	1.000	rs34529418	chr7:65403209	A/G	cg12463550	chr7:65579703	CRCP	0.7	5.7	0.33	3.21e-8	Diabetic kidney disease;
CESC	trans	rs4950322	0.580	rs4950308	chr1:146591674	C/T	cg04954894	chr8:38089920	DDHD2	-0.59	-6.45	-0.37	5.34e-10	Protein quantitative trait loci;
CESC	cis	rs1355223	0.902	rs11603774	chr11:34732891	G/T	cg11058730	chr11:34937778	PDHX;APIP	-0.48	-6.43	-0.37	5.87e-10	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs12188164	0.965	rs72717430	chr5:444502	T/C	cg15813090	chr5:442598	EXOC3;C5orf55	0.42	6.26	0.36	1.51e-9	Cystic fibrosis severity;
CESC	cis	rs614226	1.000	rs563920	chr12:121017439	A/G	cg01236616	chr12:121019343	POP5	1.5	18.36	0.75	3.79e-49	Type 1 diabetes nephropathy;
CESC	cis	rs798554	0.757	rs960273	chr7:2857876	T/C	cg19346786	chr7:2764209	NA	-0.52	-7.38	-0.41	1.99e-12	Height;
CESC	cis	rs2842992	0.915	rs2842980	chr6:160100116	A/T	cg11366901	chr6:160182831	ACAT2	0.81	9.81	0.52	1.35e-19	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs1577917	0.771	rs2842612	chr6:86303091	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.56	-7.8	-0.43	1.46e-13	Response to antipsychotic treatment;
CESC	cis	rs7107770	0.739	rs12793744	chr11:125079871	G/T	cg27629782	chr11:125073726	PKNOX2	0.34	5.32	0.31	2.2e-7	Photic sneeze reflex;
CESC	cis	rs7208859	0.673	rs73263776	chr17:29211331	G/C	cg19761014	chr17:28927070	LRRC37B2	0.73	5.75	0.33	2.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg06074448	chr4:187884817	NA	-0.37	-5.4	-0.31	1.5e-7	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs11098499	0.954	rs12507964	chr4:120413061	T/A	cg09307838	chr4:120376055	NA	0.92	12.96	0.62	4.27e-30	Corneal astigmatism;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26258877	chr1:155145555	TRIM46;KRTCAP2	0.61	6.74	0.38	9.85e-11	Gut microbiome composition (summer);
CESC	cis	rs9322193	0.887	rs9767113	chr6:150039293	T/C	cg09699651	chr6:150184138	LRP11	0.4	5.11	0.3	6.05e-7	Lung cancer;
CESC	cis	rs9905704	0.681	rs4793949	chr17:56571950	C/T	cg12560992	chr17:57184187	TRIM37	0.65	6.03	0.35	5.43e-9	Testicular germ cell tumor;
CESC	trans	rs11039798	0.511	rs717896	chr11:48375335	G/T	cg15704280	chr7:45808275	SEPT13	-0.69	-6.75	-0.38	9.32e-11	Axial length;
CESC	cis	rs561341	1.000	rs15654	chr17:30326360	A/C	cg19193384	chr17:30244184	NA	-0.7	-6.58	-0.37	2.49e-10	Hip circumference adjusted for BMI;
CESC	cis	rs875971	0.755	rs10228885	chr7:65780529	C/G	cg11764359	chr7:65958608	NA	-0.79	-11.68	-0.58	1.07e-25	Aortic root size;
CESC	cis	rs3096299	0.900	rs2911258	chr16:89480760	A/G	cg02187348	chr16:89574699	SPG7	0.61	8.39	0.46	2.88e-15	Multiple myeloma (IgH translocation);
CESC	cis	rs2235642	0.928	rs1057610	chr16:1605537	T/C	cg03771183	chr16:1608904	IFT140	0.42	6.13	0.35	3.23e-9	Coronary artery disease;
CESC	cis	rs796364	0.951	rs72932280	chr2:200996851	G/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.65	-6.27	-0.36	1.49e-9	Schizophrenia;
CESC	cis	rs6484504	0.512	rs2761594	chr11:31318244	A/G	cg14844989	chr11:31128820	NA	0.4	5.49	0.32	9.59e-8	Red blood cell count;
CESC	cis	rs10949834	0.824	rs2285026	chr7:73530404	C/T	cg07137043	chr7:73588983	EIF4H	-0.67	-5.8	-0.34	1.9e-8	Verbal memory performance (residualized delayed recall change);
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg17364743	chr2:118572626	DDX18	-0.47	-6.0	-0.35	6.44e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs17666538	0.642	rs7821983	chr8:643696	A/G	cg02524346	chr8:600233	NA	0.83	6.98	0.39	2.37e-11	IgG glycosylation;
CESC	cis	rs1005277	0.579	rs2505248	chr10:38459097	A/G	cg25517755	chr10:38738941	LOC399744	-0.47	-6.19	-0.36	2.32e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs8031584	0.541	rs1983459	chr15:31208749	C/T	cg14829155	chr15:31115871	NA	-0.72	-10.5	-0.54	8.92e-22	Huntington's disease progression;
CESC	cis	rs921968	0.643	rs524012	chr2:219433273	T/G	cg02176678	chr2:219576539	TTLL4	0.41	7.13	0.4	9.62e-12	Mean corpuscular hemoglobin concentration;
CESC	cis	rs12541335	0.639	rs11135995	chr8:22200148	C/T	cg26039829	chr8:22132926	PIWIL2	-0.4	-6.32	-0.36	1.13e-9	Hypertriglyceridemia;
CESC	cis	rs9796	0.621	rs1659227	chr15:41472398	G/A	cg18705301	chr15:41695430	NDUFAF1	0.44	6.46	0.37	4.99e-10	Menopause (age at onset);
CESC	cis	rs56104184	0.723	rs73063522	chr19:49408358	C/G	cg15549821	chr19:49342101	PLEKHA4	-0.53	-5.47	-0.32	1.06e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	cis	rs1882538	0.503	rs13240997	chr7:133135373	C/A	cg10665199	chr7:133106180	EXOC4	0.58	7.77	0.43	1.68e-13	Intelligence (multi-trait analysis);
CESC	cis	rs710216	0.957	rs841570	chr1:43435571	C/G	cg07803811	chr1:43423981	SLC2A1	0.47	5.07	0.3	7.58e-7	Red cell distribution width;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04310824	chr1:53393297	SCP2	-0.64	-7.4	-0.41	1.82e-12	Gut microbiome composition (summer);
CESC	cis	rs6460942	0.915	rs62448596	chr7:12446869	C/T	cg16278512	chr7:12443529	VWDE	-0.55	-5.87	-0.34	1.27e-8	Coronary artery disease;
CESC	cis	rs1881797	0.932	rs2387038	chr1:247674919	G/A	cg21399703	chr1:247681439	NA	0.61	7.74	0.43	2.03e-13	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs853679	0.546	rs200990	chr6:27815823	T/G	cg26587870	chr6:27730563	NA	-0.58	-5.21	-0.3	3.74e-7	Depression;
CESC	trans	rs629535	0.734	rs542288	chr8:70057149	G/T	cg21567404	chr3:27674614	NA	-0.88	-10.51	-0.54	8.12e-22	Dupuytren's disease;
CESC	cis	rs72781680	0.898	rs72782136	chr2:24047344	A/G	cg20701182	chr2:24300061	SF3B14	0.63	5.65	0.33	4.21e-8	Lymphocyte counts;
CESC	cis	rs977987	0.843	rs11641801	chr16:75455448	A/C	cg03315344	chr16:75512273	CHST6	0.41	5.9	0.34	1.08e-8	Dupuytren's disease;
CESC	cis	rs1670533	1.000	rs13119276	chr4:1051574	T/C	cg27284194	chr4:1044797	NA	0.45	5.54	0.32	7.32e-8	Recombination rate (females);
CESC	cis	rs854765	0.927	rs4925138	chr17:17992793	T/G	cg09796270	chr17:17721594	SREBF1	-0.39	-5.32	-0.31	2.26e-7	Total body bone mineral density;
CESC	cis	rs11587400	0.634	rs7553926	chr1:115202215	A/G	cg12756093	chr1:115239321	AMPD1	-0.42	-5.69	-0.33	3.28e-8	Autism;
CESC	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg04025307	chr7:1156635	C7orf50	0.53	9.42	0.5	2.27e-18	Longevity;Endometriosis;
CESC	cis	rs2735413	0.794	rs55951868	chr16:78078804	C/A	cg04733911	chr16:78082701	NA	-0.52	-8.37	-0.46	3.34e-15	Systolic blood pressure (alcohol consumption interaction);
CESC	cis	rs7666738	0.830	rs10022331	chr4:98960392	C/A	cg03467027	chr4:99064603	C4orf37	0.44	5.57	0.32	6.41e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6540559	0.673	rs6540560	chr1:209982073	A/G	cg09509183	chr1:209979624	IRF6	-0.49	-5.33	-0.31	2.15e-7	Cleft lip with or without cleft palate;
CESC	cis	rs116095464	0.558	rs6866776	chr5:264495	C/T	cg22857025	chr5:266934	NA	-1.3	-18.55	-0.75	8.05e-50	Breast cancer;
CESC	cis	rs9611565	0.918	rs7290404	chr22:41749796	C/T	cg17376030	chr22:41985996	PMM1	0.65	6.96	0.39	2.61e-11	Vitiligo;
CESC	cis	rs4711336	1.000	rs2296738	chr6:33656850	C/T	cg14003231	chr6:33640908	ITPR3	0.34	5.74	0.33	2.57e-8	Height;
CESC	cis	rs1538970	1.000	rs11211101	chr1:45849311	C/G	cg06784218	chr1:46089804	CCDC17	0.32	5.53	0.32	7.51e-8	Platelet count;
CESC	cis	rs1642645	1.000	rs1642645	chr1:42502281	A/C	cg16685388	chr1:42384056	HIVEP3	0.37	5.04	0.3	8.67e-7	Left ventricular obstructive tract defect (maternal effect);
CESC	cis	rs854765	0.663	rs3744115	chr17:17749822	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.5	-6.98	-0.39	2.36e-11	Total body bone mineral density;
CESC	cis	rs4660306	0.961	rs4660868	chr1:45986497	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.61	-7.72	-0.43	2.33e-13	Homocysteine levels;
CESC	cis	rs4665809	0.590	rs13006973	chr2:26454707	C/T	cg26314531	chr2:26401878	FAM59B	0.85	9.04	0.49	3.44e-17	Gut microbiome composition (summer);
CESC	cis	rs6060717	0.536	rs17431878	chr20:34502107	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.66	5.7	0.33	3.16e-8	Hip circumference adjusted for BMI;
CESC	cis	rs7666738	0.830	rs2903154	chr4:99048151	A/G	cg03676636	chr4:99064102	C4orf37	0.33	5.08	0.3	7.13e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs5769707	0.967	rs1018812	chr22:50010073	C/T	cg05373962	chr22:49881684	NA	-0.37	-6.38	-0.36	7.92e-10	Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs9311474	0.607	rs28661185	chr3:52567188	G/T	cg05564831	chr3:52568323	NT5DC2	0.47	7.32	0.41	2.96e-12	Electroencephalogram traits;
CESC	cis	rs113835537	0.529	rs11550299	chr11:66254085	G/T	cg24851651	chr11:66362959	CCS	0.45	5.62	0.33	4.87e-8	Airway imaging phenotypes;
CESC	trans	rs916888	0.610	rs199436	chr17:44789285	C/T	cg01341218	chr17:43662625	NA	-0.52	-6.74	-0.38	9.77e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	trans	rs3857536	0.544	rs208453	chr6:66906841	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.62	-7.27	-0.41	4.04e-12	Blood trace element (Cu levels);
CESC	cis	rs7923609	0.838	rs7909960	chr10:65239177	T/A	cg01631684	chr10:65280961	REEP3	-0.44	-5.44	-0.32	1.2e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs6460942	0.915	rs7809263	chr7:12450589	C/G	cg13733410	chr7:12443478	VWDE	-0.48	-5.08	-0.3	7.14e-7	Coronary artery disease;
CESC	trans	rs10242455	0.702	rs45461000	chr7:99052710	A/G	cg09045935	chr12:6379348	NA	0.9	7.41	0.41	1.68e-12	Blood metabolite levels;
CESC	cis	rs1065852	0.526	rs9623489	chr22:42397026	A/G	cg22189786	chr22:42395067	WBP2NL	0.43	5.4	0.31	1.46e-7	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
CESC	cis	rs17209837	0.607	rs1473152	chr7:87080350	A/C	cg00919237	chr7:87102261	ABCB4	-0.51	-6.61	-0.38	2.1e-10	Gallbladder cancer;
CESC	cis	rs10504229	0.516	rs4060631	chr8:57990757	G/A	cg24829409	chr8:58192753	C8orf71	-0.36	-5.11	-0.3	6.21e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs1707322	0.721	rs4559551	chr1:46167533	T/C	cg05343316	chr1:45956843	TESK2	0.5	6.08	0.35	4.11e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs11264213	0.786	rs72659684	chr1:36274624	C/T	cg27506609	chr1:36549197	TEKT2	0.65	5.34	0.31	1.97e-7	Schizophrenia;
CESC	cis	rs3806843	0.966	rs2563264	chr5:140137503	T/G	cg26395211	chr5:140044315	WDR55	0.39	5.17	0.3	4.51e-7	Depressive symptoms (multi-trait analysis);
CESC	trans	rs1908814	0.516	rs13252854	chr8:11792978	T/A	cg15556689	chr8:8085844	FLJ10661	0.54	6.58	0.37	2.47e-10	Neuroticism;
CESC	cis	rs35110281	0.782	rs2246602	chr21:45064296	C/A	cg21573476	chr21:45109991	RRP1B	-0.51	-7.1	-0.4	1.13e-11	Mean corpuscular volume;
CESC	cis	rs2839186	0.632	rs2839184	chr21:47689013	G/A	cg02776659	chr21:47717406	C21orf57	-0.38	-5.19	-0.3	4.16e-7	Testicular germ cell tumor;
CESC	cis	rs2302190	0.882	rs7209650	chr17:56674905	C/T	cg25885038	chr17:56607967	SEPT4	-0.4	-5.41	-0.32	1.42e-7	Vitamin D levels;
CESC	cis	rs2262909	0.962	rs55728714	chr19:22262899	A/G	cg11619707	chr19:22235551	ZNF257	0.34	5.37	0.31	1.71e-7	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
CESC	cis	rs4665809	0.590	rs6716858	chr2:26423414	G/A	cg25036284	chr2:26402008	FAM59B	-0.71	-8.57	-0.47	8.47e-16	Gut microbiome composition (summer);
CESC	cis	rs791888	0.929	rs2755431	chr10:89415104	C/T	cg13926569	chr10:89418898	PAPSS2	-0.45	-6.46	-0.37	4.92e-10	Magnesium levels;
CESC	cis	rs7267979	1.000	rs34645895	chr20:25368373	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.88	-18.14	-0.74	2.23e-48	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs2836974	0.831	rs34294410	chr21:40555160	C/G	cg27266027	chr21:40555129	PSMG1	0.45	5.34	0.31	2e-7	Cognitive function;
CESC	cis	rs4727027	0.801	rs12666337	chr7:148796253	C/T	cg23158103	chr7:148848205	ZNF398	-0.42	-6.8	-0.39	6.72e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg22542702	chr2:132384461	NA	0.36	6.03	0.35	5.49e-9	Fibrinogen levels;
CESC	cis	rs1163251	0.837	rs611365	chr1:120242571	C/T	cg19096424	chr1:120255104	PHGDH	0.52	6.67	0.38	1.52e-10	Blood metabolite levels;
CESC	cis	rs4713118	0.662	rs149969	chr6:27977737	A/G	cg19592336	chr6:28129416	ZNF389	0.54	7.45	0.42	1.31e-12	Parkinson's disease;
CESC	cis	rs6430585	0.583	rs12475516	chr2:136560761	C/G	cg07169764	chr2:136633963	MCM6	1.2	16.6	0.71	6.77e-43	Corneal structure;
CESC	cis	rs2635047	0.682	rs1980055	chr18:44792636	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.39	5.09	0.3	6.89e-7	Educational attainment;
CESC	cis	rs801193	1.000	rs2420824	chr7:66131116	G/A	cg11764359	chr7:65958608	NA	-0.69	-8.8	-0.48	1.76e-16	Aortic root size;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg08494708	chr6:108881870	FOXO3	-0.46	-6.54	-0.37	3.21e-10	Fibrinogen levels;
CESC	cis	rs921968	0.565	rs62191658	chr2:219630294	A/G	cg02176678	chr2:219576539	TTLL4	-0.43	-7.64	-0.42	4.07e-13	Mean corpuscular hemoglobin concentration;
CESC	cis	rs11214589	0.905	rs12805699	chr11:113241810	T/A	cg14159747	chr11:113255604	NA	0.32	5.6	0.33	5.38e-8	Neuroticism;
CESC	cis	rs965469	0.779	rs6139092	chr20:3334651	T/C	cg25506879	chr20:3388711	C20orf194	-0.48	-5.15	-0.3	5.18e-7	IFN-related cytopenia;
CESC	cis	rs9926296	0.512	rs11076626	chr16:89865103	T/A	cg21285383	chr16:89894308	SPIRE2	0.31	5.54	0.32	7.34e-8	Vitiligo;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13679776	chr1:64936373	CACHD1	0.53	6.24	0.36	1.76e-9	Gut microbiome composition (summer);
CESC	cis	rs950776	0.518	rs11636131	chr15:78821606	C/T	cg06917634	chr15:78832804	PSMA4	0.8	12.12	0.6	3.34e-27	Sudden cardiac arrest;
CESC	cis	rs910316	0.935	rs11159119	chr14:75636967	C/T	cg11812906	chr14:75593930	NEK9	-0.9	-14.82	-0.67	1.35e-36	Height;
CESC	cis	rs3820928	0.647	rs2115597	chr2:227791218	T/C	cg05526886	chr2:227700861	RHBDD1	-0.55	-7.61	-0.42	4.67e-13	Pulmonary function;
CESC	trans	rs1814175	0.645	rs6486022	chr11:49776137	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.42	-6.06	-0.35	4.69e-9	Height;
CESC	cis	rs7615952	0.576	rs4646759	chr3:125822946	G/C	cg15145296	chr3:125709740	NA	-0.56	-5.91	-0.34	1.06e-8	Blood pressure (smoking interaction);
CESC	cis	rs9910055	0.718	rs7212854	chr17:42254417	A/G	cg13607699	chr17:42295918	UBTF	0.61	8.15	0.45	1.44e-14	Total body bone mineral density;
CESC	cis	rs798554	0.683	rs1182155	chr7:2902890	C/G	cg09658497	chr7:2847517	GNA12	-0.36	-5.07	-0.3	7.62e-7	Height;
CESC	cis	rs763121	0.524	rs760645	chr22:39032270	C/T	cg06544989	chr22:39130855	UNC84B	0.34	5.36	0.31	1.78e-7	Menopause (age at onset);
CESC	cis	rs2882667	0.858	rs13177503	chr5:138432759	G/C	cg04439458	chr5:138467593	SIL1	-0.4	-6.21	-0.36	2.04e-9	Age-related hearing impairment (SNP x SNP interaction);
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg15188491	chr1:146644106	PRKAB2	0.51	6.66	0.38	1.61e-10	Systemic lupus erythematosus;
CESC	cis	rs7618915	1.000	rs34569561	chr3:52287293	T/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.31	5.22	0.31	3.53e-7	Bipolar disorder;
CESC	cis	rs6088590	1.000	rs6088607	chr20:33378733	C/T	cg06115741	chr20:33292138	TP53INP2	0.59	7.31	0.41	3.17e-12	Coronary artery disease;
CESC	cis	rs7208859	0.623	rs216446	chr17:28933718	T/G	cg14008862	chr17:28927542	LRRC37B2	0.73	5.52	0.32	8.23e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs1552244	0.938	rs34750074	chr3:10091740	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.79	-10.15	-0.53	1.2e-20	Alzheimer's disease;
CESC	cis	rs5769765	0.779	rs12170530	chr22:50318422	T/G	cg02269571	chr22:50332266	NA	-0.55	-6.42	-0.37	6.1e-10	Schizophrenia;
CESC	cis	rs10870270	1.000	rs7199	chr10:133769848	C/G	cg17892150	chr10:133769511	PPP2R2D	-0.86	-12.56	-0.61	1.08e-28	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	trans	rs11992162	0.636	rs4841642	chr8:11798334	C/T	cg15556689	chr8:8085844	FLJ10661	0.52	6.46	0.37	4.98e-10	Monocyte count;
CESC	cis	rs7772486	0.875	rs2777481	chr6:146310036	G/T	cg23711669	chr6:146136114	FBXO30	0.84	11.88	0.59	2.26e-26	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.98	0.52	4.19e-20	Prudent dietary pattern;
CESC	cis	rs172166	0.611	rs203883	chr6:28078356	A/G	cg17221315	chr6:27791827	HIST1H4J	0.45	5.81	0.34	1.75e-8	Cardiac Troponin-T levels;
CESC	cis	rs7264396	0.676	rs6060727	chr20:34556000	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.77	-10.29	-0.53	4.22e-21	Total cholesterol levels;
CESC	cis	rs9322193	0.962	rs9322219	chr6:150103399	C/T	cg07701084	chr6:150067640	NUP43	0.4	5.48	0.32	9.87e-8	Lung cancer;
CESC	cis	rs514406	0.830	rs533935	chr1:53308807	T/C	cg24675658	chr1:53192096	ZYG11B	-0.59	-7.66	-0.43	3.46e-13	Monocyte count;
CESC	cis	rs709400	0.628	rs7146506	chr14:103924477	A/G	cg12935359	chr14:103987150	CKB	-0.51	-7.46	-0.42	1.21e-12	Body mass index;
CESC	trans	rs9325144	0.577	rs10876008	chr12:39126750	T/C	cg23762105	chr12:34175262	ALG10	0.46	6.01	0.35	5.98e-9	Morning vs. evening chronotype;
CESC	trans	rs4596713	0.538	rs1416738	chr9:71787927	C/T	cg16512924	chr15:28394682	HERC2	0.48	6.09	0.35	4.06e-9	Headache;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05227655	chr10:26986590	PDSS1	0.52	6.11	0.35	3.5e-9	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17517865	chr1:112532085	KCND3	0.56	6.29	0.36	1.31e-9	Gut microbiome composition (summer);
CESC	cis	rs12701220	0.894	rs13224488	chr7:1052353	C/A	cg26769984	chr7:1090371	C7orf50	0.65	7.13	0.4	9.52e-12	Bronchopulmonary dysplasia;
CESC	cis	rs7811142	1.000	rs112317829	chr7:100043173	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.86	8.85	0.48	1.24e-16	Platelet count;
CESC	cis	rs13253111	0.687	rs7840565	chr8:28060783	C/T	cg26534493	chr8:28060551	NA	0.52	8.71	0.47	3.25e-16	Childhood body mass index;
CESC	cis	rs9291683	0.595	rs11731110	chr4:10037346	T/C	cg00071950	chr4:10020882	SLC2A9	0.87	15.5	0.69	5.26e-39	Bone mineral density;
CESC	cis	rs1707322	0.656	rs9429172	chr1:46092476	C/G	cg06784218	chr1:46089804	CCDC17	-0.4	-7.01	-0.4	1.97e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9354308	0.868	rs9363465	chr6:66557802	A/C	cg07460842	chr6:66804631	NA	-0.43	-5.19	-0.3	4.26e-7	Metabolite levels;
CESC	cis	rs6831352	0.842	rs1230156	chr4:99989626	C/T	cg13256891	chr4:100009986	ADH5	0.77	8.86	0.48	1.16e-16	Alcohol dependence;
CESC	cis	rs10189230	0.967	rs12993766	chr2:222350321	C/T	cg14652038	chr2:222343519	EPHA4	0.36	7.56	0.42	6.58e-13	Urate levels in lean individuals;
CESC	cis	rs1568889	1.000	rs1464897	chr11:28034844	C/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.79	11.02	0.56	1.73e-23	Bipolar disorder;
CESC	cis	rs977987	0.836	rs7199062	chr16:75474827	G/A	cg03315344	chr16:75512273	CHST6	0.43	6.2	0.36	2.11e-9	Dupuytren's disease;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg12738264	chr7:148725795	PDIA4	0.46	6.89	0.39	4.04e-11	Systemic lupus erythematosus;
CESC	cis	rs9891119	0.663	rs2883456	chr17:40552794	A/G	cg21433558	chr17:40837037	CNTNAP1	0.4	5.28	0.31	2.73e-7	Multiple sclerosis;Crohn's disease;
CESC	cis	rs10751667	0.600	rs10794342	chr11:924904	C/T	cg06064525	chr11:970664	AP2A2	-0.51	-10.06	-0.53	2.19e-20	Alzheimer's disease (late onset);
CESC	cis	rs7100689	0.646	rs1890889	chr10:82090827	G/T	cg00277334	chr10:82204260	NA	-0.61	-8.25	-0.45	7.58e-15	Post bronchodilator FEV1;
CESC	cis	rs1448094	0.511	rs34885805	chr12:86155180	A/T	cg00310523	chr12:86230176	RASSF9	0.35	5.49	0.32	9.42e-8	Major depressive disorder;
CESC	cis	rs72945132	0.882	rs7929271	chr11:70165749	A/G	cg00319359	chr11:70116639	PPFIA1	0.78	7.75	0.43	1.98e-13	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23634566	chr6:42531994	UBR2	0.66	7.51	0.42	9.01e-13	Gut microbiome composition (summer);
CESC	trans	rs561341	0.505	rs28708703	chr17:30386845	C/G	cg27661571	chr11:113659931	NA	-0.67	-6.73	-0.38	1.02e-10	Hip circumference adjusted for BMI;
CESC	cis	rs67311347	1.000	rs4246666	chr3:40407670	C/T	cg09455208	chr3:40491958	NA	0.45	7.78	0.43	1.64e-13	Renal cell carcinoma;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11609545	chr12:57024192	BAZ2A	0.6	6.82	0.39	6.03e-11	Gut microbiome composition (summer);
CESC	cis	rs2243480	1.000	rs4718315	chr7:65648541	T/C	cg18252515	chr7:66147081	NA	1.36	13.62	0.64	2.24e-32	Diabetic kidney disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05817661	chr11:93517837	MED17	0.57	6.35	0.36	9.23e-10	Gut microbiome composition (summer);
CESC	cis	rs6426558	0.537	rs2670462	chr1:227432923	C/G	cg10327440	chr1:227177885	CDC42BPA	-0.48	-5.82	-0.34	1.66e-8	Neutrophil percentage of white cells;
CESC	cis	rs780096	0.526	rs780117	chr2:27698343	C/G	cg24768116	chr2:27665128	KRTCAP3	-0.3	-5.62	-0.33	4.74e-8	Total body bone mineral density;
CESC	cis	rs2997447	0.723	rs56241003	chr1:26435919	C/T	cg24596570	chr1:26146463	FAM54B;LOC646471	0.62	5.33	0.31	2.07e-7	QRS complex (12-leadsum);
CESC	cis	rs597539	0.552	rs6591360	chr11:68718669	G/T	cg04772025	chr11:68637568	NA	0.5	5.83	0.34	1.63e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20435464	chr19:40711928	MAP3K10	-0.52	-6.01	-0.35	6.05e-9	Gut microbiome composition (summer);
CESC	cis	rs4665809	1.000	rs2384323	chr2:26306473	C/T	cg22920501	chr2:26401640	FAM59B	-0.65	-7.73	-0.43	2.27e-13	Gut microbiome composition (summer);
CESC	cis	rs6964587	0.869	rs401	chr7:91527945	T/G	cg17063962	chr7:91808500	NA	-0.53	-7.0	-0.39	2.11e-11	Breast cancer;
CESC	cis	rs7618915	0.501	rs2336149	chr3:52692124	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.61	8.97	0.48	5.62e-17	Bipolar disorder;
CESC	cis	rs4555082	0.874	rs2816620	chr14:105732704	G/T	cg13114125	chr14:105738426	BRF1	-0.89	-11.05	-0.56	1.31e-23	Mean platelet volume;Platelet distribution width;
CESC	cis	rs6594713	0.756	rs6872490	chr5:112784592	T/C	cg12552261	chr5:112820674	MCC	0.6	6.47	0.37	4.67e-10	Brain cytoarchitecture;
CESC	cis	rs1322639	0.531	rs11751421	chr6:169574993	T/C	cg04662567	chr6:169592167	NA	0.41	5.99	0.35	6.69e-9	Pulse pressure;
CESC	cis	rs2354432	0.607	rs12404113	chr1:146750343	C/A	cg25205988	chr1:146714368	CHD1L	-0.94	-8.35	-0.46	3.88e-15	Mitochondrial DNA levels;
CESC	cis	rs11112613	0.775	rs61200462	chr12:105969271	G/A	cg03607813	chr12:105948248	NA	0.56	6.26	0.36	1.58e-9	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CESC	trans	rs6931865	0.508	rs9321941	chr6:144064904	A/G	cg02864954	chr6:154535553	IPCEF1;OPRM1	-0.39	-6.51	-0.37	3.77e-10	Erectile dysfunction in type 1 diabetes;
CESC	cis	rs7927771	0.931	rs12361256	chr11:47910823	A/C	cg05585544	chr11:47624801	NA	-0.42	-6.9	-0.39	3.85e-11	Subjective well-being;
CESC	cis	rs1008375	0.966	rs2315645	chr4:17579678	G/C	cg16339924	chr4:17578868	LAP3	0.75	9.84	0.52	1.12e-19	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18861140	chr18:3449789	TGIF1	0.6	7.37	0.41	2.2e-12	Gut microbiome composition (summer);
CESC	cis	rs17253792	0.822	rs10143002	chr14:56074278	G/A	cg01858014	chr14:56050164	KTN1	-0.85	-6.96	-0.39	2.75e-11	Putamen volume;
CESC	cis	rs4523957	0.583	rs2641442	chr17:2035071	C/T	cg16513277	chr17:2031491	SMG6	-0.78	-11.57	-0.58	2.42e-25	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs131777	0.708	rs131749	chr22:51024624	C/T	cg25309564	chr22:51001381	C22orf41	-0.61	-7.81	-0.43	1.31e-13	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	cis	rs12711979	0.509	rs1031478	chr2:3827425	G/A	cg17052675	chr2:3827356	NA	-0.67	-11.25	-0.57	2.84e-24	Itch intensity from mosquito bite adjusted by bite size;
CESC	cis	rs4853012	0.887	rs2280644	chr2:74358411	G/A	cg19729930	chr2:74357872	NA	0.87	12.57	0.61	1e-28	Gestational age at birth (maternal effect);
CESC	cis	rs4253772	0.872	rs45528736	chr22:46638312	A/G	cg00784671	chr22:46762841	CELSR1	-0.51	-5.27	-0.31	2.87e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs7726839	0.507	rs60068988	chr5:597668	T/C	cg16447950	chr5:562315	NA	-0.59	-6.01	-0.35	6.18e-9	Obesity-related traits;
CESC	cis	rs4076764	0.957	rs4443867	chr1:163434917	T/C	cg06092702	chr1:163392909	NA	-0.37	-5.38	-0.31	1.67e-7	Motion sickness;
CESC	cis	rs1448094	0.511	rs61930581	chr12:86157241	G/A	cg00310523	chr12:86230176	RASSF9	0.35	5.42	0.32	1.34e-7	Major depressive disorder;
CESC	cis	rs3105593	1.000	rs3848130	chr15:50892111	A/G	cg08437265	chr15:50716283	USP8	0.41	5.19	0.3	4.1e-7	QT interval;
CESC	cis	rs7246657	0.943	rs10417503	chr19:37842735	T/C	cg23950597	chr19:37808831	NA	-0.62	-6.3	-0.36	1.26e-9	Coronary artery calcification;
CESC	cis	rs769267	0.930	rs10422819	chr19:19643028	C/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.57	7.07	0.4	1.39e-11	Tonsillectomy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07985315	chr22:39240100	NPTXR	0.58	6.55	0.37	2.98e-10	Gut microbiome composition (summer);
CESC	cis	rs7552404	0.690	rs2029681	chr1:76333846	G/A	cg10523679	chr1:76189770	ACADM	-0.66	-6.71	-0.38	1.15e-10	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs7618915	0.571	rs1961958	chr3:52585990	A/G	cg18404041	chr3:52824283	ITIH1	-0.37	-5.99	-0.35	6.83e-9	Bipolar disorder;
CESC	cis	rs9611565	0.649	rs139553	chr22:42187199	A/G	cg03806693	chr22:41940476	POLR3H	0.78	9.47	0.5	1.61e-18	Vitiligo;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23888281	chr1:45476762	HECTD3;UROD	0.53	6.18	0.35	2.4e-9	Gut microbiome composition (summer);
CESC	cis	rs3862030	0.839	rs2281880	chr10:104269217	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.37	-5.22	-0.31	3.54e-7	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
CESC	cis	rs2011503	1.000	rs11670882	chr19:19649748	C/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.47	5.03	0.3	8.99e-7	Bipolar disorder;
CESC	cis	rs11122272	0.735	rs2749709	chr1:231530476	G/T	cg06096015	chr1:231504339	EGLN1	0.42	6.08	0.35	4.21e-9	Hemoglobin concentration;
CESC	cis	rs6598955	0.724	rs869683	chr1:26570993	T/A	cg19743891	chr1:26644573	UBXN11;CD52	-0.27	-5.3	-0.31	2.43e-7	Obesity-related traits;
CESC	cis	rs780096	0.506	rs780100	chr2:27652153	G/T	cg22903471	chr2:27725779	GCKR	-0.52	-7.48	-0.42	1.07e-12	Total body bone mineral density;
CESC	cis	rs12497850	0.931	rs9840684	chr3:48893780	T/C	cg06212747	chr3:49208901	KLHDC8B	0.66	8.74	0.47	2.71e-16	Parkinson's disease;
CESC	cis	rs3733585	0.699	rs4408959	chr4:9948868	C/T	cg02734326	chr4:10020555	SLC2A9	-0.41	-5.76	-0.33	2.38e-8	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs769267	0.965	rs10419245	chr19:19383755	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.44	5.37	0.31	1.7e-7	Tonsillectomy;
CESC	cis	rs8060686	0.764	rs73599521	chr16:67733322	G/A	cg26727032	chr16:67993705	SLC12A4	-0.57	-6.0	-0.35	6.41e-9	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs1624802	0.967	rs1696432	chr12:130496976	A/G	cg15444478	chr12:130494697	NA	-0.26	-5.19	-0.3	4.09e-7	Obesity-related traits;
CESC	cis	rs4919687	0.550	rs12780827	chr10:104467954	T/C	cg04362960	chr10:104952993	NT5C2	0.47	5.34	0.31	1.99e-7	Colorectal cancer;
CESC	cis	rs6570726	0.935	rs374000	chr6:145855290	C/T	cg23711669	chr6:146136114	FBXO30	0.8	11.75	0.59	6.33e-26	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6570726	0.902	rs373321	chr6:145854150	T/A	cg23711669	chr6:146136114	FBXO30	0.8	11.74	0.58	6.58e-26	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6493487	0.505	rs8034918	chr15:51095431	A/G	cg02338191	chr15:51200825	AP4E1	-0.53	-5.09	-0.3	6.92e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs7809950	0.817	rs11535285	chr7:107143866	A/G	cg23024343	chr7:107201750	COG5	-0.55	-7.23	-0.41	5.06e-12	Coronary artery disease;
CESC	cis	rs1336900	0.637	rs35967040	chr1:150555588	A/C	cg22823121	chr1:150693482	HORMAD1	-0.4	-5.44	-0.32	1.21e-7	Blood protein levels;
CESC	cis	rs617791	0.508	rs1047464	chr11:65769456	A/T	cg09783858	chr11:65769428	EIF1AD;BANF1	0.51	6.04	0.35	5.07e-9	Breast cancer;
CESC	cis	rs763014	0.966	rs4984677	chr16:671682	A/G	cg09263875	chr16:632152	PIGQ	0.68	11.71	0.58	8.57e-26	Height;
CESC	cis	rs2710642	0.564	rs60144282	chr2:62843163	G/T	cg17519650	chr2:63277830	OTX1	0.48	6.44	0.37	5.71e-10	LDL cholesterol levels;LDL cholesterol;
CESC	cis	rs7178572	0.524	rs1473922	chr15:77656798	G/T	cg22256960	chr15:77711686	NA	-0.53	-6.79	-0.38	7.53e-11	Type 2 diabetes;
CESC	cis	rs7714584	1.000	rs59980321	chr5:150241813	A/T	cg22134413	chr5:150180641	NA	0.53	5.82	0.34	1.69e-8	Crohn's disease;
CESC	cis	rs920590	0.721	rs920587	chr8:19663339	C/A	cg17834443	chr8:19674713	INTS10	0.58	6.62	0.38	1.95e-10	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs6866344	0.697	rs61247551	chr5:178133503	G/A	cg03877680	chr5:178157825	ZNF354A	0.76	8.58	0.47	8.33e-16	Neutrophil percentage of white cells;
CESC	cis	rs3809863	0.782	rs7220606	chr17:45374795	A/G	cg08085267	chr17:45401833	C17orf57	-0.62	-8.44	-0.46	2.12e-15	Glaucoma (primary open-angle);
CESC	cis	rs4689388	0.750	rs12642481	chr4:6301058	G/A	cg25554036	chr4:6271136	WFS1	0.48	7.07	0.4	1.34e-11	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05922392	chr5:180650178	TRIM41	0.58	6.56	0.37	2.76e-10	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.830	rs13102652	chr4:99006737	T/G	cg05340658	chr4:99064831	C4orf37	0.8	12.44	0.61	2.83e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7582720	1.000	rs72936856	chr2:203775712	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.38	0.41	1.99e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs735396	0.627	rs2264778	chr12:121450354	C/A	cg25281562	chr12:121454272	C12orf43	0.53	6.79	0.39	7.19e-11	N-glycan levels;
CESC	cis	rs4906332	1.000	rs17680085	chr14:103953154	T/C	cg09975044	chr14:104007538	NA	0.47	6.36	0.36	8.93e-10	Coronary artery disease;
CESC	cis	rs637571	0.584	rs659824	chr11:65636509	A/G	cg04055107	chr11:65626734	MUS81;CFL1	-0.68	-8.61	-0.47	6.54e-16	Eosinophil percentage of white cells;
CESC	cis	rs9399135	0.967	rs6919862	chr6:135352443	C/A	cg24558204	chr6:135376177	HBS1L	0.52	7.14	0.4	8.72e-12	Red blood cell count;
CESC	cis	rs7584330	0.910	rs66509917	chr2:238395394	T/G	cg14458575	chr2:238380390	NA	0.6	8.44	0.46	2.12e-15	Prostate cancer;
CESC	cis	rs8177179	0.967	rs6439434	chr3:133450371	T/G	cg17775713	chr3:133465469	TF	0.35	6.26	0.36	1.52e-9	Iron status biomarkers (transferrin levels);
CESC	cis	rs11098499	1.000	rs28419773	chr4:120211061	T/C	cg09307838	chr4:120376055	NA	0.88	11.91	0.59	1.75e-26	Corneal astigmatism;
CESC	cis	rs853679	0.550	rs1233701	chr6:28168726	C/G	cg23281280	chr6:28129359	ZNF389	-0.5	-7.03	-0.4	1.73e-11	Depression;
CESC	cis	rs6690583	0.623	rs111687161	chr1:85443533	A/G	cg22153463	chr1:85462885	MCOLN2	0.74	7.19	0.4	6.49e-12	Serum sulfate level;
CESC	cis	rs2576037	0.583	rs680018	chr18:44409167	T/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.52	-7.14	-0.4	9.07e-12	Personality dimensions;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg07300030	chr2:165698022	COBLL1	-0.48	-6.8	-0.39	7.1e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs3733585	0.699	rs7435196	chr4:9967556	A/C	cg02734326	chr4:10020555	SLC2A9	-0.4	-5.68	-0.33	3.62e-8	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs9399135	0.527	rs61738492	chr6:135282771	G/A	cg22676075	chr6:135203613	NA	0.51	6.61	0.38	2.1e-10	Red blood cell count;
CESC	cis	rs4853012	0.539	rs9789534	chr2:74362990	A/T	cg01017244	chr2:74357527	NA	0.58	7.58	0.42	5.95e-13	Gestational age at birth (maternal effect);
CESC	cis	rs854765	0.647	rs4426402	chr17:17977926	C/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.49	-6.29	-0.36	1.3e-9	Total body bone mineral density;
CESC	trans	rs864643	0.773	rs11129837	chr3:39589963	A/G	cg13932035	chr19:11266624	SPC24	0.49	6.34	0.36	9.98e-10	Attention deficit hyperactivity disorder;
CESC	cis	rs1059312	1.000	rs3825180	chr12:129279242	A/G	cg09035930	chr12:129282057	SLC15A4	-0.78	-10.89	-0.56	4.58e-23	Systemic lupus erythematosus;
CESC	cis	rs728616	0.867	rs76239460	chr10:81723227	C/T	cg05935833	chr10:81318306	SFTPA2	-0.51	-5.04	-0.3	8.51e-7	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs2841277	0.645	rs28380382	chr14:105410827	C/T	cg17340268	chr14:105411764	AHNAK2	-0.51	-6.88	-0.39	4.35e-11	Rheumatoid arthritis;
CESC	cis	rs9858542	0.953	rs34588335	chr3:49407660	G/C	cg03060546	chr3:49711283	APEH	-0.54	-6.1	-0.35	3.73e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs9611565	0.694	rs202631	chr22:41863423	A/G	cg06481639	chr22:41940642	POLR3H	0.57	6.3	0.36	1.25e-9	Vitiligo;
CESC	cis	rs9362426	1.000	rs9362426	chr6:88089874	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.45	5.52	0.32	8.26e-8	Depressive episodes in bipolar disorder;
CESC	cis	rs721399	0.542	rs10085931	chr8:18245449	A/G	cg18736775	chr8:18248649	NAT2	-0.49	-5.42	-0.32	1.37e-7	Blood metabolite levels;
CESC	cis	rs7084402	0.967	rs1427197	chr10:60275150	A/G	cg07615347	chr10:60278583	BICC1	-0.57	-8.96	-0.48	6.01e-17	Refractive error;
CESC	cis	rs3820068	0.603	rs7537618	chr1:15977682	G/A	cg16988262	chr1:15930761	NA	0.33	5.36	0.31	1.81e-7	Systolic blood pressure;
CESC	cis	rs4595586	0.545	rs3914595	chr12:39388530	G/T	cg26384229	chr12:38710491	ALG10B	0.54	7.58	0.42	5.91e-13	Morning vs. evening chronotype;
CESC	cis	rs73206853	0.563	rs57488849	chr12:111181785	C/T	cg12870014	chr12:110450643	ANKRD13A	0.73	5.41	0.32	1.39e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	trans	rs9325144	0.560	rs7980635	chr12:38668355	G/T	cg23762105	chr12:34175262	ALG10	0.48	6.29	0.36	1.32e-9	Morning vs. evening chronotype;
CESC	cis	rs9393777	0.513	rs9379907	chr6:26654318	C/T	cg12292205	chr6:26970375	C6orf41	-0.53	-5.76	-0.33	2.33e-8	Intelligence (multi-trait analysis);
CESC	cis	rs4835473	0.932	rs34653324	chr4:144656211	A/G	cg25736465	chr4:144833511	NA	-0.33	-5.3	-0.31	2.48e-7	Immature fraction of reticulocytes;
CESC	cis	rs9311474	0.652	rs411457	chr3:52228150	A/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	-0.3	-5.39	-0.31	1.53e-7	Electroencephalogram traits;
CESC	cis	rs7809950	0.817	rs2712224	chr7:107181235	C/A	cg23024343	chr7:107201750	COG5	-0.57	-7.22	-0.41	5.44e-12	Coronary artery disease;
CESC	cis	rs875971	0.825	rs1860472	chr7:66082723	T/C	cg18252515	chr7:66147081	NA	0.47	6.18	0.36	2.35e-9	Aortic root size;
CESC	cis	rs7827545	1.000	rs9644456	chr8:135568656	G/T	cg17885191	chr8:135476712	NA	0.47	6.18	0.36	2.34e-9	Hypertension (SNP x SNP interaction);
CESC	cis	rs4242434	0.699	rs878051	chr8:22483836	T/C	cg03733263	chr8:22462867	KIAA1967	0.75	11.22	0.57	3.69e-24	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CESC	cis	rs4595586	0.525	rs7313120	chr12:39388027	A/G	cg26384229	chr12:38710491	ALG10B	0.54	7.6	0.42	4.97e-13	Morning vs. evening chronotype;
CESC	cis	rs6456156	0.811	rs975822	chr6:167516458	C/T	cg07741184	chr6:167504864	NA	-0.33	-5.54	-0.32	7.29e-8	Primary biliary cholangitis;
CESC	cis	rs11249608	0.636	rs62393070	chr5:178447943	A/G	cg01312482	chr5:178451176	ZNF879	-0.42	-5.67	-0.33	3.63e-8	Pubertal anthropometrics;
CESC	cis	rs7959452	0.535	rs11177577	chr12:69671791	C/T	cg14784868	chr12:69753453	YEATS4	0.73	10.66	0.55	2.59e-22	Blood protein levels;
CESC	cis	rs3733585	0.699	rs4276278	chr4:9948870	T/C	cg11266682	chr4:10021025	SLC2A9	-0.59	-11.14	-0.56	6.82e-24	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs3126085	0.935	rs10888470	chr1:152200472	T/C	cg03465714	chr1:152285911	FLG	-0.43	-5.24	-0.31	3.23e-7	Atopic dermatitis;
CESC	cis	rs12586317	0.576	rs2415275	chr14:35668951	G/A	cg16230307	chr14:35515116	FAM177A1	0.41	5.04	0.3	8.5e-7	Psoriasis;
CESC	cis	rs853679	0.517	rs9368557	chr6:28131537	T/C	cg26335602	chr6:28129616	ZNF389	0.52	6.81	0.39	6.59e-11	Depression;
CESC	cis	rs2404602	0.716	rs67888330	chr15:76752483	A/G	cg26408565	chr15:76604113	ETFA	-0.43	-6.25	-0.36	1.65e-9	Blood metabolite levels;
CESC	cis	rs6540559	0.611	rs61747285	chr1:210004332	G/A	cg25204440	chr1:209979598	IRF6	0.66	6.47	0.37	4.79e-10	Cleft lip with or without cleft palate;
CESC	cis	rs7927771	0.864	rs11600581	chr11:47448497	T/C	cg05585544	chr11:47624801	NA	-0.49	-7.17	-0.4	7.45e-12	Subjective well-being;
CESC	cis	rs12155623	0.578	rs13277226	chr8:49883029	G/T	cg00325661	chr8:49890786	NA	-0.38	-5.45	-0.32	1.16e-7	Sudden cardiac arrest;
CESC	cis	rs9322193	0.962	rs3805752	chr6:150116626	C/T	cg07701084	chr6:150067640	NUP43	0.42	5.49	0.32	9.2e-8	Lung cancer;
CESC	cis	rs9399135	0.967	rs1041480	chr6:135373076	G/T	cg24558204	chr6:135376177	HBS1L	0.51	6.99	0.39	2.27e-11	Red blood cell count;
CESC	cis	rs2274273	0.662	rs4040064	chr14:55678088	G/T	cg04306507	chr14:55594613	LGALS3	0.31	5.26	0.31	3.03e-7	Protein biomarker;
CESC	cis	rs36051895	0.659	rs12339666	chr9:5063296	A/C	cg02405213	chr9:5042618	JAK2	0.47	5.89	0.34	1.14e-8	Pediatric autoimmune diseases;
CESC	cis	rs1865721	0.917	rs62089506	chr18:73178913	A/G	cg26385618	chr18:73139727	C18orf62	-0.52	-7.51	-0.42	8.78e-13	Intelligence;
CESC	cis	rs10479542	1.000	rs10479542	chr5:178981241	T/A	cg19723775	chr5:179050963	HNRNPH1	0.41	5.46	0.32	1.08e-7	Lung cancer;
CESC	cis	rs11190604	1.000	rs11292	chr10:102313607	A/G	cg07080220	chr10:102295463	HIF1AN	0.56	5.59	0.33	5.51e-8	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs2294693	0.786	rs10456497	chr6:40989057	T/C	cg14418226	chr6:40996092	UNC5CL	0.52	5.73	0.33	2.72e-8	Gastric cancer;Non-cardia gastric cancer;
CESC	cis	rs7246657	0.943	rs4801803	chr19:37966923	A/G	cg23950597	chr19:37808831	NA	0.58	5.91	0.34	1.03e-8	Coronary artery calcification;
CESC	cis	rs7659604	0.539	rs11098645	chr4:122729251	G/A	cg20573242	chr4:122745356	CCNA2	0.62	7.51	0.42	9.24e-13	Type 2 diabetes;
CESC	cis	rs2836974	0.932	rs8129416	chr21:40617145	C/T	cg27266027	chr21:40555129	PSMG1	0.43	5.09	0.3	6.68e-7	Cognitive function;
CESC	cis	rs854765	0.547	rs4365348	chr17:17912548	C/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.55	7.4	0.41	1.84e-12	Total body bone mineral density;
CESC	cis	rs798554	0.757	rs1182188	chr7:2869985	T/C	cg18446336	chr7:2847575	GNA12	-0.38	-5.8	-0.34	1.84e-8	Height;
CESC	cis	rs801193	1.000	rs7785213	chr7:66138978	A/C	cg18876405	chr7:65276391	NA	-0.53	-6.89	-0.39	4.1e-11	Aortic root size;
CESC	cis	rs2120019	1.000	rs34237279	chr15:75361121	A/G	cg09165964	chr15:75287851	SCAMP5	-0.74	-8.85	-0.48	1.3e-16	Blood trace element (Zn levels);
CESC	cis	rs67478160	0.643	rs1535098	chr14:104216513	T/A	cg08213375	chr14:104286397	PPP1R13B	0.54	10.89	0.56	4.58e-23	Schizophrenia;
CESC	trans	rs17685	0.775	rs11761172	chr7:75761547	C/T	cg19862616	chr7:65841803	NCRNA00174	0.85	12.41	0.61	3.51e-28	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs7560272	0.538	rs2421575	chr2:73919522	G/A	cg20560298	chr2:73613845	ALMS1	0.45	6.16	0.35	2.73e-9	Schizophrenia;
CESC	cis	rs1862618	0.853	rs2548664	chr5:56133555	G/A	cg03609598	chr5:56110824	MAP3K1	-0.54	-5.69	-0.33	3.42e-8	Initial pursuit acceleration;
CESC	cis	rs13118159	0.801	rs1128427	chr4:1330759	T/C	cg05025164	chr4:1340916	KIAA1530	0.5	6.79	0.38	7.46e-11	Longevity;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22748686	chr17:42296315	UBTF	0.57	6.29	0.36	1.29e-9	Gut microbiome composition (summer);
CESC	trans	rs1728785	1.000	rs821167	chr16:68577222	T/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.64	7.46	0.42	1.26e-12	Ulcerative colitis;
CESC	cis	rs67478160	0.643	rs11847468	chr14:104220295	G/A	cg08213375	chr14:104286397	PPP1R13B	0.55	11.17	0.57	5.38e-24	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26251429	chr2:28113398	BRE;RBKS;LOC100302650	0.63	7.84	0.43	1.07e-13	Gut microbiome composition (summer);
CESC	cis	rs75804782	0.581	rs72987336	chr2:239365345	T/C	cg18131467	chr2:239335373	ASB1	-0.7	-5.56	-0.32	6.42e-8	Morning vs. evening chronotype;Chronotype;
CESC	cis	rs4481887	0.790	rs4382760	chr1:248422343	A/C	cg00666640	chr1:248458726	OR2T12	-0.35	-6.05	-0.35	4.89e-9	Common traits (Other);
CESC	cis	rs61008539	0.893	rs4719460	chr7:859610	C/T	cg05535760	chr7:792225	HEATR2	0.41	5.39	0.31	1.56e-7	Perceived unattractiveness to mosquitoes;
CESC	cis	rs9388451	0.537	rs1739383	chr6:126098915	G/T	cg05901451	chr6:126070800	HEY2	-0.57	-8.23	-0.45	8.71e-15	Brugada syndrome;
CESC	cis	rs929354	0.742	rs2006844	chr7:157002851	G/A	cg05182265	chr7:156933206	UBE3C	-0.49	-7.25	-0.41	4.51e-12	Body mass index;
CESC	cis	rs7959452	0.532	rs2291005	chr12:69764388	A/G	cg22834771	chr12:69754056	YEATS4	-0.48	-6.38	-0.36	7.9e-10	Blood protein levels;
CESC	cis	rs933688	1.000	rs332529	chr5:90789470	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.02	11.1	0.56	9e-24	Smoking behavior;
CESC	cis	rs4819052	0.851	rs28616694	chr21:46674786	G/C	cg11663144	chr21:46675770	NA	-0.63	-9.83	-0.52	1.24e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs3733585	0.673	rs6850143	chr4:9958924	T/C	cg02734326	chr4:10020555	SLC2A9	-0.43	-6.01	-0.35	6.1e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs727563	0.648	rs6002406	chr22:41965237	A/T	cg06634786	chr22:41940651	POLR3H	-0.68	-6.73	-0.38	1.03e-10	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs17784882	0.521	rs11713693	chr3:47074906	T/C	cg27129171	chr3:47204927	SETD2	-0.65	-9.38	-0.5	3.19e-18	QT interval;
CESC	cis	rs9583531	0.689	rs9588247	chr13:111375571	G/T	cg15841412	chr13:111365552	ING1	-0.44	-5.4	-0.31	1.47e-7	Coronary artery disease;
CESC	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	7.83	0.43	1.17e-13	Prudent dietary pattern;
CESC	trans	rs1728785	1.000	rs1728773	chr16:68563644	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.61	7.42	0.41	1.57e-12	Ulcerative colitis;
CESC	trans	rs1814175	0.817	rs7932683	chr11:49983640	G/A	cg15704280	chr7:45808275	SEPT13	-1.03	-21.34	-0.8	1.71e-59	Height;
CESC	cis	rs78456975	1.000	rs78456975	chr2:1554190	T/G	cg01028140	chr2:1542097	TPO	-0.58	-5.9	-0.34	1.1e-8	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs17431357	0.737	rs73230332	chr12:121024975	G/A	cg25045489	chr12:120971538	RNF10	-0.9	-5.23	-0.31	3.44e-7	Insulin resistance/response;
CESC	cis	rs2228479	0.867	rs17784386	chr16:89947457	A/G	cg14709524	chr16:89940631	TCF25	0.74	5.75	0.33	2.43e-8	Skin colour saturation;
CESC	cis	rs7927771	0.864	rs55927797	chr11:47446292	A/T	cg05585544	chr11:47624801	NA	-0.48	-7.0	-0.39	2.16e-11	Subjective well-being;
CESC	cis	rs4665809	1.000	rs2289022	chr2:26350136	G/T	cg25036284	chr2:26402008	FAM59B	-0.59	-6.88	-0.39	4.37e-11	Gut microbiome composition (summer);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg17766062	chr2:75062663	HK2	-0.43	-6.02	-0.35	5.75e-9	Gambling;
CESC	cis	rs854765	0.583	rs4925130	chr17:17807858	G/A	cg16928487	chr17:17741425	SREBF1	-0.59	-10.24	-0.53	5.94e-21	Total body bone mineral density;
CESC	cis	rs3820068	0.608	rs12760450	chr1:16037282	G/A	cg17385448	chr1:15911702	AGMAT	0.38	6.04	0.35	5.22e-9	Systolic blood pressure;
CESC	cis	rs7917772	0.565	rs1043450	chr10:104434209	A/G	cg22532475	chr10:104410764	TRIM8	-0.43	-6.7	-0.38	1.21e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	trans	rs60843830	0.928	rs62114494	chr2:211317	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.65	7.95	0.44	5.46e-14	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs5753618	0.583	rs5749270	chr22:31812853	C/T	cg00478049	chr22:31556069	RNF185	-0.43	-5.11	-0.3	6.22e-7	Colorectal cancer;
CESC	cis	rs4728302	0.869	rs10808273	chr7:133597691	G/C	cg10665199	chr7:133106180	EXOC4	0.42	5.83	0.34	1.58e-8	Intelligence;Intelligence (multi-trait analysis);
CESC	cis	rs7618501	0.501	rs35275715	chr3:49959148	A/G	cg24110177	chr3:50126178	RBM5	-0.55	-7.72	-0.43	2.39e-13	Intelligence (multi-trait analysis);
CESC	cis	rs10876993	0.928	rs1689586	chr12:58079586	A/T	cg18357645	chr12:58087776	OS9	0.63	10.52	0.54	7.44e-22	Celiac disease or Rheumatoid arthritis;
CESC	cis	rs6540559	0.673	rs6540561	chr1:209982255	C/T	cg23283495	chr1:209979779	IRF6	0.51	5.95	0.34	8.33e-9	Cleft lip with or without cleft palate;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg24568548	chr11:43544500	NA	-0.49	-6.95	-0.39	2.83e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs6546550	0.901	rs3771531	chr2:70164034	T/C	cg02498382	chr2:70120550	SNRNP27	-0.41	-7.13	-0.4	9.44e-12	Prevalent atrial fibrillation;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13937608	chr10:6131228	RBM17	0.55	6.11	0.35	3.46e-9	Gut microbiome composition (summer);
CESC	cis	rs514406	0.505	rs448788	chr1:53161620	A/G	cg24675658	chr1:53192096	ZYG11B	0.55	6.9	0.39	3.8e-11	Monocyte count;
CESC	cis	rs7789940	1.000	rs7789940	chr7:75951230	A/G	cg10167463	chr7:75959203	YWHAG	-0.54	-6.63	-0.38	1.9e-10	Multiple sclerosis;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg19886106	chr8:144776541	ZNF707	0.51	7.47	0.42	1.16e-12	Fibrinogen levels;
CESC	trans	rs2727020	0.894	rs3862342	chr11:49357043	C/T	cg15704280	chr7:45808275	SEPT13	-0.75	-9.28	-0.5	6.33e-18	Coronary artery disease;
CESC	cis	rs533123	0.877	rs1042114	chr1:29138975	G/T	cg08366446	chr1:29138936	OPRD1	0.51	5.08	0.3	7.02e-7	Schizophrenia;
CESC	cis	rs11958404	0.932	rs7706111	chr5:157416053	C/T	cg05962755	chr5:157440814	NA	0.48	5.59	0.32	5.75e-8	IgG glycosylation;
CESC	cis	rs8067545	0.750	rs4925079	chr17:19986861	T/A	cg13482628	chr17:19912719	NA	0.37	5.1	0.3	6.5e-7	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21503093	chr16:10674468	EMP2	0.56	6.43	0.37	6.06e-10	Gut microbiome composition (summer);
CESC	cis	rs9549367	0.789	rs6577034	chr13:113879900	T/C	cg18105134	chr13:113819100	PROZ	-0.7	-9.13	-0.49	1.87e-17	Platelet distribution width;
CESC	cis	rs6582630	0.519	rs8186992	chr12:38325848	C/T	cg26384229	chr12:38710491	ALG10B	0.69	10.31	0.53	3.6e-21	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs959260	0.765	rs12945469	chr17:73372243	G/A	cg20590849	chr17:73267439	MIF4GD	-0.58	-6.56	-0.37	2.78e-10	Systemic lupus erythematosus;
CESC	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg07308232	chr7:1071921	C7orf50	-0.59	-8.29	-0.45	5.69e-15	Longevity;Endometriosis;
CESC	cis	rs7666738	0.830	rs13137808	chr4:99047095	T/C	cg03676636	chr4:99064102	C4orf37	0.33	5.12	0.3	5.93e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs854765	0.654	rs11078400	chr17:17757728	A/G	cg09796270	chr17:17721594	SREBF1	-0.4	-5.75	-0.33	2.43e-8	Total body bone mineral density;
CESC	cis	rs514406	0.644	rs6661196	chr1:53203664	A/G	cg25767906	chr1:53392781	SCP2	0.42	5.77	0.33	2.21e-8	Monocyte count;
CESC	trans	rs7824557	0.564	rs2736300	chr8:11235579	T/G	cg06636001	chr8:8085503	FLJ10661	-0.49	-6.08	-0.35	4.21e-9	Retinal vascular caliber;
CESC	cis	rs1707322	0.752	rs11211171	chr1:46168642	A/G	cg03146154	chr1:46216737	IPP	0.82	11.53	0.58	3.39e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs6540559	1.000	rs1044516	chr1:209959614	G/T	cg10074409	chr1:209979377	IRF6	0.35	5.67	0.33	3.71e-8	Cleft lip with or without cleft palate;
CESC	cis	rs9479482	0.789	rs12204988	chr6:150339315	T/G	cg03788504	chr6:150331562	NA	-0.36	-7.05	-0.4	1.55e-11	Alopecia areata;
CESC	cis	rs1559088	0.948	rs9304844	chr19:33579935	G/T	cg17764715	chr19:33622953	WDR88	0.52	6.87	0.39	4.56e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs10791097	0.967	rs10791099	chr11:130718813	G/C	cg12179176	chr11:130786555	SNX19	0.58	8.4	0.46	2.83e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs7618915	0.570	rs4687633	chr3:52630548	G/A	cg18404041	chr3:52824283	ITIH1	-0.39	-6.55	-0.37	2.96e-10	Bipolar disorder;
CESC	cis	rs6570726	0.935	rs585292	chr6:145862228	T/C	cg23711669	chr6:146136114	FBXO30	0.8	11.78	0.59	4.84e-26	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9309473	0.607	rs7604588	chr2:73571417	C/T	cg20560298	chr2:73613845	ALMS1	-0.46	-6.27	-0.36	1.43e-9	Metabolite levels;
CESC	cis	rs1862618	0.853	rs252887	chr5:56166188	A/G	cg18230493	chr5:56204884	C5orf35	-0.74	-8.67	-0.47	4.37e-16	Initial pursuit acceleration;
CESC	cis	rs7666738	0.716	rs1426660	chr4:98876792	T/A	cg17366294	chr4:99064904	C4orf37	0.55	7.72	0.43	2.38e-13	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6429082	0.818	rs704722	chr1:235669988	G/A	cg26050004	chr1:235667680	B3GALNT2	0.66	8.15	0.45	1.43e-14	Adiposity;
CESC	cis	rs12618769	0.597	rs10199199	chr2:99061834	T/C	cg10123293	chr2:99228465	UNC50	0.42	5.62	0.33	4.91e-8	Bipolar disorder;
CESC	cis	rs362272	0.524	rs2749781	chr4:3346617	T/C	cg08886695	chr4:3369023	RGS12	-0.44	-5.84	-0.34	1.53e-8	Serum sulfate level;
CESC	cis	rs9905704	0.681	rs887206	chr17:56575084	G/C	cg12560992	chr17:57184187	TRIM37	-0.65	-5.99	-0.35	6.85e-9	Testicular germ cell tumor;
CESC	trans	rs2797160	0.684	rs1832937	chr6:125985934	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.45	6.18	0.35	2.39e-9	Endometrial cancer;
CESC	cis	rs838147	0.508	rs507711	chr19:49208564	C/T	cg21064579	chr19:49206444	FUT2	0.44	6.08	0.35	4.21e-9	Dietary macronutrient intake;
CESC	cis	rs4909189	0.957	rs71547529	chr7:158135469	G/T	cg25566285	chr7:158114605	PTPRN2	0.44	5.73	0.33	2.69e-8	Response to amphetamines;
CESC	cis	rs1801251	1.000	rs13004406	chr2:233584557	A/T	cg08000102	chr2:233561755	GIGYF2	-0.69	-9.67	-0.51	3.82e-19	Coronary artery disease;
CESC	cis	rs853679	0.517	rs35512245	chr6:28079953	T/C	cg20151795	chr6:28129481	ZNF389	0.45	5.87	0.34	1.29e-8	Depression;
CESC	cis	rs8028182	0.636	rs4299117	chr15:75789444	C/T	cg20655648	chr15:75932815	IMP3	0.47	5.87	0.34	1.33e-8	Sudden cardiac arrest;
CESC	cis	rs6952808	0.575	rs6950330	chr7:1953606	T/C	cg05863683	chr7:1912471	MAD1L1	0.38	5.85	0.34	1.42e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs6952808	0.965	rs4719318	chr7:1887930	G/A	cg04267008	chr7:1944627	MAD1L1	-0.58	-7.09	-0.4	1.2e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs7949030	0.688	rs11231155	chr11:62365619	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.55	7.65	0.43	3.83e-13	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs1448094	0.511	rs61930035	chr12:86153695	G/A	cg00310523	chr12:86230176	RASSF9	0.35	5.49	0.32	9.42e-8	Major depressive disorder;
CESC	cis	rs11718455	0.960	rs34179760	chr3:44002303	A/G	cg08738300	chr3:44038990	NA	0.46	6.13	0.35	3.17e-9	Coronary artery disease;
CESC	cis	rs2115630	0.653	rs61394864	chr15:85170174	T/C	cg11189052	chr15:85197271	WDR73	-0.45	-6.11	-0.35	3.49e-9	P wave terminal force;
CESC	cis	rs4555082	0.874	rs2816611	chr14:105722976	G/C	cg10792982	chr14:105748885	BRF1	0.42	5.59	0.32	5.74e-8	Mean platelet volume;Platelet distribution width;
CESC	cis	rs7259376	0.905	rs11879791	chr19:22536939	A/G	cg02657401	chr19:22469223	NA	-0.26	-5.23	-0.31	3.38e-7	Menopause (age at onset);
CESC	cis	rs7666738	0.830	rs28615340	chr4:98896922	T/C	cg03467027	chr4:99064603	C4orf37	0.41	5.03	0.3	9.03e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7937682	0.889	rs11213971	chr11:111529829	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.0	-16.54	-0.71	1.09e-42	Primary sclerosing cholangitis;
CESC	cis	rs7927771	0.832	rs6485753	chr11:47410200	C/T	cg20307385	chr11:47447363	PSMC3	0.63	7.77	0.43	1.76e-13	Subjective well-being;
CESC	cis	rs7666738	0.753	rs35194639	chr4:99053819	G/C	cg18180107	chr4:99064573	C4orf37	0.41	5.29	0.31	2.51e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9311474	0.539	rs12489828	chr3:52567014	G/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.38	-5.57	-0.32	6.25e-8	Electroencephalogram traits;
CESC	cis	rs4253772	0.872	rs11704508	chr22:46638540	A/G	cg00784671	chr22:46762841	CELSR1	-0.57	-5.61	-0.33	5.1e-8	LDL cholesterol;Cholesterol, total;
CESC	trans	rs2072510	0.683	rs2540487	chr12:96429783	C/T	cg03453916	chr7:31174468	NA	0.41	6.2	0.36	2.12e-9	Metabolite levels (small molecules and protein measures);
CESC	cis	rs757110	0.933	rs7124355	chr11:17412960	C/T	cg15432903	chr11:17409602	KCNJ11	-0.47	-5.91	-0.34	1.05e-8	Type 2 diabetes;
CESC	cis	rs7666738	0.546	rs6827131	chr4:98744810	C/G	cg17366294	chr4:99064904	C4orf37	0.49	6.1	0.35	3.68e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4727027	0.933	rs12704062	chr7:148827865	G/A	cg23583168	chr7:148888333	NA	-0.79	-12.21	-0.6	1.63e-27	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs6751744	0.513	rs7563368	chr2:160457075	C/T	cg08347373	chr2:160653686	CD302	0.32	5.23	0.31	3.5e-7	Dysphagia;
CESC	cis	rs959260	1.000	rs4789183	chr17:73380221	G/A	cg12999837	chr17:73267436	MIF4GD	-0.48	-5.58	-0.32	5.89e-8	Systemic lupus erythematosus;
CESC	cis	rs4819052	0.819	rs7279136	chr21:46692287	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.93	13.85	0.65	3.59e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs9916302	0.706	rs590051	chr17:37446571	T/C	cg07936489	chr17:37558343	FBXL20	0.92	10.37	0.54	2.23e-21	Glomerular filtration rate (creatinine);
CESC	trans	rs877282	0.733	rs11253342	chr10:765072	A/G	cg22713356	chr15:30763199	NA	1.16	11.35	0.57	1.37e-24	Uric acid levels;
CESC	cis	rs472109	0.934	rs360156	chr11:9756724	T/C	cg03108697	chr11:9732066	SWAP70	-0.34	-5.12	-0.3	5.9e-7	Coronary artery disease;
CESC	cis	rs4665809	1.000	rs10170359	chr2:26272219	G/T	cg04944784	chr2:26401820	FAM59B	-0.74	-8.33	-0.46	4.38e-15	Gut microbiome composition (summer);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg07454192	chr8:74888262	TMEM70	-0.44	-6.65	-0.38	1.65e-10	Gambling;
CESC	cis	rs7520050	0.966	rs1768816	chr1:46528599	T/C	cg03146154	chr1:46216737	IPP	-0.45	-5.75	-0.33	2.41e-8	Red blood cell count;Reticulocyte count;
CESC	cis	rs60871478	0.541	rs56964970	chr7:910791	G/C	cg15782153	chr7:917662	C7orf20	0.5	5.34	0.31	2.04e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs2204008	0.712	rs12371182	chr12:38321143	A/C	cg13010199	chr12:38710504	ALG10B	0.52	6.31	0.36	1.19e-9	Bladder cancer;
CESC	cis	rs7208859	0.623	rs122898	chr17:28905254	C/T	cg19761014	chr17:28927070	LRRC37B2	-0.84	-6.69	-0.38	1.29e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs7666738	0.830	rs10005173	chr4:98816062	T/C	cg05340658	chr4:99064831	C4orf37	0.72	10.44	0.54	1.3e-21	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7666738	0.830	rs10009943	chr4:99021475	G/A	cg18180107	chr4:99064573	C4orf37	0.41	5.39	0.31	1.57e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4722166	0.630	rs12700390	chr7:22777129	G/T	cg26061582	chr7:22766209	IL6	0.51	5.55	0.32	6.82e-8	Lung cancer;
CESC	trans	rs7824557	0.527	rs4631425	chr8:11239054	C/T	cg15556689	chr8:8085844	FLJ10661	-0.48	-6.09	-0.35	3.85e-9	Retinal vascular caliber;
CESC	trans	rs916888	0.687	rs199456	chr17:44797919	C/T	cg27125505	chr17:43679177	LOC644172	0.5	6.51	0.37	3.7e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs1728785	0.901	rs11642189	chr16:68583990	G/A	cg02972257	chr16:68554789	NA	-0.54	-6.27	-0.36	1.45e-9	Ulcerative colitis;
CESC	cis	rs13108904	0.901	rs13119532	chr4:1304505	G/C	cg00684032	chr4:1343700	KIAA1530	0.38	5.38	0.31	1.62e-7	Obesity-related traits;
CESC	cis	rs6570726	0.935	rs388394	chr6:145852689	C/T	cg23711669	chr6:146136114	FBXO30	0.78	11.38	0.57	1.06e-24	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6466055	0.720	rs1204066	chr7:104971987	G/T	cg04380332	chr7:105027541	SRPK2	0.4	5.21	0.3	3.78e-7	Schizophrenia;
CESC	cis	rs1665050	0.534	rs7167050	chr15:59240801	A/C	cg05156742	chr15:59063176	FAM63B	0.5	6.34	0.36	1e-9	Atopic dermatitis;
CESC	cis	rs12618769	0.597	rs4851138	chr2:99065464	A/C	cg10123293	chr2:99228465	UNC50	0.41	5.42	0.32	1.31e-7	Bipolar disorder;
CESC	cis	rs7188697	0.922	rs37060	chr16:58566304	C/T	cg21335942	chr16:58549945	SETD6	0.48	5.68	0.33	3.52e-8	QT interval;
CESC	cis	rs6951245	0.507	rs11976805	chr7:1138716	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.38	5.15	0.3	5.09e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06758143	chr1:26798177	HMGN2	0.65	7.5	0.42	9.94e-13	Gut microbiome composition (summer);
CESC	cis	rs7937682	0.632	rs1045282	chr11:111754574	A/C	cg22437258	chr11:111473054	SIK2	-0.5	-5.53	-0.32	7.6e-8	Primary sclerosing cholangitis;
CESC	cis	rs12477438	0.765	rs62154861	chr2:99590235	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.72	-10.68	-0.55	2.27e-22	Chronic sinus infection;
CESC	cis	rs11792861	0.781	rs11793272	chr9:111762102	G/A	cg13535736	chr9:111863775	C9orf5	-0.46	-6.04	-0.35	5.1e-9	Menarche (age at onset);
CESC	cis	rs6867032	0.527	rs13190594	chr5:2012474	T/C	cg26168224	chr5:2018326	NA	0.78	14.21	0.66	1.82e-34	Gut microbiome composition (winter);
CESC	cis	rs72781680	0.848	rs56371415	chr2:23932603	C/G	cg20701182	chr2:24300061	SF3B14	0.77	6.9	0.39	3.84e-11	Lymphocyte counts;
CESC	cis	rs9916302	0.861	rs12150493	chr17:37586154	T/C	cg07936489	chr17:37558343	FBXL20	-0.8	-11.5	-0.58	4.2e-25	Glomerular filtration rate (creatinine);
CESC	cis	rs763014	1.000	rs763014	chr16:675680	T/C	cg00908189	chr16:619842	PIGQ	0.63	8.8	0.48	1.86e-16	Height;
CESC	cis	rs11098499	0.913	rs56122576	chr4:120129336	A/G	cg09307838	chr4:120376055	NA	0.79	10.07	0.53	2.04e-20	Corneal astigmatism;
CESC	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg12419862	chr22:24373484	LOC391322	0.72	10.33	0.54	3e-21	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs6460942	1.000	rs62448562	chr7:12398785	T/C	cg20607287	chr7:12443886	VWDE	-0.8	-8.85	-0.48	1.3e-16	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12138063	chr19:16607096	C19orf44;CALR3	0.58	6.85	0.39	5.02e-11	Gut microbiome composition (summer);
CESC	cis	rs2370759	1.000	rs77165999	chr10:32577131	T/C	cg05361325	chr10:32636312	EPC1	-0.55	-5.18	-0.3	4.39e-7	Sexual dysfunction (female);
CESC	cis	rs7666738	0.830	rs7659006	chr4:98934529	T/C	cg03467027	chr4:99064603	C4orf37	0.48	5.91	0.34	1.03e-8	Colonoscopy-negative controls vs population controls;
CESC	trans	rs3942852	0.774	rs1039481	chr11:48182237	G/A	cg15704280	chr7:45808275	SEPT13	-0.75	-8.67	-0.47	4.34e-16	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs1862618	0.853	rs2113078	chr5:56087190	C/T	cg24549020	chr5:56110836	MAP3K1	0.66	7.33	0.41	2.81e-12	Initial pursuit acceleration;
CESC	cis	rs2718058	0.519	rs2598072	chr7:37875319	A/C	cg24998770	chr7:37888106	TXNDC3	0.4	5.85	0.34	1.41e-8	Alzheimer's disease (late onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11857246	chr1:11741390	MAD2L2	0.59	6.32	0.36	1.1e-9	Gut microbiome composition (summer);
CESC	cis	rs710216	0.917	rs4660691	chr1:43417150	T/G	cg03128534	chr1:43423976	SLC2A1	-0.56	-6.52	-0.37	3.52e-10	Red cell distribution width;
CESC	cis	rs3008870	1.000	rs11208979	chr1:67442275	C/T	cg02640540	chr1:67518911	SLC35D1	-0.51	-5.58	-0.32	5.89e-8	Lymphocyte percentage of white cells;
CESC	cis	rs66530629	0.761	rs7519508	chr1:25147750	G/A	cg22509179	chr1:25234806	RUNX3	-0.42	-5.38	-0.31	1.63e-7	Plateletcrit;
CESC	cis	rs8072100	0.688	rs8075843	chr17:45442363	C/T	cg25173405	chr17:45401733	C17orf57	-0.44	-5.48	-0.32	9.98e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs7259376	0.936	rs10423736	chr19:22596132	C/T	cg02657401	chr19:22469223	NA	0.26	5.12	0.3	5.94e-7	Menopause (age at onset);
CESC	cis	rs7927771	0.864	rs60075622	chr11:47449101	T/G	cg18512352	chr11:47633146	NA	-0.51	-7.28	-0.41	3.78e-12	Subjective well-being;
CESC	cis	rs959260	0.800	rs9895739	chr17:73399916	C/T	cg12999837	chr17:73267436	MIF4GD	-0.48	-5.54	-0.32	7.12e-8	Systemic lupus erythematosus;
CESC	cis	rs2180341	1.000	rs3798850	chr6:127613966	C/T	cg27446573	chr6:127587934	RNF146	1.08	16.13	0.7	3.14e-41	Breast cancer;
CESC	cis	rs561341	1.000	rs542132	chr17:30307193	A/T	cg12193833	chr17:30244370	NA	-0.7	-6.49	-0.37	4.19e-10	Hip circumference adjusted for BMI;
CESC	cis	rs763121	0.853	rs5750627	chr22:38982321	A/G	cg21395723	chr22:39101663	GTPBP1	0.48	6.41	0.37	6.78e-10	Menopause (age at onset);
CESC	cis	rs7618915	0.501	rs11130308	chr3:52639257	G/C	cg05564831	chr3:52568323	NT5DC2	0.48	7.64	0.42	4.06e-13	Bipolar disorder;
CESC	cis	rs2777491	0.957	rs7163788	chr15:41704789	A/G	cg20272979	chr15:41787780	ITPKA	0.46	6.78	0.38	7.74e-11	Ulcerative colitis;
CESC	cis	rs4665809	0.590	rs7588328	chr2:26469788	G/A	cg22920501	chr2:26401640	FAM59B	0.91	10.38	0.54	2.08e-21	Gut microbiome composition (summer);
CESC	trans	rs35110281	0.776	rs2838316	chr21:44990036	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.59	7.85	0.43	1.06e-13	Mean corpuscular volume;
CESC	cis	rs9522267	0.707	rs9522282	chr13:112222410	T/C	cg10483660	chr13:112241077	NA	-0.32	-5.39	-0.31	1.53e-7	Hepatitis;
CESC	cis	rs78707713	0.560	rs61848398	chr10:71226103	G/A	cg12610070	chr10:71211762	TSPAN15	-0.34	-7.07	-0.4	1.4e-11	Venous thromboembolism;
CESC	cis	rs4819052	0.724	rs9753987	chr21:46661389	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.46	5.79	0.34	2e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs1448094	0.512	rs6539928	chr12:86244920	G/A	cg02569458	chr12:86230093	RASSF9	0.49	7.27	0.41	3.98e-12	Major depressive disorder;
CESC	cis	rs11650494	0.808	rs76366926	chr17:47396628	T/C	cg08112188	chr17:47440006	ZNF652	1.31	8.51	0.46	1.31e-15	Prostate cancer;
CESC	cis	rs2730245	0.618	rs859781	chr7:158661758	G/A	cg01943577	chr7:158741284	NA	-0.45	-5.97	-0.34	7.49e-9	Height;
CESC	cis	rs72615157	0.664	rs6953580	chr7:99825275	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.6	6.8	0.39	6.87e-11	Lung function (FEV1/FVC);
CESC	cis	rs7116495	1.000	rs10751193	chr11:71785356	A/C	cg26138937	chr11:71823887	C11orf51	-0.84	-6.79	-0.38	7.37e-11	Severe influenza A (H1N1) infection;
CESC	cis	rs2933343	0.700	rs1680778	chr3:128614185	A/C	cg11901034	chr3:128598214	ACAD9	-0.4	-5.76	-0.33	2.38e-8	IgG glycosylation;
CESC	cis	rs9649213	0.593	rs6963210	chr7:97944986	G/A	cg21770322	chr7:97807741	LMTK2	0.54	8.17	0.45	1.31e-14	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs12928939	0.518	rs12445564	chr16:71943309	C/T	cg03805757	chr16:71968109	PKD1L3	-0.58	-6.67	-0.38	1.52e-10	Post bronchodilator FEV1;
CESC	cis	rs1018836	0.608	rs1033348	chr8:91464169	C/G	cg16814680	chr8:91681699	NA	-0.51	-7.03	-0.4	1.72e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs17666538	0.591	rs2878547	chr8:603416	G/A	cg02524346	chr8:600233	NA	0.77	6.32	0.36	1.12e-9	IgG glycosylation;
CESC	cis	rs1620921	0.505	rs4709467	chr6:161203079	G/A	cg01280913	chr6:161186852	NA	-0.36	-5.27	-0.31	2.81e-7	Lipoprotein (a) - cholesterol levels;
CESC	cis	rs559928	0.606	rs12417635	chr11:63912728	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.68	6.06	0.35	4.55e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CESC	cis	rs7944584	0.655	rs2856653	chr11:47361084	T/C	cg20307385	chr11:47447363	PSMC3	-0.6	-7.34	-0.41	2.56e-12	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CESC	cis	rs10504229	0.683	rs16921814	chr8:58107421	A/T	cg24829409	chr8:58192753	C8orf71	-0.55	-6.86	-0.39	4.86e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs2228479	0.557	rs57071566	chr16:89889327	T/G	cg04013166	chr16:89971882	TCF25	0.67	5.48	0.32	1.01e-7	Skin colour saturation;
CESC	cis	rs1005277	0.589	rs2749624	chr10:38529865	A/G	cg25427524	chr10:38739819	LOC399744	-0.72	-10.76	-0.55	1.2e-22	Extrinsic epigenetic age acceleration;
CESC	cis	rs412050	1.000	rs412050	chr22:22307519	C/G	cg17089214	chr22:22089827	YPEL1	0.63	6.02	0.35	5.9e-9	Attention deficit hyperactivity disorder;
CESC	cis	rs7116495	0.609	rs674319	chr11:71775391	T/C	cg26138937	chr11:71823887	C11orf51	-1.32	-8.2	-0.45	1.04e-14	Severe influenza A (H1N1) infection;
CESC	cis	rs2952156	1.000	rs2952156	chr17:37876835	A/G	cg20243544	chr17:37824526	PNMT	0.63	7.55	0.42	6.89e-13	Asthma;
CESC	cis	rs939574	0.929	rs10190834	chr2:220070301	T/G	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-0.54	-5.26	-0.31	3.03e-7	Platelet distribution width;
CESC	cis	rs2354432	0.607	rs7537483	chr1:146709877	C/G	cg25205988	chr1:146714368	CHD1L	1.01	7.96	0.44	4.9e-14	Mitochondrial DNA levels;
CESC	cis	rs875971	0.862	rs801194	chr7:66028495	T/C	cg11764359	chr7:65958608	NA	-0.78	-11.17	-0.57	5.37e-24	Aortic root size;
CESC	cis	rs6570726	0.846	rs446031	chr6:145885592	C/T	cg05347473	chr6:146136440	FBXO30	0.46	6.12	0.35	3.32e-9	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7618501	0.633	rs2624843	chr3:49997963	G/A	cg24308560	chr3:49941425	MST1R	-0.64	-9.35	-0.5	3.91e-18	Intelligence (multi-trait analysis);
CESC	cis	rs10899021	1.000	rs10899025	chr11:74367040	G/A	cg25880958	chr11:74394337	NA	-0.73	-7.2	-0.4	6.33e-12	Response to metformin (IC50);
CESC	cis	rs1799949	1.000	rs33920795	chr17:41329010	A/G	cg25072359	chr17:41440525	NA	0.48	6.52	0.37	3.45e-10	Menopause (age at onset);
CESC	cis	rs12681288	0.792	rs12678495	chr8:1000858	C/G	cg15309053	chr8:964076	NA	0.32	5.46	0.32	1.11e-7	Schizophrenia;
CESC	cis	rs4819052	0.765	rs2838827	chr21:46656146	C/T	cg11663144	chr21:46675770	NA	-0.62	-9.42	-0.5	2.26e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs67460515	0.892	rs4856769	chr3:161004549	C/A	cg03342759	chr3:160939853	NMD3	-0.52	-7.0	-0.4	2.05e-11	Parkinson's disease;
CESC	cis	rs736408	0.609	rs2268025	chr3:52795224	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	6.47	0.37	4.63e-10	Bipolar disorder;
CESC	cis	rs644799	1.000	rs1784135	chr11:95531748	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	9.15	0.49	1.61e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs6088580	0.609	rs2378205	chr20:33110803	C/G	cg24642439	chr20:33292090	TP53INP2	0.51	6.62	0.38	1.99e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs2204008	0.560	rs1315354	chr12:38165716	A/G	cg26384229	chr12:38710491	ALG10B	-0.4	-5.46	-0.32	1.11e-7	Bladder cancer;
CESC	cis	rs7618915	0.501	rs7624716	chr3:52751534	T/C	cg18337363	chr3:52569053	NT5DC2	0.29	5.28	0.31	2.66e-7	Bipolar disorder;
CESC	cis	rs6541297	1.000	rs6541296	chr1:230281953	A/G	cg20703242	chr1:230279135	GALNT2	0.73	11.12	0.56	8.07e-24	Coronary artery disease;
CESC	trans	rs1829883	0.648	rs2511925	chr5:98721872	G/A	cg23861655	chr4:57411219	NA	0.38	6.19	0.36	2.24e-9	Hemostatic factors and hematological phenotypes;
CESC	cis	rs9611565	0.921	rs3927	chr22:41722864	A/G	cg06481639	chr22:41940642	POLR3H	-0.6	-6.49	-0.37	4.22e-10	Vitiligo;
CESC	cis	rs172166	0.694	rs1631552	chr6:28089699	C/A	cg22143856	chr6:28129313	ZNF389	0.38	5.41	0.32	1.41e-7	Cardiac Troponin-T levels;
CESC	cis	rs9457247	0.765	rs6904946	chr6:167433948	C/T	cg07741184	chr6:167504864	NA	-0.36	-6.56	-0.37	2.89e-10	Crohn's disease;
CESC	trans	rs2273788	1.000	rs2273788	chr9:114348617	C/T	cg18395993	chr1:249152672	ZNF692	-0.61	-6.18	-0.35	2.41e-9	Monocyte count;
CESC	cis	rs10927875	0.722	rs6696912	chr1:16338474	T/C	cg21385522	chr1:16154831	NA	0.62	7.52	0.42	8.52e-13	Dilated cardiomyopathy;
CESC	cis	rs2380220	0.574	rs9374322	chr6:95998994	G/A	cg04719120	chr6:96025338	MANEA	0.47	5.39	0.31	1.6e-7	Behavioural disinhibition (generation interaction);
CESC	cis	rs71636778	0.543	rs71636796	chr1:27243095	T/C	cg12203394	chr1:27248618	NUDC	0.66	5.55	0.32	6.85e-8	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
CESC	cis	rs60154123	0.772	rs815358	chr1:210430437	A/G	cg22029157	chr1:209979665	IRF6	0.48	5.61	0.33	5.05e-8	Coronary artery disease;
CESC	trans	rs11098499	0.739	rs2203039	chr4:120132347	T/C	cg25214090	chr10:38739885	LOC399744	-0.53	-6.99	-0.39	2.16e-11	Corneal astigmatism;
CESC	cis	rs1371867	0.846	rs1660338	chr8:101242757	C/G	cg11906718	chr8:101322791	RNF19A	0.43	5.63	0.33	4.5e-8	Atrioventricular conduction;
CESC	cis	rs7216064	1.000	rs4791299	chr17:65930937	A/G	cg07042672	chr17:66097459	LOC651250	-0.6	-7.44	-0.42	1.39e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs780096	0.526	rs10182937	chr2:27651693	T/C	cg22903471	chr2:27725779	GCKR	-0.52	-7.39	-0.41	1.88e-12	Total body bone mineral density;
CESC	cis	rs769267	0.930	rs2288852	chr19:19605348	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.59	7.5	0.42	9.5e-13	Tonsillectomy;
CESC	cis	rs7666738	0.687	rs6839454	chr4:99073914	T/C	cg18180107	chr4:99064573	C4orf37	0.41	5.06	0.3	7.99e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs897984	0.571	rs7184567	chr16:31021078	C/T	cg00531865	chr16:30841666	NA	-0.41	-5.79	-0.33	2.03e-8	Dementia with Lewy bodies;
CESC	cis	rs3925075	0.934	rs9673522	chr16:31347648	T/C	cg02846316	chr16:31340340	ITGAM	0.41	6.52	0.37	3.54e-10	IgA nephropathy;
CESC	cis	rs10504229	0.683	rs73605816	chr8:58117167	T/C	cg24829409	chr8:58192753	C8orf71	-0.58	-7.2	-0.4	6.31e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs561341	0.830	rs7218801	chr17:30217778	A/G	cg00745463	chr17:30367425	LRRC37B	0.57	5.64	0.33	4.31e-8	Hip circumference adjusted for BMI;
CESC	cis	rs9649213	0.502	rs6465680	chr7:98005778	A/G	cg00277769	chr7:97922759	BAIAP2L1	-0.33	-5.37	-0.31	1.76e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7927592	0.763	rs7120876	chr11:68261398	C/G	cg20283391	chr11:68216788	NA	-0.45	-5.64	-0.33	4.46e-8	Total body bone mineral density;
CESC	cis	rs4906332	1.000	rs35126287	chr14:103959432	A/G	cg09975044	chr14:104007538	NA	0.47	6.39	0.37	7.49e-10	Coronary artery disease;
CESC	cis	rs875971	0.964	rs11765965	chr7:65842221	A/G	cg18876405	chr7:65276391	NA	0.5	6.64	0.38	1.75e-10	Aortic root size;
CESC	cis	rs7666738	0.830	rs7673880	chr4:99057262	A/G	cg24818145	chr4:99064322	C4orf37	0.39	5.06	0.3	7.89e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4481887	0.636	rs10788761	chr1:248410663	C/T	cg00666640	chr1:248458726	OR2T12	0.35	5.47	0.32	1.07e-7	Common traits (Other);
CESC	cis	rs4253772	0.575	rs9615956	chr22:46749634	C/T	cg00784671	chr22:46762841	CELSR1	-0.7	-6.37	-0.36	8.41e-10	LDL cholesterol;Cholesterol, total;
CESC	cis	rs763121	0.853	rs2076028	chr22:39150450	G/A	cg14440974	chr22:39074834	NA	-0.39	-5.37	-0.31	1.69e-7	Menopause (age at onset);
CESC	cis	rs4268898	0.516	rs7597149	chr2:24371962	C/T	cg20701182	chr2:24300061	SF3B14	-0.39	-5.32	-0.31	2.23e-7	Asthma;
CESC	cis	rs2276314	1.000	rs2298715	chr18:33552425	T/C	cg05985134	chr18:33552581	C18orf21	0.67	7.95	0.44	5.35e-14	Endometriosis;Drug-induced torsades de pointes;
CESC	trans	rs3780486	0.846	rs12554995	chr9:33132044	A/G	cg20290983	chr6:43655470	MRPS18A	0.99	18.35	0.75	4.06e-49	IgG glycosylation;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05788994	chr16:53089097	CHD9	0.54	6.05	0.35	4.9e-9	Gut microbiome composition (summer);
CESC	cis	rs7937682	0.889	rs1789355	chr11:111499718	T/C	cg09085632	chr11:111637200	PPP2R1B	-0.99	-15.77	-0.7	5.94e-40	Primary sclerosing cholangitis;
CESC	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg03188948	chr7:1209495	NA	0.73	7.17	0.4	7.66e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs67311347	1.000	rs28871903	chr3:40511094	T/G	cg09455208	chr3:40491958	NA	0.5	8.19	0.45	1.15e-14	Renal cell carcinoma;
CESC	cis	rs1215050	0.716	rs11940331	chr4:99054041	G/C	cg17366294	chr4:99064904	C4orf37	0.43	5.59	0.32	5.7e-8	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs3741151	0.773	rs73543000	chr11:73151774	T/C	cg17517138	chr11:73019481	ARHGEF17	1.0	7.41	0.41	1.74e-12	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs13191362	1.000	rs73035025	chr6:163000988	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.88	9.16	0.49	1.46e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs8072100	0.688	rs7221224	chr17:45419061	T/G	cg25173405	chr17:45401733	C17orf57	0.42	5.2	0.3	4.03e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs6982240	0.514	rs10095322	chr8:142262327	A/G	cg27411547	chr8:142287226	NA	-0.53	-7.32	-0.41	2.99e-12	Tonsillectomy;
CESC	cis	rs17384381	1.000	rs12140935	chr1:85855716	G/A	cg16011679	chr1:85725395	C1orf52	0.79	8.08	0.44	2.34e-14	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07878378	chr8:56987195	RPS20;SNORD54	-0.58	-6.33	-0.36	1.03e-9	Gut microbiome composition (summer);
CESC	cis	rs4925386	0.840	rs6143036	chr20:60921721	C/A	cg22633769	chr20:60982531	CABLES2	0.56	5.76	0.33	2.28e-8	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs2836974	1.000	rs2836974	chr21:40663181	A/G	cg11890956	chr21:40555474	PSMG1	-1.16	-21.02	-0.79	2.18e-58	Cognitive function;
CESC	cis	rs1153858	0.943	rs4774580	chr15:45652086	G/A	cg14582100	chr15:45693742	SPATA5L1	0.42	5.97	0.34	7.62e-9	Homoarginine levels;
CESC	cis	rs9322193	0.923	rs2184369	chr6:150097817	G/A	cg07701084	chr6:150067640	NUP43	0.43	5.8	0.34	1.91e-8	Lung cancer;
CESC	cis	rs11864453	0.826	rs2074626	chr16:72139184	C/A	cg16558253	chr16:72132732	DHX38	-0.6	-9.61	-0.51	5.77e-19	Fibrinogen levels;
CESC	cis	rs1552244	0.515	rs111560858	chr3:10166845	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.78	8.92	0.48	7.63e-17	Alzheimer's disease;
CESC	cis	rs9640161	0.830	rs36069544	chr7:150061538	G/A	cg10018233	chr7:150070692	REPIN1	0.37	5.67	0.33	3.82e-8	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs7914558	0.966	rs7096269	chr10:104736721	A/G	cg04362960	chr10:104952993	NT5C2	0.44	5.69	0.33	3.32e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs4595586	0.967	rs11169807	chr12:39244161	A/G	cg26384229	chr12:38710491	ALG10B	0.37	5.45	0.32	1.13e-7	Morning vs. evening chronotype;
CESC	cis	rs11822910	0.645	rs7122734	chr11:57190420	C/T	cg00522883	chr11:57194120	SLC43A3	-0.45	-5.43	-0.32	1.29e-7	Platelet distribution width;
CESC	trans	rs208520	1.000	rs12190187	chr6:66973207	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.85	9.39	0.5	2.78e-18	Exhaled nitric oxide output;
CESC	cis	rs3820928	0.874	rs4144328	chr2:227790187	A/C	cg11843606	chr2:227700838	RHBDD1	-0.42	-5.7	-0.33	3.25e-8	Pulmonary function;
CESC	cis	rs5758659	0.652	rs133326	chr22:42406885	G/A	cg15557168	chr22:42548783	NA	-0.42	-6.27	-0.36	1.47e-9	Cognitive function;
CESC	cis	rs9467711	0.606	rs9393715	chr6:26375645	G/A	cg12826209	chr6:26865740	GUSBL1	0.64	5.25	0.31	3.2e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs2242073	0.660	rs12464752	chr2:208996677	G/A	cg10392614	chr2:208977121	NA	0.38	5.15	0.3	5.07e-7	Attention deficit hyperactivity disorder;
CESC	cis	rs9584850	0.520	rs10508036	chr13:99157398	C/G	cg20750642	chr13:99100586	FARP1	0.4	5.77	0.33	2.19e-8	Neuroticism;
CESC	cis	rs2839186	0.500	rs13049893	chr21:47707054	C/T	cg02776659	chr21:47717406	C21orf57	-0.37	-5.05	-0.3	8.24e-7	Testicular germ cell tumor;
CESC	cis	rs703842	1.000	rs4646536	chr12:58157988	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.71	9.27	0.5	6.51e-18	Multiple sclerosis;
CESC	cis	rs5747327	0.835	rs181396	chr22:18224155	A/G	cg19898043	chr22:18121309	BCL2L13	0.41	5.18	0.3	4.34e-7	Myeloid white cell count;Granulocyte count;
CESC	cis	rs9916302	0.555	rs12940193	chr17:37652178	T/G	cg15445000	chr17:37608096	MED1	0.41	6.82	0.39	6.31e-11	Glomerular filtration rate (creatinine);
CESC	trans	rs7095944	0.614	rs10901817	chr10:126443404	A/T	cg27222157	chr11:66382978	RBM14	0.38	6.13	0.35	3.17e-9	Asthma;
CESC	cis	rs870825	0.616	rs6552809	chr4:185643984	G/A	cg04058563	chr4:185651563	MLF1IP	0.64	7.13	0.4	9.71e-12	Blood protein levels;
CESC	cis	rs262150	0.574	rs2730273	chr7:158797754	A/C	cg10570241	chr7:158785291	NA	0.31	5.17	0.3	4.51e-7	Facial morphology (factor 20);
CESC	cis	rs754466	0.606	rs11002306	chr10:79591519	A/T	cg17075019	chr10:79541650	NA	-0.86	-14.02	-0.65	8.85e-34	Liver enzyme levels (gamma-glutamyl transferase);
CESC	trans	rs723080	1.000	rs2425427	chr20:39349489	C/T	cg17737388	chr1:85724454	C1orf52	-0.38	-6.07	-0.35	4.43e-9	Paneth cell defects in Crohn's disease;
CESC	cis	rs9837602	1.000	rs793496	chr3:99507254	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.52	-7.14	-0.4	8.78e-12	Breast cancer;
CESC	cis	rs9788682	1.000	rs7181245	chr15:78814389	C/T	cg06917634	chr15:78832804	PSMA4	-0.56	-6.64	-0.38	1.72e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs1008375	0.864	rs4698196	chr4:17574735	T/C	cg27347728	chr4:17578864	LAP3	0.5	5.76	0.33	2.29e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs798554	0.567	rs2527695	chr7:2858267	T/G	cg19717773	chr7:2847554	GNA12	-0.52	-8.16	-0.45	1.32e-14	Height;
CESC	cis	rs875971	0.862	rs13232191	chr7:65986648	A/G	cg18876405	chr7:65276391	NA	0.53	7.28	0.41	3.9e-12	Aortic root size;
CESC	cis	rs1499614	1.000	rs2659913	chr7:66157336	T/A	cg12463550	chr7:65579703	CRCP	0.73	5.73	0.33	2.78e-8	Gout;
CESC	cis	rs9894429	0.621	rs9747119	chr17:79607017	A/G	cg18240062	chr17:79603768	NPLOC4	0.54	7.11	0.4	1.06e-11	Eye color traits;
CESC	cis	rs10504229	0.639	rs56066782	chr8:58105857	A/G	cg21724239	chr8:58056113	NA	0.57	5.9	0.34	1.08e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs11229555	0.645	rs12786744	chr11:58177549	T/C	cg15696309	chr11:58395628	NA	-0.42	-5.07	-0.3	7.51e-7	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs4953076	0.533	rs10173126	chr2:44446492	T/C	cg04920474	chr2:44395004	PPM1B	0.58	7.29	0.41	3.52e-12	Height;
CESC	cis	rs6831352	0.918	rs2602896	chr4:100046207	C/T	cg13256891	chr4:100009986	ADH5	-0.78	-8.84	-0.48	1.36e-16	Alcohol dependence;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg12271800	chr19:59028764	ZBTB45	-0.46	-6.18	-0.35	2.46e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs2274273	0.588	rs9919932	chr14:55814080	A/G	cg04306507	chr14:55594613	LGALS3	0.29	5.13	0.3	5.66e-7	Protein biomarker;
CESC	cis	rs2839186	1.000	rs2839181	chr21:47685939	A/G	cg13012494	chr21:47604986	C21orf56	0.48	6.37	0.36	8.51e-10	Testicular germ cell tumor;
CESC	cis	rs6089584	0.627	rs13045575	chr20:60565596	G/A	cg24733560	chr20:60626293	TAF4	0.42	6.28	0.36	1.35e-9	Body mass index;
CESC	cis	rs734999	0.549	rs2764845	chr1:2528999	G/T	cg20673091	chr1:2541236	MMEL1	-0.44	-7.49	-0.42	1.01e-12	Ulcerative colitis;
CESC	cis	rs7618915	0.547	rs2268026	chr3:52778347	T/C	cg18404041	chr3:52824283	ITIH1	-0.41	-6.75	-0.38	9.55e-11	Bipolar disorder;
CESC	cis	rs11997175	0.546	rs4545051	chr8:33608863	T/C	ch.8.33884649F	chr8:33765107	NA	0.57	7.47	0.42	1.15e-12	Body mass index;
CESC	trans	rs1814175	0.791	rs10219223	chr11:49791468	A/T	cg03929089	chr4:120376271	NA	-0.9	-14.79	-0.67	1.7e-36	Height;
CESC	cis	rs2073300	1.000	rs2207989	chr20:23446014	T/G	cg12062639	chr20:23401060	NAPB	0.74	5.43	0.32	1.3e-7	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs1707322	1.000	rs10158032	chr1:46332701	T/C	cg06784218	chr1:46089804	CCDC17	0.32	5.52	0.32	8.02e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9457247	0.715	rs6923582	chr6:167437162	T/A	cg07741184	chr6:167504864	NA	0.36	6.41	0.37	6.69e-10	Crohn's disease;
CESC	cis	rs1008375	1.000	rs7659718	chr4:17638020	A/C	cg15017067	chr4:17643749	FAM184B	0.38	5.45	0.32	1.16e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs727505	1.000	rs56387611	chr7:124479180	G/A	cg23710748	chr7:124431027	NA	-0.48	-7.61	-0.42	4.76e-13	Lewy body disease;
CESC	cis	rs1448094	0.512	rs61930137	chr12:86242930	C/T	cg19622623	chr12:86230825	RASSF9	-0.46	-5.89	-0.34	1.2e-8	Major depressive disorder;
CESC	cis	rs992157	0.798	rs7587220	chr2:219160864	C/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.66	-8.66	-0.47	4.76e-16	Colorectal cancer;
CESC	cis	rs7833790	0.553	rs9693128	chr8:82706128	A/G	cg27398817	chr8:82754497	SNX16	-0.64	-8.96	-0.48	6.01e-17	Diastolic blood pressure;
CESC	cis	rs9814567	0.964	rs9847788	chr3:134186496	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.4	-5.49	-0.32	9.46e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs8177253	0.965	rs8177260	chr3:133480458	T/A	cg01448562	chr3:133502909	NA	-0.47	-6.75	-0.38	9.3e-11	Iron status biomarkers;
CESC	cis	rs17826219	0.500	rs9891256	chr17:29072692	C/T	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.1e-10	Body mass index;
CESC	cis	rs4819052	0.851	rs1006779	chr21:46670752	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.41	5.13	0.3	5.57e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs780096	0.526	rs704791	chr2:27657167	T/C	cg02592271	chr2:27665507	KRTCAP3	-0.29	-5.79	-0.34	2e-8	Total body bone mineral density;
CESC	cis	rs1215050	0.765	rs181521	chr4:98745728	A/C	cg05340658	chr4:99064831	C4orf37	0.51	6.65	0.38	1.63e-10	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs662064	0.852	rs2056417	chr1:10581658	G/A	cg20482658	chr1:10539492	PEX14	0.41	8.44	0.46	2.06e-15	Asthma;
CESC	cis	rs9611565	0.659	rs12484175	chr22:41953739	A/C	cg06634786	chr22:41940651	POLR3H	-0.65	-6.82	-0.39	6.01e-11	Vitiligo;
CESC	cis	rs9322193	0.962	rs9688809	chr6:150109056	C/T	cg13206674	chr6:150067644	NUP43	0.42	5.89	0.34	1.19e-8	Lung cancer;
CESC	cis	rs2404602	0.530	rs11072614	chr15:76967205	G/A	cg00316803	chr15:76480434	C15orf27	0.4	5.56	0.32	6.66e-8	Blood metabolite levels;
CESC	cis	rs6142102	0.602	rs4911399	chr20:32623418	C/A	cg08999081	chr20:33150536	PIGU	0.33	5.03	0.3	9.11e-7	Skin pigmentation;
CESC	cis	rs9322193	0.923	rs56397000	chr6:150060483	C/T	cg09699651	chr6:150184138	LRP11	0.4	5.3	0.31	2.45e-7	Lung cancer;
CESC	cis	rs9291683	0.679	rs13137795	chr4:10051506	G/A	cg02734326	chr4:10020555	SLC2A9	0.47	6.71	0.38	1.2e-10	Bone mineral density;
CESC	cis	rs2625529	0.652	rs11072350	chr15:72464609	T/G	cg16672083	chr15:72433130	SENP8	0.45	6.79	0.39	7.29e-11	Red blood cell count;
CESC	cis	rs710216	0.843	rs2297972	chr1:43418026	C/T	cg07803811	chr1:43423981	SLC2A1	-0.46	-5.25	-0.31	3.13e-7	Red cell distribution width;
CESC	cis	rs1348850	0.526	rs78587445	chr2:178461339	G/T	cg23306229	chr2:178417860	TTC30B	-0.68	-5.8	-0.34	1.84e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs3015497	0.789	rs3015498	chr14:51112824	T/C	cg09863266	chr14:51125203	SAV1	-0.33	-5.17	-0.3	4.62e-7	Mean platelet volume;
CESC	cis	rs4319547	1.000	rs7295397	chr12:123116209	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.58	-6.75	-0.38	9.06e-11	Body mass index;
CESC	cis	rs6121246	0.567	rs6060263	chr20:30193110	T/C	cg13852791	chr20:30311386	BCL2L1	0.58	5.56	0.32	6.65e-8	Mean corpuscular hemoglobin;
CESC	cis	rs8062405	0.655	rs7184597	chr16:28921809	T/C	cg05966235	chr16:28915196	ATP2A1	-0.39	-5.57	-0.32	6.27e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs35306767	0.903	rs11253492	chr10:936873	T/C	cg10556349	chr10:835070	NA	0.57	5.56	0.32	6.44e-8	Eosinophil percentage of granulocytes;
CESC	cis	rs9913156	0.670	rs4416072	chr17:4570036	C/T	cg19197139	chr17:4613644	ARRB2	0.87	10.12	0.53	1.45e-20	Lymphocyte counts;
CESC	cis	rs11958404	0.615	rs7727924	chr5:157433736	A/G	cg05962755	chr5:157440814	NA	0.4	5.74	0.33	2.54e-8	IgG glycosylation;
CESC	cis	rs10504229	1.000	rs67384205	chr8:58180348	C/G	cg14926445	chr8:58193284	C8orf71	-0.51	-5.47	-0.32	1.03e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs62005083	0.867	rs72725990	chr14:74633610	C/T	cg05179529	chr14:74551516	LIN52;ALDH6A1	0.71	5.53	0.32	7.52e-8	Mean corpuscular volume;
CESC	cis	rs2836950	0.840	rs12482317	chr21:40588241	A/G	cg11890956	chr21:40555474	PSMG1	-0.63	-8.11	-0.45	1.88e-14	Menarche (age at onset);
CESC	cis	rs72772090	0.539	rs11748519	chr5:96119328	C/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.57	-5.21	-0.3	3.74e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs3105593	1.000	rs11070807	chr15:50974505	A/G	cg08437265	chr15:50716283	USP8	0.45	5.92	0.34	1e-8	QT interval;
CESC	cis	rs9486715	0.867	rs3849199	chr6:97049191	T/C	cg06623918	chr6:96969491	KIAA0776	-0.96	-15.13	-0.68	1.08e-37	Headache;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg13793354	chr5:70882903	MCCC2	-0.53	-6.8	-0.39	6.84e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs7811142	0.887	rs4074838	chr7:100032665	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.78	6.78	0.38	7.61e-11	Platelet count;
CESC	cis	rs6665290	0.904	rs9727512	chr1:227185375	G/T	cg10327440	chr1:227177885	CDC42BPA	-1.2	-31.28	-0.89	6.16e-91	Myeloid white cell count;
CESC	cis	rs853679	0.517	rs7755442	chr6:28039015	T/C	cg12963246	chr6:28129442	ZNF389	0.55	7.35	0.41	2.46e-12	Depression;
CESC	cis	rs875971	0.965	rs7794930	chr7:65778546	A/C	cg18876405	chr7:65276391	NA	-0.51	-7.05	-0.4	1.53e-11	Aortic root size;
CESC	cis	rs10504229	1.000	rs56168206	chr8:58184485	G/A	cg24829409	chr8:58192753	C8orf71	-0.76	-9.93	-0.52	5.87e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs1508086	0.695	rs10958508	chr8:57803673	A/C	cg10342016	chr8:57802622	NA	0.29	5.04	0.3	8.47e-7	Hand grip strength;
CESC	cis	rs9649213	0.593	rs6465667	chr7:97957885	G/A	cg24562669	chr7:97807699	LMTK2	0.51	7.57	0.42	6.13e-13	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg14338887	chr6:42928500	GNMT	0.35	5.19	0.3	4.25e-7	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs7560272	0.501	rs12713798	chr2:73986421	C/T	cg20560298	chr2:73613845	ALMS1	0.43	6.04	0.35	5.32e-9	Schizophrenia;
CESC	cis	rs1670533	1.000	rs11247972	chr4:1060550	A/G	cg04106633	chr4:1044584	NA	0.4	5.19	0.3	4.15e-7	Recombination rate (females);
CESC	cis	rs10754283	0.967	rs10737707	chr1:90119304	A/G	cg21401794	chr1:90099060	LRRC8C	0.66	8.77	0.47	2.18e-16	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs2050392	0.931	rs2265187	chr10:30690844	C/T	cg18806716	chr10:30721971	MAP3K8	-0.4	-5.66	-0.33	3.86e-8	Inflammatory bowel disease;
CESC	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.51	-6.68	-0.38	1.41e-10	Longevity;Endometriosis;
CESC	cis	rs4718428	0.576	rs12698546	chr7:66266906	G/T	cg25985355	chr7:65971099	NA	-0.36	-5.21	-0.3	3.83e-7	Corneal structure;
CESC	cis	rs916888	0.647	rs199524	chr17:44848438	G/T	cg17911788	chr17:44343683	NA	0.44	6.73	0.38	1.07e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs736408	0.609	rs62255396	chr3:52782839	C/T	cg07507251	chr3:52567010	NT5DC2	0.42	7.24	0.41	4.85e-12	Bipolar disorder;
CESC	cis	rs2243480	1.000	rs419603	chr7:65597341	C/T	cg12463550	chr7:65579703	CRCP	0.73	5.68	0.33	3.5e-8	Diabetic kidney disease;
CESC	cis	rs6089584	0.853	rs1746280	chr20:60577821	C/G	cg13770153	chr20:60521292	NA	-0.5	-6.23	-0.36	1.79e-9	Body mass index;
CESC	cis	rs10789491	1.000	rs35861275	chr1:47171909	A/C	cg15501359	chr1:47185051	KIAA0494	-0.75	-7.8	-0.43	1.45e-13	Response to hepatitis C treatment;
CESC	cis	rs7666738	0.753	rs9991512	chr4:99007205	T/C	cg05340658	chr4:99064831	C4orf37	0.8	12.44	0.61	2.83e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10927875	0.691	rs1048302	chr1:16340879	T/G	cg21214613	chr1:16344536	HSPB7	0.38	5.6	0.33	5.35e-8	Dilated cardiomyopathy;
CESC	cis	rs2073300	0.609	rs6137950	chr20:23418722	T/A	cg12062639	chr20:23401060	NAPB	1.04	8.1	0.45	1.97e-14	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs853679	0.517	rs4713148	chr6:28115921	G/A	cg08968635	chr6:28129556	ZNF389	0.41	5.28	0.31	2.68e-7	Depression;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08193322	chr2:74730586	LOC151534;LBX2	0.53	6.27	0.36	1.43e-9	Gut microbiome composition (summer);
CESC	trans	rs1814175	0.616	rs4881723	chr11:49788566	G/T	cg03929089	chr4:120376271	NA	-0.89	-13.67	-0.64	1.51e-32	Height;
CESC	cis	rs5758659	0.657	rs5758587	chr22:42517636	C/G	cg19513890	chr22:42538836	CYP2D7P1	0.36	5.37	0.31	1.74e-7	Cognitive function;
CESC	cis	rs11792861	0.962	rs3829084	chr9:111801724	C/G	cg13535736	chr9:111863775	C9orf5	0.5	6.7	0.38	1.28e-10	Menarche (age at onset);
CESC	cis	rs2236918	0.687	rs1776136	chr1:242026845	G/A	cg17736920	chr1:242011382	EXO1	0.56	7.18	0.4	6.97e-12	Menopause (age at onset);
CESC	cis	rs854765	0.618	rs8066982	chr17:17851377	T/C	cg16928487	chr17:17741425	SREBF1	-0.57	-9.57	-0.51	7.66e-19	Total body bone mineral density;
CESC	cis	rs6540556	0.723	rs10863785	chr1:209908876	C/T	cg05527609	chr1:210001259	C1orf107	0.6	6.93	0.39	3.2e-11	Red blood cell count;
CESC	cis	rs34779708	0.931	rs2244100	chr10:35323636	G/A	cg03585969	chr10:35415529	CREM	-0.72	-9.78	-0.51	1.74e-19	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs7833986	0.501	rs2719261	chr8:56941982	C/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.58	7.24	0.41	4.87e-12	Height;
CESC	cis	rs7267979	1.000	rs6050630	chr20:25430745	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.87	18.11	0.74	3e-48	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs2075371	0.863	rs1646638	chr7:134008706	T/C	cg00033643	chr7:134001901	SLC35B4	0.41	5.13	0.3	5.54e-7	Mean platelet volume;
CESC	cis	rs2439831	0.850	rs11856795	chr15:44160582	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.68	7.43	0.42	1.45e-12	Lung cancer in ever smokers;
CESC	cis	rs2072499	0.966	rs2853641	chr1:156181770	A/G	cg24450063	chr1:156163899	SLC25A44	0.97	19.4	0.77	9e-53	Testicular germ cell tumor;
CESC	cis	rs4953076	0.573	rs6544746	chr2:44407985	C/T	cg04920474	chr2:44395004	PPM1B	0.49	6.22	0.36	1.92e-9	Height;
CESC	cis	rs2576037	0.583	rs2187091	chr18:44520048	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.49	-6.61	-0.38	2.13e-10	Personality dimensions;
CESC	cis	rs4713118	0.621	rs4713134	chr6:28034121	T/C	cg12963246	chr6:28129442	ZNF389	0.53	6.91	0.39	3.61e-11	Parkinson's disease;
CESC	cis	rs514406	0.661	rs562641	chr1:53374666	C/T	cg08859206	chr1:53392774	SCP2	-0.68	-10.01	-0.52	3.33e-20	Monocyte count;
CESC	trans	rs9929218	1.000	rs13334471	chr16:68800452	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.63	-8.44	-0.46	2.13e-15	Colorectal cancer;
CESC	cis	rs7618915	0.547	rs2336542	chr3:52710636	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	7.02	0.4	1.82e-11	Bipolar disorder;
CESC	cis	rs8078723	0.738	rs3816472	chr17:38142677	A/C	cg17467752	chr17:38218738	THRA	-0.56	-8.21	-0.45	9.56e-15	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CESC	trans	rs17685	0.672	rs10952841	chr7:75778626	A/C	cg19862616	chr7:65841803	NCRNA00174	0.85	12.42	0.61	3.15e-28	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs6580649	0.941	rs7971668	chr12:48469696	T/C	cg24011408	chr12:48396354	COL2A1	-0.4	-5.04	-0.3	8.67e-7	Lung cancer;
CESC	cis	rs4862750	0.872	rs4862747	chr4:187877236	A/T	cg03452623	chr4:187889614	NA	0.86	15.16	0.68	8.45e-38	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg02099313	chr1:231114956	TTC13;ARV1	0.48	6.21	0.36	2.09e-9	Tetralogy of Fallot;
CESC	cis	rs13108904	0.934	rs4974596	chr4:1301052	A/G	cg22903657	chr4:1355424	KIAA1530	-0.37	-5.14	-0.3	5.34e-7	Obesity-related traits;
CESC	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg07677032	chr17:61819896	STRADA	0.45	5.92	0.34	1.01e-8	Prudent dietary pattern;
CESC	cis	rs80130819	0.748	rs2732487	chr12:48686741	T/C	cg05342945	chr12:48394962	COL2A1	-0.48	-5.23	-0.31	3.4e-7	Prostate cancer;
CESC	cis	rs11098499	0.954	rs4345162	chr4:120312959	G/A	cg24375607	chr4:120327624	NA	0.46	5.55	0.32	6.98e-8	Corneal astigmatism;
CESC	cis	rs67340775	0.541	rs200974	chr6:27855845	A/G	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.54	5.07	0.3	7.35e-7	Lung cancer in ever smokers;
CESC	cis	rs8062405	0.573	rs11645306	chr16:28983936	G/C	cg08761264	chr16:28874980	SH2B1	0.49	5.81	0.34	1.83e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs4713118	0.513	rs1225591	chr6:28148752	G/A	cg17221315	chr6:27791827	HIST1H4J	0.45	5.86	0.34	1.39e-8	Parkinson's disease;
CESC	cis	rs12451471	0.620	rs11150846	chr17:78098520	C/T	cg24585782	chr17:78113791	EIF4A3	-0.59	-8.04	-0.44	3.08e-14	Plateletcrit;Mean corpuscular hemoglobin concentration;
CESC	trans	rs4843747	0.671	rs74729706	chr16:88104159	C/T	cg26811252	chr16:29126840	RRN3P2	0.68	9.51	0.5	1.23e-18	Menopause (age at onset);
CESC	cis	rs6088580	0.634	rs6088508	chr20:33060081	A/G	cg06115741	chr20:33292138	TP53INP2	0.48	6.11	0.35	3.58e-9	Glomerular filtration rate (creatinine);
CESC	trans	rs61931739	0.929	rs1490110	chr12:34091605	A/G	cg26384229	chr12:38710491	ALG10B	-0.49	-6.9	-0.39	3.86e-11	Morning vs. evening chronotype;
CESC	cis	rs80130819	0.515	rs1793915	chr12:48386577	G/T	cg05342945	chr12:48394962	COL2A1	-0.51	-6.1	-0.35	3.71e-9	Prostate cancer;
CESC	cis	rs989128	0.572	rs6504674	chr17:48630814	T/C	cg24438145	chr17:48624694	SPATA20	0.45	5.31	0.31	2.36e-7	Type 2 diabetes;
CESC	cis	rs7772486	0.875	rs9390377	chr6:146386932	G/A	cg23711669	chr6:146136114	FBXO30	0.88	13.22	0.63	5.33e-31	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9733	0.621	rs12746899	chr1:150579678	A/T	cg13175981	chr1:150552382	MCL1	0.72	10.69	0.55	2.04e-22	Tonsillectomy;
CESC	cis	rs34779708	0.733	rs7070778	chr10:35541688	T/C	cg04310649	chr10:35416472	CREM	-0.47	-5.39	-0.31	1.59e-7	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs9814567	0.896	rs6763188	chr3:134349995	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.42	5.67	0.33	3.77e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs896854	0.654	rs4735340	chr8:95976251	A/T	cg23172400	chr8:95962367	TP53INP1	-0.45	-9.25	-0.49	8.02e-18	Type 2 diabetes;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg24848437	chr7:2645542	IQCE	0.47	6.32	0.36	1.1e-9	Ulcerative colitis;
CESC	cis	rs2479106	0.963	rs7850520	chr9:126509806	C/T	cg16191174	chr9:126692580	DENND1A	-0.48	-6.6	-0.38	2.22e-10	Polycystic ovary syndrome;
CESC	cis	rs7959452	0.535	rs7133487	chr12:69774377	G/A	cg22834771	chr12:69754056	YEATS4	-0.48	-6.47	-0.37	4.61e-10	Blood protein levels;
CESC	cis	rs17253792	0.822	rs79618862	chr14:56093971	C/T	cg01858014	chr14:56050164	KTN1	-0.83	-7.03	-0.4	1.7e-11	Putamen volume;
CESC	cis	rs2295499	0.782	rs111559317	chr4:2719058	A/G	cg08330972	chr4:2403930	ZFYVE28	-0.32	-5.29	-0.31	2.57e-7	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
CESC	cis	rs2573652	0.722	rs11636084	chr15:100543394	A/G	cg00587665	chr15:100533223	ADAMTS17	-0.4	-6.68	-0.38	1.4e-10	Height;
CESC	cis	rs7247513	0.856	rs2162863	chr19:12699777	G/T	cg01871581	chr19:12707946	ZNF490	-0.88	-15.42	-0.69	9.87e-39	Bipolar disorder;
CESC	cis	rs6570726	0.967	rs7772286	chr6:145930423	A/T	cg05347473	chr6:146136440	FBXO30	-0.45	-5.81	-0.34	1.82e-8	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs17539620	0.624	rs111868524	chr6:154839960	G/C	cg20019720	chr6:154832845	CNKSR3	0.44	5.57	0.32	6.24e-8	Lipoprotein (a) levels;
CESC	cis	rs4819052	0.959	rs8130866	chr21:46672112	G/A	cg11663144	chr21:46675770	NA	-0.5	-7.02	-0.4	1.9e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs9584850	0.834	rs17574378	chr13:99116384	T/C	cg20750642	chr13:99100586	FARP1	-0.37	-5.7	-0.33	3.16e-8	Neuroticism;
CESC	cis	rs11098499	0.775	rs10021601	chr4:120282563	G/A	cg24375607	chr4:120327624	NA	0.42	5.19	0.3	4.19e-7	Corneal astigmatism;
CESC	cis	rs17209837	0.573	rs45537841	chr7:87110640	C/T	cg00919237	chr7:87102261	ABCB4	-0.49	-6.46	-0.37	5.07e-10	Gallbladder cancer;
CESC	cis	rs926392	0.640	rs4616534	chr20:37693564	G/A	cg16355469	chr20:37678765	NA	0.56	6.35	0.36	9.32e-10	Dialysis-related mortality;
CESC	trans	rs3780486	0.846	rs12554995	chr9:33132044	A/G	cg04842962	chr6:43655489	MRPS18A	1.01	19.64	0.77	1.24e-53	IgG glycosylation;
CESC	cis	rs10752881	0.740	rs1889307	chr1:183049389	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.86	13.21	0.63	6.06e-31	Colorectal cancer;
CESC	cis	rs3820068	0.603	rs927207	chr1:15990552	A/G	cg16988262	chr1:15930761	NA	0.35	5.67	0.33	3.81e-8	Systolic blood pressure;
CESC	cis	rs4979906	1.000	rs2395494	chr10:79458340	C/T	cg07817648	chr10:79422355	NA	-0.58	-6.78	-0.38	7.85e-11	Mortality in heart failure;
CESC	cis	rs2832191	0.791	rs2832196	chr21:30497412	G/A	cg24692254	chr21:30365293	RNF160	-0.79	-12.11	-0.6	3.71e-27	Dental caries;
CESC	cis	rs5758659	0.652	rs133327	chr22:42407689	T/C	cg15557168	chr22:42548783	NA	-0.42	-6.27	-0.36	1.48e-9	Cognitive function;
CESC	cis	rs7552404	0.655	rs1146646	chr1:76265500	G/A	cg22875332	chr1:76189707	ACADM	0.7	8.81	0.48	1.73e-16	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs1218582	0.772	rs4845682	chr1:154877105	T/C	cg24250549	chr1:154909240	PMVK	0.74	11.09	0.56	1.01e-23	Prostate cancer;
CESC	cis	rs67311347	0.713	rs73073505	chr3:40310693	C/T	cg09455208	chr3:40491958	NA	0.44	7.01	0.4	1.99e-11	Renal cell carcinoma;
CESC	cis	rs7520050	0.808	rs11211196	chr1:46282296	A/T	cg03146154	chr1:46216737	IPP	-0.47	-6.19	-0.36	2.34e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs875971	0.564	rs313804	chr7:65514622	A/G	cg12463550	chr7:65579703	CRCP	0.59	7.47	0.42	1.16e-12	Aortic root size;
CESC	cis	rs853679	0.517	rs6922063	chr6:28094366	G/A	cg19592336	chr6:28129416	ZNF389	0.63	8.71	0.47	3.29e-16	Depression;
CESC	cis	rs2838344	0.776	rs2298561	chr21:45085234	A/G	cg04455712	chr21:45112962	RRP1B	0.5	7.75	0.43	2.03e-13	Coronary artery disease;
CESC	cis	rs155076	0.711	rs4769158	chr13:21881975	T/C	cg06138931	chr13:21896616	NA	0.51	5.27	0.31	2.8e-7	White matter hyperintensity burden;
CESC	cis	rs7829975	0.514	rs2979151	chr8:8258019	A/G	cg15556689	chr8:8085844	FLJ10661	-0.53	-6.88	-0.39	4.21e-11	Mood instability;
CESC	cis	rs644799	1.000	rs473148	chr11:95628606	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.47	5.62	0.33	4.8e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs6701037	0.681	rs1057239	chr1:175130204	G/A	cg00321850	chr1:175162397	KIAA0040	-0.43	-6.2	-0.36	2.1e-9	Alcohol dependence;
CESC	cis	rs7903847	0.667	rs10882931	chr10:99165794	C/A	cg20016023	chr10:99160130	RRP12	-0.3	-5.12	-0.3	5.91e-7	Granulocyte percentage of myeloid white cells;
CESC	cis	rs738322	0.718	rs3761445	chr22:38595411	G/A	cg25457927	chr22:38595422	NA	0.36	6.83	0.39	5.91e-11	Cutaneous nevi;
CESC	cis	rs116095464	0.558	rs10462755	chr5:246748	T/C	cg22857025	chr5:266934	NA	-1.28	-18.26	-0.75	8.94e-49	Breast cancer;
CESC	cis	rs2576037	0.526	rs7234570	chr18:44459656	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.57	-8.04	-0.44	3e-14	Personality dimensions;
CESC	cis	rs9894429	0.505	rs35570626	chr17:79611084	A/G	cg21984481	chr17:79567631	NPLOC4	-0.35	-5.41	-0.32	1.43e-7	Eye color traits;
CESC	cis	rs7236492	0.688	rs7241538	chr18:77191247	C/T	cg15644404	chr18:77186268	NFATC1	-0.69	-5.3	-0.31	2.39e-7	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs16910800	0.731	rs1871953	chr11:23192677	G/A	cg20040320	chr11:23191996	NA	-0.7	-7.13	-0.4	9.41e-12	Cancer;
CESC	cis	rs11122272	0.766	rs2808614	chr1:231550168	A/G	cg06096015	chr1:231504339	EGLN1	-0.41	-5.78	-0.33	2.13e-8	Hemoglobin concentration;
CESC	cis	rs2637266	1.000	rs2894339	chr10:78354104	G/A	cg18941641	chr10:78392320	NA	0.42	7.79	0.43	1.49e-13	Pulmonary function;
CESC	cis	rs909674	0.541	rs5750812	chr22:39793079	G/A	cg02038168	chr22:39784481	NA	-0.63	-8.12	-0.45	1.71e-14	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19754013	chr1:156252628	SMG5;TMEM79	0.57	6.04	0.35	5.06e-9	Gut microbiome composition (summer);
CESC	cis	rs708547	0.647	rs1718831	chr4:57886946	T/G	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.42	-5.52	-0.32	8.06e-8	Response to bleomycin (chromatid breaks);
CESC	cis	rs7071206	0.947	rs11002226	chr10:79399656	T/A	cg23888215	chr10:79422304	NA	-0.53	-5.64	-0.33	4.4e-8	Bone mineral density;
CESC	cis	rs14403	0.602	rs2994330	chr1:243647208	G/T	cg21452805	chr1:244014465	NA	0.62	6.47	0.37	4.7e-10	Schizophrenia;
CESC	cis	rs36051895	0.632	rs10974983	chr9:5149657	G/T	cg02405213	chr9:5042618	JAK2	-0.53	-6.41	-0.37	6.47e-10	Pediatric autoimmune diseases;
CESC	cis	rs7223966	1.000	rs6504168	chr17:61697469	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.57	6.68	0.38	1.41e-10	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs9649213	0.593	rs6975156	chr7:97925534	T/C	cg24562669	chr7:97807699	LMTK2	0.48	6.92	0.39	3.3e-11	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26828057	chr1:38259483	MANEAL	0.57	6.01	0.35	6.01e-9	Gut microbiome composition (summer);
CESC	cis	rs7267979	0.933	rs1130694	chr20:25276297	G/A	cg08601574	chr20:25228251	PYGB	0.38	5.45	0.32	1.16e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs736408	0.522	rs6445535	chr3:52771468	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	8.16	0.45	1.36e-14	Bipolar disorder;
CESC	cis	rs62064224	0.714	rs4794917	chr17:30636146	C/G	cg18200150	chr17:30822561	MYO1D	0.38	5.14	0.3	5.46e-7	Schizophrenia;
CESC	cis	rs1862618	0.641	rs2591954	chr5:56245044	G/C	cg22800045	chr5:56110881	MAP3K1	-0.61	-7.83	-0.43	1.21e-13	Initial pursuit acceleration;
CESC	cis	rs2625529	0.730	rs7403191	chr15:72160964	C/T	cg16672083	chr15:72433130	SENP8	-0.44	-6.44	-0.37	5.69e-10	Red blood cell count;
CESC	cis	rs10791097	0.703	rs11222360	chr11:130730871	C/T	cg12179176	chr11:130786555	SNX19	0.55	8.15	0.45	1.41e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs796364	1.000	rs281794	chr2:200846666	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.84	8.14	0.45	1.53e-14	Schizophrenia;
CESC	cis	rs9640161	0.789	rs36035506	chr7:150057843	C/T	cg10018233	chr7:150070692	REPIN1	0.39	5.59	0.32	5.7e-8	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs7615952	0.673	rs7632557	chr3:125634881	G/C	cg05084668	chr3:125655381	ALG1L	-0.49	-5.46	-0.32	1.09e-7	Blood pressure (smoking interaction);
CESC	cis	rs11718455	0.960	rs1852036	chr3:44003862	C/T	cg08738300	chr3:44038990	NA	0.45	5.98	0.35	7e-9	Coronary artery disease;
CESC	cis	rs9443645	0.527	rs9352663	chr6:79558164	T/C	cg05283184	chr6:79620031	NA	-0.37	-5.32	-0.31	2.26e-7	Intelligence (multi-trait analysis);
CESC	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg07157834	chr1:205819609	PM20D1	0.82	13.35	0.63	1.97e-31	Menarche (age at onset);
CESC	cis	rs4563143	0.675	rs55884228	chr19:29243897	G/T	cg14983838	chr19:29218262	NA	0.5	6.16	0.35	2.67e-9	Methadone dose in opioid dependence;
CESC	cis	rs1005277	0.579	rs1780115	chr10:38524773	C/T	cg00409905	chr10:38381863	ZNF37A	-0.52	-7.03	-0.4	1.8e-11	Extrinsic epigenetic age acceleration;
CESC	cis	rs7103648	0.695	rs10838726	chr11:47568344	C/G	cg20307385	chr11:47447363	PSMC3	0.83	12.3	0.6	8.59e-28	Diastolic blood pressure;Systolic blood pressure;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg14932796	chr17:55038330	COIL	0.47	6.65	0.38	1.63e-10	Systemic lupus erythematosus;
CESC	cis	rs3820928	0.839	rs13413292	chr2:227893747	G/C	cg11843606	chr2:227700838	RHBDD1	-0.48	-6.38	-0.36	7.78e-10	Pulmonary function;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12612807	chr7:1522949	INTS1	-0.53	-6.1	-0.35	3.66e-9	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13883366	chr10:29747149	SVIL	0.48	6.05	0.35	4.92e-9	Gut microbiome composition (summer);
CESC	cis	rs9911578	0.835	rs1990008	chr17:56459408	C/G	cg25039879	chr17:56429692	SUPT4H1	-0.4	-5.23	-0.31	3.39e-7	Intelligence (multi-trait analysis);
CESC	cis	rs6430585	0.527	rs961360	chr2:136393658	A/G	cg07169764	chr2:136633963	MCM6	1.01	11.6	0.58	1.92e-25	Corneal structure;
CESC	cis	rs5758659	0.622	rs129856	chr22:42399396	C/G	cg04733989	chr22:42467013	NAGA	0.43	5.72	0.33	2.81e-8	Cognitive function;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05237023	chr16:75182837	ZFP1	0.71	7.85	0.43	1e-13	Gut microbiome composition (summer);
CESC	trans	rs9951602	0.512	rs8089247	chr18:76651467	C/A	cg02800362	chr5:177631904	HNRNPAB	0.66	8.64	0.47	5.41e-16	Obesity-related traits;
CESC	cis	rs7560272	0.502	rs13013228	chr2:73925216	G/A	cg20560298	chr2:73613845	ALMS1	0.45	6.19	0.36	2.22e-9	Schizophrenia;
CESC	cis	rs34311866	0.808	rs3755958	chr4:963042	C/A	cg07828340	chr4:882639	GAK	0.86	6.68	0.38	1.37e-10	Parkinson's disease;
CESC	cis	rs853679	0.517	rs4711165	chr6:28115184	T/G	cg18032046	chr6:28092343	ZSCAN16	-0.6	-6.84	-0.39	5.51e-11	Depression;
CESC	cis	rs10504229	0.906	rs113857287	chr8:58191683	T/C	cg24829409	chr8:58192753	C8orf71	-0.77	-10.02	-0.52	2.95e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs9858542	0.953	rs9837027	chr3:49597013	C/T	cg07274523	chr3:49395745	GPX1	0.65	8.34	0.46	3.99e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20784733	chr7:66205729	RABGEF1	0.62	7.36	0.41	2.29e-12	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07798295	chr16:89715839	CHMP1A	-0.58	-6.62	-0.38	1.96e-10	Gut microbiome composition (summer);
CESC	cis	rs4077515	0.874	rs35670379	chr9:139270606	T/C	cg14169450	chr9:139327907	INPP5E	0.42	6.02	0.35	5.73e-9	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs7666738	0.830	rs2019163	chr4:99022747	C/T	cg18180107	chr4:99064573	C4orf37	0.41	5.39	0.31	1.57e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1443512	0.812	rs1975470	chr12:54336841	G/A	cg17410650	chr12:54324560	NA	-0.48	-8.07	-0.44	2.41e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
CESC	cis	rs9584850	1.000	rs9584850	chr13:99101426	G/C	cg22223119	chr13:99095684	FARP1	-0.36	-5.23	-0.31	3.41e-7	Neuroticism;
CESC	cis	rs9322193	0.923	rs2880436	chr6:150180259	T/C	cg09699651	chr6:150184138	LRP11	0.51	6.47	0.37	4.64e-10	Lung cancer;
CESC	cis	rs722599	0.639	rs12882676	chr14:75272433	A/G	cg11812906	chr14:75593930	NEK9	0.41	5.04	0.3	8.64e-7	IgG glycosylation;
CESC	cis	rs17125944	0.505	rs2295826	chr14:53174923	C/T	cg00686598	chr14:53173677	PSMC6	-1.29	-11.5	-0.58	4.39e-25	Alzheimer's disease (late onset);
CESC	cis	rs62005083	0.541	rs61059815	chr14:74536465	A/T	cg05179529	chr14:74551516	LIN52;ALDH6A1	0.55	5.65	0.33	4.03e-8	Mean corpuscular volume;
CESC	cis	rs6142102	0.625	rs1883707	chr20:32552587	A/G	cg08999081	chr20:33150536	PIGU	-0.34	-5.25	-0.31	3.07e-7	Skin pigmentation;
CESC	cis	rs7580658	0.963	rs6732279	chr2:128089540	G/T	cg10021288	chr2:128175891	PROC	-0.41	-6.46	-0.37	5.07e-10	Protein C levels;
CESC	cis	rs6987853	0.688	rs2923433	chr8:42418723	T/C	cg09913449	chr8:42400586	C8orf40	0.44	7.24	0.41	4.9e-12	Mean corpuscular hemoglobin concentration;
CESC	cis	rs7589342	0.628	rs35622044	chr2:106404095	G/A	cg16077055	chr2:106428750	NCK2	0.53	6.82	0.39	6.32e-11	Addiction;
CESC	cis	rs11828289	0.599	rs75341566	chr11:23186941	C/A	cg20040320	chr11:23191996	NA	-0.68	-5.87	-0.34	1.31e-8	Cancer;
CESC	cis	rs708547	0.957	rs781667	chr4:57798469	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.7	7.87	0.44	8.9e-14	Response to bleomycin (chromatid breaks);
CESC	cis	rs9488822	0.676	rs1556857	chr6:116325559	T/C	cg15226275	chr6:116381976	FRK	0.25	6.22	0.36	1.94e-9	Cholesterol, total;LDL cholesterol;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04090599	chr15:65281881	SPG21	0.54	6.19	0.36	2.29e-9	Gut microbiome composition (summer);
CESC	cis	rs2710642	0.678	rs11125946	chr2:63298150	C/T	cg17519650	chr2:63277830	OTX1	-0.63	-7.69	-0.43	2.93e-13	LDL cholesterol levels;LDL cholesterol;
CESC	cis	rs6665290	0.669	rs12406714	chr1:227177061	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.12	-24.44	-0.83	7.56e-70	Myeloid white cell count;
CESC	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg03188948	chr7:1209495	NA	0.73	7.17	0.4	7.66e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2997447	0.761	rs61776618	chr1:26456709	A/G	cg24596570	chr1:26146463	FAM54B;LOC646471	0.59	5.16	0.3	4.76e-7	QRS complex (12-leadsum);
CESC	trans	rs4295623	0.553	rs11250163	chr8:11596437	G/T	cg15556689	chr8:8085844	FLJ10661	0.52	6.03	0.35	5.41e-9	Morning vs. evening chronotype;
CESC	cis	rs2832191	0.692	rs2254872	chr21:30414724	C/T	cg24692254	chr21:30365293	RNF160	1.02	18.52	0.75	1.02e-49	Dental caries;
CESC	cis	rs2404602	0.647	rs12440511	chr15:76993135	A/G	cg06336613	chr15:77223807	RCN2	0.41	5.15	0.3	5.04e-7	Blood metabolite levels;
CESC	cis	rs7809950	1.000	rs2520277	chr7:107130234	C/T	cg23024343	chr7:107201750	COG5	-0.42	-5.86	-0.34	1.37e-8	Coronary artery disease;
CESC	cis	rs4718428	0.705	rs4717328	chr7:66352665	T/C	cg18252515	chr7:66147081	NA	-0.46	-5.1	-0.3	6.48e-7	Corneal structure;
CESC	cis	rs6502050	0.805	rs7406137	chr17:80084465	T/C	cg23985595	chr17:80112537	CCDC57	0.4	6.25	0.36	1.66e-9	Life satisfaction;
CESC	cis	rs6963495	0.818	rs73190184	chr7:105163736	C/T	cg13798780	chr7:105162888	PUS7	0.78	8.06	0.44	2.68e-14	Bipolar disorder (body mass index interaction);
CESC	cis	rs35110281	0.501	rs162381	chr21:44920915	A/G	cg01579765	chr21:45077557	HSF2BP	0.4	6.35	0.36	9.35e-10	Mean corpuscular volume;
CESC	cis	rs1620921	0.505	rs4708882	chr6:161203182	C/T	cg01280913	chr6:161186852	NA	-0.36	-5.27	-0.31	2.81e-7	Lipoprotein (a) - cholesterol levels;
CESC	cis	rs7843479	0.601	rs727693	chr8:21850116	A/G	cg17168535	chr8:21777572	XPO7	0.72	11.46	0.58	5.69e-25	Mean corpuscular volume;
CESC	cis	rs9929218	0.539	rs1125557	chr16:68809599	G/A	cg02972257	chr16:68554789	NA	-0.42	-5.25	-0.31	3.17e-7	Colorectal cancer;
CESC	cis	rs35079168	0.923	rs12115573	chr9:137288782	G/A	cg13941235	chr9:137270186	RXRA	-0.31	-5.51	-0.32	8.59e-8	Intelligence;
CESC	cis	rs72781680	1.000	rs17763442	chr2:24255991	C/T	cg08917208	chr2:24149416	ATAD2B	1.07	8.78	0.47	2.02e-16	Lymphocyte counts;
CESC	cis	rs1395	0.778	rs4665959	chr2:27443256	C/T	cg22903471	chr2:27725779	GCKR	-0.42	-5.13	-0.3	5.57e-7	Blood metabolite levels;
CESC	cis	rs514406	0.570	rs1332776	chr1:53189816	C/T	cg24675658	chr1:53192096	ZYG11B	-0.68	-9.65	-0.51	4.36e-19	Monocyte count;
CESC	cis	rs11969893	0.850	rs3734351	chr6:101307131	C/T	cg12253828	chr6:101329408	ASCC3	1.13	9.61	0.51	5.96e-19	Economic and political preferences (immigration/crime);
CESC	cis	rs7666738	0.830	rs6532701	chr4:98745134	C/T	cg05340658	chr4:99064831	C4orf37	0.76	11.16	0.57	5.63e-24	Colonoscopy-negative controls vs population controls;
CESC	cis	rs5750830	0.649	rs5750822	chr22:39826788	C/T	cg11247378	chr22:39784982	NA	-0.67	-9.75	-0.51	2.18e-19	Intelligence (multi-trait analysis);
CESC	trans	rs2823962	0.759	rs2211987	chr21:18016656	T/C	cg06419850	chr17:4688683	VMO1	-0.42	-6.13	-0.35	3.23e-9	Amyotrophic lateral sclerosis;
CESC	cis	rs4975709	0.589	rs4975707	chr5:1864028	C/T	cg20790798	chr5:1857306	NA	-0.4	-5.5	-0.32	9.07e-8	Cardiovascular disease risk factors;
CESC	cis	rs10504073	0.647	rs10957357	chr8:49988587	C/A	cg00325661	chr8:49890786	NA	0.53	7.81	0.43	1.32e-13	Blood metabolite ratios;
CESC	cis	rs3820928	0.900	rs6754155	chr2:227784961	A/G	cg05526886	chr2:227700861	RHBDD1	-0.46	-5.89	-0.34	1.16e-8	Pulmonary function;
CESC	cis	rs6461049	0.800	rs2398706	chr7:2156338	A/T	cg08027265	chr7:2291960	NA	-0.43	-6.62	-0.38	2.02e-10	Schizophrenia;
CESC	cis	rs11690935	0.959	rs13419987	chr2:172623914	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.97	-14.95	-0.68	4.66e-37	Schizophrenia;
CESC	trans	rs208520	0.779	rs208451	chr6:66906155	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.84	-9.54	-0.51	9.64e-19	Exhaled nitric oxide output;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg20376421	chr12:56546193	MYL6B	-0.44	-6.32	-0.36	1.08e-9	Fibrinogen levels;
CESC	cis	rs2108622	0.727	rs2158511	chr19:15986647	C/T	cg13772218	chr19:15982569	NA	0.3	5.91	0.34	1.07e-8	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CESC	cis	rs13191362	0.935	rs34063386	chr6:163041271	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.89	9.97	0.52	4.36e-20	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs2288073	0.801	rs6757275	chr2:24375230	A/G	cg06627628	chr2:24431161	ITSN2	-0.71	-9.06	-0.49	2.87e-17	Venous thromboembolism (SNP x SNP interaction);
CESC	cis	rs1707322	0.827	rs6694302	chr1:46245645	A/T	cg05343316	chr1:45956843	TESK2	0.47	5.67	0.33	3.68e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs6460942	0.597	rs13227809	chr7:12525557	G/A	cg06484146	chr7:12443880	VWDE	-0.71	-7.69	-0.43	2.88e-13	Coronary artery disease;
CESC	cis	rs1348850	0.837	rs4243388	chr2:178284604	T/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.86	12.77	0.62	1.97e-29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs2836974	0.681	rs8128827	chr21:40710547	C/T	cg11644478	chr21:40555479	PSMG1	0.95	14.26	0.66	1.25e-34	Cognitive function;
CESC	cis	rs4629710	0.545	rs11755717	chr6:131547028	A/T	cg20988616	chr6:131958144	ENPP3	0.4	5.09	0.3	6.7e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs798554	0.759	rs1636255	chr7:2892804	A/C	cg19346786	chr7:2764209	NA	0.37	5.36	0.31	1.81e-7	Height;
CESC	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	7.83	0.43	1.17e-13	Prudent dietary pattern;
CESC	cis	rs8114671	0.562	rs725521	chr20:33516071	T/C	cg24642439	chr20:33292090	TP53INP2	0.43	5.19	0.3	4.19e-7	Height;
CESC	cis	rs12413816	0.963	rs10796116	chr10:13762786	C/T	cg16485048	chr10:13749193	FRMD4A	-0.53	-7.57	-0.42	6.25e-13	Red cell distribution width;
CESC	cis	rs2439831	0.850	rs28504496	chr15:44016883	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.68	6.42	0.37	6.21e-10	Lung cancer in ever smokers;
CESC	cis	rs9796	0.840	rs1009913	chr15:41331050	C/T	cg18705301	chr15:41695430	NDUFAF1	0.4	6.02	0.35	5.74e-9	Menopause (age at onset);
CESC	cis	rs4974559	0.739	rs6845586	chr4:1323070	G/A	cg02980000	chr4:1222292	CTBP1	0.81	7.22	0.41	5.48e-12	Systolic blood pressure;
CESC	cis	rs6088580	0.570	rs6058057	chr20:33065283	G/A	cg08999081	chr20:33150536	PIGU	0.66	11.57	0.58	2.49e-25	Glomerular filtration rate (creatinine);
CESC	cis	rs13394619	0.935	rs6746291	chr2:11728381	T/C	cg07314298	chr2:11723111	GREB1	-0.47	-6.71	-0.38	1.19e-10	Endometriosis;
CESC	cis	rs1348850	0.567	rs880899	chr2:178532416	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.54	7.25	0.41	4.54e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs10870270	0.956	rs4880405	chr10:133787021	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.84	-11.79	-0.59	4.4e-26	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs1843834	0.505	rs7585047	chr2:225373897	C/T	cg12698349	chr2:225449008	CUL3	0.62	8.7	0.47	3.49e-16	IgE levels in asthmatics (D.p. specific);
CESC	cis	rs9300255	0.679	rs4759409	chr12:123719585	G/C	cg19016782	chr12:123741754	C12orf65	-0.48	-6.7	-0.38	1.22e-10	Neutrophil percentage of white cells;
CESC	cis	rs7833790	0.963	rs6473312	chr8:82732515	C/A	cg07697082	chr8:82753677	SNX16	0.38	5.21	0.31	3.72e-7	Diastolic blood pressure;
CESC	cis	rs9309473	0.687	rs6748040	chr2:73609928	A/G	cg20560298	chr2:73613845	ALMS1	0.46	6.42	0.37	6.16e-10	Metabolite levels;
CESC	cis	rs7660520	0.524	rs4862100	chr4:183732709	G/T	cg12524338	chr4:183729343	NA	0.54	5.21	0.3	3.86e-7	Pediatric autoimmune diseases;
CESC	cis	rs7296418	0.599	rs2277343	chr12:123794450	A/T	cg05973401	chr12:123451056	ABCB9	0.43	5.45	0.32	1.14e-7	Platelet count;
CESC	cis	rs7044106	0.762	rs1530370	chr9:123424552	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.62	8.17	0.45	1.32e-14	Hip circumference adjusted for BMI;
CESC	cis	rs9640161	0.789	rs6964110	chr7:150041836	A/C	cg13722127	chr7:150037890	RARRES2	0.36	5.24	0.31	3.27e-7	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs172166	0.694	rs203877	chr6:28048624	T/C	cg12963246	chr6:28129442	ZNF389	0.41	6.0	0.35	6.29e-9	Cardiac Troponin-T levels;
CESC	cis	rs832540	0.629	rs3309	chr5:56092779	A/T	cg22800045	chr5:56110881	MAP3K1	-0.52	-6.26	-0.36	1.53e-9	Coronary artery disease;
CESC	cis	rs7089973	0.966	rs36089581	chr10:116623059	G/C	cg23260525	chr10:116636907	FAM160B1	0.38	6.1	0.35	3.76e-9	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs116095464	0.558	rs10057492	chr5:239503	T/C	cg22496380	chr5:211416	CCDC127	-0.75	-8.78	-0.47	2.13e-16	Breast cancer;
CESC	cis	rs910316	0.967	rs11624893	chr14:75660124	A/G	cg08847533	chr14:75593920	NEK9	-0.9	-15.59	-0.69	2.49e-39	Height;
CESC	cis	rs9902453	1.000	rs59274738	chr17:28437635	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	7.96	0.44	5.17e-14	Coffee consumption (cups per day);
CESC	cis	rs515186	1	rs515186	chr6:36397492	T/G	cg07856975	chr6:36356162	ETV7	0.36	5.38	0.31	1.67e-7	Mean platelet volume;
CESC	cis	rs2011503	1.000	rs4808968	chr19:19644402	C/T	cg11584989	chr19:19387371	SF4	0.58	6.67	0.38	1.52e-10	Bipolar disorder;
CESC	cis	rs2279817	0.818	rs34036216	chr1:17986046	C/T	cg21791023	chr1:18019539	ARHGEF10L	-0.66	-8.02	-0.44	3.39e-14	Neuroticism;
CESC	trans	rs5769765	0.862	rs56377703	chr22:50306940	C/T	cg09872104	chr7:134855509	C7orf49	-0.55	-6.26	-0.36	1.55e-9	Schizophrenia;
CESC	cis	rs6598955	0.670	rs6663950	chr1:26560131	T/C	cg00852783	chr1:26633632	UBXN11	0.42	6.17	0.35	2.55e-9	Obesity-related traits;
CESC	cis	rs4699052	0.963	rs11943325	chr4:104178393	T/C	cg16532752	chr4:104119610	CENPE	-0.44	-6.16	-0.35	2.65e-9	Testicular germ cell tumor;
CESC	cis	rs9393777	0.623	rs9358947	chr6:26479000	G/A	cg12826209	chr6:26865740	GUSBL1	0.65	6.85	0.39	5.16e-11	Intelligence (multi-trait analysis);
CESC	cis	rs4835473	0.932	rs6852502	chr4:144908327	A/T	cg25736465	chr4:144833511	NA	0.43	6.47	0.37	4.59e-10	Immature fraction of reticulocytes;
CESC	cis	rs1348850	0.526	rs935426	chr2:178369433	T/C	cg22681709	chr2:178499509	PDE11A	-0.5	-5.26	-0.31	2.97e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs7107356	1	rs7107356	chr11:47676170	A/G	cg20307385	chr11:47447363	PSMC3	0.68	9.81	0.52	1.42e-19	Neuroticism;Neuroticism (multi-trait analysis);
CESC	cis	rs2447097	0.935	rs2447095	chr17:2293420	A/G	cg27406664	chr17:2294951	MNT	0.4	6.75	0.38	9.07e-11	Autism spectrum disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22320231	chr17:28903436	LRRC37B2	-0.5	-6.48	-0.37	4.39e-10	Gut microbiome composition (summer);
CESC	cis	rs820218	0.926	rs864234	chr17:73663313	C/A	cg01592526	chr17:73663357	RECQL5;SAP30BP	0.43	5.53	0.32	7.51e-8	Rotator cuff tears;
CESC	cis	rs72945132	0.882	rs72947012	chr11:70149472	G/A	cg00319359	chr11:70116639	PPFIA1	0.82	7.48	0.42	1.07e-12	Coronary artery disease;
CESC	cis	rs2860975	0.542	rs1926705	chr10:96818418	C/T	cg09036531	chr10:96991505	NA	-0.37	-5.3	-0.31	2.45e-7	Immune response to smallpox vaccine (IL-6);
CESC	cis	rs270601	0.770	rs4361510	chr5:131599647	C/T	cg24060327	chr5:131705240	SLC22A5	-0.47	-6.09	-0.35	4.03e-9	Acylcarnitine levels;
CESC	cis	rs6088590	0.707	rs67159833	chr20:33488079	T/C	cg08999081	chr20:33150536	PIGU	0.58	8.23	0.45	8.75e-15	Coronary artery disease;
CESC	cis	rs11030122	0.702	rs1452047	chr11:3991648	A/C	cg18678763	chr11:4115507	RRM1	-0.49	-6.42	-0.37	6.34e-10	Mean platelet volume;Platelet distribution width;
CESC	cis	rs477692	1.000	rs513736	chr10:131406489	C/T	cg05714579	chr10:131428358	MGMT	0.48	6.57	0.37	2.71e-10	Response to temozolomide;
CESC	cis	rs2842992	0.672	rs4708845	chr6:160219601	T/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.76	9.9	0.52	7.05e-20	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs2108622	0.649	rs113055956	chr19:15977312	T/A	cg13772218	chr19:15982569	NA	0.27	5.18	0.3	4.47e-7	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CESC	cis	rs1800795	0.901	rs2069833	chr7:22767664	C/T	cg26061582	chr7:22766209	IL6	0.47	5.39	0.31	1.58e-7	Cerebrospinal fluid clusterin levels in APOEe4- carriers;
CESC	cis	rs2985684	0.740	rs2883438	chr14:50044392	T/C	cg04989706	chr14:50066350	PPIL5	-0.46	-5.16	-0.3	4.92e-7	Carotid intima media thickness;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11662638	chr2:45878864	PRKCE	0.59	6.99	0.39	2.29e-11	Gut microbiome composition (summer);
CESC	cis	rs798554	0.724	rs798498	chr7:2795882	T/G	cg09658497	chr7:2847517	GNA12	-0.43	-6.14	-0.35	3.07e-9	Height;
CESC	cis	rs6087990	0.735	rs2065576	chr20:31389009	C/T	cg13636640	chr20:31349939	DNMT3B	0.79	12.92	0.62	6.22e-30	Ulcerative colitis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05014452	chr15:79603196	TMED3	-0.53	-6.31	-0.36	1.17e-9	Gut microbiome composition (summer);
CESC	trans	rs1728785	1.000	rs1728780	chr16:68567642	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.61	7.43	0.42	1.5e-12	Ulcerative colitis;
CESC	cis	rs4689388	0.926	rs10937719	chr4:6295322	C/G	cg14416269	chr4:6271139	WFS1	0.47	7.74	0.43	2.05e-13	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs875971	0.545	rs12673308	chr7:65631361	C/A	cg25405998	chr7:65216604	CCT6P1	0.45	5.06	0.3	7.71e-7	Aortic root size;
CESC	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.49	-5.2	-0.3	4.06e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7666738	0.830	rs11931166	chr4:99054187	A/T	cg24818145	chr4:99064322	C4orf37	0.38	5.04	0.3	8.49e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4722166	0.598	rs4722180	chr7:22805072	A/G	cg05472934	chr7:22766657	IL6	0.42	5.71	0.33	2.99e-8	Lung cancer;
CESC	cis	rs8014204	0.753	rs6574199	chr14:75356103	T/C	cg26191576	chr14:75389716	RPS6KL1	0.35	5.03	0.3	9.15e-7	Caffeine consumption;
CESC	cis	rs6088590	0.965	rs6119534	chr20:33441257	C/T	cg08999081	chr20:33150536	PIGU	0.57	8.67	0.47	4.32e-16	Coronary artery disease;
CESC	cis	rs909002	0.624	rs11590964	chr1:32146425	C/T	cg13919466	chr1:32135498	COL16A1	-0.38	-6.23	-0.36	1.81e-9	Intelligence (multi-trait analysis);
CESC	cis	rs853679	0.546	rs34371502	chr6:28081758	T/C	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.85	5.58	0.32	6.04e-8	Depression;
CESC	cis	rs1448094	0.549	rs12308898	chr12:86233678	G/A	cg00310523	chr12:86230176	RASSF9	0.37	5.49	0.32	9.48e-8	Major depressive disorder;
CESC	cis	rs9905704	0.918	rs302852	chr17:56685214	C/T	cg12560992	chr17:57184187	TRIM37	0.59	6.98	0.39	2.34e-11	Testicular germ cell tumor;
CESC	cis	rs875971	0.522	rs1701760	chr7:65473688	A/G	cg11764359	chr7:65958608	NA	0.66	8.59	0.47	7.42e-16	Aortic root size;
CESC	cis	rs10791323	0.581	rs2723608	chr11:133710149	A/G	cg06766960	chr11:133703094	NA	-0.41	-5.77	-0.33	2.24e-8	Childhood ear infection;
CESC	cis	rs17384381	0.863	rs12140272	chr1:85789757	G/A	cg16011679	chr1:85725395	C1orf52	0.67	6.96	0.39	2.64e-11	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18864497	chr6:7313384	SSR1	0.59	6.35	0.36	9.1e-10	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15876657	chr6:144416565	SF3B5	0.66	7.44	0.42	1.41e-12	Gut microbiome composition (summer);
CESC	cis	rs853679	1.000	rs1778508	chr6:28229881	C/T	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	-0.68	-7.18	-0.4	7.04e-12	Depression;
CESC	cis	rs193541	0.530	rs9327272	chr5:122073548	T/C	cg19412675	chr5:122181750	SNX24	0.44	5.2	0.3	3.95e-7	Glucose homeostasis traits;
CESC	cis	rs6456156	0.524	rs6932740	chr6:167466439	G/A	cg07741184	chr6:167504864	NA	0.35	6.08	0.35	4.1e-9	Primary biliary cholangitis;
CESC	cis	rs7918232	0.567	rs4749215	chr10:27312005	T/C	cg14240646	chr10:27532245	ACBD5	-0.49	-5.35	-0.31	1.87e-7	Breast cancer;
CESC	cis	rs4975709	0.589	rs931508	chr5:1861224	C/G	cg20790798	chr5:1857306	NA	-0.4	-5.35	-0.31	1.93e-7	Cardiovascular disease risk factors;
CESC	cis	rs9902453	0.765	rs2127001	chr17:28098219	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-10.41	-0.54	1.71e-21	Coffee consumption (cups per day);
CESC	cis	rs67311347	1.000	rs28536038	chr3:40496382	A/C	cg09455208	chr3:40491958	NA	0.5	7.96	0.44	5.11e-14	Renal cell carcinoma;
CESC	cis	rs12479064	0.724	rs112900993	chr2:99948805	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.66	-7.8	-0.43	1.4e-13	Chronic sinus infection;
CESC	cis	rs9399137	0.507	rs13196486	chr6:135283874	C/G	cg24558204	chr6:135376177	HBS1L	0.7	9.64	0.51	4.87e-19	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg24594830	chr12:77459352	E2F7	-0.5	-6.51	-0.37	3.82e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs12477438	0.501	rs6542868	chr2:99782848	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.79	12.62	0.61	6.6e-29	Chronic sinus infection;
CESC	cis	rs7605827	0.930	rs6722963	chr2:15527105	C/T	cg19274914	chr2:15703543	NA	0.35	6.27	0.36	1.43e-9	Educational attainment (years of education);
CESC	cis	rs1580019	0.587	rs7805311	chr7:32558302	A/G	cg06627557	chr7:32535165	LSM5;AVL9	-1.04	-17.97	-0.74	9.08e-48	Cognitive ability;
CESC	cis	rs8077577	0.895	rs11655588	chr17:18107451	C/T	cg16794390	chr17:18148240	FLII	-0.42	-5.73	-0.33	2.66e-8	Obesity-related traits;
CESC	cis	rs1200821	0.529	rs2505707	chr10:37801254	T/C	cg25427524	chr10:38739819	LOC399744	-0.44	-5.73	-0.33	2.73e-8	Hemostatic factors and hematological phenotypes;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg25096582	chr14:35183928	CFL2	-0.47	-6.43	-0.37	5.84e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs4555082	0.957	rs2975216	chr14:105713134	T/C	cg10792982	chr14:105748885	BRF1	0.42	5.81	0.34	1.75e-8	Mean platelet volume;Platelet distribution width;
CESC	cis	rs17401966	1.000	rs12129035	chr1:10291166	G/A	cg15208524	chr1:10270712	KIF1B	0.47	6.14	0.35	3.07e-9	Hepatocellular carcinoma;
CESC	cis	rs6783573	0.535	rs6442006	chr3:46629382	C/G	cg27371741	chr3:46619158	LRRC2;TDGF1	-0.35	-5.41	-0.32	1.41e-7	Cerebrospinal fluid biomarker levels;
CESC	cis	rs4604732	0.631	rs12038793	chr1:247624262	C/T	cg12754571	chr1:247694271	LOC148824;OR2C3	-0.48	-6.09	-0.35	4.03e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs10504229	0.683	rs16921937	chr8:58145010	A/G	cg02725872	chr8:58115012	NA	-0.44	-6.89	-0.39	4.12e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs798554	0.757	rs1182178	chr7:2873763	G/A	cg04166393	chr7:2884313	GNA12	0.59	7.64	0.42	4.02e-13	Height;
CESC	cis	rs7296418	0.630	rs11057238	chr12:123767971	C/A	cg05973401	chr12:123451056	ABCB9	0.43	5.46	0.32	1.07e-7	Platelet count;
CESC	cis	rs8040855	0.597	rs994989	chr15:85660716	G/C	cg08123816	chr15:85640762	PDE8A	-0.4	-5.72	-0.33	2.82e-8	Bulimia nervosa;
CESC	cis	rs6500395	0.962	rs9938126	chr16:48572121	A/T	cg04672837	chr16:48644449	N4BP1	0.44	5.29	0.31	2.57e-7	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs67478160	0.643	rs4900594	chr14:104251006	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.5	-6.96	-0.39	2.72e-11	Schizophrenia;
CESC	cis	rs9894429	0.690	rs12949956	chr17:79542813	C/T	cg18240062	chr17:79603768	NPLOC4	-0.85	-12.34	-0.6	5.95e-28	Eye color traits;
CESC	cis	rs7666738	0.830	rs58696666	chr4:99006913	C/T	cg05340658	chr4:99064831	C4orf37	0.8	12.44	0.61	2.83e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs709400	0.930	rs10134399	chr14:104083457	G/A	cg24130564	chr14:104152367	KLC1	-0.42	-5.12	-0.3	5.96e-7	Body mass index;
CESC	cis	rs599083	0.530	rs640569	chr11:68184820	A/G	cg01657329	chr11:68192670	LRP5	0.44	5.21	0.3	3.85e-7	Bone mineral density (spine);
CESC	cis	rs17384381	0.859	rs12724823	chr1:85906385	G/T	cg16011679	chr1:85725395	C1orf52	0.74	7.35	0.41	2.47e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.73	-10.3	-0.53	3.88e-21	Prudent dietary pattern;
CESC	cis	rs6674176	0.561	rs4660263	chr1:44421433	A/C	cg13606994	chr1:44402422	ARTN	-0.37	-5.55	-0.32	6.85e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs7647973	0.580	rs35218722	chr3:49275805	A/G	cg06212747	chr3:49208901	KLHDC8B	0.71	10.86	0.55	5.86e-23	Menarche (age at onset);
CESC	cis	rs11098499	0.731	rs6846966	chr4:120293208	A/G	cg09307838	chr4:120376055	NA	0.86	11.82	0.59	3.43e-26	Corneal astigmatism;
CESC	cis	rs17655565	0.581	rs74672767	chr12:52764049	C/A	cg00777198	chr12:52828273	KRT75	0.35	5.07	0.3	7.59e-7	Plasma amyloid beta peptide concentrations (ABx-42);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg04588562	chr17:46756094	NA	-0.41	-6.51	-0.37	3.76e-10	Gambling;
CESC	cis	rs4268898	0.717	rs2543662	chr2:24443271	G/T	cg06627628	chr2:24431161	ITSN2	0.85	10.38	0.54	2.07e-21	Asthma;
CESC	cis	rs7103648	0.553	rs12803857	chr11:47890172	G/A	cg20307385	chr11:47447363	PSMC3	0.8	10.73	0.55	1.57e-22	Diastolic blood pressure;Systolic blood pressure;
CESC	cis	rs8027181	0.617	rs12438864	chr15:73095668	T/C	cg25632853	chr15:73088954	NA	0.38	6.14	0.35	2.96e-9	Triglyceride levels;
CESC	cis	rs7084402	0.902	rs1658484	chr10:60288543	G/A	cg07615347	chr10:60278583	BICC1	0.59	9.2	0.49	1.13e-17	Refractive error;
CESC	cis	rs703842	1.000	rs4646536	chr12:58157988	A/G	cg00677455	chr12:58241039	CTDSP2	0.53	7.06	0.4	1.49e-11	Multiple sclerosis;
CESC	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg24642844	chr7:1081250	C7orf50	-0.76	-9.45	-0.5	1.94e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7923609	0.967	rs4454603	chr10:65012750	C/T	cg01631684	chr10:65280961	REEP3	-0.44	-5.48	-0.32	9.99e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs2243480	1.000	rs7794661	chr7:65389730	T/C	cg13147721	chr7:65941812	NA	-0.85	-8.05	-0.44	2.87e-14	Diabetic kidney disease;
CESC	cis	rs34172651	0.917	rs172066	chr16:24756449	C/T	cg06028605	chr16:24865363	SLC5A11	0.35	5.4	0.31	1.46e-7	Intelligence (multi-trait analysis);
CESC	cis	rs561341	1.000	rs546748	chr17:30324293	A/C	cg23018236	chr17:30244563	NA	-0.45	-5.49	-0.32	9.19e-8	Hip circumference adjusted for BMI;
CESC	cis	rs644799	0.965	rs598876	chr11:95560853	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	14.27	0.66	1.19e-34	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs4654899	1.000	rs7521675	chr1:21424070	T/C	cg05370193	chr1:21551575	ECE1	0.39	5.95	0.34	8.34e-9	Superior frontal gyrus grey matter volume;
CESC	cis	rs6964587	0.655	rs6465351	chr7:91773213	T/C	cg01689657	chr7:91764605	CYP51A1	0.26	5.1	0.3	6.44e-7	Breast cancer;
CESC	cis	rs2034088	0.833	rs9748016	chr17:410451	G/T	cg13332499	chr17:408570	NA	0.48	8.49	0.46	1.51e-15	Hip circumference adjusted for BMI;
CESC	cis	rs3096299	0.967	rs2911256	chr16:89485096	G/C	cg08822215	chr16:89438651	ANKRD11	-0.35	-5.31	-0.31	2.31e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs253959	0.656	rs2063249	chr5:115415657	C/T	cg23108291	chr5:115420582	COMMD10	0.4	5.05	0.3	8.37e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs6032067	0.777	rs34233258	chr20:43788265	G/A	cg11264863	chr20:43835661	SEMG1	0.5	5.35	0.31	1.86e-7	Blood protein levels;
CESC	cis	rs7666738	0.830	rs4492007	chr4:98959848	A/T	cg03467027	chr4:99064603	C4orf37	0.44	5.55	0.32	6.79e-8	Colonoscopy-negative controls vs population controls;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg15324917	chr1:230992843	C1orf198	-0.46	-6.29	-0.36	1.31e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs2637266	0.783	rs7914756	chr10:78476406	A/T	cg18941641	chr10:78392320	NA	-0.4	-7.53	-0.42	7.88e-13	Pulmonary function;
CESC	cis	rs7267979	0.866	rs2424699	chr20:25257462	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.86	16.25	0.71	1.11e-41	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs854765	0.583	rs12603148	chr17:17865257	C/T	cg09796270	chr17:17721594	SREBF1	0.41	5.64	0.33	4.34e-8	Total body bone mineral density;
CESC	cis	rs2836950	0.545	rs11700449	chr21:40522419	A/T	cg11890956	chr21:40555474	PSMG1	-0.65	-9.22	-0.49	9.49e-18	Menarche (age at onset);
CESC	cis	rs9911578	0.765	rs66954617	chr17:56999427	A/G	cg05425664	chr17:57184151	TRIM37	-0.51	-7.02	-0.4	1.89e-11	Intelligence (multi-trait analysis);
CESC	cis	rs9322193	0.736	rs10457851	chr6:150096352	T/A	cg13206674	chr6:150067644	NUP43	0.41	5.74	0.33	2.64e-8	Lung cancer;
CESC	cis	rs9513593	1.000	rs4772181	chr13:99860966	C/G	cg21788972	chr13:99853209	UBAC2	0.65	7.38	0.41	2.04e-12	Psoriasis;
CESC	cis	rs2011503	0.941	rs55762233	chr19:19367319	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.52	5.34	0.31	1.97e-7	Bipolar disorder;
CESC	trans	rs9354308	0.933	rs1938068	chr6:66607807	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.66	7.45	0.42	1.33e-12	Metabolite levels;
CESC	trans	rs1973993	0.567	rs2800431	chr1:97000998	C/T	cg10631902	chr5:14652156	NA	0.49	7.24	0.41	4.93e-12	Weight;
CESC	cis	rs7772486	0.686	rs2072911	chr6:146056801	G/A	cg05347473	chr6:146136440	FBXO30	-0.51	-6.75	-0.38	9.36e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9811920	0.893	rs9814549	chr3:99892190	A/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.42	-7.13	-0.4	9.26e-12	Axial length;
CESC	cis	rs17826219	0.568	rs7213925	chr17:29121634	A/G	cg14008862	chr17:28927542	LRRC37B2	0.65	5.14	0.3	5.34e-7	Body mass index;
CESC	cis	rs7927771	1.000	rs7927771	chr11:47781306	A/G	cg05585544	chr11:47624801	NA	-0.5	-7.88	-0.44	8.28e-14	Subjective well-being;
CESC	cis	rs61931739	0.500	rs7298322	chr12:34445489	A/T	cg23762105	chr12:34175262	ALG10	-0.4	-5.22	-0.31	3.7e-7	Morning vs. evening chronotype;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg13096541	chr6:138482936	KIAA1244	-0.42	-6.07	-0.35	4.5e-9	Gambling;
CESC	cis	rs10504229	0.683	rs72649188	chr8:58108829	A/G	cg22535103	chr8:58192502	C8orf71	-0.77	-8.73	-0.47	2.82e-16	Developmental language disorder (linguistic errors);
CESC	cis	rs7223966	1.000	rs9909992	chr17:61731931	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.56	6.72	0.38	1.12e-10	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs13256369	0.708	rs11783670	chr8:8559394	G/A	cg00074818	chr8:8560427	CLDN23	0.38	5.34	0.31	2.05e-7	Obesity-related traits;
CESC	cis	rs7552404	0.727	rs61770533	chr1:76306490	C/G	cg22875332	chr1:76189707	ACADM	0.63	6.32	0.36	1.11e-9	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs35146811	0.806	rs1534310	chr7:99699169	A/T	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.47	5.8	0.34	1.91e-8	Coronary artery disease;
CESC	cis	rs514406	0.929	rs555741	chr1:53318851	T/G	cg25767906	chr1:53392781	SCP2	-0.46	-6.03	-0.35	5.48e-9	Monocyte count;
CESC	cis	rs367943	0.547	rs11241218	chr5:112958258	T/C	cg12552261	chr5:112820674	MCC	0.43	5.24	0.31	3.26e-7	Type 2 diabetes;
CESC	cis	rs9790314	0.521	rs1376122	chr3:161087857	A/G	cg04691961	chr3:161091175	C3orf57	-0.37	-5.09	-0.3	6.66e-7	Morning vs. evening chronotype;
CESC	cis	rs7772486	0.754	rs9497419	chr6:146142609	T/C	cg05347473	chr6:146136440	FBXO30	0.54	6.96	0.39	2.63e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs3806843	0.966	rs12659129	chr5:140147248	T/C	cg16179182	chr5:140090404	VTRNA1-1	-0.37	-5.03	-0.3	9.19e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs4722166	0.564	rs1800797	chr7:22766221	A/G	cg05265849	chr7:22767390	IL6	0.44	5.45	0.32	1.15e-7	Lung cancer;
CESC	cis	rs9311474	0.597	rs13303	chr3:52558008	T/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.35	6.74	0.38	9.78e-11	Electroencephalogram traits;
CESC	cis	rs10927875	0.691	rs1048261	chr1:16340951	A/T	cg21214613	chr1:16344536	HSPB7	0.37	5.39	0.31	1.56e-7	Dilated cardiomyopathy;
CESC	cis	rs6674176	0.561	rs7161	chr1:44438974	A/G	cg23954153	chr1:44402353	ARTN	0.34	5.31	0.31	2.35e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs12042052	0.590	rs72752167	chr1:232922414	G/A	cg06935979	chr1:232941706	KIAA1383	0.62	5.48	0.32	9.65e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CESC	cis	rs28489187	0.706	rs233062	chr1:85800385	T/G	cg16011679	chr1:85725395	C1orf52	0.48	5.68	0.33	3.58e-8	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	cis	rs763121	0.815	rs9306328	chr22:39028913	C/T	cg06544989	chr22:39130855	UNC84B	0.46	8.46	0.46	1.79e-15	Menopause (age at onset);
CESC	cis	rs12142240	0.698	rs6429599	chr1:46827871	G/A	cg00530320	chr1:46809349	NSUN4	0.6	8.01	0.44	3.75e-14	Menopause (age at onset);
CESC	cis	rs739401	0.611	rs494427	chr11:3048140	A/G	cg25174290	chr11:3078921	CARS	0.54	7.71	0.43	2.5e-13	Longevity;
CESC	cis	rs4862750	0.872	rs7664463	chr4:187876686	A/C	cg22105103	chr4:187893119	NA	0.43	6.19	0.36	2.23e-9	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4665809	1.000	rs750450	chr2:26324631	A/G	cg22920501	chr2:26401640	FAM59B	-0.65	-7.79	-0.43	1.53e-13	Gut microbiome composition (summer);
CESC	cis	rs11122272	0.766	rs2790872	chr1:231540543	A/T	cg06096015	chr1:231504339	EGLN1	0.41	5.72	0.33	2.89e-8	Hemoglobin concentration;
CESC	cis	rs9611565	0.694	rs202631	chr22:41863423	A/G	cg03806693	chr22:41940476	POLR3H	1.15	15.89	0.7	2.22e-40	Vitiligo;
CESC	cis	rs12926788	0.640	rs12924246	chr16:24844629	A/G	cg04756594	chr16:24857601	SLC5A11	0.46	5.72	0.33	2.9e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs2274273	1.000	rs6573006	chr14:55610432	T/C	cg04306507	chr14:55594613	LGALS3	0.31	6.26	0.36	1.57e-9	Protein biomarker;
CESC	cis	rs896854	0.654	rs28716845	chr8:95974485	A/G	cg09323728	chr8:95962352	TP53INP1	-0.4	-8.68	-0.47	4.05e-16	Type 2 diabetes;
CESC	trans	rs875971	0.638	rs6960778	chr7:66071597	C/T	cg26939375	chr7:64535504	NA	-0.64	-8.58	-0.47	7.92e-16	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15092395	chr3:33155457	CRTAP	0.63	7.5	0.42	9.48e-13	Gut microbiome composition (summer);
CESC	cis	rs17345786	0.861	rs17402964	chr3:101067945	C/T	cg12386194	chr3:101231763	SENP7	0.54	5.79	0.34	1.94e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs929354	0.713	rs3802130	chr7:156965237	A/G	cg05182265	chr7:156933206	UBE3C	-0.5	-7.3	-0.41	3.28e-12	Body mass index;
CESC	cis	rs5758511	0.689	rs45441993	chr22:42471738	C/A	cg00645731	chr22:42541494	CYP2D7P1	0.57	6.94	0.39	3.09e-11	Birth weight;
CESC	cis	rs4819052	0.851	rs9979545	chr21:46679805	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.93	14.04	0.65	7.76e-34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs11792861	0.816	rs11790105	chr9:111731785	T/C	cg13535736	chr9:111863775	C9orf5	-0.47	-6.26	-0.36	1.53e-9	Menarche (age at onset);
CESC	trans	rs12681287	0.547	rs13249177	chr8:87513034	A/G	cg27317242	chr8:23145699	R3HCC1	-0.53	-6.31	-0.36	1.19e-9	Caudate activity during reward;
CESC	cis	rs7818345	0.845	rs11782540	chr8:19268251	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.37	6.56	0.37	2.81e-10	Language performance in older adults (adjusted for episodic memory);
CESC	cis	rs6963495	0.719	rs73190172	chr7:105161210	T/C	cg13798780	chr7:105162888	PUS7	0.78	8.04	0.44	2.99e-14	Bipolar disorder (body mass index interaction);
CESC	cis	rs832540	0.656	rs6893754	chr5:56100006	G/A	cg14703610	chr5:56206110	C5orf35	0.42	5.26	0.31	2.98e-7	Coronary artery disease;
CESC	cis	rs2878628	0.596	rs57039206	chr3:52758570	T/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.61	8.51	0.46	1.28e-15	Intelligence (multi-trait analysis);
CESC	trans	rs1557351	0.723	rs1942343	chr18:54720660	T/G	cg11433624	chr6:7146702	RREB1	0.39	6.27	0.36	1.48e-9	Multiple sclerosis (age of onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26661436	chr5:141031071	FCHSD1	0.55	6.24	0.36	1.7e-9	Gut microbiome composition (summer);
CESC	cis	rs4665809	1.000	rs6729757	chr2:26285102	A/G	cg04944784	chr2:26401820	FAM59B	-0.66	-7.66	-0.43	3.61e-13	Gut microbiome composition (summer);
CESC	cis	rs736408	0.677	rs1042779	chr3:52821011	A/G	cg05564831	chr3:52568323	NT5DC2	0.46	6.78	0.38	7.62e-11	Bipolar disorder;
CESC	cis	rs6032067	0.586	rs62208373	chr20:43764426	G/A	cg10761708	chr20:43804764	PI3	0.54	5.97	0.34	7.62e-9	Blood protein levels;
CESC	cis	rs317689	0.718	rs160827	chr12:69770147	G/A	cg14784868	chr12:69753453	YEATS4	0.64	7.55	0.42	6.85e-13	Response to diuretic therapy;
CESC	cis	rs3741404	0.609	rs651855	chr11:63870810	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.72	9.92	0.52	6.36e-20	Platelet count;
CESC	cis	rs9309711	0.544	rs9309712	chr2:3491327	G/T	cg15506890	chr2:3487001	NA	-0.51	-6.65	-0.38	1.71e-10	Neurofibrillary tangles;
CESC	trans	rs11720469	0.967	rs9874940	chr3:166471573	T/G	cg03163944	chr19:37663716	ZNF585A	-0.42	-6.05	-0.35	4.86e-9	Fast beta electroencephalogram;
CESC	cis	rs7223966	1.000	rs8066719	chr17:61825764	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.56	6.7	0.38	1.26e-10	Hip circumference adjusted for BMI;Body mass index;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16517021	chr16:11945358	RSL1D1	0.54	6.07	0.35	4.41e-9	Gut microbiome composition (summer);
CESC	cis	rs13242816	0.881	rs17138706	chr7:116109019	A/G	cg04696780	chr7:116139425	CAV2	-0.63	-5.71	-0.33	2.98e-8	P wave duration;
CESC	cis	rs875971	0.862	rs778684	chr7:65836403	A/T	cg10691866	chr7:65817282	TPST1	-0.32	-5.27	-0.31	2.89e-7	Aortic root size;
CESC	cis	rs2836974	1.000	rs12710454	chr21:40656919	A/G	cg11890956	chr21:40555474	PSMG1	1.12	18.28	0.75	7.69e-49	Cognitive function;
CESC	cis	rs6546537	1.000	rs4852892	chr2:69866769	T/A	cg10773587	chr2:69614142	GFPT1	-0.62	-7.57	-0.42	6.12e-13	Serum thyroid-stimulating hormone levels;
CESC	cis	rs10876993	0.928	rs2640636	chr12:58077544	A/G	cg18357645	chr12:58087776	OS9	0.63	10.52	0.54	7.21e-22	Celiac disease or Rheumatoid arthritis;
CESC	cis	rs7917772	0.503	rs56219824	chr10:104302337	C/T	cg22532475	chr10:104410764	TRIM8	-0.35	-5.97	-0.34	7.47e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs7208859	0.573	rs73267865	chr17:29064204	C/G	cg19761014	chr17:28927070	LRRC37B2	0.76	6.25	0.36	1.66e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs1799949	1.000	rs4793215	chr17:41318932	G/A	cg05368731	chr17:41323189	NBR1	0.78	10.61	0.55	3.74e-22	Menopause (age at onset);
CESC	cis	rs763121	0.752	rs5757222	chr22:39060473	C/T	cg21395723	chr22:39101663	GTPBP1	0.43	5.37	0.31	1.74e-7	Menopause (age at onset);
CESC	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg07677032	chr17:61819896	STRADA	0.45	5.97	0.34	7.74e-9	Prudent dietary pattern;
CESC	cis	rs9733	0.818	rs4970924	chr1:150633079	A/G	cg04414720	chr1:150670196	GOLPH3L	-0.37	-5.18	-0.3	4.37e-7	Tonsillectomy;
CESC	cis	rs7772486	0.846	rs866473	chr6:146353414	A/C	cg05347473	chr6:146136440	FBXO30	0.5	6.56	0.37	2.8e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7666738	0.861	rs5014702	chr4:99052102	C/A	cg24818145	chr4:99064322	C4orf37	0.39	5.14	0.3	5.42e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9733	0.536	rs6661415	chr1:150635869	G/A	cg17724175	chr1:150552817	MCL1	0.44	7.24	0.41	4.8e-12	Tonsillectomy;
CESC	cis	rs2820292	0.619	rs12119907	chr1:201828755	T/C	cg11586189	chr1:201857591	SHISA4	-0.36	-5.86	-0.34	1.38e-8	Waist circumference;Body mass index (joint analysis main effects and smoking interaction);Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);
CESC	cis	rs6866344	0.697	rs11748497	chr5:178130012	C/G	cg10224037	chr5:178157518	ZNF354A	0.67	7.41	0.41	1.67e-12	Neutrophil percentage of white cells;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18122310	chr12:50236657	BCDIN3D	0.6	7.12	0.4	9.98e-12	Gut microbiome composition (summer);
CESC	cis	rs1185460	0.934	rs1006195	chr11:118958869	A/C	cg23280166	chr11:118938394	VPS11	-0.49	-6.72	-0.38	1.12e-10	Coronary artery disease;
CESC	cis	rs6933660	0.745	rs9322320	chr6:151751908	C/G	cg14262678	chr6:151773367	RMND1;C6orf211	0.67	9.57	0.51	8.08e-19	Menarche (age at onset);
CESC	cis	rs1008375	1.000	rs10939738	chr4:17604295	G/C	cg16339924	chr4:17578868	LAP3	0.63	8.08	0.44	2.34e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs7662987	0.540	rs2851278	chr4:100021253	G/C	cg12011299	chr4:100065546	ADH4	0.6	6.48	0.37	4.4e-10	Smoking initiation;
CESC	cis	rs12681288	0.823	rs2701907	chr8:1003292	A/G	cg15309053	chr8:964076	NA	0.34	5.76	0.33	2.31e-8	Schizophrenia;
CESC	cis	rs6964587	0.692	rs2158138	chr7:91700879	A/G	cg17063962	chr7:91808500	NA	0.46	6.59	0.38	2.33e-10	Breast cancer;
CESC	trans	rs2727020	0.729	rs4980439	chr11:49342246	G/C	cg15704280	chr7:45808275	SEPT13	-0.88	-14.73	-0.67	2.76e-36	Coronary artery disease;
CESC	cis	rs8060686	0.565	rs36046686	chr16:68122269	T/C	cg26727032	chr16:67993705	SLC12A4	-0.54	-6.05	-0.35	4.92e-9	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs1008375	0.931	rs10019482	chr4:17578079	G/A	cg02297831	chr4:17616191	MED28	0.5	6.07	0.35	4.52e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs698833	0.819	rs2340809	chr2:44536249	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.45	5.49	0.32	9.46e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs7208859	0.623	rs28627615	chr17:29145817	G/C	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.79e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs875971	0.660	rs801193	chr7:66030612	A/C	cg06456125	chr7:65229604	NA	-0.41	-5.39	-0.31	1.55e-7	Aortic root size;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg25794979	chr16:2732314	KCTD5	-0.47	-6.73	-0.38	1.04e-10	Gambling;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05013942	chr17:36003336	DDX52	0.63	6.8	0.39	6.91e-11	Gut microbiome composition (summer);
CESC	cis	rs6951245	0.706	rs1133116	chr7:1195215	A/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.47	-5.73	-0.33	2.74e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs6089584	0.888	rs6061981	chr20:60618973	T/C	cg06108461	chr20:60628389	TAF4	-0.92	-14.55	-0.67	1.22e-35	Body mass index;
CESC	cis	rs796364	0.806	rs11684942	chr2:201009136	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.72	-6.48	-0.37	4.47e-10	Schizophrenia;
CESC	cis	rs847577	0.722	rs6951277	chr7:97711783	A/G	cg21770322	chr7:97807741	LMTK2	0.64	10.58	0.55	4.59e-22	Breast cancer;
CESC	cis	rs9457247	1.000	rs1794693	chr6:167405670	T/C	cg07741184	chr6:167504864	NA	0.29	5.31	0.31	2.32e-7	Crohn's disease;
CESC	cis	rs1048238	0.506	rs10927866	chr1:16175317	C/T	cg21385522	chr1:16154831	NA	0.45	5.84	0.34	1.53e-8	Systolic blood pressure;
CESC	cis	rs2404602	0.692	rs2117369	chr15:76748861	A/T	cg22467129	chr15:76604101	ETFA	-0.38	-5.81	-0.34	1.81e-8	Blood metabolite levels;
CESC	cis	rs7223966	1.000	rs6504182	chr17:61823672	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.62	7.83	0.43	1.16e-13	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs2742234	0.554	rs1270015	chr10:43698240	G/T	cg15436174	chr10:43711423	RASGEF1A	0.5	5.88	0.34	1.24e-8	Hirschsprung disease;
CESC	cis	rs240768	0.511	rs61289570	chr6:101403098	C/T	cg12253828	chr6:101329408	ASCC3	0.86	7.03	0.4	1.79e-11	Economic and political preferences (immigration/crime);
CESC	cis	rs7666738	0.791	rs17549003	chr4:98969132	A/C	cg17366294	chr4:99064904	C4orf37	0.59	8.43	0.46	2.22e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs929354	0.629	rs6950739	chr7:156982450	T/C	cg05182265	chr7:156933206	UBE3C	-0.51	-7.42	-0.41	1.63e-12	Body mass index;
CESC	cis	rs67478160	0.704	rs12894254	chr14:104290949	G/C	cg08213375	chr14:104286397	PPP1R13B	0.54	10.65	0.55	2.71e-22	Schizophrenia;
CESC	cis	rs597539	0.652	rs636049	chr11:68667198	A/C	cg04772025	chr11:68637568	NA	0.5	5.96	0.34	8.13e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs875971	0.965	rs6971509	chr7:65714970	G/T	cg11764359	chr7:65958608	NA	-0.91	-14.86	-0.67	9.21e-37	Aortic root size;
CESC	cis	rs7737355	0.812	rs12514547	chr5:130973304	C/G	cg06307176	chr5:131281290	NA	0.38	5.06	0.3	7.77e-7	Life satisfaction;
CESC	cis	rs4642101	0.597	rs9839768	chr3:12821403	C/T	cg05775895	chr3:12838266	CAND2	0.41	6.3	0.36	1.2e-9	QRS complex (12-leadsum);
CESC	cis	rs9911578	0.933	rs2531725	chr17:56517962	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.34	0.31	1.98e-7	Intelligence (multi-trait analysis);
CESC	cis	rs7666738	0.791	rs4699329	chr4:99056212	G/A	cg05340658	chr4:99064831	C4orf37	0.83	12.92	0.62	6.18e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6952808	0.692	rs56727870	chr7:2029940	T/C	cg21782813	chr7:2030301	MAD1L1	0.5	7.17	0.4	7.6e-12	Bipolar disorder and schizophrenia;
CESC	cis	rs875971	1.000	rs4718343	chr7:65874288	T/G	cg11764359	chr7:65958608	NA	0.98	15.79	0.7	4.71e-40	Aortic root size;
CESC	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg07157834	chr1:205819609	PM20D1	-0.71	-10.91	-0.56	4.02e-23	Menarche (age at onset);
CESC	cis	rs287982	1.000	rs287980	chr2:9971366	G/A	cg10881225	chr2:9984929	TAF1B	-0.39	-5.12	-0.3	5.88e-7	Nonsyndromic cleft lip with cleft palate;
CESC	trans	rs3942852	0.568	rs7479361	chr11:48109793	C/T	cg15704280	chr7:45808275	SEPT13	-0.73	-9.2	-0.49	1.1e-17	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs7927771	1.000	rs11039426	chr11:47863119	G/A	cg20307385	chr11:47447363	PSMC3	-0.49	-6.0	-0.35	6.54e-9	Subjective well-being;
CESC	cis	rs9486715	0.867	rs9373833	chr6:96904998	A/G	cg06623918	chr6:96969491	KIAA0776	-0.92	-14.14	-0.66	3.24e-34	Headache;
CESC	cis	rs6732160	0.525	rs2303907	chr2:73470497	T/C	cg01422370	chr2:73384389	NA	0.44	7.59	0.42	5.48e-13	Intelligence (multi-trait analysis);
CESC	cis	rs2274273	0.875	rs2075602	chr14:55609774	A/G	cg04306507	chr14:55594613	LGALS3	0.29	5.79	0.34	2e-8	Protein biomarker;
CESC	cis	rs6121246	0.559	rs6058468	chr20:30406448	C/A	cg13852791	chr20:30311386	BCL2L1	0.86	10.97	0.56	2.48e-23	Mean corpuscular hemoglobin;
CESC	cis	rs6500602	0.702	rs6500605	chr16:4502410	C/T	cg08645402	chr16:4508243	NA	0.5	7.99	0.44	4.17e-14	Schizophrenia;
CESC	trans	rs561341	0.740	rs11080174	chr17:30208521	C/A	cg20587970	chr11:113659929	NA	0.59	7.5	0.42	9.74e-13	Hip circumference adjusted for BMI;
CESC	cis	rs6912958	0.512	rs910563	chr6:88058885	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	0.33	5.56	0.32	6.64e-8	Monocyte percentage of white cells;
CESC	cis	rs589448	0.933	rs2249093	chr12:69753512	G/C	cg22834771	chr12:69754056	YEATS4	-0.55	-7.29	-0.41	3.67e-12	Cerebrospinal fluid biomarker levels;
CESC	cis	rs9309473	1.000	rs6546835	chr2:73664715	G/A	cg20560298	chr2:73613845	ALMS1	-0.46	-6.22	-0.36	1.97e-9	Metabolite levels;
CESC	cis	rs4253772	0.637	rs8139035	chr22:46651367	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.69	8.18	0.45	1.16e-14	LDL cholesterol;Cholesterol, total;
CESC	cis	rs12681366	0.537	rs2919656	chr8:95473034	C/T	cg13257157	chr8:95487014	RAD54B	0.45	5.44	0.32	1.23e-7	Nonsyndromic cleft lip with cleft palate;
CESC	cis	rs1878931	0.501	rs4785934	chr16:3419934	G/T	cg26668626	chr16:3451006	ZNF174;ZNF434	0.78	10.51	0.54	7.76e-22	Body mass index (adult);
CESC	cis	rs748404	0.697	rs501884	chr15:43553982	G/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.61	8.03	0.44	3.2e-14	Lung cancer;
CESC	cis	rs2228479	0.850	rs11644804	chr16:89976224	G/A	cg04013166	chr16:89971882	TCF25	0.65	6.46	0.37	5.1e-10	Skin colour saturation;
CESC	cis	rs7666738	0.830	rs4699574	chr4:98725544	C/T	cg05340658	chr4:99064831	C4orf37	0.76	11.17	0.57	5.6e-24	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1034435	0.755	rs6007869	chr22:48894213	A/G	cg05992904	chr22:48892994	FAM19A5	-0.57	-9.81	-0.52	1.35e-19	Late-onset Alzheimer's disease;
CESC	cis	rs4423214	0.592	rs78300366	chr11:71205514	A/G	cg05163923	chr11:71159392	DHCR7	-0.57	-5.83	-0.34	1.64e-8	Vitamin D levels;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg05942963	chr14:71787552	NA	-0.39	-6.07	-0.35	4.52e-9	Gambling;
CESC	cis	rs9527	0.590	rs11191572	chr10:104893137	A/G	cg04362960	chr10:104952993	NT5C2	0.44	5.54	0.32	7.12e-8	Arsenic metabolism;
CESC	cis	rs35306767	0.855	rs11253468	chr10:903261	G/A	cg10556349	chr10:835070	NA	0.58	5.48	0.32	1e-7	Eosinophil percentage of granulocytes;
CESC	cis	rs2204008	0.754	rs11181244	chr12:38302454	T/C	cg26384229	chr12:38710491	ALG10B	0.7	10.34	0.54	2.92e-21	Bladder cancer;
CESC	trans	rs677673	1.000	rs649368	chr20:10473109	A/G	cg16021678	chr13:55475951	NA	0.52	6.67	0.38	1.44e-10	Body mass index (change over time) in chronic obstructive pulmonary disease;
CESC	cis	rs5753618	0.583	rs34545960	chr22:31812462	G/A	cg02404636	chr22:31891804	SFI1	0.39	5.37	0.31	1.71e-7	Colorectal cancer;
CESC	cis	rs6598955	0.670	rs3795688	chr1:26560481	C/A	cg00852783	chr1:26633632	UBXN11	0.42	6.17	0.35	2.55e-9	Obesity-related traits;
CESC	cis	rs7618915	0.547	rs2164884	chr3:52629633	C/T	cg17372223	chr3:52568218	NT5DC2	0.43	6.43	0.37	5.84e-10	Bipolar disorder;
CESC	cis	rs769267	0.965	rs2315025	chr19:19426609	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.61	7.63	0.42	4.34e-13	Tonsillectomy;
CESC	cis	rs1784581	0.588	rs6455789	chr6:162417948	C/T	cg17173639	chr6:162384350	PARK2	0.56	8.62	0.47	6.34e-16	Itch intensity from mosquito bite;
CESC	cis	rs9733	0.566	rs112967224	chr1:150677263	G/A	cg22823121	chr1:150693482	HORMAD1	0.48	7.07	0.4	1.36e-11	Tonsillectomy;
CESC	cis	rs7598759	0.679	rs6740843	chr2:232332139	A/C	cg19187155	chr2:232395269	NMUR1	0.39	6.12	0.35	3.33e-9	Noise-induced hearing loss;
CESC	cis	rs2842992	0.789	rs7758895	chr6:160193465	T/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.78	9.43	0.5	2.15e-18	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs6831352	0.918	rs13112733	chr4:100050319	A/T	cg13256891	chr4:100009986	ADH5	-0.77	-8.43	-0.46	2.27e-15	Alcohol dependence;
CESC	cis	rs11809207	0.523	rs2783706	chr1:26504697	A/G	cg00147160	chr1:26503991	CNKSR1	0.27	5.13	0.3	5.58e-7	Height;
CESC	cis	rs892961	0.899	rs7222532	chr17:75413302	G/C	cg05865280	chr17:75406074	SEPT9	0.62	12.67	0.61	4.57e-29	Airflow obstruction;
CESC	trans	rs4843747	0.671	rs4075998	chr16:88106776	G/A	cg26811252	chr16:29126840	RRN3P2	0.67	9.46	0.5	1.77e-18	Menopause (age at onset);
CESC	cis	rs12134245	0.747	rs17501512	chr1:92012481	C/G	cg07090678	chr1:91966139	CDC7	-0.41	-5.65	-0.33	4.18e-8	Breast cancer;
CESC	cis	rs919433	0.680	rs12621129	chr2:198265350	T/C	cg10820045	chr2:198174542	NA	-0.38	-5.05	-0.3	8.29e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs11264213	0.686	rs645383	chr1:36373823	C/G	cg27506609	chr1:36549197	TEKT2	-0.45	-5.95	-0.34	8.23e-9	Schizophrenia;
CESC	cis	rs3008870	1.000	rs975451	chr1:67480060	T/C	cg08660285	chr1:67390436	MIER1;WDR78	1.01	13.78	0.65	5.96e-33	Lymphocyte percentage of white cells;
CESC	cis	rs7618915	0.547	rs62253733	chr3:52653414	A/G	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.29	5.13	0.3	5.61e-7	Bipolar disorder;
CESC	cis	rs2367563	0.930	rs7957253	chr12:96054414	G/A	cg19013339	chr12:96052514	NTN4	0.37	5.35	0.31	1.9e-7	Allergic dermatitis (nickel);
CESC	cis	rs6424115	0.729	rs561733	chr1:24049595	T/G	cg10978503	chr1:24200527	CNR2	0.27	5.32	0.31	2.24e-7	Immature fraction of reticulocytes;
CESC	cis	rs727563	0.562	rs5758458	chr22:42154132	G/A	cg06481639	chr22:41940642	POLR3H	0.6	5.95	0.34	8.27e-9	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs10743315	0.557	rs17505123	chr12:19301353	G/A	cg02471346	chr12:19282374	PLEKHA5	0.76	5.82	0.34	1.7e-8	Gut microbiota (bacterial taxa);
CESC	cis	rs7618915	0.547	rs1561337	chr3:52659963	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	7.24	0.41	4.73e-12	Bipolar disorder;
CESC	cis	rs950027	0.584	rs1145086	chr15:45654327	A/G	cg21132104	chr15:45694354	SPATA5L1	0.67	8.55	0.46	1.01e-15	Response to fenofibrate (adiponectin levels);
CESC	trans	rs7656342	0.808	rs10003216	chr4:9766749	A/G	cg25190999	chr2:8826175	NA	-0.57	-7.07	-0.4	1.35e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs116095464	0.558	rs7731089	chr5:290422	A/C	cg22857025	chr5:266934	NA	-1.29	-18.38	-0.75	3.21e-49	Breast cancer;
CESC	trans	rs629535	0.814	rs477200	chr8:70059584	A/G	cg21567404	chr3:27674614	NA	0.84	9.94	0.52	5.42e-20	Dupuytren's disease;
CESC	cis	rs9309473	0.607	rs7560272	chr2:73561485	A/T	cg20560298	chr2:73613845	ALMS1	-0.48	-6.72	-0.38	1.09e-10	Metabolite levels;
CESC	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	22.48	0.81	2.38e-63	Prudent dietary pattern;
CESC	cis	rs36051895	0.632	rs12336875	chr9:5138404	C/A	cg02405213	chr9:5042618	JAK2	-0.5	-6.11	-0.35	3.45e-9	Pediatric autoimmune diseases;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg24594383	chr20:62564955	DNAJC5	0.47	6.52	0.37	3.58e-10	Fibrinogen levels;
CESC	cis	rs2477686	0.526	rs1998760	chr1:2397136	C/T	cg02275930	chr1:2372054	NA	-0.54	-8.76	-0.47	2.45e-16	Non-obstructive azoospermia;
CESC	cis	rs854765	0.505	rs4924832	chr17:17897739	A/G	cg16928487	chr17:17741425	SREBF1	-0.57	-9.92	-0.52	6.42e-20	Total body bone mineral density;
CESC	cis	rs9311474	0.607	rs4234633	chr3:52557038	C/T	cg17372223	chr3:52568218	NT5DC2	0.51	7.91	0.44	6.95e-14	Electroencephalogram traits;
CESC	cis	rs77216612	0.877	rs66561220	chr12:12878765	T/C	cg09462578	chr12:12878428	APOLD1	-1.01	-15.4	-0.69	1.18e-38	Lymphocyte counts;
CESC	cis	rs7568458	0.684	rs7579147	chr2:85805654	G/A	cg02493740	chr2:85810744	VAMP5	-0.57	-8.33	-0.46	4.26e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CESC	cis	rs7829975	0.711	rs4841051	chr8:8685646	C/T	cg18904891	chr8:8559673	CLDN23	-0.42	-5.16	-0.3	4.88e-7	Mood instability;
CESC	cis	rs7923609	0.812	rs10822155	chr10:65071215	C/A	cg01631684	chr10:65280961	REEP3	-0.41	-5.11	-0.3	6.16e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs3820068	0.608	rs7516683	chr1:16020502	A/G	cg17385448	chr1:15911702	AGMAT	-0.38	-6.1	-0.35	3.74e-9	Systolic blood pressure;
CESC	cis	rs2933343	0.700	rs1683779	chr3:128642048	A/G	cg24203234	chr3:128598194	ACAD9	0.41	5.57	0.32	6.41e-8	IgG glycosylation;
CESC	cis	rs2279817	0.818	rs867984	chr1:17982559	G/A	cg21791023	chr1:18019539	ARHGEF10L	-0.61	-7.59	-0.42	5.36e-13	Neuroticism;
CESC	cis	rs875971	0.895	rs10447522	chr7:65796074	A/G	cg18876405	chr7:65276391	NA	-0.53	-7.27	-0.41	4.11e-12	Aortic root size;
CESC	trans	rs650950	0.528	rs646660	chr11:35528452	C/T	cg06096994	chr13:41635664	WBP4	0.46	6.35	0.36	9.37e-10	Bronchopulmonary dysplasia;
CESC	cis	rs7772486	0.764	rs2247211	chr6:146216379	G/A	cg05347473	chr6:146136440	FBXO30	0.53	6.92	0.39	3.46e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7660520	0.524	rs4862101	chr4:183733177	T/C	cg03209412	chr4:183728196	NA	0.59	5.24	0.31	3.23e-7	Pediatric autoimmune diseases;
CESC	cis	rs4660261	0.526	rs2906466	chr1:44322220	A/G	cg12908607	chr1:44402522	ARTN	-0.46	-6.6	-0.38	2.29e-10	Intelligence (multi-trait analysis);
CESC	cis	rs10465746	0.967	rs28567085	chr1:84428859	G/A	cg10977910	chr1:84465055	TTLL7	0.46	6.18	0.35	2.45e-9	Obesity-related traits;
CESC	cis	rs10743315	0.778	rs1586843	chr12:19354550	T/C	cg02471346	chr12:19282374	PLEKHA5	-0.47	-5.15	-0.3	5.09e-7	Gut microbiota (bacterial taxa);
CESC	cis	rs9902453	0.584	rs3809790	chr17:27955540	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.53	-6.64	-0.38	1.78e-10	Coffee consumption (cups per day);
CESC	cis	rs7819412	0.745	rs4841498	chr8:10985432	C/T	cg21775007	chr8:11205619	TDH	-0.47	-6.88	-0.39	4.24e-11	Triglycerides;
CESC	cis	rs765787	0.556	rs10851422	chr15:45513738	T/C	cg24006582	chr15:45444508	DUOX1	0.54	6.55	0.37	2.97e-10	Uric acid levels;
CESC	cis	rs524023	0.837	rs12362590	chr11:64352540	T/A	cg07220939	chr11:64358617	SLC22A12	-0.33	-5.22	-0.31	3.57e-7	Urate levels in obese individuals;
CESC	trans	rs11098499	1.000	rs6837898	chr4:120179154	C/T	cg25214090	chr10:38739885	LOC399744	0.64	8.58	0.47	8.37e-16	Corneal astigmatism;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg20962746	chr11:118436826	C11orf60	0.4	5.99	0.35	6.68e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs9929218	0.817	rs3114399	chr16:68713385	C/G	cg02972257	chr16:68554789	NA	0.52	5.29	0.31	2.52e-7	Colorectal cancer;
CESC	cis	rs6740322	0.748	rs6755601	chr2:43483044	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.76	-8.95	-0.48	6.23e-17	Coronary artery disease;
CESC	cis	rs34172651	0.517	rs8059004	chr16:24837905	G/A	cg04756594	chr16:24857601	SLC5A11	0.46	5.66	0.33	3.88e-8	Intelligence (multi-trait analysis);
CESC	cis	rs7666738	0.791	rs1830231	chr4:99026185	A/C	cg17366294	chr4:99064904	C4orf37	0.62	8.95	0.48	6.32e-17	Colonoscopy-negative controls vs population controls;
CESC	cis	rs16854884	0.690	rs35885310	chr3:143771333	A/G	cg06585982	chr3:143692056	C3orf58	0.48	6.18	0.35	2.46e-9	Economic and political preferences (feminism/equality);
CESC	cis	rs7618915	0.571	rs2251219	chr3:52584787	C/T	cg17372223	chr3:52568218	NT5DC2	-0.43	-6.0	-0.35	6.53e-9	Bipolar disorder;
CESC	cis	rs3815700	1.000	rs8109768	chr19:33095463	A/G	cg02997394	chr19:33096574	ANKRD27	0.71	7.07	0.4	1.39e-11	Eosinophilic esophagitis;
CESC	cis	rs950776	0.518	rs62008194	chr15:78813805	G/T	cg24631222	chr15:78858424	CHRNA5	-0.41	-5.21	-0.3	3.86e-7	Sudden cardiac arrest;
CESC	cis	rs4927850	0.881	rs7624638	chr3:195748729	C/T	cg12923728	chr3:195709715	SDHAP1	-0.67	-8.86	-0.48	1.23e-16	Pancreatic cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09242721	chr3:3168535	TRNT1	0.6	6.83	0.39	5.88e-11	Gut microbiome composition (summer);
CESC	cis	rs9467711	0.606	rs1977	chr6:26377546	A/G	cg12826209	chr6:26865740	GUSBL1	0.63	5.79	0.33	2.04e-8	Autism spectrum disorder or schizophrenia;
CESC	cis	rs2070488	0.804	rs35463537	chr3:38498248	T/C	cg24069376	chr3:38537580	EXOG	0.33	5.59	0.32	5.58e-8	Electrocardiographic conduction measures;
CESC	cis	rs11792861	0.591	rs10979613	chr9:111687584	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.62	9.5	0.5	1.29e-18	Menarche (age at onset);
CESC	cis	rs10791323	0.569	rs10750541	chr11:133713189	A/C	cg15485101	chr11:133734466	NA	-0.42	-6.64	-0.38	1.75e-10	Childhood ear infection;
CESC	cis	rs6121246	0.909	rs7272062	chr20:30259145	A/G	cg13852791	chr20:30311386	BCL2L1	0.81	8.49	0.46	1.51e-15	Mean corpuscular hemoglobin;
CESC	cis	rs3105593	1.000	rs17645523	chr15:50882645	T/C	cg08437265	chr15:50716283	USP8	0.42	5.46	0.32	1.1e-7	QT interval;
CESC	cis	rs8141529	0.664	rs5762861	chr22:29250505	T/G	cg15103426	chr22:29168792	CCDC117	0.52	6.49	0.37	4.28e-10	Lymphocyte counts;
CESC	cis	rs9457247	1.000	rs444988	chr6:167389674	A/T	cg25258033	chr6:167368657	RNASET2	0.38	5.72	0.33	2.82e-8	Crohn's disease;
CESC	cis	rs7727544	0.636	rs2631365	chr5:131705949	T/C	cg24060327	chr5:131705240	SLC22A5	0.67	8.93	0.48	7.55e-17	Blood metabolite levels;
CESC	cis	rs1862618	0.756	rs9292125	chr5:56107200	C/T	cg24531977	chr5:56204891	C5orf35	-0.87	-11.43	-0.57	7.1e-25	Initial pursuit acceleration;
CESC	cis	rs7927592	0.731	rs488381	chr11:68291693	G/A	cg01657329	chr11:68192670	LRP5	0.49	6.56	0.37	2.78e-10	Total body bone mineral density;
CESC	trans	rs208520	1.000	rs208523	chr6:66954195	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.85	-9.42	-0.5	2.36e-18	Exhaled nitric oxide output;
CESC	cis	rs9486719	1.000	rs2472886	chr6:96864876	C/T	cg06623918	chr6:96969491	KIAA0776	0.81	8.29	0.45	5.61e-15	Migraine;Coronary artery disease;
CESC	cis	rs400736	0.894	rs226253	chr1:8027706	T/C	cg25007680	chr1:8021821	PARK7	0.71	10.15	0.53	1.15e-20	Response to antidepressants and depression;
CESC	cis	rs875971	0.862	rs1643375	chr7:65872677	T/C	cg10691866	chr7:65817282	TPST1	-0.32	-5.25	-0.31	3.06e-7	Aortic root size;
CESC	cis	rs904092	0.678	rs1230020	chr4:100175407	G/A	cg12011299	chr4:100065546	ADH4	0.52	6.04	0.35	5.15e-9	Alcohol dependence;
CESC	cis	rs2439831	0.681	rs478104	chr15:43594900	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.9	13.48	0.64	6.76e-32	Lung cancer in ever smokers;
CESC	cis	rs4588572	0.643	rs1529499	chr5:77721431	T/C	cg11547950	chr5:77652471	NA	-0.44	-5.59	-0.32	5.64e-8	Triglycerides;
CESC	trans	rs1003719	0.715	rs762139	chr21:38568475	A/T	cg00295448	chr5:140044129	WDR55	-0.44	-6.28	-0.36	1.41e-9	Eye color traits;
CESC	cis	rs7542091	0.704	rs1883331	chr1:210043483	A/G	cg21951975	chr1:209979733	IRF6	0.47	8.25	0.45	7.51e-15	Monobrow;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09717923	chr16:1440498	NA	-0.56	-6.8	-0.39	7.07e-11	Gut microbiome composition (summer);
CESC	cis	rs7829975	0.871	rs572307	chr8:8578811	T/C	cg17143192	chr8:8559678	CLDN23	-0.45	-5.69	-0.33	3.44e-8	Mood instability;
CESC	cis	rs7666738	0.791	rs1559860	chr4:99024422	C/T	cg17366294	chr4:99064904	C4orf37	0.62	8.95	0.48	6.32e-17	Colonoscopy-negative controls vs population controls;
CESC	cis	rs736408	0.609	rs2230534	chr3:52802402	A/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.36	6.18	0.36	2.37e-9	Bipolar disorder;
CESC	cis	rs1153858	1.000	rs16942568	chr15:45677390	T/C	cg14582100	chr15:45693742	SPATA5L1	0.42	5.95	0.34	8.38e-9	Homoarginine levels;
CESC	cis	rs7412746	0.658	rs11204723	chr1:150731618	T/C	cg09365446	chr1:150670422	GOLPH3L	0.39	5.1	0.3	6.59e-7	Melanoma;
CESC	cis	rs7811142	0.943	rs66958101	chr7:100074020	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.11	11.01	0.56	1.89e-23	Platelet count;
CESC	cis	rs9875589	0.509	rs1844107	chr3:14065319	C/G	cg19554555	chr3:13937349	NA	-0.44	-5.6	-0.33	5.43e-8	Ovarian reserve;
CESC	cis	rs11122272	0.735	rs2572252	chr1:231513653	T/C	cg06096015	chr1:231504339	EGLN1	0.43	6.18	0.35	2.46e-9	Hemoglobin concentration;
CESC	cis	rs16854884	0.657	rs7610378	chr3:143711298	G/A	cg01302019	chr3:143689584	C3orf58	-0.34	-5.08	-0.3	7.28e-7	Economic and political preferences (feminism/equality);
CESC	cis	rs514406	0.793	rs4500255	chr1:53213279	A/G	cg25767906	chr1:53392781	SCP2	0.44	6.11	0.35	3.45e-9	Monocyte count;
CESC	cis	rs2933343	0.729	rs1680780	chr3:128612659	G/C	cg11901034	chr3:128598214	ACAD9	-0.36	-5.16	-0.3	4.75e-7	IgG glycosylation;
CESC	cis	rs62432291	0.681	rs3003174	chr6:159655326	T/C	cg14500486	chr6:159655392	FNDC1	-0.62	-6.21	-0.36	2.04e-9	Joint mobility (Beighton score);
CESC	cis	rs7223966	0.960	rs113155878	chr17:61706560	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.53	6.16	0.35	2.7e-9	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs2797160	0.547	rs1418645	chr6:125946476	T/A	cg05901451	chr6:126070800	HEY2	-0.39	-5.33	-0.31	2.05e-7	Endometrial cancer;
CESC	cis	rs17764205	0.777	rs113305163	chr19:3252194	G/C	cg02612712	chr19:3985498	EEF2	0.67	5.32	0.31	2.21e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs9487051	0.676	rs2222392	chr6:109602303	T/C	cg21918786	chr6:109611834	NA	-0.39	-5.75	-0.33	2.5e-8	Reticulocyte fraction of red cells;
CESC	cis	rs910316	0.875	rs12588099	chr14:75594462	A/T	cg11812906	chr14:75593930	NEK9	0.88	15.16	0.68	8.23e-38	Height;
CESC	cis	rs10883723	0.847	rs3808934	chr10:104264280	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.54	7.43	0.42	1.49e-12	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs1799949	0.602	rs8176235	chr17:41219560	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.58	6.71	0.38	1.16e-10	Menopause (age at onset);
CESC	cis	rs7246657	0.943	rs8111782	chr19:37867904	A/G	cg23950597	chr19:37808831	NA	-0.62	-6.3	-0.36	1.26e-9	Coronary artery calcification;
CESC	cis	rs7937682	0.921	rs12806479	chr11:111443192	G/C	cg09085632	chr11:111637200	PPP2R1B	0.91	10.76	0.55	1.24e-22	Primary sclerosing cholangitis;
CESC	cis	rs9462846	0.959	rs6937172	chr6:42884375	A/T	cg02353165	chr6:42928485	GNMT	0.49	5.6	0.33	5.42e-8	Blood protein levels;
CESC	cis	rs17039065	0.920	rs1017430	chr4:109474062	A/G	cg16022748	chr4:109541635	LOC285456;RPL34	0.6	5.25	0.31	3.17e-7	Gut microbiome composition (summer);
CESC	cis	rs12701220	0.595	rs12532837	chr7:1122851	T/A	cg26769984	chr7:1090371	C7orf50	0.56	6.08	0.35	4.18e-9	Bronchopulmonary dysplasia;
CESC	cis	rs7605827	0.930	rs2287264	chr2:15637592	C/G	cg19274914	chr2:15703543	NA	0.36	6.32	0.36	1.13e-9	Educational attainment (years of education);
CESC	cis	rs818427	0.548	rs374613	chr5:112192072	A/G	cg07820702	chr5:112228657	REEP5	0.39	5.28	0.31	2.66e-7	Total body bone mineral density;
CESC	cis	rs896854	0.654	rs16893776	chr8:95973604	C/T	cg26343298	chr8:95960752	TP53INP1	0.36	5.95	0.34	8.41e-9	Type 2 diabetes;
CESC	cis	rs7949030	0.596	rs71490394	chr11:62370155	G/A	cg23462726	chr11:62437636	C11orf83;C11orf48	-0.42	-5.35	-0.31	1.86e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs2985684	1.000	rs56098064	chr14:50105849	T/C	cg02151108	chr14:50098012	C14orf104	-0.39	-5.12	-0.3	5.78e-7	Carotid intima media thickness;
CESC	cis	rs2276314	0.857	rs6507158	chr18:33636066	A/C	cg05985134	chr18:33552581	C18orf21	0.61	7.3	0.41	3.39e-12	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs9858542	0.953	rs35115732	chr3:49475155	T/C	cg03060546	chr3:49711283	APEH	-0.53	-5.96	-0.34	7.95e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs9611565	0.694	rs202617	chr22:41822793	C/T	cg17376030	chr22:41985996	PMM1	-0.72	-7.6	-0.42	5.27e-13	Vitiligo;
CESC	cis	rs28374715	0.580	rs8030228	chr15:41636867	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.92	-13.86	-0.65	3.33e-33	Ulcerative colitis;
CESC	cis	rs8103278	0.507	rs16939	chr19:46276056	C/A	cg11657440	chr19:46296263	DMWD	0.81	12.61	0.61	7.09e-29	Coronary artery disease;
CESC	cis	rs7666738	0.791	rs10022061	chr4:98926821	T/C	cg03467027	chr4:99064603	C4orf37	0.46	5.59	0.32	5.78e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7772486	0.754	rs697053	chr6:145989807	T/C	cg05347473	chr6:146136440	FBXO30	-0.55	-7.07	-0.4	1.41e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9815354	0.951	rs6793520	chr3:41865289	C/G	cg03022575	chr3:42003672	ULK4	0.47	5.24	0.31	3.33e-7	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs1697139	0.583	rs1428475	chr5:66543954	G/T	cg11553311	chr5:66541588	NA	0.39	5.44	0.32	1.21e-7	Breast cancer;
CESC	cis	rs34172651	0.917	rs6497756	chr16:24798291	G/T	cg06028605	chr16:24865363	SLC5A11	0.35	5.49	0.32	9.29e-8	Intelligence (multi-trait analysis);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg27376437	chr17:56064565	VEZF1	0.44	6.01	0.35	6.21e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs727505	0.866	rs67132333	chr7:124719801	A/G	cg23710748	chr7:124431027	NA	-0.4	-6.55	-0.37	3.01e-10	Lewy body disease;
CESC	cis	rs12477438	1.000	rs995617	chr2:99857904	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.74	8.64	0.47	5.28e-16	Chronic sinus infection;
CESC	cis	rs3857536	0.813	rs7771569	chr6:66946717	C/T	cg07460842	chr6:66804631	NA	-0.42	-5.29	-0.31	2.55e-7	Blood trace element (Cu levels);
CESC	cis	rs888194	0.677	rs2164743	chr12:109875163	C/T	cg19025524	chr12:109796872	NA	-0.4	-6.03	-0.35	5.59e-9	Neuroticism;
CESC	cis	rs7312774	0.618	rs7975954	chr12:107345750	C/T	cg16260113	chr12:107380972	MTERFD3	0.82	7.48	0.42	1.11e-12	Severe influenza A (H1N1) infection;
CESC	cis	rs1256061	0.646	rs1256056	chr14:64712626	A/G	cg21174375	chr14:64681225	SYNE2	0.5	6.84	0.39	5.41e-11	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs1559088	1.000	rs7256328	chr19:33558705	G/C	cg27124370	chr19:33622961	WDR88	0.42	5.32	0.31	2.16e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs736408	0.716	rs2239549	chr3:52823126	C/T	cg07507251	chr3:52567010	NT5DC2	0.39	6.45	0.37	5.14e-10	Bipolar disorder;
CESC	trans	rs12356475	0.710	rs10822686	chr10:67733250	C/T	cg02974499	chr11:64889668	FAU;MRPL49	0.53	6.05	0.35	4.99e-9	Psoriatic arthritis;
CESC	cis	rs9303401	0.659	rs16943176	chr17:56769887	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.03	12.82	0.62	1.31e-29	Cognitive test performance;
CESC	cis	rs7580658	0.963	rs9789510	chr2:128137012	G/A	cg10021288	chr2:128175891	PROC	-0.4	-6.23	-0.36	1.84e-9	Protein C levels;
CESC	cis	rs6089584	0.507	rs6061990	chr20:60628429	T/G	cg06108461	chr20:60628389	TAF4	-0.57	-7.6	-0.42	5.04e-13	Body mass index;
CESC	cis	rs13102973	0.899	rs17496	chr4:135900227	C/T	cg14419869	chr4:135874104	NA	-0.34	-5.05	-0.3	8.38e-7	Subjective well-being;
CESC	trans	rs9850225	0.719	rs4856616	chr3:80466481	A/C	cg22792938	chr2:228337242	AGFG1	0.37	6.08	0.35	4.17e-9	Erectile dysfunction in type 1 diabetes;
CESC	cis	rs9322193	0.923	rs10782315	chr6:150064229	T/C	cg13206674	chr6:150067644	NUP43	0.44	6.46	0.37	4.86e-10	Lung cancer;
CESC	cis	rs4728302	0.869	rs10253633	chr7:133590869	A/G	cg10665199	chr7:133106180	EXOC4	0.39	5.39	0.31	1.55e-7	Intelligence;Intelligence (multi-trait analysis);
CESC	cis	rs2842992	0.662	rs2273825	chr6:160211424	A/C	cg11366901	chr6:160182831	ACAT2	0.64	8.17	0.45	1.24e-14	Age-related macular degeneration (geographic atrophy);
CESC	trans	rs2502399	0.667	rs1040591	chr6:113491096	A/T	cg00285294	chr7:1089767	C7orf50	-0.35	-6.41	-0.37	6.56e-10	Plasma clusterin levels;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05414835	chr15:59225898	SLTM	-0.45	-6.1	-0.35	3.68e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs12142240	0.659	rs67547686	chr1:46832229	G/C	cg10495392	chr1:46806563	NSUN4	0.57	6.24	0.36	1.74e-9	Menopause (age at onset);
CESC	cis	rs6460942	0.915	rs62447638	chr7:12484667	G/A	cg20607287	chr7:12443886	VWDE	-0.76	-8.58	-0.47	8.16e-16	Coronary artery disease;
CESC	trans	rs2530545	0.851	rs1582278	chr7:34692925	C/A	cg14080982	chr15:71736038	THSD4	-0.48	-6.05	-0.35	5.02e-9	IgG glycosylation;
CESC	cis	rs7412746	0.658	rs72704652	chr1:150819470	A/G	cg04414720	chr1:150670196	GOLPH3L	0.56	7.5	0.42	9.36e-13	Melanoma;
CESC	cis	rs2836974	0.965	rs8131126	chr21:40655754	A/G	cg11644478	chr21:40555479	PSMG1	1.0	14.59	0.67	8.82e-36	Cognitive function;
CESC	cis	rs947211	0.948	rs12565968	chr1:205755046	A/G	cg17178900	chr1:205818956	PM20D1	-0.4	-5.31	-0.31	2.29e-7	Parkinson's disease;
CESC	cis	rs9467711	0.790	rs72843784	chr6:26498758	G/T	cg21479132	chr6:26055353	NA	0.92	5.83	0.34	1.61e-8	Autism spectrum disorder or schizophrenia;
CESC	cis	rs7044106	0.762	rs4837790	chr9:123446325	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.69	10.09	0.53	1.84e-20	Hip circumference adjusted for BMI;
CESC	cis	rs60871478	0.579	rs56109762	chr7:925967	G/A	cg05535760	chr7:792225	HEATR2	-0.83	-7.72	-0.43	2.38e-13	Cerebrospinal P-tau181p levels;
CESC	cis	rs3862030	0.503	rs10786673	chr10:104280537	G/A	ch.10.2196322F	chr10:104248062	ACTR1A	0.42	5.18	0.3	4.34e-7	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
CESC	cis	rs1559088	0.576	rs4805852	chr19:33609441	C/T	cg17764715	chr19:33622953	WDR88	0.59	8.41	0.46	2.55e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	trans	rs60843830	1.000	rs36216559	chr2:262335	A/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.69	8.65	0.47	5.11e-16	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs910316	0.763	rs175036	chr14:75464295	C/T	cg16144293	chr14:75469539	EIF2B2	0.41	5.43	0.32	1.24e-7	Height;
CESC	cis	rs2576037	0.526	rs2032215	chr18:44439011	A/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.58	-7.94	-0.44	5.82e-14	Personality dimensions;
CESC	cis	rs7044106	0.791	rs10985004	chr9:123484937	T/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.35	5.51	0.32	8.6e-8	Hip circumference adjusted for BMI;
CESC	cis	rs911555	0.504	rs745079	chr14:104073551	G/A	cg24130564	chr14:104152367	KLC1	-0.82	-13.38	-0.63	1.58e-31	Intelligence (multi-trait analysis);
CESC	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg23131131	chr22:24373011	LOC391322	-0.7	-9.86	-0.52	9.82e-20	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs7216064	1.000	rs9913471	chr17:65874495	C/T	cg07042672	chr17:66097459	LOC651250	-0.56	-6.5	-0.37	3.96e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs2836950	0.565	rs7278297	chr21:40625752	A/C	cg11644478	chr21:40555479	PSMG1	-0.53	-7.15	-0.4	8.54e-12	Menarche (age at onset);
CESC	cis	rs17761864	0.718	rs8064885	chr17:2047564	G/A	cg16513277	chr17:2031491	SMG6	0.4	5.05	0.3	8.19e-7	Esophageal cancer (squamous cell);
CESC	cis	rs2243480	0.803	rs35480979	chr7:65357084	A/G	cg13147721	chr7:65941812	NA	-0.85	-8.51	-0.46	1.26e-15	Diabetic kidney disease;
CESC	cis	rs459571	0.959	rs465724	chr9:136910097	C/T	cg13789015	chr9:136890014	NCRNA00094	0.55	7.93	0.44	6.1e-14	Platelet distribution width;
CESC	cis	rs67311347	1.000	rs2276871	chr3:40499273	C/T	cg24209194	chr3:40518798	ZNF619	0.56	7.45	0.42	1.31e-12	Renal cell carcinoma;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25349574	chr17:4891291	CAMTA2	-0.58	-6.83	-0.39	5.84e-11	Gut microbiome composition (summer);
CESC	trans	rs9329221	0.507	rs12678938	chr8:10016969	C/T	cg15556689	chr8:8085844	FLJ10661	-0.49	-6.14	-0.35	2.98e-9	Neuroticism;
CESC	cis	rs2404602	0.583	rs12908334	chr15:76581592	C/T	cg05617483	chr15:76483344	C15orf27	0.41	5.45	0.32	1.17e-7	Blood metabolite levels;
CESC	cis	rs17376456	0.825	rs7715562	chr5:93222034	C/T	cg25358565	chr5:93447407	FAM172A	-1.02	-9.82	-0.52	1.34e-19	Diabetic retinopathy;
CESC	cis	rs9611565	0.765	rs9607800	chr22:41784562	A/G	cg17376030	chr22:41985996	PMM1	0.66	7.08	0.4	1.3e-11	Vitiligo;
CESC	cis	rs4699052	0.625	rs4481237	chr4:104254009	G/A	cg16532752	chr4:104119610	CENPE	-0.39	-5.47	-0.32	1.02e-7	Testicular germ cell tumor;
CESC	cis	rs367615	0.959	rs2201016	chr5:108947287	T/C	cg17395555	chr5:108820864	NA	0.49	6.85	0.39	5.11e-11	Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs1707322	1.000	rs4489497	chr1:46438698	C/T	cg06784218	chr1:46089804	CCDC17	0.33	5.63	0.33	4.7e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs877282	1.000	rs7100358	chr10:773681	G/A	cg22713356	chr15:30763199	NA	1.12	11.27	0.57	2.42e-24	Uric acid levels;
CESC	cis	rs17376456	0.741	rs10036829	chr5:93309897	G/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.61	5.33	0.31	2.15e-7	Diabetic retinopathy;
CESC	cis	rs875971	0.706	rs1643374	chr7:65872682	T/A	cg18876405	chr7:65276391	NA	0.64	8.65	0.47	4.98e-16	Aortic root size;
CESC	cis	rs453301	0.606	rs6601279	chr8:8908231	G/A	cg15556689	chr8:8085844	FLJ10661	-0.5	-5.96	-0.34	7.83e-9	Joint mobility (Beighton score);
CESC	cis	rs1799949	1.000	rs33926631	chr17:41304463	T/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.44	6.16	0.35	2.7e-9	Menopause (age at onset);
CESC	cis	rs2836974	0.897	rs14194	chr21:40549466	T/C	cg11644478	chr21:40555479	PSMG1	1.01	16.84	0.72	9.25e-44	Cognitive function;
CESC	cis	rs9916302	0.851	rs6503518	chr17:37660469	A/G	cg20243544	chr17:37824526	PNMT	0.5	6.37	0.36	8.22e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg26304593	chr6:42947056	PEX6	-0.45	-5.67	-0.33	3.69e-8	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs2836950	0.545	rs2836956	chr21:40623018	C/G	cg11644478	chr21:40555479	PSMG1	0.52	7.05	0.4	1.56e-11	Menarche (age at onset);
CESC	cis	rs9640161	0.742	rs2108851	chr7:150019634	T/C	cg10018233	chr7:150070692	REPIN1	0.46	7.29	0.41	3.59e-12	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs11683229	0.704	rs13000344	chr2:63289734	T/G	cg17519650	chr2:63277830	OTX1	-0.73	-5.75	-0.33	2.48e-8	Protein quantitative trait loci;
CESC	cis	rs4927850	1.000	rs10881563	chr3:195750225	A/G	cg12923728	chr3:195709715	SDHAP1	-0.69	-8.96	-0.48	6.06e-17	Pancreatic cancer;
CESC	cis	rs12136530	0.593	rs11578302	chr1:19724835	A/G	cg01832549	chr1:19774989	CAPZB	-0.46	-6.42	-0.37	6.27e-10	Lead levels in blood;
CESC	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg05025164	chr4:1340916	KIAA1530	0.88	12.0	0.59	8.77e-27	Longevity;
CESC	cis	rs4891159	0.570	rs690132	chr18:74117261	T/C	cg24786174	chr18:74118243	ZNF516	0.85	16.07	0.7	4.75e-41	Longevity;
CESC	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg07507251	chr3:52567010	NT5DC2	0.47	8.94	0.48	6.75e-17	Electroencephalogram traits;
CESC	cis	rs2191566	0.576	rs420584	chr19:44495257	C/T	cg20607764	chr19:44506953	ZNF230	0.45	5.69	0.33	3.38e-8	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs2204008	0.837	rs12146734	chr12:38237079	A/G	cg26384229	chr12:38710491	ALG10B	0.69	9.8	0.52	1.51e-19	Bladder cancer;
CESC	cis	rs9324022	0.929	rs72698718	chr14:101178555	G/A	cg18089426	chr14:101175970	NA	0.61	7.68	0.43	3.17e-13	Plateletcrit;
CESC	trans	rs3780486	0.846	rs7036812	chr9:33143822	T/C	cg04842962	chr6:43655489	MRPS18A	0.98	18.21	0.75	1.33e-48	IgG glycosylation;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03914988	chr16:4748545	ANKS3	-0.56	-6.86	-0.39	4.84e-11	Gut microbiome composition (summer);
CESC	trans	rs3780486	0.757	rs10813949	chr9:33123464	G/A	cg04842962	chr6:43655489	MRPS18A	1.0	18.71	0.75	2.35e-50	IgG glycosylation;
CESC	cis	rs9811920	0.625	rs9847283	chr3:99910320	A/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.36	-5.57	-0.32	6.34e-8	Axial length;
CESC	cis	rs9311474	0.507	rs4687644	chr3:52746541	T/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.6	8.47	0.46	1.74e-15	Electroencephalogram traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04816434	chr15:22945077	CYFIP1	-0.64	-6.86	-0.39	4.9e-11	Gut microbiome composition (summer);
CESC	cis	rs1190552	0.846	rs3742437	chr14:102965047	G/A	cg18135206	chr14:102964638	TECPR2	0.42	5.28	0.31	2.71e-7	Blood protein levels;
CESC	cis	rs798554	0.679	rs2644300	chr7:2883071	G/A	cg19717773	chr7:2847554	GNA12	-0.46	-6.75	-0.38	9.53e-11	Height;
CESC	cis	rs8060686	0.623	rs58388686	chr16:68075439	A/G	cg26727032	chr16:67993705	SLC12A4	-0.59	-8.2	-0.45	1.05e-14	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs2637266	0.783	rs1797500	chr10:78510400	G/A	cg18941641	chr10:78392320	NA	0.43	8.41	0.46	2.58e-15	Pulmonary function;
CESC	cis	rs11792861	0.816	rs17792434	chr9:111667319	C/T	cg13535736	chr9:111863775	C9orf5	-0.46	-6.01	-0.35	6.06e-9	Menarche (age at onset);
CESC	cis	rs9311474	0.607	rs11711421	chr3:52561779	C/T	cg17372223	chr3:52568218	NT5DC2	0.53	8.47	0.46	1.68e-15	Electroencephalogram traits;
CESC	cis	rs950169	0.800	rs4842847	chr15:84931199	G/A	cg17507749	chr15:85114479	UBE2QP1	0.56	6.24	0.36	1.74e-9	Schizophrenia;
CESC	cis	rs7666738	0.830	rs13328005	chr4:99055480	T/C	cg03676636	chr4:99064102	C4orf37	0.34	5.14	0.3	5.43e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7551222	0.752	rs11240755	chr1:204478649	C/T	cg20240347	chr1:204465584	NA	-0.28	-5.65	-0.33	4.03e-8	Schizophrenia;
CESC	cis	rs6546537	0.714	rs17036759	chr2:69767029	C/T	cg10773587	chr2:69614142	GFPT1	-0.65	-8.1	-0.45	2.03e-14	Serum thyroid-stimulating hormone levels;
CESC	cis	rs4253772	0.515	rs6008591	chr22:46703664	T/C	cg09491104	chr22:46646882	C22orf40	-0.52	-6.43	-0.37	5.82e-10	LDL cholesterol;Cholesterol, total;
CESC	cis	rs17125944	0.505	rs2295827	chr14:53174981	C/T	cg00686598	chr14:53173677	PSMC6	1.36	11.75	0.59	5.93e-26	Alzheimer's disease (late onset);
CESC	cis	rs4728302	0.869	rs12707131	chr7:133620982	A/G	cg10665199	chr7:133106180	EXOC4	0.4	5.39	0.31	1.52e-7	Intelligence;Intelligence (multi-trait analysis);
CESC	cis	rs875971	0.522	rs1701760	chr7:65473688	A/G	cg14393609	chr7:65229607	NA	0.53	7.22	0.41	5.5e-12	Aortic root size;
CESC	trans	rs2018683	0.707	rs10279870	chr7:28968935	A/G	cg19402173	chr7:128379420	CALU	-0.53	-7.27	-0.41	4.13e-12	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CESC	cis	rs16910800	0.689	rs7101825	chr11:23164951	C/G	cg20040320	chr11:23191996	NA	0.58	6.16	0.35	2.72e-9	Cancer;
CESC	cis	rs1045714	0.895	rs1107690	chr7:2640595	G/T	cg20813462	chr7:2646259	IQCE	0.65	5.65	0.33	4.16e-8	Urate levels in lean individuals;
CESC	cis	rs2832191	0.967	rs3787660	chr21:30520907	C/T	cg24692254	chr21:30365293	RNF160	0.73	11.16	0.57	5.7e-24	Dental caries;
CESC	cis	rs2439831	0.850	rs28564774	chr15:44125475	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.63	5.6	0.33	5.26e-8	Lung cancer in ever smokers;
CESC	cis	rs9457247	0.508	rs6918286	chr6:167505829	C/T	cg23791538	chr6:167370224	RNASET2	-0.45	-5.89	-0.34	1.2e-8	Crohn's disease;
CESC	cis	rs1178968	0.901	rs1178953	chr7:72781277	A/G	cg25889504	chr7:72793014	NA	0.52	5.54	0.32	7.16e-8	Triglyceride levels;
CESC	cis	rs2479724	0.846	rs2254805	chr6:41846110	T/G	cg17623882	chr6:41773611	USP49	-0.41	-5.78	-0.33	2.04e-8	Menarche (age at onset);
CESC	cis	rs12497850	0.931	rs62262517	chr3:49134914	T/G	cg03060546	chr3:49711283	APEH	0.51	6.17	0.35	2.58e-9	Parkinson's disease;
CESC	cis	rs72829446	0.530	rs7222404	chr17:7384198	G/A	cg02795151	chr17:7402630	POLR2A	0.55	5.86	0.34	1.41e-8	Androgen levels;
CESC	cis	rs17253792	0.822	rs78323463	chr14:56045451	T/G	cg01858014	chr14:56050164	KTN1	-0.99	-7.44	-0.42	1.43e-12	Putamen volume;
CESC	trans	rs11098499	0.955	rs35197422	chr4:120169314	T/G	cg25214090	chr10:38739885	LOC399744	0.63	8.31	0.45	4.87e-15	Corneal astigmatism;
CESC	cis	rs17253792	0.822	rs75991559	chr14:56092419	A/T	cg01858014	chr14:56050164	KTN1	-0.85	-6.99	-0.39	2.22e-11	Putamen volume;
CESC	cis	rs1552244	0.935	rs6805869	chr3:10119917	T/C	cg00149659	chr3:10157352	C3orf10	0.73	8.89	0.48	9.97e-17	Alzheimer's disease;
CESC	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg24503407	chr1:205819492	PM20D1	0.82	12.81	0.62	1.43e-29	Menarche (age at onset);
CESC	cis	rs769267	0.895	rs2916073	chr19:19528324	T/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.46	6.13	0.35	3.17e-9	Tonsillectomy;
CESC	cis	rs9311474	0.632	rs6445528	chr3:52572447	C/T	cg17372223	chr3:52568218	NT5DC2	-0.44	-7.01	-0.4	1.99e-11	Electroencephalogram traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13494355	chr1:1274420	DVL1	-0.54	-6.17	-0.35	2.57e-9	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18361730	chr7:44047039	SPDYE1;POLR2J4	-0.57	-6.93	-0.39	3.15e-11	Gut microbiome composition (summer);
CESC	cis	rs1862618	0.573	rs1550821	chr5:56242323	C/T	cg22800045	chr5:56110881	MAP3K1	-0.76	-8.66	-0.47	4.8e-16	Initial pursuit acceleration;
CESC	cis	rs7828089	0.504	rs12676477	chr8:22266425	T/C	cg13512537	chr8:22265999	SLC39A14	-0.4	-5.74	-0.33	2.58e-8	Verbal declarative memory;
CESC	cis	rs17209837	0.607	rs7793196	chr7:87122847	A/G	cg00919237	chr7:87102261	ABCB4	-0.44	-5.47	-0.32	1.02e-7	Gallbladder cancer;
CESC	cis	rs7666738	0.830	rs6854919	chr4:98947326	C/T	cg05340658	chr4:99064831	C4orf37	0.8	11.74	0.58	6.77e-26	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4862750	0.914	rs1991256	chr4:187875330	A/G	cg10295955	chr4:187884368	NA	-1.02	-18.0	-0.74	7.4e-48	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1559088	1.000	rs7256328	chr19:33558705	G/C	cg17764715	chr19:33622953	WDR88	0.45	5.62	0.33	4.92e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs9467711	0.606	rs9393706	chr6:26361500	G/A	cg12826209	chr6:26865740	GUSBL1	0.6	5.04	0.3	8.5e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs763121	0.853	rs2413544	chr22:39059404	A/C	cg21395723	chr22:39101663	GTPBP1	0.43	5.37	0.31	1.74e-7	Menopause (age at onset);
CESC	cis	rs10861342	1.000	rs7305712	chr12:105519188	A/T	cg23923672	chr12:105501055	KIAA1033	-0.63	-5.45	-0.32	1.12e-7	IgG glycosylation;
CESC	cis	rs4919694	1.000	rs74749600	chr10:104732996	T/C	cg04362960	chr10:104952993	NT5C2	0.73	5.72	0.33	2.92e-8	Arsenic metabolism;
CESC	cis	rs74781061	1.000	rs6495116	chr15:74885948	A/G	cg17294928	chr15:75287854	SCAMP5	-0.5	-5.3	-0.31	2.48e-7	Endometriosis;
CESC	cis	rs7208859	0.673	rs11652409	chr17:29182707	T/A	cg19761014	chr17:28927070	LRRC37B2	0.63	5.27	0.31	2.88e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	trans	rs116095464	0.558	rs10079760	chr5:230778	A/G	cg00938859	chr5:1591904	SDHAP3	0.6	6.58	0.37	2.55e-10	Breast cancer;
CESC	cis	rs2228479	0.867	rs35542367	chr16:89965825	G/C	cg14709524	chr16:89940631	TCF25	0.7	5.52	0.32	8.08e-8	Skin colour saturation;
CESC	cis	rs617791	0.508	rs10791837	chr11:65774596	C/T	cg09783858	chr11:65769428	EIF1AD;BANF1	0.51	6.04	0.35	5.07e-9	Breast cancer;
CESC	cis	rs9611565	0.512	rs5758436	chr22:42124265	C/T	cg06481639	chr22:41940642	POLR3H	0.59	5.91	0.34	1.07e-8	Vitiligo;
CESC	cis	rs854765	0.647	rs2974998	chr17:17995619	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.6	8.56	0.47	9.6e-16	Total body bone mineral density;
CESC	cis	rs11098499	0.818	rs12498599	chr4:120468503	C/T	cg09307838	chr4:120376055	NA	0.91	12.73	0.62	2.82e-29	Corneal astigmatism;
CESC	cis	rs2878628	0.650	rs56098033	chr3:52758571	T/A	cg07507251	chr3:52567010	NT5DC2	0.35	5.94	0.34	8.7e-9	Intelligence (multi-trait analysis);
CESC	cis	rs4665809	0.938	rs35844686	chr2:26304949	A/G	cg26119090	chr2:26468346	HADHA;HADHB	0.81	8.77	0.47	2.26e-16	Gut microbiome composition (summer);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg19855366	chr13:111267979	CARKD	-0.46	-6.66	-0.38	1.54e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs12451471	0.637	rs12452616	chr17:78090081	A/G	cg24585782	chr17:78113791	EIF4A3	0.6	7.96	0.44	4.97e-14	Plateletcrit;Mean corpuscular hemoglobin concentration;
CESC	cis	rs2425143	0.730	rs6060626	chr20:34415073	G/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.67	5.49	0.32	9.63e-8	Blood protein levels;
CESC	cis	rs801193	0.569	rs2659907	chr7:66164032	G/A	cg11764359	chr7:65958608	NA	0.73	10.55	0.54	6.1e-22	Aortic root size;
CESC	cis	rs1065852	0.526	rs739296	chr22:42389948	A/G	cg22189786	chr22:42395067	WBP2NL	-0.41	-5.11	-0.3	6.26e-7	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
CESC	cis	rs9311474	0.713	rs352170	chr3:52236077	A/G	cg15147215	chr3:52552868	STAB1	-0.29	-5.03	-0.3	9.09e-7	Electroencephalogram traits;
CESC	cis	rs2070488	0.775	rs4679066	chr3:38568527	A/G	cg24069376	chr3:38537580	EXOG	-0.32	-5.54	-0.32	7.32e-8	Electrocardiographic conduction measures;
CESC	cis	rs4835473	0.897	rs6832722	chr4:144630583	C/G	cg25736465	chr4:144833511	NA	0.4	6.09	0.35	3.86e-9	Immature fraction of reticulocytes;
CESC	cis	rs8077577	0.895	rs6502640	chr17:18122485	G/A	cg16794390	chr17:18148240	FLII	0.42	5.65	0.33	4.16e-8	Obesity-related traits;
CESC	cis	rs4927850	0.709	rs6783079	chr3:195652708	T/C	cg12923728	chr3:195709715	SDHAP1	-0.66	-7.81	-0.43	1.33e-13	Pancreatic cancer;
CESC	cis	rs4727027	0.866	rs3735311	chr7:148877737	T/C	cg23583168	chr7:148888333	NA	-0.77	-11.24	-0.57	3.14e-24	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs5167	0.504	rs4803781	chr19:45459671	C/T	cg13119609	chr19:45449297	APOC2	0.47	7.76	0.43	1.87e-13	Blood protein levels;
CESC	cis	rs425277	0.628	rs3107145	chr1:2047547	G/A	cg19257562	chr1:2043853	PRKCZ	0.41	6.68	0.38	1.4e-10	Height;
CESC	cis	rs7618915	0.547	rs34017441	chr3:52742413	T/C	cg17372223	chr3:52568218	NT5DC2	0.43	6.5	0.37	3.98e-10	Bipolar disorder;
CESC	cis	rs477895	0.653	rs66648159	chr11:63899429	G/A	cg04317338	chr11:64019027	PLCB3	0.87	9.06	0.49	3.04e-17	Mean platelet volume;
CESC	cis	rs5758659	0.714	rs5758574	chr22:42481400	G/C	cg15557168	chr22:42548783	NA	0.43	6.56	0.37	2.81e-10	Cognitive function;
CESC	cis	rs17293817	0.588	rs17221652	chr10:1416472	C/G	cg04271617	chr10:1416546	ADARB2	-0.35	-5.6	-0.33	5.39e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20029123	chr22:30783486	RNF215	0.52	6.0	0.35	6.59e-9	Gut microbiome composition (summer);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg04381898	chr2:219082190	ARPC2	-0.46	-6.02	-0.35	5.69e-9	Ulcerative colitis;
CESC	cis	rs7605827	0.930	rs10203196	chr2:15541154	A/T	cg19274914	chr2:15703543	NA	0.34	6.12	0.35	3.44e-9	Educational attainment (years of education);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13833525	chr11:819513	PNPLA2	0.57	6.2	0.36	2.13e-9	Gut microbiome composition (summer);
CESC	cis	rs861020	1.000	rs632746	chr1:209982515	C/T	cg05527609	chr1:210001259	C1orf107	1.07	13.45	0.64	8.92e-32	Orofacial clefts;
CESC	cis	rs1862618	0.671	rs252897	chr5:56223000	G/A	cg24549020	chr5:56110836	MAP3K1	0.47	5.77	0.33	2.2e-8	Initial pursuit acceleration;
CESC	cis	rs9300255	0.722	rs28458312	chr12:123863265	G/T	cg00376283	chr12:123451042	ABCB9	-0.58	-6.67	-0.38	1.45e-10	Neutrophil percentage of white cells;
CESC	cis	rs17270561	0.609	rs17267614	chr6:25730027	A/C	cg25753631	chr6:25732923	NA	-0.28	-5.35	-0.31	1.95e-7	Iron status biomarkers;
CESC	cis	rs60154123	0.730	rs12403947	chr1:210456524	A/G	cg23283495	chr1:209979779	IRF6	-0.44	-5.5	-0.32	8.87e-8	Coronary artery disease;
CESC	cis	rs10504229	0.575	rs59424848	chr8:57999219	T/C	cg24829409	chr8:58192753	C8orf71	-0.42	-5.5	-0.32	8.75e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs727563	0.580	rs202626	chr22:41847190	C/A	cg06481639	chr22:41940642	POLR3H	0.52	5.58	0.32	5.84e-8	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs2228479	0.541	rs12918575	chr16:89811151	A/G	cg06558623	chr16:89946397	TCF25	0.79	7.45	0.42	1.32e-12	Skin colour saturation;
CESC	cis	rs875971	0.619	rs12533585	chr7:65984605	G/C	cg25985355	chr7:65971099	NA	-0.33	-5.47	-0.32	1.04e-7	Aortic root size;
CESC	cis	rs854765	0.583	rs8078138	chr17:17811251	C/T	cg16928487	chr17:17741425	SREBF1	-0.59	-10.25	-0.53	5.51e-21	Total body bone mineral density;
CESC	cis	rs2273669	0.667	rs77936298	chr6:109350616	A/T	cg05315195	chr6:109294784	ARMC2	-0.67	-6.32	-0.36	1.13e-9	Prostate cancer;
CESC	cis	rs11098499	0.863	rs13136462	chr4:120543173	C/T	cg09307838	chr4:120376055	NA	0.88	12.02	0.59	7.35e-27	Corneal astigmatism;
CESC	cis	rs910316	0.712	rs175074	chr14:75504454	G/A	cg15467112	chr14:75489610	MLH3	-0.33	-5.11	-0.3	6.23e-7	Height;
CESC	cis	rs2836974	0.568	rs377098	chr21:40535216	G/A	cg17971929	chr21:40555470	PSMG1	-0.87	-12.83	-0.62	1.2e-29	Cognitive function;
CESC	cis	rs2836974	0.966	rs7283420	chr21:40666865	T/C	cg17971929	chr21:40555470	PSMG1	0.98	13.28	0.63	3.31e-31	Cognitive function;
CESC	cis	rs959260	1.000	rs4788891	chr17:73391145	A/G	cg12999837	chr17:73267436	MIF4GD	-0.48	-5.54	-0.32	7.21e-8	Systemic lupus erythematosus;
CESC	cis	rs4253772	0.530	rs8140573	chr22:46800363	G/C	cg24881330	chr22:46731750	TRMU	0.67	5.36	0.31	1.84e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs9682041	0.597	rs62295834	chr3:170075701	G/A	cg11886554	chr3:170076028	SKIL	0.54	5.31	0.31	2.32e-7	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CESC	cis	rs909674	0.541	rs5750816	chr22:39810379	A/G	cg11247378	chr22:39784982	NA	0.62	9.48	0.5	1.49e-18	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs9393777	0.513	rs9379907	chr6:26654318	C/T	cg12826209	chr6:26865740	GUSBL1	0.73	8.13	0.45	1.7e-14	Intelligence (multi-trait analysis);
CESC	cis	rs7833986	0.534	rs10504198	chr8:57006254	G/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.62	7.54	0.42	7.58e-13	Height;
CESC	cis	rs4253772	0.530	rs9615990	chr22:46804154	G/A	cg18190219	chr22:46762943	CELSR1	-0.59	-6.11	-0.35	3.54e-9	LDL cholesterol;Cholesterol, total;
CESC	cis	rs1865760	0.532	rs2794719	chr6:26088890	T/G	cg16482183	chr6:26056742	HIST1H1C	0.4	5.43	0.32	1.25e-7	Height;
CESC	cis	rs929354	0.742	rs10251112	chr7:156963524	A/G	cg05182265	chr7:156933206	UBE3C	-0.51	-7.47	-0.42	1.14e-12	Body mass index;
CESC	cis	rs2303745	0.589	rs1965717	chr19:17398559	C/T	cg22549504	chr19:17448937	GTPBP3	0.49	5.35	0.31	1.88e-7	Systemic lupus erythematosus;
CESC	cis	rs733592	0.931	rs765260	chr12:48431936	C/T	cg24011408	chr12:48396354	COL2A1	-0.5	-8.03	-0.44	3.12e-14	Plateletcrit;
CESC	cis	rs1707322	0.752	rs28507722	chr1:46206540	A/G	cg06784218	chr1:46089804	CCDC17	0.41	7.21	0.41	5.75e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2075371	0.863	rs1646638	chr7:134008706	T/C	cg11752832	chr7:134001865	SLC35B4	0.52	6.57	0.37	2.64e-10	Mean platelet volume;
CESC	cis	rs6942756	0.915	rs6966595	chr7:129006202	A/C	cg02491457	chr7:128862824	NA	-0.6	-8.39	-0.46	2.99e-15	White matter hyperintensity burden;
CESC	cis	rs66573146	0.803	rs59742225	chr4:6969942	C/T	cg00086871	chr4:6988644	TBC1D14	1.08	6.05	0.35	5e-9	Granulocyte percentage of myeloid white cells;
CESC	cis	rs7927771	0.965	rs1064608	chr11:47640429	G/C	cg05585544	chr11:47624801	NA	-0.54	-8.42	-0.46	2.32e-15	Subjective well-being;
CESC	cis	rs9739070	1	rs9739070	chr12:123771032	A/G	cg00376283	chr12:123451042	ABCB9	0.57	6.45	0.37	5.36e-10	Allergy;
CESC	cis	rs6500602	0.627	rs9938228	chr16:4530597	T/C	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.36	5.17	0.3	4.59e-7	Schizophrenia;
CESC	cis	rs7520050	0.966	rs10890352	chr1:46283628	G/A	cg24296786	chr1:45957014	TESK2	0.43	5.41	0.32	1.38e-7	Red blood cell count;Reticulocyte count;
CESC	cis	rs11122272	0.735	rs2749699	chr1:231520279	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.57	-7.82	-0.43	1.29e-13	Hemoglobin concentration;
CESC	cis	rs2290159	0.800	rs73812836	chr3:12655149	T/G	cg23032965	chr3:12705835	RAF1	0.54	5.9	0.34	1.11e-8	Cholesterol, total;
CESC	cis	rs875971	0.862	rs6460293	chr7:65810192	C/A	cg11764359	chr7:65958608	NA	-0.79	-11.58	-0.58	2.22e-25	Aortic root size;
CESC	trans	rs7395662	0.553	rs4882155	chr11:48705801	T/C	cg00717180	chr2:96193071	NA	-0.45	-6.1	-0.35	3.83e-9	HDL cholesterol;
CESC	cis	rs2625529	0.701	rs12911154	chr15:72212653	G/A	cg16672083	chr15:72433130	SENP8	-0.39	-5.03	-0.3	9.17e-7	Red blood cell count;
CESC	cis	rs3096299	0.866	rs4238829	chr16:89462262	G/A	cg08392591	chr16:89556376	ANKRD11	0.41	5.28	0.31	2.64e-7	Multiple myeloma (IgH translocation);
CESC	trans	rs10242455	0.702	rs3528	chr7:99055940	T/C	cg09045935	chr12:6379348	NA	0.91	7.82	0.43	1.25e-13	Blood metabolite levels;
CESC	cis	rs801193	0.839	rs12534943	chr7:66070520	A/G	cg18876405	chr7:65276391	NA	-0.54	-7.57	-0.42	6.03e-13	Aortic root size;
CESC	cis	rs7666738	0.830	rs1426666	chr4:99030887	A/G	cg24818145	chr4:99064322	C4orf37	0.39	5.09	0.3	6.95e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9818758	0.607	rs71324929	chr3:49044713	C/T	cg00383909	chr3:49044727	WDR6	0.89	5.83	0.34	1.62e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CESC	cis	rs9913156	0.670	rs4416072	chr17:4570036	C/T	cg00122941	chr17:4613640	ARRB2	0.84	10.29	0.53	4.1e-21	Lymphocyte counts;
CESC	cis	rs11098499	0.743	rs10003567	chr4:120241674	C/T	cg09307838	chr4:120376055	NA	0.79	10.62	0.55	3.51e-22	Corneal astigmatism;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg10134882	chr12:65563916	LEMD3	-0.41	-6.08	-0.35	4.07e-9	Gambling;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05521474	chr5:135082196	NA	-0.54	-6.6	-0.38	2.25e-10	Gut microbiome composition (summer);
CESC	cis	rs11711311	1.000	rs2566970	chr3:113462123	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	-0.63	-9.09	-0.49	2.44e-17	IgG glycosylation;
CESC	cis	rs9611565	0.659	rs9611604	chr22:41916001	C/G	cg17376030	chr22:41985996	PMM1	0.76	8.2	0.45	1.04e-14	Vitiligo;
CESC	cis	rs67366981	0.778	rs3952319	chr14:77684379	A/T	cg22824376	chr14:77648248	TMEM63C	0.79	7.5	0.42	9.69e-13	Obsessive-compulsive symptoms;
CESC	trans	rs2975734	0.676	rs4841299	chr8:10112593	A/C	cg15556689	chr8:8085844	FLJ10661	-0.59	-6.73	-0.38	1.06e-10	Morning vs. evening chronotype;Chronotype;
CESC	cis	rs722599	0.748	rs59112602	chr14:75358817	C/G	cg08847533	chr14:75593920	NEK9	-0.46	-5.45	-0.32	1.18e-7	IgG glycosylation;
CESC	cis	rs853679	1.000	rs2799077	chr6:28234597	C/T	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.7	7.39	0.41	1.88e-12	Depression;
CESC	cis	rs10540	1.000	rs61876336	chr11:489537	C/T	cg03934478	chr11:495069	RNH1	0.56	5.36	0.31	1.84e-7	Body mass index;
CESC	cis	rs9796	0.689	rs11855797	chr15:41434679	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.43	-6.35	-0.36	9.34e-10	Menopause (age at onset);
CESC	cis	rs12497850	0.931	rs4974087	chr3:48919232	A/G	cg07636037	chr3:49044803	WDR6	1.03	19.1	0.76	9.82e-52	Parkinson's disease;
CESC	cis	rs4242434	0.927	rs13264187	chr8:22506098	C/T	cg14690197	chr8:22456421	C8orf58	0.37	5.03	0.3	9.01e-7	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CESC	cis	rs4243830	1.000	rs41278014	chr1:6579653	G/C	cg22792644	chr1:6614718	TAS1R1;NOL9	0.82	6.74	0.38	9.6e-11	Body mass index;
CESC	trans	rs61931739	0.534	rs35056575	chr12:34142914	A/T	cg26384229	chr12:38710491	ALG10B	0.66	9.21	0.49	1.01e-17	Morning vs. evening chronotype;
CESC	cis	rs9747201	1.000	rs9747668	chr17:80161081	A/G	cg09264619	chr17:80180166	NA	-0.44	-5.22	-0.31	3.67e-7	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs1003719	0.645	rs8131944	chr21:38547215	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.59	-8.06	-0.44	2.72e-14	Eye color traits;
CESC	cis	rs2839186	0.558	rs2968	chr21:47608580	C/T	cg12379764	chr21:47803548	PCNT	0.46	5.85	0.34	1.47e-8	Testicular germ cell tumor;
CESC	cis	rs3808502	0.647	rs7821302	chr8:11236572	T/A	cg21775007	chr8:11205619	TDH	-0.54	-8.07	-0.44	2.52e-14	Neuroticism;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04269569	chr16:8963018	CARHSP1	0.57	6.58	0.37	2.49e-10	Gut microbiome composition (summer);
CESC	cis	rs2050392	0.517	rs7096279	chr10:30759608	C/T	cg18806716	chr10:30721971	MAP3K8	-0.47	-7.27	-0.41	3.99e-12	Inflammatory bowel disease;
CESC	cis	rs6460942	0.591	rs62451464	chr7:12363059	C/A	cg20607287	chr7:12443886	VWDE	-0.59	-6.43	-0.37	6.05e-10	Coronary artery disease;
CESC	cis	rs734999	0.550	rs2985855	chr1:2531372	A/C	cg20673091	chr1:2541236	MMEL1	-0.43	-7.12	-0.4	1.03e-11	Ulcerative colitis;
CESC	cis	rs868036	1.000	rs4633663	chr15:68106378	G/C	cg08079166	chr15:68083412	MAP2K5	0.43	6.92	0.39	3.35e-11	Restless legs syndrome;
CESC	cis	rs2303759	0.543	rs7255778	chr19:49906608	G/A	cg22307029	chr19:49891270	CCDC155	0.62	7.3	0.41	3.29e-12	Multiple sclerosis;
CESC	cis	rs2204008	0.905	rs8189449	chr12:38437377	C/A	cg13010199	chr12:38710504	ALG10B	0.42	5.43	0.32	1.28e-7	Bladder cancer;
CESC	cis	rs2337406	0.714	rs7145254	chr14:107226016	A/G	cg23076370	chr14:107095027	NA	-0.55	-5.68	-0.33	3.57e-8	Alzheimer's disease (late onset);
CESC	cis	rs7618915	0.508	rs7628578	chr3:52628321	A/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.82	0.39	6.17e-11	Bipolar disorder;
CESC	cis	rs2404602	0.716	rs12441550	chr15:76863682	A/T	cg26408565	chr15:76604113	ETFA	-0.4	-5.72	-0.33	2.92e-8	Blood metabolite levels;
CESC	cis	rs3820928	0.874	rs1114562	chr2:227788592	T/C	cg05526886	chr2:227700861	RHBDD1	-0.46	-5.89	-0.34	1.16e-8	Pulmonary function;
CESC	cis	rs7829975	0.806	rs2428	chr8:8641145	C/T	cg15556689	chr8:8085844	FLJ10661	0.5	6.41	0.37	6.74e-10	Mood instability;
CESC	cis	rs9287719	0.967	rs10929688	chr2:10756650	T/C	cg00105475	chr2:10696890	NA	0.37	5.3	0.31	2.43e-7	Prostate cancer;
CESC	cis	rs7219021	0.926	rs12150249	chr17:46852108	A/T	cg16584676	chr17:46985605	UBE2Z	-0.51	-5.84	-0.34	1.49e-8	Schizophrenia or bipolar disorder;
CESC	cis	rs5417	0.775	rs222852	chr17:7140606	A/G	cg25256661	chr17:7137939	DVL2	0.48	6.43	0.37	5.81e-10	Diastolic blood pressure;
CESC	cis	rs6894249	1.000	rs6894249	chr5:131797547	A/G	cg21138405	chr5:131827807	IRF1	0.37	6.07	0.35	4.44e-9	Asthma;
CESC	cis	rs847577	0.609	rs7791463	chr7:97819047	G/A	cg24562669	chr7:97807699	LMTK2	0.82	13.31	0.63	2.74e-31	Breast cancer;
CESC	cis	rs921968	0.565	rs6436084	chr2:219639782	A/G	cg02176678	chr2:219576539	TTLL4	-0.44	-7.74	-0.43	2.15e-13	Mean corpuscular hemoglobin concentration;
CESC	cis	rs11122272	0.735	rs2749704	chr1:231526243	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.56	-7.67	-0.43	3.27e-13	Hemoglobin concentration;
CESC	trans	rs2882926	0.590	rs7835219	chr8:63525400	C/T	cg07243138	chr11:105169034	NA	-0.61	-6.3	-0.36	1.2e-9	Periodontitis (PAL4Q3);
CESC	cis	rs6429082	0.764	rs291377	chr1:235695186	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.56	-6.64	-0.38	1.82e-10	Adiposity;
CESC	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg14159672	chr1:205819179	PM20D1	0.8	12.15	0.6	2.75e-27	Menarche (age at onset);
CESC	cis	rs250677	0.687	rs250667	chr5:148455134	A/G	cg18129178	chr5:148520854	ABLIM3	0.52	5.95	0.34	8.45e-9	Breast cancer;
CESC	cis	rs9611565	0.512	rs2050033	chr22:42159229	G/T	cg03806693	chr22:41940476	POLR3H	1.19	14.1	0.65	4.45e-34	Vitiligo;
CESC	cis	rs2576037	0.796	rs2247021	chr18:44578794	A/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.46	-6.06	-0.35	4.59e-9	Personality dimensions;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12183124	chr6:43507374	XPO5	-0.68	-7.87	-0.44	8.95e-14	Gut microbiome composition (summer);
CESC	cis	rs6496667	0.558	rs10459677	chr15:91042399	A/C	cg22089800	chr15:90895588	ZNF774	-0.47	-5.92	-0.34	9.83e-9	Rheumatoid arthritis;
CESC	cis	rs2576037	0.558	rs7244778	chr18:44541915	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.69	10.88	0.56	4.85e-23	Personality dimensions;
CESC	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg23708337	chr7:1209742	NA	0.55	5.47	0.32	1.04e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7666738	0.830	rs28515641	chr4:98726419	G/A	cg05340658	chr4:99064831	C4orf37	0.76	11.17	0.57	5.6e-24	Colonoscopy-negative controls vs population controls;
CESC	cis	rs12618769	0.597	rs4851136	chr2:99060873	A/T	cg10123293	chr2:99228465	UNC50	0.39	5.18	0.3	4.49e-7	Bipolar disorder;
CESC	cis	rs10504229	1.000	rs72650885	chr8:58175131	G/A	cg05313129	chr8:58192883	C8orf71	-0.55	-6.37	-0.36	8.42e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs1185460	0.967	rs1786684	chr11:118938435	G/A	cg23280166	chr11:118938394	VPS11	0.57	8.0	0.44	3.79e-14	Coronary artery disease;
CESC	cis	rs10256972	0.684	rs2363279	chr7:1096143	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.43	-5.88	-0.34	1.24e-8	Longevity;Endometriosis;
CESC	cis	rs473651	0.692	rs579511	chr2:239334914	C/G	cg18131467	chr2:239335373	ASB1	1.03	20.34	0.78	4.85e-56	Multiple system atrophy;
CESC	cis	rs7666738	0.830	rs13119995	chr4:99026790	T/C	cg17366294	chr4:99064904	C4orf37	0.62	8.95	0.48	6.32e-17	Colonoscopy-negative controls vs population controls;
CESC	trans	rs8073060	0.544	rs225268	chr17:33966224	A/C	cg19694781	chr19:47549865	TMEM160	-0.73	-7.03	-0.4	1.79e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	cis	rs4819052	0.819	rs13046807	chr21:46672286	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.93	13.69	0.64	1.3e-32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10823157	chr18:76829834	ATP9B	-0.68	-8.47	-0.46	1.76e-15	Gut microbiome composition (summer);
CESC	cis	rs2549003	1.000	rs7734334	chr5:131815004	C/A	cg21138405	chr5:131827807	IRF1	0.54	9.38	0.5	3.2e-18	Asthma (sex interaction);
CESC	cis	rs7666738	0.830	rs10001701	chr4:98918871	G/C	cg03467027	chr4:99064603	C4orf37	0.43	5.23	0.31	3.43e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs847577	0.609	rs17435847	chr7:97792820	G/A	cg24562669	chr7:97807699	LMTK2	0.84	14.25	0.66	1.33e-34	Breast cancer;
CESC	cis	rs2072732	0.861	rs2993510	chr1:2956666	C/T	cg03976712	chr1:2946727	NA	-0.31	-5.45	-0.32	1.13e-7	Plateletcrit;
CESC	cis	rs4665809	0.818	rs35413760	chr2:26267137	C/A	cg25036284	chr2:26402008	FAM59B	0.67	7.26	0.41	4.38e-12	Gut microbiome composition (summer);
CESC	cis	rs7216064	1.000	rs7210027	chr17:65977053	C/T	cg07042672	chr17:66097459	LOC651250	0.6	7.54	0.42	7.61e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs916888	0.773	rs199447	chr17:44812188	C/T	cg27589368	chr17:43923255	LOC100128977;IMP5	-0.4	-5.46	-0.32	1.11e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs9916302	0.904	rs801426	chr17:37441109	C/T	cg20243544	chr17:37824526	PNMT	-0.41	-5.13	-0.3	5.69e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs4835473	0.932	rs1813908	chr4:144649327	C/T	cg25736465	chr4:144833511	NA	0.36	5.42	0.32	1.31e-7	Immature fraction of reticulocytes;
CESC	cis	rs2576037	0.526	rs2032215	chr18:44439011	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.69	10.6	0.55	4.02e-22	Personality dimensions;
CESC	cis	rs1799949	0.965	rs799916	chr17:41243190	G/T	cg19454999	chr17:41278357	BRCA1;NBR2	-0.48	-6.88	-0.39	4.43e-11	Menopause (age at onset);
CESC	cis	rs7447593	0.518	rs4074995	chr5:176797343	C/T	cg16006841	chr5:176797999	RGS14	0.58	6.26	0.36	1.59e-9	Urinary electrolytes (magnesium/calcium ratio);
CESC	cis	rs17711722	1.000	rs17711722	chr7:65271197	C/T	cg14393609	chr7:65229607	NA	-0.52	-7.07	-0.4	1.36e-11	Calcium levels;
CESC	cis	rs11864453	0.928	rs3213420	chr16:72042433	C/T	cg16558253	chr16:72132732	DHX38	-0.48	-7.15	-0.4	8.32e-12	Fibrinogen levels;
CESC	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	22.5	0.81	2.02e-63	Prudent dietary pattern;
CESC	cis	rs36051895	0.594	rs7029244	chr9:5180961	A/C	cg02405213	chr9:5042618	JAK2	-0.51	-6.68	-0.38	1.43e-10	Pediatric autoimmune diseases;
CESC	cis	rs644799	0.965	rs10831426	chr11:95505888	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	14.66	0.67	4.91e-36	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs4727963	0.846	rs1608829	chr7:122707613	A/G	cg03640110	chr7:122635026	TAS2R16	0.37	5.82	0.34	1.67e-8	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
CESC	cis	rs1372520	0.873	rs2737026	chr4:90779823	A/G	cg15133208	chr4:90757351	SNCA	-0.35	-5.03	-0.3	8.84e-7	Neuroticism;
CESC	cis	rs4409675	0.576	rs7533918	chr1:28230667	G/A	cg23691781	chr1:28212827	C1orf38	0.28	5.53	0.32	7.57e-8	Corneal astigmatism;
CESC	cis	rs13191362	0.507	rs2510207	chr6:163086592	T/C	cg14584255	chr6:163149320	PACRG;PARK2	-0.42	-5.2	-0.3	3.99e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03773196	chr1:219786527	NA	-0.56	-7.42	-0.41	1.62e-12	Gut microbiome composition (summer);
CESC	cis	rs7914558	0.966	rs3902934	chr10:104746649	A/G	cg04362960	chr10:104952993	NT5C2	0.46	5.93	0.34	9.56e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	trans	rs2727020	0.595	rs10839286	chr11:49497063	C/A	cg03929089	chr4:120376271	NA	-0.85	-13.5	-0.64	5.83e-32	Coronary artery disease;
CESC	cis	rs7605827	0.780	rs34739027	chr2:15532146	C/A	cg19274914	chr2:15703543	NA	0.36	6.46	0.37	5.01e-10	Educational attainment (years of education);
CESC	cis	rs6500602	0.627	rs9938228	chr16:4530597	T/C	cg08645402	chr16:4508243	NA	0.42	5.92	0.34	1.01e-8	Schizophrenia;
CESC	cis	rs873946	0.648	rs12766050	chr10:134549108	G/A	cg06453172	chr10:134556979	INPP5A	-0.43	-5.58	-0.32	5.88e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs9322193	0.962	rs7740784	chr6:150154500	C/T	cg07701084	chr6:150067640	NUP43	0.42	5.6	0.33	5.37e-8	Lung cancer;
CESC	cis	rs9916302	0.904	rs13341996	chr17:37536862	C/T	cg15445000	chr17:37608096	MED1	-0.4	-6.52	-0.37	3.49e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs4243830	1.000	rs12046884	chr1:6594561	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	0.78	6.18	0.36	2.36e-9	Body mass index;
CESC	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	7.84	0.43	1.14e-13	Prudent dietary pattern;
CESC	cis	rs10089	1.000	rs1560636	chr5:127447987	A/G	cg19767477	chr5:127420684	SLC12A2	-0.4	-5.55	-0.32	7.07e-8	Ileal carcinoids;
CESC	cis	rs17345786	1.000	rs3762729	chr3:101308874	C/T	cg12386194	chr3:101231763	SENP7	0.57	6.56	0.37	2.81e-10	Colonoscopy-negative controls vs population controls;
CESC	cis	rs5750830	0.649	rs5750808	chr22:39790987	G/A	cg05872129	chr22:39784769	NA	-0.85	-11.73	-0.58	7.18e-26	Intelligence (multi-trait analysis);
CESC	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg07414643	chr4:187882934	NA	0.56	8.14	0.45	1.53e-14	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs3942852	0.759	rs905475	chr11:48149755	C/T	cg15704280	chr7:45808275	SEPT13	-0.65	-7.4	-0.41	1.8e-12	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs763121	0.853	rs5750672	chr22:39104168	C/T	cg06022373	chr22:39101656	GTPBP1	-0.88	-13.94	-0.65	1.63e-33	Menopause (age at onset);
CESC	cis	rs6952808	0.692	rs60755037	chr7:2030104	G/A	cg21782813	chr7:2030301	MAD1L1	0.5	7.17	0.4	7.6e-12	Bipolar disorder and schizophrenia;
CESC	cis	rs2486288	0.656	rs6493143	chr15:45570781	G/T	cg09092052	chr15:45571596	NA	0.45	5.33	0.31	2.14e-7	Glomerular filtration rate;
CESC	cis	rs6952808	0.501	rs4721429	chr7:2171704	T/C	cg02951883	chr7:2050386	MAD1L1	-0.47	-6.17	-0.35	2.52e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs9660180	0.967	rs12034740	chr1:1728969	C/A	cg17747265	chr1:1875780	NA	-0.57	-9.13	-0.49	1.81e-17	Body mass index;
CESC	cis	rs8040855	0.627	rs12900012	chr15:85590186	A/G	cg08123816	chr15:85640762	PDE8A	-0.36	-5.41	-0.32	1.39e-7	Bulimia nervosa;
CESC	cis	rs3026445	0.791	rs7309141	chr12:110587637	G/A	cg12870014	chr12:110450643	ANKRD13A	0.46	5.9	0.34	1.13e-8	QT interval;
CESC	cis	rs367615	0.704	rs17161885	chr5:108852642	A/G	cg17395555	chr5:108820864	NA	0.66	10.95	0.56	2.91e-23	Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs6502050	0.835	rs9904520	chr17:80100117	T/C	cg23985595	chr17:80112537	CCDC57	-0.42	-6.57	-0.37	2.72e-10	Life satisfaction;
CESC	cis	rs8070624	0.574	rs9914127	chr17:17875836	A/T	cg04398451	chr17:18023971	MYO15A	-0.75	-10.67	-0.55	2.48e-22	Total body bone mineral density;
CESC	cis	rs4665809	0.590	rs4665315	chr2:26416036	T/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.08	-13.24	-0.63	4.53e-31	Gut microbiome composition (summer);
CESC	cis	rs1881797	1.000	rs12081895	chr1:247686666	C/G	cg18198730	chr1:247681584	NA	0.59	7.76	0.43	1.84e-13	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs9910055	0.762	rs2631299	chr17:42219773	G/T	cg19774624	chr17:42201019	HDAC5	-0.69	-10.03	-0.52	2.7e-20	Total body bone mineral density;
CESC	cis	rs4713118	0.629	rs149899	chr6:28019979	C/T	cg12963246	chr6:28129442	ZNF389	0.49	6.34	0.36	9.71e-10	Parkinson's disease;
CESC	cis	rs6430585	0.527	rs62168792	chr2:136415217	A/G	cg07169764	chr2:136633963	MCM6	1.06	12.14	0.6	2.95e-27	Corneal structure;
CESC	cis	rs9788682	0.747	rs7177514	chr15:78907406	C/G	cg24631222	chr15:78858424	CHRNA5	0.78	9.74	0.51	2.36e-19	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs684232	0.583	rs17677436	chr17:520314	T/C	cg15660573	chr17:549704	VPS53	-0.81	-11.87	-0.59	2.38e-26	Prostate cancer;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg26998693	chr6:132834590	STX7	-0.47	-6.53	-0.37	3.33e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs7786808	0.608	rs9692003	chr7:158204696	G/A	cg09998033	chr7:158218633	PTPRN2	0.37	5.51	0.32	8.35e-8	Obesity-related traits;
CESC	cis	rs7084402	0.967	rs1658435	chr10:60327527	A/G	cg07615347	chr10:60278583	BICC1	0.59	9.44	0.5	2e-18	Refractive error;
CESC	cis	rs35146811	0.586	rs6964754	chr7:99589404	G/A	cg14163444	chr7:99595348	NA	-0.39	-5.24	-0.31	3.3e-7	Coronary artery disease;
CESC	cis	rs12477438	0.798	rs10167015	chr2:99570707	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.73	-10.32	-0.54	3.22e-21	Chronic sinus infection;
CESC	cis	rs7267979	0.934	rs2261115	chr20:25259807	G/A	cg08601574	chr20:25228251	PYGB	0.39	5.61	0.33	5e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs854765	0.583	rs4925126	chr17:17798633	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.63	9.26	0.49	7.2e-18	Total body bone mineral density;
CESC	cis	rs2637266	1.000	rs12784382	chr10:78378348	G/T	cg18941641	chr10:78392320	NA	0.42	7.87	0.44	8.96e-14	Pulmonary function;
CESC	cis	rs7267979	1.000	rs2424716	chr20:25423538	G/A	cg08601574	chr20:25228251	PYGB	0.38	5.57	0.32	6.24e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs4253772	0.688	rs113928699	chr22:46649344	G/A	cg00784671	chr22:46762841	CELSR1	-0.52	-5.49	-0.32	9.2e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs9467711	0.790	rs1979	chr6:26377591	G/T	cg14345882	chr6:26364793	BTN3A2	0.64	6.74	0.38	1.01e-10	Autism spectrum disorder or schizophrenia;
CESC	cis	rs4713118	0.513	rs183244	chr6:28031838	C/A	cg12963246	chr6:28129442	ZNF389	0.39	5.59	0.32	5.67e-8	Parkinson's disease;
CESC	cis	rs1799949	1.000	rs3092994	chr17:41215825	C/T	cg05368731	chr17:41323189	NBR1	0.79	10.91	0.56	3.89e-23	Menopause (age at onset);
CESC	cis	rs1451375	0.583	rs7776816	chr7:50583534	G/A	cg14593290	chr7:50529359	DDC	0.5	6.09	0.35	3.87e-9	Malaria;
CESC	cis	rs853679	0.517	rs6922063	chr6:28094366	G/A	cg22143856	chr6:28129313	ZNF389	0.5	6.59	0.38	2.34e-10	Depression;
CESC	trans	rs11098499	0.866	rs13105020	chr4:120285688	G/T	cg25214090	chr10:38739885	LOC399744	0.65	9.11	0.49	2.04e-17	Corneal astigmatism;
CESC	cis	rs9583531	0.574	rs61971615	chr13:111353111	C/T	cg24331049	chr13:111365604	ING1	-0.72	-10.45	-0.54	1.3e-21	Coronary artery disease;
CESC	cis	rs1552244	1.000	rs13319597	chr3:10126312	A/C	cg08888203	chr3:10149979	C3orf24	-0.52	-6.98	-0.39	2.35e-11	Alzheimer's disease;
CESC	cis	rs853679	0.550	rs1150689	chr6:28165099	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.48	-5.69	-0.33	3.36e-8	Depression;
CESC	cis	rs7552404	0.731	rs5745445	chr1:76344332	G/A	cg10523679	chr1:76189770	ACADM	0.66	6.27	0.36	1.44e-9	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs873946	0.648	rs12766166	chr10:134556403	G/C	cg27286337	chr10:134555280	INPP5A	0.61	6.89	0.39	4.15e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs3008870	0.755	rs4655662	chr1:67416432	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.63	8.38	0.46	3.04e-15	Lymphocyte percentage of white cells;
CESC	cis	rs4474465	0.646	rs7927503	chr11:78280606	G/T	cg27205649	chr11:78285834	NARS2	0.52	7.14	0.4	9.17e-12	Alzheimer's disease (survival time);
CESC	cis	rs1941023	0.584	rs2241921	chr11:60164302	C/T	cg08716584	chr11:60157161	MS4A7	-0.6	-10.27	-0.53	4.78e-21	Congenital heart disease (maternal effect);
CESC	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.89	13.67	0.64	1.49e-32	Prudent dietary pattern;
CESC	cis	rs950776	0.518	rs12910289	chr15:78822065	T/G	cg06917634	chr15:78832804	PSMA4	0.8	12.12	0.6	3.34e-27	Sudden cardiac arrest;
CESC	cis	rs2075371	0.830	rs1421478	chr7:133922793	T/A	cg20476274	chr7:133979776	SLC35B4	0.61	8.77	0.47	2.26e-16	Mean platelet volume;
CESC	cis	rs9457247	1.000	rs9457247	chr6:167392174	C/T	cg07741184	chr6:167504864	NA	0.31	5.53	0.32	7.87e-8	Crohn's disease;
CESC	cis	rs60871478	0.730	rs62432226	chr7:792973	T/C	cg00934597	chr7:893267	UNC84A	0.56	5.65	0.33	4.17e-8	Cerebrospinal P-tau181p levels;
CESC	cis	rs7666738	0.515	rs13434650	chr4:98889886	A/G	cg05340658	chr4:99064831	C4orf37	0.58	7.15	0.4	8.28e-12	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4077515	1.000	rs10781499	chr9:139266405	G/A	cg14169450	chr9:139327907	INPP5E	0.36	5.18	0.3	4.46e-7	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs11252926	0.931	rs12358336	chr10:566981	A/T	cg08603382	chr10:743973	NA	-0.59	-7.47	-0.42	1.15e-12	Psychosis in Alzheimer's disease;
CESC	cis	rs79387448	0.638	rs6741230	chr2:103069631	C/T	cg09003973	chr2:102972529	NA	0.82	6.59	0.38	2.34e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs4268898	0.662	rs2303297	chr2:24432937	C/T	cg20701182	chr2:24300061	SF3B14	0.68	7.16	0.4	7.75e-12	Asthma;
CESC	cis	rs9814567	0.964	rs9820150	chr3:134223011	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.44	-5.98	-0.35	7.05e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs9894429	0.816	rs7406040	chr17:79597583	A/C	cg13777783	chr17:79615861	NA	-0.33	-5.23	-0.31	3.45e-7	Eye color traits;
CESC	trans	rs4650994	0.525	rs4650996	chr1:178517365	A/G	cg05059571	chr16:84539110	KIAA1609	-0.4	-6.19	-0.36	2.3e-9	HDL cholesterol levels;HDL cholesterol;
CESC	cis	rs853679	0.517	rs9368557	chr6:28131537	T/C	cg23161317	chr6:28129485	ZNF389	0.52	6.48	0.37	4.37e-10	Depression;
CESC	cis	rs7692995	1.000	rs7694806	chr4:18029100	C/T	cg08925142	chr4:18023851	LCORL	-0.44	-5.2	-0.3	3.92e-7	Height;
CESC	cis	rs7246865	0.954	rs55957788	chr19:17207851	G/A	cg19418318	chr19:17219073	MYO9B	0.36	5.9	0.34	1.11e-8	Reticulocyte fraction of red cells;
CESC	cis	rs4604732	0.527	rs79329288	chr1:247626513	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.57	7.17	0.4	7.39e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs2932538	0.922	rs6659677	chr1:113087076	G/C	cg22162597	chr1:113214053	CAPZA1	0.56	7.0	0.39	2.15e-11	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CESC	cis	rs8070624	0.574	rs11078408	chr17:17876011	A/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.53	6.69	0.38	1.3100000000000001e-10	Total body bone mineral density;
CESC	cis	rs863345	0.604	rs1157525	chr1:158457253	T/C	cg12129480	chr1:158549410	OR10X1	-0.36	-7.15	-0.4	8.67e-12	Pneumococcal bacteremia;
CESC	cis	rs7666738	0.546	rs34159897	chr4:98787367	T/C	cg05340658	chr4:99064831	C4orf37	0.58	7.25	0.41	4.5e-12	Colonoscopy-negative controls vs population controls;
CESC	cis	rs60871478	1.000	rs34260834	chr7:822958	A/G	cg05535760	chr7:792225	HEATR2	0.85	10.54	0.54	6.54e-22	Cerebrospinal P-tau181p levels;
CESC	cis	rs2576037	0.526	rs564113	chr18:44364389	A/T	cg19077165	chr18:44547161	KATNAL2	-0.52	-7.58	-0.42	5.66e-13	Personality dimensions;
CESC	cis	rs644799	0.544	rs555556	chr11:95618425	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.49	6.33	0.36	1.03e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs4728302	0.869	rs13221033	chr7:133617487	T/A	cg10665199	chr7:133106180	EXOC4	0.39	5.3	0.31	2.49e-7	Intelligence;Intelligence (multi-trait analysis);
CESC	cis	rs2425143	1.000	rs8124505	chr20:34307247	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.82	-7.59	-0.42	5.42e-13	Blood protein levels;
CESC	cis	rs7799006	0.929	rs6951493	chr7:2257612	G/A	cg12745145	chr7:2261452	MAD1L1	-0.38	-5.92	-0.34	1.01e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	trans	rs7246657	0.943	rs2891699	chr19:37920237	A/G	cg01833234	chr11:6592585	DNHD1	0.52	6.0	0.35	6.5e-9	Coronary artery calcification;
CESC	cis	rs10129255	0.500	rs6576232	chr14:107195328	A/G	cg23076370	chr14:107095027	NA	-0.64	-9.33	-0.5	4.36e-18	Kawasaki disease;
CESC	cis	rs3820068	0.734	rs6669156	chr1:15905206	T/A	cg17385448	chr1:15911702	AGMAT	0.43	6.75	0.38	9.27e-11	Systolic blood pressure;
CESC	cis	rs1218582	0.741	rs2335407	chr1:154843347	A/G	cg24250549	chr1:154909240	PMVK	-0.63	-8.69	-0.47	3.89e-16	Prostate cancer;
CESC	cis	rs7666738	0.830	rs6818045	chr4:99049374	G/A	cg17366294	chr4:99064904	C4orf37	0.61	8.72	0.47	3.1e-16	Colonoscopy-negative controls vs population controls;
CESC	trans	rs7395662	0.517	rs2021248	chr11:49013054	C/T	cg15704280	chr7:45808275	SEPT13	-0.58	-7.1	-0.4	1.11e-11	HDL cholesterol;
CESC	cis	rs7666738	0.830	rs6532701	chr4:98745134	C/T	cg03467027	chr4:99064603	C4orf37	0.45	5.53	0.32	7.79e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10504229	0.817	rs55891651	chr8:58167600	C/T	cg24829409	chr8:58192753	C8orf71	-0.63	-8.99	-0.48	4.81e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs11122272	0.735	rs2808596	chr1:231530723	A/G	cg06096015	chr1:231504339	EGLN1	0.4	5.78	0.33	2.12e-8	Hemoglobin concentration;
CESC	cis	rs10447248	0.776	rs7444217	chr5:107900097	C/T	cg25075504	chr5:107899390	NA	-0.39	-5.92	-0.34	9.8e-9	Adiponectin levels;
CESC	cis	rs1862618	0.641	rs252893	chr5:56224714	T/C	cg12311346	chr5:56204834	C5orf35	-0.64	-8.74	-0.47	2.67e-16	Initial pursuit acceleration;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg17597374	chr11:61106595	DAK	0.47	6.42	0.37	6.22e-10	Fibrinogen levels;
CESC	cis	rs4975616	0.836	rs13178866	chr5:1323212	C/T	cg26373071	chr5:1325741	CLPTM1L	0.42	6.78	0.38	7.64e-11	Lung cancer;
CESC	cis	rs6460942	0.597	rs13221702	chr7:12519076	A/G	cg06484146	chr7:12443880	VWDE	0.69	7.5	0.42	9.9e-13	Coronary artery disease;
CESC	trans	rs13394619	0.565	rs12478958	chr2:11748037	A/G	cg18984002	chr17:36876514	MLLT6	-0.42	-6.22	-0.36	1.92e-9	Endometriosis;
CESC	cis	rs2235544	0.579	rs1537323	chr1:54482523	G/T	cg25741118	chr1:54482237	LDLRAD1	0.22	5.52	0.32	7.91e-8	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
CESC	cis	rs796364	1.000	rs11694369	chr2:200741720	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.94	-7.43	-0.42	1.52e-12	Schizophrenia;
CESC	cis	rs11190604	1.000	rs11190541	chr10:102203071	A/G	cg07080220	chr10:102295463	HIF1AN	0.55	5.56	0.32	6.43e-8	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs5758659	0.652	rs1063392	chr22:42454950	C/T	cg04733989	chr22:42467013	NAGA	-0.45	-6.37	-0.36	8.37e-10	Cognitive function;
CESC	cis	rs67311347	1.000	rs1466237	chr3:40462026	C/G	cg24209194	chr3:40518798	ZNF619	0.46	6.03	0.35	5.54e-9	Renal cell carcinoma;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11659435	chr20:30310674	BCL2L1	0.56	6.02	0.35	5.79e-9	Gut microbiome composition (summer);
CESC	cis	rs7246657	1.000	rs12709812	chr19:37794850	A/G	cg23950597	chr19:37808831	NA	0.62	6.45	0.37	5.15e-10	Coronary artery calcification;
CESC	cis	rs6565180	1.000	rs12930787	chr16:30381303	C/G	cg17640201	chr16:30407289	ZNF48	-0.94	-14.04	-0.65	7.5e-34	Tonsillectomy;
CESC	trans	rs61931739	0.534	rs11052973	chr12:34029708	A/G	cg26384229	chr12:38710491	ALG10B	0.59	8.27	0.45	6.34e-15	Morning vs. evening chronotype;
CESC	cis	rs2228479	0.850	rs62054610	chr16:89816920	G/A	cg00800038	chr16:89945340	TCF25	-0.91	-7.54	-0.42	7.39e-13	Skin colour saturation;
CESC	cis	rs9611565	0.512	rs5996063	chr22:42168767	G/A	cg17376030	chr22:41985996	PMM1	-0.79	-8.37	-0.46	3.43e-15	Vitiligo;
CESC	cis	rs6598955	0.612	rs12738188	chr1:26548029	G/C	cg04990556	chr1:26633338	UBXN11	-0.8	-11.48	-0.58	4.98e-25	Obesity-related traits;
CESC	cis	rs4722166	0.630	rs10950916	chr7:22799667	C/T	cg05265849	chr7:22767390	IL6	0.55	6.63	0.38	1.86e-10	Lung cancer;
CESC	cis	rs72792276	1.000	rs78529289	chr5:127405378	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.71	5.5	0.32	8.77e-8	Red cell distribution width;
CESC	cis	rs10242455	0.702	rs28460612	chr7:98993205	C/G	cg18809830	chr7:99032528	PTCD1	-0.89	-6.1	-0.35	3.84e-9	Blood metabolite levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04108570	chr2:9143163	MBOAT2	-0.56	-6.88	-0.39	4.4e-11	Gut microbiome composition (summer);
CESC	cis	rs4563143	0.647	rs34218744	chr19:29256821	A/T	cg04546413	chr19:29218101	NA	0.56	7.77	0.43	1.76e-13	Methadone dose in opioid dependence;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26431313	chr3:151987306	LOC401093;MBNL1	0.55	6.32	0.36	1.11e-9	Gut microbiome composition (summer);
CESC	cis	rs7927771	1.000	rs11039426	chr11:47863119	G/A	cg18512352	chr11:47633146	NA	-0.6	-9.47	-0.5	1.62e-18	Subjective well-being;
CESC	cis	rs17818399	0.926	rs7590693	chr2:46823992	G/A	cg02822958	chr2:46747628	ATP6V1E2	0.48	5.59	0.32	5.57e-8	Height;
CESC	cis	rs698761	0.505	rs7609180	chr2:44538484	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.52	5.29	0.31	2.51e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs4604732	0.603	rs10802512	chr1:247633730	G/T	cg12758973	chr1:247694275	LOC148824;OR2C3	0.38	5.58	0.32	6e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs10823500	0.777	rs10509321	chr10:71985733	A/G	cg04118878	chr10:71993077	PPA1	-0.51	-6.08	-0.35	4.12e-9	Blood protein levels;
CESC	cis	rs6121246	0.559	rs6121172	chr20:30296095	A/C	cg13852791	chr20:30311386	BCL2L1	0.86	11.25	0.57	2.93e-24	Mean corpuscular hemoglobin;
CESC	cis	rs28374715	0.783	rs11630656	chr15:41570909	T/G	cg20272979	chr15:41787780	ITPKA	0.42	5.1	0.3	6.53e-7	Ulcerative colitis;
CESC	cis	rs8070128	0.568	rs3935505	chr17:17882020	T/G	cg04398451	chr17:18023971	MYO15A	-0.65	-8.46	-0.46	1.79e-15	Total body bone mineral density;
CESC	cis	rs4253772	0.637	rs3087501	chr22:46647909	A/G	cg09491104	chr22:46646882	C22orf40	-0.56	-8.38	-0.46	3.1e-15	LDL cholesterol;Cholesterol, total;
CESC	cis	rs12220238	0.915	rs7922519	chr10:75976573	G/C	cg19889307	chr10:75911429	ADK;AP3M1	0.6	5.45	0.32	1.13e-7	Soluble interleukin-2 receptor subunit alpha;
CESC	cis	rs854765	0.583	rs6502619	chr17:17779704	C/G	cg09796270	chr17:17721594	SREBF1	-0.46	-6.46	-0.37	4.99e-10	Total body bone mineral density;
CESC	cis	rs4805272	0.512	rs11879141	chr19:29320335	G/A	cg14983838	chr19:29218262	NA	0.44	5.29	0.31	2.57e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
CESC	cis	rs2050392	0.517	rs593400	chr10:30762088	A/G	cg18806716	chr10:30721971	MAP3K8	0.49	7.55	0.42	7.25e-13	Inflammatory bowel disease;
CESC	cis	rs4713118	0.662	rs13218430	chr6:28029837	T/C	cg23161317	chr6:28129485	ZNF389	0.49	6.19	0.36	2.28e-9	Parkinson's disease;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg21767207	chr19:36236454	PSENEN;U2AF1L4	-0.44	-6.06	-0.35	4.56e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs116095464	0.619	rs2303741	chr5:218356	T/C	cg00938859	chr5:1591904	SDHAP3	0.6	6.66	0.38	1.55e-10	Breast cancer;
CESC	cis	rs113835537	0.529	rs2305533	chr11:66298623	A/C	cg24851651	chr11:66362959	CCS	0.5	5.96	0.34	8.04e-9	Airway imaging phenotypes;
CESC	cis	rs2760061	0.819	rs708114	chr1:228197496	G/A	cg02753203	chr1:228287806	NA	0.53	7.89	0.44	8.14e-14	Diastolic blood pressure;
CESC	cis	rs1451375	0.617	rs2329371	chr7:50615440	G/A	cg14593290	chr7:50529359	DDC	0.5	5.98	0.35	7.05e-9	Malaria;
CESC	cis	rs9311474	0.508	rs6786919	chr3:52599789	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.49	7.2	0.4	6.39e-12	Electroencephalogram traits;
CESC	cis	rs8031584	0.679	rs34017474	chr15:31230611	T/C	cg08704250	chr15:31115839	NA	-0.49	-6.61	-0.38	2.09e-10	Huntington's disease progression;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg26591553	chr5:176863129	GRK6	0.5	6.74	0.38	9.76e-11	Fibrinogen levels;
CESC	cis	rs5753618	0.504	rs8138525	chr22:32011929	T/C	cg00478049	chr22:31556069	RNF185	0.44	5.16	0.3	4.96e-7	Colorectal cancer;
CESC	cis	rs2288912	0.872	rs9304646	chr19:45450408	T/C	cg20090143	chr19:45452003	APOC2	0.38	6.49	0.37	4.3e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs6088580	0.524	rs6088575	chr20:33273403	C/T	cg08999081	chr20:33150536	PIGU	0.37	5.08	0.3	7.16e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs933688	1.000	rs10474353	chr5:90732285	A/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.17	16.18	0.7	2e-41	Smoking behavior;
CESC	cis	rs933688	1.000	rs6869717	chr5:90694797	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.18	14.27	0.66	1.16e-34	Smoking behavior;
CESC	cis	rs13242816	0.881	rs35062002	chr7:116142458	G/A	cg04696780	chr7:116139425	CAV2	-0.61	-5.55	-0.32	7.01e-8	P wave duration;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00173787	chr1:156698861	C1orf66;ISG20L2	0.6	6.94	0.39	2.95e-11	Gut microbiome composition (summer);
CESC	cis	rs3020736	0.500	rs7364293	chr22:42506370	C/T	cg12850546	chr22:42539477	CYP2D7P1	0.43	5.16	0.3	4.86e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs3806843	0.735	rs801188	chr5:140066916	G/T	cg26395211	chr5:140044315	WDR55	0.47	5.94	0.34	9e-9	Depressive symptoms (multi-trait analysis);
CESC	cis	rs10491083	0.661	rs631565	chr17:6568540	T/C	cg13067509	chr17:6538498	KIAA0753	0.58	5.13	0.3	5.65e-7	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs9916302	0.861	rs752314	chr17:37410700	C/T	cg00129232	chr17:37814104	STARD3	-0.55	-7.08	-0.4	1.28e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs7618915	0.508	rs7628578	chr3:52628321	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.58	8.23	0.45	8.8e-15	Bipolar disorder;
CESC	cis	rs11203032	0.831	rs10887928	chr10:90945861	A/T	cg16672925	chr10:90967113	CH25H	0.69	7.02	0.4	1.83e-11	Heart failure;
CESC	cis	rs11249608	0.548	rs6601007	chr5:178455796	G/C	cg01312482	chr5:178451176	ZNF879	-0.45	-6.36	-0.36	8.71e-10	Pubertal anthropometrics;
CESC	cis	rs514406	0.505	rs448788	chr1:53161620	A/G	cg16325326	chr1:53192061	ZYG11B	-0.93	-16.1	-0.7	3.88e-41	Monocyte count;
CESC	cis	rs6032067	0.777	rs62208386	chr20:43790872	G/A	cg10761708	chr20:43804764	PI3	0.56	6.55	0.37	3.01e-10	Blood protein levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09556632	chr1:40839764	SMAP2	0.56	6.54	0.37	3.07e-10	Gut microbiome composition (summer);
CESC	cis	rs7546094	1.000	rs7415820	chr1:113169449	G/A	cg22162597	chr1:113214053	CAPZA1	-0.39	-6.01	-0.35	6.14e-9	Platelet distribution width;
CESC	cis	rs7336332	0.628	rs9581855	chr13:28018014	G/A	cg22138327	chr13:27999177	GTF3A	0.61	5.58	0.32	5.99e-8	Weight;
CESC	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg04025307	chr7:1156635	C7orf50	0.54	9.55	0.51	8.88e-19	Longevity;Endometriosis;
CESC	cis	rs10479542	1.000	rs10479542	chr5:178981241	T/A	cg21226059	chr5:178986404	RUFY1	0.49	7.57	0.42	6.27e-13	Lung cancer;
CESC	cis	rs4713118	0.597	rs172166	chr6:28020820	C/G	cg12963246	chr6:28129442	ZNF389	0.5	6.41	0.37	6.57e-10	Parkinson's disease;
CESC	cis	rs55871839	0.559	rs4737526	chr8:59823372	A/G	cg07426533	chr8:59803705	TOX	0.39	5.25	0.31	3.12e-7	Pneumonia;
CESC	cis	rs4974559	0.895	rs12646130	chr4:1330530	G/C	cg02980000	chr4:1222292	CTBP1	0.77	7.06	0.4	1.49e-11	Systolic blood pressure;
CESC	cis	rs17253792	0.822	rs78824140	chr14:56042715	G/T	cg01858014	chr14:56050164	KTN1	-0.99	-7.46	-0.42	1.21e-12	Putamen volume;
CESC	cis	rs7998202	0.614	rs282571	chr13:113366234	C/G	cg02820901	chr13:113351484	ATP11A	0.66	5.74	0.33	2.63e-8	Glycated hemoglobin levels;
CESC	trans	rs9987353	0.840	rs329994	chr8:9123233	A/G	cg02948236	chr16:66864732	NAE1	-0.44	-6.0	-0.35	6.58e-9	Recombination measurement;
CESC	cis	rs1799949	0.965	rs1842147	chr17:41435192	C/T	cg23758822	chr17:41437982	NA	1.03	15.38	0.69	1.41e-38	Menopause (age at onset);
CESC	cis	rs8114671	0.836	rs6142284	chr20:33641367	G/A	cg24642439	chr20:33292090	TP53INP2	-0.45	-5.44	-0.32	1.19e-7	Height;
CESC	cis	rs514406	0.505	rs6703127	chr1:53180565	C/T	cg08736216	chr1:53307985	ZYG11A	-0.37	-6.3	-0.36	1.21e-9	Monocyte count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13594432	chr14:23451963	JUB	-0.59	-7.05	-0.4	1.58e-11	Gut microbiome composition (summer);
CESC	cis	rs1506636	0.962	rs1506640	chr7:123349627	T/G	cg03229431	chr7:123269106	ASB15	-0.52	-6.91	-0.39	3.6e-11	Plateletcrit;Platelet count;
CESC	cis	rs30380	0.553	rs27527	chr5:96151968	C/A	cg16492584	chr5:96139282	ERAP1	-0.47	-6.5	-0.37	4.03e-10	Cerebrospinal fluid biomarker levels;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg10057841	chr11:129996244	APLP2	-0.46	-6.3	-0.36	1.21e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs6772849	0.896	rs4857859	chr3:128348014	G/T	cg16766828	chr3:128327626	NA	-0.31	-5.11	-0.3	6.19e-7	Monocyte percentage of white cells;Monocyte count;
CESC	cis	rs7917772	0.503	rs11191325	chr10:104302933	G/A	cg22532475	chr10:104410764	TRIM8	-0.35	-5.97	-0.34	7.47e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs9611565	0.694	rs5751107	chr22:41857812	A/G	cg03806693	chr22:41940476	POLR3H	1.19	14.53	0.67	1.37e-35	Vitiligo;
CESC	cis	rs920590	0.758	rs7012358	chr8:19662498	C/T	cg03894339	chr8:19674705	INTS10	0.62	7.11	0.4	1.05e-11	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs6991838	0.584	rs4320587	chr8:66499226	G/A	cg13398993	chr8:66546079	ARMC1	-0.48	-5.76	-0.33	2.37e-8	Intelligence (multi-trait analysis);
CESC	cis	rs1018836	0.663	rs3950221	chr8:91478108	G/A	cg16814680	chr8:91681699	NA	-0.58	-7.65	-0.43	3.83e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs4862307	0.754	rs6846208	chr4:184991703	C/T	cg06737308	chr4:185021514	ENPP6	0.42	5.71	0.33	3.08e-8	Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	cis	rs826838	0.868	rs12322306	chr12:39130021	A/G	cg26384229	chr12:38710491	ALG10B	-0.67	-11.01	-0.56	1.82e-23	Heart rate;
CESC	cis	rs77216612	0.877	rs7956514	chr12:12879254	T/G	cg09462578	chr12:12878428	APOLD1	-1.0	-15.16	-0.68	7.99e-38	Lymphocyte counts;
CESC	cis	rs731174	0.959	rs7546741	chr1:38191397	G/C	cg12339802	chr1:38156545	C1orf109	-0.55	-6.33	-0.36	1.06e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs9527	0.590	rs7898770	chr10:104756636	A/G	cg04362960	chr10:104952993	NT5C2	-0.41	-5.22	-0.31	3.66e-7	Arsenic metabolism;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	ch.2.4963927F	chr2:242179805	HDLBP	-0.52	-6.22	-0.36	1.94e-9	Gut microbiome composition (summer);
CESC	cis	rs7618915	0.547	rs12486847	chr3:52691112	T/C	cg17372223	chr3:52568218	NT5DC2	0.43	6.43	0.37	5.82e-10	Bipolar disorder;
CESC	cis	rs4975709	0.569	rs2077269	chr5:1863506	C/T	cg10800226	chr5:1850261	NA	0.32	5.33	0.31	2.15e-7	Cardiovascular disease risk factors;
CESC	cis	rs7523050	0.730	rs11102650	chr1:109464228	C/G	cg08274380	chr1:109419600	GPSM2	0.79	5.91	0.34	1.04e-8	Fat distribution (HIV);
CESC	trans	rs1814175	0.647	rs1404157	chr11:49917301	G/C	cg15704280	chr7:45808275	SEPT13	-0.82	-11.35	-0.57	1.34e-24	Height;
CESC	cis	rs6754311	0.773	rs4988183	chr2:136622046	T/C	cg15123519	chr2:136567270	LCT	-0.29	-5.08	-0.3	7.23e-7	Mosquito bite size;
CESC	cis	rs7927592	0.913	rs7109294	chr11:68332093	A/G	cg20283391	chr11:68216788	NA	-0.61	-7.4	-0.41	1.77e-12	Total body bone mineral density;
CESC	cis	rs7618915	0.571	rs6805539	chr3:52609710	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.47	6.68	0.38	1.36e-10	Bipolar disorder;
CESC	cis	rs2074585	0.679	rs2601195	chr15:90938232	G/A	cg22089800	chr15:90895588	ZNF774	0.66	9.16	0.49	1.42e-17	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
CESC	cis	rs875971	0.895	rs4718349	chr7:65909011	C/G	cg10691866	chr7:65817282	TPST1	-0.34	-5.61	-0.33	4.98e-8	Aortic root size;
CESC	cis	rs6866344	0.570	rs59259518	chr5:178142628	C/T	cg10224037	chr5:178157518	ZNF354A	0.75	8.67	0.47	4.37e-16	Neutrophil percentage of white cells;
CESC	cis	rs6815814	0.950	rs5743789	chr4:38833173	A/T	cg02016764	chr4:38805732	TLR1	-0.61	-6.86	-0.39	4.8e-11	Breast cancer;
CESC	cis	rs7666738	0.830	rs1593569	chr4:99017485	C/G	cg17366294	chr4:99064904	C4orf37	0.6	8.58	0.47	7.97e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2415984	0.579	rs2817548	chr14:46969149	A/T	cg14871534	chr14:47121158	RPL10L	0.35	5.32	0.31	2.21e-7	Number of children ever born;
CESC	cis	rs9399137	0.507	rs4896128	chr6:135349756	A/G	cg22676075	chr6:135203613	NA	-0.51	-6.92	-0.39	3.34e-11	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	cis	rs3784262	1.000	rs12908953	chr15:58277812	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.32	-5.09	-0.3	6.71e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
CESC	cis	rs425277	0.583	rs4648807	chr1:2040898	A/G	cg13918804	chr1:2043761	PRKCZ	0.28	5.5	0.32	9.09e-8	Height;
CESC	cis	rs12148488	0.763	rs2304902	chr15:75340727	G/T	cg14664628	chr15:75095509	CSK	-0.46	-5.54	-0.32	7.17e-8	Caffeine consumption;
CESC	cis	rs11792861	0.888	rs11794648	chr9:111829792	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.44	5.65	0.33	4.11e-8	Menarche (age at onset);
CESC	cis	rs9894429	0.789	rs9747336	chr17:79584189	C/T	cg13777783	chr17:79615861	NA	-0.33	-5.24	-0.31	3.35e-7	Eye color traits;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg12448664	chr15:85143675	ZSCAN2	-0.48	-6.5	-0.37	4.06e-10	Asthma;
CESC	cis	rs11098499	0.818	rs7688802	chr4:120451668	G/A	cg09307838	chr4:120376055	NA	0.91	12.54	0.61	1.24e-28	Corneal astigmatism;
CESC	cis	rs2842992	0.789	rs2842969	chr6:160145364	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.69	8.96	0.48	5.78e-17	Age-related macular degeneration (geographic atrophy);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg07049977	chr2:37458536	CEBPZ;C2orf56	-0.48	-6.34	-0.36	9.97e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs6062302	0.522	rs6090475	chr20:62245397	C/A	cg09650180	chr20:62225654	GMEB2	-0.82	-9.38	-0.5	3.04e-18	Glioblastoma;
CESC	cis	rs801193	0.569	rs6978178	chr7:66123084	G/A	cg18252515	chr7:66147081	NA	0.48	6.47	0.37	4.62e-10	Aortic root size;
CESC	trans	rs1814175	0.817	rs10769641	chr11:49960141	A/G	cg15704280	chr7:45808275	SEPT13	-1.03	-20.41	-0.78	2.75e-56	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20018234	chr1:156084659	LMNA	0.55	6.22	0.36	1.88e-9	Gut microbiome composition (summer);
CESC	cis	rs6500395	1.000	rs1106386	chr16:48593065	C/A	cg04672837	chr16:48644449	N4BP1	0.5	6.23	0.36	1.78e-9	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs1790761	0.587	rs7934075	chr11:67295949	T/C	cg00290607	chr11:67383545	NA	-0.39	-5.78	-0.33	2.1e-8	Mean corpuscular volume;
CESC	cis	rs6460942	1.000	rs112996286	chr7:12315741	G/C	cg20607287	chr7:12443886	VWDE	-0.79	-8.51	-0.46	1.32e-15	Coronary artery disease;
CESC	cis	rs12291225	0.546	rs12291662	chr11:14342949	T/C	cg19336497	chr11:14380999	RRAS2	-0.45	-6.67	-0.38	1.48e-10	Sense of smell;
CESC	cis	rs847577	0.609	rs11765552	chr7:97822115	T/A	cg24562669	chr7:97807699	LMTK2	0.84	13.88	0.65	2.69e-33	Breast cancer;
CESC	cis	rs10751667	0.643	rs10751669	chr11:942344	C/G	cg20946044	chr11:1010712	AP2A2	0.42	5.73	0.33	2.78e-8	Alzheimer's disease (late onset);
CESC	cis	rs4555082	0.834	rs2975217	chr14:105710238	A/C	cg27165867	chr14:105738592	BRF1	-0.5	-5.46	-0.32	1.08e-7	Mean platelet volume;Platelet distribution width;
CESC	cis	rs1008375	1.000	rs10012335	chr4:17628630	C/G	cg15017067	chr4:17643749	FAM184B	0.42	5.98	0.34	7.33e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs2276314	0.857	rs7237599	chr18:33639396	T/C	cg19628046	chr18:33552617	C18orf21	0.51	5.83	0.34	1.57e-8	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs7086627	0.515	rs12245180	chr10:82211897	C/G	cg03267442	chr10:82210566	NA	-0.34	-5.66	-0.33	3.98e-8	Post bronchodilator FEV1;
CESC	cis	rs9894429	0.646	rs7406522	chr17:79615396	G/T	cg18240062	chr17:79603768	NPLOC4	0.5	6.59	0.38	2.41e-10	Eye color traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16577540	chr5:139682757	PFDN1	0.62	7.49	0.42	1.06e-12	Gut microbiome composition (summer);
CESC	cis	rs4790333	0.537	rs2447106	chr17:2257819	A/T	cg02569219	chr17:2266849	SGSM2	-0.4	-5.36	-0.31	1.84e-7	Proinsulin levels;
CESC	cis	rs2832077	0.689	rs2832052	chr21:30130073	G/C	cg08807101	chr21:30365312	RNF160	-0.5	-5.86	-0.34	1.37e-8	Cognitive test performance;
CESC	cis	rs801193	0.660	rs4610622	chr7:66224497	T/C	cg11764359	chr7:65958608	NA	0.87	13.28	0.63	3.49e-31	Aortic root size;
CESC	cis	rs2463822	0.844	rs1919359	chr11:62055703	A/G	cg06239285	chr11:62104954	ASRGL1	1.02	8.67	0.47	4.45e-16	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs6456156	0.586	rs12528689	chr6:167461746	A/G	cg07741184	chr6:167504864	NA	0.35	6.08	0.35	4.1e-9	Primary biliary cholangitis;
CESC	cis	rs4141404	0.787	rs11913992	chr22:31585220	G/A	cg02404636	chr22:31891804	SFI1	-0.39	-5.61	-0.33	5.05e-8	Paclitaxel-induced neuropathy;
CESC	cis	rs3740713	1.000	rs75487138	chr11:18461878	A/G	cg23797887	chr11:18477753	LDHAL6A	-0.54	-5.24	-0.31	3.31e-7	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs270601	0.770	rs1007602	chr5:131602166	T/C	cg18758796	chr5:131593413	PDLIM4	0.48	6.97	0.39	2.55e-11	Acylcarnitine levels;
CESC	cis	rs5758659	0.652	rs6519301	chr22:42385967	A/G	cg15557168	chr22:42548783	NA	-0.44	-6.5	-0.37	4.05e-10	Cognitive function;
CESC	cis	rs1218582	0.688	rs58629129	chr1:154910930	T/C	cg06221963	chr1:154839813	KCNN3	-0.59	-9.31	-0.5	5.24e-18	Prostate cancer;
CESC	cis	rs1348850	0.554	rs1374438	chr2:178376684	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.68	6.23	0.36	1.87e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs2836950	0.565	rs2836942	chr21:40591381	A/G	cg17971929	chr21:40555470	PSMG1	-0.54	-7.1	-0.4	1.12e-11	Menarche (age at onset);
CESC	cis	rs2249625	0.545	rs2249021	chr6:72889472	A/G	cg18830697	chr6:72922368	RIMS1	-0.47	-7.02	-0.4	1.89e-11	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CESC	cis	rs6449957	0.639	rs831227	chr5:67517646	A/C	cg23036683	chr5:67512108	NA	0.41	5.55	0.32	6.82e-8	Cleft lip with or without cleft palate;
CESC	cis	rs9322193	0.923	rs9800736	chr6:149982417	A/G	cg07701084	chr6:150067640	NUP43	0.47	6.72	0.38	1.11e-10	Lung cancer;
CESC	cis	rs6963495	0.818	rs73190187	chr7:105164401	A/T	cg13798780	chr7:105162888	PUS7	0.78	8.06	0.44	2.68e-14	Bipolar disorder (body mass index interaction);
CESC	cis	rs875971	0.825	rs66981195	chr7:66079035	C/A	cg18252515	chr7:66147081	NA	0.47	6.17	0.35	2.57e-9	Aortic root size;
CESC	cis	rs597539	0.652	rs674654	chr11:68698762	G/T	cg21963583	chr11:68658836	MRPL21	0.4	5.64	0.33	4.32e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs7089973	0.604	rs58587374	chr10:116597572	A/G	cg03647239	chr10:116582469	FAM160B1	0.44	5.55	0.32	6.83e-8	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs146201400	1	rs146201400	chr1:26645955	G/GA	cg00813993	chr1:26644493	UBXN11;CD52	-0.4	-6.38	-0.36	7.85e-10	Monocyte percentage of white cells;
CESC	cis	rs16858210	0.874	rs73177525	chr3:183570286	G/C	cg25686905	chr3:183603175	PARL	-0.33	-6.21	-0.36	2.04e-9	Menopause (age at onset);
CESC	cis	rs9916302	0.821	rs4795386	chr17:37746847	A/G	cg00129232	chr17:37814104	STARD3	-0.69	-9.03	-0.49	3.68e-17	Glomerular filtration rate (creatinine);
CESC	cis	rs896854	0.654	rs2011566	chr8:95971921	G/A	cg13393036	chr8:95962371	TP53INP1	-0.48	-10.27	-0.53	4.94e-21	Type 2 diabetes;
CESC	cis	rs1153858	1.000	rs12437887	chr15:45669094	G/A	cg14582100	chr15:45693742	SPATA5L1	0.42	5.95	0.34	8.38e-9	Homoarginine levels;
CESC	cis	rs916888	0.821	rs199507	chr17:44858855	A/G	cg01570182	chr17:44337453	NA	-0.87	-10.59	-0.55	4.47e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs13095912	0.638	rs6791369	chr3:185289989	C/A	cg11274856	chr3:185301563	NA	0.37	5.47	0.32	1.06e-7	Systolic blood pressure;
CESC	trans	rs9987353	0.840	rs329994	chr8:9123233	A/G	cg24714709	chr7:95064397	PON2	-0.46	-6.17	-0.35	2.6e-9	Recombination measurement;
CESC	cis	rs4555082	0.957	rs10140586	chr14:105749582	A/G	cg13114125	chr14:105738426	BRF1	-0.71	-8.91	-0.48	8.36e-17	Mean platelet volume;Platelet distribution width;
CESC	cis	rs7246657	0.943	rs4803347	chr19:37848017	G/A	cg23950597	chr19:37808831	NA	-0.54	-5.94	-0.34	9.05e-9	Coronary artery calcification;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21209604	chr6:26032199	HIST1H3B	0.55	6.45	0.37	5.26e-10	Gut microbiome composition (summer);
CESC	cis	rs4563143	0.514	rs55727361	chr19:29300415	A/T	cg14983838	chr19:29218262	NA	0.49	5.45	0.32	1.15e-7	Methadone dose in opioid dependence;
CESC	cis	rs6089829	0.962	rs6122350	chr20:61664617	A/G	cg16240275	chr20:61666158	NCRNA00029	0.5	8.97	0.48	5.67e-17	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs977987	0.843	rs2059256	chr16:75395835	G/T	cg03315344	chr16:75512273	CHST6	0.39	5.61	0.33	4.98e-8	Dupuytren's disease;
CESC	cis	rs1046896	0.562	rs2380172	chr17:80887719	C/A	cg19046167	chr17:80928561	B3GNTL1	0.51	6.24	0.36	1.75e-9	Glycated hemoglobin levels;
CESC	cis	rs56046484	0.956	rs34076898	chr15:85664800	A/C	cg08123816	chr15:85640762	PDE8A	-0.5	-6.19	-0.36	2.23e-9	Testicular germ cell tumor;
CESC	cis	rs1728785	1.000	rs698717	chr16:68560199	A/G	cg02972257	chr16:68554789	NA	-0.62	-6.95	-0.39	2.75e-11	Ulcerative colitis;
CESC	cis	rs9479482	1.000	rs9479403	chr6:150337746	C/T	cg03788504	chr6:150331562	NA	0.36	6.89	0.39	4.06e-11	Alopecia areata;
CESC	trans	rs66573146	0.572	rs67252699	chr4:6946411	A/G	cg07817883	chr1:32538562	TMEM39B	1.25	8.66	0.47	4.59e-16	Granulocyte percentage of myeloid white cells;
CESC	cis	rs10857712	0.703	rs1056521	chr10:135235890	T/C	cg22671611	chr10:135291010	NA	-0.34	-5.08	-0.3	7.11e-7	Systemic lupus erythematosus;
CESC	cis	rs6756513	0.509	rs11686934	chr2:70172116	C/T	cg02498382	chr2:70120550	SNRNP27	0.31	5.22	0.31	3.64e-7	Breast cancer;Platelet count;
CESC	cis	rs7659604	0.539	rs11098646	chr4:122729301	T/C	cg19748678	chr4:122722346	EXOSC9	0.78	9.68	0.51	3.7e-19	Type 2 diabetes;
CESC	cis	rs9913156	0.793	rs55782417	chr17:4562845	G/A	cg19197139	chr17:4613644	ARRB2	0.92	10.46	0.54	1.18e-21	Lymphocyte counts;
CESC	cis	rs12477438	0.501	rs12992218	chr2:99753834	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.85	15.81	0.7	4.17e-40	Chronic sinus infection;
CESC	cis	rs593982	0.920	rs645621	chr11:65490756	T/C	cg08755490	chr11:65554678	OVOL1	1.2	10.9	0.56	4.29e-23	Atopic dermatitis;
CESC	cis	rs1062177	1.000	rs2964578	chr5:151147198	T/A	cg00977110	chr5:151150581	G3BP1	0.68	7.31	0.41	3.09e-12	Preschool internalizing problems;
CESC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg04915975	chr3:139063070	MRPS22	-0.5	-6.02	-0.35	5.71e-9	Lung cancer in ever smokers;
CESC	trans	rs1838564	0.929	rs805510	chr12:28139846	C/T	cg11798959	chr1:23857321	E2F2	0.65	6.22	0.36	1.94e-9	Breast size;
CESC	cis	rs4434138	0.594	rs7653028	chr3:52763000	A/T	cg18337363	chr3:52569053	NT5DC2	0.29	5.25	0.31	3.11e-7	Intelligence (multi-trait analysis);
CESC	cis	rs7539624	0.588	rs7414311	chr1:223901497	A/G	cg10100437	chr1:223903862	CAPN2	0.44	5.64	0.33	4.3e-8	Schizophrenia;
CESC	trans	rs4295623	0.585	rs13259242	chr8:11593033	T/G	cg15556689	chr8:8085844	FLJ10661	-0.55	-6.32	-0.36	1.11e-9	Morning vs. evening chronotype;
CESC	cis	rs769267	1.000	rs2301669	chr19:19453560	C/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.64	-8.23	-0.45	8.51e-15	Tonsillectomy;
CESC	cis	rs5769765	0.825	rs9616780	chr22:50292763	T/C	cg26441486	chr22:50317300	CRELD2	0.39	5.37	0.31	1.76e-7	Schizophrenia;
CESC	cis	rs4604732	0.536	rs76191272	chr1:247628055	A/T	cg12758973	chr1:247694275	LOC148824;OR2C3	0.48	6.01	0.35	6.07e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs9815354	0.904	rs9852991	chr3:41875455	C/A	cg03022575	chr3:42003672	ULK4	0.58	6.01	0.35	5.96e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs17666538	0.585	rs4448252	chr8:615597	A/G	cg23958373	chr8:599963	NA	0.81	6.0	0.35	6.49e-9	IgG glycosylation;
CESC	cis	rs41271473	0.526	rs10916344	chr1:228737489	C/T	cg16512390	chr1:228756714	NA	0.55	5.66	0.33	3.84e-8	Chronic lymphocytic leukemia;
CESC	cis	rs7618915	0.524	rs12488461	chr3:52698417	T/C	cg18404041	chr3:52824283	ITIH1	-0.4	-6.72	-0.38	1.08e-10	Bipolar disorder;
CESC	cis	rs2760061	0.626	rs634106	chr1:228121548	C/T	cg02753203	chr1:228287806	NA	-0.49	-7.38	-0.41	2.06e-12	Diastolic blood pressure;
CESC	trans	rs61931739	0.500	rs10844845	chr12:34381117	C/T	cg26384229	chr12:38710491	ALG10B	0.52	7.33	0.41	2.75e-12	Morning vs. evening chronotype;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02979170	chr11:118972138	DPAGT1	-0.58	-6.09	-0.35	3.98e-9	Gut microbiome composition (summer);
CESC	cis	rs1005277	0.579	rs2472176	chr10:38382921	T/C	cg25517755	chr10:38738941	LOC399744	-0.48	-6.22	-0.36	1.95e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs2228479	0.702	rs62056100	chr16:89939753	C/T	cg06558623	chr16:89946397	TCF25	1.15	8.93	0.48	7.22e-17	Skin colour saturation;
CESC	trans	rs61931739	0.500	rs11053223	chr12:34481947	T/A	cg26384229	chr12:38710491	ALG10B	0.7	10.6	0.55	4.1e-22	Morning vs. evening chronotype;
CESC	cis	rs796364	0.906	rs6740981	chr2:201060216	T/C	cg23649088	chr2:200775458	C2orf69	0.5	5.21	0.3	3.84e-7	Schizophrenia;
CESC	cis	rs1005277	0.579	rs1740749	chr10:38521646	A/G	cg00409905	chr10:38381863	ZNF37A	-0.52	-7.03	-0.4	1.8e-11	Extrinsic epigenetic age acceleration;
CESC	cis	rs867529	0.695	rs335124	chr2:89052026	A/G	cg26627705	chr2:89060884	NA	0.4	5.44	0.32	1.21e-7	Height;
CESC	cis	rs7666738	0.830	rs1456208	chr4:98678563	C/T	cg17366294	chr4:99064904	C4orf37	0.55	7.36	0.41	2.26e-12	Colonoscopy-negative controls vs population controls;
CESC	cis	rs116095464	0.558	rs7710005	chr5:233572	A/G	cg22857025	chr5:266934	NA	-1.27	-17.86	-0.74	2.25e-47	Breast cancer;
CESC	cis	rs3733585	0.673	rs116046986	chr4:9957794	A/G	cg11266682	chr4:10021025	SLC2A9	-0.59	-11.01	-0.56	1.79e-23	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs2996428	0.601	rs59414187	chr1:3762815	T/C	cg13057898	chr1:3703894	LRRC47	0.45	6.12	0.35	3.33e-9	Red cell distribution width;
CESC	cis	rs735396	0.770	rs2257764	chr12:121446446	T/A	cg25281562	chr12:121454272	C12orf43	-0.5	-6.2	-0.36	2.16e-9	N-glycan levels;
CESC	cis	rs10129255	0.518	rs2006284	chr14:107132201	G/A	cg23076370	chr14:107095027	NA	-0.64	-9.86	-0.52	1e-19	Kawasaki disease;
CESC	cis	rs6951245	0.882	rs10256720	chr7:1210825	C/G	cg03188948	chr7:1209495	NA	0.77	7.71	0.43	2.49e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs11677370	0.561	rs4849990	chr2:3819558	A/G	cg17052675	chr2:3827356	NA	-0.4	-5.23	-0.31	3.44e-7	Type 2 diabetes;
CESC	cis	rs57506017	0.585	rs5011438	chr7:12268798	C/T	cg23422036	chr7:12250390	TMEM106B	0.38	5.13	0.3	5.62e-7	Neuroticism;
CESC	cis	rs2576037	0.526	rs4890707	chr18:44497724	C/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.34	5.44	0.32	1.2e-7	Personality dimensions;
CESC	cis	rs1843834	0.539	rs6713629	chr2:225410973	A/T	cg12698349	chr2:225449008	CUL3	0.62	8.88	0.48	1.03e-16	IgE levels in asthmatics (D.p. specific);
CESC	cis	rs3096299	0.802	rs3102336	chr16:89442006	C/T	cg08822215	chr16:89438651	ANKRD11	-0.46	-7.32	-0.41	2.98e-12	Multiple myeloma (IgH translocation);
CESC	cis	rs9660180	0.967	rs9660106	chr1:1797947	A/G	cg17747265	chr1:1875780	NA	-0.6	-9.81	-0.52	1.42e-19	Body mass index;
CESC	cis	rs853679	0.517	rs868987	chr6:28110148	A/G	cg22143856	chr6:28129313	ZNF389	-0.52	-6.68	-0.38	1.38e-10	Depression;
CESC	cis	rs9911578	1.000	rs2567911	chr17:56734977	A/G	cg05425664	chr17:57184151	TRIM37	-0.51	-7.21	-0.4	6.03e-12	Intelligence (multi-trait analysis);
CESC	cis	rs6840258	1.000	rs767315	chr4:87960435	C/T	cg08197287	chr4:87952173	AFF1	-0.38	-5.21	-0.3	3.77e-7	Mean corpuscular volume;Basophil percentage of granulocytes;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg24792749	chr19:33166123	ANKRD27;RGS9BP	0.47	6.1	0.35	3.65e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs589448	0.538	rs683790	chr12:69751434	T/G	cg20891283	chr12:69753455	YEATS4	0.76	10.05	0.53	2.45e-20	Cerebrospinal fluid biomarker levels;
CESC	cis	rs11098499	0.909	rs79026312	chr4:120440677	C/A	cg24375607	chr4:120327624	NA	0.44	5.27	0.31	2.85e-7	Corneal astigmatism;
CESC	cis	rs12950390	0.814	rs4794099	chr17:45838358	T/C	cg00777063	chr17:45855553	NA	-0.41	-6.12	-0.35	3.4e-9	IgG glycosylation;
CESC	cis	rs6088580	0.608	rs2105109	chr20:32971932	A/G	cg08999081	chr20:33150536	PIGU	-0.66	-11.72	-0.58	8.03e-26	Glomerular filtration rate (creatinine);
CESC	cis	rs55883249	1.000	rs55883249	chr2:9741535	C/A	cg23886495	chr2:9695866	ADAM17	0.61	5.55	0.32	7.08e-8	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
CESC	cis	rs4665809	0.590	rs10495756	chr2:26485586	A/G	cg26314531	chr2:26401878	FAM59B	0.85	9.03	0.49	3.58e-17	Gut microbiome composition (summer);
CESC	cis	rs9287719	0.967	rs4555318	chr2:10744295	C/G	cg02196655	chr2:10830764	NOL10	-0.38	-5.83	-0.34	1.61e-8	Prostate cancer;
CESC	cis	rs2836974	0.899	rs114399588	chr21:40653958	G/A	cg11644478	chr21:40555479	PSMG1	0.97	14.14	0.66	3.2e-34	Cognitive function;
CESC	cis	rs875971	0.545	rs4718364	chr7:66001340	C/A	cg18876405	chr7:65276391	NA	0.5	5.89	0.34	1.16e-8	Aortic root size;
CESC	cis	rs2408955	0.561	rs9971924	chr12:48479832	C/G	cg24011408	chr12:48396354	COL2A1	-0.49	-7.34	-0.41	2.55e-12	Glycated hemoglobin levels;
CESC	cis	rs4654899	0.865	rs61779120	chr1:21481230	T/C	cg05370193	chr1:21551575	ECE1	0.46	7.03	0.4	1.79e-11	Superior frontal gyrus grey matter volume;
CESC	cis	rs7116495	1.000	rs2508858	chr11:71805405	C/G	cg10381502	chr11:71823885	C11orf51	0.65	5.3	0.31	2.39e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs4595586	0.545	rs7967295	chr12:39376866	G/A	cg26384229	chr12:38710491	ALG10B	0.54	7.53	0.42	7.85e-13	Morning vs. evening chronotype;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg01783706	chr12:49739991	DNAJC22	0.46	6.26	0.36	1.53e-9	Thyroid stimulating hormone;
CESC	cis	rs8031584	0.918	rs35784593	chr15:31254588	G/A	cg14298792	chr15:30685198	CHRFAM7A	-0.46	-5.54	-0.32	7.38e-8	Huntington's disease progression;
CESC	cis	rs2073300	1.000	rs6137977	chr20:23464191	G/T	cg12062639	chr20:23401060	NAPB	0.92	6.06	0.35	4.62e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs2235544	1.000	rs2235544	chr1:54375570	A/C	cg25741118	chr1:54482237	LDLRAD1	-0.2	-5.32	-0.31	2.17e-7	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
CESC	cis	rs34172651	0.517	rs200526	chr16:24760511	C/T	cg06505273	chr16:24850292	NA	-0.53	-6.49	-0.37	4.27e-10	Intelligence (multi-trait analysis);
CESC	cis	rs66782572	1	rs66782572	chr3:52567617	A/G	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.41	8.05	0.44	2.86e-14	Hemoglobin concentration;
CESC	cis	rs72634258	0.891	rs404381	chr1:8080745	C/T	cg00042356	chr1:8021962	PARK7	0.45	5.2	0.3	4.01e-7	Inflammatory bowel disease;
CESC	cis	rs8060686	0.516	rs13339471	chr16:68253008	A/G	cg26727032	chr16:67993705	SLC12A4	-0.54	-7.32	-0.41	2.95e-12	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs11190604	1.000	rs10883510	chr10:102297018	C/T	cg07080220	chr10:102295463	HIF1AN	0.66	6.04	0.35	5.32e-9	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs4975709	0.569	rs2353583	chr5:1858834	G/C	cg15595755	chr5:1867978	NA	0.51	8.11	0.45	1.92e-14	Cardiovascular disease risk factors;
CESC	cis	rs1008375	0.966	rs3733576	chr4:17586703	T/C	cg16339924	chr4:17578868	LAP3	0.85	10.87	0.56	5.49e-23	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs2549003	1.000	rs10068129	chr5:131821246	A/G	cg21138405	chr5:131827807	IRF1	-0.57	-9.83	-0.52	1.17e-19	Asthma (sex interaction);
CESC	cis	rs6060717	0.654	rs6058347	chr20:34483781	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.84	-9.27	-0.49	6.63e-18	Hip circumference adjusted for BMI;
CESC	cis	rs736408	0.562	rs12497998	chr3:52793602	C/T	cg18404041	chr3:52824283	ITIH1	-0.42	-7.05	-0.4	1.56e-11	Bipolar disorder;
CESC	cis	rs10504229	0.683	rs56741275	chr8:58136108	C/G	cg24829409	chr8:58192753	C8orf71	-0.58	-7.2	-0.4	6.31e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs3820928	0.874	rs4675130	chr2:227827740	G/T	cg11843606	chr2:227700838	RHBDD1	-0.43	-5.54	-0.32	7.3900000000000007e-08	Pulmonary function;
CESC	cis	rs2072732	0.898	rs2981856	chr1:2972524	T/C	cg03976712	chr1:2946727	NA	0.3	5.13	0.3	5.66e-7	Plateletcrit;
CESC	cis	rs6456156	0.586	rs13208636	chr6:167461965	T/G	cg23791538	chr6:167370224	RNASET2	-0.49	-6.37	-0.36	8.13e-10	Primary biliary cholangitis;
CESC	cis	rs7116495	0.609	rs73531955	chr11:71687794	A/C	cg26138937	chr11:71823887	C11orf51	1.27	8.02	0.44	3.5e-14	Severe influenza A (H1N1) infection;
CESC	cis	rs1707322	1.000	rs785497	chr1:46591903	G/C	cg05343316	chr1:45956843	TESK2	-0.47	-5.52	-0.32	7.97e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9399401	0.633	rs262118	chr6:142843054	C/A	cg03128060	chr6:142623767	GPR126	0.41	6.79	0.38	7.49e-11	Chronic obstructive pulmonary disease;
CESC	cis	rs7089973	0.604	rs2420065	chr10:116583753	A/G	cg23260525	chr10:116636907	FAM160B1	0.38	6.86	0.39	4.82e-11	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs250677	0.687	rs36046	chr5:148441257	A/C	cg18129178	chr5:148520854	ABLIM3	-0.52	-5.94	-0.34	8.76e-9	Breast cancer;
CESC	cis	rs873946	0.648	rs35417213	chr10:134553749	A/G	cg27286337	chr10:134555280	INPP5A	0.69	8.15	0.45	1.43e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs2050392	0.517	rs602097	chr10:30747546	C/T	cg25182066	chr10:30743637	MAP3K8	-0.55	-8.13	-0.45	1.69e-14	Inflammatory bowel disease;
CESC	cis	rs4849845	0.637	rs13022486	chr2:121038611	C/T	cg24070213	chr2:121070622	NA	0.43	6.32	0.36	1.07e-9	Mean platelet volume;
CESC	cis	rs9457247	1.000	rs386548	chr6:167385533	A/T	cg23791538	chr6:167370224	RNASET2	0.61	8.67	0.47	4.34e-16	Crohn's disease;
CESC	cis	rs5743618	0.537	rs28413898	chr4:38768669	A/G	cg02016764	chr4:38805732	TLR1	-0.32	-5.05	-0.3	8.36e-7	Asthma;Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs1799949	1.000	rs35070007	chr17:41316747	C/G	cg25072359	chr17:41440525	NA	-0.5	-7.37	-0.41	2.13e-12	Menopause (age at onset);
CESC	cis	rs7539542	0.556	rs4950888	chr1:202872625	C/T	cg19681188	chr1:202830198	LOC148709	0.41	5.17	0.3	4.73e-7	Mean platelet volume;
CESC	cis	rs524281	0.692	rs2254388	chr11:65837599	C/T	cg14036092	chr11:66035641	RAB1B	0.51	5.61	0.33	5.13e-8	Electroencephalogram traits;
CESC	cis	rs9916302	0.904	rs9894500	chr17:37515735	G/C	cg07936489	chr17:37558343	FBXL20	0.78	10.7	0.55	1.93e-22	Glomerular filtration rate (creatinine);
CESC	cis	rs13191362	1.000	rs66594243	chr6:163169024	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.66	6.5	0.37	3.9e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs2235544	0.565	rs633315	chr1:54468689	G/A	cg25741118	chr1:54482237	LDLRAD1	0.24	5.77	0.33	2.2e-8	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
CESC	cis	rs2625529	0.938	rs8747	chr15:72115541	C/A	cg16672083	chr15:72433130	SENP8	-0.45	-5.54	-0.32	7.16e-8	Red blood cell count;
CESC	cis	rs6582630	0.502	rs1115515	chr12:38279830	C/T	cg13010199	chr12:38710504	ALG10B	0.48	6.04	0.35	5.23e-9	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs11657217	0.677	rs8071194	chr17:77698458	A/C	cg06901238	chr17:77706717	ENPP7	0.42	6.15	0.35	2.82e-9	Diastolic blood pressure response to hydrochlorothiazide in hypertension;
CESC	cis	rs559928	0.606	rs11231726	chr11:63987339	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.63	5.55	0.32	6.81e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CESC	cis	rs4851870	1.000	rs12997041	chr2:106444338	T/C	cg16077055	chr2:106428750	NCK2	-0.39	-5.04	-0.3	8.58e-7	Addiction;
CESC	cis	rs7219021	0.926	rs10468517	chr17:46862114	C/T	cg16584676	chr17:46985605	UBE2Z	-0.56	-6.44	-0.37	5.45e-10	Schizophrenia or bipolar disorder;
CESC	cis	rs7552404	0.924	rs7550974	chr1:76204185	A/G	cg10523679	chr1:76189770	ACADM	0.8	11.03	0.56	1.58e-23	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs6541297	1.000	rs1998065	chr1:230286647	T/G	cg20703242	chr1:230279135	GALNT2	0.74	11.07	0.56	1.18e-23	Coronary artery disease;
CESC	cis	rs780096	0.506	rs2303369	chr2:27715416	C/T	cg22903471	chr2:27725779	GCKR	-0.55	-7.77	-0.43	1.69e-13	Total body bone mineral density;
CESC	cis	rs1552244	0.935	rs41520445	chr3:10153141	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	0.82	11.66	0.58	1.2e-25	Alzheimer's disease;
CESC	cis	rs9906944	0.585	rs11650936	chr17:47072261	C/G	cg16584676	chr17:46985605	UBE2Z	0.44	5.39	0.31	1.56e-7	Intelligence (multi-trait analysis);Body fat percentage;
CESC	cis	rs7412746	0.658	rs897815	chr1:150879101	C/T	cg04414720	chr1:150670196	GOLPH3L	-0.51	-6.69	-0.38	1.36e-10	Melanoma;
CESC	cis	rs3741151	1.000	rs1892855	chr11:73017972	G/T	cg17517138	chr11:73019481	ARHGEF17	1.13	7.47	0.42	1.15e-12	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs722599	0.683	rs8022046	chr14:75278302	G/A	cg08847533	chr14:75593920	NEK9	0.49	5.9	0.34	1.13e-8	IgG glycosylation;
CESC	cis	rs7647973	0.696	rs7100	chr3:49053219	A/G	cg06212747	chr3:49208901	KLHDC8B	0.48	5.34	0.31	2.02e-7	Menarche (age at onset);
CESC	cis	rs9388451	0.807	rs1268065	chr6:126042783	G/A	cg05901451	chr6:126070800	HEY2	0.6	8.71	0.47	3.43e-16	Brugada syndrome;
CESC	cis	rs769267	0.965	rs12460764	chr19:19431963	G/T	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.42	-5.4	-0.31	1.51e-7	Tonsillectomy;
CESC	cis	rs57502260	0.704	rs55975204	chr11:68249124	C/T	cg20283391	chr11:68216788	NA	-0.66	-5.48	-0.32	1.01e-7	Total body bone mineral density (age 45-60);
CESC	cis	rs897984	0.574	rs11647284	chr16:31077335	G/A	cg02466173	chr16:30829666	NA	-0.45	-7.6	-0.42	5.05e-13	Dementia with Lewy bodies;
CESC	cis	rs7267979	1.000	rs447722	chr20:25443510	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.86	17.57	0.73	2.33e-46	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs8141529	0.748	rs132528	chr22:29295898	C/T	cg15103426	chr22:29168792	CCDC117	-0.61	-7.9	-0.44	7.4e-14	Lymphocyte counts;
CESC	cis	rs4523957	0.928	rs7213232	chr17:2165340	A/G	cg16513277	chr17:2031491	SMG6	-0.58	-7.86	-0.43	9.46e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	trans	rs73568641	0.669	rs73568685	chr6:154049469	A/G	cg08374472	chr16:87445639	ZCCHC14	-0.49	-6.3	-0.36	1.25e-9	Methadone dose in opioid dependence;
CESC	cis	rs11122272	0.735	rs11122280	chr1:231519816	T/C	cg06096015	chr1:231504339	EGLN1	0.43	6.05	0.35	4.97e-9	Hemoglobin concentration;
CESC	cis	rs1552244	0.572	rs59132826	chr3:10169725	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.67	-7.6	-0.42	5.23e-13	Alzheimer's disease;
CESC	cis	rs3540	0.533	rs4932342	chr15:90982923	C/T	cg10434728	chr15:90938212	IQGAP1	0.41	7.32	0.41	2.99e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs400736	0.800	rs225095	chr1:8102801	T/C	cg25007680	chr1:8021821	PARK7	0.71	9.97	0.52	4.51e-20	Response to antidepressants and depression;
CESC	trans	rs17685	0.753	rs11764129	chr7:75761890	T/C	cg19862616	chr7:65841803	NCRNA00174	0.85	12.41	0.61	3.51e-28	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs9443645	0.527	rs10943608	chr6:79674929	T/C	cg05283184	chr6:79620031	NA	-0.36	-5.26	-0.31	2.96e-7	Intelligence (multi-trait analysis);
CESC	cis	rs896854	0.517	rs896851	chr8:95950251	T/C	cg09323728	chr8:95962352	TP53INP1	-0.33	-6.0	-0.35	6.34e-9	Type 2 diabetes;
CESC	cis	rs11252926	0.507	rs4881199	chr10:428090	C/G	cg18196295	chr10:418757	DIP2C	0.53	7.32	0.41	3e-12	Psychosis in Alzheimer's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05897255	chr7:149535402	ZNF862	0.55	6.44	0.37	5.71e-10	Gut microbiome composition (summer);
CESC	cis	rs4888262	0.508	rs4887779	chr16:74647795	A/G	cg01733217	chr16:74700730	RFWD3	-0.87	-12.4	-0.61	3.82e-28	Testicular germ cell tumor;
CESC	cis	rs854765	0.583	rs9908832	chr17:17871068	C/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.47	6.05	0.35	4.85e-9	Total body bone mineral density;
CESC	cis	rs992157	1.000	rs992157	chr2:219154781	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.73	-10.25	-0.53	5.65e-21	Colorectal cancer;
CESC	cis	rs6963495	0.872	rs73190193	chr7:105164852	A/G	cg02135003	chr7:105160482	PUS7	-0.47	-5.59	-0.33	5.51e-8	Bipolar disorder (body mass index interaction);
CESC	cis	rs875971	0.798	rs6460304	chr7:65964728	G/A	cg11764359	chr7:65958608	NA	0.81	11.74	0.58	6.73e-26	Aortic root size;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg07781247	chr5:93954443	ANKRD32;C5orf36	0.46	6.01	0.35	6.18e-9	Thyroid stimulating hormone;
CESC	cis	rs7772486	0.875	rs2814874	chr6:146305895	C/T	cg05347473	chr6:146136440	FBXO30	0.56	7.37	0.41	2.14e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9649213	0.593	rs7812180	chr7:97969140	A/G	cg21770322	chr7:97807741	LMTK2	-0.65	-9.31	-0.5	5.23e-18	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7267979	1.000	rs2184000	chr20:25395878	G/A	cg08601574	chr20:25228251	PYGB	-0.37	-5.37	-0.31	1.76e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs787274	0.867	rs2798316	chr9:115462552	T/C	cg13803584	chr9:115635662	SNX30	0.52	5.04	0.3	8.51e-7	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs9311474	0.508	rs7614498	chr3:52618941	A/T	cg17372223	chr3:52568218	NT5DC2	0.42	6.45	0.37	5.43e-10	Electroencephalogram traits;
CESC	cis	rs9660992	0.547	rs12143121	chr1:205199142	A/G	cg00857998	chr1:205179979	DSTYK	0.55	6.81	0.39	6.65e-11	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs763121	0.853	rs5757231	chr22:39071658	C/T	cg06544989	chr22:39130855	UNC84B	-0.49	-8.3	-0.45	5.47e-15	Menopause (age at onset);
CESC	cis	rs5769765	1.000	rs5769760	chr22:50259696	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.45	5.22	0.31	3.61e-7	Schizophrenia;
CESC	cis	rs11031096	0.502	rs7935824	chr11:4046900	C/G	cg18678763	chr11:4115507	RRM1	-0.42	-5.59	-0.33	5.51e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	cis	rs1182196	0.502	rs757786	chr7:2836019	C/T	cg18446336	chr7:2847575	GNA12	-0.38	-6.46	-0.37	4.87e-10	Plateletcrit;
CESC	cis	rs524023	1.000	rs537246	chr11:64360630	G/A	cg07220939	chr11:64358617	SLC22A12	0.36	5.59	0.32	5.66e-8	Urate levels in obese individuals;
CESC	cis	rs9837602	0.810	rs35777905	chr3:99690970	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.49	5.05	0.3	8.29e-7	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23979971	chr5:138677953	PAIP2	0.62	7.23	0.41	5.14e-12	Gut microbiome composition (summer);
CESC	cis	rs9611565	0.694	rs5758368	chr22:41862288	C/T	cg03806693	chr22:41940476	POLR3H	-1.16	-16.25	-0.71	1.17e-41	Vitiligo;
CESC	trans	rs17508449	0.865	rs4839330	chr1:114137582	T/C	cg23028848	chr11:57092561	TNKS1BP1	-0.79	-6.26	-0.36	1.54e-9	Leprosy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05018671	chr8:27146760	TRIM35	-0.56	-6.69	-0.38	1.34e-10	Gut microbiome composition (summer);
CESC	cis	rs896854	0.631	rs10097617	chr8:95961626	T/C	cg13393036	chr8:95962371	TP53INP1	-0.55	-12.45	-0.61	2.54e-28	Type 2 diabetes;
CESC	cis	rs7786877	0.723	rs73407376	chr7:100215200	C/T	cg20848291	chr7:100343083	ZAN	-0.64	-6.73	-0.38	1.02e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs2404602	0.692	rs59088060	chr15:76859974	T/C	cg26408565	chr15:76604113	ETFA	-0.4	-5.72	-0.33	2.92e-8	Blood metabolite levels;
CESC	cis	rs920590	0.721	rs61180388	chr8:19670214	G/C	cg17834443	chr8:19674713	INTS10	0.59	6.49	0.37	4.11e-10	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs8114671	1.000	rs8114671	chr20:33789142	C/A	cg06115741	chr20:33292138	TP53INP2	-0.42	-5.11	-0.3	6.06e-7	Height;
CESC	cis	rs72945132	0.882	rs6592552	chr11:70223831	A/T	cg00319359	chr11:70116639	PPFIA1	0.72	7.04	0.4	1.64e-11	Coronary artery disease;
CESC	cis	rs7100689	0.646	rs2486302	chr10:82076600	G/A	cg00277334	chr10:82204260	NA	-0.6	-7.96	-0.44	4.91e-14	Post bronchodilator FEV1;
CESC	trans	rs2121875	0.667	rs55676975	chr5:44220818	C/T	cg07292773	chr6:156718177	NA	-0.47	-6.01	-0.35	6.16e-9	Prostate cancer;
CESC	cis	rs12134245	0.776	rs13447526	chr1:91983174	A/G	cg02896835	chr1:92012615	NA	0.45	5.48	0.32	9.97e-8	Breast cancer;
CESC	cis	rs9911578	0.967	rs6416932	chr17:57148991	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.41	5.33	0.31	2.1e-7	Intelligence (multi-trait analysis);
CESC	cis	rs9929218	0.954	rs12596834	chr16:68823199	T/C	cg02972257	chr16:68554789	NA	0.45	5.39	0.31	1.58e-7	Colorectal cancer;
CESC	cis	rs4853012	0.838	rs4563249	chr2:74354016	G/T	cg20891558	chr2:74357851	NA	0.83	12.1	0.6	3.84e-27	Gestational age at birth (maternal effect);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg09414045	chr1:110162465	AMPD2	-0.44	-6.09	-0.35	3.93e-9	Fibrinogen levels;
CESC	cis	rs733592	0.524	rs10875744	chr12:48498440	G/C	cg04545296	chr12:48745243	ZNF641	0.29	5.33	0.31	2.15e-7	Plateletcrit;
CESC	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg04234412	chr22:24373322	LOC391322	-0.58	-8.51	-0.46	1.33e-15	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs9911578	0.967	rs8075786	chr17:56819216	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.21	0.3	3.88e-7	Intelligence (multi-trait analysis);
CESC	trans	rs2099077	0.867	rs12110237	chr5:102796072	A/G	cg07434438	chr16:72961899	ZFHX3	0.5	6.77	0.38	8.2e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs4665809	1.000	rs6729757	chr2:26285102	A/G	cg25036284	chr2:26402008	FAM59B	-0.59	-6.9	-0.39	3.85e-11	Gut microbiome composition (summer);
CESC	cis	rs9715521	0.677	rs67500083	chr4:59862419	C/T	cg11281224	chr4:60001000	NA	-0.56	-7.73	-0.43	2.24e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs7945705	0.967	rs7123861	chr11:8892323	G/A	cg21881798	chr11:8931708	C11orf17;ST5	0.5	7.94	0.44	5.61e-14	Hemoglobin concentration;
CESC	cis	rs1153858	1.000	rs1554521	chr15:45664189	A/T	cg21132104	chr15:45694354	SPATA5L1	-0.85	-11.49	-0.58	4.47e-25	Homoarginine levels;
CESC	cis	rs9527	0.590	rs10883829	chr10:104840635	T/C	cg04362960	chr10:104952993	NT5C2	0.44	5.61	0.33	4.99e-8	Arsenic metabolism;
CESC	cis	rs2228479	0.850	rs34033205	chr16:89922959	G/T	cg06558623	chr16:89946397	TCF25	1.2	9.14	0.49	1.65e-17	Skin colour saturation;
CESC	cis	rs12449964	0.524	rs4925094	chr17:17569012	C/T	cg04398451	chr17:18023971	MYO15A	0.39	5.38	0.31	1.62e-7	Coronary artery disease or ischemic stroke;
CESC	cis	rs9443645	0.527	rs949846	chr6:79817596	C/T	cg05283184	chr6:79620031	NA	-0.36	-5.22	-0.31	3.53e-7	Intelligence (multi-trait analysis);
CESC	cis	rs7116495	0.609	rs1892920	chr11:71702431	A/G	cg26138937	chr11:71823887	C11orf51	-1.26	-8.25	-0.45	7.58e-15	Severe influenza A (H1N1) infection;
CESC	cis	rs10504229	0.593	rs4738567	chr8:57997033	A/C	cg24829409	chr8:58192753	C8orf71	-0.48	-5.8	-0.34	1.84e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs7586879	0.681	rs6756609	chr2:25121125	C/A	cg01884057	chr2:25150051	NA	0.36	6.91	0.39	3.66e-11	Body mass index;
CESC	cis	rs2836950	0.501	rs35994303	chr21:40686020	C/T	cg11644478	chr21:40555479	PSMG1	-0.52	-6.96	-0.39	2.69e-11	Menarche (age at onset);
CESC	cis	rs2836974	0.644	rs1882779	chr21:40690938	T/C	cg17971929	chr21:40555470	PSMG1	-0.84	-12.15	-0.6	2.64e-27	Cognitive function;
CESC	cis	rs9300255	0.602	rs1790131	chr12:123701010	G/T	cg00376283	chr12:123451042	ABCB9	0.7	8.83	0.48	1.45e-16	Neutrophil percentage of white cells;
CESC	cis	rs8028182	0.636	rs4886716	chr15:75856022	G/C	cg20655648	chr15:75932815	IMP3	0.48	5.88	0.34	1.23e-8	Sudden cardiac arrest;
CESC	cis	rs10463316	0.894	rs954339	chr5:150752161	C/A	cg03212797	chr5:150827313	SLC36A1	-0.42	-5.41	-0.32	1.41e-7	Metabolite levels (Pyroglutamine);
CESC	cis	rs896543	0.702	rs6711119	chr2:237494334	C/T	cg25295825	chr2:237489920	CXCR7	0.7	8.86	0.48	1.22e-16	Alcohol dependence (age at onset);
CESC	cis	rs9486719	1.000	rs4343922	chr6:96876903	C/T	cg18709589	chr6:96969512	KIAA0776	0.49	5.58	0.32	5.81e-8	Migraine;Coronary artery disease;
CESC	cis	rs875971	0.540	rs1723268	chr7:65473080	A/C	cg06456125	chr7:65229604	NA	0.44	5.84	0.34	1.56e-8	Aortic root size;
CESC	cis	rs7809950	0.678	rs3801966	chr7:106824580	G/A	cg23024343	chr7:107201750	COG5	-0.58	-6.51	-0.37	3.74e-10	Coronary artery disease;
CESC	cis	rs3820068	0.734	rs6669156	chr1:15905206	T/A	cg18192808	chr1:15853278	DNAJC16	0.43	5.19	0.3	4.23e-7	Systolic blood pressure;
CESC	cis	rs12431939	1.000	rs67065973	chr14:51656225	T/C	cg23942311	chr14:51606299	NA	-0.41	-5.09	-0.3	6.8e-7	Cancer;
CESC	cis	rs10504229	0.593	rs58647001	chr8:58025132	G/A	cg22535103	chr8:58192502	C8orf71	-0.56	-6.35	-0.36	9.45e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs6502050	0.871	rs11870632	chr17:80075406	T/C	cg11859384	chr17:80120422	CCDC57	0.4	5.5	0.32	8.88e-8	Life satisfaction;
CESC	cis	rs9611565	0.512	rs9611667	chr22:42187015	C/T	cg03806693	chr22:41940476	POLR3H	-1.19	-13.62	-0.64	2.26e-32	Vitiligo;
CESC	cis	rs1005277	0.579	rs1740749	chr10:38521646	A/G	cg25427524	chr10:38739819	LOC399744	-0.73	-10.95	-0.56	2.97e-23	Extrinsic epigenetic age acceleration;
CESC	cis	rs3820068	0.734	rs6674806	chr1:15902656	A/G	cg17385448	chr1:15911702	AGMAT	0.4	6.22	0.36	1.89e-9	Systolic blood pressure;
CESC	cis	rs16973500	0.711	rs72801789	chr16:71959748	C/T	cg09427745	chr16:71932006	KIAA0174	-0.5	-5.14	-0.3	5.27e-7	Response to anti-TNF therapy in rheumatoid arthritis;Attention deficit hyperactivity disorder and conduct disorder;
CESC	cis	rs1005277	0.505	rs13503	chr10:38239843	C/A	cg25517755	chr10:38738941	LOC399744	0.39	5.04	0.3	8.55e-7	Extrinsic epigenetic age acceleration;
CESC	cis	rs4319547	0.688	rs6489158	chr12:123110365	T/G	cg05707623	chr12:122985044	ZCCHC8	-0.42	-5.18	-0.3	4.35e-7	Body mass index;
CESC	cis	rs9399135	0.935	rs11759999	chr6:135370495	G/T	cg22676075	chr6:135203613	NA	0.52	7.31	0.41	3.17e-12	Red blood cell count;
CESC	cis	rs61931739	0.534	rs10506120	chr12:34235603	G/A	cg19457237	chr12:34500585	NA	-0.38	-5.29	-0.31	2.52e-7	Morning vs. evening chronotype;
CESC	cis	rs17253792	0.822	rs76201070	chr14:56063604	A/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.85	6.13	0.35	3.15e-9	Putamen volume;
CESC	cis	rs8141529	1.000	rs132534	chr22:29299806	T/C	cg15103426	chr22:29168792	CCDC117	-0.52	-6.12	-0.35	3.36e-9	Lymphocyte counts;
CESC	cis	rs3733585	0.673	rs4292333	chr4:9953871	G/A	cg00071950	chr4:10020882	SLC2A9	-0.69	-11.34	-0.57	1.42e-24	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs9911578	0.803	rs8069033	chr17:57131581	T/A	cg10487724	chr17:56770010	TEX14;RAD51C	-0.4	-5.09	-0.3	6.91e-7	Intelligence (multi-trait analysis);
CESC	cis	rs2425143	1.000	rs56116518	chr20:34286251	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.82	-7.38	-0.41	2.07e-12	Blood protein levels;
CESC	cis	rs2380220	0.678	rs4308568	chr6:96009525	A/C	cg04719120	chr6:96025338	MANEA	-0.52	-5.75	-0.33	2.45e-8	Behavioural disinhibition (generation interaction);
CESC	cis	rs3785574	0.927	rs2727313	chr17:61961914	A/G	cg07677032	chr17:61819896	STRADA	0.45	5.65	0.33	4.13e-8	Height;
CESC	cis	rs6496667	0.533	rs7172909	chr15:90991416	C/T	cg22089800	chr15:90895588	ZNF774	0.45	5.81	0.34	1.75e-8	Rheumatoid arthritis;
CESC	cis	rs6674970	1.000	rs6674970	chr1:151116279	C/T	cg11822372	chr1:151115635	SEMA6C	0.47	6.86	0.39	4.78e-11	Childhood ear infection;
CESC	cis	rs2075371	0.932	rs1862048	chr7:133978167	C/G	cg20476274	chr7:133979776	SLC35B4	-0.79	-10.17	-0.53	1e-20	Mean platelet volume;
CESC	cis	rs798554	0.724	rs798498	chr7:2795882	T/G	cg04166393	chr7:2884313	GNA12	0.62	8.07	0.44	2.41e-14	Height;
CESC	trans	rs11098499	0.697	rs28655325	chr4:120372999	A/G	cg25214090	chr10:38739885	LOC399744	0.7	9.86	0.52	9.55e-20	Corneal astigmatism;
CESC	cis	rs58688157	0.705	rs2396545	chr11:601785	T/C	cg02461776	chr11:598696	PHRF1	0.45	5.14	0.3	5.31e-7	Systemic lupus erythematosus;
CESC	cis	rs2204008	0.837	rs34381557	chr12:38181983	T/C	cg13010199	chr12:38710504	ALG10B	0.54	6.69	0.38	1.28e-10	Bladder cancer;
CESC	cis	rs1568889	0.838	rs11030185	chr11:28041904	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.82	13.94	0.65	1.69e-33	Bipolar disorder;
CESC	cis	rs7429990	0.965	rs7427418	chr3:48022707	T/C	cg11946769	chr3:48343235	NME6	-0.44	-5.37	-0.31	1.75e-7	Educational attainment (years of education);
CESC	cis	rs7044106	0.762	rs1411158	chr9:123464804	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.82	12.92	0.62	5.92e-30	Hip circumference adjusted for BMI;
CESC	cis	rs524281	0.731	rs11227439	chr11:66025679	G/A	cg14036092	chr11:66035641	RAB1B	-0.54	-5.28	-0.31	2.76e-7	Electroencephalogram traits;
CESC	cis	rs72781680	1.000	rs72796358	chr2:24160132	T/A	cg20701182	chr2:24300061	SF3B14	0.66	5.88	0.34	1.25e-8	Lymphocyte counts;
CESC	cis	rs644799	1.000	rs1784135	chr11:95531748	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.53	6.41	0.37	6.77e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs7618915	0.547	rs2164884	chr3:52629633	C/T	cg18099408	chr3:52552593	STAB1	-0.31	-5.09	-0.3	6.68e-7	Bipolar disorder;
CESC	cis	rs7937682	0.889	rs1784787	chr11:111486125	T/A	cg09085632	chr11:111637200	PPP2R1B	-0.95	-14.6	-0.67	8.26e-36	Primary sclerosing cholangitis;
CESC	cis	rs6701037	0.681	rs34370567	chr1:175131340	C/T	cg00321850	chr1:175162397	KIAA0040	-0.43	-6.42	-0.37	6.11e-10	Alcohol dependence;
CESC	cis	rs947211	0.898	rs1775146	chr1:205756168	A/G	cg24503407	chr1:205819492	PM20D1	0.39	5.15	0.3	5.05e-7	Parkinson's disease;
CESC	cis	rs10504229	0.775	rs17804888	chr8:58158315	G/T	cg22535103	chr8:58192502	C8orf71	0.95	10.17	0.53	1.01e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs10883723	0.810	rs7090034	chr10:104281155	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.55	7.59	0.42	5.46e-13	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs7666738	0.830	rs3852122	chr4:98697400	T/C	cg05340658	chr4:99064831	C4orf37	0.76	11.06	0.56	1.24e-23	Colonoscopy-negative controls vs population controls;
CESC	cis	rs8072100	0.713	rs11079776	chr17:45546893	C/T	cg25173405	chr17:45401733	C17orf57	-0.45	-5.75	-0.33	2.39e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs896854	0.812	rs2340586	chr8:95969261	G/A	cg23172400	chr8:95962367	TP53INP1	-0.46	-9.62	-0.51	5.59e-19	Type 2 diabetes;
CESC	trans	rs61931739	0.500	rs6488218	chr12:34452587	T/C	cg26384229	chr12:38710491	ALG10B	0.58	8.31	0.45	5.18e-15	Morning vs. evening chronotype;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg05108160	chr13:110790284	NA	-0.45	-6.46	-0.37	5.06e-10	Height;
CESC	cis	rs1552244	1.000	rs9849434	chr3:10133710	A/G	cg00166722	chr3:10149974	C3orf24	-0.51	-6.51	-0.37	3.79e-10	Alzheimer's disease;
CESC	cis	rs1801251	1.000	rs2592105	chr2:233645968	C/G	cg25237894	chr2:233734115	C2orf82	0.46	7.93	0.44	6.06e-14	Coronary artery disease;
CESC	cis	rs2425143	1.000	rs6060524	chr20:34221155	G/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.61	5.1	0.3	6.33e-7	Blood protein levels;
CESC	trans	rs2727020	0.729	rs1164685	chr11:49293660	G/A	cg03929089	chr4:120376271	NA	0.78	11.9	0.59	1.85e-26	Coronary artery disease;
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg04141094	chr2:54785178	SPTBN1	0.46	6.82	0.39	5.98e-11	Vertical cup-disc ratio;
CESC	cis	rs9640161	0.789	rs6964110	chr7:150041836	A/C	cg10018233	chr7:150070692	REPIN1	0.33	5.05	0.3	8.38e-7	Blood protein levels;Circulating chemerin levels;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg27511265	chr7:150102280	LOC728743	0.52	6.61	0.38	2.12e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs644799	1.000	rs516551	chr11:95588626	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.54	6.28	0.36	1.34e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs6456156	0.774	rs1012657	chr6:167525142	A/C	cg07741184	chr6:167504864	NA	-0.31	-5.26	-0.31	3e-7	Primary biliary cholangitis;
CESC	cis	rs1552244	0.706	rs279545	chr3:9972493	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.64	8.85	0.48	1.28e-16	Alzheimer's disease;
CESC	cis	rs2230307	0.536	rs684519	chr1:100604715	T/G	cg24955406	chr1:100503596	HIAT1	-0.49	-5.18	-0.3	4.29e-7	Carotid intima media thickness;
CESC	trans	rs587847	0.507	rs10518956	chr15:37808780	A/G	cg22493172	chr12:51611826	POU6F1	-0.5	-6.02	-0.35	5.85e-9	Intraocular pressure;
CESC	cis	rs9300255	0.664	rs12316131	chr12:123817796	T/C	cg19016782	chr12:123741754	C12orf65	0.44	6.13	0.35	3.09e-9	Neutrophil percentage of white cells;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00252696	chr1:31769601	ZCCHC17;SNRNP40	0.57	6.97	0.39	2.47e-11	Gut microbiome composition (summer);
CESC	cis	rs6502050	0.731	rs11867299	chr17:80088675	C/A	cg11859384	chr17:80120422	CCDC57	-0.38	-5.14	-0.3	5.31e-7	Life satisfaction;
CESC	trans	rs748404	0.631	rs1133395	chr15:43650384	G/A	cg24053811	chr14:70265306	SLC10A1	0.44	6.2	0.36	2.16e-9	Lung cancer;
CESC	cis	rs2274273	1.000	rs11621351	chr14:55616740	C/A	cg04306507	chr14:55594613	LGALS3	0.29	5.32	0.31	2.25e-7	Protein biomarker;
CESC	cis	rs7267979	0.789	rs6083841	chr20:25384564	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.7	-11.59	-0.58	2.18e-25	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs10870270	1.000	rs9971066	chr10:133788233	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.58	-7.38	-0.41	2.03e-12	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs2120019	1.000	rs7167285	chr15:75368769	A/G	cg17294928	chr15:75287854	SCAMP5	-0.59	-6.62	-0.38	1.97e-10	Blood trace element (Zn levels);
CESC	cis	rs7917772	0.532	rs10748829	chr10:104527244	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.45	-5.29	-0.31	2.59e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs1387259	0.839	rs7487682	chr12:48579665	A/C	cg04545296	chr12:48745243	ZNF641	-0.38	-6.69	-0.38	1.33e-10	Obstructive sleep apnea trait (apnea hypopnea index);
CESC	cis	rs8017423	0.872	rs7492857	chr14:90684867	T/G	cg14092571	chr14:90743983	NA	0.53	7.97	0.44	4.65e-14	Mortality in heart failure;
CESC	cis	rs13392177	0.637	rs61041183	chr2:219056380	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.57	7.51	0.42	9.04e-13	Pyoderma gangrenosum in inflammatory bowel disease;
CESC	cis	rs1878931	0.520	rs12447807	chr16:3413896	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	1.04	16.79	0.72	1.35e-43	Body mass index (adult);
CESC	cis	rs9300255	0.568	rs1047158	chr12:123644056	C/A	cg05973401	chr12:123451056	ABCB9	0.5	5.81	0.34	1.79e-8	Neutrophil percentage of white cells;
CESC	cis	rs6424115	0.830	rs2501431	chr1:24201643	G/A	cg10978503	chr1:24200527	CNR2	0.33	6.6	0.38	2.2e-10	Immature fraction of reticulocytes;
CESC	cis	rs8067545	0.611	rs7219908	chr17:20043036	A/G	cg13482628	chr17:19912719	NA	0.4	5.37	0.31	1.75e-7	Schizophrenia;
CESC	cis	rs8114671	0.562	rs725521	chr20:33516071	T/C	cg06115741	chr20:33292138	TP53INP2	0.48	5.79	0.34	1.97e-8	Height;
CESC	cis	rs6582630	0.519	rs11609739	chr12:38547969	G/A	cg26384229	chr12:38710491	ALG10B	0.72	10.77	0.55	1.13e-22	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs734999	0.611	rs10797431	chr1:2501222	G/T	cg20673091	chr1:2541236	MMEL1	0.4	6.61	0.38	2.08e-10	Ulcerative colitis;
CESC	cis	rs3747547	0.710	rs2091415	chr9:37951176	T/C	cg13774184	chr9:37916125	SHB	-0.55	-5.82	-0.34	1.71e-8	Metabolite levels (Dihydroxy docosatrienoic acid);
CESC	cis	rs875971	0.862	rs10263690	chr7:65766453	G/C	cg12463550	chr7:65579703	CRCP	-0.46	-5.81	-0.34	1.76e-8	Aortic root size;
CESC	cis	rs9926296	0.585	rs6500450	chr16:89858024	A/G	cg03388025	chr16:89894329	SPIRE2	0.42	8.12	0.45	1.76e-14	Vitiligo;
CESC	cis	rs172166	0.694	rs203876	chr6:28046673	T/C	cg20151795	chr6:28129481	ZNF389	0.35	5.06	0.3	7.95e-7	Cardiac Troponin-T levels;
CESC	cis	rs67311347	0.577	rs1317217	chr3:40271697	T/G	cg09455208	chr3:40491958	NA	0.36	5.58	0.32	5.81e-8	Renal cell carcinoma;
CESC	cis	rs4253772	0.530	rs9615349	chr22:46732418	T/G	cg00784671	chr22:46762841	CELSR1	-0.64	-6.13	-0.35	3.22e-9	LDL cholesterol;Cholesterol, total;
CESC	cis	rs2901656	0.691	rs10798005	chr1:172382965	C/T	cg03748243	chr1:172413542	C1orf105;PIGC	-0.46	-7.21	-0.41	5.8e-12	Red cell distribution width;Platelet distribution width;
CESC	cis	rs2070488	0.775	rs1132064	chr3:38566519	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.78	-12.87	-0.62	9.13e-30	Electrocardiographic conduction measures;
CESC	cis	rs9916302	0.904	rs8070695	chr17:37478062	C/T	cg07936489	chr17:37558343	FBXL20	0.75	10.13	0.53	1.32e-20	Glomerular filtration rate (creatinine);
CESC	cis	rs9902453	0.791	rs3098950	chr17:27998385	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.79	10.74	0.55	1.47e-22	Coffee consumption (cups per day);
CESC	cis	rs11792861	0.781	rs28361106	chr9:111762385	T/C	cg05043794	chr9:111880884	C9orf5	-0.34	-5.5	-0.32	9.01e-8	Menarche (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08797741	chr3:47555315	C3orf75	0.58	6.53	0.37	3.39e-10	Gut microbiome composition (summer);
CESC	cis	rs1552244	0.882	rs13066757	chr3:10045030	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.87	11.4	0.57	9.22e-25	Alzheimer's disease;
CESC	cis	rs5167	0.506	rs35193317	chr19:45470344	C/T	cg09555818	chr19:45449301	APOC2	-0.48	-7.3	-0.41	3.3e-12	Blood protein levels;
CESC	cis	rs3091242	0.933	rs9438905	chr1:25764177	A/G	cg27572855	chr1:25598939	RHD	0.44	7.35	0.41	2.45e-12	Erythrocyte sedimentation rate;
CESC	cis	rs4319547	0.656	rs10773088	chr12:122828069	A/T	cg05707623	chr12:122985044	ZCCHC8	-0.5	-5.73	-0.33	2.7e-8	Body mass index;
CESC	cis	rs2576037	0.526	rs2257027	chr18:44566990	A/T	cg19077165	chr18:44547161	KATNAL2	0.54	7.97	0.44	4.82e-14	Personality dimensions;
CESC	cis	rs6433857	0.627	rs6741769	chr2:181500545	G/A	cg23363182	chr2:181467187	NA	-0.45	-6.8	-0.39	6.88e-11	Body mass index;
CESC	cis	rs651907	0.535	rs11711903	chr3:101500748	C/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.43	5.69	0.33	3.31e-8	Colorectal cancer;
CESC	cis	rs4665809	0.590	rs7586047	chr2:26447335	A/G	cg26314531	chr2:26401878	FAM59B	-0.84	-8.92	-0.48	7.98e-17	Gut microbiome composition (summer);
CESC	cis	rs10465746	0.809	rs2389617	chr1:84437652	A/T	cg10977910	chr1:84465055	TTLL7	0.52	7.13	0.4	9.46e-12	Obesity-related traits;
CESC	cis	rs7618915	0.570	rs13068293	chr3:52672167	C/A	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.36	6.49	0.37	4.3e-10	Bipolar disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00407623	chr5:80597718	RNU5E;RNU5D;ZCCHC9	0.52	6.09	0.35	3.89e-9	Gut microbiome composition (summer);
CESC	cis	rs798554	0.797	rs1182183	chr7:2873136	C/T	cg18446336	chr7:2847575	GNA12	-0.39	-6.04	-0.35	5.12e-9	Height;
CESC	cis	rs9309473	0.519	rs4852951	chr2:73869796	C/G	cg20560298	chr2:73613845	ALMS1	0.51	7.11	0.4	1.08e-11	Metabolite levels;
CESC	cis	rs3096299	0.606	rs2965946	chr16:89516612	T/C	cg02187348	chr16:89574699	SPG7	0.5	6.07	0.35	4.31e-9	Multiple myeloma (IgH translocation);
CESC	cis	rs8070624	0.543	rs7219320	chr17:17880877	A/G	cg09796270	chr17:17721594	SREBF1	0.42	5.55	0.32	6.79e-8	Total body bone mineral density;
CESC	cis	rs1371867	0.846	rs2919469	chr8:101233896	C/T	cg11906718	chr8:101322791	RNF19A	0.5	6.34	0.36	9.95e-10	Atrioventricular conduction;
CESC	cis	rs4566357	0.521	rs78411533	chr2:227910807	G/A	cg05526886	chr2:227700861	RHBDD1	-0.45	-5.99	-0.35	6.98e-9	Coronary artery disease;
CESC	cis	rs6754311	0.593	rs10186843	chr2:136586958	C/A	cg15123519	chr2:136567270	LCT	0.34	5.7	0.33	3.11e-8	Mosquito bite size;
CESC	cis	rs13064411	0.627	rs28710051	chr3:113143531	G/A	cg18753928	chr3:113234510	CCDC52	-0.5	-5.62	-0.33	4.76e-8	Response to simvastatin treatment (PCSK9 protein level change);
CESC	cis	rs7542091	0.704	rs2142907	chr1:210039505	T/C	cg21951975	chr1:209979733	IRF6	0.46	7.82	0.43	1.29e-13	Monobrow;
CESC	cis	rs7429990	0.965	rs9854454	chr3:48012797	A/G	cg11946769	chr3:48343235	NME6	-0.46	-5.69	-0.33	3.39e-8	Educational attainment (years of education);
CESC	cis	rs9303401	0.659	rs17822908	chr17:56801778	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.03	12.82	0.62	1.31e-29	Cognitive test performance;
CESC	cis	rs2014572	0.870	rs10426580	chr19:57756221	G/A	cg24459738	chr19:57751996	ZNF805	-0.54	-7.78	-0.43	1.67e-13	Hyperactive-impulsive symptoms;
CESC	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.53	0.37	3.43e-10	Prudent dietary pattern;
CESC	cis	rs2228479	0.850	rs2283565	chr16:89827556	G/T	cg06558623	chr16:89946397	TCF25	1.17	9.29	0.5	5.76e-18	Skin colour saturation;
CESC	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	7.84	0.43	1.14e-13	Prudent dietary pattern;
CESC	cis	rs798554	0.642	rs2533871	chr7:2883006	C/G	cg19717773	chr7:2847554	GNA12	-0.48	-7.01	-0.4	1.97e-11	Height;
CESC	cis	rs6121246	0.559	rs6058462	chr20:30367674	C/T	cg13852791	chr20:30311386	BCL2L1	0.81	10.44	0.54	1.31e-21	Mean corpuscular hemoglobin;
CESC	cis	rs17764205	0.777	rs112570652	chr19:3255789	G/A	cg02612712	chr19:3985498	EEF2	0.66	5.1	0.3	6.51e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs6570726	0.935	rs12663211	chr6:145818427	G/A	cg05347473	chr6:146136440	FBXO30	0.49	6.71	0.38	1.2e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs12477438	0.520	rs11123763	chr2:99750673	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	15.46	0.69	7.45e-39	Chronic sinus infection;
CESC	cis	rs2708240	0.577	rs2373269	chr7:147567018	A/G	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	0.4	6.56	0.37	2.81e-10	QT interval (drug interaction);
CESC	cis	rs9796	0.516	rs28473405	chr15:41293170	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.59	-8.22	-0.45	9.16e-15	Menopause (age at onset);
CESC	cis	rs4481887	0.893	rs10888348	chr1:248448610	C/G	cg00666640	chr1:248458726	OR2T12	0.36	6.24	0.36	1.7e-9	Common traits (Other);
CESC	cis	rs4665809	1.000	rs4665817	chr2:26305167	G/A	cg26314531	chr2:26401878	FAM59B	-0.77	-8.56	-0.47	9.38e-16	Gut microbiome composition (summer);
CESC	cis	rs7618915	0.571	rs6798246	chr3:52599922	G/A	cg18404041	chr3:52824283	ITIH1	-0.41	-6.78	-0.38	7.61e-11	Bipolar disorder;
CESC	cis	rs7737355	0.853	rs26005	chr5:130988029	A/G	cg06307176	chr5:131281290	NA	0.47	5.61	0.33	5.22e-8	Life satisfaction;
CESC	cis	rs12478296	0.681	rs55802421	chr2:243033962	C/T	cg06360820	chr2:242988706	NA	-0.7	-7.82	-0.43	1.29e-13	Obesity-related traits;
CESC	cis	rs425277	0.606	rs262664	chr1:2083537	G/C	cg24578937	chr1:2090814	PRKCZ	0.38	6.62	0.38	2.03e-10	Height;
CESC	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg04234412	chr22:24373322	LOC391322	-0.6	-8.95	-0.48	6.51e-17	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs1348850	0.793	rs13000048	chr2:178337089	C/A	cg23306229	chr2:178417860	TTC30B	0.64	8.23	0.45	8.59e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs9457247	0.529	rs6907666	chr6:167523395	A/G	cg07741184	chr6:167504864	NA	-0.37	-6.76	-0.38	8.58e-11	Crohn's disease;
CESC	cis	rs916888	0.821	rs199512	chr17:44857352	T/C	cg15921436	chr17:44337874	NA	-0.7	-7.95	-0.44	5.35e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs736801	0.808	rs2248116	chr5:131804347	C/A	cg00255919	chr5:131827918	IRF1	0.35	5.29	0.31	2.62e-7	Breast cancer;Mosquito bite size;
CESC	cis	rs4253772	0.938	rs41329344	chr22:46636930	C/T	cg00784671	chr22:46762841	CELSR1	-0.57	-5.63	-0.33	4.54e-8	LDL cholesterol;Cholesterol, total;
CESC	trans	rs11148252	0.574	rs7139495	chr13:53283318	A/G	cg18335740	chr13:41363409	SLC25A15	0.52	7.11	0.4	1.1e-11	Lewy body disease;
CESC	trans	rs6089829	0.925	rs13041507	chr20:61666180	T/C	cg23505145	chr19:12996616	KLF1	0.52	6.8	0.39	6.85e-11	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7714584	1.000	rs11957134	chr5:150230950	A/G	cg22134413	chr5:150180641	NA	-0.56	-5.44	-0.32	1.18e-7	Crohn's disease;
CESC	cis	rs13130787	0.567	rs280112	chr4:94919953	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.39	-5.49	-0.32	9.34e-8	Colorectal cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02809009	chr19:50354510	PTOV1	0.54	6.01	0.35	5.95e-9	Gut microbiome composition (summer);
CESC	cis	rs873946	0.586	rs3793686	chr10:134569559	A/G	cg06453172	chr10:134556979	INPP5A	-0.39	-5.08	-0.3	7.01e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs4234798	0.933	rs10020957	chr4:7222436	C/T	cg18431297	chr4:7219810	SORCS2	-0.42	-7.21	-0.41	5.74e-12	Insulin-like growth factors;
CESC	cis	rs7659604	1.000	rs72678650	chr4:122666000	A/G	cg19671926	chr4:122722719	EXOSC9	-0.49	-5.92	-0.34	9.92e-9	Type 2 diabetes;
CESC	cis	rs2559856	1.000	rs10860771	chr12:102087242	A/G	cg12213457	chr12:102090980	CHPT1	-0.34	-5.1	-0.3	6.45e-7	Blood protein levels;
CESC	cis	rs12824058	0.831	rs12310049	chr12:130811260	C/G	cg24838063	chr12:130822603	PIWIL1	0.62	8.55	0.47	9.78e-16	Menopause (age at onset);
CESC	cis	rs3741489	1.000	rs10781661	chr12:133431979	G/A	cg01499426	chr12:133417423	CHFR	0.95	6.29	0.36	1.29e-9	Cognitive function;
CESC	cis	rs12930096	1.000	rs67188060	chr16:11679517	A/G	cg07439791	chr16:11680400	LITAF	0.62	5.71	0.33	2.95e-8	QT interval;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13318091	chr8:27145541	TRIM35	-0.6	-6.73	-0.38	1.04e-10	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09356193	chr14:105816327	PACS2	-0.62	-6.97	-0.39	2.48e-11	Gut microbiome composition (summer);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05332869	chr20:39658073	TOP1	0.55	7.11	0.4	1.09e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs172166	0.694	rs203877	chr6:28048624	T/C	cg19592336	chr6:28129416	ZNF389	0.47	6.86	0.39	4.78e-11	Cardiac Troponin-T levels;
CESC	cis	rs873946	0.586	rs3793682	chr10:134564563	C/T	cg26818010	chr10:134567672	INPP5A	-0.94	-11.42	-0.57	7.62e-25	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs6563842	0.563	rs4575411	chr13:41277794	C/G	cg21288729	chr13:41239152	FOXO1	0.57	7.59	0.42	5.49e-13	Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;
CESC	cis	rs2455799	0.552	rs2470516	chr3:15759050	T/G	cg16303742	chr3:15540471	COLQ	-0.4	-6.1	-0.35	3.83e-9	Mean platelet volume;
CESC	cis	rs7833986	0.501	rs72653957	chr8:56990048	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.62	7.54	0.42	7.58e-13	Height;
CESC	cis	rs17433780	0.897	rs12120863	chr1:89501522	T/C	cg09516651	chr1:89888402	LOC400759	0.68	9.56	0.51	8.55e-19	Carotid intima media thickness;
CESC	cis	rs72781680	1.000	rs72796326	chr2:24137047	G/A	cg20701182	chr2:24300061	SF3B14	0.63	5.67	0.33	3.79e-8	Lymphocyte counts;
CESC	cis	rs4132509	0.779	rs10737888	chr1:243678483	A/C	cg21452805	chr1:244014465	NA	0.42	5.15	0.3	5.03e-7	RR interval (heart rate);
CESC	cis	rs7666738	0.830	rs6532715	chr4:99016792	G/A	cg03467027	chr4:99064603	C4orf37	0.46	5.83	0.34	1.62e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs8017423	0.967	rs6575120	chr14:90725094	C/T	cg14092571	chr14:90743983	NA	-0.55	-8.27	-0.45	6.56e-15	Mortality in heart failure;
CESC	cis	rs875971	0.867	rs1002053	chr7:65798545	G/A	cg11764359	chr7:65958608	NA	-0.94	-15.05	-0.68	1.96e-37	Aortic root size;
CESC	cis	rs79387448	0.655	rs76930359	chr2:102924684	G/A	cg09003973	chr2:102972529	NA	1.06	7.89	0.44	7.91e-14	Gut microbiota (bacterial taxa);
CESC	cis	rs1862618	0.671	rs252897	chr5:56223000	G/A	cg24531977	chr5:56204891	C5orf35	-0.7	-9.5	-0.5	1.35e-18	Initial pursuit acceleration;
CESC	cis	rs1728785	0.901	rs698711	chr16:68561955	C/T	cg02972257	chr16:68554789	NA	-0.55	-6.45	-0.37	5.28e-10	Ulcerative colitis;
CESC	cis	rs4737010	0.501	rs10099197	chr8:41654458	C/T	cg08923054	chr8:41654455	ANK1	0.61	7.53	0.42	7.83e-13	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
CESC	cis	rs1018836	0.700	rs10504894	chr8:91516436	G/A	cg16814680	chr8:91681699	NA	-0.58	-7.66	-0.43	3.41e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs8114671	0.836	rs6060140	chr20:33566507	G/A	cg24642439	chr20:33292090	TP53INP2	0.45	5.37	0.31	1.71e-7	Height;
CESC	cis	rs9868809	0.881	rs13096357	chr3:48675856	C/A	cg07636037	chr3:49044803	WDR6	-0.64	-5.22	-0.31	3.66e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs4728302	0.869	rs6962865	chr7:133599433	T/A	cg10665199	chr7:133106180	EXOC4	0.42	5.83	0.34	1.57e-8	Intelligence;Intelligence (multi-trait analysis);
CESC	cis	rs9291683	0.588	rs13133766	chr4:10019732	C/T	cg02734326	chr4:10020555	SLC2A9	0.52	7.43	0.42	1.51e-12	Bone mineral density;
CESC	cis	rs13385	0.724	rs60714373	chr5:139651321	T/C	cg26211634	chr5:139558579	C5orf32	0.47	5.05	0.3	8.24e-7	Atrial fibrillation;
CESC	cis	rs2304069	0.545	rs6866616	chr5:149415401	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.48	6.66	0.38	1.58e-10	HIV-1 control;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg05577848	chr12:62798679	USP15	0.39	6.32	0.36	1.07e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs12464559	0.522	rs12472627	chr2:152633114	C/T	cg01189475	chr2:152685088	ARL5A	0.79	7.64	0.42	4.04e-13	Response to cognitive-behavioural therapy in anxiety disorder;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg18703910	chr15:23157832	NA	-0.48	-6.96	-0.39	2.63e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs9457247	1.000	rs364283	chr6:167383750	C/T	cg25258033	chr6:167368657	RNASET2	0.39	5.87	0.34	1.27e-8	Crohn's disease;
CESC	cis	rs597539	0.652	rs636049	chr11:68667198	A/C	cg01988459	chr11:68622903	NA	-0.42	-5.77	-0.33	2.25e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs1568889	0.938	rs6484358	chr11:28260364	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.79	11.2	0.57	4.32e-24	Bipolar disorder;
CESC	cis	rs909002	0.849	rs10798879	chr1:32096815	T/C	cg13919466	chr1:32135498	COL16A1	-0.47	-8.03	-0.44	3.3e-14	Intelligence (multi-trait analysis);
CESC	cis	rs9388451	0.868	rs10457467	chr6:126045148	T/A	cg05901451	chr6:126070800	HEY2	-0.6	-8.66	-0.47	4.79e-16	Brugada syndrome;
CESC	cis	rs12541635	0.966	rs1496182	chr8:107024505	C/T	cg10147462	chr8:107024639	NA	0.42	6.05	0.35	4.79e-9	Age of smoking initiation;
CESC	cis	rs6540559	0.611	rs926347	chr1:209965193	T/C	cg21951975	chr1:209979733	IRF6	0.64	7.65	0.43	3.73e-13	Cleft lip with or without cleft palate;
CESC	cis	rs9894429	1.000	rs7503679	chr17:79583843	G/C	cg13777783	chr17:79615861	NA	-0.35	-5.79	-0.34	1.99e-8	Eye color traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04346515	chr15:62360465	C2CD4A	0.53	6.03	0.35	5.57e-9	Gut microbiome composition (summer);
CESC	cis	rs1881797	0.932	rs4551631	chr1:247667663	C/T	cg05639522	chr1:247681581	NA	-0.55	-7.23	-0.41	5.18e-12	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs7666738	0.830	rs11727653	chr4:99001774	T/C	cg05340658	chr4:99064831	C4orf37	0.8	12.44	0.61	2.83e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2075671	0.903	rs11983334	chr7:100302434	C/T	cg20848291	chr7:100343083	ZAN	-0.8	-10.11	-0.53	1.53e-20	Other erythrocyte phenotypes;
CESC	cis	rs3126085	0.935	rs4845421	chr1:152173259	G/T	cg03465714	chr1:152285911	FLG	-0.45	-5.54	-0.32	7.45e-8	Atopic dermatitis;
CESC	cis	rs7824557	0.564	rs7834572	chr8:11236685	C/T	cg21775007	chr8:11205619	TDH	-0.54	-8.07	-0.44	2.52e-14	Retinal vascular caliber;
CESC	cis	rs8067354	0.645	rs56236317	chr17:57822125	C/T	cg13753209	chr17:57696993	CLTC	0.65	7.89	0.44	7.95e-14	Hemoglobin concentration;
CESC	cis	rs6088580	0.634	rs945673	chr20:32964265	C/A	cg08999081	chr20:33150536	PIGU	-0.65	-11.29	-0.57	2.13e-24	Glomerular filtration rate (creatinine);
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg08005411	chr12:69753742	YEATS4	0.5	6.42	0.37	6.13e-10	Thyroid stimulating hormone;
CESC	cis	rs2439831	0.541	rs12440854	chr15:43610672	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.91	9.91	0.52	6.91e-20	Lung cancer in ever smokers;
CESC	cis	rs1775715	0.769	rs2799030	chr10:32172935	G/T	cg18675610	chr10:32216311	ARHGAP12	0.34	5.29	0.31	2.55e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs7666738	0.830	rs13139078	chr4:99020774	C/T	cg03676636	chr4:99064102	C4orf37	0.33	5.15	0.3	5.05e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs71403859	0.502	rs34015581	chr16:71508229	T/A	cg08717414	chr16:71523259	ZNF19	-0.83	-8.0	-0.44	3.92e-14	Post bronchodilator FEV1;
CESC	cis	rs7829975	0.658	rs907181	chr8:8702875	T/C	cg01383753	chr8:8559461	CLDN23	0.39	5.1	0.3	6.41e-7	Mood instability;
CESC	cis	rs2735413	0.881	rs12918547	chr16:78082746	G/A	cg04733911	chr16:78082701	NA	-0.53	-8.89	-0.48	9.44e-17	Systolic blood pressure (alcohol consumption interaction);
CESC	cis	rs7851660	0.809	rs10115216	chr9:100657119	G/T	cg13688889	chr9:100608707	NA	0.62	8.83	0.48	1.42e-16	Strep throat;
CESC	cis	rs9300255	0.602	rs2682434	chr12:123694724	C/T	cg00376283	chr12:123451042	ABCB9	0.7	8.83	0.48	1.41e-16	Neutrophil percentage of white cells;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg17808901	chr3:39093368	WDR48	-0.46	-6.55	-0.37	2.93e-10	Gambling;
CESC	cis	rs10256972	0.900	rs7812072	chr7:1053862	A/G	cg02099474	chr7:1027990	CYP2W1	-0.35	-5.19	-0.3	4.23e-7	Longevity;Endometriosis;
CESC	cis	rs2204008	0.837	rs11183232	chr12:37941053	A/G	cg13010199	chr12:38710504	ALG10B	0.46	5.81	0.34	1.77e-8	Bladder cancer;
CESC	cis	rs853679	0.517	rs67878650	chr6:28142587	G/C	cg26335602	chr6:28129616	ZNF389	0.52	6.85	0.39	5.22e-11	Depression;
CESC	trans	rs687914	0.710	rs938662	chr2:45864578	A/G	cg13309628	chr20:3801056	C20orf29	0.6	6.08	0.35	4.07e-9	Diastolic blood pressure;
CESC	cis	rs854765	0.583	rs950966	chr17:17783748	A/G	cg04398451	chr17:18023971	MYO15A	0.63	8.87	0.48	1.09e-16	Total body bone mineral density;
CESC	cis	rs17166499	0.803	rs73070141	chr7:12897219	A/G	cg12945054	chr7:12841881	NA	0.49	5.22	0.31	3.58e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs992157	0.732	rs10932771	chr2:219170236	A/T	cg20019365	chr2:219134978	PNKD;AAMP	0.65	8.94	0.48	6.73e-17	Colorectal cancer;
CESC	cis	rs5758659	0.652	rs133322	chr22:42405659	A/G	cg19513890	chr22:42538836	CYP2D7P1	-0.38	-5.38	-0.31	1.62e-7	Cognitive function;
CESC	cis	rs1348850	0.914	rs2364854	chr2:178378452	T/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.74	10.31	0.54	3.56e-21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	13.67	0.64	1.44e-32	Prudent dietary pattern;
CESC	cis	rs7618915	0.547	rs2118540	chr3:52629386	T/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	5.53	0.32	7.67e-8	Bipolar disorder;
CESC	trans	rs561341	0.629	rs7216107	chr17:30224419	G/A	cg20587970	chr11:113659929	NA	-0.54	-7.05	-0.4	1.53e-11	Hip circumference adjusted for BMI;
CESC	cis	rs7666738	0.791	rs34152299	chr4:98929862	G/C	cg05340658	chr4:99064831	C4orf37	0.82	12.17	0.6	2.24e-27	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1059312	0.932	rs4760593	chr12:129287220	A/G	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.73	-10.11	-0.53	1.53e-20	Systemic lupus erythematosus;
CESC	cis	rs941408	0.515	rs1736188	chr19:2782368	A/G	cg06609049	chr19:2785107	THOP1	0.85	13.26	0.63	4.15e-31	Total cholesterol levels;
CESC	cis	rs7546094	1.000	rs1994604	chr1:113156426	C/T	cg22162597	chr1:113214053	CAPZA1	0.4	6.13	0.35	3.09e-9	Platelet distribution width;
CESC	cis	rs2836974	0.644	rs11088471	chr21:40699313	A/G	cg17971929	chr21:40555470	PSMG1	-0.86	-12.31	-0.6	7.36e-28	Cognitive function;
CESC	cis	rs875971	0.505	rs6955582	chr7:65431686	A/G	cg18876405	chr7:65276391	NA	0.67	9.34	0.5	4.12e-18	Aortic root size;
CESC	cis	rs2228479	0.850	rs11640209	chr16:89807828	C/A	cg00800038	chr16:89945340	TCF25	-0.88	-7.38	-0.41	2.03e-12	Skin colour saturation;
CESC	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg07157834	chr1:205819609	PM20D1	0.72	10.57	0.54	5.18e-22	Menarche (age at onset);
CESC	cis	rs9811920	0.609	rs793501	chr3:99591638	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.64	10.11	0.53	1.53e-20	Axial length;
CESC	cis	rs61996546	0.622	rs17560758	chr15:26836402	C/T	cg15066197	chr15:26874202	GABRB3	-0.35	-5.07	-0.3	7.55e-7	Response to methotrexate in juvenile idiopathic arthritis;
CESC	cis	rs1008375	0.932	rs6449317	chr4:17631253	T/C	cg16339924	chr4:17578868	LAP3	0.76	9.55	0.51	9.19e-19	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs55871839	0.643	rs10109566	chr8:59800446	A/G	cg07426533	chr8:59803705	TOX	-0.5	-7.16	-0.4	8.11e-12	Pneumonia;
CESC	cis	rs7927592	0.913	rs7107622	chr11:68374183	T/C	cg16797656	chr11:68205561	LRP5	0.37	5.27	0.31	2.81e-7	Total body bone mineral density;
CESC	cis	rs6460942	0.545	rs17448114	chr7:12524458	G/C	cg20607287	chr7:12443886	VWDE	-0.71	-7.67	-0.43	3.19e-13	Coronary artery disease;
CESC	cis	rs1799949	1.000	rs4792981	chr17:41308274	A/G	cg23758822	chr17:41437982	NA	1.04	16.2	0.71	1.74e-41	Menopause (age at onset);
CESC	cis	rs9815354	0.812	rs73081383	chr3:41920614	A/G	cg03022575	chr3:42003672	ULK4	0.68	5.92	0.34	9.93e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs212524	0.544	rs9426748	chr1:21558490	C/A	cg05370193	chr1:21551575	ECE1	0.41	6.43	0.37	5.82e-10	Height;
CESC	cis	rs2816062	0.813	rs2816051	chr1:18895460	A/G	cg18795169	chr1:18902165	NA	-0.94	-19.04	-0.76	1.61e-51	Urate levels in lean individuals;
CESC	cis	rs9325144	0.600	rs10748442	chr12:38732939	A/T	cg26384229	chr12:38710491	ALG10B	0.56	8.07	0.44	2.52e-14	Morning vs. evening chronotype;
CESC	cis	rs10751667	0.857	rs6597952	chr11:991109	C/G	cg06064525	chr11:970664	AP2A2	-0.42	-7.08	-0.4	1.27e-11	Alzheimer's disease (late onset);
CESC	cis	rs7843479	0.965	rs11784535	chr8:21857787	G/A	cg17168535	chr8:21777572	XPO7	0.48	6.58	0.37	2.51e-10	Mean corpuscular volume;
CESC	cis	rs7412746	0.658	rs12410394	chr1:150860186	G/A	cg04414720	chr1:150670196	GOLPH3L	0.52	6.81	0.39	6.62e-11	Melanoma;
CESC	cis	rs2708240	1.000	rs2538988	chr7:147580325	A/G	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.34	-5.67	-0.33	3.73e-8	QT interval (drug interaction);
CESC	cis	rs798554	0.607	rs1182151	chr7:2909225	C/G	cg13628971	chr7:2884303	GNA12	0.61	7.0	0.4	2.08e-11	Height;
CESC	cis	rs55788414	0.932	rs2873367	chr16:81184380	T/A	cg06400318	chr16:81190750	PKD1L2	-0.6	-6.82	-0.39	6.19e-11	Left ventricular obstructive tract defect (maternal effect);
CESC	trans	rs61931739	0.890	rs694706	chr12:34135323	T/C	cg26384229	chr12:38710491	ALG10B	0.44	6.08	0.35	4.25e-9	Morning vs. evening chronotype;
CESC	cis	rs2933343	1.000	rs1683778	chr3:128644595	A/G	cg25356066	chr3:128598488	ACAD9	0.61	7.52	0.42	8.33e-13	IgG glycosylation;
CESC	cis	rs5758511	0.514	rs5751221	chr22:42516366	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.63	9.78	0.52	1.69e-19	Birth weight;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg16714616	chr20:40247229	CHD6	-0.52	-7.24	-0.41	4.98e-12	Gut microbiota (bacterial taxa);
CESC	cis	rs854765	0.575	rs7207821	chr17:17891781	A/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.49	6.24	0.36	1.72e-9	Total body bone mineral density;
CESC	cis	rs6912958	0.754	rs7762864	chr6:88236213	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.32	-5.27	-0.31	2.82e-7	Monocyte percentage of white cells;
CESC	cis	rs78456975	1.000	rs10189336	chr2:1558015	G/A	cg26248373	chr2:1572462	NA	-0.6	-5.65	-0.33	4.03e-8	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs854765	0.647	rs721669	chr17:18005073	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.63	8.94	0.48	6.96e-17	Total body bone mineral density;
CESC	cis	rs12530845	0.943	rs78188670	chr7:135335163	T/C	cg23117316	chr7:135346802	PL-5283	-0.41	-5.24	-0.31	3.35e-7	Red blood cell traits;
CESC	trans	rs459571	0.883	rs2520096	chr9:136919416	A/G	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.57	-7.58	-0.42	5.76e-13	Platelet distribution width;
CESC	cis	rs9733	0.544	rs72700902	chr1:150633347	C/T	cg22823121	chr1:150693482	HORMAD1	0.47	7.04	0.4	1.62e-11	Tonsillectomy;
CESC	trans	rs35110281	0.714	rs2282526	chr21:45080552	A/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.52	6.65	0.38	1.71e-10	Mean corpuscular volume;
CESC	cis	rs4713118	0.513	rs9368547	chr6:28028067	A/G	cg23161317	chr6:28129485	ZNF389	0.38	5.3	0.31	2.4e-7	Parkinson's disease;
CESC	cis	rs1799949	1.000	rs8176296	chr17:41203591	T/C	cg25072359	chr17:41440525	NA	0.45	5.96	0.34	7.83e-9	Menopause (age at onset);
CESC	cis	rs1670533	0.697	rs658846	chr4:1084723	G/C	cg04106633	chr4:1044584	NA	0.46	5.15	0.3	5.03e-7	Recombination rate (females);
CESC	cis	rs6674176	0.597	rs4660262	chr1:44382524	G/A	cg23954153	chr1:44402353	ARTN	-0.36	-5.83	-0.34	1.57e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs4975616	0.686	rs37011	chr5:1348798	A/T	cg07493874	chr5:1342172	CLPTM1L	-0.43	-8.27	-0.45	6.75e-15	Lung cancer;
CESC	cis	rs7264396	0.747	rs6058291	chr20:34247769	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.64	7.77	0.43	1.78e-13	Total cholesterol levels;
CESC	cis	rs4835473	0.932	rs13117421	chr4:144690558	A/G	cg25736465	chr4:144833511	NA	-0.42	-6.33	-0.36	1.05e-9	Immature fraction of reticulocytes;
CESC	cis	rs6088580	0.634	rs945673	chr20:32964265	C/A	cg24642439	chr20:33292090	TP53INP2	-0.54	-7.09	-0.4	1.2e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs1018836	0.923	rs1858674	chr8:91580665	G/T	cg16814680	chr8:91681699	NA	-0.69	-9.71	-0.51	2.82e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs769267	0.965	rs2916068	chr19:19516433	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.46	5.99	0.35	6.84e-9	Tonsillectomy;
CESC	cis	rs2836633	0.931	rs2836635	chr21:40069850	A/G	cg05519781	chr21:40033154	ERG	0.52	7.91	0.44	6.9e-14	Coronary artery disease;
CESC	cis	rs9660180	0.967	rs9660106	chr1:1797947	A/G	cg03396347	chr1:1875803	NA	-0.46	-7.21	-0.41	5.71e-12	Body mass index;
CESC	cis	rs9815354	0.812	rs113144620	chr3:42008312	A/G	cg03022575	chr3:42003672	ULK4	0.68	6.35	0.36	9.13e-10	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs2180341	0.597	rs3798859	chr6:127663116	C/T	cg24812749	chr6:127587940	RNF146	0.6	8.01	0.44	3.64e-14	Breast cancer;
CESC	cis	rs2712184	0.729	rs2541390	chr2:217664020	A/G	cg05032264	chr2:217675019	NA	-0.33	-5.06	-0.3	7.74e-7	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
CESC	cis	rs60154123	0.730	rs583148	chr1:210463553	A/C	cg21951975	chr1:209979733	IRF6	0.47	6.29	0.36	1.29e-9	Coronary artery disease;
CESC	cis	rs644799	0.965	rs3789960	chr11:95509037	C/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.54	6.76	0.38	8.9e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs9910055	0.659	rs7207464	chr17:42245033	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.65	8.7	0.47	3.55e-16	Total body bone mineral density;
CESC	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg17178900	chr1:205818956	PM20D1	0.8	13.19	0.63	7.15e-31	Menarche (age at onset);
CESC	cis	rs9929218	0.731	rs72785179	chr16:68767912	C/T	cg02972257	chr16:68554789	NA	0.54	6.29	0.36	1.28e-9	Colorectal cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03386556	chr1:113499109	SLC16A1	-0.52	-6.17	-0.35	2.6e-9	Gut microbiome composition (summer);
CESC	cis	rs9359856	0.564	rs7682	chr6:90352862	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.65	-6.23	-0.36	1.83e-9	Bipolar disorder;
CESC	cis	rs2841277	0.708	rs28454709	chr14:105405942	G/A	cg21017887	chr14:105400489	NA	0.41	6.65	0.38	1.65e-10	Rheumatoid arthritis;
CESC	cis	rs1865721	0.771	rs727893	chr18:73136931	G/A	cg26385618	chr18:73139727	C18orf62	-0.49	-7.96	-0.44	5.22e-14	Intelligence;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13596910	chr17:42254336	C17orf65;ASB16	-0.54	-6.05	-0.35	5e-9	Gut microbiome composition (summer);
CESC	cis	rs7267979	0.966	rs2263204	chr20:25377688	A/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.86	-16.61	-0.71	6.07e-43	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs72634258	0.554	rs35307738	chr1:7919839	C/G	cg00042356	chr1:8021962	PARK7	0.59	5.65	0.33	4.15e-8	Inflammatory bowel disease;
CESC	cis	rs12220238	0.818	rs10430521	chr10:75913590	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.64	6.23	0.36	1.87e-9	Soluble interleukin-2 receptor subunit alpha;
CESC	cis	rs1218582	0.741	rs10908446	chr1:154869559	G/A	cg16680214	chr1:154839983	KCNN3	-0.43	-6.6	-0.38	2.2e-10	Prostate cancer;
CESC	cis	rs6011002	0.810	rs76832249	chr20:62307776	A/G	cg15212369	chr20:62274085	STMN3	-0.59	-5.11	-0.3	6.25e-7	Dental caries;
CESC	cis	rs4727027	0.933	rs1044358	chr7:148879951	C/A	cg23583168	chr7:148888333	NA	-0.83	-12.67	-0.61	4.51e-29	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs4237845	0.761	rs11172378	chr12:58298161	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.48	5.34	0.31	1.98e-7	Intelligence (multi-trait analysis);
CESC	cis	rs10504229	0.953	rs75253516	chr8:58171547	C/A	cg24829409	chr8:58192753	C8orf71	-0.75	-9.78	-0.51	1.74e-19	Developmental language disorder (linguistic errors);
CESC	cis	rs11779988	0.511	rs6586684	chr8:17925331	A/G	cg18067069	chr8:17937731	ASAH1	0.4	5.52	0.32	8.12e-8	Breast cancer;
CESC	cis	rs1448094	0.511	rs17345975	chr12:86202318	T/A	cg19622623	chr12:86230825	RASSF9	-0.45	-5.73	-0.33	2.68e-8	Major depressive disorder;
CESC	cis	rs864537	0.618	rs2995089	chr1:167431193	G/A	cg09179987	chr1:167433047	CD247	0.54	8.01	0.44	3.61e-14	Celiac disease or Rheumatoid arthritis;Celiac disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg07156929	chr6:34856927	ANKS1A;TAF11	-0.45	-6.4	-0.37	6.92e-10	Fibrinogen levels;
CESC	cis	rs6495122	0.699	rs34862454	chr15:75101530	C/T	cg14664628	chr15:75095509	CSK	-0.71	-9.75	-0.51	2.13e-19	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
CESC	cis	rs4665809	1.000	rs6546736	chr2:26293878	C/T	cg25036284	chr2:26402008	FAM59B	0.55	6.55	0.37	2.94e-10	Gut microbiome composition (summer);
CESC	cis	rs763121	0.853	rs5757226	chr22:39070550	T/C	cg14440974	chr22:39074834	NA	-0.42	-5.89	-0.34	1.14e-8	Menopause (age at onset);
CESC	cis	rs7914558	0.933	rs12763665	chr10:104653717	G/A	cg08650961	chr10:104748594	CNNM2	0.33	5.37	0.31	1.75e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs12995491	1.000	rs12995491	chr2:88527414	C/T	cg14558114	chr2:88469736	THNSL2	0.47	6.76	0.38	8.88e-11	Response to metformin (IC50);
CESC	cis	rs798554	0.797	rs798493	chr7:2798731	A/G	cg04166393	chr7:2884313	GNA12	0.58	7.3	0.41	3.4e-12	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18705916	chr5:1800069	MRPL36;NDUFS6	0.6	7.08	0.4	1.33e-11	Gut microbiome composition (summer);
CESC	trans	rs1814175	0.645	rs4598671	chr11:50003191	C/A	cg03929089	chr4:120376271	NA	-0.91	-14.65	-0.67	5.08e-36	Height;
CESC	cis	rs13102973	0.965	rs9998499	chr4:135869362	G/A	cg14419869	chr4:135874104	NA	-0.4	-6.41	-0.37	6.73e-10	Subjective well-being;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg06722285	chr1:61925875	NFIA	0.4	6.14	0.35	3.02e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs4665809	1.000	rs17040322	chr2:26351274	G/C	cg26314531	chr2:26401878	FAM59B	-0.62	-6.99	-0.39	2.29e-11	Gut microbiome composition (summer);
CESC	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg09177884	chr7:1199841	ZFAND2A	-0.54	-6.08	-0.35	4.25e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs76419734	0.558	rs10030620	chr4:106574536	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.76	9.39	0.5	2.89e-18	Post bronchodilator FEV1;
CESC	cis	rs5995756	0.761	rs6001638	chr22:40003267	T/C	cg03390717	chr22:39966585	CACNA1I	-0.35	-6.15	-0.35	2.79e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs763121	0.815	rs12168758	chr22:38997269	C/G	cg06544989	chr22:39130855	UNC84B	0.47	8.58	0.47	8.06e-16	Menopause (age at onset);
CESC	cis	rs10214930	0.671	rs3944121	chr7:27880888	A/C	cg05786569	chr7:27702416	HIBADH	0.43	5.07	0.3	7.64e-7	Hypospadias;
CESC	cis	rs7100689	0.754	rs1934695	chr10:82125230	T/C	cg00277334	chr10:82204260	NA	-0.59	-7.35	-0.41	2.39e-12	Post bronchodilator FEV1;
CESC	cis	rs7666738	0.546	rs3911415	chr4:98692401	T/A	cg17366294	chr4:99064904	C4orf37	0.49	6.04	0.35	5.12e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7165102	1.000	rs4351999	chr15:65992380	T/C	cg11441148	chr15:65824328	PTPLAD1	0.31	5.07	0.3	7.51e-7	Mean corpuscular hemoglobin;
CESC	cis	rs1862618	0.573	rs2034245	chr5:56243685	T/C	cg18230493	chr5:56204884	C5orf35	0.8	9.47	0.5	1.63e-18	Initial pursuit acceleration;
CESC	cis	rs3806843	0.868	rs2563291	chr5:140119599	T/A	cg26395211	chr5:140044315	WDR55	0.4	5.08	0.3	7.2e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs3785574	0.962	rs2727332	chr17:61878584	T/A	cg06420487	chr17:61919686	SMARCD2	0.45	5.36	0.31	1.82e-7	Height;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg27551657	chr1:109618774	TAF13	-0.44	-6.07	-0.35	4.4e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs13191362	1.000	rs55847707	chr6:163003414	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.5	5.17	0.3	4.64e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs35306767	0.903	rs765867	chr10:869901	G/T	cg26597838	chr10:835615	NA	0.9	9.51	0.5	1.2e-18	Eosinophil percentage of granulocytes;
CESC	cis	rs9788682	0.895	rs3813570	chr15:78832832	T/C	cg06917634	chr15:78832804	PSMA4	-0.57	-6.61	-0.38	2.15e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs4665809	1.000	rs1030730	chr2:26284143	T/C	cg27170947	chr2:26402098	FAM59B	-0.72	-8.31	-0.45	5.18e-15	Gut microbiome composition (summer);
CESC	cis	rs10089	1.000	rs7713877	chr5:127428825	G/T	cg19767477	chr5:127420684	SLC12A2	-0.41	-5.55	-0.32	6.89e-8	Ileal carcinoids;
CESC	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg23978390	chr7:1156363	C7orf50	0.41	5.58	0.32	6.04e-8	Longevity;Endometriosis;
CESC	cis	rs9488822	0.676	rs7774952	chr6:116380909	A/G	cg26893134	chr6:116381904	FRK	0.25	6.19	0.36	2.27e-9	Cholesterol, total;LDL cholesterol;
CESC	cis	rs8114671	0.742	rs6058161	chr20:33620026	C/T	cg24642439	chr20:33292090	TP53INP2	-0.45	-5.44	-0.32	1.19e-7	Height;
CESC	cis	rs8180040	0.845	rs295441	chr3:47333295	T/A	cg27129171	chr3:47204927	SETD2	0.66	10.09	0.53	1.82e-20	Colorectal cancer;
CESC	cis	rs722599	0.748	rs17093914	chr14:75363641	A/G	cg08847533	chr14:75593920	NEK9	0.47	5.62	0.33	4.88e-8	IgG glycosylation;
CESC	cis	rs11650494	1.000	rs11650494	chr17:47345186	G/A	cg08112188	chr17:47440006	ZNF652	0.68	5.05	0.3	8.21e-7	Prostate cancer;
CESC	cis	rs4843747	0.671	rs9933794	chr16:88116981	T/C	cg03395651	chr16:88107091	BANP	0.48	5.56	0.32	6.74e-8	Menopause (age at onset);
CESC	cis	rs17023223	0.537	rs12081198	chr1:119686104	A/C	cg05756136	chr1:119680316	WARS2	-0.46	-5.57	-0.32	6.27e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CESC	cis	rs4919087	0.683	rs11189121	chr10:99072036	T/C	cg25902810	chr10:99078978	FRAT1	-0.5	-5.67	-0.33	3.79e-8	Monocyte count;
CESC	cis	rs6460942	0.659	rs13247187	chr7:12551851	T/C	cg02935154	chr7:12443704	VWDE	-0.56	-5.66	-0.33	3.93e-8	Coronary artery disease;
CESC	cis	rs4073582	0.595	rs528842	chr11:66032390	G/A	cg14036092	chr11:66035641	RAB1B	0.57	7.86	0.43	9.65e-14	Gout;
CESC	cis	rs782590	0.522	rs12329050	chr2:55894428	G/A	cg18811423	chr2:55921094	PNPT1	-0.7	-10.68	-0.55	2.17e-22	Metabolic syndrome;
CESC	cis	rs79349575	0.783	rs12602746	chr17:47031741	A/C	cg26022315	chr17:47021804	SNF8	0.39	5.16	0.3	4.94e-7	Type 2 diabetes;
CESC	cis	rs597539	0.652	rs514833	chr11:68657734	C/T	cg04772025	chr11:68637568	NA	0.5	5.95	0.34	8.36e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs4588572	0.686	rs116246588	chr5:77683144	T/G	cg11547950	chr5:77652471	NA	0.46	5.94	0.34	8.76e-9	Triglycerides;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg05529236	chr11:62341449	EEF1G	-0.47	-6.24	-0.36	1.75e-9	Fibrinogen levels;
CESC	cis	rs7200543	0.848	rs62039480	chr16:15137450	G/A	cg07549590	chr16:15018862	NA	-0.35	-5.04	-0.3	8.81e-7	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
CESC	cis	rs10479542	0.630	rs6879664	chr5:178974576	T/G	cg09060608	chr5:178986726	RUFY1	0.46	6.44	0.37	5.53e-10	Lung cancer;
CESC	cis	rs7103648	0.630	rs7934481	chr11:47883337	C/T	cg20307385	chr11:47447363	PSMC3	0.79	11.82	0.59	3.55e-26	Diastolic blood pressure;Systolic blood pressure;
CESC	cis	rs6061231	1.000	rs13043313	chr20:60958269	A/G	cg06197360	chr20:60970103	CABLES2	-0.4	-5.19	-0.3	4.24e-7	Colorectal cancer;
CESC	cis	rs2243480	1.000	rs781149	chr7:65481284	C/T	cg13147721	chr7:65941812	NA	-0.86	-8.36	-0.46	3.7e-15	Diabetic kidney disease;
CESC	cis	rs3768617	0.510	rs4651145	chr1:183098900	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.89	14.39	0.66	4.39e-35	Fuchs's corneal dystrophy;
CESC	cis	rs7635838	0.892	rs9814907	chr3:11438645	G/A	cg00170343	chr3:11313890	ATG7	0.42	5.54	0.32	7.14e-8	HDL cholesterol;
CESC	cis	rs4535700	0.501	rs28828764	chr7:55988679	T/C	cg09872392	chr7:56161020	PHKG1	0.41	5.81	0.34	1.8e-8	Macular telangiectasia type 2;
CESC	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg03760483	chr17:6899297	ALOX12	0.44	7.93	0.44	6.01e-14	Tonsillectomy;
CESC	cis	rs4666360	1.000	rs4233757	chr2:20336077	G/A	cg23291376	chr2:20336282	NA	-0.36	-5.99	-0.35	6.84e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel);
CESC	trans	rs1436955	0.712	rs7164482	chr15:62382883	A/C	cg24704476	chr1:956799	AGRN	0.32	6.15	0.35	2.87e-9	Type 2 diabetes;
CESC	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	7.61	0.42	4.95e-13	Prudent dietary pattern;
CESC	cis	rs2979489	0.841	rs2015311	chr8:30306989	A/G	cg26383811	chr8:30366931	RBPMS	0.84	9.92	0.52	6.18e-20	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CESC	cis	rs6933660	0.745	rs9371517	chr6:151739810	G/T	cg14416726	chr6:151773293	C6orf211;RMND1	-0.54	-7.25	-0.41	4.55e-12	Menarche (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21759057	chr19:983033	WDR18	0.66	7.52	0.42	8.54e-13	Gut microbiome composition (summer);
CESC	cis	rs11608355	0.515	rs12831026	chr12:109903651	C/T	cg05360138	chr12:110035743	NA	0.82	8.92	0.48	7.93e-17	Neuroticism;
CESC	cis	rs17711722	0.640	rs13237956	chr7:65318029	G/A	cg11987759	chr7:65425863	GUSB	-0.48	-6.56	-0.37	2.82e-10	Calcium levels;
CESC	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg11301795	chr4:187892539	NA	0.8	14.15	0.66	2.94e-34	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7937682	0.921	rs1944119	chr11:111436387	A/G	cg09085632	chr11:111637200	PPP2R1B	0.95	12.0	0.59	9e-27	Primary sclerosing cholangitis;
CESC	cis	rs7310409	0.544	rs1169292	chr12:121426478	C/T	cg02403541	chr12:121454288	C12orf43	0.66	8.65	0.47	4.89e-16	Liver enzyme levels (gamma-glutamyl transferase);C-reactive protein;Pancreatic cancer;
CESC	trans	rs916888	0.821	rs199506	chr17:44859031	A/G	cg07870213	chr5:140052090	DND1	-0.62	-6.92	-0.39	3.37e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	trans	rs7980799	0.649	rs12819439	chr12:33684509	A/C	cg26384229	chr12:38710491	ALG10B	0.58	8.14	0.45	1.59e-14	Heart rate;Heart rate variability traits (RMSSD);
CESC	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.44	-6.25	-0.36	1.6e-9	Longevity;Endometriosis;
CESC	trans	rs116095464	0.558	rs7708515	chr5:234989	C/G	cg00938859	chr5:1591904	SDHAP3	0.62	6.76	0.38	8.74e-11	Breast cancer;
CESC	cis	rs3762637	0.943	rs3817040	chr3:122254769	G/A	cg24169773	chr3:122142474	KPNA1	-0.59	-6.85	-0.39	5.17e-11	LDL cholesterol levels;
CESC	cis	rs17376456	0.877	rs35747258	chr5:93310129	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.61	5.33	0.31	2.15e-7	Diabetic retinopathy;
CESC	cis	rs2070433	1.000	rs2839302	chr21:47952364	G/A	cg12379764	chr21:47803548	PCNT	0.62	7.2	0.4	6.16e-12	Lymphocyte counts;
CESC	cis	rs35849525	1.000	rs35849525	chr3:50067350	T/C	cg24110177	chr3:50126178	RBM5	-0.46	-5.41	-0.32	1.38e-7	Intelligence (multi-trait analysis);
CESC	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.53	-8.12	-0.45	1.81e-14	Longevity;Endometriosis;
CESC	cis	rs8114671	0.836	rs6142294	chr20:33671497	A/G	cg06115741	chr20:33292138	TP53INP2	-0.46	-5.52	-0.32	7.98e-8	Height;
CESC	cis	rs8044868	0.530	rs2550868	chr16:72066072	G/A	cg01557791	chr16:72042693	DHODH	-0.47	-6.44	-0.37	5.52e-10	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CESC	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.56	-6.24	-0.36	1.77e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs1005277	0.579	rs2474586	chr10:38418882	T/C	cg25517755	chr10:38738941	LOC399744	-0.46	-5.98	-0.34	7.23e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs769267	0.930	rs1047361	chr19:19606634	G/A	cg03709012	chr19:19516395	GATAD2A	1.01	15.71	0.69	9.73e-40	Tonsillectomy;
CESC	cis	rs360798	0.512	rs7562149	chr2:63008414	A/G	cg17519650	chr2:63277830	OTX1	-0.53	-7.12	-0.4	1.01e-11	Coronary artery disease;
CESC	trans	rs61931739	0.500	rs11053189	chr12:34433455	G/A	cg26384229	chr12:38710491	ALG10B	0.69	10.37	0.54	2.3e-21	Morning vs. evening chronotype;
CESC	cis	rs854765	0.547	rs28537385	chr17:17902135	G/A	cg09796270	chr17:17721594	SREBF1	0.37	5.14	0.3	5.47e-7	Total body bone mineral density;
CESC	trans	rs629535	0.862	rs662725	chr8:70029616	C/T	cg21567404	chr3:27674614	NA	0.93	11.25	0.57	2.83e-24	Dupuytren's disease;
CESC	cis	rs7586673	0.930	rs6432667	chr2:161905001	T/C	cg08807892	chr2:162101083	NA	0.49	6.33	0.36	1.03e-9	Intelligence (multi-trait analysis);
CESC	cis	rs2050392	0.760	rs10826797	chr10:30690376	A/C	cg25182066	chr10:30743637	MAP3K8	-0.4	-5.17	-0.3	4.66e-7	Inflammatory bowel disease;
CESC	cis	rs7618915	0.501	rs3733045	chr3:52643307	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.6	8.62	0.47	6.21e-16	Bipolar disorder;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg17762331	chr12:7033470	ATN1	0.44	6.24	0.36	1.76e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs1395	0.778	rs34618115	chr2:27418289	G/A	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.44	5.85	0.34	1.44e-8	Blood metabolite levels;
CESC	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg07157834	chr1:205819609	PM20D1	0.7	10.35	0.54	2.55e-21	Menarche (age at onset);
CESC	cis	rs10870270	0.956	rs67378218	chr10:133752420	A/C	cg08754478	chr10:133766260	PPP2R2D	-0.6	-7.81	-0.43	1.37e-13	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs7828089	0.935	rs896375	chr8:22262098	A/G	cg12081754	chr8:22256438	SLC39A14	0.42	5.69	0.33	3.4e-8	Verbal declarative memory;
CESC	cis	rs9916302	0.808	rs6503515	chr17:37606433	G/T	cg00129232	chr17:37814104	STARD3	-0.54	-7.14	-0.4	9.08e-12	Glomerular filtration rate (creatinine);
CESC	cis	rs853679	0.517	rs9393885	chr6:28050009	A/T	cg23161317	chr6:28129485	ZNF389	0.5	6.31	0.36	1.19e-9	Depression;
CESC	cis	rs11864453	1.000	rs2278027	chr16:72051369	A/G	cg01557791	chr16:72042693	DHODH	-0.68	-9.08	-0.49	2.58e-17	Fibrinogen levels;
CESC	cis	rs754466	0.561	rs11002344	chr10:79709725	A/T	cg17075019	chr10:79541650	NA	-0.68	-6.79	-0.38	7.55e-11	Liver enzyme levels (gamma-glutamyl transferase);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg26877198	chr19:9938416	UBL5	-0.45	-6.35	-0.36	9.26e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs1552244	0.935	rs11926481	chr3:10142102	G/T	cg00149659	chr3:10157352	C3orf10	0.72	8.92	0.48	7.79e-17	Alzheimer's disease;
CESC	cis	rs6582630	0.519	rs12372510	chr12:38293074	T/C	cg26384229	chr12:38710491	ALG10B	0.67	9.99	0.52	3.89e-20	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs1448094	0.817	rs10863108	chr12:86328249	C/T	cg02569458	chr12:86230093	RASSF9	0.45	6.43	0.37	5.79e-10	Major depressive disorder;
CESC	cis	rs9311474	0.508	rs7652191	chr3:52610415	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.5	7.43	0.42	1.46e-12	Electroencephalogram traits;
CESC	trans	rs35110281	0.774	rs2838321	chr21:44995488	A/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.49	6.55	0.37	3.02e-10	Mean corpuscular volume;
CESC	cis	rs6952808	0.595	rs3778984	chr7:2166514	T/C	cg04267008	chr7:1944627	MAD1L1	-0.6	-7.24	-0.41	4.88e-12	Bipolar disorder and schizophrenia;
CESC	cis	rs644799	1.000	rs488246	chr11:95560473	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.55	6.76	0.38	8.51e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs11098499	0.954	rs12499324	chr4:120393786	C/T	cg09307838	chr4:120376055	NA	0.92	13.14	0.63	1.06e-30	Corneal astigmatism;
CESC	cis	rs9818941	0.824	rs9838352	chr3:157760461	C/A	cg08654915	chr3:157813417	NA	-0.46	-7.48	-0.42	1.08e-12	Height;
CESC	trans	rs61931739	0.534	rs10844774	chr12:34166764	C/T	cg26384229	chr12:38710491	ALG10B	0.64	9.03	0.49	3.54e-17	Morning vs. evening chronotype;
CESC	cis	rs7618915	0.547	rs4687548	chr3:52666650	A/T	cg18099408	chr3:52552593	STAB1	-0.31	-5.07	-0.3	7.43e-7	Bipolar disorder;
CESC	cis	rs300703	0.872	rs7568288	chr2:276908	C/G	cg21211680	chr2:198530	NA	0.86	7.44	0.42	1.39e-12	Blood protein levels;
CESC	cis	rs7814319	0.838	rs10955067	chr8:97230982	C/T	cg20787634	chr8:97240163	UQCRB	-0.54	-6.6	-0.38	2.18e-10	Lung function (FVC);
CESC	cis	rs10434923	1.000	rs1524430	chr7:156256318	G/A	cg10571168	chr7:156583547	LMBR1	0.57	5.05	0.3	8.2e-7	Childhood ear infection;
CESC	cis	rs873946	0.590	rs12259699	chr10:134549692	A/G	cg18305652	chr10:134549665	INPP5A	0.51	7.67	0.43	3.3e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs6912958	1.000	rs2223880	chr6:88167897	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.35	-5.77	-0.33	2.24e-8	Monocyte percentage of white cells;
CESC	cis	rs7552404	1.000	rs4949874	chr1:76161889	T/C	cg10523679	chr1:76189770	ACADM	0.72	8.33	0.46	4.31e-15	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs7605827	0.930	rs1528622	chr2:15557535	A/T	cg19274914	chr2:15703543	NA	0.31	5.54	0.32	7.4e-8	Educational attainment (years of education);
CESC	cis	rs9318086	0.648	rs4067969	chr13:24469120	G/A	cg25267304	chr13:24462978	PCOTH;MIPEP	0.49	6.79	0.38	7.53e-11	Myopia (pathological);
CESC	cis	rs9926296	0.744	rs164747	chr16:89708680	T/G	cg01097406	chr16:89675127	NA	0.36	5.05	0.3	8.11e-7	Vitiligo;
CESC	cis	rs6580649	0.941	rs7959755	chr12:48446318	T/A	cg24011408	chr12:48396354	COL2A1	-0.42	-5.28	-0.31	2.67e-7	Lung cancer;
CESC	cis	rs17539620	0.506	rs62432749	chr6:154839219	G/A	cg17771515	chr6:154831774	CNKSR3	0.58	5.76	0.33	2.36e-8	Lipoprotein (a) levels;
CESC	cis	rs7809950	1.000	rs2237677	chr7:107202502	A/C	cg23024343	chr7:107201750	COG5	-0.37	-5.21	-0.3	3.89e-7	Coronary artery disease;
CESC	cis	rs3780486	0.505	rs10813958	chr9:33165985	A/G	cg13443165	chr9:33130375	B4GALT1	0.48	7.23	0.41	5.13e-12	IgG glycosylation;
CESC	cis	rs9467711	0.659	rs35433030	chr6:26529890	G/A	cg21479132	chr6:26055353	NA	0.72	5.15	0.3	5.19e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs514406	0.708	rs480299	chr1:53320274	G/T	cg24675658	chr1:53192096	ZYG11B	-0.69	-9.82	-0.52	1.29e-19	Monocyte count;
CESC	trans	rs4689592	0.503	rs66885632	chr4:7053738	T/C	cg07817883	chr1:32538562	TMEM39B	0.69	6.67	0.38	1.46e-10	Monocyte percentage of white cells;
CESC	cis	rs2836974	0.897	rs13052882	chr21:40555351	G/C	cg11890956	chr21:40555474	PSMG1	1.21	24.59	0.83	2.36e-70	Cognitive function;
CESC	cis	rs3106136	0.872	rs13130583	chr4:95245543	T/C	cg11021082	chr4:95130006	SMARCAD1	0.41	5.78	0.33	2.04e-8	Capecitabine sensitivity;
CESC	cis	rs870825	0.616	rs7668009	chr4:185641998	A/C	cg04058563	chr4:185651563	MLF1IP	0.66	7.1	0.4	1.18e-11	Blood protein levels;
CESC	cis	rs7845219	0.544	rs4735332	chr8:95923660	C/T	cg16049864	chr8:95962084	TP53INP1	-0.5	-7.43	-0.42	1.48e-12	Type 2 diabetes;
CESC	cis	rs11190604	1.000	rs2295774	chr10:102265847	A/C	cg07080220	chr10:102295463	HIF1AN	0.62	5.63	0.33	4.62e-8	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs514406	0.929	rs562178	chr1:53319562	T/C	cg08736216	chr1:53307985	ZYG11A	-0.4	-6.61	-0.38	2.09e-10	Monocyte count;
CESC	trans	rs7107217	1.000	rs1873872	chr11:129473993	A/T	cg22931738	chr3:128206823	GATA2	0.47	6.03	0.35	5.38e-9	Breast cancer;Type 2 diabetes;
CESC	cis	rs7818688	0.697	rs11776186	chr8:95971968	A/G	cg16049864	chr8:95962084	TP53INP1	0.57	5.64	0.33	4.29e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	trans	rs7000551	0.646	rs2979302	chr8:22359156	G/A	cg24804145	chr7:158144409	PTPRN2	-0.32	-6.1	-0.35	3.66e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CESC	cis	rs11792861	0.816	rs11791845	chr9:111683898	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.53	6.85	0.39	5.17e-11	Menarche (age at onset);
CESC	cis	rs2898857	0.545	rs12942379	chr17:47358733	C/T	cg08112188	chr17:47440006	ZNF652	0.46	5.79	0.34	1.97e-8	Cancer;
CESC	cis	rs9660992	0.573	rs4400674	chr1:205218425	A/C	cg21643547	chr1:205240462	TMCC2	0.39	5.36	0.31	1.81e-7	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs6987853	0.787	rs2974358	chr8:42434403	T/C	cg09913449	chr8:42400586	C8orf40	0.44	7.44	0.42	1.43e-12	Mean corpuscular hemoglobin concentration;
CESC	cis	rs875971	1.000	rs1144894	chr7:65542894	A/G	cg11764359	chr7:65958608	NA	-0.95	-14.12	-0.66	3.94e-34	Aortic root size;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg05886006	chr1:161359784	NA	-0.41	-6.05	-0.35	4.95e-9	Gambling;
CESC	cis	rs2836974	0.831	rs2836921	chr21:40516070	C/T	cg27266027	chr21:40555129	PSMG1	0.45	5.19	0.3	4.14e-7	Cognitive function;
CESC	cis	rs12477438	0.798	rs6740035	chr2:99576578	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-10.51	-0.54	7.92e-22	Chronic sinus infection;
CESC	cis	rs6541297	0.703	rs678050	chr1:230313911	T/C	cg20703242	chr1:230279135	GALNT2	-0.43	-5.6	-0.33	5.46e-8	Coronary artery disease;
CESC	cis	rs362272	0.545	rs3129308	chr4:3309272	C/T	cg14583973	chr4:3374767	RGS12	0.32	5.43	0.32	1.26e-7	Serum sulfate level;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02166888	chr8:144409668	TOP1MT	-0.58	-6.53	-0.37	3.37e-10	Gut microbiome composition (summer);
CESC	cis	rs7851660	0.809	rs10984230	chr9:100660284	C/T	cg13688889	chr9:100608707	NA	-0.63	-8.74	-0.47	2.77e-16	Strep throat;
CESC	cis	rs2882667	1.000	rs10515505	chr5:138313146	A/G	cg04439458	chr5:138467593	SIL1	-0.33	-5.44	-0.32	1.24e-7	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs7727544	0.716	rs3844312	chr5:131582356	C/T	cg14196790	chr5:131705035	SLC22A5	0.36	5.32	0.31	2.22e-7	Blood metabolite levels;
CESC	trans	rs2488856	0.528	rs2455977	chr14:43562207	C/A	cg14326805	chr9:71737756	TJP2	0.38	6.15	0.35	2.9e-9	Osteoprotegerin levels;
CESC	cis	rs4474465	0.850	rs4944205	chr11:78227790	T/A	cg27205649	chr11:78285834	NARS2	0.45	5.58	0.32	6.09e-8	Alzheimer's disease (survival time);
CESC	cis	rs911555	0.755	rs2756135	chr14:103962579	G/A	cg24130564	chr14:104152367	KLC1	0.48	6.21	0.36	2.09e-9	Intelligence (multi-trait analysis);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg10522326	chr1:16134171	UQCRHL	0.4	6.07	0.35	4.52e-9	Gambling;
CESC	cis	rs3091242	0.933	rs4649084	chr1:25752617	A/G	cg12412775	chr1:25698385	RHCE	-0.3	-5.42	-0.32	1.32e-7	Erythrocyte sedimentation rate;
CESC	cis	rs826838	0.935	rs1684406	chr12:39127265	A/G	cg13010199	chr12:38710504	ALG10B	-0.45	-6.26	-0.36	1.53e-9	Heart rate;
CESC	cis	rs9900062	0.586	rs6504250	chr17:62680553	T/C	cg02598441	chr17:62777298	LOC146880	-0.49	-5.14	-0.3	5.45e-7	QT interval;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg06057208	chr16:30535933	ZNF768	-0.44	-6.3	-0.36	1.25e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs11696501	0.539	rs6073849	chr20:44299385	A/T	cg11783356	chr20:44313418	WFDC10B	-0.32	-5.12	-0.3	5.77e-7	Brain structure;
CESC	cis	rs6665290	0.904	rs7541033	chr1:227188371	C/A	cg10327440	chr1:227177885	CDC42BPA	-1.2	-31.28	-0.89	6.16e-91	Myeloid white cell count;
CESC	cis	rs4727963	0.819	rs59939536	chr7:122727787	A/T	cg03640110	chr7:122635026	TAS2R16	-0.37	-5.68	-0.33	3.56e-8	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
CESC	cis	rs4253772	0.591	rs6007747	chr22:46657261	A/G	cg24881330	chr22:46731750	TRMU	0.88	9.77	0.51	1.81e-19	LDL cholesterol;Cholesterol, total;
CESC	cis	rs9291683	0.609	rs13149985	chr4:10028390	G/A	cg11266682	chr4:10021025	SLC2A9	0.7	13.98	0.65	1.25e-33	Bone mineral density;
CESC	cis	rs7615952	0.641	rs2365019	chr3:125808135	T/C	cg02807482	chr3:125708958	NA	-0.39	-5.07	-0.3	7.59e-7	Blood pressure (smoking interaction);
CESC	cis	rs17253792	0.822	rs79022053	chr14:56071721	A/G	cg01858014	chr14:56050164	KTN1	-0.85	-6.99	-0.39	2.22e-11	Putamen volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17499729	chr21:37504755	NA	-0.64	-7.5	-0.42	9.41e-13	Gut microbiome composition (summer);
CESC	cis	rs8141529	0.732	rs5997408	chr22:29207915	G/A	cg15103426	chr22:29168792	CCDC117	0.68	9.72	0.51	2.71e-19	Lymphocyte counts;
CESC	cis	rs9303280	0.806	rs8069176	chr17:38057197	G/A	cg19468946	chr17:37922297	IKZF3	-0.39	-5.18	-0.3	4.33e-7	Self-reported allergy;
CESC	cis	rs9660180	0.967	rs2272908	chr1:1721479	A/G	cg05132306	chr1:1846340	CALML6	0.3	6.38	0.36	7.91e-10	Body mass index;
CESC	cis	rs17401966	0.867	rs12403443	chr1:10423988	A/G	cg15208524	chr1:10270712	KIF1B	0.44	5.47	0.32	1.05e-7	Hepatocellular carcinoma;
CESC	cis	rs244293	0.700	rs12939352	chr17:53007655	T/G	cg19360675	chr17:53046073	COX11;STXBP4	-0.47	-6.35	-0.36	9.11e-10	Menarche (age at onset);
CESC	cis	rs4969178	0.965	rs16971105	chr17:76393975	G/T	cg05887092	chr17:76393375	PGS1	0.58	9.19	0.49	1.22e-17	HDL cholesterol levels;
CESC	cis	rs7809950	0.954	rs2894466	chr7:107242909	G/A	cg23024343	chr7:107201750	COG5	0.46	6.24	0.36	1.76e-9	Coronary artery disease;
CESC	cis	rs644799	0.763	rs2950521	chr11:95536870	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	9.13	0.49	1.83e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs1008375	0.966	rs2286773	chr4:17616214	C/A	cg16339924	chr4:17578868	LAP3	0.65	8.37	0.46	3.25e-15	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs2637266	0.905	rs4357630	chr10:78382883	T/G	cg18941641	chr10:78392320	NA	0.39	7.49	0.42	1.02e-12	Pulmonary function;
CESC	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg10862848	chr6:42927986	GNMT	-0.26	-6.53	-0.37	3.42e-10	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs4594175	0.926	rs4901083	chr14:51604998	C/A	cg23942311	chr14:51606299	NA	0.4	5.94	0.34	9.07e-9	Cancer;
CESC	cis	rs1545257	0.537	rs11125582	chr2:24646213	C/T	cg06627628	chr2:24431161	ITSN2	-0.51	-5.98	-0.35	7.04e-9	Sjögren's syndrome;
CESC	cis	rs6433857	0.536	rs12474658	chr2:181352992	G/T	cg23363182	chr2:181467187	NA	-0.4	-5.61	-0.33	5.08e-8	Body mass index;
CESC	cis	rs13191362	0.935	rs67673890	chr6:163107647	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.08	10.85	0.55	6.1e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs7178572	0.568	rs12906708	chr15:77681444	A/G	cg22256960	chr15:77711686	NA	-0.54	-6.95	-0.39	2.9e-11	Type 2 diabetes;
CESC	cis	rs9303401	0.538	rs8078280	chr17:56473132	A/G	cg25039879	chr17:56429692	SUPT4H1	0.58	6.03	0.35	5.36e-9	Cognitive test performance;
CESC	trans	rs61931739	0.534	rs28548399	chr12:34188151	G/A	cg13010199	chr12:38710504	ALG10B	0.48	5.99	0.35	6.66e-9	Morning vs. evening chronotype;
CESC	cis	rs6542838	0.702	rs6419564	chr2:99534113	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.41	-5.2	-0.3	4.06e-7	Fear of minor pain;
CESC	cis	rs2635047	0.967	rs2576060	chr18:44637106	C/T	cg19077165	chr18:44547161	KATNAL2	0.51	6.98	0.39	2.34e-11	Educational attainment;
CESC	cis	rs4665809	1.000	rs1550381	chr2:26266946	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.72	-8.13	-0.45	1.64e-14	Gut microbiome composition (summer);
CESC	cis	rs12701220	0.503	rs12702024	chr7:1129820	G/C	cg26769984	chr7:1090371	C7orf50	0.6	6.16	0.35	2.74e-9	Bronchopulmonary dysplasia;
CESC	cis	rs7666738	0.830	rs6817645	chr4:99016054	T/C	cg18180107	chr4:99064573	C4orf37	0.4	5.3	0.31	2.48e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9682041	0.696	rs35177863	chr3:170090006	A/G	cg11886554	chr3:170076028	SKIL	0.7	6.49	0.37	4.1e-10	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CESC	cis	rs270601	0.739	rs1979981	chr5:131601720	G/A	cg12564285	chr5:131593104	PDLIM4	0.38	5.8	0.34	1.92e-8	Acylcarnitine levels;
CESC	cis	rs7666738	0.830	rs72882693	chr4:98960804	T/A	cg18180107	chr4:99064573	C4orf37	0.4	5.14	0.3	5.26e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7666738	0.830	rs11725477	chr4:98803266	G/T	cg17366294	chr4:99064904	C4orf37	0.58	8.12	0.45	1.73e-14	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7296418	0.754	rs1619283	chr12:123717362	A/G	cg00376283	chr12:123451042	ABCB9	0.66	9.19	0.49	1.18e-17	Platelet count;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg23311108	chr5:115387951	NA	-0.44	-6.48	-0.37	4.52e-10	Thyroid stimulating hormone;
CESC	cis	rs28386778	0.700	rs12449555	chr17:62003982	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.98	-15.64	-0.69	1.61e-39	Prudent dietary pattern;
CESC	cis	rs7618915	0.531	rs77146033	chr3:52701501	G/T	cg18404041	chr3:52824283	ITIH1	-0.39	-6.58	-0.37	2.56e-10	Bipolar disorder;
CESC	cis	rs11792861	0.926	rs1044905	chr9:111781495	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.47	5.98	0.34	7.2e-9	Menarche (age at onset);
CESC	cis	rs40363	0.523	rs757270	chr16:3534451	C/T	cg05754148	chr16:3507555	NAT15	-0.47	-6.9	-0.39	3.92e-11	Tuberculosis;
CESC	cis	rs7267979	0.966	rs6107031	chr20:25350677	C/T	cg08601574	chr20:25228251	PYGB	-0.38	-5.55	-0.32	6.88e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs854765	0.506	rs7210400	chr17:17949957	C/T	cg04398451	chr17:18023971	MYO15A	0.71	10.43	0.54	1.44e-21	Total body bone mineral density;
CESC	trans	rs459571	0.876	rs2520095	chr9:136919568	A/G	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.67	-8.83	-0.48	1.48e-16	Platelet distribution width;
CESC	trans	rs61931739	0.534	rs11053000	chr12:34079022	C/T	cg26384229	chr12:38710491	ALG10B	0.6	8.36	0.46	3.5e-15	Morning vs. evening chronotype;
CESC	cis	rs7927771	0.524	rs10838777	chr11:47860954	A/C	cg18512352	chr11:47633146	NA	0.35	5.37	0.31	1.7e-7	Subjective well-being;
CESC	cis	rs2932538	0.961	rs1238	chr1:113214097	G/A	cg22162597	chr1:113214053	CAPZA1	-0.56	-7.11	-0.4	1.1e-11	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CESC	cis	rs616402	0.527	rs11121581	chr1:10577740	A/G	cg07384165	chr1:10488281	NA	-0.59	-8.65	-0.47	5.18e-16	Breast size;
CESC	trans	rs2121875	0.667	rs10941659	chr5:44223360	A/T	cg07292773	chr6:156718177	NA	-0.47	-6.09	-0.35	3.99e-9	Prostate cancer;
CESC	cis	rs2243480	1.000	rs1964692	chr7:65454183	G/A	cg18252515	chr7:66147081	NA	-1.19	-11.57	-0.58	2.56e-25	Diabetic kidney disease;
CESC	cis	rs3740713	1.000	rs73438686	chr11:18459785	C/T	cg23797887	chr11:18477753	LDHAL6A	-0.55	-5.21	-0.3	3.87e-7	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs3809863	0.602	rs6504833	chr17:45396087	A/G	cg08085267	chr17:45401833	C17orf57	-0.71	-9.66	-0.51	4.27e-19	Glaucoma (primary open-angle);
CESC	cis	rs3820068	0.603	rs7531396	chr1:15969870	G/C	cg17385448	chr1:15911702	AGMAT	0.42	6.76	0.38	8.54e-11	Systolic blood pressure;
CESC	cis	rs7618915	0.547	rs4687638	chr3:52651966	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	6.79	0.39	7.29e-11	Bipolar disorder;
CESC	cis	rs9910055	0.639	rs11656871	chr17:42269141	G/C	cg19774624	chr17:42201019	HDAC5	-0.91	-14.94	-0.68	5.18e-37	Total body bone mineral density;
CESC	cis	rs13191362	0.938	rs35395472	chr6:163008493	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.5	5.19	0.3	4.29e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs7937682	0.889	rs542424	chr11:111477698	T/C	cg22437258	chr11:111473054	SIK2	0.71	9.58	0.51	7.18e-19	Primary sclerosing cholangitis;
CESC	cis	rs910316	1.000	rs7145159	chr14:75583268	A/G	cg08847533	chr14:75593920	NEK9	1.0	19.2	0.76	4.31e-52	Height;
CESC	cis	rs9457247	0.663	rs9459835	chr6:167417551	G/T	cg07741184	chr6:167504864	NA	0.34	5.96	0.34	7.8e-9	Crohn's disease;
CESC	cis	rs4727027	0.866	rs7778766	chr7:148806729	A/G	cg23158103	chr7:148848205	ZNF398	-0.41	-6.46	-0.37	4.89e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs4853012	0.887	rs2280644	chr2:74358411	G/A	cg05776053	chr2:74358815	NA	0.42	5.17	0.3	4.65e-7	Gestational age at birth (maternal effect);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg19902122	chr11:1087601	MUC2	0.48	6.49	0.37	4.23e-10	Fibrinogen levels;
CESC	cis	rs7666738	0.830	rs28852677	chr4:99039509	T/G	cg17366294	chr4:99064904	C4orf37	0.61	8.78	0.47	2.13e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs875971	0.522	rs781144	chr7:65440344	C/G	cg26939375	chr7:64535504	NA	0.77	10.71	0.55	1.83e-22	Aortic root size;
CESC	cis	rs2842992	0.789	rs4709370	chr6:160210061	A/G	cg11366901	chr6:160182831	ACAT2	0.8	9.85	0.52	1.05e-19	Age-related macular degeneration (geographic atrophy);
CESC	trans	rs7819412	0.623	rs7833435	chr8:10801137	A/G	cg15556689	chr8:8085844	FLJ10661	-0.54	-6.41	-0.37	6.53e-10	Triglycerides;
CESC	cis	rs9900062	0.586	rs6504249	chr17:62676149	A/G	cg02097616	chr17:62675921	NA	0.43	5.2	0.3	3.93e-7	QT interval;
CESC	cis	rs425277	0.606	rs262663	chr1:2084598	T/C	cg12718519	chr1:2058417	PRKCZ	0.25	5.24	0.31	3.21e-7	Height;
CESC	cis	rs6500602	0.739	rs4786502	chr16:4537104	T/C	cg08645402	chr16:4508243	NA	0.57	8.99	0.48	4.75e-17	Schizophrenia;
CESC	cis	rs7618915	0.547	rs3755806	chr3:52643685	C/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	-0.32	-5.53	-0.32	7.81e-8	Bipolar disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15572692	chr19:14016919	C19orf57;CC2D1A	0.58	6.8	0.39	7.12e-11	Gut microbiome composition (summer);
CESC	cis	rs9311474	0.713	rs352167	chr3:52238656	C/T	cg05315796	chr3:52349193	DNAH1	-0.28	-5.08	-0.3	7.09e-7	Electroencephalogram traits;
CESC	cis	rs10911232	0.507	rs4397624	chr1:183053131	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.85	13.7	0.64	1.21e-32	Hypertriglyceridemia;
CESC	cis	rs3015497	0.603	rs12882292	chr14:51018362	G/A	cg26011998	chr14:51135199	SAV1	0.47	5.36	0.31	1.8e-7	Mean platelet volume;
CESC	cis	rs11051970	0.659	rs73088096	chr12:32584403	G/T	cg24626660	chr12:32551988	NA	0.36	5.14	0.3	5.42e-7	Response to tocilizumab in rheumatoid arthritis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10601968	chr5:137090200	HNRNPA0	0.59	7.37	0.41	2.17e-12	Gut microbiome composition (summer);
CESC	trans	rs3942852	0.774	rs10838811	chr11:48186795	A/G	cg03929089	chr4:120376271	NA	-0.66	-7.13	-0.4	9.73e-12	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs4253772	0.550	rs6007779	chr22:46678615	A/C	cg10231785	chr22:46692440	CN5H6.4;GTSE1	0.57	6.04	0.35	5.16e-9	LDL cholesterol;Cholesterol, total;
CESC	cis	rs11690935	0.959	rs10204622	chr2:172588982	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.97	-14.97	-0.68	4e-37	Schizophrenia;
CESC	cis	rs11190604	1.000	rs2489036	chr10:102319581	A/G	cg07080220	chr10:102295463	HIF1AN	0.62	5.9	0.34	1.1e-8	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs568617	0.953	rs1151519	chr11:65645831	G/C	cg19792802	chr11:65647270	CTSW	-0.35	-5.31	-0.31	2.33e-7	Crohn's disease;
CESC	cis	rs9868809	0.881	rs13076269	chr3:48675925	T/C	cg07636037	chr3:49044803	WDR6	-0.64	-5.22	-0.31	3.66e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs1218582	0.772	rs7528532	chr1:154874440	C/T	cg24250549	chr1:154909240	PMVK	0.74	11.09	0.56	1.01e-23	Prostate cancer;
CESC	cis	rs6121246	0.909	rs6089070	chr20:30377773	A/G	cg13852791	chr20:30311386	BCL2L1	-0.85	-7.78	-0.43	1.65e-13	Mean corpuscular hemoglobin;
CESC	cis	rs2204008	0.728	rs11495375	chr12:38282631	G/A	cg26384229	chr12:38710491	ALG10B	0.72	10.26	0.53	5.3e-21	Bladder cancer;
CESC	cis	rs9790314	1.000	rs7653361	chr3:160992291	C/T	cg03342759	chr3:160939853	NMD3	-0.45	-5.9	-0.34	1.08e-8	Morning vs. evening chronotype;
CESC	cis	rs4523957	0.651	rs1994883	chr17:2083881	T/A	cg16513277	chr17:2031491	SMG6	-0.71	-10.17	-0.53	1.04e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs6076065	0.775	rs6083114	chr20:23379528	G/T	cg11657817	chr20:23433608	CST11	0.41	6.23	0.36	1.8e-9	Facial morphology (factor 15, philtrum width);
CESC	cis	rs1559088	0.600	rs7256470	chr19:33558085	C/A	cg17764715	chr19:33622953	WDR88	0.59	8.34	0.46	4.12e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	trans	rs7246760	1.000	rs2081066	chr19:9928044	C/T	cg02900749	chr2:68251473	NA	-0.73	-6.71	-0.38	1.15e-10	Pursuit maintenance gain;
CESC	cis	rs61784830	0.710	rs61783251	chr1:46368087	G/C	cg03146154	chr1:46216737	IPP	0.69	5.59	0.33	5.51e-8	Iron status biomarkers (total iron binding capacity);
CESC	cis	rs2694528	0.686	rs6864253	chr5:59862743	A/G	cg11474532	chr5:59995715	DEPDC1B	0.77	5.83	0.34	1.57e-8	Parkinson's disease;
CESC	cis	rs11792861	0.926	rs3750451	chr9:111822866	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.43	5.38	0.31	1.62e-7	Menarche (age at onset);
CESC	cis	rs367615	0.918	rs4576198	chr5:108867350	T/G	cg17395555	chr5:108820864	NA	0.57	8.44	0.46	2.07e-15	Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs798554	0.757	rs1182181	chr7:2873247	C/G	cg13628971	chr7:2884303	GNA12	0.62	8.24	0.45	8.19e-15	Height;
CESC	cis	rs9325144	0.723	rs10161183	chr12:39182087	T/C	cg26384229	chr12:38710491	ALG10B	-0.51	-7.23	-0.41	5.23e-12	Morning vs. evening chronotype;
CESC	cis	rs9788682	1.000	rs7163730	chr15:78814681	A/G	cg24631222	chr15:78858424	CHRNA5	0.76	9.71	0.51	2.79e-19	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs4713118	0.662	rs149947	chr6:27972433	A/T	cg12963246	chr6:28129442	ZNF389	0.49	6.48	0.37	4.43e-10	Parkinson's disease;
CESC	cis	rs897984	0.683	rs9932572	chr16:30841642	A/G	cg00531865	chr16:30841666	NA	-0.58	-8.64	-0.47	5.32e-16	Dementia with Lewy bodies;
CESC	cis	rs18122	0.632	rs1483335	chr2:67526287	C/A	cg09028215	chr2:67624308	ETAA1	-0.41	-5.17	-0.3	4.53e-7	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs7937682	0.883	rs1784776	chr11:111472392	C/T	cg22437258	chr11:111473054	SIK2	0.74	9.86	0.52	9.59e-20	Primary sclerosing cholangitis;
CESC	cis	rs1862618	0.853	rs832551	chr5:56180112	T/G	cg12311346	chr5:56204834	C5orf35	-0.74	-8.81	-0.48	1.71e-16	Initial pursuit acceleration;
CESC	cis	rs3096299	0.667	rs2965947	chr16:89518670	T/C	cg02187348	chr16:89574699	SPG7	0.63	8.87	0.48	1.11e-16	Multiple myeloma (IgH translocation);
CESC	cis	rs4474465	1.000	rs6592779	chr11:78197283	G/C	cg02023728	chr11:77925099	USP35	0.39	5.05	0.3	8.34e-7	Alzheimer's disease (survival time);
CESC	trans	rs11098499	0.954	rs6838814	chr4:120392443	G/A	cg25214090	chr10:38739885	LOC399744	0.71	10.27	0.53	4.75e-21	Corneal astigmatism;
CESC	cis	rs919433	0.889	rs787995	chr2:198216853	T/G	cg10820045	chr2:198174542	NA	0.39	5.78	0.33	2.05e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	trans	rs1559777	0.702	rs8037239	chr15:58098521	T/A	cg05133900	chr22:19166543	SLC25A1	-0.6	-6.08	-0.35	4.24e-9	Myopia (pathological);
CESC	trans	rs6828577	0.862	rs298992	chr4:119641941	A/T	cg05098011	chr1:151736092	OAZ3;MRPL9	-0.49	-6.08	-0.35	4.27e-9	Perioperative myocardial infarction in coronary artery bypass surgery;
CESC	cis	rs1552244	0.808	rs17032306	chr3:10091399	C/G	cg08888203	chr3:10149979	C3orf24	0.51	6.51	0.37	3.85e-10	Alzheimer's disease;
CESC	cis	rs7833790	0.963	rs72686466	chr8:82758928	G/T	cg27398817	chr8:82754497	SNX16	0.56	6.44	0.37	5.68e-10	Diastolic blood pressure;
CESC	cis	rs6691722	0.503	rs6692646	chr1:24707629	C/T	cg02336364	chr1:24764700	NIPAL3	0.32	6.58	0.37	2.48e-10	Response to interferon beta in multiple sclerosis;
CESC	cis	rs72945132	0.882	rs7932431	chr11:70166059	A/T	cg14191688	chr11:70257035	CTTN	0.43	5.46	0.32	1.08e-7	Coronary artery disease;
CESC	cis	rs9894429	0.646	rs12948797	chr17:79617384	G/A	cg13777783	chr17:79615861	NA	-0.32	-5.32	-0.31	2.19e-7	Eye color traits;
CESC	cis	rs4727027	0.933	rs2158633	chr7:148832652	C/T	cg23158103	chr7:148848205	ZNF398	-0.42	-6.92	-0.39	3.31e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17327406	chr4:6303265	WFS1	-0.65	-7.16	-0.4	7.82e-12	Gut microbiome composition (summer);
CESC	cis	rs3820928	0.967	rs12622456	chr2:227768868	G/A	cg11843606	chr2:227700838	RHBDD1	-0.44	-5.9	-0.34	1.11e-8	Pulmonary function;
CESC	cis	rs939658	0.776	rs35382567	chr15:79440897	C/T	cg17916960	chr15:79447300	NA	-0.35	-5.98	-0.34	7.25e-9	Refractive error;
CESC	cis	rs7267979	0.966	rs2387882	chr20:25378802	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.88	-18.14	-0.74	2.4e-48	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs6831352	1.000	rs6822348	chr4:100053894	A/T	cg13256891	chr4:100009986	ADH5	0.72	8.3	0.45	5.2e-15	Alcohol dependence;
CESC	cis	rs4665809	1.000	rs1371553	chr2:26262948	G/A	cg08470875	chr2:26401718	FAM59B	-0.48	-5.21	-0.31	3.72e-7	Gut microbiome composition (summer);
CESC	cis	rs7621025	0.500	rs4678275	chr3:136653683	C/T	cg15507776	chr3:136538369	TMEM22	0.78	9.68	0.51	3.46e-19	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
CESC	cis	rs1048238	0.506	rs12023422	chr1:16187625	G/A	cg22431228	chr1:16359049	CLCNKA	-0.36	-6.23	-0.36	1.83e-9	Systolic blood pressure;
CESC	cis	rs1878931	0.582	rs27238	chr16:3441223	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.7	-8.33	-0.46	4.29e-15	Body mass index (adult);
CESC	cis	rs875971	0.545	rs1547529	chr7:65723846	T/C	cg11764359	chr7:65958608	NA	0.78	9.86	0.52	9.96e-20	Aortic root size;
CESC	cis	rs1448094	0.511	rs4462416	chr12:86150966	T/C	cg02569458	chr12:86230093	RASSF9	-0.42	-6.46	-0.37	4.89e-10	Major depressive disorder;
CESC	cis	rs10751667	0.600	rs6597948	chr11:1005308	C/T	cg06064525	chr11:970664	AP2A2	-0.32	-5.44	-0.32	1.19e-7	Alzheimer's disease (late onset);
CESC	cis	rs6060717	0.610	rs2244883	chr20:34620896	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.58	-7.74	-0.43	2.08e-13	Hip circumference adjusted for BMI;
CESC	cis	rs9388451	0.772	rs1268064	chr6:126042578	G/A	cg10911889	chr6:126070802	HEY2	-0.37	-5.29	-0.31	2.53e-7	Brugada syndrome;
CESC	cis	rs12995491	0.731	rs12992162	chr2:88508773	G/C	cg18490616	chr2:88469792	THNSL2	-0.46	-6.59	-0.38	2.34e-10	Response to metformin (IC50);
CESC	cis	rs9322193	0.926	rs3805751	chr6:150112329	G/A	cg05861140	chr6:150128134	PCMT1	-0.37	-5.36	-0.31	1.82e-7	Lung cancer;
CESC	cis	rs4964805	0.657	rs4964814	chr12:104189384	A/C	cg02344784	chr12:104178138	NT5DC3	-0.46	-6.49	-0.37	4.2e-10	Attention deficit hyperactivity disorder;
CESC	cis	rs7618915	0.547	rs35211965	chr3:52685305	C/G	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.61	0.38	2.16e-10	Bipolar disorder;
CESC	cis	rs2066819	1.000	rs78121408	chr12:56684798	C/T	cg26714650	chr12:56694279	CS	-1.52	-10.39	-0.54	1.95e-21	Psoriasis vulgaris;
CESC	cis	rs2243480	1.000	rs422164	chr7:65586605	C/G	cg18252515	chr7:66147081	NA	-1.41	-14.36	-0.66	5.44e-35	Diabetic kidney disease;
CESC	cis	rs1050631	0.564	rs1785904	chr18:33713132	T/C	cg25426722	chr18:33708991	SLC39A6;ELP2	0.59	8.21	0.45	9.51e-15	Esophageal squamous cell cancer (length of survival);
CESC	cis	rs8180040	0.966	rs17784882	chr3:47544003	C/A	cg27129171	chr3:47204927	SETD2	-0.61	-8.75	-0.47	2.54e-16	Colorectal cancer;
CESC	cis	rs2276314	0.857	rs9960670	chr18:33577712	A/G	cg19628046	chr18:33552617	C18orf21	0.5	5.49	0.32	9.29e-8	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs11792861	0.851	rs17552292	chr9:111891954	C/T	cg05043794	chr9:111880884	C9orf5	-0.42	-6.94	-0.39	3.04e-11	Menarche (age at onset);
CESC	cis	rs11690935	0.959	rs66835971	chr2:172677459	G/A	cg13550731	chr2:172543902	DYNC1I2	-0.97	-14.7	-0.67	3.66e-36	Schizophrenia;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg19419581	chr17:79482410	NA	0.54	7.13	0.4	9.33e-12	Systemic lupus erythematosus;
CESC	cis	rs9911578	0.967	rs2567892	chr17:56668929	T/C	cg05425664	chr17:57184151	TRIM37	-0.49	-6.81	-0.39	6.37e-11	Intelligence (multi-trait analysis);
CESC	cis	rs9430161	0.579	rs11121667	chr1:11038476	C/T	cg02454025	chr1:11042201	C1orf127	0.89	14.7	0.67	3.45e-36	Ewing sarcoma;
CESC	cis	rs7833790	1.000	rs7833384	chr8:82730915	T/C	cg27398817	chr8:82754497	SNX16	-0.53	-6.14	-0.35	3.06e-9	Diastolic blood pressure;
CESC	cis	rs6912958	0.559	rs395358	chr6:88057924	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.48	8.4	0.46	2.76e-15	Monocyte percentage of white cells;
CESC	cis	rs727505	1.000	rs2402751	chr7:124434760	C/T	cg23710748	chr7:124431027	NA	-0.4	-5.93	-0.34	9.5e-9	Lewy body disease;
CESC	cis	rs909674	0.524	rs5750821	chr22:39825492	A/T	cg02038168	chr22:39784481	NA	-0.61	-7.61	-0.42	4.76e-13	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs7659604	0.540	rs10001092	chr4:122677177	C/T	cg19671926	chr4:122722719	EXOSC9	0.53	6.7	0.38	1.21e-10	Type 2 diabetes;
CESC	cis	rs897080	0.515	rs1067319	chr2:44633458	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	5.91	0.34	1.07e-8	Height;
CESC	cis	rs7666738	0.830	rs11097609	chr4:99011707	C/T	cg03676636	chr4:99064102	C4orf37	0.33	5.16	0.3	4.86e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7659604	0.502	rs13108419	chr4:122687238	A/G	cg19671926	chr4:122722719	EXOSC9	0.66	8.53	0.46	1.16e-15	Type 2 diabetes;
CESC	cis	rs8044995	0.517	rs61593058	chr16:68384496	T/C	cg26727032	chr16:67993705	SLC12A4	-0.54	-6.44	-0.37	5.52e-10	Schizophrenia;
CESC	cis	rs329122	0.528	rs329114	chr5:133857708	C/G	cg26284174	chr5:133860141	NA	0.46	5.29	0.31	2.52e-7	Body mass index;Type 2 diabetes;
CESC	cis	rs9486715	1.000	rs11153085	chr6:97066355	A/T	cg06623918	chr6:96969491	KIAA0776	-0.86	-12.58	-0.61	9.16e-29	Headache;
CESC	cis	rs113835537	0.597	rs57288351	chr11:66307489	C/T	cg22134325	chr11:66188745	NPAS4	0.39	5.86	0.34	1.37e-8	Airway imaging phenotypes;
CESC	cis	rs644799	0.544	rs1622515	chr11:95523433	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.49	6.48	0.37	4.33e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg12542094	chr19:2334761	SPPL2B	0.52	6.82	0.39	6.27e-11	Fibrinogen levels;
CESC	cis	rs6714710	0.580	rs17489915	chr2:98420431	T/C	cg26665480	chr2:98280029	ACTR1B	0.56	7.96	0.44	5.02e-14	Posterior cortical atrophy and Alzheimer's disease;
CESC	cis	rs1801251	0.963	rs7591176	chr2:233581803	C/A	cg08000102	chr2:233561755	GIGYF2	0.69	9.32	0.5	4.85e-18	Coronary artery disease;
CESC	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.48	-5.2	-0.3	4.05e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs1707322	0.789	rs7540578	chr1:46252144	C/T	cg03146154	chr1:46216737	IPP	0.79	11.19	0.57	4.58e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7607369	0.536	rs12990447	chr2:219667413	T/C	cg02176678	chr2:219576539	TTLL4	-0.35	-6.13	-0.35	3.12e-9	Red blood cell count;Amyotrophic lateral sclerosis;
CESC	cis	rs2302190	0.882	rs8067183	chr17:56462023	G/A	cg25885038	chr17:56607967	SEPT4	-0.4	-5.42	-0.32	1.37e-7	Vitamin D levels;
CESC	cis	rs4595586	0.545	rs7970850	chr12:39397878	T/C	cg26384229	chr12:38710491	ALG10B	0.54	7.64	0.42	3.96e-13	Morning vs. evening chronotype;
CESC	cis	rs736408	0.648	rs3774355	chr3:52817778	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.44	5.9	0.34	1.08e-8	Bipolar disorder;
CESC	cis	rs7188697	0.922	rs28307	chr16:58577138	A/C	cg02549819	chr16:58548995	SETD6	-0.42	-5.21	-0.3	3.81e-7	QT interval;
CESC	cis	rs1957429	0.731	rs10144554	chr14:65321514	T/G	cg23373153	chr14:65346875	NA	0.85	8.91	0.48	8.47e-17	Pediatric areal bone mineral density (radius);
CESC	trans	rs17807624	1.000	rs17807624	chr8:11463015	A/G	cg15556689	chr8:8085844	FLJ10661	-0.56	-7.5	-0.42	9.48e-13	Systemic lupus erythematosus;
CESC	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg24642844	chr7:1081250	C7orf50	-0.77	-9.63	-0.51	5.27e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs910316	1.000	rs876403	chr14:75602834	A/T	cg11812906	chr14:75593930	NEK9	0.9	15.43	0.69	9.11e-39	Height;
CESC	cis	rs6089584	0.507	rs28545731	chr20:60634102	C/T	cg06108461	chr20:60628389	TAF4	-0.61	-8.11	-0.45	1.94e-14	Body mass index;
CESC	cis	rs9858542	0.953	rs9862080	chr3:49674458	A/G	cg03060546	chr3:49711283	APEH	-0.57	-6.74	-0.38	9.8e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs1003719	0.715	rs1981433	chr21:38542223	T/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.59	-7.98	-0.44	4.49e-14	Eye color traits;
CESC	cis	rs2243480	1.000	rs11538349	chr7:65421871	C/T	cg18252515	chr7:66147081	NA	-0.96	-9.28	-0.5	6.45e-18	Diabetic kidney disease;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg02340378	chr2:73298299	SFXN5	-0.45	-6.42	-0.37	6.36e-10	Gambling;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06383088	chr9:100459634	XPA	0.58	7.35	0.41	2.51e-12	Gut microbiome composition (summer);
CESC	cis	rs7552404	1.000	rs12127402	chr1:76205643	C/A	cg03433033	chr1:76189801	ACADM	0.7	8.56	0.47	9.39e-16	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs2073300	1.000	rs6114098	chr20:23444276	G/A	cg12062639	chr20:23401060	NAPB	0.77	5.68	0.33	3.48e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg07157834	chr1:205819609	PM20D1	0.68	9.83	0.52	1.2e-19	Menarche (age at onset);
CESC	cis	rs1163251	0.902	rs514491	chr1:120216743	C/T	cg19096424	chr1:120255104	PHGDH	0.43	5.22	0.31	3.62e-7	Blood metabolite levels;
CESC	cis	rs992157	0.835	rs12987219	chr2:219144149	G/A	cg00012203	chr2:219082015	ARPC2	-0.76	-9.76	-0.51	2.04e-19	Colorectal cancer;
CESC	cis	rs7020830	0.867	rs563132	chr9:37245476	A/T	cg14294708	chr9:37120828	ZCCHC7	1.2	22.07	0.8	5.6e-62	Schizophrenia;
CESC	cis	rs936229	0.906	rs9210	chr15:75128501	T/C	cg14664628	chr15:75095509	CSK	-0.88	-12.21	-0.6	1.65e-27	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CESC	trans	rs2727020	0.538	rs61885230	chr11:49128958	T/C	cg15704280	chr7:45808275	SEPT13	-0.63	-7.87	-0.44	9.15e-14	Coronary artery disease;
CESC	cis	rs6089584	0.606	rs7270469	chr20:60577258	G/A	cg24733560	chr20:60626293	TAF4	0.44	6.57	0.37	2.64e-10	Body mass index;
CESC	cis	rs1538970	0.924	rs12046816	chr1:45891543	G/T	cg24296786	chr1:45957014	TESK2	-0.46	-5.3	-0.31	2.41e-7	Platelet count;
CESC	cis	rs36051895	0.632	rs7029084	chr9:5174638	T/C	cg02405213	chr9:5042618	JAK2	-0.51	-6.54	-0.37	3.19e-10	Pediatric autoimmune diseases;
CESC	cis	rs2404602	0.716	rs56351018	chr15:76824591	T/C	cg22467129	chr15:76604101	ETFA	-0.38	-5.75	-0.33	2.43e-8	Blood metabolite levels;
CESC	cis	rs7666738	0.830	rs13130923	chr4:99046281	T/C	cg17366294	chr4:99064904	C4orf37	0.61	8.78	0.47	2.13e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7267979	0.966	rs3827014	chr20:25371559	C/T	cg08601574	chr20:25228251	PYGB	-0.38	-5.55	-0.32	6.84e-8	Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg16699022	chr16:89371566	ANKRD11	0.48	6.66	0.38	1.6e-10	Fibrinogen levels;
CESC	cis	rs3126085	0.935	rs4845431	chr1:152227977	A/G	cg03465714	chr1:152285911	FLG	-0.46	-5.55	-0.32	6.76e-8	Atopic dermatitis;
CESC	cis	rs933688	1.000	rs1363839	chr5:90671274	A/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.09	14.49	0.66	1.94e-35	Smoking behavior;
CESC	cis	rs17376456	0.569	rs2045020	chr5:93224466	T/C	cg25358565	chr5:93447407	FAM172A	-0.72	-7.59	-0.42	5.32e-13	Diabetic retinopathy;
CESC	cis	rs1577917	0.739	rs6922	chr6:86205323	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.58	7.83	0.43	1.14e-13	Response to antipsychotic treatment;
CESC	cis	rs2842992	0.768	rs2273824	chr6:160211445	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.77	11.06	0.56	1.26e-23	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs9768139	0.708	rs10234067	chr7:158114542	C/T	cg24154853	chr7:158122151	PTPRN2	0.41	6.44	0.37	5.53e-10	Calcium levels;
CESC	cis	rs17253792	0.822	rs78988988	chr14:56152404	G/A	cg01858014	chr14:56050164	KTN1	-0.97	-7.54	-0.42	7.36e-13	Putamen volume;
CESC	cis	rs514406	0.698	rs511599	chr1:53362818	T/C	cg08859206	chr1:53392774	SCP2	-0.68	-10.01	-0.52	3.33e-20	Monocyte count;
CESC	cis	rs12479064	0.694	rs4341989	chr2:100046783	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.56	-6.91	-0.39	3.59e-11	Chronic sinus infection;
CESC	cis	rs6500602	0.727	rs2058811	chr16:4575162	C/T	cg08645402	chr16:4508243	NA	0.52	8.33	0.46	4.34e-15	Schizophrenia;
CESC	cis	rs875971	0.545	rs7783889	chr7:65748353	T/A	cg11764359	chr7:65958608	NA	0.8	10.12	0.53	1.42e-20	Aortic root size;
CESC	cis	rs11958404	0.860	rs72818117	chr5:157441130	G/A	cg05962755	chr5:157440814	NA	0.62	6.66	0.38	1.57e-10	IgG glycosylation;
CESC	cis	rs9911578	1.000	rs304270	chr17:56802141	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	-0.39	-5.34	-0.31	1.96e-7	Intelligence (multi-trait analysis);
CESC	cis	rs7412746	0.634	rs12409208	chr1:150860055	A/G	cg04414720	chr1:150670196	GOLPH3L	0.52	6.81	0.39	6.62e-11	Melanoma;
CESC	cis	rs7618915	0.547	rs2164884	chr3:52629633	C/T	cg18404041	chr3:52824283	ITIH1	-0.39	-6.55	-0.37	2.91e-10	Bipolar disorder;
CESC	cis	rs8077577	1.000	rs62073605	chr17:18066791	C/T	cg16794390	chr17:18148240	FLII	0.46	6.0	0.35	6.43e-9	Obesity-related traits;
CESC	cis	rs7267979	1.000	rs2257808	chr20:25266450	G/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	18.61	0.75	5.02e-50	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs4722166	0.598	rs4722171	chr7:22785717	A/G	cg05472934	chr7:22766657	IL6	0.86	10.84	0.55	6.66e-23	Lung cancer;
CESC	cis	rs4925166	1	rs4925166	chr17:18210810	T/G	cg08201673	chr17:18167551	SMCR7	0.5	5.73	0.33	2.78e-8	Multiple sclerosis;
CESC	cis	rs7223966	1.000	rs8078462	chr17:61857937	T/G	cg11494091	chr17:61959527	GH2	0.38	5.18	0.3	4.33e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs67311347	1.000	rs73078164	chr3:40480289	G/A	cg24209194	chr3:40518798	ZNF619	0.5	6.21	0.36	2e-9	Renal cell carcinoma;
CESC	cis	rs6500602	0.727	rs11076836	chr16:4569331	G/A	cg08645402	chr16:4508243	NA	0.55	8.93	0.48	7.18e-17	Schizophrenia;
CESC	cis	rs7147624	1.000	rs7160390	chr14:66052460	G/A	cg03016385	chr14:66212404	NA	-0.5	-5.21	-0.3	3.86e-7	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs9309473	0.950	rs10178678	chr2:73762236	A/G	cg20560298	chr2:73613845	ALMS1	-0.54	-7.09	-0.4	1.19e-11	Metabolite levels;
CESC	cis	rs6502050	0.835	rs9902485	chr17:80093701	C/T	cg23985595	chr17:80112537	CCDC57	-0.42	-6.6	-0.38	2.18e-10	Life satisfaction;
CESC	cis	rs722599	0.683	rs10144860	chr14:75286426	T/C	cg08847533	chr14:75593920	NEK9	0.49	5.98	0.34	7.33e-9	IgG glycosylation;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03020000	chr10:63662887	ARID5B	-0.62	-7.66	-0.43	3.55e-13	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.830	rs10022331	chr4:98960392	C/A	cg18180107	chr4:99064573	C4orf37	0.4	5.14	0.3	5.26e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6456156	0.565	rs6921588	chr6:167494397	G/T	cg23791538	chr6:167370224	RNASET2	-0.56	-6.77	-0.38	8.44e-11	Primary biliary cholangitis;
CESC	cis	rs4233802	1.000	rs6761697	chr2:151141735	A/G	cg25300694	chr2:151184358	NA	0.89	7.95	0.44	5.53e-14	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
CESC	cis	rs854765	0.547	rs9897761	chr17:17912011	A/T	cg16928487	chr17:17741425	SREBF1	-0.58	-10.22	-0.53	6.92e-21	Total body bone mineral density;
CESC	cis	rs780096	0.526	rs75855890	chr2:27625005	G/T	cg22903471	chr2:27725779	GCKR	-0.54	-7.65	-0.43	3.75e-13	Total body bone mineral density;
CESC	trans	rs2115172	0.836	rs4835799	chr5:122762229	A/G	cg17408923	chr2:109335769	RANBP2	0.46	6.14	0.35	2.95e-9	Weight;
CESC	cis	rs4819052	0.851	rs4819046	chr21:46664955	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.75	9.95	0.52	5.14e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs6690583	0.623	rs1371141	chr1:85455372	C/A	cg22153463	chr1:85462885	MCOLN2	0.71	7.12	0.4	1.01e-11	Serum sulfate level;
CESC	cis	rs6740322	0.793	rs9808360	chr2:43546835	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.69	-7.5	-0.42	9.55e-13	Coronary artery disease;
CESC	cis	rs10463316	0.862	rs10062928	chr5:150768355	C/T	cg03212797	chr5:150827313	SLC36A1	-0.45	-5.88	-0.34	1.24e-8	Metabolite levels (Pyroglutamine);
CESC	cis	rs11969893	0.850	rs12664068	chr6:101362098	G/T	cg12253828	chr6:101329408	ASCC3	0.91	6.53	0.37	3.33e-10	Economic and political preferences (immigration/crime);
CESC	cis	rs9322193	0.923	rs4455682	chr6:150021297	C/T	cg07701084	chr6:150067640	NUP43	0.48	6.69	0.38	1.29e-10	Lung cancer;
CESC	cis	rs61935443	0.720	rs10859780	chr12:95282601	T/C	cg21533806	chr12:95267307	NA	0.59	7.21	0.4	5.89e-12	Schizophrenia;
CESC	cis	rs2742417	1.000	rs2742435	chr3:45740863	C/T	cg10512202	chr3:45649293	LIMD1	0.38	5.21	0.3	3.85e-7	Response to anti-depressant treatment in major depressive disorder;
CESC	cis	rs561341	0.941	rs4795664	chr17:30233467	C/T	cg19193384	chr17:30244184	NA	-0.56	-5.74	-0.33	2.61e-8	Hip circumference adjusted for BMI;
CESC	trans	rs1814175	0.645	rs4625470	chr11:49983769	T/C	cg03929089	chr4:120376271	NA	-0.92	-15.24	-0.68	4.38e-38	Height;
CESC	cis	rs7818345	0.967	rs11784873	chr8:19281113	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.33	5.92	0.34	1.02e-8	Language performance in older adults (adjusted for episodic memory);
CESC	cis	rs7520050	0.807	rs4660312	chr1:46110572	A/G	cg24296786	chr1:45957014	TESK2	-0.46	-5.96	-0.34	8e-9	Red blood cell count;Reticulocyte count;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg12476490	chr10:64576179	EGR2	0.49	6.88	0.39	4.42e-11	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs7662987	0.517	rs1154410	chr4:100006645	A/G	cg13256891	chr4:100009986	ADH5	0.75	8.48	0.46	1.63e-15	Smoking initiation;
CESC	cis	rs1044826	0.667	rs295471	chr3:139213922	G/C	cg00490450	chr3:139108681	COPB2	0.44	5.46	0.32	1.11e-7	Obesity-related traits;
CESC	cis	rs9467711	0.606	rs2076030	chr6:26426856	G/A	cg14345882	chr6:26364793	BTN3A2	0.61	5.84	0.34	1.56e-8	Autism spectrum disorder or schizophrenia;
CESC	cis	rs3892630	0.620	rs10413279	chr19:33182746	A/G	cg22980127	chr19:33182716	NUDT19	1.08	15.02	0.68	2.62e-37	Red blood cell traits;
CESC	cis	rs8017423	0.967	rs3825662	chr14:90723152	A/G	cg14092571	chr14:90743983	NA	-0.55	-8.31	-0.45	5.06e-15	Mortality in heart failure;
CESC	cis	rs11190604	1.000	rs11190555	chr10:102209160	A/G	cg07080220	chr10:102295463	HIF1AN	0.55	5.51	0.32	8.5e-8	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs7666738	0.830	rs62321564	chr4:98976496	C/G	cg03676636	chr4:99064102	C4orf37	0.34	5.2	0.3	3.93e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs763121	0.853	rs4821798	chr22:39021165	T/C	cg06544989	chr22:39130855	UNC84B	0.51	9.33	0.5	4.42e-18	Menopause (age at onset);
CESC	cis	rs2439831	0.702	rs495175	chr15:43798684	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.9	10.03	0.52	2.78e-20	Lung cancer in ever smokers;
CESC	cis	rs477692	0.544	rs7904404	chr10:131447612	G/A	cg05714579	chr10:131428358	MGMT	-0.71	-9.8	-0.52	1.48e-19	Response to temozolomide;
CESC	cis	rs4332037	0.539	rs57148375	chr7:2025001	G/C	cg23422044	chr7:1970798	MAD1L1	-0.5	-5.38	-0.31	1.61e-7	Bipolar disorder;
CESC	trans	rs79976124	0.797	rs79522358	chr6:66641140	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.72	8.26	0.45	6.99e-15	Type 2 diabetes;
CESC	cis	rs1538970	0.781	rs34768551	chr1:46020408	G/A	cg03146154	chr1:46216737	IPP	0.49	5.51	0.32	8.46e-8	Platelet count;
CESC	cis	rs5769765	0.955	rs4075330	chr22:50303249	G/A	cg02269571	chr22:50332266	NA	-0.53	-6.77	-0.38	8.4e-11	Schizophrenia;
CESC	cis	rs7772486	0.686	rs6570705	chr6:145961201	C/T	cg23711669	chr6:146136114	FBXO30	0.88	13.05	0.63	2.12e-30	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1218582	0.772	rs11264290	chr1:154912300	C/T	cg16680214	chr1:154839983	KCNN3	-0.45	-6.81	-0.39	6.35e-11	Prostate cancer;
CESC	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg24642844	chr7:1081250	C7orf50	-0.4	-5.18	-0.3	4.33e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs1862618	0.671	rs2591968	chr5:56233541	A/G	cg14703610	chr5:56206110	C5orf35	0.4	5.13	0.3	5.56e-7	Initial pursuit acceleration;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18430553	chr17:78795541	RPTOR	-0.5	-6.16	-0.35	2.63e-9	Gut microbiome composition (summer);
CESC	cis	rs73206853	0.764	rs3026447	chr12:110724272	C/T	cg12870014	chr12:110450643	ANKRD13A	0.61	5.3	0.31	2.42e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg23087020	chr1:167190262	POU2F1	-0.44	-6.05	-0.35	4.95e-9	Asthma;
CESC	cis	rs6951245	0.706	rs28522260	chr7:1183964	C/A	cg22907277	chr7:1156413	C7orf50	0.47	5.35	0.31	1.9e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs12900413	0.523	rs11636525	chr15:90300478	A/G	cg24249390	chr15:90295951	MESP1	-0.4	-5.35	-0.31	1.89e-7	Coronary artery aneurysm in Kawasaki disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18329780	chr15:57884048	GCOM1	0.58	6.87	0.39	4.52e-11	Gut microbiome composition (summer);
CESC	cis	rs8077889	0.672	rs1234612	chr17:41840802	A/G	cg26893861	chr17:41843967	DUSP3	1.02	19.14	0.76	7.06e-52	Triglycerides;
CESC	cis	rs1008375	1.000	rs6811887	chr4:17640858	C/T	cg16339924	chr4:17578868	LAP3	0.58	7.25	0.41	4.56e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs1552244	1.000	rs7611218	chr3:10063960	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.89	11.97	0.59	1.14e-26	Alzheimer's disease;
CESC	trans	rs116095464	0.558	rs12173244	chr5:269524	G/A	cg00938859	chr5:1591904	SDHAP3	0.63	6.88	0.39	4.31e-11	Breast cancer;
CESC	cis	rs4665809	0.531	rs10199898	chr2:26445485	T/G	cg26314531	chr2:26401878	FAM59B	-0.85	-9.04	-0.49	3.44e-17	Gut microbiome composition (summer);
CESC	cis	rs4819052	0.851	rs4819049	chr21:46673086	C/G	cg11663144	chr21:46675770	NA	-0.62	-9.64	-0.51	4.62e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs801193	0.569	rs13226966	chr7:66233623	A/G	cg18252515	chr7:66147081	NA	-0.45	-6.01	-0.35	5.99e-9	Aortic root size;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg19531713	chr17:41277059	BRCA1;NBR2	-0.49	-7.28	-0.41	3.7e-12	Gambling;
CESC	cis	rs4835473	0.832	rs66717029	chr4:144658471	A/G	cg25736465	chr4:144833511	NA	-0.33	-5.25	-0.31	3.1e-7	Immature fraction of reticulocytes;
CESC	cis	rs875971	0.660	rs79009421	chr7:66068509	G/C	cg18876405	chr7:65276391	NA	-0.57	-7.47	-0.42	1.14e-12	Aortic root size;
CESC	cis	rs853679	0.550	rs1150692	chr6:28173957	A/G	cg12963246	chr6:28129442	ZNF389	0.51	7.01	0.4	1.96e-11	Depression;
CESC	cis	rs4969178	0.965	rs8075131	chr17:76394595	T/G	cg20026190	chr17:76395443	PGS1	0.49	7.91	0.44	6.98e-14	HDL cholesterol levels;
CESC	cis	rs853679	0.517	rs34716816	chr6:28046169	C/A	cg18032046	chr6:28092343	ZSCAN16	-0.53	-6.09	-0.35	3.91e-9	Depression;
CESC	cis	rs2573652	0.722	rs8041337	chr15:100541808	T/C	cg09918751	chr15:100517450	ADAMTS17	-0.32	-6.0	-0.35	6.36e-9	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22628064	chr1:201489517	RPS10P7	-0.51	-6.24	-0.36	1.73e-9	Gut microbiome composition (summer);
CESC	cis	rs11249608	0.548	rs2132671	chr5:178457434	A/G	cg21905437	chr5:178450457	ZNF879	-0.58	-8.35	-0.46	3.76e-15	Pubertal anthropometrics;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg13807351	chr1:212458736	PPP2R5A	-0.47	-6.15	-0.35	2.83e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs7615952	0.576	rs2276727	chr3:125826243	C/T	cg04553112	chr3:125709451	NA	-0.54	-5.85	-0.34	1.42e-8	Blood pressure (smoking interaction);
CESC	cis	rs873946	0.586	rs12251911	chr10:134570595	A/G	cg18305652	chr10:134549665	INPP5A	0.47	6.66	0.38	1.59e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs5753618	0.583	rs34545960	chr22:31812462	G/A	cg13145458	chr22:31556086	RNF185	-0.5	-5.96	-0.34	7.96e-9	Colorectal cancer;
CESC	cis	rs2228479	0.850	rs2238531	chr16:89856217	C/G	cg06558623	chr16:89946397	TCF25	1.18	9.44	0.5	1.97e-18	Skin colour saturation;
CESC	cis	rs9581857	0.547	rs9581881	chr13:28106637	A/G	cg01674679	chr13:27998804	GTF3A	-0.6	-5.06	-0.3	8.03e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
CESC	cis	rs3749237	1.000	rs11717256	chr3:49868520	C/T	cg03060546	chr3:49711283	APEH	0.65	7.65	0.43	3.69e-13	Resting heart rate;
CESC	cis	rs10927875	0.619	rs2013019	chr1:16129320	T/C	cg21385522	chr1:16154831	NA	-0.75	-10.65	-0.55	2.82e-22	Dilated cardiomyopathy;
CESC	cis	rs7666738	0.753	rs2865957	chr4:99040725	G/A	cg18180107	chr4:99064573	C4orf37	0.4	5.2	0.3	4.08e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1003719	0.646	rs7276711	chr21:38578189	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.61	-8.29	-0.45	5.58e-15	Eye color traits;
CESC	cis	rs2985684	0.846	rs11157693	chr14:50048426	T/C	cg04989706	chr14:50066350	PPIL5	-0.45	-5.05	-0.3	8.24e-7	Carotid intima media thickness;
CESC	cis	rs6912958	0.781	rs7757636	chr6:88256092	T/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.32	-5.18	-0.3	4.31e-7	Monocyte percentage of white cells;
CESC	cis	rs6952808	0.531	rs73039217	chr7:2178731	G/A	cg08027265	chr7:2291960	NA	-0.49	-7.5	-0.42	9.45e-13	Bipolar disorder and schizophrenia;
CESC	cis	rs914615	0.552	rs4276914	chr1:155142229	G/A	cg02153340	chr1:155202674	NA	-0.37	-5.39	-0.31	1.54e-7	Urinary albumin-to-creatinine ratio;
CESC	cis	rs9300255	0.596	rs4460848	chr12:123677810	A/G	cg00376283	chr12:123451042	ABCB9	0.67	9.28	0.5	6.47e-18	Neutrophil percentage of white cells;
CESC	trans	rs1814175	0.676	rs1721999	chr11:49917372	A/G	cg15704280	chr7:45808275	SEPT13	-1.01	-18.94	-0.76	3.64e-51	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13078969	chr12:1799970	ADIPOR2	-0.56	-6.68	-0.38	1.4e-10	Gut microbiome composition (summer);
CESC	cis	rs7086627	0.515	rs11202960	chr10:82209807	G/A	cg00277334	chr10:82204260	NA	-0.91	-15.92	-0.7	1.67e-40	Post bronchodilator FEV1;
CESC	cis	rs12282928	0.617	rs11039638	chr11:48306990	T/G	cg26585981	chr11:48327164	OR4S1	0.38	5.3	0.31	2.44e-7	Migraine - clinic-based;
CESC	cis	rs2797160	1.000	rs1739352	chr6:126005310	T/C	cg05901451	chr6:126070800	HEY2	-0.45	-6.53	-0.37	3.43e-10	Endometrial cancer;
CESC	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.41	-5.32	-0.31	2.24e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2652834	0.851	rs7170462	chr15:63345622	A/G	cg05507819	chr15:63340323	TPM1	0.66	6.61	0.38	2.11e-10	HDL cholesterol;
CESC	cis	rs35306767	0.953	rs34405399	chr10:981015	G/A	cg10556349	chr10:835070	NA	0.51	5.46	0.32	1.11e-7	Eosinophil percentage of granulocytes;
CESC	cis	rs36051895	0.623	rs11790680	chr9:5248768	C/T	cg02405213	chr9:5042618	JAK2	-0.55	-6.14	-0.35	3.01e-9	Pediatric autoimmune diseases;
CESC	cis	rs7666738	0.753	rs35146453	chr4:98902278	A/G	cg03467027	chr4:99064603	C4orf37	0.42	5.15	0.3	5.18e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6570726	0.905	rs375692	chr6:145840368	A/G	cg05347473	chr6:146136440	FBXO30	0.42	5.75	0.33	2.43e-8	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs704	0.523	rs11080054	chr17:26645991	G/A	cg10342447	chr17:26645325	TMEM97	-0.42	-5.88	-0.34	1.22e-8	Osteoprotegerin levels;
CESC	cis	rs875971	0.628	rs6974355	chr7:65841981	A/G	cg18876405	chr7:65276391	NA	0.65	8.56	0.47	9.4e-16	Aortic root size;
CESC	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg17178900	chr1:205818956	PM20D1	0.8	12.13	0.6	3.14e-27	Menarche (age at onset);
CESC	cis	rs17711722	0.727	rs35850374	chr7:65357776	A/G	cg11764359	chr7:65958608	NA	0.67	8.67	0.47	4.34e-16	Calcium levels;
CESC	cis	rs6076065	0.775	rs761723	chr20:23330720	A/G	cg11657817	chr20:23433608	CST11	0.41	6.23	0.36	1.8e-9	Facial morphology (factor 15, philtrum width);
CESC	cis	rs7586879	0.639	rs2033653	chr2:25103446	C/T	cg01884057	chr2:25150051	NA	-0.35	-6.73	-0.38	1.03e-10	Body mass index;
CESC	cis	rs10504229	0.645	rs35142596	chr8:58128151	C/T	cg24829409	chr8:58192753	C8orf71	-0.58	-7.15	-0.4	8.21e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs637571	0.584	rs7107912	chr11:65603252	G/A	cg26695010	chr11:65641043	EFEMP2	0.57	7.29	0.41	3.64e-12	Eosinophil percentage of white cells;
CESC	cis	rs2228479	0.717	rs17226274	chr16:89850170	C/T	cg06558623	chr16:89946397	TCF25	1.06	8.9	0.48	9.15e-17	Skin colour saturation;
CESC	cis	rs6964587	0.620	rs7808587	chr7:91620096	G/A	cg17063962	chr7:91808500	NA	0.46	6.49	0.37	4.16e-10	Breast cancer;
CESC	cis	rs919433	0.927	rs1429418	chr2:198158151	G/C	cg03934865	chr2:198174659	NA	-0.41	-5.69	-0.33	3.36e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs4853012	0.838	rs60964317	chr2:74343423	A/T	cg19729930	chr2:74357872	NA	0.81	11.94	0.59	1.39e-26	Gestational age at birth (maternal effect);
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg27660165	chr1:156784036	SH2D2A	-0.45	-6.17	-0.35	2.6e-9	Height;
CESC	cis	rs941873	0.803	rs2105461	chr10:81101679	A/G	cg09469691	chr10:81107165	PPIF	-0.57	-7.74	-0.43	2.1e-13	Height;
CESC	cis	rs1552244	0.744	rs6763366	chr3:10033544	T/C	cg00149659	chr3:10157352	C3orf10	0.71	8.45	0.46	2.01e-15	Alzheimer's disease;
CESC	cis	rs9790314	1.000	rs6441373	chr3:161026717	T/G	cg04691961	chr3:161091175	C3orf57	-0.44	-5.73	-0.33	2.74e-8	Morning vs. evening chronotype;
CESC	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg22105103	chr4:187893119	NA	0.46	6.84	0.39	5.33e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs858239	0.699	rs955187	chr7:23194605	A/G	cg23682824	chr7:23144976	KLHL7	-0.43	-5.8	-0.34	1.85e-8	Cerebrospinal fluid biomarker levels;
CESC	cis	rs7666738	0.791	rs1593571	chr4:98963763	T/C	cg05340658	chr4:99064831	C4orf37	0.8	12.4	0.61	3.76e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs17601876	0.843	rs17523541	chr15:51554844	G/A	cg19946085	chr15:51559439	CYP19A1	-0.33	-5.28	-0.31	2.69e-7	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
CESC	trans	rs6780666	0.509	rs4678306	chr3:136975979	C/T	cg16900796	chr19:10755136	SLC44A2	-0.41	-6.36	-0.36	8.6e-10	Intelligence (multi-trait analysis);
CESC	cis	rs13256369	1.000	rs4840351	chr8:8573148	A/G	cg18904891	chr8:8559673	CLDN23	0.7	8.22	0.45	9.43e-15	Obesity-related traits;
CESC	cis	rs5769765	0.862	rs9616384	chr22:50313082	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.58	-6.23	-0.36	1.86e-9	Schizophrenia;
CESC	cis	rs9311474	0.508	rs6788887	chr3:52605005	T/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.67	0.38	1.47e-10	Electroencephalogram traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15774864	chr2:63272214	LOC100132215;EHBP1	-0.6	-6.54	-0.37	3.2e-10	Gut microbiome composition (summer);
CESC	cis	rs3845702	0.877	rs12693216	chr2:180839793	T/A	cg01881094	chr2:180872142	CWC22	-0.68	-7.29	-0.41	3.63e-12	Schizophrenia;
CESC	cis	rs4722166	0.603	rs7801406	chr7:22788274	A/G	cg13104385	chr7:22767384	IL6	0.47	6.25	0.36	1.59e-9	Lung cancer;
CESC	cis	rs9926296	0.656	rs7191144	chr16:89823393	C/T	cg04287289	chr16:89883240	FANCA	0.58	7.77	0.43	1.76e-13	Vitiligo;
CESC	cis	rs10911363	0.592	rs12117885	chr1:183494214	C/T	cg09173681	chr1:183549694	NCF2	-0.51	-7.49	-0.42	1.04e-12	Systemic lupus erythematosus;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg08722200	chr20:55960520	NA	0.46	6.11	0.35	3.52e-9	Fibrinogen levels;
CESC	cis	rs2439831	0.867	rs12324572	chr15:43636200	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.89	10.73	0.55	1.57e-22	Lung cancer in ever smokers;
CESC	cis	rs77106637	0.932	rs3814730	chr11:72555553	G/A	cg03713592	chr11:72463424	ARAP1	1.12	10.02	0.52	3.01e-20	Type 2 diabetes;
CESC	cis	rs36051895	0.659	rs7046511	chr9:5045695	C/T	cg02405213	chr9:5042618	JAK2	-0.43	-5.31	-0.31	2.36e-7	Pediatric autoimmune diseases;
CESC	cis	rs6977660	0.562	rs2189566	chr7:19768960	G/A	cg05791153	chr7:19748676	TWISTNB	0.73	6.75	0.38	9.05e-11	Thyroid stimulating hormone;
CESC	cis	rs736408	0.648	rs3774355	chr3:52817778	G/A	cg07507251	chr3:52567010	NT5DC2	0.36	5.84	0.34	1.5e-8	Bipolar disorder;
CESC	cis	rs6547741	0.935	rs4260197	chr2:27794150	C/G	cg27432699	chr2:27873401	GPN1	-0.44	-6.2	-0.36	2.15e-9	Oral cavity cancer;
CESC	cis	rs597539	0.690	rs635529	chr11:68626294	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.78	9.11	0.49	2.13e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs7264396	0.563	rs2425119	chr20:34324216	C/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.63	6.86	0.39	4.77e-11	Total cholesterol levels;
CESC	cis	rs208520	0.526	rs9354366	chr6:66788559	C/T	cg07460842	chr6:66804631	NA	-1.11	-26.93	-0.86	8.11e-78	Exhaled nitric oxide output;
CESC	cis	rs6558174	0.802	rs6558171	chr8:22487422	T/C	cg03733263	chr8:22462867	KIAA1967	0.42	5.15	0.3	5.02e-7	Breast cancer;
CESC	cis	rs2562152	0.613	rs216599	chr16:109671	A/G	cg02949481	chr16:131562	MPG	0.62	6.27	0.36	1.46e-9	Glioblastoma;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg25312474	chr6:142468512	VTA1	-0.44	-6.7	-0.38	1.22e-10	Gambling;
CESC	cis	rs7927771	0.832	rs4752993	chr11:47410951	T/C	cg20307385	chr11:47447363	PSMC3	0.63	7.9	0.44	7.25e-14	Subjective well-being;
CESC	cis	rs7481584	1.000	rs756693	chr11:3027889	A/G	cg25174290	chr11:3078921	CARS	-0.44	-5.44	-0.32	1.2e-7	Calcium levels;
CESC	cis	rs514406	0.607	rs6665324	chr1:53201610	G/A	cg08859206	chr1:53392774	SCP2	0.63	9.33	0.5	4.34e-18	Monocyte count;
CESC	cis	rs6570726	0.935	rs384519	chr6:145846017	C/A	cg23711669	chr6:146136114	FBXO30	0.8	11.89	0.59	2e-26	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs9693444	0.898	rs4732697	chr8:29519861	A/G	cg13665263	chr7:135662016	MTPN;LUZP6	-0.44	-6.32	-0.36	1.13e-9	Breast cancer;
CESC	cis	rs13102973	0.835	rs4280795	chr4:135857246	T/A	cg14419869	chr4:135874104	NA	0.33	5.13	0.3	5.5e-7	Subjective well-being;
CESC	cis	rs7107174	0.786	rs4945266	chr11:78027488	A/G	cg02023728	chr11:77925099	USP35	0.48	6.41	0.37	6.64e-10	Testicular germ cell tumor;
CESC	cis	rs8070624	0.543	rs57728924	chr17:17875342	A/G	cg09796270	chr17:17721594	SREBF1	0.43	5.68	0.33	3.48e-8	Total body bone mineral density;
CESC	cis	rs116095464	0.614	rs62344339	chr5:252995	T/G	cg10591111	chr5:226296	SDHA	-0.51	-6.15	-0.35	2.84e-9	Breast cancer;
CESC	cis	rs875971	1.000	rs4717292	chr7:65895598	G/A	cg10691866	chr7:65817282	TPST1	-0.34	-5.62	-0.33	4.93e-8	Aortic root size;
CESC	cis	rs7091068	0.566	rs7909925	chr10:95507170	A/G	cg20715218	chr10:95462985	C10orf4	0.61	6.0	0.35	6.31e-9	Urinary tract infection frequency;
CESC	cis	rs3741404	0.895	rs1860368	chr11:63994692	T/C	cg04317338	chr11:64019027	PLCB3	-0.52	-6.39	-0.37	7.46e-10	Platelet count;
CESC	cis	rs9303280	0.517	rs12939566	chr17:38038390	A/T	cg20243544	chr17:37824526	PNMT	0.5	6.54	0.37	3.21e-10	Self-reported allergy;
CESC	cis	rs1008375	0.966	rs11733730	chr4:17625209	G/C	cg16339924	chr4:17578868	LAP3	0.65	8.32	0.45	4.76e-15	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs10911251	0.528	rs10911255	chr1:183088868	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.89	14.36	0.66	5.49e-35	Colorectal cancer;
CESC	cis	rs2242116	0.796	rs4683297	chr3:46973673	T/C	cg27129171	chr3:47204927	SETD2	-0.55	-6.97	-0.39	2.51e-11	Birth weight;
CESC	cis	rs262150	0.630	rs2730274	chr7:158796062	C/A	cg09640425	chr7:158790006	NA	-0.36	-5.56	-0.32	6.63e-8	Facial morphology (factor 20);
CESC	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg03188948	chr7:1209495	NA	0.73	7.05	0.4	1.54e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs3925075	1.000	rs11859274	chr16:31361059	C/T	cg02846316	chr16:31340340	ITGAM	0.42	6.56	0.37	2.86e-10	IgA nephropathy;
CESC	cis	rs1144713	0.802	rs2652008	chr12:32246543	A/G	cg01321189	chr12:32259338	BICD1	0.44	6.34	0.36	9.71e-10	Obesity-related traits;
CESC	cis	rs514406	0.929	rs11206035	chr1:53323571	T/C	cg08736216	chr1:53307985	ZYG11A	-0.42	-7.0	-0.4	2.05e-11	Monocyte count;
CESC	cis	rs1048238	0.846	rs945419	chr1:16344858	C/T	cg22431228	chr1:16359049	CLCNKA	-0.54	-10.94	-0.56	3.16e-23	Systolic blood pressure;
CESC	cis	rs11785693	0.862	rs11774099	chr8:4988218	C/T	cg26367366	chr8:4980734	NA	0.62	6.32	0.36	1.08e-9	Neuroticism (multi-trait analysis);Neuroticism;
CESC	cis	rs798554	0.757	rs1182198	chr7:2862906	C/T	cg13628971	chr7:2884303	GNA12	0.67	8.48	0.46	1.59e-15	Height;
CESC	cis	rs708547	0.647	rs6843644	chr4:57891239	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.49	6.81	0.39	6.4e-11	Response to bleomycin (chromatid breaks);
CESC	cis	rs2243480	1.000	rs68189316	chr7:65409169	C/G	cg25894440	chr7:65020034	NA	-0.59	-5.07	-0.3	7.57e-7	Diabetic kidney disease;
CESC	cis	rs13191362	1.000	rs13215491	chr6:163010325	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.82	8.22	0.45	9.12e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs6032067	0.777	rs34916007	chr20:43782952	T/G	cg10761708	chr20:43804764	PI3	0.55	6.51	0.37	3.7e-10	Blood protein levels;
CESC	cis	rs7824557	0.527	rs2572376	chr8:11237756	C/A	cg21775007	chr8:11205619	TDH	-0.53	-8.05	-0.44	2.85e-14	Retinal vascular caliber;
CESC	trans	rs853679	0.556	rs45509595	chr6:27840926	T/C	cg01620082	chr3:125678407	NA	-0.79	-6.42	-0.37	6.12e-10	Depression;
CESC	cis	rs4974559	1.000	rs1882099	chr4:1352685	A/G	cg02980000	chr4:1222292	CTBP1	0.57	6.66	0.38	1.54e-10	Systolic blood pressure;
CESC	cis	rs1372520	0.935	rs1442152	chr4:90775649	C/A	cg15133208	chr4:90757351	SNCA	-0.37	-5.44	-0.32	1.18e-7	Neuroticism;
CESC	cis	rs9811920	0.609	rs793465	chr3:99627750	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.64	10.11	0.53	1.53e-20	Axial length;
CESC	cis	rs896854	0.967	rs1320164	chr8:95960767	G/A	cg09323728	chr8:95962352	TP53INP1	-0.45	-9.86	-0.52	9.98e-20	Type 2 diabetes;
CESC	cis	rs939574	0.799	rs1109867	chr2:220083453	G/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-0.55	-5.26	-0.31	2.94e-7	Platelet distribution width;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13707777	chr5:308627	AHRR;PDCD6	-0.63	-7.58	-0.42	5.95e-13	Gut microbiome composition (summer);
CESC	cis	rs2456568	0.867	rs10501810	chr11:93666589	C/G	cg26875233	chr11:93583750	C11orf90	-0.29	-5.23	-0.31	3.48e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
CESC	cis	rs67460515	0.563	rs11922957	chr3:160828865	A/C	cg03342759	chr3:160939853	NMD3	-0.54	-6.87	-0.39	4.65e-11	Parkinson's disease;
CESC	cis	rs2694528	0.686	rs7723165	chr5:59876715	A/G	cg11474532	chr5:59995715	DEPDC1B	0.91	6.37	0.36	8.39e-10	Parkinson's disease;
CESC	cis	rs17067123	1.000	rs17067113	chr4:180046510	C/G	cg26610307	chr4:180072759	NA	0.56	6.22	0.36	1.91e-9	Response to hepatitis C treatment;
CESC	cis	rs765787	0.530	rs2433227	chr15:45517119	A/T	cg24006582	chr15:45444508	DUOX1	-0.58	-7.12	-0.4	1.04e-11	Uric acid levels;
CESC	cis	rs644799	1.000	rs544119	chr11:95538624	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	9.15	0.49	1.61e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs853679	0.517	rs17711344	chr6:28077602	A/G	cg23281280	chr6:28129359	ZNF389	-0.53	-7.18	-0.4	7.02e-12	Depression;
CESC	cis	rs2230307	0.536	rs496798	chr1:100507990	G/A	cg24955406	chr1:100503596	HIAT1	0.56	5.47	0.32	1.06e-7	Carotid intima media thickness;
CESC	cis	rs8077577	0.747	rs2290505	chr17:18137141	A/G	cg16794390	chr17:18148240	FLII	-0.42	-6.38	-0.36	7.97e-10	Obesity-related traits;
CESC	cis	rs2235544	0.550	rs12075159	chr1:54470234	A/G	cg25741118	chr1:54482237	LDLRAD1	0.24	5.92	0.34	9.71e-9	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
CESC	cis	rs933688	1.000	rs933688	chr5:90762748	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.04	13.87	0.65	3.02e-33	Smoking behavior;
CESC	cis	rs870825	0.550	rs28525282	chr4:185631468	T/C	cg04058563	chr4:185651563	MLF1IP	0.64	7.0	0.4	2.05e-11	Blood protein levels;
CESC	cis	rs9815354	0.812	rs58360908	chr3:41839837	A/G	cg03022575	chr3:42003672	ULK4	0.7	6.04	0.35	5.26e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs8072100	0.817	rs12449647	chr17:45548958	C/A	cg08085267	chr17:45401833	C17orf57	-0.58	-7.7	-0.43	2.77e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs460214	0.564	rs458465	chr21:40024644	A/T	cg05519781	chr21:40033154	ERG	-0.55	-7.86	-0.43	9.65e-14	Response to cognitive-behavioural therapy in anxiety disorder;
CESC	cis	rs9457247	0.967	rs443570	chr6:167389925	G/A	cg07741184	chr6:167504864	NA	0.31	5.45	0.32	1.15e-7	Crohn's disease;
CESC	cis	rs7524258	0.835	rs7521425	chr1:7306543	C/T	cg07173049	chr1:7289937	CAMTA1	0.37	5.72	0.33	2.82e-8	Tourette's syndrome or obsessive-compulsive disorder;
CESC	cis	rs13256369	0.950	rs13255655	chr8:8577736	C/T	cg18904891	chr8:8559673	CLDN23	0.65	7.05	0.4	1.51e-11	Obesity-related traits;
CESC	cis	rs13095912	1.000	rs2034344	chr3:185337788	T/C	cg11274856	chr3:185301563	NA	0.34	5.44	0.32	1.19e-7	Systolic blood pressure;
CESC	cis	rs34779708	0.931	rs11596502	chr10:35387187	A/C	cg04310649	chr10:35416472	CREM	-0.49	-5.77	-0.33	2.15e-8	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs7552404	0.924	rs2173378	chr1:76201992	G/T	cg22875332	chr1:76189707	ACADM	0.72	9.96	0.52	4.75e-20	Blood metabolite levels;Acylcarnitine levels;
CESC	trans	rs11098499	0.691	rs9996644	chr4:120238877	G/T	cg25214090	chr10:38739885	LOC399744	0.59	8.08	0.44	2.33e-14	Corneal astigmatism;
CESC	cis	rs8017423	0.934	rs11159952	chr14:90684874	T/C	cg14092571	chr14:90743983	NA	-0.58	-8.71	-0.47	3.4e-16	Mortality in heart failure;
CESC	cis	rs6912958	0.514	rs1980792	chr6:87889917	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.74	-10.56	-0.54	5.31e-22	Monocyte percentage of white cells;
CESC	cis	rs34779708	0.733	rs11597184	chr10:35397396	G/A	cg04310649	chr10:35416472	CREM	-0.51	-6.17	-0.35	2.61e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs6546550	0.630	rs9309429	chr2:69995580	A/G	cg02498382	chr2:70120550	SNRNP27	-0.32	-5.33	-0.31	2.11e-7	Prevalent atrial fibrillation;
CESC	cis	rs11608355	0.545	rs7316375	chr12:109906998	G/C	cg05360138	chr12:110035743	NA	0.82	8.92	0.48	7.93e-17	Neuroticism;
CESC	cis	rs2777491	0.915	rs8036498	chr15:41603276	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.6	-8.92	-0.48	7.87e-17	Ulcerative colitis;
CESC	cis	rs6762	0.748	rs7928935	chr11:839127	G/A	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.76	-10.1	-0.53	1.69e-20	Mean platelet volume;
CESC	cis	rs6747952	0.866	rs6726348	chr2:239084119	C/T	cg17459225	chr2:239074497	NA	0.32	5.04	0.3	8.82e-7	Mean corpuscular hemoglobin concentration;
CESC	cis	rs17001868	0.568	rs9611310	chr22:40733777	A/G	cg07138101	chr22:40742427	ADSL	0.54	5.18	0.3	4.49e-7	Mammographic density (dense area);
CESC	cis	rs11638352	1.000	rs2412852	chr15:44303086	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	-0.66	-5.93	-0.34	9.18e-9	Lipoprotein phospholipase A2 activity in cardiovascular disease;
CESC	cis	rs7605827	0.930	rs59135666	chr2:15592448	G/A	cg19274914	chr2:15703543	NA	0.32	5.69	0.33	3.38e-8	Educational attainment (years of education);
CESC	cis	rs6693567	0.565	rs834238	chr1:150366469	G/T	cg09579323	chr1:150459698	TARS2	0.47	5.85	0.34	1.48e-8	Migraine;
CESC	cis	rs6728642	0.808	rs113319086	chr2:97633267	G/C	cg26665480	chr2:98280029	ACTR1B	-0.88	-6.55	-0.37	3.05e-10	Bipolar disorder lithium response (continuous) or schizophrenia;
CESC	cis	rs10465746	0.725	rs980417	chr1:84365331	C/A	cg10977910	chr1:84465055	TTLL7	0.56	7.78	0.43	1.62e-13	Obesity-related traits;
CESC	cis	rs12824058	0.831	rs4759450	chr12:130812732	G/A	cg23887609	chr12:130822674	PIWIL1	0.44	5.7	0.33	3.2e-8	Menopause (age at onset);
CESC	cis	rs6586111	0.967	rs6586110	chr10:82376492	G/A	cg03086067	chr10:82368399	SH2D4B	-0.28	-5.04	-0.3	8.62e-7	Capecitabine sensitivity;
CESC	cis	rs1348850	0.519	rs1544002	chr2:178529534	C/T	cg22681709	chr2:178499509	PDE11A	-0.48	-6.87	-0.39	4.57e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs7618915	0.547	rs12496476	chr3:52708737	A/G	cg18099408	chr3:52552593	STAB1	-0.31	-5.19	-0.3	4.19e-7	Bipolar disorder;
CESC	cis	rs10504229	0.562	rs2014516	chr8:58128288	C/A	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs6460942	0.597	rs6977059	chr7:12535157	T/G	cg20607287	chr7:12443886	VWDE	-0.72	-7.71	-0.43	2.51e-13	Coronary artery disease;
CESC	cis	rs1707322	1.000	rs4660895	chr1:46329739	C/T	cg05343316	chr1:45956843	TESK2	0.44	5.55	0.32	7.05e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs11098499	0.955	rs56386062	chr4:120155135	T/C	cg25214090	chr10:38739885	LOC399744	0.65	8.59	0.47	7.54e-16	Corneal astigmatism;
CESC	trans	rs2877832	0.841	rs72662391	chr14:27822340	G/T	cg13449535	chr1:1101348	MIR200B	0.55	6.65	0.38	1.67e-10	Diabetes related insulin traits;
CESC	cis	rs9527	0.590	rs763914	chr10:104841587	T/C	cg04362960	chr10:104952993	NT5C2	0.44	5.62	0.33	4.94e-8	Arsenic metabolism;
CESC	cis	rs9300255	0.602	rs1727316	chr12:123618603	C/T	cg00376283	chr12:123451042	ABCB9	0.7	8.7	0.47	3.5e-16	Neutrophil percentage of white cells;
CESC	cis	rs1223629	1.000	rs11187800	chr10:95936892	A/G	cg11276093	chr10:95123774	MYOF	0.58	5.08	0.3	7.06e-7	Glucose homeostasis traits;
CESC	cis	rs7726839	0.561	rs72703046	chr5:580129	T/C	cg09021430	chr5:549028	NA	-0.43	-5.73	-0.33	2.68e-8	Obesity-related traits;
CESC	cis	rs79387448	0.614	rs985523	chr2:102954376	G/A	cg09003973	chr2:102972529	NA	1.13	8.98	0.48	5.2e-17	Gut microbiota (bacterial taxa);
CESC	cis	rs2228479	0.850	rs62054224	chr16:89892071	C/T	cg00800038	chr16:89945340	TCF25	-0.86	-6.88	-0.39	4.34e-11	Skin colour saturation;
CESC	cis	rs7671266	0.668	rs10007416	chr4:10159457	T/C	cg00071950	chr4:10020882	SLC2A9	-0.56	-6.0	-0.35	6.43e-9	Cardiovascular disease risk factors;
CESC	cis	rs3105593	1.000	rs3131587	chr15:50845101	T/G	cg08437265	chr15:50716283	USP8	0.42	5.48	0.32	9.88e-8	QT interval;
CESC	cis	rs9916302	0.800	rs8069451	chr17:37504933	C/T	cg19468946	chr17:37922297	IKZF3	-0.42	-5.3	-0.31	2.42e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs875971	1.000	rs7783613	chr7:65805261	C/T	cg10691866	chr7:65817282	TPST1	0.35	5.78	0.33	2.13e-8	Aortic root size;
CESC	cis	rs7178909	0.872	rs3784387	chr15:90437370	G/A	cg19708238	chr15:90437601	AP3S2	0.43	6.19	0.36	2.25e-9	Common traits (Other);
CESC	cis	rs7666738	0.830	rs2865980	chr4:99027422	T/G	cg03467027	chr4:99064603	C4orf37	0.49	6.18	0.35	2.44e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7613875	0.641	rs6793528	chr3:50100188	C/A	cg24308560	chr3:49941425	MST1R	0.6	8.72	0.47	3.17e-16	Body mass index;
CESC	cis	rs7084402	0.967	rs12242287	chr10:60278340	A/G	cg07615347	chr10:60278583	BICC1	-0.58	-9.39	-0.5	2.94e-18	Refractive error;
CESC	cis	rs2991971	0.934	rs11211129	chr1:45983080	C/T	cg24296786	chr1:45957014	TESK2	0.64	8.64	0.47	5.45e-16	High light scatter reticulocyte count;
CESC	cis	rs798554	0.959	rs798556	chr7:2759002	C/A	cg13628971	chr7:2884303	GNA12	0.58	7.48	0.42	1.06e-12	Height;
CESC	cis	rs9787249	0.957	rs3738673	chr1:40204823	C/T	cg02773041	chr1:40204384	PPIE	0.54	7.73	0.43	2.17e-13	Blood protein levels;
CESC	cis	rs66573146	0.572	rs68169399	chr4:6952491	T/A	cg00086871	chr4:6988644	TBC1D14	1.03	6.83	0.39	5.93e-11	Granulocyte percentage of myeloid white cells;
CESC	cis	rs4853012	1.000	rs4853012	chr2:74361290	G/A	cg19729930	chr2:74357872	NA	0.91	11.31	0.57	1.91e-24	Gestational age at birth (maternal effect);
CESC	trans	rs11098499	0.820	rs28578366	chr4:120536905	A/G	cg25214090	chr10:38739885	LOC399744	-0.67	-9.25	-0.49	7.82e-18	Corneal astigmatism;
CESC	trans	rs3741578	0.702	rs725956	chr12:57331936	A/G	cg14720773	chr17:17603531	RAI1	0.48	6.46	0.37	4.9e-10	Asthma;
CESC	cis	rs7178572	1.000	rs6495240	chr15:77766556	T/C	cg22256960	chr15:77711686	NA	-0.6	-8.09	-0.44	2.19e-14	Type 2 diabetes;
CESC	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg18538332	chr22:24372958	LOC391322	-0.76	-11.27	-0.57	2.6e-24	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs12477438	0.798	rs6704766	chr2:99642818	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-10.57	-0.54	5.22e-22	Chronic sinus infection;
CESC	cis	rs13191362	0.810	rs34714603	chr6:163008078	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.78	8.21	0.45	9.97e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs10504229	0.683	rs7827014	chr8:58132230	G/A	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs4862750	0.914	rs1991256	chr4:187875330	A/G	cg07414643	chr4:187882934	NA	0.55	7.6	0.42	4.98e-13	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4948102	0.642	rs4948104	chr7:56142519	A/G	cg09872392	chr7:56161020	PHKG1	-0.45	-7.29	-0.41	3.48e-12	Plasma homocysteine levels (post-methionine load test);
CESC	cis	rs9287719	0.967	rs2024431	chr2:10731327	A/G	cg02196655	chr2:10830764	NOL10	-0.36	-5.57	-0.32	6.1e-8	Prostate cancer;
CESC	cis	rs7527798	0.571	rs4844611	chr1:207827538	G/C	cg21110645	chr1:207815933	NA	-0.33	-5.88	-0.34	1.21e-8	Erythrocyte sedimentation rate;
CESC	cis	rs11864453	0.793	rs7197453	chr16:72079127	G/C	cg01557791	chr16:72042693	DHODH	-0.62	-8.14	-0.45	1.54e-14	Fibrinogen levels;
CESC	cis	rs2276314	0.802	rs4799838	chr18:33597530	T/C	cg19628046	chr18:33552617	C18orf21	0.51	5.58	0.32	5.92e-8	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs637571	0.522	rs528736	chr11:65705108	A/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.4	5.83	0.34	1.64e-8	Eosinophil percentage of white cells;
CESC	cis	rs1707322	1.000	rs10789485	chr1:46407308	C/T	cg03146154	chr1:46216737	IPP	0.78	10.77	0.55	1.17e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs10504229	0.683	rs10504221	chr8:58140256	A/G	cg21724239	chr8:58056113	NA	0.58	5.95	0.34	8.37e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs910316	0.737	rs175072	chr14:75502827	T/C	cg11812906	chr14:75593930	NEK9	-0.8	-13.04	-0.63	2.33e-30	Height;
CESC	trans	rs853679	0.882	rs4713139	chr6:28092685	C/T	cg06606381	chr12:133084897	FBRSL1	-0.66	-6.49	-0.37	4.14e-10	Depression;
CESC	cis	rs910316	0.737	rs175080	chr14:75513828	G/A	cg15467112	chr14:75489610	MLH3	-0.33	-5.1	-0.3	6.5e-7	Height;
CESC	cis	rs672059	0.548	rs2480767	chr1:183257218	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.46	5.38	0.31	1.64e-7	Hypertriglyceridemia;
CESC	trans	rs12310956	0.515	rs1830086	chr12:33958874	C/T	cg26384229	chr12:38710491	ALG10B	0.59	8.35	0.46	3.79e-15	Morning vs. evening chronotype;
CESC	cis	rs17376456	0.825	rs17314825	chr5:93234937	A/G	cg25358565	chr5:93447407	FAM172A	1.06	10.5	0.54	8.89e-22	Diabetic retinopathy;
CESC	cis	rs9815354	0.812	rs55682201	chr3:41848497	A/G	cg03022575	chr3:42003672	ULK4	0.7	6.04	0.35	5.26e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs6747952	0.899	rs4663856	chr2:239089624	C/A	cg17459225	chr2:239074497	NA	0.34	5.39	0.31	1.58e-7	Mean corpuscular hemoglobin concentration;
CESC	cis	rs9311474	0.508	rs7625743	chr3:52606366	C/G	cg07507251	chr3:52567010	NT5DC2	0.32	5.63	0.33	4.6e-8	Electroencephalogram traits;
CESC	cis	rs1552244	0.808	rs17032306	chr3:10091399	C/G	cg00166722	chr3:10149974	C3orf24	0.53	6.62	0.38	2.02e-10	Alzheimer's disease;
CESC	cis	rs202126107	1	rs202126107	chr17:38006767	GCATATTATA/G	cg20243544	chr17:37824526	PNMT	0.48	6.39	0.37	7.58e-10	Eosinophil percentage of white cells;
CESC	cis	rs9901225	1	rs9901225	chr17:40755811	C/T	cg16308533	chr17:40838983	CNTNAP1	0.51	8.12	0.45	1.81e-14	Colorectal or endometrial cancer;
CESC	cis	rs1707322	1.000	rs4489497	chr1:46438698	C/T	cg05343316	chr1:45956843	TESK2	0.44	5.42	0.32	1.36e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs4699052	0.662	rs1516731	chr4:104252694	T/C	cg16532752	chr4:104119610	CENPE	-0.39	-5.47	-0.32	1.02e-7	Testicular germ cell tumor;
CESC	cis	rs1670533	1.000	rs2045065	chr4:1052488	A/G	cg27284194	chr4:1044797	NA	0.44	5.52	0.32	8.23e-8	Recombination rate (females);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21482489	chr5:121414366	LOX	-0.58	-6.92	-0.39	3.37e-11	Gut microbiome composition (summer);
CESC	cis	rs722599	0.683	rs7142898	chr14:75254310	A/T	cg08847533	chr14:75593920	NEK9	0.49	5.98	0.34	7.06e-9	IgG glycosylation;
CESC	cis	rs6964587	0.967	rs10231350	chr7:91808499	G/T	cg17063962	chr7:91808500	NA	0.58	8.17	0.45	1.28e-14	Breast cancer;
CESC	cis	rs9733	0.635	rs486836	chr1:150875967	A/T	cg13175981	chr1:150552382	MCL1	0.53	7.04	0.4	1.6e-11	Tonsillectomy;
CESC	cis	rs4665809	1.000	rs13030858	chr2:26315451	G/A	cg27170947	chr2:26402098	FAM59B	-0.6	-7.25	-0.41	4.7e-12	Gut microbiome composition (summer);
CESC	cis	rs11625487	0.957	rs10145540	chr14:77957354	C/T	cg20045696	chr14:77926864	AHSA1	-0.62	-7.02	-0.4	1.88e-11	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
CESC	trans	rs1941687	0.527	rs2000945	chr18:31365336	A/G	cg27147174	chr7:100797783	AP1S1	-0.49	-6.64	-0.38	1.74e-10	Subjective well-being (multi-trait analysis);Subjective well-being;
CESC	cis	rs6964587	0.869	rs7812219	chr7:91545727	C/T	cg17063962	chr7:91808500	NA	-0.55	-7.31	-0.41	3.19e-12	Breast cancer;
CESC	cis	rs7208859	0.623	rs35916850	chr17:29011173	G/A	cg14008862	chr17:28927542	LRRC37B2	0.73	5.82	0.34	1.67e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs7617773	0.539	rs1471217	chr3:48384895	A/C	cg11946769	chr3:48343235	NME6	0.66	8.34	0.46	4.12e-15	Coronary artery disease;
CESC	cis	rs7923609	0.841	rs10740131	chr10:65271488	A/T	cg01631684	chr10:65280961	REEP3	-0.42	-5.19	-0.3	4.1e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7589342	0.895	rs11901644	chr2:106432113	T/G	cg16077055	chr2:106428750	NCK2	0.53	7.5	0.42	9.66e-13	Addiction;
CESC	trans	rs1814175	0.615	rs12417290	chr11:49876951	G/A	cg15704280	chr7:45808275	SEPT13	-1.0	-18.65	-0.75	3.79e-50	Height;
CESC	cis	rs7666738	0.830	rs13129479	chr4:98987860	T/C	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.67e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg09496791	chr2:95787596	MRPS5	0.47	6.05	0.35	4.94e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs17826219	0.561	rs11655876	chr17:29017150	G/A	cg19761014	chr17:28927070	LRRC37B2	0.66	5.9	0.34	1.13e-8	Body mass index;
CESC	cis	rs875971	0.893	rs62465470	chr7:65601218	T/C	cg18876405	chr7:65276391	NA	-0.52	-7.14	-0.4	8.86e-12	Aortic root size;
CESC	cis	rs6598955	0.616	rs11247890	chr1:26590182	G/A	cg19743891	chr1:26644573	UBXN11;CD52	0.36	5.11	0.3	6.24e-7	Obesity-related traits;
CESC	cis	rs875971	0.520	rs12666485	chr7:65625122	T/C	cg25405998	chr7:65216604	CCT6P1	0.45	5.06	0.3	7.71e-7	Aortic root size;
CESC	cis	rs926392	0.572	rs6129156	chr20:37672209	A/C	cg16355469	chr20:37678765	NA	0.51	5.95	0.34	8.54e-9	Dialysis-related mortality;
CESC	cis	rs12824058	0.831	rs11608407	chr12:130805869	G/A	cg24838063	chr12:130822603	PIWIL1	0.61	8.02	0.44	3.32e-14	Menopause (age at onset);
CESC	cis	rs12410462	0.581	rs35141785	chr1:227553496	G/C	cg04117972	chr1:227635322	NA	0.63	5.46	0.32	1.09e-7	Major depressive disorder;
CESC	cis	rs1044826	0.642	rs176983	chr3:139213755	G/A	cg00490450	chr3:139108681	COPB2	0.42	5.08	0.3	7.25e-7	Obesity-related traits;
CESC	cis	rs11630290	0.702	rs73444597	chr15:64126503	C/T	cg12036633	chr15:63758958	NA	-0.56	-5.21	-0.3	3.74e-7	Iris characteristics;
CESC	cis	rs9430161	0.598	rs34350247	chr1:11034460	A/G	cg27631724	chr1:11040367	C1orf127	0.38	6.14	0.35	2.99e-9	Ewing sarcoma;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg14906687	chr6:157099894	ARID1B	-0.43	-6.05	-0.35	4.9e-9	Gambling;
CESC	cis	rs9790314	0.967	rs1382427	chr3:161032576	T/C	cg03342759	chr3:160939853	NMD3	-0.48	-6.25	-0.36	1.61e-9	Morning vs. evening chronotype;
CESC	cis	rs11945232	1.000	rs6854710	chr4:88334640	A/G	cg23841344	chr4:88312519	HSD17B11	-0.64	-8.08	-0.44	2.28e-14	Intelligence (multi-trait analysis);
CESC	cis	rs9815354	0.812	rs73073234	chr3:42012071	C/T	cg03022575	chr3:42003672	ULK4	0.68	6.13	0.35	3.21e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs7216064	0.861	rs12449312	chr17:65829358	A/C	cg12091567	chr17:66097778	LOC651250	-0.8	-8.71	-0.47	3.32e-16	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.58	6.51	0.37	3.77e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2404602	1.000	rs2896954	chr15:76851692	C/A	cg26408565	chr15:76604113	ETFA	-0.37	-5.29	-0.31	2.56e-7	Blood metabolite levels;
CESC	trans	rs6938574	0.813	rs17055223	chr6:128344785	C/T	cg25774020	chr5:99869796	FAM174A	-0.56	-6.27	-0.36	1.46e-9	Menarche (age at onset);
CESC	cis	rs3947	0.789	rs1293322	chr8:11692638	C/T	cg00262122	chr8:11665843	FDFT1	-0.52	-5.46	-0.32	1.11e-7	Blood protein levels;
CESC	cis	rs7659604	0.502	rs10013916	chr4:122702179	T/G	cg19671926	chr4:122722719	EXOSC9	0.66	8.73	0.47	2.96e-16	Type 2 diabetes;
CESC	cis	rs763121	0.853	rs6001184	chr22:39052116	C/T	cg14440974	chr22:39074834	NA	-0.4	-5.49	-0.32	9.53e-8	Menopause (age at onset);
CESC	cis	rs1552244	0.744	rs6763366	chr3:10033544	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.73	-9.22	-0.49	9.33e-18	Alzheimer's disease;
CESC	cis	rs7927771	1.000	rs2290850	chr11:47807774	T/C	cg05585544	chr11:47624801	NA	-0.5	-7.74	-0.43	2.05e-13	Subjective well-being;
CESC	cis	rs12681366	0.683	rs56285115	chr8:95401472	C/A	cg13257157	chr8:95487014	RAD54B	0.38	5.14	0.3	5.22e-7	Nonsyndromic cleft lip with cleft palate;
CESC	cis	rs9660992	0.674	rs72745221	chr1:205262337	G/A	cg21643547	chr1:205240462	TMCC2	-0.47	-6.25	-0.36	1.6e-9	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs921968	0.541	rs2241527	chr2:219537224	A/G	cg02176678	chr2:219576539	TTLL4	0.56	9.2	0.49	1.08e-17	Mean corpuscular hemoglobin concentration;
CESC	cis	rs8027181	0.797	rs8033580	chr15:72994968	C/A	cg25632853	chr15:73088954	NA	0.31	5.41	0.32	1.38e-7	Triglyceride levels;
CESC	cis	rs798554	0.757	rs1182181	chr7:2873247	C/G	cg18446336	chr7:2847575	GNA12	-0.37	-5.76	-0.33	2.27e-8	Height;
CESC	cis	rs1009170	0.794	rs2402112	chr14:92582172	G/A	cg10324096	chr14:92587714	CPSF2;NDUFB1	0.55	5.11	0.3	6.15e-7	Dialysis-related mortality;
CESC	cis	rs8177253	0.898	rs8177258	chr3:133480387	C/A	cg12373951	chr3:133503437	NA	0.42	6.0	0.35	6.56e-9	Iron status biomarkers;
CESC	cis	rs7246657	0.943	rs2126977	chr19:37995747	C/G	cg23950597	chr19:37808831	NA	0.48	5.34	0.31	2e-7	Coronary artery calcification;
CESC	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg24739457	chr1:205821442	NA	0.46	6.04	0.35	5.32e-9	Menarche (age at onset);
CESC	cis	rs1552244	0.935	rs66493421	chr3:10092569	G/A	cg08888203	chr3:10149979	C3orf24	0.54	6.19	0.36	2.23e-9	Alzheimer's disease;
CESC	cis	rs7267979	0.702	rs449801	chr20:25491847	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.72	12.08	0.6	4.73e-27	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs11958404	0.932	rs72816587	chr5:157434144	T/A	cg05962755	chr5:157440814	NA	0.62	6.56	0.37	2.74e-10	IgG glycosylation;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	ch.4.71452R	chr4:1726499	TACC3	-0.56	-6.76	-0.38	8.99e-11	Gut microbiome composition (summer);
CESC	cis	rs12973672	0.812	rs12979792	chr19:35748706	A/G	cg12095397	chr19:35769544	USF2	0.49	5.97	0.34	7.44e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg12475106	chr4:503275	PIGG	0.56	7.6	0.42	5.09e-13	Fibrinogen levels;
CESC	trans	rs801193	1.000	rs3857688	chr7:66127806	G/A	cg26939375	chr7:64535504	NA	-0.64	-8.57	-0.47	8.53e-16	Aortic root size;
CESC	cis	rs6570726	1.000	rs6570699	chr6:145920732	G/A	cg05347473	chr6:146136440	FBXO30	0.41	5.55	0.32	6.9e-8	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7818688	1.000	rs73276417	chr8:96026312	C/G	cg16049864	chr8:95962084	TP53INP1	0.6	5.77	0.33	2.25e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs7223966	0.960	rs2854222	chr17:61939015	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.47	-5.86	-0.34	1.34e-8	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs11155671	0.530	rs7763849	chr6:150206380	C/T	cg09699651	chr6:150184138	LRP11	0.58	8.17	0.45	1.28e-14	Testicular germ cell tumor;
CESC	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg04025307	chr7:1156635	C7orf50	0.43	5.97	0.34	7.71e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs6933660	0.536	rs3800274	chr6:151759192	T/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.67	8.55	0.47	9.7e-16	Menarche (age at onset);
CESC	cis	rs926392	0.640	rs7268716	chr20:37693214	C/T	cg16355469	chr20:37678765	NA	0.57	6.43	0.37	5.8e-10	Dialysis-related mortality;
CESC	cis	rs853679	1.000	rs11965538	chr6:28239915	G/A	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.71	7.37	0.41	2.16e-12	Depression;
CESC	cis	rs763121	0.719	rs138699	chr22:39129708	G/A	cg06022373	chr22:39101656	GTPBP1	0.88	13.6	0.64	2.62e-32	Menopause (age at onset);
CESC	cis	rs56046484	0.797	rs907260	chr15:85676757	G/A	cg08123816	chr15:85640762	PDE8A	0.44	5.44	0.32	1.2e-7	Testicular germ cell tumor;
CESC	cis	rs7107174	1.000	rs4945267	chr11:78037933	G/A	cg02023728	chr11:77925099	USP35	0.52	6.86	0.39	4.74e-11	Testicular germ cell tumor;
CESC	cis	rs8180040	0.871	rs11716661	chr3:47517773	G/T	cg27129171	chr3:47204927	SETD2	-0.64	-9.6	-0.51	6.38e-19	Colorectal cancer;
CESC	cis	rs7635838	0.892	rs3942925	chr3:11442921	T/C	cg00170343	chr3:11313890	ATG7	0.42	5.5	0.32	8.99e-8	HDL cholesterol;
CESC	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg07308232	chr7:1071921	C7orf50	-0.45	-5.99	-0.35	6.73e-9	Longevity;Endometriosis;
CESC	cis	rs9733	0.544	rs2867302	chr1:150653650	T/C	cg22823121	chr1:150693482	HORMAD1	0.48	7.09	0.4	1.21e-11	Tonsillectomy;
CESC	cis	rs3820068	0.603	rs10492986	chr1:15988702	T/C	cg13390004	chr1:15929781	NA	0.34	5.48	0.32	9.79e-8	Systolic blood pressure;
CESC	cis	rs9513593	1.000	rs16956449	chr13:99966605	A/G	cg21788972	chr13:99853209	UBAC2	0.62	7.17	0.4	7.32e-12	Psoriasis;
CESC	trans	rs57221529	0.599	rs72707027	chr5:671294	C/G	cg25482853	chr8:67687455	SGK3	0.97	9.47	0.5	1.67e-18	Lung disease severity in cystic fibrosis;
CESC	cis	rs4843747	0.671	rs4075998	chr16:88106776	G/A	cg03395651	chr16:88107091	BANP	0.46	5.36	0.31	1.85e-7	Menopause (age at onset);
CESC	cis	rs6088590	0.965	rs6088620	chr20:33412022	A/G	cg06115741	chr20:33292138	TP53INP2	0.6	7.51	0.42	9.05e-13	Coronary artery disease;
CESC	cis	rs898097	0.812	rs55794221	chr17:80849003	G/A	cg20271620	chr17:80763330	TBCD	0.46	5.43	0.32	1.27e-7	Breast cancer;
CESC	cis	rs780096	0.587	rs4665969	chr2:27574953	C/T	cg22903471	chr2:27725779	GCKR	0.48	6.89	0.39	3.96e-11	Total body bone mineral density;
CESC	cis	rs7116495	0.609	rs4945378	chr11:71668866	G/A	cg07596299	chr11:71824057	C11orf51	-0.76	-5.21	-0.3	3.77e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs11792861	0.926	rs11788904	chr9:111865052	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.41	5.12	0.3	5.97e-7	Menarche (age at onset);
CESC	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg07677032	chr17:61819896	STRADA	0.42	5.53	0.32	7.56e-8	Prudent dietary pattern;
CESC	cis	rs2243480	1.000	rs10950032	chr7:65738591	C/A	cg12463550	chr7:65579703	CRCP	-0.74	-5.73	-0.33	2.74e-8	Diabetic kidney disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00746693	chr19:34746153	KIAA0355	0.54	6.02	0.35	5.87e-9	Gut microbiome composition (summer);
CESC	cis	rs2576037	0.523	rs590923	chr18:44404259	G/C	cg19077165	chr18:44547161	KATNAL2	-0.61	-9.16	-0.49	1.46e-17	Personality dimensions;
CESC	cis	rs2576037	0.526	rs10853547	chr18:44530548	A/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.42	7.06	0.4	1.45e-11	Personality dimensions;
CESC	cis	rs1580019	0.534	rs13237495	chr7:32560687	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.51	6.66	0.38	1.57e-10	Cognitive ability;
CESC	cis	rs7520050	0.966	rs10890354	chr1:46305347	G/A	cg24296786	chr1:45957014	TESK2	0.44	5.54	0.32	7.22e-8	Red blood cell count;Reticulocyte count;
CESC	cis	rs10504229	0.639	rs67996345	chr8:58117127	A/G	cg02725872	chr8:58115012	NA	-0.45	-7.05	-0.4	1.52e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs7666738	0.830	rs6831925	chr4:98947401	T/C	cg17366294	chr4:99064904	C4orf37	0.6	8.53	0.46	1.15e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6582630	0.519	rs12578283	chr12:38325349	A/T	cg13010199	chr12:38710504	ALG10B	0.47	5.97	0.34	7.72e-9	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs5750830	0.649	rs4337572	chr22:39800704	C/G	cg02038168	chr22:39784481	NA	-0.57	-6.67	-0.38	1.46e-10	Intelligence (multi-trait analysis);
CESC	cis	rs67311347	0.956	rs9822870	chr3:40514890	A/C	cg01475735	chr3:40494733	NA	0.43	5.54	0.32	7.18e-8	Renal cell carcinoma;
CESC	cis	rs1915146	0.546	rs1715862	chr10:126856255	C/T	cg17191109	chr10:126851326	NA	-0.41	-6.72	-0.38	1.12e-10	Menarche (age at onset);
CESC	cis	rs873946	0.557	rs4880427	chr10:134591389	T/C	cg18305652	chr10:134549665	INPP5A	0.45	6.14	0.35	2.95e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs7584330	0.868	rs2325839	chr2:238386286	T/C	cg14458575	chr2:238380390	NA	0.7	10.06	0.53	2.28e-20	Prostate cancer;
CESC	cis	rs8078723	1.000	rs7214085	chr17:38169095	T/C	cg17467752	chr17:38218738	THRA	0.67	9.97	0.52	4.3e-20	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CESC	cis	rs2760061	0.819	rs964941	chr1:228193857	G/A	cg02753203	chr1:228287806	NA	0.53	7.88	0.44	8.34e-14	Diastolic blood pressure;
CESC	cis	rs6582630	0.502	rs11514371	chr12:38306306	G/C	cg26384229	chr12:38710491	ALG10B	0.7	10.34	0.54	2.92e-21	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs5753618	0.561	rs2413047	chr22:31666026	A/G	cg13145458	chr22:31556086	RNF185	0.48	5.35	0.31	1.88e-7	Colorectal cancer;
CESC	trans	rs35110281	0.807	rs28840140	chr21:45039163	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.51	6.69	0.38	1.34e-10	Mean corpuscular volume;
CESC	cis	rs7771547	0.573	rs546272	chr6:36398562	G/A	cg04289385	chr6:36355825	ETV7	0.36	5.19	0.3	4.23e-7	Platelet distribution width;
CESC	cis	rs2439831	1.000	rs28666488	chr15:43741090	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.8	11.71	0.58	8.62e-26	Lung cancer in ever smokers;
CESC	cis	rs62064224	0.546	rs1018866	chr17:30829664	A/C	cg18200150	chr17:30822561	MYO1D	0.71	10.69	0.55	2.07e-22	Schizophrenia;
CESC	cis	rs9926296	0.706	rs2159115	chr16:89831819	A/G	cg27121462	chr16:89883253	FANCA	0.51	6.19	0.36	2.27e-9	Vitiligo;
CESC	cis	rs17376456	0.542	rs2043979	chr5:93120782	T/A	cg25358565	chr5:93447407	FAM172A	-0.47	-5.21	-0.3	3.8e-7	Diabetic retinopathy;
CESC	cis	rs1775715	0.674	rs2778670	chr10:32161676	G/A	cg18675610	chr10:32216311	ARHGAP12	0.35	5.38	0.31	1.6e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs853679	0.517	rs9393896	chr6:28127703	C/T	cg17949981	chr6:28129498	ZNF389	0.45	5.56	0.32	6.54e-8	Depression;
CESC	cis	rs853679	0.517	rs9393885	chr6:28050009	A/T	cg18032046	chr6:28092343	ZSCAN16	-0.53	-6.09	-0.35	3.91e-9	Depression;
CESC	cis	rs9640161	0.830	rs76741564	chr7:150059529	A/T	cg21361702	chr7:150065534	REPIN1	0.67	8.26	0.45	6.87e-15	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs1799949	1.000	rs33946455	chr17:41321846	C/T	cg05368731	chr17:41323189	NBR1	0.79	11.08	0.56	1.1e-23	Menopause (age at onset);
CESC	cis	rs8031584	1.000	rs35239376	chr15:31290538	A/C	cg14829155	chr15:31115871	NA	-0.74	-9.3	-0.5	5.63e-18	Huntington's disease progression;
CESC	cis	rs6088590	1.000	rs6087626	chr20:33347328	C/T	cg08999081	chr20:33150536	PIGU	0.58	8.95	0.48	6.2e-17	Coronary artery disease;
CESC	cis	rs3749237	0.595	rs1464566	chr3:49459376	T/C	cg03060546	chr3:49711283	APEH	0.77	11.7	0.58	9.27e-26	Resting heart rate;
CESC	cis	rs765787	0.530	rs2433229	chr15:45515235	C/A	cg24006582	chr15:45444508	DUOX1	-0.58	-7.11	-0.4	1.11e-11	Uric acid levels;
CESC	trans	rs11165623	0.792	rs6671371	chr1:96977039	A/G	cg10631902	chr5:14652156	NA	-0.48	-7.0	-0.4	2.14e-11	Hip circumference;Waist circumference;
CESC	cis	rs589448	0.967	rs634512	chr12:69754012	C/T	cg20891283	chr12:69753455	YEATS4	1.0	17.3	0.73	2.24e-45	Cerebrospinal fluid biomarker levels;
CESC	trans	rs208520	1.000	rs12192261	chr6:66985268	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.84	9.33	0.5	4.37e-18	Exhaled nitric oxide output;
CESC	cis	rs7904368	0.806	rs4612698	chr10:16855070	C/A	cg14835575	chr10:16859367	RSU1	0.53	5.4	0.31	1.5e-7	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
CESC	cis	rs4664304	0.802	rs62175470	chr2:160858255	G/C	cg03641300	chr2:160917029	PLA2R1	-0.5	-7.0	-0.39	2.16e-11	Crohn's disease;Inflammatory bowel disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05946335	chr7:66460663	SBDS;TYW1	0.59	7.02	0.4	1.81e-11	Gut microbiome composition (summer);
CESC	trans	rs526821	0.595	rs629948	chr11:55356448	G/A	cg03929089	chr4:120376271	NA	-0.5	-6.07	-0.35	4.33e-9	Pediatric bone mineral density (spine);
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg19201477	chr8:21776851	XPO7	-0.48	-6.23	-0.36	1.77e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs2072732	0.861	rs67919793	chr1:2954230	T/C	cg03976712	chr1:2946727	NA	0.33	5.53	0.32	7.83e-8	Plateletcrit;
CESC	cis	rs9790314	0.846	rs7652267	chr3:160998497	A/G	cg03342759	chr3:160939853	NMD3	-0.53	-7.79	-0.43	1.48e-13	Morning vs. evening chronotype;
CESC	cis	rs6546537	0.911	rs4852898	chr2:69872797	C/T	cg10773587	chr2:69614142	GFPT1	-0.58	-6.52	-0.37	3.58e-10	Serum thyroid-stimulating hormone levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01102847	chr14:50053293	RPS29	0.56	6.19	0.36	2.23e-9	Gut microbiome composition (summer);
CESC	cis	rs2439831	0.867	rs2920781	chr15:43924682	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.81	8.43	0.46	2.26e-15	Lung cancer in ever smokers;
CESC	cis	rs7772486	0.875	rs2748482	chr6:146336532	T/C	cg23711669	chr6:146136114	FBXO30	0.86	12.53	0.61	1.39e-28	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs1814175	0.817	rs4881627	chr11:49953955	C/A	cg15704280	chr7:45808275	SEPT13	-1.03	-20.41	-0.78	2.75e-56	Height;
CESC	cis	rs2072732	0.861	rs67630839	chr1:2951989	C/T	cg03976712	chr1:2946727	NA	0.32	5.3	0.31	2.5e-7	Plateletcrit;
CESC	cis	rs9911578	1.000	rs12449365	chr17:56600660	C/G	cg05425664	chr17:57184151	TRIM37	0.5	7.06	0.4	1.5e-11	Intelligence (multi-trait analysis);
CESC	cis	rs8072100	0.934	rs8067286	chr17:45594590	A/G	cg08085267	chr17:45401833	C17orf57	0.46	6.29	0.36	1.29e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	trans	rs6089829	0.962	rs9679865	chr20:61666132	C/G	cg23505145	chr19:12996616	KLF1	0.52	6.8	0.39	6.85e-11	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs6714710	0.603	rs35505530	chr2:98506910	T/C	cg26665480	chr2:98280029	ACTR1B	0.56	7.88	0.44	8.37e-14	Posterior cortical atrophy and Alzheimer's disease;
CESC	cis	rs7666738	0.830	rs13112131	chr4:98976784	G/A	cg17366294	chr4:99064904	C4orf37	0.59	8.43	0.46	2.31e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6502050	0.835	rs11077981	chr17:80147243	C/T	cg11859384	chr17:80120422	CCDC57	-0.38	-5.17	-0.3	4.61e-7	Life satisfaction;
CESC	trans	rs3780486	0.505	rs10117038	chr9:33122626	T/C	cg04842962	chr6:43655489	MRPS18A	0.7	10.96	0.56	2.65e-23	IgG glycosylation;
CESC	cis	rs2795502	1.000	rs2142991	chr10:43341105	C/T	cg27426351	chr10:43362370	NA	-0.48	-6.0	-0.35	6.51e-9	Blood protein levels;
CESC	cis	rs806215	0.950	rs3757793	chr7:127225780	G/A	cg25922125	chr7:127225783	GCC1	-0.49	-5.52	-0.32	8.22e-8	Type 2 diabetes;
CESC	cis	rs7662987	0.517	rs1311618	chr4:100012612	A/G	cg12011299	chr4:100065546	ADH4	0.61	6.71	0.38	1.17e-10	Smoking initiation;
CESC	cis	rs778371	0.874	rs1083522	chr2:233745521	C/T	cg08000102	chr2:233561755	GIGYF2	-0.83	-13.23	-0.63	4.96e-31	Schizophrenia;
CESC	cis	rs11190604	1.000	rs12219158	chr10:102302923	T/C	cg07080220	chr10:102295463	HIF1AN	0.66	6.04	0.35	5.08e-9	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs5750830	0.594	rs9611165	chr22:39775250	A/G	cg11247378	chr22:39784982	NA	-0.51	-7.72	-0.43	2.36e-13	Intelligence (multi-trait analysis);
CESC	cis	rs916888	0.773	rs199448	chr17:44809001	A/G	cg01570182	chr17:44337453	NA	0.86	10.02	0.52	2.93e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs3780486	0.846	rs10971419	chr9:33124161	T/C	cg13443165	chr9:33130375	B4GALT1	0.44	6.38	0.37	7.66e-10	IgG glycosylation;
CESC	cis	rs2836974	0.584	rs7276774	chr21:40628725	T/G	cg17971929	chr21:40555470	PSMG1	-0.89	-12.71	-0.62	3.29e-29	Cognitive function;
CESC	cis	rs1008375	0.966	rs6833808	chr4:17652526	T/A	cg15017067	chr4:17643749	FAM184B	0.37	5.28	0.31	2.74e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs898097	0.756	rs11655103	chr17:80813467	T/C	cg15664640	chr17:80829946	TBCD	-0.63	-9.08	-0.49	2.57e-17	Breast cancer;
CESC	cis	rs11098499	0.644	rs28787668	chr4:120554687	G/A	cg24375607	chr4:120327624	NA	0.41	5.14	0.3	5.23e-7	Corneal astigmatism;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg05909553	chr8:145739024	RECQL4	0.47	7.18	0.4	7.08e-12	Fibrinogen levels;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg09209803	chr6:33588932	ITPR3	-0.48	-6.08	-0.35	4.08e-9	Ulcerative colitis;
CESC	cis	rs1799949	0.965	rs8176130	chr17:41258043	C/T	cg25072359	chr17:41440525	NA	0.45	6.13	0.35	3.21e-9	Menopause (age at onset);
CESC	cis	rs7216064	1.000	rs12602912	chr17:65870073	C/T	cg12091567	chr17:66097778	LOC651250	-0.85	-8.7	-0.47	3.61e-16	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs4654899	0.865	rs11807193	chr1:21420617	T/A	cg05370193	chr1:21551575	ECE1	0.41	6.06	0.35	4.6e-9	Superior frontal gyrus grey matter volume;
CESC	cis	rs28830936	0.625	rs8038764	chr15:41907905	A/C	cg17847044	chr15:42102381	MAPKBP1	0.4	6.94	0.39	3.05e-11	Diastolic blood pressure;
CESC	cis	rs736408	0.540	rs4687637	chr3:52634092	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.5	7.34	0.41	2.69e-12	Bipolar disorder;
CESC	cis	rs13095912	0.962	rs6785918	chr3:185330631	A/G	cg11274856	chr3:185301563	NA	0.34	5.44	0.32	1.21e-7	Systolic blood pressure;
CESC	cis	rs11792861	0.591	rs2275641	chr9:111696389	G/C	cg13535736	chr9:111863775	C9orf5	-0.39	-5.62	-0.33	4.92e-8	Menarche (age at onset);
CESC	cis	rs6938	0.618	rs11633472	chr15:75184084	T/G	cg17294928	chr15:75287854	SCAMP5	0.49	6.51	0.37	3.82e-10	Breast cancer;
CESC	cis	rs548181	0.545	rs76179820	chr11:125616379	A/G	cg03464685	chr11:125439445	EI24	-0.65	-5.79	-0.34	1.99e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs7223966	1.000	rs7220892	chr17:61908316	G/A	cg11494091	chr17:61959527	GH2	0.38	5.19	0.3	4.25e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs365132	0.934	rs6861925	chr5:176324729	C/G	cg16309518	chr5:176445507	NA	-0.4	-5.96	-0.34	7.9e-9	Menarche and menopause (age at onset);Menopause (age at onset);
CESC	cis	rs7264396	0.790	rs3787164	chr20:34228866	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.63	7.56	0.42	6.68e-13	Total cholesterol levels;
CESC	cis	rs7264396	0.563	rs6060560	chr20:34278890	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.9	-9.83	-0.52	1.23e-19	Total cholesterol levels;
CESC	cis	rs12950390	0.853	rs17700008	chr17:45863591	A/C	cg00777063	chr17:45855553	NA	0.36	5.26	0.31	2.91e-7	IgG glycosylation;
CESC	cis	rs2652834	0.851	rs11071721	chr15:63350218	T/C	cg05507819	chr15:63340323	TPM1	0.58	5.75	0.33	2.51e-8	HDL cholesterol;
CESC	cis	rs35110281	0.776	rs1073522	chr21:45009219	T/A	cg04455712	chr21:45112962	RRP1B	0.35	5.09	0.3	6.94e-7	Mean corpuscular volume;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg26081613	chr14:71375319	PCNX	-0.42	-6.11	-0.35	3.51e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs901683	1.000	rs12781186	chr10:46013438	A/G	cg16031567	chr10:46195673	NA	-0.77	-5.04	-0.3	8.57e-7	Red blood cell traits;Mean corpuscular volume;
CESC	cis	rs6456156	0.716	rs6905911	chr6:167521624	C/T	cg07741184	chr6:167504864	NA	0.31	5.19	0.3	4.23e-7	Primary biliary cholangitis;
CESC	cis	rs7216064	0.531	rs6504573	chr17:66015963	C/T	cg12091567	chr17:66097778	LOC651250	-0.7	-8.79	-0.48	1.94e-16	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs9311474	1.000	rs1060330	chr3:52288945	T/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.38	6.93	0.39	3.16e-11	Electroencephalogram traits;
CESC	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.75	-10.67	-0.55	2.32e-22	Prudent dietary pattern;
CESC	cis	rs41271473	0.687	rs7535661	chr1:228887667	C/T	cg00850481	chr1:228891306	NA	-0.44	-5.6	-0.33	5.46e-8	Chronic lymphocytic leukemia;
CESC	cis	rs6032067	0.929	rs35880287	chr20:43821001	G/A	cg11264863	chr20:43835661	SEMG1	0.49	5.29	0.31	2.5e-7	Blood protein levels;
CESC	cis	rs7772486	0.701	rs7772717	chr6:145954854	T/C	cg05347473	chr6:146136440	FBXO30	0.58	7.37	0.41	2.23e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2204008	0.744	rs2222344	chr12:38406832	T/G	cg26384229	chr12:38710491	ALG10B	0.68	10.35	0.54	2.71e-21	Bladder cancer;
CESC	cis	rs12220238	0.915	rs1908334	chr10:75991721	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.64	6.34	0.36	9.87e-10	Soluble interleukin-2 receptor subunit alpha;
CESC	cis	rs1355223	0.902	rs7129089	chr11:34699699	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.45	-6.02	-0.35	5.9e-9	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs9902453	0.874	rs4474741	chr17:28148117	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.63	-8.16	-0.45	1.4e-14	Coffee consumption (cups per day);
CESC	cis	rs1707322	1.000	rs7531911	chr1:46330423	A/G	cg05343316	chr1:45956843	TESK2	0.43	5.23	0.31	3.41e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs12497850	0.931	rs6791542	chr3:48787219	A/G	cg06641503	chr3:48959341	ARIH2	-0.33	-5.12	-0.3	6.02e-7	Parkinson's disease;
CESC	cis	rs1023500	0.505	rs134901	chr22:42683520	C/T	cg04733989	chr22:42467013	NAGA	0.64	9.7	0.51	3.15e-19	Schizophrenia;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg10558228	chr1:155533819	ASH1L	-0.43	-6.29	-0.36	1.34e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs4568518	0.501	rs12699920	chr7:17992949	T/C	cg03009463	chr7:17980271	SNX13	0.45	5.88	0.34	1.21e-8	Measles;
CESC	cis	rs7582720	1.000	rs76298043	chr2:203814694	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.36	0.41	2.34e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs3806843	1.000	rs1030165	chr5:140185448	G/A	cg26395211	chr5:140044315	WDR55	-0.42	-5.26	-0.31	2.96e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs6942756	0.774	rs2402944	chr7:128951402	G/T	cg02491457	chr7:128862824	NA	-0.62	-8.87	-0.48	1.11e-16	White matter hyperintensity burden;
CESC	cis	rs9322193	0.884	rs7743823	chr6:150170880	A/G	cg07701084	chr6:150067640	NUP43	0.4	5.24	0.31	3.27e-7	Lung cancer;
CESC	cis	rs7044106	0.762	rs1470307	chr9:123433039	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.85	14.07	0.65	5.96e-34	Hip circumference adjusted for BMI;
CESC	cis	rs17539620	0.624	rs62432743	chr6:154836214	T/G	cg20019720	chr6:154832845	CNKSR3	0.47	6.15	0.35	2.89e-9	Lipoprotein (a) levels;
CESC	cis	rs2228479	0.717	rs9282682	chr16:89805794	A/G	cg06558623	chr16:89946397	TCF25	0.71	6.64	0.38	1.74e-10	Skin colour saturation;
CESC	cis	rs796364	1.000	rs1704186	chr2:200769539	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	0.85	8.48	0.46	1.59e-15	Schizophrenia;
CESC	cis	rs3858526	1.000	rs10838909	chr11:5960490	G/A	cg05234568	chr11:5960015	NA	-0.63	-7.01	-0.4	2.03e-11	DNA methylation (variation);
CESC	cis	rs9311474	0.581	rs4687626	chr3:52569098	G/A	cg15147215	chr3:52552868	STAB1	-0.31	-5.24	-0.31	3.36e-7	Electroencephalogram traits;
CESC	cis	rs28647808	0.881	rs57394597	chr9:136261030	G/A	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.85	5.74	0.33	2.59e-8	Blood protein levels;
CESC	cis	rs9309473	1.000	rs7582606	chr2:73813945	A/G	cg20560298	chr2:73613845	ALMS1	-0.54	-7.1	-0.4	1.13e-11	Metabolite levels;
CESC	cis	rs919433	1.000	rs7422899	chr2:198163527	G/C	cg03934865	chr2:198174659	NA	-0.41	-5.54	-0.32	7.33e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs7666738	0.830	rs1365458	chr4:98950961	C/T	cg17366294	chr4:99064904	C4orf37	0.6	8.63	0.47	5.76e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1538970	0.961	rs7553318	chr1:45843086	A/G	cg05343316	chr1:45956843	TESK2	0.83	11.6	0.58	1.9e-25	Platelet count;
CESC	cis	rs7508679	1.000	rs10410204	chr19:7224350	C/T	cg00428638	chr19:7224713	INSR	0.49	7.69	0.43	2.87e-13	Hypothyroidism;
CESC	cis	rs6084875	0.932	rs6084856	chr20:4728491	G/A	cg05143360	chr20:4741328	NA	0.42	5.07	0.3	7.46e-7	Systemic lupus erythematosus;
CESC	cis	rs941873	0.805	rs10762860	chr10:81117794	C/G	cg11057378	chr10:81107060	PPIF	0.35	5.67	0.33	3.7e-8	Height;
CESC	cis	rs6502050	0.865	rs74480314	chr17:80117716	C/T	cg23985595	chr17:80112537	CCDC57	-0.41	-6.47	-0.37	4.79e-10	Life satisfaction;
CESC	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg18402987	chr7:1209562	NA	0.76	7.58	0.42	5.85e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs10504229	1.000	rs72650887	chr8:58177343	G/A	cg22535103	chr8:58192502	C8orf71	-1.05	-13.27	-0.63	3.63e-31	Developmental language disorder (linguistic errors);
CESC	cis	rs2880765	0.835	rs56406982	chr15:86036379	G/A	cg19183879	chr15:85880815	NA	-0.25	-5.13	-0.3	5.74e-7	Coronary artery disease;
CESC	cis	rs9790314	1.000	rs189270	chr3:161063504	T/C	cg04691961	chr3:161091175	C3orf57	-0.42	-5.36	-0.31	1.8e-7	Morning vs. evening chronotype;
CESC	cis	rs1707322	0.752	rs28719889	chr1:46202283	C/T	cg05343316	chr1:45956843	TESK2	0.5	6.21	0.36	2.02e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26884921	chr19:50370748	PNKP	0.55	6.04	0.35	5.15e-9	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21619287	chr16:3767727	TRAP1	0.63	7.15	0.4	8.32e-12	Gut microbiome composition (summer);
CESC	cis	rs7474896	0.526	rs1742235	chr10:38052256	T/C	cg00409905	chr10:38381863	ZNF37A	-0.46	-5.03	-0.3	9.04e-7	Obesity (extreme);
CESC	trans	rs1814175	0.867	rs7926002	chr11:49616018	A/G	cg03929089	chr4:120376271	NA	-0.84	-12.55	-0.61	1.19e-28	Height;
CESC	cis	rs1355223	0.583	rs1549789	chr11:34867947	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.84	12.68	0.61	4.2e-29	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs6952808	0.608	rs6461049	chr7:2017445	C/T	cg05863683	chr7:1912471	MAD1L1	-0.4	-5.87	-0.34	1.27e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs6952808	0.825	rs34296663	chr7:1935245	C/T	cg04267008	chr7:1944627	MAD1L1	-0.71	-9.11	-0.49	2.06e-17	Bipolar disorder and schizophrenia;
CESC	cis	rs3105593	0.563	rs8035851	chr15:50978042	C/A	cg08437265	chr15:50716283	USP8	0.4	5.1	0.3	6.51e-7	QT interval;
CESC	cis	rs1642645	0.831	rs6689536	chr1:42487523	T/C	cg16685388	chr1:42384056	HIVEP3	0.37	5.61	0.33	5.2e-8	Left ventricular obstructive tract defect (maternal effect);
CESC	cis	rs738322	0.934	rs133019	chr22:38573035	A/G	cg17652424	chr22:38574118	PLA2G6	-0.35	-6.2	-0.36	2.21e-9	Cutaneous nevi;
CESC	cis	rs933688	0.532	rs997737	chr5:90567031	C/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.48	-5.88	-0.34	1.23e-8	Smoking behavior;
CESC	cis	rs9322193	0.504	rs7771014	chr6:150205446	T/A	cg09699651	chr6:150184138	LRP11	0.55	7.55	0.42	7.25e-13	Lung cancer;
CESC	cis	rs597539	0.690	rs578791	chr11:68625809	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.81	9.9	0.52	7.53e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs6860806	0.661	rs2136187	chr5:131577894	T/C	cg18758796	chr5:131593413	PDLIM4	0.47	6.82	0.39	6.01e-11	Breast cancer;
CESC	cis	rs10861342	1.000	rs11112396	chr12:105568359	T/G	cg23923672	chr12:105501055	KIAA1033	0.62	5.38	0.31	1.66e-7	IgG glycosylation;
CESC	cis	rs736408	0.812	rs2240920	chr3:52831009	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.47	-5.62	-0.33	4.72e-8	Bipolar disorder;
CESC	cis	rs1005277	0.579	rs2474584	chr10:38416389	C/T	cg25517755	chr10:38738941	LOC399744	-0.46	-5.98	-0.34	7.23e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs769267	0.930	rs4808965	chr19:19631655	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.49	6.01	0.35	6.17e-9	Tonsillectomy;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg03358980	chr10:102770406	NA	0.54	7.23	0.41	5.05e-12	Thyroid stimulating hormone;
CESC	cis	rs9611565	0.546	rs5758430	chr22:42109844	G/T	cg06481639	chr22:41940642	POLR3H	0.64	6.55	0.37	2.94e-10	Vitiligo;
CESC	cis	rs9640161	0.702	rs11765692	chr7:150026567	C/T	cg13722127	chr7:150037890	RARRES2	0.34	5.15	0.3	5.13e-7	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs6938	0.534	rs1133322	chr15:75212357	A/G	cg14664628	chr15:75095509	CSK	-0.56	-7.61	-0.42	4.86e-13	Breast cancer;
CESC	cis	rs7833790	0.654	rs7835342	chr8:82698092	A/G	cg02079420	chr8:82753780	SNX16	0.5	7.56	0.42	6.82e-13	Diastolic blood pressure;
CESC	cis	rs2204008	0.782	rs117824012	chr12:38215517	T/C	cg13010199	chr12:38710504	ALG10B	0.54	6.69	0.38	1.28e-10	Bladder cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07855967	chr6:13486425	C6orf114;GFOD1	0.54	6.19	0.36	2.29e-9	Gut microbiome composition (summer);
CESC	cis	rs1348850	0.793	rs13000048	chr2:178337089	C/A	cg22681709	chr2:178499509	PDE11A	-0.39	-5.77	-0.33	2.21e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs736408	0.505	rs2083180	chr3:52668119	G/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.31	5.62	0.33	4.88e-8	Bipolar disorder;
CESC	cis	rs270601	0.770	rs4361510	chr5:131599647	C/T	cg12564285	chr5:131593104	PDLIM4	0.38	5.8	0.34	1.92e-8	Acylcarnitine levels;
CESC	trans	rs17764205	0.777	rs17696630	chr19:3261995	A/G	cg22881279	chr8:90996602	NBN	-0.79	-6.26	-0.36	1.53e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs6951245	0.810	rs117800627	chr7:1081075	G/C	cg23708337	chr7:1209742	NA	0.53	5.3	0.31	2.41e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2559856	0.904	rs2695283	chr12:102089391	G/C	cg15068132	chr12:102092402	CHPT1	-0.43	-5.64	-0.33	4.26e-8	Blood protein levels;
CESC	cis	rs10504229	0.683	rs55868006	chr8:58135703	C/T	cg02725872	chr8:58115012	NA	-0.45	-7.05	-0.4	1.52e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs4481887	0.676	rs6691314	chr1:248548020	G/A	cg26353448	chr1:248524236	OR2T4	-0.37	-5.11	-0.3	6.17e-7	Common traits (Other);
CESC	cis	rs2228479	0.850	rs17226666	chr16:89835401	G/A	cg00800038	chr16:89945340	TCF25	-0.92	-7.64	-0.42	4.02e-13	Skin colour saturation;
CESC	cis	rs875971	0.660	rs28698552	chr7:66005018	A/G	cg25985355	chr7:65971099	NA	-0.33	-5.46	-0.32	1.07e-7	Aortic root size;
CESC	cis	rs1218582	0.710	rs9793588	chr1:154878878	C/G	cg06221963	chr1:154839813	KCNN3	-0.66	-11.32	-0.57	1.71e-24	Prostate cancer;
CESC	cis	rs933688	1.000	rs1964292	chr5:90743608	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.95	11.04	0.56	1.47e-23	Smoking behavior;
CESC	cis	rs11997175	0.625	rs953617	chr8:33599158	G/C	ch.8.33884649F	chr8:33765107	NA	0.56	7.05	0.4	1.53e-11	Body mass index;
CESC	cis	rs1559088	1.000	rs12979164	chr19:33553228	G/C	cg27124370	chr19:33622961	WDR88	0.42	5.34	0.31	1.98e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs853679	0.517	rs6941992	chr6:28106141	T/C	cg22143856	chr6:28129313	ZNF389	0.52	6.77	0.38	8.31e-11	Depression;
CESC	cis	rs3744061	0.569	rs2240769	chr17:74718155	C/T	cg27546012	chr17:74684504	MXRA7	-0.55	-7.87	-0.44	8.79e-14	Retinal arteriolar caliber;
CESC	cis	rs6032067	0.929	rs7344269	chr20:43828668	C/T	cg10761708	chr20:43804764	PI3	-0.52	-6.3	-0.36	1.21e-9	Blood protein levels;
CESC	cis	rs7666738	0.535	rs6850010	chr4:98971601	A/T	cg03676636	chr4:99064102	C4orf37	0.34	5.21	0.3	3.81e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7818688	1.000	rs73276406	chr8:96021760	G/C	cg16049864	chr8:95962084	TP53INP1	0.61	5.74	0.33	2.62e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26748028	chr19:40697398	MAP3K10	0.57	6.7	0.38	1.22e-10	Gut microbiome composition (summer);
CESC	cis	rs7618915	0.501	rs2159644	chr3:52774530	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	8.15	0.45	1.44e-14	Bipolar disorder;
CESC	cis	rs910316	1.000	rs13099	chr14:75599155	G/A	cg11812906	chr14:75593930	NEK9	-0.87	-15.0	-0.68	3.09e-37	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07611531	chr2:54853149	SPTBN1	-0.57	-6.46	-0.37	5.07e-10	Gut microbiome composition (summer);
CESC	cis	rs6540559	0.673	rs17015183	chr1:209948711	A/C	cg21951975	chr1:209979733	IRF6	0.56	7.38	0.41	2.06e-12	Cleft lip with or without cleft palate;
CESC	cis	rs11792861	0.781	rs2151426	chr9:111743797	A/C	cg05043794	chr9:111880884	C9orf5	-0.38	-6.27	-0.36	1.45e-9	Menarche (age at onset);
CESC	cis	rs1707322	0.682	rs12037459	chr1:46094959	T/G	cg03146154	chr1:46216737	IPP	0.79	11.1	0.56	8.93e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs1059312	0.808	rs2170989	chr12:129291317	T/C	cg09035930	chr12:129282057	SLC15A4	-0.69	-9.15	-0.49	1.53e-17	Systemic lupus erythematosus;
CESC	cis	rs6740322	0.841	rs10211126	chr2:43551416	G/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.69	-7.3	-0.41	3.35e-12	Coronary artery disease;
CESC	cis	rs12530845	0.887	rs59400686	chr7:135360029	A/G	cg23117316	chr7:135346802	PL-5283	-0.44	-5.2	-0.3	3.94e-7	Red blood cell traits;
CESC	cis	rs4819052	0.851	rs4819046	chr21:46664955	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.9	13.19	0.63	7.09e-31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07013326	chr6:57037090	BAG2	0.6	7.43	0.42	1.5e-12	Gut microbiome composition (summer);
CESC	cis	rs4805272	0.512	rs17772319	chr19:29343064	T/A	cg12756686	chr19:29218302	NA	0.44	5.83	0.34	1.65e-8	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
CESC	cis	rs7607369	0.714	rs4674332	chr2:219604326	C/T	cg02176678	chr2:219576539	TTLL4	0.49	8.72	0.47	3.03e-16	Red blood cell count;Amyotrophic lateral sclerosis;
CESC	cis	rs3820068	0.581	rs1122386	chr1:15946877	C/T	cg13390004	chr1:15929781	NA	0.37	5.95	0.34	8.6e-9	Systolic blood pressure;
CESC	cis	rs8053891	0.615	rs2000999	chr16:72108093	G/A	cg16558253	chr16:72132732	DHX38	-0.53	-6.36	-0.36	8.8e-10	Coronary artery disease;
CESC	cis	rs4450798	0.691	rs62234793	chr3:13752409	G/A	cg05589046	chr3:13742034	LOC285375	0.37	5.52	0.32	8.18e-8	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs9814567	1.000	rs10935120	chr3:134233092	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.43	5.96	0.34	8.16e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs875971	0.825	rs66981195	chr7:66079035	C/A	cg18876405	chr7:65276391	NA	-0.53	-7.2	-0.4	6.41e-12	Aortic root size;
CESC	cis	rs9287719	0.745	rs4997810	chr2:10755540	T/A	cg00105475	chr2:10696890	NA	0.37	5.2	0.3	3.96e-7	Prostate cancer;
CESC	cis	rs7267979	0.966	rs2261784	chr20:25262396	G/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	18.61	0.75	5.11e-50	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs10256972	0.524	rs6945202	chr7:1116558	T/C	cg23978390	chr7:1156363	C7orf50	0.52	7.09	0.4	1.24e-11	Longevity;Endometriosis;
CESC	cis	rs2832191	0.791	rs2832198	chr21:30498240	C/T	cg08807101	chr21:30365312	RNF160	0.7	9.75	0.51	2.12e-19	Dental caries;
CESC	cis	rs12960472	0.577	rs13381537	chr18:52388332	A/C	cg12377874	chr18:52495404	RAB27B	-0.34	-5.07	-0.3	7.46e-7	Positive affect;
CESC	cis	rs3785574	0.927	rs2854160	chr17:61977248	C/T	cg11494091	chr17:61959527	GH2	0.4	5.65	0.33	4.03e-8	Height;
CESC	cis	rs1545257	0.505	rs12988810	chr2:24635093	G/T	cg06627628	chr2:24431161	ITSN2	-0.47	-5.73	-0.33	2.72e-8	Sjögren's syndrome;
CESC	cis	rs1005277	0.579	rs1780130	chr10:38485378	T/A	cg25517755	chr10:38738941	LOC399744	-0.49	-6.36	-0.36	9e-10	Extrinsic epigenetic age acceleration;
CESC	cis	rs875971	0.660	rs7807944	chr7:66087195	C/G	cg18876405	chr7:65276391	NA	-0.57	-7.55	-0.42	6.82e-13	Aortic root size;
CESC	cis	rs2235649	0.798	rs9932875	chr16:1848012	A/G	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.43	-5.3	-0.31	2.43e-7	Blood metabolite levels;
CESC	cis	rs875971	0.862	rs2420611	chr7:65999320	A/G	cg18252515	chr7:66147081	NA	-0.47	-6.08	-0.35	4.25e-9	Aortic root size;
CESC	cis	rs7191700	0.511	rs12923756	chr16:11359675	C/T	cg00044050	chr16:11439710	C16orf75	-0.43	-5.22	-0.31	3.67e-7	Multiple sclerosis;
CESC	cis	rs40363	0.720	rs4453493	chr16:3533881	T/C	cg00484396	chr16:3507460	NAT15	-0.5	-7.81	-0.43	1.35e-13	Tuberculosis;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg13775054	chr21:47648555	LSS;MCM3APAS	-0.44	-6.18	-0.35	2.46e-9	Fibrinogen levels;
CESC	trans	rs9354308	1.000	rs9342503	chr6:66565436	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.54	-6.56	-0.37	2.89e-10	Metabolite levels;
CESC	cis	rs611744	0.604	rs6469170	chr8:109305277	T/C	cg21045802	chr8:109455806	TTC35	0.57	7.08	0.4	1.33e-11	Dupuytren's disease;
CESC	cis	rs9486719	0.947	rs12210834	chr6:96890407	A/T	cg06623918	chr6:96969491	KIAA0776	-0.81	-8.29	-0.45	5.61e-15	Migraine;Coronary artery disease;
CESC	cis	rs7618915	0.501	rs7624716	chr3:52751534	T/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.72	0.38	1.12e-10	Bipolar disorder;
CESC	cis	rs4319547	0.656	rs9788145	chr12:122899522	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.52	-5.9	-0.34	1.12e-8	Body mass index;
CESC	cis	rs2033711	0.902	rs4801589	chr19:58953398	C/G	cg13877915	chr19:58951672	ZNF132	0.39	5.82	0.34	1.7e-8	Uric acid clearance;
CESC	cis	rs72634258	0.554	rs12061787	chr1:7888730	G/C	cg26816564	chr1:7831052	VAMP3	0.58	5.19	0.3	4.19e-7	Inflammatory bowel disease;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg00491963	chr11:57335356	UBE2L6	-0.52	-7.05	-0.4	1.58e-11	Ulcerative colitis;
CESC	cis	rs921968	0.565	rs6436071	chr2:219598041	A/T	cg02176678	chr2:219576539	TTLL4	-0.45	-8.06	-0.44	2.61e-14	Mean corpuscular hemoglobin concentration;
CESC	cis	rs6545883	0.965	rs7591345	chr2:61729641	T/A	cg15711740	chr2:61764176	XPO1	-0.41	-5.12	-0.3	5.86e-7	Tuberculosis;
CESC	cis	rs1499614	1.000	rs1267817	chr7:66110040	G/T	cg12463550	chr7:65579703	CRCP	0.75	5.85	0.34	1.42e-8	Gout;
CESC	cis	rs9649465	1.000	rs13224762	chr7:123370710	A/G	cg04330084	chr7:123175371	IQUB	-0.38	-5.18	-0.3	4.46e-7	Migraine;
CESC	cis	rs875971	0.522	rs709604	chr7:65497434	A/G	cg11764359	chr7:65958608	NA	-0.7	-9.03	-0.48	3.71e-17	Aortic root size;
CESC	cis	rs2836974	0.931	rs2989330	chr21:40716209	A/G	cg11890956	chr21:40555474	PSMG1	0.98	13.12	0.63	1.2e-30	Cognitive function;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02496295	chr4:2846155	ADD1	0.57	6.52	0.37	3.64e-10	Gut microbiome composition (summer);
CESC	cis	rs654950	0.776	rs2759252	chr1:42021854	G/A	cg06885757	chr1:42089581	HIVEP3	-0.63	-9.83	-0.52	1.23e-19	Airway imaging phenotypes;
CESC	cis	rs9611565	0.918	rs12484074	chr22:41752747	G/A	cg17376030	chr22:41985996	PMM1	0.63	6.54	0.37	3.06e-10	Vitiligo;
CESC	cis	rs559928	0.557	rs7122408	chr11:63898826	G/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.68	5.74	0.33	2.56e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CESC	trans	rs2272205	0.808	rs62226770	chr2:227954056	T/A	cg04768315	chr2:1898518	MYT1L	0.73	6.05	0.35	4.9e-9	Immune reponse to smallpox (secreted IFN-alpha);
CESC	cis	rs9894429	0.646	rs7220310	chr17:79606056	C/A	cg21984481	chr17:79567631	NPLOC4	-0.34	-5.34	-0.31	2.04e-7	Eye color traits;
CESC	cis	rs6460942	1.000	rs6460936	chr7:12404913	T/C	cg10578991	chr7:12443926	VWDE	-0.55	-5.86	-0.34	1.36e-8	Coronary artery disease;
CESC	cis	rs7202877	0.706	rs467780	chr16:75437138	A/G	cg04384234	chr16:75411784	CFDP1	0.49	5.74	0.33	2.54e-8	Type 2 diabetes;Type 1 diabetes;
CESC	cis	rs2072732	0.904	rs1138513	chr1:2976816	T/C	cg15211996	chr1:2936768	ACTRT2	0.35	6.02	0.35	5.73e-9	Plateletcrit;
CESC	cis	rs10504229	0.683	rs56192850	chr8:58135356	A/G	cg24829409	chr8:58192753	C8orf71	-0.58	-7.2	-0.4	6.31e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs9486719	0.741	rs2049927	chr6:96848958	C/G	cg06623918	chr6:96969491	KIAA0776	-0.65	-6.24	-0.36	1.73e-9	Migraine;Coronary artery disease;
CESC	cis	rs11958404	0.615	rs7737601	chr5:157448269	C/T	cg05962755	chr5:157440814	NA	-0.36	-5.31	-0.31	2.34e-7	IgG glycosylation;
CESC	cis	rs1707322	1.000	rs12403666	chr1:46431621	G/A	cg03146154	chr1:46216737	IPP	0.75	10.29	0.53	4.13e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs1218582	0.688	rs2135219	chr1:154857217	G/A	cg16680214	chr1:154839983	KCNN3	-0.44	-6.52	-0.37	3.58e-10	Prostate cancer;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg00531924	chr6:111279890	GTF3C6	-0.51	-6.73	-0.38	1.06e-10	Ulcerative colitis;
CESC	cis	rs4835473	0.715	rs4538428	chr4:144913904	A/G	cg25736465	chr4:144833511	NA	0.43	6.44	0.37	5.61e-10	Immature fraction of reticulocytes;
CESC	cis	rs2228479	0.717	rs62052210	chr16:89980158	A/G	cg06558623	chr16:89946397	TCF25	0.9	7.96	0.44	5.2e-14	Skin colour saturation;
CESC	trans	rs11098499	0.909	rs9994810	chr4:120381590	A/G	cg25214090	chr10:38739885	LOC399744	0.7	9.91	0.52	6.89e-20	Corneal astigmatism;
CESC	cis	rs35272691	1	rs35272691	chr17:38157841	T/C	cg17344932	chr17:38183730	MED24;SNORD124	0.61	9.08	0.49	2.6e-17	White blood cell count (neutrophil);
CESC	cis	rs7246657	0.941	rs7256130	chr19:37933981	T/C	cg23950597	chr19:37808831	NA	-0.54	-6.03	-0.35	5.49e-9	Coronary artery calcification;
CESC	cis	rs6933660	0.800	rs6931104	chr6:151786177	C/T	cg14416726	chr6:151773293	C6orf211;RMND1	-0.51	-6.95	-0.39	2.83e-11	Menarche (age at onset);
CESC	cis	rs875971	0.651	rs2420596	chr7:65915983	T/C	cg18252515	chr7:66147081	NA	-0.43	-5.6	-0.33	5.39e-8	Aortic root size;
CESC	cis	rs11098499	0.863	rs3775849	chr4:120450908	G/C	cg09307838	chr4:120376055	NA	0.91	12.54	0.61	1.24e-28	Corneal astigmatism;
CESC	cis	rs896854	0.715	rs12548874	chr8:95935164	A/C	cg23172400	chr8:95962367	TP53INP1	0.41	8.25	0.45	7.29e-15	Type 2 diabetes;
CESC	cis	rs7666738	0.830	rs35752787	chr4:98935202	G/A	cg05340658	chr4:99064831	C4orf37	0.82	12.54	0.61	1.29e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9902453	0.817	rs3115089	chr17:28031881	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.7	9.06	0.49	2.98e-17	Coffee consumption (cups per day);
CESC	cis	rs7202877	0.561	rs9933956	chr16:75362813	T/C	cg04384234	chr16:75411784	CFDP1	-0.49	-5.84	-0.34	1.51e-8	Type 2 diabetes;Type 1 diabetes;
CESC	cis	rs1801251	1.000	rs6746294	chr2:233583050	C/G	cg25237894	chr2:233734115	C2orf82	-0.52	-8.79	-0.48	1.92e-16	Coronary artery disease;
CESC	cis	rs3106136	0.609	rs10433970	chr4:95134165	C/G	cg11021082	chr4:95130006	SMARCAD1	-0.47	-6.43	-0.37	5.89e-10	Capecitabine sensitivity;
CESC	cis	rs2115536	0.606	rs8024713	chr15:80206958	C/G	cg00225070	chr15:80189496	MTHFS	0.56	7.0	0.4	2.07e-11	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00474734	chr12:53645975	MFSD5	0.6	6.82	0.39	6.14e-11	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.830	rs60007031	chr4:98824753	G/C	cg17366294	chr4:99064904	C4orf37	0.55	7.54	0.42	7.48e-13	Colonoscopy-negative controls vs population controls;
CESC	cis	rs72781680	0.644	rs72783627	chr2:24315685	A/C	cg08917208	chr2:24149416	ATAD2B	0.55	5.3	0.31	2.47e-7	Lymphocyte counts;
CESC	cis	rs4665809	1.000	rs11126375	chr2:26344787	G/A	cg22920501	chr2:26401640	FAM59B	-0.67	-8.09	-0.44	2.22e-14	Gut microbiome composition (summer);
CESC	cis	rs9303401	0.659	rs34468504	chr17:56648277	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.03	12.7	0.62	3.56e-29	Cognitive test performance;
CESC	cis	rs6444746	1.000	rs1797849	chr3:193511570	C/T	cg22553634	chr3:193489233	NA	-0.41	-5.06	-0.3	7.9e-7	Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
CESC	cis	rs6121246	0.523	rs6060286	chr20:30197663	C/A	cg13852791	chr20:30311386	BCL2L1	0.58	5.56	0.32	6.65e-8	Mean corpuscular hemoglobin;
CESC	cis	rs3747547	0.892	rs72724200	chr9:37952144	G/A	cg13774184	chr9:37916125	SHB	-0.72	-6.15	-0.35	2.81e-9	Metabolite levels (Dihydroxy docosatrienoic acid);
CESC	trans	rs1814175	0.676	rs1851859	chr11:49860405	A/T	cg15704280	chr7:45808275	SEPT13	-1.0	-18.48	-0.75	1.42e-49	Height;
CESC	cis	rs10504229	0.953	rs17805380	chr8:58171128	C/A	cg05313129	chr8:58192883	C8orf71	-0.55	-6.37	-0.36	8.42e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs7666738	0.830	rs36047842	chr4:99004902	C/A	cg05340658	chr4:99064831	C4orf37	0.8	12.44	0.61	2.83e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9322193	0.962	rs11155685	chr6:150102785	A/C	cg07701084	chr6:150067640	NUP43	0.42	5.78	0.33	2.07e-8	Lung cancer;
CESC	trans	rs9296661	0.522	rs6458776	chr6:51646459	C/T	cg15101985	chr10:85961501	PCDH21	-0.46	-6.03	-0.35	5.35e-9	Weight loss (gastric bypass surgery);
CESC	cis	rs7833790	0.724	rs72603871	chr8:82754460	C/G	cg07697082	chr8:82753677	SNX16	-0.37	-5.73	-0.33	2.67e-8	Diastolic blood pressure;
CESC	cis	rs9815354	1.000	rs9847975	chr3:41786904	A/G	cg03022575	chr3:42003672	ULK4	0.58	5.63	0.33	4.49e-8	Pulse pressure;Diastolic blood pressure;
CESC	trans	rs4843747	0.709	rs72818521	chr16:88058751	C/G	cg26811252	chr16:29126840	RRN3P2	0.74	9.8	0.52	1.53e-19	Menopause (age at onset);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg12713142	chr12:57081325	PTGES3	0.47	6.41	0.37	6.58e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs2439831	0.850	rs558656	chr15:43723514	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.79	11.53	0.58	3.33e-25	Lung cancer in ever smokers;
CESC	cis	rs4523957	0.583	rs2957926	chr17:2024030	C/T	cg16513277	chr17:2031491	SMG6	-0.71	-10.1	-0.53	1.62e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs9443189	0.570	rs567903	chr6:76327851	C/T	cg01950844	chr6:76311363	SENP6	0.9	9.72	0.51	2.65e-19	Prostate cancer;
CESC	cis	rs16937	0.711	rs6675633	chr1:205100480	G/A	cg00857998	chr1:205179979	DSTYK	0.39	5.2	0.3	4.05e-7	Schizophrenia;
CESC	cis	rs9309473	0.519	rs7598901	chr2:73675844	C/T	cg20560298	chr2:73613845	ALMS1	0.49	7.03	0.4	1.74e-11	Metabolite levels;
CESC	cis	rs35110281	0.715	rs2838320	chr21:44995037	A/G	cg04455712	chr21:45112962	RRP1B	0.39	5.85	0.34	1.46e-8	Mean corpuscular volume;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg05421555	chr15:85924342	AKAP13	0.47	6.3	0.36	1.25e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs986417	1.000	rs1956554	chr14:60963775	C/T	cg00859478	chr14:60978094	SIX6	-0.45	-5.11	-0.3	6.2e-7	Gut microbiota (bacterial taxa);
CESC	cis	rs2274273	0.615	rs67008693	chr14:55702693	T/C	cg04306507	chr14:55594613	LGALS3	0.31	5.2	0.3	3.97e-7	Protein biomarker;
CESC	cis	rs6964587	1.000	rs1859113	chr7:91679887	T/C	cg17063962	chr7:91808500	NA	0.59	8.15	0.45	1.48e-14	Breast cancer;
CESC	cis	rs798554	0.797	rs35957220	chr7:2812632	C/G	cg18446336	chr7:2847575	GNA12	-0.38	-5.62	-0.33	4.89e-8	Height;
CESC	cis	rs2228479	0.850	rs62052714	chr16:89857180	T/C	cg19635926	chr16:89946313	TCF25	0.67	5.08	0.3	7.19e-7	Skin colour saturation;
CESC	cis	rs1843834	0.858	rs2047136	chr2:225511361	A/T	cg22455342	chr2:225449267	CUL3	0.5	6.5	0.37	3.98e-10	IgE levels in asthmatics (D.p. specific);
CESC	cis	rs8078723	0.866	rs7502514	chr17:38188844	A/G	cg17467752	chr17:38218738	THRA	-0.69	-10.97	-0.56	2.57e-23	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CESC	cis	rs7937682	1.000	rs9734135	chr11:111536190	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.96	-15.3	-0.68	2.74e-38	Primary sclerosing cholangitis;
CESC	cis	rs7107174	1.000	rs10793302	chr11:78040961	C/T	cg02023728	chr11:77925099	USP35	0.4	5.69	0.33	3.36e-8	Testicular germ cell tumor;
CESC	cis	rs7582720	1.000	rs115396314	chr2:203721314	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.32	0.41	3.04e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs13191362	1.000	rs35754151	chr6:163074867	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.93	8.48	0.46	1.56e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs3820928	0.874	rs4144328	chr2:227790187	A/C	cg05526886	chr2:227700861	RHBDD1	-0.39	-5.07	-0.3	7.53e-7	Pulmonary function;
CESC	cis	rs12995491	0.731	rs55705009	chr2:88500718	T/G	cg14558114	chr2:88469736	THNSL2	-0.5	-7.28	-0.41	3.87e-12	Response to metformin (IC50);
CESC	cis	rs7666738	0.606	rs4637413	chr4:99088151	A/G	cg05340658	chr4:99064831	C4orf37	0.65	9.03	0.49	3.66e-17	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9322193	0.926	rs9285525	chr6:150122389	C/G	cg13206674	chr6:150067644	NUP43	0.41	5.78	0.33	2.05e-8	Lung cancer;
CESC	trans	rs11770686	0.967	rs4728289	chr7:75348505	C/T	cg06613775	chr12:88897441	KITLG	-0.36	-6.05	-0.35	4.84e-9	Essential tremor;
CESC	cis	rs17376456	1.000	rs13185608	chr5:93509688	T/G	cg21475434	chr5:93447410	FAM172A	0.9	7.77	0.43	1.68e-13	Diabetic retinopathy;
CESC	cis	rs17253792	0.822	rs79873916	chr14:56172631	G/C	cg01858014	chr14:56050164	KTN1	-0.97	-7.54	-0.42	7.36e-13	Putamen volume;
CESC	cis	rs7618915	0.570	rs11130319	chr3:52755592	A/T	cg07507251	chr3:52567010	NT5DC2	0.41	7.02	0.4	1.85e-11	Bipolar disorder;
CESC	cis	rs7772486	0.806	rs2253648	chr6:146199296	G/A	cg23711669	chr6:146136114	FBXO30	0.83	12.3	0.6	8.35e-28	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs3740713	1.000	rs73440634	chr11:18473546	T/A	cg23797887	chr11:18477753	LDHAL6A	-0.57	-5.81	-0.34	1.8e-8	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs9733	0.526	rs11204696	chr1:150658721	T/C	cg04414720	chr1:150670196	GOLPH3L	0.63	9.03	0.48	3.76e-17	Tonsillectomy;
CESC	trans	rs1667255	0.830	rs2034404	chr18:29156302	A/G	cg06193169	chr4:58030481	NA	0.41	6.01	0.35	6.13e-9	Retinol levels;
CESC	cis	rs10911363	0.592	rs2782411	chr1:183476929	G/A	cg09173681	chr1:183549694	NCF2	0.51	7.5	0.42	9.45e-13	Systemic lupus erythematosus;
CESC	cis	rs35110281	0.776	rs2838338	chr21:45075582	T/C	cg01579765	chr21:45077557	HSF2BP	-0.54	-9.11	-0.49	2.15e-17	Mean corpuscular volume;
CESC	cis	rs1799949	1.000	rs33994002	chr17:41328818	T/A	cg25072359	chr17:41440525	NA	0.48	6.52	0.37	3.45e-10	Menopause (age at onset);
CESC	cis	rs12541335	0.639	rs4871994	chr8:22206038	G/A	cg26039829	chr8:22132926	PIWIL2	0.37	5.63	0.33	4.57e-8	Hypertriglyceridemia;
CESC	cis	rs7116495	0.609	rs567026	chr11:71769952	C/T	cg10381502	chr11:71823885	C11orf51	1.1	7.06	0.4	1.43e-11	Severe influenza A (H1N1) infection;
CESC	cis	rs4566357	1.000	rs4536647	chr2:227921977	A/G	cg11843606	chr2:227700838	RHBDD1	-0.41	-5.27	-0.31	2.77e-7	Coronary artery disease;
CESC	cis	rs7546094	1.000	rs7554916	chr1:113123734	A/C	cg22162597	chr1:113214053	CAPZA1	0.37	5.67	0.33	3.64e-8	Platelet distribution width;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg15825501	chr1:936610	HES4	0.51	6.48	0.37	4.48e-10	Thyroid stimulating hormone;
CESC	cis	rs1775148	1	rs1775148	chr1:205757824	C/T	cg07157834	chr1:205819609	PM20D1	0.38	5.4	0.31	1.46e-7	Prostate cancer;
CESC	cis	rs12762955	0.507	rs7070724	chr10:1040138	C/T	cg18964960	chr10:1102726	WDR37	-0.43	-5.31	-0.31	2.28e-7	Response to angiotensin II receptor blocker therapy;
CESC	cis	rs6598955	0.724	rs10902731	chr1:26600793	A/G	cg04990556	chr1:26633338	UBXN11	-0.75	-10.67	-0.55	2.45e-22	Obesity-related traits;
CESC	cis	rs4835473	0.932	rs4835034	chr4:144742691	T/C	cg25736465	chr4:144833511	NA	-0.32	-5.07	-0.3	7.42e-7	Immature fraction of reticulocytes;
CESC	cis	rs9911578	0.933	rs2531726	chr17:56522533	C/T	cg05425664	chr17:57184151	TRIM37	0.46	6.47	0.37	4.75e-10	Intelligence (multi-trait analysis);
CESC	cis	rs889398	0.771	rs3790080	chr16:69902139	A/G	cg09409435	chr16:70099608	PDXDC2	0.39	5.03	0.3	9.19e-7	Body mass index;
CESC	cis	rs7998202	0.567	rs7982570	chr13:113370892	T/C	cg02820901	chr13:113351484	ATP11A	0.66	5.41	0.32	1.39e-7	Glycated hemoglobin levels;
CESC	cis	rs6582630	0.502	rs11181475	chr12:38348922	G/A	cg13010199	chr12:38710504	ALG10B	0.45	5.77	0.33	2.24e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs7223966	0.961	rs17631783	chr17:61687600	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.47	-5.26	-0.31	3e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs10979	1.000	rs1416205	chr6:143889397	T/C	cg25407410	chr6:143891975	LOC285740	-0.61	-9.14	-0.49	1.72e-17	Hypospadias;
CESC	cis	rs4243830	1.000	rs58415361	chr1:6592377	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	0.76	6.06	0.35	4.57e-9	Body mass index;
CESC	trans	rs875971	0.838	rs2173570	chr7:65762963	T/A	cg26939375	chr7:64535504	NA	-0.46	-6.12	-0.35	3.39e-9	Aortic root size;
CESC	cis	rs1670533	1.000	rs6812586	chr4:1069851	A/G	cg27284194	chr4:1044797	NA	0.45	5.73	0.33	2.78e-8	Recombination rate (females);
CESC	trans	rs877282	0.755	rs1769242	chr10:787896	T/C	cg22713356	chr15:30763199	NA	1.1	11.9	0.59	1.95e-26	Uric acid levels;
CESC	trans	rs1814175	0.588	rs1721994	chr11:49914050	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.43	-6.36	-0.36	8.98e-10	Height;
CESC	cis	rs1707322	0.721	rs12091503	chr1:46107868	T/C	cg03146154	chr1:46216737	IPP	0.82	11.48	0.58	4.81e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs6547741	1.000	rs10205364	chr2:27794233	C/T	cg27432699	chr2:27873401	GPN1	0.5	7.01	0.4	2.01e-11	Oral cavity cancer;
CESC	cis	rs2361718	0.933	rs8066452	chr17:78104080	A/G	cg06718696	chr17:78121285	EIF4A3	0.46	6.14	0.35	2.98e-9	Yeast infection;
CESC	cis	rs3820068	0.580	rs12747696	chr1:16002978	A/G	cg17385448	chr1:15911702	AGMAT	0.4	6.13	0.35	3.14e-9	Systolic blood pressure;
CESC	cis	rs754466	0.580	rs2579177	chr10:79529245	C/T	cg17075019	chr10:79541650	NA	-0.82	-12.28	-0.6	9.46e-28	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs9527	0.545	rs11191602	chr10:104954219	C/T	cg04362960	chr10:104952993	NT5C2	0.45	5.71	0.33	2.98e-8	Arsenic metabolism;
CESC	trans	rs2115172	0.836	rs4835799	chr5:122762229	A/G	cg23104823	chr14:45553408	PRPF39	0.47	6.54	0.37	3.16e-10	Weight;
CESC	cis	rs5750830	0.621	rs743838	chr22:39824707	T/G	cg02038168	chr22:39784481	NA	-0.61	-7.35	-0.41	2.48e-12	Intelligence (multi-trait analysis);
CESC	cis	rs9291683	0.507	rs3775940	chr4:10025163	A/T	cg02734326	chr4:10020555	SLC2A9	0.4	5.62	0.33	4.89e-8	Bone mineral density;
CESC	cis	rs7762018	1.000	rs7762018	chr6:170113244	G/T	cg05834625	chr6:170176447	C6orf70	0.55	6.53	0.37	3.38e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs4713118	0.527	rs9461433	chr6:28095172	C/T	cg19592336	chr6:28129416	ZNF389	0.6	8.08	0.44	2.36e-14	Parkinson's disease;
CESC	cis	rs9611565	0.649	rs9623450	chr22:42175231	G/A	cg06481639	chr22:41940642	POLR3H	0.47	5.28	0.31	2.67e-7	Vitiligo;
CESC	cis	rs8062405	1.000	rs62037369	chr16:28883841	C/T	cg05966235	chr16:28915196	ATP2A1	0.34	5.03	0.3	9.05e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs708547	1.000	rs2412770	chr4:57794660	C/T	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.53	-5.44	-0.32	1.23e-7	Response to bleomycin (chromatid breaks);
CESC	cis	rs1448094	0.511	rs17279261	chr12:86162714	C/T	cg02569458	chr12:86230093	RASSF9	0.54	8.12	0.45	1.72e-14	Major depressive disorder;
CESC	cis	rs875971	0.522	rs2949690	chr7:65483242	C/T	cg18876405	chr7:65276391	NA	-0.67	-9.44	-0.5	1.99e-18	Aortic root size;
CESC	cis	rs1775715	0.675	rs2808085	chr10:32148599	C/T	cg18675610	chr10:32216311	ARHGAP12	0.35	5.48	0.32	1.01e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs12136530	0.774	rs4912094	chr1:19762466	A/G	cg01832549	chr1:19774989	CAPZB	0.46	6.48	0.37	4.46e-10	Lead levels in blood;
CESC	cis	rs6088590	1.000	rs6119524	chr20:33373813	C/T	cg24642439	chr20:33292090	TP53INP2	0.84	11.75	0.59	6.33e-26	Coronary artery disease;
CESC	cis	rs644799	0.625	rs1255175	chr11:95471186	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.5	6.94	0.39	2.96e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs637571	0.584	rs594689	chr11:65635559	G/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.68	-8.47	-0.46	1.66e-15	Eosinophil percentage of white cells;
CESC	cis	rs8031584	0.678	rs36047941	chr15:31159235	A/G	cg14298792	chr15:30685198	CHRFAM7A	-0.46	-5.53	-0.32	7.81e-8	Huntington's disease progression;
CESC	cis	rs9611565	0.525	rs9611549	chr22:41705909	C/G	cg06481639	chr22:41940642	POLR3H	-0.52	-5.74	-0.33	2.57e-8	Vitiligo;
CESC	cis	rs6088590	1.000	rs1998028	chr20:33344595	A/T	cg08999081	chr20:33150536	PIGU	0.59	8.89	0.48	9.62e-17	Coronary artery disease;
CESC	cis	rs80033912	0.640	rs6785832	chr3:49224316	C/T	cg07636037	chr3:49044803	WDR6	0.48	5.8	0.34	1.89e-8	Intelligence (multi-trait analysis);
CESC	trans	rs10254160	1.000	rs2396535	chr7:112055321	A/T	cg27408540	chr10:25465171	LOC100128811;GPR158	-0.64	-6.29	-0.36	1.3e-9	Parental extreme longevity (95 years and older);
CESC	cis	rs6493487	0.512	rs71471584	chr15:51261229	T/A	cg02338191	chr15:51200825	AP4E1	0.61	5.58	0.32	6.04e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg03188948	chr7:1209495	NA	0.7	6.62	0.38	2.02e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs9916302	0.595	rs4795371	chr17:37636695	T/G	cg19468946	chr17:37922297	IKZF3	-0.39	-5.05	-0.3	8.23e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs6942756	1.000	rs56026912	chr7:128913937	A/G	cg02491457	chr7:128862824	NA	-0.69	-9.65	-0.51	4.48e-19	White matter hyperintensity burden;
CESC	cis	rs7223966	1.000	rs992416	chr17:61745905	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.54	6.44	0.37	5.7e-10	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs116095464	0.558	rs6555058	chr5:226376	C/T	cg12570787	chr5:219185	SDHA;CCDC127	-0.51	-5.42	-0.32	1.37e-7	Breast cancer;
CESC	cis	rs17253792	0.749	rs17747301	chr14:56125030	C/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.83	5.86	0.34	1.35e-8	Putamen volume;
CESC	trans	rs7824557	0.564	rs4631424	chr8:11236809	T/C	cg06636001	chr8:8085503	FLJ10661	-0.49	-6.15	-0.35	2.9e-9	Retinal vascular caliber;
CESC	trans	rs208520	0.690	rs207119	chr6:66786408	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.0	-12.83	-0.62	1.2e-29	Exhaled nitric oxide output;
CESC	cis	rs561341	0.883	rs7406056	chr17:30220224	C/T	cg12193833	chr17:30244370	NA	-0.58	-6.06	-0.35	4.77e-9	Hip circumference adjusted for BMI;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg12581730	chr6:170599861	DLL1	-0.5	-6.95	-0.39	2.85e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs5753618	0.583	rs5749270	chr22:31812853	C/T	cg13145458	chr22:31556086	RNF185	-0.5	-5.96	-0.34	7.96e-9	Colorectal cancer;
CESC	cis	rs13191362	0.507	rs2023036	chr6:163122736	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.56	6.72	0.38	1.09e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs6547741	1.000	rs6750943	chr2:27777904	T/G	cg21248554	chr2:27665150	KRTCAP3	0.24	5.06	0.3	7.83e-7	Oral cavity cancer;
CESC	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg18591801	chr3:52553433	STAB1	-0.3	-5.69	-0.33	3.39e-8	Electroencephalogram traits;
CESC	cis	rs5769765	1.000	rs910800	chr22:50278642	C/T	cg02269571	chr22:50332266	NA	0.46	6.28	0.36	1.39e-9	Schizophrenia;
CESC	cis	rs1372520	0.684	rs2197120	chr4:90729602	A/G	cg15133208	chr4:90757351	SNCA	-0.43	-5.79	-0.33	2.02e-8	Neuroticism;
CESC	cis	rs73206853	0.609	rs12311902	chr12:110883799	T/C	cg12870014	chr12:110450643	ANKRD13A	0.62	5.43	0.32	1.25e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs950776	0.518	rs2869055	chr15:78822388	G/C	cg06917634	chr15:78832804	PSMA4	-0.7	-10.61	-0.55	3.8e-22	Sudden cardiac arrest;
CESC	cis	rs17826219	0.706	rs8075357	chr17:29057197	A/C	cg19761014	chr17:28927070	LRRC37B2	0.76	6.25	0.36	1.66e-9	Body mass index;
CESC	trans	rs9467711	0.606	rs67509210	chr6:26354100	G/T	cg06606381	chr12:133084897	FBRSL1	-0.77	-7.0	-0.4	2.04e-11	Autism spectrum disorder or schizophrenia;
CESC	cis	rs3820068	0.705	rs11587541	chr1:15899478	T/C	cg18192808	chr1:15853278	DNAJC16	0.43	5.13	0.3	5.68e-7	Systolic blood pressure;
CESC	cis	rs7917772	0.536	rs4919667	chr10:104426011	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.55	-7.12	-0.4	1e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs7618915	0.547	rs11130311	chr3:52675005	T/C	cg05564831	chr3:52568323	NT5DC2	0.45	6.91	0.39	3.55e-11	Bipolar disorder;
CESC	cis	rs4727027	0.933	rs2158633	chr7:148832652	C/T	cg23583168	chr7:148888333	NA	-0.78	-12.15	-0.6	2.62e-27	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	trans	rs916888	0.779	rs199498	chr17:44865603	A/G	cg22433210	chr17:43662623	NA	0.63	7.4	0.41	1.85e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs6912958	0.754	rs1051131	chr6:88221546	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-5.11	-0.3	6.11e-7	Monocyte percentage of white cells;
CESC	trans	rs11098499	0.863	rs7657849	chr4:120455494	T/C	cg25214090	chr10:38739885	LOC399744	0.7	9.62	0.51	5.47e-19	Corneal astigmatism;
CESC	cis	rs9287719	0.967	rs759402	chr2:10729554	A/T	cg02196655	chr2:10830764	NOL10	-0.36	-5.57	-0.32	6.1e-8	Prostate cancer;
CESC	cis	rs2549003	1.000	rs2548999	chr5:131831058	G/T	cg21138405	chr5:131827807	IRF1	-0.58	-10.06	-0.53	2.22e-20	Asthma (sex interaction);
CESC	cis	rs4450798	0.793	rs4640541	chr3:13758997	C/G	cg23332027	chr3:13681764	NA	-0.38	-5.3	-0.31	2.38e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs116095464	0.558	rs10065239	chr5:275288	C/T	cg22857025	chr5:266934	NA	-1.3	-13.99	-0.65	1.1e-33	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24686684	chr20:48330546	B4GALT5	0.68	8.3	0.45	5.45e-15	Gut microbiome composition (summer);
CESC	cis	rs7267979	1.000	rs2856	chr20:25433536	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.86	17.96	0.74	1e-47	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs2288073	0.801	rs6757275	chr2:24375230	A/G	cg20701182	chr2:24300061	SF3B14	0.45	5.6	0.33	5.39e-8	Venous thromboembolism (SNP x SNP interaction);
CESC	cis	rs1552244	0.882	rs9757159	chr3:10039166	C/T	cg00149659	chr3:10157352	C3orf10	0.7	8.31	0.45	5.08e-15	Alzheimer's disease;
CESC	cis	rs853679	0.517	rs9283884	chr6:28135660	C/G	cg23281280	chr6:28129359	ZNF389	-0.56	-7.45	-0.42	1.3e-12	Depression;
CESC	cis	rs425277	0.628	rs3128340	chr1:2047496	C/G	cg23803603	chr1:2058230	PRKCZ	-0.35	-5.8	-0.34	1.91e-8	Height;
CESC	cis	rs763121	0.626	rs5757236	chr22:39073824	T/C	cg06022373	chr22:39101656	GTPBP1	0.89	14.42	0.66	3.47e-35	Menopause (age at onset);
CESC	cis	rs2380220	0.574	rs7766765	chr6:95997362	G/A	cg23517279	chr6:96025343	MANEA	0.54	5.8	0.34	1.85e-8	Behavioural disinhibition (generation interaction);
CESC	cis	rs11122272	0.735	rs722302	chr1:231480152	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-7.23	-0.41	5.18e-12	Hemoglobin concentration;
CESC	cis	rs6032067	0.929	rs6032049	chr20:43825556	C/T	cg11264863	chr20:43835661	SEMG1	0.49	5.29	0.31	2.5e-7	Blood protein levels;
CESC	cis	rs801193	0.636	rs2659895	chr7:66196471	C/A	cg10691866	chr7:65817282	TPST1	-0.35	-5.95	-0.34	8.45e-9	Aortic root size;
CESC	cis	rs9314323	0.524	rs7816609	chr8:26202482	A/C	cg11498726	chr8:26250323	BNIP3L	-0.39	-5.45	-0.32	1.16e-7	Red cell distribution width;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22239605	chr11:237153	PSMD13;SIRT3	0.53	6.36	0.36	8.7e-10	Gut microbiome composition (summer);
CESC	cis	rs941873	0.900	rs4979861	chr10:81131595	A/G	cg08514558	chr10:81106712	PPIF	0.39	6.73	0.38	1.05e-10	Height;
CESC	cis	rs9291683	0.595	rs11722930	chr4:10035454	G/A	cg02734326	chr4:10020555	SLC2A9	0.49	6.87	0.39	4.48e-11	Bone mineral density;
CESC	trans	rs12681287	0.547	rs6998303	chr8:87510185	T/C	cg27317242	chr8:23145699	R3HCC1	-0.53	-6.34	-0.36	9.67e-10	Caudate activity during reward;
CESC	cis	rs116095464	1.000	rs3777237	chr5:307641	C/T	cg22496380	chr5:211416	CCDC127	-0.9	-5.5	-0.32	9.1e-8	Breast cancer;
CESC	cis	rs853679	0.517	rs9380047	chr6:28037893	G/T	cg08968635	chr6:28129556	ZNF389	0.38	5.11	0.3	6.32e-7	Depression;
CESC	cis	rs79349575	0.783	rs4294857	chr17:46983391	G/A	cg16584676	chr17:46985605	UBE2Z	0.53	6.6	0.38	2.25e-10	Type 2 diabetes;
CESC	cis	rs1401999	0.714	rs1000002	chr3:183635768	A/G	cg01324343	chr3:183735012	ABCC5	-0.46	-8.85	-0.48	1.26e-16	Anterior chamber depth;
CESC	cis	rs4148883	0.675	rs28762430	chr4:100119257	C/A	cg12011299	chr4:100065546	ADH4	0.66	9.76	0.51	2.03e-19	Alcohol dependence;
CESC	cis	rs12479064	0.724	rs11885942	chr2:100004165	A/G	cg09787394	chr2:99771194	LIPT1;TSGA10	0.49	5.13	0.3	5.48e-7	Chronic sinus infection;
CESC	cis	rs1552244	0.510	rs13075308	chr3:10034925	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	10.84	0.55	6.79e-23	Alzheimer's disease;
CESC	cis	rs2836950	0.565	rs8134214	chr21:40542367	A/C	cg17971929	chr21:40555470	PSMG1	-0.6	-8.02	-0.44	3.31e-14	Menarche (age at onset);
CESC	cis	rs1153858	1.000	rs12437840	chr15:45669055	C/A	cg21132104	chr15:45694354	SPATA5L1	0.86	11.62	0.58	1.67e-25	Homoarginine levels;
CESC	cis	rs4319547	0.698	rs4039670	chr12:122822655	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.49	-5.77	-0.33	2.24e-8	Body mass index;
CESC	cis	rs10492096	0.947	rs10774435	chr12:6616120	G/T	cg13857086	chr12:6580257	VAMP1	0.55	5.88	0.34	1.23e-8	Hip geometry;
CESC	cis	rs473651	0.935	rs10170056	chr2:239339291	G/C	cg18131467	chr2:239335373	ASB1	0.94	14.13	0.66	3.57e-34	Multiple system atrophy;
CESC	cis	rs7537660	1.000	rs10888255	chr1:248004687	C/G	cg12080717	chr1:248004886	OR11L1	0.44	5.39	0.31	1.58e-7	Platelet distribution width;
CESC	cis	rs7116495	0.609	rs4387373	chr11:71774908	A/G	cg10381502	chr11:71823885	C11orf51	-1.14	-7.14	-0.4	8.75e-12	Severe influenza A (H1N1) infection;
CESC	cis	rs11785400	0.793	rs34875149	chr8:143736131	G/A	cg10596483	chr8:143751796	JRK	0.42	5.26	0.31	3e-7	Schizophrenia;
CESC	cis	rs7829975	0.511	rs1401390	chr8:8136410	C/T	cg06636001	chr8:8085503	FLJ10661	0.61	7.61	0.42	4.92e-13	Mood instability;
CESC	cis	rs1218582	0.772	rs2102423	chr1:154916068	A/G	cg03351412	chr1:154909251	PMVK	0.68	9.0	0.48	4.57e-17	Prostate cancer;
CESC	cis	rs7267979	1.000	rs2258563	chr20:25273435	C/T	cg08601574	chr20:25228251	PYGB	0.38	5.57	0.32	6.36e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs929354	0.742	rs10274687	chr7:156933181	T/G	cg05182265	chr7:156933206	UBE3C	-0.49	-7.04	-0.4	1.69e-11	Body mass index;
CESC	cis	rs1348850	0.598	rs12616259	chr2:178503803	C/T	cg22681709	chr2:178499509	PDE11A	-0.56	-8.81	-0.48	1.64e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs4843747	0.671	rs4075998	chr16:88106776	G/A	cg06374794	chr16:88002281	BANP	0.39	5.16	0.3	4.78e-7	Menopause (age at onset);
CESC	cis	rs7236492	0.872	rs78226032	chr18:77230822	G/A	cg15644404	chr18:77186268	NFATC1	-0.73	-5.57	-0.32	6.11e-8	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs4836694	0.574	rs3824542	chr9:132936132	C/T	cg13414629	chr9:132935646	FREQ	0.47	5.62	0.33	4.93e-8	Alzheimer's disease (cognitive decline);
CESC	cis	rs7618915	0.547	rs62255362	chr3:52699741	C/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	7.04	0.4	1.62e-11	Bipolar disorder;
CESC	cis	rs4689592	0.523	rs3857179	chr4:7070496	T/A	cg26116260	chr4:7069785	GRPEL1	0.99	14.18	0.66	2.35e-34	Monocyte percentage of white cells;
CESC	cis	rs6740322	0.857	rs11690012	chr2:43542480	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-6.93	-0.39	3.18e-11	Coronary artery disease;
CESC	cis	rs4722166	0.630	rs7808457	chr7:22798265	A/T	cg05265849	chr7:22767390	IL6	-0.46	-5.3	-0.31	2.45e-7	Lung cancer;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg04225510	chr10:12237758	CDC123;NUDT5	0.46	6.2	0.36	2.12e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs4594175	0.962	rs72688734	chr14:51634618	T/C	cg23942311	chr14:51606299	NA	0.35	5.34	0.31	2.02e-7	Cancer;
CESC	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg11494091	chr17:61959527	GH2	0.73	12.52	0.61	1.41e-28	Prudent dietary pattern;
CESC	cis	rs2502731	1.000	rs2502731	chr9:130976557	A/G	cg09976142	chr9:130955436	CIZ1	-0.53	-9.51	-0.5	1.23e-18	Attention deficit hyperactivity disorder;
CESC	cis	rs8060686	0.920	rs73594581	chr16:67955554	G/A	cg26727032	chr16:67993705	SLC12A4	-0.58	-6.75	-0.38	9.09e-11	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs597539	0.689	rs596874	chr11:68630874	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	-0.71	-8.9	-0.48	8.99e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg11494091	chr17:61959527	GH2	0.75	13.5	0.64	5.7e-32	Prudent dietary pattern;
CESC	cis	rs7107174	1.000	rs2511175	chr11:77975081	A/G	cg02023728	chr11:77925099	USP35	0.5	6.66	0.38	1.61e-10	Testicular germ cell tumor;
CESC	trans	rs801193	0.773	rs801207	chr7:66020590	T/C	cg26939375	chr7:64535504	NA	-0.53	-7.31	-0.41	3.22e-12	Aortic root size;
CESC	cis	rs7267979	1.000	rs6050609	chr20:25411751	A/G	cg08601574	chr20:25228251	PYGB	-0.38	-5.64	-0.33	4.38e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs36051895	0.623	rs17426903	chr9:5203292	A/C	cg02405213	chr9:5042618	JAK2	-0.48	-5.39	-0.31	1.55e-7	Pediatric autoimmune diseases;
CESC	cis	rs4713118	0.586	rs6905516	chr6:28086478	A/G	cg20151795	chr6:28129481	ZNF389	0.45	5.87	0.34	1.29e-8	Parkinson's disease;
CESC	trans	rs765547	1.000	rs1822200	chr8:19852829	G/T	cg12649343	chr22:47023005	GRAMD4	-0.3	-6.12	-0.35	3.27e-9	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
CESC	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg03452623	chr4:187889614	NA	-0.88	-16.16	-0.7	2.39e-41	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2797160	1.000	rs2747714	chr6:126007620	A/G	cg05901451	chr6:126070800	HEY2	0.45	6.53	0.37	3.43e-10	Endometrial cancer;
CESC	cis	rs9815354	1.000	rs1717020	chr3:41981490	A/C	cg03022575	chr3:42003672	ULK4	0.48	5.53	0.32	7.85e-8	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs7178572	0.568	rs62008452	chr15:77591007	A/G	cg22256960	chr15:77711686	NA	-0.53	-6.6	-0.38	2.26e-10	Type 2 diabetes;
CESC	cis	rs3540	0.533	rs11633692	chr15:91056043	G/A	cg22089800	chr15:90895588	ZNF774	-0.61	-8.11	-0.45	1.93e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs13108904	0.557	rs1250095	chr4:1239312	C/T	cg20887711	chr4:1340912	KIAA1530	-0.63	-8.5	-0.46	1.36e-15	Obesity-related traits;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg14136810	chr15:40213326	GPR176	-0.44	-6.43	-0.37	6.05e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs68170813	0.559	rs17427849	chr7:106864237	A/G	cg02696742	chr7:106810147	HBP1	-0.54	-5.33	-0.31	2.13e-7	Coronary artery disease;
CESC	cis	rs7927771	0.864	rs7107726	chr11:47429245	T/A	cg20307385	chr11:47447363	PSMC3	-0.63	-7.61	-0.42	4.79e-13	Subjective well-being;
CESC	cis	rs6831352	0.819	rs2851274	chr4:100025866	G/C	cg13256891	chr4:100009986	ADH5	0.68	8.19	0.45	1.11e-14	Alcohol dependence;
CESC	cis	rs933688	1.000	rs6452953	chr5:90723034	T/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.91	11.8	0.59	4.22e-26	Smoking behavior;
CESC	cis	rs1538970	0.924	rs6657284	chr1:45879088	T/C	cg24296786	chr1:45957014	TESK2	-0.45	-5.22	-0.31	3.64e-7	Platelet count;
CESC	cis	rs2742234	0.541	rs11238490	chr10:43747598	G/A	cg15436174	chr10:43711423	RASGEF1A	0.47	5.47	0.32	1.07e-7	Hirschsprung disease;
CESC	cis	rs7618915	0.501	rs12486554	chr3:52742537	A/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.33	5.8	0.34	1.87e-8	Bipolar disorder;
CESC	cis	rs765787	0.530	rs13329228	chr15:45533017	C/T	cg24006582	chr15:45444508	DUOX1	-0.55	-6.74	-0.38	9.58e-11	Uric acid levels;
CESC	cis	rs8077889	0.750	rs231541	chr17:41941788	C/G	cg26893861	chr17:41843967	DUSP3	-0.78	-7.56	-0.42	6.73e-13	Triglycerides;
CESC	cis	rs4665809	0.556	rs4665322	chr2:26434605	C/G	cg08470875	chr2:26401718	FAM59B	-0.77	-8.41	-0.46	2.62e-15	Gut microbiome composition (summer);
CESC	cis	rs9649213	0.574	rs62478236	chr7:98030377	G/A	cg21770322	chr7:97807741	LMTK2	0.58	8.76	0.47	2.36e-16	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs6933660	0.720	rs6936936	chr6:151753395	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.86	14.41	0.66	3.84e-35	Menarche (age at onset);
CESC	cis	rs7264396	0.790	rs6058290	chr20:34247702	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.86	-11.74	-0.58	6.79e-26	Total cholesterol levels;
CESC	cis	rs3892630	0.878	rs114224536	chr19:33211232	A/G	cg22980127	chr19:33182716	NUDT19	1.06	11.41	0.57	8.86e-25	Red blood cell traits;
CESC	cis	rs10504229	0.683	rs16921810	chr8:58106067	A/G	cg02725872	chr8:58115012	NA	-0.43	-6.81	-0.39	6.53e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs3768617	0.811	rs4350171	chr1:182982148	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.66	9.03	0.49	3.66e-17	Fuchs's corneal dystrophy;
CESC	cis	rs853679	0.517	rs9380057	chr6:28104634	G/T	cg23161317	chr6:28129485	ZNF389	0.51	6.63	0.38	1.85e-10	Depression;
CESC	cis	rs6500602	0.564	rs3747584	chr16:4516092	A/G	cg08645402	chr16:4508243	NA	0.43	5.99	0.35	6.91e-9	Schizophrenia;
CESC	cis	rs17253792	0.822	rs10129890	chr14:56040413	A/T	cg01858014	chr14:56050164	KTN1	-0.88	-7.51	-0.42	9.24e-13	Putamen volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09431544	chr19:14629187	DNAJB1	0.64	7.18	0.4	7.15e-12	Gut microbiome composition (summer);
CESC	cis	rs9815354	1.000	rs6790732	chr3:41864872	C/T	cg03022575	chr3:42003672	ULK4	0.46	5.29	0.31	2.57e-7	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs9291683	0.507	rs3796837	chr4:10011321	C/G	cg02734326	chr4:10020555	SLC2A9	0.43	5.84	0.34	1.49e-8	Bone mineral density;
CESC	trans	rs2018683	0.677	rs12540529	chr7:28969384	A/G	cg19402173	chr7:128379420	CALU	-0.53	-7.19	-0.4	6.57e-12	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CESC	cis	rs258892	0.895	rs11953055	chr5:72051503	C/T	cg21869765	chr5:72125136	TNPO1	-0.4	-5.26	-0.31	2.97e-7	Small cell lung carcinoma;
CESC	cis	rs1008375	0.897	rs67455495	chr4:17665238	A/T	cg02297831	chr4:17616191	MED28	-0.53	-6.06	-0.35	4.65e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	trans	rs7618501	0.573	rs2624824	chr3:50088266	T/C	cg21659725	chr3:3221576	CRBN	-0.5	-7.03	-0.4	1.79e-11	Intelligence (multi-trait analysis);
CESC	trans	rs17158675	0.793	rs73380806	chr7:83769789	G/A	cg02484411	chr2:493514	NA	-0.76	-6.02	-0.35	5.94e-9	Obesity-related traits;
CESC	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg07167872	chr1:205819463	PM20D1	0.75	12.22	0.6	1.55e-27	Menarche (age at onset);
CESC	cis	rs896854	0.517	rs1011796	chr8:95951273	A/G	cg23172400	chr8:95962367	TP53INP1	0.42	7.51	0.42	8.96e-13	Type 2 diabetes;
CESC	cis	rs2762353	0.595	rs9467591	chr6:25742699	C/T	cg12310025	chr6:25882481	NA	-0.55	-8.88	-0.48	1.07e-16	Blood metabolite levels;
CESC	cis	rs2251381	0.750	rs2251087	chr21:30527999	C/T	cg24692254	chr21:30365293	RNF160	0.78	10.6	0.55	4.11e-22	Selective IgA deficiency;
CESC	cis	rs875971	0.522	rs56028712	chr7:65466565	C/T	cg06456125	chr7:65229604	NA	0.46	6.03	0.35	5.44e-9	Aortic root size;
CESC	cis	rs4819052	0.851	rs914218	chr21:46698445	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.75	9.96	0.52	4.77e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs7618501	0.602	rs2624816	chr3:50117312	T/G	cg24110177	chr3:50126178	RBM5	0.52	7.23	0.41	5.03e-12	Intelligence (multi-trait analysis);
CESC	trans	rs61931739	0.500	rs11053261	chr12:34530810	C/T	cg13010199	chr12:38710504	ALG10B	0.51	6.58	0.37	2.47e-10	Morning vs. evening chronotype;
CESC	cis	rs561341	1.000	rs7216102	chr17:30259450	A/G	cg13647721	chr17:30228624	UTP6	0.49	5.11	0.3	6.17e-7	Hip circumference adjusted for BMI;
CESC	cis	rs56091001	0.528	rs9616387	chr22:50313219	G/A	cg02269571	chr22:50332266	NA	-0.83	-7.16	-0.4	8.03e-12	Acne (severe);
CESC	trans	rs7980799	0.905	rs4244865	chr12:33511917	C/T	cg26384229	chr12:38710491	ALG10B	-0.47	-6.4	-0.37	6.93e-10	Heart rate;Heart rate variability traits (RMSSD);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23325670	chr19:17337031	OCEL1	0.61	6.92	0.39	3.35e-11	Gut microbiome composition (summer);
CESC	cis	rs2243480	1.000	rs316327	chr7:65609201	G/T	cg18252515	chr7:66147081	NA	1.31	12.94	0.62	5.13e-30	Diabetic kidney disease;
CESC	cis	rs1707322	1.000	rs10890353	chr1:46298383	G/T	cg05343316	chr1:45956843	TESK2	0.41	5.05	0.3	8.05e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs4665809	0.590	rs4665840	chr2:26444962	C/T	cg26314531	chr2:26401878	FAM59B	-0.85	-9.04	-0.49	3.44e-17	Gut microbiome composition (summer);
CESC	cis	rs7582720	0.943	rs72934734	chr2:203739970	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.32	0.41	3.04e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs6460942	1.000	rs62448566	chr7:12403662	G/A	cg13733410	chr7:12443478	VWDE	-0.53	-5.33	-0.31	2.12e-7	Coronary artery disease;
CESC	cis	rs2040771	0.804	rs7286849	chr22:19223579	C/A	cg02655711	chr22:19163373	SLC25A1	0.41	6.03	0.35	5.51e-9	Metabolite levels (small molecules and protein measures);
CESC	cis	rs938554	0.784	rs13131257	chr4:9981889	T/C	cg00071950	chr4:10020882	SLC2A9	0.47	5.64	0.33	4.32e-8	Blood metabolite levels;
CESC	cis	rs2760061	0.599	rs644794	chr1:228148670	T/C	cg01973587	chr1:228161476	NA	0.4	6.22	0.36	1.97e-9	Diastolic blood pressure;
CESC	trans	rs561341	0.883	rs1034626	chr17:30219500	C/G	cg20587970	chr11:113659929	NA	1.0	12.42	0.61	3.24e-28	Hip circumference adjusted for BMI;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg22829908	chr10:21814466	C10orf140	0.46	6.34	0.36	9.92e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs9916302	0.851	rs12936646	chr17:37647450	A/T	cg07936489	chr17:37558343	FBXL20	-0.8	-11.95	-0.59	1.31e-26	Glomerular filtration rate (creatinine);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg09010904	chr3:51573036	NA	-0.43	-6.26	-0.36	1.54e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs2070997	0.607	rs11244147	chr9:133677168	T/G	cg11464064	chr9:133710261	ABL1	0.61	7.01	0.4	2e-11	Response to amphetamines;
CESC	cis	rs736408	0.521	rs13074853	chr3:52779801	T/C	cg17372223	chr3:52568218	NT5DC2	0.43	6.51	0.37	3.75e-10	Bipolar disorder;
CESC	cis	rs6964587	0.692	rs4729018	chr7:91644613	C/T	cg01689657	chr7:91764605	CYP51A1	0.26	5.04	0.3	8.66e-7	Breast cancer;
CESC	cis	rs7811142	0.562	rs7786844	chr7:99934008	T/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.85	9.33	0.5	4.33e-18	Platelet count;
CESC	cis	rs1348850	0.526	rs10930802	chr2:178460095	A/G	cg23306229	chr2:178417860	TTC30B	0.73	6.71	0.38	1.2e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs9911578	1.000	rs1057068	chr17:56598439	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	-0.39	-5.05	-0.3	8.12e-7	Intelligence (multi-trait analysis);
CESC	cis	rs896854	0.967	rs896853	chr8:95960855	G/C	cg09323728	chr8:95962352	TP53INP1	-0.44	-10.13	-0.53	1.37e-20	Type 2 diabetes;
CESC	cis	rs7512552	0.839	rs11587575	chr1:150451863	T/C	cg15654264	chr1:150340011	RPRD2	0.39	5.09	0.3	6.71e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs6496667	0.779	rs8041401	chr15:90958545	A/G	cg13834112	chr15:90361639	NA	0.39	5.06	0.3	7.7300000000000005e-07	Rheumatoid arthritis;
CESC	cis	rs2243480	1.000	rs458291	chr7:65520479	C/A	cg25894440	chr7:65020034	NA	-0.61	-5.3	-0.31	2.42e-7	Diabetic kidney disease;
CESC	cis	rs8044868	0.530	rs12446480	chr16:72056757	A/G	cg01557791	chr16:72042693	DHODH	-0.46	-6.39	-0.37	7.23e-10	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CESC	cis	rs4722166	0.630	rs6461667	chr7:22796743	A/G	cg05472934	chr7:22766657	IL6	0.85	10.24	0.53	6.04e-21	Lung cancer;
CESC	trans	rs61931739	0.534	rs35056575	chr12:34142914	A/T	cg13010199	chr12:38710504	ALG10B	0.48	6.01	0.35	6.15e-9	Morning vs. evening chronotype;
CESC	cis	rs7666738	0.830	rs28515641	chr4:98726419	G/A	cg03467027	chr4:99064603	C4orf37	0.44	5.45	0.32	1.18e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4077515	0.743	rs3812571	chr9:139275294	G/C	cg14169450	chr9:139327907	INPP5E	0.42	5.9	0.34	1.1e-8	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs10242455	0.702	rs17161726	chr7:99008395	C/G	cg18809830	chr7:99032528	PTCD1	-0.83	-6.09	-0.35	4e-9	Blood metabolite levels;
CESC	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	22.13	0.81	3.58e-62	Prudent dietary pattern;
CESC	cis	rs1799949	0.930	rs1554063	chr17:41287145	T/C	cg23758822	chr17:41437982	NA	0.99	16.81	0.72	1.2e-43	Menopause (age at onset);
CESC	cis	rs9322193	0.923	rs9767105	chr6:149980727	A/G	cg02462569	chr6:150064036	NUP43	-0.36	-5.14	-0.3	5.27e-7	Lung cancer;
CESC	cis	rs4728302	0.869	rs12707129	chr7:133593177	A/G	cg10665199	chr7:133106180	EXOC4	0.38	5.33	0.31	2.05e-7	Intelligence;Intelligence (multi-trait analysis);
CESC	trans	rs11039798	1.000	rs12281162	chr11:48650491	T/C	cg15704280	chr7:45808275	SEPT13	0.67	6.36	0.36	8.67e-10	Axial length;
CESC	cis	rs12618769	0.597	rs4069739	chr2:99049528	G/C	cg10123293	chr2:99228465	UNC50	0.39	5.16	0.3	4.88e-7	Bipolar disorder;
CESC	cis	rs7580658	0.613	rs6754999	chr2:128195387	G/A	cg10021288	chr2:128175891	PROC	-0.39	-5.62	-0.33	4.9e-8	Protein C levels;
CESC	cis	rs501120	1.000	rs665855	chr10:44757751	T/C	cg09554077	chr10:44749378	NA	0.52	6.91	0.39	3.59e-11	Coronary artery disease;Coronary heart disease;
CESC	cis	rs7927592	0.673	rs2510392	chr11:68394457	C/G	cg16797656	chr11:68205561	LRP5	0.5	7.39	0.41	1.94e-12	Total body bone mineral density;
CESC	cis	rs9322193	0.886	rs9322198	chr6:149944908	T/C	cg07701084	chr6:150067640	NUP43	0.45	6.39	0.37	7.37e-10	Lung cancer;
CESC	cis	rs4919694	1.000	rs12242000	chr10:104702413	A/C	cg04362960	chr10:104952993	NT5C2	0.78	6.58	0.37	2.5e-10	Arsenic metabolism;
CESC	cis	rs8062405	0.755	rs62034355	chr16:28581038	G/C	cg07382826	chr16:28625726	SULT1A1	0.39	6.29	0.36	1.34e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs8177253	0.665	rs9869535	chr3:133451581	G/A	cg18769074	chr3:133464867	TF	0.32	5.89	0.34	1.19e-8	Iron status biomarkers;
CESC	cis	rs7904368	0.806	rs4612698	chr10:16855070	C/A	cg23933602	chr10:16859644	RSU1	0.76	7.15	0.4	8.52e-12	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
CESC	cis	rs684232	0.602	rs2160955	chr17:560604	T/C	cg15660573	chr17:549704	VPS53	-0.82	-12.07	-0.6	4.98e-27	Prostate cancer;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg11346541	chr1:228327680	GUK1	-0.51	-6.01	-0.35	6.19e-9	Ulcerative colitis;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg11327004	chr7:645500	PRKAR1B	-0.42	-6.9	-0.39	3.85e-11	Gambling;
CESC	cis	rs929354	0.713	rs1034785	chr7:157002383	T/C	cg05182265	chr7:156933206	UBE3C	-0.5	-7.2	-0.4	6.07e-12	Body mass index;
CESC	cis	rs10832963	1.000	rs11024739	chr11:18645843	A/C	cg09201001	chr11:18656081	SPTY2D1	-0.82	-12.46	-0.61	2.29e-28	Breast cancer;
CESC	cis	rs7246657	0.943	rs28402338	chr19:37833923	G/A	cg23950597	chr19:37808831	NA	-0.62	-6.3	-0.36	1.26e-9	Coronary artery calcification;
CESC	cis	rs7100689	0.622	rs10736344	chr10:82133955	T/C	cg00277334	chr10:82204260	NA	-0.59	-7.81	-0.43	1.34e-13	Post bronchodilator FEV1;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg17157516	chr1:35332203	DLGAP3	-0.44	-6.06	-0.35	4.6e-9	Height;
CESC	cis	rs2070488	0.965	rs4679053	chr3:38523495	G/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.94	17.3	0.73	2.12e-45	Electrocardiographic conduction measures;
CESC	cis	rs863345	0.604	rs6664542	chr1:158462431	G/T	cg12129480	chr1:158549410	OR10X1	-0.36	-7.29	-0.41	3.49e-12	Pneumococcal bacteremia;
CESC	cis	rs911555	0.755	rs8018400	chr14:103901085	A/G	cg12935359	chr14:103987150	CKB	0.62	9.1	0.49	2.3e-17	Intelligence (multi-trait analysis);
CESC	cis	rs4555082	0.834	rs28846738	chr14:105745781	A/G	cg27165867	chr14:105738592	BRF1	-0.53	-5.99	-0.35	6.95e-9	Mean platelet volume;Platelet distribution width;
CESC	cis	rs34172651	0.517	rs189919	chr16:24737741	G/A	cg06028605	chr16:24865363	SLC5A11	-0.56	-7.83	-0.43	1.2e-13	Intelligence (multi-trait analysis);
CESC	cis	rs501120	1.000	rs527785	chr10:44762686	G/A	cg09554077	chr10:44749378	NA	0.52	6.89	0.39	4.1e-11	Coronary artery disease;Coronary heart disease;
CESC	cis	rs13242816	1.000	rs34325296	chr7:116122409	C/T	cg04696780	chr7:116139425	CAV2	-0.59	-5.23	-0.31	3.42e-7	P wave duration;
CESC	cis	rs12136530	0.774	rs58952060	chr1:19774582	G/A	cg01832549	chr1:19774989	CAPZB	-0.47	-6.84	-0.39	5.52e-11	Lead levels in blood;
CESC	cis	rs8014204	0.604	rs11159109	chr14:75389074	G/A	cg26191576	chr14:75389716	RPS6KL1	-0.4	-5.59	-0.32	5.75e-8	Caffeine consumption;
CESC	cis	rs10465746	0.967	rs28445286	chr1:84430483	A/G	cg10977910	chr1:84465055	TTLL7	0.46	6.18	0.35	2.45e-9	Obesity-related traits;
CESC	cis	rs9916302	0.904	rs7221875	chr17:37543328	G/A	cg00129232	chr17:37814104	STARD3	0.59	7.8	0.43	1.41e-13	Glomerular filtration rate (creatinine);
CESC	cis	rs4821897	0.514	rs739141	chr22:39824450	A/G	cg01416388	chr22:39784598	NA	0.45	5.67	0.33	3.73e-8	IgG glycosylation;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25739137	chr3:183851986	EIF2B5	0.68	8.09	0.45	2.1e-14	Gut microbiome composition (summer);
CESC	cis	rs11190604	1.000	rs17113137	chr10:102241998	G/C	cg07080220	chr10:102295463	HIF1AN	0.58	5.8	0.34	1.91e-8	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs965513	1.000	rs10739496	chr9:100552559	C/T	cg13688889	chr9:100608707	NA	-0.58	-8.35	-0.46	3.89e-15	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
CESC	cis	rs6089584	0.888	rs2181590	chr20:60622843	T/C	cg24733560	chr20:60626293	TAF4	0.45	6.44	0.37	5.45e-10	Body mass index;
CESC	cis	rs7412746	0.611	rs3768018	chr1:150723747	T/C	cg17724175	chr1:150552817	MCL1	0.42	6.34	0.36	9.98e-10	Melanoma;
CESC	cis	rs847577	0.748	rs940432	chr7:97716483	G/A	cg21770322	chr7:97807741	LMTK2	0.64	10.52	0.54	7.29e-22	Breast cancer;
CESC	cis	rs881375	0.678	rs10760130	chr9:123701990	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.52	7.54	0.42	7.68e-13	Rheumatoid arthritis;
CESC	cis	rs3008870	1.000	rs2815351	chr1:67477980	A/G	cg11518657	chr1:67396239	MIER1	0.49	5.44	0.32	1.21e-7	Lymphocyte percentage of white cells;
CESC	cis	rs853679	0.517	rs9393897	chr6:28127710	G/T	cg26335602	chr6:28129616	ZNF389	0.52	6.78	0.38	7.92e-11	Depression;
CESC	cis	rs36051895	0.695	rs62541534	chr9:5028921	C/G	cg02405213	chr9:5042618	JAK2	-0.47	-5.46	-0.32	1.08e-7	Pediatric autoimmune diseases;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg18268492	chr10:99185986	PGAM1	-0.49	-6.21	-0.36	2.02e-9	Ulcerative colitis;
CESC	cis	rs8038465	1.000	rs8041181	chr15:73982336	C/T	cg15420318	chr15:73925796	NPTN	0.43	6.0	0.35	6.44e-9	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs3820928	0.874	rs6740108	chr2:227889559	G/T	cg11843606	chr2:227700838	RHBDD1	0.52	6.94	0.39	3.08e-11	Pulmonary function;
CESC	cis	rs6540559	0.673	rs17317411	chr1:209961314	C/T	cg21951975	chr1:209979733	IRF6	-0.58	-6.64	-0.38	1.77e-10	Cleft lip with or without cleft palate;
CESC	cis	rs3008870	1.000	rs2755244	chr1:67484470	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-1.02	-13.89	-0.65	2.42e-33	Lymphocyte percentage of white cells;
CESC	cis	rs2280018	0.963	rs12928424	chr16:15150773	C/G	cg07549590	chr16:15018862	NA	-0.49	-8.03	-0.44	3.22e-14	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs7618915	0.547	rs7642198	chr3:52677960	T/C	cg18404041	chr3:52824283	ITIH1	-0.39	-6.55	-0.37	2.9e-10	Bipolar disorder;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg10329334	chr7:128767475	LOC407835	-0.45	-6.0	-0.35	6.5e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs10899021	0.920	rs7122710	chr11:74323175	C/T	cg25880958	chr11:74394337	NA	-0.76	-7.95	-0.44	5.53e-14	Response to metformin (IC50);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09090048	chr11:134093731	VPS26B;NCAPD3	0.61	7.5	0.42	9.67e-13	Gut microbiome composition (summer);
CESC	cis	rs10779751	0.575	rs2791655	chr1:11128654	A/G	cg08854313	chr1:11322531	MTOR	-0.66	-8.63	-0.47	5.96e-16	Body mass index;
CESC	cis	rs847577	0.609	rs11763970	chr7:97817321	A/G	cg21770322	chr7:97807741	LMTK2	0.86	14.9	0.68	6.85e-37	Breast cancer;
CESC	cis	rs8058578	1.000	rs7198250	chr16:30746822	C/A	cg02466173	chr16:30829666	NA	-0.41	-6.69	-0.38	1.3100000000000001e-10	Multiple myeloma;
CESC	cis	rs9640161	0.750	rs73170185	chr7:150030191	C/A	cg17279839	chr7:150038598	RARRES2	0.48	5.75	0.33	2.5e-8	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs2239547	0.563	rs2581820	chr3:53020544	A/G	cg11645453	chr3:52864694	ITIH4	-0.32	-5.68	-0.33	3.63e-8	Schizophrenia;
CESC	cis	rs11247915	0.501	rs34209692	chr1:26608782	C/T	cg00852783	chr1:26633632	UBXN11	0.41	5.12	0.3	5.9e-7	Obesity-related traits;
CESC	cis	rs10463316	0.894	rs6579862	chr5:150761717	T/G	cg03212797	chr5:150827313	SLC36A1	-0.44	-5.68	-0.33	3.53e-8	Metabolite levels (Pyroglutamine);
CESC	cis	rs3785574	0.886	rs62077504	chr17:61837734	A/G	cg07677032	chr17:61819896	STRADA	0.42	5.28	0.31	2.69e-7	Height;
CESC	cis	rs754466	0.580	rs11002293	chr10:79537965	C/T	cg17075019	chr10:79541650	NA	-0.88	-13.82	-0.65	4.32e-33	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs703842	0.928	rs724834	chr12:58180416	G/C	cg18357645	chr12:58087776	OS9	-0.41	-5.67	-0.33	3.8e-8	Multiple sclerosis;
CESC	cis	rs1461503	0.932	rs56778812	chr11:122840491	C/T	cg27398637	chr11:122830231	C11orf63	-0.55	-8.32	-0.45	4.77e-15	Menarche (age at onset);
CESC	cis	rs11676348	0.967	rs4674258	chr2:218990586	C/T	cg00012203	chr2:219082015	ARPC2	-0.55	-7.09	-0.4	1.19e-11	Ulcerative colitis;
CESC	cis	rs5750830	0.649	rs5757659	chr22:39812409	A/C	cg01416388	chr22:39784598	NA	-0.54	-6.37	-0.36	8.41e-10	Intelligence (multi-trait analysis);
CESC	cis	rs909674	0.818	rs5757681	chr22:39845547	A/G	cg02038168	chr22:39784481	NA	-0.62	-7.32	-0.41	2.91e-12	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs11203032	0.831	rs10887927	chr10:90940687	T/C	cg16672925	chr10:90967113	CH25H	0.68	6.99	0.39	2.24e-11	Heart failure;
CESC	cis	rs1862618	0.853	rs252902	chr5:56116085	A/G	cg12311346	chr5:56204834	C5orf35	-0.71	-8.69	-0.47	3.8e-16	Initial pursuit acceleration;
CESC	cis	rs3733585	0.673	rs4314284	chr4:9956096	C/T	cg11266682	chr4:10021025	SLC2A9	-0.57	-10.86	-0.56	5.66e-23	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs1577917	1.000	rs68171315	chr6:86707400	A/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-6.36	-0.36	8.63e-10	Response to antipsychotic treatment;
CESC	cis	rs10504229	1.000	rs67388517	chr8:58176617	C/A	cg22535103	chr8:58192502	C8orf71	-1.05	-13.27	-0.63	3.63e-31	Developmental language disorder (linguistic errors);
CESC	cis	rs9837602	0.882	rs6807176	chr3:99760864	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.5	7.23	0.41	5.26e-12	Breast cancer;
CESC	cis	rs634534	0.622	rs531612	chr11:65705432	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.56	-7.2	-0.4	6.39e-12	Sum eosinophil basophil counts;Eosinophil counts;
CESC	cis	rs589448	0.872	rs315111	chr12:69784695	G/A	cg22834771	chr12:69754056	YEATS4	-0.57	-7.62	-0.42	4.38e-13	Cerebrospinal fluid biomarker levels;
CESC	cis	rs597539	0.690	rs615644	chr11:68621806	G/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.79	9.45	0.5	1.91e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs7811142	0.830	rs6945952	chr7:99981775	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.69	6.11	0.35	3.54e-9	Platelet count;
CESC	cis	rs963731	0.649	rs6752850	chr2:39220655	C/T	cg04010122	chr2:39346883	SOS1	-0.71	-5.28	-0.31	2.65e-7	Corticobasal degeneration;
CESC	cis	rs2836974	0.899	rs34176878	chr21:40548855	C/A	cg11890956	chr21:40555474	PSMG1	1.15	22.06	0.8	6.3e-62	Cognitive function;
CESC	cis	rs3820928	0.874	rs3752896	chr2:227886925	C/T	cg11843606	chr2:227700838	RHBDD1	-0.45	-5.93	-0.34	9.66e-9	Pulmonary function;
CESC	cis	rs6142102	0.517	rs6142050	chr20:32527128	G/A	cg08999081	chr20:33150536	PIGU	0.35	5.26	0.31	3.03e-7	Skin pigmentation;
CESC	cis	rs7666738	0.753	rs2903143	chr4:99040480	C/T	cg17366294	chr4:99064904	C4orf37	0.6	8.51	0.46	1.33e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs116095464	0.510	rs73016876	chr5:244475	T/C	cg12570787	chr5:219185	SDHA;CCDC127	0.5	5.23	0.31	3.45e-7	Breast cancer;
CESC	cis	rs11166629	1.000	rs6577713	chr8:135645592	C/A	cg27224718	chr8:135614730	ZFAT	0.51	6.34	0.36	9.8e-10	Smoking quantity;
CESC	cis	rs9467711	0.659	rs3823158	chr6:26463271	T/A	cg14345882	chr6:26364793	BTN3A2	0.65	5.57	0.32	6.18e-8	Autism spectrum disorder or schizophrenia;
CESC	cis	rs9309711	0.736	rs9678647	chr2:3497036	A/G	cg10845886	chr2:3471009	TTC15	0.59	7.54	0.42	7.56e-13	Neurofibrillary tangles;
CESC	cis	rs853679	0.517	rs12332979	chr6:28141548	T/G	cg19592336	chr6:28129416	ZNF389	0.59	7.78	0.43	1.63e-13	Depression;
CESC	cis	rs1552244	0.938	rs7625049	chr3:10115619	C/T	cg00166722	chr3:10149974	C3orf24	0.54	6.89	0.39	4.08e-11	Alzheimer's disease;
CESC	cis	rs116095464	0.558	rs7715108	chr5:264661	A/G	cg22496380	chr5:211416	CCDC127	-0.74	-8.46	-0.46	1.86e-15	Breast cancer;
CESC	cis	rs28374715	0.635	rs8023530	chr15:41647775	T/C	cg02330683	chr15:41787940	ITPKA	0.43	5.78	0.33	2.11e-8	Ulcerative colitis;
CESC	cis	rs12464559	0.579	rs11682909	chr2:152651592	A/G	cg01189475	chr2:152685088	ARL5A	0.66	5.81	0.34	1.74e-8	Response to cognitive-behavioural therapy in anxiety disorder;
CESC	cis	rs17293817	0.617	rs2387658	chr10:1423905	A/C	cg04271617	chr10:1416546	ADARB2	-0.31	-5.19	-0.3	4.24e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs453301	0.652	rs2043129	chr8:8825504	C/G	cg15556689	chr8:8085844	FLJ10661	0.43	5.03	0.3	9.04e-7	Joint mobility (Beighton score);
CESC	cis	rs2797160	1.000	rs2211420	chr6:125995549	A/G	cg05901451	chr6:126070800	HEY2	-0.46	-6.77	-0.38	8.46e-11	Endometrial cancer;
CESC	cis	rs798554	0.759	rs1636255	chr7:2892804	A/C	cg03185022	chr7:2884158	GNA12	-0.43	-5.22	-0.31	3.55e-7	Height;
CESC	cis	rs2991971	0.903	rs2991973	chr1:46020632	G/A	cg24296786	chr1:45957014	TESK2	0.62	8.24	0.45	8.18e-15	High light scatter reticulocyte count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01227078	chr5:110074645	SLC25A46	0.54	6.09	0.35	3.89e-9	Gut microbiome composition (summer);
CESC	cis	rs2479724	0.935	rs1887718	chr6:41857691	C/T	cg17623882	chr6:41773611	USP49	-0.41	-5.91	-0.34	1.07e-8	Menarche (age at onset);
CESC	cis	rs4713118	0.512	rs2622319	chr6:28120401	G/C	cg19592336	chr6:28129416	ZNF389	0.48	7.01	0.4	2e-11	Parkinson's disease;
CESC	cis	rs2625529	0.652	rs2957728	chr15:72236432	G/T	cg16672083	chr15:72433130	SENP8	0.42	6.35	0.36	9.2e-10	Red blood cell count;
CESC	cis	rs2576037	0.526	rs626217	chr18:44429182	T/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.32	5.16	0.3	4.77e-7	Personality dimensions;
CESC	cis	rs853679	0.517	rs17711801	chr6:28092307	C/G	cg17949981	chr6:28129498	ZNF389	0.44	5.58	0.32	5.97e-8	Depression;
CESC	cis	rs7605827	0.893	rs741437	chr2:15626327	A/G	cg19274914	chr2:15703543	NA	0.36	6.42	0.37	6.36e-10	Educational attainment (years of education);
CESC	cis	rs11122272	0.735	rs1076804	chr1:231498460	T/C	cg06096015	chr1:231504339	EGLN1	0.43	6.27	0.36	1.47e-9	Hemoglobin concentration;
CESC	cis	rs4566357	1.000	rs4566357	chr2:227922015	C/T	cg11843606	chr2:227700838	RHBDD1	0.39	5.05	0.3	8.42e-7	Coronary artery disease;
CESC	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.54	-7.33	-0.41	2.83e-12	Longevity;Endometriosis;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg11620074	chr11:33722319	C11orf91	0.5	6.63	0.38	1.9e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs2228479	0.702	rs17233441	chr16:89817998	C/G	cg00800038	chr16:89945340	TCF25	-0.91	-7.54	-0.42	7.39e-13	Skin colour saturation;
CESC	cis	rs9649213	0.593	rs6465662	chr7:97917801	A/T	cg00277769	chr7:97922759	BAIAP2L1	-0.35	-5.74	-0.33	2.55e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs4730250	0.707	rs257373	chr7:106798290	G/A	cg02696742	chr7:106810147	HBP1	-0.55	-5.18	-0.3	4.32e-7	Osteoarthritis;
CESC	cis	rs875971	0.862	rs35378740	chr7:65987712	C/A	cg12463550	chr7:65579703	CRCP	0.51	6.36	0.36	8.66e-10	Aortic root size;
CESC	cis	rs2282802	0.651	rs6863474	chr5:139630862	C/T	cg26211634	chr5:139558579	C5orf32	0.53	7.66	0.43	3.52e-13	Intelligence (multi-trait analysis);
CESC	cis	rs2380220	0.606	rs4571572	chr6:96004823	T/C	cg23517279	chr6:96025343	MANEA	0.54	5.87	0.34	1.28e-8	Behavioural disinhibition (generation interaction);
CESC	cis	rs1545257	0.560	rs7561752	chr2:24643834	A/G	cg06627628	chr2:24431161	ITSN2	0.51	6.13	0.35	3.24e-9	Sjögren's syndrome;
CESC	cis	rs6665290	0.669	rs3768419	chr1:227173477	C/G	cg10327440	chr1:227177885	CDC42BPA	-1.11	-23.48	-0.82	1.07e-66	Myeloid white cell count;
CESC	cis	rs270601	0.633	rs4535443	chr5:131572561	A/G	cg18758796	chr5:131593413	PDLIM4	0.42	5.61	0.33	5.09e-8	Acylcarnitine levels;
CESC	cis	rs7923609	0.934	rs10761763	chr10:65188318	T/C	cg01631684	chr10:65280961	REEP3	-0.44	-5.48	-0.32	9.84e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs9457247	0.967	rs387733	chr6:167409771	C/T	cg07741184	chr6:167504864	NA	-0.31	-5.56	-0.32	6.71e-8	Crohn's disease;
CESC	cis	rs7927592	0.956	rs7106259	chr11:68298512	T/G	cg16797656	chr11:68205561	LRP5	0.38	5.27	0.31	2.88e-7	Total body bone mineral density;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg18807030	chr7:931980	C7orf20	0.47	6.39	0.37	7.64e-10	Fibrinogen levels;
CESC	cis	rs2040771	0.711	rs361639	chr22:19268024	A/G	cg02655711	chr22:19163373	SLC25A1	0.4	5.75	0.33	2.45e-8	Metabolite levels (small molecules and protein measures);
CESC	cis	rs1799949	1.000	rs34059614	chr17:41303071	C/T	cg05368731	chr17:41323189	NBR1	0.78	10.79	0.55	9.37e-23	Menopause (age at onset);
CESC	cis	rs7077164	1.000	rs1227775	chr10:71580862	C/G	cg07630274	chr10:71583235	COL13A1	-0.39	-7.65	-0.43	3.62e-13	Non-alcoholic fatty liver disease histology (lobular);
CESC	trans	rs916888	0.821	rs70602	chr17:44859715	T/C	cg22968622	chr17:43663579	NA	-1.19	-16.0	-0.7	8.93e-41	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs798554	0.757	rs1182187	chr7:2870454	T/G	cg18446336	chr7:2847575	GNA12	-0.37	-5.63	-0.33	4.49e-8	Height;
CESC	cis	rs1707322	0.752	rs7529699	chr1:46134634	C/T	cg03146154	chr1:46216737	IPP	0.82	11.51	0.58	3.87e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9837602	1.000	rs10212525	chr3:99713377	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.53	7.24	0.41	4.82e-12	Breast cancer;
CESC	cis	rs10489202	0.632	rs149912	chr1:167957803	A/T	cg24449463	chr1:168025552	DCAF6	-0.41	-5.23	-0.31	3.46e-7	Schizophrenia;
CESC	cis	rs4713118	0.662	rs156744	chr6:27967274	G/A	cg23161317	chr6:28129485	ZNF389	0.51	6.56	0.37	2.88e-10	Parkinson's disease;
CESC	trans	rs875971	0.830	rs7799834	chr7:65880694	A/C	cg26939375	chr7:64535504	NA	0.47	6.14	0.35	3.07e-9	Aortic root size;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg04816434	chr15:22945077	CYFIP1	0.54	7.03	0.4	1.77e-11	Fibrinogen levels;
CESC	cis	rs2120019	1.000	rs35736167	chr15:75332002	T/G	cg09165964	chr15:75287851	SCAMP5	-0.78	-9.31	-0.5	5.02e-18	Blood trace element (Zn levels);
CESC	cis	rs36051895	0.626	rs10283563	chr9:5075603	C/T	cg02405213	chr9:5042618	JAK2	-0.44	-5.4	-0.31	1.48e-7	Pediatric autoimmune diseases;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg25750404	chr12:6579648	VAMP1	0.5	6.45	0.37	5.25e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs2236918	1.000	rs851782	chr1:242033783	A/G	cg17736920	chr1:242011382	EXO1	0.71	8.87	0.48	1.1e-16	Menopause (age at onset);
CESC	cis	rs9814567	1.000	rs1814337	chr3:134200682	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.45	-6.08	-0.35	4.15e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs6500395	1.000	rs6500395	chr16:48621402	T/C	cg04672837	chr16:48644449	N4BP1	0.52	6.64	0.38	1.81e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs208515	0.525	rs12191500	chr6:66668681	A/G	cg07460842	chr6:66804631	NA	0.83	10.33	0.54	3.09e-21	Exhaled nitric oxide levels;
CESC	cis	rs7618915	0.547	rs33967311	chr3:52683864	G/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.39	7.26	0.41	4.33e-12	Bipolar disorder;
CESC	cis	rs3858526	0.959	rs1840179	chr11:5949148	A/G	cg13902645	chr11:5959945	NA	-0.66	-7.89	-0.44	8.17e-14	DNA methylation (variation);
CESC	cis	rs7666738	0.830	rs4699584	chr4:98952019	A/G	cg17366294	chr4:99064904	C4orf37	0.59	8.47	0.46	1.74e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1862618	0.853	rs3099459	chr5:56137170	G/C	cg12311346	chr5:56204834	C5orf35	-0.74	-8.81	-0.48	1.63e-16	Initial pursuit acceleration;
CESC	cis	rs7247513	0.964	rs12104149	chr19:12721088	A/G	cg01871581	chr19:12707946	ZNF490	-0.88	-14.67	-0.67	4.5e-36	Bipolar disorder;
CESC	cis	rs6736093	0.966	rs13033393	chr2:112697632	C/G	cg12686935	chr2:112915763	FBLN7	-0.43	-5.56	-0.32	6.75e-8	Coronary artery disease;
CESC	cis	rs9329289	0.510	rs12356215	chr10:2545390	C/G	cg15501526	chr10:2543763	NA	0.5	7.88	0.44	8.68e-14	Age-related hearing impairment;
CESC	cis	rs6750795	0.746	rs1667301	chr2:232423717	C/T	cg19187155	chr2:232395269	NMUR1	0.68	11.72	0.58	7.8e-26	Height;
CESC	cis	rs9341808	0.527	rs2505946	chr6:80810683	A/G	cg08355045	chr6:80787529	NA	0.36	5.72	0.33	2.93e-8	Sitting height ratio;
CESC	trans	rs11165623	0.740	rs11165638	chr1:96921357	C/A	cg10631902	chr5:14652156	NA	-0.55	-8.24	-0.45	8.07e-15	Hip circumference;Waist circumference;
CESC	cis	rs9951602	0.651	rs2959408	chr18:76681702	T/C	cg00806245	chr18:76673096	NA	0.51	6.16	0.35	2.63e-9	Obesity-related traits;
CESC	trans	rs62103177	0.733	rs62096748	chr18:77619699	T/C	cg05926928	chr17:57297772	GDPD1	1.2	10.81	0.55	8.31e-23	Opioid sensitivity;
CESC	cis	rs26868	0.742	rs26848	chr16:2263516	A/G	cg27608139	chr16:2294856	DCI	0.35	5.03	0.3	9e-7	Height;
CESC	cis	rs1707322	0.721	rs11211165	chr1:46157906	C/T	cg05343316	chr1:45956843	TESK2	0.51	6.22	0.36	1.96e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9549260	0.577	rs6563841	chr13:41239178	A/C	cg21288729	chr13:41239152	FOXO1	0.68	8.65	0.47	5.17e-16	Red blood cell count;
CESC	cis	rs3026401	0.562	rs762972	chr11:31797603	A/G	cg14844989	chr11:31128820	NA	0.51	6.2	0.36	2.14e-9	Body mass index;
CESC	cis	rs7662987	0.540	rs2851257	chr4:100039499	G/C	cg12011299	chr4:100065546	ADH4	0.6	6.56	0.37	2.83e-10	Smoking initiation;
CESC	cis	rs9649213	0.613	rs10953256	chr7:97951886	G/C	cg21770322	chr7:97807741	LMTK2	0.54	8.15	0.45	1.45e-14	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs4332037	0.707	rs62435130	chr7:1890002	C/T	cg13880726	chr7:1868755	MAD1L1	-0.48	-5.08	-0.3	7.23e-7	Bipolar disorder;
CESC	trans	rs3942852	0.806	rs4752807	chr11:48128751	T/G	cg15704280	chr7:45808275	SEPT13	-0.63	-7.33	-0.41	2.76e-12	Acute lymphoblastic leukemia (childhood);
CESC	trans	rs208520	0.586	rs208442	chr6:66900618	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.66	-8.02	-0.44	3.5e-14	Exhaled nitric oxide output;
CESC	cis	rs1059312	1.000	rs7135854	chr12:129279988	G/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.74	-10.51	-0.54	8.05e-22	Systemic lupus erythematosus;
CESC	cis	rs4604732	0.631	rs34330532	chr1:247626844	G/C	cg12754571	chr1:247694271	LOC148824;OR2C3	0.44	5.44	0.32	1.21e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs1018836	0.632	rs2879361	chr8:91481909	C/T	cg16814680	chr8:91681699	NA	0.53	7.42	0.41	1.56e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs35306767	0.903	rs12240651	chr10:943656	A/G	cg10556349	chr10:835070	NA	0.59	5.69	0.33	3.3e-8	Eosinophil percentage of granulocytes;
CESC	cis	rs4665809	1.000	rs4665305	chr2:26313524	C/T	cg26314531	chr2:26401878	FAM59B	-0.63	-6.99	-0.39	2.29e-11	Gut microbiome composition (summer);
CESC	cis	rs72781680	0.948	rs72796385	chr2:24170360	T/A	cg20701182	chr2:24300061	SF3B14	0.64	5.74	0.33	2.63e-8	Lymphocyte counts;
CESC	cis	rs597539	0.690	rs552517	chr11:68625286	T/G	cg04772025	chr11:68637568	NA	0.57	6.65	0.38	1.64e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs62344088	0.744	rs76038312	chr5:229005	A/G	cg22857025	chr5:266934	NA	-1.28	-7.51	-0.42	8.79e-13	Asthma (childhood onset);
CESC	cis	rs2735413	0.752	rs11642442	chr16:78080800	A/C	cg04733911	chr16:78082701	NA	-0.53	-9.01	-0.48	4.08e-17	Systolic blood pressure (alcohol consumption interaction);
CESC	cis	rs4665809	1.000	rs6720314	chr2:26334852	G/A	cg26314531	chr2:26401878	FAM59B	-0.76	-8.49	-0.46	1.47e-15	Gut microbiome composition (summer);
CESC	cis	rs477895	0.653	rs34113693	chr11:63900123	G/T	cg18225595	chr11:63971243	STIP1	0.52	5.13	0.3	5.55e-7	Mean platelet volume;
CESC	cis	rs938554	0.956	rs12507606	chr4:9934561	C/T	cg00071950	chr4:10020882	SLC2A9	-0.4	-5.07	-0.3	7.59e-7	Blood metabolite levels;
CESC	cis	rs4979906	1.000	rs68092325	chr10:79446719	T/A	cg00983440	chr10:79422392	NA	-0.48	-5.08	-0.3	7.19e-7	Mortality in heart failure;
CESC	cis	rs2236918	1.000	rs1635511	chr1:242026172	C/T	cg17736920	chr1:242011382	EXO1	0.71	9.6	0.51	6.2e-19	Menopause (age at onset);
CESC	cis	rs13102973	0.932	rs13112852	chr4:135838470	C/T	cg14419869	chr4:135874104	NA	0.34	5.32	0.31	2.26e-7	Subjective well-being;
CESC	cis	rs514406	0.861	rs6588443	chr1:53250650	G/A	cg08736216	chr1:53307985	ZYG11A	0.43	7.23	0.41	5.21e-12	Monocyte count;
CESC	cis	rs4975709	0.589	rs4975747	chr5:1862836	G/A	cg14773178	chr5:1868261	NA	0.32	5.7	0.33	3.12e-8	Cardiovascular disease risk factors;
CESC	cis	rs13108904	0.967	rs11247987	chr4:1294532	G/A	cg22903657	chr4:1355424	KIAA1530	-0.38	-5.13	-0.3	5.55e-7	Obesity-related traits;
CESC	cis	rs4919694	1.000	rs4917988	chr10:104752830	T/G	cg04362960	chr10:104952993	NT5C2	0.74	6.44	0.37	5.71e-10	Arsenic metabolism;
CESC	cis	rs11098499	0.820	rs6534140	chr4:120455311	C/T	cg24375607	chr4:120327624	NA	0.43	5.21	0.3	3.82e-7	Corneal astigmatism;
CESC	cis	rs796364	0.806	rs79333757	chr2:200915716	T/C	cg23649088	chr2:200775458	C2orf69	-0.55	-5.05	-0.3	8.29e-7	Schizophrenia;
CESC	cis	rs11190604	1.000	rs11190572	chr10:102232879	A/G	cg07080220	chr10:102295463	HIF1AN	0.55	5.56	0.32	6.68e-8	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs9916302	0.904	rs3744348	chr17:37417575	C/G	cg00129232	chr17:37814104	STARD3	-0.57	-7.48	-0.42	1.1e-12	Glomerular filtration rate (creatinine);
CESC	cis	rs9303280	0.773	rs12949100	chr17:38057189	G/A	cg19468946	chr17:37922297	IKZF3	-0.41	-5.33	-0.31	2.1e-7	Self-reported allergy;
CESC	cis	rs736408	0.522	rs11716747	chr3:52748857	C/T	cg07507251	chr3:52567010	NT5DC2	0.35	5.96	0.34	7.85e-9	Bipolar disorder;
CESC	cis	rs4423214	0.959	rs11606033	chr11:71154204	A/G	cg05163923	chr11:71159392	DHCR7	0.89	12.95	0.62	4.74e-30	Vitamin D levels;
CESC	cis	rs4722166	0.630	rs1829927	chr7:22779918	G/A	cg26061582	chr7:22766209	IL6	0.51	5.55	0.32	6.82e-8	Lung cancer;
CESC	cis	rs3733585	0.673	rs7377578	chr4:9952775	T/C	cg02734326	chr4:10020555	SLC2A9	-0.39	-5.64	-0.33	4.43e-8	Cleft plate (environmental tobacco smoke interaction);
CESC	trans	rs66573146	0.831	rs68111914	chr4:6986677	C/T	cg07817883	chr1:32538562	TMEM39B	1.21	7.98	0.44	4.38e-14	Granulocyte percentage of myeloid white cells;
CESC	cis	rs748404	0.690	rs2924369	chr15:43777985	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	-0.57	-7.35	-0.41	2.53e-12	Lung cancer;
CESC	cis	rs9322193	0.923	rs9479810	chr6:150072495	C/T	cg04369109	chr6:150039330	LATS1	-0.38	-5.19	-0.3	4.09e-7	Lung cancer;
CESC	cis	rs3008870	0.959	rs3008852	chr1:67383416	G/A	cg08660285	chr1:67390436	MIER1;WDR78	1.05	14.93	0.68	5.6e-37	Lymphocyte percentage of white cells;
CESC	cis	rs10504229	1.000	rs73607871	chr8:58173007	T/C	cg05313129	chr8:58192883	C8orf71	-0.55	-6.37	-0.36	8.42e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs7666738	0.962	rs11932892	chr4:99072967	C/T	cg03676636	chr4:99064102	C4orf37	0.38	5.31	0.31	2.33e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs523522	0.962	rs7488320	chr12:120981630	G/T	cg27279351	chr12:120934652	DYNLL1	0.69	9.11	0.49	2.02e-17	High light scatter reticulocyte count;
CESC	cis	rs2249694	1.000	rs4512750	chr10:135358664	A/G	cg20169779	chr10:135381914	SYCE1	0.42	5.88	0.34	1.26e-8	Obesity-related traits;
CESC	cis	rs9322193	0.923	rs7769101	chr6:150169904	C/A	cg09699651	chr6:150184138	LRP11	0.49	5.99	0.35	6.72e-9	Lung cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23188378	chr11:118901631	SLC37A4	0.55	6.22	0.36	1.98e-9	Gut microbiome composition (summer);
CESC	cis	rs4819052	0.851	rs2838858	chr21:46681093	T/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.77	10.4	0.54	1.87e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs9649213	0.593	rs2240349	chr7:97984663	C/T	cg08684580	chr7:98029266	BAIAP2L1	-0.35	-5.8	-0.34	1.85e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs9611565	0.500	rs10775759	chr22:42088158	T/C	cg06481639	chr22:41940642	POLR3H	0.6	6.4	0.37	6.86e-10	Vitiligo;
CESC	cis	rs12142240	0.698	rs7515598	chr1:46818479	C/T	cg00530320	chr1:46809349	NSUN4	0.58	7.89	0.44	8.15e-14	Menopause (age at onset);
CESC	cis	rs9309711	0.623	rs7569694	chr2:3483390	T/G	cg15506890	chr2:3487001	NA	-0.48	-6.12	-0.35	3.33e-9	Neurofibrillary tangles;
CESC	cis	rs3741404	0.620	rs12787945	chr11:63977546	G/A	cg18225595	chr11:63971243	STIP1	0.61	8.59	0.47	7.78e-16	Platelet count;
CESC	cis	rs10911232	0.507	rs4483371	chr1:182988352	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.84	13.3	0.63	2.79e-31	Hypertriglyceridemia;
CESC	cis	rs965469	0.817	rs6515806	chr20:3359138	A/G	cg25506879	chr20:3388711	C20orf194	-0.5	-5.4	-0.31	1.46e-7	IFN-related cytopenia;
CESC	cis	rs1348850	0.574	rs11691740	chr2:178445161	A/G	cg22681709	chr2:178499509	PDE11A	0.43	5.11	0.3	6.12e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	trans	rs11098499	0.575	rs907204	chr4:120238654	G/A	cg25214090	chr10:38739885	LOC399744	0.61	8.51	0.46	1.33e-15	Corneal astigmatism;
CESC	cis	rs12893668	0.572	rs4906356	chr14:104138701	C/T	cg08213375	chr14:104286397	PPP1R13B	0.33	5.41	0.32	1.4e-7	Reticulocyte count;
CESC	cis	rs12497850	0.931	rs13316620	chr3:49045355	T/C	cg02487422	chr3:49467188	NICN1	0.45	5.72	0.33	2.9e-8	Parkinson's disease;
CESC	cis	rs8141529	0.748	rs1318026	chr22:29283518	A/G	cg15103426	chr22:29168792	CCDC117	0.62	8.01	0.44	3.62e-14	Lymphocyte counts;
CESC	cis	rs854765	0.693	rs9907246	chr17:17770965	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.49	-6.88	-0.39	4.22e-11	Total body bone mineral density;
CESC	cis	rs7208859	0.623	rs11657990	chr17:29124200	C/T	cg19761014	chr17:28927070	LRRC37B2	0.8	6.59	0.38	2.31e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs2247341	1.000	rs2247341	chr4:1701317	C/T	cg07465881	chr4:1713556	SLBP	-0.52	-6.65	-0.38	1.67e-10	Hip circumference adjusted for BMI;Height;
CESC	cis	rs8070624	0.543	rs8068175	chr17:17874486	C/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.6	7.71	0.43	2.59e-13	Total body bone mineral density;
CESC	cis	rs116095464	0.558	rs7356561	chr5:284381	G/C	cg20965017	chr5:231967	SDHA	-0.46	-5.2	-0.3	4.02e-7	Breast cancer;
CESC	cis	rs7937682	0.681	rs7107378	chr11:111401840	C/A	cg09085632	chr11:111637200	PPP2R1B	0.54	6.18	0.35	2.47e-9	Primary sclerosing cholangitis;
CESC	cis	rs6430585	0.702	rs3213890	chr2:136552188	G/A	cg07169764	chr2:136633963	MCM6	1.3	17.6	0.73	1.86e-46	Corneal structure;
CESC	cis	rs9325144	0.600	rs1817648	chr12:38733424	C/T	cg26384229	chr12:38710491	ALG10B	-0.58	-8.64	-0.47	5.27e-16	Morning vs. evening chronotype;
CESC	cis	rs6912958	0.712	rs7755167	chr6:88338752	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.32	-5.24	-0.31	3.32e-7	Monocyte percentage of white cells;
CESC	cis	rs10771431	0.597	rs7976807	chr12:9352459	G/A	cg08997352	chr12:9597637	DDX12	-0.71	-8.89	-0.48	9.87e-17	Breast size;
CESC	cis	rs7071206	0.947	rs1356090	chr10:79395312	T/C	cg00983440	chr10:79422392	NA	-0.68	-8.11	-0.45	1.92e-14	Bone mineral density;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg14712964	chr3:9773672	BRPF1	-0.46	-6.19	-0.36	2.32e-9	Fibrinogen levels;
CESC	cis	rs1862618	0.853	rs252910	chr5:56192983	G/A	cg18230493	chr5:56204884	C5orf35	-0.78	-8.96	-0.48	6.13e-17	Initial pursuit acceleration;
CESC	cis	rs4919687	0.577	rs12765459	chr10:104465687	G/C	cg04362960	chr10:104952993	NT5C2	0.48	5.11	0.3	6.11e-7	Colorectal cancer;
CESC	cis	rs6519955	0.897	rs4073601	chr22:46434686	A/G	cg05468064	chr22:46423449	NA	0.42	6.89	0.39	4.03e-11	Dupuytren's disease;
CESC	cis	rs9287719	0.934	rs4629131	chr2:10744159	C/T	cg02196655	chr2:10830764	NOL10	-0.38	-5.83	-0.34	1.61e-8	Prostate cancer;
CESC	cis	rs6688613	0.649	rs2294195	chr1:166838281	T/C	ch.1.3259774R	chr1:166827647	TADA1	0.56	5.38	0.31	1.66e-7	Refractive astigmatism;
CESC	cis	rs9611565	0.512	rs2050033	chr22:42159229	G/T	cg17376030	chr22:41985996	PMM1	-0.77	-8.15	-0.45	1.45e-14	Vitiligo;
CESC	cis	rs12477438	0.501	rs1133977	chr2:99741984	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.78	-13.44	-0.64	9.52e-32	Chronic sinus infection;
CESC	cis	rs6693567	0.545	rs4970922	chr1:150458094	C/A	cg09579323	chr1:150459698	TARS2	0.47	5.77	0.33	2.24e-8	Migraine;
CESC	cis	rs4986811	1.000	rs11031781	chr11:32454262	C/T	cg27409910	chr11:32454216	WT1	0.45	5.83	0.34	1.57e-8	Rubella-specific interleukin-6 secretion;
CESC	cis	rs1801251	0.835	rs1446310	chr2:233683245	G/C	cg25237894	chr2:233734115	C2orf82	-0.36	-6.39	-0.37	7.24e-10	Coronary artery disease;
CESC	cis	rs7103648	1.000	rs10838705	chr11:47424931	G/A	cg20307385	chr11:47447363	PSMC3	0.95	16.29	0.71	8.21e-42	Diastolic blood pressure;Systolic blood pressure;
CESC	trans	rs267567	0.626	rs559715	chr3:37570399	A/C	ch.2.2685596F	chr2:128768557	SAP130	-0.43	-6.0	-0.35	6.49e-9	PR interval;
CESC	trans	rs7922314	0.571	rs61865687	chr10:64726329	C/G	cg06935979	chr1:232941706	KIAA1383	-0.66	-5.99	-0.35	6.67e-9	Cutaneous psoriasis;
CESC	cis	rs3008870	0.755	rs1024229	chr1:67512903	G/T	cg08660285	chr1:67390436	MIER1;WDR78	0.56	7.05	0.4	1.58e-11	Lymphocyte percentage of white cells;
CESC	cis	rs5753037	0.543	rs131267	chr22:30147861	A/G	cg01021169	chr22:30184971	ASCC2	-0.55	-7.8	-0.43	1.39e-13	Type 1 diabetes;
CESC	cis	rs6460942	0.915	rs7809263	chr7:12450589	C/G	cg17427002	chr7:12443146	VWDE	-0.53	-5.65	-0.33	4.2e-8	Coronary artery disease;
CESC	cis	rs7666738	0.830	rs35951881	chr4:98999474	A/C	cg17366294	chr4:99064904	C4orf37	0.6	8.61	0.47	6.47e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1499972	0.618	rs7649429	chr3:117640167	G/C	cg07612923	chr3:117604196	NA	0.68	6.27	0.36	1.45e-9	Schizophrenia;
CESC	cis	rs67460515	0.563	rs4679672	chr3:160901020	G/A	cg03342759	chr3:160939853	NMD3	-0.54	-7.25	-0.41	4.5e-12	Parkinson's disease;
CESC	trans	rs7448080	0.510	rs330450	chr5:123284140	C/T	cg10971134	chr1:56877429	NA	0.93	6.3	0.36	1.21e-9	Alcohol dependence (age at onset);
CESC	cis	rs2637266	1.000	rs2637264	chr10:78322794	A/C	cg18941641	chr10:78392320	NA	0.4	7.34	0.41	2.56e-12	Pulmonary function;
CESC	cis	rs634534	0.622	rs624273	chr11:65712413	A/G	cg04055107	chr11:65626734	MUS81;CFL1	0.47	5.66	0.33	3.87e-8	Sum eosinophil basophil counts;Eosinophil counts;
CESC	cis	rs7618915	0.501	rs2164885	chr3:52731269	T/C	cg05564831	chr3:52568323	NT5DC2	0.46	7.29	0.41	3.58e-12	Bipolar disorder;
CESC	cis	rs1218582	0.651	rs4845396	chr1:154828409	A/G	cg24250549	chr1:154909240	PMVK	-0.43	-5.83	-0.34	1.59e-8	Prostate cancer;
CESC	cis	rs2836633	0.929	rs11702165	chr21:40035313	C/T	cg12884169	chr21:40033163	ERG	0.39	6.27	0.36	1.47e-9	Coronary artery disease;
CESC	cis	rs1707322	0.896	rs809774	chr1:46560244	T/A	cg06784218	chr1:46089804	CCDC17	-0.35	-5.94	-0.34	8.74e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs6088590	0.561	rs764597	chr20:33161225	C/T	cg06115741	chr20:33292138	TP53INP2	0.5	6.52	0.37	3.61e-10	Coronary artery disease;
CESC	cis	rs9916302	0.800	rs11869259	chr17:37518141	C/A	cg15445000	chr17:37608096	MED1	-0.41	-6.74	-0.38	9.82e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg06873352	chr17:61820015	STRADA	0.73	12.96	0.62	4.25e-30	Prudent dietary pattern;
CESC	cis	rs7580658	0.891	rs3768866	chr2:128045415	G/A	cg10021288	chr2:128175891	PROC	-0.41	-6.53	-0.37	3.32e-10	Protein C levels;
CESC	cis	rs12893668	0.572	rs7148857	chr14:104143237	C/G	cg08213375	chr14:104286397	PPP1R13B	0.32	5.39	0.31	1.55e-7	Reticulocyte count;
CESC	cis	rs853679	0.517	rs9468297	chr6:28118874	G/T	cg22143856	chr6:28129313	ZNF389	0.53	6.71	0.38	1.2e-10	Depression;
CESC	cis	rs7937682	0.663	rs7116280	chr11:111659111	T/C	cg09085632	chr11:111637200	PPP2R1B	0.91	11.19	0.57	4.54e-24	Primary sclerosing cholangitis;
CESC	cis	rs2228479	0.850	rs62054609	chr16:89816569	C/A	cg14709524	chr16:89940631	TCF25	0.93	6.94	0.39	3.03e-11	Skin colour saturation;
CESC	cis	rs2074585	0.517	rs11637971	chr15:91079863	A/C	cg10434728	chr15:90938212	IQGAP1	-0.32	-5.23	-0.31	3.42e-7	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
CESC	cis	rs2650000	0.798	rs2701175	chr12:121391671	C/A	cg25281562	chr12:121454272	C12orf43	-0.46	-5.77	-0.33	2.18e-8	Metabolic traits;LDL cholesterol;
CESC	cis	rs7666738	0.830	rs28516388	chr4:98987449	A/G	cg05340658	chr4:99064831	C4orf37	0.8	12.42	0.61	3.31e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6460942	1.000	rs6970095	chr7:12403840	G/A	cg13733410	chr7:12443478	VWDE	-0.53	-5.33	-0.31	2.12e-7	Coronary artery disease;
CESC	cis	rs11785400	0.762	rs7460801	chr8:143730972	C/A	cg24634471	chr8:143751801	JRK	0.45	5.78	0.33	2.12e-8	Schizophrenia;
CESC	cis	rs8092503	1.000	rs8085272	chr18:52481583	A/G	cg12377874	chr18:52495404	RAB27B	-0.35	-5.99	-0.35	6.86e-9	Childhood body mass index;
CESC	cis	rs1050631	0.592	rs1789546	chr18:33725874	A/C	cg25426722	chr18:33708991	SLC39A6;ELP2	0.48	6.28	0.36	1.37e-9	Esophageal squamous cell cancer (length of survival);
CESC	cis	rs1552244	0.810	rs35711405	chr3:10116939	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	11.61	0.58	1.82e-25	Alzheimer's disease;
CESC	cis	rs6060717	0.698	rs8123175	chr20:34609872	T/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.47	5.66	0.33	3.92e-8	Hip circumference adjusted for BMI;
CESC	trans	rs61931739	0.500	rs73103774	chr12:34482279	C/T	cg26384229	chr12:38710491	ALG10B	0.7	10.54	0.54	6.6e-22	Morning vs. evening chronotype;
CESC	cis	rs780096	0.526	rs2911713	chr2:27640980	G/A	cg02592271	chr2:27665507	KRTCAP3	-0.29	-5.75	-0.33	2.42e-8	Total body bone mineral density;
CESC	cis	rs6860806	0.695	rs6867282	chr5:131583120	G/C	cg22638593	chr5:131593259	PDLIM4	0.4	5.13	0.3	5.56e-7	Breast cancer;
CESC	cis	rs4665809	0.590	rs1469523	chr2:26474631	T/A	cg04944784	chr2:26401820	FAM59B	0.96	10.5	0.54	8.76e-22	Gut microbiome composition (summer);
CESC	cis	rs709400	0.663	rs17679475	chr14:103916958	A/G	cg12935359	chr14:103987150	CKB	-0.55	-8.33	-0.46	4.26e-15	Body mass index;
CESC	cis	rs13382862	0.823	rs12710743	chr2:20880714	T/C	cg05481257	chr2:20870211	GDF7	-0.38	-5.83	-0.34	1.61e-8	Abdominal aortic aneurysm;
CESC	cis	rs2012796	0.665	rs72703728	chr14:81834523	G/A	cg02996355	chr14:81879375	NA	0.64	7.97	0.44	4.66e-14	Night sleep phenotypes;
CESC	cis	rs60871478	1.000	rs35488064	chr7:812722	G/C	cg27478167	chr7:817139	HEATR2	-0.46	-5.34	-0.31	2e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs17608059	0.504	rs11656981	chr17:13978777	A/G	cg27005118	chr17:13972210	COX10	-0.42	-6.36	-0.36	8.57e-10	Temperament;
CESC	cis	rs2295499	0.610	rs17164090	chr4:2676016	G/C	cg27239842	chr4:2403781	ZFYVE28	-0.31	-5.2	-0.3	3.96e-7	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
CESC	cis	rs875971	0.505	rs1167385	chr7:65513308	G/A	cg11987759	chr7:65425863	GUSB	0.45	6.06	0.35	4.53e-9	Aortic root size;
CESC	cis	rs6088580	0.524	rs1321306	chr20:33266379	T/A	cg08999081	chr20:33150536	PIGU	-0.45	-6.29	-0.36	1.33e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs7605827	0.857	rs10185835	chr2:15495763	A/G	cg19274914	chr2:15703543	NA	0.33	5.82	0.34	1.69e-8	Educational attainment (years of education);
CESC	cis	rs3768617	0.510	rs2333621	chr1:183090751	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.89	14.39	0.66	4.39e-35	Fuchs's corneal dystrophy;
CESC	cis	rs7762018	0.607	rs75999653	chr6:170066927	A/G	cg19338460	chr6:170058176	WDR27	-0.99	-8.06	-0.44	2.62e-14	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs2658782	1.000	rs2658782	chr11:93166731	T/G	cg15737290	chr11:93063684	CCDC67	0.51	6.48	0.37	4.55e-10	Pulmonary function decline;
CESC	cis	rs6061231	1.000	rs11908473	chr20:60957770	C/G	cg24112000	chr20:60950667	NA	-0.59	-7.97	-0.44	4.72e-14	Colorectal cancer;
CESC	trans	rs35110281	0.591	rs162390	chr21:44936826	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.49	6.7	0.38	1.27e-10	Mean corpuscular volume;
CESC	cis	rs4862750	0.872	rs9997374	chr4:187877549	T/A	cg10295955	chr4:187884368	NA	-1.04	-19.32	-0.76	1.73e-52	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg10295955	chr4:187884368	NA	1.01	19.84	0.77	2.64e-54	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg01644481	chr6:106809170	NA	0.48	6.1	0.35	3.67e-9	Gut microbiota (bacterial taxa);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg14532426	chr21:33245908	HUNK	-0.47	-6.24	-0.36	1.75e-9	Fibrinogen levels;
CESC	cis	rs9309473	0.687	rs6706235	chr2:73613558	C/G	cg20560298	chr2:73613845	ALMS1	-0.5	-6.75	-0.38	9.21e-11	Metabolite levels;
CESC	cis	rs2109514	0.967	rs55883210	chr7:116160524	G/A	cg12739419	chr7:116140593	CAV2	-0.36	-6.55	-0.37	3.02e-10	Prevalent atrial fibrillation;
CESC	cis	rs12476592	1.000	rs12476592	chr2:63850098	G/C	cg10828910	chr2:63850056	LOC388955	-0.49	-5.26	-0.31	2.94e-7	Childhood ear infection;
CESC	cis	rs3767633	0.925	rs1806594	chr1:161858860	T/C	cg09175582	chr1:161736000	ATF6	0.86	6.87	0.39	4.53e-11	IgG glycosylation;
CESC	cis	rs36051895	0.623	rs10283467	chr9:5244356	C/G	cg02405213	chr9:5042618	JAK2	0.53	6.39	0.37	7.61e-10	Pediatric autoimmune diseases;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg26468130	chr11:64053342	BAD;GPR137	-0.44	-6.03	-0.35	5.54e-9	Fibrinogen levels;
CESC	cis	rs709400	0.659	rs7160366	chr14:103944137	C/T	cg12935359	chr14:103987150	CKB	-0.54	-8.02	-0.44	3.39e-14	Body mass index;
CESC	cis	rs4924935	1.000	rs9905565	chr17:18758641	C/T	cg26378065	chr17:18585709	ZNF286B	0.47	5.91	0.34	1.03e-8	Pancreatic cancer;
CESC	cis	rs5769765	0.773	rs9616382	chr22:50312979	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.58	-6.23	-0.36	1.86e-9	Schizophrenia;
CESC	cis	rs950169	0.545	rs4354897	chr15:84644971	T/C	cg17507749	chr15:85114479	UBE2QP1	0.62	6.01	0.35	6.07e-9	Schizophrenia;
CESC	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg16145915	chr7:1198662	ZFAND2A	-0.47	-6.6	-0.38	2.2e-10	Longevity;Endometriosis;
CESC	cis	rs13191362	0.507	rs2846566	chr6:163059714	G/A	cg06582575	chr6:163149167	PACRG;PARK2	-0.52	-6.06	-0.35	4.74e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10589950	chr19:36231534	TMEM149	-0.56	-6.33	-0.36	1.02e-9	Gut microbiome composition (summer);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg16416718	chr1:6844519	CAMTA1	-0.47	-6.05	-0.35	5.04e-9	Ulcerative colitis;
CESC	trans	rs11098499	0.913	rs67073020	chr4:120152557	C/T	cg25214090	chr10:38739885	LOC399744	0.64	8.35	0.46	3.93e-15	Corneal astigmatism;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg11074549	chr14:75642944	TMED10	-0.51	-6.87	-0.39	4.56e-11	Fibrinogen levels;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg26105702	chr2:209120195	IDH1	-0.46	-6.23	-0.36	1.85e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs763121	0.853	rs2235230	chr22:39124467	A/G	cg14440974	chr22:39074834	NA	0.45	6.08	0.35	4.21e-9	Menopause (age at onset);
CESC	cis	rs713587	0.571	rs563590	chr2:25331172	A/G	cg01884057	chr2:25150051	NA	-0.3	-5.03	-0.3	8.85e-7	Body mass index in non-asthmatics;
CESC	cis	rs9309473	1.000	rs2056486	chr2:73717567	G/T	cg20560298	chr2:73613845	ALMS1	-0.47	-6.29	-0.36	1.28e-9	Metabolite levels;
CESC	cis	rs10089	1.000	rs10057122	chr5:127512063	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.72	9.28	0.5	6.38e-18	Ileal carcinoids;
CESC	cis	rs477692	0.673	rs579952	chr10:131356084	A/T	cg05714579	chr10:131428358	MGMT	-0.39	-5.06	-0.3	8.02e-7	Response to temozolomide;
CESC	cis	rs4835473	0.800	rs1988209	chr4:144912633	C/A	cg25736465	chr4:144833511	NA	0.44	6.64	0.38	1.8e-10	Immature fraction of reticulocytes;
CESC	cis	rs9916302	0.861	rs4795377	chr17:37669056	C/T	cg00129232	chr17:37814104	STARD3	-0.54	-7.13	-0.4	9.71e-12	Glomerular filtration rate (creatinine);
CESC	cis	rs7084402	0.967	rs7921371	chr10:60330531	G/C	cg07615347	chr10:60278583	BICC1	-0.55	-8.29	-0.45	5.55e-15	Refractive error;
CESC	cis	rs11809207	0.574	rs2783633	chr1:26505265	A/G	cg00147160	chr1:26503991	CNKSR1	0.27	5.14	0.3	5.4e-7	Height;
CESC	cis	rs473651	0.503	rs515342	chr2:239367296	A/G	cg01753270	chr2:239240285	TRAF3IP1	-0.45	-5.82	-0.34	1.68e-8	Multiple system atrophy;
CESC	cis	rs9543976	1.000	rs55927305	chr13:76135349	A/G	cg01531495	chr13:76123901	UCHL3	-0.56	-5.52	-0.32	8.15e-8	Diabetic retinopathy;
CESC	cis	rs1670533	0.585	rs6827206	chr4:1065071	A/T	cg27284194	chr4:1044797	NA	0.48	6.06	0.35	4.69e-9	Recombination rate (females);
CESC	cis	rs11031096	0.655	rs56172516	chr11:4182004	G/T	cg18678763	chr11:4115507	RRM1	-0.43	-5.95	-0.34	8.24e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	cis	rs875971	0.638	rs6460305	chr7:66060408	G/A	cg11764359	chr7:65958608	NA	-0.7	-9.25	-0.49	7.64e-18	Aortic root size;
CESC	cis	rs10504229	0.679	rs72649109	chr8:58031274	A/T	cg02725872	chr8:58115012	NA	-0.38	-5.09	-0.3	6.64e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs12136530	0.774	rs4912096	chr1:19775113	T/C	cg01832549	chr1:19774989	CAPZB	-0.47	-6.82	-0.39	6.32e-11	Lead levels in blood;
CESC	cis	rs6912958	0.781	rs3918467	chr6:88180388	C/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.45	-6.16	-0.35	2.72e-9	Monocyte percentage of white cells;
CESC	cis	rs4835473	0.831	rs7694353	chr4:144894940	T/G	cg25736465	chr4:144833511	NA	0.39	5.97	0.34	7.43e-9	Immature fraction of reticulocytes;
CESC	cis	rs35110281	0.715	rs2838353	chr21:45119228	C/T	cg21573476	chr21:45109991	RRP1B	-0.51	-7.29	-0.41	3.61e-12	Mean corpuscular volume;
CESC	cis	rs11098499	0.908	rs9995234	chr4:120321827	A/G	cg09307838	chr4:120376055	NA	0.9	11.83	0.59	3.4e-26	Corneal astigmatism;
CESC	cis	rs12893668	0.572	rs11540512	chr14:104147377	C/T	cg24130564	chr14:104152367	KLC1	-0.48	-6.36	-0.36	8.88e-10	Reticulocyte count;
CESC	cis	rs7412746	0.611	rs11204726	chr1:150743492	T/C	cg22823121	chr1:150693482	HORMAD1	0.47	6.57	0.37	2.6e-10	Melanoma;
CESC	cis	rs7772486	0.655	rs2142981	chr6:146071695	G/C	cg23711669	chr6:146136114	FBXO30	-1.01	-15.7	-0.69	1.03e-39	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs3105593	1.000	rs3131580	chr15:50854926	T/G	cg08437265	chr15:50716283	USP8	0.4	5.15	0.3	5.13e-7	QT interval;
CESC	cis	rs6938	0.575	rs12902515	chr15:75160998	G/C	cg14664628	chr15:75095509	CSK	-0.58	-8.21	-0.45	9.96e-15	Breast cancer;
CESC	cis	rs4727963	0.846	rs6466852	chr7:122706689	T/G	cg03640110	chr7:122635026	TAS2R16	-0.37	-5.7	-0.33	3.11e-8	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
CESC	cis	rs7618915	0.547	rs11130311	chr3:52675005	T/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.5	0.37	3.92e-10	Bipolar disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01777103	chr8:145550585	DGAT1	0.54	6.28	0.36	1.36e-9	Gut microbiome composition (summer);
CESC	trans	rs9354308	0.933	rs2802062	chr6:66561973	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.7	7.82	0.43	1.27e-13	Metabolite levels;
CESC	cis	rs2075371	0.611	rs34573600	chr7:134018937	C/T	cg20476274	chr7:133979776	SLC35B4	0.58	7.7	0.43	2.73e-13	Mean platelet volume;
CESC	cis	rs2070677	0.932	rs2987786	chr10:135365303	C/T	cg20169779	chr10:135381914	SYCE1	-0.71	-8.94	-0.48	6.99e-17	Gout;
CESC	trans	rs9325144	0.600	rs10880934	chr12:38730455	C/T	cg23762105	chr12:34175262	ALG10	0.48	6.22	0.36	1.89e-9	Morning vs. evening chronotype;
CESC	cis	rs4835473	0.932	rs5015757	chr4:144659297	C/T	cg25736465	chr4:144833511	NA	0.32	5.13	0.3	5.66e-7	Immature fraction of reticulocytes;
CESC	cis	rs3743266	0.507	rs56261931	chr15:60731618	C/T	cg22293140	chr15:60689852	ANXA2	-0.66	-7.42	-0.41	1.56e-12	Menarche (age at onset);
CESC	cis	rs3540	0.597	rs10152221	chr15:91047664	A/G	cg22089800	chr15:90895588	ZNF774	-0.65	-8.95	-0.48	6.18e-17	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs8014204	0.804	rs2241274	chr14:75251331	G/A	cg08847533	chr14:75593920	NEK9	0.46	5.87	0.34	1.27e-8	Caffeine consumption;
CESC	cis	rs116095464	0.681	rs9687745	chr5:229309	C/T	cg12570787	chr5:219185	SDHA;CCDC127	0.54	5.78	0.33	2.04e-8	Breast cancer;
CESC	cis	rs13095912	0.962	rs11916386	chr3:185308069	G/T	cg11274856	chr3:185301563	NA	0.37	6.13	0.35	3.15e-9	Systolic blood pressure;
CESC	cis	rs6540556	0.954	rs7536882	chr1:209936673	C/G	cg05527609	chr1:210001259	C1orf107	-0.46	-5.74	-0.33	2.65e-8	Red blood cell count;
CESC	cis	rs568617	0.767	rs2231884	chr11:65656564	C/T	cg19792802	chr11:65647270	CTSW	0.38	5.13	0.3	5.55e-7	Crohn's disease;
CESC	cis	rs7827545	1.000	rs6578232	chr8:135565690	G/A	cg17885191	chr8:135476712	NA	0.48	6.28	0.36	1.39e-9	Hypertension (SNP x SNP interaction);
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg22435810	chr17:18164253	SMCR7	0.48	6.16	0.35	2.63e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs2645694	0.603	rs2703123	chr4:77821154	C/T	cg18351406	chr4:77819688	ANKRD56	0.55	6.89	0.39	4.12e-11	Emphysema distribution in smoking;
CESC	cis	rs4835473	0.932	rs4835455	chr4:144883443	A/C	cg25736465	chr4:144833511	NA	0.37	5.29	0.31	2.6e-7	Immature fraction of reticulocytes;
CESC	cis	rs965469	1.000	rs6051723	chr20:3278512	C/A	cg25506879	chr20:3388711	C20orf194	-0.58	-6.15	-0.35	2.79e-9	IFN-related cytopenia;
CESC	cis	rs11676348	0.846	rs4674260	chr2:219002376	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.46	-6.1	-0.35	3.81e-9	Ulcerative colitis;
CESC	cis	rs4642101	0.662	rs3901664	chr3:12824660	T/C	cg05775895	chr3:12838266	CAND2	0.39	5.92	0.34	9.97e-9	QRS complex (12-leadsum);
CESC	cis	rs7605827	0.866	rs4668901	chr2:15521677	A/G	cg19274914	chr2:15703543	NA	0.35	6.27	0.36	1.43e-9	Educational attainment (years of education);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg05787931	chr3:52232012	ALAS1	-0.45	-6.4	-0.37	6.82e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs4728302	0.838	rs6954700	chr7:133588739	G/A	cg10665199	chr7:133106180	EXOC4	0.39	5.43	0.32	1.29e-7	Intelligence;Intelligence (multi-trait analysis);
CESC	cis	rs34330	0.562	rs10492235	chr12:12851339	T/G	cg04607235	chr12:12878440	APOLD1	-0.84	-9.05	-0.49	3.09e-17	Systemic lupus erythematosus;
CESC	cis	rs9611519	0.929	rs9611465	chr22:41426139	G/A	cg03806693	chr22:41940476	POLR3H	-0.58	-6.03	-0.35	5.58e-9	Neuroticism;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg15203618	chr11:85646125	NA	0.47	6.61	0.38	2.15e-10	Fibrinogen levels;
CESC	cis	rs9467711	0.790	rs1979	chr6:26377591	G/T	cg12826209	chr6:26865740	GUSBL1	0.64	5.41	0.32	1.39e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs7949030	0.588	rs2512563	chr11:62311249	C/G	cg13298116	chr11:62369859	EML3;MTA2	0.58	8.57	0.47	8.59e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs1799949	0.965	rs4793237	chr17:41436595	A/T	cg23758822	chr17:41437982	NA	1.0	17.07	0.72	1.38e-44	Menopause (age at onset);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg20314660	chr19:14530105	DDX39	-0.5	-6.49	-0.37	4.25e-10	Ulcerative colitis;
CESC	cis	rs6686643	1.000	rs957644	chr1:165616157	C/T	cg19407955	chr1:165599744	MGST3	-0.5	-5.12	-0.3	5.84e-7	Total ventricular volume;
CESC	cis	rs4819052	0.580	rs419322	chr21:46551702	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.51	5.43	0.32	1.3e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg09392819	chr2:26568944	SELI;GPR113	0.48	6.31	0.36	1.18e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs4819052	0.959	rs8130866	chr21:46672112	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.81	10.44	0.54	1.35e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs3733585	0.638	rs7377625	chr4:9953099	T/C	cg02734326	chr4:10020555	SLC2A9	-0.39	-5.58	-0.32	6e-8	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs8077889	0.956	rs17742347	chr17:41846468	A/G	cg26893861	chr17:41843967	DUSP3	-0.83	-9.55	-0.51	9.06e-19	Triglycerides;
CESC	cis	rs748404	0.697	rs473016	chr15:43558823	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.61	7.77	0.43	1.69e-13	Lung cancer;
CESC	cis	rs9303401	0.538	rs2240259	chr17:56458129	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.96	10.83	0.55	6.93e-23	Cognitive test performance;
CESC	cis	rs5769707	0.967	rs2051626	chr22:50008973	G/A	cg05373962	chr22:49881684	NA	-0.36	-6.25	-0.36	1.65e-9	Monocyte count;Monocyte percentage of white cells;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg11339840	chr1:203596058	ATP2B4	0.49	6.54	0.37	3.24e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs6502050	0.871	rs6502056	chr17:80070912	C/G	cg23985595	chr17:80112537	CCDC57	0.41	6.44	0.37	5.6e-10	Life satisfaction;
CESC	cis	rs736408	0.716	rs2300149	chr3:52822921	C/T	cg18099408	chr3:52552593	STAB1	-0.32	-5.14	-0.3	5.46e-7	Bipolar disorder;
CESC	cis	rs7020830	0.898	rs997318	chr9:37364094	C/T	cg14294708	chr9:37120828	ZCCHC7	1.13	19.5	0.77	3.97e-53	Schizophrenia;
CESC	cis	rs4853012	1.000	rs4853012	chr2:74361290	G/A	cg05890377	chr2:74357713	NA	0.72	7.83	0.43	1.16e-13	Gestational age at birth (maternal effect);
CESC	cis	rs933688	0.526	rs2973468	chr5:90540879	A/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.54	-5.38	-0.31	1.64e-7	Smoking behavior;
CESC	cis	rs6665290	0.904	rs6664955	chr1:227183434	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.21	-33.23	-0.9	1.68e-96	Myeloid white cell count;
CESC	cis	rs7208859	0.673	rs56146117	chr17:29153325	C/T	cg13385521	chr17:29058706	SUZ12P	0.75	6.0	0.35	6.29e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs1862618	0.641	rs170733	chr5:56249251	A/G	cg24549020	chr5:56110836	MAP3K1	-0.5	-6.07	-0.35	4.29e-9	Initial pursuit acceleration;
CESC	cis	rs10504229	0.773	rs1874374	chr8:58194422	A/G	cg24829409	chr8:58192753	C8orf71	-0.72	-8.22	-0.45	9.34e-15	Developmental language disorder (linguistic errors);
CESC	cis	rs1808579	0.839	rs1788808	chr18:21090023	A/G	cg14672496	chr18:21087552	C18orf8	0.4	5.64	0.33	4.37e-8	Hip circumference;Body mass index;BMI (adjusted for smoking behaviour);
CESC	cis	rs514406	0.861	rs72637996	chr1:53249618	A/T	cg08736216	chr1:53307985	ZYG11A	0.32	5.74	0.33	2.63e-8	Monocyte count;
CESC	cis	rs10743315	0.557	rs74465549	chr12:19344365	A/C	cg02471346	chr12:19282374	PLEKHA5	0.72	5.43	0.32	1.28e-7	Gut microbiota (bacterial taxa);
CESC	cis	rs8031584	0.678	rs8035703	chr15:31168472	T/C	cg14298792	chr15:30685198	CHRFAM7A	-0.46	-5.59	-0.32	5.55e-8	Huntington's disease progression;
CESC	cis	rs60871478	1.000	rs62432861	chr7:807649	G/A	cg05535760	chr7:792225	HEATR2	0.88	11.02	0.56	1.76e-23	Cerebrospinal P-tau181p levels;
CESC	cis	rs2842992	0.724	rs15982	chr6:160199687	T/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.83	11.64	0.58	1.46e-25	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs6032067	0.929	rs56131549	chr20:43842014	A/T	cg11264863	chr20:43835661	SEMG1	0.48	5.26	0.31	2.99e-7	Blood protein levels;
CESC	cis	rs568617	0.953	rs658938	chr11:65651830	A/G	cg00576331	chr11:65640516	EFEMP2	0.45	5.3	0.31	2.48e-7	Crohn's disease;
CESC	cis	rs6570726	0.791	rs6902404	chr6:145905254	G/A	cg23711669	chr6:146136114	FBXO30	0.84	12.46	0.61	2.29e-28	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs11252926	0.528	rs11252090	chr10:436547	C/T	cg16386425	chr10:429943	DIP2C	0.5	6.4	0.37	7.11e-10	Psychosis in Alzheimer's disease;
CESC	cis	rs9649213	0.593	rs11760930	chr7:97915789	G/A	cg08684580	chr7:98029266	BAIAP2L1	-0.33	-5.22	-0.31	3.64e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs17376456	0.877	rs10476598	chr5:93367281	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.63	-5.5	-0.32	8.79e-8	Diabetic retinopathy;
CESC	cis	rs57083693	0.518	rs12317211	chr12:101704521	C/T	cg22051763	chr12:101673672	UTP20	-0.45	-5.69	-0.33	3.4e-8	Alcohol dependence (age at onset);
CESC	cis	rs6456156	0.792	rs10946213	chr6:167516095	A/G	cg07741184	chr6:167504864	NA	-0.33	-5.94	-0.34	8.82e-9	Primary biliary cholangitis;
CESC	cis	rs7267979	0.966	rs416745	chr20:25438868	T/C	cg08601574	chr20:25228251	PYGB	0.37	5.31	0.31	2.31e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs769267	1.000	rs7246748	chr19:19433105	C/T	cg03709012	chr19:19516395	GATAD2A	-0.96	-14.2	-0.66	2.12e-34	Tonsillectomy;
CESC	cis	rs6860806	0.507	rs272880	chr5:131670178	C/T	cg18758796	chr5:131593413	PDLIM4	0.38	5.26	0.31	2.95e-7	Breast cancer;
CESC	cis	rs9399135	0.967	rs4637662	chr6:135298158	T/C	cg24558204	chr6:135376177	HBS1L	0.5	6.75	0.38	9.09e-11	Red blood cell count;
CESC	cis	rs1832871	0.711	rs12527510	chr6:158657299	T/G	cg07165851	chr6:158734300	TULP4	0.56	5.79	0.34	1.96e-8	Height;
CESC	cis	rs34172651	0.876	rs7186893	chr16:24806420	G/T	cg06028605	chr16:24865363	SLC5A11	0.41	6.22	0.36	1.94e-9	Intelligence (multi-trait analysis);
CESC	cis	rs4665809	0.590	rs4665837	chr2:26434022	C/A	cg26119090	chr2:26468346	HADHA;HADHB	-1.09	-12.46	-0.61	2.41e-28	Gut microbiome composition (summer);
CESC	cis	rs7772486	0.790	rs2265469	chr6:146219049	T/C	cg05347473	chr6:146136440	FBXO30	0.55	7.05	0.4	1.57e-11	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs2814021	0.545	rs10994777	chr10:63233988	G/A	cg08188886	chr14:105633697	JAG2	0.43	6.38	0.36	7.75e-10	Obesity-related traits;
CESC	cis	rs4713118	0.662	rs149970	chr6:27980220	C/T	cg26335602	chr6:28129616	ZNF389	0.43	5.88	0.34	1.21e-8	Parkinson's disease;
CESC	cis	rs28735056	0.903	rs56185453	chr18:77638297	A/G	cg20368463	chr18:77673604	PQLC1	-0.4	-5.17	-0.3	4.55e-7	Schizophrenia;
CESC	cis	rs2303759	0.709	rs10414921	chr19:49823047	C/T	cg22590775	chr19:49891494	CCDC155	0.45	5.04	0.3	8.62e-7	Multiple sclerosis;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg08337184	chr19:11558539	PRKCSH	0.46	6.67	0.38	1.48e-10	Fibrinogen levels;
CESC	trans	rs57221529	0.766	rs56278696	chr5:582669	A/G	cg25482853	chr8:67687455	SGK3	1.0	9.94	0.52	5.32e-20	Lung disease severity in cystic fibrosis;
CESC	cis	rs11098499	0.865	rs28634456	chr4:120375778	A/G	cg24375607	chr4:120327624	NA	0.46	5.66	0.33	3.94e-8	Corneal astigmatism;
CESC	cis	rs1538970	0.748	rs11211137	chr1:46013892	T/A	cg03146154	chr1:46216737	IPP	0.52	5.81	0.34	1.81e-8	Platelet count;
CESC	cis	rs3008870	0.920	rs3008865	chr1:67402838	T/C	cg08660285	chr1:67390436	MIER1;WDR78	1.02	14.14	0.66	3.43e-34	Lymphocyte percentage of white cells;
CESC	cis	rs9843304	0.616	rs4681177	chr3:149203000	G/T	cg20906640	chr3:149182207	NA	-0.33	-5.13	-0.3	5.64e-7	Gallstone disease;
CESC	cis	rs875971	0.862	rs937494	chr7:65764678	T/A	cg12463550	chr7:65579703	CRCP	-0.46	-5.86	-0.34	1.34e-8	Aortic root size;
CESC	cis	rs3760982	0.585	rs8109478	chr19:44298256	C/T	cg11993925	chr19:44307056	LYPD5	0.33	5.68	0.33	3.47e-8	Breast cancer (estrogen-receptor negative);Breast cancer;
CESC	cis	rs9916302	0.904	rs9944411	chr17:37483599	T/C	cg00129232	chr17:37814104	STARD3	0.51	6.37	0.36	8.22e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs832540	0.656	rs2408597	chr5:56098632	G/A	cg12311346	chr5:56204834	C5orf35	-0.41	-5.08	-0.3	7.3e-7	Coronary artery disease;
CESC	cis	rs35110281	0.837	rs7279968	chr21:45077398	C/G	cg01579765	chr21:45077557	HSF2BP	-0.57	-9.97	-0.52	4.43e-20	Mean corpuscular volume;
CESC	cis	rs644799	0.511	rs10831420	chr11:95478209	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.41	5.14	0.3	5.29e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.58	7.49	0.42	1.04e-12	Prudent dietary pattern;
CESC	cis	rs3733585	0.673	rs4467563	chr4:9953460	A/T	cg02734326	chr4:10020555	SLC2A9	-0.39	-5.64	-0.33	4.45e-8	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs916888	0.610	rs199442	chr17:44820122	G/A	cg17911788	chr17:44343683	NA	-0.43	-6.76	-0.38	8.86e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs4862750	0.874	rs6822062	chr4:187895553	T/C	cg22105103	chr4:187893119	NA	0.49	7.23	0.41	5.11e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1580019	0.563	rs896137	chr7:32579345	G/T	cg06627557	chr7:32535165	LSM5;AVL9	1.07	18.41	0.75	2.5e-49	Cognitive ability;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg03068646	chr9:97136929	HIATL1	-0.45	-6.54	-0.37	3.2e-10	Gambling;
CESC	cis	rs11031096	0.678	rs61899754	chr11:4201312	A/T	cg18678763	chr11:4115507	RRM1	-0.39	-5.06	-0.3	7.72e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	cis	rs4568518	0.740	rs11543650	chr7:18009880	T/C	cg03009463	chr7:17980271	SNX13	0.48	6.28	0.36	1.38e-9	Measles;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg03956833	chr1:1051711	C1orf159	-0.46	-6.64	-0.38	1.73e-10	Gambling;
CESC	cis	rs11122272	0.735	rs2790893	chr1:231508976	T/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.57	-7.78	-0.43	1.63e-13	Hemoglobin concentration;
CESC	cis	rs6460942	0.915	rs62448621	chr7:12459941	G/A	cg10578991	chr7:12443926	VWDE	-0.51	-5.61	-0.33	5.17e-8	Coronary artery disease;
CESC	cis	rs8062405	1.000	rs12446589	chr16:28870962	G/A	cg05966235	chr16:28915196	ATP2A1	0.35	5.18	0.3	4.38e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs916888	0.821	rs415430	chr17:44859144	C/T	cg14517863	chr17:44321492	NA	-0.4	-5.17	-0.3	4.56e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs7666738	0.649	rs28865589	chr4:98954279	C/A	cg03467027	chr4:99064603	C4orf37	0.45	5.57	0.32	6.34e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs79349575	0.715	rs62075844	chr17:47002389	G/A	cg26022315	chr17:47021804	SNF8	0.39	5.18	0.3	4.5e-7	Type 2 diabetes;
CESC	cis	rs1461503	0.966	rs1461501	chr11:122844416	A/G	cg27398637	chr11:122830231	C11orf63	-0.55	-8.32	-0.45	4.77e-15	Menarche (age at onset);
CESC	cis	rs7017914	0.967	rs12680166	chr8:71678638	G/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.22	-0.31	3.65e-7	Bone mineral density;
CESC	cis	rs13256369	0.951	rs13260947	chr8:8565883	A/G	cg00074818	chr8:8560427	CLDN23	0.37	5.43	0.32	1.26e-7	Obesity-related traits;
CESC	cis	rs9733	0.596	rs6587516	chr1:150623221	C/T	cg04414720	chr1:150670196	GOLPH3L	0.63	9.04	0.49	3.47e-17	Tonsillectomy;
CESC	cis	rs2414059	0.518	rs3098176	chr15:50781963	T/A	cg08437265	chr15:50716283	USP8	0.47	5.91	0.34	1.03e-8	QT interval;
CESC	cis	rs7412746	0.658	rs12090215	chr1:150893660	C/A	cg22823121	chr1:150693482	HORMAD1	0.4	5.64	0.33	4.46e-8	Melanoma;
CESC	cis	rs76419734	0.510	rs2216515	chr4:106750214	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	-0.6	-6.14	-0.35	3.02e-9	Post bronchodilator FEV1;
CESC	cis	rs666930	1.000	rs666930	chr1:120258970	A/G	cg19096424	chr1:120255104	PHGDH	0.46	6.03	0.35	5.37e-9	Breast cancer;
CESC	cis	rs561341	1.000	rs72821952	chr17:30248133	T/A	cg12193833	chr17:30244370	NA	-0.71	-6.37	-0.36	8.43e-10	Hip circumference adjusted for BMI;
CESC	cis	rs11098499	1.000	rs35643470	chr4:120184948	T/C	cg09307838	chr4:120376055	NA	0.89	11.91	0.59	1.77e-26	Corneal astigmatism;
CESC	cis	rs7666738	0.830	rs6855393	chr4:99056534	T/C	cg17366294	chr4:99064904	C4orf37	0.62	8.85	0.48	1.3e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs780096	0.546	rs7563162	chr2:27631191	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.32	-6.02	-0.35	5.91e-9	Total body bone mineral density;
CESC	cis	rs2370759	1.000	rs78959390	chr10:32616346	C/T	cg01819863	chr10:32635814	EPC1	1.16	12.42	0.61	3.2e-28	Sexual dysfunction (female);
CESC	cis	rs2635047	1.000	rs2635043	chr18:44679769	A/G	cg19077165	chr18:44547161	KATNAL2	-0.44	-5.93	-0.34	9.55e-9	Educational attainment;
CESC	cis	rs7267979	0.966	rs4815425	chr20:25398876	G/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.87	-18.09	-0.74	3.47e-48	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs1538970	0.816	rs9727262	chr1:45998579	T/G	cg05343316	chr1:45956843	TESK2	0.86	11.41	0.57	8.44e-25	Platelet count;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg02099313	chr1:231114956	TTC13;ARV1	0.5	6.53	0.37	3.39e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs2637266	0.783	rs11001866	chr10:78486774	C/T	cg18941641	chr10:78392320	NA	0.45	8.84	0.48	1.41e-16	Pulmonary function;
CESC	cis	rs1185460	0.967	rs1784461	chr11:118937985	G/A	cg01677386	chr11:118938358	VPS11	-0.44	-5.63	-0.33	4.69e-8	Coronary artery disease;
CESC	cis	rs2836974	0.863	rs12483216	chr21:40539614	T/C	cg11890956	chr21:40555474	PSMG1	1.17	22.42	0.81	3.65e-63	Cognitive function;
CESC	cis	rs769267	0.930	rs1063966	chr19:19616742	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	7.46	0.42	1.23e-12	Tonsillectomy;
CESC	cis	rs3540	0.533	rs2256110	chr15:90971036	T/C	cg10434728	chr15:90938212	IQGAP1	0.41	7.4	0.41	1.8e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs1799949	0.602	rs8176257	chr17:41216205	G/T	cg23758822	chr17:41437982	NA	1.03	12.64	0.61	5.44e-29	Menopause (age at onset);
CESC	cis	rs9311474	0.507	rs6787154	chr3:52784416	C/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.31	5.65	0.33	4.11e-8	Electroencephalogram traits;
CESC	cis	rs5758511	0.680	rs5751243	chr22:42617177	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.57	8.51	0.46	1.28e-15	Birth weight;
CESC	cis	rs832540	0.564	rs33329	chr5:56145068	T/C	cg22800045	chr5:56110881	MAP3K1	0.49	5.88	0.34	1.24e-8	Coronary artery disease;
CESC	trans	rs3780486	0.505	rs10813958	chr9:33165985	A/G	cg04842962	chr6:43655489	MRPS18A	0.67	10.15	0.53	1.16e-20	IgG glycosylation;
CESC	cis	rs7937682	0.889	rs7926485	chr11:111536670	G/A	cg22437258	chr11:111473054	SIK2	0.68	9.21	0.49	1e-17	Primary sclerosing cholangitis;
CESC	cis	rs30380	0.587	rs469674	chr5:96130015	G/C	cg16492584	chr5:96139282	ERAP1	-0.49	-6.73	-0.38	1.05e-10	Cerebrospinal fluid biomarker levels;
CESC	cis	rs1707322	0.685	rs11211177	chr1:46226349	A/G	cg05343316	chr1:45956843	TESK2	0.49	6.21	0.36	2.08e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg13763503	chr9:99801410	CTSL2	0.48	6.33	0.36	1.07e-9	Systemic lupus erythematosus;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg12633985	chr6:26056540	HIST1H1C	0.47	6.25	0.36	1.65e-9	Thyroid stimulating hormone;
CESC	cis	rs7635838	0.892	rs9870881	chr3:11447082	A/G	cg00170343	chr3:11313890	ATG7	0.42	5.57	0.32	6.23e-8	HDL cholesterol;
CESC	cis	rs13108904	0.901	rs12509700	chr4:1296321	A/G	cg16405210	chr4:1374714	KIAA1530	-0.48	-6.13	-0.35	3.1e-9	Obesity-related traits;
CESC	cis	rs611744	0.608	rs612744	chr8:109245991	G/A	cg21045802	chr8:109455806	TTC35	0.46	5.72	0.33	2.92e-8	Dupuytren's disease;
CESC	cis	rs2243480	1.000	rs160634	chr7:65528664	C/T	cg12463550	chr7:65579703	CRCP	-0.59	-5.19	-0.3	4.22e-7	Diabetic kidney disease;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg07081388	chr14:50065245	PPIL5	-0.54	-6.77	-0.38	8.02e-11	Ulcerative colitis;
CESC	cis	rs7618915	0.547	rs10865973	chr3:52718154	A/T	cg18404041	chr3:52824283	ITIH1	-0.4	-6.73	-0.38	1.02e-10	Bipolar disorder;
CESC	cis	rs7927592	0.956	rs6591341	chr11:68335478	C/T	cg01657329	chr11:68192670	LRP5	-0.4	-5.13	-0.3	5.61e-7	Total body bone mineral density;
CESC	trans	rs5769765	0.908	rs9616388	chr22:50313438	T/C	cg09872104	chr7:134855509	C7orf49	-0.55	-6.32	-0.36	1.11e-9	Schizophrenia;
CESC	cis	rs514406	0.861	rs11206011	chr1:53235910	T/C	cg27535305	chr1:53392650	SCP2	0.31	5.51	0.32	8.35e-8	Monocyte count;
CESC	cis	rs17711722	0.740	rs7809991	chr7:65406218	A/G	cg14393609	chr7:65229607	NA	0.53	7.22	0.41	5.48e-12	Calcium levels;
CESC	cis	rs78456975	0.622	rs11896517	chr2:1518112	A/G	cg26248373	chr2:1572462	NA	-0.53	-5.47	-0.32	1.07e-7	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs654950	0.875	rs116747365	chr1:41994792	C/T	cg06885757	chr1:42089581	HIVEP3	-0.44	-6.82	-0.39	6.21e-11	Airway imaging phenotypes;
CESC	cis	rs950027	0.620	rs2486274	chr15:45666228	G/T	cg21132104	chr15:45694354	SPATA5L1	0.67	8.55	0.46	1.01e-15	Response to fenofibrate (adiponectin levels);
CESC	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg04155289	chr7:94953770	PON1	-0.49	-6.93	-0.39	3.15e-11	Paraoxonase activity;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg10891888	chr12:46765615	SLC38A2	-0.4	-6.1	-0.35	3.84e-9	Gambling;
CESC	cis	rs36051895	0.564	rs7874624	chr9:5179865	A/G	cg02405213	chr9:5042618	JAK2	-0.51	-6.56	-0.37	2.87e-10	Pediatric autoimmune diseases;
CESC	cis	rs9583531	0.657	rs7337126	chr13:111376788	A/G	cg15841412	chr13:111365552	ING1	0.44	5.42	0.32	1.37e-7	Coronary artery disease;
CESC	cis	rs2991971	1.000	rs622798	chr1:46015271	T/G	cg03146154	chr1:46216737	IPP	-0.45	-5.58	-0.32	5.83e-8	High light scatter reticulocyte count;
CESC	cis	rs4891159	0.527	rs689642	chr18:74119120	A/C	cg24786174	chr18:74118243	ZNF516	0.86	16.2	0.71	1.71e-41	Longevity;
CESC	cis	rs10504229	0.679	rs12675340	chr8:58035501	T/A	cg24829409	chr8:58192753	C8orf71	-0.46	-5.9	-0.34	1.08e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs1552244	0.935	rs28815328	chr3:10062227	G/A	cg00149659	chr3:10157352	C3orf10	0.75	9.12	0.49	1.96e-17	Alzheimer's disease;
CESC	cis	rs523522	1.000	rs1563333	chr12:120934407	C/T	cg12219531	chr12:120966889	COQ5	0.75	9.95	0.52	5.02e-20	High light scatter reticulocyte count;
CESC	cis	rs6998277	0.830	rs12543008	chr8:103603747	C/T	cg10187029	chr8:103597600	NA	0.74	9.75	0.51	2.16e-19	Migraine;
CESC	cis	rs959260	1.000	rs4789186	chr17:73386086	C/T	cg20590849	chr17:73267439	MIF4GD	-0.57	-6.41	-0.37	6.55e-10	Systemic lupus erythematosus;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg25469252	chr19:55994021	ZNF628	0.42	6.23	0.36	1.82e-9	Fibrinogen levels;
CESC	trans	rs561341	0.825	rs2008368	chr17:30347397	T/C	cg27661571	chr11:113659931	NA	-0.83	-7.34	-0.41	2.56e-12	Hip circumference adjusted for BMI;
CESC	cis	rs7264396	0.779	rs6087723	chr20:34175783	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	0.6	7.1	0.4	1.15e-11	Total cholesterol levels;
CESC	cis	rs1348850	0.567	rs12994392	chr2:178536640	A/G	cg23306229	chr2:178417860	TTC30B	0.53	6.97	0.39	2.55e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs801193	1.000	rs6975195	chr7:66124774	T/A	cg25985355	chr7:65971099	NA	0.32	5.23	0.31	3.53e-7	Aortic root size;
CESC	cis	rs1801251	1.000	rs283475	chr2:233654381	A/C	cg08000102	chr2:233561755	GIGYF2	-0.7	-10.06	-0.53	2.24e-20	Coronary artery disease;
CESC	trans	rs57221529	0.766	rs1399381	chr5:589853	G/T	cg25482853	chr8:67687455	SGK3	1.0	10.06	0.53	2.27e-20	Lung disease severity in cystic fibrosis;
CESC	cis	rs9837602	1.000	rs7627991	chr3:99808338	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.49	6.83	0.39	5.64e-11	Breast cancer;
CESC	cis	rs3785574	0.962	rs62077483	chr17:61806380	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.58	7.16	0.4	7.84e-12	Height;
CESC	cis	rs9549367	0.826	rs2302755	chr13:113898418	C/T	cg00898013	chr13:113819073	PROZ	-0.54	-7.67	-0.43	3.27e-13	Platelet distribution width;
CESC	cis	rs7044106	0.762	rs1530370	chr9:123424552	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.76	10.85	0.55	6.01e-23	Hip circumference adjusted for BMI;
CESC	cis	rs9549260	0.755	rs9532571	chr13:41218670	C/T	cg21288729	chr13:41239152	FOXO1	0.63	8.18	0.45	1.22e-14	Red blood cell count;
CESC	cis	rs8103278	0.507	rs4802275	chr19:46260375	C/T	cg12641515	chr19:46296257	DMWD	0.73	9.8	0.52	1.5e-19	Coronary artery disease;
CESC	cis	rs10129255	0.500	rs6576231	chr14:107191930	T/C	cg23076370	chr14:107095027	NA	-0.65	-9.51	-0.5	1.23e-18	Kawasaki disease;
CESC	trans	rs66573146	0.561	rs67245546	chr4:6947164	T/C	cg07817883	chr1:32538562	TMEM39B	1.35	8.85	0.48	1.24e-16	Granulocyte percentage of myeloid white cells;
CESC	cis	rs3540	0.553	rs8042861	chr15:90977333	G/T	cg22089800	chr15:90895588	ZNF774	0.64	8.92	0.48	7.76e-17	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs9309473	0.519	rs1881246	chr2:73650122	T/A	cg20560298	chr2:73613845	ALMS1	0.5	7.21	0.4	5.96e-12	Metabolite levels;
CESC	cis	rs79349575	0.783	rs56046215	chr17:47008757	A/T	cg16584676	chr17:46985605	UBE2Z	0.54	6.68	0.38	1.44e-10	Type 2 diabetes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19507727	chr1:233086292	C1orf57	0.65	7.1	0.4	1.15e-11	Gut microbiome composition (summer);
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg11421459	chr7:91763989	CYP51A1	-0.53	-7.07	-0.4	1.4e-11	Asthma;
CESC	cis	rs9488822	0.702	rs6909746	chr6:116352750	C/T	cg26893134	chr6:116381904	FRK	0.25	6.03	0.35	5.41e-9	Cholesterol, total;LDL cholesterol;
CESC	cis	rs2992756	1.000	rs2992756	chr1:18807339	T/C	cg05040210	chr1:18807594	KLHDC7A	-0.37	-6.75	-0.38	9.08e-11	Breast cancer;
CESC	cis	rs62064224	0.714	rs62064225	chr17:30635429	C/T	cg18200150	chr17:30822561	MYO1D	0.38	5.14	0.3	5.46e-7	Schizophrenia;
CESC	cis	rs644799	1.000	rs617999	chr11:95589935	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.87	12.56	0.61	1.04e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs72627123	0.867	rs57685514	chr14:74487592	A/G	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.78	5.82	0.34	1.74e-8	Morning vs. evening chronotype;
CESC	cis	rs6499255	0.951	rs76407217	chr16:69690355	A/T	cg15192750	chr16:69999425	NA	0.46	5.34	0.31	2.04e-7	IgE levels;
CESC	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.77	-10.59	-0.55	4.53e-22	Prudent dietary pattern;
CESC	cis	rs35110281	0.774	rs2838323	chr21:44999086	G/A	cg04455712	chr21:45112962	RRP1B	0.39	5.81	0.34	1.78e-8	Mean corpuscular volume;
CESC	cis	rs654950	0.776	rs2759254	chr1:42035683	G/C	cg06885757	chr1:42089581	HIVEP3	-0.63	-9.95	-0.52	5.21e-20	Airway imaging phenotypes;
CESC	cis	rs1552244	1.000	rs4260416	chr3:10125283	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.85	-11.88	-0.59	2.2e-26	Alzheimer's disease;
CESC	cis	rs9914988	0.832	rs34901720	chr17:27179518	A/G	cg20469991	chr17:27169893	C17orf63	-0.43	-5.14	-0.3	5.43e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CESC	cis	rs2777491	0.872	rs7163649	chr15:41586798	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.6	-9.07	-0.49	2.7e-17	Ulcerative colitis;
CESC	cis	rs9811920	0.732	rs793446	chr3:99578114	A/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.39	-5.05	-0.3	8.14e-7	Axial length;
CESC	cis	rs9649213	0.593	rs34776142	chr7:97899873	C/T	cg00277769	chr7:97922759	BAIAP2L1	-0.32	-5.1	-0.3	6.4e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs72634258	0.554	rs13306061	chr1:7913445	C/T	cg00042356	chr1:8021962	PARK7	0.57	5.51	0.32	8.3e-8	Inflammatory bowel disease;
CESC	cis	rs8092503	1.000	rs1965662	chr18:52486080	C/T	cg12377874	chr18:52495404	RAB27B	0.39	6.39	0.37	7.28e-10	Childhood body mass index;
CESC	cis	rs2735413	0.918	rs11150037	chr16:78075774	A/G	cg04733911	chr16:78082701	NA	-0.53	-9.01	-0.48	4.08e-17	Systolic blood pressure (alcohol consumption interaction);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg26731060	chr17:27229515	DHRS13	-0.49	-6.45	-0.37	5.16e-10	Ulcerative colitis;
CESC	cis	rs250677	0.522	rs12523526	chr5:148349107	A/C	cg18129178	chr5:148520854	ABLIM3	0.47	5.04	0.3	8.62e-7	Breast cancer;
CESC	cis	rs3820068	0.581	rs16849152	chr1:15921774	A/C	cg13390004	chr1:15929781	NA	0.34	5.36	0.31	1.85e-7	Systolic blood pressure;
CESC	cis	rs6088580	0.634	rs6059875	chr20:33086090	T/G	cg24642439	chr20:33292090	TP53INP2	0.5	6.55	0.37	3.05e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs7267979	1.000	rs4815417	chr20:25379526	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.87	-17.84	-0.74	2.73e-47	Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs629535	0.773	rs686683	chr8:70070364	G/A	cg21567404	chr3:27674614	NA	0.88	10.34	0.54	2.74e-21	Dupuytren's disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg15060598	chr10:65186990	JMJD1C	0.49	6.44	0.37	5.68e-10	Fibrinogen levels;
CESC	cis	rs4665809	0.590	rs13016300	chr2:26468365	G/C	cg26314531	chr2:26401878	FAM59B	0.85	9.04	0.49	3.44e-17	Gut microbiome composition (summer);
CESC	cis	rs2839186	0.619	rs55689527	chr21:47622727	A/G	cg10351095	chr21:47802916	PCNT	-0.43	-5.58	-0.32	5.84e-8	Testicular germ cell tumor;
CESC	cis	rs708547	0.647	rs1626594	chr4:57878254	G/A	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.42	-5.58	-0.32	6.06e-8	Response to bleomycin (chromatid breaks);
CESC	cis	rs4891159	0.790	rs56077581	chr18:74116865	T/G	cg24786174	chr18:74118243	ZNF516	-0.74	-11.59	-0.58	2.15e-25	Longevity;
CESC	cis	rs1552244	0.832	rs3732968	chr3:10013273	A/G	cg08888203	chr3:10149979	C3orf24	0.48	6.0	0.35	6.3e-9	Alzheimer's disease;
CESC	cis	rs225245	0.755	rs6505493	chr17:34028901	A/G	cg05299278	chr17:33885742	SLFN14	0.39	5.55	0.32	7.07e-8	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05291119	chr3:75484440	FAM86D	-0.63	-7.17	-0.4	7.41e-12	Gut microbiome composition (summer);
CESC	cis	rs7615952	0.641	rs60839048	chr3:125807938	G/A	cg04553112	chr3:125709451	NA	-0.55	-5.82	-0.34	1.71e-8	Blood pressure (smoking interaction);
CESC	cis	rs3540	0.597	rs4620932	chr15:91036569	G/A	cg22089800	chr15:90895588	ZNF774	0.61	8.14	0.45	1.57e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs798554	0.836	rs798490	chr7:2801542	C/T	cg18446336	chr7:2847575	GNA12	-0.38	-5.75	-0.33	2.44e-8	Height;
CESC	cis	rs7552404	0.727	rs6678348	chr1:76332463	C/T	cg10523679	chr1:76189770	ACADM	0.69	6.69	0.38	1.32e-10	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs1055129	0.560	rs3682	chr17:73942150	A/G	cg08125733	chr17:73851984	WBP2	0.47	6.38	0.37	7.65e-10	White matter hyperintensity burden;
CESC	cis	rs6460942	1.000	rs73053527	chr7:12313008	C/A	cg20607287	chr7:12443886	VWDE	-0.79	-8.51	-0.46	1.32e-15	Coronary artery disease;
CESC	cis	rs12142240	0.698	rs17361915	chr1:46847321	C/T	cg10495392	chr1:46806563	NSUN4	0.56	6.15	0.35	2.86e-9	Menopause (age at onset);
CESC	cis	rs654950	0.743	rs115951861	chr1:41992488	C/T	cg06885757	chr1:42089581	HIVEP3	-0.44	-6.75	-0.38	9.38e-11	Airway imaging phenotypes;
CESC	trans	rs916888	0.773	rs538628	chr17:44787313	G/C	cg23590916	chr17:43697445	MGC57346	0.66	6.72	0.38	1.09e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs6456156	0.586	rs7742305	chr6:167485723	C/T	cg23791538	chr6:167370224	RNASET2	-0.5	-6.37	-0.36	8.51e-10	Primary biliary cholangitis;
CESC	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg23708337	chr7:1209742	NA	0.52	5.16	0.3	4.88e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs17253792	0.822	rs13379342	chr14:56050452	A/G	cg01858014	chr14:56050164	KTN1	-0.95	-7.37	-0.41	2.23e-12	Putamen volume;
CESC	cis	rs801193	0.660	rs974239	chr7:66213491	G/A	cg12463550	chr7:65579703	CRCP	0.56	7.13	0.4	9.77e-12	Aortic root size;
CESC	trans	rs3808502	0.549	rs11991139	chr8:11428395	C/T	cg15556689	chr8:8085844	FLJ10661	-0.63	-7.51	-0.42	9.29e-13	Neuroticism;
CESC	trans	rs1850744	0.510	rs10003673	chr4:9862300	G/A	cg06372015	chr11:43602000	MIR129-2	0.59	6.0	0.35	6.4e-9	Economic and political preferences;
CESC	cis	rs796364	0.806	rs188102	chr2:200903189	T/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.83	-7.71	-0.43	2.49e-13	Schizophrenia;
CESC	cis	rs854765	0.547	rs2955372	chr17:17970229	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.62	-8.86	-0.48	1.18e-16	Total body bone mineral density;
CESC	cis	rs870825	0.616	rs2141258	chr4:185609576	A/C	cg04058563	chr4:185651563	MLF1IP	-0.59	-6.18	-0.36	2.36e-9	Blood protein levels;
CESC	cis	rs736408	0.812	rs1075653	chr3:52825528	T/C	cg05564831	chr3:52568323	NT5DC2	0.45	6.48	0.37	4.36e-10	Bipolar disorder;
CESC	cis	rs801193	1.000	rs2659912	chr7:66157999	G/C	cg14393609	chr7:65229607	NA	0.47	6.31	0.36	1.15e-9	Aortic root size;
CESC	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.48	-5.2	-0.3	4.05e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs3820928	0.874	rs1320407	chr2:227867385	G/T	cg11843606	chr2:227700838	RHBDD1	-0.41	-5.28	-0.31	2.66e-7	Pulmonary function;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg22482658	chr9:111624589	ACTL7A	0.43	6.3	0.36	1.23e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14611774	chr19:9929570	FBXL12	0.55	6.2	0.36	2.18e-9	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02184338	chr7:101331866	NA	0.62	7.17	0.4	7.69e-12	Gut microbiome composition (summer);
CESC	cis	rs10885582	0.781	rs11196783	chr10:116304133	T/A	cg17056676	chr10:116301354	ABLIM1	-0.29	-5.22	-0.31	3.6e-7	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23466916	chr2:192543328	OBFC2A	-0.56	-6.53	-0.37	3.34e-10	Gut microbiome composition (summer);
CESC	cis	rs4566357	0.615	rs3769642	chr2:227917323	T/C	cg11843606	chr2:227700838	RHBDD1	-0.53	-7.15	-0.4	8.33e-12	Coronary artery disease;
CESC	cis	rs698833	0.859	rs17580340	chr2:44602554	C/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.45	5.76	0.33	2.3e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs7264396	0.635	rs6060673	chr20:34482396	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	-0.54	-6.44	-0.37	5.44e-10	Total cholesterol levels;
CESC	cis	rs16857609	0.564	rs13406698	chr2:218283085	A/G	cg15335768	chr2:218268053	DIRC3	-0.39	-5.41	-0.32	1.42e-7	Breast cancer;Breast cancer (estrogen-receptor negative);
CESC	cis	rs1506636	0.854	rs6466879	chr7:123276197	G/A	cg03229431	chr7:123269106	ASB15	-0.52	-6.85	-0.39	5.16e-11	Plateletcrit;Platelet count;
CESC	cis	rs4722166	0.630	rs10950916	chr7:22799667	C/T	cg13104385	chr7:22767384	IL6	0.46	5.84	0.34	1.54e-8	Lung cancer;
CESC	cis	rs798554	0.679	rs2533868	chr7:2886559	G/A	cg19717773	chr7:2847554	GNA12	-0.45	-6.56	-0.37	2.79e-10	Height;
CESC	cis	rs10504229	1.000	rs56255635	chr8:58178264	T/C	cg05313129	chr8:58192883	C8orf71	-0.55	-6.37	-0.36	8.42e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs868036	1.000	rs4325504	chr15:68055570	A/G	cg08079166	chr15:68083412	MAP2K5	-0.42	-6.51	-0.37	3.67e-10	Restless legs syndrome;
CESC	cis	rs3749237	0.595	rs11130192	chr3:49467206	C/G	cg07636037	chr3:49044803	WDR6	0.6	8.73	0.47	2.98e-16	Resting heart rate;
CESC	cis	rs2075371	0.863	rs2075370	chr7:133967812	A/G	cg20476274	chr7:133979776	SLC35B4	0.67	9.97	0.52	4.46e-20	Mean platelet volume;
CESC	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg16014989	chr1:156023859	ROBLD3;UBQLN4	0.48	6.03	0.35	5.42e-9	Myopia (pathological);
CESC	cis	rs1005277	0.579	rs1740747	chr10:38520465	G/A	cg00409905	chr10:38381863	ZNF37A	-0.52	-7.03	-0.4	1.8e-11	Extrinsic epigenetic age acceleration;
CESC	trans	rs561341	1.000	rs72823789	chr17:30284084	G/A	cg20587970	chr11:113659929	NA	-1.48	-19.48	-0.77	4.55e-53	Hip circumference adjusted for BMI;
CESC	cis	rs2295499	0.610	rs12502642	chr4:2714023	T/C	cg08330972	chr4:2403930	ZFYVE28	-0.32	-5.32	-0.31	2.17e-7	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09952564	chr10:5979174	FBXO18	-0.58	-6.52	-0.37	3.5e-10	Gut microbiome composition (summer);
CESC	trans	rs7307889	0.793	rs56201315	chr12:6013379	G/C	cg18407955	chr7:158110685	PTPRN2	-0.78	-6.69	-0.38	1.34e-10	Obesity-related traits;
CESC	cis	rs17253792	0.822	rs45501402	chr14:56140115	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.81	5.68	0.33	3.46e-8	Putamen volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25282353	chr6:144416767	SF3B5	0.56	6.29	0.36	1.28e-9	Gut microbiome composition (summer);
CESC	cis	rs5750830	0.546	rs4821891	chr22:39785381	C/T	cg02038168	chr22:39784481	NA	-0.61	-7.88	-0.44	8.31e-14	Intelligence (multi-trait analysis);
CESC	trans	rs61869271	0.805	rs7086663	chr10:116766336	A/T	cg17463145	chr7:79084011	MAGI2	0.31	6.08	0.35	4.1e-9	Tonsillectomy;
CESC	cis	rs763121	0.813	rs2179143	chr22:39037984	A/G	cg06022373	chr22:39101656	GTPBP1	0.81	13.07	0.63	1.76e-30	Menopause (age at onset);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg21069814	chr3:47891476	DHX30	0.44	6.15	0.35	2.78e-9	Fibrinogen levels;
CESC	cis	rs736408	0.609	rs13061423	chr3:52790213	T/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.31	5.32	0.31	2.17e-7	Bipolar disorder;
CESC	cis	rs7818345	1.000	rs4392916	chr8:19309355	T/C	cg11303988	chr8:19266685	CSGALNACT1	0.35	6.18	0.35	2.39e-9	Language performance in older adults (adjusted for episodic memory);
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg24995798	chr10:25305002	ENKUR;THNSL1	-0.49	-6.29	-0.36	1.33e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs4665809	0.590	rs1122972	chr2:26418788	A/C	cg27170947	chr2:26402098	FAM59B	-0.83	-9.92	-0.52	6.22e-20	Gut microbiome composition (summer);
CESC	cis	rs6460942	0.545	rs17448114	chr7:12524458	G/C	cg06484146	chr7:12443880	VWDE	-0.71	-7.69	-0.43	2.88e-13	Coronary artery disease;
CESC	cis	rs7666738	0.791	rs17549003	chr4:98969132	A/C	cg03676636	chr4:99064102	C4orf37	0.34	5.2	0.3	4.04e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9443645	0.869	rs4706080	chr6:79760997	C/T	cg05283184	chr6:79620031	NA	-0.44	-6.76	-0.38	8.65e-11	Intelligence (multi-trait analysis);
CESC	cis	rs3733585	0.673	rs4459990	chr4:9954005	T/C	cg11266682	chr4:10021025	SLC2A9	-0.58	-11.0	-0.56	2.04e-23	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs798554	0.797	rs2107964	chr7:2863574	G/A	cg13628971	chr7:2884303	GNA12	0.67	8.58	0.47	7.89e-16	Height;
CESC	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.5	-5.36	-0.31	1.82e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs911555	0.755	rs8014013	chr14:103937372	A/G	cg24130564	chr14:104152367	KLC1	0.52	6.68	0.38	1.38e-10	Intelligence (multi-trait analysis);
CESC	cis	rs9487051	0.676	rs13210693	chr6:109598964	A/G	cg12927641	chr6:109611667	NA	0.35	5.18	0.3	4.44e-7	Reticulocyte fraction of red cells;
CESC	cis	rs2439831	0.850	rs28578398	chr15:44075046	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.7	6.72	0.38	1.14e-10	Lung cancer in ever smokers;
CESC	cis	rs875971	0.522	rs1968127	chr7:66056803	C/T	cg11764359	chr7:65958608	NA	-0.72	-9.55	-0.51	9e-19	Aortic root size;
CESC	cis	rs4889855	0.505	rs12952775	chr17:78607820	A/G	cg16591659	chr17:78472290	NA	-0.34	-5.49	-0.32	9.53e-8	Fractional excretion of uric acid;
CESC	cis	rs1538970	1.000	rs4520450	chr1:45834773	A/G	cg03146154	chr1:46216737	IPP	0.46	5.51	0.32	8.63e-8	Platelet count;
CESC	cis	rs896854	0.653	rs13266313	chr8:95975302	C/T	cg26343298	chr8:95960752	TP53INP1	0.36	5.98	0.34	7.06e-9	Type 2 diabetes;
CESC	cis	rs425277	0.628	rs3107145	chr1:2047547	G/A	cg16545954	chr1:2118288	C1orf86	-0.32	-5.8	-0.34	1.89e-8	Height;
CESC	cis	rs1448094	0.512	rs1900701	chr12:86236231	T/C	cg00310523	chr12:86230176	RASSF9	0.35	5.42	0.32	1.35e-7	Major depressive disorder;
CESC	trans	rs1814175	0.586	rs2866862	chr11:49954588	T/C	cg15704280	chr7:45808275	SEPT13	-0.98	-18.56	-0.75	7.41e-50	Height;
CESC	cis	rs193541	0.593	rs30042	chr5:122272641	A/G	cg19412675	chr5:122181750	SNX24	0.43	5.19	0.3	4.13e-7	Glucose homeostasis traits;
CESC	trans	rs35110281	0.782	rs2246602	chr21:45064296	C/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.55	7.17	0.4	7.43e-12	Mean corpuscular volume;
CESC	cis	rs6938	0.575	rs12909335	chr15:75214789	T/G	cg14664628	chr15:75095509	CSK	-0.54	-7.17	-0.4	7.28e-12	Breast cancer;
CESC	cis	rs2243480	0.803	rs34804747	chr7:65412942	G/C	cg13147721	chr7:65941812	NA	-0.83	-7.97	-0.44	4.85e-14	Diabetic kidney disease;
CESC	cis	rs9435341	0.731	rs4914939	chr1:107558361	A/T	cg09367891	chr1:107599246	PRMT6	0.65	7.79	0.43	1.56e-13	Facial morphology (factor 21, depth of nasal alae);
CESC	cis	rs634534	0.591	rs688862	chr11:65733393	A/G	cg26695010	chr11:65641043	EFEMP2	-0.4	-5.09	-0.3	6.72e-7	Sum eosinophil basophil counts;Eosinophil counts;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12384262	chr21:45744725	PFKL	-0.48	-6.0	-0.35	6.54e-9	Gut microbiome composition (summer);
CESC	cis	rs6460942	0.915	rs6966791	chr7:12439714	T/C	cg16278512	chr7:12443529	VWDE	-0.5	-5.08	-0.3	7.3e-7	Coronary artery disease;
CESC	cis	rs1862618	0.671	rs2591964	chr5:56236900	T/G	cg18230493	chr5:56204884	C5orf35	0.61	8.09	0.44	2.17e-14	Initial pursuit acceleration;
CESC	cis	rs10256972	0.869	rs4720158	chr7:1040325	A/G	cg07308232	chr7:1071921	C7orf50	-0.41	-5.61	-0.33	5.19e-8	Longevity;Endometriosis;
CESC	cis	rs258892	0.895	rs10077575	chr5:72084557	A/C	cg21869765	chr5:72125136	TNPO1	-0.43	-5.51	-0.32	8.4e-8	Small cell lung carcinoma;
CESC	cis	rs3820068	0.581	rs67806552	chr1:15927138	T/C	cg16988262	chr1:15930761	NA	0.33	5.35	0.31	1.89e-7	Systolic blood pressure;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg22614265	chr7:100425456	EPHB4	0.49	6.4	0.37	6.9e-10	Systemic lupus erythematosus;
CESC	trans	rs7178375	1.000	rs11070678	chr15:31219764	A/G	cg04373760	chr16:53404718	NA	0.54	7.07	0.4	1.34e-11	Hypertriglyceridemia;
CESC	cis	rs4819052	0.851	rs1999335	chr21:46670613	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.75	9.89	0.52	7.53e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs8062405	1.000	rs62036657	chr16:28844365	G/A	cg08761264	chr16:28874980	SH2B1	-0.46	-5.72	-0.33	2.9e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs17711722	0.727	rs35850374	chr7:65357776	A/G	cg14393609	chr7:65229607	NA	0.51	7.0	0.39	2.14e-11	Calcium levels;
CESC	cis	rs4764487	0.735	rs2072372	chr12:6344600	C/A	cg08284733	chr12:6341482	CD9	0.41	5.95	0.34	8.44e-9	Mean platelet volume;
CESC	cis	rs11608355	0.545	rs7969313	chr12:109907303	A/G	cg05360138	chr12:110035743	NA	0.82	8.92	0.48	7.93e-17	Neuroticism;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg02262786	chr10:103816019	C10orf76	0.53	7.42	0.41	1.57e-12	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs10504229	1.000	rs17805602	chr8:58179915	A/G	cg24829409	chr8:58192753	C8orf71	-0.76	-10.0	-0.52	3.53e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs6460942	1.000	rs75564554	chr7:12319362	A/C	cg20607287	chr7:12443886	VWDE	-0.79	-8.51	-0.46	1.32e-15	Coronary artery disease;
CESC	cis	rs7193541	0.662	rs8058133	chr16:74657485	A/T	cg01733217	chr16:74700730	RFWD3	1.07	20.8	0.79	1.26e-57	Multiple myeloma;
CESC	cis	rs514406	0.929	rs12410420	chr1:53323754	T/C	cg16325326	chr1:53192061	ZYG11B	0.82	12.7	0.62	3.43e-29	Monocyte count;
CESC	cis	rs4819052	0.851	rs7279011	chr21:46655995	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.46	5.63	0.33	4.68e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs146671954	1	rs146671954	chr9:136934203	G/A	cg10765909	chr12:53715428	AAAS	-0.72	-6.48	-0.37	4.43e-10	Red cell distribution width;
CESC	cis	rs79387448	0.638	rs74731686	chr2:103043981	G/A	cg09003973	chr2:102972529	NA	0.94	7.74	0.43	2.04e-13	Gut microbiota (bacterial taxa);
CESC	cis	rs2732480	0.538	rs2732462	chr12:48696384	A/G	cg04545296	chr12:48745243	ZNF641	0.41	6.88	0.39	4.32e-11	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs1348850	0.793	rs12990917	chr2:178487259	T/G	cg22681709	chr2:178499509	PDE11A	-0.48	-7.47	-0.42	1.17e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs7474896	0.583	rs10764144	chr10:37975732	G/C	cg25427524	chr10:38739819	LOC399744	-0.45	-5.24	-0.31	3.29e-7	Obesity (extreme);
CESC	cis	rs1879734	0.648	rs7554633	chr1:54163128	A/G	cg23596471	chr1:54105337	GLIS1	0.33	5.41	0.32	1.38e-7	Mitral valve prolapse;
CESC	cis	rs763121	0.853	rs2072796	chr22:39064230	A/G	cg06022373	chr22:39101656	GTPBP1	0.88	13.95	0.65	1.51e-33	Menopause (age at onset);
CESC	cis	rs17253792	0.822	rs8018142	chr14:56173288	C/T	cg01858014	chr14:56050164	KTN1	-0.6	-5.51	-0.32	8.7e-8	Putamen volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07496882	chr10:112631570	LOC282997;PDCD4	0.58	6.88	0.39	4.33e-11	Gut microbiome composition (summer);
CESC	cis	rs6032067	0.777	rs13039211	chr20:43784396	C/T	cg11264863	chr20:43835661	SEMG1	0.5	5.35	0.31	1.86e-7	Blood protein levels;
CESC	cis	rs6598955	0.614	rs1134584	chr1:26608828	G/A	cg04990556	chr1:26633338	UBXN11	-0.77	-10.97	-0.56	2.48e-23	Obesity-related traits;
CESC	cis	rs9911578	0.741	rs2611776	chr17:56819636	G/T	cg05425664	chr17:57184151	TRIM37	-0.49	-6.72	-0.38	1.11e-10	Intelligence (multi-trait analysis);
CESC	cis	rs2070729	0.523	rs743562	chr5:131872383	C/T	cg00255919	chr5:131827918	IRF1	-0.31	-5.14	-0.3	5.22e-7	Platelet count;
CESC	cis	rs2836974	0.863	rs8132333	chr21:40527900	A/G	cg27266027	chr21:40555129	PSMG1	0.48	5.91	0.34	1.06e-8	Cognitive function;
CESC	cis	rs2644899	0.859	rs2604893	chr19:41293543	A/G	cg10585486	chr19:41304133	EGLN2	-0.35	-5.05	-0.3	8.07e-7	Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs10242455	0.867	rs2257401	chr7:99306685	C/G	cg07715041	chr7:99302981	CYP3A7	-0.41	-5.21	-0.3	3.78e-7	Blood metabolite levels;
CESC	cis	rs12200560	0.505	rs211176	chr6:97073821	G/A	cg06623918	chr6:96969491	KIAA0776	0.52	6.65	0.38	1.71e-10	Coronary heart disease;
CESC	cis	rs6860806	0.507	rs272872	chr5:131675864	C/T	cg07395648	chr5:131743802	NA	0.42	5.5	0.32	9.14e-8	Breast cancer;
CESC	cis	rs6540559	1.000	rs2073485	chr1:209962794	G/A	cg25204440	chr1:209979598	IRF6	0.66	8.35	0.46	3.91e-15	Cleft lip with or without cleft palate;
CESC	cis	rs4819052	0.851	rs2838856	chr21:46680766	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.74	10.09	0.53	1.8e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10440939	chr17:27493798	MYO18A	-0.64	-7.22	-0.41	5.52e-12	Gut microbiome composition (summer);
CESC	cis	rs7592578	0.771	rs62181034	chr2:191354963	C/A	cg27211696	chr2:191398769	TMEM194B	-0.58	-5.25	-0.31	3.09e-7	Diastolic blood pressure;
CESC	cis	rs208520	0.690	rs12202913	chr6:66734198	C/T	cg07460842	chr6:66804631	NA	0.96	12.8	0.62	1.54e-29	Exhaled nitric oxide output;
CESC	cis	rs11577318	0.796	rs4625269	chr1:26626967	C/A	cg00813993	chr1:26644493	UBXN11;CD52	-0.4	-6.46	-0.37	5.05e-10	Granulocyte percentage of myeloid white cells;
CESC	cis	rs2236918	0.710	rs2526702	chr1:242017983	G/A	cg17736920	chr1:242011382	EXO1	0.57	7.39	0.41	1.93e-12	Menopause (age at onset);
CESC	cis	rs7618915	0.508	rs13065851	chr3:52644836	T/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	6.89	0.39	4.08e-11	Bipolar disorder;
CESC	cis	rs875971	0.862	rs709596	chr7:65825913	A/G	cg12463550	chr7:65579703	CRCP	0.49	6.26	0.36	1.53e-9	Aortic root size;
CESC	cis	rs7762018	0.891	rs3088346	chr6:170149793	T/C	cg05834625	chr6:170176447	C6orf70	0.64	6.98	0.39	2.35e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs10744422	1.000	rs1532835	chr12:123330665	G/A	cg25930673	chr12:123319894	HIP1R	-0.72	-5.73	-0.33	2.79e-8	Schizophrenia;
CESC	cis	rs2304069	0.550	rs216144	chr5:149445480	T/C	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.7	8.46	0.46	1.79e-15	HIV-1 control;
CESC	cis	rs9640161	0.789	rs2098053	chr7:150043205	G/A	cg13722127	chr7:150037890	RARRES2	0.38	5.08	0.3	7.09e-7	Blood protein levels;Circulating chemerin levels;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg06976634	chr11:886709	CHID1	0.45	6.2	0.36	2.11e-9	Fibrinogen levels;
CESC	trans	rs916888	0.610	rs199444	chr17:44818276	T/C	cg10053473	chr17:62856997	LRRC37A3	-0.66	-9.2	-0.49	1.09e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs4523957	0.583	rs2760745	chr17:2035591	T/C	cg16513277	chr17:2031491	SMG6	-0.79	-11.73	-0.58	6.95e-26	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs2721195	0.967	rs1480000	chr8:145702007	C/T	cg11211951	chr8:145729740	GPT	-0.43	-7.1	-0.4	1.15e-11	Age at first birth;
CESC	cis	rs765787	0.530	rs4238376	chr15:45541887	T/C	cg24006582	chr15:45444508	DUOX1	-0.59	-7.32	-0.41	3.04e-12	Uric acid levels;
CESC	cis	rs1669338	0.588	rs62228620	chr3:3184913	C/T	cg16797762	chr3:3221439	CRBN	-0.61	-6.59	-0.38	2.43e-10	White matter integrity;
CESC	cis	rs7520050	0.966	rs4134386	chr1:46395089	G/A	cg03146154	chr1:46216737	IPP	-0.47	-6.1	-0.35	3.66e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs11155671	0.530	rs9383940	chr6:150226059	T/G	cg09699651	chr6:150184138	LRP11	0.43	5.75	0.33	2.43e-8	Testicular germ cell tumor;
CESC	cis	rs4713118	0.662	rs9468271	chr6:28024570	A/G	cg22143856	chr6:28129313	ZNF389	0.42	5.25	0.31	3.16e-7	Parkinson's disease;
CESC	cis	rs35110281	0.748	rs4997353	chr21:45002329	A/C	cg21573476	chr21:45109991	RRP1B	-0.43	-6.09	-0.35	3.88e-9	Mean corpuscular volume;
CESC	cis	rs477692	1.000	rs4750759	chr10:131436603	G/A	cg05714579	chr10:131428358	MGMT	-0.47	-6.28	-0.36	1.35e-9	Response to temozolomide;
CESC	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg05215748	chr17:6898738	ALOX12	0.33	6.86	0.39	4.71e-11	Tonsillectomy;
CESC	cis	rs2243480	1.000	rs1404147	chr7:65264524	C/T	cg13147721	chr7:65941812	NA	-0.84	-8.4	-0.46	2.8e-15	Diabetic kidney disease;
CESC	cis	rs2361718	0.500	rs4889970	chr17:78096086	C/T	cg20811857	chr17:78079795	GAA	0.43	6.11	0.35	3.47e-9	Yeast infection;
CESC	cis	rs9649213	0.574	rs7791321	chr7:97944125	G/C	cg21770322	chr7:97807741	LMTK2	0.57	8.75	0.47	2.56e-16	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs2841277	0.646	rs3742935	chr14:105405599	G/C	cg14403583	chr14:105418241	AHNAK2	-0.57	-7.86	-0.44	9.41e-14	Rheumatoid arthritis;
CESC	cis	rs11683229	0.632	rs2302567	chr2:63170921	C/G	cg17519650	chr2:63277830	OTX1	-0.65	-5.19	-0.3	4.19e-7	Protein quantitative trait loci;
CESC	cis	rs7772486	0.790	rs2243665	chr6:146208120	A/C	cg23711669	chr6:146136114	FBXO30	0.87	11.34	0.57	1.45e-24	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2243480	1.000	rs73142166	chr7:65375832	A/G	cg18252515	chr7:66147081	NA	-1.23	-11.37	-0.57	1.14e-24	Diabetic kidney disease;
CESC	cis	rs10883723	0.810	rs7093028	chr10:104259417	A/G	ch.10.2196322F	chr10:104248062	ACTR1A	0.42	5.08	0.3	6.99e-7	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs6598955	0.670	rs12733645	chr1:26540356	G/T	cg00852783	chr1:26633632	UBXN11	0.4	5.81	0.34	1.79e-8	Obesity-related traits;
CESC	cis	rs7605827	0.930	rs7586201	chr2:15575735	G/A	cg19274914	chr2:15703543	NA	0.32	5.69	0.33	3.38e-8	Educational attainment (years of education);
CESC	cis	rs965469	1.000	rs1040726	chr20:3264267	C/T	cg25506879	chr20:3388711	C20orf194	-0.55	-5.98	-0.35	7.01e-9	IFN-related cytopenia;
CESC	cis	rs11792861	0.855	rs72607165	chr9:111814498	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.45	5.62	0.33	4.83e-8	Menarche (age at onset);
CESC	cis	rs875971	0.522	rs709604	chr7:65497434	A/G	cg06456125	chr7:65229604	NA	-0.48	-6.24	-0.36	1.76e-9	Aortic root size;
CESC	cis	rs904092	0.720	rs1229970	chr4:100204380	A/C	cg12011299	chr4:100065546	ADH4	-0.56	-6.34	-0.36	9.78e-10	Alcohol dependence;
CESC	cis	rs9768139	0.708	rs10233815	chr7:158114348	C/T	cg25566285	chr7:158114605	PTPRN2	0.54	9.09	0.49	2.33e-17	Calcium levels;
CESC	cis	rs6951245	0.507	rs10227709	chr7:1180515	T/G	cg18402987	chr7:1209562	NA	0.5	6.03	0.35	5.6e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs10870270	0.957	rs9971084	chr10:133788747	G/C	cg08754478	chr10:133766260	PPP2R2D	-0.58	-7.49	-0.42	1.01e-12	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs2011503	0.597	rs8103992	chr19:19665643	A/C	cg11584989	chr19:19387371	SF4	-0.47	-5.43	-0.32	1.28e-7	Bipolar disorder;
CESC	cis	rs801193	0.844	rs7779971	chr7:66161790	T/C	cg18876405	chr7:65276391	NA	0.54	7.28	0.41	3.88e-12	Aortic root size;
CESC	cis	rs372883	0.600	rs2832293	chr21:30738872	C/G	cg08807101	chr21:30365312	RNF160	0.45	5.22	0.31	3.55e-7	Pancreatic cancer;
CESC	cis	rs9910055	0.659	rs6503488	chr17:42246158	T/G	cg19774624	chr17:42201019	HDAC5	-0.88	-14.32	-0.66	7.95e-35	Total body bone mineral density;
CESC	cis	rs798554	0.759	rs2644309	chr7:2889034	T/C	cg19717773	chr7:2847554	GNA12	-0.48	-6.61	-0.38	2.14e-10	Height;
CESC	cis	rs4654899	0.965	rs10753513	chr1:21492168	T/C	cg05370193	chr1:21551575	ECE1	-0.39	-5.77	-0.33	2.19e-8	Superior frontal gyrus grey matter volume;
CESC	cis	rs4268898	0.662	rs2891380	chr2:24525830	G/A	cg20701182	chr2:24300061	SF3B14	0.63	6.88	0.39	4.25e-11	Asthma;
CESC	cis	rs1018836	0.663	rs12674903	chr8:91475774	T/C	cg16814680	chr8:91681699	NA	-0.55	-7.29	-0.41	3.5e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.63	0.38	1.9e-10	Prudent dietary pattern;
CESC	cis	rs6545977	0.531	rs2539982	chr2:63111004	G/A	cg17519650	chr2:63277830	OTX1	0.61	8.51	0.46	1.28e-15	Prostate cancer;
CESC	cis	rs9911578	0.692	rs412000	chr17:56709058	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.41	5.44	0.32	1.21e-7	Intelligence (multi-trait analysis);
CESC	trans	rs3942852	0.806	rs10734562	chr11:48128189	A/T	cg15704280	chr7:45808275	SEPT13	0.6	6.85	0.39	5.01e-11	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs7772486	0.806	rs4075695	chr6:146250959	A/G	cg05347473	chr6:146136440	FBXO30	-0.48	-6.42	-0.37	6.21e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2204008	0.537	rs28680519	chr12:38502946	C/T	cg26384229	chr12:38710491	ALG10B	0.71	10.51	0.54	8.26e-22	Bladder cancer;
CESC	cis	rs77106637	0.932	rs7109082	chr11:72707441	A/C	cg03713592	chr11:72463424	ARAP1	1.09	10.08	0.53	1.94e-20	Type 2 diabetes;
CESC	cis	rs10791097	0.694	rs4457753	chr11:130755575	A/G	cg09137382	chr11:130731461	NA	0.36	5.35	0.31	1.92e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs13223928	0.621	rs4722440	chr7:3155901	C/T	cg19214707	chr7:3157722	NA	0.4	5.55	0.32	6.94e-8	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
CESC	cis	rs916888	0.773	rs538628	chr17:44787313	G/C	cg15921436	chr17:44337874	NA	0.76	8.15	0.45	1.47e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs3126085	0.935	rs11204937	chr1:152193851	C/T	cg03465714	chr1:152285911	FLG	-0.41	-5.05	-0.3	8.35e-7	Atopic dermatitis;
CESC	cis	rs4077515	0.839	rs10781518	chr9:139300547	C/T	cg14169450	chr9:139327907	INPP5E	-0.41	-5.23	-0.31	3.48e-7	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg26172013	chr20:32031452	SNTA1	-0.42	-5.28	-0.31	2.68e-7	Ulcerative colitis;
CESC	cis	rs12765878	0.967	rs7920217	chr10:105668172	C/T	cg24587175	chr10:105670608	OBFC1	0.32	5.29	0.31	2.63e-7	Coronary artery disease;
CESC	cis	rs1879734	0.636	rs17109200	chr1:54175548	A/G	cg23596471	chr1:54105337	GLIS1	0.29	5.1	0.3	6.5e-7	Mitral valve prolapse;
CESC	cis	rs12701220	0.894	rs10263252	chr7:1049949	G/A	cg20821713	chr7:1055600	C7orf50	-0.51	-5.35	-0.31	1.89e-7	Bronchopulmonary dysplasia;
CESC	cis	rs10504229	1.000	rs73607874	chr8:58173433	G/C	cg14926445	chr8:58193284	C8orf71	-0.51	-5.47	-0.32	1.03e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs6835098	1.000	rs4695826	chr4:174089426	T/G	cg08422745	chr4:174089978	GALNT7	-0.82	-12.01	-0.59	7.93e-27	Dementia and core Alzheimer's disease neuropathologic changes;
CESC	cis	rs2455799	0.613	rs10510443	chr3:15829127	A/G	cg16303742	chr3:15540471	COLQ	-0.39	-6.02	-0.35	5.68e-9	Mean platelet volume;
CESC	cis	rs10206020	0.885	rs6720797	chr2:1574340	T/C	cg12573674	chr2:1569213	NA	-0.46	-5.2	-0.3	3.96e-7	IgG glycosylation;
CESC	cis	rs7680126	0.596	rs4637402	chr4:10045430	C/T	cg02734326	chr4:10020555	SLC2A9	0.48	5.29	0.31	2.63e-7	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg14893161	chr1:205819251	PM20D1	0.94	17.62	0.73	1.56e-46	Menarche (age at onset);
CESC	trans	rs6759922	1.000	rs4330131	chr2:22445880	G/A	cg21162304	chr4:80247171	NAA11	0.38	6.24	0.36	1.72e-9	Subjective well-being (multi-trait analysis);
CESC	cis	rs3733585	0.648	rs13103497	chr4:9979262	A/G	cg11266682	chr4:10021025	SLC2A9	0.55	9.92	0.52	6.09e-20	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs4835473	0.932	rs36018946	chr4:144902095	G/T	cg25736465	chr4:144833511	NA	-0.43	-6.59	-0.38	2.36e-10	Immature fraction of reticulocytes;
CESC	cis	rs763014	0.966	rs4984675	chr16:670117	T/C	cg07256732	chr16:621771	PIGQ	-0.34	-5.88	-0.34	1.21e-8	Height;
CESC	cis	rs11958404	0.546	rs7727054	chr5:157442692	G/A	cg05962755	chr5:157440814	NA	0.38	5.5	0.32	8.89e-8	IgG glycosylation;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg14182682	chr14:57857589	NAA30	-0.46	-6.07	-0.35	4.3e-9	Thyroid stimulating hormone;
CESC	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg07167872	chr1:205819463	PM20D1	0.76	12.94	0.62	5.37e-30	Menarche (age at onset);
CESC	cis	rs61931739	0.817	rs1705772	chr12:34174756	G/A	cg19457237	chr12:34500585	NA	-0.4	-5.57	-0.32	6.13e-8	Morning vs. evening chronotype;
CESC	cis	rs57221529	0.709	rs72706612	chr5:561198	C/T	cg09021430	chr5:549028	NA	-0.43	-5.41	-0.32	1.43e-7	Lung disease severity in cystic fibrosis;
CESC	cis	rs10256972	0.869	rs13236369	chr7:1033799	G/T	cg04025307	chr7:1156635	C7orf50	0.38	6.08	0.35	4.12e-9	Longevity;Endometriosis;
CESC	cis	rs2933343	1.000	rs1683782	chr3:128640277	A/G	cg25356066	chr3:128598488	ACAD9	0.61	7.52	0.42	8.33e-13	IgG glycosylation;
CESC	cis	rs6942756	1.000	rs17168512	chr7:128955033	A/G	cg02491457	chr7:128862824	NA	-0.69	-9.36	-0.5	3.61e-18	White matter hyperintensity burden;
CESC	cis	rs7216064	1.000	rs12452511	chr17:65832576	A/G	cg07042672	chr17:66097459	LOC651250	-0.53	-5.5	-0.32	8.85e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs4722166	0.630	rs13311199	chr7:22789793	A/C	cg05472934	chr7:22766657	IL6	0.83	10.33	0.54	3.1e-21	Lung cancer;
CESC	cis	rs2836974	0.644	rs2836982	chr21:40689171	C/A	cg11890956	chr21:40555474	PSMG1	-0.9	-14.19	-0.66	2.18e-34	Cognitive function;
CESC	cis	rs7666738	0.715	rs116787789	chr4:98718720	G/A	cg03467027	chr4:99064603	C4orf37	0.44	5.46	0.32	1.09e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3780486	0.846	rs73484568	chr9:33132492	G/A	cg13443165	chr9:33130375	B4GALT1	0.43	6.26	0.36	1.55e-9	IgG glycosylation;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26440361	chr12:122064389	ORAI1	0.56	6.03	0.35	5.39e-9	Gut microbiome composition (summer);
CESC	cis	rs9611565	0.579	rs73178621	chr22:41921665	A/G	cg06634786	chr22:41940651	POLR3H	-0.69	-7.05	-0.4	1.59e-11	Vitiligo;
CESC	cis	rs9911578	1.000	rs2531734	chr17:56550804	T/C	cg05425664	chr17:57184151	TRIM37	0.5	6.94	0.39	2.97e-11	Intelligence (multi-trait analysis);
CESC	cis	rs3015497	0.646	rs2172673	chr14:51115807	A/G	cg26011998	chr14:51135199	SAV1	-0.56	-6.27	-0.36	1.45e-9	Mean platelet volume;
CESC	cis	rs9467711	0.606	rs9358932	chr6:26362705	A/G	cg12826209	chr6:26865740	GUSBL1	-0.58	-5.04	-0.3	8.79e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs13333054	1.000	rs12232384	chr16:86009760	A/C	cg08215318	chr16:86016387	NA	-0.49	-6.04	-0.35	5.25e-9	Multiple sclerosis;
CESC	cis	rs9322193	0.962	rs9688940	chr6:150110113	G/A	cg05861140	chr6:150128134	PCMT1	-0.36	-5.14	-0.3	5.22e-7	Lung cancer;
CESC	cis	rs13256369	0.851	rs13266562	chr8:8564065	T/C	cg17143192	chr8:8559678	CLDN23	0.78	8.81	0.48	1.63e-16	Obesity-related traits;
CESC	cis	rs4819052	0.851	rs7279182	chr21:46656112	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.91	12.8	0.62	1.52e-29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs6456156	0.846	rs7774396	chr6:167519786	G/A	cg07741184	chr6:167504864	NA	0.37	6.54	0.37	3.07e-10	Primary biliary cholangitis;
CESC	cis	rs6693567	0.545	rs1313568	chr1:150344180	C/G	cg09579323	chr1:150459698	TARS2	0.47	6.05	0.35	4.99e-9	Migraine;
CESC	cis	rs7512552	0.809	rs2794685	chr1:150312268	C/T	cg15654264	chr1:150340011	RPRD2	0.39	5.12	0.3	5.94e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs11792861	0.926	rs17628095	chr9:111889172	A/G	cg13535736	chr9:111863775	C9orf5	0.49	6.39	0.37	7.35e-10	Menarche (age at onset);
CESC	cis	rs2274273	0.638	rs67416413	chr14:55702263	A/G	cg04306507	chr14:55594613	LGALS3	0.31	5.2	0.3	3.97e-7	Protein biomarker;
CESC	cis	rs17253792	0.822	rs78826571	chr14:56048906	G/A	cg01858014	chr14:56050164	KTN1	-0.99	-7.44	-0.42	1.43e-12	Putamen volume;
CESC	cis	rs13191362	1.000	rs71567659	chr6:163001736	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.88	9.16	0.49	1.46e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs7613875	0.620	rs11721204	chr3:49982765	C/T	cg24110177	chr3:50126178	RBM5	-0.55	-7.45	-0.42	1.3e-12	Body mass index;
CESC	cis	rs12220238	1.000	rs12359456	chr10:75937994	C/G	cg19889307	chr10:75911429	ADK;AP3M1	0.57	5.11	0.3	6.25e-7	Soluble interleukin-2 receptor subunit alpha;
CESC	cis	rs9768139	0.627	rs57920447	chr7:158121243	A/G	cg24154853	chr7:158122151	PTPRN2	0.4	6.25	0.36	1.66e-9	Calcium levels;
CESC	cis	rs10851478	0.872	rs925104	chr15:49916655	T/G	cg08060515	chr15:49448048	GALK2;COPS2	0.42	5.2	0.3	3.95e-7	Oral cavity cancer;
CESC	trans	rs7618501	0.635	rs7635002	chr3:49989155	T/G	cg21659725	chr3:3221576	CRBN	0.55	7.6	0.42	5.29e-13	Intelligence (multi-trait analysis);
CESC	cis	rs7666738	1.000	rs13144055	chr4:99026849	A/G	cg05340658	chr4:99064831	C4orf37	0.64	8.35	0.46	3.77e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs734999	0.566	rs4648563	chr1:2536002	C/G	cg18854424	chr1:2615690	NA	0.27	5.24	0.31	3.32e-7	Ulcerative colitis;
CESC	cis	rs10791097	0.667	rs1893019	chr11:130756664	C/G	cg12179176	chr11:130786555	SNX19	0.67	10.54	0.54	6.34e-22	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs9611565	0.694	rs2142505	chr22:41820541	A/G	cg17376030	chr22:41985996	PMM1	-0.75	-7.86	-0.43	9.43e-14	Vitiligo;
CESC	cis	rs1552244	1.000	rs17032414	chr3:10158302	C/G	cg00166722	chr3:10149974	C3orf24	0.5	6.59	0.38	2.37e-10	Alzheimer's disease;
CESC	cis	rs7927771	0.524	rs3816605	chr11:47857253	T/C	cg18512352	chr11:47633146	NA	0.35	5.39	0.31	1.53e-7	Subjective well-being;
CESC	cis	rs8027181	0.839	rs2277598	chr15:73027478	T/C	cg25632853	chr15:73088954	NA	0.3	5.25	0.31	3.06e-7	Triglyceride levels;
CESC	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.55	-6.22	-0.36	1.92e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs7615952	0.866	rs13063119	chr3:125643847	G/A	cg07211511	chr3:129823064	LOC729375	-1.16	-16.42	-0.71	2.9e-42	Blood pressure (smoking interaction);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg23614605	chr14:35761327	PSMA6	-0.46	-6.19	-0.36	2.25e-9	Gut microbiota (bacterial taxa);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg21047528	chr22:42915898	RRP7A	0.5	6.47	0.37	4.69e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs6783573	0.711	rs3806701	chr3:46617337	G/A	cg27371741	chr3:46619158	LRRC2;TDGF1	-0.38	-5.95	-0.34	8.42e-9	Cerebrospinal fluid biomarker levels;
CESC	cis	rs7666738	0.830	rs17027216	chr4:99009152	G/C	cg18180107	chr4:99064573	C4orf37	0.4	5.3	0.31	2.48e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9814567	0.929	rs13316205	chr3:134223563	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.42	-5.73	-0.33	2.73e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs4253772	0.550	rs6007818	chr22:46703776	C/T	cg10541313	chr22:46663664	TTC38	0.68	6.0	0.35	6.32e-9	LDL cholesterol;Cholesterol, total;
CESC	cis	rs597539	0.731	rs664229	chr11:68624483	C/G	cg06028808	chr11:68637592	NA	0.48	5.64	0.33	4.34e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs4629180	0.651	rs9653468	chr2:102108403	A/G	cg21388029	chr2:102003306	CREG2	0.32	5.17	0.3	4.55e-7	Chronic rhinosinusitis with nasal polyps;
CESC	cis	rs4665809	1.000	rs10170359	chr2:26272219	G/T	cg08470875	chr2:26401718	FAM59B	-0.56	-6.01	-0.35	5.98e-9	Gut microbiome composition (summer);
CESC	cis	rs67311347	1.000	rs9848083	chr3:40466979	A/G	cg24209194	chr3:40518798	ZNF619	-0.45	-6.13	-0.35	3.22e-9	Renal cell carcinoma;
CESC	cis	rs238295	0.846	rs6053528	chr20:5582598	G/T	cg24001556	chr20:5591874	RP5-1022P6.2	-0.46	-5.22	-0.31	3.64e-7	Occipital cortical area (total cortical area interaction);
CESC	cis	rs12079745	0.793	rs3737683	chr1:169438180	A/G	cg09363564	chr1:169337483	NME7;BLZF1	-1.16	-6.82	-0.39	6e-11	QT interval;
CESC	cis	rs7582720	1.000	rs77268589	chr2:203751981	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.39	0.41	1.96e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs17345786	0.602	rs11923273	chr3:101337863	T/C	cg12386194	chr3:101231763	SENP7	0.53	6.53	0.37	3.35e-10	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7666738	0.753	rs28463863	chr4:98844444	T/C	cg05340658	chr4:99064831	C4orf37	0.74	10.5	0.54	8.68e-22	Colonoscopy-negative controls vs population controls;
CESC	cis	rs853679	0.517	rs4713141	chr6:28101678	G/C	cg12963246	chr6:28129442	ZNF389	0.57	7.81	0.43	1.31e-13	Depression;
CESC	cis	rs3091242	0.933	rs10903129	chr1:25768937	A/G	cg12412775	chr1:25698385	RHCE	-0.28	-5.08	-0.3	7.1e-7	Erythrocyte sedimentation rate;
CESC	cis	rs6952808	0.792	rs4421257	chr7:1955152	T/C	cg04267008	chr7:1944627	MAD1L1	-0.73	-10.11	-0.53	1.58e-20	Bipolar disorder and schizophrenia;
CESC	cis	rs780096	0.506	rs56076827	chr2:27676287	A/T	cg12648201	chr2:27665141	KRTCAP3	-0.31	-5.65	-0.33	4.22e-8	Total body bone mineral density;
CESC	cis	rs35110281	0.837	rs2838343	chr21:45078035	C/T	cg21573476	chr21:45109991	RRP1B	-0.5	-7.0	-0.39	2.13e-11	Mean corpuscular volume;
CESC	cis	rs7824557	0.614	rs2293860	chr8:11219386	G/T	cg21775007	chr8:11205619	TDH	0.62	9.77	0.51	1.87e-19	Retinal vascular caliber;
CESC	cis	rs7914558	1.000	rs7077291	chr10:104945751	C/T	cg04362960	chr10:104952993	NT5C2	0.46	6.16	0.35	2.74e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs270601	0.770	rs61352298	chr5:131600589	G/C	cg04518342	chr5:131593106	PDLIM4	0.4	5.96	0.34	7.99e-9	Acylcarnitine levels;
CESC	cis	rs12142240	0.698	rs17361887	chr1:46834775	A/G	cg00530320	chr1:46809349	NSUN4	0.61	8.02	0.44	3.5e-14	Menopause (age at onset);
CESC	cis	rs34779708	0.966	rs12775799	chr10:35488264	C/T	cg04310649	chr10:35416472	CREM	-0.52	-6.26	-0.36	1.54e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs2836974	0.831	rs2836964	chr21:40631006	T/C	cg11644478	chr21:40555479	PSMG1	1.05	16.66	0.72	3.85e-43	Cognitive function;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg03811519	chr9:134001305	NUP214	0.44	6.17	0.35	2.55e-9	Systemic lupus erythematosus;
CESC	cis	rs3096299	0.719	rs2965818	chr16:89510494	A/G	cg00750074	chr16:89608354	SPG7	-0.39	-5.61	-0.33	5.12e-8	Multiple myeloma (IgH translocation);
CESC	cis	rs3796352	1.000	rs2336541	chr3:52974630	G/C	cg12962167	chr3:53033115	SFMBT1	0.6	5.09	0.3	6.95e-7	Immune reponse to smallpox (secreted IL-2);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg15702823	chr6:10838819	NA	-0.53	-6.49	-0.37	4.2e-10	Ulcerative colitis;
CESC	cis	rs4665809	0.590	rs7606351	chr2:26292545	A/C	cg25036284	chr2:26402008	FAM59B	-0.75	-8.46	-0.46	1.79e-15	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.830	rs13144771	chr4:99026935	G/C	cg03467027	chr4:99064603	C4orf37	0.49	6.18	0.35	2.44e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7216064	0.953	rs2086744	chr17:65849275	C/G	cg12091567	chr17:66097778	LOC651250	-0.85	-8.69	-0.47	3.85e-16	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03564166	chr16:70380888	DDX19A	0.63	6.93	0.39	3.26e-11	Gut microbiome composition (summer);
CESC	cis	rs62064224	0.614	rs9916114	chr17:30766950	T/C	cg18200150	chr17:30822561	MYO1D	0.4	5.16	0.3	4.76e-7	Schizophrenia;
CESC	cis	rs9311474	1.000	rs7629072	chr3:52305633	C/T	cg05564831	chr3:52568323	NT5DC2	0.42	6.68	0.38	1.41e-10	Electroencephalogram traits;
CESC	cis	rs4906332	0.899	rs12888042	chr14:103891709	G/A	cg09975044	chr14:104007538	NA	0.46	6.38	0.36	7.81e-10	Coronary artery disease;
CESC	cis	rs9733	0.596	rs12403255	chr1:150660412	C/T	cg09365446	chr1:150670422	GOLPH3L	0.43	6.02	0.35	5.86e-9	Tonsillectomy;
CESC	trans	rs916888	0.647	rs199524	chr17:44848438	G/T	cg22433210	chr17:43662623	NA	-0.63	-8.08	-0.44	2.23e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs894734	0.535	rs7301643	chr12:54325796	G/T	cg12374095	chr12:54320830	NA	-0.42	-6.08	-0.35	4.28e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
CESC	cis	rs875971	1.000	rs11974264	chr7:65647582	C/G	cg10691866	chr7:65817282	TPST1	0.35	5.77	0.33	2.23e-8	Aortic root size;
CESC	cis	rs8016982	0.674	rs28890880	chr14:81708031	A/G	cg01989461	chr14:81687754	GTF2A1	0.66	9.76	0.51	2.07e-19	Schizophrenia;
CESC	cis	rs9611565	0.729	rs73176686	chr22:41782119	C/T	cg03806693	chr22:41940476	POLR3H	-1.18	-14.76	-0.67	2.13e-36	Vitiligo;
CESC	cis	rs6860806	0.507	rs272883	chr5:131668698	A/G	cg18758796	chr5:131593413	PDLIM4	0.38	5.17	0.3	4.59e-7	Breast cancer;
CESC	cis	rs9916302	0.904	rs55660616	chr17:37684990	C/A	cg00129232	chr17:37814104	STARD3	-0.56	-7.37	-0.41	2.15e-12	Glomerular filtration rate (creatinine);
CESC	cis	rs8141529	0.732	rs5997408	chr22:29207915	G/A	cg02153584	chr22:29168773	CCDC117	0.64	9.29	0.5	5.89e-18	Lymphocyte counts;
CESC	cis	rs113835537	0.529	rs10501397	chr11:66272976	G/T	cg22134325	chr11:66188745	NPAS4	0.33	5.2	0.3	3.98e-7	Airway imaging phenotypes;
CESC	cis	rs9487051	0.676	rs6925716	chr6:109597641	T/C	cg21918786	chr6:109611834	NA	-0.38	-5.52	-0.32	7.88e-8	Reticulocyte fraction of red cells;
CESC	cis	rs10791097	0.967	rs10750450	chr11:130719061	G/T	cg14779329	chr11:130786720	SNX19	0.39	6.17	0.35	2.55e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs6540556	0.723	rs3766618	chr1:209895437	G/T	cg05527609	chr1:210001259	C1orf107	-0.78	-7.79	-0.43	1.51e-13	Red blood cell count;
CESC	cis	rs11098499	0.863	rs1010739	chr4:120463471	C/T	cg24375607	chr4:120327624	NA	0.48	5.91	0.34	1.06e-8	Corneal astigmatism;
CESC	cis	rs2075371	1.000	rs2244694	chr7:133987093	C/T	cg11752832	chr7:134001865	SLC35B4	0.54	7.02	0.4	1.88e-11	Mean platelet volume;
CESC	cis	rs875971	0.862	rs908915	chr7:65614651	G/T	cg18252515	chr7:66147081	NA	0.4	5.25	0.31	3.16e-7	Aortic root size;
CESC	cis	rs9811920	0.535	rs792833	chr3:99475268	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.32	5.19	0.3	4.09e-7	Axial length;
CESC	cis	rs10911232	0.507	rs12037623	chr1:183000148	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.84	13.19	0.63	6.74e-31	Hypertriglyceridemia;
CESC	cis	rs9462846	0.959	rs9471958	chr6:42883669	C/T	cg05552183	chr6:42928497	GNMT	0.46	5.25	0.31	3.1e-7	Blood protein levels;
CESC	cis	rs1215050	0.740	rs783963	chr4:98989070	A/G	cg05340658	chr4:99064831	C4orf37	0.61	8.48	0.46	1.56e-15	Waist-to-hip ratio adjusted for body mass index;
CESC	trans	rs6089829	0.962	rs4809455	chr20:61660781	G/C	cg23505145	chr19:12996616	KLF1	0.52	6.7	0.38	1.24e-10	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs7246657	0.943	rs9676967	chr19:37928089	G/C	cg01833234	chr11:6592585	DNHD1	0.52	6.0	0.35	6.5e-9	Coronary artery calcification;
CESC	cis	rs11822910	0.911	rs11828218	chr11:57196223	C/G	cg00522883	chr11:57194120	SLC43A3	0.59	7.12	0.4	1.02e-11	Platelet distribution width;
CESC	cis	rs4148883	0.603	rs6833176	chr4:100131163	G/C	cg12011299	chr4:100065546	ADH4	-0.5	-7.2	-0.4	6.04e-12	Alcohol dependence;
CESC	cis	rs863345	0.604	rs879637	chr1:158462697	C/T	cg12129480	chr1:158549410	OR10X1	-0.35	-6.97	-0.39	2.53e-11	Pneumococcal bacteremia;
CESC	cis	rs7666738	0.830	rs969049	chr4:98988857	C/T	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.6e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs854765	0.547	rs2955378	chr17:17930253	G/A	cg16928487	chr17:17741425	SREBF1	-0.56	-9.54	-0.51	9.69e-19	Total body bone mineral density;
CESC	cis	rs9926296	0.605	rs1800287	chr16:89858525	C/G	cg03388025	chr16:89894329	SPIRE2	0.41	8.11	0.45	1.89e-14	Vitiligo;
CESC	cis	rs7618915	0.501	rs7611731	chr3:52692721	T/C	cg17372223	chr3:52568218	NT5DC2	0.42	6.47	0.37	4.6e-10	Bipolar disorder;
CESC	cis	rs7618915	0.571	rs6805539	chr3:52609710	T/A	cg18404041	chr3:52824283	ITIH1	-0.4	-6.58	-0.37	2.57e-10	Bipolar disorder;
CESC	cis	rs801193	1.000	rs2707854	chr7:66212597	G/A	cg14393609	chr7:65229607	NA	0.47	6.31	0.36	1.17e-9	Aortic root size;
CESC	cis	rs4072980	0.545	rs11210870	chr1:38449910	T/C	cg12658694	chr1:38397304	INPP5B	-0.65	-8.4	-0.46	2.7e-15	Coronary artery disease;
CESC	cis	rs1505368	0.789	rs13419353	chr2:213271459	A/T	cg20637307	chr2:213403960	ERBB4	-0.37	-5.46	-0.32	1.08e-7	Symmetrical dimethylarginine levels;
CESC	cis	rs1448094	0.511	rs61930582	chr12:86157387	T/C	cg02569458	chr12:86230093	RASSF9	0.51	7.69	0.43	2.85e-13	Major depressive disorder;
CESC	cis	rs7811142	0.830	rs705866	chr7:99965285	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.99	9.38	0.5	3.07e-18	Platelet count;
CESC	cis	rs9911578	1.000	rs2009948	chr17:56611920	A/C	cg05425664	chr17:57184151	TRIM37	0.5	7.06	0.4	1.5e-11	Intelligence (multi-trait analysis);
CESC	cis	rs9393692	0.620	rs9379842	chr6:26289310	C/T	cg05868516	chr6:26286170	HIST1H4H	-0.39	-5.5	-0.32	8.72e-8	Educational attainment;
CESC	cis	rs7100689	0.622	rs10749569	chr10:82129892	G/A	cg00277334	chr10:82204260	NA	-0.58	-7.76	-0.43	1.84e-13	Post bronchodilator FEV1;
CESC	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg03188948	chr7:1209495	NA	0.57	6.63	0.38	1.86e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7267979	0.903	rs6050481	chr20:25224580	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.82	15.6	0.69	2.21e-39	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs748404	0.660	rs690472	chr15:43764368	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	8.21	0.45	9.59e-15	Lung cancer;
CESC	cis	rs1355223	0.902	rs1258468	chr11:34729731	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.48	-6.41	-0.37	6.58e-10	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs7605827	0.930	rs7580672	chr2:15586646	A/G	cg19274914	chr2:15703543	NA	0.32	5.69	0.33	3.38e-8	Educational attainment (years of education);
CESC	cis	rs3091242	0.902	rs36003018	chr1:25784318	A/G	cg02931644	chr1:25747376	RHCE	-0.39	-6.54	-0.37	3.17e-10	Erythrocyte sedimentation rate;
CESC	cis	rs7208859	0.673	rs11655623	chr17:29162173	T/C	cg19761014	chr17:28927070	LRRC37B2	0.62	5.24	0.31	3.34e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs4665809	1.000	rs6750681	chr2:26329677	C/T	cg04944784	chr2:26401820	FAM59B	-0.65	-7.4	-0.41	1.8e-12	Gut microbiome composition (summer);
CESC	trans	rs7922314	0.571	rs61865719	chr10:64741119	C/T	cg06935979	chr1:232941706	KIAA1383	-0.63	-6.02	-0.35	5.66e-9	Cutaneous psoriasis;
CESC	cis	rs12142240	0.698	rs56909107	chr1:46808224	A/C	cg10495392	chr1:46806563	NSUN4	0.59	6.34	0.36	9.65e-10	Menopause (age at onset);
CESC	cis	rs7811142	1.000	rs60844404	chr7:100080474	A/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.98	10.55	0.54	5.96e-22	Platelet count;
CESC	cis	rs12220238	0.908	rs4746179	chr10:75940169	C/G	cg19889307	chr10:75911429	ADK;AP3M1	0.6	5.75	0.33	2.43e-8	Soluble interleukin-2 receptor subunit alpha;
CESC	cis	rs1448094	0.512	rs1584368	chr12:86245117	A/C	cg02569458	chr12:86230093	RASSF9	0.49	7.28	0.41	3.89e-12	Major depressive disorder;
CESC	cis	rs7635838	0.684	rs2606758	chr3:11353064	G/A	cg00170343	chr3:11313890	ATG7	0.54	7.66	0.43	3.45e-13	HDL cholesterol;
CESC	cis	rs8002861	0.846	rs12867732	chr13:44483084	C/A	cg14210620	chr13:44453864	C13orf31;CCDC122	-0.43	-5.57	-0.32	6.35e-8	Leprosy;
CESC	cis	rs7811142	1.000	rs6975729	chr7:100028187	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.15	11.48	0.58	4.99e-25	Platelet count;
CESC	cis	rs2243480	0.901	rs73142137	chr7:65343442	A/T	cg25894440	chr7:65020034	NA	-0.63	-5.42	-0.32	1.33e-7	Diabetic kidney disease;
CESC	cis	rs35306767	0.903	rs11253494	chr10:937047	C/T	cg10556349	chr10:835070	NA	0.55	5.22	0.31	3.6e-7	Eosinophil percentage of granulocytes;
CESC	cis	rs6952808	0.656	rs73048919	chr7:2103637	C/A	cg21782813	chr7:2030301	MAD1L1	0.52	7.38	0.41	2.03e-12	Bipolar disorder and schizophrenia;
CESC	cis	rs12621445	1	rs12621445	chr2:24154964	C/T	cg20701182	chr2:24300061	SF3B14	0.79	6.9	0.39	3.91e-11	Immature fraction of reticulocytes;
CESC	cis	rs853679	0.517	rs9393897	chr6:28127710	G/T	cg20151795	chr6:28129481	ZNF389	0.44	5.57	0.32	6.17e-8	Depression;
CESC	trans	rs9914544	0.628	rs4924924	chr17:18677774	C/G	cg04702396	chr17:15466718	FAM18B2	0.55	6.79	0.38	7.52e-11	Educational attainment (years of education);
CESC	cis	rs11235843	0.636	rs1464908	chr11:73402679	A/C	cg18195628	chr11:73498948	MRPL48	-0.48	-5.27	-0.31	2.83e-7	Hand grip strength;
CESC	cis	rs3785574	0.962	rs13030	chr17:61908556	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.79	10.52	0.54	7.36e-22	Height;
CESC	cis	rs9926296	0.656	rs2376881	chr16:89827011	C/G	cg04287289	chr16:89883240	FANCA	0.59	7.64	0.43	3.87e-13	Vitiligo;
CESC	cis	rs769267	0.895	rs2965182	chr19:19548246	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.47	6.08	0.35	4.06e-9	Tonsillectomy;
CESC	trans	rs853679	0.556	rs34588114	chr6:28080628	C/A	cg06606381	chr12:133084897	FBRSL1	-1.1	-8.36	-0.46	3.51e-15	Depression;
CESC	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg07677032	chr17:61819896	STRADA	0.45	5.97	0.34	7.8e-9	Prudent dietary pattern;
CESC	cis	rs847577	0.575	rs41278842	chr7:97815999	A/G	cg21770322	chr7:97807741	LMTK2	-0.49	-7.12	-0.4	1.04e-11	Breast cancer;
CESC	cis	rs4713118	0.662	rs9380045	chr6:28025279	A/G	cg12963246	chr6:28129442	ZNF389	0.5	6.4	0.37	6.93e-10	Parkinson's disease;
CESC	cis	rs763014	0.931	rs62030903	chr16:638323	T/A	cg09263875	chr16:632152	PIGQ	0.69	11.33	0.57	1.61e-24	Height;
CESC	cis	rs853679	0.517	rs9380062	chr6:28137569	G/A	cg12963246	chr6:28129442	ZNF389	0.54	7.12	0.4	1.02e-11	Depression;
CESC	cis	rs10392	0.571	rs4812335	chr20:37537612	C/T	cg27552599	chr20:37590471	DHX35	0.37	5.38	0.31	1.61e-7	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
CESC	trans	rs1728785	0.901	rs698715	chr16:68560896	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.63	7.39	0.41	1.96e-12	Ulcerative colitis;
CESC	cis	rs35146811	0.961	rs35991721	chr7:99728790	G/T	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.48	5.77	0.33	2.16e-8	Coronary artery disease;
CESC	trans	rs7829975	0.742	rs882462	chr8:8678530	G/A	cg21775007	chr8:11205619	TDH	0.41	6.04	0.35	5.29e-9	Mood instability;
CESC	cis	rs2836974	0.899	rs2836938	chr21:40574191	C/T	cg11890956	chr21:40555474	PSMG1	1.17	21.57	0.8	2.76e-60	Cognitive function;
CESC	cis	rs6089829	0.962	rs9680064	chr20:61666168	G/A	cg16240275	chr20:61666158	NCRNA00029	0.5	8.96	0.48	6.1e-17	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs11122272	0.705	rs2790879	chr1:231534389	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.47	-6.03	-0.35	5.57e-9	Hemoglobin concentration;
CESC	trans	rs17685	0.753	rs7788763	chr7:75651665	T/C	cg19862616	chr7:65841803	NCRNA00174	-0.82	-11.9	-0.59	1.95e-26	Coffee consumption;Coffee consumption (cups per day);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10909163	chr13:41635251	WBP4	0.52	6.1	0.35	3.8e-9	Gut microbiome composition (summer);
CESC	trans	rs4596713	0.508	rs12056979	chr9:71778946	A/G	cg16512924	chr15:28394682	HERC2	0.48	6.14	0.35	2.95e-9	Headache;
CESC	cis	rs9379850	0.730	rs9393738	chr6:26620658	G/A	cg12826209	chr6:26865740	GUSBL1	0.76	8.73	0.47	2.93e-16	Intelligence (multi-trait analysis);
CESC	cis	rs11098499	0.955	rs4145951	chr4:120155817	A/G	cg24375607	chr4:120327624	NA	0.42	5.05	0.3	8.26e-7	Corneal astigmatism;
CESC	cis	rs6005807	0.543	rs2235432	chr22:29169420	T/G	cg15103426	chr22:29168792	CCDC117	0.5	5.16	0.3	4.89e-7	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
CESC	cis	rs1178968	0.688	rs2528708	chr7:72788583	C/A	cg25889504	chr7:72793014	NA	0.44	5.13	0.3	5.64e-7	Triglyceride levels;
CESC	trans	rs2109514	0.505	rs1633714	chr7:116022538	C/T	cg26334671	chr3:172037094	FNDC3B	0.43	6.01	0.35	6.15e-9	Prevalent atrial fibrillation;
CESC	cis	rs208520	0.955	rs12204033	chr6:67001525	T/C	cg07460842	chr6:66804631	NA	0.77	8.99	0.48	4.98e-17	Exhaled nitric oxide output;
CESC	cis	rs3020736	0.500	rs2413672	chr22:42513261	C/T	cg04733989	chr22:42467013	NAGA	-0.78	-11.9	-0.59	1.87e-26	Autism spectrum disorder or schizophrenia;
CESC	cis	rs10504229	0.679	rs17801003	chr8:58050930	A/G	cg21724239	chr8:58056113	NA	0.58	5.23	0.31	3.48e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs1572438	0.896	rs9405366	chr6:858296	A/C	cg21062780	chr6:887772	NA	-0.39	-5.52	-0.32	8.25e-8	Aging;
CESC	trans	rs12356475	0.710	rs10822686	chr10:67733250	C/T	cg16554516	chr1:206680868	RASSF5	0.49	6.03	0.35	5.45e-9	Psoriatic arthritis;
CESC	cis	rs922182	0.547	rs12594348	chr15:64269127	C/T	cg24729988	chr15:64271149	DAPK2	-0.6	-8.97	-0.48	5.6e-17	Blood protein levels;
CESC	trans	rs7615952	0.799	rs13315434	chr3:125641394	T/G	cg07211511	chr3:129823064	LOC729375	-1.13	-16.52	-0.71	1.28e-42	Blood pressure (smoking interaction);
CESC	cis	rs2302190	1.000	rs2302190	chr17:56584508	A/G	cg25885038	chr17:56607967	SEPT4	-0.37	-5.31	-0.31	2.3e-7	Vitamin D levels;
CESC	cis	rs11690935	0.959	rs6724337	chr2:172735329	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.96	-14.51	-0.67	1.65e-35	Schizophrenia;
CESC	cis	rs875971	0.895	rs6460278	chr7:65662736	T/C	cg18252515	chr7:66147081	NA	0.46	5.97	0.34	7.62e-9	Aortic root size;
CESC	cis	rs57506017	0.585	rs3823612	chr7:12258755	C/G	cg23422036	chr7:12250390	TMEM106B	0.39	5.26	0.31	2.93e-7	Neuroticism;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26859690	chr20:3869672	PANK2	0.55	6.51	0.37	3.82e-10	Gut microbiome composition (summer);
CESC	cis	rs6988985	0.560	rs5301	chr8:143955273	T/C	cg10324643	chr8:143916377	GML	0.35	5.22	0.31	3.63e-7	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
CESC	cis	rs12549902	0.966	rs4737000	chr8:41509727	A/C	cg00088007	chr8:41504566	NKX6-3	0.29	5.05	0.3	8.26e-7	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
CESC	cis	rs35306767	0.903	rs12244253	chr10:889320	G/T	cg10556349	chr10:835070	NA	0.57	5.48	0.32	9.88e-8	Eosinophil percentage of granulocytes;
CESC	trans	rs2797160	0.651	rs9491503	chr6:126031682	G/A	cg05039488	chr6:79577232	IRAK1BP1	0.54	7.23	0.41	5.04e-12	Endometrial cancer;
CESC	cis	rs875971	0.862	rs7783779	chr7:65796626	A/G	cg10691866	chr7:65817282	TPST1	0.3	5.06	0.3	7.74e-7	Aortic root size;
CESC	cis	rs2832077	0.527	rs11088095	chr21:30223188	A/T	cg24692254	chr21:30365293	RNF160	-0.66	-9.15	-0.49	1.56e-17	Cognitive test performance;
CESC	cis	rs6032067	0.704	rs62205505	chr20:43874856	C/T	cg10761708	chr20:43804764	PI3	0.51	6.13	0.35	3.16e-9	Blood protein levels;
CESC	cis	rs9911578	0.805	rs12601867	chr17:56455260	C/G	cg12560992	chr17:57184187	TRIM37	-0.76	-11.97	-0.59	1.14e-26	Intelligence (multi-trait analysis);
CESC	cis	rs4642101	0.662	rs9840766	chr3:12821870	G/A	cg24848339	chr3:12840334	CAND2	0.41	6.33	0.36	1.06e-9	QRS complex (12-leadsum);
CESC	cis	rs2576037	0.545	rs9948405	chr18:44494527	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.51	-6.96	-0.39	2.6e-11	Personality dimensions;
CESC	cis	rs2404602	0.735	rs2957614	chr15:76696635	C/T	cg23625390	chr15:77176239	SCAPER	0.42	5.87	0.34	1.27e-8	Blood metabolite levels;
CESC	cis	rs1552244	0.882	rs13077641	chr3:10022935	G/A	cg00166722	chr3:10149974	C3orf24	0.49	6.04	0.35	5.3e-9	Alzheimer's disease;
CESC	cis	rs60154123	0.505	rs7540237	chr1:210053325	C/T	cg25204440	chr1:209979598	IRF6	0.69	6.43	0.37	5.76e-10	Coronary artery disease;
CESC	cis	rs6933660	0.800	rs9383900	chr6:151782816	A/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.64	9.08	0.49	2.57e-17	Menarche (age at onset);
CESC	cis	rs9487051	0.676	rs6928622	chr6:109595112	C/T	cg21918786	chr6:109611834	NA	-0.37	-5.44	-0.32	1.22e-7	Reticulocyte fraction of red cells;
CESC	cis	rs17209837	0.915	rs17149637	chr7:87085209	G/A	cg00919237	chr7:87102261	ABCB4	-0.5	-5.83	-0.34	1.6e-8	Gallbladder cancer;
CESC	trans	rs61931739	0.500	rs11513287	chr12:34584351	G/A	cg13010199	chr12:38710504	ALG10B	0.52	6.63	0.38	1.86e-10	Morning vs. evening chronotype;
CESC	cis	rs1862618	0.802	rs832560	chr5:56124423	T/A	cg24549020	chr5:56110836	MAP3K1	0.65	7.54	0.42	7.42e-13	Initial pursuit acceleration;
CESC	trans	rs208520	1.000	rs208537	chr6:66963544	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.85	-9.42	-0.5	2.36e-18	Exhaled nitric oxide output;
CESC	cis	rs7647973	1.000	rs9871024	chr3:49554241	T/C	cg06212747	chr3:49208901	KLHDC8B	-0.6	-7.97	-0.44	4.76e-14	Menarche (age at onset);
CESC	cis	rs12447180	0.527	rs4782365	chr16:88516171	C/G	cg26884787	chr16:88543447	ZFPM1	0.34	5.2	0.3	3.96e-7	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
CESC	cis	rs34779708	0.897	rs35784065	chr10:35353574	C/T	cg04310649	chr10:35416472	CREM	-0.5	-5.89	-0.34	1.15e-8	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs6740322	0.748	rs6720087	chr2:43468745	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.68	7.76	0.43	1.9e-13	Coronary artery disease;
CESC	cis	rs7845219	0.544	rs2945554	chr8:95939594	C/A	cg23172400	chr8:95962367	TP53INP1	-0.37	-6.79	-0.38	7.51e-11	Type 2 diabetes;
CESC	cis	rs7772486	0.719	rs2206141	chr6:146086192	A/G	cg05347473	chr6:146136440	FBXO30	-0.55	-6.97	-0.39	2.54e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs11122272	0.735	rs2808602	chr1:231537303	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.55	-7.44	-0.42	1.38e-12	Hemoglobin concentration;
CESC	cis	rs1865760	0.566	rs9348706	chr6:26065481	G/C	cg16482183	chr6:26056742	HIST1H1C	0.39	5.46	0.32	1.12e-7	Height;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg24886033	chr12:10265096	NA	-0.52	-7.16	-0.4	7.88e-12	Gut microbiota (bacterial taxa);
CESC	cis	rs9287719	0.967	rs7600728	chr2:10739999	A/G	cg02196655	chr2:10830764	NOL10	-0.37	-5.72	-0.33	2.87e-8	Prostate cancer;
CESC	cis	rs2929278	0.588	rs1975364	chr15:44150189	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.48	7.31	0.41	3.25e-12	Schizophrenia;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg23652038	chr6:111136640	CDK19	-0.49	-6.08	-0.35	4.2e-9	Ulcerative colitis;
CESC	cis	rs34330	0.562	rs12229100	chr12:12865836	A/G	cg09462578	chr12:12878428	APOLD1	0.79	8.76	0.47	2.41e-16	Systemic lupus erythematosus;
CESC	cis	rs965469	0.779	rs6037528	chr20:3260978	A/G	cg25506879	chr20:3388711	C20orf194	-0.49	-5.34	-0.31	1.99e-7	IFN-related cytopenia;
CESC	cis	rs7772486	0.686	rs9386131	chr6:146121608	G/A	cg05347473	chr6:146136440	FBXO30	0.52	6.84	0.39	5.37e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs796364	0.616	rs1523818	chr2:200684704	G/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.58	5.45	0.32	1.15e-7	Schizophrenia;
CESC	cis	rs10479542	0.784	rs7703730	chr5:178986632	C/A	cg19626725	chr5:178986131	RUFY1	-0.4	-6.24	-0.36	1.7e-9	Lung cancer;
CESC	cis	rs9611565	0.694	rs202637	chr22:41853928	A/G	cg06481639	chr22:41940642	POLR3H	0.62	6.2	0.36	2.19e-9	Vitiligo;
CESC	cis	rs3733585	0.699	rs6449174	chr4:9966422	C/T	cg11266682	chr4:10021025	SLC2A9	-0.54	-9.99	-0.52	3.71e-20	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs801193	0.569	rs11761542	chr7:66218196	G/A	cg11764359	chr7:65958608	NA	0.73	10.38	0.54	2.09e-21	Aortic root size;
CESC	cis	rs4689388	0.856	rs4308430	chr4:6294095	A/G	cg00701064	chr4:6280414	WFS1	0.69	11.74	0.58	6.7e-26	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs11098499	1.000	rs11098499	chr4:120187611	C/T	cg24375607	chr4:120327624	NA	0.41	5.03	0.3	9e-7	Corneal astigmatism;
CESC	cis	rs7617773	0.817	rs936427	chr3:48301074	A/G	cg11946769	chr3:48343235	NME6	-0.88	-11.65	-0.58	1.34e-25	Coronary artery disease;
CESC	cis	rs6772849	1.000	rs2712379	chr3:128309060	C/T	cg16766828	chr3:128327626	NA	-0.32	-5.12	-0.3	5.95e-7	Monocyte percentage of white cells;Monocyte count;
CESC	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg19678392	chr7:94953810	PON1	-0.57	-8.74	-0.47	2.68e-16	Paraoxonase activity;
CESC	cis	rs2688608	0.592	rs11000757	chr10:75486815	T/C	cg23231163	chr10:75533350	FUT11	-0.35	-5.27	-0.31	2.81e-7	Inflammatory bowel disease;
CESC	cis	rs7084402	0.967	rs2842083	chr10:60329230	A/C	cg07615347	chr10:60278583	BICC1	0.59	9.18	0.49	1.26e-17	Refractive error;
CESC	cis	rs1799949	0.931	rs34474989	chr17:41445410	A/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.53	7.68	0.43	3.04e-13	Menopause (age at onset);
CESC	cis	rs7084402	0.967	rs1658452	chr10:60311114	A/T	cg07615347	chr10:60278583	BICC1	0.59	9.34	0.5	4.21e-18	Refractive error;
CESC	cis	rs9486719	0.690	rs2092094	chr6:96844123	G/C	cg18709589	chr6:96969512	KIAA0776	0.55	5.64	0.33	4.26e-8	Migraine;Coronary artery disease;
CESC	cis	rs12530845	0.945	rs59664351	chr7:135314717	C/A	cg23117316	chr7:135346802	PL-5283	-0.44	-5.6	-0.33	5.48e-8	Red blood cell traits;
CESC	cis	rs2295499	0.649	rs55679022	chr4:2707325	T/G	cg08330972	chr4:2403930	ZFYVE28	-0.33	-5.41	-0.32	1.41e-7	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
CESC	cis	rs6543140	0.927	rs917999	chr2:103067869	G/A	cg04239558	chr2:103089729	SLC9A4	0.45	5.66	0.33	3.94e-8	Blood protein levels;
CESC	cis	rs1799949	0.965	rs799912	chr17:41257134	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.48	6.9	0.39	3.86e-11	Menopause (age at onset);
CESC	cis	rs16854884	0.739	rs56196484	chr3:143786160	G/T	cg06585982	chr3:143692056	C3orf58	0.47	5.98	0.34	7.16e-9	Economic and political preferences (feminism/equality);
CESC	cis	rs992157	0.735	rs13393821	chr2:219076742	C/G	cg20019365	chr2:219134978	PNKD;AAMP	0.68	9.57	0.51	8.06e-19	Colorectal cancer;
CESC	cis	rs2839186	0.721	rs3788252	chr21:47661235	C/T	cg13012494	chr21:47604986	C21orf56	0.48	6.55	0.37	2.96e-10	Testicular germ cell tumor;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg00167275	chr10:88854588	FAM35A;GLUD1	-0.44	-6.1	-0.35	3.73e-9	Ulcerative colitis;
CESC	cis	rs514406	0.505	rs856721	chr1:53162156	C/A	cg27535305	chr1:53392650	SCP2	-0.34	-5.55	-0.32	6.99e-8	Monocyte count;
CESC	cis	rs7219021	0.739	rs58376900	chr17:46962853	C/G	cg16584676	chr17:46985605	UBE2Z	-0.66	-7.42	-0.41	1.61e-12	Schizophrenia or bipolar disorder;
CESC	cis	rs10504229	0.683	rs1495865	chr8:58141160	T/G	cg22535103	chr8:58192502	C8orf71	-0.8	-9.09	-0.49	2.46e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs736408	0.812	rs1075653	chr3:52825528	T/C	cg07507251	chr3:52567010	NT5DC2	0.34	5.45	0.32	1.15e-7	Bipolar disorder;
CESC	cis	rs4555082	0.834	rs2816652	chr14:105712493	C/T	cg06808227	chr14:105710500	BRF1	-0.51	-5.81	-0.34	1.77e-8	Mean platelet volume;Platelet distribution width;
CESC	cis	rs1008375	1.000	rs56308330	chr4:17643050	G/A	cg15017067	chr4:17643749	FAM184B	0.37	5.23	0.31	3.39e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs938554	0.657	rs9994216	chr4:9984541	G/T	cg00071950	chr4:10020882	SLC2A9	0.51	6.7	0.38	1.22e-10	Blood metabolite levels;
CESC	cis	rs7592578	0.882	rs7569128	chr2:191446691	C/A	cg10560079	chr2:191398806	TMEM194B	0.62	5.48	0.32	1e-7	Diastolic blood pressure;
CESC	cis	rs763121	0.819	rs4560233	chr22:38982442	A/T	cg06022373	chr22:39101656	GTPBP1	0.82	12.13	0.6	3.16e-27	Menopause (age at onset);
CESC	cis	rs7223966	1.000	rs9893348	chr17:61676534	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.47	5.12	0.3	6.01e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs4665809	1.000	rs4665309	chr2:26335502	T/C	cg04944784	chr2:26401820	FAM59B	-0.66	-7.62	-0.42	4.62e-13	Gut microbiome composition (summer);
CESC	cis	rs2066819	1.000	rs2066808	chr12:56737973	A/G	cg26316697	chr12:56727976	PAN2	0.72	6.9	0.39	3.81e-11	Psoriasis vulgaris;
CESC	cis	rs11828289	0.660	rs11027043	chr11:23212893	C/T	cg20040320	chr11:23191996	NA	-0.72	-5.98	-0.35	7.05e-9	Cancer;
CESC	cis	rs965469	0.779	rs6051780	chr20:3334167	A/C	cg17110299	chr20:3385021	C20orf194	0.4	5.24	0.31	3.22e-7	IFN-related cytopenia;
CESC	cis	rs514406	0.505	rs447581	chr1:53177098	T/C	cg27535305	chr1:53392650	SCP2	-0.33	-5.62	-0.33	4.92e-8	Monocyte count;
CESC	cis	rs9911578	1.000	rs1267545	chr17:56646909	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.16	0.3	4.79e-7	Intelligence (multi-trait analysis);
CESC	cis	rs910316	0.712	rs175015	chr14:75457075	A/C	cg11812906	chr14:75593930	NEK9	-0.8	-12.6	-0.61	7.66e-29	Height;
CESC	cis	rs6951245	0.706	rs1133116	chr7:1195215	A/C	cg16145915	chr7:1198662	ZFAND2A	-0.5	-5.64	-0.33	4.29e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs9291683	0.704	rs11726271	chr4:10098192	G/A	cg00071950	chr4:10020882	SLC2A9	-0.56	-8.71	-0.47	3.35e-16	Bone mineral density;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03661160	chr7:97881541	TECPR1	0.57	7.02	0.4	1.87e-11	Gut microbiome composition (summer);
CESC	cis	rs919433	0.817	rs10931780	chr2:198175297	G/C	cg10820045	chr2:198174542	NA	-0.44	-7.01	-0.4	2e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg18402987	chr7:1209562	NA	0.76	7.79	0.43	1.5e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs6032067	0.929	rs17333555	chr20:43809761	C/T	cg11264863	chr20:43835661	SEMG1	0.49	5.36	0.31	1.81e-7	Blood protein levels;
CESC	cis	rs919433	0.963	rs1429417	chr2:198158171	T/G	cg03934865	chr2:198174659	NA	-0.47	-7.1	-0.4	1.12e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs6570726	0.967	rs373527	chr6:145801861	C/T	cg23711669	chr6:146136114	FBXO30	0.73	10.72	0.55	1.63e-22	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2235642	0.859	rs12599207	chr16:1606445	A/G	cg03771183	chr16:1608904	IFT140	0.41	5.93	0.34	9.31e-9	Coronary artery disease;
CESC	cis	rs7666738	0.830	rs62321569	chr4:98984250	T/A	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.67e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1552244	0.882	rs34779351	chr3:10021801	A/G	cg00149659	chr3:10157352	C3orf10	0.73	8.54	0.46	1.05e-15	Alzheimer's disease;
CESC	cis	rs9467711	0.606	rs9379851	chr6:26354780	A/C	cg12826209	chr6:26865740	GUSBL1	0.62	5.3	0.31	2.42e-7	Autism spectrum disorder or schizophrenia;
CESC	trans	rs7947523	0.813	rs4999940	chr11:80942337	C/T	cg16956456	chr5:172483378	C5orf41	0.48	6.28	0.36	1.35e-9	Emphysema imaging phenotypes;
CESC	cis	rs4819052	0.851	rs2838855	chr21:46680566	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.75	-10.27	-0.53	4.65e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs9487051	0.714	rs9487053	chr6:109619697	T/C	cg12927641	chr6:109611667	NA	-0.36	-5.25	-0.31	3.08e-7	Reticulocyte fraction of red cells;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01671314	chr6:135502610	MYB	0.59	6.55	0.37	3.06e-10	Gut microbiome composition (summer);
CESC	cis	rs870825	0.616	rs10013562	chr4:185610486	A/G	cg04058563	chr4:185651563	MLF1IP	0.61	7.0	0.39	2.15e-11	Blood protein levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00670742	chr2:87034831	CD8A	0.51	6.05	0.35	5.01e-9	Gut microbiome composition (summer);
CESC	cis	rs847577	0.569	rs2394817	chr7:97690438	C/T	cg21770322	chr7:97807741	LMTK2	0.81	14.38	0.66	4.75e-35	Breast cancer;
CESC	cis	rs896854	0.812	rs2340586	chr8:95969261	G/A	cg13393036	chr8:95962371	TP53INP1	-0.51	-11.09	-0.56	9.71e-24	Type 2 diabetes;
CESC	cis	rs6540559	0.673	rs17015361	chr1:210018901	C/G	cg22029157	chr1:209979665	IRF6	0.66	7.44	0.42	1.4e-12	Cleft lip with or without cleft palate;
CESC	cis	rs6893300	0.961	rs11738269	chr5:179209059	A/C	cg14593053	chr5:179126677	CANX	0.52	5.8	0.34	1.86e-8	Resting heart rate;
CESC	cis	rs875971	0.660	rs7807944	chr7:66087195	C/G	cg14393609	chr7:65229607	NA	-0.47	-6.27	-0.36	1.49e-9	Aortic root size;
CESC	cis	rs2997447	0.846	rs61775427	chr1:26408768	G/A	cg24596570	chr1:26146463	FAM54B;LOC646471	0.61	5.37	0.31	1.71e-7	QRS complex (12-leadsum);
CESC	cis	rs919433	0.929	rs4850788	chr2:198182940	G/A	cg10820045	chr2:198174542	NA	-0.44	-6.86	-0.39	4.76e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs12586317	0.547	rs74462850	chr14:35500093	G/T	cg05294307	chr14:35346193	BAZ1A	-0.51	-5.4	-0.31	1.49e-7	Psoriasis;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg12792894	chr1:115123975	BCAS2	0.42	6.11	0.35	3.54e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs367943	1.000	rs348930	chr5:112814763	T/C	cg12552261	chr5:112820674	MCC	-0.62	-7.72	-0.43	2.34e-13	Type 2 diabetes;
CESC	cis	rs2836974	0.931	rs2776309	chr21:40715791	A/G	cg11644478	chr21:40555479	PSMG1	0.95	13.43	0.64	9.81e-32	Cognitive function;
CESC	cis	rs2228479	0.850	rs3785279	chr16:89824562	G/C	cg04013166	chr16:89971882	TCF25	0.79	6.75	0.38	9.14e-11	Skin colour saturation;
CESC	cis	rs920590	0.684	rs57837509	chr8:19670088	A/G	cg03894339	chr8:19674705	INTS10	0.68	7.78	0.43	1.59e-13	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs13256369	1.000	rs12545771	chr8:8567977	C/G	cg18904891	chr8:8559673	CLDN23	0.67	7.49	0.42	1.01e-12	Obesity-related traits;
CESC	cis	rs9467711	0.606	rs9379854	chr6:26362854	T/C	cg14345882	chr6:26364793	BTN3A2	0.62	6.53	0.37	3.29e-10	Autism spectrum disorder or schizophrenia;
CESC	cis	rs34779708	0.966	rs4934538	chr10:35472150	T/C	cg04310649	chr10:35416472	CREM	-0.51	-6.27	-0.36	1.43e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs4523957	0.748	rs12603592	chr17:2119818	A/T	cg16513277	chr17:2031491	SMG6	-0.61	-8.23	-0.45	8.58e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs6952808	0.792	rs12531315	chr7:1953650	C/G	cg04267008	chr7:1944627	MAD1L1	-0.74	-10.0	-0.52	3.37e-20	Bipolar disorder and schizophrenia;
CESC	cis	rs7666738	0.830	rs59751489	chr4:98933802	A/G	cg03467027	chr4:99064603	C4orf37	0.48	5.91	0.34	1.03e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7811142	1.000	rs112317829	chr7:100043173	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.92	9.69	0.51	3.29e-19	Platelet count;
CESC	cis	rs6088580	0.634	rs1890002	chr20:32919219	A/G	cg06115741	chr20:33292138	TP53INP2	-0.43	-5.53	-0.32	7.76e-8	Glomerular filtration rate (creatinine);
CESC	trans	rs61931739	0.500	rs7488438	chr12:34531359	G/T	cg13010199	chr12:38710504	ALG10B	0.52	6.65	0.38	1.7e-10	Morning vs. evening chronotype;
CESC	cis	rs12900413	0.687	rs28493563	chr15:90309505	C/T	cg24249390	chr15:90295951	MESP1	-0.4	-5.5	-0.32	8.88e-8	Coronary artery aneurysm in Kawasaki disease;
CESC	cis	rs7246657	0.943	rs12981532	chr19:37889280	G/A	cg23950597	chr19:37808831	NA	-0.61	-6.19	-0.36	2.31e-9	Coronary artery calcification;
CESC	cis	rs8133932	0.564	rs452797	chr21:47348455	C/G	cg14185626	chr21:47401492	COL6A1	-0.48	-5.33	-0.31	2.07e-7	Schizophrenia;
CESC	cis	rs2011503	1.000	rs75667002	chr19:19592232	T/A	cg11584989	chr19:19387371	SF4	0.62	7.22	0.41	5.54e-12	Bipolar disorder;
CESC	cis	rs17401966	0.838	rs61775885	chr1:10281445	T/C	cg15208524	chr1:10270712	KIF1B	0.42	5.45	0.32	1.17e-7	Hepatocellular carcinoma;
CESC	cis	rs473651	0.935	rs483166	chr2:239346641	C/T	cg21699342	chr2:239360505	ASB1	-0.54	-9.38	-0.5	2.98e-18	Multiple system atrophy;
CESC	trans	rs6794880	1.000	rs6794880	chr3:84451512	G/A	cg03554283	chr8:76319451	NA	-0.56	-6.08	-0.35	4.27e-9	Body mass index (joint analysis main effects and smoking interaction);BMI in non-smokers;BMI (adjusted for smoking behaviour);
CESC	cis	rs17209837	1.000	rs2302387	chr7:87092185	G/A	cg00919237	chr7:87102261	ABCB4	-0.5	-5.83	-0.34	1.6e-8	Gallbladder cancer;
CESC	cis	rs240110	0.515	rs12530388	chr6:101329173	A/C	cg09795085	chr6:101329169	ASCC3	0.46	5.98	0.34	7.08e-9	Neuroticism;
CESC	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg04234412	chr22:24373322	LOC391322	-0.41	-5.88	-0.34	1.21e-8	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs7575873	1	rs7575873	chr2:23962647	A/G	cg08917208	chr2:24149416	ATAD2B	1.13	10.18	0.53	9.42e-21	Birth weight;
CESC	cis	rs7264396	0.561	rs6058388	chr20:34571846	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.7	-8.9	-0.48	9.01e-17	Total cholesterol levels;
CESC	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg03647317	chr4:187891568	NA	-0.38	-5.64	-0.33	4.38e-8	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7811142	1.000	rs4472444	chr7:100070758	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.13	13.32	0.63	2.4e-31	Platelet count;
CESC	cis	rs9902453	0.868	rs7212162	chr17:28321328	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.76	9.9	0.52	7e-20	Coffee consumption (cups per day);
CESC	trans	rs2727020	0.576	rs12293522	chr11:49558425	T/A	cg15704280	chr7:45808275	SEPT13	-0.95	-17.21	-0.73	4.36e-45	Coronary artery disease;
CESC	cis	rs9388451	0.839	rs9321054	chr6:126079968	A/G	cg05901451	chr6:126070800	HEY2	0.65	9.51	0.5	1.21e-18	Brugada syndrome;
CESC	cis	rs1707322	0.963	rs4553121	chr1:46375253	G/A	cg05343316	chr1:45956843	TESK2	0.44	5.55	0.32	7.05e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs597539	0.652	rs686390	chr11:68656077	T/C	cg21963583	chr11:68658836	MRPL21	0.4	5.55	0.32	7.03e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs2842992	0.750	rs2758354	chr6:160125854	A/G	cg11366901	chr6:160182831	ACAT2	0.82	10.45	0.54	1.24e-21	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs1499614	1.000	rs1267818	chr7:66107024	C/T	cg12463550	chr7:65579703	CRCP	0.75	5.85	0.34	1.42e-8	Gout;
CESC	cis	rs7618915	0.547	rs8906	chr3:52739520	T/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.38	6.74	0.38	9.59e-11	Bipolar disorder;
CESC	cis	rs853679	0.517	rs55747925	chr6:28044337	T/C	cg12963246	chr6:28129442	ZNF389	0.55	7.35	0.41	2.46e-12	Depression;
CESC	cis	rs78456975	1.000	rs78456975	chr2:1554190	T/G	cg26248373	chr2:1572462	NA	-0.58	-5.22	-0.31	3.68e-7	Placebo response in major depressive disorder (% change in symptom score);
CESC	trans	rs17508449	0.819	rs41352847	chr1:114189880	G/A	cg23028848	chr11:57092561	TNKS1BP1	-0.75	-6.05	-0.35	4.88e-9	Leprosy;
CESC	cis	rs4654899	0.758	rs7556221	chr1:21455559	C/G	cg05370193	chr1:21551575	ECE1	0.38	5.82	0.34	1.7e-8	Superior frontal gyrus grey matter volume;
CESC	cis	rs7811142	0.830	rs7792525	chr7:99972122	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.71	6.23	0.36	1.82e-9	Platelet count;
CESC	trans	rs208520	0.690	rs12201156	chr6:66720874	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.9	11.51	0.58	3.9e-25	Exhaled nitric oxide output;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg13195266	chr15:75660973	MAN2C1	-0.51	-6.04	-0.35	5.24e-9	Ulcerative colitis;
CESC	cis	rs2235544	0.513	rs10158824	chr1:54480398	C/G	cg09175620	chr1:54484536	LDLRAD1	0.28	5.1	0.3	6.35e-7	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
CESC	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg04915975	chr3:139063070	MRPS22	0.46	6.09	0.35	3.94e-9	Myopia (pathological);
CESC	cis	rs4953076	0.573	rs67537903	chr2:44422111	G/A	cg04920474	chr2:44395004	PPM1B	0.6	7.62	0.42	4.44e-13	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21042902	chr5:176873577	PRR7	0.54	6.02	0.35	5.69e-9	Gut microbiome composition (summer);
CESC	cis	rs72829446	0.556	rs9907042	chr17:7402985	A/G	cg02795151	chr17:7402630	POLR2A	-0.62	-6.63	-0.38	1.83e-10	Androgen levels;
CESC	cis	rs9303401	0.538	rs3785493	chr17:56472119	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.9	-9.72	-0.51	2.6e-19	Cognitive test performance;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg07871153	chr10:79602008	DLG5	-0.47	-6.39	-0.37	7.38e-10	Gut microbiota (bacterial taxa);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21578066	chr4:111119297	ELOVL6	-0.7	-9.07	-0.49	2.83e-17	Gut microbiome composition (summer);
CESC	cis	rs514406	0.861	rs4926576	chr1:53226775	C/T	cg16325326	chr1:53192061	ZYG11B	-0.89	-15.32	-0.69	2.26e-38	Monocyte count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12515684	chr10:8203261	NA	-0.59	-7.0	-0.4	2.12e-11	Gut microbiome composition (summer);
CESC	trans	rs61931739	0.517	rs11053067	chr12:34191391	T/C	cg13010199	chr12:38710504	ALG10B	0.48	5.99	0.35	6.66e-9	Morning vs. evening chronotype;
CESC	cis	rs1348850	0.632	rs11678875	chr2:178509068	A/G	cg23306229	chr2:178417860	TTC30B	0.58	7.35	0.41	2.41e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs11098499	0.874	rs6832670	chr4:120118792	A/G	cg09307838	chr4:120376055	NA	0.74	9.2	0.49	1.07e-17	Corneal astigmatism;
CESC	cis	rs654384	0.613	rs4236342	chr7:4177712	A/C	cg26275264	chr7:4183598	SDK1	0.36	5.18	0.3	4.29e-7	Positive affect;
CESC	cis	rs2228479	0.850	rs62054609	chr16:89816569	C/A	cg06558623	chr16:89946397	TCF25	1.16	9.28	0.5	6.08e-18	Skin colour saturation;
CESC	cis	rs10883723	0.810	rs2296588	chr10:104248087	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.54	7.48	0.42	1.09e-12	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs703842	0.616	rs1875125	chr12:58227241	T/G	cg02175503	chr12:58329896	NA	0.48	5.99	0.35	6.99e-9	Multiple sclerosis;
CESC	cis	rs137699	0.959	rs5757631	chr22:39755953	T/C	cg24399712	chr22:39784796	NA	-0.4	-5.19	-0.3	4.23e-7	IgG glycosylation;
CESC	cis	rs854765	0.547	rs2955380	chr17:17944349	A/G	cg16928487	chr17:17741425	SREBF1	0.55	9.13	0.49	1.86e-17	Total body bone mineral density;
CESC	cis	rs644799	1.000	rs534497	chr11:95562868	C/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.55	6.74	0.38	9.71e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs1983170	1.000	rs12563578	chr1:91993702	T/C	cg02896835	chr1:92012615	NA	0.58	6.58	0.37	2.54e-10	Eosinophil percentage of white cells;
CESC	cis	rs3126085	0.560	rs3120667	chr1:152318161	A/G	cg03465714	chr1:152285911	FLG	0.42	5.05	0.3	8.42e-7	Atopic dermatitis;
CESC	trans	rs875971	0.895	rs3857684	chr7:65938158	G/C	cg26939375	chr7:64535504	NA	0.47	6.07	0.35	4.45e-9	Aortic root size;
CESC	cis	rs10791097	0.765	rs4622274	chr11:130729486	C/T	cg09137382	chr11:130731461	NA	0.37	5.4	0.32	1.46e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs35110281	0.681	rs162343	chr21:44957072	A/G	cg01579765	chr21:45077557	HSF2BP	-0.55	-9.52	-0.5	1.12e-18	Mean corpuscular volume;
CESC	cis	rs2841277	0.708	rs28600075	chr14:105408315	T/C	cg21017887	chr14:105400489	NA	0.41	6.8	0.39	7.06e-11	Rheumatoid arthritis;
CESC	cis	rs9858542	0.953	rs9858280	chr3:49597737	T/C	cg07274523	chr3:49395745	GPX1	0.65	8.45	0.46	1.91e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs9611565	0.546	rs739132	chr22:42123099	A/T	cg06634786	chr22:41940651	POLR3H	0.65	6.57	0.37	2.6200000000000003e-10	Vitiligo;
CESC	cis	rs9911578	1.000	rs9807057	chr17:56889952	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.24	0.31	3.23e-7	Intelligence (multi-trait analysis);
CESC	cis	rs5769765	0.646	rs9627789	chr22:50300562	A/G	cg02269571	chr22:50332266	NA	-0.52	-6.31	-0.36	1.18e-9	Schizophrenia;
CESC	cis	rs2576037	0.583	rs2576050	chr18:44558912	T/C	cg19077165	chr18:44547161	KATNAL2	0.65	10.07	0.53	2.03e-20	Personality dimensions;
CESC	cis	rs2836974	0.605	rs2836971	chr21:40652040	A/C	cg17971929	chr21:40555470	PSMG1	-0.87	-12.71	-0.62	3.27e-29	Cognitive function;
CESC	cis	rs2228479	0.557	rs62054639	chr16:89821489	C/T	cg19635926	chr16:89946313	TCF25	0.67	5.09	0.3	6.82e-7	Skin colour saturation;
CESC	cis	rs2841277	0.802	rs2841269	chr14:105386149	C/G	cg19901468	chr14:105411992	AHNAK2	-0.61	-8.78	-0.47	2.08e-16	Rheumatoid arthritis;
CESC	cis	rs7552404	0.731	rs11161845	chr1:76367559	T/C	cg03433033	chr1:76189801	ACADM	0.57	5.65	0.33	4.21e-8	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs4953076	0.573	rs2054005	chr2:44401843	C/T	cg04920474	chr2:44395004	PPM1B	0.56	7.24	0.41	4.78e-12	Height;
CESC	cis	rs8114671	0.562	rs1013677	chr20:33468793	C/T	cg07148914	chr20:33460835	GGT7	0.44	6.11	0.35	3.63e-9	Height;
CESC	cis	rs7851660	1.000	rs7851660	chr9:100610759	C/A	cg13688889	chr9:100608707	NA	-0.68	-10.52	-0.54	7.66e-22	Strep throat;
CESC	cis	rs6963495	0.818	rs114865717	chr7:105158526	C/T	cg02135003	chr7:105160482	PUS7	-0.46	-5.55	-0.32	6.92e-8	Bipolar disorder (body mass index interaction);
CESC	cis	rs61931739	0.500	rs6488224	chr12:34537205	T/C	cg06521331	chr12:34319734	NA	-0.37	-5.15	-0.3	5.19e-7	Morning vs. evening chronotype;
CESC	cis	rs4665809	1.000	rs2384321	chr2:26290054	A/G	cg08470875	chr2:26401718	FAM59B	-0.62	-6.71	-0.38	1.2e-10	Gut microbiome composition (summer);
CESC	cis	rs4704187	0.687	rs58067979	chr5:74523555	C/T	cg03227963	chr5:74354835	NA	0.28	5.13	0.3	5.48e-7	Response to amphetamines;
CESC	cis	rs6502050	0.871	rs8072702	chr17:80074280	C/T	cg23985595	chr17:80112537	CCDC57	0.41	6.4	0.37	6.88e-10	Life satisfaction;
CESC	cis	rs2243480	1.000	rs781156	chr7:65479141	C/A	cg25894440	chr7:65020034	NA	-0.65	-5.63	-0.33	4.5e-8	Diabetic kidney disease;
CESC	cis	rs7927771	0.832	rs4992357	chr11:47393638	C/T	cg05585544	chr11:47624801	NA	-0.43	-6.41	-0.37	6.6e-10	Subjective well-being;
CESC	cis	rs8177253	0.761	rs35332919	chr3:133519002	T/A	cg12373951	chr3:133503437	NA	0.52	7.77	0.43	1.7e-13	Iron status biomarkers;
CESC	cis	rs4132509	1.000	rs2290754	chr1:243806268	A/C	cg21452805	chr1:244014465	NA	0.44	5.2	0.3	3.91e-7	RR interval (heart rate);
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg11253136	chr11:70116457	PPFIA1	0.54	6.89	0.39	3.96e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs6598163	0.712	rs10751695	chr12:132291061	A/C	cg26750617	chr12:132293702	NA	-0.42	-5.43	-0.32	1.25e-7	Migraine;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03600697	chr3:142315064	PLS1	-0.43	-6.05	-0.35	4.9e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs7107174	0.892	rs3018313	chr11:77989644	C/T	cg02023728	chr11:77925099	USP35	0.48	6.56	0.37	2.79e-10	Testicular germ cell tumor;
CESC	cis	rs6089584	0.853	rs1746280	chr20:60577821	C/G	cg06108461	chr20:60628389	TAF4	-0.79	-10.4	-0.54	1.85e-21	Body mass index;
CESC	cis	rs7615952	0.641	rs7632497	chr3:125783086	A/C	cg02807482	chr3:125708958	NA	-0.4	-5.32	-0.31	2.26e-7	Blood pressure (smoking interaction);
CESC	trans	rs7902708	0.841	rs73333526	chr10:54424528	A/G	cg26219051	chr22:43739629	SCUBE1	-0.48	-6.07	-0.35	4.3e-9	Bone properties (heel);
CESC	cis	rs801193	1.000	rs6958520	chr7:66151453	T/C	cg06456125	chr7:65229604	NA	0.4	5.25	0.31	3.09e-7	Aortic root size;
CESC	cis	rs9875589	0.509	rs2733556	chr3:14100172	A/T	cg19554555	chr3:13937349	NA	-0.46	-5.9	-0.34	1.09e-8	Ovarian reserve;
CESC	cis	rs56399783	0.901	rs73051444	chr7:2866529	G/A	cg19731401	chr7:2775893	GNA12	0.64	5.6	0.33	5.44e-8	Childhood ear infection;
CESC	cis	rs35110281	0.712	rs167930	chr21:44946625	G/A	cg21573476	chr21:45109991	RRP1B	-0.37	-5.25	-0.31	3.13e-7	Mean corpuscular volume;
CESC	trans	rs2727020	0.553	rs3862350	chr11:49595912	A/C	cg03929089	chr4:120376271	NA	-0.82	-12.21	-0.6	1.63e-27	Coronary artery disease;
CESC	cis	rs7084402	0.935	rs10763559	chr10:60347410	C/T	cg07615347	chr10:60278583	BICC1	0.54	8.32	0.46	4.65e-15	Refractive error;
CESC	cis	rs660498	0.507	rs12413784	chr10:27729599	C/G	cg25705717	chr10:27608719	NA	0.49	5.83	0.34	1.58e-8	Asthma (childhood onset);
CESC	cis	rs853679	0.517	rs12332979	chr6:28141548	T/G	cg23281280	chr6:28129359	ZNF389	0.56	7.61	0.42	4.91e-13	Depression;
CESC	cis	rs6121246	0.821	rs7265413	chr20:30317923	G/A	cg13852791	chr20:30311386	BCL2L1	0.8	8.55	0.46	1.02e-15	Mean corpuscular hemoglobin;
CESC	cis	rs7264396	1.000	rs224433	chr20:34153850	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.5	-6.03	-0.35	5.61e-9	Total cholesterol levels;
CESC	cis	rs9308433	0.529	rs4655244	chr1:214497580	A/G	cg06198575	chr1:214491504	SMYD2	0.49	5.98	0.34	7.22e-9	IgG glycosylation;
CESC	cis	rs2304069	0.545	rs4705404	chr5:149381952	A/C	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.45	6.15	0.35	2.83e-9	HIV-1 control;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg12473036	chr20:62611207	SAMD10;PRPF6	0.51	6.48	0.37	4.4e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs7666738	0.925	rs2865952	chr4:99040305	C/T	cg05340658	chr4:99064831	C4orf37	0.63	8.21	0.45	9.8e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1003719	0.751	rs55992706	chr21:38542749	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.57	-7.66	-0.43	3.53e-13	Eye color traits;
CESC	cis	rs3782089	0.793	rs34789990	chr11:65252477	G/T	cg21890820	chr11:65308645	LTBP3	0.66	5.66	0.33	3.93e-8	Height;
CESC	cis	rs3916	0.641	rs2393749	chr12:121131891	C/T	cg00257296	chr12:120799373	MSI1	0.36	5.44	0.32	1.24e-7	Urinary metabolites (H-NMR features);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg07274506	chr1:6614341	TAS1R1;NOL9	-0.39	-6.24	-0.36	1.71e-9	Gambling;
CESC	cis	rs1552244	0.882	rs7636817	chr3:10014876	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.75	-9.49	-0.5	1.38e-18	Alzheimer's disease;
CESC	cis	rs873946	0.504	rs3829132	chr10:134579044	A/C	cg18305652	chr10:134549665	INPP5A	0.49	7.29	0.41	3.54e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs11608355	0.545	rs9943764	chr12:109905720	G/A	cg05360138	chr12:110035743	NA	0.82	8.92	0.48	7.93e-17	Neuroticism;
CESC	cis	rs8062405	1.000	rs3888190	chr16:28889486	C/A	cg08761264	chr16:28874980	SH2B1	-0.46	-5.72	-0.33	2.81e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs9811920	0.638	rs796977	chr3:99549723	T/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.49	-5.81	-0.34	1.74e-8	Axial length;
CESC	cis	rs2979489	1.000	rs2979469	chr8:30285091	C/G	cg26383811	chr8:30366931	RBPMS	0.67	8.86	0.48	1.22e-16	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CESC	cis	rs3931020	0.548	rs17618340	chr1:75247617	G/A	cg21535942	chr1:75199100	CRYZ;TYW3	0.44	5.68	0.33	3.52e-8	Resistin levels;
CESC	cis	rs2073300	1.000	rs12625999	chr20:23442085	A/G	cg12062639	chr20:23401060	NAPB	-0.91	-6.41	-0.37	6.71e-10	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs936229	0.656	rs12898397	chr15:75130093	T/C	cg17294928	chr15:75287854	SCAMP5	0.43	5.57	0.32	6.13e-8	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CESC	cis	rs2296342	0.522	rs1536036	chr6:33632014	A/G	cg14003231	chr6:33640908	ITPR3	0.32	5.78	0.33	2.14e-8	Schizophrenia;
CESC	cis	rs12983728	0.831	rs79222418	chr19:58664418	T/C	cg08687515	chr19:58661962	ZNF329	0.55	5.26	0.31	3.02e-7	Cholesterol, total;
CESC	cis	rs643506	0.790	rs688095	chr11:111678771	T/C	cg17089665	chr11:111648010	NA	-0.35	-5.11	-0.3	6.19e-7	Breast cancer;
CESC	trans	rs6716963	0.870	rs6748251	chr2:194468524	A/G	cg13775856	chr19:36486874	SDHAF1	-0.45	-6.12	-0.35	3.39e-9	Schizophrenia;
CESC	cis	rs3540	0.533	rs1869179	chr15:90895564	A/C	cg10434728	chr15:90938212	IQGAP1	0.4	7.09	0.4	1.21e-11	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	trans	rs3780486	0.757	rs10121987	chr9:33119818	A/G	cg20290983	chr6:43655470	MRPS18A	0.96	17.31	0.73	2.01e-45	IgG glycosylation;
CESC	cis	rs9875589	0.509	rs2731336	chr3:14091908	G/A	cg19554555	chr3:13937349	NA	-0.46	-5.98	-0.35	7.03e-9	Ovarian reserve;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10091738	chr6:26204643	HIST1H4E	-0.55	-6.35	-0.36	9.3e-10	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20986421	chr1:201798455	IPO9	0.58	6.43	0.37	5.99e-10	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12588470	chr4:89444909	PIGY	0.64	7.16	0.4	8.1e-12	Gut microbiome composition (summer);
CESC	cis	rs10870270	0.913	rs4880326	chr10:133745547	C/A	cg17892150	chr10:133769511	PPP2R2D	-0.86	-12.61	-0.61	6.93e-29	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs72781680	1.000	rs12617839	chr2:24166277	A/T	cg20701182	chr2:24300061	SF3B14	0.64	5.74	0.33	2.63e-8	Lymphocyte counts;
CESC	cis	rs2274273	0.967	rs2340931	chr14:55616937	T/G	cg04306507	chr14:55594613	LGALS3	0.28	5.66	0.33	3.85e-8	Protein biomarker;
CESC	cis	rs4648845	0.777	rs2477689	chr1:2395538	G/C	cg07700843	chr1:2391317	NA	-0.49	-9.0	-0.48	4.51e-17	Schizophrenia;
CESC	trans	rs72681920	0.881	rs12504365	chr4:100203037	C/T	cg22948791	chr15:71404101	CT62	-0.54	-6.14	-0.35	2.96e-9	Alcohol dependence;
CESC	cis	rs12926788	0.546	rs200531	chr16:24756172	G/A	cg06028605	chr16:24865363	SLC5A11	-0.54	-8.07	-0.44	2.39e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs172166	0.637	rs1071893	chr6:28167635	G/C	cg17221315	chr6:27791827	HIST1H4J	0.43	5.62	0.33	4.83e-8	Cardiac Troponin-T levels;
CESC	cis	rs6025261	0.761	rs6099359	chr20:55509896	G/T	cg04763273	chr20:55502381	NA	-0.3	-5.22	-0.31	3.7e-7	Verbal memory performance (delayed recall level);
CESC	cis	rs4460629	0.742	rs11264314	chr1:155078423	C/G	cg01019262	chr1:155095195	NA	-0.3	-5.1	-0.3	6.49e-7	Serum magnesium levels;
CESC	cis	rs67311347	0.956	rs4974029	chr3:40521318	C/G	cg09455208	chr3:40491958	NA	0.5	8.71	0.47	3.31e-16	Renal cell carcinoma;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg07421368	chr2:67624930	ETAA1	-0.43	-6.14	-0.35	2.93e-9	Gambling;
CESC	cis	rs2072499	0.966	rs1060604	chr1:156184268	T/C	cg24450063	chr1:156163899	SLC25A44	0.92	14.11	0.66	4.18e-34	Testicular germ cell tumor;
CESC	cis	rs6541297	0.775	rs4846910	chr1:230291441	C/A	cg05784532	chr1:230284198	GALNT2	0.51	5.64	0.33	4.37e-8	Coronary artery disease;
CESC	cis	rs7772486	0.840	rs11155451	chr6:146422524	A/G	cg05347473	chr6:146136440	FBXO30	0.5	6.57	0.37	2.61e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6964587	1.000	rs7785971	chr7:91736794	T/A	cg17063962	chr7:91808500	NA	0.54	7.37	0.41	2.16e-12	Breast cancer;
CESC	cis	rs12541635	0.677	rs11781234	chr8:107012342	G/T	cg10147462	chr8:107024639	NA	0.48	7.12	0.4	1.03e-11	Age of smoking initiation;
CESC	cis	rs4819052	0.851	rs4819046	chr21:46664955	C/T	cg11663144	chr21:46675770	NA	-0.63	-9.96	-0.52	4.72e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs875971	0.660	rs801192	chr7:66031952	C/G	cg26939375	chr7:64535504	NA	-0.64	-8.8	-0.48	1.77e-16	Aortic root size;
CESC	cis	rs9443645	0.869	rs4706747	chr6:79722639	A/G	cg05283184	chr6:79620031	NA	-0.43	-6.61	-0.38	2.06e-10	Intelligence (multi-trait analysis);
CESC	cis	rs7945705	0.747	rs1980429	chr11:9010474	C/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.4	-6.46	-0.37	5.08e-10	Hemoglobin concentration;
CESC	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.93	14.26	0.66	1.22e-34	Prudent dietary pattern;
CESC	cis	rs13191362	0.872	rs73017702	chr6:163257695	C/A	cg21926612	chr6:163149169	PACRG;PARK2	0.66	6.44	0.37	5.45e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs477895	1.000	rs66968227	chr11:64070930	T/C	cg04317338	chr11:64019027	PLCB3	0.69	5.58	0.32	5.98e-8	Mean platelet volume;
CESC	cis	rs72781680	0.898	rs56303870	chr2:24086944	G/A	cg20701182	chr2:24300061	SF3B14	0.62	5.66	0.33	3.87e-8	Lymphocyte counts;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg04498971	chr17:56084468	SFRS1	-0.47	-6.88	-0.39	4.32e-11	Gambling;
CESC	cis	rs4588572	0.601	rs4305631	chr5:77668698	G/T	cg11547950	chr5:77652471	NA	0.45	5.75	0.33	2.48e-8	Triglycerides;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg23260255	chr3:187871479	LPP	0.47	6.2	0.36	2.14e-9	Systemic lupus erythematosus;
CESC	cis	rs11958404	0.932	rs72816541	chr5:157414686	G/A	cg05962755	chr5:157440814	NA	0.58	6.53	0.37	3.31e-10	IgG glycosylation;
CESC	cis	rs12477438	0.798	rs10202452	chr2:99569409	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.72	-10.6	-0.55	4.22e-22	Chronic sinus infection;
CESC	cis	rs8180040	0.620	rs6414435	chr3:47121140	A/G	cg27129171	chr3:47204927	SETD2	0.66	9.71	0.51	2.81e-19	Colorectal cancer;
CESC	cis	rs9309711	0.666	rs6723101	chr2:3484443	T/C	cg15506890	chr2:3487001	NA	-0.48	-6.03	-0.35	5.51e-9	Neurofibrillary tangles;
CESC	cis	rs367943	0.644	rs348942	chr5:112824039	T/C	cg12552261	chr5:112820674	MCC	-0.64	-8.02	-0.44	3.49e-14	Type 2 diabetes;
CESC	trans	rs7307889	0.793	rs12314345	chr12:6008880	A/G	cg18407955	chr7:158110685	PTPRN2	0.72	6.68	0.38	1.41e-10	Obesity-related traits;
CESC	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg12419862	chr22:24373484	LOC391322	-0.97	-16.27	-0.71	9.59e-42	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs12477438	0.765	rs6722164	chr2:99561527	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.65	-8.75	-0.47	2.6e-16	Chronic sinus infection;
CESC	cis	rs8030485	0.536	rs12595749	chr15:79432359	A/G	cg17916960	chr15:79447300	NA	0.31	5.1	0.3	6.41e-7	Left ventricle wall thickness;
CESC	cis	rs2979489	0.591	rs62508371	chr8:30422060	C/T	cg26383811	chr8:30366931	RBPMS	-0.7	-8.45	-0.46	1.98e-15	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CESC	cis	rs7666738	0.830	rs4502686	chr4:98765117	T/C	cg03467027	chr4:99064603	C4orf37	0.44	5.4	0.32	1.46e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2243480	1.000	rs34193460	chr7:65393110	A/G	cg12463550	chr7:65579703	CRCP	0.72	5.53	0.32	7.65e-8	Diabetic kidney disease;
CESC	cis	rs7020830	0.789	rs17408112	chr9:37114065	A/G	cg14294708	chr9:37120828	ZCCHC7	1.28	25.68	0.84	7.54e-74	Schizophrenia;
CESC	cis	rs8177253	0.555	rs4481157	chr3:133464684	G/A	cg16262614	chr3:133464971	TF	0.29	5.45	0.32	1.14e-7	Iron status biomarkers;
CESC	cis	rs116095464	0.558	rs9687898	chr5:253952	A/G	cg10591111	chr5:226296	SDHA	-0.51	-6.15	-0.35	2.84e-9	Breast cancer;
CESC	cis	rs35160687	0.623	rs35408390	chr2:86471782	C/T	cg01119172	chr2:86362222	SNORD94;PTCD3	-0.39	-5.33	-0.31	2.14e-7	Night sleep phenotypes;
CESC	cis	rs3740713	1.000	rs75647856	chr11:18459806	T/C	cg23797887	chr11:18477753	LDHAL6A	-0.53	-5.11	-0.3	6.1e-7	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs4727963	0.846	rs10953969	chr7:122730629	A/G	cg03640110	chr7:122635026	TAS2R16	-0.37	-5.68	-0.33	3.52e-8	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
CESC	cis	rs875971	0.660	rs801190	chr7:66033033	C/T	cg14393609	chr7:65229607	NA	-0.45	-6.13	-0.35	3.17e-9	Aortic root size;
CESC	cis	rs74781061	0.932	rs7161903	chr15:74940270	A/G	cg20004910	chr15:75018852	CYP1A1	-0.4	-5.58	-0.32	6.05e-8	Endometriosis;
CESC	cis	rs7582720	1.000	rs72934740	chr2:203741362	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.35	0.41	2.53e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs6964587	1.000	rs2282971	chr7:91584356	A/G	cg17063962	chr7:91808500	NA	0.53	7.34	0.41	2.66e-12	Breast cancer;
CESC	cis	rs7116495	0.609	rs1541304	chr11:71714078	T/C	cg18441811	chr11:71824068	C11orf51	-0.81	-5.36	-0.31	1.85e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs6754311	0.678	rs309181	chr2:136614813	C/G	cg07169764	chr2:136633963	MCM6	-0.69	-8.56	-0.47	9.42e-16	Mosquito bite size;
CESC	trans	rs1814175	0.817	rs11040700	chr11:50023832	C/T	cg15704280	chr7:45808275	SEPT13	-1.05	-21.18	-0.79	6.15e-59	Height;
CESC	cis	rs10504073	0.647	rs11785310	chr8:50025035	G/A	cg00325661	chr8:49890786	NA	0.58	8.62	0.47	6.16e-16	Blood metabolite ratios;
CESC	cis	rs9914988	0.943	rs9913801	chr17:27132105	G/A	cg20469991	chr17:27169893	C17orf63	-0.48	-5.25	-0.31	3.18e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CESC	cis	rs10751667	0.666	rs7396509	chr11:956761	G/A	cg06064525	chr11:970664	AP2A2	-0.48	-9.52	-0.5	1.15e-18	Alzheimer's disease (late onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05462360	chr17:18218585	TOP3A;SMCR8	0.52	6.09	0.35	3.94e-9	Gut microbiome composition (summer);
CESC	cis	rs875971	1.000	rs6956179	chr7:65806659	C/T	cg11764359	chr7:65958608	NA	-0.94	-14.76	-0.67	2.09e-36	Aortic root size;
CESC	trans	rs7819412	0.521	rs11777887	chr8:11036799	C/G	cg06636001	chr8:8085503	FLJ10661	0.54	6.28	0.36	1.36e-9	Triglycerides;
CESC	cis	rs9814567	0.963	rs9844537	chr3:134238341	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.43	-5.82	-0.34	1.69e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs7474896	0.583	rs1735621	chr10:38167723	G/T	cg00409905	chr10:38381863	ZNF37A	0.46	5.1	0.3	6.59e-7	Obesity (extreme);
CESC	cis	rs1784581	0.588	rs9458428	chr6:162424579	A/G	cg17173639	chr6:162384350	PARK2	-0.57	-8.8	-0.48	1.86e-16	Itch intensity from mosquito bite;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg07052796	chr10:5708731	ASB13	-0.46	-6.38	-0.36	7.77e-10	Gambling;
CESC	cis	rs7412746	0.611	rs12085336	chr1:150775780	A/T	cg04414720	chr1:150670196	GOLPH3L	0.6	8.13	0.45	1.63e-14	Melanoma;
CESC	cis	rs6540559	0.605	rs3753518	chr1:209977964	G/C	cg10074409	chr1:209979377	IRF6	0.4	5.29	0.31	2.59e-7	Cleft lip with or without cleft palate;
CESC	cis	rs9787249	1.000	rs9787249	chr1:40212878	G/A	cg24920358	chr1:40204285	PPIE	0.42	6.39	0.37	7.54e-10	Blood protein levels;
CESC	cis	rs7769051	0.522	rs3736725	chr6:133095172	A/G	cg22852734	chr6:133119734	C6orf192	0.85	7.89	0.44	7.82e-14	Type 2 diabetes nephropathy;
CESC	cis	rs6912958	0.559	rs6921504	chr6:88058972	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.72	10.81	0.55	8.16e-23	Monocyte percentage of white cells;
CESC	cis	rs9916302	0.904	rs35285898	chr17:37555872	A/C	cg00129232	chr17:37814104	STARD3	0.56	7.35	0.41	2.4e-12	Glomerular filtration rate (creatinine);
CESC	trans	rs9467711	0.606	rs13203358	chr6:26590578	A/T	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.73	6.0	0.35	6.3e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs4268898	0.610	rs72791170	chr2:24449776	C/T	cg20701182	chr2:24300061	SF3B14	0.65	6.96	0.39	2.59e-11	Asthma;
CESC	trans	rs921968	0.541	rs576901	chr2:219424364	A/G	cg15547669	chr20:2781122	CPXM1	0.35	6.0	0.35	6.51e-9	Mean corpuscular hemoglobin concentration;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04789687	chr15:83481869	WHAMM	-0.44	-6.13	-0.35	3.22e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs9787249	0.957	rs7518431	chr1:40214944	C/T	cg02773041	chr1:40204384	PPIE	-0.52	-7.36	-0.41	2.28e-12	Blood protein levels;
CESC	cis	rs2742540	0.503	rs2653556	chr11:8906636	C/G	cg14711859	chr11:8959438	ASCL3	0.41	6.24	0.36	1.73e-9	Hematocrit;
CESC	cis	rs1475911	1.000	rs2839467	chr21:43513200	A/G	cg14562523	chr21:43528734	C21orf128;UMODL1	0.38	5.57	0.32	6.16e-8	IgG glycosylation;
CESC	cis	rs1371867	0.846	rs1660332	chr8:101309490	A/G	cg11906718	chr8:101322791	RNF19A	-0.45	-5.79	-0.33	2.04e-8	Atrioventricular conduction;
CESC	cis	rs3096299	1.000	rs3096299	chr16:89448663	G/A	cg02187348	chr16:89574699	SPG7	0.52	6.73	0.38	1.04e-10	Multiple myeloma (IgH translocation);
CESC	cis	rs12425791	0.500	rs34336285	chr12:721769	G/T	cg01201512	chr12:740338	NINJ2	-0.6	-5.8	-0.34	1.93e-8	Stroke;Paclitaxel disposition in epithelial ovarian cancer;
CESC	cis	rs2075371	1.000	rs1421484	chr7:133979795	T/C	cg20476274	chr7:133979776	SLC35B4	0.66	9.79	0.52	1.6e-19	Mean platelet volume;
CESC	cis	rs12497850	0.931	rs9311434	chr3:48884147	T/C	cg03060546	chr3:49711283	APEH	0.45	5.64	0.33	4.42e-8	Parkinson's disease;
CESC	cis	rs7811142	0.887	rs111972532	chr7:100069088	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.8	6.84	0.39	5.34e-11	Platelet count;
CESC	cis	rs514406	0.679	rs545719	chr1:53304922	T/C	cg27535305	chr1:53392650	SCP2	-0.3	-5.29	-0.31	2.6e-7	Monocyte count;
CESC	cis	rs1595825	0.891	rs112898725	chr2:198650006	C/T	cg00982548	chr2:198649783	BOLL	-0.47	-5.08	-0.3	7.12e-7	Ulcerative colitis;
CESC	cis	rs1862618	0.641	rs2591954	chr5:56245044	G/C	cg24531977	chr5:56204891	C5orf35	0.7	9.44	0.5	2.05e-18	Initial pursuit acceleration;
CESC	cis	rs9309473	0.583	rs11126397	chr2:73588733	C/T	cg20560298	chr2:73613845	ALMS1	-0.5	-6.92	-0.39	3.33e-11	Metabolite levels;
CESC	cis	rs9916302	0.861	rs632202	chr17:37453294	C/A	cg15445000	chr17:37608096	MED1	-0.4	-6.5	-0.37	3.91e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs4595586	0.525	rs12812749	chr12:39363254	C/T	cg26384229	chr12:38710491	ALG10B	0.53	7.23	0.41	5.29e-12	Morning vs. evening chronotype;
CESC	cis	rs9300255	0.639	rs1716171	chr12:123716376	C/T	cg00376283	chr12:123451042	ABCB9	0.72	8.89	0.48	9.37e-17	Neutrophil percentage of white cells;
CESC	cis	rs6456156	0.565	rs12525345	chr6:167478875	T/C	cg23791538	chr6:167370224	RNASET2	-0.5	-6.44	-0.37	5.46e-10	Primary biliary cholangitis;
CESC	cis	rs2832191	0.935	rs11910316	chr21:30519729	G/A	cg24692254	chr21:30365293	RNF160	-0.75	-11.23	-0.57	3.46e-24	Dental caries;
CESC	cis	rs9388451	0.839	rs11154331	chr6:126111429	A/T	cg05901451	chr6:126070800	HEY2	-0.61	-8.88	-0.48	1.06e-16	Brugada syndrome;
CESC	trans	rs7656342	0.808	rs10003216	chr4:9766749	A/G	cg01112643	chr6:157802216	ZDHHC14	-0.56	-6.34	-0.36	9.94e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs1799949	1.000	rs33918839	chr17:41329172	T/C	cg05368731	chr17:41323189	NBR1	0.79	10.98	0.56	2.21e-23	Menopause (age at onset);
CESC	cis	rs763121	0.853	rs6001173	chr22:39015302	A/G	cg21395723	chr22:39101663	GTPBP1	0.5	6.6	0.38	2.25e-10	Menopause (age at onset);
CESC	cis	rs9926296	0.568	rs886950	chr16:89836872	T/C	cg03388025	chr16:89894329	SPIRE2	0.42	8.13	0.45	1.65e-14	Vitiligo;
CESC	cis	rs7666738	0.830	rs35531558	chr4:98938217	A/G	cg03467027	chr4:99064603	C4orf37	0.48	5.91	0.34	1.03e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9300255	0.568	rs1790108	chr12:123636841	A/G	cg00376283	chr12:123451042	ABCB9	0.7	8.88	0.48	1.03e-16	Neutrophil percentage of white cells;
CESC	cis	rs12541335	0.639	rs13257108	chr8:22165043	T/C	cg02463440	chr8:22132932	PIWIL2	0.37	5.66	0.33	3.94e-8	Hypertriglyceridemia;
CESC	cis	rs5417	0.662	rs8067500	chr17:7172631	A/G	cg25256661	chr17:7137939	DVL2	0.73	9.21	0.49	9.96e-18	Diastolic blood pressure;
CESC	cis	rs4835473	0.932	rs7667092	chr4:144889757	C/T	cg25736465	chr4:144833511	NA	0.41	6.27	0.36	1.43e-9	Immature fraction of reticulocytes;
CESC	trans	rs7246760	1.000	rs7250487	chr19:9886358	T/C	cg02900749	chr2:68251473	NA	-0.73	-6.82	-0.39	6.17e-11	Pursuit maintenance gain;
CESC	cis	rs4148883	0.603	rs1893883	chr4:100124716	C/G	cg13256891	chr4:100009986	ADH5	0.45	6.02	0.35	5.91e-9	Alcohol dependence;
CESC	cis	rs9486715	0.867	rs4839687	chr6:96951732	C/A	cg18709589	chr6:96969512	KIAA0776	0.46	6.48	0.37	4.41e-10	Headache;
CESC	cis	rs60843830	0.928	rs2306060	chr2:230912	A/C	cg00108164	chr2:264199	ACP1;SH3YL1	0.78	9.97	0.52	4.5e-20	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs2991971	0.967	rs60608374	chr1:46008913	G/A	cg24296786	chr1:45957014	TESK2	0.63	8.47	0.46	1.74e-15	High light scatter reticulocyte count;
CESC	cis	rs10744422	1.000	rs3852536	chr12:123333824	C/T	cg22842854	chr12:123319900	HIP1R	-0.61	-5.03	-0.3	9e-7	Schizophrenia;
CESC	cis	rs7712401	0.601	rs246287	chr5:122245426	A/T	cg19412675	chr5:122181750	SNX24	0.4	5.03	0.3	8.89e-7	Mean platelet volume;
CESC	cis	rs769267	0.859	rs2916076	chr19:19545990	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.47	6.08	0.35	4.23e-9	Tonsillectomy;
CESC	cis	rs8092503	1.000	rs35413162	chr18:52498290	C/G	cg12377874	chr18:52495404	RAB27B	0.36	6.07	0.35	4.43e-9	Childhood body mass index;
CESC	cis	rs12142240	0.698	rs1053627	chr1:46827728	A/C	cg10495392	chr1:46806563	NSUN4	0.58	6.32	0.36	1.09e-9	Menopause (age at onset);
CESC	cis	rs7772486	0.875	rs56181683	chr6:146286620	A/G	cg05347473	chr6:146136440	FBXO30	-0.5	-6.64	-0.38	1.77e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1949733	1.000	rs868105	chr4:8501030	G/T	cg11789530	chr4:8429930	ACOX3	-0.78	-10.97	-0.56	2.51e-23	Response to antineoplastic agents;
CESC	cis	rs4862750	0.872	rs7664463	chr4:187876686	A/C	cg10295955	chr4:187884368	NA	-1.01	-18.92	-0.76	4.14e-51	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs7618501	0.699	rs6446187	chr3:49907111	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.47	6.59	0.38	2.35e-10	Intelligence (multi-trait analysis);
CESC	cis	rs9858542	1.000	rs9858542	chr3:49701983	A/G	cg07274523	chr3:49395745	GPX1	-0.65	-8.39	-0.46	2.94e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs9611565	0.918	rs4820438	chr22:41767135	C/T	cg03806693	chr22:41940476	POLR3H	-0.9	-10.33	-0.54	3.05e-21	Vitiligo;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18580865	chr12:93323267	EEA1	0.51	6.06	0.35	4.56e-9	Gut microbiome composition (summer);
CESC	cis	rs7927771	0.793	rs12803525	chr11:47413475	G/A	cg25783544	chr11:47291846	MADD	-0.45	-5.1	-0.3	6.57e-7	Subjective well-being;
CESC	cis	rs9733	0.596	rs6692960	chr1:150695965	G/A	cg18016565	chr1:150552671	MCL1	0.34	5.28	0.31	2.67e-7	Tonsillectomy;
CESC	cis	rs1448094	0.549	rs10863085	chr12:86236328	G/A	cg19622623	chr12:86230825	RASSF9	-0.43	-5.22	-0.31	3.68e-7	Major depressive disorder;
CESC	cis	rs1215050	1.000	rs1215050	chr4:98849826	A/G	cg05340658	chr4:99064831	C4orf37	-0.51	-6.1	-0.35	3.77e-9	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs7481584	0.564	rs7948848	chr11:2981896	G/A	cg08508325	chr11:3079039	CARS	0.33	5.44	0.32	1.24e-7	Calcium levels;
CESC	cis	rs7666738	0.830	rs7664051	chr4:98766970	C/G	cg03467027	chr4:99064603	C4orf37	0.42	5.22	0.31	3.62e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs62064224	0.560	rs12162135	chr17:30805795	A/C	cg09324608	chr17:30823087	MYO1D	0.45	7.4	0.41	1.76e-12	Schizophrenia;
CESC	cis	rs6461049	0.800	rs3800909	chr7:2159594	C/G	cg04267008	chr7:1944627	MAD1L1	-0.47	-5.58	-0.32	5.82e-8	Schizophrenia;
CESC	cis	rs7937682	1.000	rs2186839	chr11:111534442	T/G	cg09085632	chr11:111637200	PPP2R1B	-1.02	-16.31	-0.71	6.77e-42	Primary sclerosing cholangitis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00094269	chr1:17265567	CROCC	-0.57	-7.09	-0.4	1.18e-11	Gut microbiome composition (summer);
CESC	cis	rs7208859	0.524	rs28760584	chr17:29141017	G/A	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.79e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	trans	rs1814175	0.615	rs12417290	chr11:49876951	G/A	cg03929089	chr4:120376271	NA	-0.9	-14.51	-0.67	1.62e-35	Height;
CESC	cis	rs9287719	0.967	rs6748036	chr2:10717489	C/T	cg00105475	chr2:10696890	NA	0.39	5.76	0.33	2.34e-8	Prostate cancer;
CESC	cis	rs250677	0.522	rs4705302	chr5:148354962	G/C	cg18129178	chr5:148520854	ABLIM3	0.5	5.49	0.32	9.59e-8	Breast cancer;
CESC	cis	rs6582630	0.502	rs4385963	chr12:38295264	G/A	cg13010199	chr12:38710504	ALG10B	0.45	5.65	0.33	4.06e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs9929218	1.000	rs9936621	chr16:68798682	A/G	cg02972257	chr16:68554789	NA	0.43	5.22	0.31	3.65e-7	Colorectal cancer;
CESC	cis	rs12586317	0.586	rs74243591	chr14:35520917	C/T	cg16230307	chr14:35515116	FAM177A1	1.13	11.81	0.59	3.79e-26	Psoriasis;
CESC	cis	rs17384381	1.000	rs17384381	chr1:85897570	C/G	cg16011679	chr1:85725395	C1orf52	0.7	7.13	0.4	9.3e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6860806	0.695	rs6867282	chr5:131583120	G/C	cg04518342	chr5:131593106	PDLIM4	0.4	6.04	0.35	5.29e-9	Breast cancer;
CESC	cis	rs7666738	0.791	rs6851549	chr4:99029827	G/A	cg18180107	chr4:99064573	C4orf37	0.42	5.46	0.32	1.11e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg17317561	chr3:97663926	MINA	0.46	6.26	0.36	1.55e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs2304069	0.545	rs1864998	chr5:149389465	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.48	6.51	0.37	3.82e-10	HIV-1 control;
CESC	cis	rs10129255	0.500	rs10131875	chr14:107201036	T/C	cg07958169	chr14:107095056	NA	-0.53	-8.18	-0.45	1.23e-14	Kawasaki disease;
CESC	cis	rs67311347	1.000	rs2276870	chr3:40499182	C/T	cg24209194	chr3:40518798	ZNF619	-0.53	-6.76	-0.38	8.61e-11	Renal cell carcinoma;
CESC	cis	rs7833790	0.929	rs28464834	chr8:82797356	A/T	cg17211192	chr8:82754475	SNX16	0.71	8.74	0.47	2.64e-16	Diastolic blood pressure;
CESC	cis	rs6724607	0.875	rs9630991	chr2:191432139	G/A	cg10560079	chr2:191398806	TMEM194B	0.51	7.04	0.4	1.61e-11	Pulse pressure;
CESC	cis	rs7794273	0.963	rs2588637	chr7:18854186	C/T	cg13420273	chr7:18810212	HDAC9	0.35	5.2	0.3	3.91e-7	Night sleep phenotypes;
CESC	cis	rs1005277	0.579	rs2474568	chr10:38383147	A/T	cg25517755	chr10:38738941	LOC399744	-0.48	-6.34	-0.36	9.71e-10	Extrinsic epigenetic age acceleration;
CESC	cis	rs6089584	0.819	rs1467593	chr20:60601432	T/G	cg13770153	chr20:60521292	NA	0.53	6.71	0.38	1.15e-10	Body mass index;
CESC	cis	rs1707322	0.686	rs2991977	chr1:46053683	G/A	cg05343316	chr1:45956843	TESK2	-0.55	-6.78	-0.38	7.74e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs734999	0.588	rs6701238	chr1:2520500	G/A	cg18854424	chr1:2615690	NA	0.29	5.58	0.32	5.79e-8	Ulcerative colitis;
CESC	trans	rs9325144	0.600	rs10785615	chr12:38733627	G/C	cg23762105	chr12:34175262	ALG10	-0.47	-6.35	-0.36	9.35e-10	Morning vs. evening chronotype;
CESC	cis	rs28374715	0.662	rs691906	chr15:41474636	T/A	cg18705301	chr15:41695430	NDUFAF1	0.74	9.83	0.52	1.25e-19	Ulcerative colitis;
CESC	cis	rs12464559	0.649	rs4605370	chr2:152628288	C/T	cg01189475	chr2:152685088	ARL5A	-0.61	-5.45	-0.32	1.17e-7	Response to cognitive-behavioural therapy in anxiety disorder;
CESC	cis	rs10504229	0.906	rs67389108	chr8:58193718	G/A	cg02725872	chr8:58115012	NA	-0.34	-5.09	-0.3	6.69e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs35110281	0.627	rs1595167	chr21:44965874	T/G	cg01579765	chr21:45077557	HSF2BP	-0.51	-8.35	-0.46	3.84e-15	Mean corpuscular volume;
CESC	trans	rs2272205	0.711	rs62226769	chr2:227951253	A/G	cg04768315	chr2:1898518	MYT1L	0.74	6.11	0.35	3.56e-9	Immune reponse to smallpox (secreted IFN-alpha);
CESC	cis	rs9399135	0.967	rs9389253	chr6:135329755	T/C	cg24558204	chr6:135376177	HBS1L	0.53	7.28	0.41	3.85e-12	Red blood cell count;
CESC	cis	rs2204008	0.744	rs11180504	chr12:38236313	C/T	cg13010199	chr12:38710504	ALG10B	0.49	6.1	0.35	3.78e-9	Bladder cancer;
CESC	cis	rs2836974	0.568	rs4816620	chr21:40613786	A/G	cg11890956	chr21:40555474	PSMG1	-0.94	-15.48	-0.69	6.2e-39	Cognitive function;
CESC	cis	rs4563143	0.675	rs112383987	chr19:29261081	C/T	cg12667521	chr19:29218732	NA	0.48	6.4	0.37	6.97e-10	Methadone dose in opioid dependence;
CESC	cis	rs73001065	0.591	rs56273306	chr19:19621004	T/C	cg03709012	chr19:19516395	GATAD2A	0.91	6.99	0.39	2.27e-11	LDL cholesterol;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02294991	chr11:47927148	NA	-0.55	-6.74	-0.38	1.01e-10	Gut microbiome composition (summer);
CESC	cis	rs8114671	0.562	rs6087641	chr20:33467717	T/C	cg07148914	chr20:33460835	GGT7	0.47	6.3	0.36	1.24e-9	Height;
CESC	cis	rs1670533	1.000	rs10084889	chr4:1053815	G/A	cg04106633	chr4:1044584	NA	0.41	5.2	0.3	3.94e-7	Recombination rate (females);
CESC	cis	rs1153858	1.000	rs11070453	chr15:45645154	C/G	cg14582100	chr15:45693742	SPATA5L1	0.42	5.95	0.34	8.45e-9	Homoarginine levels;
CESC	cis	rs75477785	1.000	rs12062600	chr1:210051454	G/A	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.79	5.15	0.3	5.08e-7	Cleft lip with or without cleft palate;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00775781	chr1:27976168	NA	-0.61	-7.31	-0.41	3.19e-12	Gut microbiome composition (summer);
CESC	cis	rs7707921	0.505	rs12516434	chr5:81428072	T/A	cg15871215	chr5:81402204	ATG10	0.46	6.43	0.37	6.07e-10	Breast cancer;
CESC	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.89	13.3	0.63	2.89e-31	Prudent dietary pattern;
CESC	cis	rs6433857	0.505	rs16867320	chr2:181362312	A/G	cg23363182	chr2:181467187	NA	0.42	5.92	0.34	9.92e-9	Body mass index;
CESC	cis	rs6502050	0.835	rs10163485	chr17:80110750	C/T	cg23985595	chr17:80112537	CCDC57	-0.42	-6.58	-0.37	2.43e-10	Life satisfaction;
CESC	cis	rs8014204	0.720	rs34752362	chr14:75232306	G/A	cg08847533	chr14:75593920	NEK9	0.46	5.85	0.34	1.45e-8	Caffeine consumption;
CESC	cis	rs2439831	0.867	rs45585139	chr15:43700427	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.83	7.8	0.43	1.41e-13	Lung cancer in ever smokers;
CESC	cis	rs3733585	0.773	rs13107466	chr4:10019390	G/A	cg02734326	chr4:10020555	SLC2A9	0.52	7.43	0.42	1.51e-12	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs2832191	0.720	rs4643617	chr21:30485278	T/C	cg08807101	chr21:30365312	RNF160	-0.77	-11.23	-0.57	3.52e-24	Dental caries;
CESC	cis	rs7927771	0.965	rs34958982	chr11:47547046	T/C	cg20307385	chr11:47447363	PSMC3	-0.52	-6.29	-0.36	1.32e-9	Subjective well-being;
CESC	cis	rs4727027	0.933	rs10277119	chr7:148849942	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.41	5.14	0.3	5.42e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs7223966	1.000	rs2854218	chr17:61942940	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.47	-5.37	-0.31	1.7e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs1110701	0.525	rs11764792	chr7:50496841	C/T	cg18232548	chr7:50535776	DDC	-0.44	-6.05	-0.35	4.82e-9	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs57221529	0.766	rs17563576	chr5:560476	A/G	cg09021430	chr5:549028	NA	-0.41	-5.03	-0.3	9.05e-7	Lung disease severity in cystic fibrosis;
CESC	cis	rs2549003	1.000	rs2548997	chr5:131835395	C/T	cg02551604	chr5:131831745	NA	0.39	5.36	0.31	1.84e-7	Asthma (sex interaction);
CESC	cis	rs7274811	0.744	rs6120316	chr20:32177079	T/C	cg21523528	chr20:32077966	CBFA2T2	0.62	7.16	0.4	7.82e-12	Height;
CESC	cis	rs782590	0.537	rs12619903	chr2:55884106	T/A	cg18811423	chr2:55921094	PNPT1	-0.6	-7.91	-0.44	6.78e-14	Metabolic syndrome;
CESC	cis	rs6089584	0.526	rs6089316	chr20:60627552	C/T	cg24733560	chr20:60626293	TAF4	0.48	7.12	0.4	1e-11	Body mass index;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01123518	chr16:10837605	NUBP1	0.64	7.09	0.4	1.2e-11	Gut microbiome composition (summer);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03239638	chr21:37529510	NA	-0.52	-6.5	-0.37	4.05e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs67311347	1.000	rs6599102	chr3:40468406	G/A	cg24209194	chr3:40518798	ZNF619	0.47	6.12	0.35	3.37e-9	Renal cell carcinoma;
CESC	cis	rs34779708	0.931	rs4934723	chr10:35381763	A/G	cg04310649	chr10:35416472	CREM	-0.51	-6.06	-0.35	4.62e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs7259376	0.840	rs3862494	chr19:22519522	G/A	cg02657401	chr19:22469223	NA	-0.26	-5.39	-0.31	1.59e-7	Menopause (age at onset);
CESC	cis	rs1882538	0.512	rs13241734	chr7:133122742	C/G	cg10665199	chr7:133106180	EXOC4	0.58	7.83	0.43	1.2e-13	Intelligence (multi-trait analysis);
CESC	cis	rs35110281	0.666	rs2236665	chr21:45108987	C/A	cg21573476	chr21:45109991	RRP1B	-0.56	-8.12	-0.45	1.77e-14	Mean corpuscular volume;
CESC	cis	rs2228479	0.557	rs34420680	chr16:89809171	C/T	cg04013166	chr16:89971882	TCF25	0.76	6.46	0.37	4.94e-10	Skin colour saturation;
CESC	cis	rs7666738	0.830	rs2865979	chr4:99027137	T/C	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.58e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7605827	0.930	rs6715487	chr2:15540579	T/C	cg19274914	chr2:15703543	NA	0.36	6.4	0.37	7.05e-10	Educational attainment (years of education);
CESC	cis	rs2880765	0.835	rs7169429	chr15:86036648	C/T	cg10818794	chr15:86012489	AKAP13	-0.34	-5.24	-0.31	3.23e-7	Coronary artery disease;
CESC	cis	rs7772486	0.720	rs991507	chr6:146023609	G/A	cg05347473	chr6:146136440	FBXO30	-0.57	-7.25	-0.41	4.46e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7618915	0.571	rs2289249	chr3:52597664	G/A	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	5.66	0.33	4e-8	Bipolar disorder;
CESC	cis	rs3126085	0.935	rs10749669	chr1:152177289	A/C	cg26876637	chr1:152193138	HRNR	-0.46	-5.2	-0.3	3.98e-7	Atopic dermatitis;
CESC	cis	rs7666738	0.830	rs4699577	chr4:98846513	G/A	cg17366294	chr4:99064904	C4orf37	0.51	6.98	0.39	2.43e-11	Colonoscopy-negative controls vs population controls;
CESC	cis	rs798554	0.567	rs1182192	chr7:2869274	G/A	cg13628971	chr7:2884303	GNA12	0.43	5.77	0.33	2.17e-8	Height;
CESC	cis	rs4073582	0.595	rs9326370	chr11:65992008	A/G	cg14036092	chr11:66035641	RAB1B	0.53	7.48	0.42	1.09e-12	Gout;
CESC	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg07092213	chr7:1199455	ZFAND2A	-0.51	-5.99	-0.35	6.74e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs9911578	0.900	rs717828	chr17:56535932	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.41	5.41	0.32	1.38e-7	Intelligence (multi-trait analysis);
CESC	cis	rs1059312	0.545	rs7312683	chr12:129280105	T/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.42	-5.21	-0.3	3.86e-7	Systemic lupus erythematosus;
CESC	cis	rs2425143	1.000	rs11907811	chr20:34428078	A/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.63	5.59	0.32	5.54e-8	Blood protein levels;
CESC	trans	rs7615952	0.736	rs11921945	chr3:125643719	A/G	cg07211511	chr3:129823064	LOC729375	-1.09	-15.44	-0.69	8.42e-39	Blood pressure (smoking interaction);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg12477297	chr1:150336859	RPRD2	-0.47	-6.92	-0.39	3.33e-11	Gambling;
CESC	cis	rs6088590	0.523	rs6059913	chr20:33143288	G/A	cg24642439	chr20:33292090	TP53INP2	0.61	8.15	0.45	1.5e-14	Coronary artery disease;
CESC	cis	rs2836974	0.899	rs35774464	chr21:40580169	G/A	cg17971929	chr21:40555470	PSMG1	1.0	13.76	0.65	7.01e-33	Cognitive function;
CESC	cis	rs8067545	0.611	rs12936443	chr17:20033446	T/G	cg13482628	chr17:19912719	NA	0.39	5.12	0.3	5.84e-7	Schizophrenia;
CESC	trans	rs7656342	0.808	rs10003216	chr4:9766749	A/G	cg15038082	chr3:184016876	PSMD2	-0.51	-6.22	-0.36	1.89e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs9649213	0.593	rs6970801	chr7:97925240	T/C	cg00277769	chr7:97922759	BAIAP2L1	-0.34	-5.62	-0.33	4.89e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs10504229	0.679	rs111843870	chr8:58126798	A/G	cg24829409	chr8:58192753	C8orf71	-0.59	-7.24	-0.41	4.79e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs11166629	1.000	rs4909331	chr8:135644540	T/C	cg27224718	chr8:135614730	ZFAT	0.5	6.37	0.36	8.2e-10	Smoking quantity;
CESC	cis	rs2243480	0.901	rs778687	chr7:65835819	G/A	cg13147721	chr7:65941812	NA	-0.95	-8.95	-0.48	6.27e-17	Diabetic kidney disease;
CESC	cis	rs12900413	0.687	rs7176981	chr15:90315757	A/G	cg24249390	chr15:90295951	MESP1	-0.41	-5.73	-0.33	2.78e-8	Coronary artery aneurysm in Kawasaki disease;
CESC	cis	rs2456568	0.835	rs1518578	chr11:93656854	G/T	cg26875233	chr11:93583750	C11orf90	-0.32	-5.6	-0.33	5.46e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
CESC	cis	rs10461617	0.617	rs79742142	chr5:56104377	A/G	cg24531977	chr5:56204891	C5orf35	-0.88	-11.1	-0.56	9.44e-24	Type 2 diabetes;
CESC	cis	rs4862750	0.832	rs6836426	chr4:187897837	T/G	cg07414643	chr4:187882934	NA	0.52	7.22	0.41	5.6e-12	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg09115837	chr10:79541592	NA	0.56	7.49	0.42	1.05e-12	Fibrinogen levels;
CESC	cis	rs1691799	0.867	rs1168332	chr12:66761548	C/T	cg16791601	chr12:66731901	HELB	-0.76	-13.16	-0.63	8.86e-31	White blood cell count (basophil);
CESC	cis	rs721399	0.553	rs13282367	chr8:18244986	T/G	cg18736775	chr8:18248649	NAT2	-0.56	-5.7	-0.33	3.17e-8	Blood metabolite levels;
CESC	cis	rs3015497	0.603	rs3015451	chr14:51071091	C/A	cg26011998	chr14:51135199	SAV1	-0.46	-5.22	-0.31	3.6e-7	Mean platelet volume;
CESC	cis	rs854765	0.604	rs12948749	chr17:17949802	G/A	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.46	-5.95	-0.34	8.3e-9	Total body bone mineral density;
CESC	cis	rs6089584	0.546	rs6061980	chr20:60618877	G/A	cg23463467	chr20:60627584	TAF4	0.34	5.08	0.3	7.18e-7	Body mass index;
CESC	cis	rs35306767	0.903	rs12264711	chr10:929525	T/C	cg25019033	chr10:957182	NA	-0.56	-6.07	-0.35	4.48e-9	Eosinophil percentage of granulocytes;
CESC	cis	rs853679	0.517	rs9380056	chr6:28104476	C/T	cg19592336	chr6:28129416	ZNF389	0.61	8.24	0.45	8.13e-15	Depression;
CESC	cis	rs61931739	0.500	rs3922568	chr12:34560107	A/C	cg06521331	chr12:34319734	NA	-0.36	-5.04	-0.3	8.47e-7	Morning vs. evening chronotype;
CESC	cis	rs2282802	0.685	rs2053055	chr5:139646776	C/T	cg26211634	chr5:139558579	C5orf32	0.52	7.59	0.42	5.57e-13	Intelligence (multi-trait analysis);
CESC	cis	rs5753618	0.509	rs2413033	chr22:31574213	A/G	cg13145458	chr22:31556086	RNF185	0.45	5.05	0.3	8.06e-7	Colorectal cancer;
CESC	cis	rs372883	0.613	rs1153274	chr21:30660026	T/C	cg08807101	chr21:30365312	RNF160	-0.46	-5.52	-0.32	8.03e-8	Pancreatic cancer;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg27465384	chr16:1435426	NA	0.46	6.28	0.36	1.39e-9	Fibrinogen levels;
CESC	cis	rs7666738	0.830	rs7662596	chr4:99019962	G/T	cg03676636	chr4:99064102	C4orf37	0.33	5.15	0.3	5.05e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10791097	0.702	rs10894267	chr11:130714861	C/T	cg14779329	chr11:130786720	SNX19	-0.34	-5.07	-0.3	7.56e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs12497850	0.897	rs7432989	chr3:49105136	A/G	cg07636037	chr3:49044803	WDR6	1.06	19.21	0.76	3.89e-52	Parkinson's disease;
CESC	cis	rs34779708	0.966	rs17591781	chr10:35498538	G/A	cg04310649	chr10:35416472	CREM	-0.52	-6.33	-0.36	1.06e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs72781680	0.898	rs10490751	chr2:24001356	A/G	cg20701182	chr2:24300061	SF3B14	0.63	5.65	0.33	4.21e-8	Lymphocyte counts;
CESC	cis	rs1799949	1.000	rs11657835	chr17:41291953	C/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.64	8.64	0.47	5.23e-16	Menopause (age at onset);
CESC	cis	rs7100689	0.784	rs10749562	chr10:82108253	G/T	cg00277334	chr10:82204260	NA	-0.6	-7.66	-0.43	3.42e-13	Post bronchodilator FEV1;
CESC	cis	rs2235642	0.787	rs2235646	chr16:1601287	A/G	cg03771183	chr16:1608904	IFT140	0.41	5.94	0.34	8.79e-9	Coronary artery disease;
CESC	cis	rs7666738	0.800	rs13106995	chr4:99028790	A/T	cg18180107	chr4:99064573	C4orf37	0.42	5.43	0.32	1.29e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs12497850	0.931	rs13064784	chr3:49135961	C/G	cg07636037	chr3:49044803	WDR6	1.06	19.29	0.76	2.09e-52	Parkinson's disease;
CESC	cis	rs4819052	0.959	rs9976074	chr21:46655638	G/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.58	6.77	0.38	8.26e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs7666738	0.800	rs10008654	chr4:98820498	C/A	cg05340658	chr4:99064831	C4orf37	0.73	10.49	0.54	9.13e-22	Colonoscopy-negative controls vs population controls;
CESC	cis	rs911555	0.723	rs12894652	chr14:103926024	A/G	cg24130564	chr14:104152367	KLC1	0.49	6.22	0.36	1.95e-9	Intelligence (multi-trait analysis);
CESC	cis	rs916888	0.821	rs199504	chr17:44861003	C/T	cg17911788	chr17:44343683	NA	0.55	7.29	0.41	3.68e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs9403521	1.000	rs117303301	chr6:143999003	C/T	cg21026257	chr6:143998961	PHACTR2	0.46	5.03	0.3	8.98e-7	Obesity-related traits;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg11738299	chr1:112282125	C1orf183	-0.43	-6.11	-0.35	3.6e-9	Gambling;
CESC	cis	rs4141404	0.818	rs6518737	chr22:31582662	A/G	cg13145458	chr22:31556086	RNF185	0.49	6.14	0.35	2.99e-9	Paclitaxel-induced neuropathy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23206777	chr17:66031448	KPNA2	-0.51	-6.09	-0.35	4.05e-9	Gut microbiome composition (summer);
CESC	cis	rs13108904	0.967	rs4974582	chr4:1279687	C/T	cg22903657	chr4:1355424	KIAA1530	-0.38	-5.18	-0.3	4.5e-7	Obesity-related traits;
CESC	cis	rs7666738	0.830	rs7657982	chr4:99044015	G/A	cg17366294	chr4:99064904	C4orf37	0.6	8.56	0.47	9.09e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10463316	0.817	rs2112419	chr5:150797804	T/C	cg03212797	chr5:150827313	SLC36A1	-0.51	-6.68	-0.38	1.43e-10	Metabolite levels (Pyroglutamine);
CESC	cis	rs9322193	0.962	rs7818	chr6:150132092	A/G	cg04369109	chr6:150039330	LATS1	-0.37	-5.19	-0.3	4.24e-7	Lung cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18517677	chr9:131799243	FAM73B	0.6	6.85	0.39	5.11e-11	Gut microbiome composition (summer);
CESC	cis	rs9314323	0.767	rs13271042	chr8:26190212	T/G	cg11498726	chr8:26250323	BNIP3L	-0.49	-6.78	-0.38	7.75e-11	Red cell distribution width;
CESC	cis	rs11098499	0.644	rs34835603	chr4:120553428	C/T	cg24375607	chr4:120327624	NA	0.41	5.18	0.3	4.4e-7	Corneal astigmatism;
CESC	cis	rs1218582	0.741	rs11264283	chr1:154869552	A/G	cg09359103	chr1:154839909	KCNN3	-0.65	-12.19	-0.6	1.91e-27	Prostate cancer;
CESC	cis	rs300703	0.542	rs300697	chr2:184496	C/T	cg21211680	chr2:198530	NA	-0.85	-9.2	-0.49	1.08e-17	Blood protein levels;
CESC	cis	rs367943	0.626	rs7718480	chr5:112704486	G/T	cg12552261	chr5:112820674	MCC	0.42	5.53	0.32	7.73e-8	Type 2 diabetes;
CESC	cis	rs8028182	0.636	rs28432989	chr15:75768297	T/C	cg20655648	chr15:75932815	IMP3	0.47	5.89	0.34	1.19e-8	Sudden cardiac arrest;
CESC	cis	rs910316	1.000	rs4903279	chr14:75546583	C/T	cg08847533	chr14:75593920	NEK9	0.99	18.86	0.76	6.94e-51	Height;
CESC	cis	rs4925386	0.840	rs8124907	chr20:60913127	A/G	cg24112000	chr20:60950667	NA	-0.47	-5.89	-0.34	1.15e-8	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs3820068	0.581	rs68052904	chr1:15916714	T/C	cg17385448	chr1:15911702	AGMAT	0.45	7.19	0.4	6.53e-12	Systolic blood pressure;
CESC	cis	rs2439831	0.850	rs16963953	chr15:44081719	A/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.67	7.78	0.43	1.66e-13	Lung cancer in ever smokers;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03749393	chr13:31191824	USPL1	-0.55	-6.14	-0.35	2.96e-9	Gut microbiome composition (summer);
CESC	cis	rs2625529	0.586	rs7170456	chr15:72469946	G/C	cg16672083	chr15:72433130	SENP8	0.5	7.49	0.42	1.02e-12	Red blood cell count;
CESC	trans	rs916888	0.773	rs199533	chr17:44828931	G/A	cg07870213	chr5:140052090	DND1	0.63	6.87	0.39	4.59e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04254320	chr11:16628010	NA	-0.54	-6.4	-0.37	6.85e-10	Gut microbiome composition (summer);
CESC	cis	rs2645694	0.626	rs2703116	chr4:77824289	C/T	cg10057126	chr4:77819792	ANKRD56	-0.57	-8.24	-0.45	7.96e-15	Emphysema distribution in smoking;
CESC	cis	rs7647973	0.580	rs4955432	chr3:49266772	C/T	cg06212747	chr3:49208901	KLHDC8B	0.7	10.4	0.54	1.76e-21	Menarche (age at onset);
CESC	cis	rs7666738	0.546	rs13148080	chr4:98680947	A/G	cg05340658	chr4:99064831	C4orf37	0.55	6.6	0.38	2.24e-10	Colonoscopy-negative controls vs population controls;
CESC	cis	rs796364	0.789	rs176008	chr2:200814720	A/T	cg23649088	chr2:200775458	C2orf69	0.54	5.09	0.3	6.71e-7	Schizophrenia;
CESC	cis	rs6500395	1.000	rs9922734	chr16:48603192	A/G	cg04672837	chr16:48644449	N4BP1	-0.49	-6.25	-0.36	1.6e-9	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs4803468	1.000	rs284658	chr19:41929988	G/A	cg09537434	chr19:41945824	ATP5SL	-1.04	-18.76	-0.76	1.48e-50	Height;
CESC	cis	rs12497850	0.931	rs7636057	chr3:48992582	C/T	cg03060546	chr3:49711283	APEH	0.5	6.16	0.35	2.75e-9	Parkinson's disease;
CESC	cis	rs7666738	0.791	rs1527516	chr4:98967937	A/C	cg05340658	chr4:99064831	C4orf37	0.79	12.12	0.6	3.52e-27	Colonoscopy-negative controls vs population controls;
CESC	cis	rs62344088	0.590	rs6889904	chr5:177264	A/C	cg22857025	chr5:266934	NA	-1.11	-8.88	-0.48	1.01e-16	Asthma (childhood onset);
CESC	cis	rs854765	0.547	rs2955385	chr17:17939247	C/T	cg09796270	chr17:17721594	SREBF1	0.38	5.19	0.3	4.11e-7	Total body bone mineral density;
CESC	cis	rs35306767	0.761	rs1871621	chr10:1049596	C/T	cg25019033	chr10:957182	NA	-0.56	-5.57	-0.32	6.34e-8	Eosinophil percentage of granulocytes;
CESC	cis	rs7216064	1.000	rs2046323	chr17:65849927	T/G	cg12091567	chr17:66097778	LOC651250	-0.85	-8.69	-0.47	3.85e-16	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs4253772	0.530	rs11704350	chr22:46671507	C/T	cg18190219	chr22:46762943	CELSR1	-0.59	-5.7	-0.33	3.26e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs9910055	0.571	rs28897216	chr17:42240824	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.49	7.21	0.41	5.7e-12	Total body bone mineral density;
CESC	cis	rs8180040	0.932	rs1531875	chr3:47452786	G/A	cg27129171	chr3:47204927	SETD2	0.64	9.67	0.51	3.73e-19	Colorectal cancer;
CESC	cis	rs11608355	0.597	rs9943699	chr12:109840876	G/C	cg19025524	chr12:109796872	NA	-0.52	-7.25	-0.41	4.65e-12	Neuroticism;
CESC	cis	rs12477438	0.798	rs10198293	chr2:99602929	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-10.57	-0.54	5.22e-22	Chronic sinus infection;
CESC	trans	rs7866350	0.604	rs1935389	chr9:100994470	A/G	cg15012766	chr1:41832369	NA	0.42	6.17	0.35	2.56e-9	Post-traumatic stress disorder;
CESC	cis	rs875971	0.862	rs2088653	chr7:65808608	G/A	cg18252515	chr7:66147081	NA	0.45	5.88	0.34	1.22e-8	Aortic root size;
CESC	cis	rs72634258	0.519	rs35267144	chr1:7934258	G/A	cg00042356	chr1:8021962	PARK7	0.54	5.58	0.32	5.79e-8	Inflammatory bowel disease;
CESC	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.51	6.97	0.39	2.51e-11	Lymphocyte counts;
CESC	cis	rs506597	0.920	rs2432929	chr7:100299028	C/T	cg10426581	chr7:100472382	SRRT	-0.67	-5.21	-0.3	3.81e-7	Pursuit maintenance gain in psychotic disorders;
CESC	cis	rs10504229	0.683	rs58438731	chr8:58134790	C/T	cg02725872	chr8:58115012	NA	-0.45	-7.05	-0.4	1.52e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs1509123	0.609	rs114532955	chr17:6728700	G/A	cg12642237	chr17:6703447	TEKT1	-0.64	-5.26	-0.31	2.94e-7	Blood metabolite levels;
CESC	cis	rs6502050	0.731	rs9892653	chr17:80100191	G/T	cg11859384	chr17:80120422	CCDC57	-0.38	-5.11	-0.3	6.21e-7	Life satisfaction;
CESC	trans	rs10953454	1.000	rs10243336	chr7:104494560	C/A	cg04245439	chr3:142607978	PCOLCE2	-0.76	-6.14	-0.35	2.96e-9	Obesity;
CESC	cis	rs1847202	0.826	rs11922892	chr3:72952186	T/G	cg25664220	chr3:72788482	NA	-0.39	-5.67	-0.33	3.68e-8	Motion sickness;
CESC	cis	rs4974559	1.000	rs10006789	chr4:1330333	T/C	cg02980000	chr4:1222292	CTBP1	0.64	7.35	0.41	2.43e-12	Systolic blood pressure;
CESC	cis	rs7647973	0.769	rs11130181	chr3:49109919	G/A	cg07636037	chr3:49044803	WDR6	0.89	13.08	0.63	1.67e-30	Menarche (age at onset);
CESC	cis	rs7666738	0.830	rs13121766	chr4:98935766	A/C	cg17366294	chr4:99064904	C4orf37	0.59	8.32	0.46	4.7e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs782590	0.643	rs13032503	chr2:55739093	C/T	cg18811423	chr2:55921094	PNPT1	-0.57	-7.77	-0.43	1.7e-13	Metabolic syndrome;
CESC	cis	rs2708240	1.000	rs2247149	chr7:147581161	T/C	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.34	-5.55	-0.32	7.07e-8	QT interval (drug interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05827346	chr20:48732560	UBE2V1;TMEM189-UBE2V1	0.58	6.5	0.37	3.9e-10	Gut microbiome composition (summer);
CESC	cis	rs853679	0.517	rs12174753	chr6:28042465	C/G	cg20151795	chr6:28129481	ZNF389	0.44	5.59	0.33	5.5e-8	Depression;
CESC	cis	rs2836974	0.583	rs2735307	chr21:40713358	C/T	cg11890956	chr21:40555474	PSMG1	0.69	9.5	0.5	1.31e-18	Cognitive function;
CESC	trans	rs916888	0.821	rs199504	chr17:44861003	C/T	cg01341218	chr17:43662625	NA	-0.87	-10.56	-0.54	5.35e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs6952808	0.862	rs4721167	chr7:1933224	C/T	cg04267008	chr7:1944627	MAD1L1	-0.71	-9.18	-0.49	1.24e-17	Bipolar disorder and schizophrenia;
CESC	cis	rs1448094	0.511	rs61930581	chr12:86157241	G/A	cg02569458	chr12:86230093	RASSF9	0.51	7.69	0.43	2.85e-13	Major depressive disorder;
CESC	cis	rs2243480	1.000	rs313809	chr7:65499983	G/A	cg25894440	chr7:65020034	NA	-0.68	-5.84	-0.34	1.51e-8	Diabetic kidney disease;
CESC	cis	rs1336900	0.637	rs35967040	chr1:150555588	A/C	cg04414720	chr1:150670196	GOLPH3L	-0.48	-6.07	-0.35	4.43e-9	Blood protein levels;
CESC	cis	rs9486719	0.843	rs2499789	chr6:96844510	T/C	cg06623918	chr6:96969491	KIAA0776	0.78	7.39	0.41	1.89e-12	Migraine;Coronary artery disease;
CESC	cis	rs2315504	0.626	rs2469823	chr17:39006842	A/G	cg05063374	chr17:38953512	KRT28	0.38	5.27	0.31	2.84e-7	Height;
CESC	cis	rs6460942	1.000	rs73053527	chr7:12313008	C/A	cg02935154	chr7:12443704	VWDE	-0.59	-5.84	-0.34	1.5e-8	Coronary artery disease;
CESC	cis	rs2066819	1.000	rs2695782	chr12:56722830	C/T	cg26316697	chr12:56727976	PAN2	-0.67	-5.87	-0.34	1.32e-8	Psoriasis vulgaris;
CESC	cis	rs2463822	0.925	rs1881535	chr11:62121623	C/T	cg06239285	chr11:62104954	ASRGL1	0.86	8.63	0.47	5.79e-16	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs9768139	0.708	rs921616	chr7:158117960	A/G	cg24154853	chr7:158122151	PTPRN2	0.43	6.78	0.38	7.65e-11	Calcium levels;
CESC	cis	rs3026101	0.671	rs2407	chr17:5289028	G/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.38	5.16	0.3	4.87e-7	Body mass index;
CESC	trans	rs1908814	0.541	rs7824267	chr8:11794279	G/T	cg15556689	chr8:8085844	FLJ10661	0.51	6.32	0.36	1.1e-9	Neuroticism;
CESC	cis	rs2076222	1.000	rs2076349	chr1:209800230	C/T	cg00257659	chr1:209800214	LAMB3	-0.87	-7.95	-0.44	5.49e-14	Fentanyl consumption in laparoscopic-assisted colectomy (first 24 hours);
CESC	cis	rs2236918	1.000	rs2995544	chr1:242020495	C/T	cg17736920	chr1:242011382	EXO1	0.72	9.08	0.49	2.55e-17	Menopause (age at onset);
CESC	cis	rs7772486	0.790	rs9497425	chr6:146234197	G/A	cg05347473	chr6:146136440	FBXO30	-0.53	-6.92	-0.39	3.46e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2455799	0.613	rs1393969	chr3:15730257	G/A	cg16303742	chr3:15540471	COLQ	-0.38	-5.8	-0.34	1.87e-8	Mean platelet volume;
CESC	cis	rs3741151	0.773	rs73544711	chr11:73164870	T/A	cg17517138	chr11:73019481	ARHGEF17	1.0	7.41	0.41	1.74e-12	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs769267	0.864	rs7245983	chr19:19657632	A/C	cg03709012	chr19:19516395	GATAD2A	1.0	15.2	0.68	5.96e-38	Tonsillectomy;
CESC	cis	rs9910055	0.573	rs228768	chr17:42191893	A/C	cg08499158	chr17:42289980	UBTF	-0.45	-5.61	-0.33	5.19e-8	Total body bone mineral density;
CESC	trans	rs7618501	1.000	rs6775384	chr3:49853073	G/A	cg21659725	chr3:3221576	CRBN	0.81	12.97	0.62	4.11e-30	Intelligence (multi-trait analysis);
CESC	cis	rs10129255	0.500	rs9324092	chr14:107139823	A/G	cg23076370	chr14:107095027	NA	0.69	10.54	0.54	6.39e-22	Kawasaki disease;
CESC	cis	rs12819124	0.502	rs10875718	chr12:48411102	G/T	cg04545296	chr12:48745243	ZNF641	0.34	5.78	0.33	2.15e-8	Glycated hemoglobin levels;
CESC	cis	rs7267979	1.000	rs2424710	chr20:25283886	C/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.86	16.82	0.72	1.06e-43	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs2404602	0.692	rs4886503	chr15:77108874	C/T	cg22467129	chr15:76604101	ETFA	0.36	5.39	0.31	1.56e-7	Blood metabolite levels;
CESC	cis	rs2180341	0.695	rs6569487	chr6:127726196	C/T	cg24812749	chr6:127587940	RNF146	-0.74	-10.77	-0.55	1.13e-22	Breast cancer;
CESC	cis	rs4253772	0.678	rs1053332	chr22:46640179	A/G	cg09491104	chr22:46646882	C22orf40	-0.57	-8.75	-0.47	2.46e-16	LDL cholesterol;Cholesterol, total;
CESC	trans	rs2814021	0.653	rs2787697	chr10:63296825	T/A	cg08188886	chr14:105633697	JAG2	-0.42	-6.1	-0.35	3.73e-9	Obesity-related traits;
CESC	cis	rs290268	0.817	rs291006	chr9:93540244	A/C	cg02608019	chr9:93564028	SYK	0.57	8.38	0.46	3.05e-15	Platelet count;
CESC	cis	rs6460942	0.591	rs62448727	chr7:12332362	G/C	cg02935154	chr7:12443704	VWDE	-0.53	-5.5	-0.32	9.01e-8	Coronary artery disease;
CESC	cis	rs7811142	0.943	rs11769886	chr7:99998607	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.99	9.32	0.5	4.59e-18	Platelet count;
CESC	cis	rs9902453	0.904	rs9900974	chr17:28364456	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.67	-8.69	-0.47	3.84e-16	Coffee consumption (cups per day);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg02237855	chr2:74329332	TET3	0.5	6.68	0.38	1.42e-10	Fibrinogen levels;
CESC	cis	rs12545109	0.800	rs1996106	chr8:57412963	A/G	cg09654669	chr8:57350985	NA	-0.46	-6.28	-0.36	1.4e-9	Obesity-related traits;
CESC	cis	rs9457247	0.534	rs9347170	chr6:167405187	C/T	cg25258033	chr6:167368657	RNASET2	-0.35	-5.12	-0.3	6.01e-7	Crohn's disease;
CESC	cis	rs853679	0.546	rs34295134	chr6:27828151	T/A	cg26587870	chr6:27730563	NA	-0.58	-5.08	-0.3	7.2e-7	Depression;
CESC	cis	rs9486719	1.000	rs13208422	chr6:96892119	C/T	cg06623918	chr6:96969491	KIAA0776	-0.81	-8.29	-0.45	5.61e-15	Migraine;Coronary artery disease;
CESC	cis	rs6582630	0.555	rs2197308	chr12:38281261	A/G	cg26384229	chr12:38710491	ALG10B	-0.43	-5.6	-0.33	5.46e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs67311347	1.000	rs11707278	chr3:40487075	A/T	cg09455208	chr3:40491958	NA	0.49	8.1	0.45	2.06e-14	Renal cell carcinoma;
CESC	trans	rs4904167	0.841	rs12587485	chr14:84685194	A/G	cg06870609	chr15:89787223	FANCI	0.46	6.01	0.35	6.03e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs7945705	0.902	rs10743093	chr11:8869129	A/G	cg12365402	chr11:9010492	NRIP3	0.36	5.5	0.32	8.77e-8	Hemoglobin concentration;
CESC	cis	rs9733	0.596	rs72702570	chr1:150688196	C/T	cg17724175	chr1:150552817	MCL1	0.45	7.31	0.41	3.23e-12	Tonsillectomy;
CESC	cis	rs77741769	0.571	rs3809313	chr12:121329967	T/C	cg02419362	chr12:121203948	SPPL3	0.34	5.57	0.32	6.38e-8	Mean corpuscular volume;
CESC	cis	rs9419702	0.639	rs9419624	chr10:133534822	G/A	cg04492858	chr10:133558786	NA	0.39	5.52	0.32	7.87e-8	Survival in rectal cancer;
CESC	cis	rs863345	0.604	rs2023632	chr1:158459034	T/C	cg12129480	chr1:158549410	OR10X1	-0.36	-7.15	-0.4	8.67e-12	Pneumococcal bacteremia;
CESC	cis	rs12220238	1.000	rs10824113	chr10:75969018	G/C	cg19889307	chr10:75911429	ADK;AP3M1	0.6	5.44	0.32	1.24e-7	Soluble interleukin-2 receptor subunit alpha;
CESC	cis	rs2836974	0.836	rs8129355	chr21:40579869	A/G	cg27266027	chr21:40555129	PSMG1	0.45	5.29	0.31	2.5e-7	Cognitive function;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26976744	chr8:120845108	TAF2	0.58	6.13	0.35	3.13e-9	Gut microbiome composition (summer);
CESC	trans	rs916888	0.738	rs199515	chr17:44856641	C/G	cg22433210	chr17:43662623	NA	-0.88	-10.59	-0.55	4.45e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs16854884	0.632	rs59287916	chr3:143638337	G/A	cg06585982	chr3:143692056	C3orf58	0.53	6.95	0.39	2.87e-11	Economic and political preferences (feminism/equality);
CESC	trans	rs1728785	1.000	rs7202306	chr16:68587684	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.64	7.76	0.43	1.89e-13	Ulcerative colitis;
CESC	cis	rs854765	0.547	rs9913277	chr17:17919749	G/T	cg09796270	chr17:17721594	SREBF1	0.38	5.3	0.31	2.43e-7	Total body bone mineral density;
CESC	cis	rs4718428	0.705	rs10267335	chr7:66403220	G/T	cg12165864	chr7:66369176	NA	-0.67	-7.73	-0.43	2.18e-13	Corneal structure;
CESC	cis	rs1153858	1.000	rs59889118	chr15:45618730	G/A	cg14582100	chr15:45693742	SPATA5L1	0.41	5.71	0.33	3.06e-8	Homoarginine levels;
CESC	cis	rs7267979	0.844	rs1555330	chr20:25232097	A/C	cg08601574	chr20:25228251	PYGB	0.42	5.81	0.34	1.82e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7527798	0.592	rs6702222	chr1:207825627	C/T	cg21110645	chr1:207815933	NA	-0.33	-5.88	-0.34	1.21e-8	Erythrocyte sedimentation rate;
CESC	cis	rs4889855	0.556	rs11150863	chr17:78532321	A/G	cg16591659	chr17:78472290	NA	-0.33	-5.47	-0.32	1.05e-7	Fractional excretion of uric acid;
CESC	cis	rs853679	0.546	rs200995	chr6:27813694	C/T	cg26587870	chr6:27730563	NA	0.57	5.35	0.31	1.87e-7	Depression;
CESC	cis	rs9611565	0.592	rs4822046	chr22:41987543	G/A	cg17376030	chr22:41985996	PMM1	0.79	8.34	0.46	4.03e-15	Vitiligo;
CESC	cis	rs7336332	0.598	rs77055070	chr13:28010516	C/G	cg22138327	chr13:27999177	GTF3A	0.62	5.82	0.34	1.71e-8	Weight;
CESC	cis	rs9322193	0.923	rs11155670	chr6:149966128	C/G	cg13206674	chr6:150067644	NUP43	0.43	6.3	0.36	1.27e-9	Lung cancer;
CESC	cis	rs36051895	0.632	rs7850484	chr9:5147817	C/T	cg02405213	chr9:5042618	JAK2	-0.45	-5.44	-0.32	1.23e-7	Pediatric autoimmune diseases;
CESC	cis	rs950776	0.518	rs12907169	chr15:78825498	G/C	cg06917634	chr15:78832804	PSMA4	0.8	12.12	0.6	3.34e-27	Sudden cardiac arrest;
CESC	cis	rs2932538	0.922	rs9429694	chr1:113158289	G/A	cg22162597	chr1:113214053	CAPZA1	0.59	7.44	0.42	1.39e-12	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CESC	cis	rs3105593	1.000	rs3131590	chr15:50840955	G/T	cg08437265	chr15:50716283	USP8	0.43	5.66	0.33	4.02e-8	QT interval;
CESC	cis	rs1348850	0.558	rs4337505	chr2:178529714	A/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.54	6.71	0.38	1.2e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs7615952	0.609	rs13088451	chr3:125553499	G/C	cg05084668	chr3:125655381	ALG1L	-0.46	-5.3	-0.31	2.42e-7	Blood pressure (smoking interaction);
CESC	cis	rs748404	0.660	rs509306	chr15:43715171	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.57	7.57	0.42	6.3e-13	Lung cancer;
CESC	cis	rs7666738	0.830	rs7664340	chr4:99037820	C/T	cg03676636	chr4:99064102	C4orf37	0.33	5.08	0.3	7.22e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs8016982	0.698	rs12590764	chr14:81704417	G/A	cg01989461	chr14:81687754	GTF2A1	0.68	10.36	0.54	2.42e-21	Schizophrenia;
CESC	trans	rs35740288	0.822	rs17574774	chr15:86233370	C/T	cg11485152	chr3:3171664	TRNT1	0.46	6.16	0.35	2.74e-9	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
CESC	cis	rs10504229	0.593	rs11781042	chr8:57993056	A/T	cg24829409	chr8:58192753	C8orf71	-0.49	-5.88	-0.34	1.21e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs977987	0.736	rs4888392	chr16:75412262	T/C	cg03315344	chr16:75512273	CHST6	0.4	5.74	0.33	2.65e-8	Dupuytren's disease;
CESC	cis	rs35306767	0.715	rs12772979	chr10:1034412	C/T	cg20503657	chr10:835505	NA	0.7	6.12	0.35	3.35e-9	Eosinophil percentage of granulocytes;
CESC	cis	rs78487399	0.519	rs11124929	chr2:43582103	A/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.55	-5.08	-0.3	7.16e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
CESC	cis	rs3820928	0.874	rs10183633	chr2:227887828	A/G	cg05526886	chr2:227700861	RHBDD1	-0.43	-5.49	-0.32	9.36e-8	Pulmonary function;
CESC	cis	rs2204008	0.606	rs1581358	chr12:38391582	G/T	cg26384229	chr12:38710491	ALG10B	0.72	10.14	0.53	1.29e-20	Bladder cancer;
CESC	cis	rs9549260	0.683	rs4941988	chr13:41196006	T/G	cg21288729	chr13:41239152	FOXO1	0.62	7.9	0.44	7.34e-14	Red blood cell count;
CESC	cis	rs1371867	0.846	rs1616833	chr8:101271821	C/T	cg11906718	chr8:101322791	RNF19A	-0.42	-5.38	-0.31	1.67e-7	Atrioventricular conduction;
CESC	cis	rs7714584	1.000	rs7734928	chr5:150256613	G/A	cg22134413	chr5:150180641	NA	0.51	5.92	0.34	9.88e-9	Crohn's disease;
CESC	cis	rs763121	0.853	rs4821812	chr22:39075235	G/C	cg06544989	chr22:39130855	UNC84B	0.52	9.08	0.49	2.57e-17	Menopause (age at onset);
CESC	cis	rs9921222	0.632	rs11649268	chr16:398643	A/C	cg12437481	chr16:420112	MRPL28	-0.51	-6.71	-0.38	1.2e-10	Bone mineral density (spine);Bone mineral density;
CESC	cis	rs8072100	0.875	rs7208530	chr17:45544107	C/T	cg08085267	chr17:45401833	C17orf57	-0.56	-7.43	-0.42	1.51e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs1153858	1.000	rs3809472	chr15:45694318	G/T	cg14582100	chr15:45693742	SPATA5L1	0.42	5.88	0.34	1.22e-8	Homoarginine levels;
CESC	cis	rs708547	0.647	rs4864609	chr4:57878141	T/A	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.42	-5.58	-0.32	6.06e-8	Response to bleomycin (chromatid breaks);
CESC	cis	rs7666738	0.962	rs11932892	chr4:99072967	C/T	cg05340658	chr4:99064831	C4orf37	0.65	8.07	0.44	2.45e-14	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1215050	0.765	rs1588018	chr4:98756324	G/C	cg05340658	chr4:99064831	C4orf37	0.5	6.45	0.37	5.14e-10	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs60871478	0.579	rs56109762	chr7:925967	G/A	cg27478167	chr7:817139	HEATR2	0.57	5.38	0.31	1.62e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs6121246	0.909	rs2376992	chr20:30263418	T/C	cg13852791	chr20:30311386	BCL2L1	0.77	8.18	0.45	1.17e-14	Mean corpuscular hemoglobin;
CESC	cis	rs208520	0.690	rs4618506	chr6:66756889	A/C	cg07460842	chr6:66804631	NA	-0.89	-11.71	-0.58	8.53e-26	Exhaled nitric oxide output;
CESC	cis	rs11098499	0.913	rs35271032	chr4:120156659	C/T	cg24375607	chr4:120327624	NA	0.43	5.15	0.3	5.05e-7	Corneal astigmatism;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08578505	chr19:45582924	GEMIN7	-0.54	-6.26	-0.36	1.5e-9	Gut microbiome composition (summer);
CESC	cis	rs796364	0.901	rs13030683	chr2:201061535	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.59	5.87	0.34	1.31e-8	Schizophrenia;
CESC	cis	rs9814567	1.000	rs9864346	chr3:134312352	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.42	-5.71	-0.33	2.97e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs7666738	0.830	rs10012003	chr4:99064881	A/G	cg03467027	chr4:99064603	C4orf37	0.48	5.95	0.34	8.67e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7084402	0.967	rs1649019	chr10:60288111	T/C	cg07615347	chr10:60278583	BICC1	0.6	9.41	0.5	2.54e-18	Refractive error;
CESC	cis	rs9790314	0.846	rs1478568	chr3:161014276	C/T	cg03342759	chr3:160939853	NMD3	-0.45	-6.15	-0.35	2.89e-9	Morning vs. evening chronotype;
CESC	cis	rs6460942	0.505	rs73055515	chr7:12328804	A/G	cg06484146	chr7:12443880	VWDE	-0.62	-6.38	-0.36	7.88e-10	Coronary artery disease;
CESC	cis	rs854765	0.583	rs9635697	chr17:17870394	T/A	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.55	7.06	0.4	1.45e-11	Total body bone mineral density;
CESC	cis	rs1728785	1.000	rs12918861	chr16:68566508	G/A	cg02972257	chr16:68554789	NA	-0.55	-6.37	-0.36	8.21e-10	Ulcerative colitis;
CESC	trans	rs7819412	0.715	rs2409727	chr8:11043236	C/T	cg15556689	chr8:8085844	FLJ10661	-0.54	-6.54	-0.37	3.16e-10	Triglycerides;
CESC	cis	rs57244997	0.725	rs73028490	chr6:162421657	T/C	cg17173639	chr6:162384350	PARK2	-0.53	-5.66	-0.33	3.91e-8	Mosquito bite size;
CESC	cis	rs9300255	0.596	rs10732573	chr12:123743883	G/C	cg05973401	chr12:123451056	ABCB9	0.44	5.37	0.31	1.76e-7	Neutrophil percentage of white cells;
CESC	cis	rs10754283	0.934	rs10754284	chr1:90113702	A/C	cg21401794	chr1:90099060	LRRC8C	0.69	9.34	0.5	4.06e-18	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs34779708	0.658	rs4934715	chr10:35364992	G/T	cg04310649	chr10:35416472	CREM	-0.54	-6.47	-0.37	4.63e-10	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs56775891	0.959	rs7238071	chr18:77579812	C/T	cg13263691	chr18:77568018	NA	-0.47	-6.95	-0.39	2.92e-11	Schizophrenia;
CESC	cis	rs6952808	0.895	rs12669518	chr7:1921429	G/C	cg00106254	chr7:1943704	MAD1L1	-0.46	-5.7	-0.33	3.24e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs7618915	0.571	rs6778844	chr3:52596398	C/T	cg18404041	chr3:52824283	ITIH1	0.42	6.96	0.39	2.71e-11	Bipolar disorder;
CESC	cis	rs3767633	0.858	rs4300199	chr1:161852057	A/G	cg09175582	chr1:161736000	ATF6	0.86	6.95	0.39	2.83e-11	IgG glycosylation;
CESC	cis	rs4563143	0.514	rs73029076	chr19:29292032	G/T	cg12756686	chr19:29218302	NA	0.54	6.3	0.36	1.22e-9	Methadone dose in opioid dependence;
CESC	cis	rs2243480	1.000	rs6958289	chr7:65657111	T/G	cg18252515	chr7:66147081	NA	1.36	13.62	0.64	2.24e-32	Diabetic kidney disease;
CESC	cis	rs13082711	0.554	rs66854845	chr3:27387008	C/T	cg02860705	chr3:27208620	NA	0.77	8.66	0.47	4.61e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CESC	cis	rs17345786	0.861	rs11707689	chr3:101086475	A/G	cg12386194	chr3:101231763	SENP7	0.57	6.05	0.35	4.88e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs870825	0.616	rs7682677	chr4:185640717	C/G	cg04058563	chr4:185651563	MLF1IP	0.64	7.1	0.4	1.15e-11	Blood protein levels;
CESC	cis	rs1799949	1.000	rs12952790	chr17:41299607	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.45	6.31	0.36	1.17e-9	Menopause (age at onset);
CESC	cis	rs4665809	0.941	rs6735145	chr2:26270302	T/C	cg27170947	chr2:26402098	FAM59B	-0.61	-7.15	-0.4	8.53e-12	Gut microbiome composition (summer);
CESC	cis	rs9894429	0.646	rs7405937	chr17:79597811	G/A	cg21984481	chr17:79567631	NPLOC4	-0.34	-5.2	-0.3	4.08e-7	Eye color traits;
CESC	cis	rs1568889	1.000	rs66702115	chr11:28181703	T/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.78	10.81	0.55	8.6e-23	Bipolar disorder;
CESC	cis	rs35306767	0.953	rs12259801	chr10:959306	C/G	cg25019033	chr10:957182	NA	-0.65	-7.87	-0.44	8.8e-14	Eosinophil percentage of granulocytes;
CESC	cis	rs2235649	0.798	rs4100646	chr16:1850446	C/T	cg03715980	chr16:1756201	MAPK8IP3	0.43	5.5	0.32	8.95e-8	Blood metabolite levels;
CESC	cis	rs7336332	0.800	rs9805452	chr13:28047908	C/T	cg22138327	chr13:27999177	GTF3A	0.56	6.37	0.36	8.14e-10	Weight;
CESC	cis	rs7586673	0.930	rs7591506	chr2:161960925	T/G	cg21518248	chr2:162101506	NA	0.47	6.37	0.36	8.38e-10	Intelligence (multi-trait analysis);
CESC	cis	rs9322193	0.923	rs1080670	chr6:149941297	C/G	cg07701084	chr6:150067640	NUP43	0.46	6.45	0.37	5.26e-10	Lung cancer;
CESC	cis	rs7818688	0.674	rs74632106	chr8:95978032	A/G	cg16049864	chr8:95962084	TP53INP1	0.57	5.73	0.33	2.79e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs116095464	0.558	rs13354585	chr5:242263	G/C	cg22857025	chr5:266934	NA	-1.27	-18.21	-0.75	1.27e-48	Breast cancer;
CESC	cis	rs651907	0.535	rs11919389	chr3:101424458	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.45	5.9	0.34	1.1e-8	Colorectal cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14001360	chr2:28113654	BRE;LOC100302650;RBKS	0.62	7.19	0.4	6.71e-12	Gut microbiome composition (summer);
CESC	trans	rs4824093	0.610	rs60036544	chr22:50264019	C/T	cg09872104	chr7:134855509	C7orf49	-0.97	-6.92	-0.39	3.45e-11	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs7116495	0.881	rs7128974	chr11:71677032	C/G	cg10381502	chr11:71823885	C11orf51	0.67	5.48	0.32	9.83e-8	Severe influenza A (H1N1) infection;
CESC	cis	rs7044106	0.762	rs966397	chr9:123453312	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.81	12.82	0.62	1.3e-29	Hip circumference adjusted for BMI;
CESC	trans	rs7618501	1.000	rs6775384	chr3:49853073	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.56	7.96	0.44	4.91e-14	Intelligence (multi-trait analysis);
CESC	cis	rs854765	0.583	rs4553680	chr17:17857722	A/G	cg09796270	chr17:17721594	SREBF1	0.48	6.53	0.37	3.37e-10	Total body bone mineral density;
CESC	cis	rs2115536	1.000	rs11072871	chr15:80197931	T/C	cg11839771	chr15:80205821	ST20	-0.41	-5.89	-0.34	1.19e-8	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CESC	cis	rs6570726	0.791	rs10872577	chr6:145900560	G/T	cg05347473	chr6:146136440	FBXO30	0.59	7.78	0.43	1.59e-13	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7771547	0.573	rs9470274	chr6:36397229	G/A	cg04289385	chr6:36355825	ETV7	0.38	5.57	0.32	6.41e-8	Platelet distribution width;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg19729279	chr5:133861951	PHF15	-0.44	-6.18	-0.35	2.36e-9	Gambling;
CESC	cis	rs1801251	0.711	rs2592117	chr2:233735693	C/T	cg25237894	chr2:233734115	C2orf82	-0.5	-8.76	-0.47	2.34e-16	Coronary artery disease;
CESC	cis	rs1799949	0.896	rs8176098	chr17:41268206	A/C	cg23758822	chr17:41437982	NA	1.02	15.58	0.69	2.64e-39	Menopause (age at onset);
CESC	cis	rs9303401	0.614	rs12950028	chr17:56510140	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.96	12.09	0.6	4.46e-27	Cognitive test performance;
CESC	cis	rs870825	0.616	rs28444118	chr4:185621692	T/C	cg04058563	chr4:185651563	MLF1IP	0.64	7.05	0.4	1.59e-11	Blood protein levels;
CESC	cis	rs644799	1.000	rs481630	chr11:95582447	G/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.69	8.57	0.47	8.62e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs9549367	0.664	rs9549689	chr13:113848387	G/A	cg00898013	chr13:113819073	PROZ	-0.55	-7.46	-0.42	1.24e-12	Platelet distribution width;
CESC	trans	rs4942242	1.000	rs4942242	chr13:44217064	A/G	cg19169023	chr15:41853346	TYRO3	0.43	6.1	0.35	3.64e-9	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs13385	0.769	rs7707814	chr5:139583728	C/G	cg26211634	chr5:139558579	C5orf32	0.46	5.11	0.3	6.05e-7	Atrial fibrillation;
CESC	cis	rs829880	1.000	rs829880	chr12:98845331	G/T	cg25150519	chr12:98850993	NA	0.8	11.58	0.58	2.29e-25	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6952808	0.789	rs35729895	chr7:1885069	C/T	cg10360139	chr7:1886902	MAD1L1	-0.4	-5.05	-0.3	8.09e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs6952808	0.531	rs73039217	chr7:2178731	G/A	cg04267008	chr7:1944627	MAD1L1	-0.57	-6.77	-0.38	8.2e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs4555082	1.000	rs7146643	chr14:105757392	A/G	cg13114125	chr14:105738426	BRF1	-0.69	-9.02	-0.48	3.84e-17	Mean platelet volume;Platelet distribution width;
CESC	cis	rs4654899	0.931	rs3125161	chr1:21126346	A/G	cg05370193	chr1:21551575	ECE1	-0.38	-5.64	-0.33	4.32e-8	Superior frontal gyrus grey matter volume;
CESC	cis	rs6912958	0.712	rs9444526	chr6:88326402	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.31	-5.08	-0.3	7.04e-7	Monocyte percentage of white cells;
CESC	cis	rs7666738	0.830	rs12233741	chr4:98950296	C/T	cg03467027	chr4:99064603	C4orf37	0.45	5.67	0.33	3.69e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2354432	0.556	rs2353977	chr1:146839637	G/T	cg25205988	chr1:146714368	CHD1L	1.01	8.86	0.48	1.18e-16	Mitochondrial DNA levels;
CESC	cis	rs62344088	0.590	rs62346174	chr5:296308	C/A	cg22496380	chr5:211416	CCDC127	-0.89	-5.35	-0.31	1.9e-7	Asthma (childhood onset);
CESC	cis	rs8180040	0.800	rs11920354	chr3:47262246	C/A	cg27129171	chr3:47204927	SETD2	-0.67	-9.65	-0.51	4.46e-19	Colorectal cancer;
CESC	cis	rs6964587	0.900	rs6465352	chr7:91775117	A/G	cg17063962	chr7:91808500	NA	0.59	8.22	0.45	8.94e-15	Breast cancer;
CESC	trans	rs1941687	0.524	rs6507062	chr18:31374197	G/C	cg27147174	chr7:100797783	AP1S1	-0.49	-6.75	-0.38	9.04e-11	Subjective well-being (multi-trait analysis);Subjective well-being;
CESC	cis	rs853679	0.517	rs6922063	chr6:28094366	G/A	cg08968635	chr6:28129556	ZNF389	0.42	5.73	0.33	2.7e-8	Depression;
CESC	cis	rs3741151	1.000	rs76570090	chr11:73066321	A/T	cg17517138	chr11:73019481	ARHGEF17	1.05	7.11	0.4	1.09e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs6762	0.719	rs28655651	chr11:837121	G/C	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.69	-9.18	-0.49	1.23e-17	Mean platelet volume;
CESC	cis	rs113835537	0.935	rs117131621	chr11:66422334	C/T	cg24851651	chr11:66362959	CCS	0.63	5.68	0.33	3.48e-8	Airway imaging phenotypes;
CESC	cis	rs1005277	0.579	rs2504140	chr10:38387579	T/G	cg00409905	chr10:38381863	ZNF37A	-0.47	-6.3	-0.36	1.23e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs2425143	1.000	rs4504072	chr20:34448773	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.78	-7.05	-0.4	1.57e-11	Blood protein levels;
CESC	cis	rs6500602	0.727	rs4786516	chr16:4578641	C/T	cg08645402	chr16:4508243	NA	0.51	8.37	0.46	3.41e-15	Schizophrenia;
CESC	cis	rs7100689	0.784	rs1972370	chr10:82127180	A/G	cg00277334	chr10:82204260	NA	-0.59	-7.35	-0.41	2.39e-12	Post bronchodilator FEV1;
CESC	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg23708337	chr7:1209742	NA	0.53	5.18	0.3	4.34e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs202629	1	rs202629	chr22:41849975	C/T	cg06481639	chr22:41940642	POLR3H	0.53	5.8	0.34	1.86e-8	Cannabis dependence symptom count;
CESC	cis	rs4891159	0.790	rs17059379	chr18:74160316	A/T	cg24786174	chr18:74118243	ZNF516	0.7	10.4	0.54	1.82e-21	Longevity;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05790002	chr16:82033681	SDR42E1	-0.57	-6.45	-0.37	5.34e-10	Gut microbiome composition (summer);
CESC	cis	rs597539	0.654	rs619727	chr11:68627535	A/G	cg04772025	chr11:68637568	NA	0.55	6.39	0.37	7.48e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	trans	rs9379850	0.527	rs9393704	chr6:26358775	T/C	cg06606381	chr12:133084897	FBRSL1	-0.76	-6.87	-0.39	4.66e-11	Intelligence (multi-trait analysis);
CESC	cis	rs3204270	0.530	rs57707013	chr17:79635281	C/T	cg26965718	chr17:79658957	HGS	-0.64	-5.12	-0.3	5.99e-7	Dental caries;
CESC	cis	rs317689	0.513	rs317678	chr12:69692166	C/G	cg22834771	chr12:69754056	YEATS4	-0.42	-5.18	-0.3	4.42e-7	Response to diuretic therapy;
CESC	cis	rs2120019	0.608	rs4886414	chr15:75308650	C/T	cg17294928	chr15:75287854	SCAMP5	0.9	14.01	0.65	9.17e-34	Blood trace element (Zn levels);
CESC	cis	rs6714710	0.603	rs10432626	chr2:98561153	C/A	cg26665480	chr2:98280029	ACTR1B	0.56	7.9	0.44	7.59e-14	Posterior cortical atrophy and Alzheimer's disease;
CESC	cis	rs7666738	0.830	rs7682991	chr4:98982595	C/A	cg03467027	chr4:99064603	C4orf37	0.44	5.54	0.32	7.12e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2721195	0.654	rs4610795	chr8:145881333	C/T	cg11211951	chr8:145729740	GPT	-0.32	-5.5	-0.32	9.06e-8	Age at first birth;
CESC	cis	rs11098499	0.754	rs28643450	chr4:120245242	G/A	cg09307838	chr4:120376055	NA	0.78	10.55	0.54	5.92e-22	Corneal astigmatism;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03576787	chr11:32112632	RCN1	0.53	6.21	0.36	2.01e-9	Gut microbiome composition (summer);
CESC	cis	rs7165102	1.000	rs6494528	chr15:65865632	T/G	cg11441148	chr15:65824328	PTPLAD1	0.31	5.27	0.31	2.8e-7	Mean corpuscular hemoglobin;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17676327	chr2:121010539	RALB	0.55	6.33	0.36	1.04e-9	Gut microbiome composition (summer);
CESC	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.46	6.11	0.35	3.49e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs6963495	0.872	rs73190193	chr7:105164852	A/G	cg13798780	chr7:105162888	PUS7	0.78	8.06	0.44	2.68e-14	Bipolar disorder (body mass index interaction);
CESC	cis	rs533581	0.866	rs475796	chr16:88970776	C/G	cg16701003	chr16:89028210	CBFA2T3	0.49	7.18	0.4	7.14e-12	Social autistic-like traits;
CESC	cis	rs796364	0.806	rs34381014	chr2:200916403	C/T	cg23649088	chr2:200775458	C2orf69	-0.55	-5.05	-0.3	8.29e-7	Schizophrenia;
CESC	cis	rs9457247	0.846	rs2757052	chr6:167380174	T/C	cg25258033	chr6:167368657	RNASET2	-0.42	-6.25	-0.36	1.63e-9	Crohn's disease;
CESC	cis	rs875971	0.767	rs61348003	chr7:66005934	C/T	cg19163074	chr7:65112434	INTS4L2	-0.43	-5.34	-0.31	2e-7	Aortic root size;
CESC	cis	rs3733585	0.725	rs10939636	chr4:9972640	T/G	cg00071950	chr4:10020882	SLC2A9	-0.71	-11.36	-0.57	1.22e-24	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs6456156	0.586	rs6456149	chr6:167463902	T/C	cg23791538	chr6:167370224	RNASET2	-0.49	-6.29	-0.36	1.3e-9	Primary biliary cholangitis;
CESC	cis	rs6951245	0.882	rs11764817	chr7:1064610	T/C	cg18402987	chr7:1209562	NA	0.61	6.42	0.37	6.29e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs9303280	0.901	rs869402	chr17:38068043	C/T	cg20243544	chr17:37824526	PNMT	0.47	6.53	0.37	3.41e-10	Self-reported allergy;
CESC	cis	rs9640161	0.789	rs1464751	chr7:150021282	C/T	cg13722127	chr7:150037890	RARRES2	0.34	5.17	0.3	4.56e-7	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs3008870	0.755	rs2815349	chr1:67472280	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.62	8.04	0.44	3.01e-14	Lymphocyte percentage of white cells;
CESC	cis	rs6952808	0.691	rs2398709	chr7:2112548	C/T	cg02951883	chr7:2050386	MAD1L1	-0.46	-6.04	-0.35	5.28e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs11098499	0.954	rs2389803	chr4:120393511	A/G	cg24375607	chr4:120327624	NA	-0.45	-5.65	-0.33	4.15e-8	Corneal astigmatism;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08672023	chr6:35423591	FANCE	-0.63	-7.32	-0.41	2.89e-12	Gut microbiome composition (summer);
CESC	trans	rs11722228	0.522	rs7662229	chr4:10133014	A/T	cg26043149	chr18:55253948	FECH	1.0	12.65	0.61	5.33e-29	Gout;Urate levels;Serum uric acid levels;
CESC	cis	rs9322193	0.923	rs9689723	chr6:149977071	C/A	cg13206674	chr6:150067644	NUP43	0.45	6.43	0.37	5.79e-10	Lung cancer;
CESC	cis	rs4919694	1.000	rs112240253	chr10:104753726	C/T	cg04362960	chr10:104952993	NT5C2	0.72	5.64	0.33	4.42e-8	Arsenic metabolism;
CESC	cis	rs17376456	0.877	rs12153506	chr5:93360953	T/G	cg21475434	chr5:93447410	FAM172A	0.77	6.93	0.39	3.17e-11	Diabetic retinopathy;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg07317108	chr10:11575102	USP6NL	-0.36	-6.07	-0.35	4.44e-9	Gambling;
CESC	cis	rs7666738	0.830	rs28761309	chr4:98867393	C/T	cg05340658	chr4:99064831	C4orf37	0.74	10.7	0.55	1.97e-22	Colonoscopy-negative controls vs population controls;
CESC	trans	rs28549925	0.590	rs6949186	chr7:16992446	A/T	cg12639933	chr12:57626296	SHMT2	-0.95	-6.1	-0.35	3.74e-9	Congenital heart disease (maternal effect);Conotruncal heart defects (maternal effects);
CESC	cis	rs11252926	0.583	rs2066317	chr10:520309	C/T	cg03684893	chr10:554711	DIP2C	-0.43	-6.64	-0.38	1.78e-10	Psychosis in Alzheimer's disease;
CESC	cis	rs568617	0.953	rs658524	chr11:65647260	A/G	cg04055107	chr11:65626734	MUS81;CFL1	-0.69	-7.4	-0.41	1.81e-12	Crohn's disease;
CESC	cis	rs875971	0.862	rs11765791	chr7:65936574	A/G	cg18252515	chr7:66147081	NA	-0.47	-6.09	-0.35	4.02e-9	Aortic root size;
CESC	cis	rs11227306	0.934	rs2303385	chr11:65640562	G/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.49	-5.43	-0.32	1.29e-7	DNA methylation (variation);
CESC	cis	rs10870270	1.000	rs7199	chr10:133769848	C/G	cg08754478	chr10:133766260	PPP2R2D	-0.59	-7.57	-0.42	6.29e-13	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs9322193	0.962	rs9322223	chr6:150122645	G/A	cg09699651	chr6:150184138	LRP11	0.4	5.1	0.3	6.34e-7	Lung cancer;
CESC	cis	rs936229	0.954	rs936230	chr15:75145098	C/T	cg14664628	chr15:75095509	CSK	0.79	10.81	0.55	8.13e-23	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CESC	cis	rs863345	0.604	rs2873593	chr1:158504711	T/C	cg12129480	chr1:158549410	OR10X1	-0.34	-6.84	-0.39	5.41e-11	Pneumococcal bacteremia;
CESC	cis	rs9916302	0.904	rs10852933	chr17:37698194	G/T	cg20243544	chr17:37824526	PNMT	0.51	6.5	0.37	3.89e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs477895	0.653	rs11601577	chr11:63928574	C/T	cg04317338	chr11:64019027	PLCB3	0.88	9.16	0.49	1.45e-17	Mean platelet volume;
CESC	cis	rs7582720	1.000	rs114899426	chr2:203771652	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.39	0.41	1.96e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs7647973	0.580	rs2334958	chr3:49252364	C/T	cg03060546	chr3:49711283	APEH	0.51	6.91	0.39	3.56e-11	Menarche (age at onset);
CESC	cis	rs4737010	0.501	rs12548116	chr8:41645074	A/G	cg08923054	chr8:41654455	ANK1	0.6	7.47	0.42	1.18e-12	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
CESC	cis	rs2235642	0.717	rs2236269	chr16:1652614	T/A	cg03771183	chr16:1608904	IFT140	0.38	5.48	0.32	9.93e-8	Coronary artery disease;
CESC	cis	rs11098499	0.863	rs10018280	chr4:120478139	T/G	cg24375607	chr4:120327624	NA	0.44	5.34	0.31	1.99e-7	Corneal astigmatism;
CESC	cis	rs7116495	0.786	rs1573501	chr11:71735693	C/T	cg10381502	chr11:71823885	C11orf51	-1.16	-6.94	-0.39	3.1e-11	Severe influenza A (H1N1) infection;
CESC	cis	rs7267979	1.000	rs6115159	chr20:25350944	T/C	cg08601574	chr20:25228251	PYGB	-0.38	-5.55	-0.32	6.88e-8	Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs12599106	0.839	rs3853177	chr16:34498532	A/G	cg01516881	chr6:292596	DUSP22	-0.52	-6.66	-0.38	1.59e-10	Menopause (age at onset);
CESC	cis	rs2115630	0.641	rs11073613	chr15:85185893	G/A	cg11189052	chr15:85197271	WDR73	-0.38	-5.09	-0.3	6.66e-7	P wave terminal force;
CESC	cis	rs11122272	0.735	rs2739518	chr1:231537633	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.55	-7.44	-0.42	1.38e-12	Hemoglobin concentration;
CESC	cis	rs7208859	0.524	rs11653098	chr17:29122501	C/T	cg14008862	chr17:28927542	LRRC37B2	0.65	5.14	0.3	5.34e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs17253792	0.822	rs78988988	chr14:56152404	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.81	5.68	0.33	3.46e-8	Putamen volume;
CESC	cis	rs9611565	0.649	rs79009	chr22:41860864	C/A	cg03806693	chr22:41940476	POLR3H	1.2	15.07	0.68	1.8e-37	Vitiligo;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg09089653	chr5:134734307	H2AFY	-0.47	-6.25	-0.36	1.64e-9	Asthma;
CESC	trans	rs9693444	0.898	rs4732697	chr8:29519861	A/G	cg21400344	chr1:25870172	LDLRAP1	-0.49	-7.36	-0.41	2.3e-12	Breast cancer;
CESC	cis	rs9300255	0.739	rs4759415	chr12:123743674	C/T	cg05973401	chr12:123451056	ABCB9	-0.5	-5.74	-0.33	2.57e-8	Neutrophil percentage of white cells;
CESC	cis	rs6424115	1.000	rs1018396	chr1:24133612	G/A	cg10978503	chr1:24200527	CNR2	0.28	5.61	0.33	5.09e-8	Immature fraction of reticulocytes;
CESC	cis	rs9733	0.818	rs11204695	chr1:150657011	T/G	cg22823121	chr1:150693482	HORMAD1	-0.41	-6.29	-0.36	1.29e-9	Tonsillectomy;
CESC	cis	rs7666738	0.515	rs11733968	chr4:98906448	A/C	cg05340658	chr4:99064831	C4orf37	-0.58	-7.88	-0.44	8.28e-14	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7085104	0.700	rs6163	chr10:104596924	C/A	cg04362960	chr10:104952993	NT5C2	0.51	6.59	0.38	2.39e-10	Immature fraction of reticulocytes;Schizophrenia;
CESC	cis	rs1862618	0.853	rs832578	chr5:56164223	C/T	cg24549020	chr5:56110836	MAP3K1	0.64	7.31	0.41	3.24e-12	Initial pursuit acceleration;
CESC	cis	rs6714710	0.535	rs13033383	chr2:98339513	C/T	cg26665480	chr2:98280029	ACTR1B	0.58	7.59	0.42	5.55e-13	Posterior cortical atrophy and Alzheimer's disease;
CESC	cis	rs2742417	0.603	rs1468542	chr3:45779136	A/T	cg04837898	chr3:45731254	SACM1L	0.46	6.1	0.35	3.66e-9	Response to anti-depressant treatment in major depressive disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18371567	chr11:85376025	CREBZF	0.58	6.1	0.35	3.68e-9	Gut microbiome composition (summer);
CESC	cis	rs72627123	0.867	rs61522544	chr14:74481953	G/A	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.73	5.65	0.33	4.21e-8	Morning vs. evening chronotype;
CESC	cis	rs7267979	0.789	rs6050472	chr20:25219852	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.6	9.42	0.5	2.37e-18	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs1003719	0.788	rs2835602	chr21:38469069	G/C	cg10648535	chr21:38446584	PIGP;TTC3	0.62	8.51	0.46	1.31e-15	Eye color traits;
CESC	cis	rs3096299	0.838	rs3102384	chr16:89411661	T/G	cg02187348	chr16:89574699	SPG7	0.51	6.3	0.36	1.22e-9	Multiple myeloma (IgH translocation);
CESC	cis	rs754466	0.958	rs11002341	chr10:79701363	A/C	cg17075019	chr10:79541650	NA	-0.68	-8.29	-0.45	5.91e-15	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs7508	0.640	rs6988638	chr8:17911732	C/G	cg18067069	chr8:17937731	ASAH1	-0.39	-5.32	-0.31	2.26e-7	Atrial fibrillation;
CESC	cis	rs9322193	0.962	rs9322218	chr6:150103319	A/G	cg05861140	chr6:150128134	PCMT1	-0.35	-5.07	-0.3	7.45e-7	Lung cancer;
CESC	cis	rs644799	0.672	rs11021347	chr11:95653494	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.66	8.97	0.48	5.49e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs11792861	0.926	rs75472294	chr9:111804239	G/A	cg14384093	chr9:111878565	C9orf5	-0.41	-5.14	-0.3	5.42e-7	Menarche (age at onset);
CESC	cis	rs8112211	0.954	rs7252835	chr19:38832946	G/A	cg14299480	chr19:38876666	GGN	-0.45	-6.11	-0.35	3.52e-9	Blood protein levels;
CESC	trans	rs11098499	0.874	rs10022508	chr4:120115228	A/G	cg25214090	chr10:38739885	LOC399744	0.61	8.04	0.44	2.91e-14	Corneal astigmatism;
CESC	cis	rs9875589	1.000	rs9875589	chr3:13961157	A/C	cg19554555	chr3:13937349	NA	0.43	5.6	0.33	5.36e-8	Ovarian reserve;
CESC	trans	rs7618501	1.000	rs7649348	chr3:49772375	G/A	cg21659725	chr3:3221576	CRBN	-0.83	-13.61	-0.64	2.43e-32	Intelligence (multi-trait analysis);
CESC	cis	rs7666738	0.830	rs7657490	chr4:99043973	C/T	cg05340658	chr4:99064831	C4orf37	0.82	12.88	0.62	8.44e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs67311347	0.911	rs6773917	chr3:40469254	G/T	cg24209194	chr3:40518798	ZNF619	0.47	6.18	0.36	2.37e-9	Renal cell carcinoma;
CESC	cis	rs60871478	0.636	rs4719520	chr7:875216	C/G	cg05535760	chr7:792225	HEATR2	-0.74	-7.81	-0.43	1.35e-13	Cerebrospinal P-tau181p levels;
CESC	cis	rs4555082	0.874	rs2816626	chr14:105735425	G/A	cg10792982	chr14:105748885	BRF1	0.41	5.26	0.31	2.95e-7	Mean platelet volume;Platelet distribution width;
CESC	cis	rs62103177	0.608	rs4442895	chr18:77826399	C/G	cg12964065	chr18:77638022	KCNG2	-0.46	-5.52	-0.32	8.23e-8	Opioid sensitivity;
CESC	cis	rs3008870	1.000	rs2815351	chr1:67477980	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.98	13.64	0.64	1.82e-32	Lymphocyte percentage of white cells;
CESC	cis	rs35146811	1.000	rs35146811	chr7:99720994	A/C	cg22906224	chr7:99728672	NA	0.46	5.46	0.32	1.07e-7	Coronary artery disease;
CESC	cis	rs17253792	0.822	rs74940664	chr14:56135065	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.81	5.68	0.33	3.46e-8	Putamen volume;
CESC	cis	rs769267	1.000	rs8103197	chr19:19443466	C/T	cg03709012	chr19:19516395	GATAD2A	-0.97	-14.63	-0.67	6.08e-36	Tonsillectomy;
CESC	cis	rs12701220	0.655	rs7778968	chr7:1144622	C/G	cg23978390	chr7:1156363	C7orf50	0.5	5.17	0.3	4.69e-7	Bronchopulmonary dysplasia;
CESC	cis	rs10208940	0.920	rs35005506	chr2:68814238	A/T	cg12452813	chr2:68675892	NA	0.53	5.29	0.31	2.54e-7	Urate levels in lean individuals;
CESC	cis	rs17401966	0.964	rs2027331	chr1:10276718	C/T	cg15208524	chr1:10270712	KIF1B	0.53	6.91	0.39	3.5e-11	Hepatocellular carcinoma;
CESC	cis	rs11864453	0.612	rs12708925	chr16:72122706	A/T	cg01557791	chr16:72042693	DHODH	-0.44	-5.68	-0.33	3.54e-8	Fibrinogen levels;
CESC	cis	rs919433	0.889	rs12693816	chr2:198208420	T/A	cg03934865	chr2:198174659	NA	-0.47	-6.75	-0.38	9.27e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	trans	rs11088226	1.000	rs2833888	chr21:33927560	A/G	cg09050820	chr6:167586206	TCP10L2	0.6	6.07	0.35	4.38e-9	Gastritis;
CESC	cis	rs1003719	0.680	rs2154537	chr21:38502012	G/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-8.54	-0.46	1.04e-15	Eye color traits;
CESC	cis	rs6693567	0.565	rs834237	chr1:150363930	A/G	cg09579323	chr1:150459698	TARS2	0.48	6.03	0.35	5.58e-9	Migraine;
CESC	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg22535103	chr8:58192502	C8orf71	-0.94	-10.38	-0.54	2.05e-21	Developmental language disorder (linguistic errors);
CESC	cis	rs10504229	0.773	rs1874374	chr8:58194422	A/G	cg05313129	chr8:58192883	C8orf71	-0.51	-5.24	-0.31	3.27e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs1008375	0.932	rs964012	chr4:17619184	A/G	cg04450456	chr4:17643702	FAM184B	0.37	5.17	0.3	4.72e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs10504229	1.000	rs17216711	chr8:58170856	T/C	cg22535103	chr8:58192502	C8orf71	-1.05	-13.27	-0.63	3.63e-31	Developmental language disorder (linguistic errors);
CESC	cis	rs870825	0.587	rs7682995	chr4:185640684	G/A	cg04058563	chr4:185651563	MLF1IP	0.64	7.1	0.4	1.15e-11	Blood protein levels;
CESC	cis	rs2304069	0.507	rs4705407	chr5:149404983	G/T	cg12661370	chr5:149340060	SLC26A2	0.46	6.53	0.37	3.4e-10	HIV-1 control;
CESC	cis	rs10918270	0.934	rs9783069	chr1:161936121	A/C	cg19735514	chr1:161762739	ATF6	-0.38	-5.7	-0.33	3.24e-8	Parkinson's disease (age of onset);
CESC	cis	rs13118159	0.550	rs10016557	chr4:1363628	C/T	cg02018176	chr4:1364513	KIAA1530	-0.49	-6.36	-0.36	8.91e-10	Longevity;
CESC	cis	rs208520	1.000	rs12194996	chr6:66973366	G/C	cg07460842	chr6:66804631	NA	0.75	8.7	0.47	3.46e-16	Exhaled nitric oxide output;
CESC	cis	rs1046896	0.538	rs3803771	chr17:80687758	G/A	cg05255149	chr17:80675120	FN3KRP	-0.47	-5.92	-0.34	9.8e-9	Glycated hemoglobin levels;
CESC	cis	rs138880	0.580	rs28562884	chr22:50312869	T/C	cg02269571	chr22:50332266	NA	-0.68	-6.71	-0.38	1.17e-10	Schizophrenia;
CESC	cis	rs9399135	0.967	rs6929661	chr6:135328792	G/A	cg22676075	chr6:135203613	NA	0.51	7.23	0.41	5.22e-12	Red blood cell count;
CESC	cis	rs763014	0.966	rs4247097	chr16:654224	G/A	cg07343612	chr16:622815	PIGQ	-0.55	-8.07	-0.44	2.44e-14	Height;
CESC	cis	rs6912958	0.559	rs173333	chr6:88047754	T/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.44	7.8	0.43	1.47e-13	Monocyte percentage of white cells;
CESC	cis	rs3617	0.625	rs7652667	chr3:52866535	C/A	cg11645453	chr3:52864694	ITIH4	-0.26	-5.18	-0.3	4.48e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
CESC	cis	rs7640424	0.750	rs13074183	chr3:107851467	G/A	cg09227934	chr3:107805635	CD47	-0.46	-5.86	-0.34	1.35e-8	Body mass index;
CESC	cis	rs769267	0.896	rs10405625	chr19:19579046	T/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.47	5.87	0.34	1.33e-8	Tonsillectomy;
CESC	cis	rs72945132	0.619	rs34053053	chr11:70260598	C/T	cg14191688	chr11:70257035	CTTN	0.48	5.97	0.34	7.65e-9	Coronary artery disease;
CESC	cis	rs208520	0.526	rs7775830	chr6:66755249	A/G	cg07460842	chr6:66804631	NA	1.02	21.41	0.8	9.82e-60	Exhaled nitric oxide output;
CESC	cis	rs10779751	1.000	rs4845987	chr1:11306279	G/C	cg08854313	chr1:11322531	MTOR	0.91	14.45	0.66	2.77e-35	Body mass index;
CESC	cis	rs1499614	0.901	rs3936	chr7:66126489	C/T	cg08632164	chr7:65971372	NA	-0.49	-5.12	-0.3	5.92e-7	Gout;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07475957	chr5:140590251	PCDHB12	-0.47	-6.17	-0.35	2.55e-9	Gut microbiome composition (summer);
CESC	cis	rs6860806	0.631	rs4705931	chr5:131588345	T/C	cg24060327	chr5:131705240	SLC22A5	-0.42	-5.34	-0.31	1.96e-7	Breast cancer;
CESC	cis	rs9309473	0.519	rs2421574	chr2:73908767	C/G	cg20560298	chr2:73613845	ALMS1	0.5	7.16	0.4	7.75e-12	Metabolite levels;
CESC	cis	rs2033711	0.622	rs975947	chr19:58898193	C/T	cg26874164	chr19:58962979	ZNF324B	0.42	5.52	0.32	8.06e-8	Uric acid clearance;
CESC	cis	rs1163251	0.837	rs660073	chr1:120245173	T/C	cg19096424	chr1:120255104	PHGDH	0.52	6.67	0.38	1.52e-10	Blood metabolite levels;
CESC	cis	rs6964587	1.000	rs7791138	chr7:91686789	A/G	cg17063962	chr7:91808500	NA	0.57	7.85	0.43	1.05e-13	Breast cancer;
CESC	cis	rs921968	0.565	rs4674328	chr2:219593203	T/C	cg02176678	chr2:219576539	TTLL4	-0.43	-7.46	-0.42	1.23e-12	Mean corpuscular hemoglobin concentration;
CESC	cis	rs2072732	0.861	rs12046233	chr1:2960608	A/G	cg15211996	chr1:2936768	ACTRT2	0.34	5.44	0.32	1.19e-7	Plateletcrit;
CESC	cis	rs16917546	1.000	rs10995260	chr10:64410580	G/A	cg03961010	chr10:64397487	ZNF365	-0.37	-6.11	-0.35	3.55e-9	Basal cell carcinoma;
CESC	cis	rs7224685	0.569	rs2123841	chr17:4022557	G/A	cg07607921	chr17:4047574	ZZEF1;CYB5D2	0.49	5.09	0.3	6.96e-7	Type 2 diabetes;
CESC	cis	rs4481887	0.741	rs28616194	chr1:248531904	T/A	cg26353448	chr1:248524236	OR2T4	-0.38	-5.35	-0.31	1.9e-7	Common traits (Other);
CESC	cis	rs79387448	0.564	rs77375846	chr2:103155075	T/C	cg09003973	chr2:102972529	NA	0.96	7.26	0.41	4.43e-12	Gut microbiota (bacterial taxa);
CESC	cis	rs7208859	0.673	rs216418	chr17:28936537	G/A	cg19761014	chr17:28927070	LRRC37B2	0.79	7.48	0.42	1.12e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs826838	1.000	rs11168505	chr12:38939057	A/T	cg26384229	chr12:38710491	ALG10B	-0.79	-14.01	-0.65	9.85e-34	Heart rate;
CESC	cis	rs7666738	0.830	rs17026973	chr4:98680041	T/A	cg05340658	chr4:99064831	C4orf37	0.76	10.99	0.56	2.11e-23	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9487051	0.735	rs396000	chr6:109519611	A/G	cg01475377	chr6:109611718	NA	0.38	5.71	0.33	2.96e-8	Reticulocyte fraction of red cells;
CESC	cis	rs875971	0.545	rs6979636	chr7:65741625	A/G	cg11764359	chr7:65958608	NA	0.79	9.42	0.5	2.29e-18	Aortic root size;
CESC	cis	rs1348850	0.651	rs4893936	chr2:178240676	C/G	cg22681709	chr2:178499509	PDE11A	-0.37	-5.63	-0.33	4.51e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15380607	chr6:138188545	TNFAIP3	0.59	6.86	0.39	4.88e-11	Gut microbiome composition (summer);
CESC	cis	rs847577	0.630	rs11764933	chr7:97825188	G/A	cg24562669	chr7:97807699	LMTK2	0.84	13.88	0.65	2.69e-33	Breast cancer;
CESC	cis	rs6964587	0.967	rs9656003	chr7:91766322	A/C	cg17063962	chr7:91808500	NA	0.56	7.84	0.43	1.09e-13	Breast cancer;
CESC	cis	rs4253772	0.591	rs6519993	chr22:46656479	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.69	8.17	0.45	1.28e-14	LDL cholesterol;Cholesterol, total;
CESC	trans	rs3857536	0.611	rs6927407	chr6:66870010	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.58	-7.58	-0.42	5.87e-13	Blood trace element (Cu levels);
CESC	cis	rs7208859	0.673	rs423151	chr17:28952286	A/G	cg04154034	chr17:28927549	LRRC37B2	0.68	6.14	0.35	3.08e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs7246657	1.000	rs6508710	chr19:37749886	A/G	cg23950597	chr19:37808831	NA	-0.57	-6.23	-0.36	1.79e-9	Coronary artery calcification;
CESC	cis	rs763014	0.865	rs8675	chr16:633843	A/G	cg00908189	chr16:619842	PIGQ	0.66	9.11	0.49	2.12e-17	Height;
CESC	cis	rs9649213	0.593	rs12672092	chr7:97986557	C/A	cg08684580	chr7:98029266	BAIAP2L1	-0.35	-5.8	-0.34	1.85e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7666738	0.515	rs11733968	chr4:98906448	A/C	cg03676636	chr4:99064102	C4orf37	-0.34	-5.22	-0.31	3.65e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2273669	0.588	rs12205061	chr6:109338161	T/C	cg05315195	chr6:109294784	ARMC2	-0.67	-6.33	-0.36	1.03e-9	Prostate cancer;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg09645772	chr5:180688272	TRIM52	-0.46	-6.18	-0.35	2.47e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs7565301	0.589	rs1123573	chr2:60707588	C/T	cg05806717	chr16:30102542	TBX6	-0.37	-6.11	-0.35	3.48e-9	Intelligence (multi-trait analysis);F-cell distribution;
CESC	cis	rs6032067	0.852	rs2233882	chr20:43835683	T/A	cg10761708	chr20:43804764	PI3	0.5	5.94	0.34	8.83e-9	Blood protein levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13426340	chr1:167131977	NA	-0.61	-6.69	-0.38	1.3e-10	Gut microbiome composition (summer);
CESC	cis	rs2303745	0.589	rs6512179	chr19:17399105	T/C	cg10664184	chr19:17420304	DDA1	0.44	5.18	0.3	4.35e-7	Systemic lupus erythematosus;
CESC	cis	rs11122272	0.735	rs2486729	chr1:231535584	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.57	-7.74	-0.43	2.14e-13	Hemoglobin concentration;
CESC	cis	rs9900062	0.546	rs2676289	chr17:62705738	A/G	cg02598441	chr17:62777298	LOC146880	0.48	5.15	0.3	5.21e-7	QT interval;
CESC	cis	rs9549367	0.577	rs776904	chr13:113810542	C/T	cg00898013	chr13:113819073	PROZ	-0.51	-6.38	-0.36	7.82e-10	Platelet distribution width;
CESC	cis	rs12893668	0.703	rs2274267	chr14:104029449	G/A	cg24130564	chr14:104152367	KLC1	-0.46	-5.43	-0.32	1.27e-7	Reticulocyte count;
CESC	cis	rs6570726	0.791	rs12208019	chr6:145935572	T/C	cg23711669	chr6:146136114	FBXO30	0.99	15.04	0.68	2.25e-37	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6496667	0.557	rs2526002	chr15:90965655	C/T	cg10434728	chr15:90938212	IQGAP1	0.31	5.45	0.32	1.15e-7	Rheumatoid arthritis;
CESC	cis	rs16854884	0.657	rs6783089	chr3:143738034	T/C	cg06585982	chr3:143692056	C3orf58	0.5	6.7	0.38	1.26e-10	Economic and political preferences (feminism/equality);
CESC	cis	rs8060686	0.516	rs7194894	chr16:68145062	C/T	cg26727032	chr16:67993705	SLC12A4	-0.52	-6.33	-0.36	1.05e-9	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs9733	0.544	rs2867302	chr1:150653650	T/C	cg18016565	chr1:150552671	MCL1	0.33	5.14	0.3	5.34e-7	Tonsillectomy;
CESC	cis	rs60843830	1.000	rs2126129	chr2:212548	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.85	11.23	0.57	3.53e-24	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs9393692	0.620	rs9379844	chr6:26291527	A/G	cg00631329	chr6:26305371	NA	0.35	5.7	0.33	3.24e-8	Educational attainment;
CESC	cis	rs4713118	0.513	rs1225591	chr6:28148752	G/A	cg12963246	chr6:28129442	ZNF389	0.41	5.97	0.34	7.49e-9	Parkinson's disease;
CESC	trans	rs10242455	0.702	rs73401510	chr7:99065812	A/C	cg09045935	chr12:6379348	NA	0.85	7.12	0.4	1.03e-11	Blood metabolite levels;
CESC	cis	rs694739	0.726	rs17857342	chr11:64138905	T/G	cg23796481	chr11:64053134	BAD;GPR137	0.58	7.05	0.4	1.58e-11	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CESC	cis	rs17384381	1.000	rs79695640	chr1:85836073	T/C	cg16011679	chr1:85725395	C1orf52	0.82	8.18	0.45	1.21e-14	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs67311347	1.000	rs2168111	chr3:40395325	T/G	cg24209194	chr3:40518798	ZNF619	0.45	5.96	0.34	7.9e-9	Renal cell carcinoma;
CESC	cis	rs8077577	0.895	rs1563373	chr17:18114228	G/A	cg16794390	chr17:18148240	FLII	0.41	5.63	0.33	4.55e-8	Obesity-related traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	ch.20.50358104F	chr20:50924697	NA	-0.52	-6.11	-0.35	3.57e-9	Gut microbiome composition (summer);
CESC	cis	rs763121	0.853	rs2413546	chr22:39107001	G/A	cg21395723	chr22:39101663	GTPBP1	0.43	5.45	0.32	1.13e-7	Menopause (age at onset);
CESC	cis	rs782590	0.837	rs2627769	chr2:55927288	G/C	cg18811423	chr2:55921094	PNPT1	0.83	13.82	0.65	4.6e-33	Metabolic syndrome;
CESC	cis	rs3106136	0.967	rs2632399	chr4:95153741	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.46	-7.01	-0.4	1.94e-11	Capecitabine sensitivity;
CESC	cis	rs2836974	0.897	rs2836928	chr21:40543320	C/T	cg27266027	chr21:40555129	PSMG1	0.46	5.41	0.32	1.38e-7	Cognitive function;
CESC	cis	rs7666738	0.962	rs2865950	chr4:99040061	T/C	cg05340658	chr4:99064831	C4orf37	0.69	9.38	0.5	3.07e-18	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9929218	0.954	rs2059254	chr16:68817439	C/T	cg05785947	chr16:68771059	CDH1	0.38	5.2	0.3	4.04e-7	Colorectal cancer;
CESC	cis	rs2243480	1.000	rs313831	chr7:65551226	C/T	cg13147721	chr7:65941812	NA	-1.02	-9.7	-0.51	3.08e-19	Diabetic kidney disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10261751	chr16:1505328	CLCN7	-0.64	-7.36	-0.41	2.31e-12	Gut microbiome composition (summer);
CESC	cis	rs4481887	1.000	rs6697735	chr1:248465315	G/C	cg00666640	chr1:248458726	OR2T12	0.37	6.04	0.35	5.32e-9	Common traits (Other);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04016606	chr6:167041530	RPS6KA2	0.53	6.02	0.35	5.69e-9	Gut microbiome composition (summer);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg05636869	chr5:52777880	FST	-0.48	-6.43	-0.37	5.89e-10	Fibrinogen levels;
CESC	cis	rs4919087	0.561	rs61861844	chr10:99064171	G/A	cg25902810	chr10:99078978	FRAT1	-0.51	-5.14	-0.3	5.21e-7	Monocyte count;
CESC	cis	rs853679	0.517	rs9393885	chr6:28050009	A/T	cg26335602	chr6:28129616	ZNF389	0.53	7.05	0.4	1.55e-11	Depression;
CESC	cis	rs6598955	0.724	rs12726972	chr1:26639634	A/G	cg19743891	chr1:26644573	UBXN11;CD52	0.26	5.1	0.3	6.37e-7	Obesity-related traits;
CESC	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg06420487	chr17:61919686	SMARCD2	-0.44	-5.21	-0.3	3.83e-7	Prudent dietary pattern;
CESC	cis	rs9916302	0.861	rs644173	chr17:37430519	T/C	cg00129232	chr17:37814104	STARD3	-0.54	-7.03	-0.4	1.78e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs36051895	0.664	rs884132	chr9:5114522	G/A	cg02405213	chr9:5042618	JAK2	-0.51	-6.22	-0.36	1.98e-9	Pediatric autoimmune diseases;
CESC	cis	rs10504229	0.815	rs75577263	chr8:58188434	A/G	cg24829409	chr8:58192753	C8orf71	-0.76	-9.93	-0.52	5.87e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs11718455	0.921	rs11130020	chr3:44009459	C/T	cg08738300	chr3:44038990	NA	0.46	6.24	0.36	1.68e-9	Coronary artery disease;
CESC	cis	rs9611565	0.921	rs2235846	chr22:41741042	G/C	cg03806693	chr22:41940476	POLR3H	-0.71	-8.52	-0.46	1.2e-15	Vitiligo;
CESC	cis	rs7762018	0.655	rs2184195	chr6:170148397	C/T	cg13891659	chr6:170190454	C6orf122;C6orf208	0.67	6.53	0.37	3.28e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg15254786	chr2:207630414	MDH1B;FASTKD2	-0.5	-6.77	-0.38	8.3e-11	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs72945132	0.882	rs7128969	chr11:70205017	C/A	cg00319359	chr11:70116639	PPFIA1	0.73	6.87	0.39	4.64e-11	Coronary artery disease;
CESC	cis	rs875971	0.545	rs4718325	chr7:65680310	G/A	cg18876405	chr7:65276391	NA	0.49	5.35	0.31	1.89e-7	Aortic root size;
CESC	cis	rs7937682	0.889	rs10749984	chr11:111492861	T/C	cg22437258	chr11:111473054	SIK2	0.72	9.66	0.51	4.24e-19	Primary sclerosing cholangitis;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14321424	chr11:46403087	MDK	0.47	6.12	0.35	3.34e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs7296418	0.961	rs10848428	chr12:123572495	C/T	cg00376283	chr12:123451042	ABCB9	0.76	10.96	0.56	2.75e-23	Platelet count;
CESC	trans	rs459571	0.920	rs417142	chr9:136891370	G/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.57	-7.3	-0.41	3.37e-12	Platelet distribution width;
CESC	cis	rs1707322	0.721	rs10430123	chr1:46221440	T/C	cg03146154	chr1:46216737	IPP	0.82	11.54	0.58	3.18e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs17345786	0.798	rs1609159	chr3:101275902	A/C	cg11279151	chr3:101281821	RG9MTD1	-0.44	-5.6	-0.33	5.48e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2635047	1.000	rs2635049	chr18:44687303	C/T	cg24371990	chr18:44770781	NA	-0.34	-5.38	-0.31	1.67e-7	Educational attainment;
CESC	cis	rs13191362	0.872	rs73020362	chr6:163005737	A/C	cg21926612	chr6:163149169	PACRG;PARK2	0.87	9.04	0.49	3.35e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs9733	0.593	rs10888384	chr1:150574256	C/T	cg17724175	chr1:150552817	MCL1	-0.35	-5.6	-0.33	5.37e-8	Tonsillectomy;
CESC	cis	rs4072980	0.545	rs7528185	chr1:38452059	C/T	cg18451016	chr1:38461880	NA	-0.4	-5.53	-0.32	7.54e-8	Coronary artery disease;
CESC	cis	rs2204008	0.626	rs11520260	chr12:38330092	C/T	cg13010199	chr12:38710504	ALG10B	0.48	6.11	0.35	3.53e-9	Bladder cancer;
CESC	cis	rs8067354	0.609	rs1292066	chr17:57932314	T/A	cg02344993	chr17:57696989	CLTC	0.7	8.66	0.47	4.61e-16	Hemoglobin concentration;
CESC	cis	rs1552244	0.882	rs3755783	chr3:10029289	A/G	cg00149659	chr3:10157352	C3orf10	0.6	6.3	0.36	1.27e-9	Alzheimer's disease;
CESC	cis	rs1538970	0.816	rs12029322	chr1:45970446	C/T	cg03146154	chr1:46216737	IPP	0.49	5.57	0.32	6.31e-8	Platelet count;
CESC	cis	rs4713118	0.621	rs4713132	chr6:28034035	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.53	-6.06	-0.35	4.65e-9	Parkinson's disease;
CESC	cis	rs7666738	0.830	rs13144564	chr4:98939276	A/G	cg05340658	chr4:99064831	C4orf37	0.82	12.54	0.61	1.29e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3806701	0.619	rs6442008	chr3:46645753	C/T	cg21489266	chr3:46619131	LRRC2;TDGF1	-0.41	-6.24	-0.36	1.73e-9	Blood protein levels;
CESC	cis	rs367615	1.000	rs367615	chr5:108948937	C/T	cg17395555	chr5:108820864	NA	-0.46	-6.81	-0.39	6.5e-11	Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs10838687	0.736	rs4647741	chr11:47254010	T/C	cg25783544	chr11:47291846	MADD	0.58	6.63	0.38	1.9e-10	Proinsulin levels;
CESC	cis	rs9815354	0.680	rs73073263	chr3:42018666	C/A	cg03022575	chr3:42003672	ULK4	0.74	6.64	0.38	1.79e-10	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs1256061	0.533	rs2357479	chr14:64792764	G/T	cg21174375	chr14:64681225	SYNE2	0.53	7.02	0.4	1.91e-11	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs9443645	0.527	rs12196485	chr6:79556871	A/G	cg05283184	chr6:79620031	NA	-0.37	-5.32	-0.31	2.26e-7	Intelligence (multi-trait analysis);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg15356780	chr14:90422831	TDP1	-0.45	-6.56	-0.37	2.74e-10	Gambling;
CESC	cis	rs2404602	0.692	rs4442773	chr15:77031633	T/C	cg22467129	chr15:76604101	ETFA	-0.34	-5.16	-0.3	4.84e-7	Blood metabolite levels;
CESC	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg11494091	chr17:61959527	GH2	0.73	12.52	0.61	1.45e-28	Prudent dietary pattern;
CESC	trans	rs1814175	0.645	rs4625470	chr11:49983769	T/C	cg15704280	chr7:45808275	SEPT13	-1.01	-19.02	-0.76	1.83e-51	Height;
CESC	cis	rs698813	0.674	rs11678787	chr2:44496315	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.49	5.41	0.32	1.39e-7	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
CESC	cis	rs2576037	0.526	rs649076	chr18:44414614	A/G	cg19077165	chr18:44547161	KATNAL2	-0.53	-7.82	-0.43	1.22e-13	Personality dimensions;
CESC	cis	rs34779708	0.931	rs11592404	chr10:35273476	G/A	cg04310649	chr10:35416472	CREM	-0.5	-5.97	-0.34	7.61e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs2032447	0.869	rs2230655	chr6:26033506	A/G	cg12310025	chr6:25882481	NA	0.45	6.48	0.37	4.54e-10	Intelligence (multi-trait analysis);
CESC	cis	rs4642101	0.640	rs12629398	chr3:12826799	A/G	cg05775895	chr3:12838266	CAND2	0.4	6.15	0.35	2.91e-9	QRS complex (12-leadsum);
CESC	cis	rs853679	0.517	rs35512245	chr6:28079953	T/C	cg23161317	chr6:28129485	ZNF389	0.51	6.53	0.37	3.44e-10	Depression;
CESC	cis	rs5758659	0.657	rs5758587	chr22:42517636	C/G	cg00645731	chr22:42541494	CYP2D7P1	0.32	5.55	0.32	6.8e-8	Cognitive function;
CESC	cis	rs7662987	0.517	rs2602865	chr4:100034841	T/C	cg13256891	chr4:100009986	ADH5	0.75	8.03	0.44	3.29e-14	Smoking initiation;
CESC	cis	rs9768139	0.733	rs12698209	chr7:158117595	A/G	cg25566285	chr7:158114605	PTPRN2	-0.45	-7.63	-0.42	4.2e-13	Calcium levels;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg02667081	chr16:71880439	ATXN1L	-0.44	-6.34	-0.36	1.01e-9	Gambling;
CESC	cis	rs11077998	0.967	rs4614761	chr17:80505809	C/T	cg20173014	chr17:80541737	FOXK2	-0.33	-5.23	-0.31	3.42e-7	Reticulocyte fraction of red cells;
CESC	cis	rs3015497	0.646	rs871643	chr14:51107452	T/C	cg26011998	chr14:51135199	SAV1	-0.6	-6.72	-0.38	1.13e-10	Mean platelet volume;
CESC	cis	rs910316	0.737	rs398896	chr14:75482827	C/A	cg11812906	chr14:75593930	NEK9	-0.81	-13.04	-0.63	2.4e-30	Height;
CESC	cis	rs9549367	0.713	rs9549691	chr13:113861606	A/C	cg00898013	chr13:113819073	PROZ	-0.57	-8.05	-0.44	2.75e-14	Platelet distribution width;
CESC	cis	rs796364	0.616	rs2030653	chr2:200677625	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.55	5.14	0.3	5.3e-7	Schizophrenia;
CESC	cis	rs4835473	0.766	rs6537222	chr4:144892612	T/C	cg25736465	chr4:144833511	NA	0.39	5.95	0.34	8.36e-9	Immature fraction of reticulocytes;
CESC	cis	rs9300255	0.739	rs10846491	chr12:123753492	C/G	cg00376283	chr12:123451042	ABCB9	0.73	9.19	0.49	1.2e-17	Neutrophil percentage of white cells;
CESC	cis	rs9902453	0.817	rs2729449	chr17:28089751	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.67	-8.61	-0.47	6.65e-16	Coffee consumption (cups per day);
CESC	cis	rs4665809	1.000	rs6729080	chr2:26301282	G/A	cg04944784	chr2:26401820	FAM59B	-0.67	-7.75	-0.43	2e-13	Gut microbiome composition (summer);
CESC	cis	rs2404602	0.532	rs744336	chr15:76674624	T/C	cg23625390	chr15:77176239	SCAPER	0.35	5.05	0.3	8.32e-7	Blood metabolite levels;
CESC	cis	rs79349575	0.783	rs62075839	chr17:46996434	G/C	cg16584676	chr17:46985605	UBE2Z	0.53	6.6	0.38	2.25e-10	Type 2 diabetes;
CESC	cis	rs12824058	0.831	rs12829373	chr12:130814114	G/C	cg23887609	chr12:130822674	PIWIL1	0.45	5.82	0.34	1.69e-8	Menopause (age at onset);
CESC	cis	rs736408	0.562	rs2072390	chr3:52780509	A/T	cg18337363	chr3:52569053	NT5DC2	0.31	5.56	0.32	6.63e-8	Bipolar disorder;
CESC	cis	rs1862618	0.853	rs832582	chr5:56177743	G/A	cg18230493	chr5:56204884	C5orf35	-0.74	-8.69	-0.47	3.77e-16	Initial pursuit acceleration;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg02505454	chr12:38493678	NA	0.41	6.02	0.35	5.66e-9	Fibrinogen levels;
CESC	cis	rs8031584	1.000	rs1474380	chr15:31269235	T/C	cg08109568	chr15:31115862	NA	-0.7	-9.3	-0.5	5.56e-18	Huntington's disease progression;
CESC	cis	rs7122539	0.646	rs569818	chr11:66570749	G/A	cg24851651	chr11:66362959	CCS	0.49	7.05	0.4	1.51e-11	HIV-1 susceptibility;
CESC	trans	rs11039798	0.582	rs1304193	chr11:48688588	C/T	cg15704280	chr7:45808275	SEPT13	0.65	6.5	0.37	4.05e-10	Axial length;
CESC	cis	rs12137294	0.866	rs1077883	chr1:205210415	G/T	cg21643547	chr1:205240462	TMCC2	-0.34	-5.48	-0.32	9.82e-8	Red cell distribution width;
CESC	trans	rs561341	0.769	rs9899093	chr17:30191954	C/G	cg20587970	chr11:113659929	NA	-1.0	-11.16	-0.57	5.94e-24	Hip circumference adjusted for BMI;
CESC	cis	rs13242816	1.000	rs66985071	chr7:116130433	C/T	cg04696780	chr7:116139425	CAV2	-0.61	-5.56	-0.32	6.58e-8	P wave duration;
CESC	cis	rs6812193	0.518	rs2869881	chr4:77205745	T/C	cg20311846	chr4:77356250	SHROOM3	-0.31	-5.55	-0.32	7.07e-8	Parkinson's disease;
CESC	cis	rs6088580	0.634	rs9789792	chr20:32957709	G/A	cg08999081	chr20:33150536	PIGU	-0.65	-11.33	-0.57	1.54e-24	Glomerular filtration rate (creatinine);
CESC	cis	rs6866344	0.697	rs72812613	chr5:178135257	G/A	cg10224037	chr5:178157518	ZNF354A	0.69	7.69	0.43	2.83e-13	Neutrophil percentage of white cells;
CESC	cis	rs9486715	0.838	rs7452350	chr6:96883326	C/A	cg18709589	chr6:96969512	KIAA0776	0.45	6.46	0.37	5.05e-10	Headache;
CESC	cis	rs4523957	0.548	rs7225623	chr17:2089548	T/C	cg16513277	chr17:2031491	SMG6	-0.63	-8.81	-0.48	1.7e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs7512552	0.698	rs12028001	chr1:150407820	C/T	cg15654264	chr1:150340011	RPRD2	0.4	5.29	0.31	2.55e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs718433	0.584	rs2075478	chr14:22218051	C/T	cg02257791	chr14:22217085	NA	-0.32	-5.08	-0.3	7.19e-7	Intraocular pressure;
CESC	cis	rs2836974	0.796	rs77153312	chr21:40695499	G/A	cg27266027	chr21:40555129	PSMG1	0.44	5.23	0.31	3.4e-7	Cognitive function;
CESC	cis	rs7103648	0.966	rs11500477	chr11:47409051	T/A	cg20307385	chr11:47447363	PSMC3	0.96	15.56	0.69	3.3e-39	Diastolic blood pressure;Systolic blood pressure;
CESC	cis	rs597539	0.690	rs647661	chr11:68625875	T/C	cg18350739	chr11:68623251	NA	-0.44	-6.42	-0.37	6.13e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs933688	0.938	rs7705465	chr5:90680949	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.18	14.27	0.66	1.16e-34	Smoking behavior;
CESC	cis	rs2576037	0.901	rs2576036	chr18:44587102	G/T	cg19077165	chr18:44547161	KATNAL2	-0.57	-8.04	-0.44	2.98e-14	Personality dimensions;
CESC	cis	rs4234798	1.000	rs4234798	chr4:7219933	G/T	cg18431297	chr4:7219810	SORCS2	-0.45	-7.27	-0.41	4.06e-12	Insulin-like growth factors;
CESC	cis	rs2243480	1.000	rs906134	chr7:65444288	G/C	cg18252515	chr7:66147081	NA	-1.24	-12.17	-0.6	2.31e-27	Diabetic kidney disease;
CESC	trans	rs11098499	0.697	rs4373140	chr4:120307698	A/G	cg25214090	chr10:38739885	LOC399744	0.68	9.2	0.49	1.14e-17	Corneal astigmatism;
CESC	trans	rs561341	0.882	rs72825748	chr17:30367396	G/A	cg27661571	chr11:113659931	NA	-0.85	-7.76	-0.43	1.87e-13	Hip circumference adjusted for BMI;
CESC	cis	rs4132509	0.793	rs6694738	chr1:243715210	C/A	cg21452805	chr1:244014465	NA	0.61	6.48	0.37	4.48e-10	RR interval (heart rate);
CESC	cis	rs2440129	0.611	rs11571335	chr17:6904263	C/T	cg05215272	chr17:6899095	ALOX12	0.44	8.41	0.46	2.61e-15	Tonsillectomy;
CESC	cis	rs12530845	0.943	rs60858457	chr7:135336918	T/C	cg23117316	chr7:135346802	PL-5283	-0.45	-5.46	-0.32	1.07e-7	Red blood cell traits;
CESC	cis	rs7927592	0.731	rs7108376	chr11:68347870	A/G	cg01657329	chr11:68192670	LRP5	0.48	6.31	0.36	1.14e-9	Total body bone mineral density;
CESC	trans	rs1973993	0.669	rs510552	chr1:96891671	A/G	cg10631902	chr5:14652156	NA	0.61	9.43	0.5	2.11e-18	Weight;
CESC	cis	rs9815354	0.597	rs79626430	chr3:42023786	A/G	cg03022575	chr3:42003672	ULK4	0.75	6.64	0.38	1.72e-10	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs2046867	0.818	rs1502758	chr3:72865126	A/G	cg25664220	chr3:72788482	NA	-0.45	-6.63	-0.38	1.85e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CESC	cis	rs287982	0.800	rs13429581	chr2:9963443	T/C	cg10881225	chr2:9984929	TAF1B	0.42	5.31	0.31	2.37e-7	Nonsyndromic cleft lip with cleft palate;
CESC	cis	rs228437	1.000	rs228448	chr6:134903308	C/T	cg24504307	chr6:134963096	NA	0.53	5.71	0.33	2.95e-8	Melanoma;
CESC	cis	rs72945132	0.882	rs12289915	chr11:70131956	G/C	cg00319359	chr11:70116639	PPFIA1	0.78	7.78	0.43	1.6e-13	Coronary artery disease;
CESC	cis	rs7130144	0.541	rs60642492	chr11:130465155	G/A	cg26307797	chr11:130446613	NA	-0.79	-7.11	-0.4	1.07e-11	Urate levels in lean individuals;
CESC	cis	rs3820068	0.524	rs34094056	chr1:15824154	G/T	cg18192808	chr1:15853278	DNAJC16	0.44	5.16	0.3	4.93e-7	Systolic blood pressure;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27194164	chr19:17666205	GLT25D1	0.56	6.36	0.36	8.94e-10	Gut microbiome composition (summer);
CESC	cis	rs4713118	0.662	rs156744	chr6:27967274	G/A	cg08968635	chr6:28129556	ZNF389	0.37	5.04	0.3	8.56e-7	Parkinson's disease;
CESC	cis	rs597539	0.690	rs635529	chr11:68626294	C/T	cg21963583	chr11:68658836	MRPL21	0.41	5.5	0.32	9.14e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs3820068	0.608	rs7516683	chr1:16020502	A/G	cg18133145	chr1:16060689	PLEKHM2	0.41	5.28	0.31	2.71e-7	Systolic blood pressure;
CESC	cis	rs853679	0.882	rs9380064	chr6:28143118	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.75	-6.42	-0.37	6.32e-10	Depression;
CESC	cis	rs2180341	0.814	rs9401959	chr6:127736464	T/C	cg24812749	chr6:127587940	RNF146	0.84	12.05	0.59	5.93e-27	Breast cancer;
CESC	cis	rs780096	0.506	rs72819512	chr2:27614449	G/A	cg21248554	chr2:27665150	KRTCAP3	-0.35	-7.03	-0.4	1.74e-11	Total body bone mineral density;
CESC	cis	rs1799949	0.965	rs9646413	chr17:41426157	A/G	cg07153921	chr17:41440717	NA	-0.43	-5.69	-0.33	3.27e-8	Menopause (age at onset);
CESC	cis	rs801193	0.569	rs11772819	chr7:66217970	T/C	cg18252515	chr7:66147081	NA	-0.44	-5.96	-0.34	8.18e-9	Aortic root size;
CESC	cis	rs4700695	0.719	rs27087	chr5:65453050	G/A	cg21114390	chr5:65439923	SFRS12	-0.48	-5.9	-0.34	1.14e-8	Facial morphology (factor 19);
CESC	cis	rs6577655	0.517	rs6983560	chr8:135584553	C/T	cg17885191	chr8:135476712	NA	-0.44	-5.07	-0.3	7.59e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CESC	cis	rs10504229	1.000	rs17816781	chr8:58186161	A/T	cg05313129	chr8:58192883	C8orf71	-0.55	-6.29	-0.36	1.34e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs6424115	0.830	rs1130320	chr1:24200606	A/G	cg10978503	chr1:24200527	CNR2	0.33	6.62	0.38	1.93e-10	Immature fraction of reticulocytes;
CESC	cis	rs17253792	0.822	rs77250916	chr14:56042208	A/G	cg01858014	chr14:56050164	KTN1	-0.99	-7.46	-0.42	1.21e-12	Putamen volume;
CESC	cis	rs12130219	0.500	rs4845743	chr1:152184149	A/G	cg26879891	chr1:152191343	HRNR	-0.42	-6.68	-0.38	1.38e-10	Inflammatory skin disease;
CESC	cis	rs9611565	0.649	rs79009	chr22:41860864	C/A	cg06481639	chr22:41940642	POLR3H	0.64	6.65	0.38	1.64e-10	Vitiligo;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16702713	chr5:118407037	DMXL1	0.54	6.74	0.38	9.6e-11	Gut microbiome composition (summer);
CESC	trans	rs634534	0.562	rs1151505	chr11:65734539	C/T	cg17712092	chr4:129076599	LARP1B	0.63	8.49	0.46	1.49e-15	Sum eosinophil basophil counts;Eosinophil counts;
CESC	cis	rs4654899	0.965	rs6692081	chr1:21296363	T/C	cg05370193	chr1:21551575	ECE1	0.39	5.9	0.34	1.12e-8	Superior frontal gyrus grey matter volume;
CESC	cis	rs9611565	0.729	rs12165508	chr22:41819960	T/C	cg06634786	chr22:41940651	POLR3H	0.45	5.33	0.31	2.08e-7	Vitiligo;
CESC	cis	rs7618915	0.524	rs35249778	chr3:52661640	G/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.3	5.38	0.31	1.66e-7	Bipolar disorder;
CESC	cis	rs9916302	0.861	rs8079590	chr17:37426201	T/C	cg15445000	chr17:37608096	MED1	0.4	6.45	0.37	5.35e-10	Glomerular filtration rate (creatinine);
CESC	trans	rs12356475	0.710	rs10822686	chr10:67733250	C/T	cg10735211	chr4:4310922	ZNF509	-0.51	-6.38	-0.36	7.92e-10	Psoriatic arthritis;
CESC	cis	rs7246657	0.943	rs1382357	chr19:37977609	G/A	cg23950597	chr19:37808831	NA	-0.58	-6.39	-0.37	7.52e-10	Coronary artery calcification;
CESC	cis	rs10479542	0.544	rs7706275	chr5:178990305	A/G	cg19723775	chr5:179050963	HNRNPH1	0.4	5.1	0.3	6.4e-7	Lung cancer;
CESC	cis	rs9300255	0.510	rs1790109	chr12:123637752	C/G	cg19016782	chr12:123741754	C12orf65	-0.4	-5.68	-0.33	3.46e-8	Neutrophil percentage of white cells;
CESC	cis	rs7084402	0.934	rs1649067	chr10:60305240	T/C	cg07615347	chr10:60278583	BICC1	0.59	9.33	0.5	4.35e-18	Refractive error;
CESC	trans	rs7937682	0.889	rs567859	chr11:111486738	A/G	cg18187862	chr3:45730750	SACM1L	0.48	6.01	0.35	6.26e-9	Primary sclerosing cholangitis;
CESC	cis	rs4819052	0.788	rs35323494	chr21:46703739	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.8	10.47	0.54	1.08e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs10504229	0.679	rs2317991	chr8:58035080	C/T	cg22535103	chr8:58192502	C8orf71	0.58	6.65	0.38	1.68e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs9788682	1.000	rs35212593	chr15:78831826	G/A	cg24631222	chr15:78858424	CHRNA5	0.81	10.53	0.54	6.79e-22	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs9905704	0.671	rs2068710	chr17:56594535	C/G	cg12560992	chr17:57184187	TRIM37	-0.63	-5.99	-0.35	6.89e-9	Testicular germ cell tumor;
CESC	trans	rs61931739	0.534	rs11053010	chr12:34093228	G/A	cg26384229	chr12:38710491	ALG10B	0.59	8.25	0.45	7.65e-15	Morning vs. evening chronotype;
CESC	cis	rs11122272	0.735	rs2491410	chr1:231532287	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.58	-8.05	-0.44	2.72e-14	Hemoglobin concentration;
CESC	cis	rs4722166	0.630	rs12700391	chr7:22777327	C/A	cg13104385	chr7:22767384	IL6	0.48	6.43	0.37	5.96e-10	Lung cancer;
CESC	cis	rs2735413	0.709	rs4395084	chr16:78088011	C/G	cg04733911	chr16:78082701	NA	-0.53	-8.44	-0.46	2.05e-15	Systolic blood pressure (alcohol consumption interaction);
CESC	cis	rs9399401	0.667	rs6922607	chr6:142703483	A/G	cg03128060	chr6:142623767	GPR126	0.37	6.56	0.37	2.73e-10	Chronic obstructive pulmonary disease;
CESC	cis	rs4642101	0.765	rs9872103	chr3:12827452	G/T	cg05775895	chr3:12838266	CAND2	0.38	5.69	0.33	3.31e-8	QRS complex (12-leadsum);
CESC	cis	rs28374715	0.578	rs7169543	chr15:41620405	T/C	cg20272979	chr15:41787780	ITPKA	0.47	5.57	0.32	6.19e-8	Ulcerative colitis;
CESC	cis	rs2404602	0.647	rs12440965	chr15:76958591	G/A	cg23625390	chr15:77176239	SCAPER	-0.39	-5.04	-0.3	8.6e-7	Blood metabolite levels;
CESC	cis	rs3008870	0.755	rs6657065	chr1:67384639	T/G	cg08660285	chr1:67390436	MIER1;WDR78	0.64	8.45	0.46	1.98e-15	Lymphocyte percentage of white cells;
CESC	cis	rs9913156	0.793	rs55677157	chr17:4576620	C/T	cg19197139	chr17:4613644	ARRB2	0.93	10.48	0.54	9.99e-22	Lymphocyte counts;
CESC	cis	rs372883	0.648	rs2832297	chr21:30742996	A/C	cg24692254	chr21:30365293	RNF160	0.48	6.06	0.35	4.68e-9	Pancreatic cancer;
CESC	cis	rs35306767	0.903	rs17159950	chr10:875287	T/G	cg10556349	chr10:835070	NA	0.63	5.98	0.34	7.25e-9	Eosinophil percentage of granulocytes;
CESC	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg07677032	chr17:61819896	STRADA	0.51	6.75	0.38	9.15e-11	Prudent dietary pattern;
CESC	trans	rs79976124	0.837	rs12194087	chr6:66644399	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.71	8.16	0.45	1.39e-14	Type 2 diabetes;
CESC	cis	rs6665290	0.904	rs2297416	chr1:227172935	C/G	cg10327440	chr1:227177885	CDC42BPA	-1.21	-28.92	-0.87	5.81e-84	Myeloid white cell count;
CESC	cis	rs7412746	0.611	rs2280627	chr1:150935872	A/G	cg17724175	chr1:150552817	MCL1	0.32	5.03	0.3	8.98e-7	Melanoma;
CESC	cis	rs6088590	0.965	rs6087639	chr20:33443866	G/A	cg24642439	chr20:33292090	TP53INP2	0.85	11.98	0.59	1.06e-26	Coronary artery disease;
CESC	cis	rs3771570	1.000	rs62193204	chr2:242315443	A/G	cg21155796	chr2:242212141	HDLBP	0.6	5.27	0.31	2.89e-7	Prostate cancer;
CESC	cis	rs2456568	0.570	rs1518579	chr11:93656821	A/G	cg26875233	chr11:93583750	C11orf90	-0.33	-5.87	-0.34	1.28e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
CESC	cis	rs8028182	0.636	rs10152155	chr15:75701554	A/T	cg20655648	chr15:75932815	IMP3	0.48	5.99	0.35	6.87e-9	Sudden cardiac arrest;
CESC	cis	rs7833790	0.700	rs7834483	chr8:82704828	A/G	cg17211192	chr8:82754475	SNX16	-0.61	-7.92	-0.44	6.75e-14	Diastolic blood pressure;
CESC	cis	rs7447927	0.950	rs13181561	chr5:138850905	A/G	cg26929925	chr5:138714136	SLC23A1	-0.42	-6.73	-0.38	1.04e-10	Esophageal squamous cell carcinoma;
CESC	cis	rs35110281	0.744	rs8131027	chr21:45104908	G/C	cg21573476	chr21:45109991	RRP1B	-0.43	-6.15	-0.35	2.84e-9	Mean corpuscular volume;
CESC	cis	rs11072804	1	rs11072804	chr15:79078486	T/G	cg04896959	chr15:78267971	NA	0.34	5.11	0.3	6.16e-7	Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs9393777	0.513	rs9368451	chr6:26654333	A/G	cg14345882	chr6:26364793	BTN3A2	0.41	5.12	0.3	5.79e-7	Intelligence (multi-trait analysis);
CESC	cis	rs7666738	0.830	rs11721726	chr4:98996314	T/C	cg03467027	chr4:99064603	C4orf37	0.44	5.51	0.32	8.65e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7552404	0.696	rs67487205	chr1:76373756	T/C	cg10523679	chr1:76189770	ACADM	0.64	6.1	0.35	3.73e-9	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs2404602	0.532	rs206205	chr15:76736091	T/G	cg00316803	chr15:76480434	C15orf27	-0.37	-5.73	-0.33	2.74e-8	Blood metabolite levels;
CESC	cis	rs8028182	0.501	rs11072553	chr15:75932777	C/T	cg20655648	chr15:75932815	IMP3	0.55	6.69	0.38	1.34e-10	Sudden cardiac arrest;
CESC	cis	rs367943	0.730	rs2914174	chr5:112978531	C/T	cg12552261	chr5:112820674	MCC	-0.46	-5.43	-0.32	1.27e-7	Type 2 diabetes;
CESC	cis	rs2412819	0.542	rs62018894	chr15:43912987	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.45	6.68	0.38	1.38e-10	Lung cancer;
CESC	cis	rs3820928	1.000	rs6752707	chr2:227766822	C/G	cg11843606	chr2:227700838	RHBDD1	-0.43	-5.71	-0.33	3.04e-8	Pulmonary function;
CESC	cis	rs2228479	0.850	rs2238532	chr16:89863672	T/C	cg14709524	chr16:89940631	TCF25	0.91	6.77	0.38	8.14e-11	Skin colour saturation;
CESC	cis	rs6089829	0.851	rs4809460	chr20:61661355	T/C	cg08564027	chr20:61660810	NA	0.9	15.36	0.69	1.69e-38	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs561341	0.843	rs2028067	chr17:30239698	T/C	cg13647721	chr17:30228624	UTP6	0.76	8.74	0.47	2.66e-16	Hip circumference adjusted for BMI;
CESC	cis	rs3820068	0.603	rs6429768	chr1:15963531	G/A	cg13390004	chr1:15929781	NA	0.37	5.9	0.34	1.11e-8	Systolic blood pressure;
CESC	cis	rs2249694	0.919	rs10857769	chr10:135405047	T/C	cg19469447	chr10:135341870	CYP2E1	0.36	5.06	0.3	7.96e-7	Obesity-related traits;
CESC	cis	rs7917772	0.502	rs2296584	chr10:104244323	T/A	cg22532475	chr10:104410764	TRIM8	-0.33	-5.65	-0.33	4.1e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs9910055	0.552	rs4793084	chr17:42317371	G/T	cg19774624	chr17:42201019	HDAC5	0.47	6.07	0.35	4.35e-9	Total body bone mineral density;
CESC	cis	rs2294693	0.947	rs4714417	chr6:40987782	A/G	cg14769373	chr6:40998127	UNC5CL	-0.48	-6.49	-0.37	4.16e-10	Gastric cancer;Non-cardia gastric cancer;
CESC	cis	rs6089829	0.926	rs1060491	chr20:61665817	C/A	cg16240275	chr20:61666158	NCRNA00029	-0.5	-8.58	-0.47	8.36e-16	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7589728	0.563	rs78685993	chr2:88447026	T/C	cg18490616	chr2:88469792	THNSL2	0.55	5.25	0.31	3.06e-7	Plasma clusterin levels;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg18789337	chr6:114180353	MARCKS	-0.45	-6.17	-0.35	2.59e-9	Height;
CESC	cis	rs10504229	0.683	rs11781690	chr8:58132931	C/G	cg24829409	chr8:58192753	C8orf71	-0.58	-7.2	-0.4	6.31e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs916888	0.821	rs70602	chr17:44859715	T/C	cg17911788	chr17:44343683	NA	0.53	7.06	0.4	1.46e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs1957429	0.520	rs72625647	chr14:65344106	T/C	cg23373153	chr14:65346875	NA	-0.84	-6.32	-0.36	1.13e-9	Pediatric areal bone mineral density (radius);
CESC	cis	rs9768139	0.733	rs71545585	chr7:158118672	G/A	cg25566285	chr7:158114605	PTPRN2	0.47	7.45	0.42	1.35e-12	Calcium levels;
CESC	cis	rs11677416	1.000	rs2071375	chr2:113535438	C/T	cg27083787	chr2:113543245	IL1A	0.6	7.49	0.42	1.01e-12	Response to antipsychotic treatment in schizophrenia (working memory);
CESC	cis	rs926938	0.584	rs1286561	chr1:115375428	T/C	cg12756093	chr1:115239321	AMPD1	-0.45	-6.13	-0.35	3.19e-9	Autism;
CESC	cis	rs875971	0.545	rs1796222	chr7:66057154	T/C	cg11764359	chr7:65958608	NA	-0.82	-9.47	-0.5	1.64e-18	Aortic root size;
CESC	trans	rs7902708	0.920	rs7095538	chr10:54425675	G/A	cg26219051	chr22:43739629	SCUBE1	-0.5	-6.34	-0.36	9.72e-10	Bone properties (heel);
CESC	cis	rs7666738	0.830	rs13108705	chr4:99044438	T/C	cg03467027	chr4:99064603	C4orf37	0.47	5.98	0.34	7.19e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4803468	1.000	rs10417997	chr19:41902361	G/A	cg14132834	chr19:41945861	ATP5SL	-0.57	-7.1	-0.4	1.13e-11	Height;
CESC	cis	rs1005277	0.579	rs2472174	chr10:38375382	A/G	cg00409905	chr10:38381863	ZNF37A	-0.45	-6.04	-0.35	5.25e-9	Extrinsic epigenetic age acceleration;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg00040446	chr1:40367965	MYCL1	-0.43	-6.28	-0.36	1.34e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg12038521	chr19:2111714	AP3D1	0.47	6.43	0.37	5.79e-10	Fibrinogen levels;
CESC	cis	rs7666738	0.830	rs10011009	chr4:98981749	G/A	cg18180107	chr4:99064573	C4orf37	0.39	5.13	0.3	5.6e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7072216	0.727	rs6584199	chr10:100169983	A/G	cg26618903	chr10:100175079	PYROXD2	-0.37	-5.76	-0.33	2.33e-8	Metabolite levels;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg18093619	chr15:28367157	HERC2	0.43	6.01	0.35	6.14e-9	Fibrinogen levels;
CESC	cis	rs4642101	0.765	rs1985428	chr3:12829315	A/G	cg05775895	chr3:12838266	CAND2	-0.35	-5.08	-0.3	7.19e-7	QRS complex (12-leadsum);
CESC	cis	rs7586879	0.681	rs6705446	chr2:25118608	T/C	cg01884057	chr2:25150051	NA	0.37	7.12	0.4	1.03e-11	Body mass index;
CESC	trans	rs1908814	0.516	rs10113042	chr8:11793178	A/G	cg15556689	chr8:8085844	FLJ10661	0.52	6.32	0.36	1.12e-9	Neuroticism;
CESC	cis	rs7551222	0.749	rs2887429	chr1:204565012	G/T	cg20240347	chr1:204465584	NA	-0.26	-5.39	-0.31	1.57e-7	Schizophrenia;
CESC	cis	rs7618501	0.521	rs11709573	chr3:49956628	C/T	cg24110177	chr3:50126178	RBM5	-0.52	-7.12	-0.4	1.04e-11	Intelligence (multi-trait analysis);
CESC	trans	rs1945213	0.694	rs34537090	chr11:55843285	G/C	cg15704280	chr7:45808275	SEPT13	0.69	6.68	0.38	1.4e-10	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs524281	0.861	rs2889313	chr11:65966066	G/C	cg14036092	chr11:66035641	RAB1B	-0.6	-6.1	-0.35	3.77e-9	Electroencephalogram traits;
CESC	cis	rs2997447	0.601	rs61776580	chr1:26432719	C/T	cg24596570	chr1:26146463	FAM54B;LOC646471	0.65	5.58	0.32	6.05e-8	QRS complex (12-leadsum);
CESC	cis	rs1862618	0.853	rs6450408	chr5:56098146	T/C	cg12311346	chr5:56204834	C5orf35	-0.73	-8.81	-0.48	1.71e-16	Initial pursuit acceleration;
CESC	cis	rs4835473	0.932	rs12509642	chr4:144658233	C/T	cg25736465	chr4:144833511	NA	-0.33	-5.2	-0.3	4.04e-7	Immature fraction of reticulocytes;
CESC	cis	rs62064224	0.509	rs2302276	chr17:30791503	C/T	cg18200150	chr17:30822561	MYO1D	0.43	5.55	0.32	6.81e-8	Schizophrenia;
CESC	cis	rs1008375	1.000	rs10032326	chr4:17630717	A/T	cg04450456	chr4:17643702	FAM184B	0.4	5.6	0.33	5.39e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs6584283	0.716	rs10786558	chr10:101287610	G/A	cg09788492	chr10:101292477	NKX2-3	0.32	5.89	0.34	1.15e-8	Ulcerative colitis;
CESC	cis	rs595982	0.559	rs17206700	chr19:49361255	A/G	cg15549821	chr19:49342101	PLEKHA4	-0.71	-8.12	-0.45	1.75e-14	Red cell distribution width;
CESC	cis	rs4665809	0.878	rs892448	chr2:26366205	A/G	cg27170947	chr2:26402098	FAM59B	-0.62	-7.53	-0.42	8.16e-13	Gut microbiome composition (summer);
CESC	cis	rs11997175	0.603	rs7462153	chr8:33814607	C/T	ch.8.33884649F	chr8:33765107	NA	0.49	5.9	0.34	1.09e-8	Body mass index;
CESC	cis	rs3858526	0.883	rs11039686	chr11:5948725	T/C	cg05234568	chr11:5960015	NA	-0.65	-7.71	-0.43	2.51e-13	DNA methylation (variation);
CESC	cis	rs9768139	0.708	rs896782	chr7:158114115	G/A	cg06219351	chr7:158114137	PTPRN2	-0.56	-8.97	-0.48	5.67e-17	Calcium levels;
CESC	cis	rs5769765	0.954	rs5769762	chr22:50264042	G/A	cg26441486	chr22:50317300	CRELD2	-0.39	-5.5	-0.32	8.72e-8	Schizophrenia;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg23475963	chr7:128379258	CALU	-0.42	-6.04	-0.35	5.15e-9	Gambling;
CESC	cis	rs1005277	0.579	rs1780136	chr10:38501453	A/G	cg25517755	chr10:38738941	LOC399744	-0.44	-5.7	-0.33	3.12e-8	Extrinsic epigenetic age acceleration;
CESC	cis	rs7772486	0.686	rs4896828	chr6:145953339	A/C	cg23711669	chr6:146136114	FBXO30	0.91	13.45	0.64	8.62e-32	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9457247	0.508	rs6902119	chr6:167505791	T/C	cg23791538	chr6:167370224	RNASET2	-0.45	-5.89	-0.34	1.2e-8	Crohn's disease;
CESC	cis	rs6582630	0.502	rs8186661	chr12:38380781	G/A	cg13010199	chr12:38710504	ALG10B	0.53	6.62	0.38	2.03e-10	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs73001065	0.818	rs12610191	chr19:19721976	C/T	cg03709012	chr19:19516395	GATAD2A	0.96	6.02	0.35	5.77e-9	LDL cholesterol;
CESC	cis	rs79057730	0.528	rs4719313	chr7:822501	C/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.84	7.22	0.41	5.45e-12	Initial pursuit acceleration;
CESC	cis	rs2790457	0.958	rs2772433	chr10:28895946	A/G	cg04045419	chr10:28823091	WAC	0.42	5.12	0.3	5.76e-7	Multiple myeloma;
CESC	cis	rs9287719	0.935	rs6751075	chr2:10723546	C/G	cg00105475	chr2:10696890	NA	0.39	5.69	0.33	3.35e-8	Prostate cancer;
CESC	cis	rs7959452	0.718	rs10878963	chr12:69717166	T/G	cg14784868	chr12:69753453	YEATS4	0.51	6.67	0.38	1.48e-10	Blood protein levels;
CESC	cis	rs9926296	0.585	rs6500441	chr16:89828669	C/G	cg07648498	chr16:89883185	FANCA	0.43	5.37	0.31	1.69e-7	Vitiligo;
CESC	cis	rs3820928	0.874	rs4461255	chr2:227846524	C/T	cg11843606	chr2:227700838	RHBDD1	0.47	6.03	0.35	5.45e-9	Pulmonary function;
CESC	cis	rs992157	0.710	rs12996912	chr2:219110555	A/G	cg00012203	chr2:219082015	ARPC2	0.86	12.48	0.61	2.02e-28	Colorectal cancer;
CESC	cis	rs4891159	0.790	rs17059325	chr18:74119567	A/C	cg24786174	chr18:74118243	ZNF516	-0.61	-8.4	-0.46	2.67e-15	Longevity;
CESC	cis	rs4969178	0.930	rs4580257	chr17:76403028	T/G	cg20026190	chr17:76395443	PGS1	0.46	7.13	0.4	9.46e-12	HDL cholesterol levels;
CESC	cis	rs950776	0.518	rs3813572	chr15:78832588	T/C	cg24631222	chr15:78858424	CHRNA5	-0.42	-5.33	-0.31	2.06e-7	Sudden cardiac arrest;
CESC	cis	rs116095464	0.558	rs28729548	chr5:229025	C/T	cg12570787	chr5:219185	SDHA;CCDC127	0.53	5.69	0.33	3.34e-8	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04318602	chr14:53162623	ERO1L	0.55	6.01	0.35	6.04e-9	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00892999	chr4:892055	GAK	-0.51	-6.38	-0.36	7.99e-10	Gut microbiome composition (summer);
CESC	cis	rs10857712	0.904	rs36118799	chr10:135222369	T/G	cg01444801	chr10:135216882	MTG1	-0.47	-5.61	-0.33	5.02e-8	Systemic lupus erythematosus;
CESC	cis	rs7640424	0.819	rs162070	chr3:107835448	G/A	cg09227934	chr3:107805635	CD47	0.48	6.07	0.35	4.4e-9	Body mass index;
CESC	cis	rs7580658	0.676	rs12465955	chr2:128007074	A/T	cg10021288	chr2:128175891	PROC	-0.37	-5.95	-0.34	8.36e-9	Protein C levels;
CESC	cis	rs2832077	0.527	rs2142375	chr21:30223742	G/A	cg24692254	chr21:30365293	RNF160	-0.66	-9.15	-0.49	1.56e-17	Cognitive test performance;
CESC	cis	rs7927771	0.965	rs4752881	chr11:47898535	A/G	cg20307385	chr11:47447363	PSMC3	-0.47	-5.63	-0.33	4.55e-8	Subjective well-being;
CESC	cis	rs11229555	0.645	rs7947248	chr11:58197750	C/T	cg15696309	chr11:58395628	NA	-0.42	-5.05	-0.3	8.13e-7	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs2710642	0.611	rs974345	chr2:62882774	C/T	cg17519650	chr2:63277830	OTX1	0.44	5.26	0.31	2.91e-7	LDL cholesterol levels;LDL cholesterol;
CESC	trans	rs208520	0.821	rs9363572	chr6:67012231	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.81	7.68	0.43	3.1400000000000003e-13	Exhaled nitric oxide output;
CESC	cis	rs7208859	0.623	rs11658945	chr17:29122509	T/C	cg14008862	chr17:28927542	LRRC37B2	0.65	5.14	0.3	5.34e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs11030122	0.645	rs11493482	chr11:4034772	A/G	cg18678763	chr11:4115507	RRM1	-0.49	-6.63	-0.38	1.91e-10	Mean platelet volume;Platelet distribution width;
CESC	cis	rs28374715	0.681	rs7165396	chr15:41586947	T/C	cg20272979	chr15:41787780	ITPKA	0.43	5.11	0.3	6.18e-7	Ulcerative colitis;
CESC	trans	rs12356475	0.710	rs10822686	chr10:67733250	C/T	cg19598685	chr12:109592525	ACACB	0.49	6.13	0.35	3.2e-9	Psoriatic arthritis;
CESC	trans	rs7944735	0.938	rs59185955	chr11:47961566	G/C	cg15704280	chr7:45808275	SEPT13	0.61	6.28	0.36	1.35e-9	Intraocular pressure;
CESC	cis	rs17601876	0.843	rs6493494	chr15:51549835	G/A	cg19946085	chr15:51559439	CYP19A1	-0.33	-5.15	-0.3	5.14e-7	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
CESC	cis	rs1707322	1.000	rs11211219	chr1:46359478	G/C	cg06784218	chr1:46089804	CCDC17	0.32	5.57	0.32	6.35e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs965469	0.947	rs7274193	chr20:3329750	C/T	cg25506879	chr20:3388711	C20orf194	-0.54	-5.78	-0.33	2.14e-8	IFN-related cytopenia;
CESC	cis	rs9916302	0.904	rs2061342	chr17:37405657	T/G	cg15445000	chr17:37608096	MED1	0.4	6.38	0.36	7.97e-10	Glomerular filtration rate (creatinine);
CESC	trans	rs1977584	0.725	rs76416597	chr10:45396081	A/G	cg09262100	chr14:103416268	CDC42BPB	0.61	6.14	0.35	3.02e-9	Selective IgA deficiency;
CESC	cis	rs7927771	0.931	rs12361256	chr11:47910823	A/C	cg20307385	chr11:47447363	PSMC3	-0.43	-5.49	-0.32	9.32e-8	Subjective well-being;
CESC	cis	rs7223966	1.000	rs2854223	chr17:61939014	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.47	-5.86	-0.34	1.34e-8	Hip circumference adjusted for BMI;Body mass index;
CESC	trans	rs6480314	0.522	rs10047355	chr10:70060078	C/T	cg04882175	chr6:131122610	NA	-0.65	-6.07	-0.35	4.31e-9	Optic nerve measurement (disc area);
CESC	cis	rs798554	0.610	rs2527696	chr7:2858315	T/C	cg13628971	chr7:2884303	GNA12	0.42	5.68	0.33	3.5e-8	Height;
CESC	cis	rs6121246	0.609	rs6060652	chr20:30266845	A/G	cg13852791	chr20:30311386	BCL2L1	0.75	9.61	0.51	6.08e-19	Mean corpuscular hemoglobin;
CESC	cis	rs10479542	0.892	rs7736163	chr5:178980316	G/C	cg19626725	chr5:178986131	RUFY1	0.39	6.37	0.36	8.51e-10	Lung cancer;
CESC	cis	rs3126085	0.825	rs10788830	chr1:152206898	A/C	cg03465714	chr1:152285911	FLG	-0.42	-5.07	-0.3	7.3e-7	Atopic dermatitis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08845439	chr1:151512945	TUFT1	0.54	6.14	0.35	2.96e-9	Gut microbiome composition (summer);
CESC	cis	rs4665809	1.000	rs4665819	chr2:26309073	A/G	cg26314531	chr2:26401878	FAM59B	-0.62	-7.07	-0.4	1.37e-11	Gut microbiome composition (summer);
CESC	cis	rs2249694	0.537	rs9418988	chr10:135327632	C/T	cg20169779	chr10:135381914	SYCE1	0.4	5.35	0.31	1.88e-7	Obesity-related traits;
CESC	cis	rs9549367	0.826	rs2287249	chr13:113889355	A/G	cg18105134	chr13:113819100	PROZ	-0.65	-7.73	-0.43	2.24e-13	Platelet distribution width;
CESC	trans	rs1814175	0.616	rs1794139	chr11:49910855	C/T	cg15704280	chr7:45808275	SEPT13	-1.01	-18.6	-0.75	5.48e-50	Height;
CESC	cis	rs1707322	0.963	rs1768815	chr1:46528603	G/A	cg05343316	chr1:45956843	TESK2	-0.43	-5.18	-0.3	4.37e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs713587	0.566	rs497567	chr2:25335089	G/A	cg01884057	chr2:25150051	NA	-0.3	-5.21	-0.3	3.89e-7	Body mass index in non-asthmatics;
CESC	cis	rs644799	1.000	rs623191	chr11:95548359	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.92	13.87	0.65	2.93e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs5763662	1.000	rs5753015	chr22:30517325	G/A	cg21388335	chr22:29999516	NF2	-0.79	-5.14	-0.3	5.3e-7	LDL cholesterol levels;LDL cholesterol;
CESC	cis	rs2072732	0.756	rs55949537	chr1:2936746	A/T	cg15211996	chr1:2936768	ACTRT2	0.34	5.51	0.32	8.71e-8	Plateletcrit;
CESC	cis	rs62064224	0.614	rs6505294	chr17:30687415	C/T	cg18200150	chr17:30822561	MYO1D	0.39	5.05	0.3	8.22e-7	Schizophrenia;
CESC	trans	rs2472476	0.900	rs10820722	chr9:107517680	G/T	cg14553338	chr2:66689807	MEIS1	0.42	6.09	0.35	3.95e-9	Obesity-related traits;
CESC	cis	rs9902453	0.967	rs55748380	chr17:28469782	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	8.01	0.44	3.58e-14	Coffee consumption (cups per day);
CESC	cis	rs7726839	0.555	rs4541696	chr5:581053	A/G	cg16447950	chr5:562315	NA	-0.47	-6.99	-0.39	2.26e-11	Obesity-related traits;
CESC	cis	rs6987853	0.563	rs2974301	chr8:42442238	A/G	cg09913449	chr8:42400586	C8orf40	0.32	5.03	0.3	8.93e-7	Mean corpuscular hemoglobin concentration;
CESC	cis	rs898097	0.812	rs56405605	chr17:80843663	T/C	cg20271620	chr17:80763330	TBCD	0.46	5.33	0.31	2.06e-7	Breast cancer;
CESC	cis	rs6987853	0.749	rs13250124	chr8:42404737	G/A	cg09913449	chr8:42400586	C8orf40	0.45	7.6	0.42	5.18e-13	Mean corpuscular hemoglobin concentration;
CESC	cis	rs2204008	0.775	rs3900361	chr12:38238936	A/G	cg13010199	chr12:38710504	ALG10B	-0.48	-5.91	-0.34	1.04e-8	Bladder cancer;
CESC	cis	rs863345	0.604	rs10797011	chr1:158465371	T/C	cg12129480	chr1:158549410	OR10X1	-0.35	-6.97	-0.39	2.46e-11	Pneumococcal bacteremia;
CESC	cis	rs684232	0.666	rs425961	chr17:573714	G/A	cg15660573	chr17:549704	VPS53	-0.64	-8.84	-0.48	1.35e-16	Prostate cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14838070	chr5:150030486	SYNPO	-0.54	-6.13	-0.35	3.25e-9	Gut microbiome composition (summer);
CESC	cis	rs6460942	0.659	rs17192500	chr7:12545379	A/G	cg20607287	chr7:12443886	VWDE	-0.72	-7.71	-0.43	2.51e-13	Coronary artery disease;
CESC	cis	rs13108904	0.935	rs922698	chr4:1282722	C/T	cg16405210	chr4:1374714	KIAA1530	0.45	5.59	0.32	5.7e-8	Obesity-related traits;
CESC	cis	rs11098499	0.954	rs3890049	chr4:120326283	T/A	cg24375607	chr4:120327624	NA	0.48	5.93	0.34	9.24e-9	Corneal astigmatism;
CESC	cis	rs7937682	0.924	rs7938360	chr11:111539875	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.99	-16.23	-0.71	1.37e-41	Primary sclerosing cholangitis;
CESC	cis	rs2228479	0.702	rs17233253	chr16:89828437	A/G	cg14709524	chr16:89940631	TCF25	0.91	6.75	0.38	9.26e-11	Skin colour saturation;
CESC	cis	rs7631605	0.905	rs60490177	chr3:37254925	G/C	cg22985146	chr3:37219077	LRRFIP2	-0.36	-5.75	-0.33	2.46e-8	Cerebrospinal P-tau181p levels;
CESC	cis	rs2072499	0.750	rs55675376	chr1:156165881	C/T	cg24450063	chr1:156163899	SLC25A44	0.97	12.22	0.6	1.54e-27	Testicular germ cell tumor;
CESC	cis	rs4665809	0.878	rs4143538	chr2:26290178	A/C	cg04944784	chr2:26401820	FAM59B	-0.79	-8.83	-0.48	1.42e-16	Gut microbiome composition (summer);
CESC	cis	rs4319547	0.695	rs1973463	chr12:122938003	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.51	-5.99	-0.35	6.95e-9	Body mass index;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05947499	chr12:113704091	TPCN1	-0.71	-7.93	-0.44	6.16e-14	Gut microbiome composition (summer);
CESC	cis	rs7605827	0.897	rs7590963	chr2:15527888	T/C	cg19274914	chr2:15703543	NA	0.35	6.27	0.36	1.43e-9	Educational attainment (years of education);
CESC	cis	rs941873	0.838	rs2233713	chr10:81107135	A/C	cg11057378	chr10:81107060	PPIF	0.37	5.87	0.34	1.31e-8	Height;
CESC	cis	rs12701220	0.553	rs34062359	chr7:1139076	C/T	cg26769984	chr7:1090371	C7orf50	0.61	6.31	0.36	1.17e-9	Bronchopulmonary dysplasia;
CESC	cis	rs9633740	0.773	rs1870148	chr10:82271341	G/A	cg00277334	chr10:82204260	NA	-0.55	-5.51	-0.32	8.63e-8	Post bronchodilator FEV1;
CESC	cis	rs2235642	0.601	rs2235647	chr16:1601331	C/A	cg03771183	chr16:1608904	IFT140	0.38	5.39	0.31	1.53e-7	Coronary artery disease;
CESC	cis	rs2991971	0.729	rs10890328	chr1:45905383	G/T	cg05343316	chr1:45956843	TESK2	0.59	8.52	0.46	1.23e-15	High light scatter reticulocyte count;
CESC	cis	rs7772486	0.754	rs9390356	chr6:146118983	A/T	cg05347473	chr6:146136440	FBXO30	-0.57	-7.34	-0.41	2.62e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs17376456	0.542	rs1453003	chr5:93151611	T/C	cg21475434	chr5:93447410	FAM172A	-0.5	-5.11	-0.3	6.26e-7	Diabetic retinopathy;
CESC	cis	rs6582630	0.519	rs11495376	chr12:38284957	A/C	cg26384229	chr12:38710491	ALG10B	0.7	10.34	0.54	2.92e-21	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs17253792	0.822	rs75763956	chr14:56071176	A/G	cg01858014	chr14:56050164	KTN1	-0.85	-6.99	-0.39	2.22e-11	Putamen volume;
CESC	cis	rs12541635	0.966	rs62525736	chr8:107000638	G/C	cg10147462	chr8:107024639	NA	0.41	5.68	0.33	3.6e-8	Age of smoking initiation;
CESC	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg18110333	chr6:292329	DUSP22	-0.75	-10.21	-0.53	7.28e-21	Menopause (age at onset);
CESC	cis	rs2836974	0.584	rs34436313	chr21:40685246	A/G	cg17971929	chr21:40555470	PSMG1	-0.88	-12.57	-0.61	9.49e-29	Cognitive function;
CESC	cis	rs28386778	0.769	rs6504179	chr17:61812995	T/G	cg07677032	chr17:61819896	STRADA	0.45	5.97	0.34	7.61e-9	Prudent dietary pattern;
CESC	cis	rs9811920	0.638	rs2452321	chr3:99638836	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.61	9.74	0.51	2.34e-19	Axial length;
CESC	cis	rs17384381	1.000	rs1608536	chr1:85885836	C/T	cg16011679	chr1:85725395	C1orf52	0.73	7.51	0.42	8.79e-13	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs3020736	0.500	rs7364293	chr22:42506370	C/T	cg15557168	chr22:42548783	NA	0.45	6.3	0.36	1.25e-9	Autism spectrum disorder or schizophrenia;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg24028381	chr8:145133668	EXOSC4	0.44	6.17	0.35	2.6e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs2658782	0.951	rs117384439	chr11:93111478	T/G	cg15737290	chr11:93063684	CCDC67	-0.52	-6.49	-0.37	4.29e-10	Pulmonary function decline;
CESC	cis	rs4819052	0.679	rs2838860	chr21:46684904	A/G	cg11663144	chr21:46675770	NA	-0.43	-6.55	-0.37	2.93e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs9303280	0.719	rs56750287	chr17:38062944	A/C	cg19468946	chr17:37922297	IKZF3	-0.4	-5.22	-0.31	3.64e-7	Self-reported allergy;
CESC	cis	rs1670533	1.000	rs13107058	chr4:1054379	G/A	cg27284194	chr4:1044797	NA	0.46	5.83	0.34	1.61e-8	Recombination rate (females);
CESC	cis	rs9322193	0.962	rs9322218	chr6:150103319	A/G	cg04369109	chr6:150039330	LATS1	-0.42	-5.95	-0.34	8.52e-9	Lung cancer;
CESC	cis	rs7927771	1.000	rs10838757	chr11:47763016	T/C	cg05585544	chr11:47624801	NA	-0.51	-7.99	-0.44	4.28e-14	Subjective well-being;
CESC	cis	rs965469	0.947	rs6037529	chr20:3261006	C/T	cg25506879	chr20:3388711	C20orf194	-0.57	-6.12	-0.35	3.26e-9	IFN-related cytopenia;
CESC	cis	rs11711311	1.000	rs13070720	chr3:113473754	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.59	7.78	0.43	1.58e-13	IgG glycosylation;
CESC	cis	rs7727544	0.684	rs2631363	chr5:131707095	A/G	cg07395648	chr5:131743802	NA	0.39	5.14	0.3	5.25e-7	Blood metabolite levels;
CESC	cis	rs7666738	0.753	rs10033138	chr4:98981922	A/C	cg17366294	chr4:99064904	C4orf37	0.59	8.57	0.47	8.46e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs15676	0.783	rs7033070	chr9:131586374	G/A	cg00228799	chr9:131580591	ENDOG	-0.54	-6.74	-0.38	9.81e-11	Blood metabolite levels;
CESC	cis	rs6693567	0.516	rs7554686	chr1:150265619	A/T	cg09579323	chr1:150459698	TARS2	-0.47	-6.02	-0.35	5.87e-9	Migraine;
CESC	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	23.37	0.82	2.54e-66	Prudent dietary pattern;
CESC	cis	rs10479542	0.721	rs6894113	chr5:178974789	G/C	cg19626725	chr5:178986131	RUFY1	0.33	5.05	0.3	8.35e-7	Lung cancer;
CESC	cis	rs6973256	0.637	rs12707116	chr7:133424909	C/T	cg10665199	chr7:133106180	EXOC4	-0.41	-5.66	-0.33	3.84e-8	Intelligence (multi-trait analysis);
CESC	cis	rs1008375	0.932	rs2302391	chr4:17660237	T/C	cg02297831	chr4:17616191	MED28	0.59	7.26	0.41	4.36e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs875971	0.522	rs781144	chr7:65440344	C/G	cg11987759	chr7:65425863	GUSB	-0.49	-6.43	-0.37	6.06e-10	Aortic root size;
CESC	cis	rs2439831	0.850	rs16977798	chr15:44151948	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.58	5.14	0.3	5.39e-7	Lung cancer in ever smokers;
CESC	cis	rs2836974	0.932	rs2234543	chr21:40572072	G/A	cg11890956	chr21:40555474	PSMG1	1.17	21.82	0.8	4.14e-61	Cognitive function;
CESC	cis	rs6032067	1.000	rs6017526	chr20:43871555	A/T	cg10761708	chr20:43804764	PI3	0.52	6.19	0.36	2.24e-9	Blood protein levels;
CESC	cis	rs6987853	0.830	rs4361746	chr8:42355041	C/T	cg09913449	chr8:42400586	C8orf40	-0.34	-5.3	-0.31	2.41e-7	Mean corpuscular hemoglobin concentration;
CESC	cis	rs7208859	0.673	rs9911989	chr17:29237702	A/C	cg19761014	chr17:28927070	LRRC37B2	-0.76	-5.92	-0.34	1.02e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs3858526	0.606	rs10838883	chr11:5952147	G/A	cg13902645	chr11:5959945	NA	0.74	10.62	0.55	3.41e-22	DNA methylation (variation);
CESC	cis	rs9486719	1.000	rs3798289	chr6:97023632	T/C	cg06623918	chr6:96969491	KIAA0776	-0.8	-8.28	-0.45	6.29e-15	Migraine;Coronary artery disease;
CESC	cis	rs6496667	1.000	rs6496669	chr15:90895265	A/G	cg22089800	chr15:90895588	ZNF774	-0.55	-5.27	-0.31	2.86e-7	Rheumatoid arthritis;
CESC	cis	rs6424115	0.830	rs2503002	chr1:24196957	C/G	cg15997130	chr1:24165203	NA	0.39	5.25	0.31	3.05e-7	Immature fraction of reticulocytes;
CESC	cis	rs4689592	0.546	rs2359012	chr4:7066053	A/C	cg06697600	chr4:7070879	GRPEL1	-0.48	-7.14	-0.4	9.16e-12	Monocyte percentage of white cells;
CESC	trans	rs12356475	0.710	rs10822686	chr10:67733250	C/T	cg11768411	chr8:144329279	ZFP41	0.52	6.06	0.35	4.55e-9	Psoriatic arthritis;
CESC	cis	rs28386778	0.799	rs12450683	chr17:61984299	C/G	cg07677032	chr17:61819896	STRADA	0.46	6.4	0.37	7.02e-10	Prudent dietary pattern;
CESC	cis	rs1862618	0.713	rs832550	chr5:56182589	C/T	cg12311346	chr5:56204834	C5orf35	-0.74	-8.81	-0.48	1.71e-16	Initial pursuit acceleration;
CESC	cis	rs1448094	0.534	rs11613070	chr12:86167544	T/A	cg02569458	chr12:86230093	RASSF9	0.57	8.27	0.45	6.76e-15	Major depressive disorder;
CESC	cis	rs2204008	0.659	rs4002655	chr12:38169881	T/G	cg13010199	chr12:38710504	ALG10B	0.52	6.6	0.38	2.18e-10	Bladder cancer;
CESC	trans	rs9929218	0.817	rs3114399	chr16:68713385	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.76	-8.59	-0.47	7.81e-16	Colorectal cancer;
CESC	cis	rs4853012	0.838	rs2177707	chr2:74356850	A/G	cg05776053	chr2:74358815	NA	0.43	5.07	0.3	7.45e-7	Gestational age at birth (maternal effect);
CESC	cis	rs11098499	0.874	rs6826823	chr4:120112098	G/C	cg09307838	chr4:120376055	NA	0.67	8.32	0.45	4.79e-15	Corneal astigmatism;
CESC	cis	rs72627509	0.951	rs6554401	chr4:57825336	C/G	cg26694713	chr4:57773883	REST	0.58	5.62	0.33	4.85e-8	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CESC	cis	rs9858542	1.000	rs11718165	chr3:49696797	A/G	cg07274523	chr3:49395745	GPX1	0.66	8.24	0.45	7.92e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs7666738	0.830	rs28887893	chr4:98963006	G/A	cg03676636	chr4:99064102	C4orf37	0.33	5.14	0.3	5.39e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7072216	0.763	rs10732782	chr10:100166506	C/A	cg26618903	chr10:100175079	PYROXD2	-0.36	-5.49	-0.32	9.42e-8	Metabolite levels;
CESC	cis	rs42648	0.869	rs6973816	chr7:89921072	C/T	cg23697855	chr7:89950296	NA	0.28	5.45	0.32	1.17e-7	Homocysteine levels;
CESC	cis	rs3743266	0.507	rs11637887	chr15:60765216	C/T	cg22293140	chr15:60689852	ANXA2	-0.7	-7.37	-0.41	2.12e-12	Menarche (age at onset);
CESC	cis	rs3806843	1.000	rs4151682	chr5:140201264	C/T	cg16179182	chr5:140090404	VTRNA1-1	-0.4	-5.15	-0.3	4.97e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs1552244	0.816	rs13059144	chr3:10010197	A/C	cg00166722	chr3:10149974	C3orf24	0.46	5.72	0.33	2.8e-8	Alzheimer's disease;
CESC	cis	rs7618915	0.571	rs34115864	chr3:52612178	A/G	cg07507251	chr3:52567010	NT5DC2	0.43	7.43	0.41	1.54e-12	Bipolar disorder;
CESC	cis	rs16948098	1	rs16948098	chr15:44219607	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.61	5.07	0.3	7.6e-7	Serum albumin level;
CESC	cis	rs853679	0.550	rs1233707	chr6:28172953	G/A	cg23161317	chr6:28129485	ZNF389	0.45	5.92	0.34	9.82e-9	Depression;
CESC	cis	rs3091242	0.867	rs602052	chr1:25722206	T/C	cg02931644	chr1:25747376	RHCE	0.39	6.44	0.37	5.7e-10	Erythrocyte sedimentation rate;
CESC	cis	rs1062177	0.756	rs2915815	chr5:151115883	G/C	cg00977110	chr5:151150581	G3BP1	-0.61	-6.36	-0.36	9e-10	Preschool internalizing problems;
CESC	trans	rs7937682	0.924	rs875258	chr11:111530607	C/A	cg18187862	chr3:45730750	SACM1L	0.48	6.08	0.35	4.15e-9	Primary sclerosing cholangitis;
CESC	cis	rs7851660	0.809	rs7036589	chr9:100657720	A/T	cg13688889	chr9:100608707	NA	0.63	8.84	0.48	1.4e-16	Strep throat;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04416821	chr6:43477544	C6orf154	0.58	6.1	0.35	3.71e-9	Gut microbiome composition (summer);
CESC	cis	rs478304	0.651	rs948493	chr11:65552154	C/T	cg10518572	chr11:65560635	OVOL1	-0.31	-5.76	-0.33	2.37e-8	Acne (severe);
CESC	cis	rs11997175	0.624	rs17701219	chr8:33728795	T/A	ch.8.33884649F	chr8:33765107	NA	0.56	7.32	0.41	3.02e-12	Body mass index;
CESC	cis	rs2243480	1.000	rs937108	chr7:65428452	G/A	cg12463550	chr7:65579703	CRCP	0.67	5.52	0.32	8.15e-8	Diabetic kidney disease;
CESC	cis	rs13108904	0.557	rs1680030	chr4:1245500	A/T	cg20887711	chr4:1340912	KIAA1530	-0.66	-8.85	-0.48	1.29e-16	Obesity-related traits;
CESC	cis	rs116095464	0.558	rs62346506	chr5:201594	T/C	cg16372103	chr5:203701	NA	0.51	5.7	0.33	3.12e-8	Breast cancer;
CESC	cis	rs1707322	1.000	rs785493	chr1:46584859	A/G	cg06784218	chr1:46089804	CCDC17	-0.36	-5.93	-0.34	9.35e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs4819052	0.851	rs9754134	chr21:46661751	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.91	13.24	0.63	4.51e-31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs858239	0.636	rs7808488	chr7:23221870	T/C	cg23682824	chr7:23144976	KLHL7	0.43	5.74	0.33	2.59e-8	Cerebrospinal fluid biomarker levels;
CESC	cis	rs2294693	0.786	rs10456497	chr6:40989057	T/C	cg14769373	chr6:40998127	UNC5CL	-0.44	-5.41	-0.32	1.44e-7	Gastric cancer;Non-cardia gastric cancer;
CESC	trans	rs7246760	1.000	rs28441975	chr19:9897631	C/A	cg02900749	chr2:68251473	NA	-0.74	-6.84	-0.39	5.62e-11	Pursuit maintenance gain;
CESC	cis	rs11997175	0.670	rs34985841	chr8:33661889	C/A	ch.8.33884649F	chr8:33765107	NA	0.68	8.78	0.47	2.13e-16	Body mass index;
CESC	cis	rs7586673	0.866	rs7579662	chr2:161915810	G/A	cg16506815	chr2:162101123	NA	0.43	5.8	0.34	1.86e-8	Intelligence (multi-trait analysis);
CESC	cis	rs9488822	0.636	rs1544155	chr6:116346394	C/A	cg15226275	chr6:116381976	FRK	0.26	6.48	0.37	4.43e-10	Cholesterol, total;LDL cholesterol;
CESC	cis	rs17102423	0.692	rs762810	chr14:65544367	C/A	cg11161011	chr14:65562177	MAX	-0.48	-5.38	-0.31	1.61e-7	Obesity-related traits;
CESC	cis	rs2806561	0.929	rs9426694	chr1:23539742	T/C	cg12483005	chr1:23474871	LUZP1	0.33	5.2	0.3	4.01e-7	Height;
CESC	cis	rs7267979	1.000	rs6050565	chr20:25347563	A/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.85	-17.91	-0.74	1.5e-47	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs8017423	1.000	rs4900028	chr14:90685594	C/T	cg14092571	chr14:90743983	NA	-0.58	-8.72	-0.47	3.19e-16	Mortality in heart failure;
CESC	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.44	0.37	5.5e-10	Prudent dietary pattern;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg01140579	chr3:48541502	SHISA5	-0.48	-6.52	-0.37	3.56e-10	Ulcerative colitis;
CESC	cis	rs921968	0.509	rs556468	chr2:219355794	G/A	cg02176678	chr2:219576539	TTLL4	0.5	8.98	0.48	5.22e-17	Mean corpuscular hemoglobin concentration;
CESC	cis	rs7267979	1.000	rs2482919	chr20:25299756	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.84	-16.08	-0.7	4.65e-41	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs9457247	0.967	rs2149092	chr6:167372978	C/T	cg25258033	chr6:167368657	RNASET2	-0.41	-6.2	-0.36	2.17e-9	Crohn's disease;
CESC	cis	rs7827545	1.000	rs1372662	chr8:135567046	C/G	cg17885191	chr8:135476712	NA	0.48	6.46	0.37	5.03e-10	Hypertension (SNP x SNP interaction);
CESC	cis	rs6691722	0.506	rs12030365	chr1:24739220	T/A	cg18323236	chr1:24743029	NIPAL3	0.48	7.36	0.41	2.3e-12	Response to interferon beta in multiple sclerosis;
CESC	cis	rs2836974	0.932	rs8128734	chr21:40569511	G/A	cg17971929	chr21:40555470	PSMG1	1.06	16.26	0.71	1.02e-41	Cognitive function;
CESC	cis	rs4555082	0.830	rs2255575	chr14:105727251	T/C	cg13114125	chr14:105738426	BRF1	-0.82	-10.21	-0.53	7.24e-21	Mean platelet volume;Platelet distribution width;
CESC	cis	rs10911251	0.528	rs10911248	chr1:183080564	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.87	13.96	0.65	1.41e-33	Colorectal cancer;
CESC	cis	rs9443189	0.950	rs6938349	chr6:76484280	A/T	cg01950844	chr6:76311363	SENP6	0.63	6.44	0.37	5.69e-10	Prostate cancer;
CESC	cis	rs17376456	0.877	rs7734897	chr5:93305402	G/A	cg25358565	chr5:93447407	FAM172A	1.07	10.7	0.55	1.86e-22	Diabetic retinopathy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07755343	chr16:1712697	CRAMP1L	-0.57	-6.79	-0.38	7.3e-11	Gut microbiome composition (summer);
CESC	cis	rs736408	0.609	rs13087772	chr3:52782274	T/G	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.38	6.56	0.37	2.76e-10	Bipolar disorder;
CESC	cis	rs473651	0.935	rs482775	chr2:239335403	G/C	cg21699342	chr2:239360505	ASB1	0.54	9.26	0.49	7.3e-18	Multiple system atrophy;
CESC	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg11494091	chr17:61959527	GH2	0.72	12.38	0.61	4.46e-28	Prudent dietary pattern;
CESC	trans	rs72766638	0.848	rs11789898	chr9:136925663	A/C	cg10765909	chr12:53715428	AAAS	0.6	6.06	0.35	4.62e-9	Mosquito bite size;
CESC	cis	rs7208859	0.623	rs73267858	chr17:29059737	A/G	cg14008862	chr17:28927542	LRRC37B2	0.65	5.12	0.3	5.86e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs7178572	0.889	rs7170877	chr15:77832019	C/G	cg22256960	chr15:77711686	NA	-0.52	-7.12	-0.4	9.94e-12	Type 2 diabetes;
CESC	cis	rs36051895	0.659	rs62541539	chr9:5038180	C/T	cg02405213	chr9:5042618	JAK2	-0.48	-5.77	-0.33	2.2e-8	Pediatric autoimmune diseases;
CESC	trans	rs11039798	0.591	rs74992349	chr11:49019252	G/A	cg15704280	chr7:45808275	SEPT13	0.67	6.71	0.38	1.16e-10	Axial length;
CESC	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.64	7.45	0.42	1.33e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7666738	0.753	rs13122897	chr4:98936185	C/A	cg05340658	chr4:99064831	C4orf37	0.82	12.54	0.61	1.29e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11958404	0.615	rs6556333	chr5:157445659	T/C	cg05962755	chr5:157440814	NA	0.38	5.67	0.33	3.75e-8	IgG glycosylation;
CESC	cis	rs7243790	0.805	rs62091574	chr18:51939063	C/A	cg04730925	chr18:51795821	POLI	-0.43	-5.75	-0.33	2.4e-8	Diastolic blood pressure;
CESC	cis	rs3782089	0.546	rs76146604	chr11:65277512	G/T	cg21890820	chr11:65308645	LTBP3	1.12	8.53	0.46	1.13e-15	Height;
CESC	cis	rs9303401	0.659	rs17741087	chr17:56550300	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.99	12.3	0.6	8.24e-28	Cognitive test performance;
CESC	trans	rs35110281	0.748	rs162403	chr21:44963365	C/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.56	7.37	0.41	2.13e-12	Mean corpuscular volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02678462	chr19:5154735	NA	-0.64	-7.27	-0.41	4.1e-12	Gut microbiome composition (summer);
CESC	cis	rs9308731	0.623	rs11674517	chr2:111903832	C/T	cg04202892	chr2:111875749	ACOXL	0.44	6.15	0.35	2.92e-9	Chronic lymphocytic leukemia;
CESC	cis	rs8031584	0.505	rs2959036	chr15:31219742	T/G	cg14829155	chr15:31115871	NA	0.74	10.59	0.55	4.45e-22	Huntington's disease progression;
CESC	cis	rs7959452	0.535	rs7133487	chr12:69774377	G/A	cg20891283	chr12:69753455	YEATS4	0.9	15.06	0.68	1.92e-37	Blood protein levels;
CESC	cis	rs6736093	0.932	rs7595212	chr2:112662767	A/G	cg12686935	chr2:112915763	FBLN7	-0.42	-5.17	-0.3	4.56e-7	Coronary artery disease;
CESC	trans	rs6089829	0.962	rs6122347	chr20:61661866	C/T	cg23505145	chr19:12996616	KLF1	0.52	6.74	0.38	1e-10	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7089973	0.604	rs11196939	chr10:116593175	A/G	cg25233709	chr10:116636983	FAM160B1	-0.36	-5.6	-0.33	5.42e-8	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs96067	0.805	rs3767705	chr1:36602044	A/T	cg24686825	chr1:36642396	MAP7D1	-0.46	-5.38	-0.31	1.63e-7	Corneal structure;
CESC	cis	rs3096299	0.933	rs28608022	chr16:89454292	C/T	cg16743903	chr16:89593216	SPG7	-0.42	-5.32	-0.31	2.19e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs11122272	0.735	rs2749707	chr1:231527316	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.56	-7.7	-0.43	2.63e-13	Hemoglobin concentration;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg23819836	chr6:15663134	DTNBP1	-0.43	-6.19	-0.36	2.23e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs3733585	0.598	rs28677023	chr4:9958326	C/A	cg02734326	chr4:10020555	SLC2A9	-0.43	-6.01	-0.35	6.1e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08543242	chr3:45017843	ZDHHC3;EXOSC7	0.57	6.68	0.38	1.41e-10	Gut microbiome composition (summer);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg03369668	chr7:2578307	C7orf27	0.47	6.52	0.37	3.52e-10	Fibrinogen levels;
CESC	cis	rs2522056	1.000	rs2706379	chr5:131805735	C/T	cg24060327	chr5:131705240	SLC22A5	0.61	6.93	0.39	3.22e-11	Lymphocyte counts;Fibrinogen;
CESC	cis	rs10911251	0.528	rs6669199	chr1:183082421	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.87	14.12	0.66	3.98e-34	Colorectal cancer;
CESC	cis	rs7811142	0.830	rs78256546	chr7:99952970	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.87	8.33	0.46	4.25e-15	Platelet count;
CESC	cis	rs597539	0.652	rs1249474	chr11:68654774	C/T	cg06028808	chr11:68637592	NA	0.4	5.06	0.3	7.67e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs7666738	0.791	rs11729596	chr4:99045461	A/G	cg18180107	chr4:99064573	C4orf37	0.41	5.29	0.31	2.51e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1499614	0.901	rs3936	chr7:66126489	C/T	cg12463550	chr7:65579703	CRCP	0.74	5.71	0.33	3.03e-8	Gout;
CESC	cis	rs9649213	0.593	rs12704989	chr7:98029438	G/T	cg00277769	chr7:97922759	BAIAP2L1	-0.31	-5.14	-0.3	5.46e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs2832191	0.791	rs2832187	chr21:30485543	T/C	cg08807101	chr21:30365312	RNF160	-0.77	-11.23	-0.57	3.52e-24	Dental caries;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13319975	chr6:146136371	FBXO30	0.58	7.03	0.4	1.79e-11	Gut microbiome composition (summer);
CESC	cis	rs853679	0.517	rs9368556	chr6:28131153	T/C	cg23281280	chr6:28129359	ZNF389	0.59	7.9	0.44	7.47e-14	Depression;
CESC	cis	rs9858542	1.000	rs9822268	chr3:49719729	G/A	cg07274523	chr3:49395745	GPX1	0.67	8.65	0.47	5.08e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs9457247	0.967	rs1590257	chr6:167377782	G/T	cg07741184	chr6:167504864	NA	-0.3	-5.38	-0.31	1.62e-7	Crohn's disease;
CESC	cis	rs722599	0.748	rs1059326	chr14:75369385	C/T	cg08847533	chr14:75593920	NEK9	-0.47	-5.62	-0.33	4.89e-8	IgG glycosylation;
CESC	cis	rs6831352	0.703	rs2602862	chr4:100033221	A/G	cg12011299	chr4:100065546	ADH4	0.57	6.88	0.39	4.34e-11	Alcohol dependence;
CESC	cis	rs72781680	0.898	rs17509001	chr2:24021231	T/C	cg08917208	chr2:24149416	ATAD2B	0.95	8.71	0.47	3.45e-16	Lymphocyte counts;
CESC	cis	rs17039065	0.920	rs58451659	chr4:109446003	T/C	cg16022748	chr4:109541635	LOC285456;RPL34	0.62	5.61	0.33	5.08e-8	Gut microbiome composition (summer);
CESC	cis	rs6724607	0.905	rs10173771	chr2:191439248	T/C	cg27211696	chr2:191398769	TMEM194B	0.52	7.62	0.42	4.53e-13	Pulse pressure;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg00081019	chr1:243658800	SDCCAG8;AKT3	0.51	7.02	0.4	1.82e-11	Fibrinogen levels;
CESC	trans	rs7335046	1.000	rs3759444	chr13:99910263	C/T	cg14259717	chr11:18433732	LDHC	0.6	6.05	0.35	4.97e-9	Basal cell carcinoma;
CESC	cis	rs1348850	0.526	rs1345138	chr2:178387100	A/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.69	6.19	0.36	2.22e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs963731	0.522	rs297148	chr2:39323166	A/G	cg04010122	chr2:39346883	SOS1	-0.74	-5.39	-0.31	1.54e-7	Corticobasal degeneration;
CESC	cis	rs1448094	0.512	rs1349063	chr12:86264237	C/T	cg00310523	chr12:86230176	RASSF9	0.33	5.18	0.3	4.47e-7	Major depressive disorder;
CESC	cis	rs9902453	0.765	rs2729440	chr17:28106874	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-10.34	-0.54	2.82e-21	Coffee consumption (cups per day);
CESC	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.12	11.36	0.57	1.25e-24	Platelet count;
CESC	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg26338869	chr17:61819248	STRADA	0.69	9.11	0.49	2.04e-17	Prudent dietary pattern;
CESC	cis	rs1461503	0.966	rs10790547	chr11:122842110	T/A	cg27398637	chr11:122830231	C11orf63	-0.55	-8.23	-0.45	8.8e-15	Menarche (age at onset);
CESC	cis	rs1707322	1.000	rs11211219	chr1:46359478	G/C	cg03146154	chr1:46216737	IPP	0.71	9.86	0.52	9.69e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9815354	0.812	rs111277902	chr3:41950312	C/T	cg03022575	chr3:42003672	ULK4	0.68	5.92	0.34	9.9e-9	Pulse pressure;Diastolic blood pressure;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21956150	chr19:1438388	RPS15	0.56	6.87	0.39	4.65e-11	Gut microbiome composition (summer);
CESC	cis	rs4664304	0.772	rs17830558	chr2:160878364	A/C	cg03641300	chr2:160917029	PLA2R1	-0.47	-6.63	-0.38	1.83e-10	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs35110281	0.782	rs2051407	chr21:45079245	T/C	cg01579765	chr21:45077557	HSF2BP	-0.56	-9.31	-0.5	4.98e-18	Mean corpuscular volume;
CESC	cis	rs1707322	1.000	rs10890372	chr1:46391020	T/G	cg06784218	chr1:46089804	CCDC17	0.33	5.63	0.33	4.7e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg13565492	chr6:43139072	SRF	-0.74	-9.0	-0.48	4.53e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs12190007	1.000	rs12211973	chr6:169727141	T/C	cg16388071	chr6:169726476	NA	-0.42	-5.71	-0.33	2.99e-8	Obesity-related traits;
CESC	cis	rs763121	0.853	rs9610993	chr22:39042818	C/A	cg21395723	chr22:39101663	GTPBP1	0.43	5.33	0.31	2.09e-7	Menopause (age at onset);
CESC	cis	rs36051895	0.632	rs10118789	chr9:5141178	G/A	cg02405213	chr9:5042618	JAK2	-0.51	-6.12	-0.35	3.36e-9	Pediatric autoimmune diseases;
CESC	cis	rs72772090	0.539	rs10515248	chr5:96112005	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.6	-5.05	-0.3	8.29e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs12824058	0.831	rs11060826	chr12:130809931	G/C	cg26677194	chr12:130822605	PIWIL1	0.52	6.81	0.39	6.58e-11	Menopause (age at onset);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg21403912	chr1:155239301	CLK2	0.44	6.11	0.35	3.47e-9	Fibrinogen levels;
CESC	trans	rs17428076	0.831	rs55957712	chr2:172587956	C/T	cg16863673	chr2:240905040	NDUFA10	0.54	6.13	0.35	3.15e-9	Myopia;
CESC	cis	rs9858542	0.953	rs6809216	chr3:49412559	G/A	cg03060546	chr3:49711283	APEH	-0.54	-6.16	-0.35	2.67e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs34779708	0.966	rs12769484	chr10:35465746	G/A	cg04310649	chr10:35416472	CREM	-0.53	-6.49	-0.37	4.32e-10	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs644799	0.965	rs602512	chr11:95561682	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	9.13	0.49	1.83e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs9457247	1.000	rs444988	chr6:167389674	A/T	cg07741184	chr6:167504864	NA	0.3	5.52	0.32	8.14e-8	Crohn's disease;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg00894870	chr1:19578612	MRTO4;KIAA0090	0.51	6.88	0.39	4.3e-11	Systemic lupus erythematosus;
CESC	cis	rs16854884	0.657	rs35309714	chr3:143735011	T/A	cg06585982	chr3:143692056	C3orf58	0.5	6.56	0.37	2.84e-10	Economic and political preferences (feminism/equality);
CESC	cis	rs12618769	0.656	rs3820943	chr2:99123177	G/C	cg10123293	chr2:99228465	UNC50	0.39	5.13	0.3	5.6e-7	Bipolar disorder;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg06156157	chr1:47799348	CMPK1	0.51	6.64	0.38	1.8e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs7605827	0.930	rs7593184	chr2:15598461	T/G	cg19274914	chr2:15703543	NA	0.33	5.82	0.34	1.73e-8	Educational attainment (years of education);
CESC	cis	rs965469	0.652	rs4507156	chr20:3228460	A/G	cg25506879	chr20:3388711	C20orf194	0.54	6.28	0.36	1.37e-9	IFN-related cytopenia;
CESC	cis	rs9322193	0.962	rs17673294	chr6:150134993	G/A	cg05861140	chr6:150128134	PCMT1	-0.37	-5.33	-0.31	2.13e-7	Lung cancer;
CESC	cis	rs1178121	0.517	rs12540265	chr7:18830464	A/G	cg12955305	chr7:19759345	TMEM196	-0.41	-5.05	-0.3	8.38e-7	Systemic juvenile idiopathic arthritis;
CESC	cis	rs9733	0.818	rs11204702	chr1:150663507	C/A	cg18016565	chr1:150552671	MCL1	-0.36	-5.98	-0.34	7.07e-9	Tonsillectomy;
CESC	cis	rs1348850	0.632	rs12616288	chr2:178503813	G/T	cg22681709	chr2:178499509	PDE11A	-0.56	-8.6	-0.47	7.16e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs7408868	0.831	rs11672004	chr19:15277282	T/A	cg14696996	chr19:15285081	NOTCH3	0.85	9.39	0.5	2.95e-18	Pulse pressure;
CESC	cis	rs2742234	0.541	rs11238476	chr10:43711436	G/T	cg15436174	chr10:43711423	RASGEF1A	0.47	5.53	0.32	7.48e-8	Hirschsprung disease;
CESC	trans	rs17685	0.753	rs4398845	chr7:75716781	G/A	cg19862616	chr7:65841803	NCRNA00174	0.84	12.06	0.6	5.65e-27	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs910316	0.737	rs175071	chr14:75498177	A/G	cg11812906	chr14:75593930	NEK9	-0.8	-13.09	-0.63	1.5e-30	Height;
CESC	cis	rs7312933	0.703	rs2406567	chr12:42551479	G/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.47	6.17	0.35	2.48e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs2549003	0.933	rs3846731	chr5:131814264	T/C	cg02551604	chr5:131831745	NA	-0.36	-5.08	-0.3	7.22e-7	Asthma (sex interaction);
CESC	cis	rs11658309	1	rs11658309	chr17:17762247	T/G	cg04398451	chr17:18023971	MYO15A	0.64	9.39	0.5	2.84e-18	Strep throat;
CESC	trans	rs1814175	0.647	rs61306292	chr11:49856040	G/C	cg15704280	chr7:45808275	SEPT13	-1.04	-21.01	-0.79	2.32e-58	Height;
CESC	cis	rs2033711	0.870	rs11084545	chr19:58951693	G/C	cg26874164	chr19:58962979	ZNF324B	0.59	8.24	0.45	8.08e-15	Uric acid clearance;
CESC	cis	rs7666738	0.962	rs4699596	chr4:99012924	C/T	cg17366294	chr4:99064904	C4orf37	0.56	7.57	0.42	6.31e-13	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6460942	0.915	rs1595802	chr7:12439672	C/T	cg02935154	chr7:12443704	VWDE	-0.61	-6.93	-0.39	3.11e-11	Coronary artery disease;
CESC	cis	rs12986413	0.967	rs2108524	chr19:2170764	A/G	cg09261902	chr19:2140048	AP3D1	0.32	5.08	0.3	7.19e-7	Height;
CESC	trans	rs11621135	0.594	rs8023180	chr14:71683412	C/T	cg19986472	chr17:41561315	DHX8	-0.45	-6.02	-0.35	5.95e-9	Hair greying;
CESC	cis	rs2635047	0.638	rs12953864	chr18:44625245	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.41	5.56	0.32	6.6e-8	Educational attainment;
CESC	cis	rs155076	0.666	rs9509640	chr13:21872880	T/C	cg06138931	chr13:21896616	NA	0.5	5.16	0.3	4.84e-7	White matter hyperintensity burden;
CESC	cis	rs6580649	0.941	rs4760614	chr12:48427884	A/G	cg24011408	chr12:48396354	COL2A1	-0.41	-5.2	-0.3	3.93e-7	Lung cancer;
CESC	cis	rs863345	0.967	rs863357	chr1:158544253	C/G	cg12129480	chr1:158549410	OR10X1	-0.32	-6.46	-0.37	5.08e-10	Pneumococcal bacteremia;
CESC	cis	rs6594499	0.872	rs1379298	chr5:110435726	T/C	cg04022379	chr5:110408740	TSLP	0.33	5.9	0.34	1.11e-8	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs2070677	0.935	rs12255182	chr10:135404096	G/A	cg20169779	chr10:135381914	SYCE1	-0.77	-9.97	-0.52	4.29e-20	Gout;
CESC	cis	rs172166	0.694	rs203884	chr6:28077374	G/T	cg12963246	chr6:28129442	ZNF389	0.42	5.86	0.34	1.34e-8	Cardiac Troponin-T levels;
CESC	cis	rs637571	0.522	rs556643	chr11:65733289	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.71	10.13	0.53	1.31e-20	Eosinophil percentage of white cells;
CESC	cis	rs1862618	0.853	rs1423620	chr5:56100996	G/T	cg22800045	chr5:56110881	MAP3K1	0.68	8.5	0.46	1.44e-15	Initial pursuit acceleration;
CESC	cis	rs6089829	0.962	rs6122347	chr20:61661866	C/T	cg16240275	chr20:61666158	NCRNA00029	0.5	8.97	0.48	5.67e-17	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs8017423	0.647	rs12882973	chr14:90820502	G/A	cg14092571	chr14:90743983	NA	0.43	6.55	0.37	2.91e-10	Mortality in heart failure;
CESC	cis	rs1552244	1.000	rs6789156	chr3:10124120	C/T	cg00166722	chr3:10149974	C3orf24	0.53	6.52	0.37	3.49e-10	Alzheimer's disease;
CESC	cis	rs6570726	0.935	rs7757387	chr6:145816726	G/T	cg23711669	chr6:146136114	FBXO30	0.77	11.32	0.57	1.74e-24	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs826838	0.967	rs7136593	chr12:39128265	C/T	cg26384229	chr12:38710491	ALG10B	-0.67	-11.01	-0.56	1.82e-23	Heart rate;
CESC	cis	rs11864453	0.826	rs9941087	chr16:72118324	G/A	cg16558253	chr16:72132732	DHX38	-0.56	-8.57	-0.47	8.5e-16	Fibrinogen levels;
CESC	cis	rs116095464	0.558	rs6878061	chr5:223072	A/G	cg10591111	chr5:226296	SDHA	-0.51	-6.35	-0.36	9.22e-10	Breast cancer;
CESC	cis	rs3750965	0.959	rs3168115	chr11:68858090	A/T	cg01403660	chr11:68851641	TPCN2	-0.39	-5.29	-0.31	2.6e-7	Hair color;
CESC	cis	rs12121840	0.790	rs7533908	chr1:165519700	T/C	cg16553119	chr1:165599451	MGST3	-0.46	-5.22	-0.31	3.69e-7	Interleukin-1-receptor antagonist levels;
CESC	trans	rs208520	0.909	rs62414636	chr6:67015723	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.81	7.68	0.43	3.1400000000000003e-13	Exhaled nitric oxide output;
CESC	cis	rs1775715	0.737	rs2799000	chr10:32124894	C/T	cg18675610	chr10:32216311	ARHGAP12	0.34	5.23	0.31	3.36e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs6977955	0.838	rs2189966	chr7:28172066	C/T	cg23620719	chr7:28220237	JAZF1	-0.5	-5.51	-0.32	8.61e-8	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs7772486	0.754	rs6932863	chr6:146021255	A/T	cg23711669	chr6:146136114	FBXO30	-1.04	-15.13	-0.68	1.04e-37	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs61931739	0.500	rs11053193	chr12:34438838	G/T	cg26384229	chr12:38710491	ALG10B	0.69	10.44	0.54	1.39e-21	Morning vs. evening chronotype;
CESC	cis	rs1552244	0.554	rs3732963	chr3:10048885	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.56	-7.27	-0.41	4.1e-12	Alzheimer's disease;
CESC	cis	rs7618915	0.547	rs68021750	chr3:52624769	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.48	6.8	0.39	6.78e-11	Bipolar disorder;
CESC	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg23978390	chr7:1156363	C7orf50	0.58	8.0	0.44	3.89e-14	Longevity;Endometriosis;
CESC	cis	rs7246865	0.510	rs2305752	chr19:17186127	A/C	cg16202187	chr19:17186497	HAUS8;MYO9B	0.5	6.39	0.37	7.49e-10	Reticulocyte fraction of red cells;
CESC	cis	rs4727027	0.704	rs12704073	chr7:148905067	G/A	cg23583168	chr7:148888333	NA	-0.93	-16.64	-0.71	4.58e-43	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs7618915	0.501	rs3774366	chr3:52641255	T/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.36	6.43	0.37	5.96e-10	Bipolar disorder;
CESC	cis	rs1256061	0.624	rs944047	chr14:64700292	C/T	cg23250157	chr14:64679961	SYNE2	0.52	7.38	0.41	2.1e-12	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs2247341	1.000	rs8051	chr4:1694809	C/T	cg07465881	chr4:1713556	SLBP	0.52	6.52	0.37	3.47e-10	Hip circumference adjusted for BMI;Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09859416	chr12:34262100	NA	-0.54	-6.1	-0.35	3.69e-9	Gut microbiome composition (summer);
CESC	cis	rs9303401	0.573	rs34097494	chr17:57171917	C/T	cg25039879	chr17:56429692	SUPT4H1	0.5	5.29	0.31	2.58e-7	Cognitive test performance;
CESC	cis	rs7618915	0.501	rs12635140	chr3:52738165	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	-0.38	-6.82	-0.39	6.12e-11	Bipolar disorder;
CESC	cis	rs4808199	0.948	rs757000	chr19:19448301	A/G	cg03709012	chr19:19516395	GATAD2A	1.14	12.23	0.6	1.49e-27	Nonalcoholic fatty liver disease;
CESC	trans	rs1814175	0.566	rs1811673	chr11:49602134	A/G	cg03929089	chr4:120376271	NA	-0.75	-8.56	-0.47	9.04e-16	Height;
CESC	cis	rs7552404	0.924	rs2275378	chr1:76198436	T/C	cg03433033	chr1:76189801	ACADM	0.74	10.37	0.54	2.21e-21	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs12995491	0.763	rs1914735	chr2:88511953	A/T	cg18490616	chr2:88469792	THNSL2	-0.53	-7.93	-0.44	6.03e-14	Response to metformin (IC50);
CESC	cis	rs3820928	0.874	rs4675131	chr2:227836742	T/G	cg05526886	chr2:227700861	RHBDD1	-0.44	-5.53	-0.32	7.61e-8	Pulmonary function;
CESC	cis	rs853679	0.517	rs35512245	chr6:28079953	T/C	cg22143856	chr6:28129313	ZNF389	0.52	6.71	0.38	1.21e-10	Depression;
CESC	cis	rs11638352	1.000	rs7166715	chr15:44417606	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.61	-5.62	-0.33	4.75e-8	Lipoprotein phospholipase A2 activity in cardiovascular disease;
CESC	cis	rs651907	0.557	rs11924013	chr3:101366698	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.51	6.89	0.39	4.12e-11	Colorectal cancer;
CESC	cis	rs950776	0.518	rs12910978	chr15:78810017	A/G	cg24631222	chr15:78858424	CHRNA5	-0.4	-5.09	-0.3	6.79e-7	Sudden cardiac arrest;
CESC	cis	rs798554	0.616	rs1636251	chr7:2884720	T/C	cg13628971	chr7:2884303	GNA12	0.46	6.23	0.36	1.87e-9	Height;
CESC	cis	rs780096	0.546	rs1528533	chr2:27595756	G/C	cg12648201	chr2:27665141	KRTCAP3	-0.35	-6.7	-0.38	1.24e-10	Total body bone mineral density;
CESC	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg14926445	chr8:58193284	C8orf71	-0.54	-5.18	-0.3	4.5e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs796364	0.756	rs2949006	chr2:200715388	T/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.83	7.86	0.43	9.64e-14	Schizophrenia;
CESC	cis	rs6500395	0.962	rs11648101	chr16:48714178	C/T	cg04672837	chr16:48644449	N4BP1	0.46	5.27	0.31	2.77e-7	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs57709857	0.957	rs11989357	chr8:38194561	C/G	cg01506891	chr8:38243824	LETM2	0.45	5.05	0.3	8.39e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs4665809	0.590	rs62128455	chr2:26466530	G/A	cg27170947	chr2:26402098	FAM59B	0.87	9.89	0.52	7.6e-20	Gut microbiome composition (summer);
CESC	cis	rs2014572	0.901	rs35658377	chr19:57755627	T/G	cg24459738	chr19:57751996	ZNF805	-0.54	-7.76	-0.43	1.84e-13	Hyperactive-impulsive symptoms;
CESC	cis	rs13118159	0.714	rs6843025	chr4:1334418	C/G	cg00684032	chr4:1343700	KIAA1530	0.36	5.56	0.32	6.59e-8	Longevity;
CESC	cis	rs10883723	0.775	rs7917158	chr10:104246471	C/A	cg22532475	chr10:104410764	TRIM8	-0.33	-5.68	-0.33	3.59e-8	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs9815354	0.597	rs73073281	chr3:42026366	C/T	cg03022575	chr3:42003672	ULK4	0.75	6.64	0.38	1.72e-10	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs3096299	0.679	rs3096322	chr16:89441123	A/G	cg08822215	chr16:89438651	ANKRD11	0.48	7.64	0.42	4e-13	Multiple myeloma (IgH translocation);
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg07155664	chr5:149829590	RPS14	-0.44	-6.13	-0.35	3.16e-9	Asthma;
CESC	cis	rs4665809	0.887	rs4665825	chr2:26333100	A/G	cg04944784	chr2:26401820	FAM59B	-0.66	-7.62	-0.42	4.62e-13	Gut microbiome composition (summer);
CESC	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg05457628	chr5:178986728	RUFY1	-0.57	-8.75	-0.47	2.61e-16	Lung cancer;
CESC	cis	rs769267	0.930	rs2304098	chr19:19646272	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.47	5.83	0.34	1.59e-8	Tonsillectomy;
CESC	cis	rs6121246	0.909	rs6058463	chr20:30385192	C/T	cg13852791	chr20:30311386	BCL2L1	0.81	8.61	0.47	6.48e-16	Mean corpuscular hemoglobin;
CESC	cis	rs12545109	0.800	rs1467123	chr8:57418870	C/T	cg09654669	chr8:57350985	NA	-0.45	-6.27	-0.36	1.47e-9	Obesity-related traits;
CESC	cis	rs1005277	0.522	rs1208681	chr10:38092975	C/T	cg00409905	chr10:38381863	ZNF37A	-0.5	-7.04	-0.4	1.61e-11	Extrinsic epigenetic age acceleration;
CESC	cis	rs796364	0.806	rs74706215	chr2:200941367	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.77	-6.8	-0.39	6.95e-11	Schizophrenia;
CESC	cis	rs2839186	0.770	rs2839171	chr21:47673247	C/T	cg13012494	chr21:47604986	C21orf56	-0.51	-7.0	-0.39	2.12e-11	Testicular germ cell tumor;
CESC	cis	rs712039	0.652	rs17137970	chr17:35771826	C/T	cg16670864	chr17:35848621	DUSP14	0.42	5.27	0.31	2.88e-7	Tuberculosis;
CESC	cis	rs4906332	0.966	rs7401563	chr14:103964425	G/A	cg09975044	chr14:104007538	NA	0.47	6.34	0.36	1.01e-9	Coronary artery disease;
CESC	cis	rs875971	0.895	rs7782806	chr7:65657897	C/T	cg10691866	chr7:65817282	TPST1	0.31	5.24	0.31	3.34e-7	Aortic root size;
CESC	cis	rs5758659	0.652	rs5758553	chr22:42431429	G/A	cg15557168	chr22:42548783	NA	-0.48	-7.52	-0.42	8.44e-13	Cognitive function;
CESC	cis	rs2777491	0.957	rs6493002	chr15:41709195	C/G	cg02330683	chr15:41787940	ITPKA	0.48	7.11	0.4	1.07e-11	Ulcerative colitis;
CESC	cis	rs12681288	0.578	rs10503154	chr8:969343	C/G	cg15309053	chr8:964076	NA	0.54	8.84	0.48	1.38e-16	Schizophrenia;
CESC	cis	rs965469	0.696	rs6037570	chr20:3334292	C/A	cg17110299	chr20:3385021	C20orf194	0.43	5.6	0.33	5.48e-8	IFN-related cytopenia;
CESC	cis	rs11871801	0.915	rs647397	chr17:40679398	G/A	cg21433558	chr17:40837037	CNTNAP1	0.45	5.18	0.3	4.32e-7	Crohn's disease;
CESC	cis	rs17253792	0.822	rs8009239	chr14:56062490	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.84	5.62	0.33	4.81e-8	Putamen volume;
CESC	cis	rs172166	0.694	rs1225716	chr6:28113746	A/C	cg20151795	chr6:28129481	ZNF389	0.36	5.18	0.3	4.31e-7	Cardiac Troponin-T levels;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg09800235	chr12:133250183	POLE	-0.47	-6.22	-0.36	1.95e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs34375054	0.624	rs4073534	chr12:125671800	C/T	cg25124228	chr12:125621409	AACS	-0.46	-5.24	-0.31	3.23e-7	Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs3750965	0.919	rs12280942	chr11:68859683	A/G	cg01403660	chr11:68851641	TPCN2	-0.4	-5.69	-0.33	3.34e-8	Hair color;
CESC	cis	rs2485892	0.553	rs4844954	chr1:210337043	A/G	cg21951975	chr1:209979733	IRF6	0.45	5.7	0.33	3.24e-8	Manic episodes in bipolar disorder;
CESC	cis	rs919433	0.783	rs2565158	chr2:198236103	T/A	cg03934865	chr2:198174659	NA	0.43	6.21	0.36	2.03e-9	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	trans	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg13565492	chr6:43139072	SRF	-0.75	-8.94	-0.48	7.05e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg16590910	chr6:42928470	GNMT	0.44	6.42	0.37	6.31e-10	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs4282054	0.631	rs13081155	chr3:52732429	A/G	cg17372223	chr3:52568218	NT5DC2	0.45	7.44	0.42	1.39e-12	Cognitive function;
CESC	cis	rs854765	0.603	rs4506967	chr17:17990474	A/C	cg16928487	chr17:17741425	SREBF1	-0.53	-8.76	-0.47	2.34e-16	Total body bone mineral density;
CESC	cis	rs2952156	0.920	rs12940986	chr17:37836581	A/G	cg00129232	chr17:37814104	STARD3	0.76	11.31	0.57	1.84e-24	Asthma;
CESC	cis	rs13191362	1.000	rs13207671	chr6:162979056	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.82	8.45	0.46	2e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs12477438	0.748	rs10200974	chr2:99675227	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.64	-8.66	-0.47	4.63e-16	Chronic sinus infection;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg05832119	chr17:41132480	AARSD1;RUNDC1	-0.53	-6.53	-0.37	3.38e-10	Ulcerative colitis;
CESC	trans	rs9325144	0.671	rs12818797	chr12:39019409	A/G	cg23762105	chr12:34175262	ALG10	0.47	6.27	0.36	1.44e-9	Morning vs. evening chronotype;
CESC	cis	rs1448094	0.512	rs6539927	chr12:86244486	T/C	cg00310523	chr12:86230176	RASSF9	0.35	5.4	0.32	1.45e-7	Major depressive disorder;
CESC	cis	rs11718455	0.960	rs35711021	chr3:44004791	G/A	cg08738300	chr3:44038990	NA	0.46	6.12	0.35	3.34e-9	Coronary artery disease;
CESC	cis	rs6540556	0.723	rs12120361	chr1:209913473	A/C	cg05527609	chr1:210001259	C1orf107	-0.62	-7.33	-0.41	2.73e-12	Red blood cell count;
CESC	cis	rs2012796	0.785	rs61986599	chr14:81860917	G/A	cg02996355	chr14:81879375	NA	0.66	8.31	0.45	4.93e-15	Night sleep phenotypes;
CESC	cis	rs3960554	0.740	rs10216079	chr7:75690988	A/C	cg17325771	chr7:75508891	RHBDD2	-0.35	-5.23	-0.31	3.42e-7	Eotaxin levels;
CESC	cis	rs11864453	0.713	rs12708927	chr16:72126165	C/T	cg16558253	chr16:72132732	DHX38	-0.56	-8.7	-0.47	3.62e-16	Fibrinogen levels;
CESC	cis	rs875971	0.862	rs6460279	chr7:65662761	T/C	cg19163074	chr7:65112434	INTS4L2	0.44	5.5	0.32	9.04e-8	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07474652	chr3:47823067	SMARCC1	0.53	6.04	0.35	5.16e-9	Gut microbiome composition (summer);
CESC	cis	rs7659604	0.605	rs2071486	chr4:122740162	C/T	cg19748678	chr4:122722346	EXOSC9	0.72	9.27	0.49	6.93e-18	Type 2 diabetes;
CESC	cis	rs9902453	0.933	rs7225462	chr17:28321226	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.68	8.75	0.47	2.61e-16	Coffee consumption (cups per day);
CESC	cis	rs7927771	0.542	rs3886262	chr11:47817010	T/G	cg20307385	chr11:47447363	PSMC3	0.62	8.62	0.47	6.37e-16	Subjective well-being;
CESC	cis	rs4481887	0.927	rs4244184	chr1:248486895	G/T	cg00666640	chr1:248458726	OR2T12	0.36	6.17	0.35	2.56e-9	Common traits (Other);
CESC	cis	rs17001868	0.614	rs5995849	chr22:40777072	C/G	cg07138101	chr22:40742427	ADSL	-0.5	-5.18	-0.3	4.5e-7	Mammographic density (dense area);
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg10507156	chr12:121903328	KDM2B	-0.48	-6.43	-0.37	5.81e-10	Systemic lupus erythematosus;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg01087869	chr16:31501642	C16orf58;SLC5A2	0.43	6.48	0.37	4.57e-10	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs709400	0.628	rs1989565	chr14:103862193	G/A	cg18329187	chr14:103989711	CKB	-0.29	-5.11	-0.3	6.3e-7	Body mass index;
CESC	cis	rs4820294	1.000	rs41280035	chr22:38054038	A/G	cg21798802	chr22:38057573	PDXP	0.43	7.15	0.4	8.32e-12	Fat distribution (HIV);
CESC	cis	rs3204270	0.639	rs62077183	chr17:79658940	C/A	cg26965718	chr17:79658957	HGS	-0.76	-5.67	-0.33	3.81e-8	Dental caries;
CESC	cis	rs6499255	0.904	rs12595927	chr16:69716338	C/G	cg15192750	chr16:69999425	NA	0.48	5.48	0.32	9.78e-8	IgE levels;
CESC	cis	rs77741769	0.571	rs989987	chr12:121274062	C/T	cg02419362	chr12:121203948	SPPL3	0.34	5.5	0.32	8.97e-8	Mean corpuscular volume;
CESC	cis	rs3857536	0.813	rs9360190	chr6:66942302	T/C	cg07460842	chr6:66804631	NA	-0.41	-5.28	-0.31	2.71e-7	Blood trace element (Cu levels);
CESC	cis	rs2243480	1.000	rs73142166	chr7:65375832	A/G	cg12463550	chr7:65579703	CRCP	0.72	5.53	0.32	7.65e-8	Diabetic kidney disease;
CESC	cis	rs71277158	0.688	rs12492606	chr3:169808354	A/G	cg04067573	chr3:169899625	PHC3	-0.62	-6.24	-0.36	1.71e-9	Prostate cancer;
CESC	cis	rs6496667	0.779	rs7163560	chr15:91038620	A/T	cg13834112	chr15:90361639	NA	0.4	5.37	0.31	1.71e-7	Rheumatoid arthritis;
CESC	cis	rs2243480	1.000	rs6974723	chr7:65637939	C/T	cg12463550	chr7:65579703	CRCP	-0.73	-5.71	-0.33	3.1e-8	Diabetic kidney disease;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg02836479	chr16:21964489	UQCRC2	-0.46	-6.21	-0.36	2.02e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs2832077	0.506	rs2832093	chr21:30164855	C/T	cg08807101	chr21:30365312	RNF160	-0.46	-5.14	-0.3	5.46e-7	Cognitive test performance;
CESC	cis	rs2075371	1.000	rs2241336	chr7:133979578	A/G	cg11752832	chr7:134001865	SLC35B4	0.54	7.1	0.4	1.13e-11	Mean platelet volume;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg13284070	chr3:128483832	RAB7A	0.48	6.07	0.35	4.37e-9	Fibrinogen levels;
CESC	cis	rs896854	0.625	rs4735336	chr8:95973410	A/C	cg13393036	chr8:95962371	TP53INP1	0.46	9.73	0.51	2.54e-19	Type 2 diabetes;
CESC	trans	rs1814175	0.527	rs10769595	chr11:49638212	A/G	cg03929089	chr4:120376271	NA	-0.71	-8.38	-0.46	3.16e-15	Height;
CESC	cis	rs4635969	1.000	rs4635969	chr5:1308552	C/T	cg06550200	chr5:1325588	CLPTM1L	-0.71	-7.61	-0.42	4.78e-13	Testicular germ cell tumor;Testicular germ cell cancer;
CESC	cis	rs10504229	0.679	rs12675340	chr8:58035501	T/A	cg22535103	chr8:58192502	C8orf71	-0.61	-6.84	-0.39	5.31e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg04025307	chr7:1156635	C7orf50	0.48	6.68	0.38	1.4e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7726839	0.561	rs6555357	chr5:560923	A/G	cg16447950	chr5:562315	NA	-0.62	-7.2	-0.4	6.29e-12	Obesity-related traits;
CESC	cis	rs9487051	0.837	rs1915834	chr6:109597624	C/A	cg21918786	chr6:109611834	NA	-0.39	-6.04	-0.35	5.1e-9	Reticulocyte fraction of red cells;
CESC	cis	rs72781680	0.611	rs72781692	chr2:24263319	T/G	cg06627628	chr2:24431161	ITSN2	-0.63	-5.96	-0.34	8.13e-9	Lymphocyte counts;
CESC	cis	rs782590	0.967	rs1975487	chr2:55809054	A/G	cg18811423	chr2:55921094	PNPT1	0.8	12.7	0.62	3.46e-29	Metabolic syndrome;
CESC	cis	rs1044826	0.619	rs7375091	chr3:139090389	T/A	cg00490450	chr3:139108681	COPB2	-0.42	-5.15	-0.3	5.21e-7	Obesity-related traits;
CESC	cis	rs11098499	0.526	rs10026625	chr4:120280136	T/C	cg09307838	chr4:120376055	NA	0.66	9.0	0.48	4.57e-17	Corneal astigmatism;
CESC	cis	rs2455799	0.613	rs13071730	chr3:15891035	C/T	cg16303742	chr3:15540471	COLQ	-0.35	-5.3	-0.31	2.4e-7	Mean platelet volume;
CESC	cis	rs1005277	0.579	rs2474594	chr10:38426661	G/C	cg00409905	chr10:38381863	ZNF37A	-0.47	-6.31	-0.36	1.16e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs6723226	0.764	rs176403	chr2:32637864	C/A	cg02381751	chr2:32503542	YIPF4	-0.84	-12.01	-0.59	7.79e-27	Intelligence (multi-trait analysis);
CESC	cis	rs13118159	0.872	rs4974605	chr4:1346389	C/G	cg20887711	chr4:1340912	KIAA1530	0.46	6.13	0.35	3.19e-9	Longevity;
CESC	cis	rs9311474	1.000	rs2276834	chr3:52325759	A/G	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.4	7.4	0.41	1.83e-12	Electroencephalogram traits;
CESC	cis	rs68170813	0.559	rs6947675	chr7:106817184	T/C	cg02696742	chr7:106810147	HBP1	-0.55	-5.33	-0.31	2.1e-7	Coronary artery disease;
CESC	cis	rs5758659	0.714	rs7245	chr22:42481849	G/A	cg15557168	chr22:42548783	NA	0.49	7.53	0.42	7.97e-13	Cognitive function;
CESC	cis	rs12200560	0.505	rs9400166	chr6:97077101	G/A	cg06623918	chr6:96969491	KIAA0776	0.5	6.42	0.37	6.42e-10	Coronary heart disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10139015	chr11:47448256	PSMC3	-0.72	-8.85	-0.48	1.24e-16	Gut microbiome composition (summer);
CESC	trans	rs17685	0.753	rs1637037	chr7:75692927	C/T	cg19862616	chr7:65841803	NCRNA00174	0.83	12.37	0.61	4.74e-28	Coffee consumption;Coffee consumption (cups per day);
CESC	trans	rs5758511	0.773	rs12167978	chr22:42346475	G/A	cg15080870	chr19:47770746	CCDC9	0.49	6.1	0.35	3.78e-9	Birth weight;
CESC	cis	rs6570726	0.764	rs367065	chr6:145882309	T/G	cg05347473	chr6:146136440	FBXO30	0.55	7.06	0.4	1.45e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1801251	1.000	rs56777991	chr2:233635388	A/C	cg25237894	chr2:233734115	C2orf82	0.44	7.67	0.43	3.27e-13	Coronary artery disease;
CESC	cis	rs5769765	0.542	rs1033666	chr22:50252783	T/C	cg02269571	chr22:50332266	NA	0.46	5.45	0.32	1.16e-7	Schizophrenia;
CESC	cis	rs4704187	0.649	rs1422701	chr5:74510517	T/G	cg03227963	chr5:74354835	NA	0.28	5.04	0.3	8.66e-7	Response to amphetamines;
CESC	cis	rs7914558	0.966	rs10883805	chr10:104708251	T/C	cg15744005	chr10:104629667	AS3MT	-0.35	-5.49	-0.32	9.41e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs2637266	1.000	rs10824429	chr10:78346196	G/T	cg18941641	chr10:78392320	NA	0.41	7.74	0.43	2.04e-13	Pulmonary function;
CESC	cis	rs2839186	0.647	rs9976233	chr21:47616913	G/A	cg00612595	chr21:47717864	NA	0.42	5.69	0.33	3.43e-8	Testicular germ cell tumor;
CESC	cis	rs9796	0.689	rs9888710	chr15:41446153	G/C	cg12426344	chr15:41135900	SPINT1	-0.25	-5.48	-0.32	1e-7	Menopause (age at onset);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg11038604	chr10:14996337	DCLRE1C	0.45	6.14	0.35	3.01e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs6570726	0.905	rs442435	chr6:145815559	C/T	cg05347473	chr6:146136440	FBXO30	0.49	6.66	0.38	1.53e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4076764	0.515	rs4657268	chr1:163376507	A/T	cg24596788	chr1:163392923	NA	-0.34	-5.31	-0.31	2.31e-7	Motion sickness;
CESC	cis	rs4148883	0.675	rs34511427	chr4:100105405	G/T	cg12011299	chr4:100065546	ADH4	0.66	9.68	0.51	3.46e-19	Alcohol dependence;
CESC	cis	rs11122272	0.735	rs2250734	chr1:231485958	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.53	-7.43	-0.42	1.53e-12	Hemoglobin concentration;
CESC	trans	rs7943203	1.000	rs4753842	chr11:108311606	G/C	cg24643211	chr18:11851603	GNAL;CHMP1B	-0.48	-6.05	-0.35	5.01e-9	Red blood cell count;Mean corpuscular volume;
CESC	cis	rs270601	0.770	rs10463891	chr5:131597392	C/T	cg22638593	chr5:131593259	PDLIM4	-0.39	-5.09	-0.3	6.81e-7	Acylcarnitine levels;
CESC	cis	rs9291683	0.655	rs35750364	chr4:10049049	T/C	cg00071950	chr4:10020882	SLC2A9	0.85	14.85	0.67	1.04e-36	Bone mineral density;
CESC	cis	rs2404602	0.647	rs920712	chr15:77033934	G/A	cg23625390	chr15:77176239	SCAPER	-0.47	-6.56	-0.37	2.75e-10	Blood metabolite levels;
CESC	cis	rs17401966	1.000	rs17401966	chr1:10385471	C/T	cg15208524	chr1:10270712	KIF1B	-0.48	-6.19	-0.36	2.25e-9	Hepatocellular carcinoma;
CESC	cis	rs9287719	0.837	rs4331474	chr2:10755583	G/A	cg02196655	chr2:10830764	NOL10	-0.36	-5.43	-0.32	1.26e-7	Prostate cancer;
CESC	cis	rs644799	1.000	rs500054	chr11:95593806	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.51	5.86	0.34	1.39e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs11997175	0.646	rs67480501	chr8:33736315	C/T	ch.8.33884649F	chr8:33765107	NA	0.56	7.08	0.4	1.33e-11	Body mass index;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg21892522	chr3:10052995	LOC401052	-0.45	-6.56	-0.37	2.79e-10	Fibrinogen levels;
CESC	cis	rs7589728	0.563	rs79892776	chr2:88470593	G/A	cg18490616	chr2:88469792	THNSL2	0.56	5.38	0.31	1.64e-7	Plasma clusterin levels;
CESC	cis	rs10504229	1.000	rs67384205	chr8:58180348	C/G	cg22535103	chr8:58192502	C8orf71	-1.05	-13.27	-0.63	3.63e-31	Developmental language disorder (linguistic errors);
CESC	cis	rs8133932	0.654	rs413517	chr21:47347545	C/G	cg14185626	chr21:47401492	COL6A1	-0.48	-5.33	-0.31	2.07e-7	Schizophrenia;
CESC	cis	rs8072100	0.817	rs9905581	chr17:45547185	C/T	cg25173405	chr17:45401733	C17orf57	-0.47	-6.16	-0.35	2.72e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs3857536	0.813	rs1891599	chr6:66941699	A/G	cg07460842	chr6:66804631	NA	-0.41	-5.28	-0.31	2.71e-7	Blood trace element (Cu levels);
CESC	cis	rs2297440	0.506	rs2236504	chr20:62224762	C/T	cg06363034	chr20:62225388	GMEB2	-0.52	-6.68	-0.38	1.42e-10	Glioma;Non-glioblastoma glioma;Glioblastoma;
CESC	cis	rs853679	0.517	rs9357061	chr6:28051772	A/G	cg23281280	chr6:28129359	ZNF389	0.57	7.78	0.43	1.61e-13	Depression;
CESC	cis	rs7618915	0.547	rs68021750	chr3:52624769	G/A	cg17372223	chr3:52568218	NT5DC2	0.43	6.43	0.37	5.84e-10	Bipolar disorder;
CESC	cis	rs35306767	0.903	rs12250937	chr10:900209	C/T	cg10556349	chr10:835070	NA	0.57	5.48	0.32	9.87e-8	Eosinophil percentage of granulocytes;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg25151688	chr15:66585534	DIS3L	-0.44	-6.2	-0.36	2.21e-9	Asthma;
CESC	cis	rs763014	0.931	rs3752568	chr16:628302	A/G	cg07343612	chr16:622815	PIGQ	-0.58	-8.47	-0.46	1.72e-15	Height;
CESC	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	14.01	0.65	9.7e-34	Prudent dietary pattern;
CESC	cis	rs7666738	0.830	rs13121558	chr4:99002848	G/A	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.62e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1218582	0.682	rs12046459	chr1:154912017	A/C	cg24250549	chr1:154909240	PMVK	0.71	10.28	0.53	4.54e-21	Prostate cancer;
CESC	cis	rs12136530	0.774	rs880361	chr1:19773421	A/T	cg01832549	chr1:19774989	CAPZB	-0.47	-6.5	-0.37	3.88e-10	Lead levels in blood;
CESC	cis	rs2635047	0.811	rs12958943	chr18:44786818	T/C	cg24371990	chr18:44770781	NA	0.41	6.49	0.37	4.2e-10	Educational attainment;
CESC	trans	rs1814175	0.645	rs10839456	chr11:49964093	C/T	cg03929089	chr4:120376271	NA	-0.89	-14.87	-0.67	8.52e-37	Height;
CESC	cis	rs12950390	0.853	rs56137679	chr17:45862112	C/G	cg00777063	chr17:45855553	NA	-0.38	-5.68	-0.33	3.49e-8	IgG glycosylation;
CESC	cis	rs11690935	0.885	rs6752812	chr2:172851502	C/A	cg13550731	chr2:172543902	DYNC1I2	-0.83	-12.24	-0.6	1.31e-27	Schizophrenia;
CESC	cis	rs2070488	0.699	rs13064938	chr3:38440237	T/C	cg24069376	chr3:38537580	EXOG	0.34	5.67	0.33	3.74e-8	Electrocardiographic conduction measures;
CESC	cis	rs9322193	0.962	rs9322219	chr6:150103399	C/T	cg13206674	chr6:150067644	NUP43	0.39	5.58	0.32	5.93e-8	Lung cancer;
CESC	cis	rs17253792	0.822	rs76192881	chr14:56034654	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.83	5.5	0.32	8.98e-8	Putamen volume;
CESC	cis	rs116095464	0.558	rs6882584	chr5:223411	A/C	cg10591111	chr5:226296	SDHA	-0.51	-6.35	-0.36	9.22e-10	Breast cancer;
CESC	cis	rs7829975	0.902	rs485107	chr8:8581408	C/G	cg17143192	chr8:8559678	CLDN23	-0.44	-5.38	-0.31	1.62e-7	Mood instability;
CESC	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.44	-5.68	-0.33	3.56e-8	Longevity;Endometriosis;
CESC	cis	rs4481887	0.893	rs9651175	chr1:248446888	G/T	cg00666640	chr1:248458726	OR2T12	0.38	6.48	0.37	4.49e-10	Common traits (Other);
CESC	cis	rs2777491	0.507	rs11854081	chr15:41646398	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.05	-16.77	-0.72	1.61e-43	Ulcerative colitis;
CESC	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg14893161	chr1:205819251	PM20D1	0.79	12.37	0.61	4.66e-28	Menarche (age at onset);
CESC	cis	rs7223966	0.691	rs9893518	chr17:62006997	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.45	5.2	0.3	4.02e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs10504229	1.000	rs67344620	chr8:58187537	C/A	cg24829409	chr8:58192753	C8orf71	-0.76	-9.93	-0.52	5.87e-20	Developmental language disorder (linguistic errors);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg09590094	chr22:18506583	MICAL3	-0.49	-6.14	-0.35	2.94e-9	Ulcerative colitis;
CESC	cis	rs11098499	0.954	rs11098525	chr4:120390152	G/A	cg09307838	chr4:120376055	NA	0.95	13.98	0.65	1.2e-33	Corneal astigmatism;
CESC	cis	rs763121	0.819	rs3747173	chr22:39069045	A/G	cg14440974	chr22:39074834	NA	-0.42	-5.89	-0.34	1.14e-8	Menopause (age at onset);
CESC	trans	rs11098499	0.754	rs2036857	chr4:120249240	T/C	cg25214090	chr10:38739885	LOC399744	0.62	8.64	0.47	5.24e-16	Corneal astigmatism;
CESC	cis	rs10883723	0.810	rs2281879	chr10:104268877	C/G	ch.10.2196322F	chr10:104248062	ACTR1A	0.44	5.42	0.32	1.32e-7	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs11122272	0.735	rs2808596	chr1:231530723	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.53	-7.16	-0.4	8.14e-12	Hemoglobin concentration;
CESC	cis	rs6545883	0.899	rs1562309	chr2:61770126	C/A	cg15711740	chr2:61764176	XPO1	-0.43	-5.29	-0.31	2.56e-7	Tuberculosis;
CESC	cis	rs7542091	0.704	rs1883331	chr1:210043483	A/G	cg25204440	chr1:209979598	IRF6	0.37	5.1	0.3	6.55e-7	Monobrow;
CESC	cis	rs6582630	0.502	rs12815350	chr12:38439921	A/T	cg26384229	chr12:38710491	ALG10B	0.69	10.28	0.53	4.42e-21	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs10791097	0.690	rs12284540	chr11:130729772	T/C	cg09137382	chr11:130731461	NA	0.39	5.69	0.33	3.36e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15043642	chr5:141061863	ARAP3	0.6	6.89	0.39	4.03e-11	Gut microbiome composition (summer);
CESC	cis	rs9311474	0.508	rs11714565	chr3:52606292	C/T	cg05564831	chr3:52568323	NT5DC2	0.47	7.46	0.42	1.24e-12	Electroencephalogram traits;
CESC	cis	rs6982240	0.514	rs1865247	chr8:142274654	A/T	cg27411547	chr8:142287226	NA	-0.52	-7.28	-0.41	3.82e-12	Tonsillectomy;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg09326880	chr3:43147587	C3orf39	-0.43	-6.4	-0.37	7.01e-10	Fibrinogen levels;
CESC	cis	rs2380220	0.576	rs7751219	chr6:96018915	G/A	cg15832292	chr6:96025679	MANEA	0.74	7.75	0.43	1.95e-13	Behavioural disinhibition (generation interaction);
CESC	cis	rs7589342	0.831	rs11124062	chr2:106455967	G/A	cg16077055	chr2:106428750	NCK2	0.49	7.04	0.4	1.7e-11	Addiction;
CESC	cis	rs2777491	0.574	rs316611	chr15:41751678	A/G	cg18705301	chr15:41695430	NDUFAF1	0.97	15.29	0.68	2.91e-38	Ulcerative colitis;
CESC	cis	rs1008375	0.966	rs6449325	chr4:17699509	C/T	cg16339924	chr4:17578868	LAP3	-0.49	-5.76	-0.33	2.27e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs13242816	1.000	rs2402078	chr7:116128648	A/C	cg04696780	chr7:116139425	CAV2	-0.61	-5.56	-0.32	6.58e-8	P wave duration;
CESC	cis	rs4237845	0.804	rs11172372	chr12:58286273	T/C	cg00677455	chr12:58241039	CTDSP2	0.43	5.73	0.33	2.77e-8	Intelligence (multi-trait analysis);
CESC	cis	rs875971	0.862	rs3893216	chr7:65790707	G/C	cg19163074	chr7:65112434	INTS4L2	0.41	5.12	0.3	5.9e-7	Aortic root size;
CESC	trans	rs7726839	0.574	rs72705014	chr5:619815	C/G	cg25482853	chr8:67687455	SGK3	1.02	9.93	0.52	5.72e-20	Obesity-related traits;
CESC	cis	rs7618915	0.571	rs34115864	chr3:52612178	A/G	cg18404041	chr3:52824283	ITIH1	-0.41	-6.78	-0.38	7.75e-11	Bipolar disorder;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg08886546	chr19:19051335	HOMER3	-0.51	-6.88	-0.39	4.2e-11	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs1552244	1.000	rs17032277	chr3:10077023	T/C	cg08888203	chr3:10149979	C3orf24	0.46	5.9	0.34	1.11e-8	Alzheimer's disease;
CESC	cis	rs4921915	0.526	rs13277738	chr8:18241507	C/T	cg18736775	chr8:18248649	NAT2	-0.51	-5.13	-0.3	5.48e-7	Iron status biomarkers (transferrin levels);
CESC	cis	rs6089584	0.546	rs6061980	chr20:60618877	G/A	cg24733560	chr20:60626293	TAF4	0.45	6.7	0.38	1.24e-10	Body mass index;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg24342864	chr17:17184608	COPS3	0.43	6.36	0.36	8.57e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs4561483	0.771	rs12924398	chr16:11972948	T/A	cg08843971	chr16:11963173	GSPT1	-0.4	-5.61	-0.33	5.1e-8	Testicular germ cell tumor;
CESC	cis	rs644799	1.000	rs693597	chr11:95589629	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	13.27	0.63	3.57e-31	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs1707322	0.752	rs28507722	chr1:46206540	A/G	cg05343316	chr1:45956843	TESK2	0.51	6.32	0.36	1.09e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs6460942	0.915	rs79232243	chr7:12459494	G/A	cg10578991	chr7:12443926	VWDE	-0.51	-5.61	-0.33	5.17e-8	Coronary artery disease;
CESC	cis	rs870825	0.616	rs28672716	chr4:185647345	G/A	cg04058563	chr4:185651563	MLF1IP	0.63	6.96	0.39	2.59e-11	Blood protein levels;
CESC	cis	rs7103648	0.966	rs1534576	chr11:47419663	A/C	cg20307385	chr11:47447363	PSMC3	-0.97	-17.32	-0.73	1.76e-45	Diastolic blood pressure;Systolic blood pressure;
CESC	cis	rs2066819	1.000	rs2643623	chr12:56689725	G/C	cg26316697	chr12:56727976	PAN2	-0.69	-6.64	-0.38	1.74e-10	Psoriasis vulgaris;
CESC	cis	rs9733	0.519	rs3768005	chr1:150680988	A/T	cg13175981	chr1:150552382	MCL1	-0.4	-5.09	-0.3	6.96e-7	Tonsillectomy;
CESC	cis	rs477895	0.653	rs7939784	chr11:63910153	C/T	cg04317338	chr11:64019027	PLCB3	0.87	9.06	0.49	3.04e-17	Mean platelet volume;
CESC	cis	rs12681288	0.676	rs34282191	chr8:991290	G/A	cg15309053	chr8:964076	NA	0.39	6.49	0.37	4.2e-10	Schizophrenia;
CESC	cis	rs2617583	0.967	rs2617594	chr5:1448288	A/G	cg07151155	chr5:1473589	LPCAT1	-0.36	-5.5	-0.32	8.87e-8	Breast cancer;
CESC	cis	rs9354308	0.933	rs2802062	chr6:66561973	C/G	cg07460842	chr6:66804631	NA	0.66	7.52	0.42	8.27e-13	Metabolite levels;
CESC	cis	rs514406	0.571	rs11206004	chr1:53210958	G/A	cg27535305	chr1:53392650	SCP2	0.35	6.09	0.35	4.04e-9	Monocyte count;
CESC	cis	rs6570726	0.846	rs9399559	chr6:145945778	C/T	cg23711669	chr6:146136114	FBXO30	0.87	12.7	0.61	3.59e-29	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs35110281	0.681	rs162343	chr21:44957072	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.5	6.7	0.38	1.26e-10	Mean corpuscular volume;
CESC	cis	rs875971	0.830	rs778715	chr7:65849209	C/T	cg12463550	chr7:65579703	CRCP	0.49	6.21	0.36	2.07e-9	Aortic root size;
CESC	cis	rs12995491	0.731	rs17435439	chr2:88511391	A/G	cg04511125	chr2:88470314	THNSL2	-0.51	-7.42	-0.41	1.64e-12	Response to metformin (IC50);
CESC	cis	rs4563143	0.675	rs56123392	chr19:29255631	A/C	cg12756686	chr19:29218302	NA	0.57	7.39	0.41	1.95e-12	Methadone dose in opioid dependence;
CESC	cis	rs7503807	0.664	rs35524093	chr17:78574246	A/G	cg09596252	chr17:78655493	RPTOR	0.39	5.26	0.31	2.96e-7	Obesity;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04186169	chr6:139695202	CITED2	-0.54	-6.08	-0.35	4.09e-9	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04473235	chr5:77080995	NA	-0.67	-8.33	-0.46	4.49e-15	Gut microbiome composition (summer);
CESC	cis	rs9457247	0.967	rs2149092	chr6:167372978	C/T	cg07741184	chr6:167504864	NA	-0.3	-5.39	-0.31	1.6e-7	Crohn's disease;
CESC	cis	rs875971	0.895	rs4718349	chr7:65909011	C/G	cg18876405	chr7:65276391	NA	0.52	6.97	0.39	2.54e-11	Aortic root size;
CESC	cis	rs2408955	0.522	rs7139330	chr12:48483484	A/C	cg04545296	chr12:48745243	ZNF641	-0.35	-6.13	-0.35	3.2e-9	Glycated hemoglobin levels;
CESC	cis	rs2880765	0.566	rs11630381	chr15:86012503	A/G	cg10818794	chr15:86012489	AKAP13	-0.36	-5.04	-0.3	8.8e-7	Coronary artery disease;
CESC	cis	rs2249625	0.545	rs2496495	chr6:72882414	G/A	cg18830697	chr6:72922368	RIMS1	-0.47	-6.88	-0.39	4.4e-11	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CESC	cis	rs2070677	1.000	rs2070677	chr10:135351174	A/T	cg20169779	chr10:135381914	SYCE1	-0.67	-8.24	-0.45	8.23e-15	Gout;
CESC	cis	rs10504229	0.683	rs55660024	chr8:58128943	G/A	cg02725872	chr8:58115012	NA	-0.45	-7.05	-0.4	1.52e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs7666738	0.830	rs3846444	chr4:99032888	T/C	cg18180107	chr4:99064573	C4orf37	0.42	5.43	0.32	1.29e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3106136	0.933	rs35718240	chr4:95164030	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.38	-5.52	-0.32	7.95e-8	Capecitabine sensitivity;
CESC	cis	rs12458462	0.851	rs3859317	chr18:77443093	A/C	cg11879182	chr18:77439856	CTDP1	0.86	13.41	0.64	1.19e-31	Monocyte count;
CESC	cis	rs9815354	0.812	rs4299460	chr3:41952445	A/C	cg03022575	chr3:42003672	ULK4	0.68	5.92	0.34	9.9e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs7131987	0.903	rs1991114	chr12:29392082	G/T	cg09582351	chr12:29534625	ERGIC2	-0.33	-5.25	-0.31	3.13e-7	QT interval;
CESC	cis	rs6598955	0.724	rs12732295	chr1:26602251	C/T	cg00852783	chr1:26633632	UBXN11	0.42	6.15	0.35	2.9e-9	Obesity-related traits;
CESC	cis	rs6835098	1.000	rs10031414	chr4:174084953	A/C	cg08422745	chr4:174089978	GALNT7	-0.84	-12.18	-0.6	2.12e-27	Dementia and core Alzheimer's disease neuropathologic changes;
CESC	cis	rs1799949	1.000	rs11653231	chr17:41331460	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.62	8.39	0.46	2.99e-15	Menopause (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27646848	chr11:62389601	B3GAT3	0.68	8.27	0.45	6.64e-15	Gut microbiome composition (summer);
CESC	cis	rs4660306	0.961	rs4660860	chr1:45946233	T/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.61	-7.69	-0.43	2.86e-13	Homocysteine levels;
CESC	cis	rs7250872	0.619	rs2396359	chr19:1819125	T/C	cg05970437	chr19:1864622	KLF16	0.5	5.84	0.34	1.52e-8	Bipolar disorder;
CESC	cis	rs12410462	0.581	rs4329477	chr1:227552494	A/G	cg04117972	chr1:227635322	NA	-0.59	-5.59	-0.32	5.66e-8	Major depressive disorder;
CESC	cis	rs763121	0.853	rs3827357	chr22:39079413	A/G	cg21395723	chr22:39101663	GTPBP1	0.43	5.29	0.31	2.55e-7	Menopause (age at onset);
CESC	cis	rs2070488	0.965	rs2284820	chr3:38562579	C/T	cg24069376	chr3:38537580	EXOG	-0.45	-8.39	-0.46	2.9e-15	Electrocardiographic conduction measures;
CESC	cis	rs7208859	0.673	rs36056619	chr17:29172284	T/C	cg19761014	chr17:28927070	LRRC37B2	0.72	5.71	0.33	3.06e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs6933660	0.800	rs6931104	chr6:151786177	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.86	14.63	0.67	6.08e-36	Menarche (age at onset);
CESC	cis	rs861020	0.606	rs2184919	chr1:210000015	C/T	cg05527609	chr1:210001259	C1orf107	-0.71	-9.64	-0.51	4.71e-19	Orofacial clefts;
CESC	cis	rs9287719	0.904	rs55738250	chr2:10757132	G/A	cg02196655	chr2:10830764	NOL10	-0.37	-5.67	-0.33	3.73e-8	Prostate cancer;
CESC	cis	rs929354	0.772	rs10230895	chr7:157007038	T/C	cg05182265	chr7:156933206	UBE3C	-0.49	-7.25	-0.41	4.51e-12	Body mass index;
CESC	cis	rs17253792	0.822	rs76055105	chr14:56069127	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.79	5.91	0.34	1.06e-8	Putamen volume;
CESC	cis	rs801193	0.967	rs2707841	chr7:66157020	A/G	cg06456125	chr7:65229604	NA	0.39	5.05	0.3	8.06e-7	Aortic root size;
CESC	cis	rs826838	0.678	rs11182781	chr12:38610178	C/T	cg13010199	chr12:38710504	ALG10B	0.53	6.88	0.39	4.41e-11	Heart rate;
CESC	cis	rs796364	0.806	rs79053279	chr2:201057443	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.82	-6.91	-0.39	3.63e-11	Schizophrenia;
CESC	cis	rs6904897	0.538	rs4639353	chr6:135224328	A/G	cg24558204	chr6:135376177	HBS1L	-0.52	-7.07	-0.4	1.4e-11	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	cis	rs62344088	1.000	rs6898413	chr5:173927	A/C	cg22857025	chr5:266934	NA	-1.18	-7.34	-0.41	2.66e-12	Asthma (childhood onset);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg08092446	chr19:58987653	ZNF446	-0.47	-6.52	-0.37	3.51e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs9462846	0.959	rs9471954	chr6:42880326	C/A	cg02353165	chr6:42928485	GNMT	0.5	5.94	0.34	9.01e-9	Blood protein levels;
CESC	trans	rs9329221	0.621	rs522483	chr8:9812969	C/G	cg06636001	chr8:8085503	FLJ10661	-0.53	-7.14	-0.4	8.94e-12	Neuroticism;
CESC	cis	rs7666738	0.924	rs13124368	chr4:99039615	T/C	cg17366294	chr4:99064904	C4orf37	0.61	8.78	0.47	2.13e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1005277	0.691	rs2474558	chr10:38486141	A/C	cg25427524	chr10:38739819	LOC399744	0.6	7.79	0.43	1.51e-13	Extrinsic epigenetic age acceleration;
CESC	cis	rs4713118	0.662	rs149901	chr6:27965503	C/T	cg23161317	chr6:28129485	ZNF389	0.46	6.19	0.36	2.32e-9	Parkinson's disease;
CESC	cis	rs7772486	0.521	rs9485017	chr6:146023326	C/T	cg05347473	chr6:146136440	FBXO30	0.69	9.29	0.5	5.7e-18	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2228479	0.717	rs62052210	chr16:89980158	A/G	cg04013166	chr16:89971882	TCF25	0.72	7.14	0.4	9.22e-12	Skin colour saturation;
CESC	trans	rs1116547	0.602	rs6883441	chr5:112798855	G/A	cg10115368	chr14:100435663	NA	0.5	6.1	0.35	3.68e-9	Cerebral amyloid angiopathy;
CESC	trans	rs9987353	0.840	rs329994	chr8:9123233	A/G	cg21462697	chr17:80765655	TBCD	0.48	6.32	0.36	1.08e-9	Recombination measurement;
CESC	cis	rs6088580	0.634	rs6142164	chr20:33006597	C/T	cg08999081	chr20:33150536	PIGU	-0.64	-11.19	-0.57	4.76e-24	Glomerular filtration rate (creatinine);
CESC	cis	rs4481887	0.636	rs6672981	chr1:248407200	C/T	cg00666640	chr1:248458726	OR2T12	0.34	5.21	0.3	3.86e-7	Common traits (Other);
CESC	trans	rs13098911	0.540	rs13066062	chr3:46018344	G/A	cg10236987	chr1:228114221	WNT9A	0.6	6.17	0.35	2.61e-9	Celiac disease;
CESC	cis	rs2456568	0.778	rs7940973	chr11:93682045	C/G	cg05188948	chr11:93754288	HEPHL1	-0.27	-5.36	-0.31	1.79e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
CESC	cis	rs597539	0.690	rs7129960	chr11:68622456	A/G	cg01988459	chr11:68622903	NA	-0.41	-5.3	-0.31	2.45e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs6952808	0.595	rs3778982	chr7:2166233	T/C	cg08027265	chr7:2291960	NA	-0.46	-7.0	-0.39	2.13e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs67478160	0.643	rs12880821	chr14:104276049	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.51	-6.81	-0.39	6.53e-11	Schizophrenia;
CESC	cis	rs763014	0.898	rs916416	chr16:632198	T/A	cg07256732	chr16:621771	PIGQ	-0.3	-5.14	-0.3	5.22e-7	Height;
CESC	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg02951883	chr7:2050386	MAD1L1	-0.44	-5.69	-0.33	3.4e-8	Bipolar disorder and schizophrenia;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg21184075	chr14:58766462	ARID4A	-0.48	-7.04	-0.4	1.67e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs6502050	0.835	rs67106357	chr17:80116826	T/G	cg23985595	chr17:80112537	CCDC57	-0.41	-6.46	-0.37	4.88e-10	Life satisfaction;
CESC	cis	rs9611565	0.918	rs4820438	chr22:41767135	C/T	cg06481639	chr22:41940642	POLR3H	-0.62	-6.8	-0.39	7.07e-11	Vitiligo;
CESC	cis	rs7044106	0.734	rs10491784	chr9:123432289	A/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.69	10.09	0.53	1.84e-20	Hip circumference adjusted for BMI;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21808837	chr5:176778472	LMAN2	-0.63	-7.12	-0.4	9.88e-12	Gut microbiome composition (summer);
CESC	cis	rs80282103	0.618	rs74120451	chr10:1126866	T/C	cg08668510	chr10:1095578	IDI1	0.72	5.72	0.33	2.85e-8	Glomerular filtration rate (creatinine);
CESC	trans	rs9929218	0.953	rs16260	chr16:68771034	C/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.76	-10.07	-0.53	2.13e-20	Colorectal cancer;
CESC	cis	rs4727027	0.933	rs62505074	chr7:148834780	C/T	cg23158103	chr7:148848205	ZNF398	-0.4	-6.51	-0.37	3.67e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs875971	0.617	rs810400	chr7:66022889	G/C	cg14393609	chr7:65229607	NA	-0.47	-6.31	-0.36	1.14e-9	Aortic root size;
CESC	cis	rs798554	0.660	rs2644275	chr7:2854010	G/A	cg13628971	chr7:2884303	GNA12	0.41	5.41	0.32	1.39e-7	Height;
CESC	cis	rs798554	0.836	rs798500	chr7:2790685	C/T	cg19717773	chr7:2847554	GNA12	0.56	7.98	0.44	4.43e-14	Height;
CESC	cis	rs1707322	0.752	rs4586014	chr1:46150443	A/G	cg05343316	chr1:45956843	TESK2	0.51	6.32	0.36	1.09e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs853679	0.517	rs4713143	chr6:28106759	A/C	cg20151795	chr6:28129481	ZNF389	0.45	5.92	0.34	9.77e-9	Depression;
CESC	cis	rs1799949	1.000	rs1060915	chr17:41234470	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	8.65	0.47	5.19e-16	Menopause (age at onset);
CESC	cis	rs2842992	0.724	rs4709368	chr6:160204127	C/T	cg26839252	chr6:160211577	TCP1;MRPL18	-0.48	-5.99	-0.35	6.75e-9	Age-related macular degeneration (geographic atrophy);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21251000	chr13:103452780	BIVM;KDELC1	0.54	6.15	0.35	2.89e-9	Gut microbiome composition (summer);
CESC	cis	rs13385	0.769	rs4913074	chr5:139613567	T/C	cg26211634	chr5:139558579	C5orf32	0.48	5.24	0.31	3.28e-7	Atrial fibrillation;
CESC	cis	rs1580019	0.587	rs2392069	chr7:32547154	A/G	cg06627557	chr7:32535165	LSM5;AVL9	1.06	18.8	0.76	1.12e-50	Cognitive ability;
CESC	cis	rs6460942	0.915	rs6966791	chr7:12439714	T/C	cg20607287	chr7:12443886	VWDE	-0.77	-9.04	-0.49	3.38e-17	Coronary artery disease;
CESC	cis	rs10845606	0.781	rs7972866	chr12:12828320	C/T	cg04607235	chr12:12878440	APOLD1	-0.56	-6.82	-0.39	6.27e-11	Systemic lupus erythematosus;
CESC	cis	rs7666738	0.830	rs6823718	chr4:99063202	C/T	cg18180107	chr4:99064573	C4orf37	0.4	5.14	0.3	5.21e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7845219	0.544	rs9643351	chr8:95917290	C/T	cg16049864	chr8:95962084	TP53INP1	-0.5	-7.29	-0.41	3.66e-12	Type 2 diabetes;
CESC	cis	rs2952156	0.920	rs903502	chr17:37829604	C/T	cg07936489	chr17:37558343	FBXL20	-0.59	-7.52	-0.42	8.39e-13	Asthma;
CESC	cis	rs6502050	0.764	rs35713597	chr17:80119016	C/G	cg23985595	chr17:80112537	CCDC57	-0.41	-6.46	-0.37	4.95e-10	Life satisfaction;
CESC	cis	rs875971	0.545	rs2707851	chr7:66089165	C/T	cg18876405	chr7:65276391	NA	-0.49	-5.61	-0.33	5.18e-8	Aortic root size;
CESC	cis	rs4561483	0.583	rs11075032	chr16:12004450	C/T	cg08843971	chr16:11963173	GSPT1	0.46	6.46	0.37	5.06e-10	Testicular germ cell tumor;
CESC	cis	rs651907	0.557	rs12629954	chr3:101360623	C/A	cg12386194	chr3:101231763	SENP7	0.43	5.41	0.32	1.4e-7	Colorectal cancer;
CESC	cis	rs11760633	0.672	rs6460870	chr7:1843200	C/G	cg23422044	chr7:1970798	MAD1L1	-0.48	-5.54	-0.32	7.14e-8	Coronary artery disease;
CESC	cis	rs2836950	0.565	rs7278297	chr21:40625752	A/C	cg17971929	chr21:40555470	PSMG1	-0.6	-7.77	-0.43	1.68e-13	Menarche (age at onset);
CESC	cis	rs11098499	0.739	rs951570	chr4:120150467	T/C	cg09307838	chr4:120376055	NA	-0.66	-8.15	-0.45	1.41e-14	Corneal astigmatism;
CESC	cis	rs7618915	0.547	rs10780035	chr3:52764624	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.49	6.96	0.39	2.69e-11	Bipolar disorder;
CESC	cis	rs72781680	0.784	rs72798406	chr2:24180144	T/C	cg08917208	chr2:24149416	ATAD2B	0.69	6.74	0.38	1e-10	Lymphocyte counts;
CESC	cis	rs4975709	0.589	rs4975747	chr5:1862836	G/A	cg12288994	chr5:1860383	NA	0.4	6.64	0.38	1.79e-10	Cardiovascular disease risk factors;
CESC	cis	rs9322193	0.886	rs9322198	chr6:149944908	T/C	cg13206674	chr6:150067644	NUP43	0.43	6.18	0.35	2.39e-9	Lung cancer;
CESC	cis	rs858239	0.932	rs1728313	chr7:23271031	A/C	cg23682824	chr7:23144976	KLHL7	0.45	6.04	0.35	5.17e-9	Cerebrospinal fluid biomarker levels;
CESC	cis	rs6063312	1.000	rs6095261	chr20:47346494	C/A	cg18078177	chr20:47281410	PREX1	0.56	5.49	0.32	9.43e-8	Tonometry;
CESC	cis	rs7914558	0.966	rs10786724	chr10:104668942	A/G	cg08650961	chr10:104748594	CNNM2	0.32	5.09	0.3	6.7e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs7666738	0.830	rs11727235	chr4:98946331	T/C	cg03467027	chr4:99064603	C4orf37	0.46	5.82	0.34	1.74e-8	Colonoscopy-negative controls vs population controls;
CESC	trans	rs3780486	0.718	rs7859454	chr9:33119583	T/A	cg04842962	chr6:43655489	MRPS18A	0.72	8.84	0.48	1.35e-16	IgG glycosylation;
CESC	cis	rs1448094	0.580	rs11615323	chr12:86282171	T/C	cg19622623	chr12:86230825	RASSF9	-0.44	-5.3	-0.31	2.38e-7	Major depressive disorder;
CESC	cis	rs7666738	0.830	rs10025174	chr4:98914172	A/G	cg03676636	chr4:99064102	C4orf37	0.35	5.2	0.3	3.93e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03436653	chr3:9932323	JAGN1	0.57	6.23	0.36	1.81e-9	Gut microbiome composition (summer);
CESC	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.52	0.37	3.52e-10	Prudent dietary pattern;
CESC	cis	rs6120849	0.518	rs11696652	chr20:33637060	T/G	cg06115741	chr20:33292138	TP53INP2	0.53	5.05	0.3	8.15e-7	Protein C levels;
CESC	cis	rs4595586	0.545	rs12823487	chr12:39391286	A/G	cg26384229	chr12:38710491	ALG10B	0.54	7.64	0.42	3.96e-13	Morning vs. evening chronotype;
CESC	cis	rs79349575	0.783	rs4793998	chr17:47019899	C/T	cg26022315	chr17:47021804	SNF8	0.39	5.16	0.3	4.94e-7	Type 2 diabetes;
CESC	cis	rs897984	0.609	rs1108431	chr16:31054607	C/T	cg02466173	chr16:30829666	NA	-0.44	-7.68	-0.43	3.08e-13	Dementia with Lewy bodies;
CESC	cis	rs1580019	0.563	rs4723169	chr7:32567577	G/A	cg06627557	chr7:32535165	LSM5;AVL9	1.06	18.97	0.76	2.73e-51	Cognitive ability;
CESC	cis	rs2806561	0.929	rs856508	chr1:23532995	A/C	cg12483005	chr1:23474871	LUZP1	0.32	5.05	0.3	8.18e-7	Height;
CESC	cis	rs10979	1.000	rs9386036	chr6:143890709	A/G	cg25407410	chr6:143891975	LOC285740	-0.61	-9.14	-0.49	1.72e-17	Hypospadias;
CESC	cis	rs9814567	0.762	rs13071253	chr3:134316653	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.45	6.05	0.35	4.86e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20935933	chr6:143382018	AIG1	0.59	6.68	0.38	1.37e-10	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19960880	chr10:97050830	PDLIM1	0.57	6.32	0.36	1.1e-9	Gut microbiome composition (summer);
CESC	cis	rs72781680	0.678	rs11125293	chr2:24102423	A/G	cg08917208	chr2:24149416	ATAD2B	0.6	6.02	0.35	5.77e-9	Lymphocyte counts;
CESC	cis	rs1950626	0.833	rs12892225	chr14:101415413	T/C	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.77	9.9	0.52	7.01e-20	Pelvic organ prolapse (moderate/severe);
CESC	cis	rs477692	1.000	rs569235	chr10:131411620	T/C	cg05714579	chr10:131428358	MGMT	0.48	6.43	0.37	5.82e-10	Response to temozolomide;
CESC	cis	rs7811142	0.830	rs11771936	chr7:99943283	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.05	10.66	0.55	2.52e-22	Platelet count;
CESC	cis	rs4595586	0.545	rs1400284	chr12:39400419	G/A	cg26384229	chr12:38710491	ALG10B	0.54	7.64	0.42	3.96e-13	Morning vs. evening chronotype;
CESC	cis	rs6546537	0.868	rs62133967	chr2:69891708	G/C	cg10773587	chr2:69614142	GFPT1	-0.59	-6.86	-0.39	4.74e-11	Serum thyroid-stimulating hormone levels;
CESC	cis	rs4148883	0.737	rs13148577	chr4:100060836	G/A	cg12011299	chr4:100065546	ADH4	0.71	10.56	0.54	5.49e-22	Alcohol dependence;
CESC	cis	rs12042052	0.590	rs2357332	chr1:232948252	C/T	cg00951395	chr1:232941775	KIAA1383	-0.54	-5.2	-0.3	4.08e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CESC	cis	rs9399135	0.660	rs4267967	chr6:135272477	T/G	cg24558204	chr6:135376177	HBS1L	0.59	8.24	0.45	7.91e-15	Red blood cell count;
CESC	cis	rs926938	0.501	rs360686	chr1:115502524	C/T	cg12756093	chr1:115239321	AMPD1	0.41	5.45	0.32	1.13e-7	Autism;
CESC	cis	rs2073300	0.609	rs6132606	chr20:23367453	G/A	cg16736954	chr20:23401023	NAPB	0.8	6.25	0.36	1.67e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs6547741	1.000	rs1080060	chr2:27768808	T/A	cg27432699	chr2:27873401	GPN1	0.49	6.86	0.39	4.85e-11	Oral cavity cancer;
CESC	cis	rs9914988	0.832	rs9903248	chr17:27127439	G/T	cg20469991	chr17:27169893	C17orf63	-0.48	-5.25	-0.31	3.18e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CESC	cis	rs3105593	0.965	rs62017197	chr15:50940491	G/A	cg08437265	chr15:50716283	USP8	0.42	5.49	0.32	9.47e-8	QT interval;
CESC	cis	rs11650494	0.710	rs11651666	chr17:47474571	C/T	cg08112188	chr17:47440006	ZNF652	1.15	7.89	0.44	7.86e-14	Prostate cancer;
CESC	cis	rs7474896	0.515	rs675628	chr10:38305331	C/G	cg25427524	chr10:38739819	LOC399744	0.5	5.62	0.33	4.91e-8	Obesity (extreme);
CESC	cis	rs11997175	0.626	rs6468189	chr8:33648189	C/A	ch.8.33884649F	chr8:33765107	NA	0.54	6.72	0.38	1.11e-10	Body mass index;
CESC	cis	rs2072732	0.716	rs72856433	chr1:2954061	G/A	cg15211996	chr1:2936768	ACTRT2	0.31	5.51	0.32	8.53e-8	Plateletcrit;
CESC	cis	rs3820068	0.581	rs72645877	chr1:15928106	G/T	cg16988262	chr1:15930761	NA	0.35	5.65	0.33	4.18e-8	Systolic blood pressure;
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg05694744	chr17:8191820	RANGRF;SLC25A35	-0.46	-6.83	-0.39	5.67e-11	Vertical cup-disc ratio;
CESC	cis	rs7584330	0.737	rs7568588	chr2:238364342	G/T	cg14458575	chr2:238380390	NA	0.62	8.43	0.46	2.3e-15	Prostate cancer;
CESC	cis	rs8017423	0.935	rs59179255	chr14:90691773	A/C	cg14092571	chr14:90743983	NA	-0.56	-8.25	-0.45	7.35e-15	Mortality in heart failure;
CESC	cis	rs12477438	0.765	rs2309520	chr2:99570477	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.64	8.72	0.47	3.22e-16	Chronic sinus infection;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14005384	chr15:89877925	POLG	0.56	6.2	0.36	2.2e-9	Gut microbiome composition (summer);
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg02756545	chr1:94884060	ABCD3	0.48	6.64	0.38	1.73e-10	Systemic lupus erythematosus;
CESC	cis	rs7580658	0.724	rs6712446	chr2:127998399	G/T	cg10021288	chr2:128175891	PROC	-0.4	-6.37	-0.36	8.33e-10	Protein C levels;
CESC	cis	rs12410462	1.000	rs12410243	chr1:227669474	A/G	cg04117972	chr1:227635322	NA	0.66	6.61	0.38	2.13e-10	Major depressive disorder;
CESC	cis	rs35110281	0.594	rs230641	chr21:44915441	T/C	cg01579765	chr21:45077557	HSF2BP	0.43	7.19	0.4	6.53e-12	Mean corpuscular volume;
CESC	cis	rs11864453	0.749	rs7192730	chr16:72124219	T/C	cg01557791	chr16:72042693	DHODH	-0.46	-5.92	-0.34	9.98e-9	Fibrinogen levels;
CESC	cis	rs13108904	0.935	rs13148614	chr4:1248357	G/C	cg16405210	chr4:1374714	KIAA1530	-0.44	-5.86	-0.34	1.36e-8	Obesity-related traits;
CESC	cis	rs2180341	0.960	rs7773484	chr6:127670779	T/C	cg24812749	chr6:127587940	RNF146	1.05	15.07	0.68	1.77e-37	Breast cancer;
CESC	cis	rs1005224	1.000	rs1158282	chr14:76172916	C/G	cg25116370	chr14:76127843	TTLL5;C14orf1	-0.39	-5.3	-0.31	2.42e-7	Large artery stroke;
CESC	cis	rs7084402	0.967	rs2170779	chr10:60277249	G/A	cg07615347	chr10:60278583	BICC1	-0.59	-9.45	-0.5	1.94e-18	Refractive error;
CESC	cis	rs7615952	0.512	rs4646765	chr3:125820707	G/A	cg04553112	chr3:125709451	NA	-0.54	-5.82	-0.34	1.71e-8	Blood pressure (smoking interaction);
CESC	trans	rs1814175	0.645	rs7928714	chr11:49887622	G/A	cg03929089	chr4:120376271	NA	-0.88	-14.39	-0.66	4.31e-35	Height;
CESC	cis	rs769267	0.895	rs2916074	chr19:19530270	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.45	5.89	0.34	1.15e-8	Tonsillectomy;
CESC	cis	rs12541635	0.677	rs2880950	chr8:106983624	C/A	cg10147462	chr8:107024639	NA	0.46	6.71	0.38	1.19e-10	Age of smoking initiation;
CESC	cis	rs722599	0.715	rs8008785	chr14:75307600	G/A	cg08847533	chr14:75593920	NEK9	-0.48	-6.1	-0.35	3.82e-9	IgG glycosylation;
CESC	cis	rs425277	0.583	rs3107151	chr1:2051513	T/G	cg19257562	chr1:2043853	PRKCZ	0.4	6.58	0.37	2.44e-10	Height;
CESC	cis	rs7296418	0.630	rs11057238	chr12:123767971	C/A	cg00376283	chr12:123451042	ABCB9	0.58	7.91	0.44	7.01e-14	Platelet count;
CESC	cis	rs896854	0.654	rs13248607	chr8:95986637	T/G	cg23172400	chr8:95962367	TP53INP1	-0.44	-9.11	-0.49	2.05e-17	Type 2 diabetes;
CESC	cis	rs5769765	0.720	rs138820	chr22:50164078	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.48	-5.19	-0.3	4.12e-7	Schizophrenia;
CESC	cis	rs56399783	0.901	rs56356906	chr7:2774383	G/A	cg19731401	chr7:2775893	GNA12	0.69	6.13	0.35	3.19e-9	Childhood ear infection;
CESC	cis	rs4819052	0.851	rs7276828	chr21:46695039	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.93	13.85	0.65	3.59e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs861020	1.000	rs680923	chr1:209986672	T/C	cg05527609	chr1:210001259	C1orf107	1.07	13.45	0.64	8.92e-32	Orofacial clefts;
CESC	trans	rs12599106	0.715	rs34006830	chr16:34878550	C/A	cg21548813	chr6:291882	DUSP22	-0.75	-9.73	-0.51	2.48e-19	Menopause (age at onset);
CESC	cis	rs1003719	0.715	rs2835659	chr21:38567902	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.59	-8.14	-0.45	1.59e-14	Eye color traits;
CESC	cis	rs1218582	0.741	rs11264281	chr1:154867221	A/G	cg03351412	chr1:154909251	PMVK	0.59	7.47	0.42	1.14e-12	Prostate cancer;
CESC	cis	rs7100689	0.577	rs2282367	chr10:82040346	A/G	cg00277334	chr10:82204260	NA	-0.52	-6.78	-0.38	7.96e-11	Post bronchodilator FEV1;
CESC	cis	rs2839186	0.770	rs2839171	chr21:47673247	C/T	cg13126279	chr21:47581558	C21orf56	0.52	7.14	0.4	8.98e-12	Testicular germ cell tumor;
CESC	cis	rs9487051	0.646	rs55677234	chr6:109621974	G/A	cg01475377	chr6:109611718	NA	-0.39	-5.39	-0.31	1.55e-7	Reticulocyte fraction of red cells;
CESC	cis	rs9916302	0.904	rs12952384	chr17:37669536	T/C	cg07936489	chr17:37558343	FBXL20	-0.81	-12.02	-0.59	7.28e-27	Glomerular filtration rate (creatinine);
CESC	cis	rs7208859	0.623	rs59447372	chr17:29057585	C/T	cg14008862	chr17:28927542	LRRC37B2	0.65	5.12	0.3	5.86e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg15112475	chr7:1198522	ZFAND2A	-0.36	-5.77	-0.33	2.2e-8	Longevity;Endometriosis;
CESC	cis	rs34779708	0.733	rs12254018	chr10:35550641	T/A	cg04310649	chr10:35416472	CREM	-0.46	-5.22	-0.31	3.55e-7	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs6540556	0.723	rs1000282	chr1:209894785	T/C	cg05527609	chr1:210001259	C1orf107	-0.66	-7.34	-0.41	2.56e-12	Red blood cell count;
CESC	cis	rs7618915	0.571	rs2289249	chr3:52597664	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.47	6.49	0.37	4.31e-10	Bipolar disorder;
CESC	cis	rs959260	0.610	rs9906825	chr17:73350580	C/T	cg20590849	chr17:73267439	MIF4GD	-0.56	-6.27	-0.36	1.49e-9	Systemic lupus erythematosus;
CESC	cis	rs10875746	0.729	rs1990028	chr12:48408013	A/G	cg24011408	chr12:48396354	COL2A1	-0.42	-5.12	-0.3	5.87e-7	Longevity (90 years and older);
CESC	cis	rs599083	0.530	rs583545	chr11:68178635	T/C	cg01657329	chr11:68192670	LRP5	0.44	5.23	0.31	3.39e-7	Bone mineral density (spine);
CESC	cis	rs3741151	0.773	rs17244596	chr11:73179236	A/G	cg17517138	chr11:73019481	ARHGEF17	0.95	6.99	0.39	2.29e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs1697139	0.583	rs11739727	chr5:66540940	G/A	cg11553311	chr5:66541588	NA	0.39	5.46	0.32	1.12e-7	Breast cancer;
CESC	cis	rs7811142	0.830	rs73401443	chr7:99977582	T/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.91	9.82	0.52	1.26e-19	Platelet count;
CESC	cis	rs6582630	0.555	rs10785454	chr12:38476260	C/T	cg13010199	chr12:38710504	ALG10B	0.47	6.11	0.35	3.63e-9	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs17376456	0.877	rs12153506	chr5:93360953	T/G	cg25358565	chr5:93447407	FAM172A	1.1	10.93	0.56	3.31e-23	Diabetic retinopathy;
CESC	cis	rs3749237	0.595	rs11720264	chr3:49580347	C/T	cg06212747	chr3:49208901	KLHDC8B	0.47	6.32	0.36	1.13e-9	Resting heart rate;
CESC	trans	rs459571	0.959	rs460888	chr9:136913123	C/G	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.66	-8.64	-0.47	5.55e-16	Platelet distribution width;
CESC	cis	rs10751667	0.600	rs1128419	chr11:1010750	G/A	cg01483505	chr11:975446	AP2A2	0.41	5.39	0.31	1.6e-7	Alzheimer's disease (late onset);
CESC	cis	rs2842992	0.768	rs2273824	chr6:160211445	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.85	12.01	0.59	8.38e-27	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs761746	0.960	rs4535154	chr22:31896232	T/C	cg25791279	chr22:32026902	PISD	-0.51	-5.65	-0.33	4.17e-8	Intelligence;
CESC	cis	rs1691799	0.867	rs961049	chr12:66762591	A/C	cg16791601	chr12:66731901	HELB	0.56	8.79	0.47	1.98e-16	White blood cell count (basophil);
CESC	cis	rs9457247	0.663	rs7749278	chr6:167435325	C/T	cg07741184	chr6:167504864	NA	-0.33	-5.79	-0.34	1.98e-8	Crohn's disease;
CESC	cis	rs17376456	1.000	rs61132622	chr5:93539684	G/A	cg21475434	chr5:93447410	FAM172A	0.86	7.69	0.43	2.82e-13	Diabetic retinopathy;
CESC	cis	rs6089584	1.000	rs6089585	chr20:60564395	G/A	cg13770153	chr20:60521292	NA	-0.45	-5.9	-0.34	1.12e-8	Body mass index;
CESC	cis	rs898097	0.690	rs12452304	chr17:80811659	G/A	cg15664640	chr17:80829946	TBCD	-0.63	-9.1	-0.49	2.3e-17	Breast cancer;
CESC	cis	rs826838	0.934	rs10875647	chr12:38856995	G/A	cg26384229	chr12:38710491	ALG10B	0.83	14.57	0.67	1.05e-35	Heart rate;
CESC	cis	rs4925386	0.840	rs6143024	chr20:60914229	A/G	cg22633769	chr20:60982531	CABLES2	0.55	5.63	0.33	4.64e-8	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs2839186	0.771	rs2280957	chr21:47642272	A/G	cg05896524	chr21:47604654	C21orf56	-0.39	-5.11	-0.3	6.31e-7	Testicular germ cell tumor;
CESC	cis	rs12477438	0.798	rs1453562	chr2:99615850	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-10.57	-0.54	5.22e-22	Chronic sinus infection;
CESC	cis	rs7605827	0.930	rs7578787	chr2:15655119	T/C	cg19274914	chr2:15703543	NA	0.37	6.65	0.38	1.7e-10	Educational attainment (years of education);
CESC	cis	rs6460942	0.597	rs17544637	chr7:12521871	T/C	cg20607287	chr7:12443886	VWDE	-0.63	-7.11	-0.4	1.1e-11	Coronary artery disease;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg24005340	chr5:168006702	PANK3	-0.42	-6.05	-0.35	4.82e-9	Gambling;
CESC	cis	rs2440129	0.611	rs434473	chr17:6904934	A/G	cg21237687	chr17:6899380	ALOX12	-0.44	-7.01	-0.4	1.92e-11	Tonsillectomy;
CESC	cis	rs13191362	1.000	rs13220048	chr6:163004325	T/A	cg14584255	chr6:163149320	PACRG;PARK2	0.5	5.17	0.3	4.64e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs6952808	0.929	rs12532128	chr7:1925454	T/C	cg00106254	chr7:1943704	MAD1L1	-0.47	-5.82	-0.34	1.7e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs7666738	0.830	rs3907021	chr4:99038668	C/T	cg03467027	chr4:99064603	C4orf37	0.47	5.98	0.34	7.19e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7107174	1.000	rs4945261	chr11:77990260	A/G	cg02023728	chr11:77925099	USP35	-0.47	-6.48	-0.37	4.39e-10	Testicular germ cell tumor;
CESC	cis	rs2303745	0.544	rs12710308	chr19:17395879	T/A	cg04248312	chr19:17393744	ANKLE1	-0.94	-15.37	-0.69	1.53e-38	Systemic lupus erythematosus;
CESC	cis	rs2573652	1.000	rs2573625	chr15:100513158	A/G	cg09918751	chr15:100517450	ADAMTS17	0.42	8.06	0.44	2.56e-14	Height;
CESC	cis	rs11098499	0.909	rs28714195	chr4:120316950	A/T	cg09307838	chr4:120376055	NA	0.92	12.46	0.61	2.41e-28	Corneal astigmatism;
CESC	cis	rs9611565	0.559	rs4822048	chr22:41988225	C/T	cg06481639	chr22:41940642	POLR3H	-0.65	-6.38	-0.37	7.65e-10	Vitiligo;
CESC	cis	rs7408868	0.563	rs11085949	chr19:15296917	G/T	cg14696996	chr19:15285081	NOTCH3	0.98	9.89	0.52	7.82e-20	Pulse pressure;
CESC	cis	rs4665809	0.531	rs12990692	chr2:26464939	C/T	cg27170947	chr2:26402098	FAM59B	0.87	10.16	0.53	1.05e-20	Gut microbiome composition (summer);
CESC	cis	rs2066819	1.000	rs57870697	chr12:56752874	A/G	cg26734620	chr12:56694298	CS	0.97	5.8	0.34	1.92e-8	Psoriasis vulgaris;
CESC	cis	rs10504229	0.775	rs56155911	chr8:58163247	C/T	cg24829409	chr8:58192753	C8orf71	-0.67	-7.97	-0.44	4.6e-14	Developmental language disorder (linguistic errors);
CESC	cis	rs4555082	0.834	rs2735819	chr14:105713449	C/T	cg27165867	chr14:105738592	BRF1	-0.48	-5.16	-0.3	4.75e-7	Mean platelet volume;Platelet distribution width;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg05981015	chr17:27717136	TAOK1	-0.49	-6.62	-0.38	2.03e-10	Height;
CESC	cis	rs7945705	0.967	rs10769968	chr11:8907583	G/C	cg09997546	chr11:8931473	C11orf17;ST5	0.32	5.06	0.3	7.68e-7	Hemoglobin concentration;
CESC	cis	rs116095464	1.000	rs62346511	chr5:208265	C/T	cg22496380	chr5:211416	CCDC127	-0.92	-5.48	-0.32	9.95e-8	Breast cancer;
CESC	cis	rs722599	0.715	rs2300598	chr14:75359229	T/C	cg08847533	chr14:75593920	NEK9	-0.45	-5.34	-0.31	2.05e-7	IgG glycosylation;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02075454	chr13:111364916	ING1	0.59	6.42	0.37	6.16e-10	Gut microbiome composition (summer);
CESC	cis	rs62064224	0.658	rs62065460	chr17:30715007	A/G	cg18200150	chr17:30822561	MYO1D	0.68	10.38	0.54	2.04e-21	Schizophrenia;
CESC	cis	rs1144333	0.655	rs114383686	chr1:76325327	C/T	cg10523679	chr1:76189770	ACADM	0.56	5.38	0.31	1.61e-7	Attention function in attention deficit hyperactive disorder;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg12506373	chr2:27440548	CAD	0.57	7.84	0.43	1.12e-13	Gut microbiota (bacterial taxa);
CESC	cis	rs853679	0.517	rs9393886	chr6:28050039	T/G	cg22143856	chr6:28129313	ZNF389	0.49	6.3	0.36	1.2e-9	Depression;
CESC	cis	rs7726839	0.794	rs11739663	chr5:594083	A/G	cg09021430	chr5:549028	NA	-0.43	-6.09	-0.35	4.04e-9	Obesity-related traits;
CESC	cis	rs7586879	0.639	rs6545776	chr2:25099357	A/C	cg01884057	chr2:25150051	NA	0.38	7.3	0.41	3.44e-12	Body mass index;
CESC	cis	rs5758659	0.652	rs133322	chr22:42405659	A/G	cg15557168	chr22:42548783	NA	-0.45	-6.68	-0.38	1.39e-10	Cognitive function;
CESC	cis	rs12545109	0.671	rs35500854	chr8:57424303	G/A	cg09654669	chr8:57350985	NA	-0.56	-6.67	-0.38	1.46e-10	Obesity-related traits;
CESC	cis	rs6121246	0.954	rs6089093	chr20:30421459	C/T	cg13852791	chr20:30311386	BCL2L1	0.8	7.9	0.44	7.58e-14	Mean corpuscular hemoglobin;
CESC	cis	rs8114671	0.836	rs6141526	chr20:33615255	G/T	cg07148914	chr20:33460835	GGT7	-0.42	-5.48	-0.32	9.89e-8	Height;
CESC	cis	rs1712517	0.526	rs113528138	chr10:105125451	C/A	cg04362960	chr10:104952993	NT5C2	-0.46	-5.55	-0.32	6.86e-8	Migraine;
CESC	trans	rs6499188	0.571	rs1645975	chr16:68564448	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.61	7.42	0.41	1.57e-12	Ulcerative colitis;
CESC	cis	rs7917772	0.502	rs10748827	chr10:104368336	G/T	ch.10.2196322F	chr10:104248062	ACTR1A	0.43	5.31	0.31	2.28e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs8180040	0.654	rs6773521	chr3:47234419	A/G	cg27129171	chr3:47204927	SETD2	-0.66	-9.64	-0.51	4.74e-19	Colorectal cancer;
CESC	trans	rs8073060	0.544	rs8071584	chr17:33999435	G/A	cg19694781	chr19:47549865	TMEM160	-0.74	-6.91	-0.39	3.64e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	cis	rs2880765	0.835	rs4280192	chr15:86043020	G/A	cg19183879	chr15:85880815	NA	-0.26	-5.33	-0.31	2.15e-7	Coronary artery disease;
CESC	cis	rs736408	0.570	rs11130327	chr3:52793239	A/G	cg17372223	chr3:52568218	NT5DC2	0.42	6.09	0.35	3.86e-9	Bipolar disorder;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg22187094	chr15:89878452	POLG	0.51	6.67	0.38	1.46e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs9325144	0.560	rs11182952	chr12:38636278	C/A	cg26384229	chr12:38710491	ALG10B	-0.61	-8.58	-0.47	8.35e-16	Morning vs. evening chronotype;
CESC	cis	rs10876993	0.890	rs1678539	chr12:58060359	A/G	cg18357645	chr12:58087776	OS9	0.63	10.11	0.53	1.54e-20	Celiac disease or Rheumatoid arthritis;
CESC	cis	rs10504229	0.906	rs73607869	chr8:58172665	G/T	cg14926445	chr8:58193284	C8orf71	-0.51	-5.47	-0.32	1.03e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs4555082	0.830	rs2255575	chr14:105727251	T/C	cg06808227	chr14:105710500	BRF1	-0.64	-7.65	-0.43	3.72e-13	Mean platelet volume;Platelet distribution width;
CESC	cis	rs8072100	0.790	rs11079783	chr17:45686016	C/T	cg08085267	chr17:45401833	C17orf57	0.48	5.96	0.34	8.02e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs9322193	0.886	rs12525871	chr6:150097018	A/G	cg07701084	chr6:150067640	NUP43	0.43	5.8	0.34	1.9e-8	Lung cancer;
CESC	cis	rs9611565	0.512	rs4512	chr22:42206084	G/C	cg03806693	chr22:41940476	POLR3H	-1.2	-13.55	-0.64	3.84e-32	Vitiligo;
CESC	cis	rs9814567	1.000	rs6804770	chr3:134230234	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.42	-5.76	-0.33	2.38e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs4595586	0.545	rs12821810	chr12:39375858	T/C	cg26384229	chr12:38710491	ALG10B	0.54	7.53	0.42	7.85e-13	Morning vs. evening chronotype;
CESC	cis	rs13082711	0.554	rs9310843	chr3:27371260	A/G	cg02860705	chr3:27208620	NA	0.51	6.55	0.37	2.99e-10	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CESC	cis	rs2644899	0.750	rs2607414	chr19:41267129	C/T	cg24958765	chr19:41283667	RAB4B	0.57	6.62	0.38	1.95e-10	Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs1218582	0.741	rs10908444	chr1:154840287	G/A	cg24250549	chr1:154909240	PMVK	0.74	11.1	0.56	9.2e-24	Prostate cancer;
CESC	trans	rs1814175	0.817	rs7950856	chr11:49976394	C/T	cg03929089	chr4:120376271	NA	-0.93	-16.32	-0.71	6.51e-42	Height;
CESC	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg22520471	chr17:61851767	DDX42;CCDC47	-0.9	-13.83	-0.65	3.99e-33	Prudent dietary pattern;
CESC	cis	rs7666738	0.830	rs28497822	chr4:98906873	C/T	cg17366294	chr4:99064904	C4orf37	0.55	7.63	0.42	4.35e-13	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26350446	chr7:111202682	IMMP2L	-0.53	-6.17	-0.35	2.52e-9	Gut microbiome composition (summer);
CESC	cis	rs4819052	0.679	rs28623526	chr21:46712324	T/C	cg11663144	chr21:46675770	NA	-0.46	-7.09	-0.4	1.23e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs1506636	1.000	rs684548	chr7:123397102	A/T	cg03229431	chr7:123269106	ASB15	0.52	6.96	0.39	2.64e-11	Plateletcrit;Platelet count;
CESC	cis	rs561341	0.709	rs11542477	chr17:30185892	A/G	cg12193833	chr17:30244370	NA	0.63	6.08	0.35	4.25e-9	Hip circumference adjusted for BMI;
CESC	cis	rs9322193	0.923	rs2297932	chr6:150039361	C/G	cg09699651	chr6:150184138	LRP11	0.39	5.04	0.3	8.83e-7	Lung cancer;
CESC	cis	rs7542091	0.704	rs1108628	chr1:210041150	A/G	cg21951975	chr1:209979733	IRF6	0.45	7.73	0.43	2.21e-13	Monobrow;
CESC	trans	rs61931739	0.824	rs406753	chr12:34117408	A/G	cg26384229	chr12:38710491	ALG10B	0.44	6.05	0.35	4.95e-9	Morning vs. evening chronotype;
CESC	cis	rs12145833	0.596	rs12043646	chr1:243281992	G/A	cg02356786	chr1:243265016	LOC731275	0.77	6.4	0.37	7.06e-10	Obesity (early onset extreme);
CESC	cis	rs10791323	0.546	rs55801927	chr11:133713094	A/C	cg14349672	chr11:133703707	NA	-0.36	-5.06	-0.3	7.92e-7	Childhood ear infection;
CESC	cis	rs2836950	0.520	rs59916147	chr21:40634702	T/G	cg11890956	chr21:40555474	PSMG1	-0.66	-9.09	-0.49	2.4e-17	Menarche (age at onset);
CESC	cis	rs9467711	0.559	rs13208916	chr6:26601940	G/A	cg12826209	chr6:26865740	GUSBL1	0.67	6.06	0.35	4.68e-9	Autism spectrum disorder or schizophrenia;
CESC	trans	rs7987251	0.609	rs3736470	chr13:60617106	A/C	cg27049993	chr17:65370839	NA	0.77	6.18	0.35	2.42e-9	Trans fatty acid levels;
CESC	cis	rs7017914	0.934	rs1389202	chr8:71852285	C/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.42	-5.33	-0.31	2.11e-7	Bone mineral density;
CESC	cis	rs28830936	1.000	rs17678767	chr15:42096422	C/G	cg11010575	chr15:42129464	JMJD7-PLA2G4B;JMJD7	-0.41	-5.59	-0.32	5.56e-8	Diastolic blood pressure;
CESC	cis	rs921968	0.541	rs6717433	chr2:219375711	G/C	cg02176678	chr2:219576539	TTLL4	-0.53	-9.3	-0.5	5.42e-18	Mean corpuscular hemoglobin concentration;
CESC	cis	rs9649213	0.593	rs6948540	chr7:97960066	A/G	cg00277769	chr7:97922759	BAIAP2L1	-0.34	-5.63	-0.33	4.68e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs12893668	0.703	rs8017993	chr14:104047734	A/G	cg24130564	chr14:104152367	KLC1	-0.46	-5.76	-0.33	2.35e-8	Reticulocyte count;
CESC	cis	rs11122272	0.735	rs2250749	chr1:231485763	C/G	cg06096015	chr1:231504339	EGLN1	0.4	5.84	0.34	1.5e-8	Hemoglobin concentration;
CESC	cis	rs7216064	0.817	rs12601921	chr17:65825354	C/T	cg12091567	chr17:66097778	LOC651250	-0.87	-8.62	-0.47	6.33e-16	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs77106637	0.929	rs1059000	chr11:72504972	G/C	cg03713592	chr11:72463424	ARAP1	1.23	11.1	0.56	9.02e-24	Type 2 diabetes;
CESC	cis	rs2836974	0.965	rs34578707	chr21:40675167	G/A	cg11644478	chr21:40555479	PSMG1	0.96	13.64	0.64	1.85e-32	Cognitive function;
CESC	cis	rs6547741	1.000	rs4665381	chr2:27757150	A/C	cg27432699	chr2:27873401	GPN1	0.49	6.78	0.38	7.74e-11	Oral cavity cancer;
CESC	cis	rs936229	0.656	rs2290572	chr15:75130573	A/G	cg14664628	chr15:75095509	CSK	-0.56	-7.42	-0.41	1.58e-12	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CESC	cis	rs7296418	0.961	rs1790094	chr12:123586688	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.32	-5.03	-0.3	8.87e-7	Platelet count;
CESC	cis	rs7267979	1.000	rs447722	chr20:25443510	C/T	cg08601574	chr20:25228251	PYGB	0.37	5.31	0.31	2.31e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs1552244	1.000	rs9827740	chr3:10120531	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.85	-11.68	-0.58	1.06e-25	Alzheimer's disease;
CESC	cis	rs736408	0.608	rs6445534	chr3:52743384	G/A	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.64	0.38	1.78e-10	Bipolar disorder;
CESC	cis	rs7267979	0.903	rs2474769	chr20:25248725	C/T	cg08601574	chr20:25228251	PYGB	0.43	6.32	0.36	1.1e-9	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs9768139	0.733	rs13221388	chr7:158119270	G/A	cg25566285	chr7:158114605	PTPRN2	0.49	8.13	0.45	1.64e-14	Calcium levels;
CESC	cis	rs4342066	0.593	rs6792215	chr3:28276784	A/T	cg15038811	chr3:28283857	CMC1	0.39	5.07	0.3	7.31e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs896854	0.540	rs2011567	chr8:95971920	G/A	cg23172400	chr8:95962367	TP53INP1	-0.44	-8.97	-0.48	5.48e-17	Type 2 diabetes;
CESC	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg23034840	chr1:205782522	SLC41A1	0.66	7.97	0.44	4.68e-14	Menarche (age at onset);
CESC	cis	rs8050907	0.744	rs13335503	chr16:4529028	T/C	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.89	6.26	0.36	1.51e-9	Obesity-related traits;
CESC	cis	rs1448094	0.512	rs7313035	chr12:86250100	C/G	cg19622623	chr12:86230825	RASSF9	-0.46	-5.93	-0.34	9.45e-9	Major depressive disorder;
CESC	cis	rs6582630	0.519	rs12366667	chr12:38332632	C/T	cg26384229	chr12:38710491	ALG10B	0.73	10.9	0.56	4.29e-23	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs2439831	0.867	rs16957632	chr15:43642897	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.9	10.37	0.54	2.22e-21	Lung cancer in ever smokers;
CESC	cis	rs4704187	0.687	rs4704179	chr5:74457273	C/T	cg03227963	chr5:74354835	NA	0.3	5.49	0.32	9.27e-8	Response to amphetamines;
CESC	cis	rs929596	0.583	rs77070100	chr2:234587847	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.43	-5.28	-0.31	2.75e-7	Total bilirubin levels in HIV-1 infection;
CESC	cis	rs6500602	0.702	rs1051308	chr16:4560301	A/G	cg08645402	chr16:4508243	NA	-0.59	-9.72	-0.51	2.72e-19	Schizophrenia;
CESC	cis	rs12142240	0.698	rs66972124	chr1:46807445	A/G	cg10495392	chr1:46806563	NSUN4	0.59	6.34	0.36	9.65e-10	Menopause (age at onset);
CESC	cis	rs875971	0.651	rs2420596	chr7:65915983	T/C	cg10691866	chr7:65817282	TPST1	-0.31	-5.16	-0.3	4.78e-7	Aortic root size;
CESC	cis	rs10751667	0.666	rs7934963	chr11:957220	C/T	cg20946044	chr11:1010712	AP2A2	-0.39	-5.35	-0.31	1.89e-7	Alzheimer's disease (late onset);
CESC	cis	rs7618915	0.547	rs11130313	chr3:52676190	A/C	cg18099408	chr3:52552593	STAB1	-0.3	-5.04	-0.3	8.71e-7	Bipolar disorder;
CESC	cis	rs425277	0.539	rs3107142	chr1:2044542	T/C	cg19257562	chr1:2043853	PRKCZ	0.41	6.68	0.38	1.37e-10	Height;
CESC	cis	rs17253792	0.822	rs7145064	chr14:56088860	C/T	cg01858014	chr14:56050164	KTN1	-0.91	-7.19	-0.4	6.43e-12	Putamen volume;
CESC	cis	rs72781680	1.000	rs72798417	chr2:24188656	C/T	cg08917208	chr2:24149416	ATAD2B	0.94	8.54	0.46	1.09e-15	Lymphocyte counts;
CESC	cis	rs9522267	0.535	rs9522303	chr13:112237301	T/C	cg10483660	chr13:112241077	NA	-0.33	-5.78	-0.33	2.14e-8	Hepatitis;
CESC	cis	rs875971	0.723	rs28391294	chr7:65654315	T/C	cg10691866	chr7:65817282	TPST1	0.31	5.24	0.31	3.34e-7	Aortic root size;
CESC	cis	rs4665809	0.590	rs13006973	chr2:26454707	C/T	cg27170947	chr2:26402098	FAM59B	0.87	9.89	0.52	7.6e-20	Gut microbiome composition (summer);
CESC	cis	rs7264396	0.563	rs6060558	chr20:34271092	C/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.6	5.87	0.34	1.33e-8	Total cholesterol levels;
CESC	cis	rs637571	0.607	rs574586	chr11:65697083	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.43	6.1	0.35	3.66e-9	Eosinophil percentage of white cells;
CESC	cis	rs11690935	0.918	rs11757	chr2:172641045	C/G	cg13550731	chr2:172543902	DYNC1I2	-0.97	-14.95	-0.68	4.66e-37	Schizophrenia;
CESC	cis	rs10504229	1.000	rs66495524	chr8:58187365	C/T	cg14926445	chr8:58193284	C8orf71	-0.51	-5.52	-0.32	8.28e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs763121	0.886	rs1013339	chr22:38974680	C/T	cg06544989	chr22:39130855	UNC84B	0.51	9.31	0.5	4.98e-18	Menopause (age at onset);
CESC	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg00738919	chr7:1100172	C7orf50	0.53	5.38	0.31	1.65e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs514406	0.861	rs35517489	chr1:53304062	G/C	cg24675658	chr1:53192096	ZYG11B	-0.6	-7.72	-0.43	2.43e-13	Monocyte count;
CESC	cis	rs939658	0.805	rs11634903	chr15:79436192	C/T	cg17916960	chr15:79447300	NA	0.35	5.9	0.34	1.12e-8	Refractive error;
CESC	cis	rs9522267	0.502	rs9522297	chr13:112234419	C/T	cg10483660	chr13:112241077	NA	-0.33	-5.79	-0.33	2.04e-8	Hepatitis;
CESC	cis	rs6089584	0.927	rs3787427	chr20:60579789	T/C	cg24733560	chr20:60626293	TAF4	0.41	5.91	0.34	1.04e-8	Body mass index;
CESC	cis	rs7777484	0.534	rs2258709	chr7:2832365	C/T	cg19717773	chr7:2847554	GNA12	0.66	11.33	0.57	1.63e-24	Height;
CESC	cis	rs1707322	0.721	rs4559551	chr1:46167533	T/C	cg06784218	chr1:46089804	CCDC17	0.43	7.58	0.42	5.74e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7666738	0.830	rs1426670	chr4:98923572	A/G	cg05340658	chr4:99064831	C4orf37	0.82	12.21	0.6	1.68e-27	Colonoscopy-negative controls vs population controls;
CESC	trans	rs1814175	0.935	rs7482690	chr11:49648814	C/T	cg03929089	chr4:120376271	NA	-0.85	-12.82	-0.62	1.34e-29	Height;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg14571620	chr12:123717888	C12orf65	0.48	6.31	0.36	1.16e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs733592	0.507	rs10747529	chr12:48473369	G/A	cg24011408	chr12:48396354	COL2A1	-0.5	-8.24	-0.45	7.74e-15	Plateletcrit;
CESC	cis	rs7116495	1.000	rs659513	chr11:71812411	C/T	cg26138937	chr11:71823887	C11orf51	0.87	7.39	0.41	1.95e-12	Severe influenza A (H1N1) infection;
CESC	cis	rs9611565	0.921	rs8137373	chr22:41729216	A/G	cg03806693	chr22:41940476	POLR3H	0.85	9.58	0.51	7.31e-19	Vitiligo;
CESC	cis	rs9925964	0.591	rs11649653	chr16:30918487	C/G	cg00531865	chr16:30841666	NA	0.41	5.14	0.3	5.44e-7	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs9733	0.596	rs72700897	chr1:150626038	C/G	cg17724175	chr1:150552817	MCL1	0.44	7.21	0.41	5.75e-12	Tonsillectomy;
CESC	cis	rs870825	0.518	rs56034065	chr4:185655402	A/G	cg07424746	chr4:185654737	MLF1IP	-0.71	-5.19	-0.3	4.1e-7	Blood protein levels;
CESC	cis	rs763014	0.932	rs2384975	chr16:651115	G/T	cg07256732	chr16:621771	PIGQ	-0.3	-5.33	-0.31	2.07e-7	Height;
CESC	cis	rs4642101	0.662	rs9874893	chr3:12833079	C/G	cg05775895	chr3:12838266	CAND2	0.38	5.6	0.33	5.22e-8	QRS complex (12-leadsum);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12169852	chr17:57231726	SKA2;PRR11	-0.6	-7.44	-0.42	1.42e-12	Gut microbiome composition (summer);
CESC	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg07677032	chr17:61819896	STRADA	0.44	5.85	0.34	1.44e-8	Prudent dietary pattern;
CESC	cis	rs1799949	0.930	rs4445938	chr17:41337900	A/C	cg23758822	chr17:41437982	NA	1.04	16.01	0.7	7.99e-41	Menopause (age at onset);
CESC	cis	rs12048904	0.930	rs11166529	chr1:101333733	C/T	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.43	5.12	0.3	6e-7	Multiple sclerosis;
CESC	cis	rs1862618	0.853	rs43184	chr5:56141777	G/C	cg18230493	chr5:56204884	C5orf35	-0.74	-8.84	-0.48	1.37e-16	Initial pursuit acceleration;
CESC	cis	rs13191362	0.507	rs2023037	chr6:163120385	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.51	6.2	0.36	2.11e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	10.16	0.53	1.09e-20	Prudent dietary pattern;
CESC	cis	rs1799949	0.965	rs8176087	chr17:41270666	C/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.43	5.84	0.34	1.56e-8	Menopause (age at onset);
CESC	cis	rs9905704	0.918	rs430973	chr17:56709206	T/G	cg12560992	chr17:57184187	TRIM37	0.59	6.98	0.39	2.34e-11	Testicular germ cell tumor;
CESC	cis	rs10129255	0.536	rs6576201	chr14:107139713	A/G	cg23076370	chr14:107095027	NA	0.53	7.75	0.43	2e-13	Kawasaki disease;
CESC	cis	rs2228479	0.850	rs2238527	chr16:89840708	C/A	cg06558623	chr16:89946397	TCF25	1.17	9.29	0.5	5.84e-18	Skin colour saturation;
CESC	cis	rs748404	0.660	rs690012	chr15:43719755	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	8.21	0.45	9.85e-15	Lung cancer;
CESC	cis	rs3096299	0.933	rs747485	chr16:89474094	T/C	cg08392591	chr16:89556376	ANKRD11	0.4	5.12	0.3	5.82e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs2625529	0.878	rs2929511	chr15:72231682	C/T	cg16672083	chr15:72433130	SENP8	0.43	6.45	0.37	5.37e-10	Red blood cell count;
CESC	cis	rs1538970	0.781	rs34768551	chr1:46020408	G/A	cg06784218	chr1:46089804	CCDC17	0.38	6.05	0.35	4.81e-9	Platelet count;
CESC	cis	rs11048434	0.723	rs1805737	chr12:9084670	A/T	cg23795048	chr12:9217529	LOC144571	0.36	5.68	0.33	3.53e-8	Sjögren's syndrome;
CESC	cis	rs4076764	1.000	rs4076764	chr1:163441286	A/G	cg06092702	chr1:163392909	NA	-0.36	-5.25	-0.31	3.1e-7	Motion sickness;
CESC	cis	rs3820928	0.874	rs4423583	chr2:227874957	A/G	cg11843606	chr2:227700838	RHBDD1	0.47	6.06	0.35	4.66e-9	Pulmonary function;
CESC	cis	rs12148488	0.816	rs11854975	chr15:75363876	C/T	cg14664628	chr15:75095509	CSK	-0.43	-5.34	-0.31	2.01e-7	Caffeine consumption;
CESC	cis	rs12188164	1.000	rs34453673	chr5:434722	G/C	cg21144161	chr5:423903	AHRR	0.37	6.14	0.35	2.96e-9	Cystic fibrosis severity;
CESC	cis	rs9527	0.590	rs11191513	chr10:104772984	T/G	cg04362960	chr10:104952993	NT5C2	0.4	5.1	0.3	6.39e-7	Arsenic metabolism;
CESC	cis	rs9910055	0.614	rs12944572	chr17:42245241	T/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.67	8.91	0.48	8.58e-17	Total body bone mineral density;
CESC	cis	rs798554	0.759	rs798495	chr7:2797267	T/C	cg04166393	chr7:2884313	GNA12	0.59	7.37	0.41	2.2e-12	Height;
CESC	cis	rs727563	0.648	rs6002406	chr22:41965237	A/T	cg06481639	chr22:41940642	POLR3H	-0.66	-6.62	-0.38	2e-10	Crohn's disease;Inflammatory bowel disease;
CESC	trans	rs802075	0.905	rs9395522	chr6:49637975	T/A	cg06254729	chr2:28550422	BRE	-0.36	-6.13	-0.35	3.23e-9	Bone mineral density (hip) and age at menarche;
CESC	cis	rs17826219	0.568	rs59858012	chr17:29078582	C/T	cg13385521	chr17:29058706	SUZ12P	0.84	6.04	0.35	5.22e-9	Body mass index;
CESC	cis	rs3806843	1.000	rs6579987	chr5:140183659	T/C	cg16179182	chr5:140090404	VTRNA1-1	-0.41	-5.26	-0.31	2.95e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs7385804	0.796	rs10277087	chr7:100307538	C/G	cg20848291	chr7:100343083	ZAN	0.51	6.93	0.39	3.12e-11	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
CESC	cis	rs7923609	0.967	rs7076310	chr10:65135672	C/A	cg01631684	chr10:65280961	REEP3	-0.42	-5.18	-0.3	4.35e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs8058578	1.000	rs2289442	chr16:30739919	A/G	cg02466173	chr16:30829666	NA	-0.46	-7.33	-0.41	2.71e-12	Multiple myeloma;
CESC	cis	rs12618769	0.597	rs10496327	chr2:99066827	A/G	cg10123293	chr2:99228465	UNC50	0.39	5.07	0.3	7.32e-7	Bipolar disorder;
CESC	cis	rs7959452	0.640	rs11177599	chr12:69721970	G/A	cg20891283	chr12:69753455	YEATS4	0.77	11.28	0.57	2.4e-24	Blood protein levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00082540	chr21:46396774	C21orf70	-0.53	-6.38	-0.36	8.05e-10	Gut microbiome composition (summer);
CESC	cis	rs2836974	0.931	rs2836972	chr21:40652142	G/A	cg11644478	chr21:40555479	PSMG1	1.05	16.84	0.72	9.02e-44	Cognitive function;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01857591	chr8:81083836	TPD52	0.57	6.13	0.35	3.09e-9	Gut microbiome composition (summer);
CESC	cis	rs2290159	0.800	rs9849807	chr3:12675026	A/G	cg23032965	chr3:12705835	RAF1	0.54	5.7	0.33	3.23e-8	Cholesterol, total;
CESC	cis	rs4595586	0.545	rs12819061	chr12:39386976	C/T	cg26384229	chr12:38710491	ALG10B	0.54	7.53	0.42	7.85e-13	Morning vs. evening chronotype;
CESC	cis	rs2108622	0.727	rs62107764	chr19:15982658	A/G	cg13772218	chr19:15982569	NA	0.29	5.8	0.34	1.85e-8	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CESC	cis	rs4642101	0.597	rs9839769	chr3:12821405	C/T	cg24848339	chr3:12840334	CAND2	0.39	6.1	0.35	3.65e-9	QRS complex (12-leadsum);
CESC	cis	rs7613875	0.521	rs4688754	chr3:50074641	G/T	cg24308560	chr3:49941425	MST1R	0.58	8.37	0.46	3.27e-15	Body mass index;
CESC	cis	rs6694270	0.529	rs12565650	chr1:19108355	G/A	cg26220594	chr1:19110978	NA	-0.39	-5.03	-0.3	9.18e-7	Drug-induced liver injury (nitrofurantoin);
CESC	cis	rs568617	0.953	rs1151519	chr11:65645831	G/C	cg04055107	chr11:65626734	MUS81;CFL1	-0.69	-7.4	-0.41	1.81e-12	Crohn's disease;
CESC	cis	rs34375054	1.000	rs34375054	chr12:125665896	A/T	cg25124228	chr12:125621409	AACS	-0.47	-6.09	-0.35	4.03e-9	Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs875971	0.545	rs313828	chr7:65552614	T/C	cg18876405	chr7:65276391	NA	-0.55	-6.01	-0.35	6.19e-9	Aortic root size;
CESC	cis	rs2842992	0.673	rs6930904	chr6:160217433	T/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.78	9.64	0.51	4.81e-19	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs875971	0.790	rs10257911	chr7:65743770	A/G	cg10691866	chr7:65817282	TPST1	0.33	5.5	0.32	8.83e-8	Aortic root size;
CESC	cis	rs79839061	0.610	rs11732965	chr4:869359	C/A	cg07828340	chr4:882639	GAK	1.07	8.28	0.45	6.09e-15	Intelligence (multi-trait analysis);
CESC	cis	rs9796	0.745	rs2947493	chr15:41375694	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.43	-6.28	-0.36	1.39e-9	Menopause (age at onset);
CESC	cis	rs6502050	0.835	rs11077981	chr17:80147243	C/T	cg23985595	chr17:80112537	CCDC57	-0.42	-6.57	-0.37	2.59e-10	Life satisfaction;
CESC	trans	rs6572548	0.504	rs1956082	chr14:49665496	A/C	cg25276849	chr3:195808919	TFRC	-0.55	-6.28	-0.36	1.42e-9	Subjective well-being;
CESC	cis	rs1797885	0.902	rs905644	chr3:12530828	C/T	cg26432171	chr3:12704882	RAF1	-0.48	-5.97	-0.34	7.75e-9	Immature fraction of reticulocytes;
CESC	cis	rs17253792	0.822	rs10137364	chr14:56059987	G/A	cg01858014	chr14:56050164	KTN1	-0.85	-6.79	-0.38	7.45e-11	Putamen volume;
CESC	cis	rs10911251	0.528	rs10911265	chr1:183115071	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.86	13.53	0.64	4.76e-32	Colorectal cancer;
CESC	cis	rs10752881	1.000	rs6424879	chr1:182986592	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.84	13.3	0.63	2.79e-31	Colorectal cancer;
CESC	cis	rs16867321	0.627	rs13411336	chr2:181588696	A/G	cg23363182	chr2:181467187	NA	-0.44	-5.74	-0.33	2.59e-8	Obesity;
CESC	cis	rs12541635	0.966	rs12550587	chr8:106978289	C/T	cg10147462	chr8:107024639	NA	0.39	5.37	0.31	1.69e-7	Age of smoking initiation;
CESC	cis	rs10751667	0.621	rs7394681	chr11:952111	C/T	cg01483505	chr11:975446	AP2A2	0.37	5.05	0.3	8.23e-7	Alzheimer's disease (late onset);
CESC	cis	rs10927875	0.894	rs34957618	chr1:16320499	G/C	cg22431228	chr1:16359049	CLCNKA	0.35	5.76	0.33	2.38e-8	Dilated cardiomyopathy;
CESC	cis	rs826838	0.967	rs1719856	chr12:39127201	C/T	cg13010199	chr12:38710504	ALG10B	-0.45	-6.26	-0.36	1.53e-9	Heart rate;
CESC	cis	rs3733585	0.648	rs35954357	chr4:9978758	G/C	cg02734326	chr4:10020555	SLC2A9	0.41	5.84	0.34	1.51e-8	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs7208859	0.573	rs58920731	chr17:29191746	G/T	cg19761014	chr17:28927070	LRRC37B2	0.63	5.27	0.31	2.88e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs35110281	0.837	rs7279958	chr21:45016016	C/A	cg01579765	chr21:45077557	HSF2BP	-0.58	-10.09	-0.53	1.83e-20	Mean corpuscular volume;
CESC	cis	rs1862618	0.754	rs252899	chr5:56188569	G/C	cg03609598	chr5:56110824	MAP3K1	-0.51	-5.41	-0.32	1.43e-7	Initial pursuit acceleration;
CESC	cis	rs2302190	0.769	rs6503864	chr17:56549671	C/A	cg25885038	chr17:56607967	SEPT4	-0.41	-5.38	-0.31	1.67e-7	Vitamin D levels;
CESC	cis	rs8114671	0.562	rs2889861	chr20:33405664	C/T	cg07148914	chr20:33460835	GGT7	0.42	5.59	0.32	5.73e-8	Height;
CESC	cis	rs6835098	0.887	rs12644699	chr4:174142874	A/G	cg08422745	chr4:174089978	GALNT7	0.63	7.67	0.43	3.31e-13	Dementia and core Alzheimer's disease neuropathologic changes;
CESC	cis	rs875971	0.545	rs11766183	chr7:65839160	G/C	cg11764359	chr7:65958608	NA	0.82	9.37	0.5	3.25e-18	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02850329	chr1:24829455	RCAN3	0.52	6.0	0.35	6.36e-9	Gut microbiome composition (summer);
CESC	cis	rs714031	0.934	rs4820387	chr22:40070446	A/G	cg21377881	chr22:40064566	CACNA1I	-0.34	-5.39	-0.31	1.55e-7	Schizophrenia;
CESC	cis	rs2228479	0.867	rs17784386	chr16:89947457	A/G	cg04013166	chr16:89971882	TCF25	0.77	7.14	0.4	8.86e-12	Skin colour saturation;
CESC	cis	rs40363	0.680	rs4010628	chr16:3529779	G/A	cg21433313	chr16:3507492	NAT15	0.64	6.92	0.39	3.43e-11	Tuberculosis;
CESC	cis	rs77956314	0.515	rs60940473	chr12:117462582	C/T	cg25972092	chr12:117363249	FBXW8	-0.53	-5.56	-0.32	6.66e-8	Subcortical brain region volumes;Hippocampal volume;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg17999743	chr8:38239693	WHSC1L1	-0.44	-6.03	-0.35	5.57e-9	Fibrinogen levels;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg19098314	chr17:28804347	GOSR1	0.46	6.68	0.38	1.43e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs60843830	0.661	rs55987018	chr2:106655	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.51	6.08	0.35	4.21e-9	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs362296	0.698	rs3095081	chr4:3263776	C/T	cg08886695	chr4:3369023	RGS12	0.36	5.06	0.3	7.84e-7	Parental longevity (mother's age at death);
CESC	cis	rs854765	0.547	rs9913277	chr17:17919749	G/T	cg16928487	chr17:17741425	SREBF1	-0.59	-10.42	-0.54	1.59e-21	Total body bone mineral density;
CESC	cis	rs6977955	1.000	rs2893312	chr7:28170403	C/T	cg23620719	chr7:28220237	JAZF1	-0.58	-6.52	-0.37	3.6e-10	Allergic disease (asthma, hay fever or eczema);
CESC	trans	rs16946160	0.718	rs9589279	chr13:92185178	G/A	cg09924998	chr12:122751933	VPS33A	0.52	6.03	0.35	5.46e-9	Nephrotic syndrome (acquired);
CESC	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg26338869	chr17:61819248	STRADA	0.73	9.65	0.51	4.47e-19	Prudent dietary pattern;
CESC	cis	rs1707322	0.717	rs2991988	chr1:46082431	C/A	cg06784218	chr1:46089804	CCDC17	-0.41	-7.08	-0.4	1.31e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs10504073	0.584	rs7818507	chr8:49918423	G/T	cg00325661	chr8:49890786	NA	0.53	8.13	0.45	1.62e-14	Blood metabolite ratios;
CESC	cis	rs36051895	0.632	rs10974980	chr9:5140671	C/G	cg02405213	chr9:5042618	JAK2	-0.5	-6.07	-0.35	4.52e-9	Pediatric autoimmune diseases;
CESC	cis	rs8008758	1.000	rs12432879	chr14:101688977	A/G	cg26224664	chr14:101693935	NA	0.35	5.6	0.33	5.48e-8	Body mass index (alcohol intake interaction);
CESC	cis	rs2860975	0.542	rs1579029	chr10:96811010	T/C	cg09036531	chr10:96991505	NA	-0.36	-5.22	-0.31	3.61e-7	Immune response to smallpox vaccine (IL-6);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg14657458	chr10:134469026	INPP5A	0.44	6.28	0.36	1.41e-9	Fibrinogen levels;
CESC	cis	rs9733	0.596	rs6587518	chr1:150661787	T/C	cg17724175	chr1:150552817	MCL1	0.44	7.16	0.4	8.15e-12	Tonsillectomy;
CESC	cis	rs2777491	0.872	rs7176588	chr15:41588872	C/T	cg02330683	chr15:41787940	ITPKA	0.42	6.18	0.35	2.45e-9	Ulcerative colitis;
CESC	cis	rs7130144	0.541	rs7925596	chr11:130463610	C/G	cg26307797	chr11:130446613	NA	-0.8	-6.65	-0.38	1.64e-10	Urate levels in lean individuals;
CESC	cis	rs7267979	1.000	rs2424713	chr20:25418482	C/T	cg08601574	chr20:25228251	PYGB	0.35	5.04	0.3	8.82e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs56104184	0.725	rs4347731	chr19:49385154	A/G	cg15549821	chr19:49342101	PLEKHA4	-0.59	-5.46	-0.32	1.07e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	cis	rs2204008	0.805	rs7296063	chr12:37964775	T/G	cg26384229	chr12:38710491	ALG10B	0.73	10.68	0.55	2.17e-22	Bladder cancer;
CESC	cis	rs11190604	0.943	rs7900678	chr10:102229016	T/C	cg07080220	chr10:102295463	HIF1AN	0.55	5.56	0.32	6.43e-8	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.58	7.47	0.42	1.19e-12	Prudent dietary pattern;
CESC	cis	rs9660992	0.710	rs1668872	chr1:205236069	G/A	cg21643547	chr1:205240462	TMCC2	-0.47	-6.34	-0.36	1.01e-9	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs79349575	0.811	rs1057897	chr17:47005509	T/G	cg26022315	chr17:47021804	SNF8	0.38	5.06	0.3	7.79e-7	Type 2 diabetes;
CESC	cis	rs3793683	1.000	rs3793683	chr10:134568387	G/T	cg26818010	chr10:134567672	INPP5A	0.51	6.3	0.36	1.2e-9	Migraine;
CESC	cis	rs2235649	0.798	rs9932983	chr16:1848184	A/G	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.41	-5.04	-0.3	8.48e-7	Blood metabolite levels;
CESC	cis	rs763121	0.853	rs9622833	chr22:39000397	G/A	cg14440974	chr22:39074834	NA	-0.4	-5.32	-0.31	2.22e-7	Menopause (age at onset);
CESC	cis	rs832540	0.593	rs96844	chr5:56196604	G/A	cg24531977	chr5:56204891	C5orf35	-0.51	-6.31	-0.36	1.17e-9	Coronary artery disease;
CESC	cis	rs3820928	0.874	rs9288618	chr2:227872617	A/G	cg05526886	chr2:227700861	RHBDD1	-0.43	-5.5	-0.32	8.97e-8	Pulmonary function;
CESC	cis	rs854765	0.583	rs9635697	chr17:17870394	T/A	cg04398451	chr17:18023971	MYO15A	-0.7	-9.85	-0.52	1.04e-19	Total body bone mineral density;
CESC	cis	rs9916302	0.861	rs4795377	chr17:37669056	C/T	cg15445000	chr17:37608096	MED1	0.41	6.87	0.39	4.66e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs2011503	0.882	rs72999053	chr19:19375372	G/A	cg11584989	chr19:19387371	SF4	0.63	7.58	0.42	5.75e-13	Bipolar disorder;
CESC	cis	rs1153858	0.945	rs7182300	chr15:45634928	G/A	cg21132104	chr15:45694354	SPATA5L1	0.82	11.02	0.56	1.72e-23	Homoarginine levels;
CESC	cis	rs516243	0.841	rs6540944	chr1:10740405	C/T	cg02903756	chr1:10750680	CASZ1	-0.39	-5.6	-0.33	5.27e-8	Migraine - clinic-based;
CESC	cis	rs634534	0.563	rs470192	chr11:65724291	C/T	cg02202077	chr11:65769826	EIF1AD;BANF1	0.48	6.51	0.37	3.66e-10	Sum eosinophil basophil counts;Eosinophil counts;
CESC	cis	rs12134245	0.776	rs12122066	chr1:92005140	C/T	cg02896835	chr1:92012615	NA	-0.53	-6.78	-0.38	7.89e-11	Breast cancer;
CESC	cis	rs2290159	0.752	rs5746182	chr3:12672550	A/G	cg23032965	chr3:12705835	RAF1	0.53	5.68	0.33	3.63e-8	Cholesterol, total;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg22622495	chr1:91966418	CDC7	-0.43	-6.2	-0.36	2.18e-9	Fibrinogen levels;
CESC	cis	rs3015497	0.583	rs12881560	chr14:51018253	A/G	cg26011998	chr14:51135199	SAV1	0.47	5.36	0.31	1.8e-7	Mean platelet volume;
CESC	cis	rs7618915	0.547	rs2336542	chr3:52710636	A/G	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	5.64	0.33	4.33e-8	Bipolar disorder;
CESC	cis	rs1707322	0.963	rs10890373	chr1:46393755	A/C	cg06784218	chr1:46089804	CCDC17	0.37	6.37	0.36	8.5e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs1124376	1.000	rs9819739	chr3:20140760	G/A	cg05072819	chr3:20081367	KAT2B	0.49	5.55	0.32	7e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs8002861	0.846	rs12869355	chr13:44478193	A/C	cg19180546	chr13:44453867	C13orf31;CCDC122	0.44	5.63	0.33	4.56e-8	Leprosy;
CESC	cis	rs765787	0.530	rs11636018	chr15:45539137	T/C	cg24006582	chr15:45444508	DUOX1	-0.59	-7.32	-0.41	3.04e-12	Uric acid levels;
CESC	cis	rs11577318	0.853	rs7537477	chr1:26618829	C/T	cg00813993	chr1:26644493	UBXN11;CD52	-0.4	-6.37	-0.36	8.2e-10	Granulocyte percentage of myeloid white cells;
CESC	cis	rs3820928	0.904	rs2217359	chr2:227759892	C/T	cg05526886	chr2:227700861	RHBDD1	-0.43	-5.47	-0.32	1.02e-7	Pulmonary function;
CESC	trans	rs7335046	0.901	rs72649510	chr13:99957621	C/T	cg14259717	chr11:18433732	LDHC	0.64	6.26	0.36	1.56e-9	Basal cell carcinoma;
CESC	cis	rs7264396	0.635	rs7263302	chr20:34545858	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.57	6.97	0.39	2.48e-11	Total cholesterol levels;
CESC	cis	rs801193	1.000	rs11773829	chr7:66141074	G/A	cg14393609	chr7:65229607	NA	-0.46	-6.14	-0.35	3.03e-9	Aortic root size;
CESC	trans	rs7618501	0.966	rs9882639	chr3:49799475	A/C	cg21659725	chr3:3221576	CRBN	0.83	13.56	0.64	3.67e-32	Intelligence (multi-trait analysis);
CESC	cis	rs1018836	0.770	rs12543806	chr8:91664011	C/T	cg16814680	chr8:91681699	NA	-0.89	-13.93	-0.65	1.85e-33	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs2841277	0.708	rs11623422	chr14:105407031	A/G	cg17340268	chr14:105411764	AHNAK2	-0.52	-6.91	-0.39	3.56e-11	Rheumatoid arthritis;
CESC	cis	rs6964587	0.620	rs6967588	chr7:91643402	G/T	cg01689657	chr7:91764605	CYP51A1	0.26	5.04	0.3	8.66e-7	Breast cancer;
CESC	trans	rs1973993	0.567	rs2800433	chr1:96998126	T/A	cg10631902	chr5:14652156	NA	0.47	7.05	0.4	1.54e-11	Weight;
CESC	cis	rs9322193	0.884	rs2095375	chr6:150128173	C/A	cg04369109	chr6:150039330	LATS1	-0.41	-5.54	-0.32	7.2e-8	Lung cancer;
CESC	cis	rs9916302	0.898	rs8072297	chr17:37478048	A/T	cg07936489	chr17:37558343	FBXL20	0.79	11.03	0.56	1.52e-23	Glomerular filtration rate (creatinine);
CESC	cis	rs829883	0.664	rs865509	chr12:98854444	T/A	cg25150519	chr12:98850993	NA	0.87	14.67	0.67	4.52e-36	Colorectal adenoma (advanced);
CESC	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg07092213	chr7:1199455	ZFAND2A	-0.44	-5.9	-0.34	1.08e-8	Longevity;Endometriosis;
CESC	cis	rs8060686	0.668	rs255056	chr16:68016185	G/C	cg26727032	chr16:67993705	SLC12A4	-0.5	-5.73	-0.33	2.68e-8	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs898097	0.625	rs7406464	chr17:80891460	A/G	cg10494973	chr17:80897199	TBCD	0.46	5.97	0.34	7.4e-9	Breast cancer;
CESC	cis	rs965469	1.000	rs6051779	chr20:3333449	A/G	cg25506879	chr20:3388711	C20orf194	-0.55	-5.87	-0.34	1.31e-8	IFN-related cytopenia;
CESC	cis	rs992157	0.735	rs2271541	chr2:219082119	G/T	cg20019365	chr2:219134978	PNKD;AAMP	0.68	9.61	0.51	5.92e-19	Colorectal cancer;
CESC	cis	rs7605378	1.000	rs2346662	chr2:200679158	C/T	cg23649088	chr2:200775458	C2orf69	0.5	6.28	0.36	1.36e-9	Osteoporosis;
CESC	cis	rs7809799	0.850	rs10248890	chr7:98752384	A/G	cg05967295	chr7:98741636	SMURF1	-0.77	-5.56	-0.32	6.74e-8	Ulcerative colitis;
CESC	cis	rs8077577	0.848	rs12600694	chr17:18091019	C/T	cg16794390	chr17:18148240	FLII	0.4	5.65	0.33	4.19e-8	Obesity-related traits;
CESC	cis	rs10479542	0.544	rs10056863	chr5:179005100	G/A	cg19723775	chr5:179050963	HNRNPH1	0.41	5.37	0.31	1.76e-7	Lung cancer;
CESC	cis	rs7044106	0.762	rs3904197	chr9:123480378	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.69	10.23	0.53	6.35e-21	Hip circumference adjusted for BMI;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20811730	chr1:150293902	PRPF3	0.61	6.77	0.38	8.17e-11	Gut microbiome composition (summer);
CESC	cis	rs6542838	0.582	rs6542845	chr2:99537600	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.52	-6.64	-0.38	1.81e-10	Fear of minor pain;
CESC	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.58	7.49	0.42	1.01e-12	Prudent dietary pattern;
CESC	cis	rs9322193	0.923	rs4869750	chr6:150177132	C/T	cg07701084	chr6:150067640	NUP43	0.45	5.75	0.33	2.48e-8	Lung cancer;
CESC	cis	rs7923609	0.967	rs6479896	chr10:65126832	T/C	cg01631684	chr10:65280961	REEP3	-0.42	-5.17	-0.3	4.66e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs929354	1.000	rs1182414	chr7:157058363	G/A	cg05182265	chr7:156933206	UBE3C	0.45	6.24	0.36	1.71e-9	Body mass index;
CESC	cis	rs2251381	0.565	rs2832279	chr21:30613466	G/T	cg08807101	chr21:30365312	RNF160	0.53	6.2	0.36	2.21e-9	Selective IgA deficiency;
CESC	cis	rs11078917	1	rs11078917	chr17:37746359	A/C	cg20243544	chr17:37824526	PNMT	0.56	6.87	0.39	4.69e-11	Mean corpuscular volume;
CESC	cis	rs9926296	0.618	rs8058179	chr16:89846987	C/T	cg27121462	chr16:89883253	FANCA	-0.5	-6.32	-0.36	1.11e-9	Vitiligo;
CESC	cis	rs597539	0.652	rs478647	chr11:68700424	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.8	10.58	0.54	4.7e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs7618915	0.547	rs7642198	chr3:52677960	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	7.01	0.4	2e-11	Bipolar disorder;
CESC	trans	rs2963826	0.589	rs298091	chr5:58996603	A/T	cg03811519	chr9:134001305	NUP214	0.49	6.79	0.38	7.46e-11	Obesity-related traits;
CESC	cis	rs7811142	0.830	rs73401451	chr7:99981895	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.89	8.54	0.46	1.04e-15	Platelet count;
CESC	cis	rs9815354	0.680	rs112310714	chr3:42024797	A/C	cg03022575	chr3:42003672	ULK4	0.75	6.64	0.38	1.72e-10	Pulse pressure;Diastolic blood pressure;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg16702713	chr5:118407037	DMXL1	-0.42	-6.32	-0.36	1.07e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs7811142	0.830	rs10085549	chr7:99983135	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.95	10.57	0.54	4.97e-22	Platelet count;
CESC	cis	rs8062405	1.000	rs4451951	chr16:28836205	T/C	cg08761264	chr16:28874980	SH2B1	-0.47	-5.91	-0.34	1.07e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	trans	rs748404	0.631	rs28702649	chr15:43648629	C/T	cg24053811	chr14:70265306	SLC10A1	0.45	6.26	0.36	1.55e-9	Lung cancer;
CESC	cis	rs9926296	0.609	rs4785714	chr16:89798404	G/T	cg27121462	chr16:89883253	FANCA	-0.63	-8.12	-0.45	1.82e-14	Vitiligo;
CESC	cis	rs4563143	0.675	rs55976444	chr19:29265214	G/C	cg12756686	chr19:29218302	NA	0.58	7.52	0.42	8.38e-13	Methadone dose in opioid dependence;
CESC	cis	rs2286503	0.650	rs1990279	chr7:22890742	A/G	cg13679077	chr7:22862647	TOMM7	0.4	5.03	0.3	9.08e-7	Fibrinogen;
CESC	cis	rs10540	1.000	rs79440439	chr11:478147	A/C	cg03576123	chr11:487126	PTDSS2	-1.1	-11.08	-0.56	1.11e-23	Body mass index;
CESC	cis	rs703842	1.000	rs3782130	chr12:58161898	G/C	cg18357645	chr12:58087776	OS9	-0.41	-5.77	-0.33	2.25e-8	Multiple sclerosis;
CESC	cis	rs10465746	0.570	rs12402130	chr1:84479838	G/A	cg10977910	chr1:84465055	TTLL7	0.45	5.79	0.34	1.98e-8	Obesity-related traits;
CESC	cis	rs1862618	0.853	rs3099459	chr5:56137170	G/C	cg22800045	chr5:56110881	MAP3K1	0.83	9.98	0.52	3.92e-20	Initial pursuit acceleration;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg24689585	chr15:22957012	CYFIP1	0.44	6.37	0.36	8.48e-10	Fibrinogen levels;
CESC	cis	rs4862750	0.914	rs11945845	chr4:187874136	T/C	cg06074448	chr4:187884817	NA	-0.36	-5.04	-0.3	8.76e-7	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7772486	0.846	rs2892453	chr6:146377717	C/A	cg23711669	chr6:146136114	FBXO30	0.77	11.36	0.57	1.24e-24	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7927592	0.956	rs2155730	chr11:68329474	T/C	cg16797656	chr11:68205561	LRP5	0.39	5.39	0.31	1.57e-7	Total body bone mineral density;
CESC	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	20.91	0.79	5.34e-58	Prudent dietary pattern;
CESC	cis	rs7809950	0.906	rs2395907	chr7:107253304	A/G	cg23024343	chr7:107201750	COG5	0.46	6.19	0.36	2.23e-9	Coronary artery disease;
CESC	cis	rs9487051	0.714	rs6902892	chr6:109627601	G/T	cg12927641	chr6:109611667	NA	-0.36	-5.31	-0.31	2.31e-7	Reticulocyte fraction of red cells;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg25937155	chr17:20408772	MGC102966	0.39	6.15	0.35	2.82e-9	Fibrinogen levels;
CESC	cis	rs722599	0.748	rs55707505	chr14:75362552	T/C	cg11812906	chr14:75593930	NEK9	-0.45	-5.52	-0.32	8.19e-8	IgG glycosylation;
CESC	cis	rs9486719	1.000	rs3798296	chr6:97052286	G/A	cg06623918	chr6:96969491	KIAA0776	-0.83	-8.65	-0.47	5.09e-16	Migraine;Coronary artery disease;
CESC	cis	rs1005277	0.579	rs2474595	chr10:38426782	C/G	cg25517755	chr10:38738941	LOC399744	0.5	6.52	0.37	3.63e-10	Extrinsic epigenetic age acceleration;
CESC	cis	rs6951245	0.580	rs10257426	chr7:1213694	G/A	cg22907277	chr7:1156413	C7orf50	0.5	5.96	0.34	8.01e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2991971	1.000	rs667626	chr1:46020551	T/C	cg05343316	chr1:45956843	TESK2	-0.51	-6.5	-0.37	3.93e-10	High light scatter reticulocyte count;
CESC	cis	rs933688	1.000	rs11950530	chr5:90688740	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.18	14.27	0.66	1.16e-34	Smoking behavior;
CESC	cis	rs10504229	1.000	rs67630725	chr8:58185580	G/A	cg24829409	chr8:58192753	C8orf71	-0.76	-9.93	-0.52	5.87e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs11871801	0.541	rs4793090	chr17:40686342	G/A	cg14558262	chr17:40713999	COASY	-0.43	-5.22	-0.31	3.58e-7	Crohn's disease;
CESC	cis	rs9768139	0.733	rs13309408	chr7:158122261	C/T	cg06219351	chr7:158114137	PTPRN2	-0.53	-8.18	-0.45	1.16e-14	Calcium levels;
CESC	cis	rs8031584	0.958	rs1043742	chr15:31232581	A/C	cg14829155	chr15:31115871	NA	-0.69	-9.17	-0.49	1.34e-17	Huntington's disease progression;
CESC	cis	rs10200159	1.000	rs10195281	chr2:55848021	C/T	cg13617705	chr2:55845095	SMEK2	0.78	5.46	0.32	1.11e-7	Vitiligo;
CESC	cis	rs7552404	0.727	rs7547508	chr1:76327958	A/G	cg10523679	chr1:76189770	ACADM	-0.65	-6.61	-0.38	2.12e-10	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs7216064	1.000	rs73352808	chr17:65875157	G/A	cg07042672	chr17:66097459	LOC651250	-0.54	-6.04	-0.35	5.12e-9	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs875971	0.895	rs6460278	chr7:65662736	T/C	cg13147721	chr7:65941812	NA	0.37	5.04	0.3	8.53e-7	Aortic root size;
CESC	cis	rs4853012	0.941	rs60291089	chr2:74344890	T/G	cg19729930	chr2:74357872	NA	0.84	12.54	0.61	1.2e-28	Gestational age at birth (maternal effect);
CESC	cis	rs2730245	0.527	rs842700	chr7:158697565	G/A	cg24397884	chr7:158709396	WDR60	0.86	8.92	0.48	7.93e-17	Height;
CESC	cis	rs6430585	0.591	rs12477421	chr2:136433740	A/G	cg07169764	chr2:136633963	MCM6	1.17	13.25	0.63	4.42e-31	Corneal structure;
CESC	cis	rs3749237	0.595	rs6797765	chr3:49423976	A/G	cg06212747	chr3:49208901	KLHDC8B	0.49	6.6	0.38	2.22e-10	Resting heart rate;
CESC	cis	rs11676348	0.846	rs4674257	chr2:218988774	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.46	-6.03	-0.35	5.37e-9	Ulcerative colitis;
CESC	cis	rs4780401	0.609	rs8055247	chr16:11827543	G/A	cg01061890	chr16:11836724	TXNDC11	-0.54	-7.41	-0.41	1.7e-12	Rheumatoid arthritis;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg11376330	chr3:49131570	QRICH1	-0.42	-6.0	-0.35	6.46e-9	Gambling;
CESC	cis	rs1348850	0.668	rs6705405	chr2:178493713	A/G	cg22681709	chr2:178499509	PDE11A	-0.41	-5.9	-0.34	1.09e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs2204008	0.537	rs11170128	chr12:38006632	G/A	cg26384229	chr12:38710491	ALG10B	0.74	10.77	0.55	1.12e-22	Bladder cancer;
CESC	cis	rs708547	0.836	rs1612191	chr4:57724320	A/C	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.56	-6.25	-0.36	1.67e-9	Response to bleomycin (chromatid breaks);
CESC	cis	rs2204008	0.580	rs11174421	chr12:38105138	A/G	cg13010199	chr12:38710504	ALG10B	0.52	6.23	0.36	1.82e-9	Bladder cancer;
CESC	cis	rs10256972	0.621	rs2280725	chr7:1087426	G/T	cg07308232	chr7:1071921	C7orf50	-0.56	-8.07	-0.44	2.4e-14	Longevity;Endometriosis;
CESC	cis	rs13191362	1.000	rs35103567	chr6:163183400	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.59	5.72	0.33	2.89e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs12971120	0.947	rs7241558	chr18:72169267	A/T	cg25817165	chr18:72167213	CNDP2	-0.56	-7.72	-0.43	2.31e-13	Refractive error;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg03305624	chr19:17283537	MYO9B	0.49	6.72	0.38	1.12e-10	Fibrinogen levels;
CESC	cis	rs425277	0.606	rs3128295	chr1:2068480	C/T	cg24578937	chr1:2090814	PRKCZ	-0.35	-5.97	-0.34	7.8e-9	Height;
CESC	cis	rs6952808	0.760	rs11764960	chr7:1950532	G/A	cg08027265	chr7:2291960	NA	-0.34	-5.08	-0.3	7.07e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs3796352	1.000	rs2564926	chr3:53094730	G/A	cg15956490	chr3:53032818	SFMBT1	-0.61	-5.46	-0.32	1.09e-7	Immune reponse to smallpox (secreted IL-2);
CESC	cis	rs9611565	0.546	rs5758426	chr22:42098763	T/G	cg17376030	chr22:41985996	PMM1	-0.45	-5.15	-0.3	5.21e-7	Vitiligo;
CESC	cis	rs8077889	0.917	rs6503479	chr17:41917003	A/G	cg26893861	chr17:41843967	DUSP3	0.74	9.8	0.52	1.52e-19	Triglycerides;
CESC	cis	rs7584330	0.784	rs6724766	chr2:238413600	A/G	cg14458575	chr2:238380390	NA	0.54	7.28	0.41	3.85e-12	Prostate cancer;
CESC	cis	rs6952808	0.531	rs3778991	chr7:2172455	G/A	cg08027265	chr7:2291960	NA	-0.45	-6.94	-0.39	2.96e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs12824058	0.831	rs11609362	chr12:130810526	T/C	cg24838063	chr12:130822603	PIWIL1	0.62	8.55	0.47	9.78e-16	Menopause (age at onset);
CESC	cis	rs1707322	0.721	rs6697821	chr1:46216722	A/G	cg03146154	chr1:46216737	IPP	0.82	11.54	0.58	3.18e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs35306767	0.903	rs1341741	chr10:888073	A/G	cg20503657	chr10:835505	NA	0.76	7.62	0.42	4.63e-13	Eosinophil percentage of granulocytes;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg12473036	chr20:62611207	SAMD10;PRPF6	-0.45	-6.36	-0.36	8.93e-10	Gambling;
CESC	cis	rs3747547	0.710	rs16934658	chr9:37950543	C/A	cg13774184	chr9:37916125	SHB	-0.57	-5.83	-0.34	1.57e-8	Metabolite levels (Dihydroxy docosatrienoic acid);
CESC	cis	rs9443645	0.527	rs12194642	chr6:79538791	G/A	cg05283184	chr6:79620031	NA	-0.37	-5.43	-0.32	1.28e-7	Intelligence (multi-trait analysis);
CESC	cis	rs875971	1.000	rs778706	chr7:65860424	A/G	cg11764359	chr7:65958608	NA	0.98	15.79	0.7	4.71e-40	Aortic root size;
CESC	cis	rs2425143	1.000	rs73902908	chr20:34365112	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.79	-7.16	-0.4	8.09e-12	Blood protein levels;
CESC	cis	rs1461503	0.903	rs7124683	chr11:122834036	A/G	cg27398637	chr11:122830231	C11orf63	0.51	7.28	0.41	3.89e-12	Menarche (age at onset);
CESC	cis	rs11997175	0.646	rs4612298	chr8:33713451	G/A	ch.8.33884649F	chr8:33765107	NA	0.55	7.36	0.41	2.26e-12	Body mass index;
CESC	cis	rs7560272	0.723	rs4852927	chr2:73641557	C/T	cg20560298	chr2:73613845	ALMS1	0.5	7.17	0.4	7.57e-12	Schizophrenia;
CESC	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg22535103	chr8:58192502	C8orf71	-0.93	-10.31	-0.53	3.63e-21	Developmental language disorder (linguistic errors);
CESC	cis	rs2276314	1.000	rs2298715	chr18:33552425	T/C	cg19628046	chr18:33552617	C18orf21	0.6	6.75	0.38	9.53e-11	Endometriosis;Drug-induced torsades de pointes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14195377	chr11:60928647	VPS37C	0.68	8.03	0.44	3.23e-14	Gut microbiome composition (summer);
CESC	cis	rs1448094	0.511	rs59858864	chr12:86166404	G/A	cg00310523	chr12:86230176	RASSF9	0.41	6.17	0.35	2.61e-9	Major depressive disorder;
CESC	cis	rs11048434	0.736	rs12424026	chr12:9110993	T/C	cg23795048	chr12:9217529	LOC144571	0.35	5.35	0.31	1.9e-7	Sjögren's syndrome;
CESC	cis	rs1707322	0.721	rs4431884	chr1:46101323	C/T	cg05343316	chr1:45956843	TESK2	0.5	6.34	0.36	9.93e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9287719	0.967	rs6744599	chr2:10747013	C/G	cg02196655	chr2:10830764	NOL10	0.37	5.66	0.33	3.86e-8	Prostate cancer;
CESC	cis	rs7615952	0.515	rs4267608	chr3:125680500	C/T	cg05084668	chr3:125655381	ALG1L	-0.52	-5.77	-0.33	2.19e-8	Blood pressure (smoking interaction);
CESC	cis	rs703842	1.000	rs8181644	chr12:58173466	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.72	9.31	0.5	5.09e-18	Multiple sclerosis;
CESC	cis	rs2576037	0.583	rs504668	chr18:44410749	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.78	12.9	0.62	7.29e-30	Personality dimensions;
CESC	cis	rs5757676	1.000	rs5757676	chr22:39841700	T/C	cg05872129	chr22:39784769	NA	-0.83	-8.92	-0.48	7.69e-17	IgG glycosylation;
CESC	cis	rs17376456	0.877	rs13153245	chr5:93374891	G/A	cg21475434	chr5:93447410	FAM172A	0.77	6.95	0.39	2.86e-11	Diabetic retinopathy;
CESC	cis	rs4919694	0.611	rs7091462	chr10:104948615	C/T	cg04362960	chr10:104952993	NT5C2	0.64	6.38	0.36	7.81e-10	Arsenic metabolism;
CESC	trans	rs7107217	1.000	rs1873872	chr11:129473993	A/T	cg01172785	chr16:50092553	NA	-0.49	-6.23	-0.36	1.85e-9	Breast cancer;Type 2 diabetes;
CESC	trans	rs35110281	0.837	rs7279968	chr21:45077398	C/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.51	6.75	0.38	9.14e-11	Mean corpuscular volume;
CESC	cis	rs9287719	0.601	rs12995465	chr2:10716828	G/A	cg00105475	chr2:10696890	NA	0.39	5.33	0.31	2.1e-7	Prostate cancer;
CESC	cis	rs2820315	0.540	rs10920259	chr1:201797696	C/T	cg11586189	chr1:201857591	SHISA4	-0.32	-5.37	-0.31	1.75e-7	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
CESC	cis	rs8180040	0.932	rs11712445	chr3:47434552	T/C	cg27129171	chr3:47204927	SETD2	0.63	9.65	0.51	4.34e-19	Colorectal cancer;
CESC	cis	rs1801251	1.000	rs6746294	chr2:233583050	C/G	cg08000102	chr2:233561755	GIGYF2	-0.65	-8.62	-0.47	6.18e-16	Coronary artery disease;
CESC	cis	rs2180341	0.781	rs7760652	chr6:127572096	A/G	cg24812749	chr6:127587940	RNF146	0.84	11.79	0.59	4.6e-26	Breast cancer;
CESC	cis	rs4132509	0.948	rs12032342	chr1:243834360	G/A	cg21452805	chr1:244014465	NA	0.52	5.72	0.33	2.91e-8	RR interval (heart rate);
CESC	cis	rs4975709	0.610	rs4975705	chr5:1860359	T/C	cg15595755	chr5:1867978	NA	0.51	8.38	0.46	3.17e-15	Cardiovascular disease risk factors;
CESC	cis	rs597539	0.652	rs546382	chr11:68704264	C/T	cg18350739	chr11:68623251	NA	-0.44	-6.81	-0.39	6.64e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs4237845	0.537	rs7312623	chr12:58262523	G/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.51	5.74	0.33	2.63e-8	Intelligence (multi-trait analysis);
CESC	cis	rs6582630	0.638	rs12424222	chr12:38548273	C/T	cg26384229	chr12:38710491	ALG10B	-0.42	-5.67	-0.33	3.67e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs769267	0.930	rs1865034	chr19:19605763	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.46	5.74	0.33	2.61e-8	Tonsillectomy;
CESC	cis	rs5758511	0.524	rs738257	chr22:42569298	C/A	cg00645731	chr22:42541494	CYP2D7P1	0.59	8.76	0.47	2.3e-16	Birth weight;
CESC	cis	rs10791097	0.720	rs6590515	chr11:130733365	A/G	cg09137382	chr11:130731461	NA	-0.34	-5.03	-0.3	8.92e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs2806561	0.808	rs2235546	chr1:23409538	A/G	cg12483005	chr1:23474871	LUZP1	0.34	5.33	0.31	2.15e-7	Height;
CESC	cis	rs172166	0.637	rs1225597	chr6:28162087	C/T	cg19592336	chr6:28129416	ZNF389	0.42	6.09	0.35	3.89e-9	Cardiac Troponin-T levels;
CESC	cis	rs35110281	0.720	rs162376	chr21:44926759	G/T	cg21573476	chr21:45109991	RRP1B	0.44	6.06	0.35	4.74e-9	Mean corpuscular volume;
CESC	cis	rs798502	0.541	rs2644307	chr7:2832973	G/A	cg13628971	chr7:2884303	GNA12	0.42	5.56	0.32	6.68e-8	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Inflammatory bowel disease;Waist circumference adjusted for BMI in non-smokers;Ulcerative colitis;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
CESC	cis	rs7666738	0.830	rs17558151	chr4:99048699	T/C	cg03467027	chr4:99064603	C4orf37	0.47	5.96	0.34	8.08e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7927771	0.524	rs7122182	chr11:47843133	A/C	cg18512352	chr11:47633146	NA	-0.36	-5.55	-0.32	6.84e-8	Subjective well-being;
CESC	cis	rs6582630	0.554	rs7299735	chr12:38450890	A/C	cg26384229	chr12:38710491	ALG10B	-0.42	-5.52	-0.32	8.27e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs801193	1.000	rs62466794	chr7:66191579	G/A	cg14393609	chr7:65229607	NA	0.48	6.5	0.37	4e-10	Aortic root size;
CESC	cis	rs4665809	1.000	rs4665298	chr2:26256378	G/A	cg22920501	chr2:26401640	FAM59B	-0.67	-8.01	-0.44	3.53e-14	Gut microbiome composition (summer);
CESC	cis	rs11098499	0.865	rs4507344	chr4:120307485	C/A	cg09307838	chr4:120376055	NA	0.92	12.66	0.61	4.96e-29	Corneal astigmatism;
CESC	cis	rs12451471	0.529	rs2278620	chr17:78083565	G/A	cg24585782	chr17:78113791	EIF4A3	-0.58	-7.65	-0.43	3.63e-13	Plateletcrit;Mean corpuscular hemoglobin concentration;
CESC	cis	rs10751667	0.643	rs10794343	chr11:925493	C/T	cg06064525	chr11:970664	AP2A2	-0.51	-10.06	-0.53	2.19e-20	Alzheimer's disease (late onset);
CESC	cis	rs116095464	1.000	rs56075848	chr5:308352	T/C	cg12570787	chr5:219185	SDHA;CCDC127	0.64	5.08	0.3	7.3e-7	Breast cancer;
CESC	cis	rs2204008	0.694	rs11179394	chr12:38210389	A/G	cg26384229	chr12:38710491	ALG10B	-0.42	-5.72	-0.33	2.93e-8	Bladder cancer;
CESC	cis	rs4862750	0.872	rs6830426	chr4:187897270	T/A	cg22105103	chr4:187893119	NA	0.5	7.32	0.41	2.98e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs12048904	0.964	rs12027668	chr1:101330984	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.51	6.54	0.37	3.12e-10	Multiple sclerosis;
CESC	cis	rs698833	0.624	rs7564087	chr2:44693647	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.42	5.59	0.32	5.64e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs60871478	1.000	rs12531530	chr7:827366	T/C	cg13798912	chr7:905769	UNC84A	0.52	5.16	0.3	4.9e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs597539	0.690	rs578791	chr11:68625809	C/T	cg04772025	chr11:68637568	NA	0.58	6.66	0.38	1.61e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs1443512	0.588	rs3759162	chr12:54331154	G/C	cg17410650	chr12:54324560	NA	-0.46	-5.72	-0.33	2.93e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
CESC	cis	rs3814231	0.531	rs17090904	chr10:115476138	C/T	cg24846397	chr10:115438155	CASP7	-0.32	-5.26	-0.31	2.96e-7	Vitiligo;
CESC	cis	rs55692411	0.537	rs62262118	chr3:50003586	G/A	cg24308560	chr3:49941425	MST1R	-0.52	-6.33	-0.36	1.04e-9	Intelligence (multi-trait analysis);
CESC	cis	rs7666738	0.830	rs11931166	chr4:99054187	A/T	cg03676636	chr4:99064102	C4orf37	0.33	5.12	0.3	5.93e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs56235845	0.694	rs11949401	chr5:176765989	A/G	cg16006841	chr5:176797999	RGS14	0.46	5.72	0.33	2.81e-8	Hemoglobin concentration;Hematocrit;
CESC	cis	rs7833790	0.700	rs28390260	chr8:82769175	A/T	cg07697082	chr8:82753677	SNX16	-0.37	-5.84	-0.34	1.48e-8	Diastolic blood pressure;
CESC	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.52	0.37	3.63e-10	Prudent dietary pattern;
CESC	cis	rs2816062	0.813	rs2816050	chr1:18894432	A/G	cg18795169	chr1:18902165	NA	-0.94	-19.04	-0.76	1.61e-51	Urate levels in lean individuals;
CESC	cis	rs11677370	0.574	rs11686118	chr2:3854938	C/T	cg17052675	chr2:3827356	NA	-0.44	-5.53	-0.32	7.7e-8	Type 2 diabetes;
CESC	cis	rs2576037	0.526	rs605487	chr18:44444778	G/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.32	5.09	0.3	6.85e-7	Personality dimensions;
CESC	cis	rs2455799	0.613	rs7642876	chr3:15883094	A/G	cg16303742	chr3:15540471	COLQ	-0.38	-5.74	-0.33	2.62e-8	Mean platelet volume;
CESC	cis	rs4660306	1.000	rs7534467	chr1:45988691	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.61	-7.72	-0.43	2.33e-13	Homocysteine levels;
CESC	cis	rs34638657	0.732	rs61111557	chr16:82201102	A/C	cg09439754	chr16:82129088	HSD17B2	-0.36	-6.24	-0.36	1.71e-9	Lung adenocarcinoma;
CESC	cis	rs1577917	1.000	rs6933377	chr6:86705255	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.43	6.13	0.35	3.22e-9	Response to antipsychotic treatment;
CESC	cis	rs10489202	1.000	rs12404574	chr1:167961235	C/T	cg24449463	chr1:168025552	DCAF6	0.46	5.37	0.31	1.73e-7	Schizophrenia;
CESC	cis	rs514406	0.571	rs11206004	chr1:53210958	G/A	cg16325326	chr1:53192061	ZYG11B	-0.7	-11.23	-0.57	3.41e-24	Monocyte count;
CESC	cis	rs7746199	0.736	rs58616630	chr6:27474715	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.75	-5.03	-0.3	9.02e-7	Gait speed in old age;Autism spectrum disorder or schizophrenia;
CESC	cis	rs636291	0.517	rs670666	chr1:10549380	C/T	cg07384165	chr1:10488281	NA	0.57	8.34	0.46	4.11e-15	Prostate cancer;
CESC	cis	rs11122272	0.735	rs2256908	chr1:231506557	G/A	cg06096015	chr1:231504339	EGLN1	0.43	6.11	0.35	3.49e-9	Hemoglobin concentration;
CESC	trans	rs3942852	0.568	rs6485807	chr11:48102867	G/A	cg03929089	chr4:120376271	NA	-0.63	-7.78	-0.43	1.64e-13	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs8114671	0.836	rs6120778	chr20:33565169	T/C	cg24642439	chr20:33292090	TP53INP2	0.46	5.47	0.32	1.06e-7	Height;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg24816464	chr3:86061715	CADM2	0.45	6.46	0.37	5.12e-10	Fibrinogen levels;
CESC	cis	rs34638657	0.732	rs12595971	chr16:82200309	T/C	cg09439754	chr16:82129088	HSD17B2	-0.36	-6.28	-0.36	1.37e-9	Lung adenocarcinoma;
CESC	cis	rs9486715	0.838	rs9386473	chr6:96873341	C/A	cg06623918	chr6:96969491	KIAA0776	0.78	11.16	0.57	5.91e-24	Headache;
CESC	cis	rs9457247	0.544	rs6920858	chr6:167464630	G/A	cg23791538	chr6:167370224	RNASET2	-0.52	-6.87	-0.39	4.45e-11	Crohn's disease;
CESC	cis	rs61524473	1	rs61524473	chr15:45646283	T/C	cg14582100	chr15:45693742	SPATA5L1	0.42	5.95	0.34	8.45e-9	Metabolite levels (small molecules and protein measures);
CESC	cis	rs1355223	0.506	rs11032898	chr11:34870111	C/G	cg11622362	chr11:34938112	PDHX;APIP	0.44	5.14	0.3	5.23e-7	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs8027181	0.617	rs11072389	chr15:73088483	C/T	cg25632853	chr15:73088954	NA	-0.41	-6.32	-0.36	1.11e-9	Triglyceride levels;
CESC	cis	rs763121	0.853	rs5757203	chr22:39044152	G/C	cg06022373	chr22:39101656	GTPBP1	0.88	13.79	0.65	5.43e-33	Menopause (age at onset);
CESC	cis	rs9487051	0.872	rs1111865	chr6:109610863	A/G	cg01475377	chr6:109611718	NA	0.51	8.43	0.46	2.31e-15	Reticulocyte fraction of red cells;
CESC	cis	rs1862618	0.641	rs170733	chr5:56249251	A/G	cg14703610	chr5:56206110	C5orf35	-0.42	-5.2	-0.3	4.06e-7	Initial pursuit acceleration;
CESC	cis	rs2075371	0.796	rs10954440	chr7:134005657	C/T	cg20476274	chr7:133979776	SLC35B4	0.6	8.54	0.46	1.04e-15	Mean platelet volume;
CESC	cis	rs1448094	0.512	rs11832503	chr12:86240797	A/G	cg19622623	chr12:86230825	RASSF9	-0.47	-6.07	-0.35	4.34e-9	Major depressive disorder;
CESC	cis	rs7666738	0.753	rs17483788	chr4:98985623	G/A	cg03467027	chr4:99064603	C4orf37	0.44	5.54	0.32	7.12e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4523957	0.928	rs216219	chr17:2147291	T/C	cg16513277	chr17:2031491	SMG6	0.6	8.27	0.45	6.35e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs2243480	1.000	rs34192067	chr7:65887657	C/A	cg12463550	chr7:65579703	CRCP	0.71	5.49	0.32	9.37e-8	Diabetic kidney disease;
CESC	cis	rs12973672	1.000	rs28365136	chr19:35769561	T/G	cg12095397	chr19:35769544	USF2	0.54	7.35	0.41	2.49e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs2180341	0.960	rs9398840	chr6:127669744	G/A	cg27446573	chr6:127587934	RNF146	1.06	15.51	0.69	4.62e-39	Breast cancer;
CESC	cis	rs9039	1.000	rs11075212	chr16:9203899	G/A	cg08831531	chr16:9218945	NA	-0.59	-7.64	-0.42	3.98e-13	Menopause (age at onset);
CESC	trans	rs55704346	0.566	rs13434761	chr4:25388545	T/C	cg01822600	chr1:245751692	KIF26B	0.42	6.17	0.35	2.58e-9	Tonsillectomy;
CESC	cis	rs752010	0.902	rs28635337	chr1:42101391	G/A	cg06885757	chr1:42089581	HIVEP3	0.5	8.2	0.45	1.03e-14	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs8141529	0.702	rs132536	chr22:29302906	A/G	cg02153584	chr22:29168773	CCDC117	-0.57	-7.43	-0.42	1.48e-12	Lymphocyte counts;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16280683	chr5:61708653	IPO11	0.59	6.45	0.37	5.27e-10	Gut microbiome composition (summer);
CESC	cis	rs642803	1.000	rs557675	chr11:65566719	G/T	cg10518572	chr11:65560635	OVOL1	-0.3	-6.47	-0.37	4.74e-10	Urate levels;
CESC	cis	rs10754283	0.967	rs2185195	chr1:90106697	T/C	cg21401794	chr1:90099060	LRRC8C	0.69	9.34	0.5	4.06e-18	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs12973672	1.000	rs62109572	chr19:35778919	T/C	cg12095397	chr19:35769544	USF2	0.59	7.57	0.42	6.1e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs4665809	1.000	rs6729080	chr2:26301282	G/A	cg26314531	chr2:26401878	FAM59B	-0.62	-7.07	-0.4	1.37e-11	Gut microbiome composition (summer);
CESC	cis	rs735396	0.627	rs2264778	chr12:121450354	C/A	cg15155738	chr12:121454335	C12orf43	0.45	5.23	0.31	3.44e-7	N-glycan levels;
CESC	cis	rs11785400	0.793	rs12546978	chr8:143750205	T/A	cg10596483	chr8:143751796	JRK	-0.44	-5.3	-0.31	2.41e-7	Schizophrenia;
CESC	cis	rs10791097	0.694	rs7125622	chr11:130743388	T/C	cg12179176	chr11:130786555	SNX19	0.65	10.05	0.53	2.42e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg24642844	chr7:1081250	C7orf50	-0.77	-9.63	-0.51	5.27e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs1568889	1.000	rs9783281	chr11:28033786	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.74	9.68	0.51	3.52e-19	Bipolar disorder;
CESC	cis	rs875971	0.767	rs1643394	chr7:65836094	A/G	cg18876405	chr7:65276391	NA	0.5	6.85	0.39	5.04e-11	Aortic root size;
CESC	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg24642844	chr7:1081250	C7orf50	-0.66	-8.39	-0.46	2.85e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs11191205	0.954	rs11191191	chr10:103800979	G/A	cg15320455	chr10:103880129	LDB1	0.76	6.63	0.38	1.83e-10	Intelligence (multi-trait analysis);
CESC	cis	rs2115630	0.645	rs4842978	chr15:85197253	T/C	cg11189052	chr15:85197271	WDR73	-0.51	-7.02	-0.4	1.84e-11	P wave terminal force;
CESC	cis	rs9905704	0.831	rs12939500	chr17:56848677	T/C	cg12560992	chr17:57184187	TRIM37	0.62	7.34	0.41	2.64e-12	Testicular germ cell tumor;
CESC	cis	rs6541297	0.878	rs4846905	chr1:230279582	C/T	cg20703242	chr1:230279135	GALNT2	-0.62	-9.66	-0.51	4.25e-19	Coronary artery disease;
CESC	cis	rs3806843	1.000	rs6885319	chr5:140200611	A/C	cg26395211	chr5:140044315	WDR55	-0.41	-5.04	-0.3	8.56e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs17384381	0.953	rs2284797	chr1:85792383	C/T	cg16011679	chr1:85725395	C1orf52	0.79	7.98	0.44	4.35e-14	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2439831	0.681	rs2444036	chr15:43694108	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.88	10.53	0.54	7.06e-22	Lung cancer in ever smokers;
CESC	cis	rs1003719	0.715	rs9980353	chr21:38558812	T/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.61	-8.29	-0.45	5.68e-15	Eye color traits;
CESC	cis	rs6598955	0.671	rs12089149	chr1:26638500	C/A	cg19743891	chr1:26644573	UBXN11;CD52	0.37	5.31	0.31	2.35e-7	Obesity-related traits;
CESC	cis	rs9914988	0.943	rs11658884	chr17:27132742	A/G	cg20469991	chr17:27169893	C17orf63	0.48	5.25	0.31	3.18e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CESC	cis	rs7216064	0.953	rs4791300	chr17:65930772	A/G	cg12091567	chr17:66097778	LOC651250	-0.72	-8.23	-0.45	8.28e-15	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg18606378	chr6:57087261	RAB23	-0.53	-6.34	-0.36	1.01e-9	Ulcerative colitis;
CESC	cis	rs710216	0.843	rs710220	chr1:43415346	G/T	cg22176566	chr1:43424700	SLC2A1	0.47	5.36	0.31	1.8e-7	Red cell distribution width;
CESC	cis	rs12586317	0.547	rs76770287	chr14:35487210	C/A	cg16230307	chr14:35515116	FAM177A1	0.98	10.57	0.54	5.22e-22	Psoriasis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02685945	chr6:22570146	HDGFL1	-0.73	-7.96	-0.44	5.07e-14	Gut microbiome composition (summer);
CESC	cis	rs13118159	0.836	rs2293630	chr4:1342521	G/A	cg20887711	chr4:1340912	KIAA1530	0.64	8.96	0.48	5.8e-17	Longevity;
CESC	trans	rs10463316	0.894	rs7719630	chr5:150760961	C/T	cg24389359	chr12:111284228	CCDC63	-0.33	-6.02	-0.35	5.68e-9	Metabolite levels (Pyroglutamine);
CESC	cis	rs7964748	0.769	rs73179285	chr12:103026921	G/C	cg02806658	chr12:102513592	C12orf48;NUP37	-0.57	-5.07	-0.3	7.56e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs62229266	0.804	rs998383	chr21:37445739	C/G	cg12218747	chr21:37451666	NA	-0.43	-5.94	-0.34	8.83e-9	Mitral valve prolapse;
CESC	cis	rs72627509	0.904	rs3796529	chr4:57797414	C/T	cg26694713	chr4:57773883	REST	0.56	5.57	0.32	6.15e-8	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CESC	cis	rs13242816	1.000	rs7809755	chr7:116110732	C/T	cg04696780	chr7:116139425	CAV2	-0.59	-5.28	-0.31	2.65e-7	P wave duration;
CESC	cis	rs2576037	0.523	rs4890705	chr18:44509758	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.79	13.12	0.63	1.24e-30	Personality dimensions;
CESC	cis	rs4819052	0.851	rs2838844	chr21:46670733	A/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.93	13.67	0.64	1.54e-32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs62103177	0.564	rs11874805	chr18:77697110	T/C	cg12964065	chr18:77638022	KCNG2	0.5	5.58	0.32	5.9e-8	Opioid sensitivity;
CESC	cis	rs2842992	0.872	rs2758328	chr6:160090731	T/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.64	7.44	0.42	1.39e-12	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs9303401	0.646	rs7342863	chr17:57227010	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.57	7.4	0.41	1.82e-12	Cognitive test performance;
CESC	trans	rs7107217	1.000	rs1873872	chr11:129473993	A/T	cg21871583	chr3:15374148	SH3BP5	0.51	7.41	0.41	1.65e-12	Breast cancer;Type 2 diabetes;
CESC	cis	rs66573146	0.831	rs56031152	chr4:6973832	C/A	cg00086871	chr4:6988644	TBC1D14	1.15	7.48	0.42	1.08e-12	Granulocyte percentage of myeloid white cells;
CESC	cis	rs7726839	0.561	rs11955068	chr5:582324	C/T	cg16447950	chr5:562315	NA	-0.55	-6.19	-0.36	2.29e-9	Obesity-related traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13316255	chr15:75165642	SCAMP2	0.52	6.0	0.35	6.63e-9	Gut microbiome composition (summer);
CESC	cis	rs3011225	0.710	rs3011224	chr1:44318483	C/T	cg13606994	chr1:44402422	ARTN	-0.35	-5.19	-0.3	4.11e-7	Amyotrophic lateral sclerosis (age of onset);
CESC	cis	rs929354	1.000	rs1182378	chr7:157048322	T/C	cg05182265	chr7:156933206	UBE3C	0.43	5.99	0.35	6.69e-9	Body mass index;
CESC	cis	rs9309473	0.948	rs11884776	chr2:73746923	C/T	cg20560298	chr2:73613845	ALMS1	-0.48	-6.43	-0.37	5.96e-10	Metabolite levels;
CESC	cis	rs977987	0.806	rs6564252	chr16:75388940	C/T	cg03315344	chr16:75512273	CHST6	0.4	5.83	0.34	1.61e-8	Dupuytren's disease;
CESC	cis	rs6741892	0.536	rs13024840	chr2:38895920	T/A	cg23643435	chr2:38893251	GALM	-0.66	-9.11	-0.49	2.13e-17	5-HTT brain serotonin transporter levels;
CESC	cis	rs9910055	0.718	rs2526022	chr17:42213216	C/T	cg13607699	chr17:42295918	UBTF	0.63	8.36	0.46	3.49e-15	Total body bone mineral density;
CESC	cis	rs79839061	0.610	rs9994159	chr4:891150	C/T	cg07828340	chr4:882639	GAK	1.09	8.63	0.47	5.83e-16	Intelligence (multi-trait analysis);
CESC	trans	rs61931739	0.500	rs11053251	chr12:34520743	A/G	cg26384229	chr12:38710491	ALG10B	0.54	7.55	0.42	7.05e-13	Morning vs. evening chronotype;
CESC	cis	rs13242816	1.000	rs56180538	chr7:116079711	C/T	cg04696780	chr7:116139425	CAV2	-0.65	-5.7	-0.33	3.2e-8	P wave duration;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg24380168	chr7:45040141	CCM2	-0.51	-6.05	-0.35	4.88e-9	Ulcerative colitis;
CESC	cis	rs2180341	0.961	rs7775493	chr6:127615000	C/A	cg24812749	chr6:127587940	RNF146	1.06	15.35	0.69	1.74e-38	Breast cancer;
CESC	cis	rs1552244	1.000	rs1552244	chr3:10135577	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.89	12.81	0.62	1.48e-29	Alzheimer's disease;
CESC	cis	rs7666738	0.830	rs10031292	chr4:99056877	A/G	cg24818145	chr4:99064322	C4orf37	0.38	5.05	0.3	8.04e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9916302	0.904	rs4795359	chr17:37573146	C/T	cg00129232	chr17:37814104	STARD3	-0.56	-7.35	-0.41	2.4e-12	Glomerular filtration rate (creatinine);
CESC	cis	rs2070677	1.000	rs743534	chr10:135349226	G/T	cg20169779	chr10:135381914	SYCE1	0.67	7.94	0.44	5.86e-14	Gout;
CESC	cis	rs6500395	0.735	rs7204345	chr16:48666726	T/C	cg04672837	chr16:48644449	N4BP1	0.49	6.28	0.36	1.38e-9	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs7666738	0.830	rs1967980	chr4:98966426	C/G	cg17366294	chr4:99064904	C4orf37	0.58	8.25	0.45	7.46e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7267979	1.000	rs7267979	chr20:25298087	C/T	cg08601574	chr20:25228251	PYGB	0.39	5.52	0.32	8.17e-8	Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs9858542	0.953	rs3811699	chr3:49396360	T/C	cg21659725	chr3:3221576	CRBN	-0.54	-6.37	-0.36	8.2e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs6762	0.748	rs7936838	chr11:839093	G/C	cg23754390	chr11:835074	CD151	0.31	5.28	0.31	2.75e-7	Mean platelet volume;
CESC	cis	rs3806843	0.966	rs2563262	chr5:140137712	C/G	cg16179182	chr5:140090404	VTRNA1-1	0.38	5.03	0.3	8.99e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs4523957	0.890	rs11078024	chr17:2189324	T/C	cg16513277	chr17:2031491	SMG6	0.59	8.07	0.44	2.51e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs113835537	0.529	rs11227512	chr11:66281291	T/C	cg24851651	chr11:66362959	CCS	0.45	5.55	0.32	6.92e-8	Airway imaging phenotypes;
CESC	cis	rs6582630	0.574	rs12146797	chr12:38436499	T/C	cg26384229	chr12:38710491	ALG10B	0.69	10.55	0.54	5.83e-22	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs2933343	0.729	rs6767104	chr3:128648117	G/T	cg24203234	chr3:128598194	ACAD9	-0.43	-5.61	-0.33	5.02e-8	IgG glycosylation;
CESC	cis	rs2066819	1.000	rs77853814	chr12:56687572	G/T	cg26804944	chr12:56660921	COQ10A	-0.81	-5.03	-0.3	8.95e-7	Psoriasis vulgaris;
CESC	cis	rs6736093	1.000	rs6736093	chr2:112655242	C/T	cg12686935	chr2:112915763	FBLN7	0.44	5.54	0.32	7.45e-8	Coronary artery disease;
CESC	cis	rs1395	0.778	rs2580759	chr2:27432500	G/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	-0.38	-5.24	-0.31	3.24e-7	Blood metabolite levels;
CESC	cis	rs7772486	0.805	rs4896831	chr6:145959481	T/C	cg05347473	chr6:146136440	FBXO30	0.49	6.51	0.37	3.71e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs8103278	0.793	rs59093775	chr19:46374037	G/A	cg11657440	chr19:46296263	DMWD	-0.47	-5.57	-0.32	6.26e-8	Coronary artery disease;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg22411068	chr5:10442103	ROPN1L	-0.46	-6.62	-0.38	1.98e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs425277	0.539	rs3107142	chr1:2044542	T/C	cg13918804	chr1:2043761	PRKCZ	0.27	5.12	0.3	5.81e-7	Height;
CESC	cis	rs9818758	0.607	rs73084135	chr3:49272218	A/G	cg00383909	chr3:49044727	WDR6	0.91	6.12	0.35	3.28e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CESC	cis	rs7927592	0.763	rs7119422	chr11:68331154	C/T	cg20283391	chr11:68216788	NA	0.44	5.58	0.32	5.86e-8	Total body bone mineral density;
CESC	cis	rs10416265	0.527	rs11084699	chr19:33538393	A/T	cg17764715	chr19:33622953	WDR88	0.59	8.13	0.45	1.67e-14	Bone properties (heel);
CESC	cis	rs4853012	0.887	rs2280642	chr2:74358252	T/A	cg05890377	chr2:74357713	NA	0.74	9.2	0.49	1.1e-17	Gestational age at birth (maternal effect);
CESC	cis	rs9814567	1.000	rs4974483	chr3:134219001	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.41	-5.66	-0.33	3.91e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs6582630	0.623	rs12299293	chr12:38436288	G/A	cg26384229	chr12:38710491	ALG10B	-0.41	-5.49	-0.32	9.35e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs9467711	0.516	rs523383	chr6:25869848	A/G	cg21479132	chr6:26055353	NA	0.58	6.34	0.36	9.83e-10	Autism spectrum disorder or schizophrenia;
CESC	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg04352962	chr1:209979756	IRF6	0.44	6.17	0.35	2.56e-9	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
CESC	cis	rs2279817	1.000	rs1339801	chr1:18020298	A/G	cg21791023	chr1:18019539	ARHGEF10L	0.57	8.35	0.46	3.75e-15	Neuroticism;
CESC	cis	rs16870629	1.000	rs16870629	chr5:1015063	C/T	cg00278107	chr5:1061253	SLC12A7	-0.71	-11.4	-0.57	9.16e-25	QT interval;
CESC	cis	rs523522	0.962	rs2233676	chr12:120933607	G/A	cg12219531	chr12:120966889	COQ5	0.75	9.99	0.52	3.7e-20	High light scatter reticulocyte count;
CESC	cis	rs2901656	0.934	rs9425311	chr1:172388778	G/T	cg03748243	chr1:172413542	C1orf105;PIGC	0.46	6.83	0.39	5.8200000000000003e-11	Red cell distribution width;Platelet distribution width;
CESC	cis	rs72781680	0.752	rs55806536	chr2:23912697	A/G	cg08917208	chr2:24149416	ATAD2B	1.14	10.27	0.53	4.72e-21	Lymphocyte counts;
CESC	cis	rs933688	1.000	rs12655973	chr5:90736537	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.14	15.49	0.69	5.83e-39	Smoking behavior;
CESC	cis	rs875971	1.000	rs709595	chr7:65817333	G/C	cg12463550	chr7:65579703	CRCP	0.57	7.33	0.41	2.73e-12	Aortic root size;
CESC	cis	rs2519796	0.529	rs2073885	chr9:136814491	T/C	cg13751417	chr9:136814406	VAV2	-0.41	-5.21	-0.3	3.88e-7	Hematocrit;Hemoglobin concentration;
CESC	cis	rs11828289	0.660	rs76379912	chr11:23182498	A/G	cg20040320	chr11:23191996	NA	-0.68	-5.88	-0.34	1.25e-8	Cancer;
CESC	cis	rs2070677	0.935	rs2070676	chr10:135351137	C/G	cg20169779	chr10:135381914	SYCE1	0.67	8.1	0.45	1.97e-14	Gout;
CESC	cis	rs4822044	0.617	rs13054514	chr22:42130383	A/G	cg03806693	chr22:41940476	POLR3H	0.78	9.54	0.51	9.81e-19	Cannabis dependence symptom count;
CESC	cis	rs17711722	0.565	rs73372653	chr7:65442795	A/T	cg12143784	chr7:64541923	NA	0.4	5.34	0.31	2.03e-7	Calcium levels;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg20990694	chr7:150417431	GIMAP1	0.44	6.2	0.36	2.12e-9	Ulcerative colitis;
CESC	cis	rs748404	0.660	rs548704	chr15:43791706	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.57	7.5	0.42	9.94e-13	Lung cancer;
CESC	cis	rs2286503	0.780	rs929464	chr7:22874770	T/C	cg11367502	chr7:22862612	TOMM7	0.43	5.58	0.32	5.9e-8	Fibrinogen;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03229959	chr8:38089560	DDHD2	0.52	6.65	0.38	1.64e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs9837602	1.000	rs1021103	chr3:99603230	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.55	7.42	0.41	1.57e-12	Breast cancer;
CESC	cis	rs6502050	0.835	rs4789737	chr17:80123269	G/A	cg11859384	chr17:80120422	CCDC57	-0.39	-5.34	-0.31	1.98e-7	Life satisfaction;
CESC	cis	rs2180341	1.000	rs6937287	chr6:127645719	T/A	cg27446573	chr6:127587934	RNF146	1.09	16.35	0.71	5.12e-42	Breast cancer;
CESC	cis	rs2835872	0.758	rs1787399	chr21:39037883	A/G	cg06728970	chr21:39037746	KCNJ6	0.3	5.59	0.32	5.72e-8	Electroencephalographic traits in alcoholism;
CESC	cis	rs74925218	1	rs74925218	chr15:78796732	C/T	cg24631222	chr15:78858424	CHRNA5	0.63	7.03	0.4	1.8e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs4555082	0.830	rs2735812	chr14:105727575	A/G	cg06808227	chr14:105710500	BRF1	-0.6	-7.01	-0.4	1.94e-11	Mean platelet volume;Platelet distribution width;
CESC	trans	rs801193	0.967	rs3800823	chr7:66147110	C/A	cg26939375	chr7:64535504	NA	-0.62	-8.28	-0.45	6.22e-15	Aortic root size;
CESC	cis	rs806215	0.547	rs59140894	chr7:127430797	C/T	cg25922125	chr7:127225783	GCC1	-0.39	-5.06	-0.3	7.93e-7	Type 2 diabetes;
CESC	cis	rs11792861	0.926	rs72607171	chr9:111837776	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.42	5.18	0.3	4.44e-7	Menarche (age at onset);
CESC	cis	rs35110281	0.776	rs1073522	chr21:45009219	T/A	cg21573476	chr21:45109991	RRP1B	-0.45	-6.15	-0.35	2.83e-9	Mean corpuscular volume;
CESC	trans	rs11992162	0.613	rs6998690	chr8:11798796	A/T	cg15556689	chr8:8085844	FLJ10661	0.52	6.48	0.37	4.44e-10	Monocyte count;
CESC	cis	rs4665809	1.000	rs4233710	chr2:26291565	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.82	-9.22	-0.49	9.78e-18	Gut microbiome composition (summer);
CESC	cis	rs6089584	0.526	rs6061965	chr20:60607858	A/C	cg06108461	chr20:60628389	TAF4	-0.58	-7.79	-0.43	1.54e-13	Body mass index;
CESC	cis	rs67478160	0.619	rs1187416	chr14:104311465	A/G	cg08213375	chr14:104286397	PPP1R13B	0.53	10.41	0.54	1.75e-21	Schizophrenia;
CESC	cis	rs8072100	0.582	rs3826536	chr17:45501967	T/A	cg25173405	chr17:45401733	C17orf57	-0.43	-5.43	-0.32	1.26e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs4862750	0.872	rs6811837	chr4:187898162	G/A	cg22105103	chr4:187893119	NA	0.51	7.61	0.42	4.66e-13	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs8114671	0.836	rs4911461	chr20:33629993	A/C	cg24642439	chr20:33292090	TP53INP2	-0.45	-5.44	-0.32	1.19e-7	Height;
CESC	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.54	6.71	0.38	1.2e-10	Prudent dietary pattern;
CESC	trans	rs7246657	0.941	rs7256130	chr19:37933981	T/C	cg24637308	chr11:6592297	DNHD1	0.54	6.32	0.36	1.09e-9	Coronary artery calcification;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg14162927	chr1:155145774	TRIM46;KRTCAP2	-0.43	-6.21	-0.36	2.01e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs910316	0.967	rs7146523	chr14:75659880	T/C	cg11812906	chr14:75593930	NEK9	-0.84	-13.76	-0.65	6.99e-33	Height;
CESC	cis	rs4888262	0.507	rs9888976	chr16:74580924	C/T	cg01733217	chr16:74700730	RFWD3	0.8	11.2	0.57	4.42e-24	Testicular germ cell tumor;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg17160590	chr1:222886778	C1orf58;AIDA	-0.52	-6.31	-0.36	1.18e-9	Ulcerative colitis;
CESC	cis	rs11532322	1	rs11532322	chr12:123731423	A/G	cg05973401	chr12:123451056	ABCB9	0.46	5.51	0.32	8.36e-8	Schizophrenia;
CESC	cis	rs896854	0.902	rs726816	chr8:95968413	T/G	cg09323728	chr8:95962352	TP53INP1	-0.42	-9.06	-0.49	3.05e-17	Type 2 diabetes;
CESC	cis	rs9911578	0.967	rs11656413	chr17:57082013	A/C	cg12560992	chr17:57184187	TRIM37	-0.99	-17.67	-0.74	1.1e-46	Intelligence (multi-trait analysis);
CESC	cis	rs1448094	0.512	rs11832503	chr12:86240797	A/G	cg00310523	chr12:86230176	RASSF9	0.36	5.71	0.33	3.02e-8	Major depressive disorder;
CESC	cis	rs7666738	0.830	rs6854703	chr4:98977586	A/T	cg03676636	chr4:99064102	C4orf37	0.33	5.12	0.3	5.91e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs992157	0.710	rs12612347	chr2:219057338	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.66	-9.31	-0.5	5.05e-18	Colorectal cancer;
CESC	cis	rs8070128	0.688	rs59304093	chr17:17875407	A/G	cg04398451	chr17:18023971	MYO15A	-0.69	-9.51	-0.5	1.19e-18	Total body bone mineral density;
CESC	trans	rs2898290	0.540	rs12677146	chr8:11450737	C/G	cg15556689	chr8:8085844	FLJ10661	-0.55	-6.86	-0.39	4.95e-11	Systolic blood pressure;
CESC	trans	rs7866350	0.604	rs1935389	chr9:100994470	A/G	cg13229245	chr11:125366238	FEZ1	0.41	6.1	0.35	3.84e-9	Post-traumatic stress disorder;
CESC	cis	rs2228479	0.702	rs11646374	chr16:89857935	G/A	cg14709524	chr16:89940631	TCF25	0.94	7.0	0.39	2.13e-11	Skin colour saturation;
CESC	cis	rs617791	0.530	rs55947178	chr11:65754230	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.43	-5.06	-0.3	8e-7	Breast cancer;
CESC	cis	rs2841277	0.616	rs1048257	chr14:105404384	T/C	cg21017887	chr14:105400489	NA	0.42	6.75	0.38	9.42e-11	Rheumatoid arthritis;
CESC	cis	rs9388451	0.839	rs1811852	chr6:126071575	G/C	cg10911889	chr6:126070802	HEY2	0.41	5.68	0.33	3.6e-8	Brugada syndrome;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04250904	chr19:12623422	ZNF709	-0.48	-6.72	-0.38	1.13e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs28374715	0.532	rs11070328	chr15:41651569	T/C	cg20272979	chr15:41787780	ITPKA	0.41	5.06	0.3	7.68e-7	Ulcerative colitis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05210131	chr2:182757482	SSFA2	0.61	6.97	0.39	2.53e-11	Gut microbiome composition (summer);
CESC	cis	rs2290159	0.800	rs59821954	chr3:12687613	T/C	cg23032965	chr3:12705835	RAF1	0.51	5.5	0.32	9.11e-8	Cholesterol, total;
CESC	cis	rs7605827	0.930	rs6431705	chr2:15599988	C/G	cg19274914	chr2:15703543	NA	-0.32	-5.67	-0.33	3.67e-8	Educational attainment (years of education);
CESC	trans	rs2999987	0.506	rs2066416	chr1:72712404	C/T	cg00292001	chr3:46853850	NA	0.54	6.03	0.35	5.36e-9	Intelligence (multi-trait analysis);
CESC	cis	rs2645694	0.651	rs2703144	chr4:77830505	C/G	cg18351406	chr4:77819688	ANKRD56	0.52	6.28	0.36	1.38e-9	Emphysema distribution in smoking;
CESC	cis	rs873946	0.648	rs12766050	chr10:134549108	G/A	cg26818010	chr10:134567672	INPP5A	-0.88	-10.73	-0.55	1.56e-22	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs9814567	0.896	rs4245907	chr3:134347876	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.42	-5.67	-0.33	3.63e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs898097	0.801	rs68141193	chr17:80878816	C/T	cg15664640	chr17:80829946	TBCD	-0.66	-9.98	-0.52	4.09e-20	Breast cancer;
CESC	cis	rs72945132	0.882	rs17160753	chr11:70131462	A/G	cg00319359	chr11:70116639	PPFIA1	0.78	7.78	0.43	1.6e-13	Coronary artery disease;
CESC	cis	rs193541	0.632	rs246276	chr5:122239957	G/A	cg19412675	chr5:122181750	SNX24	0.49	5.75	0.33	2.47e-8	Glucose homeostasis traits;
CESC	cis	rs2836974	0.897	rs13339986	chr21:40605982	T/C	cg17971929	chr21:40555470	PSMG1	1.01	13.78	0.65	6.34e-33	Cognitive function;
CESC	cis	rs853679	0.517	rs9368555	chr6:28108967	T/C	cg23161317	chr6:28129485	ZNF389	0.5	6.4	0.37	7.04e-10	Depression;
CESC	cis	rs7618915	0.570	rs2336145	chr3:52629750	A/C	cg18099408	chr3:52552593	STAB1	-0.33	-5.41	-0.32	1.4e-7	Bipolar disorder;
CESC	trans	rs116095464	0.558	rs10055993	chr5:264296	A/C	cg00938859	chr5:1591904	SDHAP3	0.7	6.28	0.36	1.35e-9	Breast cancer;
CESC	cis	rs4253772	0.591	rs11703435	chr22:46685563	C/T	cg18190219	chr22:46762943	CELSR1	-0.59	-5.46	-0.32	1.09e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs9549260	0.599	rs12870023	chr13:41244222	T/A	cg21288729	chr13:41239152	FOXO1	0.68	8.46	0.46	1.82e-15	Red blood cell count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18281101	chr1:157015843	ARHGEF11	0.54	6.02	0.35	5.85e-9	Gut microbiome composition (summer);
CESC	cis	rs79387448	0.701	rs11465584	chr2:102982629	G/A	cg09003973	chr2:102972529	NA	1.19	9.18	0.49	1.27e-17	Gut microbiota (bacterial taxa);
CESC	cis	rs13095912	0.785	rs4686682	chr3:185307402	C/T	cg11274856	chr3:185301563	NA	0.39	5.94	0.34	9.09e-9	Systolic blood pressure;
CESC	cis	rs4141404	0.757	rs5749272	chr22:31830351	C/T	cg02404636	chr22:31891804	SFI1	-0.4	-5.7	-0.33	3.19e-8	Paclitaxel-induced neuropathy;
CESC	cis	rs9430161	0.611	rs12081197	chr1:11034239	T/C	cg27631724	chr1:11040367	C1orf127	0.38	6.21	0.36	2.02e-9	Ewing sarcoma;
CESC	cis	rs11098499	0.955	rs1511015	chr4:120170473	A/C	cg24375607	chr4:120327624	NA	0.43	5.22	0.31	3.66e-7	Corneal astigmatism;
CESC	cis	rs1707322	0.717	rs11211161	chr1:46148138	A/C	cg03146154	chr1:46216737	IPP	0.82	11.53	0.58	3.39e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs853679	0.607	rs201002	chr6:27808192	A/G	cg06606381	chr12:133084897	FBRSL1	-0.73	-7.51	-0.42	9.03e-13	Depression;
CESC	cis	rs9649213	0.593	rs6970801	chr7:97925240	T/C	cg08684580	chr7:98029266	BAIAP2L1	-0.35	-5.68	-0.33	3.49e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs11696501	0.688	rs2072974	chr20:44313401	G/A	cg11783356	chr20:44313418	WFDC10B	-0.34	-5.25	-0.31	3.05e-7	Brain structure;
CESC	trans	rs4904167	0.841	rs1599581	chr14:84681620	A/T	cg06870609	chr15:89787223	FANCI	0.46	6.06	0.35	4.73e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs1215050	0.755	rs1238462	chr4:98850603	A/G	cg05340658	chr4:99064831	C4orf37	-0.5	-6.59	-0.38	2.32e-10	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs1008375	0.872	rs2315552	chr4:17627294	A/G	cg16339924	chr4:17578868	LAP3	0.57	7.18	0.4	6.9e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs765787	0.530	rs12915027	chr15:45512626	G/A	cg24006582	chr15:45444508	DUOX1	0.52	6.32	0.36	1.13e-9	Uric acid levels;
CESC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg10515953	chr10:61666281	CCDC6	-0.56	-6.73	-0.38	1.05e-10	Lung cancer in ever smokers;
CESC	cis	rs58785573	0.504	rs9522	chr4:38666972	C/T	cg18361445	chr4:38666374	KLF3;FLJ13197	0.54	7.52	0.42	8.71e-13	Lymphocyte percentage of white cells;
CESC	cis	rs7255436	0.965	rs11666003	chr19:8452102	G/A	cg10174797	chr19:8464628	RAB11B	0.39	5.57	0.32	6.11e-8	HDL cholesterol;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11539173	chr22:19843009	GNB1L;C22orf29	0.59	6.52	0.37	3.62e-10	Gut microbiome composition (summer);
CESC	cis	rs11122272	0.766	rs2486732	chr1:231531476	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.6	-8.36	-0.46	3.55e-15	Hemoglobin concentration;
CESC	cis	rs10899021	0.920	rs10899014	chr11:74325109	A/G	cg25880958	chr11:74394337	NA	-0.74	-7.91	-0.44	7.23e-14	Response to metformin (IC50);
CESC	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg24642844	chr7:1081250	C7orf50	-0.77	-9.41	-0.5	2.48e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14474793	chr4:39460697	RPL9;LIAS	0.56	6.16	0.35	2.66e-9	Gut microbiome composition (summer);
CESC	cis	rs3806843	0.801	rs801170	chr5:140115343	C/T	cg16179182	chr5:140090404	VTRNA1-1	0.38	5.05	0.3	8.28e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs6893300	0.785	rs3797762	chr5:179202688	A/G	cg14593053	chr5:179126677	CANX	-0.49	-5.86	-0.34	1.34e-8	Resting heart rate;
CESC	trans	rs916888	0.821	rs199505	chr17:44859410	A/G	cg07870213	chr5:140052090	DND1	-0.58	-6.45	-0.37	5.28e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs7666738	0.830	rs4619898	chr4:98959646	G/A	cg03676636	chr4:99064102	C4orf37	0.33	5.12	0.3	5.76e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11864453	0.647	rs3764314	chr16:72127078	T/C	cg16558253	chr16:72132732	DHX38	-0.55	-8.54	-0.46	1.08e-15	Fibrinogen levels;
CESC	cis	rs9682041	0.696	rs10936627	chr3:170104406	C/T	cg11886554	chr3:170076028	SKIL	0.7	6.46	0.37	4.94e-10	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CESC	cis	rs1707322	1.000	rs6695421	chr1:46380207	T/C	cg03146154	chr1:46216737	IPP	0.72	9.88	0.52	8.36e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7949030	0.626	rs1061093	chr11:62334908	G/C	cg23462726	chr11:62437636	C11orf83;C11orf48	-0.4	-5.23	-0.31	3.46e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs7666738	0.830	rs4440224	chr4:99044924	G/A	cg03676636	chr4:99064102	C4orf37	0.33	5.12	0.3	5.93e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4835473	0.932	rs13130345	chr4:144842092	C/T	cg25736465	chr4:144833511	NA	0.37	5.33	0.31	2.11e-7	Immature fraction of reticulocytes;
CESC	trans	rs2832077	0.527	rs59730679	chr21:30226244	T/C	cg14791747	chr16:20752902	THUMPD1	0.53	7.48	0.42	1.12e-12	Cognitive test performance;
CESC	cis	rs34779708	0.931	rs6481935	chr10:35342959	C/T	cg03585969	chr10:35415529	CREM	0.77	10.1	0.53	1.63e-20	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs12931792	0.682	rs12373078	chr16:30187676	T/G	cg17640201	chr16:30407289	ZNF48	0.6	8.24	0.45	8.18e-15	Tonsillectomy;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg24448245	chr7:66461718	SBDS;TYW1	0.53	6.72	0.38	1.09e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs6088580	0.634	rs1890002	chr20:32919219	A/G	cg24642439	chr20:33292090	TP53INP2	-0.5	-6.59	-0.38	2.42e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs892961	0.899	rs747482	chr17:75412109	T/C	cg05865280	chr17:75406074	SEPT9	0.62	12.7	0.62	3.53e-29	Airflow obstruction;
CESC	cis	rs12586317	0.525	rs10144430	chr14:35433682	T/A	cg16230307	chr14:35515116	FAM177A1	0.83	10.07	0.53	2.06e-20	Psoriasis;
CESC	cis	rs644799	0.896	rs4430471	chr11:95646774	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.82	12.0	0.59	8.65e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs7818688	0.585	rs1031388	chr8:96049684	C/T	cg16049864	chr8:95962084	TP53INP1	-0.5	-5.62	-0.33	4.73e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg23586394	chr17:8286572	RPL26	-0.47	-6.78	-0.38	7.98e-11	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg15729423	chr14:74318413	PTGR2	0.49	6.16	0.35	2.65e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs7216064	0.651	rs12947658	chr17:65903006	A/G	cg12091567	chr17:66097778	LOC651250	0.55	6.85	0.39	5.18e-11	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs1865721	0.682	rs7242637	chr18:73147492	A/C	cg26385618	chr18:73139727	C18orf62	-0.47	-7.52	-0.42	8.61e-13	Intelligence;
CESC	cis	rs7666738	0.606	rs6839946	chr4:99076132	A/C	cg17366294	chr4:99064904	C4orf37	0.45	6.04	0.35	5.27e-9	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11637445	0.603	rs1478941	chr15:68127141	A/G	cg14583481	chr3:118865028	C3orf30;IGSF11	0.43	6.11	0.35	3.58e-9	Posterior cortical atrophy and Alzheimer's disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg04935666	chr14:105817407	PACS2	0.43	6.38	0.36	7.93e-10	Fibrinogen levels;
CESC	cis	rs9916302	0.904	rs7221875	chr17:37543328	G/A	cg20243544	chr17:37824526	PNMT	-0.49	-6.18	-0.35	2.42e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs6667605	0.527	rs12046118	chr1:2540343	A/C	cg18854424	chr1:2615690	NA	0.3	5.99	0.35	6.97e-9	Inflammatory bowel disease;Ulcerative colitis;
CESC	cis	rs7474896	0.537	rs1208587	chr10:38207759	A/G	cg25427524	chr10:38739819	LOC399744	0.46	5.42	0.32	1.31e-7	Obesity (extreme);
CESC	cis	rs2230307	0.536	rs56215716	chr1:100447486	G/A	cg24955406	chr1:100503596	HIAT1	0.53	5.39	0.31	1.56e-7	Carotid intima media thickness;
CESC	cis	rs514406	0.708	rs546334	chr1:53326210	T/C	cg08736216	chr1:53307985	ZYG11A	-0.4	-7.16	-0.4	7.76e-12	Monocyte count;
CESC	cis	rs1348850	0.789	rs2197611	chr2:178369036	G/C	cg23306229	chr2:178417860	TTC30B	0.65	8.07	0.44	2.47e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	trans	rs561341	1.000	rs72825712	chr17:30316119	A/T	cg27661571	chr11:113659931	NA	-0.87	-8.06	-0.44	2.57e-14	Hip circumference adjusted for BMI;
CESC	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.76	10.71	0.55	1.78e-22	Prudent dietary pattern;
CESC	cis	rs708547	0.874	rs1718837	chr4:57871203	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.67	8.77	0.47	2.23e-16	Response to bleomycin (chromatid breaks);
CESC	cis	rs4660306	0.677	rs6429566	chr1:45941852	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.48	-5.29	-0.31	2.57e-7	Homocysteine levels;
CESC	cis	rs10504229	0.728	rs17804335	chr8:58151428	G/T	cg24829409	chr8:58192753	C8orf71	0.62	7.63	0.42	4.25e-13	Developmental language disorder (linguistic errors);
CESC	cis	rs1448094	0.845	rs11117129	chr12:86349390	A/G	cg02569458	chr12:86230093	RASSF9	0.39	5.68	0.33	3.61e-8	Major depressive disorder;
CESC	cis	rs1799949	0.965	rs8176198	chr17:41230537	A/T	cg05368731	chr17:41323189	NBR1	0.54	7.1	0.4	1.13e-11	Menopause (age at onset);
CESC	cis	rs36051895	0.664	rs17425637	chr9:5110000	C/T	cg02405213	chr9:5042618	JAK2	-0.52	-6.33	-0.36	1.02e-9	Pediatric autoimmune diseases;
CESC	cis	rs9457247	0.765	rs9459849	chr6:167444160	G/T	cg07741184	chr6:167504864	NA	0.35	6.42	0.37	6.25e-10	Crohn's disease;
CESC	cis	rs1461503	0.966	rs11218905	chr11:122840303	A/G	cg27398637	chr11:122830231	C11orf63	0.55	8.36	0.46	3.63e-15	Menarche (age at onset);
CESC	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.64	7.2	0.4	6.35e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs10129255	0.957	rs10140904	chr14:107184797	C/T	cg23076370	chr14:107095027	NA	-0.48	-6.2	-0.36	2.16e-9	Kawasaki disease;
CESC	cis	rs3820928	0.874	rs67513858	chr2:227804819	A/C	cg11843606	chr2:227700838	RHBDD1	-0.43	-5.66	-0.33	3.83e-8	Pulmonary function;
CESC	trans	rs4665809	0.838	rs6546780	chr2:26352857	T/C	cg09258813	chr8:37823409	ADRB3	-0.37	-6.1	-0.35	3.73e-9	Gut microbiome composition (summer);
CESC	cis	rs9649213	0.593	rs6945554	chr7:97972946	T/C	cg21770322	chr7:97807741	LMTK2	0.57	8.84	0.48	1.39e-16	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs60843830	1.000	rs62114501	chr2:231741	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.79	10.05	0.53	2.44e-20	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs60871478	0.636	rs12532761	chr7:905229	C/T	cg05535760	chr7:792225	HEATR2	-0.79	-8.18	-0.45	1.21e-14	Cerebrospinal P-tau181p levels;
CESC	cis	rs9660180	0.967	rs10907191	chr1:1774820	A/T	cg05132306	chr1:1846340	CALML6	-0.3	-6.37	-0.36	8.33e-10	Body mass index;
CESC	cis	rs734999	0.566	rs10797435	chr1:2534801	G/C	cg20673091	chr1:2541236	MMEL1	0.43	7.16	0.4	7.78e-12	Ulcerative colitis;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg20459655	chr2:135675569	CCNT2	0.38	6.19	0.36	2.32e-9	Gambling;
CESC	cis	rs2070488	1.000	rs1002675	chr3:38445226	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.91	16.26	0.71	1.07e-41	Electrocardiographic conduction measures;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03041742	chr1:43147857	YBX1	0.59	6.01	0.35	6.12e-9	Gut microbiome composition (summer);
CESC	cis	rs10751667	0.666	rs6597967	chr11:950583	G/T	cg06064525	chr11:970664	AP2A2	-0.49	-9.81	-0.52	1.42e-19	Alzheimer's disease (late onset);
CESC	cis	rs4665809	0.567	rs12999875	chr2:26414847	A/C	cg22920501	chr2:26401640	FAM59B	0.86	10.01	0.52	3.25e-20	Gut microbiome composition (summer);
CESC	cis	rs13034020	0.522	rs35217978	chr2:61246548	A/G	cg18625361	chr2:61244694	PEX13;PUS10	0.66	5.9	0.34	1.13e-8	Hodgkin's lymphoma;
CESC	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	13.74	0.64	8.59e-33	Prudent dietary pattern;
CESC	cis	rs7666738	0.830	rs10011009	chr4:98981749	G/A	cg17366294	chr4:99064904	C4orf37	0.58	8.39	0.46	2.88e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs17601876	0.814	rs28674681	chr15:51559917	A/C	cg19946085	chr15:51559439	CYP19A1	-0.34	-5.52	-0.32	7.94e-8	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
CESC	cis	rs2046867	0.818	rs17010204	chr3:72879099	G/A	cg25664220	chr3:72788482	NA	-0.37	-5.36	-0.31	1.82e-7	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CESC	cis	rs7429990	0.965	rs7642590	chr3:48099750	G/A	cg11946769	chr3:48343235	NME6	-0.5	-6.13	-0.35	3.17e-9	Educational attainment (years of education);
CESC	cis	rs873946	0.648	rs12767283	chr10:134557094	C/G	cg26818010	chr10:134567672	INPP5A	-0.9	-10.88	-0.56	4.78e-23	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs2439831	1.000	rs689596	chr15:43761717	A/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.83	12.17	0.6	2.26e-27	Lung cancer in ever smokers;
CESC	cis	rs1552244	0.882	rs113268531	chr3:10167069	A/G	cg00149659	chr3:10157352	C3orf10	0.72	9.27	0.49	6.61e-18	Alzheimer's disease;
CESC	cis	rs4665809	0.887	rs4665814	chr2:26273687	G/T	cg22920501	chr2:26401640	FAM59B	-0.66	-7.85	-0.43	1.01e-13	Gut microbiome composition (summer);
CESC	cis	rs2836974	0.590	rs11911822	chr21:40607843	C/T	cg11644478	chr21:40555479	PSMG1	-0.82	-12.36	-0.6	5.28e-28	Cognitive function;
CESC	cis	rs28386778	0.700	rs11079515	chr17:62005645	C/G	cg06873352	chr17:61820015	STRADA	-0.6	-9.7	-0.51	3.17e-19	Prudent dietary pattern;
CESC	cis	rs7618915	0.570	rs11130312	chr3:52675055	A/C	cg07507251	chr3:52567010	NT5DC2	0.4	7.11	0.4	1.1e-11	Bipolar disorder;
CESC	cis	rs10256972	0.685	rs10263665	chr7:1110628	A/G	cg23978390	chr7:1156363	C7orf50	0.5	6.65	0.38	1.66e-10	Longevity;Endometriosis;
CESC	cis	rs7814319	0.899	rs1878638	chr8:97258719	C/T	cg20787634	chr8:97240163	UQCRB	-0.58	-7.5	-0.42	9.91e-13	Lung function (FVC);
CESC	cis	rs6499255	0.951	rs60099379	chr16:69582104	A/G	cg15192750	chr16:69999425	NA	0.54	6.14	0.35	2.98e-9	IgE levels;
CESC	cis	rs514406	0.505	rs427319	chr1:53178807	T/G	cg16325326	chr1:53192061	ZYG11B	0.91	15.9	0.7	2.02e-40	Monocyte count;
CESC	cis	rs7429990	0.965	rs7431572	chr3:48027851	G/T	cg11946769	chr3:48343235	NME6	-0.44	-5.38	-0.31	1.65e-7	Educational attainment (years of education);
CESC	cis	rs2204008	0.537	rs28680519	chr12:38502946	C/T	cg13010199	chr12:38710504	ALG10B	0.52	6.7	0.38	1.25e-10	Bladder cancer;
CESC	cis	rs10504229	0.906	rs61638902	chr8:58193511	A/C	cg24829409	chr8:58192753	C8orf71	-0.71	-9.63	-0.51	5.28e-19	Developmental language disorder (linguistic errors);
CESC	cis	rs7927771	0.965	rs35184771	chr11:47475189	G/T	cg05585544	chr11:47624801	NA	-0.52	-7.77	-0.43	1.76e-13	Subjective well-being;
CESC	cis	rs933688	1.000	rs2367353	chr5:90686568	G/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.07	14.21	0.66	1.95e-34	Smoking behavior;
CESC	trans	rs4335177	0.671	rs7028638	chr9:109374085	C/G	cg12580783	chr12:49362475	WNT10B	-0.37	-6.36	-0.36	8.78e-10	Response to paliperidone in schizophrenia (positive Marder score);
CESC	cis	rs1506636	1.000	rs615410	chr7:123437765	T/C	cg03229431	chr7:123269106	ASB15	0.46	5.95	0.34	8.51e-9	Plateletcrit;Platelet count;
CESC	cis	rs1577917	0.958	rs28442244	chr6:86701236	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.41	5.35	0.31	1.86e-7	Response to antipsychotic treatment;
CESC	cis	rs10811516	0.520	rs4568676	chr9:21184475	C/G	cg23029519	chr9:21187344	IFNA4	0.36	5.81	0.34	1.83e-8	Response to mepolizumab in severe asthma;
CESC	cis	rs2380220	0.808	rs2613554	chr6:95916782	C/A	cg15832292	chr6:96025679	MANEA	-0.65	-5.95	-0.34	8.46e-9	Behavioural disinhibition (generation interaction);
CESC	cis	rs67311347	1.000	rs73080126	chr3:40509153	A/G	cg09455208	chr3:40491958	NA	0.5	8.19	0.45	1.15e-14	Renal cell carcinoma;
CESC	cis	rs7666738	0.830	rs13108422	chr4:99059267	G/A	cg18180107	chr4:99064573	C4orf37	0.4	5.16	0.3	4.84e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7589342	0.929	rs7590652	chr2:106440306	A/G	cg16077055	chr2:106428750	NCK2	0.49	6.93	0.39	3.11e-11	Addiction;
CESC	cis	rs300703	0.935	rs10193882	chr2:246301	A/T	cg21211680	chr2:198530	NA	-0.85	-7.07	-0.4	1.36e-11	Blood protein levels;
CESC	trans	rs2797160	0.651	rs1268066	chr6:126035041	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.53	7.17	0.4	7.49e-12	Endometrial cancer;
CESC	cis	rs4642101	0.737	rs9877165	chr3:12828497	C/T	cg05775895	chr3:12838266	CAND2	0.35	5.2	0.3	4.04e-7	QRS complex (12-leadsum);
CESC	cis	rs1050631	0.564	rs1785910	chr18:33729871	A/G	cg25426722	chr18:33708991	SLC39A6;ELP2	0.59	8.21	0.45	9.72e-15	Esophageal squamous cell cancer (length of survival);
CESC	cis	rs3767633	0.925	rs2499856	chr1:161926637	C/T	cg09175582	chr1:161736000	ATF6	-0.8	-7.37	-0.41	2.12e-12	IgG glycosylation;
CESC	cis	rs7592578	1.000	rs7592578	chr2:191439591	T/G	cg27211696	chr2:191398769	TMEM194B	0.62	5.6	0.33	5.29e-8	Diastolic blood pressure;
CESC	cis	rs1348850	0.914	rs12693120	chr2:178283288	A/G	cg22681709	chr2:178499509	PDE11A	-0.43	-6.3	-0.36	1.2e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs1799949	0.930	rs3765640	chr17:41276247	A/G	cg06001716	chr17:41278141	BRCA1;NBR2	0.39	5.28	0.31	2.75e-7	Menopause (age at onset);
CESC	cis	rs10927875	0.632	rs4481843	chr1:16128205	G/A	cg18973939	chr1:16164122	FLJ37453	0.37	5.52	0.32	8.2e-8	Dilated cardiomyopathy;
CESC	cis	rs7618915	0.501	rs1866268	chr3:52719398	C/A	cg07507251	chr3:52567010	NT5DC2	0.32	5.61	0.33	5.12e-8	Bipolar disorder;
CESC	cis	rs7552404	0.924	rs114752222	chr1:76180878	C/T	cg10523679	chr1:76189770	ACADM	0.76	9.99	0.52	3.74e-20	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs7937682	0.889	rs578022	chr11:111490552	G/T	cg09085632	chr11:111637200	PPP2R1B	-0.95	-14.6	-0.67	8.26e-36	Primary sclerosing cholangitis;
CESC	cis	rs1163251	0.623	rs493427	chr1:120207482	A/T	cg19096424	chr1:120255104	PHGDH	-0.39	-5.05	-0.3	8.35e-7	Blood metabolite levels;
CESC	cis	rs875971	0.862	rs6460293	chr7:65810192	C/A	cg19163074	chr7:65112434	INTS4L2	0.41	5.18	0.3	4.32e-7	Aortic root size;
CESC	cis	rs5753618	0.583	rs7287267	chr22:31748415	C/T	cg13145458	chr22:31556086	RNF185	-0.47	-5.4	-0.31	1.49e-7	Colorectal cancer;
CESC	cis	rs2777491	1.000	rs2730057	chr15:41736275	C/A	cg02330683	chr15:41787940	ITPKA	0.47	6.81	0.39	6.36e-11	Ulcerative colitis;
CESC	cis	rs4319547	0.774	rs10773394	chr12:123124778	C/A	cg05707623	chr12:122985044	ZCCHC8	-0.48	-5.87	-0.34	1.31e-8	Body mass index;
CESC	cis	rs2073300	0.536	rs6137947	chr20:23414630	C/A	cg16736954	chr20:23401023	NAPB	0.78	5.78	0.33	2.05e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs7927592	0.626	rs11228279	chr11:68309680	C/T	cg01657329	chr11:68192670	LRP5	0.48	6.33	0.36	1.05e-9	Total body bone mineral density;
CESC	cis	rs60154123	0.730	rs588197	chr1:210463515	A/T	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.45	5.15	0.3	5.11e-7	Coronary artery disease;
CESC	cis	rs2842992	0.915	rs1322427	chr6:160075454	C/A	cg11366901	chr6:160182831	ACAT2	0.77	9.41	0.5	2.45e-18	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs853679	0.550	rs1233699	chr6:28169158	A/T	cg26335602	chr6:28129616	ZNF389	0.49	6.82	0.39	6.23e-11	Depression;
CESC	cis	rs7819412	0.775	rs11773990	chr8:10935082	T/C	cg21775007	chr8:11205619	TDH	-0.37	-5.05	-0.3	8.14e-7	Triglycerides;
CESC	cis	rs116095464	0.558	rs62347683	chr5:230331	C/T	cg10591111	chr5:226296	SDHA	-0.54	-6.65	-0.38	1.72e-10	Breast cancer;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg19916409	chr4:103266691	SLC39A8	-0.42	-6.6	-0.38	2.24e-10	Gambling;
CESC	cis	rs1847202	1.000	rs11918615	chr3:72942407	T/C	cg25664220	chr3:72788482	NA	-0.34	-5.08	-0.3	7.05e-7	Motion sickness;
CESC	cis	rs5750830	0.597	rs4821889	chr22:39777254	T/C	cg11247378	chr22:39784982	NA	-0.5	-7.85	-0.43	1.02e-13	Intelligence (multi-trait analysis);
CESC	cis	rs875971	0.522	rs10807697	chr7:65416170	A/G	cg18876405	chr7:65276391	NA	0.69	9.61	0.51	5.83e-19	Aortic root size;
CESC	cis	rs8114671	0.836	rs2425006	chr20:33571228	T/G	cg06115741	chr20:33292138	TP53INP2	-0.44	-5.24	-0.31	3.22e-7	Height;
CESC	cis	rs11785400	0.793	rs35985277	chr8:143736137	C/T	cg24634471	chr8:143751801	JRK	0.46	5.84	0.34	1.52e-8	Schizophrenia;
CESC	cis	rs3015497	0.789	rs8003372	chr14:51102351	G/A	cg09863266	chr14:51125203	SAV1	-0.34	-5.35	-0.31	1.89e-7	Mean platelet volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00287636	chr16:49892218	NA	0.49	6.16	0.35	2.69e-9	Gut microbiome composition (summer);
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg07508260	chr11:111742291	ALG9	-0.46	-7.03	-0.4	1.76e-11	Vertical cup-disc ratio;
CESC	cis	rs1372520	0.873	rs2583990	chr4:90771499	A/G	cg15133208	chr4:90757351	SNCA	-0.39	-5.61	-0.33	5.06e-8	Neuroticism;
CESC	cis	rs2637266	0.549	rs10824433	chr10:78412843	T/C	cg18941641	chr10:78392320	NA	-0.32	-5.18	-0.3	4.34e-7	Pulmonary function;
CESC	cis	rs868036	0.645	rs4776987	chr15:68123915	A/T	cg24579218	chr15:68104479	NA	0.37	5.08	0.3	7.14e-7	Restless legs syndrome;
CESC	cis	rs7662987	0.517	rs1311618	chr4:100012612	A/G	cg13256891	chr4:100009986	ADH5	0.74	7.97	0.44	4.75e-14	Smoking initiation;
CESC	cis	rs2576037	0.583	rs487386	chr18:44377004	A/G	cg19077165	chr18:44547161	KATNAL2	-0.58	-8.56	-0.47	9.18e-16	Personality dimensions;
CESC	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg24829409	chr8:58192753	C8orf71	-0.67	-8.14	-0.45	1.54e-14	Developmental language disorder (linguistic errors);
CESC	cis	rs8044868	0.530	rs9924964	chr16:72085561	T/A	cg16558253	chr16:72132732	DHX38	-0.39	-6.08	-0.35	4.15e-9	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CESC	cis	rs7618915	0.547	rs4687636	chr3:52633929	G/A	cg17372223	chr3:52568218	NT5DC2	0.43	6.39	0.37	7.25e-10	Bipolar disorder;
CESC	trans	rs7615952	0.611	rs7632305	chr3:125634767	C/T	cg07211511	chr3:129823064	LOC729375	-0.89	-8.15	-0.45	1.47e-14	Blood pressure (smoking interaction);
CESC	cis	rs6894249	0.874	rs11745587	chr5:131796922	A/G	cg00255919	chr5:131827918	IRF1	-0.34	-5.55	-0.32	6.9e-8	Asthma;
CESC	cis	rs8103278	1.000	rs8109951	chr19:46289503	C/T	cg14061069	chr19:46274453	DMPK	-0.37	-5.16	-0.3	4.94e-7	Coronary artery disease;
CESC	cis	rs2836950	0.772	rs62222988	chr21:40569508	T/C	cg11644478	chr21:40555479	PSMG1	-0.52	-6.42	-0.37	6.17e-10	Menarche (age at onset);
CESC	cis	rs7296418	0.675	rs1879379	chr12:123727443	G/A	cg05973401	chr12:123451056	ABCB9	0.49	6.32	0.36	1.08e-9	Platelet count;
CESC	cis	rs9467711	0.659	rs35433030	chr6:26529890	G/A	cg14345882	chr6:26364793	BTN3A2	0.61	5.24	0.31	3.27e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.43	5.88	0.34	1.26e-8	Lymphocyte counts;
CESC	cis	rs4077515	0.870	rs11793497	chr9:139271850	A/G	cg14169450	chr9:139327907	INPP5E	0.37	5.4	0.31	1.47e-7	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs6938	0.662	rs12487	chr15:75136694	A/G	cg09165964	chr15:75287851	SCAMP5	0.52	6.9	0.39	3.72e-11	Breast cancer;
CESC	cis	rs1799949	1.000	rs33946455	chr17:41321846	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	8.55	0.47	9.74e-16	Menopause (age at onset);
CESC	cis	rs4950928	0.823	rs10920579	chr1:203158972	A/G	cg14085262	chr1:203155938	CHI3L1	-0.5	-5.2	-0.3	3.9e-7	YKL-40 levels;
CESC	cis	rs1348850	0.645	rs11887886	chr2:178425730	C/T	cg23306229	chr2:178417860	TTC30B	0.83	9.07	0.49	2.73e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs9393777	0.623	rs9358946	chr6:26478927	G/A	cg12826209	chr6:26865740	GUSBL1	0.65	6.85	0.39	5.16e-11	Intelligence (multi-trait analysis);
CESC	cis	rs10504229	0.815	rs72650877	chr8:58164510	T/C	cg24829409	chr8:58192753	C8orf71	-0.67	-7.97	-0.44	4.6e-14	Developmental language disorder (linguistic errors);
CESC	cis	rs123509	0.913	rs339686	chr3:42769688	T/C	cg12982090	chr3:42733453	KBTBD5	0.7	8.4	0.46	2.67e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs9815354	0.761	rs17280777	chr3:41806167	C/T	cg03022575	chr3:42003672	ULK4	0.7	6.18	0.35	2.42e-9	Pulse pressure;Diastolic blood pressure;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg25910647	chr15:62539093	NA	0.46	6.42	0.37	6.21e-10	Fibrinogen levels;
CESC	cis	rs11122272	0.701	rs7414807	chr1:231476874	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.43	-5.73	-0.33	2.7e-8	Hemoglobin concentration;
CESC	cis	rs1552244	1.000	rs17032278	chr3:10077955	A/G	cg00149659	chr3:10157352	C3orf10	0.77	9.66	0.51	4.22e-19	Alzheimer's disease;
CESC	cis	rs9814567	1.000	rs1534025	chr3:134313304	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.47	6.28	0.36	1.41e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs11098499	0.863	rs1383532	chr4:120434404	A/T	cg09307838	chr4:120376055	NA	-0.9	-12.45	-0.61	2.44e-28	Corneal astigmatism;
CESC	cis	rs9611519	0.780	rs9611527	chr22:41644428	G/A	cg03806693	chr22:41940476	POLR3H	-0.69	-7.73	-0.43	2.21e-13	Neuroticism;
CESC	trans	rs10489896	0.541	rs16843220	chr1:234589999	T/C	cg23817893	chr11:86085932	CCDC81	-0.45	-6.2	-0.36	2.14e-9	Cognitive test performance;
CESC	cis	rs9300255	0.544	rs10772995	chr12:123671761	T/C	cg05973401	chr12:123451056	ABCB9	0.49	5.49	0.32	9.51e-8	Neutrophil percentage of white cells;
CESC	cis	rs73411413	0.661	rs11599981	chr11:1520063	C/T	cg18133074	chr11:1473084	BRSK2	-0.37	-5.07	-0.3	7.4e-7	Myringotomy;
CESC	cis	rs7830933	1.000	rs7830933	chr8:23603324	A/G	cg04349084	chr8:23602677	NA	0.43	5.28	0.31	2.65e-7	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI in non-smokers;
CESC	cis	rs7666738	0.830	rs35213297	chr4:98984049	T/C	cg03676636	chr4:99064102	C4orf37	0.34	5.24	0.31	3.23e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs939658	0.805	rs35230534	chr15:79441093	T/C	cg17916960	chr15:79447300	NA	-0.35	-5.98	-0.34	7.25e-9	Refractive error;
CESC	cis	rs2273669	0.667	rs12198088	chr6:109338433	C/T	cg05315195	chr6:109294784	ARMC2	-0.67	-6.32	-0.36	1.13e-9	Prostate cancer;
CESC	cis	rs10504229	0.861	rs67966192	chr8:58188172	A/C	cg05313129	chr8:58192883	C8orf71	-0.46	-5.7	-0.33	3.26e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs533581	0.816	rs1559446	chr16:88975332	A/G	cg16701003	chr16:89028210	CBFA2T3	0.56	7.87	0.44	9.31e-14	Social autistic-like traits;
CESC	cis	rs644799	0.965	rs602512	chr11:95561682	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	14.24	0.66	1.53e-34	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs1552244	1.000	rs6442150	chr3:10122575	T/C	cg00166722	chr3:10149974	C3orf24	0.52	6.61	0.38	2.15e-10	Alzheimer's disease;
CESC	cis	rs2439831	0.850	rs3825783	chr15:44102309	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.69	7.67	0.43	3.2e-13	Lung cancer in ever smokers;
CESC	cis	rs4268898	0.722	rs2288072	chr2:24390517	G/A	cg06627628	chr2:24431161	ITSN2	0.54	6.95	0.39	2.81e-11	Asthma;
CESC	cis	rs9640161	0.789	rs66688634	chr7:150053806	G/A	cg17279839	chr7:150038598	RARRES2	0.46	5.52	0.32	8.03e-8	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs7618915	0.547	rs13085331	chr3:52627486	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.48	6.8	0.39	6.78e-11	Bipolar disorder;
CESC	cis	rs1862618	0.853	rs2432195	chr5:56120413	C/T	cg22800045	chr5:56110881	MAP3K1	0.82	10.18	0.53	9.04e-21	Initial pursuit acceleration;
CESC	cis	rs2629540	0.847	rs10901807	chr10:126384610	G/A	cg08799069	chr10:126477246	METTL10	0.58	7.22	0.41	5.49e-12	Cocaine dependence;
CESC	trans	rs66573146	0.831	rs67702333	chr4:6983040	C/G	cg07817883	chr1:32538562	TMEM39B	1.27	8.51	0.46	1.34e-15	Granulocyte percentage of myeloid white cells;
CESC	cis	rs72627123	0.867	rs77320708	chr14:74478482	T/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.73	5.63	0.33	4.49e-8	Morning vs. evening chronotype;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg00390735	chr8:143553436	BAI1	-0.41	-6.02	-0.35	5.74e-9	Gambling;
CESC	cis	rs3026101	0.671	rs9789002	chr17:5298792	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.43	5.68	0.33	3.57e-8	Body mass index;
CESC	cis	rs11577318	0.853	rs4333841	chr1:26631927	T/C	cg19743891	chr1:26644573	UBXN11;CD52	-0.28	-5.11	-0.3	6.05e-7	Granulocyte percentage of myeloid white cells;
CESC	cis	rs6938	0.618	rs12901190	chr15:75231452	T/C	cg17294928	chr15:75287854	SCAMP5	0.51	6.65	0.38	1.66e-10	Breast cancer;
CESC	cis	rs7618915	0.547	rs2286800	chr3:52778051	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	6.63	0.38	1.84e-10	Bipolar disorder;
CESC	cis	rs6866344	0.697	rs56159071	chr5:178127246	T/A	cg03877680	chr5:178157825	ZNF354A	0.75	8.5	0.46	1.36e-15	Neutrophil percentage of white cells;
CESC	cis	rs887829	0.569	rs3806596	chr2:234637707	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.49	6.53	0.37	3.35e-10	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CESC	cis	rs2120019	0.608	rs4886414	chr15:75308650	C/T	cg09165964	chr15:75287851	SCAMP5	0.94	16.41	0.71	3.03e-42	Blood trace element (Zn levels);
CESC	cis	rs270601	0.683	rs81598	chr5:131587960	C/G	cg18758796	chr5:131593413	PDLIM4	0.41	5.53	0.32	7.5e-8	Acylcarnitine levels;
CESC	cis	rs7412746	0.658	rs11204739	chr1:150865760	A/G	cg17724175	chr1:150552817	MCL1	0.39	6.02	0.35	5.81e-9	Melanoma;
CESC	cis	rs8077577	0.747	rs7405677	chr17:18131236	C/T	cg16794390	chr17:18148240	FLII	-0.44	-6.26	-0.36	1.54e-9	Obesity-related traits;
CESC	cis	rs4665809	0.838	rs7565843	chr2:26292912	G/C	cg26314531	chr2:26401878	FAM59B	-0.59	-6.67	-0.38	1.5e-10	Gut microbiome composition (summer);
CESC	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	10.5	0.54	8.86e-22	Prudent dietary pattern;
CESC	cis	rs2708240	0.905	rs2538984	chr7:147581460	T/C	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.34	-5.55	-0.32	7.07e-8	QT interval (drug interaction);
CESC	cis	rs6964587	0.626	rs6972945	chr7:91549576	C/G	cg17063962	chr7:91808500	NA	-0.46	-6.36	-0.36	9.03e-10	Breast cancer;
CESC	cis	rs56235845	0.694	rs4532376	chr5:176774403	G/A	cg16006841	chr5:176797999	RGS14	0.43	5.17	0.3	4.68e-7	Hemoglobin concentration;Hematocrit;
CESC	cis	rs3015497	0.603	rs61476576	chr14:51021765	G/A	cg26011998	chr14:51135199	SAV1	0.47	5.36	0.31	1.8e-7	Mean platelet volume;
CESC	cis	rs250677	0.798	rs11168080	chr5:148409821	C/T	cg18129178	chr5:148520854	ABLIM3	-0.52	-5.54	-0.32	7.29e-8	Breast cancer;
CESC	cis	rs10504229	1.000	rs57186557	chr8:58177277	A/G	cg22535103	chr8:58192502	C8orf71	-1.05	-13.27	-0.63	3.63e-31	Developmental language disorder (linguistic errors);
CESC	cis	rs4654899	0.758	rs35913932	chr1:21423025	G/T	cg05370193	chr1:21551575	ECE1	0.36	5.44	0.32	1.23e-7	Superior frontal gyrus grey matter volume;
CESC	cis	rs7945705	0.935	rs10769971	chr11:8925276	C/T	cg12365402	chr11:9010492	NRIP3	0.4	6.09	0.35	3.86e-9	Hemoglobin concentration;
CESC	cis	rs7385804	0.727	rs221790	chr7:100278282	G/C	cg20848291	chr7:100343083	ZAN	0.56	7.57	0.42	6.06e-13	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
CESC	cis	rs7208859	0.623	rs383436	chr17:28959179	A/G	cg14008862	chr17:28927542	LRRC37B2	0.75	5.5	0.32	9.05e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs72781680	0.611	rs72783625	chr2:24315540	C/T	cg20701182	chr2:24300061	SF3B14	0.92	10.55	0.54	6.09e-22	Lymphocyte counts;
CESC	cis	rs62045849	0.557	rs6500534	chr16:89190313	C/T	cg26950739	chr16:89183275	ACSF3	0.56	5.06	0.3	7.98e-7	Red blood cell count;
CESC	cis	rs524281	0.861	rs11607393	chr11:65875149	C/A	cg14036092	chr11:66035641	RAB1B	-0.62	-6.29	-0.36	1.27e-9	Electroencephalogram traits;
CESC	cis	rs853679	0.517	rs9348794	chr6:28117757	T/A	cg23281280	chr6:28129359	ZNF389	0.6	8.0	0.44	3.86e-14	Depression;
CESC	cis	rs854765	0.647	rs854770	chr17:18019048	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.59	8.27	0.45	6.76e-15	Total body bone mineral density;
CESC	cis	rs6460942	0.556	rs10228123	chr7:12374025	A/C	cg02935154	chr7:12443704	VWDE	-0.39	-5.16	-0.3	4.78e-7	Coronary artery disease;
CESC	cis	rs2439831	0.867	rs2251844	chr15:43836478	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.72	9.26	0.49	7.22e-18	Lung cancer in ever smokers;
CESC	cis	rs524023	0.874	rs495130	chr11:64449307	C/T	cg07220939	chr11:64358617	SLC22A12	-0.35	-5.42	-0.32	1.35e-7	Urate levels in obese individuals;
CESC	cis	rs9549367	0.789	rs34989271	chr13:113894766	G/A	cg00898013	chr13:113819073	PROZ	-0.51	-6.98	-0.39	2.43e-11	Platelet distribution width;
CESC	cis	rs4919694	1.000	rs4917382	chr10:104838510	G/A	cg04362960	chr10:104952993	NT5C2	0.78	6.93	0.39	3.25e-11	Arsenic metabolism;
CESC	cis	rs9303542	0.559	rs12603976	chr17:46617163	C/A	cg04904318	chr17:46607828	HOXB1	-0.58	-5.67	-0.33	3.64e-8	Ovarian cancer;Epithelial ovarian cancer;
CESC	cis	rs9309473	0.687	rs6706409	chr2:73606508	G/T	cg20560298	chr2:73613845	ALMS1	0.46	6.39	0.37	7.5e-10	Metabolite levels;
CESC	cis	rs7692995	1.000	rs34683079	chr4:17939302	T/C	cg08925142	chr4:18023851	LCORL	-0.45	-5.28	-0.31	2.65e-7	Height;
CESC	cis	rs1775715	0.707	rs2808079	chr10:32167385	C/T	cg18675610	chr10:32216311	ARHGAP12	0.35	5.46	0.32	1.07e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs12449000	1	rs12449000	chr16:89872970	T/C	cg03388025	chr16:89894329	SPIRE2	0.42	8.18	0.45	1.21e-14	Schizophrenia;
CESC	cis	rs6860806	0.603	rs112300250	chr5:131583292	G/A	cg04518342	chr5:131593106	PDLIM4	0.41	6.25	0.36	1.59e-9	Breast cancer;
CESC	cis	rs7084402	0.967	rs1346302	chr10:60267137	G/A	cg07615347	chr10:60278583	BICC1	-0.59	-9.0	-0.48	4.4e-17	Refractive error;
CESC	cis	rs826838	1.000	rs11183160	chr12:38676702	T/C	cg26384229	chr12:38710491	ALG10B	0.84	14.9	0.68	7.16e-37	Heart rate;
CESC	cis	rs1062177	0.756	rs2915826	chr5:151119963	G/A	cg12924095	chr5:151150029	G3BP1	-0.43	-5.34	-0.31	2e-7	Preschool internalizing problems;
CESC	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg24642844	chr7:1081250	C7orf50	-0.77	-9.63	-0.51	5.27e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs599083	0.530	rs689179	chr11:68179166	A/G	cg16797656	chr11:68205561	LRP5	-0.38	-5.09	-0.3	6.79e-7	Bone mineral density (spine);
CESC	cis	rs1387259	0.759	rs7960122	chr12:48777000	C/T	cg04545296	chr12:48745243	ZNF641	-0.38	-6.39	-0.37	7.54e-10	Obstructive sleep apnea trait (apnea hypopnea index);
CESC	cis	rs2274273	0.905	rs4652	chr14:55605036	A/C	cg04306507	chr14:55594613	LGALS3	0.29	5.79	0.34	1.96e-8	Protein biomarker;
CESC	cis	rs58785573	0.570	rs1824652	chr4:38644597	C/T	cg18361445	chr4:38666374	KLF3;FLJ13197	0.49	6.92	0.39	3.48e-11	Lymphocyte percentage of white cells;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15345415	chr5:151150903	G3BP1	0.53	6.2	0.36	2.12e-9	Gut microbiome composition (summer);
CESC	cis	rs6088580	0.567	rs6088520	chr20:33132364	A/G	cg24642439	chr20:33292090	TP53INP2	-0.47	-6.04	-0.35	5.18e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs6426558	0.515	rs7521110	chr1:227384459	T/A	cg10327440	chr1:227177885	CDC42BPA	-0.47	-5.85	-0.34	1.48e-8	Neutrophil percentage of white cells;
CESC	cis	rs853679	0.517	rs3173443	chr6:28137027	T/G	cg19592336	chr6:28129416	ZNF389	0.58	7.71	0.43	2.54e-13	Depression;
CESC	cis	rs910316	1.000	rs10142626	chr14:75555636	A/T	cg11812906	chr14:75593930	NEK9	0.91	15.5	0.69	5.27e-39	Height;
CESC	cis	rs17253792	0.822	rs78386830	chr14:56069224	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.79	5.91	0.34	1.06e-8	Putamen volume;
CESC	cis	rs9309473	1.000	rs2421555	chr2:73816955	G/A	cg20560298	chr2:73613845	ALMS1	-0.47	-6.5	-0.37	4e-10	Metabolite levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25635913	chr19:4497977	HDGF2	-0.58	-6.51	-0.37	3.85e-10	Gut microbiome composition (summer);
CESC	cis	rs17209837	0.607	rs45478299	chr7:87111321	G/A	cg00919237	chr7:87102261	ABCB4	-0.49	-6.5	-0.37	4.02e-10	Gallbladder cancer;
CESC	cis	rs1008375	1.000	rs1558377	chr4:17650758	A/G	cg15017067	chr4:17643749	FAM184B	0.38	5.35	0.31	1.86e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs477895	0.639	rs35858916	chr11:63950529	T/G	cg04317338	chr11:64019027	PLCB3	0.9	9.42	0.5	2.3e-18	Mean platelet volume;
CESC	cis	rs4862750	0.837	rs1863404	chr4:187874654	T/C	cg22105103	chr4:187893119	NA	0.46	6.66	0.38	1.61e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6032067	0.538	rs62206431	chr20:43737073	G/A	cg10761708	chr20:43804764	PI3	0.46	5.15	0.3	5.05e-7	Blood protein levels;
CESC	cis	rs28489187	0.706	rs233131	chr1:85795259	G/A	cg16011679	chr1:85725395	C1orf52	0.47	5.6	0.33	5.46e-8	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	cis	rs7799006	0.634	rs34502289	chr7:2311266	G/A	cg12745145	chr7:2261452	MAD1L1	-0.35	-5.4	-0.31	1.5e-7	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs10426930	0.607	rs858423	chr19:5048374	T/C	cg18473234	chr19:5097819	KDM4B	-0.52	-5.08	-0.3	7.3e-7	Monocyte percentage of white cells;
CESC	cis	rs896854	0.967	rs2879813	chr8:95960947	A/G	cg16049864	chr8:95962084	TP53INP1	-0.7	-12.91	-0.62	6.44e-30	Type 2 diabetes;
CESC	cis	rs3106136	0.527	rs2664894	chr4:95153831	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.7	-11.56	-0.58	2.74e-25	Capecitabine sensitivity;
CESC	cis	rs7507204	0.530	rs4807469	chr19:3443382	G/C	cg08380311	chr19:3435252	NFIC	0.8	11.98	0.59	1.01e-26	Height;
CESC	trans	rs3780486	0.505	rs7868663	chr9:33141229	A/G	cg04842962	chr6:43655489	MRPS18A	0.71	11.11	0.56	8.44e-24	IgG glycosylation;
CESC	trans	rs60180747	1.000	rs17851970	chr15:66612965	C/T	cg01218494	chr17:71160864	SSTR2	-0.45	-6.08	-0.35	4.19e-9	Testicular germ cell tumor;
CESC	cis	rs6141600	0.506	rs2590990	chr20:34671179	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.43	-6.02	-0.35	5.94e-9	Height;Hip circumference;
CESC	cis	rs6121246	0.512	rs45443696	chr20:30311396	A/C	cg13852791	chr20:30311386	BCL2L1	0.86	11.26	0.57	2.66e-24	Mean corpuscular hemoglobin;
CESC	cis	rs3820068	0.580	rs7556473	chr1:15996858	C/T	cg13390004	chr1:15929781	NA	-0.34	-5.1	-0.3	6.44e-7	Systolic blood pressure;
CESC	cis	rs9486715	1.000	rs11153082	chr6:97059666	A/G	cg06623918	chr6:96969491	KIAA0776	-0.92	-13.79	-0.65	5.63e-33	Headache;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16492828	chr12:100567203	GOLGA2L1	-0.71	-7.61	-0.42	4.95e-13	Gut microbiome composition (summer);
CESC	cis	rs1552244	0.935	rs28815328	chr3:10062227	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.87	11.56	0.58	2.73e-25	Alzheimer's disease;
CESC	cis	rs79349575	0.715	rs55724082	chr17:47017879	G/A	cg16584676	chr17:46985605	UBE2Z	0.54	6.67	0.38	1.45e-10	Type 2 diabetes;
CESC	cis	rs9660992	0.649	rs12128254	chr1:205268097	C/T	cg00857998	chr1:205179979	DSTYK	0.48	5.33	0.31	2.15e-7	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs6912958	0.500	rs9342104	chr6:87798512	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.39	-5.78	-0.33	2.09e-8	Monocyte percentage of white cells;
CESC	cis	rs4665809	0.590	rs4665840	chr2:26444962	C/T	cg08470875	chr2:26401718	FAM59B	-0.75	-7.79	-0.43	1.49e-13	Gut microbiome composition (summer);
CESC	cis	rs3820928	0.874	rs10933163	chr2:227815286	A/G	cg11843606	chr2:227700838	RHBDD1	-0.43	-5.66	-0.33	3.91e-8	Pulmonary function;
CESC	cis	rs2816062	0.760	rs2745319	chr1:18895078	G/A	cg18795169	chr1:18902165	NA	-0.94	-19.04	-0.76	1.61e-51	Urate levels in lean individuals;
CESC	cis	rs7726839	0.540	rs7558	chr5:660491	C/T	cg16447950	chr5:562315	NA	-0.61	-6.66	-0.38	1.56e-10	Obesity-related traits;
CESC	cis	rs17253792	0.822	rs2147114	chr14:56077118	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.76	5.39	0.31	1.56e-7	Putamen volume;
CESC	cis	rs7618915	0.547	rs13065019	chr3:52685244	T/C	cg05564831	chr3:52568323	NT5DC2	0.44	6.72	0.38	1.09e-10	Bipolar disorder;
CESC	cis	rs561341	1.000	rs113676348	chr17:30244327	A/G	cg12193833	chr17:30244370	NA	-0.71	-7.31	-0.41	3.09e-12	Hip circumference adjusted for BMI;
CESC	cis	rs17376456	0.825	rs35496867	chr5:93220400	T/C	cg21475434	chr5:93447410	FAM172A	0.81	7.07	0.4	1.38e-11	Diabetic retinopathy;
CESC	cis	rs11677416	1.000	rs6542090	chr2:113524795	T/C	cg27083787	chr2:113543245	IL1A	0.41	5.16	0.3	4.75e-7	Response to antipsychotic treatment in schizophrenia (working memory);
CESC	cis	rs7772486	0.869	rs2777473	chr6:146301494	G/A	cg23711669	chr6:146136114	FBXO30	0.75	10.71	0.55	1.72e-22	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2559856	0.904	rs2695283	chr12:102089391	G/C	cg12213457	chr12:102090980	CHPT1	-0.37	-5.48	-0.32	9.79e-8	Blood protein levels;
CESC	cis	rs4664293	0.967	rs1346325	chr2:160542506	C/T	cg08347373	chr2:160653686	CD302	-0.33	-5.39	-0.31	1.55e-7	Monocyte percentage of white cells;
CESC	cis	rs4919694	0.901	rs79331374	chr10:104882913	G/A	cg04362960	chr10:104952993	NT5C2	0.8	6.81	0.39	6.36e-11	Arsenic metabolism;
CESC	cis	rs2404602	0.735	rs4886495	chr15:76738959	C/T	cg23625390	chr15:77176239	SCAPER	0.44	6.08	0.35	4.07e-9	Blood metabolite levels;
CESC	cis	rs7312933	0.703	rs11181378	chr12:42600658	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.49	6.51	0.37	3.8e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs7520050	0.778	rs2088102	chr1:46032974	T/C	cg24296786	chr1:45957014	TESK2	0.5	6.29	0.36	1.29e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs35955747	0.902	rs131209	chr22:31732461	A/G	cg25791279	chr22:32026902	PISD	0.48	5.86	0.34	1.4e-8	Neutrophil count;Sum basophil neutrophil counts;
CESC	cis	rs7666738	0.830	rs7696686	chr4:98938445	T/C	cg05340658	chr4:99064831	C4orf37	0.82	12.54	0.61	1.29e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2576037	0.526	rs2156050	chr18:44455873	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.57	-8.04	-0.44	3e-14	Personality dimensions;
CESC	cis	rs6754311	0.689	rs191079	chr2:136633771	T/C	cg07169764	chr2:136633963	MCM6	0.69	8.32	0.45	4.8e-15	Mosquito bite size;
CESC	cis	rs875971	0.895	rs12531677	chr7:65769086	G/A	cg12463550	chr7:65579703	CRCP	-0.46	-5.94	-0.34	8.81e-9	Aortic root size;
CESC	cis	rs4665809	1.000	rs4665823	chr2:26312723	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.71	-8.13	-0.45	1.65e-14	Gut microbiome composition (summer);
CESC	cis	rs17253792	0.822	rs7150841	chr14:56088986	T/C	cg01858014	chr14:56050164	KTN1	-0.93	-7.33	-0.41	2.71e-12	Putamen volume;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg14235685	chr19:44096461	IRGQ	0.43	6.45	0.37	5.33e-10	Fibrinogen levels;
CESC	cis	rs2109514	0.840	rs13223362	chr7:116137006	G/A	cg12739419	chr7:116140593	CAV2	-0.38	-6.84	-0.39	5.51e-11	Prevalent atrial fibrillation;
CESC	cis	rs7216064	1.000	rs59950564	chr17:65860859	A/G	cg07042672	chr17:66097459	LOC651250	-0.54	-5.67	-0.33	3.79e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	trans	rs35110281	0.811	rs7275705	chr21:45056453	G/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.54	7.11	0.4	1.1e-11	Mean corpuscular volume;
CESC	cis	rs2996428	0.709	rs12127399	chr1:3721609	G/A	cg22529645	chr1:3704559	LRRC47	0.39	5.03	0.3	9.13e-7	Red cell distribution width;
CESC	cis	rs7666738	0.753	rs13122897	chr4:98936185	C/A	cg17366294	chr4:99064904	C4orf37	0.61	8.56	0.47	9.36e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs12618769	0.652	rs3769701	chr2:99195111	A/C	cg10123293	chr2:99228465	UNC50	0.41	5.31	0.31	2.32e-7	Bipolar disorder;
CESC	cis	rs769267	1.000	rs2074089	chr19:19449603	G/A	cg15052019	chr19:19431593	KIAA0892;SF4	-0.41	-5.2	-0.3	3.93e-7	Tonsillectomy;
CESC	cis	rs7091068	0.671	rs1764322	chr10:95406276	T/G	cg20715218	chr10:95462985	C10orf4	-0.54	-5.85	-0.34	1.42e-8	Urinary tract infection frequency;
CESC	cis	rs2635047	0.638	rs2668760	chr18:44682891	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.32	5.03	0.3	9.22e-7	Educational attainment;
CESC	cis	rs7537052	0.646	rs6680302	chr1:36653540	C/T	cg24686825	chr1:36642396	MAP7D1	-0.6	-9.1	-0.49	2.24e-17	Schizophrenia;
CESC	cis	rs9322193	0.923	rs9767652	chr6:150055638	A/T	cg00933542	chr6:150070202	PCMT1	0.3	5.11	0.3	6.15e-7	Lung cancer;
CESC	cis	rs514406	0.895	rs1925673	chr1:53326984	T/G	cg16325326	chr1:53192061	ZYG11B	0.82	12.7	0.62	3.43e-29	Monocyte count;
CESC	cis	rs17023223	0.537	rs12092807	chr1:119750644	A/G	cg05756136	chr1:119680316	WARS2	0.48	5.03	0.3	9.19e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CESC	cis	rs9611565	0.918	rs4820438	chr22:41767135	C/T	cg06634786	chr22:41940651	POLR3H	-0.57	-6.04	-0.35	5.24e-9	Vitiligo;
CESC	cis	rs9549260	0.755	rs4943797	chr13:41201633	A/G	cg21288729	chr13:41239152	FOXO1	-0.66	-8.64	-0.47	5.24e-16	Red blood cell count;
CESC	cis	rs3768617	0.706	rs8179460	chr1:183056222	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.03	0.52	2.82e-20	Fuchs's corneal dystrophy;
CESC	cis	rs13102973	0.899	rs10212820	chr4:135899842	G/T	cg14419869	chr4:135874104	NA	-0.34	-5.18	-0.3	4.49e-7	Subjective well-being;
CESC	cis	rs9858542	0.953	rs11710037	chr3:49675334	C/G	cg07274523	chr3:49395745	GPX1	0.68	8.59	0.47	7.34e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs854765	0.520	rs9899355	chr17:17898243	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.52	7.19	0.4	6.47e-12	Total body bone mineral density;
CESC	cis	rs3106136	0.546	rs183993	chr4:95130025	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.7	-11.24	-0.57	3.07e-24	Capecitabine sensitivity;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02856952	chr12:111885521	SH2B3	-0.59	-6.42	-0.37	6.12e-10	Gut microbiome composition (summer);
CESC	cis	rs3785574	0.962	rs2584628	chr17:61894578	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.8	10.53	0.54	6.83e-22	Height;
CESC	cis	rs9901225	1	rs9901225	chr17:40755811	C/T	cg20126647	chr17:40714003	COASY	0.49	6.62	0.38	1.96e-10	Colorectal or endometrial cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25789511	chr20:60757919	GTPBP5	0.61	7.64	0.42	3.96e-13	Gut microbiome composition (summer);
CESC	cis	rs4835473	0.932	rs34950821	chr4:144659327	G/A	cg25736465	chr4:144833511	NA	-0.32	-5.16	-0.3	4.85e-7	Immature fraction of reticulocytes;
CESC	cis	rs116095464	0.558	rs10055354	chr5:243794	G/A	cg12570787	chr5:219185	SDHA;CCDC127	0.5	5.27	0.31	2.9e-7	Breast cancer;
CESC	cis	rs909002	0.800	rs2176807	chr1:32092735	T/G	cg13919466	chr1:32135498	COL16A1	-0.46	-8.3	-0.45	5.27e-15	Intelligence (multi-trait analysis);
CESC	cis	rs9929218	1.000	rs13339591	chr16:68809273	T/C	cg02972257	chr16:68554789	NA	0.43	5.12	0.3	5.89e-7	Colorectal cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10301338	chr18:24129315	KCTD1	-0.59	-6.48	-0.37	4.54e-10	Gut microbiome composition (summer);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg07353731	chr12:123341735	HIP1R	0.56	7.81	0.43	1.37e-13	Fibrinogen levels;
CESC	cis	rs6840258	1.000	rs55787557	chr4:87950825	A/G	cg08197287	chr4:87952173	AFF1	-0.4	-5.37	-0.31	1.7e-7	Mean corpuscular volume;Basophil percentage of granulocytes;
CESC	cis	rs7044106	0.791	rs735109	chr9:123488879	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.35	5.57	0.32	6.27e-8	Hip circumference adjusted for BMI;
CESC	trans	rs8073060	0.586	rs225294	chr17:33925762	G/A	cg19694781	chr19:47549865	TMEM160	-0.72	-6.95	-0.39	2.85e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	cis	rs1322639	0.614	rs9294967	chr6:169565406	C/T	cg03254818	chr6:169586852	NA	-0.51	-5.81	-0.34	1.75e-8	Pulse pressure;
CESC	cis	rs2303745	0.544	rs12710308	chr19:17395879	T/A	cg22549504	chr19:17448937	GTPBP3	0.5	5.54	0.32	7.3e-8	Systemic lupus erythematosus;
CESC	cis	rs875971	0.862	rs1968126	chr7:66057004	A/G	cg19163074	chr7:65112434	INTS4L2	0.41	5.21	0.3	3.76e-7	Aortic root size;
CESC	cis	rs965469	1.000	rs8123289	chr20:3253831	T/C	cg25506879	chr20:3388711	C20orf194	-0.59	-6.07	-0.35	4.52e-9	IFN-related cytopenia;
CESC	cis	rs7503807	0.967	rs7215486	chr17:78612034	C/T	cg09596252	chr17:78655493	RPTOR	0.47	6.86	0.39	4.73e-11	Obesity;
CESC	cis	rs1707322	1.000	rs11211235	chr1:46440375	G/A	cg05343316	chr1:45956843	TESK2	0.44	5.42	0.32	1.36e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9322193	0.736	rs3828701	chr6:150112199	C/T	cg05861140	chr6:150128134	PCMT1	-0.38	-5.52	-0.32	7.97e-8	Lung cancer;
CESC	cis	rs763014	0.966	rs35642938	chr16:642249	T/C	cg09263875	chr16:632152	PIGQ	0.67	11.6	0.58	1.95e-25	Height;
CESC	cis	rs10883723	0.810	rs10786671	chr10:104271303	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.55	7.58	0.42	5.73e-13	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs3026101	0.671	rs72634032	chr17:5303437	G/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.42	5.6	0.33	5.39e-8	Body mass index;
CESC	cis	rs1059312	0.808	rs10847694	chr12:129292457	C/A	cg09035930	chr12:129282057	SLC15A4	0.69	9.2	0.49	1.1e-17	Systemic lupus erythematosus;
CESC	cis	rs17293817	0.589	rs2387654	chr10:1419953	C/T	cg04271617	chr10:1416546	ADARB2	0.36	5.73	0.33	2.8e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs9814567	1.000	rs62271513	chr3:134298412	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.45	6.02	0.35	5.85e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs8044868	0.606	rs7189591	chr16:72099011	G/T	cg01557791	chr16:72042693	DHODH	-0.43	-5.89	-0.34	1.17e-8	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CESC	cis	rs1218582	0.774	rs4845680	chr1:154863195	A/G	cg24250549	chr1:154909240	PMVK	0.72	10.85	0.55	6.34e-23	Prostate cancer;
CESC	cis	rs362272	0.545	rs2749785	chr4:3325179	G/C	cg08886695	chr4:3369023	RGS12	-0.41	-5.52	-0.32	8.04e-8	Serum sulfate level;
CESC	cis	rs10791097	0.748	rs2282579	chr11:130735482	C/T	cg12179176	chr11:130786555	SNX19	0.63	9.66	0.51	4.17e-19	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs7267979	1.000	rs10966	chr20:25282944	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.88	18.59	0.75	6.14e-50	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs4957048	0.541	rs12519390	chr5:676546	A/G	cg16447950	chr5:562315	NA	-0.66	-6.55	-0.37	3e-10	Ulcerative colitis;
CESC	trans	rs9929218	1.000	rs28450087	chr16:68803726	T/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.62	-8.21	-0.45	9.51e-15	Colorectal cancer;
CESC	cis	rs34779708	0.733	rs4298846	chr10:35547380	A/G	cg04310649	chr10:35416472	CREM	-0.45	-5.14	-0.3	5.34e-7	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs7586879	0.558	rs6718510	chr2:25122323	A/C	cg01884057	chr2:25150051	NA	0.38	7.42	0.41	1.56e-12	Body mass index;
CESC	cis	rs7000551	0.751	rs1116085	chr8:22394920	A/G	cg12081754	chr8:22256438	SLC39A14	0.44	5.84	0.34	1.56e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CESC	trans	rs1814175	0.817	rs11493756	chr11:50017885	T/C	cg03929089	chr4:120376271	NA	-0.94	-15.59	-0.69	2.56e-39	Height;
CESC	cis	rs2929278	0.617	rs2955969	chr15:44114527	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	-0.47	-7.25	-0.41	4.44e-12	Schizophrenia;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg06536150	chr1:2458209	PANK4	-0.47	-6.06	-0.35	4.54e-9	Ulcerative colitis;
CESC	cis	rs2404602	0.610	rs28823285	chr15:77050395	T/C	cg23625390	chr15:77176239	SCAPER	-0.47	-6.52	-0.37	3.54e-10	Blood metabolite levels;
CESC	cis	rs2361718	1.000	rs2361718	chr17:78103466	C/T	cg06718696	chr17:78121285	EIF4A3	0.46	6.21	0.36	2.05e-9	Yeast infection;
CESC	cis	rs858239	0.600	rs7776649	chr7:23119317	C/T	cg23682824	chr7:23144976	KLHL7	0.55	7.68	0.43	3.08e-13	Cerebrospinal fluid biomarker levels;
CESC	cis	rs36051895	0.664	rs10815157	chr9:5108771	C/G	cg02405213	chr9:5042618	JAK2	-0.5	-6.29	-0.36	1.28e-9	Pediatric autoimmune diseases;
CESC	cis	rs6662572	0.737	rs7532388	chr1:46472734	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.46	5.07	0.3	7.55e-7	Blood protein levels;
CESC	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg12419862	chr22:24373484	LOC391322	-0.72	-10.05	-0.53	2.51e-20	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs9322193	0.923	rs2151913	chr6:150130642	C/T	cg04369109	chr6:150039330	LATS1	-0.41	-5.54	-0.32	7.11e-8	Lung cancer;
CESC	cis	rs9640161	0.789	rs1464751	chr7:150021282	C/T	cg10018233	chr7:150070692	REPIN1	0.43	6.98	0.39	2.42e-11	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs7044106	0.791	rs7043969	chr9:123493989	A/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.72	10.5	0.54	8.51e-22	Hip circumference adjusted for BMI;
CESC	cis	rs7072216	0.763	rs2274244	chr10:100175218	A/G	cg26618903	chr10:100175079	PYROXD2	-0.38	-5.85	-0.34	1.41e-8	Metabolite levels;
CESC	cis	rs710216	0.917	rs900836	chr1:43412727	T/C	cg07803811	chr1:43423981	SLC2A1	-0.5	-5.47	-0.32	1.02e-7	Red cell distribution width;
CESC	cis	rs72945132	0.882	rs12278125	chr11:70134016	T/C	cg14191688	chr11:70257035	CTTN	0.41	5.19	0.3	4.24e-7	Coronary artery disease;
CESC	cis	rs1005277	0.505	rs200910	chr10:38108176	C/T	cg25427524	chr10:38739819	LOC399744	-0.67	-10.06	-0.53	2.28e-20	Extrinsic epigenetic age acceleration;
CESC	cis	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg21782813	chr7:2030301	MAD1L1	0.5	7.25	0.41	4.48e-12	Bipolar disorder and schizophrenia;
CESC	cis	rs4689388	0.889	rs10026334	chr4:6294607	G/A	cg00701064	chr4:6280414	WFS1	0.68	11.71	0.58	8.68e-26	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs2735413	0.918	rs7190752	chr16:78077430	T/C	cg04733911	chr16:78082701	NA	-0.53	-9.01	-0.48	4.08e-17	Systolic blood pressure (alcohol consumption interaction);
CESC	cis	rs7098414	0.530	rs4146515	chr10:82116602	G/A	cg00277334	chr10:82204260	NA	-0.53	-7.95	-0.44	5.57e-14	Post bronchodilator FEV1;
CESC	cis	rs7580658	0.895	rs62157549	chr2:128066007	A/G	cg10021288	chr2:128175891	PROC	-0.41	-6.59	-0.38	2.34e-10	Protein C levels;
CESC	cis	rs7666738	0.830	rs28622458	chr4:98916651	A/G	cg05340658	chr4:99064831	C4orf37	0.75	10.74	0.55	1.42e-22	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2559856	1.000	rs2559855	chr12:102090080	A/G	cg15068132	chr12:102092402	CHPT1	0.43	6.21	0.36	2e-9	Blood protein levels;
CESC	cis	rs3772130	0.540	rs57791671	chr3:121608433	T/A	cg20356878	chr3:121714668	ILDR1	0.42	6.12	0.35	3.37e-9	Cognitive performance;
CESC	cis	rs5750830	0.594	rs1010170	chr22:39778327	C/T	cg05872129	chr22:39784769	NA	0.78	10.1	0.53	1.66e-20	Intelligence (multi-trait analysis);
CESC	cis	rs9913156	0.793	rs72835633	chr17:4562643	C/T	cg00122941	chr17:4613640	ARRB2	0.85	9.99	0.52	3.79e-20	Lymphocyte counts;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg14737592	chr12:57914238	DDIT3	-0.48	-6.27	-0.36	1.45e-9	Height;
CESC	cis	rs1568889	1.000	rs16917687	chr11:28062614	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.77	10.83	0.55	7.35e-23	Bipolar disorder;
CESC	cis	rs3743266	0.507	rs9630426	chr15:60739053	C/T	cg22293140	chr15:60689852	ANXA2	-0.72	-7.58	-0.42	5.76e-13	Menarche (age at onset);
CESC	cis	rs3026101	0.671	rs56344067	chr17:5316459	A/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.41	5.27	0.31	2.82e-7	Body mass index;
CESC	cis	rs34779708	0.733	rs4102764	chr10:35545392	T/C	cg03585969	chr10:35415529	CREM	0.55	6.14	0.35	3.04e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs854765	0.693	rs12941039	chr17:17765655	C/T	cg16928487	chr17:17741425	SREBF1	0.62	11.33	0.57	1.61e-24	Total body bone mineral density;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16280946	chr22:20716554	NA	-0.67	-7.94	-0.44	5.74e-14	Gut microbiome composition (summer);
CESC	cis	rs9611565	0.694	rs19573	chr22:41865809	C/A	cg06481639	chr22:41940642	POLR3H	0.55	6.07	0.35	4.3e-9	Vitiligo;
CESC	cis	rs9399135	0.933	rs7755680	chr6:135294259	A/G	cg24558204	chr6:135376177	HBS1L	0.5	6.75	0.38	9.09e-11	Red blood cell count;
CESC	cis	rs977987	0.800	rs1011121	chr16:75325933	A/G	cg03315344	chr16:75512273	CHST6	0.37	5.34	0.31	2e-7	Dupuytren's disease;
CESC	cis	rs561341	1.000	rs8069199	chr17:30281845	A/G	cg19193384	chr17:30244184	NA	-0.61	-6.41	-0.37	6.51e-10	Hip circumference adjusted for BMI;
CESC	cis	rs172166	0.637	rs1225597	chr6:28162087	C/T	cg23281280	chr6:28129359	ZNF389	0.39	5.76	0.33	2.31e-8	Cardiac Troponin-T levels;
CESC	cis	rs155076	0.666	rs2015241	chr13:21888254	A/G	cg21970626	chr13:21893289	NA	-0.44	-5.04	-0.3	8.54e-7	White matter hyperintensity burden;
CESC	cis	rs4665809	0.941	rs2289021	chr2:26362515	A/C	cg22920501	chr2:26401640	FAM59B	0.53	6.6	0.38	2.24e-10	Gut microbiome composition (summer);
CESC	cis	rs2228479	0.850	rs1800339	chr16:89839637	C/A	cg04013166	chr16:89971882	TCF25	0.78	6.69	0.38	1.3e-10	Skin colour saturation;
CESC	cis	rs6120849	0.754	rs6120793	chr20:33604407	T/C	cg24642439	chr20:33292090	TP53INP2	0.67	6.62	0.38	1.94e-10	Protein C levels;
CESC	cis	rs9488822	0.676	rs12202181	chr6:116327102	A/G	cg05304507	chr6:116381966	FRK	0.26	6.56	0.37	2.86e-10	Cholesterol, total;LDL cholesterol;
CESC	cis	rs6141600	0.760	rs2746103	chr20:34703934	T/G	cg07747181	chr20:34652970	NA	-0.38	-5.16	-0.3	4.75e-7	Height;Hip circumference;
CESC	cis	rs3820928	0.934	rs66959645	chr2:227761582	C/A	cg05526886	chr2:227700861	RHBDD1	-0.42	-5.37	-0.31	1.69e-7	Pulmonary function;
CESC	cis	rs524281	0.861	rs10791854	chr11:65963543	A/T	cg14036092	chr11:66035641	RAB1B	-0.59	-6.15	-0.35	2.84e-9	Electroencephalogram traits;
CESC	cis	rs477692	0.648	rs10829599	chr10:131321881	C/T	cg24747557	chr10:131355152	MGMT	-0.38	-5.26	-0.31	2.95e-7	Response to temozolomide;
CESC	cis	rs1218582	0.710	rs7553195	chr1:154837796	T/C	cg06221963	chr1:154839813	KCNN3	-0.7	-12.26	-0.6	1.16e-27	Prostate cancer;
CESC	cis	rs6063312	0.518	rs6122718	chr20:47346225	A/G	cg18078177	chr20:47281410	PREX1	-0.6	-7.59	-0.42	5.47e-13	Tonometry;
CESC	cis	rs12681366	0.708	rs2930958	chr8:95440553	A/G	cg13257157	chr8:95487014	RAD54B	0.38	5.19	0.3	4.26e-7	Nonsyndromic cleft lip with cleft palate;
CESC	cis	rs7208859	0.673	rs9898858	chr17:29156211	A/T	cg13385521	chr17:29058706	SUZ12P	0.75	6.0	0.35	6.29e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs2204008	0.743	rs2127952	chr12:37995364	G/T	cg26384229	chr12:38710491	ALG10B	0.66	9.47	0.5	1.58e-18	Bladder cancer;
CESC	cis	rs9815354	0.556	rs55953604	chr3:42004428	A/G	cg03022575	chr3:42003672	ULK4	0.64	5.83	0.34	1.62e-8	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs3820068	0.603	rs6660234	chr1:15962590	T/C	cg13390004	chr1:15929781	NA	0.37	5.89	0.34	1.18e-8	Systolic blood pressure;
CESC	cis	rs17641971	0.684	rs11990854	chr8:49992048	T/C	cg00325661	chr8:49890786	NA	0.39	5.5	0.32	8.94e-8	Blood metabolite levels;
CESC	cis	rs8114671	0.933	rs6087683	chr20:33774444	C/T	cg24642439	chr20:33292090	TP53INP2	0.43	5.18	0.3	4.41e-7	Height;
CESC	cis	rs17376456	1.000	rs13174700	chr5:93554644	G/A	cg25358565	chr5:93447407	FAM172A	1.21	11.29	0.57	2.11e-24	Diabetic retinopathy;
CESC	cis	rs2204008	0.869	rs34438288	chr12:38211582	G/T	cg13010199	chr12:38710504	ALG10B	0.54	6.69	0.38	1.28e-10	Bladder cancer;
CESC	cis	rs7264396	0.676	rs6060723	chr20:34549947	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.77	-10.23	-0.53	6.44e-21	Total cholesterol levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18888595	chr8:92082609	OTUD6B	-0.65	-7.36	-0.41	2.26e-12	Gut microbiome composition (summer);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg12730826	chr1:205179972	DSTYK	-0.43	-6.25	-0.36	1.62e-9	Gambling;
CESC	cis	rs1005277	0.522	rs289643	chr10:37941494	T/G	cg25427524	chr10:38739819	LOC399744	-0.62	-8.82	-0.48	1.57e-16	Extrinsic epigenetic age acceleration;
CESC	cis	rs3747547	0.581	rs72726097	chr9:38135087	C/T	cg13774184	chr9:37916125	SHB	-0.62	-5.11	-0.3	6.23e-7	Metabolite levels (Dihydroxy docosatrienoic acid);
CESC	cis	rs7949030	0.591	rs35880596	chr11:62369884	C/G	cg22862634	chr11:62369728	EML3;MTA2	0.59	7.95	0.44	5.33e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs7089973	0.668	rs10885622	chr10:116643844	C/T	cg25233709	chr10:116636983	FAM160B1	0.38	6.03	0.35	5.53e-9	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs11608355	0.545	rs11615949	chr12:109894347	G/A	cg05360138	chr12:110035743	NA	0.82	8.92	0.48	7.93e-17	Neuroticism;
CESC	cis	rs12188164	0.965	rs11744539	chr5:451425	C/T	cg21144161	chr5:423903	AHRR	0.36	5.86	0.34	1.35e-8	Cystic fibrosis severity;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg22046830	chr8:145133508	EXOSC4	-0.45	-6.48	-0.37	4.41e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs1348850	0.634	rs2293471	chr2:178487729	T/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.5	5.54	0.32	7.32e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg25944898	chr11:64085532	PRDX5;TRMT112	-0.49	-6.7	-0.38	1.27e-10	Fibrinogen levels;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg13195218	chr1:223900468	CAPN2	-0.48	-6.01	-0.35	6.25e-9	Ulcerative colitis;
CESC	cis	rs727505	1.000	rs727505	chr7:124462081	C/T	cg23710748	chr7:124431027	NA	-0.46	-7.18	-0.4	7.09e-12	Lewy body disease;
CESC	cis	rs514406	0.505	rs416968	chr1:53183513	A/G	cg08859206	chr1:53392774	SCP2	-0.57	-7.8	-0.43	1.39e-13	Monocyte count;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg12893361	chr12:122124854	NA	-0.46	-6.35	-0.36	9.24e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg04203298	chr11:59521722	STX3	-0.46	-6.26	-0.36	1.55e-9	Ulcerative colitis;
CESC	cis	rs910316	0.763	rs735452	chr14:75497984	A/G	cg11812906	chr14:75593930	NEK9	-0.81	-12.9	-0.62	7.16e-30	Height;
CESC	cis	rs79976124	0.797	rs79522358	chr6:66641140	C/G	cg07460842	chr6:66804631	NA	0.71	8.33	0.46	4.36e-15	Type 2 diabetes;
CESC	cis	rs798766	1.000	rs11729657	chr4:1737585	T/C	cg05874882	chr4:1763078	NA	-0.58	-8.12	-0.45	1.8e-14	Bladder cancer;Urinary bladder cancer;
CESC	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg07677032	chr17:61819896	STRADA	0.45	5.96	0.34	8.19e-9	Prudent dietary pattern;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg11429632	chr9:123964581	RAB14	-0.56	-7.35	-0.41	2.44e-12	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs6546550	0.901	rs7573442	chr2:70154037	G/A	cg02498382	chr2:70120550	SNRNP27	-0.4	-6.95	-0.39	2.78e-11	Prevalent atrial fibrillation;
CESC	cis	rs270601	0.909	rs2569265	chr5:131704519	T/C	cg18758796	chr5:131593413	PDLIM4	-0.43	-5.8	-0.34	1.85e-8	Acylcarnitine levels;
CESC	cis	rs10979	1.000	rs1054752	chr6:143890097	G/A	cg25407410	chr6:143891975	LOC285740	-0.61	-9.14	-0.49	1.72e-17	Hypospadias;
CESC	cis	rs17253792	0.822	rs12323476	chr14:56172722	C/T	cg01858014	chr14:56050164	KTN1	0.59	5.45	0.32	1.14e-7	Putamen volume;
CESC	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg09177884	chr7:1199841	ZFAND2A	-0.57	-6.38	-0.36	8.04e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs875971	0.660	rs13224319	chr7:66007363	A/G	cg18876405	chr7:65276391	NA	0.57	7.64	0.42	4.04e-13	Aortic root size;
CESC	cis	rs1005277	0.502	rs2800484	chr10:38542415	C/T	cg00409905	chr10:38381863	ZNF37A	-0.51	-6.84	-0.39	5.62e-11	Extrinsic epigenetic age acceleration;
CESC	cis	rs11638352	0.661	rs2615286	chr15:44417068	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.58	-5.48	-0.32	1e-7	Lipoprotein phospholipase A2 activity in cardiovascular disease;
CESC	cis	rs6860806	0.603	rs112300250	chr5:131583292	G/A	cg12564285	chr5:131593104	PDLIM4	0.4	6.18	0.35	2.46e-9	Breast cancer;
CESC	cis	rs12701220	0.655	rs7784403	chr7:1153077	G/A	cg23978390	chr7:1156363	C7orf50	0.58	5.84	0.34	1.52e-8	Bronchopulmonary dysplasia;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg23649784	chr1:156105746	LMNA	0.47	6.2	0.36	2.12e-9	Fibrinogen levels;
CESC	cis	rs561341	0.714	rs473535	chr17:30312365	A/G	cg12193833	chr17:30244370	NA	-0.67	-6.16	-0.35	2.71e-9	Hip circumference adjusted for BMI;
CESC	cis	rs9287719	0.601	rs6755281	chr2:10769855	T/C	cg00105475	chr2:10696890	NA	0.37	5.04	0.3	8.5e-7	Prostate cancer;
CESC	cis	rs17826219	0.500	rs9891256	chr17:29072692	C/T	cg14008862	chr17:28927542	LRRC37B2	0.65	5.14	0.3	5.34e-7	Body mass index;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02333352	chr5:1076627	SLC12A7	-0.53	-6.35	-0.36	9.36e-10	Gut microbiome composition (summer);
CESC	cis	rs4665809	0.590	rs34728554	chr2:26481959	C/G	cg22920501	chr2:26401640	FAM59B	0.91	10.38	0.54	2.08e-21	Gut microbiome composition (summer);
CESC	cis	rs4450131	0.522	rs3781463	chr10:126337190	C/T	cg20435097	chr10:126320824	FAM53B	0.3	5.29	0.31	2.5e-7	White blood cell count (basophil);
CESC	cis	rs12476592	0.571	rs1446565	chr2:63731575	T/C	cg17519650	chr2:63277830	OTX1	-0.47	-5.4	-0.31	1.46e-7	Childhood ear infection;
CESC	cis	rs1577917	1.000	rs10944170	chr6:86685469	A/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.45	-5.92	-0.34	9.76e-9	Response to antipsychotic treatment;
CESC	cis	rs710216	0.718	rs841851	chr1:43401829	A/G	cg03128534	chr1:43423976	SLC2A1	0.44	5.13	0.3	5.73e-7	Red cell distribution width;
CESC	cis	rs763121	0.819	rs138700	chr22:39129999	A/G	cg06544989	chr22:39130855	UNC84B	0.48	8.68	0.47	4.1e-16	Menopause (age at onset);
CESC	cis	rs4975616	0.839	rs2447853	chr5:1333077	A/G	cg06550200	chr5:1325588	CLPTM1L	-0.68	-10.62	-0.55	3.57e-22	Lung cancer;
CESC	trans	rs7786808	0.579	rs4045391	chr7:158181826	T/C	cg03441993	chr4:55093323	NA	0.41	6.36	0.36	9.01e-10	Obesity-related traits;
CESC	cis	rs2228479	0.850	rs34033205	chr16:89922959	G/T	cg14709524	chr16:89940631	TCF25	0.87	6.12	0.35	3.27e-9	Skin colour saturation;
CESC	cis	rs1552244	0.882	rs13063098	chr3:10009919	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.86	11.02	0.56	1.63e-23	Alzheimer's disease;
CESC	cis	rs9929218	0.551	rs6499193	chr16:68727069	C/T	cg01251360	chr16:68772225	CDH1	-0.23	-5.14	-0.3	5.35e-7	Colorectal cancer;
CESC	cis	rs7618915	0.571	rs33964154	chr3:52596914	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	6.89	0.39	4e-11	Bipolar disorder;
CESC	cis	rs9625935	0.536	rs9608819	chr22:30260809	A/C	cg01021169	chr22:30184971	ASCC2	0.41	6.43	0.37	5.79e-10	Tonsillectomy;
CESC	cis	rs6964587	0.839	rs62466159	chr7:91450507	A/G	cg17063962	chr7:91808500	NA	0.5	6.39	0.37	7.42e-10	Breast cancer;
CESC	trans	rs6054906	0.710	rs6117744	chr20:7265038	A/C	cg18229107	chr14:64854676	MTHFD1	0.46	6.13	0.35	3.09e-9	Response to amphetamines;
CESC	cis	rs67311347	1.000	rs73078158	chr3:40472567	G/C	cg09455208	chr3:40491958	NA	0.49	8.09	0.45	2.1e-14	Renal cell carcinoma;
CESC	cis	rs4979906	1.000	rs11002247	chr10:79446901	T/C	cg07817648	chr10:79422355	NA	-0.47	-5.53	-0.32	7.61e-8	Mortality in heart failure;
CESC	cis	rs888194	0.686	rs11067376	chr12:110027795	A/G	cg05360138	chr12:110035743	NA	0.39	5.1	0.3	6.63e-7	Neuroticism;
CESC	cis	rs9291683	0.530	rs73227883	chr4:9979279	T/C	cg11266682	chr4:10021025	SLC2A9	0.62	12.7	0.62	3.45e-29	Bone mineral density;
CESC	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg11494091	chr17:61959527	GH2	0.73	12.52	0.61	1.45e-28	Prudent dietary pattern;
CESC	cis	rs10504229	1.000	rs17805602	chr8:58179915	A/G	cg05313129	chr8:58192883	C8orf71	-0.55	-6.37	-0.36	8.42e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs7208859	0.623	rs8075163	chr17:29106310	A/G	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.17e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs858239	0.863	rs274058	chr7:23391509	C/G	cg23682824	chr7:23144976	KLHL7	0.39	5.23	0.31	3.48e-7	Cerebrospinal fluid biomarker levels;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg07277190	chr12:48723631	H1FNT	0.47	6.25	0.36	1.63e-9	Fibrinogen levels;
CESC	cis	rs7904368	0.806	rs6602161	chr10:16862280	A/G	cg14835575	chr10:16859367	RSU1	0.53	5.61	0.33	5.16e-8	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
CESC	cis	rs2933343	0.729	rs813945	chr3:128660937	A/G	cg25356066	chr3:128598488	ACAD9	0.59	8.39	0.46	2.87e-15	IgG glycosylation;
CESC	cis	rs798554	1.000	rs798540	chr7:2764130	G/A	cg19717773	chr7:2847554	GNA12	-0.58	-8.43	-0.46	2.24e-15	Height;
CESC	cis	rs1799949	1.000	rs3092994	chr17:41215825	C/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.43	5.83	0.34	1.64e-8	Menopause (age at onset);
CESC	cis	rs6500602	0.627	rs2270363	chr16:4526292	A/G	cg08645402	chr16:4508243	NA	0.43	6.03	0.35	5.41e-9	Schizophrenia;
CESC	cis	rs2991971	1.000	rs622798	chr1:46015271	T/G	cg24296786	chr1:45957014	TESK2	0.63	8.16	0.45	1.37e-14	High light scatter reticulocyte count;
CESC	cis	rs2073300	1.000	rs12625160	chr20:23442008	T/C	cg12062639	chr20:23401060	NAPB	0.91	6.41	0.37	6.71e-10	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02629833	chr17:80349836	NA	-0.56	-6.94	-0.39	3e-11	Gut microbiome composition (summer);
CESC	cis	rs9660180	0.967	rs9660106	chr1:1797947	A/G	cg05132306	chr1:1846340	CALML6	-0.3	-6.3	-0.36	1.26e-9	Body mass index;
CESC	cis	rs11785693	0.862	rs6995565	chr8:4990461	C/T	cg26367366	chr8:4980734	NA	-0.56	-5.14	-0.3	5.3e-7	Neuroticism (multi-trait analysis);Neuroticism;
CESC	cis	rs4704187	0.663	rs1477935	chr5:74448494	C/T	cg03227963	chr5:74354835	NA	0.3	5.5	0.32	8.75e-8	Response to amphetamines;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24005309	chr10:1095235	IDI1	0.57	6.04	0.35	5.25e-9	Gut microbiome composition (summer);
CESC	cis	rs3020736	0.500	rs6002597	chr22:42488160	C/A	cg15557168	chr22:42548783	NA	0.45	6.18	0.35	2.46e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs6500395	1.000	rs8059819	chr16:48682834	A/G	cg04672837	chr16:48644449	N4BP1	-0.51	-6.29	-0.36	1.29e-9	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs708547	1.000	rs2412770	chr4:57794660	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.7	7.87	0.44	8.82e-14	Response to bleomycin (chromatid breaks);
CESC	cis	rs2832191	0.679	rs2705659	chr21:30363908	G/C	cg24692254	chr21:30365293	RNF160	1.02	18.29	0.75	6.82e-49	Dental caries;
CESC	trans	rs2727020	0.930	rs1164686	chr11:49291822	C/T	cg15704280	chr7:45808275	SEPT13	0.8	11.17	0.57	5.5e-24	Coronary artery disease;
CESC	cis	rs769267	0.929	rs2905421	chr19:19457908	G/T	cg03709012	chr19:19516395	GATAD2A	0.89	12.55	0.61	1.19e-28	Tonsillectomy;
CESC	trans	rs61931739	0.857	rs1828514	chr12:34139600	A/G	cg26384229	chr12:38710491	ALG10B	0.44	6.07	0.35	4.4e-9	Morning vs. evening chronotype;
CESC	cis	rs4728302	0.838	rs2042453	chr7:133580730	G/A	cg10665199	chr7:133106180	EXOC4	0.4	5.48	0.32	9.86e-8	Intelligence;Intelligence (multi-trait analysis);
CESC	trans	rs10242455	0.702	rs74416635	chr7:99180569	G/A	cg09045935	chr12:6379348	NA	0.93	7.66	0.43	3.53e-13	Blood metabolite levels;
CESC	cis	rs3960554	0.808	rs867973	chr7:75686007	G/A	cg17325771	chr7:75508891	RHBDD2	-0.36	-5.24	-0.31	3.25e-7	Eotaxin levels;
CESC	cis	rs454510	0.542	rs10754417	chr1:120177454	G/T	cg16322792	chr1:120165303	ZNF697	0.35	5.82	0.34	1.71e-8	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
CESC	cis	rs7917772	0.503	rs2031602	chr10:104307955	G/C	ch.10.2196322F	chr10:104248062	ACTR1A	0.43	5.38	0.31	1.64e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	trans	rs11098499	0.820	rs12503082	chr4:120284317	A/G	cg25214090	chr10:38739885	LOC399744	0.65	9.11	0.49	2.04e-17	Corneal astigmatism;
CESC	cis	rs433852	0.718	rs386551	chr19:49138286	C/G	cg06530960	chr19:49140787	SEC1;DBP	-0.42	-5.13	-0.3	5.72e-7	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;
CESC	cis	rs798554	0.731	rs2283779	chr7:2815140	G/A	cg09658497	chr7:2847517	GNA12	-0.36	-5.33	-0.31	2.1e-7	Height;
CESC	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg03188948	chr7:1209495	NA	0.7	6.71	0.38	1.17e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs12477438	0.765	rs7607578	chr2:99669771	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.62	-8.67	-0.47	4.43e-16	Chronic sinus infection;
CESC	cis	rs1865721	0.804	rs719179	chr18:73146396	A/G	cg26385618	chr18:73139727	C18orf62	-0.53	-8.32	-0.46	4.61e-15	Intelligence;
CESC	cis	rs4566357	0.615	rs3769643	chr2:227917270	T/C	cg11843606	chr2:227700838	RHBDD1	-0.53	-7.15	-0.4	8.33e-12	Coronary artery disease;
CESC	cis	rs6461049	0.734	rs1558465	chr7:2151398	G/C	cg08027265	chr7:2291960	NA	-0.43	-6.45	-0.37	5.18e-10	Schizophrenia;
CESC	cis	rs1023500	0.505	rs134874	chr22:42661144	A/G	cg15557168	chr22:42548783	NA	-0.42	-6.33	-0.36	1.04e-9	Schizophrenia;
CESC	cis	rs3754214	0.857	rs488271	chr1:150284534	A/G	cg09579323	chr1:150459698	TARS2	-0.46	-6.03	-0.35	5.58e-9	Cerebrospinal fluid biomarker levels;
CESC	cis	rs2425143	1.000	rs55761608	chr20:34344226	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.84	-7.89	-0.44	8.21e-14	Blood protein levels;
CESC	cis	rs6964587	0.839	rs6949700	chr7:91467435	A/G	cg17063962	chr7:91808500	NA	0.5	6.64	0.38	1.75e-10	Breast cancer;
CESC	cis	rs9916302	0.851	rs4794810	chr17:37603774	T/C	cg19468946	chr17:37922297	IKZF3	-0.39	-5.11	-0.3	6.24e-7	Glomerular filtration rate (creatinine);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19940975	chr18:32820997	ZNF397	0.56	6.2	0.36	2.17e-9	Gut microbiome composition (summer);
CESC	cis	rs9649213	0.537	rs6465663	chr7:97918883	C/G	cg21770322	chr7:97807741	LMTK2	0.59	8.76	0.47	2.37e-16	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs3806843	1.000	rs2240692	chr5:140183585	A/G	cg26395211	chr5:140044315	WDR55	-0.42	-5.33	-0.31	2.07e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs950776	0.714	rs615470	chr15:78885988	T/C	cg06917634	chr15:78832804	PSMA4	-0.51	-6.14	-0.35	3.07e-9	Sudden cardiac arrest;
CESC	cis	rs9908102	0.740	rs56266951	chr17:12905139	G/A	cg26162695	chr17:12921313	ELAC2	0.5	5.49	0.32	9.61e-8	Schizophrenia;
CESC	cis	rs10861342	0.892	rs11112366	chr12:105486108	G/A	cg23923672	chr12:105501055	KIAA1033	0.71	5.31	0.31	2.29e-7	IgG glycosylation;
CESC	cis	rs6060717	0.536	rs7271036	chr20:34467215	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.76	6.93	0.39	3.22e-11	Hip circumference adjusted for BMI;
CESC	cis	rs7618915	0.570	rs11130312	chr3:52675055	A/C	cg17372223	chr3:52568218	NT5DC2	0.43	6.47	0.37	4.6e-10	Bipolar disorder;
CESC	cis	rs1448094	0.511	rs61930587	chr12:86158793	T/C	cg00310523	chr12:86230176	RASSF9	0.34	5.38	0.31	1.65e-7	Major depressive disorder;
CESC	cis	rs4253772	0.938	rs41427746	chr22:46637239	T/C	cg00784671	chr22:46762841	CELSR1	-0.48	-5.86	-0.34	1.39e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs9863	0.828	rs7135314	chr12:124478566	A/T	cg17562584	chr12:124393655	DNAH10	0.29	5.03	0.3	9.21e-7	White blood cell count;
CESC	trans	rs9371601	1.000	rs9371601	chr6:152790573	A/C	cg22268271	chr22:39548261	CBX7	-0.46	-6.56	-0.37	2.82e-10	Bipolar disorder;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs6879260	1.000	rs7725605	chr5:179732678	T/G	cg02891314	chr5:179741120	GFPT2	-0.71	-9.84	-0.52	1.09e-19	Height;
CESC	cis	rs4665809	0.590	rs7606351	chr2:26292545	A/C	cg22920501	chr2:26401640	FAM59B	-0.82	-9.6	-0.51	6.25e-19	Gut microbiome composition (summer);
CESC	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg23602909	chr7:157956050	PTPRN2	-0.54	-9.42	-0.5	2.33e-18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CESC	cis	rs2075371	0.829	rs10954442	chr7:134007587	A/G	cg20476274	chr7:133979776	SLC35B4	-0.42	-5.57	-0.32	6.16e-8	Mean platelet volume;
CESC	cis	rs4722585	0.533	rs2158359	chr7:26193309	A/C	cg07876897	chr7:26191696	NFE2L3	-0.42	-5.52	-0.32	8.13e-8	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
CESC	cis	rs116095464	0.558	rs6869925	chr5:264036	A/G	cg20965017	chr5:231967	SDHA	-0.48	-5.43	-0.32	1.25e-7	Breast cancer;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg27539858	chr16:29367194	RUNDC2C	0.47	6.48	0.37	4.54e-10	Fibrinogen levels;
CESC	cis	rs763014	0.966	rs7198877	chr16:661439	A/G	cg09263875	chr16:632152	PIGQ	0.66	11.27	0.57	2.5e-24	Height;
CESC	cis	rs3820928	0.874	rs10167086	chr2:227792729	A/T	cg11843606	chr2:227700838	RHBDD1	0.43	5.7	0.33	3.11e-8	Pulmonary function;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg18993626	chr8:74463939	STAU2	0.48	7.57	0.42	6.07e-13	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs1048238	0.605	rs1889785	chr1:16348729	G/A	cg22431228	chr1:16359049	CLCNKA	-0.49	-9.43	-0.5	2.18e-18	Systolic blood pressure;
CESC	cis	rs2075371	0.932	rs34664116	chr7:133984878	G/A	cg20476274	chr7:133979776	SLC35B4	0.63	9.0	0.48	4.56e-17	Mean platelet volume;
CESC	cis	rs9915657	0.715	rs9906100	chr17:70095365	C/T	cg09344028	chr17:70110421	NA	0.44	8.67	0.47	4.44e-16	Thyroid hormone levels;
CESC	cis	rs1862618	0.802	rs2591949	chr5:56132627	T/C	cg03609598	chr5:56110824	MAP3K1	-0.54	-5.69	-0.33	3.42e-8	Initial pursuit acceleration;
CESC	cis	rs7811142	0.830	rs28495773	chr7:99943583	A/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.93	9.08	0.49	2.65e-17	Platelet count;
CESC	cis	rs7647973	1.000	rs13322887	chr3:49555583	G/A	cg07636037	chr3:49044803	WDR6	-0.72	-10.34	-0.54	2.85e-21	Menarche (age at onset);
CESC	cis	rs9487051	0.676	rs7773213	chr6:109601885	C/T	cg01475377	chr6:109611718	NA	-0.45	-7.1	-0.4	1.13e-11	Reticulocyte fraction of red cells;
CESC	cis	rs4523957	0.928	rs4790321	chr17:2173499	C/T	cg16513277	chr17:2031491	SMG6	-0.59	-7.99	-0.44	4.21e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs7605827	0.930	rs1019360	chr2:15524741	C/T	cg19274914	chr2:15703543	NA	0.35	6.27	0.36	1.43e-9	Educational attainment (years of education);
CESC	cis	rs10504073	0.669	rs341809	chr8:50042557	C/T	cg00325661	chr8:49890786	NA	0.49	7.16	0.4	8.18e-12	Blood metabolite ratios;
CESC	cis	rs7107174	1.000	rs11603112	chr11:78073491	G/A	cg02023728	chr11:77925099	USP35	0.38	5.39	0.31	1.57e-7	Testicular germ cell tumor;
CESC	cis	rs7666738	0.830	rs7678557	chr4:99057329	A/G	cg05340658	chr4:99064831	C4orf37	0.83	12.74	0.62	2.5e-29	Colonoscopy-negative controls vs population controls;
CESC	cis	rs425277	0.958	rs262687	chr1:2117155	G/A	cg04315214	chr1:2043799	PRKCZ	-0.38	-5.26	-0.31	3.02e-7	Height;
CESC	cis	rs1506636	0.720	rs2456552	chr7:123441400	A/G	cg03229431	chr7:123269106	ASB15	0.41	5.71	0.33	2.98e-8	Plateletcrit;Platelet count;
CESC	cis	rs11122272	0.735	rs2749707	chr1:231527316	C/T	cg06096015	chr1:231504339	EGLN1	0.43	6.15	0.35	2.9e-9	Hemoglobin concentration;
CESC	cis	rs8067354	0.574	rs2526353	chr17:57988607	G/T	cg02344993	chr17:57696989	CLTC	0.53	5.48	0.32	9.75e-8	Hemoglobin concentration;
CESC	trans	rs459571	0.606	rs457420	chr9:136909261	A/G	cg10765909	chr12:53715428	AAAS	0.46	6.02	0.35	5.88e-9	Platelet distribution width;
CESC	cis	rs10504229	0.911	rs77203035	chr8:58175458	C/A	cg14926445	chr8:58193284	C8orf71	-0.51	-5.47	-0.32	1.03e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs7666738	1.000	rs13106934	chr4:99028685	C/T	cg17366294	chr4:99064904	C4orf37	0.58	7.76	0.43	1.85e-13	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7666738	0.830	rs6854994	chr4:98977624	C/G	cg03467027	chr4:99064603	C4orf37	0.43	5.4	0.31	1.49e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs561341	0.556	rs542244	chr17:30307242	T/C	cg19193384	chr17:30244184	NA	-0.67	-6.34	-0.36	9.81e-10	Hip circumference adjusted for BMI;
CESC	cis	rs6547741	0.935	rs4665384	chr2:27848397	A/G	cg21248554	chr2:27665150	KRTCAP3	0.25	5.2	0.3	4.02e-7	Oral cavity cancer;
CESC	cis	rs936229	0.861	rs7162232	chr15:75115895	G/A	cg14664628	chr15:75095509	CSK	-1.0	-16.33	-0.71	6.1e-42	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CESC	cis	rs17826219	0.561	rs11655876	chr17:29017150	G/A	cg14008862	chr17:28927542	LRRC37B2	0.6	5.23	0.31	3.41e-7	Body mass index;
CESC	cis	rs8002861	0.846	rs12867732	chr13:44483084	C/A	cg19180546	chr13:44453867	C13orf31;CCDC122	-0.45	-5.86	-0.34	1.39e-8	Leprosy;
CESC	cis	rs910316	0.967	rs8013444	chr14:75661981	A/G	cg08847533	chr14:75593920	NEK9	-0.93	-16.29	-0.71	8.2e-42	Height;
CESC	cis	rs2075371	1.000	rs1862051	chr7:133981021	G/A	cg20476274	chr7:133979776	SLC35B4	0.65	9.44	0.5	2.08e-18	Mean platelet volume;
CESC	cis	rs2404602	0.622	rs4886506	chr15:77207277	G/T	cg23625390	chr15:77176239	SCAPER	0.45	6.21	0.36	2.01e-9	Blood metabolite levels;
CESC	cis	rs963731	0.649	rs4670903	chr2:39220975	G/A	cg04010122	chr2:39346883	SOS1	-0.72	-5.36	-0.31	1.82e-7	Corticobasal degeneration;
CESC	cis	rs9902453	1.000	rs9906340	chr17:28398977	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.64	-7.96	-0.44	5.11e-14	Coffee consumption (cups per day);
CESC	cis	rs2361718	0.522	rs11867921	chr17:78121170	G/T	cg23534315	chr17:78082725	GAA	0.43	5.61	0.33	5.12e-8	Yeast infection;
CESC	cis	rs12912251	0.947	rs12899449	chr15:38995491	A/G	cg01338139	chr15:38987640	C15orf53	-0.44	-5.03	-0.3	8.95e-7	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
CESC	cis	rs6570726	0.935	rs425717	chr6:145838620	A/T	cg05347473	chr6:146136440	FBXO30	0.49	6.69	0.38	1.3100000000000001e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs950776	0.518	rs3813572	chr15:78832588	T/C	cg06917634	chr15:78832804	PSMA4	0.81	12.32	0.6	6.91e-28	Sudden cardiac arrest;
CESC	cis	rs4713118	0.540	rs469227	chr6:27970705	A/C	cg19592336	chr6:28129416	ZNF389	0.46	6.19	0.36	2.28e-9	Parkinson's disease;
CESC	cis	rs7072216	0.763	rs7923729	chr10:100169465	C/T	cg26618903	chr10:100175079	PYROXD2	-0.37	-5.76	-0.33	2.33e-8	Metabolite levels;
CESC	cis	rs9894429	0.789	rs6565611	chr17:79598319	T/C	cg13777783	chr17:79615861	NA	-0.33	-5.23	-0.31	3.49e-7	Eye color traits;
CESC	cis	rs7178572	0.568	rs11630689	chr15:77520094	C/T	cg22256960	chr15:77711686	NA	-0.53	-6.69	-0.38	1.33e-10	Type 2 diabetes;
CESC	cis	rs9640161	0.659	rs17837498	chr7:150009679	A/G	cg10018233	chr7:150070692	REPIN1	0.46	7.32	0.41	2.89e-12	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs9513593	1.000	rs2149262	chr13:99940671	C/G	cg21788972	chr13:99853209	UBAC2	-0.56	-6.58	-0.37	2.47e-10	Psoriasis;
CESC	cis	rs2040771	0.745	rs362148	chr22:19262852	T/C	cg02655711	chr22:19163373	SLC25A1	0.4	5.75	0.33	2.48e-8	Metabolite levels (small molecules and protein measures);
CESC	cis	rs17376456	0.569	rs2045019	chr5:93201971	C/T	cg21475434	chr5:93447410	FAM172A	-0.51	-5.17	-0.3	4.51e-7	Diabetic retinopathy;
CESC	cis	rs7613875	0.600	rs2247510	chr3:50126215	A/C	cg24110177	chr3:50126178	RBM5	-0.57	-7.93	-0.44	5.97e-14	Body mass index;
CESC	cis	rs72781680	0.898	rs10490752	chr2:24025132	C/T	cg20701182	chr2:24300061	SF3B14	0.63	5.65	0.33	4.21e-8	Lymphocyte counts;
CESC	cis	rs6938	0.534	rs12913293	chr15:75184458	G/C	cg10253484	chr15:75165896	SCAMP2	-0.53	-7.05	-0.4	1.6e-11	Breast cancer;
CESC	cis	rs6540555	0.505	rs11811440	chr1:209882900	C/A	cg05527609	chr1:210001259	C1orf107	-0.72	-7.07	-0.4	1.37e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	10.31	0.54	3.43e-21	Prudent dietary pattern;
CESC	cis	rs67517081	1	rs67517081	chr16:30987380	GT/G	cg00531865	chr16:30841666	NA	0.48	6.25	0.36	1.61e-9	Mean corpuscular hemoglobin;
CESC	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg22535103	chr8:58192502	C8orf71	-0.96	-9.85	-0.52	1.05e-19	Developmental language disorder (linguistic errors);
CESC	cis	rs5821446	1	rs5821446	chr17:65962538	A/AT	cg12091567	chr17:66097778	LOC651250	0.74	8.68	0.47	4.07e-16	Eosinophil percentage of granulocytes;
CESC	cis	rs4665809	0.652	rs7585891	chr2:26403766	G/A	cg22920501	chr2:26401640	FAM59B	-0.86	-10.03	-0.52	2.73e-20	Gut microbiome composition (summer);
CESC	cis	rs798554	0.757	rs1182178	chr7:2873763	G/A	cg19717773	chr7:2847554	GNA12	-0.56	-8.04	-0.44	3.1e-14	Height;
CESC	cis	rs17764205	0.713	rs17696611	chr19:3259171	C/A	cg02612712	chr19:3985498	EEF2	0.65	5.1	0.3	6.36e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs4950928	0.823	rs2486065	chr1:203167871	A/G	cg17014757	chr1:203156097	CHI3L1	-0.51	-5.11	-0.3	6.1e-7	YKL-40 levels;
CESC	cis	rs7914558	1.000	rs12255047	chr10:104760752	G/A	cg08650961	chr10:104748594	CNNM2	0.33	5.53	0.32	7.81e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.64	7.45	0.42	1.33e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs7246760	1.000	rs7246760	chr19:9918229	G/A	cg02900749	chr2:68251473	NA	-0.74	-6.84	-0.39	5.62e-11	Pursuit maintenance gain;
CESC	trans	rs9325144	0.555	rs1843867	chr12:38703855	A/G	cg23762105	chr12:34175262	ALG10	0.46	6.24	0.36	1.71e-9	Morning vs. evening chronotype;
CESC	cis	rs1878931	0.697	rs10048148	chr16:3417450	C/G	cg00484396	chr16:3507460	NAT15	-0.33	-5.03	-0.3	9.21e-7	Body mass index (adult);
CESC	cis	rs7084402	0.967	rs1658478	chr10:60289551	C/T	cg07615347	chr10:60278583	BICC1	0.6	9.41	0.5	2.54e-18	Refractive error;
CESC	trans	rs62110082	0.522	rs10445582	chr19:52328510	T/C	cg18094401	chr15:25434150	SNORD115-29;SNORD115-36;SNORD115-43;SNORD115-11	-0.6	-6.41	-0.37	6.74e-10	Bipolar disorder (body mass index interaction);
CESC	cis	rs116095464	0.850	rs10055295	chr5:243749	G/A	cg12570787	chr5:219185	SDHA;CCDC127	0.5	5.27	0.31	2.9e-7	Breast cancer;
CESC	cis	rs6089584	0.508	rs6061988	chr20:60626300	C/T	cg24733560	chr20:60626293	TAF4	0.49	7.31	0.41	3.19e-12	Body mass index;
CESC	cis	rs7666738	0.830	rs1869897	chr4:98730997	C/T	cg03467027	chr4:99064603	C4orf37	0.43	5.31	0.31	2.33e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2290159	0.800	rs5746195	chr3:12653800	A/G	cg23032965	chr3:12705835	RAF1	0.54	5.9	0.34	1.14e-8	Cholesterol, total;
CESC	cis	rs40363	0.645	rs250630	chr16:3524242	C/T	cg05754148	chr16:3507555	NAT15	0.57	8.57	0.47	8.86e-16	Tuberculosis;
CESC	cis	rs6547741	1.000	rs76784350	chr2:27764278	A/G	cg21248554	chr2:27665150	KRTCAP3	0.25	5.16	0.3	4.9e-7	Oral cavity cancer;
CESC	cis	rs2075371	0.966	rs1646646	chr7:133996905	G/T	cg00033643	chr7:134001901	SLC35B4	0.44	5.71	0.33	3.04e-8	Mean platelet volume;
CESC	trans	rs61931739	0.517	rs11612493	chr12:34114272	A/C	cg26384229	chr12:38710491	ALG10B	0.6	8.42	0.46	2.36e-15	Morning vs. evening chronotype;
CESC	cis	rs514406	0.644	rs7552663	chr1:53204352	C/T	cg08859206	chr1:53392774	SCP2	0.64	9.35	0.5	3.74e-18	Monocyte count;
CESC	cis	rs2243480	0.908	rs55876148	chr7:65379800	G/A	cg25894440	chr7:65020034	NA	-0.62	-5.16	-0.3	4.73e-7	Diabetic kidney disease;
CESC	cis	rs4132509	1.000	rs6429433	chr1:243857994	C/T	cg21452805	chr1:244014465	NA	0.43	5.03	0.3	8.89e-7	RR interval (heart rate);
CESC	cis	rs4862750	0.874	rs6822062	chr4:187895553	T/C	cg07414643	chr4:187882934	NA	0.55	7.93	0.44	6.16e-14	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	10.16	0.53	1.11e-20	Prudent dietary pattern;
CESC	cis	rs9660992	0.710	rs7367930	chr1:205235512	A/G	cg21643547	chr1:205240462	TMCC2	-0.47	-6.28	-0.36	1.39e-9	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs11785400	0.793	rs4301430	chr8:143737416	A/G	cg10596483	chr8:143751796	JRK	0.41	5.11	0.3	6.08e-7	Schizophrenia;
CESC	cis	rs2380220	0.935	rs7748857	chr6:96001887	A/G	cg15832292	chr6:96025679	MANEA	0.63	5.99	0.35	6.89e-9	Behavioural disinhibition (generation interaction);
CESC	cis	rs78944489	0.558	rs9917370	chr2:73480204	A/G	cg01422370	chr2:73384389	NA	0.52	5.15	0.3	5.03e-7	Schizophrenia;
CESC	cis	rs7811142	0.830	rs7792525	chr7:99972122	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.09	10.93	0.56	3.28e-23	Platelet count;
CESC	cis	rs9611565	0.506	rs1984839	chr22:41685937	G/C	cg06481639	chr22:41940642	POLR3H	-0.53	-5.88	-0.34	1.21e-8	Vitiligo;
CESC	cis	rs2262909	0.962	rs11667209	chr19:22259467	A/G	cg11619707	chr19:22235551	ZNF257	0.33	5.17	0.3	4.65e-7	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
CESC	trans	rs12599106	0.584	rs12929704	chr16:34898258	C/A	cg05064044	chr6:292385	DUSP22	-0.65	-8.16	-0.45	1.38e-14	Menopause (age at onset);
CESC	cis	rs6540556	0.608	rs4314885	chr1:209902704	G/A	cg05527609	chr1:210001259	C1orf107	-0.44	-5.28	-0.31	2.68e-7	Red blood cell count;
CESC	cis	rs4665809	0.590	rs13016807	chr2:26496186	G/C	cg22920501	chr2:26401640	FAM59B	0.89	9.91	0.52	6.61e-20	Gut microbiome composition (summer);
CESC	cis	rs4665809	0.590	rs6730310	chr2:26419470	C/G	cg08470875	chr2:26401718	FAM59B	-0.73	-7.98	-0.44	4.5e-14	Gut microbiome composition (summer);
CESC	cis	rs2425143	0.818	rs6060726	chr20:34555878	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.79	-7.11	-0.4	1.1e-11	Blood protein levels;
CESC	cis	rs7703051	0.901	rs984976	chr5:74910870	A/G	cg03227963	chr5:74354835	NA	0.28	5.06	0.3	7.8e-7	LDL cholesterol;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
CESC	cis	rs9614461	0.609	rs9614653	chr22:45767391	A/G	cg22884516	chr22:45809543	SMC1B;RIBC2	-0.54	-5.31	-0.31	2.37e-7	Tonsillectomy;
CESC	cis	rs7129220	0.588	rs61878581	chr11:10083808	C/T	cg01453529	chr11:10209919	SBF2	-0.46	-5.09	-0.3	6.9e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CESC	cis	rs7666738	0.830	rs7661264	chr4:98961574	G/A	cg17366294	chr4:99064904	C4orf37	0.6	8.52	0.46	1.2e-15	Colonoscopy-negative controls vs population controls;
CESC	trans	rs1814175	0.645	rs7395438	chr11:49877379	G/T	cg03929089	chr4:120376271	NA	-0.87	-14.17	-0.66	2.64e-34	Height;
CESC	cis	rs853679	0.542	rs9380063	chr6:28137853	A/G	cg17949981	chr6:28129498	ZNF389	0.42	5.21	0.3	3.83e-7	Depression;
CESC	cis	rs3126085	0.825	rs4298736	chr1:152240269	A/T	cg03465714	chr1:152285911	FLG	-0.45	-5.59	-0.32	5.7e-8	Atopic dermatitis;
CESC	cis	rs4986811	1.000	rs2234582	chr11:32456694	C/A	cg27409910	chr11:32454216	WT1	0.43	5.65	0.33	4.04e-8	Rubella-specific interleukin-6 secretion;
CESC	cis	rs4654899	0.802	rs115818417	chr1:21200411	C/T	cg05370193	chr1:21551575	ECE1	0.4	5.7	0.33	3.26e-8	Superior frontal gyrus grey matter volume;
CESC	cis	rs7786877	0.723	rs62482239	chr7:100217810	C/T	cg16850897	chr7:100343110	ZAN	-0.61	-6.68	-0.38	1.37e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs17021463	0.807	rs6532480	chr4:95277038	T/C	cg11021082	chr4:95130006	SMARCAD1	0.49	7.25	0.41	4.51e-12	Testicular germ cell tumor;
CESC	cis	rs4803468	1.000	rs10853751	chr19:41903220	G/A	cg08477640	chr19:41863820	B9D2	0.38	5.07	0.3	7.53e-7	Height;
CESC	cis	rs8177179	0.967	rs6439434	chr3:133450371	T/G	cg24879335	chr3:133465180	TF	0.47	9.17	0.49	1.4e-17	Iron status biomarkers (transferrin levels);
CESC	cis	rs116095464	0.558	rs6882584	chr5:223411	A/C	cg12570787	chr5:219185	SDHA;CCDC127	0.53	5.74	0.33	2.63e-8	Breast cancer;
CESC	cis	rs7580658	0.864	rs34832797	chr2:128119441	T/C	cg10021288	chr2:128175891	PROC	-0.41	-6.41	-0.37	6.54e-10	Protein C levels;
CESC	cis	rs12618769	0.597	rs3769724	chr2:99105981	C/T	cg10123293	chr2:99228465	UNC50	0.39	5.13	0.3	5.6e-7	Bipolar disorder;
CESC	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.46	-6.01	-0.35	6.09e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7904368	0.754	rs7091240	chr10:16855683	G/A	cg23933602	chr10:16859644	RSU1	0.66	6.14	0.35	2.97e-9	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	ch.2.1420302F	chr2:62093097	NA	0.42	6.16	0.35	2.65e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs79387448	0.935	rs7567133	chr2:103253128	C/A	cg15446670	chr7:87257547	ABCB1;RUNDC3B	-0.55	-6.27	-0.36	1.43e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs6951245	0.882	rs56048221	chr7:1092533	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.47	5.61	0.33	5.08e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg05001908	chr7:128045859	IMPDH1	-0.39	-6.15	-0.35	2.92e-9	Gambling;
CESC	cis	rs61931739	0.500	rs11053274	chr12:34547605	G/A	cg19457237	chr12:34500585	NA	-0.37	-5.12	-0.3	5.85e-7	Morning vs. evening chronotype;
CESC	cis	rs7193541	0.673	rs12716769	chr16:74652537	T/C	cg05580060	chr16:74700937	RFWD3	-0.44	-5.64	-0.33	4.47e-8	Multiple myeloma;
CESC	cis	rs72781680	0.898	rs12623316	chr2:24087857	A/G	cg20701182	chr2:24300061	SF3B14	0.62	5.65	0.33	4.04e-8	Lymphocyte counts;
CESC	cis	rs916888	0.773	rs199535	chr17:44822662	A/G	cg27589368	chr17:43923255	LOC100128977;IMP5	-0.36	-5.11	-0.3	6.14e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs1448094	0.512	rs7960130	chr12:86243191	T/C	cg00310523	chr12:86230176	RASSF9	0.35	5.44	0.32	1.21e-7	Major depressive disorder;
CESC	cis	rs2839186	0.500	rs13052701	chr21:47660045	A/T	cg09417038	chr21:47716443	C21orf57	-0.49	-6.88	-0.39	4.3e-11	Testicular germ cell tumor;
CESC	cis	rs12971120	1.000	rs3829640	chr18:72174980	A/G	cg26446133	chr18:72167187	CNDP2	-0.77	-10.27	-0.53	4.8e-21	Refractive error;
CESC	cis	rs6723226	0.842	rs1901355	chr2:32835664	A/G	cg02381751	chr2:32503542	YIPF4	-0.84	-11.35	-0.57	1.33e-24	Intelligence (multi-trait analysis);
CESC	cis	rs12497850	0.897	rs6795025	chr3:49081247	T/C	cg07636037	chr3:49044803	WDR6	1.06	18.94	0.76	3.54e-51	Parkinson's disease;
CESC	cis	rs7631605	0.905	rs6786584	chr3:37225728	T/C	cg22985146	chr3:37219077	LRRFIP2	-0.32	-5.24	-0.31	3.21e-7	Cerebrospinal P-tau181p levels;
CESC	trans	rs61931739	0.500	rs11053201	chr12:34453903	T/A	cg13010199	chr12:38710504	ALG10B	0.48	6.28	0.36	1.38e-9	Morning vs. evening chronotype;
CESC	cis	rs7927771	0.800	rs55876153	chr11:47416636	G/A	cg18512352	chr11:47633146	NA	-0.53	-7.86	-0.43	9.88e-14	Subjective well-being;
CESC	cis	rs4243830	0.737	rs4908909	chr1:6599041	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.86	-7.53	-0.42	7.77e-13	Body mass index;
CESC	cis	rs763121	0.853	rs5750652	chr22:39048316	A/G	cg21395723	chr22:39101663	GTPBP1	0.5	6.66	0.38	1.6e-10	Menopause (age at onset);
CESC	cis	rs796364	0.865	rs769948	chr2:200728475	C/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.89	8.76	0.47	2.4e-16	Schizophrenia;
CESC	cis	rs910316	0.870	rs7147712	chr14:75670707	C/G	cg08847533	chr14:75593920	NEK9	-0.93	-16.54	-0.71	1.07e-42	Height;
CESC	cis	rs17125944	0.505	rs2274275	chr14:53235728	G/T	cg13660082	chr14:53194042	PSMC6	-0.68	-5.9	-0.34	1.13e-8	Alzheimer's disease (late onset);
CESC	cis	rs8141529	0.748	rs6005936	chr22:29289250	T/C	cg15103426	chr22:29168792	CCDC117	0.61	8.06	0.44	2.58e-14	Lymphocyte counts;
CESC	cis	rs3020736	0.500	rs7292241	chr22:42492063	G/A	cg04733989	chr22:42467013	NAGA	-0.82	-12.04	-0.59	6.5e-27	Autism spectrum disorder or schizophrenia;
CESC	cis	rs7508	0.765	rs2898458	chr8:17913813	G/A	cg18067069	chr8:17937731	ASAH1	-0.42	-5.34	-0.31	2.01e-7	Atrial fibrillation;
CESC	cis	rs9611565	0.546	rs132793	chr22:42063681	A/G	cg17376030	chr22:41985996	PMM1	-0.82	-8.87	-0.48	1.14e-16	Vitiligo;
CESC	cis	rs7264396	0.690	rs17093156	chr20:34438583	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.62	7.35	0.41	2.49e-12	Total cholesterol levels;
CESC	cis	rs28374715	0.662	rs72737786	chr15:41500361	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.79	-10.1	-0.53	1.63e-20	Ulcerative colitis;
CESC	cis	rs9581857	0.615	rs79793528	chr13:28007823	G/A	cg22138327	chr13:27999177	GTF3A	0.66	5.32	0.31	2.17e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
CESC	cis	rs896854	0.625	rs7823886	chr8:95986459	A/T	cg16049864	chr8:95962084	TP53INP1	-0.64	-11.11	-0.56	8.83e-24	Type 2 diabetes;
CESC	cis	rs738322	0.967	rs133024	chr22:38574066	C/T	cg17652424	chr22:38574118	PLA2G6	0.32	5.76	0.33	2.36e-8	Cutaneous nevi;
CESC	cis	rs11112613	0.762	rs73184077	chr12:105949999	G/A	cg03607813	chr12:105948248	NA	0.67	8.31	0.45	5.16e-15	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CESC	cis	rs514406	0.861	rs11206011	chr1:53235910	T/C	cg25767906	chr1:53392781	SCP2	0.43	6.06	0.35	4.75e-9	Monocyte count;
CESC	cis	rs6460942	0.915	rs2216050	chr7:12304073	T/C	cg20607287	chr7:12443886	VWDE	-0.41	-5.94	-0.34	8.83e-9	Coronary artery disease;
CESC	cis	rs3762637	1.000	rs76599189	chr3:122124076	G/A	cg24169773	chr3:122142474	KPNA1	-0.53	-6.19	-0.36	2.3e-9	LDL cholesterol levels;
CESC	cis	rs4242434	0.927	rs3735901	chr8:22462374	T/C	cg03733263	chr8:22462867	KIAA1967	0.96	16.09	0.7	4.03e-41	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CESC	cis	rs1707322	0.686	rs3014242	chr1:46087577	G/A	cg03146154	chr1:46216737	IPP	-0.79	-10.86	-0.55	5.89e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs4450798	0.793	rs28687597	chr3:13757613	T/C	cg23332027	chr3:13681764	NA	0.44	5.78	0.33	2.14e-8	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs9303280	0.901	rs7359623	chr17:38049589	C/T	cg19468946	chr17:37922297	IKZF3	-0.4	-5.34	-0.31	1.98e-7	Self-reported allergy;
CESC	trans	rs1814175	0.708	rs10839464	chr11:49981386	T/C	cg03929089	chr4:120376271	NA	-0.92	-15.24	-0.68	4.38e-38	Height;
CESC	cis	rs2197308	0.703	rs10880251	chr12:37903297	G/A	cg26384229	chr12:38710491	ALG10B	0.75	11.12	0.56	8.21e-24	Morning vs. evening chronotype;
CESC	cis	rs4713118	0.662	rs469228	chr6:27970704	A/G	cg23281280	chr6:28129359	ZNF389	0.45	6.18	0.35	2.39e-9	Parkinson's disease;
CESC	cis	rs7809950	0.678	rs62482499	chr7:106975059	C/G	cg23024343	chr7:107201750	COG5	-0.5	-6.43	-0.37	5.78e-10	Coronary artery disease;
CESC	cis	rs10540	1.000	rs12794284	chr11:477623	C/T	cg03352830	chr11:487213	PTDSS2	0.75	7.61	0.42	4.93e-13	Body mass index;
CESC	cis	rs1348850	0.567	rs4144276	chr2:178523420	T/C	cg22681709	chr2:178499509	PDE11A	-0.51	-7.49	-0.42	1.04e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs8058578	0.887	rs28421305	chr16:30838128	G/A	cg02466173	chr16:30829666	NA	-0.48	-7.71	-0.43	2.61e-13	Multiple myeloma;
CESC	cis	rs10743315	0.557	rs78468792	chr12:19351592	T/A	cg02471346	chr12:19282374	PLEKHA5	0.69	5.14	0.3	5.24e-7	Gut microbiota (bacterial taxa);
CESC	cis	rs916888	0.821	rs70600	chr17:44860021	C/T	cg01570182	chr17:44337453	NA	0.91	10.47	0.54	1.11e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	trans	rs7618501	1.000	rs1491986	chr3:49739086	C/T	cg21659725	chr3:3221576	CRBN	-0.82	-13.41	-0.64	1.16e-31	Intelligence (multi-trait analysis);
CESC	cis	rs3733585	0.699	rs7663079	chr4:9966771	T/C	cg02734326	chr4:10020555	SLC2A9	-0.39	-5.58	-0.32	5.91e-8	Cleft plate (environmental tobacco smoke interaction);
CESC	trans	rs3942852	0.806	rs1503188	chr11:48117478	C/T	cg03929089	chr4:120376271	NA	-0.57	-6.48	-0.37	4.38e-10	Acute lymphoblastic leukemia (childhood);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14654587	chr19:1880126	FAM108A1	-0.62	-6.93	-0.39	3.16e-11	Gut microbiome composition (summer);
CESC	trans	rs61931739	0.534	rs10844728	chr12:34020109	G/C	cg26384229	chr12:38710491	ALG10B	0.59	8.24	0.45	8.19e-15	Morning vs. evening chronotype;
CESC	cis	rs6089829	0.925	rs4809270	chr20:61676709	C/A	cg16240275	chr20:61666158	NCRNA00029	0.49	8.29	0.45	5.66e-15	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs9486719	0.895	rs12195315	chr6:96905711	T/G	cg06623918	chr6:96969491	KIAA0776	-0.8	-8.21	-0.45	9.55e-15	Migraine;Coronary artery disease;
CESC	cis	rs13082711	0.522	rs653886	chr3:27343549	C/T	cg02860705	chr3:27208620	NA	0.39	5.22	0.31	3.69e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg03046325	chr10:93558661	TNKS2	-0.4	-6.36	-0.36	8.99e-10	Gambling;
CESC	trans	rs7618501	0.633	rs12485600	chr3:50025530	A/G	cg21659725	chr3:3221576	CRBN	0.53	7.37	0.41	2.19e-12	Intelligence (multi-trait analysis);
CESC	cis	rs11577318	0.853	rs4333841	chr1:26631927	T/C	cg00813993	chr1:26644493	UBXN11;CD52	-0.4	-6.46	-0.37	5.05e-10	Granulocyte percentage of myeloid white cells;
CESC	cis	rs7851660	0.809	rs10984235	chr9:100660896	C/T	cg13688889	chr9:100608707	NA	-0.62	-8.87	-0.48	1.11e-16	Strep throat;
CESC	cis	rs9311474	1.000	rs6445358	chr3:52308845	C/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.38	5.52	0.32	7.91e-8	Electroencephalogram traits;
CESC	cis	rs611744	0.550	rs1448154	chr8:109281053	T/C	cg21045802	chr8:109455806	TTC35	0.47	5.93	0.34	9.3e-9	Dupuytren's disease;
CESC	cis	rs7412746	0.621	rs7518156	chr1:150945794	A/C	cg17724175	chr1:150552817	MCL1	0.33	5.18	0.3	4.4e-7	Melanoma;
CESC	cis	rs6963495	0.585	rs1728653	chr7:105191335	A/G	cg13798780	chr7:105162888	PUS7	0.49	5.8	0.34	1.93e-8	Bipolar disorder (body mass index interaction);
CESC	cis	rs2769264	0.602	rs11204777	chr1:151072049	G/A	cg04469105	chr1:151031679	CDC42SE1;MLLT11	-0.59	-6.58	-0.37	2.53e-10	Blood trace element (Cu levels);
CESC	cis	rs2730245	1.000	rs2657365	chr7:158722753	A/T	cg24397884	chr7:158709396	WDR60	-0.89	-13.45	-0.64	8.49e-32	Height;
CESC	cis	rs11249608	0.548	rs2132672	chr5:178457742	A/C	cg21905437	chr5:178450457	ZNF879	0.58	7.98	0.44	4.35e-14	Pubertal anthropometrics;
CESC	cis	rs9488822	0.636	rs6937104	chr6:116375302	A/G	cg18764771	chr6:116381957	FRK	0.24	5.9	0.34	1.09e-8	Cholesterol, total;LDL cholesterol;
CESC	cis	rs875971	0.756	rs2901210	chr7:66017505	G/A	cg10691866	chr7:65817282	TPST1	0.33	5.51	0.32	8.62e-8	Aortic root size;
CESC	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg11965913	chr1:205819406	PM20D1	-0.69	-11.65	-0.58	1.37e-25	Monocyte percentage of white cells;
CESC	cis	rs1927790	0.697	rs61966875	chr13:96936525	C/A	cg02571835	chr13:96230311	CLDN10	-0.39	-5.51	-0.32	8.55e-8	Body mass index;
CESC	cis	rs1552244	1.000	rs6782602	chr3:10116541	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-11.04	-0.56	1.41e-23	Alzheimer's disease;
CESC	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg11494091	chr17:61959527	GH2	-0.76	-13.35	-0.63	1.91e-31	Prudent dietary pattern;
CESC	cis	rs208520	1.000	rs12195505	chr6:66986279	T/A	cg07460842	chr6:66804631	NA	0.88	10.12	0.53	1.49e-20	Exhaled nitric oxide output;
CESC	cis	rs7618915	0.501	rs13060048	chr3:52598608	G/A	cg05564831	chr3:52568323	NT5DC2	0.47	7.46	0.42	1.24e-12	Bipolar disorder;
CESC	cis	rs10504229	1.000	rs66870803	chr8:58180022	G/C	cg05313129	chr8:58192883	C8orf71	-0.55	-6.37	-0.36	8.42e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs73019876	0.869	rs7247121	chr19:22161490	T/C	cg11619707	chr19:22235551	ZNF257	-0.29	-5.43	-0.32	1.29e-7	Testicular germ cell tumor;
CESC	cis	rs9916302	0.851	rs11870631	chr17:37645129	C/T	cg15445000	chr17:37608096	MED1	0.41	6.76	0.38	8.83e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs7762018	0.941	rs4716384	chr6:170109184	T/A	cg05834625	chr6:170176447	C6orf70	0.64	7.53	0.42	8.16e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs1799949	1.000	rs11653069	chr17:41283377	C/T	cg05368731	chr17:41323189	NBR1	0.8	11.27	0.57	2.51e-24	Menopause (age at onset);
CESC	cis	rs2180341	0.814	rs9385424	chr6:127726796	A/G	cg27446573	chr6:127587934	RNF146	0.83	12.03	0.59	6.99e-27	Breast cancer;
CESC	cis	rs3008870	0.701	rs2815367	chr1:67500762	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.61	7.91	0.44	7.21e-14	Lymphocyte percentage of white cells;
CESC	cis	rs8058578	0.943	rs3747486	chr16:30786927	C/T	cg02466173	chr16:30829666	NA	-0.39	-6.34	-0.36	9.69e-10	Multiple myeloma;
CESC	cis	rs9399135	1.000	rs11754265	chr6:135356216	C/G	cg24558204	chr6:135376177	HBS1L	0.49	6.69	0.38	1.33e-10	Red blood cell count;
CESC	cis	rs7666738	0.830	rs11938686	chr4:98964470	A/G	cg05340658	chr4:99064831	C4orf37	0.78	11.83	0.59	3.34e-26	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1577917	0.710	rs1059306	chr6:86388109	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.55	7.5	0.42	9.74e-13	Response to antipsychotic treatment;
CESC	cis	rs863345	0.604	rs6666609	chr1:158498124	G/A	cg12129480	chr1:158549410	OR10X1	-0.35	-6.87	-0.39	4.57e-11	Pneumococcal bacteremia;
CESC	cis	rs4243830	0.850	rs2412309	chr1:6603151	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.99	-10.01	-0.52	3.22e-20	Body mass index;
CESC	cis	rs10489202	0.632	rs275137	chr1:168051266	A/C	cg24449463	chr1:168025552	DCAF6	0.4	5.12	0.3	5.84e-7	Schizophrenia;
CESC	trans	rs9951602	0.512	rs56009939	chr18:76644497	T/G	cg02800362	chr5:177631904	HNRNPAB	0.62	8.1	0.45	1.96e-14	Obesity-related traits;
CESC	cis	rs7666738	0.830	rs6854703	chr4:98977586	A/T	cg05340658	chr4:99064831	C4orf37	0.77	11.71	0.58	8.52e-26	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4821897	0.514	rs739141	chr22:39824450	A/G	cg11247378	chr22:39784982	NA	0.54	8.15	0.45	1.43e-14	IgG glycosylation;
CESC	cis	rs875971	0.660	rs62465434	chr7:66005152	A/C	cg14393609	chr7:65229607	NA	0.47	6.29	0.36	1.28e-9	Aortic root size;
CESC	cis	rs6582630	0.638	rs61931383	chr12:38513845	G/A	cg26384229	chr12:38710491	ALG10B	-0.43	-5.78	-0.33	2.11e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs896854	0.936	rs10108430	chr8:95961794	C/T	cg26343298	chr8:95960752	TP53INP1	0.37	6.1	0.35	3.7e-9	Type 2 diabetes;
CESC	cis	rs875971	0.929	rs4122249	chr7:65920936	T/C	cg12463550	chr7:65579703	CRCP	0.55	6.89	0.39	4.02e-11	Aortic root size;
CESC	cis	rs959260	1.000	rs4789181	chr17:73374640	T/A	cg20590849	chr17:73267439	MIF4GD	-0.58	-6.61	-0.38	2.14e-10	Systemic lupus erythematosus;
CESC	cis	rs9314323	0.964	rs2304300	chr8:26249018	G/A	cg11498726	chr8:26250323	BNIP3L	-0.44	-6.6	-0.38	2.26e-10	Red cell distribution width;
CESC	cis	rs6860806	0.631	rs7736284	chr5:131588151	T/C	cg14196790	chr5:131705035	SLC22A5	0.31	5.05	0.3	8.24e-7	Breast cancer;
CESC	cis	rs16858210	0.648	rs79478990	chr3:183587094	C/T	cg25686905	chr3:183603175	PARL	-0.34	-6.21	-0.36	2.06e-9	Menopause (age at onset);
CESC	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg07677032	chr17:61819896	STRADA	0.46	6.12	0.35	3.27e-9	Prudent dietary pattern;
CESC	cis	rs798554	0.759	rs1182189	chr7:2869522	G/A	cg19346786	chr7:2764209	NA	-0.45	-6.21	-0.36	2e-9	Height;
CESC	cis	rs1005277	0.579	rs2800485	chr10:38542588	G/A	cg25517755	chr10:38738941	LOC399744	-0.45	-5.74	-0.33	2.56e-8	Extrinsic epigenetic age acceleration;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg04631757	chr12:58176492	TSFM	-0.48	-6.21	-0.36	2.02e-9	Height;
CESC	cis	rs7089973	0.584	rs7908665	chr10:116611337	G/A	cg03647239	chr10:116582469	FAM160B1	0.48	6.17	0.35	2.52e-9	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs9649465	1.000	rs3807634	chr7:123382290	C/T	cg04330084	chr7:123175371	IQUB	-0.39	-5.18	-0.3	4.39e-7	Migraine;
CESC	cis	rs2415984	0.579	rs10135740	chr14:46957379	G/A	cg14871534	chr14:47121158	RPL10L	-0.35	-5.22	-0.31	3.62e-7	Number of children ever born;
CESC	cis	rs6088590	0.965	rs6120730	chr20:33385102	G/C	cg08999081	chr20:33150536	PIGU	0.62	9.34	0.5	4.01e-18	Coronary artery disease;
CESC	cis	rs2066819	1.000	rs78121408	chr12:56684798	C/T	cg26734620	chr12:56694298	CS	1.07	6.58	0.37	2.56e-10	Psoriasis vulgaris;
CESC	cis	rs9640161	0.789	rs34311995	chr7:150059255	T/C	cg21361702	chr7:150065534	REPIN1	0.66	8.15	0.45	1.48e-14	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs7953249	0.564	rs1183910	chr12:121420807	G/A	cg02403541	chr12:121454288	C12orf43	0.62	7.79	0.43	1.56e-13	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
CESC	cis	rs4843747	0.671	rs8053377	chr16:88106465	A/G	cg06915872	chr16:87998081	BANP	0.46	5.46	0.32	1.11e-7	Menopause (age at onset);
CESC	cis	rs7666738	0.830	rs4699595	chr4:99012827	A/G	cg05340658	chr4:99064831	C4orf37	0.8	12.51	0.61	1.52e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6690583	1.000	rs2304641	chr1:85513398	C/T	cg22153463	chr1:85462885	MCOLN2	0.73	7.86	0.43	9.45e-14	Serum sulfate level;
CESC	cis	rs6963495	0.818	rs75116202	chr7:105160059	C/T	cg02135003	chr7:105160482	PUS7	-0.46	-5.55	-0.32	6.92e-8	Bipolar disorder (body mass index interaction);
CESC	cis	rs4665809	1.000	rs4665820	chr2:26309150	T/C	cg22920501	chr2:26401640	FAM59B	-0.67	-8.12	-0.45	1.72e-14	Gut microbiome composition (summer);
CESC	cis	rs6570726	0.791	rs9373463	chr6:145894762	C/T	cg23711669	chr6:146136114	FBXO30	0.97	14.77	0.67	2.05e-36	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6032067	0.929	rs17424723	chr20:43814520	G/T	cg10761708	chr20:43804764	PI3	-0.44	-5.12	-0.3	5.94e-7	Blood protein levels;
CESC	cis	rs2758596	0.850	rs2241110	chr1:156172487	A/G	cg24450063	chr1:156163899	SLC25A44	0.84	8.69	0.47	3.84e-16	Paclitaxel disposition in epithelial ovarian cancer;
CESC	cis	rs5753037	0.547	rs140140	chr22:30166437	G/A	cg01021169	chr22:30184971	ASCC2	-0.56	-8.34	-0.46	4.19e-15	Type 1 diabetes;
CESC	cis	rs367943	0.660	rs9632462	chr5:112697801	T/C	cg12552261	chr5:112820674	MCC	0.43	5.58	0.32	6.06e-8	Type 2 diabetes;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg14095850	chr21:45196584	CSTB	-0.42	-6.73	-0.38	1.02e-10	Gambling;
CESC	cis	rs6502050	0.835	rs62080004	chr17:80079079	C/T	cg23985595	chr17:80112537	CCDC57	0.42	6.56	0.37	2.87e-10	Life satisfaction;
CESC	cis	rs2836974	0.897	rs68090597	chr21:40535633	A/G	cg11890956	chr21:40555474	PSMG1	1.18	23.91	0.83	4.19e-68	Cognitive function;
CESC	cis	rs7647973	1.000	rs7644148	chr3:49545241	G/A	cg07636037	chr3:49044803	WDR6	-0.72	-10.25	-0.53	5.58e-21	Menarche (age at onset);
CESC	cis	rs3768617	0.510	rs35968946	chr1:183114871	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.86	13.56	0.64	3.46e-32	Fuchs's corneal dystrophy;
CESC	cis	rs2839186	0.605	rs2839170	chr21:47671305	A/G	cg00815214	chr21:47717953	NA	-0.35	-5.11	-0.3	6.22e-7	Testicular germ cell tumor;
CESC	cis	rs7267979	1.000	rs4815404	chr20:25301845	T/G	cg08601574	chr20:25228251	PYGB	-0.39	-5.58	-0.32	5.94e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs79976124	0.877	rs79507557	chr6:66640908	C/A	cg07460842	chr6:66804631	NA	0.72	8.33	0.46	4.47e-15	Type 2 diabetes;
CESC	cis	rs6831352	0.918	rs13133647	chr4:100058727	C/T	cg13256891	chr4:100009986	ADH5	-0.77	-8.45	-0.46	1.97e-15	Alcohol dependence;
CESC	cis	rs7666738	0.830	rs7657497	chr4:99044028	A/G	cg05340658	chr4:99064831	C4orf37	0.82	12.88	0.62	8.44e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2839186	0.616	rs4819213	chr21:47619300	G/A	cg00612595	chr21:47717864	NA	0.42	5.69	0.33	3.43e-8	Testicular germ cell tumor;
CESC	cis	rs13108904	0.901	rs12642410	chr4:1308409	A/G	cg22903657	chr4:1355424	KIAA1530	-0.38	-5.26	-0.31	3.02e-7	Obesity-related traits;
CESC	cis	rs3785574	0.962	rs2727332	chr17:61878584	T/A	cg06873352	chr17:61820015	STRADA	0.47	6.85	0.39	5.3e-11	Height;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg23439621	chr14:102228216	PPP2R5C	-0.45	-6.08	-0.35	4.2e-9	Ulcerative colitis;
CESC	cis	rs4654899	0.865	rs12123300	chr1:21323568	T/C	cg05370193	chr1:21551575	ECE1	0.44	6.39	0.37	7.58e-10	Superior frontal gyrus grey matter volume;
CESC	cis	rs9815354	1.000	rs7646144	chr3:41853125	T/A	cg03022575	chr3:42003672	ULK4	0.54	5.78	0.33	2.06e-8	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs7089973	0.872	rs7075888	chr10:116627117	C/T	cg23260525	chr10:116636907	FAM160B1	0.38	6.42	0.37	6.35e-10	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs3204270	0.500	rs62077175	chr17:79649568	G/T	cg18367735	chr17:79674897	NA	0.62	5.38	0.31	1.61e-7	Dental caries;
CESC	cis	rs7264396	0.635	rs6060673	chr20:34482396	C/T	cg17201900	chr20:34330562	RBM39	-0.48	-5.07	-0.3	7.43e-7	Total cholesterol levels;
CESC	cis	rs4474465	0.850	rs11237537	chr11:78248397	C/T	cg01578073	chr11:78285783	NARS2	0.48	5.05	0.3	8.17e-7	Alzheimer's disease (survival time);
CESC	cis	rs12579753	0.879	rs11115009	chr12:82165409	G/T	cg23701643	chr12:82153290	PPFIA2	0.36	5.18	0.3	4.33e-7	Resting heart rate;
CESC	cis	rs9522267	0.535	rs7326875	chr13:112236231	C/T	cg10483660	chr13:112241077	NA	-0.33	-5.78	-0.33	2.14e-8	Hepatitis;
CESC	cis	rs3092073	0.624	rs11906879	chr20:44591324	C/T	cg27529037	chr20:44575021	PCIF1	-0.64	-9.85	-0.52	1.06e-19	Intelligence (multi-trait analysis);
CESC	cis	rs35110281	0.607	rs4819212	chr21:44977455	G/A	cg01579765	chr21:45077557	HSF2BP	-0.5	-8.14	-0.45	1.54e-14	Mean corpuscular volume;
CESC	cis	rs72615157	0.539	rs72615159	chr7:99674286	G/A	cg22004693	chr7:99632812	ZKSCAN1	0.43	5.48	0.32	9.67e-8	Lung function (FEV1/FVC);
CESC	cis	rs1218582	0.774	rs12036859	chr1:154859940	A/C	cg03351412	chr1:154909251	PMVK	-0.56	-7.01	-0.4	1.98e-11	Prostate cancer;
CESC	cis	rs7582720	0.943	rs72936879	chr2:203792628	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.34	0.41	2.54e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs4423214	1.000	rs12791871	chr11:71164544	A/C	cg05163923	chr11:71159392	DHCR7	0.76	10.16	0.53	1.05e-20	Vitamin D levels;
CESC	cis	rs9457247	1.000	rs400063	chr6:167386592	C/T	cg23791538	chr6:167370224	RNASET2	-0.59	-8.36	-0.46	3.55e-15	Crohn's disease;
CESC	cis	rs45535039	1.000	rs12286018	chr11:119110947	G/A	cg16724696	chr11:118992527	HINFP	0.39	5.08	0.3	7.18e-7	Plateletcrit;
CESC	cis	rs8005677	0.828	rs12589539	chr14:23396680	A/G	cg25600027	chr14:23388339	RBM23	-0.41	-5.07	-0.3	7.43e-7	Cognitive ability (multi-trait analysis);
CESC	cis	rs853679	0.517	rs9380052	chr6:28064623	A/G	cg23281280	chr6:28129359	ZNF389	0.53	7.01	0.4	1.92e-11	Depression;
CESC	trans	rs6073597	1.000	rs6031980	chr20:43714384	C/T	cg06899053	chr1:33896703	NA	0.43	6.1	0.35	3.72e-9	Positive affect;
CESC	cis	rs3785574	0.962	rs2597632	chr17:61894739	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.57	7.08	0.4	1.32e-11	Height;
CESC	cis	rs4594175	0.892	rs10135768	chr14:51671017	G/T	cg23942311	chr14:51606299	NA	0.38	5.8	0.34	1.89e-8	Cancer;
CESC	cis	rs55882075	0.583	rs9637934	chr5:179114025	G/C	cg14593053	chr5:179126677	CANX	0.53	6.67	0.38	1.52e-10	Monocyte percentage of white cells;
CESC	cis	rs853679	0.550	rs9295762	chr6:28155418	C/T	cg17949981	chr6:28129498	ZNF389	-0.41	-5.37	-0.31	1.72e-7	Depression;
CESC	cis	rs4704187	0.687	rs1544756	chr5:74508412	G/T	cg03227963	chr5:74354835	NA	0.28	5.19	0.3	4.17e-7	Response to amphetamines;
CESC	cis	rs8077889	0.871	rs7212648	chr17:41917962	A/C	cg26893861	chr17:41843967	DUSP3	0.81	9.73	0.51	2.41e-19	Triglycerides;
CESC	cis	rs11690935	1.000	rs34542126	chr2:172542705	C/T	cg13550731	chr2:172543902	DYNC1I2	1.0	16.61	0.71	5.86e-43	Schizophrenia;
CESC	cis	rs2274273	0.840	rs943590	chr14:55738596	T/C	cg04306507	chr14:55594613	LGALS3	0.28	5.52	0.32	8.24e-8	Protein biomarker;
CESC	cis	rs2204008	0.702	rs8175764	chr12:38363690	T/C	cg26384229	chr12:38710491	ALG10B	0.73	10.95	0.56	2.81e-23	Bladder cancer;
CESC	cis	rs2559856	1.000	rs10745921	chr12:102087193	A/G	cg12213457	chr12:102090980	CHPT1	-0.34	-5.1	-0.3	6.45e-7	Blood protein levels;
CESC	cis	rs12586317	0.547	rs2383693	chr14:35500205	A/C	cg05294307	chr14:35346193	BAZ1A	-0.54	-5.64	-0.33	4.35e-8	Psoriasis;
CESC	cis	rs654950	0.840	rs116241899	chr1:41994546	T/C	cg06885757	chr1:42089581	HIVEP3	-0.44	-6.82	-0.39	6.21e-11	Airway imaging phenotypes;
CESC	cis	rs8072100	0.811	rs9889709	chr17:45445229	C/T	cg25173405	chr17:45401733	C17orf57	-0.44	-5.72	-0.33	2.81e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs898097	0.841	rs8180	chr17:80901036	C/G	cg15664640	chr17:80829946	TBCD	0.62	9.31	0.5	5.22e-18	Breast cancer;
CESC	cis	rs6963495	0.818	rs55983796	chr7:105170941	C/T	cg19920283	chr7:105172520	RINT1	0.68	6.44	0.37	5.53e-10	Bipolar disorder (body mass index interaction);
CESC	cis	rs7615952	0.641	rs12487875	chr3:125787224	C/A	cg15145296	chr3:125709740	NA	-0.54	-5.73	-0.33	2.67e-8	Blood pressure (smoking interaction);
CESC	cis	rs597539	0.652	rs673821	chr11:68678718	G/T	cg18350739	chr11:68623251	NA	-0.48	-7.45	-0.42	1.32e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg04776990	chr17:42853002	ADAM11	-0.45	-6.38	-0.36	7.7e-10	Gambling;
CESC	cis	rs6728642	0.908	rs9973669	chr2:97679094	T/C	cg26665480	chr2:98280029	ACTR1B	-0.81	-7.59	-0.42	5.47e-13	Bipolar disorder lithium response (continuous) or schizophrenia;
CESC	trans	rs17685	0.753	rs10264760	chr7:75749694	A/G	cg19862616	chr7:65841803	NCRNA00174	0.83	11.87	0.59	2.4e-26	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs3820068	0.705	rs951225	chr1:15826292	G/A	cg18192808	chr1:15853278	DNAJC16	0.47	5.78	0.33	2.05e-8	Systolic blood pressure;
CESC	cis	rs12431939	0.948	rs12435444	chr14:51656071	C/T	cg23942311	chr14:51606299	NA	-0.41	-5.09	-0.3	6.8e-7	Cancer;
CESC	cis	rs854765	0.616	rs8076747	chr17:17853595	C/T	cg16928487	chr17:17741425	SREBF1	-0.54	-9.02	-0.48	4.02e-17	Total body bone mineral density;
CESC	cis	rs2228479	0.867	rs17784386	chr16:89947457	A/G	cg00800038	chr16:89945340	TCF25	-0.88	-7.85	-0.43	1.01e-13	Skin colour saturation;
CESC	cis	rs2832077	0.943	rs2832097	chr21:30173340	A/T	cg03476357	chr21:30257390	N6AMT1	0.47	5.07	0.3	7.63e-7	Cognitive test performance;
CESC	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg21280719	chr6:42927975	GNMT	-0.31	-7.3	-0.41	3.43e-12	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs1552244	1.000	rs66838678	chr3:10150350	G/A	cg16606324	chr3:10149918	C3orf24	0.41	5.03	0.3	8.88e-7	Alzheimer's disease;
CESC	cis	rs3793683	0.928	rs2148666	chr10:134553785	A/G	cg18305652	chr10:134549665	INPP5A	0.33	5.3	0.31	2.41e-7	Migraine;
CESC	cis	rs7847628	0.666	rs2031974	chr9:123527521	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.62	7.8	0.43	1.47e-13	Birth weight;
CESC	cis	rs4819052	0.851	rs9974891	chr21:46680767	T/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.46	5.95	0.34	8.57e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs9894429	0.738	rs8077038	chr17:79577127	T/G	cg21984481	chr17:79567631	NPLOC4	0.58	9.48	0.5	1.5e-18	Eye color traits;
CESC	cis	rs2710642	0.962	rs1828398	chr2:63034870	A/G	cg17519650	chr2:63277830	OTX1	-0.52	-6.74	-0.38	9.98e-11	LDL cholesterol levels;LDL cholesterol;
CESC	cis	rs9457247	0.663	rs9457257	chr6:167440736	G/A	cg25258033	chr6:167368657	RNASET2	0.36	5.16	0.3	4.88e-7	Crohn's disease;
CESC	cis	rs713587	0.563	rs2384057	chr2:25100167	C/G	cg01884057	chr2:25150051	NA	0.34	6.36	0.36	8.69e-10	Body mass index in non-asthmatics;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27376817	chr7:75931888	HSPB1	-0.6	-6.98	-0.39	2.39e-11	Gut microbiome composition (summer);
CESC	cis	rs6952808	0.500	rs3778996	chr7:2177190	G/A	cg23048001	chr7:2026167	MAD1L1	0.42	5.31	0.31	2.31e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs3772130	0.564	rs35178434	chr3:121595936	G/A	cg20356878	chr3:121714668	ILDR1	0.42	6.19	0.36	2.32e-9	Cognitive performance;
CESC	cis	rs9910055	1.000	rs2071167	chr17:42287519	A/G	cg08499158	chr17:42289980	UBTF	0.64	7.83	0.43	1.2e-13	Total body bone mineral density;
CESC	cis	rs77106637	0.858	rs117819392	chr11:72514503	C/T	cg03713592	chr11:72463424	ARAP1	1.22	11.0	0.56	2.03e-23	Type 2 diabetes;
CESC	cis	rs858239	0.601	rs6461693	chr7:23160133	A/G	cg23682824	chr7:23144976	KLHL7	-0.54	-7.47	-0.42	1.17e-12	Cerebrospinal fluid biomarker levels;
CESC	cis	rs1799949	1.000	rs11654731	chr17:41326940	G/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.39	5.18	0.3	4.32e-7	Menopause (age at onset);
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg02576610	chr16:75657395	ADAT1	-0.45	-6.1	-0.35	3.69e-9	Asthma;
CESC	cis	rs662064	0.962	rs648399	chr1:10556485	T/C	cg20482658	chr1:10539492	PEX14	-0.36	-7.13	-0.4	9.5e-12	Asthma;
CESC	cis	rs4704187	0.687	rs1345704	chr5:74489998	G/A	cg03227963	chr5:74354835	NA	0.28	5.1	0.3	6.6e-7	Response to amphetamines;
CESC	cis	rs7666738	0.716	rs11721453	chr4:99045485	G/T	cg03467027	chr4:99064603	C4orf37	0.47	5.98	0.34	7.19e-9	Colonoscopy-negative controls vs population controls;
CESC	trans	rs12599106	0.818	rs17723574	chr16:34602945	C/G	cg21548813	chr6:291882	DUSP22	-0.45	-6.09	-0.35	4.01e-9	Menopause (age at onset);
CESC	trans	rs17126268	0.502	rs9628983	chr1:102895348	A/T	cg08072251	chr3:11033977	SLC6A1	0.47	6.11	0.35	3.56e-9	Glomerular filtration rate;
CESC	cis	rs9487051	0.676	rs1608041	chr6:109595903	G/A	cg01475377	chr6:109611718	NA	-0.45	-7.04	-0.4	1.6e-11	Reticulocyte fraction of red cells;
CESC	cis	rs9910055	0.529	rs400460	chr17:42182770	A/G	cg19774624	chr17:42201019	HDAC5	0.55	7.75	0.43	1.97e-13	Total body bone mineral density;
CESC	cis	rs2274273	1.000	rs67805055	chr14:55587552	C/T	cg04306507	chr14:55594613	LGALS3	0.3	5.5	0.32	8.9e-8	Protein biomarker;
CESC	cis	rs2404618	0.593	rs7815979	chr8:1484887	A/G	cg02903104	chr8:1507517	DLGAP2	0.3	5.87	0.34	1.27e-8	Lung cancer;
CESC	cis	rs11583043	0.831	rs6667818	chr1:101412313	A/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.54	6.01	0.35	6.1e-9	Ulcerative colitis;Inflammatory bowel disease;
CESC	cis	rs3096299	0.967	rs2965827	chr16:89457350	A/C	cg02187348	chr16:89574699	SPG7	-0.54	-7.4	-0.41	1.77e-12	Multiple myeloma (IgH translocation);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01801182	chr1:46998715	NA	0.5	6.01	0.35	6e-9	Gut microbiome composition (summer);
CESC	cis	rs941207	0.526	rs12229457	chr12:57033680	T/A	cg05584118	chr12:57595605	LRP1	0.39	5.12	0.3	5.99e-7	Platelet count;
CESC	cis	rs7589728	0.514	rs78204719	chr2:88460747	G/C	cg04511125	chr2:88470314	THNSL2	0.64	6.24	0.36	1.7e-9	Plasma clusterin levels;
CESC	cis	rs6121246	0.609	rs2149281	chr20:30417918	G/A	cg13852791	chr20:30311386	BCL2L1	0.83	10.75	0.55	1.3e-22	Mean corpuscular hemoglobin;
CESC	cis	rs4727963	0.765	rs1464877	chr7:122734266	G/A	cg03640110	chr7:122635026	TAS2R16	0.4	6.2	0.36	2.14e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
CESC	cis	rs3617	0.573	rs12492391	chr3:52912296	C/A	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.32	5.27	0.31	2.82e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
CESC	cis	rs4654899	0.785	rs9426656	chr1:21505932	T/G	cg05370193	chr1:21551575	ECE1	0.39	6.04	0.35	5.15e-9	Superior frontal gyrus grey matter volume;
CESC	cis	rs7914558	1.000	rs10883826	chr10:104830819	A/G	cg15744005	chr10:104629667	AS3MT	-0.33	-5.36	-0.31	1.77e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs11148252	0.904	rs9526927	chr13:53051627	C/T	cg00495681	chr13:53174319	NA	0.38	5.13	0.3	5.5e-7	Lewy body disease;
CESC	cis	rs2404602	0.692	rs1471780	chr15:77026526	T/C	cg26408565	chr15:76604113	ETFA	-0.38	-5.52	-0.32	8.03e-8	Blood metabolite levels;
CESC	cis	rs10504229	0.906	rs7003276	chr8:58173089	A/T	cg14926445	chr8:58193284	C8orf71	-0.49	-5.31	-0.31	2.37e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs2991971	0.967	rs644915	chr1:46007002	T/C	cg24296786	chr1:45957014	TESK2	0.63	8.26	0.45	6.93e-15	High light scatter reticulocyte count;
CESC	cis	rs7116495	1.000	rs548961	chr11:71793887	G/A	cg10381502	chr11:71823885	C11orf51	-0.66	-5.4	-0.31	1.51e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs9910055	0.718	rs2526022	chr17:42213216	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.61	8.0	0.44	3.92e-14	Total body bone mineral density;
CESC	cis	rs113835537	0.935	rs3867133	chr11:66451962	A/G	cg24851651	chr11:66362959	CCS	-0.62	-5.74	-0.33	2.64e-8	Airway imaging phenotypes;
CESC	cis	rs4253772	0.637	rs6008357	chr22:46652104	T/G	cg09491104	chr22:46646882	C22orf40	-0.59	-9.15	-0.49	1.58e-17	LDL cholesterol;Cholesterol, total;
CESC	cis	rs7666738	0.791	rs10022061	chr4:98926821	T/C	cg17366294	chr4:99064904	C4orf37	0.6	8.23	0.45	8.65e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11190604	1.000	rs2295772	chr10:102265183	G/A	cg07080220	chr10:102295463	HIF1AN	0.64	5.88	0.34	1.23e-8	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs2228479	0.850	rs62056103	chr16:89942781	G/A	cg00800038	chr16:89945340	TCF25	-0.94	-7.79	-0.43	1.52e-13	Skin colour saturation;
CESC	cis	rs1967309	0.604	rs8061182	chr16:4070333	A/G	cg00061520	chr16:4070371	ADCY9	0.45	7.2	0.4	6.38e-12	Response to Dalcetrapib treatment in acute coronary syndrome;
CESC	cis	rs7520050	0.807	rs3013595	chr1:46153203	G/A	cg03146154	chr1:46216737	IPP	0.52	6.86	0.39	4.96e-11	Red blood cell count;Reticulocyte count;
CESC	cis	rs6541297	1.000	rs6681042	chr1:230278979	G/A	cg20703242	chr1:230279135	GALNT2	0.68	10.87	0.56	5.47e-23	Coronary artery disease;
CESC	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg07677032	chr17:61819896	STRADA	0.44	5.9	0.34	1.1e-8	Prudent dietary pattern;
CESC	cis	rs79390637	1	rs79390637	chr11:47456867	C/A	cg20307385	chr11:47447363	PSMC3	0.5	6.09	0.35	3.87e-9	Intraocular pressure;
CESC	cis	rs950169	0.922	rs12915832	chr15:85111457	C/T	cg17507749	chr15:85114479	UBE2QP1	0.54	6.27	0.36	1.49e-9	Schizophrenia;
CESC	cis	rs17376456	0.877	rs17374627	chr5:93296306	C/T	cg21475434	chr5:93447410	FAM172A	0.76	6.55	0.37	2.97e-10	Diabetic retinopathy;
CESC	cis	rs7267979	1.000	rs7268053	chr20:25328286	A/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.87	-18.09	-0.74	3.41e-48	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7552404	1.000	rs11163924	chr1:76132070	A/C	cg03433033	chr1:76189801	ACADM	-0.67	-7.85	-0.43	1.05e-13	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs8018808	0.935	rs4903584	chr14:77934758	A/G	cg20045696	chr14:77926864	AHSA1	0.43	5.9	0.34	1.13e-8	Myeloid white cell count;
CESC	cis	rs9916302	0.904	rs10491128	chr17:37551988	G/A	cg20243544	chr17:37824526	PNMT	-0.49	-5.92	-0.34	9.98e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs9911578	1.000	rs6503887	chr17:56993320	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.39	5.05	0.3	8.26e-7	Intelligence (multi-trait analysis);
CESC	cis	rs72627123	0.867	rs79250763	chr14:74491121	G/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.8	5.37	0.31	1.71e-7	Morning vs. evening chronotype;
CESC	cis	rs8018808	0.935	rs4899655	chr14:77898077	G/A	cg20045696	chr14:77926864	AHSA1	0.42	5.85	0.34	1.43e-8	Myeloid white cell count;
CESC	cis	rs7000551	0.725	rs2461486	chr8:22392008	T/C	cg12081754	chr8:22256438	SLC39A14	0.38	5.11	0.3	6.05e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CESC	cis	rs561341	0.824	rs1978115	chr17:30220776	A/C	cg12193833	chr17:30244370	NA	-0.59	-6.1	-0.35	3.82e-9	Hip circumference adjusted for BMI;
CESC	cis	rs7666738	0.830	rs34164616	chr4:99015251	G/A	cg05340658	chr4:99064831	C4orf37	0.8	12.51	0.61	1.52e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4072980	0.545	rs10890285	chr1:38453576	A/C	cg17077180	chr1:38461687	NA	-0.42	-5.87	-0.34	1.28e-8	Coronary artery disease;
CESC	cis	rs12479064	0.604	rs11893359	chr2:99954608	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.56	-6.87	-0.39	4.44e-11	Chronic sinus infection;
CESC	cis	rs710216	0.917	rs900836	chr1:43412727	T/C	cg03128534	chr1:43423976	SLC2A1	-0.56	-6.49	-0.37	4.09e-10	Red cell distribution width;
CESC	cis	rs4901847	0.643	rs36051876	chr14:58596241	C/T	cg15908186	chr14:58618357	C14orf37	0.35	5.15	0.3	4.98e-7	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs642803	0.551	rs1308020	chr11:65497558	G/A	cg02870584	chr11:65547924	DKFZp761E198	0.54	6.71	0.38	1.18e-10	Urate levels;
CESC	cis	rs2637266	0.935	rs1866891	chr10:78396941	C/A	cg18941641	chr10:78392320	NA	0.45	8.6	0.47	7.12e-16	Pulmonary function;
CESC	cis	rs2481665	0.775	rs2476201	chr1:62619960	C/T	cg18591186	chr1:62594603	INADL	0.52	6.16	0.35	2.62e-9	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs4253772	0.591	rs9615935	chr22:46686115	T/G	cg18190219	chr22:46762943	CELSR1	-0.59	-5.46	-0.32	1.09e-7	LDL cholesterol;Cholesterol, total;
CESC	trans	rs12356475	0.710	rs10822686	chr10:67733250	C/T	cg24896697	chr17:25660093	NA	0.5	6.09	0.35	3.96e-9	Psoriatic arthritis;
CESC	cis	rs4853525	0.522	rs6434412	chr2:191585275	A/G	cg10560079	chr2:191398806	TMEM194B	-0.42	-5.3	-0.31	2.43e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
CESC	cis	rs1728785	1.000	rs1364109	chr16:68595505	T/C	cg02972257	chr16:68554789	NA	-0.59	-6.7	-0.38	1.23e-10	Ulcerative colitis;
CESC	cis	rs8018808	1.000	rs2193595	chr14:77845121	A/G	cg20045696	chr14:77926864	AHSA1	-0.38	-5.18	-0.3	4.32e-7	Myeloid white cell count;
CESC	cis	rs854765	0.551	rs12600546	chr17:17867614	A/G	cg09796270	chr17:17721594	SREBF1	0.45	6.17	0.35	2.61e-9	Total body bone mineral density;
CESC	cis	rs9611565	0.512	rs9611672	chr22:42209922	A/G	cg06481639	chr22:41940642	POLR3H	-0.58	-5.61	-0.33	5.08e-8	Vitiligo;
CESC	cis	rs116095464	0.558	rs10076655	chr5:239464	G/C	cg22496380	chr5:211416	CCDC127	-0.76	-8.92	-0.48	8.07e-17	Breast cancer;
CESC	cis	rs4588572	0.686	rs4352584	chr5:77682948	C/G	cg11547950	chr5:77652471	NA	0.46	5.94	0.34	8.76e-9	Triglycerides;
CESC	cis	rs9457247	0.756	rs2345572	chr6:167403441	A/T	cg23791538	chr6:167370224	RNASET2	-0.57	-8.05	-0.44	2.77e-14	Crohn's disease;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg23549086	chr19:8008681	TIMM44	-0.44	-6.03	-0.35	5.6e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs769267	1.000	rs769267	chr19:19446936	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.42	5.06	0.3	7.76e-7	Tonsillectomy;
CESC	cis	rs2806561	0.765	rs2806556	chr1:23502850	G/A	cg12483005	chr1:23474871	LUZP1	0.39	6.21	0.36	2.06e-9	Height;
CESC	cis	rs5769707	0.967	rs2187891	chr22:49994094	C/T	cg05373962	chr22:49881684	NA	-0.32	-5.25	-0.31	3.15e-7	Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs2985684	0.894	rs4900928	chr14:50020817	A/G	cg02151108	chr14:50098012	C14orf104	-0.38	-5.13	-0.3	5.64e-7	Carotid intima media thickness;
CESC	cis	rs34638657	0.789	rs2967363	chr16:82204132	C/G	cg09439754	chr16:82129088	HSD17B2	-0.38	-6.04	-0.35	5.1e-9	Lung adenocarcinoma;
CESC	cis	rs2637266	0.745	rs2583039	chr10:78440187	A/G	cg18941641	chr10:78392320	NA	0.42	7.82	0.43	1.27e-13	Pulmonary function;
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg23682824	chr7:23144976	KLHL7	-0.49	-7.43	-0.42	1.49e-12	Vertical cup-disc ratio;
CESC	cis	rs72781680	1.000	rs72798418	chr2:24188922	A/G	cg20701182	chr2:24300061	SF3B14	0.64	5.74	0.33	2.56e-8	Lymphocyte counts;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg21164723	chr1:214776304	CENPF	-0.45	-7.06	-0.4	1.48e-11	Gambling;
CESC	cis	rs962856	1.000	rs6546294	chr2:67562230	C/T	cg09028215	chr2:67624308	ETAA1	-0.4	-5.11	-0.3	6.19e-7	Pancreatic cancer;
CESC	cis	rs950169	0.922	rs12912934	chr15:85114447	C/T	cg17507749	chr15:85114479	UBE2QP1	0.54	6.11	0.35	3.61e-9	Schizophrenia;
CESC	cis	rs7552404	1.000	rs211718	chr1:76106675	C/T	cg22875332	chr1:76189707	ACADM	0.63	7.58	0.42	5.7e-13	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs4466137	0.904	rs6887104	chr5:83003535	G/A	cg16102102	chr5:83017553	HAPLN1	-0.47	-6.74	-0.38	9.88e-11	Prostate cancer;
CESC	cis	rs10479542	0.544	rs10056863	chr5:179005100	G/A	cg26516362	chr5:178986906	RUFY1	0.45	6.96	0.39	2.64e-11	Lung cancer;
CESC	cis	rs2742234	0.541	rs10793422	chr10:43703874	G/A	cg15436174	chr10:43711423	RASGEF1A	0.5	5.91	0.34	1.06e-8	Hirschsprung disease;
CESC	cis	rs4975616	0.714	rs27069	chr5:1347128	C/T	cg06550200	chr5:1325588	CLPTM1L	-0.64	-9.39	-0.5	2.83e-18	Lung cancer;
CESC	cis	rs7618915	1.000	rs34569561	chr3:52287293	T/C	cg07507251	chr3:52567010	NT5DC2	0.36	5.76	0.33	2.31e-8	Bipolar disorder;
CESC	cis	rs2797160	0.967	rs2226158	chr6:125995467	C/T	cg05901451	chr6:126070800	HEY2	-0.45	-6.39	-0.37	7.52e-10	Endometrial cancer;
CESC	cis	rs6540559	1.000	rs7522250	chr1:209962539	T/C	cg09509183	chr1:209979624	IRF6	0.48	6.04	0.35	5.18e-9	Cleft lip with or without cleft palate;
CESC	cis	rs6460942	0.908	rs73677570	chr7:12280329	T/C	cg20607287	chr7:12443886	VWDE	-0.55	-5.86	-0.34	1.38e-8	Coronary artery disease;
CESC	cis	rs1055129	0.516	rs7218498	chr17:73931847	C/G	cg02678768	chr17:74002944	EVPL	0.4	5.67	0.33	3.69e-8	White matter hyperintensity burden;
CESC	cis	rs3749237	0.595	rs1464568	chr3:49458266	G/A	cg02487422	chr3:49467188	NICN1	0.54	8.03	0.44	3.17e-14	Resting heart rate;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14788749	chr22:35937309	RASD2	0.58	6.1	0.35	3.83e-9	Gut microbiome composition (summer);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg16418258	chr15:42840397	LRRC57;HAUS2	0.44	5.99	0.35	6.66e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs3780486	0.505	rs10217267	chr9:33146528	T/C	cg04842962	chr6:43655489	MRPS18A	0.67	10.02	0.52	3.02e-20	IgG glycosylation;
CESC	cis	rs4891159	0.505	rs680253	chr18:74167427	A/C	cg24786174	chr18:74118243	ZNF516	-0.77	-13.54	-0.64	4.12e-32	Longevity;
CESC	cis	rs921968	0.565	rs2272191	chr2:219609776	G/A	cg02176678	chr2:219576539	TTLL4	-0.47	-8.3	-0.45	5.29e-15	Mean corpuscular hemoglobin concentration;
CESC	cis	rs763014	0.931	rs7191939	chr16:630089	C/T	cg07256732	chr16:621771	PIGQ	-0.3	-5.07	-0.3	7.46e-7	Height;
CESC	cis	rs796364	0.951	rs7608668	chr2:201000017	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.63	-6.3	-0.36	1.24e-9	Schizophrenia;
CESC	cis	rs1577917	0.958	rs34622605	chr6:86456519	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.53	-6.89	-0.39	4.05e-11	Response to antipsychotic treatment;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12893361	chr12:122124854	NA	0.59	6.72	0.38	1.12e-10	Gut microbiome composition (summer);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg11948421	chr20:3451504	ATRN	-0.49	-6.05	-0.35	4.92e-9	Ulcerative colitis;
CESC	cis	rs4819052	0.851	rs4819041	chr21:46659955	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.45	5.83	0.34	1.58e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs7412746	0.553	rs59337856	chr1:150746406	G/T	cg22823121	chr1:150693482	HORMAD1	0.47	6.57	0.37	2.6e-10	Melanoma;
CESC	cis	rs72945132	0.882	rs60917762	chr11:70211384	C/T	cg14191688	chr11:70257035	CTTN	0.4	5.05	0.3	8.19e-7	Coronary artery disease;
CESC	cis	rs1552244	1.000	rs17032268	chr3:10067972	C/T	cg00166722	chr3:10149974	C3orf24	0.5	6.37	0.36	8.41e-10	Alzheimer's disease;
CESC	cis	rs11711311	1.000	rs9854504	chr3:113532381	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.58	7.58	0.42	5.99e-13	IgG glycosylation;
CESC	cis	rs2463822	0.925	rs74692811	chr11:62156572	G/A	cg06239285	chr11:62104954	ASRGL1	-0.89	-8.83	-0.48	1.48e-16	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs1801251	1.000	rs35085837	chr2:233624363	A/G	cg25237894	chr2:233734115	C2orf82	0.45	7.9	0.44	7.6e-14	Coronary artery disease;
CESC	cis	rs6502050	0.871	rs62079994	chr17:80076516	T/C	cg23985595	chr17:80112537	CCDC57	0.41	6.42	0.37	6.41e-10	Life satisfaction;
CESC	cis	rs965469	0.895	rs6051843	chr20:3400538	A/G	cg25506879	chr20:3388711	C20orf194	-0.63	-6.55	-0.37	3.01e-10	IFN-related cytopenia;
CESC	cis	rs951366	0.903	rs708723	chr1:205739266	C/T	cg24503407	chr1:205819492	PM20D1	0.53	7.89	0.44	7.89e-14	Menarche (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26069066	chr20:44044698	PIGT	0.58	6.95	0.39	2.88e-11	Gut microbiome composition (summer);
CESC	cis	rs12893668	0.667	rs11844466	chr14:104066422	G/A	cg24130564	chr14:104152367	KLC1	-0.51	-6.38	-0.36	7.91e-10	Reticulocyte count;
CESC	cis	rs7666738	0.830	rs11097598	chr4:98946057	T/C	cg05340658	chr4:99064831	C4orf37	0.82	12.67	0.61	4.33e-29	Colonoscopy-negative controls vs population controls;
CESC	cis	rs172166	0.694	rs9295760	chr6:28147385	G/A	cg12963246	chr6:28129442	ZNF389	0.41	5.97	0.34	7.4e-9	Cardiac Troponin-T levels;
CESC	cis	rs2270431	1	rs2270431	chr14:75270635	T/C	cg08847533	chr14:75593920	NEK9	0.47	5.85	0.34	1.43e-8	Neuroticism;
CESC	cis	rs589448	0.872	rs315111	chr12:69784695	G/A	cg20891283	chr12:69753455	YEATS4	0.96	16.03	0.7	7.07e-41	Cerebrospinal fluid biomarker levels;
CESC	cis	rs76419734	0.510	rs12511885	chr4:106662118	G/A	cg24545054	chr4:106630052	GSTCD;INTS12	0.7	8.63	0.47	5.96e-16	Post bronchodilator FEV1;
CESC	cis	rs72781680	0.950	rs56128748	chr2:24126809	T/G	cg20701182	chr2:24300061	SF3B14	0.63	5.64	0.33	4.33e-8	Lymphocyte counts;
CESC	cis	rs67311347	1.000	rs73076035	chr3:40439881	G/C	cg24209194	chr3:40518798	ZNF619	0.5	6.13	0.35	3.09e-9	Renal cell carcinoma;
CESC	cis	rs7605378	0.528	rs281780	chr2:200756331	G/C	cg23649088	chr2:200775458	C2orf69	0.75	9.44	0.5	2.06e-18	Osteoporosis;
CESC	cis	rs1552244	1.000	rs7651058	chr3:10066964	C/T	cg00149659	chr3:10157352	C3orf10	0.73	9.0	0.48	4.43e-17	Alzheimer's disease;
CESC	cis	rs3015497	0.583	rs3783408	chr14:51000193	C/T	cg26011998	chr14:51135199	SAV1	0.51	5.78	0.33	2.05e-8	Mean platelet volume;
CESC	cis	rs34779708	0.966	rs12761675	chr10:35438337	C/T	cg03585969	chr10:35415529	CREM	-0.74	-9.67	-0.51	3.9e-19	Inflammatory bowel disease;Crohn's disease;
CESC	trans	rs877282	0.898	rs12354872	chr10:763362	G/A	cg22713356	chr15:30763199	NA	1.16	11.35	0.57	1.37e-24	Uric acid levels;
CESC	cis	rs875971	0.522	rs1617484	chr7:65463095	G/A	cg11764359	chr7:65958608	NA	0.61	7.44	0.42	1.43e-12	Aortic root size;
CESC	cis	rs17253792	0.730	rs77079997	chr14:56155250	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.71	5.39	0.31	1.58e-7	Putamen volume;
CESC	cis	rs7772486	0.686	rs9485019	chr6:146046381	C/G	cg23711669	chr6:146136114	FBXO30	-0.89	-13.24	-0.63	4.85e-31	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7772486	0.558	rs9497403	chr6:146054695	T/G	cg05347473	chr6:146136440	FBXO30	-0.7	-8.98	-0.48	5.21e-17	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs736408	0.634	rs11717836	chr3:52807736	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.48	6.52	0.37	3.51e-10	Bipolar disorder;
CESC	cis	rs9859260	0.744	rs3933	chr3:195784997	C/T	cg12923728	chr3:195709715	SDHAP1	0.5	6.59	0.38	2.39e-10	Mean corpuscular volume;
CESC	cis	rs4595586	0.563	rs11169769	chr12:39233134	C/G	cg13010199	chr12:38710504	ALG10B	0.57	7.66	0.43	3.45e-13	Morning vs. evening chronotype;
CESC	cis	rs7712401	0.601	rs154501	chr5:122211594	T/C	cg19412675	chr5:122181750	SNX24	0.41	5.06	0.3	7.77e-7	Mean platelet volume;
CESC	cis	rs28489187	0.617	rs7547571	chr1:85884091	G/T	cg16011679	chr1:85725395	C1orf52	-0.43	-5.18	-0.3	4.43e-7	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	cis	rs35079168	0.809	rs11103483	chr9:137287874	G/A	cg13941235	chr9:137270186	RXRA	-0.31	-5.66	-0.33	3.86e-8	Intelligence;
CESC	cis	rs9660180	0.935	rs2180311	chr1:1748734	T/C	cg23982607	chr1:1823379	GNB1	-0.78	-12.68	-0.61	4.08e-29	Body mass index;
CESC	cis	rs7671266	0.668	rs10007416	chr4:10159457	T/C	cg11266682	chr4:10021025	SLC2A9	-0.48	-6.0	-0.35	6.29e-9	Cardiovascular disease risk factors;
CESC	cis	rs8072100	0.688	rs7221224	chr17:45419061	T/G	cg08085267	chr17:45401833	C17orf57	0.52	6.46	0.37	4.88e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs9488822	0.676	rs12196579	chr6:116351724	G/T	cg05304507	chr6:116381966	FRK	0.26	6.59	0.38	2.37e-10	Cholesterol, total;LDL cholesterol;
CESC	cis	rs9908102	0.710	rs56317483	chr17:12904995	T/G	cg26162695	chr17:12921313	ELAC2	0.53	5.82	0.34	1.69e-8	Schizophrenia;
CESC	cis	rs4728302	0.869	rs10255193	chr7:133608911	C/G	cg10665199	chr7:133106180	EXOC4	0.4	5.56	0.32	6.69e-8	Intelligence;Intelligence (multi-trait analysis);
CESC	trans	rs60380162	0.963	rs4281305	chr1:87725937	T/G	cg20163645	chr8:1900353	ARHGEF10	-0.43	-6.03	-0.35	5.48e-9	Loneliness (linear analysis);
CESC	cis	rs2153904	0.793	rs12748961	chr1:205676263	T/C	cg23034840	chr1:205782522	SLC41A1	-0.56	-5.17	-0.3	4.59e-7	Prostate-specific antigen levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09015028	chr6:116892464	RWDD1	0.57	6.48	0.37	4.47e-10	Gut microbiome composition (summer);
CESC	cis	rs2721195	0.719	rs4925812	chr8:145808035	C/T	cg15857475	chr8:145742913	RECQL4;LRRC14	0.77	11.17	0.57	5.32e-24	Age at first birth;
CESC	trans	rs916888	0.821	rs199509	chr17:44858728	G/A	cg23590916	chr17:43697445	MGC57346	-0.61	-6.51	-0.37	3.66e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs6499255	0.951	rs8052086	chr16:69692468	A/C	cg15192750	chr16:69999425	NA	0.5	5.77	0.33	2.19e-8	IgE levels;
CESC	cis	rs909674	0.515	rs9611170	chr22:39784845	G/C	cg24399712	chr22:39784796	NA	-0.88	-12.52	-0.61	1.44e-28	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs7927592	0.912	rs55767696	chr11:68375120	C/G	cg16797656	chr11:68205561	LRP5	0.4	5.69	0.33	3.34e-8	Total body bone mineral density;
CESC	cis	rs7980687	0.657	rs10744151	chr12:123723735	G/C	cg19016782	chr12:123741754	C12orf65	-0.36	-5.31	-0.31	2.34e-7	Height;Educational attainment;Head circumference (infant);
CESC	cis	rs854765	0.583	rs4925123	chr17:17784374	A/G	cg16928487	chr17:17741425	SREBF1	0.61	10.73	0.55	1.58e-22	Total body bone mineral density;
CESC	trans	rs4950322	0.580	rs7541393	chr1:146588768	C/T	cg04954894	chr8:38089920	DDHD2	-0.59	-6.43	-0.37	5.98e-10	Protein quantitative trait loci;
CESC	cis	rs1559088	1.000	rs1974783	chr19:33551507	C/G	cg17764715	chr19:33622953	WDR88	0.45	5.68	0.33	3.6e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg10844818	chr11:60609393	CCDC86	0.43	6.09	0.35	3.98e-9	Systemic lupus erythematosus;
CESC	cis	rs4862750	0.872	rs7679956	chr4:187900229	C/T	cg11301795	chr4:187892539	NA	-0.81	-14.54	-0.67	1.34e-35	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7412746	0.658	rs12097963	chr1:150870450	T/C	cg22823121	chr1:150693482	HORMAD1	0.4	5.68	0.33	3.61e-8	Melanoma;
CESC	cis	rs7959452	0.557	rs899224	chr12:69784774	A/G	cg14784868	chr12:69753453	YEATS4	0.84	13.21	0.63	6.15e-31	Blood protein levels;
CESC	cis	rs12188164	0.543	rs2434694	chr5:462734	C/T	cg16584290	chr5:462447	EXOC3	0.47	7.09	0.4	1.19e-11	Cystic fibrosis severity;
CESC	cis	rs4718428	0.705	rs62465692	chr7:66295745	T/C	cg12165864	chr7:66369176	NA	-0.64	-7.21	-0.4	5.96e-12	Corneal structure;
CESC	cis	rs9911578	1.000	rs1057068	chr17:56598439	T/C	cg12560992	chr17:57184187	TRIM37	-0.92	-15.35	-0.69	1.7e-38	Intelligence (multi-trait analysis);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg07664667	chr16:778351	HAGHL	-0.41	-6.16	-0.35	2.67e-9	Gambling;
CESC	cis	rs5750830	0.649	rs5757664	chr22:39821536	A/G	cg11247378	chr22:39784982	NA	-0.66	-9.78	-0.51	1.76e-19	Intelligence (multi-trait analysis);
CESC	cis	rs9487051	0.676	rs6929438	chr6:109595506	C/T	cg12927641	chr6:109611667	NA	-0.37	-5.5	-0.32	9.03e-8	Reticulocyte fraction of red cells;
CESC	cis	rs4523957	0.855	rs12601834	chr17:2112431	C/T	cg16513277	chr17:2031491	SMG6	-0.65	-9.02	-0.48	4.04e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	trans	rs2207136	0.868	rs7769860	chr6:50831567	C/T	cg06522515	chr3:184090630	THPO	-0.38	-6.63	-0.38	1.9e-10	Myopia;
CESC	trans	rs208520	0.690	rs7764570	chr6:66827600	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.85	-11.22	-0.57	3.54e-24	Exhaled nitric oxide output;
CESC	cis	rs8060686	0.623	rs28700885	chr16:68154544	A/G	cg26727032	chr16:67993705	SLC12A4	-0.58	-8.16	-0.45	1.34e-14	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs6963495	0.818	rs56251768	chr7:105165591	A/G	cg02135003	chr7:105160482	PUS7	-0.47	-5.59	-0.33	5.51e-8	Bipolar disorder (body mass index interaction);
CESC	cis	rs7618915	0.571	rs33964154	chr3:52596914	A/G	cg18337363	chr3:52569053	NT5DC2	0.29	5.12	0.3	5.79e-7	Bipolar disorder;
CESC	cis	rs1046896	0.552	rs12602280	chr17:80805421	G/C	cg05255149	chr17:80675120	FN3KRP	0.46	5.05	0.3	8.13e-7	Glycated hemoglobin levels;
CESC	cis	rs2651899	0.902	rs1624023	chr1:3079337	C/T	cg07622451	chr1:3079886	PRDM16	0.31	5.57	0.32	6.33e-8	Migraine;
CESC	cis	rs1707322	1.000	rs10890353	chr1:46298383	G/T	cg06784218	chr1:46089804	CCDC17	0.32	5.47	0.32	1.04e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9902453	0.817	rs2729435	chr17:28121532	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.66	-8.47	-0.46	1.74e-15	Coffee consumption (cups per day);
CESC	cis	rs34172651	0.917	rs11640931	chr16:24797919	A/G	cg06028605	chr16:24865363	SLC5A11	0.35	5.43	0.32	1.25e-7	Intelligence (multi-trait analysis);
CESC	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.59	-7.75	-0.43	2.02e-13	Prudent dietary pattern;
CESC	cis	rs2180341	0.920	rs7756880	chr6:127683999	A/T	cg24812749	chr6:127587940	RNF146	1.05	15.07	0.68	1.77e-37	Breast cancer;
CESC	cis	rs2952156	0.920	rs2517954	chr17:37843550	T/C	cg07936489	chr17:37558343	FBXL20	-0.52	-6.23	-0.36	1.79e-9	Asthma;
CESC	cis	rs7666738	0.716	rs11721453	chr4:99045485	G/T	cg24818145	chr4:99064322	C4orf37	0.38	5.04	0.3	8.49e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11792861	0.816	rs7021366	chr9:111727670	C/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.53	6.66	0.38	1.55e-10	Menarche (age at onset);
CESC	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg11494091	chr17:61959527	GH2	0.73	12.39	0.61	4.19e-28	Prudent dietary pattern;
CESC	cis	rs7998202	0.667	rs282583	chr13:113349642	G/T	cg02820901	chr13:113351484	ATP11A	0.63	5.96	0.34	7.8e-9	Glycated hemoglobin levels;
CESC	cis	rs2479106	0.656	rs10117940	chr9:126469730	A/G	cg16191174	chr9:126692580	DENND1A	0.42	5.3	0.31	2.41e-7	Polycystic ovary syndrome;
CESC	cis	rs854765	0.618	rs8068820	chr17:17834119	A/G	cg04398451	chr17:18023971	MYO15A	-0.67	-9.61	-0.51	6.01e-19	Total body bone mineral density;
CESC	cis	rs7216064	1.000	rs2128792	chr17:65857177	C/T	cg12091567	chr17:66097778	LOC651250	-0.85	-8.7	-0.47	3.54e-16	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs7927771	0.965	rs34958982	chr11:47547046	T/C	cg20135002	chr11:47629003	NA	-0.4	-5.1	-0.3	6.41e-7	Subjective well-being;
CESC	cis	rs8103278	0.507	rs10401971	chr19:46261982	C/T	cg11657440	chr19:46296263	DMWD	0.77	11.86	0.59	2.54e-26	Coronary artery disease;
CESC	cis	rs710216	0.843	rs710214	chr1:43439282	C/T	cg03128534	chr1:43423976	SLC2A1	0.49	5.46	0.32	1.12e-7	Red cell distribution width;
CESC	cis	rs9323205	0.862	rs11629399	chr14:51612814	T/C	cg23942311	chr14:51606299	NA	-0.45	-5.75	-0.33	2.5e-8	Cancer;
CESC	cis	rs7811142	0.830	rs7792959	chr7:99972403	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.93	10.32	0.54	3.22e-21	Platelet count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00400810	chr15:42066822	MAPKBP1	0.65	7.27	0.41	4.09e-12	Gut microbiome composition (summer);
CESC	cis	rs11792861	0.816	rs3818932	chr9:111664178	T/C	cg05043794	chr9:111880884	C9orf5	-0.37	-6.19	-0.36	2.33e-9	Menarche (age at onset);
CESC	cis	rs782590	0.902	rs782602	chr2:55849309	A/G	cg18811423	chr2:55921094	PNPT1	0.76	11.71	0.58	8.62e-26	Metabolic syndrome;
CESC	cis	rs10131894	0.611	rs174995	chr14:75434183	T/C	cg08847533	chr14:75593920	NEK9	-0.75	-11.77	-0.59	5.43e-26	Coronary artery disease;
CESC	cis	rs3858526	0.523	rs10742818	chr11:5882535	T/C	cg02574844	chr11:5959923	NA	-0.48	-6.97	-0.39	2.49e-11	DNA methylation (variation);
CESC	trans	rs2727020	0.521	rs2088526	chr11:49531968	G/A	cg03929089	chr4:120376271	NA	0.69	7.89	0.44	8.11e-14	Coronary artery disease;
CESC	cis	rs72945132	0.769	rs680571	chr11:70187441	G/A	cg14191688	chr11:70257035	CTTN	0.43	5.51	0.32	8.64e-8	Coronary artery disease;
CESC	cis	rs11696501	0.688	rs11696685	chr20:44295134	A/G	cg11783356	chr20:44313418	WFDC10B	-0.34	-5.19	-0.3	4.2e-7	Brain structure;
CESC	cis	rs4662945	0.603	rs10496678	chr2:130262209	C/T	cg05903289	chr2:130345205	NA	-0.42	-6.21	-0.36	2.03e-9	Response to cytidine analogues (gemcitabine);
CESC	cis	rs5758659	0.714	rs7245	chr22:42481849	G/A	cg05082376	chr22:42548792	NA	0.36	5.17	0.3	4.67e-7	Cognitive function;
CESC	cis	rs11626933	1.000	rs45463097	chr14:90744188	G/A	cg14092571	chr14:90743983	NA	-0.98	-15.22	-0.68	5.3e-38	Gut microbiota (bacterial taxa);
CESC	cis	rs6867032	1.000	rs7729761	chr5:2015783	G/T	cg26168224	chr5:2018326	NA	0.96	19.64	0.77	1.3e-53	Gut microbiome composition (winter);
CESC	cis	rs1862618	0.802	rs7733041	chr5:56107377	A/C	cg24549020	chr5:56110836	MAP3K1	0.59	6.73	0.38	1.06e-10	Initial pursuit acceleration;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg11306783	chr4:25314649	ZCCHC4	0.45	6.17	0.35	2.52e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs35110281	0.805	rs3788062	chr21:44991159	C/T	cg01579765	chr21:45077557	HSF2BP	-0.58	-10.06	-0.53	2.19e-20	Mean corpuscular volume;
CESC	cis	rs1943345	0.556	rs523414	chr11:82910666	C/G	cg07047830	chr11:82868014	PCF11	0.41	5.11	0.3	6.13e-7	Obesity-related traits;
CESC	cis	rs4588572	0.688	rs2362829	chr5:77724036	T/A	cg11547950	chr5:77652471	NA	-0.4	-5.47	-0.32	1.03e-7	Triglycerides;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25713684	chr10:105127687	TAF5	-0.56	-6.19	-0.36	2.25e-9	Gut microbiome composition (summer);
CESC	trans	rs3960554	0.696	rs10952869	chr7:75846453	A/G	cg19862616	chr7:65841803	NCRNA00174	0.58	7.13	0.4	9.31e-12	Eotaxin levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20866375	chr17:3572559	TAX1BP3;TMEM93	0.59	6.53	0.37	3.41e-10	Gut microbiome composition (summer);
CESC	cis	rs11608355	0.515	rs7136048	chr12:109903926	A/G	cg05360138	chr12:110035743	NA	0.82	8.92	0.48	7.93e-17	Neuroticism;
CESC	cis	rs7666738	0.830	rs4699589	chr4:98973889	A/G	cg03676636	chr4:99064102	C4orf37	0.34	5.2	0.3	3.93e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7520050	0.931	rs6686134	chr1:46378268	A/G	cg24296786	chr1:45957014	TESK2	0.44	5.58	0.32	5.79e-8	Red blood cell count;Reticulocyte count;
CESC	cis	rs77106637	1.000	rs3862791	chr11:72501002	C/T	cg04827223	chr11:72435913	ARAP1	-0.56	-5.77	-0.33	2.16e-8	Type 2 diabetes;
CESC	cis	rs9682041	0.736	rs34237232	chr3:170063753	C/T	cg11886554	chr3:170076028	SKIL	-0.88	-7.67	-0.43	3.24e-13	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CESC	cis	rs763014	0.932	rs2384974	chr16:651279	C/G	cg07256732	chr16:621771	PIGQ	-0.29	-5.09	-0.3	6.74e-7	Height;
CESC	cis	rs68170813	0.559	rs76020313	chr7:106877468	A/G	cg02696742	chr7:106810147	HBP1	-0.52	-5.08	-0.3	7.2e-7	Coronary artery disease;
CESC	cis	rs55871839	0.640	rs4738734	chr8:59814330	A/T	cg07426533	chr8:59803705	TOX	-0.48	-7.07	-0.4	1.41e-11	Pneumonia;
CESC	cis	rs113835537	0.529	rs7950790	chr11:66258053	G/A	cg24851651	chr11:66362959	CCS	0.44	5.46	0.32	1.09e-7	Airway imaging phenotypes;
CESC	cis	rs1355223	1.000	rs1355223	chr11:34764479	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.47	-6.1	-0.35	3.8e-9	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs7264396	0.635	rs6119672	chr20:34479767	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.59	7.17	0.4	7.61e-12	Total cholesterol levels;
CESC	cis	rs10214930	0.697	rs757397	chr7:27908541	T/C	cg05786569	chr7:27702416	HIBADH	0.44	5.23	0.31	3.39e-7	Hypospadias;
CESC	cis	rs35110281	0.837	rs2838341	chr21:45076443	A/G	cg01579765	chr21:45077557	HSF2BP	-0.57	-9.74	-0.51	2.34e-19	Mean corpuscular volume;
CESC	cis	rs897984	0.609	rs72800847	chr16:31022639	G/A	cg02466173	chr16:30829666	NA	-0.48	-7.62	-0.42	4.4e-13	Dementia with Lewy bodies;
CESC	cis	rs854765	0.693	rs35451946	chr17:17764061	C/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.5	-6.75	-0.38	9.22e-11	Total body bone mineral density;
CESC	cis	rs1475911	1.000	rs55645900	chr21:43515728	G/T	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.43	-6.17	-0.35	2.58e-9	IgG glycosylation;
CESC	cis	rs79349575	0.783	rs55771415	chr17:46999937	C/T	cg16584676	chr17:46985605	UBE2Z	0.54	6.7	0.38	1.24e-10	Type 2 diabetes;
CESC	cis	rs6674176	0.597	rs2352990	chr1:44393276	T/A	cg12908607	chr1:44402522	ARTN	-0.5	-7.24	-0.41	4.84e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg03188948	chr7:1209495	NA	0.72	6.98	0.39	2.42e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24616553	chr3:113557638	GRAMD1C	0.57	6.51	0.37	3.67e-10	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.830	rs13102652	chr4:99006737	T/G	cg03467027	chr4:99064603	C4orf37	0.44	5.51	0.32	8.65e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6545883	0.929	rs7606167	chr2:61742654	C/G	cg15711740	chr2:61764176	XPO1	-0.44	-5.4	-0.31	1.47e-7	Tuberculosis;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg14158690	chr7:151826540	NA	0.5	6.23	0.36	1.82e-9	Fibrinogen levels;
CESC	trans	rs10435719	0.871	rs7815186	chr8:11792062	C/G	cg15556689	chr8:8085844	FLJ10661	0.52	6.39	0.37	7.33e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
CESC	cis	rs734999	0.545	rs28532547	chr1:2561286	T/G	cg20673091	chr1:2541236	MMEL1	-0.48	-8.01	-0.44	3.71e-14	Ulcerative colitis;
CESC	cis	rs11229555	1.000	rs2275993	chr11:58379987	A/G	cg15696309	chr11:58395628	NA	-0.43	-5.64	-0.33	4.3e-8	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs10791097	0.702	rs10894267	chr11:130714861	C/T	cg12179176	chr11:130786555	SNX19	-0.56	-7.84	-0.43	1.09e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs4665809	0.887	rs4665814	chr2:26273687	G/T	cg08470875	chr2:26401718	FAM59B	-0.48	-5.24	-0.31	3.31e-7	Gut microbiome composition (summer);
CESC	cis	rs7100689	0.784	rs2153455	chr10:82139732	T/C	cg00277334	chr10:82204260	NA	-0.59	-7.5	-0.42	9.95e-13	Post bronchodilator FEV1;
CESC	cis	rs9300255	0.510	rs1790086	chr12:123672518	A/G	cg19016782	chr12:123741754	C12orf65	-0.42	-5.9	-0.34	1.09e-8	Neutrophil percentage of white cells;
CESC	cis	rs763121	0.853	rs2064088	chr22:39053382	A/G	cg21395723	chr22:39101663	GTPBP1	0.43	5.39	0.31	1.54e-7	Menopause (age at onset);
CESC	cis	rs7666738	0.830	rs13144564	chr4:98939276	A/G	cg03467027	chr4:99064603	C4orf37	0.48	5.91	0.34	1.03e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7520050	0.807	rs6671802	chr1:46124663	A/G	cg03146154	chr1:46216737	IPP	0.52	6.88	0.39	4.27e-11	Red blood cell count;Reticulocyte count;
CESC	cis	rs1348850	0.574	rs2365617	chr2:178421934	C/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.63	5.51	0.32	8.52e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs9527	0.590	rs2274339	chr10:104860053	T/A	cg04362960	chr10:104952993	NT5C2	0.42	5.22	0.31	3.55e-7	Arsenic metabolism;
CESC	cis	rs7551222	0.752	rs10793767	chr1:204549564	A/C	cg20240347	chr1:204465584	NA	-0.3	-5.98	-0.34	7.15e-9	Schizophrenia;
CESC	cis	rs7542091	0.648	rs688464	chr1:209992539	C/T	cg21951975	chr1:209979733	IRF6	-0.51	-8.62	-0.47	6.06e-16	Monobrow;
CESC	cis	rs13191362	0.507	rs13207363	chr6:163201285	C/G	cg21926612	chr6:163149169	PACRG;PARK2	-0.52	-6.14	-0.35	3.02e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs2929278	0.589	rs2411284	chr15:44038899	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.49	-7.81	-0.43	1.33e-13	Schizophrenia;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg20034209	chr17:66287369	ARSG;SLC16A6	-0.48	-7.09	-0.4	1.2e-11	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs1832871	0.644	rs56180963	chr6:158773990	G/A	cg07165851	chr6:158734300	TULP4	0.59	6.34	0.36	1.01e-9	Height;
CESC	cis	rs798554	0.600	rs2679259	chr7:2885322	C/G	cg13628971	chr7:2884303	GNA12	0.46	6.23	0.36	1.87e-9	Height;
CESC	cis	rs7618915	1.000	rs3852064	chr3:52349412	G/T	cg14092988	chr3:52407081	DNAH1	0.43	5.5	0.32	9.09e-8	Bipolar disorder;
CESC	cis	rs6570726	0.818	rs9390338	chr6:145908265	A/G	cg23711669	chr6:146136114	FBXO30	0.92	13.58	0.64	3.16e-32	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs801193	1.000	rs13239306	chr7:66136017	T/G	cg14393609	chr7:65229607	NA	-0.44	-5.76	-0.33	2.34e-8	Aortic root size;
CESC	cis	rs3796352	1.000	rs13072395	chr3:52980573	T/C	cg12962167	chr3:53033115	SFMBT1	0.67	5.28	0.31	2.73e-7	Immune reponse to smallpox (secreted IL-2);
CESC	cis	rs6032067	0.852	rs17424751	chr20:43814622	T/C	cg10761708	chr20:43804764	PI3	0.53	6.38	0.36	7.98e-10	Blood protein levels;
CESC	cis	rs16854884	0.657	rs16854816	chr3:143734147	A/G	cg06585982	chr3:143692056	C3orf58	0.5	6.56	0.37	2.84e-10	Economic and political preferences (feminism/equality);
CESC	cis	rs8177179	0.904	rs1130459	chr3:133465283	A/G	cg18769074	chr3:133464867	TF	0.3	5.75	0.33	2.42e-8	Iron status biomarkers (transferrin levels);
CESC	cis	rs1355223	0.902	rs286858	chr11:34717357	T/C	cg11058730	chr11:34937778	PDHX;APIP	0.49	6.73	0.38	1.03e-10	Systemic lupus erythematosus and Systemic sclerosis;
CESC	trans	rs7726839	0.561	rs72703044	chr5:579737	G/A	cg25482853	chr8:67687455	SGK3	0.88	9.47	0.5	1.62e-18	Obesity-related traits;
CESC	cis	rs9302635	0.550	rs35959677	chr16:72200801	G/T	cg01557791	chr16:72042693	DHODH	-0.62	-6.97	-0.39	2.5e-11	Blood protein levels;
CESC	cis	rs11098499	0.821	rs10032151	chr4:120391628	C/T	cg09307838	chr4:120376055	NA	0.94	13.94	0.65	1.68e-33	Corneal astigmatism;
CESC	trans	rs1814175	0.645	rs28627251	chr11:50048125	G/T	cg03929089	chr4:120376271	NA	-0.92	-15.22	-0.68	5.15e-38	Height;
CESC	cis	rs7552404	0.696	rs10518521	chr1:76461214	G/A	cg03433033	chr1:76189801	ACADM	0.61	5.69	0.33	3.32e-8	Blood metabolite levels;Acylcarnitine levels;
CESC	trans	rs55704346	0.566	rs9654100	chr4:25397695	G/T	cg01822600	chr1:245751692	KIF26B	0.44	6.28	0.36	1.37e-9	Tonsillectomy;
CESC	trans	rs9858542	0.953	rs1987628	chr3:49399259	G/A	cg21659725	chr3:3221576	CRBN	-0.55	-6.53	-0.37	3.38e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs35306767	0.903	rs11813210	chr10:919796	G/A	cg20503657	chr10:835505	NA	0.78	7.74	0.43	2.08e-13	Eosinophil percentage of granulocytes;
CESC	cis	rs60843830	1.000	rs55936726	chr2:258210	T/C	cg00108164	chr2:264199	ACP1;SH3YL1	0.8	10.28	0.53	4.45e-21	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs8070128	0.688	rs59304093	chr17:17875407	A/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.6	7.71	0.43	2.59e-13	Total body bone mineral density;
CESC	cis	rs28489187	0.629	rs2012683	chr1:85841485	C/T	cg16011679	chr1:85725395	C1orf52	0.48	5.7	0.33	3.21e-8	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24035898	chr1:159825595	VSIG8;C1orf204	-0.59	-6.94	-0.39	3.06e-11	Gut microbiome composition (summer);
CESC	cis	rs3892630	0.878	rs8108621	chr19:33183291	G/A	cg13157960	chr19:33183277	NUDT19	0.57	5.61	0.33	5.17e-8	Red blood cell traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19816667	chr12:49741715	DNAJC22	0.57	6.33	0.36	1.06e-9	Gut microbiome composition (summer);
CESC	cis	rs3857067	0.806	rs4560373	chr4:95113229	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.6	-9.12	-0.49	1.97e-17	QT interval;
CESC	cis	rs933688	1.000	rs35712350	chr5:90679519	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.13	14.91	0.68	6.31e-37	Smoking behavior;
CESC	cis	rs68170813	0.641	rs61511581	chr7:106948091	T/A	cg02696742	chr7:106810147	HBP1	-0.53	-5.19	-0.3	4.22e-7	Coronary artery disease;
CESC	cis	rs9291683	0.588	rs3756236	chr4:10013463	T/A	cg11266682	chr4:10021025	SLC2A9	0.72	14.87	0.67	8.7e-37	Bone mineral density;
CESC	cis	rs6502050	0.835	rs8081783	chr17:80117388	G/A	cg23985595	chr17:80112537	CCDC57	-0.41	-6.47	-0.37	4.81e-10	Life satisfaction;
CESC	cis	rs7746199	0.736	rs6904596	chr6:27491299	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.7	-5.03	-0.3	9.12e-7	Gait speed in old age;Autism spectrum disorder or schizophrenia;
CESC	cis	rs6860806	0.695	rs6867282	chr5:131583120	G/C	cg24060327	chr5:131705240	SLC22A5	-0.41	-5.11	-0.3	6.13e-7	Breast cancer;
CESC	cis	rs6460942	1.000	rs7792759	chr7:12311715	A/G	cg02935154	chr7:12443704	VWDE	0.49	5.06	0.3	7.96e-7	Coronary artery disease;
CESC	cis	rs2033711	0.840	rs3764533	chr19:58929194	A/G	cg13877915	chr19:58951672	ZNF132	0.39	5.7	0.33	3.16e-8	Uric acid clearance;
CESC	cis	rs17021463	0.872	rs34181160	chr4:95275157	T/G	cg11021082	chr4:95130006	SMARCAD1	0.53	7.71	0.43	2.53e-13	Testicular germ cell tumor;
CESC	cis	rs10504229	1.000	rs58947041	chr8:58188934	G/A	cg24829409	chr8:58192753	C8orf71	-0.76	-9.93	-0.52	5.87e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs8141529	0.719	rs5762825	chr22:29223642	A/G	cg15103426	chr22:29168792	CCDC117	0.68	9.65	0.51	4.52e-19	Lymphocyte counts;
CESC	cis	rs12579753	0.879	rs11115009	chr12:82165409	G/T	cg21193143	chr12:82153300	PPFIA2	0.34	5.07	0.3	7.44e-7	Resting heart rate;
CESC	cis	rs7208859	0.673	rs423151	chr17:28952286	A/G	cg14008862	chr17:28927542	LRRC37B2	0.71	6.45	0.37	5.31e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs6570726	0.764	rs9386125	chr6:145911677	C/T	cg05347473	chr6:146136440	FBXO30	0.57	7.44	0.42	1.37e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs10504229	0.683	rs55714371	chr8:58131846	T/G	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg17208363	chr15:41851964	TYRO3	0.49	6.52	0.37	3.48e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs7727544	0.716	rs7720230	chr5:131592405	T/G	cg14196790	chr5:131705035	SLC22A5	0.37	5.49	0.32	9.54e-8	Blood metabolite levels;
CESC	cis	rs1949733	0.543	rs62287446	chr4:8535988	G/A	cg11789530	chr4:8429930	ACOX3	-0.53	-7.09	-0.4	1.23e-11	Response to antineoplastic agents;
CESC	cis	rs3096299	0.900	rs4785666	chr16:89462771	C/G	cg08392591	chr16:89556376	ANKRD11	0.41	5.28	0.31	2.68e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs2933343	0.621	rs789242	chr3:128585707	T/C	cg25356066	chr3:128598488	ACAD9	0.56	7.83	0.43	1.15e-13	IgG glycosylation;
CESC	trans	rs66573146	1.000	rs6838042	chr4:6973049	G/T	cg07817883	chr1:32538562	TMEM39B	1.13	7.72	0.43	2.38e-13	Granulocyte percentage of myeloid white cells;
CESC	cis	rs9596863	1.000	rs9568948	chr13:54437693	A/C	ch.13.53330881F	chr13:54432880	NA	0.62	5.09	0.3	6.83e-7	Epilepsy and lamotrigine-induced maculopapular eruptions;
CESC	cis	rs10088262	0.629	rs6990565	chr8:124785645	C/A	cg15047889	chr8:124780837	FAM91A1	-0.49	-6.0	-0.35	6.35e-9	Pancreatic cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18160291	chr1:210502147	HHAT	0.55	6.11	0.35	3.52e-9	Gut microbiome composition (summer);
CESC	cis	rs9287719	0.967	rs963831	chr2:10745184	T/C	cg00105475	chr2:10696890	NA	0.38	5.55	0.32	6.76e-8	Prostate cancer;
CESC	cis	rs34638657	0.702	rs62044258	chr16:82199461	C/T	cg09439754	chr16:82129088	HSD17B2	-0.37	-6.42	-0.37	6.31e-10	Lung adenocarcinoma;
CESC	cis	rs3749237	0.636	rs1568662	chr3:49521263	A/G	cg02487422	chr3:49467188	NICN1	0.57	8.3	0.45	5.33e-15	Resting heart rate;
CESC	cis	rs4665809	1.000	rs6750681	chr2:26329677	C/T	cg22920501	chr2:26401640	FAM59B	-0.65	-7.85	-0.43	1.06e-13	Gut microbiome composition (summer);
CESC	cis	rs4713118	0.513	rs149951	chr6:28033087	T/C	cg17221315	chr6:27791827	HIST1H4J	0.42	5.4	0.32	1.46e-7	Parkinson's disease;
CESC	cis	rs60871478	0.635	rs4311567	chr7:792295	T/C	cg05535760	chr7:792225	HEATR2	0.98	11.15	0.57	6.25e-24	Cerebrospinal P-tau181p levels;
CESC	cis	rs4975709	0.589	rs4975707	chr5:1864028	C/T	cg15595755	chr5:1867978	NA	0.52	8.67	0.47	4.37e-16	Cardiovascular disease risk factors;
CESC	cis	rs858239	0.570	rs6968242	chr7:23167411	T/G	cg23682824	chr7:23144976	KLHL7	0.55	7.73	0.43	2.27e-13	Cerebrospinal fluid biomarker levels;
CESC	cis	rs4803468	0.935	rs284660	chr19:41932084	G/T	cg14132834	chr19:41945861	ATP5SL	-0.59	-7.26	-0.41	4.34e-12	Height;
CESC	cis	rs2033711	0.870	rs3764534	chr19:58929136	G/A	cg11952622	chr19:58962976	ZNF324B	0.46	6.13	0.35	3.11e-9	Uric acid clearance;
CESC	cis	rs11853189	0.938	rs77185764	chr15:78556076	G/A	cg05392364	chr15:78556860	DNAJA4	0.64	5.15	0.3	5e-7	Red cell distribution width;
CESC	cis	rs6570726	0.846	rs870491	chr6:145933390	T/G	cg23711669	chr6:146136114	FBXO30	0.87	12.93	0.62	5.52e-30	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs8038465	0.874	rs2291013	chr15:74000506	T/G	cg15420318	chr15:73925796	NPTN	0.4	5.64	0.33	4.32e-8	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs896854	0.684	rs10099059	chr8:95986972	G/C	cg09323728	chr8:95962352	TP53INP1	-0.4	-8.97	-0.48	5.42e-17	Type 2 diabetes;
CESC	cis	rs17666538	0.585	rs6559063	chr8:623051	C/T	cg02524346	chr8:600233	NA	0.84	5.69	0.33	3.35e-8	IgG glycosylation;
CESC	cis	rs6547741	1.000	rs1972669	chr2:27767107	T/G	cg27432699	chr2:27873401	GPN1	0.49	6.94	0.39	2.93e-11	Oral cavity cancer;
CESC	cis	rs1046896	0.586	rs9897951	chr17:80810662	T/C	cg02711726	chr17:80685570	FN3KRP	-0.44	-5.85	-0.34	1.47e-8	Glycated hemoglobin levels;
CESC	cis	rs9733	0.596	rs6685702	chr1:150656307	A/G	cg09365446	chr1:150670422	GOLPH3L	0.42	5.9	0.34	1.09e-8	Tonsillectomy;
CESC	cis	rs2050392	1.000	rs2050392	chr10:30691503	G/A	cg18806716	chr10:30721971	MAP3K8	-0.39	-5.54	-0.32	7.17e-8	Inflammatory bowel disease;
CESC	trans	rs3942852	0.545	rs10838798	chr11:48091303	T/G	cg15704280	chr7:45808275	SEPT13	-0.73	-9.53	-0.51	1.06e-18	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs1707322	0.686	rs11211179	chr1:46228082	A/C	cg03146154	chr1:46216737	IPP	0.74	10.62	0.55	3.46e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs8031584	0.560	rs7171208	chr15:31198929	A/G	cg08704250	chr15:31115839	NA	0.63	8.88	0.48	1.02e-16	Huntington's disease progression;
CESC	cis	rs10791097	0.642	rs7107568	chr11:130779668	T/C	cg14779329	chr11:130786720	SNX19	0.41	6.42	0.37	6.3e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs2303759	0.881	rs10412811	chr19:49884495	G/A	cg22590775	chr19:49891494	CCDC155	0.59	6.79	0.38	7.4e-11	Multiple sclerosis;
CESC	cis	rs1005277	0.557	rs2983338	chr10:38550734	C/T	cg25427524	chr10:38739819	LOC399744	-0.72	-10.62	-0.55	3.51e-22	Extrinsic epigenetic age acceleration;
CESC	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg15112475	chr7:1198522	ZFAND2A	-0.39	-6.12	-0.35	3.4e-9	Longevity;Endometriosis;
CESC	cis	rs2243480	1.000	rs316325	chr7:65609518	G/A	cg12463550	chr7:65579703	CRCP	0.75	5.84	0.34	1.56e-8	Diabetic kidney disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01174859	chr7:128379317	CALU	0.72	8.73	0.47	2.99e-16	Gut microbiome composition (summer);
CESC	cis	rs2294693	0.945	rs742494	chr6:41007835	A/T	cg14769373	chr6:40998127	UNC5CL	-0.45	-5.72	-0.33	2.87e-8	Gastric cancer;Non-cardia gastric cancer;
CESC	trans	rs2727020	0.688	rs2734002	chr11:49234162	A/G	cg15704280	chr7:45808275	SEPT13	0.84	13.51	0.64	5.34e-32	Coronary artery disease;
CESC	cis	rs9318086	0.578	rs75752641	chr13:24473240	A/G	cg25267304	chr13:24462978	PCOTH;MIPEP	0.44	6.31	0.36	1.19e-9	Myopia (pathological);
CESC	cis	rs854765	0.647	rs712267	chr17:18021607	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.59	8.05	0.44	2.73e-14	Total body bone mineral density;
CESC	cis	rs4332037	0.508	rs56758848	chr7:1868727	A/G	cg13880726	chr7:1868755	MAD1L1	-0.52	-5.17	-0.3	4.67e-7	Bipolar disorder;
CESC	trans	rs1973993	0.691	rs6658131	chr1:96889314	C/T	cg10631902	chr5:14652156	NA	0.63	9.9	0.52	7.12e-20	Weight;
CESC	trans	rs7246760	1.000	rs73507215	chr19:9887312	C/T	cg02900749	chr2:68251473	NA	-0.82	-7.08	-0.4	1.33e-11	Pursuit maintenance gain;
CESC	cis	rs4077515	0.839	rs1132005	chr9:139296927	T/C	cg14169450	chr9:139327907	INPP5E	0.36	5.07	0.3	7.55e-7	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs2075371	0.863	rs1421479	chr7:133949345	T/G	cg00033643	chr7:134001901	SLC35B4	0.4	5.14	0.3	5.46e-7	Mean platelet volume;
CESC	cis	rs1799949	1.000	rs11651341	chr17:41428061	T/C	cg25072359	chr17:41440525	NA	0.48	6.54	0.37	3.13e-10	Menopause (age at onset);
CESC	cis	rs10206020	0.797	rs72778008	chr2:1573182	T/G	cg12573674	chr2:1569213	NA	-0.48	-5.48	-0.32	9.85e-8	IgG glycosylation;
CESC	cis	rs1799949	0.896	rs35908185	chr17:41255111	A/T	cg05368731	chr17:41323189	NBR1	0.79	11.18	0.57	4.95e-24	Menopause (age at onset);
CESC	cis	rs10504229	1.000	rs66796009	chr8:58174529	G/A	cg14926445	chr8:58193284	C8orf71	-0.51	-5.47	-0.32	1.03e-7	Developmental language disorder (linguistic errors);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05048922	chr8:6565434	AGPAT5	0.5	6.33	0.36	1.03e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs1707322	0.752	rs11211147	chr1:46110094	A/G	cg05343316	chr1:45956843	TESK2	0.5	6.18	0.35	2.46e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs3091242	0.809	rs660129	chr1:25727438	C/T	cg12412775	chr1:25698385	RHCE	-0.32	-5.72	-0.33	2.92e-8	Erythrocyte sedimentation rate;
CESC	cis	rs7095944	0.614	rs10901818	chr10:126449428	G/A	cg08799069	chr10:126477246	METTL10	-0.35	-5.15	-0.3	5.19e-7	Asthma;
CESC	cis	rs10464366	0.746	rs12674262	chr7:39141728	G/T	cg18850127	chr7:39170497	POU6F2	0.37	5.09	0.3	6.76e-7	IgG glycosylation;
CESC	cis	rs863345	0.967	rs11265025	chr1:158513286	T/G	cg12129480	chr1:158549410	OR10X1	-0.32	-6.45	-0.37	5.4e-10	Pneumococcal bacteremia;
CESC	cis	rs7216064	0.589	rs8072723	chr17:66056970	T/A	cg12091567	chr17:66097778	LOC651250	0.92	12.28	0.6	9.74e-28	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg15716185	chr18:60190644	ZCCHC2	0.46	6.11	0.35	3.53e-9	Systemic lupus erythematosus;
CESC	cis	rs9399137	0.507	rs4580893	chr6:135297662	G/A	cg24558204	chr6:135376177	HBS1L	0.7	9.61	0.51	5.93e-19	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg22884899	chr17:6939299	SLC16A13	0.51	6.52	0.37	3.64e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs796364	0.806	rs10931889	chr2:201101900	G/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.78	-6.59	-0.38	2.33e-10	Schizophrenia;
CESC	cis	rs6502050	0.835	rs67682841	chr17:80117745	T/C	cg11859384	chr17:80120422	CCDC57	-0.38	-5.18	-0.3	4.43e-7	Life satisfaction;
CESC	trans	rs7824557	0.527	rs2572369	chr8:11238597	C/T	cg15556689	chr8:8085844	FLJ10661	-0.49	-6.17	-0.35	2.53e-9	Retinal vascular caliber;
CESC	trans	rs3087243	0.755	rs3116514	chr2:204694784	G/A	cg01841312	chr10:38069945	NA	0.38	6.33	0.36	1.03e-9	Rheumatoid arthritis;Hypothyroidism;Type 1 diabetes;
CESC	cis	rs8017423	0.607	rs12885664	chr14:90845697	T/C	cg14092571	chr14:90743983	NA	0.46	6.65	0.38	1.69e-10	Mortality in heart failure;
CESC	cis	rs7618501	0.699	rs2777888	chr3:49898000	A/G	cg24110177	chr3:50126178	RBM5	-0.45	-6.04	-0.35	5.06e-9	Intelligence (multi-trait analysis);
CESC	cis	rs2832191	0.755	rs2832192	chr21:30491173	G/T	cg08807101	chr21:30365312	RNF160	-0.67	-8.87	-0.48	1.12e-16	Dental caries;
CESC	cis	rs6541297	1.000	rs6658942	chr1:230287517	A/C	cg20703242	chr1:230279135	GALNT2	0.72	11.05	0.56	1.31e-23	Coronary artery disease;
CESC	cis	rs7208859	0.623	rs3752021	chr17:29111043	G/C	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.17e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg21144587	chr2:27851409	GPN1;CCDC121	-0.36	-6.23	-0.36	1.78e-9	Gambling;
CESC	cis	rs7927592	0.763	rs11822059	chr11:68300822	T/G	cg20283391	chr11:68216788	NA	-0.41	-5.15	-0.3	5.18e-7	Total body bone mineral density;
CESC	cis	rs5750830	0.649	rs5757663	chr22:39821319	T/C	cg02038168	chr22:39784481	NA	-0.62	-7.71	-0.43	2.46e-13	Intelligence (multi-trait analysis);
CESC	cis	rs2857078	0.654	rs4793083	chr17:42312973	C/T	cg08499158	chr17:42289980	UBTF	0.45	5.48	0.32	9.98e-8	Red cell distribution width;Reticulocyte count;
CESC	trans	rs1728785	1.000	rs1645979	chr16:68603660	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.7	8.22	0.45	9.15e-15	Ulcerative colitis;
CESC	cis	rs2836950	0.565	rs2836931	chr21:40546569	T/G	cg11644478	chr21:40555479	PSMG1	-0.57	-7.9	-0.44	7.71e-14	Menarche (age at onset);
CESC	cis	rs6835098	0.961	rs1574314	chr4:174106663	C/T	cg08422745	chr4:174089978	GALNT7	-0.72	-9.42	-0.5	2.4e-18	Dementia and core Alzheimer's disease neuropathologic changes;
CESC	cis	rs7666738	0.830	rs3846443	chr4:99032666	G/A	cg03676636	chr4:99064102	C4orf37	0.34	5.14	0.3	5.32e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22122680	chr1:220219742	EPRS	0.67	7.73	0.43	2.3e-13	Gut microbiome composition (summer);
CESC	cis	rs1008375	0.966	rs2010053	chr4:17583806	A/C	cg16339924	chr4:17578868	LAP3	0.75	9.76	0.51	2.05e-19	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs8060686	0.545	rs7199878	chr16:68186301	A/G	cg26727032	chr16:67993705	SLC12A4	-0.5	-5.45	-0.32	1.16e-7	HDL cholesterol;Metabolic syndrome;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg05896465	chr22:45560692	NUP50	-0.5	-6.6	-0.38	2.19e-10	Height;
CESC	cis	rs9309473	1.000	rs9309473	chr2:73743982	A/G	cg20560298	chr2:73613845	ALMS1	-0.53	-6.9	-0.39	3.82e-11	Metabolite levels;
CESC	cis	rs4727963	0.846	rs12670195	chr7:122712925	T/G	cg03640110	chr7:122635026	TAS2R16	0.38	5.87	0.34	1.28e-8	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
CESC	cis	rs477895	0.713	rs12575642	chr11:63979643	G/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.76	7.92	0.44	6.53e-14	Mean platelet volume;
CESC	cis	rs6460942	1.000	rs77010200	chr7:12290724	G/A	cg02935154	chr7:12443704	VWDE	-0.59	-5.79	-0.34	1.96e-8	Coronary artery disease;
CESC	cis	rs807669	0.807	rs807431	chr22:19242361	G/A	cg02655711	chr22:19163373	SLC25A1	0.54	8.02	0.44	3.48e-14	Metabolite levels;
CESC	cis	rs2576037	0.583	rs478820	chr18:44397782	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.78	12.9	0.62	7.29e-30	Personality dimensions;
CESC	cis	rs4253772	0.550	rs6007779	chr22:46678615	A/C	cg09491104	chr22:46646882	C22orf40	-0.59	-8.78	-0.47	2e-16	LDL cholesterol;Cholesterol, total;
CESC	trans	rs916888	0.821	rs199505	chr17:44859410	A/G	cg10053473	chr17:62856997	LRRC37A3	0.67	7.42	0.41	1.61e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs4862750	0.872	rs9997374	chr4:187877549	T/A	cg03647317	chr4:187891568	NA	-0.41	-5.91	-0.34	1.02e-8	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1008375	1.000	rs7654345	chr4:17691796	A/G	cg02297831	chr4:17616191	MED28	0.5	5.95	0.34	8.38e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs4819052	0.851	rs4819046	chr21:46664955	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.48	5.97	0.34	7.58e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs7940866	0.845	rs10894294	chr11:130830748	G/T	cg12179176	chr11:130786555	SNX19	0.59	8.03	0.44	3.21e-14	Schizophrenia;
CESC	cis	rs4835473	0.864	rs2089837	chr4:144886191	G/A	cg25736465	chr4:144833511	NA	0.41	6.25	0.36	1.64e-9	Immature fraction of reticulocytes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24834479	chr5:133702818	CDKL3	0.58	6.11	0.35	3.58e-9	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.791	rs7684521	chr4:99071219	A/G	cg18180107	chr4:99064573	C4orf37	0.4	5.03	0.3	9.07e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6860806	0.631	rs7736284	chr5:131588151	T/C	cg18301423	chr5:131593218	PDLIM4	0.37	5.36	0.31	1.78e-7	Breast cancer;
CESC	cis	rs1348850	0.914	rs6710575	chr2:178377311	C/T	cg23306229	chr2:178417860	TTC30B	0.63	7.8	0.43	1.41e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs10242455	0.867	rs2404770	chr7:99321612	A/G	cg07715041	chr7:99302981	CYP3A7	-0.43	-5.42	-0.32	1.36e-7	Blood metabolite levels;
CESC	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	13.67	0.64	1.44e-32	Prudent dietary pattern;
CESC	cis	rs1862618	0.671	rs2591957	chr5:56243146	A/T	cg12311346	chr5:56204834	C5orf35	0.64	8.64	0.47	5.57e-16	Initial pursuit acceleration;
CESC	cis	rs1799949	1.000	rs34059614	chr17:41303071	C/T	cg25072359	chr17:41440525	NA	0.46	6.1	0.35	3.77e-9	Menopause (age at onset);
CESC	cis	rs2952156	0.920	rs12940986	chr17:37836581	A/G	cg20243544	chr17:37824526	PNMT	-0.61	-8.21	-0.45	1.01e-14	Asthma;
CESC	cis	rs2228479	0.850	rs11644804	chr16:89976224	G/A	cg06558623	chr16:89946397	TCF25	0.79	6.96	0.39	2.68e-11	Skin colour saturation;
CESC	trans	rs12542260	0.817	rs117952028	chr8:125471390	C/A	cg09438698	chr12:133365205	GOLGA3	-0.51	-6.56	-0.37	2.75e-10	Colonoscopy-negative controls vs population controls;
CESC	cis	rs5758659	0.714	rs5751220	chr22:42516205	A/C	cg00645731	chr22:42541494	CYP2D7P1	0.33	5.62	0.33	4.75e-8	Cognitive function;
CESC	cis	rs4812048	1.000	rs6070696	chr20:57597645	A/G	cg14073986	chr20:57617431	SLMO2	0.61	5.94	0.34	8.75e-9	Mean platelet volume;
CESC	cis	rs7267979	0.966	rs8123949	chr20:25388133	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.87	-18.03	-0.74	5.81e-48	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs11098499	0.954	rs4345162	chr4:120312959	G/A	cg09307838	chr4:120376055	NA	0.92	12.66	0.61	4.96e-29	Corneal astigmatism;
CESC	cis	rs4664308	0.618	rs3749117	chr2:160885442	T/C	cg03641300	chr2:160917029	PLA2R1	-0.54	-7.62	-0.42	4.63e-13	Idiopathic membranous nephropathy;
CESC	cis	rs1862618	0.853	rs832584	chr5:56179212	A/G	cg03609598	chr5:56110824	MAP3K1	0.49	5.17	0.3	4.71e-7	Initial pursuit acceleration;
CESC	cis	rs7617480	0.648	rs6796790	chr3:48780317	G/A	cg06212747	chr3:49208901	KLHDC8B	0.48	5.91	0.34	1.05e-8	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CESC	cis	rs7811142	1.000	rs73161759	chr7:100009994	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.15	11.52	0.58	3.59e-25	Platelet count;
CESC	trans	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg13565492	chr6:43139072	SRF	-0.75	-9.1	-0.49	2.18e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs3820068	0.603	rs6696286	chr1:15968770	C/T	cg17385448	chr1:15911702	AGMAT	0.42	6.82	0.39	6.1e-11	Systolic blood pressure;
CESC	cis	rs123509	0.913	rs339661	chr3:42753904	G/A	cg12982090	chr3:42733453	KBTBD5	0.72	8.9	0.48	9.29e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs4664304	0.772	rs6737904	chr2:160872526	G/C	cg03641300	chr2:160917029	PLA2R1	-0.5	-7.01	-0.4	1.97e-11	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs2836974	0.932	rs2836955	chr21:40619887	G/A	cg11890956	chr21:40555474	PSMG1	1.11	17.84	0.74	2.65e-47	Cognitive function;
CESC	cis	rs10089	1.000	rs10089	chr5:127522543	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.76	9.53	0.51	1.07e-18	Ileal carcinoids;
CESC	cis	rs3106136	0.527	rs10030586	chr4:95150805	A/C	cg11021082	chr4:95130006	SMARCAD1	-0.7	-11.56	-0.58	2.74e-25	Capecitabine sensitivity;
CESC	cis	rs317689	0.690	rs618470	chr12:69672060	A/G	cg20891283	chr12:69753455	YEATS4	0.48	5.19	0.3	4.16e-7	Response to diuretic therapy;
CESC	cis	rs9911578	1.000	rs6503870	chr17:56659018	C/T	cg12560992	chr17:57184187	TRIM37	0.93	15.48	0.69	6.05e-39	Intelligence (multi-trait analysis);
CESC	cis	rs898097	0.690	rs12452304	chr17:80811659	G/A	cg05255149	chr17:80675120	FN3KRP	-0.45	-5.27	-0.31	2.78e-7	Breast cancer;
CESC	cis	rs4891159	0.548	rs690082	chr18:74116668	C/T	cg24786174	chr18:74118243	ZNF516	0.85	16.07	0.7	4.75e-41	Longevity;
CESC	cis	rs9326248	0.530	rs2155583	chr11:116915217	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.6	5.43	0.32	1.28e-7	Blood protein levels;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg05142592	chr10:135097800	TUBGCP2	-0.42	-7.43	-0.42	1.51e-12	Gambling;
CESC	cis	rs9863	0.827	rs12823740	chr12:124458002	C/A	cg00084347	chr12:124393913	DNAH10	0.27	5.13	0.3	5.59e-7	White blood cell count;
CESC	cis	rs7660520	0.524	rs6839881	chr4:183729137	A/T	cg09197432	chr4:183729176	NA	0.58	6.17	0.35	2.54e-9	Pediatric autoimmune diseases;
CESC	cis	rs853679	0.569	rs9348798	chr6:28143011	G/A	cg22143856	chr6:28129313	ZNF389	0.46	5.84	0.34	1.56e-8	Depression;
CESC	cis	rs9611565	0.729	rs137831	chr22:41903813	A/C	cg17376030	chr22:41985996	PMM1	0.49	5.83	0.34	1.58e-8	Vitiligo;
CESC	cis	rs4835473	0.864	rs2323418	chr4:144890294	C/T	cg25736465	chr4:144833511	NA	0.41	6.25	0.36	1.66e-9	Immature fraction of reticulocytes;
CESC	cis	rs7824557	0.767	rs1897951	chr8:11169854	C/T	cg21775007	chr8:11205619	TDH	0.47	6.95	0.39	2.85e-11	Retinal vascular caliber;
CESC	cis	rs3126085	0.935	rs10888468	chr1:152181539	C/T	cg03465714	chr1:152285911	FLG	-0.43	-5.16	-0.3	4.81e-7	Atopic dermatitis;
CESC	cis	rs11696845	0.666	rs13042905	chr20:43379454	T/C	cg25301532	chr20:43378953	KCNK15	0.38	6.08	0.35	4.26e-9	Obesity-related traits;
CESC	cis	rs67311347	1.000	rs7648952	chr3:40457038	C/T	cg24209194	chr3:40518798	ZNF619	-0.43	-5.71	-0.33	3.04e-8	Renal cell carcinoma;
CESC	cis	rs8040855	0.627	rs3816105	chr15:85640911	G/A	cg08123816	chr15:85640762	PDE8A	-0.41	-6.16	-0.35	2.7e-9	Bulimia nervosa;
CESC	cis	rs1552244	1.000	rs28684871	chr3:10072635	C/A	cg00166722	chr3:10149974	C3orf24	0.49	6.27	0.36	1.44e-9	Alzheimer's disease;
CESC	cis	rs7511006	0.893	rs2038049	chr22:50654888	G/C	cg07895657	chr22:50616420	PANX2	-0.37	-5.62	-0.33	4.76e-8	Obesity-related traits;
CESC	cis	rs920590	0.684	rs3899017	chr8:19669198	A/T	cg01411142	chr8:19674711	INTS10	0.56	6.19	0.36	2.27e-9	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs1005277	0.579	rs1548255	chr10:38417193	T/C	cg25427524	chr10:38739819	LOC399744	-0.69	-10.0	-0.52	3.4e-20	Extrinsic epigenetic age acceleration;
CESC	cis	rs4474465	0.688	rs7940507	chr11:78284453	T/C	cg27205649	chr11:78285834	NARS2	0.51	6.91	0.39	3.54e-11	Alzheimer's disease (survival time);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg20762182	chr15:69727293	KIF23	0.52	7.2	0.4	6.03e-12	Fibrinogen levels;
CESC	cis	rs9660992	0.573	rs12140422	chr1:205187981	G/A	cg21643547	chr1:205240462	TMCC2	-0.39	-5.56	-0.32	6.46e-8	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs17711722	0.727	rs35850374	chr7:65357776	A/G	cg26939375	chr7:64535504	NA	0.76	10.87	0.56	5.31e-23	Calcium levels;
CESC	cis	rs9303280	0.806	rs36038753	chr17:38035370	G/T	cg19468946	chr17:37922297	IKZF3	-0.41	-5.42	-0.32	1.31e-7	Self-reported allergy;
CESC	trans	rs17808461	1.000	rs1468197	chr17:31372945	C/T	cg01914314	chr5:157117640	NA	0.51	6.22	0.36	1.98e-9	Obesity-related traits;
CESC	cis	rs1552244	1.000	rs55882090	chr3:10139082	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	12.72	0.62	2.88e-29	Alzheimer's disease;
CESC	cis	rs1348850	0.539	rs1453371	chr2:178227862	T/G	cg22681709	chr2:178499509	PDE11A	-0.37	-5.36	-0.31	1.79e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs10823500	0.549	rs10999204	chr10:72007306	G/A	cg02100629	chr10:71892760	AIFM2	-0.32	-5.32	-0.31	2.23e-7	Blood protein levels;
CESC	cis	rs4665809	0.590	rs4665318	chr2:26424517	C/T	cg25036284	chr2:26402008	FAM59B	0.79	8.65	0.47	5e-16	Gut microbiome composition (summer);
CESC	cis	rs6032067	0.929	rs17333555	chr20:43809761	C/T	cg10761708	chr20:43804764	PI3	0.52	6.27	0.36	1.45e-9	Blood protein levels;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg21192376	chr14:53020168	GPR137C;TXNDC16	0.49	6.33	0.36	1.05e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs76419734	0.510	rs2553461	chr4:106731410	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	-0.62	-6.36	-0.36	8.88e-10	Post bronchodilator FEV1;
CESC	cis	rs12912251	1.000	rs12903120	chr15:38988097	G/T	cg01338139	chr15:38987640	C15orf53	-0.47	-5.43	-0.32	1.26e-7	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
CESC	trans	rs9987353	0.840	rs329994	chr8:9123233	A/G	cg21454386	chr13:114292018	TFDP1	0.47	6.0	0.35	6.34e-9	Recombination measurement;
CESC	trans	rs2733310	0.739	rs72747165	chr15:57147334	G/A	cg13494055	chr3:59115467	NA	-0.43	-5.99	-0.35	6.64e-9	Mean platelet volume;
CESC	cis	rs780096	0.526	rs7602534	chr2:27592423	C/T	cg21248554	chr2:27665150	KRTCAP3	-0.35	-7.22	-0.41	5.62e-12	Total body bone mineral density;
CESC	cis	rs2842992	0.830	rs1535475	chr6:160148935	T/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.74	9.33	0.5	4.52e-18	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs12711979	0.509	rs13035992	chr2:3826597	G/A	cg17052675	chr2:3827356	NA	-0.67	-11.26	-0.57	2.77e-24	Itch intensity from mosquito bite adjusted by bite size;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg21701354	chr7:129592850	UBE2H	-0.45	-6.16	-0.35	2.7e-9	Ulcerative colitis;
CESC	cis	rs4665809	0.878	rs4143538	chr2:26290178	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.82	-9.06	-0.49	2.95e-17	Gut microbiome composition (summer);
CESC	cis	rs2933343	0.621	rs789249	chr3:128578453	T/C	cg25356066	chr3:128598488	ACAD9	0.6	8.53	0.46	1.17e-15	IgG glycosylation;
CESC	cis	rs9487051	0.872	rs1111864	chr6:109611138	A/G	cg21918786	chr6:109611834	NA	-0.4	-5.99	-0.35	6.87e-9	Reticulocyte fraction of red cells;
CESC	cis	rs11153306	0.765	rs7740180	chr6:111944538	G/A	cg22127309	chr6:111907043	TRAF3IP2	-0.4	-6.09	-0.35	3.87e-9	Tonsillectomy;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg00920043	chr1:11333412	UBIAD1	-0.44	-6.72	-0.38	1.14e-10	Gambling;
CESC	cis	rs6582630	0.638	rs12231073	chr12:38526901	T/G	cg26384229	chr12:38710491	ALG10B	-0.42	-5.59	-0.32	5.66e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs3213545	0.659	rs2259690	chr12:121457914	T/G	cg15155738	chr12:121454335	C12orf43	0.5	6.07	0.35	4.35e-9	Subjective well-being;Cardiovascular disease risk factors;
CESC	cis	rs17711722	0.701	rs4467826	chr7:65368708	A/G	cg18876405	chr7:65276391	NA	0.69	9.67	0.51	3.96e-19	Calcium levels;
CESC	cis	rs7020830	0.830	rs13296413	chr9:37258105	C/T	cg14294708	chr9:37120828	ZCCHC7	1.2	22.49	0.81	2.13e-63	Schizophrenia;
CESC	cis	rs7223966	1.000	rs15637	chr17:61772050	C/G	cg11494091	chr17:61959527	GH2	0.38	5.42	0.32	1.33e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs2952156	0.920	rs732083	chr17:37834367	G/A	cg00129232	chr17:37814104	STARD3	-0.77	-11.37	-0.57	1.13e-24	Asthma;
CESC	cis	rs7786808	0.707	rs62479983	chr7:158227613	G/A	cg01191920	chr7:158217561	PTPRN2	-0.44	-7.74	-0.43	2.13e-13	Obesity-related traits;
CESC	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg11494091	chr17:61959527	GH2	0.73	12.66	0.61	4.86e-29	Prudent dietary pattern;
CESC	cis	rs7666738	0.830	rs11947027	chr4:99005941	T/C	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.62e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6728642	0.901	rs7584641	chr2:97607655	A/T	cg26665480	chr2:98280029	ACTR1B	-0.53	-5.38	-0.31	1.66e-7	Bipolar disorder lithium response (continuous) or schizophrenia;
CESC	cis	rs12477438	0.748	rs7558239	chr2:99640581	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.75	-10.87	-0.56	5.17e-23	Chronic sinus infection;
CESC	cis	rs425277	0.539	rs3128337	chr1:2045882	A/G	cg24578937	chr1:2090814	PRKCZ	-0.35	-6.01	-0.35	5.96e-9	Height;
CESC	cis	rs7084402	0.967	rs1427224	chr10:60290620	G/A	cg07615347	chr10:60278583	BICC1	0.6	9.41	0.5	2.54e-18	Refractive error;
CESC	cis	rs79349575	0.783	rs55771415	chr17:46999937	C/T	cg26022315	chr17:47021804	SNF8	0.39	5.18	0.3	4.5e-7	Type 2 diabetes;
CESC	cis	rs7666738	0.893	rs11729640	chr4:99052699	C/T	cg18180107	chr4:99064573	C4orf37	0.41	5.29	0.31	2.51e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3733585	0.781	rs6449183	chr4:9970691	C/A	cg02734326	chr4:10020555	SLC2A9	-0.46	-6.74	-0.38	9.94e-11	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs6912958	0.712	rs7772561	chr6:88331299	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.5	-6.76	-0.38	8.85e-11	Monocyte percentage of white cells;
CESC	cis	rs2243480	1.000	rs6964530	chr7:65718851	G/C	cg13147721	chr7:65941812	NA	0.94	8.82	0.48	1.55e-16	Diabetic kidney disease;
CESC	cis	rs10979	1.000	rs6570566	chr6:143899534	G/A	cg25407410	chr6:143891975	LOC285740	-0.61	-9.03	-0.48	3.7e-17	Hypospadias;
CESC	cis	rs6912958	0.703	rs6903219	chr6:88096498	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.46	7.69	0.43	2.8e-13	Monocyte percentage of white cells;
CESC	cis	rs9902453	0.765	rs62068653	chr17:28212663	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	8.58	0.47	8.08e-16	Coffee consumption (cups per day);
CESC	cis	rs34311866	0.808	rs11248060	chr4:964359	C/T	cg07828340	chr4:882639	GAK	0.86	6.95	0.39	2.9e-11	Parkinson's disease;
CESC	cis	rs2235642	0.893	rs2076445	chr16:1592266	A/T	cg08296037	chr16:1584118	IFT140;TMEM204	-0.34	-5.56	-0.32	6.55e-8	Coronary artery disease;
CESC	cis	rs7666738	0.716	rs13108535	chr4:99046324	A/G	cg24818145	chr4:99064322	C4orf37	0.38	5.04	0.3	8.49e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10818894	0.571	rs4838069	chr9:126316511	C/T	cg16191174	chr9:126692580	DENND1A	0.5	5.71	0.33	3e-8	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
CESC	cis	rs9649213	0.593	rs13246725	chr7:97914898	C/G	cg00277769	chr7:97922759	BAIAP2L1	-0.35	-5.74	-0.33	2.55e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs4665809	1.000	rs11126375	chr2:26344787	G/A	cg25036284	chr2:26402008	FAM59B	-0.59	-6.88	-0.39	4.37e-11	Gut microbiome composition (summer);
CESC	trans	rs4129059	0.765	rs58247568	chr1:214711855	G/A	cg08821431	chr12:34491090	NA	0.55	6.16	0.35	2.75e-9	Age-related hearing impairment (SNP x SNP interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00060500	chr3:197476529	KIAA0226;FYTTD1	0.52	6.04	0.35	5.2e-9	Gut microbiome composition (summer);
CESC	cis	rs4588572	0.686	rs4703756	chr5:77683490	T/C	cg11547950	chr5:77652471	NA	0.46	5.94	0.34	8.76e-9	Triglycerides;
CESC	cis	rs858239	0.601	rs929508	chr7:23166709	C/A	cg23682824	chr7:23144976	KLHL7	0.54	7.61	0.42	4.95e-13	Cerebrospinal fluid biomarker levels;
CESC	cis	rs3793683	0.545	rs12784446	chr10:134589094	T/G	cg27297192	chr10:134578999	INPP5A	0.4	5.42	0.32	1.34e-7	Migraine;
CESC	cis	rs17125944	0.686	rs73304351	chr14:53375140	G/A	cg00686598	chr14:53173677	PSMC6	0.97	7.16	0.4	8.16e-12	Alzheimer's disease (late onset);
CESC	cis	rs16937	0.711	rs12142514	chr1:205122529	A/G	cg00857998	chr1:205179979	DSTYK	0.4	5.23	0.31	3.43e-7	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03252697	chr11:65623186	CFL1	-0.6	-6.96	-0.39	2.73e-11	Gut microbiome composition (summer);
CESC	trans	rs7307889	1.000	rs73052336	chr12:5982664	G/T	cg18407955	chr7:158110685	PTPRN2	-0.72	-6.02	-0.35	5.71e-9	Obesity-related traits;
CESC	cis	rs13382862	0.895	rs2289082	chr2:20881958	A/T	cg05481257	chr2:20870211	GDF7	0.37	6.18	0.35	2.4e-9	Abdominal aortic aneurysm;
CESC	cis	rs10024216	0.559	rs115820155	chr4:38772730	G/T	cg02016764	chr4:38805732	TLR1	-0.33	-5.16	-0.3	4.93e-7	Systemic sclerosis (anti-topoisomerase-positive);
CESC	cis	rs7666738	0.830	rs7672127	chr4:98938477	A/G	cg05340658	chr4:99064831	C4orf37	0.83	12.56	0.61	1.05e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6502050	0.835	rs8065981	chr17:80091393	G/T	cg01763666	chr17:80159506	CCDC57	-0.37	-5.1	-0.3	6.55e-7	Life satisfaction;
CESC	cis	rs12048904	0.930	rs11166529	chr1:101333733	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.58	7.55	0.42	6.82e-13	Multiple sclerosis;
CESC	trans	rs1373453	0.808	rs17106957	chr12:70075022	A/G	cg19702771	chr4:82058885	PRKG2	0.76	6.08	0.35	4.2e-9	Orofacial clefts;
CESC	cis	rs1348850	0.750	rs13031008	chr2:178477114	G/A	cg22681709	chr2:178499509	PDE11A	-0.42	-6.27	-0.36	1.43e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs763014	0.931	rs2071981	chr16:630025	C/G	cg07343612	chr16:622815	PIGQ	-0.58	-8.49	-0.46	1.53e-15	Height;
CESC	cis	rs7607369	0.536	rs7566656	chr2:219664519	A/G	cg02176678	chr2:219576539	TTLL4	-0.36	-6.39	-0.37	7.24e-10	Red blood cell count;Amyotrophic lateral sclerosis;
CESC	cis	rs9815354	0.812	rs73073352	chr3:41842184	T/C	cg03022575	chr3:42003672	ULK4	0.7	6.04	0.35	5.26e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs10189230	0.967	rs13026380	chr2:222352715	G/A	cg14652038	chr2:222343519	EPHA4	0.37	7.76	0.43	1.85e-13	Urate levels in lean individuals;
CESC	cis	rs17711722	0.740	rs7809991	chr7:65406218	A/G	cg05332525	chr7:65337924	VKORC1L1	0.51	6.38	0.36	7.81e-10	Calcium levels;
CESC	cis	rs826838	0.967	rs73096706	chr12:38860563	G/A	cg13010199	chr12:38710504	ALG10B	0.6	8.39	0.46	2.99e-15	Heart rate;
CESC	cis	rs4689388	0.853	rs6817447	chr4:6286847	G/T	cg14416269	chr4:6271139	WFS1	0.48	8.2	0.45	1.02e-14	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs853679	0.517	rs9380050	chr6:28048538	A/G	cg08968635	chr6:28129556	ZNF389	0.39	5.22	0.31	3.64e-7	Depression;
CESC	cis	rs3785574	0.962	rs2727324	chr17:61922102	G/C	cg06873352	chr17:61820015	STRADA	0.45	6.73	0.38	1.04e-10	Height;
CESC	cis	rs9926296	0.744	rs154657	chr16:89708096	A/G	cg03605463	chr16:89740564	NA	-0.64	-7.84	-0.43	1.09e-13	Vitiligo;
CESC	trans	rs3784262	0.669	rs12909423	chr15:58292433	C/G	cg20199333	chr11:46740790	F2	0.38	6.11	0.35	3.55e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
CESC	cis	rs7216064	0.953	rs10445361	chr17:65962238	G/T	cg12091567	chr17:66097778	LOC651250	0.73	8.0	0.44	3.87e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs3820928	0.874	rs4423583	chr2:227874957	A/G	cg05526886	chr2:227700861	RHBDD1	0.44	5.47	0.32	1.05e-7	Pulmonary function;
CESC	cis	rs875971	1.000	rs2220626	chr7:65546062	C/T	cg10691866	chr7:65817282	TPST1	0.33	5.16	0.3	4.76e-7	Aortic root size;
CESC	cis	rs9902453	0.817	rs17226179	chr17:28168573	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	8.45	0.46	2.01e-15	Coffee consumption (cups per day);
CESC	trans	rs916888	0.610	rs199444	chr17:44818276	T/C	cg22433210	chr17:43662623	NA	0.62	8.06	0.44	2.71e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs4237845	0.537	rs7312623	chr12:58262523	G/T	cg00677455	chr12:58241039	CTDSP2	0.78	10.45	0.54	1.24e-21	Intelligence (multi-trait analysis);
CESC	cis	rs8002861	0.905	rs11617551	chr13:44443977	T/C	cg19180546	chr13:44453867	C13orf31;CCDC122	-0.42	-5.36	-0.31	1.79e-7	Leprosy;
CESC	cis	rs9875589	0.957	rs13077668	chr3:13929756	A/G	cg19554555	chr3:13937349	NA	-0.54	-7.19	-0.4	6.82e-12	Ovarian reserve;
CESC	trans	rs945270	0.512	rs868199	chr14:56195994	A/T	cg18102697	chr4:83542773	C4orf11	-0.43	-6.55	-0.37	3.06e-10	Subcortical brain region volumes;
CESC	cis	rs1799949	1.000	rs35070007	chr17:41316747	C/G	cg23758822	chr17:41437982	NA	-1.02	-17.62	-0.73	1.65e-46	Menopause (age at onset);
CESC	cis	rs7917772	0.508	rs2252147	chr10:104467774	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.51	5.78	0.33	2.1e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs60154123	0.505	rs7540237	chr1:210053325	C/T	cg23283495	chr1:209979779	IRF6	0.52	5.52	0.32	8.02e-8	Coronary artery disease;
CESC	cis	rs11958404	0.932	rs111802867	chr5:157424971	G/A	cg05962755	chr5:157440814	NA	0.6	6.38	0.36	8e-10	IgG glycosylation;
CESC	cis	rs477692	0.905	rs563859	chr10:131417586	T/C	cg05714579	chr10:131428358	MGMT	0.54	7.64	0.42	4.09e-13	Response to temozolomide;
CESC	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.6	6.83	0.39	5.8200000000000003e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2066819	0.892	rs77415512	chr12:56627300	A/G	cg26734620	chr12:56694298	CS	1.04	6.26	0.36	1.51e-9	Psoriasis vulgaris;
CESC	cis	rs2777491	0.957	rs7163788	chr15:41704789	A/G	cg02330683	chr15:41787940	ITPKA	0.48	7.12	0.4	1.02e-11	Ulcerative colitis;
CESC	cis	rs3096299	0.967	rs28644774	chr16:89472181	G/C	cg02187348	chr16:89574699	SPG7	0.52	7.0	0.39	2.14e-11	Multiple myeloma (IgH translocation);
CESC	cis	rs8020095	0.571	rs6573734	chr14:67366929	A/T	cg19548862	chr14:67692701	FAM71D	-0.48	-5.76	-0.33	2.34e-8	Depression (quantitative trait);
CESC	cis	rs2839186	0.709	rs2839176	chr21:47678173	A/G	cg11766577	chr21:47581405	C21orf56	-0.48	-6.5	-0.37	3.99e-10	Testicular germ cell tumor;
CESC	cis	rs9926296	0.609	rs4785710	chr16:89796756	C/T	cg27121462	chr16:89883253	FANCA	-0.63	-8.01	-0.44	3.7e-14	Vitiligo;
CESC	cis	rs6732160	0.932	rs768851	chr2:73378241	G/A	cg01422370	chr2:73384389	NA	0.5	8.59	0.47	7.75e-16	Intelligence (multi-trait analysis);
CESC	trans	rs2727020	0.567	rs1164687	chr11:49290669	G/A	cg15704280	chr7:45808275	SEPT13	0.8	11.17	0.57	5.5e-24	Coronary artery disease;
CESC	cis	rs769267	0.965	rs2269873	chr19:19392401	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.43	5.33	0.31	2.11e-7	Tonsillectomy;
CESC	trans	rs561341	0.882	rs563539	chr17:30307958	A/G	cg27661571	chr11:113659931	NA	-0.69	-7.04	-0.4	1.6e-11	Hip circumference adjusted for BMI;
CESC	cis	rs561341	0.941	rs72825736	chr17:30330286	G/A	cg00745463	chr17:30367425	LRRC37B	-0.83	-7.54	-0.42	7.69e-13	Hip circumference adjusted for BMI;
CESC	cis	rs116095464	0.558	rs7714335	chr5:263513	T/C	cg22496380	chr5:211416	CCDC127	-0.74	-7.84	-0.43	1.1e-13	Breast cancer;
CESC	cis	rs3796352	1.000	rs59583591	chr3:53119581	T/C	cg26060971	chr3:52407402	DNAH1	-0.44	-5.15	-0.3	4.99e-7	Immune reponse to smallpox (secreted IL-2);
CESC	cis	rs9790314	0.875	rs7615592	chr3:160981548	A/C	cg04691961	chr3:161091175	C3orf57	-0.41	-5.22	-0.31	3.65e-7	Morning vs. evening chronotype;
CESC	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	10.43	0.54	1.5e-21	Prudent dietary pattern;
CESC	cis	rs9487051	0.752	rs9372209	chr6:109601684	T/C	cg21918786	chr6:109611834	NA	-0.37	-5.39	-0.31	1.55e-7	Reticulocyte fraction of red cells;
CESC	cis	rs2839186	0.708	rs17183123	chr21:47671961	G/C	cg13012494	chr21:47604986	C21orf56	0.5	6.78	0.38	7.7e-11	Testicular germ cell tumor;
CESC	trans	rs916888	0.821	rs199512	chr17:44857352	T/C	cg22433210	chr17:43662623	NA	-0.91	-10.81	-0.55	8.16e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs9487051	0.872	rs9374079	chr6:109609619	A/G	cg21918786	chr6:109611834	NA	-0.4	-6.01	-0.35	6.17e-9	Reticulocyte fraction of red cells;
CESC	cis	rs4820539	1.000	rs2267003	chr22:23457098	A/G	cg14186256	chr22:23484241	RTDR1	0.82	14.3	0.66	9.35e-35	Bone mineral density;
CESC	cis	rs2991971	1.000	rs667626	chr1:46020551	T/C	cg06784218	chr1:46089804	CCDC17	-0.3	-5.11	-0.3	6.3e-7	High light scatter reticulocyte count;
CESC	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.55	-6.13	-0.35	3.19e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs8014204	0.781	rs10143492	chr14:75212114	G/C	cg08847533	chr14:75593920	NEK9	0.42	5.34	0.31	2.02e-7	Caffeine consumption;
CESC	cis	rs9902453	0.817	rs9909128	chr17:28161482	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.78	10.19	0.53	8.43e-21	Coffee consumption (cups per day);
CESC	cis	rs8114671	0.562	rs8117491	chr20:33510120	T/C	cg07148914	chr20:33460835	GGT7	0.52	6.8	0.39	6.88e-11	Height;
CESC	cis	rs6912958	1.000	rs13214153	chr6:88153983	G/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.32	-5.16	-0.3	4.87e-7	Monocyte percentage of white cells;
CESC	cis	rs896854	0.684	rs2340534	chr8:95992330	G/A	cg23172400	chr8:95962367	TP53INP1	-0.42	-8.57	-0.47	8.93e-16	Type 2 diabetes;
CESC	cis	rs9858542	0.953	rs9878943	chr3:49434654	G/A	cg07274523	chr3:49395745	GPX1	0.68	8.44	0.46	2.17e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs1799949	0.896	rs35908185	chr17:41255111	A/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.67	9.44	0.5	2.01e-18	Menopause (age at onset);
CESC	cis	rs2576037	0.526	rs4890707	chr18:44497724	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.72	11.54	0.58	3.09e-25	Personality dimensions;
CESC	cis	rs12497850	0.931	rs6446196	chr3:49004723	A/G	cg02487422	chr3:49467188	NICN1	0.46	5.81	0.34	1.82e-8	Parkinson's disease;
CESC	trans	rs7107217	1.000	rs1873872	chr11:129473993	A/T	cg08265551	chr1:151032119	CDC42SE1;MLLT11	0.45	6.32	0.36	1.08e-9	Breast cancer;Type 2 diabetes;
CESC	cis	rs1862618	0.853	rs252902	chr5:56116085	A/G	cg18230493	chr5:56204884	C5orf35	-0.68	-8.18	-0.45	1.2e-14	Initial pursuit acceleration;
CESC	cis	rs6963495	0.745	rs68153235	chr7:105184832	A/C	cg19920283	chr7:105172520	RINT1	0.72	8.19	0.45	1.1e-14	Bipolar disorder (body mass index interaction);
CESC	cis	rs13382862	0.823	rs12710743	chr2:20880714	T/C	cg10553204	chr2:20871195	GDF7	-0.37	-5.2	-0.3	4.04e-7	Abdominal aortic aneurysm;
CESC	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg18402987	chr7:1209562	NA	0.77	7.88	0.44	8.56e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs10479542	0.630	rs6879664	chr5:178974576	T/G	cg14820908	chr5:178986412	RUFY1	0.44	6.16	0.35	2.69e-9	Lung cancer;
CESC	cis	rs67478160	0.643	rs12891175	chr14:104274166	T/C	cg08213375	chr14:104286397	PPP1R13B	0.54	10.76	0.55	1.22e-22	Schizophrenia;
CESC	cis	rs4835473	0.932	rs1849112	chr4:144883655	T/C	cg25736465	chr4:144833511	NA	0.39	5.64	0.33	4.34e-8	Immature fraction of reticulocytes;
CESC	cis	rs11690935	0.550	rs62183801	chr2:172867475	G/A	cg13550731	chr2:172543902	DYNC1I2	0.49	6.75	0.38	9.18e-11	Schizophrenia;
CESC	trans	rs6570726	0.846	rs372904	chr6:145887425	T/C	cg03826317	chr10:25465503	LOC100128811;GPR158	0.31	6.15	0.35	2.82e-9	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs796364	0.806	rs78527234	chr2:200913453	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.85	-7.93	-0.44	6.07e-14	Schizophrenia;
CESC	cis	rs7555523	0.943	rs4537525	chr1:165711089	T/G	cg24409356	chr1:165738333	TMCO1	0.97	8.67	0.47	4.48e-16	Intraocular pressure;Glaucoma (high intraocular pressure);
CESC	cis	rs1878931	0.501	rs9635547	chr16:3416664	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	0.74	9.7	0.51	3.16e-19	Body mass index (adult);
CESC	trans	rs1814175	0.645	rs1608632	chr11:49967148	C/T	cg03929089	chr4:120376271	NA	-0.92	-15.24	-0.68	4.38e-38	Height;
CESC	cis	rs896854	0.738	rs1713669	chr8:95958637	C/G	cg16049864	chr8:95962084	TP53INP1	-0.63	-10.11	-0.53	1.51e-20	Type 2 diabetes;
CESC	cis	rs17376456	0.569	rs2924374	chr5:93151141	T/C	cg25358565	chr5:93447407	FAM172A	-0.7	-7.37	-0.41	2.17e-12	Diabetic retinopathy;
CESC	trans	rs6089829	0.925	rs3746748	chr20:61667526	C/T	cg23505145	chr19:12996616	KLF1	0.51	6.68	0.38	1.37e-10	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs270601	0.721	rs270621	chr5:131605821	C/A	cg09877947	chr5:131593287	PDLIM4	0.45	5.47	0.32	1.02e-7	Acylcarnitine levels;
CESC	cis	rs1552244	1.000	rs35198334	chr3:10104553	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.8	-10.14	-0.53	1.22e-20	Alzheimer's disease;
CESC	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg18402987	chr7:1209562	NA	0.43	5.62	0.33	4.86e-8	Longevity;Endometriosis;
CESC	cis	rs11098499	0.954	rs28685688	chr4:120420334	T/C	cg09307838	chr4:120376055	NA	0.93	12.93	0.62	5.46e-30	Corneal astigmatism;
CESC	cis	rs13191362	1.000	rs13209100	chr6:163159350	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.7	7.51	0.42	9.29e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs7527798	0.637	rs7515149	chr1:207838352	T/G	cg21110645	chr1:207815933	NA	-0.34	-5.84	-0.34	1.55e-8	Erythrocyte sedimentation rate;
CESC	trans	rs561341	0.714	rs75861674	chr17:30304317	A/G	cg27661571	chr11:113659931	NA	-0.71	-7.4	-0.41	1.78e-12	Hip circumference adjusted for BMI;
CESC	cis	rs13095912	0.778	rs7651346	chr3:185300395	G/A	cg11274856	chr3:185301563	NA	0.38	5.69	0.33	3.35e-8	Systolic blood pressure;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12477533	chr2:98703450	VWA3B	0.57	6.07	0.35	4.3e-9	Gut microbiome composition (summer);
CESC	cis	rs6598955	0.671	rs11247909	chr1:26640135	G/A	cg19743891	chr1:26644573	UBXN11;CD52	0.36	5.19	0.3	4.09e-7	Obesity-related traits;
CESC	cis	rs4654899	1.000	rs10799686	chr1:21486445	A/T	cg05370193	chr1:21551575	ECE1	-0.39	-5.77	-0.33	2.19e-8	Superior frontal gyrus grey matter volume;
CESC	cis	rs7833790	0.654	rs7835342	chr8:82698092	A/G	cg17211192	chr8:82754475	SNX16	-0.58	-7.62	-0.42	4.64e-13	Diastolic blood pressure;
CESC	cis	rs10504229	0.683	rs56208052	chr8:58130207	A/T	cg24829409	chr8:58192753	C8orf71	-0.58	-7.2	-0.4	6.31e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs7789940	1.000	rs73140069	chr7:75986790	T/A	cg10167463	chr7:75959203	YWHAG	-0.56	-7.09	-0.4	1.23e-11	Multiple sclerosis;
CESC	cis	rs514406	0.505	rs416968	chr1:53183513	A/G	cg16325326	chr1:53192061	ZYG11B	0.83	14.04	0.65	7.5e-34	Monocyte count;
CESC	cis	rs6142102	0.517	rs6059577	chr20:32527686	T/C	cg08999081	chr20:33150536	PIGU	0.35	5.26	0.31	3.03e-7	Skin pigmentation;
CESC	cis	rs1580019	0.563	rs13244332	chr7:32537679	G/A	cg07520158	chr7:32535189	LSM5;AVL9	0.51	6.45	0.37	5.2400000000000005e-10	Cognitive ability;
CESC	cis	rs10927875	0.632	rs2862162	chr1:16142960	A/C	cg18973939	chr1:16164122	FLJ37453	-0.38	-5.72	-0.33	2.84e-8	Dilated cardiomyopathy;
CESC	cis	rs7116495	0.609	rs73531955	chr11:71687794	A/C	cg10381502	chr11:71823885	C11orf51	1.19	7.71	0.43	2.49e-13	Severe influenza A (H1N1) infection;
CESC	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg16132339	chr22:24313637	DDTL;DDT	0.35	5.26	0.31	2.96e-7	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs873946	0.648	rs12767283	chr10:134557094	C/G	cg18305652	chr10:134549665	INPP5A	0.48	6.75	0.38	9.22e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs7552404	0.924	rs1146581	chr1:76213024	T/G	cg10523679	chr1:76189770	ACADM	0.74	9.81	0.52	1.37e-19	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs898097	1.000	rs898097	chr17:80904310	C/T	cg15664640	chr17:80829946	TBCD	0.5	6.95	0.39	2.81e-11	Breast cancer;
CESC	cis	rs9916302	0.904	rs2061338	chr17:37421767	T/C	cg00129232	chr17:37814104	STARD3	-0.53	-6.89	-0.39	4.12e-11	Glomerular filtration rate (creatinine);
CESC	trans	rs7615952	0.673	rs35955861	chr3:125626201	T/C	cg07211511	chr3:129823064	LOC729375	-0.87	-8.14	-0.45	1.59e-14	Blood pressure (smoking interaction);
CESC	cis	rs7586879	0.616	rs13410999	chr2:25097939	T/C	cg01884057	chr2:25150051	NA	0.38	7.4	0.41	1.85e-12	Body mass index;
CESC	cis	rs7613875	0.580	rs12634780	chr3:50043341	A/T	cg24308560	chr3:49941425	MST1R	0.58	8.41	0.46	2.58e-15	Body mass index;
CESC	cis	rs4547160	0.781	rs12228037	chr12:63484560	C/T	cg26727693	chr12:63544175	AVPR1A	0.35	5.3	0.31	2.46e-7	Morning vs. evening chronotype;
CESC	cis	rs72792276	1.000	rs72792279	chr5:127374404	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.68	5.24	0.31	3.26e-7	Red cell distribution width;
CESC	cis	rs2130392	0.926	rs4610379	chr4:185624388	A/G	cg21366198	chr4:185655624	MLF1IP	-0.47	-6.89	-0.39	3.95e-11	Kawasaki disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg13131263	chr1:9324393	H6PD	0.47	6.19	0.36	2.33e-9	Fibrinogen levels;
CESC	cis	rs959260	1.000	rs9902966	chr17:73362147	C/T	cg12999837	chr17:73267436	MIF4GD	-0.47	-5.36	-0.31	1.78e-7	Systemic lupus erythematosus;
CESC	cis	rs2797160	1.000	rs2747720	chr6:126009458	A/G	cg05901451	chr6:126070800	HEY2	0.45	6.59	0.38	2.39e-10	Endometrial cancer;
CESC	cis	rs7115242	0.720	rs10790169	chr11:116877159	A/C	cg01368799	chr11:117014884	PAFAH1B2	0.59	5.44	0.32	1.2e-7	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
CESC	cis	rs736408	0.609	rs13095332	chr3:52787242	C/T	cg17372223	chr3:52568218	NT5DC2	0.44	6.57	0.37	2.71e-10	Bipolar disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26322913	chr14:50999702	MAP4K5;ATL1	0.55	6.22	0.36	1.88e-9	Gut microbiome composition (summer);
CESC	cis	rs4665809	1.000	rs4233708	chr2:26291345	C/T	cg22920501	chr2:26401640	FAM59B	-0.69	-8.44	-0.46	2.06e-15	Gut microbiome composition (summer);
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg13837895	chr19:50145301	SCAF1	0.54	7.49	0.42	1.05e-12	Systemic lupus erythematosus;
CESC	cis	rs12188164	0.965	rs1056465	chr5:442438	T/A	cg26850624	chr5:429559	AHRR	-0.49	-6.62	-0.38	1.95e-10	Cystic fibrosis severity;
CESC	cis	rs8020095	0.571	rs6573736	chr14:67374684	C/T	cg19548862	chr14:67692701	FAM71D	-0.48	-5.81	-0.34	1.81e-8	Depression (quantitative trait);
CESC	cis	rs11645898	0.935	rs17603936	chr16:72169002	C/A	cg14768367	chr16:72042858	DHODH	-0.76	-6.48	-0.37	4.36e-10	Blood protein levels;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg25266327	chr19:16435660	KLF2	-0.47	-6.15	-0.35	2.91e-9	Ulcerative colitis;
CESC	cis	rs6963495	0.932	rs55700120	chr7:105148460	G/T	cg02135003	chr7:105160482	PUS7	-0.47	-5.61	-0.33	5.12e-8	Bipolar disorder (body mass index interaction);
CESC	cis	rs11741688	0.557	rs2004503	chr5:178337122	C/T	cg20935368	chr5:178288625	ZNF354B	0.35	5.51	0.32	8.63e-8	Sleep duration;
CESC	cis	rs2635047	0.967	rs12960444	chr18:44607314	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.59	8.29	0.45	5.74e-15	Educational attainment;
CESC	cis	rs7666738	0.753	rs7659724	chr4:98944063	C/T	cg17366294	chr4:99064904	C4orf37	0.61	8.52	0.46	1.25e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2576037	0.526	rs1539878	chr18:44523004	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.55	-7.54	-0.42	7.32e-13	Personality dimensions;
CESC	cis	rs36051895	0.732	rs7046736	chr9:5015732	C/A	cg02405213	chr9:5042618	JAK2	-0.47	-5.73	-0.33	2.72e-8	Pediatric autoimmune diseases;
CESC	cis	rs66887589	0.870	rs10518336	chr4:120522934	G/A	cg09307838	chr4:120376055	NA	0.55	7.21	0.4	5.87e-12	Diastolic blood pressure;
CESC	trans	rs1493916	0.870	rs8083723	chr18:31384398	C/T	cg27147174	chr7:100797783	AP1S1	-0.49	-6.72	-0.38	1.13e-10	Life satisfaction;
CESC	cis	rs9916302	0.847	rs7218670	chr17:37500424	G/A	cg15445000	chr17:37608096	MED1	-0.41	-6.8	-0.39	6.8e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs933688	0.532	rs2973478	chr5:90553428	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.44	-5.11	-0.3	6.1e-7	Smoking behavior;
CESC	cis	rs7296418	0.699	rs11608297	chr12:123826642	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.32	-5.11	-0.3	6.23e-7	Platelet count;
CESC	trans	rs7577696	0.962	rs13022197	chr2:32343167	A/T	cg05346536	chr7:128769728	NA	0.37	6.06	0.35	4.61e-9	Inflammatory biomarkers;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg18632102	chr5:154238496	CNOT8	-0.53	-7.0	-0.4	2.15e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg26807261	chr1:202857904	RABIF	-0.47	-6.03	-0.35	5.43e-9	Ulcerative colitis;
CESC	cis	rs17253792	0.822	rs76267907	chr14:56066969	C/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.85	6.13	0.35	3.15e-9	Putamen volume;
CESC	cis	rs10791097	0.547	rs10791101	chr11:130739133	C/T	cg14779329	chr11:130786720	SNX19	0.34	5.12	0.3	5.95e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs9443189	0.813	rs2647410	chr6:76433825	A/G	cg01950844	chr6:76311363	SENP6	-0.6	-6.71	-0.38	1.15e-10	Prostate cancer;
CESC	cis	rs12477438	0.520	rs11123764	chr2:99750677	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.91	15.68	0.69	1.18e-39	Chronic sinus infection;
CESC	cis	rs1348850	0.526	rs4144278	chr2:178412378	C/T	cg23306229	chr2:178417860	TTC30B	0.73	6.74	0.38	1.01e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs1799949	1.000	rs1060915	chr17:41234470	A/G	cg23758822	chr17:41437982	NA	1.01	15.33	0.69	2.06e-38	Menopause (age at onset);
CESC	cis	rs10751667	1.000	rs4074232	chr11:977682	C/G	cg01483505	chr11:975446	AP2A2	0.38	5.11	0.3	6.25e-7	Alzheimer's disease (late onset);
CESC	trans	rs1218282	0.655	rs17771893	chr13:79466495	C/T	cg17329304	chr1:6546083	PLEKHG5	0.8	6.28	0.36	1.42e-9	Response to statin therapy;
CESC	cis	rs2070997	0.607	rs11244143	chr9:133670111	C/T	cg11464064	chr9:133710261	ABL1	-0.59	-6.89	-0.39	4.11e-11	Response to amphetamines;
CESC	cis	rs7552404	1.000	rs1498315	chr1:76159225	G/A	cg10523679	chr1:76189770	ACADM	0.72	8.33	0.46	4.31e-15	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs8141529	0.687	rs6005867	chr22:29165120	T/C	cg15103426	chr22:29168792	CCDC117	0.73	10.06	0.53	2.17e-20	Lymphocyte counts;
CESC	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg01238044	chr22:24384105	GSTT1	-0.66	-8.42	-0.46	2.34e-15	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs763121	0.853	rs138704	chr22:39133410	A/G	cg21395723	chr22:39101663	GTPBP1	0.5	6.9	0.39	3.89e-11	Menopause (age at onset);
CESC	cis	rs9287719	0.753	rs2018512	chr2:10759279	T/G	cg00105475	chr2:10696890	NA	0.35	5.07	0.3	7.65e-7	Prostate cancer;
CESC	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	21.57	0.8	2.94e-60	Prudent dietary pattern;
CESC	cis	rs9929218	0.954	rs9929479	chr16:68821271	G/C	cg02972257	chr16:68554789	NA	0.49	5.73	0.33	2.76e-8	Colorectal cancer;
CESC	cis	rs694739	0.595	rs11606015	chr11:64136877	C/G	cg02228329	chr11:64053129	BAD;GPR137	0.62	7.67	0.43	3.25e-13	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CESC	cis	rs8018808	0.875	rs11159258	chr14:77880593	T/C	cg20045696	chr14:77926864	AHSA1	0.47	6.5	0.37	3.87e-10	Myeloid white cell count;
CESC	cis	rs7085104	0.514	rs284855	chr10:104574422	A/G	cg23093090	chr10:104574429	C10orf26	0.34	5.41	0.32	1.42e-7	Immature fraction of reticulocytes;Schizophrenia;
CESC	cis	rs4595586	0.545	rs67985200	chr12:39386891	C/T	cg13010199	chr12:38710504	ALG10B	0.44	5.51	0.32	8.37e-8	Morning vs. evening chronotype;
CESC	cis	rs2228479	0.702	rs11076621	chr16:89837927	A/G	cg06558623	chr16:89946397	TCF25	1.17	9.29	0.5	5.84e-18	Skin colour saturation;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg02092590	chr10:3827595	KLF6	0.43	6.11	0.35	3.53e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs7188697	0.922	rs9926577	chr16:58613431	C/T	cg21335942	chr16:58549945	SETD6	-0.45	-5.24	-0.31	3.34e-7	QT interval;
CESC	cis	rs9611565	0.659	rs9607812	chr22:41941243	G/A	cg06481639	chr22:41940642	POLR3H	-0.62	-6.57	-0.37	2.59e-10	Vitiligo;
CESC	cis	rs2635047	0.638	rs2668761	chr18:44673049	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.41	5.51	0.32	8.62e-8	Educational attainment;
CESC	cis	rs2933343	0.729	rs789231	chr3:128602847	A/G	cg25356066	chr3:128598488	ACAD9	0.66	9.18	0.49	1.27e-17	IgG glycosylation;
CESC	cis	rs796364	1.000	rs281785	chr2:200749566	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.87	8.38	0.46	3.1e-15	Schizophrenia;
CESC	cis	rs17376456	0.825	rs12153021	chr5:93073913	A/G	cg21475434	chr5:93447410	FAM172A	0.83	7.31	0.41	3.16e-12	Diabetic retinopathy;
CESC	cis	rs6912958	0.516	rs242278	chr6:88047059	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.44	7.68	0.43	3.18e-13	Monocyte percentage of white cells;
CESC	cis	rs4665809	1.000	rs6546768	chr2:26328800	A/G	cg26314531	chr2:26401878	FAM59B	-0.61	-6.87	-0.39	4.62e-11	Gut microbiome composition (summer);
CESC	cis	rs875971	1.000	rs7781698	chr7:65896312	A/T	cg11764359	chr7:65958608	NA	0.94	14.78	0.67	1.83e-36	Aortic root size;
CESC	cis	rs4819052	0.851	rs10470258	chr21:46658989	C/T	cg11663144	chr21:46675770	NA	-0.63	-10.02	-0.52	3.12e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs736408	0.609	rs2268025	chr3:52795224	A/T	cg17372223	chr3:52568218	NT5DC2	0.43	6.13	0.35	3.09e-9	Bipolar disorder;
CESC	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg02018176	chr4:1364513	KIAA1530	0.58	7.13	0.4	9.75e-12	Longevity;
CESC	cis	rs514406	0.698	rs576891	chr1:53364976	A/G	cg08736216	chr1:53307985	ZYG11A	-0.38	-6.48	-0.37	4.45e-10	Monocyte count;
CESC	cis	rs72615157	0.561	rs113844570	chr7:99873778	A/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.7	6.59	0.38	2.36e-10	Lung function (FEV1/FVC);
CESC	cis	rs10504229	0.683	rs11786043	chr8:58133174	T/C	cg21724239	chr8:58056113	NA	0.58	5.95	0.34	8.29e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.5	-6.38	-0.36	7.97e-10	Longevity;Endometriosis;
CESC	cis	rs9486719	0.843	rs2103539	chr6:96844342	T/A	cg18709589	chr6:96969512	KIAA0776	0.55	5.64	0.33	4.26e-8	Migraine;Coronary artery disease;
CESC	cis	rs2228479	0.850	rs62056065	chr16:89905115	C/G	cg00800038	chr16:89945340	TCF25	-0.89	-6.89	-0.39	4.13e-11	Skin colour saturation;
CESC	trans	rs916888	0.773	rs199451	chr17:44801784	G/A	cg10053473	chr17:62856997	LRRC37A3	-0.73	-7.76	-0.43	1.87e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg10295955	chr4:187884368	NA	-1.1	-22.78	-0.81	2.32e-64	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9796	0.621	rs9972349	chr15:41491656	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.45	-6.61	-0.38	2.16e-10	Menopause (age at onset);
CESC	cis	rs4819052	0.851	rs2877020	chr21:46658742	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.75	9.98	0.52	4.1e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg03491503	chr16:69458309	CYB5B	-0.5	-6.24	-0.36	1.73e-9	Ulcerative colitis;
CESC	cis	rs4282054	0.631	rs13081155	chr3:52732429	A/G	cg07507251	chr3:52567010	NT5DC2	0.38	7.18	0.4	6.86e-12	Cognitive function;
CESC	cis	rs3741404	0.609	rs641378	chr11:63869493	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.72	10.02	0.52	2.95e-20	Platelet count;
CESC	cis	rs7914558	0.932	rs4307650	chr10:104959852	C/A	cg04362960	chr10:104952993	NT5C2	0.47	6.4	0.37	6.83e-10	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs8017423	1.000	rs769044	chr14:90671138	A/G	cg14092571	chr14:90743983	NA	-0.54	-7.93	-0.44	6.3e-14	Mortality in heart failure;
CESC	cis	rs3820928	0.647	rs2115597	chr2:227791218	T/C	cg11843606	chr2:227700838	RHBDD1	-0.58	-8.25	-0.45	7.39e-15	Pulmonary function;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg12894883	chr22:22288473	PPM1F	0.48	6.09	0.35	3.9e-9	Fibrinogen levels;
CESC	cis	rs4268898	0.662	rs2303292	chr2:24432138	C/T	cg20701182	chr2:24300061	SF3B14	0.68	7.16	0.4	7.75e-12	Asthma;
CESC	cis	rs11098499	0.739	rs10031033	chr4:120151452	C/T	cg09307838	chr4:120376055	NA	0.67	8.48	0.46	1.57e-15	Corneal astigmatism;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg05998816	chr21:47859926	PCNT	0.44	6.52	0.37	3.55e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs10129255	0.500	rs4774189	chr14:107176517	G/T	cg23076370	chr14:107095027	NA	-0.6	-8.81	-0.48	1.73e-16	Kawasaki disease;
CESC	cis	rs4965006	0.749	rs6598176	chr12:132425448	A/G	cg00588090	chr12:132412438	PUS1	-0.47	-6.49	-0.37	4.13e-10	Posterior cortical atrophy and Alzheimer's disease;
CESC	cis	rs6089829	0.962	rs6122344	chr20:61661738	C/T	cg16240275	chr20:61666158	NCRNA00029	0.5	8.95	0.48	6.42e-17	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs10751667	1.000	rs10794349	chr11:945678	T/C	cg00159523	chr10:114713187	TCF7L2	-0.4	-6.08	-0.35	4.26e-9	Alzheimer's disease (late onset);
CESC	cis	rs561341	0.883	rs7219239	chr17:30212016	A/G	cg12193833	chr17:30244370	NA	0.54	5.5	0.32	9.16e-8	Hip circumference adjusted for BMI;
CESC	cis	rs910316	1.000	rs4322591	chr14:75600697	C/T	cg11812906	chr14:75593930	NEK9	0.9	15.43	0.69	9.11e-39	Height;
CESC	cis	rs7945705	0.967	rs7123861	chr11:8892323	G/A	cg12365402	chr11:9010492	NRIP3	0.36	5.61	0.33	5.01e-8	Hemoglobin concentration;
CESC	cis	rs6500602	0.627	rs3848372	chr16:4587875	C/A	cg08645402	chr16:4508243	NA	0.45	6.63	0.38	1.82e-10	Schizophrenia;
CESC	cis	rs6089584	0.854	rs6061985	chr20:60622362	T/C	cg24733560	chr20:60626293	TAF4	0.45	6.44	0.37	5.45e-10	Body mass index;
CESC	cis	rs2050392	0.792	rs303434	chr10:30714440	G/A	cg25182066	chr10:30743637	MAP3K8	-0.42	-5.76	-0.33	2.35e-8	Inflammatory bowel disease;
CESC	cis	rs2415984	0.579	rs12147941	chr14:46972907	A/G	cg14871534	chr14:47121158	RPL10L	-0.34	-5.07	-0.3	7.39e-7	Number of children ever born;
CESC	cis	rs9611565	0.729	rs132902	chr22:41797758	A/G	cg06481639	chr22:41940642	POLR3H	-0.57	-6.29	-0.36	1.27e-9	Vitiligo;
CESC	cis	rs9926296	0.568	rs1230	chr16:89804855	A/G	cg07648498	chr16:89883185	FANCA	-0.49	-6.16	-0.35	2.63e-9	Vitiligo;
CESC	cis	rs9894429	1.000	rs4074916	chr17:79579248	G/A	cg13777783	chr17:79615861	NA	0.34	5.74	0.33	2.59e-8	Eye color traits;
CESC	cis	rs847577	0.748	rs13221897	chr7:97719699	G/A	cg21770322	chr7:97807741	LMTK2	0.64	10.36	0.54	2.38e-21	Breast cancer;
CESC	cis	rs4862750	0.794	rs7672272	chr4:187896774	T/G	cg10295955	chr4:187884368	NA	-1.08	-22.84	-0.81	1.42e-64	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs8002861	0.727	rs9525852	chr13:44405197	G/C	cg19180546	chr13:44453867	C13orf31;CCDC122	-0.39	-5.11	-0.3	6.17e-7	Leprosy;
CESC	cis	rs1218582	0.682	rs12144978	chr1:154850445	G/A	cg24250549	chr1:154909240	PMVK	0.58	7.72	0.43	2.35e-13	Prostate cancer;
CESC	cis	rs447	0.945	rs13310638	chr7:83761086	A/G	cg22846510	chr7:83753280	SEMA3A	-0.45	-5.57	-0.32	6.4e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs7520050	0.807	rs4468203	chr1:46113272	T/C	cg24296786	chr1:45957014	TESK2	-0.46	-5.96	-0.34	8e-9	Red blood cell count;Reticulocyte count;
CESC	trans	rs2593957	0.503	rs9821382	chr3:108812154	A/G	cg20104688	chr17:76183078	TK1;AFMID	-0.54	-6.05	-0.35	5.04e-9	Colorectal cancer (diet interaction);
CESC	cis	rs11249608	0.548	rs34054398	chr5:178458371	A/G	cg01312482	chr5:178451176	ZNF879	-0.45	-6.04	-0.35	5.28e-9	Pubertal anthropometrics;
CESC	cis	rs13256369	0.851	rs12541477	chr8:8563895	G/A	cg18904891	chr8:8559673	CLDN23	0.73	8.12	0.45	1.74e-14	Obesity-related traits;
CESC	cis	rs1046896	0.731	rs9906115	chr17:80791469	G/A	cg19046167	chr17:80928561	B3GNTL1	0.43	5.04	0.3	8.55e-7	Glycated hemoglobin levels;
CESC	cis	rs270601	0.710	rs371709	chr5:131583240	A/G	cg18758796	chr5:131593413	PDLIM4	0.43	5.89	0.34	1.2e-8	Acylcarnitine levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02912345	chr19:48308208	TPRX1	-0.57	-7.24	-0.41	4.94e-12	Gut microbiome composition (summer);
CESC	cis	rs858239	0.571	rs6953020	chr7:23172132	T/C	cg23682824	chr7:23144976	KLHL7	0.53	7.33	0.41	2.73e-12	Cerebrospinal fluid biomarker levels;
CESC	cis	rs4242434	0.927	rs7843616	chr8:22466541	T/C	cg03733263	chr8:22462867	KIAA1967	0.96	15.88	0.7	2.42e-40	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CESC	cis	rs12618769	0.597	rs72821924	chr2:99114924	C/T	cg10123293	chr2:99228465	UNC50	0.4	5.38	0.31	1.64e-7	Bipolar disorder;
CESC	cis	rs4253772	0.515	rs9615969	chr22:46773592	C/G	cg00784671	chr22:46762841	CELSR1	-0.65	-5.64	-0.33	4.45e-8	LDL cholesterol;Cholesterol, total;
CESC	trans	rs9951602	0.512	rs9958497	chr18:76655296	G/C	cg02800362	chr5:177631904	HNRNPAB	0.65	8.51	0.46	1.31e-15	Obesity-related traits;
CESC	cis	rs1511802	0.666	rs3817184	chr4:187122304	C/T	cg24794857	chr4:187113578	CYP4V2	0.44	5.84	0.34	1.56e-8	Blood protein levels;
CESC	cis	rs6952808	0.529	rs73038442	chr7:2139457	C/T	cg21782813	chr7:2030301	MAD1L1	0.49	7.01	0.4	1.98e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs1790761	0.692	rs1148883	chr11:67304686	A/G	cg24690094	chr11:67383802	NA	0.36	6.05	0.35	4.91e-9	Mean corpuscular volume;
CESC	cis	rs3845702	0.935	rs6433822	chr2:180840422	G/C	cg01881094	chr2:180872142	CWC22	-0.65	-6.85	-0.39	5.06e-11	Schizophrenia;
CESC	cis	rs72627123	0.867	rs57731447	chr14:74487521	G/A	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.78	5.82	0.34	1.74e-8	Morning vs. evening chronotype;
CESC	cis	rs7818382	1.000	rs7818382	chr8:96054000	C/T	cg23172400	chr8:95962367	TP53INP1	-0.36	-7.18	-0.4	6.93e-12	Alzheimer's disease (late onset);
CESC	cis	rs9309473	0.950	rs73947808	chr2:73721250	A/C	cg20560298	chr2:73613845	ALMS1	-0.52	-6.4	-0.37	6.93e-10	Metabolite levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04204438	chr8:145634756	CPSF1	0.58	6.44	0.37	5.69e-10	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23312248	chr12:123465515	ARL6IP4	0.57	6.23	0.36	1.84e-9	Gut microbiome composition (summer);
CESC	cis	rs35995292	0.517	rs6948026	chr7:38920854	A/G	cg19327137	chr7:38886074	VPS41	0.66	10.86	0.55	5.69e-23	Subjective well-being (multi-trait analysis);
CESC	cis	rs9611565	0.571	rs2050032	chr22:42152429	C/T	cg06481639	chr22:41940642	POLR3H	0.45	5.21	0.3	3.83e-7	Vitiligo;
CESC	cis	rs116988415	0.584	rs74859785	chr14:65249684	C/T	cg25083366	chr14:65239357	SPTB	0.66	5.14	0.3	5.23e-7	Daytime sleep phenotypes;
CESC	cis	rs2228479	0.850	rs11641552	chr16:89838700	C/A	cg14709524	chr16:89940631	TCF25	0.91	6.74	0.38	1e-10	Skin colour saturation;
CESC	cis	rs60733400	0.644	rs28774982	chr1:2621352	C/G	cg20673091	chr1:2541236	MMEL1	-0.47	-7.52	-0.42	8.62e-13	Multiple sclerosis;
CESC	cis	rs854765	0.583	rs4341796	chr17:17839024	C/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.52	7.13	0.4	9.44e-12	Total body bone mineral density;
CESC	cis	rs13256369	0.802	rs11781257	chr8:8559663	A/T	cg00074818	chr8:8560427	CLDN23	0.37	5.18	0.3	4.44e-7	Obesity-related traits;
CESC	cis	rs12479064	0.724	rs10496336	chr2:99996165	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.6	-7.3	-0.41	3.46e-12	Chronic sinus infection;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg10024446	chr10:22048429	DNAJC1	0.56	7.43	0.42	1.49e-12	Fibrinogen levels;
CESC	cis	rs875971	0.660	rs3857686	chr7:66036191	C/T	cg11764359	chr7:65958608	NA	-0.71	-9.5	-0.5	1.32e-18	Aortic root size;
CESC	cis	rs4713118	0.662	rs9468277	chr6:28028390	C/A	cg22143856	chr6:28129313	ZNF389	0.42	5.26	0.31	2.91e-7	Parkinson's disease;
CESC	cis	rs1862618	0.671	rs2591965	chr5:56236176	T/C	cg12311346	chr5:56204834	C5orf35	0.65	8.63	0.47	5.69e-16	Initial pursuit acceleration;
CESC	cis	rs1348850	0.597	rs4893964	chr2:178447658	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.48	5.11	0.3	6.03e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs262150	0.851	rs2730249	chr7:158767628	A/G	cg09640425	chr7:158790006	NA	0.35	5.36	0.31	1.84e-7	Facial morphology (factor 20);
CESC	cis	rs2276314	0.857	rs6507158	chr18:33636066	A/C	cg19628046	chr18:33552617	C18orf21	0.52	5.96	0.34	8.11e-9	Endometriosis;Drug-induced torsades de pointes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21403912	chr1:155239301	CLK2	-0.56	-6.5	-0.37	3.96e-10	Gut microbiome composition (summer);
CESC	cis	rs6121246	0.909	rs6060793	chr20:30288830	T/G	cg13852791	chr20:30311386	BCL2L1	0.79	8.3	0.45	5.47e-15	Mean corpuscular hemoglobin;
CESC	cis	rs4713118	0.662	rs9393881	chr6:28023751	C/G	cg12963246	chr6:28129442	ZNF389	0.48	6.28	0.36	1.37e-9	Parkinson's disease;
CESC	cis	rs8017423	0.935	rs7144335	chr14:90732280	A/G	cg14092571	chr14:90743983	NA	0.55	8.14	0.45	1.55e-14	Mortality in heart failure;
CESC	cis	rs4253772	0.530	rs9615990	chr22:46804154	G/A	cg24881330	chr22:46731750	TRMU	0.67	5.35	0.31	1.92e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs2243480	1.000	rs316313	chr7:65593548	G/A	cg18252515	chr7:66147081	NA	-1.41	-14.36	-0.66	5.44e-35	Diabetic kidney disease;
CESC	cis	rs769267	0.929	rs2905431	chr19:19482882	G/A	cg03709012	chr19:19516395	GATAD2A	-0.98	-15.39	-0.69	1.25e-38	Tonsillectomy;
CESC	cis	rs8028182	0.636	rs8036884	chr15:75862893	T/C	cg20655648	chr15:75932815	IMP3	0.5	6.17	0.35	2.57e-9	Sudden cardiac arrest;
CESC	cis	rs2832191	0.791	rs2832197	chr21:30497790	T/C	cg08807101	chr21:30365312	RNF160	-0.72	-9.88	-0.52	8.5e-20	Dental caries;
CESC	cis	rs1797885	0.564	rs2596819	chr3:12600529	T/C	cg26432171	chr3:12704882	RAF1	-0.51	-6.69	-0.38	1.29e-10	Immature fraction of reticulocytes;
CESC	cis	rs6062302	0.522	rs4809312	chr20:62234240	C/T	cg09650180	chr20:62225654	GMEB2	-0.82	-9.27	-0.49	6.91e-18	Glioblastoma;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04562739	chr20:5107446	CDS2;PCNA	-0.48	-6.58	-0.37	2.58e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs7772486	0.790	rs2247206	chr6:146216184	C/T	cg05347473	chr6:146136440	FBXO30	0.53	6.92	0.39	3.46e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs10779751	1.000	rs4845854	chr1:11261929	T/C	cg08854313	chr1:11322531	MTOR	0.88	12.81	0.62	1.4e-29	Body mass index;
CESC	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg24503407	chr1:205819492	PM20D1	-0.72	-9.95	-0.52	4.94e-20	Menarche (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16632891	chr1:54872978	SSBP3	0.68	7.57	0.42	6.21e-13	Gut microbiome composition (summer);
CESC	cis	rs2235642	0.826	rs8048410	chr16:1614097	A/G	cg03771183	chr16:1608904	IFT140	0.43	6.24	0.36	1.7e-9	Coronary artery disease;
CESC	cis	rs9894429	0.546	rs9906979	chr17:79608765	A/G	cg18240062	chr17:79603768	NPLOC4	0.67	8.91	0.48	8.4e-17	Eye color traits;
CESC	trans	rs7307889	0.793	rs7489044	chr12:6009595	A/G	cg18407955	chr7:158110685	PTPRN2	-0.71	-6.58	-0.37	2.48e-10	Obesity-related traits;
CESC	cis	rs4563143	0.663	rs5025682	chr19:29238670	A/C	cg12667521	chr19:29218732	NA	0.49	6.66	0.38	1.6e-10	Methadone dose in opioid dependence;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg00747290	chr2:42721154	KCNG3	-0.48	-6.22	-0.36	1.93e-9	Fibrinogen levels;
CESC	cis	rs7618915	0.501	rs13085775	chr3:52678370	C/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.31	5.64	0.33	4.35e-8	Bipolar disorder;
CESC	cis	rs561341	1.000	rs111454793	chr17:30319267	T/C	cg23018236	chr17:30244563	NA	-0.53	-5.21	-0.3	3.76e-7	Hip circumference adjusted for BMI;
CESC	cis	rs17433710	0.516	rs6689396	chr1:162676698	C/T	cg21140079	chr1:162667252	DDR2	-0.39	-5.09	-0.3	6.85e-7	Dupuytren's disease;
CESC	cis	rs11214589	0.807	rs2155463	chr11:113242301	T/C	cg14159747	chr11:113255604	NA	0.3	5.48	0.32	9.93e-8	Neuroticism;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09297334	chr8:71520303	TRAM1	-0.67	-7.74	-0.43	2.15e-13	Gut microbiome composition (summer);
CESC	cis	rs9640161	0.742	rs2159235	chr7:150017228	T/C	cg21361702	chr7:150065534	REPIN1	0.55	6.44	0.37	5.71e-10	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs896854	0.654	rs4735337	chr8:95973465	T/C	cg16049864	chr8:95962084	TP53INP1	-0.65	-11.37	-0.57	1.18e-24	Type 2 diabetes;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg14173624	chr17:72199366	RPL38	-0.44	-5.99	-0.35	6.63e-9	Height;
CESC	trans	rs526821	0.595	rs551665	chr11:55343268	G/A	cg03929089	chr4:120376271	NA	-0.5	-6.07	-0.35	4.34e-9	Pediatric bone mineral density (spine);
CESC	cis	rs72781680	0.611	rs72797819	chr2:24351141	T/G	cg08917208	chr2:24149416	ATAD2B	0.61	5.85	0.34	1.43e-8	Lymphocyte counts;
CESC	cis	rs12188164	1.000	rs56042615	chr5:437667	G/A	cg21144161	chr5:423903	AHRR	0.37	6.09	0.35	3.9e-9	Cystic fibrosis severity;
CESC	cis	rs12461016	1	rs12461016	chr19:17161687	G/A	cg16202187	chr19:17186497	HAUS8;MYO9B	0.51	6.63	0.38	1.84e-10	Diastolic blood pressure;
CESC	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.07	10.75	0.55	1.35e-22	Platelet count;
CESC	cis	rs2463822	0.583	rs72919472	chr11:62040655	C/T	cg06239285	chr11:62104954	ASRGL1	-1.06	-8.68	-0.47	4.09e-16	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs9948	0.655	rs6758151	chr2:97388884	A/G	cg01990225	chr2:97406019	LMAN2L	-0.87	-7.31	-0.41	3.22e-12	Erectile dysfunction and prostate cancer treatment;
CESC	cis	rs4253772	0.530	rs6008662	chr22:46713917	G/A	cg07012999	chr22:46692446	CN5H6.4;GTSE1	0.54	5.59	0.33	5.51e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs7831492	0.564	rs7831530	chr8:41614567	G/A	cg17182837	chr8:41585554	ANK1	-0.41	-6.34	-0.36	9.67e-10	Colorectal cancer;
CESC	cis	rs1451375	0.607	rs7807335	chr7:50631862	A/C	cg14593290	chr7:50529359	DDC	-0.45	-5.43	-0.32	1.29e-7	Malaria;
CESC	cis	rs637571	0.522	rs1786175	chr11:65754808	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.44	6.51	0.37	3.81e-10	Eosinophil percentage of white cells;
CESC	cis	rs6500602	0.674	rs7191664	chr16:4541924	T/C	cg08645402	chr16:4508243	NA	0.43	6.32	0.36	1.09e-9	Schizophrenia;
CESC	cis	rs2380220	0.510	rs9387562	chr6:96057006	G/T	cg04719120	chr6:96025338	MANEA	0.63	6.74	0.38	1.01e-10	Behavioural disinhibition (generation interaction);
CESC	cis	rs3096299	0.629	rs12929744	chr16:89493580	G/C	cg02187348	chr16:89574699	SPG7	0.5	6.06	0.35	4.74e-9	Multiple myeloma (IgH translocation);
CESC	cis	rs9309711	0.623	rs4641971	chr2:3481857	A/C	cg10845886	chr2:3471009	TTC15	0.68	9.23	0.49	9.14e-18	Neurofibrillary tangles;
CESC	cis	rs6964587	1.000	rs3753109	chr7:91630001	G/C	cg17063962	chr7:91808500	NA	0.57	7.74	0.43	2.04e-13	Breast cancer;
CESC	cis	rs672059	1.000	rs544352	chr1:183157546	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.54	6.97	0.39	2.51e-11	Hypertriglyceridemia;
CESC	cis	rs9911578	1.000	rs11079365	chr17:56945430	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.16	0.3	4.87e-7	Intelligence (multi-trait analysis);
CESC	cis	rs1448094	0.872	rs1026085	chr12:86355735	A/G	cg02569458	chr12:86230093	RASSF9	0.35	5.2	0.3	4.06e-7	Major depressive disorder;
CESC	cis	rs4808199	0.948	rs2074300	chr19:19380996	G/T	cg03709012	chr19:19516395	GATAD2A	1.08	11.68	0.58	1.02e-25	Nonalcoholic fatty liver disease;
CESC	cis	rs6952809	0.532	rs6461361	chr7:2432167	A/G	cg23289794	chr7:2394357	EIF3B	-0.87	-7.7	-0.43	2.69e-13	Multiple sclerosis;
CESC	trans	rs17508449	0.819	rs77892281	chr1:114163617	A/T	cg23028848	chr11:57092561	TNKS1BP1	-0.74	-6.0	-0.35	6.52e-9	Leprosy;
CESC	cis	rs116095464	0.558	rs62346506	chr5:201594	T/C	cg22857025	chr5:266934	NA	-1.27	-14.49	-0.66	2e-35	Breast cancer;
CESC	cis	rs7811142	0.830	rs61735533	chr7:99955866	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.13	11.76	0.59	5.69e-26	Platelet count;
CESC	cis	rs6582630	0.539	rs8189604	chr12:38308546	G/T	cg26384229	chr12:38710491	ALG10B	-0.44	-5.76	-0.33	2.35e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs798554	0.797	rs798486	chr7:2803037	A/G	cg09658497	chr7:2847517	GNA12	-0.44	-6.14	-0.35	3.06e-9	Height;
CESC	cis	rs6912958	0.703	rs6903219	chr6:88096498	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.72	10.36	0.54	2.38e-21	Monocyte percentage of white cells;
CESC	cis	rs4964805	0.586	rs934846	chr12:104185297	C/T	cg02344784	chr12:104178138	NT5DC3	0.5	7.26	0.41	4.23e-12	Attention deficit hyperactivity disorder;
CESC	trans	rs968059	0.669	rs4670455	chr2:35448902	C/G	cg14806518	chr2:503692	NA	0.39	6.0	0.35	6.59e-9	Body mass index;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg16754766	chr12:42877927	PRICKLE1	0.52	6.82	0.39	6.09e-11	Systemic lupus erythematosus;
CESC	cis	rs9611565	0.512	rs5751148	chr22:42139078	A/G	cg06634786	chr22:41940651	POLR3H	0.68	6.72	0.38	1.13e-10	Vitiligo;
CESC	cis	rs6570726	0.791	rs436498	chr6:145876347	G/A	cg23711669	chr6:146136114	FBXO30	1.03	15.86	0.7	2.71e-40	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs3749237	0.595	rs7621003	chr3:49411404	T/C	cg06212747	chr3:49208901	KLHDC8B	0.53	7.2	0.4	6.08e-12	Resting heart rate;
CESC	trans	rs11039798	0.588	rs1847640	chr11:49004025	C/T	cg15704280	chr7:45808275	SEPT13	0.69	6.79	0.38	7.18e-11	Axial length;
CESC	cis	rs7666738	0.800	rs7684523	chr4:98983175	G/T	cg05340658	chr4:99064831	C4orf37	0.8	12.42	0.61	3.31e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs593982	0.920	rs1151501	chr11:65484883	A/G	cg08755490	chr11:65554678	OVOL1	1.18	10.7	0.55	1.97e-22	Atopic dermatitis;
CESC	cis	rs722599	0.748	rs929579	chr14:75330697	C/T	cg08847533	chr14:75593920	NEK9	-0.45	-5.64	-0.33	4.44e-8	IgG glycosylation;
CESC	cis	rs10876993	0.890	rs774887	chr12:58034835	A/G	cg18357645	chr12:58087776	OS9	0.59	9.13	0.49	1.77e-17	Celiac disease or Rheumatoid arthritis;
CESC	cis	rs854765	0.547	rs2955356	chr17:17964717	G/A	cg16928487	chr17:17741425	SREBF1	0.56	9.38	0.5	3e-18	Total body bone mineral density;
CESC	cis	rs7116495	1.000	rs2511116	chr11:71802160	G/A	cg26138937	chr11:71823887	C11orf51	-0.86	-7.03	-0.4	1.75e-11	Severe influenza A (H1N1) infection;
CESC	cis	rs453301	0.686	rs17702602	chr8:8908596	C/T	cg15556689	chr8:8085844	FLJ10661	-0.52	-6.3	-0.36	1.26e-9	Joint mobility (Beighton score);
CESC	cis	rs10779751	0.726	rs1205593	chr1:11252716	T/C	cg08854313	chr1:11322531	MTOR	0.75	8.89	0.48	9.58e-17	Body mass index;
CESC	cis	rs9560113	0.597	rs1163644	chr13:112241223	C/T	cg10483660	chr13:112241077	NA	-0.46	-7.9	-0.44	7.51e-14	Menarche (age at onset);
CESC	cis	rs868036	1.000	rs4776377	chr15:68103387	T/C	cg08079166	chr15:68083412	MAP2K5	0.43	6.92	0.39	3.35e-11	Restless legs syndrome;
CESC	cis	rs5769765	1.000	rs4597652	chr22:50270570	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.46	5.32	0.31	2.21e-7	Schizophrenia;
CESC	cis	rs561341	1.000	rs550923	chr17:30327013	G/C	cg23018236	chr17:30244563	NA	-0.52	-5.11	-0.3	6.12e-7	Hip circumference adjusted for BMI;
CESC	cis	rs7412746	0.658	rs1027699	chr1:150811712	T/C	cg09365446	chr1:150670422	GOLPH3L	0.4	5.39	0.31	1.59e-7	Melanoma;
CESC	cis	rs11190604	0.945	rs11190573	chr10:102233172	T/C	cg07080220	chr10:102295463	HIF1AN	0.55	5.56	0.32	6.43e-8	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs780096	0.526	rs11127013	chr2:27692973	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.31	-5.65	-0.33	4.22e-8	Total body bone mineral density;
CESC	cis	rs35110281	0.591	rs162366	chr21:44935383	C/T	cg21573476	chr21:45109991	RRP1B	0.38	5.38	0.31	1.68e-7	Mean corpuscular volume;
CESC	cis	rs875971	0.558	rs4433015	chr7:65639723	A/C	cg11764359	chr7:65958608	NA	-0.62	-7.83	-0.43	1.18e-13	Aortic root size;
CESC	cis	rs6842047	1.000	rs10471184	chr4:187122904	C/T	cg23442198	chr4:187126114	CYP4V2	-0.68	-5.41	-0.32	1.38e-7	Blood protein levels;
CESC	cis	rs1005277	0.579	rs2472173	chr10:38374638	G/A	cg25427524	chr10:38739819	LOC399744	-0.66	-9.52	-0.5	1.15e-18	Extrinsic epigenetic age acceleration;
CESC	cis	rs9322193	0.772	rs7738696	chr6:150170121	A/G	cg13206674	chr6:150067644	NUP43	0.42	5.67	0.33	3.66e-8	Lung cancer;
CESC	cis	rs2075371	0.829	rs9641970	chr7:134004887	C/A	cg11752832	chr7:134001865	SLC35B4	0.51	6.53	0.37	3.4e-10	Mean platelet volume;
CESC	cis	rs2262909	0.962	rs422344	chr19:22230956	C/G	cg11619707	chr19:22235551	ZNF257	0.32	5.29	0.31	2.53e-7	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
CESC	cis	rs7772486	0.743	rs9390344	chr6:146012755	C/G	cg05347473	chr6:146136440	FBXO30	-0.47	-6.09	-0.35	3.88e-9	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7590720	0.704	rs7603645	chr2:216876949	C/G	cg12620499	chr2:216877984	MREG	0.9	14.32	0.66	7.73e-35	Alcohol dependence;
CESC	cis	rs9894429	0.550	rs6565617	chr17:79612333	G/A	cg18240062	chr17:79603768	NPLOC4	0.54	7.05	0.4	1.56e-11	Eye color traits;
CESC	cis	rs1552244	0.882	rs6443279	chr3:10053599	C/A	cg00166722	chr3:10149974	C3orf24	0.48	5.98	0.34	7.15e-9	Alzheimer's disease;
CESC	cis	rs1707322	1.000	rs1768807	chr1:46510570	A/G	cg03146154	chr1:46216737	IPP	-0.72	-9.73	-0.51	2.49e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2249625	1.000	rs55970804	chr6:72923351	G/A	cg18830697	chr6:72922368	RIMS1	0.37	5.17	0.3	4.58e-7	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CESC	cis	rs644799	0.544	rs1527450	chr11:95467777	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.66	9.41	0.5	2.48e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs9488822	0.676	rs3798227	chr6:116324898	A/G	cg26893134	chr6:116381904	FRK	0.25	6.04	0.35	5.06e-9	Cholesterol, total;LDL cholesterol;
CESC	cis	rs634534	0.622	rs501353	chr11:65739549	T/G	cg04055107	chr11:65626734	MUS81;CFL1	0.44	5.59	0.32	5.77e-8	Sum eosinophil basophil counts;Eosinophil counts;
CESC	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg11494091	chr17:61959527	GH2	0.72	12.39	0.61	4.12e-28	Prudent dietary pattern;
CESC	cis	rs9902453	0.904	rs9894893	chr17:28270350	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	9.16	0.49	1.49e-17	Coffee consumption (cups per day);
CESC	cis	rs1580019	0.813	rs2044839	chr7:32500805	A/C	cg07520158	chr7:32535189	LSM5;AVL9	0.43	5.13	0.3	5.64e-7	Cognitive ability;
CESC	cis	rs9487051	0.700	rs7773815	chr6:109602343	A/C	cg01475377	chr6:109611718	NA	-0.44	-7.01	-0.4	2.01e-11	Reticulocyte fraction of red cells;
CESC	cis	rs6598955	0.724	rs12096059	chr1:26596709	G/A	cg04990556	chr1:26633338	UBXN11	-0.78	-11.2	-0.57	4.2e-24	Obesity-related traits;
CESC	cis	rs6424115	0.793	rs2502998	chr1:24198327	T/A	cg15997130	chr1:24165203	NA	0.38	5.11	0.3	6.3e-7	Immature fraction of reticulocytes;
CESC	trans	rs11098499	0.618	rs28491261	chr4:120294900	C/A	cg25214090	chr10:38739885	LOC399744	0.69	9.31	0.5	4.95e-18	Corneal astigmatism;
CESC	cis	rs2299587	0.554	rs9325823	chr8:17735871	A/G	cg08627089	chr8:17753878	FGL1	0.42	5.97	0.34	7.74e-9	Economic and political preferences;
CESC	cis	rs7666738	0.830	rs13148913	chr4:99009732	C/T	cg05340658	chr4:99064831	C4orf37	0.8	12.51	0.61	1.52e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4803468	1.000	rs4803469	chr19:41922775	A/C	cg14132834	chr19:41945861	ATP5SL	-0.68	-8.41	-0.46	2.55e-15	Height;
CESC	cis	rs780096	0.526	rs3845686	chr2:27655447	T/G	cg12648201	chr2:27665141	KRTCAP3	-0.32	-5.67	-0.33	3.81e-8	Total body bone mineral density;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21765577	chr8:145150022	CYC1	0.57	6.74	0.38	9.6e-11	Gut microbiome composition (summer);
CESC	cis	rs7264396	0.690	rs2425164	chr20:34434916	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.63	7.39	0.41	1.97e-12	Total cholesterol levels;
CESC	cis	rs11630290	0.566	rs4777395	chr15:64161693	T/G	cg12036633	chr15:63758958	NA	0.44	5.25	0.31	3.05e-7	Iris characteristics;
CESC	cis	rs459571	0.792	rs55923934	chr9:136888233	C/G	cg13789015	chr9:136890014	NCRNA00094	0.56	8.06	0.44	2.65e-14	Platelet distribution width;
CESC	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg18402987	chr7:1209562	NA	0.75	8.45	0.46	1.94e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs4423214	0.569	rs4944044	chr11:71120213	G/A	cg05163923	chr11:71159392	DHCR7	0.56	7.5	0.42	9.41e-13	Vitamin D levels;
CESC	cis	rs34638657	0.872	rs6420435	chr16:82184201	A/C	cg09439754	chr16:82129088	HSD17B2	-0.34	-5.14	-0.3	5.27e-7	Lung adenocarcinoma;
CESC	cis	rs1552244	1.000	rs7651058	chr3:10066964	C/T	cg08888203	chr3:10149979	C3orf24	0.49	6.33	0.36	1.05e-9	Alzheimer's disease;
CESC	cis	rs7551222	0.752	rs16853865	chr1:204465659	A/G	cg20240347	chr1:204465584	NA	-0.26	-5.32	-0.31	2.22e-7	Schizophrenia;
CESC	cis	rs9913156	0.793	rs55677157	chr17:4576620	C/T	cg00122941	chr17:4613640	ARRB2	0.86	10.05	0.53	2.34e-20	Lymphocyte counts;
CESC	cis	rs2832191	0.791	rs2832186	chr21:30484151	A/C	cg08807101	chr21:30365312	RNF160	-0.73	-10.3	-0.53	3.86e-21	Dental caries;
CESC	cis	rs7605827	0.866	rs13016989	chr2:15514338	T/A	cg19274914	chr2:15703543	NA	0.32	5.54	0.32	7.25e-8	Educational attainment (years of education);
CESC	cis	rs4925386	0.802	rs6142735	chr20:60918087	G/C	cg22633769	chr20:60982531	CABLES2	0.56	5.59	0.32	5.57e-8	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs3008870	0.917	rs12044492	chr1:67461667	T/C	cg08660285	chr1:67390436	MIER1;WDR78	-1.06	-15.19	-0.68	6.65e-38	Lymphocyte percentage of white cells;
CESC	cis	rs10504229	0.679	rs17801003	chr8:58050930	A/G	cg02725872	chr8:58115012	NA	-0.4	-5.26	-0.31	2.91e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs2070488	0.775	rs7649984	chr3:38570221	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.76	-11.59	-0.58	2.17e-25	Electrocardiographic conduction measures;
CESC	cis	rs798554	0.679	rs1639066	chr7:2892972	A/G	cg09658497	chr7:2847517	GNA12	-0.36	-5.11	-0.3	6.19e-7	Height;
CESC	cis	rs780096	0.546	rs12473776	chr2:27636474	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.28	-5.7	-0.33	3.25e-8	Total body bone mineral density;
CESC	cis	rs1371867	0.846	rs2083499	chr8:101230534	T/A	cg11906718	chr8:101322791	RNF19A	-0.5	-6.19	-0.36	2.22e-9	Atrioventricular conduction;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04184623	chr2:217277352	SMARCAL1	0.43	6.11	0.35	3.48e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs208520	0.661	rs207099	chr6:66796373	A/C	cg07460842	chr6:66804631	NA	-1.01	-13.47	-0.64	7.24e-32	Exhaled nitric oxide output;
CESC	cis	rs7537660	0.704	rs4925741	chr1:248007696	A/G	cg12080717	chr1:248004886	OR11L1	-0.42	-5.07	-0.3	7.31e-7	Platelet distribution width;
CESC	cis	rs6088580	0.608	rs2105109	chr20:32971932	A/G	cg06115741	chr20:33292138	TP53INP2	-0.46	-5.96	-0.34	7.8e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg06074448	chr4:187884817	NA	-0.48	-7.37	-0.41	2.15e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2836974	0.836	rs1041440	chr21:40627325	C/T	cg27266027	chr21:40555129	PSMG1	0.44	5.23	0.31	3.42e-7	Cognitive function;
CESC	cis	rs6502050	0.835	rs6502068	chr17:80112223	C/T	cg11859384	chr17:80120422	CCDC57	-0.4	-5.46	-0.32	1.11e-7	Life satisfaction;
CESC	trans	rs62103177	0.810	rs62103188	chr18:77627661	G/A	cg05926928	chr17:57297772	GDPD1	1.18	10.14	0.53	1.27e-20	Opioid sensitivity;
CESC	cis	rs10870270	0.957	rs3753008	chr10:133785129	A/C	cg17892150	chr10:133769511	PPP2R2D	-0.82	-11.95	-0.59	1.34e-26	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs10089	1.000	rs6887847	chr5:127473807	A/G	cg19767477	chr5:127420684	SLC12A2	-0.4	-5.41	-0.32	1.42e-7	Ileal carcinoids;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg10688328	chr15:31684499	NA	0.51	6.7	0.38	1.24e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs7666738	0.800	rs10008654	chr4:98820498	C/A	cg17366294	chr4:99064904	C4orf37	0.55	7.51	0.42	9.06e-13	Colonoscopy-negative controls vs population controls;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg11942622	chr15:79298659	RASGRF1	0.45	6.39	0.37	7.62e-10	Fibrinogen levels;
CESC	trans	rs17508449	0.819	rs4589108	chr1:114259625	T/A	cg23028848	chr11:57092561	TNKS1BP1	-0.76	-6.06	-0.35	4.57e-9	Leprosy;
CESC	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg06873352	chr17:61820015	STRADA	0.73	12.83	0.62	1.24e-29	Prudent dietary pattern;
CESC	cis	rs11645898	0.872	rs72787093	chr16:72190766	C/T	cg14768367	chr16:72042858	DHODH	-0.75	-6.29	-0.36	1.32e-9	Blood protein levels;
CESC	cis	rs801193	1.000	rs7789184	chr7:66210195	A/T	cg06456125	chr7:65229604	NA	0.4	5.23	0.31	3.51e-7	Aortic root size;
CESC	cis	rs79349575	0.783	rs17635252	chr17:47006950	T/C	cg16584676	chr17:46985605	UBE2Z	0.53	6.54	0.37	3.16e-10	Type 2 diabetes;
CESC	cis	rs9910055	0.821	rs4473241	chr17:42281282	G/T	cg19774624	chr17:42201019	HDAC5	-0.88	-13.31	-0.63	2.75e-31	Total body bone mineral density;
CESC	cis	rs2836974	0.627	rs8127986	chr21:40687211	A/T	cg11890956	chr21:40555474	PSMG1	-0.92	-14.67	-0.67	4.52e-36	Cognitive function;
CESC	cis	rs798554	0.757	rs1182188	chr7:2869985	T/C	cg19717773	chr7:2847554	GNA12	-0.57	-8.4	-0.46	2.78e-15	Height;
CESC	trans	rs208520	0.954	rs12190073	chr6:66983740	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.84	9.33	0.5	4.5e-18	Exhaled nitric oxide output;
CESC	cis	rs9733	0.596	rs17606613	chr1:150683015	C/T	cg18016565	chr1:150552671	MCL1	0.35	5.36	0.31	1.86e-7	Tonsillectomy;
CESC	trans	rs748404	0.578	rs512628	chr15:43618734	A/G	cg24053811	chr14:70265306	SLC10A1	0.42	6.03	0.35	5.55e-9	Lung cancer;
CESC	cis	rs1799949	0.859	rs11657004	chr17:41442751	A/G	cg25072359	chr17:41440525	NA	0.45	6.76	0.38	8.79e-11	Menopause (age at onset);
CESC	cis	rs10411936	0.712	rs10414751	chr19:16591695	G/A	cg10248733	chr19:16607483	C19orf44;CALR3	0.57	6.81	0.39	6.51e-11	White blood cell count;Multiple sclerosis;
CESC	cis	rs9457247	0.967	rs2769346	chr6:167370999	A/G	cg25258033	chr6:167368657	RNASET2	-0.42	-6.24	-0.36	1.73e-9	Crohn's disease;
CESC	cis	rs3091242	0.967	rs665372	chr1:25719235	A/C	cg27572855	chr1:25598939	RHD	0.44	7.32	0.41	3.02e-12	Erythrocyte sedimentation rate;
CESC	cis	rs11048434	0.736	rs12812913	chr12:9110836	C/G	cg23795048	chr12:9217529	LOC144571	0.35	5.4	0.31	1.52e-7	Sjögren's syndrome;
CESC	cis	rs73206853	0.609	rs7966169	chr12:111045898	T/C	cg12870014	chr12:110450643	ANKRD13A	0.68	5.87	0.34	1.33e-8	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs2204008	0.774	rs9669565	chr12:38294428	C/A	cg26384229	chr12:38710491	ALG10B	0.7	10.34	0.54	2.92e-21	Bladder cancer;
CESC	cis	rs7666738	0.830	rs28451101	chr4:99001190	T/C	cg18180107	chr4:99064573	C4orf37	0.4	5.23	0.31	3.41e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7116495	0.737	rs6592456	chr11:71737663	G/A	cg10381502	chr11:71823885	C11orf51	-1.12	-6.73	-0.38	1.03e-10	Severe influenza A (H1N1) infection;
CESC	cis	rs11249608	0.548	rs13161528	chr5:178452958	C/G	cg21905437	chr5:178450457	ZNF879	0.6	8.72	0.47	3.05e-16	Pubertal anthropometrics;
CESC	cis	rs1348850	0.872	rs4893825	chr2:178298687	A/G	cg23306229	chr2:178417860	TTC30B	0.58	6.88	0.39	4.28e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs858239	0.539	rs10254544	chr7:23220235	T/C	cg23682824	chr7:23144976	KLHL7	0.45	5.83	0.34	1.58e-8	Cerebrospinal fluid biomarker levels;
CESC	cis	rs904092	0.720	rs1230019	chr4:100172691	A/G	cg12011299	chr4:100065546	ADH4	0.54	6.13	0.35	3.23e-9	Alcohol dependence;
CESC	cis	rs3774749	0.565	rs2518796	chr3:50207075	A/G	cg24308560	chr3:49941425	MST1R	-0.43	-5.75	-0.33	2.43e-8	Intelligence (multi-trait analysis);
CESC	cis	rs9926296	0.712	rs258332	chr16:89727683	G/A	cg01097406	chr16:89675127	NA	0.37	5.27	0.31	2.87e-7	Vitiligo;
CESC	cis	rs7044106	0.791	rs4837793	chr9:123483621	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.39	6.22	0.36	1.96e-9	Hip circumference adjusted for BMI;
CESC	cis	rs6032067	0.777	rs2868234	chr20:43794026	C/T	cg11264863	chr20:43835661	SEMG1	0.5	5.35	0.31	1.86e-7	Blood protein levels;
CESC	cis	rs11190604	1.000	rs3750633	chr10:102308214	C/T	cg07080220	chr10:102295463	HIF1AN	0.62	5.65	0.33	4.17e-8	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs1707322	0.686	rs2230658	chr1:46078854	A/G	cg06784218	chr1:46089804	CCDC17	-0.43	-7.41	-0.41	1.7e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2242116	0.761	rs6780601	chr3:46965856	A/G	cg02527881	chr3:46936655	PTH1R	-0.5	-7.06	-0.4	1.46e-11	Birth weight;
CESC	cis	rs3126085	0.935	rs6587651	chr1:152193121	G/T	cg03465714	chr1:152285911	FLG	-0.42	-5.14	-0.3	5.24e-7	Atopic dermatitis;
CESC	cis	rs11190604	1.000	rs7080356	chr10:102266735	A/C	cg07080220	chr10:102295463	HIF1AN	0.61	5.78	0.33	2.06e-8	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs28830936	0.510	rs2412640	chr15:42124082	C/T	cg11010575	chr15:42129464	JMJD7-PLA2G4B;JMJD7	0.35	5.43	0.32	1.29e-7	Diastolic blood pressure;
CESC	trans	rs8073060	0.586	rs3859284	chr17:34012792	C/T	cg19694781	chr19:47549865	TMEM160	-0.74	-6.91	-0.39	3.64e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	cis	rs9911578	0.933	rs2531725	chr17:56517962	G/A	cg05425664	chr17:57184151	TRIM37	-0.49	-6.82	-0.39	6.08e-11	Intelligence (multi-trait analysis);
CESC	cis	rs919433	1.000	rs2195510	chr2:198161195	A/G	cg03934865	chr2:198174659	NA	-0.47	-7.15	-0.4	8.41e-12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs12136530	0.774	rs12137192	chr1:19763458	C/G	cg01832549	chr1:19774989	CAPZB	-0.46	-6.5	-0.37	3.9e-10	Lead levels in blood;
CESC	cis	rs10256972	1.000	rs10256972	chr7:1039003	G/T	cg07308232	chr7:1071921	C7orf50	0.45	6.25	0.36	1.65e-9	Longevity;Endometriosis;
CESC	cis	rs1707322	1.000	rs4524994	chr1:46370263	A/G	cg06784218	chr1:46089804	CCDC17	0.32	5.57	0.32	6.35e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs6460942	0.915	rs6968695	chr7:12443878	G/C	cg16278512	chr7:12443529	VWDE	-0.55	-5.87	-0.34	1.27e-8	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11241278	chr17:74023465	EVPL	-0.48	-6.83	-0.39	5.96e-11	Gut microbiome composition (summer);
CESC	cis	rs5758659	0.714	rs6002626	chr22:42517989	C/G	cg05082376	chr22:42548792	NA	0.35	5.11	0.3	6.08e-7	Cognitive function;
CESC	cis	rs6860806	0.695	rs11952099	chr5:131576772	A/G	cg18301423	chr5:131593218	PDLIM4	0.38	5.54	0.32	7.36e-8	Breast cancer;
CESC	cis	rs9916302	0.904	rs9904334	chr17:37468336	G/A	cg19468946	chr17:37922297	IKZF3	0.4	5.13	0.3	5.56e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs6503863	1	rs6503863	chr17:56517034	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.49	6.64	0.38	1.74e-10	Intelligence (multi-trait analysis);
CESC	cis	rs7532866	0.848	rs12401866	chr1:26726967	C/G	cg17456097	chr1:26900765	RPS6KA1	-0.49	-6.34	-0.36	9.91e-10	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24748448	chr17:3493352	TRPV1	-0.54	-6.43	-0.37	5.8e-10	Gut microbiome composition (summer);
CESC	cis	rs10504073	0.584	rs56078938	chr8:49940342	A/C	cg00325661	chr8:49890786	NA	0.59	8.79	0.47	1.99e-16	Blood metabolite ratios;
CESC	cis	rs3767633	1.000	rs3767633	chr1:161826615	T/A	cg09175582	chr1:161736000	ATF6	0.86	6.88	0.39	4.35e-11	IgG glycosylation;
CESC	cis	rs2273669	0.585	rs6900472	chr6:109372120	G/A	cg05315195	chr6:109294784	ARMC2	-0.67	-6.32	-0.36	1.13e-9	Prostate cancer;
CESC	cis	rs7247513	1.000	rs2042947	chr19:12693103	A/G	cg01871581	chr19:12707946	ZNF490	-0.87	-14.92	-0.68	5.76e-37	Bipolar disorder;
CESC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg21790971	chr4:54244117	FIP1L1	0.47	6.04	0.35	5.17e-9	Tetralogy of Fallot;
CESC	cis	rs9488822	0.676	rs6918059	chr6:116349041	C/T	cg18764771	chr6:116381957	FRK	0.23	5.7	0.33	3.15e-8	Cholesterol, total;LDL cholesterol;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17785250	chr5:140554081	PCDHB7	-0.54	-6.31	-0.36	1.18e-9	Gut microbiome composition (summer);
CESC	cis	rs7827545	0.545	rs6988000	chr8:135559534	C/T	cg17885191	chr8:135476712	NA	0.51	5.61	0.33	4.98e-8	Hypertension (SNP x SNP interaction);
CESC	cis	rs1185460	0.967	rs1786690	chr11:118942067	A/G	cg23280166	chr11:118938394	VPS11	0.5	6.57	0.37	2.6e-10	Coronary artery disease;
CESC	cis	rs6748734	0.843	rs6749674	chr2:241834501	G/C	cg15164180	chr2:241846931	NA	-0.34	-5.16	-0.3	4.77e-7	Urinary metabolites;
CESC	cis	rs3741151	0.892	rs77127734	chr11:73018413	T/A	cg17517138	chr11:73019481	ARHGEF17	0.75	6.24	0.36	1.76e-9	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs7312933	0.584	rs7974654	chr12:42630466	C/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.46	6.07	0.35	4.44e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs12477438	0.765	rs72957180	chr2:99694452	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.75	-10.87	-0.56	5.17e-23	Chronic sinus infection;
CESC	cis	rs1799949	1.000	rs8176126	chr17:41259049	A/G	cg05368731	chr17:41323189	NBR1	-0.79	-11.32	-0.57	1.76e-24	Menopause (age at onset);
CESC	cis	rs9916302	0.808	rs12947281	chr17:37652210	G/T	cg20243544	chr17:37824526	PNMT	0.51	6.5	0.37	3.97e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs8114671	0.836	rs3746432	chr20:33592763	C/T	cg07148914	chr20:33460835	GGT7	-0.41	-5.37	-0.31	1.75e-7	Height;
CESC	cis	rs12681288	0.676	rs34435811	chr8:990630	T/A	cg15309053	chr8:964076	NA	0.37	6.32	0.36	1.08e-9	Schizophrenia;
CESC	cis	rs796364	0.951	rs13029537	chr2:200998950	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.68	-6.65	-0.38	1.7e-10	Schizophrenia;
CESC	cis	rs7508	0.640	rs373983	chr8:17911905	C/T	cg18067069	chr8:17937731	ASAH1	-0.38	-5.18	-0.3	4.3e-7	Atrial fibrillation;
CESC	cis	rs2486288	0.656	rs12910009	chr15:45572408	A/G	cg09092052	chr15:45571596	NA	0.44	5.23	0.31	3.44e-7	Glomerular filtration rate;
CESC	cis	rs6724607	1.000	rs10165399	chr2:191441595	A/G	cg27211696	chr2:191398769	TMEM194B	0.5	7.49	0.42	1.06e-12	Pulse pressure;
CESC	cis	rs7666738	0.830	rs1559859	chr4:99024325	C/T	cg18180107	chr4:99064573	C4orf37	0.42	5.38	0.31	1.63e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6714710	0.580	rs1838797	chr2:98454572	G/C	cg26665480	chr2:98280029	ACTR1B	0.57	8.02	0.44	3.49e-14	Posterior cortical atrophy and Alzheimer's disease;
CESC	cis	rs9311474	0.508	rs4687629	chr3:52615227	G/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.38	6.94	0.39	3e-11	Electroencephalogram traits;
CESC	cis	rs6088580	0.634	rs1205336	chr20:32926336	G/A	cg24642439	chr20:33292090	TP53INP2	-0.51	-6.63	-0.38	1.85e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs2933343	0.729	rs1680785	chr3:128644816	C/T	cg25356066	chr3:128598488	ACAD9	0.6	8.44	0.46	2.09e-15	IgG glycosylation;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09087777	chr3:150321365	SELT	0.55	6.31	0.36	1.19e-9	Gut microbiome composition (summer);
CESC	cis	rs9303401	0.614	rs35245220	chr17:56510305	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.91	10.51	0.54	8.15e-22	Cognitive test performance;
CESC	cis	rs4563143	0.675	rs73029049	chr19:29275534	C/A	cg14983838	chr19:29218262	NA	0.5	6.16	0.35	2.67e-9	Methadone dose in opioid dependence;
CESC	trans	rs7173947	0.646	rs11634297	chr15:95267564	A/T	cg04728121	chr14:89883534	FOXN3	-0.47	-6.37	-0.36	8.34e-10	Hematological and biochemical traits;
CESC	cis	rs3096299	0.933	rs28608022	chr16:89454292	C/T	cg08822215	chr16:89438651	ANKRD11	-0.4	-6.08	-0.35	4.26e-9	Multiple myeloma (IgH translocation);
CESC	cis	rs11792861	1.000	rs11792861	chr9:111809295	A/C	cg05043794	chr9:111880884	C9orf5	-0.39	-6.38	-0.37	7.65e-10	Menarche (age at onset);
CESC	cis	rs1385374	0.858	rs10847698	chr12:129300222	T/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.6	5.22	0.31	3.61e-7	Systemic lupus erythematosus;
CESC	cis	rs9611565	0.592	rs5751139	chr22:42099981	G/C	cg06481639	chr22:41940642	POLR3H	0.59	5.95	0.34	8.35e-9	Vitiligo;
CESC	cis	rs853679	0.517	rs4713144	chr6:28106790	C/G	cg18032046	chr6:28092343	ZSCAN16	-0.55	-6.39	-0.37	7.41e-10	Depression;
CESC	cis	rs8067545	0.611	rs12949481	chr17:20190974	C/A	cg13482628	chr17:19912719	NA	-0.42	-5.62	-0.33	4.73e-8	Schizophrenia;
CESC	cis	rs9527	0.590	rs7092029	chr10:104823909	A/T	cg04362960	chr10:104952993	NT5C2	0.45	5.76	0.33	2.34e-8	Arsenic metabolism;
CESC	cis	rs11958404	0.789	rs72800604	chr5:157502940	C/T	cg05962755	chr5:157440814	NA	0.55	6.33	0.36	1.04e-9	IgG glycosylation;
CESC	cis	rs5498	0.869	rs892188	chr19:10409793	A/G	cg22910295	chr19:10403862	ICAM5	-0.42	-5.9	-0.34	1.11e-8	Lymphocyte counts;Soluble ICAM-1;Blood protein levels;
CESC	cis	rs9322193	0.847	rs62439808	chr6:149950826	C/T	cg07701084	chr6:150067640	NUP43	0.43	6.0	0.35	6.62e-9	Lung cancer;
CESC	cis	rs651907	0.557	rs7645391	chr3:101361506	C/G	cg12386194	chr3:101231763	SENP7	0.44	5.42	0.32	1.31e-7	Colorectal cancer;
CESC	cis	rs2933343	0.601	rs1680758	chr3:128594897	T/C	cg25356066	chr3:128598488	ACAD9	0.63	8.81	0.48	1.64e-16	IgG glycosylation;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14843989	chr17:10600751	C17orf48;SCO1	0.52	6.07	0.35	4.39e-9	Gut microbiome composition (summer);
CESC	cis	rs1005277	0.579	rs2505196	chr10:38393563	G/A	cg00409905	chr10:38381863	ZNF37A	-0.47	-6.3	-0.36	1.24e-9	Extrinsic epigenetic age acceleration;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09313436	chr12:49960191	MCRS1	-0.53	-6.15	-0.35	2.91e-9	Gut microbiome composition (summer);
CESC	cis	rs7552404	1.000	rs1498316	chr1:76159198	G/A	cg22875332	chr1:76189707	ACADM	0.63	7.33	0.41	2.78e-12	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs4604732	0.578	rs112449432	chr1:247624180	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	7.39	0.41	1.98e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs6540556	0.954	rs6540555	chr1:209936571	A/G	cg23920097	chr1:209922102	NA	-0.36	-5.28	-0.31	2.7e-7	Red blood cell count;
CESC	cis	rs6748734	1.000	rs3936203	chr2:241834654	C/T	cg07537917	chr2:241836409	C2orf54	0.25	5.32	0.31	2.18e-7	Urinary metabolites;
CESC	trans	rs17536732	0.786	rs10517756	chr4:162847919	C/T	cg12177677	chr2:158300475	CYTIP	-0.64	-6.25	-0.36	1.66e-9	Risky sexual behaviors (alcohol dependence interaction);
CESC	cis	rs2842992	0.915	rs1967802	chr6:160097791	G/A	cg11366901	chr6:160182831	ACAT2	0.8	9.78	0.52	1.69e-19	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs7605827	0.897	rs13014906	chr2:15614404	T/C	cg19274914	chr2:15703543	NA	0.35	6.22	0.36	1.93e-9	Educational attainment (years of education);
CESC	cis	rs11608355	0.521	rs6606707	chr12:109830241	T/G	cg19025524	chr12:109796872	NA	-0.54	-7.7	-0.43	2.8e-13	Neuroticism;
CESC	cis	rs7666738	0.830	rs4699592	chr4:98974202	A/C	cg03467027	chr4:99064603	C4orf37	0.43	5.4	0.31	1.49e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs12497850	0.931	rs9876848	chr3:48844059	G/A	cg03060546	chr3:49711283	APEH	0.44	5.44	0.32	1.18e-7	Parkinson's disease;
CESC	cis	rs684232	0.602	rs448465	chr17:559888	A/T	cg15660573	chr17:549704	VPS53	-0.75	-10.74	-0.55	1.41e-22	Prostate cancer;
CESC	cis	rs6748734	0.625	rs9288743	chr2:241821569	C/G	cg04034577	chr2:241836375	C2orf54	-0.29	-5.32	-0.31	2.23e-7	Urinary metabolites;
CESC	cis	rs7089973	0.604	rs17663387	chr10:116588060	C/G	cg25233709	chr10:116636983	FAM160B1	0.35	5.71	0.33	2.97e-8	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs8072100	1.000	rs8065669	chr17:45724996	G/A	cg08085267	chr17:45401833	C17orf57	-0.43	-5.58	-0.32	5.97e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs2415984	0.579	rs61993338	chr14:46969142	T/C	cg14871534	chr14:47121158	RPL10L	-0.35	-5.23	-0.31	3.52e-7	Number of children ever born;
CESC	cis	rs2576037	0.583	rs8096263	chr18:44515216	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.35	5.71	0.33	3.08e-8	Personality dimensions;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25533943	chr17:43325323	LOC100133991	0.58	6.43	0.37	5.94e-10	Gut microbiome composition (summer);
CESC	cis	rs801193	0.591	rs721717	chr7:66130292	G/T	cg11764359	chr7:65958608	NA	-0.73	-10.48	-0.54	1.01e-21	Aortic root size;
CESC	cis	rs4853012	0.887	rs6737314	chr2:74339586	A/G	cg01017244	chr2:74357527	NA	0.53	6.96	0.39	2.68e-11	Gestational age at birth (maternal effect);
CESC	cis	rs9733	0.596	rs72702556	chr1:150680115	C/T	cg17724175	chr1:150552817	MCL1	0.45	7.33	0.41	2.83e-12	Tonsillectomy;
CESC	cis	rs684232	0.602	rs8064796	chr17:525937	A/C	cg12384639	chr17:618140	VPS53	0.42	5.42	0.32	1.32e-7	Prostate cancer;
CESC	cis	rs9311474	0.508	rs6786043	chr3:52604861	A/G	cg07507251	chr3:52567010	NT5DC2	0.32	5.64	0.33	4.4e-8	Electroencephalogram traits;
CESC	cis	rs4727027	0.933	rs9718383	chr7:148857624	A/T	cg23158103	chr7:148848205	ZNF398	0.42	6.73	0.38	1.04e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs4803468	1.000	rs1043413	chr19:41939297	C/G	cg09537434	chr19:41945824	ATP5SL	1.06	19.78	0.77	4.24e-54	Height;
CESC	cis	rs2836974	0.623	rs34240248	chr21:40685239	A/G	cg11890956	chr21:40555474	PSMG1	-0.94	-14.72	-0.67	2.99e-36	Cognitive function;
CESC	cis	rs3733585	0.683	rs13112015	chr4:9933796	C/T	cg02734326	chr4:10020555	SLC2A9	-0.4	-5.87	-0.34	1.28e-8	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs35306767	0.855	rs34318754	chr10:890714	G/A	cg26597838	chr10:835615	NA	1.2	11.12	0.56	7.74e-24	Eosinophil percentage of granulocytes;
CESC	cis	rs875971	0.642	rs35526611	chr7:66094008	C/T	cg11764359	chr7:65958608	NA	-0.71	-9.33	-0.5	4.44e-18	Aortic root size;
CESC	cis	rs9733	0.744	rs12125650	chr1:150760174	A/G	cg22823121	chr1:150693482	HORMAD1	-0.38	-5.76	-0.33	2.33e-8	Tonsillectomy;
CESC	cis	rs17253792	0.822	rs45501402	chr14:56140115	C/T	cg01858014	chr14:56050164	KTN1	-0.97	-7.54	-0.42	7.36e-13	Putamen volume;
CESC	trans	rs116095464	0.558	rs56127718	chr5:270273	G/T	cg00938859	chr5:1591904	SDHAP3	0.63	6.88	0.39	4.31e-11	Breast cancer;
CESC	cis	rs769267	0.930	rs4808203	chr19:19568659	A/G	cg03709012	chr19:19516395	GATAD2A	1.02	15.3	0.68	2.7e-38	Tonsillectomy;
CESC	cis	rs644799	0.965	rs10831430	chr11:95509638	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.54	6.63	0.38	1.82e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs9916302	0.904	rs755500	chr17:37409865	C/T	cg07936489	chr17:37558343	FBXL20	-0.76	-10.43	-0.54	1.43e-21	Glomerular filtration rate (creatinine);
CESC	cis	rs60871478	0.730	rs13222476	chr7:826630	T/C	cg05535760	chr7:792225	HEATR2	0.97	11.19	0.57	4.78e-24	Cerebrospinal P-tau181p levels;
CESC	cis	rs8062405	1.000	rs4788095	chr16:28831359	T/C	cg08761264	chr16:28874980	SH2B1	-0.47	-5.84	-0.34	1.55e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs9905704	0.624	rs4932691	chr17:57094617	T/C	cg12560992	chr17:57184187	TRIM37	-0.61	-7.57	-0.42	6.31e-13	Testicular germ cell tumor;
CESC	cis	rs6542838	0.641	rs13005124	chr2:99527680	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.5	-6.19	-0.36	2.25e-9	Fear of minor pain;
CESC	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg11494091	chr17:61959527	GH2	0.72	12.33	0.6	6.37e-28	Prudent dietary pattern;
CESC	cis	rs644799	1.000	rs651445	chr11:95539122	T/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.92	13.87	0.65	2.93e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs6952808	0.825	rs11761818	chr7:1935273	C/T	cg08027265	chr7:2291960	NA	-0.34	-5.13	-0.3	5.48e-7	Bipolar disorder and schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06120425	chr2:148602075	ACVR2A	0.6	7.13	0.4	9.69e-12	Gut microbiome composition (summer);
CESC	cis	rs2594989	0.943	rs2594995	chr3:11369117	A/G	cg00170343	chr3:11313890	ATG7	-0.55	-5.1	-0.3	6.42e-7	Circulating chemerin levels;
CESC	cis	rs4899554	0.509	rs78368951	chr14:75730348	A/G	cg18117039	chr14:75741733	NA	0.45	5.84	0.34	1.49e-8	Inflammatory bowel disease;
CESC	cis	rs10779751	0.734	rs2791650	chr1:11132541	G/C	cg08854313	chr1:11322531	MTOR	0.76	10.24	0.53	5.91e-21	Body mass index;
CESC	cis	rs863345	0.604	rs12025831	chr1:158496282	G/A	cg12129480	chr1:158549410	OR10X1	-0.35	-6.87	-0.39	4.55e-11	Pneumococcal bacteremia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05468429	chr6:7248862	RREB1	-0.53	-6.33	-0.36	1.05e-9	Gut microbiome composition (summer);
CESC	cis	rs7210086	0.948	rs72849448	chr17:70638323	C/A	cg04206342	chr17:70636940	NA	-0.35	-6.01	-0.35	6.05e-9	Ulcerative colitis;
CESC	cis	rs9311474	0.508	rs4687546	chr3:52605943	T/A	cg07507251	chr3:52567010	NT5DC2	0.33	5.69	0.33	3.36e-8	Electroencephalogram traits;
CESC	cis	rs34172651	0.876	rs2547033	chr16:24743657	C/T	cg06028605	chr16:24865363	SLC5A11	0.4	6.18	0.36	2.37e-9	Intelligence (multi-trait analysis);
CESC	cis	rs9616064	0.531	rs867212	chr22:47063330	C/T	cg25730555	chr22:47059586	GRAMD4	-0.48	-6.29	-0.36	1.3e-9	Urate levels in obese individuals;
CESC	cis	rs873946	0.648	rs1548281	chr10:134552982	C/T	cg27286337	chr10:134555280	INPP5A	0.68	8.0	0.44	3.93e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs796364	0.760	rs2881594	chr2:201026183	T/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.74	-6.24	-0.36	1.76e-9	Schizophrenia;
CESC	cis	rs62432291	0.681	rs3003173	chr6:159665692	G/T	cg14500486	chr6:159655392	FNDC1	-0.65	-6.12	-0.35	3.27e-9	Joint mobility (Beighton score);
CESC	cis	rs2073300	0.609	rs6132610	chr20:23403987	C/T	cg16736954	chr20:23401023	NAPB	0.78	5.69	0.33	3.37e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs5758659	1.000	rs5758677	chr22:42643039	A/C	cg15557168	chr22:42548783	NA	-0.49	-7.75	-0.43	1.92e-13	Cognitive function;
CESC	cis	rs60871478	0.636	rs73045423	chr7:893952	G/A	cg13798912	chr7:905769	UNC84A	-0.56	-5.53	-0.32	7.82e-8	Cerebrospinal P-tau181p levels;
CESC	cis	rs6121246	0.909	rs6119725	chr20:30385557	G/T	cg13852791	chr20:30311386	BCL2L1	0.81	8.61	0.47	6.48e-16	Mean corpuscular hemoglobin;
CESC	cis	rs7605827	0.930	rs7588148	chr2:15706392	G/A	cg19274914	chr2:15703543	NA	0.36	6.47	0.37	4.83e-10	Educational attainment (years of education);
CESC	cis	rs3126085	1.000	rs72698906	chr1:152307184	G/A	cg03465714	chr1:152285911	FLG	0.48	5.45	0.32	1.17e-7	Atopic dermatitis;
CESC	cis	rs2191566	0.648	rs62115511	chr19:44583289	T/C	cg20607764	chr19:44506953	ZNF230	-0.42	-5.33	-0.31	2.09e-7	Acute lymphoblastic leukemia (childhood);
CESC	trans	rs561341	1.000	rs55643307	chr17:30263074	T/C	cg20587970	chr11:113659929	NA	-1.43	-17.68	-0.74	9.48e-47	Hip circumference adjusted for BMI;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08252855	chr14:24550926	NRL	0.54	6.64	0.38	1.75e-10	Gut microbiome composition (summer);
CESC	cis	rs8020095	0.528	rs1955604	chr14:67436440	G/C	cg19548862	chr14:67692701	FAM71D	-0.48	-5.72	-0.33	2.86e-8	Depression (quantitative trait);
CESC	cis	rs1799949	0.930	rs33968979	chr17:41297992	G/T	cg05368731	chr17:41323189	NBR1	0.8	11.27	0.57	2.51e-24	Menopause (age at onset);
CESC	cis	rs372883	0.600	rs2832294	chr21:30739671	A/C	cg24692254	chr21:30365293	RNF160	0.58	7.23	0.41	5.32e-12	Pancreatic cancer;
CESC	cis	rs9943753	0.508	rs5013021	chr12:109790752	C/A	cg19025524	chr12:109796872	NA	-0.48	-6.9	-0.39	3.9e-11	HDL cholesterol;
CESC	cis	rs9486719	0.947	rs6916232	chr6:96985959	A/T	cg18709589	chr6:96969512	KIAA0776	0.55	6.31	0.36	1.18e-9	Migraine;Coronary artery disease;
CESC	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.55	7.35	0.41	2.47e-12	Lymphocyte counts;
CESC	cis	rs875971	0.862	rs6955837	chr7:66043142	C/T	cg11764359	chr7:65958608	NA	-0.78	-11.17	-0.57	5.37e-24	Aortic root size;
CESC	cis	rs8060686	0.858	rs8057986	chr16:67893879	A/G	cg26727032	chr16:67993705	SLC12A4	-0.66	-9.63	-0.51	5.27e-19	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs9318086	0.712	rs9510917	chr13:24442846	C/T	cg25267304	chr13:24462978	PCOTH;MIPEP	0.39	5.25	0.31	3.17e-7	Myopia (pathological);
CESC	cis	rs67311347	0.911	rs6776044	chr3:40377503	T/G	cg09455208	chr3:40491958	NA	0.49	8.42	0.46	2.47e-15	Renal cell carcinoma;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19121055	chr22:20307793	DGCR6L	0.55	6.22	0.36	1.89e-9	Gut microbiome composition (summer);
CESC	cis	rs41271473	0.526	rs10916344	chr1:228737489	C/T	cg10167378	chr1:228756711	NA	0.51	5.28	0.31	2.73e-7	Chronic lymphocytic leukemia;
CESC	trans	rs1728785	0.901	rs1631910	chr16:68603335	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	8.03	0.44	3.13e-14	Ulcerative colitis;
CESC	cis	rs7827545	0.644	rs4909452	chr8:135521053	C/G	cg17885191	chr8:135476712	NA	-0.56	-7.58	-0.42	5.86e-13	Hypertension (SNP x SNP interaction);
CESC	cis	rs1862618	0.853	rs252915	chr5:56121754	C/T	cg03609598	chr5:56110824	MAP3K1	0.52	5.62	0.33	4.84e-8	Initial pursuit acceleration;
CESC	cis	rs10484885	0.878	rs55750696	chr6:90552336	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.76	-7.22	-0.41	5.66e-12	QRS interval (sulfonylurea treatment interaction);
CESC	cis	rs644799	1.000	rs627568	chr11:95569253	A/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.69	8.64	0.47	5.31e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs7927592	0.913	rs6591346	chr11:68384618	T/A	cg20283391	chr11:68216788	NA	-0.47	-5.97	-0.34	7.58e-9	Total body bone mineral density;
CESC	cis	rs929354	0.772	rs3802123	chr7:156970641	G/A	cg05182265	chr7:156933206	UBE3C	-0.46	-6.6	-0.38	2.29e-10	Body mass index;
CESC	cis	rs7537660	0.866	rs4925738	chr1:248005613	G/T	cg12080717	chr1:248004886	OR11L1	-0.43	-5.27	-0.31	2.88e-7	Platelet distribution width;
CESC	cis	rs2635047	0.624	rs2289036	chr18:44595809	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.5	-6.96	-0.39	2.69e-11	Educational attainment;
CESC	cis	rs9611565	0.512	rs5751147	chr22:42139054	G/A	cg17376030	chr22:41985996	PMM1	-0.78	-8.33	-0.46	4.43e-15	Vitiligo;
CESC	cis	rs1538970	0.810	rs12067642	chr1:45927517	G/T	cg05343316	chr1:45956843	TESK2	0.84	11.95	0.59	1.29e-26	Platelet count;
CESC	cis	rs2836974	0.897	rs13049280	chr21:40594656	C/G	cg11644478	chr21:40555479	PSMG1	0.98	14.24	0.66	1.45e-34	Cognitive function;
CESC	cis	rs5769707	0.732	rs135865	chr22:50004829	G/A	cg05373962	chr22:49881684	NA	-0.39	-6.51	-0.37	3.69e-10	Monocyte count;Monocyte percentage of white cells;
CESC	trans	rs9325144	0.560	rs61929893	chr12:38653366	G/A	cg23762105	chr12:34175262	ALG10	0.48	6.31	0.36	1.15e-9	Morning vs. evening chronotype;
CESC	cis	rs9322193	0.923	rs11155683	chr6:150100477	T/C	cg13206674	chr6:150067644	NUP43	0.41	5.78	0.33	2.05e-8	Lung cancer;
CESC	cis	rs853679	0.517	rs56364346	chr6:28050762	T/G	cg20151795	chr6:28129481	ZNF389	0.44	5.59	0.33	5.5e-8	Depression;
CESC	cis	rs2439831	0.717	rs9806227	chr15:43680115	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.91	11.14	0.56	6.61e-24	Lung cancer in ever smokers;
CESC	trans	rs10028773	0.600	rs4001390	chr4:120265783	G/C	cg25214090	chr10:38739885	LOC399744	0.59	8.14	0.45	1.55e-14	Educational attainment;
CESC	cis	rs728616	0.614	rs57342950	chr10:82105081	G/A	cg05935833	chr10:81318306	SFTPA2	-0.37	-5.22	-0.31	3.54e-7	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs853679	0.517	rs9368550	chr6:28051803	T/A	cg12963246	chr6:28129442	ZNF389	0.55	7.35	0.41	2.46e-12	Depression;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18510056	chr10:77163383	C10orf41	-0.69	-8.74	-0.47	2.79e-16	Gut microbiome composition (summer);
CESC	cis	rs7208859	0.673	rs61223749	chr17:29163747	G/A	cg19761014	chr17:28927070	LRRC37B2	0.72	5.68	0.33	3.48e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	trans	rs11098499	0.738	rs28687057	chr4:120280812	A/G	cg25214090	chr10:38739885	LOC399744	0.65	9.11	0.49	2.04e-17	Corneal astigmatism;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg06905471	chr2:29092871	TRMT61B	-0.53	-8.04	-0.44	3.02e-14	Gambling;
CESC	trans	rs7107217	1.000	rs1873872	chr11:129473993	A/T	cg20490126	chr1:25870007	LDLRAP1	0.52	6.76	0.38	9.02e-11	Breast cancer;Type 2 diabetes;
CESC	cis	rs2842992	0.830	rs2842966	chr6:160141592	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.7	8.69	0.47	3.79e-16	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs2404602	0.716	rs67920045	chr15:76800084	G/A	cg26408565	chr15:76604113	ETFA	-0.39	-5.71	-0.33	3.04e-8	Blood metabolite levels;
CESC	cis	rs4629180	0.675	rs6742474	chr2:102091075	G/A	cg04415270	chr2:102091202	RFX8	-0.33	-5.59	-0.32	5.72e-8	Chronic rhinosinusitis with nasal polyps;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02473084	chr2:37551451	NA	0.68	7.87	0.44	9.06e-14	Gut microbiome composition (summer);
CESC	cis	rs61542988	0.570	rs10950919	chr7:22833821	A/G	cg11367502	chr7:22862612	TOMM7	0.54	6.48	0.37	4.33e-10	Fibrinogen levels;
CESC	cis	rs9322193	0.847	rs12191643	chr6:149950048	C/T	cg07701084	chr6:150067640	NUP43	0.44	6.15	0.35	2.83e-9	Lung cancer;
CESC	cis	rs1505368	0.789	rs13419353	chr2:213271459	A/T	cg16329650	chr2:213403929	ERBB4	-0.41	-5.77	-0.33	2.15e-8	Symmetrical dimethylarginine levels;
CESC	cis	rs9915657	0.933	rs17246133	chr17:70140485	A/G	cg09344028	chr17:70110421	NA	0.3	5.68	0.33	3.51e-8	Thyroid hormone levels;
CESC	cis	rs7552404	0.727	rs6683437	chr1:76316619	G/A	cg03433033	chr1:76189801	ACADM	0.63	6.24	0.36	1.68e-9	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs1008375	0.966	rs10939758	chr4:17698255	C/T	cg02297831	chr4:17616191	MED28	0.44	5.37	0.31	1.73e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs6952808	0.594	rs3778965	chr7:2138296	G/A	cg08027265	chr7:2291960	NA	-0.45	-6.96	-0.39	2.71e-11	Bipolar disorder and schizophrenia;
CESC	trans	rs1814175	0.519	rs10839291	chr11:49514321	G/A	cg15704280	chr7:45808275	SEPT13	0.82	9.88	0.52	8.15e-20	Height;
CESC	cis	rs2197308	0.623	rs1672426	chr12:38118671	C/T	cg26384229	chr12:38710491	ALG10B	-0.42	-5.75	-0.33	2.5e-8	Morning vs. evening chronotype;
CESC	cis	rs3845702	0.736	rs72962517	chr2:180861452	G/A	cg01881094	chr2:180872142	CWC22	1.08	9.4	0.5	2.75e-18	Schizophrenia;
CESC	cis	rs6942756	1.000	rs68076553	chr7:128959632	A/G	cg02491457	chr7:128862824	NA	-0.66	-8.95	-0.48	6.38e-17	White matter hyperintensity burden;
CESC	cis	rs4132509	1.000	rs6675851	chr1:243787494	G/A	cg21452805	chr1:244014465	NA	0.43	5.06	0.3	7.8e-7	RR interval (heart rate);
CESC	trans	rs10905099	0.708	rs11254970	chr10:7094554	G/A	cg05230642	chr15:25439252	SNORD115-14	-0.73	-6.17	-0.35	2.6e-9	Orofacial clefts;
CESC	trans	rs17125944	0.615	rs2025633	chr14:53317340	C/T	cg01134794	chr4:78529898	CXCL13	0.54	6.2	0.36	2.13e-9	Alzheimer's disease (late onset);
CESC	cis	rs40363	0.723	rs8060367	chr16:3537919	C/A	cg21433313	chr16:3507492	NAT15	-0.61	-6.71	-0.38	1.16e-10	Tuberculosis;
CESC	cis	rs425277	0.585	rs3128294	chr1:2065343	G/C	cg23803603	chr1:2058230	PRKCZ	-0.31	-5.08	-0.3	7.14e-7	Height;
CESC	cis	rs9814567	1.000	rs1874883	chr3:134205071	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.45	-6.22	-0.36	1.92e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs853679	0.517	rs9295759	chr6:28124469	C/T	cg20151795	chr6:28129481	ZNF389	0.46	5.74	0.33	2.6e-8	Depression;
CESC	cis	rs965469	1.000	rs2236089	chr20:3257194	C/A	cg25506879	chr20:3388711	C20orf194	-0.59	-6.27	-0.36	1.48e-9	IFN-related cytopenia;
CESC	cis	rs7833986	0.501	rs72653948	chr8:56955689	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.6	7.34	0.41	2.58e-12	Height;
CESC	cis	rs7084402	0.967	rs2114564	chr10:60314729	T/C	cg07615347	chr10:60278583	BICC1	0.58	8.82	0.48	1.52e-16	Refractive error;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg00745731	chr19:929724	ARID3A	0.45	6.29	0.36	1.34e-9	Fibrinogen levels;
CESC	cis	rs7000551	0.751	rs2461490	chr8:22370115	G/C	cg12081754	chr8:22256438	SLC39A14	0.39	5.19	0.3	4.1e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CESC	cis	rs1950626	0.750	rs12895798	chr14:101442793	T/C	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.83	11.29	0.57	2.14e-24	Pelvic organ prolapse (moderate/severe);
CESC	cis	rs561341	1.000	rs113676348	chr17:30244327	A/G	cg19193384	chr17:30244184	NA	-0.66	-6.97	-0.39	2.5e-11	Hip circumference adjusted for BMI;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg19655070	chr17:43237981	HEXIM2	-0.44	-6.06	-0.35	4.74e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs17384381	0.953	rs1498374	chr1:85787334	C/T	cg16011679	chr1:85725395	C1orf52	0.79	7.98	0.44	4.35e-14	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs3808502	0.549	rs11991139	chr8:11428395	C/T	cg06636001	chr8:8085503	FLJ10661	-0.55	-6.51	-0.37	3.71e-10	Neuroticism;
CESC	trans	rs10435719	0.867	rs34465618	chr8:11791356	C/T	cg15556689	chr8:8085844	FLJ10661	0.52	6.35	0.36	9.52e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
CESC	cis	rs769267	0.930	rs7256149	chr19:19566255	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.46	5.93	0.34	9.3e-9	Tonsillectomy;
CESC	cis	rs11252926	0.801	rs11252332	chr10:467318	A/T	cg18196295	chr10:418757	DIP2C	0.47	5.63	0.33	4.51e-8	Psychosis in Alzheimer's disease;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg10869376	chr13:41345315	MRPS31	0.46	6.12	0.35	3.44e-9	Systemic lupus erythematosus;
CESC	cis	rs9915657	0.870	rs11077595	chr17:70130030	C/T	cg06234051	chr17:70120541	SOX9	-0.44	-6.38	-0.37	7.69e-10	Thyroid hormone levels;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg09093137	chr7:105028539	SRPK2	-0.49	-7.41	-0.41	1.71e-12	Gambling;
CESC	cis	rs769267	0.931	rs2965197	chr19:19470910	C/T	cg15052019	chr19:19431593	KIAA0892;SF4	-0.42	-5.31	-0.31	2.38e-7	Tonsillectomy;
CESC	cis	rs40363	1.000	rs1635393	chr16:3520493	C/T	cg22508957	chr16:3507546	NAT15	0.68	8.58	0.47	7.9e-16	Tuberculosis;
CESC	cis	rs7833790	0.660	rs10091077	chr8:82705464	A/G	cg27398817	chr8:82754497	SNX16	-0.42	-5.25	-0.31	3.13e-7	Diastolic blood pressure;
CESC	cis	rs826838	0.967	rs1352122	chr12:39130885	G/A	cg26384229	chr12:38710491	ALG10B	-0.67	-11.03	-0.56	1.63e-23	Heart rate;
CESC	cis	rs10751667	0.643	rs7396623	chr11:934104	G/A	cg06064525	chr11:970664	AP2A2	-0.49	-9.61	-0.51	5.84e-19	Alzheimer's disease (late onset);
CESC	cis	rs7827545	0.960	rs1372661	chr8:135566859	A/G	cg17885191	chr8:135476712	NA	0.48	6.28	0.36	1.35e-9	Hypertension (SNP x SNP interaction);
CESC	cis	rs2404602	0.647	rs116090606	chr15:77075209	A/G	cg23625390	chr15:77176239	SCAPER	-0.47	-6.5	-0.37	3.86e-10	Blood metabolite levels;
CESC	cis	rs35110281	0.633	rs762400	chr21:45113629	C/G	cg04455712	chr21:45112962	RRP1B	-0.46	-7.39	-0.41	1.94e-12	Mean corpuscular volume;
CESC	cis	rs7843479	1.000	rs2306641	chr8:21833965	A/G	cg17168535	chr8:21777572	XPO7	-0.48	-6.73	-0.38	1.02e-10	Mean corpuscular volume;
CESC	cis	rs681343	1.000	rs679574	chr19:49206108	C/G	cg21064579	chr19:49206444	FUT2	0.52	7.36	0.41	2.36e-12	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
CESC	trans	rs2415984	0.818	rs10149370	chr14:46850711	T/C	cg14945696	chr3:52713679	PBRM1	-0.4	-6.19	-0.36	2.32e-9	Number of children ever born;
CESC	cis	rs34779708	0.966	rs34776628	chr10:35426324	G/A	cg04310649	chr10:35416472	CREM	-0.52	-6.45	-0.37	5.15e-10	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs9287719	0.753	rs1990613	chr2:10781975	C/T	cg00105475	chr2:10696890	NA	-0.34	-5.23	-0.31	3.46e-7	Prostate cancer;
CESC	cis	rs11792861	0.855	rs116127510	chr9:111868344	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.41	5.15	0.3	5.08e-7	Menarche (age at onset);
CESC	cis	rs4901847	0.562	rs11627221	chr14:58617216	G/T	cg15908186	chr14:58618357	C14orf37	0.37	5.75	0.33	2.5e-8	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs9303401	0.659	rs35928756	chr17:56702652	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.03	13.13	0.63	1.12e-30	Cognitive test performance;
CESC	cis	rs3820068	0.603	rs6429767	chr1:15963334	G/A	cg17385448	chr1:15911702	AGMAT	0.42	6.89	0.39	4.06e-11	Systolic blood pressure;
CESC	cis	rs6952808	0.595	rs3800917	chr7:2167939	A/G	cg04267008	chr7:1944627	MAD1L1	0.56	6.57	0.37	2.66e-10	Bipolar disorder and schizophrenia;
CESC	cis	rs5758659	0.622	rs129856	chr22:42399396	C/G	cg15557168	chr22:42548783	NA	-0.43	-6.3	-0.36	1.22e-9	Cognitive function;
CESC	trans	rs11039798	1.000	rs10838942	chr11:48557163	C/G	cg15704280	chr7:45808275	SEPT13	0.7	6.53	0.37	3.42e-10	Axial length;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg05463257	chr3:182782445	MCCC1	-0.46	-6.32	-0.36	1.07e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs644799	0.930	rs2186782	chr11:95649543	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.8	11.62	0.58	1.66e-25	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs1538970	0.847	rs1771550	chr1:45883565	C/T	cg24296786	chr1:45957014	TESK2	0.44	5.41	0.32	1.4e-7	Platelet count;
CESC	cis	rs2479106	0.549	rs7855648	chr9:126380439	A/G	cg16191174	chr9:126692580	DENND1A	0.38	5.32	0.31	2.2e-7	Polycystic ovary syndrome;
CESC	cis	rs514406	0.505	rs7543239	chr1:53162416	A/G	cg24675658	chr1:53192096	ZYG11B	-0.52	-6.6	-0.38	2.19e-10	Monocyte count;
CESC	cis	rs7937682	0.924	rs7938360	chr11:111539875	A/G	cg22437258	chr11:111473054	SIK2	0.69	9.16	0.49	1.44e-17	Primary sclerosing cholangitis;
CESC	cis	rs2710642	0.611	rs1843779	chr2:62866762	T/C	cg17519650	chr2:63277830	OTX1	0.47	5.54	0.32	7.36e-8	LDL cholesterol levels;LDL cholesterol;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg27512018	chr19:11039304	YIPF2;C19orf52	-0.44	-6.81	-0.39	6.33e-11	Gambling;
CESC	cis	rs34638686	1	rs34638686	chr3:48682658	C/T	cg07636037	chr3:49044803	WDR6	-0.66	-5.19	-0.3	4.09e-7	Educational attainment (years of education);
CESC	cis	rs7103648	0.864	rs10742802	chr11:47432725	T/G	cg03711944	chr11:47377212	SPI1	-0.31	-5.04	-0.3	8.72e-7	Diastolic blood pressure;Systolic blood pressure;
CESC	cis	rs62064224	0.546	rs1018866	chr17:30829664	A/C	cg09324608	chr17:30823087	MYO1D	0.49	7.3	0.41	3.46e-12	Schizophrenia;
CESC	cis	rs9896933	0.623	rs77166830	chr17:80833525	T/C	cg20578329	chr17:80767326	TBCD	-0.75	-7.78	-0.43	1.62e-13	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
CESC	cis	rs7809950	0.678	rs75617662	chr7:107030439	G/A	cg23024343	chr7:107201750	COG5	-0.58	-7.26	-0.41	4.42e-12	Coronary artery disease;
CESC	cis	rs6430585	0.528	rs309161	chr2:136688749	A/G	cg07169764	chr2:136633963	MCM6	-1.06	-14.93	-0.68	5.44e-37	Corneal structure;
CESC	cis	rs7208859	0.623	rs73269945	chr17:29108759	G/A	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.91e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs1799949	0.965	rs4793230	chr17:41427403	A/C	cg25072359	chr17:41440525	NA	0.52	7.74	0.43	2.12e-13	Menopause (age at onset);
CESC	cis	rs2637266	0.783	rs846634	chr10:78535323	C/A	cg18941641	chr10:78392320	NA	0.42	8.31	0.45	5.01e-15	Pulmonary function;
CESC	cis	rs4930103	1.000	rs4929983	chr11:2024579	C/T	cg23202291	chr11:1979235	NA	0.37	5.61	0.33	4.99e-8	DNA methylation (parent-of-origin);DNA methylation (variation);
CESC	cis	rs597539	0.580	rs7935851	chr11:68731122	A/G	cg01988459	chr11:68622903	NA	-0.43	-5.76	-0.33	2.38e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs8070128	0.600	rs8071238	chr17:17900990	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.62	8.75	0.47	2.51e-16	Total body bone mineral density;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25589956	chr3:186545102	NA	0.53	6.21	0.36	2.02e-9	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19901472	chr1:29557379	MECR	-0.56	-6.15	-0.35	2.8e-9	Gut microbiome composition (summer);
CESC	cis	rs875971	0.830	rs7799834	chr7:65880694	A/C	cg18876405	chr7:65276391	NA	0.52	6.87	0.39	4.49e-11	Aortic root size;
CESC	cis	rs853679	0.550	rs1150692	chr6:28173957	A/G	cg23281280	chr6:28129359	ZNF389	0.5	6.94	0.39	3.07e-11	Depression;
CESC	cis	rs747782	0.646	rs17198158	chr11:47477849	A/G	cg25783544	chr11:47291846	MADD	0.52	5.13	0.3	5.6e-7	Intraocular pressure;
CESC	cis	rs1008375	0.931	rs6831211	chr4:17697009	G/A	cg27347728	chr4:17578864	LAP3	0.43	5.04	0.3	8.51e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs1215050	0.740	rs1214994	chr4:99035577	C/T	cg17366294	chr4:99064904	C4orf37	0.4	5.17	0.3	4.54e-7	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs55883249	1.000	rs17453724	chr2:9764001	A/G	cg23886495	chr2:9695866	ADAM17	0.61	5.51	0.32	8.34e-8	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
CESC	cis	rs9811920	0.799	rs9832134	chr3:99836722	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.42	5.18	0.3	4.32e-7	Axial length;
CESC	cis	rs116095464	0.558	rs10043002	chr5:226753	G/A	cg22857025	chr5:266934	NA	-1.28	-18.58	-0.75	6.78e-50	Breast cancer;
CESC	cis	rs2455799	0.574	rs2455798	chr3:15700505	G/C	cg16303742	chr3:15540471	COLQ	-0.39	-6.06	-0.35	4.71e-9	Mean platelet volume;
CESC	cis	rs8077577	0.562	rs8081042	chr17:18199067	C/G	cg16794390	chr17:18148240	FLII	0.41	6.44	0.37	5.57e-10	Obesity-related traits;
CESC	trans	rs7672847	0.547	rs72973034	chr4:170369366	A/G	cg19308436	chr1:237949471	RYR2	0.6	6.27	0.36	1.46e-9	Subjective well-being;
CESC	cis	rs9649213	0.593	rs6970990	chr7:97925382	T/G	cg00277769	chr7:97922759	BAIAP2L1	-0.33	-5.42	-0.32	1.31e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs514406	0.505	rs436363	chr1:53172163	T/C	cg24675658	chr1:53192096	ZYG11B	-0.52	-6.43	-0.37	5.97e-10	Monocyte count;
CESC	cis	rs6032067	0.929	rs55726011	chr20:43855229	C/T	cg10761708	chr20:43804764	PI3	0.5	6.15	0.35	2.83e-9	Blood protein levels;
CESC	cis	rs875971	1.000	rs778710	chr7:65854834	T/C	cg18876405	chr7:65276391	NA	0.52	6.87	0.39	4.49e-11	Aortic root size;
CESC	cis	rs2243480	0.901	rs313808	chr7:65499873	T/G	cg13147721	chr7:65941812	NA	-0.86	-8.3	-0.45	5.53e-15	Diabetic kidney disease;
CESC	cis	rs9488822	0.676	rs4354188	chr6:116327936	T/C	cg18764771	chr6:116381957	FRK	0.22	5.42	0.32	1.35e-7	Cholesterol, total;LDL cholesterol;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21830480	chr12:72057690	THAP2;ZFC3H1	-0.69	-7.87	-0.44	9.06e-14	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00903962	chr6:26056695	HIST1H1C	0.58	6.74	0.38	9.9e-11	Gut microbiome composition (summer);
CESC	cis	rs1862618	0.853	rs252898	chr5:56188931	T/C	cg24531977	chr5:56204891	C5orf35	-0.88	-11.2	-0.57	4.22e-24	Initial pursuit acceleration;
CESC	cis	rs10751667	0.600	rs7394783	chr11:1005108	C/T	cg20946044	chr11:1010712	AP2A2	0.53	7.3	0.41	3.29e-12	Alzheimer's disease (late onset);
CESC	cis	rs2120019	1.000	rs7175720	chr15:75348962	C/G	cg17294928	chr15:75287854	SCAMP5	0.64	6.9	0.39	3.93e-11	Blood trace element (Zn levels);
CESC	cis	rs12618769	0.652	rs17513468	chr2:99235169	T/G	cg10123293	chr2:99228465	UNC50	0.4	5.42	0.32	1.35e-7	Bipolar disorder;
CESC	cis	rs2479106	0.727	rs10986139	chr9:126689150	C/G	cg16191174	chr9:126692580	DENND1A	0.51	6.13	0.35	3.1e-9	Polycystic ovary syndrome;
CESC	cis	rs6121246	0.512	rs6060938	chr20:30363645	T/C	cg13852791	chr20:30311386	BCL2L1	0.85	11.17	0.57	5.35e-24	Mean corpuscular hemoglobin;
CESC	cis	rs9487051	0.676	rs9372208	chr6:109596168	A/G	cg12927641	chr6:109611667	NA	-0.37	-5.5	-0.32	8.91e-8	Reticulocyte fraction of red cells;
CESC	trans	rs4824093	0.535	rs73441802	chr22:50273916	G/A	cg09872104	chr7:134855509	C7orf49	-0.95	-6.67	-0.38	1.52e-10	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs425277	0.565	rs2480711	chr1:2111376	A/G	cg12718519	chr1:2058417	PRKCZ	0.26	5.68	0.33	3.57e-8	Height;
CESC	trans	rs9319321	0.571	rs1927509	chr13:27414894	C/A	cg14332112	chr6:47277683	TNFRSF21	-0.49	-6.25	-0.36	1.67e-9	Asthma (toluene diisocyanate-induced);
CESC	cis	rs10504229	1.000	rs57186557	chr8:58177277	A/G	cg24829409	chr8:58192753	C8orf71	-0.76	-10.0	-0.52	3.53e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs80130819	0.748	rs901962	chr12:48741219	A/T	cg05342945	chr12:48394962	COL2A1	-0.51	-5.46	-0.32	1.09e-7	Prostate cancer;
CESC	cis	rs8002861	0.875	rs12867890	chr13:44423088	A/G	cg14210620	chr13:44453864	C13orf31;CCDC122	-0.42	-5.2	-0.3	3.93e-7	Leprosy;
CESC	cis	rs853679	0.550	rs1225598	chr6:28160799	T/G	cg18032046	chr6:28092343	ZSCAN16	-0.49	-5.75	-0.33	2.48e-8	Depression;
CESC	cis	rs2303759	0.830	rs7257053	chr19:49894456	C/G	cg22590775	chr19:49891494	CCDC155	0.63	7.45	0.42	1.32e-12	Multiple sclerosis;
CESC	cis	rs2708240	1.000	rs2708243	chr7:147580412	A/T	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.36	-5.99	-0.35	6.79e-9	QT interval (drug interaction);
CESC	cis	rs2836633	0.895	rs2836598	chr21:40024758	C/G	cg05519781	chr21:40033154	ERG	0.78	12.85	0.62	1.02e-29	Coronary artery disease;
CESC	cis	rs8031584	0.958	rs11637469	chr15:31238783	T/C	cg08109568	chr15:31115862	NA	-0.71	-9.44	-0.5	2.03e-18	Huntington's disease progression;
CESC	cis	rs10883723	0.810	rs7094751	chr10:104274818	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.55	7.58	0.42	5.73e-13	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg03452623	chr4:187889614	NA	0.93	18.96	0.76	2.94e-51	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	10.38	0.54	2.06e-21	Prudent dietary pattern;
CESC	cis	rs2282802	0.685	rs12188849	chr5:139621570	G/A	cg26211634	chr5:139558579	C5orf32	0.52	7.53	0.42	8.03e-13	Intelligence (multi-trait analysis);
CESC	trans	rs116095464	0.558	rs10065584	chr5:253997	G/A	cg00938859	chr5:1591904	SDHAP3	0.71	6.48	0.37	4.51e-10	Breast cancer;
CESC	cis	rs6860806	0.661	rs4705927	chr5:131578608	C/G	cg09877947	chr5:131593287	PDLIM4	0.47	6.09	0.35	3.91e-9	Breast cancer;
CESC	trans	rs72681920	0.881	rs28364333	chr4:100200153	C/T	cg22948791	chr15:71404101	CT62	-0.54	-6.12	-0.35	3.4e-9	Alcohol dependence;
CESC	cis	rs34779708	0.931	rs4934711	chr10:35360310	G/A	cg04310649	chr10:35416472	CREM	-0.52	-6.23	-0.36	1.84e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs9787249	0.957	rs2274949	chr1:40221067	G/A	cg24920358	chr1:40204285	PPIE	0.4	5.91	0.34	1.07e-8	Blood protein levels;
CESC	cis	rs7666738	0.830	rs13138438	chr4:99050545	C/A	cg18180107	chr4:99064573	C4orf37	0.41	5.29	0.31	2.51e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs365132	1.000	rs365132	chr5:176378574	G/T	cg16309518	chr5:176445507	NA	-0.38	-5.5	-0.32	8.86e-8	Menarche and menopause (age at onset);Menopause (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05095230	chr13:50367060	KPNA3	-0.69	-8.05	-0.44	2.8e-14	Gut microbiome composition (summer);
CESC	cis	rs8067545	0.514	rs12449662	chr17:19897845	T/C	cg12073167	chr17:19770448	ULK2	-0.44	-5.03	-0.3	9.14e-7	Schizophrenia;
CESC	cis	rs938554	0.779	rs13106991	chr4:9959011	G/A	cg11266682	chr4:10021025	SLC2A9	-0.38	-5.03	-0.3	8.92e-7	Blood metabolite levels;
CESC	cis	rs3740713	1.000	rs73438668	chr11:18456536	C/T	cg23797887	chr11:18477753	LDHAL6A	-0.53	-5.11	-0.3	6.1e-7	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs6582630	0.519	rs11514078	chr12:38408817	G/C	cg13010199	chr12:38710504	ALG10B	0.47	5.85	0.34	1.47e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs11997175	0.603	rs11778978	chr8:33804743	G/T	ch.8.33884649F	chr8:33765107	NA	0.44	5.3	0.31	2.49e-7	Body mass index;
CESC	cis	rs7605827	0.893	rs2098463	chr2:15512175	C/G	cg19274914	chr2:15703543	NA	0.32	5.58	0.32	5.95e-8	Educational attainment (years of education);
CESC	cis	rs2425143	0.730	rs2095819	chr20:34353278	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.8	-7.75	-0.43	1.96e-13	Blood protein levels;
CESC	cis	rs71277158	0.688	rs17236830	chr3:169891246	G/A	cg04067573	chr3:169899625	PHC3	0.71	7.12	0.4	9.91e-12	Prostate cancer;
CESC	cis	rs929354	0.742	rs6459734	chr7:156935454	A/G	cg05182265	chr7:156933206	UBE3C	-0.49	-7.04	-0.4	1.69e-11	Body mass index;
CESC	cis	rs7647973	0.710	rs1491983	chr3:49639803	G/T	cg13072238	chr3:49761600	GMPPB	-0.51	-6.14	-0.35	3.03e-9	Menarche (age at onset);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg25228510	chr10:62538235	CDK1;CDC2	-0.43	-6.88	-0.39	4.27e-11	Gambling;
CESC	cis	rs9473147	0.571	rs9395285	chr6:47554177	G/A	cg20196966	chr6:47445060	CD2AP	0.4	5.16	0.3	4.75e-7	Platelet distribution width;Mean platelet volume;
CESC	trans	rs3087243	0.755	rs12986861	chr2:204694952	G/A	cg01841312	chr10:38069945	NA	-0.38	-6.24	-0.36	1.71e-9	Rheumatoid arthritis;Hypothyroidism;Type 1 diabetes;
CESC	cis	rs853679	0.517	rs9357065	chr6:28129580	T/C	cg19592336	chr6:28129416	ZNF389	0.61	8.0	0.44	3.95e-14	Depression;
CESC	cis	rs514406	0.505	rs431459	chr1:53183230	T/G	cg27535305	chr1:53392650	SCP2	-0.32	-5.29	-0.31	2.54e-7	Monocyte count;
CESC	trans	rs11098499	0.789	rs12498994	chr4:120250818	A/C	cg25214090	chr10:38739885	LOC399744	0.62	8.7	0.47	3.58e-16	Corneal astigmatism;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg07150777	chr2:239996253	HDAC4	0.44	6.41	0.37	6.49e-10	Fibrinogen levels;
CESC	cis	rs7208859	0.623	rs7223209	chr17:29107220	C/A	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.91e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs6484504	0.532	rs10835756	chr11:31267622	C/T	cg14844989	chr11:31128820	NA	-0.41	-5.82	-0.34	1.73e-8	Red blood cell count;
CESC	cis	rs853679	0.882	rs4713140	chr6:28097193	C/T	cg23372001	chr6:27791640	HIST1H4J	0.55	5.03	0.3	8.86e-7	Depression;
CESC	cis	rs6952808	0.823	rs58222895	chr7:1885064	G/A	cg10360139	chr7:1886902	MAD1L1	-0.4	-5.05	-0.3	8.09e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs477692	0.699	rs578932	chr10:131370724	C/A	cg05714579	chr10:131428358	MGMT	0.41	5.37	0.31	1.7e-7	Response to temozolomide;
CESC	cis	rs873946	0.586	rs12783078	chr10:134569706	C/T	cg27286337	chr10:134555280	INPP5A	0.69	7.74	0.43	2.06e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs4820539	0.902	rs737846	chr22:23460669	A/G	cg14186256	chr22:23484241	RTDR1	0.84	15.14	0.68	9.43e-38	Bone mineral density;
CESC	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg03188948	chr7:1209495	NA	0.72	6.91	0.39	3.61e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs2727020	0.521	rs937430	chr11:49542457	A/G	cg03929089	chr4:120376271	NA	0.72	8.45	0.46	1.91e-15	Coronary artery disease;
CESC	trans	rs2727020	0.595	rs7924311	chr11:49507573	G/A	cg03929089	chr4:120376271	NA	-0.85	-13.26	-0.63	3.91e-31	Coronary artery disease;
CESC	cis	rs2228479	0.571	rs62052183	chr16:89966921	C/A	cg14709524	chr16:89940631	TCF25	0.72	5.45	0.32	1.16e-7	Skin colour saturation;
CESC	cis	rs6430585	0.583	rs11886852	chr2:136589379	G/A	cg07169764	chr2:136633963	MCM6	1.17	17.56	0.73	2.66e-46	Corneal structure;
CESC	cis	rs6723226	0.572	rs176411	chr2:32643528	A/G	cg02381751	chr2:32503542	YIPF4	0.49	6.59	0.38	2.31e-10	Intelligence (multi-trait analysis);
CESC	trans	rs1814175	0.616	rs10769644	chr11:49987676	C/A	cg03929089	chr4:120376271	NA	-0.92	-15.24	-0.68	4.38e-38	Height;
CESC	cis	rs2953174	0.720	rs2975794	chr2:241515813	C/T	cg07929629	chr2:241523174	NA	0.56	6.3	0.36	1.22e-9	Bipolar disorder;
CESC	cis	rs300703	0.935	rs300749	chr2:208143	G/T	cg21211680	chr2:198530	NA	0.99	8.6	0.47	7.15e-16	Blood protein levels;
CESC	cis	rs2637266	0.667	rs2395405	chr10:78380518	C/T	cg18941641	chr10:78392320	NA	0.4	7.34	0.41	2.59e-12	Pulmonary function;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg21333964	chr11:118955461	HMBS	0.45	6.04	0.35	5.23e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs853679	0.517	rs67878650	chr6:28142587	G/C	cg12963246	chr6:28129442	ZNF389	0.54	7.18	0.4	6.92e-12	Depression;
CESC	cis	rs6088580	0.608	rs1205342	chr20:32921842	C/T	cg24642439	chr20:33292090	TP53INP2	-0.52	-6.77	-0.38	8.14e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs2625529	0.526	rs7179942	chr15:72563074	C/G	cg16672083	chr15:72433130	SENP8	0.43	6.46	0.37	4.88e-10	Red blood cell count;
CESC	cis	rs13191362	0.872	rs35672319	chr6:163245464	C/A	cg14584255	chr6:163149320	PACRG;PARK2	0.5	5.24	0.31	3.3e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs4665809	1.000	rs4665304	chr2:26313406	C/T	cg08470875	chr2:26401718	FAM59B	-0.48	-5.34	-0.31	2e-7	Gut microbiome composition (summer);
CESC	cis	rs4319547	0.737	rs4758646	chr12:122946507	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.48	-6.03	-0.35	5.46e-9	Body mass index;
CESC	cis	rs2996428	0.667	rs7545274	chr1:3744261	G/T	cg10555106	chr1:3691387	LOC388588	0.39	5.24	0.31	3.27e-7	Red cell distribution width;
CESC	cis	rs9467773	0.523	rs2498399	chr6:26706544	T/C	cg11502198	chr6:26597334	ABT1	0.41	5.46	0.32	1.11e-7	Intelligence (multi-trait analysis);
CESC	trans	rs650950	0.528	rs646660	chr11:35528452	C/T	cg08884094	chr12:133286970	PGAM5	0.48	6.1	0.35	3.68e-9	Bronchopulmonary dysplasia;
CESC	cis	rs7072216	0.763	rs10883091	chr10:100167239	C/T	cg26618903	chr10:100175079	PYROXD2	-0.35	-5.38	-0.31	1.66e-7	Metabolite levels;
CESC	cis	rs6942756	0.774	rs2566885	chr7:128917587	C/T	cg02491457	chr7:128862824	NA	0.65	9.41	0.5	2.49e-18	White matter hyperintensity burden;
CESC	cis	rs77972916	0.505	rs34247383	chr2:43532780	A/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.63	-5.88	-0.34	1.24e-8	Granulocyte percentage of myeloid white cells;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14493055	chr9:88514270	NA	-0.56	-6.0	-0.35	6.57e-9	Gut microbiome composition (summer);
CESC	cis	rs11098499	0.908	rs28559989	chr4:120386627	C/T	cg24375607	chr4:120327624	NA	0.44	5.48	0.32	9.91e-8	Corneal astigmatism;
CESC	cis	rs11758351	0.660	rs11757754	chr6:26219744	A/C	cg23601095	chr6:26197514	HIST1H3D	0.91	9.96	0.52	4.64e-20	Gout;Renal underexcretion gout;
CESC	cis	rs1707322	1.000	rs785504	chr1:46595696	C/T	cg06784218	chr1:46089804	CCDC17	-0.33	-5.57	-0.32	6.35e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7824557	0.628	rs7005469	chr8:11194457	G/A	cg21775007	chr8:11205619	TDH	0.55	8.74	0.47	2.75e-16	Retinal vascular caliber;
CESC	cis	rs7618915	0.501	rs7622694	chr3:52663882	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	7.66	0.43	3.59e-13	Bipolar disorder;
CESC	cis	rs7666738	0.830	rs7657490	chr4:99043973	C/T	cg24818145	chr4:99064322	C4orf37	0.38	5.04	0.3	8.49e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2463822	0.858	rs2513037	chr11:62084822	A/T	cg06239285	chr11:62104954	ASRGL1	-0.89	-8.97	-0.48	5.46e-17	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs8141529	0.778	rs9625566	chr22:29162506	G/A	cg02153584	chr22:29168773	CCDC117	0.68	9.78	0.51	1.77e-19	Lymphocyte counts;
CESC	cis	rs208520	0.690	rs851459	chr6:66813989	A/G	cg07460842	chr6:66804631	NA	-0.98	-13.33	-0.63	2.28e-31	Exhaled nitric oxide output;
CESC	cis	rs6502050	0.835	rs55679819	chr17:80105450	C/T	cg11859384	chr17:80120422	CCDC57	-0.38	-5.15	-0.3	5.12e-7	Life satisfaction;
CESC	cis	rs854765	0.583	rs8070722	chr17:17813562	C/T	cg09796270	chr17:17721594	SREBF1	0.43	6.05	0.35	4.94e-9	Total body bone mineral density;
CESC	cis	rs4481887	0.893	rs10888337	chr1:248428227	A/G	cg00666640	chr1:248458726	OR2T12	-0.32	-5.59	-0.32	5.62e-8	Common traits (Other);
CESC	cis	rs4901847	0.529	rs12895032	chr14:58618345	T/G	cg15908186	chr14:58618357	C14orf37	0.4	5.96	0.34	7.94e-9	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs8067354	0.574	rs1292042	chr17:57934995	A/G	cg02344993	chr17:57696989	CLTC	0.52	5.46	0.32	1.08e-7	Hemoglobin concentration;
CESC	cis	rs780096	0.526	rs1260342	chr2:27663416	G/T	cg17158414	chr2:27665306	KRTCAP3	-0.32	-5.97	-0.34	7.45e-9	Total body bone mineral density;
CESC	cis	rs11792861	0.505	rs12377869	chr9:111907803	C/A	cg05043794	chr9:111880884	C9orf5	-0.31	-5.31	-0.31	2.33e-7	Menarche (age at onset);
CESC	cis	rs2486288	0.656	rs6493145	chr15:45573862	G/T	cg21132104	chr15:45694354	SPATA5L1	-0.58	-7.0	-0.4	2.07e-11	Glomerular filtration rate;
CESC	cis	rs7851660	0.844	rs4743139	chr9:100638420	A/G	cg13688889	chr9:100608707	NA	-0.64	-8.94	-0.48	6.74e-17	Strep throat;
CESC	cis	rs1552244	1.000	rs6442147	chr3:10078247	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.86	11.65	0.58	1.32e-25	Alzheimer's disease;
CESC	cis	rs17376456	0.825	rs28412976	chr5:93248377	T/C	cg25358565	chr5:93447407	FAM172A	1.16	9.99	0.52	3.83e-20	Diabetic retinopathy;
CESC	cis	rs9649213	0.593	rs6970801	chr7:97925240	T/C	cg21770322	chr7:97807741	LMTK2	0.54	8.13	0.45	1.67e-14	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs12822507	0.811	rs34946234	chr12:12781812	A/G	cg11838227	chr12:12764436	CREBL2	-0.41	-5.33	-0.31	2.1e-7	Systemic lupus erythematosus;
CESC	cis	rs28386778	0.734	rs12946669	chr17:62006007	A/G	cg11494091	chr17:61959527	GH2	0.79	14.11	0.65	4.36e-34	Prudent dietary pattern;
CESC	cis	rs7267979	0.932	rs417130	chr20:25458320	T/C	cg08601574	chr20:25228251	PYGB	0.36	5.28	0.31	2.76e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs736408	0.609	rs1029871	chr3:52797634	G/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.31	5.16	0.3	4.8e-7	Bipolar disorder;
CESC	cis	rs916888	0.773	rs199443	chr17:44819565	C/T	cg17911788	chr17:44343683	NA	-0.6	-7.98	-0.44	4.53e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg00219956	chr16:30794205	ZNF629	0.52	7.57	0.42	6.13e-13	Fibrinogen levels;
CESC	cis	rs1552244	1.000	rs6768102	chr3:10149380	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	12.22	0.6	1.56e-27	Alzheimer's disease;
CESC	cis	rs4925325	0.956	rs1776263	chr20:60515820	A/G	cg18761221	chr20:60518478	NA	0.56	8.05	0.44	2.82e-14	Obesity-related traits;
CESC	cis	rs9513593	1.000	rs4772186	chr13:99957987	G/A	cg21788972	chr13:99853209	UBAC2	0.55	6.17	0.35	2.5e-9	Psoriasis;
CESC	cis	rs10887741	0.646	rs1358865	chr10:89432645	C/A	cg13926569	chr10:89418898	PAPSS2	0.44	6.77	0.38	8.34e-11	Exercise (leisure time);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg25010622	chr20:32700257	EIF2S2	-0.46	-6.17	-0.35	2.54e-9	Ulcerative colitis;
CESC	cis	rs5758659	0.737	rs10854749	chr22:42447341	G/T	cg04733989	chr22:42467013	NAGA	0.39	5.21	0.3	3.82e-7	Cognitive function;
CESC	cis	rs9914988	0.943	rs11656256	chr17:27153553	G/A	cg20469991	chr17:27169893	C17orf63	-0.48	-5.25	-0.31	3.18e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CESC	cis	rs11122272	0.735	rs2808592	chr1:231523757	G/A	cg06096015	chr1:231504339	EGLN1	0.43	6.18	0.35	2.46e-9	Hemoglobin concentration;
CESC	cis	rs244293	0.765	rs7503269	chr17:53019712	T/C	cg19360675	chr17:53046073	COX11;STXBP4	-0.45	-6.06	-0.35	4.64e-9	Menarche (age at onset);
CESC	cis	rs10242455	0.867	rs1357319	chr7:99310181	G/T	cg07715041	chr7:99302981	CYP3A7	0.43	5.46	0.32	1.12e-7	Blood metabolite levels;
CESC	cis	rs7089973	0.604	rs17663670	chr10:116596269	A/C	cg23260525	chr10:116636907	FAM160B1	-0.4	-7.44	-0.42	1.4e-12	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs1218582	0.710	rs9793588	chr1:154878878	C/G	cg16680214	chr1:154839983	KCNN3	-0.44	-6.69	-0.38	1.28e-10	Prostate cancer;
CESC	cis	rs501120	0.929	rs2576355	chr10:44750362	A/G	cg09554077	chr10:44749378	NA	0.49	6.54	0.37	3.11e-10	Coronary artery disease;Coronary heart disease;
CESC	cis	rs3096299	0.967	rs753853	chr16:89446525	G/T	cg08392591	chr16:89556376	ANKRD11	0.42	5.31	0.31	2.34e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs829880	0.570	rs844205	chr12:98846053	A/G	cg25150519	chr12:98850993	NA	0.83	10.88	0.56	4.87e-23	Colonoscopy-negative controls vs population controls;
CESC	cis	rs924607	0.510	rs1709542	chr5:662543	A/G	cg07001201	chr5:642380	CEP72	-0.39	-5.38	-0.31	1.61e-7	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs3857536	0.813	rs1891600	chr6:66941645	G/C	cg07460842	chr6:66804631	NA	-0.41	-5.28	-0.31	2.71e-7	Blood trace element (Cu levels);
CESC	cis	rs72772090	0.539	rs72773923	chr5:96117579	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.57	-5.21	-0.3	3.74e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs3859192	0.599	rs12451897	chr17:38179275	G/T	cg17467752	chr17:38218738	THRA	-0.45	-6.02	-0.35	5.83e-9	White blood cell count;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg03342113	chr11:61197477	CPSF7;SDHAF2	-0.47	-6.22	-0.36	1.92e-9	Ulcerative colitis;
CESC	cis	rs1568889	1.000	rs10767693	chr11:28093926	G/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.8	13.49	0.64	6.09e-32	Bipolar disorder;
CESC	cis	rs1348850	0.608	rs10176632	chr2:178225934	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.67	9.14	0.49	1.65e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	trans	rs7246657	0.943	rs13345116	chr19:37847098	A/T	cg24637308	chr11:6592297	DNHD1	0.53	6.17	0.35	2.55e-9	Coronary artery calcification;
CESC	cis	rs9790314	0.967	rs460165	chr3:161087710	G/A	cg03342759	chr3:160939853	NMD3	-0.39	-5.04	-0.3	8.63e-7	Morning vs. evening chronotype;
CESC	cis	rs2011503	1.000	rs45556231	chr19:19654189	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.52	5.09	0.3	6.68e-7	Bipolar disorder;
CESC	cis	rs11190604	1.000	rs3750627	chr10:102275642	G/T	cg07080220	chr10:102295463	HIF1AN	0.67	6.3	0.36	1.21e-9	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs16854884	0.586	rs4613453	chr3:143735600	C/G	cg06585982	chr3:143692056	C3orf58	0.51	6.96	0.39	2.68e-11	Economic and political preferences (feminism/equality);
CESC	cis	rs12325245	0.536	rs12925676	chr16:58625326	C/T	cg05725404	chr16:58534157	NDRG4	-0.63	-5.34	-0.31	2.01e-7	Schizophrenia;
CESC	cis	rs2985684	0.947	rs1952013	chr14:50087357	C/G	cg10008539	chr14:50087325	RPL36AL;MGAT2	-0.49	-5.66	-0.33	4.02e-8	Carotid intima media thickness;
CESC	cis	rs2075371	0.932	rs1035328	chr7:133978419	T/C	cg00033643	chr7:134001901	SLC35B4	0.42	5.39	0.31	1.52e-7	Mean platelet volume;
CESC	cis	rs6570726	0.967	rs9403706	chr6:145795187	C/T	cg23711669	chr6:146136114	FBXO30	-0.72	-10.5	-0.54	8.41e-22	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9640161	0.789	rs2373751	chr7:150021599	G/C	cg17279839	chr7:150038598	RARRES2	0.49	5.61	0.33	5.17e-8	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs72781680	0.898	rs72788212	chr2:24087385	G/A	cg08917208	chr2:24149416	ATAD2B	0.91	8.38	0.46	3.17e-15	Lymphocyte counts;
CESC	cis	rs7520050	0.966	rs6695809	chr1:46285461	T/C	cg03146154	chr1:46216737	IPP	-0.47	-6.15	-0.35	2.8e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg07157834	chr1:205819609	PM20D1	0.42	6.07	0.35	4.4e-9	Menarche (age at onset);
CESC	cis	rs4713118	0.662	rs149946	chr6:27970031	A/C	cg23161317	chr6:28129485	ZNF389	-0.5	-6.24	-0.36	1.68e-9	Parkinson's disease;
CESC	cis	rs9326248	0.530	rs6589589	chr11:116932428	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.58	5.32	0.31	2.16e-7	Blood protein levels;
CESC	cis	rs35306767	0.855	rs12771179	chr10:872347	A/G	cg26597838	chr10:835615	NA	1.18	11.47	0.58	5.21e-25	Eosinophil percentage of granulocytes;
CESC	cis	rs7666738	0.830	rs6854594	chr4:99065312	A/T	cg18180107	chr4:99064573	C4orf37	0.4	5.1	0.3	6.55e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs875971	0.830	rs778715	chr7:65849209	C/T	cg18876405	chr7:65276391	NA	0.5	6.87	0.39	4.63e-11	Aortic root size;
CESC	cis	rs7959452	0.590	rs11177644	chr12:69785748	A/G	cg14784868	chr12:69753453	YEATS4	0.84	13.62	0.64	2.29e-32	Blood protein levels;
CESC	cis	rs1552244	0.935	rs7618815	chr3:10151045	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	12.27	0.6	1.07e-27	Alzheimer's disease;
CESC	cis	rs2439831	0.867	rs8039638	chr15:43634405	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.89	10.73	0.55	1.57e-22	Lung cancer in ever smokers;
CESC	cis	rs1775715	0.737	rs2151047	chr10:32102110	G/A	cg18675610	chr10:32216311	ARHGAP12	0.33	5.1	0.3	6.52e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	trans	rs875971	0.660	rs10950044	chr7:66042976	A/G	cg26939375	chr7:64535504	NA	-0.64	-8.62	-0.47	6.05e-16	Aortic root size;
CESC	cis	rs1144333	1.000	rs5745327	chr1:76270040	A/T	cg10523679	chr1:76189770	ACADM	-0.58	-5.83	-0.34	1.65e-8	Attention function in attention deficit hyperactive disorder;
CESC	cis	rs116988415	0.584	rs11622171	chr14:65258644	C/G	cg25083366	chr14:65239357	SPTB	0.72	5.11	0.3	6.32e-7	Daytime sleep phenotypes;
CESC	cis	rs116095464	0.558	rs1541822	chr5:269234	A/C	cg10591111	chr5:226296	SDHA	0.5	6.01	0.35	6.02e-9	Breast cancer;
CESC	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	7.79	0.43	1.48e-13	Prudent dietary pattern;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg26823989	chr1:87380673	SEP15;HS2ST1	0.46	6.3	0.36	1.25e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05888406	chr7:5280109	NA	0.47	6.69	0.38	1.35e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs875971	0.862	rs709609	chr7:65560561	A/G	cg12463550	chr7:65579703	CRCP	-0.54	-6.55	-0.37	2.91e-10	Aortic root size;
CESC	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg06873352	chr17:61820015	STRADA	0.72	12.84	0.62	1.18e-29	Prudent dietary pattern;
CESC	cis	rs748404	0.697	rs505249	chr15:43559960	T/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.59	7.72	0.43	2.43e-13	Lung cancer;
CESC	cis	rs10504229	0.593	rs4738567	chr8:57997033	A/C	cg22535103	chr8:58192502	C8orf71	-0.65	-7.05	-0.4	1.58e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs1577917	1.000	rs12200330	chr6:86656653	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.47	-6.0	-0.35	6.34e-9	Response to antipsychotic treatment;
CESC	cis	rs367943	1.000	rs348954	chr5:112821716	A/G	cg12552261	chr5:112820674	MCC	-0.63	-8.02	-0.44	3.43e-14	Type 2 diabetes;
CESC	trans	rs61931739	0.534	rs1705757	chr12:34091637	A/G	cg26384229	chr12:38710491	ALG10B	0.52	7.04	0.4	1.66e-11	Morning vs. evening chronotype;
CESC	cis	rs2075371	0.501	rs1643043	chr7:134013902	C/T	cg20476274	chr7:133979776	SLC35B4	0.48	6.11	0.35	3.61e-9	Mean platelet volume;
CESC	trans	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg13565492	chr6:43139072	SRF	-0.67	-6.8	-0.39	6.9e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs6502050	0.799	rs6502088	chr17:80169484	C/T	cg23985595	chr17:80112537	CCDC57	-0.4	-6.28	-0.36	1.41e-9	Life satisfaction;
CESC	cis	rs6088580	0.634	rs6059824	chr20:33014543	T/C	cg06115741	chr20:33292138	TP53INP2	0.47	6.02	0.35	5.82e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs1050631	1.000	rs1785916	chr18:33696156	A/G	cg25426722	chr18:33708991	SLC39A6;ELP2	0.44	5.67	0.33	3.75e-8	Esophageal squamous cell cancer (length of survival);
CESC	cis	rs17253792	0.822	rs17685078	chr14:56127202	T/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.81	5.68	0.33	3.46e-8	Putamen volume;
CESC	cis	rs7223966	1.000	rs9899788	chr17:61756384	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.46	-5.6	-0.33	5.23e-8	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs2933343	1.000	rs2929859	chr3:128608341	T/G	cg25356066	chr3:128598488	ACAD9	0.6	7.51	0.42	9.13e-13	IgG glycosylation;
CESC	cis	rs896854	0.517	rs9643353	chr8:95957063	A/G	cg13393036	chr8:95962371	TP53INP1	0.49	9.29	0.5	5.81e-18	Type 2 diabetes;
CESC	cis	rs7937682	0.961	rs4936682	chr11:111629743	T/G	cg09085632	chr11:111637200	PPP2R1B	1.11	15.11	0.68	1.22e-37	Primary sclerosing cholangitis;
CESC	cis	rs780096	0.506	rs1647286	chr2:27714517	A/T	cg02592271	chr2:27665507	KRTCAP3	-0.28	-5.73	-0.33	2.78e-8	Total body bone mineral density;
CESC	cis	rs9896933	0.778	rs80243549	chr17:80821485	G/T	cg20578329	chr17:80767326	TBCD	-0.72	-7.36	-0.41	2.26e-12	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02068989	chr1:10458939	PGD	0.64	7.2	0.4	6.25e-12	Gut microbiome composition (summer);
CESC	cis	rs11690935	0.959	rs7586207	chr2:172671094	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.95	-14.48	-0.66	2.12e-35	Schizophrenia;
CESC	trans	rs1977584	0.725	rs61853975	chr10:45392633	G/A	cg09262100	chr14:103416268	CDC42BPB	0.61	6.13	0.35	3.16e-9	Selective IgA deficiency;
CESC	cis	rs3806843	1.000	rs1548700	chr5:140164889	A/T	cg16179182	chr5:140090404	VTRNA1-1	-0.4	-5.18	-0.3	4.31e-7	Depressive symptoms (multi-trait analysis);
CESC	trans	rs1973993	0.967	rs2181375	chr1:96940119	A/G	cg10631902	chr5:14652156	NA	0.5	6.7	0.38	1.28e-10	Weight;
CESC	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg07362569	chr17:61921086	SMARCD2	-0.35	-5.04	-0.3	8.61e-7	Prudent dietary pattern;
CESC	cis	rs6502050	0.835	rs6502059	chr17:80082886	T/C	cg23985595	chr17:80112537	CCDC57	0.42	6.55	0.37	2.99e-10	Life satisfaction;
CESC	cis	rs597539	0.652	rs602364	chr11:68662167	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.8	10.48	0.54	9.64e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs7666738	0.830	rs7657497	chr4:99044028	A/G	cg03676636	chr4:99064102	C4orf37	0.33	5.12	0.3	5.93e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6866344	0.570	rs4266420	chr5:178137161	C/G	cg03877680	chr5:178157825	ZNF354A	0.83	10.39	0.54	1.95e-21	Neutrophil percentage of white cells;
CESC	cis	rs2274273	1.000	rs3825613	chr14:55593172	A/C	cg04306507	chr14:55594613	LGALS3	0.28	5.11	0.3	6.23e-7	Protein biomarker;
CESC	cis	rs7666738	0.830	rs1426669	chr4:98945534	C/T	cg03467027	chr4:99064603	C4orf37	0.46	5.82	0.34	1.74e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1707322	0.721	rs11211151	chr1:46112752	T/C	cg05343316	chr1:45956843	TESK2	0.5	6.05	0.35	4.9e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7678296	0.730	rs73126371	chr4:37227154	A/G	cg06805348	chr4:37245195	KIAA1239	0.4	5.04	0.3	8.47e-7	3-hydroxypropylmercapturic acid levels in smokers;
CESC	cis	rs7551222	0.716	rs11240751	chr1:204462050	A/G	cg20240347	chr1:204465584	NA	-0.26	-5.14	-0.3	5.42e-7	Schizophrenia;
CESC	cis	rs4919694	1.000	rs12246689	chr10:104817031	C/T	cg04362960	chr10:104952993	NT5C2	0.79	7.08	0.4	1.27e-11	Arsenic metabolism;
CESC	cis	rs938554	0.692	rs13125209	chr4:9982044	A/C	cg00071950	chr4:10020882	SLC2A9	0.48	5.69	0.33	3.44e-8	Blood metabolite levels;
CESC	cis	rs3931020	0.530	rs12125889	chr1:75241971	A/G	cg26855724	chr1:75198818	TYW3;CRYZ	0.52	6.84	0.39	5.33e-11	Resistin levels;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg01484320	chr1:109757057	SARS	0.51	6.52	0.37	3.56e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs7666738	0.830	rs10011009	chr4:98981749	G/A	cg03467027	chr4:99064603	C4orf37	0.43	5.44	0.32	1.24e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7116495	0.609	rs10450664	chr11:71636655	A/G	cg10381502	chr11:71823885	C11orf51	-1.1	-7.08	-0.4	1.33e-11	Severe influenza A (H1N1) infection;
CESC	cis	rs873946	0.557	rs34854637	chr10:134582962	A/G	cg27286337	chr10:134555280	INPP5A	0.63	7.16	0.4	7.94e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	trans	rs7246657	1.000	rs7246657	chr19:37747108	C/T	cg24637308	chr11:6592297	DNHD1	-0.52	-6.07	-0.35	4.49e-9	Coronary artery calcification;
CESC	cis	rs10465746	0.967	rs12759527	chr1:84434425	T/C	cg10977910	chr1:84465055	TTLL7	0.46	6.32	0.36	1.08e-9	Obesity-related traits;
CESC	cis	rs921968	0.643	rs832802	chr2:219386899	C/T	cg02176678	chr2:219576539	TTLL4	0.43	7.75	0.43	1.97e-13	Mean corpuscular hemoglobin concentration;
CESC	cis	rs5769765	0.542	rs1535189	chr22:50249131	T/C	cg02269571	chr22:50332266	NA	0.46	5.44	0.32	1.19e-7	Schizophrenia;
CESC	cis	rs9486719	1.000	rs12205655	chr6:96891733	T/A	cg18709589	chr6:96969512	KIAA0776	-0.53	-5.81	-0.34	1.75e-8	Migraine;Coronary artery disease;
CESC	cis	rs2033711	0.870	rs11669741	chr19:58960481	C/T	cg00825309	chr19:58991885	ZNF446	0.57	8.74	0.47	2.8e-16	Uric acid clearance;
CESC	cis	rs9291683	0.530	rs17246501	chr4:9985710	A/C	cg11266682	chr4:10021025	SLC2A9	0.6	11.86	0.59	2.52e-26	Bone mineral density;
CESC	cis	rs853679	0.546	rs200948	chr6:27835272	T/C	cg26587870	chr6:27730563	NA	-0.6	-5.29	-0.31	2.58e-7	Depression;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg14774160	chr17:4901081	INCA1;KIF1C	-0.48	-6.43	-0.37	6.02e-10	Ulcerative colitis;
CESC	cis	rs17253792	0.915	rs77161327	chr14:56178565	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.74	5.1	0.3	6.53e-7	Putamen volume;
CESC	cis	rs9911578	0.842	rs12450766	chr17:56832965	G/C	cg12560992	chr17:57184187	TRIM37	-0.83	-11.38	-0.57	1.04e-24	Intelligence (multi-trait analysis);
CESC	cis	rs7829975	0.840	rs572366	chr8:8578794	A/T	cg17143192	chr8:8559678	CLDN23	0.44	5.44	0.32	1.2e-7	Mood instability;
CESC	cis	rs2425143	0.512	rs2425126	chr20:34331730	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.88	-10.7	-0.55	1.96e-22	Blood protein levels;
CESC	cis	rs1707322	1.000	rs12124847	chr1:46380850	T/A	cg03146154	chr1:46216737	IPP	0.79	10.79	0.55	9.83e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2576037	0.583	rs578451	chr18:44404525	T/A	cg19077165	chr18:44547161	KATNAL2	-0.62	-9.34	-0.5	4.05e-18	Personality dimensions;
CESC	cis	rs597539	0.652	rs488363	chr11:68658298	C/G	cg04772025	chr11:68637568	NA	0.5	5.95	0.34	8.36e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs950169	0.960	rs35159785	chr15:84804014	G/A	cg17507749	chr15:85114479	UBE2QP1	0.6	6.65	0.38	1.7e-10	Schizophrenia;
CESC	cis	rs35306767	0.953	rs12354639	chr10:963681	G/A	cg20503657	chr10:835505	NA	0.71	8.03	0.44	3.24e-14	Eosinophil percentage of granulocytes;
CESC	trans	rs208520	0.661	rs7740835	chr6:66865548	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.0	-12.94	-0.62	5.1e-30	Exhaled nitric oxide output;
CESC	cis	rs2280018	0.963	rs11075255	chr16:15166232	A/G	cg27102117	chr16:15229624	NA	0.5	7.86	0.43	9.89e-14	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs7771547	0.573	rs566742	chr6:36395668	C/T	cg07856975	chr6:36356162	ETV7	0.36	5.31	0.31	2.31e-7	Platelet distribution width;
CESC	cis	rs9322193	0.923	rs57938011	chr6:149964105	T/A	cg04369109	chr6:150039330	LATS1	-0.39	-5.44	-0.32	1.23e-7	Lung cancer;
CESC	cis	rs2243480	1.000	rs160644	chr7:65558186	C/T	cg18252515	chr7:66147081	NA	-1.39	-13.81	-0.65	4.83e-33	Diabetic kidney disease;
CESC	cis	rs10129255	0.500	rs7161740	chr14:107184358	G/T	cg07958169	chr14:107095056	NA	-0.53	-8.41	-0.46	2.5e-15	Kawasaki disease;
CESC	cis	rs295140	0.605	rs159320	chr2:201187775	A/G	cg23649088	chr2:200775458	C2orf69	0.47	6.31	0.36	1.15e-9	QT interval;
CESC	cis	rs12369635	1.000	rs73159540	chr12:129559421	C/T	cg01909103	chr12:129572610	TMEM132D	-0.69	-5.9	-0.34	1.09e-8	Schizophrenia (inflammation and infection response interaction);
CESC	cis	rs801193	0.773	rs801207	chr7:66020590	T/C	cg11764359	chr7:65958608	NA	-0.53	-6.98	-0.39	2.34e-11	Aortic root size;
CESC	cis	rs2576037	0.558	rs7244778	chr18:44541915	T/C	cg19077165	chr18:44547161	KATNAL2	-0.54	-7.98	-0.44	4.51e-14	Personality dimensions;
CESC	cis	rs7666738	0.830	rs9307218	chr4:99024885	T/C	cg24818145	chr4:99064322	C4orf37	0.38	5.04	0.3	8.61e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3096299	0.658	rs12443705	chr16:89547054	C/G	cg02034447	chr16:89574710	SPG7	0.47	5.97	0.34	7.76e-9	Multiple myeloma (IgH translocation);
CESC	cis	rs1448094	0.556	rs11614513	chr12:86167756	G/C	cg02569458	chr12:86230093	RASSF9	0.57	8.34	0.46	4.13e-15	Major depressive disorder;
CESC	cis	rs738322	0.804	rs4821742	chr22:38514839	T/C	cg17652424	chr22:38574118	PLA2G6	-0.29	-5.1	-0.3	6.59e-7	Cutaneous nevi;
CESC	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.55	-6.1	-0.35	3.69e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs889398	0.770	rs8052225	chr16:69883653	G/A	cg09409435	chr16:70099608	PDXDC2	0.42	5.22	0.31	3.56e-7	Body mass index;
CESC	cis	rs2832191	1.000	rs2832189	chr21:30487414	C/T	cg08807101	chr21:30365312	RNF160	-0.67	-9.14	-0.49	1.73e-17	Dental caries;
CESC	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	13.76	0.65	7.41e-33	Prudent dietary pattern;
CESC	cis	rs1882538	0.596	rs10281827	chr7:133081810	A/G	cg10665199	chr7:133106180	EXOC4	0.6	8.33	0.46	4.28e-15	Intelligence (multi-trait analysis);
CESC	cis	rs1559088	0.901	rs7249983	chr19:33598851	C/A	cg17764715	chr19:33622953	WDR88	0.5	6.52	0.37	3.56e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs9733	0.596	rs11204697	chr1:150658971	C/T	cg09365446	chr1:150670422	GOLPH3L	0.42	5.91	0.34	1.03e-8	Tonsillectomy;
CESC	trans	rs62103177	0.513	rs9945153	chr18:77598450	C/T	cg05926928	chr17:57297772	GDPD1	1.14	11.6	0.58	1.95e-25	Opioid sensitivity;
CESC	cis	rs6963495	0.818	rs117028299	chr7:105162310	T/C	cg02135003	chr7:105160482	PUS7	-0.46	-5.55	-0.32	6.92e-8	Bipolar disorder (body mass index interaction);
CESC	cis	rs11190604	1.000	rs28522614	chr10:102323141	T/A	cg07080220	chr10:102295463	HIF1AN	0.64	6.13	0.35	3.14e-9	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs2204008	0.635	rs1283298	chr12:38147630	G/A	cg26384229	chr12:38710491	ALG10B	-0.43	-5.87	-0.34	1.28e-8	Bladder cancer;
CESC	cis	rs12571093	0.773	rs7895164	chr10:69985415	T/C	cg06988349	chr10:69991859	ATOH7	0.33	5.19	0.3	4.12e-7	Optic nerve measurement (disc area);
CESC	cis	rs718433	0.614	rs8017132	chr14:22209363	T/C	cg02257791	chr14:22217085	NA	-0.34	-5.23	-0.31	3.41e-7	Intraocular pressure;
CESC	cis	rs1003719	0.788	rs2251161	chr21:38467857	C/G	cg10648535	chr21:38446584	PIGP;TTC3	0.63	8.77	0.47	2.14e-16	Eye color traits;
CESC	cis	rs2361718	0.500	rs8064429	chr17:78096187	A/C	cg27427491	chr17:78079615	GAA	-0.4	-5.75	-0.33	2.48e-8	Yeast infection;
CESC	cis	rs6460942	0.915	rs62448598	chr7:12453762	T/C	cg02935154	chr7:12443704	VWDE	-0.58	-6.16	-0.35	2.73e-9	Coronary artery disease;
CESC	cis	rs2204008	0.777	rs11179774	chr12:38219559	A/C	cg26384229	chr12:38710491	ALG10B	0.74	10.65	0.55	2.74e-22	Bladder cancer;
CESC	cis	rs72781680	1.000	rs72781658	chr2:24220141	A/G	cg20701182	chr2:24300061	SF3B14	0.81	6.9	0.39	3.82e-11	Lymphocyte counts;
CESC	cis	rs8028313	0.504	rs338364	chr15:68173921	A/G	cg26545918	chr15:68124484	LBXCOR1	0.31	5.27	0.31	2.86e-7	Obesity;
CESC	cis	rs853679	0.517	rs9380059	chr6:28132358	A/C	cg26335602	chr6:28129616	ZNF389	0.52	6.81	0.39	6.59e-11	Depression;
CESC	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg11905131	chr22:24372483	LOC391322	-0.86	-13.7	-0.64	1.18e-32	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs763121	0.853	rs6001185	chr22:39052155	G/A	cg06544989	chr22:39130855	UNC84B	0.49	8.52	0.46	1.22e-15	Menopause (age at onset);
CESC	cis	rs7512552	0.839	rs12046446	chr1:150460855	T/G	cg15654264	chr1:150340011	RPRD2	0.39	5.09	0.3	6.94e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs798554	0.679	rs1636254	chr7:2885724	T/C	cg04166393	chr7:2884313	GNA12	0.61	8.24	0.45	8.02e-15	Height;
CESC	cis	rs1862618	0.853	rs3099459	chr5:56137170	G/C	cg24531977	chr5:56204891	C5orf35	-0.89	-11.26	-0.57	2.62e-24	Initial pursuit acceleration;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg08021833	chr19:5785663	PRR22;DUS3L	0.48	6.54	0.37	3.09e-10	Fibrinogen levels;
CESC	cis	rs926938	0.563	rs360576	chr1:115459174	A/C	cg12756093	chr1:115239321	AMPD1	-0.43	-5.66	-0.33	3.88e-8	Autism;
CESC	cis	rs13118159	0.550	rs4974617	chr4:1373658	T/C	cg16405210	chr4:1374714	KIAA1530	-1.0	-14.25	-0.66	1.33e-34	Longevity;
CESC	cis	rs5753618	0.539	rs8135344	chr22:31671932	G/T	cg00478049	chr22:31556069	RNF185	0.46	5.21	0.3	3.8e-7	Colorectal cancer;
CESC	cis	rs2645694	0.651	rs2703128	chr4:77819187	C/G	cg10057126	chr4:77819792	ANKRD56	0.62	8.84	0.48	1.36e-16	Emphysema distribution in smoking;
CESC	cis	rs2549003	1.000	rs2070724	chr5:131822072	A/G	cg00255919	chr5:131827918	IRF1	0.51	8.68	0.47	4.19e-16	Asthma (sex interaction);
CESC	cis	rs2836974	0.932	rs8129416	chr21:40617145	C/T	cg17971929	chr21:40555470	PSMG1	1.05	15.94	0.7	1.48e-40	Cognitive function;
CESC	cis	rs1256061	0.603	rs928554	chr14:64694195	C/T	cg23250157	chr14:64679961	SYNE2	0.53	7.53	0.42	8.15e-13	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs9649213	0.537	rs6465663	chr7:97918883	C/G	cg08684580	chr7:98029266	BAIAP2L1	-0.34	-5.35	-0.31	1.86e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7918232	0.556	rs788209	chr10:27434716	G/T	cg14240646	chr10:27532245	ACBD5	-0.72	-5.46	-0.32	1.12e-7	Breast cancer;
CESC	cis	rs7193541	0.684	rs7201320	chr16:74694058	T/G	cg01733217	chr16:74700730	RFWD3	1.05	20.28	0.78	7.58e-56	Multiple myeloma;
CESC	cis	rs5753618	0.561	rs714909	chr22:31741067	G/A	cg13145458	chr22:31556086	RNF185	-0.49	-5.53	-0.32	7.87e-8	Colorectal cancer;
CESC	cis	rs7582720	1.000	rs77230711	chr2:203805552	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.38	0.41	1.99e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs1799949	0.965	rs8070179	chr17:41202688	G/A	cg23758822	chr17:41437982	NA	0.95	16.4	0.71	3.22e-42	Menopause (age at onset);
CESC	cis	rs13242816	1.000	rs13221364	chr7:116083544	C/T	cg04696780	chr7:116139425	CAV2	-0.63	-5.6	-0.33	5.33e-8	P wave duration;
CESC	cis	rs4819052	0.851	rs2838826	chr21:46655785	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.88	11.8	0.59	4.14e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs7605827	0.808	rs13001585	chr2:15517790	T/C	cg19274914	chr2:15703543	NA	0.35	6.27	0.36	1.43e-9	Educational attainment (years of education);
CESC	cis	rs559928	0.597	rs947939	chr11:63885287	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.65	5.47	0.32	1.04e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CESC	cis	rs7937682	0.924	rs11213968	chr11:111527629	G/C	cg22437258	chr11:111473054	SIK2	0.7	9.25	0.49	7.57e-18	Primary sclerosing cholangitis;
CESC	cis	rs6893300	0.560	rs1019443	chr5:179207547	A/G	cg14593053	chr5:179126677	CANX	-0.54	-7.95	-0.44	5.46e-14	Resting heart rate;
CESC	cis	rs73019876	0.869	rs2079062	chr19:22125212	T/G	cg11619707	chr19:22235551	ZNF257	-0.29	-5.46	-0.32	1.07e-7	Testicular germ cell tumor;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg18044720	chr4:87857031	AFF1	-0.52	-6.65	-0.38	1.67e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs1371867	0.875	rs1660311	chr8:101330579	C/T	cg11906718	chr8:101322791	RNF19A	0.53	6.86	0.39	4.86e-11	Atrioventricular conduction;
CESC	cis	rs3858526	0.959	rs11039699	chr11:5951091	G/A	cg13902645	chr11:5959945	NA	-0.66	-7.99	-0.44	4.21e-14	DNA methylation (variation);
CESC	cis	rs9487051	0.597	rs12664455	chr6:109590739	C/T	cg01475377	chr6:109611718	NA	-0.42	-5.23	-0.31	3.51e-7	Reticulocyte fraction of red cells;
CESC	cis	rs875971	0.564	rs313804	chr7:65514622	A/G	cg10691866	chr7:65817282	TPST1	-0.34	-5.49	-0.32	9.58e-8	Aortic root size;
CESC	trans	rs57221529	0.766	rs56350081	chr5:583198	G/A	cg25482853	chr8:67687455	SGK3	1.01	9.99	0.52	3.67e-20	Lung disease severity in cystic fibrosis;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg06549955	chr12:110434341	GIT2	-0.4	-6.13	-0.35	3.09e-9	Gambling;
CESC	cis	rs2075371	1.000	rs2241335	chr7:133979368	C/T	cg20476274	chr7:133979776	SLC35B4	0.65	9.43	0.5	2.11e-18	Mean platelet volume;
CESC	cis	rs10504229	0.683	rs7843919	chr8:58130792	T/C	cg02725872	chr8:58115012	NA	-0.45	-7.05	-0.4	1.52e-11	Developmental language disorder (linguistic errors);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg01159149	chr11:10830970	EIF4G2	-0.45	-6.62	-0.38	1.96e-10	Gambling;
CESC	trans	rs9951602	0.512	rs12455566	chr18:76655926	A/G	cg02800362	chr5:177631904	HNRNPAB	0.65	8.51	0.46	1.31e-15	Obesity-related traits;
CESC	cis	rs1008375	1.000	rs4698200	chr4:17657051	G/A	cg02297831	chr4:17616191	MED28	0.53	6.64	0.38	1.76e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs5750830	0.645	rs4821890	chr22:39777523	G/A	cg01416388	chr22:39784598	NA	-0.49	-6.68	-0.38	1.38e-10	Intelligence (multi-trait analysis);
CESC	cis	rs6963495	0.651	rs3892298	chr7:105152187	A/G	cg19920283	chr7:105172520	RINT1	0.67	6.36	0.36	8.79e-10	Bipolar disorder (body mass index interaction);
CESC	cis	rs672059	0.966	rs492228	chr1:183156476	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.54	6.99	0.39	2.28e-11	Hypertriglyceridemia;
CESC	cis	rs9322193	0.923	rs10782316	chr6:150073891	A/C	cg07701084	chr6:150067640	NUP43	0.48	6.75	0.38	9.54e-11	Lung cancer;
CESC	cis	rs9911578	0.967	rs12938821	chr17:56959422	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.4	5.29	0.31	2.53e-7	Intelligence (multi-trait analysis);
CESC	cis	rs17818399	0.533	rs13420857	chr2:46798005	C/G	cg02822958	chr2:46747628	ATP6V1E2	-0.44	-5.82	-0.34	1.71e-8	Height;
CESC	cis	rs5167	0.525	rs11083752	chr19:45454363	G/A	cg20090143	chr19:45452003	APOC2	0.37	6.39	0.37	7.51e-10	Blood protein levels;
CESC	cis	rs1957429	0.901	rs1951491	chr14:65346950	G/A	cg23373153	chr14:65346875	NA	0.96	11.51	0.58	4.06e-25	Pediatric areal bone mineral density (radius);
CESC	cis	rs7927592	0.956	rs12281742	chr11:68303629	C/T	cg20283391	chr11:68216788	NA	0.47	6.05	0.35	4.94e-9	Total body bone mineral density;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg23209537	chr7:5463409	TNRC18	-0.45	-6.07	-0.35	4.49e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs12530845	0.887	rs73725434	chr7:135313657	T/C	cg23117316	chr7:135346802	PL-5283	-0.48	-5.83	-0.34	1.58e-8	Red blood cell traits;
CESC	cis	rs2304206	0.614	rs12104272	chr19:50148052	A/G	cg09250473	chr19:50168907	IRF3;BCL2L12	-0.59	-7.21	-0.4	5.95e-12	Vitiligo;
CESC	trans	rs66573146	0.901	rs55882710	chr4:7030704	G/A	cg07817883	chr1:32538562	TMEM39B	1.09	6.46	0.37	4.88e-10	Granulocyte percentage of myeloid white cells;
CESC	cis	rs2933343	0.601	rs1680759	chr3:128594896	C/G	cg25356066	chr3:128598488	ACAD9	0.63	8.81	0.48	1.64e-16	IgG glycosylation;
CESC	cis	rs9733	0.596	rs12063547	chr1:150674053	G/T	cg17724175	chr1:150552817	MCL1	-0.43	-7.03	-0.4	1.76e-11	Tonsillectomy;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg10261819	chr16:22448417	RRN3P3;LOC641298	-0.49	-6.42	-0.37	6.21e-10	Fibrinogen levels;
CESC	cis	rs6500602	0.701	rs4786508	chr16:4568043	G/A	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.35	5.12	0.3	5.88e-7	Schizophrenia;
CESC	cis	rs8141529	0.732	rs3788409	chr22:29198151	T/G	cg02153584	chr22:29168773	CCDC117	0.69	9.81	0.52	1.43e-19	Lymphocyte counts;
CESC	cis	rs2243480	1.000	rs937108	chr7:65428452	G/A	cg25894440	chr7:65020034	NA	-0.63	-5.6	-0.33	5.4e-8	Diabetic kidney disease;
CESC	cis	rs13242816	1.000	rs34082946	chr7:116154313	G/A	cg04696780	chr7:116139425	CAV2	-0.61	-5.55	-0.32	7.01e-8	P wave duration;
CESC	cis	rs17253792	0.915	rs79100824	chr14:56179606	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.74	5.1	0.3	6.53e-7	Putamen volume;
CESC	cis	rs798554	0.757	rs2533882	chr7:2846894	G/T	cg04166393	chr7:2884313	GNA12	0.62	7.7	0.43	2.71e-13	Height;
CESC	cis	rs2066819	1.000	rs59626664	chr12:56636975	C/G	cg26734620	chr12:56694298	CS	1.04	6.73	0.38	1.06e-10	Psoriasis vulgaris;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23837683	chr19:3959058	DAPK3	-0.63	-7.44	-0.42	1.4e-12	Gut microbiome composition (summer);
CESC	cis	rs10504229	1.000	rs17216957	chr8:58179893	C/T	cg22535103	chr8:58192502	C8orf71	-1.05	-13.27	-0.63	3.63e-31	Developmental language disorder (linguistic errors);
CESC	cis	rs10465746	0.780	rs1324486	chr1:84384825	A/G	cg10977910	chr1:84465055	TTLL7	-0.51	-6.89	-0.39	4.15e-11	Obesity-related traits;
CESC	cis	rs4409675	0.576	rs2078328	chr1:28224976	A/G	cg23691781	chr1:28212827	C1orf38	0.28	5.67	0.33	3.72e-8	Corneal astigmatism;
CESC	cis	rs10754283	0.967	rs6657988	chr1:90106745	G/C	cg21401794	chr1:90099060	LRRC8C	0.69	9.34	0.5	4.06e-18	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs12701220	0.500	rs6463224	chr7:1140418	C/A	cg23978390	chr7:1156363	C7orf50	0.68	7.25	0.41	4.72e-12	Bronchopulmonary dysplasia;
CESC	cis	rs853679	0.550	rs1233704	chr6:28166923	A/G	cg26335602	chr6:28129616	ZNF389	-0.47	-6.54	-0.37	3.23e-10	Depression;
CESC	cis	rs13095912	1.000	rs13100034	chr3:185318804	G/A	cg11274856	chr3:185301563	NA	0.37	6.02	0.35	5.74e-9	Systolic blood pressure;
CESC	trans	rs7246760	1.000	rs68176351	chr19:9864222	G/A	cg02900749	chr2:68251473	NA	-0.79	-6.66	-0.38	1.57e-10	Pursuit maintenance gain;
CESC	cis	rs3126085	0.935	rs1496051	chr1:152164923	G/A	cg03465714	chr1:152285911	FLG	-0.45	-5.53	-0.32	7.86e-8	Atopic dermatitis;
CESC	cis	rs1008375	1.000	rs1006722	chr4:17618713	A/G	cg02297831	chr4:17616191	MED28	-0.51	-6.45	-0.37	5.43e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs2070488	0.775	rs4407366	chr3:38521425	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.78	12.05	0.59	6.07e-27	Electrocardiographic conduction measures;
CESC	cis	rs6461049	0.608	rs3800923	chr7:2184673	A/G	cg23048001	chr7:2026167	MAD1L1	0.46	6.24	0.36	1.75e-9	Schizophrenia;
CESC	cis	rs3785574	0.962	rs62077512	chr17:61851435	C/T	cg06873352	chr17:61820015	STRADA	0.48	7.0	0.4	2.07e-11	Height;
CESC	cis	rs798554	0.721	rs2527680	chr7:2892361	C/T	cg19717773	chr7:2847554	GNA12	-0.46	-6.45	-0.37	5.34e-10	Height;
CESC	cis	rs3096299	0.967	rs2911253	chr16:89488587	T/G	cg16743903	chr16:89593216	SPG7	-0.44	-5.74	-0.33	2.54e-8	Multiple myeloma (IgH translocation);
CESC	trans	rs61931739	1.000	rs12424741	chr12:34022771	C/T	cg26384229	chr12:38710491	ALG10B	-0.45	-6.21	-0.36	1.98e-9	Morning vs. evening chronotype;
CESC	cis	rs2882667	0.824	rs12173085	chr5:138480025	A/G	cg04439458	chr5:138467593	SIL1	-0.38	-5.75	-0.33	2.5e-8	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs9311474	1.000	rs6445358	chr3:52308845	C/G	cg25934064	chr3:52569026	NT5DC2	0.27	5.48	0.32	9.91e-8	Electroencephalogram traits;
CESC	cis	rs2404602	0.735	rs4886493	chr15:76679026	A/G	cg23625390	chr15:77176239	SCAPER	-0.44	-6.02	-0.35	5.72e-9	Blood metabolite levels;
CESC	cis	rs798554	0.723	rs798518	chr7:2777825	A/G	cg13628971	chr7:2884303	GNA12	0.63	8.11	0.45	1.95e-14	Height;
CESC	cis	rs7666738	0.761	rs28758886	chr4:99059704	C/T	cg18180107	chr4:99064573	C4orf37	0.41	5.26	0.31	2.99e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05896563	chr6:7390048	CAGE1;RIOK1	0.56	6.46	0.37	4.94e-10	Gut microbiome composition (summer);
CESC	cis	rs1577917	1.000	rs12154056	chr6:86634094	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.44	-5.78	-0.33	2.14e-8	Response to antipsychotic treatment;
CESC	cis	rs9733	0.596	rs34600506	chr1:150687808	C/G	cg17724175	chr1:150552817	MCL1	0.45	7.31	0.41	3.23e-12	Tonsillectomy;
CESC	cis	rs7542091	0.813	rs2049999	chr1:210031331	A/G	cg23283495	chr1:209979779	IRF6	0.32	5.1	0.3	6.59e-7	Monobrow;
CESC	cis	rs7772486	0.790	rs6570724	chr6:146151283	T/C	cg23711669	chr6:146136114	FBXO30	0.9	13.27	0.63	3.71e-31	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9747201	0.832	rs4072580	chr17:80160337	A/C	cg09264619	chr17:80180166	NA	-0.44	-5.22	-0.31	3.67e-7	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs8067545	0.611	rs1859407	chr17:20078137	T/C	cg13482628	chr17:19912719	NA	-0.44	-5.83	-0.34	1.58e-8	Schizophrenia;
CESC	cis	rs12995491	0.933	rs7590305	chr2:88513131	C/T	cg14558114	chr2:88469736	THNSL2	-0.5	-6.99	-0.39	2.24e-11	Response to metformin (IC50);
CESC	cis	rs6973256	0.569	rs12532950	chr7:133434286	C/T	cg10665199	chr7:133106180	EXOC4	0.41	5.71	0.33	3.07e-8	Intelligence (multi-trait analysis);
CESC	cis	rs763121	0.853	rs5995610	chr22:39064681	C/T	cg06022373	chr22:39101656	GTPBP1	0.88	13.95	0.65	1.51e-33	Menopause (age at onset);
CESC	cis	rs11871801	0.517	rs646123	chr17:40720632	G/A	cg16308533	chr17:40838983	CNTNAP1	0.4	5.17	0.3	4.61e-7	Crohn's disease;
CESC	cis	rs6540556	0.723	rs9430016	chr1:209916884	A/G	cg23920097	chr1:209922102	NA	-0.4	-5.88	-0.34	1.22e-8	Red blood cell count;
CESC	cis	rs6952808	0.595	rs3778983	chr7:2166319	T/G	cg02951883	chr7:2050386	MAD1L1	-0.48	-6.4	-0.37	6.92e-10	Bipolar disorder and schizophrenia;
CESC	cis	rs3125734	0.633	rs10821968	chr10:63993905	C/T	cg09941381	chr10:64027924	RTKN2	0.31	5.2	0.3	3.92e-7	Rheumatoid arthritis;
CESC	cis	rs4460629	0.742	rs11581730	chr1:155082158	A/T	cg01019262	chr1:155095195	NA	-0.3	-5.09	-0.3	6.75e-7	Serum magnesium levels;
CESC	cis	rs3096299	0.874	rs3102342	chr16:89451575	T/C	cg00750074	chr16:89608354	SPG7	-0.39	-5.51	-0.32	8.38e-8	Multiple myeloma (IgH translocation);
CESC	cis	rs367615	0.704	rs55956735	chr5:108845042	A/G	cg17395555	chr5:108820864	NA	0.63	11.15	0.57	6.1e-24	Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs4665809	1.000	rs4665821	chr2:26309949	A/C	cg04944784	chr2:26401820	FAM59B	-0.66	-7.53	-0.42	7.95e-13	Gut microbiome composition (summer);
CESC	cis	rs9513627	0.573	rs4771336	chr13:100210610	T/G	cg25919922	chr13:100150906	NA	0.71	8.22	0.45	8.86e-15	Obesity-related traits;
CESC	cis	rs9916302	0.821	rs12938268	chr17:37572139	G/A	cg00129232	chr17:37814104	STARD3	-0.53	-6.59	-0.38	2.35e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs921968	0.565	rs6745700	chr2:219639862	T/C	cg02176678	chr2:219576539	TTLL4	-0.43	-7.66	-0.43	3.42e-13	Mean corpuscular hemoglobin concentration;
CESC	cis	rs6952808	0.595	rs2398705	chr7:2164995	G/A	cg21782813	chr7:2030301	MAD1L1	0.5	7.26	0.41	4.36e-12	Bipolar disorder and schizophrenia;
CESC	cis	rs3741798	1.000	rs3825259	chr12:12496635	A/G	cg08615371	chr12:12503544	MANSC1	0.74	5.36	0.31	1.82e-7	Cerebrospinal fluid biomarker levels;
CESC	cis	rs10504229	0.683	rs62621195	chr8:58133964	G/A	cg02725872	chr8:58115012	NA	-0.45	-7.05	-0.4	1.52e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs10504229	1.000	rs57941207	chr8:58169821	A/G	cg14926445	chr8:58193284	C8orf71	-0.51	-5.48	-0.32	1.01e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs3617	0.625	rs6769789	chr3:52874446	C/T	cg07507251	chr3:52567010	NT5DC2	-0.32	-5.41	-0.32	1.4e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
CESC	cis	rs28493229	0.522	rs2287692	chr19:41289756	G/A	cg21869046	chr19:41225005	ITPKC	0.53	6.45	0.37	5.29e-10	Kawasaki disease;
CESC	cis	rs6815814	0.950	rs5743571	chr4:38805489	C/T	cg02016764	chr4:38805732	TLR1	-0.62	-7.23	-0.41	5.15e-12	Breast cancer;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg26406407	chr10:438229	DIP2C	0.44	6.06	0.35	4.7e-9	Fibrinogen levels;
CESC	cis	rs514406	0.607	rs6665324	chr1:53201610	G/A	cg24675658	chr1:53192096	ZYG11B	0.63	8.81	0.48	1.7e-16	Monocyte count;
CESC	cis	rs7267979	0.966	rs6083817	chr20:25343998	G/C	cg08601574	chr20:25228251	PYGB	-0.38	-5.46	-0.32	1.12e-7	Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg08810106	chr16:18936940	SMG1	-0.43	-6.0	-0.35	6.31e-9	Gambling;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg26215009	chr5:34008104	AMACR	0.46	6.07	0.35	4.5e-9	Systemic lupus erythematosus;
CESC	cis	rs7666738	0.830	rs34164616	chr4:99015251	G/A	cg18180107	chr4:99064573	C4orf37	0.4	5.3	0.31	2.48e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs35160687	0.644	rs11127024	chr2:86505453	C/T	cg01119172	chr2:86362222	SNORD94;PTCD3	-0.4	-5.39	-0.31	1.59e-7	Night sleep phenotypes;
CESC	cis	rs9303280	0.806	rs10445308	chr17:37938047	C/T	cg20243544	chr17:37824526	PNMT	0.52	7.01	0.4	1.99e-11	Self-reported allergy;
CESC	cis	rs769267	0.895	rs2965182	chr19:19548246	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.47	5.94	0.34	8.83e-9	Tonsillectomy;
CESC	cis	rs72781680	0.716	rs6731314	chr2:24048338	C/T	cg08917208	chr2:24149416	ATAD2B	-0.65	-6.38	-0.36	7.81e-10	Lymphocyte counts;
CESC	cis	rs10256972	0.621	rs2280725	chr7:1087426	G/T	cg16145915	chr7:1198662	ZFAND2A	-0.48	-7.02	-0.4	1.8e-11	Longevity;Endometriosis;
CESC	cis	rs7666738	0.791	rs1426661	chr4:98874303	C/G	cg05340658	chr4:99064831	C4orf37	0.75	11.1	0.56	9.43e-24	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04228104	chr1:150551925	MCL1	0.59	6.42	0.37	6.25e-10	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04456437	chr3:119217424	C3orf1	0.54	6.01	0.35	6.06e-9	Gut microbiome composition (summer);
CESC	cis	rs3741151	0.773	rs57673166	chr11:73232557	T/A	cg17517138	chr11:73019481	ARHGEF17	1.05	7.72	0.43	2.46e-13	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs1862618	0.853	rs190414	chr5:56116772	C/A	cg03609598	chr5:56110824	MAP3K1	-0.5	-5.29	-0.31	2.51e-7	Initial pursuit acceleration;
CESC	cis	rs3749237	0.964	rs2234385	chr3:49846041	G/A	cg03060546	chr3:49711283	APEH	0.65	7.65	0.43	3.69e-13	Resting heart rate;
CESC	cis	rs2294693	0.945	rs9369252	chr6:40986028	C/T	cg14769373	chr6:40998127	UNC5CL	0.49	6.37	0.36	8.54e-10	Gastric cancer;Non-cardia gastric cancer;
CESC	cis	rs1461503	0.934	rs7107560	chr11:122845380	T/C	cg27398637	chr11:122830231	C11orf63	-0.55	-8.03	-0.44	3.2e-14	Menarche (age at onset);
CESC	cis	rs13040088	1.000	rs12480870	chr20:61543606	A/C	cg23096297	chr20:61557774	DIDO1	0.97	10.83	0.55	7.35e-23	Menopause (age at onset);
CESC	cis	rs4948102	0.924	rs13241866	chr7:56090878	C/G	cg09872392	chr7:56161020	PHKG1	-0.4	-6.28	-0.36	1.4e-9	Plasma homocysteine levels (post-methionine load test);
CESC	cis	rs1046896	0.512	rs3785513	chr17:80886748	G/A	cg19046167	chr17:80928561	B3GNTL1	0.46	6.11	0.35	3.62e-9	Glycated hemoglobin levels;
CESC	cis	rs4472734	0.796	rs12757404	chr1:214629616	A/G	cg00063699	chr1:214624242	PTPN14	-0.33	-5.08	-0.3	7.25e-7	Height;
CESC	cis	rs56399783	0.614	rs11765492	chr7:2771642	G/A	cg19731401	chr7:2775893	GNA12	0.69	6.06	0.35	4.74e-9	Childhood ear infection;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01304440	chr3:32726769	CNOT10	-0.57	-6.23	-0.36	1.8e-9	Gut microbiome composition (summer);
CESC	cis	rs5753618	0.583	rs5753628	chr22:31860322	A/G	cg00478049	chr22:31556069	RNF185	-0.43	-5.15	-0.3	5.09e-7	Colorectal cancer;
CESC	cis	rs6088590	0.813	rs1884668	chr20:33285514	A/G	cg24642439	chr20:33292090	TP53INP2	0.68	9.04	0.49	3.51e-17	Coronary artery disease;
CESC	cis	rs6964587	0.839	rs10808086	chr7:91447515	T/C	cg17063962	chr7:91808500	NA	0.51	6.45	0.37	5.2e-10	Breast cancer;
CESC	cis	rs12765878	0.967	rs34887477	chr10:105643436	C/T	cg11005552	chr10:105648138	OBFC1	0.35	5.1	0.3	6.34e-7	Coronary artery disease;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05935374	chr11:82782929	RAB30	0.47	6.28	0.36	1.36e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs7208859	0.614	rs73265646	chr17:29244023	C/T	cg19761014	chr17:28927070	LRRC37B2	0.71	5.56	0.32	6.59e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs10861342	1.000	rs11112390	chr12:105542200	A/C	cg23923672	chr12:105501055	KIAA1033	0.7	5.94	0.34	9.01e-9	IgG glycosylation;
CESC	cis	rs875971	0.508	rs10258739	chr7:66062935	A/T	cg19163074	chr7:65112434	INTS4L2	0.43	5.57	0.32	6.21e-8	Aortic root size;
CESC	cis	rs12477438	0.501	rs13008171	chr2:99743419	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.79	12.63	0.61	6.22e-29	Chronic sinus infection;
CESC	trans	rs1505368	0.836	rs10201067	chr2:213284411	A/G	cg00572323	chr16:29706151	QPRT	0.37	6.17	0.35	2.61e-9	Symmetrical dimethylarginine levels;
CESC	cis	rs2635047	0.967	rs2576056	chr18:44675462	G/C	cg19077165	chr18:44547161	KATNAL2	-0.43	-5.73	-0.33	2.73e-8	Educational attainment;
CESC	cis	rs8017423	0.967	rs11159958	chr14:90716051	T/C	cg14092571	chr14:90743983	NA	-0.58	-8.84	-0.48	1.41e-16	Mortality in heart failure;
CESC	cis	rs11098499	0.865	rs3956464	chr4:120256764	T/C	cg09307838	chr4:120376055	NA	0.81	10.94	0.56	3.14e-23	Corneal astigmatism;
CESC	trans	rs2727020	0.637	rs1164673	chr11:49328356	C/G	cg15704280	chr7:45808275	SEPT13	0.69	9.34	0.5	4.03e-18	Coronary artery disease;
CESC	cis	rs6690583	0.623	rs12033900	chr1:85478559	T/C	cg22488158	chr1:85528044	WDR63	0.55	5.16	0.3	4.76e-7	Serum sulfate level;
CESC	cis	rs8077577	0.671	rs12450760	chr17:18253822	C/T	cg16794390	chr17:18148240	FLII	0.38	6.25	0.36	1.59e-9	Obesity-related traits;
CESC	cis	rs875971	0.964	rs9691480	chr7:65944306	A/C	cg18876405	chr7:65276391	NA	0.51	6.82	0.39	6.05e-11	Aortic root size;
CESC	trans	rs35110281	0.720	rs162392	chr21:44941406	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.54	7.29	0.41	3.65e-12	Mean corpuscular volume;
CESC	cis	rs11122272	0.735	rs2256908	chr1:231506557	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.56	-7.68	-0.43	3.02e-13	Hemoglobin concentration;
CESC	cis	rs9486715	1.000	rs6905568	chr6:97066382	T/C	cg06623918	chr6:96969491	KIAA0776	-0.86	-12.58	-0.61	9.16e-29	Headache;
CESC	cis	rs2933343	0.700	rs1680788	chr3:128625318	C/T	cg11901034	chr3:128598214	ACAD9	-0.39	-5.71	-0.33	3.1e-8	IgG glycosylation;
CESC	cis	rs9649213	0.574	rs3801257	chr7:97991792	A/G	cg21770322	chr7:97807741	LMTK2	0.55	8.41	0.46	2.49e-15	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs12497850	0.931	rs9311434	chr3:48884147	T/C	cg02487422	chr3:49467188	NICN1	0.39	5.09	0.3	6.86e-7	Parkinson's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02322435	chr11:67815326	TCIRG1	-0.59	-6.57	-0.37	2.66e-10	Gut microbiome composition (summer);
CESC	cis	rs8067354	0.958	rs2333563	chr17:57839568	A/G	cg02344993	chr17:57696989	CLTC	0.48	6.29	0.36	1.29e-9	Hemoglobin concentration;
CESC	cis	rs763121	0.785	rs6001203	chr22:39099602	T/C	cg06544989	chr22:39130855	UNC84B	0.52	9.88	0.52	8.35e-20	Menopause (age at onset);
CESC	cis	rs9916302	0.904	rs634365	chr17:37436966	C/T	cg00129232	chr17:37814104	STARD3	-0.54	-7.05	-0.4	1.59e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs926392	0.666	rs35166252	chr20:37695601	C/T	cg16355469	chr20:37678765	NA	0.53	5.86	0.34	1.36e-8	Dialysis-related mortality;
CESC	cis	rs4563143	0.663	rs10417671	chr19:29235335	T/C	cg12667521	chr19:29218732	NA	0.42	6.35	0.36	9.3e-10	Methadone dose in opioid dependence;
CESC	cis	rs72781680	0.898	rs72796158	chr2:23935727	T/C	cg08917208	chr2:24149416	ATAD2B	1.1	10.15	0.53	1.18e-20	Lymphocyte counts;
CESC	cis	rs9325144	0.560	rs10506125	chr12:39120287	C/T	cg26384229	chr12:38710491	ALG10B	0.52	7.61	0.42	4.94e-13	Morning vs. evening chronotype;
CESC	cis	rs7539624	0.947	rs6683379	chr1:223906421	A/G	cg10100437	chr1:223903862	CAPN2	-0.35	-5.24	-0.31	3.28e-7	Schizophrenia;
CESC	cis	rs4253772	0.637	rs6008357	chr22:46652104	T/G	cg10231785	chr22:46692440	CN5H6.4;GTSE1	0.48	5.11	0.3	6.16e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs2249625	0.874	rs7451395	chr6:72924499	G/A	cg18830697	chr6:72922368	RIMS1	-0.41	-5.73	-0.33	2.79e-8	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CESC	cis	rs9322193	0.962	rs3805748	chr6:150093678	C/T	cg07701084	chr6:150067640	NUP43	0.44	5.93	0.34	9.65e-9	Lung cancer;
CESC	cis	rs853679	0.517	rs4713150	chr6:28136212	G/A	cg23161317	chr6:28129485	ZNF389	0.47	5.89	0.34	1.18e-8	Depression;
CESC	cis	rs798554	0.644	rs7783400	chr7:2894434	A/C	cg04166393	chr7:2884313	GNA12	-0.6	-7.35	-0.41	2.4e-12	Height;
CESC	cis	rs9911578	0.935	rs7216698	chr17:57007495	G/A	cg12560992	chr17:57184187	TRIM37	0.8	12.47	0.61	2.22e-28	Intelligence (multi-trait analysis);
CESC	cis	rs1707322	0.752	rs12062535	chr1:46222880	G/A	cg03146154	chr1:46216737	IPP	0.82	11.53	0.58	3.39e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs853679	0.607	rs71559070	chr6:28038929	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.82	-5.06	-0.3	7.83e-7	Depression;
CESC	cis	rs2066819	1.000	rs17118439	chr12:56667604	C/T	cg26714650	chr12:56694279	CS	1.34	9.29	0.5	6.05e-18	Psoriasis vulgaris;
CESC	cis	rs9486719	1.000	rs2205755	chr6:96864704	A/G	cg06623918	chr6:96969491	KIAA0776	0.81	8.29	0.45	5.61e-15	Migraine;Coronary artery disease;
CESC	cis	rs8180040	0.726	rs34344887	chr3:47042161	A/G	cg27129171	chr3:47204927	SETD2	0.69	10.19	0.53	8.8e-21	Colorectal cancer;
CESC	cis	rs9583531	0.600	rs1441042	chr13:111365589	T/G	cg15841412	chr13:111365552	ING1	0.49	6.16	0.35	2.71e-9	Coronary artery disease;
CESC	cis	rs656900	0.874	rs685487	chr15:80136129	A/G	cg02196730	chr15:80188777	MTHFS	-0.42	-5.37	-0.31	1.7e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs4711336	1.000	rs3818523	chr6:33660371	G/A	cg14003231	chr6:33640908	ITPR3	0.32	5.42	0.32	1.34e-7	Height;
CESC	cis	rs889312	0.500	rs832585	chr5:56125904	T/C	cg14703610	chr5:56206110	C5orf35	0.52	6.91	0.39	3.62e-11	Breast cancer;Breast cancer (early onset);
CESC	cis	rs826838	1.000	rs826889	chr12:39101076	G/A	cg13010199	chr12:38710504	ALG10B	-0.42	-5.86	-0.34	1.37e-8	Heart rate;
CESC	cis	rs4713118	0.527	rs9461433	chr6:28095172	C/T	cg22143856	chr6:28129313	ZNF389	0.51	6.62	0.38	2e-10	Parkinson's disease;
CESC	trans	rs801193	0.839	rs12534943	chr7:66070520	A/G	cg26939375	chr7:64535504	NA	-0.54	-7.43	-0.42	1.54e-12	Aortic root size;
CESC	cis	rs1005277	0.602	rs1780141	chr10:38504299	T/C	cg25517755	chr10:38738941	LOC399744	-0.44	-5.7	-0.33	3.12e-8	Extrinsic epigenetic age acceleration;
CESC	cis	rs660899	0.595	rs11577684	chr1:44254280	C/G	cg11704212	chr1:44303111	ST3GAL3	-0.38	-5.12	-0.3	5.99e-7	Hypertension risk in short sleep duration;
CESC	cis	rs6484504	0.576	rs158136	chr11:31220712	C/T	cg14844989	chr11:31128820	NA	-0.42	-5.96	-0.34	7.83e-9	Red blood cell count;
CESC	cis	rs262150	0.567	rs2040897	chr7:158803848	C/T	cg19418458	chr7:158789849	NA	-0.38	-5.78	-0.33	2.11e-8	Facial morphology (factor 20);
CESC	cis	rs11626933	0.959	rs8005973	chr14:90774951	C/T	cg14092571	chr14:90743983	NA	-0.92	-15.34	-0.69	1.96e-38	Gut microbiota (bacterial taxa);
CESC	cis	rs3820928	1.000	rs4675116	chr2:227769607	A/C	cg11843606	chr2:227700838	RHBDD1	-0.43	-5.79	-0.34	1.97e-8	Pulmonary function;
CESC	cis	rs651907	0.557	rs7651404	chr3:101393294	C/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.47	6.08	0.35	4.17e-9	Colorectal cancer;
CESC	cis	rs2688608	0.592	rs7080579	chr10:75504029	T/A	cg23231163	chr10:75533350	FUT11	-0.35	-5.4	-0.32	1.45e-7	Inflammatory bowel disease;
CESC	cis	rs7481584	0.624	rs412149	chr11:3069943	G/A	cg25174290	chr11:3078921	CARS	-0.52	-7.31	-0.41	3.09e-12	Calcium levels;
CESC	cis	rs1215050	0.791	rs1215054	chr4:98863009	T/G	cg05340658	chr4:99064831	C4orf37	-0.5	-6.65	-0.38	1.66e-10	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs4268898	0.679	rs2551181	chr2:24437548	C/T	cg20701182	chr2:24300061	SF3B14	-0.55	-6.15	-0.35	2.89e-9	Asthma;
CESC	cis	rs6831352	0.918	rs13107558	chr4:100050200	C/A	cg12011299	chr4:100065546	ADH4	-0.55	-6.28	-0.36	1.38e-9	Alcohol dependence;
CESC	cis	rs10197940	0.662	rs4592848	chr2:152337822	G/A	cg06191203	chr2:152266755	RIF1	-0.45	-5.29	-0.31	2.59e-7	Lung cancer;
CESC	cis	rs12451471	0.559	rs1042396	chr17:78084769	G/A	cg24585782	chr17:78113791	EIF4A3	-0.58	-7.63	-0.42	4.35e-13	Plateletcrit;Mean corpuscular hemoglobin concentration;
CESC	cis	rs3733585	0.699	rs6856127	chr4:9965443	T/C	cg02734326	chr4:10020555	SLC2A9	-0.43	-6.03	-0.35	5.47e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs477692	0.655	rs7906680	chr10:131442671	C/G	cg05714579	chr10:131428358	MGMT	-0.59	-8.48	-0.46	1.61e-15	Response to temozolomide;
CESC	trans	rs4534636	0.812	rs11045985	chr12:8666378	A/C	cg14536431	chr21:40030097	ERG	-0.41	-6.08	-0.35	4.11e-9	Response to radiotherapy in prostate cancer (toxicity, urinary frequency);
CESC	cis	rs1949733	0.656	rs6845969	chr4:8402465	A/T	cg11789530	chr4:8429930	ACOX3	0.69	9.88	0.52	8.38e-20	Response to antineoplastic agents;
CESC	cis	rs7191700	0.511	rs8043625	chr16:11361895	C/G	cg00044050	chr16:11439710	C16orf75	-0.44	-5.38	-0.31	1.62e-7	Multiple sclerosis;
CESC	cis	rs2361718	0.500	rs4889970	chr17:78096086	C/T	cg21238619	chr17:78079768	GAA	0.4	5.85	0.34	1.42e-8	Yeast infection;
CESC	cis	rs4523957	0.690	rs11867782	chr17:2090507	T/G	cg16513277	chr17:2031491	SMG6	-0.72	-10.08	-0.53	1.92e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs2637266	0.935	rs1907300	chr10:78325091	A/G	cg18941641	chr10:78392320	NA	0.38	6.83	0.39	5.66e-11	Pulmonary function;
CESC	trans	rs747782	0.528	rs16905753	chr11:48285906	C/T	cg15704280	chr7:45808275	SEPT13	0.69	6.46	0.37	4.95e-10	Intraocular pressure;
CESC	cis	rs2576037	0.562	rs9959877	chr18:44522293	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.77	12.63	0.61	6.21e-29	Personality dimensions;
CESC	cis	rs9359856	0.517	rs17506515	chr6:90507332	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.66	-6.74	-0.38	9.61e-11	Bipolar disorder;
CESC	cis	rs9322193	0.962	rs9322218	chr6:150103319	A/G	cg09699651	chr6:150184138	LRP11	0.4	5.1	0.3	6.34e-7	Lung cancer;
CESC	cis	rs926938	0.618	rs1286560	chr1:115375930	C/T	cg12756093	chr1:115239321	AMPD1	-0.45	-6.15	-0.35	2.9e-9	Autism;
CESC	cis	rs4665809	1.000	rs4665299	chr2:26256840	A/C	cg27170947	chr2:26402098	FAM59B	-0.71	-8.2	-0.45	1.02e-14	Gut microbiome composition (summer);
CESC	cis	rs2637266	0.783	rs12258504	chr10:78477055	C/T	cg18941641	chr10:78392320	NA	0.4	7.59	0.42	5.51e-13	Pulmonary function;
CESC	cis	rs1062177	0.756	rs2915827	chr5:151119705	T/A	cg00977110	chr5:151150581	G3BP1	-0.62	-6.47	-0.37	4.72e-10	Preschool internalizing problems;
CESC	cis	rs965469	0.895	rs6139124	chr20:3398144	C/T	cg25506879	chr20:3388711	C20orf194	-0.63	-6.59	-0.38	2.3e-10	IFN-related cytopenia;
CESC	cis	rs7267979	0.873	rs6115093	chr20:25210730	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.82	14.59	0.67	8.75e-36	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs9443189	0.570	rs569731	chr6:76357593	G/A	cg01950844	chr6:76311363	SENP6	0.87	9.27	0.49	6.59e-18	Prostate cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11017490	chr15:79044350	NA	-0.49	-6.93	-0.39	3.21e-11	Gut microbiome composition (summer);
CESC	cis	rs16917546	1.000	rs10995251	chr10:64398466	C/T	cg03961010	chr10:64397487	ZNF365	-0.38	-6.11	-0.35	3.58e-9	Basal cell carcinoma;
CESC	cis	rs1008375	1.000	rs4698200	chr4:17657051	G/A	cg15017067	chr4:17643749	FAM184B	0.37	5.23	0.31	3.39e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs7429990	0.965	rs7649981	chr3:47999337	T/A	cg11946769	chr3:48343235	NME6	0.44	5.38	0.31	1.61e-7	Educational attainment (years of education);
CESC	cis	rs2806561	0.704	rs1757039	chr1:23508657	A/G	cg12483005	chr1:23474871	LUZP1	0.39	6.06	0.35	4.58e-9	Height;
CESC	cis	rs1005277	0.579	rs2474575	chr10:38387901	C/T	cg25517755	chr10:38738941	LOC399744	-0.47	-6.05	-0.35	4.86e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs2997447	0.601	rs61776577	chr1:26431931	T/C	cg24596570	chr1:26146463	FAM54B;LOC646471	0.62	5.33	0.31	2.07e-7	QRS complex (12-leadsum);
CESC	cis	rs6674176	0.660	rs6801	chr1:44396646	C/G	cg12908607	chr1:44402522	ARTN	0.53	7.92	0.44	6.48e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs10089	1.000	rs1962291	chr5:127445373	A/G	cg19767477	chr5:127420684	SLC12A2	0.41	5.57	0.32	6.15e-8	Ileal carcinoids;
CESC	trans	rs9951602	0.512	rs9958376	chr18:76655167	G/T	cg02800362	chr5:177631904	HNRNPAB	0.66	8.63	0.47	5.9e-16	Obesity-related traits;
CESC	cis	rs34172651	0.517	rs11642954	chr16:24824248	G/A	cg00339695	chr16:24857497	SLC5A11	0.49	6.29	0.36	1.33e-9	Intelligence (multi-trait analysis);
CESC	cis	rs7208859	0.673	rs216410	chr17:28903831	C/G	cg04154034	chr17:28927549	LRRC37B2	-0.57	-5.63	-0.33	4.65e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg11064206	chr12:123459532	OGFOD2;ABCB9	0.45	6.03	0.35	5.43e-9	Systemic lupus erythematosus;
CESC	cis	rs801193	0.636	rs10233806	chr7:66118248	G/C	cg12463550	chr7:65579703	CRCP	-0.57	-7.29	-0.41	3.57e-12	Aortic root size;
CESC	cis	rs68170813	0.559	rs80307895	chr7:106907781	T/A	cg02696742	chr7:106810147	HBP1	-0.52	-5.09	-0.3	6.84e-7	Coronary artery disease;
CESC	cis	rs12497850	0.864	rs7431857	chr3:48900347	G/A	cg02487422	chr3:49467188	NICN1	0.4	5.11	0.3	6.09e-7	Parkinson's disease;
CESC	cis	rs3785574	0.962	rs35448669	chr17:61938923	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.57	7.26	0.41	4.27e-12	Height;
CESC	cis	rs4819052	0.851	rs1056099	chr21:46678892	G/A	cg11663144	chr21:46675770	NA	-0.47	-6.99	-0.39	2.27e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs7618915	0.547	rs12487591	chr3:52642936	A/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.36	6.02	0.35	5.67e-9	Bipolar disorder;
CESC	cis	rs12410462	0.579	rs115037090	chr1:227666191	A/G	cg04117972	chr1:227635322	NA	0.8	6.85	0.39	5.16e-11	Major depressive disorder;
CESC	trans	rs13169113	0.782	rs7447513	chr5:125348925	G/A	cg26424645	chr1:227729598	NA	-0.39	-6.25	-0.36	1.63e-9	Cognitive performance;
CESC	cis	rs7772486	0.754	rs6570703	chr6:145957052	C/T	cg05347473	chr6:146136440	FBXO30	0.53	6.96	0.39	2.72e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1552244	0.872	rs7646073	chr3:10097405	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-11.04	-0.56	1.41e-23	Alzheimer's disease;
CESC	cis	rs6582630	0.537	rs3942440	chr12:38459672	A/G	cg26384229	chr12:38710491	ALG10B	0.71	10.82	0.55	7.82e-23	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs9303401	0.614	rs34058624	chr17:57118121	T/C	cg12560992	chr17:57184187	TRIM37	0.5	5.2	0.3	3.94e-7	Cognitive test performance;
CESC	cis	rs1878931	0.624	rs27235	chr16:3439138	G/C	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.75	-9.25	-0.49	7.57e-18	Body mass index (adult);
CESC	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.49	-5.33	-0.31	2.06e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs4076764	1.000	rs7528020	chr1:163426537	G/A	cg06092702	chr1:163392909	NA	-0.37	-5.38	-0.31	1.65e-7	Motion sickness;
CESC	cis	rs2732480	0.500	rs7315820	chr12:48598938	C/T	cg04545296	chr12:48745243	ZNF641	0.4	6.74	0.38	9.66e-11	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs4975709	0.589	rs1466606	chr5:1865055	C/T	cg11168104	chr5:1857477	NA	-0.36	-5.28	-0.31	2.76e-7	Cardiovascular disease risk factors;
CESC	cis	rs2650000	0.798	rs2701175	chr12:121391671	C/A	cg02403541	chr12:121454288	C12orf43	-0.53	-6.88	-0.39	4.43e-11	Metabolic traits;LDL cholesterol;
CESC	cis	rs9309473	0.898	rs6546851	chr2:73833283	C/T	cg20560298	chr2:73613845	ALMS1	-0.45	-6.07	-0.35	4.36e-9	Metabolite levels;
CESC	cis	rs7666738	0.791	rs2865958	chr4:99040732	G/T	cg18180107	chr4:99064573	C4orf37	0.41	5.29	0.31	2.51e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9354352	0.784	rs2062327	chr6:66689923	C/G	cg07460842	chr6:66804631	NA	-0.71	-10.34	-0.54	2.78e-21	Initial pursuit acceleration in psychotic disorders;
CESC	cis	rs7267979	0.966	rs2227890	chr20:25260931	A/G	cg08601574	chr20:25228251	PYGB	0.39	5.65	0.33	4.14e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs1728785	1.000	rs1645981	chr16:68571648	T/C	cg02972257	chr16:68554789	NA	-0.55	-6.34	-0.36	9.7e-10	Ulcerative colitis;
CESC	cis	rs6424115	0.800	rs2229581	chr1:24201094	G/C	cg10978503	chr1:24200527	CNR2	0.33	6.64	0.38	1.73e-10	Immature fraction of reticulocytes;
CESC	cis	rs8072100	0.512	rs9674670	chr17:45386157	G/A	cg08085267	chr17:45401833	C17orf57	-0.55	-7.27	-0.41	4.17e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg26289012	chr17:3540036	CTNS;SHPK	-0.48	-6.3	-0.36	1.26e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs2836974	0.602	rs2037925	chr21:40699931	C/T	cg22974920	chr21:40686053	BRWD1	-0.42	-5.19	-0.3	4.1e-7	Cognitive function;
CESC	cis	rs4555082	0.834	rs28846738	chr14:105745781	A/G	cg06808227	chr14:105710500	BRF1	-0.6	-7.17	-0.4	7.32e-12	Mean platelet volume;Platelet distribution width;
CESC	cis	rs35520189	0.845	rs34899562	chr2:113641472	C/T	cg06156847	chr2:113672199	IL1F7	0.36	5.47	0.32	1.04e-7	Obstructive sleep apnea trait (apnea hypopnea index);
CESC	cis	rs959260	1.000	rs2385264	chr17:73364992	C/T	cg20590849	chr17:73267439	MIF4GD	-0.55	-6.4	-0.37	6.95e-10	Systemic lupus erythematosus;
CESC	cis	rs2072732	0.861	rs56176404	chr1:2940998	A/G	cg15211996	chr1:2936768	ACTRT2	0.34	5.23	0.31	3.5e-7	Plateletcrit;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg07522190	chr16:28925877	RABEP2	0.43	6.11	0.35	3.5e-9	Fibrinogen levels;
CESC	cis	rs3806843	1.000	rs11167600	chr5:140174865	G/C	cg16179182	chr5:140090404	VTRNA1-1	-0.4	-5.12	-0.3	5.99e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs10504229	1.000	rs56740825	chr8:58175617	A/G	cg22535103	chr8:58192502	C8orf71	-1.05	-13.27	-0.63	3.63e-31	Developmental language disorder (linguistic errors);
CESC	cis	rs9399135	0.967	rs9321481	chr6:135352648	C/G	cg22676075	chr6:135203613	NA	-0.49	-6.62	-0.38	2.02e-10	Red blood cell count;
CESC	cis	rs9399401	0.710	rs12197866	chr6:142706063	C/T	cg03128060	chr6:142623767	GPR126	0.37	6.08	0.35	4.08e-9	Chronic obstructive pulmonary disease;
CESC	cis	rs7771547	0.573	rs9470274	chr6:36397229	G/A	cg07856975	chr6:36356162	ETV7	0.36	5.38	0.31	1.67e-7	Platelet distribution width;
CESC	cis	rs9488822	0.676	rs6918059	chr6:116349041	C/T	cg05304507	chr6:116381966	FRK	0.26	6.74	0.38	9.69e-11	Cholesterol, total;LDL cholesterol;
CESC	cis	rs7666738	0.830	rs10034619	chr4:98970067	G/C	cg03676636	chr4:99064102	C4orf37	0.33	5.11	0.3	6.08e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs977987	0.806	rs4638613	chr16:75425553	C/T	cg03315344	chr16:75512273	CHST6	0.42	6.05	0.35	4.89e-9	Dupuytren's disease;
CESC	cis	rs796364	0.951	rs12463436	chr2:201061962	C/G	cg23649088	chr2:200775458	C2orf69	0.53	5.65	0.33	4.23e-8	Schizophrenia;
CESC	cis	rs4728302	0.869	rs13233715	chr7:133617471	C/T	cg10665199	chr7:133106180	EXOC4	0.39	5.3	0.31	2.49e-7	Intelligence;Intelligence (multi-trait analysis);
CESC	cis	rs7914558	1.000	rs4917380	chr10:104775335	C/G	cg15744005	chr10:104629667	AS3MT	-0.33	-5.38	-0.31	1.63e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs2880765	0.835	rs1872074	chr15:86033184	T/G	cg19183879	chr15:85880815	NA	-0.25	-5.18	-0.3	4.49e-7	Coronary artery disease;
CESC	cis	rs10242455	0.557	rs59672032	chr7:99058697	T/C	cg13560068	chr7:99070416	ZNF789	0.67	5.15	0.3	5.11e-7	Blood metabolite levels;
CESC	cis	rs3087591	0.920	rs4795592	chr17:29612620	C/G	cg24425628	chr17:29625626	OMG;NF1	-0.45	-5.63	-0.33	4.5e-8	Hip circumference;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg09676606	chr12:102132872	SYCP3	0.48	6.26	0.36	1.5e-9	Fibrinogen levels;
CESC	cis	rs1552244	1.000	rs67852463	chr3:10157205	G/C	cg00166722	chr3:10149974	C3orf24	0.49	6.32	0.36	1.13e-9	Alzheimer's disease;
CESC	cis	rs265548	0.646	rs36692	chr19:17906839	C/T	cg21960279	chr19:17905606	B3GNT3	0.47	7.1	0.4	1.18e-11	Tumor biomarkers;
CESC	cis	rs9287719	0.935	rs1309	chr2:10743546	A/G	cg02196655	chr2:10830764	NOL10	-0.38	-5.83	-0.34	1.61e-8	Prostate cancer;
CESC	cis	rs9487051	0.714	rs6930733	chr6:109631587	T/C	cg01475377	chr6:109611718	NA	-0.46	-7.2	-0.4	6.15e-12	Reticulocyte fraction of red cells;
CESC	cis	rs3096299	0.632	rs4399533	chr16:89539382	G/C	cg08392591	chr16:89556376	ANKRD11	0.6	8.25	0.45	7.33e-15	Multiple myeloma (IgH translocation);
CESC	cis	rs7618915	0.547	rs4130905	chr3:52709831	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.49	7.01	0.4	1.92e-11	Bipolar disorder;
CESC	cis	rs7666738	0.830	rs2865980	chr4:99027422	T/G	cg05340658	chr4:99064831	C4orf37	0.83	13.1	0.63	1.43e-30	Colonoscopy-negative controls vs population controls;
CESC	trans	rs7980799	0.682	rs1351682	chr12:33598775	G/A	cg26384229	chr12:38710491	ALG10B	-0.54	-7.68	-0.43	3.1400000000000003e-13	Heart rate;Heart rate variability traits (RMSSD);
CESC	cis	rs35110281	0.807	rs28840140	chr21:45039163	T/C	cg04455712	chr21:45112962	RRP1B	0.42	6.33	0.36	1.02e-9	Mean corpuscular volume;
CESC	cis	rs6061231	0.544	rs2427314	chr20:60973666	C/T	cg24112000	chr20:60950667	NA	-0.52	-7.56	-0.42	6.63e-13	Colorectal cancer;
CESC	cis	rs1355223	0.902	rs6484726	chr11:34697558	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.48	-6.24	-0.36	1.7e-9	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs9303280	0.776	rs9891174	chr17:38031802	T/A	cg20243544	chr17:37824526	PNMT	0.5	6.51	0.37	3.84e-10	Self-reported allergy;
CESC	cis	rs116095464	0.558	rs7713524	chr5:276200	C/T	cg10591111	chr5:226296	SDHA	0.49	5.99	0.35	6.77e-9	Breast cancer;
CESC	cis	rs9905704	0.647	rs11652713	chr17:57079742	C/T	cg12560992	chr17:57184187	TRIM37	0.64	7.98	0.44	4.3e-14	Testicular germ cell tumor;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg11321298	chr22:40766510	SGSM3	0.44	6.02	0.35	5.7e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs4720575	1.000	rs4720575	chr7:47086805	A/G	cg00036614	chr7:47093842	NA	-0.43	-6.57	-0.37	2.59e-10	Angiotensin-converting enzyme inhibitor intolerance;
CESC	cis	rs9291683	0.595	rs13145442	chr4:10037261	C/A	cg00071950	chr4:10020882	SLC2A9	0.87	15.5	0.69	5.26e-39	Bone mineral density;
CESC	cis	rs919433	0.927	rs1429412	chr2:198190894	A/G	cg20885578	chr2:198174922	NA	-0.39	-5.09	-0.3	6.83e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs6446731	0.517	rs2071671	chr4:3269787	C/G	cg08886695	chr4:3369023	RGS12	0.39	5.67	0.33	3.67e-8	Mean platelet volume;
CESC	cis	rs6540559	0.673	rs926346	chr1:209962204	A/T	cg22029157	chr1:209979665	IRF6	0.76	8.93	0.48	7.36e-17	Cleft lip with or without cleft palate;
CESC	cis	rs1559088	0.842	rs12977993	chr19:33580453	T/A	cg17764715	chr19:33622953	WDR88	0.52	6.87	0.39	4.56e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs6570726	0.791	rs9373464	chr6:145907167	T/C	cg23711669	chr6:146136114	FBXO30	0.91	13.64	0.64	1.96e-32	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6964587	1.000	rs2237568	chr7:91622676	G/A	cg17063962	chr7:91808500	NA	0.57	7.82	0.43	1.22e-13	Breast cancer;
CESC	cis	rs11098499	0.866	rs13125526	chr4:120288019	G/A	cg24375607	chr4:120327624	NA	0.42	5.19	0.3	4.19e-7	Corneal astigmatism;
CESC	cis	rs9611565	0.765	rs202659	chr22:41811620	T/C	cg06481639	chr22:41940642	POLR3H	0.62	6.52	0.37	3.49e-10	Vitiligo;
CESC	cis	rs798554	0.660	rs2644274	chr7:2854380	A/T	cg09658497	chr7:2847517	GNA12	-0.34	-5.09	-0.3	6.75e-7	Height;
CESC	cis	rs1552244	1.000	rs7631678	chr3:10078816	T/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.78	-10.37	-0.54	2.25e-21	Alzheimer's disease;
CESC	cis	rs4665809	1.000	rs4233709	chr2:26291493	C/T	cg26119090	chr2:26468346	HADHA;HADHB	0.65	7.42	0.41	1.57e-12	Gut microbiome composition (summer);
CESC	cis	rs7618915	0.570	rs4687633	chr3:52630548	G/A	cg05564831	chr3:52568323	NT5DC2	0.45	6.96	0.39	2.68e-11	Bipolar disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01143375	chr3:191670642	NA	-0.56	-6.28	-0.36	1.35e-9	Gut microbiome composition (summer);
CESC	cis	rs116095464	0.542	rs28650039	chr5:273954	C/A	cg22857025	chr5:266934	NA	-1.3	-18.68	-0.75	2.81e-50	Breast cancer;
CESC	cis	rs6580649	0.941	rs57054831	chr12:48486892	C/T	cg05342945	chr12:48394962	COL2A1	0.5	5.74	0.33	2.59e-8	Lung cancer;
CESC	cis	rs3087591	0.922	rs2905799	chr17:29536901	G/A	cg24425628	chr17:29625626	OMG;NF1	0.44	5.53	0.32	7.56e-8	Hip circumference;
CESC	cis	rs9908102	0.740	rs8071615	chr17:12914535	G/T	cg26162695	chr17:12921313	ELAC2	0.49	5.18	0.3	4.41e-7	Schizophrenia;
CESC	cis	rs6963495	0.674	rs75880756	chr7:105163821	G/C	cg13798780	chr7:105162888	PUS7	0.78	8.06	0.44	2.68e-14	Bipolar disorder (body mass index interaction);
CESC	trans	rs11165623	0.792	rs9437609	chr1:96977961	A/C	cg10631902	chr5:14652156	NA	-0.49	-7.3	-0.41	3.42e-12	Hip circumference;Waist circumference;
CESC	cis	rs78456975	0.550	rs11904276	chr2:1524006	T/C	cg26248373	chr2:1572462	NA	-0.56	-6.49	-0.37	4.15e-10	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs7772486	0.713	rs2328704	chr6:146020494	T/C	cg05347473	chr6:146136440	FBXO30	-0.48	-6.34	-0.36	1.01e-9	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs10506458	0.834	rs17738403	chr12:63389200	A/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.33	-17.85	-0.74	2.4e-47	Hemostatic factors and hematological phenotypes;
CESC	cis	rs7927592	0.731	rs7108376	chr11:68347870	A/G	cg20283391	chr11:68216788	NA	0.42	5.24	0.31	3.21e-7	Total body bone mineral density;
CESC	cis	rs798554	0.718	rs1636247	chr7:2881917	A/G	cg19346786	chr7:2764209	NA	-0.39	-5.67	-0.33	3.81e-8	Height;
CESC	cis	rs7552404	0.690	rs12723575	chr1:76335203	T/C	cg03433033	chr1:76189801	ACADM	-0.63	-6.61	-0.38	2.14e-10	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs4819052	0.851	rs1056101	chr21:46678702	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.81	11.01	0.56	1.89e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs9522267	0.535	rs914036	chr13:112235542	G/A	cg10483660	chr13:112241077	NA	-0.33	-5.78	-0.33	2.14e-8	Hepatitis;
CESC	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg18402987	chr7:1209562	NA	0.4	5.19	0.3	4.14e-7	Longevity;Endometriosis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06431105	chr19:18572378	ELL	-0.54	-6.36	-0.36	8.92e-10	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26339992	chr1:28241106	RPA2	0.64	7.0	0.4	2.07e-11	Gut microbiome composition (summer);
CESC	cis	rs896854	0.738	rs509594	chr8:95967156	C/G	cg16049864	chr8:95962084	TP53INP1	0.63	9.82	0.52	1.33e-19	Type 2 diabetes;
CESC	cis	rs698813	0.674	rs3738985	chr2:44502788	A/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.46	5.08	0.3	7.17e-7	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
CESC	cis	rs853679	0.517	rs17711801	chr6:28092307	C/G	cg12963246	chr6:28129442	ZNF389	0.56	7.62	0.42	4.43e-13	Depression;
CESC	cis	rs10504229	0.679	rs78941440	chr8:58052095	A/G	cg22535103	chr8:58192502	C8orf71	-0.63	-7.09	-0.4	1.25e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs6460942	1.000	rs7796485	chr7:12405676	G/A	cg10578991	chr7:12443926	VWDE	-0.55	-5.86	-0.34	1.36e-8	Coronary artery disease;
CESC	cis	rs9902453	0.791	rs3115090	chr17:28035014	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.76	10.4	0.54	1.88e-21	Coffee consumption (cups per day);
CESC	cis	rs514406	0.505	rs416968	chr1:53183513	A/G	cg24675658	chr1:53192096	ZYG11B	-0.53	-6.96	-0.39	2.74e-11	Monocyte count;
CESC	cis	rs4665809	1.000	rs6546766	chr2:26328680	T/C	cg08470875	chr2:26401718	FAM59B	-0.48	-5.29	-0.31	2.56e-7	Gut microbiome composition (summer);
CESC	cis	rs61332075	0.518	rs72994950	chr2:239422993	T/C	cg18131467	chr2:239335373	ASB1	-0.72	-5.45	-0.32	1.18e-7	Lung function (FEV1/FVC);
CESC	cis	rs13118159	0.934	rs4974608	chr4:1356780	C/T	cg16405210	chr4:1374714	KIAA1530	-0.45	-5.99	-0.35	6.91e-9	Longevity;
CESC	cis	rs1799949	1.000	rs3092988	chr17:41201702	C/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.39	5.14	0.3	5.43e-7	Menopause (age at onset);
CESC	cis	rs6502050	0.835	rs4499294	chr17:80148346	C/T	cg23985595	chr17:80112537	CCDC57	-0.42	-6.57	-0.37	2.59e-10	Life satisfaction;
CESC	cis	rs7618915	0.501	rs7622694	chr3:52663882	G/A	cg18404041	chr3:52824283	ITIH1	-0.38	-6.5	-0.37	3.98e-10	Bipolar disorder;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg21411534	chr10:93558674	TNKS2	0.45	6.14	0.35	3.02e-9	Systemic lupus erythematosus;
CESC	cis	rs7264396	0.790	rs2425115	chr20:34322418	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.63	7.61	0.42	4.76e-13	Total cholesterol levels;
CESC	trans	rs1506636	0.924	rs4370458	chr7:123260968	G/A	cg12383159	chr11:1262597	MUC5B	0.36	6.07	0.35	4.36e-9	Plateletcrit;Platelet count;
CESC	cis	rs763121	0.962	rs909564	chr22:39126508	A/G	cg06022373	chr22:39101656	GTPBP1	0.78	12.88	0.62	8.54e-30	Menopause (age at onset);
CESC	cis	rs853679	0.517	rs9368556	chr6:28131153	T/C	cg22143856	chr6:28129313	ZNF389	0.49	6.24	0.36	1.73e-9	Depression;
CESC	cis	rs9488822	0.676	rs12202641	chr6:116314634	A/G	cg05304507	chr6:116381966	FRK	-0.25	-6.35	-0.36	9.05e-10	Cholesterol, total;LDL cholesterol;
CESC	cis	rs3020736	0.500	rs6002616	chr22:42504679	A/G	cg04733989	chr22:42467013	NAGA	-0.83	-12.49	-0.61	1.9e-28	Autism spectrum disorder or schizophrenia;
CESC	cis	rs7584330	0.554	rs6705908	chr2:238433965	A/G	cg14458575	chr2:238380390	NA	0.39	5.14	0.3	5.25e-7	Prostate cancer;
CESC	cis	rs172166	0.694	rs9295760	chr6:28147385	G/A	cg17221315	chr6:27791827	HIST1H4J	0.45	5.83	0.34	1.62e-8	Cardiac Troponin-T levels;
CESC	cis	rs7953508	0.506	rs10777530	chr12:93961110	C/T	cg18151635	chr12:93972918	NA	-0.42	-5.62	-0.33	4.86e-8	Pubertal anthropometrics;
CESC	cis	rs4819052	0.788	rs35323494	chr21:46703739	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.59	7.46	0.42	1.22e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs262150	0.503	rs11769917	chr7:158817498	C/T	cg19418458	chr7:158789849	NA	-0.41	-6.22	-0.36	1.91e-9	Facial morphology (factor 20);
CESC	cis	rs7116495	0.609	rs17161751	chr11:71688347	G/A	cg07596299	chr11:71824057	C11orf51	0.83	5.19	0.3	4.24e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs644799	1.000	rs564675	chr11:95561873	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	9.15	0.49	1.57e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs3858526	0.959	rs10838797	chr11:5920977	A/G	cg13902645	chr11:5959945	NA	-0.6	-7.24	-0.41	4.72e-12	DNA methylation (variation);
CESC	cis	rs769267	0.930	rs7254927	chr19:19404786	C/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.43	5.27	0.31	2.88e-7	Tonsillectomy;
CESC	cis	rs12048904	0.505	rs6577209	chr1:101255080	A/C	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.46	5.28	0.31	2.74e-7	Multiple sclerosis;
CESC	cis	rs9457247	1.000	rs429083	chr6:167383972	T/C	cg23791538	chr6:167370224	RNASET2	-0.6	-8.65	-0.47	5.12e-16	Crohn's disease;
CESC	cis	rs6570726	0.935	rs452552	chr6:145820781	G/A	cg05347473	chr6:146136440	FBXO30	0.49	6.71	0.38	1.2e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs10883723	0.737	rs7074444	chr10:104249922	A/G	ch.10.2196322F	chr10:104248062	ACTR1A	0.42	5.1	0.3	6.33e-7	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs9910055	0.664	rs433610	chr17:42197281	A/G	cg13607699	chr17:42295918	UBTF	-0.67	-9.12	-0.49	2.01e-17	Total body bone mineral density;
CESC	cis	rs6570726	0.967	rs439017	chr6:145806123	T/C	cg05347473	chr6:146136440	FBXO30	0.42	5.66	0.33	3.89e-8	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs660899	0.595	rs37453	chr1:44295047	A/G	cg11704212	chr1:44303111	ST3GAL3	-0.39	-5.16	-0.3	4.95e-7	Hypertension risk in short sleep duration;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24407859	chr22:43411083	NA	0.56	6.34	0.36	9.78e-10	Gut microbiome composition (summer);
CESC	cis	rs116095464	0.558	rs10462755	chr5:246748	T/C	cg22496380	chr5:211416	CCDC127	-0.75	-8.7	-0.47	3.49e-16	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00304673	chr4:187112763	CYP4V2	0.59	6.55	0.37	2.99e-10	Gut microbiome composition (summer);
CESC	cis	rs4737010	0.501	rs7000282	chr8:41647493	A/C	cg08923054	chr8:41654455	ANK1	0.61	7.61	0.42	4.95e-13	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
CESC	cis	rs3126085	0.935	rs1552993	chr1:152171483	A/G	cg26876637	chr1:152193138	HRNR	0.44	5.11	0.3	6.25e-7	Atopic dermatitis;
CESC	cis	rs2839186	0.609	rs2839189	chr21:47694357	C/T	cg00815214	chr21:47717953	NA	0.45	6.15	0.35	2.84e-9	Testicular germ cell tumor;
CESC	cis	rs734999	0.588	rs3001837	chr1:2532506	G/A	cg18854424	chr1:2615690	NA	-0.28	-5.34	-0.31	1.99e-7	Ulcerative colitis;
CESC	cis	rs3857067	1.000	rs899133	chr4:95019609	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.52	-8.04	-0.44	3.05e-14	QT interval;
CESC	cis	rs6987853	0.563	rs2923406	chr8:42448873	G/T	cg09913449	chr8:42400586	C8orf40	0.34	5.37	0.31	1.71e-7	Mean corpuscular hemoglobin concentration;
CESC	trans	rs7980799	0.682	rs10161491	chr12:33623806	T/C	cg26384229	chr12:38710491	ALG10B	-0.58	-8.26	-0.45	7.19e-15	Heart rate;Heart rate variability traits (RMSSD);
CESC	cis	rs2439831	0.850	rs28524541	chr15:44124831	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.63	5.69	0.33	3.28e-8	Lung cancer in ever smokers;
CESC	cis	rs12200560	0.505	rs211177	chr6:97074088	C/T	cg06623918	chr6:96969491	KIAA0776	0.52	6.65	0.38	1.71e-10	Coronary heart disease;
CESC	cis	rs736408	0.688	rs2239551	chr3:52818579	A/G	cg05564831	chr3:52568323	NT5DC2	-0.43	-6.43	-0.37	5.77e-10	Bipolar disorder;
CESC	cis	rs1801251	1.000	rs2305137	chr2:233712049	G/A	cg25237894	chr2:233734115	C2orf82	-0.47	-8.47	-0.46	1.66e-15	Coronary artery disease;
CESC	cis	rs1413885	0.538	rs1570869	chr1:65830905	A/C	cg14976592	chr1:65886160	LEPROT;LEPR	0.43	5.44	0.32	1.2e-7	Anticoagulant levels;
CESC	cis	rs11745587	0.539	rs6897597	chr5:131743465	C/T	cg00255919	chr5:131827918	IRF1	0.38	5.99	0.35	6.81e-9	Asthma;
CESC	cis	rs6545883	0.965	rs1992765	chr2:61751333	A/G	cg15711740	chr2:61764176	XPO1	-0.43	-5.22	-0.31	3.63e-7	Tuberculosis;
CESC	cis	rs3026101	0.624	rs1058383	chr17:5288203	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.44	5.93	0.34	9.58e-9	Body mass index;
CESC	cis	rs514406	0.644	rs7552663	chr1:53204352	C/T	cg27535305	chr1:53392650	SCP2	0.35	6.14	0.35	3.05e-9	Monocyte count;
CESC	cis	rs11098499	0.866	rs12499602	chr4:120284387	T/A	cg24375607	chr4:120327624	NA	0.42	5.19	0.3	4.19e-7	Corneal astigmatism;
CESC	cis	rs514406	0.825	rs7523761	chr1:53250915	T/C	cg16325326	chr1:53192061	ZYG11B	-0.71	-11.75	-0.59	6.35e-26	Monocyte count;
CESC	cis	rs780096	0.647	rs11682083	chr2:27752296	A/G	cg22903471	chr2:27725779	GCKR	-0.52	-7.15	-0.4	8.3e-12	Total body bone mineral density;
CESC	cis	rs13191362	1.000	rs66534429	chr6:163003322	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.83	8.86	0.48	1.15e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs7845219	0.544	rs10956930	chr8:95919786	C/G	cg23172400	chr8:95962367	TP53INP1	-0.37	-6.78	-0.38	7.89e-11	Type 2 diabetes;
CESC	cis	rs35096708	1.000	rs35096708	chr16:89887249	G/A	cg02875869	chr16:89901417	SPIRE2	-0.47	-5.97	-0.34	7.78e-9	Skin aging (microtopography measurement);
CESC	cis	rs798554	0.642	rs2533871	chr7:2883006	C/G	cg09658497	chr7:2847517	GNA12	-0.35	-5.09	-0.3	6.89e-7	Height;
CESC	cis	rs116979167	0.575	rs67661063	chr7:105187259	T/G	cg13798780	chr7:105162888	PUS7	0.52	6.34	0.36	9.9e-10	Bipolar disorder (body mass index interaction);
CESC	cis	rs9929218	1.000	rs4500718	chr16:68754312	A/G	cg02972257	chr16:68554789	NA	0.53	6.25	0.36	1.67e-9	Colorectal cancer;
CESC	cis	rs11122272	0.735	rs2739516	chr1:231505527	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.57	-7.82	-0.43	1.29e-13	Hemoglobin concentration;
CESC	cis	rs11203032	0.831	rs10887921	chr10:90925667	T/G	cg16672925	chr10:90967113	CH25H	0.71	6.72	0.38	1.12e-10	Heart failure;
CESC	cis	rs4243830	0.850	rs12410405	chr1:6581283	C/G	cg05709478	chr1:6581295	PLEKHG5	0.48	5.41	0.32	1.44e-7	Body mass index;
CESC	cis	rs7071206	0.947	rs716255	chr10:79419679	A/T	cg23888215	chr10:79422304	NA	-0.51	-5.49	-0.32	9.26e-8	Bone mineral density;
CESC	cis	rs60843830	1.000	rs79716074	chr2:277003	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.89	12.09	0.6	4.21e-27	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs9311474	0.607	rs4234633	chr3:52557038	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.7	0.38	1.23e-10	Electroencephalogram traits;
CESC	cis	rs9309473	0.519	rs1083922	chr2:73704003	A/G	cg20560298	chr2:73613845	ALMS1	0.48	6.88	0.39	4.22e-11	Metabolite levels;
CESC	cis	rs3540	0.512	rs3862437	chr15:91084632	A/G	cg10434728	chr15:90938212	IQGAP1	-0.41	-7.1	-0.4	1.13e-11	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs1847202	0.787	rs13071878	chr3:72951084	G/A	cg10804678	chr3:72788309	NA	-0.41	-5.37	-0.31	1.72e-7	Motion sickness;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg05129591	chr1:43637803	WDR65;EBNA1BP2	0.45	6.13	0.35	3.17e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs929354	1.000	rs1182413	chr7:157058557	G/A	cg05182265	chr7:156933206	UBE3C	0.45	6.21	0.36	2.07e-9	Body mass index;
CESC	trans	rs55704346	0.566	rs28658549	chr4:25397036	T/G	cg01822600	chr1:245751692	KIF26B	0.42	6.12	0.35	3.41e-9	Tonsillectomy;
CESC	cis	rs5753618	0.583	rs2273249	chr22:31836486	T/C	cg02404636	chr22:31891804	SFI1	0.41	5.6	0.33	5.26e-8	Colorectal cancer;
CESC	cis	rs2836974	0.583	rs2776306	chr21:40713754	A/G	cg17971929	chr21:40555470	PSMG1	0.59	7.63	0.42	4.25e-13	Cognitive function;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08847296	chr1:155278656	FDPS	0.57	7.05	0.4	1.51e-11	Gut microbiome composition (summer);
CESC	cis	rs5753037	0.653	rs140102	chr22:30128443	T/C	cg01021169	chr22:30184971	ASCC2	-0.42	-5.79	-0.33	2.04e-8	Type 1 diabetes;
CESC	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.41	-5.44	-0.32	1.2e-7	Longevity;Endometriosis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05227288	chr16:32489822	NA	-0.53	-6.25	-0.36	1.66e-9	Gut microbiome composition (summer);
CESC	cis	rs12477438	0.561	rs2084988	chr2:99655755	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.64	-8.73	-0.47	2.94e-16	Chronic sinus infection;
CESC	cis	rs933688	1.000	rs6865495	chr5:90746424	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.1	14.79	0.67	1.71e-36	Smoking behavior;
CESC	cis	rs4566357	0.595	rs1320406	chr2:227920474	C/T	cg05526886	chr2:227700861	RHBDD1	-0.46	-6.2	-0.36	2.19e-9	Coronary artery disease;
CESC	cis	rs6740322	0.895	rs11684601	chr2:43574242	G/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.64	-7.18	-0.4	7e-12	Coronary artery disease;
CESC	cis	rs12410462	0.579	rs78343168	chr1:227621090	G/A	cg23173402	chr1:227635558	NA	0.74	6.78	0.38	7.9e-11	Major depressive disorder;
CESC	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	10.25	0.53	5.71e-21	Prudent dietary pattern;
CESC	cis	rs8077577	0.708	rs7211573	chr17:18131613	T/C	cg16794390	chr17:18148240	FLII	-0.43	-6.33	-0.36	1.04e-9	Obesity-related traits;
CESC	cis	rs4906332	1.000	rs55930273	chr14:103960298	G/A	cg09975044	chr14:104007538	NA	0.47	6.39	0.37	7.49e-10	Coronary artery disease;
CESC	cis	rs6964587	0.773	rs10488514	chr7:91951842	C/A	cg17063962	chr7:91808500	NA	0.54	6.81	0.39	6.41e-11	Breast cancer;
CESC	cis	rs796364	1.000	rs281763	chr2:200794870	C/T	cg23649088	chr2:200775458	C2orf69	0.54	5.33	0.31	2.13e-7	Schizophrenia;
CESC	cis	rs561341	0.882	rs2521594	chr17:30302087	C/T	cg19193384	chr17:30244184	NA	-0.67	-6.36	-0.36	8.74e-10	Hip circumference adjusted for BMI;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg22515636	chr2:109150313	NA	-0.53	-7.07	-0.4	1.37e-11	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24729617	chr1:165551210	LOC400794	-0.69	-8.12	-0.45	1.78e-14	Gut microbiome composition (summer);
CESC	cis	rs1018836	0.886	rs10956750	chr8:91621704	G/C	cg16814680	chr8:91681699	NA	-0.72	-10.09	-0.53	1.82e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs896854	0.608	rs6991067	chr8:95875676	A/G	cg09323728	chr8:95962352	TP53INP1	-0.35	-7.39	-0.41	1.88e-12	Type 2 diabetes;
CESC	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg23978390	chr7:1156363	C7orf50	0.59	8.17	0.45	1.24e-14	Longevity;Endometriosis;
CESC	cis	rs9611565	1.000	rs1109151	chr22:41752944	A/G	cg03806693	chr22:41940476	POLR3H	-0.75	-9.04	-0.49	3.38e-17	Vitiligo;
CESC	cis	rs10504229	0.683	rs55714371	chr8:58131846	T/G	cg21724239	chr8:58056113	NA	0.58	5.95	0.34	8.29e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs12477438	0.520	rs4850897	chr2:99768419	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.79	12.63	0.61	6.22e-29	Chronic sinus infection;
CESC	cis	rs12530845	0.832	rs56306315	chr7:135329107	C/T	cg23117316	chr7:135346802	PL-5283	-0.41	-5.29	-0.31	2.52e-7	Red blood cell traits;
CESC	cis	rs7071206	0.947	rs10824560	chr10:79416901	C/T	cg23888215	chr10:79422304	NA	-0.52	-5.65	-0.33	4.17e-8	Bone mineral density;
CESC	cis	rs6912958	0.559	rs242279	chr6:88048191	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.72	10.99	0.56	2.06e-23	Monocyte percentage of white cells;
CESC	cis	rs1552244	1.000	rs113522867	chr3:10154503	T/C	cg00149659	chr3:10157352	C3orf10	0.7	8.47	0.46	1.68e-15	Alzheimer's disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg23329543	chr19:53432372	ZNF321	0.43	6.31	0.36	1.17e-9	Fibrinogen levels;
CESC	cis	rs1559088	0.600	rs7256470	chr19:33558085	C/A	cg27124370	chr19:33622961	WDR88	0.53	7.47	0.42	1.19e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs4563143	0.663	rs2218396	chr19:29236392	C/T	cg14983838	chr19:29218262	NA	0.39	5.24	0.31	3.3e-7	Methadone dose in opioid dependence;
CESC	cis	rs2070997	0.607	rs2855190	chr9:133708361	C/T	cg11464064	chr9:133710261	ABL1	-0.69	-8.15	-0.45	1.43e-14	Response to amphetamines;
CESC	cis	rs4727027	0.901	rs11760293	chr7:148811725	A/G	cg23158103	chr7:148848205	ZNF398	-0.41	-6.75	-0.38	9.31e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs637571	0.544	rs500161	chr11:65695438	C/T	cg02202077	chr11:65769826	EIF1AD;BANF1	0.45	5.78	0.33	2.07e-8	Eosinophil percentage of white cells;
CESC	cis	rs9611565	0.512	rs2050031	chr22:42152266	A/G	cg17376030	chr22:41985996	PMM1	-0.77	-8.15	-0.45	1.45e-14	Vitiligo;
CESC	cis	rs977987	0.843	rs11644741	chr16:75466433	C/A	cg03315344	chr16:75512273	CHST6	0.41	5.93	0.34	9.5e-9	Dupuytren's disease;
CESC	cis	rs10208940	0.920	rs6751531	chr2:68794528	G/T	cg12452813	chr2:68675892	NA	0.52	5.25	0.31	3.12e-7	Urate levels in lean individuals;
CESC	cis	rs12618769	0.597	rs72819986	chr2:99045867	G/C	cg10123293	chr2:99228465	UNC50	0.39	5.18	0.3	4.49e-7	Bipolar disorder;
CESC	cis	rs854765	0.624	rs9899634	chr17:17727943	A/T	cg16928487	chr17:17741425	SREBF1	0.63	11.05	0.56	1.39e-23	Total body bone mineral density;
CESC	cis	rs4073405	0.584	rs7395419	chr11:45309171	G/A	cg27235148	chr11:45376932	NA	0.29	5.03	0.3	9.22e-7	Schizophrenia;
CESC	cis	rs17125944	0.615	rs7151474	chr14:53313680	C/T	cg00686598	chr14:53173677	PSMC6	-0.56	-5.08	-0.3	7.1e-7	Alzheimer's disease (late onset);
CESC	cis	rs34779708	0.931	rs7908573	chr10:35309513	T/C	cg04310649	chr10:35416472	CREM	-0.48	-5.84	-0.34	1.53e-8	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs2075371	0.863	rs1646635	chr7:134006728	T/C	cg20476274	chr7:133979776	SLC35B4	0.6	8.54	0.46	1.04e-15	Mean platelet volume;
CESC	cis	rs2790457	0.958	rs2772431	chr10:28890160	C/T	cg04045419	chr10:28823091	WAC	-0.43	-5.17	-0.3	4.63e-7	Multiple myeloma;
CESC	cis	rs1707322	0.964	rs1707339	chr1:46513179	A/G	cg03146154	chr1:46216737	IPP	-0.72	-9.73	-0.51	2.49e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs17039065	1.000	rs72889361	chr4:109381063	T/G	cg16022748	chr4:109541635	LOC285456;RPL34	0.6	5.06	0.3	8.01e-7	Gut microbiome composition (summer);
CESC	cis	rs7809950	1.000	rs2520249	chr7:107146748	A/G	cg23024343	chr7:107201750	COG5	-0.42	-5.91	-0.34	1.05e-8	Coronary artery disease;
CESC	cis	rs9486719	0.947	rs9398072	chr6:96911304	T/C	cg06623918	chr6:96969491	KIAA0776	0.89	10.42	0.54	1.6e-21	Migraine;Coronary artery disease;
CESC	cis	rs1957429	0.901	rs3813422	chr14:65347404	G/A	cg23373153	chr14:65346875	NA	0.96	11.49	0.58	4.43e-25	Pediatric areal bone mineral density (radius);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg22118131	chr15:78369834	TBC1D2B	0.55	7.4	0.41	1.86e-12	Gut microbiota (bacterial taxa);
CESC	cis	rs736408	0.527	rs2577831	chr3:52628056	C/A	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.33	6.49	0.37	4.17e-10	Bipolar disorder;
CESC	cis	rs910316	0.967	rs175479	chr14:75561871	A/C	cg08847533	chr14:75593920	NEK9	-0.97	-18.54	-0.75	9.05e-50	Height;
CESC	cis	rs6543140	0.964	rs918000	chr2:103067862	C/T	cg04239558	chr2:103089729	SLC9A4	0.45	5.66	0.33	3.94e-8	Blood protein levels;
CESC	cis	rs7631605	0.875	rs7616105	chr3:37229522	G/A	cg22985146	chr3:37219077	LRRFIP2	-0.32	-5.24	-0.31	3.3e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs6580649	0.941	rs7963934	chr12:48477086	C/G	cg05342945	chr12:48394962	COL2A1	0.5	5.74	0.33	2.59e-8	Lung cancer;
CESC	cis	rs11722228	1.000	rs4697695	chr4:9915850	C/T	cg00071950	chr4:10020882	SLC2A9	0.56	8.2	0.45	1.04e-14	Gout;Urate levels;Serum uric acid levels;
CESC	cis	rs7647973	0.626	rs4855846	chr3:49683526	G/A	cg03060546	chr3:49711283	APEH	0.68	8.3	0.45	5.3e-15	Menarche (age at onset);
CESC	cis	rs3785574	0.927	rs2854183	chr17:61968002	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.59	7.14	0.4	8.95e-12	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20088969	chr10:74032886	DDIT4	0.55	6.46	0.37	4.92e-10	Gut microbiome composition (summer);
CESC	cis	rs801193	0.569	rs2659907	chr7:66164032	G/A	cg12463550	chr7:65579703	CRCP	0.49	6.33	0.36	1.03e-9	Aortic root size;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg04677295	chr13:100153866	TM9SF2	0.46	6.45	0.37	5.29e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10927534	chr5:141392688	GNPDA1	0.56	6.01	0.35	6.06e-9	Gut microbiome composition (summer);
CESC	cis	rs79349575	0.749	rs519537	chr17:46971140	G/A	cg16584676	chr17:46985605	UBE2Z	0.54	6.64	0.38	1.76e-10	Type 2 diabetes;
CESC	cis	rs17666538	0.535	rs1669613	chr8:617565	G/C	cg02524346	chr8:600233	NA	0.86	6.17	0.35	2.53e-9	IgG glycosylation;
CESC	cis	rs7599312	0.534	rs6735626	chr2:213403972	G/A	cg20637307	chr2:213403960	ERBB4	0.57	8.92	0.48	7.78e-17	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs780094	0.544	rs2303370	chr2:27651375	C/T	cg21248554	chr2:27665150	KRTCAP3	-0.29	-6.18	-0.36	2.37e-9	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
CESC	cis	rs9815354	1.000	rs17062109	chr3:41810364	C/T	cg03022575	chr3:42003672	ULK4	0.49	5.42	0.32	1.32e-7	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs7552404	0.889	rs2211080	chr1:76243438	G/A	cg22875332	chr1:76189707	ACADM	0.6	6.86	0.39	4.79e-11	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs6724607	0.905	rs7603849	chr2:191438741	A/C	cg27211696	chr2:191398769	TMEM194B	0.52	7.62	0.42	4.53e-13	Pulse pressure;
CESC	trans	rs10435719	0.834	rs6985792	chr8:11795335	T/C	cg15556689	chr8:8085844	FLJ10661	0.49	6.09	0.35	3.95e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
CESC	cis	rs11638352	1.000	rs11854312	chr15:44279709	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	-0.53	-5.46	-0.32	1.09e-7	Lipoprotein phospholipase A2 activity in cardiovascular disease;
CESC	cis	rs7520050	0.966	rs10890352	chr1:46283628	G/A	cg03146154	chr1:46216737	IPP	-0.47	-6.19	-0.36	2.34e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs12136530	0.774	rs10158117	chr1:19766747	G/C	cg01832549	chr1:19774989	CAPZB	-0.47	-6.57	-0.37	2.65e-10	Lead levels in blood;
CESC	cis	rs3015497	0.763	rs2934689	chr14:51118327	A/C	cg09863266	chr14:51125203	SAV1	-0.34	-5.34	-0.31	1.98e-7	Mean platelet volume;
CESC	cis	rs875971	0.660	rs801217	chr7:66010577	C/T	cg14393609	chr7:65229607	NA	-0.47	-6.3	-0.36	1.24e-9	Aortic root size;
CESC	cis	rs15676	0.783	rs2280845	chr9:131583170	T/C	cg00228799	chr9:131580591	ENDOG	0.54	6.9	0.39	3.73e-11	Blood metabolite levels;
CESC	cis	rs796364	0.806	rs11679658	chr2:200923081	A/G	cg23649088	chr2:200775458	C2orf69	-0.58	-5.23	-0.31	3.38e-7	Schizophrenia;
CESC	cis	rs57221529	0.766	rs72703075	chr5:592819	C/T	cg16447950	chr5:562315	NA	-0.6	-5.7	-0.33	3.2e-8	Lung disease severity in cystic fibrosis;
CESC	cis	rs875971	0.862	rs6955837	chr7:66043142	C/T	cg18252515	chr7:66147081	NA	0.46	5.96	0.34	8.03e-9	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03084103	chr4:38869707	MIR574;FAM114A1	-0.51	-6.32	-0.36	1.08e-9	Gut microbiome composition (summer);
CESC	cis	rs801193	0.839	rs12534943	chr7:66070520	A/G	cg06456125	chr7:65229604	NA	-0.4	-5.58	-0.32	5.96e-8	Aortic root size;
CESC	cis	rs4409675	0.576	rs11247705	chr1:28212272	G/A	cg23691781	chr1:28212827	C1orf38	0.28	5.67	0.33	3.79e-8	Corneal astigmatism;
CESC	cis	rs903027	0.752	rs16927470	chr8:62458019	A/G	cg06626168	chr8:61834373	NA	-0.35	-5.14	-0.3	5.37e-7	Whole-brain volume;
CESC	cis	rs7680126	0.633	rs11730631	chr4:10292968	C/T	cg11266682	chr4:10021025	SLC2A9	0.42	5.68	0.33	3.58e-8	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	cis	rs9549367	1.000	rs9549367	chr13:113911532	C/G	cg18105134	chr13:113819100	PROZ	-0.62	-7.62	-0.42	4.55e-13	Platelet distribution width;
CESC	cis	rs3858526	0.959	rs10838795	chr11:5920721	A/G	cg13902645	chr11:5959945	NA	0.58	7.07	0.4	1.38e-11	DNA methylation (variation);
CESC	trans	rs61931739	0.500	rs9795938	chr12:34587739	C/T	cg26384229	chr12:38710491	ALG10B	-0.53	-7.43	-0.42	1.46e-12	Morning vs. evening chronotype;
CESC	cis	rs7937682	0.632	rs7128862	chr11:111755435	C/T	cg22437258	chr11:111473054	SIK2	-0.5	-5.53	-0.32	7.6e-8	Primary sclerosing cholangitis;
CESC	trans	rs7922314	0.571	rs61865715	chr10:64737789	C/T	cg06935979	chr1:232941706	KIAA1383	-0.63	-6.09	-0.35	3.89e-9	Cutaneous psoriasis;
CESC	trans	rs945270	0.512	rs17128756	chr14:56192794	G/A	cg18102697	chr4:83542773	C4orf11	-0.42	-6.32	-0.36	1.11e-9	Subcortical brain region volumes;
CESC	cis	rs10504229	0.636	rs115738451	chr8:58055133	A/T	cg21724239	chr8:58056113	NA	0.57	5.41	0.32	1.41e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs1799949	1.000	rs3092988	chr17:41201702	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.6	7.93	0.44	6.25e-14	Menopause (age at onset);
CESC	cis	rs17253792	0.822	rs78395034	chr14:56069783	G/A	cg01858014	chr14:56050164	KTN1	-0.93	-7.33	-0.41	2.71e-12	Putamen volume;
CESC	cis	rs853679	0.517	rs6932109	chr6:28078303	A/G	cg08968635	chr6:28129556	ZNF389	-0.42	-5.77	-0.33	2.17e-8	Depression;
CESC	cis	rs7618915	0.547	rs3774365	chr3:52642487	T/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.36	6.35	0.36	9.21e-10	Bipolar disorder;
CESC	trans	rs9834373	0.573	rs36083074	chr3:78525501	A/G	cg21593409	chr16:88706389	IL17C	-0.42	-6.04	-0.35	5.2e-9	Protein quantitative trait loci;
CESC	cis	rs7618915	0.571	rs6762457	chr3:52609157	G/A	cg18337363	chr3:52569053	NT5DC2	0.29	5.15	0.3	5.16e-7	Bipolar disorder;
CESC	cis	rs2290405	0.527	rs6829987	chr4:932974	C/G	cg04824913	chr4:887549	GAK	-0.68	-8.87	-0.48	1.13e-16	Systemic sclerosis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05494152	chr7:75544339	POR	0.57	6.88	0.39	4.41e-11	Gut microbiome composition (summer);
CESC	cis	rs514406	0.760	rs475969	chr1:53292607	T/A	cg27535305	chr1:53392650	SCP2	-0.34	-5.86	-0.34	1.33e-8	Monocyte count;
CESC	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg26338869	chr17:61819248	STRADA	0.69	9.11	0.49	2.04e-17	Prudent dietary pattern;
CESC	cis	rs10885582	0.781	rs10885571	chr10:116293421	T/G	cg17056676	chr10:116301354	ABLIM1	-0.28	-5.05	-0.3	8.15e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs9796	0.870	rs7162992	chr15:41290861	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.47	-7.11	-0.4	1.08e-11	Menopause (age at onset);
CESC	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg07677032	chr17:61819896	STRADA	0.44	5.86	0.34	1.36e-8	Prudent dietary pattern;
CESC	trans	rs2109514	0.505	rs1633714	chr7:116022538	C/T	cg00026222	chr1:2144244	NA	0.47	6.21	0.36	2.04e-9	Prevalent atrial fibrillation;
CESC	cis	rs7666738	0.830	rs13110903	chr4:98946373	A/G	cg17366294	chr4:99064904	C4orf37	0.6	8.53	0.46	1.15e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10416265	0.527	rs6510337	chr19:33545701	C/T	cg03563238	chr19:33554763	RHPN2	-0.31	-5.48	-0.32	9.82e-8	Bone properties (heel);
CESC	cis	rs4901869	0.966	rs1820557	chr14:59334863	C/G	cg02291164	chr14:59296302	NA	0.45	7.73	0.43	2.21e-13	Panic disorder;
CESC	cis	rs7072216	0.763	rs6584205	chr10:100173806	C/T	cg26618903	chr10:100175079	PYROXD2	-0.38	-5.85	-0.34	1.41e-8	Metabolite levels;
CESC	cis	rs1691799	0.899	rs1168320	chr12:66744849	C/T	cg16791601	chr12:66731901	HELB	-0.79	-14.34	-0.66	6.63e-35	White blood cell count (basophil);
CESC	cis	rs2120019	0.935	rs8042409	chr15:75350433	G/A	cg17294928	chr15:75287854	SCAMP5	-0.65	-7.04	-0.4	1.67e-11	Blood trace element (Zn levels);
CESC	cis	rs17433780	0.860	rs61798916	chr1:89493957	G/A	cg09516651	chr1:89888402	LOC400759	0.68	9.49	0.5	1.43e-18	Carotid intima media thickness;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01980454	chr1:859173	NA	0.54	6.18	0.35	2.41e-9	Gut microbiome composition (summer);
CESC	cis	rs853679	0.517	rs9393885	chr6:28050009	A/T	cg19592336	chr6:28129416	ZNF389	0.6	7.97	0.44	4.69e-14	Depression;
CESC	cis	rs1799949	0.965	rs8176323	chr17:41195711	G/C	cg23758822	chr17:41437982	NA	1.0	14.9	0.68	6.88e-37	Menopause (age at onset);
CESC	cis	rs2281558	0.793	rs6115227	chr20:25591377	A/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.51	6.91	0.39	3.68e-11	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;
CESC	cis	rs875971	0.520	rs160645	chr7:65556307	A/G	cg25405998	chr7:65216604	CCT6P1	-0.5	-5.28	-0.31	2.64e-7	Aortic root size;
CESC	cis	rs2228479	0.867	rs11642451	chr16:89958127	T/C	cg00800038	chr16:89945340	TCF25	-0.87	-7.73	-0.43	2.3e-13	Skin colour saturation;
CESC	cis	rs3785574	0.962	rs2584614	chr17:61929445	C/T	cg06420487	chr17:61919686	SMARCD2	0.46	5.59	0.32	5.67e-8	Height;
CESC	cis	rs4862750	0.872	rs6553030	chr4:187899234	T/C	cg07414643	chr4:187882934	NA	0.54	7.97	0.44	4.82e-14	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6461049	0.800	rs1860831	chr7:2160931	T/C	cg21782813	chr7:2030301	MAD1L1	0.41	5.78	0.33	2.1e-8	Schizophrenia;
CESC	cis	rs4713675	0.565	rs4713659	chr6:33667839	A/G	cg15676125	chr6:33679581	C6orf125	0.33	5.05	0.3	8.31e-7	Plateletcrit;
CESC	cis	rs10504229	1.000	rs67388517	chr8:58176617	C/A	cg24829409	chr8:58192753	C8orf71	-0.76	-10.0	-0.52	3.53e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs2404602	0.583	rs12913096	chr15:76551852	C/T	cg22467129	chr15:76604101	ETFA	-0.39	-6.05	-0.35	5.01e-9	Blood metabolite levels;
CESC	cis	rs4689388	0.926	rs10937719	chr4:6295322	C/G	cg25554036	chr4:6271136	WFS1	0.52	8.41	0.46	2.62e-15	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs2576037	0.899	rs7233515	chr18:44585955	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.49	-6.23	-0.36	1.79e-9	Personality dimensions;
CESC	cis	rs4803468	0.967	rs3826713	chr19:41892269	C/T	cg09537434	chr19:41945824	ATP5SL	-1.02	-18.19	-0.75	1.57e-48	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16986746	chr3:48594219	PFKFB4	0.57	6.02	0.35	5.92e-9	Gut microbiome composition (summer);
CESC	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg27094323	chr7:1216898	NA	-0.44	-6.38	-0.36	7.83e-10	Longevity;Endometriosis;
CESC	cis	rs3816788	0.792	rs729180	chr8:21817245	C/T	cg17168535	chr8:21777572	XPO7	0.74	11.86	0.59	2.55e-26	Lung cancer in ever smokers;
CESC	cis	rs79349575	0.681	rs56080003	chr17:47019049	A/T	cg26022315	chr17:47021804	SNF8	0.39	5.16	0.3	4.94e-7	Type 2 diabetes;
CESC	cis	rs1941023	0.503	rs7944025	chr11:60142538	C/A	cg08716584	chr11:60157161	MS4A7	-0.57	-9.44	-0.5	1.96e-18	Congenital heart disease (maternal effect);
CESC	trans	rs61931739	0.517	rs4931748	chr12:34140827	C/T	cg26384229	chr12:38710491	ALG10B	0.6	8.3	0.45	5.26e-15	Morning vs. evening chronotype;
CESC	cis	rs28647808	0.881	rs41316984	chr9:136259231	T/C	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.85	5.74	0.33	2.59e-8	Blood protein levels;
CESC	cis	rs2273669	0.667	rs2145763	chr6:109306963	C/A	cg05315195	chr6:109294784	ARMC2	-0.65	-5.82	-0.34	1.71e-8	Prostate cancer;
CESC	trans	rs17764205	0.929	rs8112130	chr19:3253928	A/G	cg19548313	chr19:1065712	HMHA1	0.48	6.09	0.35	3.87e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs7666738	0.830	rs17558193	chr4:99049593	A/G	cg05340658	chr4:99064831	C4orf37	0.82	12.88	0.62	8.44e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4233802	1.000	rs11895581	chr2:151125904	A/G	cg25300694	chr2:151184358	NA	0.9	7.5	0.42	9.95e-13	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
CESC	cis	rs1784581	0.588	rs1784606	chr6:162405992	A/T	cg17173639	chr6:162384350	PARK2	-0.44	-6.27	-0.36	1.47e-9	Itch intensity from mosquito bite;
CESC	cis	rs1728785	0.748	rs889560	chr16:68605784	A/G	cg02972257	chr16:68554789	NA	-0.59	-6.71	-0.38	1.2e-10	Ulcerative colitis;
CESC	cis	rs6665290	0.901	rs2104860	chr1:227208637	G/C	cg10327440	chr1:227177885	CDC42BPA	-1.16	-24.88	-0.84	2.83e-71	Myeloid white cell count;
CESC	cis	rs72781680	0.799	rs17508218	chr2:23976536	C/T	cg08917208	chr2:24149416	ATAD2B	0.96	8.7	0.47	3.55e-16	Lymphocyte counts;
CESC	cis	rs73206853	0.764	rs7980838	chr12:110672978	T/A	cg12870014	chr12:110450643	ANKRD13A	0.73	6.55	0.37	2.98e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs56104184	0.779	rs17206686	chr19:49356317	A/G	cg15549821	chr19:49342101	PLEKHA4	-0.78	-9.0	-0.48	4.37e-17	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15207091	chr17:4795168	MINK1	-0.59	-7.2	-0.4	6.03e-12	Gut microbiome composition (summer);
CESC	cis	rs9457247	0.902	rs34560498	chr6:167395862	A/G	cg07741184	chr6:167504864	NA	0.29	5.21	0.3	3.78e-7	Crohn's disease;
CESC	cis	rs4665809	0.941	rs1470096	chr2:26311482	T/C	cg27170947	chr2:26402098	FAM59B	-0.71	-8.27	-0.45	6.5e-15	Gut microbiome composition (summer);
CESC	cis	rs870825	0.616	rs28582728	chr4:185646920	C/T	cg04058563	chr4:185651563	MLF1IP	0.63	6.96	0.39	2.59e-11	Blood protein levels;
CESC	cis	rs1707322	0.964	rs10437063	chr1:46273666	G/A	cg06784218	chr1:46089804	CCDC17	0.33	5.75	0.33	2.42e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs5750830	0.649	rs5757663	chr22:39821319	T/C	cg11247378	chr22:39784982	NA	-0.62	-9.02	-0.48	4.03e-17	Intelligence (multi-trait analysis);
CESC	cis	rs5769765	1.000	rs8184990	chr22:50273174	A/G	cg02269571	chr22:50332266	NA	0.47	6.38	0.36	7.99e-10	Schizophrenia;
CESC	cis	rs6951245	0.744	rs10275401	chr7:1213943	A/C	cg23708337	chr7:1209742	NA	0.53	5.74	0.33	2.54e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7264396	0.790	rs6060541	chr20:34248066	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.86	-11.84	-0.59	3.14e-26	Total cholesterol levels;
CESC	cis	rs1499614	1.000	rs2707832	chr7:66136549	C/T	cg18252515	chr7:66147081	NA	-1.39	-13.77	-0.65	6.55e-33	Gout;
CESC	cis	rs13191362	1.000	rs73008453	chr6:163013384	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.82	8.22	0.45	9.12e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg24677674	chr10:113943468	GPAM	-0.48	-6.92	-0.39	3.33e-11	Gambling;
CESC	cis	rs483180	0.512	rs612430	chr1:120216025	A/G	cg19096424	chr1:120255104	PHGDH	0.42	5.13	0.3	5.49e-7	Macular telangiectasia type 2;
CESC	cis	rs7949030	0.588	rs2512562	chr11:62312156	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.49	6.89	0.39	4.13e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07715894	chr16:11439533	C16orf75	-0.65	-7.39	-0.41	1.92e-12	Gut microbiome composition (summer);
CESC	cis	rs10504229	0.593	rs77607045	chr8:58010464	T/C	cg05313129	chr8:58192883	C8orf71	-0.5	-5.05	-0.3	8.06e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs853679	0.517	rs9295758	chr6:28120663	C/G	cg23281280	chr6:28129359	ZNF389	0.6	8.04	0.44	2.95e-14	Depression;
CESC	cis	rs6546550	0.901	rs11902198	chr2:70144596	C/A	cg02498382	chr2:70120550	SNRNP27	-0.41	-7.26	-0.41	4.34e-12	Prevalent atrial fibrillation;
CESC	cis	rs2797685	1.000	rs707472	chr1:7906008	A/C	cg04725166	chr1:7887271	PER3	0.46	6.31	0.36	1.19e-9	Crohn's disease;
CESC	cis	rs3733585	0.699	rs6844787	chr4:9959233	A/G	cg02734326	chr4:10020555	SLC2A9	-0.43	-6.01	-0.35	6.1e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs2243480	1.000	rs402418	chr7:65509469	G/A	cg13147721	chr7:65941812	NA	-0.95	-9.04	-0.49	3.39e-17	Diabetic kidney disease;
CESC	cis	rs7917772	0.503	rs2031601	chr10:104308064	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.56	7.87	0.44	9.28e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs6963495	0.818	rs116845562	chr7:105217038	T/C	cg13798780	chr7:105162888	PUS7	0.74	7.4	0.41	1.79e-12	Bipolar disorder (body mass index interaction);
CESC	cis	rs854765	0.583	rs11078404	chr17:17820487	A/T	cg04398451	chr17:18023971	MYO15A	-0.67	-9.74	-0.51	2.33e-19	Total body bone mineral density;
CESC	cis	rs9487051	0.872	rs9400269	chr6:109606065	C/G	cg12927641	chr6:109611667	NA	-0.42	-6.45	-0.37	5.22e-10	Reticulocyte fraction of red cells;
CESC	cis	rs10905065	0.895	rs3736462	chr10:5804455	A/G	cg11519256	chr10:5708881	ASB13	0.44	5.87	0.34	1.28e-8	Menopause (age at onset);
CESC	cis	rs514406	0.679	rs541852	chr1:53256834	A/G	cg24675658	chr1:53192096	ZYG11B	0.77	11.82	0.59	3.5e-26	Monocyte count;
CESC	cis	rs9815354	0.680	rs73830596	chr3:42028223	G/A	cg03022575	chr3:42003672	ULK4	0.72	6.4	0.37	6.9e-10	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs9300255	0.602	rs949142	chr12:123634043	T/C	cg00376283	chr12:123451042	ABCB9	0.71	8.76	0.47	2.38e-16	Neutrophil percentage of white cells;
CESC	cis	rs6032067	1.000	rs35284867	chr20:43845836	A/T	cg10761708	chr20:43804764	PI3	0.5	5.87	0.34	1.28e-8	Blood protein levels;
CESC	cis	rs853679	0.517	rs9283884	chr6:28135660	C/G	cg23161317	chr6:28129485	ZNF389	-0.49	-6.18	-0.35	2.41e-9	Depression;
CESC	cis	rs854765	0.583	rs4925125	chr17:17794444	T/C	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.46	-5.92	-0.34	9.93e-9	Total body bone mineral density;
CESC	cis	rs858239	0.796	rs433395	chr7:23401955	G/T	cg23682824	chr7:23144976	KLHL7	0.38	5.14	0.3	5.22e-7	Cerebrospinal fluid biomarker levels;
CESC	cis	rs12500824	0.564	rs62300858	chr4:77285721	A/C	cg20311846	chr4:77356250	SHROOM3	0.37	6.86	0.39	4.82e-11	Coronary artery disease;
CESC	cis	rs9916302	0.904	rs8065963	chr17:37681332	C/T	cg07936489	chr17:37558343	FBXL20	-0.8	-11.57	-0.58	2.46e-25	Glomerular filtration rate (creatinine);
CESC	cis	rs34779708	0.897	rs35784065	chr10:35353574	C/T	cg03585969	chr10:35415529	CREM	0.73	9.4	0.5	2.63e-18	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs7666738	0.791	rs6853608	chr4:99047916	A/G	cg05340658	chr4:99064831	C4orf37	0.82	12.88	0.62	8.44e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6912958	0.703	rs9353483	chr6:88097180	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.46	7.62	0.42	4.57e-13	Monocyte percentage of white cells;
CESC	cis	rs75229567	0.618	rs11495622	chr12:70161286	G/A	cg10114359	chr12:70132523	RAB3IP	1.11	7.59	0.42	5.44e-13	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
CESC	cis	rs863345	0.565	rs59188837	chr1:158500636	C/G	cg12129480	chr1:158549410	OR10X1	-0.34	-6.76	-0.38	8.6e-11	Pneumococcal bacteremia;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg24504843	chr4:56896641	CEP135	0.51	6.71	0.38	1.17e-10	Fibrinogen levels;
CESC	cis	rs61931739	0.500	rs10844862	chr12:34531965	A/T	cg06521331	chr12:34319734	NA	-0.37	-5.15	-0.3	5.19e-7	Morning vs. evening chronotype;
CESC	cis	rs67311347	1.000	rs12638199	chr3:40475285	A/G	cg01475735	chr3:40494733	NA	-0.4	-5.08	-0.3	7.14e-7	Renal cell carcinoma;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg23660191	chr16:30582942	ZNF688	-0.42	-6.26	-0.36	1.57e-9	Gambling;
CESC	cis	rs2657888	0.965	rs2694909	chr12:56934928	T/C	cg23002907	chr12:56915593	RBMS2	0.39	5.19	0.3	4.12e-7	Adiponectin levels;
CESC	cis	rs1577917	0.958	rs12212480	chr6:86458777	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.53	-6.91	-0.39	3.68e-11	Response to antipsychotic treatment;
CESC	cis	rs1986734	0.555	rs12512288	chr4:77416817	C/G	cg20311846	chr4:77356250	SHROOM3	-0.27	-5.4	-0.31	1.51e-7	Eosinophilic esophagitis (pediatric);Metabolite levels (small molecules and protein measures);
CESC	cis	rs6968419	0.755	rs2896181	chr7:115897884	A/G	cg02561103	chr7:115862891	TES	0.41	5.48	0.32	1.01e-7	Intraocular pressure;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg27620946	chr8:42011116	AP3M2	-0.46	-6.63	-0.38	1.83e-10	Gambling;
CESC	cis	rs2075371	0.863	rs1646638	chr7:134008706	T/C	cg20476274	chr7:133979776	SLC35B4	0.6	8.25	0.45	7.65e-15	Mean platelet volume;
CESC	trans	rs11663156	0.793	rs8082807	chr18:51010902	A/C	cg06077405	chr7:2313805	SNX8	-0.46	-6.07	-0.35	4.42e-9	Intelligence (multi-trait analysis);
CESC	cis	rs941873	0.868	rs2145998	chr10:81121696	T/A	cg08514558	chr10:81106712	PPIF	0.34	5.98	0.34	7.25e-9	Height;
CESC	cis	rs79349575	0.783	rs2088139	chr17:47000110	C/T	cg16584676	chr17:46985605	UBE2Z	0.53	6.58	0.37	2.46e-10	Type 2 diabetes;
CESC	trans	rs6084875	0.641	rs6052806	chr20:4721871	A/G	cg10192164	chr16:30419175	ZNF771	-0.51	-6.15	-0.35	2.78e-9	Systemic lupus erythematosus;
CESC	trans	rs9329221	0.683	rs525726	chr8:9887797	G/C	cg06636001	chr8:8085503	FLJ10661	-0.53	-7.08	-0.4	1.33e-11	Neuroticism;
CESC	cis	rs11871801	0.517	rs646123	chr17:40720632	G/A	cg14558262	chr17:40713999	COASY	0.51	5.95	0.34	8.31e-9	Crohn's disease;
CESC	cis	rs4689388	0.926	rs4458523	chr4:6289986	G/T	cg00701064	chr4:6280414	WFS1	-0.73	-12.9	-0.62	6.98e-30	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs7628338	0.525	rs13072744	chr3:72509637	C/T	cg16990174	chr3:72496875	RYBP	-0.24	-5.59	-0.32	5.78e-8	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
CESC	cis	rs7647973	0.600	rs11920267	chr3:49275964	G/A	cg07636037	chr3:49044803	WDR6	0.81	13.44	0.64	9.07e-32	Menarche (age at onset);
CESC	cis	rs1707322	1.000	rs785490	chr1:46577124	T/C	cg05343316	chr1:45956843	TESK2	-0.47	-5.52	-0.32	7.97e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs72781680	0.821	rs116583405	chr2:24208221	T/C	cg08917208	chr2:24149416	ATAD2B	0.64	6.33	0.36	1.07e-9	Lymphocyte counts;
CESC	cis	rs11645898	0.765	rs112439757	chr16:72168337	C/T	cg14768367	chr16:72042858	DHODH	-0.57	-5.17	-0.3	4.61e-7	Blood protein levels;
CESC	trans	rs7088591	0.867	rs115213581	chr10:59732069	G/A	cg10559231	chr5:14188039	TRIO	0.76	6.28	0.36	1.38e-9	Blood pressure;
CESC	cis	rs929354	0.557	rs62491947	chr7:156960813	G/A	cg05182265	chr7:156933206	UBE3C	-0.5	-7.29	-0.41	3.49e-12	Body mass index;
CESC	cis	rs72945132	0.882	rs11235739	chr11:70132780	C/T	cg14191688	chr11:70257035	CTTN	0.4	5.29	0.31	2.56e-7	Coronary artery disease;
CESC	cis	rs72781680	0.561	rs72783615	chr2:24296397	C/A	cg08917208	chr2:24149416	ATAD2B	0.6	5.66	0.33	3.99e-8	Lymphocyte counts;
CESC	cis	rs9297145	0.585	rs10953283	chr7:98782750	A/G	cg05967295	chr7:98741636	SMURF1	0.6	8.18	0.45	1.17e-14	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
CESC	cis	rs17376456	0.877	rs10057814	chr5:93399092	C/G	cg25358565	chr5:93447407	FAM172A	1.12	11.21	0.57	3.87e-24	Diabetic retinopathy;
CESC	cis	rs654950	0.783	rs640688	chr1:42001831	A/G	cg06885757	chr1:42089581	HIVEP3	-0.49	-8.02	-0.44	3.35e-14	Airway imaging phenotypes;
CESC	cis	rs17376456	0.825	rs10057130	chr5:93282557	C/T	cg25358565	chr5:93447407	FAM172A	1.11	10.04	0.53	2.56e-20	Diabetic retinopathy;
CESC	cis	rs2276314	1.000	rs56050783	chr18:33553791	A/G	cg19628046	chr18:33552617	C18orf21	0.57	6.41	0.37	6.53e-10	Endometriosis;Drug-induced torsades de pointes;
CESC	trans	rs3780486	0.757	rs10758189	chr9:33125804	A/G	cg04842962	chr6:43655489	MRPS18A	0.99	18.98	0.76	2.56e-51	IgG glycosylation;
CESC	cis	rs79349575	0.783	rs318096	chr17:46975370	G/A	cg16584676	chr17:46985605	UBE2Z	0.53	6.58	0.37	2.57e-10	Type 2 diabetes;
CESC	cis	rs17376456	1.000	rs34854140	chr5:93538169	G/A	cg25358565	chr5:93447407	FAM172A	1.16	11.45	0.58	6.45e-25	Diabetic retinopathy;
CESC	cis	rs9649213	0.574	rs7802560	chr7:97903806	A/G	cg21770322	chr7:97807741	LMTK2	-0.55	-8.17	-0.45	1.31e-14	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs3026101	0.624	rs7426	chr17:5288983	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.48	6.37	0.36	8.39e-10	Body mass index;
CESC	cis	rs11030122	0.702	rs12286710	chr11:3967171	T/G	cg18678763	chr11:4115507	RRM1	-0.45	-5.96	-0.34	7.84e-9	Mean platelet volume;Platelet distribution width;
CESC	cis	rs9815354	1.000	rs9846634	chr3:41894049	G/A	cg03022575	chr3:42003672	ULK4	0.58	5.94	0.34	9.04e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs151234	0.741	rs151230	chr16:28583215	G/A	cg01378222	chr16:28622494	SULT1A1	-0.57	-7.19	-0.4	6.79e-12	Platelet distribution width;
CESC	cis	rs733175	0.855	rs10018666	chr4:10004805	C/T	cg11266682	chr4:10021025	SLC2A9	0.39	5.24	0.31	3.29e-7	Psychosis and Alzheimer's disease;
CESC	cis	rs3858526	0.628	rs4237762	chr11:5956626	A/C	cg05234568	chr11:5960015	NA	-0.64	-8.25	-0.45	7.47e-15	DNA methylation (variation);
CESC	cis	rs9549367	0.789	rs9577220	chr13:113908294	T/A	cg18105134	chr13:113819100	PROZ	-0.68	-8.71	-0.47	3.37e-16	Platelet distribution width;
CESC	cis	rs3733585	0.660	rs13122290	chr4:9933832	A/G	cg00071950	chr4:10020882	SLC2A9	-0.73	-12.59	-0.61	8.62e-29	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs9467711	0.591	rs17586553	chr6:25928775	C/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.57	5.27	0.31	2.82e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs6496667	0.532	rs2601207	chr15:90963542	C/G	cg10434728	chr15:90938212	IQGAP1	-0.3	-5.2	-0.3	4.02e-7	Rheumatoid arthritis;
CESC	cis	rs1577917	0.958	rs10806337	chr6:86474249	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.52	-6.81	-0.39	6.5500000000000006e-11	Response to antipsychotic treatment;
CESC	cis	rs7188697	0.848	rs37062	chr16:58567238	A/G	cg21335942	chr16:58549945	SETD6	0.46	5.37	0.31	1.7e-7	QT interval;
CESC	cis	rs7131987	0.903	rs2216853	chr12:29413248	C/G	cg09582351	chr12:29534625	ERGIC2	-0.35	-5.72	-0.33	2.9e-8	QT interval;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg12241299	chr14:20929705	TMEM55B	0.45	6.23	0.36	1.8e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs35110281	0.837	rs12627667	chr21:45071396	A/C	cg01579765	chr21:45077557	HSF2BP	-0.58	-9.91	-0.52	6.71e-20	Mean corpuscular volume;
CESC	cis	rs2836950	0.527	rs2836958	chr21:40623526	T/C	cg11644478	chr21:40555479	PSMG1	-0.53	-7.14	-0.4	9.02e-12	Menarche (age at onset);
CESC	cis	rs16973500	0.808	rs1049794	chr16:71950450	C/T	cg09427745	chr16:71932006	KIAA0174	-0.52	-5.3	-0.31	2.39e-7	Response to anti-TNF therapy in rheumatoid arthritis;Attention deficit hyperactivity disorder and conduct disorder;
CESC	cis	rs17253792	0.822	rs78432811	chr14:56051545	T/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.84	5.54	0.32	7.35e-8	Putamen volume;
CESC	cis	rs7811142	0.830	rs41280971	chr7:99954457	G/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.72	6.41	0.37	6.71e-10	Platelet count;
CESC	cis	rs11055034	0.560	rs2024385	chr12:12888438	A/T	cg09462578	chr12:12878428	APOLD1	0.58	8.1	0.45	1.98e-14	Birth weight;
CESC	cis	rs2243480	1.000	rs7778911	chr7:65694506	T/C	cg18252515	chr7:66147081	NA	1.41	14.3	0.66	9.43e-35	Diabetic kidney disease;
CESC	cis	rs3204270	0.639	rs11871678	chr17:79654285	G/A	cg26965718	chr17:79658957	HGS	-0.84	-5.88	-0.34	1.25e-8	Dental caries;
CESC	cis	rs4481887	0.927	rs7555310	chr1:248487638	A/G	cg00666640	chr1:248458726	OR2T12	0.35	5.98	0.35	7.04e-9	Common traits (Other);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05380570	chr1:17866686	ARHGEF10L	-0.6	-7.41	-0.41	1.74e-12	Gut microbiome composition (summer);
CESC	cis	rs12971120	0.685	rs34780792	chr18:72173278	G/A	cg26446133	chr18:72167187	CNDP2	-0.77	-9.23	-0.49	9.2e-18	Refractive error;
CESC	cis	rs6547741	0.935	rs6547738	chr2:27852637	A/G	cg27432699	chr2:27873401	GPN1	0.48	6.82	0.39	6.31e-11	Oral cavity cancer;
CESC	cis	rs736801	0.891	rs10900809	chr5:131826322	G/A	cg21138405	chr5:131827807	IRF1	-0.46	-5.99	-0.35	6.71e-9	Breast cancer;Mosquito bite size;
CESC	cis	rs7666738	0.830	rs13328005	chr4:99055480	T/C	cg18180107	chr4:99064573	C4orf37	0.4	5.15	0.3	5.15e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs524281	0.817	rs10791859	chr11:65978453	C/T	cg14036092	chr11:66035641	RAB1B	-0.58	-5.92	-0.34	9.73e-9	Electroencephalogram traits;
CESC	cis	rs7772486	0.840	rs2814867	chr6:146334030	C/A	cg05347473	chr6:146136440	FBXO30	0.49	6.44	0.37	5.75e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs34779708	0.931	rs11597392	chr10:35288575	T/C	cg03585969	chr10:35415529	CREM	0.74	9.48	0.5	1.51e-18	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs11098499	0.863	rs12498539	chr4:120468370	C/T	cg24375607	chr4:120327624	NA	0.43	5.32	0.31	2.16e-7	Corneal astigmatism;
CESC	cis	rs4843747	0.671	rs4072871	chr16:88106614	C/T	cg03395651	chr16:88107091	BANP	0.46	5.36	0.31	1.82e-7	Menopause (age at onset);
CESC	cis	rs2777491	0.957	rs316614	chr15:41746625	A/G	cg02330683	chr15:41787940	ITPKA	0.47	7.04	0.4	1.64e-11	Ulcerative colitis;
CESC	cis	rs7772486	0.754	rs6937661	chr6:146113299	T/C	cg05347473	chr6:146136440	FBXO30	-0.52	-6.7	-0.38	1.24e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7845219	0.544	rs7016078	chr8:95922615	G/A	cg16049864	chr8:95962084	TP53INP1	-0.5	-7.42	-0.41	1.63e-12	Type 2 diabetes;
CESC	cis	rs7264396	0.690	rs2425175	chr20:34445563	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.62	7.36	0.41	2.25e-12	Total cholesterol levels;
CESC	cis	rs9611565	0.694	rs202618	chr22:41822856	A/G	cg06481639	chr22:41940642	POLR3H	0.64	6.41	0.37	6.73e-10	Vitiligo;
CESC	cis	rs11792861	0.781	rs72607158	chr9:111763010	T/C	cg05043794	chr9:111880884	C9orf5	-0.38	-6.16	-0.35	2.76e-9	Menarche (age at onset);
CESC	cis	rs9322193	0.923	rs3924871	chr6:149983216	G/A	cg07701084	chr6:150067640	NUP43	0.46	6.42	0.37	6.12e-10	Lung cancer;
CESC	cis	rs9733	0.519	rs10788792	chr1:150638572	T/G	cg17724175	chr1:150552817	MCL1	0.45	7.34	0.41	2.6e-12	Tonsillectomy;
CESC	cis	rs11792861	0.816	rs3818932	chr9:111664178	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.51	6.61	0.38	2.14e-10	Menarche (age at onset);
CESC	trans	rs1728785	0.748	rs889560	chr16:68605784	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.65	7.93	0.44	6e-14	Ulcerative colitis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10197162	chr2:61108677	REL	0.63	7.23	0.41	5.14e-12	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27430682	chr10:65225552	JMJD1C;LOC84989	0.59	6.54	0.37	3.07e-10	Gut microbiome composition (summer);
CESC	cis	rs4601790	0.601	rs4930295	chr11:65390554	C/G	cg06492744	chr11:65406254	SIPA1	0.42	5.1	0.3	6.4e-7	Blood pressure (age interaction);
CESC	cis	rs554111	0.560	rs592060	chr1:21050958	A/G	cg21184320	chr1:21044207	KIF17	-0.44	-5.12	-0.3	5.79e-7	Facial morphology (factor 17, height of vermillion upper lip);
CESC	cis	rs9811920	0.809	rs793437	chr3:99559854	C/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.46	-7.65	-0.43	3.62e-13	Axial length;
CESC	cis	rs4689592	0.503	rs56099074	chr4:7071259	A/G	cg19539972	chr4:7069911	GRPEL1	-0.71	-7.34	-0.41	2.64e-12	Monocyte percentage of white cells;
CESC	cis	rs425277	0.958	rs7546523	chr1:2043792	G/A	cg04315214	chr1:2043799	PRKCZ	-0.44	-6.02	-0.35	5.69e-9	Height;
CESC	cis	rs6087771	0.890	rs6089056	chr20:30325773	A/G	cg13852791	chr20:30311386	BCL2L1	0.85	11.17	0.57	5.35e-24	Subcortical brain region volumes;Putamen volume;
CESC	cis	rs636291	0.517	rs12565133	chr1:10544988	A/C	cg07384165	chr1:10488281	NA	0.54	7.9	0.44	7.28e-14	Prostate cancer;
CESC	cis	rs11166927	1.000	rs13256946	chr8:140805101	G/A	cg16909799	chr8:140841666	TRAPPC9	0.61	8.98	0.48	5.04e-17	Pediatric non-alcoholic fatty liver disease activity score;
CESC	cis	rs2295359	1.000	rs4655683	chr1:67611613	C/T	cg03340356	chr1:67600835	NA	0.3	5.04	0.3	8.67e-7	Psoriasis;
CESC	cis	rs10504229	0.569	rs75466737	chr8:58055034	A/G	cg22535103	chr8:58192502	C8orf71	-0.94	-9.38	-0.5	3.05e-18	Developmental language disorder (linguistic errors);
CESC	cis	rs4665809	1.000	rs4665811	chr2:26260017	A/G	cg25036284	chr2:26402008	FAM59B	-0.6	-6.91	-0.39	3.64e-11	Gut microbiome composition (summer);
CESC	trans	rs7980799	0.682	rs10437795	chr12:33635336	C/G	cg26384229	chr12:38710491	ALG10B	-0.6	-8.66	-0.47	4.71e-16	Heart rate;Heart rate variability traits (RMSSD);
CESC	cis	rs1580019	0.961	rs1580021	chr7:32497702	T/G	cg06627557	chr7:32535165	LSM5;AVL9	0.73	10.13	0.53	1.34e-20	Cognitive ability;
CESC	cis	rs9811920	0.638	rs793461	chr3:99615758	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.59	7.22	0.41	5.61e-12	Axial length;
CESC	cis	rs8077577	0.638	rs4386179	chr17:18134774	A/G	cg16794390	chr17:18148240	FLII	-0.44	-6.43	-0.37	5.97e-10	Obesity-related traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02159896	chr18:11908181	MPPE1	-0.54	-6.11	-0.35	3.51e-9	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10737766	chr2:98280628	ACTR1B	0.62	6.84	0.39	5.4e-11	Gut microbiome composition (summer);
CESC	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.55	7.4	0.41	1.84e-12	Lymphocyte counts;
CESC	cis	rs7586879	0.639	rs13407913	chr2:25097644	A/G	cg01884057	chr2:25150051	NA	0.38	7.4	0.41	1.85e-12	Body mass index;
CESC	trans	rs11165623	0.792	rs12123543	chr1:96964549	T/C	cg10631902	chr5:14652156	NA	-0.5	-7.4	-0.41	1.76e-12	Hip circumference;Waist circumference;
CESC	cis	rs76419734	0.510	rs7659526	chr4:106621643	T/C	cg24545054	chr4:106630052	GSTCD;INTS12	0.74	9.22	0.49	9.47e-18	Post bronchodilator FEV1;
CESC	cis	rs317689	0.690	rs604168	chr12:69671158	C/T	cg14784868	chr12:69753453	YEATS4	0.48	5.26	0.31	3e-7	Response to diuretic therapy;
CESC	cis	rs8092503	1.000	rs2871673	chr18:52491427	G/T	cg12377874	chr18:52495404	RAB27B	-0.43	-6.49	-0.37	4.11e-10	Childhood body mass index;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg04233664	chr10:126848743	CTBP2	-0.45	-6.26	-0.36	1.57e-9	Fibrinogen levels;
CESC	cis	rs367943	1.000	rs1057827	chr5:112823768	T/C	cg12552261	chr5:112820674	MCC	0.63	7.96	0.44	4.96e-14	Type 2 diabetes;
CESC	cis	rs5758659	0.519	rs133307	chr22:42396568	C/A	cg04733989	chr22:42467013	NAGA	0.44	5.82	0.34	1.7e-8	Cognitive function;
CESC	cis	rs7666738	0.677	rs13120306	chr4:99036099	A/T	cg18180107	chr4:99064573	C4orf37	0.43	5.4	0.31	1.5e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2576037	0.507	rs2571019	chr18:44585287	A/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.34	-5.41	-0.32	1.4e-7	Personality dimensions;
CESC	cis	rs10504229	1.000	rs67895971	chr8:58177994	A/G	cg14926445	chr8:58193284	C8orf71	-0.51	-5.47	-0.32	1.03e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs7937682	0.883	rs11213941	chr11:111434094	T/C	cg22437258	chr11:111473054	SIK2	-0.72	-8.72	-0.47	3.05e-16	Primary sclerosing cholangitis;
CESC	cis	rs734999	0.572	rs4310388	chr1:2507415	G/T	cg18854424	chr1:2615690	NA	0.26	5.06	0.3	7.87e-7	Ulcerative colitis;
CESC	cis	rs13382862	0.862	rs340595	chr2:20889714	A/G	cg07755735	chr2:20870362	GDF7	-0.47	-7.03	-0.4	1.8e-11	Abdominal aortic aneurysm;
CESC	cis	rs765787	0.530	rs4775836	chr15:45537664	T/C	cg24006582	chr15:45444508	DUOX1	-0.59	-7.32	-0.41	3.04e-12	Uric acid levels;
CESC	cis	rs1355223	0.752	rs896856	chr11:34676842	G/T	cg11058730	chr11:34937778	PDHX;APIP	-0.47	-5.99	-0.35	6.66e-9	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs6088590	1.000	rs2180276	chr20:33360785	T/A	cg08999081	chr20:33150536	PIGU	0.58	8.98	0.48	5.31e-17	Coronary artery disease;
CESC	cis	rs11792861	0.926	rs75472294	chr9:111804239	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.48	6.07	0.35	4.29e-9	Menarche (age at onset);
CESC	cis	rs735396	0.627	rs2264778	chr12:121450354	C/A	cg02403541	chr12:121454288	C12orf43	0.8	11.7	0.58	9.06e-26	N-glycan levels;
CESC	cis	rs5758659	0.714	rs133376	chr22:42466905	C/T	cg15557168	chr22:42548783	NA	-0.48	-7.52	-0.42	8.34e-13	Cognitive function;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg00773818	chr12:52426922	NA	-0.47	-6.09	-0.35	3.88e-9	Fibrinogen levels;
CESC	cis	rs2404602	0.692	rs12913810	chr15:77166675	T/C	cg26408565	chr15:76604113	ETFA	-0.39	-5.68	-0.33	3.6e-8	Blood metabolite levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11176889	chr7:32997094	FKBP9	0.54	6.0	0.35	6.59e-9	Gut microbiome composition (summer);
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg21883765	chr7:127032075	ZNF800	-0.47	-6.35	-0.36	9.36e-10	Asthma;
CESC	trans	rs208520	1.000	rs12200490	chr6:66976084	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.85	9.39	0.5	2.86e-18	Exhaled nitric oxide output;
CESC	cis	rs694739	1.000	rs11231757	chr11:64106317	C/T	cg02228329	chr11:64053129	BAD;GPR137	0.68	8.74	0.47	2.74e-16	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CESC	cis	rs1799949	1.000	rs8176083	chr17:41275151	G/C	cg25072359	chr17:41440525	NA	0.47	6.21	0.36	2.04e-9	Menopause (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16458507	chr12:113376293	OAS3	0.59	6.96	0.39	2.68e-11	Gut microbiome composition (summer);
CESC	cis	rs477692	0.673	rs7909964	chr10:131338714	T/C	cg24747557	chr10:131355152	MGMT	-0.39	-5.41	-0.32	1.44e-7	Response to temozolomide;
CESC	cis	rs593982	0.920	rs72922791	chr11:65567395	G/A	cg08755490	chr11:65554678	OVOL1	-1.15	-11.04	-0.56	1.5e-23	Atopic dermatitis;
CESC	cis	rs7584330	0.554	rs111512641	chr2:238429538	G/A	cg14458575	chr2:238380390	NA	0.53	5.76	0.33	2.32e-8	Prostate cancer;
CESC	cis	rs977987	0.815	rs4887829	chr16:75488935	C/T	cg03315344	chr16:75512273	CHST6	0.44	6.44	0.37	5.73e-10	Dupuytren's disease;
CESC	cis	rs6500602	0.626	rs7665	chr16:4562512	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.41	5.83	0.34	1.59e-8	Schizophrenia;
CESC	cis	rs4971059	0.617	rs12025371	chr1:155119327	A/T	cg22049894	chr1:155113146	DPM3	0.46	5.87	0.34	1.3e-8	Breast cancer;
CESC	cis	rs1218582	0.772	rs6699043	chr1:154913021	T/C	cg24250549	chr1:154909240	PMVK	0.71	10.45	0.54	1.29e-21	Prostate cancer;
CESC	cis	rs9322193	0.923	rs2880436	chr6:150180259	T/C	cg13206674	chr6:150067644	NUP43	0.41	5.5	0.32	8.99e-8	Lung cancer;
CESC	cis	rs7940866	0.804	rs10894287	chr11:130808483	C/T	cg12179176	chr11:130786555	SNX19	0.62	9.65	0.51	4.39e-19	Schizophrenia;
CESC	cis	rs2228479	1.000	rs62052180	chr16:89963289	C/G	cg00800038	chr16:89945340	TCF25	-0.84	-7.29	-0.41	3.49e-12	Skin colour saturation;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg02330394	chr6:10695063	C6orf52;PAK1IP1	0.46	6.02	0.35	5.66e-9	Asthma;
CESC	cis	rs9399401	0.667	rs11155242	chr6:142691549	A/C	cg04461802	chr6:142623433	GPR126	0.36	5.31	0.31	2.29e-7	Chronic obstructive pulmonary disease;
CESC	cis	rs7666738	0.830	rs3846445	chr4:99032939	T/A	cg24818145	chr4:99064322	C4orf37	0.39	5.09	0.3	6.95e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9325144	0.581	rs6582564	chr12:38671282	G/A	cg26384229	chr12:38710491	ALG10B	-0.62	-9.6	-0.51	6.3e-19	Morning vs. evening chronotype;
CESC	cis	rs875971	0.638	rs7793569	chr7:66116633	T/G	cg06456125	chr7:65229604	NA	-0.39	-5.09	-0.3	6.82e-7	Aortic root size;
CESC	cis	rs1878931	0.507	rs1218762	chr16:3405986	G/A	cg02880119	chr16:3481970	NA	0.39	5.08	0.3	7.19e-7	Body mass index (adult);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg01261044	chr14:35451962	SRP54	0.47	6.33	0.36	1.02e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs9911578	0.692	rs412000	chr17:56709058	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.42	5.67	0.33	3.82e-8	Intelligence (multi-trait analysis);
CESC	cis	rs12926788	0.542	rs6497759	chr16:24801737	G/A	cg06028605	chr16:24865363	SLC5A11	0.55	8.13	0.45	1.62e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs116095464	0.558	rs9654452	chr5:299561	C/T	cg22496380	chr5:211416	CCDC127	-0.75	-8.55	-0.46	1.03e-15	Breast cancer;
CESC	cis	rs10949834	0.715	rs710968	chr7:73497728	A/G	cg07137043	chr7:73588983	EIF4H	0.65	7.19	0.4	6.54e-12	Verbal memory performance (residualized delayed recall change);
CESC	cis	rs9733	0.596	rs12086630	chr1:150650955	T/C	cg17724175	chr1:150552817	MCL1	0.44	7.21	0.41	5.8e-12	Tonsillectomy;
CESC	cis	rs7666738	0.546	rs7679681	chr4:98882221	A/G	cg17366294	chr4:99064904	C4orf37	0.52	6.66	0.38	1.56e-10	Colonoscopy-negative controls vs population controls;
CESC	cis	rs853679	0.517	rs9368550	chr6:28051803	T/A	cg23161317	chr6:28129485	ZNF389	0.5	6.31	0.36	1.19e-9	Depression;
CESC	cis	rs9815354	0.868	rs1716653	chr3:41975598	C/A	cg03022575	chr3:42003672	ULK4	-0.46	-5.37	-0.31	1.74e-7	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs9926296	0.605	rs886952	chr16:89836781	G/A	cg21285383	chr16:89894308	SPIRE2	0.32	5.85	0.34	1.46e-8	Vitiligo;
CESC	cis	rs7618915	0.570	rs11130319	chr3:52755592	A/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.38	6.58	0.37	2.5e-10	Bipolar disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00837765	chr8:74884459	TCEB1	0.59	6.37	0.36	8.23e-10	Gut microbiome composition (summer);
CESC	cis	rs7605827	0.930	rs10184585	chr2:15683091	G/A	cg19274914	chr2:15703543	NA	0.37	6.7	0.38	1.22e-10	Educational attainment (years of education);
CESC	cis	rs1707322	0.929	rs785513	chr1:46538320	T/C	cg03146154	chr1:46216737	IPP	-0.7	-9.01	-0.48	4.28e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs4862750	0.914	rs9995391	chr4:187873749	A/T	cg03452623	chr4:187889614	NA	0.79	12.65	0.61	5.08e-29	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs8114671	0.839	rs6142290	chr20:33654672	A/C	cg06115741	chr20:33292138	TP53INP2	-0.44	-5.31	-0.31	2.27e-7	Height;
CESC	cis	rs1355223	0.816	rs2136506	chr11:34748260	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.47	-6.13	-0.35	3.23e-9	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs4268898	0.662	rs9917315	chr2:24431501	C/A	cg06627628	chr2:24431161	ITSN2	-1.02	-11.2	-0.57	4.2e-24	Asthma;
CESC	cis	rs514406	0.825	rs3863643	chr1:53224577	C/T	cg16325326	chr1:53192061	ZYG11B	-0.89	-15.32	-0.69	2.26e-38	Monocyte count;
CESC	cis	rs9297145	0.585	rs10953281	chr7:98772131	C/T	cg05967295	chr7:98741636	SMURF1	-0.6	-8.26	-0.45	7.19e-15	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
CESC	cis	rs57506017	0.585	rs3800841	chr7:12272568	A/T	cg23422036	chr7:12250390	TMEM106B	0.39	5.17	0.3	4.57e-7	Neuroticism;
CESC	cis	rs897080	0.515	rs1065784	chr2:44660777	G/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.46	5.07	0.3	7.49e-7	Height;
CESC	cis	rs10461617	0.535	rs7709874	chr5:56047451	C/T	cg24549020	chr5:56110836	MAP3K1	0.43	5.1	0.3	6.47e-7	Type 2 diabetes;
CESC	cis	rs4665809	0.590	rs17528653	chr2:26507724	T/C	cg22920501	chr2:26401640	FAM59B	0.91	9.92	0.52	6.43e-20	Gut microbiome composition (summer);
CESC	cis	rs1799949	0.930	rs35292991	chr17:41334016	C/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.38	5.04	0.3	8.73e-7	Menopause (age at onset);
CESC	cis	rs7786808	0.615	rs4909209	chr7:158194329	C/T	cg09998033	chr7:158218633	PTPRN2	-0.38	-5.54	-0.32	7.25e-8	Obesity-related traits;
CESC	cis	rs425277	1.000	rs425277	chr1:2069172	C/T	cg16545954	chr1:2118288	C1orf86	0.33	5.58	0.32	5.83e-8	Height;
CESC	cis	rs8060686	0.641	rs7204974	chr16:68033539	G/A	cg26727032	chr16:67993705	SLC12A4	-0.55	-7.02	-0.4	1.81e-11	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs988913	0.723	rs7761785	chr6:55002037	C/T	cg03513858	chr6:54763001	FAM83B	0.33	5.05	0.3	8.26e-7	Menarche (age at onset);
CESC	cis	rs1005277	0.579	rs1780122	chr10:38529509	C/A	cg25517755	chr10:38738941	LOC399744	-0.49	-6.39	-0.37	7.49e-10	Extrinsic epigenetic age acceleration;
CESC	cis	rs754466	0.580	rs10762763	chr10:79560803	C/G	cg17075019	chr10:79541650	NA	-0.78	-12.48	-0.61	2.06e-28	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs2072732	0.821	rs12034766	chr1:2944038	A/G	cg15211996	chr1:2936768	ACTRT2	0.35	5.74	0.33	2.65e-8	Plateletcrit;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg17214737	chr10:75757811	VCL	0.52	7.37	0.41	2.22e-12	Systemic lupus erythematosus;
CESC	cis	rs1670533	1.000	rs641987	chr4:1077542	C/T	cg27284194	chr4:1044797	NA	0.47	5.91	0.34	1.04e-8	Recombination rate (females);
CESC	cis	rs1707322	0.647	rs6686944	chr1:46156308	G/T	cg05343316	chr1:45956843	TESK2	0.5	6.14	0.35	3e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2456568	0.803	rs10765642	chr11:93640355	C/T	cg26875233	chr11:93583750	C11orf90	0.3	5.47	0.32	1.03e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
CESC	cis	rs523522	0.571	rs11065120	chr12:120875456	C/T	cg27279351	chr12:120934652	DYNLL1	0.5	5.55	0.32	7.1e-8	High light scatter reticulocyte count;
CESC	cis	rs2295499	0.673	rs73189408	chr4:2705644	T/A	cg08330972	chr4:2403930	ZFYVE28	-0.32	-5.2	-0.3	3.91e-7	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
CESC	cis	rs6693567	0.565	rs6684939	chr1:150440563	G/A	cg09579323	chr1:150459698	TARS2	-0.45	-5.78	-0.33	2.11e-8	Migraine;
CESC	cis	rs12887734	0.566	rs3742366	chr14:104198351	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.45	-5.73	-0.33	2.71e-8	Schizophrenia;Autism spectrum disorder or schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00472393	chr6:97730957	C6orf167;MIR548H3	0.53	6.08	0.35	4.29e-9	Gut microbiome composition (summer);
CESC	cis	rs736408	0.677	rs1042779	chr3:52821011	A/G	cg18337363	chr3:52569053	NT5DC2	0.35	6.19	0.36	2.31e-9	Bipolar disorder;
CESC	cis	rs9902453	0.933	rs7216494	chr17:28502651	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	7.48	0.42	1.11e-12	Coffee consumption (cups per day);
CESC	cis	rs3796352	1.000	rs11710292	chr3:53117798	T/C	cg15956490	chr3:53032818	SFMBT1	0.63	5.23	0.31	3.38e-7	Immune reponse to smallpox (secreted IL-2);
CESC	cis	rs2274273	0.868	rs6573007	chr14:55625938	T/G	cg04306507	chr14:55594613	LGALS3	0.29	5.82	0.34	1.71e-8	Protein biomarker;
CESC	trans	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg01341218	chr17:43662625	NA	0.89	11.19	0.57	4.64e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs548181	0.611	rs609200	chr11:125383808	G/A	cg03464685	chr11:125439445	EI24	-1.4	-11.25	-0.57	2.83e-24	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs1448094	0.549	rs7297996	chr12:86235899	C/T	cg00310523	chr12:86230176	RASSF9	0.37	5.56	0.32	6.42e-8	Major depressive disorder;
CESC	cis	rs9311474	1.000	rs6445358	chr3:52308845	C/G	cg05564831	chr3:52568323	NT5DC2	0.39	6.07	0.35	4.5e-9	Electroencephalogram traits;
CESC	cis	rs7949030	0.688	rs2849031	chr11:62365665	G/A	cg22862634	chr11:62369728	EML3;MTA2	-0.54	-7.45	-0.42	1.32e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs13082711	0.513	rs7612102	chr3:27372826	A/G	cg02860705	chr3:27208620	NA	-0.62	-7.34	-0.41	2.62e-12	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CESC	cis	rs9902453	0.904	rs4547389	chr17:28364768	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.67	-8.69	-0.47	3.78e-16	Coffee consumption (cups per day);
CESC	cis	rs7100689	0.784	rs4258322	chr10:82184770	T/C	cg00277334	chr10:82204260	NA	-0.62	-7.51	-0.42	8.99e-13	Post bronchodilator FEV1;
CESC	trans	rs7107217	1.000	rs1873872	chr11:129473993	A/T	cg18816107	chr1:151227233	PSMD4	0.47	6.09	0.35	3.9e-9	Breast cancer;Type 2 diabetes;
CESC	cis	rs11625487	0.609	rs74063385	chr14:77966859	C/T	cg20045696	chr14:77926864	AHSA1	-0.7	-5.42	-0.32	1.33e-7	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
CESC	cis	rs116095464	0.558	rs7356561	chr5:284381	G/C	cg10591111	chr5:226296	SDHA	-0.53	-6.43	-0.37	6.03e-10	Breast cancer;
CESC	cis	rs9733	0.596	rs11582840	chr1:150688487	A/G	cg04414720	chr1:150670196	GOLPH3L	0.62	8.86	0.48	1.21e-16	Tonsillectomy;
CESC	cis	rs644799	1.000	rs3748256	chr11:95521953	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	14.73	0.67	2.69e-36	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs1862618	0.853	rs832578	chr5:56164223	C/T	cg12311346	chr5:56204834	C5orf35	-0.72	-8.77	-0.47	2.14e-16	Initial pursuit acceleration;
CESC	cis	rs7520050	0.966	rs10789481	chr1:46383583	C/G	cg03146154	chr1:46216737	IPP	-0.47	-6.08	-0.35	4.13e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs3096299	0.685	rs8050512	chr16:89552320	C/G	cg16743903	chr16:89593216	SPG7	-0.44	-5.73	-0.33	2.74e-8	Multiple myeloma (IgH translocation);
CESC	cis	rs4819052	0.851	rs10470245	chr21:46658912	A/G	cg11663144	chr21:46675770	NA	-0.63	-10.02	-0.52	3.12e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs12900413	0.687	rs12908468	chr15:90304236	T/G	cg24249390	chr15:90295951	MESP1	-0.4	-5.61	-0.33	5.2e-8	Coronary artery aneurysm in Kawasaki disease;
CESC	cis	rs617791	0.530	rs10896073	chr11:65762814	T/C	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.43	-5.06	-0.3	8e-7	Breast cancer;
CESC	cis	rs6582630	0.519	rs1851130	chr12:38507819	C/T	cg26384229	chr12:38710491	ALG10B	0.69	10.32	0.54	3.31e-21	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs7613875	0.641	rs2624845	chr3:50062437	C/A	cg24308560	chr3:49941425	MST1R	0.56	8.0	0.44	4.01e-14	Body mass index;
CESC	cis	rs7527798	0.592	rs6667238	chr1:207822856	G/A	cg21110645	chr1:207815933	NA	-0.33	-5.94	-0.34	9.12e-9	Erythrocyte sedimentation rate;
CESC	cis	rs1552244	1.000	rs6764168	chr3:10123805	A/G	cg00166722	chr3:10149974	C3orf24	0.52	6.61	0.38	2.15e-10	Alzheimer's disease;
CESC	cis	rs919433	0.929	rs1366836	chr2:198172148	T/G	cg03934865	chr2:198174659	NA	-0.48	-7.4	-0.41	1.83e-12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs11785400	0.963	rs4579507	chr8:143733663	C/G	cg10596483	chr8:143751796	JRK	0.43	5.6	0.33	5.24e-8	Schizophrenia;
CESC	cis	rs853679	0.542	rs9380063	chr6:28137853	A/G	cg26335602	chr6:28129616	ZNF389	0.52	6.84	0.39	5.54e-11	Depression;
CESC	trans	rs8073060	0.516	rs2376177	chr17:33938089	T/G	cg19694781	chr19:47549865	TMEM160	-0.71	-6.99	-0.39	2.2e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	cis	rs6540559	1.000	rs6540559	chr1:209982025	G/A	cg22029157	chr1:209979665	IRF6	0.69	10.12	0.53	1.49e-20	Cleft lip with or without cleft palate;
CESC	cis	rs780096	0.506	rs1262430	chr2:27673798	T/C	cg12648201	chr2:27665141	KRTCAP3	-0.35	-6.57	-0.37	2.64e-10	Total body bone mineral density;
CESC	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	10.31	0.54	3.45e-21	Prudent dietary pattern;
CESC	cis	rs9611565	0.694	rs202622	chr22:41825342	T/G	cg17376030	chr22:41985996	PMM1	-0.76	-8.1	-0.45	2.03e-14	Vitiligo;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg26037239	chr1:153643678	ILF2	-0.43	-6.13	-0.35	3.09e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	trans	rs459571	0.959	rs410876	chr9:136893867	C/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.58	-7.5	-0.42	9.62e-13	Platelet distribution width;
CESC	cis	rs7615952	0.599	rs6766327	chr3:125723677	C/G	cg04553112	chr3:125709451	NA	-0.51	-5.57	-0.32	6.4e-8	Blood pressure (smoking interaction);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg25927753	chr2:74153795	DGUOK	0.49	6.66	0.38	1.53e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs11039798	1.000	rs6485908	chr11:48652198	C/T	cg15704280	chr7:45808275	SEPT13	-0.64	-6.34	-0.36	9.86e-10	Axial length;
CESC	cis	rs853679	0.517	rs17711344	chr6:28077602	A/G	cg19592336	chr6:28129416	ZNF389	-0.56	-7.47	-0.42	1.2e-12	Depression;
CESC	cis	rs1008375	0.966	rs11947836	chr4:17697187	A/G	cg02297831	chr4:17616191	MED28	-0.51	-6.15	-0.35	2.86e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs7666738	0.830	rs6532715	chr4:99016792	G/A	cg03676636	chr4:99064102	C4orf37	0.33	5.14	0.3	5.3e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7811142	0.830	rs118119933	chr7:99939050	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.89	7.89	0.44	7.81e-14	Platelet count;
CESC	cis	rs7666738	0.791	rs11730069	chr4:98945772	A/G	cg17366294	chr4:99064904	C4orf37	0.6	8.53	0.46	1.15e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs13418410	0.539	rs11695597	chr2:33840024	A/G	cg04131969	chr2:33951647	MYADML	0.55	6.79	0.39	7.25e-11	Non-response to antidepressants and depression;
CESC	cis	rs13191362	1.000	rs67046187	chr6:163068532	C/A	cg06582575	chr6:163149167	PACRG;PARK2	0.88	8.93	0.48	7.4e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs1018836	0.739	rs4734247	chr8:91569144	A/G	cg16814680	chr8:91681699	NA	-0.6	-8.37	-0.46	3.34e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs3820068	0.581	rs16851848	chr1:15927698	G/A	cg17385448	chr1:15911702	AGMAT	0.41	6.69	0.38	1.33e-10	Systolic blood pressure;
CESC	cis	rs2576037	0.501	rs8089938	chr18:44459497	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.6	8.76	0.47	2.32e-16	Personality dimensions;
CESC	cis	rs8180040	1.000	rs4858888	chr3:47405305	C/T	cg27129171	chr3:47204927	SETD2	-0.65	-9.61	-0.51	5.86e-19	Colorectal cancer;
CESC	cis	rs1862618	0.853	rs252910	chr5:56192983	G/A	cg24531977	chr5:56204891	C5orf35	-0.92	-11.16	-0.57	5.79e-24	Initial pursuit acceleration;
CESC	cis	rs55728055	0.661	rs10428007	chr22:31646653	C/T	cg01338084	chr22:32026380	PISD	0.76	5.93	0.34	9.43e-9	Age-related hearing impairment;
CESC	trans	rs3942852	0.955	rs1532754	chr11:48115279	A/T	cg15704280	chr7:45808275	SEPT13	-0.62	-6.89	-0.39	4.06e-11	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs7605827	0.930	rs6723148	chr2:15592019	G/T	cg19274914	chr2:15703543	NA	0.32	5.6	0.33	5.4e-8	Educational attainment (years of education);
CESC	cis	rs57506017	0.540	rs4721061	chr7:12267559	G/C	cg23422036	chr7:12250390	TMEM106B	0.38	5.13	0.3	5.58e-7	Neuroticism;
CESC	cis	rs2991971	0.934	rs7903	chr1:45976472	G/C	cg15605315	chr1:45957053	TESK2	0.5	6.63	0.38	1.83e-10	High light scatter reticulocyte count;
CESC	cis	rs67460515	0.563	rs11717272	chr3:160810355	A/G	cg03342759	chr3:160939853	NMD3	-0.51	-6.38	-0.37	7.65e-10	Parkinson's disease;
CESC	cis	rs7647973	0.516	rs4308307	chr3:49193216	C/T	cg07636037	chr3:49044803	WDR6	0.89	15.27	0.68	3.33e-38	Menarche (age at onset);
CESC	cis	rs4689592	0.619	rs3796908	chr4:7061378	G/A	cg06697600	chr4:7070879	GRPEL1	-0.57	-8.25	-0.45	7.58e-15	Monocyte percentage of white cells;
CESC	cis	rs9303401	0.659	rs7223708	chr17:56896398	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	1.01	12.68	0.61	4.11e-29	Cognitive test performance;
CESC	cis	rs425277	0.561	rs11584491	chr1:2042543	A/G	cg23803603	chr1:2058230	PRKCZ	-0.37	-6.62	-0.38	1.94e-10	Height;
CESC	cis	rs7618915	0.508	rs11717043	chr3:52656092	A/T	cg18404041	chr3:52824283	ITIH1	-0.38	-6.34	-0.36	9.62e-10	Bipolar disorder;
CESC	cis	rs4629180	0.920	rs4851458	chr2:102108794	T/C	cg04415270	chr2:102091202	RFX8	-0.44	-7.23	-0.41	5.31e-12	Chronic rhinosinusitis with nasal polyps;
CESC	cis	rs477692	0.604	rs1008982	chr10:131445731	T/C	cg05714579	chr10:131428358	MGMT	-0.61	-8.49	-0.46	1.49e-15	Response to temozolomide;
CESC	cis	rs7953249	0.618	rs2650000	chr12:121388962	G/T	cg25281562	chr12:121454272	C12orf43	0.44	5.67	0.33	3.82e-8	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
CESC	cis	rs796364	0.806	rs11679676	chr2:201040981	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.8	-6.17	-0.35	2.52e-9	Schizophrenia;
CESC	cis	rs11122272	0.670	rs2474632	chr1:231484361	C/T	cg06096015	chr1:231504339	EGLN1	0.44	6.46	0.37	5.12e-10	Hemoglobin concentration;
CESC	cis	rs910316	1.000	rs10149880	chr14:75633008	A/G	cg08847533	chr14:75593920	NEK9	-1.0	-18.49	-0.75	1.41e-49	Height;
CESC	cis	rs1218582	0.804	rs869506	chr1:154859581	A/C	cg03351412	chr1:154909251	PMVK	0.66	8.89	0.48	9.97e-17	Prostate cancer;
CESC	cis	rs12449000	1	rs12449000	chr16:89872970	T/C	cg07648498	chr16:89883185	FANCA	0.55	7.01	0.4	1.94e-11	Schizophrenia;
CESC	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg26354017	chr1:205819088	PM20D1	0.84	13.62	0.64	2.19e-32	Menarche (age at onset);
CESC	cis	rs6662572	0.737	rs2067635	chr1:46537946	T/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.48	5.3	0.31	2.43e-7	Blood protein levels;
CESC	cis	rs9660180	0.967	rs10907191	chr1:1774820	A/T	cg13866156	chr1:1669148	SLC35E2	-0.51	-6.75	-0.38	9.36e-11	Body mass index;
CESC	cis	rs6461049	0.765	rs3800908	chr7:2159437	C/T	cg08027265	chr7:2291960	NA	-0.38	-5.71	-0.33	3.01e-8	Schizophrenia;
CESC	cis	rs10788972	0.933	rs4492560	chr1:54568488	G/A	cg25741118	chr1:54482237	LDLRAD1	-0.23	-5.45	-0.32	1.13e-7	Parkinson disease and lewy body pathology;
CESC	cis	rs78456975	1.000	rs72776298	chr2:1570163	C/G	cg26248373	chr2:1572462	NA	-0.56	-5.21	-0.31	3.72e-7	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs6987853	0.787	rs2974300	chr8:42440532	C/T	cg09913449	chr8:42400586	C8orf40	0.46	7.8	0.43	1.45e-13	Mean corpuscular hemoglobin concentration;
CESC	cis	rs10791323	0.569	rs11533204	chr11:133743644	A/G	cg15485101	chr11:133734466	NA	0.3	5.22	0.31	3.6e-7	Childhood ear infection;
CESC	cis	rs1865760	0.532	rs2006736	chr6:26086017	C/T	cg17691542	chr6:26056736	HIST1H1C	0.42	5.57	0.32	6.13e-8	Height;
CESC	cis	rs4819052	0.851	rs2330012	chr21:46658592	G/A	cg11663144	chr21:46675770	NA	-0.63	-10.02	-0.52	3.12e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs6772849	0.930	rs9813197	chr3:128369104	G/A	cg16766828	chr3:128327626	NA	-0.31	-5.08	-0.3	7.13e-7	Monocyte percentage of white cells;Monocyte count;
CESC	cis	rs1692580	0.840	rs262679	chr1:2169792	C/T	cg24578937	chr1:2090814	PRKCZ	0.33	5.34	0.31	2.05e-7	Coronary artery disease;
CESC	cis	rs7786808	0.741	rs11765319	chr7:158226790	A/G	cg01191920	chr7:158217561	PTPRN2	-0.43	-7.99	-0.44	4.03e-14	Obesity-related traits;
CESC	cis	rs12142240	0.698	rs6679898	chr1:46820589	A/C	cg00530320	chr1:46809349	NSUN4	0.6	8.04	0.44	2.96e-14	Menopause (age at onset);
CESC	cis	rs780096	0.526	rs4803	chr2:27667297	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.3	-5.57	-0.32	6.2e-8	Total body bone mineral density;
CESC	cis	rs8072100	0.967	rs9894905	chr17:45485982	C/T	cg08085267	chr17:45401833	C17orf57	-0.53	-7.26	-0.41	4.38e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs6500602	0.701	rs4785971	chr16:4577090	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.38	5.25	0.31	3.11e-7	Schizophrenia;
CESC	cis	rs854765	0.583	rs4925129	chr17:17807186	A/G	cg16928487	chr17:17741425	SREBF1	-0.59	-9.94	-0.52	5.26e-20	Total body bone mineral density;
CESC	cis	rs704	0.585	rs3093680	chr17:26664806	T/C	cg10342447	chr17:26645325	TMEM97	-0.45	-6.29	-0.36	1.29e-9	Osteoprotegerin levels;
CESC	cis	rs875971	0.895	rs3857684	chr7:65938158	G/C	cg18876405	chr7:65276391	NA	0.51	6.86	0.39	4.82e-11	Aortic root size;
CESC	cis	rs748404	0.578	rs552701	chr15:43613810	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.55	8.75	0.47	2.5e-16	Lung cancer;
CESC	cis	rs6860806	0.507	rs274570	chr5:131713226	C/T	cg24060327	chr5:131705240	SLC22A5	0.73	9.83	0.52	1.18e-19	Breast cancer;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg13610055	chr14:68676965	RAD51L1	0.4	6.13	0.35	3.21e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs1348850	0.958	rs4243390	chr2:178468008	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.64	8.8	0.48	1.79e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs12497850	1.000	rs12493578	chr3:48730116	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.68	-8.19	-0.45	1.11e-14	Parkinson's disease;
CESC	trans	rs7944735	0.517	rs1827503	chr11:48225115	G/T	cg15704280	chr7:45808275	SEPT13	0.7	6.41	0.37	6.46e-10	Intraocular pressure;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24274347	chr12:132497611	EP400	-0.56	-6.17	-0.35	2.54e-9	Gut microbiome composition (summer);
CESC	cis	rs4253772	0.591	rs8135363	chr22:46651713	T/C	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.69	8.18	0.45	1.16e-14	LDL cholesterol;Cholesterol, total;
CESC	cis	rs7178572	0.568	rs12908262	chr15:77493256	G/A	cg22256960	chr15:77711686	NA	-0.53	-6.69	-0.38	1.33e-10	Type 2 diabetes;
CESC	cis	rs9308433	0.529	rs11120298	chr1:214500620	A/G	cg06198575	chr1:214491504	SMYD2	0.5	6.1	0.35	3.74e-9	IgG glycosylation;
CESC	cis	rs4604732	0.536	rs78019731	chr1:247626430	C/T	cg12758973	chr1:247694275	LOC148824;OR2C3	0.51	6.36	0.36	8.65e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs35160687	0.623	rs11127019	chr2:86467618	G/A	cg01119172	chr2:86362222	SNORD94;PTCD3	-0.39	-5.23	-0.31	3.42e-7	Night sleep phenotypes;
CESC	cis	rs2721195	0.614	rs12719778	chr8:145879883	T/C	cg11211951	chr8:145729740	GPT	0.43	7.24	0.41	4.81e-12	Age at first birth;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg13410609	chr19:50291885	AP2A1	0.5	7.15	0.4	8.55e-12	Fibrinogen levels;
CESC	cis	rs7208859	0.623	rs9900144	chr17:29208389	T/C	cg19761014	chr17:28927070	LRRC37B2	0.63	5.27	0.31	2.88e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs1707322	1.000	rs11211217	chr1:46348229	C/G	cg06784218	chr1:46089804	CCDC17	0.32	5.57	0.32	6.35e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs1799949	0.965	rs33961729	chr17:41287924	C/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.42	5.77	0.33	2.25e-8	Menopause (age at onset);
CESC	cis	rs9467711	0.606	rs68072215	chr6:26377927	T/C	cg12826209	chr6:26865740	GUSBL1	0.63	5.11	0.3	6.25e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs2625529	0.617	rs16956369	chr15:72182813	C/T	cg16672083	chr15:72433130	SENP8	0.35	5.17	0.3	4.62e-7	Red blood cell count;
CESC	cis	rs1670533	0.932	rs9992925	chr4:1050909	A/T	cg27284194	chr4:1044797	NA	0.45	5.54	0.32	7.32e-8	Recombination rate (females);
CESC	cis	rs6460942	0.659	rs17192500	chr7:12545379	A/G	cg02935154	chr7:12443704	VWDE	-0.57	-5.7	-0.33	3.23e-8	Coronary artery disease;
CESC	cis	rs514406	0.505	rs269293	chr1:53187767	A/C	cg24675658	chr1:53192096	ZYG11B	-0.5	-6.2	-0.36	2.16e-9	Monocyte count;
CESC	cis	rs875971	0.619	rs12533585	chr7:65984605	G/C	cg14393609	chr7:65229607	NA	0.45	6.11	0.35	3.6e-9	Aortic root size;
CESC	cis	rs9926296	0.572	rs2079671	chr16:89884981	T/C	cg04287289	chr16:89883240	FANCA	0.65	9.05	0.49	3.23e-17	Vitiligo;
CESC	cis	rs873946	0.648	rs12767283	chr10:134557094	C/G	cg06453172	chr10:134556979	INPP5A	-0.42	-5.32	-0.31	2.19e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg06296021	chr5:133702588	CDKL3	0.52	6.65	0.38	1.67e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs9611565	0.765	rs132909	chr22:41802031	G/A	cg17376030	chr22:41985996	PMM1	-0.59	-6.24	-0.36	1.69e-9	Vitiligo;
CESC	cis	rs798554	0.797	rs35957220	chr7:2812632	C/G	cg19346786	chr7:2764209	NA	-0.5	-7.16	-0.4	8.12e-12	Height;
CESC	cis	rs72772090	0.539	rs11738810	chr5:96119055	T/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.57	-5.21	-0.3	3.74e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs4253772	0.550	rs12165597	chr22:46705584	A/G	cg10541313	chr22:46663664	TTC38	0.61	5.23	0.31	3.38e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs7193541	0.684	rs4888265	chr16:74683737	T/C	cg05580060	chr16:74700937	RFWD3	-0.49	-6.45	-0.37	5.33e-10	Multiple myeloma;
CESC	cis	rs13256369	0.901	rs12679831	chr8:8566411	T/G	cg17143192	chr8:8559678	CLDN23	0.71	8.17	0.45	1.27e-14	Obesity-related traits;
CESC	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg06877462	chr1:205807181	PM20D1	0.46	7.03	0.4	1.76e-11	Menarche (age at onset);
CESC	cis	rs2777491	0.574	rs316616	chr15:41746276	G/A	cg02330683	chr15:41787940	ITPKA	0.42	5.07	0.3	7.48e-7	Ulcerative colitis;
CESC	cis	rs7116495	1.000	rs585228	chr11:71773289	G/C	cg10381502	chr11:71823885	C11orf51	-0.67	-5.66	-0.33	3.92e-8	Severe influenza A (H1N1) infection;
CESC	cis	rs977987	0.843	rs4888372	chr16:75313485	G/A	cg03315344	chr16:75512273	CHST6	0.38	5.4	0.31	1.5e-7	Dupuytren's disease;
CESC	cis	rs875971	0.545	rs1638724	chr7:66040481	A/G	cg11764359	chr7:65958608	NA	-0.82	-9.95	-0.52	4.98e-20	Aortic root size;
CESC	cis	rs9911578	1.000	rs12453459	chr17:56624291	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.41	-5.53	-0.32	7.63e-8	Intelligence (multi-trait analysis);
CESC	cis	rs741677	0.663	rs441438	chr17:491006	C/T	cg15660573	chr17:549704	VPS53	0.43	5.62	0.33	4.75e-8	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
CESC	cis	rs2011503	1.000	rs76790018	chr19:19652157	G/A	cg11584989	chr19:19387371	SF4	0.58	6.67	0.38	1.52e-10	Bipolar disorder;
CESC	cis	rs12477438	0.765	rs7571390	chr2:99626593	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-8.99	-0.48	4.8e-17	Chronic sinus infection;
CESC	cis	rs7811142	0.779	rs77370288	chr7:99947897	A/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.05	10.66	0.55	2.52e-22	Platelet count;
CESC	cis	rs7552404	0.924	rs1858536	chr1:76161595	G/T	cg10523679	chr1:76189770	ACADM	0.76	9.99	0.52	3.63e-20	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs4253772	0.591	rs9627324	chr22:46656511	A/G	cg10231785	chr22:46692440	CN5H6.4;GTSE1	0.48	5.08	0.3	7.09e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs1878931	0.668	rs2074366	chr16:3439676	G/A	cg22508957	chr16:3507546	NAT15	-0.42	-6.04	-0.35	5.09e-9	Body mass index (adult);
CESC	cis	rs6582630	0.502	rs11495393	chr12:38341194	T/C	cg13010199	chr12:38710504	ALG10B	0.44	5.63	0.33	4.49e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs801193	0.569	rs2707847	chr7:66202871	C/G	cg12463550	chr7:65579703	CRCP	0.49	6.35	0.36	9.51e-10	Aortic root size;
CESC	cis	rs2708240	0.577	rs13235812	chr7:147556653	C/T	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	0.3	5.04	0.3	8.82e-7	QT interval (drug interaction);
CESC	cis	rs9291683	0.546	rs7442336	chr4:10045783	G/A	cg02734326	chr4:10020555	SLC2A9	0.45	6.18	0.36	2.35e-9	Bone mineral density;
CESC	cis	rs875971	0.862	rs1983372	chr7:65611351	C/T	cg12463550	chr7:65579703	CRCP	-0.51	-6.54	-0.37	3.18e-10	Aortic root size;
CESC	cis	rs17036350	1	rs17036350	chr1:11171226	C/T	cg18435880	chr1:11160013	EXOSC10	0.93	6.8	0.39	7.04e-11	Corneal curvature;
CESC	trans	rs10506458	0.915	rs1463821	chr12:63402875	C/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	1.32	17.07	0.72	1.42e-44	Hemostatic factors and hematological phenotypes;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg14005384	chr15:89877925	POLG	-0.46	-6.16	-0.35	2.67e-9	Fibrinogen levels;
CESC	cis	rs2281558	0.833	rs55792313	chr20:25521255	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.55	7.61	0.42	4.83e-13	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;
CESC	cis	rs9660180	0.967	rs12034740	chr1:1728969	C/A	cg23982607	chr1:1823379	GNB1	-0.76	-12.02	-0.59	7.68e-27	Body mass index;
CESC	cis	rs12410462	0.901	rs79626242	chr1:227650385	A/G	cg23173402	chr1:227635558	NA	0.55	5.41	0.32	1.41e-7	Major depressive disorder;
CESC	cis	rs9303401	0.614	rs2240719	chr17:56582477	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.01	12.43	0.61	2.87e-28	Cognitive test performance;
CESC	cis	rs7223966	1.000	rs2854223	chr17:61939014	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.54	6.9	0.39	3.94e-11	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs7824557	0.564	rs2736302	chr8:11236419	T/C	cg21775007	chr8:11205619	TDH	-0.54	-8.07	-0.44	2.52e-14	Retinal vascular caliber;
CESC	cis	rs769267	0.930	rs4808964	chr19:19603692	A/C	cg20644253	chr19:19431407	KIAA0892;SF4	-0.59	-7.54	-0.42	7.38e-13	Tonsillectomy;
CESC	cis	rs9486719	1.000	rs2142652	chr6:96868504	A/C	cg06623918	chr6:96969491	KIAA0776	0.81	8.29	0.45	5.61e-15	Migraine;Coronary artery disease;
CESC	cis	rs854765	0.547	rs2955383	chr17:17941364	A/G	cg04398451	chr17:18023971	MYO15A	-0.71	-10.43	-0.54	1.44e-21	Total body bone mineral density;
CESC	cis	rs589448	0.902	rs315124	chr12:69771727	G/A	cg22834771	chr12:69754056	YEATS4	-0.57	-7.68	-0.43	3.15e-13	Cerebrospinal fluid biomarker levels;
CESC	cis	rs4908760	0.811	rs301802	chr1:8497307	A/T	cg00120948	chr1:8484417	RERE	-0.38	-5.88	-0.34	1.21e-8	Vitiligo;
CESC	cis	rs7089973	0.604	rs7920216	chr10:116611794	G/A	cg03647239	chr10:116582469	FAM160B1	0.43	5.31	0.31	2.38e-7	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs7666738	0.830	rs28687737	chr4:99009226	G/A	cg17366294	chr4:99064904	C4orf37	0.6	8.62	0.47	6.37e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9611565	0.694	rs202631	chr22:41863423	A/G	cg17376030	chr22:41985996	PMM1	-0.59	-6.55	-0.37	2.91e-10	Vitiligo;
CESC	cis	rs1843834	0.539	rs6749402	chr2:225443901	T/G	cg12698349	chr2:225449008	CUL3	0.62	8.74	0.47	2.73e-16	IgE levels in asthmatics (D.p. specific);
CESC	cis	rs7301826	0.651	rs12228959	chr12:131296068	T/G	cg11011512	chr12:131303247	STX2	0.47	5.84	0.34	1.52e-8	Plasma plasminogen activator levels;
CESC	cis	rs9479482	0.967	rs9479478	chr6:150354608	T/G	cg03788504	chr6:150331562	NA	-0.3	-5.84	-0.34	1.52e-8	Alopecia areata;
CESC	cis	rs1707322	0.686	rs61784833	chr1:46233772	T/C	cg06784218	chr1:46089804	CCDC17	0.41	7.19	0.4	6.5e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7091068	0.566	rs7082701	chr10:95501042	G/T	cg20715218	chr10:95462985	C10orf4	0.57	5.28	0.31	2.64e-7	Urinary tract infection frequency;
CESC	cis	rs3768617	0.510	rs2296290	chr1:183079412	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.88	14.14	0.66	3.44e-34	Fuchs's corneal dystrophy;
CESC	cis	rs910316	0.763	rs175042	chr14:75470833	A/T	cg11812906	chr14:75593930	NEK9	-0.8	-12.71	-0.62	3.25e-29	Height;
CESC	cis	rs11190604	1.000	rs11190569	chr10:102227409	C/T	cg07080220	chr10:102295463	HIF1AN	0.59	6.05	0.35	4.87e-9	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs12472274	0.941	rs2880131	chr2:239089151	A/C	cg17459225	chr2:239074497	NA	0.61	9.0	0.48	4.41e-17	Phospholipid levels (plasma);
CESC	cis	rs3087591	0.922	rs2953013	chr17:29496343	A/C	cg24425628	chr17:29625626	OMG;NF1	-0.45	-5.3	-0.31	2.42e-7	Hip circumference;
CESC	trans	rs116095464	0.558	rs10057492	chr5:239503	T/C	cg00938859	chr5:1591904	SDHAP3	0.64	6.99	0.39	2.27e-11	Breast cancer;
CESC	cis	rs9322193	0.884	rs10872648	chr6:150079835	A/G	cg02462569	chr6:150064036	NUP43	-0.38	-5.42	-0.32	1.32e-7	Lung cancer;
CESC	trans	rs10435719	0.610	rs80269926	chr8:11790527	T/C	cg15556689	chr8:8085844	FLJ10661	0.53	6.51	0.37	3.7e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
CESC	cis	rs7552404	0.883	rs11161493	chr1:76206254	T/A	cg03433033	chr1:76189801	ACADM	0.76	10.66	0.55	2.64e-22	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs7552404	0.889	rs2211080	chr1:76243438	G/A	cg10523679	chr1:76189770	ACADM	0.66	7.42	0.41	1.6e-12	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs2559856	1.000	rs2559860	chr12:102087636	C/T	cg12213457	chr12:102090980	CHPT1	-0.34	-5.09	-0.3	6.71e-7	Blood protein levels;
CESC	cis	rs1799949	1.000	rs3092994	chr17:41215825	C/T	cg25072359	chr17:41440525	NA	0.46	6.14	0.35	2.97e-9	Menopause (age at onset);
CESC	cis	rs989128	0.517	rs1809284	chr17:48632310	A/G	cg24438145	chr17:48624694	SPATA20	0.44	5.15	0.3	5e-7	Type 2 diabetes;
CESC	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg26338869	chr17:61819248	STRADA	0.69	9.1	0.49	2.16e-17	Prudent dietary pattern;
CESC	cis	rs317689	0.819	rs317664	chr12:69704747	C/A	cg14784868	chr12:69753453	YEATS4	0.49	5.17	0.3	4.66e-7	Response to diuretic therapy;
CESC	cis	rs4434138	0.594	rs7653028	chr3:52763000	A/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	5.81	0.34	1.8e-8	Intelligence (multi-trait analysis);
CESC	cis	rs684232	0.602	rs379998	chr17:556884	A/G	cg15660573	chr17:549704	VPS53	-0.8	-11.75	-0.59	6.18e-26	Prostate cancer;
CESC	cis	rs17376456	0.825	rs28705226	chr5:93233135	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.64	5.54	0.32	7.12e-8	Diabetic retinopathy;
CESC	cis	rs10791097	0.694	rs61910787	chr11:130744473	G/A	cg12179176	chr11:130786555	SNX19	0.64	9.94	0.52	5.35e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs6558174	0.965	rs2404655	chr8:22490209	T/C	cg03733263	chr8:22462867	KIAA1967	0.46	6.32	0.36	1.08e-9	Breast cancer;
CESC	cis	rs9549367	0.577	rs3024718	chr13:113813853	C/T	cg18105134	chr13:113819100	PROZ	0.71	8.76	0.47	2.32e-16	Platelet distribution width;
CESC	cis	rs9311474	0.508	rs7652191	chr3:52610415	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.6	8.53	0.46	1.13e-15	Electroencephalogram traits;
CESC	cis	rs7666738	0.830	rs1559859	chr4:99024325	C/T	cg17366294	chr4:99064904	C4orf37	0.61	8.76	0.47	2.42e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs875971	0.789	rs10260426	chr7:65736042	G/T	cg18252515	chr7:66147081	NA	0.43	5.73	0.33	2.67e-8	Aortic root size;
CESC	cis	rs916888	0.821	rs199504	chr17:44861003	C/T	cg01570182	chr17:44337453	NA	-0.9	-10.86	-0.56	5.67e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs6460942	0.778	rs74993124	chr7:12462917	A/G	cg16278512	chr7:12443529	VWDE	-0.45	-5.13	-0.3	5.62e-7	Coronary artery disease;
CESC	cis	rs35306767	0.855	rs55697724	chr10:885622	T/C	cg26597838	chr10:835615	NA	1.18	11.37	0.57	1.12e-24	Eosinophil percentage of granulocytes;
CESC	cis	rs909674	0.865	rs5757682	chr22:39848259	T/G	cg02038168	chr22:39784481	NA	-0.63	-7.27	-0.41	4.03e-12	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs12476592	0.602	rs1446564	chr2:63731682	A/G	cg17519650	chr2:63277830	OTX1	-0.47	-5.4	-0.31	1.46e-7	Childhood ear infection;
CESC	cis	rs1030877	0.960	rs3792049	chr2:105901908	A/C	cg02079111	chr2:105885981	TGFBRAP1	-0.67	-10.47	-0.54	1.06e-21	Obesity-related traits;
CESC	cis	rs35306767	0.903	rs11253492	chr10:936873	T/C	cg20503657	chr10:835505	NA	0.82	8.47	0.46	1.66e-15	Eosinophil percentage of granulocytes;
CESC	cis	rs7647973	0.626	rs2131108	chr3:49665390	C/T	cg03060546	chr3:49711283	APEH	0.63	7.71	0.43	2.5e-13	Menarche (age at onset);
CESC	cis	rs992157	0.560	rs6738394	chr2:219110625	G/A	cg00012203	chr2:219082015	ARPC2	-0.76	-10.06	-0.53	2.22e-20	Colorectal cancer;
CESC	trans	rs11098499	1.000	rs11098500	chr4:120219239	T/A	cg25214090	chr10:38739885	LOC399744	0.68	9.36	0.5	3.61e-18	Corneal astigmatism;
CESC	cis	rs3096299	0.719	rs2911265	chr16:89511328	G/A	cg02187348	chr16:89574699	SPG7	0.63	8.78	0.47	2.04e-16	Multiple myeloma (IgH translocation);
CESC	cis	rs7666738	0.830	rs13108422	chr4:99059267	G/A	cg03676636	chr4:99064102	C4orf37	0.33	5.05	0.3	8.16e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7659604	0.676	rs7691955	chr4:122700462	A/T	cg20573242	chr4:122745356	CCNA2	0.53	6.59	0.38	2.34e-10	Type 2 diabetes;
CESC	cis	rs1862618	0.671	rs2591961	chr5:56238597	A/G	cg12311346	chr5:56204834	C5orf35	0.65	8.62	0.47	6.03e-16	Initial pursuit acceleration;
CESC	cis	rs2204008	0.682	rs2320517	chr12:38259239	A/T	cg26384229	chr12:38710491	ALG10B	0.72	10.26	0.53	5.3e-21	Bladder cancer;
CESC	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.63	7.15	0.4	8.37e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs11514810	1.000	rs11514810	chr7:1428476	C/T	cg24899294	chr7:1481343	MICALL2	-0.59	-5.2	-0.3	3.9e-7	Executive inhibition (Stroop WIT and CIT) in attention deficit hyperactivity disorder;
CESC	cis	rs35110281	0.667	rs2838354	chr21:45119857	T/C	cg21573476	chr21:45109991	RRP1B	-0.57	-8.14	-0.45	1.52e-14	Mean corpuscular volume;
CESC	cis	rs7914558	0.966	rs10883817	chr10:104755431	C/T	cg04362960	chr10:104952993	NT5C2	0.45	5.97	0.34	7.49e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs12477438	0.834	rs11903311	chr2:99701807	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.7	-10.07	-0.53	2.12e-20	Chronic sinus infection;
CESC	cis	rs3204270	0.714	rs7503307	chr17:79674929	C/G	cg26965718	chr17:79658957	HGS	-0.69	-5.21	-0.3	3.74e-7	Dental caries;
CESC	trans	rs1994135	0.654	rs1384591	chr12:33734170	T/C	cg26384229	chr12:38710491	ALG10B	0.46	6.61	0.38	2.09e-10	Resting heart rate;
CESC	cis	rs889312	0.961	rs961847	chr5:56041064	C/T	cg14703610	chr5:56206110	C5orf35	0.4	5.05	0.3	8.38e-7	Breast cancer;Breast cancer (early onset);
CESC	cis	rs17711722	0.510	rs73142128	chr7:65331109	A/C	cg18876405	chr7:65276391	NA	0.49	6.3	0.36	1.24e-9	Calcium levels;
CESC	cis	rs7267979	0.932	rs433352	chr20:25467992	C/T	cg08601574	chr20:25228251	PYGB	-0.38	-5.55	-0.32	6.77e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs1215050	0.904	rs165246	chr4:98688541	C/T	cg05340658	chr4:99064831	C4orf37	0.43	5.04	0.3	8.73e-7	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs644799	0.965	rs2950522	chr11:95524719	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.55	6.75	0.38	9.4e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs739401	0.611	rs572373	chr11:3055361	T/C	cg08508325	chr11:3079039	CARS	-0.55	-10.86	-0.55	5.83e-23	Longevity;
CESC	cis	rs2279817	0.908	rs12137775	chr1:18018927	G/T	cg21791023	chr1:18019539	ARHGEF10L	0.57	7.81	0.43	1.38e-13	Neuroticism;
CESC	cis	rs2996428	0.561	rs16824192	chr1:3748605	G/A	cg13057898	chr1:3703894	LRRC47	0.35	5.21	0.3	3.84e-7	Red cell distribution width;
CESC	cis	rs4665809	1.000	rs7599132	chr2:26279810	A/T	cg04944784	chr2:26401820	FAM59B	0.73	8.38	0.46	3.22e-15	Gut microbiome composition (summer);
CESC	cis	rs12995849	0.714	rs11124064	chr2:106458891	A/G	cg16077055	chr2:106428750	NCK2	0.4	6.17	0.35	2.58e-9	Addiction;
CESC	trans	rs208520	0.690	rs1318604	chr6:66825278	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.01	-12.92	-0.62	5.99e-30	Exhaled nitric oxide output;
CESC	cis	rs3749237	0.615	rs11130202	chr3:49566715	C/T	cg07636037	chr3:49044803	WDR6	0.6	8.82	0.48	1.6e-16	Resting heart rate;
CESC	cis	rs5498	0.809	rs2228615	chr19:10403368	G/A	cg22910295	chr19:10403862	ICAM5	0.43	6.06	0.35	4.55e-9	Lymphocyte counts;Soluble ICAM-1;Blood protein levels;
CESC	cis	rs7044106	0.791	rs4837793	chr9:123483621	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.75	11.08	0.56	1.04e-23	Hip circumference adjusted for BMI;
CESC	cis	rs10754283	0.967	rs7523518	chr1:90110010	G/A	cg21401794	chr1:90099060	LRRC8C	0.68	9.24	0.49	8.33e-18	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs9303401	0.659	rs17822837	chr17:56737838	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.95	10.87	0.56	5.36e-23	Cognitive test performance;
CESC	cis	rs1862618	0.802	rs832547	chr5:56183941	C/G	cg12311346	chr5:56204834	C5orf35	-0.74	-8.81	-0.48	1.71e-16	Initial pursuit acceleration;
CESC	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg06873352	chr17:61820015	STRADA	0.74	13.26	0.63	3.95e-31	Prudent dietary pattern;
CESC	cis	rs3820928	1.000	rs9288617	chr2:227762815	G/C	cg05526886	chr2:227700861	RHBDD1	-0.42	-5.5	-0.32	8.95e-8	Pulmonary function;
CESC	cis	rs2191566	0.576	rs393536	chr19:44493018	T/C	cg20607764	chr19:44506953	ZNF230	0.44	5.67	0.33	3.63e-8	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs832540	0.593	rs252912	chr5:56195792	C/T	cg12311346	chr5:56204834	C5orf35	-0.45	-5.52	-0.32	8.16e-8	Coronary artery disease;
CESC	cis	rs13191362	1.000	rs35723993	chr6:163008197	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.5	5.19	0.3	4.29e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs4253772	0.530	rs9615989	chr22:46803774	A/T	cg18190219	chr22:46762943	CELSR1	-0.81	-6.13	-0.35	3.12e-9	LDL cholesterol;Cholesterol, total;
CESC	cis	rs116095464	0.510	rs7723883	chr5:270798	T/C	cg22857025	chr5:266934	NA	-1.28	-18.48	-0.75	1.51e-49	Breast cancer;
CESC	cis	rs1364705	0.955	rs4871600	chr8:120226576	C/G	cg09273054	chr8:120220131	MAL2	-0.65	-7.15	-0.4	8.26e-12	Hippocampal atrophy;
CESC	cis	rs4660261	0.526	rs2906466	chr1:44322220	A/G	cg13606994	chr1:44402422	ARTN	-0.35	-5.16	-0.3	4.91e-7	Intelligence (multi-trait analysis);
CESC	cis	rs2455799	0.594	rs11128769	chr3:15926230	C/T	cg16303742	chr3:15540471	COLQ	-0.34	-5.34	-0.31	1.97e-7	Mean platelet volume;
CESC	cis	rs11711311	0.747	rs11928494	chr3:113343219	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.44	5.86	0.34	1.38e-8	IgG glycosylation;
CESC	cis	rs7843479	0.965	rs878872	chr8:21834567	A/G	cg17168535	chr8:21777572	XPO7	0.51	7.09	0.4	1.23e-11	Mean corpuscular volume;
CESC	cis	rs11792861	0.926	rs11788904	chr9:111865052	T/C	cg13535736	chr9:111863775	C9orf5	-0.5	-6.65	-0.38	1.68e-10	Menarche (age at onset);
CESC	trans	rs1728785	1.000	rs1364109	chr16:68595505	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.65	7.84	0.43	1.09e-13	Ulcerative colitis;
CESC	cis	rs72387598	1	rs72387598	chr1:45922977	CAT/C	cg06784218	chr1:46089804	CCDC17	0.35	5.52	0.32	8.19e-8	Platelet distribution width;
CESC	cis	rs2549003	0.966	rs2706385	chr5:131831766	T/G	cg21138405	chr5:131827807	IRF1	-0.6	-10.45	-0.54	1.29e-21	Asthma (sex interaction);
CESC	cis	rs1862618	0.713	rs832549	chr5:56183542	C/T	cg03609598	chr5:56110824	MAP3K1	-0.52	-5.5	-0.32	8.78e-8	Initial pursuit acceleration;
CESC	cis	rs6570726	0.791	rs6914203	chr6:145899975	C/A	cg05347473	chr6:146136440	FBXO30	0.54	7.13	0.4	9.5e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6788895	0.661	rs1533711	chr3:150469996	C/T	cg09723797	chr3:150481914	SIAH2	-0.62	-5.56	-0.32	6.42e-8	Breast cancer;
CESC	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg26338869	chr17:61819248	STRADA	0.69	9.08	0.49	2.62e-17	Prudent dietary pattern;
CESC	cis	rs2075371	0.932	rs1862048	chr7:133978167	C/G	cg22540129	chr7:134855664	C7orf49	0.41	5.19	0.3	4.21e-7	Mean platelet volume;
CESC	cis	rs35110281	0.805	rs4818855	chr21:45038951	C/T	cg21573476	chr21:45109991	RRP1B	-0.41	-5.75	-0.33	2.47e-8	Mean corpuscular volume;
CESC	cis	rs7649275	0.882	rs2612023	chr3:53780217	T/C	cg21503701	chr3:53781065	CACNA1D	-0.4	-5.28	-0.31	2.66e-7	Trans fatty acid levels;
CESC	cis	rs853679	0.550	rs1237875	chr6:28173010	A/G	cg18032046	chr6:28092343	ZSCAN16	0.52	6.13	0.35	3.12e-9	Depression;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg09529023	chr16:2097506	TSC2;NTHL1	-0.41	-6.17	-0.35	2.61e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs477692	0.647	rs524804	chr10:131430686	G/A	cg24747557	chr10:131355152	MGMT	0.38	5.5	0.32	9.16e-8	Response to temozolomide;
CESC	cis	rs11677416	1.000	rs2856837	chr2:113541925	G/A	cg27083787	chr2:113543245	IL1A	0.61	7.53	0.42	7.75e-13	Response to antipsychotic treatment in schizophrenia (working memory);
CESC	cis	rs7824557	0.583	rs6601585	chr8:11233659	A/G	cg21775007	chr8:11205619	TDH	-0.55	-8.22	-0.45	9.13e-15	Retinal vascular caliber;
CESC	trans	rs17536732	0.685	rs113735807	chr4:162851661	T/A	cg12177677	chr2:158300475	CYTIP	-0.64	-6.25	-0.36	1.62e-9	Risky sexual behaviors (alcohol dependence interaction);
CESC	cis	rs9287719	0.935	rs61424402	chr2:10758371	T/A	cg00105475	chr2:10696890	NA	0.39	5.65	0.33	4.2e-8	Prostate cancer;
CESC	cis	rs2842992	0.830	rs2842974	chr6:160159034	C/T	cg11366901	chr6:160182831	ACAT2	0.8	10.56	0.54	5.43e-22	Age-related macular degeneration (geographic atrophy);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25721516	chr17:42276931	ATXN7L3	0.55	6.02	0.35	5.8e-9	Gut microbiome composition (summer);
CESC	cis	rs875971	0.545	rs4718335	chr7:65804606	C/T	cg18876405	chr7:65276391	NA	0.47	5.25	0.31	3.18e-7	Aortic root size;
CESC	cis	rs12926788	0.640	rs73551577	chr16:24845143	G/A	cg06028605	chr16:24865363	SLC5A11	0.55	8.31	0.45	5.1e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs9322193	0.923	rs2185352	chr6:150035776	T/G	cg13206674	chr6:150067644	NUP43	0.46	6.65	0.38	1.63e-10	Lung cancer;
CESC	cis	rs67311347	0.955	rs12487955	chr3:40412853	T/C	cg09455208	chr3:40491958	NA	0.53	9.01	0.48	4.18e-17	Renal cell carcinoma;
CESC	cis	rs2228479	0.850	rs17227064	chr16:89816314	A/G	cg00800038	chr16:89945340	TCF25	-0.91	-7.54	-0.42	7.39e-13	Skin colour saturation;
CESC	cis	rs12497850	0.931	rs9876848	chr3:48844059	G/A	cg06212747	chr3:49208901	KLHDC8B	0.64	8.55	0.46	9.98e-16	Parkinson's disease;
CESC	trans	rs2115172	0.836	rs4835799	chr5:122762229	A/G	cg23901904	chr1:10855062	CASZ1	0.47	6.23	0.36	1.87e-9	Weight;
CESC	cis	rs9894429	0.621	rs7502337	chr17:79588470	T/C	cg18240062	chr17:79603768	NPLOC4	0.5	6.56	0.37	2.89e-10	Eye color traits;
CESC	cis	rs4236601	0.586	rs6466581	chr7:116162985	T/A	cg12739419	chr7:116140593	CAV2	-0.3	-5.13	-0.3	5.56e-7	Intraocular pressure;Glaucoma (primary open-angle);
CESC	cis	rs9911578	1.000	rs11870671	chr17:56605360	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	-0.41	-5.53	-0.32	7.63e-8	Intelligence (multi-trait analysis);
CESC	cis	rs10504229	1.000	rs72650899	chr8:58180525	G/T	cg22535103	chr8:58192502	C8orf71	-1.05	-13.27	-0.63	3.63e-31	Developmental language disorder (linguistic errors);
CESC	cis	rs3091242	0.933	rs34933589	chr1:25788198	T/C	cg27572855	chr1:25598939	RHD	-0.43	-7.06	-0.4	1.42e-11	Erythrocyte sedimentation rate;
CESC	trans	rs7246657	0.943	rs6508711	chr19:37815134	G/T	cg24637308	chr11:6592297	DNHD1	0.53	6.24	0.36	1.74e-9	Coronary artery calcification;
CESC	cis	rs910316	1.000	rs2098297	chr14:75619118	G/T	cg16144293	chr14:75469539	EIF2B2	0.39	5.03	0.3	9.09e-7	Height;
CESC	cis	rs72945132	1.000	rs56913804	chr11:70114673	G/A	cg00319359	chr11:70116639	PPFIA1	0.84	8.25	0.45	7.56e-15	Coronary artery disease;
CESC	cis	rs17209837	0.607	rs4148820	chr7:87080482	T/C	cg00919237	chr7:87102261	ABCB4	-0.48	-6.31	-0.36	1.17e-9	Gallbladder cancer;
CESC	cis	rs9733	0.596	rs11204704	chr1:150671630	T/C	cg09365446	chr1:150670422	GOLPH3L	0.42	5.88	0.34	1.23e-8	Tonsillectomy;
CESC	cis	rs7116495	1.000	rs4945435	chr11:71759219	C/T	cg26138937	chr11:71823887	C11orf51	-0.82	-6.93	-0.39	3.24e-11	Severe influenza A (H1N1) infection;
CESC	cis	rs9309473	1.000	rs1114380	chr2:73804708	A/G	cg20560298	chr2:73613845	ALMS1	-0.55	-7.22	-0.41	5.49e-12	Metabolite levels;
CESC	cis	rs8077889	1.000	rs8077889	chr17:41878166	G/T	cg26893861	chr17:41843967	DUSP3	-0.64	-7.71	-0.43	2.56e-13	Triglycerides;
CESC	cis	rs7089973	0.604	rs7904188	chr10:116610271	G/C	cg03647239	chr10:116582469	FAM160B1	0.43	5.35	0.31	1.94e-7	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs17125944	0.686	rs7143400	chr14:53324891	A/C	cg00686598	chr14:53173677	PSMC6	-0.67	-5.71	-0.33	3.04e-8	Alzheimer's disease (late onset);
CESC	cis	rs17376456	0.932	rs3940842	chr5:93534858	C/A	cg21475434	chr5:93447410	FAM172A	0.89	7.75	0.43	2e-13	Diabetic retinopathy;
CESC	cis	rs12618769	0.597	rs11884553	chr2:99131206	T/C	cg10123293	chr2:99228465	UNC50	0.4	5.38	0.31	1.64e-7	Bipolar disorder;
CESC	cis	rs7618915	0.508	rs13065851	chr3:52644836	T/A	cg17372223	chr3:52568218	NT5DC2	0.43	6.3	0.36	1.25e-9	Bipolar disorder;
CESC	cis	rs66573146	0.808	rs55942328	chr4:6990960	T/G	cg00086871	chr4:6988644	TBC1D14	1.18	7.59	0.42	5.45e-13	Granulocyte percentage of myeloid white cells;
CESC	cis	rs6502050	0.835	rs7208673	chr17:80165908	G/C	cg23985595	chr17:80112537	CCDC57	-0.4	-6.37	-0.36	8.19e-10	Life satisfaction;
CESC	cis	rs698833	0.926	rs1067342	chr2:44622256	A/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.51	6.59	0.38	2.33e-10	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs2708240	0.666	rs2710117	chr7:147601772	T/A	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.35	-5.77	-0.33	2.18e-8	QT interval (drug interaction);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg13069247	chr12:100967381	GAS2L3	0.47	6.04	0.35	5.06e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs4253772	0.530	rs9615362	chr22:46795141	A/C	cg18190219	chr22:46762943	CELSR1	0.47	5.83	0.34	1.62e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs12956009	0.518	rs11663852	chr18:44887542	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.52	6.81	0.39	6.63e-11	Educational attainment (years of education);
CESC	cis	rs546131	0.890	rs485845	chr11:34830389	G/T	cg06937548	chr11:34938143	PDHX;APIP	-0.48	-5.75	-0.33	2.39e-8	Lung disease severity in cystic fibrosis;
CESC	trans	rs11098499	0.564	rs11098507	chr4:120288286	G/A	cg25214090	chr10:38739885	LOC399744	0.65	9.1	0.49	2.26e-17	Corneal astigmatism;
CESC	cis	rs2710642	0.611	rs6752010	chr2:62859042	C/T	cg17519650	chr2:63277830	OTX1	-0.47	-5.52	-0.32	8.17e-8	LDL cholesterol levels;LDL cholesterol;
CESC	cis	rs36051895	0.589	rs62543574	chr9:5204090	A/T	cg02405213	chr9:5042618	JAK2	-0.49	-5.69	-0.33	3.41e-8	Pediatric autoimmune diseases;
CESC	cis	rs1865721	0.958	rs57073257	chr18:73172316	A/G	cg26385618	chr18:73139727	C18orf62	-0.43	-6.46	-0.37	4.93e-10	Intelligence;
CESC	cis	rs12618769	0.597	rs17033136	chr2:99149404	C/T	cg10123293	chr2:99228465	UNC50	-0.38	-5.04	-0.3	8.8e-7	Bipolar disorder;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg00327537	chr2:74406064	MOBKL1B	0.45	6.22	0.36	1.96e-9	Thyroid stimulating hormone;
CESC	cis	rs2040771	0.745	rs361956	chr22:19265799	C/T	cg17887427	chr22:19166691	SLC25A1	-0.39	-5.05	-0.3	8.28e-7	Metabolite levels (small molecules and protein measures);
CESC	cis	rs60871478	0.786	rs55899111	chr7:827843	C/G	cg00934597	chr7:893267	UNC84A	-0.51	-5.22	-0.31	3.63e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs929354	0.742	rs886677	chr7:157003782	T/A	cg05182265	chr7:156933206	UBE3C	-0.49	-7.25	-0.41	4.51e-12	Body mass index;
CESC	cis	rs8067354	0.830	rs57510610	chr17:57889406	T/A	cg02344993	chr17:57696989	CLTC	0.48	6.3	0.36	1.2e-9	Hemoglobin concentration;
CESC	cis	rs9487051	0.872	rs9487042	chr6:109610443	T/G	cg01475377	chr6:109611718	NA	-0.51	-8.36	-0.46	3.66e-15	Reticulocyte fraction of red cells;
CESC	cis	rs2239547	0.618	rs1573815	chr3:52870132	A/G	cg11645453	chr3:52864694	ITIH4	-0.36	-6.61	-0.38	2.16e-10	Schizophrenia;
CESC	cis	rs155076	0.666	rs9509640	chr13:21872880	T/C	cg11317459	chr13:21872234	NA	1.2	15.22	0.68	5.27e-38	White matter hyperintensity burden;
CESC	cis	rs2820292	0.595	rs4950796	chr1:201835409	G/A	cg11586189	chr1:201857591	SHISA4	-0.36	-5.65	-0.33	4.18e-8	Waist circumference;Body mass index (joint analysis main effects and smoking interaction);Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);
CESC	cis	rs11608355	0.515	rs12579916	chr12:109924528	T/G	cg05360138	chr12:110035743	NA	0.81	8.75	0.47	2.52e-16	Neuroticism;
CESC	cis	rs1957429	0.808	rs11628910	chr14:65332392	A/G	cg23373153	chr14:65346875	NA	0.88	9.2	0.49	1.13e-17	Pediatric areal bone mineral density (radius);
CESC	cis	rs71277158	0.688	rs77216745	chr3:169913020	A/T	cg04067573	chr3:169899625	PHC3	0.67	6.4	0.37	7.18e-10	Prostate cancer;
CESC	cis	rs548181	1.000	rs548181	chr11:125461709	A/G	cg03464685	chr11:125439445	EI24	1.09	8.83	0.48	1.43e-16	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs568617	0.859	rs1204650	chr11:65645580	A/C	cg00576331	chr11:65640516	EFEMP2	0.45	5.3	0.31	2.48e-7	Crohn's disease;
CESC	cis	rs8040855	0.658	rs11634877	chr15:85611477	G/A	cg08123816	chr15:85640762	PDE8A	-0.41	-6.01	-0.35	6.21e-9	Bulimia nervosa;
CESC	cis	rs2991971	0.967	rs644915	chr1:46007002	T/C	cg03146154	chr1:46216737	IPP	-0.44	-5.58	-0.32	5.84e-8	High light scatter reticulocyte count;
CESC	cis	rs12545109	0.800	rs2610058	chr8:57409120	G/A	cg09654669	chr8:57350985	NA	-0.56	-6.65	-0.38	1.67e-10	Obesity-related traits;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg03670158	chr17:41323431	NBR1	-0.43	-6.24	-0.36	1.73e-9	Gambling;
CESC	cis	rs12477438	0.501	rs2632284	chr2:99775865	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.86	15.08	0.68	1.62e-37	Chronic sinus infection;
CESC	cis	rs3749237	0.595	rs1464567	chr3:49459252	C/G	cg03060546	chr3:49711283	APEH	-0.73	-10.79	-0.55	9.43e-23	Resting heart rate;
CESC	cis	rs2456568	0.900	rs1518571	chr11:93667420	C/A	cg26875233	chr11:93583750	C11orf90	-0.29	-5.07	-0.3	7.58e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
CESC	cis	rs763121	0.819	rs8137829	chr22:39061030	G/A	cg14440974	chr22:39074834	NA	-0.4	-5.5	-0.32	9.03e-8	Menopause (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09138430	chr7:44084267	DBNL	0.61	7.24	0.41	4.98e-12	Gut microbiome composition (summer);
CESC	cis	rs4629180	1.000	rs6744495	chr2:102099956	T/C	cg04415270	chr2:102091202	RFX8	-0.46	-7.4	-0.41	1.76e-12	Chronic rhinosinusitis with nasal polyps;
CESC	cis	rs769267	0.930	rs3794990	chr19:19610030	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.59	7.48	0.42	1.1e-12	Tonsillectomy;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg03146079	chr4:2929622	ADD1	0.53	7.12	0.4	1.02e-11	Fibrinogen levels;
CESC	cis	rs7809799	0.850	rs2395051	chr7:98761201	A/G	cg05967295	chr7:98741636	SMURF1	-0.77	-5.41	-0.32	1.37e-7	Ulcerative colitis;
CESC	cis	rs853679	0.607	rs201002	chr6:27808192	A/G	cg02228804	chr6:27775720	HIST1H2AI;HIST1H2BL	0.62	5.92	0.34	1.01e-8	Depression;
CESC	cis	rs9929218	0.817	rs3114402	chr16:68719607	C/T	cg02972257	chr16:68554789	NA	0.57	6.52	0.37	3.59e-10	Colorectal cancer;
CESC	cis	rs4689388	0.926	rs11732178	chr4:6292643	G/C	cg00701064	chr4:6280414	WFS1	0.74	13.26	0.63	4.04e-31	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs3026101	0.671	rs13341936	chr17:5298858	A/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.46	6.14	0.35	2.97e-9	Body mass index;
CESC	cis	rs1799949	1.000	rs16940	chr17:41245237	A/G	cg23758822	chr17:41437982	NA	0.99	14.89	0.68	7.27e-37	Menopause (age at onset);
CESC	cis	rs6582630	0.519	rs7305570	chr12:38349285	G/A	cg13010199	chr12:38710504	ALG10B	0.48	6.06	0.35	4.62e-9	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs6460942	0.749	rs62448592	chr7:12435985	A/T	cg20607287	chr7:12443886	VWDE	-0.77	-9.04	-0.49	3.38e-17	Coronary artery disease;
CESC	cis	rs4665809	0.556	rs4665322	chr2:26434605	C/G	cg22920501	chr2:26401640	FAM59B	-0.96	-11.86	-0.59	2.62e-26	Gut microbiome composition (summer);
CESC	cis	rs4253772	0.530	rs9615958	chr22:46751122	A/G	cg10541313	chr22:46663664	TTC38	0.7	5.34	0.31	2.02e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs6120849	0.707	rs6120826	chr20:33671831	G/A	cg24642439	chr20:33292090	TP53INP2	0.67	6.62	0.38	1.94e-10	Protein C levels;
CESC	cis	rs11577318	0.853	rs17645	chr1:26646730	A/G	cg00852783	chr1:26633632	UBXN11	0.49	6.82	0.39	6.07e-11	Granulocyte percentage of myeloid white cells;
CESC	cis	rs9527	0.637	rs11191424	chr10:104625886	G/A	cg15744005	chr10:104629667	AS3MT	-0.4	-6.01	-0.35	6.14e-9	Arsenic metabolism;
CESC	cis	rs76419734	0.510	rs2553446	chr4:106696476	G/A	cg24545054	chr4:106630052	GSTCD;INTS12	-0.58	-6.04	-0.35	5.28e-9	Post bronchodilator FEV1;
CESC	cis	rs13256369	0.901	rs13251887	chr8:8568678	G/A	cg17143192	chr8:8559678	CLDN23	0.71	7.99	0.44	4.15e-14	Obesity-related traits;
CESC	cis	rs3741151	0.881	rs7951174	chr11:73093135	G/C	cg17517138	chr11:73019481	ARHGEF17	0.8	5.54	0.32	7.25e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs7666738	0.716	rs6817529	chr4:99023213	T/C	cg05340658	chr4:99064831	C4orf37	0.82	12.99	0.62	3.34e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10540	0.730	rs34690033	chr11:492677	G/C	cg03352830	chr11:487213	PTDSS2	0.69	6.72	0.38	1.13e-10	Body mass index;
CESC	cis	rs7927771	0.524	rs7101597	chr11:47797917	A/T	cg20307385	chr11:47447363	PSMC3	0.62	8.69	0.47	3.96e-16	Subjective well-being;
CESC	cis	rs9300255	0.602	rs1716172	chr12:123712712	G/T	cg00376283	chr12:123451042	ABCB9	0.71	8.87	0.48	1.15e-16	Neutrophil percentage of white cells;
CESC	cis	rs12681288	0.676	rs2701913	chr8:999982	A/T	cg15309053	chr8:964076	NA	0.39	6.6	0.38	2.24e-10	Schizophrenia;
CESC	cis	rs4689388	0.791	rs1046317	chr4:6304242	T/C	cg14416269	chr4:6271139	WFS1	0.42	6.48	0.37	4.33e-10	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs11997175	0.838	rs10954934	chr8:33669637	T/C	ch.8.33884649F	chr8:33765107	NA	0.58	7.12	0.4	1.04e-11	Body mass index;
CESC	cis	rs4595586	0.545	rs12827197	chr12:39404362	C/T	cg26384229	chr12:38710491	ALG10B	0.54	7.64	0.42	3.96e-13	Morning vs. evening chronotype;
CESC	cis	rs4689592	0.513	rs4689586	chr4:7067413	A/G	cg19539972	chr4:7069911	GRPEL1	0.77	9.71	0.51	2.99e-19	Monocyte percentage of white cells;
CESC	cis	rs798554	0.757	rs1182177	chr7:2874540	C/T	cg19346786	chr7:2764209	NA	-0.46	-6.59	-0.38	2.34e-10	Height;
CESC	cis	rs172166	0.694	rs1225716	chr6:28113746	A/C	cg23161317	chr6:28129485	ZNF389	0.39	5.45	0.32	1.17e-7	Cardiac Troponin-T levels;
CESC	cis	rs9488822	0.596	rs13206506	chr6:116324460	A/G	cg15226275	chr6:116381976	FRK	0.23	5.54	0.32	7.24e-8	Cholesterol, total;LDL cholesterol;
CESC	cis	rs7617773	0.817	rs9837228	chr3:48324466	A/T	cg11946769	chr3:48343235	NME6	-0.82	-11.36	-0.57	1.24e-24	Coronary artery disease;
CESC	trans	rs7142881	0.508	rs1954441	chr14:32118713	A/G	cg10452522	chr19:34663544	LSM14A	-0.42	-6.11	-0.35	3.53e-9	Response to iloperidone treatment (QT prolongation);
CESC	cis	rs7809950	1.000	rs10243340	chr7:107090955	A/G	cg23024343	chr7:107201750	COG5	-0.4	-5.63	-0.33	4.51e-8	Coronary artery disease;
CESC	cis	rs9311474	0.713	rs352167	chr3:52238656	C/T	cg07507251	chr3:52567010	NT5DC2	-0.35	-6.34	-0.36	9.9e-10	Electroencephalogram traits;
CESC	cis	rs1008375	1.000	rs10805357	chr4:17652352	G/A	cg02297831	chr4:17616191	MED28	0.53	6.71	0.38	1.2e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs4819052	0.851	rs4818768	chr21:46659818	T/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.75	9.98	0.52	4.1e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs6424115	0.830	rs2229585	chr1:24200921	T/C	cg10978503	chr1:24200527	CNR2	0.33	6.64	0.38	1.73e-10	Immature fraction of reticulocytes;
CESC	cis	rs9611565	0.659	rs9607815	chr22:41950671	A/T	cg06634786	chr22:41940651	POLR3H	-0.65	-6.78	-0.38	7.73e-11	Vitiligo;
CESC	cis	rs6952808	0.823	rs58222895	chr7:1885064	G/A	cg05863683	chr7:1912471	MAD1L1	0.37	5.38	0.31	1.64e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs6762477	0.748	rs11711407	chr3:50225029	A/G	cg24308560	chr3:49941425	MST1R	0.4	5.07	0.3	7.31e-7	Menarche (age at onset);
CESC	cis	rs5753618	0.509	rs1034589	chr22:31579233	C/T	cg13145458	chr22:31556086	RNF185	0.45	5.05	0.3	8.36e-7	Colorectal cancer;
CESC	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg07414643	chr4:187882934	NA	-0.47	-6.76	-0.38	8.84e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs12497850	0.931	rs6446205	chr3:49035211	C/T	cg06212747	chr3:49208901	KLHDC8B	0.69	9.19	0.49	1.22e-17	Parkinson's disease;
CESC	cis	rs854765	0.565	rs4072738	chr17:17884547	A/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.48	6.76	0.38	9.02e-11	Total body bone mineral density;
CESC	cis	rs1707322	0.721	rs9793568	chr1:46130373	G/A	cg03146154	chr1:46216737	IPP	0.82	11.52	0.58	3.64e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs6570726	0.791	rs9376953	chr6:145912226	G/T	cg05347473	chr6:146136440	FBXO30	0.57	7.24	0.41	4.72e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg17178900	chr1:205818956	PM20D1	0.88	15.71	0.69	9.2e-40	Menarche (age at onset);
CESC	cis	rs9341808	1.000	rs9341808	chr6:80953257	C/A	cg08355045	chr6:80787529	NA	0.31	5.04	0.3	8.66e-7	Sitting height ratio;
CESC	cis	rs12681366	0.734	rs16916802	chr8:95409508	T/C	cg13257157	chr8:95487014	RAD54B	0.37	5.09	0.3	6.85e-7	Nonsyndromic cleft lip with cleft palate;
CESC	trans	rs7819412	0.740	rs7844536	chr8:11034028	A/G	cg15556689	chr8:8085844	FLJ10661	-0.59	-6.89	-0.39	4.04e-11	Triglycerides;
CESC	cis	rs9913156	0.515	rs11658808	chr17:4577112	C/T	cg19197139	chr17:4613644	ARRB2	-0.63	-7.61	-0.42	4.88e-13	Lymphocyte counts;
CESC	cis	rs9457247	0.534	rs4710154	chr6:167394634	A/T	cg23791538	chr6:167370224	RNASET2	0.69	9.95	0.52	4.97e-20	Crohn's disease;
CESC	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg07157834	chr1:205819609	PM20D1	0.69	10.26	0.53	5.31e-21	Menarche (age at onset);
CESC	cis	rs36051895	0.659	rs1322224	chr9:5267889	C/A	cg02405213	chr9:5042618	JAK2	-0.48	-5.73	-0.33	2.73e-8	Pediatric autoimmune diseases;
CESC	cis	rs7937682	0.847	rs11213948	chr11:111464401	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.9	-12.87	-0.62	9.33e-30	Primary sclerosing cholangitis;
CESC	cis	rs9733	0.596	rs12089731	chr1:150647798	T/C	cg17724175	chr1:150552817	MCL1	0.44	7.23	0.41	5.25e-12	Tonsillectomy;
CESC	cis	rs9902453	0.833	rs7216631	chr17:28495112	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.65	8.43	0.46	2.29e-15	Coffee consumption (cups per day);
CESC	cis	rs796364	0.806	rs112305133	chr2:201010380	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.64	-6.04	-0.35	5.26e-9	Schizophrenia;
CESC	cis	rs2279817	0.675	rs1416853	chr1:18024880	G/C	cg21791023	chr1:18019539	ARHGEF10L	0.53	7.75	0.43	1.98e-13	Neuroticism;
CESC	cis	rs2249694	0.803	rs3020501	chr10:135381592	C/G	cg20169779	chr10:135381914	SYCE1	0.4	5.66	0.33	3.91e-8	Obesity-related traits;
CESC	cis	rs6500395	1.000	rs7187513	chr16:48591638	T/C	cg04672837	chr16:48644449	N4BP1	0.5	6.23	0.36	1.78e-9	Response to tocilizumab in rheumatoid arthritis;
CESC	trans	rs11658311	0.850	rs11651383	chr17:17657478	C/T	cg01883427	chr16:15242839	NA	0.6	6.31	0.36	1.17e-9	Obsessive-compulsive symptoms;
CESC	cis	rs5753037	0.653	rs131277	chr22:30154101	C/A	cg01021169	chr22:30184971	ASCC2	-0.45	-6.32	-0.36	1.11e-9	Type 1 diabetes;
CESC	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.89	13.62	0.64	2.27e-32	Prudent dietary pattern;
CESC	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg03188948	chr7:1209495	NA	0.68	6.75	0.38	9.19e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs854765	0.547	rs7212167	chr17:17913504	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.56	7.96	0.44	5.18e-14	Total body bone mineral density;
CESC	cis	rs12142240	0.698	rs66972124	chr1:46807445	A/G	cg00530320	chr1:46809349	NSUN4	0.6	7.98	0.44	4.48e-14	Menopause (age at onset);
CESC	cis	rs896854	1.000	rs7003387	chr8:95961979	C/G	cg16049864	chr8:95962084	TP53INP1	-0.72	-13.04	-0.63	2.36e-30	Type 2 diabetes;
CESC	cis	rs703842	1.000	rs10431505	chr12:58178589	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.7	9.07	0.49	2.69e-17	Multiple sclerosis;
CESC	cis	rs3796352	1.000	rs11707780	chr3:53084326	A/G	cg12962167	chr3:53033115	SFMBT1	-0.57	-5.99	-0.35	6.67e-9	Immune reponse to smallpox (secreted IL-2);
CESC	cis	rs875971	1.000	rs2420168	chr7:65630631	C/G	cg12463550	chr7:65579703	CRCP	-0.57	-7.35	-0.41	2.54e-12	Aortic root size;
CESC	cis	rs9596863	0.851	rs1379832	chr13:54429818	C/T	ch.13.53330881F	chr13:54432880	NA	0.66	5.25	0.31	3.08e-7	Epilepsy and lamotrigine-induced maculopapular eruptions;
CESC	cis	rs9311474	0.607	rs11711421	chr3:52561779	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.39	7.14	0.4	9.08e-12	Electroencephalogram traits;
CESC	cis	rs2011503	1.000	rs11670761	chr19:19649327	G/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.52	5.09	0.3	6.68e-7	Bipolar disorder;
CESC	cis	rs4481887	0.927	rs4517383	chr1:248426484	C/T	cg00666640	chr1:248458726	OR2T12	0.36	6.26	0.36	1.55e-9	Common traits (Other);
CESC	cis	rs3806843	1.000	rs3806845	chr5:140180737	C/T	cg16179182	chr5:140090404	VTRNA1-1	-0.4	-5.16	-0.3	4.96e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs2820292	0.710	rs2047264	chr1:201886402	C/T	cg11586189	chr1:201857591	SHISA4	0.32	5.33	0.31	2.11e-7	Waist circumference;Body mass index (joint analysis main effects and smoking interaction);Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);
CESC	cis	rs9300255	0.722	rs10846515	chr12:123801672	T/G	cg19016782	chr12:123741754	C12orf65	-0.43	-6.0	-0.35	6.54e-9	Neutrophil percentage of white cells;
CESC	cis	rs9926296	0.624	rs1110331	chr16:89774396	A/G	cg03605463	chr16:89740564	NA	0.47	5.95	0.34	8.51e-9	Vitiligo;
CESC	cis	rs7937682	0.663	rs7116280	chr11:111659111	T/C	cg22437258	chr11:111473054	SIK2	-0.51	-5.44	-0.32	1.18e-7	Primary sclerosing cholangitis;
CESC	cis	rs910316	0.726	rs61979167	chr14:75663610	C/T	cg11812906	chr14:75593930	NEK9	-0.78	-12.28	-0.6	9.89e-28	Height;
CESC	cis	rs10979	1.000	rs9496673	chr6:143885393	C/G	cg25407410	chr6:143891975	LOC285740	-0.62	-9.51	-0.5	1.21e-18	Hypospadias;
CESC	trans	rs116095464	0.850	rs10055295	chr5:243749	G/A	cg00938859	chr5:1591904	SDHAP3	0.64	6.98	0.39	2.36e-11	Breast cancer;
CESC	cis	rs1008375	1.000	rs4235388	chr4:17682030	G/A	cg02297831	chr4:17616191	MED28	0.45	5.74	0.33	2.6e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs7312774	0.618	rs7979117	chr12:107345883	C/T	cg16260113	chr12:107380972	MTERFD3	0.8	7.35	0.41	2.42e-12	Severe influenza A (H1N1) infection;
CESC	cis	rs10779751	1.000	rs11121711	chr1:11317661	A/T	cg08854313	chr1:11322531	MTOR	0.84	11.96	0.59	1.16e-26	Body mass index;
CESC	cis	rs9354308	1.000	rs9360161	chr6:66565457	C/T	cg07460842	chr6:66804631	NA	0.51	6.16	0.35	2.64e-9	Metabolite levels;
CESC	cis	rs965469	0.901	rs6139080	chr20:3314506	A/G	cg25506879	chr20:3388711	C20orf194	-0.51	-5.65	-0.33	4.06e-8	IFN-related cytopenia;
CESC	cis	rs11638352	0.661	rs2706492	chr15:44423846	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	-0.56	-5.29	-0.31	2.53e-7	Lipoprotein phospholipase A2 activity in cardiovascular disease;
CESC	cis	rs1862618	0.802	rs252900	chr5:56185281	T/A	cg03609598	chr5:56110824	MAP3K1	-0.51	-5.32	-0.31	2.22e-7	Initial pursuit acceleration;
CESC	cis	rs28647808	0.786	rs4962136	chr9:136256794	A/G	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.85	5.74	0.33	2.59e-8	Blood protein levels;
CESC	cis	rs1008375	1.000	rs1121090	chr4:17676437	C/G	cg16339924	chr4:17578868	LAP3	0.51	6.44	0.37	5.73e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg02475777	chr4:1388615	CRIPAK	-0.71	-8.98	-0.48	5.19e-17	Longevity;
CESC	cis	rs7296418	0.663	rs28450974	chr12:123861420	G/A	cg00376283	chr12:123451042	ABCB9	0.58	7.83	0.43	1.16e-13	Platelet count;
CESC	cis	rs6728642	0.708	rs115507803	chr2:97752054	T/C	cg26665480	chr2:98280029	ACTR1B	-0.84	-6.63	-0.38	1.83e-10	Bipolar disorder lithium response (continuous) or schizophrenia;
CESC	cis	rs1008375	0.900	rs4698622	chr4:17589557	C/T	cg27347728	chr4:17578864	LAP3	0.49	5.61	0.33	5.07e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs734999	0.505	rs4073286	chr1:2539901	A/C	cg18854424	chr1:2615690	NA	0.3	5.97	0.34	7.58e-9	Ulcerative colitis;
CESC	cis	rs796364	0.806	rs34510964	chr2:201010676	C/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.64	-6.04	-0.35	5.26e-9	Schizophrenia;
CESC	cis	rs1048257	0.553	rs2819421	chr14:105408811	A/G	cg20257916	chr14:105219517	SIVA1	0.41	5.18	0.3	4.38e-7	Systemic lupus erythematosus;
CESC	cis	rs2836974	0.799	rs13047550	chr21:40515495	T/C	cg11644478	chr21:40555479	PSMG1	0.93	13.15	0.63	9.78e-31	Cognitive function;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07135626	chr7:73588538	EIF4H	0.58	6.65	0.38	1.62e-10	Gut microbiome composition (summer);
CESC	cis	rs11048434	0.698	rs10842537	chr12:9066158	T/C	cg04155231	chr12:9217510	LOC144571	0.33	5.35	0.31	1.9e-7	Sjögren's syndrome;
CESC	trans	rs7246657	0.714	rs12972195	chr19:37752505	T/C	cg01833234	chr11:6592585	DNHD1	0.52	6.03	0.35	5.59e-9	Coronary artery calcification;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg19996838	chr1:244211323	NA	0.52	6.81	0.39	6.37e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs7552404	0.924	rs3818855	chr1:76198785	C/T	cg03433033	chr1:76189801	ACADM	0.75	10.47	0.54	1.06e-21	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs2440129	0.611	rs1126667	chr17:6902760	C/T	cg03407747	chr17:6899364	ALOX12	-0.5	-8.79	-0.47	1.99e-16	Tonsillectomy;
CESC	cis	rs12540874	0.794	rs1470750	chr7:50576648	C/G	cg18232548	chr7:50535776	DDC	-0.41	-5.5	-0.32	8.91e-8	Systemic sclerosis;
CESC	cis	rs12681288	0.550	rs72507624	chr8:961324	G/A	cg15309053	chr8:964076	NA	0.55	9.11	0.49	2.08e-17	Schizophrenia;
CESC	cis	rs9393777	0.513	rs3999471	chr6:26650306	T/C	cg14345882	chr6:26364793	BTN3A2	0.41	5.12	0.3	5.79e-7	Intelligence (multi-trait analysis);
CESC	cis	rs7666738	0.830	rs10012167	chr4:99048579	T/C	cg18180107	chr4:99064573	C4orf37	0.41	5.29	0.31	2.51e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs453301	0.653	rs11784393	chr8:8903134	C/T	cg06636001	chr8:8085503	FLJ10661	0.51	6.54	0.37	3.19e-10	Joint mobility (Beighton score);
CESC	cis	rs2243480	0.803	rs34804747	chr7:65412942	G/C	cg18252515	chr7:66147081	NA	-1.01	-9.32	-0.5	4.6e-18	Diabetic kidney disease;
CESC	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	10.4	0.54	1.87e-21	Prudent dietary pattern;
CESC	cis	rs2479724	0.846	rs2254805	chr6:41846110	T/G	cg08135965	chr6:41755394	TOMM6	0.41	5.52	0.32	8.22e-8	Menarche (age at onset);
CESC	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg11494091	chr17:61959527	GH2	0.72	12.38	0.61	4.46e-28	Prudent dietary pattern;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24856420	chr20:46130460	NCOA3	0.56	6.63	0.38	1.92e-10	Gut microbiome composition (summer);
CESC	cis	rs1215050	0.904	rs260898	chr4:98706492	C/G	cg05340658	chr4:99064831	C4orf37	-0.45	-5.21	-0.3	3.79e-7	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs875971	1.000	rs3735148	chr7:65971009	T/G	cg12463550	chr7:65579703	CRCP	0.56	7.05	0.4	1.52e-11	Aortic root size;
CESC	cis	rs17253792	0.822	rs112739186	chr14:56065167	A/T	cg01858014	chr14:56050164	KTN1	-0.96	-7.13	-0.4	9.72e-12	Putamen volume;
CESC	cis	rs1862618	0.853	rs252919	chr5:56124111	T/C	cg24531977	chr5:56204891	C5orf35	-0.88	-11.15	-0.57	6.07e-24	Initial pursuit acceleration;
CESC	cis	rs7666738	0.830	rs13122054	chr4:98972974	G/A	cg18180107	chr4:99064573	C4orf37	0.39	5.05	0.3	8.12e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1799949	1.000	rs3092994	chr17:41215825	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.64	8.64	0.47	5.5e-16	Menopause (age at onset);
CESC	cis	rs2576037	0.583	rs8086286	chr18:44467515	A/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.36	-5.7	-0.33	3.21e-8	Personality dimensions;
CESC	cis	rs6121246	0.821	rs6119718	chr20:30331074	A/G	cg13852791	chr20:30311386	BCL2L1	0.82	8.74	0.47	2.63e-16	Mean corpuscular hemoglobin;
CESC	cis	rs7666738	0.830	rs1426664	chr4:98988264	A/C	cg05340658	chr4:99064831	C4orf37	0.8	12.42	0.61	3.09e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs472402	0.580	rs6884552	chr5:6661966	C/T	cg10789808	chr5:6633262	NSUN2;SRD5A1	-0.49	-6.39	-0.37	7.51e-10	Response to amphetamines;
CESC	cis	rs4423214	1.000	rs4944956	chr11:71167765	C/T	cg05163923	chr11:71159392	DHCR7	0.84	11.56	0.58	2.73e-25	Vitamin D levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10714403	chr17:55162284	AKAP1	0.55	6.23	0.36	1.82e-9	Gut microbiome composition (summer);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg04902049	chr1:36622448	MAP7D1	-0.43	-6.35	-0.36	9.08e-10	Gambling;
CESC	trans	rs948562	0.744	rs12363774	chr11:58225035	G/T	cg24637035	chr12:120445227	CCDC64	-0.52	-6.26	-0.36	1.58e-9	Lymphoma;
CESC	cis	rs17826219	0.636	rs8080829	chr17:29058730	C/T	cg13385521	chr17:29058706	SUZ12P	0.81	6.53	0.37	3.28e-10	Body mass index;
CESC	cis	rs7618501	0.633	rs55751738	chr3:49972101	A/G	cg24308560	chr3:49941425	MST1R	-0.64	-9.35	-0.5	3.91e-18	Intelligence (multi-trait analysis);
CESC	cis	rs854765	0.533	rs2955354	chr17:17948716	G/C	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.5	-6.33	-0.36	1.03e-9	Total body bone mineral density;
CESC	cis	rs10463316	0.862	rs13354553	chr5:150758128	G/A	cg03212797	chr5:150827313	SLC36A1	-0.52	-6.83	-0.39	5.75e-11	Metabolite levels (Pyroglutamine);
CESC	cis	rs9858542	0.953	rs4625	chr3:49572140	A/G	cg07274523	chr3:49395745	GPX1	0.65	8.48	0.46	1.59e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	trans	rs2502399	0.652	rs2502371	chr6:113506182	C/A	cg00285294	chr7:1089767	C7orf50	-0.34	-6.36	-0.36	8.86e-10	Plasma clusterin levels;
CESC	trans	rs61869271	0.797	rs6585313	chr10:116745558	T/A	cg17463145	chr7:79084011	MAGI2	0.32	6.36	0.36	8.92e-10	Tonsillectomy;
CESC	cis	rs1775715	0.870	rs1775737	chr10:32256871	T/C	cg18675610	chr10:32216311	ARHGAP12	0.32	5.11	0.3	6.16e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs798554	0.757	rs1182176	chr7:2874601	A/G	cg19346786	chr7:2764209	NA	-0.41	-6.1	-0.35	3.8e-9	Height;
CESC	cis	rs7824557	0.933	rs6601576	chr8:11100275	A/T	cg21775007	chr8:11205619	TDH	-0.37	-5.5	-0.32	9.05e-8	Retinal vascular caliber;
CESC	cis	rs2274273	0.662	rs60445539	chr14:55624245	C/T	cg04306507	chr14:55594613	LGALS3	0.31	5.26	0.31	2.99e-7	Protein biomarker;
CESC	cis	rs924607	1.000	rs12523022	chr5:598643	C/T	cg09021430	chr5:549028	NA	0.39	6.96	0.39	2.61e-11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs75477785	0.590	rs4545339	chr1:209912742	C/G	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.8	5.15	0.3	5.1e-7	Cleft lip with or without cleft palate;
CESC	cis	rs896854	0.530	rs10956934	chr8:95992473	C/A	cg26343298	chr8:95960752	TP53INP1	0.35	5.7	0.33	3.19e-8	Type 2 diabetes;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg12588470	chr4:89444909	PIGY	-0.48	-6.49	-0.37	4.25e-10	Fibrinogen levels;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg27130364	chr5:36151796	LMBRD2;SKP2	-0.48	-6.68	-0.38	1.38e-10	Fibrinogen levels;
CESC	cis	rs897984	0.568	rs8063565	chr16:30883965	G/C	cg02466173	chr16:30829666	NA	0.45	6.56	0.37	2.82e-10	Dementia with Lewy bodies;
CESC	cis	rs4722166	0.532	rs4719712	chr7:22755807	C/T	cg05472934	chr7:22766657	IL6	0.52	6.92	0.39	3.39e-11	Lung cancer;
CESC	trans	rs9467711	0.606	rs9379901	chr6:26603866	T/C	cg01620082	chr3:125678407	NA	-0.64	-6.33	-0.36	1.03e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs9311474	0.508	rs7614498	chr3:52618941	A/T	cg18099408	chr3:52552593	STAB1	-0.31	-5.27	-0.31	2.85e-7	Electroencephalogram traits;
CESC	cis	rs8077889	0.917	rs9894873	chr17:41911832	A/G	cg26893861	chr17:41843967	DUSP3	0.74	9.32	0.5	4.61e-18	Triglycerides;
CESC	cis	rs9435341	0.965	rs1730862	chr1:107614003	G/A	cg09367891	chr1:107599246	PRMT6	-0.69	-8.29	-0.45	5.81e-15	Facial morphology (factor 21, depth of nasal alae);
CESC	cis	rs9399135	1.000	rs4896130	chr6:135355118	C/T	cg24558204	chr6:135376177	HBS1L	0.49	6.66	0.38	1.53e-10	Red blood cell count;
CESC	cis	rs12995491	0.843	rs1878809	chr2:88518315	C/T	cg07952391	chr2:88470173	THNSL2	-0.56	-8.11	-0.45	1.89e-14	Response to metformin (IC50);
CESC	cis	rs34779708	0.931	rs10508815	chr10:35332621	A/C	cg03585969	chr10:35415529	CREM	0.77	10.3	0.53	3.95e-21	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs9291683	0.551	rs2240720	chr4:10020480	C/T	cg00071950	chr4:10020882	SLC2A9	0.92	17.67	0.74	1.1e-46	Bone mineral density;
CESC	cis	rs2625529	0.761	rs972028	chr15:72173092	C/T	cg16672083	chr15:72433130	SENP8	-0.4	-5.38	-0.31	1.63e-7	Red blood cell count;
CESC	cis	rs7845219	0.525	rs7820818	chr8:95919231	G/A	cg16049864	chr8:95962084	TP53INP1	-0.51	-7.48	-0.42	1.09e-12	Type 2 diabetes;
CESC	cis	rs9300255	0.544	rs1727309	chr12:123658258	A/G	cg00376283	chr12:123451042	ABCB9	0.61	6.2	0.36	2.2e-9	Neutrophil percentage of white cells;
CESC	cis	rs875971	0.825	rs10281499	chr7:66048966	A/G	cg19163074	chr7:65112434	INTS4L2	0.42	5.25	0.31	3.16e-7	Aortic root size;
CESC	cis	rs6952808	0.689	rs12670737	chr7:2046830	C/T	cg08027265	chr7:2291960	NA	-0.35	-5.26	-0.31	3.02e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs7312933	0.558	rs1669936	chr12:42813509	C/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.51	-6.75	-0.38	9.47e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs17376456	0.877	rs10057605	chr5:93443950	T/G	cg21475434	chr5:93447410	FAM172A	0.91	7.7	0.43	2.71e-13	Diabetic retinopathy;
CESC	cis	rs7666738	0.830	rs13125432	chr4:98961253	G/A	cg05340658	chr4:99064831	C4orf37	0.8	12.39	0.61	3.96e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1461503	0.966	rs7944630	chr11:122838844	G/A	cg27398637	chr11:122830231	C11orf63	-0.56	-8.42	-0.46	2.35e-15	Menarche (age at onset);
CESC	cis	rs28829049	0.597	rs72651403	chr1:19519887	G/C	cg13387374	chr1:19411106	UBR4	0.45	5.8	0.34	1.85e-8	QRS duration in Tripanosoma cruzi seropositivity;
CESC	cis	rs1215050	0.791	rs984940	chr4:98811756	T/A	cg05340658	chr4:99064831	C4orf37	0.52	6.82	0.39	6.19e-11	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs7267979	1.000	rs6037099	chr20:25356876	T/G	cg08601574	chr20:25228251	PYGB	-0.38	-5.55	-0.32	6.88e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs9457247	0.765	rs6900701	chr6:167434112	A/G	cg23791538	chr6:167370224	RNASET2	-0.52	-7.17	-0.4	7.67e-12	Crohn's disease;
CESC	cis	rs3096299	0.509	rs4785691	chr16:89597221	A/G	cg16743903	chr16:89593216	SPG7	-0.49	-6.3	-0.36	1.21e-9	Multiple myeloma (IgH translocation);
CESC	cis	rs72781680	0.611	rs78861366	chr2:24354428	A/G	cg08917208	chr2:24149416	ATAD2B	0.63	6.02	0.35	5.68e-9	Lymphocyte counts;
CESC	cis	rs9640161	0.830	rs3735165	chr7:150068371	T/C	cg21361702	chr7:150065534	REPIN1	0.5	6.59	0.38	2.38e-10	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs62432291	0.681	rs378339	chr6:159658852	C/T	cg14500486	chr6:159655392	FNDC1	-0.62	-6.34	-0.36	9.83e-10	Joint mobility (Beighton score);
CESC	cis	rs7918232	0.574	rs10458708	chr10:27455605	C/T	cg14240646	chr10:27532245	ACBD5	-0.75	-10.83	-0.55	7.44e-23	Breast cancer;
CESC	cis	rs6542838	0.588	rs4851175	chr2:99530118	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.47	-5.98	-0.34	7.18e-9	Fear of minor pain;
CESC	cis	rs714031	0.730	rs5757766	chr22:40069490	T/C	cg21377881	chr22:40064566	CACNA1I	-0.32	-5.1	-0.3	6.38e-7	Schizophrenia;
CESC	cis	rs1552244	0.935	rs7618815	chr3:10151045	A/G	cg00166722	chr3:10149974	C3orf24	0.46	5.78	0.33	2.08e-8	Alzheimer's disease;
CESC	cis	rs709400	1.000	rs56660916	chr14:104126137	G/T	cg12935359	chr14:103987150	CKB	-0.45	-6.08	-0.35	4.23e-9	Body mass index;
CESC	cis	rs8114671	0.562	rs6088642	chr20:33483186	G/T	cg07148914	chr20:33460835	GGT7	0.45	5.9	0.34	1.09e-8	Height;
CESC	cis	rs1552244	0.572	rs6785976	chr3:10168647	A/G	cg00149659	chr3:10157352	C3orf10	1.02	12.77	0.62	1.96e-29	Alzheimer's disease;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg01391346	chr6:99873300	SFRS18	0.47	6.46	0.37	4.94e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs1691799	0.867	rs1039056	chr12:66760391	C/T	cg16791601	chr12:66731901	HELB	-0.77	-13.34	-0.63	2.15e-31	White blood cell count (basophil);
CESC	cis	rs28647808	0.786	rs28590601	chr9:136256224	G/A	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.85	5.74	0.33	2.59e-8	Blood protein levels;
CESC	cis	rs12477438	0.798	rs10167015	chr2:99570707	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.69	-10.09	-0.53	1.85e-20	Chronic sinus infection;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg12542604	chr6:34856704	ANKS1A;TAF11	-0.46	-6.09	-0.35	3.89e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs3733585	0.598	rs28677023	chr4:9958326	C/A	cg11266682	chr4:10021025	SLC2A9	-0.6	-11.2	-0.57	4.42e-24	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs4665809	1.000	rs7573118	chr2:26308086	A/G	cg26314531	chr2:26401878	FAM59B	-0.62	-7.07	-0.4	1.37e-11	Gut microbiome composition (summer);
CESC	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg05564831	chr3:52568323	NT5DC2	0.55	9.47	0.5	1.61e-18	Electroencephalogram traits;
CESC	cis	rs921968	0.608	rs7598056	chr2:219352511	A/C	cg02176678	chr2:219576539	TTLL4	0.42	7.49	0.42	1.04e-12	Mean corpuscular hemoglobin concentration;
CESC	cis	rs3820068	0.705	rs4646087	chr1:15822404	A/G	cg17385448	chr1:15911702	AGMAT	0.4	6.12	0.35	3.37e-9	Systolic blood pressure;
CESC	cis	rs2576037	0.901	rs2060416	chr18:44576240	G/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.62	-9.14	-0.49	1.66e-17	Personality dimensions;
CESC	cis	rs10189230	0.546	rs6436266	chr2:222357235	T/C	cg14652038	chr2:222343519	EPHA4	0.33	5.66	0.33	3.9e-8	Urate levels in lean individuals;
CESC	cis	rs2204008	0.837	rs11180821	chr12:38242843	A/G	cg26384229	chr12:38710491	ALG10B	0.64	8.89	0.48	9.98e-17	Bladder cancer;
CESC	cis	rs72781680	0.898	rs72786278	chr2:24063243	C/T	cg20701182	chr2:24300061	SF3B14	0.62	5.6	0.33	5.24e-8	Lymphocyte counts;
CESC	cis	rs12682352	0.602	rs11783966	chr8:8665147	A/G	cg06636001	chr8:8085503	FLJ10661	-0.43	-5.34	-0.31	2.03e-7	Neuroticism;
CESC	cis	rs780096	0.525	rs13388159	chr2:27648284	A/T	cg17158414	chr2:27665306	KRTCAP3	-0.3	-5.55	-0.32	7e-8	Total body bone mineral density;
CESC	cis	rs10129255	0.518	rs8004895	chr14:107193377	T/C	cg23076370	chr14:107095027	NA	-0.65	-9.53	-0.51	1.09e-18	Kawasaki disease;
CESC	cis	rs6120849	0.707	rs6088694	chr20:33652371	G/A	cg24642439	chr20:33292090	TP53INP2	0.67	6.62	0.38	1.94e-10	Protein C levels;
CESC	cis	rs10089	1.000	rs3792866	chr5:127479900	A/G	cg19767477	chr5:127420684	SLC12A2	-0.39	-5.17	-0.3	4.62e-7	Ileal carcinoids;
CESC	trans	rs2502399	0.689	rs1040590	chr6:113491019	T/C	cg00285294	chr7:1089767	C7orf50	-0.35	-6.41	-0.37	6.56e-10	Plasma clusterin levels;
CESC	cis	rs300703	0.719	rs400040	chr2:199422	G/T	cg21211680	chr2:198530	NA	1.02	10.89	0.56	4.57e-23	Blood protein levels;
CESC	cis	rs72627509	0.904	rs58408429	chr4:57769824	T/C	cg26694713	chr4:57773883	REST	0.58	5.55	0.32	6.87e-8	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CESC	cis	rs7264396	0.790	rs6060539	chr20:34239382	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.86	-11.84	-0.59	3.14e-26	Total cholesterol levels;
CESC	cis	rs57221529	0.654	rs77015126	chr5:670909	G/A	cg16447950	chr5:562315	NA	-0.67	-7.09	-0.4	1.22e-11	Lung disease severity in cystic fibrosis;
CESC	cis	rs7208859	0.623	rs7214570	chr17:29147164	A/G	cg19761014	chr17:28927070	LRRC37B2	0.71	6.02	0.35	5.85e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs17666538	0.535	rs896522	chr8:616991	A/G	cg02524346	chr8:600233	NA	0.86	6.17	0.35	2.53e-9	IgG glycosylation;
CESC	cis	rs2404602	0.692	rs1838048	chr15:76931679	A/G	cg22467129	chr15:76604101	ETFA	-0.36	-5.24	-0.31	3.26e-7	Blood metabolite levels;
CESC	cis	rs6495122	0.644	rs11630087	chr15:75261673	G/T	cg09165964	chr15:75287851	SCAMP5	0.49	6.49	0.37	4.14e-10	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
CESC	cis	rs875971	0.755	rs76288834	chr7:66069802	G/A	cg11764359	chr7:65958608	NA	-0.76	-10.75	-0.55	1.3e-22	Aortic root size;
CESC	cis	rs9583531	0.527	rs12875067	chr13:111365104	A/G	cg15841412	chr13:111365552	ING1	0.48	6.22	0.36	1.93e-9	Coronary artery disease;
CESC	cis	rs16854884	0.657	rs7642774	chr3:143723272	T/A	cg06585982	chr3:143692056	C3orf58	0.48	6.17	0.35	2.54e-9	Economic and political preferences (feminism/equality);
CESC	cis	rs514406	0.505	rs436363	chr1:53172163	T/C	cg08736216	chr1:53307985	ZYG11A	-0.41	-6.84	-0.39	5.42e-11	Monocyte count;
CESC	cis	rs2180341	1.000	rs6569483	chr6:127658855	G/A	cg24812749	chr6:127587940	RNF146	1.07	15.4	0.69	1.16e-38	Breast cancer;
CESC	cis	rs34172651	0.537	rs8049014	chr16:24698903	A/G	cg06505273	chr16:24850292	NA	0.46	5.63	0.33	4.6e-8	Intelligence (multi-trait analysis);
CESC	cis	rs7103648	0.695	rs6485758	chr11:47530024	G/A	cg20307385	chr11:47447363	PSMC3	0.84	12.54	0.61	1.2e-28	Diastolic blood pressure;Systolic blood pressure;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04811502	chr14:21979673	METTL3	-0.66	-8.18	-0.45	1.21e-14	Gut microbiome composition (summer);
CESC	cis	rs798554	0.757	rs1182178	chr7:2873763	G/A	cg18446336	chr7:2847575	GNA12	-0.37	-5.65	-0.33	4.17e-8	Height;
CESC	cis	rs73206853	0.841	rs73206854	chr12:110731375	C/T	cg12870014	chr12:110450643	ANKRD13A	0.62	5.13	0.3	5.68e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs854765	0.583	rs8078583	chr17:17811465	C/T	cg04398451	chr17:18023971	MYO15A	-0.65	-9.23	-0.49	9.1e-18	Total body bone mineral density;
CESC	cis	rs10242455	0.867	rs2687077	chr7:99306566	C/T	cg07715041	chr7:99302981	CYP3A7	-0.41	-5.21	-0.3	3.78e-7	Blood metabolite levels;
CESC	cis	rs6952808	0.531	rs4721441	chr7:2184060	A/G	cg02951883	chr7:2050386	MAD1L1	-0.41	-5.4	-0.31	1.46e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs4253772	0.530	rs9615933	chr22:46677298	G/A	cg18190219	chr22:46762943	CELSR1	-0.59	-5.68	-0.33	3.46e-8	LDL cholesterol;Cholesterol, total;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02259255	chr5:176944032	DDX41	0.55	6.42	0.37	6.19e-10	Gut microbiome composition (summer);
CESC	cis	rs1862618	0.525	rs832403	chr5:56265992	G/T	cg22800045	chr5:56110881	MAP3K1	-0.68	-7.61	-0.42	4.77e-13	Initial pursuit acceleration;
CESC	cis	rs561341	1.000	rs72821971	chr17:30269343	T/G	cg12193833	chr17:30244370	NA	-0.71	-6.55	-0.37	3.04e-10	Hip circumference adjusted for BMI;
CESC	cis	rs854765	0.724	rs62072049	chr17:17906520	T/C	cg16928487	chr17:17741425	SREBF1	-0.58	-10.31	-0.53	3.59e-21	Total body bone mineral density;
CESC	cis	rs12618769	0.625	rs12618524	chr2:99064029	T/A	cg10123293	chr2:99228465	UNC50	0.39	5.18	0.3	4.49e-7	Bipolar disorder;
CESC	cis	rs12325245	0.536	rs34676074	chr16:58549321	G/C	cg02549819	chr16:58548995	SETD6	0.97	6.12	0.35	3.44e-9	Schizophrenia;
CESC	trans	rs79976124	0.837	rs11751145	chr6:66642039	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.7	8.24	0.45	7.81e-15	Type 2 diabetes;
CESC	trans	rs239339	1.000	rs239339	chr1:4444539	A/C	cg06451177	chr17:79412583	BAHCC1	-0.5	-6.03	-0.35	5.53e-9	Obesity-related traits;
CESC	cis	rs6964587	1.000	rs6953515	chr7:91658620	C/T	cg17063962	chr7:91808500	NA	0.54	7.38	0.41	2.03e-12	Breast cancer;
CESC	cis	rs708547	0.874	rs1718837	chr4:57871203	A/G	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.53	-6.33	-0.36	1.04e-9	Response to bleomycin (chromatid breaks);
CESC	cis	rs2204008	0.597	rs4002591	chr12:38133841	A/G	cg26384229	chr12:38710491	ALG10B	0.71	10.13	0.53	1.3e-20	Bladder cancer;
CESC	cis	rs10504229	0.680	rs11777459	chr8:58044241	A/T	cg22535103	chr8:58192502	C8orf71	-0.67	-7.27	-0.41	4.08e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs1003719	0.708	rs2000417	chr21:38502868	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-8.47	-0.46	1.69e-15	Eye color traits;
CESC	cis	rs6499188	0.571	rs1645975	chr16:68564448	C/T	cg02972257	chr16:68554789	NA	-0.55	-6.37	-0.36	8.21e-10	Ulcerative colitis;
CESC	cis	rs1008375	0.966	rs28441502	chr4:17598384	G/A	cg16339924	chr4:17578868	LAP3	0.65	8.19	0.45	1.15e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs919433	1.000	rs2195510	chr2:198161195	A/G	cg10820045	chr2:198174542	NA	-0.43	-6.56	-0.37	2.76e-10	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs6732160	0.706	rs1430348	chr2:73367058	C/T	cg01422370	chr2:73384389	NA	0.41	6.84	0.39	5.58e-11	Intelligence (multi-trait analysis);
CESC	cis	rs4953318	0.619	rs10183887	chr2:46361808	T/A	cg12428440	chr2:46370979	PRKCE	0.5	6.68	0.38	1.4e-10	Red blood cell count;Hematocrit;Red blood cell traits;
CESC	cis	rs1045714	0.887	rs73033694	chr7:2637139	G/A	cg20813462	chr7:2646259	IQCE	0.67	5.8	0.34	1.92e-8	Urate levels in lean individuals;
CESC	trans	rs7246760	1.000	rs10425775	chr19:9912917	G/A	cg02900749	chr2:68251473	NA	-0.73	-6.52	-0.37	3.46e-10	Pursuit maintenance gain;
CESC	cis	rs858239	0.863	rs274054	chr7:23390467	G/C	cg23682824	chr7:23144976	KLHL7	0.44	5.89	0.34	1.17e-8	Cerebrospinal fluid biomarker levels;
CESC	cis	rs1215050	0.904	rs890469	chr4:98923293	T/C	cg05340658	chr4:99064831	C4orf37	-0.54	-6.69	-0.38	1.36e-10	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs4692589	1.000	rs4519759	chr4:170933919	T/C	cg19918862	chr4:170955249	NA	0.37	5.83	0.34	1.59e-8	Anxiety disorder;
CESC	cis	rs12474201	0.928	rs13429704	chr2:46960329	G/T	cg06386533	chr2:46925753	SOCS5	0.82	11.49	0.58	4.62e-25	Height;
CESC	cis	rs2637266	0.703	rs846625	chr10:78541353	T/G	cg18941641	chr10:78392320	NA	0.4	7.74	0.43	2.12e-13	Pulmonary function;
CESC	cis	rs12368653	0.693	rs2640610	chr12:58037435	T/A	cg00700412	chr12:58011837	NA	0.36	5.43	0.32	1.25e-7	Multiple sclerosis;
CESC	cis	rs2733201	1.000	rs2412849	chr15:44276555	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.52	-5.42	-0.32	1.36e-7	Lipoprotein phospholipase A2 activity in cardiovascular disease;
CESC	cis	rs3749237	0.595	rs7643845	chr3:49530711	A/G	cg03060546	chr3:49711283	APEH	0.77	11.82	0.59	3.5e-26	Resting heart rate;
CESC	cis	rs728616	0.867	rs118134654	chr10:81744381	G/A	cg05935833	chr10:81318306	SFTPA2	-0.52	-5.06	-0.3	7.72e-7	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs9660992	0.674	rs1151785	chr1:205232299	C/T	cg21643547	chr1:205240462	TMCC2	-0.47	-6.34	-0.36	1.01e-9	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs7799006	0.722	rs33981648	chr7:2288669	T/C	cg12745145	chr7:2261452	MAD1L1	-0.34	-5.29	-0.31	2.56e-7	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg07822143	chr4:146019674	ABCE1;ANAPC10	0.44	6.17	0.35	2.59e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs2749592	0.550	rs7917262	chr10:37874602	A/C	cg00409905	chr10:38381863	ZNF37A	0.43	5.79	0.34	1.96e-8	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs4975709	0.569	rs931509	chr5:1858821	A/T	cg12288994	chr5:1860383	NA	0.43	6.94	0.39	2.99e-11	Cardiovascular disease risk factors;
CESC	cis	rs17023223	0.537	rs12087987	chr1:119734821	C/A	cg05756136	chr1:119680316	WARS2	-0.47	-5.72	-0.33	2.81e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CESC	cis	rs2456568	0.548	rs7105031	chr11:93661207	C/T	cg26875233	chr11:93583750	C11orf90	-0.33	-5.84	-0.34	1.52e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
CESC	cis	rs9910055	0.529	rs183462	chr17:42183376	G/C	cg19774624	chr17:42201019	HDAC5	0.61	8.44	0.46	2.14e-15	Total body bone mineral density;
CESC	cis	rs16937	0.711	rs10751430	chr1:205107497	A/G	cg00857998	chr1:205179979	DSTYK	0.39	5.25	0.31	3.11e-7	Schizophrenia;
CESC	cis	rs3096299	0.967	rs753853	chr16:89446525	G/T	cg02187348	chr16:89574699	SPG7	0.56	7.25	0.41	4.68e-12	Multiple myeloma (IgH translocation);
CESC	cis	rs3892630	1.000	rs3892630	chr19:33181484	A/G	cg13157960	chr19:33183277	NUDT19	-0.56	-5.51	-0.32	8.34e-8	Red blood cell traits;
CESC	trans	rs7246657	0.943	rs2126977	chr19:37995747	C/G	cg01833234	chr11:6592585	DNHD1	-0.51	-6.06	-0.35	4.65e-9	Coronary artery calcification;
CESC	cis	rs11608355	0.521	rs4766595	chr12:109846998	A/T	cg19025524	chr12:109796872	NA	-0.52	-7.0	-0.39	2.13e-11	Neuroticism;
CESC	cis	rs763121	0.925	rs17032	chr22:39130843	C/G	cg06544989	chr22:39130855	UNC84B	0.52	10.04	0.53	2.52e-20	Menopause (age at onset);
CESC	cis	rs911555	0.692	rs60235428	chr14:103904350	T/C	cg12935359	chr14:103987150	CKB	0.66	9.72	0.51	2.74e-19	Intelligence (multi-trait analysis);
CESC	cis	rs6076065	0.748	rs6076055	chr20:23333917	G/C	cg11657817	chr20:23433608	CST11	0.42	6.36	0.36	8.65e-10	Facial morphology (factor 15, philtrum width);
CESC	cis	rs933688	1.000	rs2367526	chr5:90740525	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.95	11.04	0.56	1.47e-23	Smoking behavior;
CESC	cis	rs7107174	0.901	rs10899498	chr11:78124575	C/G	cg02023728	chr11:77925099	USP35	0.37	5.14	0.3	5.35e-7	Testicular germ cell tumor;
CESC	cis	rs2842992	0.747	rs733319	chr6:160221475	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.76	9.75	0.51	2.18e-19	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs8114671	0.527	rs6088650	chr20:33514465	C/T	cg07148914	chr20:33460835	GGT7	-0.45	-5.97	-0.34	7.5e-9	Height;
CESC	cis	rs698833	0.692	rs786410	chr2:44731156	C/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.56	6.83	0.39	5.81e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs5753618	0.561	rs5753521	chr22:31638027	T/C	cg13145458	chr22:31556086	RNF185	0.46	5.19	0.3	4.27e-7	Colorectal cancer;
CESC	trans	rs1814175	0.791	rs11040472	chr11:49703116	C/T	cg15704280	chr7:45808275	SEPT13	-1.03	-19.79	-0.77	3.87e-54	Height;
CESC	cis	rs7071206	0.947	rs1356090	chr10:79395312	T/C	cg23888215	chr10:79422304	NA	-0.54	-5.78	-0.33	2.15e-8	Bone mineral density;
CESC	cis	rs57506017	0.585	rs12699332	chr7:12269762	G/T	cg23422036	chr7:12250390	TMEM106B	0.38	5.13	0.3	5.58e-7	Neuroticism;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23319546	chr10:75173760	ANXA7	-0.59	-6.45	-0.37	5.17e-10	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08853494	chr4:76439657	RCHY1;THAP6	0.6	6.56	0.37	2.74e-10	Gut microbiome composition (summer);
CESC	cis	rs58785573	0.504	rs11947292	chr4:38634749	A/T	cg18361445	chr4:38666374	KLF3;FLJ13197	0.5	7.11	0.4	1.11e-11	Lymphocyte percentage of white cells;
CESC	cis	rs9925964	0.967	rs749767	chr16:31124407	C/T	cg02466173	chr16:30829666	NA	-0.32	-5.06	-0.3	7.68e-7	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs10504229	0.954	rs903717	chr8:58167856	A/G	cg24829409	chr8:58192753	C8orf71	-0.59	-8.31	-0.45	4.9e-15	Developmental language disorder (linguistic errors);
CESC	cis	rs11098499	0.909	rs73842633	chr4:120375464	G/A	cg09307838	chr4:120376055	NA	0.92	12.08	0.6	4.68e-27	Corneal astigmatism;
CESC	cis	rs1035144	0.785	rs4903962	chr14:81464486	A/G	cg06600135	chr14:81408086	NA	0.38	5.2	0.3	4.06e-7	Male sexual orientation;
CESC	cis	rs6831352	0.918	rs17218602	chr4:100061073	A/G	cg12011299	chr4:100065546	ADH4	-0.59	-6.59	-0.38	2.35e-10	Alcohol dependence;
CESC	cis	rs2836974	0.627	rs7278985	chr21:40653767	C/T	cg11890956	chr21:40555474	PSMG1	-0.97	-15.94	-0.7	1.46e-40	Cognitive function;
CESC	cis	rs1799949	1.000	rs12951869	chr17:41187567	T/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.4	5.15	0.3	4.99e-7	Menopause (age at onset);
CESC	trans	rs7618501	1.000	rs6802890	chr3:49832261	A/G	cg21659725	chr3:3221576	CRBN	0.83	13.42	0.64	1.11e-31	Intelligence (multi-trait analysis);
CESC	cis	rs13191362	1.000	rs66594243	chr6:163169024	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.04	10.28	0.53	4.33e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs4819052	0.766	rs4819035	chr21:46645715	A/C	cg11663144	chr21:46675770	NA	-0.42	-5.57	-0.32	6.22e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs916888	0.821	rs199514	chr17:44856881	G/A	cg27125505	chr17:43679177	LOC644172	-0.49	-6.64	-0.38	1.73e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs1707322	0.638	rs1707302	chr1:46600917	A/G	cg03146154	chr1:46216737	IPP	-0.58	-7.02	-0.4	1.87e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2249625	0.545	rs2496505	chr6:72891063	C/G	cg18830697	chr6:72922368	RIMS1	-0.46	-6.92	-0.39	3.35e-11	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CESC	cis	rs1348850	0.608	rs2364845	chr2:178226240	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.76	10.83	0.55	7.38e-23	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs7618501	0.602	rs34831713	chr3:50118748	T/C	cg24110177	chr3:50126178	RBM5	0.53	7.37	0.41	2.2e-12	Intelligence (multi-trait analysis);
CESC	cis	rs10791097	0.720	rs6590517	chr11:130733505	C/T	cg12179176	chr11:130786555	SNX19	0.61	9.15	0.49	1.59e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs873946	0.564	rs12772704	chr10:134557318	G/A	cg18305652	chr10:134549665	INPP5A	0.48	6.75	0.38	9.22e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs4911259	0.507	rs8118663	chr20:31398876	A/G	cg13636640	chr20:31349939	DNMT3B	0.45	5.49	0.32	9.36e-8	Inflammatory bowel disease;
CESC	cis	rs2463822	1.000	rs951677	chr11:62107249	G/C	cg06239285	chr11:62104954	ASRGL1	0.97	8.71	0.47	3.45e-16	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs722599	0.683	rs7145246	chr14:75242394	A/T	cg08847533	chr14:75593920	NEK9	-0.49	-6.03	-0.35	5.43e-9	IgG glycosylation;
CESC	cis	rs8180040	0.966	rs11710322	chr3:47331136	C/T	cg27129171	chr3:47204927	SETD2	-0.66	-10.07	-0.53	2.14e-20	Colorectal cancer;
CESC	cis	rs6598955	0.671	rs11247905	chr1:26627907	G/C	cg19743891	chr1:26644573	UBXN11;CD52	0.37	5.45	0.32	1.18e-7	Obesity-related traits;
CESC	cis	rs3820068	0.705	rs59502343	chr1:15872617	T/C	cg18192808	chr1:15853278	DNAJC16	0.46	5.63	0.33	4.49e-8	Systolic blood pressure;
CESC	cis	rs7589342	0.507	rs6543338	chr2:106403911	C/G	cg16077055	chr2:106428750	NCK2	0.37	5.4	0.32	1.46e-7	Addiction;
CESC	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg19626725	chr5:178986131	RUFY1	0.41	6.61	0.38	2.12e-10	Lung cancer;
CESC	cis	rs754466	1.000	rs12220902	chr10:79682918	C/T	cg17075019	chr10:79541650	NA	-0.7	-8.97	-0.48	5.56e-17	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs2832191	0.740	rs2832168	chr21:30463695	G/A	cg08807101	chr21:30365312	RNF160	0.92	13.62	0.64	2.27e-32	Dental caries;
CESC	cis	rs35146811	0.586	rs12705067	chr7:99594726	T/C	cg14163444	chr7:99595348	NA	-0.4	-5.34	-0.31	1.98e-7	Coronary artery disease;
CESC	cis	rs9486715	0.867	rs3849199	chr6:97049191	T/C	cg18709589	chr6:96969512	KIAA0776	-0.45	-6.21	-0.36	2.05e-9	Headache;
CESC	cis	rs1348850	0.567	rs3770011	chr2:178537890	C/T	cg22681709	chr2:178499509	PDE11A	-0.49	-7.22	-0.41	5.66e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs2228479	0.850	rs2238531	chr16:89856217	C/G	cg14709524	chr16:89940631	TCF25	0.94	7.06	0.4	1.5e-11	Skin colour saturation;
CESC	cis	rs4474465	0.850	rs4590904	chr11:78263847	C/T	cg27205649	chr11:78285834	NARS2	0.43	5.5	0.32	8.94e-8	Alzheimer's disease (survival time);
CESC	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.61	-9.25	-0.49	7.84e-18	Longevity;Endometriosis;
CESC	cis	rs11122272	0.735	rs2790880	chr1:231534259	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.49	-6.53	-0.37	3.31e-10	Hemoglobin concentration;
CESC	cis	rs4253772	0.575	rs9615979	chr22:46789021	G/T	cg18190219	chr22:46762943	CELSR1	-0.69	-6.01	-0.35	6.24e-9	LDL cholesterol;Cholesterol, total;
CESC	cis	rs9916302	0.904	rs2338800	chr17:37498149	C/G	cg15445000	chr17:37608096	MED1	-0.41	-6.83	-0.39	5.65e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs5771242	0.776	rs6010198	chr22:50610628	A/G	cg16473166	chr22:50639996	SELO	-0.75	-8.95	-0.48	6.56e-17	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
CESC	cis	rs2839186	0.588	rs2839140	chr21:47616080	G/A	cg12379764	chr21:47803548	PCNT	0.47	6.04	0.35	5.07e-9	Testicular germ cell tumor;
CESC	trans	rs7839040	0.698	rs13258597	chr8:82923733	A/G	cg14472086	chr9:107730925	NA	-0.47	-6.33	-0.36	1.02e-9	Response to methotrexate in juvenile idiopathic arthritis;
CESC	cis	rs10170846	0.861	rs6740452	chr2:223518452	C/T	cg25565276	chr2:223520875	FARSB	0.5	6.97	0.39	2.5e-11	Schizophrenia (inflammation and infection response interaction);
CESC	cis	rs1395	0.634	rs72817542	chr2:27526681	C/G	cg22903471	chr2:27725779	GCKR	-0.5	-6.05	-0.35	5.04e-9	Blood metabolite levels;
CESC	cis	rs2228479	0.702	rs17233253	chr16:89828437	A/G	cg04013166	chr16:89971882	TCF25	0.78	6.69	0.38	1.33e-10	Skin colour saturation;
CESC	cis	rs4253772	0.678	rs1053332	chr22:46640179	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.58	6.74	0.38	9.67e-11	LDL cholesterol;Cholesterol, total;
CESC	cis	rs6540559	1.000	rs12070337	chr1:209992127	G/A	cg12034118	chr1:209979487	IRF6	0.51	6.17	0.35	2.61e-9	Cleft lip with or without cleft palate;
CESC	cis	rs710216	0.957	rs3738514	chr1:43426591	A/G	cg03128534	chr1:43423976	SLC2A1	-0.54	-6.25	-0.36	1.64e-9	Red cell distribution width;
CESC	cis	rs3862030	0.668	rs12781718	chr10:104227433	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.37	-5.17	-0.3	4.71e-7	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
CESC	cis	rs9910055	0.529	rs190144	chr17:42164584	A/G	cg19774624	chr17:42201019	HDAC5	0.52	6.93	0.39	3.26e-11	Total body bone mineral density;
CESC	cis	rs6732160	0.564	rs60796597	chr2:73382914	C/T	cg01422370	chr2:73384389	NA	0.57	8.95	0.48	6.19e-17	Intelligence (multi-trait analysis);
CESC	cis	rs12497850	1.000	rs4858828	chr3:48724811	C/T	cg06212747	chr3:49208901	KLHDC8B	0.61	8.26	0.45	7.08e-15	Parkinson's disease;
CESC	trans	rs7618501	0.966	rs13085679	chr3:49869631	G/A	cg21659725	chr3:3221576	CRBN	0.82	13.26	0.63	4e-31	Intelligence (multi-trait analysis);
CESC	cis	rs2742234	0.590	rs2115817	chr10:43686552	C/T	cg07801480	chr10:43725741	RASGEF1A	0.41	5.29	0.31	2.56e-7	Hirschsprung disease;
CESC	cis	rs1801251	0.893	rs6733151	chr2:233592341	A/C	cg08000102	chr2:233561755	GIGYF2	0.69	9.75	0.51	2.22e-19	Coronary artery disease;
CESC	cis	rs7178572	0.568	rs11632966	chr15:77621805	A/C	cg22256960	chr15:77711686	NA	-0.54	-6.86	-0.39	4.9e-11	Type 2 diabetes;
CESC	cis	rs10504229	1.000	rs116995796	chr8:58181960	G/A	cg05313129	chr8:58192883	C8orf71	-0.55	-6.29	-0.36	1.34e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs4906332	1.000	rs12879663	chr14:103874215	A/G	cg09975044	chr14:104007538	NA	0.43	5.91	0.34	1.07e-8	Coronary artery disease;
CESC	cis	rs9486715	0.867	rs2223238	chr6:96871855	G/A	cg06623918	chr6:96969491	KIAA0776	0.9	13.69	0.64	1.26e-32	Headache;
CESC	cis	rs9815354	0.638	rs56194645	chr3:41843593	T/C	cg03022575	chr3:42003672	ULK4	0.7	6.04	0.35	5.26e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs9311474	0.507	rs6787154	chr3:52784416	C/T	cg07507251	chr3:52567010	NT5DC2	0.33	5.67	0.33	3.7e-8	Electroencephalogram traits;
CESC	cis	rs425277	1.000	rs1401138	chr1:2063149	C/T	cg16545954	chr1:2118288	C1orf86	0.34	5.65	0.33	4.15e-8	Height;
CESC	cis	rs13385	0.769	rs10079286	chr5:139599134	G/A	cg26211634	chr5:139558579	C5orf32	0.47	5.19	0.3	4.12e-7	Atrial fibrillation;
CESC	trans	rs1814175	0.817	rs12277258	chr11:49940216	T/C	cg15704280	chr7:45808275	SEPT13	-1.03	-21.21	-0.79	4.77e-59	Height;
CESC	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg21724239	chr8:58056113	NA	0.6	5.45	0.32	1.17e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs2073300	1.000	rs6137962	chr20:23443966	T/C	cg12062639	chr20:23401060	NAPB	0.91	6.41	0.37	6.71e-10	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs698833	0.624	rs2166453	chr2:44693424	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	-0.4	-5.08	-0.3	7.16e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11839334	chr14:21152763	RNASE4;ANG	-0.58	-6.52	-0.37	3.49e-10	Gut microbiome composition (summer);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg16083082	chr10:51371691	LOC728407;PARG	0.45	6.46	0.37	4.92e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs9951602	0.512	rs12454617	chr18:76656007	C/T	cg02800362	chr5:177631904	HNRNPAB	0.65	8.51	0.46	1.31e-15	Obesity-related traits;
CESC	cis	rs61931739	0.782	rs3903201	chr12:34248275	G/A	cg19457237	chr12:34500585	NA	-0.42	-5.72	-0.33	2.86e-8	Morning vs. evening chronotype;
CESC	cis	rs1144713	0.531	rs1716941	chr12:32255094	A/G	cg01321189	chr12:32259338	BICD1	0.43	5.67	0.33	3.7e-8	Obesity-related traits;
CESC	cis	rs9291683	0.517	rs11736479	chr4:10017387	G/C	cg02734326	chr4:10020555	SLC2A9	0.52	7.43	0.42	1.51e-12	Bone mineral density;
CESC	cis	rs2236918	0.932	rs1776131	chr1:242024245	T/A	cg17736920	chr1:242011382	EXO1	0.71	9.03	0.49	3.53e-17	Menopause (age at onset);
CESC	cis	rs3796352	1.000	rs7622420	chr3:53111069	A/G	cg26060971	chr3:52407402	DNAH1	-0.42	-5.06	-0.3	7.98e-7	Immune reponse to smallpox (secreted IL-2);
CESC	cis	rs7659604	0.539	rs56159666	chr4:122782879	G/A	cg20573242	chr4:122745356	CCNA2	0.65	8.05	0.44	2.81e-14	Type 2 diabetes;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg10989441	chr1:231347308	TRIM67	-0.43	-6.1	-0.35	3.7e-9	Gambling;
CESC	trans	rs60843830	1.000	rs62114497	chr2:214837	G/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.64	7.8	0.43	1.44e-13	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs1355223	1.000	rs11607300	chr11:34759319	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.47	-6.08	-0.35	4.16e-9	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs861020	0.563	rs35898529	chr1:210053096	G/A	cg05527609	chr1:210001259	C1orf107	-0.99	-10.87	-0.56	5.24e-23	Orofacial clefts;
CESC	cis	rs8005677	0.770	rs56180741	chr14:23377246	T/C	cg01529538	chr14:23388837	RBM23	0.43	5.95	0.34	8.44e-9	Cognitive ability (multi-trait analysis);
CESC	cis	rs7618501	0.633	rs4688689	chr3:50035542	C/T	cg24110177	chr3:50126178	RBM5	-0.51	-7.09	-0.4	1.19e-11	Intelligence (multi-trait analysis);
CESC	cis	rs2742234	1.000	rs2742234	chr10:43612609	A/G	cg15436174	chr10:43711423	RASGEF1A	0.41	5.26	0.31	3.01e-7	Hirschsprung disease;
CESC	cis	rs8031584	0.872	rs11634761	chr15:31243173	A/C	cg08109568	chr15:31115862	NA	-0.67	-8.66	-0.47	4.55e-16	Huntington's disease progression;
CESC	cis	rs11077998	0.933	rs3736204	chr17:80530279	C/T	cg10255544	chr17:80519551	FOXK2	0.55	8.73	0.47	2.83e-16	Reticulocyte fraction of red cells;
CESC	cis	rs9549367	0.789	rs9549716	chr13:113908478	G/A	cg18105134	chr13:113819100	PROZ	-0.68	-8.71	-0.47	3.37e-16	Platelet distribution width;
CESC	cis	rs4654899	0.758	rs6690574	chr1:21504279	G/A	cg05370193	chr1:21551575	ECE1	0.39	6.04	0.35	5.15e-9	Superior frontal gyrus grey matter volume;
CESC	cis	rs1008375	0.966	rs4698619	chr4:17580955	G/A	cg02297831	chr4:17616191	MED28	0.5	6.07	0.35	4.52e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs4555082	0.874	rs4677	chr14:105717279	T/C	cg27165867	chr14:105738592	BRF1	-0.54	-6.08	-0.35	4.18e-9	Mean platelet volume;Platelet distribution width;
CESC	cis	rs992157	0.560	rs1514132	chr2:219084082	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.57	-7.39	-0.41	1.96e-12	Colorectal cancer;
CESC	cis	rs8031584	0.678	rs8028173	chr15:31155749	A/G	cg08109568	chr15:31115862	NA	-0.72	-9.73	-0.51	2.44e-19	Huntington's disease progression;
CESC	cis	rs561341	1.000	rs111454793	chr17:30319267	T/C	cg00745463	chr17:30367425	LRRC37B	-0.8	-7.25	-0.41	4.55e-12	Hip circumference adjusted for BMI;
CESC	cis	rs13191362	1.000	rs4260737	chr6:163137746	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.05	10.33	0.54	2.97e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs11690935	0.959	rs7597387	chr2:172577116	T/C	cg13550731	chr2:172543902	DYNC1I2	-1.0	-16.26	-0.71	1.08e-41	Schizophrenia;
CESC	cis	rs12971120	0.891	rs11151961	chr18:72177340	C/T	cg26446133	chr18:72167187	CNDP2	-0.74	-9.14	-0.49	1.69e-17	Refractive error;
CESC	cis	rs2797160	1.000	rs2211418	chr6:125995503	G/A	cg05901451	chr6:126070800	HEY2	-0.46	-6.67	-0.38	1.52e-10	Endometrial cancer;
CESC	cis	rs7618915	0.571	rs11130307	chr3:52607682	G/A	cg05564831	chr3:52568323	NT5DC2	0.46	6.93	0.39	3.15e-11	Bipolar disorder;
CESC	cis	rs1499972	0.590	rs62264775	chr3:117648002	A/C	cg07612923	chr3:117604196	NA	0.7	6.33	0.36	1.02e-9	Schizophrenia;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg07545714	chr3:122135128	WDR5B	-0.57	-7.32	-0.41	3e-12	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs875971	0.830	rs427973	chr7:65526648	C/A	cg26939375	chr7:64535504	NA	0.48	6.17	0.35	2.57e-9	Aortic root size;
CESC	cis	rs13040088	1.000	rs6090155	chr20:61527378	G/A	cg23096297	chr20:61557774	DIDO1	0.96	10.68	0.55	2.3e-22	Menopause (age at onset);
CESC	cis	rs1953600	0.870	rs2788295	chr10:81941007	C/G	cg00277334	chr10:82204260	NA	0.45	6.28	0.36	1.39e-9	Sarcoidosis;
CESC	cis	rs11098499	0.754	rs10213267	chr4:120239074	A/G	cg09307838	chr4:120376055	NA	0.79	10.77	0.55	1.17e-22	Corneal astigmatism;
CESC	cis	rs2290720	0.930	rs1379486	chr12:101699347	T/C	cg22051763	chr12:101673672	UTP20	-0.45	-5.68	-0.33	3.59e-8	Brain structure (hippocampal volume);
CESC	cis	rs34172651	0.571	rs9922156	chr16:24704329	C/A	cg04756594	chr16:24857601	SLC5A11	-0.53	-6.85	-0.39	5.11e-11	Intelligence (multi-trait analysis);
CESC	trans	rs3942852	0.774	rs10838814	chr11:48187178	G/A	cg03929089	chr4:120376271	NA	-0.65	-7.1	-0.4	1.15e-11	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs7223966	1.000	rs55868506	chr17:61851686	T/G	cg11494091	chr17:61959527	GH2	0.38	5.18	0.3	4.33e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs7202877	0.706	rs247450	chr16:75490017	C/A	cg04384234	chr16:75411784	CFDP1	0.48	5.41	0.32	1.44e-7	Type 2 diabetes;Type 1 diabetes;
CESC	cis	rs7542091	0.704	rs7550330	chr1:210044587	G/A	cg09509183	chr1:209979624	IRF6	0.4	5.78	0.33	2.12e-8	Monobrow;
CESC	cis	rs3806843	0.676	rs2569159	chr5:140030710	C/T	cg16179182	chr5:140090404	VTRNA1-1	0.4	5.08	0.3	7.23e-7	Depressive symptoms (multi-trait analysis);
CESC	trans	rs11098499	0.754	rs12510269	chr4:120241646	A/G	cg25214090	chr10:38739885	LOC399744	0.61	8.46	0.46	1.86e-15	Corneal astigmatism;
CESC	cis	rs763121	0.853	rs2179142	chr22:39037954	G/A	cg14440974	chr22:39074834	NA	-0.37	-5.09	-0.3	6.66e-7	Menopause (age at onset);
CESC	cis	rs7259376	0.869	rs11673228	chr19:22596084	G/A	cg02657401	chr19:22469223	NA	0.26	5.14	0.3	5.46e-7	Menopause (age at onset);
CESC	cis	rs6860806	0.507	rs2631371	chr5:131703691	G/A	cg04518342	chr5:131593106	PDLIM4	-0.35	-5.06	-0.3	7.79e-7	Breast cancer;
CESC	cis	rs4665809	1.000	rs17040322	chr2:26351274	G/C	cg25036284	chr2:26402008	FAM59B	-0.59	-6.88	-0.39	4.37e-11	Gut microbiome composition (summer);
CESC	cis	rs2985684	1.000	rs2985697	chr14:50092902	A/G	cg02151108	chr14:50098012	C14orf104	-0.45	-5.9	-0.34	1.09e-8	Carotid intima media thickness;
CESC	cis	rs9308433	0.529	rs10465697	chr1:214499948	T/C	cg06198575	chr1:214491504	SMYD2	0.5	6.0	0.35	6.37e-9	IgG glycosylation;
CESC	cis	rs7829975	0.742	rs882462	chr8:8678530	G/A	cg15556689	chr8:8085844	FLJ10661	0.45	5.69	0.33	3.29e-8	Mood instability;
CESC	cis	rs13191362	0.935	rs34063386	chr6:163041271	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.84	9.11	0.49	2.05e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.71	9.9	0.52	7.02e-20	Prudent dietary pattern;
CESC	cis	rs55794721	0.509	rs2982358	chr1:25745204	G/T	cg03538708	chr1:25844672	NA	-0.4	-6.06	-0.35	4.59e-9	Plateletcrit;Mean corpuscular volume;
CESC	cis	rs875971	0.862	rs6460293	chr7:65810192	C/A	cg10691866	chr7:65817282	TPST1	0.32	5.42	0.32	1.35e-7	Aortic root size;
CESC	cis	rs7312933	0.558	rs7965743	chr12:42736822	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.49	-6.46	-0.37	5.02e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	trans	rs116095464	0.558	rs9688045	chr5:254035	T/C	cg00938859	chr5:1591904	SDHAP3	0.63	6.77	0.38	8.35e-11	Breast cancer;
CESC	cis	rs2651899	0.865	rs2817126	chr1:3083246	T/G	cg07622451	chr1:3079886	PRDM16	0.29	5.22	0.31	3.55e-7	Migraine;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg21813473	chr20:40247231	CHD6	-0.42	-6.02	-0.35	5.68e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs208346	0.612	rs208356	chr7:2775825	A/T	cg18446336	chr7:2847575	GNA12	0.43	6.98	0.39	2.3e-11	Loneliness (linear analysis);
CESC	cis	rs9612	0.948	rs12609587	chr19:44268654	T/C	cg08581076	chr19:44259116	C19orf61	0.49	5.76	0.33	2.35e-8	Exhaled nitric oxide output;
CESC	cis	rs920590	0.876	rs3907477	chr8:19657744	C/T	cg03894339	chr8:19674705	INTS10	0.54	6.42	0.37	6.28e-10	Acute lymphoblastic leukemia (childhood);
CESC	trans	rs673604	0.505	rs676614	chr1:36107510	G/T	cg12623088	chr15:66585521	DIS3L	0.54	6.04	0.35	5.17e-9	Endometrial cancer;
CESC	cis	rs9911578	0.967	rs57869245	chr17:57106630	A/G	cg05425664	chr17:57184151	TRIM37	0.51	7.08	0.4	1.26e-11	Intelligence (multi-trait analysis);
CESC	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.64	7.2	0.4	6.15e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs5753618	0.561	rs2283881	chr22:31638932	G/A	cg13145458	chr22:31556086	RNF185	0.46	5.21	0.3	3.86e-7	Colorectal cancer;
CESC	cis	rs13108904	0.935	rs4246685	chr4:1279727	T/C	cg22903657	chr4:1355424	KIAA1530	-0.38	-5.18	-0.3	4.5e-7	Obesity-related traits;
CESC	cis	rs2075371	1.000	rs2544210	chr7:133971535	C/T	cg20476274	chr7:133979776	SLC35B4	0.69	10.23	0.53	6.29e-21	Mean platelet volume;
CESC	cis	rs7520050	0.966	rs785495	chr1:46587887	A/G	cg24296786	chr1:45957014	TESK2	0.42	5.32	0.31	2.23e-7	Red blood cell count;Reticulocyte count;
CESC	cis	rs4563143	0.577	rs73025093	chr19:29254618	T/G	cg12756686	chr19:29218302	NA	0.58	7.52	0.42	8.38e-13	Methadone dose in opioid dependence;
CESC	cis	rs2573652	0.723	rs2573655	chr15:100515709	A/C	cg09918751	chr15:100517450	ADAMTS17	-0.45	-9.02	-0.48	3.92e-17	Height;
CESC	cis	rs1034435	0.755	rs5768681	chr22:48894501	C/T	cg05992904	chr22:48892994	FAM19A5	-0.57	-9.76	-0.51	2e-19	Late-onset Alzheimer's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04018571	chr2:96874059	STARD7	0.59	7.02	0.4	1.91e-11	Gut microbiome composition (summer);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg18632102	chr5:154238496	CNOT8	0.5	6.7	0.38	1.22e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs722599	0.683	rs11848876	chr14:75224626	C/G	cg08847533	chr14:75593920	NEK9	0.49	6.0	0.35	6.52e-9	IgG glycosylation;
CESC	cis	rs2011503	0.891	rs2965186	chr19:19497195	T/G	cg11584989	chr19:19387371	SF4	-0.63	-7.42	-0.41	1.63e-12	Bipolar disorder;
CESC	cis	rs6540556	0.723	rs9430012	chr1:209900615	G/C	cg05527609	chr1:210001259	C1orf107	-0.66	-7.35	-0.41	2.44e-12	Red blood cell count;
CESC	cis	rs3008870	1.000	rs1925411	chr1:67370292	C/T	cg08660285	chr1:67390436	MIER1;WDR78	1.01	13.55	0.64	3.74e-32	Lymphocyte percentage of white cells;
CESC	cis	rs1475911	1.000	rs1475911	chr21:43513480	A/C	cg03240473	chr21:43526662	UMODL1;C21orf128	-0.42	-5.28	-0.31	2.73e-7	IgG glycosylation;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18816107	chr1:151227233	PSMD4	0.57	6.27	0.36	1.49e-9	Gut microbiome composition (summer);
CESC	cis	rs861020	0.630	rs585627	chr1:210004199	C/G	cg05527609	chr1:210001259	C1orf107	0.74	9.67	0.51	3.97e-19	Orofacial clefts;
CESC	cis	rs111756027	0.593	rs11862987	chr16:77247504	C/T	cg01504555	chr16:77246968	SYCE1L	0.58	5.44	0.32	1.18e-7	Bone mineral density (Ward's triangle area);
CESC	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg04025307	chr7:1156635	C7orf50	0.43	7.0	0.39	2.11e-11	Longevity;Endometriosis;
CESC	cis	rs826838	0.967	rs2892410	chr12:38990282	A/G	cg13010199	chr12:38710504	ALG10B	-0.6	-8.59	-0.47	7.43e-16	Heart rate;
CESC	cis	rs2235544	0.664	rs41366847	chr1:54476967	C/G	cg09175620	chr1:54484536	LDLRAD1	-0.29	-5.09	-0.3	6.88e-7	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg11412256	chr1:228612818	HIST3H3	0.5	6.73	0.38	1.04e-10	Fibrinogen levels;
CESC	cis	rs8017423	0.933	rs7150378	chr14:90724566	G/A	cg14092571	chr14:90743983	NA	-0.55	-8.41	-0.46	2.56e-15	Mortality in heart failure;
CESC	cis	rs698833	0.886	rs4953091	chr2:44565266	A/C	cg18685995	chr2:44588913	PREPL;C2orf34	-0.53	-6.9	-0.39	3.88e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs7949030	0.653	rs2849030	chr11:62366986	G/A	cg13298116	chr11:62369859	EML3;MTA2	-0.62	-9.14	-0.49	1.64e-17	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs2228479	0.702	rs62053701	chr16:89860584	G/A	cg19635926	chr16:89946313	TCF25	0.68	5.17	0.3	4.65e-7	Skin colour saturation;
CESC	cis	rs870825	0.655	rs2017101	chr4:185637381	G/A	cg04058563	chr4:185651563	MLF1IP	0.62	6.86	0.39	4.91e-11	Blood protein levels;
CESC	cis	rs10876993	0.893	rs3825078	chr12:58089413	A/T	cg18357645	chr12:58087776	OS9	0.64	10.62	0.55	3.61e-22	Celiac disease or Rheumatoid arthritis;
CESC	trans	rs4714598	1.000	rs4714598	chr6:42282393	A/G	cg23980859	chr1:55844285	NA	0.36	6.01	0.35	6.22e-9	Eosinophil percentage of white cells;
CESC	trans	rs9325144	0.671	rs7306605	chr12:38730471	C/T	cg23762105	chr12:34175262	ALG10	-0.48	-6.36	-0.36	8.87e-10	Morning vs. evening chronotype;
CESC	cis	rs9311474	1.000	rs2276834	chr3:52325759	A/G	cg18099408	chr3:52552593	STAB1	-0.3	-5.07	-0.3	7.59e-7	Electroencephalogram traits;
CESC	cis	rs2228479	0.850	rs2238525	chr16:89809902	T/C	cg04287289	chr16:89883240	FANCA	0.7	6.04	0.35	5.3300000000000004e-09	Skin colour saturation;
CESC	cis	rs1003719	0.788	rs1543750	chr21:38446918	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.62	8.7	0.47	3.48e-16	Eye color traits;
CESC	cis	rs6570726	0.577	rs9497315	chr6:145791967	C/T	cg05347473	chr6:146136440	FBXO30	-0.72	-9.17	-0.49	1.4e-17	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1005277	0.557	rs176887	chr10:38406094	T/C	cg25517755	chr10:38738941	LOC399744	-0.46	-5.98	-0.34	7.15e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs412050	0.696	rs113366054	chr22:22267184	A/C	cg17089214	chr22:22089827	YPEL1	0.73	6.02	0.35	5.9e-9	Attention deficit hyperactivity disorder;
CESC	trans	rs9951418	0.559	rs72968934	chr18:73853667	A/G	cg00711132	chr7:87506492	DBF4;SLC25A40	-0.6	-6.0	-0.35	6.38e-9	Interleukin-10 levels;
CESC	cis	rs9649213	0.593	rs13246868	chr7:97986453	T/C	cg21770322	chr7:97807741	LMTK2	0.57	8.84	0.48	1.39e-16	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs2732480	0.577	rs2634678	chr12:48735538	C/G	cg04545296	chr12:48745243	ZNF641	0.43	7.15	0.4	8.63e-12	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs2486288	0.656	rs2413771	chr15:45553140	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.54	-6.51	-0.37	3.85e-10	Glomerular filtration rate;
CESC	cis	rs997295	0.554	rs28568344	chr15:68096527	A/G	cg08079166	chr15:68083412	MAP2K5	0.4	6.39	0.37	7.62e-10	Motion sickness;
CESC	cis	rs1552244	0.935	rs7621551	chr3:10114205	C/T	cg16606324	chr3:10149918	C3orf24	0.43	5.22	0.31	3.71e-7	Alzheimer's disease;
CESC	cis	rs7666738	0.962	rs2865986	chr4:99067907	A/G	cg18180107	chr4:99064573	C4orf37	0.41	5.07	0.3	7.43e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9522267	0.511	rs1163626	chr13:112225200	A/C	cg10483660	chr13:112241077	NA	-0.32	-5.67	-0.33	3.71e-8	Hepatitis;
CESC	trans	rs801193	0.967	rs2420827	chr7:66147101	G/A	cg26939375	chr7:64535504	NA	-0.6	-7.89	-0.44	8.14e-14	Aortic root size;
CESC	cis	rs3106136	1.000	rs2632401	chr4:95147055	C/G	cg11021082	chr4:95130006	SMARCAD1	0.49	7.58	0.42	5.77e-13	Capecitabine sensitivity;
CESC	cis	rs5753037	0.640	rs131260	chr22:30132964	A/C	cg01021169	chr22:30184971	ASCC2	-0.47	-6.61	-0.38	2.08e-10	Type 1 diabetes;
CESC	cis	rs2243480	1.000	rs781149	chr7:65481284	C/T	cg18252515	chr7:66147081	NA	-1.13	-10.9	-0.56	4.18e-23	Diabetic kidney disease;
CESC	cis	rs929354	0.772	rs1182444	chr7:157024510	A/G	cg05182265	chr7:156933206	UBE3C	0.52	7.56	0.42	6.76e-13	Body mass index;
CESC	cis	rs9303401	0.625	rs10515159	chr17:56802693	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.03	12.82	0.62	1.31e-29	Cognitive test performance;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg24371536	chr6:79943342	HMGN3	-0.57	-8.37	-0.46	3.38e-15	Gambling;
CESC	cis	rs2882667	0.822	rs11738376	chr5:138398172	G/A	cg04439458	chr5:138467593	SIL1	-0.37	-5.81	-0.34	1.78e-8	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs1008375	0.933	rs4698637	chr4:17632843	A/T	cg02297831	chr4:17616191	MED28	0.56	6.9	0.39	3.84e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs7044106	0.664	rs7861679	chr9:123375589	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	-0.35	-5.64	-0.33	4.29e-8	Hip circumference adjusted for BMI;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg07931792	chr19:12707809	ZNF490	0.55	7.26	0.41	4.23e-12	Fibrinogen levels;
CESC	cis	rs4975709	0.589	rs1466607	chr5:1864856	A/G	cg17650747	chr5:1873721	NA	0.45	6.22	0.36	1.95e-9	Cardiovascular disease risk factors;
CESC	cis	rs514406	0.825	rs487453	chr1:53271225	T/C	cg27535305	chr1:53392650	SCP2	0.3	5.34	0.31	2.03e-7	Monocyte count;
CESC	cis	rs12142240	0.698	rs17361936	chr1:46862893	C/T	cg00530320	chr1:46809349	NSUN4	0.6	8.17	0.45	1.25e-14	Menopause (age at onset);
CESC	cis	rs2456568	0.548	rs10466335	chr11:93663820	G/C	cg26875233	chr11:93583750	C11orf90	-0.32	-5.79	-0.34	1.95e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
CESC	cis	rs11214589	0.651	rs11214596	chr11:113264511	C/G	cg14159747	chr11:113255604	NA	0.36	6.37	0.36	8.16e-10	Neuroticism;
CESC	cis	rs597539	0.652	rs646586	chr11:68681653	C/T	cg04772025	chr11:68637568	NA	-0.48	-5.89	-0.34	1.19e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg11905131	chr22:24372483	LOC391322	-0.7	-9.99	-0.52	3.8e-20	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs798554	0.836	rs2260230	chr7:2822986	T/A	cg18446336	chr7:2847575	GNA12	-0.4	-6.02	-0.35	5.92e-9	Height;
CESC	cis	rs7618501	0.633	rs7628058	chr3:50039474	C/T	cg24308560	chr3:49941425	MST1R	-0.61	-8.81	-0.48	1.63e-16	Intelligence (multi-trait analysis);
CESC	cis	rs6460942	0.591	rs10262667	chr7:12385391	C/T	cg02935154	chr7:12443704	VWDE	-0.45	-6.01	-0.35	6.15e-9	Coronary artery disease;
CESC	cis	rs11098499	0.955	rs11944880	chr4:120159334	A/G	cg24375607	chr4:120327624	NA	-0.44	-5.29	-0.31	2.5e-7	Corneal astigmatism;
CESC	cis	rs780096	0.546	rs1104	chr2:27599875	T/G	cg17158414	chr2:27665306	KRTCAP3	-0.32	-5.97	-0.34	7.69e-9	Total body bone mineral density;
CESC	cis	rs2243480	1.000	rs1392104	chr7:65759107	G/A	cg12463550	chr7:65579703	CRCP	-0.74	-5.73	-0.33	2.74e-8	Diabetic kidney disease;
CESC	cis	rs9811920	0.665	rs1872609	chr3:99906579	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.36	-5.51	-0.32	8.43e-8	Axial length;
CESC	cis	rs28374715	0.532	rs11854820	chr15:41676526	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.08	-17.72	-0.74	7.19e-47	Ulcerative colitis;
CESC	cis	rs35306767	0.903	rs12250937	chr10:900209	C/T	cg20503657	chr10:835505	NA	0.78	7.72	0.43	2.41e-13	Eosinophil percentage of granulocytes;
CESC	cis	rs1552244	0.882	rs13099507	chr3:10031603	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.7	-8.29	-0.45	5.67e-15	Alzheimer's disease;
CESC	cis	rs7927592	0.956	rs12281742	chr11:68303629	C/T	cg01657329	chr11:68192670	LRP5	0.39	5.13	0.3	5.6e-7	Total body bone mineral density;
CESC	cis	rs2832077	0.527	rs9981922	chr21:30212718	A/G	cg24692254	chr21:30365293	RNF160	-0.64	-8.66	-0.47	4.77e-16	Cognitive test performance;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg13830646	chr11:65668067	FOSL1	-0.41	-6.14	-0.35	2.98e-9	Fibrinogen levels;
CESC	cis	rs763121	0.853	rs5750673	chr22:39110124	G/A	cg06544989	chr22:39130855	UNC84B	0.5	8.75	0.47	2.49e-16	Menopause (age at onset);
CESC	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg06074448	chr4:187884817	NA	-0.48	-7.37	-0.41	2.15e-12	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11963202	chr7:98985799	ARPC1B	-0.6	-7.26	-0.41	4.38e-12	Gut microbiome composition (summer);
CESC	cis	rs8060686	0.545	rs17688076	chr16:68286427	C/A	cg26727032	chr16:67993705	SLC12A4	-0.52	-5.58	-0.32	5.79e-8	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs9911578	0.839	rs7208505	chr17:57187729	C/T	cg12560992	chr17:57184187	TRIM37	0.98	17.15	0.73	7.51e-45	Intelligence (multi-trait analysis);
CESC	cis	rs7829975	0.564	rs2921060	chr8:8317817	G/T	cg06636001	chr8:8085503	FLJ10661	-0.5	-6.56	-0.37	2.88e-10	Mood instability;
CESC	trans	rs875971	0.964	rs2161065	chr7:65932905	A/G	cg26939375	chr7:64535504	NA	0.47	6.09	0.35	4.06e-9	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20306180	chr22:32340197	C22orf24;YWHAH	-0.69	-8.81	-0.48	1.73e-16	Gut microbiome composition (summer);
CESC	cis	rs10504229	0.683	rs10504221	chr8:58140256	A/G	cg22535103	chr8:58192502	C8orf71	-0.8	-9.09	-0.49	2.46e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs116095464	0.558	rs6555056	chr5:226222	T/C	cg22857025	chr5:266934	NA	-1.27	-18.8	-0.76	1.13e-50	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10088075	chr16:30407103	ZNF48	0.57	6.15	0.35	2.85e-9	Gut microbiome composition (summer);
CESC	cis	rs3540	0.597	rs10152221	chr15:91047664	A/G	cg10434728	chr15:90938212	IQGAP1	-0.43	-7.79	-0.43	1.53e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs6439153	0.933	rs1871951	chr3:128720487	A/G	cg25356066	chr3:128598488	ACAD9	0.54	7.0	0.4	2.1e-11	Pneumococcal bacteremia;
CESC	cis	rs10744422	1.000	rs897386	chr12:123341289	A/C	cg22842854	chr12:123319900	HIP1R	-0.63	-5.26	-0.31	3e-7	Schizophrenia;
CESC	cis	rs763014	0.898	rs62030902	chr16:638264	C/G	cg07343612	chr16:622815	PIGQ	-0.5	-6.83	-0.39	5.66e-11	Height;
CESC	cis	rs9910055	0.512	rs7209801	chr17:42323376	G/A	cg13607699	chr17:42295918	UBTF	0.85	12.21	0.6	1.73e-27	Total body bone mineral density;
CESC	cis	rs1707322	1.000	rs1707322	chr1:46505147	C/T	cg06784218	chr1:46089804	CCDC17	0.33	5.64	0.33	4.44e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs3845702	1.000	rs10497555	chr2:180864967	A/G	cg01881094	chr2:180872142	CWC22	0.62	6.43	0.37	6.05e-10	Schizophrenia;
CESC	cis	rs6088580	0.634	rs6059892	chr20:33105766	A/G	cg06115741	chr20:33292138	TP53INP2	0.45	5.8	0.34	1.88e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs2204008	0.902	rs11520218	chr12:38223227	G/A	cg13010199	chr12:38710504	ALG10B	0.54	6.69	0.38	1.35e-10	Bladder cancer;
CESC	cis	rs7100689	0.577	rs873395	chr10:82037215	C/T	cg09936400	chr10:82049201	MAT1A	-0.41	-5.96	-0.34	8.22e-9	Post bronchodilator FEV1;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11967563	chr10:3186147	PITRM1	-0.57	-6.42	-0.37	6.13e-10	Gut microbiome composition (summer);
CESC	cis	rs7824557	0.564	rs4631424	chr8:11236809	T/C	cg21775007	chr8:11205619	TDH	-0.54	-8.07	-0.44	2.52e-14	Retinal vascular caliber;
CESC	trans	rs11098499	1.000	rs58601355	chr4:120186367	T/C	cg25214090	chr10:38739885	LOC399744	0.63	8.32	0.46	4.54e-15	Corneal astigmatism;
CESC	cis	rs11621710	0.557	rs799474	chr14:35516099	C/G	cg16230307	chr14:35515116	FAM177A1	0.57	7.31	0.41	3.2e-12	Granulocyte percentage of myeloid white cells;
CESC	cis	rs9814567	0.896	rs6799110	chr3:134206749	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.44	-6.08	-0.35	4.26e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs801193	0.569	rs3846973	chr7:66120035	T/C	cg18252515	chr7:66147081	NA	0.48	6.43	0.37	5.77e-10	Aortic root size;
CESC	cis	rs66782572	1	rs66782572	chr3:52567617	A/G	cg05564831	chr3:52568323	NT5DC2	0.51	8.59	0.47	7.82e-16	Hemoglobin concentration;
CESC	cis	rs3733585	0.605	rs7656624	chr4:10121097	T/C	cg11266682	chr4:10021025	SLC2A9	-0.57	-10.97	-0.56	2.54e-23	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs11871801	0.517	rs60929812	chr17:40759448	G/A	cg21433558	chr17:40837037	CNTNAP1	0.48	5.84	0.34	1.56e-8	Crohn's disease;
CESC	cis	rs6912958	0.703	rs9362427	chr6:88097634	G/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.33	5.29	0.31	2.54e-7	Monocyte percentage of white cells;
CESC	cis	rs11098499	0.661	rs10015965	chr4:120268237	A/G	cg09307838	chr4:120376055	NA	0.76	10.0	0.52	3.52e-20	Corneal astigmatism;
CESC	cis	rs3818285	0.556	rs2084607	chr10:111681411	C/T	cg00817464	chr10:111662876	XPNPEP1	0.52	7.6	0.42	5.26e-13	Superior crus of antihelix expression;
CESC	cis	rs1461503	0.932	rs7107575	chr11:122845406	C/T	cg27398637	chr11:122830231	C11orf63	0.53	7.69	0.43	2.85e-13	Menarche (age at onset);
CESC	cis	rs854765	0.547	rs7223696	chr17:17915791	G/T	cg04398451	chr17:18023971	MYO15A	-0.69	-10.29	-0.53	4.08e-21	Total body bone mineral density;
CESC	cis	rs5769765	0.526	rs5770722	chr22:50253220	G/C	cg02269571	chr22:50332266	NA	0.46	5.45	0.32	1.16e-7	Schizophrenia;
CESC	cis	rs6842047	1.000	rs10471184	chr4:187122904	C/T	cg02012338	chr4:187126139	CYP4V2	-0.73	-5.84	-0.34	1.53e-8	Blood protein levels;
CESC	cis	rs6815814	0.898	rs17582830	chr4:38867427	A/G	cg02016764	chr4:38805732	TLR1	-0.59	-7.22	-0.41	5.38e-12	Breast cancer;
CESC	cis	rs7945705	0.935	rs2568062	chr11:8887945	A/G	cg12365402	chr11:9010492	NRIP3	-0.31	-5.1	-0.3	6.41e-7	Hemoglobin concentration;
CESC	cis	rs12497850	0.931	rs4072859	chr3:49032205	G/C	cg03060546	chr3:49711283	APEH	0.51	6.07	0.35	4.49e-9	Parkinson's disease;
CESC	cis	rs172166	0.611	rs203882	chr6:28078502	G/A	cg19592336	chr6:28129416	ZNF389	0.47	6.96	0.39	2.68e-11	Cardiac Troponin-T levels;
CESC	cis	rs832540	0.966	rs33321	chr5:56206073	G/T	cg24531977	chr5:56204891	C5orf35	-0.43	-5.36	-0.31	1.78e-7	Coronary artery disease;
CESC	cis	rs9611565	0.659	rs11090049	chr22:41915329	C/T	cg06481639	chr22:41940642	POLR3H	-0.64	-6.55	-0.37	3.02e-10	Vitiligo;
CESC	trans	rs2085496	0.764	rs1596751	chr2:193807860	A/G	cg26210255	chr12:100594894	ACTR6	0.46	6.39	0.37	7.3e-10	Neuroticism;
CESC	trans	rs208515	0.556	rs12214562	chr6:66681011	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.89	11.12	0.56	7.77e-24	Exhaled nitric oxide levels;
CESC	cis	rs6582630	0.502	rs11520278	chr12:38359642	T/A	cg26384229	chr12:38710491	ALG10B	0.73	10.65	0.55	2.87e-22	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs7786877	0.723	rs10487157	chr7:100214487	C/G	cg16850897	chr7:100343110	ZAN	-0.57	-6.14	-0.35	2.93e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs3820068	0.705	rs4646092	chr1:15821673	C/T	cg17385448	chr1:15911702	AGMAT	0.39	6.18	0.35	2.44e-9	Systolic blood pressure;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg21587861	chr12:32260103	BICD1	-0.44	-6.31	-0.36	1.16e-9	Gambling;
CESC	cis	rs9311474	0.607	rs34005367	chr3:52558904	A/T	cg05564831	chr3:52568323	NT5DC2	0.45	7.03	0.4	1.72e-11	Electroencephalogram traits;
CESC	cis	rs6460942	0.841	rs17443848	chr7:12443688	A/G	cg17427002	chr7:12443146	VWDE	-0.53	-6.5	-0.37	3.91e-10	Coronary artery disease;
CESC	cis	rs10540	0.730	rs61876338	chr11:493730	A/G	cg03352830	chr11:487213	PTDSS2	0.73	7.08	0.4	1.26e-11	Body mass index;
CESC	cis	rs12497850	0.931	rs6442130	chr3:48778027	A/G	cg06212747	chr3:49208901	KLHDC8B	0.57	7.03	0.4	1.74e-11	Parkinson's disease;
CESC	cis	rs672059	0.513	rs627064	chr1:183165716	C/T	cg23696949	chr1:183155644	LAMC2	-0.25	-5.82	-0.34	1.69e-8	Hypertriglyceridemia;
CESC	cis	rs7078219	0.714	rs11190139	chr10:101288099	C/G	cg09788492	chr10:101292477	NKX2-3	0.32	5.07	0.3	7.55e-7	Dental caries;
CESC	trans	rs687914	0.710	rs938662	chr2:45864578	A/G	cg15351736	chr11:111808104	DIXDC1	0.59	6.13	0.35	3.24e-9	Diastolic blood pressure;
CESC	trans	rs709082	0.709	rs709097	chr3:191469255	T/C	cg25305879	chr2:106814630	NA	0.4	6.46	0.37	5.04e-10	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9733	0.519	rs1336900	chr1:150679033	C/T	cg18016565	chr1:150552671	MCL1	0.32	5.03	0.3	8.96e-7	Tonsillectomy;
CESC	cis	rs12142240	0.698	rs10158572	chr1:46822440	G/T	cg00530320	chr1:46809349	NSUN4	0.6	8.04	0.44	2.96e-14	Menopause (age at onset);
CESC	cis	rs589448	0.967	rs634512	chr12:69754012	C/T	cg14784868	chr12:69753453	YEATS4	0.92	14.62	0.67	6.85e-36	Cerebrospinal fluid biomarker levels;
CESC	cis	rs4076764	0.830	rs10917770	chr1:163442214	G/C	cg06092702	chr1:163392909	NA	-0.37	-5.43	-0.32	1.26e-7	Motion sickness;
CESC	cis	rs7552404	0.731	rs10873787	chr1:76367797	G/A	cg10523679	chr1:76189770	ACADM	0.63	6.09	0.35	4.06e-9	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs763121	0.853	rs2205802	chr22:39046327	T/C	cg06022373	chr22:39101656	GTPBP1	0.88	13.79	0.65	5.43e-33	Menopause (age at onset);
CESC	trans	rs61931739	0.534	rs1826144	chr12:34094272	A/G	cg26384229	chr12:38710491	ALG10B	0.59	8.25	0.45	7.65e-15	Morning vs. evening chronotype;
CESC	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg16145915	chr7:1198662	ZFAND2A	-0.49	-6.04	-0.35	5.1e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs6831352	0.918	rs2851247	chr4:100046091	C/G	cg13256891	chr4:100009986	ADH5	-0.82	-8.79	-0.47	1.98e-16	Alcohol dependence;
CESC	cis	rs7605378	1.000	rs7605378	chr2:200676926	A/C	cg23649088	chr2:200775458	C2orf69	0.5	6.45	0.37	5.39e-10	Osteoporosis;
CESC	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.65	0.38	1.71e-10	Prudent dietary pattern;
CESC	cis	rs854765	0.655	rs4470201	chr17:17844870	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.57	8.17	0.45	1.3e-14	Total body bone mineral density;
CESC	cis	rs2985684	0.894	rs4900927	chr14:50018741	G/T	cg02151108	chr14:50098012	C14orf104	-0.38	-5.14	-0.3	5.35e-7	Carotid intima media thickness;
CESC	cis	rs7208859	0.573	rs7222803	chr17:29119897	A/G	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.1e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs4780401	0.703	rs3190321	chr16:11773662	C/G	cg01061890	chr16:11836724	TXNDC11	-0.5	-6.75	-0.38	9.45e-11	Rheumatoid arthritis;
CESC	trans	rs3942852	0.868	rs7118232	chr11:48106274	T/C	cg15704280	chr7:45808275	SEPT13	-0.67	-7.65	-0.43	3.62e-13	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs873946	0.586	rs12776770	chr10:134564831	T/C	cg18305652	chr10:134549665	INPP5A	0.47	6.77	0.38	8.43e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs801193	0.805	rs12532355	chr7:66070584	C/G	cg14393609	chr7:65229607	NA	-0.42	-5.86	-0.34	1.34e-8	Aortic root size;
CESC	cis	rs1881797	0.932	rs10925071	chr1:247686521	C/T	cg11166453	chr1:247681781	NA	-0.44	-6.33	-0.36	1.06e-9	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs1577917	0.771	rs2842613	chr6:86305702	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.52	7.25	0.41	4.58e-12	Response to antipsychotic treatment;
CESC	cis	rs6597981	0.675	rs4963120	chr11:825777	A/G	cg20225915	chr11:805726	LRDD	0.3	5.06	0.3	7.81e-7	Breast cancer;
CESC	cis	rs67311347	1.000	rs7634375	chr3:40431946	C/T	cg24209194	chr3:40518798	ZNF619	0.5	6.24	0.36	1.74e-9	Renal cell carcinoma;
CESC	cis	rs4986811	1.000	rs11031779	chr11:32452888	C/T	cg27409910	chr11:32454216	WT1	0.49	6.33	0.36	1.04e-9	Rubella-specific interleukin-6 secretion;
CESC	cis	rs2806561	0.929	rs641452	chr1:23538386	A/G	cg12483005	chr1:23474871	LUZP1	0.32	5.12	0.3	5.8e-7	Height;
CESC	cis	rs1670533	1.000	rs2045066	chr4:1052401	C/T	cg27284194	chr4:1044797	NA	0.45	5.75	0.33	2.43e-8	Recombination rate (females);
CESC	cis	rs9303401	0.555	rs8073699	chr17:57236317	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.64	7.98	0.44	4.36e-14	Cognitive test performance;
CESC	cis	rs1862618	0.853	rs861283	chr5:56184610	C/T	cg18230493	chr5:56204884	C5orf35	-0.73	-8.57	-0.47	8.93e-16	Initial pursuit acceleration;
CESC	cis	rs4964805	0.802	rs934847	chr12:104185693	C/T	cg02344784	chr12:104178138	NT5DC3	0.39	5.42	0.32	1.31e-7	Attention deficit hyperactivity disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18737971	chr15:43941642	CATSPER2	-0.74	-8.71	-0.47	3.45e-16	Gut microbiome composition (summer);
CESC	cis	rs35306767	0.903	rs12249828	chr10:894838	C/T	cg26597838	chr10:835615	NA	0.83	9.05	0.49	3.21e-17	Eosinophil percentage of granulocytes;
CESC	cis	rs10465746	0.967	rs11163874	chr1:84424437	G/C	cg10977910	chr1:84465055	TTLL7	0.47	6.28	0.36	1.38e-9	Obesity-related traits;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg24337108	chr10:11797422	ECHDC3	-0.42	-6.07	-0.35	4.43e-9	Systemic lupus erythematosus;
CESC	cis	rs12893668	0.572	rs12590968	chr14:104136633	G/C	cg24130564	chr14:104152367	KLC1	-0.49	-6.46	-0.37	4.98e-10	Reticulocyte count;
CESC	cis	rs34779708	0.966	rs12260130	chr10:35467671	C/T	cg04310649	chr10:35416472	CREM	-0.54	-6.78	-0.38	7.74e-11	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs2760061	0.598	rs632832	chr1:228121838	G/T	cg02753203	chr1:228287806	NA	-0.5	-7.4	-0.41	1.75e-12	Diastolic blood pressure;
CESC	cis	rs6662572	0.855	rs7517418	chr1:46252418	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.45	-5.06	-0.3	7.79e-7	Blood protein levels;
CESC	cis	rs7539624	0.588	rs61823966	chr1:223895942	C/T	cg10100437	chr1:223903862	CAPN2	0.43	5.44	0.32	1.22e-7	Schizophrenia;
CESC	cis	rs2072732	0.821	rs58052947	chr1:2950094	T/C	cg15211996	chr1:2936768	ACTRT2	0.32	5.67	0.33	3.8e-8	Plateletcrit;
CESC	cis	rs9549260	0.755	rs3892360	chr13:41184078	C/G	cg21288729	chr13:41239152	FOXO1	0.64	8.31	0.45	4.98e-15	Red blood cell count;
CESC	cis	rs798554	0.797	rs1182184	chr7:2872446	G/A	cg13628971	chr7:2884303	GNA12	0.63	8.47	0.46	1.7e-15	Height;
CESC	cis	rs4819052	0.851	rs8130285	chr21:46671701	G/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.45	5.59	0.32	5.76e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs11229555	1.000	rs2298608	chr11:58404467	A/G	cg15696309	chr11:58395628	NA	0.46	5.94	0.34	8.95e-9	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs6499255	0.951	rs57565297	chr16:69723122	G/T	cg15192750	chr16:69999425	NA	0.5	5.73	0.33	2.67e-8	IgE levels;
CESC	trans	rs4130047	0.606	rs8096948	chr18:40681293	T/C	cg27079740	chr4:176733877	GPM6A	0.42	6.02	0.35	5.79e-9	Parkinson's disease;
CESC	cis	rs477895	0.713	rs12787852	chr11:63954648	G/A	cg18225595	chr11:63971243	STIP1	0.52	5.16	0.3	4.77e-7	Mean platelet volume;
CESC	cis	rs4654899	0.865	rs6691824	chr1:21417577	T/G	cg05370193	chr1:21551575	ECE1	0.43	6.73	0.38	1.07e-10	Superior frontal gyrus grey matter volume;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg01889112	chr15:59063272	FAM63B	-0.53	-6.9	-0.39	3.82e-11	Ulcerative colitis;
CESC	cis	rs7666738	0.830	rs1593573	chr4:98925293	T/C	cg03467027	chr4:99064603	C4orf37	0.46	5.59	0.32	5.78e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9916302	0.898	rs8072297	chr17:37478048	A/T	cg20243544	chr17:37824526	PNMT	-0.45	-5.53	-0.32	7.78e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs4713118	0.527	rs35949862	chr6:28115367	A/G	cg17949981	chr6:28129498	ZNF389	0.45	5.49	0.32	9.35e-8	Parkinson's disease;
CESC	cis	rs798554	0.797	rs798487	chr7:2802943	G/A	cg09658497	chr7:2847517	GNA12	-0.44	-6.14	-0.35	3.06e-9	Height;
CESC	cis	rs7216064	0.765	rs6504550	chr17:65894542	A/G	cg12091567	chr17:66097778	LOC651250	-0.65	-8.19	-0.45	1.14e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs13427251	0.868	rs1901284	chr2:100146040	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.51	6.73	0.38	1.07e-10	Chronic sinus infection;
CESC	cis	rs13392177	0.660	rs10932762	chr2:219076213	G/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.52	-6.43	-0.37	5.9e-10	Pyoderma gangrenosum in inflammatory bowel disease;
CESC	cis	rs10871290	1.000	rs10871290	chr16:74472696	C/T	cg01733217	chr16:74700730	RFWD3	-0.65	-8.64	-0.47	5.55e-16	Breast cancer;
CESC	cis	rs7772486	0.790	rs4280983	chr6:146280790	G/C	cg23711669	chr6:146136114	FBXO30	-0.93	-13.53	-0.64	4.58e-32	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs5769765	0.908	rs9616396	chr22:50317825	T/C	cg26441486	chr22:50317300	CRELD2	0.48	5.75	0.33	2.44e-8	Schizophrenia;
CESC	cis	rs561341	0.528	rs11650908	chr17:30195425	T/C	cg13647721	chr17:30228624	UTP6	-0.69	-8.22	-0.45	9.08e-15	Hip circumference adjusted for BMI;
CESC	cis	rs1421811	0.532	rs17540044	chr5:32692238	C/G	cg16267343	chr5:32710456	NPR3	-0.55	-6.06	-0.35	4.73e-9	Blood pressure;
CESC	cis	rs3820928	0.874	rs2229812	chr2:227896886	C/T	cg05526886	chr2:227700861	RHBDD1	-0.45	-5.65	-0.33	4.22e-8	Pulmonary function;
CESC	trans	rs637571	0.522	rs566590	chr11:65754062	C/T	cg17712092	chr4:129076599	LARP1B	0.72	9.89	0.52	7.93e-20	Eosinophil percentage of white cells;
CESC	cis	rs7084402	0.967	rs1658490	chr10:60281616	G/A	cg07615347	chr10:60278583	BICC1	-0.6	-9.49	-0.5	1.43e-18	Refractive error;
CESC	trans	rs11098499	0.562	rs58583086	chr4:120556362	A/G	cg25214090	chr10:38739885	LOC399744	-0.53	-7.68	-0.43	3.02e-13	Corneal astigmatism;
CESC	cis	rs1862618	0.671	rs173763	chr5:56225418	G/A	cg22800045	chr5:56110881	MAP3K1	0.59	7.76	0.43	1.86e-13	Initial pursuit acceleration;
CESC	cis	rs10411936	0.712	rs9305079	chr19:16591464	C/T	cg10248733	chr19:16607483	C19orf44;CALR3	0.58	7.25	0.41	4.6e-12	White blood cell count;Multiple sclerosis;
CESC	cis	rs7666738	0.962	rs1527515	chr4:99025733	C/A	cg05340658	chr4:99064831	C4orf37	0.63	8.31	0.45	4.9e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2072499	0.750	rs7534339	chr1:156156219	A/G	cg25208724	chr1:156163844	SLC25A44	0.99	12.47	0.61	2.09e-28	Testicular germ cell tumor;
CESC	cis	rs2243480	1.000	rs778691	chr7:65873092	G/C	cg12463550	chr7:65579703	CRCP	0.71	5.49	0.32	9.37e-8	Diabetic kidney disease;
CESC	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.6	-7.86	-0.43	9.62e-14	Prudent dietary pattern;
CESC	cis	rs3806843	0.735	rs801168	chr5:140080298	A/G	cg26395211	chr5:140044315	WDR55	0.49	6.25	0.36	1.67e-9	Depressive symptoms (multi-trait analysis);
CESC	cis	rs6674176	0.660	rs3791112	chr1:44379248	T/G	cg13606994	chr1:44402422	ARTN	-0.41	-6.28	-0.36	1.37e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs769267	0.859	rs2916076	chr19:19545990	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.47	5.95	0.34	8.58e-9	Tonsillectomy;
CESC	cis	rs10927875	1.000	rs10927875	chr1:16299312	A/G	cg22431228	chr1:16359049	CLCNKA	-0.37	-5.82	-0.34	1.7e-8	Dilated cardiomyopathy;
CESC	cis	rs4074961	0.669	rs6687545	chr1:38071195	C/T	cg13401533	chr1:37979913	MEAF6	0.52	7.05	0.4	1.51e-11	Axial length;
CESC	trans	rs208520	0.690	rs4710311	chr6:66823223	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.86	-11.54	-0.58	3.09e-25	Exhaled nitric oxide output;
CESC	cis	rs3105593	0.933	rs4775894	chr15:50903600	C/T	cg08437265	chr15:50716283	USP8	0.42	5.33	0.31	2.05e-7	QT interval;
CESC	cis	rs12079745	0.793	rs11805562	chr1:169292916	A/C	cg09363564	chr1:169337483	NME7;BLZF1	-1.13	-6.56	-0.37	2.81e-10	QT interval;
CESC	cis	rs11690935	0.571	rs13020884	chr2:172901699	T/G	cg13550731	chr2:172543902	DYNC1I2	0.46	6.1	0.35	3.68e-9	Schizophrenia;
CESC	cis	rs7680126	0.633	rs11727390	chr4:10296760	C/T	cg11266682	chr4:10021025	SLC2A9	-0.42	-5.66	-0.33	4.01e-8	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	cis	rs9910055	0.659	rs227578	chr17:42210189	C/A	cg08499158	chr17:42289980	UBTF	0.5	6.34	0.36	1.01e-9	Total body bone mineral density;
CESC	cis	rs4561483	0.583	rs33636	chr16:11990323	C/G	cg08843971	chr16:11963173	GSPT1	-0.49	-6.93	-0.39	3.13e-11	Testicular germ cell tumor;
CESC	cis	rs910316	0.763	rs6574205	chr14:75453039	G/C	cg16144293	chr14:75469539	EIF2B2	-0.4	-5.23	-0.31	3.38e-7	Height;
CESC	cis	rs2243480	1.000	rs781150	chr7:65480973	C/T	cg18252515	chr7:66147081	NA	-1.26	-12.38	-0.61	4.54e-28	Diabetic kidney disease;
CESC	cis	rs3768617	0.510	rs3768615	chr1:183103604	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.89	14.36	0.66	5.5800000000000005e-35	Fuchs's corneal dystrophy;
CESC	cis	rs4523957	0.757	rs1002135	chr17:2097583	T/G	cg16513277	chr17:2031491	SMG6	-0.57	-7.84	-0.43	1.08e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs4629710	0.538	rs11754401	chr6:131582197	G/A	cg12606694	chr6:131520996	AKAP7	0.49	5.99	0.35	6.95e-9	Multiple myeloma (IgH translocation);
CESC	cis	rs62244186	0.566	rs2135531	chr3:44881158	C/G	cg15225532	chr3:44803084	KIF15;KIAA1143	0.41	5.36	0.31	1.85e-7	Depressive symptoms;
CESC	cis	rs1215050	0.740	rs1084784	chr4:98961711	T/G	cg17366294	chr4:99064904	C4orf37	-0.38	-5.03	-0.3	8.96e-7	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs644799	1.000	rs693364	chr11:95621926	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.47	5.53	0.32	7.48e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs4665809	0.627	rs13032756	chr2:26489730	A/T	cg04944784	chr2:26401820	FAM59B	0.96	10.82	0.55	7.56e-23	Gut microbiome composition (summer);
CESC	cis	rs4665809	1.000	rs6704930	chr2:26325705	G/A	cg08470875	chr2:26401718	FAM59B	-0.47	-5.22	-0.31	3.6e-7	Gut microbiome composition (summer);
CESC	cis	rs1163251	0.902	rs839605	chr1:120217524	C/A	cg19096424	chr1:120255104	PHGDH	0.43	5.22	0.31	3.62e-7	Blood metabolite levels;
CESC	cis	rs6580649	0.941	rs17122612	chr12:48459488	C/G	cg24011408	chr12:48396354	COL2A1	-0.41	-5.3	-0.31	2.43e-7	Lung cancer;
CESC	cis	rs977987	0.750	rs4888414	chr16:75447233	A/G	cg03315344	chr16:75512273	CHST6	0.41	5.83	0.34	1.59e-8	Dupuytren's disease;
CESC	cis	rs2415984	0.622	rs61993302	chr14:46949684	C/T	cg14871534	chr14:47121158	RPL10L	-0.38	-5.67	-0.33	3.72e-8	Number of children ever born;
CESC	cis	rs17539620	0.624	rs12665520	chr6:154835273	C/T	cg20019720	chr6:154832845	CNKSR3	0.44	5.91	0.34	1.03e-8	Lipoprotein (a) levels;
CESC	cis	rs2204008	0.506	rs11495470	chr12:38026904	C/T	cg26384229	chr12:38710491	ALG10B	0.66	9.39	0.5	2.96e-18	Bladder cancer;
CESC	cis	rs8177253	0.665	rs9869257	chr3:133451412	G/T	cg24879335	chr3:133465180	TF	0.37	6.47	0.37	4.62e-10	Iron status biomarkers;
CESC	cis	rs9388451	0.874	rs7739566	chr6:126094757	A/T	cg10911889	chr6:126070802	HEY2	0.36	5.09	0.3	6.91e-7	Brugada syndrome;
CESC	cis	rs9611565	0.918	rs9611566	chr22:41768625	A/G	cg06481639	chr22:41940642	POLR3H	0.68	7.26	0.41	4.43e-12	Vitiligo;
CESC	cis	rs11252926	0.674	rs11598550	chr10:504778	A/C	cg18196295	chr10:418757	DIP2C	-0.52	-7.08	-0.4	1.33e-11	Psychosis in Alzheimer's disease;
CESC	cis	rs7927771	0.542	rs11039336	chr11:47706141	A/G	cg18512352	chr11:47633146	NA	-0.36	-5.65	-0.33	4.17e-8	Subjective well-being;
CESC	cis	rs10751667	1.000	rs10751667	chr11:941941	A/T	cg20946044	chr11:1010712	AP2A2	-0.39	-5.2	-0.3	4.04e-7	Alzheimer's disease (late onset);
CESC	cis	rs9910055	0.762	rs6503489	chr17:42246289	G/A	cg13607699	chr17:42295918	UBTF	0.69	9.37	0.5	3.23e-18	Total body bone mineral density;
CESC	cis	rs290268	0.874	rs772407	chr9:93560850	A/C	cg02608019	chr9:93564028	SYK	0.67	10.22	0.53	6.84e-21	Platelet count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15573879	chr1:36851774	STK40	-0.68	-8.15	-0.45	1.48e-14	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00634145	chr1:155108588	RAG1AP1	0.61	6.64	0.38	1.75e-10	Gut microbiome composition (summer);
CESC	cis	rs3806843	1.000	rs10038174	chr5:140210616	G/A	cg26395211	chr5:140044315	WDR55	-0.41	-5.05	-0.3	8.38e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs9815354	0.951	rs1717028	chr3:41902964	C/T	cg03022575	chr3:42003672	ULK4	0.45	5.23	0.31	3.46e-7	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg03188948	chr7:1209495	NA	0.7	6.71	0.38	1.2e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs1153858	0.895	rs12593402	chr15:45617392	G/A	cg14582100	chr15:45693742	SPATA5L1	0.4	5.62	0.33	4.8e-8	Homoarginine levels;
CESC	cis	rs6460942	0.915	rs62448598	chr7:12453762	T/C	cg06484146	chr7:12443880	VWDE	-0.78	-9.14	-0.49	1.68e-17	Coronary artery disease;
CESC	cis	rs597539	0.654	rs655816	chr11:68626405	A/G	cg06028808	chr11:68637592	NA	0.48	5.71	0.33	3e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs76917914	0.820	rs7041811	chr9:100821028	C/T	cg03040243	chr9:100819229	NANS	0.51	5.78	0.33	2.1e-8	Immature fraction of reticulocytes;
CESC	cis	rs748404	0.697	rs493177	chr15:43543258	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.61	8.11	0.45	1.83e-14	Lung cancer;
CESC	cis	rs10242455	0.702	rs78640327	chr7:99167139	G/C	cg25640893	chr7:99214727	ZNF498	1.19	7.16	0.4	7.79e-12	Blood metabolite levels;
CESC	cis	rs9584850	0.915	rs7983438	chr13:99103317	T/C	cg20750642	chr13:99100586	FARP1	-0.38	-5.7	-0.33	3.23e-8	Neuroticism;
CESC	cis	rs11030122	0.661	rs10767811	chr11:4066398	G/A	cg18678763	chr11:4115507	RRM1	-0.44	-5.94	-0.34	8.74e-9	Mean platelet volume;Platelet distribution width;
CESC	cis	rs72781680	0.898	rs72780188	chr2:24006065	G/A	cg08917208	chr2:24149416	ATAD2B	0.95	8.71	0.47	3.45e-16	Lymphocyte counts;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg24829313	chr11:63684597	RCOR2	-0.45	-6.53	-0.37	3.31e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs6542838	0.704	rs56125264	chr2:99516699	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.42	-5.23	-0.31	3.43e-7	Fear of minor pain;
CESC	cis	rs12682352	0.602	rs6988939	chr8:8666916	C/T	cg06636001	chr8:8085503	FLJ10661	0.42	5.3	0.31	2.4e-7	Neuroticism;
CESC	cis	rs2070488	1.000	rs2276540	chr3:38512507	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.95	17.45	0.73	6.36e-46	Electrocardiographic conduction measures;
CESC	cis	rs66561647	0.719	rs4733582	chr8:128947967	C/T	cg05480350	chr8:128972681	MIR1205;PVT1	0.4	5.34	0.31	1.98e-7	Hemoglobin concentration;
CESC	cis	rs7617773	0.817	rs11709691	chr3:48303669	A/G	cg11946769	chr3:48343235	NME6	0.86	11.61	0.58	1.78e-25	Coronary artery disease;
CESC	cis	rs568617	0.626	rs10896050	chr11:65577516	G/T	cg04055107	chr11:65626734	MUS81;CFL1	0.73	6.63	0.38	1.87e-10	Crohn's disease;
CESC	cis	rs13191362	0.935	rs73008456	chr6:163013697	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.87	8.98	0.48	5.33e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs344364	0.511	rs12596510	chr16:1949480	G/A	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.55	-6.2	-0.36	2.15e-9	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs3820068	0.705	rs72643683	chr1:15824905	C/A	cg17385448	chr1:15911702	AGMAT	0.4	6.12	0.35	3.37e-9	Systolic blood pressure;
CESC	cis	rs2228479	0.850	rs2286393	chr16:89809548	C/A	cg06558623	chr16:89946397	TCF25	1.09	8.78	0.47	2e-16	Skin colour saturation;
CESC	cis	rs10504229	0.593	rs17192845	chr8:58053339	C/T	cg21724239	chr8:58056113	NA	0.59	5.24	0.31	3.36e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs9470366	0.772	rs9918353	chr6:36622677	A/C	cg08179530	chr6:36648295	CDKN1A	0.56	6.7	0.38	1.28e-10	QRS duration;
CESC	cis	rs6952808	0.692	rs59619245	chr7:2068630	C/T	cg05863683	chr7:1912471	MAD1L1	0.44	6.51	0.37	3.79e-10	Bipolar disorder and schizophrenia;
CESC	cis	rs2033711	0.870	rs1465789	chr19:58946056	C/T	cg26874164	chr19:58962979	ZNF324B	0.53	7.17	0.4	7.42e-12	Uric acid clearance;
CESC	cis	rs12220238	0.730	rs4746177	chr10:75913033	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.64	6.55	0.37	3.04e-10	Soluble interleukin-2 receptor subunit alpha;
CESC	cis	rs4665809	0.838	rs6546749	chr2:26306288	T/C	cg26314531	chr2:26401878	FAM59B	-0.77	-8.56	-0.47	9.38e-16	Gut microbiome composition (summer);
CESC	cis	rs765787	0.530	rs4442750	chr15:45535328	G/T	cg24006582	chr15:45444508	DUOX1	-0.59	-7.23	-0.41	5.15e-12	Uric acid levels;
CESC	cis	rs17428076	0.793	rs12622772	chr2:172625737	T/C	cg13550731	chr2:172543902	DYNC1I2	0.46	5.16	0.3	4.9e-7	Myopia;
CESC	cis	rs7618915	0.547	rs62255362	chr3:52699741	C/G	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.71	0.38	1.17e-10	Bipolar disorder;
CESC	cis	rs8018808	1.000	rs4575469	chr14:77860543	G/A	cg20045696	chr14:77926864	AHSA1	-0.38	-5.18	-0.3	4.46e-7	Myeloid white cell count;
CESC	cis	rs4073221	0.520	rs66659472	chr3:18196527	G/A	cg07694806	chr3:18168406	NA	-0.67	-5.27	-0.31	2.79e-7	Parkinson's disease;
CESC	cis	rs3091242	0.935	rs3093632	chr1:25684012	C/T	cg02931644	chr1:25747376	RHCE	0.47	7.99	0.44	4.14e-14	Erythrocyte sedimentation rate;
CESC	cis	rs7520050	0.966	rs1085244	chr1:46563680	C/A	cg03146154	chr1:46216737	IPP	-0.43	-5.52	-0.32	8.27e-8	Red blood cell count;Reticulocyte count;
CESC	cis	rs13394619	0.744	rs10929759	chr2:11722012	C/G	cg07314298	chr2:11723111	GREB1	0.45	6.59	0.38	2.34e-10	Endometriosis;
CESC	cis	rs597539	0.689	rs596874	chr11:68630874	C/T	cg06028808	chr11:68637592	NA	-0.42	-5.13	-0.3	5.5e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs60871478	0.786	rs55899111	chr7:827843	C/G	cg05535760	chr7:792225	HEATR2	-0.96	-11.08	-0.56	1.08e-23	Cerebrospinal P-tau181p levels;
CESC	cis	rs11098499	0.954	rs10014845	chr4:120301077	T/G	cg09307838	chr4:120376055	NA	0.92	12.66	0.61	4.96e-29	Corneal astigmatism;
CESC	cis	rs6460942	0.915	rs62448619	chr7:12457743	C/T	cg06484146	chr7:12443880	VWDE	-0.78	-9.14	-0.49	1.68e-17	Coronary artery disease;
CESC	cis	rs11677416	1.000	rs6542091	chr2:113525311	G/A	cg27083787	chr2:113543245	IL1A	0.41	5.16	0.3	4.75e-7	Response to antipsychotic treatment in schizophrenia (working memory);
CESC	cis	rs847577	0.722	rs1013887	chr7:97709345	G/T	cg24562669	chr7:97807699	LMTK2	0.61	9.8	0.52	1.52e-19	Breast cancer;
CESC	cis	rs1008375	1.000	rs6848360	chr4:17634442	G/T	cg02297831	chr4:17616191	MED28	0.62	7.91	0.44	7.23e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs6691722	0.503	rs1064842	chr1:24706269	A/G	cg18323236	chr1:24743029	NIPAL3	0.37	5.61	0.33	5.09e-8	Response to interferon beta in multiple sclerosis;
CESC	cis	rs262150	0.842	rs2657398	chr7:158784911	T/C	cg04111992	chr7:158790115	NA	-0.33	-5.22	-0.31	3.59e-7	Facial morphology (factor 20);
CESC	cis	rs9733	0.596	rs2867301	chr1:150653795	C/T	cg04414720	chr1:150670196	GOLPH3L	0.63	9.01	0.48	4.11e-17	Tonsillectomy;
CESC	cis	rs763014	0.966	rs4247097	chr16:654224	G/A	cg07256732	chr16:621771	PIGQ	-0.31	-5.36	-0.31	1.82e-7	Height;
CESC	cis	rs72781680	0.898	rs79023848	chr2:24038174	C/A	cg20701182	chr2:24300061	SF3B14	0.78	6.7	0.38	1.22e-10	Lymphocyte counts;
CESC	cis	rs7618915	0.547	rs11130317	chr3:52731483	C/T	cg05564831	chr3:52568323	NT5DC2	0.44	6.69	0.38	1.33e-10	Bipolar disorder;
CESC	cis	rs6964587	1.000	rs7797834	chr7:91743150	C/T	cg17063962	chr7:91808500	NA	-0.58	-7.95	-0.44	5.26e-14	Breast cancer;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg05358183	chr16:85112625	KIAA0513	-0.47	-6.52	-0.37	3.46e-10	Systemic lupus erythematosus;
CESC	cis	rs12348691	0.503	rs3021523	chr9:100616583	T/C	cg13688889	chr9:100608707	NA	-0.9	-13.65	-0.64	1.78e-32	Alopecia areata;
CESC	cis	rs2832191	0.740	rs6516890	chr21:30476812	T/A	cg24692254	chr21:30365293	RNF160	0.8	12.54	0.61	1.25e-28	Dental caries;
CESC	cis	rs6879260	1.000	rs729568	chr5:179732350	C/T	cg02891314	chr5:179741120	GFPT2	0.56	7.75	0.43	1.93e-13	Height;
CESC	cis	rs2836950	0.502	rs2150411	chr21:40574552	G/T	cg17971929	chr21:40555470	PSMG1	-0.6	-8.06	-0.44	2.64e-14	Menarche (age at onset);
CESC	cis	rs1799949	0.965	rs33961729	chr17:41287924	C/A	cg25072359	chr17:41440525	NA	0.45	6.04	0.35	5.14e-9	Menopause (age at onset);
CESC	cis	rs1552244	0.572	rs57268864	chr3:10164233	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.79	8.79	0.47	1.98e-16	Alzheimer's disease;
CESC	cis	rs2842992	0.789	rs2342446	chr6:160220687	A/G	cg26839252	chr6:160211577	TCP1;MRPL18	0.44	5.03	0.3	9.06e-7	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs4132509	0.744	rs6687181	chr1:243878518	C/T	cg21452805	chr1:244014465	NA	0.56	6.47	0.37	4.66e-10	RR interval (heart rate);
CESC	cis	rs796364	0.715	rs78988795	chr2:201095739	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.73	-5.11	-0.3	6.23e-7	Schizophrenia;
CESC	cis	rs926938	0.563	rs360635	chr1:115420518	A/C	cg12756093	chr1:115239321	AMPD1	0.45	6.06	0.35	4.72e-9	Autism;
CESC	cis	rs1008375	0.898	rs61047804	chr4:17593965	G/A	cg27347728	chr4:17578864	LAP3	0.44	5.24	0.31	3.33e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs6987853	0.966	rs2923439	chr8:42429122	A/G	cg09913449	chr8:42400586	C8orf40	0.41	6.46	0.37	4.86e-10	Mean corpuscular hemoglobin concentration;
CESC	cis	rs7552404	0.727	rs2172507	chr1:76331320	A/G	cg10523679	chr1:76189770	ACADM	-0.65	-6.55	-0.37	3e-10	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs12368653	0.651	rs2307097	chr12:58195801	T/C	cg00677455	chr12:58241039	CTDSP2	-0.46	-5.84	-0.34	1.51e-8	Multiple sclerosis;
CESC	cis	rs4665809	0.590	rs62128457	chr2:26467347	C/A	cg22920501	chr2:26401640	FAM59B	0.91	10.33	0.54	3.07e-21	Gut microbiome composition (summer);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg18085405	chr10:29779942	SVIL	0.46	6.13	0.35	3.21e-9	Fibrinogen levels;
CESC	cis	rs7959452	0.558	rs1478464	chr12:69779789	G/C	cg22834771	chr12:69754056	YEATS4	-0.47	-6.18	-0.36	2.35e-9	Blood protein levels;
CESC	cis	rs17376456	0.877	rs10066791	chr5:93350255	G/T	cg21475434	chr5:93447410	FAM172A	0.74	6.57	0.37	2.6e-10	Diabetic retinopathy;
CESC	trans	rs1814175	0.791	rs11040513	chr11:49778153	G/C	cg15704280	chr7:45808275	SEPT13	-1.02	-19.96	-0.77	1.02e-54	Height;
CESC	trans	rs77808099	0.590	rs7519812	chr1:16024189	C/T	cg06826283	chr7:600452	PRKAR1B	0.69	6.14	0.35	3e-9	Alcoholic chronic pancreatitis;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg26759515	chr16:67515027	ATP6V0D1	-0.45	-6.17	-0.35	2.6e-9	Fibrinogen levels;
CESC	cis	rs4665809	0.549	rs3828255	chr2:26413252	G/A	cg25036284	chr2:26402008	FAM59B	0.74	7.85	0.43	1.01e-13	Gut microbiome composition (summer);
CESC	cis	rs17711722	0.523	rs313812	chr7:65505043	T/C	cg25405998	chr7:65216604	CCT6P1	-0.45	-5.79	-0.33	2.04e-8	Calcium levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01052087	chr20:10414899	C20orf94;MKKS	0.59	6.41	0.37	6.82e-10	Gut microbiome composition (summer);
CESC	trans	rs561341	0.941	rs2428336	chr17:30290577	T/C	cg20587970	chr11:113659929	NA	-1.11	-13.49	-0.64	6.31e-32	Hip circumference adjusted for BMI;
CESC	cis	rs873946	0.586	rs36084869	chr10:134566069	G/A	cg27297192	chr10:134578999	INPP5A	0.4	5.13	0.3	5.54e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	trans	rs66887589	0.616	rs7659403	chr4:120207254	T/A	cg25214090	chr10:38739885	LOC399744	0.43	6.02	0.35	5.75e-9	Diastolic blood pressure;
CESC	cis	rs4604732	0.642	rs7515859	chr1:247640057	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.46	6.5	0.37	3.87e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.54	6.71	0.38	1.14e-10	Prudent dietary pattern;
CESC	cis	rs7618915	0.547	rs35211965	chr3:52685305	C/G	cg17372223	chr3:52568218	NT5DC2	0.43	6.46	0.37	5.02e-10	Bipolar disorder;
CESC	cis	rs826838	0.967	rs1684411	chr12:39128494	C/T	cg26384229	chr12:38710491	ALG10B	-0.66	-10.31	-0.54	3.42e-21	Heart rate;
CESC	cis	rs735396	0.595	rs1169279	chr12:121455873	C/T	cg02403541	chr12:121454288	C12orf43	0.81	11.96	0.59	1.21e-26	N-glycan levels;
CESC	trans	rs6601327	0.602	rs7829463	chr8:9649691	C/G	cg15556689	chr8:8085844	FLJ10661	-0.51	-6.06	-0.35	4.71e-9	Multiple myeloma (hyperdiploidy);
CESC	cis	rs9916302	0.861	rs8079590	chr17:37426201	T/C	cg20243544	chr17:37824526	PNMT	0.46	5.76	0.33	2.31e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs3617	0.573	rs3821873	chr3:52913006	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	-0.31	-5.29	-0.31	2.59e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
CESC	cis	rs75477785	0.590	rs72649938	chr1:210208472	C/T	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.92	6.49	0.37	4.26e-10	Cleft lip with or without cleft palate;
CESC	cis	rs9926296	0.533	rs10852623	chr16:89865242	T/C	cg04287289	chr16:89883240	FANCA	0.91	16.23	0.71	1.36e-41	Vitiligo;
CESC	cis	rs1348850	0.958	rs1548067	chr2:178462914	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.62	8.78	0.47	2.13e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs9902453	0.874	rs7213517	chr17:28401740	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.69	-9.08	-0.49	2.59e-17	Coffee consumption (cups per day);
CESC	cis	rs4665809	0.878	rs6748745	chr2:26364190	C/T	cg08470875	chr2:26401718	FAM59B	-0.56	-6.35	-0.36	9.51e-10	Gut microbiome composition (summer);
CESC	cis	rs11871801	0.560	rs8068844	chr17:40571284	T/C	cg21433558	chr17:40837037	CNTNAP1	0.46	5.82	0.34	1.65e-8	Crohn's disease;
CESC	cis	rs8141529	0.719	rs5762880	chr22:29287816	T/G	cg02153584	chr22:29168773	CCDC117	0.59	7.62	0.42	4.46e-13	Lymphocyte counts;
CESC	cis	rs9393777	0.513	rs9379905	chr6:26630990	G/A	cg11502198	chr6:26597334	ABT1	0.52	5.34	0.31	1.99e-7	Intelligence (multi-trait analysis);
CESC	cis	rs514406	0.560	rs1889033	chr1:53211887	A/G	cg08859206	chr1:53392774	SCP2	0.54	6.88	0.39	4.27e-11	Monocyte count;
CESC	cis	rs1707322	0.721	rs12069121	chr1:46231984	G/A	cg06784218	chr1:46089804	CCDC17	0.41	7.19	0.4	6.5e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9906944	0.933	rs4794018	chr17:47093398	T/C	cg09029085	chr17:47094198	IGF2BP1	0.26	5.16	0.3	4.82e-7	Intelligence (multi-trait analysis);Body fat percentage;
CESC	cis	rs3749237	0.576	rs4241406	chr3:49600426	C/T	cg07636037	chr3:49044803	WDR6	0.63	9.21	0.49	1.02e-17	Resting heart rate;
CESC	cis	rs4664304	0.531	rs11691616	chr2:160758680	G/C	cg03641300	chr2:160917029	PLA2R1	-0.39	-5.23	-0.31	3.51e-7	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs818427	0.896	rs455412	chr5:112224389	G/T	cg07820702	chr5:112228657	REEP5	-0.43	-5.36	-0.31	1.85e-7	Total body bone mineral density;
CESC	cis	rs9733	0.596	rs6661872	chr1:150628357	C/G	cg22823121	chr1:150693482	HORMAD1	0.48	7.12	0.4	1.03e-11	Tonsillectomy;
CESC	trans	rs2727020	0.688	rs2734002	chr11:49234162	A/G	cg03929089	chr4:120376271	NA	0.79	11.81	0.59	3.94e-26	Coronary artery disease;
CESC	cis	rs875971	0.862	rs12698521	chr7:65939489	T/C	cg18876405	chr7:65276391	NA	0.52	7.03	0.4	1.8e-11	Aortic root size;
CESC	cis	rs2243480	0.708	rs35310401	chr7:65390359	A/G	cg18252515	chr7:66147081	NA	-1.06	-9.79	-0.52	1.67e-19	Diabetic kidney disease;
CESC	cis	rs9733	0.596	rs7549795	chr1:150656873	G/A	cg09365446	chr1:150670422	GOLPH3L	0.42	5.9	0.34	1.09e-8	Tonsillectomy;
CESC	cis	rs6089584	0.861	rs2180302	chr20:60576369	A/G	cg24733560	chr20:60626293	TAF4	0.41	5.79	0.34	2e-8	Body mass index;
CESC	cis	rs477692	0.699	rs528549	chr10:131381574	A/G	cg05714579	chr10:131428358	MGMT	0.42	5.52	0.32	7.9e-8	Response to temozolomide;
CESC	cis	rs11098499	0.954	rs6838814	chr4:120392443	G/A	cg09307838	chr4:120376055	NA	0.94	13.94	0.65	1.68e-33	Corneal astigmatism;
CESC	cis	rs2073300	0.609	rs17757228	chr20:23351288	A/T	cg12062639	chr20:23401060	NAPB	0.98	7.59	0.42	5.37e-13	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs910316	0.967	rs175498	chr14:75536369	G/A	cg11812906	chr14:75593930	NEK9	-0.87	-14.67	-0.67	4.61e-36	Height;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04769218	chr7:99098020	ZNF394	0.44	6.29	0.36	1.34e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs3768617	0.510	rs7542640	chr1:183063738	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.88	14.24	0.66	1.45e-34	Fuchs's corneal dystrophy;
CESC	cis	rs2735413	0.918	rs1922621	chr16:78075015	A/G	cg04733911	chr16:78082701	NA	-0.53	-9.0	-0.48	4.44e-17	Systolic blood pressure (alcohol consumption interaction);
CESC	cis	rs2573652	1.000	rs2581343	chr15:100514418	C/G	cg00587665	chr15:100533223	ADAMTS17	-0.41	-6.46	-0.37	4.99e-10	Height;
CESC	cis	rs7598759	0.712	rs997400	chr2:232332847	C/T	cg19187155	chr2:232395269	NMUR1	0.39	6.12	0.35	3.36e-9	Noise-induced hearing loss;
CESC	cis	rs1784581	0.588	rs6455790	chr6:162418447	C/T	cg17173639	chr6:162384350	PARK2	-0.57	-8.57	-0.47	8.94e-16	Itch intensity from mosquito bite;
CESC	cis	rs8062405	0.965	rs7359397	chr16:28885659	C/T	cg08761264	chr16:28874980	SH2B1	-0.45	-5.49	-0.32	9.61e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs1799949	1.000	rs11653460	chr17:41331306	C/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.38	5.04	0.3	8.73e-7	Menopause (age at onset);
CESC	cis	rs1448094	0.533	rs7955135	chr12:86146350	G/A	cg02569458	chr12:86230093	RASSF9	-0.42	-6.44	-0.37	5.67e-10	Major depressive disorder;
CESC	cis	rs2637266	1.000	rs2130798	chr10:78329563	C/T	cg18941641	chr10:78392320	NA	0.42	7.93	0.44	6.17e-14	Pulmonary function;
CESC	cis	rs5769765	0.862	rs138870	chr22:50209737	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.5	-5.52	-0.32	7.91e-8	Schizophrenia;
CESC	cis	rs344364	0.511	rs1657132	chr16:1949924	C/T	cg03013636	chr16:1946785	NA	0.48	6.62	0.38	2.02e-10	Glomerular filtration rate in chronic kidney disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11102324	chr15:49658865	C15orf33	-0.58	-6.16	-0.35	2.69e-9	Gut microbiome composition (summer);
CESC	cis	rs561341	1.000	rs7214017	chr17:30332220	T/C	cg12193833	chr17:30244370	NA	-0.58	-5.95	-0.34	8.58e-9	Hip circumference adjusted for BMI;
CESC	cis	rs13382862	0.823	rs12710743	chr2:20880714	T/C	cg09074113	chr2:20870087	GDF7	-0.42	-6.7	-0.38	1.26e-10	Abdominal aortic aneurysm;
CESC	cis	rs9733	0.596	rs7418501	chr1:150711896	A/T	cg18016565	chr1:150552671	MCL1	0.34	5.28	0.31	2.67e-7	Tonsillectomy;
CESC	cis	rs7666738	0.830	rs13134216	chr4:98919765	C/T	cg05340658	chr4:99064831	C4orf37	0.78	11.64	0.58	1.43e-25	Colonoscopy-negative controls vs population controls;
CESC	cis	rs55823223	0.648	rs936393	chr17:73847613	A/G	cg10935138	chr17:73851978	WBP2	0.84	10.01	0.52	3.17e-20	Psoriasis;
CESC	cis	rs2439831	0.850	rs8042868	chr15:43939642	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.71	7.45	0.42	1.36e-12	Lung cancer in ever smokers;
CESC	cis	rs854765	0.619	rs1101727	chr17:18016148	T/C	cg04398451	chr17:18023971	MYO15A	-0.79	-11.56	-0.58	2.65e-25	Total body bone mineral density;
CESC	cis	rs10256972	0.521	rs871019	chr7:1105230	A/G	cg23978390	chr7:1156363	C7orf50	0.43	5.7	0.33	3.23e-8	Longevity;Endometriosis;
CESC	cis	rs412050	0.547	rs76200689	chr22:22154644	G/A	cg17089214	chr22:22089827	YPEL1	0.67	5.8	0.34	1.92e-8	Attention deficit hyperactivity disorder;
CESC	cis	rs9649213	0.593	rs56286037	chr7:98019522	C/T	cg00277769	chr7:97922759	BAIAP2L1	-0.31	-5.05	-0.3	8.27e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs240764	0.764	rs13201976	chr6:100933185	T/A	cg21058520	chr6:100914733	NA	0.4	6.24	0.36	1.7e-9	Neuroticism;
CESC	cis	rs7772486	0.719	rs4391282	chr6:146276780	A/T	cg23711669	chr6:146136114	FBXO30	-0.81	-11.35	-0.57	1.37e-24	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1348850	0.567	rs880897	chr2:178532503	C/T	cg23306229	chr2:178417860	TTC30B	0.53	6.37	0.36	8.45e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs9341808	0.718	rs2322630	chr6:80841033	A/G	cg08355045	chr6:80787529	NA	0.34	5.46	0.32	1.07e-7	Sitting height ratio;
CESC	cis	rs3741489	1.000	rs11147098	chr12:133406374	G/A	cg01499426	chr12:133417423	CHFR	0.86	5.27	0.31	2.81e-7	Cognitive function;
CESC	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg05313129	chr8:58192883	C8orf71	-0.49	-5.32	-0.31	2.23e-7	Developmental language disorder (linguistic errors);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01391346	chr6:99873300	SFRS18	-0.55	-6.23	-0.36	1.83e-9	Gut microbiome composition (summer);
CESC	cis	rs7618501	0.633	rs2883057	chr3:49998282	C/T	cg24110177	chr3:50126178	RBM5	-0.54	-7.23	-0.41	5.19e-12	Intelligence (multi-trait analysis);
CESC	cis	rs9894429	1.000	rs11651264	chr17:79576394	A/G	cg21984481	chr17:79567631	NPLOC4	0.49	8.04	0.44	2.97e-14	Eye color traits;
CESC	cis	rs10504229	0.683	rs7835498	chr8:58129780	A/C	cg02725872	chr8:58115012	NA	-0.45	-7.05	-0.4	1.52e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs7586879	1.000	rs10175064	chr2:25117537	T/C	cg01884057	chr2:25150051	NA	0.28	5.1	0.3	6.54e-7	Body mass index;
CESC	cis	rs2439831	0.681	rs999047	chr15:43688916	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.88	10.53	0.54	7.06e-22	Lung cancer in ever smokers;
CESC	cis	rs6582630	0.519	rs1851121	chr12:38389467	T/C	cg26384229	chr12:38710491	ALG10B	0.73	11.08	0.56	1.07e-23	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs2997447	0.761	rs112552200	chr1:26456947	G/A	cg24596570	chr1:26146463	FAM54B;LOC646471	0.62	5.41	0.32	1.44e-7	QRS complex (12-leadsum);
CESC	cis	rs11696501	0.688	rs6065866	chr20:44323440	G/A	cg11783356	chr20:44313418	WFDC10B	-0.31	-5.08	-0.3	7.02e-7	Brain structure;
CESC	cis	rs4332037	0.539	rs55790766	chr7:2021248	C/T	cg23422044	chr7:1970798	MAD1L1	-0.5	-5.38	-0.31	1.61e-7	Bipolar disorder;
CESC	cis	rs589448	0.902	rs315124	chr12:69771727	G/A	cg14784868	chr12:69753453	YEATS4	0.89	14.22	0.66	1.68e-34	Cerebrospinal fluid biomarker levels;
CESC	cis	rs9399135	0.967	rs45544135	chr6:135324051	T/C	cg24558204	chr6:135376177	HBS1L	0.53	7.26	0.41	4.2e-12	Red blood cell count;
CESC	cis	rs4727027	0.933	rs12154382	chr7:148862284	C/T	cg23158103	chr7:148848205	ZNF398	-0.42	-6.92	-0.39	3.45e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	trans	rs1814175	0.645	rs11040535	chr11:49808669	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.42	-6.04	-0.35	5.06e-9	Height;
CESC	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.77	-13.07	-0.63	1.81e-30	Longevity;Endometriosis;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg23544526	chr7:66368779	NA	0.47	6.16	0.35	2.63e-9	Fibrinogen levels;
CESC	cis	rs7772486	0.720	rs4896837	chr6:146014168	C/T	cg23711669	chr6:146136114	FBXO30	-0.99	-14.22	-0.66	1.8e-34	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs1829883	0.739	rs1829882	chr5:98728778	G/A	cg23861655	chr4:57411219	NA	0.39	6.43	0.37	6e-10	Hemostatic factors and hematological phenotypes;
CESC	cis	rs6665290	0.669	rs3795445	chr1:227180947	A/C	cg10327440	chr1:227177885	CDC42BPA	-1.12	-24.88	-0.84	2.72e-71	Myeloid white cell count;
CESC	cis	rs9291683	0.530	rs4697698	chr4:9942577	C/T	cg11266682	chr4:10021025	SLC2A9	0.59	11.95	0.59	1.27e-26	Bone mineral density;
CESC	cis	rs7666738	0.830	rs3846443	chr4:99032666	G/A	cg24818145	chr4:99064322	C4orf37	0.4	5.17	0.3	4.55e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7927771	0.524	rs10838760	chr11:47786414	A/G	cg20307385	chr11:47447363	PSMC3	0.61	8.59	0.47	7.41e-16	Subjective well-being;
CESC	cis	rs6952809	0.532	rs2023969	chr7:2449980	T/C	cg23289794	chr7:2394357	EIF3B	-0.77	-6.98	-0.39	2.32e-11	Multiple sclerosis;
CESC	cis	rs6456156	0.565	rs7750209	chr6:167482895	T/G	cg23791538	chr6:167370224	RNASET2	-0.51	-6.44	-0.37	5.67e-10	Primary biliary cholangitis;
CESC	cis	rs826838	1.000	rs826838	chr12:39106731	C/T	cg13010199	chr12:38710504	ALG10B	-0.41	-5.78	-0.33	2.06e-8	Heart rate;
CESC	trans	rs11088226	0.846	rs2833884	chr21:33923075	A/G	cg09050820	chr6:167586206	TCP10L2	0.63	6.56	0.37	2.74e-10	Gastritis;
CESC	cis	rs478304	0.619	rs10791822	chr11:65428706	T/C	cg27068330	chr11:65405492	SIPA1	-0.47	-5.33	-0.31	2.13e-7	Acne (severe);
CESC	cis	rs769267	0.929	rs2905431	chr19:19482882	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	-0.48	-6.19	-0.36	2.33e-9	Tonsillectomy;
CESC	cis	rs6831352	0.879	rs29001208	chr4:100052539	A/C	cg12011299	chr4:100065546	ADH4	-0.59	-6.52	-0.37	3.62e-10	Alcohol dependence;
CESC	cis	rs1595825	0.891	rs7592344	chr2:198572461	C/T	cg00982548	chr2:198649783	BOLL	-0.49	-5.21	-0.3	3.88e-7	Ulcerative colitis;
CESC	cis	rs7210086	0.948	rs17780256	chr17:70642923	A/C	cg04206342	chr17:70636940	NA	-0.31	-5.46	-0.32	1.07e-7	Ulcerative colitis;
CESC	cis	rs116095464	0.558	rs6866776	chr5:264495	C/T	cg20965017	chr5:231967	SDHA	-0.48	-5.43	-0.32	1.25e-7	Breast cancer;
CESC	cis	rs1218582	0.804	rs4845678	chr1:154853295	A/G	cg24250549	chr1:154909240	PMVK	0.69	10.33	0.54	2.98e-21	Prostate cancer;
CESC	cis	rs2456568	0.835	rs8181533	chr11:93638614	C/T	cg26875233	chr11:93583750	C11orf90	-0.31	-5.4	-0.31	1.5e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
CESC	cis	rs11098499	0.604	rs10022185	chr4:120571765	C/G	cg24375607	chr4:120327624	NA	0.44	5.35	0.31	1.87e-7	Corneal astigmatism;
CESC	cis	rs9486719	1.000	rs12214469	chr6:97019471	G/T	cg06623918	chr6:96969491	KIAA0776	-0.8	-8.28	-0.45	6.29e-15	Migraine;Coronary artery disease;
CESC	cis	rs4862750	0.914	rs9995391	chr4:187873749	A/T	cg07414643	chr4:187882934	NA	-0.48	-6.56	-0.37	2.84e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs11711311	1.000	rs12637067	chr3:113527606	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.72	10.17	0.53	1.02e-20	IgG glycosylation;
CESC	cis	rs853679	0.546	rs35744819	chr6:28318331	G/T	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.85	5.58	0.32	6.07e-8	Depression;
CESC	cis	rs2708240	0.561	rs1723441	chr7:147549011	G/T	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.37	-5.74	-0.33	2.63e-8	QT interval (drug interaction);
CESC	cis	rs2797160	1.000	rs6927161	chr6:126015954	T/C	cg05901451	chr6:126070800	HEY2	0.46	6.55	0.37	2.89e-10	Endometrial cancer;
CESC	cis	rs4234798	0.933	rs7678751	chr4:7219035	A/G	cg18431297	chr4:7219810	SORCS2	0.43	7.39	0.41	1.9e-12	Insulin-like growth factors;
CESC	cis	rs2180341	1.000	rs4897207	chr6:127605898	C/T	cg27446573	chr6:127587934	RNF146	1.08	16.13	0.7	3.14e-41	Breast cancer;
CESC	cis	rs2108622	0.727	rs55954696	chr19:15981805	A/G	cg13772218	chr19:15982569	NA	0.3	5.99	0.35	6.85e-9	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CESC	cis	rs6812193	0.518	rs17001729	chr4:77188418	C/G	cg20311846	chr4:77356250	SHROOM3	0.28	5.14	0.3	5.41e-7	Parkinson's disease;
CESC	cis	rs1799949	1.000	rs8176145	chr17:41249094	A/G	cg06001716	chr17:41278141	BRCA1;NBR2	0.39	5.4	0.31	1.51e-7	Menopause (age at onset);
CESC	cis	rs2576037	0.583	rs512699	chr18:44374681	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.49	6.74	0.38	1e-10	Personality dimensions;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg10486909	chr13:46038825	COG3	-0.45	-6.04	-0.35	5.24e-9	Asthma;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg26240433	chr14:94547826	DDX24;IFI27L1	-0.43	-6.02	-0.35	5.76e-9	Asthma;
CESC	cis	rs853679	0.517	rs9393894	chr6:28112562	A/G	cg12963246	chr6:28129442	ZNF389	0.58	7.55	0.42	7e-13	Depression;
CESC	cis	rs2991971	0.729	rs10890328	chr1:45905383	G/T	cg24296786	chr1:45957014	TESK2	-0.61	-8.67	-0.47	4.46e-16	High light scatter reticulocyte count;
CESC	cis	rs9581857	0.685	rs10467687	chr13:28036516	G/A	cg22138327	chr13:27999177	GTF3A	0.61	5.04	0.3	8.78e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
CESC	cis	rs2066819	0.892	rs117305040	chr12:56657888	A/G	cg26714650	chr12:56694279	CS	-1.41	-9.99	-0.52	3.69e-20	Psoriasis vulgaris;
CESC	cis	rs7267979	1.000	rs2387881	chr20:25378172	A/G	cg08601574	chr20:25228251	PYGB	-0.37	-5.4	-0.32	1.46e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs875971	0.862	rs778702	chr7:65864835	G/A	cg18252515	chr7:66147081	NA	-0.43	-5.59	-0.32	5.73e-8	Aortic root size;
CESC	cis	rs4704187	0.687	rs4703655	chr5:74455063	A/G	cg03227963	chr5:74354835	NA	0.3	5.52	0.32	8.2e-8	Response to amphetamines;
CESC	cis	rs59574136	1	rs59574136	chr7:2036460	T/C	cg21782813	chr7:2030301	MAD1L1	0.49	7.15	0.4	8.57e-12	Autism spectrum disorder or schizophrenia;
CESC	cis	rs9814567	1.000	rs11708531	chr3:134224902	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.42	-5.73	-0.33	2.73e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg07604202	chr20:50701378	ZFP64	0.47	6.8	0.39	7.08e-11	Fibrinogen levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12997958	chr17:18161617	FLII	-0.68	-7.35	-0.41	2.4e-12	Gut microbiome composition (summer);
CESC	cis	rs2228479	0.702	rs62053701	chr16:89860584	G/A	cg06558623	chr16:89946397	TCF25	1.18	9.47	0.5	1.65e-18	Skin colour saturation;
CESC	cis	rs17401966	0.838	rs1556916	chr1:10403482	G/A	cg15208524	chr1:10270712	KIF1B	0.4	5.12	0.3	5.76e-7	Hepatocellular carcinoma;
CESC	cis	rs7666738	0.830	rs13118945	chr4:98968586	T/G	cg05340658	chr4:99064831	C4orf37	0.79	12.28	0.6	9.45e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1267303	0.675	rs2476164	chr1:46985274	T/C	cg25110126	chr1:46999211	NA	-0.71	-8.85	-0.48	1.31e-16	Monobrow;
CESC	cis	rs3741151	0.773	rs113465107	chr11:73210416	T/G	cg17517138	chr11:73019481	ARHGEF17	0.98	7.25	0.41	4.61e-12	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs7945705	0.967	rs7123861	chr11:8892323	G/A	cg09997546	chr11:8931473	C11orf17;ST5	0.36	5.85	0.34	1.48e-8	Hemoglobin concentration;
CESC	cis	rs2732480	0.577	rs2634684	chr12:48730875	C/T	cg04545296	chr12:48745243	ZNF641	-0.45	-7.45	-0.42	1.32e-12	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs12477438	0.798	rs896886	chr2:99652713	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.75	10.66	0.55	2.68e-22	Chronic sinus infection;
CESC	cis	rs801193	0.935	rs2286683	chr7:66129843	G/A	cg06456125	chr7:65229604	NA	-0.39	-5.09	-0.3	6.82e-7	Aortic root size;
CESC	cis	rs11583043	0.918	rs6675403	chr1:101418569	T/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.54	6.06	0.35	4.57e-9	Ulcerative colitis;Inflammatory bowel disease;
CESC	cis	rs8038465	0.662	rs57771618	chr15:73967578	T/C	cg15420318	chr15:73925796	NPTN	0.52	7.84	0.43	1.07e-13	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs7107174	0.786	rs4945262	chr11:77990831	T/C	cg02023728	chr11:77925099	USP35	0.47	6.25	0.36	1.6e-9	Testicular germ cell tumor;
CESC	cis	rs7927771	0.690	rs35496532	chr11:47450338	C/T	cg05585544	chr11:47624801	NA	-0.48	-7.01	-0.4	2.01e-11	Subjective well-being;
CESC	cis	rs2072732	0.808	rs74048148	chr1:2954031	A/G	cg03976712	chr1:2946727	NA	0.33	5.51	0.32	8.63e-8	Plateletcrit;
CESC	cis	rs2075371	1.000	rs2598286	chr7:133976029	G/A	cg11752832	chr7:134001865	SLC35B4	0.53	6.92	0.39	3.47e-11	Mean platelet volume;
CESC	trans	rs3780486	0.541	rs10738909	chr9:33148834	T/C	cg20290983	chr6:43655470	MRPS18A	0.73	11.44	0.57	6.87e-25	IgG glycosylation;
CESC	cis	rs1062177	1.000	rs2964612	chr5:151198750	G/A	cg12924095	chr5:151150029	G3BP1	0.5	6.43	0.37	5.92e-10	Preschool internalizing problems;
CESC	cis	rs2635047	0.967	rs2668786	chr18:44708472	A/G	cg19077165	chr18:44547161	KATNAL2	-0.43	-5.83	-0.34	1.6e-8	Educational attainment;
CESC	cis	rs769267	0.631	rs7252981	chr19:19692579	T/C	cg03709012	chr19:19516395	GATAD2A	-0.64	-7.92	-0.44	6.38e-14	Tonsillectomy;
CESC	cis	rs11031096	0.678	rs12292724	chr11:4176671	T/A	cg18678763	chr11:4115507	RRM1	-0.42	-5.81	-0.34	1.83e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg12857652	chr6:64289969	PTP4A1	0.47	6.49	0.37	4.19e-10	Fibrinogen levels;
CESC	cis	rs7666738	0.819	rs62318904	chr4:99036101	A/T	cg17366294	chr4:99064904	C4orf37	0.62	8.62	0.47	6.05e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs8070740	1.000	rs8080400	chr17:5328633	G/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.54	6.53	0.37	3.32e-10	Menopause (age at onset);
CESC	cis	rs1448094	0.511	rs4897823	chr12:86161484	C/T	cg02569458	chr12:86230093	RASSF9	0.47	7.39	0.41	1.88e-12	Major depressive disorder;
CESC	cis	rs17253792	0.731	rs79483151	chr14:56048851	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.85	5.74	0.33	2.53e-8	Putamen volume;
CESC	cis	rs7408868	1.000	rs7247906	chr19:15271135	T/G	cg14696996	chr19:15285081	NOTCH3	1.11	11.47	0.58	5.57e-25	Pulse pressure;
CESC	cis	rs7927592	0.763	rs7129248	chr11:68263276	A/T	cg01657329	chr11:68192670	LRP5	-0.46	-6.12	-0.35	3.31e-9	Total body bone mineral density;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg09755102	chr1:33283495	S100PBP;YARS	-0.44	-6.47	-0.37	4.78e-10	Gambling;
CESC	cis	rs9303401	0.659	rs62083362	chr17:56846464	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	1.01	12.68	0.61	4.11e-29	Cognitive test performance;
CESC	cis	rs1005277	0.522	rs1208684	chr10:38093936	G/A	cg00409905	chr10:38381863	ZNF37A	-0.5	-6.97	-0.39	2.53e-11	Extrinsic epigenetic age acceleration;
CESC	cis	rs4665809	0.556	rs6730311	chr2:26419474	C/T	cg27170947	chr2:26402098	FAM59B	-0.88	-11.12	-0.56	7.95e-24	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.791	rs7377018	chr4:99034962	C/T	cg17366294	chr4:99064904	C4orf37	0.62	8.86	0.48	1.22e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7927771	0.524	rs11039377	chr11:47789776	C/T	cg18512352	chr11:47633146	NA	0.34	5.24	0.31	3.35e-7	Subjective well-being;
CESC	cis	rs3091242	0.933	rs9438905	chr1:25764177	A/G	cg03538708	chr1:25844672	NA	-0.4	-5.93	-0.34	9.53e-9	Erythrocyte sedimentation rate;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19636311	chr20:16710621	SNRPB2	0.6	6.76	0.38	8.95e-11	Gut microbiome composition (summer);
CESC	cis	rs2836974	0.932	rs8128734	chr21:40569511	G/A	cg27266027	chr21:40555129	PSMG1	0.45	5.33	0.31	2.07e-7	Cognitive function;
CESC	cis	rs15676	0.783	rs2977998	chr9:131580570	A/G	cg00228799	chr9:131580591	ENDOG	0.54	7.01	0.4	1.97e-11	Blood metabolite levels;
CESC	cis	rs9487051	1.000	rs6568569	chr6:109613196	C/A	cg21918786	chr6:109611834	NA	-0.35	-5.03	-0.3	8.9e-7	Reticulocyte fraction of red cells;
CESC	cis	rs7116495	0.609	rs4945392	chr11:71694645	C/T	cg26138937	chr11:71823887	C11orf51	-1.26	-8.07	-0.44	2.43e-14	Severe influenza A (H1N1) infection;
CESC	cis	rs13102973	0.614	rs56199725	chr4:135873448	T/C	cg14419869	chr4:135874104	NA	-0.36	-5.36	-0.31	1.77e-7	Subjective well-being;
CESC	trans	rs1545843	0.593	rs58319517	chr12:84795836	C/T	cg03015433	chr16:56623111	MT3	-0.34	-6.12	-0.35	3.37e-9	Major depressive disorder;
CESC	cis	rs11098499	0.754	rs4443261	chr4:120249301	T/C	cg09307838	chr4:120376055	NA	0.77	10.35	0.54	2.54e-21	Corneal astigmatism;
CESC	cis	rs34779708	0.931	rs17591135	chr10:35465190	T/A	cg03585969	chr10:35415529	CREM	0.78	10.34	0.54	2.76e-21	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs7811142	0.830	rs6955367	chr7:99961194	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.83	9.61	0.51	6.16e-19	Platelet count;
CESC	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg14159672	chr1:205819179	PM20D1	0.48	6.94	0.39	2.92e-11	Menarche (age at onset);
CESC	cis	rs6066835	1.000	rs6125428	chr20:47292823	C/G	cg18078177	chr20:47281410	PREX1	0.72	5.1	0.3	6.38e-7	Multiple myeloma;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16557308	chr1:52082719	OSBPL9	0.53	6.04	0.35	5.07e-9	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.830	rs6846229	chr4:99016546	C/T	cg03676636	chr4:99064102	C4orf37	0.33	5.14	0.3	5.3e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6502050	0.865	rs56193110	chr17:80151501	A/G	cg23985595	chr17:80112537	CCDC57	-0.41	-6.42	-0.37	6.19e-10	Life satisfaction;
CESC	cis	rs10751667	0.666	rs7395488	chr11:954111	T/C	cg06064525	chr11:970664	AP2A2	-0.48	-9.52	-0.5	1.15e-18	Alzheimer's disease (late onset);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg17760058	chr19:2321626	LSM7	0.41	6.01	0.35	6.23e-9	Fibrinogen levels;
CESC	cis	rs10927875	0.518	rs945416	chr1:16344402	G/A	cg22431228	chr1:16359049	CLCNKA	-0.52	-10.02	-0.52	3.09e-20	Dilated cardiomyopathy;
CESC	cis	rs11864453	0.713	rs7190995	chr16:72124157	A/G	cg16558253	chr16:72132732	DHX38	-0.56	-8.7	-0.47	3.62e-16	Fibrinogen levels;
CESC	cis	rs12134245	0.776	rs625525	chr1:91997593	C/T	cg25838465	chr1:92012736	NA	-0.62	-9.62	-0.51	5.45e-19	Breast cancer;
CESC	cis	rs10504229	0.683	rs10504223	chr8:58140944	G/A	cg24829409	chr8:58192753	C8orf71	-0.59	-7.31	-0.41	3.16e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs896854	0.608	rs6991067	chr8:95875676	A/G	cg13393036	chr8:95962371	TP53INP1	-0.43	-9.01	-0.48	4.33e-17	Type 2 diabetes;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg08204369	chr17:73150733	HN1	-0.41	-6.05	-0.35	4.91e-9	Gambling;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg07996345	chr11:47600851	KBTBD4;NDUFS3	-0.47	-6.71	-0.38	1.15e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs896854	0.654	rs13278601	chr8:95972974	G/C	cg13393036	chr8:95962371	TP53INP1	-0.49	-10.46	-0.54	1.17e-21	Type 2 diabetes;
CESC	cis	rs796364	0.662	rs11688415	chr2:201143409	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.75	5.76	0.33	2.27e-8	Schizophrenia;
CESC	cis	rs9811920	0.638	rs793461	chr3:99615758	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.64	10.11	0.53	1.53e-20	Axial length;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04127825	chr1:167503222	NA	0.46	6.0	0.35	6.52e-9	Gut microbiota (bacterial taxa);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg27180880	chr18:74844787	MBP	-0.46	-6.07	-0.35	4.47e-9	Fibrinogen levels;
CESC	cis	rs1372520	0.684	rs2619341	chr4:90741773	A/G	cg15133208	chr4:90757351	SNCA	-0.38	-5.09	-0.3	6.69e-7	Neuroticism;
CESC	cis	rs9611565	0.765	rs202663	chr22:41812819	T/C	cg03806693	chr22:41940476	POLR3H	1.05	12.35	0.6	5.55e-28	Vitiligo;
CESC	cis	rs919433	0.783	rs3097383	chr2:198236887	A/G	cg10820045	chr2:198174542	NA	0.41	5.93	0.34	9.6e-9	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg23034840	chr1:205782522	SLC41A1	0.66	7.85	0.43	1.04e-13	Menarche (age at onset);
CESC	cis	rs2832191	0.671	rs2832212	chr21:30511417	G/A	cg08807101	chr21:30365312	RNF160	-0.54	-6.29	-0.36	1.33e-9	Dental caries;
CESC	trans	rs945270	0.512	rs1953353	chr14:56189751	A/G	cg18102697	chr4:83542773	C4orf11	0.41	6.21	0.36	2e-9	Subcortical brain region volumes;
CESC	cis	rs1707322	1.000	rs6429588	chr1:46454058	T/G	cg06784218	chr1:46089804	CCDC17	0.33	5.67	0.33	3.8e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs11039798	0.557	rs4436575	chr11:48398894	T/C	cg15704280	chr7:45808275	SEPT13	-0.69	-6.75	-0.38	9.03e-11	Axial length;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg02949969	chr10:43048471	ZNF37B	0.45	6.27	0.36	1.45e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs7089973	0.604	rs7915943	chr10:116618077	G/A	cg25233709	chr10:116636983	FAM160B1	0.39	6.12	0.35	3.34e-9	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00404177	chr1:51425685	FAF1	0.56	6.5	0.37	4.01e-10	Gut microbiome composition (summer);
CESC	cis	rs1005277	0.522	rs289643	chr10:37941494	T/G	cg25517755	chr10:38738941	LOC399744	-0.4	-5.11	-0.3	6.17e-7	Extrinsic epigenetic age acceleration;
CESC	cis	rs79349575	0.783	rs62078372	chr17:47028989	T/C	cg26022315	chr17:47021804	SNF8	0.39	5.16	0.3	4.94e-7	Type 2 diabetes;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg18156793	chr20:32031936	SNTA1	-0.48	-6.46	-0.37	4.93e-10	Height;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg04761648	chr13:26829199	CDK8	0.47	6.12	0.35	3.27e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs1008375	1.000	rs10805357	chr4:17652352	G/A	cg15017067	chr4:17643749	FAM184B	0.35	5.07	0.3	7.59e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs12618769	0.597	rs3769723	chr2:99105988	A/G	cg10123293	chr2:99228465	UNC50	0.4	5.38	0.31	1.64e-7	Bipolar disorder;
CESC	cis	rs9291683	0.546	rs4575994	chr4:9997979	G/A	cg11266682	chr4:10021025	SLC2A9	0.65	12.18	0.6	2.21e-27	Bone mineral density;
CESC	cis	rs4862750	0.872	rs7671914	chr4:187878165	A/G	cg03452623	chr4:187889614	NA	-0.86	-15.23	-0.68	4.57e-38	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7107174	1.000	rs10793304	chr11:78064907	A/G	cg02023728	chr11:77925099	USP35	0.39	5.46	0.32	1.08e-7	Testicular germ cell tumor;
CESC	cis	rs875971	0.522	rs10807697	chr7:65416170	A/G	cg11987759	chr7:65425863	GUSB	-0.46	-6.26	-0.36	1.54e-9	Aortic root size;
CESC	cis	rs4237845	0.537	rs10747786	chr12:58260601	G/T	cg00677455	chr12:58241039	CTDSP2	0.77	10.18	0.53	9.07e-21	Intelligence (multi-trait analysis);
CESC	cis	rs9905704	0.918	rs2611779	chr17:56791832	A/G	cg12560992	chr17:57184187	TRIM37	0.6	7.09	0.4	1.18e-11	Testicular germ cell tumor;
CESC	cis	rs875971	0.830	rs28714531	chr7:65968237	G/A	cg12463550	chr7:65579703	CRCP	0.5	6.3	0.36	1.21e-9	Aortic root size;
CESC	cis	rs4689388	0.853	rs1079216	chr4:6282473	T/C	cg14416269	chr4:6271139	WFS1	0.46	7.45	0.42	1.35e-12	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs1153858	1.000	rs4775895	chr15:45617957	T/A	cg21132104	chr15:45694354	SPATA5L1	0.84	11.12	0.56	8.16e-24	Homoarginine levels;
CESC	cis	rs34779708	0.931	rs11010077	chr10:35328088	C/T	cg03585969	chr10:35415529	CREM	-0.75	-10.21	-0.53	7.43e-21	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs2302190	1.000	rs8065388	chr17:56562132	C/T	cg25885038	chr17:56607967	SEPT4	-0.4	-5.54	-0.32	7.29e-8	Vitamin D levels;
CESC	cis	rs9916302	0.904	rs8068427	chr17:37511517	G/A	cg15445000	chr17:37608096	MED1	-0.41	-6.6	-0.38	2.18e-10	Glomerular filtration rate (creatinine);
CESC	trans	rs629535	0.590	rs55988608	chr8:70133619	A/G	cg21567404	chr3:27674614	NA	-0.86	-9.47	-0.5	1.63e-18	Dupuytren's disease;
CESC	cis	rs875971	0.862	rs2909688	chr7:65841612	C/A	cg12463550	chr7:65579703	CRCP	0.51	6.47	0.37	4.66e-10	Aortic root size;
CESC	cis	rs9926296	0.744	rs164748	chr16:89708292	C/G	cg04287289	chr16:89883240	FANCA	-0.46	-5.85	-0.34	1.47e-8	Vitiligo;
CESC	cis	rs7520050	0.807	rs4468203	chr1:46113272	T/C	cg06784218	chr1:46089804	CCDC17	0.33	5.95	0.34	8.33e-9	Red blood cell count;Reticulocyte count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13884470	chr9:86595151	HNRNPK;RMI1	0.58	6.59	0.38	2.41e-10	Gut microbiome composition (summer);
CESC	cis	rs4589502	0.502	rs2169460	chr15:67197240	A/G	cg09911534	chr15:67153556	NA	0.37	5.35	0.31	1.95e-7	Lung cancer (smoking interaction);
CESC	cis	rs258892	0.895	rs7737643	chr5:72058445	G/T	cg21869765	chr5:72125136	TNPO1	-0.43	-5.37	-0.31	1.76e-7	Small cell lung carcinoma;
CESC	cis	rs13191362	0.507	rs1954810	chr6:163061749	C/T	cg21926612	chr6:163149169	PACRG;PARK2	-0.56	-6.83	-0.39	5.63e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs3782089	1.000	rs11600543	chr11:65298939	G/A	cg21890820	chr11:65308645	LTBP3	1.14	8.54	0.46	1.05e-15	Height;
CESC	cis	rs3820068	0.603	rs10492986	chr1:15988702	T/C	cg18133145	chr1:16060689	PLEKHM2	-0.4	-5.11	-0.3	6.28e-7	Systolic blood pressure;
CESC	trans	rs2727020	0.635	rs7124266	chr11:49280857	T/G	cg03929089	chr4:120376271	NA	0.74	9.46	0.5	1.7e-18	Coronary artery disease;
CESC	trans	rs3198697	0.617	rs11075253	chr16:15148646	C/A	cg04146151	chr16:2155961	PKD1	-0.57	-6.31	-0.36	1.14e-9	Triglycerides;
CESC	cis	rs9611565	0.592	rs4822044	chr22:41979668	G/C	cg17376030	chr22:41985996	PMM1	0.79	8.35	0.46	3.87e-15	Vitiligo;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg07936931	chr19:21933455	LOC641367;ZNF100	0.45	6.17	0.35	2.59e-9	Fibrinogen levels;
CESC	cis	rs1580019	0.844	rs1376290	chr7:32486922	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.88	12.35	0.6	5.7e-28	Cognitive ability;
CESC	trans	rs7819412	0.715	rs35223712	chr8:11043926	C/T	cg06636001	chr8:8085503	FLJ10661	-0.6	-7.63	-0.42	4.32e-13	Triglycerides;
CESC	cis	rs12618769	0.625	rs72821955	chr2:99159792	G/A	cg10123293	chr2:99228465	UNC50	0.4	5.21	0.31	3.73e-7	Bipolar disorder;
CESC	cis	rs796364	0.806	rs34582889	chr2:201010527	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.64	-6.04	-0.35	5.26e-9	Schizophrenia;
CESC	cis	rs1218582	0.710	rs9794000	chr1:154878876	T/A	cg06221963	chr1:154839813	KCNN3	-0.66	-11.32	-0.57	1.71e-24	Prostate cancer;
CESC	cis	rs6565180	0.962	rs35480350	chr16:30366039	G/A	cg17640201	chr16:30407289	ZNF48	-0.93	-13.57	-0.64	3.44e-32	Tonsillectomy;
CESC	cis	rs10838687	1.000	rs10838687	chr11:47312892	T/G	cg25783544	chr11:47291846	MADD	0.6	7.45	0.42	1.3e-12	Proinsulin levels;
CESC	cis	rs1364705	1.000	rs13281087	chr8:120224470	T/C	cg09273054	chr8:120220131	MAL2	0.62	6.96	0.39	2.6e-11	Hippocampal atrophy;
CESC	cis	rs8072100	0.713	rs1912486	chr17:45515167	A/G	cg25173405	chr17:45401733	C17orf57	-0.43	-5.43	-0.32	1.26e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs1728785	0.901	rs1170444	chr16:68573287	T/C	cg02972257	chr16:68554789	NA	-0.55	-6.34	-0.36	9.7e-10	Ulcerative colitis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00078194	chr11:46402949	MDK	0.58	7.11	0.4	1.09e-11	Gut microbiome composition (summer);
CESC	cis	rs34172651	0.517	rs2303084	chr16:24834581	G/C	cg04756594	chr16:24857601	SLC5A11	0.5	5.66	0.33	4.02e-8	Intelligence (multi-trait analysis);
CESC	cis	rs4803468	0.967	rs4605279	chr19:41888131	C/G	cg09537434	chr19:41945824	ATP5SL	-1.02	-17.99	-0.74	7.57e-48	Height;
CESC	cis	rs6714710	0.603	rs13034929	chr2:98402772	G/C	cg26665480	chr2:98280029	ACTR1B	0.68	9.4	0.5	2.59e-18	Posterior cortical atrophy and Alzheimer's disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg04710198	chr22:47189600	TBC1D22A	0.48	6.29	0.36	1.3e-9	Fibrinogen levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03828693	chr10:63661686	ARID5B	-0.56	-6.68	-0.38	1.4e-10	Gut microbiome composition (summer);
CESC	cis	rs933688	1.000	rs2367353	chr5:90686568	G/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.92	12.54	0.61	1.26e-28	Smoking behavior;
CESC	cis	rs4927850	1.000	rs7614767	chr3:195753451	C/T	cg12923728	chr3:195709715	SDHAP1	-0.62	-8.58	-0.47	8.17e-16	Pancreatic cancer;
CESC	cis	rs7223966	1.000	rs7214312	chr17:61870863	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.74	0.38	9.84e-11	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs9788333	0.695	rs12871086	chr13:21890224	A/T	cg25811766	chr13:21894605	NA	0.79	11.75	0.59	6.03e-26	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs2952156	0.920	rs2517955	chr17:37843681	C/T	cg19468946	chr17:37922297	IKZF3	-0.41	-5.18	-0.3	4.35e-7	Asthma;
CESC	cis	rs62481355	1.000	rs55791028	chr7:127204881	T/C	cg25922125	chr7:127225783	GCC1	-0.42	-5.6	-0.33	5.42e-8	Type 2 diabetes;
CESC	cis	rs4722166	0.598	rs7804146	chr7:22800929	C/G	cg05472934	chr7:22766657	IL6	0.41	5.5	0.32	8.86e-8	Lung cancer;
CESC	cis	rs9322193	0.962	rs13215691	chr6:150113802	T/C	cg09699651	chr6:150184138	LRP11	0.39	5.03	0.3	9.15e-7	Lung cancer;
CESC	cis	rs6502050	0.723	rs8077209	chr17:80163221	A/G	cg23985595	chr17:80112537	CCDC57	-0.4	-6.21	-0.36	1.99e-9	Life satisfaction;
CESC	cis	rs8105265	1	rs8105265	chr19:2920705	A/G	cg10661629	chr19:2900748	ZNF57	0.65	5.43	0.32	1.28e-7	Dementia and core Alzheimer's disease neuropathologic changes;
CESC	cis	rs11048434	0.736	rs11048345	chr12:9123056	T/G	cg23795048	chr12:9217529	LOC144571	0.33	5.03	0.3	9.05e-7	Sjögren's syndrome;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01997089	chr14:105881679	NA	-0.55	-6.42	-0.37	6.1e-10	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13537471	chr19:41351924	CYP2A6	-0.51	-6.88	-0.39	4.33e-11	Gut microbiome composition (summer);
CESC	cis	rs2000999	0.514	rs36061252	chr16:72217613	T/G	cg04254540	chr16:71951199	KIAA0174	-0.68	-5.87	-0.34	1.31e-8	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
CESC	cis	rs10504229	1.000	rs67105789	chr8:58192002	G/T	cg14926445	chr8:58193284	C8orf71	-0.51	-5.52	-0.32	8.28e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs736408	0.812	rs6778329	chr3:52824610	G/A	cg18404041	chr3:52824283	ITIH1	-0.47	-7.77	-0.43	1.69e-13	Bipolar disorder;
CESC	cis	rs7894051	0.717	rs4838741	chr10:135206873	C/T	cg05676341	chr10:135206831	MTG1	0.65	5.69	0.33	3.38e-8	Lifespan;
CESC	cis	rs4654899	0.865	rs6685831	chr1:21507888	G/A	cg05370193	chr1:21551575	ECE1	0.46	7.08	0.4	1.28e-11	Superior frontal gyrus grey matter volume;
CESC	cis	rs1152591	0.792	rs1152595	chr14:64674981	T/C	cg21174375	chr14:64681225	SYNE2	0.57	7.49	0.42	1.03e-12	Atrial fibrillation;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26707263	chr2:241526101	CAPN10	0.66	7.2	0.4	6.25e-12	Gut microbiome composition (summer);
CESC	cis	rs2549003	0.966	rs10072571	chr5:131816711	A/C	cg00255919	chr5:131827918	IRF1	0.51	8.59	0.47	7.76e-16	Asthma (sex interaction);
CESC	cis	rs6088580	0.634	rs6059890	chr20:33101653	G/C	cg08999081	chr20:33150536	PIGU	0.66	11.5	0.58	4.1e-25	Glomerular filtration rate (creatinine);
CESC	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.88	13.16	0.63	9.11e-31	Prudent dietary pattern;
CESC	cis	rs67478160	0.643	rs11160762	chr14:104255083	A/G	cg01849466	chr14:104193079	ZFYVE21	0.51	7.17	0.4	7.31e-12	Schizophrenia;
CESC	cis	rs7666738	0.830	rs28852677	chr4:99039509	T/G	cg05340658	chr4:99064831	C4orf37	0.82	12.88	0.62	8.44e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2797160	0.874	rs58305111	chr6:126008386	G/T	cg05901451	chr6:126070800	HEY2	0.45	6.6	0.38	2.17e-10	Endometrial cancer;
CESC	cis	rs1395	0.677	rs113353646	chr2:27492674	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.42	5.51	0.32	8.7e-8	Blood metabolite levels;
CESC	cis	rs875971	0.965	rs697968	chr7:65535033	G/A	cg10691866	chr7:65817282	TPST1	0.33	5.21	0.3	3.74e-7	Aortic root size;
CESC	cis	rs1552244	0.882	rs17050672	chr3:10025463	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.71	-8.18	-0.45	1.18e-14	Alzheimer's disease;
CESC	cis	rs9291683	0.632	rs11734375	chr4:10046298	A/G	cg02734326	chr4:10020555	SLC2A9	0.47	6.6	0.38	2.23e-10	Bone mineral density;
CESC	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.58	0.37	2.48e-10	Prudent dietary pattern;
CESC	cis	rs7927771	0.839	rs7124681	chr11:47529947	C/A	cg05585544	chr11:47624801	NA	-0.41	-6.45	-0.37	5.28e-10	Subjective well-being;
CESC	cis	rs9325144	0.560	rs1843910	chr12:38677408	T/C	cg13010199	chr12:38710504	ALG10B	-0.45	-6.15	-0.35	2.8e-9	Morning vs. evening chronotype;
CESC	trans	rs650950	0.528	rs646660	chr11:35528452	C/T	cg00408597	chr11:9685941	SWAP70	0.45	6.1	0.35	3.74e-9	Bronchopulmonary dysplasia;
CESC	cis	rs72781680	0.898	rs72788214	chr2:24087621	A/C	cg08917208	chr2:24149416	ATAD2B	0.91	8.38	0.46	3.17e-15	Lymphocyte counts;
CESC	cis	rs9916302	0.821	rs412430	chr17:37737094	C/G	cg00129232	chr17:37814104	STARD3	-0.61	-7.92	-0.44	6.38e-14	Glomerular filtration rate (creatinine);
CESC	cis	rs12048904	0.619	rs10875347	chr1:101333737	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.84	11.21	0.57	3.95e-24	Multiple sclerosis;
CESC	cis	rs28493229	0.522	rs17713068	chr19:41270055	A/C	cg21869046	chr19:41225005	ITPKC	0.52	6.84	0.39	5.53e-11	Kawasaki disease;
CESC	cis	rs3820068	0.705	rs4646096	chr1:15820758	A/G	cg17385448	chr1:15911702	AGMAT	0.39	6.18	0.35	2.44e-9	Systolic blood pressure;
CESC	cis	rs832540	0.931	rs33318	chr5:56208414	G/T	cg24531977	chr5:56204891	C5orf35	-0.44	-5.51	-0.32	8.33e-8	Coronary artery disease;
CESC	cis	rs1153858	1.000	rs7164602	chr15:45671325	A/G	cg14582100	chr15:45693742	SPATA5L1	0.42	5.95	0.34	8.38e-9	Homoarginine levels;
CESC	cis	rs7267979	1.000	rs6050555	chr20:25328543	A/G	cg08601574	chr20:25228251	PYGB	-0.36	-5.12	-0.3	6e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs6582630	0.638	rs1829584	chr12:38526299	G/T	cg26384229	chr12:38710491	ALG10B	-0.47	-6.35	-0.36	9.33e-10	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs367943	0.688	rs10063452	chr5:112734165	C/T	cg12552261	chr5:112820674	MCC	0.4	5.29	0.31	2.57e-7	Type 2 diabetes;
CESC	trans	rs7726839	0.561	rs72703050	chr5:582917	A/C	cg25482853	chr8:67687455	SGK3	0.87	9.18	0.49	1.31e-17	Obesity-related traits;
CESC	cis	rs1707322	1.000	rs785493	chr1:46584859	A/G	cg05343316	chr1:45956843	TESK2	-0.47	-5.52	-0.32	7.97e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs3105593	1.000	rs8036588	chr15:50956834	C/G	cg08437265	chr15:50716283	USP8	0.45	5.9	0.34	1.09e-8	QT interval;
CESC	cis	rs2295499	0.673	rs12506536	chr4:2712403	T/C	cg08330972	chr4:2403930	ZFYVE28	-0.32	-5.24	-0.31	3.34e-7	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
CESC	cis	rs9733	0.596	rs12072339	chr1:150686099	A/G	cg04414720	chr1:150670196	GOLPH3L	0.62	8.86	0.48	1.21e-16	Tonsillectomy;
CESC	cis	rs7618915	0.571	rs67539070	chr3:52711974	T/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	5.64	0.33	4.33e-8	Bipolar disorder;
CESC	cis	rs12477438	0.520	rs13010904	chr2:99754289	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.86	15.92	0.7	1.72e-40	Chronic sinus infection;
CESC	cis	rs4713118	0.662	rs469228	chr6:27970704	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.54	-6.5	-0.37	3.97e-10	Parkinson's disease;
CESC	cis	rs2836633	0.929	rs62217518	chr21:40033189	T/G	cg05519781	chr21:40033154	ERG	0.79	13.49	0.64	6.12e-32	Coronary artery disease;
CESC	cis	rs2249625	0.874	rs2463727	chr6:72894609	C/T	cg18830697	chr6:72922368	RIMS1	-0.37	-5.31	-0.31	2.35e-7	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CESC	cis	rs4481887	0.927	rs28524655	chr1:248474331	C/T	cg00666640	chr1:248458726	OR2T12	0.35	5.93	0.34	9.43e-9	Common traits (Other);
CESC	cis	rs17376456	0.935	rs13156002	chr5:93508931	G/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.61	5.04	0.3	8.6e-7	Diabetic retinopathy;
CESC	cis	rs9910055	0.659	rs2246287	chr17:42232442	C/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.68	9.05	0.49	3.11e-17	Total body bone mineral density;
CESC	cis	rs4925114	0.568	rs4925109	chr17:17661802	A/G	cg09796270	chr17:17721594	SREBF1	-0.47	-6.15	-0.35	2.86e-9	Body mass index;
CESC	cis	rs12618769	0.597	rs3769734	chr2:99096149	A/T	cg10123293	chr2:99228465	UNC50	0.39	5.14	0.3	5.22e-7	Bipolar disorder;
CESC	cis	rs2842992	0.958	rs2758318	chr6:160069637	C/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.63	7.67	0.43	3.32e-13	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs1499614	1.000	rs1267817	chr7:66110040	G/T	cg13147721	chr7:65941812	NA	-0.91	-8.45	-0.46	1.99e-15	Gout;
CESC	cis	rs4588572	0.643	rs7716529	chr5:77738637	A/T	cg11547950	chr5:77652471	NA	-0.44	-5.47	-0.32	1.03e-7	Triglycerides;
CESC	cis	rs7208859	0.673	rs216424	chr17:28943064	T/G	cg13385521	chr17:29058706	SUZ12P	0.65	5.57	0.32	6.13e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs7772486	0.764	rs2247211	chr6:146216379	G/A	cg23711669	chr6:146136114	FBXO30	0.82	11.64	0.58	1.47e-25	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs12995491	0.731	rs12992162	chr2:88508773	G/C	cg04511125	chr2:88470314	THNSL2	-0.47	-6.75	-0.38	9.08e-11	Response to metformin (IC50);
CESC	cis	rs7208859	0.673	rs73263785	chr17:29214808	C/T	cg19761014	chr17:28927070	LRRC37B2	0.73	5.79	0.34	1.95e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs736408	0.648	rs3774355	chr3:52817778	G/A	cg17372223	chr3:52568218	NT5DC2	0.4	5.59	0.32	5.68e-8	Bipolar disorder;
CESC	cis	rs853679	0.517	rs9380055	chr6:28081629	A/G	cg23281280	chr6:28129359	ZNF389	0.58	7.93	0.44	6.31e-14	Depression;
CESC	cis	rs9325144	0.600	rs10785615	chr12:38733627	G/C	cg26384229	chr12:38710491	ALG10B	0.55	7.81	0.43	1.32e-13	Morning vs. evening chronotype;
CESC	cis	rs2439831	0.867	rs496584	chr15:43831923	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.73	8.8	0.48	1.84e-16	Lung cancer in ever smokers;
CESC	cis	rs2228479	0.867	rs35542367	chr16:89965825	G/C	cg00800038	chr16:89945340	TCF25	-0.85	-7.67	-0.43	3.2e-13	Skin colour saturation;
CESC	cis	rs769267	0.930	rs2304098	chr19:19646272	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.57	7.24	0.41	4.92e-12	Tonsillectomy;
CESC	cis	rs644799	0.710	rs11021309	chr11:95501898	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	11.79	0.59	4.45e-26	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs67311347	1.000	rs7628247	chr3:40512682	G/T	cg09455208	chr3:40491958	NA	-0.49	-8.32	-0.46	4.59e-15	Renal cell carcinoma;
CESC	cis	rs4566357	0.615	rs6436644	chr2:227914275	T/A	cg05526886	chr2:227700861	RHBDD1	-0.46	-6.15	-0.35	2.88e-9	Coronary artery disease;
CESC	cis	rs78456975	0.527	rs11901028	chr2:1557972	A/G	cg12573674	chr2:1569213	NA	-0.45	-5.31	-0.31	2.38e-7	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs9513593	1.000	rs7325957	chr13:99965155	C/T	cg21788972	chr13:99853209	UBAC2	-0.61	-7.25	-0.41	4.52e-12	Psoriasis;
CESC	cis	rs4665809	0.590	rs7260	chr2:26413917	C/T	cg04944784	chr2:26401820	FAM59B	-0.87	-10.27	-0.53	4.6e-21	Gut microbiome composition (summer);
CESC	cis	rs1580019	0.587	rs6968990	chr7:32552159	C/T	cg07520158	chr7:32535189	LSM5;AVL9	-0.54	-6.69	-0.38	1.3e-10	Cognitive ability;
CESC	cis	rs853679	0.517	rs9393894	chr6:28112562	A/G	cg23161317	chr6:28129485	ZNF389	0.5	6.22	0.36	1.89e-9	Depression;
CESC	cis	rs7267979	0.966	rs910996	chr20:25264196	A/G	cg08601574	chr20:25228251	PYGB	0.4	5.76	0.33	2.32e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs72829446	0.530	rs4796422	chr17:7380004	T/C	cg02795151	chr17:7402630	POLR2A	0.57	6.07	0.35	4.53e-9	Androgen levels;
CESC	cis	rs9811920	0.609	rs6809988	chr3:99656615	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.59	-7.31	-0.41	3.2e-12	Axial length;
CESC	cis	rs2120019	0.938	rs2289582	chr15:75310394	T/C	cg09165964	chr15:75287851	SCAMP5	-0.77	-9.53	-0.51	1.07e-18	Blood trace element (Zn levels);
CESC	cis	rs9894429	1.000	rs7209180	chr17:79581519	C/A	cg18240062	chr17:79603768	NPLOC4	0.72	10.27	0.53	4.71e-21	Eye color traits;
CESC	cis	rs9611565	0.559	rs13056262	chr22:42081921	A/G	cg03806693	chr22:41940476	POLR3H	1.09	12.68	0.61	4.09e-29	Vitiligo;
CESC	cis	rs698833	0.819	rs698772	chr2:44580634	G/A	cg04920474	chr2:44395004	PPM1B	0.36	5.03	0.3	9.04e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs2836974	0.584	rs34436313	chr21:40685246	A/G	cg22974920	chr21:40686053	BRWD1	-0.43	-5.22	-0.31	3.61e-7	Cognitive function;
CESC	cis	rs7638909	0.512	rs6793245	chr3:38599037	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.4	5.16	0.3	4.85e-7	Electrocardiographic conduction measures;
CESC	cis	rs4423214	0.592	rs11233933	chr11:71210070	C/T	cg05163923	chr11:71159392	DHCR7	-0.55	-5.66	-0.33	3.91e-8	Vitamin D levels;
CESC	cis	rs7116495	0.609	rs10501408	chr11:71680590	C/T	cg10381502	chr11:71823885	C11orf51	-1.13	-6.48	-0.37	4.49e-10	Severe influenza A (H1N1) infection;
CESC	cis	rs1707322	1.000	rs785480	chr1:46492164	C/G	cg06784218	chr1:46089804	CCDC17	0.35	5.96	0.34	8.03e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs425277	0.583	rs3107151	chr1:2051513	T/G	cg23803603	chr1:2058230	PRKCZ	-0.35	-6.15	-0.35	2.77e-9	Height;
CESC	cis	rs60154123	0.505	rs2206043	chr1:210042983	G/A	cg22029157	chr1:209979665	IRF6	0.7	7.59	0.42	5.54e-13	Coronary artery disease;
CESC	cis	rs1799949	0.965	rs7223952	chr17:41194885	T/C	cg23758822	chr17:41437982	NA	0.97	15.7	0.69	1.06e-39	Menopause (age at onset);
CESC	cis	rs7615952	0.736	rs13063122	chr3:125643860	G/A	cg05084668	chr3:125655381	ALG1L	-0.5	-5.94	-0.34	8.89e-9	Blood pressure (smoking interaction);
CESC	cis	rs2404602	0.532	rs744336	chr15:76674624	T/C	cg00316803	chr15:76480434	C15orf27	-0.36	-5.45	-0.32	1.14e-7	Blood metabolite levels;
CESC	cis	rs875971	0.929	rs34406470	chr7:65929956	A/G	cg11764359	chr7:65958608	NA	0.97	15.14	0.68	1.02e-37	Aortic root size;
CESC	cis	rs6088580	0.634	rs6087577	chr20:32955423	C/T	cg24642439	chr20:33292090	TP53INP2	0.49	6.39	0.37	7.54e-10	Glomerular filtration rate (creatinine);
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg16418258	chr15:42840397	LRRC57;HAUS2	-0.45	-6.03	-0.35	5.61e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs2836950	0.501	rs62223052	chr21:40708702	A/C	cg17971929	chr21:40555470	PSMG1	-0.64	-8.44	-0.46	2.03e-15	Menarche (age at onset);
CESC	cis	rs6088590	0.687	rs8115656	chr20:33282780	G/C	cg24642439	chr20:33292090	TP53INP2	0.69	9.2	0.49	1.09e-17	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13848568	chr1:45965625	CCDC163P;MMACHC	0.58	6.27	0.36	1.46e-9	Gut microbiome composition (summer);
CESC	cis	rs801193	0.527	rs2707837	chr7:66181073	G/C	cg18876405	chr7:65276391	NA	0.45	6.09	0.35	3.92e-9	Aortic root size;
CESC	cis	rs3749237	0.595	rs7637999	chr3:49535115	C/T	cg06212747	chr3:49208901	KLHDC8B	0.49	6.55	0.37	3.02e-10	Resting heart rate;
CESC	cis	rs3105593	0.933	rs3098202	chr15:50838236	C/G	cg08437265	chr15:50716283	USP8	0.42	5.43	0.32	1.3e-7	QT interval;
CESC	trans	rs61931739	0.534	rs11052986	chr12:34052578	T/C	cg26384229	chr12:38710491	ALG10B	0.51	6.94	0.39	2.97e-11	Morning vs. evening chronotype;
CESC	cis	rs55728055	0.661	rs62237791	chr22:31973124	A/G	cg01338084	chr22:32026380	PISD	1.26	8.55	0.47	9.7e-16	Age-related hearing impairment;
CESC	cis	rs6691722	0.503	rs3765427	chr1:24705567	G/A	cg02336364	chr1:24764700	NIPAL3	0.34	6.84	0.39	5.52e-11	Response to interferon beta in multiple sclerosis;
CESC	cis	rs244293	0.931	rs244354	chr17:53194142	C/T	cg19360675	chr17:53046073	COX11;STXBP4	-0.39	-5.05	-0.3	8.18e-7	Menarche (age at onset);
CESC	cis	rs7267979	1.000	rs1046073	chr20:25281333	G/A	cg08601574	chr20:25228251	PYGB	0.39	5.57	0.32	6.14e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs752092	0.802	rs2412005	chr15:101767591	T/A	cg19997662	chr15:101784653	CHSY1	-0.42	-5.83	-0.34	1.57e-8	Corneal structure;
CESC	cis	rs1816752	0.905	rs3818938	chr13:25029083	C/T	cg02811702	chr13:24901961	NA	0.35	5.11	0.3	6.04e-7	Obesity-related traits;
CESC	cis	rs10870270	1.000	rs6560694	chr10:133773448	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.59	-7.57	-0.42	6.29e-13	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	10.23	0.53	6.6e-21	Prudent dietary pattern;
CESC	cis	rs116095464	0.558	rs9688136	chr5:229348	T/C	cg20965017	chr5:231967	SDHA	-0.45	-5.08	-0.3	7.29e-7	Breast cancer;
CESC	trans	rs208520	0.690	rs207091	chr6:66799847	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.99	-12.82	-0.62	1.32e-29	Exhaled nitric oxide output;
CESC	cis	rs34779708	0.897	rs7900480	chr10:35338699	A/G	cg03585969	chr10:35415529	CREM	-0.71	-8.88	-0.48	1.04e-16	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs909002	0.962	rs7537646	chr1:32135495	G/A	cg13919466	chr1:32135498	COL16A1	-0.55	-10.24	-0.53	5.92e-21	Intelligence (multi-trait analysis);
CESC	cis	rs7412746	0.658	rs11204723	chr1:150731618	T/C	cg04414720	chr1:150670196	GOLPH3L	0.58	7.56	0.42	6.44e-13	Melanoma;
CESC	trans	rs7107217	1.000	rs1873872	chr11:129473993	A/T	cg13089318	chr1:80961776	NA	-0.44	-6.04	-0.35	5.06e-9	Breast cancer;Type 2 diabetes;
CESC	trans	rs2727020	0.573	rs7925419	chr11:49231859	C/T	cg15704280	chr7:45808275	SEPT13	-0.68	-9.01	-0.48	4.1e-17	Coronary artery disease;
CESC	cis	rs8031584	0.652	rs2691683	chr15:31135060	A/G	cg14829155	chr15:31115871	NA	0.77	10.69	0.55	2e-22	Huntington's disease progression;
CESC	cis	rs1559088	0.576	rs11084707	chr19:33612873	C/T	cg27124370	chr19:33622961	WDR88	0.52	7.42	0.41	1.64e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs7833986	0.534	rs72653924	chr8:56906088	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.58	7.09	0.4	1.2e-11	Height;
CESC	cis	rs3768617	0.510	rs10752903	chr1:183100863	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.89	14.39	0.66	4.39e-35	Fuchs's corneal dystrophy;
CESC	cis	rs9611565	0.649	rs139559	chr22:42191636	A/G	cg03806693	chr22:41940476	POLR3H	-0.78	-9.42	-0.5	2.28e-18	Vitiligo;
CESC	trans	rs3942852	0.806	rs10769317	chr11:48150712	T/C	cg15704280	chr7:45808275	SEPT13	-0.64	-7.37	-0.41	2.13e-12	Acute lymphoblastic leukemia (childhood);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07105891	chr1:21031312	KIF17	-0.57	-6.49	-0.37	4.19e-10	Gut microbiome composition (summer);
CESC	cis	rs9733	0.650	rs4970923	chr1:150608300	A/G	cg22823121	chr1:150693482	HORMAD1	-0.41	-6.09	-0.35	3.95e-9	Tonsillectomy;
CESC	cis	rs4555082	0.874	rs2816625	chr14:105734565	G/A	cg27165867	chr14:105738592	BRF1	-0.54	-5.82	-0.34	1.72e-8	Mean platelet volume;Platelet distribution width;
CESC	cis	rs5750830	0.597	rs4821889	chr22:39777254	T/C	cg02038168	chr22:39784481	NA	-0.56	-7.63	-0.42	4.28e-13	Intelligence (multi-trait analysis);
CESC	cis	rs5750830	0.594	rs9611165	chr22:39775250	A/G	cg02038168	chr22:39784481	NA	-0.56	-7.35	-0.41	2.5e-12	Intelligence (multi-trait analysis);
CESC	cis	rs6912958	0.535	rs1753153	chr6:88032834	T/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.81	12.34	0.6	6.17e-28	Monocyte percentage of white cells;
CESC	cis	rs7945705	0.902	rs2016942	chr11:8938787	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.52	8.43	0.46	2.3e-15	Hemoglobin concentration;
CESC	cis	rs2842992	0.830	rs1853259	chr6:160147441	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	-0.72	-8.98	-0.48	5.29e-17	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs7845219	0.544	rs34208552	chr8:95908067	C/G	cg13393036	chr8:95962371	TP53INP1	-0.44	-8.2	-0.45	1.07e-14	Type 2 diabetes;
CESC	cis	rs875971	0.545	rs313830	chr7:65551931	T/C	cg18876405	chr7:65276391	NA	-0.55	-6.01	-0.35	6.19e-9	Aortic root size;
CESC	cis	rs881375	0.678	rs7037195	chr9:123684000	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.39	5.57	0.32	6.13e-8	Rheumatoid arthritis;
CESC	cis	rs9435341	0.965	rs1335053	chr1:107622823	C/T	cg09367891	chr1:107599246	PRMT6	-0.72	-8.63	-0.47	5.8e-16	Facial morphology (factor 21, depth of nasal alae);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10225325	chr1:167683897	NA	0.59	6.72	0.38	1.09e-10	Gut microbiome composition (summer);
CESC	trans	rs801193	1.000	rs2707845	chr7:66198798	C/T	cg26939375	chr7:64535504	NA	0.64	8.77	0.47	2.19e-16	Aortic root size;
CESC	cis	rs12618769	0.652	rs72823794	chr2:99216593	T/A	cg10123293	chr2:99228465	UNC50	0.4	5.19	0.3	4.2e-7	Bipolar disorder;
CESC	cis	rs6662572	0.703	rs72690847	chr1:46256929	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.46	5.06	0.3	7.99e-7	Blood protein levels;
CESC	cis	rs7267979	0.966	rs2424714	chr20:25418681	T/G	cg08601574	chr20:25228251	PYGB	0.38	5.64	0.33	4.4e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs9948	0.655	rs62156210	chr2:97393736	A/T	cg01990225	chr2:97406019	LMAN2L	-1.02	-7.77	-0.43	1.76e-13	Erectile dysfunction and prostate cancer treatment;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08391942	chr5:1386647	NA	0.56	6.11	0.35	3.47e-9	Gut microbiome composition (summer);
CESC	cis	rs4604732	0.631	rs11490198	chr1:247625703	A/G	cg12758973	chr1:247694275	LOC148824;OR2C3	0.51	6.36	0.36	8.65e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs2228479	0.702	rs62053701	chr16:89860584	G/A	cg00800038	chr16:89945340	TCF25	-0.9	-7.49	-0.42	1.01e-12	Skin colour saturation;
CESC	cis	rs1552244	0.882	rs56332224	chr3:10037321	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.87	11.4	0.57	9.22e-25	Alzheimer's disease;
CESC	cis	rs12900413	0.603	rs12905689	chr15:90301343	G/A	cg24249390	chr15:90295951	MESP1	-0.38	-5.03	-0.3	9.13e-7	Coronary artery aneurysm in Kawasaki disease;
CESC	cis	rs1378770	0.508	rs679685	chr7:114364364	A/G	cg05338976	chr7:114561850	MDFIC	0.36	5.08	0.3	7.17e-7	Pelvic organ prolapse (moderate/severe);
CESC	cis	rs13294100	0.929	rs8181077	chr9:17580616	A/T	cg11213383	chr9:17579734	SH3GL2	-0.39	-5.95	-0.34	8.28e-9	Parkinson's disease;
CESC	trans	rs2235573	0.625	rs139900	chr22:38405417	C/T	cg19894588	chr14:64061835	NA	0.52	6.6	0.38	2.17e-10	Glioblastoma;Glioma;
CESC	cis	rs897080	0.515	rs1085444	chr2:44624155	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	5.91	0.34	1.07e-8	Height;
CESC	cis	rs4588572	0.644	rs2115435	chr5:77723700	A/C	cg11547950	chr5:77652471	NA	-0.48	-6.79	-0.38	7.4e-11	Triglycerides;
CESC	cis	rs875971	0.862	rs1968126	chr7:66057004	A/G	cg10691866	chr7:65817282	TPST1	0.33	5.49	0.32	9.61e-8	Aortic root size;
CESC	cis	rs5769765	0.955	rs4075330	chr22:50303249	G/A	cg26441486	chr22:50317300	CRELD2	0.43	5.64	0.33	4.32e-8	Schizophrenia;
CESC	cis	rs7084402	0.967	rs1658485	chr10:60288331	A/G	cg07615347	chr10:60278583	BICC1	0.6	9.41	0.5	2.54e-18	Refractive error;
CESC	cis	rs9894429	0.752	rs7502883	chr17:79588557	T/C	cg13777783	chr17:79615861	NA	-0.33	-5.24	-0.31	3.35e-7	Eye color traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17059263	chr4:154266522	MND1	-0.56	-6.48	-0.37	4.41e-10	Gut microbiome composition (summer);
CESC	cis	rs4423214	0.592	rs7114252	chr11:71237606	G/A	cg05163923	chr11:71159392	DHCR7	-0.54	-5.64	-0.33	4.34e-8	Vitamin D levels;
CESC	cis	rs728616	0.867	rs12412226	chr10:81735288	C/T	cg05935833	chr10:81318306	SFTPA2	-0.51	-5.04	-0.3	8.51e-7	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs5769765	0.908	rs9616216	chr22:50318927	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.62	-6.38	-0.37	7.75e-10	Schizophrenia;
CESC	cis	rs9467711	0.606	rs2073529	chr6:26375159	C/T	cg14345882	chr6:26364793	BTN3A2	-0.66	-6.37	-0.36	8.35e-10	Autism spectrum disorder or schizophrenia;
CESC	cis	rs7824557	0.505	rs2736313	chr8:11086942	C/T	cg21775007	chr8:11205619	TDH	0.38	5.44	0.32	1.22e-7	Retinal vascular caliber;
CESC	cis	rs11958404	0.932	rs72816547	chr5:157417820	G/T	cg05962755	chr5:157440814	NA	0.62	6.47	0.37	4.68e-10	IgG glycosylation;
CESC	cis	rs8067545	0.611	rs77449863	chr17:20191860	C/G	cg13482628	chr17:19912719	NA	-0.42	-5.61	-0.33	5.2e-8	Schizophrenia;
CESC	cis	rs9430161	0.611	rs34032547	chr1:11034374	C/G	cg02454025	chr1:11042201	C1orf127	0.99	16.1	0.7	3.84e-41	Ewing sarcoma;
CESC	cis	rs2249625	0.508	rs60020363	chr6:72844706	C/T	cg18830697	chr6:72922368	RIMS1	0.43	6.23	0.36	1.81e-9	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CESC	cis	rs2836974	0.583	rs2735307	chr21:40713358	C/T	cg11644478	chr21:40555479	PSMG1	0.61	8.23	0.45	8.45e-15	Cognitive function;
CESC	cis	rs7618915	0.501	rs34754793	chr3:52629177	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.6	8.56	0.47	9.4e-16	Bipolar disorder;
CESC	cis	rs7917772	0.628	rs4604806	chr10:104373904	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.39	5.41	0.32	1.43e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs9596863	1.000	rs1545659	chr13:54433788	G/A	ch.13.53330881F	chr13:54432880	NA	-0.63	-5.37	-0.31	1.74e-7	Epilepsy and lamotrigine-induced maculopapular eruptions;
CESC	cis	rs1790761	0.667	rs1254123	chr11:67334812	T/C	cg00290607	chr11:67383545	NA	0.39	5.48	0.32	1.01e-7	Mean corpuscular volume;
CESC	cis	rs7917772	0.582	rs10786682	chr10:104318322	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.41	-5.65	-0.33	4.17e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs6061231	0.561	rs67072353	chr20:60940702	G/A	cg22601191	chr20:60968625	CABLES2	0.49	5.06	0.3	7.81e-7	Colorectal cancer;
CESC	cis	rs7552404	0.627	rs12127049	chr1:76353248	G/A	cg22875332	chr1:76189707	ACADM	0.59	5.78	0.33	2.09e-8	Blood metabolite levels;Acylcarnitine levels;
CESC	trans	rs61931739	0.500	rs7310237	chr12:34483435	G/A	cg26384229	chr12:38710491	ALG10B	0.55	7.58	0.42	5.66e-13	Morning vs. evening chronotype;
CESC	cis	rs2075671	0.903	rs4727459	chr7:100276821	T/C	cg16850897	chr7:100343110	ZAN	-0.7	-8.88	-0.48	1.04e-16	Other erythrocyte phenotypes;
CESC	cis	rs2836974	0.897	rs34599551	chr21:40594898	C/A	cg27266027	chr21:40555129	PSMG1	0.48	5.72	0.33	2.87e-8	Cognitive function;
CESC	cis	rs7089973	0.872	rs7918253	chr10:116614501	T/C	cg25233709	chr10:116636983	FAM160B1	0.35	5.08	0.3	7.02e-7	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs651907	0.535	rs36060163	chr3:101360963	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.46	5.87	0.34	1.32e-8	Colorectal cancer;
CESC	cis	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg22963979	chr7:1858916	MAD1L1	-0.43	-5.89	-0.34	1.2e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs10129255	0.701	rs2005643	chr14:107132304	C/T	cg23076370	chr14:107095027	NA	-0.52	-7.23	-0.41	5.23e-12	Kawasaki disease;
CESC	cis	rs1707322	0.752	rs28623463	chr1:46170758	A/C	cg03146154	chr1:46216737	IPP	0.82	11.53	0.58	3.39e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9549260	0.755	rs59308928	chr13:41245079	C/T	cg21288729	chr13:41239152	FOXO1	0.68	8.49	0.46	1.51e-15	Red blood cell count;
CESC	cis	rs4523957	0.928	rs11872068	chr17:2176528	G/A	cg16513277	chr17:2031491	SMG6	-0.56	-7.42	-0.41	1.55e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs875971	0.862	rs4718330	chr7:65715243	G/A	cg10691866	chr7:65817282	TPST1	0.3	5.17	0.3	4.51e-7	Aortic root size;
CESC	cis	rs3126085	0.935	rs6587651	chr1:152193121	G/T	cg26876637	chr1:152193138	HRNR	0.48	5.51	0.32	8.31e-8	Atopic dermatitis;
CESC	cis	rs11650494	0.908	rs77488129	chr17:47448970	G/A	cg08112188	chr17:47440006	ZNF652	1.28	8.54	0.46	1.1e-15	Prostate cancer;
CESC	cis	rs7599312	0.534	rs7607363	chr2:213402705	A/G	cg20637307	chr2:213403960	ERBB4	0.57	8.92	0.48	7.78e-17	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg11604216	chr8:124031034	DERL1	0.41	6.01	0.35	5.97e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs367943	0.667	rs13173069	chr5:113011778	T/G	cg12552261	chr5:112820674	MCC	0.44	5.3	0.31	2.48e-7	Type 2 diabetes;
CESC	cis	rs7666738	0.830	rs13121558	chr4:99002848	G/A	cg05340658	chr4:99064831	C4orf37	0.8	12.44	0.61	2.83e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs12971120	0.838	rs2241510	chr18:72180739	G/A	cg25817165	chr18:72167213	CNDP2	-0.63	-7.64	-0.42	4.08e-13	Refractive error;
CESC	cis	rs6426558	0.559	rs7549520	chr1:227258858	G/C	cg10327440	chr1:227177885	CDC42BPA	0.47	5.75	0.33	2.42e-8	Neutrophil percentage of white cells;
CESC	cis	rs1580019	0.534	rs13237495	chr7:32560687	A/G	cg06627557	chr7:32535165	LSM5;AVL9	1.03	18.4	0.75	2.8e-49	Cognitive ability;
CESC	cis	rs763014	0.931	rs7191939	chr16:630089	C/T	cg07343612	chr16:622815	PIGQ	-0.58	-8.44	-0.46	2.07e-15	Height;
CESC	cis	rs9611565	0.659	rs9611609	chr22:41945357	C/A	cg06634786	chr22:41940651	POLR3H	-0.65	-6.85	-0.39	5.03e-11	Vitiligo;
CESC	cis	rs10504229	0.654	rs903705	chr8:58128185	T/A	cg21724239	chr8:58056113	NA	0.58	5.95	0.34	8.29e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs10924309	0.686	rs4658796	chr1:245854680	A/G	cg00036263	chr1:245852353	KIF26B	-0.51	-6.44	-0.37	5.51e-10	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
CESC	cis	rs1545257	0.505	rs2584950	chr2:24632762	A/G	cg06627628	chr2:24431161	ITSN2	-0.48	-5.82	-0.34	1.74e-8	Sjögren's syndrome;
CESC	cis	rs1005277	0.540	rs7903942	chr10:37929276	C/T	cg25517755	chr10:38738941	LOC399744	0.41	5.38	0.31	1.64e-7	Extrinsic epigenetic age acceleration;
CESC	cis	rs1670533	1.000	rs2290408	chr4:1067267	A/C	cg27284194	chr4:1044797	NA	-0.47	-6.11	-0.35	3.61e-9	Recombination rate (females);
CESC	cis	rs875971	0.638	rs10249404	chr7:66046724	G/A	cg14393609	chr7:65229607	NA	-0.46	-6.16	-0.35	2.65e-9	Aortic root size;
CESC	cis	rs3820928	0.933	rs1429267	chr2:227767593	G/C	cg11843606	chr2:227700838	RHBDD1	-0.43	-5.71	-0.33	3.04e-8	Pulmonary function;
CESC	cis	rs10088262	0.591	rs13270541	chr8:124794849	G/A	cg15047889	chr8:124780837	FAM91A1	-0.52	-6.58	-0.37	2.57e-10	Pancreatic cancer;
CESC	cis	rs897984	0.609	rs17839567	chr16:31057945	A/G	cg02466173	chr16:30829666	NA	-0.39	-6.77	-0.38	8.4e-11	Dementia with Lewy bodies;
CESC	cis	rs9549367	0.789	rs2287253	chr13:113891075	G/A	cg00898013	chr13:113819073	PROZ	0.48	6.75	0.38	9.17e-11	Platelet distribution width;
CESC	cis	rs965469	0.603	rs6115892	chr20:3411569	C/T	cg25506879	chr20:3388711	C20orf194	-0.46	-5.58	-0.32	6.07e-8	IFN-related cytopenia;
CESC	cis	rs10504229	0.813	rs6999878	chr8:58197243	C/G	cg22535103	chr8:58192502	C8orf71	-0.75	-8.89	-0.48	9.68e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs2777491	1.000	rs316613	chr15:41747598	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.64	-9.84	-0.52	1.16e-19	Ulcerative colitis;
CESC	trans	rs35110281	0.563	rs162371	chr21:44931489	G/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.49	6.62	0.38	1.94e-10	Mean corpuscular volume;
CESC	trans	rs7937682	0.889	rs559482	chr11:111497902	G/A	cg18187862	chr3:45730750	SACM1L	0.52	6.57	0.37	2.6e-10	Primary sclerosing cholangitis;
CESC	cis	rs6540559	1.000	rs6696825	chr1:209982372	A/G	cg25204440	chr1:209979598	IRF6	0.6	7.66	0.43	3.51e-13	Cleft lip with or without cleft palate;
CESC	cis	rs818427	0.593	rs419155	chr5:112210415	A/T	cg07820702	chr5:112228657	REEP5	-0.4	-5.34	-0.31	2.02e-7	Total body bone mineral density;
CESC	cis	rs4808199	1.000	rs60003758	chr19:19557353	A/G	cg03709012	chr19:19516395	GATAD2A	1.14	13.23	0.63	4.9e-31	Nonalcoholic fatty liver disease;
CESC	cis	rs6933660	0.745	rs9397405	chr6:151736084	G/T	cg14262678	chr6:151773367	RMND1;C6orf211	0.66	9.32	0.5	4.58e-18	Menarche (age at onset);
CESC	cis	rs28386778	0.700	rs12449555	chr17:62003982	T/A	cg11494091	chr17:61959527	GH2	-0.81	-14.38	-0.66	4.62e-35	Prudent dietary pattern;
CESC	cis	rs2295359	0.892	rs10789224	chr1:67605134	C/T	cg03340356	chr1:67600835	NA	-0.31	-5.21	-0.3	3.86e-7	Psoriasis;
CESC	cis	rs1904096	0.506	rs4558832	chr4:95148042	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.7	-11.56	-0.58	2.74e-25	Type 2 diabetes;
CESC	cis	rs4665809	0.590	rs7604564	chr2:26501953	C/A	cg25036284	chr2:26402008	FAM59B	0.86	9.41	0.5	2.53e-18	Gut microbiome composition (summer);
CESC	trans	rs1814175	0.546	rs1614397	chr11:49913384	G/C	cg15704280	chr7:45808275	SEPT13	-1.03	-20.27	-0.78	8.31e-56	Height;
CESC	cis	rs992157	0.560	rs7578940	chr2:219083318	G/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.58	-7.54	-0.42	7.32e-13	Colorectal cancer;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg08283932	chr20:43280707	ADA	-0.49	-6.54	-0.37	3.13e-10	Thyroid stimulating hormone;
CESC	cis	rs889398	0.835	rs62050037	chr16:69784670	T/C	cg09409435	chr16:70099608	PDXDC2	-0.41	-5.06	-0.3	7.72e-7	Body mass index;
CESC	trans	rs2727020	0.658	rs10839269	chr11:49385596	A/G	cg15704280	chr7:45808275	SEPT13	-0.91	-15.87	-0.7	2.58e-40	Coronary artery disease;
CESC	cis	rs2228479	0.541	rs12918575	chr16:89811151	A/G	cg14709524	chr16:89940631	TCF25	0.63	5.69	0.33	3.43e-8	Skin colour saturation;
CESC	cis	rs6493487	0.512	rs28366661	chr15:51258315	A/G	cg02338191	chr15:51200825	AP4E1	0.6	5.6	0.33	5.43e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs965469	0.779	rs6051785	chr20:3339199	C/T	cg17110299	chr20:3385021	C20orf194	0.4	5.26	0.31	3.02e-7	IFN-related cytopenia;
CESC	cis	rs17764205	0.929	rs57643778	chr19:3257020	C/T	cg04171554	chr19:2761892	SGTA	-0.54	-5.06	-0.3	7.98e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs7264396	0.690	rs2425180	chr20:34447160	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.85	-11.57	-0.58	2.56e-25	Total cholesterol levels;
CESC	cis	rs2370759	1.000	rs2225152	chr10:32574759	T/C	cg18270830	chr10:32634957	EPC1	0.73	7.28	0.41	3.73e-12	Sexual dysfunction (female);
CESC	cis	rs7618915	0.501	rs2164885	chr3:52731269	T/C	cg18337363	chr3:52569053	NT5DC2	0.29	5.31	0.31	2.32e-7	Bipolar disorder;
CESC	cis	rs3796352	0.764	rs11714902	chr3:53101544	G/C	cg12962167	chr3:53033115	SFMBT1	0.72	6.37	0.36	8.3e-10	Immune reponse to smallpox (secreted IL-2);
CESC	cis	rs116095464	0.558	rs6555056	chr5:226222	T/C	cg12570787	chr5:219185	SDHA;CCDC127	0.52	5.58	0.32	5.88e-8	Breast cancer;
CESC	cis	rs6460942	0.778	rs17444259	chr7:12462428	C/T	cg02935154	chr7:12443704	VWDE	-0.53	-6.68	-0.38	1.38e-10	Coronary artery disease;
CESC	cis	rs7202877	0.656	rs9923834	chr16:75507253	T/A	cg03315344	chr16:75512273	CHST6	0.53	5.26	0.31	3.03e-7	Type 2 diabetes;Type 1 diabetes;
CESC	cis	rs78707713	0.560	rs55668536	chr10:71242655	A/G	cg12610070	chr10:71211762	TSPAN15	-0.33	-7.01	-0.4	1.99e-11	Venous thromboembolism;
CESC	cis	rs7824557	0.778	rs3808502	chr8:11179458	G/T	cg21775007	chr8:11205619	TDH	0.48	6.94	0.39	3.05e-11	Retinal vascular caliber;
CESC	cis	rs11048434	0.612	rs7299653	chr12:9058993	A/T	cg23795048	chr12:9217529	LOC144571	0.32	5.03	0.3	9.05e-7	Sjögren's syndrome;
CESC	cis	rs6866344	0.697	rs58549512	chr5:178133204	C/T	cg10224037	chr5:178157518	ZNF354A	0.66	7.23	0.41	5.03e-12	Neutrophil percentage of white cells;
CESC	cis	rs72781680	0.716	rs72788284	chr2:24097539	A/G	cg08917208	chr2:24149416	ATAD2B	0.58	5.81	0.34	1.82e-8	Lymphocyte counts;
CESC	cis	rs10870270	1.000	rs10870271	chr10:133754807	A/G	cg08754478	chr10:133766260	PPP2R2D	0.63	8.23	0.45	8.79e-15	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11815682	chr21:44486381	CBS	-0.59	-6.3	-0.36	1.24e-9	Gut microbiome composition (summer);
CESC	cis	rs668210	0.947	rs559161	chr11:65761637	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.47	5.17	0.3	4.62e-7	Cerebrospinal fluid biomarker levels;
CESC	cis	rs137603	0.644	rs137635	chr22:39720656	G/C	cg01093212	chr22:39715156	SNORD43;RPL3	-0.43	-5.6	-0.33	5.33e-8	Primary biliary cholangitis;
CESC	cis	rs763121	0.853	rs4821810	chr22:39072098	C/G	cg06022373	chr22:39101656	GTPBP1	0.94	18.23	0.75	1.15e-48	Menopause (age at onset);
CESC	cis	rs7520050	0.966	rs6429582	chr1:46321843	C/T	cg03146154	chr1:46216737	IPP	0.48	6.23	0.36	1.82e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs4660306	0.961	rs1337902	chr1:45952066	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.61	-7.76	-0.43	1.85e-13	Homocysteine levels;
CESC	cis	rs4535700	0.501	rs57251705	chr7:55981083	A/G	cg09872392	chr7:56161020	PHKG1	0.41	5.81	0.34	1.8e-8	Macular telangiectasia type 2;
CESC	cis	rs8180040	0.654	rs13078131	chr3:47204939	G/T	cg27129171	chr3:47204927	SETD2	0.72	11.24	0.57	3.23e-24	Colorectal cancer;
CESC	cis	rs870825	0.520	rs10022842	chr4:185649459	A/G	cg04058563	chr4:185651563	MLF1IP	0.63	6.96	0.39	2.59e-11	Blood protein levels;
CESC	cis	rs9354308	0.899	rs2802058	chr6:66550787	T/G	cg07460842	chr6:66804631	NA	0.6	6.77	0.38	8.12e-11	Metabolite levels;
CESC	cis	rs4930561	0.739	rs10896303	chr11:67974292	C/A	cg16338278	chr11:67432957	ALDH3B2	0.43	5.3	0.31	2.43e-7	Breast cancer in childhood cancer survivors;IgG glycosylation;
CESC	cis	rs45535039	1.000	rs7113047	chr11:119108112	A/G	cg16724696	chr11:118992527	HINFP	0.42	5.42	0.32	1.33e-7	Plateletcrit;
CESC	cis	rs7949030	0.596	rs11231138	chr11:62316195	C/G	cg11742103	chr11:62369870	EML3;MTA2	0.63	9.34	0.5	4.06e-18	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs12136530	0.594	rs4912082	chr1:19716796	T/C	cg01832549	chr1:19774989	CAPZB	-0.4	-5.63	-0.33	4.51e-8	Lead levels in blood;
CESC	cis	rs921968	0.565	rs7605055	chr2:219627050	G/C	cg02176678	chr2:219576539	TTLL4	-0.44	-7.73	-0.43	2.21e-13	Mean corpuscular hemoglobin concentration;
CESC	cis	rs7666738	0.519	rs28539191	chr4:98821552	C/T	cg17366294	chr4:99064904	C4orf37	0.49	5.94	0.34	9.14e-9	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24322668	chr19:3838098	ZFR2	-0.5	-6.32	-0.36	1.12e-9	Gut microbiome composition (summer);
CESC	cis	rs4604732	0.588	rs12045675	chr1:247623915	C/A	cg12758973	chr1:247694275	LOC148824;OR2C3	0.49	6.07	0.35	4.52e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs73072330	0.643	rs56298666	chr3:47667218	A/G	cg04507495	chr3:47563649	NA	1.12	7.57	0.42	6.32e-13	Stem cell growth factor beta levels;
CESC	cis	rs367943	0.712	rs1607159	chr5:112681044	C/A	cg12552261	chr5:112820674	MCC	0.4	5.25	0.31	3.09e-7	Type 2 diabetes;
CESC	cis	rs6840360	0.615	rs7669465	chr4:152609289	C/T	cg22705602	chr4:152727874	NA	-0.36	-5.04	-0.3	8.52e-7	Intelligence (multi-trait analysis);
CESC	cis	rs9486719	0.895	rs11152960	chr6:96900398	A/G	cg06623918	chr6:96969491	KIAA0776	-0.81	-8.3	-0.45	5.21e-15	Migraine;Coronary artery disease;
CESC	trans	rs9354352	1.000	rs9354352	chr6:66696272	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.68	9.93	0.52	5.77e-20	Initial pursuit acceleration in psychotic disorders;
CESC	cis	rs9733	0.596	rs72702552	chr1:150677462	G/A	cg04414720	chr1:150670196	GOLPH3L	0.63	9.0	0.48	4.53e-17	Tonsillectomy;
CESC	cis	rs9911578	1.000	rs9898916	chr17:57048660	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.38	5.08	0.3	7.21e-7	Intelligence (multi-trait analysis);
CESC	cis	rs9443645	0.869	rs9448591	chr6:79606490	C/T	cg05283184	chr6:79620031	NA	-0.43	-6.59	-0.38	2.34e-10	Intelligence (multi-trait analysis);
CESC	cis	rs2991971	0.967	rs512026	chr1:46009946	G/T	cg24296786	chr1:45957014	TESK2	0.63	8.45	0.46	1.99e-15	High light scatter reticulocyte count;
CESC	cis	rs1218582	0.744	rs6674853	chr1:154892753	G/C	cg24250549	chr1:154909240	PMVK	0.6	8.12	0.45	1.74e-14	Prostate cancer;
CESC	trans	rs10435719	0.902	rs7459545	chr8:11804389	G/T	cg15556689	chr8:8085844	FLJ10661	0.53	6.71	0.38	1.14e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
CESC	cis	rs6430585	0.528	rs309165	chr2:136667301	T/C	cg07169764	chr2:136633963	MCM6	1.08	16.51	0.71	1.41e-42	Corneal structure;
CESC	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg06873352	chr17:61820015	STRADA	0.73	12.89	0.62	7.87e-30	Prudent dietary pattern;
CESC	cis	rs9287719	0.967	rs7566875	chr2:10754792	T/C	cg00105475	chr2:10696890	NA	0.38	5.42	0.32	1.34e-7	Prostate cancer;
CESC	cis	rs5769707	0.967	rs4524218	chr22:50018639	G/A	cg05373962	chr22:49881684	NA	-0.38	-6.73	-0.38	1.04e-10	Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs9611565	0.545	rs5758432	chr22:42111693	T/C	cg17376030	chr22:41985996	PMM1	-0.81	-8.6	-0.47	7.13e-16	Vitiligo;
CESC	cis	rs854765	0.547	rs8075189	chr17:17901946	C/G	cg04398451	chr17:18023971	MYO15A	-0.69	-10.33	-0.54	3.02e-21	Total body bone mineral density;
CESC	cis	rs875971	0.862	rs11765791	chr7:65936574	A/G	cg19163074	chr7:65112434	INTS4L2	-0.41	-5.1	-0.3	6.39e-7	Aortic root size;
CESC	cis	rs67311347	0.955	rs4974068	chr3:40376929	T/C	cg09455208	chr3:40491958	NA	0.52	9.12	0.49	1.91e-17	Renal cell carcinoma;
CESC	cis	rs13256369	0.950	rs13248096	chr8:8577476	C/T	cg00074818	chr8:8560427	CLDN23	0.36	5.41	0.32	1.42e-7	Obesity-related traits;
CESC	trans	rs2207136	0.868	rs2207138	chr6:50841355	G/A	cg06522515	chr3:184090630	THPO	-0.35	-6.18	-0.35	2.43e-9	Myopia;
CESC	cis	rs7264396	0.790	rs2425096	chr20:34308588	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.62	7.38	0.41	2.01e-12	Total cholesterol levels;
CESC	cis	rs1568889	0.938	rs1464898	chr11:28034748	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.79	11.02	0.56	1.73e-23	Bipolar disorder;
CESC	cis	rs367943	0.871	rs348940	chr5:112824530	C/A	cg12552261	chr5:112820674	MCC	-0.59	-7.57	-0.42	6.04e-13	Type 2 diabetes;
CESC	cis	rs3857536	0.776	rs2040593	chr6:66944076	G/A	cg07460842	chr6:66804631	NA	-0.41	-5.22	-0.31	3.67e-7	Blood trace element (Cu levels);
CESC	cis	rs9640161	0.789	rs66688634	chr7:150053806	G/A	cg10018233	chr7:150070692	REPIN1	0.41	5.88	0.34	1.24e-8	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs4304924	0.500	rs12585725	chr13:79220899	C/A	cg07926092	chr13:79233506	RNF219	0.61	6.68	0.38	1.43e-10	Large artery stroke;
CESC	cis	rs896854	0.596	rs7823059	chr8:95974961	T/C	cg09323728	chr8:95962352	TP53INP1	-0.4	-8.68	-0.47	4.05e-16	Type 2 diabetes;
CESC	cis	rs8114671	0.562	rs2424999	chr20:33386430	G/A	cg07148914	chr20:33460835	GGT7	0.47	5.9	0.34	1.12e-8	Height;
CESC	cis	rs1707322	0.681	rs12048866	chr1:46117492	T/G	cg03146154	chr1:46216737	IPP	0.82	11.51	0.58	3.87e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs617791	0.530	rs10896073	chr11:65762814	T/C	cg04055107	chr11:65626734	MUS81;CFL1	-0.44	-5.04	-0.3	8.66e-7	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07936931	chr19:21933455	LOC641367;ZNF100	-0.55	-6.08	-0.35	4.09e-9	Gut microbiome composition (summer);
CESC	cis	rs6545883	0.965	rs6545872	chr2:61724568	G/A	cg15711740	chr2:61764176	XPO1	-0.42	-5.27	-0.31	2.81e-7	Tuberculosis;
CESC	cis	rs2439831	0.867	rs2242068	chr15:43699304	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.8	10.67	0.55	2.47e-22	Lung cancer in ever smokers;
CESC	cis	rs3733585	0.660	rs13122290	chr4:9933832	A/G	cg11266682	chr4:10021025	SLC2A9	-0.55	-10.42	-0.54	1.54e-21	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs4835473	0.778	rs75562808	chr4:144700218	T/A	cg25736465	chr4:144833511	NA	-0.33	-5.14	-0.3	5.37e-7	Immature fraction of reticulocytes;
CESC	cis	rs728616	0.614	rs56147535	chr10:82027625	G/T	cg05935833	chr10:81318306	SFTPA2	-0.44	-5.72	-0.33	2.9e-8	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs9486719	1.000	rs12205728	chr6:96891838	T/C	cg06623918	chr6:96969491	KIAA0776	-0.81	-8.29	-0.45	5.61e-15	Migraine;Coronary artery disease;
CESC	cis	rs4819052	0.851	rs2838867	chr21:46713092	C/T	cg11663144	chr21:46675770	NA	-0.62	-9.33	-0.5	4.43e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg18555811	chr3:193852889	HES1	0.48	6.82	0.39	6.15e-11	Myopia (pathological);
CESC	cis	rs2880765	0.835	rs7161880	chr15:86018746	C/T	cg10818794	chr15:86012489	AKAP13	-0.33	-5.17	-0.3	4.6e-7	Coronary artery disease;
CESC	cis	rs116095464	0.558	rs13357299	chr5:242211	T/C	cg10591111	chr5:226296	SDHA	-0.51	-6.26	-0.36	1.54e-9	Breast cancer;
CESC	cis	rs6460942	1.000	rs62448563	chr7:12400040	G/A	cg20607287	chr7:12443886	VWDE	-0.67	-7.72	-0.43	2.43e-13	Coronary artery disease;
CESC	cis	rs514406	0.861	rs7526275	chr1:53245849	C/T	cg16325326	chr1:53192061	ZYG11B	-0.88	-15.06	-0.68	1.8e-37	Monocyte count;
CESC	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg10150615	chr22:24372951	LOC391322	0.56	7.6	0.42	5.07e-13	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs7973683	0.541	rs6488910	chr12:124393697	G/T	cg12597309	chr12:124393772	DNAH10	0.25	5.75	0.33	2.39e-8	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
CESC	trans	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg13565492	chr6:43139072	SRF	-0.75	-9.04	-0.49	3.45e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7666738	0.830	rs34273190	chr4:99004568	C/T	cg03467027	chr4:99064603	C4orf37	0.44	5.51	0.32	8.65e-8	Colonoscopy-negative controls vs population controls;
CESC	trans	rs853679	0.882	rs9468300	chr6:28126840	C/T	cg06606381	chr12:133084897	FBRSL1	-0.67	-6.37	-0.36	8.17e-10	Depression;
CESC	cis	rs9611565	0.649	rs79005	chr22:41835544	G/A	cg17376030	chr22:41985996	PMM1	-0.56	-6.22	-0.36	1.92e-9	Vitiligo;
CESC	cis	rs1062746	1.000	rs1062746	chr16:87364650	A/G	cg02258303	chr16:87377426	FBXO31	-0.42	-5.33	-0.31	2.15e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
CESC	cis	rs6582630	0.555	rs10785443	chr12:38463792	A/C	cg26384229	chr12:38710491	ALG10B	0.66	10.07	0.53	2.14e-20	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs7666738	0.791	rs7660866	chr4:98961335	G/A	cg03467027	chr4:99064603	C4orf37	0.44	5.57	0.32	6.41e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2404602	0.669	rs12148877	chr15:76919959	T/G	cg26408565	chr15:76604113	ETFA	-0.39	-5.51	-0.32	8.57e-8	Blood metabolite levels;
CESC	cis	rs1799949	0.965	rs11650132	chr17:41326087	T/G	cg25072359	chr17:41440525	NA	0.5	6.78	0.38	7.72e-11	Menopause (age at onset);
CESC	cis	rs10504229	0.683	rs6984765	chr8:58127124	T/C	cg24829409	chr8:58192753	C8orf71	-0.59	-7.24	-0.41	4.79e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs977987	0.866	rs12932606	chr16:75493944	C/T	cg03315344	chr16:75512273	CHST6	0.54	7.77	0.43	1.75e-13	Dupuytren's disease;
CESC	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg07167872	chr1:205819463	PM20D1	0.83	14.85	0.67	1.07e-36	Menarche (age at onset);
CESC	cis	rs10088262	0.629	rs9918907	chr8:124816862	A/G	cg20713898	chr8:124780851	FAM91A1	-0.66	-8.75	-0.47	2.61e-16	Pancreatic cancer;
CESC	cis	rs11148252	0.574	rs61958118	chr13:53170226	C/T	cg00495681	chr13:53174319	NA	0.64	8.91	0.48	8.65e-17	Lewy body disease;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg03760316	chr18:3594197	DLGAP1;FLJ35776	-0.45	-6.35	-0.36	9.27e-10	Gambling;
CESC	cis	rs6461049	0.765	rs10224497	chr7:2149967	A/G	cg23048001	chr7:2026167	MAD1L1	0.44	5.76	0.33	2.33e-8	Schizophrenia;
CESC	cis	rs10751667	0.580	rs11246363	chr11:971667	T/C	cg06064525	chr11:970664	AP2A2	-0.45	-8.8	-0.48	1.82e-16	Alzheimer's disease (late onset);
CESC	cis	rs7202877	0.706	rs37605	chr16:75506572	G/C	cg04384234	chr16:75411784	CFDP1	0.49	5.9	0.34	1.13e-8	Type 2 diabetes;Type 1 diabetes;
CESC	cis	rs2066819	1.000	rs11575234	chr12:56744276	C/G	cg26316697	chr12:56727976	PAN2	0.72	6.94	0.39	2.92e-11	Psoriasis vulgaris;
CESC	cis	rs6489785	0.710	rs3213566	chr12:121222578	T/C	cg02419362	chr12:121203948	SPPL3	0.36	5.87	0.34	1.27e-8	Longevity;Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs4474465	0.688	rs7940720	chr11:78276674	C/T	cg27205649	chr11:78285834	NARS2	0.46	6.21	0.36	2.06e-9	Alzheimer's disease (survival time);
CESC	cis	rs6540556	0.859	rs11119340	chr1:209940560	A/T	cg05527609	chr1:210001259	C1orf107	0.73	8.24	0.45	8.03e-15	Red blood cell count;
CESC	cis	rs7582720	1.000	rs114155121	chr2:203718682	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.32	0.41	3.04e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs2243480	0.901	rs12530490	chr7:65691647	G/A	cg13147721	chr7:65941812	NA	0.98	9.24	0.49	8.25e-18	Diabetic kidney disease;
CESC	cis	rs892961	1.000	rs2164449	chr17:75401190	G/A	cg05865280	chr17:75406074	SEPT9	0.66	13.11	0.63	1.34e-30	Airflow obstruction;
CESC	cis	rs9467711	0.606	rs13203358	chr6:26590578	A/T	cg21479132	chr6:26055353	NA	0.64	5.42	0.32	1.31e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs35955747	0.869	rs8141987	chr22:31587155	C/G	cg25791279	chr22:32026902	PISD	-0.41	-5.11	-0.3	6.14e-7	Neutrophil count;Sum basophil neutrophil counts;
CESC	cis	rs8068544	0.818	rs8079958	chr17:40155467	C/T	cg18442075	chr17:40169520	DNAJC7;NKIRAS2	-0.94	-8.56	-0.47	9.34e-16	Reticulocyte fraction of red cells;Reticulocyte count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08830818	chr3:122514143	HSPBAP1;DIRC2	0.52	6.47	0.37	4.82e-10	Gut microbiome composition (summer);
CESC	cis	rs2865126	0.743	rs2865120	chr18:10754921	A/G	cg21165219	chr18:10698044	FAM38B	-0.5	-5.18	-0.3	4.48e-7	Metabolite levels (5-HIAA/ MHPG Ratio);
CESC	cis	rs3931020	0.548	rs17618340	chr1:75247617	G/A	cg00121533	chr1:75199117	CRYZ;TYW3	0.54	7.24	0.41	4.98e-12	Resistin levels;
CESC	cis	rs36051895	0.589	rs10122037	chr9:5192874	A/G	cg02405213	chr9:5042618	JAK2	0.51	6.27	0.36	1.45e-9	Pediatric autoimmune diseases;
CESC	cis	rs2976388	0.556	rs4736323	chr8:143830359	C/T	cg10596483	chr8:143751796	JRK	-0.46	-5.26	-0.31	3.01e-7	Urinary tract infection frequency;
CESC	cis	rs2066819	1.000	rs41363748	chr12:56696056	C/T	cg26734620	chr12:56694298	CS	-1.06	-6.59	-0.38	2.42e-10	Psoriasis vulgaris;
CESC	cis	rs12368653	1.000	rs12368653	chr12:58133256	A/G	cg00677455	chr12:58241039	CTDSP2	0.42	5.54	0.32	7.43e-8	Multiple sclerosis;
CESC	cis	rs4689388	0.889	rs13101355	chr4:6293446	T/C	cg25554036	chr4:6271136	WFS1	0.51	8.37	0.46	3.31e-15	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs2795502	1.000	rs2795502	chr10:43340662	G/A	cg27426351	chr10:43362370	NA	-0.48	-6.0	-0.35	6.51e-9	Blood protein levels;
CESC	cis	rs1799949	0.965	rs4793233	chr17:41435437	G/C	cg25072359	chr17:41440525	NA	0.46	6.21	0.36	2.01e-9	Menopause (age at onset);
CESC	cis	rs34375054	0.573	rs12581813	chr12:125656402	A/G	cg25124228	chr12:125621409	AACS	-0.5	-5.35	-0.31	1.94e-7	Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs11608355	0.545	rs11066782	chr12:109910552	C/T	cg05360138	chr12:110035743	NA	0.81	8.75	0.47	2.52e-16	Neuroticism;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25198656	chr7:5013641	RNF216L	0.63	7.48	0.42	1.09e-12	Gut microbiome composition (summer);
CESC	cis	rs4423214	1.000	rs11600860	chr11:71164019	T/C	cg05163923	chr11:71159392	DHCR7	0.76	10.16	0.53	1.05e-20	Vitamin D levels;
CESC	cis	rs9911578	0.967	rs2567892	chr17:56668929	T/C	cg12560992	chr17:57184187	TRIM37	0.93	15.43	0.69	9.21e-39	Intelligence (multi-trait analysis);
CESC	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.64	-8.53	-0.46	1.16e-15	Longevity;Endometriosis;
CESC	cis	rs2204008	0.805	rs11514348	chr12:38243427	T/C	cg26384229	chr12:38710491	ALG10B	0.71	10.11	0.53	1.52e-20	Bladder cancer;
CESC	cis	rs7666738	0.830	rs4502686	chr4:98765117	T/C	cg17366294	chr4:99064904	C4orf37	0.57	7.98	0.44	4.33e-14	Colonoscopy-negative controls vs population controls;
CESC	trans	rs916888	0.821	rs199513	chr17:44856932	A/G	cg22433210	chr17:43662623	NA	-0.85	-9.75	-0.51	2.16e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.98	9.78	0.52	1.7e-19	Platelet count;
CESC	cis	rs10744422	0.858	rs7980541	chr12:123379477	C/T	cg22842854	chr12:123319900	HIP1R	-0.64	-5.35	-0.31	1.87e-7	Schizophrenia;
CESC	cis	rs4950322	0.570	rs72692914	chr1:146774637	T/A	cg22381352	chr1:146742008	CHD1L	-0.47	-5.11	-0.3	6.24e-7	Protein quantitative trait loci;
CESC	cis	rs2836974	0.526	rs418359	chr21:40536734	T/C	cg27266027	chr21:40555129	PSMG1	-0.4	-5.13	-0.3	5.63e-7	Cognitive function;
CESC	cis	rs7795096	0.743	rs9648730	chr7:151537785	G/A	cg17008978	chr7:151542804	PRKAG2	0.39	7.37	0.41	2.15e-12	Bipolar disorder (age of onset and psychotic symptoms);
CESC	cis	rs2191566	1.000	rs2356549	chr19:44511202	A/T	cg20607764	chr19:44506953	ZNF230	-0.6	-7.76	-0.43	1.9e-13	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs1008375	1.000	rs10009541	chr4:17682218	C/T	cg02297831	chr4:17616191	MED28	-0.48	-5.81	-0.34	1.77e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs7209460	0.556	rs2316513	chr17:1988377	A/T	cg20777128	chr17:1945076	DPH1;OVCA2	-0.43	-5.06	-0.3	7.83e-7	Coronary artery disease;Total body bone mineral density;
CESC	cis	rs4481887	0.830	rs10888341	chr1:248441995	T/C	cg00666640	chr1:248458726	OR2T12	0.39	6.6	0.38	2.23e-10	Common traits (Other);
CESC	trans	rs12599106	0.625	rs12923277	chr16:34896261	G/A	cg01516881	chr6:292596	DUSP22	-0.84	-11.22	-0.57	3.59e-24	Menopause (age at onset);
CESC	trans	rs17685	0.753	rs6465000	chr7:75787417	G/A	cg19862616	chr7:65841803	NCRNA00174	0.85	12.42	0.61	3.15e-28	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs965469	0.553	rs6051767	chr20:3324521	C/T	cg25506879	chr20:3388711	C20orf194	-0.44	-5.25	-0.31	3.08e-7	IFN-related cytopenia;
CESC	cis	rs1348850	0.526	rs2218575	chr2:178368997	C/A	cg23306229	chr2:178417860	TTC30B	0.8	7.39	0.41	1.96e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs6088580	0.634	rs6059850	chr20:33044784	C/G	cg08999081	chr20:33150536	PIGU	0.67	12.04	0.59	6.52e-27	Glomerular filtration rate (creatinine);
CESC	cis	rs4664304	0.772	rs12692572	chr2:160743793	G/A	cg03641300	chr2:160917029	PLA2R1	0.42	5.99	0.35	6.71e-9	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs1790761	0.505	rs7941648	chr11:67347595	C/T	cg14500267	chr11:67383377	NA	-0.31	-5.12	-0.3	5.81e-7	Mean corpuscular volume;
CESC	cis	rs8141529	0.732	rs5762788	chr22:29174770	G/T	cg15103426	chr22:29168792	CCDC117	0.73	10.22	0.53	7.13e-21	Lymphocyte counts;
CESC	cis	rs1018836	0.923	rs1476427	chr8:91552791	A/G	cg16814680	chr8:91681699	NA	0.65	8.87	0.48	1.07e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs875971	0.825	rs4587224	chr7:65736182	G/A	cg11764359	chr7:65958608	NA	-0.79	-12.0	-0.59	9.01e-27	Aortic root size;
CESC	cis	rs853679	0.517	rs56310871	chr6:28044482	A/G	cg17949981	chr6:28129498	ZNF389	0.45	5.62	0.33	4.9e-8	Depression;
CESC	cis	rs4819052	1.000	rs733739	chr21:46666210	A/G	cg11663144	chr21:46675770	NA	-0.48	-6.61	-0.38	2.05e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs796364	0.813	rs4672686	chr2:201065044	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.58	5.61	0.33	5.22e-8	Schizophrenia;
CESC	cis	rs763121	0.853	rs35565791	chr22:39063011	C/A	cg06544989	chr22:39130855	UNC84B	0.48	8.4	0.46	2.69e-15	Menopause (age at onset);
CESC	cis	rs7084402	0.967	rs1658446	chr10:60314183	A/C	cg07615347	chr10:60278583	BICC1	0.61	9.59	0.51	7.04e-19	Refractive error;
CESC	cis	rs6952808	0.756	rs12537348	chr7:1948172	C/G	cg21782813	chr7:2030301	MAD1L1	0.41	5.87	0.34	1.29e-8	Bipolar disorder and schizophrenia;
CESC	trans	rs5763662	1.000	rs5763854	chr22:30577589	A/G	cg23513814	chr17:72857430	GRIN2C	-0.53	-6.05	-0.35	4.81e-9	LDL cholesterol levels;LDL cholesterol;
CESC	cis	rs13191362	0.935	rs7767254	chr6:162954674	T/G	cg06582575	chr6:163149167	PACRG;PARK2	0.76	7.37	0.41	2.13e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs9467711	0.606	rs2073531	chr6:26375256	A/G	cg12826209	chr6:26865740	GUSBL1	0.65	5.35	0.31	1.88e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs10426930	0.621	rs6510833	chr19:5008399	G/A	cg18115693	chr19:4968519	KDM4B	-0.52	-5.09	-0.3	6.91e-7	Monocyte percentage of white cells;
CESC	cis	rs4253772	0.550	rs6008613	chr22:46707924	G/T	cg09491104	chr22:46646882	C22orf40	-0.49	-5.96	-0.34	8.16e-9	LDL cholesterol;Cholesterol, total;
CESC	cis	rs9858542	0.903	rs11917431	chr3:49644012	C/T	cg07274523	chr3:49395745	GPX1	0.66	8.45	0.46	2e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs172166	0.694	rs9295760	chr6:28147385	G/A	cg19592336	chr6:28129416	ZNF389	0.46	6.81	0.39	6.58e-11	Cardiac Troponin-T levels;
CESC	cis	rs12478296	0.591	rs6746311	chr2:243001279	A/G	cg06360820	chr2:242988706	NA	-0.62	-8.19	-0.45	1.12e-14	Obesity-related traits;
CESC	cis	rs17533156	0.525	rs77932036	chr17:75207586	T/G	cg11416367	chr17:75137675	SEC14L1	0.71	7.44	0.42	1.39e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs3820928	0.874	rs6706802	chr2:227850776	A/G	cg11843606	chr2:227700838	RHBDD1	-0.42	-5.29	-0.31	2.59e-7	Pulmonary function;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18283712	chr14:57735581	MUDENG;EXOC5	0.62	7.72	0.43	2.39e-13	Gut microbiome composition (summer);
CESC	cis	rs873946	0.648	rs35417213	chr10:134553749	A/G	cg26818010	chr10:134567672	INPP5A	-0.87	-10.74	-0.55	1.46e-22	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs11677370	0.533	rs12711971	chr2:3820821	G/C	cg17052675	chr2:3827356	NA	-0.45	-5.97	-0.34	7.45e-9	Type 2 diabetes;
CESC	cis	rs11190604	1.000	rs2298074	chr10:102247526	G/C	cg07080220	chr10:102295463	HIF1AN	0.58	5.16	0.3	4.8e-7	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs17407555	0.518	rs16891234	chr4:9946163	A/G	cg00071950	chr4:10020882	SLC2A9	-0.65	-6.83	-0.39	5.73e-11	Schizophrenia (age at onset);
CESC	cis	rs7829975	0.511	rs2980426	chr8:8145609	T/C	cg08975724	chr8:8085496	FLJ10661	0.41	5.03	0.3	9.04e-7	Mood instability;
CESC	cis	rs7527798	0.592	rs1323722	chr1:207823405	C/T	cg21110645	chr1:207815933	NA	-0.33	-5.7	-0.33	3.18e-8	Erythrocyte sedimentation rate;
CESC	cis	rs2412459	0.611	rs4924402	chr15:40245754	C/T	cg25407064	chr15:40226267	EIF2AK4	-0.54	-6.14	-0.35	3.01e-9	Response to haloperidol in psychosis;
CESC	cis	rs116095464	0.681	rs10060016	chr5:241100	T/C	cg12570787	chr5:219185	SDHA;CCDC127	0.5	5.27	0.31	2.9e-7	Breast cancer;
CESC	cis	rs6831352	0.744	rs2602847	chr4:100025963	T/C	cg12011299	chr4:100065546	ADH4	0.6	6.6	0.38	2.23e-10	Alcohol dependence;
CESC	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg24846343	chr22:24311635	DDTL	0.59	9.8	0.52	1.52e-19	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs7666738	0.830	rs6532724	chr4:99060993	C/T	cg03676636	chr4:99064102	C4orf37	0.34	5.07	0.3	7.32e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2243480	1.000	rs1404147	chr7:65264524	C/T	cg12463550	chr7:65579703	CRCP	0.71	5.96	0.34	7.96e-9	Diabetic kidney disease;
CESC	cis	rs7116495	0.867	rs4378421	chr11:71761996	T/C	cg18441811	chr11:71824068	C11orf51	-0.91	-5.42	-0.32	1.37e-7	Severe influenza A (H1N1) infection;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg13649253	chr19:13198798	NFIX	-0.42	-6.77	-0.38	8.28e-11	Gambling;
CESC	cis	rs796364	0.806	rs34582889	chr2:201010527	A/G	cg23649088	chr2:200775458	C2orf69	-0.58	-5.71	-0.33	3.07e-8	Schizophrenia;
CESC	cis	rs3785574	0.962	rs2727331	chr17:61926990	G/T	cg07677032	chr17:61819896	STRADA	0.4	5.03	0.3	8.87e-7	Height;
CESC	cis	rs68170813	0.559	rs78404515	chr7:106909126	G/A	cg02696742	chr7:106810147	HBP1	-0.52	-5.07	-0.3	7.42e-7	Coronary artery disease;
CESC	cis	rs4332037	0.539	rs4470910	chr7:2071723	C/T	cg02743256	chr7:2109353	MAD1L1	-0.48	-5.05	-0.3	8.26e-7	Bipolar disorder;
CESC	cis	rs3106136	0.967	rs17310526	chr4:95222227	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.45	-6.73	-0.38	1.02e-10	Capecitabine sensitivity;
CESC	cis	rs6762	0.748	rs1130719	chr11:838760	T/A	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.75	-10.17	-0.53	9.89e-21	Mean platelet volume;
CESC	cis	rs9894429	1.000	rs3935543	chr17:79579874	T/C	cg18240062	chr17:79603768	NPLOC4	0.72	10.27	0.53	4.71e-21	Eye color traits;
CESC	cis	rs2414059	0.525	rs58368325	chr15:50971539	C/A	cg08437265	chr15:50716283	USP8	0.42	5.36	0.31	1.78e-7	QT interval;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22998206	chr12:49239429	DDX23	-0.67	-7.46	-0.42	1.24e-12	Gut microbiome composition (summer);
CESC	trans	rs2154294	0.625	rs72672573	chr14:42631039	C/T	cg07368857	chr3:71276336	FOXP1	-0.32	-6.05	-0.35	5.01e-9	Alcoholism (12-month weekly alcohol consumption);
CESC	cis	rs3857067	0.773	rs2865344	chr4:95103040	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.6	-9.01	-0.48	4.22e-17	QT interval;
CESC	cis	rs736408	0.812	rs1075653	chr3:52825528	T/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.12	0.35	3.42e-9	Bipolar disorder;
CESC	cis	rs3806843	0.735	rs2530241	chr5:140054485	C/T	cg16179182	chr5:140090404	VTRNA1-1	0.41	5.41	0.32	1.42e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs35306767	0.903	rs12260800	chr10:927933	T/C	cg25019033	chr10:957182	NA	-0.57	-6.38	-0.37	7.76e-10	Eosinophil percentage of granulocytes;
CESC	cis	rs2354432	0.607	rs1530335	chr1:146685288	T/C	cg25205988	chr1:146714368	CHD1L	1.15	8.65	0.47	4.98e-16	Mitochondrial DNA levels;
CESC	cis	rs68170813	0.559	rs1548524	chr7:106944563	G/T	cg02696742	chr7:106810147	HBP1	0.52	5.09	0.3	6.66e-7	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10689147	chr6:43336734	ZNF318	0.55	6.12	0.35	3.27e-9	Gut microbiome composition (summer);
CESC	cis	rs8002861	0.665	rs2065926	chr13:44422371	A/G	cg19180546	chr13:44453867	C13orf31;CCDC122	-0.4	-5.26	-0.31	2.99e-7	Leprosy;
CESC	cis	rs7412746	0.646	rs10399947	chr1:150861960	G/A	cg22823121	chr1:150693482	HORMAD1	0.36	5.04	0.3	8.78e-7	Melanoma;
CESC	cis	rs6142102	0.602	rs2268086	chr20:32648738	C/T	cg08999081	chr20:33150536	PIGU	-0.33	-5.13	-0.3	5.72e-7	Skin pigmentation;
CESC	cis	rs7824557	0.564	rs2736290	chr8:11234298	C/T	cg21775007	chr8:11205619	TDH	-0.55	-8.1	-0.45	1.97e-14	Retinal vascular caliber;
CESC	cis	rs4853012	0.838	rs4563249	chr2:74354016	G/T	cg05776053	chr2:74358815	NA	0.42	5.22	0.31	3.62e-7	Gestational age at birth (maternal effect);
CESC	cis	rs9916302	0.851	rs12947620	chr17:37605364	T/C	cg19468946	chr17:37922297	IKZF3	-0.39	-5.08	-0.3	7.08e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs6740322	1.000	rs6756736	chr2:43558743	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.59	-6.37	-0.36	8.37e-10	Coronary artery disease;
CESC	cis	rs7089973	0.604	rs11196936	chr10:116588630	C/T	cg25233709	chr10:116636983	FAM160B1	0.38	5.9	0.34	1.12e-8	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs1018836	0.847	rs4735226	chr8:91569238	T/A	cg16814680	chr8:91681699	NA	-0.72	-10.29	-0.53	4.01e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs36051895	0.659	rs12336577	chr9:5063690	T/A	cg02405213	chr9:5042618	JAK2	-0.51	-6.17	-0.35	2.52e-9	Pediatric autoimmune diseases;
CESC	cis	rs660498	0.507	rs34773871	chr10:27727645	G/A	cg08398567	chr10:27609333	NA	0.42	5.65	0.33	4.06e-8	Asthma (childhood onset);
CESC	cis	rs7949030	0.588	rs2428549	chr11:62312394	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.57	8.67	0.47	4.35e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs2404602	0.716	rs284895	chr15:76751225	C/G	cg22467129	chr15:76604101	ETFA	0.36	5.2	0.3	3.99e-7	Blood metabolite levels;
CESC	cis	rs7219021	0.926	rs68169424	chr17:46851676	T/C	cg16584676	chr17:46985605	UBE2Z	-0.52	-5.87	-0.34	1.3e-8	Schizophrenia or bipolar disorder;
CESC	cis	rs1008375	0.932	rs2302391	chr4:17660237	T/C	cg16339924	chr4:17578868	LAP3	0.59	7.18	0.4	6.89e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs2576037	0.526	rs2571027	chr18:44561516	C/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.42	-6.95	-0.39	2.78e-11	Personality dimensions;
CESC	cis	rs1707322	0.682	rs28490344	chr1:46197948	C/T	cg05343316	chr1:45956843	TESK2	0.51	6.2	0.36	2.19e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7107174	0.901	rs1055248	chr11:77925573	T/C	cg02023728	chr11:77925099	USP35	0.48	6.67	0.38	1.51e-10	Testicular germ cell tumor;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16489582	chr16:28223388	XPO6	-0.57	-6.77	-0.38	8.43e-11	Gut microbiome composition (summer);
CESC	cis	rs7599312	1.000	rs7599312	chr2:213413231	C/T	cg20637307	chr2:213403960	ERBB4	0.43	5.38	0.31	1.61e-7	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs12476592	0.602	rs7608470	chr2:63691478	T/C	cg17519650	chr2:63277830	OTX1	-0.48	-5.35	-0.31	1.94e-7	Childhood ear infection;
CESC	cis	rs4665809	0.590	rs7260	chr2:26413917	C/T	cg25036284	chr2:26402008	FAM59B	-0.79	-9.27	-0.49	6.83e-18	Gut microbiome composition (summer);
CESC	cis	rs13223928	0.542	rs12540595	chr7:3131792	G/A	cg19214707	chr7:3157722	NA	-0.4	-5.62	-0.33	4.85e-8	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
CESC	cis	rs7927592	0.731	rs10896350	chr11:68386373	A/C	cg01657329	chr11:68192670	LRP5	-0.47	-6.1	-0.35	3.69e-9	Total body bone mineral density;
CESC	cis	rs7937682	0.883	rs472465	chr11:111468962	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.9	-12.87	-0.62	9.33e-30	Primary sclerosing cholangitis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06895436	chr8:82434543	NA	-0.58	-6.17	-0.35	2.48e-9	Gut microbiome composition (summer);
CESC	cis	rs10504229	0.683	rs7000349	chr8:58114569	C/A	cg02725872	chr8:58115012	NA	-0.45	-7.04	-0.4	1.66e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs7851660	0.933	rs13302470	chr9:100615553	A/G	cg13688889	chr9:100608707	NA	-0.69	-10.57	-0.54	4.92e-22	Strep throat;
CESC	cis	rs7666738	0.830	rs17027225	chr4:99028564	C/T	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.58e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2645694	0.626	rs904050	chr4:77826089	T/G	cg18351406	chr4:77819688	ANKRD56	0.54	6.67	0.38	1.47e-10	Emphysema distribution in smoking;
CESC	cis	rs3820068	0.581	rs72645893	chr1:15930943	C/G	cg13390004	chr1:15929781	NA	0.35	5.58	0.32	5.83e-8	Systolic blood pressure;
CESC	cis	rs2204008	0.806	rs35534445	chr12:38279093	C/T	cg13010199	chr12:38710504	ALG10B	0.51	6.34	0.36	1e-9	Bladder cancer;
CESC	cis	rs714031	0.867	rs5750868	chr22:40063012	G/A	cg21377881	chr22:40064566	CACNA1I	-0.39	-6.39	-0.37	7.43e-10	Schizophrenia;
CESC	cis	rs3820068	0.603	rs7529759	chr1:15977877	A/G	cg16988262	chr1:15930761	NA	0.33	5.36	0.31	1.81e-7	Systolic blood pressure;
CESC	cis	rs12136530	0.593	rs12121189	chr1:19740421	G/A	cg01832549	chr1:19774989	CAPZB	-0.43	-6.13	-0.35	3.09e-9	Lead levels in blood;
CESC	cis	rs8114671	0.562	rs6119545	chr20:33522869	T/C	cg07148914	chr20:33460835	GGT7	0.46	6.13	0.35	3.19e-9	Height;
CESC	cis	rs6570726	0.791	rs427128	chr6:145865917	T/C	cg05347473	chr6:146136440	FBXO30	0.58	7.33	0.41	2.84e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7267979	1.000	rs4815411	chr20:25350223	A/G	cg08601574	chr20:25228251	PYGB	-0.38	-5.49	-0.32	9.26e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs34779708	0.931	rs4934702	chr10:35323074	T/C	cg03585969	chr10:35415529	CREM	0.75	9.88	0.52	8.12e-20	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs2404602	0.716	rs12917430	chr15:76674360	T/C	cg26408565	chr15:76604113	ETFA	-0.41	-5.93	-0.34	9.46e-9	Blood metabolite levels;
CESC	cis	rs6430585	0.941	rs7589832	chr2:136504101	A/C	cg07169764	chr2:136633963	MCM6	0.99	12.74	0.62	2.62e-29	Corneal structure;
CESC	cis	rs763121	0.853	rs2294296	chr22:39053049	T/C	cg14440974	chr22:39074834	NA	-0.4	-5.42	-0.32	1.34e-7	Menopause (age at onset);
CESC	trans	rs17685	0.753	rs13240967	chr7:75658197	C/T	cg19862616	chr7:65841803	NCRNA00174	-0.84	-12.47	-0.61	2.15e-28	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs748404	0.660	rs518288	chr15:43763999	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.57	7.51	0.42	9.18e-13	Lung cancer;
CESC	cis	rs977987	0.742	rs34624768	chr16:75331572	G/A	cg03315344	chr16:75512273	CHST6	0.38	5.47	0.32	1.06e-7	Dupuytren's disease;
CESC	cis	rs10392	0.543	rs2867240	chr20:37538354	C/T	cg27552599	chr20:37590471	DHX35	0.39	5.65	0.33	4.08e-8	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
CESC	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg27588902	chr6:42928151	GNMT	-0.28	-5.17	-0.3	4.53e-7	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs798554	0.660	rs2283783	chr7:2855326	G/A	cg19717773	chr7:2847554	GNA12	-0.56	-8.69	-0.47	3.93e-16	Height;
CESC	cis	rs8038465	0.592	rs1542579	chr15:73935897	A/G	cg15420318	chr15:73925796	NPTN	0.51	7.14	0.4	8.99e-12	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs7017914	0.967	rs1471114	chr8:71675547	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.2	-0.3	3.94e-7	Bone mineral density;
CESC	cis	rs9399137	0.507	rs6569986	chr6:135311641	T/C	cg24558204	chr6:135376177	HBS1L	0.72	10.08	0.53	1.92e-20	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03269368	chr19:19431604	KIAA0892;SF4	0.53	6.37	0.36	8.14e-10	Gut microbiome composition (summer);
CESC	cis	rs6460942	0.818	rs73299043	chr7:12251595	C/G	cg06484146	chr7:12443880	VWDE	-0.56	-5.67	-0.33	3.66e-8	Coronary artery disease;
CESC	cis	rs7927771	0.524	rs7111576	chr11:47787445	G/A	cg18512352	chr11:47633146	NA	0.34	5.24	0.31	3.22e-7	Subjective well-being;
CESC	cis	rs801193	0.548	rs6975044	chr7:66227482	C/T	cg11764359	chr7:65958608	NA	0.69	9.57	0.51	7.85e-19	Aortic root size;
CESC	cis	rs11155671	0.530	rs6557133	chr6:150195384	G/T	cg09699651	chr6:150184138	LRP11	0.42	5.54	0.32	7.35e-8	Testicular germ cell tumor;
CESC	cis	rs35110281	0.682	rs162379	chr21:44925334	A/G	cg04455712	chr21:45112962	RRP1B	-0.33	-5.27	-0.31	2.83e-7	Mean corpuscular volume;
CESC	cis	rs1005277	0.505	rs200939	chr10:38139483	T/C	cg00409905	chr10:38381863	ZNF37A	-0.55	-7.6	-0.42	5.08e-13	Extrinsic epigenetic age acceleration;
CESC	cis	rs7605827	0.930	rs4571032	chr2:15685038	A/G	cg19274914	chr2:15703543	NA	0.37	6.7	0.38	1.22e-10	Educational attainment (years of education);
CESC	cis	rs7542091	0.669	rs7540534	chr1:210044824	A/T	cg22029157	chr1:209979665	IRF6	0.5	7.98	0.44	4.32e-14	Monobrow;
CESC	cis	rs7640424	0.620	rs34910554	chr3:107816733	C/T	cg09227934	chr3:107805635	CD47	-0.46	-5.69	-0.33	3.34e-8	Body mass index;
CESC	cis	rs7605827	0.930	rs11694485	chr2:15676154	C/T	cg19274914	chr2:15703543	NA	0.38	6.78	0.38	7.69e-11	Educational attainment (years of education);
CESC	cis	rs7605827	0.930	rs2287274	chr2:15658577	T/C	cg19274914	chr2:15703543	NA	0.32	5.66	0.33	3.88e-8	Educational attainment (years of education);
CESC	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg24642844	chr7:1081250	C7orf50	-0.76	-9.26	-0.49	7.23e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs6539267	0.741	rs35816179	chr12:106693710	T/C	cg00173435	chr12:106696525	TCP11L2	0.69	8.18	0.45	1.18e-14	Tourette syndrome;
CESC	cis	rs4588572	0.643	rs35299318	chr5:77668322	A/C	cg11547950	chr5:77652471	NA	0.44	5.58	0.32	5.84e-8	Triglycerides;
CESC	cis	rs798554	1.000	rs798550	chr7:2760609	A/G	cg19717773	chr7:2847554	GNA12	-0.51	-7.57	-0.42	6.05e-13	Height;
CESC	cis	rs6952808	0.929	rs11768206	chr7:1932151	T/G	cg00106254	chr7:1943704	MAD1L1	-0.48	-6.01	-0.35	6.28e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs853679	0.517	rs9348793	chr6:28084189	G/A	cg19592336	chr6:28129416	ZNF389	0.6	7.98	0.44	4.4e-14	Depression;
CESC	cis	rs13191362	1.000	rs36107456	chr6:162997399	T/G	cg14584255	chr6:163149320	PACRG;PARK2	0.49	5.34	0.31	2.01e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs1045714	0.895	rs73035504	chr7:2642878	G/A	cg20813462	chr7:2646259	IQCE	0.65	5.67	0.33	3.66e-8	Urate levels in lean individuals;
CESC	cis	rs1218582	0.741	rs10908446	chr1:154869559	G/A	cg03351412	chr1:154909251	PMVK	0.69	9.32	0.5	4.71e-18	Prostate cancer;
CESC	cis	rs1218582	0.772	rs12069356	chr1:154849771	C/T	cg03351412	chr1:154909251	PMVK	0.58	7.55	0.42	7.15e-13	Prostate cancer;
CESC	cis	rs782590	0.902	rs782595	chr2:55845596	C/G	cg18811423	chr2:55921094	PNPT1	0.81	13.01	0.62	3.07e-30	Metabolic syndrome;
CESC	cis	rs4819052	0.851	rs10470258	chr21:46658989	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.75	9.98	0.52	4.1e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.63	7.16	0.4	7.99e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs6545883	0.895	rs796597	chr2:61681060	A/G	cg15711740	chr2:61764176	XPO1	-0.4	-5.2	-0.3	4.06e-7	Tuberculosis;
CESC	cis	rs2011503	1.000	rs4808970	chr19:19651140	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.52	5.09	0.3	6.68e-7	Bipolar disorder;
CESC	cis	rs8141529	0.711	rs5752797	chr22:29179998	C/T	cg02153584	chr22:29168773	CCDC117	0.47	5.19	0.3	4.26e-7	Lymphocyte counts;
CESC	cis	rs71636778	0.543	rs75305560	chr1:27242521	T/G	cg12203394	chr1:27248618	NUDC	0.66	5.55	0.32	6.85e-8	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
CESC	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg09177884	chr7:1199841	ZFAND2A	-0.5	-6.3	-0.36	1.24e-9	Longevity;Endometriosis;
CESC	trans	rs61931739	0.500	rs11053273	chr12:34547255	C/T	cg26384229	chr12:38710491	ALG10B	0.72	10.84	0.55	6.43e-23	Morning vs. evening chronotype;
CESC	cis	rs4523957	0.928	rs216189	chr17:2187401	A/G	cg16513277	chr17:2031491	SMG6	-0.59	-7.95	-0.44	5.35e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg26494424	chr12:124118326	EIF2B1;GTF2H3	-0.44	-6.06	-0.35	4.75e-9	Fibrinogen levels;
CESC	cis	rs7267979	0.844	rs6115188	chr20:25432170	G/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.78	14.82	0.67	1.38e-36	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs709400	1.000	rs3915733	chr14:104147353	G/A	cg24130564	chr14:104152367	KLC1	-0.43	-5.48	-0.32	9.93e-8	Body mass index;
CESC	cis	rs9486715	0.867	rs2499775	chr6:97007340	C/T	cg06623918	chr6:96969491	KIAA0776	-0.95	-15.11	-0.68	1.22e-37	Headache;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04257877	chr7:66309953	LOC729156	0.61	6.63	0.38	1.86e-10	Gut microbiome composition (summer);
CESC	cis	rs16867321	0.627	rs6759191	chr2:181573120	A/G	cg23363182	chr2:181467187	NA	0.43	6.31	0.36	1.14e-9	Obesity;
CESC	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg14159672	chr1:205819179	PM20D1	0.82	12.83	0.62	1.23e-29	Menarche (age at onset);
CESC	cis	rs561341	0.941	rs2428338	chr17:30299629	T/C	cg00745463	chr17:30367425	LRRC37B	-0.67	-6.68	-0.38	1.39e-10	Hip circumference adjusted for BMI;
CESC	cis	rs116095464	0.558	rs10077076	chr5:231940	C/T	cg22857025	chr5:266934	NA	-1.29	-18.53	-0.75	9.59e-50	Breast cancer;
CESC	cis	rs66573146	0.572	rs55740475	chr4:6954092	C/G	cg00086871	chr4:6988644	TBC1D14	1.05	6.99	0.39	2.26e-11	Granulocyte percentage of myeloid white cells;
CESC	cis	rs920590	0.758	rs1907799	chr8:19664668	A/G	cg01411142	chr8:19674711	INTS10	-0.5	-5.85	-0.34	1.43e-8	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs7666738	0.800	rs11941885	chr4:99072921	A/C	cg03676636	chr4:99064102	C4orf37	0.34	5.07	0.3	7.47e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs75477785	0.590	rs11119384	chr1:210160689	A/G	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.89	6.01	0.35	6.09e-9	Cleft lip with or without cleft palate;
CESC	cis	rs4555082	0.957	rs2816608	chr14:105718407	A/G	cg27165867	chr14:105738592	BRF1	0.42	5.07	0.3	7.66e-7	Mean platelet volume;Platelet distribution width;
CESC	cis	rs7089973	0.872	rs7074729	chr10:116632257	C/G	cg23260525	chr10:116636907	FAM160B1	0.37	6.15	0.35	2.84e-9	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs1552244	0.515	rs111560858	chr3:10166845	G/A	cg00149659	chr3:10157352	C3orf10	1.01	12.53	0.61	1.33e-28	Alzheimer's disease;
CESC	cis	rs514406	0.698	rs576891	chr1:53364976	A/G	cg24675658	chr1:53192096	ZYG11B	-0.66	-9.13	-0.49	1.78e-17	Monocyte count;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg20980112	chr1:155108432	RAG1AP1	-0.52	-6.61	-0.38	2.11e-10	Ulcerative colitis;
CESC	cis	rs2228479	0.718	rs62054253	chr16:89896932	T/C	cg04013166	chr16:89971882	TCF25	0.72	5.71	0.33	3.01e-8	Skin colour saturation;
CESC	cis	rs1799949	1.000	rs11654452	chr17:41189383	G/T	cg25072359	chr17:41440525	NA	0.5	6.46	0.37	4.89e-10	Menopause (age at onset);
CESC	cis	rs7824557	0.527	rs10109537	chr8:11239640	C/T	cg21775007	chr8:11205619	TDH	-0.52	-7.79	-0.43	1.53e-13	Retinal vascular caliber;
CESC	cis	rs533123	0.818	rs556408	chr1:29166323	C/A	cg08366446	chr1:29138936	OPRD1	0.5	5.88	0.34	1.26e-8	Schizophrenia;
CESC	cis	rs11864453	0.713	rs9925763	chr16:72142595	C/A	cg16558253	chr16:72132732	DHX38	-0.54	-8.55	-0.46	9.99e-16	Fibrinogen levels;
CESC	cis	rs1153858	1.000	rs4775911	chr15:45649787	G/T	cg21132104	chr15:45694354	SPATA5L1	-0.83	-11.3	-0.57	2.06e-24	Homoarginine levels;
CESC	cis	rs6860806	0.661	rs2136187	chr5:131577894	T/C	cg14196790	chr5:131705035	SLC22A5	0.33	5.31	0.31	2.3e-7	Breast cancer;
CESC	cis	rs16867321	0.588	rs1919156	chr2:181456978	C/T	cg23363182	chr2:181467187	NA	-0.51	-7.57	-0.42	6.06e-13	Obesity;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg22520562	chr4:82392859	RASGEF1B	-0.44	-6.03	-0.35	5.59e-9	Fibrinogen levels;
CESC	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg26668828	chr6:292823	DUSP22	0.71	9.52	0.5	1.17e-18	Menopause (age at onset);
CESC	cis	rs941873	0.805	rs10762860	chr10:81117794	C/G	cg08514558	chr10:81106712	PPIF	0.34	5.9	0.34	1.13e-8	Height;
CESC	cis	rs11792861	0.566	rs966466	chr9:111851333	T/A	cg05043794	chr9:111880884	C9orf5	-0.29	-5.13	-0.3	5.62e-7	Menarche (age at onset);
CESC	cis	rs4704187	0.687	rs6885071	chr5:74460045	A/G	cg03227963	chr5:74354835	NA	0.29	5.32	0.31	2.25e-7	Response to amphetamines;
CESC	cis	rs1005277	0.579	rs2505198	chr10:38393183	A/C	cg25517755	chr10:38738941	LOC399744	-0.44	-5.74	-0.33	2.57e-8	Extrinsic epigenetic age acceleration;
CESC	cis	rs6446731	0.593	rs2530601	chr4:3272378	C/G	cg08886695	chr4:3369023	RGS12	-0.37	-5.32	-0.31	2.23e-7	Mean platelet volume;
CESC	cis	rs6987853	0.931	rs2923444	chr8:42397004	C/T	cg09913449	chr8:42400586	C8orf40	0.39	6.13	0.35	3.15e-9	Mean corpuscular hemoglobin concentration;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09418519	chr4:15683124	LOC285550	0.62	7.09	0.4	1.2e-11	Gut microbiome composition (summer);
CESC	cis	rs9300255	0.602	rs1716165	chr12:123648881	C/T	cg00376283	chr12:123451042	ABCB9	0.7	8.86	0.48	1.16e-16	Neutrophil percentage of white cells;
CESC	cis	rs8180040	0.726	rs7628747	chr3:47001990	A/T	cg27129171	chr3:47204927	SETD2	0.69	10.01	0.52	3.22e-20	Colorectal cancer;
CESC	cis	rs7917772	0.582	rs10786691	chr10:104364652	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.42	5.66	0.33	4.02e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs10905065	0.895	rs1567707	chr10:5853817	G/C	cg11519256	chr10:5708881	ASB13	-0.41	-5.26	-0.31	2.95e-7	Menopause (age at onset);
CESC	cis	rs2072499	0.966	rs2842882	chr1:156165342	T/G	cg25208724	chr1:156163844	SLC25A44	1.01	19.18	0.76	4.95e-52	Testicular germ cell tumor;
CESC	trans	rs11148252	0.574	rs9536247	chr13:53279542	T/C	cg18335740	chr13:41363409	SLC25A15	0.53	7.16	0.4	7.78e-12	Lewy body disease;
CESC	cis	rs9916302	0.904	rs4794814	chr17:37696852	G/A	cg07936489	chr17:37558343	FBXL20	-0.8	-11.52	-0.58	3.68e-25	Glomerular filtration rate (creatinine);
CESC	cis	rs9814567	0.793	rs55940445	chr3:134306064	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.45	6.05	0.35	4.79e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs13336428	0.730	rs28653458	chr16:1525850	T/C	cg08008072	chr16:1524255	CLCN7	-0.73	-12.39	-0.61	4.13e-28	Bone mineral density;
CESC	cis	rs2721195	0.967	rs748193	chr8:145682115	C/T	cg26752003	chr8:145688521	CYHR1	-0.55	-7.32	-0.41	2.95e-12	Age at first birth;
CESC	cis	rs10504229	1.000	rs55787104	chr8:58178519	C/T	cg14926445	chr8:58193284	C8orf71	-0.51	-5.45	-0.32	1.17e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs9913156	0.793	rs9436	chr17:4574751	T/A	cg00122941	chr17:4613640	ARRB2	0.87	10.06	0.53	2.27e-20	Lymphocyte counts;
CESC	cis	rs7833986	0.501	rs2976036	chr8:57031721	G/T	cg26371346	chr8:56986568	SNORD54;RPS20	0.57	5.41	0.32	1.42e-7	Height;
CESC	cis	rs61935443	0.614	rs61935662	chr12:95313296	A/G	cg21533806	chr12:95267307	NA	0.48	5.18	0.3	4.42e-7	Schizophrenia;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg09268800	chr1:153914384	DENND4B	0.44	6.16	0.35	2.76e-9	Fibrinogen levels;
CESC	cis	rs1005277	0.579	rs1740749	chr10:38521646	A/G	cg25517755	chr10:38738941	LOC399744	-0.44	-5.72	-0.33	2.85e-8	Extrinsic epigenetic age acceleration;
CESC	cis	rs116095464	0.614	rs62344292	chr5:244630	G/A	cg20965017	chr5:231967	SDHA	-0.47	-5.38	-0.31	1.65e-7	Breast cancer;
CESC	cis	rs7772486	0.686	rs1337839	chr6:146010239	A/G	cg23711669	chr6:146136114	FBXO30	-0.89	-12.64	-0.61	5.62e-29	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1401999	0.724	rs1016752	chr3:183665062	C/G	cg01324343	chr3:183735012	ABCC5	-0.56	-9.96	-0.52	4.62e-20	Anterior chamber depth;
CESC	cis	rs4319547	0.915	rs11058402	chr12:122981053	A/G	cg23029597	chr12:123009494	RSRC2	-0.5	-5.43	-0.32	1.26e-7	Body mass index;
CESC	cis	rs3008870	1.000	rs12117131	chr1:67451922	C/T	cg02640540	chr1:67518911	SLC35D1	-0.52	-5.59	-0.33	5.5e-8	Lymphocyte percentage of white cells;
CESC	cis	rs3733585	0.638	rs6414766	chr4:9956474	G/A	cg02734326	chr4:10020555	SLC2A9	-0.41	-5.81	-0.34	1.74e-8	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs2204008	0.840	rs11181795	chr12:38401129	A/G	cg26384229	chr12:38710491	ALG10B	0.72	10.94	0.56	3.12e-23	Bladder cancer;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg01068102	chr11:65620199	SNX32	0.47	6.55	0.37	2.95e-10	Fibrinogen levels;
CESC	cis	rs9640161	0.711	rs3800781	chr7:150027324	T/A	cg17279839	chr7:150038598	RARRES2	0.43	5.17	0.3	4.61e-7	Blood protein levels;Circulating chemerin levels;
CESC	trans	rs11250098	0.574	rs4240672	chr8:10767917	G/A	cg06636001	chr8:8085503	FLJ10661	-0.49	-6.02	-0.35	5.79e-9	Morning vs. evening chronotype;
CESC	cis	rs7165102	1.000	rs7496335	chr15:65758868	A/T	cg11441148	chr15:65824328	PTPLAD1	0.32	5.26	0.31	2.91e-7	Mean corpuscular hemoglobin;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08857039	chr6:42110396	C6orf132	0.56	6.97	0.39	2.48e-11	Gut microbiome composition (summer);
CESC	cis	rs1461503	0.934	rs930983	chr11:122834414	A/G	cg27398637	chr11:122830231	C11orf63	-0.49	-6.95	-0.39	2.86e-11	Menarche (age at onset);
CESC	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg23708337	chr7:1209742	NA	0.55	5.46	0.32	1.07e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs36051895	0.553	rs12338854	chr9:5057568	G/C	cg02405213	chr9:5042618	JAK2	-0.43	-5.28	-0.31	2.66e-7	Pediatric autoimmune diseases;
CESC	cis	rs9325144	0.560	rs7980635	chr12:38668355	G/T	cg26384229	chr12:38710491	ALG10B	-0.6	-8.5	-0.46	1.44e-15	Morning vs. evening chronotype;
CESC	cis	rs9291683	0.530	rs11723970	chr4:9980462	T/C	cg11266682	chr4:10021025	SLC2A9	0.62	12.65	0.61	5.16e-29	Bone mineral density;
CESC	cis	rs6540559	0.611	rs926347	chr1:209965193	T/C	cg09509183	chr1:209979624	IRF6	0.6	5.99	0.35	6.69e-9	Cleft lip with or without cleft palate;
CESC	cis	rs2760061	0.819	rs708115	chr1:228198046	C/T	cg02753203	chr1:228287806	NA	0.53	7.89	0.44	8.14e-14	Diastolic blood pressure;
CESC	cis	rs11587400	0.679	rs2014836	chr1:115080875	A/G	cg12756093	chr1:115239321	AMPD1	0.43	5.86	0.34	1.36e-8	Autism;
CESC	cis	rs2072499	1.000	rs2253809	chr1:156172125	T/C	cg25208724	chr1:156163844	SLC25A44	0.98	18.11	0.74	3.06e-48	Testicular germ cell tumor;
CESC	cis	rs9913156	0.515	rs11658808	chr17:4577112	C/T	cg00122941	chr17:4613640	ARRB2	-0.61	-7.71	-0.43	2.61e-13	Lymphocyte counts;
CESC	cis	rs7100689	0.646	rs1047952	chr10:82126808	C/G	cg00277334	chr10:82204260	NA	-0.58	-7.76	-0.43	1.84e-13	Post bronchodilator FEV1;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09472211	chr10:89622126	PTEN;KILLIN	0.59	6.9	0.39	3.83e-11	Gut microbiome composition (summer);
CESC	cis	rs2742234	0.955	rs2075910	chr10:43614230	G/A	cg07801480	chr10:43725741	RASGEF1A	0.38	5.27	0.31	2.82e-7	Hirschsprung disease;
CESC	cis	rs1059312	0.545	rs7312683	chr12:129280105	T/C	cg09035930	chr12:129282057	SLC15A4	0.54	6.83	0.39	5.74e-11	Systemic lupus erythematosus;
CESC	cis	rs2836974	0.931	rs7283569	chr21:40644062	T/G	cg27266027	chr21:40555129	PSMG1	0.45	5.34	0.31	2.05e-7	Cognitive function;
CESC	trans	rs66573146	1.000	rs7686186	chr4:6986094	C/T	cg07817883	chr1:32538562	TMEM39B	1.48	9.1	0.49	2.16e-17	Granulocyte percentage of myeloid white cells;
CESC	cis	rs2070488	0.965	rs13079145	chr3:38517992	T/G	cg24069376	chr3:38537580	EXOG	0.48	8.82	0.48	1.52e-16	Electrocardiographic conduction measures;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg01857591	chr8:81083836	TPD52	-0.47	-6.16	-0.35	2.67e-9	Fibrinogen levels;
CESC	cis	rs2963155	0.518	rs174048	chr5:142650404	T/C	cg17617527	chr5:142782415	NR3C1	0.86	7.62	0.42	4.41e-13	Breast cancer;
CESC	cis	rs7590720	1.000	rs7559031	chr2:216902583	A/G	cg12620499	chr2:216877984	MREG	0.91	12.38	0.61	4.23e-28	Alcohol dependence;
CESC	cis	rs9467711	0.606	rs9379897	chr6:26601526	T/C	cg12826209	chr6:26865740	GUSBL1	0.67	6.06	0.35	4.68e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs77741769	0.571	rs12580949	chr12:121298164	A/G	cg02419362	chr12:121203948	SPPL3	0.34	5.59	0.32	5.6e-8	Mean corpuscular volume;
CESC	cis	rs2820292	0.740	rs12137232	chr1:201885446	G/T	cg06775570	chr1:201857621	SHISA4	-0.32	-5.28	-0.31	2.67e-7	Waist circumference;Body mass index (joint analysis main effects and smoking interaction);Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);
CESC	cis	rs2603127	0.768	rs9870145	chr3:108477874	A/T	cg03329597	chr3:108125523	MYH15	0.6	5.35	0.31	1.91e-7	Hemostatic factors and hematological phenotypes;
CESC	cis	rs8067354	0.645	rs2645492	chr17:57875554	A/G	cg13753209	chr17:57696993	CLTC	-0.59	-6.74	-0.38	1e-10	Hemoglobin concentration;
CESC	cis	rs992157	0.560	rs4674274	chr2:219089131	A/T	cg00012203	chr2:219082015	ARPC2	-0.74	-9.9	-0.52	7.06e-20	Colorectal cancer;
CESC	cis	rs40363	0.951	rs72778117	chr16:3531827	T/C	cg22508957	chr16:3507546	NAT15	0.73	8.9	0.48	8.91e-17	Tuberculosis;
CESC	cis	rs9815354	0.812	rs73069209	chr3:41939781	G/A	cg03022575	chr3:42003672	ULK4	0.71	6.4	0.37	7.01e-10	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs7542091	0.739	rs10863793	chr1:210037420	G/A	cg25204440	chr1:209979598	IRF6	0.4	5.24	0.31	3.26e-7	Monobrow;
CESC	cis	rs28647808	1.000	rs35179461	chr9:136270293	T/C	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.9	5.73	0.33	2.75e-8	Blood protein levels;
CESC	cis	rs2404602	1.000	rs2404740	chr15:76852143	C/T	cg26408565	chr15:76604113	ETFA	-0.37	-5.29	-0.31	2.56e-7	Blood metabolite levels;
CESC	cis	rs7552404	0.731	rs5745491	chr1:76350159	T/G	cg10523679	chr1:76189770	ACADM	-0.61	-6.1	-0.35	3.7e-9	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs3767633	0.800	rs2341479	chr1:161885352	C/A	cg09175582	chr1:161736000	ATF6	0.68	5.99	0.35	6.75e-9	IgG glycosylation;
CESC	cis	rs1448094	0.511	rs10779210	chr12:86162432	T/C	cg02569458	chr12:86230093	RASSF9	-0.43	-6.5	-0.37	4.05e-10	Major depressive disorder;
CESC	cis	rs1451375	0.617	rs745043	chr7:50543955	T/G	cg14593290	chr7:50529359	DDC	-0.53	-6.0	-0.35	6.62e-9	Malaria;
CESC	cis	rs8114671	0.562	rs4911447	chr20:33479445	T/A	cg24642439	chr20:33292090	TP53INP2	0.44	5.31	0.31	2.38e-7	Height;
CESC	cis	rs1580019	0.587	rs2392069	chr7:32547154	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.51	6.39	0.37	7.42e-10	Cognitive ability;
CESC	cis	rs6540556	0.954	rs2076150	chr1:209933540	A/G	cg05527609	chr1:210001259	C1orf107	-0.45	-5.63	-0.33	4.66e-8	Red blood cell count;
CESC	cis	rs7267979	0.833	rs6138556	chr20:25243310	C/T	cg08601574	chr20:25228251	PYGB	0.4	5.7	0.33	3.25e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs6570726	0.791	rs952406	chr6:145925616	C/A	cg05347473	chr6:146136440	FBXO30	0.5	6.61	0.38	2.11e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs10504229	0.593	rs7000752	chr8:58026980	C/G	cg24829409	chr8:58192753	C8orf71	-0.45	-5.76	-0.33	2.34e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs17253792	0.822	rs77741349	chr14:56097462	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.76	5.39	0.31	1.56e-7	Putamen volume;
CESC	cis	rs763014	0.931	rs7199839	chr16:636126	T/C	cg09781414	chr16:715207	WDR90	-0.33	-5.04	-0.3	8.57e-7	Height;
CESC	cis	rs6952808	0.792	rs4721184	chr7:1950784	T/C	cg00106254	chr7:1943704	MAD1L1	-0.49	-6.16	-0.35	2.67e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs7666738	0.830	rs6832568	chr4:98994061	G/A	cg03467027	chr4:99064603	C4orf37	0.44	5.51	0.32	8.65e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4654899	0.865	rs12131353	chr1:21321163	C/G	cg05370193	chr1:21551575	ECE1	0.42	6.26	0.36	1.55e-9	Superior frontal gyrus grey matter volume;
CESC	cis	rs897984	0.721	rs28360557	chr16:30983260	A/C	cg00531865	chr16:30841666	NA	0.5	6.85	0.39	5.2e-11	Dementia with Lewy bodies;
CESC	cis	rs2404602	0.647	rs12898416	chr15:77042292	C/G	cg23625390	chr15:77176239	SCAPER	-0.4	-5.2	-0.3	4e-7	Blood metabolite levels;
CESC	cis	rs6460942	1.000	rs79964328	chr7:12319392	A/C	cg06484146	chr7:12443880	VWDE	-0.81	-8.78	-0.47	2.13e-16	Coronary artery disease;
CESC	cis	rs1448094	0.512	rs2405632	chr12:86252456	A/G	cg00310523	chr12:86230176	RASSF9	0.35	5.41	0.32	1.43e-7	Major depressive disorder;
CESC	cis	rs2836974	0.644	rs1882779	chr21:40690938	T/C	cg11644478	chr21:40555479	PSMG1	-0.78	-11.42	-0.57	8.11e-25	Cognitive function;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg22333733	chr11:31391482	DNAJC24;DCDC1	0.39	6.38	0.36	7.65e-10	Gambling;
CESC	cis	rs6089584	0.927	rs2296081	chr20:60572663	G/T	cg06108461	chr20:60628389	TAF4	-0.8	-12.19	-0.6	1.92e-27	Body mass index;
CESC	cis	rs12497850	0.764	rs6784111	chr3:49178846	T/C	cg06212747	chr3:49208901	KLHDC8B	0.74	9.74	0.51	2.27e-19	Parkinson's disease;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg23713813	chr1:25071889	CLIC4	-0.5	-6.37	-0.36	8.25e-10	Ulcerative colitis;
CESC	cis	rs9388451	0.839	rs3966775	chr6:126067655	C/A	cg10911889	chr6:126070802	HEY2	0.42	5.87	0.34	1.3e-8	Brugada syndrome;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg24696268	chr4:49526636	NA	-0.41	-6.0	-0.35	6.5e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs9926296	0.632	rs7206546	chr16:89799079	C/T	cg03388025	chr16:89894329	SPIRE2	-0.29	-5.1	-0.3	6.52e-7	Vitiligo;
CESC	cis	rs6460942	0.908	rs77894875	chr7:12248257	T/C	cg06484146	chr7:12443880	VWDE	-0.69	-6.86	-0.39	4.71e-11	Coronary artery disease;
CESC	cis	rs4704187	0.687	rs10064409	chr5:74527134	A/G	cg03227963	chr5:74354835	NA	0.28	5.04	0.3	8.66e-7	Response to amphetamines;
CESC	cis	rs270601	0.690	rs162904	chr5:131595784	C/T	cg09877947	chr5:131593287	PDLIM4	-0.43	-5.25	-0.31	3.17e-7	Acylcarnitine levels;
CESC	cis	rs4819052	1.000	rs2297286	chr21:46707897	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.87	11.27	0.57	2.42e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs172166	0.637	rs1225592	chr6:28150242	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.42	-5.55	-0.32	6.99e-8	Cardiac Troponin-T levels;
CESC	cis	rs6570726	0.720	rs412623	chr6:145883257	C/A	cg05347473	chr6:146136440	FBXO30	0.49	6.35	0.36	9.1e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs801193	0.548	rs6975044	chr7:66227482	C/T	cg10691866	chr7:65817282	TPST1	-0.32	-5.42	-0.32	1.37e-7	Aortic root size;
CESC	cis	rs7078219	0.505	rs7916751	chr10:101285650	T/A	cg09788492	chr10:101292477	NKX2-3	0.33	6.28	0.36	1.37e-9	Dental caries;
CESC	trans	rs6952808	1.000	rs6953693	chr7:1886388	C/G	cg24247370	chr13:99142703	STK24	-0.41	-6.14	-0.35	2.99e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs56104184	0.723	rs116909499	chr19:49407733	C/T	cg21252483	chr19:49399788	TULP2	-0.49	-5.56	-0.32	6.67e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	cis	rs11122272	0.614	rs78172021	chr1:231525160	A/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.56	-7.69	-0.43	2.8e-13	Hemoglobin concentration;
CESC	cis	rs7223966	1.000	rs9908044	chr17:61747032	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.58	7.42	0.41	1.55e-12	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs1799949	0.536	rs4793227	chr17:41412250	A/C	cg23758822	chr17:41437982	NA	1.03	17.53	0.73	3.37e-46	Menopause (age at onset);
CESC	cis	rs3820928	0.874	rs10166736	chr2:227900419	C/T	cg05526886	chr2:227700861	RHBDD1	-0.45	-5.64	-0.33	4.29e-8	Pulmonary function;
CESC	cis	rs826838	1.000	rs9795768	chr12:39012479	T/C	cg13010199	chr12:38710504	ALG10B	0.58	8.1	0.45	2.01e-14	Heart rate;
CESC	cis	rs6120849	0.754	rs6120812	chr20:33629427	T/C	cg06115741	chr20:33292138	TP53INP2	0.53	5.05	0.3	8.15e-7	Protein C levels;
CESC	cis	rs17376456	0.825	rs28610997	chr5:93248374	T/C	cg21475434	chr5:93447410	FAM172A	0.76	6.2	0.36	2.16e-9	Diabetic retinopathy;
CESC	cis	rs853679	0.517	rs9283884	chr6:28135660	C/G	cg08968635	chr6:28129556	ZNF389	-0.4	-5.3	-0.31	2.46e-7	Depression;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg03651904	chr19:2807229	THOP1	0.54	7.25	0.41	4.48e-12	Fibrinogen levels;
CESC	cis	rs7927771	0.524	rs7123952	chr11:47852057	T/C	cg18512352	chr11:47633146	NA	0.35	5.4	0.31	1.51e-7	Subjective well-being;
CESC	cis	rs524281	1.000	rs565198	chr11:65913508	A/T	cg14036092	chr11:66035641	RAB1B	0.53	6.23	0.36	1.79e-9	Electroencephalogram traits;
CESC	cis	rs7520050	0.771	rs4660882	chr1:46116292	C/T	cg03146154	chr1:46216737	IPP	0.52	6.97	0.39	2.55e-11	Red blood cell count;Reticulocyte count;
CESC	trans	rs7726839	0.540	rs3762951	chr5:662613	C/G	cg25482853	chr8:67687455	SGK3	0.96	9.84	0.52	1.09e-19	Obesity-related traits;
CESC	cis	rs1552244	0.572	rs12107622	chr3:10171898	T/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.77	8.58	0.47	8.32e-16	Alzheimer's disease;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg11222527	chr1:226926964	ITPKB	0.48	6.11	0.35	3.6e-9	Thyroid stimulating hormone;
CESC	cis	rs9916302	0.904	rs650106	chr17:37451559	A/G	cg20243544	chr17:37824526	PNMT	-0.45	-5.48	-0.32	9.91e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs7631605	0.819	rs1392748	chr3:37265313	T/C	cg22985146	chr3:37219077	LRRFIP2	-0.34	-5.33	-0.31	2.13e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs1448094	0.512	rs7309500	chr12:86249647	C/T	cg19622623	chr12:86230825	RASSF9	-0.46	-5.87	-0.34	1.28e-8	Major depressive disorder;
CESC	cis	rs5769765	0.862	rs56377703	chr22:50306940	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.58	-6.15	-0.35	2.78e-9	Schizophrenia;
CESC	cis	rs362296	0.698	rs3135172	chr4:3258735	A/G	cg08886695	chr4:3369023	RGS12	0.43	5.68	0.33	3.57e-8	Parental longevity (mother's age at death);
CESC	cis	rs9863	0.828	rs4765562	chr12:124472571	T/C	cg00084347	chr12:124393913	DNAH10	0.27	5.23	0.31	3.4e-7	White blood cell count;
CESC	cis	rs8180040	0.966	rs13059519	chr3:47539969	C/T	cg27129171	chr3:47204927	SETD2	0.6	8.92	0.48	7.75e-17	Colorectal cancer;
CESC	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg03188948	chr7:1209495	NA	0.73	7.05	0.4	1.54e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs75477785	1.000	rs12078157	chr1:210049901	C/T	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.79	5.15	0.3	5.08e-7	Cleft lip with or without cleft palate;
CESC	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg18402987	chr7:1209562	NA	0.61	7.13	0.4	9.46e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs7618501	0.602	rs2526743	chr3:50115245	G/A	cg21659725	chr3:3221576	CRBN	-0.51	-7.03	-0.4	1.7e-11	Intelligence (multi-trait analysis);
CESC	cis	rs1348850	0.874	rs13013752	chr2:178456862	A/G	cg23306229	chr2:178417860	TTC30B	0.57	7.44	0.42	1.43e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs1448094	0.842	rs7978562	chr12:86451478	A/G	cg02569458	chr12:86230093	RASSF9	0.34	5.1	0.3	6.37e-7	Major depressive disorder;
CESC	cis	rs7618915	0.547	rs12496634	chr3:52709259	A/C	cg18404041	chr3:52824283	ITIH1	-0.39	-6.58	-0.37	2.52e-10	Bipolar disorder;
CESC	cis	rs66561647	0.563	rs4733580	chr8:128932677	G/A	cg05480350	chr8:128972681	MIR1205;PVT1	0.4	5.37	0.31	1.7e-7	Hemoglobin concentration;
CESC	cis	rs6432018	1.000	rs11887863	chr2:9739429	G/T	cg23886495	chr2:9695866	ADAM17	0.45	5.28	0.31	2.67e-7	Heart rate variability traits;
CESC	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg11905131	chr22:24372483	LOC391322	-0.82	-12.38	-0.61	4.47e-28	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs73206853	0.764	rs55913108	chr12:110816507	T/C	cg12870014	chr12:110450643	ANKRD13A	0.63	5.23	0.31	3.48e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs7210086	0.898	rs61463201	chr17:70636951	C/T	cg04206342	chr17:70636940	NA	-0.31	-5.48	-0.32	9.7e-8	Ulcerative colitis;
CESC	cis	rs2733201	1.000	rs2114421	chr15:44313055	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	-0.66	-5.93	-0.34	9.18e-9	Lipoprotein phospholipase A2 activity in cardiovascular disease;
CESC	cis	rs6772849	0.965	rs67790930	chr3:128310036	C/T	cg16766828	chr3:128327626	NA	-0.31	-5.06	-0.3	7.77e-7	Monocyte percentage of white cells;Monocyte count;
CESC	cis	rs12079745	0.793	rs12063863	chr1:169269557	G/A	cg09363564	chr1:169337483	NME7;BLZF1	-1.0	-6.04	-0.35	5.12e-9	QT interval;
CESC	cis	rs8044868	0.530	rs7185840	chr16:72102112	A/G	cg16558253	chr16:72132732	DHX38	-0.38	-5.91	-0.34	1.06e-8	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CESC	cis	rs8141529	0.732	rs3788409	chr22:29198151	T/G	cg15103426	chr22:29168792	CCDC117	0.7	9.94	0.52	5.45e-20	Lymphocyte counts;
CESC	cis	rs4689592	0.587	rs3822269	chr4:7069901	T/C	cg19539972	chr4:7069911	GRPEL1	0.79	9.58	0.51	7.51e-19	Monocyte percentage of white cells;
CESC	cis	rs34779708	0.733	rs12777960	chr10:35541026	C/A	cg04310649	chr10:35416472	CREM	-0.47	-5.39	-0.31	1.59e-7	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs4642101	0.737	rs9877165	chr3:12828497	C/T	cg24848339	chr3:12840334	CAND2	0.36	5.51	0.32	8.6e-8	QRS complex (12-leadsum);
CESC	cis	rs12048904	0.512	rs932798	chr1:101249355	G/C	cg15686842	chr1:101360669	SLC30A7;EXTL2	-0.56	-6.4	-0.37	6.89e-10	Multiple sclerosis;
CESC	cis	rs28595532	0.702	rs72670252	chr4:119337546	A/C	cg21605333	chr4:119757512	SEC24D	1.01	5.58	0.32	5.98e-8	Cannabis dependence symptom count;
CESC	cis	rs11608355	0.545	rs1073780	chr12:109895143	T/C	cg05360138	chr12:110035743	NA	0.79	8.25	0.45	7.43e-15	Neuroticism;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg10620530	chr9:139922595	C9orf139;ABCA2	-0.41	-6.23	-0.36	1.78e-9	Gambling;
CESC	cis	rs9309473	1.000	rs7598396	chr2:73652628	A/G	cg20560298	chr2:73613845	ALMS1	-0.56	-7.33	-0.41	2.86e-12	Metabolite levels;
CESC	cis	rs7017914	0.967	rs6472543	chr8:71664408	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.2	-0.3	3.94e-7	Bone mineral density;
CESC	cis	rs6088580	0.634	rs6058070	chr20:33103521	G/C	cg06115741	chr20:33292138	TP53INP2	0.45	5.74	0.33	2.53e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs3762637	1.000	rs9878699	chr3:122194231	T/A	cg24169773	chr3:122142474	KPNA1	-0.54	-6.33	-0.36	1.04e-9	LDL cholesterol levels;
CESC	cis	rs4969178	0.965	rs2292643	chr17:76395421	G/A	cg20026190	chr17:76395443	PGS1	0.49	7.73	0.43	2.17e-13	HDL cholesterol levels;
CESC	cis	rs2235642	0.821	rs2281234	chr16:1602938	A/G	cg07639376	chr16:1584516	IFT140;TMEM204	-0.31	-5.07	-0.3	7.41e-7	Coronary artery disease;
CESC	cis	rs1552244	1.000	rs9875081	chr3:10083935	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.88	12.07	0.6	5.1e-27	Alzheimer's disease;
CESC	cis	rs8072100	0.967	rs8078880	chr17:45676526	G/C	cg08085267	chr17:45401833	C17orf57	0.39	5.08	0.3	7.08e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs2070997	0.756	rs7026988	chr9:133667899	C/T	cg11464064	chr9:133710261	ABL1	0.5	5.44	0.32	1.21e-7	Response to amphetamines;
CESC	cis	rs1003719	0.715	rs2835644	chr21:38545610	G/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.59	-8.06	-0.44	2.72e-14	Eye color traits;
CESC	cis	rs7044106	0.734	rs12553070	chr9:123485266	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.85	13.84	0.65	3.68e-33	Hip circumference adjusted for BMI;
CESC	cis	rs34779708	0.931	rs59418206	chr10:35331624	G/A	cg03585969	chr10:35415529	CREM	0.78	10.23	0.53	6.43e-21	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs6912958	0.781	rs4464759	chr6:88282621	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.5	-6.75	-0.38	9.22e-11	Monocyte percentage of white cells;
CESC	cis	rs2880765	0.835	rs4842887	chr15:86035810	T/C	cg19183879	chr15:85880815	NA	-0.25	-5.04	-0.3	8.58e-7	Coronary artery disease;
CESC	cis	rs7666738	0.830	rs6851253	chr4:99029980	A/G	cg18180107	chr4:99064573	C4orf37	0.42	5.43	0.32	1.29e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2625529	0.730	rs1481860	chr15:72241857	T/C	cg16672083	chr15:72433130	SENP8	0.42	5.96	0.34	7.88e-9	Red blood cell count;
CESC	cis	rs3091242	0.935	rs3093632	chr1:25684012	C/T	cg27572855	chr1:25598939	RHD	0.5	8.45	0.46	1.99e-15	Erythrocyte sedimentation rate;
CESC	cis	rs4555082	0.957	rs10140586	chr14:105749582	A/G	cg10792982	chr14:105748885	BRF1	0.37	5.14	0.3	5.47e-7	Mean platelet volume;Platelet distribution width;
CESC	cis	rs9910055	0.659	rs3826412	chr17:42255097	A/G	cg08499158	chr17:42289980	UBTF	-0.56	-6.93	-0.39	3.2e-11	Total body bone mineral density;
CESC	cis	rs6728642	1.000	rs75297860	chr2:97600078	G/A	cg26665480	chr2:98280029	ACTR1B	-0.81	-6.31	-0.36	1.17e-9	Bipolar disorder lithium response (continuous) or schizophrenia;
CESC	cis	rs2637266	0.935	rs2583055	chr10:78400029	C/T	cg18941641	chr10:78392320	NA	0.45	8.65	0.47	5e-16	Pulmonary function;
CESC	cis	rs6542838	0.580	rs1607256	chr2:99543444	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.41	-5.26	-0.31	3.04e-7	Fear of minor pain;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg01348873	chr3:52349823	DNAH1	0.45	6.31	0.36	1.2e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs3126085	0.825	rs11204938	chr1:152193990	A/G	cg26876637	chr1:152193138	HRNR	0.47	5.43	0.32	1.28e-7	Atopic dermatitis;
CESC	cis	rs12497850	0.931	rs7621015	chr3:49016056	A/G	cg03060546	chr3:49711283	APEH	0.51	6.18	0.35	2.4e-9	Parkinson's disease;
CESC	cis	rs2976388	0.556	rs10956985	chr8:143818750	C/A	cg24634471	chr8:143751801	JRK	-0.46	-5.04	-0.3	8.52e-7	Urinary tract infection frequency;
CESC	cis	rs13382862	0.895	rs2289082	chr2:20881958	A/T	cg07755735	chr2:20870362	GDF7	0.4	6.45	0.37	5.28e-10	Abdominal aortic aneurysm;
CESC	trans	rs17685	0.623	rs7782808	chr7:75768645	C/T	cg19862616	chr7:65841803	NCRNA00174	0.85	12.41	0.61	3.51e-28	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs2072732	0.716	rs72856433	chr1:2954061	G/A	cg03976712	chr1:2946727	NA	0.33	5.59	0.32	5.59e-8	Plateletcrit;
CESC	cis	rs1552244	1.000	rs17032396	chr3:10153559	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	0.85	11.3	0.57	2.02e-24	Alzheimer's disease;
CESC	cis	rs12477438	0.765	rs6749059	chr2:99591021	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.72	-10.28	-0.53	4.31e-21	Chronic sinus infection;
CESC	cis	rs193541	0.564	rs62377434	chr5:122340569	C/A	cg19412675	chr5:122181750	SNX24	-0.46	-5.39	-0.31	1.58e-7	Glucose homeostasis traits;
CESC	cis	rs3540	0.960	rs8030390	chr15:90943471	C/T	cg22089800	chr15:90895588	ZNF774	0.41	5.07	0.3	7.61e-7	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs6088580	0.601	rs6059827	chr20:33016358	C/T	cg24642439	chr20:33292090	TP53INP2	0.53	7.03	0.4	1.74e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs9796	0.621	rs7170049	chr15:41484287	C/A	cg12426344	chr15:41135900	SPINT1	-0.24	-5.13	-0.3	5.68e-7	Menopause (age at onset);
CESC	cis	rs1062177	1.000	rs2964576	chr5:151150602	T/G	cg12924095	chr5:151150029	G3BP1	0.48	6.19	0.36	2.3e-9	Preschool internalizing problems;
CESC	cis	rs10463316	0.817	rs1318783	chr5:150814807	T/G	cg03212797	chr5:150827313	SLC36A1	-0.51	-6.63	-0.38	1.85e-10	Metabolite levels (Pyroglutamine);
CESC	cis	rs35110281	0.712	rs8133523	chr21:45062403	A/G	cg21573476	chr21:45109991	RRP1B	-0.5	-6.94	-0.39	2.95e-11	Mean corpuscular volume;
CESC	cis	rs2204008	0.624	rs2320449	chr12:38224190	T/C	cg13010199	chr12:38710504	ALG10B	0.53	6.67	0.38	1.51e-10	Bladder cancer;
CESC	cis	rs10392	0.543	rs12626105	chr20:37534582	A/G	cg27552599	chr20:37590471	DHX35	0.38	5.41	0.32	1.44e-7	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
CESC	trans	rs804280	0.517	rs7815179	chr8:11792048	C/G	cg15556689	chr8:8085844	FLJ10661	0.52	6.39	0.37	7.33e-10	Myopia (pathological);
CESC	cis	rs2637266	0.703	rs7096185	chr10:78470287	C/T	cg18941641	chr10:78392320	NA	0.39	7.16	0.4	7.83e-12	Pulmonary function;
CESC	cis	rs1707322	0.752	rs3811436	chr1:46125880	T/C	cg03146154	chr1:46216737	IPP	0.82	11.51	0.58	3.87e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9359856	0.564	rs56084221	chr6:90365349	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.65	-6.35	-0.36	9.29e-10	Bipolar disorder;
CESC	cis	rs7618915	0.679	rs6802320	chr3:52241835	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.43	5.35	0.31	1.93e-7	Bipolar disorder;
CESC	cis	rs832540	0.656	rs6862118	chr5:56106474	G/A	cg22800045	chr5:56110881	MAP3K1	0.49	5.98	0.34	7.31e-9	Coronary artery disease;
CESC	cis	rs10751667	1.000	rs7396798	chr11:970510	G/T	cg20946044	chr11:1010712	AP2A2	-0.43	-5.72	-0.33	2.92e-8	Alzheimer's disease (late onset);
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg12229505	chr15:80351983	ZFAND6	-0.48	-6.3	-0.36	1.24e-9	Thyroid stimulating hormone;
CESC	cis	rs2629540	0.765	rs7097177	chr10:126539839	A/G	cg08799069	chr10:126477246	METTL10	-0.53	-7.49	-0.42	1.04e-12	Cocaine dependence;
CESC	trans	rs4942242	0.617	rs9590778	chr13:44199007	C/G	cg19169023	chr15:41853346	TYRO3	-0.58	-7.44	-0.42	1.42e-12	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs6582630	0.537	rs1949610	chr12:38387838	C/T	cg13010199	chr12:38710504	ALG10B	0.47	6.02	0.35	5.68e-9	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs2228479	0.702	rs2074963	chr16:89877269	T/C	cg06558623	chr16:89946397	TCF25	1.09	8.0	0.44	3.87e-14	Skin colour saturation;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg26335430	chr17:73780571	UNK	-0.43	-6.05	-0.35	4.9e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs4689388	0.824	rs114669221	chr4:6301459	G/A	cg25554036	chr4:6271136	WFS1	0.53	8.73	0.47	2.87e-16	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs4810685	0.816	rs1316709	chr20:46407509	C/T	cg08288986	chr20:46415360	SULF2	-0.55	-6.83	-0.39	5.89e-11	Attention deficit hyperactivity disorder (time to onset);
CESC	cis	rs2243480	1.000	rs313813	chr7:65503500	C/T	cg25894440	chr7:65020034	NA	-0.6	-5.06	-0.3	7.7300000000000005e-07	Diabetic kidney disease;
CESC	cis	rs9309473	0.898	rs10170786	chr2:73812988	C/T	cg20560298	chr2:73613845	ALMS1	-0.47	-6.46	-0.37	4.96e-10	Metabolite levels;
CESC	cis	rs3857067	0.901	rs4693368	chr4:95046907	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.52	-7.78	-0.43	1.65e-13	QT interval;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg05270305	chr10:14880273	HSPA14;CDNF	-0.46	-6.56	-0.37	2.75e-10	Fibrinogen levels;
CESC	cis	rs62432291	0.681	rs419836	chr6:159659481	C/T	cg14500486	chr6:159655392	FNDC1	-0.62	-6.34	-0.36	9.83e-10	Joint mobility (Beighton score);
CESC	cis	rs10504229	0.636	rs72649123	chr8:58045789	A/T	cg22535103	chr8:58192502	C8orf71	-0.65	-6.98	-0.39	2.38e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs514406	0.798	rs575138	chr1:53328394	C/G	cg25767906	chr1:53392781	SCP2	-0.51	-6.76	-0.38	8.8e-11	Monocyte count;
CESC	cis	rs4332037	0.539	rs11763750	chr7:2080114	G/A	cg23422044	chr7:1970798	MAD1L1	-0.48	-5.15	-0.3	5e-7	Bipolar disorder;
CESC	cis	rs35306767	0.903	rs35567307	chr10:915804	G/C	cg25019033	chr10:957182	NA	-0.59	-6.34	-0.36	9.88e-10	Eosinophil percentage of granulocytes;
CESC	cis	rs780094	0.585	rs3739095	chr2:27556721	C/T	cg12648201	chr2:27665141	KRTCAP3	-0.28	-5.42	-0.32	1.32e-7	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
CESC	cis	rs7223966	1.000	rs73337598	chr17:61732576	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.46	-5.56	-0.32	6.58e-8	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs13191362	0.507	rs2803051	chr6:163034979	G/A	cg21926612	chr6:163149169	PACRG;PARK2	-0.54	-6.89	-0.39	3.97e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs9902453	0.740	rs2617884	chr17:28120430	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-10.34	-0.54	2.82e-21	Coffee consumption (cups per day);
CESC	cis	rs9902453	1.000	rs9890886	chr17:28391076	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.62	-7.87	-0.44	9.09e-14	Coffee consumption (cups per day);
CESC	cis	rs7666738	0.830	rs7672720	chr4:98938760	A/T	cg17366294	chr4:99064904	C4orf37	0.6	8.4	0.46	2.75e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7647973	0.580	rs4955432	chr3:49266772	C/T	cg03060546	chr3:49711283	APEH	0.52	7.03	0.4	1.76e-11	Menarche (age at onset);
CESC	cis	rs10851478	0.529	rs9920722	chr15:49735112	C/T	cg08060515	chr15:49448048	GALK2;COPS2	-0.44	-5.83	-0.34	1.57e-8	Oral cavity cancer;
CESC	cis	rs854765	0.547	rs2955355	chr17:17948475	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.56	-8.0	-0.44	3.85e-14	Total body bone mineral density;
CESC	cis	rs7605827	0.930	rs2287260	chr2:15624810	T/C	cg19274914	chr2:15703543	NA	0.33	5.95	0.34	8.34e-9	Educational attainment (years of education);
CESC	cis	rs853679	0.542	rs6934769	chr6:28090931	A/G	cg08968635	chr6:28129556	ZNF389	0.41	5.51	0.32	8.4e-8	Depression;
CESC	cis	rs1215050	0.740	rs13134479	chr4:99067723	G/A	cg17366294	chr4:99064904	C4orf37	0.4	5.16	0.3	4.9e-7	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs2635047	0.837	rs2571009	chr18:44650279	A/G	cg19077165	chr18:44547161	KATNAL2	-0.47	-6.65	-0.38	1.66e-10	Educational attainment;
CESC	cis	rs4664293	0.967	rs1006192	chr2:160567589	G/T	cg08347373	chr2:160653686	CD302	-0.32	-5.05	-0.3	8.26e-7	Monocyte percentage of white cells;
CESC	cis	rs2290720	0.813	rs1979269	chr12:101755380	C/G	cg22051763	chr12:101673672	UTP20	-0.42	-5.17	-0.3	4.59e-7	Brain structure (hippocampal volume);
CESC	cis	rs6540556	0.768	rs6692012	chr1:209935490	A/G	cg05527609	chr1:210001259	C1orf107	-0.44	-5.55	-0.32	6.87e-8	Red blood cell count;
CESC	cis	rs7586673	0.866	rs7579662	chr2:161915810	G/A	cg22496339	chr2:162101262	NA	0.5	6.57	0.37	2.69e-10	Intelligence (multi-trait analysis);
CESC	cis	rs10479542	0.784	rs7702303	chr5:178986436	G/A	cg14820908	chr5:178986412	RUFY1	0.5	7.73	0.43	2.27e-13	Lung cancer;
CESC	cis	rs10744422	0.925	rs897391	chr12:123326374	G/A	cg25930673	chr12:123319894	HIP1R	-0.65	-5.28	-0.31	2.72e-7	Schizophrenia;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg04825775	chr5:176981128	FAM193B	-0.44	-6.03	-0.35	5.37e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs11122272	0.766	rs2486732	chr1:231531476	A/C	cg06096015	chr1:231504339	EGLN1	0.41	5.8	0.34	1.91e-8	Hemoglobin concentration;
CESC	cis	rs7524258	0.868	rs6577428	chr1:7314655	C/T	cg07173049	chr1:7289937	CAMTA1	-0.39	-5.82	-0.34	1.65e-8	Tourette's syndrome or obsessive-compulsive disorder;
CESC	cis	rs372883	0.648	rs368322	chr21:30717151	C/T	cg24692254	chr21:30365293	RNF160	-0.51	-6.39	-0.37	7.42e-10	Pancreatic cancer;
CESC	cis	rs977987	0.806	rs12449170	chr16:75463012	C/T	cg03315344	chr16:75512273	CHST6	0.41	5.91	0.34	1.07e-8	Dupuytren's disease;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg16097330	chr5:171615472	STK10	-0.46	-6.6	-0.38	2.27e-10	Gambling;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11301069	chr17:8027502	HES7	0.57	7.0	0.4	2.06e-11	Gut microbiome composition (summer);
CESC	cis	rs9581857	0.556	rs9581863	chr13:28040171	A/G	cg22138327	chr13:27999177	GTF3A	0.64	7.1	0.4	1.16e-11	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
CESC	cis	rs7833790	0.963	rs2400473	chr8:82703403	C/T	cg02079420	chr8:82753780	SNX16	0.54	7.42	0.41	1.64e-12	Diastolic blood pressure;
CESC	cis	rs4665809	0.816	rs2384359	chr2:26371364	T/C	cg27170947	chr2:26402098	FAM59B	-0.78	-9.4	-0.5	2.75e-18	Gut microbiome composition (summer);
CESC	cis	rs1832871	0.505	rs11757895	chr6:158812456	G/T	cg07165851	chr6:158734300	TULP4	0.54	5.15	0.3	5.09e-7	Height;
CESC	cis	rs9649213	0.593	rs3801256	chr7:97992095	C/G	cg24562669	chr7:97807699	LMTK2	0.51	7.63	0.42	4.29e-13	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs2727020	0.556	rs2866365	chr11:49390731	A/G	cg03929089	chr4:120376271	NA	-0.69	-7.7	-0.43	2.66e-13	Coronary artery disease;
CESC	cis	rs853679	0.517	rs9348793	chr6:28084189	G/A	cg23281280	chr6:28129359	ZNF389	0.58	7.93	0.44	6.31e-14	Depression;
CESC	cis	rs12464559	0.649	rs10171724	chr2:152672482	T/A	cg01189475	chr2:152685088	ARL5A	0.66	5.81	0.34	1.74e-8	Response to cognitive-behavioural therapy in anxiety disorder;
CESC	cis	rs13031619	0.660	rs34855424	chr2:3702780	C/A	cg10645314	chr2:3704589	ALLC	-0.62	-6.02	-0.35	5.68e-9	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CESC	cis	rs9790314	0.967	rs336586	chr3:161081347	G/A	cg03342759	chr3:160939853	NMD3	-0.49	-6.41	-0.37	6.54e-10	Morning vs. evening chronotype;
CESC	cis	rs13392177	0.647	rs6718220	chr2:219066518	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.51	-6.32	-0.36	1.07e-9	Pyoderma gangrenosum in inflammatory bowel disease;
CESC	cis	rs2952156	0.684	rs11658786	chr17:37815899	G/A	cg07936489	chr17:37558343	FBXL20	-0.58	-7.62	-0.42	4.56e-13	Asthma;
CESC	cis	rs875971	1.000	rs12532998	chr7:65967459	A/C	cg12463550	chr7:65579703	CRCP	0.56	7.08	0.4	1.33e-11	Aortic root size;
CESC	cis	rs72781680	1.000	rs11125372	chr2:24257582	A/T	cg20701182	chr2:24300061	SF3B14	-0.75	-7.38	-0.41	2.1e-12	Lymphocyte counts;
CESC	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg04025307	chr7:1156635	C7orf50	0.56	9.56	0.51	8.34e-19	Longevity;Endometriosis;
CESC	cis	rs1797081	0.811	rs1797076	chr10:16853076	A/G	cg23933602	chr10:16859644	RSU1	1.0	17.79	0.74	4.04e-47	Platelet distribution width;
CESC	cis	rs11122272	0.735	rs2808604	chr1:231538916	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.55	-7.47	-0.42	1.14e-12	Hemoglobin concentration;
CESC	cis	rs1862618	0.853	rs6450408	chr5:56098146	T/C	cg18230493	chr5:56204884	C5orf35	-0.71	-8.43	-0.46	2.25e-15	Initial pursuit acceleration;
CESC	cis	rs7208859	0.623	rs7503542	chr17:29073830	A/C	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.79e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs17739167	0.550	rs6493014	chr15:42225008	A/G	cg20935245	chr15:42234343	EHD4	-0.36	-5.11	-0.3	6.3e-7	Monocyte count;
CESC	cis	rs9435341	0.965	rs55924375	chr1:107566690	C/A	cg09367891	chr1:107599246	PRMT6	0.7	8.2	0.45	1.04e-14	Facial morphology (factor 21, depth of nasal alae);
CESC	cis	rs75804782	0.641	rs55844289	chr2:239323207	C/T	cg18131467	chr2:239335373	ASB1	-0.69	-5.73	-0.33	2.75e-8	Morning vs. evening chronotype;Chronotype;
CESC	cis	rs7811142	1.000	rs1073	chr7:100031612	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.15	11.48	0.58	4.99e-25	Platelet count;
CESC	cis	rs1065852	0.526	rs9623490	chr22:42398266	G/C	cg22189786	chr22:42395067	WBP2NL	0.43	5.37	0.31	1.72e-7	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
CESC	cis	rs7940866	0.817	rs961491	chr11:130866090	G/T	cg12179176	chr11:130786555	SNX19	0.63	8.89	0.48	9.59e-17	Schizophrenia;
CESC	cis	rs2073300	0.609	rs2281428	chr20:23400050	C/T	cg16736954	chr20:23401023	NAPB	0.76	5.61	0.33	5.2100000000000003e-08	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs10129255	0.500	rs1024350	chr14:107141122	C/T	cg23076370	chr14:107095027	NA	-0.62	-9.39	-0.5	2.85e-18	Kawasaki disease;
CESC	cis	rs4563143	0.675	rs73029050	chr19:29276554	G/T	cg12756686	chr19:29218302	NA	0.58	7.33	0.41	2.79e-12	Methadone dose in opioid dependence;
CESC	cis	rs9287719	0.934	rs12692418	chr2:10745870	T/C	cg02196655	chr2:10830764	NOL10	-0.38	-5.78	-0.33	2.05e-8	Prostate cancer;
CESC	cis	rs2204008	0.720	rs11181343	chr12:38323616	G/T	cg26384229	chr12:38710491	ALG10B	0.7	10.35	0.54	2.72e-21	Bladder cancer;
CESC	cis	rs10876993	0.890	rs115106209	chr12:58059331	G/A	cg18357645	chr12:58087776	OS9	0.63	10.3	0.53	3.8e-21	Celiac disease or Rheumatoid arthritis;
CESC	cis	rs593982	1.000	rs470360	chr11:65500530	T/C	cg08755490	chr11:65554678	OVOL1	1.31	20.14	0.78	2.41e-55	Atopic dermatitis;
CESC	cis	rs5753037	0.543	rs140119	chr22:30138149	A/T	cg01021169	chr22:30184971	ASCC2	-0.55	-7.87	-0.44	9.34e-14	Type 1 diabetes;
CESC	cis	rs3750082	0.852	rs2392152	chr7:32900549	A/G	cg08946731	chr7:32981826	RP9P	-0.36	-5.17	-0.3	4.69e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs8078723	0.714	rs3859187	chr17:38150613	C/A	cg17467752	chr17:38218738	THRA	-0.56	-8.52	-0.46	1.22e-15	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CESC	cis	rs11871801	0.517	rs665268	chr17:40722029	A/G	cg16308533	chr17:40838983	CNTNAP1	0.4	5.26	0.31	3e-7	Crohn's disease;
CESC	cis	rs1927790	0.697	rs7981931	chr13:96934176	C/T	cg02571835	chr13:96230311	CLDN10	-0.39	-5.51	-0.32	8.55e-8	Body mass index;
CESC	cis	rs11608355	0.515	rs61941592	chr12:109930497	G/A	cg05360138	chr12:110035743	NA	0.81	8.63	0.47	5.62e-16	Neuroticism;
CESC	cis	rs11690935	0.885	rs10202823	chr2:172780132	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.84	-12.32	-0.6	7.06e-28	Schizophrenia;
CESC	cis	rs10479542	1.000	rs10479542	chr5:178981241	T/A	cg14820908	chr5:178986412	RUFY1	0.46	7.12	0.4	1.03e-11	Lung cancer;
CESC	cis	rs9549367	0.762	rs9549694	chr13:113870510	G/A	cg18105134	chr13:113819100	PROZ	-0.73	-9.72	-0.51	2.74e-19	Platelet distribution width;
CESC	cis	rs9811920	0.893	rs9814549	chr3:99892190	A/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.38	-5.13	-0.3	5.59e-7	Axial length;
CESC	trans	rs12599106	0.584	rs12929704	chr16:34898258	C/A	cg15383120	chr6:291909	DUSP22	-0.66	-8.25	-0.45	7.55e-15	Menopause (age at onset);
CESC	cis	rs7605827	0.930	rs1861768	chr2:15625186	C/A	cg19274914	chr2:15703543	NA	0.36	6.41	0.37	6.6e-10	Educational attainment (years of education);
CESC	cis	rs858239	0.601	rs987257	chr7:23147840	G/A	cg23682824	chr7:23144976	KLHL7	0.54	7.44	0.42	1.41e-12	Cerebrospinal fluid biomarker levels;
CESC	cis	rs2637266	1.000	rs12413656	chr10:78379666	A/C	cg18941641	chr10:78392320	NA	0.43	8.17	0.45	1.28e-14	Pulmonary function;
CESC	cis	rs9815354	0.812	rs73071344	chr3:41827062	C/T	cg03022575	chr3:42003672	ULK4	0.69	6.08	0.35	4.18e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs4700695	0.719	rs27086	chr5:65453185	A/G	cg21114390	chr5:65439923	SFRS12	-0.48	-5.9	-0.34	1.14e-8	Facial morphology (factor 19);
CESC	cis	rs7799006	0.606	rs878534	chr7:2314652	G/A	cg08027265	chr7:2291960	NA	-0.58	-9.79	-0.52	1.56e-19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs2576037	0.583	rs9916891	chr18:44493521	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.78	12.99	0.62	3.52e-30	Personality dimensions;
CESC	cis	rs722599	0.628	rs12896360	chr14:75278181	A/C	cg08847533	chr14:75593920	NEK9	0.47	5.85	0.34	1.46e-8	IgG glycosylation;
CESC	cis	rs4253772	0.550	rs6008615	chr22:46707928	G/A	cg24881330	chr22:46731750	TRMU	0.79	6.93	0.39	3.24e-11	LDL cholesterol;Cholesterol, total;
CESC	cis	rs7943191	0.810	rs7942991	chr11:62337203	A/G	cg23462726	chr11:62437636	C11orf83;C11orf48	0.41	5.53	0.32	7.82e-8	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
CESC	cis	rs853679	0.517	rs9380061	chr6:28132803	T/C	cg23161317	chr6:28129485	ZNF389	0.52	6.48	0.37	4.37e-10	Depression;
CESC	cis	rs751728	0.664	rs943475	chr6:33749978	C/T	cg25922239	chr6:33757077	LEMD2	-0.4	-5.68	-0.33	3.5e-8	Crohn's disease;
CESC	cis	rs2777491	0.915	rs28583065	chr15:41608470	T/C	cg20272979	chr15:41787780	ITPKA	0.36	5.16	0.3	4.84e-7	Ulcerative colitis;
CESC	cis	rs11123610	0.520	rs60644898	chr2:3718646	G/A	cg10645314	chr2:3704589	ALLC	-0.46	-5.18	-0.3	4.35e-7	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CESC	cis	rs9543976	0.623	rs8192756	chr13:76164938	C/T	cg01531495	chr13:76123901	UCHL3	0.5	5.03	0.3	9.04e-7	Diabetic retinopathy;
CESC	cis	rs9611565	0.802	rs9611571	chr22:41784867	G/A	cg06634786	chr22:41940651	POLR3H	-0.63	-6.8	-0.39	6.78e-11	Vitiligo;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg13649253	chr19:13198798	NFIX	0.47	6.78	0.38	7.68e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs9322193	0.923	rs9800806	chr6:150061486	G/T	cg09699651	chr6:150184138	LRP11	0.39	5.04	0.3	8.78e-7	Lung cancer;
CESC	cis	rs5747327	0.775	rs5747308	chr22:18133500	A/C	cg19898043	chr22:18121309	BCL2L13	-0.4	-5.09	-0.3	6.74e-7	Myeloid white cell count;Granulocyte count;
CESC	cis	rs6690583	0.697	rs10873684	chr1:85522196	T/C	cg22153463	chr1:85462885	MCOLN2	-0.66	-8.3	-0.45	5.4e-15	Serum sulfate level;
CESC	cis	rs11785400	0.793	rs2976399	chr8:143746050	C/T	cg24634471	chr8:143751801	JRK	0.44	5.57	0.32	6.23e-8	Schizophrenia;
CESC	cis	rs72781680	0.898	rs72786276	chr2:24062566	G/A	cg08917208	chr2:24149416	ATAD2B	1.13	10.31	0.54	3.47e-21	Lymphocyte counts;
CESC	cis	rs72829446	0.530	rs7210231	chr17:7357864	C/A	cg02795151	chr17:7402630	POLR2A	0.53	5.8	0.34	1.86e-8	Androgen levels;
CESC	cis	rs9733	0.596	rs11204687	chr1:150629880	C/A	cg22823121	chr1:150693482	HORMAD1	0.48	7.12	0.4	1.03e-11	Tonsillectomy;
CESC	cis	rs3540	0.597	rs4932346	chr15:91048991	T/C	cg22089800	chr15:90895588	ZNF774	-0.6	-7.97	-0.44	4.73e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs12500824	0.564	rs62303271	chr4:77329036	C/T	cg20311846	chr4:77356250	SHROOM3	0.39	7.5	0.42	9.73e-13	Coronary artery disease;
CESC	cis	rs1003719	0.680	rs2835619	chr21:38505380	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-8.56	-0.47	9.46e-16	Eye color traits;
CESC	cis	rs7086627	0.515	rs7077373	chr10:82211615	C/T	cg00277334	chr10:82204260	NA	-0.91	-16.25	-0.71	1.13e-41	Post bronchodilator FEV1;
CESC	cis	rs317689	0.690	rs618470	chr12:69672060	A/G	cg14784868	chr12:69753453	YEATS4	0.5	5.46	0.32	1.09e-7	Response to diuretic therapy;
CESC	trans	rs7395662	0.591	rs4882233	chr11:48739653	A/G	cg15704280	chr7:45808275	SEPT13	-0.54	-6.54	-0.37	3.07e-10	HDL cholesterol;
CESC	cis	rs1552244	0.938	rs7652951	chr3:10063763	A/C	cg00149659	chr3:10157352	C3orf10	0.75	9.05	0.49	3.07e-17	Alzheimer's disease;
CESC	cis	rs35306767	0.668	rs12356612	chr10:1055055	C/T	cg26597838	chr10:835615	NA	0.67	6.29	0.36	1.32e-9	Eosinophil percentage of granulocytes;
CESC	cis	rs12618769	0.520	rs11892744	chr2:99237792	C/T	cg10123293	chr2:99228465	UNC50	0.42	5.27	0.31	2.85e-7	Bipolar disorder;
CESC	cis	rs4665809	0.590	rs2303894	chr2:26508187	A/G	cg27170947	chr2:26402098	FAM59B	0.82	8.77	0.47	2.17e-16	Gut microbiome composition (summer);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg07908229	chr1:182353640	GLUL	0.49	6.12	0.35	3.44e-9	Ulcerative colitis;
CESC	cis	rs1707322	0.721	rs11211178	chr1:46227566	G/T	cg05343316	chr1:45956843	TESK2	0.5	6.16	0.35	2.65e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs854765	0.547	rs2955377	chr17:17932818	G/A	cg04398451	chr17:18023971	MYO15A	-0.71	-10.37	-0.54	2.34e-21	Total body bone mineral density;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg03481159	chr7:5269161	WIPI2	-0.37	-6.03	-0.35	5.63e-9	Gambling;
CESC	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.64	7.2	0.4	6.15e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs1862618	0.529	rs978406	chr5:56259808	A/T	cg18230493	chr5:56204884	C5orf35	0.71	8.67	0.47	4.54e-16	Initial pursuit acceleration;
CESC	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.56	0.37	2.89e-10	Prudent dietary pattern;
CESC	cis	rs4862750	0.872	rs9998172	chr4:187898773	T/C	cg06074448	chr4:187884817	NA	-0.37	-5.45	-0.32	1.16e-7	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9916302	0.904	rs4794807	chr17:37531718	T/A	cg15445000	chr17:37608096	MED1	-0.38	-6.16	-0.35	2.71e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs787274	1.000	rs787292	chr9:115508529	A/G	cg13803584	chr9:115635662	SNX30	0.65	5.5	0.32	9.04e-8	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs7772486	0.686	rs9403741	chr6:146030548	G/A	cg23711669	chr6:146136114	FBXO30	-0.89	-13.24	-0.63	4.85e-31	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs3749237	0.615	rs11130202	chr3:49566715	C/T	cg02487422	chr3:49467188	NICN1	0.55	8.13	0.45	1.68e-14	Resting heart rate;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg14266436	chr19:34302242	KCTD15	0.46	6.09	0.35	4.03e-9	Fibrinogen levels;
CESC	cis	rs892961	0.932	rs11657961	chr17:75405407	C/T	cg05865280	chr17:75406074	SEPT9	0.58	10.64	0.55	2.94e-22	Airflow obstruction;
CESC	cis	rs1023500	0.506	rs6002625	chr22:42517689	A/G	cg04733989	chr22:42467013	NAGA	-0.8	-11.35	-0.57	1.33e-24	Schizophrenia;
CESC	cis	rs9902453	0.934	rs7223645	chr17:28491029	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	7.88	0.44	8.52e-14	Coffee consumption (cups per day);
CESC	cis	rs2066819	1.000	rs1274493	chr12:56682371	C/T	cg26316697	chr12:56727976	PAN2	-0.69	-6.64	-0.38	1.74e-10	Psoriasis vulgaris;
CESC	cis	rs7188697	0.921	rs12445577	chr16:58587164	T/C	cg21335942	chr16:58549945	SETD6	-0.45	-5.23	-0.31	3.43e-7	QT interval;
CESC	cis	rs6460942	0.514	rs118124486	chr7:12470381	T/G	cg20607287	chr7:12443886	VWDE	-0.53	-8.43	-0.46	2.23e-15	Coronary artery disease;
CESC	cis	rs67311347	1.000	rs28434528	chr3:40484893	A/G	cg01475735	chr3:40494733	NA	-0.4	-5.05	-0.3	8.35e-7	Renal cell carcinoma;
CESC	cis	rs1018836	0.608	rs2142146	chr8:91464808	T/C	cg16814680	chr8:91681699	NA	-0.51	-7.09	-0.4	1.2e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs2243480	1.000	rs34702770	chr7:65344823	T/C	cg13147721	chr7:65941812	NA	-0.87	-8.7	-0.47	3.54e-16	Diabetic kidney disease;
CESC	cis	rs8092503	1.000	rs1833282	chr18:52501012	A/G	cg12377874	chr18:52495404	RAB27B	0.37	6.12	0.35	3.4e-9	Childhood body mass index;
CESC	cis	rs801193	0.935	rs2286683	chr7:66129843	G/A	cg11764359	chr7:65958608	NA	-0.68	-8.81	-0.48	1.68e-16	Aortic root size;
CESC	cis	rs5769765	0.773	rs9616206	chr22:50310847	G/T	cg26441486	chr22:50317300	CRELD2	0.41	5.09	0.3	6.92e-7	Schizophrenia;
CESC	cis	rs79839061	0.610	rs62297062	chr4:869698	C/T	cg07828340	chr4:882639	GAK	1.07	8.26	0.45	6.86e-15	Intelligence (multi-trait analysis);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg11192808	chr8:101170185	SPAG1	-0.44	-6.24	-0.36	1.73e-9	Fibrinogen levels;
CESC	trans	rs863345	0.967	rs1342958	chr1:158468676	A/C	cg11186933	chr8:109455379	TTC35	-0.48	-6.68	-0.38	1.37e-10	Pneumococcal bacteremia;
CESC	cis	rs35110281	0.774	rs9978811	chr21:44998683	C/T	cg21573476	chr21:45109991	RRP1B	-0.42	-5.94	-0.34	9.12e-9	Mean corpuscular volume;
CESC	cis	rs854765	0.583	rs950966	chr17:17783748	A/G	cg09796270	chr17:17721594	SREBF1	-0.45	-6.33	-0.36	1.05e-9	Total body bone mineral density;
CESC	cis	rs2120019	0.638	rs12050628	chr15:75333494	G/A	cg17294928	chr15:75287854	SCAMP5	0.9	13.77	0.65	6.65e-33	Blood trace element (Zn levels);
CESC	cis	rs472402	0.540	rs3776431	chr5:6618756	T/C	cg10789808	chr5:6633262	NSUN2;SRD5A1	-0.5	-6.67	-0.38	1.45e-10	Response to amphetamines;
CESC	cis	rs10504229	0.683	rs56204590	chr8:58131642	T/G	cg24829409	chr8:58192753	C8orf71	-0.58	-7.2	-0.4	6.31e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs9910055	0.762	rs2526020	chr17:42216588	G/T	cg08499158	chr17:42289980	UBTF	-0.57	-7.34	-0.41	2.69e-12	Total body bone mineral density;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23654174	chr1:47779667	STIL	-0.55	-6.28	-0.36	1.41e-9	Gut microbiome composition (summer);
CESC	cis	rs1005277	0.579	rs2474574	chr10:38387295	C/T	cg25427524	chr10:38739819	LOC399744	-0.66	-9.5	-0.5	1.29e-18	Extrinsic epigenetic age acceleration;
CESC	cis	rs6570726	0.905	rs430248	chr6:145874104	A/G	cg05347473	chr6:146136440	FBXO30	0.47	6.33	0.36	1.02e-9	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs3820068	0.603	rs72647120	chr1:15956769	G/T	cg13390004	chr1:15929781	NA	0.37	5.89	0.34	1.17e-8	Systolic blood pressure;
CESC	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg24642844	chr7:1081250	C7orf50	-0.4	-5.19	-0.3	4.23e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs10927875	0.894	rs34957618	chr1:16320499	G/C	cg21385522	chr1:16154831	NA	-0.6	-7.57	-0.42	6.04e-13	Dilated cardiomyopathy;
CESC	cis	rs10504229	0.683	rs72650839	chr8:58130029	C/T	cg22535103	chr8:58192502	C8orf71	-0.8	-8.99	-0.48	4.78e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs13256369	0.851	rs13266562	chr8:8564065	T/C	cg00074818	chr8:8560427	CLDN23	0.38	5.46	0.32	1.1e-7	Obesity-related traits;
CESC	cis	rs514406	0.708	rs514881	chr1:53336737	A/G	cg24675658	chr1:53192096	ZYG11B	0.62	8.66	0.47	4.77e-16	Monocyte count;
CESC	cis	rs10504229	0.906	rs58251024	chr8:58172259	G/C	cg14926445	chr8:58193284	C8orf71	-0.51	-5.49	-0.32	9.5e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs2777491	0.874	rs1655556	chr15:41777935	A/C	cg02330683	chr15:41787940	ITPKA	0.49	7.24	0.41	4.75e-12	Ulcerative colitis;
CESC	cis	rs875971	0.508	rs10253883	chr7:66061138	T/C	cg14393609	chr7:65229607	NA	-0.41	-5.78	-0.33	2.1e-8	Aortic root size;
CESC	cis	rs67478160	0.654	rs1997913	chr14:104213960	C/T	cg08213375	chr14:104286397	PPP1R13B	0.54	10.8	0.55	9.16e-23	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25867650	chr15:75743273	SIN3A	0.55	6.54	0.37	3.23e-10	Gut microbiome composition (summer);
CESC	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg10862848	chr6:42927986	GNMT	-0.26	-6.61	-0.38	2.09e-10	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs2439831	0.867	rs2255440	chr15:43830467	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.69	9.01	0.48	4.24e-17	Lung cancer in ever smokers;
CESC	cis	rs2997447	0.761	rs61776575	chr1:26429844	G/A	cg24596570	chr1:26146463	FAM54B;LOC646471	0.62	5.31	0.31	2.31e-7	QRS complex (12-leadsum);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg19803043	chr1:167691022	MPZL1	-0.49	-6.02	-0.35	5.95e-9	Ulcerative colitis;
CESC	cis	rs35110281	0.511	rs2298562	chr21:45085236	A/G	cg01579765	chr21:45077557	HSF2BP	-0.53	-9.35	-0.5	3.92e-18	Mean corpuscular volume;
CESC	cis	rs4268898	0.735	rs34125395	chr2:24558242	C/T	cg06627628	chr2:24431161	ITSN2	0.52	6.59	0.38	2.38e-10	Asthma;
CESC	cis	rs12618769	0.652	rs7585747	chr2:99219071	T/C	cg10123293	chr2:99228465	UNC50	0.4	5.19	0.3	4.2e-7	Bipolar disorder;
CESC	cis	rs4566357	0.615	rs10184991	chr2:227916533	G/A	cg11843606	chr2:227700838	RHBDD1	-0.51	-6.92	-0.39	3.33e-11	Coronary artery disease;
CESC	cis	rs3008870	0.755	rs3929738	chr1:67397865	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.63	8.29	0.45	5.85e-15	Lymphocyte percentage of white cells;
CESC	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg11301795	chr4:187892539	NA	-0.74	-12.21	-0.6	1.69e-27	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2730245	1.000	rs2730245	chr7:158724789	G/C	cg24397884	chr7:158709396	WDR60	-0.88	-13.37	-0.63	1.71e-31	Height;
CESC	cis	rs11252926	0.831	rs816570	chr10:680475	C/T	cg08603382	chr10:743973	NA	-0.59	-7.89	-0.44	7.94e-14	Psychosis in Alzheimer's disease;
CESC	cis	rs13256369	0.802	rs11249884	chr8:8561552	C/T	cg00074818	chr8:8560427	CLDN23	-0.36	-5.19	-0.3	4.11e-7	Obesity-related traits;
CESC	cis	rs2230307	0.505	rs482873	chr1:100589757	C/T	cg24955406	chr1:100503596	HIAT1	-0.54	-5.41	-0.32	1.43e-7	Carotid intima media thickness;
CESC	cis	rs3096299	0.781	rs2965819	chr16:89501030	G/T	cg08392591	chr16:89556376	ANKRD11	-0.54	-7.23	-0.41	5.04e-12	Multiple myeloma (IgH translocation);
CESC	cis	rs6500395	1.000	rs7198773	chr16:48606091	T/C	cg04672837	chr16:48644449	N4BP1	0.51	6.38	0.36	7.94e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs2463822	0.925	rs17157227	chr11:62169772	A/G	cg06239285	chr11:62104954	ASRGL1	0.81	7.22	0.41	5.56e-12	Chronic obstructive pulmonary disease-related biomarkers;
CESC	trans	rs9542155	0.532	rs2472285	chr13:70580104	C/A	cg11781847	chr8:67837483	SNHG6	0.58	6.02	0.35	5.85e-9	Tonsillectomy;
CESC	cis	rs10504229	0.906	rs73607869	chr8:58172665	G/T	cg22535103	chr8:58192502	C8orf71	-1.05	-13.27	-0.63	3.63e-31	Developmental language disorder (linguistic errors);
CESC	cis	rs6460942	1.000	rs6944134	chr7:12418036	T/C	cg06484146	chr7:12443880	VWDE	-0.75	-8.85	-0.48	1.23e-16	Coronary artery disease;
CESC	cis	rs72781680	0.611	rs2303289	chr2:24342242	C/G	cg20701182	chr2:24300061	SF3B14	-0.93	-10.44	-0.54	1.31e-21	Lymphocyte counts;
CESC	cis	rs7580658	0.637	rs4560059	chr2:127972228	T/C	cg10021288	chr2:128175891	PROC	-0.37	-5.69	-0.33	3.31e-8	Protein C levels;
CESC	cis	rs6445967	0.569	rs17636819	chr3:58283722	C/T	cg23715586	chr3:58305044	RPP14	0.46	7.37	0.41	2.12e-12	Platelet count;
CESC	cis	rs2594989	1.000	rs2594978	chr3:11383347	C/A	cg00170343	chr3:11313890	ATG7	0.56	5.17	0.3	4.71e-7	Circulating chemerin levels;
CESC	cis	rs16854884	0.657	rs62268458	chr3:143736219	T/C	cg06585982	chr3:143692056	C3orf58	0.49	6.14	0.35	2.96e-9	Economic and political preferences (feminism/equality);
CESC	cis	rs763014	0.931	rs56048717	chr16:634867	A/G	cg00908189	chr16:619842	PIGQ	0.64	9.0	0.48	4.57e-17	Height;
CESC	cis	rs40363	0.723	rs2736	chr16:3536872	G/A	cg05754148	chr16:3507555	NAT15	-0.64	-6.12	-0.35	3.34e-9	Tuberculosis;
CESC	cis	rs6580649	0.941	rs78649179	chr12:48508196	T/A	cg05342945	chr12:48394962	COL2A1	0.55	6.3	0.36	1.25e-9	Lung cancer;
CESC	cis	rs1008375	0.931	rs6449326	chr4:17699790	G/T	cg16339924	chr4:17578868	LAP3	0.59	7.36	0.41	2.29e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs2836974	0.863	rs8132333	chr21:40527900	A/G	cg17971929	chr21:40555470	PSMG1	1.03	16.03	0.7	6.94e-41	Cognitive function;
CESC	cis	rs7772486	0.686	rs9390357	chr6:146129347	A/G	cg23711669	chr6:146136114	FBXO30	0.86	12.94	0.62	5.31e-30	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9457247	0.534	rs2757053	chr6:167380338	A/C	cg25258033	chr6:167368657	RNASET2	-0.4	-5.74	-0.33	2.56e-8	Crohn's disease;
CESC	cis	rs7618501	0.633	rs6792892	chr3:49995518	T/C	cg24110177	chr3:50126178	RBM5	-0.54	-7.23	-0.41	5.19e-12	Intelligence (multi-trait analysis);
CESC	cis	rs9300255	0.602	rs1616181	chr12:123619856	T/A	cg19016782	chr12:123741754	C12orf65	-0.38	-5.15	-0.3	5.08e-7	Neutrophil percentage of white cells;
CESC	cis	rs2361710	0.611	rs12451471	chr17:78102517	C/T	cg24585782	chr17:78113791	EIF4A3	-0.51	-6.93	-0.39	3.13e-11	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
CESC	cis	rs780096	0.526	rs1647266	chr2:27693485	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.32	-5.97	-0.34	7.45e-9	Total body bone mineral density;
CESC	cis	rs6952808	0.760	rs11764960	chr7:1950532	G/A	cg05863683	chr7:1912471	MAD1L1	0.44	6.62	0.38	2.01e-10	Bipolar disorder and schizophrenia;
CESC	cis	rs736408	0.608	rs6445534	chr3:52743384	G/A	cg18099408	chr3:52552593	STAB1	-0.3	-5.09	-0.3	6.8e-7	Bipolar disorder;
CESC	cis	rs1348850	0.914	rs3902850	chr2:178315899	G/A	cg22681709	chr2:178499509	PDE11A	-0.41	-5.95	-0.34	8.53e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs897984	0.762	rs12930545	chr16:30938811	A/G	cg02466173	chr16:30829666	NA	0.49	8.33	0.46	4.26e-15	Dementia with Lewy bodies;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24179850	chr19:56154938	ZNF581	0.55	6.65	0.38	1.68e-10	Gut microbiome composition (summer);
CESC	cis	rs1799949	0.896	rs8176086	chr17:41274778	G/A	cg23758822	chr17:41437982	NA	1.02	15.6	0.69	2.35e-39	Menopause (age at onset);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04811502	chr14:21979673	METTL3	-0.45	-6.4	-0.37	7.04e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs6963495	0.818	rs55825845	chr7:105166713	A/G	cg19920283	chr7:105172520	RINT1	0.7	6.68	0.38	1.39e-10	Bipolar disorder (body mass index interaction);
CESC	cis	rs8005677	1.000	rs4982710	chr14:23398902	C/T	cg01529538	chr14:23388837	RBM23	0.5	6.79	0.38	7.31e-11	Cognitive ability (multi-trait analysis);
CESC	cis	rs7191439	0.674	rs4782430	chr16:88792047	A/G	cg02389323	chr16:88786976	FAM38A	0.91	8.18	0.45	1.19e-14	Plateletcrit;
CESC	cis	rs561341	0.556	rs542244	chr17:30307242	T/C	cg23018236	chr17:30244563	NA	-0.52	-5.11	-0.3	6.28e-7	Hip circumference adjusted for BMI;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg09592463	chr17:40995321	PSME3;AOC2	0.44	6.09	0.35	4.03e-9	Thyroid stimulating hormone;
CESC	cis	rs9916302	0.904	rs11078898	chr17:37536480	A/G	cg07936489	chr17:37558343	FBXL20	0.82	11.86	0.59	2.58e-26	Glomerular filtration rate (creatinine);
CESC	cis	rs1336900	0.641	rs6587756	chr1:150546865	A/T	cg04414720	chr1:150670196	GOLPH3L	-0.48	-6.07	-0.35	4.32e-9	Blood protein levels;
CESC	cis	rs6089829	0.962	rs6062393	chr20:61663230	G/A	cg16240275	chr20:61666158	NCRNA00029	0.5	8.97	0.48	5.67e-17	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs875971	1.000	rs2077593	chr7:65892530	A/G	cg11764359	chr7:65958608	NA	0.97	15.56	0.69	3.06e-39	Aortic root size;
CESC	cis	rs4853012	0.793	rs6723185	chr2:74344884	T/A	cg19729930	chr2:74357872	NA	0.88	13.24	0.63	4.76e-31	Gestational age at birth (maternal effect);
CESC	cis	rs947211	0.898	rs1772153	chr1:205745782	C/T	cg26354017	chr1:205819088	PM20D1	-0.41	-5.11	-0.3	6.14e-7	Parkinson's disease;
CESC	trans	rs11098499	0.775	rs10021601	chr4:120282563	G/A	cg25214090	chr10:38739885	LOC399744	0.65	9.11	0.49	2.04e-17	Corneal astigmatism;
CESC	trans	rs3741489	1.000	rs11147098	chr12:133406374	G/A	cg24132527	chr5:140019269	TMCO6	1.1	7.33	0.41	2.74e-12	Cognitive function;
CESC	cis	rs3740713	1.000	rs76586692	chr11:18453726	A/G	cg23797887	chr11:18477753	LDHAL6A	-0.53	-5.27	-0.31	2.89e-7	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs4665809	0.590	rs4665315	chr2:26416036	T/G	cg25036284	chr2:26402008	FAM59B	-0.84	-9.59	-0.51	7.03e-19	Gut microbiome composition (summer);
CESC	cis	rs6860806	0.661	rs3763112	chr5:131586480	A/G	cg09877947	chr5:131593287	PDLIM4	0.47	6.12	0.35	3.31e-9	Breast cancer;
CESC	cis	rs7618915	0.547	rs6762813	chr3:52726695	C/T	cg18404041	chr3:52824283	ITIH1	-0.4	-6.73	-0.38	1.02e-10	Bipolar disorder;
CESC	cis	rs9322193	0.923	rs35830138	chr6:149989771	T/C	cg04369109	chr6:150039330	LATS1	-0.4	-5.51	-0.32	8.45e-8	Lung cancer;
CESC	cis	rs2836974	0.897	rs2836929	chr21:40543811	T/C	cg11890956	chr21:40555474	PSMG1	1.17	22.29	0.81	1.05e-62	Cognitive function;
CESC	cis	rs7107174	1.000	rs7107174	chr11:77997936	C/T	cg02023728	chr11:77925099	USP35	0.51	6.79	0.38	7.31e-11	Testicular germ cell tumor;
CESC	cis	rs6987853	0.787	rs2923436	chr8:42425298	G/A	cg09913449	chr8:42400586	C8orf40	0.45	7.62	0.42	4.61e-13	Mean corpuscular hemoglobin concentration;
CESC	cis	rs853679	0.517	rs4713148	chr6:28115921	G/A	cg12963246	chr6:28129442	ZNF389	0.59	7.68	0.43	3e-13	Depression;
CESC	cis	rs7552404	0.731	rs1493367	chr1:76344011	C/A	cg10523679	chr1:76189770	ACADM	-0.61	-6.16	-0.35	2.75e-9	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs8060686	0.641	rs57408712	chr16:68242573	G/C	cg26727032	chr16:67993705	SLC12A4	-0.53	-5.93	-0.34	9.49e-9	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs1799949	1.000	rs11652332	chr17:41295489	G/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.42	5.77	0.33	2.25e-8	Menopause (age at onset);
CESC	cis	rs2070997	0.534	rs6597640	chr9:133669338	G/T	cg11464064	chr9:133710261	ABL1	0.55	6.46	0.37	4.91e-10	Response to amphetamines;
CESC	cis	rs4974559	0.790	rs28712208	chr4:1316695	A/T	cg02980000	chr4:1222292	CTBP1	0.67	7.42	0.41	1.55e-12	Systolic blood pressure;
CESC	cis	rs9300255	0.510	rs1727322	chr12:123699520	A/G	cg00376283	chr12:123451042	ABCB9	0.61	6.34	0.36	9.86e-10	Neutrophil percentage of white cells;
CESC	cis	rs7312774	0.748	rs10492211	chr12:107298213	T/C	cg16260113	chr12:107380972	MTERFD3	0.63	5.97	0.34	7.77e-9	Severe influenza A (H1N1) infection;
CESC	cis	rs1401999	0.934	rs1132776	chr3:183696402	A/G	cg01324343	chr3:183735012	ABCC5	0.62	13.06	0.63	2.04e-30	Anterior chamber depth;
CESC	cis	rs752010	0.806	rs11210500	chr1:42089737	A/G	cg12614395	chr1:42085415	HIVEP3	0.31	5.35	0.31	1.93e-7	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs13256369	0.755	rs11776987	chr8:8559401	C/G	cg17143192	chr8:8559678	CLDN23	0.77	8.6	0.47	7.18e-16	Obesity-related traits;
CESC	cis	rs61931739	0.500	rs7296061	chr12:34435009	A/G	cg19457237	chr12:34500585	NA	0.38	5.35	0.31	1.91e-7	Morning vs. evening chronotype;
CESC	cis	rs854765	0.547	rs4368210	chr17:17896090	A/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.48	-6.18	-0.35	2.39e-9	Total body bone mineral density;
CESC	cis	rs7267979	1.000	rs2184000	chr20:25395878	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.87	-18.03	-0.74	5.81e-48	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs6456156	0.792	rs10946214	chr6:167516122	G/A	cg07741184	chr6:167504864	NA	0.35	6.28	0.36	1.34e-9	Primary biliary cholangitis;
CESC	cis	rs2243480	1.000	rs6958289	chr7:65657111	T/G	cg13147721	chr7:65941812	NA	0.97	9.16	0.49	1.47e-17	Diabetic kidney disease;
CESC	cis	rs2836974	0.897	rs2836929	chr21:40543811	T/C	cg27266027	chr21:40555129	PSMG1	0.45	5.49	0.32	9.25e-8	Cognitive function;
CESC	cis	rs3105169	0.696	rs1492077	chr8:100350841	A/G	cg05586662	chr8:100024465	VPS13B	0.39	5.09	0.3	6.9e-7	Smoking initiation;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg12782834	chr3:196439273	PIGX;C3orf34	-0.44	-6.15	-0.35	2.83e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg23708337	chr7:1209742	NA	0.55	5.41	0.32	1.41e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs1814175	0.817	rs7947286	chr11:49874657	C/T	cg15704280	chr7:45808275	SEPT13	-1.03	-20.77	-0.79	1.6e-57	Height;
CESC	cis	rs1878931	0.507	rs67218524	chr16:3403057	G/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.74	-9.12	-0.49	1.93e-17	Body mass index (adult);
CESC	cis	rs12950390	0.820	rs58391889	chr17:45865959	A/G	cg00777063	chr17:45855553	NA	-0.39	-5.77	-0.33	2.24e-8	IgG glycosylation;
CESC	cis	rs7208859	0.673	rs3764420	chr17:29164154	A/G	cg19761014	chr17:28927070	LRRC37B2	0.72	5.68	0.33	3.48e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs4423214	1.000	rs2276362	chr11:71174452	A/G	cg05163923	chr11:71159392	DHCR7	0.84	11.4	0.57	9.55e-25	Vitamin D levels;
CESC	cis	rs7246865	0.859	rs1379281	chr19:17189786	A/G	cg19418318	chr19:17219073	MYO9B	-0.32	-5.04	-0.3	8.83e-7	Reticulocyte fraction of red cells;
CESC	cis	rs4665809	0.590	rs4665315	chr2:26416036	T/G	cg22920501	chr2:26401640	FAM59B	-0.85	-10.05	-0.53	2.5e-20	Gut microbiome composition (summer);
CESC	cis	rs7914558	0.933	rs1538204	chr10:104733893	T/A	cg08650961	chr10:104748594	CNNM2	0.31	5.05	0.3	8.15e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04733624	chr10:75936339	ADK	0.61	7.29	0.41	3.61e-12	Gut microbiome composition (summer);
CESC	trans	rs7839040	0.698	rs12543816	chr8:82932223	C/T	cg14472086	chr9:107730925	NA	-0.48	-6.45	-0.37	5.4e-10	Response to methotrexate in juvenile idiopathic arthritis;
CESC	cis	rs4950928	0.712	rs7518666	chr1:203163590	C/T	cg14085262	chr1:203155938	CHI3L1	-0.51	-5.57	-0.32	6.25e-8	YKL-40 levels;
CESC	cis	rs7937682	0.824	rs510866	chr11:111484113	A/C	cg09085632	chr11:111637200	PPP2R1B	-0.95	-14.7	-0.67	3.4e-36	Primary sclerosing cholangitis;
CESC	cis	rs7615952	0.604	rs9837847	chr3:125623919	G/A	cg05084668	chr3:125655381	ALG1L	-0.78	-8.05	-0.44	2.83e-14	Blood pressure (smoking interaction);
CESC	cis	rs1799949	0.501	rs35399157	chr17:41411602	G/C	cg06001716	chr17:41278141	BRCA1;NBR2	0.38	5.13	0.3	5.72e-7	Menopause (age at onset);
CESC	cis	rs1552244	0.626	rs2886396	chr3:10037670	C/T	cg00166722	chr3:10149974	C3orf24	0.48	5.92	0.34	9.76e-9	Alzheimer's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00357593	chr19:14530417	DDX39	0.6	7.15	0.4	8.7e-12	Gut microbiome composition (summer);
CESC	cis	rs853679	0.517	rs4713145	chr6:28106827	T/C	cg22143856	chr6:28129313	ZNF389	0.52	6.75	0.38	9.54e-11	Depression;
CESC	cis	rs6834538	0.597	rs2029211	chr4:113488134	A/G	cg05166686	chr4:113558556	LARP7;C4orf21	0.44	5.43	0.32	1.28e-7	Free thyroxine concentration;
CESC	cis	rs1215050	0.791	rs1585088	chr4:98675071	C/A	cg05340658	chr4:99064831	C4orf37	-0.47	-6.04	-0.35	5.08e-9	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs9788333	0.962	rs34853044	chr13:21883784	C/T	cg25811766	chr13:21894605	NA	0.76	10.97	0.56	2.54e-23	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	trans	rs1493916	1.000	rs11081827	chr18:31390228	C/A	cg27147174	chr7:100797783	AP1S1	-0.5	-6.66	-0.38	1.53e-10	Life satisfaction;
CESC	cis	rs3733585	0.631	rs4697707	chr4:10119787	G/T	cg11266682	chr4:10021025	SLC2A9	-0.55	-10.3	-0.53	3.87e-21	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs73058052	1.000	rs73058052	chr19:50099422	C/T	cg09250473	chr19:50168907	IRF3;BCL2L12	0.62	5.33	0.31	2.07e-7	Fibrinogen levels;
CESC	cis	rs9768139	0.708	rs11771764	chr7:158119871	A/G	cg06219351	chr7:158114137	PTPRN2	-0.49	-7.45	-0.42	1.29e-12	Calcium levels;
CESC	cis	rs7336332	0.598	rs1885988	chr13:28010262	C/T	cg01674679	chr13:27998804	GTF3A	0.59	5.56	0.32	6.52e-8	Weight;
CESC	cis	rs1190552	0.894	rs4906203	chr14:102928991	C/T	cg18135206	chr14:102964638	TECPR2	0.4	5.04	0.3	8.49e-7	Blood protein levels;
CESC	cis	rs3752962	0.569	rs3803806	chr17:1940713	T/C	cg24156229	chr17:1948635	NA	-0.63	-9.57	-0.51	7.67e-19	Itch intensity from mosquito bite;
CESC	cis	rs6696846	0.765	rs72757524	chr1:205086473	C/T	cg00857998	chr1:205179979	DSTYK	0.57	7.44	0.42	1.4e-12	Red blood cell count;
CESC	cis	rs2120019	1.000	rs35577967	chr15:75354621	G/A	cg17294928	chr15:75287854	SCAMP5	-0.65	-6.96	-0.39	2.66e-11	Blood trace element (Zn levels);
CESC	cis	rs9527	0.590	rs1926029	chr10:104855670	C/T	cg04362960	chr10:104952993	NT5C2	0.42	5.09	0.3	6.86e-7	Arsenic metabolism;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg17746819	chr1:100715586	DBT	0.48	6.06	0.35	4.73e-9	Ulcerative colitis;
CESC	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg18765753	chr7:1198926	ZFAND2A	-0.41	-5.15	-0.3	5.19e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs9837602	0.688	rs793488	chr3:99495567	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.42	-5.44	-0.32	1.19e-7	Breast cancer;
CESC	cis	rs8067545	0.611	rs2042046	chr17:20018841	A/G	cg13482628	chr17:19912719	NA	0.41	5.45	0.32	1.13e-7	Schizophrenia;
CESC	cis	rs7772486	0.875	rs6909827	chr6:146365738	A/G	cg23711669	chr6:146136114	FBXO30	0.76	11.14	0.56	6.6e-24	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs10463316	0.894	rs10042030	chr5:150768028	T/C	cg03212797	chr5:150827313	SLC36A1	-0.47	-6.15	-0.35	2.86e-9	Metabolite levels (Pyroglutamine);
CESC	cis	rs939574	0.720	rs6714820	chr2:220071803	C/G	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-0.54	-5.26	-0.31	3.03e-7	Platelet distribution width;
CESC	cis	rs7949030	0.653	rs2849030	chr11:62366986	G/A	cg11742103	chr11:62369870	EML3;MTA2	-0.61	-9.29	-0.5	6.02e-18	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs6499129	0.764	rs7186310	chr16:67305513	A/C	cg26727032	chr16:67993705	SLC12A4	-0.51	-5.64	-0.33	4.36e-8	Waist-to-hip ratio adjusted for body mass index;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25788012	chr8:145133899	EXOSC4	0.55	6.3	0.36	1.26e-9	Gut microbiome composition (summer);
CESC	cis	rs6582630	0.519	rs8189461	chr12:38374870	G/T	cg13010199	chr12:38710504	ALG10B	0.48	6.06	0.35	4.62e-9	Drug-induced liver injury (flucloxacillin);
CESC	trans	rs12356475	0.710	rs10822686	chr10:67733250	C/T	cg08538778	chr1:115212897	DENND2C	0.48	6.03	0.35	5.5e-9	Psoriatic arthritis;
CESC	cis	rs7727544	0.661	rs273900	chr5:131694606	G/A	cg07395648	chr5:131743802	NA	-0.4	-5.17	-0.3	4.56e-7	Blood metabolite levels;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg04315863	chr15:34330588	AVEN;CHRM5	0.47	6.34	0.36	9.86e-10	Systemic lupus erythematosus;
CESC	cis	rs7267979	1.000	rs6050565	chr20:25347563	A/C	cg08601574	chr20:25228251	PYGB	-0.37	-5.55	-0.32	6.81e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7914558	1.000	rs11191541	chr10:104824199	A/G	cg15744005	chr10:104629667	AS3MT	-0.34	-5.49	-0.32	9.49e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs6502050	0.761	rs13949	chr17:80059596	T/C	cg23985595	chr17:80112537	CCDC57	0.38	5.85	0.34	1.47e-8	Life satisfaction;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	ch.14.1168716F	chr14:77543787	NA	-0.59	-7.4	-0.41	1.85e-12	Gut microbiome composition (summer);
CESC	cis	rs258892	0.895	rs34656	chr5:72148117	C/T	cg21869765	chr5:72125136	TNPO1	0.44	5.55	0.32	6.92e-8	Small cell lung carcinoma;
CESC	cis	rs59918340	0.764	rs4961338	chr8:142230192	C/T	cg23750338	chr8:142222470	SLC45A4	-0.62	-9.61	-0.51	6.07e-19	Immature fraction of reticulocytes;
CESC	cis	rs9926296	0.527	rs1800335	chr16:89846195	A/G	cg27121462	chr16:89883253	FANCA	0.77	11.14	0.56	6.67e-24	Vitiligo;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16778319	chr15:40733174	BAHD1	0.6	6.94	0.39	2.94e-11	Gut microbiome composition (summer);
CESC	cis	rs6938	0.618	rs11633472	chr15:75184084	T/G	cg14664628	chr15:75095509	CSK	-0.52	-6.85	-0.39	5.25e-11	Breast cancer;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg06296553	chr12:124810874	NCOR2	0.46	6.64	0.38	1.8e-10	Fibrinogen levels;
CESC	trans	rs9354308	0.867	rs2802051	chr6:66536403	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.6	6.67	0.38	1.5e-10	Metabolite levels;
CESC	cis	rs7223966	1.000	rs2854219	chr17:61942682	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.5	5.78	0.33	2.13e-8	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs2191566	0.664	rs4803669	chr19:44539962	C/A	cg20607764	chr19:44506953	ZNF230	-0.43	-5.52	-0.32	8.25e-8	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs9322193	0.923	rs7740278	chr6:149961252	C/T	cg07701084	chr6:150067640	NUP43	0.46	6.52	0.37	3.54e-10	Lung cancer;
CESC	cis	rs117623576	0.941	rs211422	chr10:32398589	A/G	cg03047570	chr10:32398778	NA	0.78	8.22	0.45	9.22e-15	Anti-saccade response;
CESC	cis	rs514406	0.793	rs12402415	chr1:53218539	G/T	cg24675658	chr1:53192096	ZYG11B	0.56	7.64	0.42	4.03e-13	Monocyte count;
CESC	cis	rs2522056	1.000	rs11242113	chr5:131777234	G/A	cg24060327	chr5:131705240	SLC22A5	0.68	8.14	0.45	1.56e-14	Lymphocyte counts;Fibrinogen;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12389545	chr11:72353604	PDE2A	0.5	6.07	0.35	4.49e-9	Gut microbiome composition (summer);
CESC	cis	rs12586317	0.513	rs11156871	chr14:35481196	G/A	cg05294307	chr14:35346193	BAZ1A	-0.51	-5.45	-0.32	1.16e-7	Psoriasis;
CESC	cis	rs7927771	0.832	rs6485753	chr11:47410200	C/T	cg18512352	chr11:47633146	NA	0.54	7.97	0.44	4.64e-14	Subjective well-being;
CESC	cis	rs9322193	0.923	rs9505823	chr6:149950035	A/C	cg13206674	chr6:150067644	NUP43	0.43	6.27	0.36	1.44e-9	Lung cancer;
CESC	cis	rs10504229	1.000	rs67594249	chr8:58180521	T/A	cg05313129	chr8:58192883	C8orf71	-0.55	-6.37	-0.36	8.42e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs7618915	0.547	rs62255362	chr3:52699741	C/G	cg17372223	chr3:52568218	NT5DC2	0.44	6.63	0.38	1.86e-10	Bipolar disorder;
CESC	cis	rs1552244	0.882	rs56332224	chr3:10037321	G/A	cg00166722	chr3:10149974	C3orf24	0.48	5.95	0.34	8.39e-9	Alzheimer's disease;
CESC	cis	rs12497850	0.764	rs6784111	chr3:49178846	T/C	cg02487422	chr3:49467188	NICN1	0.5	6.35	0.36	9.14e-10	Parkinson's disease;
CESC	cis	rs990171	0.506	rs9284725	chr2:102744854	C/A	cg22835712	chr2:102737379	NA	0.43	6.01	0.35	6.14e-9	Lymphocyte counts;
CESC	cis	rs79057730	0.599	rs4720893	chr7:804434	G/A	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.92	8.08	0.44	2.36e-14	Initial pursuit acceleration;
CESC	cis	rs3768617	0.510	rs20563	chr1:183085755	C/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.88	-14.2	-0.66	2.08e-34	Fuchs's corneal dystrophy;
CESC	cis	rs796364	1.000	rs281759	chr2:200787719	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.87	8.3	0.45	5.2e-15	Schizophrenia;
CESC	cis	rs35306767	0.855	rs11253465	chr10:897208	A/C	cg25019033	chr10:957182	NA	-0.58	-6.32	-0.36	1.12e-9	Eosinophil percentage of granulocytes;
CESC	cis	rs6598163	0.520	rs12813376	chr12:132302324	C/T	cg22244940	chr12:132335942	MMP17	0.4	5.41	0.32	1.39e-7	Migraine;
CESC	cis	rs7618915	0.524	rs12488461	chr3:52698417	T/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.38	6.68	0.38	1.39e-10	Bipolar disorder;
CESC	cis	rs3008870	0.755	rs4655660	chr1:67402953	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.63	8.34	0.46	4.16e-15	Lymphocyte percentage of white cells;
CESC	cis	rs9611565	0.765	rs202659	chr22:41811620	T/C	cg03806693	chr22:41940476	POLR3H	1.04	12.37	0.61	4.76e-28	Vitiligo;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg23666278	chr2:171785822	GORASP2	-0.5	-6.78	-0.38	8e-11	Fibrinogen levels;
CESC	cis	rs6893300	0.524	rs62404348	chr5:179146026	G/A	cg14593053	chr5:179126677	CANX	0.6	8.88	0.48	1.05e-16	Resting heart rate;
CESC	cis	rs9916302	0.904	rs587343	chr17:37440603	C/T	cg00129232	chr17:37814104	STARD3	0.49	6.16	0.35	2.69e-9	Glomerular filtration rate (creatinine);
CESC	trans	rs11165623	0.792	rs9437607	chr1:96977788	G/A	cg10631902	chr5:14652156	NA	-0.47	-6.91	-0.39	3.59e-11	Hip circumference;Waist circumference;
CESC	cis	rs6741892	0.536	rs6761563	chr2:38891406	A/T	cg23643435	chr2:38893251	GALM	-0.66	-9.13	-0.49	1.85e-17	5-HTT brain serotonin transporter levels;
CESC	cis	rs7216064	1.000	rs62084240	chr17:65859233	C/A	cg12091567	chr17:66097778	LOC651250	-0.85	-8.6	-0.47	7.26e-16	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs10463316	0.894	rs6864722	chr5:150752942	G/A	cg03212797	chr5:150827313	SLC36A1	-0.42	-5.41	-0.32	1.41e-7	Metabolite levels (Pyroglutamine);
CESC	cis	rs7312933	0.670	rs10880258	chr12:42547531	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.47	6.16	0.35	2.68e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs9522267	0.535	rs4773393	chr13:112229755	A/G	cg10483660	chr13:112241077	NA	-0.33	-5.82	-0.34	1.67e-8	Hepatitis;
CESC	cis	rs703842	1.000	rs2069502	chr12:58144665	A/G	cg00677455	chr12:58241039	CTDSP2	-0.52	-6.66	-0.38	1.62e-10	Multiple sclerosis;
CESC	cis	rs7618915	0.547	rs34173654	chr3:52634605	T/C	cg05564831	chr3:52568323	NT5DC2	0.46	6.96	0.39	2.61e-11	Bipolar disorder;
CESC	cis	rs9411298	0.630	rs9411299	chr9:139938793	C/G	cg14024893	chr9:139943146	ENTPD2	-0.45	-6.27	-0.36	1.47e-9	Monocyte percentage of white cells;
CESC	cis	rs3091242	0.933	rs35403885	chr1:25784551	G/A	cg27572855	chr1:25598939	RHD	-0.43	-7.19	-0.4	6.65e-12	Erythrocyte sedimentation rate;
CESC	cis	rs17095355	1.000	rs7080576	chr10:111710817	C/T	cg00817464	chr10:111662876	XPNPEP1	0.43	5.19	0.3	4.26e-7	Biliary atresia;
CESC	cis	rs4065321	0.522	rs34648856	chr17:38149411	G/A	cg17467752	chr17:38218738	THRA	-0.45	-5.91	-0.34	1.04e-8	White blood cell count (basophil);White blood cell count;
CESC	cis	rs9611565	0.625	rs9611606	chr22:41931074	A/G	cg03806693	chr22:41940476	POLR3H	-1.25	-17.05	-0.72	1.64e-44	Vitiligo;
CESC	cis	rs853679	0.760	rs9468317	chr6:28198456	A/G	cg12963246	chr6:28129442	ZNF389	0.4	5.24	0.31	3.24e-7	Depression;
CESC	cis	rs10028773	0.546	rs13117947	chr4:120257060	A/G	cg09307838	chr4:120376055	NA	0.53	7.19	0.4	6.64e-12	Educational attainment;
CESC	cis	rs66561647	0.719	rs7812386	chr8:128937609	C/A	cg05480350	chr8:128972681	MIR1205;PVT1	0.42	5.56	0.32	6.7e-8	Hemoglobin concentration;
CESC	cis	rs9733	0.519	rs11807450	chr1:150677719	C/T	cg17724175	chr1:150552817	MCL1	0.43	6.87	0.39	4.68e-11	Tonsillectomy;
CESC	cis	rs10899021	0.790	rs10899022	chr11:74339386	C/T	cg25880958	chr11:74394337	NA	-0.74	-7.86	-0.43	9.76e-14	Response to metformin (IC50);
CESC	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg26338869	chr17:61819248	STRADA	0.69	9.1	0.49	2.2e-17	Prudent dietary pattern;
CESC	cis	rs9311474	0.539	rs12489828	chr3:52567014	G/T	cg15147215	chr3:52552868	STAB1	-0.37	-6.67	-0.38	1.52e-10	Electroencephalogram traits;
CESC	cis	rs2735413	0.918	rs11643649	chr16:78081199	T/C	cg04733911	chr16:78082701	NA	-0.53	-9.01	-0.48	4.08e-17	Systolic blood pressure (alcohol consumption interaction);
CESC	cis	rs4588572	0.643	rs1864173	chr5:77691158	C/T	cg11547950	chr5:77652471	NA	0.45	5.71	0.33	3.06e-8	Triglycerides;
CESC	cis	rs7267979	0.844	rs6132824	chr20:25238173	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.72	11.88	0.59	2.27e-26	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs6460942	0.915	rs62448600	chr7:12454944	T/G	cg02935154	chr7:12443704	VWDE	-0.58	-6.16	-0.35	2.73e-9	Coronary artery disease;
CESC	trans	rs459571	0.635	rs379471	chr9:136890649	G/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.57	-7.3	-0.41	3.37e-12	Platelet distribution width;
CESC	cis	rs8078723	0.714	rs8070444	chr17:38151960	A/G	cg17467752	chr17:38218738	THRA	-0.56	-8.39	-0.46	3.01e-15	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CESC	cis	rs1153858	1.000	rs16942000	chr15:45633003	C/T	cg21132104	chr15:45694354	SPATA5L1	0.82	11.02	0.56	1.72e-23	Homoarginine levels;
CESC	cis	rs9457247	1.000	rs239935	chr6:167411788	G/A	cg25258033	chr6:167368657	RNASET2	0.4	6.08	0.35	4.07e-9	Crohn's disease;
CESC	cis	rs12142240	0.738	rs67545510	chr1:46806242	G/T	cg00530320	chr1:46809349	NSUN4	0.59	7.85	0.43	1.02e-13	Menopause (age at onset);
CESC	cis	rs2836950	0.501	rs4818019	chr21:40694456	T/A	cg11644478	chr21:40555479	PSMG1	-0.55	-7.42	-0.41	1.55e-12	Menarche (age at onset);
CESC	cis	rs56104184	0.615	rs73061693	chr19:49399941	C/A	cg15549821	chr19:49342101	PLEKHA4	-0.6	-5.99	-0.35	6.95e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	cis	rs4144743	1.000	rs34492688	chr17:45321622	C/A	cg18085866	chr17:45331354	ITGB3	-0.64	-7.03	-0.4	1.78e-11	Body mass index;
CESC	cis	rs6502050	0.835	rs11077971	chr17:80090629	A/G	cg23985595	chr17:80112537	CCDC57	-0.42	-6.59	-0.38	2.38e-10	Life satisfaction;
CESC	trans	rs507506	0.771	rs929229	chr17:7105399	C/T	cg15655154	chr3:113604241	GRAMD1C	0.64	8.65	0.47	4.97e-16	Adiponectin levels;
CESC	cis	rs1800795	0.599	rs1546762	chr7:22757503	C/T	cg05472934	chr7:22766657	IL6	0.52	6.9	0.39	3.81e-11	Cerebrospinal fluid clusterin levels in APOEe4- carriers;
CESC	cis	rs875971	0.522	rs4502988	chr7:65297746	A/G	cg11764359	chr7:65958608	NA	0.67	8.6	0.47	7.12e-16	Aortic root size;
CESC	cis	rs1707322	0.721	rs11211151	chr1:46112752	T/C	cg03146154	chr1:46216737	IPP	0.82	11.49	0.58	4.71e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs11599315	0.757	rs11250392	chr10:1342543	T/C	cg01270228	chr10:1369114	ADARB2	0.35	5.11	0.3	6.11e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs6500395	1.000	rs12597928	chr16:48714366	G/A	cg04672837	chr16:48644449	N4BP1	-0.51	-6.53	-0.37	3.33e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs2777491	0.957	rs3743038	chr15:41694743	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.66	-10.25	-0.53	5.55e-21	Ulcerative colitis;
CESC	trans	rs13035304	0.686	rs13005792	chr2:130508303	T/G	cg18827756	chr15:42130735	JMJD7-PLA2G4B;PLA2G4B	-0.45	-7.15	-0.4	8.33e-12	Age at smoking initiation in chronic obstructive pulmonary disease;
CESC	cis	rs831571	1.000	rs831571	chr3:64048297	A/G	cg16258503	chr3:63850278	ATXN7;THOC7	0.51	5.16	0.3	4.77e-7	Type 2 diabetes;
CESC	cis	rs4481887	0.927	rs4244181	chr1:248471118	A/G	cg00666640	chr1:248458726	OR2T12	0.4	6.57	0.37	2.7e-10	Common traits (Other);
CESC	cis	rs6460942	0.597	rs4721108	chr7:12535247	C/T	cg06484146	chr7:12443880	VWDE	-0.73	-7.77	-0.43	1.68e-13	Coronary artery disease;
CESC	cis	rs4727027	0.933	rs6955564	chr7:148866173	A/G	cg23583168	chr7:148888333	NA	-0.69	-10.42	-0.54	1.59e-21	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs6461049	0.765	rs4719432	chr7:2140330	A/G	cg23048001	chr7:2026167	MAD1L1	0.43	5.72	0.33	2.86e-8	Schizophrenia;
CESC	trans	rs1814175	0.645	rs866427	chr11:49923853	G/A	cg03929089	chr4:120376271	NA	-0.92	-15.2	-0.68	6e-38	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06349981	chr2:10443745	HPCAL1	0.63	6.94	0.39	3.01e-11	Gut microbiome composition (summer);
CESC	cis	rs847577	0.506	rs7808528	chr7:97721425	G/T	cg21770322	chr7:97807741	LMTK2	0.85	15.08	0.68	1.63e-37	Breast cancer;
CESC	cis	rs7589728	0.563	rs78168096	chr2:88473575	G/A	cg18490616	chr2:88469792	THNSL2	0.56	5.2	0.3	4.05e-7	Plasma clusterin levels;
CESC	cis	rs7264396	0.635	rs6060692	chr20:34517925	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.76	10.58	0.54	4.88e-22	Total cholesterol levels;
CESC	cis	rs2299587	0.554	rs2073562	chr8:17742929	A/G	cg08627089	chr8:17753878	FGL1	-0.4	-5.82	-0.34	1.67e-8	Economic and political preferences;
CESC	cis	rs7186908	0.711	rs9923344	chr16:72190653	T/C	cg16558253	chr16:72132732	DHX38	-0.44	-5.38	-0.31	1.6e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs6062302	0.545	rs2297430	chr20:62229244	T/C	cg06363034	chr20:62225388	GMEB2	-0.53	-6.81	-0.39	6.5e-11	Glioblastoma;
CESC	cis	rs13118159	0.725	rs71614967	chr4:1341291	A/G	cg05025164	chr4:1340916	KIAA1530	0.47	6.26	0.36	1.53e-9	Longevity;
CESC	cis	rs8060686	0.668	rs8048034	chr16:68210604	A/G	cg26727032	chr16:67993705	SLC12A4	-0.58	-8.22	-0.45	9.17e-15	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs17293817	0.618	rs35155296	chr10:1433333	C/T	cg04271617	chr10:1416546	ADARB2	0.33	5.05	0.3	8.19e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs6912958	0.781	rs4707379	chr6:88310623	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-5.07	-0.3	7.4e-7	Monocyte percentage of white cells;
CESC	cis	rs514406	0.861	rs562182	chr1:53270010	C/T	cg16325326	chr1:53192061	ZYG11B	0.9	15.28	0.68	3.2e-38	Monocyte count;
CESC	cis	rs9911578	1.000	rs3744108	chr17:56585872	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	-0.4	-5.42	-0.32	1.37e-7	Intelligence (multi-trait analysis);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg14063914	chr6:158588963	GTF2H5;SERAC1	-0.39	-6.04	-0.35	5.21e-9	Gambling;
CESC	cis	rs7089973	0.628	rs11196953	chr10:116607707	A/G	cg03647239	chr10:116582469	FAM160B1	0.43	5.35	0.31	1.94e-7	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs7312933	0.524	rs11181465	chr12:42765098	T/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.5	6.37	0.36	8.11e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs2997447	0.846	rs61775431	chr1:26411275	T/G	cg24596570	chr1:26146463	FAM54B;LOC646471	0.62	5.33	0.31	2.14e-7	QRS complex (12-leadsum);
CESC	cis	rs17253792	0.545	rs17745459	chr14:56008549	T/A	cg01858014	chr14:56050164	KTN1	-0.87	-6.66	-0.38	1.56e-10	Putamen volume;
CESC	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg22907277	chr7:1156413	C7orf50	0.42	5.89	0.34	1.15e-8	Longevity;Endometriosis;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg04874326	chr6:2634942	C6orf195	0.48	6.61	0.38	2.09e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs9811920	0.609	rs7638900	chr3:99670773	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.61	-9.74	-0.51	2.37e-19	Axial length;
CESC	trans	rs1814175	0.645	rs7395438	chr11:49877379	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.42	-6.16	-0.35	2.66e-9	Height;
CESC	cis	rs1799949	0.965	rs6503726	chr17:41284742	T/C	cg07153921	chr17:41440717	NA	-0.38	-5.18	-0.3	4.3e-7	Menopause (age at onset);
CESC	cis	rs6089829	0.926	rs1060491	chr20:61665817	C/A	cg08564027	chr20:61660810	NA	-0.91	-14.9	-0.68	6.89e-37	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs1046896	0.514	rs67735447	chr17:80823042	G/T	cg02711726	chr17:80685570	FN3KRP	-0.38	-5.07	-0.3	7.65e-7	Glycated hemoglobin levels;
CESC	cis	rs155076	0.625	rs4769159	chr13:21881978	A/C	cg25811766	chr13:21894605	NA	0.56	5.64	0.33	4.32e-8	White matter hyperintensity burden;
CESC	cis	rs524281	0.682	rs4483592	chr11:65990439	C/T	cg14036092	chr11:66035641	RAB1B	-0.53	-5.31	-0.31	2.38e-7	Electroencephalogram traits;
CESC	cis	rs344364	0.511	rs1742464	chr16:1947335	A/G	cg09830162	chr16:1889614	FAHD1;C16orf73	0.54	6.13	0.35	3.23e-9	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs10504229	0.817	rs78138632	chr8:58191341	G/T	cg05313129	chr8:58192883	C8orf71	-0.52	-5.32	-0.31	2.19e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs1448094	0.511	rs7976647	chr12:86158766	A/G	cg00310523	chr12:86230176	RASSF9	0.32	5.15	0.3	5.03e-7	Major depressive disorder;
CESC	cis	rs17376456	0.825	rs28534784	chr5:93063332	C/A	cg21475434	chr5:93447410	FAM172A	0.79	7.15	0.4	8.67e-12	Diabetic retinopathy;
CESC	cis	rs472109	0.900	rs491205	chr11:9767559	G/A	cg03108697	chr11:9732066	SWAP70	-0.35	-5.2	-0.3	3.96e-7	Coronary artery disease;
CESC	cis	rs11792861	0.888	rs72607168	chr9:111832192	G/C	cg05043794	chr9:111880884	C9orf5	-0.39	-6.39	-0.37	7.25e-10	Menarche (age at onset);
CESC	cis	rs910316	1.000	rs876403	chr14:75602834	A/T	cg16144293	chr14:75469539	EIF2B2	-0.39	-5.13	-0.3	5.63e-7	Height;
CESC	cis	rs67478160	0.619	rs11160761	chr14:104254856	A/T	cg01849466	chr14:104193079	ZFYVE21	-0.52	-7.31	-0.41	3.18e-12	Schizophrenia;
CESC	trans	rs2727020	0.894	rs3862342	chr11:49357043	C/T	cg03929089	chr4:120376271	NA	-0.64	-7.4	-0.41	1.82e-12	Coronary artery disease;
CESC	cis	rs10089	1.000	rs3805607	chr5:127477418	T/C	cg19767477	chr5:127420684	SLC12A2	-0.39	-5.34	-0.31	1.96e-7	Ileal carcinoids;
CESC	cis	rs4975709	0.569	rs2077269	chr5:1863506	C/T	cg20790798	chr5:1857306	NA	-0.41	-5.49	-0.32	9.32e-8	Cardiovascular disease risk factors;
CESC	cis	rs2708240	0.967	rs2247042	chr7:147580224	T/C	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.36	-5.99	-0.35	6.79e-9	QT interval (drug interaction);
CESC	cis	rs12142240	0.698	rs66911505	chr1:46823298	A/G	cg00530320	chr1:46809349	NSUN4	0.6	8.04	0.44	2.96e-14	Menopause (age at onset);
CESC	cis	rs910316	0.737	rs2098251	chr14:75492696	G/A	cg16144293	chr14:75469539	EIF2B2	-0.4	-5.32	-0.31	2.22e-7	Height;
CESC	cis	rs2760061	0.598	rs2796056	chr1:228122901	G/A	cg01973587	chr1:228161476	NA	0.39	5.99	0.35	6.64e-9	Diastolic blood pressure;
CESC	cis	rs798554	0.607	rs1182151	chr7:2909225	C/G	cg19717773	chr7:2847554	GNA12	-0.51	-6.46	-0.37	4.85e-10	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18706879	chr14:74353254	ZNF410	0.58	6.47	0.37	4.77e-10	Gut microbiome composition (summer);
CESC	cis	rs2836974	0.568	rs414850	chr21:40543337	A/C	cg11644478	chr21:40555479	PSMG1	0.83	12.75	0.62	2.36e-29	Cognitive function;
CESC	cis	rs8017423	0.845	rs114583024	chr14:90727628	T/C	cg14092571	chr14:90743983	NA	-0.55	-8.17	-0.45	1.24e-14	Mortality in heart failure;
CESC	cis	rs7811142	1.000	rs2406253	chr7:100077273	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.01	11.06	0.56	1.27e-23	Platelet count;
CESC	cis	rs4665809	0.590	rs13387855	chr2:26420708	T/G	cg25036284	chr2:26402008	FAM59B	-0.84	-9.66	-0.51	4.19e-19	Gut microbiome composition (summer);
CESC	cis	rs6674176	0.593	rs3791120	chr1:44431715	T/C	cg12908607	chr1:44402522	ARTN	-0.49	-6.92	-0.39	3.44e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs35955747	0.870	rs4820969	chr22:31773573	C/G	cg25791279	chr22:32026902	PISD	-0.47	-5.78	-0.33	2.08e-8	Neutrophil count;Sum basophil neutrophil counts;
CESC	cis	rs6430585	0.583	rs4988145	chr2:136632300	A/C	cg07169764	chr2:136633963	MCM6	1.31	20.14	0.78	2.38e-55	Corneal structure;
CESC	trans	rs61931739	0.534	rs7302688	chr12:34235064	A/G	cg26384229	chr12:38710491	ALG10B	0.65	9.25	0.49	7.67e-18	Morning vs. evening chronotype;
CESC	cis	rs9911578	0.935	rs34523895	chr17:57034095	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.38	5.12	0.3	5.86e-7	Intelligence (multi-trait analysis);
CESC	cis	rs4423214	0.592	rs10898223	chr11:71219264	G/A	cg24826892	chr11:71159390	DHCR7	-0.51	-5.15	-0.3	5.04e-7	Vitamin D levels;
CESC	cis	rs12497850	0.627	rs4974078	chr3:49009386	C/T	cg02487422	chr3:49467188	NICN1	0.42	5.74	0.33	2.59e-8	Parkinson's disease;
CESC	cis	rs2932538	0.922	rs2273369	chr1:113072477	A/G	cg22162597	chr1:113214053	CAPZA1	0.53	6.51	0.37	3.68e-10	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CESC	cis	rs6502050	0.835	rs9898697	chr17:80100498	A/G	cg23985595	chr17:80112537	CCDC57	-0.42	-6.59	-0.38	2.39e-10	Life satisfaction;
CESC	cis	rs742614	0.533	rs2747536	chr20:32404128	C/G	cg06304546	chr20:32448765	NA	-0.46	-5.78	-0.33	2.07e-8	Stearic acid (18:0) levels;
CESC	trans	rs8073060	0.586	rs225257	chr17:33956625	G/A	cg19694781	chr19:47549865	TMEM160	-0.73	-7.03	-0.4	1.79e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	cis	rs477692	0.905	rs509041	chr10:131424948	A/G	cg26102564	chr10:131424627	MGMT	0.36	5.39	0.31	1.52e-7	Response to temozolomide;
CESC	cis	rs7666738	0.830	rs28465658	chr4:99035866	T/C	cg03676636	chr4:99064102	C4orf37	0.33	5.12	0.3	6.01e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11577318	0.853	rs4526602	chr1:26648034	C/T	cg00852783	chr1:26633632	UBXN11	0.48	6.54	0.37	3.08e-10	Granulocyte percentage of myeloid white cells;
CESC	cis	rs6964587	1.000	rs3753108	chr7:91629984	T/G	cg17063962	chr7:91808500	NA	0.55	7.58	0.42	5.66e-13	Breast cancer;
CESC	cis	rs72781680	0.898	rs17762609	chr2:24114729	G/T	cg20701182	chr2:24300061	SF3B14	0.64	5.82	0.34	1.73e-8	Lymphocyte counts;
CESC	cis	rs28386778	0.799	rs12450683	chr17:61984299	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.98	17.62	0.73	1.61e-46	Prudent dietary pattern;
CESC	cis	rs3749237	0.595	rs10865955	chr3:49499829	G/A	cg02487422	chr3:49467188	NICN1	0.56	8.15	0.45	1.48e-14	Resting heart rate;
CESC	cis	rs9300255	0.550	rs10772997	chr12:123719880	C/A	cg00376283	chr12:123451042	ABCB9	0.67	9.01	0.48	4.2e-17	Neutrophil percentage of white cells;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26428032	chr11:67387935	NA	-0.52	-7.06	-0.4	1.49e-11	Gut microbiome composition (summer);
CESC	cis	rs714031	0.934	rs5750870	chr22:40067640	G/A	cg21377881	chr22:40064566	CACNA1I	-0.33	-5.25	-0.31	3.07e-7	Schizophrenia;
CESC	cis	rs60871478	0.898	rs62432897	chr7:825429	A/G	cg05535760	chr7:792225	HEATR2	0.94	10.78	0.55	1.05e-22	Cerebrospinal P-tau181p levels;
CESC	cis	rs896854	0.654	rs28716845	chr8:95974485	A/G	cg23172400	chr8:95962367	TP53INP1	-0.45	-9.25	-0.49	8.02e-18	Type 2 diabetes;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg12545570	chr21:27108482	ATP5J;GABPA	0.47	6.15	0.35	2.9e-9	Gut microbiota (bacterial taxa);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18916626	chr20:33265164	PIGU	0.57	6.53	0.37	3.42e-10	Gut microbiome composition (summer);
CESC	cis	rs4555082	0.830	rs2816648	chr14:105708289	C/T	cg27165867	chr14:105738592	BRF1	-0.53	-5.64	-0.33	4.44e-8	Mean platelet volume;Platelet distribution width;
CESC	cis	rs11048434	0.736	rs2377673	chr12:9112551	A/G	cg23795048	chr12:9217529	LOC144571	0.35	5.4	0.31	1.52e-7	Sjögren's syndrome;
CESC	cis	rs3916	0.662	rs2138249	chr12:121124142	A/C	cg26008908	chr12:120799332	MSI1	0.36	5.85	0.34	1.47e-8	Urinary metabolites (H-NMR features);
CESC	cis	rs10461617	0.592	rs6450403	chr5:56062737	A/C	cg18230493	chr5:56204884	C5orf35	-0.42	-5.04	-0.3	8.72e-7	Type 2 diabetes;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg00521863	chr2:171783942	NA	0.43	6.11	0.35	3.61e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg16681268	chr7:117067616	ASZ1	0.44	6.18	0.35	2.46e-9	Fibrinogen levels;
CESC	cis	rs801193	1.000	rs3800812	chr7:66223461	T/C	cg18876405	chr7:65276391	NA	0.54	7.06	0.4	1.5e-11	Aortic root size;
CESC	cis	rs13256369	1.000	rs4841016	chr8:8572561	C/T	cg17143192	chr8:8559678	CLDN23	0.75	8.9	0.48	8.72e-17	Obesity-related traits;
CESC	cis	rs7833790	0.660	rs67666182	chr8:82772037	A/G	cg17211192	chr8:82754475	SNX16	0.49	6.32	0.36	1.09e-9	Diastolic blood pressure;
CESC	cis	rs1387259	0.839	rs7486941	chr12:48578631	C/G	cg24011408	chr12:48396354	COL2A1	-0.45	-6.82	-0.39	6.1e-11	Obstructive sleep apnea trait (apnea hypopnea index);
CESC	cis	rs367615	0.704	rs7705399	chr5:108850351	G/C	cg17395555	chr5:108820864	NA	0.63	11.21	0.57	3.84e-24	Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs6120849	0.586	rs2025096	chr20:33540000	G/A	cg24642439	chr20:33292090	TP53INP2	0.69	6.83	0.39	5.7e-11	Protein C levels;
CESC	cis	rs763014	0.966	rs4144003	chr16:645968	C/T	cg07343612	chr16:622815	PIGQ	-0.55	-7.94	-0.44	5.64e-14	Height;
CESC	cis	rs9611519	0.828	rs28814423	chr22:41452301	G/A	cg03806693	chr22:41940476	POLR3H	-0.57	-5.92	-0.34	1.01e-8	Neuroticism;
CESC	cis	rs6460942	0.908	rs6948654	chr7:12418546	T/A	cg02935154	chr7:12443704	VWDE	-0.57	-6.42	-0.37	6.27e-10	Coronary artery disease;
CESC	cis	rs644799	1.000	rs509720	chr11:95562771	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	14.27	0.66	1.19e-34	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs10504229	1.000	rs116444534	chr8:58181915	A/G	cg22535103	chr8:58192502	C8orf71	-1.01	-12.77	-0.62	1.97e-29	Developmental language disorder (linguistic errors);
CESC	trans	rs35110281	0.837	rs7279958	chr21:45016016	C/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.5	6.6	0.38	2.26e-10	Mean corpuscular volume;
CESC	trans	rs116095464	0.558	rs2288459	chr5:231143	T/C	cg00938859	chr5:1591904	SDHAP3	0.63	6.87	0.39	4.48e-11	Breast cancer;
CESC	cis	rs7666738	0.830	rs7669407	chr4:98750251	G/A	cg17366294	chr4:99064904	C4orf37	0.57	7.98	0.44	4.33e-14	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17498856	chr1:1457042	ATAD3A	-0.6	-7.0	-0.4	2.13e-11	Gut microbiome composition (summer);
CESC	cis	rs787274	0.619	rs58643876	chr9:115627285	C/A	cg13803584	chr9:115635662	SNX30	-0.66	-5.84	-0.34	1.54e-8	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs7017914	0.935	rs7826483	chr8:71702893	T/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.42	-5.3	-0.31	2.38e-7	Bone mineral density;
CESC	cis	rs10504229	0.683	rs882429	chr8:58129292	A/G	cg02725872	chr8:58115012	NA	-0.45	-7.05	-0.4	1.52e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs9467711	0.606	rs9393710	chr6:26367833	A/G	cg12826209	chr6:26865740	GUSBL1	0.62	5.22	0.31	3.66e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs2979489	0.891	rs2979511	chr8:30394968	G/A	cg26383811	chr8:30366931	RBPMS	-0.81	-10.03	-0.52	2.89e-20	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CESC	cis	rs10461617	0.512	rs7715746	chr5:56048837	C/T	cg24549020	chr5:56110836	MAP3K1	0.43	5.09	0.3	6.95e-7	Type 2 diabetes;
CESC	cis	rs9611565	0.506	rs4822020	chr22:41700203	C/T	cg03806693	chr22:41940476	POLR3H	-0.78	-8.92	-0.48	7.96e-17	Vitiligo;
CESC	cis	rs2839186	0.708	rs6518285	chr21:47644667	T/C	cg11766577	chr21:47581405	C21orf56	-0.47	-6.43	-0.37	5.77e-10	Testicular germ cell tumor;
CESC	cis	rs6121246	0.909	rs6119651	chr20:30259246	G/T	cg13852791	chr20:30311386	BCL2L1	0.77	8.15	0.45	1.44e-14	Mean corpuscular hemoglobin;
CESC	cis	rs7618501	0.521	rs3796386	chr3:49899795	G/A	cg24308560	chr3:49941425	MST1R	-0.64	-9.29	-0.5	5.76e-18	Intelligence (multi-trait analysis);
CESC	cis	rs9926296	0.548	rs6500439	chr16:89808275	A/C	cg04287289	chr16:89883240	FANCA	0.93	16.27	0.71	9.74e-42	Vitiligo;
CESC	cis	rs10504229	1.000	rs17216957	chr8:58179893	C/T	cg24829409	chr8:58192753	C8orf71	-0.76	-10.0	-0.52	3.53e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs11958404	0.615	rs7717235	chr5:157447772	C/G	cg05962755	chr5:157440814	NA	0.38	5.67	0.33	3.75e-8	IgG glycosylation;
CESC	cis	rs78366141	0.649	rs61737091	chr4:89671721	C/T	cg01026744	chr4:89619053	NAP1L5;HERC3	0.75	5.34	0.31	1.97e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
CESC	cis	rs7605827	0.897	rs2380650	chr2:15533689	T/C	cg19274914	chr2:15703543	NA	0.36	6.59	0.38	2.3e-10	Educational attainment (years of education);
CESC	cis	rs12478296	0.792	rs6740738	chr2:243007368	A/C	cg06360820	chr2:242988706	NA	-0.73	-8.84	-0.48	1.36e-16	Obesity-related traits;
CESC	cis	rs7084402	0.905	rs7098329	chr10:60276915	C/T	cg07615347	chr10:60278583	BICC1	-0.59	-9.42	-0.5	2.24e-18	Refractive error;
CESC	cis	rs769267	0.965	rs7254230	chr19:19434350	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	-0.46	-5.69	-0.33	3.45e-8	Tonsillectomy;
CESC	cis	rs6500395	1.000	rs9931123	chr16:48614293	G/T	cg04672837	chr16:48644449	N4BP1	0.51	6.5	0.37	3.95e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26480745	chr17:7184899	SLC2A4	-0.58	-6.65	-0.38	1.69e-10	Gut microbiome composition (summer);
CESC	cis	rs4481887	0.708	rs6688853	chr1:248548006	G/A	cg26353448	chr1:248524236	OR2T4	-0.38	-5.37	-0.31	1.68e-7	Common traits (Other);
CESC	cis	rs11030122	0.702	rs995498	chr11:3967791	A/G	cg18678763	chr11:4115507	RRM1	-0.5	-6.64	-0.38	1.78e-10	Mean platelet volume;Platelet distribution width;
CESC	cis	rs6860806	0.603	rs112300250	chr5:131583292	G/A	cg11843238	chr5:131593191	PDLIM4	0.36	5.32	0.31	2.2e-7	Breast cancer;
CESC	cis	rs6142102	0.625	rs6141431	chr20:32540314	G/A	cg08999081	chr20:33150536	PIGU	0.33	5.08	0.3	7.27e-7	Skin pigmentation;
CESC	cis	rs1862618	0.853	rs832569	chr5:56154584	T/A	cg22800045	chr5:56110881	MAP3K1	0.83	9.95	0.52	4.88e-20	Initial pursuit acceleration;
CESC	cis	rs10504229	1.000	rs59071610	chr8:58186301	A/C	cg22535103	chr8:58192502	C8orf71	-1.05	-13.08	-0.63	1.71e-30	Developmental language disorder (linguistic errors);
CESC	cis	rs754466	0.580	rs10824573	chr10:79540969	T/C	cg17075019	chr10:79541650	NA	-0.88	-14.04	-0.65	7.39e-34	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs208520	0.837	rs208489	chr6:66927584	G/A	cg07460842	chr6:66804631	NA	-0.88	-10.57	-0.54	5.07e-22	Exhaled nitric oxide output;
CESC	cis	rs7923609	0.935	rs10995477	chr10:65010672	T/C	cg01631684	chr10:65280961	REEP3	-0.44	-5.51	-0.32	8.45e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs11098499	0.863	rs3775858	chr4:120486028	A/G	cg25214090	chr10:38739885	LOC399744	0.67	9.14	0.49	1.7e-17	Corneal astigmatism;
CESC	cis	rs3126085	0.877	rs11204968	chr1:152250211	A/T	cg03465714	chr1:152285911	FLG	-0.45	-5.56	-0.32	6.52e-8	Atopic dermatitis;
CESC	cis	rs9287719	0.967	rs728281	chr2:10750355	T/C	cg02196655	chr2:10830764	NOL10	-0.38	-5.79	-0.34	1.96e-8	Prostate cancer;
CESC	cis	rs8060686	0.641	rs7201742	chr16:68099821	T/G	cg26727032	chr16:67993705	SLC12A4	-0.53	-6.41	-0.37	6.68e-10	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs12936587	0.535	rs8065154	chr17:17614947	A/G	cg04398451	chr17:18023971	MYO15A	-0.38	-5.07	-0.3	7.36e-7	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
CESC	cis	rs8031584	0.958	rs7176569	chr15:31244495	G/T	cg14829155	chr15:31115871	NA	0.72	9.61	0.51	5.97e-19	Huntington's disease progression;
CESC	cis	rs703842	1.000	rs11172344	chr12:58193448	T/C	cg18357645	chr12:58087776	OS9	-0.39	-5.56	-0.32	6.57e-8	Multiple sclerosis;
CESC	cis	rs6831352	1.000	rs10017466	chr4:100055800	C/T	cg13256891	chr4:100009986	ADH5	0.63	7.47	0.42	1.19e-12	Alcohol dependence;
CESC	cis	rs763121	0.853	rs5757208	chr22:39049230	A/C	cg14440974	chr22:39074834	NA	-0.4	-5.49	-0.32	9.53e-8	Menopause (age at onset);
CESC	cis	rs12136530	0.651	rs12140654	chr1:19716801	C/T	cg01832549	chr1:19774989	CAPZB	-0.41	-5.72	-0.33	2.91e-8	Lead levels in blood;
CESC	cis	rs875971	1.000	rs12533997	chr7:65965377	A/G	cg11764359	chr7:65958608	NA	0.94	14.73	0.67	2.83e-36	Aortic root size;
CESC	cis	rs875971	0.893	rs62465470	chr7:65601218	T/C	cg11764359	chr7:65958608	NA	-0.79	-11.41	-0.57	8.63e-25	Aortic root size;
CESC	cis	rs13191362	1.000	rs7769686	chr6:163199467	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.95	9.17	0.49	1.4e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs1799949	1.000	rs4793229	chr17:41418334	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	-0.64	-8.54	-0.46	1.04e-15	Menopause (age at onset);
CESC	cis	rs6474412	1.000	rs7004381	chr8:42551161	A/G	cg25026480	chr8:42547641	NA	0.33	5.23	0.31	3.43e-7	Smoking behavior;
CESC	cis	rs7264396	0.635	rs6058358	chr20:34492560	A/T	cg17201900	chr20:34330562	RBM39	0.49	5.1	0.3	6.63e-7	Total cholesterol levels;
CESC	cis	rs17401966	1.000	rs17401924	chr1:10384439	A/G	cg15208524	chr1:10270712	KIF1B	0.49	6.3	0.36	1.25e-9	Hepatocellular carcinoma;
CESC	cis	rs548181	0.545	rs4486648	chr11:125610589	T/A	cg03464685	chr11:125439445	EI24	-0.69	-6.05	-0.35	5.02e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs9815354	1.000	rs1716676	chr3:41903208	T/C	cg03022575	chr3:42003672	ULK4	0.45	5.23	0.31	3.46e-7	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs34375054	0.573	rs12581367	chr12:125654641	T/C	cg25124228	chr12:125621409	AACS	-0.51	-5.66	-0.33	3.98e-8	Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs12912251	0.894	rs7183893	chr15:38996981	A/C	cg01338139	chr15:38987640	C15orf53	-0.51	-5.65	-0.33	4.06e-8	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
CESC	cis	rs3768617	0.510	rs1547712	chr1:183088013	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.89	14.36	0.66	5.49e-35	Fuchs's corneal dystrophy;
CESC	cis	rs1005277	0.540	rs2145487	chr10:38010077	A/G	cg25517755	chr10:38738941	LOC399744	-0.4	-5.13	-0.3	5.53e-7	Extrinsic epigenetic age acceleration;
CESC	cis	rs1862618	0.802	rs252900	chr5:56185281	T/A	cg24531977	chr5:56204891	C5orf35	-0.87	-10.87	-0.56	5.43e-23	Initial pursuit acceleration;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg07355693	chr12:125667907	NA	-0.4	-6.43	-0.37	5.99e-10	Gambling;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07511080	chr5:2749715	IRX2	-0.54	-6.67	-0.38	1.45e-10	Gut microbiome composition (summer);
CESC	cis	rs17601876	0.814	rs8042086	chr15:51561478	C/T	cg19946085	chr15:51559439	CYP19A1	-0.33	-5.37	-0.31	1.76e-7	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
CESC	cis	rs698833	0.852	rs698768	chr2:44576549	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.47	5.9	0.34	1.1e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs13064411	0.696	rs7613546	chr3:113228019	G/A	cg18753928	chr3:113234510	CCDC52	-0.5	-6.13	-0.35	3.23e-9	Response to simvastatin treatment (PCSK9 protein level change);
CESC	trans	rs7107217	1.000	rs1873872	chr11:129473993	A/T	cg15555402	chr12:19593456	AEBP2	0.47	6.31	0.36	1.15e-9	Breast cancer;Type 2 diabetes;
CESC	trans	rs7904368	0.901	rs7923189	chr10:16850214	C/T	cg14916108	chr12:2027993	CACNA2D4	-0.34	-6.06	-0.35	4.54e-9	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
CESC	cis	rs7615952	0.576	rs4646763	chr3:125822129	G/A	cg04553112	chr3:125709451	NA	-0.54	-5.82	-0.34	1.71e-8	Blood pressure (smoking interaction);
CESC	cis	rs6952808	0.929	rs34145223	chr7:1926237	G/A	cg00106254	chr7:1943704	MAD1L1	-0.47	-5.82	-0.34	1.7e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs6694270	0.529	rs12565650	chr1:19108355	G/A	cg19637330	chr1:19110922	NA	-0.52	-6.4	-0.37	6.86e-10	Drug-induced liver injury (nitrofurantoin);
CESC	cis	rs9303401	0.659	rs17741087	chr17:56550300	C/T	cg12560992	chr17:57184187	TRIM37	0.51	5.08	0.3	7.08e-7	Cognitive test performance;
CESC	cis	rs2637266	1.000	rs2395387	chr10:78357029	T/C	cg18941641	chr10:78392320	NA	0.42	7.79	0.43	1.49e-13	Pulmonary function;
CESC	cis	rs2842992	0.692	rs1128661	chr6:160211554	T/G	cg11366901	chr6:160182831	ACAT2	0.64	8.17	0.45	1.24e-14	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs1008375	0.966	rs6839660	chr4:17667987	C/T	cg16339924	chr4:17578868	LAP3	0.52	6.6	0.38	2.17e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs514406	0.621	rs881198	chr1:53196440	C/T	cg27535305	chr1:53392650	SCP2	0.32	5.14	0.3	5.39e-7	Monocyte count;
CESC	cis	rs875971	0.862	rs11769079	chr7:65842128	G/A	cg12463550	chr7:65579703	CRCP	0.49	6.26	0.36	1.56e-9	Aortic root size;
CESC	cis	rs7818382	0.967	rs7812465	chr8:96050557	C/T	cg23172400	chr8:95962367	TP53INP1	0.37	7.61	0.42	4.74e-13	Alzheimer's disease (late onset);
CESC	cis	rs731174	0.959	rs11264092	chr1:38190625	T/C	cg06917450	chr1:38156652	C1orf109	-0.43	-5.34	-0.31	1.97e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs10200159	1.000	rs3748955	chr2:55853470	G/C	cg13617705	chr2:55845095	SMEK2	0.7	5.22	0.31	3.53e-7	Vitiligo;
CESC	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg03647317	chr4:187891568	NA	-0.43	-6.69	-0.38	1.3100000000000001e-10	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg23074401	chr11:108535840	DDX10	-0.46	-6.56	-0.37	2.77e-10	Vertical cup-disc ratio;
CESC	cis	rs8180040	0.966	rs3736177	chr3:47451411	C/T	cg27129171	chr3:47204927	SETD2	-0.64	-9.86	-0.52	1e-19	Colorectal cancer;
CESC	cis	rs7829975	0.714	rs12544992	chr8:8661681	C/G	cg15556689	chr8:8085844	FLJ10661	0.45	5.71	0.33	3.03e-8	Mood instability;
CESC	trans	rs11098499	0.738	rs34566984	chr4:120361270	G/A	cg25214090	chr10:38739885	LOC399744	0.7	9.92	0.52	6.5e-20	Corneal astigmatism;
CESC	cis	rs1552244	0.882	rs13089863	chr3:10032259	G/T	cg00149659	chr3:10157352	C3orf10	-0.6	-6.31	-0.36	1.16e-9	Alzheimer's disease;
CESC	cis	rs863345	0.604	rs11264999	chr1:158488860	T/C	cg12129480	chr1:158549410	OR10X1	-0.36	-7.09	-0.4	1.2e-11	Pneumococcal bacteremia;
CESC	cis	rs1552244	0.872	rs115331527	chr3:10154504	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.85	-11.94	-0.59	1.36e-26	Alzheimer's disease;
CESC	cis	rs7647973	1.000	rs6783003	chr3:49524778	G/C	cg07636037	chr3:49044803	WDR6	-0.7	-9.53	-0.51	1.06e-18	Menarche (age at onset);
CESC	cis	rs6580649	1.000	rs6580647	chr12:48403229	G/T	cg24011408	chr12:48396354	COL2A1	-0.4	-5.46	-0.32	1.07e-7	Lung cancer;
CESC	cis	rs9329289	0.632	rs2452187	chr10:2551147	C/G	cg05625103	chr10:2543513	NA	0.52	7.16	0.4	7.91e-12	Age-related hearing impairment;
CESC	cis	rs116095464	0.558	rs55664502	chr5:270485	T/C	cg22496380	chr5:211416	CCDC127	-0.73	-8.47	-0.46	1.75e-15	Breast cancer;
CESC	cis	rs7615952	0.641	rs60839048	chr3:125807938	G/A	cg15145296	chr3:125709740	NA	-0.56	-5.97	-0.34	7.65e-9	Blood pressure (smoking interaction);
CESC	cis	rs7927771	1.000	rs7105282	chr11:47805614	C/A	cg18512352	chr11:47633146	NA	-0.61	-9.65	-0.51	4.46e-19	Subjective well-being;
CESC	cis	rs7312774	0.618	rs73385161	chr12:107300164	G/A	cg16260113	chr12:107380972	MTERFD3	0.64	6.12	0.35	3.43e-9	Severe influenza A (H1N1) infection;
CESC	cis	rs9715521	0.900	rs62301182	chr4:59834267	A/G	cg11281224	chr4:60001000	NA	-0.51	-6.74	-0.38	9.64e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12830119	chr14:100154292	CYP46A1	-0.55	-6.43	-0.37	5.77e-10	Gut microbiome composition (summer);
CESC	cis	rs4588572	0.570	rs2115433	chr5:77700363	C/T	cg11547950	chr5:77652471	NA	-0.4	-5.61	-0.33	5.13e-8	Triglycerides;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24460917	chr20:18269097	ZNF133	0.7	8.16	0.45	1.35e-14	Gut microbiome composition (summer);
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg08882774	chr16:28875105	SH2B1	-0.44	-6.03	-0.35	5.38e-9	Asthma;
CESC	cis	rs6952808	0.510	rs13227554	chr7:2048220	G/C	cg23048001	chr7:2026167	MAD1L1	-0.49	-6.39	-0.37	7.43e-10	Bipolar disorder and schizophrenia;
CESC	cis	rs9611519	0.929	rs9611469	chr22:41433319	T/C	cg03806693	chr22:41940476	POLR3H	-0.57	-5.94	-0.34	9.05e-9	Neuroticism;
CESC	cis	rs10751667	0.600	rs7950955	chr11:1011490	G/A	cg01483505	chr11:975446	AP2A2	0.43	5.55	0.32	7.09e-8	Alzheimer's disease (late onset);
CESC	cis	rs950776	0.518	rs12914694	chr15:78814444	G/A	cg06917634	chr15:78832804	PSMA4	0.78	11.4	0.57	9.32e-25	Sudden cardiac arrest;
CESC	cis	rs9815354	0.597	rs80066790	chr3:42000843	A/G	cg03022575	chr3:42003672	ULK4	0.64	5.83	0.34	1.62e-8	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs10504229	0.683	rs2873638	chr8:58114593	G/A	cg22535103	chr8:58192502	C8orf71	-0.81	-9.13	-0.49	1.82e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs4689388	0.856	rs1046314	chr4:6303955	A/G	cg25554036	chr4:6271136	WFS1	-0.53	-8.79	-0.48	1.89e-16	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs7772486	0.754	rs697054	chr6:146003770	C/T	cg05347473	chr6:146136440	FBXO30	0.55	6.82	0.39	6.21e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs11098499	0.909	rs28555550	chr4:120211040	C/G	cg24375607	chr4:120327624	NA	0.42	5.03	0.3	8.94e-7	Corneal astigmatism;
CESC	cis	rs1008375	1.000	rs10009541	chr4:17682218	C/T	cg16339924	chr4:17578868	LAP3	-0.56	-6.89	-0.39	4.17e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs523522	0.962	rs7136951	chr12:120941927	C/T	cg27279351	chr12:120934652	DYNLL1	0.69	8.94	0.48	6.79e-17	High light scatter reticulocyte count;
CESC	cis	rs1943345	1.000	rs1943345	chr11:82876270	G/T	cg07047830	chr11:82868014	PCF11	-0.57	-7.13	-0.4	9.57e-12	Obesity-related traits;
CESC	cis	rs9814567	1.000	rs13059720	chr3:134242021	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.45	6.08	0.35	4.21e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs6754311	0.517	rs1469995	chr2:136542559	G/A	cg07169764	chr2:136633963	MCM6	0.99	12.69	0.61	3.67e-29	Mosquito bite size;
CESC	cis	rs501120	1.000	rs671765	chr10:44752976	A/G	cg09554077	chr10:44749378	NA	0.5	6.28	0.36	1.4e-9	Coronary artery disease;Coronary heart disease;
CESC	cis	rs367943	0.712	rs27567	chr5:112741798	C/T	cg12552261	chr5:112820674	MCC	0.4	5.32	0.31	2.17e-7	Type 2 diabetes;
CESC	cis	rs3096299	0.685	rs4785571	chr16:89565169	A/G	cg02187348	chr16:89574699	SPG7	0.67	9.61	0.51	6.07e-19	Multiple myeloma (IgH translocation);
CESC	cis	rs4665809	0.590	rs35746418	chr2:26455002	C/G	cg04944784	chr2:26401820	FAM59B	0.96	10.55	0.54	5.79e-22	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03520265	chr6:138785472	NHSL1	-0.51	-6.42	-0.37	6.16e-10	Gut microbiome composition (summer);
CESC	cis	rs116988415	0.584	rs2269307	chr14:65245007	G/A	cg25083366	chr14:65239357	SPTB	0.71	5.23	0.31	3.44e-7	Daytime sleep phenotypes;
CESC	cis	rs597539	0.652	rs488363	chr11:68658298	C/G	cg01988459	chr11:68622903	NA	-0.39	-5.42	-0.32	1.31e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs13064411	0.696	rs9860549	chr3:113148368	G/A	cg18753928	chr3:113234510	CCDC52	-0.47	-5.56	-0.32	6.63e-8	Response to simvastatin treatment (PCSK9 protein level change);
CESC	trans	rs11992162	0.636	rs4841645	chr8:11798684	G/T	cg15556689	chr8:8085844	FLJ10661	-0.51	-6.29	-0.36	1.34e-9	Monocyte count;
CESC	cis	rs172166	0.611	rs203883	chr6:28078356	A/G	cg20151795	chr6:28129481	ZNF389	0.36	5.23	0.31	3.44e-7	Cardiac Troponin-T levels;
CESC	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	10.16	0.53	1.09e-20	Prudent dietary pattern;
CESC	cis	rs3092073	0.624	rs7275164	chr20:44604822	G/A	cg27529037	chr20:44575021	PCIF1	0.65	9.67	0.51	3.83e-19	Intelligence (multi-trait analysis);
CESC	cis	rs4975616	0.869	rs455433	chr5:1336243	A/G	cg26373071	chr5:1325741	CLPTM1L	0.43	6.88	0.39	4.26e-11	Lung cancer;
CESC	cis	rs7100689	0.646	rs11202751	chr10:82147802	G/A	cg00277334	chr10:82204260	NA	-0.58	-7.62	-0.42	4.52e-13	Post bronchodilator FEV1;
CESC	cis	rs1801251	1.000	rs6745879	chr2:233590007	A/G	cg25237894	chr2:233734115	C2orf82	0.48	8.19	0.45	1.08e-14	Coronary artery disease;
CESC	cis	rs7599312	0.534	rs10182996	chr2:213404834	T/C	cg20637307	chr2:213403960	ERBB4	0.57	8.92	0.48	7.78e-17	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg07092213	chr7:1199455	ZFAND2A	-0.48	-5.28	-0.31	2.67e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs769267	1.000	rs2301669	chr19:19453560	C/A	cg03709012	chr19:19516395	GATAD2A	-0.96	-14.11	-0.66	4.09e-34	Tonsillectomy;
CESC	trans	rs11021065	0.764	rs10765714	chr11:94913701	T/A	cg04819096	chr12:54339167	HOXC13	-0.24	-6.21	-0.36	2e-9	Common carotid intima-media thickness in HIV infection;Common carotid intima-media thickness;
CESC	cis	rs2404602	0.716	rs4886813	chr15:76838221	C/T	cg22467129	chr15:76604101	ETFA	0.36	5.53	0.32	7.66e-8	Blood metabolite levels;
CESC	cis	rs6087990	0.735	rs6058892	chr20:31388461	C/T	cg13636640	chr20:31349939	DNMT3B	0.77	12.28	0.6	9.43e-28	Ulcerative colitis;
CESC	cis	rs7824557	0.527	rs2736305	chr8:11237773	T/C	cg21775007	chr8:11205619	TDH	-0.53	-8.05	-0.44	2.85e-14	Retinal vascular caliber;
CESC	cis	rs644799	0.526	rs693172	chr11:95636618	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.48	6.37	0.36	8.28e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	trans	rs1814175	0.676	rs1721999	chr11:49917372	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.43	-6.36	-0.36	8.98e-10	Height;
CESC	trans	rs7615952	0.932	rs13325495	chr3:125637416	T/G	cg07211511	chr3:129823064	LOC729375	-1.11	-13.83	-0.65	3.93e-33	Blood pressure (smoking interaction);
CESC	cis	rs7666738	0.546	rs28444809	chr4:98916934	C/T	cg05340658	chr4:99064831	C4orf37	0.54	6.47	0.37	4.73e-10	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10214930	0.560	rs42089	chr7:27702940	C/T	cg05786569	chr7:27702416	HIBADH	-0.46	-6.04	-0.35	5.11e-9	Hypospadias;
CESC	trans	rs1029576	0.861	rs1029578	chr7:17065815	T/C	cg03113285	chr6:46098122	ENPP4	-0.42	-6.04	-0.35	5.16e-9	Residual cognition;
CESC	cis	rs4969178	0.965	rs2292642	chr17:76395430	C/T	cg20026190	chr17:76395443	PGS1	0.49	7.73	0.43	2.17e-13	HDL cholesterol levels;
CESC	trans	rs1814175	0.817	rs7109440	chr11:49966296	C/T	cg15704280	chr7:45808275	SEPT13	-1.03	-20.41	-0.78	2.75e-56	Height;
CESC	cis	rs244293	1.000	rs244296	chr17:53242878	A/G	cg19360675	chr17:53046073	COX11;STXBP4	-0.39	-5.05	-0.3	8.15e-7	Menarche (age at onset);
CESC	cis	rs9926296	0.605	rs3743859	chr16:89846050	A/G	cg21285383	chr16:89894308	SPIRE2	-0.3	-5.45	-0.32	1.13e-7	Vitiligo;
CESC	cis	rs1691799	0.899	rs1168314	chr12:66746937	A/G	cg16791601	chr12:66731901	HELB	-0.79	-14.43	-0.66	3.27e-35	White blood cell count (basophil);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg09365624	chr1:87597710	LOC339524	-0.47	-7.08	-0.4	1.26e-11	Gambling;
CESC	cis	rs2836974	0.865	rs34778912	chr21:40667037	T/G	cg11890956	chr21:40555474	PSMG1	1.17	21.55	0.8	3.39e-60	Cognitive function;
CESC	cis	rs4925386	0.765	rs6142737	chr20:60919800	C/G	cg22633769	chr20:60982531	CABLES2	0.53	5.53	0.32	7.56e-8	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs10876993	0.890	rs10783844	chr12:58098425	A/C	cg18357645	chr12:58087776	OS9	0.63	10.41	0.54	1.74e-21	Celiac disease or Rheumatoid arthritis;
CESC	cis	rs7923609	0.967	rs7085018	chr10:65286667	T/C	cg01631684	chr10:65280961	REEP3	-0.44	-5.53	-0.32	7.8e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7582720	1.000	rs74421437	chr2:203831252	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.36	0.41	2.34e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg03188948	chr7:1209495	NA	0.69	7.66	0.43	3.45e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2228479	0.764	rs11641201	chr16:89983276	T/C	cg04013166	chr16:89971882	TCF25	0.76	8.43	0.46	2.22e-15	Skin colour saturation;
CESC	cis	rs17711722	0.565	rs4717276	chr7:65294741	G/T	cg14393609	chr7:65229607	NA	0.48	6.55	0.37	2.89e-10	Calcium levels;
CESC	cis	rs1882538	0.569	rs11562036	chr7:133076862	T/C	cg10665199	chr7:133106180	EXOC4	0.58	8.03	0.44	3.29e-14	Intelligence (multi-trait analysis);
CESC	cis	rs887829	0.569	rs4294999	chr2:234635467	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.53	-7.32	-0.41	3e-12	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CESC	cis	rs6089829	0.925	rs6062396	chr20:61667949	T/C	cg08564027	chr20:61660810	NA	0.9	15.44	0.69	8.75e-39	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs10540	1.000	rs61876326	chr11:467368	A/G	cg03576123	chr11:487126	PTDSS2	-1.06	-10.99	-0.56	2.1e-23	Body mass index;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17482197	chr20:56285683	PMEPA1	0.58	6.28	0.36	1.37e-9	Gut microbiome composition (summer);
CESC	cis	rs3785574	0.962	rs2597632	chr17:61894739	A/T	cg06873352	chr17:61820015	STRADA	0.47	6.86	0.39	4.85e-11	Height;
CESC	cis	rs4450798	0.649	rs73137996	chr3:13771796	C/A	cg05589046	chr3:13742034	LOC285375	0.34	5.15	0.3	5e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06774618	chr1:24117530	LYPLA2	0.61	6.67	0.38	1.49e-10	Gut microbiome composition (summer);
CESC	cis	rs9322193	0.962	rs9767122	chr6:150104689	T/G	cg05861140	chr6:150128134	PCMT1	-0.36	-5.14	-0.3	5.22e-7	Lung cancer;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg08120044	chr21:42539440	BACE2	-0.49	-6.16	-0.35	2.69e-9	Ulcerative colitis;
CESC	cis	rs9910055	0.552	rs4793084	chr17:42317371	G/T	cg08499158	chr17:42289980	UBTF	0.49	6.06	0.35	4.68e-9	Total body bone mineral density;
CESC	cis	rs7666738	0.962	rs17027204	chr4:98997049	G/A	cg05340658	chr4:99064831	C4orf37	0.66	9.01	0.48	4.1e-17	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2280018	0.526	rs2966129	chr16:15152927	A/C	cg07549590	chr16:15018862	NA	0.59	9.62	0.51	5.55e-19	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs7917772	0.536	rs17783771	chr10:104410736	C/T	cg22532475	chr10:104410764	TRIM8	-0.43	-6.61	-0.38	2.06e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs7615952	0.736	rs11921945	chr3:125643719	A/G	cg05084668	chr3:125655381	ALG1L	-0.44	-5.28	-0.31	2.72e-7	Blood pressure (smoking interaction);
CESC	cis	rs6952808	0.595	rs3800917	chr7:2167939	A/G	cg08027265	chr7:2291960	NA	0.44	6.7	0.38	1.24e-10	Bipolar disorder and schizophrenia;
CESC	cis	rs13102973	0.965	rs6535050	chr4:135874115	A/C	cg14419869	chr4:135874104	NA	-0.38	-5.88	-0.34	1.24e-8	Subjective well-being;
CESC	cis	rs9309473	0.632	rs6546825	chr2:73592253	G/C	cg20560298	chr2:73613845	ALMS1	-0.44	-5.86	-0.34	1.39e-8	Metabolite levels;
CESC	cis	rs4253772	0.530	rs6008623	chr22:46710024	G/A	cg24881330	chr22:46731750	TRMU	0.78	6.83	0.39	5.79e-11	LDL cholesterol;Cholesterol, total;
CESC	cis	rs1348850	0.561	rs4893956	chr2:178373452	C/T	cg22681709	chr2:178499509	PDE11A	-0.5	-5.26	-0.31	2.97e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs60843830	1.000	rs4497901	chr2:239969	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.88	12.15	0.6	2.63e-27	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs9322193	0.923	rs17745062	chr6:150042215	T/A	cg04369109	chr6:150039330	LATS1	-0.39	-5.43	-0.32	1.28e-7	Lung cancer;
CESC	cis	rs4700695	0.545	rs29441	chr5:65509116	G/T	cg21114390	chr5:65439923	SFRS12	-0.47	-5.67	-0.33	3.82e-8	Facial morphology (factor 19);
CESC	cis	rs1372520	0.506	rs356198	chr4:90682504	C/T	cg15133208	chr4:90757351	SNCA	0.43	5.12	0.3	5.78e-7	Neuroticism;
CESC	trans	rs9852859	0.530	rs71316820	chr3:85958279	G/C	cg10416071	chr15:75628863	COMMD4	0.63	6.19	0.36	2.22e-9	Body mass index;
CESC	cis	rs3796352	0.881	rs13100714	chr3:53074824	T/G	cg12962167	chr3:53033115	SFMBT1	0.61	5.09	0.3	6.68e-7	Immune reponse to smallpox (secreted IL-2);
CESC	cis	rs6089829	0.962	rs6062776	chr20:61663736	A/G	cg03213289	chr20:61660250	NA	0.39	6.07	0.35	4.42e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg00080972	chr5:178986291	RUFY1	-0.47	-7.74	-0.43	2.12e-13	Lung cancer;
CESC	cis	rs4909189	1.000	rs62493650	chr7:158135570	G/T	cg24154853	chr7:158122151	PTPRN2	0.46	6.2	0.36	2.22e-9	Response to amphetamines;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg05415724	chr2:113033170	ZC3H6	-0.46	-6.0	-0.35	6.45e-9	Ulcerative colitis;
CESC	cis	rs6598163	0.700	rs12813179	chr12:132302228	C/G	cg10319629	chr12:132285459	NA	0.53	7.31	0.41	3.06e-12	Migraine;
CESC	cis	rs9733	0.596	rs6587516	chr1:150623221	C/T	cg18016565	chr1:150552671	MCL1	0.33	5.13	0.3	5.67e-7	Tonsillectomy;
CESC	cis	rs3733585	0.605	rs4697926	chr4:10124567	G/T	cg00071950	chr4:10020882	SLC2A9	0.64	9.79	0.52	1.64e-19	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs9901225	1	rs9901225	chr17:40755811	C/T	cg03582285	chr17:40700314	NA	-0.39	-5.74	-0.33	2.63e-8	Colorectal or endometrial cancer;
CESC	cis	rs7666738	0.546	rs10025064	chr4:98914060	A/G	cg05340658	chr4:99064831	C4orf37	0.6	7.49	0.42	1.06e-12	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10504229	0.683	rs7843919	chr8:58130792	T/C	cg24829409	chr8:58192753	C8orf71	-0.58	-7.2	-0.4	6.31e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs501120	1.000	rs487465	chr10:44758197	A/C	cg09554077	chr10:44749378	NA	0.52	6.91	0.39	3.59e-11	Coronary artery disease;Coronary heart disease;
CESC	cis	rs2204008	0.657	rs8186888	chr12:38334260	T/G	cg26384229	chr12:38710491	ALG10B	0.5	7.13	0.4	9.41e-12	Bladder cancer;
CESC	cis	rs9834373	0.853	rs2314126	chr3:78474658	A/C	cg06138941	chr3:78371609	NA	-0.44	-5.3	-0.31	2.45e-7	Protein quantitative trait loci;
CESC	cis	rs2180341	0.920	rs4472373	chr6:127705983	G/A	cg27446573	chr6:127587934	RNF146	1.04	14.9	0.68	6.79e-37	Breast cancer;
CESC	trans	rs4906172	0.773	rs941792	chr14:102514713	A/G	cg17920195	chr4:129149383	NA	-0.31	-6.08	-0.35	4.07e-9	Menopause (age at onset);
CESC	cis	rs4925325	1.000	rs4925325	chr20:60514224	G/A	cg23262073	chr20:60523788	NA	0.53	7.1	0.4	1.17e-11	Obesity-related traits;
CESC	cis	rs9303280	0.901	rs9303277	chr17:37976469	C/T	cg19468946	chr17:37922297	IKZF3	-0.38	-5.37	-0.31	1.73e-7	Self-reported allergy;
CESC	cis	rs870825	0.616	rs28608669	chr4:185632890	T/C	cg04058563	chr4:185651563	MLF1IP	0.63	6.91	0.39	3.51e-11	Blood protein levels;
CESC	cis	rs9487051	0.700	rs9400266	chr6:109596193	T/A	cg12927641	chr6:109611667	NA	-0.37	-5.5	-0.32	8.91e-8	Reticulocyte fraction of red cells;
CESC	cis	rs36051895	0.664	rs3780373	chr9:5098223	T/C	cg02405213	chr9:5042618	JAK2	-0.5	-6.27	-0.36	1.48e-9	Pediatric autoimmune diseases;
CESC	cis	rs7666738	0.830	rs4699588	chr4:98973789	A/G	cg03467027	chr4:99064603	C4orf37	0.43	5.4	0.31	1.49e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs116095464	1.000	rs1567956	chr5:315616	C/A	cg10591111	chr5:226296	SDHA	-0.62	-5.75	-0.33	2.5e-8	Breast cancer;
CESC	cis	rs56235845	0.796	rs13153019	chr5:176782218	T/C	cg17509989	chr5:176798049	RGS14	0.76	8.01	0.44	3.67e-14	Hemoglobin concentration;Hematocrit;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22727364	chr8:126443014	TRIB1	0.54	6.57	0.37	2.65e-10	Gut microbiome composition (summer);
CESC	cis	rs7249921	0.802	rs62111399	chr19:35668771	C/T	cg15419183	chr19:35660584	FXYD5	0.56	8.27	0.45	6.54e-15	Platelet count;
CESC	cis	rs11645898	0.935	rs11641721	chr16:72155241	G/A	cg14768367	chr16:72042858	DHODH	-0.66	-5.84	-0.34	1.56e-8	Blood protein levels;
CESC	cis	rs4727027	0.704	rs12704083	chr7:148909759	G/A	cg23583168	chr7:148888333	NA	-0.93	-16.23	-0.71	1.38e-41	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg17304635	chr2:2633447	NA	0.43	6.28	0.36	1.38e-9	Fibrinogen levels;
CESC	cis	rs9311474	0.607	rs11711421	chr3:52561779	C/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.3	5.54	0.32	7.43e-8	Electroencephalogram traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16196077	chr10:64028521	RTKN2	0.52	6.15	0.35	2.82e-9	Gut microbiome composition (summer);
CESC	cis	rs875971	0.666	rs13242072	chr7:65765988	A/G	cg11764359	chr7:65958608	NA	-0.67	-8.51	-0.46	1.32e-15	Aortic root size;
CESC	cis	rs72781680	0.752	rs72796130	chr2:23919740	T/C	cg08917208	chr2:24149416	ATAD2B	1.13	10.24	0.53	5.87e-21	Lymphocyte counts;
CESC	cis	rs7296418	0.738	rs1568428	chr12:123738876	A/G	cg05973401	chr12:123451056	ABCB9	-0.5	-6.5	-0.37	3.93e-10	Platelet count;
CESC	trans	rs2727020	0.704	rs2988340	chr11:49176057	C/T	cg03929089	chr4:120376271	NA	-0.76	-10.97	-0.56	2.56e-23	Coronary artery disease;
CESC	cis	rs4722166	0.532	rs1546763	chr7:22757843	G/A	cg05472934	chr7:22766657	IL6	0.52	6.9	0.39	3.81e-11	Lung cancer;
CESC	cis	rs2455799	0.613	rs2470549	chr3:15737698	T/C	cg16303742	chr3:15540471	COLQ	-0.36	-5.63	-0.33	4.5e-8	Mean platelet volume;
CESC	cis	rs4664304	0.629	rs17239981	chr2:160847667	C/T	cg03641300	chr2:160917029	PLA2R1	-0.43	-5.82	-0.34	1.69e-8	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs763121	0.853	rs926299	chr22:39095698	C/G	cg06544989	chr22:39130855	UNC84B	0.52	9.88	0.52	8.35e-20	Menopause (age at onset);
CESC	cis	rs13095912	1.000	rs1823238	chr3:185341970	G/A	cg11274856	chr3:185301563	NA	0.32	5.13	0.3	5.67e-7	Systolic blood pressure;
CESC	cis	rs651907	0.535	rs11707250	chr3:101509371	A/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.43	-5.78	-0.33	2.11e-8	Colorectal cancer;
CESC	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.48	-6.32	-0.36	1.09e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs9486719	1.000	rs3906199	chr6:97049899	C/A	cg06623918	chr6:96969491	KIAA0776	-0.83	-8.62	-0.47	6.02e-16	Migraine;Coronary artery disease;
CESC	cis	rs66887589	0.870	rs59590064	chr4:120539753	T/C	cg09307838	chr4:120376055	NA	-0.46	-6.27	-0.36	1.42e-9	Diastolic blood pressure;
CESC	cis	rs9649213	0.593	rs13246843	chr7:98002661	G/T	cg00277769	chr7:97922759	BAIAP2L1	-0.33	-5.41	-0.32	1.41e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs6831352	0.918	rs17218073	chr4:100055739	G/A	cg12011299	chr4:100065546	ADH4	-0.6	-6.62	-0.38	2.04e-10	Alcohol dependence;
CESC	cis	rs425277	0.606	rs2257182	chr1:2082566	C/T	cg24578937	chr1:2090814	PRKCZ	-0.32	-5.78	-0.33	2.07e-8	Height;
CESC	cis	rs2072732	0.861	rs12039132	chr1:2949355	C/T	cg15211996	chr1:2936768	ACTRT2	0.35	6.12	0.35	3.42e-9	Plateletcrit;
CESC	cis	rs9487051	0.837	rs932223	chr6:109586656	A/G	cg21918786	chr6:109611834	NA	-0.37	-5.53	-0.32	7.72e-8	Reticulocyte fraction of red cells;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00975115	chr16:30958403	FBXL19	-0.62	-6.46	-0.37	4.91e-10	Gut microbiome composition (summer);
CESC	cis	rs7561273	0.565	rs6545275	chr2:24331860	A/G	cg01493198	chr2:24299560	SF3B14	0.41	5.05	0.3	8.11e-7	Quantitative traits;
CESC	cis	rs6964587	0.692	rs6953256	chr7:91575417	C/T	cg17063962	chr7:91808500	NA	-0.45	-6.32	-0.36	1.13e-9	Breast cancer;
CESC	trans	rs1887596	0.624	rs9553858	chr13:27138472	A/G	cg19523213	chr12:21927973	KCNJ8	-0.36	-6.0	-0.35	6.41e-9	Facial morphology (factor 3, length of philtrum);
CESC	cis	rs13256369	0.951	rs13270852	chr8:8566853	A/G	cg18904891	chr8:8559673	CLDN23	0.69	7.94	0.44	5.6e-14	Obesity-related traits;
CESC	cis	rs858239	0.899	rs2268747	chr7:23313462	A/G	cg23682824	chr7:23144976	KLHL7	0.44	5.58	0.32	5.93e-8	Cerebrospinal fluid biomarker levels;
CESC	cis	rs6499255	0.951	rs11639947	chr16:69646122	C/T	cg15192750	chr16:69999425	NA	0.55	6.47	0.37	4.59e-10	IgE levels;
CESC	cis	rs698813	0.604	rs2340814	chr2:44490977	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	5.6	0.33	5.26e-8	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
CESC	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg04234412	chr22:24373322	LOC391322	0.52	7.14	0.4	9e-12	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs2710642	0.611	rs6705835	chr2:62870408	C/T	cg17519650	chr2:63277830	OTX1	0.45	5.32	0.31	2.24e-7	LDL cholesterol levels;LDL cholesterol;
CESC	cis	rs2337406	0.714	rs7152055	chr14:107227228	C/T	cg23076370	chr14:107095027	NA	-0.53	-5.15	-0.3	5.01e-7	Alzheimer's disease (late onset);
CESC	cis	rs10504229	0.817	rs10504230	chr8:58197150	A/G	cg24829409	chr8:58192753	C8orf71	0.64	7.44	0.42	1.37e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs11098499	0.779	rs28495013	chr4:120375831	A/C	cg24375607	chr4:120327624	NA	0.47	5.89	0.34	1.14e-8	Corneal astigmatism;
CESC	cis	rs7503807	0.905	rs62068345	chr17:78608040	C/T	cg09596252	chr17:78655493	RPTOR	0.52	7.66	0.43	3.49e-13	Obesity;
CESC	cis	rs12541635	0.966	rs11786829	chr8:107023752	C/G	cg10147462	chr8:107024639	NA	0.42	6.05	0.35	4.79e-9	Age of smoking initiation;
CESC	cis	rs12477438	1.000	rs6732980	chr2:99921613	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.61	-7.15	-0.4	8.59e-12	Chronic sinus infection;
CESC	cis	rs3733585	0.699	rs4621431	chr4:9947590	C/T	cg11266682	chr4:10021025	SLC2A9	-0.59	-10.12	-0.53	1.39e-20	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs116095464	0.558	rs28558836	chr5:285748	C/G	cg10591111	chr5:226296	SDHA	-0.52	-6.31	-0.36	1.17e-9	Breast cancer;
CESC	cis	rs6952808	0.692	rs6950627	chr7:2086672	C/T	cg04267008	chr7:1944627	MAD1L1	-0.62	-7.42	-0.41	1.57e-12	Bipolar disorder and schizophrenia;
CESC	cis	rs9894429	0.572	rs112417725	chr17:79578219	A/G	cg18240062	chr17:79603768	NPLOC4	-0.54	-7.18	-0.4	7.17e-12	Eye color traits;
CESC	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg24846343	chr22:24311635	DDTL	0.63	11.04	0.56	1.43e-23	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs4665809	0.590	rs7586047	chr2:26447335	A/G	cg27170947	chr2:26402098	FAM59B	-0.87	-9.87	-0.52	9.27e-20	Gut microbiome composition (summer);
CESC	cis	rs514406	0.825	rs6588441	chr1:53223494	G/A	cg16325326	chr1:53192061	ZYG11B	-0.89	-15.32	-0.69	2.26e-38	Monocyte count;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg06972998	chr10:76585851	MYST4	0.47	6.45	0.37	5.38e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs1552244	1.000	rs17032276	chr3:10076975	A/C	cg00166722	chr3:10149974	C3orf24	0.47	5.95	0.34	8.68e-9	Alzheimer's disease;
CESC	trans	rs2099077	0.867	rs12518613	chr5:102788222	C/T	cg07434438	chr16:72961899	ZFHX3	0.49	6.67	0.38	1.52e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs3812565	0.530	rs10781538	chr9:139320929	C/G	cg14019695	chr9:139328340	INPP5E	-0.34	-5.23	-0.31	3.39e-7	Granulocyte percentage of myeloid white cells;
CESC	cis	rs4523957	0.583	rs923864	chr17:2031507	C/T	cg16513277	chr17:2031491	SMG6	-0.79	-11.73	-0.58	6.95e-26	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs3008870	0.959	rs1886686	chr1:67390468	C/G	cg08660285	chr1:67390436	MIER1;WDR78	1.04	14.42	0.66	3.56e-35	Lymphocyte percentage of white cells;
CESC	trans	rs208520	0.874	rs208514	chr6:66945520	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.81	-9.4	-0.5	2.72e-18	Exhaled nitric oxide output;
CESC	cis	rs62103177	0.564	rs1715230	chr18:77848002	C/T	cg12964065	chr18:77638022	KCNG2	0.48	5.68	0.33	3.52e-8	Opioid sensitivity;
CESC	cis	rs7833986	0.501	rs9650314	chr8:56903610	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.58	7.09	0.4	1.2e-11	Height;
CESC	cis	rs477692	0.563	rs7079165	chr10:131430240	G/A	cg26102564	chr10:131424627	MGMT	-0.34	-5.09	-0.3	6.71e-7	Response to temozolomide;
CESC	cis	rs6860806	0.631	rs4705931	chr5:131588345	T/C	cg12564285	chr5:131593104	PDLIM4	0.4	6.06	0.35	4.61e-9	Breast cancer;
CESC	cis	rs472402	0.580	rs7720479	chr5:6640049	A/G	cg10789808	chr5:6633262	NSUN2;SRD5A1	-0.54	-7.03	-0.4	1.8e-11	Response to amphetamines;
CESC	cis	rs4721295	0.573	rs3779000	chr7:2181628	G/A	cg21782813	chr7:2030301	MAD1L1	0.49	6.96	0.39	2.69e-11	Schizophrenia, schizoaffective disorder or bipolar disorder;
CESC	cis	rs73206853	0.702	rs7960516	chr12:110529238	T/A	cg12870014	chr12:110450643	ANKRD13A	0.61	6.11	0.35	3.47e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs7666738	0.784	rs4699602	chr4:99034903	T/C	cg17366294	chr4:99064904	C4orf37	0.64	8.96	0.48	6.14e-17	Colonoscopy-negative controls vs population controls;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg18468176	chr14:95623969	FLJ45244;DICER1	-0.56	-7.32	-0.41	3.04e-12	Gut microbiota (bacterial taxa);
CESC	cis	rs12681288	0.823	rs2701906	chr8:1003316	T/C	cg04851639	chr8:1020857	NA	-0.34	-7.47	-0.42	1.14e-12	Schizophrenia;
CESC	cis	rs6951245	0.706	rs1133116	chr7:1195215	A/C	cg23708337	chr7:1209742	NA	0.5	5.41	0.32	1.38e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs6750047	0.515	rs13417487	chr2:38289162	G/T	cg07380506	chr2:38303506	CYP1B1	0.41	5.25	0.31	3.11e-7	Cutaneous malignant melanoma;Melanoma;
CESC	cis	rs751837	0.591	rs12100549	chr14:103417030	C/T	cg10087771	chr14:103399429	CDC42BPB	0.72	6.24	0.36	1.69e-9	Large B-cell lymphoma;
CESC	cis	rs72781680	0.898	rs12623333	chr2:24111823	T/G	cg20701182	chr2:24300061	SF3B14	0.64	5.79	0.34	1.97e-8	Lymphocyte counts;
CESC	cis	rs7084402	1.000	rs7084402	chr10:60265404	C/T	cg07615347	chr10:60278583	BICC1	0.56	8.65	0.47	5.12e-16	Refractive error;
CESC	trans	rs2018683	0.707	rs917215	chr7:28971367	C/T	cg19402173	chr7:128379420	CALU	-0.54	-7.23	-0.41	5.32e-12	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CESC	cis	rs6570726	0.935	rs7757387	chr6:145816726	G/T	cg05347473	chr6:146136440	FBXO30	0.49	6.68	0.38	1.39e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2032447	0.670	rs198834	chr6:26114372	G/A	cg03517284	chr6:25882590	NA	0.43	5.97	0.34	7.79e-9	Intelligence (multi-trait analysis);
CESC	cis	rs769267	0.965	rs2269873	chr19:19392401	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	7.34	0.41	2.56e-12	Tonsillectomy;
CESC	cis	rs4665809	1.000	rs12469163	chr2:26283587	T/C	cg22920501	chr2:26401640	FAM59B	-0.69	-8.46	-0.46	1.82e-15	Gut microbiome composition (summer);
CESC	cis	rs9584850	0.834	rs745639	chr13:99119279	C/T	cg20750642	chr13:99100586	FARP1	-0.38	-5.84	-0.34	1.54e-8	Neuroticism;
CESC	cis	rs875971	0.862	rs28470208	chr7:65584700	A/G	cg11764359	chr7:65958608	NA	-0.79	-11.05	-0.56	1.31e-23	Aortic root size;
CESC	cis	rs7811142	0.830	rs41280971	chr7:99954457	G/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.87	8.33	0.46	4.25e-15	Platelet count;
CESC	cis	rs12681366	0.708	rs3019279	chr8:95447905	G/C	cg13257157	chr8:95487014	RAD54B	0.38	5.14	0.3	5.25e-7	Nonsyndromic cleft lip with cleft palate;
CESC	cis	rs947211	0.846	rs708726	chr1:205762139	G/T	cg26354017	chr1:205819088	PM20D1	-0.46	-6.19	-0.36	2.22e-9	Parkinson's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17899198	chr3:127323650	MCM2	-0.53	-6.05	-0.35	4.95e-9	Gut microbiome composition (summer);
CESC	cis	rs9733	0.596	rs7412396	chr1:150666797	C/T	cg04414720	chr1:150670196	GOLPH3L	0.51	6.64	0.38	1.75e-10	Tonsillectomy;
CESC	cis	rs17362650	0.883	rs35744046	chr2:9662410	T/C	cg12832956	chr2:9616023	IAH1	-0.52	-5.11	-0.3	6.21e-7	Alcohol dependence (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06972998	chr10:76585851	MYST4	-0.63	-7.34	-0.41	2.57e-12	Gut microbiome composition (summer);
CESC	cis	rs9611565	0.571	rs7364123	chr22:42216326	A/G	cg03806693	chr22:41940476	POLR3H	-0.73	-8.88	-0.48	1.07e-16	Vitiligo;
CESC	trans	rs116095464	0.542	rs28650039	chr5:273954	C/A	cg00938859	chr5:1591904	SDHAP3	0.65	6.98	0.39	2.31e-11	Breast cancer;
CESC	cis	rs12824058	0.831	rs4759655	chr12:130815740	A/G	cg26677194	chr12:130822605	PIWIL1	-0.53	-6.99	-0.39	2.23e-11	Menopause (age at onset);
CESC	cis	rs5758511	0.637	rs5751244	chr22:42617411	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.57	8.44	0.46	2.14e-15	Birth weight;
CESC	cis	rs8038465	0.874	rs11072434	chr15:74002854	A/G	cg15420318	chr15:73925796	NPTN	-0.39	-5.52	-0.32	8.07e-8	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs9287719	0.967	rs3815521	chr2:10743654	G/C	cg02196655	chr2:10830764	NOL10	-0.38	-5.83	-0.34	1.61e-8	Prostate cancer;
CESC	cis	rs959260	0.925	rs1108355	chr17:73383913	A/T	cg20590849	chr17:73267439	MIF4GD	-0.61	-6.94	-0.39	3.07e-11	Systemic lupus erythematosus;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg19141861	chr12:120966964	COQ5	-0.44	-6.06	-0.35	4.7e-9	Fibrinogen levels;
CESC	trans	rs7307889	1.000	rs73047647	chr12:6011088	A/G	cg18407955	chr7:158110685	PTPRN2	-0.72	-6.32	-0.36	1.12e-9	Obesity-related traits;
CESC	cis	rs3733585	0.577	rs28558552	chr4:9964913	G/A	cg02734326	chr4:10020555	SLC2A9	-0.41	-5.54	-0.32	7.24e-8	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs7089973	0.604	rs7895830	chr10:116625776	A/G	cg23260525	chr10:116636907	FAM160B1	0.42	8.12	0.45	1.8e-14	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs6028335	0.502	rs8114962	chr20:37635979	A/G	cg27552599	chr20:37590471	DHX35	0.39	5.67	0.33	3.72e-8	Alcohol and nicotine co-dependence;
CESC	cis	rs4481887	0.927	rs12042598	chr1:248482016	C/T	cg00666640	chr1:248458726	OR2T12	0.35	5.71	0.33	3.09e-8	Common traits (Other);
CESC	cis	rs11098499	0.863	rs12498539	chr4:120468370	C/T	cg09307838	chr4:120376055	NA	0.9	12.48	0.61	1.95e-28	Corneal astigmatism;
CESC	cis	rs344364	0.511	rs2982452	chr16:1949511	G/A	cg26617929	chr16:1858877	NA	-0.49	-5.15	-0.3	5.09e-7	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs854765	0.893	rs712265	chr17:18008447	G/A	cg04398451	chr17:18023971	MYO15A	0.68	9.32	0.5	4.58e-18	Total body bone mineral density;
CESC	cis	rs7666738	0.830	rs6854594	chr4:99065312	A/T	cg17366294	chr4:99064904	C4orf37	0.61	8.61	0.47	6.69e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4535700	0.543	rs2174459	chr7:55991293	T/C	cg09872392	chr7:56161020	PHKG1	0.41	5.81	0.34	1.8e-8	Macular telangiectasia type 2;
CESC	cis	rs1707322	0.821	rs11211182	chr1:46240170	G/A	cg05343316	chr1:45956843	TESK2	0.49	5.92	0.34	9.7e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9910055	0.659	rs7216294	chr17:42251095	T/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.74	10.22	0.53	6.66e-21	Total body bone mineral density;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg11200644	chr18:72265018	LOC400657	0.48	6.32	0.36	1.11e-9	Systemic lupus erythematosus;
CESC	cis	rs916888	0.610	rs199454	chr17:44800110	G/A	cg15921436	chr17:44337874	NA	-0.44	-5.52	-0.32	8.23e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs2243480	1.000	rs6958420	chr7:65751171	A/G	cg12463550	chr7:65579703	CRCP	-0.74	-5.73	-0.33	2.74e-8	Diabetic kidney disease;
CESC	cis	rs2637266	0.783	rs864676	chr10:78509385	A/G	cg18941641	chr10:78392320	NA	0.43	8.41	0.46	2.58e-15	Pulmonary function;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01925393	chr1:24194307	FUCA1	0.53	6.1	0.35	3.71e-9	Gut microbiome composition (summer);
CESC	cis	rs7659604	0.540	rs11724322	chr4:122697850	A/T	cg19748678	chr4:122722346	EXOSC9	-0.45	-5.7	-0.33	3.15e-8	Type 2 diabetes;
CESC	trans	rs916888	0.773	rs169201	chr17:44790203	A/G	cg27125505	chr17:43679177	LOC644172	0.51	6.58	0.37	2.46e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs11608355	0.515	rs56244055	chr12:109936211	G/A	cg05360138	chr12:110035743	NA	0.82	8.85	0.48	1.27e-16	Neuroticism;
CESC	cis	rs2836974	0.565	rs34304022	chr21:40579619	G/A	cg11644478	chr21:40555479	PSMG1	0.77	8.09	0.45	2.11e-14	Cognitive function;
CESC	cis	rs6540559	0.673	rs17015218	chr1:209967915	A/G	cg23283495	chr1:209979779	IRF6	0.52	6.2	0.36	2.1e-9	Cleft lip with or without cleft palate;
CESC	cis	rs2228479	0.867	rs75110337	chr16:89962635	C/A	cg14709524	chr16:89940631	TCF25	0.72	5.45	0.32	1.16e-7	Skin colour saturation;
CESC	trans	rs9929218	0.911	rs1075959	chr16:68832750	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.64	-8.03	-0.44	3.21e-14	Colorectal cancer;
CESC	cis	rs2204008	0.643	rs1315347	chr12:38162494	C/T	cg26384229	chr12:38710491	ALG10B	-0.42	-5.74	-0.33	2.61e-8	Bladder cancer;
CESC	cis	rs9322193	0.923	rs11155674	chr6:150032247	T/C	cg07701084	chr6:150067640	NUP43	0.48	6.85	0.39	5.03e-11	Lung cancer;
CESC	cis	rs6695640	0.820	rs2489611	chr1:17759245	T/C	cg01904812	chr1:17746340	RCC2	0.34	5.09	0.3	6.69e-7	Mean platelet volume;
CESC	cis	rs2576037	0.583	rs892586	chr18:44560429	C/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.49	6.51	0.37	3.83e-10	Personality dimensions;
CESC	cis	rs9560113	0.573	rs61955236	chr13:112242861	G/A	cg10483660	chr13:112241077	NA	0.44	7.31	0.41	3.18e-12	Menarche (age at onset);
CESC	cis	rs2463822	1.000	rs7481995	chr11:62129312	G/C	cg06239285	chr11:62104954	ASRGL1	0.86	8.63	0.47	5.79e-16	Chronic obstructive pulmonary disease-related biomarkers;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg25774098	chr1:161359705	NA	-0.51	-6.1	-0.35	3.82e-9	Ulcerative colitis;
CESC	cis	rs4812048	0.649	rs6100319	chr20:57626568	A/C	cg14073986	chr20:57617431	SLMO2	0.84	7.18	0.4	6.92e-12	Mean platelet volume;
CESC	cis	rs1552244	0.882	rs68080705	chr3:10025743	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.87	11.31	0.57	1.8e-24	Alzheimer's disease;
CESC	cis	rs9527	0.590	rs3861984	chr10:104916980	T/C	cg04362960	chr10:104952993	NT5C2	0.44	5.42	0.32	1.34e-7	Arsenic metabolism;
CESC	cis	rs561341	1.000	rs550923	chr17:30327013	G/C	cg00745463	chr17:30367425	LRRC37B	-0.82	-7.51	-0.42	9.09e-13	Hip circumference adjusted for BMI;
CESC	cis	rs2404602	0.532	rs12591100	chr15:76700801	C/A	cg23625390	chr15:77176239	SCAPER	-0.36	-5.07	-0.3	7.5e-7	Blood metabolite levels;
CESC	cis	rs7980687	0.627	rs1727325	chr12:123698332	G/C	cg05973401	chr12:123451056	ABCB9	0.49	5.63	0.33	4.63e-8	Height;Educational attainment;Head circumference (infant);
CESC	cis	rs9487051	0.652	rs9372210	chr6:109601703	G/C	cg01475377	chr6:109611718	NA	-0.45	-7.12	-0.4	1e-11	Reticulocyte fraction of red cells;
CESC	cis	rs1832871	0.672	rs9457363	chr6:158777515	C/T	cg07165851	chr6:158734300	TULP4	0.48	5.09	0.3	6.94e-7	Height;
CESC	cis	rs6831352	0.703	rs4235435	chr4:100039578	C/T	cg12011299	chr4:100065546	ADH4	0.57	6.88	0.39	4.34e-11	Alcohol dependence;
CESC	cis	rs62229266	0.773	rs878606	chr21:37406692	G/A	cg12218747	chr21:37451666	NA	-0.46	-6.44	-0.37	5.46e-10	Mitral valve prolapse;
CESC	cis	rs9649213	0.593	rs2158553	chr7:97951131	G/A	cg00277769	chr7:97922759	BAIAP2L1	-0.34	-5.61	-0.33	4.97e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7267979	1.000	rs6138572	chr20:25435934	G/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.82	15.34	0.69	1.94e-38	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs55871839	0.708	rs4738733	chr8:59813760	T/C	cg07426533	chr8:59803705	TOX	-0.47	-7.01	-0.4	1.95e-11	Pneumonia;
CESC	cis	rs2952156	0.959	rs2952151	chr17:37828496	T/C	cg20243544	chr17:37824526	PNMT	0.63	7.86	0.43	9.51e-14	Asthma;
CESC	cis	rs9733	0.744	rs12758227	chr1:150844583	C/A	cg22823121	chr1:150693482	HORMAD1	-0.37	-5.45	-0.32	1.15e-7	Tonsillectomy;
CESC	cis	rs3793683	0.597	rs2182620	chr10:134590715	C/T	cg18305652	chr10:134549665	INPP5A	0.48	6.82	0.39	6.13e-11	Migraine;
CESC	cis	rs7666738	0.830	rs13148363	chr4:98847498	T/C	cg17366294	chr4:99064904	C4orf37	0.51	6.87	0.39	4.61e-11	Colonoscopy-negative controls vs population controls;
CESC	cis	rs55728055	0.661	rs62237772	chr22:31964975	A/C	cg01338084	chr22:32026380	PISD	1.29	8.76	0.47	2.44e-16	Age-related hearing impairment;
CESC	cis	rs681343	1.000	rs516316	chr19:49206145	C/G	cg21064579	chr19:49206444	FUT2	0.52	7.45	0.42	1.3e-12	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
CESC	cis	rs9929218	0.954	rs2059254	chr16:68817439	C/T	cg02972257	chr16:68554789	NA	0.45	5.5	0.32	9.12e-8	Colorectal cancer;
CESC	cis	rs477895	0.713	rs2282490	chr11:63962152	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.95	10.43	0.54	1.45e-21	Mean platelet volume;
CESC	cis	rs4683142	0.518	rs4682811	chr3:46164795	A/G	cg18004856	chr3:46029278	FYCO1	0.42	5.05	0.3	8.18e-7	Methadone dose in opioid dependence;
CESC	cis	rs3008870	1.000	rs3008853	chr1:67385488	C/T	cg08660285	chr1:67390436	MIER1;WDR78	1.06	14.96	0.68	4.41e-37	Lymphocyte percentage of white cells;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg00177013	chr20:62339100	ARFRP1;ZGPAT	-0.43	-6.41	-0.37	6.82e-10	Gambling;
CESC	cis	rs6540556	0.723	rs6540551	chr1:209925295	C/T	cg05527609	chr1:210001259	C1orf107	-0.47	-5.73	-0.33	2.7e-8	Red blood cell count;
CESC	cis	rs4665809	0.590	rs3792007	chr2:26497541	C/T	cg27170947	chr2:26402098	FAM59B	0.81	8.91	0.48	8.12e-17	Gut microbiome composition (summer);
CESC	cis	rs875971	0.862	rs2420174	chr7:65645361	C/T	cg10691866	chr7:65817282	TPST1	0.31	5.24	0.31	3.34e-7	Aortic root size;
CESC	cis	rs4713118	0.662	rs9468271	chr6:28024570	A/G	cg23281280	chr6:28129359	ZNF389	0.49	6.54	0.37	3.24e-10	Parkinson's disease;
CESC	cis	rs561341	1.000	rs564714	chr17:30318404	C/T	cg19193384	chr17:30244184	NA	-0.71	-6.61	-0.38	2.14e-10	Hip circumference adjusted for BMI;
CESC	cis	rs7408868	1.000	rs7254735	chr19:15263385	A/G	cg14696996	chr19:15285081	NOTCH3	1.0	10.51	0.54	7.9e-22	Pulse pressure;
CESC	cis	rs4665809	0.590	rs1560865	chr2:26452197	C/A	cg27170947	chr2:26402098	FAM59B	-0.87	-10.16	-0.53	1.05e-20	Gut microbiome composition (summer);
CESC	cis	rs3820068	0.603	rs35509554	chr1:15993514	C/T	cg13390004	chr1:15929781	NA	0.33	5.24	0.31	3.36e-7	Systolic blood pressure;
CESC	cis	rs7264396	0.790	rs2425083	chr20:34300456	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.86	-11.69	-0.58	9.64e-26	Total cholesterol levels;
CESC	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg07677032	chr17:61819896	STRADA	0.44	5.84	0.34	1.5e-8	Prudent dietary pattern;
CESC	cis	rs1008375	0.900	rs7658447	chr4:17579415	T/C	cg27347728	chr4:17578864	LAP3	0.49	5.56	0.32	6.68e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs1153858	1.000	rs11852800	chr15:45639131	A/G	cg10760299	chr15:45669010	GATM	-0.39	-5.17	-0.3	4.55e-7	Homoarginine levels;
CESC	cis	rs7824557	0.767	rs28507159	chr8:11166076	C/T	cg21775007	chr8:11205619	TDH	0.5	7.27	0.41	4e-12	Retinal vascular caliber;
CESC	cis	rs12477438	0.798	rs6542849	chr2:99578493	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.7	-10.22	-0.53	6.79e-21	Chronic sinus infection;
CESC	cis	rs7666738	0.830	rs2903154	chr4:99048151	A/G	cg05340658	chr4:99064831	C4orf37	0.8	12.39	0.61	3.91e-28	Colonoscopy-negative controls vs population controls;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg00894870	chr1:19578612	MRTO4;KIAA0090	0.5	6.48	0.37	4.47e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs60871478	0.636	rs73045423	chr7:893952	G/A	cg05535760	chr7:792225	HEATR2	-0.78	-8.24	-0.45	8.16e-15	Cerebrospinal P-tau181p levels;
CESC	cis	rs7084402	0.967	rs1658463	chr10:60298208	C/T	cg07615347	chr10:60278583	BICC1	0.6	9.46	0.5	1.77e-18	Refractive error;
CESC	trans	rs28549925	0.590	rs28376061	chr7:16990425	G/A	cg12639933	chr12:57626296	SHMT2	0.95	6.1	0.35	3.83e-9	Congenital heart disease (maternal effect);Conotruncal heart defects (maternal effects);
CESC	cis	rs4665809	0.618	rs7579199	chr2:26266496	G/A	cg04944784	chr2:26401820	FAM59B	-0.65	-7.35	-0.41	2.42e-12	Gut microbiome composition (summer);
CESC	cis	rs9291683	0.530	rs10939620	chr4:9946132	C/T	cg11266682	chr4:10021025	SLC2A9	-0.59	-11.76	-0.59	5.89e-26	Bone mineral density;
CESC	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg14893161	chr1:205819251	PM20D1	0.5	7.37	0.41	2.16e-12	Menarche (age at onset);
CESC	cis	rs6088580	0.609	rs6058029	chr20:32969643	T/C	cg06115741	chr20:33292138	TP53INP2	-0.46	-5.96	-0.34	7.8e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs6430585	0.528	rs115553816	chr2:136692893	G/A	cg07169764	chr2:136633963	MCM6	1.26	17.43	0.73	7.33e-46	Corneal structure;
CESC	cis	rs2625529	0.617	rs13858	chr15:72433144	C/T	cg16672083	chr15:72433130	SENP8	-0.33	-5.15	-0.3	5.12e-7	Red blood cell count;
CESC	trans	rs1977584	0.725	rs17507956	chr10:45401394	C/T	cg09262100	chr14:103416268	CDC42BPB	0.61	6.14	0.35	3.02e-9	Selective IgA deficiency;
CESC	cis	rs7618915	0.547	rs34173654	chr3:52634605	T/C	cg18099408	chr3:52552593	STAB1	-0.32	-5.36	-0.31	1.78e-7	Bipolar disorder;
CESC	cis	rs864537	0.676	rs1773561	chr1:167421951	C/T	cg22356347	chr1:167427500	CD247	-0.39	-8.05	-0.44	2.81e-14	Celiac disease or Rheumatoid arthritis;Celiac disease;
CESC	cis	rs4819052	0.851	rs7276103	chr21:46666078	G/A	cg11663144	chr21:46675770	NA	-0.49	-7.42	-0.41	1.57e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs8177253	0.761	rs1830083	chr3:133508551	G/A	cg18769074	chr3:133464867	TF	0.31	5.58	0.32	5.89e-8	Iron status biomarkers;
CESC	cis	rs9815354	1.000	rs6802340	chr3:41894034	T/C	cg03022575	chr3:42003672	ULK4	0.45	5.23	0.31	3.48e-7	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs736408	0.634	rs11717836	chr3:52807736	A/G	cg05564831	chr3:52568323	NT5DC2	0.42	6.14	0.35	3.04e-9	Bipolar disorder;
CESC	cis	rs752010	0.695	rs10890155	chr1:42107843	C/T	cg06885757	chr1:42089581	HIVEP3	0.49	7.87	0.44	9.35e-14	Lupus nephritis in systemic lupus erythematosus;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg22766368	chr14:105119774	NA	-0.41	-6.11	-0.35	3.55e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs13095912	0.752	rs9758141	chr3:185315085	A/T	cg11274856	chr3:185301563	NA	0.4	6.07	0.35	4.38e-9	Systolic blood pressure;
CESC	trans	rs9987353	0.840	rs329994	chr8:9123233	A/G	cg19972591	chr12:120966863	COQ5	-0.47	-6.05	-0.35	4.97e-9	Recombination measurement;
CESC	cis	rs1707322	0.893	rs9919275	chr1:46441360	A/C	cg05343316	chr1:45956843	TESK2	0.44	5.42	0.32	1.36e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs12410462	1.000	rs76233861	chr1:227673909	G/A	cg23173402	chr1:227635558	NA	0.58	5.64	0.33	4.34e-8	Major depressive disorder;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg11726039	chr2:208490019	FAM119A	-0.5	-6.56	-0.37	2.83e-10	Fibrinogen levels;
CESC	cis	rs863345	0.604	rs2051450	chr1:158464062	A/G	cg12129480	chr1:158549410	OR10X1	-0.35	-6.97	-0.39	2.46e-11	Pneumococcal bacteremia;
CESC	cis	rs6430585	0.527	rs62168833	chr2:136449254	G/A	cg07169764	chr2:136633963	MCM6	1.09	12.56	0.61	1.07e-28	Corneal structure;
CESC	cis	rs965469	0.947	rs6051692	chr20:3244098	T/C	cg25506879	chr20:3388711	C20orf194	-0.61	-6.45	-0.37	5.27e-10	IFN-related cytopenia;
CESC	cis	rs2235642	0.928	rs9932984	chr16:1605051	A/G	cg03771183	chr16:1608904	IFT140	0.42	6.16	0.35	2.62e-9	Coronary artery disease;
CESC	cis	rs7264396	0.690	rs2425170	chr20:34442672	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.88	-11.53	-0.58	3.36e-25	Total cholesterol levels;
CESC	cis	rs763121	0.853	rs6519119	chr22:38989007	C/G	cg14440974	chr22:39074834	NA	-0.4	-5.29	-0.31	2.61e-7	Menopause (age at onset);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg26602477	chr1:1476845	C1orf70	-0.45	-6.04	-0.35	5.09e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs11997175	0.653	rs4268089	chr8:33626532	G/A	ch.8.33884649F	chr8:33765107	NA	0.54	6.78	0.38	7.65e-11	Body mass index;
CESC	cis	rs4268898	0.552	rs4665663	chr2:24372139	G/C	cg20701182	chr2:24300061	SF3B14	-0.39	-5.32	-0.31	2.23e-7	Asthma;
CESC	cis	rs13191362	1.000	rs13210412	chr6:163019478	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.79	8.15	0.45	1.43e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08028037	chr13:52027479	INTS6	0.56	6.97	0.39	2.58e-11	Gut microbiome composition (summer);
CESC	cis	rs1707322	1.000	rs785493	chr1:46584859	A/G	cg03146154	chr1:46216737	IPP	-0.74	-9.64	-0.51	4.75e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs67311347	1.000	rs7636719	chr3:40432084	C/T	cg24209194	chr3:40518798	ZNF619	0.47	6.07	0.35	4.32e-9	Renal cell carcinoma;
CESC	cis	rs17433780	0.612	rs7911	chr1:89518120	A/G	cg09516651	chr1:89888402	LOC400759	0.59	8.86	0.48	1.19e-16	Carotid intima media thickness;
CESC	cis	rs6840258	1.000	rs10516788	chr4:87960857	A/G	cg08197287	chr4:87952173	AFF1	-0.39	-5.28	-0.31	2.65e-7	Mean corpuscular volume;Basophil percentage of granulocytes;
CESC	cis	rs1008375	1.000	rs7688682	chr4:17693794	A/G	cg16339924	chr4:17578868	LAP3	-0.59	-7.29	-0.41	3.49e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs10504229	0.906	rs7006539	chr8:58178799	A/T	cg22535103	chr8:58192502	C8orf71	-1.07	-13.52	-0.64	5.05e-32	Developmental language disorder (linguistic errors);
CESC	cis	rs1185460	0.967	rs1786684	chr11:118938435	G/A	cg01677386	chr11:118938358	VPS11	-0.44	-5.68	-0.33	3.61e-8	Coronary artery disease;
CESC	cis	rs6952808	1.000	rs4449693	chr7:1884630	G/C	cg21782813	chr7:2030301	MAD1L1	0.41	5.61	0.33	5.17e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs6060717	0.536	rs17432470	chr20:34547763	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-6.66	-0.38	1.58e-10	Hip circumference adjusted for BMI;
CESC	cis	rs5769765	0.955	rs9616394	chr22:50314927	G/C	cg26441486	chr22:50317300	CRELD2	0.43	5.16	0.3	4.75e-7	Schizophrenia;
CESC	cis	rs9948	0.786	rs62156225	chr2:97414118	T/C	cg01990225	chr2:97406019	LMAN2L	-0.96	-7.6	-0.42	5.16e-13	Erectile dysfunction and prostate cancer treatment;
CESC	cis	rs9311474	0.507	rs6787154	chr3:52784416	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	8.01	0.44	3.7e-14	Electroencephalogram traits;
CESC	cis	rs113835537	0.569	rs17496586	chr11:66315512	G/C	cg24851651	chr11:66362959	CCS	0.55	6.39	0.37	7.32e-10	Airway imaging phenotypes;
CESC	cis	rs10876993	0.890	rs812304	chr12:58074853	A/C	cg18357645	chr12:58087776	OS9	0.65	10.63	0.55	3.37e-22	Celiac disease or Rheumatoid arthritis;
CESC	cis	rs6426558	0.502	rs2813970	chr1:227410637	C/T	cg10327440	chr1:227177885	CDC42BPA	0.49	6.21	0.36	2.01e-9	Neutrophil percentage of white cells;
CESC	cis	rs796364	1.000	rs4263095	chr2:200830137	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.88	-9.14	-0.49	1.72e-17	Schizophrenia;
CESC	cis	rs2404602	0.716	rs12592171	chr15:76755133	G/C	cg26408565	chr15:76604113	ETFA	-0.43	-6.25	-0.36	1.65e-9	Blood metabolite levels;
CESC	cis	rs3820068	0.544	rs7551750	chr1:16035008	T/C	cg13390004	chr1:15929781	NA	0.33	5.13	0.3	5.64e-7	Systolic blood pressure;
CESC	cis	rs1008375	1.000	rs3933453	chr4:17636319	A/C	cg04450456	chr4:17643702	FAM184B	0.38	5.35	0.31	1.87e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs10206020	0.842	rs7590900	chr2:1574902	A/G	cg12573674	chr2:1569213	NA	-0.46	-5.2	-0.3	3.96e-7	IgG glycosylation;
CESC	cis	rs2370759	1.000	rs2769241	chr10:32556229	T/C	cg18270830	chr10:32634957	EPC1	-0.72	-6.61	-0.38	2.06e-10	Sexual dysfunction (female);
CESC	cis	rs2486288	0.656	rs12908581	chr15:45548635	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.44	-5.28	-0.31	2.74e-7	Glomerular filtration rate;
CESC	cis	rs4764487	0.760	rs4764486	chr12:6327989	A/G	cg08284733	chr12:6341482	CD9	0.4	6.08	0.35	4.14e-9	Mean platelet volume;
CESC	cis	rs11112613	0.713	rs2374502	chr12:105938939	T/C	cg03607813	chr12:105948248	NA	0.66	8.07	0.44	2.54e-14	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20683454	chr8:124412914	NA	-0.43	-6.06	-0.35	4.63e-9	Gut microbiome composition (summer);
CESC	cis	rs8114671	0.935	rs633198	chr20:33778434	T/C	cg24642439	chr20:33292090	TP53INP2	-0.42	-5.04	-0.3	8.77e-7	Height;
CESC	cis	rs875971	0.862	rs7782704	chr7:65805366	G/A	cg11764359	chr7:65958608	NA	-0.8	-11.89	-0.59	2.01e-26	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14469191	chr9:68380472	NA	-0.45	-6.06	-0.35	4.56e-9	Gut microbiome composition (summer);
CESC	cis	rs9457247	0.967	rs86755	chr6:167403108	T/C	cg25258033	chr6:167368657	RNASET2	0.4	5.98	0.34	7.15e-9	Crohn's disease;
CESC	trans	rs743002	0.554	rs113784934	chr22:41377326	G/A	cg21776993	chr19:1449424	APC2	-0.66	-6.22	-0.36	1.93e-9	Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;Eosinophil counts;
CESC	cis	rs9487051	0.714	rs1546722	chr6:109625797	A/G	cg12927641	chr6:109611667	NA	-0.36	-5.26	-0.31	3e-7	Reticulocyte fraction of red cells;
CESC	cis	rs10751667	1.000	rs4074232	chr11:977682	C/G	cg20946044	chr11:1010712	AP2A2	-0.44	-5.91	-0.34	1.07e-8	Alzheimer's disease (late onset);
CESC	cis	rs10823500	0.748	rs2394668	chr10:71943951	G/A	cg02100629	chr10:71892760	AIFM2	-0.34	-5.24	-0.31	3.33e-7	Blood protein levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10757027	chr7:150783788	AGAP3	0.52	6.36	0.36	8.6e-10	Gut microbiome composition (summer);
CESC	cis	rs9303401	0.703	rs9911583	chr17:57210721	A/G	cg12560992	chr17:57184187	TRIM37	-0.44	-5.23	-0.31	3.39e-7	Cognitive test performance;
CESC	cis	rs72781680	0.611	rs72781696	chr2:24267014	C/T	cg20701182	chr2:24300061	SF3B14	0.94	10.66	0.55	2.67e-22	Lymphocyte counts;
CESC	cis	rs1942	1.000	rs1942	chr15:41774423	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.53	-7.42	-0.41	1.58e-12	Eosinophil percentage of granulocytes;
CESC	cis	rs7666738	0.678	rs7670805	chr4:99008763	A/G	cg18180107	chr4:99064573	C4orf37	0.4	5.23	0.31	3.41e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs35110281	0.627	rs7282704	chr21:44966253	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.57	7.55	0.42	7.17e-13	Mean corpuscular volume;
CESC	cis	rs1163251	0.902	rs639761	chr1:120217558	G/A	cg19096424	chr1:120255104	PHGDH	0.43	5.22	0.31	3.62e-7	Blood metabolite levels;
CESC	cis	rs7927592	0.913	rs10896338	chr11:68299360	G/A	cg20283391	chr11:68216788	NA	-0.62	-7.44	-0.42	1.42e-12	Total body bone mineral density;
CESC	cis	rs1218582	0.772	rs6656435	chr1:154876869	G/A	cg09359103	chr1:154839909	KCNN3	-0.65	-12.33	-0.6	6.58e-28	Prostate cancer;
CESC	cis	rs4689388	0.929	rs1046320	chr4:6304344	C/T	cg14416269	chr4:6271139	WFS1	0.47	7.89	0.44	7.84e-14	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs7412746	0.658	rs3768016	chr1:150809919	T/C	cg04414720	chr1:150670196	GOLPH3L	0.56	7.34	0.41	2.57e-12	Melanoma;
CESC	cis	rs12497850	0.644	rs11928552	chr3:48739883	T/C	cg06212747	chr3:49208901	KLHDC8B	0.59	7.44	0.42	1.43e-12	Parkinson's disease;
CESC	cis	rs736408	0.522	rs6445535	chr3:52771468	T/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	5.69	0.33	3.39e-8	Bipolar disorder;
CESC	cis	rs3820068	0.532	rs6701009	chr1:15935614	T/C	cg13390004	chr1:15929781	NA	0.36	5.81	0.34	1.8e-8	Systolic blood pressure;
CESC	cis	rs9815354	0.812	rs17214987	chr3:41810481	C/T	cg03022575	chr3:42003672	ULK4	-0.66	-6.17	-0.35	2.56e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs6460942	0.915	rs62448620	chr7:12458170	C/T	cg06484146	chr7:12443880	VWDE	-0.78	-9.14	-0.49	1.68e-17	Coronary artery disease;
CESC	cis	rs9926296	0.605	rs886952	chr16:89836781	G/A	cg07648498	chr16:89883185	FANCA	0.43	5.35	0.31	1.91e-7	Vitiligo;
CESC	cis	rs2976388	0.578	rs4736324	chr8:143830462	G/A	cg20862496	chr8:143823734	SLURP1	0.35	5.37	0.31	1.71e-7	Urinary tract infection frequency;
CESC	cis	rs2361718	0.501	rs8065486	chr17:78138196	A/G	cg21238619	chr17:78079768	GAA	0.37	5.23	0.31	3.5e-7	Yeast infection;
CESC	cis	rs6465657	0.903	rs11767962	chr7:97778576	C/T	cg24562669	chr7:97807699	LMTK2	0.82	13.45	0.64	8.74e-32	Prostate cancer (SNP x SNP interaction);Prostate cancer;
CESC	cis	rs1023500	0.505	rs134889	chr22:42674350	A/T	cg15557168	chr22:42548783	NA	-0.45	-7.03	-0.4	1.78e-11	Schizophrenia;
CESC	cis	rs17376456	0.569	rs6556839	chr5:93206292	T/C	cg21475434	chr5:93447410	FAM172A	-0.52	-5.25	-0.31	3.13e-7	Diabetic retinopathy;
CESC	cis	rs34375054	0.526	rs117431213	chr12:125675271	C/G	cg00522288	chr12:125625016	AACS	-0.34	-5.28	-0.31	2.69e-7	Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs7949030	0.626	rs72927213	chr11:62351198	G/C	cg02375832	chr11:62437615	C11orf48	-0.36	-5.08	-0.3	7.14e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs13191362	0.935	rs13212137	chr6:163010261	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.82	8.22	0.45	9.12e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs875971	0.660	rs2013222	chr7:66035936	C/G	cg18876405	chr7:65276391	NA	-0.62	-8.27	-0.45	6.72e-15	Aortic root size;
CESC	cis	rs116095464	0.558	rs73031482	chr5:227594	G/A	cg22496380	chr5:211416	CCDC127	-0.72	-8.45	-0.46	1.92e-15	Breast cancer;
CESC	cis	rs6502050	1.000	rs6502050	chr17:80058236	C/G	cg01763666	chr17:80159506	CCDC57	0.37	5.11	0.3	6.21e-7	Life satisfaction;
CESC	cis	rs11792861	0.926	rs1051474	chr9:111881856	T/C	cg05043794	chr9:111880884	C9orf5	-0.41	-6.74	-0.38	9.84e-11	Menarche (age at onset);
CESC	cis	rs2742234	0.910	rs2505511	chr10:43641029	T/A	cg15436174	chr10:43711423	RASGEF1A	-0.41	-5.25	-0.31	3.18e-7	Hirschsprung disease;
CESC	cis	rs7633770	0.786	rs1520488	chr3:46677459	C/T	cg11219411	chr3:46661640	NA	0.33	5.29	0.31	2.51e-7	Coronary artery disease;
CESC	cis	rs7945705	0.840	rs10840136	chr11:8885024	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.4	-6.51	-0.37	3.73e-10	Hemoglobin concentration;
CESC	cis	rs875971	1.000	rs1167612	chr7:65567976	C/A	cg18876405	chr7:65276391	NA	-0.54	-7.03	-0.4	1.73e-11	Aortic root size;
CESC	cis	rs425277	1.000	rs74877653	chr1:2065949	C/T	cg16545954	chr1:2118288	C1orf86	0.33	5.56	0.32	6.55e-8	Height;
CESC	cis	rs35110281	0.641	rs4818861	chr21:45123807	A/G	cg21573476	chr21:45109991	RRP1B	-0.58	-7.94	-0.44	5.78e-14	Mean corpuscular volume;
CESC	cis	rs8072100	0.713	rs3871595	chr17:45511388	C/T	cg08085267	chr17:45401833	C17orf57	-0.52	-6.6	-0.38	2.28e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	trans	rs1814175	0.935	rs7950947	chr11:49668369	C/T	cg15704280	chr7:45808275	SEPT13	-1.0	-17.79	-0.74	4.04e-47	Height;
CESC	cis	rs7044106	0.791	rs10985000	chr9:123484115	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.81	13.03	0.63	2.43e-30	Hip circumference adjusted for BMI;
CESC	cis	rs13191362	1.000	rs13190742	chr6:163008758	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.5	5.19	0.3	4.29e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs10256972	0.869	rs1007766	chr7:1034903	G/A	cg23978390	chr7:1156363	C7orf50	0.43	5.53	0.32	7.87e-8	Longevity;Endometriosis;
CESC	cis	rs9487051	0.768	rs386696	chr6:109520166	G/A	cg01475377	chr6:109611718	NA	-0.45	-6.86	-0.39	4.74e-11	Reticulocyte fraction of red cells;
CESC	cis	rs13064447	0.753	rs9868500	chr3:12747690	A/G	cg23032965	chr3:12705835	RAF1	0.41	5.25	0.31	3.09e-7	Major depression and alcohol dependence;
CESC	cis	rs12530845	1.000	rs60179239	chr7:135333028	A/G	cg23117316	chr7:135346802	PL-5283	-0.41	-5.24	-0.31	3.35e-7	Red blood cell traits;
CESC	cis	rs1707322	0.964	rs785496	chr1:46588006	T/C	cg03146154	chr1:46216737	IPP	-0.74	-9.64	-0.51	4.75e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs425277	0.606	rs262669	chr1:2082489	A/G	cg24578937	chr1:2090814	PRKCZ	-0.38	-6.71	-0.38	1.15e-10	Height;
CESC	cis	rs727563	0.635	rs5751141	chr22:42107745	A/G	cg06634786	chr22:41940651	POLR3H	0.63	6.33	0.36	1.05e-9	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs4665809	0.590	rs62128457	chr2:26467347	C/A	cg25036284	chr2:26402008	FAM59B	0.86	9.4	0.5	2.74e-18	Gut microbiome composition (summer);
CESC	trans	rs1814175	0.616	rs4881723	chr11:49788566	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.42	-6.06	-0.35	4.69e-9	Height;
CESC	cis	rs3768617	0.966	rs10911253	chr1:183086190	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.64	8.88	0.48	1.03e-16	Fuchs's corneal dystrophy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19916409	chr4:103266691	SLC39A8	0.63	7.52	0.42	8.32e-13	Gut microbiome composition (summer);
CESC	cis	rs6541297	0.703	rs2748117	chr1:230320156	C/T	cg20703242	chr1:230279135	GALNT2	-0.41	-5.36	-0.31	1.84e-7	Coronary artery disease;
CESC	cis	rs7267979	1.000	rs6115146	chr20:25304507	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.88	-18.41	-0.75	2.54e-49	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs854765	0.693	rs8080061	chr17:17776389	C/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.5	-6.75	-0.38	9.18e-11	Total body bone mineral density;
CESC	trans	rs1829883	0.600	rs2461966	chr5:98733594	A/G	cg23861655	chr4:57411219	NA	0.4	6.49	0.37	4.16e-10	Hemostatic factors and hematological phenotypes;
CESC	cis	rs854765	0.547	rs6502632	chr17:17913057	A/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.53	7.01	0.4	2.02e-11	Total body bone mineral density;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17391929	chr14:24702094	GMPR2;NEDD8	-0.63	-7.15	-0.4	8.59e-12	Gut microbiome composition (summer);
CESC	cis	rs4253772	0.550	rs6008762	chr22:46736228	T/C	cg09491104	chr22:46646882	C22orf40	-0.55	-6.48	-0.37	4.46e-10	LDL cholesterol;Cholesterol, total;
CESC	cis	rs9858542	0.953	rs11713474	chr3:49611457	A/G	cg07274523	chr3:49395745	GPX1	0.65	8.3	0.45	5.23e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs9788333	0.962	rs12584792	chr13:21887208	C/T	cg21970626	chr13:21893289	NA	-0.42	-6.09	-0.35	3.85e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs17253792	0.822	rs112308750	chr14:56080073	G/A	cg01858014	chr14:56050164	KTN1	-0.93	-7.33	-0.41	2.71e-12	Putamen volume;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg21250466	chr4:854474	GAK	0.46	6.56	0.37	2.73e-10	Fibrinogen levels;
CESC	cis	rs7208859	0.623	rs55961983	chr17:29119286	G/A	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.79e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs965469	1.000	rs6051747	chr20:3307945	T/C	cg25506879	chr20:3388711	C20orf194	-0.57	-6.15	-0.35	2.79e-9	IFN-related cytopenia;
CESC	cis	rs17376456	1.000	rs58734583	chr5:93532155	C/T	cg21475434	chr5:93447410	FAM172A	0.87	7.83	0.43	1.18e-13	Diabetic retinopathy;
CESC	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg03188948	chr7:1209495	NA	0.71	7.06	0.4	1.5e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs9611565	0.512	rs2899349	chr22:42164660	T/C	cg17376030	chr22:41985996	PMM1	-0.79	-8.37	-0.46	3.43e-15	Vitiligo;
CESC	cis	rs55728055	0.661	rs62237849	chr22:32029807	T/C	cg01338084	chr22:32026380	PISD	1.26	8.23	0.45	8.62e-15	Age-related hearing impairment;
CESC	cis	rs13191362	1.000	rs67025553	chr6:163011552	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.5	5.17	0.3	4.63e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs344364	0.511	rs1657133	chr16:1950300	A/G	cg03013636	chr16:1946785	NA	0.48	6.62	0.38	2.02e-10	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs12477438	1.000	rs73963398	chr2:99887025	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.7	-8.1	-0.45	2e-14	Chronic sinus infection;
CESC	cis	rs27434	0.615	rs61112531	chr5:96191820	G/A	cg16492584	chr5:96139282	ERAP1	0.52	6.19	0.36	2.23e-9	Ankylosing spondylitis;
CESC	cis	rs6541297	1.000	rs6686680	chr1:230280522	T/C	cg20703242	chr1:230279135	GALNT2	0.73	11.12	0.56	8.07e-24	Coronary artery disease;
CESC	cis	rs933688	1.000	rs9293568	chr5:90737845	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.15	13.79	0.65	5.53e-33	Smoking behavior;
CESC	cis	rs9926296	0.605	rs3743859	chr16:89846050	A/G	cg07648498	chr16:89883185	FANCA	-0.44	-5.44	-0.32	1.19e-7	Vitiligo;
CESC	cis	rs875971	0.522	rs34973832	chr7:65396204	A/G	cg05332525	chr7:65337924	VKORC1L1	0.51	6.38	0.36	7.81e-10	Aortic root size;
CESC	cis	rs6466055	0.720	rs6466057	chr7:104952483	A/G	cg04380332	chr7:105027541	SRPK2	0.4	5.42	0.32	1.32e-7	Schizophrenia;
CESC	cis	rs11583043	0.958	rs11583674	chr1:101396560	C/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.55	6.34	0.36	9.81e-10	Ulcerative colitis;Inflammatory bowel disease;
CESC	cis	rs367943	0.712	rs7734304	chr5:112730165	G/A	cg12552261	chr5:112820674	MCC	0.39	5.26	0.31	2.99e-7	Type 2 diabetes;
CESC	cis	rs7959452	0.503	rs7300266	chr12:69654187	A/G	cg20891283	chr12:69753455	YEATS4	0.75	11.21	0.57	3.97e-24	Blood protein levels;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg15383980	chr1:113741483	NA	0.52	6.67	0.38	1.52e-10	Fibrinogen levels;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg20853569	chr17:79247697	SLC38A10	0.46	6.01	0.35	6.19e-9	Fibrinogen levels;
CESC	cis	rs2228479	0.850	rs2238525	chr16:89809902	T/C	cg14709524	chr16:89940631	TCF25	0.75	6.48	0.37	4.39e-10	Skin colour saturation;
CESC	cis	rs2732480	0.523	rs34286639	chr12:48629044	C/T	cg24011408	chr12:48396354	COL2A1	0.43	5.9	0.34	1.11e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs116095464	0.558	rs6874745	chr5:264527	A/G	cg10591111	chr5:226296	SDHA	-0.52	-6.35	-0.36	9.51e-10	Breast cancer;
CESC	cis	rs8114671	0.836	rs6060165	chr20:33619480	A/C	cg07148914	chr20:33460835	GGT7	-0.41	-5.33	-0.31	2.13e-7	Height;
CESC	cis	rs875971	0.660	rs12698534	chr7:65986845	C/T	cg18876405	chr7:65276391	NA	0.56	7.57	0.42	6.22e-13	Aortic root size;
CESC	cis	rs2839186	0.619	rs55689527	chr21:47622727	A/G	cg12516959	chr21:47718080	NA	-0.41	-5.93	-0.34	9.51e-9	Testicular germ cell tumor;
CESC	cis	rs4805272	0.626	rs6509072	chr19:29331703	C/G	cg14983838	chr19:29218262	NA	0.44	5.95	0.34	8.33e-9	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
CESC	cis	rs9900062	0.586	rs2676307	chr17:62690713	C/G	cg02097616	chr17:62675921	NA	0.43	5.17	0.3	4.58e-7	QT interval;
CESC	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg19723775	chr5:179050963	HNRNPH1	-0.44	-5.84	-0.34	1.51e-8	Lung cancer;
CESC	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg11965913	chr1:205819406	PM20D1	0.81	13.76	0.65	7.16e-33	Menarche (age at onset);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg22798821	chr11:11864085	USP47	0.55	7.08	0.4	1.27e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs10479542	0.630	rs6879664	chr5:178974576	T/G	cg05457628	chr5:178986728	RUFY1	0.45	6.11	0.35	3.46e-9	Lung cancer;
CESC	cis	rs751837	0.518	rs74085588	chr14:103456702	C/T	cg10087771	chr14:103399429	CDC42BPB	0.61	5.41	0.32	1.4e-7	Large B-cell lymphoma;
CESC	cis	rs6831352	0.918	rs29001209	chr4:100052340	C/A	cg12011299	chr4:100065546	ADH4	-0.59	-6.52	-0.37	3.62e-10	Alcohol dependence;
CESC	cis	rs780096	0.506	rs1647265	chr2:27692261	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.32	-5.97	-0.34	7.45e-9	Total body bone mineral density;
CESC	cis	rs68170813	0.559	rs7794965	chr7:106826439	A/G	cg02696742	chr7:106810147	HBP1	0.56	5.41	0.32	1.41e-7	Coronary artery disease;
CESC	cis	rs11214589	0.905	rs2186799	chr11:113242533	G/T	cg14159747	chr11:113255604	NA	0.33	5.84	0.34	1.53e-8	Neuroticism;
CESC	cis	rs7017914	0.934	rs13255152	chr8:71859619	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.16	-0.3	4.74e-7	Bone mineral density;
CESC	cis	rs556990	0.760	rs3024739	chr13:113819948	G/A	cg00898013	chr13:113819073	PROZ	-0.52	-6.72	-0.38	1.08e-10	Blood protein levels;
CESC	trans	rs10838801	1	rs10838801	chr11:48098280	G/A	cg03929089	chr4:120376271	NA	-0.62	-7.7	-0.43	2.7e-13	Height;
CESC	cis	rs853679	0.517	rs9393891	chr6:28079160	C/T	cg08968635	chr6:28129556	ZNF389	0.4	5.36	0.31	1.84e-7	Depression;
CESC	cis	rs1348850	1.000	rs3927978	chr2:178443854	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.64	-8.99	-0.48	4.81e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs11098499	0.863	rs6858592	chr4:120458692	G/A	cg09307838	chr4:120376055	NA	0.88	11.94	0.59	1.39e-26	Corneal astigmatism;
CESC	cis	rs11871801	1.000	rs35272895	chr17:40580669	T/A	cg21433558	chr17:40837037	CNTNAP1	0.45	5.04	0.3	8.46e-7	Crohn's disease;
CESC	cis	rs17407555	0.821	rs4473652	chr4:10141617	G/C	cg11266682	chr4:10021025	SLC2A9	-0.49	-5.18	-0.3	4.33e-7	Schizophrenia (age at onset);
CESC	cis	rs34779708	0.931	rs4007289	chr10:35269790	G/A	cg04310649	chr10:35416472	CREM	-0.52	-6.35	-0.36	9.54e-10	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs59918340	0.764	rs3824234	chr8:142229370	T/C	cg16341495	chr8:142228727	SLC45A4	-0.44	-5.34	-0.31	1.98e-7	Immature fraction of reticulocytes;
CESC	cis	rs17376456	0.569	rs7729807	chr5:93104089	C/T	cg21475434	chr5:93447410	FAM172A	0.49	5.03	0.3	9.16e-7	Diabetic retinopathy;
CESC	cis	rs250677	0.687	rs2915809	chr5:148452111	A/T	cg18129178	chr5:148520854	ABLIM3	-0.5	-5.77	-0.33	2.22e-8	Breast cancer;
CESC	cis	rs3820068	0.705	rs11577225	chr1:15864242	T/C	cg17385448	chr1:15911702	AGMAT	0.37	5.91	0.34	1.03e-8	Systolic blood pressure;
CESC	cis	rs7666738	0.791	rs11729596	chr4:99045461	A/G	cg03676636	chr4:99064102	C4orf37	0.33	5.12	0.3	5.93e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6502050	0.605	rs35158616	chr17:80094480	A/G	cg01763666	chr17:80159506	CCDC57	-0.37	-5.05	-0.3	8.22e-7	Life satisfaction;
CESC	cis	rs6570726	0.935	rs369214	chr6:145856709	G/A	cg05347473	chr6:146136440	FBXO30	0.48	6.44	0.37	5.7e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs10540	1.000	rs35898083	chr11:484469	C/T	cg03352830	chr11:487213	PTDSS2	0.74	7.5	0.42	9.59e-13	Body mass index;
CESC	cis	rs896854	0.875	rs4735333	chr8:95955074	G/A	cg09323728	chr8:95962352	TP53INP1	-0.42	-9.45	-0.5	1.83e-18	Type 2 diabetes;
CESC	cis	rs8114671	0.869	rs2145559	chr20:33651725	G/A	cg24642439	chr20:33292090	TP53INP2	-0.49	-5.88	-0.34	1.23e-8	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21235025	chr13:72249355	DACH1	-0.52	-6.19	-0.36	2.29e-9	Gut microbiome composition (summer);
CESC	cis	rs113835537	0.935	rs1127145	chr11:66373305	G/A	cg22134325	chr11:66188745	NPAS4	0.5	5.76	0.33	2.27e-8	Airway imaging phenotypes;
CESC	cis	rs9914988	0.943	rs4313850	chr17:27080768	T/C	cg20469991	chr17:27169893	C17orf63	-0.47	-5.09	-0.3	6.85e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CESC	cis	rs875971	0.862	rs7786892	chr7:65628876	G/A	cg12463550	chr7:65579703	CRCP	-0.49	-6.3	-0.36	1.21e-9	Aortic root size;
CESC	cis	rs9910055	0.614	rs12944572	chr17:42245241	T/C	cg13607699	chr17:42295918	UBTF	0.56	7.21	0.41	5.79e-12	Total body bone mineral density;
CESC	cis	rs9399135	0.935	rs11760000	chr6:135370496	G/A	cg22676075	chr6:135203613	NA	0.52	7.31	0.41	3.17e-12	Red blood cell count;
CESC	cis	rs78456975	1.000	rs11903168	chr2:1560497	C/G	cg01028140	chr2:1542097	TPO	-0.5	-5.37	-0.31	1.69e-7	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs9916302	0.706	rs4332770	chr17:37704712	T/C	cg00129232	chr17:37814104	STARD3	-0.55	-5.69	-0.33	3.39e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs739401	0.611	rs2239899	chr11:3024624	A/G	cg08508325	chr11:3079039	CARS	0.51	9.28	0.5	6.49e-18	Longevity;
CESC	cis	rs10540	1.000	rs12419716	chr11:503385	C/G	cg21784768	chr11:537496	LRRC56	-0.54	-5.08	-0.3	7.13e-7	Body mass index;
CESC	cis	rs17376456	0.569	rs1349711	chr5:93179032	C/T	cg21475434	chr5:93447410	FAM172A	-0.5	-5.14	-0.3	5.44e-7	Diabetic retinopathy;
CESC	cis	rs7605827	0.930	rs3828465	chr2:15535497	A/T	cg19274914	chr2:15703543	NA	0.35	6.22	0.36	1.98e-9	Educational attainment (years of education);
CESC	cis	rs2880765	0.743	rs12906308	chr15:86008059	C/T	cg10818794	chr15:86012489	AKAP13	0.33	5.12	0.3	6.02e-7	Coronary artery disease;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg08138407	chr1:35582349	NA	0.43	6.12	0.35	3.42e-9	Thyroid stimulating hormone;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg10297430	chr16:11272440	CLEC16A	0.49	6.29	0.36	1.33e-9	Fibrinogen levels;
CESC	cis	rs4974559	0.793	rs10025954	chr4:1351382	C/T	cg02980000	chr4:1222292	CTBP1	0.71	6.68	0.38	1.38e-10	Systolic blood pressure;
CESC	cis	rs7674212	0.510	rs55715738	chr4:104130189	A/G	cg16532752	chr4:104119610	CENPE	-0.38	-5.21	-0.3	3.8e-7	Type 2 diabetes;
CESC	cis	rs4654899	0.627	rs667071	chr1:21045726	T/C	cg05370193	chr1:21551575	ECE1	0.35	5.03	0.3	9.1e-7	Superior frontal gyrus grey matter volume;
CESC	cis	rs3858526	0.959	rs11039699	chr11:5951091	G/A	cg05234568	chr11:5960015	NA	-0.63	-7.53	-0.42	8.12e-13	DNA methylation (variation);
CESC	cis	rs9926296	0.605	rs886952	chr16:89836781	G/A	cg27121462	chr16:89883253	FANCA	0.75	10.77	0.55	1.1e-22	Vitiligo;
CESC	cis	rs9733	0.596	rs6587516	chr1:150623221	C/T	cg09365446	chr1:150670422	GOLPH3L	0.42	5.98	0.34	7.35e-9	Tonsillectomy;
CESC	cis	rs17253792	0.822	rs17683614	chr14:56041058	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.84	5.73	0.33	2.76e-8	Putamen volume;
CESC	cis	rs796364	0.806	rs34381014	chr2:200916403	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.85	-7.93	-0.44	6.07e-14	Schizophrenia;
CESC	cis	rs473651	0.837	rs563458	chr2:239345613	T/A	cg21699342	chr2:239360505	ASB1	0.55	9.45	0.5	1.85e-18	Multiple system atrophy;
CESC	trans	rs79976124	0.719	rs34488909	chr6:66637850	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.69	7.91	0.44	6.93e-14	Type 2 diabetes;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg04513197	chr1:100504319	HIAT1	0.46	6.22	0.36	1.95e-9	Systemic lupus erythematosus;
CESC	cis	rs3733585	0.673	rs6849729	chr4:9958732	T/C	cg00071950	chr4:10020882	SLC2A9	-0.73	-11.79	-0.59	4.58e-26	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs1568889	0.838	rs12273631	chr11:28042135	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.82	13.89	0.65	2.49e-33	Bipolar disorder;
CESC	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg06873352	chr17:61820015	STRADA	-0.69	-11.28	-0.57	2.38e-24	Prudent dietary pattern;
CESC	cis	rs1865721	0.771	rs4622605	chr18:73139008	T/C	cg26385618	chr18:73139727	C18orf62	-0.49	-8.0	-0.44	3.82e-14	Intelligence;
CESC	cis	rs425277	0.606	rs262669	chr1:2082489	A/G	cg04315214	chr1:2043799	PRKCZ	0.47	7.56	0.42	6.63e-13	Height;
CESC	cis	rs9303280	0.651	rs59716545	chr17:38031857	T/G	cg20243544	chr17:37824526	PNMT	0.53	6.86	0.39	4.8e-11	Self-reported allergy;
CESC	cis	rs3740713	0.920	rs112818034	chr11:18455180	T/C	cg23797887	chr11:18477753	LDHAL6A	-0.53	-5.11	-0.3	6.1e-7	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs9303401	0.614	rs28651036	chr17:57080471	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.86	10.75	0.55	1.32e-22	Cognitive test performance;
CESC	cis	rs6545883	0.894	rs12622458	chr2:61523554	A/C	cg15711740	chr2:61764176	XPO1	0.4	5.13	0.3	5.74e-7	Tuberculosis;
CESC	cis	rs10504229	1.000	rs72650892	chr8:58179714	A/G	cg24829409	chr8:58192753	C8orf71	-0.76	-10.0	-0.52	3.53e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs875971	0.545	rs66594357	chr7:65792784	G/A	cg18876405	chr7:65276391	NA	0.49	5.91	0.34	1.05e-8	Aortic root size;
CESC	cis	rs8017423	0.647	rs12883357	chr14:90815032	A/G	cg14092571	chr14:90743983	NA	0.5	7.62	0.42	4.61e-13	Mortality in heart failure;
CESC	cis	rs7552404	0.960	rs12134854	chr1:76137606	A/G	cg22875332	chr1:76189707	ACADM	0.66	7.83	0.43	1.15e-13	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs2742417	0.603	rs2673062	chr3:45763635	A/G	cg04837898	chr3:45731254	SACM1L	-0.47	-6.21	-0.36	2.08e-9	Response to anti-depressant treatment in major depressive disorder;
CESC	cis	rs1218582	0.772	rs10796934	chr1:154849479	C/G	cg03351412	chr1:154909251	PMVK	0.66	8.96	0.48	5.83e-17	Prostate cancer;
CESC	cis	rs7680126	0.597	rs78917351	chr4:10208063	A/C	cg11266682	chr4:10021025	SLC2A9	-0.44	-5.72	-0.33	2.88e-8	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	cis	rs7618915	0.547	rs2268026	chr3:52778347	T/C	cg07507251	chr3:52567010	NT5DC2	0.42	7.2	0.4	6.23e-12	Bipolar disorder;
CESC	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg03188948	chr7:1209495	NA	0.71	7.06	0.4	1.5e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs3749237	0.595	rs885592	chr3:49497883	T/G	cg03060546	chr3:49711283	APEH	0.77	11.84	0.59	2.98e-26	Resting heart rate;
CESC	cis	rs7666738	0.822	rs28512427	chr4:98919029	G/A	cg05340658	chr4:99064831	C4orf37	0.75	10.76	0.55	1.26e-22	Colonoscopy-negative controls vs population controls;
CESC	cis	rs12681288	0.823	rs2701903	chr8:1004029	A/G	cg04851639	chr8:1020857	NA	0.33	7.3	0.41	3.46e-12	Schizophrenia;
CESC	trans	rs561341	1.000	rs2470267	chr17:30274132	G/A	cg20587970	chr11:113659929	NA	-1.14	-14.26	-0.66	1.22e-34	Hip circumference adjusted for BMI;
CESC	cis	rs864537	0.646	rs1723016	chr1:167433056	T/C	cg09179987	chr1:167433047	CD247	0.53	8.2	0.45	1.07e-14	Celiac disease or Rheumatoid arthritis;Celiac disease;
CESC	cis	rs4561483	0.549	rs154149	chr16:11956118	T/A	cg08843971	chr16:11963173	GSPT1	-0.52	-7.32	-0.41	3e-12	Testicular germ cell tumor;
CESC	cis	rs4665809	0.652	rs4665832	chr2:26404775	A/G	cg22920501	chr2:26401640	FAM59B	-0.86	-10.06	-0.53	2.22e-20	Gut microbiome composition (summer);
CESC	trans	rs2115172	0.836	rs4835799	chr5:122762229	A/G	cg25998860	chr5:126853954	PRRC1	0.45	6.03	0.35	5.53e-9	Weight;
CESC	cis	rs2243480	1.000	rs35820085	chr7:65442758	C/T	cg25894440	chr7:65020034	NA	-0.68	-5.88	-0.34	1.23e-8	Diabetic kidney disease;
CESC	trans	rs6572548	0.504	rs1956082	chr14:49665496	A/C	cg00941241	chr1:9885960	CLSTN1	-0.48	-6.37	-0.36	8.54e-10	Subjective well-being;
CESC	cis	rs853679	0.517	rs6941992	chr6:28106141	T/C	cg23161317	chr6:28129485	ZNF389	0.51	6.63	0.38	1.85e-10	Depression;
CESC	cis	rs736408	0.812	rs9324	chr3:52825585	T/C	cg07507251	chr3:52567010	NT5DC2	0.35	5.54	0.32	7.43e-8	Bipolar disorder;
CESC	cis	rs3809566	0.963	rs4775608	chr15:63331940	A/G	cg05507819	chr15:63340323	TPM1	0.52	6.37	0.36	8.15e-10	Platelet count;
CESC	cis	rs12476592	0.543	rs262539	chr2:63908270	G/A	cg17519650	chr2:63277830	OTX1	0.46	5.04	0.3	8.79e-7	Childhood ear infection;
CESC	cis	rs6952808	0.862	rs4721135	chr7:1912222	A/G	cg08027265	chr7:2291960	NA	-0.33	-5.08	-0.3	7.15e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs1256061	0.603	rs1256037	chr14:64743301	G/A	cg23250157	chr14:64679961	SYNE2	0.53	7.63	0.42	4.14e-13	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs875971	0.830	rs778715	chr7:65849209	C/T	cg10691866	chr7:65817282	TPST1	-0.32	-5.25	-0.31	3.06e-7	Aortic root size;
CESC	cis	rs514406	0.798	rs575138	chr1:53328394	C/G	cg08859206	chr1:53392774	SCP2	-0.68	-9.49	-0.5	1.38e-18	Monocyte count;
CESC	cis	rs9649213	0.613	rs7777415	chr7:97959214	A/T	cg21770322	chr7:97807741	LMTK2	0.57	8.73	0.47	2.84e-16	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs35110281	0.807	rs1598206	chr21:45058776	A/G	cg21573476	chr21:45109991	RRP1B	-0.46	-6.42	-0.37	6.38e-10	Mean corpuscular volume;
CESC	cis	rs4481887	0.927	rs4534422	chr1:248479482	A/G	cg00666640	chr1:248458726	OR2T12	0.35	5.67	0.33	3.82e-8	Common traits (Other);
CESC	cis	rs9611565	0.729	rs73176686	chr22:41782119	C/T	cg06481639	chr22:41940642	POLR3H	-0.63	-6.57	-0.37	2.63e-10	Vitiligo;
CESC	cis	rs6088580	0.634	rs13041646	chr20:33082881	T/A	cg06115741	chr20:33292138	TP53INP2	0.45	5.74	0.33	2.62e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs875971	0.767	rs12668005	chr7:65909021	T/C	cg19163074	chr7:65112434	INTS4L2	-0.41	-5.09	-0.3	6.96e-7	Aortic root size;
CESC	cis	rs929354	0.772	rs6459739	chr7:156998863	A/T	cg05182265	chr7:156933206	UBE3C	-0.51	-7.47	-0.42	1.2e-12	Body mass index;
CESC	cis	rs7927771	0.507	rs1483988	chr11:47899030	C/T	cg18512352	chr11:47633146	NA	0.38	5.87	0.34	1.28e-8	Subjective well-being;
CESC	cis	rs514406	0.505	rs856721	chr1:53162156	C/A	cg24675658	chr1:53192096	ZYG11B	-0.54	-6.7	-0.38	1.25e-10	Monocyte count;
CESC	cis	rs7178572	0.524	rs2175941	chr15:77584498	T/C	cg22256960	chr15:77711686	NA	-0.53	-6.6	-0.38	2.26e-10	Type 2 diabetes;
CESC	trans	rs11098499	0.866	rs12501602	chr4:120287935	A/T	cg25214090	chr10:38739885	LOC399744	0.66	9.2	0.49	1.13e-17	Corneal astigmatism;
CESC	cis	rs7552404	0.924	rs1146588	chr1:76229787	C/G	cg22875332	chr1:76189707	ACADM	0.71	9.86	0.52	9.97e-20	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs9787249	0.874	rs7520588	chr1:40214525	T/A	cg19912559	chr1:40204330	PPIE	0.42	6.48	0.37	4.37e-10	Blood protein levels;
CESC	cis	rs736408	0.716	rs2300149	chr3:52822921	C/T	cg17372223	chr3:52568218	NT5DC2	0.38	5.33	0.31	2.09e-7	Bipolar disorder;
CESC	cis	rs3617	0.625	rs2535633	chr3:52859630	C/G	cg11041457	chr3:52719354	GNL3;PBRM1	-0.36	-5.09	-0.3	6.71e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg11064206	chr12:123459532	OGFOD2;ABCB9	-0.42	-6.15	-0.35	2.81e-9	Gambling;
CESC	cis	rs1044826	0.692	rs188420	chr3:139233865	G/A	cg00490450	chr3:139108681	COPB2	-0.44	-5.45	-0.32	1.13e-7	Obesity-related traits;
CESC	cis	rs769267	0.965	rs8101938	chr19:19390497	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.43	5.33	0.31	2.11e-7	Tonsillectomy;
CESC	cis	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg23978390	chr7:1156363	C7orf50	0.53	7.1	0.4	1.16e-11	Longevity;Endometriosis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14380045	chr9:15527817	NA	-0.59	-6.96	-0.39	2.59e-11	Gut microbiome composition (summer);
CESC	cis	rs34779708	0.966	rs4934737	chr10:35512799	T/C	cg03585969	chr10:35415529	CREM	0.75	9.46	0.5	1.78e-18	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs7129220	0.512	rs57618276	chr11:10129276	C/T	cg01453529	chr11:10209919	SBF2	-0.47	-5.37	-0.31	1.7e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CESC	cis	rs7814319	0.700	rs871798	chr8:97257982	T/C	cg20787634	chr8:97240163	UQCRB	-0.53	-6.37	-0.36	8.41e-10	Lung function (FVC);
CESC	cis	rs10865397	0.506	rs60764301	chr2:73384850	G/A	cg01422370	chr2:73384389	NA	0.46	7.27	0.41	4.11e-12	Intelligence (multi-trait analysis);
CESC	trans	rs673604	0.505	rs676614	chr1:36107510	G/T	cg12857786	chr4:83934023	LIN54	0.55	6.17	0.35	2.51e-9	Endometrial cancer;
CESC	cis	rs6736093	0.966	rs3811634	chr2:112754943	C/T	cg12686935	chr2:112915763	FBLN7	-0.42	-5.51	-0.32	8.34e-8	Coronary artery disease;
CESC	cis	rs7208859	0.623	rs9898084	chr17:29082334	C/G	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.91e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs2204008	0.807	rs11182461	chr12:38539288	T/C	cg13010199	chr12:38710504	ALG10B	0.53	6.86	0.39	4.74e-11	Bladder cancer;
CESC	cis	rs1949733	0.628	rs2688231	chr4:8490981	G/A	cg11789530	chr4:8429930	ACOX3	0.72	10.15	0.53	1.18e-20	Response to antineoplastic agents;
CESC	cis	rs9311474	0.659	rs7638808	chr3:52572056	C/T	cg18099408	chr3:52552593	STAB1	0.36	6.62	0.38	2e-10	Electroencephalogram traits;
CESC	cis	rs6088580	0.634	rs4142007	chr20:32990050	G/T	cg06115741	chr20:33292138	TP53INP2	-0.47	-6.14	-0.35	3.06e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs7647973	0.961	rs6778080	chr3:49317338	C/T	cg07636037	chr3:49044803	WDR6	-0.58	-8.28	-0.45	6.15e-15	Menarche (age at onset);
CESC	cis	rs123509	0.687	rs73075297	chr3:42832466	A/G	cg12982090	chr3:42733453	KBTBD5	-0.66	-7.52	-0.42	8.26e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs1538970	0.816	rs868351	chr1:46009818	G/T	cg03146154	chr1:46216737	IPP	0.45	5.34	0.31	2e-7	Platelet count;
CESC	cis	rs12142240	0.698	rs72677599	chr1:46834251	G/A	cg00530320	chr1:46809349	NSUN4	0.6	8.11	0.45	1.85e-14	Menopause (age at onset);
CESC	cis	rs9916302	0.851	rs677888	chr17:37461018	T/G	cg07936489	chr17:37558343	FBXL20	0.72	9.28	0.5	6.35e-18	Glomerular filtration rate (creatinine);
CESC	cis	rs9399401	0.667	rs17071756	chr6:142715195	C/T	cg03128060	chr6:142623767	GPR126	-0.37	-6.33	-0.36	1.06e-9	Chronic obstructive pulmonary disease;
CESC	cis	rs4975616	0.804	rs459961	chr5:1337106	T/A	cg26373071	chr5:1325741	CLPTM1L	0.44	7.08	0.4	1.31e-11	Lung cancer;
CESC	cis	rs6502050	0.835	rs8080423	chr17:80102279	A/G	cg11859384	chr17:80120422	CCDC57	-0.38	-5.11	-0.3	6.21e-7	Life satisfaction;
CESC	cis	rs9325144	0.560	rs11183046	chr12:38655270	A/T	cg26384229	chr12:38710491	ALG10B	-0.6	-8.49	-0.46	1.45e-15	Morning vs. evening chronotype;
CESC	cis	rs713587	0.563	rs10865315	chr2:25100738	C/A	cg01884057	chr2:25150051	NA	0.33	6.17	0.35	2.49e-9	Body mass index in non-asthmatics;
CESC	cis	rs9300255	0.620	rs1716173	chr12:123660721	A/T	cg19016782	chr12:123741754	C12orf65	-0.45	-6.21	-0.36	2.01e-9	Neutrophil percentage of white cells;
CESC	cis	rs9322193	0.884	rs933055	chr6:150130837	A/G	cg13206674	chr6:150067644	NUP43	0.42	5.82	0.34	1.66e-8	Lung cancer;
CESC	cis	rs873946	0.648	rs3750578	chr10:134563366	A/G	cg27297192	chr10:134578999	INPP5A	0.42	5.48	0.32	9.68e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs2625529	0.590	rs12904652	chr15:72548765	T/C	cg16672083	chr15:72433130	SENP8	-0.39	-5.45	-0.32	1.16e-7	Red blood cell count;
CESC	cis	rs6952808	0.895	rs4513875	chr7:1928159	C/T	cg05863683	chr7:1912471	MAD1L1	0.51	7.79	0.43	1.49e-13	Bipolar disorder and schizophrenia;
CESC	cis	rs637571	0.726	rs689274	chr11:65665988	A/G	cg26695010	chr11:65641043	EFEMP2	0.5	6.43	0.37	5.84e-10	Eosinophil percentage of white cells;
CESC	cis	rs7542091	0.669	rs11119357	chr1:210042382	C/T	cg22029157	chr1:209979665	IRF6	0.49	7.58	0.42	5.74e-13	Monobrow;
CESC	cis	rs6681460	0.966	rs10889643	chr1:67143368	G/C	cg02459107	chr1:67143332	SGIP1	0.38	5.47	0.32	1.03e-7	Presence of antiphospholipid antibodies;
CESC	cis	rs329122	0.528	rs11242219	chr5:133848760	A/G	cg26284174	chr5:133860141	NA	0.45	5.13	0.3	5.62e-7	Body mass index;Type 2 diabetes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14475554	chr1:209799191	LAMB3	-0.57	-6.6	-0.38	2.21e-10	Gut microbiome composition (summer);
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg24641125	chr21:40721130	HMGN1	-0.46	-6.02	-0.35	5.67e-9	Asthma;
CESC	cis	rs514406	0.505	rs835609	chr1:53170494	T/C	cg27535305	chr1:53392650	SCP2	-0.33	-5.47	-0.32	1.06e-7	Monocyte count;
CESC	cis	rs7116495	0.609	rs2155142	chr11:71642524	A/G	cg26138937	chr11:71823887	C11orf51	1.18	8.24	0.45	8.18e-15	Severe influenza A (H1N1) infection;
CESC	cis	rs7666738	0.962	rs17027204	chr4:98997049	G/A	cg03676636	chr4:99064102	C4orf37	0.34	5.07	0.3	7.65e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9916302	0.861	rs2338801	chr17:37490780	G/T	cg20243544	chr17:37824526	PNMT	-0.46	-5.86	-0.34	1.37e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs6499755	0.712	rs31091	chr16:55363818	T/C	cg02859129	chr16:55357253	IRX6	0.32	5.05	0.3	8.04e-7	Hypospadias;
CESC	cis	rs12971120	0.891	rs4891558	chr18:72170359	A/G	cg25817165	chr18:72167213	CNDP2	-0.58	-6.78	-0.38	7.61e-11	Refractive error;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15168842	chr8:144766844	ZNF707	0.57	6.34	0.36	1.01e-9	Gut microbiome composition (summer);
CESC	cis	rs3762318	1.000	rs12090164	chr1:67600163	G/A	cg17031739	chr1:67600172	NA	0.52	5.54	0.32	7.2e-8	Leprosy;
CESC	cis	rs17253792	0.822	rs79291233	chr14:56065302	G/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.84	5.62	0.33	4.81e-8	Putamen volume;
CESC	cis	rs4835473	0.900	rs10003922	chr4:144842388	C/T	cg25736465	chr4:144833511	NA	-0.46	-7.12	-0.4	1.02e-11	Immature fraction of reticulocytes;
CESC	cis	rs3733585	0.578	rs6837224	chr4:9955255	G/T	cg00071950	chr4:10020882	SLC2A9	-0.69	-11.31	-0.57	1.83e-24	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs17376456	0.877	rs10050465	chr5:93349963	C/A	cg25358565	chr5:93447407	FAM172A	1.1	10.7	0.55	1.98e-22	Diabetic retinopathy;
CESC	cis	rs6582630	0.537	rs1829579	chr12:38420555	A/G	cg13010199	chr12:38710504	ALG10B	0.47	6.1	0.35	3.7e-9	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs7402982	0.625	rs12905392	chr15:99199212	G/A	cg03437748	chr15:99193247	IGF1R	0.66	8.6	0.47	7.04e-16	Birth weight;
CESC	cis	rs7100689	0.577	rs2236569	chr10:82043576	G/A	cg00277334	chr10:82204260	NA	-0.52	-6.86	-0.39	4.86e-11	Post bronchodilator FEV1;
CESC	cis	rs10838687	0.736	rs3781620	chr11:47259264	G/C	cg25783544	chr11:47291846	MADD	0.57	6.52	0.37	3.55e-10	Proinsulin levels;
CESC	cis	rs4665809	1.000	rs4665816	chr2:26305094	G/C	cg27170947	chr2:26402098	FAM59B	-0.57	-6.75	-0.38	9.43e-11	Gut microbiome composition (summer);
CESC	cis	rs6952808	0.792	rs4421257	chr7:1955152	T/C	cg02951883	chr7:2050386	MAD1L1	-0.42	-5.68	-0.33	3.58e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs2370759	1.000	rs11594459	chr10:32561858	A/C	cg01819863	chr10:32635814	EPC1	1.16	12.08	0.6	4.67e-27	Sexual dysfunction (female);
CESC	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg09060608	chr5:178986726	RUFY1	0.54	8.48	0.46	1.59e-15	Lung cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18046087	chr11:66035276	KLC2;RAB1B	-0.67	-7.84	-0.43	1.12e-13	Gut microbiome composition (summer);
CESC	cis	rs561341	1.000	rs55643307	chr17:30263074	T/C	cg00745463	chr17:30367425	LRRC37B	-0.83	-7.43	-0.42	1.49e-12	Hip circumference adjusted for BMI;
CESC	cis	rs4563143	0.592	rs12151001	chr19:29283386	C/G	cg12756686	chr19:29218302	NA	0.55	6.67	0.38	1.51e-10	Methadone dose in opioid dependence;
CESC	cis	rs7666738	0.830	rs1834645	chr4:98979593	T/A	cg03676636	chr4:99064102	C4orf37	0.34	5.2	0.3	3.93e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg17541715	chr7:1216824	NA	-0.38	-5.16	-0.3	4.91e-7	Longevity;Endometriosis;
CESC	cis	rs7659604	0.517	rs56311153	chr4:122729685	T/C	cg06713675	chr4:122721982	EXOSC9	-0.51	-7.01	-0.4	1.94e-11	Type 2 diabetes;
CESC	cis	rs933688	0.941	rs6452954	chr5:90735692	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.12	15.37	0.69	1.48e-38	Smoking behavior;
CESC	cis	rs854765	0.583	rs4553680	chr17:17857722	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.55	7.47	0.42	1.16e-12	Total body bone mineral density;
CESC	cis	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg21782813	chr7:2030301	MAD1L1	-0.43	-6.15	-0.35	2.89e-9	Bipolar disorder and schizophrenia;
CESC	trans	rs11098499	0.909	rs10017335	chr4:120381523	C/G	cg25214090	chr10:38739885	LOC399744	-0.66	-9.15	-0.49	1.61e-17	Corneal astigmatism;
CESC	cis	rs72945132	0.882	rs72945168	chr11:70131471	G/C	cg00319359	chr11:70116639	PPFIA1	0.78	7.78	0.43	1.6e-13	Coronary artery disease;
CESC	cis	rs10416265	0.527	rs7246814	chr19:33538414	G/T	cg03563238	chr19:33554763	RHPN2	-0.31	-5.58	-0.32	5.97e-8	Bone properties (heel);
CESC	cis	rs7613875	0.578	rs2624822	chr3:50107219	T/C	cg24308560	chr3:49941425	MST1R	0.6	8.72	0.47	3.17e-16	Body mass index;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17888837	chr1:27986674	NA	0.56	6.43	0.37	6.06e-10	Gut microbiome composition (summer);
CESC	cis	rs7811142	0.830	rs6945952	chr7:99981775	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.08	10.92	0.56	3.59e-23	Platelet count;
CESC	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	22.0	0.8	9.67e-62	Prudent dietary pattern;
CESC	cis	rs4253772	0.530	rs11704350	chr22:46671507	C/T	cg24881330	chr22:46731750	TRMU	0.78	5.86	0.34	1.34e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs4819052	0.851	rs2838829	chr21:46664040	A/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.47	5.86	0.34	1.37e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs17376456	0.825	rs13164315	chr5:93147421	A/G	cg21475434	chr5:93447410	FAM172A	0.83	7.35	0.41	2.41e-12	Diabetic retinopathy;
CESC	cis	rs9399137	0.507	rs35571217	chr6:135290355	T/C	cg24558204	chr6:135376177	HBS1L	0.7	9.64	0.51	4.87e-19	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg02056921	chr1:901892	PLEKHN1	-0.44	-6.24	-0.36	1.68e-9	Gambling;
CESC	cis	rs9733	0.596	rs72700897	chr1:150626038	C/G	cg18016565	chr1:150552671	MCL1	0.33	5.13	0.3	5.67e-7	Tonsillectomy;
CESC	cis	rs7312933	0.703	rs1059360	chr12:42554505	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.47	6.13	0.35	3.23e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs921968	0.643	rs484085	chr2:219396684	C/T	cg02176678	chr2:219576539	TTLL4	0.42	7.44	0.42	1.43e-12	Mean corpuscular hemoglobin concentration;
CESC	cis	rs8038465	0.874	rs12591553	chr15:73993755	G/A	cg15420318	chr15:73925796	NPTN	0.41	5.83	0.34	1.57e-8	Liver enzyme levels (gamma-glutamyl transferase);
CESC	trans	rs970548	0.697	rs11239540	chr10:45999209	T/C	cg16175941	chr6:154779103	CNKSR3	0.59	6.46	0.37	4.95e-10	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
CESC	cis	rs780096	0.526	rs1260342	chr2:27663416	G/T	cg22903471	chr2:27725779	GCKR	-0.52	-7.39	-0.41	1.88e-12	Total body bone mineral density;
CESC	cis	rs2230307	0.536	rs482466	chr1:100488177	C/T	cg24955406	chr1:100503596	HIAT1	0.53	5.35	0.31	1.91e-7	Carotid intima media thickness;
CESC	cis	rs2839186	0.709	rs2839176	chr21:47678173	A/G	cg05896524	chr21:47604654	C21orf56	0.42	5.39	0.31	1.58e-7	Testicular germ cell tumor;
CESC	trans	rs561341	1.000	rs8077092	chr17:30281992	T/C	cg27661571	chr11:113659931	NA	-0.7	-7.19	-0.4	6.82e-12	Hip circumference adjusted for BMI;
CESC	cis	rs7072216	0.763	rs10748729	chr10:100171371	G/C	cg26618903	chr10:100175079	PYROXD2	-0.38	-5.78	-0.33	2.05e-8	Metabolite levels;
CESC	cis	rs7089973	0.584	rs7908665	chr10:116611337	G/A	cg25233709	chr10:116636983	FAM160B1	0.4	6.63	0.38	1.93e-10	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs7714584	1.000	rs12054923	chr5:150249059	A/G	cg22134413	chr5:150180641	NA	0.51	5.64	0.33	4.46e-8	Crohn's disease;
CESC	cis	rs9322193	0.923	rs55993747	chr6:149943152	A/G	cg13206674	chr6:150067644	NUP43	0.43	6.23	0.36	1.82e-9	Lung cancer;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg13456812	chr6:167369504	RNASET2	0.46	6.3	0.36	1.22e-9	Systemic lupus erythematosus;
CESC	cis	rs2243480	1.000	rs781150	chr7:65480973	C/T	cg12463550	chr7:65579703	CRCP	0.69	5.5	0.32	9.17e-8	Diabetic kidney disease;
CESC	trans	rs6460942	0.556	rs10228123	chr7:12374025	A/C	cg16269144	chr1:2003326	PRKCZ	0.5	6.16	0.35	2.73e-9	Coronary artery disease;
CESC	trans	rs877282	0.838	rs34912955	chr10:772222	T/C	cg22713356	chr15:30763199	NA	1.26	12.75	0.62	2.39e-29	Uric acid levels;
CESC	trans	rs61931739	0.500	rs34418276	chr12:34535976	C/T	cg26384229	chr12:38710491	ALG10B	0.71	10.54	0.54	6.28e-22	Morning vs. evening chronotype;
CESC	cis	rs10504229	0.683	rs903706	chr8:58128134	T/G	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs9487051	0.714	rs6927569	chr6:109621494	T/C	cg01475377	chr6:109611718	NA	-0.43	-6.64	-0.38	1.74e-10	Reticulocyte fraction of red cells;
CESC	cis	rs921968	0.541	rs667251	chr2:219384384	C/G	cg02176678	chr2:219576539	TTLL4	0.5	9.09	0.49	2.31e-17	Mean corpuscular hemoglobin concentration;
CESC	cis	rs733175	0.855	rs9291640	chr4:10007086	C/T	cg00071950	chr4:10020882	SLC2A9	0.54	6.53	0.37	3.27e-10	Psychosis and Alzheimer's disease;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg02099313	chr1:231114956	TTC13;ARV1	-0.43	-6.24	-0.36	1.74e-9	Gambling;
CESC	cis	rs1799949	1.000	rs9646417	chr17:41424253	G/A	cg05368731	chr17:41323189	NBR1	0.78	10.53	0.54	6.98e-22	Menopause (age at onset);
CESC	cis	rs4843747	0.671	rs28451517	chr16:88109127	A/C	cg06915872	chr16:87998081	BANP	0.45	5.32	0.31	2.26e-7	Menopause (age at onset);
CESC	trans	rs11098499	0.697	rs28458294	chr4:120238924	T/C	cg25214090	chr10:38739885	LOC399744	0.59	8.11	0.45	1.85e-14	Corneal astigmatism;
CESC	cis	rs55788414	0.932	rs35066366	chr16:81185280	G/A	cg06400318	chr16:81190750	PKD1L2	-0.6	-6.82	-0.39	6.19e-11	Left ventricular obstructive tract defect (maternal effect);
CESC	cis	rs425277	1.000	rs262654	chr1:2089526	G/A	cg24578937	chr1:2090814	PRKCZ	0.53	8.99	0.48	4.93e-17	Height;
CESC	trans	rs11165623	0.715	rs1980769	chr1:96888201	A/T	cg10631902	chr5:14652156	NA	-0.55	-8.35	-0.46	3.81e-15	Hip circumference;Waist circumference;
CESC	cis	rs4808199	0.895	rs4808194	chr19:19435680	T/G	cg03709012	chr19:19516395	GATAD2A	1.08	12.07	0.6	5.22e-27	Nonalcoholic fatty liver disease;
CESC	cis	rs72781680	1.000	rs72781675	chr2:24232092	G/A	cg08917208	chr2:24149416	ATAD2B	1.06	9.33	0.5	4.33e-18	Lymphocyte counts;
CESC	cis	rs734999	0.588	rs4648562	chr1:2535613	C/A	cg18854424	chr1:2615690	NA	0.27	5.24	0.31	3.32e-7	Ulcerative colitis;
CESC	cis	rs6691722	0.503	rs7546875	chr1:24703667	T/C	cg18323236	chr1:24743029	NIPAL3	0.36	5.38	0.31	1.63e-7	Response to interferon beta in multiple sclerosis;
CESC	cis	rs8177253	1.000	rs8177248	chr3:133479626	C/T	cg11941060	chr3:133502564	NA	-0.47	-6.32	-0.36	1.13e-9	Iron status biomarkers;
CESC	cis	rs7666738	0.830	rs62318471	chr4:98925848	G/A	cg17366294	chr4:99064904	C4orf37	0.6	8.23	0.45	8.65e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2228479	0.541	rs62052173	chr16:89950739	T/C	cg04013166	chr16:89971882	TCF25	0.72	8.82	0.48	1.58e-16	Skin colour saturation;
CESC	cis	rs9611565	0.765	rs132915	chr22:41805782	T/C	cg06634786	chr22:41940651	POLR3H	0.71	7.47	0.42	1.16e-12	Vitiligo;
CESC	cis	rs4704187	0.624	rs35719345	chr5:74551962	T/C	cg03227963	chr5:74354835	NA	0.29	5.34	0.31	2.04e-7	Response to amphetamines;
CESC	trans	rs7618501	0.602	rs2526754	chr3:50125996	G/A	cg21659725	chr3:3221576	CRBN	-0.51	-7.04	-0.4	1.66e-11	Intelligence (multi-trait analysis);
CESC	cis	rs5769765	0.955	rs2319465	chr22:50265784	A/C	cg22709217	chr22:50311962	ALG12;CRELD2	0.46	5.32	0.31	2.21e-7	Schizophrenia;
CESC	cis	rs10129255	0.500	rs988134	chr14:107184937	A/G	cg23076370	chr14:107095027	NA	-0.66	-9.85	-0.52	1.01e-19	Kawasaki disease;
CESC	cis	rs1003719	0.788	rs9975168	chr21:38450557	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-8.67	-0.47	4.29e-16	Eye color traits;
CESC	cis	rs11638352	0.661	rs2114415	chr15:44432894	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	-0.56	-5.29	-0.31	2.53e-7	Lipoprotein phospholipase A2 activity in cardiovascular disease;
CESC	cis	rs8033133	0.678	rs7496110	chr15:25347013	A/G	cg14481604	chr15:25334117	SNORD116-22	-0.35	-5.46	-0.32	1.12e-7	Blood osmolality (transformed sodium);
CESC	trans	rs7089973	0.523	rs11197017	chr10:116737738	C/A	cg17463145	chr7:79084011	MAGI2	0.31	6.15	0.35	2.89e-9	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs9818941	0.824	rs12632906	chr3:157726384	T/A	cg08654915	chr3:157813417	NA	-0.45	-7.55	-0.42	6.85e-13	Height;
CESC	cis	rs8114671	0.586	rs734111	chr20:33533736	A/C	cg07148914	chr20:33460835	GGT7	0.52	6.8	0.39	6.92e-11	Height;
CESC	cis	rs3820068	0.822	rs2901964	chr1:15792426	C/G	cg18192808	chr1:15853278	DNAJC16	0.48	5.73	0.33	2.65e-8	Systolic blood pressure;
CESC	cis	rs4076764	0.846	rs12035840	chr1:163419177	G/C	cg24596788	chr1:163392923	NA	-0.41	-5.84	-0.34	1.51e-8	Motion sickness;
CESC	cis	rs8180040	0.934	rs62260710	chr3:47564462	C/G	cg27129171	chr3:47204927	SETD2	-0.61	-8.52	-0.46	1.23e-15	Colorectal cancer;
CESC	cis	rs8005677	0.828	rs8016027	chr14:23420153	T/C	cg01529538	chr14:23388837	RBM23	0.44	5.83	0.34	1.64e-8	Cognitive ability (multi-trait analysis);
CESC	cis	rs10170846	0.626	rs9288575	chr2:223495133	A/C	cg25565276	chr2:223520875	FARSB	1.09	14.97	0.68	3.99e-37	Schizophrenia (inflammation and infection response interaction);
CESC	cis	rs9322193	0.962	rs3805753	chr6:150116798	C/T	cg13206674	chr6:150067644	NUP43	0.41	5.67	0.33	3.77e-8	Lung cancer;
CESC	cis	rs67478160	0.643	rs2887282	chr14:104280734	A/G	cg08213375	chr14:104286397	PPP1R13B	0.48	9.11	0.49	2.02e-17	Schizophrenia;
CESC	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg10295955	chr4:187884368	NA	-1.08	-23.01	-0.82	4.07e-65	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1048238	0.846	rs945419	chr1:16344858	C/T	cg21214613	chr1:16344536	HSPB7	0.34	5.61	0.33	5.06e-8	Systolic blood pressure;
CESC	cis	rs524023	0.914	rs11231845	chr11:64407419	G/A	cg07220939	chr11:64358617	SLC22A12	-0.35	-5.33	-0.31	2.14e-7	Urate levels in obese individuals;
CESC	cis	rs1729951	0.575	rs16844325	chr3:136678161	C/G	cg25687071	chr3:136751404	NA	0.39	5.07	0.3	7.55e-7	Neuroticism;
CESC	cis	rs7259376	0.936	rs7259586	chr19:22537862	C/T	cg02657401	chr19:22469223	NA	-0.25	-5.23	-0.31	3.38e-7	Menopause (age at onset);
CESC	cis	rs1580019	0.587	rs7806113	chr7:32553084	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.52	6.69	0.38	1.33e-10	Cognitive ability;
CESC	trans	rs1728785	1.000	rs1624718	chr16:68580385	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.61	7.49	0.42	1.04e-12	Ulcerative colitis;
CESC	cis	rs7927771	1.000	rs4752873	chr11:47857520	C/T	cg20307385	chr11:47447363	PSMC3	-0.49	-6.04	-0.35	5.24e-9	Subjective well-being;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg13888710	chr4:39699558	UBE2K	-0.47	-6.12	-0.35	3.28e-9	Fibrinogen levels;
CESC	cis	rs2066819	1.000	rs75598973	chr12:56746558	C/T	cg26734620	chr12:56694298	CS	0.97	5.81	0.34	1.76e-8	Psoriasis vulgaris;
CESC	cis	rs2777491	0.574	rs11858812	chr15:41731550	G/A	cg20272979	chr15:41787780	ITPKA	0.43	5.31	0.31	2.37e-7	Ulcerative colitis;
CESC	cis	rs8103278	0.740	rs72626215	chr19:46294136	G/A	cg12641515	chr19:46296257	DMWD	-0.57	-5.74	-0.33	2.65e-8	Coronary artery disease;
CESC	cis	rs2243480	1.000	rs10807702	chr7:65767843	C/T	cg18252515	chr7:66147081	NA	-1.27	-11.84	-0.59	3.11e-26	Diabetic kidney disease;
CESC	cis	rs758324	0.617	rs12719447	chr5:131118100	C/A	cg06307176	chr5:131281290	NA	0.43	5.16	0.3	4.9e-7	Alzheimer's disease in APOE e4- carriers;
CESC	cis	rs4713118	0.540	rs469227	chr6:27970705	A/C	cg18032046	chr6:28092343	ZSCAN16	-0.54	-6.5	-0.37	3.97e-10	Parkinson's disease;
CESC	cis	rs8177179	0.967	rs9820225	chr3:133449189	A/G	cg18769074	chr3:133464867	TF	0.32	6.1	0.35	3.64e-9	Iron status biomarkers (transferrin levels);
CESC	cis	rs6942756	0.840	rs963465	chr7:128875612	C/G	cg02491457	chr7:128862824	NA	0.64	9.54	0.51	1.02e-18	White matter hyperintensity burden;
CESC	cis	rs6977660	0.652	rs10486362	chr7:19755224	A/G	cg07541023	chr7:19748670	TWISTNB	-0.83	-7.21	-0.41	5.77e-12	Thyroid stimulating hormone;
CESC	cis	rs7208859	0.673	rs9891179	chr17:29208160	G/T	cg19761014	chr17:28927070	LRRC37B2	0.72	5.71	0.33	3.06e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs9913156	0.707	rs11657052	chr17:4570573	C/T	cg19197139	chr17:4613644	ARRB2	-0.84	-9.8	-0.52	1.55e-19	Lymphocyte counts;
CESC	cis	rs4835473	0.932	rs4383567	chr4:144710026	G/A	cg25736465	chr4:144833511	NA	0.31	5.03	0.3	8.84e-7	Immature fraction of reticulocytes;
CESC	cis	rs698813	0.604	rs768006	chr2:44487612	C/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	5.6	0.33	5.26e-8	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
CESC	cis	rs2050392	0.517	rs656600	chr10:30765654	G/A	cg18806716	chr10:30721971	MAP3K8	-0.45	-6.81	-0.39	6.52e-11	Inflammatory bowel disease;
CESC	cis	rs507506	0.771	rs929229	chr17:7105399	C/T	cg25256661	chr17:7137939	DVL2	0.59	7.64	0.42	4.08e-13	Adiponectin levels;
CESC	cis	rs9611565	0.592	rs28750375	chr22:41990644	A/C	cg03806693	chr22:41940476	POLR3H	-0.86	-10.18	-0.53	9.25e-21	Vitiligo;
CESC	cis	rs3767633	0.925	rs4656335	chr1:161822078	A/G	cg09175582	chr1:161736000	ATF6	0.8	6.06	0.35	4.57e-9	IgG glycosylation;
CESC	cis	rs6578985	0.636	rs3213225	chr11:2156536	C/T	cg25406011	chr11:1254421	MUC5B	-0.33	-5.19	-0.3	4.25e-7	Femoral neck bone geometry and menarche (age at onset);
CESC	cis	rs66887589	0.660	rs4833613	chr4:120150156	A/C	cg09307838	chr4:120376055	NA	-0.46	-6.02	-0.35	5.82e-9	Diastolic blood pressure;
CESC	cis	rs7809950	1.000	rs2293658	chr7:107270567	C/T	cg23024343	chr7:107201750	COG5	-0.51	-7.19	-0.4	6.65e-12	Coronary artery disease;
CESC	cis	rs864537	0.676	rs2056626	chr1:167420425	T/G	cg22356347	chr1:167427500	CD247	-0.39	-8.1	-0.45	1.97e-14	Celiac disease or Rheumatoid arthritis;Celiac disease;
CESC	cis	rs72792276	1.000	rs13357283	chr5:127423114	G/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.65	5.91	0.34	1.07e-8	Red cell distribution width;
CESC	cis	rs853679	0.760	rs9468317	chr6:28198456	A/G	cg19592336	chr6:28129416	ZNF389	0.42	5.47	0.32	1.04e-7	Depression;
CESC	cis	rs514406	0.861	rs2065477	chr1:53250213	C/T	cg08859206	chr1:53392774	SCP2	-0.55	-7.19	-0.4	6.76e-12	Monocyte count;
CESC	cis	rs12541635	0.677	rs7846149	chr8:107053417	T/C	cg10147462	chr8:107024639	NA	0.48	7.18	0.4	6.92e-12	Age of smoking initiation;
CESC	cis	rs559928	0.548	rs11231713	chr11:63931849	C/T	cg18225595	chr11:63971243	STIP1	0.74	6.28	0.36	1.39e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CESC	cis	rs4662945	0.525	rs10174479	chr2:130296287	A/C	cg05903289	chr2:130345205	NA	-0.44	-7.02	-0.4	1.91e-11	Response to cytidine analogues (gemcitabine);
CESC	cis	rs7762018	1.000	rs4716380	chr6:170090399	A/G	cg05834625	chr6:170176447	C6orf70	0.62	7.44	0.42	1.36e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs6032067	0.777	rs979641	chr20:43786336	C/T	cg10761708	chr20:43804764	PI3	0.56	6.55	0.37	3.01e-10	Blood protein levels;
CESC	trans	rs864643	0.773	rs11129837	chr3:39589963	A/G	cg02372393	chr17:45973417	SP2	0.52	6.65	0.38	1.63e-10	Attention deficit hyperactivity disorder;
CESC	cis	rs7814319	0.840	rs10504961	chr8:97240129	C/T	cg20787634	chr8:97240163	UQCRB	-0.63	-8.2	-0.45	1.03e-14	Lung function (FVC);
CESC	cis	rs344364	0.511	rs1657144	chr16:1963989	C/A	cg03013636	chr16:1946785	NA	0.44	5.57	0.32	6.2e-8	Glomerular filtration rate in chronic kidney disease;
CESC	trans	rs239339	0.959	rs75411	chr1:4425414	C/T	cg06451177	chr17:79412583	BAHCC1	0.52	6.11	0.35	3.63e-9	Obesity-related traits;
CESC	cis	rs9322193	0.962	rs2342764	chr6:150156204	G/A	cg09699651	chr6:150184138	LRP11	0.45	5.74	0.33	2.56e-8	Lung cancer;
CESC	cis	rs7618915	0.501	rs767418	chr3:52767427	C/T	cg07507251	chr3:52567010	NT5DC2	0.33	5.64	0.33	4.28e-8	Bipolar disorder;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg24663683	chr5:39721720	NA	0.49	6.72	0.38	1.13e-10	Fibrinogen levels;
CESC	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg05552183	chr6:42928497	GNMT	0.78	12.08	0.6	4.61e-27	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs524281	0.861	rs580891	chr11:65954681	A/C	cg14036092	chr11:66035641	RAB1B	-0.5	-5.6	-0.33	5.34e-8	Electroencephalogram traits;
CESC	cis	rs9649213	0.593	rs12704982	chr7:97926053	C/T	cg00277769	chr7:97922759	BAIAP2L1	-0.34	-5.62	-0.33	4.89e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs2235544	0.588	rs662603	chr1:54467767	T/C	cg25741118	chr1:54482237	LDLRAD1	0.24	5.77	0.33	2.2e-8	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
CESC	cis	rs26868	0.766	rs27556	chr16:2249325	T/C	cg02248941	chr16:2239361	CASKIN1	0.39	6.2	0.36	2.19e-9	Height;
CESC	cis	rs4689388	0.727	rs1801213	chr4:6293696	C/G	cg25554036	chr4:6271136	WFS1	0.49	7.55	0.42	7.23e-13	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg14290704	chr9:2015039	SMARCA2	-0.47	-6.45	-0.37	5.18e-10	Asthma;
CESC	cis	rs250677	0.522	rs6580589	chr5:148360335	C/G	cg18129178	chr5:148520854	ABLIM3	0.47	5.16	0.3	4.93e-7	Breast cancer;
CESC	cis	rs875971	0.660	rs801211	chr7:66015689	T/G	cg14393609	chr7:65229607	NA	-0.47	-6.31	-0.36	1.14e-9	Aortic root size;
CESC	cis	rs9399401	0.601	rs262130	chr6:142853486	C/T	cg03128060	chr6:142623767	GPR126	0.33	5.41	0.32	1.44e-7	Chronic obstructive pulmonary disease;
CESC	cis	rs798554	0.757	rs1182171	chr7:2878510	A/G	cg09658497	chr7:2847517	GNA12	-0.42	-5.91	-0.34	1.04e-8	Height;
CESC	cis	rs853679	0.517	rs9357065	chr6:28129580	T/C	cg17949981	chr6:28129498	ZNF389	0.45	5.52	0.32	8.18e-8	Depression;
CESC	cis	rs6540556	0.768	rs6692012	chr1:209935490	A/G	cg23920097	chr1:209922102	NA	-0.37	-5.59	-0.32	5.64e-8	Red blood cell count;
CESC	cis	rs2050392	0.630	rs303427	chr10:30739780	G/A	cg18806716	chr10:30721971	MAP3K8	-0.43	-6.3	-0.36	1.2e-9	Inflammatory bowel disease;
CESC	trans	rs4716602	0.596	rs10258969	chr7:156157753	A/G	cg07175507	chr18:77160758	NFATC1	-0.45	-6.13	-0.35	3.13e-9	Anti-saccade response;
CESC	cis	rs8114671	0.628	rs6060130	chr20:33549319	C/T	cg24642439	chr20:33292090	TP53INP2	0.42	5.06	0.3	7.84e-7	Height;
CESC	cis	rs7680126	0.632	rs11731464	chr4:10148376	G/A	cg11266682	chr4:10021025	SLC2A9	-0.49	-5.99	-0.35	6.87e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	cis	rs7618915	0.501	rs1866268	chr3:52719398	C/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.53	8.02	0.44	3.41e-14	Bipolar disorder;
CESC	cis	rs9549367	0.789	rs6577035	chr13:113879997	G/A	cg00898013	chr13:113819073	PROZ	-0.49	-6.87	-0.39	4.59e-11	Platelet distribution width;
CESC	cis	rs72949976	0.934	rs1922794	chr2:214026181	G/A	cg08319019	chr2:214017104	IKZF2	-0.47	-5.94	-0.34	9.11e-9	Lung cancer;Squamous cell lung carcinoma;
CESC	cis	rs9486719	0.857	rs6568392	chr6:96861476	G/T	cg06623918	chr6:96969491	KIAA0776	0.88	10.34	0.54	2.8e-21	Migraine;Coronary artery disease;
CESC	cis	rs9611565	0.512	rs9611667	chr22:42187015	C/T	cg06634786	chr22:41940651	POLR3H	-0.67	-6.45	-0.37	5.19e-10	Vitiligo;
CESC	cis	rs12926788	0.640	rs12924246	chr16:24844629	A/G	cg06505273	chr16:24850292	NA	0.52	6.4	0.37	6.83e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs17490626	0.533	rs12771890	chr10:71189483	T/A	cg12610070	chr10:71211762	TSPAN15	-0.35	-7.37	-0.41	2.24e-12	Thrombosis;
CESC	cis	rs344364	0.511	rs1742463	chr16:1946110	A/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.55	-6.2	-0.36	2.15e-9	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs11871801	1.000	rs34610643	chr17:40574388	A/C	cg21433558	chr17:40837037	CNTNAP1	0.45	5.04	0.3	8.46e-7	Crohn's disease;
CESC	cis	rs1801251	1.000	rs1022330	chr2:233577330	G/A	cg25237894	chr2:233734115	C2orf82	0.48	8.11	0.45	1.86e-14	Coronary artery disease;
CESC	cis	rs7178909	0.872	rs3867167	chr15:90433790	T/C	cg19708238	chr15:90437601	AP3S2	0.37	5.12	0.3	5.94e-7	Common traits (Other);
CESC	cis	rs7666738	0.830	rs11947027	chr4:99005941	T/C	cg05340658	chr4:99064831	C4orf37	0.8	12.44	0.61	2.83e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2857078	0.627	rs1476512	chr17:42330122	C/T	cg08499158	chr17:42289980	UBTF	0.4	5.11	0.3	6.26e-7	Red cell distribution width;Reticulocyte count;
CESC	cis	rs4803468	1.000	rs3810175	chr19:41904396	C/T	cg09537434	chr19:41945824	ATP5SL	1.07	19.38	0.77	1.01e-52	Height;
CESC	cis	rs6089829	0.962	rs2277769	chr20:61666805	C/T	cg16240275	chr20:61666158	NCRNA00029	0.51	9.47	0.5	1.64e-18	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs854765	0.547	rs8069811	chr17:17922280	G/A	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.54	7.32	0.41	2.99e-12	Total body bone mineral density;
CESC	cis	rs929354	0.742	rs6956046	chr7:156962874	G/A	cg05182265	chr7:156933206	UBE3C	-0.5	-7.3	-0.41	3.44e-12	Body mass index;
CESC	cis	rs6831352	0.918	rs2602895	chr4:100045840	C/T	cg12011299	chr4:100065546	ADH4	0.59	6.68	0.38	1.41e-10	Alcohol dependence;
CESC	cis	rs8141529	0.748	rs5752826	chr22:29269808	A/G	cg15103426	chr22:29168792	CCDC117	0.6	7.85	0.43	1.01e-13	Lymphocyte counts;
CESC	cis	rs7212590	0.748	rs7211208	chr17:57957109	A/C	cg20303301	chr17:57937339	TUBD1	-0.55	-5.5	-0.32	8.8e-8	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs9354308	0.868	rs1938063	chr6:66559098	T/G	cg07460842	chr6:66804631	NA	-0.51	-6.18	-0.35	2.44e-9	Metabolite levels;
CESC	cis	rs7618915	0.501	rs13085775	chr3:52678370	C/T	cg17372223	chr3:52568218	NT5DC2	0.42	6.49	0.37	4.27e-10	Bipolar disorder;
CESC	cis	rs798554	0.679	rs2533870	chr7:2885274	C/G	cg13628971	chr7:2884303	GNA12	-0.64	-9.05	-0.49	3.17e-17	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06821919	chr20:16710653	SNRPB2	0.57	6.65	0.38	1.67e-10	Gut microbiome composition (summer);
CESC	cis	rs2836633	0.929	rs58120977	chr21:40037346	C/T	cg05519781	chr21:40033154	ERG	0.78	13.52	0.64	5.12e-32	Coronary artery disease;
CESC	trans	rs61931739	0.534	rs4001713	chr12:34154195	A/C	cg26384229	chr12:38710491	ALG10B	-0.64	-9.08	-0.49	2.6e-17	Morning vs. evening chronotype;
CESC	trans	rs11874712	1.000	rs1800639	chr18:43671240	G/T	cg00163037	chr11:43964802	LOC387763	-0.35	-5.99	-0.35	6.67e-9	Migraine - clinic-based;
CESC	cis	rs4835473	0.900	rs34264936	chr4:144701447	A/G	cg25736465	chr4:144833511	NA	-0.42	-6.42	-0.37	6.21e-10	Immature fraction of reticulocytes;
CESC	cis	rs911555	0.662	rs4906322	chr14:103879032	A/G	cg24130564	chr14:104152367	KLC1	0.48	6.33	0.36	1.05e-9	Intelligence (multi-trait analysis);
CESC	cis	rs7927592	0.763	rs4340059	chr11:68362433	A/G	cg01657329	chr11:68192670	LRP5	-0.47	-6.13	-0.35	3.09e-9	Total body bone mineral density;
CESC	cis	rs6424115	0.867	rs34902309	chr1:24192200	A/G	cg15997130	chr1:24165203	NA	-0.43	-5.78	-0.33	2.07e-8	Immature fraction of reticulocytes;
CESC	cis	rs80282103	0.571	rs56183119	chr10:1068370	C/T	cg08668510	chr10:1095578	IDI1	0.69	5.63	0.33	4.62e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs9611519	0.964	rs5995992	chr22:41487218	T/C	cg03806693	chr22:41940476	POLR3H	-0.55	-5.54	-0.32	7.36e-8	Neuroticism;
CESC	cis	rs6920364	1	rs6920364	chr6:167376466	G/C	cg07741184	chr6:167504864	NA	-0.3	-5.38	-0.31	1.66e-7	Lung cancer;
CESC	cis	rs561341	0.941	rs501773	chr17:30314435	T/G	cg12193833	chr17:30244370	NA	-0.57	-5.86	-0.34	1.37e-8	Hip circumference adjusted for BMI;
CESC	cis	rs10865541	0.545	rs10176868	chr2:3383662	C/T	cg11855769	chr2:3383351	TTC15	-0.45	-5.54	-0.32	7.47e-8	Obesity-related traits;
CESC	cis	rs317689	0.690	rs7969559	chr12:69655167	A/G	cg20891283	chr12:69753455	YEATS4	0.49	5.5	0.32	9.05e-8	Response to diuretic therapy;
CESC	cis	rs13385	0.769	rs17118739	chr5:139597910	C/T	cg26211634	chr5:139558579	C5orf32	0.47	5.19	0.3	4.12e-7	Atrial fibrillation;
CESC	cis	rs3091242	0.933	rs61775167	chr1:25780893	A/G	cg03538708	chr1:25844672	NA	0.39	5.96	0.34	7.91e-9	Erythrocyte sedimentation rate;
CESC	cis	rs17021463	0.872	rs11097417	chr4:95268071	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.51	-7.44	-0.42	1.39e-12	Testicular germ cell tumor;
CESC	cis	rs55823223	0.648	rs936393	chr17:73847613	A/G	cg23806715	chr17:73775811	H3F3B	0.61	6.79	0.38	7.55e-11	Psoriasis;
CESC	cis	rs9549367	0.577	rs3024711	chr13:113813268	A/G	cg18105134	chr13:113819100	PROZ	-0.75	-8.64	-0.47	5.49e-16	Platelet distribution width;
CESC	cis	rs67311347	1.000	rs9835219	chr3:40424093	C/T	cg09455208	chr3:40491958	NA	0.42	6.94	0.39	3.09e-11	Renal cell carcinoma;
CESC	cis	rs9910055	0.659	rs112114764	chr17:42201041	G/T	cg10896456	chr17:42255109	ASB16;C17orf65	-0.49	-7.35	-0.41	2.43e-12	Total body bone mineral density;
CESC	cis	rs4849845	0.653	rs34874174	chr2:121011980	A/C	cg24070213	chr2:121070622	NA	0.44	6.34	0.36	1.01e-9	Mean platelet volume;
CESC	cis	rs4523957	0.928	rs7406247	chr17:2157925	G/A	cg16513277	chr17:2031491	SMG6	0.6	8.29	0.45	5.67e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs3820068	0.603	rs10492986	chr1:15988702	T/C	cg17385448	chr1:15911702	AGMAT	0.43	7.11	0.4	1.1e-11	Systolic blood pressure;
CESC	cis	rs6991838	0.612	rs7842162	chr8:66556292	T/G	cg13398993	chr8:66546079	ARMC1	0.49	5.97	0.34	7.6e-9	Intelligence (multi-trait analysis);
CESC	cis	rs7116495	1.000	rs58991229	chr11:71839878	G/A	cg10381502	chr11:71823885	C11orf51	0.65	5.23	0.31	3.43e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs9302635	0.513	rs8061459	chr16:72156063	C/T	cg16558253	chr16:72132732	DHX38	-0.46	-6.04	-0.35	5.09e-9	Blood protein levels;
CESC	cis	rs4970988	0.556	rs6681426	chr1:150586971	G/A	cg22823121	chr1:150693482	HORMAD1	-0.41	-5.67	-0.33	3.82e-8	Urate levels;
CESC	cis	rs2730245	0.510	rs2788471	chr7:158649786	G/T	cg15303052	chr7:158526867	ESYT2	-0.4	-5.09	-0.3	6.69e-7	Height;
CESC	cis	rs6540559	0.673	rs7511996	chr1:210018473	C/A	cg22029157	chr1:209979665	IRF6	0.66	7.44	0.42	1.4e-12	Cleft lip with or without cleft palate;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17602823	chr1:28586543	SESN2	0.65	7.82	0.43	1.22e-13	Gut microbiome composition (summer);
CESC	cis	rs4568518	0.616	rs11766586	chr7:18003965	T/C	cg03009463	chr7:17980271	SNX13	0.43	5.72	0.33	2.91e-8	Measles;
CESC	cis	rs2952156	0.920	rs2934953	chr17:37832315	T/A	cg07936489	chr17:37558343	FBXL20	-0.55	-6.66	-0.38	1.55e-10	Asthma;
CESC	cis	rs11098499	0.697	rs6832410	chr4:120296800	A/G	cg09307838	chr4:120376055	NA	0.92	12.66	0.61	4.96e-29	Corneal astigmatism;
CESC	cis	rs6540559	0.605	rs3753518	chr1:209977964	G/C	cg25204440	chr1:209979598	IRF6	0.65	6.68	0.38	1.42e-10	Cleft lip with or without cleft palate;
CESC	cis	rs7131987	0.903	rs1035604	chr12:29393102	G/A	cg09582351	chr12:29534625	ERGIC2	-0.33	-5.25	-0.31	3.13e-7	QT interval;
CESC	cis	rs4704187	0.687	rs10050948	chr5:74484275	C/T	cg03227963	chr5:74354835	NA	0.28	5.1	0.3	6.6e-7	Response to amphetamines;
CESC	cis	rs9527	0.535	rs4917999	chr10:104963051	C/G	cg04362960	chr10:104952993	NT5C2	-0.49	-6.04	-0.35	5.16e-9	Arsenic metabolism;
CESC	cis	rs9039	1.000	rs9039	chr16:9205363	A/G	cg08831531	chr16:9218945	NA	-0.47	-6.44	-0.37	5.71e-10	Menopause (age at onset);
CESC	cis	rs9399135	0.967	rs4388304	chr6:135309597	T/A	cg24558204	chr6:135376177	HBS1L	0.5	6.72	0.38	1.11e-10	Red blood cell count;
CESC	trans	rs6981523	0.566	rs34162231	chr8:11003088	A/T	cg06636001	chr8:8085503	FLJ10661	-0.53	-6.4	-0.37	6.85e-10	Neuroticism;
CESC	cis	rs10504229	0.679	rs12679920	chr8:58051710	G/T	cg24829409	chr8:58192753	C8orf71	-0.5	-6.08	-0.35	4.07e-9	Developmental language disorder (linguistic errors);
CESC	trans	rs9858542	0.953	rs6766581	chr3:49539401	T/C	cg21659725	chr3:3221576	CRBN	-0.55	-6.49	-0.37	4.22e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs1124376	0.935	rs28716666	chr3:20148409	C/T	cg05072819	chr3:20081367	KAT2B	0.47	5.14	0.3	5.39e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs2762353	0.595	rs10498728	chr6:25751320	A/T	cg03517284	chr6:25882590	NA	-0.58	-8.26	-0.45	6.88e-15	Blood metabolite levels;
CESC	cis	rs11828289	0.607	rs76811253	chr11:23222885	G/A	cg20040320	chr11:23191996	NA	-0.68	-5.65	-0.33	4.04e-8	Cancer;
CESC	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.6	0.38	2.17e-10	Prudent dietary pattern;
CESC	cis	rs7267979	1.000	rs6050562	chr20:25336186	C/G	cg08601574	chr20:25228251	PYGB	-0.38	-5.49	-0.32	9.3e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs2839186	0.564	rs4819215	chr21:47623573	G/A	cg00612595	chr21:47717864	NA	-0.41	-5.54	-0.32	7.17e-8	Testicular germ cell tumor;
CESC	cis	rs35306767	0.761	rs11253558	chr10:1043983	T/C	cg25019033	chr10:957182	NA	-0.57	-5.58	-0.32	5.79e-8	Eosinophil percentage of granulocytes;
CESC	cis	rs9814567	0.752	rs6764764	chr3:134331167	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	0.39	6.11	0.35	3.49e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg24458846	chr11:66512593	C11orf80	-0.51	-6.45	-0.37	5.2e-10	Asthma;
CESC	cis	rs950169	0.614	rs765524	chr15:84681782	G/T	cg17507749	chr15:85114479	UBE2QP1	0.58	5.95	0.34	8.4e-9	Schizophrenia;
CESC	cis	rs896854	0.654	rs16893776	chr8:95973604	C/T	cg13393036	chr8:95962371	TP53INP1	-0.46	-9.56	-0.51	8.37e-19	Type 2 diabetes;
CESC	cis	rs6066835	0.572	rs6125413	chr20:47257145	G/A	cg18078177	chr20:47281410	PREX1	0.68	5.06	0.3	8.03e-7	Multiple myeloma;
CESC	trans	rs1545843	0.565	rs7953925	chr12:84792044	A/C	cg03015433	chr16:56623111	MT3	-0.34	-6.12	-0.35	3.37e-9	Major depressive disorder;
CESC	cis	rs712039	0.652	rs866465	chr17:35859404	G/A	cg16670864	chr17:35848621	DUSP14	0.48	5.96	0.34	8.07e-9	Tuberculosis;
CESC	cis	rs1595825	0.891	rs79845692	chr2:198523541	T/C	cg10820045	chr2:198174542	NA	0.41	5.21	0.3	3.79e-7	Ulcerative colitis;
CESC	cis	rs4819052	0.851	rs1006779	chr21:46670752	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.73	9.85	0.52	1.03e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs708547	0.836	rs1625691	chr4:57845740	T/C	cg16868167	chr4:57843880	C4orf14;POLR2B	0.76	10.09	0.53	1.82e-20	Response to bleomycin (chromatid breaks);
CESC	cis	rs9911578	1.000	rs1631237	chr17:56734695	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.27	0.31	2.87e-7	Intelligence (multi-trait analysis);
CESC	cis	rs10870270	1.000	rs7898755	chr10:133777122	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.59	-7.57	-0.42	6.29e-13	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs7589342	0.929	rs1465640	chr2:106439103	C/T	cg16077055	chr2:106428750	NCK2	0.49	6.98	0.39	2.38e-11	Addiction;
CESC	trans	rs11098499	0.954	rs6849561	chr4:120409694	C/G	cg25214090	chr10:38739885	LOC399744	-0.7	-9.73	-0.51	2.5e-19	Corneal astigmatism;
CESC	cis	rs477692	0.544	rs12251589	chr10:131417354	C/A	cg05714579	chr10:131428358	MGMT	-0.73	-10.7	-0.55	1.88e-22	Response to temozolomide;
CESC	cis	rs6570726	0.935	rs386344	chr6:145855622	A/G	cg05347473	chr6:146136440	FBXO30	0.46	5.97	0.34	7.4e-9	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2576037	0.526	rs2010834	chr18:44560875	C/A	cg19077165	chr18:44547161	KATNAL2	0.54	8.01	0.44	3.56e-14	Personality dimensions;
CESC	cis	rs801193	1.000	rs4717319	chr7:66242593	A/G	cg25985355	chr7:65971099	NA	-0.31	-5.15	-0.3	5.13e-7	Aortic root size;
CESC	cis	rs9457247	0.905	rs377232	chr6:167409638	C/A	cg23791538	chr6:167370224	RNASET2	-0.59	-8.44	-0.46	2.06e-15	Crohn's disease;
CESC	cis	rs2439831	0.850	rs3097773	chr15:43893072	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.64	-8.25	-0.45	7.26e-15	Lung cancer in ever smokers;
CESC	cis	rs10479542	0.892	rs7736163	chr5:178980316	G/C	cg26516362	chr5:178986906	RUFY1	0.44	7.03	0.4	1.7e-11	Lung cancer;
CESC	cis	rs4654899	1.000	rs7522722	chr1:21481840	G/A	cg05370193	chr1:21551575	ECE1	0.41	6.24	0.36	1.72e-9	Superior frontal gyrus grey matter volume;
CESC	cis	rs950169	0.920	rs2135551	chr15:84707851	A/G	cg17507749	chr15:85114479	UBE2QP1	0.63	6.93	0.39	3.26e-11	Schizophrenia;
CESC	cis	rs4268898	0.610	rs34216622	chr2:24463445	G/C	cg06627628	chr2:24431161	ITSN2	-0.98	-11.11	-0.56	8.86e-24	Asthma;
CESC	cis	rs1707322	0.686	rs3014235	chr1:46091512	A/G	cg06784218	chr1:46089804	CCDC17	-0.4	-7.01	-0.4	1.97e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs3087243	0.755	rs231790	chr2:204700574	A/C	cg01841312	chr10:38069945	NA	-0.37	-6.38	-0.36	8.06e-10	Rheumatoid arthritis;Hypothyroidism;Type 1 diabetes;
CESC	cis	rs514406	0.627	rs485128	chr1:53344583	T/C	cg24675658	chr1:53192096	ZYG11B	-0.65	-8.42	-0.46	2.42e-15	Monocyte count;
CESC	cis	rs4689388	0.890	rs6838400	chr4:6295427	C/G	cg25554036	chr4:6271136	WFS1	0.51	8.37	0.46	3.31e-15	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs875971	0.545	rs73378304	chr7:65640747	G/A	cg25405998	chr7:65216604	CCT6P1	0.44	5.17	0.3	4.58e-7	Aortic root size;
CESC	cis	rs8177253	1.000	rs6762719	chr3:133480817	A/G	cg01448562	chr3:133502909	NA	-0.43	-6.11	-0.35	3.5e-9	Iron status biomarkers;
CESC	cis	rs854765	0.718	rs7224815	chr17:17845800	A/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.46	6.02	0.35	5.87e-9	Total body bone mineral density;
CESC	cis	rs910316	0.789	rs4899552	chr14:75667921	C/A	cg11812906	chr14:75593930	NEK9	-0.79	-12.06	-0.6	5.63e-27	Height;
CESC	cis	rs10504229	1.000	rs66477954	chr8:58187810	C/T	cg22535103	chr8:58192502	C8orf71	-1.05	-13.08	-0.63	1.71e-30	Developmental language disorder (linguistic errors);
CESC	cis	rs7552404	0.691	rs5745449	chr1:76344711	A/T	cg03433033	chr1:76189801	ACADM	-0.58	-5.97	-0.34	7.72e-9	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs7666738	0.830	rs13124904	chr4:98856973	T/C	cg05340658	chr4:99064831	C4orf37	0.75	11.16	0.57	5.89e-24	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1046896	0.553	rs1044661	chr17:80901020	G/A	cg19046167	chr17:80928561	B3GNTL1	0.54	6.56	0.37	2.78e-10	Glycated hemoglobin levels;
CESC	cis	rs9768139	0.611	rs12698211	chr7:158119623	G/A	cg25566285	chr7:158114605	PTPRN2	0.49	8.13	0.45	1.64e-14	Calcium levels;
CESC	cis	rs1552244	1.000	rs17032299	chr3:10087638	C/T	cg08888203	chr3:10149979	C3orf24	0.48	5.99	0.35	6.84e-9	Alzheimer's disease;
CESC	cis	rs1799949	1.000	rs8176133	chr17:41257458	A/C	cg23758822	chr17:41437982	NA	1.01	15.35	0.69	1.81e-38	Menopause (age at onset);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg00676969	chr14:74485475	ENTPD5;C14orf45	-0.56	-7.21	-0.4	5.8e-12	Ulcerative colitis;
CESC	cis	rs13064411	0.696	rs35860985	chr3:113209828	C/T	cg18753928	chr3:113234510	CCDC52	-0.52	-6.31	-0.36	1.17e-9	Response to simvastatin treatment (PCSK9 protein level change);
CESC	cis	rs977987	0.836	rs35209155	chr16:75470496	G/A	cg03315344	chr16:75512273	CHST6	0.42	6.12	0.35	3.38e-9	Dupuytren's disease;
CESC	cis	rs13082711	0.911	rs4973770	chr3:27425815	C/T	cg02860705	chr3:27208620	NA	0.52	6.53	0.37	3.36e-10	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CESC	cis	rs62229266	0.804	rs2835241	chr21:37411380	G/T	cg12218747	chr21:37451666	NA	0.42	5.89	0.34	1.15e-8	Mitral valve prolapse;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11309342	chr7:1014982	COX19	0.56	6.46	0.37	4.92e-10	Gut microbiome composition (summer);
CESC	cis	rs17711722	0.653	rs2460421	chr7:65491123	A/T	cg26939375	chr7:64535504	NA	-0.64	-9.09	-0.49	2.32e-17	Calcium levels;
CESC	cis	rs7178572	0.568	rs1602925	chr15:77685857	T/C	cg22256960	chr15:77711686	NA	-0.54	-6.95	-0.39	2.9e-11	Type 2 diabetes;
CESC	cis	rs2952156	0.920	rs14050	chr17:37828072	C/T	cg00129232	chr17:37814104	STARD3	-0.76	-10.36	-0.54	2.52e-21	Asthma;
CESC	cis	rs9322193	0.923	rs12529698	chr6:149972087	G/A	cg07701084	chr6:150067640	NUP43	0.47	6.7	0.38	1.27e-10	Lung cancer;
CESC	trans	rs5417	0.788	rs2654185	chr17:7183362	G/T	cg15655154	chr3:113604241	GRAMD1C	0.49	6.66	0.38	1.61e-10	Diastolic blood pressure;
CESC	trans	rs5756813	0.754	rs13057133	chr22:38179473	C/T	cg19894588	chr14:64061835	NA	-0.65	-8.14	-0.45	1.57e-14	Optic cup area;Vertical cup-disc ratio;
CESC	cis	rs8177253	0.965	rs4854761	chr3:133498789	A/G	cg11941060	chr3:133502564	NA	0.43	5.82	0.34	1.7e-8	Iron status biomarkers;
CESC	cis	rs72781680	0.611	rs55983206	chr2:24333995	A/C	cg08917208	chr2:24149416	ATAD2B	0.62	5.93	0.34	9.57e-9	Lymphocyte counts;
CESC	cis	rs1707322	0.682	rs12037459	chr1:46094959	T/G	cg06784218	chr1:46089804	CCDC17	0.4	7.04	0.4	1.67e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7208859	0.623	rs9893422	chr17:29111715	A/G	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.17e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs2836974	0.583	rs9981884	chr21:40585633	G/A	cg11644478	chr21:40555479	PSMG1	0.58	7.75	0.43	2.03e-13	Cognitive function;
CESC	cis	rs9640161	0.789	rs13223702	chr7:150058968	G/A	cg10018233	chr7:150070692	REPIN1	0.38	5.42	0.32	1.35e-7	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs798554	0.797	rs2107964	chr7:2863574	G/A	cg09658497	chr7:2847517	GNA12	-0.44	-5.99	-0.35	6.65e-9	Height;
CESC	cis	rs3126085	0.935	rs3126088	chr1:152305785	A/G	cg03465714	chr1:152285911	FLG	0.43	5.22	0.31	3.62e-7	Atopic dermatitis;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05522848	chr5:68710359	RAD17;MARVELD2	-0.43	-6.11	-0.35	3.6e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs13223928	0.541	rs17132968	chr7:3136074	T/G	cg19214707	chr7:3157722	NA	-0.39	-5.34	-0.31	1.96e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
CESC	trans	rs8073060	0.586	rs225291	chr17:33927126	A/G	cg19694781	chr19:47549865	TMEM160	-0.61	-6.88	-0.39	4.26e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	cis	rs2842992	0.789	rs7765490	chr6:160204326	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.75	8.9	0.48	9.05e-17	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs6060717	0.698	rs8123175	chr20:34609872	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.6	-7.57	-0.42	6.33e-13	Hip circumference adjusted for BMI;
CESC	cis	rs10883723	0.962	rs1056739	chr10:104236542	T/C	cg22532475	chr10:104410764	TRIM8	-0.34	-5.67	-0.33	3.77e-8	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs1185460	1.000	rs4614	chr11:118952371	A/G	cg23280166	chr11:118938394	VPS11	0.43	5.64	0.33	4.25e-8	Coronary artery disease;
CESC	cis	rs1552244	1.000	rs3826	chr3:10141065	T/G	cg00149659	chr3:10157352	C3orf10	0.72	9.04	0.49	3.45e-17	Alzheimer's disease;
CESC	cis	rs780096	0.527	rs12471703	chr2:27738854	C/T	cg12648201	chr2:27665141	KRTCAP3	-0.36	-6.31	-0.36	1.15e-9	Total body bone mineral density;
CESC	cis	rs35110281	0.720	rs162372	chr21:44928863	C/T	cg01579765	chr21:45077557	HSF2BP	0.53	8.93	0.48	7.4e-17	Mean corpuscular volume;
CESC	cis	rs7666738	0.830	rs13101352	chr4:98957544	C/T	cg03467027	chr4:99064603	C4orf37	0.45	5.61	0.33	4.97e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs853679	0.517	rs4713143	chr6:28106759	A/C	cg12963246	chr6:28129442	ZNF389	0.57	7.78	0.43	1.65e-13	Depression;
CESC	cis	rs1904096	0.506	rs6823404	chr4:95197520	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.66	-10.44	-0.54	1.36e-21	Type 2 diabetes;
CESC	cis	rs3824867	0.920	rs7948705	chr11:47447955	C/G	cg20307385	chr11:47447363	PSMC3	-0.46	-5.39	-0.31	1.53e-7	Mean corpuscular hemoglobin;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24079455	chr10:127408106	C10orf137	0.58	6.78	0.38	7.93e-11	Gut microbiome composition (summer);
CESC	cis	rs2486288	0.656	rs2413772	chr15:45549862	G/A	cg21132104	chr15:45694354	SPATA5L1	-0.54	-6.54	-0.37	3.21e-10	Glomerular filtration rate;
CESC	cis	rs5771242	0.518	rs7290465	chr22:50679758	C/T	cg16473166	chr22:50639996	SELO	-0.54	-6.28	-0.36	1.34e-9	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
CESC	cis	rs875971	0.862	rs778697	chr7:65870426	G/A	cg18252515	chr7:66147081	NA	-0.46	-6.05	-0.35	5e-9	Aortic root size;
CESC	cis	rs9303280	0.773	rs11078925	chr17:38025208	T/C	cg20243544	chr17:37824526	PNMT	0.53	6.93	0.39	3.14e-11	Self-reported allergy;
CESC	trans	rs9325144	0.647	rs12424190	chr12:39111206	A/T	cg23762105	chr12:34175262	ALG10	0.45	6.07	0.35	4.45e-9	Morning vs. evening chronotype;
CESC	cis	rs6977955	1.000	rs67250450	chr7:28174986	T/C	cg23620719	chr7:28220237	JAZF1	0.6	6.69	0.38	1.29e-10	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs7617480	0.648	rs7653408	chr3:48972351	A/C	cg07636037	chr3:49044803	WDR6	0.81	11.41	0.57	8.63e-25	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CESC	cis	rs1003719	0.591	rs2835618	chr21:38503126	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.61	-7.94	-0.44	5.94e-14	Eye color traits;
CESC	cis	rs8067545	1.000	rs2108980	chr17:19920518	G/A	cg13482628	chr17:19912719	NA	0.48	6.37	0.36	8.11e-10	Schizophrenia;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg15344021	chr17:2240169	TSR1;SGSM2	-0.43	-6.09	-0.35	4.03e-9	Gambling;
CESC	cis	rs9859260	0.744	rs3933	chr3:195784997	C/T	cg18569988	chr3:195679450	NA	-0.35	-5.2	-0.3	3.9e-7	Mean corpuscular volume;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg08118649	chr12:99038419	APAF1;IKBIP	-0.48	-6.4	-0.37	7.11e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs2280018	0.963	rs4985147	chr16:15168760	T/C	cg27102117	chr16:15229624	NA	0.49	7.65	0.43	3.82e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs9303401	0.659	rs35103007	chr17:56900738	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.01	12.71	0.62	3.22e-29	Cognitive test performance;
CESC	cis	rs7666738	0.830	rs13328005	chr4:99055480	T/C	cg05340658	chr4:99064831	C4orf37	0.81	12.35	0.6	5.63e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs12497850	0.931	rs11705888	chr3:48817289	T/C	cg07636037	chr3:49044803	WDR6	1.01	18.13	0.74	2.51e-48	Parkinson's disease;
CESC	cis	rs7618915	0.547	rs10865973	chr3:52718154	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	6.89	0.39	4.03e-11	Bipolar disorder;
CESC	cis	rs3008870	0.755	rs4655661	chr1:67408828	A/C	cg02640540	chr1:67518911	SLC35D1	0.46	5.58	0.32	5.81e-8	Lymphocyte percentage of white cells;
CESC	cis	rs4835473	0.897	rs2219912	chr4:144629062	C/T	cg25736465	chr4:144833511	NA	0.4	6.24	0.36	1.74e-9	Immature fraction of reticulocytes;
CESC	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg26338869	chr17:61819248	STRADA	0.71	9.42	0.5	2.4e-18	Prudent dietary pattern;
CESC	cis	rs9815354	0.812	rs17284313	chr3:41986787	G/T	cg03022575	chr3:42003672	ULK4	-0.67	-6.2	-0.36	2.12e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs9467711	0.606	rs12174623	chr6:26373086	C/T	cg14345882	chr6:26364793	BTN3A2	0.61	6.49	0.37	4.12e-10	Autism spectrum disorder or schizophrenia;
CESC	cis	rs2204008	0.811	rs11520277	chr12:38359611	G/A	cg26384229	chr12:38710491	ALG10B	0.69	10.42	0.54	1.6e-21	Bladder cancer;
CESC	cis	rs7216064	1.000	rs62084213	chr17:65842016	A/G	cg07042672	chr17:66097459	LOC651250	-0.54	-5.67	-0.33	3.73e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	trans	rs11098499	0.730	rs12505735	chr4:120532956	G/T	cg25214090	chr10:38739885	LOC399744	0.65	8.98	0.48	5.01e-17	Corneal astigmatism;
CESC	cis	rs708547	0.874	rs1718869	chr4:57880232	A/C	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.56	-5.78	-0.33	2.06e-8	Response to bleomycin (chromatid breaks);
CESC	cis	rs9311474	0.607	rs4687625	chr3:52563718	C/T	cg05564831	chr3:52568323	NT5DC2	0.46	7.08	0.4	1.31e-11	Electroencephalogram traits;
CESC	cis	rs6662572	0.737	rs4660315	chr1:46270942	G/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.45	-5.11	-0.3	6.16e-7	Blood protein levels;
CESC	cis	rs9926296	0.568	rs7203907	chr16:89833774	C/G	cg07648498	chr16:89883185	FANCA	0.42	5.13	0.3	5.57e-7	Vitiligo;
CESC	cis	rs9649213	0.537	rs6971825	chr7:97979548	C/T	cg24562669	chr7:97807699	LMTK2	0.51	7.63	0.42	4.29e-13	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs8077889	0.956	rs61608877	chr17:41848713	A/C	cg26893861	chr17:41843967	DUSP3	0.74	8.79	0.48	1.87e-16	Triglycerides;
CESC	cis	rs1552244	0.935	rs35586456	chr3:10116938	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-10.83	-0.55	7.07e-23	Alzheimer's disease;
CESC	cis	rs3780486	0.757	rs10813949	chr9:33123464	G/A	cg13443165	chr9:33130375	B4GALT1	0.43	6.17	0.35	2.58e-9	IgG glycosylation;
CESC	cis	rs8040855	0.627	rs4842863	chr15:85642205	T/A	cg08123816	chr15:85640762	PDE8A	-0.39	-5.84	-0.34	1.52e-8	Bulimia nervosa;
CESC	cis	rs9611565	0.659	rs4822036	chr22:41936019	A/G	cg06634786	chr22:41940651	POLR3H	-0.63	-6.6	-0.38	2.2e-10	Vitiligo;
CESC	cis	rs9814567	0.752	rs7649910	chr3:134241310	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.47	-6.44	-0.37	5.64e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs1552244	1.000	rs17032277	chr3:10077023	T/C	cg00166722	chr3:10149974	C3orf24	0.46	5.88	0.34	1.21e-8	Alzheimer's disease;
CESC	cis	rs3747547	0.642	rs11792690	chr9:38087453	C/T	cg13774184	chr9:37916125	SHB	-0.63	-5.32	-0.31	2.17e-7	Metabolite levels (Dihydroxy docosatrienoic acid);
CESC	cis	rs7617773	0.780	rs13079728	chr3:48339360	A/G	cg11946769	chr3:48343235	NME6	0.89	12.15	0.6	2.74e-27	Coronary artery disease;
CESC	cis	rs453301	0.522	rs1964356	chr8:8853270	G/T	cg15556689	chr8:8085844	FLJ10661	0.42	5.36	0.31	1.78e-7	Joint mobility (Beighton score);
CESC	cis	rs7615952	0.599	rs60847438	chr3:125746005	T/C	cg02807482	chr3:125708958	NA	-0.39	-5.11	-0.3	6.31e-7	Blood pressure (smoking interaction);
CESC	cis	rs7551222	0.789	rs2290855	chr1:204515863	C/T	cg20240347	chr1:204465584	NA	-0.29	-5.87	-0.34	1.31e-8	Schizophrenia;
CESC	cis	rs2991971	1.000	rs2934859	chr1:46017836	C/T	cg15605315	chr1:45957053	TESK2	0.43	5.36	0.31	1.82e-7	High light scatter reticulocyte count;
CESC	cis	rs7618915	0.508	rs7628578	chr3:52628321	A/T	cg18337363	chr3:52569053	NT5DC2	0.29	5.3	0.31	2.48e-7	Bipolar disorder;
CESC	cis	rs66887589	0.560	rs9684327	chr4:120365441	A/G	cg09307838	chr4:120376055	NA	0.52	7.01	0.4	1.95e-11	Diastolic blood pressure;
CESC	cis	rs72781680	1.000	rs12614452	chr2:24194608	C/T	cg20701182	chr2:24300061	SF3B14	0.64	5.74	0.33	2.56e-8	Lymphocyte counts;
CESC	cis	rs3815700	1.000	rs8104729	chr19:33093979	C/T	cg24916020	chr19:33096688	ANKRD27	0.6	5.84	0.34	1.56e-8	Eosinophilic esophagitis;
CESC	cis	rs7666738	0.830	rs34273190	chr4:99004568	C/T	cg18180107	chr4:99064573	C4orf37	0.4	5.23	0.31	3.41e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10504229	0.679	rs11781858	chr8:58038406	C/T	cg02725872	chr8:58115012	NA	-0.39	-5.12	-0.3	5.75e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs3820928	0.874	rs10176882	chr2:227896432	A/T	cg11843606	chr2:227700838	RHBDD1	-0.42	-5.54	-0.32	7.29e-8	Pulmonary function;
CESC	cis	rs916888	0.773	rs199439	chr17:44793503	A/G	cg15921436	chr17:44337874	NA	0.76	8.29	0.45	5.64e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs7949030	0.626	rs72927213	chr11:62351198	G/C	cg22862634	chr11:62369728	EML3;MTA2	0.59	8.25	0.45	7.65e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs7084402	0.967	rs10763552	chr10:60273977	C/T	cg07615347	chr10:60278583	BICC1	-0.58	-9.07	-0.49	2.75e-17	Refractive error;
CESC	cis	rs2412488	0.853	rs12508701	chr4:54353243	C/T	cg22241045	chr4:54363911	LNX1	0.36	5.15	0.3	5.09e-7	DNA methylation (variation);
CESC	trans	rs7174755	0.772	rs8025474	chr15:68386523	C/T	cg00239025	chr2:96937097	CIAO1	-0.47	-6.12	-0.35	3.29e-9	Major depressive disorder;
CESC	cis	rs1879734	0.731	rs6694399	chr1:54159198	C/T	cg23596471	chr1:54105337	GLIS1	0.35	5.67	0.33	3.77e-8	Mitral valve prolapse;
CESC	cis	rs13191362	1.000	rs1333963	chr6:163192571	A/G	cg06582575	chr6:163149167	PACRG;PARK2	1.02	9.31	0.5	5.03e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25884424	chr2:113522513	CKAP2L	0.57	6.32	0.36	1.08e-9	Gut microbiome composition (summer);
CESC	cis	rs35306767	0.855	rs61830932	chr10:934183	T/C	cg10556349	chr10:835070	NA	0.56	5.43	0.32	1.3e-7	Eosinophil percentage of granulocytes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00846248	chr7:86849067	C7orf23	0.63	7.55	0.42	7.04e-13	Gut microbiome composition (summer);
CESC	cis	rs6089584	0.706	rs6089625	chr20:60620622	T/C	cg06108461	chr20:60628389	TAF4	-0.93	-14.69	-0.67	3.68e-36	Body mass index;
CESC	cis	rs4604732	0.603	rs10802513	chr1:247633919	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.45	6.62	0.38	2.03e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs5769765	0.954	rs1569954	chr22:50244071	C/T	cg26441486	chr22:50317300	CRELD2	-0.4	-5.52	-0.32	8.04e-8	Schizophrenia;
CESC	cis	rs72945132	0.714	rs117232799	chr11:70157182	G/A	cg14191688	chr11:70257035	CTTN	0.57	6.42	0.37	6.34e-10	Coronary artery disease;
CESC	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg11965913	chr1:205819406	PM20D1	0.79	12.44	0.61	2.66e-28	Menarche (age at onset);
CESC	cis	rs1707322	0.682	rs10890334	chr1:46100378	A/T	cg05343316	chr1:45956843	TESK2	0.51	6.35	0.36	9.44e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9309473	1.000	rs6736866	chr2:73661986	C/G	cg20560298	chr2:73613845	ALMS1	-0.55	-6.97	-0.39	2.51e-11	Metabolite levels;
CESC	cis	rs7552404	0.628	rs5745442	chr1:76342858	T/G	cg03433033	chr1:76189801	ACADM	0.59	5.77	0.33	2.22e-8	Blood metabolite levels;Acylcarnitine levels;
CESC	trans	rs6572548	0.504	rs1956082	chr14:49665496	A/C	cg20615951	chr1:246730188	CNST;TFB2M	-0.54	-6.15	-0.35	2.82e-9	Subjective well-being;
CESC	cis	rs12142240	0.770	rs112869704	chr1:46780285	C/T	cg00530320	chr1:46809349	NSUN4	0.55	6.83	0.39	5.66e-11	Menopause (age at onset);
CESC	cis	rs3753275	0.690	rs926951	chr1:8608106	A/G	cg00120948	chr1:8484417	RERE	-0.4	-5.03	-0.3	9.14e-7	Educational attainment;
CESC	cis	rs35146811	0.771	rs1060544	chr7:99613476	C/T	cg22906224	chr7:99728672	NA	0.49	5.77	0.33	2.23e-8	Coronary artery disease;
CESC	cis	rs344364	0.511	rs2982446	chr16:1947153	C/T	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.55	-6.2	-0.36	2.15e-9	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs12926788	0.689	rs34365165	chr16:24856208	G/A	cg02428538	chr16:24856791	SLC5A11	-0.67	-6.98	-0.39	2.39e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs7572263	0.724	rs6705133	chr2:209054422	G/A	cg23998903	chr2:209048830	C2orf80	-0.39	-5.14	-0.3	5.4e-7	Glioma;Non-glioblastoma glioma;
CESC	cis	rs6460942	0.597	rs7798779	chr7:12543490	A/G	cg02935154	chr7:12443704	VWDE	-0.56	-5.5	-0.32	8.72e-8	Coronary artery disease;
CESC	cis	rs2839186	0.587	rs35679325	chr21:47640980	A/G	cg10351095	chr21:47802916	PCNT	0.44	5.89	0.34	1.18e-8	Testicular germ cell tumor;
CESC	cis	rs9905704	0.645	rs34852567	chr17:57027770	T/C	cg12560992	chr17:57184187	TRIM37	0.64	5.79	0.34	1.97e-8	Testicular germ cell tumor;
CESC	cis	rs11690935	0.959	rs6433314	chr2:172660971	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.96	-14.68	-0.67	4.14e-36	Schizophrenia;
CESC	cis	rs769267	0.930	rs4808959	chr19:19572108	T/G	cg03709012	chr19:19516395	GATAD2A	1.01	15.76	0.7	6.38e-40	Tonsillectomy;
CESC	cis	rs9303401	0.659	rs12150264	chr17:56939927	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.01	12.45	0.61	2.57e-28	Cognitive test performance;
CESC	cis	rs7539409	0.604	rs6689821	chr1:84316605	A/G	cg10977910	chr1:84465055	TTLL7	0.78	7.42	0.41	1.61e-12	Alzheimer's disease;
CESC	trans	rs4927850	0.958	rs1975582	chr3:195751439	G/T	cg21051086	chr3:73046214	PPP4R2	-0.43	-6.02	-0.35	5.73e-9	Pancreatic cancer;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg11150068	chr10:111683422	XPNPEP1	0.49	6.3	0.36	1.25e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs4423214	0.592	rs1790349	chr11:71142350	A/G	cg05163923	chr11:71159392	DHCR7	-0.52	-5.26	-0.31	2.94e-7	Vitamin D levels;
CESC	cis	rs2243480	0.901	rs35256305	chr7:65306405	T/C	cg18252515	chr7:66147081	NA	-1.01	-9.73	-0.51	2.51e-19	Diabetic kidney disease;
CESC	cis	rs910316	0.591	rs7157158	chr14:75457238	A/G	cg16144293	chr14:75469539	EIF2B2	-0.4	-5.29	-0.31	2.52e-7	Height;
CESC	cis	rs2835872	0.758	rs1787401	chr21:39038893	C/T	cg06728970	chr21:39037746	KCNJ6	0.3	5.57	0.32	6.32e-8	Electroencephalographic traits in alcoholism;
CESC	trans	rs7656342	0.808	rs10003216	chr4:9766749	A/G	cg05409038	chr2:71221890	TEX261	-0.54	-5.99	-0.35	6.64e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs769267	0.895	rs2965189	chr19:19519518	G/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.48	6.27	0.36	1.45e-9	Tonsillectomy;
CESC	cis	rs4523957	0.690	rs11078855	chr17:2091308	A/G	cg16513277	chr17:2031491	SMG6	0.65	8.78	0.47	2.12e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs12458462	0.892	rs12456692	chr18:77482189	C/T	cg11879182	chr18:77439856	CTDP1	0.88	13.34	0.63	2.05e-31	Monocyte count;
CESC	cis	rs9486719	0.843	rs2499792	chr6:96846264	A/C	cg06623918	chr6:96969491	KIAA0776	0.78	7.39	0.41	1.89e-12	Migraine;Coronary artery disease;
CESC	cis	rs9916302	0.851	rs12936996	chr17:37665554	A/G	cg07936489	chr17:37558343	FBXL20	0.8	12.04	0.59	6.17e-27	Glomerular filtration rate (creatinine);
CESC	cis	rs9300255	0.602	rs1051431	chr12:123645803	G/A	cg19016782	chr12:123741754	C12orf65	-0.4	-5.77	-0.33	2.27e-8	Neutrophil percentage of white cells;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24542492	chr17:61818870	STRADA	0.59	6.62	0.38	2.02e-10	Gut microbiome composition (summer);
CESC	cis	rs4472734	0.965	rs4655345	chr1:214608704	A/G	cg00063699	chr1:214624242	PTPN14	-0.33	-5.28	-0.31	2.73e-7	Height;
CESC	cis	rs1552244	0.882	rs55962400	chr3:10044457	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.7	-8.29	-0.45	5.67e-15	Alzheimer's disease;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg04145264	chr11:65190825	NEAT1	-0.44	-6.59	-0.38	2.4e-10	Gambling;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg21173440	chr5:55008212	SLC38A9	-0.45	-6.42	-0.37	6.2e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs68170813	0.559	rs12533767	chr7:106860245	A/C	cg02696742	chr7:106810147	HBP1	-0.52	-5.08	-0.3	7.2e-7	Coronary artery disease;
CESC	cis	rs12497850	0.897	rs9850134	chr3:48957147	A/G	cg02487422	chr3:49467188	NICN1	0.4	5.2	0.3	4.08e-7	Parkinson's disease;
CESC	cis	rs7089973	0.604	rs35319791	chr10:116602296	C/A	cg03647239	chr10:116582469	FAM160B1	0.43	5.35	0.31	1.94e-7	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs1062177	1.000	rs892006	chr5:151180890	G/T	cg12924095	chr5:151150029	G3BP1	0.51	6.77	0.38	8.32e-11	Preschool internalizing problems;
CESC	cis	rs524281	0.861	rs10750780	chr11:65974592	G/A	cg14036092	chr11:66035641	RAB1B	-0.6	-6.11	-0.35	3.56e-9	Electroencephalogram traits;
CESC	cis	rs6005807	0.543	rs2294431	chr22:29177200	C/T	cg15103426	chr22:29168792	CCDC117	0.5	5.08	0.3	7.15e-7	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
CESC	cis	rs644799	1.000	rs566204	chr11:95580926	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	8.7	0.47	3.64e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs644799	1.000	rs518919	chr11:95623313	G/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.83	11.55	0.58	2.79e-25	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs6430585	0.528	rs309122	chr2:136761853	A/G	cg07169764	chr2:136633963	MCM6	1.14	17.94	0.74	1.19e-47	Corneal structure;
CESC	cis	rs6938	0.534	rs1133322	chr15:75212357	A/G	cg10253484	chr15:75165896	SCAMP2	-0.42	-5.32	-0.31	2.23e-7	Breast cancer;
CESC	cis	rs367943	0.666	rs7700413	chr5:112704435	T/C	cg12552261	chr5:112820674	MCC	0.42	5.53	0.32	7.73e-8	Type 2 diabetes;
CESC	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg24829409	chr8:58192753	C8orf71	-0.67	-7.99	-0.44	4.08e-14	Developmental language disorder (linguistic errors);
CESC	cis	rs67311347	1.000	rs73080138	chr3:40516417	A/G	cg24209194	chr3:40518798	ZNF619	0.58	7.78	0.43	1.63e-13	Renal cell carcinoma;
CESC	cis	rs73001065	0.818	rs73004975	chr19:19727152	A/G	cg03709012	chr19:19516395	GATAD2A	0.95	6.37	0.36	8.22e-10	LDL cholesterol;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg24715473	chr16:50059017	TMEM188	0.53	6.92	0.39	3.46e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs6582630	0.502	rs2387603	chr12:38353389	A/C	cg13010199	chr12:38710504	ALG10B	0.45	5.77	0.33	2.24e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs1570884	0.890	rs6561541	chr13:50127280	C/T	cg17099306	chr13:50123645	RCBTB1	-0.4	-5.15	-0.3	5.21e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
CESC	cis	rs56399783	0.901	rs73047387	chr7:2774125	G/A	cg19731401	chr7:2775893	GNA12	0.69	6.02	0.35	5.85e-9	Childhood ear infection;
CESC	cis	rs7191439	0.789	rs4598894	chr16:88776141	G/A	cg02389323	chr16:88786976	FAM38A	1.0	8.0	0.44	4.02e-14	Plateletcrit;
CESC	cis	rs367943	0.698	rs4538600	chr5:112963488	T/C	cg12552261	chr5:112820674	MCC	0.45	5.8	0.34	1.88e-8	Type 2 diabetes;
CESC	cis	rs7666738	0.830	rs6848404	chr4:98946750	A/G	cg03676636	chr4:99064102	C4orf37	0.34	5.11	0.3	6.15e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1862618	0.525	rs2662021	chr5:56261691	C/T	cg12311346	chr5:56204834	C5orf35	0.74	9.24	0.49	8.4e-18	Initial pursuit acceleration;
CESC	trans	rs11191205	0.686	rs11191067	chr10:103379882	G/T	cg12418535	chr2:119607192	EN1	-0.4	-6.0	-0.35	6.56e-9	Intelligence (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27238079	chr10:33247273	ITGB1	0.56	6.47	0.37	4.84e-10	Gut microbiome composition (summer);
CESC	cis	rs4665809	1.000	rs12471809	chr2:26307140	A/G	cg26314531	chr2:26401878	FAM59B	-0.61	-6.89	-0.39	4e-11	Gut microbiome composition (summer);
CESC	trans	rs11098499	0.865	rs4507344	chr4:120307485	C/A	cg25214090	chr10:38739885	LOC399744	0.68	9.2	0.49	1.14e-17	Corneal astigmatism;
CESC	trans	rs7246760	1.000	rs67359088	chr19:9863668	C/T	cg02900749	chr2:68251473	NA	-0.79	-6.66	-0.38	1.57e-10	Pursuit maintenance gain;
CESC	cis	rs3126085	0.932	rs72696991	chr1:152250235	T/C	cg03465714	chr1:152285911	FLG	0.49	5.43	0.32	1.24e-7	Atopic dermatitis;
CESC	cis	rs4835473	0.900	rs35230778	chr4:144655489	G/A	cg25736465	chr4:144833511	NA	-0.33	-5.15	-0.3	5.08e-7	Immature fraction of reticulocytes;
CESC	trans	rs9329221	0.935	rs3750311	chr8:10283602	C/A	cg06636001	chr8:8085503	FLJ10661	-0.56	-6.51	-0.37	3.82e-10	Neuroticism;
CESC	cis	rs523522	0.962	rs670568	chr12:121021206	C/T	cg27279351	chr12:120934652	DYNLL1	0.7	9.06	0.49	2.86e-17	High light scatter reticulocyte count;
CESC	cis	rs4835473	0.838	rs34505330	chr4:144656359	T/G	cg25736465	chr4:144833511	NA	-0.33	-5.3	-0.31	2.48e-7	Immature fraction of reticulocytes;
CESC	cis	rs12410462	1.000	rs75198003	chr1:227623853	C/A	cg04117972	chr1:227635322	NA	0.62	6.34	0.36	9.91e-10	Major depressive disorder;
CESC	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg23708337	chr7:1209742	NA	0.55	5.41	0.32	1.44e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2267137	0.903	rs715494	chr22:29782433	G/T	cg07256473	chr22:29710276	RASL10A	-0.42	-6.32	-0.36	1.08e-9	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	trans	rs9325144	0.600	rs61931871	chr12:38829889	G/A	cg10679878	chr6:156759499	NA	-0.34	-6.07	-0.35	4.44e-9	Morning vs. evening chronotype;
CESC	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.52	7.0	0.4	2.05e-11	Lymphocyte counts;
CESC	cis	rs3796352	1.000	rs7625448	chr3:53120766	C/A	cg07884673	chr3:53033167	SFMBT1	0.51	5.09	0.3	6.87e-7	Immune reponse to smallpox (secreted IL-2);
CESC	trans	rs5769765	0.773	rs58375955	chr22:50312630	A/G	cg09872104	chr7:134855509	C7orf49	-0.55	-6.27	-0.36	1.47e-9	Schizophrenia;
CESC	cis	rs1862618	0.525	rs832403	chr5:56265992	G/T	cg24549020	chr5:56110836	MAP3K1	-0.55	-5.9	-0.34	1.09e-8	Initial pursuit acceleration;
CESC	cis	rs9470366	0.848	rs9470361	chr6:36623379	G/A	cg08179530	chr6:36648295	CDKN1A	0.53	6.19	0.36	2.33e-9	QRS duration;
CESC	cis	rs7937682	1.000	rs7937682	chr11:111579939	C/G	cg22437258	chr11:111473054	SIK2	0.66	7.97	0.44	4.89e-14	Primary sclerosing cholangitis;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg01246405	chr11:3876562	STIM1	0.48	6.24	0.36	1.72e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs2599510	0.811	rs2754523	chr2:32837110	A/G	cg02381751	chr2:32503542	YIPF4	0.51	6.42	0.37	6.26e-10	Interleukin-18 levels;
CESC	cis	rs6502050	0.799	rs7212023	chr17:80170354	G/A	cg01763666	chr17:80159506	CCDC57	-0.36	-5.13	-0.3	5.57e-7	Life satisfaction;
CESC	cis	rs7552404	0.731	rs5745491	chr1:76350159	T/G	cg22875332	chr1:76189707	ACADM	-0.58	-5.96	-0.34	8.04e-9	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs2019216	0.521	rs9807074	chr17:21930856	T/C	cg22648282	chr17:21454238	C17orf51	-0.39	-5.09	-0.3	6.93e-7	Pelvic organ prolapse;
CESC	cis	rs2243480	1.000	rs313798	chr7:65493031	A/G	cg12463550	chr7:65579703	CRCP	0.69	5.5	0.32	9.17e-8	Diabetic kidney disease;
CESC	cis	rs113835537	0.529	rs3179961	chr11:66244454	A/G	cg22134325	chr11:66188745	NPAS4	0.37	5.73	0.33	2.74e-8	Airway imaging phenotypes;
CESC	trans	rs11098499	0.955	rs13113112	chr4:120156040	C/T	cg25214090	chr10:38739885	LOC399744	0.64	8.56	0.47	9.18e-16	Corneal astigmatism;
CESC	cis	rs3845702	1.000	rs3768837	chr2:180835792	T/A	cg01881094	chr2:180872142	CWC22	-0.66	-7.18	-0.4	6.88e-12	Schizophrenia;
CESC	cis	rs8002861	0.691	rs9525851	chr13:44402132	T/A	cg19180546	chr13:44453867	C13orf31;CCDC122	-0.39	-5.12	-0.3	5.84e-7	Leprosy;
CESC	cis	rs2455799	0.573	rs2062824	chr3:15757901	T/C	cg09340198	chr3:15902540	ANKRD28	-0.33	-5.16	-0.3	4.91e-7	Mean platelet volume;
CESC	cis	rs7149242	0.849	rs10146962	chr14:101170540	A/G	cg18089426	chr14:101175970	NA	0.39	6.72	0.38	1.08e-10	Platelet count;
CESC	cis	rs2882667	0.858	rs11744972	chr5:138428789	A/G	cg04439458	chr5:138467593	SIL1	-0.38	-5.97	-0.34	7.49e-9	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs9393777	0.623	rs56296968	chr6:26474571	C/T	cg12826209	chr6:26865740	GUSBL1	0.65	6.88	0.39	4.21e-11	Intelligence (multi-trait analysis);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg16266895	chr12:101674004	UTP20	0.48	6.22	0.36	1.88e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs965513	0.627	rs10124220	chr9:100583074	T/C	cg13688889	chr9:100608707	NA	-0.53	-7.75	-0.43	2e-13	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
CESC	cis	rs1215050	0.791	rs783959	chr4:98893476	C/T	cg05340658	chr4:99064831	C4orf37	-0.51	-6.77	-0.38	8.15e-11	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs2228479	0.702	rs17233868	chr16:89803629	C/T	cg14709524	chr16:89940631	TCF25	0.87	6.42	0.37	6.36e-10	Skin colour saturation;
CESC	trans	rs2157926	1.000	rs4728709	chr7:87233602	A/G	cg21546022	chr12:47052349	NA	-0.58	-6.05	-0.35	4.79e-9	Bone mineral density (spine) and age at menarche;
CESC	cis	rs1577917	1.000	rs12196037	chr6:86694631	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.49	-6.31	-0.36	1.2e-9	Response to antipsychotic treatment;
CESC	cis	rs1847202	0.517	rs13062803	chr3:72951840	T/A	cg10804678	chr3:72788309	NA	-0.4	-5.31	-0.31	2.34e-7	Motion sickness;
CESC	cis	rs829880	0.558	rs249817	chr12:98896910	T/A	cg25150519	chr12:98850993	NA	0.51	5.93	0.34	9.24e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3796352	0.764	rs11714902	chr3:53101544	G/C	cg07884673	chr3:53033167	SFMBT1	0.69	5.92	0.34	9.89e-9	Immune reponse to smallpox (secreted IL-2);
CESC	cis	rs708547	0.599	rs2948348	chr4:57848772	G/A	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.5	-6.74	-0.38	9.93e-11	Response to bleomycin (chromatid breaks);
CESC	cis	rs7809950	1.000	rs4727684	chr7:107226470	C/T	cg23024343	chr7:107201750	COG5	-0.44	-6.08	-0.35	4.07e-9	Coronary artery disease;
CESC	cis	rs6502050	0.835	rs7218857	chr17:80161000	T/C	cg23985595	chr17:80112537	CCDC57	-0.4	-6.35	-0.36	9.4e-10	Life satisfaction;
CESC	cis	rs10743315	0.557	rs16915108	chr12:19290406	T/C	cg02471346	chr12:19282374	PLEKHA5	0.71	5.4	0.31	1.51e-7	Gut microbiota (bacterial taxa);
CESC	cis	rs1057239	0.510	rs3766694	chr1:175143207	T/C	cg00321850	chr1:175162397	KIAA0040	-0.47	-6.6	-0.38	2.19e-10	Diastolic blood pressure;
CESC	cis	rs1707322	0.752	rs3811435	chr1:46125790	C/A	cg03146154	chr1:46216737	IPP	0.82	11.52	0.58	3.64e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9911578	0.967	rs2567892	chr17:56668929	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.24	0.31	3.26e-7	Intelligence (multi-trait analysis);
CESC	cis	rs35306767	0.903	rs1341741	chr10:888073	A/G	cg10556349	chr10:835070	NA	0.53	5.09	0.3	6.75e-7	Eosinophil percentage of granulocytes;
CESC	cis	rs910316	0.737	rs175055	chr14:75488946	T/G	cg08847533	chr14:75593920	NEK9	-0.9	-15.98	-0.7	1.06e-40	Height;
CESC	cis	rs7605827	0.930	rs6748451	chr2:15521088	A/G	cg19274914	chr2:15703543	NA	0.35	6.27	0.36	1.43e-9	Educational attainment (years of education);
CESC	cis	rs3026101	0.578	rs1806237	chr17:5295399	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.43	5.68	0.33	3.57e-8	Body mass index;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22792938	chr2:228337242	AGFG1	0.54	6.72	0.38	1.09e-10	Gut microbiome composition (summer);
CESC	cis	rs875971	0.508	rs10950045	chr7:66066373	T/C	cg14393609	chr7:65229607	NA	-0.41	-5.78	-0.33	2.1e-8	Aortic root size;
CESC	cis	rs796364	1.000	rs281760	chr2:200787804	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.87	8.3	0.45	5.2e-15	Schizophrenia;
CESC	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg11494091	chr17:61959527	GH2	0.73	12.52	0.61	1.5e-28	Prudent dietary pattern;
CESC	cis	rs10504229	0.683	rs6999984	chr8:58115079	G/A	cg02725872	chr8:58115012	NA	-0.45	-7.05	-0.4	1.52e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs4481887	1.000	rs7511706	chr1:248467360	G/A	cg00666640	chr1:248458726	OR2T12	0.39	6.36	0.36	8.71e-10	Common traits (Other);
CESC	cis	rs6952808	0.689	rs12668156	chr7:2019875	G/A	cg02951883	chr7:2050386	MAD1L1	-0.55	-7.14	-0.4	8.75e-12	Bipolar disorder and schizophrenia;
CESC	cis	rs4812048	0.696	rs6070694	chr20:57591126	G/A	cg14073986	chr20:57617431	SLMO2	0.84	6.04	0.35	5.23e-9	Mean platelet volume;
CESC	cis	rs9303280	0.806	rs12232498	chr17:38040363	T/C	cg19468946	chr17:37922297	IKZF3	-0.41	-5.42	-0.32	1.31e-7	Self-reported allergy;
CESC	cis	rs7408868	0.908	rs4809028	chr19:15273231	A/G	cg14696996	chr19:15285081	NOTCH3	1.11	11.47	0.58	5.57e-25	Pulse pressure;
CESC	trans	rs2207136	0.901	rs2076309	chr6:50789451	T/C	cg06522515	chr3:184090630	THPO	0.35	6.07	0.35	4.34e-9	Myopia;
CESC	cis	rs7746199	0.673	rs35501037	chr6:27739566	T/A	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.82	5.56	0.32	6.51e-8	Gait speed in old age;Autism spectrum disorder or schizophrenia;
CESC	cis	rs28374715	0.681	rs28728213	chr15:41653602	T/A	cg20272979	chr15:41787780	ITPKA	0.42	5.64	0.33	4.34e-8	Ulcerative colitis;
CESC	cis	rs9611565	0.765	rs28604950	chr22:41785812	A/G	cg17376030	chr22:41985996	PMM1	0.67	7.19	0.4	6.44e-12	Vitiligo;
CESC	cis	rs1691799	0.867	rs1027400	chr12:66760922	A/T	cg16791601	chr12:66731901	HELB	-0.75	-12.63	-0.61	5.94e-29	White blood cell count (basophil);
CESC	cis	rs950776	0.518	rs12910100	chr15:78822667	C/T	cg06917634	chr15:78832804	PSMA4	0.8	12.12	0.6	3.34e-27	Sudden cardiac arrest;
CESC	cis	rs1538970	0.884	rs1771551	chr1:45883643	C/G	cg24296786	chr1:45957014	TESK2	-0.44	-5.45	-0.32	1.15e-7	Platelet count;
CESC	cis	rs2404602	0.669	rs12595313	chr15:76978370	A/G	cg26408565	chr15:76604113	ETFA	-0.39	-5.72	-0.33	2.94e-8	Blood metabolite levels;
CESC	cis	rs10751667	1.000	rs7394449	chr11:962190	T/C	cg06064525	chr11:970664	AP2A2	-0.38	-6.77	-0.38	8.06e-11	Alzheimer's disease (late onset);
CESC	cis	rs2806561	0.704	rs856510	chr1:23524407	A/C	cg12483005	chr1:23474871	LUZP1	0.43	6.55	0.37	2.93e-10	Height;
CESC	cis	rs8044868	0.521	rs7203821	chr16:72101165	T/C	cg16558253	chr16:72132732	DHX38	-0.41	-6.3	-0.36	1.26e-9	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CESC	cis	rs8031584	0.918	rs61997139	chr15:31273602	C/G	cg08109568	chr15:31115862	NA	-0.7	-9.29	-0.5	5.7e-18	Huntington's disease progression;
CESC	cis	rs11155671	0.530	rs9383577	chr6:150207195	C/T	cg09699651	chr6:150184138	LRP11	0.56	7.75	0.43	2.01e-13	Testicular germ cell tumor;
CESC	cis	rs12956009	0.518	rs10163861	chr18:44820214	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.48	6.38	0.37	7.74e-10	Educational attainment (years of education);
CESC	cis	rs2075371	0.966	rs1646676	chr7:133999267	G/A	cg11752832	chr7:134001865	SLC35B4	0.54	7.02	0.4	1.9e-11	Mean platelet volume;
CESC	cis	rs6500395	0.926	rs11076570	chr16:48597915	G/A	cg04672837	chr16:48644449	N4BP1	0.46	5.54	0.32	7.22e-8	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs4925386	0.840	rs6143024	chr20:60914229	A/G	cg22541963	chr20:60982533	CABLES2	0.5	5.23	0.31	3.49e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs12200560	0.505	rs211165	chr6:97068520	A/T	cg06623918	chr6:96969491	KIAA0776	0.46	5.85	0.34	1.47e-8	Coronary heart disease;
CESC	cis	rs2952156	0.920	rs2952152	chr17:37832735	T/C	cg07936489	chr17:37558343	FBXL20	-0.58	-7.38	-0.41	2.1e-12	Asthma;
CESC	cis	rs4843747	0.671	rs9921236	chr16:88117015	G/T	cg17633681	chr16:88106987	BANP	0.77	10.33	0.54	3.01e-21	Menopause (age at onset);
CESC	cis	rs4253772	0.591	rs6008365	chr22:46652929	G/A	cg10231785	chr22:46692440	CN5H6.4;GTSE1	0.49	5.19	0.3	4.28e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs8141529	0.843	rs1065497	chr22:29279991	C/T	cg02153584	chr22:29168773	CCDC117	0.56	7.11	0.4	1.1e-11	Lymphocyte counts;
CESC	cis	rs9457247	0.967	rs382009	chr6:167403121	G/C	cg23791538	chr6:167370224	RNASET2	-0.59	-8.35	-0.46	3.72e-15	Crohn's disease;
CESC	cis	rs2479106	0.549	rs7041880	chr9:126397776	T/A	cg16191174	chr9:126692580	DENND1A	0.38	5.29	0.31	2.62e-7	Polycystic ovary syndrome;
CESC	cis	rs6089584	1.000	rs6089587	chr20:60564829	C/T	cg24733560	chr20:60626293	TAF4	0.4	5.77	0.33	2.15e-8	Body mass index;
CESC	cis	rs875971	0.545	rs316324	chr7:65610614	A/G	cg11764359	chr7:65958608	NA	-0.79	-9.51	-0.5	1.18e-18	Aortic root size;
CESC	cis	rs2404602	0.583	rs12913096	chr15:76551852	C/T	cg05617483	chr15:76483344	C15orf27	0.4	5.42	0.32	1.34e-7	Blood metabolite levels;
CESC	cis	rs8180040	0.966	rs878659	chr3:47500662	G/A	cg27129171	chr3:47204927	SETD2	0.62	9.24	0.49	8.07e-18	Colorectal cancer;
CESC	cis	rs7932354	0.528	rs10838660	chr11:47152273	C/T	cg25783544	chr11:47291846	MADD	-0.43	-5.79	-0.34	1.99e-8	Bone mineral density (hip);Bone mineral density;
CESC	cis	rs561341	1.000	rs508192	chr17:30315147	C/T	cg00745463	chr17:30367425	LRRC37B	0.72	6.36	0.36	8.88e-10	Hip circumference adjusted for BMI;
CESC	cis	rs11098499	0.954	rs2306455	chr4:120421969	G/A	cg09307838	chr4:120376055	NA	0.93	13.08	0.63	1.67e-30	Corneal astigmatism;
CESC	cis	rs9910055	0.593	rs2905983	chr17:42212429	T/G	cg10896456	chr17:42255109	ASB16;C17orf65	-0.5	-7.41	-0.41	1.64e-12	Total body bone mineral density;
CESC	cis	rs6724607	1.000	rs6434402	chr2:191469322	C/T	cg21644426	chr2:191273491	MFSD6	-0.48	-6.65	-0.38	1.69e-10	Pulse pressure;
CESC	cis	rs12681288	0.550	rs12549204	chr8:959085	G/T	cg04851639	chr8:1020857	NA	-0.28	-5.59	-0.32	5.55e-8	Schizophrenia;
CESC	cis	rs7296418	0.663	rs28450974	chr12:123861420	G/A	cg05973401	chr12:123451056	ABCB9	0.44	5.58	0.32	5.85e-8	Platelet count;
CESC	cis	rs2070488	0.804	rs13100195	chr3:38482539	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.83	13.43	0.64	1e-31	Electrocardiographic conduction measures;
CESC	cis	rs2120019	1.000	rs8036197	chr15:75370232	T/C	cg17294928	chr15:75287854	SCAMP5	-0.59	-6.65	-0.38	1.64e-10	Blood trace element (Zn levels);
CESC	cis	rs7084402	0.967	rs1649027	chr10:60280911	T/G	cg07615347	chr10:60278583	BICC1	-0.59	-9.45	-0.5	1.94e-18	Refractive error;
CESC	cis	rs2732480	0.500	rs12828309	chr12:48641160	C/T	cg24011408	chr12:48396354	COL2A1	0.44	6.25	0.36	1.68e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs2279817	0.863	rs12757678	chr1:17983680	G/C	cg21791023	chr1:18019539	ARHGEF10L	-0.66	-8.09	-0.45	2.17e-14	Neuroticism;
CESC	cis	rs17711722	0.565	rs4275112	chr7:65198619	T/G	cg07424592	chr7:64974309	NA	0.35	5.06	0.3	7.9e-7	Calcium levels;
CESC	cis	rs854765	0.533	rs2955354	chr17:17948716	G/C	cg04398451	chr17:18023971	MYO15A	0.73	10.55	0.54	5.95e-22	Total body bone mineral density;
CESC	cis	rs7216064	1.000	rs2052187	chr17:65834737	T/C	cg07042672	chr17:66097459	LOC651250	-0.62	-7.44	-0.42	1.39e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs8180040	1.000	rs807931	chr3:47389317	C/T	cg27129171	chr3:47204927	SETD2	0.68	10.75	0.55	1.36e-22	Colorectal cancer;
CESC	cis	rs853679	0.550	rs9295762	chr6:28155418	C/T	cg18032046	chr6:28092343	ZSCAN16	0.48	5.84	0.34	1.54e-8	Depression;
CESC	cis	rs6952808	0.895	rs4513875	chr7:1928159	C/T	cg21782813	chr7:2030301	MAD1L1	0.43	6.02	0.35	5.76e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs4629180	0.675	rs10195061	chr2:102093974	T/G	cg21388029	chr2:102003306	CREG2	0.32	5.04	0.3	8.68e-7	Chronic rhinosinusitis with nasal polyps;
CESC	cis	rs2836974	0.966	rs2836977	chr21:40666066	T/C	cg11644478	chr21:40555479	PSMG1	1.02	16.23	0.71	1.34e-41	Cognitive function;
CESC	cis	rs7666738	0.830	rs7687958	chr4:99014495	T/C	cg03467027	chr4:99064603	C4orf37	0.44	5.63	0.33	4.57e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4692589	1.000	rs11732126	chr4:170937416	A/G	cg19918862	chr4:170955249	NA	0.37	5.76	0.33	2.36e-8	Anxiety disorder;
CESC	cis	rs1707322	0.721	rs12049027	chr1:46118184	A/T	cg06784218	chr1:46089804	CCDC17	0.43	7.48	0.42	1.07e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9916302	0.904	rs35335692	chr17:37710006	A/G	cg15445000	chr17:37608096	MED1	0.42	6.81	0.39	6.44e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs1163251	0.837	rs595283	chr1:120247887	C/G	cg19096424	chr1:120255104	PHGDH	-0.51	-6.46	-0.37	5e-10	Blood metabolite levels;
CESC	cis	rs67478160	0.608	rs11160760	chr14:104248938	G/T	cg08213375	chr14:104286397	PPP1R13B	0.55	11.0	0.56	2.01e-23	Schizophrenia;
CESC	cis	rs116095464	0.614	rs10059220	chr5:242813	C/T	cg22496380	chr5:211416	CCDC127	-0.96	-10.05	-0.53	2.39e-20	Breast cancer;
CESC	cis	rs10876993	0.890	rs2640630	chr12:58067267	T/C	cg18357645	chr12:58087776	OS9	0.61	10.25	0.53	5.6e-21	Celiac disease or Rheumatoid arthritis;
CESC	cis	rs10463316	0.817	rs7701271	chr5:150776708	A/G	cg03212797	chr5:150827313	SLC36A1	0.4	5.04	0.3	8.83e-7	Metabolite levels (Pyroglutamine);
CESC	trans	rs916888	0.610	rs199530	chr17:44836653	C/T	cg10053473	chr17:62856997	LRRC37A3	0.61	8.54	0.46	1.07e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs11711311	0.747	rs11928590	chr3:113343478	T/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.5	6.6	0.38	2.24e-10	IgG glycosylation;
CESC	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.52	7.13	0.4	9.37e-12	Lymphocyte counts;
CESC	cis	rs4566357	0.930	rs1917128	chr2:227927936	G/C	cg11843606	chr2:227700838	RHBDD1	-0.4	-5.17	-0.3	4.62e-7	Coronary artery disease;
CESC	cis	rs6089829	0.855	rs6090203	chr20:61663632	G/A	cg08564027	chr20:61660810	NA	0.9	15.42	0.69	9.97e-39	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7342306	0.788	rs11832287	chr12:6291307	A/G	cg23019886	chr12:6277045	NA	0.22	5.08	0.3	7.09e-7	Platelet count;
CESC	cis	rs6748734	1.000	rs4675868	chr2:241828542	A/C	cg07537917	chr2:241836409	C2orf54	-0.25	-5.14	-0.3	5.44e-7	Urinary metabolites;
CESC	cis	rs763121	0.651	rs738249	chr22:39037979	T/C	cg06544989	chr22:39130855	UNC84B	0.5	8.54	0.46	1.1e-15	Menopause (age at onset);
CESC	cis	rs7264396	0.697	rs6142416	chr20:34174092	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.47	5.88	0.34	1.2e-8	Total cholesterol levels;
CESC	cis	rs2742234	0.541	rs60845448	chr10:43721462	C/T	cg07801480	chr10:43725741	RASGEF1A	-0.4	-5.24	-0.31	3.22e-7	Hirschsprung disease;
CESC	cis	rs57506017	0.540	rs1435524	chr7:12262801	G/A	cg23422036	chr7:12250390	TMEM106B	0.39	5.23	0.31	3.51e-7	Neuroticism;
CESC	cis	rs7937682	0.883	rs1612013	chr11:111456293	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.93	-13.47	-0.64	7.49e-32	Primary sclerosing cholangitis;
CESC	cis	rs1062177	1.000	rs17804178	chr5:151197729	T/G	cg12924095	chr5:151150029	G3BP1	0.5	6.44	0.37	5.44e-10	Preschool internalizing problems;
CESC	cis	rs6484504	0.576	rs176373	chr11:31136026	G/T	cg14844989	chr11:31128820	NA	-0.41	-5.77	-0.33	2.19e-8	Red blood cell count;
CESC	cis	rs7666738	0.830	rs991169	chr4:98928567	C/A	cg05340658	chr4:99064831	C4orf37	0.82	12.2	0.6	1.81e-27	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1355223	0.902	rs35032224	chr11:34698154	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.46	-6.2	-0.36	2.15e-9	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs72945132	0.825	rs2298411	chr11:70206046	G/A	cg14191688	chr11:70257035	CTTN	0.43	5.42	0.32	1.34e-7	Coronary artery disease;
CESC	cis	rs7918232	0.941	rs6482598	chr10:27426375	T/C	cg14442939	chr10:27389572	ANKRD26	0.68	6.73	0.38	1.04e-10	Breast cancer;
CESC	cis	rs12079745	0.793	rs75134881	chr1:169186127	T/C	cg09363564	chr1:169337483	NME7;BLZF1	-1.1	-6.51	-0.37	3.77e-10	QT interval;
CESC	cis	rs7845219	0.544	rs4735330	chr8:95917770	A/C	cg13393036	chr8:95962371	TP53INP1	-0.42	-7.77	-0.43	1.69e-13	Type 2 diabetes;
CESC	cis	rs9649213	0.593	rs62478233	chr7:98023092	T/C	cg08684580	chr7:98029266	BAIAP2L1	-0.36	-5.73	-0.33	2.66e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7552404	0.920	rs2788654	chr1:76219569	C/T	cg22875332	chr1:76189707	ACADM	0.7	9.65	0.51	4.56e-19	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs6594713	0.756	rs10053341	chr5:112784007	G/T	cg12552261	chr5:112820674	MCC	0.54	5.23	0.31	3.48e-7	Brain cytoarchitecture;
CESC	cis	rs9640161	0.789	rs6964110	chr7:150041836	A/C	cg17279839	chr7:150038598	RARRES2	0.51	6.64	0.38	1.74e-10	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs1707322	1.000	rs7517560	chr1:46425943	A/G	cg03146154	chr1:46216737	IPP	0.72	9.82	0.52	1.31e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs12142240	0.698	rs6703669	chr1:46862555	C/T	cg10495392	chr1:46806563	NSUN4	0.56	6.17	0.35	2.61e-9	Menopause (age at onset);
CESC	cis	rs55871839	0.684	rs9298002	chr8:59815118	T/C	cg07426533	chr8:59803705	TOX	-0.51	-7.39	-0.41	1.97e-12	Pneumonia;
CESC	cis	rs208520	1.000	rs72880045	chr6:66965232	A/C	cg07460842	chr6:66804631	NA	0.9	10.34	0.54	2.79e-21	Exhaled nitric oxide output;
CESC	cis	rs208515	0.525	rs12214310	chr6:66666308	A/G	cg07460842	chr6:66804631	NA	0.83	10.33	0.54	3.09e-21	Exhaled nitric oxide levels;
CESC	cis	rs2243480	1.000	rs1723270	chr7:65469830	T/G	cg12463550	chr7:65579703	CRCP	0.68	5.46	0.32	1.09e-7	Diabetic kidney disease;
CESC	trans	rs10242455	0.702	rs73711280	chr7:99039604	C/T	cg09045935	chr12:6379348	NA	0.91	7.41	0.41	1.73e-12	Blood metabolite levels;
CESC	cis	rs3617	0.573	rs9850563	chr3:52912214	G/A	cg13284614	chr3:52569169	NT5DC2;LOC440957	-0.31	-5.32	-0.31	2.2e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
CESC	cis	rs941408	0.515	rs759067	chr19:2775668	C/T	cg02580895	chr19:2754563	NA	-0.41	-5.28	-0.31	2.74e-7	Total cholesterol levels;
CESC	cis	rs7772486	0.754	rs9386132	chr6:146140751	T/C	cg23711669	chr6:146136114	FBXO30	1.02	15.69	0.69	1.08e-39	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs7902708	0.920	rs7099953	chr10:54426489	G/T	cg26219051	chr22:43739629	SCUBE1	-0.48	-6.19	-0.36	2.25e-9	Bone properties (heel);
CESC	cis	rs897984	0.759	rs13708	chr16:31000809	G/A	cg02466173	chr16:30829666	NA	0.48	8.16	0.45	1.32e-14	Dementia with Lewy bodies;
CESC	cis	rs116095464	0.510	rs7714944	chr5:231765	C/T	cg22496380	chr5:211416	CCDC127	-0.72	-8.33	-0.46	4.36e-15	Breast cancer;
CESC	cis	rs17401966	1.000	rs12136376	chr1:10296452	C/T	cg15208524	chr1:10270712	KIF1B	0.47	6.14	0.35	3.07e-9	Hepatocellular carcinoma;
CESC	cis	rs6089829	0.888	rs4809468	chr20:61673566	T/C	cg08564027	chr20:61660810	NA	0.91	14.61	0.67	7.09e-36	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs9788682	0.747	rs2656069	chr15:78745707	C/T	cg24631222	chr15:78858424	CHRNA5	-0.61	-7.25	-0.41	4.65e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs6912958	0.712	rs9444525	chr6:88324142	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.5	-6.63	-0.38	1.92e-10	Monocyte percentage of white cells;
CESC	cis	rs67311347	1.000	rs56992941	chr3:40472434	A/T	cg01475735	chr3:40494733	NA	-0.41	-5.32	-0.31	2.17e-7	Renal cell carcinoma;
CESC	cis	rs12701220	0.894	rs12539012	chr7:1052133	G/A	cg26769984	chr7:1090371	C7orf50	0.65	7.13	0.4	9.52e-12	Bronchopulmonary dysplasia;
CESC	cis	rs1218582	0.772	rs10796935	chr1:154891363	G/T	cg09359103	chr1:154839909	KCNN3	-0.65	-12.26	-0.6	1.15e-27	Prostate cancer;
CESC	cis	rs6991838	0.557	rs13266834	chr8:66543538	C/A	cg13398993	chr8:66546079	ARMC1	0.46	5.65	0.33	4.19e-8	Intelligence (multi-trait analysis);
CESC	cis	rs1862618	0.802	rs832560	chr5:56124423	T/A	cg18230493	chr5:56204884	C5orf35	-0.72	-8.78	-0.47	2.09e-16	Initial pursuit acceleration;
CESC	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.89	13.57	0.64	3.26e-32	Prudent dietary pattern;
CESC	cis	rs7267979	1.000	rs2424704	chr20:25273929	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	18.72	0.75	2.09e-50	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7474896	0.537	rs2472149	chr10:38262196	A/C	cg00409905	chr10:38381863	ZNF37A	0.46	5.14	0.3	5.46e-7	Obesity (extreme);
CESC	cis	rs6011002	0.808	rs1291211	chr20:62337622	A/G	cg04115418	chr20:62273971	STMN3	0.49	5.31	0.31	2.29e-7	Dental caries;
CESC	cis	rs4919087	0.748	rs793516	chr10:98987985	G/T	cg25902810	chr10:99078978	FRAT1	-0.49	-5.4	-0.31	1.5e-7	Monocyte count;
CESC	cis	rs8062405	0.964	rs7193733	chr16:28875482	A/G	cg08761264	chr16:28874980	SH2B1	-0.47	-5.85	-0.34	1.42e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs16854884	0.657	rs62269895	chr3:143749085	C/G	cg06585982	chr3:143692056	C3orf58	0.5	6.71	0.38	1.18e-10	Economic and political preferences (feminism/equality);
CESC	cis	rs1413885	0.516	rs6588137	chr1:65837282	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.47	6.01	0.35	6.09e-9	Anticoagulant levels;
CESC	cis	rs7843479	0.601	rs1058486	chr8:21862551	A/G	cg17168535	chr8:21777572	XPO7	0.73	11.5	0.58	4.18e-25	Mean corpuscular volume;
CESC	cis	rs854765	0.583	rs10048206	chr17:17866897	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.59	8.26	0.45	7.24e-15	Total body bone mineral density;
CESC	cis	rs2075371	1.000	rs2598296	chr7:133992985	C/T	cg20476274	chr7:133979776	SLC35B4	0.67	9.67	0.51	3.81e-19	Mean platelet volume;
CESC	cis	rs10876993	0.928	rs1689587	chr12:58075398	A/G	cg18357645	chr12:58087776	OS9	0.63	10.52	0.54	7.21e-22	Celiac disease or Rheumatoid arthritis;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg00734895	chr19:7532157	ARHGEF18	0.47	6.03	0.35	5.6e-9	Fibrinogen levels;
CESC	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.51	-5.8	-0.34	1.86e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs9911578	0.967	rs8075786	chr17:56819216	T/C	cg05425664	chr17:57184151	TRIM37	-0.49	-6.72	-0.38	1.11e-10	Intelligence (multi-trait analysis);
CESC	cis	rs12188164	0.561	rs2251843	chr5:457955	C/T	cg16584290	chr5:462447	EXOC3	-0.46	-7.05	-0.4	1.6e-11	Cystic fibrosis severity;
CESC	cis	rs9487051	0.676	rs6933326	chr6:109601333	C/T	cg01475377	chr6:109611718	NA	-0.45	-7.24	-0.41	4.93e-12	Reticulocyte fraction of red cells;
CESC	cis	rs8180040	0.966	rs57346147	chr3:47410564	C/G	cg27129171	chr3:47204927	SETD2	-0.67	-10.29	-0.53	4.09e-21	Colorectal cancer;
CESC	cis	rs4132509	1.000	rs73124169	chr1:243804939	T/C	cg21452805	chr1:244014465	NA	0.45	5.46	0.32	1.12e-7	RR interval (heart rate);
CESC	cis	rs6952808	0.723	rs60995052	chr7:2030007	G/C	cg02951883	chr7:2050386	MAD1L1	-0.58	-7.77	-0.43	1.72e-13	Bipolar disorder and schizophrenia;
CESC	cis	rs909674	0.524	rs5750821	chr22:39825492	A/T	cg05872129	chr22:39784769	NA	-0.82	-11.22	-0.57	3.66e-24	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs7607369	0.536	rs4646535	chr2:219664663	C/T	cg02176678	chr2:219576539	TTLL4	-0.37	-6.38	-0.36	7.83e-10	Red blood cell count;Amyotrophic lateral sclerosis;
CESC	cis	rs7086627	0.515	rs10887903	chr10:82210641	C/T	cg00277334	chr10:82204260	NA	-0.92	-17.11	-0.72	1.02e-44	Post bronchodilator FEV1;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23121350	chr17:38219361	THRA	-0.61	-6.4	-0.37	6.94e-10	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05742564	chr16:23568708	UBFD1;EARS2	0.69	8.7	0.47	3.49e-16	Gut microbiome composition (summer);
CESC	cis	rs4268898	0.636	rs9636438	chr2:24460566	C/T	cg06627628	chr2:24431161	ITSN2	0.96	11.0	0.56	1.96e-23	Asthma;
CESC	cis	rs2228479	0.850	rs34033205	chr16:89922959	G/T	cg00800038	chr16:89945340	TCF25	-0.95	-7.51	-0.42	9.15e-13	Skin colour saturation;
CESC	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg01516881	chr6:292596	DUSP22	-0.83	-11.37	-0.57	1.16e-24	Menopause (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19484299	chr2:234775274	MSL3L2	-0.71	-8.25	-0.45	7.67e-15	Gut microbiome composition (summer);
CESC	cis	rs12477438	0.798	rs6705583	chr2:99602625	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-10.6	-0.55	4.17e-22	Chronic sinus infection;
CESC	cis	rs7927592	0.956	rs10896343	chr11:68317860	G/C	cg20283391	chr11:68216788	NA	-0.5	-5.89	-0.34	1.16e-8	Total body bone mineral density;
CESC	cis	rs9467711	0.606	rs9379864	chr6:26372584	G/A	cg14345882	chr6:26364793	BTN3A2	0.6	6.21	0.36	2.07e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs10256972	1.000	rs10256972	chr7:1039003	G/T	cg02099474	chr7:1027990	CYP2W1	0.34	5.09	0.3	6.76e-7	Longevity;Endometriosis;
CESC	cis	rs61931739	0.500	rs7489132	chr12:34539712	C/T	cg19457237	chr12:34500585	NA	-0.37	-5.08	-0.3	6.97e-7	Morning vs. evening chronotype;
CESC	cis	rs10870270	0.956	rs6557	chr10:133781449	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.59	-7.6	-0.42	5.25e-13	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs651907	0.535	rs13094911	chr3:101519021	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.46	6.05	0.35	4.95e-9	Colorectal cancer;
CESC	cis	rs7666738	0.830	rs11932942	chr4:98998939	T/C	cg03467027	chr4:99064603	C4orf37	0.44	5.51	0.32	8.65e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs8103278	1.000	rs8108590	chr19:46301620	A/G	cg12641515	chr19:46296257	DMWD	-0.52	-5.81	-0.34	1.76e-8	Coronary artery disease;
CESC	cis	rs9796	0.870	rs2925342	chr15:41305733	A/G	cg18705301	chr15:41695430	NDUFAF1	0.43	6.36	0.36	8.58e-10	Menopause (age at onset);
CESC	cis	rs11098499	0.954	rs13151285	chr4:120314741	C/A	cg24375607	chr4:120327624	NA	0.46	5.55	0.32	6.98e-8	Corneal astigmatism;
CESC	cis	rs597539	0.652	rs654071	chr11:68653432	A/C	cg01988459	chr11:68622903	NA	-0.39	-5.42	-0.32	1.37e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs2842992	0.915	rs2758335	chr6:160111011	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.65	7.91	0.44	7.12e-14	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs35995292	0.500	rs28369620	chr7:38921872	C/T	cg19327137	chr7:38886074	VPS41	0.66	10.86	0.55	5.69e-23	Subjective well-being (multi-trait analysis);
CESC	cis	rs644799	0.965	rs10831426	chr11:95505888	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.54	6.76	0.38	8.71e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs2228479	0.681	rs11641790	chr16:89961957	A/G	cg06558623	chr16:89946397	TCF25	-0.58	-5.76	-0.33	2.27e-8	Skin colour saturation;
CESC	cis	rs7666738	0.830	rs35752787	chr4:98935202	G/A	cg03467027	chr4:99064603	C4orf37	0.48	5.91	0.34	1.03e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7618915	0.547	rs11709448	chr3:52647449	T/C	cg17372223	chr3:52568218	NT5DC2	0.43	6.3	0.36	1.25e-9	Bipolar disorder;
CESC	cis	rs1018836	0.892	rs11776824	chr8:91553256	T/C	cg16814680	chr8:91681699	NA	-0.64	-9.06	-0.49	2.98e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs9309473	0.687	rs6546827	chr2:73606493	C/T	cg20560298	chr2:73613845	ALMS1	-0.46	-6.43	-0.37	5.87e-10	Metabolite levels;
CESC	cis	rs258892	0.895	rs13170247	chr5:72069684	A/G	cg21869765	chr5:72125136	TNPO1	-0.41	-5.04	-0.3	8.82e-7	Small cell lung carcinoma;
CESC	cis	rs651907	0.535	rs58658478	chr3:101511667	G/A	cg12386194	chr3:101231763	SENP7	0.42	5.35	0.31	1.86e-7	Colorectal cancer;
CESC	cis	rs7259376	0.936	rs7247220	chr19:22589489	C/G	cg02657401	chr19:22469223	NA	0.26	5.12	0.3	5.76e-7	Menopause (age at onset);
CESC	cis	rs6570726	0.577	rs9497315	chr6:145791967	C/T	cg23711669	chr6:146136114	FBXO30	-0.94	-12.58	-0.61	9.22e-29	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs3026101	0.671	rs11868032	chr17:5283617	A/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.43	5.84	0.34	1.56e-8	Body mass index;
CESC	cis	rs2832191	0.967	rs3787660	chr21:30520907	C/T	cg08807101	chr21:30365312	RNF160	0.69	9.59	0.51	7.08e-19	Dental caries;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg10996070	chr17:43025229	KIF18B	-0.49	-6.07	-0.35	4.37e-9	Asthma;
CESC	cis	rs2239547	0.657	rs6445539	chr3:52874296	G/A	cg11645453	chr3:52864694	ITIH4	0.34	6.34	0.36	9.85e-10	Schizophrenia;
CESC	cis	rs951366	0.677	rs1775140	chr1:205672107	C/A	cg17178900	chr1:205818956	PM20D1	0.76	11.26	0.57	2.61e-24	Menarche (age at onset);
CESC	cis	rs7107174	0.901	rs10899494	chr11:78122208	G/T	cg02023728	chr11:77925099	USP35	0.43	5.54	0.32	7.31e-8	Testicular germ cell tumor;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg18957721	chr13:99197425	STK24	0.41	6.13	0.35	3.22e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs72949976	1.000	rs6747328	chr2:214032156	C/G	cg08319019	chr2:214017104	IKZF2	-0.42	-5.38	-0.31	1.61e-7	Lung cancer;Squamous cell lung carcinoma;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg09378111	chr2:211036309	C2orf67	0.47	6.21	0.36	2.03e-9	Systemic lupus erythematosus;
CESC	cis	rs12618769	0.625	rs72819984	chr2:99044762	G/C	cg10123293	chr2:99228465	UNC50	0.4	5.34	0.31	1.97e-7	Bipolar disorder;
CESC	cis	rs9875589	0.509	rs6442423	chr3:14016062	G/A	cg19554555	chr3:13937349	NA	-0.44	-5.61	-0.33	5.2e-8	Ovarian reserve;
CESC	cis	rs3741151	0.687	rs56857598	chr11:73234173	G/A	cg17517138	chr11:73019481	ARHGEF17	1.05	7.72	0.43	2.46e-13	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs1862618	0.511	rs2591952	chr5:56120769	T/A	cg24531977	chr5:56204891	C5orf35	-0.88	-11.55	-0.58	2.79e-25	Initial pursuit acceleration;
CESC	cis	rs35955841	0.569	rs1570295	chr14:65310367	C/T	cg23373153	chr14:65346875	NA	0.43	5.62	0.33	4.8e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
CESC	cis	rs7786808	0.530	rs7785656	chr7:158184164	C/G	cg09998033	chr7:158218633	PTPRN2	-0.44	-6.47	-0.37	4.8e-10	Obesity-related traits;
CESC	cis	rs7707921	0.522	rs12374541	chr5:81491408	A/G	cg15871215	chr5:81402204	ATG10	0.47	6.8	0.39	6.74e-11	Breast cancer;
CESC	cis	rs9910055	0.573	rs228768	chr17:42191893	A/C	cg19774624	chr17:42201019	HDAC5	-0.72	-10.72	-0.55	1.69e-22	Total body bone mineral density;
CESC	cis	rs7424096	0.555	rs75219072	chr2:37225706	C/T	cg14987922	chr2:37194071	STRN	0.49	5.42	0.32	1.34e-7	High light scatter reticulocyte percentage of red cells;
CESC	cis	rs10540	0.818	rs12806089	chr11:501468	G/A	cg03352830	chr11:487213	PTDSS2	0.74	7.21	0.4	5.99e-12	Body mass index;
CESC	cis	rs9311474	0.597	rs13303	chr3:52558008	T/C	cg18337363	chr3:52569053	NT5DC2	0.35	6.78	0.38	8e-11	Electroencephalogram traits;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg25031380	chr1:40157119	HPCAL4	-0.45	-6.19	-0.36	2.26e-9	Height;
CESC	cis	rs7833986	0.501	rs2667983	chr8:56894087	T/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.58	7.16	0.4	8.04e-12	Height;
CESC	trans	rs9325144	0.723	rs11169518	chr12:39177237	C/A	cg23762105	chr12:34175262	ALG10	0.45	6.04	0.35	5.09e-9	Morning vs. evening chronotype;
CESC	cis	rs400736	0.740	rs225118	chr1:8108754	G/A	cg25007680	chr1:8021821	PARK7	0.58	8.17	0.45	1.3e-14	Response to antidepressants and depression;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16384552	chr7:74938386	SPDYE8P	-0.61	-6.53	-0.37	3.35e-10	Gut microbiome composition (summer);
CESC	cis	rs2594989	0.943	rs901865	chr3:11300707	T/C	cg00170343	chr3:11313890	ATG7	0.49	5.13	0.3	5.59e-7	Circulating chemerin levels;
CESC	cis	rs965469	0.779	rs2236112	chr20:3294983	C/G	cg25506879	chr20:3388711	C20orf194	-0.48	-5.35	-0.31	1.92e-7	IFN-related cytopenia;
CESC	cis	rs4969178	0.965	rs11077362	chr17:76397219	A/T	cg05887092	chr17:76393375	PGS1	0.58	9.22	0.49	9.9e-18	HDL cholesterol levels;
CESC	cis	rs832540	0.931	rs832529	chr5:56229288	C/T	cg14703610	chr5:56206110	C5orf35	0.54	7.32	0.41	3.03e-12	Coronary artery disease;
CESC	cis	rs1858740	0.509	rs196375	chr3:38422919	C/T	cg24069376	chr3:38537580	EXOG	0.33	5.35	0.31	1.88e-7	Schizophrenia;
CESC	cis	rs698813	0.572	rs12613771	chr2:44490660	C/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	5.65	0.33	4.17e-8	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
CESC	cis	rs72945132	0.882	rs17425511	chr11:70183737	C/G	cg00319359	chr11:70116639	PPFIA1	0.81	7.47	0.42	1.16e-12	Coronary artery disease;
CESC	cis	rs10504229	1.000	rs73607874	chr8:58173433	G/C	cg22535103	chr8:58192502	C8orf71	-1.05	-13.27	-0.63	3.63e-31	Developmental language disorder (linguistic errors);
CESC	cis	rs1878931	0.668	rs11643983	chr16:3438865	G/A	cg22508957	chr16:3507546	NAT15	-0.38	-5.58	-0.32	5.82e-8	Body mass index (adult);
CESC	cis	rs67478160	0.608	rs4906368	chr14:104242397	A/C	cg08213375	chr14:104286397	PPP1R13B	0.46	8.92	0.48	7.93e-17	Schizophrenia;
CESC	cis	rs250677	0.522	rs891920	chr5:148369418	G/T	cg18129178	chr5:148520854	ABLIM3	-0.46	-5.08	-0.3	7.01e-7	Breast cancer;
CESC	cis	rs60843830	1.000	rs3791224	chr2:221981	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.78	9.72	0.51	2.75e-19	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs6732160	0.691	rs13432787	chr2:73430234	T/C	cg01422370	chr2:73384389	NA	0.42	7.0	0.39	2.12e-11	Intelligence (multi-trait analysis);
CESC	cis	rs7809950	0.817	rs62483725	chr7:107201575	G/A	cg23024343	chr7:107201750	COG5	-0.59	-7.42	-0.41	1.64e-12	Coronary artery disease;
CESC	cis	rs2404602	0.647	rs11072619	chr15:77043242	A/C	cg23625390	chr15:77176239	SCAPER	-0.47	-6.52	-0.37	3.54e-10	Blood metabolite levels;
CESC	cis	rs992157	0.735	rs13392177	chr2:219112956	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.65	-9.06	-0.49	3e-17	Colorectal cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15380588	chr6:144606480	NA	0.6	6.71	0.38	1.16e-10	Gut microbiome composition (summer);
CESC	cis	rs9549260	0.604	rs9549273	chr13:41302147	C/G	cg21288729	chr13:41239152	FOXO1	-0.55	-5.26	-0.31	3.04e-7	Red blood cell count;
CESC	cis	rs6977660	0.507	rs28402966	chr7:19774469	A/C	cg05791153	chr7:19748676	TWISTNB	0.75	6.76	0.38	8.75e-11	Thyroid stimulating hormone;
CESC	trans	rs61931739	0.853	rs7137146	chr12:34102394	G/A	cg26384229	chr12:38710491	ALG10B	-0.47	-6.47	-0.37	4.67e-10	Morning vs. evening chronotype;
CESC	cis	rs208520	1.000	rs12189683	chr6:66977716	A/C	cg07460842	chr6:66804631	NA	-0.87	-10.11	-0.53	1.55e-20	Exhaled nitric oxide output;
CESC	cis	rs9311474	0.607	rs4234633	chr3:52557038	C/T	cg07507251	chr3:52567010	NT5DC2	0.47	8.72	0.47	3.21e-16	Electroencephalogram traits;
CESC	cis	rs7395581	0.959	rs35879051	chr11:47275882	C/G	cg25783544	chr11:47291846	MADD	0.6	7.8	0.43	1.47e-13	HDL cholesterol;
CESC	cis	rs9488822	0.676	rs7774952	chr6:116380909	A/G	cg15226275	chr6:116381976	FRK	0.25	6.47	0.37	4.8e-10	Cholesterol, total;LDL cholesterol;
CESC	cis	rs9393777	0.920	rs35869525	chr6:26946687	C/T	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.81	5.63	0.33	4.69e-8	Intelligence (multi-trait analysis);
CESC	cis	rs947211	0.846	rs708726	chr1:205762139	G/T	cg24503407	chr1:205819492	PM20D1	-0.4	-5.57	-0.32	6.4e-8	Parkinson's disease;
CESC	cis	rs7552404	0.960	rs12134854	chr1:76137606	A/G	cg03433033	chr1:76189801	ACADM	0.68	8.23	0.45	8.38e-15	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs9633740	1.000	rs10748526	chr10:82273079	T/C	cg00277334	chr10:82204260	NA	-0.53	-5.68	-0.33	3.6e-8	Post bronchodilator FEV1;
CESC	cis	rs6060717	0.536	rs11699899	chr20:34525646	G/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.65	5.58	0.32	6.02e-8	Hip circumference adjusted for BMI;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg26999933	chr16:11944926	RSL1D1	-0.49	-6.25	-0.36	1.61e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs9435341	0.965	rs56111229	chr1:107566689	T/A	cg09367891	chr1:107599246	PRMT6	0.7	8.21	0.45	9.8e-15	Facial morphology (factor 21, depth of nasal alae);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11326919	chr17:43324904	LOC100133991	0.55	6.12	0.35	3.33e-9	Gut microbiome composition (summer);
CESC	cis	rs2635047	0.638	rs2571008	chr18:44649950	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.39	5.32	0.31	2.19e-7	Educational attainment;
CESC	cis	rs61332075	0.540	rs55986470	chr2:239363773	A/G	cg18131467	chr2:239335373	ASB1	-0.66	-5.87	-0.34	1.32e-8	Lung function (FEV1/FVC);
CESC	cis	rs2303745	0.622	rs1864113	chr19:17393504	G/C	cg22549504	chr19:17448937	GTPBP3	0.5	5.56	0.32	6.74e-8	Systemic lupus erythematosus;
CESC	cis	rs7542091	0.704	rs12022221	chr1:210046178	A/C	cg22029157	chr1:209979665	IRF6	0.5	8.03	0.44	3.1e-14	Monobrow;
CESC	cis	rs3820928	0.839	rs4673174	chr2:227801316	A/T	cg05526886	chr2:227700861	RHBDD1	-0.4	-5.15	-0.3	5.12e-7	Pulmonary function;
CESC	cis	rs7216064	0.648	rs61676547	chr17:65892507	G/C	cg12091567	chr17:66097778	LOC651250	-0.74	-8.3	-0.45	5.44e-15	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs4889855	0.530	rs78012645	chr17:78550939	C/T	cg16591659	chr17:78472290	NA	0.35	5.74	0.33	2.62e-8	Fractional excretion of uric acid;
CESC	cis	rs7044106	0.762	rs1547267	chr9:123408736	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.76	11.04	0.56	1.44e-23	Hip circumference adjusted for BMI;
CESC	cis	rs7100689	0.725	rs10749574	chr10:82136856	T/C	cg00277334	chr10:82204260	NA	-0.58	-7.29	-0.41	3.66e-12	Post bronchodilator FEV1;
CESC	cis	rs6701037	0.566	rs10753091	chr1:175134571	T/C	cg00321850	chr1:175162397	KIAA0040	0.44	6.32	0.36	1.11e-9	Alcohol dependence;
CESC	cis	rs6547741	1.000	rs76784350	chr2:27764278	A/G	cg27432699	chr2:27873401	GPN1	0.49	6.74	0.38	9.86e-11	Oral cavity cancer;
CESC	cis	rs7666738	0.830	rs13108422	chr4:99059267	G/A	cg03467027	chr4:99064603	C4orf37	0.48	5.97	0.34	7.41e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs853679	0.517	rs1904841	chr6:28108085	C/T	cg08968635	chr6:28129556	ZNF389	0.42	5.76	0.33	2.27e-8	Depression;
CESC	cis	rs1620921	0.505	rs9456588	chr6:161212564	C/G	cg01280913	chr6:161186852	NA	-0.37	-5.24	-0.31	3.3e-7	Lipoprotein (a) - cholesterol levels;
CESC	cis	rs826838	0.967	rs34496261	chr12:39023829	G/A	cg26384229	chr12:38710491	ALG10B	0.8	13.91	0.65	2.13e-33	Heart rate;
CESC	cis	rs561341	0.882	rs111484028	chr17:30287701	G/A	cg12193833	chr17:30244370	NA	-0.59	-6.02	-0.35	5.78e-9	Hip circumference adjusted for BMI;
CESC	cis	rs8114671	0.869	rs2038503	chr20:33675900	G/A	cg06115741	chr20:33292138	TP53INP2	-0.44	-5.23	-0.31	3.47e-7	Height;
CESC	cis	rs9341808	0.935	rs2298307	chr6:80816296	A/G	cg08355045	chr6:80787529	NA	0.32	5.26	0.31	2.96e-7	Sitting height ratio;
CESC	cis	rs4927850	1.000	rs10881564	chr3:195750326	C/T	cg01181863	chr3:195395398	SDHAP2	-0.48	-5.6	-0.33	5.38e-8	Pancreatic cancer;
CESC	cis	rs12971120	0.891	rs4891557	chr18:72170299	C/T	cg26446133	chr18:72167187	CNDP2	-0.78	-9.58	-0.51	7.36e-19	Refractive error;
CESC	cis	rs2066819	0.901	rs1274490	chr12:56649601	A/G	cg26734620	chr12:56694298	CS	-0.94	-9.79	-0.52	1.56e-19	Psoriasis vulgaris;
CESC	cis	rs12049330	1.000	rs12049330	chr1:110031188	T/G	cg05049280	chr1:110155535	GNAT2	0.43	5.06	0.3	7.87e-7	Major depressive disorder;
CESC	cis	rs10781543	0.845	rs10781540	chr9:139321836	G/A	cg14169450	chr9:139327907	INPP5E	0.54	8.47	0.46	1.7e-15	Monocyte percentage of white cells;
CESC	cis	rs4975709	0.589	rs4975747	chr5:1862836	G/A	cg15595755	chr5:1867978	NA	0.51	8.24	0.45	7.89e-15	Cardiovascular disease risk factors;
CESC	cis	rs1008375	0.902	rs6844984	chr4:17651304	C/G	cg04450456	chr4:17643702	FAM184B	0.37	5.23	0.31	3.4e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs7044106	0.708	rs920745	chr9:123429943	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.69	10.09	0.53	1.84e-20	Hip circumference adjusted for BMI;
CESC	cis	rs10045504	0.502	rs17352751	chr5:38737836	G/A	cg15396434	chr5:38725168	NA	-0.73	-6.84	-0.39	5.61e-11	Night sleep phenotypes;
CESC	cis	rs9303401	0.703	rs9911583	chr17:57210721	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	-0.56	-7.21	-0.41	5.72e-12	Cognitive test performance;
CESC	cis	rs875971	0.862	rs1695820	chr7:65844563	G/A	cg10691866	chr7:65817282	TPST1	-0.32	-5.25	-0.31	3.06e-7	Aortic root size;
CESC	cis	rs6674176	0.597	rs3762422	chr1:44400532	T/A	cg13606994	chr1:44402422	ARTN	-0.41	-6.52	-0.37	3.57e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs9682041	0.808	rs9875109	chr3:170064776	A/G	cg11886554	chr3:170076028	SKIL	-0.47	-5.18	-0.3	4.49e-7	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CESC	cis	rs9399137	0.507	rs6918512	chr6:135284839	T/G	cg24558204	chr6:135376177	HBS1L	0.7	9.64	0.51	4.87e-19	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	cis	rs2637266	1.000	rs12258924	chr10:78364758	G/A	cg18941641	chr10:78392320	NA	0.42	7.87	0.44	8.96e-14	Pulmonary function;
CESC	cis	rs2370759	1.000	rs11594963	chr10:32625736	G/A	cg18270830	chr10:32634957	EPC1	0.7	6.76	0.38	8.99e-11	Sexual dysfunction (female);
CESC	cis	rs2268241	0.938	rs9974603	chr21:34776300	C/A	cg14850771	chr21:34775459	IFNGR2	0.92	10.85	0.55	6.4e-23	Obesity-related traits;
CESC	cis	rs863345	0.604	rs2317970	chr1:158504770	T/C	cg12129480	chr1:158549410	OR10X1	-0.34	-6.84	-0.39	5.41e-11	Pneumococcal bacteremia;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg13755614	chr9:131710194	DOLK;NUP188	-0.46	-6.2	-0.36	2.17e-9	Ulcerative colitis;
CESC	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.64	7.25	0.41	4.65e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs854765	0.547	rs9912096	chr17:17896673	A/C	cg16928487	chr17:17741425	SREBF1	-0.57	-9.84	-0.52	1.09e-19	Total body bone mineral density;
CESC	trans	rs11051970	0.636	rs2733704	chr12:32567858	C/T	cg19743254	chr11:132735814	OPCML	0.36	6.05	0.35	4.99e-9	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs34638657	0.872	rs6420436	chr16:82186719	C/G	cg09439754	chr16:82129088	HSD17B2	-0.35	-5.25	-0.31	3.12e-7	Lung adenocarcinoma;
CESC	cis	rs4713118	0.662	rs469228	chr6:27970704	A/G	cg26335602	chr6:28129616	ZNF389	0.41	5.43	0.32	1.25e-7	Parkinson's disease;
CESC	cis	rs959260	1.000	rs4789185	chr17:73383368	C/T	cg12999837	chr17:73267436	MIF4GD	-0.48	-5.58	-0.32	5.89e-8	Systemic lupus erythematosus;
CESC	cis	rs12477438	0.520	rs13010904	chr2:99754289	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	15.16	0.68	8.27e-38	Chronic sinus infection;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg02741808	chr17:73780792	UNK	-0.43	-6.11	-0.35	3.6e-9	Gambling;
CESC	cis	rs10751667	0.643	rs10751671	chr11:944479	T/G	cg06064525	chr11:970664	AP2A2	-0.5	-10.04	-0.52	2.69e-20	Alzheimer's disease (late onset);
CESC	trans	rs561341	0.941	rs736678	chr17:30347423	G/T	cg20587970	chr11:113659929	NA	-1.47	-18.13	-0.74	2.44e-48	Hip circumference adjusted for BMI;
CESC	cis	rs9649213	0.593	rs13232181	chr7:97935671	C/G	cg21770322	chr7:97807741	LMTK2	0.56	8.23	0.45	8.29e-15	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs914615	0.552	rs4971088	chr1:155142883	T/A	cg02153340	chr1:155202674	NA	-0.37	-5.39	-0.31	1.54e-7	Urinary albumin-to-creatinine ratio;
CESC	cis	rs4970966	0.855	rs11204701	chr1:150662179	A/T	cg13175981	chr1:150552382	MCL1	0.58	6.11	0.35	3.48e-9	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs60843830	1.000	rs56321614	chr2:268191	G/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.78	10.22	0.53	6.97e-21	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs7605827	0.930	rs2160693	chr2:15654669	A/T	cg19274914	chr2:15703543	NA	0.37	6.65	0.38	1.65e-10	Educational attainment (years of education);
CESC	cis	rs2075671	0.903	rs62482252	chr7:100274063	C/A	cg20848291	chr7:100343083	ZAN	-0.78	-9.47	-0.5	1.67e-18	Other erythrocyte phenotypes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17808635	chr1:156105758	LMNA	-0.51	-6.27	-0.36	1.47e-9	Gut microbiome composition (summer);
CESC	cis	rs7116495	1.000	rs12272213	chr11:71816219	G/A	cg10381502	chr11:71823885	C11orf51	0.66	5.35	0.31	1.93e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs8177253	0.930	rs12595	chr3:133496553	T/C	cg12373951	chr3:133503437	NA	0.37	5.22	0.31	3.7e-7	Iron status biomarkers;
CESC	cis	rs17039065	1.000	rs59029263	chr4:109403907	G/A	cg16022748	chr4:109541635	LOC285456;RPL34	0.66	5.45	0.32	1.15e-7	Gut microbiome composition (summer);
CESC	cis	rs6088580	0.601	rs6059872	chr20:33082775	C/A	cg24642439	chr20:33292090	TP53INP2	0.53	6.96	0.39	2.6e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs9443645	0.901	rs6940637	chr6:79705845	C/T	cg05283184	chr6:79620031	NA	-0.43	-6.54	-0.37	3.18e-10	Intelligence (multi-trait analysis);
CESC	cis	rs798554	0.836	rs13243214	chr7:2817455	G/T	cg13628971	chr7:2884303	GNA12	0.61	7.6	0.42	5.18e-13	Height;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg01799338	chr1:36348937	EIF2C1	-0.47	-6.35	-0.36	9.38e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs9633740	1.000	rs7097656	chr10:82250831	T/C	cg00277334	chr10:82204260	NA	-0.57	-5.73	-0.33	2.69e-8	Post bronchodilator FEV1;
CESC	cis	rs2440129	0.611	rs434473	chr17:6904934	A/G	cg02493798	chr17:6899577	ALOX12	-0.38	-6.29	-0.36	1.31e-9	Tonsillectomy;
CESC	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg11494091	chr17:61959527	GH2	0.72	12.38	0.61	4.46e-28	Prudent dietary pattern;
CESC	cis	rs8050907	0.590	rs17878588	chr16:4556450	A/T	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.8	5.38	0.31	1.61e-7	Obesity-related traits;
CESC	cis	rs10504229	0.683	rs61201557	chr8:58138370	T/C	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs12541635	0.966	rs2345070	chr8:107072027	A/G	cg10147462	chr8:107024639	NA	-0.37	-5.24	-0.31	3.33e-7	Age of smoking initiation;
CESC	cis	rs921968	0.565	rs4674329	chr2:219595507	A/G	cg02176678	chr2:219576539	TTLL4	-0.43	-7.6	-0.42	5.22e-13	Mean corpuscular hemoglobin concentration;
CESC	cis	rs10504229	0.593	rs58647001	chr8:58025132	G/A	cg24829409	chr8:58192753	C8orf71	-0.44	-5.68	-0.33	3.61e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs13223928	0.536	rs12700594	chr7:3156701	G/A	cg19214707	chr7:3157722	NA	0.44	6.09	0.35	3.88e-9	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
CESC	trans	rs2832077	0.527	rs2250141	chr21:30241984	A/T	cg14791747	chr16:20752902	THUMPD1	-0.49	-6.67	-0.38	1.51e-10	Cognitive test performance;
CESC	cis	rs4523957	0.890	rs216218	chr17:2145329	A/G	cg16513277	chr17:2031491	SMG6	0.6	8.27	0.45	6.35e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs801193	0.935	rs2659916	chr7:66151352	C/G	cg06456125	chr7:65229604	NA	0.4	5.25	0.31	3.09e-7	Aortic root size;
CESC	cis	rs72627123	0.867	rs118113209	chr14:74432158	G/A	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.77	5.13	0.3	5.7e-7	Morning vs. evening chronotype;
CESC	cis	rs10752881	1.000	rs10752881	chr1:182973491	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.83	13.28	0.63	3.33e-31	Colorectal cancer;
CESC	cis	rs9291683	0.546	rs13110307	chr4:10044364	T/C	cg00071950	chr4:10020882	SLC2A9	0.81	13.65	0.64	1.7e-32	Bone mineral density;
CESC	cis	rs7259376	0.936	rs4932759	chr19:22540105	C/T	cg02657401	chr19:22469223	NA	-0.25	-5.09	-0.3	6.84e-7	Menopause (age at onset);
CESC	cis	rs854765	0.583	rs9908832	chr17:17871068	C/T	cg16928487	chr17:17741425	SREBF1	-0.52	-8.63	-0.47	5.93e-16	Total body bone mineral density;
CESC	cis	rs56979318	1	rs56979318	chr17:80522718	A/T	cg10255544	chr17:80519551	FOXK2	0.55	8.78	0.47	2.02e-16	Reticulocyte count;
CESC	cis	rs9443645	0.527	rs2063123	chr6:79658535	T/C	cg05283184	chr6:79620031	NA	-0.37	-5.28	-0.31	2.63e-7	Intelligence (multi-trait analysis);
CESC	cis	rs898097	0.585	rs9893200	chr17:80893028	A/C	cg10494973	chr17:80897199	TBCD	-0.48	-6.0	-0.35	6.41e-9	Breast cancer;
CESC	trans	rs9916302	0.752	rs9901219	chr17:37558369	T/G	cg04245439	chr3:142607978	PCOLCE2	-0.51	-6.19	-0.36	2.33e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs12220238	1.000	rs11000909	chr10:75944828	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.59	5.39	0.31	1.59e-7	Soluble interleukin-2 receptor subunit alpha;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20270775	chr3:28282967	CMC1	0.58	6.68	0.38	1.37e-10	Gut microbiome composition (summer);
CESC	cis	rs7552404	0.924	rs1303169	chr1:76195041	T/C	cg03433033	chr1:76189801	ACADM	0.71	9.73	0.51	2.54e-19	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs589448	0.538	rs622656	chr12:69753595	C/T	cg14784868	chr12:69753453	YEATS4	0.74	9.73	0.51	2.42e-19	Cerebrospinal fluid biomarker levels;
CESC	cis	rs910316	0.737	rs108621	chr14:75480637	T/C	cg16144293	chr14:75469539	EIF2B2	0.39	5.11	0.3	6.03e-7	Height;
CESC	cis	rs4665809	0.887	rs28699126	chr2:26357294	C/T	cg26314531	chr2:26401878	FAM59B	-0.58	-6.6	-0.38	2.24e-10	Gut microbiome composition (summer);
CESC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg07387570	chr22:46663686	TTC38	0.47	6.23	0.36	1.85e-9	Tetralogy of Fallot;
CESC	cis	rs4665809	0.887	rs28699126	chr2:26357294	C/T	cg27170947	chr2:26402098	FAM59B	-0.56	-6.77	-0.38	8.35e-11	Gut microbiome composition (summer);
CESC	cis	rs8038465	1.000	rs8038465	chr15:73978337	A/G	cg15420318	chr15:73925796	NPTN	-0.42	-5.72	-0.33	2.9e-8	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs9611565	0.918	rs4820438	chr22:41767135	C/T	cg17376030	chr22:41985996	PMM1	0.56	6.12	0.35	3.41e-9	Vitiligo;
CESC	cis	rs12701220	0.655	rs7799656	chr7:1140515	C/T	cg26769984	chr7:1090371	C7orf50	0.61	7.0	0.4	2.1e-11	Bronchopulmonary dysplasia;
CESC	cis	rs360798	0.532	rs360797	chr2:62942840	C/T	cg17519650	chr2:63277830	OTX1	-0.58	-7.14	-0.4	9.25e-12	Coronary artery disease;
CESC	cis	rs3806843	0.735	rs2530242	chr5:140053351	G/C	cg26395211	chr5:140044315	WDR55	0.47	5.99	0.35	6.69e-9	Depressive symptoms (multi-trait analysis);
CESC	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg24642844	chr7:1081250	C7orf50	-0.78	-9.49	-0.5	1.38e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs9522267	0.535	rs2039916	chr13:112238863	A/C	cg10483660	chr13:112241077	NA	-0.32	-5.63	-0.33	4.64e-8	Hepatitis;
CESC	cis	rs875971	0.862	rs11763189	chr7:65983529	G/A	cg18876405	chr7:65276391	NA	0.5	6.65	0.38	1.64e-10	Aortic root size;
CESC	trans	rs757081	0.667	rs569780	chr11:17206745	C/T	cg00391031	chr10:72237473	KIAA1274	0.31	6.01	0.35	6.14e-9	Systolic blood pressure;
CESC	cis	rs2637266	0.935	rs2579720	chr10:78399918	T/C	cg18941641	chr10:78392320	NA	0.44	8.52	0.46	1.22e-15	Pulmonary function;
CESC	cis	rs7772486	0.817	rs12198065	chr6:146385286	G/C	cg23711669	chr6:146136114	FBXO30	0.88	13.06	0.63	2.03e-30	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs10781543	0.776	rs11145760	chr9:139382594	G/A	cg14169450	chr9:139327907	INPP5E	0.51	7.78	0.43	1.65e-13	Monocyte percentage of white cells;
CESC	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg03647317	chr4:187891568	NA	0.4	5.73	0.33	2.76e-8	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7208859	0.623	rs216446	chr17:28933718	T/G	cg19761014	chr17:28927070	LRRC37B2	0.85	6.59	0.38	2.33e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	trans	rs4957048	0.577	rs56294732	chr5:568144	T/C	cg25482853	chr8:67687455	SGK3	0.97	10.84	0.55	6.55e-23	Ulcerative colitis;
CESC	cis	rs11785400	0.793	rs2978973	chr8:143747271	C/G	cg24634471	chr8:143751801	JRK	0.49	5.99	0.35	6.98e-9	Schizophrenia;
CESC	cis	rs832540	0.898	rs252888	chr5:56227326	T/A	cg14703610	chr5:56206110	C5orf35	0.45	5.92	0.34	1.02e-8	Coronary artery disease;
CESC	cis	rs13242816	1.000	rs62468978	chr7:116127099	A/G	cg04696780	chr7:116139425	CAV2	-0.62	-5.68	-0.33	3.58e-8	P wave duration;
CESC	cis	rs11166629	1.000	rs1867059	chr8:135647019	A/G	cg27224718	chr8:135614730	ZFAT	0.54	6.9	0.39	3.73e-11	Smoking quantity;
CESC	cis	rs11630290	0.736	rs7183958	chr15:64155534	C/G	cg12036633	chr15:63758958	NA	-0.52	-5.32	-0.31	2.22e-7	Iris characteristics;
CESC	cis	rs11690935	0.632	rs9789538	chr2:172618474	G/C	cg13550731	chr2:172543902	DYNC1I2	0.61	8.42	0.46	2.46e-15	Schizophrenia;
CESC	trans	rs709082	0.771	rs1068686	chr3:191455571	T/A	cg25305879	chr2:106814630	NA	0.4	6.33	0.36	1.03e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs826838	0.616	rs11182893	chr12:38627715	C/G	cg26384229	chr12:38710491	ALG10B	-0.45	-6.01	-0.35	5.95e-9	Heart rate;
CESC	trans	rs7949030	0.504	rs2516633	chr11:62371773	A/C	cg02469871	chr12:103218581	NA	0.32	6.19	0.36	2.33e-9	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs7264396	0.563	rs2425122	chr20:34328848	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.63	6.86	0.39	4.77e-11	Total cholesterol levels;
CESC	cis	rs875971	0.862	rs17747530	chr7:65994729	G/C	cg18252515	chr7:66147081	NA	-0.47	-6.08	-0.35	4.25e-9	Aortic root size;
CESC	cis	rs4780401	0.609	rs4781141	chr16:11808769	A/C	cg01061890	chr16:11836724	TXNDC11	-0.56	-7.59	-0.42	5.59e-13	Rheumatoid arthritis;
CESC	cis	rs2952156	1.000	rs2643195	chr17:37853118	A/G	cg07936489	chr17:37558343	FBXL20	-0.52	-6.38	-0.37	7.71e-10	Asthma;
CESC	cis	rs6570726	0.791	rs6900040	chr6:145893134	C/T	cg23711669	chr6:146136114	FBXO30	0.97	14.77	0.67	2.05e-36	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2836974	0.897	rs36113648	chr21:40555497	G/A	cg17971929	chr21:40555470	PSMG1	1.07	16.73	0.72	2.16e-43	Cognitive function;
CESC	cis	rs2576037	0.583	rs2187091	chr18:44520048	T/C	cg19077165	chr18:44547161	KATNAL2	-0.63	-9.56	-0.51	8.76e-19	Personality dimensions;
CESC	cis	rs780096	0.587	rs1049817	chr2:27550967	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.31	-5.85	-0.34	1.44e-8	Total body bone mineral density;
CESC	trans	rs1559088	0.512	rs60197880	chr19:33562695	C/A	cg13714067	chr14:103989336	CKB	0.66	6.23	0.36	1.87e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs1707322	1.000	rs1768818	chr1:46514286	G/C	cg05343316	chr1:45956843	TESK2	-0.44	-5.44	-0.32	1.2e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg01238044	chr22:24384105	GSTT1	0.69	9.2	0.49	1.14e-17	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs1552244	1.000	rs17032299	chr3:10087638	C/T	cg00166722	chr3:10149974	C3orf24	0.47	5.83	0.34	1.59e-8	Alzheimer's disease;
CESC	cis	rs524281	0.861	rs2177054	chr11:65944612	C/A	cg14036092	chr11:66035641	RAB1B	-0.56	-5.49	-0.32	9.43e-8	Electroencephalogram traits;
CESC	cis	rs3125734	0.633	rs4979782	chr10:63998527	C/T	cg09941381	chr10:64027924	RTKN2	-0.31	-5.1	-0.3	6.39e-7	Rheumatoid arthritis;
CESC	cis	rs72781680	0.611	rs56326157	chr2:24312407	T/C	cg06627628	chr2:24431161	ITSN2	-0.67	-6.33	-0.36	1.06e-9	Lymphocyte counts;
CESC	cis	rs2645424	0.635	rs6980952	chr8:11716473	C/G	cg21281001	chr8:11725306	CTSB	-0.51	-6.39	-0.37	7.42e-10	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);
CESC	cis	rs9517313	0.770	rs9517301	chr13:99095088	A/G	cg07423050	chr13:99094983	FARP1	-0.3	-5.45	-0.32	1.13e-7	Neuroticism;
CESC	cis	rs7666738	0.830	rs2167892	chr4:99048503	G/C	cg05340658	chr4:99064831	C4orf37	0.82	12.88	0.62	8.44e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1707322	1.000	rs10890378	chr1:46410657	A/G	cg06784218	chr1:46089804	CCDC17	-0.33	-5.63	-0.33	4.7e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs897984	0.609	rs11862744	chr16:31057800	G/A	cg00531865	chr16:30841666	NA	-0.39	-5.48	-0.32	9.95e-8	Dementia with Lewy bodies;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05787931	chr3:52232012	ALAS1	0.61	7.25	0.41	4.52e-12	Gut microbiome composition (summer);
CESC	cis	rs736801	0.836	rs2522052	chr5:131798487	C/T	cg21138405	chr5:131827807	IRF1	0.37	5.52	0.32	7.93e-8	Breast cancer;Mosquito bite size;
CESC	cis	rs710216	0.957	rs2886876	chr1:43432741	A/G	cg03128534	chr1:43423976	SLC2A1	-0.5	-5.89	-0.34	1.15e-8	Red cell distribution width;
CESC	cis	rs25645	0.771	rs10445310	chr17:38205396	C/A	cg17344932	chr17:38183730	MED24;SNORD124	0.54	7.42	0.41	1.62e-12	Myeloid white cell count;
CESC	cis	rs1348850	0.747	rs1047884	chr2:178488281	C/G	cg22681709	chr2:178499509	PDE11A	-0.39	-5.92	-0.34	1e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs2842992	0.789	rs4235925	chr6:160202860	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.73	8.81	0.48	1.68e-16	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs7615952	0.611	rs9681518	chr3:125615130	A/G	cg05084668	chr3:125655381	ALG1L	-0.77	-7.94	-0.44	5.82e-14	Blood pressure (smoking interaction);
CESC	cis	rs1499972	0.938	rs846184	chr3:117749852	C/T	cg07612923	chr3:117604196	NA	-0.79	-5.81	-0.34	1.75e-8	Schizophrenia;
CESC	cis	rs7666738	0.830	rs28618180	chr4:98912184	A/C	cg05340658	chr4:99064831	C4orf37	0.76	11.15	0.57	6.32e-24	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1595825	0.735	rs6752760	chr2:198918164	G/T	cg10820045	chr2:198174542	NA	0.42	5.21	0.3	3.79e-7	Ulcerative colitis;
CESC	cis	rs1801251	1.000	rs4973053	chr2:233670099	G/A	cg08000102	chr2:233561755	GIGYF2	-0.67	-9.77	-0.51	1.93e-19	Coronary artery disease;
CESC	cis	rs7552404	0.727	rs6678348	chr1:76332463	C/T	cg22875332	chr1:76189707	ACADM	0.64	6.42	0.37	6.23e-10	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs919433	0.889	rs788004	chr2:198219032	C/T	cg03934865	chr2:198174659	NA	0.44	6.47	0.37	4.71e-10	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs9650657	0.504	rs10093053	chr8:11037187	T/C	cg21775007	chr8:11205619	TDH	-0.39	-5.56	-0.32	6.47e-8	Neuroticism;
CESC	cis	rs9325144	0.560	rs7980358	chr12:38640396	C/G	cg26384229	chr12:38710491	ALG10B	0.59	8.26	0.45	7.18e-15	Morning vs. evening chronotype;
CESC	trans	rs2797160	0.714	rs1777220	chr6:126022602	G/T	cg05039488	chr6:79577232	IRAK1BP1	0.51	6.88	0.39	4.41e-11	Endometrial cancer;
CESC	cis	rs4737010	0.501	rs55694640	chr8:41649439	T/G	cg08923054	chr8:41654455	ANK1	0.6	7.42	0.41	1.55e-12	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
CESC	cis	rs13191362	1.000	rs36007635	chr6:163009335	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.82	8.29	0.45	5.87e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs1799949	1.000	rs16941	chr17:41244435	T/C	cg25072359	chr17:41440525	NA	0.47	6.42	0.37	6.23e-10	Menopause (age at onset);
CESC	cis	rs826838	0.967	rs1719858	chr12:39124505	C/T	cg13010199	chr12:38710504	ALG10B	-0.46	-6.44	-0.37	5.5e-10	Heart rate;
CESC	cis	rs6964587	1.000	rs2097739	chr7:91711466	C/T	cg17063962	chr7:91808500	NA	0.59	8.22	0.45	9.37e-15	Breast cancer;
CESC	cis	rs62064224	0.765	rs62065463	chr17:30732405	G/T	cg24550644	chr17:30846204	MYO1D	-0.35	-5.03	-0.3	8.94e-7	Schizophrenia;
CESC	cis	rs7267979	0.933	rs2424708	chr20:25281398	C/T	cg08601574	chr20:25228251	PYGB	0.36	5.09	0.3	6.75e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs12477438	0.520	rs6542865	chr2:99764521	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.85	15.81	0.7	4.17e-40	Chronic sinus infection;
CESC	cis	rs10256972	1.000	rs10256972	chr7:1039003	G/T	cg00431813	chr7:1051703	C7orf50	0.35	5.47	0.32	1.03e-7	Longevity;Endometriosis;
CESC	cis	rs826838	0.616	rs9668847	chr12:38614669	C/T	cg26384229	chr12:38710491	ALG10B	0.46	6.62	0.38	1.96e-10	Heart rate;
CESC	cis	rs11077998	0.935	rs12185276	chr17:80498997	T/C	cg10255544	chr17:80519551	FOXK2	0.55	8.85	0.48	1.27e-16	Reticulocyte fraction of red cells;
CESC	cis	rs7412746	0.658	rs57818453	chr1:150763139	G/A	cg17724175	chr1:150552817	MCL1	0.42	6.33	0.36	1.02e-9	Melanoma;
CESC	cis	rs919433	0.680	rs4685	chr2:198257795	C/T	cg03934865	chr2:198174659	NA	-0.38	-5.09	-0.3	6.76e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs2050392	0.965	rs1543725	chr10:30698873	A/G	cg18806716	chr10:30721971	MAP3K8	-0.42	-6.04	-0.35	5.11e-9	Inflammatory bowel disease;
CESC	cis	rs56104184	0.775	rs17272707	chr19:49404535	T/G	cg15549821	chr19:49342101	PLEKHA4	-0.53	-5.47	-0.32	1.06e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	cis	rs35110281	0.782	rs9981291	chr21:45031458	A/G	cg21573476	chr21:45109991	RRP1B	-0.49	-6.82	-0.39	6.32e-11	Mean corpuscular volume;
CESC	cis	rs7772486	0.754	rs6570718	chr6:146088443	T/G	cg05347473	chr6:146136440	FBXO30	-0.54	-6.88	-0.39	4.35e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1267303	0.537	rs59935547	chr1:47001423	A/G	cg25110126	chr1:46999211	NA	0.84	10.81	0.55	8.55e-23	Monobrow;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04113056	chr14:64010798	PPP2R5E	0.58	7.25	0.41	4.58e-12	Gut microbiome composition (summer);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg27362115	chr11:65172423	FRMD8	0.48	6.19	0.36	2.24e-9	Fibrinogen levels;
CESC	cis	rs6952808	0.792	rs2056481	chr7:1955435	A/G	cg02951883	chr7:2050386	MAD1L1	-0.48	-6.46	-0.37	5.05e-10	Bipolar disorder and schizophrenia;
CESC	cis	rs9911578	1.000	rs2270097	chr17:56572070	G/A	cg12560992	chr17:57184187	TRIM37	-0.92	-15.44	-0.69	8.54e-39	Intelligence (multi-trait analysis);
CESC	cis	rs17376456	0.825	rs17374166	chr5:93238655	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.62	5.24	0.31	3.26e-7	Diabetic retinopathy;
CESC	cis	rs66573146	0.572	rs66611116	chr4:6953270	A/G	cg00086871	chr4:6988644	TBC1D14	1.03	6.92	0.39	3.38e-11	Granulocyte percentage of myeloid white cells;
CESC	cis	rs2276314	0.857	rs62101402	chr18:33629435	A/G	cg05985134	chr18:33552581	C18orf21	0.62	7.36	0.41	2.32e-12	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs752010	0.631	rs1073197	chr1:42059822	C/T	cg06885757	chr1:42089581	HIVEP3	-0.68	-11.01	-0.56	1.83e-23	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs11098499	0.908	rs11729050	chr4:120300066	T/C	cg09307838	chr4:120376055	NA	0.92	12.66	0.61	4.96e-29	Corneal astigmatism;
CESC	trans	rs1994135	0.654	rs1447872	chr12:33718343	C/A	cg26384229	chr12:38710491	ALG10B	0.56	7.59	0.42	5.47e-13	Resting heart rate;
CESC	cis	rs35146811	0.806	rs1534310	chr7:99699169	A/T	cg13334819	chr7:99746414	C7orf59	-0.44	-5.24	-0.31	3.34e-7	Coronary artery disease;
CESC	cis	rs703842	0.642	rs73123375	chr12:58063664	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.5	5.34	0.31	1.95e-7	Multiple sclerosis;
CESC	cis	rs6460942	1.000	rs62448565	chr7:12400458	G/A	cg20607287	chr7:12443886	VWDE	-0.67	-7.7	-0.43	2.67e-13	Coronary artery disease;
CESC	cis	rs7408868	0.908	rs10416777	chr19:15276923	C/T	cg14696996	chr19:15285081	NOTCH3	1.11	11.51	0.58	3.92e-25	Pulse pressure;
CESC	trans	rs1814175	0.817	rs1794162	chr11:49899506	A/C	cg15704280	chr7:45808275	SEPT13	-1.03	-21.21	-0.79	4.77e-59	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03674076	chr20:524243	CSNK2A1	0.59	7.0	0.4	2.11e-11	Gut microbiome composition (summer);
CESC	cis	rs7727544	0.684	rs272889	chr5:131665378	A/G	cg07395648	chr5:131743802	NA	-0.43	-5.67	-0.33	3.64e-8	Blood metabolite levels;
CESC	cis	rs2439831	0.867	rs2412778	chr15:43660982	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.92	11.04	0.56	1.5e-23	Lung cancer in ever smokers;
CESC	cis	rs2842992	0.872	rs1570318	chr6:160111473	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.65	7.91	0.44	7.12e-14	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs6748734	1.000	rs4344931	chr2:241818527	A/C	cg04034577	chr2:241836375	C2orf54	-0.48	-8.43	-0.46	2.17e-15	Urinary metabolites;
CESC	cis	rs9911578	0.967	rs7222789	chr17:56819853	C/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.21	0.3	3.88e-7	Intelligence (multi-trait analysis);
CESC	cis	rs8031584	0.505	rs2959036	chr15:31219742	T/G	cg19680485	chr15:31195859	MTMR15	0.5	6.05	0.35	4.83e-9	Huntington's disease progression;
CESC	cis	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg05863683	chr7:1912471	MAD1L1	0.42	6.21	0.36	2.09e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs4919087	0.892	rs10786319	chr10:99008951	T/C	cg25902810	chr10:99078978	FRAT1	0.64	9.06	0.49	2.9e-17	Monocyte count;
CESC	cis	rs1552244	1.000	rs6442146	chr3:10073544	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-10.98	-0.56	2.38e-23	Alzheimer's disease;
CESC	trans	rs7866350	0.604	rs1935389	chr9:100994470	A/G	cg03221778	chr16:89284213	ZNF778	0.44	6.16	0.35	2.72e-9	Post-traumatic stress disorder;
CESC	cis	rs172166	0.637	rs1225595	chr6:28151340	A/T	cg18032046	chr6:28092343	ZSCAN16	-0.42	-5.55	-0.32	6.99e-8	Cardiac Troponin-T levels;
CESC	cis	rs6582630	0.513	rs11181246	chr12:38302670	C/T	cg13010199	chr12:38710504	ALG10B	0.45	5.65	0.33	4.06e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs933688	0.536	rs332537	chr5:90794973	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.86	-8.33	-0.46	4.48e-15	Smoking behavior;
CESC	cis	rs4699052	0.963	rs6816055	chr4:104143160	T/C	cg16532752	chr4:104119610	CENPE	-0.39	-5.35	-0.31	1.9e-7	Testicular germ cell tumor;
CESC	cis	rs3746446	0.678	rs6120777	chr20:33560172	G/A	cg24642439	chr20:33292090	TP53INP2	0.69	6.06	0.35	4.72e-9	Congenital left-sided heart lesions;
CESC	cis	rs7267979	0.966	rs2482918	chr20:25412135	C/T	cg08601574	chr20:25228251	PYGB	-0.36	-5.13	-0.3	5.55e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs12586317	0.508	rs10134914	chr14:35425012	T/G	cg05294307	chr14:35346193	BAZ1A	-0.51	-6.37	-0.36	8.28e-10	Psoriasis;
CESC	cis	rs12458462	0.859	rs34242155	chr18:77425192	G/A	cg23301140	chr18:77439876	CTDP1	0.57	7.41	0.41	1.74e-12	Monocyte count;
CESC	cis	rs727563	0.635	rs2899348	chr22:42164516	C/G	cg06481639	chr22:41940642	POLR3H	0.6	5.92	0.34	9.88e-9	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg11494091	chr17:61959527	GH2	0.76	13.36	0.63	1.73e-31	Prudent dietary pattern;
CESC	cis	rs9467711	0.584	rs34244947	chr6:26761745	T/C	cg14345882	chr6:26364793	BTN3A2	0.64	5.81	0.34	1.8e-8	Autism spectrum disorder or schizophrenia;
CESC	cis	rs3096299	0.606	rs4785573	chr16:89565403	A/G	cg16743903	chr16:89593216	SPG7	-0.53	-6.65	-0.38	1.7e-10	Multiple myeloma (IgH translocation);
CESC	trans	rs1814175	0.935	rs7950947	chr11:49668369	C/T	cg03929089	chr4:120376271	NA	-0.87	-13.36	-0.63	1.83e-31	Height;
CESC	cis	rs61931739	0.533	rs4270002	chr12:34313126	G/T	cg19457237	chr12:34500585	NA	-0.42	-5.67	-0.33	3.79e-8	Morning vs. evening chronotype;
CESC	cis	rs7927592	0.956	rs7126340	chr11:68257293	C/T	cg20283391	chr11:68216788	NA	-0.5	-6.14	-0.35	2.96e-9	Total body bone mineral density;
CESC	cis	rs10256972	0.527	rs2949170	chr7:1216438	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.63	-8.04	-0.44	3.08e-14	Longevity;Endometriosis;
CESC	cis	rs10905065	0.931	rs11255228	chr10:5837671	T/C	cg11519256	chr10:5708881	ASB13	0.45	6.22	0.36	1.9e-9	Menopause (age at onset);
CESC	trans	rs11098499	0.863	rs3733525	chr4:120447048	A/G	cg25214090	chr10:38739885	LOC399744	0.7	9.68	0.51	3.69e-19	Corneal astigmatism;
CESC	cis	rs6547741	0.935	rs4666004	chr2:27855052	T/A	cg27432699	chr2:27873401	GPN1	0.45	6.16	0.35	2.7e-9	Oral cavity cancer;
CESC	cis	rs12458462	0.892	rs3786228	chr18:77464170	C/T	cg11879182	chr18:77439856	CTDP1	-0.86	-13.87	-0.65	3.01e-33	Monocyte count;
CESC	cis	rs11758351	0.660	rs2143345	chr6:26229148	C/T	cg23601095	chr6:26197514	HIST1H3D	0.91	9.93	0.52	5.8e-20	Gout;Renal underexcretion gout;
CESC	cis	rs950169	0.922	rs11635505	chr15:85097034	A/C	cg17507749	chr15:85114479	UBE2QP1	-0.59	-6.75	-0.38	9.1e-11	Schizophrenia;
CESC	cis	rs4563143	0.647	rs73029014	chr19:29257655	G/C	cg14983838	chr19:29218262	NA	0.5	6.1	0.35	3.67e-9	Methadone dose in opioid dependence;
CESC	cis	rs1401999	0.668	rs6806313	chr3:183642152	G/C	cg01324343	chr3:183735012	ABCC5	0.47	9.48	0.5	1.47e-18	Anterior chamber depth;
CESC	cis	rs7116495	1.000	rs610041	chr11:71797968	A/G	cg10381502	chr11:71823885	C11orf51	-0.66	-5.4	-0.31	1.51e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs116095464	0.558	rs10052012	chr5:231908	T/C	cg22857025	chr5:266934	NA	-1.29	-18.53	-0.75	9.59e-50	Breast cancer;
CESC	cis	rs7618915	0.501	rs12486554	chr3:52742537	A/T	cg18099408	chr3:52552593	STAB1	-0.33	-5.49	-0.32	9.35e-8	Bipolar disorder;
CESC	cis	rs208520	0.661	rs150263	chr6:66777620	T/C	cg07460842	chr6:66804631	NA	-0.99	-13.11	-0.63	1.36e-30	Exhaled nitric oxide output;
CESC	cis	rs4835473	0.832	rs35398499	chr4:144658868	C/A	cg25736465	chr4:144833511	NA	-0.33	-5.2	-0.3	4.08e-7	Immature fraction of reticulocytes;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg20540378	chr5:149340137	SLC26A2	-0.47	-6.17	-0.35	2.58e-9	Height;
CESC	cis	rs933688	0.532	rs2367292	chr5:90556785	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.45	-5.21	-0.3	3.74e-7	Smoking behavior;
CESC	cis	rs911555	0.504	rs8021368	chr14:104074810	G/A	cg24130564	chr14:104152367	KLC1	-0.8	-12.94	-0.62	5.2e-30	Intelligence (multi-trait analysis);
CESC	cis	rs3892630	0.588	rs8106748	chr19:33282797	G/A	cg22980127	chr19:33182716	NUDT19	1.13	14.68	0.67	4.09e-36	Red blood cell traits;
CESC	cis	rs8092503	1.000	rs7236335	chr18:52475073	G/A	cg12377874	chr18:52495404	RAB27B	0.38	6.13	0.35	3.17e-9	Childhood body mass index;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg21140054	chr3:42632404	SS18L2	-0.43	-6.64	-0.38	1.82e-10	Gambling;
CESC	cis	rs9910055	0.659	rs186603	chr17:42207884	C/T	cg19774624	chr17:42201019	HDAC5	0.84	13.09	0.63	1.55e-30	Total body bone mineral density;
CESC	cis	rs1185460	0.934	rs10892328	chr11:118942654	T/A	cg23280166	chr11:118938394	VPS11	0.51	6.51	0.37	3.82e-10	Coronary artery disease;
CESC	cis	rs8070740	0.617	rs9908179	chr17:5323631	A/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.56	7.49	0.42	1.05e-12	Menopause (age at onset);
CESC	cis	rs57221529	0.766	rs12521051	chr5:560440	A/G	cg16447950	chr5:562315	NA	0.69	8.06	0.44	2.59e-14	Lung disease severity in cystic fibrosis;
CESC	cis	rs7219021	0.705	rs2270576	chr17:47007963	C/T	cg16584676	chr17:46985605	UBE2Z	-0.62	-7.06	-0.4	1.46e-11	Schizophrenia or bipolar disorder;
CESC	cis	rs4891159	0.790	rs72975925	chr18:74143902	G/A	cg24786174	chr18:74118243	ZNF516	-0.74	-10.97	-0.56	2.44e-23	Longevity;
CESC	trans	rs11098499	0.604	rs12642411	chr4:120580525	T/C	cg25214090	chr10:38739885	LOC399744	0.62	8.15	0.45	1.47e-14	Corneal astigmatism;
CESC	cis	rs12824058	0.831	rs12322456	chr12:130813594	A/G	cg23887609	chr12:130822674	PIWIL1	0.46	5.99	0.35	6.63e-9	Menopause (age at onset);
CESC	cis	rs863345	0.604	rs1342952	chr1:158464430	C/A	cg12129480	chr1:158549410	OR10X1	-0.35	-6.97	-0.39	2.46e-11	Pneumococcal bacteremia;
CESC	cis	rs4660306	0.961	rs3748643	chr1:45965703	G/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.61	-7.69	-0.43	2.86e-13	Homocysteine levels;
CESC	cis	rs2742417	0.624	rs2673030	chr3:45757900	T/G	cg04837898	chr3:45731254	SACM1L	-0.48	-6.55	-0.37	2.96e-10	Response to anti-depressant treatment in major depressive disorder;
CESC	cis	rs9911578	0.967	rs8082544	chr17:57185807	C/T	cg05425664	chr17:57184151	TRIM37	0.53	7.3	0.41	3.31e-12	Intelligence (multi-trait analysis);
CESC	cis	rs11683229	0.704	rs11683005	chr2:63302629	C/T	cg17519650	chr2:63277830	OTX1	-0.7	-5.48	-0.32	9.76e-8	Protein quantitative trait loci;
CESC	trans	rs9329221	0.683	rs555200	chr8:9888729	A/G	cg15556689	chr8:8085844	FLJ10661	-0.58	-7.68	-0.43	3.16e-13	Neuroticism;
CESC	cis	rs2315504	0.509	rs2051806	chr17:39031451	C/T	cg05063374	chr17:38953512	KRT28	-0.42	-5.92	-0.34	9.99e-9	Height;
CESC	cis	rs1005277	0.579	rs2472182	chr10:38388865	T/C	cg25517755	chr10:38738941	LOC399744	-0.47	-6.05	-0.35	4.86e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs7000551	0.689	rs6996872	chr8:22316753	T/C	cg12081754	chr8:22256438	SLC39A14	0.39	5.13	0.3	5.57e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CESC	cis	rs9303280	0.806	rs35569035	chr17:38035624	C/T	cg19468946	chr17:37922297	IKZF3	-0.41	-5.49	-0.32	9.59e-8	Self-reported allergy;
CESC	cis	rs909002	0.800	rs3753613	chr1:32082000	C/T	cg13919466	chr1:32135498	COL16A1	0.46	8.24	0.45	7.88e-15	Intelligence (multi-trait analysis);
CESC	cis	rs9649213	0.593	rs6947208	chr7:97912204	C/T	cg00277769	chr7:97922759	BAIAP2L1	-0.36	-5.73	-0.33	2.69e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs10392	0.543	rs748063	chr20:37548730	A/G	cg27552599	chr20:37590471	DHX35	0.39	5.67	0.33	3.77e-8	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
CESC	cis	rs611744	0.647	rs587340	chr8:109246032	C/A	cg21045802	chr8:109455806	TTC35	0.46	5.72	0.33	2.92e-8	Dupuytren's disease;
CESC	cis	rs9614461	0.826	rs9614649	chr22:45746097	C/A	cg13318129	chr22:45737514	FAM118A	0.54	5.81	0.34	1.75e-8	Tonsillectomy;
CESC	cis	rs1448094	0.512	rs7308229	chr12:86239849	A/T	cg02569458	chr12:86230093	RASSF9	-0.48	-7.27	-0.41	3.94e-12	Major depressive disorder;
CESC	cis	rs736408	0.545	rs6445529	chr3:52662722	T/A	cg18404041	chr3:52824283	ITIH1	-0.38	-6.5	-0.37	3.97e-10	Bipolar disorder;
CESC	cis	rs1163251	0.837	rs839612	chr1:120247176	T/C	cg19096424	chr1:120255104	PHGDH	0.52	6.67	0.38	1.52e-10	Blood metabolite levels;
CESC	cis	rs16895831	0.549	rs12204274	chr6:42607841	C/T	cg10605015	chr6:42532144	UBR2	-0.48	-5.33	-0.31	2.06e-7	Granulocyte percentage of myeloid white cells;Neutrophil percentage of white cells;Eosinophil percentage of white cells;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Neutrophil count;Sum basophil neutrophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
CESC	cis	rs12142240	0.698	rs66847432	chr1:46832013	G/A	cg10495392	chr1:46806563	NSUN4	0.57	6.24	0.36	1.74e-9	Menopause (age at onset);
CESC	cis	rs897984	0.609	rs55979739	chr16:31049155	A/G	cg02466173	chr16:30829666	NA	-0.42	-7.18	-0.4	6.88e-12	Dementia with Lewy bodies;
CESC	cis	rs1448094	0.512	rs7303330	chr12:86255123	G/A	cg19622623	chr12:86230825	RASSF9	-0.48	-6.11	-0.35	3.64e-9	Major depressive disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09901100	chr7:134867116	NA	-0.58	-6.22	-0.36	1.98e-9	Gut microbiome composition (summer);
CESC	cis	rs314370	0.951	rs17884589	chr7:100493711	G/A	cg10426581	chr7:100472382	SRRT	0.84	8.18	0.45	1.23e-14	Resting heart rate;
CESC	cis	rs2952156	0.920	rs9303274	chr17:37836353	T/C	cg20243544	chr17:37824526	PNMT	0.64	8.63	0.47	5.62e-16	Asthma;
CESC	cis	rs6732160	0.613	rs58317144	chr2:73388153	C/T	cg01422370	chr2:73384389	NA	0.54	8.62	0.47	6.17e-16	Intelligence (multi-trait analysis);
CESC	cis	rs2425143	0.818	rs12481545	chr20:34407698	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.73	-6.16	-0.35	2.65e-9	Blood protein levels;
CESC	cis	rs7714584	1.000	rs1428552	chr5:150259831	T/C	cg22134413	chr5:150180641	NA	0.47	5.23	0.31	3.45e-7	Crohn's disease;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg04590956	chr2:70057467	GMCL1	0.52	6.91	0.39	3.57e-11	Systemic lupus erythematosus;
CESC	cis	rs60871478	0.588	rs6952577	chr7:872100	C/T	cg13798912	chr7:905769	UNC84A	0.6	6.08	0.35	4.24e-9	Cerebrospinal P-tau181p levels;
CESC	cis	rs9914544	1.000	rs9914544	chr17:18787828	A/C	cg26378065	chr17:18585709	ZNF286B	0.46	5.62	0.33	4.89e-8	Educational attainment (years of education);
CESC	cis	rs1799949	1.000	rs8176126	chr17:41259049	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	-0.65	-9.06	-0.49	2.99e-17	Menopause (age at onset);
CESC	trans	rs11971186	0.824	rs1204522	chr7:126507693	C/G	cg10894441	chr11:111169905	C11orf92;C11orf93	-0.52	-6.54	-0.37	3.09e-10	Chemerin levels;
CESC	cis	rs7084402	0.967	rs7078900	chr10:60273430	G/A	cg07615347	chr10:60278583	BICC1	-0.56	-8.58	-0.47	7.96e-16	Refractive error;
CESC	cis	rs6964587	0.869	rs7778667	chr7:91520816	C/G	cg17063962	chr7:91808500	NA	-0.53	-6.97	-0.39	2.58e-11	Breast cancer;
CESC	cis	rs9399135	0.967	rs1023179	chr6:135343829	T/A	cg24558204	chr6:135376177	HBS1L	0.52	7.29	0.41	3.48e-12	Red blood cell count;
CESC	cis	rs17253792	0.822	rs77761669	chr14:56034216	G/A	cg01858014	chr14:56050164	KTN1	-0.82	-6.56	-0.37	2.83e-10	Putamen volume;
CESC	cis	rs2836974	0.865	rs7282624	chr21:40667040	C/T	cg11890956	chr21:40555474	PSMG1	1.17	21.44	0.8	7.97e-60	Cognitive function;
CESC	cis	rs6088580	0.524	rs6088575	chr20:33273403	C/T	cg07148914	chr20:33460835	GGT7	0.42	5.34	0.31	1.96e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs698833	0.962	rs1067387	chr2:44642797	A/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	6.48	0.37	4.47e-10	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs10256972	0.527	rs28671326	chr7:1174973	G/A	cg18765753	chr7:1198926	ZFAND2A	-0.45	-6.61	-0.38	2.1e-10	Longevity;Endometriosis;
CESC	cis	rs2204008	0.583	rs12307593	chr12:38317803	A/G	cg26384229	chr12:38710491	ALG10B	0.4	5.33	0.31	2.06e-7	Bladder cancer;
CESC	cis	rs17666538	0.535	rs1669613	chr8:617565	G/C	cg23958373	chr8:599963	NA	0.83	6.1	0.35	3.7e-9	IgG glycosylation;
CESC	cis	rs847577	0.609	rs705308	chr7:97695363	C/A	cg24562669	chr7:97807699	LMTK2	-0.79	-13.68	-0.64	1.38e-32	Breast cancer;
CESC	cis	rs7178909	0.902	rs3853640	chr15:90443720	A/C	cg19708238	chr15:90437601	AP3S2	0.41	5.63	0.33	4.59e-8	Common traits (Other);
CESC	cis	rs4253772	0.591	rs6520010	chr22:46721223	G/A	cg24881330	chr22:46731750	TRMU	0.91	10.0	0.52	3.44e-20	LDL cholesterol;Cholesterol, total;
CESC	cis	rs11249608	0.789	rs903989	chr5:178434434	C/T	cg01312482	chr5:178451176	ZNF879	-0.43	-6.06	-0.35	4.74e-9	Pubertal anthropometrics;
CESC	trans	rs11088226	0.801	rs2833886	chr21:33923872	C/A	cg09050820	chr6:167586206	TCP10L2	0.64	6.93	0.39	3.21e-11	Gastritis;
CESC	cis	rs829661	0.532	rs9789517	chr2:30785824	C/G	cg12454169	chr2:30669597	LCLAT1	0.43	5.36	0.31	1.84e-7	Midgestational circulating levels of PBDEs (fetal genetic effect);
CESC	cis	rs9549367	0.713	rs510160	chr13:113822481	A/G	cg18105134	chr13:113819100	PROZ	0.57	7.36	0.41	2.26e-12	Platelet distribution width;
CESC	cis	rs1552244	0.882	rs9757159	chr3:10039166	C/T	cg08888203	chr3:10149979	C3orf24	0.48	6.1	0.35	3.84e-9	Alzheimer's disease;
CESC	cis	rs7552404	1.000	rs12123977	chr1:76209754	A/G	cg03433033	chr1:76189801	ACADM	-0.68	-7.3	-0.41	3.37e-12	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs761746	0.960	rs5753733	chr22:32027922	A/G	cg25791279	chr22:32026902	PISD	0.56	6.75	0.38	9.26e-11	Intelligence;
CESC	cis	rs514406	0.861	rs72637996	chr1:53249618	A/T	cg27535305	chr1:53392650	SCP2	0.31	5.51	0.32	8.71e-8	Monocyte count;
CESC	cis	rs1003719	0.523	rs1063949	chr21:38574675	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.59	-8.02	-0.44	3.34e-14	Eye color traits;
CESC	cis	rs7666738	0.830	rs13124127	chr4:98990729	G/A	cg03676636	chr4:99064102	C4orf37	0.33	5.13	0.3	5.51e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs796364	0.806	rs11684895	chr2:201009026	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.75	-6.83	-0.39	5.71e-11	Schizophrenia;
CESC	cis	rs9322193	0.886	rs17672976	chr6:150097343	T/A	cg13206674	chr6:150067644	NUP43	0.41	5.74	0.33	2.64e-8	Lung cancer;
CESC	cis	rs7223966	1.000	rs8075422	chr17:61804686	G/A	cg11494091	chr17:61959527	GH2	0.39	5.4	0.32	1.46e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg22333733	chr11:31391482	DNAJC24;DCDC1	-0.46	-6.77	-0.38	8.08e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs6502050	0.835	rs3935403	chr17:80114145	C/T	cg11859384	chr17:80120422	CCDC57	-0.38	-5.23	-0.31	3.53e-7	Life satisfaction;
CESC	cis	rs2070488	0.965	rs2284819	chr3:38557161	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.91	15.51	0.69	4.6e-39	Electrocardiographic conduction measures;
CESC	cis	rs1215050	0.740	rs1084777	chr4:99017542	C/T	cg05340658	chr4:99064831	C4orf37	-0.58	-7.81	-0.43	1.38e-13	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs965469	1.000	rs6037538	chr20:3282978	T/C	cg25506879	chr20:3388711	C20orf194	-0.54	-5.88	-0.34	1.21e-8	IFN-related cytopenia;
CESC	cis	rs1552244	1.000	rs3895942	chr3:10108745	G/C	cg00166722	chr3:10149974	C3orf24	0.54	6.89	0.39	4.08e-11	Alzheimer's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24402755	chr1:87380200	HS2ST1;SEP15	0.58	6.28	0.36	1.4e-9	Gut microbiome composition (summer);
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg09845883	chr1:154197610	UBAP2L	-0.47	-6.31	-0.36	1.17e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7666738	0.830	rs7657497	chr4:99044028	A/G	cg18180107	chr4:99064573	C4orf37	0.41	5.29	0.31	2.51e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7615952	0.599	rs60847438	chr3:125746005	T/C	cg04553112	chr3:125709451	NA	-0.51	-5.38	-0.31	1.65e-7	Blood pressure (smoking interaction);
CESC	cis	rs1538970	0.962	rs9429075	chr1:45818421	G/A	cg03146154	chr1:46216737	IPP	0.45	5.39	0.31	1.54e-7	Platelet count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03066657	chr11:9116583	FLJ46111	-0.51	-6.47	-0.37	4.76e-10	Gut microbiome composition (summer);
CESC	cis	rs1008375	0.966	rs10939735	chr4:17578891	A/G	cg16339924	chr4:17578868	LAP3	0.84	10.82	0.55	7.97e-23	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs208520	0.955	rs12216176	chr6:67005130	G/T	cg07460842	chr6:66804631	NA	0.77	8.82	0.48	1.57e-16	Exhaled nitric oxide output;
CESC	cis	rs2303745	0.589	rs891018	chr19:17396761	C/T	cg02221750	chr19:17393354	ANKLE1	0.53	6.29	0.36	1.3e-9	Systemic lupus erythematosus;
CESC	cis	rs3015497	0.587	rs1353204	chr14:51081515	C/T	cg09863266	chr14:51125203	SAV1	-0.32	-5.03	-0.3	9e-7	Mean platelet volume;
CESC	cis	rs1050631	0.564	rs681757	chr18:33744766	A/C	cg25426722	chr18:33708991	SLC39A6;ELP2	0.6	8.31	0.45	5.09e-15	Esophageal squamous cell cancer (length of survival);
CESC	cis	rs2637266	0.678	rs846606	chr10:78562819	A/T	cg18941641	chr10:78392320	NA	-0.39	-7.45	-0.42	1.29e-12	Pulmonary function;
CESC	cis	rs2832191	0.716	rs1984012	chr21:30392472	T/C	cg24692254	chr21:30365293	RNF160	1.02	18.45	0.75	1.95e-49	Dental caries;
CESC	cis	rs172166	0.694	rs1150666	chr6:28123928	T/C	cg23281280	chr6:28129359	ZNF389	0.44	6.4	0.37	7.19e-10	Cardiac Troponin-T levels;
CESC	cis	rs2280018	1.000	rs2280018	chr16:15150833	A/C	cg27102117	chr16:15229624	NA	0.49	7.7	0.43	2.78e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs17608059	0.566	rs17676459	chr17:13910515	A/G	cg11395062	chr17:14139857	CDRT15	0.45	5.59	0.32	5.61e-8	Temperament;
CESC	cis	rs709400	0.663	rs72708893	chr14:103929535	G/A	cg12935359	chr14:103987150	CKB	-0.57	-8.37	-0.46	3.41e-15	Body mass index;
CESC	cis	rs6782228	1.000	rs12495411	chr3:128395695	G/A	cg15607142	chr3:128420513	NA	-0.39	-5.21	-0.3	3.85e-7	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
CESC	cis	rs10504229	0.683	rs7816733	chr8:58129855	G/A	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs965469	0.947	rs965470	chr20:3381588	C/G	cg25506879	chr20:3388711	C20orf194	-0.57	-6.1	-0.35	3.75e-9	IFN-related cytopenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09333889	chr11:18211133	NA	-0.61	-7.79	-0.43	1.55e-13	Gut microbiome composition (summer);
CESC	cis	rs10504229	0.683	rs56058640	chr8:58128862	C/T	cg21724239	chr8:58056113	NA	0.58	5.95	0.34	8.29e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs7772486	0.790	rs7753696	chr6:146279098	G/T	cg23711669	chr6:146136114	FBXO30	-0.93	-13.48	-0.64	6.97e-32	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19001237	chr11:18548595	TSG101	-0.55	-6.18	-0.35	2.39e-9	Gut microbiome composition (summer);
CESC	cis	rs10242455	0.702	rs55927283	chr7:99057191	G/C	cg13560068	chr7:99070416	ZNF789	0.66	5.06	0.3	8.01e-7	Blood metabolite levels;
CESC	cis	rs11098499	0.820	rs11737395	chr4:120520704	C/G	cg24375607	chr4:120327624	NA	0.46	5.53	0.32	7.85e-8	Corneal astigmatism;
CESC	cis	rs8092503	1.000	rs6566871	chr18:52475904	T/C	cg12377874	chr18:52495404	RAB27B	-0.35	-5.99	-0.35	6.86e-9	Childhood body mass index;
CESC	cis	rs7246657	0.943	rs7255996	chr19:37971699	G/A	cg23950597	chr19:37808831	NA	-0.58	-6.44	-0.37	5.71e-10	Coronary artery calcification;
CESC	cis	rs10504229	0.639	rs67002486	chr8:58117218	A/G	cg24829409	chr8:58192753	C8orf71	-0.58	-7.2	-0.4	6.31e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs2040771	0.745	rs2283646	chr22:19273902	A/G	cg02655711	chr22:19163373	SLC25A1	-0.4	-5.87	-0.34	1.28e-8	Metabolite levels (small molecules and protein measures);
CESC	trans	rs561341	1.000	rs113115092	chr17:30284164	G/A	cg27661571	chr11:113659931	NA	-0.83	-7.69	-0.43	2.82e-13	Hip circumference adjusted for BMI;
CESC	cis	rs9815354	1.000	rs73077367	chr3:41851959	G/A	cg03022575	chr3:42003672	ULK4	0.48	5.45	0.32	1.16e-7	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs2040771	0.872	rs12485084	chr22:19162326	A/G	cg17887427	chr22:19166691	SLC25A1	-0.39	-5.07	-0.3	7.63e-7	Metabolite levels (small molecules and protein measures);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12626968	chr5:43603169	NNT	0.66	7.95	0.44	5.42e-14	Gut microbiome composition (summer);
CESC	cis	rs1799949	0.965	rs11654051	chr17:41419656	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.61	8.06	0.44	2.6e-14	Menopause (age at onset);
CESC	cis	rs858239	0.600	rs6978827	chr7:23125544	A/T	cg23682824	chr7:23144976	KLHL7	0.55	7.63	0.42	4.21e-13	Cerebrospinal fluid biomarker levels;
CESC	cis	rs2070488	1.000	rs2276540	chr3:38512507	G/A	cg24069376	chr3:38537580	EXOG	0.49	8.83	0.48	1.49e-16	Electrocardiographic conduction measures;
CESC	cis	rs9467711	0.606	rs28362606	chr6:26365586	T/C	cg14345882	chr6:26364793	BTN3A2	0.61	6.34	0.36	1e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs992157	1.000	rs2168704	chr2:219142492	G/A	cg00012203	chr2:219082015	ARPC2	0.82	11.06	0.56	1.27e-23	Colorectal cancer;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg04215179	chr7:23719682	C7orf46	-0.42	-6.0	-0.35	6.59e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs11785693	0.862	rs17350978	chr8:4983418	G/C	cg26367366	chr8:4980734	NA	0.92	8.51	0.46	1.29e-15	Neuroticism (multi-trait analysis);Neuroticism;
CESC	cis	rs6963495	0.818	rs56268110	chr7:105166712	T/C	cg13798780	chr7:105162888	PUS7	0.78	8.02	0.44	3.36e-14	Bipolar disorder (body mass index interaction);
CESC	cis	rs7927771	0.793	rs12803525	chr11:47413475	G/A	cg20307385	chr11:47447363	PSMC3	-0.6	-7.41	-0.41	1.68e-12	Subjective well-being;
CESC	cis	rs425277	0.628	rs262662	chr1:2085033	A/G	cg04315214	chr1:2043799	PRKCZ	-0.45	-7.13	-0.4	9.3e-12	Height;
CESC	cis	rs2070677	0.736	rs7099806	chr10:135414896	C/T	cg20169779	chr10:135381914	SYCE1	-0.8	-8.86	-0.48	1.23e-16	Gout;
CESC	cis	rs9929218	0.954	rs9923925	chr16:68819444	G/A	cg02972257	chr16:68554789	NA	0.46	5.55	0.32	7.01e-8	Colorectal cancer;
CESC	cis	rs4704187	0.687	rs4704176	chr5:74420596	G/C	cg03227963	chr5:74354835	NA	0.31	5.7	0.33	3.22e-8	Response to amphetamines;
CESC	cis	rs8077577	0.789	rs11078411	chr17:18088094	C/T	cg16794390	chr17:18148240	FLII	0.41	5.71	0.33	3.05e-8	Obesity-related traits;
CESC	cis	rs561341	1.000	rs561341	chr17:30316385	T/G	cg19193384	chr17:30244184	NA	-0.67	-6.36	-0.36	8.74e-10	Hip circumference adjusted for BMI;
CESC	cis	rs7811142	0.887	rs35111986	chr7:100000274	C/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.97	9.41	0.5	2.47e-18	Platelet count;
CESC	cis	rs11122272	0.735	rs2355873	chr1:231477442	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.43	-5.74	-0.33	2.62e-8	Hemoglobin concentration;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03385944	chr11:798041	NA	0.6	6.63	0.38	1.84e-10	Gut microbiome composition (summer);
CESC	cis	rs9322193	1.000	rs9322193	chr6:149919143	T/G	cg07701084	chr6:150067640	NUP43	0.4	5.47	0.32	1.02e-7	Lung cancer;
CESC	cis	rs9929218	1.000	rs12443730	chr16:68804342	T/C	cg02972257	chr16:68554789	NA	0.43	5.18	0.3	4.5e-7	Colorectal cancer;
CESC	cis	rs72945132	0.714	rs66542029	chr11:70196302	A/T	cg14191688	chr11:70257035	CTTN	0.41	5.05	0.3	8.16e-7	Coronary artery disease;
CESC	cis	rs1784581	0.894	rs1790000	chr6:162388707	A/G	cg17173639	chr6:162384350	PARK2	0.81	13.34	0.63	2.1e-31	Itch intensity from mosquito bite;
CESC	cis	rs72781680	0.752	rs56343114	chr2:23900629	C/G	cg08917208	chr2:24149416	ATAD2B	1.08	9.78	0.51	1.75e-19	Lymphocyte counts;
CESC	cis	rs9393777	0.513	rs7754159	chr6:26620312	G/A	cg12292205	chr6:26970375	C6orf41	-0.49	-5.44	-0.32	1.24e-7	Intelligence (multi-trait analysis);
CESC	cis	rs2836950	0.501	rs11088470	chr21:40689162	A/G	cg11644478	chr21:40555479	PSMG1	-0.55	-7.49	-0.42	1.03e-12	Menarche (age at onset);
CESC	cis	rs2273669	0.667	rs11153147	chr6:109304058	A/G	cg05315195	chr6:109294784	ARMC2	-0.67	-6.07	-0.35	4.34e-9	Prostate cancer;
CESC	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg05552183	chr6:42928497	GNMT	0.75	11.45	0.58	6.22e-25	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs75804782	0.521	rs56120037	chr2:239398464	G/A	cg18131467	chr2:239335373	ASB1	-0.68	-5.66	-0.33	3.85e-8	Morning vs. evening chronotype;Chronotype;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg02878701	chr21:47706221	MCM3AP;C21orf57	-0.45	-6.1	-0.35	3.78e-9	Fibrinogen levels;
CESC	trans	rs7937682	0.924	rs12791699	chr11:111505880	T/C	cg18187862	chr3:45730750	SACM1L	0.51	6.47	0.37	4.81e-10	Primary sclerosing cholangitis;
CESC	cis	rs75804782	0.521	rs72993044	chr2:239397949	C/T	cg18131467	chr2:239335373	ASB1	-0.68	-5.66	-0.33	3.85e-8	Morning vs. evening chronotype;Chronotype;
CESC	cis	rs11785693	0.862	rs11778367	chr8:4988398	T/C	cg26367366	chr8:4980734	NA	0.61	6.23	0.36	1.85e-9	Neuroticism (multi-trait analysis);Neuroticism;
CESC	cis	rs875971	1.000	rs6961155	chr7:65933295	T/C	cg10691866	chr7:65817282	TPST1	-0.34	-5.62	-0.33	4.93e-8	Aortic root size;
CESC	cis	rs7116495	1.000	rs116781589	chr11:71825006	G/T	cg10381502	chr11:71823885	C11orf51	0.69	5.61	0.33	5.03e-8	Severe influenza A (H1N1) infection;
CESC	trans	rs11088226	0.645	rs2409457	chr21:33929895	T/C	cg09050820	chr6:167586206	TCP10L2	0.87	8.52	0.46	1.23e-15	Gastritis;
CESC	trans	rs354225	0.512	rs6753004	chr2:54962723	C/A	cg08887902	chr7:77428575	PHTF2;TMEM60	-0.62	-6.22	-0.36	1.95e-9	Schizophrenia;
CESC	cis	rs7772486	0.558	rs702322	chr6:146007166	G/A	cg05347473	chr6:146136440	FBXO30	-0.71	-8.55	-0.46	1.02e-15	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7666738	0.791	rs60028147	chr4:99046618	G/A	cg03467027	chr4:99064603	C4orf37	0.47	5.96	0.34	8.08e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs875971	0.505	rs6955582	chr7:65431686	A/G	cg06456125	chr7:65229604	NA	0.45	5.87	0.34	1.28e-8	Aortic root size;
CESC	cis	rs7714584	1.000	rs6862814	chr5:150245259	G/A	cg22134413	chr5:150180641	NA	0.5	5.76	0.33	2.3e-8	Crohn's disease;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	ch.12.1204902R	chr12:57570411	LRP1	-0.45	-6.14	-0.35	2.94e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs875971	0.862	rs778697	chr7:65870426	G/A	cg11764359	chr7:65958608	NA	0.78	11.31	0.57	1.86e-24	Aortic root size;
CESC	cis	rs2839186	0.872	rs2250213	chr21:47674275	G/A	cg10351095	chr21:47802916	PCNT	-0.49	-6.63	-0.38	1.85e-10	Testicular germ cell tumor;
CESC	trans	rs1973993	0.691	rs4000303	chr1:96913765	A/G	cg10631902	chr5:14652156	NA	0.62	9.75	0.51	2.1e-19	Weight;
CESC	cis	rs2073300	1.000	rs6137966	chr20:23444359	A/T	cg12062639	chr20:23401060	NAPB	0.91	6.41	0.37	6.71e-10	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs6812193	0.518	rs6810903	chr4:77198363	C/T	cg20311846	chr4:77356250	SHROOM3	0.32	5.14	0.3	5.45e-7	Parkinson's disease;
CESC	cis	rs116095464	0.558	rs6555056	chr5:226222	T/C	cg10591111	chr5:226296	SDHA	-0.53	-6.61	-0.38	2.15e-10	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24099023	chr17:56770189	TEX14;RAD51C	0.62	6.91	0.39	3.53e-11	Gut microbiome composition (summer);
CESC	cis	rs1348850	0.958	rs10497501	chr2:178462299	C/G	cg23306229	chr2:178417860	TTC30B	0.57	7.52	0.42	8.3e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs2295359	0.892	rs17375018	chr1:67655147	A/G	cg17031739	chr1:67600172	NA	-0.39	-5.29	-0.31	2.55e-7	Psoriasis;
CESC	cis	rs3026101	0.624	rs17635627	chr17:5296059	C/T	cg24500398	chr17:5266808	RABEP1	-0.42	-5.96	-0.34	8.18e-9	Body mass index;
CESC	cis	rs2066819	1.000	rs57137641	chr12:56741228	G/A	cg26714650	chr12:56694279	CS	-1.39	-9.17	-0.49	1.33e-17	Psoriasis vulgaris;
CESC	cis	rs748404	0.697	rs524547	chr15:43551023	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	7.96	0.44	5.16e-14	Lung cancer;
CESC	cis	rs597583	0.715	rs2276340	chr11:117391966	G/A	cg27161313	chr11:117392002	DSCAML1	-0.53	-6.25	-0.36	1.6e-9	Putamen volume;
CESC	cis	rs10504229	0.906	rs17805439	chr8:58172400	T/C	cg22535103	chr8:58192502	C8orf71	-1.05	-13.27	-0.63	3.63e-31	Developmental language disorder (linguistic errors);
CESC	cis	rs9715521	0.835	rs9714848	chr4:59824650	C/T	cg11281224	chr4:60001000	NA	-0.51	-6.67	-0.38	1.45e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs300703	0.654	rs401364	chr2:119493	G/A	cg21211680	chr2:198530	NA	-1.03	-10.03	-0.52	2.8e-20	Blood protein levels;
CESC	cis	rs919433	1.000	rs2889363	chr2:198163699	A/G	cg03934865	chr2:198174659	NA	-0.45	-6.68	-0.38	1.37e-10	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs3733585	0.699	rs6856127	chr4:9965443	T/C	cg11266682	chr4:10021025	SLC2A9	-0.6	-11.2	-0.57	4.34e-24	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs10089	1.000	rs17164310	chr5:127493679	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.73	9.36	0.5	3.49e-18	Ileal carcinoids;
CESC	cis	rs3733585	0.673	rs7672947	chr4:9961368	G/C	cg00071950	chr4:10020882	SLC2A9	-0.73	-11.79	-0.59	4.58e-26	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs4423214	1.000	rs4423214	chr11:71173254	C/T	cg05163923	chr11:71159392	DHCR7	0.83	11.29	0.57	2.17e-24	Vitamin D levels;
CESC	cis	rs7116495	0.867	rs612255	chr11:71778664	A/G	cg07596299	chr11:71824057	C11orf51	-0.89	-5.56	-0.32	6.63e-8	Severe influenza A (H1N1) infection;
CESC	cis	rs9660180	0.967	rs6603802	chr1:1812521	C/T	cg20999797	chr1:1681921	NA	0.27	5.38	0.31	1.63e-7	Body mass index;
CESC	cis	rs9300255	0.566	rs10744150	chr12:123721614	A/C	cg00376283	chr12:123451042	ABCB9	0.67	8.91	0.48	8.16e-17	Neutrophil percentage of white cells;
CESC	cis	rs2243480	1.000	rs35046236	chr7:65408613	T/C	cg12463550	chr7:65579703	CRCP	0.7	5.58	0.32	5.87e-8	Diabetic kidney disease;
CESC	cis	rs9287719	0.967	rs6432114	chr2:10744930	C/T	cg02196655	chr2:10830764	NOL10	-0.38	-5.83	-0.34	1.6e-8	Prostate cancer;
CESC	trans	rs9929218	1.000	rs8044058	chr16:68807088	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.63	-8.36	-0.46	3.68e-15	Colorectal cancer;
CESC	cis	rs2637266	0.935	rs2583053	chr10:78402416	A/G	cg18941641	chr10:78392320	NA	0.45	8.65	0.47	4.9e-16	Pulmonary function;
CESC	cis	rs3760982	0.585	rs4803659	chr19:44290235	C/T	cg11993925	chr19:44307056	LYPD5	0.32	5.42	0.32	1.37e-7	Breast cancer (estrogen-receptor negative);Breast cancer;
CESC	cis	rs1267303	0.675	rs7519040	chr1:46986641	A/G	cg25110126	chr1:46999211	NA	0.72	8.95	0.48	6.36e-17	Monobrow;
CESC	cis	rs67311347	0.568	rs9864544	chr3:40336204	T/C	cg09455208	chr3:40491958	NA	0.37	6.51	0.37	3.82e-10	Renal cell carcinoma;
CESC	cis	rs709400	0.691	rs12888077	chr14:103872553	G/T	cg12935359	chr14:103987150	CKB	0.5	7.5	0.42	9.63e-13	Body mass index;
CESC	cis	rs1799949	0.965	rs33988650	chr17:41287880	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.67	9.36	0.5	3.44e-18	Menopause (age at onset);
CESC	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.47	-5.64	-0.33	4.35e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7833986	0.501	rs72653959	chr8:56996516	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.62	7.54	0.42	7.58e-13	Height;
CESC	cis	rs8060686	0.858	rs7196789	chr16:67927124	C/T	cg26727032	chr16:67993705	SLC12A4	-0.67	-10.03	-0.52	2.87e-20	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs7762018	0.891	rs12529402	chr6:170147675	A/T	cg05834625	chr6:170176447	C6orf70	0.65	7.17	0.4	7.57e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs6831352	0.918	rs29001199	chr4:100053891	A/G	cg13256891	chr4:100009986	ADH5	-0.77	-8.34	-0.46	4.19e-15	Alcohol dependence;
CESC	cis	rs7412746	0.634	rs2124952	chr1:150923774	T/A	cg04414720	chr1:150670196	GOLPH3L	0.52	6.88	0.39	4.32e-11	Melanoma;
CESC	trans	rs801193	0.761	rs2659888	chr7:66230171	T/G	cg26939375	chr7:64535504	NA	0.66	9.12	0.49	1.98e-17	Aortic root size;
CESC	cis	rs7512552	0.839	rs1694385	chr1:150377960	G/A	cg15654264	chr1:150340011	RPRD2	0.4	5.29	0.31	2.52e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs12042938	0.902	rs1094658	chr1:231773397	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.45	6.18	0.35	2.39e-9	Neuranatomic and neurocognitive phenotypes;
CESC	cis	rs9443645	0.869	rs9361467	chr6:79621098	A/G	cg05283184	chr6:79620031	NA	-0.43	-6.5	-0.37	3.95e-10	Intelligence (multi-trait analysis);
CESC	cis	rs7605827	0.930	rs2380653	chr2:15635011	C/A	cg19274914	chr2:15703543	NA	0.37	6.64	0.38	1.76e-10	Educational attainment (years of education);
CESC	cis	rs13064411	0.696	rs7610638	chr3:113139656	A/G	cg18753928	chr3:113234510	CCDC52	-0.5	-5.66	-0.33	3.9e-8	Response to simvastatin treatment (PCSK9 protein level change);
CESC	cis	rs10883723	0.775	rs7917158	chr10:104246471	C/A	ch.10.2196322F	chr10:104248062	ACTR1A	0.42	5.18	0.3	4.35e-7	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs2228479	0.850	rs17233567	chr16:89813821	G/A	cg00800038	chr16:89945340	TCF25	-0.9	-7.51	-0.42	9.11e-13	Skin colour saturation;
CESC	cis	rs708547	0.830	rs1713994	chr4:57868367	G/A	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.55	-6.28	-0.36	1.39e-9	Response to bleomycin (chromatid breaks);
CESC	cis	rs11608355	0.538	rs7305165	chr12:109804222	G/A	cg19025524	chr12:109796872	NA	-0.52	-7.59	-0.42	5.31e-13	Neuroticism;
CESC	cis	rs4803468	1.000	rs2288871	chr19:41917868	C/T	cg09537434	chr19:41945824	ATP5SL	-1.03	-18.3	-0.75	6.46e-49	Height;
CESC	cis	rs9649465	1.000	rs1506635	chr7:123317184	C/T	cg04330084	chr7:123175371	IQUB	-0.38	-5.22	-0.31	3.69e-7	Migraine;
CESC	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg11494091	chr17:61959527	GH2	0.73	12.49	0.61	1.88e-28	Prudent dietary pattern;
CESC	cis	rs4795419	1	rs4795419	chr17:38166003	G/A	cg17467752	chr17:38218738	THRA	0.68	10.18	0.53	9.27e-21	Monocyte percentage of white cells;
CESC	cis	rs801193	0.613	rs2659900	chr7:66184443	G/C	cg18876405	chr7:65276391	NA	0.46	6.19	0.36	2.27e-9	Aortic root size;
CESC	cis	rs73206853	0.563	rs73194026	chr12:111140219	G/T	cg12870014	chr12:110450643	ANKRD13A	0.72	6.19	0.36	2.27e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs62344088	1.000	rs56315075	chr5:103904	G/A	cg22857025	chr5:266934	NA	-1.08	-6.64	-0.38	1.77e-10	Asthma (childhood onset);
CESC	cis	rs425277	0.958	rs262652	chr1:2090816	T/C	cg24578937	chr1:2090814	PRKCZ	0.55	9.48	0.5	1.47e-18	Height;
CESC	cis	rs113835537	0.559	rs11227498	chr11:66269714	A/G	cg24851651	chr11:66362959	CCS	0.43	5.29	0.31	2.62e-7	Airway imaging phenotypes;
CESC	cis	rs1475911	1.000	rs2839467	chr21:43513200	A/G	cg03240473	chr21:43526662	UMODL1;C21orf128	0.43	5.53	0.32	7.62e-8	IgG glycosylation;
CESC	cis	rs1799949	1.000	rs12952790	chr17:41299607	A/G	cg25072359	chr17:41440525	NA	0.43	5.83	0.34	1.61e-8	Menopause (age at onset);
CESC	cis	rs6582630	0.502	rs11520279	chr12:38360871	A/G	cg13010199	chr12:38710504	ALG10B	0.45	5.77	0.33	2.24e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs1552244	0.572	rs6785976	chr3:10168647	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.8	9.18	0.49	1.27e-17	Alzheimer's disease;
CESC	cis	rs796364	0.906	rs6740981	chr2:201060216	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.6	6.04	0.35	5.22e-9	Schizophrenia;
CESC	cis	rs8017423	1.000	rs8011810	chr14:90685669	A/G	cg14092571	chr14:90743983	NA	-0.58	-8.74	-0.47	2.81e-16	Mortality in heart failure;
CESC	cis	rs847577	0.630	rs2132276	chr7:97826340	G/A	cg21770322	chr7:97807741	LMTK2	0.86	14.66	0.67	4.82e-36	Breast cancer;
CESC	cis	rs34779708	0.966	rs1148245	chr10:35511894	C/T	cg03585969	chr10:35415529	CREM	0.73	9.06	0.49	2.99e-17	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs9322193	0.962	rs9478848	chr6:150146216	G/T	cg07701084	chr6:150067640	NUP43	0.42	5.82	0.34	1.66e-8	Lung cancer;
CESC	cis	rs926392	0.547	rs6129161	chr20:37678327	T/G	cg16355469	chr20:37678765	NA	0.6	7.2	0.4	6.11e-12	Dialysis-related mortality;
CESC	cis	rs977987	0.866	rs17696831	chr16:75493298	C/G	cg03315344	chr16:75512273	CHST6	0.54	7.9	0.44	7.59e-14	Dupuytren's disease;
CESC	cis	rs9549260	0.755	rs9549255	chr13:41235213	C/T	cg21288729	chr13:41239152	FOXO1	0.66	8.58	0.47	8.21e-16	Red blood cell count;
CESC	cis	rs7524258	0.868	rs4908451	chr1:7299618	C/G	cg07173049	chr1:7289937	CAMTA1	-0.44	-6.65	-0.38	1.7e-10	Tourette's syndrome or obsessive-compulsive disorder;
CESC	cis	rs7412746	0.658	rs72704652	chr1:150819470	A/G	cg22823121	chr1:150693482	HORMAD1	0.44	6.19	0.36	2.28e-9	Melanoma;
CESC	cis	rs2836974	0.931	rs2735306	chr21:40713134	A/G	cg11890956	chr21:40555474	PSMG1	-1.04	-16.43	-0.71	2.7e-42	Cognitive function;
CESC	cis	rs1348850	0.567	rs7605609	chr2:178534942	C/G	cg23306229	chr2:178417860	TTC30B	0.54	6.46	0.37	4.91e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs7312933	0.898	rs10880221	chr12:42384589	C/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.38	5.03	0.3	8.96e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs2303759	0.918	rs9749416	chr19:49885005	G/A	cg24324837	chr19:49891574	CCDC155	0.45	5.28	0.31	2.74e-7	Multiple sclerosis;
CESC	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.45	6.0	0.35	6.37e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs17826219	0.500	rs2449749	chr17:29078298	C/T	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.17e-10	Body mass index;
CESC	cis	rs9640161	0.711	rs3735170	chr7:150034184	T/C	cg17279839	chr7:150038598	RARRES2	0.45	5.44	0.32	1.2e-7	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs12540874	0.542	rs3807562	chr7:50566671	G/A	cg18232548	chr7:50535776	DDC	-0.35	-5.1	-0.3	6.58e-7	Systemic sclerosis;
CESC	cis	rs3820068	0.580	rs12747696	chr1:16002978	A/G	cg18133145	chr1:16060689	PLEKHM2	-0.41	-5.03	-0.3	8.85e-7	Systolic blood pressure;
CESC	cis	rs9300255	0.602	rs2851438	chr12:123643689	T/C	cg00376283	chr12:123451042	ABCB9	0.7	8.86	0.48	1.16e-16	Neutrophil percentage of white cells;
CESC	cis	rs11122272	0.637	rs2808593	chr1:231524228	G/T	cg06096015	chr1:231504339	EGLN1	0.43	6.18	0.35	2.46e-9	Hemoglobin concentration;
CESC	trans	rs681383	1.000	rs681383	chr18:8323984	A/T	cg27042584	chr16:51168485	NA	-0.52	-6.35	-0.36	9.28e-10	Sitting height ratio;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06717492	chr7:65447339	GUSB	0.55	6.53	0.37	3.32e-10	Gut microbiome composition (summer);
CESC	trans	rs7088969	0.670	rs7094126	chr10:119551326	G/A	cg11827998	chr14:105995685	TMEM121	-0.42	-6.18	-0.35	2.46e-9	Homeostasis model assessment of beta-cell function (dietary factor interaction);
CESC	cis	rs9309473	0.519	rs13027816	chr2:73897691	C/T	cg20560298	chr2:73613845	ALMS1	0.53	7.32	0.41	3.04e-12	Metabolite levels;
CESC	cis	rs3747547	0.642	rs7018920	chr9:38088018	C/T	cg13774184	chr9:37916125	SHB	-0.61	-5.27	-0.31	2.8e-7	Metabolite levels (Dihydroxy docosatrienoic acid);
CESC	cis	rs2243480	0.901	rs35087093	chr7:65405208	C/T	cg13147721	chr7:65941812	NA	-0.85	-8.1	-0.45	2e-14	Diabetic kidney disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05666571	chr18:34409053	C18orf10;KIAA1328	0.65	7.64	0.42	3.98e-13	Gut microbiome composition (summer);
CESC	cis	rs9354352	0.967	rs6455062	chr6:66694131	T/A	cg07460842	chr6:66804631	NA	0.66	9.82	0.52	1.33e-19	Initial pursuit acceleration in psychotic disorders;
CESC	cis	rs34375054	0.525	rs7133864	chr12:125606180	C/T	cg25124228	chr12:125621409	AACS	-0.57	-7.24	-0.41	4.91e-12	Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs66561647	0.661	rs35851359	chr8:128935626	G/C	cg05480350	chr8:128972681	MIR1205;PVT1	0.38	5.14	0.3	5.39e-7	Hemoglobin concentration;
CESC	cis	rs2425143	0.512	rs2425126	chr20:34331730	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.63	6.84	0.39	5.48e-11	Blood protein levels;
CESC	cis	rs9611565	0.512	rs6519289	chr22:42170432	A/C	cg06634786	chr22:41940651	POLR3H	0.69	6.84	0.39	5.55e-11	Vitiligo;
CESC	cis	rs7917772	0.582	rs10786685	chr10:104323103	C/T	ch.10.2196322F	chr10:104248062	ACTR1A	0.44	5.46	0.32	1.1e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg02847575	chr16:30382517	TBC1D10B	-0.45	-6.19	-0.36	2.28e-9	Gambling;
CESC	cis	rs2839186	0.739	rs2280958	chr21:47642016	C/T	cg11766577	chr21:47581405	C21orf56	-0.46	-6.36	-0.36	8.73e-10	Testicular germ cell tumor;
CESC	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg24829409	chr8:58192753	C8orf71	-0.65	-7.36	-0.41	2.29e-12	Developmental language disorder (linguistic errors);
CESC	trans	rs6543990	0.766	rs1510734	chr2:36189067	C/A	cg04092111	chr11:58728533	NA	0.39	6.05	0.35	4.95e-9	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16872795	chr11:111957488	SDHD;TIMM8B	0.55	6.39	0.37	7.26e-10	Gut microbiome composition (summer);
CESC	cis	rs854765	0.964	rs854810	chr17:18006421	G/C	cg16928487	chr17:17741425	SREBF1	0.57	9.57	0.51	7.75e-19	Total body bone mineral density;
CESC	trans	rs35110281	0.774	rs2838327	chr21:45018566	A/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.47	6.31	0.36	1.15e-9	Mean corpuscular volume;
CESC	cis	rs873946	0.586	rs12776770	chr10:134564831	T/C	cg26818010	chr10:134567672	INPP5A	-0.9	-11.14	-0.56	6.82e-24	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs10504229	0.679	rs11781858	chr8:58038406	C/T	cg22535103	chr8:58192502	C8orf71	-0.93	-9.17	-0.49	1.35e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs514406	0.830	rs533935	chr1:53308807	T/C	cg08859206	chr1:53392774	SCP2	-0.62	-8.48	-0.46	1.63e-15	Monocyte count;
CESC	cis	rs1799949	0.929	rs12937015	chr17:41307473	A/C	cg05368731	chr17:41323189	NBR1	0.79	11.16	0.57	5.74e-24	Menopause (age at onset);
CESC	cis	rs113835537	0.529	rs80100524	chr11:66245936	C/T	cg22134325	chr11:66188745	NPAS4	0.35	5.47	0.32	1.05e-7	Airway imaging phenotypes;
CESC	cis	rs7193541	0.646	rs4888267	chr16:74687906	A/G	cg05580060	chr16:74700937	RFWD3	-0.49	-6.3	-0.36	1.27e-9	Multiple myeloma;
CESC	cis	rs12500482	0.935	rs12644638	chr4:2413461	C/T	cg08330972	chr4:2403930	ZFYVE28	-0.37	-5.75	-0.33	2.46e-8	Cognitive function;
CESC	cis	rs9611565	0.921	rs5751081	chr22:41742788	A/T	cg06481639	chr22:41940642	POLR3H	-0.45	-5.21	-0.3	3.74e-7	Vitiligo;
CESC	trans	rs1814175	0.817	rs4881648	chr11:49812901	A/G	cg03929089	chr4:120376271	NA	-0.91	-15.23	-0.68	4.84e-38	Height;
CESC	cis	rs12530845	1.000	rs12530845	chr7:135329978	T/C	cg23117316	chr7:135346802	PL-5283	-0.41	-5.29	-0.31	2.52e-7	Red blood cell traits;
CESC	cis	rs16854884	0.586	rs6795008	chr3:143738421	A/G	cg06585982	chr3:143692056	C3orf58	0.51	6.92	0.39	3.46e-11	Economic and political preferences (feminism/equality);
CESC	cis	rs4722166	0.630	rs13311155	chr7:22789789	A/C	cg13104385	chr7:22767384	IL6	0.49	6.56	0.37	2.81e-10	Lung cancer;
CESC	cis	rs7546094	1.000	rs6691932	chr1:113144263	T/C	cg22162597	chr1:113214053	CAPZA1	0.39	5.95	0.34	8.37e-9	Platelet distribution width;
CESC	cis	rs801193	0.548	rs7805152	chr7:66209253	C/T	cg18876405	chr7:65276391	NA	0.44	6.06	0.35	4.76e-9	Aortic root size;
CESC	trans	rs656319	0.638	rs670044	chr8:9892529	G/T	cg06636001	chr8:8085503	FLJ10661	0.5	6.58	0.37	2.47e-10	Myopia (pathological);
CESC	cis	rs2276314	0.857	rs28379448	chr18:33604364	C/A	cg05985134	chr18:33552581	C18orf21	0.61	7.07	0.4	1.39e-11	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs6921919	0.583	rs7764722	chr6:28354533	C/T	cg21251018	chr6:28226885	NKAPL	0.35	6.06	0.35	4.75e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs4648845	0.579	rs4592207	chr1:2369498	A/G	cg02275930	chr1:2372054	NA	-0.36	-5.79	-0.34	1.98e-8	Schizophrenia;
CESC	cis	rs3859192	0.539	rs2302774	chr17:38183090	G/T	cg17344932	chr17:38183730	MED24;SNORD124	0.63	9.39	0.5	2.83e-18	White blood cell count;
CESC	cis	rs1808579	0.935	rs58609749	chr18:21108613	T/C	cg14672496	chr18:21087552	C18orf8	0.4	6.09	0.35	4e-9	Hip circumference;Body mass index;BMI (adjusted for smoking behaviour);
CESC	cis	rs4713118	0.621	rs4713134	chr6:28034121	T/C	cg26335602	chr6:28129616	ZNF389	0.48	6.14	0.35	3.05e-9	Parkinson's disease;
CESC	cis	rs769267	0.965	rs2315281	chr19:19480099	G/A	cg03709012	chr19:19516395	GATAD2A	-0.99	-15.52	-0.69	4.48e-39	Tonsillectomy;
CESC	cis	rs959260	0.528	rs9909443	chr17:73308346	C/T	cg14668889	chr17:73230827	NUP85	0.57	6.7	0.38	1.22e-10	Systemic lupus erythematosus;
CESC	cis	rs9287719	0.967	rs6706542	chr2:10742491	A/C	cg02196655	chr2:10830764	NOL10	-0.38	-5.83	-0.34	1.61e-8	Prostate cancer;
CESC	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg24829409	chr8:58192753	C8orf71	-0.67	-7.99	-0.44	4.08e-14	Developmental language disorder (linguistic errors);
CESC	cis	rs2836974	0.533	rs4817999	chr21:40554355	C/A	cg11644478	chr21:40555479	PSMG1	-0.84	-12.87	-0.62	9.03e-30	Cognitive function;
CESC	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	13.3	0.63	2.94e-31	Prudent dietary pattern;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg24306779	chr16:58060336	MMP15	0.47	6.07	0.35	4.38e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs4253772	0.530	rs9615980	chr22:46791143	A/T	cg18190219	chr22:46762943	CELSR1	-0.66	-6.08	-0.35	4.18e-9	LDL cholesterol;Cholesterol, total;
CESC	cis	rs7582720	1.000	rs72936881	chr2:203794262	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.38	0.41	1.99e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs34779708	0.897	rs7897827	chr10:35386237	C/T	cg03585969	chr10:35415529	CREM	0.78	10.4	0.54	1.78e-21	Inflammatory bowel disease;Crohn's disease;
CESC	trans	rs561341	0.654	rs6505265	chr17:30172580	C/T	cg20587970	chr11:113659929	NA	0.92	9.74	0.51	2.4e-19	Hip circumference adjusted for BMI;
CESC	cis	rs6736093	0.966	rs1122970	chr2:112716697	A/C	cg12686935	chr2:112915763	FBLN7	-0.41	-5.31	-0.31	2.29e-7	Coronary artery disease;
CESC	cis	rs3540	0.597	rs7498113	chr15:91051192	C/G	cg10434728	chr15:90938212	IQGAP1	-0.41	-7.26	-0.41	4.23e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs4819052	0.819	rs7279136	chr21:46692287	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.75	10.07	0.53	2.09e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs644799	0.544	rs555556	chr11:95618425	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.55	7.12	0.4	1.02e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14264489	chr6:43018788	CUL7	-0.61	-6.5	-0.37	3.99e-10	Gut microbiome composition (summer);
CESC	cis	rs1506636	0.962	rs17623873	chr7:123417100	C/A	cg03229431	chr7:123269106	ASB15	0.5	6.39	0.37	7.27e-10	Plateletcrit;Platelet count;
CESC	cis	rs2204008	0.774	rs7959048	chr12:37948276	T/A	cg13010199	chr12:38710504	ALG10B	0.5	6.42	0.37	6.42e-10	Bladder cancer;
CESC	cis	rs11148252	0.574	rs3742297	chr13:53278067	T/C	cg00495681	chr13:53174319	NA	0.62	8.56	0.47	9.42e-16	Lewy body disease;
CESC	cis	rs35110281	0.782	rs1454651	chr21:45012476	A/G	cg21573476	chr21:45109991	RRP1B	-0.49	-6.96	-0.39	2.7e-11	Mean corpuscular volume;
CESC	cis	rs78456975	0.527	rs7590743	chr2:1575048	A/G	cg26248373	chr2:1572462	NA	-0.59	-6.93	-0.39	3.22e-11	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs4974559	0.739	rs10032327	chr4:1323537	C/T	cg02980000	chr4:1222292	CTBP1	0.82	7.38	0.41	2.05e-12	Systolic blood pressure;
CESC	cis	rs7666738	0.830	rs13138059	chr4:99050430	A/G	cg05340658	chr4:99064831	C4orf37	0.82	12.75	0.62	2.34e-29	Colonoscopy-negative controls vs population controls;
CESC	cis	rs965513	1.000	rs4743131	chr9:100554907	C/G	cg13688889	chr9:100608707	NA	-0.58	-8.26	-0.45	6.88e-15	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
CESC	cis	rs4268898	0.552	rs7560342	chr2:24371691	T/C	cg06627628	chr2:24431161	ITSN2	0.6	8.31	0.45	5.17e-15	Asthma;
CESC	cis	rs9443645	0.869	rs9443621	chr6:79576499	A/G	cg05283184	chr6:79620031	NA	-0.43	-6.56	-0.37	2.88e-10	Intelligence (multi-trait analysis);
CESC	cis	rs7662987	0.517	rs2602845	chr4:100023944	T/C	cg12011299	chr4:100065546	ADH4	0.6	6.6	0.38	2.23e-10	Smoking initiation;
CESC	cis	rs4727027	0.866	rs1358062	chr7:148783743	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.42	5.25	0.31	3.18e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs3820928	1.000	rs11686072	chr2:227777493	A/T	cg11843606	chr2:227700838	RHBDD1	-0.43	-5.81	-0.34	1.74e-8	Pulmonary function;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06697471	chr10:133606998	NA	-0.4	-6.53	-0.37	3.26e-10	Gut microbiome composition (summer);
CESC	cis	rs12142240	0.698	rs67142569	chr1:46828460	C/T	cg10495392	chr1:46806563	NSUN4	0.58	6.32	0.36	1.12e-9	Menopause (age at onset);
CESC	cis	rs708547	0.914	rs2412760	chr4:57735192	A/T	cg25525207	chr4:57843836	C4orf14;POLR2B	0.53	5.33	0.31	2.11e-7	Response to bleomycin (chromatid breaks);
CESC	cis	rs9487051	0.646	rs7773490	chr6:109623048	T/C	cg01475377	chr6:109611718	NA	-0.4	-5.48	-0.32	9.91e-8	Reticulocyte fraction of red cells;
CESC	cis	rs7909074	1.000	rs10751360	chr10:45396971	G/A	cg05187965	chr10:45406764	TMEM72	-0.33	-5.1	-0.3	6.34e-7	Mean corpuscular volume;
CESC	cis	rs9457247	0.765	rs12212247	chr6:167413539	T/C	cg07741184	chr6:167504864	NA	0.34	6.23	0.36	1.78e-9	Crohn's disease;
CESC	cis	rs7223966	0.961	rs35844156	chr17:61837568	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.45	-5.08	-0.3	6.98e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs7666738	0.830	rs1813251	chr4:98921170	A/G	cg05340658	chr4:99064831	C4orf37	0.78	11.59	0.58	2.05e-25	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3741404	0.791	rs7102177	chr11:63909228	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.9	13.31	0.63	2.68e-31	Platelet count;
CESC	cis	rs6460942	0.597	rs6944517	chr7:12515283	C/T	cg20607287	chr7:12443886	VWDE	-0.63	-7.11	-0.4	1.1e-11	Coronary artery disease;
CESC	cis	rs7917772	0.560	rs3862030	chr10:104327584	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.41	5.61	0.33	5.05e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs9790314	1.000	rs2218803	chr3:161047973	T/G	cg03342759	chr3:160939853	NMD3	-0.45	-5.81	-0.34	1.77e-8	Morning vs. evening chronotype;
CESC	cis	rs7666738	0.830	rs35939134	chr4:98980311	A/G	cg18180107	chr4:99064573	C4orf37	0.39	5.07	0.3	7.39e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg07146723	chr14:21559356	ZNF219	0.49	6.55	0.37	3.05e-10	Fibrinogen levels;
CESC	cis	rs9487051	0.604	rs9320282	chr6:109619377	A/G	cg21918786	chr6:109611834	NA	-0.38	-5.46	-0.32	1.11e-7	Reticulocyte fraction of red cells;
CESC	cis	rs736408	0.505	rs2083180	chr3:52668119	G/T	cg18337363	chr3:52569053	NT5DC2	0.28	5.09	0.3	6.67e-7	Bipolar disorder;
CESC	cis	rs7618915	0.547	rs11130323	chr3:52770277	T/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.49	0.37	4.1e-10	Bipolar disorder;
CESC	cis	rs12464483	0.591	rs72800120	chr2:30897122	G/A	cg12454169	chr2:30669597	LCLAT1	0.6	6.16	0.35	2.71e-9	Pre-treatment pain in head and neck squamous cell carcinoma;
CESC	cis	rs763014	0.966	rs4984904	chr16:680809	C/G	cg00908189	chr16:619842	PIGQ	0.64	8.99	0.48	4.97e-17	Height;
CESC	cis	rs7208859	0.673	rs216435	chr17:28922737	G/T	cg19761014	chr17:28927070	LRRC37B2	0.8	7.35	0.41	2.52e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs8008758	0.963	rs10132271	chr14:101688874	C/T	cg26224664	chr14:101693935	NA	-0.36	-5.62	-0.33	4.96e-8	Body mass index (alcohol intake interaction);
CESC	cis	rs344364	0.511	rs1657132	chr16:1949924	C/T	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.55	-6.2	-0.36	2.15e-9	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs12586317	0.620	rs12437439	chr14:35585669	C/A	cg16230307	chr14:35515116	FAM177A1	0.96	10.33	0.54	2.95e-21	Psoriasis;
CESC	cis	rs7651039	0.619	rs7640807	chr3:15685137	A/G	cg16303742	chr3:15540471	COLQ	0.47	7.48	0.42	1.08e-12	Coronary heart disease;
CESC	cis	rs4713118	0.515	rs9368549	chr6:28050047	T/A	cg26335602	chr6:28129616	ZNF389	0.53	7.05	0.4	1.55e-11	Parkinson's disease;
CESC	cis	rs1218582	0.772	rs1976559	chr1:154879788	A/T	cg06221963	chr1:154839813	KCNN3	-0.66	-11.32	-0.57	1.71e-24	Prostate cancer;
CESC	cis	rs1552244	0.882	rs3732966	chr3:10015740	C/T	cg00166722	chr3:10149974	C3orf24	0.49	5.98	0.34	7.37e-9	Alzheimer's disease;
CESC	cis	rs708547	0.647	rs1718831	chr4:57886946	T/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.48	6.68	0.38	1.38e-10	Response to bleomycin (chromatid breaks);
CESC	cis	rs826838	0.967	rs11168985	chr12:39045983	A/C	cg13010199	chr12:38710504	ALG10B	-0.56	-7.64	-0.42	3.99e-13	Heart rate;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15197342	chr1:110950013	HBXIP	0.59	6.78	0.38	7.7e-11	Gut microbiome composition (summer);
CESC	cis	rs2735413	0.918	rs7197254	chr16:78063353	C/G	cg04733911	chr16:78082701	NA	-0.48	-7.56	-0.42	6.42e-13	Systolic blood pressure (alcohol consumption interaction);
CESC	cis	rs798554	0.757	rs2533879	chr7:2859847	G/A	cg18446336	chr7:2847575	GNA12	-0.37	-5.5	-0.32	8.96e-8	Height;
CESC	cis	rs1005277	0.522	rs289648	chr10:37971837	T/C	cg00409905	chr10:38381863	ZNF37A	-0.46	-6.31	-0.36	1.17e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs7666738	0.830	rs2865981	chr4:99031493	G/A	cg05340658	chr4:99064831	C4orf37	0.84	13.17	0.63	8.25e-31	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6446731	0.593	rs6446726	chr4:3274214	T/C	cg08886695	chr4:3369023	RGS12	-0.39	-5.62	-0.33	4.82e-8	Mean platelet volume;
CESC	cis	rs875971	1.000	rs6946143	chr7:65579722	A/C	cg18876405	chr7:65276391	NA	0.48	6.0	0.35	6.34e-9	Aortic root size;
CESC	cis	rs5769765	1.000	rs2295408	chr22:50261051	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.46	5.28	0.31	2.69e-7	Schizophrenia;
CESC	cis	rs875971	0.522	rs1617484	chr7:65463095	G/A	cg18876405	chr7:65276391	NA	0.72	10.02	0.52	2.97e-20	Aortic root size;
CESC	cis	rs6977660	0.562	rs2189566	chr7:19768960	G/A	cg07541023	chr7:19748670	TWISTNB	0.77	7.2	0.4	6.39e-12	Thyroid stimulating hormone;
CESC	trans	rs800888	0.772	rs3808460	chr8:116597635	A/G	cg19047077	chr12:105044897	CHST11	-0.46	-6.04	-0.35	5.11e-9	Monocyte percentage of white cells;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg22218536	chr3:40518595	ZNF619	-0.52	-6.52	-0.37	3.52e-10	Ulcerative colitis;
CESC	cis	rs9902453	0.934	rs7213902	chr17:28322935	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.64	7.92	0.44	6.76e-14	Coffee consumption (cups per day);
CESC	cis	rs7666738	0.830	rs10021709	chr4:99030587	G/A	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.58e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10465746	0.780	rs10874424	chr1:84424033	C/T	cg10977910	chr1:84465055	TTLL7	0.52	7.07	0.4	1.35e-11	Obesity-related traits;
CESC	cis	rs7914558	0.966	rs4532960	chr10:104667406	C/T	cg04362960	chr10:104952993	NT5C2	0.43	5.57	0.32	6.11e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11238366	chr2:38830691	HNRPLL	-0.52	-6.11	-0.35	3.49e-9	Gut microbiome composition (summer);
CESC	cis	rs7552404	0.727	rs6683437	chr1:76316619	G/A	cg22875332	chr1:76189707	ACADM	0.63	6.33	0.36	1.03e-9	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs763121	0.853	rs5750662	chr22:39072472	G/A	cg21395723	chr22:39101663	GTPBP1	0.42	5.32	0.31	2.17e-7	Menopause (age at onset);
CESC	cis	rs9311474	0.508	rs11720159	chr3:52617802	T/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.6	8.63	0.47	5.81e-16	Electroencephalogram traits;
CESC	cis	rs9911578	0.967	rs4076229	chr17:56937256	C/T	cg05425664	chr17:57184151	TRIM37	-0.5	-6.92	-0.39	3.44e-11	Intelligence (multi-trait analysis);
CESC	trans	rs2121875	0.667	rs4637558	chr5:44224783	G/A	cg07292773	chr6:156718177	NA	-0.48	-6.08	-0.35	4.11e-9	Prostate cancer;
CESC	cis	rs57221529	0.709	rs4957056	chr5:570105	T/C	cg16447950	chr5:562315	NA	-0.66	-7.0	-0.39	2.12e-11	Lung disease severity in cystic fibrosis;
CESC	cis	rs4253772	0.591	rs6007747	chr22:46657261	A/G	cg10231785	chr22:46692440	CN5H6.4;GTSE1	0.49	5.16	0.3	4.91e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg18402987	chr7:1209562	NA	0.76	7.56	0.42	6.59e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs853679	0.517	rs34716816	chr6:28046169	C/A	cg08968635	chr6:28129556	ZNF389	0.39	5.22	0.31	3.64e-7	Depression;
CESC	trans	rs4671386	0.901	rs6545797	chr2:60520885	T/C	cg24386296	chr4:1723849	TMEM129;TACC3	0.49	6.17	0.35	2.54e-9	Acne (severe);
CESC	cis	rs7582720	1.000	rs72928620	chr2:203840973	G/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.83	7.26	0.41	4.31e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	trans	rs7819412	0.715	rs2409727	chr8:11043236	C/T	cg06636001	chr8:8085503	FLJ10661	-0.61	-7.77	-0.43	1.74e-13	Triglycerides;
CESC	cis	rs28386778	0.700	rs11079515	chr17:62005645	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.55	-6.98	-0.39	2.36e-11	Prudent dietary pattern;
CESC	cis	rs7666738	0.830	rs10019087	chr4:99030211	C/T	cg24818145	chr4:99064322	C4orf37	0.39	5.09	0.3	6.95e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9488822	0.596	rs13192549	chr6:116338352	C/A	cg26893134	chr6:116381904	FRK	0.22	5.22	0.31	3.63e-7	Cholesterol, total;LDL cholesterol;
CESC	cis	rs1545257	0.550	rs66943245	chr2:24631075	G/A	cg06627628	chr2:24431161	ITSN2	-0.45	-5.3	-0.31	2.5e-7	Sjögren's syndrome;
CESC	cis	rs1728785	1.000	rs1728764	chr16:68572292	G/C	cg02972257	chr16:68554789	NA	-0.55	-6.34	-0.36	9.7e-10	Ulcerative colitis;
CESC	cis	rs13256369	0.802	rs11249888	chr8:8564934	T/C	cg17143192	chr8:8559678	CLDN23	0.78	8.81	0.48	1.63e-16	Obesity-related traits;
CESC	cis	rs16854884	0.657	rs1025984	chr3:143756187	C/G	cg06585982	chr3:143692056	C3orf58	-0.43	-5.93	-0.34	9.39e-9	Economic and political preferences (feminism/equality);
CESC	trans	rs3780486	0.801	rs6476398	chr9:33119241	C/T	cg04842962	chr6:43655489	MRPS18A	0.99	18.06	0.74	4.6e-48	IgG glycosylation;
CESC	trans	rs875971	0.543	rs801191	chr7:66032955	G/A	cg26939375	chr7:64535504	NA	-0.53	-7.31	-0.41	3.22e-12	Aortic root size;
CESC	cis	rs933688	1.000	rs2367353	chr5:90686568	G/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.11	15.95	0.7	1.34e-40	Smoking behavior;
CESC	cis	rs9911578	1.000	rs9892062	chr17:56976981	G/A	cg12560992	chr17:57184187	TRIM37	0.93	15.26	0.68	3.55e-38	Intelligence (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13174343	chr10:51767556	AGAP6	-0.52	-6.69	-0.38	1.35e-10	Gut microbiome composition (summer);
CESC	cis	rs561341	1.000	rs113676348	chr17:30244327	A/G	cg00745463	chr17:30367425	LRRC37B	-0.6	-5.82	-0.34	1.72e-8	Hip circumference adjusted for BMI;
CESC	cis	rs7666738	0.822	rs11097599	chr4:98959562	T/A	cg17366294	chr4:99064904	C4orf37	0.59	8.45	0.46	1.9e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs896854	0.846	rs13254283	chr8:95914103	G/T	cg26343298	chr8:95960752	TP53INP1	0.32	5.25	0.31	3.06e-7	Type 2 diabetes;
CESC	cis	rs12497850	0.864	rs4279134	chr3:49156676	A/G	cg02487422	chr3:49467188	NICN1	0.46	5.81	0.34	1.75e-8	Parkinson's disease;
CESC	cis	rs9457247	0.663	rs9457258	chr6:167444254	T/C	cg23791538	chr6:167370224	RNASET2	-0.57	-7.7	-0.43	2.7e-13	Crohn's disease;
CESC	cis	rs11711311	0.955	rs7617313	chr3:113391740	T/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.66	8.62	0.47	6.11e-16	IgG glycosylation;
CESC	cis	rs7811142	1.000	rs7783550	chr7:99987805	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	-1.13	-12.6	-0.61	7.67e-29	Platelet count;
CESC	cis	rs6696846	0.765	rs3738155	chr1:205074424	C/T	cg00857998	chr1:205179979	DSTYK	0.55	7.19	0.4	6.58e-12	Red blood cell count;
CESC	cis	rs478304	0.934	rs669742	chr11:65501291	C/T	cg08755490	chr11:65554678	OVOL1	0.47	6.21	0.36	2.06e-9	Acne (severe);
CESC	cis	rs7953508	0.506	rs10859532	chr12:93960917	G/C	cg18151635	chr12:93972918	NA	-0.45	-5.99	-0.35	7e-9	Pubertal anthropometrics;
CESC	cis	rs9287719	0.967	rs4470306	chr2:10743998	C/T	cg02196655	chr2:10830764	NOL10	-0.38	-5.82	-0.34	1.71e-8	Prostate cancer;
CESC	cis	rs1707322	1.000	rs12077546	chr1:46431806	C/T	cg03146154	chr1:46216737	IPP	0.72	9.82	0.52	1.31e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs11098499	0.542	rs10440343	chr4:120309787	G/C	cg09307838	chr4:120376055	NA	0.92	12.66	0.61	4.96e-29	Corneal astigmatism;
CESC	cis	rs9926296	0.632	rs72807526	chr16:89775946	A/G	cg04287289	chr16:89883240	FANCA	-0.64	-8.61	-0.47	6.55e-16	Vitiligo;
CESC	cis	rs9858542	0.951	rs1800668	chr3:49395757	G/A	cg07274523	chr3:49395745	GPX1	0.66	8.22	0.45	8.84e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs10771431	0.935	rs1117735	chr12:9372728	G/A	cg08997352	chr12:9597637	DDX12	-0.68	-9.07	-0.49	2.75e-17	Breast size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15273368	chr10:104221031	TMEM180	0.57	6.61	0.38	2.11e-10	Gut microbiome composition (summer);
CESC	cis	rs7937682	0.575	rs7950926	chr11:111776437	G/C	cg22437258	chr11:111473054	SIK2	-0.52	-6.18	-0.35	2.42e-9	Primary sclerosing cholangitis;
CESC	cis	rs1546924	0.692	rs197379	chr1:112292303	T/C	cg23955903	chr1:112298873	DDX20;C1orf183	0.42	5.46	0.32	1.08e-7	Body mass index;
CESC	cis	rs3806843	0.801	rs2531358	chr5:140117437	A/G	cg16179182	chr5:140090404	VTRNA1-1	0.41	5.34	0.31	1.97e-7	Depressive symptoms (multi-trait analysis);
CESC	trans	rs1814175	0.645	rs1851857	chr11:49855589	A/C	cg03929089	chr4:120376271	NA	-0.9	-14.42	-0.66	3.37e-35	Height;
CESC	cis	rs801193	0.548	rs2659904	chr7:66178602	C/A	cg18876405	chr7:65276391	NA	0.44	5.84	0.34	1.5e-8	Aortic root size;
CESC	cis	rs11871801	0.517	rs10454087	chr17:40735641	C/T	cg21433558	chr17:40837037	CNTNAP1	0.48	5.85	0.34	1.45e-8	Crohn's disease;
CESC	cis	rs2857078	0.772	rs2079008	chr17:42322132	C/A	cg08499158	chr17:42289980	UBTF	0.46	5.59	0.32	5.59e-8	Red cell distribution width;Reticulocyte count;
CESC	cis	rs7208859	0.673	rs11080138	chr17:29224542	A/G	cg19761014	chr17:28927070	LRRC37B2	0.73	5.77	0.33	2.22e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs12928939	0.517	rs71384782	chr16:71978591	A/G	cg03805757	chr16:71968109	PKD1L3	-0.57	-6.46	-0.37	5.1e-10	Post bronchodilator FEV1;
CESC	cis	rs9486719	1.000	rs2472886	chr6:96864876	C/T	cg18709589	chr6:96969512	KIAA0776	0.53	5.81	0.34	1.75e-8	Migraine;Coronary artery disease;
CESC	cis	rs1799949	0.965	rs34633610	chr17:41419385	A/G	cg23758822	chr17:41437982	NA	1.05	15.68	0.69	1.15e-39	Menopause (age at onset);
CESC	cis	rs2228479	0.702	rs2074963	chr16:89877269	T/C	cg14709524	chr16:89940631	TCF25	0.85	5.92	0.34	1.01e-8	Skin colour saturation;
CESC	cis	rs5758659	0.714	rs6002607	chr22:42496506	C/T	cg15557168	chr22:42548783	NA	0.49	7.61	0.42	4.91e-13	Cognitive function;
CESC	cis	rs9322193	0.962	rs13215691	chr6:150113802	T/C	cg04369109	chr6:150039330	LATS1	-0.42	-5.91	-0.34	1.07e-8	Lung cancer;
CESC	cis	rs7589728	0.844	rs77144652	chr2:88496684	G/A	cg04511125	chr2:88470314	THNSL2	0.55	5.24	0.31	3.21e-7	Plasma clusterin levels;
CESC	trans	rs10411161	0.752	rs10402107	chr19:52384600	A/G	cg22319618	chr22:45562946	NUP50	-0.71	-7.04	-0.4	1.66e-11	Breast cancer;
CESC	cis	rs3008870	0.755	rs2815380	chr1:67510857	A/G	cg02640540	chr1:67518911	SLC35D1	-0.66	-8.6	-0.47	7.24e-16	Lymphocyte percentage of white cells;
CESC	cis	rs9355610	0.609	rs3756838	chr6:167371251	G/A	cg23791538	chr6:167370224	RNASET2	0.5	5.84	0.34	1.51e-8	Graves' disease;
CESC	cis	rs1448094	0.512	rs61930864	chr12:86246740	G/A	cg02569458	chr12:86230093	RASSF9	0.49	7.27	0.41	4.07e-12	Major depressive disorder;
CESC	cis	rs17826219	0.568	rs9903854	chr17:29153998	C/T	cg19761014	chr17:28927070	LRRC37B2	0.72	5.91	0.34	1.03e-8	Body mass index;
CESC	cis	rs12545109	0.800	rs990301	chr8:57406021	G/C	cg09654669	chr8:57350985	NA	-0.48	-6.63	-0.38	1.87e-10	Obesity-related traits;
CESC	cis	rs9611565	0.659	rs28530678	chr22:41934961	G/C	cg06481639	chr22:41940642	POLR3H	-0.69	-6.85	-0.39	5.18e-11	Vitiligo;
CESC	cis	rs7666738	0.830	rs13122054	chr4:98972974	G/A	cg03676636	chr4:99064102	C4orf37	0.33	5.1	0.3	6.37e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10078	0.528	rs2434697	chr5:466811	T/C	cg08916839	chr5:415575	AHRR	0.58	6.72	0.38	1.1e-10	Fat distribution (HIV);
CESC	cis	rs2066819	1.000	rs117683816	chr12:56638267	T/C	cg26734620	chr12:56694298	CS	1.04	6.73	0.38	1.06e-10	Psoriasis vulgaris;
CESC	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	7.73	0.43	2.23e-13	Prudent dietary pattern;
CESC	cis	rs7666738	0.830	rs10007872	chr4:99001904	T/C	cg17366294	chr4:99064904	C4orf37	0.59	8.43	0.46	2.2e-15	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05971751	chr4:39699140	UBE2K	-0.54	-6.29	-0.36	1.33e-9	Gut microbiome composition (summer);
CESC	cis	rs10504229	0.817	rs114173899	chr8:58170640	G/T	cg14926445	chr8:58193284	C8orf71	-0.52	-5.59	-0.32	5.77e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs34779708	0.771	rs12098283	chr10:35478115	G/T	cg04310649	chr10:35416472	CREM	-0.49	-5.74	-0.33	2.58e-8	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs12142240	0.659	rs72677602	chr1:46837487	G/A	cg10495392	chr1:46806563	NSUN4	0.58	6.02	0.35	5.95e-9	Menopause (age at onset);
CESC	cis	rs2439831	1.000	rs7173487	chr15:43750239	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.81	10.22	0.53	6.88e-21	Lung cancer in ever smokers;
CESC	cis	rs6952808	1.000	rs6957894	chr7:1887362	G/A	cg04267008	chr7:1944627	MAD1L1	-0.58	-7.09	-0.4	1.2e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs798554	0.679	rs2527677	chr7:2882621	A/G	cg19717773	chr7:2847554	GNA12	-0.48	-7.01	-0.4	1.97e-11	Height;
CESC	cis	rs748404	0.697	rs492743	chr15:43560945	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.6	7.71	0.43	2.46e-13	Lung cancer;
CESC	cis	rs1048238	0.818	rs945421	chr1:16345393	T/C	cg22431228	chr1:16359049	CLCNKA	-0.55	-10.9	-0.56	4.13e-23	Systolic blood pressure;
CESC	cis	rs1707322	0.717	rs2275086	chr1:46085879	C/G	cg06784218	chr1:46089804	CCDC17	-0.4	-6.85	-0.39	5.21e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs898097	0.585	rs9893200	chr17:80893028	A/C	cg15664640	chr17:80829946	TBCD	0.4	5.73	0.33	2.69e-8	Breast cancer;
CESC	cis	rs8020095	0.528	rs8013943	chr14:67383335	T/C	cg19548862	chr14:67692701	FAM71D	-0.49	-5.94	-0.34	8.86e-9	Depression (quantitative trait);
CESC	trans	rs324780	0.544	rs3110202	chr12:83890080	C/G	cg22140261	chr22:42466895	NAGA	0.47	6.04	0.35	5.24e-9	Vertical cup-disc ratio;
CESC	cis	rs7258465	1.000	rs2007981	chr19:18567555	C/A	cg25828334	chr19:18545568	ISYNA1	-0.32	-5.22	-0.31	3.63e-7	Breast cancer;
CESC	cis	rs10242455	0.867	rs2687086	chr7:99295450	C/T	cg07715041	chr7:99302981	CYP3A7	-0.44	-5.56	-0.32	6.73e-8	Blood metabolite levels;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg26724186	chr19:3676340	PIP5K1C	0.43	6.02	0.35	5.88e-9	Fibrinogen levels;
CESC	cis	rs6426558	0.524	rs2813948	chr1:227459621	A/T	cg10327440	chr1:227177885	CDC42BPA	0.49	6.09	0.35	4.02e-9	Neutrophil percentage of white cells;
CESC	cis	rs35110281	0.667	rs2155722	chr21:45096206	A/G	cg04455712	chr21:45112962	RRP1B	-0.48	-7.97	-0.44	4.69e-14	Mean corpuscular volume;
CESC	cis	rs514406	0.644	rs6661196	chr1:53203664	A/G	cg24675658	chr1:53192096	ZYG11B	0.63	8.7	0.47	3.6e-16	Monocyte count;
CESC	cis	rs1577917	0.771	rs4419647	chr6:86225739	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.57	7.92	0.44	6.7e-14	Response to antipsychotic treatment;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12848118	chr14:89626305	FOXN3	-0.59	-6.99	-0.39	2.27e-11	Gut microbiome composition (summer);
CESC	cis	rs11190604	1.000	rs10883492	chr10:102206089	G/A	cg07080220	chr10:102295463	HIF1AN	0.55	5.51	0.32	8.5e-8	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg05552183	chr6:42928497	GNMT	0.76	11.53	0.58	3.3e-25	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs62229266	0.839	rs11702763	chr21:37470704	A/G	cg12218747	chr21:37451666	NA	-0.49	-6.61	-0.38	2.13e-10	Mitral valve prolapse;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18501264	chr19:33555827	RHPN2	0.65	7.33	0.41	2.8e-12	Gut microbiome composition (summer);
CESC	cis	rs11098499	0.754	rs7689729	chr4:120256192	A/G	cg09307838	chr4:120376055	NA	0.8	10.88	0.56	5.04e-23	Corneal astigmatism;
CESC	trans	rs11722228	0.549	rs41268389	chr4:10099277	G/A	cg26043149	chr18:55253948	FECH	0.92	10.95	0.56	2.93e-23	Gout;Urate levels;Serum uric acid levels;
CESC	cis	rs10751667	0.643	rs7479473	chr11:929111	C/T	cg06064525	chr11:970664	AP2A2	-0.52	-10.25	-0.53	5.74e-21	Alzheimer's disease (late onset);
CESC	cis	rs929354	0.772	rs6459737	chr7:156975136	G/A	cg05182265	chr7:156933206	UBE3C	-0.51	-7.48	-0.42	1.11e-12	Body mass index;
CESC	cis	rs10885582	0.754	rs10787533	chr10:116288063	A/T	cg17056676	chr10:116301354	ABLIM1	0.29	5.14	0.3	5.22e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs6088580	0.634	rs1205334	chr20:32930369	T/C	cg08999081	chr20:33150536	PIGU	-0.65	-11.36	-0.57	1.3e-24	Glomerular filtration rate (creatinine);
CESC	cis	rs113835537	0.529	rs10501397	chr11:66272976	G/T	cg24851651	chr11:66362959	CCS	0.41	5.11	0.3	6.21e-7	Airway imaging phenotypes;
CESC	cis	rs9300255	0.537	rs1727334	chr12:123714236	A/G	cg05973401	chr12:123451056	ABCB9	0.5	5.58	0.32	5.95e-8	Neutrophil percentage of white cells;
CESC	cis	rs4665809	0.652	rs10779956	chr2:26405985	A/G	cg22920501	chr2:26401640	FAM59B	-0.87	-10.22	-0.53	6.67e-21	Gut microbiome composition (summer);
CESC	cis	rs11122272	0.735	rs2790882	chr1:231532783	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.55	7.51	0.42	9.13e-13	Hemoglobin concentration;
CESC	cis	rs1707322	0.691	rs12031182	chr1:46220999	C/T	cg05343316	chr1:45956843	TESK2	0.51	6.2	0.36	2.19e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7959452	0.590	rs56054057	chr12:69775972	C/T	cg22834771	chr12:69754056	YEATS4	-0.48	-6.37	-0.36	8.31e-10	Blood protein levels;
CESC	cis	rs791888	0.698	rs7893652	chr10:89431060	A/G	cg13926569	chr10:89418898	PAPSS2	-0.52	-7.56	-0.42	6.76e-13	Magnesium levels;
CESC	cis	rs72781680	0.821	rs72796325	chr2:24134537	G/A	cg08917208	chr2:24149416	ATAD2B	0.57	5.62	0.33	4.79e-8	Lymphocyte counts;
CESC	cis	rs344364	0.511	rs911391	chr16:1947016	C/A	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.55	-6.2	-0.36	2.15e-9	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs9733	0.519	rs10788792	chr1:150638572	T/G	cg04414720	chr1:150670196	GOLPH3L	0.63	9.02	0.48	3.78e-17	Tonsillectomy;
CESC	trans	rs983392	0.805	rs7933805	chr11:59967526	A/G	cg02363969	chr19:56048075	SBK2	0.41	6.07	0.35	4.3e-9	Alzheimer's disease (late onset);
CESC	cis	rs1670533	0.769	rs6814833	chr4:1057679	A/C	cg27284194	chr4:1044797	NA	0.48	6.06	0.35	4.7e-9	Recombination rate (females);
CESC	cis	rs2236918	1.000	rs1635512	chr1:242024500	A/G	cg17736920	chr1:242011382	EXO1	-0.69	-9.29	-0.5	5.93e-18	Menopause (age at onset);
CESC	cis	rs4862750	0.914	rs9995391	chr4:187873749	A/T	cg11301795	chr4:187892539	NA	0.68	10.35	0.54	2.63e-21	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1538970	0.924	rs10890327	chr1:45891458	C/T	cg03146154	chr1:46216737	IPP	0.44	5.09	0.3	6.74e-7	Platelet count;
CESC	cis	rs10197940	0.624	rs10497082	chr2:152355258	T/C	cg06191203	chr2:152266755	RIF1	-0.45	-5.2	-0.3	4e-7	Lung cancer;
CESC	cis	rs66887589	0.777	rs1814815	chr4:120258091	C/T	cg09307838	chr4:120376055	NA	0.55	7.47	0.42	1.14e-12	Diastolic blood pressure;
CESC	cis	rs10131894	0.611	rs175001	chr14:75436452	A/C	cg11812906	chr14:75593930	NEK9	0.64	9.49	0.5	1.45e-18	Coronary artery disease;
CESC	cis	rs9467160	1.000	rs9295624	chr6:24439600	A/G	cg20631270	chr6:24437470	GPLD1	-0.43	-5.18	-0.3	4.48e-7	Liver enzyme levels;
CESC	cis	rs1198430	0.852	rs909537	chr1:23810063	C/G	cg22040403	chr1:23858016	E2F2	0.67	5.4	0.31	1.47e-7	Total cholesterol levels;
CESC	cis	rs858239	0.601	rs10263110	chr7:23160551	G/A	cg23682824	chr7:23144976	KLHL7	0.54	7.38	0.41	2.09e-12	Cerebrospinal fluid biomarker levels;
CESC	cis	rs7086627	0.515	rs4934189	chr10:82214792	C/T	cg03267442	chr10:82210566	NA	-0.33	-5.43	-0.32	1.27e-7	Post bronchodilator FEV1;
CESC	cis	rs4595586	0.545	rs12828790	chr12:39401043	G/A	cg26384229	chr12:38710491	ALG10B	0.61	8.69	0.47	3.92e-16	Morning vs. evening chronotype;
CESC	cis	rs875971	0.965	rs9969301	chr7:65781655	G/A	cg12463550	chr7:65579703	CRCP	-0.54	-6.96	-0.39	2.66e-11	Aortic root size;
CESC	trans	rs650950	0.528	rs646660	chr11:35528452	C/T	cg03342113	chr11:61197477	CPSF7;SDHAF2	0.44	6.06	0.35	4.66e-9	Bronchopulmonary dysplasia;
CESC	trans	rs11098499	0.909	rs10014719	chr4:120320715	G/A	cg25214090	chr10:38739885	LOC399744	0.72	9.92	0.52	6.25e-20	Corneal astigmatism;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg07611531	chr2:54853149	SPTBN1	0.47	6.56	0.37	2.81e-10	Fibrinogen levels;
CESC	cis	rs16948098	1	rs16948098	chr15:44219607	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.77	5.5	0.32	9.09e-8	Serum albumin level;
CESC	cis	rs6448317	0.954	rs7666033	chr4:24925272	A/G	cg21108841	chr4:24914750	CCDC149	-0.47	-5.89	-0.34	1.14e-8	Heschl's gyrus morphology;
CESC	cis	rs208520	0.690	rs12198297	chr6:66714665	G/A	cg07460842	chr6:66804631	NA	0.97	13.03	0.62	2.61e-30	Exhaled nitric oxide output;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg07736927	chr7:56171097	CHCHD2	0.51	6.89	0.39	3.97e-11	Fibrinogen levels;
CESC	cis	rs5750830	0.594	rs5757648	chr22:39775156	G/A	cg05872129	chr22:39784769	NA	-0.75	-10.71	-0.55	1.76e-22	Intelligence (multi-trait analysis);
CESC	cis	rs875971	1.000	rs11971949	chr7:65626014	A/G	cg10691866	chr7:65817282	TPST1	0.34	5.76	0.33	2.32e-8	Aortic root size;
CESC	cis	rs798554	0.959	rs798558	chr7:2758935	T/G	cg19717773	chr7:2847554	GNA12	-0.55	-7.85	-0.43	1.05e-13	Height;
CESC	cis	rs514406	0.893	rs522287	chr1:53365493	C/T	cg25767906	chr1:53392781	SCP2	-0.49	-6.26	-0.36	1.55e-9	Monocyte count;
CESC	cis	rs7107174	1.000	rs2511170	chr11:77980582	A/G	cg02023728	chr11:77925099	USP35	0.45	6.55	0.37	3.01e-10	Testicular germ cell tumor;
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg08575399	chr20:60719638	PSMA7;SS18L1	-0.44	-6.43	-0.37	5.94e-10	Vertical cup-disc ratio;
CESC	cis	rs9733	0.526	rs6587542	chr1:150907701	G/T	cg17724175	chr1:150552817	MCL1	0.33	5.08	0.3	7.16e-7	Tonsillectomy;
CESC	cis	rs6460942	0.915	rs10267801	chr7:12451931	G/A	cg06484146	chr7:12443880	VWDE	-0.67	-8.8	-0.48	1.86e-16	Coronary artery disease;
CESC	cis	rs6933660	0.744	rs3800279	chr6:151766162	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.47	5.42	0.32	1.33e-7	Menarche (age at onset);
CESC	cis	rs3796352	1.000	rs75217232	chr3:53132373	A/C	cg12962167	chr3:53033115	SFMBT1	0.54	5.13	0.3	5.5e-7	Immune reponse to smallpox (secreted IL-2);
CESC	cis	rs3858526	0.523	rs10769289	chr11:5886607	C/T	cg02574844	chr11:5959923	NA	-0.47	-7.33	-0.41	2.86e-12	DNA methylation (variation);
CESC	cis	rs10504229	0.817	rs58957714	chr8:58195864	G/A	cg05313129	chr8:58192883	C8orf71	-0.56	-5.57	-0.32	6.13e-8	Developmental language disorder (linguistic errors);
CESC	trans	rs561341	1.000	rs1681718	chr17:30296445	G/A	cg20587970	chr11:113659929	NA	-1.43	-18.65	-0.75	3.85e-50	Hip circumference adjusted for BMI;
CESC	trans	rs1814175	0.534	rs1983448	chr11:49933856	C/A	cg15704280	chr7:45808275	SEPT13	-1.01	-18.44	-0.75	2.03e-49	Height;
CESC	cis	rs11677370	0.603	rs11696104	chr2:3849512	C/G	cg17052675	chr2:3827356	NA	-0.42	-5.46	-0.32	1.08e-7	Type 2 diabetes;
CESC	cis	rs597539	0.652	rs674654	chr11:68698762	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.81	10.5	0.54	8.5e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	trans	rs35146811	0.735	rs1636978	chr7:99813912	G/A	cg13215871	chr17:75784724	NA	-0.35	-6.39	-0.37	7.48e-10	Coronary artery disease;
CESC	cis	rs2070433	0.752	rs11701058	chr21:47776382	T/C	cg12379764	chr21:47803548	PCNT	0.67	7.44	0.42	1.38e-12	Lymphocyte counts;
CESC	cis	rs6582630	0.502	rs4559747	chr12:38436235	G/A	cg26384229	chr12:38710491	ALG10B	0.64	9.78	0.51	1.76e-19	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs1707322	0.686	rs1250	chr1:46094027	A/G	cg03146154	chr1:46216737	IPP	0.78	10.84	0.55	6.67e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9902453	1.000	rs6505158	chr17:28403348	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.63	-8.05	-0.44	2.78e-14	Coffee consumption (cups per day);
CESC	cis	rs12477438	0.501	rs11683188	chr2:99724512	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	12.81	0.62	1.43e-29	Chronic sinus infection;
CESC	cis	rs9796	0.804	rs28688742	chr15:41403638	G/A	cg20272979	chr15:41787780	ITPKA	0.37	5.62	0.33	4.95e-8	Menopause (age at onset);
CESC	cis	rs123509	0.687	rs6865	chr3:42826041	A/C	cg12982090	chr3:42733453	KBTBD5	-0.65	-7.47	-0.42	1.15e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs4713118	0.662	rs9357060	chr6:28024486	C/G	cg12963246	chr6:28129442	ZNF389	0.49	6.39	0.37	7.29e-10	Parkinson's disease;
CESC	cis	rs965469	0.948	rs6051769	chr20:3326438	G/A	cg17110299	chr20:3385021	C20orf194	0.41	5.04	0.3	8.61e-7	IFN-related cytopenia;
CESC	cis	rs863345	0.604	rs11264983	chr1:158462218	A/C	cg12129480	chr1:158549410	OR10X1	-0.36	-7.29	-0.41	3.49e-12	Pneumococcal bacteremia;
CESC	cis	rs3862260	0.509	rs10923879	chr1:120163831	A/G	cg11530693	chr1:120165357	ZNF697	0.69	10.58	0.55	4.58e-22	Systemic lupus erythematosus;
CESC	cis	rs9911578	1.000	rs304270	chr17:56802141	A/G	cg05425664	chr17:57184151	TRIM37	0.5	7.06	0.4	1.43e-11	Intelligence (multi-trait analysis);
CESC	cis	rs3008870	0.920	rs12132532	chr1:67457015	G/T	cg08660285	chr1:67390436	MIER1;WDR78	-1.02	-14.14	-0.66	3.43e-34	Lymphocyte percentage of white cells;
CESC	cis	rs9910055	0.762	rs227579	chr17:42223134	A/T	cg19774624	chr17:42201019	HDAC5	0.74	11.07	0.56	1.14e-23	Total body bone mineral density;
CESC	cis	rs3008870	1.000	rs4655663	chr1:67430103	C/T	cg08660285	chr1:67390436	MIER1;WDR78	1.06	15.06	0.68	1.87e-37	Lymphocyte percentage of white cells;
CESC	cis	rs2816062	0.775	rs2816048	chr1:18893763	T/C	cg18795169	chr1:18902165	NA	-0.94	-19.08	-0.76	1.16e-51	Urate levels in lean individuals;
CESC	cis	rs4862750	0.914	rs11945845	chr4:187874136	T/C	cg03647317	chr4:187891568	NA	-0.36	-5.07	-0.3	7.33e-7	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs60154123	0.772	rs701942	chr1:210429392	C/G	cg23283495	chr1:209979779	IRF6	0.41	5.1	0.3	6.52e-7	Coronary artery disease;
CESC	cis	rs3741404	0.560	rs17699798	chr11:63898806	C/G	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.61	-8.52	-0.46	1.21e-15	Platelet count;
CESC	cis	rs763014	0.898	rs916416	chr16:632198	T/A	cg00908189	chr16:619842	PIGQ	0.67	9.34	0.5	4.24e-18	Height;
CESC	cis	rs798554	0.796	rs2158694	chr7:2863443	T/G	cg09658497	chr7:2847517	GNA12	-0.41	-5.8	-0.34	1.85e-8	Height;
CESC	cis	rs3087591	0.960	rs2905794	chr17:29470002	G/A	cg24425628	chr17:29625626	OMG;NF1	0.41	5.13	0.3	5.71e-7	Hip circumference;
CESC	cis	rs853679	0.517	rs9368557	chr6:28131537	T/C	cg23281280	chr6:28129359	ZNF389	0.59	7.9	0.44	7.47e-14	Depression;
CESC	cis	rs9811920	0.809	rs1384062	chr3:99597928	A/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.46	7.72	0.43	2.44e-13	Axial length;
CESC	cis	rs4566357	0.576	rs3769644	chr2:227917240	C/G	cg11843606	chr2:227700838	RHBDD1	-0.53	-7.15	-0.4	8.33e-12	Coronary artery disease;
CESC	cis	rs6460942	0.841	rs17443848	chr7:12443688	A/G	cg10578991	chr7:12443926	VWDE	-0.4	-5.4	-0.32	1.45e-7	Coronary artery disease;
CESC	cis	rs7923609	1.000	rs10822161	chr10:65118203	G/A	cg01631684	chr10:65280961	REEP3	-0.42	-5.17	-0.3	4.72e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs741677	1.000	rs741677	chr17:463843	C/T	cg06217071	chr17:408420	NA	-0.31	-5.39	-0.31	1.57e-7	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
CESC	cis	rs7949030	0.523	rs12223627	chr11:62368557	G/C	cg02375832	chr11:62437615	C11orf48	-0.38	-5.48	-0.32	9.81e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	trans	rs7246657	0.943	rs7257672	chr19:37823859	G/C	cg24637308	chr11:6592297	DNHD1	0.53	6.24	0.36	1.74e-9	Coronary artery calcification;
CESC	cis	rs7552404	1.000	rs7552404	chr1:76135946	A/G	cg10523679	chr1:76189770	ACADM	0.72	8.45	0.46	2.02e-15	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs1215050	0.791	rs165242	chr4:98686482	A/C	cg05340658	chr4:99064831	C4orf37	-0.47	-5.91	-0.34	1.07e-8	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs6860806	0.507	rs2631369	chr5:131705266	G/C	cg04518342	chr5:131593106	PDLIM4	-0.36	-5.05	-0.3	8.21e-7	Breast cancer;
CESC	cis	rs10979	0.651	rs9321921	chr6:143895053	C/T	cg25407410	chr6:143891975	LOC285740	-0.53	-7.38	-0.41	1.99e-12	Hypospadias;
CESC	cis	rs7786808	0.615	rs4909212	chr7:158197037	G/T	cg01191920	chr7:158217561	PTPRN2	-0.33	-5.47	-0.32	1.04e-7	Obesity-related traits;
CESC	cis	rs17209837	1.000	rs2302385	chr7:87091826	T/C	cg00919237	chr7:87102261	ABCB4	-0.53	-6.03	-0.35	5.36e-9	Gallbladder cancer;
CESC	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.43	5.49	0.32	9.18e-8	Lymphocyte counts;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg08151828	chr19:11093828	SMARCA4	-0.43	-6.14	-0.35	2.96e-9	Systemic lupus erythematosus;
CESC	cis	rs4704187	0.687	rs2216638	chr5:74512987	A/G	cg03227963	chr5:74354835	NA	0.28	5.04	0.3	8.66e-7	Response to amphetamines;
CESC	cis	rs6089829	0.962	rs7273930	chr20:61666017	G/A	cg03213289	chr20:61660250	NA	0.39	6.14	0.35	2.96e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs35995292	0.534	rs2392604	chr7:38918012	C/T	cg19327137	chr7:38886074	VPS41	0.66	11.04	0.56	1.47e-23	Subjective well-being (multi-trait analysis);
CESC	cis	rs6570726	0.905	rs421032	chr6:145827771	A/G	cg23711669	chr6:146136114	FBXO30	0.78	11.62	0.58	1.64e-25	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs3931020	0.548	rs969435	chr1:75273866	A/G	cg26855724	chr1:75198818	TYW3;CRYZ	-0.51	-6.56	-0.37	2.83e-10	Resistin levels;
CESC	trans	rs1814175	0.791	rs10769593	chr11:49616217	T/C	cg03929089	chr4:120376271	NA	-0.88	-14.07	-0.65	5.83e-34	Height;
CESC	trans	rs637571	0.522	rs3016868	chr11:65764383	C/T	cg17712092	chr4:129076599	LARP1B	0.75	10.57	0.54	5.01e-22	Eosinophil percentage of white cells;
CESC	cis	rs6088580	0.634	rs6059867	chr20:33078103	C/T	cg06115741	chr20:33292138	TP53INP2	0.46	5.86	0.34	1.34e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs2066819	1.000	rs2371494	chr12:56728000	G/A	cg26316697	chr12:56727976	PAN2	0.71	6.85	0.39	5.09e-11	Psoriasis vulgaris;
CESC	cis	rs3540	0.597	rs4620932	chr15:91036569	G/A	cg10434728	chr15:90938212	IQGAP1	0.42	7.46	0.42	1.28e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs2479106	0.926	rs7868740	chr9:126502000	A/G	cg16191174	chr9:126692580	DENND1A	0.48	6.57	0.37	2.65e-10	Polycystic ovary syndrome;
CESC	cis	rs295140	0.566	rs295141	chr2:201163556	C/T	cg23649088	chr2:200775458	C2orf69	-0.44	-6.05	-0.35	4.83e-9	QT interval;
CESC	cis	rs9039	1.000	rs67302637	chr16:9221100	C/T	cg08831531	chr16:9218945	NA	-0.53	-7.02	-0.4	1.87e-11	Menopause (age at onset);
CESC	cis	rs11122272	0.701	rs2474628	chr1:231526000	C/T	cg06096015	chr1:231504339	EGLN1	0.43	6.18	0.35	2.46e-9	Hemoglobin concentration;
CESC	cis	rs4722166	0.630	rs6969258	chr7:22782528	C/T	cg05472934	chr7:22766657	IL6	0.87	10.94	0.56	3.06e-23	Lung cancer;
CESC	cis	rs56163509	1	rs56163509	chr16:28864471	A/G	cg05966235	chr16:28915196	ATP2A1	0.34	5.03	0.3	9.05e-7	Tonsillectomy;Mean corpuscular volume;
CESC	cis	rs3733585	0.726	rs4306953	chr4:9955776	G/A	cg11266682	chr4:10021025	SLC2A9	-0.57	-10.92	-0.56	3.75e-23	Cleft plate (environmental tobacco smoke interaction);
CESC	trans	rs116095464	0.558	rs9687898	chr5:253952	A/G	cg00938859	chr5:1591904	SDHAP3	0.63	6.77	0.38	8.35e-11	Breast cancer;
CESC	cis	rs1552244	1.000	rs6764068	chr3:10153842	A/G	cg08888203	chr3:10149979	C3orf24	0.44	5.71	0.33	3.09e-8	Alzheimer's disease;
CESC	cis	rs1395	0.778	rs6749393	chr2:27451000	C/T	cg22903471	chr2:27725779	GCKR	-0.42	-5.12	-0.3	5.99e-7	Blood metabolite levels;
CESC	cis	rs7044106	0.791	rs4836829	chr9:123482747	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.85	13.7	0.64	1.16e-32	Hip circumference adjusted for BMI;
CESC	cis	rs1538970	0.962	rs9429077	chr1:45820667	C/A	cg03146154	chr1:46216737	IPP	0.45	5.39	0.31	1.54e-7	Platelet count;
CESC	cis	rs9487051	0.676	rs7753705	chr6:109593302	A/C	cg21918786	chr6:109611834	NA	-0.37	-5.41	-0.32	1.39e-7	Reticulocyte fraction of red cells;
CESC	cis	rs7666738	0.830	rs28795113	chr4:98951331	A/G	cg05340658	chr4:99064831	C4orf37	0.8	12.48	0.61	2e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9549367	0.789	rs9549365	chr13:113907391	C/T	cg18105134	chr13:113819100	PROZ	0.69	8.8	0.48	1.78e-16	Platelet distribution width;
CESC	cis	rs11048434	0.673	rs2159961	chr12:9061456	G/T	cg23795048	chr12:9217529	LOC144571	0.33	5.23	0.31	3.49e-7	Sjögren's syndrome;
CESC	cis	rs35110281	0.574	rs1836856	chr21:44964638	A/T	cg01579765	chr21:45077557	HSF2BP	-0.52	-8.68	-0.47	4.24e-16	Mean corpuscular volume;
CESC	cis	rs4472734	1.000	rs10494977	chr1:214622253	C/T	cg00063699	chr1:214624242	PTPN14	-0.33	-5.23	-0.31	3.45e-7	Height;
CESC	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.42	5.61	0.33	5.1e-8	Lymphocyte counts;
CESC	cis	rs9811920	0.541	rs1016914	chr3:99640121	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.59	7.22	0.41	5.61e-12	Axial length;
CESC	cis	rs7613875	0.600	rs2624832	chr3:50030858	C/T	cg24110177	chr3:50126178	RBM5	-0.55	-7.48	-0.42	1.09e-12	Body mass index;
CESC	cis	rs6942756	1.000	rs67820265	chr7:128887925	A/G	cg02491457	chr7:128862824	NA	-0.71	-10.31	-0.54	3.49e-21	White matter hyperintensity burden;
CESC	cis	rs2281845	0.929	rs6704363	chr1:201096383	A/G	cg17810781	chr1:201082982	CACNA1S	0.4	5.56	0.32	6.72e-8	Permanent tooth development;
CESC	cis	rs4665809	0.531	rs12987980	chr2:26462093	A/T	cg27170947	chr2:26402098	FAM59B	0.87	9.85	0.52	1.01e-19	Gut microbiome composition (summer);
CESC	cis	rs7809950	0.817	rs2807	chr7:107260778	G/A	cg23024343	chr7:107201750	COG5	0.58	7.55	0.42	6.9e-13	Coronary artery disease;
CESC	cis	rs3784262	1.000	rs12903474	chr15:58276747	A/C	cg12031962	chr15:58353849	ALDH1A2	0.34	5.39	0.31	1.58e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
CESC	cis	rs4654899	0.897	rs59537090	chr1:21498737	C/T	cg05370193	chr1:21551575	ECE1	0.41	6.22	0.36	1.96e-9	Superior frontal gyrus grey matter volume;
CESC	cis	rs6460942	0.915	rs1595800	chr7:12439816	G/A	cg20607287	chr7:12443886	VWDE	-0.71	-8.7	-0.47	3.54e-16	Coronary artery disease;
CESC	cis	rs4253772	0.637	rs8139035	chr22:46651367	A/G	cg10231785	chr22:46692440	CN5H6.4;GTSE1	0.48	5.11	0.3	6.16e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs12220238	1.000	rs10824125	chr10:75997498	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.64	6.22	0.36	1.89e-9	Soluble interleukin-2 receptor subunit alpha;
CESC	cis	rs2839186	0.709	rs2156117	chr21:47669300	C/A	cg11766577	chr21:47581405	C21orf56	-0.47	-6.32	-0.36	1.12e-9	Testicular germ cell tumor;
CESC	trans	rs9388451	0.513	rs1268069	chr6:126039994	A/C	cg05039488	chr6:79577232	IRAK1BP1	-0.49	-6.54	-0.37	3.19e-10	Brugada syndrome;
CESC	cis	rs6800768	0.633	rs6769284	chr3:24148448	T/G	cg10674438	chr3:24145617	LOC152024	-0.47	-6.46	-0.37	5.08e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs4665809	0.938	rs35844686	chr2:26304949	A/G	cg04944784	chr2:26401820	FAM59B	0.75	8.12	0.45	1.72e-14	Gut microbiome composition (summer);
CESC	cis	rs2658782	1.000	rs2019814	chr11:93168885	A/G	cg15737290	chr11:93063684	CCDC67	0.52	6.47	0.37	4.7e-10	Pulmonary function decline;
CESC	cis	rs2425143	0.818	rs73902932	chr20:34489009	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.77	-7.0	-0.39	2.11e-11	Blood protein levels;
CESC	cis	rs1218582	0.772	rs6669791	chr1:154845484	G/T	cg24250549	chr1:154909240	PMVK	0.71	10.52	0.54	7.24e-22	Prostate cancer;
CESC	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg24739457	chr1:205821442	NA	0.46	6.03	0.35	5.48e-9	Menarche (age at onset);
CESC	cis	rs12479064	0.724	rs2305352	chr2:100015124	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.65	-7.7	-0.43	2.79e-13	Chronic sinus infection;
CESC	cis	rs10504073	0.647	rs4873096	chr8:49995201	A/G	cg00325661	chr8:49890786	NA	0.55	8.17	0.45	1.29e-14	Blood metabolite ratios;
CESC	cis	rs3857067	0.806	rs9307137	chr4:95135712	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.57	-8.39	-0.46	2.9e-15	QT interval;
CESC	cis	rs35306767	0.855	rs12761180	chr10:872086	C/T	cg26597838	chr10:835615	NA	1.17	11.32	0.57	1.77e-24	Eosinophil percentage of granulocytes;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg00271154	chr2:113033418	ZC3H6	0.44	6.25	0.36	1.61e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs875971	0.545	rs6961853	chr7:66002022	G/A	cg25405998	chr7:65216604	CCT6P1	0.46	5.21	0.3	3.87e-7	Aortic root size;
CESC	cis	rs929596	0.556	rs10168416	chr2:234597087	C/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.48	-6.01	-0.35	6.26e-9	Total bilirubin levels in HIV-1 infection;
CESC	cis	rs6089584	0.546	rs6061978	chr20:60615604	C/T	cg06108461	chr20:60628389	TAF4	-0.59	-8.01	-0.44	3.65e-14	Body mass index;
CESC	cis	rs2243480	1.000	rs316321	chr7:65611613	G/A	cg18252515	chr7:66147081	NA	-1.41	-14.48	-0.66	2.11e-35	Diabetic kidney disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg05848389	chr14:102508999	DYNC1H1	0.43	6.01	0.35	6.05e-9	Fibrinogen levels;
CESC	cis	rs17666538	0.710	rs7834337	chr8:655828	A/G	cg07234876	chr8:600039	NA	0.82	6.7	0.38	1.24e-10	IgG glycosylation;
CESC	cis	rs28437878	1	rs28437878	chr15:78807872	C/T	cg24631222	chr15:78858424	CHRNA5	0.78	9.5	0.5	1.31e-18	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs951366	0.576	rs1832775	chr1:205734032	C/T	cg14893161	chr1:205819251	PM20D1	-0.4	-5.07	-0.3	7.35e-7	Menarche (age at onset);
CESC	cis	rs10751667	0.666	rs6597967	chr11:950583	G/T	cg20946044	chr11:1010712	AP2A2	-0.39	-5.35	-0.31	1.86e-7	Alzheimer's disease (late onset);
CESC	cis	rs6540559	0.673	rs6694552	chr1:209976459	A/C	cg09509183	chr1:209979624	IRF6	0.56	5.86	0.34	1.4e-8	Cleft lip with or without cleft palate;
CESC	cis	rs7772486	0.875	rs10457796	chr6:146416087	T/G	cg23711669	chr6:146136114	FBXO30	0.81	12.17	0.6	2.27e-27	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9948	0.708	rs116121826	chr2:97441914	A/G	cg01990225	chr2:97406019	LMAN2L	-0.92	-7.51	-0.42	9.04e-13	Erectile dysfunction and prostate cancer treatment;
CESC	cis	rs9649213	0.593	rs10953255	chr7:97923198	A/G	cg00277769	chr7:97922759	BAIAP2L1	-0.35	-5.64	-0.33	4.37e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs10256972	1.000	rs10256972	chr7:1039003	G/T	cg07930192	chr7:1003750	NA	-0.43	-5.89	-0.34	1.17e-8	Longevity;Endometriosis;
CESC	cis	rs11583043	1.000	rs12750667	chr1:101498682	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.52	5.57	0.32	6.2e-8	Ulcerative colitis;Inflammatory bowel disease;
CESC	cis	rs12220238	0.841	rs10824212	chr10:76371068	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.54	5.04	0.3	8.72e-7	Soluble interleukin-2 receptor subunit alpha;
CESC	cis	rs11098499	0.866	rs10518329	chr4:120401835	A/G	cg09307838	chr4:120376055	NA	0.76	10.53	0.54	7.06e-22	Corneal astigmatism;
CESC	cis	rs708547	0.836	rs1315005	chr4:57858237	C/G	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.57	-6.62	-0.38	2.03e-10	Response to bleomycin (chromatid breaks);
CESC	cis	rs9322193	0.962	rs12175575	chr6:150084487	G/A	cg07701084	chr6:150067640	NUP43	0.44	5.95	0.34	8.59e-9	Lung cancer;
CESC	cis	rs6964587	0.967	rs28615927	chr7:91600648	C/A	cg17063962	chr7:91808500	NA	0.57	7.74	0.43	2.11e-13	Breast cancer;
CESC	cis	rs12497850	0.931	rs7431710	chr3:48935583	G/A	cg07636037	chr3:49044803	WDR6	0.98	18.37	0.75	3.7e-49	Parkinson's disease;
CESC	cis	rs28374715	0.532	rs11070328	chr15:41651569	T/C	cg02330683	chr15:41787940	ITPKA	0.42	5.05	0.3	8.08e-7	Ulcerative colitis;
CESC	cis	rs67311347	1.000	rs73076046	chr3:40447724	C/T	cg24209194	chr3:40518798	ZNF619	0.51	6.27	0.36	1.46e-9	Renal cell carcinoma;
CESC	cis	rs10883723	0.810	rs11191304	chr10:104255284	C/T	cg22532475	chr10:104410764	TRIM8	-0.34	-5.73	-0.33	2.77e-8	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs11098499	0.866	rs7677068	chr4:120291704	C/T	cg09307838	chr4:120376055	NA	0.87	12.16	0.6	2.41e-27	Corneal astigmatism;
CESC	cis	rs4689388	0.856	rs4308430	chr4:6294095	A/G	cg14416269	chr4:6271139	WFS1	0.46	7.73	0.43	2.23e-13	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs11098499	0.863	rs6534139	chr4:120449456	A/G	cg24375607	chr4:120327624	NA	-0.43	-5.12	-0.3	5.91e-7	Corneal astigmatism;
CESC	cis	rs7818688	0.653	rs4075834	chr8:95833747	C/T	cg16049864	chr8:95962084	TP53INP1	0.55	5.62	0.33	4.81e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs73206853	0.764	rs7960988	chr12:110749918	G/A	cg12870014	chr12:110450643	ANKRD13A	0.65	5.48	0.32	9.9e-8	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs425277	0.606	rs262653	chr1:2090095	T/G	cg16545954	chr1:2118288	C1orf86	0.36	7.05	0.4	1.58e-11	Height;
CESC	trans	rs1814175	0.935	rs6485999	chr11:49658986	G/C	cg03929089	chr4:120376271	NA	-0.88	-13.45	-0.64	8.7e-32	Height;
CESC	cis	rs992157	0.560	rs1514132	chr2:219084082	C/T	cg00012203	chr2:219082015	ARPC2	-0.74	-9.79	-0.52	1.66e-19	Colorectal cancer;
CESC	cis	rs9788682	0.706	rs2656055	chr15:78720194	C/A	cg24631222	chr15:78858424	CHRNA5	-0.58	-6.44	-0.37	5.54e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs1448094	0.520	rs12304244	chr12:86272823	C/T	cg19622623	chr12:86230825	RASSF9	-0.5	-6.28	-0.36	1.39e-9	Major depressive disorder;
CESC	cis	rs7546094	1.000	rs11102497	chr1:113109274	T/C	cg22162597	chr1:113214053	CAPZA1	0.37	5.67	0.33	3.69e-8	Platelet distribution width;
CESC	cis	rs7147624	1.000	rs2898816	chr14:66008160	T/C	cg03016385	chr14:66212404	NA	-0.49	-5.09	-0.3	6.95e-7	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs2439831	0.702	rs16977724	chr15:44151299	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.7	7.36	0.41	2.32e-12	Lung cancer in ever smokers;
CESC	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg18765753	chr7:1198926	ZFAND2A	0.37	5.45	0.32	1.17e-7	Longevity;Endometriosis;
CESC	cis	rs7605378	0.528	rs281767	chr2:200823281	C/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.5	5.59	0.32	5.61e-8	Osteoporosis;
CESC	cis	rs9916302	0.904	rs600010	chr17:37433517	T/C	cg00129232	chr17:37814104	STARD3	-0.56	-7.34	-0.41	2.64e-12	Glomerular filtration rate (creatinine);
CESC	cis	rs2832191	0.967	rs2898160	chr21:30487496	A/G	cg08807101	chr21:30365312	RNF160	-0.66	-9.01	-0.48	4.11e-17	Dental caries;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07007080	chr20:44718510	NCOA5	0.55	6.19	0.36	2.3e-9	Gut microbiome composition (summer);
CESC	cis	rs2404602	0.692	rs72738889	chr15:76992063	G/A	cg22467129	chr15:76604101	ETFA	-0.34	-5.11	-0.3	6.27e-7	Blood metabolite levels;
CESC	cis	rs2795502	1.000	rs2795503	chr10:43347224	T/A	cg27426351	chr10:43362370	NA	-0.48	-6.05	-0.35	4.79e-9	Blood protein levels;
CESC	cis	rs17780086	0.527	rs72827711	chr17:30537920	T/A	cg00745463	chr17:30367425	LRRC37B	-0.74	-5.61	-0.33	5.04e-8	Height;
CESC	cis	rs62408225	1.000	rs72925996	chr6:90930513	T/C	cg06866423	chr6:90926672	BACH2	0.45	5.35	0.31	1.88e-7	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs7829975	0.502	rs7820738	chr8:8702607	C/G	cg06636001	chr8:8085503	FLJ10661	-0.42	-5.25	-0.31	3.16e-7	Mood instability;
CESC	cis	rs754466	0.580	rs17516020	chr10:79538734	C/T	cg17075019	chr10:79541650	NA	-0.8	-9.91	-0.52	6.87e-20	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs10463316	0.894	rs869196	chr5:150746287	G/T	cg03212797	chr5:150827313	SLC36A1	-0.47	-6.17	-0.35	2.6e-9	Metabolite levels (Pyroglutamine);
CESC	cis	rs875971	0.638	rs6460305	chr7:66060408	G/A	cg06456125	chr7:65229604	NA	-0.41	-5.41	-0.32	1.4e-7	Aortic root size;
CESC	cis	rs5753618	0.561	rs715510	chr22:31690528	T/A	cg13145458	chr22:31556086	RNF185	0.49	5.47	0.32	1.03e-7	Colorectal cancer;
CESC	cis	rs6088580	0.634	rs2225837	chr20:33005634	C/T	cg06115741	chr20:33292138	TP53INP2	-0.46	-5.98	-0.34	7.28e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs611744	0.647	rs2594357	chr8:109255989	A/G	cg21045802	chr8:109455806	TTC35	0.47	5.75	0.33	2.4e-8	Dupuytren's disease;
CESC	cis	rs12956009	0.583	rs919979	chr18:44902739	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.5	6.56	0.37	2.82e-10	Educational attainment (years of education);
CESC	cis	rs798554	1.000	rs798560	chr7:2758309	A/G	cg09658497	chr7:2847517	GNA12	-0.36	-5.13	-0.3	5.66e-7	Height;
CESC	cis	rs12893668	0.638	rs11851616	chr14:104065600	G/A	cg24130564	chr14:104152367	KLC1	-0.51	-6.46	-0.37	5.02e-10	Reticulocyte count;
CESC	cis	rs7818345	0.845	rs17407039	chr8:19268056	G/A	cg11303988	chr8:19266685	CSGALNACT1	0.38	6.6	0.38	2.2e-10	Language performance in older adults (adjusted for episodic memory);
CESC	cis	rs1401999	1.000	rs6767013	chr3:183680102	G/A	cg01324343	chr3:183735012	ABCC5	0.63	13.54	0.64	4.16e-32	Anterior chamber depth;
CESC	cis	rs2066819	1.000	rs2629447	chr12:56700809	G/A	cg26316697	chr12:56727976	PAN2	-0.69	-6.58	-0.37	2.52e-10	Psoriasis vulgaris;
CESC	cis	rs6500602	0.627	rs6500610	chr16:4529613	A/G	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.36	5.17	0.3	4.59e-7	Schizophrenia;
CESC	cis	rs72901758	0.768	rs56046325	chr17:76251998	G/T	cg26068271	chr17:76253126	NA	0.46	6.54	0.37	3.17e-10	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
CESC	cis	rs4588572	0.643	rs3885254	chr5:77686468	G/A	cg11547950	chr5:77652471	NA	0.42	5.21	0.3	3.89e-7	Triglycerides;
CESC	cis	rs7666738	0.830	rs1426664	chr4:98988264	A/C	cg18180107	chr4:99064573	C4orf37	0.4	5.2	0.3	3.92e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs853679	0.517	rs67878650	chr6:28142587	G/C	cg22143856	chr6:28129313	ZNF389	0.46	5.84	0.34	1.56e-8	Depression;
CESC	cis	rs17376456	0.877	rs10063045	chr5:93457584	A/T	cg25358565	chr5:93447407	FAM172A	1.22	10.94	0.56	3.21e-23	Diabetic retinopathy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20365403	chr8:123793477	ZHX2	-0.59	-7.11	-0.4	1.1e-11	Gut microbiome composition (summer);
CESC	cis	rs3126085	0.877	rs1969019	chr1:152211502	A/C	cg03465714	chr1:152285911	FLG	-0.43	-5.17	-0.3	4.53e-7	Atopic dermatitis;
CESC	cis	rs4629710	0.592	rs67399092	chr6:131582936	G/A	cg12606694	chr6:131520996	AKAP7	0.49	5.9	0.34	1.09e-8	Multiple myeloma (IgH translocation);
CESC	cis	rs801193	0.569	rs11761542	chr7:66218196	G/A	cg10691866	chr7:65817282	TPST1	-0.33	-5.61	-0.33	5.2100000000000003e-08	Aortic root size;
CESC	cis	rs11638352	1.000	rs890465	chr15:44356463	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.5	5.58	0.32	6.01e-8	Lipoprotein phospholipase A2 activity in cardiovascular disease;
CESC	cis	rs5769765	0.740	rs2103932	chr22:50272515	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.44	5.16	0.3	4.76e-7	Schizophrenia;
CESC	cis	rs123509	0.687	rs73077214	chr3:42838020	G/A	cg12982090	chr3:42733453	KBTBD5	-0.66	-7.52	-0.42	8.26e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs9863	0.828	rs4765541	chr12:124465995	T/C	cg00084347	chr12:124393913	DNAH10	0.27	5.21	0.3	3.88e-7	White blood cell count;
CESC	cis	rs9926296	0.568	rs4420527	chr16:89814188	C/T	cg21285383	chr16:89894308	SPIRE2	-0.31	-5.51	-0.32	8.63e-8	Vitiligo;
CESC	cis	rs854765	0.583	rs9912895	chr17:17826020	C/T	cg04398451	chr17:18023971	MYO15A	0.67	9.64	0.51	4.71e-19	Total body bone mineral density;
CESC	cis	rs13108904	0.518	rs4974603	chr4:1343168	C/T	cg22903657	chr4:1355424	KIAA1530	-0.37	-5.08	-0.3	7.13e-7	Obesity-related traits;
CESC	cis	rs3733585	0.781	rs6449183	chr4:9970691	C/A	cg00071950	chr4:10020882	SLC2A9	-0.77	-13.79	-0.65	5.54e-33	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs3820068	0.705	rs4646072	chr1:15827711	G/A	cg17385448	chr1:15911702	AGMAT	0.4	6.14	0.35	3.04e-9	Systolic blood pressure;
CESC	cis	rs7647973	0.667	rs4241405	chr3:49642027	C/T	cg07636037	chr3:49044803	WDR6	0.61	7.16	0.4	8.07e-12	Menarche (age at onset);
CESC	cis	rs12325245	0.536	rs12709002	chr16:58614337	A/C	cg05725404	chr16:58534157	NDRG4	-0.61	-5.24	-0.31	3.35e-7	Schizophrenia;
CESC	cis	rs11239930	0.538	rs4950359	chr1:146558743	C/A	cg16700924	chr1:146552102	NA	-0.38	-5.04	-0.3	8.56e-7	AIDS progression;
CESC	trans	rs1814175	0.645	rs11040699	chr11:50023798	C/G	cg03929089	chr4:120376271	NA	-0.91	-14.8	-0.67	1.58e-36	Height;
CESC	cis	rs6430585	0.528	rs79826902	chr2:136670419	G/A	cg07169764	chr2:136633963	MCM6	1.23	16.56	0.71	8.67e-43	Corneal structure;
CESC	cis	rs769267	0.965	rs4808937	chr19:19398005	A/G	cg03709012	chr19:19516395	GATAD2A	0.95	13.98	0.65	1.22e-33	Tonsillectomy;
CESC	cis	rs9325144	0.555	rs1973292	chr12:38679626	T/C	cg26384229	chr12:38710491	ALG10B	0.58	8.32	0.45	4.83e-15	Morning vs. evening chronotype;
CESC	cis	rs9815354	1.000	rs7632387	chr3:41853161	C/T	cg03022575	chr3:42003672	ULK4	0.54	5.78	0.33	2.06e-8	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs270601	0.690	rs162907	chr5:131580152	A/G	cg18758796	chr5:131593413	PDLIM4	-0.44	-6.13	-0.35	3.16e-9	Acylcarnitine levels;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg01945625	chr16:1437845	NA	0.43	6.2	0.36	2.1e-9	Fibrinogen levels;
CESC	cis	rs28386778	0.863	rs3760252	chr17:61852186	G/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.54	6.7	0.38	1.25e-10	Prudent dietary pattern;
CESC	cis	rs3916	0.688	rs9204	chr12:121177778	A/G	cg21892295	chr12:121157589	UNC119B	-0.34	-5.13	-0.3	5.71e-7	Urinary metabolites (H-NMR features);
CESC	cis	rs11191205	0.774	rs11191203	chr10:103824920	C/T	cg15320455	chr10:103880129	LDB1	0.76	6.58	0.37	2.44e-10	Intelligence (multi-trait analysis);
CESC	cis	rs11098499	0.954	rs10031665	chr4:120422852	T/C	cg24375607	chr4:120327624	NA	0.46	5.66	0.33	3.87e-8	Corneal astigmatism;
CESC	cis	rs2228479	0.571	rs62052183	chr16:89966921	C/A	cg04013166	chr16:89971882	TCF25	0.76	6.94	0.39	3.06e-11	Skin colour saturation;
CESC	cis	rs854765	0.583	rs12452254	chr17:17829434	G/A	cg04398451	chr17:18023971	MYO15A	-0.65	-9.23	-0.49	9.1e-18	Total body bone mineral density;
CESC	cis	rs1448094	0.512	rs6539933	chr12:86247611	T/C	cg02569458	chr12:86230093	RASSF9	0.49	7.27	0.41	4.07e-12	Major depressive disorder;
CESC	cis	rs8044868	0.586	rs8182213	chr16:72080005	C/T	cg01557791	chr16:72042693	DHODH	-0.43	-5.89	-0.34	1.17e-8	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CESC	cis	rs6582630	0.519	rs11495373	chr12:38275470	T/C	cg13010199	chr12:38710504	ALG10B	0.48	6.04	0.35	5.23e-9	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs7249142	0.549	rs62135499	chr19:19294237	T/C	cg27384695	chr19:19271486	LOC729991-MEF2B;MEF2B	0.31	5.74	0.33	2.58e-8	IgG glycosylation;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg01213128	chr5:138629571	MATR3	-0.46	-6.54	-0.37	3.14e-10	Fibrinogen levels;
CESC	cis	rs910316	0.737	rs175045	chr14:75475275	A/C	cg11812906	chr14:75593930	NEK9	-0.77	-11.23	-0.57	3.41e-24	Height;
CESC	cis	rs514406	0.929	rs1242224	chr1:53314887	G/A	cg08859206	chr1:53392774	SCP2	-0.65	-8.86	-0.48	1.22e-16	Monocyte count;
CESC	cis	rs3026101	0.671	rs2107151	chr17:5297338	G/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.43	5.68	0.33	3.57e-8	Body mass index;
CESC	cis	rs9916302	0.707	rs11078903	chr17:37631924	G/A	cg00129232	chr17:37814104	STARD3	-0.53	-6.91	-0.39	3.67e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs4237845	0.537	rs1599931	chr12:58258850	A/G	cg02175503	chr12:58329896	NA	0.49	5.82	0.34	1.69e-8	Intelligence (multi-trait analysis);
CESC	cis	rs7412746	0.658	rs7528773	chr1:150915875	G/A	cg04414720	chr1:150670196	GOLPH3L	0.52	6.88	0.39	4.32e-11	Melanoma;
CESC	cis	rs6502050	0.835	rs7405738	chr17:80084227	A/G	cg11859384	chr17:80120422	CCDC57	0.38	5.12	0.3	6.01e-7	Life satisfaction;
CESC	cis	rs9911578	1.000	rs12947785	chr17:57045160	A/C	cg12560992	chr17:57184187	TRIM37	0.92	15.24	0.68	4.34e-38	Intelligence (multi-trait analysis);
CESC	cis	rs17376456	1.000	rs13154249	chr5:93550508	C/T	cg25358565	chr5:93447407	FAM172A	1.15	11.09	0.56	1.02e-23	Diabetic retinopathy;
CESC	cis	rs933688	1.000	rs889213	chr5:90682151	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.18	14.27	0.66	1.16e-34	Smoking behavior;
CESC	cis	rs2066819	1.000	rs76430365	chr12:56699993	A/C	cg26804944	chr12:56660921	COQ10A	-0.85	-5.14	-0.3	5.39e-7	Psoriasis vulgaris;
CESC	cis	rs7833986	0.501	rs2953922	chr8:56977485	G/A	cg26371346	chr8:56986568	SNORD54;RPS20	0.57	5.16	0.3	4.9e-7	Height;
CESC	cis	rs2276314	1.000	rs8086395	chr18:33564592	C/G	cg19628046	chr18:33552617	C18orf21	0.55	6.03	0.35	5.49e-9	Endometriosis;Drug-induced torsades de pointes;
CESC	trans	rs931812	0.825	rs6993937	chr8:101898707	A/G	cg20993868	chr7:22813445	NA	0.54	7.69	0.43	2.84e-13	Attention deficit hyperactivity disorder and conduct disorder;
CESC	cis	rs3820068	0.603	rs1980607	chr1:15975237	A/G	cg17385448	chr1:15911702	AGMAT	0.41	6.93	0.39	3.24e-11	Systolic blood pressure;
CESC	trans	rs561341	1.000	rs7214017	chr17:30332220	T/C	cg27661571	chr11:113659931	NA	-0.7	-7.23	-0.41	5.2e-12	Hip circumference adjusted for BMI;
CESC	cis	rs11792861	0.591	rs7027874	chr9:111717112	A/G	cg13535736	chr9:111863775	C9orf5	-0.39	-5.72	-0.33	2.92e-8	Menarche (age at onset);
CESC	cis	rs77741769	0.571	rs11065284	chr12:121266621	G/A	cg02419362	chr12:121203948	SPPL3	0.33	5.43	0.32	1.31e-7	Mean corpuscular volume;
CESC	cis	rs2070488	0.662	rs6599203	chr3:38487802	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.69	8.95	0.48	6.3e-17	Electrocardiographic conduction measures;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg17157516	chr1:35332203	DLGAP3	0.45	6.07	0.35	4.37e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs4889855	0.545	rs61171555	chr17:78465975	T/G	cg16591659	chr17:78472290	NA	-0.52	-7.67	-0.43	3.36e-13	Fractional excretion of uric acid;
CESC	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.92	13.64	0.64	1.92e-32	Prudent dietary pattern;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27426082	chr6:122720652	HSF2	0.59	6.22	0.36	1.9e-9	Gut microbiome composition (summer);
CESC	cis	rs4523957	0.614	rs7217108	chr17:2059408	G/C	cg16513277	chr17:2031491	SMG6	-0.69	-9.59	-0.51	6.97e-19	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs9858542	0.537	rs9873994	chr3:49359943	T/C	cg00383909	chr3:49044727	WDR6	0.56	5.07	0.3	7.53e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs9733	0.596	rs12089731	chr1:150647798	T/C	cg04414720	chr1:150670196	GOLPH3L	0.63	9.02	0.48	3.87e-17	Tonsillectomy;
CESC	cis	rs11676348	0.811	rs4674255	chr2:218987325	C/T	cg00012203	chr2:219082015	ARPC2	-0.57	-7.46	-0.42	1.27e-12	Ulcerative colitis;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg08265551	chr1:151032119	CDC42SE1;MLLT11	-0.47	-6.23	-0.36	1.83e-9	Ulcerative colitis;
CESC	cis	rs7605827	0.930	rs4668449	chr2:15530141	T/C	cg19274914	chr2:15703543	NA	0.36	6.43	0.37	6.02e-10	Educational attainment (years of education);
CESC	cis	rs6987853	0.933	rs2974355	chr8:42414117	C/T	cg09913449	chr8:42400586	C8orf40	0.4	6.35	0.36	9.55e-10	Mean corpuscular hemoglobin concentration;
CESC	cis	rs765787	0.530	rs28756676	chr15:45540360	G/A	cg24006582	chr15:45444508	DUOX1	-0.59	-7.32	-0.41	3.04e-12	Uric acid levels;
CESC	cis	rs798554	0.796	rs2533884	chr7:2836848	T/G	cg19346786	chr7:2764209	NA	-0.52	-7.44	-0.42	1.44e-12	Height;
CESC	cis	rs780096	0.526	rs704791	chr2:27657167	T/C	cg24768116	chr2:27665128	KRTCAP3	-0.3	-5.57	-0.32	6.2e-8	Total body bone mineral density;
CESC	cis	rs950776	0.518	rs2292117	chr15:78834689	C/T	cg24631222	chr15:78858424	CHRNA5	-0.4	-5.15	-0.3	5.02e-7	Sudden cardiac arrest;
CESC	cis	rs9916302	0.800	rs11869259	chr17:37518141	C/A	cg00129232	chr17:37814104	STARD3	0.59	7.82	0.43	1.22e-13	Glomerular filtration rate (creatinine);
CESC	cis	rs2635047	0.638	rs9956809	chr18:44655843	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.4	5.51	0.32	8.4e-8	Educational attainment;
CESC	cis	rs9640161	0.789	rs1464752	chr7:150021284	C/T	cg13722127	chr7:150037890	RARRES2	0.34	5.11	0.3	6.29e-7	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs262150	1.000	rs262154	chr7:158773936	G/A	cg09640425	chr7:158790006	NA	-0.37	-5.65	-0.33	4.21e-8	Facial morphology (factor 20);
CESC	cis	rs12995491	0.933	rs34029976	chr2:88537797	T/C	cg14558114	chr2:88469736	THNSL2	-0.49	-7.13	-0.4	9.46e-12	Response to metformin (IC50);
CESC	cis	rs3540	0.574	rs8035980	chr15:90974390	C/G	cg22089800	chr15:90895588	ZNF774	0.62	8.56	0.47	9.01e-16	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	trans	rs11098499	0.909	rs73842633	chr4:120375464	G/A	cg25214090	chr10:38739885	LOC399744	0.71	9.48	0.5	1.51e-18	Corneal astigmatism;
CESC	cis	rs933688	1.000	rs332544	chr5:90778848	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.84	10.99	0.56	2.12e-23	Smoking behavior;
CESC	cis	rs7131987	1.000	rs7131987	chr12:29406488	G/T	cg09582351	chr12:29534625	ERGIC2	-0.33	-5.42	-0.32	1.34e-7	QT interval;
CESC	cis	rs875971	0.660	rs10950044	chr7:66042976	A/G	cg11764359	chr7:65958608	NA	-0.73	-9.77	-0.51	1.93e-19	Aortic root size;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg05383670	chr11:64879206	TM7SF2	-0.41	-6.28	-0.36	1.37e-9	Gambling;
CESC	cis	rs5753618	0.539	rs2228619	chr22:31663842	C/G	cg13145458	chr22:31556086	RNF185	0.48	5.35	0.31	1.88e-7	Colorectal cancer;
CESC	cis	rs11587400	0.514	rs222499	chr1:115146488	C/A	cg12756093	chr1:115239321	AMPD1	-0.41	-5.54	-0.32	7.18e-8	Autism;
CESC	cis	rs8070128	0.534	rs2955350	chr17:17953548	G/A	cg04398451	chr17:18023971	MYO15A	0.73	10.55	0.54	5.95e-22	Total body bone mineral density;
CESC	cis	rs561341	1.000	rs55978022	chr17:30275937	T/C	cg12193833	chr17:30244370	NA	-0.79	-7.22	-0.41	5.57e-12	Hip circumference adjusted for BMI;
CESC	cis	rs977987	0.843	rs17696749	chr16:75403062	C/G	cg03315344	chr16:75512273	CHST6	0.4	5.77	0.33	2.26e-8	Dupuytren's disease;
CESC	cis	rs1552244	0.816	rs56271597	chr3:10042790	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.87	11.4	0.57	9.22e-25	Alzheimer's disease;
CESC	cis	rs11098499	0.863	rs10018280	chr4:120478139	T/G	cg09307838	chr4:120376055	NA	0.9	12.46	0.61	2.29e-28	Corneal astigmatism;
CESC	cis	rs2842992	0.830	rs1475123	chr6:160178007	A/G	cg11366901	chr6:160182831	ACAT2	0.76	8.82	0.48	1.57e-16	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg26338869	chr17:61819248	STRADA	0.69	9.08	0.49	2.62e-17	Prudent dietary pattern;
CESC	cis	rs2228479	0.850	rs17233567	chr16:89813821	G/A	cg19635926	chr16:89946313	TCF25	0.68	5.17	0.3	4.67e-7	Skin colour saturation;
CESC	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg22535103	chr8:58192502	C8orf71	-0.93	-10.32	-0.54	3.27e-21	Developmental language disorder (linguistic errors);
CESC	cis	rs35110281	0.748	rs162403	chr21:44963365	C/G	cg01579765	chr21:45077557	HSF2BP	-0.55	-9.17	-0.49	1.4e-17	Mean corpuscular volume;
CESC	cis	rs7084402	0.967	rs1658480	chr10:60289374	C/G	cg07615347	chr10:60278583	BICC1	0.61	9.68	0.51	3.68e-19	Refractive error;
CESC	cis	rs12497850	0.863	rs4858799	chr3:48728204	G/C	cg07636037	chr3:49044803	WDR6	0.92	15.42	0.69	1.03e-38	Parkinson's disease;
CESC	cis	rs796364	0.951	rs971232	chr2:200792881	C/T	cg23649088	chr2:200775458	C2orf69	0.55	5.24	0.31	3.29e-7	Schizophrenia;
CESC	cis	rs7216064	1.000	rs7216064	chr17:65898809	G/A	cg07042672	chr17:66097459	LOC651250	-0.55	-5.96	-0.34	8.12e-9	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs3091242	0.933	rs932372	chr1:25755014	G/A	cg02931644	chr1:25747376	RHCE	0.42	7.0	0.4	2.06e-11	Erythrocyte sedimentation rate;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11312980	chr14:64931897	AKAP5	-0.64	-7.99	-0.44	4.13e-14	Gut microbiome composition (summer);
CESC	cis	rs9649213	0.593	rs7796611	chr7:97908223	A/G	cg24562669	chr7:97807699	LMTK2	0.49	6.98	0.39	2.41e-11	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs909002	0.849	rs10914453	chr1:32075036	A/G	cg13919466	chr1:32135498	COL16A1	-0.48	-8.47	-0.46	1.66e-15	Intelligence (multi-trait analysis);
CESC	cis	rs2708240	1.000	rs2538983	chr7:147581837	C/T	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.34	-5.55	-0.32	7.07e-8	QT interval (drug interaction);
CESC	cis	rs2228479	0.717	rs2286392	chr16:89809549	A/G	cg27121462	chr16:89883253	FANCA	0.63	5.51	0.32	8.36e-8	Skin colour saturation;
CESC	cis	rs4713118	0.586	rs6905522	chr6:28086479	A/C	cg18032046	chr6:28092343	ZSCAN16	-0.58	-6.75	-0.38	9.45e-11	Parkinson's disease;
CESC	cis	rs4728302	0.869	rs2059298	chr7:133603245	C/G	cg10665199	chr7:133106180	EXOC4	0.4	5.56	0.32	6.62e-8	Intelligence;Intelligence (multi-trait analysis);
CESC	cis	rs7618501	0.633	rs2353579	chr3:50027774	C/T	cg24308560	chr3:49941425	MST1R	-0.63	-9.14	-0.49	1.64e-17	Intelligence (multi-trait analysis);
CESC	cis	rs4665809	0.652	rs6728090	chr2:26524726	C/T	cg26314531	chr2:26401878	FAM59B	-0.59	-6.07	-0.35	4.5e-9	Gut microbiome composition (summer);
CESC	cis	rs9467711	0.516	rs1324088	chr6:25841122	C/T	cg08501292	chr6:25962987	TRIM38	0.54	5.88	0.34	1.2e-8	Autism spectrum disorder or schizophrenia;
CESC	cis	rs7618915	0.547	rs34610878	chr3:52759169	G/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.31	5.49	0.32	9.47e-8	Bipolar disorder;
CESC	cis	rs11030122	0.687	rs10835521	chr11:4056004	A/T	cg18678763	chr11:4115507	RRM1	-0.44	-6.0	-0.35	6.52e-9	Mean platelet volume;Platelet distribution width;
CESC	cis	rs1008375	0.932	rs6449321	chr4:17644472	A/G	cg16339924	chr4:17578868	LAP3	0.63	8.03	0.44	3.2e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg00989853	chr1:209979345	IRF6	0.36	6.5	0.37	3.93e-10	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
CESC	cis	rs9287719	0.967	rs12995602	chr2:10753542	C/A	cg02196655	chr2:10830764	NOL10	-0.37	-5.69	-0.33	3.39e-8	Prostate cancer;
CESC	cis	rs9486719	1.000	rs2499804	chr6:96861216	A/G	cg18709589	chr6:96969512	KIAA0776	0.49	5.45	0.32	1.15e-7	Migraine;Coronary artery disease;
CESC	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg24829409	chr8:58192753	C8orf71	-0.61	-7.02	-0.4	1.9e-11	Developmental language disorder (linguistic errors);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20650035	chr12:29542837	NA	-0.63	-7.73	-0.43	2.29e-13	Gut microbiome composition (summer);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg11161882	chr1:228594712	TRIM11	-0.51	-6.07	-0.35	4.33e-9	Ulcerative colitis;
CESC	cis	rs3015497	0.616	rs4901044	chr14:51090295	A/G	cg09863266	chr14:51125203	SAV1	-0.32	-5.06	-0.3	7.7300000000000005e-07	Mean platelet volume;
CESC	trans	rs561341	1.000	rs4795667	chr17:30244443	T/C	cg20587970	chr11:113659929	NA	-1.11	-13.67	-0.64	1.52e-32	Hip circumference adjusted for BMI;
CESC	cis	rs7267979	0.903	rs2500423	chr20:25374882	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.84	-15.92	-0.7	1.72e-40	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs2075371	1.000	rs2544210	chr7:133971535	C/T	cg00033643	chr7:134001901	SLC35B4	0.4	5.13	0.3	5.53e-7	Mean platelet volume;
CESC	cis	rs2243480	0.901	rs3813708	chr7:65305632	C/A	cg25894440	chr7:65020034	NA	-0.65	-5.57	-0.32	6.4e-8	Diabetic kidney disease;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg12977448	chr10:14920832	SUV39H2	-0.49	-6.64	-0.38	1.78e-10	Height;
CESC	trans	rs629535	0.862	rs638412	chr8:70047690	C/T	cg21567404	chr3:27674614	NA	0.93	11.25	0.57	2.83e-24	Dupuytren's disease;
CESC	cis	rs9291683	0.588	rs4697705	chr4:10108127	G/A	cg11266682	chr4:10021025	SLC2A9	-0.47	-8.47	-0.46	1.74e-15	Bone mineral density;
CESC	cis	rs10504229	0.683	rs57866073	chr8:58139138	A/G	cg21724239	chr8:58056113	NA	0.58	5.95	0.34	8.45e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs9430161	0.579	rs9659356	chr1:11034817	A/G	cg02454025	chr1:11042201	C1orf127	0.96	15.62	0.69	1.91e-39	Ewing sarcoma;
CESC	cis	rs56046484	0.956	rs12908535	chr15:85601525	C/G	cg08123816	chr15:85640762	PDE8A	-0.51	-6.28	-0.36	1.36e-9	Testicular germ cell tumor;
CESC	cis	rs2573652	0.674	rs11630619	chr15:100543367	G/A	cg09918751	chr15:100517450	ADAMTS17	-0.3	-5.57	-0.32	6.12e-8	Height;
CESC	cis	rs9905704	0.836	rs12952429	chr17:56843070	C/T	cg12560992	chr17:57184187	TRIM37	0.63	7.72	0.43	2.41e-13	Testicular germ cell tumor;
CESC	cis	rs4409675	0.576	rs6662916	chr1:28219873	G/T	cg23691781	chr1:28212827	C1orf38	0.3	5.92	0.34	1.02e-8	Corneal astigmatism;
CESC	cis	rs3008870	0.755	rs1570838	chr1:67403315	C/T	cg02640540	chr1:67518911	SLC35D1	0.46	5.58	0.32	5.81e-8	Lymphocyte percentage of white cells;
CESC	cis	rs35306767	0.855	rs2050944	chr10:918910	T/C	cg25019033	chr10:957182	NA	-0.58	-6.18	-0.35	2.45e-9	Eosinophil percentage of granulocytes;
CESC	cis	rs9467773	0.620	rs9467810	chr6:26608261	A/C	cg20266910	chr6:26577678	NA	0.35	5.85	0.34	1.44e-8	Intelligence (multi-trait analysis);
CESC	cis	rs2251381	0.750	rs2255055	chr21:30537045	C/T	cg08807101	chr21:30365312	RNF160	0.66	8.21	0.45	9.48e-15	Selective IgA deficiency;
CESC	cis	rs10752881	0.935	rs3935221	chr1:182969010	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.86	13.7	0.64	1.16e-32	Colorectal cancer;
CESC	cis	rs919433	1.000	rs1429414	chr2:198162430	C/T	cg03934865	chr2:198174659	NA	-0.43	-6.26	-0.36	1.55e-9	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs11690961	0.627	rs11690238	chr2:46371723	C/T	cg12428440	chr2:46370979	PRKCE	-0.51	-5.46	-0.32	1.1e-7	Pulse pressure;
CESC	cis	rs4253772	0.515	rs9615968	chr22:46772695	A/G	cg00784671	chr22:46762841	CELSR1	-0.71	-5.98	-0.34	7.38e-9	LDL cholesterol;Cholesterol, total;
CESC	cis	rs1712517	0.588	rs12220267	chr10:105075712	C/T	cg04362960	chr10:104952993	NT5C2	-0.46	-5.49	-0.32	9.22e-8	Migraine;
CESC	cis	rs9354308	0.834	rs12212376	chr6:66598879	T/C	cg07460842	chr6:66804631	NA	0.62	7.1	0.4	1.16e-11	Metabolite levels;
CESC	cis	rs6537837	0.793	rs12045311	chr1:110087405	T/C	cg05049280	chr1:110155535	GNAT2	0.39	5.56	0.32	6.71e-8	Major depressive disorder;
CESC	cis	rs3736594	0.765	rs12994085	chr2:27952406	C/T	cg27432699	chr2:27873401	GPN1	-0.37	-5.14	-0.3	5.32e-7	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CESC	cis	rs1018836	0.828	rs4735236	chr8:91583909	A/G	cg16814680	chr8:91681699	NA	-0.67	-9.74	-0.51	2.4e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs2777491	1.000	rs316610	chr15:41752852	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.65	-9.9	-0.52	7.01e-20	Ulcerative colitis;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg25632300	chr5:174905618	SFXN1	0.44	6.08	0.35	4.08e-9	Height;
CESC	cis	rs10911232	0.560	rs10911221	chr1:183046737	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.82	12.63	0.61	6.02e-29	Hypertriglyceridemia;
CESC	cis	rs7107174	1.000	rs4945268	chr11:78037936	T/C	cg02023728	chr11:77925099	USP35	0.52	6.86	0.39	4.74e-11	Testicular germ cell tumor;
CESC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg23260799	chr11:451101	PTDSS2	0.48	6.08	0.35	4.12e-9	Tetralogy of Fallot;
CESC	cis	rs524281	0.731	rs3829937	chr11:65787666	G/A	cg14036092	chr11:66035641	RAB1B	-0.63	-5.73	-0.33	2.79e-8	Electroencephalogram traits;
CESC	cis	rs3733585	0.699	rs28613263	chr4:9964880	C/T	cg02734326	chr4:10020555	SLC2A9	-0.43	-6.01	-0.35	6.1e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs6582630	0.593	rs7134006	chr12:38596245	A/C	cg26384229	chr12:38710491	ALG10B	0.73	10.91	0.56	4.06e-23	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs16854884	0.537	rs16855026	chr3:143868350	A/C	cg06585982	chr3:143692056	C3orf58	0.45	5.76	0.33	2.37e-8	Economic and political preferences (feminism/equality);
CESC	cis	rs765787	0.530	rs11636410	chr15:45535913	A/C	cg24006582	chr15:45444508	DUOX1	0.57	6.76	0.38	8.71e-11	Uric acid levels;
CESC	cis	rs6860806	0.507	rs273917	chr5:131659618	A/G	cg07395648	chr5:131743802	NA	-0.44	-5.82	-0.34	1.71e-8	Breast cancer;
CESC	cis	rs4555082	0.874	rs2816613	chr14:105726367	C/T	cg10792982	chr14:105748885	BRF1	0.41	5.26	0.31	2.96e-7	Mean platelet volume;Platelet distribution width;
CESC	cis	rs5753618	0.583	rs9606843	chr22:31853371	A/C	cg13145458	chr22:31556086	RNF185	-0.51	-5.97	-0.34	7.59e-9	Colorectal cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08470759	chr2:95825297	ZNF514	0.61	7.04	0.4	1.63e-11	Gut microbiome composition (summer);
CESC	cis	rs13191362	0.935	rs34347104	chr6:163055716	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.87	8.79	0.47	1.98e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs6570726	0.764	rs9403731	chr6:145907937	G/A	cg05347473	chr6:146136440	FBXO30	0.55	7.2	0.4	6.24e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2842992	0.830	rs2495279	chr6:160138796	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.69	9.01	0.48	4.25e-17	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs3096299	0.746	rs9931120	chr16:89501357	A/G	cg08392591	chr16:89556376	ANKRD11	0.51	6.6	0.38	2.18e-10	Multiple myeloma (IgH translocation);
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg13495167	chr12:114395501	RBM19	0.5	6.35	0.36	9.18e-10	Cleft plate (environmental tobacco smoke interaction);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg07881228	chr7:30068068	PLEKHA8	-0.42	-6.05	-0.35	5.05e-9	Fibrinogen levels;
CESC	cis	rs7116495	0.737	rs670802	chr11:71799668	A/C	cg26138937	chr11:71823887	C11orf51	-0.84	-6.76	-0.38	8.55e-11	Severe influenza A (H1N1) infection;
CESC	cis	rs3087591	0.960	rs9896041	chr17:29571326	C/G	cg24425628	chr17:29625626	OMG;NF1	-0.42	-5.03	-0.3	9.19e-7	Hip circumference;
CESC	cis	rs5769765	0.955	rs9616366	chr22:50301178	C/T	cg02269571	chr22:50332266	NA	-0.49	-6.5	-0.37	4.02e-10	Schizophrenia;
CESC	cis	rs4555082	1.000	rs7146683	chr14:105759385	A/G	cg06808227	chr14:105710500	BRF1	-0.54	-6.74	-0.38	9.61e-11	Mean platelet volume;Platelet distribution width;
CESC	cis	rs10751667	0.643	rs10902237	chr11:944801	C/A	cg06064525	chr11:970664	AP2A2	-0.54	-10.94	-0.56	3.16e-23	Alzheimer's disease (late onset);
CESC	cis	rs9322193	0.962	rs13215691	chr6:150113802	T/C	cg07701084	chr6:150067640	NUP43	0.4	5.51	0.32	8.53e-8	Lung cancer;
CESC	cis	rs1949733	0.523	rs16842560	chr4:8544238	G/A	cg11789530	chr4:8429930	ACOX3	-0.57	-7.06	-0.4	1.43e-11	Response to antineoplastic agents;
CESC	cis	rs7818345	0.904	rs11780388	chr8:19271554	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.32	5.6	0.33	5.44e-8	Language performance in older adults (adjusted for episodic memory);
CESC	cis	rs1577917	1.000	rs1999852	chr6:86705738	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-6.43	-0.37	5.9e-10	Response to antipsychotic treatment;
CESC	cis	rs4568518	0.740	rs10428925	chr7:18009205	T/G	cg03009463	chr7:17980271	SNX13	0.46	6.0	0.35	6.45e-9	Measles;
CESC	cis	rs7507204	0.530	rs4807470	chr19:3443470	A/T	cg08380311	chr19:3435252	NFIC	0.8	12.3	0.6	8.38e-28	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24688909	chr22:47059079	GRAMD4	-0.66	-7.92	-0.44	6.49e-14	Gut microbiome composition (summer);
CESC	cis	rs9287719	0.967	rs759403	chr2:10729897	C/T	cg02196655	chr2:10830764	NOL10	-0.36	-5.57	-0.32	6.1e-8	Prostate cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09260951	chr22:39096513	JOSD1	0.57	6.57	0.37	2.6e-10	Gut microbiome composition (summer);
CESC	cis	rs2516839	0.605	rs12749496	chr1:161021893	G/C	cg11161846	chr1:160990452	F11R	-0.39	-5.3	-0.31	2.42e-7	Granulocyte percentage of myeloid white cells;
CESC	cis	rs9581857	0.556	rs9579085	chr13:28041039	G/A	cg22138327	chr13:27999177	GTF3A	0.65	7.19	0.4	6.76e-12	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
CESC	cis	rs6748734	1.000	rs6751693	chr2:241837332	T/C	cg07537917	chr2:241836409	C2orf54	-0.26	-5.45	-0.32	1.17e-7	Urinary metabolites;
CESC	cis	rs10242455	0.702	rs7794068	chr7:99146873	A/T	cg25640893	chr7:99214727	ZNF498	0.76	5.92	0.34	9.75e-9	Blood metabolite levels;
CESC	cis	rs2832191	0.716	rs1888439	chr21:30454457	A/G	cg24692254	chr21:30365293	RNF160	0.97	16.85	0.72	8.59e-44	Dental caries;
CESC	cis	rs7918232	0.941	rs7096505	chr10:27326999	T/C	cg14442939	chr10:27389572	ANKRD26	0.62	5.98	0.34	7.18e-9	Breast cancer;
CESC	cis	rs6598955	0.670	rs7520517	chr1:26556385	A/C	cg04990556	chr1:26633338	UBXN11	-0.76	-10.75	-0.55	1.34e-22	Obesity-related traits;
CESC	cis	rs2228479	0.557	rs11648881	chr16:89862434	T/C	cg06558623	chr16:89946397	TCF25	1.13	8.85	0.48	1.3e-16	Skin colour saturation;
CESC	cis	rs9987353	0.566	rs34491841	chr8:9065510	C/A	cg06636001	chr8:8085503	FLJ10661	-0.6	-7.09	-0.4	1.24e-11	Recombination measurement;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg09921884	chr19:1138906	SBNO2	0.45	6.09	0.35	3.92e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs9467711	0.659	rs66757203	chr6:26454956	C/T	cg14345882	chr6:26364793	BTN3A2	0.64	5.28	0.31	2.67e-7	Autism spectrum disorder or schizophrenia;
CESC	trans	rs757081	0.606	rs679201	chr11:17200891	T/C	cg00391031	chr10:72237473	KIAA1274	0.31	6.05	0.35	4.99e-9	Systolic blood pressure;
CESC	trans	rs1814175	0.645	rs11040699	chr11:50023798	C/G	cg15704280	chr7:45808275	SEPT13	-1.0	-18.54	-0.75	9.01e-50	Height;
CESC	cis	rs1499972	0.941	rs62263115	chr3:117622116	G/A	cg07612923	chr3:117604196	NA	0.88	7.62	0.42	4.47e-13	Schizophrenia;
CESC	cis	rs3741151	0.686	rs7118982	chr11:73110668	T/C	cg17517138	chr11:73019481	ARHGEF17	0.72	6.09	0.35	4.05e-9	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs4555082	0.872	rs7153832	chr14:105730563	G/T	cg10792982	chr14:105748885	BRF1	0.4	5.38	0.31	1.64e-7	Mean platelet volume;Platelet distribution width;
CESC	cis	rs28489187	0.597	rs1001604	chr1:85879524	C/G	cg16011679	chr1:85725395	C1orf52	-0.43	-5.1	-0.3	6.49e-7	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	cis	rs1941023	0.568	rs1373064	chr11:60168200	C/T	cg08716584	chr11:60157161	MS4A7	-0.55	-9.03	-0.48	3.7e-17	Congenital heart disease (maternal effect);
CESC	cis	rs861020	0.606	rs695140	chr1:210005061	G/A	cg05527609	chr1:210001259	C1orf107	0.74	9.67	0.51	3.97e-19	Orofacial clefts;
CESC	cis	rs926938	0.527	rs360679	chr1:115494121	G/T	cg12756093	chr1:115239321	AMPD1	0.46	6.37	0.36	8.1e-10	Autism;
CESC	cis	rs72634258	0.945	rs7522911	chr1:8097145	C/T	cg00042356	chr1:8021962	PARK7	0.8	7.14	0.4	9.2e-12	Inflammatory bowel disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05747105	chr6:53224391	NA	0.63	7.77	0.43	1.73e-13	Gut microbiome composition (summer);
CESC	cis	rs9910055	0.615	rs189049	chr17:42197213	A/C	cg13607699	chr17:42295918	UBTF	-0.6	-7.85	-0.43	1.06e-13	Total body bone mineral density;
CESC	cis	rs9908102	0.740	rs8079600	chr17:12910706	T/C	cg26162695	chr17:12921313	ELAC2	0.52	5.71	0.33	3.04e-8	Schizophrenia;
CESC	cis	rs7615952	0.599	rs66532274	chr3:125731845	G/A	cg15145296	chr3:125709740	NA	-0.47	-5.22	-0.31	3.63e-7	Blood pressure (smoking interaction);
CESC	cis	rs2412208	0.585	rs11120824	chr1:7113591	G/A	cg20434152	chr1:7120926	CAMTA1	-0.32	-5.14	-0.3	5.27e-7	Survival in sporadic amyotrophic lateral sclerosis;
CESC	cis	rs798554	0.797	rs1182183	chr7:2873136	C/T	cg09658497	chr7:2847517	GNA12	-0.44	-6.51	-0.37	3.81e-10	Height;
CESC	cis	rs2836974	0.899	rs34978594	chr21:40580003	C/T	cg17971929	chr21:40555470	PSMG1	1.07	16.31	0.71	7.07e-42	Cognitive function;
CESC	cis	rs9303401	0.734	rs8073316	chr17:57211381	A/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.65	-8.25	-0.45	7.64e-15	Cognitive test performance;
CESC	cis	rs3858526	0.917	rs10769386	chr11:5973420	C/T	cg05234568	chr11:5960015	NA	0.51	5.8	0.34	1.84e-8	DNA methylation (variation);
CESC	cis	rs66530629	0.874	rs1890449	chr1:25075801	G/T	cg22509179	chr1:25234806	RUNX3	0.42	5.38	0.31	1.66e-7	Plateletcrit;
CESC	cis	rs2066819	0.901	rs773665	chr12:56717466	C/T	cg26316697	chr12:56727976	PAN2	-0.69	-6.58	-0.37	2.52e-10	Psoriasis vulgaris;
CESC	cis	rs965469	0.779	rs6051772	chr20:3328654	C/G	cg17110299	chr20:3385021	C20orf194	0.4	5.25	0.31	3.1e-7	IFN-related cytopenia;
CESC	cis	rs4835473	0.800	rs1849117	chr4:144910944	C/T	cg25736465	chr4:144833511	NA	0.41	6.3	0.36	1.2e-9	Immature fraction of reticulocytes;
CESC	cis	rs10504229	1.000	rs17216648	chr8:58169429	C/T	cg24829409	chr8:58192753	C8orf71	-0.76	-9.96	-0.52	4.63e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs2294693	0.947	rs10456496	chr6:40988840	A/G	cg14418226	chr6:40996092	UNC5CL	-0.43	-5.6	-0.33	5.4e-8	Gastric cancer;Non-cardia gastric cancer;
CESC	cis	rs34172651	0.517	rs2303083	chr16:24835168	G/A	cg02428538	chr16:24856791	SLC5A11	-0.6	-5.88	-0.34	1.26e-8	Intelligence (multi-trait analysis);
CESC	cis	rs1862618	0.802	rs4389648	chr5:56103602	A/G	cg22800045	chr5:56110881	MAP3K1	0.84	10.31	0.53	3.63e-21	Initial pursuit acceleration;
CESC	cis	rs3749237	0.595	rs4855861	chr3:49525962	G/T	cg07636037	chr3:49044803	WDR6	0.61	8.81	0.48	1.66e-16	Resting heart rate;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg00597555	chr15:90177036	KIF7	0.46	6.06	0.35	4.72e-9	Fibrinogen levels;
CESC	cis	rs9393777	0.623	rs34313099	chr6:26489607	C/T	cg14345882	chr6:26364793	BTN3A2	0.44	5.39	0.31	1.59e-7	Intelligence (multi-trait analysis);
CESC	cis	rs9796	0.866	rs544744	chr15:41366290	G/C	cg18705301	chr15:41695430	NDUFAF1	-0.42	-6.23	-0.36	1.78e-9	Menopause (age at onset);
CESC	cis	rs1801251	1.000	rs7578299	chr2:233573469	G/T	cg08000102	chr2:233561755	GIGYF2	0.68	9.27	0.49	6.96e-18	Coronary artery disease;
CESC	cis	rs873946	0.648	rs3793673	chr10:134547732	A/C	cg18305652	chr10:134549665	INPP5A	0.51	7.53	0.42	8.2e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs3741798	1.000	rs61922026	chr12:12486428	C/G	cg08615371	chr12:12503544	MANSC1	0.88	6.45	0.37	5.4e-10	Cerebrospinal fluid biomarker levels;
CESC	cis	rs7666738	0.830	rs13108705	chr4:99044438	T/C	cg24818145	chr4:99064322	C4orf37	0.38	5.04	0.3	8.49e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9303401	0.703	rs9909925	chr17:57210069	C/T	cg12560992	chr17:57184187	TRIM37	-0.49	-5.87	-0.34	1.33e-8	Cognitive test performance;
CESC	cis	rs6866344	0.697	rs58549512	chr5:178133204	C/T	cg03877680	chr5:178157825	ZNF354A	0.75	8.41	0.46	2.52e-15	Neutrophil percentage of white cells;
CESC	trans	rs1814175	0.935	rs10839317	chr11:49657228	A/C	cg03929089	chr4:120376271	NA	-0.88	-13.45	-0.64	8.7e-32	Height;
CESC	cis	rs9910055	0.762	rs2526021	chr17:42213347	G/A	cg13607699	chr17:42295918	UBTF	0.63	8.36	0.46	3.49e-15	Total body bone mineral density;
CESC	cis	rs7264396	0.790	rs8125090	chr20:34360015	C/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.64	7.66	0.43	3.4e-13	Total cholesterol levels;
CESC	cis	rs9929218	0.906	rs9933844	chr16:68747001	G/A	cg02972257	chr16:68554789	NA	0.57	6.4	0.37	7.06e-10	Colorectal cancer;
CESC	cis	rs2882667	0.858	rs17207870	chr5:138387737	T/C	cg04439458	chr5:138467593	SIL1	-0.39	-6.28	-0.36	1.37e-9	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs17116334	1.000	rs17116334	chr11:113961762	C/T	cg12598837	chr11:113845788	HTR3A	0.29	5.76	0.33	2.37e-8	Conduct disorder (maternal expressed emotions interaction);
CESC	cis	rs10089	0.953	rs1012851	chr5:127360241	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.75	9.53	0.51	1.09e-18	Ileal carcinoids;
CESC	cis	rs9790314	0.586	rs1811483	chr3:161130900	A/G	cg03342759	chr3:160939853	NMD3	-0.41	-5.18	-0.3	4.35e-7	Morning vs. evening chronotype;
CESC	cis	rs7666738	0.830	rs1869897	chr4:98730997	C/T	cg05340658	chr4:99064831	C4orf37	0.74	10.56	0.54	5.51e-22	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4919694	1.000	rs7100592	chr10:104769098	T/G	cg04362960	chr10:104952993	NT5C2	0.75	6.44	0.37	5.54e-10	Arsenic metabolism;
CESC	cis	rs11690935	1.000	rs12053003	chr2:172537350	A/C	cg13550731	chr2:172543902	DYNC1I2	0.96	14.94	0.68	4.88e-37	Schizophrenia;
CESC	cis	rs637571	0.524	rs674363	chr11:65699134	G/A	cg26695010	chr11:65641043	EFEMP2	0.42	5.22	0.31	3.67e-7	Eosinophil percentage of white cells;
CESC	cis	rs8099014	0.861	rs8097365	chr18:56131080	G/A	cg19312305	chr18:56117016	MIR122	-0.27	-5.3	-0.31	2.4e-7	Platelet count;
CESC	cis	rs11122272	0.735	rs2491412	chr1:231535880	A/T	cg06096015	chr1:231504339	EGLN1	0.39	5.53	0.32	7.83e-8	Hemoglobin concentration;
CESC	cis	rs977987	0.778	rs11149825	chr16:75434878	C/T	cg03315344	chr16:75512273	CHST6	0.39	5.61	0.33	5.15e-8	Dupuytren's disease;
CESC	trans	rs55704346	0.566	rs2292410	chr4:25394339	A/G	cg01822600	chr1:245751692	KIF26B	0.42	6.17	0.35	2.58e-9	Tonsillectomy;
CESC	cis	rs3785574	0.962	rs7215915	chr17:61828385	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.11	19.33	0.76	1.54e-52	Height;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg07136949	chr6:7986672	MGC26597	-0.42	-5.99	-0.35	6.65e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs1371867	0.846	rs1788203	chr8:101303721	T/C	cg11906718	chr8:101322791	RNF19A	0.54	6.93	0.39	3.24e-11	Atrioventricular conduction;
CESC	cis	rs9443189	0.901	rs2038624	chr6:76560707	T/C	cg01950844	chr6:76311363	SENP6	-0.59	-6.22	-0.36	1.88e-9	Prostate cancer;
CESC	cis	rs7520050	0.931	rs11211198	chr1:46282673	G/A	cg24296786	chr1:45957014	TESK2	0.43	5.41	0.32	1.38e-7	Red blood cell count;Reticulocyte count;
CESC	cis	rs1707322	0.686	rs2230658	chr1:46078854	A/G	cg05343316	chr1:45956843	TESK2	-0.53	-6.45	-0.37	5.42e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2228479	0.717	rs12917681	chr16:89810941	C/A	cg27121462	chr16:89883253	FANCA	0.64	5.6	0.33	5.41e-8	Skin colour saturation;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg17810853	chr3:53879737	IL17RB;CHDH	-0.46	-6.37	-0.36	8.44e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15825928	chr6:126964945	NA	-0.5	-6.26	-0.36	1.56e-9	Gut microbiome composition (summer);
CESC	cis	rs9486719	0.947	rs72932805	chr6:96902933	T/G	cg18709589	chr6:96969512	KIAA0776	-0.54	-5.97	-0.34	7.42e-9	Migraine;Coronary artery disease;
CESC	cis	rs10504229	0.683	rs6982990	chr8:58115275	C/T	cg24829409	chr8:58192753	C8orf71	0.59	7.31	0.41	3.16e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs7615952	0.641	rs6805074	chr3:125772274	T/A	cg15145296	chr3:125709740	NA	-0.52	-5.47	-0.32	1.06e-7	Blood pressure (smoking interaction);
CESC	cis	rs3733585	0.673	rs4407505	chr4:9953367	T/G	cg00071950	chr4:10020882	SLC2A9	-0.69	-11.34	-0.57	1.42e-24	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs7071206	0.853	rs57420220	chr10:79428886	C/T	cg00983440	chr10:79422392	NA	-0.66	-7.91	-0.44	7.23e-14	Bone mineral density;
CESC	cis	rs3741151	0.881	rs12099129	chr11:73091318	T/G	cg17517138	chr11:73019481	ARHGEF17	0.97	6.53	0.37	3.3e-10	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg08974500	chr6:170863287	PSMB1;TBP	-0.45	-6.85	-0.39	5.11e-11	Gambling;
CESC	cis	rs9625935	0.518	rs9614086	chr22:30259608	A/C	cg01021169	chr22:30184971	ASCC2	0.41	6.41	0.37	6.8e-10	Tonsillectomy;
CESC	cis	rs1878931	0.697	rs1044390	chr16:3432594	T/A	cg21433313	chr16:3507492	NAT15	-0.37	-5.54	-0.32	7.38e-8	Body mass index (adult);
CESC	cis	rs6674176	0.660	rs2108202	chr1:44395786	A/G	cg15962314	chr1:44399869	ARTN	-0.28	-5.15	-0.3	5.13e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs9393777	0.513	rs7740197	chr6:26663478	C/T	cg12826209	chr6:26865740	GUSBL1	-0.77	-8.79	-0.48	1.92e-16	Intelligence (multi-trait analysis);
CESC	cis	rs9616064	0.531	rs66909472	chr22:47050210	G/A	cg05621596	chr22:47072043	GRAMD4	-0.68	-9.8	-0.52	1.45e-19	Urate levels in obese individuals;
CESC	cis	rs778371	0.578	rs2675956	chr2:233753340	G/A	cg08000102	chr2:233561755	GIGYF2	-0.77	-12.05	-0.59	5.84e-27	Schizophrenia;
CESC	cis	rs870825	0.698	rs2696046	chr4:185599972	G/A	cg04058563	chr4:185651563	MLF1IP	-0.51	-5.05	-0.3	8.2e-7	Blood protein levels;
CESC	cis	rs9660992	0.626	rs1172113	chr1:205226288	T/C	cg00857998	chr1:205179979	DSTYK	0.5	6.25	0.36	1.62e-9	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs2303759	0.709	rs8102574	chr19:49828897	A/G	cg22307029	chr19:49891270	CCDC155	0.54	5.97	0.34	7.51e-9	Multiple sclerosis;
CESC	cis	rs10504229	0.683	rs7816733	chr8:58129855	G/A	cg21724239	chr8:58056113	NA	0.58	5.95	0.34	8.29e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs8067545	0.611	rs2526477	chr17:20131193	A/G	cg13482628	chr17:19912719	NA	-0.4	-5.32	-0.31	2.23e-7	Schizophrenia;
CESC	cis	rs1799949	1.000	rs9646412	chr17:41425893	A/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.38	5.08	0.3	7.24e-7	Menopause (age at onset);
CESC	cis	rs3091242	0.804	rs631133	chr1:25724146	T/C	cg03538708	chr1:25844672	NA	-0.38	-5.63	-0.33	4.61e-8	Erythrocyte sedimentation rate;
CESC	cis	rs1552244	0.882	rs55808392	chr3:10054681	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.75	-9.48	-0.5	1.49e-18	Alzheimer's disease;
CESC	cis	rs7666738	0.830	rs6830124	chr4:99054872	C/T	cg03467027	chr4:99064603	C4orf37	-0.46	-5.73	-0.33	2.73e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2440129	0.611	rs1042356	chr17:6902743	G/A	cg12262378	chr17:6899522	ALOX12	0.39	6.61	0.38	2.07e-10	Tonsillectomy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23200970	chr4:111119917	ELOVL6	0.61	6.94	0.39	2.95e-11	Gut microbiome composition (summer);
CESC	cis	rs1707322	0.721	rs10157795	chr1:46228192	G/A	cg06784218	chr1:46089804	CCDC17	0.4	7.33	0.41	2.85e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs854765	0.964	rs12943202	chr17:17994332	T/A	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.46	-5.83	-0.34	1.64e-8	Total body bone mineral density;
CESC	cis	rs213032	1.000	rs213028	chr1:21652177	A/G	cg16416158	chr1:21652298	ECE1	-0.32	-5.41	-0.32	1.43e-7	Obesity-related traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00423702	chr7:66747538	NA	-0.41	-6.01	-0.35	6.08e-9	Gut microbiome composition (summer);
CESC	cis	rs6540556	0.517	rs1474654	chr1:209884387	A/G	cg05527609	chr1:210001259	C1orf107	-0.73	-7.15	-0.4	8.66e-12	Red blood cell count;
CESC	cis	rs2576037	0.796	rs2571020	chr18:44584189	A/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.44	5.61	0.33	4.97e-8	Personality dimensions;
CESC	cis	rs9733	0.596	rs11803569	chr1:150664077	C/T	cg18016565	chr1:150552671	MCL1	0.33	5.16	0.3	4.96e-7	Tonsillectomy;
CESC	cis	rs4665809	0.590	rs11897162	chr2:26503654	T/C	cg25036284	chr2:26402008	FAM59B	0.81	8.91	0.48	8.33e-17	Gut microbiome composition (summer);
CESC	cis	rs7829975	0.514	rs2976929	chr8:8258712	T/C	cg15556689	chr8:8085844	FLJ10661	0.57	7.52	0.42	8.55e-13	Mood instability;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00923803	chr7:5862740	ZNF815	0.53	6.81	0.39	6.47e-11	Gut microbiome composition (summer);
CESC	cis	rs11650494	0.908	rs75092916	chr17:47412578	T/C	cg08112188	chr17:47440006	ZNF652	1.31	8.52	0.46	1.22e-15	Prostate cancer;
CESC	cis	rs7589342	0.929	rs7562054	chr2:106433513	G/C	cg16077055	chr2:106428750	NCK2	0.53	7.56	0.42	6.6e-13	Addiction;
CESC	cis	rs28489187	0.706	rs66811655	chr1:85831544	T/G	cg16011679	chr1:85725395	C1orf52	0.57	6.38	0.36	7.83e-10	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	trans	rs11088226	0.581	rs2833856	chr21:33877691	A/G	cg09050820	chr6:167586206	TCP10L2	-0.47	-6.03	-0.35	5.53e-9	Gastritis;
CESC	cis	rs910316	0.967	rs12147532	chr14:75651858	T/G	cg08847533	chr14:75593920	NEK9	-0.93	-15.99	-0.7	9.36e-41	Height;
CESC	cis	rs11098499	0.863	rs7695620	chr4:120452776	G/A	cg09307838	chr4:120376055	NA	0.91	12.54	0.61	1.24e-28	Corneal astigmatism;
CESC	trans	rs2727020	0.521	rs4980445	chr11:49570183	C/T	cg03929089	chr4:120376271	NA	-0.73	-8.38	-0.46	3.16e-15	Coronary artery disease;
CESC	cis	rs13385	0.769	rs17118759	chr5:139617407	A/G	cg26211634	chr5:139558579	C5orf32	0.48	5.27	0.31	2.79e-7	Atrial fibrillation;
CESC	cis	rs11696501	0.688	rs6065861	chr20:44311056	A/G	cg11783356	chr20:44313418	WFDC10B	-0.31	-5.07	-0.3	7.57e-7	Brain structure;
CESC	cis	rs782590	0.556	rs782579	chr2:55917604	A/G	cg18811423	chr2:55921094	PNPT1	0.74	11.56	0.58	2.72e-25	Metabolic syndrome;
CESC	cis	rs1670533	1.000	rs688785	chr4:1082707	G/C	cg27284194	chr4:1044797	NA	0.48	6.07	0.35	4.52e-9	Recombination rate (females);
CESC	cis	rs6964587	1.000	rs6465343	chr7:91618208	T/C	cg17063962	chr7:91808500	NA	0.56	7.66	0.43	3.61e-13	Breast cancer;
CESC	cis	rs7828089	0.582	rs13282084	chr8:22266280	T/C	cg23129673	chr8:22266227	SLC39A14	0.37	5.47	0.32	1.03e-7	Verbal declarative memory;
CESC	cis	rs7727544	0.735	rs274566	chr5:131715011	A/G	cg07395648	chr5:131743802	NA	0.49	6.55	0.37	2.98e-10	Blood metabolite levels;
CESC	cis	rs1448094	0.791	rs7300340	chr12:86329867	G/T	cg02569458	chr12:86230093	RASSF9	0.45	6.43	0.37	5.79e-10	Major depressive disorder;
CESC	cis	rs17826219	0.500	rs117560728	chr17:29070938	A/C	cg13385521	chr17:29058706	SUZ12P	0.78	5.47	0.32	1.04e-7	Body mass index;
CESC	cis	rs11123610	0.520	rs7576701	chr2:3718227	T/C	cg19052272	chr2:3704530	ALLC	-0.48	-5.97	-0.34	7.67e-9	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CESC	cis	rs6867032	0.917	rs10474733	chr5:2004160	A/G	cg26168224	chr5:2018326	NA	-0.83	-13.67	-0.64	1.5e-32	Gut microbiome composition (winter);
CESC	cis	rs514406	0.793	rs12402415	chr1:53218539	G/T	cg08859206	chr1:53392774	SCP2	0.6	8.86	0.48	1.2e-16	Monocyte count;
CESC	cis	rs250677	0.522	rs6872701	chr5:148359086	C/G	cg18129178	chr5:148520854	ABLIM3	0.47	5.16	0.3	4.93e-7	Breast cancer;
CESC	trans	rs11098499	1.000	rs6849889	chr4:120186348	A/C	cg25214090	chr10:38739885	LOC399744	0.63	8.35	0.46	3.71e-15	Corneal astigmatism;
CESC	cis	rs7932354	0.710	rs10838621	chr11:46851459	C/T	cg25783544	chr11:47291846	MADD	-0.39	-5.1	-0.3	6.39e-7	Bone mineral density (hip);Bone mineral density;
CESC	cis	rs7605827	0.897	rs1990756	chr2:15616030	C/T	cg19274914	chr2:15703543	NA	0.35	6.13	0.35	3.19e-9	Educational attainment (years of education);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14377169	chr1:113162381	ST7L;CAPZA1	0.64	6.68	0.38	1.38e-10	Gut microbiome composition (summer);
CESC	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.58	0.37	2.53e-10	Prudent dietary pattern;
CESC	cis	rs801193	0.935	rs2659916	chr7:66151352	C/G	cg10691866	chr7:65817282	TPST1	-0.31	-5.04	-0.3	8.79e-7	Aortic root size;
CESC	cis	rs4253772	0.550	rs6008729	chr22:46727428	C/G	cg09491104	chr22:46646882	C22orf40	0.46	6.56	0.37	2.74e-10	LDL cholesterol;Cholesterol, total;
CESC	trans	rs6840360	0.571	rs718801	chr4:152549247	C/T	cg16197925	chr7:121944282	FEZF1	0.36	6.04	0.35	5.16e-9	Intelligence (multi-trait analysis);
CESC	cis	rs4073582	0.595	rs801739	chr11:65922589	A/G	cg14036092	chr11:66035641	RAB1B	0.53	7.2	0.4	6.4e-12	Gout;
CESC	cis	rs6089829	0.925	rs6062396	chr20:61667949	T/C	cg03213289	chr20:61660250	NA	0.39	6.06	0.35	4.6e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs708547	0.874	rs781551	chr4:57718406	A/T	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.5	-5.44	-0.32	1.2e-7	Response to bleomycin (chromatid breaks);
CESC	cis	rs4588572	0.643	rs2012562	chr5:77768088	T/A	cg11547950	chr5:77652471	NA	-0.42	-5.26	-0.31	2.96e-7	Triglycerides;
CESC	cis	rs703842	1.000	rs11172342	chr12:58187758	G/T	cg18357645	chr12:58087776	OS9	-0.43	-5.98	-0.34	7.09e-9	Multiple sclerosis;
CESC	cis	rs3785574	0.927	rs2008018	chr17:61954471	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.94	14.58	0.67	9.63e-36	Height;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg04958845	chr8:101170202	SPAG1	-0.46	-6.15	-0.35	2.85e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs6502050	0.805	rs7406682	chr17:80084368	C/T	cg11859384	chr17:80120422	CCDC57	0.38	5.12	0.3	6.01e-7	Life satisfaction;
CESC	cis	rs546131	0.928	rs546521	chr11:34824773	G/C	cg11058730	chr11:34937778	PDHX;APIP	0.52	6.43	0.37	5.85e-10	Lung disease severity in cystic fibrosis;
CESC	cis	rs10779751	0.960	rs11121712	chr1:11320329	G/C	cg08854313	chr1:11322531	MTOR	0.91	14.45	0.66	2.77e-35	Body mass index;
CESC	cis	rs854765	0.583	rs4925126	chr17:17798633	C/T	cg16928487	chr17:17741425	SREBF1	-0.51	-8.52	-0.46	1.22e-15	Total body bone mineral density;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26684574	chr20:48532295	SPATA2	0.72	8.32	0.46	4.62e-15	Gut microbiome composition (summer);
CESC	cis	rs80282103	0.618	rs11819230	chr10:1128812	A/G	cg08668510	chr10:1095578	IDI1	0.72	5.72	0.33	2.85e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs3820068	0.581	rs72645877	chr1:15928106	G/T	cg13390004	chr1:15929781	NA	0.35	5.58	0.32	5.83e-8	Systolic blood pressure;
CESC	cis	rs1401999	0.659	rs4912518	chr3:183752027	C/T	cg01324343	chr3:183735012	ABCC5	-0.5	-8.46	-0.46	1.79e-15	Anterior chamber depth;
CESC	cis	rs6570726	0.935	rs407721	chr6:145871354	A/C	cg23711669	chr6:146136114	FBXO30	0.8	11.92	0.59	1.67e-26	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7666738	0.791	rs1426661	chr4:98874303	C/G	cg17366294	chr4:99064904	C4orf37	0.55	7.68	0.43	2.99e-13	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2832191	0.716	rs1888440	chr21:30454484	C/T	cg08807101	chr21:30365312	RNF160	0.94	14.55	0.67	1.17e-35	Dental caries;
CESC	cis	rs17431357	1.000	rs76181214	chr12:121013785	T/C	cg25045489	chr12:120971538	RNF10	-0.9	-5.23	-0.31	3.44e-7	Insulin resistance/response;
CESC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg04590956	chr2:70057467	GMCL1	-0.55	-6.03	-0.35	5.42e-9	Lung cancer in ever smokers;
CESC	cis	rs818427	0.593	rs2545170	chr5:112204170	G/A	cg07820702	chr5:112228657	REEP5	0.41	5.52	0.32	7.91e-8	Total body bone mineral density;
CESC	cis	rs763121	0.853	rs3747170	chr22:39067331	G/A	cg06022373	chr22:39101656	GTPBP1	0.87	13.83	0.65	4.07e-33	Menopause (age at onset);
CESC	cis	rs3857536	0.842	rs2188590	chr6:66939534	A/G	cg07460842	chr6:66804631	NA	-0.42	-5.34	-0.31	1.96e-7	Blood trace element (Cu levels);
CESC	cis	rs11711311	0.955	rs12630791	chr3:113387717	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	-0.54	-6.94	-0.39	3e-11	IgG glycosylation;
CESC	cis	rs8031584	0.706	rs798084	chr15:31126935	C/T	cg08704250	chr15:31115839	NA	-0.64	-8.54	-0.46	1.05e-15	Huntington's disease progression;
CESC	cis	rs11051970	0.546	rs11051989	chr12:32560890	A/G	cg24626660	chr12:32551988	NA	0.36	5.2	0.3	4.09e-7	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs372883	0.648	rs1153288	chr21:30686091	A/G	cg24692254	chr21:30365293	RNF160	0.53	6.74	0.38	9.73e-11	Pancreatic cancer;
CESC	trans	rs6445797	0.821	rs6445806	chr3:56670306	T/C	cg15444621	chr13:113611794	NA	0.32	6.01	0.35	6.11e-9	Gastritis;
CESC	cis	rs77741769	0.571	rs12822123	chr12:121298644	C/T	cg02419362	chr12:121203948	SPPL3	0.34	5.59	0.32	5.6e-8	Mean corpuscular volume;
CESC	cis	rs875971	0.545	rs7787063	chr7:65628999	G/A	cg11764359	chr7:65958608	NA	0.79	9.51	0.5	1.18e-18	Aortic root size;
CESC	cis	rs3820068	0.603	rs72647118	chr1:15956535	G/T	cg17385448	chr1:15911702	AGMAT	0.43	6.93	0.39	3.22e-11	Systolic blood pressure;
CESC	cis	rs2415984	0.622	rs61993296	chr14:46934216	C/T	cg14871534	chr14:47121158	RPL10L	-0.35	-5.31	-0.31	2.37e-7	Number of children ever born;
CESC	cis	rs6963495	0.745	rs55906043	chr7:105165367	T/G	cg13798780	chr7:105162888	PUS7	0.78	8.04	0.44	2.99e-14	Bipolar disorder (body mass index interaction);
CESC	cis	rs1799949	0.965	rs8176322	chr17:41195773	A/G	cg25072359	chr17:41440525	NA	0.44	5.89	0.34	1.16e-8	Menopause (age at onset);
CESC	cis	rs7122539	0.646	rs608248	chr11:66562248	C/T	cg24851651	chr11:66362959	CCS	-0.5	-7.36	-0.41	2.37e-12	HIV-1 susceptibility;
CESC	cis	rs4665809	0.549	rs3828255	chr2:26413252	G/A	cg08470875	chr2:26401718	FAM59B	0.67	6.96	0.39	2.72e-11	Gut microbiome composition (summer);
CESC	cis	rs12928939	0.517	rs12445641	chr16:71967783	C/T	cg03805757	chr16:71968109	PKD1L3	-0.59	-6.62	-0.38	2.01e-10	Post bronchodilator FEV1;
CESC	cis	rs2075371	0.966	rs1619682	chr7:133996703	T/G	cg20476274	chr7:133979776	SLC35B4	0.65	9.4	0.5	2.68e-18	Mean platelet volume;
CESC	cis	rs6460942	0.597	rs12699381	chr7:12527026	G/A	cg02935154	chr7:12443704	VWDE	-0.55	-5.58	-0.32	6.01e-8	Coronary artery disease;
CESC	trans	rs11098499	0.789	rs1980024	chr4:120253047	C/T	cg25214090	chr10:38739885	LOC399744	0.62	8.7	0.47	3.58e-16	Corneal astigmatism;
CESC	cis	rs3091242	0.933	rs28530483	chr1:25740847	A/C	cg12412775	chr1:25698385	RHCE	-0.29	-5.11	-0.3	6.12e-7	Erythrocyte sedimentation rate;
CESC	cis	rs2836974	0.568	rs429955	chr21:40539760	G/A	cg27266027	chr21:40555129	PSMG1	0.4	5.1	0.3	6.35e-7	Cognitive function;
CESC	cis	rs12926788	0.640	rs73551577	chr16:24845143	G/A	cg06505273	chr16:24850292	NA	0.51	6.32	0.36	1.09e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs9322193	0.923	rs9688938	chr6:150110077	G/A	cg13206674	chr6:150067644	NUP43	0.42	5.89	0.34	1.19e-8	Lung cancer;
CESC	cis	rs9443645	0.901	rs1354832	chr6:79613763	A/G	cg05283184	chr6:79620031	NA	0.46	7.01	0.4	2e-11	Intelligence (multi-trait analysis);
CESC	cis	rs9811920	0.529	rs793442	chr3:99581062	A/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.52	-6.35	-0.36	9.49e-10	Axial length;
CESC	cis	rs12541635	0.966	rs7819043	chr8:106989783	T/C	cg10147462	chr8:107024639	NA	0.37	5.14	0.3	5.44e-7	Age of smoking initiation;
CESC	cis	rs1915146	0.546	rs2681919	chr10:126859029	A/G	cg17191109	chr10:126851326	NA	0.41	6.6	0.38	2.29e-10	Menarche (age at onset);
CESC	cis	rs7605827	0.780	rs2287279	chr2:15667778	G/A	cg19274914	chr2:15703543	NA	0.38	6.69	0.38	1.34e-10	Educational attainment (years of education);
CESC	cis	rs400736	0.859	rs379920	chr1:8028865	G/C	cg25007680	chr1:8021821	PARK7	0.72	10.16	0.53	1.11e-20	Response to antidepressants and depression;
CESC	cis	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.45	-5.59	-0.32	5.65e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs9611565	0.532	rs4401299	chr22:42156517	A/G	cg06481639	chr22:41940642	POLR3H	0.5	5.81	0.34	1.78e-8	Vitiligo;
CESC	cis	rs763014	0.932	rs35067229	chr16:649638	T/C	cg07343612	chr16:622815	PIGQ	-0.55	-8.08	-0.44	2.32e-14	Height;
CESC	cis	rs7100689	0.622	rs7897994	chr10:82133304	T/G	cg00277334	chr10:82204260	NA	-0.58	-7.76	-0.43	1.84e-13	Post bronchodilator FEV1;
CESC	cis	rs10479542	0.544	rs10056863	chr5:179005100	G/A	cg21226059	chr5:178986404	RUFY1	0.49	7.29	0.41	3.49e-12	Lung cancer;
CESC	cis	rs3020736	0.500	rs9620026	chr22:42498578	C/T	cg15557168	chr22:42548783	NA	0.45	6.57	0.37	2.72e-10	Autism spectrum disorder or schizophrenia;
CESC	cis	rs7937682	0.855	rs490897	chr11:111487914	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.94	-14.45	-0.66	2.76e-35	Primary sclerosing cholangitis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18844589	chr2:238707052	RBM44	-0.52	-6.05	-0.35	4.88e-9	Gut microbiome composition (summer);
CESC	cis	rs4642101	0.662	rs57411588	chr3:12820384	C/G	cg05775895	chr3:12838266	CAND2	0.41	6.36	0.36	8.94e-10	QRS complex (12-leadsum);
CESC	cis	rs10779751	0.734	rs2791653	chr1:11129848	A/G	cg08854313	chr1:11322531	MTOR	0.74	9.19	0.49	1.16e-17	Body mass index;
CESC	cis	rs4689388	0.853	rs4293850	chr4:6292020	A/C	cg00701064	chr4:6280414	WFS1	0.62	10.21	0.53	7.39e-21	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs7666738	0.791	rs10005118	chr4:99038196	A/C	cg05340658	chr4:99064831	C4orf37	0.82	12.88	0.62	8.45e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs79349575	0.783	rs832410	chr17:46972865	C/T	cg16584676	chr17:46985605	UBE2Z	0.54	6.6	0.38	2.26e-10	Type 2 diabetes;
CESC	cis	rs1050631	0.564	rs12185396	chr18:33738496	C/T	cg25426722	chr18:33708991	SLC39A6;ELP2	0.6	8.08	0.44	2.32e-14	Esophageal squamous cell cancer (length of survival);
CESC	cis	rs9926296	0.605	rs6500453	chr16:89858657	C/G	cg03388025	chr16:89894329	SPIRE2	0.41	8.11	0.45	1.94e-14	Vitiligo;
CESC	cis	rs367943	0.712	rs26967	chr5:112741467	C/G	cg12552261	chr5:112820674	MCC	0.4	5.32	0.31	2.17e-7	Type 2 diabetes;
CESC	cis	rs11250464	0.833	rs11250467	chr10:1409662	A/G	cg08668359	chr10:1443807	ADARB2	0.59	7.3	0.41	3.35e-12	Radiation response;
CESC	cis	rs11785400	0.793	rs4301430	chr8:143737416	A/G	cg24634471	chr8:143751801	JRK	0.44	5.48	0.32	1.01e-7	Schizophrenia;
CESC	cis	rs11577318	0.853	rs1071849	chr1:26646726	A/G	cg00813993	chr1:26644493	UBXN11;CD52	-0.4	-6.36	-0.36	8.77e-10	Granulocyte percentage of myeloid white cells;
CESC	cis	rs10751667	1.000	rs4074232	chr11:977682	C/G	cg06064525	chr11:970664	AP2A2	-0.38	-6.75	-0.38	9.49e-11	Alzheimer's disease (late onset);
CESC	cis	rs4660306	1.000	rs6429569	chr1:46001330	A/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.48	-6.2	-0.36	2.1e-9	Homocysteine levels;
CESC	cis	rs7044106	0.762	rs10760112	chr9:123467570	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.72	10.74	0.55	1.42e-22	Hip circumference adjusted for BMI;
CESC	cis	rs9355610	0.609	rs62436424	chr6:167374258	A/G	cg23791538	chr6:167370224	RNASET2	0.5	5.89	0.34	1.16e-8	Graves' disease;
CESC	cis	rs959260	1.000	rs2891713	chr17:73386622	G/C	cg20590849	chr17:73267439	MIF4GD	-0.55	-6.36	-0.36	8.61e-10	Systemic lupus erythematosus;
CESC	cis	rs2066819	0.892	rs17118431	chr12:56667100	A/G	cg26734620	chr12:56694298	CS	1.04	6.71	0.38	1.18e-10	Psoriasis vulgaris;
CESC	cis	rs3806843	0.735	rs3776129	chr5:140072292	G/A	cg26395211	chr5:140044315	WDR55	0.47	5.95	0.34	8.29e-9	Depressive symptoms (multi-trait analysis);
CESC	cis	rs9325144	0.624	rs10506126	chr12:39123244	G/A	cg26384229	chr12:38710491	ALG10B	-0.53	-7.27	-0.41	4.14e-12	Morning vs. evening chronotype;
CESC	cis	rs7833790	1.000	rs28696138	chr8:82770794	G/A	cg07697082	chr8:82753677	SNX16	-0.39	-5.32	-0.31	2.19e-7	Diastolic blood pressure;
CESC	cis	rs2262909	0.962	rs1526884	chr19:22303651	A/G	cg11619707	chr19:22235551	ZNF257	0.33	5.29	0.31	2.51e-7	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
CESC	cis	rs7618915	0.501	rs1468638	chr3:52748058	T/C	cg07507251	chr3:52567010	NT5DC2	0.34	5.92	0.34	9.68e-9	Bipolar disorder;
CESC	cis	rs11587400	0.679	rs12090305	chr1:115109441	G/A	cg12756093	chr1:115239321	AMPD1	0.43	5.76	0.33	2.27e-8	Autism;
CESC	cis	rs950027	0.620	rs1145080	chr15:45681338	C/T	cg21132104	chr15:45694354	SPATA5L1	0.67	8.55	0.46	1.01e-15	Response to fenofibrate (adiponectin levels);
CESC	cis	rs6582630	0.519	rs8186992	chr12:38325848	C/T	cg13010199	chr12:38710504	ALG10B	0.44	5.68	0.33	3.51e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs6088590	1.000	rs2236270	chr20:33523155	G/T	cg24642439	chr20:33292090	TP53INP2	0.87	11.98	0.59	1.02e-26	Coronary artery disease;
CESC	cis	rs798554	0.679	rs1639036	chr7:2885089	G/A	cg13628971	chr7:2884303	GNA12	0.65	9.14	0.49	1.69e-17	Height;
CESC	trans	rs2235573	0.527	rs139862	chr22:38351986	T/C	cg19894588	chr14:64061835	NA	0.63	8.28	0.45	6.09e-15	Glioblastoma;Glioma;
CESC	cis	rs7552404	0.727	rs12122939	chr1:76276353	T/C	cg22875332	chr1:76189707	ACADM	0.59	6.01	0.35	5.96e-9	Blood metabolite levels;Acylcarnitine levels;
CESC	trans	rs1814175	0.791	rs11040472	chr11:49703116	C/T	cg03929089	chr4:120376271	NA	-0.92	-15.12	-0.68	1.14e-37	Height;
CESC	trans	rs5417	0.775	rs222852	chr17:7140606	A/G	cg15655154	chr3:113604241	GRAMD1C	0.5	6.85	0.39	5.02e-11	Diastolic blood pressure;
CESC	cis	rs6460942	0.591	rs62448729	chr7:12333720	G/C	cg02935154	chr7:12443704	VWDE	-0.53	-5.5	-0.32	9.01e-8	Coronary artery disease;
CESC	trans	rs7824557	0.545	rs2736303	chr8:11236850	C/T	cg06636001	chr8:8085503	FLJ10661	-0.5	-6.16	-0.35	2.7e-9	Retinal vascular caliber;
CESC	cis	rs9649213	0.593	rs6465666	chr7:97937258	C/T	cg24562669	chr7:97807699	LMTK2	-0.51	-7.5	-0.42	9.77e-13	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs889398	0.802	rs12919094	chr16:69843357	A/G	cg09409435	chr16:70099608	PDXDC2	-0.42	-5.3	-0.31	2.44e-7	Body mass index;
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg09247696	chr2:74756297	HTRA2;AUP1	-0.4	-6.18	-0.35	2.39e-9	Vertical cup-disc ratio;
CESC	cis	rs870825	0.655	rs10033035	chr4:185630880	T/C	cg04058563	chr4:185651563	MLF1IP	0.64	7.0	0.4	2.05e-11	Blood protein levels;
CESC	cis	rs1030268	0.715	rs13235840	chr7:133505091	A/T	cg10665199	chr7:133106180	EXOC4	0.54	5.38	0.31	1.63e-7	Intelligence (multi-trait analysis);
CESC	cis	rs929596	0.574	rs75444879	chr2:234587848	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.43	-5.34	-0.31	2.01e-7	Total bilirubin levels in HIV-1 infection;
CESC	cis	rs10504229	0.906	rs59336968	chr8:58176857	T/C	cg24829409	chr8:58192753	C8orf71	-0.76	-10.0	-0.52	3.53e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs2066819	0.786	rs116934693	chr12:56696545	T/G	cg26734620	chr12:56694298	CS	1.07	6.58	0.37	2.56e-10	Psoriasis vulgaris;
CESC	cis	rs7212590	0.618	rs35806089	chr17:57943906	A/G	cg20303301	chr17:57937339	TUBD1	-0.53	-5.25	-0.31	3.06e-7	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg17309711	chr11:45826527	SLC35C1	0.46	6.1	0.35	3.72e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs761746	0.920	rs5998011	chr22:31889566	T/C	cg25791279	chr22:32026902	PISD	-0.5	-5.57	-0.32	6.25e-8	Intelligence;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg13094338	chr20:62258937	GMEB2	-0.5	-6.75	-0.38	9.08e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs11645898	0.872	rs72787070	chr16:72151101	T/C	cg14768367	chr16:72042858	DHODH	-0.75	-6.38	-0.37	7.71e-10	Blood protein levels;
CESC	cis	rs1552244	1.000	rs6442147	chr3:10078247	A/G	cg08888203	chr3:10149979	C3orf24	0.46	5.94	0.34	8.69e-9	Alzheimer's disease;
CESC	cis	rs9311474	0.508	rs6788887	chr3:52605005	T/C	cg18404041	chr3:52824283	ITIH1	-0.38	-6.5	-0.37	4e-10	Electroencephalogram traits;
CESC	cis	rs1707322	0.721	rs7519900	chr1:46234947	C/T	cg03146154	chr1:46216737	IPP	0.82	11.5	0.58	4.28e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14247862	chr17:80764631	TBCD	-0.55	-6.37	-0.36	8.38e-10	Gut microbiome composition (summer);
CESC	cis	rs3020736	0.500	rs8143153	chr22:42515637	G/C	cg15557168	chr22:42548783	NA	0.44	6.2	0.36	2.18e-9	Autism spectrum disorder or schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07604202	chr20:50701378	ZFP64	-0.59	-7.02	-0.4	1.87e-11	Gut microbiome composition (summer);
CESC	cis	rs74781061	0.929	rs8029215	chr15:74853488	A/G	cg17294928	chr15:75287854	SCAMP5	-0.49	-5.24	-0.31	3.28e-7	Endometriosis;
CESC	cis	rs9905704	0.647	rs7221274	chr17:57008128	A/G	cg12560992	chr17:57184187	TRIM37	0.62	7.8	0.43	1.47e-13	Testicular germ cell tumor;
CESC	trans	rs11250097	0.535	rs11250086	chr8:10769783	A/G	cg06636001	chr8:8085503	FLJ10661	-0.49	-6.08	-0.35	4.28e-9	Neuroticism;
CESC	cis	rs13118159	0.767	rs2141656	chr4:1317192	C/T	cg05025164	chr4:1340916	KIAA1530	0.51	7.0	0.39	2.14e-11	Longevity;
CESC	cis	rs7613875	0.578	rs2624822	chr3:50107219	T/C	cg24110177	chr3:50126178	RBM5	0.58	8.17	0.45	1.28e-14	Body mass index;
CESC	cis	rs10465746	0.905	rs12738214	chr1:84359050	C/A	cg10977910	chr1:84465055	TTLL7	0.48	6.34	0.36	9.89e-10	Obesity-related traits;
CESC	cis	rs4819052	0.851	rs2838837	chr21:46665988	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.91	13.46	0.64	8.33e-32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs7615952	0.673	rs3811677	chr3:125648080	G/A	cg07211511	chr3:129823064	LOC729375	-1.13	-15.13	-0.68	1.07e-37	Blood pressure (smoking interaction);
CESC	cis	rs8060686	0.920	rs56047901	chr16:67742326	G/A	cg26727032	chr16:67993705	SLC12A4	-0.57	-6.0	-0.35	6.41e-9	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs11711311	0.824	rs9833810	chr3:113363762	C/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.65	8.27	0.45	6.63e-15	IgG glycosylation;
CESC	cis	rs10504229	1.000	rs116995796	chr8:58181960	G/A	cg14926445	chr8:58193284	C8orf71	-0.51	-5.52	-0.32	8.28e-8	Developmental language disorder (linguistic errors);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14161438	chr18:72920197	ZADH2	-0.7	-8.55	-0.46	9.74e-16	Gut microbiome composition (summer);
CESC	cis	rs11997175	0.574	rs9642707	chr8:33645789	C/G	ch.8.33884649F	chr8:33765107	NA	0.68	8.99	0.48	4.7e-17	Body mass index;
CESC	cis	rs12142240	0.692	rs7532149	chr1:46824932	A/C	cg00530320	chr1:46809349	NSUN4	0.6	8.04	0.44	2.96e-14	Menopause (age at onset);
CESC	trans	rs330048	0.561	rs330088	chr8:9149746	T/C	cg15556689	chr8:8085844	FLJ10661	0.58	7.6	0.42	5.26e-13	Systemic lupus erythematosus;
CESC	cis	rs2250402	0.510	rs2291619	chr15:40329033	C/T	cg10636054	chr15:40330586	SRP14	-0.85	-6.58	-0.37	2.49e-10	Corneal curvature;
CESC	cis	rs11650494	0.634	rs8072520	chr17:47466640	T/G	cg08112188	chr17:47440006	ZNF652	0.86	6.32	0.36	1.11e-9	Prostate cancer;
CESC	cis	rs9868809	0.881	rs2276852	chr3:48666923	A/G	cg07636037	chr3:49044803	WDR6	-0.65	-6.08	-0.35	4.25e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs34375054	0.526	rs4412800	chr12:125674742	C/T	cg00522288	chr12:125625016	AACS	0.33	5.25	0.31	3.06e-7	Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs4704187	0.687	rs6453123	chr5:74519049	G/A	cg03227963	chr5:74354835	NA	0.28	5.04	0.3	8.66e-7	Response to amphetamines;
CESC	cis	rs8067545	0.611	rs8078716	chr17:20044291	G/A	cg13482628	chr17:19912719	NA	0.4	5.37	0.31	1.75e-7	Schizophrenia;
CESC	cis	rs2228479	0.557	rs2293584	chr16:89888686	C/G	cg14709524	chr16:89940631	TCF25	0.87	6.05	0.35	4.99e-9	Skin colour saturation;
CESC	cis	rs8177253	0.665	rs7646118	chr3:133450039	C/T	cg16262614	chr3:133464971	TF	0.3	5.33	0.31	2.14e-7	Iron status biomarkers;
CESC	cis	rs4822044	0.617	rs13054514	chr22:42130383	A/G	cg06481639	chr22:41940642	POLR3H	0.5	5.81	0.34	1.78e-8	Cannabis dependence symptom count;
CESC	cis	rs11785400	0.793	rs2978973	chr8:143747271	C/G	cg10596483	chr8:143751796	JRK	0.47	5.75	0.33	2.46e-8	Schizophrenia;
CESC	cis	rs12618769	0.597	rs2278212	chr2:99136266	T/C	cg10123293	chr2:99228465	UNC50	0.4	5.38	0.31	1.64e-7	Bipolar disorder;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg05221349	chr4:100870488	LOC256880;H2AFZ	-0.44	-6.27	-0.36	1.47e-9	Ulcerative colitis;
CESC	cis	rs7247513	1.000	rs7247513	chr19:12691185	C/T	cg01871581	chr19:12707946	ZNF490	-0.87	-15.08	-0.68	1.59e-37	Bipolar disorder;
CESC	trans	rs1814175	0.617	rs6486020	chr11:49769149	T/G	cg03929089	chr4:120376271	NA	-0.89	-13.67	-0.64	1.51e-32	Height;
CESC	cis	rs7619708	1	rs7619708	chr3:195810187	T/C	cg01181863	chr3:195395398	SDHAP2	0.66	6.55	0.37	2.91e-10	Red cell distribution width;
CESC	cis	rs2191566	0.664	rs7254261	chr19:44565427	A/G	cg20607764	chr19:44506953	ZNF230	-0.41	-5.35	-0.31	1.93e-7	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs1461503	0.900	rs7110039	chr11:122834001	C/T	cg27398637	chr11:122830231	C11orf63	0.59	9.1	0.49	2.19e-17	Menarche (age at onset);
CESC	cis	rs2777491	0.574	rs11635906	chr15:41779260	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.06	-16.0	-0.7	8.47e-41	Ulcerative colitis;
CESC	cis	rs7845219	0.544	rs10956932	chr8:95948202	C/T	cg16049864	chr8:95962084	TP53INP1	0.4	5.79	0.34	1.95e-8	Type 2 diabetes;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg12133393	chr1:3816695	C1orf174;LOC100133612	-0.46	-6.01	-0.35	6.06e-9	Ulcerative colitis;
CESC	cis	rs514406	0.698	rs567880	chr1:53348564	T/G	cg08859206	chr1:53392774	SCP2	-0.67	-9.83	-0.52	1.23e-19	Monocyte count;
CESC	cis	rs9393777	0.513	rs11967852	chr6:26612870	G/T	cg12292205	chr6:26970375	C6orf41	-0.47	-5.25	-0.31	3.15e-7	Intelligence (multi-trait analysis);
CESC	cis	rs72945132	0.882	rs2276001	chr11:70181560	T/C	cg14191688	chr11:70257035	CTTN	0.43	5.41	0.32	1.39e-7	Coronary artery disease;
CESC	cis	rs722599	0.651	rs12887044	chr14:75255659	C/T	cg11812906	chr14:75593930	NEK9	0.45	5.48	0.32	9.8e-8	IgG glycosylation;
CESC	cis	rs4555082	0.830	rs2816648	chr14:105708289	C/T	cg10792982	chr14:105748885	BRF1	0.4	5.03	0.3	9.04e-7	Mean platelet volume;Platelet distribution width;
CESC	cis	rs10214930	0.697	rs6942908	chr7:27905918	G/A	cg05786569	chr7:27702416	HIBADH	0.46	5.49	0.32	9.56e-8	Hypospadias;
CESC	cis	rs3806843	1.000	rs2879089	chr5:140191893	A/T	cg16179182	chr5:140090404	VTRNA1-1	-0.4	-5.11	-0.3	6.18e-7	Depressive symptoms (multi-trait analysis);
CESC	trans	rs7786808	0.712	rs2335170	chr7:158207101	G/A	cg03441993	chr4:55093323	NA	0.4	6.06	0.35	4.59e-9	Obesity-related traits;
CESC	cis	rs59574136	1	rs59574136	chr7:2036460	T/C	cg23048001	chr7:2026167	MAD1L1	0.46	6.09	0.35	3.99e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs6499255	0.951	rs12595869	chr16:69729794	T/G	cg15192750	chr16:69999425	NA	0.52	6.0	0.35	6.51e-9	IgE levels;
CESC	cis	rs1577917	1.000	rs1577919	chr6:86757296	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-6.01	-0.35	5.96e-9	Response to antipsychotic treatment;
CESC	cis	rs919433	0.783	rs55725278	chr2:198238223	C/T	cg20885578	chr2:198174922	NA	0.4	5.35	0.31	1.88e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs7762018	0.891	rs3088346	chr6:170149793	T/C	cg13891659	chr6:170190454	C6orf122;C6orf208	0.65	6.35	0.36	9.55e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs6964587	1.000	rs6946356	chr7:91727385	G/A	cg17063962	chr7:91808500	NA	0.56	7.73	0.43	2.31e-13	Breast cancer;
CESC	cis	rs796364	0.806	rs76112266	chr2:201087157	C/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.76	-6.63	-0.38	1.84e-10	Schizophrenia;
CESC	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg10150615	chr22:24372951	LOC391322	-0.55	-7.31	-0.41	3.06e-12	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs910316	0.664	rs2098252	chr14:75492732	T/C	cg16144293	chr14:75469539	EIF2B2	-0.4	-5.32	-0.31	2.22e-7	Height;
CESC	cis	rs72781680	0.898	rs55657921	chr2:24008091	C/G	cg08917208	chr2:24149416	ATAD2B	0.95	8.71	0.47	3.45e-16	Lymphocyte counts;
CESC	cis	rs796364	0.806	rs11688168	chr2:200916004	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.84	-7.75	-0.43	1.94e-13	Schizophrenia;
CESC	cis	rs4862750	0.837	rs1863404	chr4:187874654	T/C	cg10295955	chr4:187884368	NA	-0.98	-17.53	-0.73	3.27e-46	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00566492	chr22:39096679	JOSD1	0.56	6.25	0.36	1.62e-9	Gut microbiome composition (summer);
CESC	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg09060608	chr5:178986726	RUFY1	-0.55	-8.6	-0.47	7.21e-16	Lung cancer;
CESC	cis	rs10504073	0.647	rs341807	chr8:50032676	C/T	cg00325661	chr8:49890786	NA	0.51	7.5	0.42	9.61e-13	Blood metabolite ratios;
CESC	trans	rs11098499	0.954	rs11098525	chr4:120390152	G/A	cg25214090	chr10:38739885	LOC399744	0.71	10.34	0.54	2.77e-21	Corneal astigmatism;
CESC	cis	rs654950	0.967	rs621727	chr1:41984612	C/T	cg06885757	chr1:42089581	HIVEP3	-0.53	-7.9	-0.44	7.69e-14	Airway imaging phenotypes;
CESC	cis	rs72945132	1.000	rs72945129	chr11:70110808	C/T	cg14191688	chr11:70257035	CTTN	0.42	5.1	0.3	6.56e-7	Coronary artery disease;
CESC	cis	rs7208859	0.573	rs8064686	chr17:29134839	C/T	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.79e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg04090027	chr2:97760622	FAHD2B	-0.45	-7.0	-0.4	2.11e-11	Vertical cup-disc ratio;
CESC	cis	rs4665809	0.567	rs6711402	chr2:26430983	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.03	-11.57	-0.58	2.49e-25	Gut microbiome composition (summer);
CESC	cis	rs769267	0.931	rs2965193	chr19:19454828	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.43	-5.42	-0.32	1.34e-7	Tonsillectomy;
CESC	cis	rs10851478	0.558	rs4389093	chr15:49743069	A/G	cg08060515	chr15:49448048	GALK2;COPS2	0.5	6.35	0.36	9.27e-10	Oral cavity cancer;
CESC	cis	rs9894429	0.789	rs7219915	chr17:79591813	C/T	cg21984481	chr17:79567631	NPLOC4	-0.56	-8.99	-0.48	4.98e-17	Eye color traits;
CESC	cis	rs1577917	1.000	rs1577917	chr6:86691940	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.51	-6.46	-0.37	4.93e-10	Response to antipsychotic treatment;
CESC	cis	rs736408	0.609	rs2336545	chr3:52787603	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.49	-6.54	-0.37	3.08e-10	Bipolar disorder;
CESC	cis	rs9837602	1.000	rs9878931	chr3:99712634	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.53	7.24	0.41	4.82e-12	Breast cancer;
CESC	cis	rs67311347	0.544	rs4974040	chr3:40331059	G/A	cg09455208	chr3:40491958	NA	0.35	6.24	0.36	1.68e-9	Renal cell carcinoma;
CESC	cis	rs1355223	0.506	rs11032899	chr11:34870234	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.55	-6.64	-0.38	1.81e-10	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs72945132	0.882	rs7943547	chr11:70133282	C/A	cg14191688	chr11:70257035	CTTN	0.41	5.19	0.3	4.24e-7	Coronary artery disease;
CESC	trans	rs7246657	0.943	rs1382357	chr19:37977609	G/A	cg24637308	chr11:6592297	DNHD1	0.53	6.13	0.35	3.16e-9	Coronary artery calcification;
CESC	cis	rs7824557	0.583	rs2263512	chr8:11233419	T/G	cg21775007	chr8:11205619	TDH	-0.55	-8.22	-0.45	9.13e-15	Retinal vascular caliber;
CESC	cis	rs863345	0.604	rs1873510	chr1:158461418	G/A	cg12129480	chr1:158549410	OR10X1	-0.35	-7.17	-0.4	7.58e-12	Pneumococcal bacteremia;
CESC	cis	rs2562784	0.597	rs2562785	chr15:84286021	G/T	cg17507749	chr15:85114479	UBE2QP1	0.57	5.37	0.31	1.74e-7	Height;
CESC	cis	rs7178572	0.568	rs3743478	chr15:77400388	T/C	cg22256960	chr15:77711686	NA	-0.53	-6.65	-0.38	1.69e-10	Type 2 diabetes;
CESC	cis	rs6674176	0.660	rs6680421	chr1:44408969	A/C	cg12908607	chr1:44402522	ARTN	0.49	7.42	0.41	1.63e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	trans	rs6677604	1.000	rs16840639	chr1:196824773	T/C	cg02859443	chr16:53737878	RPGRIP1L;FTO	-0.62	-6.07	-0.35	4.34e-9	IgA nephropathy;Nephropathy;Blood protein levels;
CESC	cis	rs780096	0.526	rs1260342	chr2:27663416	G/T	cg24768116	chr2:27665128	KRTCAP3	-0.3	-5.57	-0.32	6.2e-8	Total body bone mineral density;
CESC	trans	rs1814175	0.616	rs847641	chr11:49919261	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.43	-6.36	-0.36	8.98e-10	Height;
CESC	cis	rs8017423	0.765	rs8017170	chr14:90721849	T/A	cg14092571	chr14:90743983	NA	-0.55	-8.31	-0.45	5.07e-15	Mortality in heart failure;
CESC	cis	rs2228479	0.850	rs11640188	chr16:89807732	C/T	cg06558623	chr16:89946397	TCF25	1.15	9.22	0.49	9.66e-18	Skin colour saturation;
CESC	cis	rs10504073	0.647	rs2292399	chr8:49987230	A/G	cg00325661	chr8:49890786	NA	0.55	8.17	0.45	1.29e-14	Blood metabolite ratios;
CESC	cis	rs10504229	0.871	rs56048296	chr8:58163781	C/T	cg05313129	chr8:58192883	C8orf71	-0.43	-5.41	-0.32	1.43e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs7799006	0.691	rs10447541	chr7:2301578	T/G	cg12745145	chr7:2261452	MAD1L1	-0.33	-5.22	-0.31	3.56e-7	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs9611565	0.649	rs139540	chr22:42178040	C/T	cg03806693	chr22:41940476	POLR3H	-0.8	-9.68	-0.51	3.51e-19	Vitiligo;
CESC	cis	rs2075371	0.933	rs1868784	chr7:133945932	A/G	cg20476274	chr7:133979776	SLC35B4	0.64	9.32	0.5	4.57e-18	Mean platelet volume;
CESC	cis	rs798554	0.679	rs1636254	chr7:2885724	T/C	cg19717773	chr7:2847554	GNA12	-0.47	-6.75	-0.38	9.38e-11	Height;
CESC	cis	rs853679	0.517	rs1947863	chr6:28099344	G/A	cg23281280	chr6:28129359	ZNF389	0.59	8.16	0.45	1.34e-14	Depression;
CESC	cis	rs1707322	1.000	rs4660336	chr1:46487976	T/C	cg03146154	chr1:46216737	IPP	-0.71	-9.69	-0.51	3.37e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs11252926	0.801	rs12358553	chr10:558014	C/T	cg18196295	chr10:418757	DIP2C	-0.48	-5.71	-0.33	3.02e-8	Psychosis in Alzheimer's disease;
CESC	cis	rs9549367	0.713	rs2476319	chr13:113836519	C/T	cg18105134	chr13:113819100	PROZ	0.55	7.12	0.4	1.04e-11	Platelet distribution width;
CESC	cis	rs7264396	1.000	rs224435	chr20:34154087	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.51	-6.04	-0.35	5.27e-9	Total cholesterol levels;
CESC	cis	rs597539	0.552	rs6591360	chr11:68718669	G/T	cg18350739	chr11:68623251	NA	-0.38	-5.7	-0.33	3.14e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs2742417	0.603	rs9826208	chr3:45773991	C/T	cg04837898	chr3:45731254	SACM1L	-0.46	-6.11	-0.35	3.5e-9	Response to anti-depressant treatment in major depressive disorder;
CESC	cis	rs1218582	0.741	rs2335407	chr1:154843347	A/G	cg06221963	chr1:154839813	KCNN3	0.72	12.47	0.61	2.13e-28	Prostate cancer;
CESC	cis	rs6088590	1.000	rs2295353	chr20:33356511	C/T	cg24642439	chr20:33292090	TP53INP2	0.86	11.84	0.59	3.04e-26	Coronary artery disease;
CESC	cis	rs6800768	0.633	rs57903454	chr3:24092407	A/T	cg10674438	chr3:24145617	LOC152024	-0.42	-5.69	-0.33	3.32e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs6952808	0.792	rs11771973	chr7:1950440	C/G	cg00106254	chr7:1943704	MAD1L1	-0.48	-6.09	-0.35	4.03e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs782590	0.967	rs2627759	chr2:55853341	T/C	cg18811423	chr2:55921094	PNPT1	0.83	13.52	0.64	4.95e-32	Metabolic syndrome;
CESC	cis	rs1595825	0.628	rs6760078	chr2:198563742	A/T	cg00982548	chr2:198649783	BOLL	-0.52	-5.82	-0.34	1.73e-8	Ulcerative colitis;
CESC	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.48	-5.11	-0.3	6.3e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs763121	0.785	rs5750646	chr22:39013830	T/C	cg06022373	chr22:39101656	GTPBP1	0.95	17.28	0.73	2.5e-45	Menopause (age at onset);
CESC	trans	rs9325144	0.647	rs12227834	chr12:38849246	G/C	cg23762105	chr12:34175262	ALG10	0.46	6.04	0.35	5.3e-9	Morning vs. evening chronotype;
CESC	cis	rs6679073	1.000	rs10494874	chr1:205754688	C/G	cg23034840	chr1:205782522	SLC41A1	0.75	9.71	0.51	2.83e-19	Prostate-specific antigen levels;
CESC	cis	rs798554	0.660	rs2644296	chr7:2859061	A/T	cg19717773	chr7:2847554	GNA12	-0.52	-8.07	-0.44	2.43e-14	Height;
CESC	trans	rs61931739	0.929	rs10844748	chr12:34092930	G/T	cg26384229	chr12:38710491	ALG10B	-0.47	-6.57	-0.37	2.71e-10	Morning vs. evening chronotype;
CESC	cis	rs2576037	0.562	rs612519	chr18:44379490	G/A	cg19077165	chr18:44547161	KATNAL2	-0.62	-9.41	-0.5	2.43e-18	Personality dimensions;
CESC	cis	rs3747547	0.892	rs72726029	chr9:38032868	C/T	cg13774184	chr9:37916125	SHB	-0.72	-6.04	-0.35	5.24e-9	Metabolite levels (Dihydroxy docosatrienoic acid);
CESC	cis	rs9682041	1.000	rs6773095	chr3:170082181	A/G	cg11886554	chr3:170076028	SKIL	1.05	8.52	0.46	1.25e-15	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CESC	cis	rs7666738	0.830	rs28785514	chr4:98959135	G/A	cg03676636	chr4:99064102	C4orf37	0.33	5.12	0.3	5.76e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4727027	0.704	rs12537763	chr7:148903984	G/A	cg23583168	chr7:148888333	NA	-0.93	-17.07	-0.72	1.37e-44	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs597539	0.652	rs627731	chr11:68698663	A/C	cg04772025	chr11:68637568	NA	0.56	6.57	0.37	2.6200000000000003e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs11723261	0.582	rs11732336	chr4:140512	A/G	cg12746427	chr4:53362	ZNF718;ZNF595	0.49	6.21	0.36	1.99e-9	Immune response to smallpox vaccine (IL-6);
CESC	cis	rs9513593	1.000	rs9585040	chr13:100015539	T/C	cg21788972	chr13:99853209	UBAC2	0.69	7.6	0.42	5.03e-13	Psoriasis;
CESC	cis	rs1975974	0.511	rs56047890	chr17:21733405	G/A	cg18423549	chr17:21743878	NA	-0.62	-8.74	-0.47	2.81e-16	Psoriasis;
CESC	cis	rs896854	1.000	rs7003387	chr8:95961979	C/G	cg23172400	chr8:95962367	TP53INP1	-0.5	-10.43	-0.54	1.43e-21	Type 2 diabetes;
CESC	cis	rs637571	0.522	rs28578718	chr11:65748400	C/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.73	10.65	0.55	2.82e-22	Eosinophil percentage of white cells;
CESC	cis	rs4819052	0.765	rs2838854	chr21:46680364	A/G	cg11663144	chr21:46675770	NA	-0.62	-9.78	-0.51	1.79e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs265548	0.646	rs36689	chr19:17910639	A/G	cg16024904	chr19:17905718	B3GNT3	0.43	5.73	0.33	2.74e-8	Tumor biomarkers;
CESC	cis	rs11864453	0.826	rs12448315	chr16:72147242	G/T	cg16558253	chr16:72132732	DHX38	-0.61	-9.68	-0.51	3.71e-19	Fibrinogen levels;
CESC	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg17178900	chr1:205818956	PM20D1	-0.66	-10.93	-0.56	3.48e-23	Monocyte percentage of white cells;
CESC	cis	rs4901847	0.562	rs11628678	chr14:58611623	A/C	cg15908186	chr14:58618357	C14orf37	0.36	5.38	0.31	1.61e-7	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs7216064	1.000	rs11079706	chr17:65835470	G/T	cg12091567	chr17:66097778	LOC651250	-0.86	-8.83	-0.48	1.49e-16	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs1799949	0.965	rs8070179	chr17:41202688	G/A	cg05368731	chr17:41323189	NBR1	0.5	6.86	0.39	4.72e-11	Menopause (age at onset);
CESC	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg26338869	chr17:61819248	STRADA	0.67	8.77	0.47	2.24e-16	Prudent dietary pattern;
CESC	cis	rs3126085	0.867	rs12748016	chr1:152197235	T/C	cg03465714	chr1:152285911	FLG	0.44	5.25	0.31	3.15e-7	Atopic dermatitis;
CESC	trans	rs1814175	0.616	rs1794131	chr11:49904194	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.43	-6.36	-0.36	8.98e-10	Height;
CESC	cis	rs6572548	0.504	rs1956082	chr14:49665496	A/C	cg13402779	chr14:50101323	C14orf104	-0.47	-5.23	-0.31	3.49e-7	Subjective well-being;
CESC	cis	rs7208859	0.673	rs216435	chr17:28922737	G/T	cg17105886	chr17:28927953	LRRC37B2	0.62	5.48	0.32	1.01e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs11763147	1	rs11763147	chr7:65326821	C/T	cg26939375	chr7:64535504	NA	-0.75	-10.64	-0.55	2.96e-22	Corneal structure;
CESC	cis	rs131777	0.708	rs131749	chr22:51024624	C/T	cg00083937	chr22:51039805	MAPK8IP2	-0.4	-5.66	-0.33	3.88e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	cis	rs9926296	0.533	rs9938865	chr16:89867797	A/G	cg07648498	chr16:89883185	FANCA	0.51	6.41	0.37	6.66e-10	Vitiligo;
CESC	trans	rs9650657	0.529	rs10108618	chr8:10953092	A/G	cg15556689	chr8:8085844	FLJ10661	-0.48	-6.18	-0.35	2.46e-9	Neuroticism;
CESC	cis	rs2066819	1.000	rs59811639	chr12:56695954	C/T	cg26804944	chr12:56660921	COQ10A	-0.85	-5.19	-0.3	4.22e-7	Psoriasis vulgaris;
CESC	cis	rs1003719	0.667	rs28666643	chr21:38455999	T/G	cg10648535	chr21:38446584	PIGP;TTC3	0.52	6.57	0.37	2.58e-10	Eye color traits;
CESC	cis	rs12477438	0.765	rs7340412	chr2:99661148	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.64	-8.73	-0.47	2.94e-16	Chronic sinus infection;
CESC	cis	rs875971	0.964	rs778735	chr7:65814809	C/A	cg18876405	chr7:65276391	NA	0.49	6.54	0.37	3.11e-10	Aortic root size;
CESC	cis	rs34779708	0.931	rs3740083	chr10:35320383	C/T	cg04310649	chr10:35416472	CREM	-0.51	-6.24	-0.36	1.76e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs10791097	1.000	rs10791098	chr11:130718711	T/G	cg12179176	chr11:130786555	SNX19	0.58	8.39	0.46	2.91e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs3749237	0.595	rs7621003	chr3:49411404	T/C	cg07636037	chr3:49044803	WDR6	0.62	8.98	0.48	5.18e-17	Resting heart rate;
CESC	cis	rs736801	0.808	rs72797303	chr5:131796163	T/C	cg00255919	chr5:131827918	IRF1	-0.35	-5.11	-0.3	6.23e-7	Breast cancer;Mosquito bite size;
CESC	cis	rs7208859	0.623	rs11650271	chr17:29213943	C/T	cg19761014	chr17:28927070	LRRC37B2	0.73	5.75	0.33	2.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs1401999	0.966	rs2313212	chr3:183700928	A/G	cg01324343	chr3:183735012	ABCC5	0.64	13.52	0.64	5.02e-32	Anterior chamber depth;
CESC	cis	rs561341	0.830	rs7218801	chr17:30217778	A/G	cg19193384	chr17:30244184	NA	0.49	5.14	0.3	5.37e-7	Hip circumference adjusted for BMI;
CESC	cis	rs4555082	0.794	rs2735829	chr14:105708472	C/T	cg13114125	chr14:105738426	BRF1	-0.8	-9.77	-0.51	1.83e-19	Mean platelet volume;Platelet distribution width;
CESC	trans	rs12478296	0.901	rs67951957	chr2:243004901	A/G	cg18288967	chr1:45987694	PRDX1	0.6	6.62	0.38	1.93e-10	Obesity-related traits;
CESC	cis	rs4665809	0.590	rs1368902	chr2:26440576	T/C	cg27170947	chr2:26402098	FAM59B	-0.87	-9.89	-0.52	7.6e-20	Gut microbiome composition (summer);
CESC	cis	rs9658691	0.607	rs12412701	chr10:90782323	C/T	cg03111039	chr10:90751583	FAS;ACTA2	-0.61	-5.34	-0.31	2.05e-7	Mosquito bite size;
CESC	cis	rs9916302	0.861	rs11078913	chr17:37671714	G/T	cg00129232	chr17:37814104	STARD3	-0.58	-7.8	-0.43	1.44e-13	Glomerular filtration rate (creatinine);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04749066	chr2:192746843	NA	-0.76	-9.12	-0.49	1.89e-17	Gut microbiome composition (summer);
CESC	cis	rs1144333	1.000	rs5745392	chr1:76306809	C/T	cg10523679	chr1:76189770	ACADM	0.56	5.26	0.31	3.04e-7	Attention function in attention deficit hyperactive disorder;
CESC	cis	rs17608059	0.545	rs736261	chr17:13936404	A/G	cg11395062	chr17:14139857	CDRT15	0.46	5.79	0.34	1.99e-8	Temperament;
CESC	cis	rs9611565	0.659	rs56364401	chr22:41951243	T/G	cg17376030	chr22:41985996	PMM1	0.67	7.27	0.41	3.96e-12	Vitiligo;
CESC	cis	rs1552244	0.935	rs7621551	chr3:10114205	C/T	cg08888203	chr3:10149979	C3orf24	0.53	6.72	0.38	1.11e-10	Alzheimer's disease;
CESC	cis	rs1448094	0.556	rs11610627	chr12:86167752	C/T	cg00310523	chr12:86230176	RASSF9	0.41	6.23	0.36	1.85e-9	Major depressive disorder;
CESC	cis	rs2204008	0.628	rs10876106	chr12:37990767	A/G	cg26384229	chr12:38710491	ALG10B	0.66	9.47	0.5	1.58e-18	Bladder cancer;
CESC	cis	rs2985684	0.894	rs2354439	chr14:50019417	G/C	cg04989706	chr14:50066350	PPIL5	-0.44	-5.06	-0.3	7.85e-7	Carotid intima media thickness;
CESC	cis	rs10504229	1.000	rs66731170	chr8:58187895	C/G	cg05313129	chr8:58192883	C8orf71	-0.55	-6.29	-0.36	1.34e-9	Developmental language disorder (linguistic errors);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10323457	chr2:208890222	PLEKHM3	0.55	6.14	0.35	3.08e-9	Gut microbiome composition (summer);
CESC	cis	rs8114671	0.647	rs6060268	chr20:33734293	T/C	cg24642439	chr20:33292090	TP53INP2	0.51	6.5	0.37	3.86e-10	Height;
CESC	cis	rs875971	0.929	rs12673810	chr7:65923853	T/A	cg18876405	chr7:65276391	NA	0.51	6.82	0.39	6.05e-11	Aortic root size;
CESC	cis	rs9733	0.519	rs7511673	chr1:150707636	A/T	cg04414720	chr1:150670196	GOLPH3L	0.61	8.81	0.48	1.72e-16	Tonsillectomy;
CESC	cis	rs7927592	0.763	rs2513277	chr11:68360887	T/G	cg20283391	chr11:68216788	NA	-0.42	-5.16	-0.3	4.88e-7	Total body bone mineral density;
CESC	cis	rs137603	0.644	rs137619	chr22:39706360	A/C	cg01093212	chr22:39715156	SNORD43;RPL3	-0.4	-5.11	-0.3	6.04e-7	Primary biliary cholangitis;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg12838843	chr3:141205758	RASA2	-0.5	-6.16	-0.35	2.65e-9	Ulcerative colitis;
CESC	cis	rs1448094	0.512	rs7970842	chr12:86243258	C/T	cg02569458	chr12:86230093	RASSF9	0.49	7.21	0.41	5.78e-12	Major depressive disorder;
CESC	cis	rs7949030	0.588	rs2428548	chr11:62311462	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.58	8.57	0.47	8.59e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs7089973	0.872	rs10490908	chr10:116616162	T/C	cg25233709	chr10:116636983	FAM160B1	0.35	5.08	0.3	7.02e-7	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs2865126	0.779	rs4796905	chr18:10755251	T/C	cg21165219	chr18:10698044	FAM38B	-0.5	-5.18	-0.3	4.48e-7	Metabolite levels (5-HIAA/ MHPG Ratio);
CESC	cis	rs9611565	0.659	rs4822034	chr22:41931010	T/C	cg06481639	chr22:41940642	POLR3H	-0.61	-6.39	-0.37	7.34e-10	Vitiligo;
CESC	cis	rs11997175	0.550	rs6468206	chr8:33780878	A/C	ch.8.33884649F	chr8:33765107	NA	0.63	7.85	0.43	1e-13	Body mass index;
CESC	cis	rs4588572	0.643	rs1560196	chr5:77701982	G/C	cg11547950	chr5:77652471	NA	0.46	5.95	0.34	8.49e-9	Triglycerides;
CESC	cis	rs17376456	0.877	rs34184666	chr5:93444584	T/C	cg21475434	chr5:93447410	FAM172A	0.85	7.6	0.42	5.01e-13	Diabetic retinopathy;
CESC	cis	rs3008870	0.701	rs2815358	chr1:67493778	T/C	cg02640540	chr1:67518911	SLC35D1	0.44	5.36	0.31	1.84e-7	Lymphocyte percentage of white cells;
CESC	cis	rs6460942	1.000	rs75564554	chr7:12319362	A/C	cg06484146	chr7:12443880	VWDE	-0.81	-8.78	-0.47	2.13e-16	Coronary artery disease;
CESC	cis	rs12497850	0.805	rs6446198	chr3:49007638	T/A	cg03060546	chr3:49711283	APEH	0.51	6.07	0.35	4.29e-9	Parkinson's disease;
CESC	cis	rs4588572	0.644	rs1428864	chr5:77780263	C/T	cg11547950	chr5:77652471	NA	-0.37	-5.23	-0.31	3.52e-7	Triglycerides;
CESC	cis	rs12291225	0.546	rs11023199	chr11:14394258	A/G	cg19336497	chr11:14380999	RRAS2	-0.43	-6.29	-0.36	1.28e-9	Sense of smell;
CESC	cis	rs17666538	0.642	rs7821983	chr8:643696	A/G	cg23958373	chr8:599963	NA	0.77	6.5	0.37	3.86e-10	IgG glycosylation;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg11687679	chr13:37573611	EXOSC8;ALG5	-0.42	-6.45	-0.37	5.37e-10	Gambling;
CESC	cis	rs7618915	0.547	rs6762813	chr3:52726695	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.38	6.69	0.38	1.34e-10	Bipolar disorder;
CESC	cis	rs7666738	0.830	rs2015828	chr4:98984594	A/G	cg03467027	chr4:99064603	C4orf37	0.43	5.43	0.32	1.29e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2635047	0.967	rs2571016	chr18:44639175	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.55	-7.67	-0.43	3.35e-13	Educational attainment;
CESC	cis	rs6032067	0.632	rs35632684	chr20:43802889	C/T	cg10761708	chr20:43804764	PI3	0.56	6.65	0.38	1.7e-10	Blood protein levels;
CESC	cis	rs2072732	0.644	rs75787210	chr1:2942465	A/G	cg15211996	chr1:2936768	ACTRT2	0.34	5.63	0.33	4.63e-8	Plateletcrit;
CESC	cis	rs1472360	0.505	rs2645049	chr8:86272555	A/G	cg21346043	chr8:86351067	CA3	-0.38	-5.25	-0.31	3.15e-7	Mean corpuscular hemoglobin concentration;
CESC	cis	rs2710642	0.611	rs1534419	chr2:62883936	C/A	cg17519650	chr2:63277830	OTX1	0.45	5.3	0.31	2.47e-7	LDL cholesterol levels;LDL cholesterol;
CESC	cis	rs6088580	0.634	rs6087580	chr20:32992592	A/G	cg08999081	chr20:33150536	PIGU	-0.67	-11.93	-0.59	1.56e-26	Glomerular filtration rate (creatinine);
CESC	cis	rs7580658	0.864	rs10928761	chr2:128003247	C/T	cg10021288	chr2:128175891	PROC	-0.37	-5.91	-0.34	1.07e-8	Protein C levels;
CESC	cis	rs4971059	0.654	rs4971052	chr1:155126018	C/T	cg22049894	chr1:155113146	DPM3	0.47	6.07	0.35	4.4e-9	Breast cancer;
CESC	cis	rs6500602	0.893	rs4785962	chr16:4484328	A/G	cg08645402	chr16:4508243	NA	0.42	6.2	0.36	2.13e-9	Schizophrenia;
CESC	cis	rs858239	0.539	rs6956828	chr7:23187347	A/G	cg23682824	chr7:23144976	KLHL7	0.5	6.58	0.37	2.5e-10	Cerebrospinal fluid biomarker levels;
CESC	cis	rs11252926	0.770	rs2124585	chr10:680428	G/A	cg16386425	chr10:429943	DIP2C	-0.47	-5.89	-0.34	1.16e-8	Psychosis in Alzheimer's disease;
CESC	trans	rs1814175	0.935	rs7925863	chr11:49615802	C/A	cg03929089	chr4:120376271	NA	-0.88	-13.25	-0.63	4.46e-31	Height;
CESC	cis	rs1552244	0.554	rs13079240	chr3:10047246	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.62	7.99	0.44	4.24e-14	Alzheimer's disease;
CESC	cis	rs950776	0.518	rs11632604	chr15:78821914	T/C	cg24631222	chr15:78858424	CHRNA5	-0.42	-5.33	-0.31	2.09e-7	Sudden cardiac arrest;
CESC	cis	rs875971	0.522	rs7784623	chr7:65395034	T/G	cg11764359	chr7:65958608	NA	0.66	8.56	0.47	9.38e-16	Aortic root size;
CESC	cis	rs41563	0.609	rs4727614	chr7:104600854	C/A	cg04380332	chr7:105027541	SRPK2	-0.38	-5.46	-0.32	1.09e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs7408868	1.000	rs8107180	chr19:15275430	T/C	cg14696996	chr19:15285081	NOTCH3	1.11	11.47	0.58	5.57e-25	Pulse pressure;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21157234	chr9:101984918	ALG2;SEC61B	0.59	6.83	0.39	5.8200000000000003e-11	Gut microbiome composition (summer);
CESC	cis	rs9916302	0.861	rs4795377	chr17:37669056	C/T	cg19468946	chr17:37922297	IKZF3	-0.39	-5.06	-0.3	7.91e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs1018836	0.851	rs7004287	chr8:91620842	G/C	cg16814680	chr8:91681699	NA	-0.77	-11.99	-0.59	9.5e-27	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs10504229	0.645	rs35142596	chr8:58128151	C/T	cg22535103	chr8:58192502	C8orf71	-0.8	-8.89	-0.48	9.73e-17	Developmental language disorder (linguistic errors);
CESC	trans	rs9354308	0.966	rs1909533	chr6:66565658	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.71	7.98	0.44	4.55e-14	Metabolite levels;
CESC	cis	rs1552244	0.816	rs13076197	chr3:10019773	T/C	cg00149659	chr3:10157352	C3orf10	0.71	8.4	0.46	2.72e-15	Alzheimer's disease;
CESC	cis	rs4665809	1.000	rs4665820	chr2:26309150	T/C	cg08470875	chr2:26401718	FAM59B	-0.48	-5.27	-0.31	2.79e-7	Gut microbiome composition (summer);
CESC	cis	rs79839061	0.610	rs2279181	chr4:882643	A/G	cg07828340	chr4:882639	GAK	-0.83	-7.05	-0.4	1.51e-11	Intelligence (multi-trait analysis);
CESC	trans	rs4942242	1.000	rs9533566	chr13:44224691	T/C	cg19169023	chr15:41853346	TYRO3	-0.45	-6.48	-0.37	4.53e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs9926296	0.744	rs154657	chr16:89708096	A/G	cg01097406	chr16:89675127	NA	-0.37	-5.46	-0.32	1.08e-7	Vitiligo;
CESC	cis	rs6087990	0.731	rs2424897	chr20:31338098	A/T	cg13636640	chr20:31349939	DNMT3B	0.84	14.85	0.67	1.07e-36	Ulcerative colitis;
CESC	cis	rs1670533	0.932	rs11731289	chr4:1057773	T/G	cg27284194	chr4:1044797	NA	0.48	6.06	0.35	4.7e-9	Recombination rate (females);
CESC	cis	rs262150	0.659	rs2657340	chr7:158796968	C/T	cg09640425	chr7:158790006	NA	0.36	5.59	0.32	5.71e-8	Facial morphology (factor 20);
CESC	cis	rs8017423	0.647	rs12883000	chr14:90820557	G/A	cg14092571	chr14:90743983	NA	0.43	6.55	0.37	2.93e-10	Mortality in heart failure;
CESC	cis	rs727505	0.909	rs7810427	chr7:124645103	C/T	cg23710748	chr7:124431027	NA	-0.44	-6.9	-0.39	3.88e-11	Lewy body disease;
CESC	cis	rs3815700	1.000	rs8113165	chr19:33096316	C/T	cg24916020	chr19:33096688	ANKRD27	0.61	6.09	0.35	4.01e-9	Eosinophilic esophagitis;
CESC	cis	rs2070488	1.000	rs1002676	chr3:38444932	A/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.91	-16.26	-0.71	1.05e-41	Electrocardiographic conduction measures;
CESC	cis	rs7937682	0.924	rs6589244	chr11:111534333	T/C	cg22437258	chr11:111473054	SIK2	0.7	9.2	0.49	1.1e-17	Primary sclerosing cholangitis;
CESC	cis	rs17376456	0.877	rs35747258	chr5:93310129	C/T	cg25358565	chr5:93447407	FAM172A	1.07	10.61	0.55	3.7e-22	Diabetic retinopathy;
CESC	cis	rs73071352	0.577	rs73075228	chr3:42049629	T/G	cg03022575	chr3:42003672	ULK4	0.76	6.66	0.38	1.53e-10	Multiple myeloma and monoclonal gammopathy;Multiple myeloma;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10831391	chr10:3109765	PFKP	0.55	6.64	0.38	1.77e-10	Gut microbiome composition (summer);
CESC	cis	rs1580019	0.961	rs766660	chr7:32499077	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.73	10.1	0.53	1.62e-20	Cognitive ability;
CESC	cis	rs9910055	0.530	rs11652651	chr17:42302907	A/G	cg19774624	chr17:42201019	HDAC5	0.61	8.74	0.47	2.81e-16	Total body bone mineral density;
CESC	cis	rs9341808	0.667	rs2490239	chr6:80826289	G/A	cg08355045	chr6:80787529	NA	0.34	5.28	0.31	2.7e-7	Sitting height ratio;
CESC	cis	rs12410462	0.901	rs16847844	chr1:227638110	A/G	cg23173402	chr1:227635558	NA	0.58	5.88	0.34	1.24e-8	Major depressive disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02183680	chr14:75530768	ACYP1	-0.59	-6.98	-0.39	2.43e-11	Gut microbiome composition (summer);
CESC	cis	rs2303759	0.918	rs8107548	chr19:49870643	T/C	cg22590775	chr19:49891494	CCDC155	0.58	6.74	0.38	9.91e-11	Multiple sclerosis;
CESC	cis	rs7208859	0.623	rs80355557	chr17:29154421	C/T	cg13385521	chr17:29058706	SUZ12P	0.75	5.95	0.34	8.3e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs1003719	0.788	rs1543749	chr21:38446621	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.62	8.7	0.47	3.48e-16	Eye color traits;
CESC	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg18765753	chr7:1198926	ZFAND2A	-0.54	-8.2	-0.45	1.06e-14	Longevity;Endometriosis;
CESC	cis	rs4595586	0.546	rs11169801	chr12:39241429	G/A	cg26384229	chr12:38710491	ALG10B	0.68	10.2	0.53	7.99e-21	Morning vs. evening chronotype;
CESC	cis	rs3733585	0.673	rs6849729	chr4:9958732	T/C	cg02734326	chr4:10020555	SLC2A9	-0.43	-6.01	-0.35	6.1e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs7851660	0.967	rs1867280	chr9:100616066	G/C	cg13688889	chr9:100608707	NA	-0.69	-10.57	-0.54	4.92e-22	Strep throat;
CESC	cis	rs1401999	0.690	rs3805112	chr3:183645662	C/T	cg01324343	chr3:183735012	ABCC5	0.48	9.22	0.49	9.33e-18	Anterior chamber depth;
CESC	cis	rs4654899	1.000	rs7550267	chr1:21448792	T/C	cg05370193	chr1:21551575	ECE1	0.42	6.34	0.36	9.68e-10	Superior frontal gyrus grey matter volume;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg09287717	chr20:45035259	ELMO2	-0.41	-5.99	-0.35	6.66e-9	Gambling;
CESC	cis	rs13191362	1.000	rs13212608	chr6:163032128	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.81	8.44	0.46	2.13e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs3785574	0.962	rs2665840	chr17:61873307	C/T	cg06420487	chr17:61919686	SMARCD2	-0.43	-5.22	-0.31	3.61e-7	Height;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg23197559	chr2:232573080	PTMA	0.47	6.36	0.36	9e-10	Thyroid stimulating hormone;
CESC	cis	rs8177179	0.565	rs4355280	chr3:133468425	A/G	cg18769074	chr3:133464867	TF	0.29	5.27	0.31	2.89e-7	Iron status biomarkers (transferrin levels);
CESC	cis	rs2282802	0.685	rs10077671	chr5:139689505	C/T	cg26211634	chr5:139558579	C5orf32	0.47	6.7	0.38	1.28e-10	Intelligence (multi-trait analysis);
CESC	cis	rs4481887	1.000	rs10888358	chr1:248471467	C/A	cg00666640	chr1:248458726	OR2T12	0.4	6.57	0.37	2.7e-10	Common traits (Other);
CESC	cis	rs17001868	0.568	rs9611316	chr22:40737027	A/G	cg07138101	chr22:40742427	ADSL	0.57	5.38	0.31	1.66e-7	Mammographic density (dense area);
CESC	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg22535103	chr8:58192502	C8orf71	-0.49	-6.34	-0.36	9.76e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs7666738	0.830	rs34870112	chr4:99045815	T/G	cg03676636	chr4:99064102	C4orf37	0.33	5.12	0.3	5.93e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs7726839	0.526	rs11960159	chr5:568685	C/T	cg25482853	chr8:67687455	SGK3	0.97	10.92	0.56	3.67e-23	Obesity-related traits;
CESC	cis	rs3617	0.573	rs6795646	chr3:52922621	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	-0.34	-5.78	-0.33	2.13e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
CESC	cis	rs780096	0.546	rs35073769	chr2:27731376	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.3	-5.24	-0.31	3.21e-7	Total body bone mineral density;
CESC	cis	rs9325144	0.723	rs11169519	chr12:39177441	G/A	cg26384229	chr12:38710491	ALG10B	-0.51	-7.36	-0.41	2.26e-12	Morning vs. evening chronotype;
CESC	cis	rs238295	0.805	rs6085211	chr20:5552847	G/C	cg24001556	chr20:5591874	RP5-1022P6.2	-0.46	-5.11	-0.3	6.12e-7	Occipital cortical area (total cortical area interaction);
CESC	cis	rs6860806	0.507	rs156322	chr5:131653925	C/T	cg04518342	chr5:131593106	PDLIM4	0.37	5.24	0.31	3.31e-7	Breast cancer;
CESC	cis	rs5769765	1.000	rs764813	chr22:50286172	T/C	cg02269571	chr22:50332266	NA	-0.46	-6.26	-0.36	1.53e-9	Schizophrenia;
CESC	cis	rs2842992	0.830	rs2842974	chr6:160159034	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.7	9.25	0.49	7.84e-18	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs9910055	0.636	rs7089	chr17:42269017	T/C	cg19774624	chr17:42201019	HDAC5	-0.9	-14.62	-0.67	6.95e-36	Total body bone mineral density;
CESC	cis	rs7412746	0.658	rs3843843	chr1:150918084	C/T	cg17724175	chr1:150552817	MCL1	0.38	5.9	0.34	1.13e-8	Melanoma;
CESC	cis	rs9457247	1.000	rs2757047	chr6:167374489	C/T	cg25258033	chr6:167368657	RNASET2	-0.42	-6.29	-0.36	1.31e-9	Crohn's disease;
CESC	cis	rs7917772	0.565	rs1043450	chr10:104434209	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.59	7.25	0.41	4.63e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17042849	chr6:26104293	HIST1H4C	0.55	6.52	0.37	3.61e-10	Gut microbiome composition (summer);
CESC	cis	rs7129220	0.858	rs61878630	chr11:10132815	A/T	cg01453529	chr11:10209919	SBF2	-0.48	-5.54	-0.32	7.12e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24830314	chr6:83775579	UBE2CBP	0.61	7.5	0.42	9.66e-13	Gut microbiome composition (summer);
CESC	cis	rs6088580	0.524	rs6087612	chr20:33230822	T/G	cg24642439	chr20:33292090	TP53INP2	-0.45	-5.26	-0.31	2.96e-7	Glomerular filtration rate (creatinine);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24720361	chr12:57882021	MARS	-0.57	-6.65	-0.38	1.68e-10	Gut microbiome composition (summer);
CESC	cis	rs919433	0.783	rs2565158	chr2:198236103	T/A	cg20885578	chr2:198174922	NA	0.41	5.38	0.31	1.62e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs13108904	0.870	rs11721789	chr4:1254414	C/A	cg00684032	chr4:1343700	KIAA1530	0.41	5.84	0.34	1.49e-8	Obesity-related traits;
CESC	cis	rs2718058	0.519	rs2722242	chr7:37873610	A/G	cg15028436	chr7:37888078	TXNDC3	-0.46	-6.94	-0.39	2.94e-11	Alzheimer's disease (late onset);
CESC	cis	rs9322193	0.923	rs12175504	chr6:149985215	T/G	cg13206674	chr6:150067644	NUP43	0.4	5.52	0.32	8.03e-8	Lung cancer;
CESC	cis	rs2073300	1.000	rs6132628	chr20:23446734	G/A	cg12062639	chr20:23401060	NAPB	1.02	7.12	0.4	1.04e-11	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs9549260	1.000	rs9549260	chr13:41254104	G/T	cg21288729	chr13:41239152	FOXO1	0.55	6.26	0.36	1.54e-9	Red blood cell count;
CESC	cis	rs9910055	0.639	rs227583	chr17:42231698	C/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.49	7.37	0.41	2.19e-12	Total body bone mineral density;
CESC	cis	rs12618769	0.597	rs72821946	chr2:99142411	G/C	cg10123293	chr2:99228465	UNC50	0.41	5.44	0.32	1.24e-7	Bipolar disorder;
CESC	cis	rs798554	0.721	rs2527680	chr7:2892361	C/T	cg18446336	chr7:2847575	GNA12	-0.34	-5.16	-0.3	4.83e-7	Height;
CESC	cis	rs875971	0.540	rs736270	chr7:65428822	T/C	cg14393609	chr7:65229607	NA	0.5	6.67	0.38	1.52e-10	Aortic root size;
CESC	cis	rs3126085	0.935	rs10888475	chr1:152226012	C/T	cg03465714	chr1:152285911	FLG	-0.43	-5.5	-0.32	9.02e-8	Atopic dermatitis;
CESC	trans	rs7615952	0.599	rs6438953	chr3:125724951	T/C	cg07211511	chr3:129823064	LOC729375	-0.59	-7.29	-0.41	3.66e-12	Blood pressure (smoking interaction);
CESC	cis	rs36051895	0.530	rs4425810	chr9:5222208	A/G	cg02405213	chr9:5042618	JAK2	-0.52	-6.3	-0.36	1.26e-9	Pediatric autoimmune diseases;
CESC	cis	rs2276314	1.000	rs1789513	chr18:33545630	A/G	cg05985134	chr18:33552581	C18orf21	-0.67	-7.94	-0.44	5.61e-14	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs13108904	0.539	rs11247997	chr4:1361057	T/C	cg00684032	chr4:1343700	KIAA1530	0.5	6.87	0.39	4.52e-11	Obesity-related traits;
CESC	cis	rs6460942	1.000	rs2033871	chr7:12405098	C/A	cg06484146	chr7:12443880	VWDE	-0.7	-8.15	-0.45	1.5e-14	Coronary artery disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg19230709	chr19:4933046	UHRF1	0.49	6.41	0.37	6.81e-10	Fibrinogen levels;
CESC	cis	rs4595586	0.525	rs12818844	chr12:39423806	A/G	cg13010199	chr12:38710504	ALG10B	0.44	5.42	0.32	1.31e-7	Morning vs. evening chronotype;
CESC	cis	rs7927771	1.000	rs10838747	chr11:47716324	G/C	cg05585544	chr11:47624801	NA	-0.5	-7.9	-0.44	7.51e-14	Subjective well-being;
CESC	cis	rs4908768	0.539	rs1809332	chr1:8656434	C/T	cg00120948	chr1:8484417	RERE	-0.32	-5.03	-0.3	9.13e-7	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
CESC	cis	rs1729951	0.575	rs1654904	chr3:136681149	T/C	cg04103450	chr3:136751342	NA	0.4	5.28	0.31	2.67e-7	Neuroticism;
CESC	cis	rs933688	1.000	rs2052553	chr5:90729906	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.17	16.18	0.7	2e-41	Smoking behavior;
CESC	cis	rs7927592	0.913	rs10896346	chr11:68352671	C/T	cg20283391	chr11:68216788	NA	-0.61	-7.29	-0.41	3.48e-12	Total body bone mineral density;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18442181	chr17:29233375	C17orf42	0.59	6.93	0.39	3.23e-11	Gut microbiome composition (summer);
CESC	cis	rs854765	0.583	rs8075965	chr17:17853180	A/T	cg09796270	chr17:17721594	SREBF1	0.44	6.05	0.35	4.92e-9	Total body bone mineral density;
CESC	cis	rs13108904	0.934	rs13124383	chr4:1299986	C/T	cg22903657	chr4:1355424	KIAA1530	-0.37	-5.1	-0.3	6.6e-7	Obesity-related traits;
CESC	cis	rs55871839	0.619	rs6471756	chr8:59802159	A/G	cg07426533	chr8:59803705	TOX	-0.5	-7.23	-0.41	5.26e-12	Pneumonia;
CESC	cis	rs4764487	0.735	rs2072370	chr12:6345080	A/G	cg08284733	chr12:6341482	CD9	-0.41	-6.22	-0.36	1.97e-9	Mean platelet volume;
CESC	cis	rs597539	0.652	rs544370	chr11:68653232	C/T	cg04772025	chr11:68637568	NA	0.51	6.38	0.36	7.84e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs10170846	0.789	rs972650	chr2:223520287	C/T	cg25565276	chr2:223520875	FARSB	0.5	6.97	0.39	2.5e-11	Schizophrenia (inflammation and infection response interaction);
CESC	cis	rs34779708	0.931	rs7099036	chr10:35349574	C/T	cg03585969	chr10:35415529	CREM	0.76	10.04	0.52	2.64e-20	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs1552244	0.882	rs13064570	chr3:9997545	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.72	-9.34	-0.5	3.96e-18	Alzheimer's disease;
CESC	trans	rs10510829	1.000	rs11715209	chr3:60123590	A/G	cg02594498	chr15:22893147	CYFIP1	0.56	6.02	0.35	5.83e-9	Adverse response to lamotrigine and phenytoin;
CESC	cis	rs12477438	0.765	rs7591794	chr2:99567514	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.65	-9.4	-0.5	2.65e-18	Chronic sinus infection;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26593967	chr16:89926151	SPIRE2	-0.48	-6.07	-0.35	4.48e-9	Gut microbiome composition (summer);
CESC	cis	rs2952156	0.883	rs907089	chr17:37833600	C/T	cg00129232	chr17:37814104	STARD3	-0.72	-10.14	-0.53	1.25e-20	Asthma;
CESC	cis	rs3733585	0.673	rs4292333	chr4:9953871	G/A	cg11266682	chr4:10021025	SLC2A9	-0.58	-11.0	-0.56	2.04e-23	Cleft plate (environmental tobacco smoke interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03993171	chr6:86388501	SNORD50B;SNORD50A;SNHG5	0.55	6.51	0.37	3.66e-10	Gut microbiome composition (summer);
CESC	cis	rs763121	0.853	rs2072798	chr22:39148483	G/A	cg06544989	chr22:39130855	UNC84B	0.5	8.92	0.48	7.59e-17	Menopause (age at onset);
CESC	cis	rs1552244	0.882	rs13064570	chr3:9997545	G/C	cg00166722	chr3:10149974	C3orf24	0.48	6.18	0.36	2.38e-9	Alzheimer's disease;
CESC	cis	rs4642101	0.662	rs1969154	chr3:12829156	A/G	cg24848339	chr3:12840334	CAND2	0.36	5.47	0.32	1.06e-7	QRS complex (12-leadsum);
CESC	cis	rs9660992	0.573	rs12144980	chr1:205185104	C/T	cg21643547	chr1:205240462	TMCC2	-0.39	-5.5	-0.32	8.97e-8	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs9858542	0.953	rs9841110	chr3:49492481	C/G	cg07274523	chr3:49395745	GPX1	0.65	7.92	0.44	6.77e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs116095464	0.558	rs9312956	chr5:201812	T/C	cg22496380	chr5:211416	CCDC127	-0.95	-10.44	-0.54	1.37e-21	Breast cancer;
CESC	cis	rs72945132	0.882	rs3900797	chr11:70186614	C/T	cg14191688	chr11:70257035	CTTN	0.44	5.62	0.33	4.82e-8	Coronary artery disease;
CESC	cis	rs875971	0.638	rs801205	chr7:66022144	C/A	cg11764359	chr7:65958608	NA	-0.73	-9.8	-0.52	1.49e-19	Aortic root size;
CESC	cis	rs55794721	0.509	rs873308	chr1:25758655	A/G	cg02931644	chr1:25747376	RHCE	-0.47	-8.21	-0.45	9.84e-15	Plateletcrit;Mean corpuscular volume;
CESC	cis	rs10465746	0.780	rs2389648	chr1:84403031	C/T	cg10977910	chr1:84465055	TTLL7	0.53	7.18	0.4	7.19e-12	Obesity-related traits;
CESC	cis	rs614226	0.935	rs3887875	chr12:120895749	A/G	cg01236616	chr12:121019343	POP5	-1.39	-15.84	-0.7	3.24e-40	Type 1 diabetes nephropathy;
CESC	trans	rs7741085	0.967	rs11752730	chr6:44639100	C/G	cg04735960	chr13:21006388	CRYL1	0.44	6.08	0.35	4.09e-9	Total body bone mineral density;
CESC	cis	rs13191362	1.000	rs13209728	chr6:162997533	A/C	cg06582575	chr6:163149167	PACRG;PARK2	0.79	8.31	0.45	5.17e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs7208859	0.623	rs28433704	chr17:29084285	G/C	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.91e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	trans	rs916888	0.647	rs199449	chr17:44808902	G/A	cg01341218	chr17:43662625	NA	0.55	7.39	0.41	1.86e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs2242116	0.796	rs7645278	chr3:46974100	A/C	cg02527881	chr3:46936655	PTH1R	-0.51	-7.38	-0.41	2.01e-12	Birth weight;
CESC	cis	rs3785574	0.962	rs2727332	chr17:61878584	T/A	cg07677032	chr17:61819896	STRADA	0.41	5.17	0.3	4.59e-7	Height;
CESC	cis	rs853679	0.517	rs9380050	chr6:28048538	A/G	cg17949981	chr6:28129498	ZNF389	0.45	5.62	0.33	4.9e-8	Depression;
CESC	cis	rs72945132	0.882	rs17160762	chr11:70134766	A/G	cg14191688	chr11:70257035	CTTN	-0.42	-5.24	-0.31	3.35e-7	Coronary artery disease;
CESC	cis	rs12900413	0.603	rs2882678	chr15:90299542	A/G	cg24249390	chr15:90295951	MESP1	-0.4	-5.42	-0.32	1.33e-7	Coronary artery aneurysm in Kawasaki disease;
CESC	cis	rs7223966	1.000	rs2013288	chr17:61785904	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.57	7.04	0.4	1.61e-11	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs7666738	0.830	rs13113899	chr4:99050422	T/C	cg18180107	chr4:99064573	C4orf37	0.39	5.05	0.3	8.17e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9322193	0.923	rs9767123	chr6:149981459	A/G	cg07701084	chr6:150067640	NUP43	0.45	6.26	0.36	1.55e-9	Lung cancer;
CESC	cis	rs7666738	0.830	rs11941844	chr4:99042722	A/T	cg03676636	chr4:99064102	C4orf37	0.33	5.12	0.3	5.93e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs853679	0.517	rs17774663	chr6:28120898	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.6	-6.82	-0.39	6.29e-11	Depression;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19136717	chr15:72766740	ARIH1	0.66	7.65	0.43	3.62e-13	Gut microbiome composition (summer);
CESC	cis	rs116095464	0.558	rs57335027	chr5:262907	A/G	cg12570787	chr5:219185	SDHA;CCDC127	0.53	5.49	0.32	9.44e-8	Breast cancer;
CESC	cis	rs4076764	0.801	rs12046142	chr1:163375247	G/A	cg24596788	chr1:163392923	NA	-0.42	-5.99	-0.35	6.85e-9	Motion sickness;
CESC	cis	rs10754283	0.935	rs1934046	chr1:90119290	A/T	cg21401794	chr1:90099060	LRRC8C	-0.66	-8.7	-0.47	3.61e-16	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs6952808	0.929	rs11768206	chr7:1932151	T/G	cg21782813	chr7:2030301	MAD1L1	0.42	5.98	0.35	7e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs7131987	0.845	rs2042511	chr12:29408780	C/T	cg09582351	chr12:29534625	ERGIC2	-0.35	-5.59	-0.32	5.57e-8	QT interval;
CESC	cis	rs7666738	0.753	rs1830230	chr4:99026186	G/C	cg18180107	chr4:99064573	C4orf37	0.42	5.43	0.32	1.29e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2576037	0.523	rs1539881	chr18:44477897	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.38	6.16	0.35	2.66e-9	Personality dimensions;
CESC	cis	rs727505	0.521	rs66787780	chr7:124791849	G/A	cg23710748	chr7:124431027	NA	-0.4	-6.2	-0.36	2.11e-9	Lewy body disease;
CESC	cis	rs9660180	0.967	rs6603802	chr1:1812521	C/T	cg03396347	chr1:1875803	NA	-0.44	-6.96	-0.39	2.68e-11	Body mass index;
CESC	cis	rs17854409	0.536	rs3765464	chr20:61485236	T/C	cg05147244	chr20:61493195	TCFL5	1.0	7.42	0.41	1.64e-12	Obesity-related traits;
CESC	cis	rs8018808	1.000	rs11844594	chr14:77843814	T/C	cg20045696	chr14:77926864	AHSA1	-0.38	-5.18	-0.3	4.32e-7	Myeloid white cell count;
CESC	cis	rs7605827	0.538	rs62120660	chr2:15659613	T/C	cg19274914	chr2:15703543	NA	0.36	6.31	0.36	1.18e-9	Educational attainment (years of education);
CESC	cis	rs4555082	0.681	rs28588570	chr14:105709606	A/T	cg06808227	chr14:105710500	BRF1	-0.61	-7.43	-0.42	1.48e-12	Mean platelet volume;Platelet distribution width;
CESC	cis	rs1538970	0.739	rs4660863	chr1:45955868	T/C	cg03146154	chr1:46216737	IPP	0.49	5.57	0.32	6.31e-8	Platelet count;
CESC	cis	rs13108904	0.539	rs11247997	chr4:1361057	T/C	cg02018176	chr4:1364513	KIAA1530	0.41	5.04	0.3	8.73e-7	Obesity-related traits;
CESC	cis	rs35955747	0.714	rs4820048	chr22:31854370	A/G	cg25791279	chr22:32026902	PISD	-0.44	-5.22	-0.31	3.56e-7	Neutrophil count;Sum basophil neutrophil counts;
CESC	cis	rs6502050	0.740	rs4789748	chr17:80093061	A/C	cg11859384	chr17:80120422	CCDC57	-0.38	-5.16	-0.3	4.92e-7	Life satisfaction;
CESC	cis	rs7917772	0.545	rs10786681	chr10:104317357	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.41	5.69	0.33	3.27e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs7666738	0.791	rs1115615	chr4:99006614	G/A	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.62e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6754311	0.773	rs309125	chr2:136643555	C/T	cg07169764	chr2:136633963	MCM6	0.68	8.53	0.46	1.14e-15	Mosquito bite size;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg23393291	chr15:101142359	ASB7;LINS1	-0.45	-6.01	-0.35	6.16e-9	Height;
CESC	cis	rs1152591	0.811	rs1255986	chr14:64655161	A/G	cg23250157	chr14:64679961	SYNE2	-0.52	-7.58	-0.42	6.01e-13	Atrial fibrillation;
CESC	cis	rs1707322	1.000	rs785486	chr1:46575148	G/C	cg06784218	chr1:46089804	CCDC17	-0.33	-5.63	-0.33	4.67e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2354432	0.607	rs11579626	chr1:146741960	A/C	cg25205988	chr1:146714368	CHD1L	-0.9	-7.78	-0.43	1.64e-13	Mitochondrial DNA levels;
CESC	trans	rs7937840	0.562	rs1047739	chr11:61919693	C/T	cg10934129	chr5:172655841	NA	-0.45	-6.41	-0.37	6.71e-10	Breast cancer;
CESC	cis	rs2836974	0.549	rs34160989	chr21:40554118	C/G	cg11644478	chr21:40555479	PSMG1	0.79	8.31	0.45	4.88e-15	Cognitive function;
CESC	cis	rs4253772	0.591	rs6008361	chr22:46652372	A/G	cg10231785	chr22:46692440	CN5H6.4;GTSE1	-0.48	-5.1	-0.3	6.43e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs4901847	0.609	rs11158198	chr14:58576320	G/T	cg15908186	chr14:58618357	C14orf37	-0.36	-5.55	-0.32	7.1e-8	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs853679	0.542	rs9380063	chr6:28137853	A/G	cg12963246	chr6:28129442	ZNF389	0.54	7.19	0.4	6.57e-12	Depression;
CESC	cis	rs2760061	0.598	rs658238	chr1:228121291	A/G	cg02753203	chr1:228287806	NA	-0.51	-7.36	-0.41	2.26e-12	Diastolic blood pressure;
CESC	cis	rs10256972	0.527	rs2949170	chr7:1216438	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.67	-10.01	-0.52	3.22e-20	Longevity;Endometriosis;
CESC	cis	rs793571	0.744	rs12901551	chr15:59160069	A/T	cg05156742	chr15:59063176	FAM63B	-0.47	-6.15	-0.35	2.78e-9	Schizophrenia;
CESC	cis	rs832540	0.656	rs702689	chr5:56177443	G/A	cg12311346	chr5:56204834	C5orf35	-0.42	-5.14	-0.3	5.32e-7	Coronary artery disease;
CESC	cis	rs13191362	0.935	rs4273664	chr6:162955494	T/G	cg21926612	chr6:163149169	PACRG;PARK2	0.79	7.79	0.43	1.52e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs2072732	0.861	rs10909865	chr1:2956163	A/G	cg03976712	chr1:2946727	NA	0.33	5.53	0.32	7.83e-8	Plateletcrit;
CESC	trans	rs1005277	0.579	rs1614236	chr10:38502996	C/T	cg27523141	chr10:43048294	ZNF37B	0.46	6.02	0.35	5.91e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs7937682	0.961	rs7106104	chr11:111635655	T/C	cg22437258	chr11:111473054	SIK2	-0.59	-6.54	-0.37	3.21e-10	Primary sclerosing cholangitis;
CESC	cis	rs7666738	0.791	rs13120773	chr4:98972589	C/T	cg03467027	chr4:99064603	C4orf37	0.43	5.4	0.31	1.49e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11864453	0.786	rs1050362	chr16:72130815	C/A	cg16558253	chr16:72132732	DHX38	-0.61	-9.61	-0.51	6.02e-19	Fibrinogen levels;
CESC	cis	rs1775715	0.707	rs2065443	chr10:32164236	C/G	cg18675610	chr10:32216311	ARHGAP12	0.34	5.29	0.31	2.55e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs11123610	0.520	rs7576146	chr2:3718393	A/C	cg10645314	chr2:3704589	ALLC	-0.46	-5.18	-0.3	4.35e-7	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CESC	cis	rs1218582	0.711	rs4845677	chr1:154838050	C/T	cg09359103	chr1:154839909	KCNN3	-0.68	-13.02	-0.62	2.79e-30	Prostate cancer;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg22122361	chr4:79697742	BMP2K	-0.49	-6.1	-0.35	3.71e-9	Ulcerative colitis;
CESC	cis	rs16854884	0.657	rs35959290	chr3:143725566	T/A	cg06585982	chr3:143692056	C3orf58	0.47	5.77	0.33	2.18e-8	Economic and political preferences (feminism/equality);
CESC	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg22907277	chr7:1156413	C7orf50	0.47	5.43	0.32	1.27e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs9815354	0.812	rs73073323	chr3:41834051	C/T	cg03022575	chr3:42003672	ULK4	0.7	6.04	0.35	5.26e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs3092073	0.603	rs4810477	chr20:44544654	C/T	cg00125455	chr20:44574271	PCIF1	0.37	5.67	0.33	3.64e-8	Intelligence (multi-trait analysis);
CESC	cis	rs10465746	0.967	rs6670658	chr1:84461268	A/G	cg10977910	chr1:84465055	TTLL7	0.47	6.41	0.37	6.56e-10	Obesity-related traits;
CESC	cis	rs7980687	0.657	rs10744151	chr12:123723735	G/C	cg00376283	chr12:123451042	ABCB9	0.67	8.93	0.48	7.19e-17	Height;Educational attainment;Head circumference (infant);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg19567168	chr12:6438502	TNFRSF1A	0.51	6.9	0.39	3.76e-11	Fibrinogen levels;
CESC	cis	rs9322193	0.923	rs57938011	chr6:149964105	T/A	cg07701084	chr6:150067640	NUP43	0.41	5.57	0.32	6.38e-8	Lung cancer;
CESC	cis	rs6752107	0.936	rs6431660	chr2:234167234	A/G	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.4	6.07	0.35	4.35e-9	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs7267979	0.706	rs6138542	chr20:25207773	C/A	cg08601574	chr20:25228251	PYGB	0.43	6.01	0.35	6.19e-9	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs9902453	0.740	rs2617867	chr17:28049399	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.76	-10.15	-0.53	1.14e-20	Coffee consumption (cups per day);
CESC	cis	rs9905704	0.918	rs302862	chr17:56697444	G/T	cg12560992	chr17:57184187	TRIM37	0.59	7.02	0.4	1.86e-11	Testicular germ cell tumor;
CESC	cis	rs1005277	0.579	rs1780139	chr10:38503018	C/T	cg00409905	chr10:38381863	ZNF37A	-0.52	-7.04	-0.4	1.69e-11	Extrinsic epigenetic age acceleration;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13559099	chr11:62554740	TMEM179B;TAF6L	0.59	7.03	0.4	1.8e-11	Gut microbiome composition (summer);
CESC	cis	rs7258465	1.000	rs8107367	chr19:18564705	A/G	cg25828334	chr19:18545568	ISYNA1	-0.32	-5.1	-0.3	6.57e-7	Breast cancer;
CESC	cis	rs35740288	0.580	rs34526042	chr15:86339956	C/T	cg20737812	chr15:86336631	KLHL25	-0.42	-5.31	-0.31	2.28e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
CESC	cis	rs11690935	0.802	rs34636594	chr2:172911094	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.86	-11.03	-0.56	1.54e-23	Schizophrenia;
CESC	cis	rs453301	0.571	rs330048	chr8:9087278	A/C	cg17143192	chr8:8559678	CLDN23	-0.45	-5.41	-0.32	1.38e-7	Joint mobility (Beighton score);
CESC	cis	rs3820928	0.967	rs4675118	chr2:227773157	C/A	cg05526886	chr2:227700861	RHBDD1	-0.38	-5.03	-0.3	9.03e-7	Pulmonary function;
CESC	cis	rs9811920	0.609	rs4244711	chr3:99657205	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.6	-7.27	-0.41	4.12e-12	Axial length;
CESC	cis	rs2415984	0.622	rs28487986	chr14:46924435	T/G	cg14871534	chr14:47121158	RPL10L	-0.35	-5.28	-0.31	2.64e-7	Number of children ever born;
CESC	cis	rs10883723	0.810	rs2296586	chr10:104245575	C/T	cg22532475	chr10:104410764	TRIM8	-0.34	-5.75	-0.33	2.44e-8	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs7772486	0.790	rs1133832	chr6:146205604	C/T	cg23711669	chr6:146136114	FBXO30	-0.8	-11.78	-0.59	4.95e-26	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7208859	0.573	rs73267872	chr17:29067207	T/C	cg19761014	chr17:28927070	LRRC37B2	0.78	6.46	0.37	5.11e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs2070997	0.607	rs10901283	chr9:133663242	G/A	cg11464064	chr9:133710261	ABL1	0.54	6.16	0.35	2.65e-9	Response to amphetamines;
CESC	cis	rs910316	1.000	rs175443	chr14:75601963	C/T	cg11812906	chr14:75593930	NEK9	-0.87	-14.66	-0.67	4.88e-36	Height;
CESC	trans	rs4904167	0.841	rs7148526	chr14:84688008	C/T	cg06870609	chr15:89787223	FANCI	0.46	6.06	0.35	4.6e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs1401999	0.546	rs4148593	chr3:183649870	A/G	cg01324343	chr3:183735012	ABCC5	0.37	6.38	0.36	7.82e-10	Anterior chamber depth;
CESC	cis	rs7618915	0.501	rs9917834	chr3:52634619	A/C	cg18404041	chr3:52824283	ITIH1	-0.38	-6.52	-0.37	3.57e-10	Bipolar disorder;
CESC	cis	rs4819052	0.959	rs9976074	chr21:46655638	G/T	cg11663144	chr21:46675770	NA	-0.48	-6.37	-0.36	8.26e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs650950	0.528	rs646660	chr11:35528452	C/T	cg04329845	chr19:14640100	MIR639;TECR	0.48	6.57	0.37	2.7e-10	Bronchopulmonary dysplasia;
CESC	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg24642844	chr7:1081250	C7orf50	-0.76	-9.45	-0.5	1.94e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs611744	0.625	rs6469168	chr8:109288399	G/T	cg21045802	chr8:109455806	TTC35	0.55	6.84	0.39	5.44e-11	Dupuytren's disease;
CESC	cis	rs3617	0.625	rs11719137	chr3:52876389	G/T	cg07507251	chr3:52567010	NT5DC2	-0.32	-5.44	-0.32	1.22e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
CESC	cis	rs67478160	0.643	rs2295145	chr14:104202304	G/A	cg08213375	chr14:104286397	PPP1R13B	0.52	10.26	0.53	5.03e-21	Schizophrenia;
CESC	cis	rs9549260	0.534	rs4943810	chr13:41297405	C/A	cg21288729	chr13:41239152	FOXO1	0.57	5.15	0.3	5.1e-7	Red blood cell count;
CESC	cis	rs5769765	0.862	rs9616774	chr22:50290599	G/A	cg02269571	chr22:50332266	NA	-0.45	-6.07	-0.35	4.4e-9	Schizophrenia;
CESC	cis	rs801193	1.000	rs4717319	chr7:66242593	A/G	cg11764359	chr7:65958608	NA	0.67	8.84	0.48	1.32e-16	Aortic root size;
CESC	cis	rs9322193	0.884	rs9397036	chr6:150172923	C/T	cg13206674	chr6:150067644	NUP43	0.38	5.12	0.3	5.81e-7	Lung cancer;
CESC	cis	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg08365687	chr3:52569147	NT5DC2;LOC440957	-0.31	-5.07	-0.3	7.45e-7	Bipolar disorder;
CESC	cis	rs929354	0.742	rs7807556	chr7:156934329	T/C	cg05182265	chr7:156933206	UBE3C	-0.48	-7.02	-0.4	1.86e-11	Body mass index;
CESC	cis	rs35306767	0.953	rs11253509	chr10:964306	C/T	cg26597838	chr10:835615	NA	0.78	9.15	0.49	1.6e-17	Eosinophil percentage of granulocytes;
CESC	cis	rs13385	0.769	rs35543394	chr5:139592844	T/A	cg26211634	chr5:139558579	C5orf32	0.46	5.2	0.3	3.99e-7	Atrial fibrillation;
CESC	cis	rs6061231	0.631	rs2427318	chr20:60975727	G/T	cg15674680	chr20:60982522	CABLES2	0.42	5.35	0.31	1.89e-7	Colorectal cancer;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg19263974	chr12:3103878	TEAD4	0.44	6.09	0.35	3.86e-9	Fibrinogen levels;
CESC	cis	rs909674	0.690	rs5750825	chr22:39831278	A/G	cg05872129	chr22:39784769	NA	-0.78	-10.46	-0.54	1.13e-21	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs698833	0.537	rs698826	chr2:44728418	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.48	5.35	0.31	1.92e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs6860806	0.507	rs582490	chr5:131710095	G/A	cg18758796	chr5:131593413	PDLIM4	-0.43	-5.96	-0.34	8.15e-9	Breast cancer;
CESC	cis	rs10876993	0.806	rs1689598	chr12:58050500	G/C	cg18357645	chr12:58087776	OS9	0.6	9.23	0.49	8.88e-18	Celiac disease or Rheumatoid arthritis;
CESC	trans	rs6818288	0.778	rs12503609	chr4:30077578	G/A	cg12528397	chr3:62933670	NA	0.42	6.13	0.35	3.2e-9	Obesity-related traits;
CESC	cis	rs7656342	0.636	rs1914874	chr4:9839490	C/A	cg00071950	chr4:10020882	SLC2A9	-0.42	-5.53	-0.32	7.74e-8	Gut microbiota (bacterial taxa);
CESC	cis	rs3617	0.625	rs2535633	chr3:52859630	C/G	cg07507251	chr3:52567010	NT5DC2	-0.34	-6.0	-0.35	6.47e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
CESC	cis	rs35306767	0.903	rs12254002	chr10:929133	A/G	cg25019033	chr10:957182	NA	0.58	6.71	0.38	1.2e-10	Eosinophil percentage of granulocytes;
CESC	cis	rs4474465	0.688	rs4944210	chr11:78282878	C/T	cg27205649	chr11:78285834	NARS2	0.49	6.38	0.37	7.72e-10	Alzheimer's disease (survival time);
CESC	cis	rs12348691	0.503	rs7024345	chr9:100595238	A/G	cg13688889	chr9:100608707	NA	-0.9	-13.3	-0.63	3.01e-31	Alopecia areata;
CESC	cis	rs7412746	0.611	rs111842513	chr1:150712926	G/A	cg04414720	chr1:150670196	GOLPH3L	0.61	8.65	0.47	5.17e-16	Melanoma;
CESC	cis	rs9291683	0.507	rs6845554	chr4:10013173	T/G	cg00071950	chr4:10020882	SLC2A9	0.82	13.81	0.65	4.68e-33	Bone mineral density;
CESC	cis	rs6460942	0.597	rs6961238	chr7:12535428	C/T	cg02935154	chr7:12443704	VWDE	-0.57	-5.7	-0.33	3.23e-8	Coronary artery disease;
CESC	cis	rs7178909	0.902	rs8038480	chr15:90441597	T/C	cg19708238	chr15:90437601	AP3S2	0.45	6.41	0.37	6.78e-10	Common traits (Other);
CESC	cis	rs6754459	0.502	rs34759180	chr2:3707394	C/T	cg19052272	chr2:3704530	ALLC	-0.79	-9.52	-0.5	1.1e-18	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CESC	cis	rs12701220	0.522	rs12334290	chr7:1054517	A/G	cg23978390	chr7:1156363	C7orf50	0.42	5.21	0.31	3.74e-7	Bronchopulmonary dysplasia;
CESC	cis	rs11252926	0.673	rs7096559	chr10:499188	C/T	cg03684893	chr10:554711	DIP2C	-0.42	-6.39	-0.37	7.59e-10	Psychosis in Alzheimer's disease;
CESC	cis	rs6121246	0.909	rs6060679	chr20:30270772	C/G	cg13852791	chr20:30311386	BCL2L1	-0.75	-7.94	-0.44	5.91e-14	Mean corpuscular hemoglobin;
CESC	cis	rs4604732	0.642	rs4266925	chr1:247639165	T/C	cg12758973	chr1:247694275	LOC148824;OR2C3	0.38	5.46	0.32	1.1e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs1728785	0.818	rs1170430	chr16:68604954	T/C	cg02972257	chr16:68554789	NA	-0.59	-6.71	-0.38	1.2e-10	Ulcerative colitis;
CESC	cis	rs6933660	0.665	rs6921042	chr6:151732385	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.87	14.29	0.66	1e-34	Menarche (age at onset);
CESC	cis	rs228769	0.562	rs228762	chr17:42138392	C/T	cg19774624	chr17:42201019	HDAC5	0.54	6.28	0.36	1.38e-9	Bone mineral density (hip);Bone mineral density (spine);
CESC	cis	rs6499255	0.951	rs10454066	chr16:69699005	A/T	cg15192750	chr16:69999425	NA	0.51	5.87	0.34	1.29e-8	IgE levels;
CESC	cis	rs561341	0.882	rs28649357	chr17:30367190	A/G	cg13647721	chr17:30228624	UTP6	0.54	5.05	0.3	8.04e-7	Hip circumference adjusted for BMI;
CESC	cis	rs4835937	0.645	rs4836348	chr5:127278773	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.52	5.07	0.3	7.35e-7	Cancer;
CESC	cis	rs34172651	0.517	rs200528	chr16:24759131	A/G	cg02428538	chr16:24856791	SLC5A11	0.47	5.03	0.3	9.12e-7	Intelligence (multi-trait analysis);
CESC	cis	rs875971	0.756	rs2901210	chr7:66017505	G/A	cg18876405	chr7:65276391	NA	-0.53	-7.19	-0.4	6.72e-12	Aortic root size;
CESC	cis	rs6062302	0.522	rs3787107	chr20:62230576	G/A	cg06363034	chr20:62225388	GMEB2	-0.52	-6.66	-0.38	1.6e-10	Glioblastoma;
CESC	cis	rs6752107	1.000	rs13391356	chr2:234170369	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.48	6.71	0.38	1.21e-10	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs546131	0.928	rs552868	chr11:34830694	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.51	6.52	0.37	3.49e-10	Lung disease severity in cystic fibrosis;
CESC	cis	rs7927592	0.913	rs7127948	chr11:68363062	G/A	cg20283391	chr11:68216788	NA	-0.61	-7.29	-0.41	3.48e-12	Total body bone mineral density;
CESC	cis	rs863345	0.526	rs2051067	chr1:158507398	G/T	cg12129480	chr1:158549410	OR10X1	-0.35	-7.03	-0.4	1.73e-11	Pneumococcal bacteremia;
CESC	cis	rs6540559	0.808	rs11119358	chr1:210042456	T/C	cg22442454	chr1:209979470	IRF6	0.45	5.09	0.3	6.76e-7	Cleft lip with or without cleft palate;
CESC	cis	rs10465746	0.780	rs11163866	chr1:84367123	A/G	cg10977910	chr1:84465055	TTLL7	0.52	7.06	0.4	1.46e-11	Obesity-related traits;
CESC	cis	rs780096	0.526	rs10182937	chr2:27651693	T/C	cg12648201	chr2:27665141	KRTCAP3	-0.35	-6.56	-0.37	2.79e-10	Total body bone mineral density;
CESC	cis	rs6088580	0.524	rs7274854	chr20:33228672	A/C	cg08999081	chr20:33150536	PIGU	0.42	5.92	0.34	1.01e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs916888	0.821	rs199525	chr17:44847834	T/G	cg17911788	chr17:44343683	NA	-0.6	-7.81	-0.43	1.32e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs524023	1.000	rs505802	chr11:64357072	T/C	cg07220939	chr11:64358617	SLC22A12	0.36	5.54	0.32	7.2e-8	Urate levels in obese individuals;
CESC	cis	rs2904967	0.636	rs239253	chr11:64984743	C/T	cg23743554	chr11:65321226	LTBP3	-0.39	-5.14	-0.3	5.38e-7	Mean corpuscular volume;
CESC	cis	rs7412746	0.646	rs10399947	chr1:150861960	G/A	cg04414720	chr1:150670196	GOLPH3L	0.45	5.85	0.34	1.48e-8	Melanoma;
CESC	cis	rs10504229	0.679	rs17804870	chr8:58158071	A/G	cg22535103	chr8:58192502	C8orf71	-0.87	-7.96	-0.44	5.16e-14	Developmental language disorder (linguistic errors);
CESC	trans	rs7937682	0.924	rs1784782	chr11:111525764	A/C	cg18187862	chr3:45730750	SACM1L	0.51	6.47	0.37	4.81e-10	Primary sclerosing cholangitis;
CESC	cis	rs6032067	0.929	rs2143944	chr20:43819370	G/A	cg10761708	chr20:43804764	PI3	0.53	6.39	0.37	7.37e-10	Blood protein levels;
CESC	cis	rs561341	0.843	rs4795666	chr17:30241409	A/G	cg13647721	chr17:30228624	UTP6	0.78	8.91	0.48	8.27e-17	Hip circumference adjusted for BMI;
CESC	cis	rs561341	0.709	rs8068049	chr17:30183857	T/C	cg12193833	chr17:30244370	NA	0.6	5.41	0.32	1.42e-7	Hip circumference adjusted for BMI;
CESC	cis	rs7772486	0.632	rs9386128	chr6:146049053	G/A	cg23711669	chr6:146136114	FBXO30	-0.87	-12.9	-0.62	7e-30	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9649465	0.561	rs600420	chr7:123408050	G/A	cg03229431	chr7:123269106	ASB15	0.42	5.78	0.33	2.12e-8	Migraine;
CESC	cis	rs6570726	0.935	rs367643	chr6:145859602	A/C	cg05347473	chr6:146136440	FBXO30	0.48	6.44	0.37	5.7e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9649213	0.593	rs6947340	chr7:97912241	A/G	cg21770322	chr7:97807741	LMTK2	-0.49	-7.32	-0.41	2.96e-12	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs10504229	0.683	rs2291765	chr8:58142874	C/T	cg02725872	chr8:58115012	NA	-0.39	-6.8	-0.39	7.05e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs7089973	0.604	rs11196932	chr10:116584386	C/T	cg25233709	chr10:116636983	FAM160B1	0.35	5.47	0.32	1.05e-7	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg11108432	chr8:10697698	PINX1	0.48	6.17	0.35	2.58e-9	Tetralogy of Fallot;
CESC	cis	rs13256369	1.000	rs10095733	chr8:8574646	A/G	cg18904891	chr8:8559673	CLDN23	0.69	8.08	0.44	2.26e-14	Obesity-related traits;
CESC	cis	rs6582630	0.519	rs4002440	chr12:38485012	A/G	cg26384229	chr12:38710491	ALG10B	0.69	10.39	0.54	1.95e-21	Drug-induced liver injury (flucloxacillin);
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg16668921	chr6:107077373	RTN4IP1;QRSL1	-0.52	-6.7	-0.38	1.25e-10	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs1215050	0.740	rs783949	chr4:99001933	A/G	cg05340658	chr4:99064831	C4orf37	-0.57	-7.58	-0.42	5.78e-13	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs2228479	0.850	rs12598316	chr16:89916600	C/A	cg04013166	chr16:89971882	TCF25	0.73	5.7	0.33	3.2e-8	Skin colour saturation;
CESC	cis	rs12973672	0.680	rs564117	chr19:35718938	C/T	cg12095397	chr19:35769544	USF2	0.43	5.46	0.32	1.12e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs13102973	0.965	rs11735381	chr4:135850474	T/C	cg14419869	chr4:135874104	NA	0.33	5.15	0.3	5.11e-7	Subjective well-being;
CESC	cis	rs642803	1.000	rs642803	chr11:65560620	C/T	cg02870584	chr11:65547924	DKFZp761E198	0.43	5.45	0.32	1.16e-7	Urate levels;
CESC	cis	rs4819052	0.851	rs10470245	chr21:46658912	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.46	5.79	0.34	2e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs793571	0.543	rs11854073	chr15:58972995	G/A	cg05156742	chr15:59063176	FAM63B	0.58	7.86	0.43	9.42e-14	Schizophrenia;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg23604151	chr20:50766090	ZFP64	0.45	6.57	0.37	2.59e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs910316	1.000	rs11159117	chr14:75584867	C/T	cg08847533	chr14:75593920	NEK9	1.02	19.72	0.77	6.58e-54	Height;
CESC	cis	rs2742234	0.578	rs2742241	chr10:43625223	G/A	cg15436174	chr10:43711423	RASGEF1A	-0.47	-5.55	-0.32	6.93e-8	Hirschsprung disease;
CESC	trans	rs3780486	0.718	rs7859454	chr9:33119583	T/A	cg20290983	chr6:43655470	MRPS18A	0.67	8.05	0.44	2.83e-14	IgG glycosylation;
CESC	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.43	-5.75	-0.33	2.51e-8	Longevity;Endometriosis;
CESC	cis	rs2046867	0.774	rs1393585	chr3:72886722	A/G	cg25664220	chr3:72788482	NA	-0.46	-6.4	-0.37	7.09e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CESC	cis	rs11642862	1.000	rs111954099	chr16:30789623	A/G	cg02466173	chr16:30829666	NA	-0.54	-5.52	-0.32	8.18e-8	Tonsillectomy;
CESC	cis	rs1707322	1.000	rs785498	chr1:46592414	C/T	cg06784218	chr1:46089804	CCDC17	-0.35	-5.94	-0.34	8.74e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs9596009	0.591	rs73480227	chr13:49342549	C/T	cg13176070	chr2:32503943	YIPF4	0.52	6.08	0.35	4.25e-9	Cough in response to angiotensin-converting enzyme inhibitor drugs;
CESC	cis	rs11098499	0.739	rs4833612	chr4:120147596	A/C	cg09307838	chr4:120376055	NA	-0.68	-8.42	-0.46	2.43e-15	Corneal astigmatism;
CESC	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg26338869	chr17:61819248	STRADA	0.71	9.47	0.5	1.6e-18	Prudent dietary pattern;
CESC	cis	rs7631605	0.905	rs11129752	chr3:37257793	A/G	cg22985146	chr3:37219077	LRRFIP2	0.35	5.57	0.32	6.37e-8	Cerebrospinal P-tau181p levels;
CESC	cis	rs875971	0.862	rs937494	chr7:65764678	T/A	cg11764359	chr7:65958608	NA	-0.8	-12.02	-0.59	7.52e-27	Aortic root size;
CESC	cis	rs4853012	0.539	rs9789534	chr2:74362990	A/T	cg20891558	chr2:74357851	NA	0.57	7.05	0.4	1.55e-11	Gestational age at birth (maternal effect);
CESC	cis	rs57221529	0.563	rs4957057	chr5:569230	C/G	cg16447950	chr5:562315	NA	-0.67	-7.5	-0.42	9.39e-13	Lung disease severity in cystic fibrosis;
CESC	cis	rs561341	0.769	rs9899093	chr17:30191954	C/G	cg12193833	chr17:30244370	NA	-0.58	-5.59	-0.32	5.72e-8	Hip circumference adjusted for BMI;
CESC	cis	rs2030401	0.604	rs2682427	chr12:123656809	C/T	cg00376283	chr12:123451042	ABCB9	0.38	5.04	0.3	8.49e-7	Intelligence (multi-trait analysis);
CESC	cis	rs4704187	0.663	rs12523187	chr5:74379625	A/T	cg03227963	chr5:74354835	NA	0.32	5.95	0.34	8.68e-9	Response to amphetamines;
CESC	cis	rs73001065	0.792	rs16996148	chr19:19658472	G/T	cg03709012	chr19:19516395	GATAD2A	0.94	6.62	0.38	1.99e-10	LDL cholesterol;
CESC	cis	rs12142240	0.698	rs61519400	chr1:46855298	A/G	cg10495392	chr1:46806563	NSUN4	0.56	6.15	0.35	2.86e-9	Menopause (age at onset);
CESC	cis	rs9814567	1.000	rs4535272	chr3:134299916	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.44	5.85	0.34	1.44e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs247833	0.507	rs2013847	chr16:84587960	G/T	cg06393589	chr16:84581885	NA	0.35	6.24	0.36	1.75e-9	Monocyte count;
CESC	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	7.72	0.43	2.43e-13	Prudent dietary pattern;
CESC	cis	rs4253772	0.591	rs9615934	chr22:46682310	C/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.74	6.61	0.38	2.17e-10	LDL cholesterol;Cholesterol, total;
CESC	trans	rs2727020	0.729	rs7924782	chr11:49267249	A/G	cg03929089	chr4:120376271	NA	-0.79	-11.88	-0.59	2.24e-26	Coronary artery disease;
CESC	cis	rs425277	1.000	rs427811	chr1:2075560	T/G	cg24578937	chr1:2090814	PRKCZ	0.55	9.47	0.5	1.62e-18	Height;
CESC	cis	rs597539	0.552	rs10896384	chr11:68720011	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	-0.73	-8.95	-0.48	6.49e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14733936	chr2:70476139	TIA1	0.59	6.34	0.36	9.97e-10	Gut microbiome composition (summer);
CESC	cis	rs9443645	0.869	rs1567168	chr6:79536455	G/T	cg05283184	chr6:79620031	NA	-0.45	-6.92	-0.39	3.36e-11	Intelligence (multi-trait analysis);
CESC	cis	rs6582630	0.555	rs11613249	chr12:38519339	T/C	cg26384229	chr12:38710491	ALG10B	0.73	11.35	0.57	1.32e-24	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs11758351	0.660	rs2143345	chr6:26229148	C/T	cg01420254	chr6:26195488	NA	0.77	8.48	0.46	1.59e-15	Gout;Renal underexcretion gout;
CESC	cis	rs7727544	0.660	rs274563	chr5:131717859	C/A	cg07395648	chr5:131743802	NA	0.44	5.89	0.34	1.15e-8	Blood metabolite levels;
CESC	cis	rs7726839	0.540	rs72703095	chr5:601789	T/C	cg16447950	chr5:562315	NA	-0.6	-6.06	-0.35	4.78e-9	Obesity-related traits;
CESC	cis	rs71277158	0.572	rs77964281	chr3:169916180	T/C	cg04067573	chr3:169899625	PHC3	0.68	6.5	0.37	3.99e-10	Prostate cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13873920	chr18:72163386	CNDP2	0.56	6.05	0.35	4.96e-9	Gut microbiome composition (summer);
CESC	cis	rs1046896	0.553	rs3744160	chr17:80828303	G/A	cg05255149	chr17:80675120	FN3KRP	0.45	5.04	0.3	8.76e-7	Glycated hemoglobin levels;
CESC	cis	rs2072732	0.821	rs12037307	chr1:2947756	C/A	cg15211996	chr1:2936768	ACTRT2	0.35	5.55	0.32	6.98e-8	Plateletcrit;
CESC	cis	rs9341835	0.518	rs2622293	chr6:64218491	T/C	cg03326410	chr6:64151739	NA	0.32	5.15	0.3	5.1e-7	Schizophrenia;
CESC	cis	rs4808199	0.948	rs12982276	chr19:19459800	T/C	cg03709012	chr19:19516395	GATAD2A	1.07	12.42	0.61	3.25e-28	Nonalcoholic fatty liver disease;
CESC	cis	rs826838	1.000	rs826886	chr12:39095797	A/G	cg13010199	chr12:38710504	ALG10B	0.42	5.88	0.34	1.22e-8	Heart rate;
CESC	cis	rs1371867	0.817	rs1660315	chr8:101332956	G/A	cg11906718	chr8:101322791	RNF19A	0.53	6.86	0.39	4.86e-11	Atrioventricular conduction;
CESC	cis	rs8020095	0.571	rs8019510	chr14:67523915	T/C	cg19548862	chr14:67692701	FAM71D	-0.5	-6.2	-0.36	2.16e-9	Depression (quantitative trait);
CESC	cis	rs7412746	0.658	rs12090215	chr1:150893660	C/A	cg04414720	chr1:150670196	GOLPH3L	0.51	6.76	0.38	8.61e-11	Melanoma;
CESC	cis	rs3540	0.576	rs10152871	chr15:91047469	G/A	cg22089800	chr15:90895588	ZNF774	-0.65	-8.98	-0.48	5.25e-17	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg24511898	chr2:242576823	ATG4B;THAP4	-0.46	-7.17	-0.4	7.65e-12	Gambling;
CESC	cis	rs514406	0.893	rs512723	chr1:53343880	C/T	cg16325326	chr1:53192061	ZYG11B	-0.84	-13.48	-0.64	6.62e-32	Monocyte count;
CESC	cis	rs2880765	0.835	rs4842884	chr15:86035174	T/C	cg19183879	chr15:85880815	NA	-0.25	-5.3	-0.31	2.49e-7	Coronary artery disease;
CESC	trans	rs6572548	0.504	rs1956082	chr14:49665496	A/C	cg16868751	chr10:96162146	TBC1D12	-0.5	-6.44	-0.37	5.48e-10	Subjective well-being;
CESC	cis	rs7811142	1.000	rs4989959	chr7:100032288	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.06	10.39	0.54	1.98e-21	Platelet count;
CESC	cis	rs6828523	0.698	rs73869044	chr4:175852900	T/C	cg14561282	chr4:175839468	ADAM29	0.43	5.07	0.3	7.33e-7	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06824641	chr8:22298455	PPP3CC	0.59	7.17	0.4	7.39e-12	Gut microbiome composition (summer);
CESC	cis	rs17711722	0.522	rs62469933	chr7:65265639	G/A	cg25405998	chr7:65216604	CCT6P1	0.44	5.68	0.33	3.62e-8	Calcium levels;
CESC	cis	rs12477438	0.798	rs972768	chr2:99682397	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-10.57	-0.54	5.22e-22	Chronic sinus infection;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22225685	chr22:38203998	GCAT	0.59	7.15	0.4	8.57e-12	Gut microbiome composition (summer);
CESC	cis	rs6493487	0.512	rs35655196	chr15:51321908	A/G	cg02338191	chr15:51200825	AP4E1	0.57	5.39	0.31	1.58e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs6570726	0.935	rs421690	chr6:145834594	A/C	cg23711669	chr6:146136114	FBXO30	0.8	12.02	0.59	7.3e-27	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9325144	0.647	rs12831609	chr12:39051576	C/A	cg26384229	chr12:38710491	ALG10B	-0.52	-7.29	-0.41	3.56e-12	Morning vs. evening chronotype;
CESC	cis	rs3747547	0.892	rs2103241	chr9:37950936	C/T	cg13774184	chr9:37916125	SHB	-0.62	-5.84	-0.34	1.49e-8	Metabolite levels (Dihydroxy docosatrienoic acid);
CESC	cis	rs7246657	0.943	rs10405407	chr19:37839164	C/T	cg23950597	chr19:37808831	NA	-0.55	-6.09	-0.35	3.96e-9	Coronary artery calcification;
CESC	cis	rs7666738	0.861	rs5010991	chr4:98972179	A/G	cg03676636	chr4:99064102	C4orf37	0.34	5.2	0.3	3.93e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11098499	0.865	rs4507344	chr4:120307485	C/A	cg24375607	chr4:120327624	NA	0.46	5.55	0.32	6.98e-8	Corneal astigmatism;
CESC	cis	rs11098499	0.954	rs878373	chr4:120237484	A/T	cg09307838	chr4:120376055	NA	0.92	12.74	0.62	2.56e-29	Corneal astigmatism;
CESC	cis	rs9649213	0.593	rs1859482	chr7:97983774	C/T	cg00277769	chr7:97922759	BAIAP2L1	-0.33	-5.41	-0.32	1.41e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs801193	1.000	rs4717310	chr7:66161007	C/T	cg18876405	chr7:65276391	NA	0.53	7.06	0.4	1.42e-11	Aortic root size;
CESC	cis	rs17209837	1.000	rs45590633	chr7:87090480	C/T	cg00919237	chr7:87102261	ABCB4	-0.55	-5.61	-0.33	5.09e-8	Gallbladder cancer;
CESC	cis	rs12410462	0.681	rs6670816	chr1:227610592	G/T	cg23173402	chr1:227635558	NA	-0.67	-6.52	-0.37	3.64e-10	Major depressive disorder;
CESC	cis	rs3096299	0.685	rs8050512	chr16:89552320	C/G	cg02034447	chr16:89574710	SPG7	0.51	6.7	0.38	1.26e-10	Multiple myeloma (IgH translocation);
CESC	trans	rs2391518	0.639	rs2968998	chr4:130784655	A/G	cg04981619	chr2:43328122	NA	0.38	6.11	0.35	3.61e-9	Body mass index;
CESC	trans	rs208520	0.690	rs12197578	chr6:66725905	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.95	12.24	0.6	1.32e-27	Exhaled nitric oxide output;
CESC	cis	rs6754311	0.773	rs309178	chr2:136611624	C/T	cg07169764	chr2:136633963	MCM6	-0.69	-8.56	-0.47	9.42e-16	Mosquito bite size;
CESC	trans	rs1814175	0.817	rs11518158	chr11:49985633	G/T	cg15704280	chr7:45808275	SEPT13	-1.03	-20.38	-0.78	3.6e-56	Height;
CESC	cis	rs8114671	0.836	rs6141526	chr20:33615255	G/T	cg06115741	chr20:33292138	TP53INP2	-0.47	-5.59	-0.32	5.54e-8	Height;
CESC	cis	rs9818758	0.607	rs73074866	chr3:49626666	C/T	cg00383909	chr3:49044727	WDR6	0.81	5.35	0.31	1.9e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CESC	trans	rs2391518	0.595	rs2969005	chr4:130781514	A/G	cg04981619	chr2:43328122	NA	0.38	6.0	0.35	6.59e-9	Body mass index;
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg10678486	chr18:48494218	ELAC1	-0.42	-6.06	-0.35	4.65e-9	Vertical cup-disc ratio;
CESC	cis	rs9858542	0.903	rs9875617	chr3:49634696	G/A	cg03060546	chr3:49711283	APEH	-0.51	-5.93	-0.34	9.4e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs55794721	0.509	rs873308	chr1:25758655	A/G	cg03538708	chr1:25844672	NA	0.42	6.53	0.37	3.29e-10	Plateletcrit;Mean corpuscular volume;
CESC	cis	rs9916302	0.904	rs8079560	chr17:37497661	C/T	cg15445000	chr17:37608096	MED1	-0.42	-6.87	-0.39	4.46e-11	Glomerular filtration rate (creatinine);
CESC	trans	rs4596713	0.538	rs4421408	chr9:71760884	G/T	cg16512924	chr15:28394682	HERC2	0.5	6.38	0.36	7.96e-10	Headache;
CESC	cis	rs7605827	0.897	rs1996516	chr2:15517246	G/A	cg19274914	chr2:15703543	NA	0.35	6.27	0.36	1.43e-9	Educational attainment (years of education);
CESC	cis	rs7116495	1.000	rs4338555	chr11:71755696	T/C	cg10381502	chr11:71823885	C11orf51	-0.69	-5.89	-0.34	1.17e-8	Severe influenza A (H1N1) infection;
CESC	cis	rs4604732	1.000	rs4604732	chr1:247623872	C/T	cg12758973	chr1:247694275	LOC148824;OR2C3	-0.37	-5.03	-0.3	8.9e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs6500395	0.735	rs74017013	chr16:48664120	G/A	cg04672837	chr16:48644449	N4BP1	0.49	6.27	0.36	1.46e-9	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs7412746	0.622	rs11552229	chr1:150783985	T/C	cg17724175	chr1:150552817	MCL1	0.41	6.33	0.36	1.06e-9	Melanoma;
CESC	cis	rs7811142	0.830	rs77861211	chr7:99962096	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.07	11.24	0.57	3.07e-24	Platelet count;
CESC	cis	rs662064	0.962	rs683864	chr1:10561954	T/C	cg20482658	chr1:10539492	PEX14	0.38	7.59	0.42	5.56e-13	Asthma;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25332325	chr10:71906362	TYSND1	0.58	6.83	0.39	5.65e-11	Gut microbiome composition (summer);
CESC	cis	rs9894429	0.550	rs6565617	chr17:79612333	G/A	cg13777783	chr17:79615861	NA	-0.37	-6.2	-0.36	2.14e-9	Eye color traits;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg18931685	chr19:45505298	RELB	0.47	6.17	0.35	2.61e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs4835473	0.663	rs1511423	chr4:144911289	T/C	cg25736465	chr4:144833511	NA	0.42	6.39	0.37	7.37e-10	Immature fraction of reticulocytes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09648315	chr5:65892099	MAST4	0.48	6.04	0.35	5.32e-9	Gut microbiome composition (summer);
CESC	cis	rs4843185	0.516	rs374029	chr16:85725953	G/A	cg05245094	chr16:85669572	KIAA0182	0.41	5.05	0.3	8.12e-7	Platelet distribution width;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg12232852	chr3:69129018	UBA3	-0.5	-7.38	-0.41	2.04e-12	Gambling;
CESC	trans	rs7615952	0.641	rs4490307	chr3:125712676	T/G	cg07211511	chr3:129823064	LOC729375	-0.58	-6.92	-0.39	3.3e-11	Blood pressure (smoking interaction);
CESC	cis	rs17253792	0.822	rs8009608	chr14:56062590	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.85	6.13	0.35	3.15e-9	Putamen volume;
CESC	cis	rs6499129	1.000	rs6499129	chr16:67458251	A/C	cg26727032	chr16:67993705	SLC12A4	-0.57	-6.01	-0.35	5.97e-9	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs7666738	0.716	rs28792413	chr4:99083707	G/A	cg03467027	chr4:99064603	C4orf37	0.42	5.04	0.3	8.53e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3815700	1.000	rs3815700	chr19:33093252	T/C	cg02997394	chr19:33096574	ANKRD27	0.73	7.3	0.41	3.26e-12	Eosinophilic esophagitis;
CESC	cis	rs4478858	0.775	rs6701861	chr1:31708125	A/C	cg00250761	chr1:31883323	NA	-0.27	-5.35	-0.31	1.9e-7	Alcohol dependence;
CESC	cis	rs13095912	0.785	rs6800725	chr3:185298156	C/A	cg11274856	chr3:185301563	NA	0.38	5.72	0.33	2.9e-8	Systolic blood pressure;
CESC	cis	rs4819052	0.851	rs13050359	chr21:46672671	T/G	cg11663144	chr21:46675770	NA	-0.63	-9.9	-0.52	7.47e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs10504229	0.679	rs72649114	chr8:58037491	G/T	cg24829409	chr8:58192753	C8orf71	-0.49	-6.15	-0.35	2.91e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs1552244	1.000	rs9849434	chr3:10133710	A/G	cg00149659	chr3:10157352	C3orf10	-0.74	-9.19	-0.49	1.15e-17	Alzheimer's disease;
CESC	cis	rs2760061	0.545	rs1745423	chr1:228224153	G/T	cg02753203	chr1:228287806	NA	-0.58	-8.55	-0.46	1.02e-15	Diastolic blood pressure;
CESC	cis	rs34779708	0.966	rs2045917	chr10:35418526	G/A	cg03585969	chr10:35415529	CREM	0.76	10.09	0.53	1.79e-20	Inflammatory bowel disease;Crohn's disease;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg08077726	chr17:74734280	SFRS2;MFSD11	-0.42	-6.22	-0.36	1.95e-9	Gambling;
CESC	cis	rs9815354	0.812	rs55916855	chr3:42002761	A/G	cg03022575	chr3:42003672	ULK4	0.66	5.77	0.33	2.17e-8	Pulse pressure;Diastolic blood pressure;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg03705947	chr1:68152081	GADD45A	-0.43	-6.39	-0.37	7.5e-10	Gambling;
CESC	cis	rs763121	0.889	rs9607557	chr22:39040279	G/A	cg06022373	chr22:39101656	GTPBP1	0.89	15.16	0.68	8.51e-38	Menopause (age at onset);
CESC	trans	rs7107217	1.000	rs1873872	chr11:129473993	A/T	cg27003951	chr16:11350045	SOCS1	0.45	6.2	0.36	2.16e-9	Breast cancer;Type 2 diabetes;
CESC	cis	rs9916302	0.904	rs11078915	chr17:37715426	T/C	cg20243544	chr17:37824526	PNMT	0.51	6.5	0.37	3.97e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs2820292	0.741	rs12086240	chr1:201885791	G/A	cg06775570	chr1:201857621	SHISA4	-0.34	-5.8	-0.34	1.85e-8	Waist circumference;Body mass index (joint analysis main effects and smoking interaction);Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);
CESC	cis	rs12497850	0.931	rs9755490	chr3:48871664	A/C	cg06212747	chr3:49208901	KLHDC8B	0.66	8.74	0.47	2.71e-16	Parkinson's disease;
CESC	cis	rs28489187	0.643	rs997251	chr1:85845367	T/C	cg16011679	chr1:85725395	C1orf52	0.53	6.17	0.35	2.49e-9	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	cis	rs9910055	0.573	rs113184718	chr17:42206543	A/T	cg09913183	chr17:42254507	C17orf65;ASB16	-0.64	-8.55	-0.46	1.01e-15	Total body bone mineral density;
CESC	cis	rs2242663	0.531	rs2511225	chr11:66248431	A/C	cg04006266	chr11:66300458	BBS1	0.34	5.42	0.32	1.36e-7	Bipolar disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26381048	chr12:132632420	NOC4L	-0.54	-6.28	-0.36	1.37e-9	Gut microbiome composition (summer);
CESC	cis	rs3749237	0.555	rs2117939	chr3:49415179	C/A	cg06212747	chr3:49208901	KLHDC8B	0.49	6.6	0.38	2.22e-10	Resting heart rate;
CESC	cis	rs1008375	0.966	rs4235389	chr4:17696280	A/G	cg16339924	chr4:17578868	LAP3	0.52	6.62	0.38	2.03e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs910316	1.000	rs28626045	chr14:75589195	G/C	cg16144293	chr14:75469539	EIF2B2	-0.4	-5.21	-0.3	3.82e-7	Height;
CESC	cis	rs10870270	0.917	rs9971362	chr10:133790150	T/C	cg08754478	chr10:133766260	PPP2R2D	-0.56	-7.08	-0.4	1.29e-11	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs698833	0.798	rs4953082	chr2:44524064	G/A	cg04920474	chr2:44395004	PPM1B	0.39	5.57	0.32	6.24e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs6963495	0.719	rs73190174	chr7:105161216	T/G	cg13798780	chr7:105162888	PUS7	0.78	8.04	0.44	2.99e-14	Bipolar disorder (body mass index interaction);
CESC	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg11965913	chr1:205819406	PM20D1	0.81	12.67	0.61	4.26e-29	Menarche (age at onset);
CESC	cis	rs9322193	0.962	rs1413655	chr6:150142951	A/G	cg09699651	chr6:150184138	LRP11	0.4	5.09	0.3	6.7e-7	Lung cancer;
CESC	cis	rs6662572	0.806	rs56067046	chr1:46044314	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.52	5.68	0.33	3.51e-8	Blood protein levels;
CESC	cis	rs1552244	0.882	rs67631672	chr3:10004768	G/A	cg00166722	chr3:10149974	C3orf24	0.44	5.39	0.31	1.54e-7	Alzheimer's disease;
CESC	cis	rs8064299	0.597	rs9944506	chr17:72782726	C/G	cg25054828	chr17:72772726	NAT9;TMEM104	0.85	14.36	0.66	5.44e-35	Monocyte count;
CESC	cis	rs7618915	0.501	rs2336149	chr3:52692124	G/A	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	5.85	0.34	1.46e-8	Bipolar disorder;
CESC	cis	rs523522	0.962	rs3742052	chr12:120966921	A/G	cg27279351	chr12:120934652	DYNLL1	0.69	9.11	0.49	2.02e-17	High light scatter reticulocyte count;
CESC	trans	rs57221529	0.766	rs72703075	chr5:592819	C/T	cg25482853	chr8:67687455	SGK3	1.08	9.89	0.52	7.84e-20	Lung disease severity in cystic fibrosis;
CESC	cis	rs7208859	0.623	rs73271842	chr17:29137155	T/C	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.79e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs7617773	0.817	rs4131362	chr3:48329036	A/C	cg11946769	chr3:48343235	NME6	0.8	10.89	0.56	4.71e-23	Coronary artery disease;
CESC	cis	rs2836950	0.520	rs11911087	chr21:40665192	G/A	cg11644478	chr21:40555479	PSMG1	-0.54	-7.3	-0.41	3.41e-12	Menarche (age at onset);
CESC	cis	rs2299587	0.607	rs2237848	chr8:17874604	A/C	cg08627089	chr8:17753878	FGL1	-0.38	-5.19	-0.3	4.22e-7	Economic and political preferences;
CESC	cis	rs9325144	0.723	rs11169535	chr12:39183494	C/T	cg26384229	chr12:38710491	ALG10B	-0.51	-7.23	-0.41	5.23e-12	Morning vs. evening chronotype;
CESC	cis	rs4862750	0.872	rs7671914	chr4:187878165	A/G	cg22105103	chr4:187893119	NA	0.49	7.24	0.41	4.79e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs875971	0.798	rs57739047	chr7:65972566	A/T	cg18876405	chr7:65276391	NA	0.49	6.55	0.37	3e-10	Aortic root size;
CESC	cis	rs6973256	0.583	rs2430768	chr7:133340287	T/C	cg10665199	chr7:133106180	EXOC4	-0.45	-6.13	-0.35	3.17e-9	Intelligence (multi-trait analysis);
CESC	cis	rs7552404	1.000	rs7534754	chr1:76185308	G/A	cg10523679	chr1:76189770	ACADM	0.71	8.23	0.45	8.39e-15	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs3020736	0.500	rs8138678	chr22:42516229	A/G	cg15557168	chr22:42548783	NA	0.45	6.43	0.37	5.91e-10	Autism spectrum disorder or schizophrenia;
CESC	cis	rs60154123	0.772	rs845452	chr1:210417861	C/T	cg25204440	chr1:209979598	IRF6	0.49	5.12	0.3	5.85e-7	Coronary artery disease;
CESC	cis	rs432925	0.600	rs214249	chr16:348687	T/G	cg06233593	chr16:337645	AXIN1	0.49	7.48	0.42	1.12e-12	Morning vs. evening chronotype;
CESC	cis	rs61931739	0.857	rs999715	chr12:34143253	G/C	cg19457237	chr12:34500585	NA	-0.36	-5.06	-0.3	7.79e-7	Morning vs. evening chronotype;
CESC	cis	rs2046867	0.862	rs75638790	chr3:72830502	C/T	cg25664220	chr3:72788482	NA	-0.44	-6.23	-0.36	1.78e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CESC	cis	rs6740322	0.748	rs13432574	chr2:43544328	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.71	-7.66	-0.43	3.57e-13	Coronary artery disease;
CESC	cis	rs992157	0.560	rs12987130	chr2:219104990	T/C	cg00012203	chr2:219082015	ARPC2	-0.76	-10.12	-0.53	1.46e-20	Colorectal cancer;
CESC	cis	rs514406	0.505	rs269286	chr1:53169018	C/T	cg27535305	chr1:53392650	SCP2	0.33	5.63	0.33	4.59e-8	Monocyte count;
CESC	cis	rs270601	0.710	rs4705852	chr5:131602807	A/G	cg18758796	chr5:131593413	PDLIM4	0.48	6.96	0.39	2.71e-11	Acylcarnitine levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10318825	chr7:75611554	POR	-0.52	-6.1	-0.35	3.84e-9	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.830	rs7662114	chr4:99019985	A/G	cg05340658	chr4:99064831	C4orf37	0.82	12.99	0.62	3.34e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs947211	0.898	rs1775146	chr1:205756168	A/G	cg26354017	chr1:205819088	PM20D1	0.44	5.63	0.33	4.55e-8	Parkinson's disease;
CESC	cis	rs13256369	0.802	rs12153	chr8:8560909	G/C	cg00074818	chr8:8560427	CLDN23	0.36	5.22	0.31	3.68e-7	Obesity-related traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06484986	chr15:42841099	LRRC57;HAUS2	0.57	6.68	0.38	1.38e-10	Gut microbiome composition (summer);
CESC	cis	rs8038465	1.000	rs67257650	chr15:73979507	C/T	cg15420318	chr15:73925796	NPTN	0.43	6.05	0.35	4.94e-9	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs477895	0.838	rs11605738	chr11:64013406	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.9	10.01	0.52	3.13e-20	Mean platelet volume;
CESC	cis	rs9926296	0.585	rs4785595	chr16:89835521	C/T	cg03388025	chr16:89894329	SPIRE2	-0.41	-7.68	-0.43	3.12e-13	Vitiligo;
CESC	cis	rs6952808	0.656	rs12699646	chr7:2093162	T/G	cg08027265	chr7:2291960	NA	0.42	6.41	0.37	6.45e-10	Bipolar disorder and schizophrenia;
CESC	cis	rs7937682	0.924	rs495460	chr11:111504777	G/A	cg22437258	chr11:111473054	SIK2	0.7	9.35	0.5	3.83e-18	Primary sclerosing cholangitis;
CESC	cis	rs10744422	0.843	rs3896870	chr12:123333611	T/C	cg25930673	chr12:123319894	HIP1R	-0.73	-5.71	-0.33	3.02e-8	Schizophrenia;
CESC	cis	rs709400	1.000	rs2403205	chr14:104143385	C/T	cg24130564	chr14:104152367	KLC1	-0.43	-5.48	-0.32	9.93e-8	Body mass index;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg24008668	chr6:26158556	HIST1H2BD	0.46	6.04	0.35	5.27e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs9790314	1.000	rs464766	chr3:161087592	C/G	cg03342759	chr3:160939853	NMD3	-0.44	-5.6	-0.33	5.25e-8	Morning vs. evening chronotype;
CESC	cis	rs6998277	0.830	rs6981007	chr8:103598257	G/C	cg10187029	chr8:103597600	NA	0.75	9.93	0.52	5.94e-20	Migraine;
CESC	cis	rs4699052	0.739	rs11936824	chr4:104238003	T/G	cg16532752	chr4:104119610	CENPE	-0.37	-5.25	-0.31	3.09e-7	Testicular germ cell tumor;
CESC	cis	rs9487051	0.738	rs449850	chr6:109525045	A/G	cg01475377	chr6:109611718	NA	-0.46	-6.93	-0.39	3.27e-11	Reticulocyte fraction of red cells;
CESC	cis	rs1799949	1.000	rs2298862	chr17:41176688	T/C	cg05368731	chr17:41323189	NBR1	0.8	10.68	0.55	2.21e-22	Menopause (age at onset);
CESC	cis	rs9486719	1.000	rs11757063	chr6:96884886	C/T	cg18709589	chr6:96969512	KIAA0776	-0.53	-5.87	-0.34	1.3e-8	Migraine;Coronary artery disease;
CESC	cis	rs7089973	0.584	rs6585300	chr10:116639889	A/C	cg25233709	chr10:116636983	FAM160B1	0.39	6.38	0.36	7.78e-10	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs939574	0.790	rs72955444	chr2:220094673	T/G	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.88	7.38	0.41	2e-12	Platelet distribution width;
CESC	cis	rs9815354	0.812	rs55788971	chr3:41843965	T/A	cg03022575	chr3:42003672	ULK4	0.7	6.04	0.35	5.26e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs56046484	0.620	rs34585903	chr15:85528124	G/T	cg08123816	chr15:85640762	PDE8A	-0.48	-5.14	-0.3	5.46e-7	Testicular germ cell tumor;
CESC	cis	rs7666738	0.830	rs7667796	chr4:99071415	G/T	cg05340658	chr4:99064831	C4orf37	-0.85	-12.75	-0.62	2.33e-29	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4595586	0.545	rs11610886	chr12:39390613	C/G	cg26384229	chr12:38710491	ALG10B	0.54	7.64	0.42	3.96e-13	Morning vs. evening chronotype;
CESC	cis	rs1801251	1.000	rs2044449	chr2:233718808	G/A	cg08000102	chr2:233561755	GIGYF2	-0.7	-10.07	-0.53	2.13e-20	Coronary artery disease;
CESC	cis	rs10751667	0.666	rs7944815	chr11:959776	C/T	cg01483505	chr11:975446	AP2A2	0.37	5.09	0.3	6.77e-7	Alzheimer's disease (late onset);
CESC	cis	rs854765	0.583	rs7214002	chr17:17852104	G/C	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.47	6.08	0.35	4.28e-9	Total body bone mineral density;
CESC	cis	rs12476592	0.602	rs262505	chr2:63861786	C/T	cg17519650	chr2:63277830	OTX1	-0.46	-5.08	-0.3	6.98e-7	Childhood ear infection;
CESC	cis	rs9611565	0.659	rs17367716	chr22:41913844	A/G	cg06481639	chr22:41940642	POLR3H	-0.63	-6.42	-0.37	6.29e-10	Vitiligo;
CESC	cis	rs899997	1.000	rs12899940	chr15:79001699	A/G	cg04896959	chr15:78267971	NA	-0.46	-7.26	-0.41	4.36e-12	Coronary artery disease or large artery stroke;
CESC	cis	rs10504229	0.554	rs17802082	chr8:58095867	C/T	cg22535103	chr8:58192502	C8orf71	-0.63	-6.61	-0.38	2.09e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs936229	0.690	rs2472299	chr15:75033400	C/T	cg14664628	chr15:75095509	CSK	0.8	10.81	0.55	8.21e-23	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CESC	cis	rs9486719	0.843	rs2205754	chr6:96843134	T/C	cg06623918	chr6:96969491	KIAA0776	0.78	7.39	0.41	1.89e-12	Migraine;Coronary artery disease;
CESC	cis	rs13114435	0.723	rs3886768	chr4:183817324	A/G	cg00486011	chr4:183851557	NA	-0.37	-5.49	-0.32	9.23e-8	Obesity-related traits;
CESC	cis	rs9733	0.596	rs12077833	chr1:150674333	C/T	cg09365446	chr1:150670422	GOLPH3L	0.42	5.91	0.34	1.03e-8	Tonsillectomy;
CESC	cis	rs2073300	0.609	rs17757442	chr20:23421101	A/G	cg16736954	chr20:23401023	NAPB	-0.8	-6.31	-0.36	1.18e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs2996428	0.709	rs6424052	chr1:3713746	A/G	cg23277830	chr1:3704460	LRRC47	0.36	5.2	0.3	3.91e-7	Red cell distribution width;
CESC	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg23708337	chr7:1209742	NA	0.49	5.13	0.3	5.69e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18778933	chr5:52760204	NA	0.5	6.1	0.35	3.68e-9	Gut microbiome composition (summer);
CESC	cis	rs67614146	1	rs67614146	chr6:87821827	AC/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.44	-7.16	-0.4	7.77e-12	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs208520	0.837	rs208488	chr6:66926902	C/T	cg07460842	chr6:66804631	NA	-0.9	-10.93	-0.56	3.28e-23	Exhaled nitric oxide output;
CESC	cis	rs7927771	0.965	rs12364432	chr11:47902883	G/A	cg05585544	chr11:47624801	NA	-0.5	-7.57	-0.42	6.07e-13	Subjective well-being;
CESC	cis	rs9467773	0.620	rs3800303	chr6:26598188	A/G	cg26531700	chr6:26746687	NA	-0.42	-6.42	-0.37	6.13e-10	Intelligence (multi-trait analysis);
CESC	cis	rs7937682	0.889	rs1940529	chr11:111498523	G/C	cg22437258	chr11:111473054	SIK2	0.7	9.08	0.49	2.59e-17	Primary sclerosing cholangitis;
CESC	cis	rs735396	0.770	rs2259820	chr12:121435342	C/T	cg02403541	chr12:121454288	C12orf43	0.73	10.33	0.54	2.99e-21	N-glycan levels;
CESC	cis	rs35306767	0.903	rs12244355	chr10:944465	T/C	cg25019033	chr10:957182	NA	-0.56	-6.09	-0.35	3.92e-9	Eosinophil percentage of granulocytes;
CESC	cis	rs2072499	0.900	rs2248080	chr1:156195971	T/A	cg25208724	chr1:156163844	SLC25A44	0.95	15.17	0.68	7.91e-38	Testicular germ cell tumor;
CESC	cis	rs2073300	0.609	rs6132609	chr20:23400412	A/C	cg12062639	chr20:23401060	NAPB	1.07	8.23	0.45	8.58e-15	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs4819052	0.851	rs2838848	chr21:46671017	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.93	13.67	0.64	1.54e-32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs7666738	0.791	rs4440223	chr4:99044796	G/A	cg03676636	chr4:99064102	C4orf37	0.33	5.12	0.3	5.93e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24351916	chr3:39452635	SNORA62;RPSA	-0.52	-6.2	-0.36	2.21e-9	Gut microbiome composition (summer);
CESC	cis	rs9291683	0.620	rs4444830	chr4:10124819	A/G	cg11266682	chr4:10021025	SLC2A9	-0.49	-7.93	-0.44	5.99e-14	Bone mineral density;
CESC	cis	rs4604732	0.578	rs7525209	chr1:247627404	C/T	cg12758973	chr1:247694275	LOC148824;OR2C3	0.51	6.36	0.36	8.65e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs780096	0.565	rs10169261	chr2:27727314	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.36	-6.47	-0.37	4.8e-10	Total body bone mineral density;
CESC	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.89	13.44	0.64	9.54e-32	Prudent dietary pattern;
CESC	trans	rs116095464	0.558	rs10057674	chr5:266813	C/T	cg00938859	chr5:1591904	SDHAP3	0.63	6.77	0.38	8.38e-11	Breast cancer;
CESC	trans	rs2727020	0.521	rs1909220	chr11:49572109	T/C	cg03929089	chr4:120376271	NA	-0.73	-8.46	-0.46	1.79e-15	Coronary artery disease;
CESC	cis	rs8060686	0.641	rs28548264	chr16:68211321	A/G	cg26727032	chr16:67993705	SLC12A4	-0.51	-6.18	-0.36	2.35e-9	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs853679	0.517	rs9393884	chr6:28046789	A/G	cg22143856	chr6:28129313	ZNF389	0.49	6.28	0.36	1.38e-9	Depression;
CESC	cis	rs761746	0.960	rs4820983	chr22:31929654	C/T	cg25791279	chr22:32026902	PISD	-0.46	-5.34	-0.31	2e-7	Intelligence;
CESC	cis	rs1878931	0.624	rs39728	chr16:3453076	A/T	cg26668626	chr16:3451006	ZNF174;ZNF434	0.73	9.42	0.5	2.26e-18	Body mass index (adult);
CESC	cis	rs9649213	0.574	rs3801257	chr7:97991792	A/G	cg24562669	chr7:97807699	LMTK2	0.49	7.17	0.4	7.33e-12	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs9908102	0.740	rs4791522	chr17:12902688	C/G	cg26162695	chr17:12921313	ELAC2	0.5	5.49	0.32	9.61e-8	Schizophrenia;
CESC	cis	rs3820068	0.581	rs72645861	chr1:15920314	A/G	cg17385448	chr1:15911702	AGMAT	0.42	6.72	0.38	1.13e-10	Systolic blood pressure;
CESC	cis	rs11098499	0.954	rs59394118	chr4:120295551	A/G	cg24375607	chr4:120327624	NA	0.47	5.62	0.33	4.89e-8	Corneal astigmatism;
CESC	cis	rs4665809	1.000	rs4665308	chr2:26330514	C/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.67	-7.53	-0.42	7.92e-13	Gut microbiome composition (summer);
CESC	cis	rs6912958	0.582	rs242285	chr6:88070743	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	0.36	5.88	0.34	1.21e-8	Monocyte percentage of white cells;
CESC	cis	rs2191566	0.960	rs11083732	chr19:44520743	T/C	cg20607764	chr19:44506953	ZNF230	-0.57	-7.45	-0.42	1.29e-12	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs4523957	0.583	rs923863	chr17:2031387	A/G	cg16513277	chr17:2031491	SMG6	-0.79	-11.73	-0.58	6.95e-26	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs11153306	0.791	rs9387017	chr6:111944006	A/G	cg22127309	chr6:111907043	TRAF3IP2	-0.4	-6.03	-0.35	5.42e-9	Tonsillectomy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10137979	chr8:110346498	ENY2;NUDCD1	0.51	6.01	0.35	6.22e-9	Gut microbiome composition (summer);
CESC	cis	rs12142240	0.698	rs56344958	chr1:46814518	G/A	cg10495392	chr1:46806563	NSUN4	0.57	6.28	0.36	1.39e-9	Menopause (age at onset);
CESC	cis	rs4689388	0.926	rs4689394	chr4:6291003	C/G	cg14416269	chr4:6271139	WFS1	-0.45	-7.5	-0.42	9.93e-13	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs748404	0.697	rs1814323	chr15:43563237	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	-0.51	-7.93	-0.44	6.18e-14	Lung cancer;
CESC	trans	rs916888	0.610	rs199536	chr17:44820425	T/C	cg22968622	chr17:43663579	NA	-0.75	-10.16	-0.53	1.05e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs9611565	0.649	rs139540	chr22:42178040	C/T	cg06634786	chr22:41940651	POLR3H	-0.48	-5.41	-0.32	1.41e-7	Vitiligo;
CESC	cis	rs4595586	0.756	rs1400283	chr12:39364596	G/C	cg26384229	chr12:38710491	ALG10B	0.42	6.21	0.36	2.07e-9	Morning vs. evening chronotype;
CESC	cis	rs2832191	0.716	rs1543652	chr21:30448000	G/C	cg24692254	chr21:30365293	RNF160	0.99	17.29	0.73	2.32e-45	Dental caries;
CESC	cis	rs4901847	0.577	rs10782436	chr14:58574964	T/C	cg15908186	chr14:58618357	C14orf37	0.38	5.71	0.33	2.95e-8	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs2882667	0.858	rs11242448	chr5:138443154	C/A	cg04439458	chr5:138467593	SIL1	-0.39	-6.11	-0.35	3.51e-9	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs11098499	0.954	rs2389803	chr4:120393511	A/G	cg09307838	chr4:120376055	NA	-0.94	-13.85	-0.65	3.54e-33	Corneal astigmatism;
CESC	cis	rs7084402	0.967	rs1427196	chr10:60278573	C/T	cg07615347	chr10:60278583	BICC1	-0.59	-9.45	-0.5	1.94e-18	Refractive error;
CESC	cis	rs9925964	0.967	rs12716981	chr16:31118024	C/A	cg02466173	chr16:30829666	NA	0.33	5.16	0.3	4.77e-7	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs14403	1.000	rs67027895	chr1:243667216	C/T	cg21452805	chr1:244014465	NA	0.45	5.32	0.31	2.23e-7	Schizophrenia;
CESC	cis	rs6685188	0.920	rs10751444	chr1:205662144	A/G	cg07157834	chr1:205819609	PM20D1	-0.4	-5.36	-0.31	1.77e-7	White blood cell count (basophil);Basophil percentage of white cells;
CESC	cis	rs735539	1.000	rs6490605	chr13:21285009	C/T	cg04906043	chr13:21280425	IL17D	-0.35	-5.52	-0.32	8.25e-8	Dental caries;
CESC	trans	rs11098499	0.874	rs28452522	chr4:120110784	A/G	cg25214090	chr10:38739885	LOC399744	0.55	7.2	0.4	6.26e-12	Corneal astigmatism;
CESC	cis	rs1865721	0.804	rs62089468	chr18:73158850	C/T	cg26385618	chr18:73139727	C18orf62	-0.46	-6.98	-0.39	2.32e-11	Intelligence;
CESC	cis	rs9388451	0.626	rs7748729	chr6:126077381	C/T	cg05901451	chr6:126070800	HEY2	-0.61	-9.13	-0.49	1.79e-17	Brugada syndrome;
CESC	trans	rs7944735	0.507	rs10838802	chr11:48102478	A/G	cg03929089	chr4:120376271	NA	0.55	6.77	0.38	8.46e-11	Intraocular pressure;
CESC	cis	rs1023500	0.573	rs133381	chr22:42470608	C/G	cg15557168	chr22:42548783	NA	-0.44	-6.02	-0.35	5.64e-9	Schizophrenia;
CESC	cis	rs9611565	0.659	rs12484228	chr22:41939739	A/G	cg17376030	chr22:41985996	PMM1	0.68	7.52	0.42	8.57e-13	Vitiligo;
CESC	cis	rs7193541	0.684	rs4887783	chr16:74700743	G/C	cg05580060	chr16:74700937	RFWD3	-0.42	-5.39	-0.31	1.6e-7	Multiple myeloma;
CESC	cis	rs7084402	0.967	rs1658419	chr10:60332812	A/C	cg07615347	chr10:60278583	BICC1	0.59	9.22	0.49	9.9e-18	Refractive error;
CESC	cis	rs11760633	0.607	rs11761457	chr7:1829228	C/T	cg23422044	chr7:1970798	MAD1L1	-0.42	-5.1	-0.3	6.6e-7	Coronary artery disease;
CESC	cis	rs870825	0.616	rs6552802	chr4:185620751	C/G	cg04058563	chr4:185651563	MLF1IP	0.64	7.05	0.4	1.59e-11	Blood protein levels;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg18644787	chr2:208890461	PLEKHM3	-0.45	-6.15	-0.35	2.87e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs7216064	0.953	rs62086044	chr17:65970837	G/T	cg12091567	chr17:66097778	LOC651250	-0.76	-8.1	-0.45	2.02e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs3784262	0.967	rs35511675	chr15:58266978	T/A	cg12031962	chr15:58353849	ALDH1A2	-0.31	-5.07	-0.3	7.57e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
CESC	cis	rs1707322	1.000	rs946527	chr1:46485970	C/T	cg06784218	chr1:46089804	CCDC17	0.32	5.56	0.32	6.73e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs4862750	0.872	rs7679956	chr4:187900229	C/T	cg22105103	chr4:187893119	NA	0.46	6.88	0.39	4.28e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7208859	0.623	rs28433704	chr17:29084285	G/C	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.17e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs2635047	0.656	rs1355594	chr18:44763994	T/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.42	5.62	0.33	4.79e-8	Educational attainment;
CESC	cis	rs644799	0.542	rs10831415	chr11:95466159	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.5	6.43	0.37	5.86e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs7726839	0.540	rs28364691	chr5:664084	G/A	cg16447950	chr5:562315	NA	-0.62	-6.54	-0.37	3.09e-10	Obesity-related traits;
CESC	trans	rs2963826	0.589	rs298091	chr5:58996603	A/T	cg09299307	chr5:86709023	CCNH	0.48	6.26	0.36	1.58e-9	Obesity-related traits;
CESC	cis	rs35306767	0.953	rs11253521	chr10:976416	G/C	cg26597838	chr10:835615	NA	0.7	8.31	0.45	5.1e-15	Eosinophil percentage of granulocytes;
CESC	trans	rs2727020	0.729	rs588458	chr11:49214048	C/A	cg15704280	chr7:45808275	SEPT13	0.85	14.02	0.65	8.72e-34	Coronary artery disease;
CESC	cis	rs9905704	0.633	rs2680697	chr17:56478711	T/A	cg12560992	chr17:57184187	TRIM37	-0.61	-5.75	-0.33	2.49e-8	Testicular germ cell tumor;
CESC	cis	rs17376456	0.877	rs12374470	chr5:93481046	A/G	cg25358565	chr5:93447407	FAM172A	1.15	10.91	0.56	3.79e-23	Diabetic retinopathy;
CESC	cis	rs12145833	0.596	rs12134228	chr1:243447618	C/T	cg02356786	chr1:243265016	LOC731275	0.72	5.23	0.31	3.48e-7	Obesity (early onset extreme);
CESC	cis	rs4665809	0.938	rs35844686	chr2:26304949	A/G	cg26314531	chr2:26401878	FAM59B	0.7	7.47	0.42	1.17e-12	Gut microbiome composition (summer);
CESC	cis	rs2637266	0.935	rs2583057	chr10:78396019	C/T	cg18941641	chr10:78392320	NA	0.45	8.6	0.47	7.12e-16	Pulmonary function;
CESC	cis	rs2303745	0.589	rs1465576	chr19:17398487	G/A	cg22549504	chr19:17448937	GTPBP3	0.49	5.46	0.32	1.12e-7	Systemic lupus erythematosus;
CESC	cis	rs7927771	0.757	rs1057233	chr11:47376448	G/A	cg20307385	chr11:47447363	PSMC3	0.61	7.29	0.41	3.51e-12	Subjective well-being;
CESC	cis	rs9487051	0.735	rs351745	chr6:109529169	C/T	cg01475377	chr6:109611718	NA	0.4	5.98	0.35	7.01e-9	Reticulocyte fraction of red cells;
CESC	cis	rs9910055	0.636	rs7089	chr17:42269017	T/C	cg10896456	chr17:42255109	ASB16;C17orf65	0.48	7.19	0.4	6.56e-12	Total body bone mineral density;
CESC	cis	rs67478160	0.619	rs11623546	chr14:104269098	A/G	cg08213375	chr14:104286397	PPP1R13B	0.54	10.79	0.55	9.69e-23	Schizophrenia;
CESC	cis	rs761746	0.960	rs4820982	chr22:31929480	T/C	cg25791279	chr22:32026902	PISD	-0.47	-5.59	-0.32	5.65e-8	Intelligence;
CESC	cis	rs992157	0.710	rs56364928	chr2:219059058	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.67	9.23	0.49	8.83e-18	Colorectal cancer;
CESC	trans	rs7938889	0.517	rs505689	chr11:95930072	A/G	cg20932348	chr4:26862197	STIM2	0.46	6.17	0.35	2.51e-9	Methadone dose in opioid dependence;
CESC	cis	rs3733585	0.699	rs17245723	chr4:9962218	A/T	cg02734326	chr4:10020555	SLC2A9	-0.44	-6.15	-0.35	2.85e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs432925	0.600	rs214247	chr16:349221	A/G	cg06233593	chr16:337645	AXIN1	0.49	7.62	0.42	4.51e-13	Morning vs. evening chronotype;
CESC	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	13.66	0.64	1.57e-32	Prudent dietary pattern;
CESC	cis	rs7618501	1.000	rs7372730	chr3:49790682	C/G	cg24308560	chr3:49941425	MST1R	0.5	6.71	0.38	1.15e-10	Intelligence (multi-trait analysis);
CESC	cis	rs4481887	0.741	rs6681758	chr1:248540413	T/A	cg26353448	chr1:248524236	OR2T4	-0.39	-5.35	-0.31	1.94e-7	Common traits (Other);
CESC	cis	rs6120849	0.754	rs6120813	chr20:33642112	T/C	cg06115741	chr20:33292138	TP53INP2	0.53	5.05	0.3	8.15e-7	Protein C levels;
CESC	cis	rs4450798	0.649	rs59100699	chr3:13791438	A/G	cg23332027	chr3:13681764	NA	0.38	5.13	0.3	5.63e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs7927771	0.864	rs11604680	chr11:47457539	A/G	cg20307385	chr11:47447363	PSMC3	-0.65	-7.57	-0.42	6.2e-13	Subjective well-being;
CESC	cis	rs9309473	0.948	rs6719753	chr2:73749054	T/G	cg20560298	chr2:73613845	ALMS1	-0.45	-6.04	-0.35	5.24e-9	Metabolite levels;
CESC	cis	rs9322193	0.923	rs9800736	chr6:149982417	A/G	cg04369109	chr6:150039330	LATS1	-0.43	-6.09	-0.35	3.99e-9	Lung cancer;
CESC	cis	rs7520050	0.801	rs6703960	chr1:46232723	C/T	cg03146154	chr1:46216737	IPP	-0.5	-6.6	-0.38	2.2e-10	Red blood cell count;Reticulocyte count;
CESC	cis	rs561341	0.883	rs4795661	chr17:30201774	T/A	cg00745463	chr17:30367425	LRRC37B	0.57	5.68	0.33	3.63e-8	Hip circumference adjusted for BMI;
CESC	cis	rs910316	0.967	rs175432	chr14:75615246	C/G	cg11812906	chr14:75593930	NEK9	-0.9	-15.54	-0.69	3.63e-39	Height;
CESC	cis	rs4523957	0.690	rs7213715	chr17:2093511	A/T	cg16513277	chr17:2031491	SMG6	-0.72	-9.79	-0.52	1.63e-19	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs6860806	0.507	rs2631372	chr5:131703578	C/G	cg24060327	chr5:131705240	SLC22A5	-0.74	-8.94	-0.48	6.87e-17	Breast cancer;
CESC	cis	rs2073300	0.609	rs6137937	chr20:23385419	G/A	cg16736954	chr20:23401023	NAPB	0.8	6.25	0.36	1.67e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs13108904	0.967	rs1316419	chr4:1293997	C/T	cg22903657	chr4:1355424	KIAA1530	-0.38	-5.13	-0.3	5.55e-7	Obesity-related traits;
CESC	cis	rs1670533	0.932	rs935968	chr4:1063187	G/T	cg27284194	chr4:1044797	NA	0.45	5.73	0.33	2.67e-8	Recombination rate (females);
CESC	cis	rs9341808	0.667	rs2505929	chr6:80834208	A/G	cg08355045	chr6:80787529	NA	0.33	5.36	0.31	1.81e-7	Sitting height ratio;
CESC	cis	rs9467711	0.790	rs13195401	chr6:26463574	G/T	cg21479132	chr6:26055353	NA	0.82	5.71	0.33	3.05e-8	Autism spectrum disorder or schizophrenia;
CESC	cis	rs7618915	1.000	rs59565798	chr3:52307169	G/A	cg18404041	chr3:52824283	ITIH1	-0.36	-5.52	-0.32	8.1e-8	Bipolar disorder;
CESC	cis	rs708547	0.647	rs1277308	chr4:57897864	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.52	7.21	0.41	5.73e-12	Response to bleomycin (chromatid breaks);
CESC	cis	rs1552244	1.000	rs12152515	chr3:10143976	C/T	cg00149659	chr3:10157352	C3orf10	0.74	9.26	0.49	7.35e-18	Alzheimer's disease;
CESC	cis	rs3936840	0.752	rs2181343	chr14:102993303	A/C	cg18135206	chr14:102964638	TECPR2	-0.47	-6.18	-0.35	2.47e-9	Plateletcrit;
CESC	cis	rs6912958	1.000	rs6454630	chr6:88171357	C/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.3	5.1	0.3	6.43e-7	Monocyte percentage of white cells;
CESC	cis	rs13242816	1.000	rs62471189	chr7:116101588	G/A	cg04696780	chr7:116139425	CAV2	-0.62	-5.69	-0.33	3.31e-8	P wave duration;
CESC	cis	rs3857067	0.806	rs9996975	chr4:95101338	C/G	cg11021082	chr4:95130006	SMARCAD1	-0.59	-8.69	-0.47	3.91e-16	QT interval;
CESC	cis	rs6088590	0.931	rs6088624	chr20:33436852	T/A	cg06115741	chr20:33292138	TP53INP2	0.61	7.66	0.43	3.46e-13	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18788524	chr1:145096602	SEC22B	0.67	7.58	0.42	5.67e-13	Gut microbiome composition (summer);
CESC	cis	rs735396	0.770	rs2259820	chr12:121435342	C/T	cg25281562	chr12:121454272	C12orf43	0.53	6.79	0.38	7.44e-11	N-glycan levels;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg20299236	chr22:32870557	FBXO7	0.48	6.34	0.36	1.01e-9	Gut microbiota (bacterial taxa);
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg09235138	chr15:40987404	RAD51	0.47	6.56	0.37	2.79e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs2120019	0.938	rs1867150	chr15:75321139	T/C	cg17294928	chr15:75287854	SCAMP5	-0.77	-9.0	-0.48	4.47e-17	Blood trace element (Zn levels);
CESC	cis	rs546131	0.890	rs496558	chr11:34826425	C/T	cg06937548	chr11:34938143	PDHX;APIP	0.49	6.13	0.35	3.1e-9	Lung disease severity in cystic fibrosis;
CESC	cis	rs9660992	0.573	rs1318187	chr1:205206172	T/A	cg21643547	chr1:205240462	TMCC2	-0.39	-5.37	-0.31	1.76e-7	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs9916302	0.768	rs62077464	chr17:37656056	C/G	cg20243544	chr17:37824526	PNMT	0.48	6.03	0.35	5.4e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs2204008	0.818	rs7313608	chr12:38383428	C/A	cg26384229	chr12:38710491	ALG10B	-0.67	-9.96	-0.52	4.67e-20	Bladder cancer;
CESC	cis	rs7674212	0.539	rs6821617	chr4:104128410	G/A	cg16532752	chr4:104119610	CENPE	-0.39	-5.3	-0.31	2.43e-7	Type 2 diabetes;
CESC	cis	rs9811920	0.683	rs813218	chr3:99592596	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.4	6.49	0.37	4.14e-10	Axial length;
CESC	trans	rs62103177	1.000	rs62103177	chr18:77624479	G/A	cg05926928	chr17:57297772	GDPD1	1.14	9.97	0.52	4.45e-20	Opioid sensitivity;
CESC	cis	rs13191362	1.000	rs13218900	chr6:163081638	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.62	6.4	0.37	7.19e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	trans	rs7178375	1.000	rs1474381	chr15:31214991	T/C	cg04373760	chr16:53404718	NA	0.54	7.24	0.41	4.94e-12	Hypertriglyceridemia;
CESC	cis	rs7772486	0.686	rs9399565	chr6:146081906	G/T	cg23711669	chr6:146136114	FBXO30	-0.87	-12.87	-0.62	9.2e-30	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs909002	0.849	rs6664789	chr1:32072406	C/G	cg13919466	chr1:32135498	COL16A1	-0.47	-8.44	-0.46	2.13e-15	Intelligence (multi-trait analysis);
CESC	cis	rs3738443	0.545	rs12566906	chr1:247388206	G/T	cg07706540	chr1:247373924	NA	-0.45	-5.51	-0.32	8.4e-8	Alcohol dependence;
CESC	cis	rs4713118	0.662	rs149969	chr6:27977737	A/G	cg12963246	chr6:28129442	ZNF389	0.48	6.69	0.38	1.34e-10	Parkinson's disease;
CESC	cis	rs7208859	0.623	rs7208088	chr17:29143667	C/T	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.79e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs116095464	0.558	rs62347677	chr5:227453	A/G	cg12570787	chr5:219185	SDHA;CCDC127	0.53	5.69	0.33	3.42e-8	Breast cancer;
CESC	trans	rs11098499	0.754	rs11098502	chr4:120252063	T/A	cg25214090	chr10:38739885	LOC399744	0.62	8.7	0.47	3.58e-16	Corneal astigmatism;
CESC	cis	rs10504229	1.000	rs67546820	chr8:58168567	G/A	cg14926445	chr8:58193284	C8orf71	-0.49	-5.21	-0.3	3.76e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs10392	0.571	rs4812350	chr20:37631192	C/T	cg27552599	chr20:37590471	DHX35	0.39	5.76	0.33	2.31e-8	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
CESC	cis	rs713587	0.967	rs713586	chr2:25158008	A/G	cg01884057	chr2:25150051	NA	0.42	8.13	0.45	1.61e-14	Body mass index in non-asthmatics;
CESC	cis	rs709400	1.000	rs861536	chr14:104167564	A/G	cg24130564	chr14:104152367	KLC1	-0.44	-5.59	-0.32	5.67e-8	Body mass index;
CESC	cis	rs858239	1.000	rs858240	chr7:23284237	A/G	cg23682824	chr7:23144976	KLHL7	0.42	5.51	0.32	8.68e-8	Cerebrospinal fluid biomarker levels;
CESC	cis	rs7098414	0.511	rs10788603	chr10:82148137	G/T	cg00277334	chr10:82204260	NA	-0.54	-8.0	-0.44	3.82e-14	Post bronchodilator FEV1;
CESC	cis	rs514406	0.861	rs4926576	chr1:53226775	C/T	cg08859206	chr1:53392774	SCP2	0.53	7.09	0.4	1.19e-11	Monocyte count;
CESC	cis	rs7520050	0.902	rs4638056	chr1:46458153	T/G	cg03146154	chr1:46216737	IPP	-0.48	-6.16	-0.35	2.71e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs2479724	0.935	rs7753507	chr6:41784094	C/T	cg08135965	chr6:41755394	TOMM6	-0.4	-5.57	-0.32	6.12e-8	Menarche (age at onset);
CESC	cis	rs533581	0.873	rs579740	chr16:88973937	A/G	cg16701003	chr16:89028210	CBFA2T3	-0.57	-8.26	-0.45	6.79e-15	Social autistic-like traits;
CESC	cis	rs6540556	0.769	rs12030655	chr1:209922123	G/T	cg23920097	chr1:209922102	NA	-0.38	-5.42	-0.32	1.37e-7	Red blood cell count;
CESC	cis	rs2072499	0.966	rs2244144	chr1:156184598	G/A	cg24450063	chr1:156163899	SLC25A44	0.92	14.14	0.66	3.37e-34	Testicular germ cell tumor;
CESC	cis	rs950169	1.000	rs12902672	chr15:84716986	G/A	cg17507749	chr15:85114479	UBE2QP1	0.63	6.93	0.39	3.26e-11	Schizophrenia;
CESC	cis	rs9611565	0.559	rs12483860	chr22:41961916	C/T	cg06634786	chr22:41940651	POLR3H	-0.62	-6.83	-0.39	5.85e-11	Vitiligo;
CESC	cis	rs9733	0.596	rs7529998	chr1:150662531	C/T	cg04414720	chr1:150670196	GOLPH3L	0.63	9.02	0.48	3.87e-17	Tonsillectomy;
CESC	cis	rs8068544	0.818	rs78333491	chr17:40163138	A/G	cg26502583	chr17:39992600	KLHL10;NT5C3L	-0.76	-6.07	-0.35	4.34e-9	Reticulocyte fraction of red cells;Reticulocyte count;
CESC	cis	rs9611565	0.649	rs6002480	chr22:42176917	A/T	cg06481639	chr22:41940642	POLR3H	-0.49	-5.64	-0.33	4.39e-8	Vitiligo;
CESC	cis	rs2984613	1	rs2984613	chr1:156197380	C/T	cg24450063	chr1:156163899	SLC25A44	0.8	11.76	0.59	5.75e-26	Intracerebral hemorrhage;White matter hyperintensity burden;
CESC	cis	rs1707322	0.752	rs6658700	chr1:46160260	C/T	cg06784218	chr1:46089804	CCDC17	0.41	7.21	0.41	5.75e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs703842	1.000	rs10877019	chr12:58172929	A/G	cg00677455	chr12:58241039	CTDSP2	-0.49	-6.09	-0.35	3.98e-9	Multiple sclerosis;
CESC	cis	rs3806843	0.900	rs2563286	chr5:140125199	T/A	cg26395211	chr5:140044315	WDR55	0.39	5.14	0.3	5.35e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs6964587	0.934	rs73226382	chr7:91692760	T/C	cg17063962	chr7:91808500	NA	0.6	8.37	0.46	3.39e-15	Breast cancer;
CESC	cis	rs11048434	0.761	rs2110191	chr12:9136263	G/A	cg23795048	chr12:9217529	LOC144571	0.35	5.37	0.31	1.76e-7	Sjögren's syndrome;
CESC	cis	rs1862618	0.853	rs252921	chr5:56137787	G/A	cg24531977	chr5:56204891	C5orf35	-0.88	-11.51	-0.58	3.94e-25	Initial pursuit acceleration;
CESC	cis	rs1003719	0.788	rs2835574	chr21:38455324	C/A	cg10648535	chr21:38446584	PIGP;TTC3	0.62	8.67	0.47	4.41e-16	Eye color traits;
CESC	cis	rs7618915	0.571	rs1961959	chr3:52585760	G/C	cg18099408	chr3:52552593	STAB1	-0.34	-5.47	-0.32	1.05e-7	Bipolar disorder;
CESC	cis	rs367615	0.918	rs10054960	chr5:108866448	C/A	cg17395555	chr5:108820864	NA	0.55	8.12	0.45	1.81e-14	Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs1707322	0.752	rs28545085	chr1:46201950	G/A	cg06784218	chr1:46089804	CCDC17	0.41	7.21	0.41	5.75e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs933688	1.000	rs10041402	chr5:90738948	A/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.96	12.8	0.62	1.61e-29	Smoking behavior;
CESC	trans	rs60843830	1.000	rs60484953	chr2:221560	G/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.66	8.01	0.44	3.76e-14	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs72781680	0.898	rs17462558	chr2:24020812	T/C	cg20701182	chr2:24300061	SF3B14	0.63	5.65	0.33	4.21e-8	Lymphocyte counts;
CESC	cis	rs4819052	0.851	rs7275874	chr21:46671223	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.92	13.57	0.64	3.24e-32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs12048904	0.505	rs11166511	chr1:101240686	G/C	cg15686842	chr1:101360669	SLC30A7;EXTL2	-0.55	-6.19	-0.36	2.29e-9	Multiple sclerosis;
CESC	cis	rs7809950	0.678	rs4730235	chr7:107022506	T/C	cg23024343	chr7:107201750	COG5	-0.59	-7.46	-0.42	1.22e-12	Coronary artery disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg15244168	chr11:65403161	PCNXL3	0.47	6.66	0.38	1.59e-10	Fibrinogen levels;
CESC	cis	rs7107174	1.000	rs11237480	chr11:78110385	C/A	cg02023728	chr11:77925099	USP35	0.38	5.54	0.32	7.16e-8	Testicular germ cell tumor;
CESC	cis	rs6674176	1.000	rs11210937	chr1:44405563	T/C	cg13606994	chr1:44402422	ARTN	-0.38	-5.56	-0.32	6.53e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs3126085	0.825	rs4845428	chr1:152225261	T/C	cg03465714	chr1:152285911	FLG	-0.44	-5.43	-0.32	1.25e-7	Atopic dermatitis;
CESC	cis	rs922182	0.538	rs16947599	chr15:64260944	C/T	cg24729988	chr15:64271149	DAPK2	-0.4	-5.57	-0.32	6.38e-8	Blood protein levels;
CESC	cis	rs7666738	0.830	rs7696715	chr4:98938486	T/C	cg03467027	chr4:99064603	C4orf37	0.48	5.91	0.34	1.03e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs798554	0.704	rs798513	chr7:2782493	C/T	cg09658497	chr7:2847517	GNA12	-0.35	-5.26	-0.31	2.92e-7	Height;
CESC	cis	rs909674	0.541	rs5750812	chr22:39793079	G/A	cg11247378	chr22:39784982	NA	-0.64	-9.68	-0.51	3.5e-19	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs7666738	0.830	rs13108871	chr4:98803872	T/C	cg24818145	chr4:99064322	C4orf37	0.39	5.18	0.3	4.43e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6690583	0.623	rs6700723	chr1:85514234	C/T	cg22153463	chr1:85462885	MCOLN2	0.74	7.53	0.42	8.03e-13	Serum sulfate level;
CESC	cis	rs7412746	0.586	rs2864882	chr1:150883037	C/T	cg22823121	chr1:150693482	HORMAD1	0.36	5.13	0.3	5.55e-7	Melanoma;
CESC	cis	rs244293	0.730	rs9303362	chr17:53062553	G/A	cg19360675	chr17:53046073	COX11;STXBP4	-0.47	-6.15	-0.35	2.8e-9	Menarche (age at onset);
CESC	cis	rs4975616	0.836	rs421629	chr5:1320136	G/A	cg07493874	chr5:1342172	CLPTM1L	-0.42	-7.83	-0.43	1.15e-13	Lung cancer;
CESC	cis	rs5769707	0.749	rs8137251	chr22:50036669	G/A	cg20744362	chr22:50050164	C22orf34	0.43	6.94	0.39	3e-11	Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs4689388	0.926	rs4234730	chr4:6296343	A/G	cg00701064	chr4:6280414	WFS1	0.67	11.29	0.57	2.09e-24	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs6542838	0.704	rs13011428	chr2:99528305	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.4	-5.09	-0.3	6.67e-7	Fear of minor pain;
CESC	cis	rs6942756	1.000	rs10954226	chr7:128953095	T/G	cg02491457	chr7:128862824	NA	-0.66	-8.93	-0.48	7.56e-17	White matter hyperintensity burden;
CESC	cis	rs2486288	0.656	rs11632777	chr15:45551045	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.54	-6.55	-0.37	3.03e-10	Glomerular filtration rate;
CESC	cis	rs172166	0.694	rs1631552	chr6:28089699	C/A	cg18032046	chr6:28092343	ZSCAN16	-0.47	-6.17	-0.35	2.48e-9	Cardiac Troponin-T levels;
CESC	cis	rs1799949	1.000	rs4793229	chr17:41418334	C/T	cg25067162	chr17:41277974	BRCA1;NBR2	-0.41	-5.55	-0.32	6.82e-8	Menopause (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10633147	chr2:68384753	WDR92;PNO1	0.56	6.44	0.37	5.75e-10	Gut microbiome composition (summer);
CESC	cis	rs13191362	1.000	rs13220181	chr6:163004401	T/A	cg14584255	chr6:163149320	PACRG;PARK2	0.49	5.36	0.31	1.78e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs514406	0.505	rs427319	chr1:53178807	T/G	cg24675658	chr1:53192096	ZYG11B	-0.5	-6.19	-0.36	2.22e-9	Monocyte count;
CESC	cis	rs9733	0.596	rs2065900	chr1:150652202	A/G	cg22823121	chr1:150693482	HORMAD1	0.48	7.09	0.4	1.21e-11	Tonsillectomy;
CESC	cis	rs1707322	0.686	rs2991987	chr1:46081422	C/G	cg05343316	chr1:45956843	TESK2	-0.52	-6.39	-0.37	7.26e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg05881776	chr2:235860554	SH3BP4	0.53	7.18	0.4	7.01e-12	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs2835872	0.733	rs2850124	chr21:39036763	T/A	cg06728970	chr21:39037746	KCNJ6	0.3	5.41	0.32	1.44e-7	Electroencephalographic traits in alcoholism;
CESC	cis	rs4965006	0.915	rs7969545	chr12:132419157	C/T	cg00588090	chr12:132412438	PUS1	-0.51	-7.23	-0.41	5.14e-12	Posterior cortical atrophy and Alzheimer's disease;
CESC	cis	rs1413885	0.548	rs6588136	chr1:65837119	C/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.46	5.94	0.34	9.02e-9	Anticoagulant levels;
CESC	cis	rs10870270	0.956	rs11146325	chr10:133767529	A/G	cg26149184	chr10:133730230	NA	0.38	5.17	0.3	4.57e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg25743584	chr17:27402893	TIAF1;MYO18A	0.43	6.01	0.35	6.16e-9	Fibrinogen levels;
CESC	cis	rs2952156	0.920	rs14050	chr17:37828072	C/T	cg20243544	chr17:37824526	PNMT	0.63	8.05	0.44	2.85e-14	Asthma;
CESC	cis	rs1843834	0.755	rs10192196	chr2:225577135	C/T	cg22455342	chr2:225449267	CUL3	0.42	5.5	0.32	8.87e-8	IgE levels in asthmatics (D.p. specific);
CESC	cis	rs400736	0.702	rs225134	chr1:8098730	A/G	cg25007680	chr1:8021821	PARK7	0.71	9.97	0.52	4.51e-20	Response to antidepressants and depression;
CESC	cis	rs60154123	0.772	rs815358	chr1:210430437	A/G	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.48	5.09	0.3	6.91e-7	Coronary artery disease;
CESC	cis	rs2249625	0.545	rs2463746	chr6:72876954	C/G	cg18830697	chr6:72922368	RIMS1	-0.49	-7.25	-0.41	4.49e-12	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CESC	cis	rs11031096	0.711	rs4910890	chr11:4153407	C/T	cg18678763	chr11:4115507	RRM1	-0.46	-6.31	-0.36	1.19e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	cis	rs9581857	0.579	rs1759861	chr13:27996406	A/C	cg22138327	chr13:27999177	GTF3A	-0.61	-5.11	-0.3	6.07e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
CESC	cis	rs858239	0.539	rs28624974	chr7:23188936	T/C	cg23682824	chr7:23144976	KLHL7	0.51	6.83	0.39	5.81e-11	Cerebrospinal fluid biomarker levels;
CESC	cis	rs4434138	0.683	rs13063160	chr3:52602274	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.6	8.66	0.47	4.81e-16	Intelligence (multi-trait analysis);
CESC	trans	rs61931739	1.000	rs12304768	chr12:34000986	T/G	cg26384229	chr12:38710491	ALG10B	-0.45	-6.25	-0.36	1.63e-9	Morning vs. evening chronotype;
CESC	cis	rs78456975	1.000	rs6744743	chr2:1558161	C/T	cg26248373	chr2:1572462	NA	0.57	5.45	0.32	1.14e-7	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs875971	0.545	rs2460427	chr7:65619205	T/C	cg11764359	chr7:65958608	NA	-0.79	-9.51	-0.5	1.18e-18	Aortic root size;
CESC	trans	rs3780486	0.505	rs1411609	chr9:33137303	C/T	cg20290983	chr6:43655470	MRPS18A	0.75	11.77	0.59	5.18e-26	IgG glycosylation;
CESC	cis	rs2040771	0.745	rs2283646	chr22:19273902	A/G	cg17887427	chr22:19166691	SLC25A1	0.4	5.15	0.3	5e-7	Metabolite levels (small molecules and protein measures);
CESC	cis	rs2576037	0.583	rs478820	chr18:44397782	G/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.33	5.29	0.31	2.52e-7	Personality dimensions;
CESC	cis	rs9811920	0.535	rs793483	chr3:99489825	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.34	-5.44	-0.32	1.19e-7	Axial length;
CESC	cis	rs4862750	0.872	rs13101380	chr4:187894744	G/A	cg22105103	chr4:187893119	NA	0.45	6.6	0.38	2.25e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs780096	0.565	rs10169261	chr2:27727314	C/T	cg12648201	chr2:27665141	KRTCAP3	-0.39	-7.12	-0.4	1.01e-11	Total body bone mineral density;
CESC	cis	rs6430585	0.527	rs76622824	chr2:136411879	A/G	cg07169764	chr2:136633963	MCM6	1.06	12.14	0.6	2.95e-27	Corneal structure;
CESC	trans	rs8073060	0.660	rs58266733	chr17:34003812	A/T	cg19694781	chr19:47549865	TMEM160	-0.71	-6.74	-0.38	9.95e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg07167872	chr1:205819463	PM20D1	-0.63	-10.57	-0.54	5.2e-22	Monocyte percentage of white cells;
CESC	cis	rs56046484	0.913	rs12906544	chr15:85576063	G/A	cg08123816	chr15:85640762	PDE8A	-0.49	-6.25	-0.36	1.63e-9	Testicular germ cell tumor;
CESC	cis	rs9682041	0.866	rs6444926	chr3:170133235	T/C	cg11886554	chr3:170076028	SKIL	0.92	7.8	0.43	1.43e-13	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CESC	cis	rs6474412	0.957	rs6474414	chr8:42560336	A/C	cg25026480	chr8:42547641	NA	0.32	5.09	0.3	6.85e-7	Smoking behavior;
CESC	cis	rs11122272	0.735	rs2474623	chr1:231513993	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.57	-7.82	-0.43	1.29e-13	Hemoglobin concentration;
CESC	cis	rs4911259	0.552	rs6057663	chr20:31463071	G/T	cg13636640	chr20:31349939	DNMT3B	-0.53	-7.41	-0.41	1.66e-12	Inflammatory bowel disease;
CESC	cis	rs9300255	0.568	rs1621194	chr12:123651018	T/C	cg19016782	chr12:123741754	C12orf65	-0.4	-5.77	-0.33	2.27e-8	Neutrophil percentage of white cells;
CESC	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg24642844	chr7:1081250	C7orf50	-0.76	-9.26	-0.49	7.23e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs4722585	0.533	rs757371	chr7:26199207	A/G	cg07876897	chr7:26191696	NFE2L3	0.44	5.68	0.33	3.46e-8	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
CESC	cis	rs7084402	0.967	rs1658462	chr10:60298284	A/C	cg07615347	chr10:60278583	BICC1	0.6	9.46	0.5	1.77e-18	Refractive error;
CESC	cis	rs9522267	0.535	rs56330641	chr13:112233538	C/T	cg10483660	chr13:112241077	NA	-0.33	-5.79	-0.33	2.04e-8	Hepatitis;
CESC	trans	rs1003719	0.715	rs762139	chr21:38568475	A/T	cg26370409	chr1:10002828	NMNAT1;LZIC	-0.43	-6.01	-0.35	6.25e-9	Eye color traits;
CESC	cis	rs6952808	0.624	rs60137119	chr7:2083664	A/G	cg04267008	chr7:1944627	MAD1L1	-0.63	-7.63	-0.42	4.15e-13	Bipolar disorder and schizophrenia;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14771734	chr5:79703670	ZFYVE16	-0.48	-6.24	-0.36	1.76e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs7605827	0.897	rs4668899	chr2:15511575	C/A	cg19274914	chr2:15703543	NA	0.32	5.58	0.32	5.99e-8	Educational attainment (years of education);
CESC	cis	rs9487051	0.621	rs566164	chr6:109506461	C/T	cg01475377	chr6:109611718	NA	-0.39	-5.13	-0.3	5.65e-7	Reticulocyte fraction of red cells;
CESC	cis	rs853679	0.517	rs56310871	chr6:28044482	A/G	cg23281280	chr6:28129359	ZNF389	0.57	7.78	0.43	1.61e-13	Depression;
CESC	cis	rs7818345	1.000	rs11991105	chr8:19290655	C/T	cg11303988	chr8:19266685	CSGALNACT1	0.33	5.88	0.34	1.24e-8	Language performance in older adults (adjusted for episodic memory);
CESC	cis	rs7212590	0.748	rs7220187	chr17:57897609	C/T	cg20303301	chr17:57937339	TUBD1	-0.59	-5.57	-0.32	6.14e-8	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs2777491	0.957	rs8026197	chr15:41711447	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.65	-9.86	-0.52	9.78e-20	Ulcerative colitis;
CESC	trans	rs8073060	0.586	rs225250	chr17:33941963	A/G	cg19694781	chr19:47549865	TMEM160	-0.71	-6.99	-0.39	2.2e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	cis	rs2296225	0.722	rs58464781	chr1:21051430	C/A	cg24673385	chr1:21051448	SH2D5	0.33	5.37	0.31	1.74e-7	Eosinophilic esophagitis;
CESC	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg03188948	chr7:1209495	NA	0.72	6.91	0.39	3.61e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs3749237	0.964	rs1799845	chr3:49847623	A/G	cg03060546	chr3:49711283	APEH	0.68	8.16	0.45	1.4e-14	Resting heart rate;
CESC	cis	rs73194058	1	rs73194058	chr21:34764288	C/A	cg14850771	chr21:34775459	IFNGR2	0.79	7.98	0.44	4.39e-14	Rheumatoid arthritis;
CESC	cis	rs12477438	0.765	rs10181344	chr2:99692829	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.62	-8.67	-0.47	4.43e-16	Chronic sinus infection;
CESC	cis	rs854765	0.927	rs4925138	chr17:17992793	T/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.44	-5.81	-0.34	1.79e-8	Total body bone mineral density;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg11827907	chr15:83654871	FAM103A1	-0.47	-6.02	-0.35	5.65e-9	Ulcerative colitis;
CESC	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg06877462	chr1:205807181	PM20D1	0.47	7.08	0.4	1.28e-11	Menarche (age at onset);
CESC	cis	rs2635047	0.811	rs12956009	chr18:44768024	T/C	cg24371990	chr18:44770781	NA	0.43	6.95	0.39	2.92e-11	Educational attainment;
CESC	cis	rs7944584	0.632	rs7116451	chr11:47322327	G/A	cg20307385	chr11:47447363	PSMC3	0.61	7.54	0.42	7.28e-13	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CESC	trans	rs9858542	0.953	rs11711485	chr3:49491983	G/T	cg21659725	chr3:3221576	CRBN	-0.55	-6.55	-0.37	2.95e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs2073499	0.935	rs3755832	chr3:50305234	G/A	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.74	6.11	0.35	3.63e-9	Schizophrenia;
CESC	cis	rs3806843	0.900	rs2261651	chr5:140136804	A/C	cg26395211	chr5:140044315	WDR55	0.43	5.46	0.32	1.07e-7	Depressive symptoms (multi-trait analysis);
CESC	trans	rs12310956	0.532	rs1525904	chr12:33962448	T/C	cg26384229	chr12:38710491	ALG10B	0.59	8.35	0.46	3.79e-15	Morning vs. evening chronotype;
CESC	cis	rs1451375	0.550	rs10239830	chr7:50603829	A/G	cg14593290	chr7:50529359	DDC	0.5	6.05	0.35	5.03e-9	Malaria;
CESC	cis	rs1218582	0.741	rs11264281	chr1:154867221	A/G	cg09359103	chr1:154839909	KCNN3	-0.68	-12.71	-0.62	3.15e-29	Prostate cancer;
CESC	cis	rs10823500	0.777	rs10999196	chr10:71982305	T/C	cg04118878	chr10:71993077	PPA1	0.47	5.56	0.32	6.61e-8	Blood protein levels;
CESC	cis	rs1003719	0.591	rs1053966	chr21:38568009	G/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.5	-6.28	-0.36	1.35e-9	Eye color traits;
CESC	cis	rs2075371	0.932	rs34664116	chr7:133984878	G/A	cg11752832	chr7:134001865	SLC35B4	0.53	6.92	0.39	3.47e-11	Mean platelet volume;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg11810498	chr9:130477698	PTRH1;TTC16	-0.45	-6.26	-0.36	1.52e-9	Gambling;
CESC	cis	rs3768617	0.528	rs4651144	chr1:183097421	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.89	14.27	0.66	1.13e-34	Fuchs's corneal dystrophy;
CESC	cis	rs7659604	0.539	rs7686200	chr4:122764553	C/T	cg20573242	chr4:122745356	CCNA2	0.62	7.47	0.42	1.2e-12	Type 2 diabetes;
CESC	cis	rs4964805	0.657	rs73192049	chr12:104187993	T/C	cg02344784	chr12:104178138	NT5DC3	0.46	6.57	0.37	2.73e-10	Attention deficit hyperactivity disorder;
CESC	cis	rs1881797	0.872	rs2141544	chr1:247690800	A/G	cg18198730	chr1:247681584	NA	0.58	8.78	0.47	2.01e-16	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs5769765	0.913	rs28670284	chr22:50221973	C/T	cg02269571	chr22:50332266	NA	-0.62	-6.95	-0.39	2.88e-11	Schizophrenia;
CESC	cis	rs2070488	1.000	rs2268757	chr3:38505853	C/T	cg24069376	chr3:38537580	EXOG	0.45	8.22	0.45	9.37e-15	Electrocardiographic conduction measures;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14032528	chr1:11866380	CLCN6;MTHFR	-0.55	-6.12	-0.35	3.38e-9	Gut microbiome composition (summer);
CESC	trans	rs61931739	0.614	rs6488172	chr12:33745669	A/G	cg26384229	chr12:38710491	ALG10B	0.43	6.31	0.36	1.18e-9	Morning vs. evening chronotype;
CESC	cis	rs34172651	0.517	rs11862923	chr16:24767303	G/T	cg00339695	chr16:24857497	SLC5A11	0.5	6.57	0.37	2.58e-10	Intelligence (multi-trait analysis);
CESC	cis	rs7555523	0.832	rs7524755	chr1:165694897	A/G	cg24409356	chr1:165738333	TMCO1	0.69	6.52	0.37	3.46e-10	Intraocular pressure;Glaucoma (high intraocular pressure);
CESC	cis	rs2836974	0.863	rs12483216	chr21:40539614	T/C	cg27266027	chr21:40555129	PSMG1	0.45	5.46	0.32	1.11e-7	Cognitive function;
CESC	cis	rs2228479	0.850	rs62056069	chr16:89912000	C/T	cg00800038	chr16:89945340	TCF25	-0.89	-6.89	-0.39	4.13e-11	Skin colour saturation;
CESC	cis	rs4604732	0.536	rs61184655	chr1:247651342	T/C	cg12754571	chr1:247694271	LOC148824;OR2C3	0.39	5.07	0.3	7.62e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs941873	0.900	rs7092536	chr10:81131332	A/C	cg11057378	chr10:81107060	PPIF	0.32	5.15	0.3	5.15e-7	Height;
CESC	cis	rs1799949	0.965	rs799908	chr17:41278916	A/G	cg07153921	chr17:41440717	NA	-0.38	-5.04	-0.3	8.65e-7	Menopause (age at onset);
CESC	cis	rs2249625	0.761	rs2496500	chr6:72884438	G/C	cg18830697	chr6:72922368	RIMS1	-0.39	-5.5	-0.32	8.88e-8	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CESC	cis	rs2274273	0.840	rs2009291	chr14:55838230	A/C	cg04306507	chr14:55594613	LGALS3	-0.32	-6.34	-0.36	9.91e-10	Protein biomarker;
CESC	cis	rs736408	0.522	rs11130310	chr3:52674667	C/T	cg18404041	chr3:52824283	ITIH1	-0.38	-6.56	-0.37	2.75e-10	Bipolar disorder;
CESC	cis	rs4253772	0.591	rs6008546	chr22:46686377	T/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.69	6.94	0.39	2.93e-11	LDL cholesterol;Cholesterol, total;
CESC	cis	rs79839061	0.656	rs11726508	chr4:888937	C/T	cg07828340	chr4:882639	GAK	0.82	7.08	0.4	1.31e-11	Intelligence (multi-trait analysis);
CESC	cis	rs2228479	0.850	rs12597296	chr16:89822331	C/T	cg14709524	chr16:89940631	TCF25	0.93	6.94	0.39	3.03e-11	Skin colour saturation;
CESC	trans	rs2727020	0.521	rs1909220	chr11:49572109	T/C	cg15704280	chr7:45808275	SEPT13	-0.86	-10.72	-0.55	1.6e-22	Coronary artery disease;
CESC	cis	rs2070433	0.528	rs68063691	chr21:47759237	T/C	cg12379764	chr21:47803548	PCNT	0.67	7.39	0.41	1.93e-12	Lymphocyte counts;
CESC	cis	rs5750830	0.645	rs4821890	chr22:39777523	G/A	cg02038168	chr22:39784481	NA	-0.56	-7.63	-0.42	4.28e-13	Intelligence (multi-trait analysis);
CESC	cis	rs7520050	0.931	rs11211224	chr1:46384388	G/A	cg03146154	chr1:46216737	IPP	-0.47	-6.1	-0.35	3.67e-9	Red blood cell count;Reticulocyte count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19403339	chr2:183580841	DNAJC10	0.55	6.13	0.35	3.25e-9	Gut microbiome composition (summer);
CESC	cis	rs514406	0.607	rs1930305	chr1:53195481	G/T	cg24675658	chr1:53192096	ZYG11B	0.64	7.98	0.44	4.39e-14	Monocyte count;
CESC	cis	rs3796352	1.000	rs2564926	chr3:53094730	G/A	cg07884673	chr3:53033167	SFMBT1	-0.65	-6.01	-0.35	6.06e-9	Immune reponse to smallpox (secreted IL-2);
CESC	cis	rs6088580	0.584	rs2378203	chr20:32993846	A/T	cg06115741	chr20:33292138	TP53INP2	-0.49	-6.32	-0.36	1.13e-9	Glomerular filtration rate (creatinine);
CESC	trans	rs7824557	0.527	rs2572447	chr8:11239510	G/A	cg06636001	chr8:8085503	FLJ10661	-0.48	-6.15	-0.35	2.88e-9	Retinal vascular caliber;
CESC	cis	rs597539	0.615	rs583182	chr11:68678634	C/T	cg04772025	chr11:68637568	NA	0.53	6.49	0.37	4.12e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs9359856	0.564	rs10484885	chr6:90395016	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.65	-5.99	-0.35	6.91e-9	Bipolar disorder;
CESC	cis	rs863345	0.584	rs6672789	chr1:158497139	T/C	cg12129480	chr1:158549410	OR10X1	-0.35	-6.95	-0.39	2.8e-11	Pneumococcal bacteremia;
CESC	cis	rs9486715	0.867	rs2475025	chr6:96988696	A/T	cg06623918	chr6:96969491	KIAA0776	-0.96	-15.2	-0.68	5.77e-38	Headache;
CESC	cis	rs9902453	0.726	rs3115088	chr17:28031275	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.77	10.47	0.54	1.11e-21	Coffee consumption (cups per day);
CESC	cis	rs9435341	1.000	rs9435341	chr1:107616641	T/C	cg09367891	chr1:107599246	PRMT6	-0.53	-6.76	-0.38	8.94e-11	Facial morphology (factor 21, depth of nasal alae);
CESC	cis	rs7107174	1.000	rs1567890	chr11:78101700	T/C	cg02023728	chr11:77925099	USP35	0.47	6.28	0.36	1.37e-9	Testicular germ cell tumor;
CESC	cis	rs514406	0.505	rs7543239	chr1:53162416	A/G	cg27535305	chr1:53392650	SCP2	-0.33	-5.42	-0.32	1.31e-7	Monocyte count;
CESC	cis	rs7546094	1.000	rs7544663	chr1:113089006	A/G	cg22162597	chr1:113214053	CAPZA1	-0.36	-5.53	-0.32	7.79e-8	Platelet distribution width;
CESC	cis	rs2191566	0.576	rs381888	chr19:44493005	C/T	cg20607764	chr19:44506953	ZNF230	0.44	5.58	0.32	5.9e-8	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs854765	0.964	rs72827413	chr17:17988299	C/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.45	-5.63	-0.33	4.56e-8	Total body bone mineral density;
CESC	cis	rs2014572	0.967	rs10426174	chr19:57756055	G/A	cg12963866	chr19:57752005	ZNF805	-0.49	-6.49	-0.37	4.09e-10	Hyperactive-impulsive symptoms;
CESC	cis	rs7927592	0.913	rs55883802	chr11:68278829	G/A	cg20283391	chr11:68216788	NA	-0.63	-7.61	-0.42	4.78e-13	Total body bone mineral density;
CESC	cis	rs7618915	0.501	rs1866268	chr3:52719398	C/A	cg17372223	chr3:52568218	NT5DC2	0.43	6.65	0.38	1.62e-10	Bipolar disorder;
CESC	trans	rs11098499	0.909	rs11723757	chr4:120299669	C/T	cg25214090	chr10:38739885	LOC399744	0.68	9.2	0.49	1.14e-17	Corneal astigmatism;
CESC	cis	rs8050907	0.744	rs9922933	chr16:4572602	T/C	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.72	5.17	0.3	4.53e-7	Obesity-related traits;
CESC	cis	rs9915657	0.933	rs8075603	chr17:70136833	G/T	cg06234051	chr17:70120541	SOX9	-0.34	-5.04	-0.3	8.63e-7	Thyroid hormone levels;
CESC	cis	rs763121	0.853	rs5750630	chr22:38985818	A/C	cg06022373	chr22:39101656	GTPBP1	0.83	12.0	0.59	8.7e-27	Menopause (age at onset);
CESC	cis	rs61931739	0.500	rs35030191	chr12:34548865	C/T	cg19457237	chr12:34500585	NA	-0.37	-5.08	-0.3	6.97e-7	Morning vs. evening chronotype;
CESC	cis	rs2842992	0.714	rs2495278	chr6:160123674	G/A	cg11366901	chr6:160182831	ACAT2	0.83	10.58	0.54	4.83e-22	Age-related macular degeneration (geographic atrophy);
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg20228115	chr3:167813730	GOLIM4	0.39	6.0	0.35	6.53e-9	Vertical cup-disc ratio;
CESC	trans	rs1945213	0.659	rs2086558	chr11:55844453	T/G	cg03929089	chr4:120376271	NA	0.76	7.26	0.41	4.31e-12	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs595982	0.546	rs12461075	chr19:49399821	G/A	cg21252483	chr19:49399788	TULP2	-0.39	-5.55	-0.32	6.87e-8	Red cell distribution width;
CESC	cis	rs12042052	1.000	rs12042052	chr1:232935719	C/T	cg00951395	chr1:232941775	KIAA1383	-0.8	-6.78	-0.38	7.61e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CESC	cis	rs2228479	0.850	rs17227057	chr16:89816333	C/T	cg04013166	chr16:89971882	TCF25	0.77	6.66	0.38	1.58e-10	Skin colour saturation;
CESC	cis	rs4474465	0.646	rs10793337	chr11:78285875	A/T	cg27205649	chr11:78285834	NARS2	0.53	7.05	0.4	1.54e-11	Alzheimer's disease (survival time);
CESC	cis	rs244293	0.760	rs1990673	chr17:53050025	C/T	cg19360675	chr17:53046073	COX11;STXBP4	-0.47	-6.16	-0.35	2.72e-9	Menarche (age at onset);
CESC	cis	rs3091242	0.781	rs71652378	chr1:25721457	G/C	cg02931644	chr1:25747376	RHCE	0.4	6.64	0.38	1.75e-10	Erythrocyte sedimentation rate;
CESC	cis	rs9987353	0.519	rs13276350	chr8:9063157	T/C	cg06636001	chr8:8085503	FLJ10661	-0.55	-6.54	-0.37	3.1e-10	Recombination measurement;
CESC	cis	rs6951245	0.872	rs57068908	chr7:1060084	A/C	cg03188948	chr7:1209495	NA	0.54	5.53	0.32	7.66e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs5760092	0.618	rs4461358	chr22:24260106	T/C	cg18538332	chr22:24372958	LOC391322	0.72	9.34	0.5	4.15e-18	Urinary 1,3-butadiene metabolite levels in smokers;
CESC	cis	rs7811142	1.000	rs112317829	chr7:100043173	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.82	8.13	0.45	1.7e-14	Platelet count;
CESC	cis	rs7927592	0.956	rs7126340	chr11:68257293	C/T	cg16797656	chr11:68205561	LRP5	0.39	5.51	0.32	8.45e-8	Total body bone mineral density;
CESC	cis	rs7666738	0.830	rs3857217	chr4:99034347	T/C	cg18180107	chr4:99064573	C4orf37	0.42	5.4	0.31	1.48e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs796364	1.000	rs11680723	chr2:200810957	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.88	-6.62	-0.38	1.97e-10	Schizophrenia;
CESC	cis	rs2688608	0.587	rs2894040	chr10:75478159	A/C	cg23231163	chr10:75533350	FUT11	-0.34	-5.28	-0.31	2.75e-7	Inflammatory bowel disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14993530	chr1:245027115	HNRNPU	0.52	6.02	0.35	5.75e-9	Gut microbiome composition (summer);
CESC	cis	rs12410462	1.000	rs12407171	chr1:227642282	G/A	cg23173402	chr1:227635558	NA	0.56	5.57	0.32	6.19e-8	Major depressive disorder;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg19827167	chr1:94312206	MIR760	-0.45	-6.27	-0.36	1.45e-9	Asthma;
CESC	cis	rs9911578	0.967	rs11079368	chr17:57086473	C/T	cg05425664	chr17:57184151	TRIM37	0.53	7.37	0.41	2.16e-12	Intelligence (multi-trait analysis);
CESC	cis	rs5769765	0.773	rs6520065	chr22:50294470	A/T	cg02269571	chr22:50332266	NA	-0.45	-6.03	-0.35	5.63e-9	Schizophrenia;
CESC	cis	rs62229266	0.771	rs11701590	chr21:37384730	A/C	cg12218747	chr21:37451666	NA	-0.38	-5.36	-0.31	1.83e-7	Mitral valve prolapse;
CESC	cis	rs2439831	1.000	rs690436	chr15:43761205	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.9	10.56	0.54	5.46e-22	Lung cancer in ever smokers;
CESC	cis	rs12497850	0.829	rs8926	chr3:49052785	T/A	cg06212747	chr3:49208901	KLHDC8B	0.7	9.34	0.5	4.23e-18	Parkinson's disease;
CESC	cis	rs514406	0.893	rs1242330	chr1:53396842	T/G	cg25767906	chr1:53392781	SCP2	-0.44	-5.51	-0.32	8.62e-8	Monocyte count;
CESC	cis	rs2180341	1.000	rs6569480	chr6:127621748	A/G	cg24812749	chr6:127587940	RNF146	1.0	14.92	0.68	6.1e-37	Breast cancer;
CESC	cis	rs227584	0.663	rs2040810	chr17:42243771	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	-0.55	-7.33	-0.41	2.73e-12	Bone mineral density (hip);Bone mineral density;
CESC	cis	rs752010	0.967	rs4083593	chr1:42099583	A/G	cg06885757	chr1:42089581	HIVEP3	0.5	8.06	0.44	2.56e-14	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs6141600	0.506	rs2590990	chr20:34671179	A/G	cg07747181	chr20:34652970	NA	-0.37	-5.12	-0.3	5.79e-7	Height;Hip circumference;
CESC	cis	rs9733	0.596	rs7529998	chr1:150662531	C/T	cg22823121	chr1:150693482	HORMAD1	0.48	7.1	0.4	1.14e-11	Tonsillectomy;
CESC	cis	rs9811920	0.625	rs9290003	chr3:99906993	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.38	5.87	0.34	1.28e-8	Axial length;
CESC	cis	rs4268898	0.722	rs11680491	chr2:24416292	T/A	cg06627628	chr2:24431161	ITSN2	0.59	7.74	0.43	2.05e-13	Asthma;
CESC	cis	rs4561483	0.545	rs9927446	chr16:11957164	A/T	cg08843971	chr16:11963173	GSPT1	0.46	6.42	0.37	6.41e-10	Testicular germ cell tumor;
CESC	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg06873352	chr17:61820015	STRADA	0.73	12.96	0.62	4.25e-30	Prudent dietary pattern;
CESC	cis	rs1322639	0.614	rs7751131	chr6:169578710	G/A	cg03254818	chr6:169586852	NA	0.55	5.95	0.34	8.28e-9	Pulse pressure;
CESC	cis	rs6695640	0.854	rs2762890	chr1:17736578	A/G	cg01904812	chr1:17746340	RCC2	0.37	5.2	0.3	3.98e-7	Mean platelet volume;
CESC	cis	rs9287719	0.745	rs4997809	chr2:10755542	G/A	cg02196655	chr2:10830764	NOL10	-0.37	-5.51	-0.32	8.5e-8	Prostate cancer;
CESC	cis	rs2011503	1.000	rs8101219	chr19:19643715	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.52	5.09	0.3	6.68e-7	Bipolar disorder;
CESC	cis	rs3096299	0.967	rs753852	chr16:89446419	G/A	cg08822215	chr16:89438651	ANKRD11	-0.42	-6.35	-0.36	9.47e-10	Multiple myeloma (IgH translocation);
CESC	cis	rs2073300	0.609	rs6137910	chr20:23346515	C/G	cg16736954	chr20:23401023	NAPB	0.77	5.74	0.33	2.6e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs898097	0.812	rs55794221	chr17:80849003	G/A	cg10494973	chr17:80897199	TBCD	0.5	5.69	0.33	3.34e-8	Breast cancer;
CESC	trans	rs35883536	1.000	rs9803842	chr1:101134877	G/T	cg16931499	chr17:42786676	DBF4B	0.42	6.14	0.35	3.01e-9	Monocyte count;
CESC	cis	rs9926296	0.605	rs1800287	chr16:89858525	C/G	cg01097406	chr16:89675127	NA	-0.33	-5.05	-0.3	8.41e-7	Vitiligo;
CESC	cis	rs6964587	0.692	rs4727268	chr7:91840724	T/C	cg17063962	chr7:91808500	NA	0.46	6.56	0.37	2.8e-10	Breast cancer;
CESC	cis	rs72945132	0.882	rs66989619	chr11:70202127	G/C	cg00319359	chr11:70116639	PPFIA1	0.73	6.96	0.39	2.63e-11	Coronary artery disease;
CESC	cis	rs514406	0.798	rs504816	chr1:53307957	T/G	cg25767906	chr1:53392781	SCP2	-0.48	-6.4	-0.37	6.99e-10	Monocyte count;
CESC	cis	rs9399135	0.935	rs11760000	chr6:135370496	G/A	cg24558204	chr6:135376177	HBS1L	0.51	6.94	0.39	3.01e-11	Red blood cell count;
CESC	cis	rs736408	0.609	rs62255396	chr3:52782839	C/T	cg17372223	chr3:52568218	NT5DC2	0.44	6.57	0.37	2.6e-10	Bipolar disorder;
CESC	cis	rs7666738	0.578	rs1989109	chr4:98881246	T/A	cg17366294	chr4:99064904	C4orf37	0.56	7.87	0.44	9.05e-14	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1904096	0.506	rs13435702	chr4:95167751	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.63	-10.06	-0.53	2.2e-20	Type 2 diabetes;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg12311644	chr22:31687046	PIK3IP1	0.49	6.2	0.36	2.2e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	13.65	0.64	1.8e-32	Prudent dietary pattern;
CESC	cis	rs7192380	0.639	rs12448486	chr16:69802878	G/A	cg15192750	chr16:69999425	NA	-0.37	-5.12	-0.3	5.99e-7	Sjögren's syndrome;
CESC	cis	rs7666738	0.830	rs2865980	chr4:99027422	T/G	cg17366294	chr4:99064904	C4orf37	0.62	8.95	0.48	6.32e-17	Colonoscopy-negative controls vs population controls;
CESC	cis	rs853679	0.517	rs6941992	chr6:28106141	T/C	cg08968635	chr6:28129556	ZNF389	0.42	5.72	0.33	2.82e-8	Depression;
CESC	cis	rs7811142	0.830	rs6945952	chr7:99981775	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.1	11.2	0.57	4.36e-24	Platelet count;
CESC	cis	rs4595586	0.545	rs1375796	chr12:39410592	G/T	cg13010199	chr12:38710504	ALG10B	0.44	5.57	0.32	6.35e-8	Morning vs. evening chronotype;
CESC	cis	rs1559088	0.522	rs7254912	chr19:33554151	A/G	cg27124370	chr19:33622961	WDR88	0.54	7.46	0.42	1.23e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs875971	0.577	rs35072105	chr7:65609817	A/G	cg06456125	chr7:65229604	NA	-0.4	-5.16	-0.3	4.83e-7	Aortic root size;
CESC	cis	rs9916302	0.861	rs11078912	chr17:37671490	A/G	cg15445000	chr17:37608096	MED1	0.38	6.39	0.37	7.3e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs10129255	0.500	rs6576230	chr14:107186778	C/A	cg23076370	chr14:107095027	NA	-0.66	-10.03	-0.52	2.9e-20	Kawasaki disease;
CESC	cis	rs9322193	0.923	rs62439840	chr6:149995775	G/A	cg04369109	chr6:150039330	LATS1	-0.43	-5.83	-0.34	1.6e-8	Lung cancer;
CESC	cis	rs6598955	0.724	rs12757113	chr1:26597144	C/T	cg04990556	chr1:26633338	UBXN11	-0.8	-11.67	-0.58	1.15e-25	Obesity-related traits;
CESC	cis	rs7044106	0.791	rs7036196	chr9:123479457	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.84	13.61	0.64	2.42e-32	Hip circumference adjusted for BMI;
CESC	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg21724239	chr8:58056113	NA	0.6	5.45	0.32	1.17e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs35306767	0.859	rs11817793	chr10:878895	C/T	cg10556349	chr10:835070	NA	0.57	5.55	0.32	6.8e-8	Eosinophil percentage of granulocytes;
CESC	cis	rs2439831	0.681	rs511673	chr15:43618863	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.89	10.71	0.55	1.74e-22	Lung cancer in ever smokers;
CESC	cis	rs9815354	1.000	rs2625667	chr3:41900951	C/A	cg03022575	chr3:42003672	ULK4	0.45	5.23	0.31	3.48e-7	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	7.89	0.44	7.83e-14	Prudent dietary pattern;
CESC	cis	rs8062405	0.755	rs56209193	chr16:28585636	C/T	cg07382826	chr16:28625726	SULT1A1	0.4	6.52	0.37	3.46e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs1707322	0.682	rs3014241	chr1:46087879	A/G	cg05343316	chr1:45956843	TESK2	-0.54	-6.65	-0.38	1.68e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs61931739	0.578	rs12582423	chr12:33596502	G/C	cg26384229	chr12:38710491	ALG10B	-0.44	-6.32	-0.36	1.1e-9	Morning vs. evening chronotype;
CESC	cis	rs17711722	0.510	rs73142128	chr7:65331109	A/C	cg26939375	chr7:64535504	NA	0.66	8.81	0.48	1.64e-16	Calcium levels;
CESC	cis	rs1862618	0.853	rs2548665	chr5:56131805	T/A	cg22800045	chr5:56110881	MAP3K1	0.83	9.98	0.52	3.92e-20	Initial pursuit acceleration;
CESC	cis	rs7116495	1.000	rs1573502	chr11:71747428	C/T	cg10381502	chr11:71823885	C11orf51	-0.68	-5.65	-0.33	4.05e-8	Severe influenza A (H1N1) infection;
CESC	cis	rs7208859	0.623	rs216439	chr17:28927884	T/C	cg13385521	chr17:29058706	SUZ12P	0.77	5.67	0.33	3.8e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs4253772	0.515	rs6008591	chr22:46703664	T/C	cg24881330	chr22:46731750	TRMU	0.86	7.93	0.44	6.15e-14	LDL cholesterol;Cholesterol, total;
CESC	cis	rs10504229	1.000	rs114312649	chr8:58182539	C/G	cg05313129	chr8:58192883	C8orf71	-0.55	-6.29	-0.36	1.34e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs5750830	0.649	rs6001588	chr22:39819049	G/C	cg24399712	chr22:39784796	NA	-0.81	-10.81	-0.55	8.51e-23	Intelligence (multi-trait analysis);
CESC	trans	rs17536732	0.786	rs114318946	chr4:162848455	A/G	cg12177677	chr2:158300475	CYTIP	-0.64	-6.25	-0.36	1.66e-9	Risky sexual behaviors (alcohol dependence interaction);
CESC	cis	rs1023500	0.551	rs133379	chr22:42468535	A/G	cg15557168	chr22:42548783	NA	-0.39	-5.32	-0.31	2.19e-7	Schizophrenia;
CESC	cis	rs2228479	0.867	rs11642451	chr16:89958127	T/C	cg14709524	chr16:89940631	TCF25	0.73	5.64	0.33	4.36e-8	Skin colour saturation;
CESC	cis	rs7712401	0.601	rs154500	chr5:122211991	T/G	cg19412675	chr5:122181750	SNX24	0.41	5.15	0.3	5.07e-7	Mean platelet volume;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg11989942	chr17:80067146	CCDC57	0.44	6.15	0.35	2.89e-9	Fibrinogen levels;
CESC	cis	rs911555	0.617	rs7156036	chr14:103908142	A/G	cg12935359	chr14:103987150	CKB	0.65	9.56	0.51	8.31e-19	Intelligence (multi-trait analysis);
CESC	cis	rs240764	0.635	rs6901854	chr6:100932291	C/T	cg21058520	chr6:100914733	NA	0.4	6.07	0.35	4.31e-9	Neuroticism;
CESC	cis	rs7666738	0.830	rs7672901	chr4:98938781	C/T	cg05340658	chr4:99064831	C4orf37	0.82	12.48	0.61	1.93e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4132509	0.649	rs12038981	chr1:243866855	G/A	cg21452805	chr1:244014465	NA	0.48	5.13	0.3	5.55e-7	RR interval (heart rate);
CESC	cis	rs9916302	0.904	rs4795359	chr17:37573146	C/T	cg20243544	chr17:37824526	PNMT	0.51	6.5	0.37	4.03e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs798554	0.797	rs2107964	chr7:2863574	G/A	cg04166393	chr7:2884313	GNA12	0.65	8.26	0.45	7.21e-15	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24764865	chr14:36295508	BRMS1L	0.55	6.06	0.35	4.74e-9	Gut microbiome composition (summer);
CESC	cis	rs16866061	0.962	rs16866045	chr2:225413020	G/A	cg12698349	chr2:225449008	CUL3	0.75	11.56	0.58	2.78e-25	Acute graft versus host disease in bone marrow transplantation (recipient effect);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg23748172	chr11:66633713	PC	0.46	6.87	0.39	4.64e-11	Fibrinogen levels;
CESC	cis	rs1008375	0.835	rs9760627	chr4:17651508	C/T	cg02297831	chr4:17616191	MED28	0.61	7.68	0.43	3.1400000000000003e-13	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs1552244	0.882	rs13099136	chr3:10031431	G/A	cg00166722	chr3:10149974	C3orf24	0.48	5.92	0.34	9.76e-9	Alzheimer's disease;
CESC	trans	rs61931739	0.534	rs11052979	chr12:34035774	G/T	cg26384229	chr12:38710491	ALG10B	0.59	8.27	0.45	6.35e-15	Morning vs. evening chronotype;
CESC	cis	rs9796	0.717	rs2947494	chr15:41375741	C/T	cg12426344	chr15:41135900	SPINT1	-0.23	-5.1	-0.3	6.45e-7	Menopause (age at onset);
CESC	cis	rs9611565	0.592	rs4822038	chr22:41958495	G/A	cg03806693	chr22:41940476	POLR3H	-1.16	-13.46	-0.64	7.72e-32	Vitiligo;
CESC	cis	rs4595586	0.525	rs11609150	chr12:39408622	A/C	cg26384229	chr12:38710491	ALG10B	0.62	8.72	0.47	3.18e-16	Morning vs. evening chronotype;
CESC	cis	rs589691	0.502	rs487662	chr11:64481880	G/A	cg07220939	chr11:64358617	SLC22A12	-0.35	-5.11	-0.3	6.17e-7	Urate levels;
CESC	cis	rs72634258	0.945	rs4908724	chr1:8119251	G/T	cg00042356	chr1:8021962	PARK7	0.8	7.14	0.4	9.2e-12	Inflammatory bowel disease;
CESC	cis	rs11552708	0.504	rs9890935	chr17:7391282	A/G	cg02795151	chr17:7402630	POLR2A	0.55	5.88	0.34	1.26e-8	IgM levels;
CESC	cis	rs4713118	0.662	rs149948	chr6:27974817	C/G	cg19592336	chr6:28129416	ZNF389	0.47	6.32	0.36	1.09e-9	Parkinson's disease;
CESC	cis	rs7193541	0.965	rs8050262	chr16:74661159	T/C	cg01733217	chr16:74700730	RFWD3	0.92	13.55	0.64	4.03e-32	Multiple myeloma;
CESC	cis	rs35110281	0.715	rs969060	chr21:45080852	T/G	cg04455712	chr21:45112962	RRP1B	0.42	6.04	0.35	5.25e-9	Mean corpuscular volume;
CESC	cis	rs9733	0.519	rs3768005	chr1:150680988	A/T	cg04414720	chr1:150670196	GOLPH3L	0.57	8.01	0.44	3.64e-14	Tonsillectomy;
CESC	cis	rs2273669	0.667	rs77002235	chr6:109321497	G/A	cg05315195	chr6:109294784	ARMC2	-0.66	-6.01	-0.35	6.04e-9	Prostate cancer;
CESC	cis	rs3793683	0.928	rs10781585	chr10:134553369	C/A	cg26818010	chr10:134567672	INPP5A	0.48	6.05	0.35	4.82e-9	Migraine;
CESC	cis	rs1008375	0.898	rs9998130	chr4:17593905	A/G	cg16339924	chr4:17578868	LAP3	0.85	10.69	0.55	2e-22	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs7542091	1.000	rs7542091	chr1:210031948	G/C	cg22029157	chr1:209979665	IRF6	0.48	7.62	0.42	4.64e-13	Monobrow;
CESC	cis	rs1620921	0.505	rs1991598	chr6:161204488	G/A	cg01280913	chr6:161186852	NA	-0.36	-5.27	-0.31	2.81e-7	Lipoprotein (a) - cholesterol levels;
CESC	cis	rs1062177	0.756	rs2964592	chr5:151115688	A/G	cg12924095	chr5:151150029	G3BP1	-0.42	-5.48	-0.32	1.01e-7	Preschool internalizing problems;
CESC	cis	rs425277	0.606	rs2257684	chr1:2077872	A/G	cg24578937	chr1:2090814	PRKCZ	0.38	6.62	0.38	2.03e-10	Height;
CESC	cis	rs6570726	0.846	rs9376954	chr6:145943737	T/A	cg23711669	chr6:146136114	FBXO30	0.87	12.7	0.61	3.59e-29	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4563143	0.514	rs73029081	chr19:29295583	C/G	cg04546413	chr19:29218101	NA	0.49	6.05	0.35	4.79e-9	Methadone dose in opioid dependence;
CESC	cis	rs2842992	0.830	rs2273819	chr6:160183325	G/C	cg11366901	chr6:160182831	ACAT2	0.83	10.52	0.54	7.54e-22	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs17401966	1.000	rs7520935	chr1:10354271	G/T	cg15208524	chr1:10270712	KIF1B	0.49	6.26	0.36	1.53e-9	Hepatocellular carcinoma;
CESC	cis	rs5498	0.869	rs2569702	chr19:10403947	A/G	cg22910295	chr19:10403862	ICAM5	0.43	6.06	0.35	4.61e-9	Lymphocyte counts;Soluble ICAM-1;Blood protein levels;
CESC	cis	rs1055129	0.655	rs3744006	chr17:73838816	G/A	cg08125733	chr17:73851984	WBP2	0.55	7.46	0.42	1.23e-12	White matter hyperintensity burden;
CESC	cis	rs9910055	0.718	rs2526022	chr17:42213216	C/T	cg19774624	chr17:42201019	HDAC5	-0.69	-10.03	-0.52	2.7e-20	Total body bone mineral density;
CESC	cis	rs11122272	0.735	rs2247124	chr1:231493687	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.58	-7.9	-0.44	7.28e-14	Hemoglobin concentration;
CESC	cis	rs2070488	0.804	rs13059256	chr3:38504315	T/C	cg24069376	chr3:38537580	EXOG	0.33	5.56	0.32	6.63e-8	Electrocardiographic conduction measures;
CESC	cis	rs875971	0.895	rs7782806	chr7:65657897	C/T	cg18876405	chr7:65276391	NA	-0.53	-7.38	-0.41	2.09e-12	Aortic root size;
CESC	cis	rs950169	1.000	rs11638297	chr15:84782417	A/C	cg17507749	chr15:85114479	UBE2QP1	0.59	6.6	0.38	2.18e-10	Schizophrenia;
CESC	cis	rs853679	0.517	rs9368554	chr6:28082711	T/C	cg08968635	chr6:28129556	ZNF389	0.4	5.36	0.31	1.84e-7	Depression;
CESC	cis	rs34734847	0.750	rs708783	chr12:121173932	A/G	cg21892295	chr12:121157589	UNC119B	-0.34	-5.3	-0.31	2.43e-7	Mean corpuscular volume;
CESC	cis	rs654950	0.806	rs941971	chr1:42040893	T/C	cg06885757	chr1:42089581	HIVEP3	-0.63	-10.16	-0.53	1.05e-20	Airway imaging phenotypes;
CESC	cis	rs7246657	0.943	rs2891699	chr19:37920237	A/G	cg23950597	chr19:37808831	NA	-0.55	-5.99	-0.35	6.69e-9	Coronary artery calcification;
CESC	cis	rs7843479	1.000	rs7821592	chr8:21811530	C/G	cg17168535	chr8:21777572	XPO7	0.47	6.34	0.36	9.91e-10	Mean corpuscular volume;
CESC	trans	rs9987353	0.840	rs329994	chr8:9123233	A/G	cg19183748	chr11:64863586	C11orf2	-0.45	-6.11	-0.35	3.64e-9	Recombination measurement;
CESC	cis	rs4472734	1.000	rs12751657	chr1:214607849	G/A	cg00063699	chr1:214624242	PTPN14	-0.34	-5.42	-0.32	1.32e-7	Height;
CESC	cis	rs4728302	0.869	rs2042455	chr7:133580545	A/G	cg10665199	chr7:133106180	EXOC4	0.4	5.47	0.32	1.03e-7	Intelligence;Intelligence (multi-trait analysis);
CESC	cis	rs1008375	0.966	rs10006317	chr4:17702525	A/G	cg02297831	chr4:17616191	MED28	0.48	5.76	0.33	2.36e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs12410462	0.681	rs76705164	chr1:227615570	G/A	cg23173402	chr1:227635558	NA	0.72	6.71	0.38	1.19e-10	Major depressive disorder;
CESC	cis	rs9910055	0.659	rs7212573	chr17:42254281	A/G	cg08499158	chr17:42289980	UBTF	-0.45	-5.49	-0.32	9.5e-8	Total body bone mineral density;
CESC	trans	rs78049276	0.688	rs17612693	chr4:148365339	T/A	cg13149281	chr14:23389818	RBM23;PRMT5	-0.6	-6.32	-0.36	1.13e-9	Pulse pressure;
CESC	cis	rs2273669	0.667	rs12200531	chr6:109320441	T/C	cg05315195	chr6:109294784	ARMC2	-0.66	-6.37	-0.36	8.17e-10	Prostate cancer;
CESC	cis	rs6540556	0.769	rs627670	chr1:209929299	G/A	cg23920097	chr1:209922102	NA	0.38	5.31	0.31	2.27e-7	Red blood cell count;
CESC	cis	rs7937682	1.000	rs505372	chr11:111507189	A/C	cg22437258	chr11:111473054	SIK2	0.71	9.59	0.51	6.77e-19	Primary sclerosing cholangitis;
CESC	cis	rs6938	0.534	rs12907898	chr15:75207872	C/T	cg17294928	chr15:75287854	SCAMP5	0.47	6.23	0.36	1.81e-9	Breast cancer;
CESC	trans	rs7824557	0.527	rs2572376	chr8:11237756	C/A	cg06636001	chr8:8085503	FLJ10661	-0.48	-6.13	-0.35	3.25e-9	Retinal vascular caliber;
CESC	trans	rs16893526	1.000	rs35392002	chr6:82558665	T/C	cg07163173	chr2:67624373	ETAA1	0.83	6.31	0.36	1.14e-9	Coronary heart disease;
CESC	cis	rs11645898	0.935	rs4788605	chr16:72154682	G/T	cg14768367	chr16:72042858	DHODH	-0.66	-5.84	-0.34	1.56e-8	Blood protein levels;
CESC	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg11494091	chr17:61959527	GH2	0.72	12.39	0.61	4.12e-28	Prudent dietary pattern;
CESC	cis	rs9926296	0.585	rs8058009	chr16:89856439	G/C	cg02875869	chr16:89901417	SPIRE2	-0.64	-7.48	-0.42	1.09e-12	Vitiligo;
CESC	cis	rs524281	0.773	rs10750781	chr11:66037270	A/G	cg14036092	chr11:66035641	RAB1B	-0.55	-5.38	-0.31	1.62e-7	Electroencephalogram traits;
CESC	cis	rs807669	0.903	rs807668	chr22:19162686	A/G	cg02655711	chr22:19163373	SLC25A1	0.99	14.81	0.67	1.47e-36	Metabolite levels;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05821866	chr1:167905319	DCAF6;BRP44	0.52	6.85	0.39	5.05e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs6732160	0.588	rs1430344	chr2:73373344	G/A	cg01422370	chr2:73384389	NA	0.57	9.1	0.49	2.29e-17	Intelligence (multi-trait analysis);
CESC	trans	rs66573146	1.000	rs28384174	chr4:6961107	G/T	cg07817883	chr1:32538562	TMEM39B	1.36	8.74	0.47	2.78e-16	Granulocyte percentage of myeloid white cells;
CESC	cis	rs13242816	1.000	rs36004201	chr7:116126310	C/A	cg04696780	chr7:116139425	CAV2	-0.62	-5.68	-0.33	3.58e-8	P wave duration;
CESC	cis	rs2479724	0.905	rs2149274	chr6:41839092	T/C	cg08135965	chr6:41755394	TOMM6	0.4	5.55	0.32	6.92e-8	Menarche (age at onset);
CESC	cis	rs17039065	0.834	rs17039112	chr4:109439739	G/A	cg16022748	chr4:109541635	LOC285456;RPL34	0.65	6.06	0.35	4.68e-9	Gut microbiome composition (summer);
CESC	cis	rs7605827	0.675	rs2111449	chr2:15616215	C/T	cg19274914	chr2:15703543	NA	0.32	5.19	0.3	4.15e-7	Educational attainment (years of education);
CESC	cis	rs10791323	0.572	rs1114367	chr11:133737304	G/T	cg03690763	chr11:133734501	NA	-0.31	-5.15	-0.3	5.07e-7	Childhood ear infection;
CESC	cis	rs10504229	1.000	rs67388517	chr8:58176617	C/A	cg14926445	chr8:58193284	C8orf71	-0.51	-5.47	-0.32	1.03e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs10411936	0.712	rs8103521	chr19:16589750	A/G	cg10248733	chr19:16607483	C19orf44;CALR3	0.56	6.7	0.38	1.27e-10	White blood cell count;Multiple sclerosis;
CESC	cis	rs1552244	0.938	rs66915020	chr3:10110174	A/G	cg08888203	chr3:10149979	C3orf24	0.53	6.83	0.39	5.8200000000000003e-11	Alzheimer's disease;
CESC	cis	rs4604732	0.631	rs1106719	chr1:247624713	A/G	cg12754571	chr1:247694271	LOC148824;OR2C3	-0.43	-5.48	-0.32	9.86e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs2486288	0.656	rs11632419	chr15:45557456	C/A	cg21132104	chr15:45694354	SPATA5L1	-0.55	-6.71	-0.38	1.16e-10	Glomerular filtration rate;
CESC	cis	rs9649465	1.000	rs2109725	chr7:123325459	C/T	cg04330084	chr7:123175371	IQUB	-0.38	-5.22	-0.31	3.69e-7	Migraine;
CESC	cis	rs116095464	0.558	rs10057626	chr5:239720	T/G	cg22857025	chr5:266934	NA	-1.29	-18.85	-0.76	7.29e-51	Breast cancer;
CESC	cis	rs4969178	0.965	rs12450500	chr17:76395750	C/T	cg05887092	chr17:76393375	PGS1	0.58	9.22	0.49	9.9e-18	HDL cholesterol levels;
CESC	cis	rs6835098	0.962	rs4377567	chr4:174083590	C/G	cg08422745	chr4:174089978	GALNT7	0.83	11.8	0.59	4.07e-26	Dementia and core Alzheimer's disease neuropathologic changes;
CESC	cis	rs854765	0.583	rs4257260	chr17:17857003	A/G	cg16928487	chr17:17741425	SREBF1	-0.57	-9.57	-0.51	7.66e-19	Total body bone mineral density;
CESC	cis	rs6952808	0.895	rs12669518	chr7:1921429	G/C	cg04267008	chr7:1944627	MAD1L1	-0.63	-7.87	-0.44	9.09e-14	Bipolar disorder and schizophrenia;
CESC	cis	rs2718058	0.515	rs1584611	chr7:37874039	T/C	cg15028436	chr7:37888078	TXNDC3	0.34	5.59	0.32	5.61e-8	Alzheimer's disease (late onset);
CESC	cis	rs1707322	0.789	rs7540578	chr1:46252144	C/T	cg05343316	chr1:45956843	TESK2	0.49	6.02	0.35	5.87e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2742234	0.541	rs11238476	chr10:43711436	G/T	cg07801480	chr10:43725741	RASGEF1A	-0.41	-5.25	-0.31	3.08e-7	Hirschsprung disease;
CESC	cis	rs6502050	0.814	rs62079997	chr17:80076888	C/T	cg11859384	chr17:80120422	CCDC57	0.4	5.5	0.32	8.88e-8	Life satisfaction;
CESC	cis	rs6540559	0.673	rs17015330	chr1:210012795	T/G	cg25204440	chr1:209979598	IRF6	0.52	5.15	0.3	5.05e-7	Cleft lip with or without cleft palate;
CESC	cis	rs6598955	0.724	rs10902731	chr1:26600793	A/G	cg00852783	chr1:26633632	UBXN11	0.42	6.19	0.36	2.27e-9	Obesity-related traits;
CESC	cis	rs1348850	0.914	rs4893957	chr2:178380409	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.88	12.65	0.61	5.06e-29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs904092	0.592	rs1229969	chr4:100206718	C/T	cg12011299	chr4:100065546	ADH4	-0.55	-6.3	-0.36	1.23e-9	Alcohol dependence;
CESC	cis	rs1879734	0.773	rs67319173	chr1:54133723	T/A	cg23596471	chr1:54105337	GLIS1	0.37	5.69	0.33	3.44e-8	Mitral valve prolapse;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg10651637	chr15:45315642	SORD	-0.42	-6.18	-0.35	2.36e-9	Fibrinogen levels;
CESC	cis	rs72627123	0.867	rs112965033	chr14:74461117	T/A	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.75	5.27	0.31	2.89e-7	Morning vs. evening chronotype;
CESC	cis	rs763121	0.853	rs4821810	chr22:39072098	C/G	cg06544989	chr22:39130855	UNC84B	0.52	9.99	0.52	3.63e-20	Menopause (age at onset);
CESC	cis	rs12822507	0.811	rs34946234	chr12:12781812	A/G	cg04607235	chr12:12878440	APOLD1	-0.5	-6.45	-0.37	5.29e-10	Systemic lupus erythematosus;
CESC	cis	rs6460942	0.841	rs62448597	chr7:12449110	G/C	cg16278512	chr7:12443529	VWDE	-0.55	-5.87	-0.34	1.27e-8	Coronary artery disease;
CESC	cis	rs8114671	0.628	rs6060130	chr20:33549319	C/T	cg07148914	chr20:33460835	GGT7	0.44	5.75	0.33	2.44e-8	Height;
CESC	cis	rs13102973	0.965	rs13142779	chr4:135872841	G/T	cg14419869	chr4:135874104	NA	0.36	5.76	0.33	2.37e-8	Subjective well-being;
CESC	cis	rs2274273	0.901	rs112870553	chr14:55790062	T/G	cg04306507	chr14:55594613	LGALS3	0.32	6.38	0.36	8.01e-10	Protein biomarker;
CESC	cis	rs2933343	0.661	rs2630259	chr3:128606322	C/T	cg25356066	chr3:128598488	ACAD9	0.66	9.18	0.49	1.27e-17	IgG glycosylation;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg26297968	chr2:211035960	C2orf67	0.38	6.06	0.35	4.73e-9	Gambling;
CESC	cis	rs916888	0.773	rs199533	chr17:44828931	G/A	cg15921436	chr17:44337874	NA	0.74	8.01	0.44	3.59e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs7618501	1.000	rs2271961	chr3:49878113	C/T	cg24308560	chr3:49941425	MST1R	0.52	7.15	0.4	8.3e-12	Intelligence (multi-trait analysis);
CESC	cis	rs9948	0.529	rs2139406	chr2:97366779	A/G	cg01990225	chr2:97406019	LMAN2L	-0.75	-6.9	-0.39	3.88e-11	Erectile dysfunction and prostate cancer treatment;
CESC	cis	rs4555082	0.834	rs2816623	chr14:105733295	G/A	cg27165867	chr14:105738592	BRF1	-0.52	-5.59	-0.32	5.65e-8	Mean platelet volume;Platelet distribution width;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg08588859	chr8:128903227	PVT1	-0.47	-6.25	-0.36	1.61e-9	Systemic lupus erythematosus;
CESC	cis	rs963731	0.649	rs78905728	chr2:39339241	G/T	cg04010122	chr2:39346883	SOS1	0.76	5.65	0.33	4.06e-8	Corticobasal degeneration;
CESC	cis	rs11227306	0.934	rs2234458	chr11:65639374	C/T	cg04055107	chr11:65626734	MUS81;CFL1	-0.46	-5.24	-0.31	3.21e-7	DNA methylation (variation);
CESC	cis	rs7116495	0.609	rs2735787	chr11:71717873	T/C	cg07596299	chr11:71824057	C11orf51	-0.81	-5.35	-0.31	1.95e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs3813567	0.702	rs7164665	chr15:78953919	T/C	cg05914723	chr15:78953907	NA	0.45	5.77	0.33	2.24e-8	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18997990	chr15:44084145	SERF2	-0.57	-6.55	-0.37	2.94e-10	Gut microbiome composition (summer);
CESC	cis	rs1371867	0.846	rs1660346	chr8:101312497	A/G	cg11906718	chr8:101322791	RNF19A	0.54	6.93	0.39	3.1e-11	Atrioventricular conduction;
CESC	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg19268477	chr7:157951471	PTPRN2	0.32	6.39	0.37	7.44e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CESC	cis	rs2836974	0.899	rs8127087	chr21:40544502	C/T	cg11890956	chr21:40555474	PSMG1	1.18	22.66	0.81	6.1e-64	Cognitive function;
CESC	trans	rs2764766	0.721	rs151881	chr5:127188432	A/T	cg15764593	chr10:829463	NA	-0.4	-6.19	-0.36	2.33e-9	Schizophrenia;
CESC	cis	rs796364	0.951	rs971232	chr2:200792881	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.86	8.47	0.46	1.75e-15	Schizophrenia;
CESC	cis	rs6570726	0.905	rs419575	chr6:145840174	A/G	cg23711669	chr6:146136114	FBXO30	0.8	12.02	0.59	7.36e-27	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7811142	0.830	rs75636500	chr7:99947657	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.12	10.57	0.54	4.92e-22	Platelet count;
CESC	cis	rs7119	0.717	rs34194537	chr15:77795761	G/A	cg17802220	chr15:77601643	NA	-0.52	-7.15	-0.4	8.61e-12	Type 2 diabetes;
CESC	cis	rs9300255	0.596	rs11057207	chr12:123730891	T/G	cg19016782	chr12:123741754	C12orf65	-0.36	-5.3	-0.31	2.43e-7	Neutrophil percentage of white cells;
CESC	cis	rs12973672	0.904	rs10424619	chr19:35768237	A/T	cg12095397	chr19:35769544	USF2	0.55	7.12	0.4	1.03e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs826838	1.000	rs1393537	chr12:38920961	C/T	cg26384229	chr12:38710491	ALG10B	0.82	14.44	0.66	2.91e-35	Heart rate;
CESC	trans	rs853679	0.546	rs34295134	chr6:27828151	T/A	cg06606381	chr12:133084897	FBRSL1	-0.82	-7.68	-0.43	3.01e-13	Depression;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11767426	chr14:50319892	SDCCAG1	-0.5	-6.18	-0.35	2.46e-9	Gut microbiome composition (summer);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg09225442	chr16:30662040	PRR14	-0.46	-6.14	-0.35	2.93e-9	Fibrinogen levels;
CESC	cis	rs9649213	0.593	rs6945554	chr7:97972946	T/C	cg08684580	chr7:98029266	BAIAP2L1	-0.35	-5.8	-0.34	1.85e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs2730245	0.569	rs1188955	chr7:158690866	A/G	cg01943577	chr7:158741284	NA	-0.4	-5.21	-0.3	3.78e-7	Height;
CESC	cis	rs2294693	0.947	rs736795	chr6:40998141	G/A	cg14418226	chr6:40996092	UNC5CL	0.54	6.77	0.38	8.07e-11	Gastric cancer;Non-cardia gastric cancer;
CESC	cis	rs2228479	0.702	rs11076620	chr16:89831520	A/T	cg00800038	chr16:89945340	TCF25	-0.92	-7.64	-0.42	4.02e-13	Skin colour saturation;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg16506072	chr16:85833520	COX4NB;COX4I1	-0.47	-6.11	-0.35	3.64e-9	Ulcerative colitis;
CESC	cis	rs929596	0.556	rs10202865	chr2:234587707	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.46	-5.64	-0.33	4.32e-8	Total bilirubin levels in HIV-1 infection;
CESC	cis	rs2288912	0.807	rs3760626	chr19:45457105	A/G	cg13119609	chr19:45449297	APOC2	0.49	8.03	0.44	3.23e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs9640161	0.750	rs4395803	chr7:150025367	A/C	cg27494647	chr7:150038898	RARRES2	0.41	5.11	0.3	6.15e-7	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs7481584	0.581	rs366422	chr11:3053873	C/T	cg08508325	chr11:3079039	CARS	0.29	5.19	0.3	4.29e-7	Calcium levels;
CESC	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg21856205	chr7:94953877	PON1	-0.51	-7.96	-0.44	5.21e-14	Paraoxonase activity;
CESC	trans	rs637571	0.522	rs550435	chr11:65732651	G/A	cg17712092	chr4:129076599	LARP1B	0.69	9.58	0.51	7.33e-19	Eosinophil percentage of white cells;
CESC	cis	rs8017423	1.000	rs4904644	chr14:90665689	A/G	cg14092571	chr14:90743983	NA	0.52	7.7	0.43	2.63e-13	Mortality in heart failure;
CESC	cis	rs9611565	0.568	rs5758441	chr22:42132888	C/A	cg06481639	chr22:41940642	POLR3H	0.5	5.81	0.34	1.78e-8	Vitiligo;
CESC	cis	rs8067354	0.574	rs2250526	chr17:57951973	G/A	cg13753209	chr17:57696993	CLTC	0.52	5.69	0.33	3.4e-8	Hemoglobin concentration;
CESC	cis	rs10927875	0.864	rs6674071	chr1:16144855	G/C	cg21385522	chr1:16154831	NA	-0.93	-11.81	-0.59	3.99e-26	Dilated cardiomyopathy;
CESC	trans	rs629535	0.814	rs506931	chr8:70068129	T/G	cg21567404	chr3:27674614	NA	0.88	10.34	0.54	2.74e-21	Dupuytren's disease;
CESC	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg18765753	chr7:1198926	ZFAND2A	-0.41	-5.21	-0.31	3.72e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs9611565	0.649	rs5751108	chr22:41858035	T/C	cg03806693	chr22:41940476	POLR3H	1.19	14.53	0.67	1.37e-35	Vitiligo;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg01688293	chr12:133428407	CHFR	0.45	6.14	0.35	2.99e-9	Fibrinogen levels;
CESC	cis	rs763121	0.889	rs9607557	chr22:39040279	G/A	cg21395723	chr22:39101663	GTPBP1	0.45	5.92	0.34	1.01e-8	Menopause (age at onset);
CESC	cis	rs12579753	0.879	rs11115008	chr12:82164859	C/T	cg24719984	chr12:82153464	PPFIA2	-0.36	-5.28	-0.31	2.64e-7	Resting heart rate;
CESC	trans	rs2727020	0.930	rs1164688	chr11:49290604	C/G	cg03929089	chr4:120376271	NA	0.71	9.26	0.49	7.34e-18	Coronary artery disease;
CESC	cis	rs4604732	0.527	rs7546805	chr1:247627259	G/A	cg12754571	chr1:247694271	LOC148824;OR2C3	0.44	5.46	0.32	1.09e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg26338869	chr17:61819248	STRADA	0.66	8.51	0.46	1.27e-15	Prudent dietary pattern;
CESC	cis	rs854765	0.505	rs4506969	chr17:17899839	A/G	cg09796270	chr17:17721594	SREBF1	0.37	5.15	0.3	5.12e-7	Total body bone mineral density;
CESC	trans	rs60843830	1.000	rs17714252	chr2:285471	G/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.66	8.31	0.45	4.98e-15	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs7666738	0.753	rs34164013	chr4:98976333	A/G	cg03676636	chr4:99064102	C4orf37	0.34	5.2	0.3	3.93e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs17384381	1.000	rs12140170	chr1:85849723	G/A	cg16011679	chr1:85725395	C1orf52	0.79	8.08	0.44	2.34e-14	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1552244	1.000	rs7622963	chr3:10139825	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	12.72	0.62	2.88e-29	Alzheimer's disease;
CESC	cis	rs9640161	0.750	rs73170185	chr7:150030191	C/A	cg13722127	chr7:150037890	RARRES2	0.38	5.27	0.31	2.87e-7	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs6831352	0.734	rs1311620	chr4:100013091	C/T	cg12011299	chr4:100065546	ADH4	0.59	7.16	0.4	7.75e-12	Alcohol dependence;
CESC	cis	rs10088262	0.629	rs1367829	chr8:124797135	A/G	cg02993010	chr8:124780839	FAM91A1	-0.67	-8.55	-0.46	1.01e-15	Pancreatic cancer;
CESC	cis	rs3947	1.000	rs2645425	chr8:11701278	G/A	cg00262122	chr8:11665843	FDFT1	-0.5	-5.15	-0.3	5.07e-7	Blood protein levels;
CESC	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.66	7.68	0.43	3.11e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs17376456	1.000	rs35184505	chr5:93561535	A/G	cg25358565	chr5:93447407	FAM172A	1.16	10.76	0.55	1.2e-22	Diabetic retinopathy;
CESC	cis	rs1707322	0.896	rs785518	chr1:46568422	A/T	cg03146154	chr1:46216737	IPP	-0.69	-9.13	-0.49	1.84e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs1801251	0.896	rs7573208	chr2:233696701	C/A	cg08000102	chr2:233561755	GIGYF2	-0.73	-11.63	-0.58	1.55e-25	Coronary artery disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg22855052	chr12:6982535	SPSB2	-0.46	-6.62	-0.38	1.94e-10	Fibrinogen levels;
CESC	cis	rs12597458	0.752	rs8051239	chr16:72036257	T/A	cg16558253	chr16:72132732	DHX38	0.38	5.53	0.32	7.76e-8	Prostate cancer;
CESC	cis	rs4423214	0.879	rs1792282	chr11:71135166	G/A	cg05163923	chr11:71159392	DHCR7	-0.59	-6.82	-0.39	6e-11	Vitamin D levels;
CESC	cis	rs870825	0.616	rs28459754	chr4:185636280	C/A	cg04058563	chr4:185651563	MLF1IP	0.62	6.86	0.39	4.91e-11	Blood protein levels;
CESC	cis	rs875971	0.522	rs1701760	chr7:65473688	A/G	cg10691866	chr7:65817282	TPST1	-0.34	-5.41	-0.32	1.39e-7	Aortic root size;
CESC	cis	rs698833	0.518	rs7562945	chr2:44552772	G/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.49	5.19	0.3	4.17e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs9815354	0.812	rs58442057	chr3:41827209	G/A	cg03022575	chr3:42003672	ULK4	0.7	6.04	0.35	5.26e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs561341	0.941	rs8081016	chr17:30331751	A/G	cg19193384	chr17:30244184	NA	-0.7	-6.62	-0.38	2e-10	Hip circumference adjusted for BMI;
CESC	cis	rs3096299	0.685	rs4238830	chr16:89540241	C/T	cg08392591	chr16:89556376	ANKRD11	0.59	8.07	0.44	2.49e-14	Multiple myeloma (IgH translocation);
CESC	cis	rs2816062	0.760	rs2244192	chr1:18890939	A/T	cg18795169	chr1:18902165	NA	-0.95	-18.57	-0.75	7.28e-50	Urate levels in lean individuals;
CESC	cis	rs9815354	0.680	rs73075219	chr3:42038429	A/C	cg03022575	chr3:42003672	ULK4	0.75	6.57	0.37	2.63e-10	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs9894429	0.789	rs35887231	chr17:79587126	G/A	cg13777783	chr17:79615861	NA	-0.33	-5.24	-0.31	3.35e-7	Eye color traits;
CESC	cis	rs9916302	0.904	rs12450559	chr17:37694709	G/A	cg07936489	chr17:37558343	FBXL20	-0.8	-11.52	-0.58	3.68e-25	Glomerular filtration rate (creatinine);
CESC	cis	rs4665809	0.618	rs7579199	chr2:26266496	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.68	-7.61	-0.42	4.86e-13	Gut microbiome composition (summer);
CESC	trans	rs7107217	1.000	rs1873872	chr11:129473993	A/T	cg07181902	chr2:85829892	TMEM150A	0.48	6.01	0.35	6.17e-9	Breast cancer;Type 2 diabetes;
CESC	cis	rs568617	1.000	rs656980	chr11:65656282	G/A	cg19792802	chr11:65647270	CTSW	0.36	5.44	0.32	1.24e-7	Crohn's disease;
CESC	cis	rs7267979	0.966	rs2424714	chr20:25418681	T/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.87	18.11	0.74	3e-48	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs2742234	0.590	rs2435338	chr10:43642115	A/G	cg07801480	chr10:43725741	RASGEF1A	0.42	5.31	0.31	2.34e-7	Hirschsprung disease;
CESC	cis	rs4919694	0.572	rs7080935	chr10:104929113	C/A	cg04362960	chr10:104952993	NT5C2	0.64	6.44	0.37	5.66e-10	Arsenic metabolism;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25223263	chr11:119020168	ABCG4	0.62	7.69	0.43	2.92e-13	Gut microbiome composition (summer);
CESC	cis	rs12497850	0.864	rs7431857	chr3:48900347	G/A	cg03060546	chr3:49711283	APEH	0.44	5.38	0.31	1.61e-7	Parkinson's disease;
CESC	cis	rs7216064	0.954	rs4790973	chr17:65951133	C/T	cg07042672	chr17:66097459	LOC651250	-0.54	-5.8	-0.34	1.84e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs17826219	0.706	rs8075357	chr17:29057197	A/C	cg13385521	chr17:29058706	SUZ12P	0.81	6.53	0.37	3.28e-10	Body mass index;
CESC	cis	rs1707322	0.685	rs28617418	chr1:46189526	T/A	cg03146154	chr1:46216737	IPP	0.82	11.54	0.58	3.18e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs59918340	0.728	rs4961340	chr8:142232002	G/A	cg23750338	chr8:142222470	SLC45A4	0.64	9.83	0.52	1.18e-19	Immature fraction of reticulocytes;
CESC	trans	rs208520	0.690	rs851468	chr6:66825875	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.01	-12.92	-0.62	5.99e-30	Exhaled nitric oxide output;
CESC	cis	rs9486719	0.948	rs2472881	chr6:96862562	C/T	cg18709589	chr6:96969512	KIAA0776	0.52	5.67	0.33	3.8e-8	Migraine;Coronary artery disease;
CESC	cis	rs9322193	0.847	rs12234128	chr6:149948689	T/C	cg13206674	chr6:150067644	NUP43	0.41	5.92	0.34	1.02e-8	Lung cancer;
CESC	cis	rs116095464	0.558	rs10055405	chr5:265666	C/T	cg22496380	chr5:211416	CCDC127	-0.73	-8.29	-0.45	5.78e-15	Breast cancer;
CESC	cis	rs2228479	0.850	rs2283565	chr16:89827556	G/T	cg04013166	chr16:89971882	TCF25	0.78	6.69	0.38	1.33e-10	Skin colour saturation;
CESC	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg16145915	chr7:1198662	ZFAND2A	-0.47	-5.48	-0.32	9.95e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs6088590	1.000	rs6119535	chr20:33442138	A/C	cg24642439	chr20:33292090	TP53INP2	0.76	10.42	0.54	1.57e-21	Coronary artery disease;
CESC	cis	rs863345	0.526	rs857676	chr1:158615702	G/A	cg12129480	chr1:158549410	OR10X1	-0.3	-5.76	-0.33	2.27e-8	Pneumococcal bacteremia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11333835	chr1:23495430	LUZP1	-0.62	-7.42	-0.41	1.56e-12	Gut microbiome composition (summer);
CESC	cis	rs6867032	0.527	rs4371796	chr5:1977785	C/T	cg26168224	chr5:2018326	NA	-0.75	-10.31	-0.54	3.53e-21	Gut microbiome composition (winter);
CESC	cis	rs7615952	0.599	rs7652883	chr3:125707977	T/G	cg04553112	chr3:125709451	NA	-0.51	-5.69	-0.33	3.36e-8	Blood pressure (smoking interaction);
CESC	cis	rs4713118	0.513	rs149951	chr6:28033087	T/C	cg12963246	chr6:28129442	ZNF389	0.39	5.6	0.33	5.36e-8	Parkinson's disease;
CESC	trans	rs4950322	0.570	rs72691004	chr1:146705955	G/A	cg04954894	chr8:38089920	DDHD2	-0.58	-6.17	-0.35	2.55e-9	Protein quantitative trait loci;
CESC	cis	rs524281	0.773	rs10791862	chr11:66013664	T/C	cg14036092	chr11:66035641	RAB1B	-0.53	-5.31	-0.31	2.38e-7	Electroencephalogram traits;
CESC	cis	rs35306767	0.622	rs66462130	chr10:1022108	C/T	cg26597838	chr10:835615	NA	0.76	7.14	0.4	8.95e-12	Eosinophil percentage of granulocytes;
CESC	cis	rs2243480	1.000	rs4718334	chr7:65789454	G/A	cg18252515	chr7:66147081	NA	1.27	12.94	0.62	4.98e-30	Diabetic kidney disease;
CESC	cis	rs10465746	0.545	rs12145516	chr1:84480376	A/G	cg10977910	chr1:84465055	TTLL7	0.45	5.65	0.33	4.17e-8	Obesity-related traits;
CESC	cis	rs7095944	0.554	rs11245344	chr10:126418782	C/T	cg08799069	chr10:126477246	METTL10	-0.4	-5.91	-0.34	1.07e-8	Asthma;
CESC	cis	rs1552244	1.000	rs7615764	chr3:10082592	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.88	12.06	0.6	5.29e-27	Alzheimer's disease;
CESC	cis	rs1552244	0.935	rs66493421	chr3:10092569	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.86	9.67	0.51	3.9e-19	Alzheimer's disease;
CESC	cis	rs2816062	0.786	rs2745317	chr1:18896552	G/A	cg18795169	chr1:18902165	NA	-0.94	-19.04	-0.76	1.61e-51	Urate levels in lean individuals;
CESC	cis	rs9916302	0.904	rs11867312	chr17:37597748	C/T	cg07936489	chr17:37558343	FBXL20	-0.8	-11.5	-0.58	4.2e-25	Glomerular filtration rate (creatinine);
CESC	cis	rs2070677	0.877	rs1581935	chr10:135360448	T/G	cg20169779	chr10:135381914	SYCE1	0.75	9.01	0.48	4.31e-17	Gout;
CESC	cis	rs3091242	0.933	rs926438	chr1:25753638	C/T	cg27572855	chr1:25598939	RHD	0.44	7.28	0.41	3.8e-12	Erythrocyte sedimentation rate;
CESC	cis	rs8078723	1.000	rs2227336	chr17:38174855	T/G	cg17467752	chr17:38218738	THRA	0.66	9.91	0.52	6.68e-20	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CESC	cis	rs2075371	0.796	rs1643040	chr7:134011703	G/C	cg20476274	chr7:133979776	SLC35B4	0.53	7.21	0.41	5.79e-12	Mean platelet volume;
CESC	cis	rs10504229	0.861	rs57942497	chr8:58171239	G/T	cg24829409	chr8:58192753	C8orf71	-0.76	-10.0	-0.52	3.53e-20	Developmental language disorder (linguistic errors);
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg23555592	chr10:91174309	IFIT5	-0.51	-6.27	-0.36	1.5e-9	Thyroid stimulating hormone;
CESC	trans	rs10435719	0.647	rs10092605	chr8:11787395	T/G	cg15556689	chr8:8085844	FLJ10661	0.51	6.29	0.36	1.3e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
CESC	cis	rs858239	0.539	rs4365988	chr7:23190871	T/C	cg23682824	chr7:23144976	KLHL7	0.51	6.77	0.38	8.05e-11	Cerebrospinal fluid biomarker levels;
CESC	cis	rs6570726	0.791	rs435671	chr6:145881215	A/G	cg05347473	chr6:146136440	FBXO30	0.55	7.06	0.4	1.45e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6741892	0.536	rs7590835	chr2:38893950	A/G	cg19391498	chr2:38892846	GALM	0.53	7.28	0.41	3.81e-12	5-HTT brain serotonin transporter levels;
CESC	trans	rs10242455	0.557	rs45529541	chr7:99048143	C/A	cg09045935	chr12:6379348	NA	0.92	7.49	0.42	9.97e-13	Blood metabolite levels;
CESC	cis	rs2243480	1.000	rs36068983	chr7:65408991	C/T	cg18252515	chr7:66147081	NA	-1.06	-9.79	-0.52	1.67e-19	Diabetic kidney disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09304653	chr7:141251275	AGK	0.53	6.06	0.35	4.69e-9	Gut microbiome composition (summer);
CESC	cis	rs11690935	0.959	rs12692970	chr2:172594197	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.97	-14.99	-0.68	3.42e-37	Schizophrenia;
CESC	cis	rs6568686	0.627	rs174374	chr6:111906055	A/G	cg22127309	chr6:111907043	TRAF3IP2	0.5	5.08	0.3	7.07e-7	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
CESC	trans	rs208520	0.955	rs12204033	chr6:67001525	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.77	8.7	0.47	3.56e-16	Exhaled nitric oxide output;
CESC	cis	rs853679	0.517	rs9468297	chr6:28118874	G/T	cg20151795	chr6:28129481	ZNF389	0.46	5.83	0.34	1.65e-8	Depression;
CESC	cis	rs1801251	0.964	rs6748027	chr2:233629552	T/C	cg25237894	chr2:233734115	C2orf82	0.45	7.9	0.44	7.6e-14	Coronary artery disease;
CESC	cis	rs10540	1.000	rs35898083	chr11:484469	C/T	cg03934478	chr11:495069	RNH1	0.53	5.34	0.31	2.03e-7	Body mass index;
CESC	cis	rs7208859	0.725	rs7210904	chr17:29170205	G/A	cg19761014	chr17:28927070	LRRC37B2	0.56	5.68	0.33	3.47e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs258892	0.895	rs16901102	chr5:72048749	C/T	cg21869765	chr5:72125136	TNPO1	-0.4	-5.17	-0.3	4.51e-7	Small cell lung carcinoma;
CESC	cis	rs477895	0.653	rs11606544	chr11:63896901	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.92	10.16	0.53	1.05e-20	Mean platelet volume;
CESC	cis	rs7107174	1.000	rs10899455	chr11:77999163	T/C	cg02023728	chr11:77925099	USP35	0.43	6.05	0.35	4.97e-9	Testicular germ cell tumor;
CESC	cis	rs4969178	0.965	rs4969179	chr17:76391454	A/C	cg20026190	chr17:76395443	PGS1	0.49	7.84	0.43	1.13e-13	HDL cholesterol levels;
CESC	cis	rs250677	0.522	rs2895837	chr5:148357535	C/T	cg18129178	chr5:148520854	ABLIM3	0.5	5.45	0.32	1.13e-7	Breast cancer;
CESC	cis	rs6089584	0.888	rs6061981	chr20:60618973	T/C	cg13770153	chr20:60521292	NA	-0.44	-5.7	-0.33	3.2e-8	Body mass index;
CESC	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg24739457	chr1:205821442	NA	-0.44	-6.14	-0.35	3.02e-9	Monocyte percentage of white cells;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05592363	chr5:78908495	PAPD4	0.56	6.71	0.38	1.18e-10	Gut microbiome composition (summer);
CESC	cis	rs826838	0.874	rs11183816	chr12:38834656	T/G	cg13010199	chr12:38710504	ALG10B	0.6	8.53	0.46	1.18e-15	Heart rate;
CESC	cis	rs875971	0.964	rs55748098	chr7:65763618	T/C	cg10691866	chr7:65817282	TPST1	0.33	5.59	0.32	5.54e-8	Aortic root size;
CESC	cis	rs9633740	0.947	rs7096909	chr10:82284512	A/T	cg00277334	chr10:82204260	NA	0.52	5.44	0.32	1.23e-7	Post bronchodilator FEV1;
CESC	cis	rs78889164	0.955	rs77339594	chr19:33855252	C/A	cg02272751	chr19:33882848	PEPD	-0.51	-6.46	-0.37	5.02e-10	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg02108556	chr8:131271127	ASAP1	0.42	6.67	0.38	1.45e-10	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs11098499	0.909	rs35111518	chr4:120440682	A/G	cg24375607	chr4:120327624	NA	0.44	5.27	0.31	2.85e-7	Corneal astigmatism;
CESC	cis	rs9905704	0.633	rs2531731	chr17:56546524	A/C	cg12560992	chr17:57184187	TRIM37	-0.63	-5.75	-0.33	2.48e-8	Testicular germ cell tumor;
CESC	cis	rs4803468	1.000	rs10853751	chr19:41903220	G/A	cg09537434	chr19:41945824	ATP5SL	-1.06	-19.22	-0.76	3.86e-52	Height;
CESC	cis	rs9393777	0.623	rs2093169	chr6:26495099	C/T	cg14345882	chr6:26364793	BTN3A2	0.44	5.34	0.31	2.01e-7	Intelligence (multi-trait analysis);
CESC	cis	rs10504229	0.953	rs115634610	chr8:58190533	G/A	cg22535103	chr8:58192502	C8orf71	-1.04	-13.21	-0.63	5.76e-31	Developmental language disorder (linguistic errors);
CESC	cis	rs6430585	0.528	rs309119	chr2:136710372	T/C	cg07169764	chr2:136633963	MCM6	1.08	15.44	0.69	8.54e-39	Corneal structure;
CESC	cis	rs13191362	0.810	rs13209784	chr6:162961274	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.77	7.21	0.4	5.86e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs4862750	0.872	rs1991254	chr4:187875375	T/G	cg11301795	chr4:187892539	NA	-0.72	-10.8	-0.55	8.89e-23	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs6700559	0.810	rs2809344	chr1:200596606	C/A	cg05185519	chr16:2972941	FLYWCH1	0.47	6.16	0.35	2.73e-9	Coronary artery disease;
CESC	cis	rs1046896	0.553	rs72634343	chr17:80827392	T/C	cg02711726	chr17:80685570	FN3KRP	-0.39	-5.14	-0.3	5.32e-7	Glycated hemoglobin levels;
CESC	cis	rs9291683	0.609	rs3796836	chr4:10011345	A/G	cg00071950	chr4:10020882	SLC2A9	0.89	17.05	0.72	1.7e-44	Bone mineral density;
CESC	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.75	10.57	0.54	5.21e-22	Prudent dietary pattern;
CESC	cis	rs7927592	0.913	rs7925275	chr11:68290433	T/C	cg20283391	chr11:68216788	NA	-0.62	-7.54	-0.42	7.69e-13	Total body bone mineral density;
CESC	cis	rs4955124	0.818	rs12639463	chr3:32042746	G/A	cg05935571	chr3:32023257	ZNF860;OSBPL10	0.67	5.33	0.31	2.14e-7	Schizophrenia;
CESC	cis	rs763121	0.752	rs5757222	chr22:39060473	C/T	cg06544989	chr22:39130855	UNC84B	0.49	8.49	0.46	1.53e-15	Menopause (age at onset);
CESC	cis	rs1707322	0.752	rs11211171	chr1:46168642	A/G	cg06784218	chr1:46089804	CCDC17	0.41	7.21	0.41	5.75e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs2488856	0.504	rs2455971	chr14:43540163	A/T	cg09730170	chr20:23586680	CST9	0.41	6.54	0.37	3.18e-10	Osteoprotegerin levels;
CESC	cis	rs75804782	0.521	rs72982596	chr2:239454919	G/C	cg18131467	chr2:239335373	ASB1	-0.69	-5.57	-0.32	6.11e-8	Morning vs. evening chronotype;Chronotype;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22152050	chr18:60987904	BCL2	0.56	6.22	0.36	1.97e-9	Gut microbiome composition (summer);
CESC	cis	rs898097	0.801	rs68141193	chr17:80878816	C/T	cg15369054	chr17:80825471	TBCD	0.51	7.18	0.4	6.87e-12	Breast cancer;
CESC	cis	rs1008375	1.000	rs28552744	chr4:17620165	A/G	cg16339924	chr4:17578868	LAP3	0.56	7.02	0.4	1.91e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs3125734	0.660	rs4979780	chr10:63992740	A/C	cg09941381	chr10:64027924	RTKN2	-0.31	-5.14	-0.3	5.41e-7	Rheumatoid arthritis;
CESC	cis	rs3806843	0.966	rs3806844	chr5:140206263	A/T	cg26395211	chr5:140044315	WDR55	-0.42	-5.14	-0.3	5.3e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs1707322	0.716	rs28375469	chr1:46195375	T/C	cg05343316	chr1:45956843	TESK2	0.51	6.32	0.36	1.09e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2273669	0.667	rs7767882	chr6:109334971	C/A	cg05315195	chr6:109294784	ARMC2	-0.67	-6.32	-0.36	1.13e-9	Prostate cancer;
CESC	cis	rs4148883	0.689	rs1154415	chr4:99999033	T/C	cg13256891	chr4:100009986	ADH5	0.52	6.81	0.39	6.69e-11	Alcohol dependence;
CESC	cis	rs6060717	0.528	rs73905955	chr20:34332938	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.8	-7.48	-0.42	1.09e-12	Hip circumference adjusted for BMI;
CESC	cis	rs28386778	0.700	rs11079515	chr17:62005645	C/G	cg11494091	chr17:61959527	GH2	-0.78	-13.9	-0.65	2.38e-33	Prudent dietary pattern;
CESC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg09311052	chr1:154531418	UBE2Q1	0.48	6.38	0.36	7.87e-10	Tetralogy of Fallot;
CESC	cis	rs6690583	0.623	rs12037219	chr1:85505951	G/A	cg22153463	chr1:85462885	MCOLN2	0.78	7.43	0.42	1.49e-12	Serum sulfate level;
CESC	cis	rs2243480	0.901	rs1701759	chr7:65470932	G/T	cg18252515	chr7:66147081	NA	-1.13	-10.9	-0.56	4.18e-23	Diabetic kidney disease;
CESC	cis	rs9916302	0.904	rs8079560	chr17:37497661	C/T	cg19468946	chr17:37922297	IKZF3	0.39	5.09	0.3	6.85e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs4268898	0.931	rs2551121	chr2:24539967	T/C	cg06627628	chr2:24431161	ITSN2	-0.71	-8.59	-0.47	7.69e-16	Asthma;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg14851846	chr7:99716985	TAF6;CNPY4	-0.49	-6.15	-0.35	2.86e-9	Ulcerative colitis;
CESC	cis	rs4656958	0.538	rs2184066	chr1:160883896	G/C	cg20012024	chr1:160991549	F11R	0.29	5.06	0.3	7.72e-7	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
CESC	cis	rs9916302	0.851	rs11078907	chr17:37662954	C/T	cg15445000	chr17:37608096	MED1	0.41	6.76	0.38	8.83e-11	Glomerular filtration rate (creatinine);
CESC	trans	rs13063635	0.831	rs35209528	chr3:46003496	T/C	cg10236987	chr1:228114221	WNT9A	0.57	6.07	0.35	4.38e-9	Eosinophil percentage of granulocytes;
CESC	cis	rs9487051	0.872	rs9400271	chr6:109607556	G/A	cg01475377	chr6:109611718	NA	-0.51	-8.36	-0.46	3.66e-15	Reticulocyte fraction of red cells;
CESC	trans	rs11098499	0.954	rs10024844	chr4:120311528	A/G	cg25214090	chr10:38739885	LOC399744	0.68	9.2	0.49	1.14e-17	Corneal astigmatism;
CESC	cis	rs67311347	1.000	rs4128740	chr3:40519532	C/A	cg09455208	chr3:40491958	NA	0.52	8.64	0.47	5.57e-16	Renal cell carcinoma;
CESC	trans	rs5763662	1.000	rs5763763	chr22:30488627	G/A	cg23513814	chr17:72857430	GRIN2C	-0.53	-6.0	-0.35	6.28e-9	LDL cholesterol levels;LDL cholesterol;
CESC	cis	rs4665809	0.590	rs3806515	chr2:26466975	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.1	12.68	0.61	4e-29	Gut microbiome composition (summer);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg24048372	chr5:93954560	C5orf36;ANKRD32	-0.47	-6.11	-0.35	3.47e-9	Ulcerative colitis;
CESC	cis	rs9910055	0.762	rs2631299	chr17:42219773	G/T	cg08499158	chr17:42289980	UBTF	-0.56	-7.32	-0.41	2.94e-12	Total body bone mineral density;
CESC	cis	rs73206853	0.764	rs55991901	chr12:110962702	C/A	cg12870014	chr12:110450643	ANKRD13A	0.62	5.2	0.3	3.98e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15323937	chr11:64599019	CDC42BPG	-0.55	-6.16	-0.35	2.7e-9	Gut microbiome composition (summer);
CESC	cis	rs9399401	0.667	rs7757571	chr6:142702589	A/C	cg04461802	chr6:142623433	GPR126	0.36	5.4	0.31	1.52e-7	Chronic obstructive pulmonary disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21063480	chr14:78082891	SPTLC2	0.63	6.94	0.39	2.92e-11	Gut microbiome composition (summer);
CESC	cis	rs77106637	0.858	rs7109575	chr11:72463435	G/A	cg03713592	chr11:72463424	ARAP1	1.26	10.6	0.55	4.01e-22	Type 2 diabetes;
CESC	cis	rs4727027	0.933	rs34578816	chr7:148847606	G/A	cg23158103	chr7:148848205	ZNF398	-0.43	-7.11	-0.4	1.06e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs7618915	0.501	rs10865974	chr3:52718280	A/C	cg17372223	chr3:52568218	NT5DC2	-0.39	-6.07	-0.35	4.47e-9	Bipolar disorder;
CESC	cis	rs3008870	0.755	rs2755254	chr1:67470855	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.62	8.12	0.45	1.73e-14	Lymphocyte percentage of white cells;
CESC	cis	rs3785574	0.962	rs2597632	chr17:61894739	A/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.8	10.54	0.54	6.22e-22	Height;
CESC	cis	rs7552404	1.000	rs4949876	chr1:76173377	C/T	cg22875332	chr1:76189707	ACADM	0.66	7.81	0.43	1.31e-13	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs637571	0.544	rs55704213	chr11:65730002	C/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.43	6.22	0.36	1.92e-9	Eosinophil percentage of white cells;
CESC	cis	rs7959452	0.527	rs4761157	chr12:69780907	A/G	cg20891283	chr12:69753455	YEATS4	0.91	15.03	0.68	2.41e-37	Blood protein levels;
CESC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg22418859	chr21:37518821	CBR3	-0.45	-6.88	-0.39	4.34e-11	Intelligence (multi-trait analysis);
CESC	cis	rs2933343	0.700	rs1683779	chr3:128642048	A/G	cg25356066	chr3:128598488	ACAD9	0.62	8.76	0.47	2.42e-16	IgG glycosylation;
CESC	cis	rs3820068	0.581	rs2861387	chr1:15951296	G/A	cg17385448	chr1:15911702	AGMAT	0.43	6.87	0.39	4.57e-11	Systolic blood pressure;
CESC	cis	rs3820068	0.603	rs17448778	chr1:15985306	A/G	cg17385448	chr1:15911702	AGMAT	0.45	7.67	0.43	3.27e-13	Systolic blood pressure;
CESC	cis	rs11083475	0.714	rs1471432	chr19:39260282	G/A	cg26703956	chr19:39260304	NA	-0.29	-5.41	-0.32	1.38e-7	Heart rate;
CESC	cis	rs780096	0.526	rs704791	chr2:27657167	T/C	cg22903471	chr2:27725779	GCKR	-0.52	-7.39	-0.41	1.88e-12	Total body bone mineral density;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg21155778	chr12:95611301	FGD6;VEZT	-0.49	-6.04	-0.35	5.09e-9	Ulcerative colitis;
CESC	cis	rs9487051	0.676	rs7773775	chr6:109600339	T/C	cg21918786	chr6:109611834	NA	-0.37	-5.5	-0.32	9.15e-8	Reticulocyte fraction of red cells;
CESC	cis	rs6835098	0.962	rs10014010	chr4:174083230	C/T	cg08422745	chr4:174089978	GALNT7	-0.82	-11.83	-0.59	3.26e-26	Dementia and core Alzheimer's disease neuropathologic changes;
CESC	cis	rs4906332	0.966	rs12185021	chr14:103927805	A/G	cg09975044	chr14:104007538	NA	0.47	6.45	0.37	5.25e-10	Coronary artery disease;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg08270031	chr1:180472207	ACBD6	-0.46	-6.26	-0.36	1.52e-9	Thyroid stimulating hormone;
CESC	cis	rs12121840	0.790	rs16846756	chr1:165516102	C/T	cg16553119	chr1:165599451	MGST3	-0.48	-5.26	-0.31	3.03e-7	Interleukin-1-receptor antagonist levels;
CESC	cis	rs10504229	0.871	rs7002070	chr8:58153817	A/G	cg22535103	chr8:58192502	C8orf71	-0.9	-11.03	-0.56	1.55e-23	Developmental language disorder (linguistic errors);
CESC	trans	rs7618501	0.633	rs3774733	chr3:50037123	C/G	cg21659725	chr3:3221576	CRBN	0.54	7.54	0.42	7.33e-13	Intelligence (multi-trait analysis);
CESC	cis	rs5750830	0.649	rs5757659	chr22:39812409	A/C	cg02038168	chr22:39784481	NA	-0.6	-7.21	-0.4	5.96e-12	Intelligence (multi-trait analysis);
CESC	cis	rs1865721	1.000	rs17283692	chr18:73193911	T/C	cg26385618	chr18:73139727	C18orf62	-0.51	-7.56	-0.42	6.81e-13	Intelligence;
CESC	cis	rs1799949	1.000	rs8176083	chr17:41275151	G/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.43	5.84	0.34	1.56e-8	Menopause (age at onset);
CESC	cis	rs7618915	0.501	rs11130308	chr3:52639257	G/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	5.83	0.34	1.59e-8	Bipolar disorder;
CESC	cis	rs7149337	0.805	rs3007164	chr14:51646935	A/G	cg23942311	chr14:51606299	NA	0.45	7.75	0.43	1.91e-13	Cancer;
CESC	cis	rs1799949	0.965	rs8176140	chr17:41251646	T/A	cg25072359	chr17:41440525	NA	0.44	6.04	0.35	5.21e-9	Menopause (age at onset);
CESC	cis	rs727505	1.000	rs66922607	chr7:124512555	T/A	cg23710748	chr7:124431027	NA	-0.48	-7.52	-0.42	8.49e-13	Lewy body disease;
CESC	cis	rs4819052	0.851	rs2838867	chr21:46713092	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.92	12.96	0.62	4.35e-30	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs798554	0.759	rs798495	chr7:2797267	T/C	cg19346786	chr7:2764209	NA	-0.52	-7.46	-0.42	1.26e-12	Height;
CESC	cis	rs6783573	0.965	rs7650998	chr3:46607255	C/T	cg21489266	chr3:46619131	LRRC2;TDGF1	0.42	6.49	0.37	4.16e-10	Cerebrospinal fluid biomarker levels;
CESC	cis	rs10504229	1.000	rs60231757	chr8:58169937	T/C	cg05313129	chr8:58192883	C8orf71	-0.55	-6.37	-0.36	8.42e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs13191362	1.000	rs7769686	chr6:163199467	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.97	9.49	0.5	1.45e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs769267	0.930	rs747050	chr19:19584987	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	7.45	0.42	1.34e-12	Tonsillectomy;
CESC	cis	rs7412746	0.587	rs3849279	chr1:150944707	T/C	cg04414720	chr1:150670196	GOLPH3L	0.45	5.95	0.34	8.58e-9	Melanoma;
CESC	trans	rs853679	0.824	rs1321505	chr6:28052823	A/C	cg06606381	chr12:133084897	FBRSL1	-0.66	-6.0	-0.35	6.41e-9	Depression;
CESC	cis	rs2836974	0.897	rs34394827	chr21:40528087	T/C	cg11644478	chr21:40555479	PSMG1	1.02	16.67	0.72	3.53e-43	Cognitive function;
CESC	cis	rs9400467	0.506	rs10456872	chr6:111586667	C/T	cg15721981	chr6:111408429	SLC16A10	0.52	5.03	0.3	8.93e-7	Blood metabolite levels;Amino acid levels;
CESC	cis	rs7660520	0.524	rs4862101	chr4:183733177	T/C	cg04526738	chr4:183727387	NA	0.7	6.51	0.37	3.71e-10	Pediatric autoimmune diseases;
CESC	cis	rs4594175	0.926	rs4131365	chr14:51622444	C/T	cg23942311	chr14:51606299	NA	0.36	5.36	0.31	1.77e-7	Cancer;
CESC	trans	rs7937682	0.847	rs583032	chr11:111432757	C/T	cg18187862	chr3:45730750	SACM1L	0.51	6.22	0.36	1.88e-9	Primary sclerosing cholangitis;
CESC	cis	rs7666738	0.791	rs1426661	chr4:98874303	C/G	cg03467027	chr4:99064603	C4orf37	0.41	5.14	0.3	5.32e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7726839	0.574	rs72705017	chr5:623733	G/A	cg16447950	chr5:562315	NA	-0.59	-6.06	-0.35	4.72e-9	Obesity-related traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18252731	chr15:93198700	FAM174B	-0.56	-6.61	-0.38	2.08e-10	Gut microbiome composition (summer);
CESC	cis	rs2243480	1.000	rs451396	chr7:65484074	T/A	cg12463550	chr7:65579703	CRCP	0.72	5.81	0.34	1.8e-8	Diabetic kidney disease;
CESC	cis	rs116095464	0.681	rs9687745	chr5:229309	C/T	cg22496380	chr5:211416	CCDC127	-0.74	-8.6	-0.47	7.1e-16	Breast cancer;
CESC	cis	rs5753618	0.561	rs9609254	chr22:31705942	G/A	cg13145458	chr22:31556086	RNF185	-0.49	-5.57	-0.32	6.36e-8	Colorectal cancer;
CESC	cis	rs6674176	0.696	rs4448553	chr1:44411589	A/G	cg23954153	chr1:44402353	ARTN	-0.33	-5.06	-0.3	7.89e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs17253792	0.822	rs10142497	chr14:56047948	C/T	cg01858014	chr14:56050164	KTN1	0.74	6.05	0.35	4.92e-9	Putamen volume;
CESC	cis	rs3741151	0.686	rs11822984	chr11:73261467	A/C	cg17517138	chr11:73019481	ARHGEF17	0.86	6.84	0.39	5.62e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs3761218	0.714	rs1968648	chr20:3763349	C/T	cg25011176	chr20:3776985	CDC25B	0.43	5.95	0.34	8.44e-9	Bipolar disorder;
CESC	cis	rs4555082	0.834	rs2735817	chr14:105717796	A/G	cg13114125	chr14:105738426	BRF1	0.82	10.11	0.53	1.54e-20	Mean platelet volume;Platelet distribution width;
CESC	cis	rs9814567	0.806	rs2293294	chr3:134322814	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.42	5.56	0.32	6.59e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs2933343	0.649	rs728839	chr3:128589359	A/G	cg25356066	chr3:128598488	ACAD9	0.59	8.34	0.46	3.97e-15	IgG glycosylation;
CESC	cis	rs2075371	1.000	rs2244694	chr7:133987093	C/T	cg00033643	chr7:134001901	SLC35B4	0.44	5.6	0.33	5.4e-8	Mean platelet volume;
CESC	cis	rs12973672	0.812	rs35250673	chr19:35762548	G/A	cg12095397	chr19:35769544	USF2	0.48	5.68	0.33	3.46e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs7635838	0.596	rs347598	chr3:11258289	G/C	cg00170343	chr3:11313890	ATG7	0.54	7.58	0.42	5.88e-13	HDL cholesterol;
CESC	trans	rs561341	0.883	rs886224	chr17:30229902	T/C	cg20587970	chr11:113659929	NA	-1.08	-13.13	-0.63	1.11e-30	Hip circumference adjusted for BMI;
CESC	cis	rs754466	0.580	rs10824577	chr10:79577408	G/C	cg17075019	chr10:79541650	NA	-0.87	-13.8	-0.65	5.26e-33	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs9787249	0.957	rs7548120	chr1:40204424	A/T	cg24920358	chr1:40204285	PPIE	0.43	6.47	0.37	4.74e-10	Blood protein levels;
CESC	cis	rs7811142	0.779	rs77370288	chr7:99947897	A/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.7	6.21	0.36	2.04e-9	Platelet count;
CESC	cis	rs7811142	1.000	rs6972167	chr7:100080013	G/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.99	10.67	0.55	2.36e-22	Platelet count;
CESC	cis	rs798554	0.634	rs1182180	chr7:2873279	G/T	cg19717773	chr7:2847554	GNA12	-0.52	-8.4	-0.46	2.7e-15	Height;
CESC	cis	rs2011503	0.941	rs11555053	chr19:19390185	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.5	5.04	0.3	8.44e-7	Bipolar disorder;
CESC	cis	rs736408	0.509	rs13083798	chr3:52649748	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.45	6.4	0.37	6.91e-10	Bipolar disorder;
CESC	cis	rs10883723	0.810	rs2296581	chr10:104242886	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.53	7.29	0.41	3.52e-12	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs2531992	0.800	rs2601782	chr16:4021051	T/C	cg05927578	chr16:4029543	ADCY9	0.46	5.78	0.33	2.14e-8	Waist circumference;
CESC	cis	rs2070488	0.965	rs2284819	chr3:38557161	C/T	cg24069376	chr3:38537580	EXOG	0.44	7.68	0.43	2.99e-13	Electrocardiographic conduction measures;
CESC	cis	rs67311347	1.000	rs11539046	chr3:40503809	G/A	cg09455208	chr3:40491958	NA	-0.48	-8.13	-0.45	1.65e-14	Renal cell carcinoma;
CESC	cis	rs10504229	0.953	rs116564484	chr8:58172818	T/C	cg22535103	chr8:58192502	C8orf71	-1.03	-12.78	-0.62	1.84e-29	Developmental language disorder (linguistic errors);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10314221	chr15:85174505	SCAND2	-0.53	-6.31	-0.36	1.17e-9	Gut microbiome composition (summer);
CESC	cis	rs875971	0.862	rs10282433	chr7:65721439	G/A	cg11764359	chr7:65958608	NA	-0.79	-12.03	-0.59	6.79e-27	Aortic root size;
CESC	cis	rs6088580	0.634	rs4258875	chr20:32924895	C/A	cg06115741	chr20:33292138	TP53INP2	-0.44	-5.65	-0.33	4.13e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs7937682	0.889	rs484013	chr11:111495779	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.95	-14.66	-0.67	4.83e-36	Primary sclerosing cholangitis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05598546	chr1:76251766	SNORD45C;RABGGTB	-0.59	-7.24	-0.41	4.99e-12	Gut microbiome composition (summer);
CESC	cis	rs1799949	1.000	rs3950989	chr17:41237953	G/A	cg25072359	chr17:41440525	NA	0.44	6.0	0.35	6.54e-9	Menopause (age at onset);
CESC	cis	rs10791323	0.628	rs2853117	chr11:133705266	T/G	cg15485101	chr11:133734466	NA	0.4	6.6	0.38	2.21e-10	Childhood ear infection;
CESC	cis	rs2273669	0.667	rs75263286	chr6:109350489	G/C	cg05315195	chr6:109294784	ARMC2	-0.67	-6.06	-0.35	4.74e-9	Prostate cancer;
CESC	cis	rs698833	0.859	rs786612	chr2:44600819	G/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.44	5.63	0.33	4.58e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs7945705	0.869	rs7925728	chr11:9013002	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.46	-7.79	-0.43	1.49e-13	Hemoglobin concentration;
CESC	cis	rs151234	0.741	rs3194168	chr16:28603012	A/G	cg01378222	chr16:28622494	SULT1A1	-0.57	-7.18	-0.4	7.06e-12	Platelet distribution width;
CESC	cis	rs853679	0.517	rs9468292	chr6:28095355	G/A	cg08968635	chr6:28129556	ZNF389	0.41	5.51	0.32	8.4e-8	Depression;
CESC	cis	rs1799949	1.000	rs2271574	chr17:41327648	T/C	cg05368731	chr17:41323189	NBR1	0.8	11.11	0.56	8.39e-24	Menopause (age at onset);
CESC	cis	rs6570726	0.875	rs12524077	chr6:145866333	G/C	cg23711669	chr6:146136114	FBXO30	0.8	11.78	0.59	4.84e-26	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6032067	0.641	rs13038485	chr20:43767759	T/A	cg10761708	chr20:43804764	PI3	0.55	6.12	0.35	3.4e-9	Blood protein levels;
CESC	trans	rs13035304	0.686	rs6726681	chr2:130508316	C/G	cg18827756	chr15:42130735	JMJD7-PLA2G4B;PLA2G4B	-0.44	-6.91	-0.39	3.58e-11	Age at smoking initiation in chronic obstructive pulmonary disease;
CESC	cis	rs1941023	0.503	rs10792269	chr11:60117126	C/T	cg08716584	chr11:60157161	MS4A7	-0.5	-7.93	-0.44	6.26e-14	Congenital heart disease (maternal effect);
CESC	cis	rs514406	0.505	rs416968	chr1:53183513	A/G	cg08736216	chr1:53307985	ZYG11A	-0.35	-5.87	-0.34	1.33e-8	Monocyte count;
CESC	trans	rs875971	0.929	rs34406470	chr7:65929956	A/G	cg26939375	chr7:64535504	NA	0.47	6.0	0.35	6.6e-9	Aortic root size;
CESC	cis	rs9398803	0.678	rs9388500	chr6:126876580	C/G	cg19875578	chr6:126661172	C6orf173	0.43	5.91	0.34	1.08e-8	Male-pattern baldness;
CESC	cis	rs4665809	1.000	rs750450	chr2:26324631	A/G	cg26314531	chr2:26401878	FAM59B	-0.64	-7.29	-0.41	3.48e-12	Gut microbiome composition (summer);
CESC	cis	rs9479482	0.935	rs5017315	chr6:150333574	C/T	cg25797454	chr6:150327115	RAET1K	0.26	5.14	0.3	5.27e-7	Alopecia areata;
CESC	cis	rs780096	0.526	rs7594812	chr2:27611469	A/G	cg22903471	chr2:27725779	GCKR	-0.5	-7.08	-0.4	1.27e-11	Total body bone mineral density;
CESC	cis	rs12190007	0.573	rs3006218	chr6:169868769	G/A	cg15038512	chr6:170123185	PHF10	-0.54	-7.97	-0.44	4.64e-14	Obesity-related traits;
CESC	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg03188948	chr7:1209495	NA	0.56	6.41	0.37	6.55e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs72781680	0.848	rs56218741	chr2:23977377	A/C	cg20701182	chr2:24300061	SF3B14	0.63	5.54	0.32	7.13e-8	Lymphocyte counts;
CESC	cis	rs2735413	0.914	rs11150035	chr16:78066449	G/C	cg04733911	chr16:78082701	NA	-0.49	-7.7	-0.43	2.75e-13	Systolic blood pressure (alcohol consumption interaction);
CESC	cis	rs2290159	0.800	rs5746214	chr3:12644753	A/G	cg23032965	chr3:12705835	RAF1	0.52	5.69	0.33	3.27e-8	Cholesterol, total;
CESC	cis	rs3026101	0.671	rs1806240	chr17:5298320	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.43	5.68	0.33	3.57e-8	Body mass index;
CESC	cis	rs6831352	0.918	rs13143133	chr4:100054970	A/G	cg13256891	chr4:100009986	ADH5	-0.77	-8.45	-0.46	1.97e-15	Alcohol dependence;
CESC	cis	rs6142102	0.625	rs4911384	chr20:32555807	C/T	cg08999081	chr20:33150536	PIGU	0.34	5.03	0.3	9.02e-7	Skin pigmentation;
CESC	trans	rs10411161	0.702	rs75647161	chr19:52398984	T/C	cg22319618	chr22:45562946	NUP50	-0.75	-7.3	-0.41	3.33e-12	Breast cancer;
CESC	cis	rs13382862	0.895	rs13385499	chr2:20882413	A/G	cg05481257	chr2:20870211	GDF7	-0.38	-5.79	-0.33	2.02e-8	Abdominal aortic aneurysm;
CESC	cis	rs1005277	0.541	rs2263163	chr10:38389887	G/A	cg25517755	chr10:38738941	LOC399744	-0.46	-5.89	-0.34	1.17e-8	Extrinsic epigenetic age acceleration;
CESC	cis	rs4595586	0.546	rs11609849	chr12:39258090	C/G	cg26384229	chr12:38710491	ALG10B	0.69	10.45	0.54	1.25e-21	Morning vs. evening chronotype;
CESC	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.88	13.4	0.64	1.29e-31	Prudent dietary pattern;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18355869	chr19:55897121	RPL28	0.63	6.98	0.39	2.41e-11	Gut microbiome composition (summer);
CESC	cis	rs11997175	0.653	rs7005254	chr8:33641781	A/T	ch.8.33884649F	chr8:33765107	NA	0.54	6.74	0.38	9.86e-11	Body mass index;
CESC	cis	rs1801251	0.778	rs709934	chr2:233733352	A/G	cg08000102	chr2:233561755	GIGYF2	-0.59	-8.18	-0.45	1.19e-14	Coronary artery disease;
CESC	cis	rs7618915	0.547	rs33967311	chr3:52683864	G/T	cg05564831	chr3:52568323	NT5DC2	0.45	7.11	0.4	1.06e-11	Bipolar disorder;
CESC	cis	rs17293817	0.617	rs36024747	chr10:1410594	G/C	cg04271617	chr10:1416546	ADARB2	0.33	5.05	0.3	8.13e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs5758659	0.714	rs5758589	chr22:42518382	A/G	cg15557168	chr22:42548783	NA	0.42	6.46	0.37	4.94e-10	Cognitive function;
CESC	cis	rs9549260	0.755	rs9577091	chr13:41227865	G/A	cg21288729	chr13:41239152	FOXO1	0.65	8.51	0.46	1.27e-15	Red blood cell count;
CESC	cis	rs3859192	0.599	rs34342173	chr17:38161507	T/C	cg17467752	chr17:38218738	THRA	-0.44	-5.86	-0.34	1.37e-8	White blood cell count;
CESC	cis	rs79976124	0.837	rs11751145	chr6:66642039	T/C	cg07460842	chr6:66804631	NA	0.69	8.25	0.45	7.48e-15	Type 2 diabetes;
CESC	cis	rs5758659	0.716	rs2143138	chr22:42618340	T/C	cg00645731	chr22:42541494	CYP2D7P1	-0.31	-5.35	-0.31	1.92e-7	Cognitive function;
CESC	cis	rs1218582	0.772	rs4845689	chr1:154885524	A/G	cg09359103	chr1:154839909	KCNN3	-0.65	-12.23	-0.6	1.46e-27	Prostate cancer;
CESC	cis	rs7809950	0.953	rs3094383	chr7:107143164	G/A	cg23024343	chr7:107201750	COG5	-0.43	-6.08	-0.35	4.11e-9	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26807261	chr1:202857904	RABIF	0.54	6.07	0.35	4.32e-9	Gut microbiome composition (summer);
CESC	cis	rs1448094	0.740	rs4919774	chr12:86337560	G/T	cg02569458	chr12:86230093	RASSF9	0.45	6.34	0.36	9.64e-10	Major depressive disorder;
CESC	cis	rs10779751	0.686	rs1148478	chr1:11174067	A/T	cg08854313	chr1:11322531	MTOR	0.73	8.67	0.47	4.47e-16	Body mass index;
CESC	cis	rs2952156	0.920	rs2934953	chr17:37832315	T/A	cg00129232	chr17:37814104	STARD3	-0.71	-9.35	-0.5	3.86e-18	Asthma;
CESC	cis	rs17655565	1.000	rs17126640	chr12:52704991	C/T	cg08257133	chr12:52711352	KRT83	0.49	6.06	0.35	4.57e-9	Plasma amyloid beta peptide concentrations (ABx-42);
CESC	cis	rs3026101	0.671	rs62072674	chr17:5317806	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.4	5.22	0.31	3.64e-7	Body mass index;
CESC	cis	rs2652834	1.000	rs7182618	chr15:63398622	T/C	cg05507819	chr15:63340323	TPM1	0.57	5.26	0.31	2.95e-7	HDL cholesterol;
CESC	cis	rs9287719	0.967	rs6759100	chr2:10746710	A/G	cg00105475	chr2:10696890	NA	0.38	5.55	0.32	6.76e-8	Prostate cancer;
CESC	cis	rs9303401	0.659	rs8074016	chr17:56840587	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.96	12.11	0.6	3.74e-27	Cognitive test performance;
CESC	cis	rs2180341	1.000	rs6903878	chr6:127638600	C/G	cg27446573	chr6:127587934	RNF146	1.09	16.38	0.71	3.79e-42	Breast cancer;
CESC	cis	rs1790761	0.692	rs1148883	chr11:67304686	A/G	cg00290607	chr11:67383545	NA	0.4	5.76	0.33	2.36e-8	Mean corpuscular volume;
CESC	cis	rs11785400	0.793	rs9297972	chr8:143723660	C/T	cg10596483	chr8:143751796	JRK	0.42	5.36	0.31	1.84e-7	Schizophrenia;
CESC	cis	rs9894429	0.789	rs35887231	chr17:79587126	G/A	cg18240062	chr17:79603768	NPLOC4	0.89	13.21	0.63	6.03e-31	Eye color traits;
CESC	cis	rs2463822	0.583	rs72919462	chr11:62035663	G/A	cg06239285	chr11:62104954	ASRGL1	-1.03	-8.34	-0.46	4.02e-15	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs9790314	0.560	rs1450521	chr3:161091237	C/A	cg03342759	chr3:160939853	NMD3	-0.41	-5.73	-0.33	2.72e-8	Morning vs. evening chronotype;
CESC	cis	rs9611565	0.506	rs2024567	chr22:41699206	G/C	cg03806693	chr22:41940476	POLR3H	-0.78	-8.92	-0.48	7.96e-17	Vitiligo;
CESC	cis	rs13108904	0.967	rs900027	chr4:1279360	G/A	cg00684032	chr4:1343700	KIAA1530	0.4	5.56	0.32	6.51e-8	Obesity-related traits;
CESC	cis	rs12701220	0.817	rs1058729	chr7:1087283	C/T	cg26769984	chr7:1090371	C7orf50	0.58	6.91	0.39	3.68e-11	Bronchopulmonary dysplasia;
CESC	trans	rs17685	0.753	rs4732595	chr7:75755139	A/G	cg19862616	chr7:65841803	NCRNA00174	0.85	12.57	0.61	1e-28	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs939658	0.805	rs12902831	chr15:79433171	G/A	cg17916960	chr15:79447300	NA	-0.36	-5.97	-0.34	7.73e-9	Refractive error;
CESC	cis	rs1707322	0.893	rs9919275	chr1:46441360	A/C	cg06784218	chr1:46089804	CCDC17	0.33	5.63	0.33	4.7e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs55728055	0.661	rs41302569	chr22:32046953	C/A	cg01338084	chr22:32026380	PISD	1.26	8.24	0.45	8.13e-15	Age-related hearing impairment;
CESC	cis	rs5747327	0.809	rs4819623	chr22:18208641	G/A	cg19898043	chr22:18121309	BCL2L13	-0.4	-5.12	-0.3	6e-7	Myeloid white cell count;Granulocyte count;
CESC	cis	rs7089973	0.872	rs11818114	chr10:116634878	G/C	cg25233709	chr10:116636983	FAM160B1	0.34	5.03	0.3	9.07e-7	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs2404602	0.692	rs7174673	chr15:77071998	T/C	cg22467129	chr15:76604101	ETFA	-0.34	-5.16	-0.3	4.84e-7	Blood metabolite levels;
CESC	cis	rs2425143	1.000	rs2378409	chr20:34392464	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.68	5.93	0.34	9.19e-9	Blood protein levels;
CESC	cis	rs9311474	1.000	rs1060330	chr3:52288945	T/C	cg05564831	chr3:52568323	NT5DC2	0.44	6.9	0.39	3.9e-11	Electroencephalogram traits;
CESC	trans	rs7618501	1.000	rs6785549	chr3:49736565	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.58	-8.34	-0.46	4.21e-15	Intelligence (multi-trait analysis);
CESC	cis	rs2070488	0.965	rs1046048	chr3:38524742	C/T	cg24069376	chr3:38537580	EXOG	0.49	9.02	0.48	3.79e-17	Electrocardiographic conduction measures;
CESC	cis	rs11112613	0.713	rs12580741	chr12:105941328	A/G	cg03607813	chr12:105948248	NA	-0.57	-6.87	-0.39	4.51e-11	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CESC	cis	rs1018836	0.608	rs6986165	chr8:91477062	C/G	cg16814680	chr8:91681699	NA	-0.57	-7.83	-0.43	1.17e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs1881797	0.932	rs41305741	chr1:247689543	A/G	cg18198730	chr1:247681584	NA	0.59	7.77	0.43	1.76e-13	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs1577917	1.000	rs12664335	chr6:86597774	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.49	6.53	0.37	3.42e-10	Response to antipsychotic treatment;
CESC	cis	rs7927771	0.524	rs7933896	chr11:47882782	C/T	cg20307385	chr11:47447363	PSMC3	0.63	8.84	0.48	1.39e-16	Subjective well-being;
CESC	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg27532560	chr4:187881888	NA	-0.4	-6.08	-0.35	4.1e-9	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.54	6.72	0.38	1.09e-10	Prudent dietary pattern;
CESC	cis	rs9457247	0.846	rs2757052	chr6:167380174	T/C	cg07741184	chr6:167504864	NA	-0.3	-5.38	-0.31	1.62e-7	Crohn's disease;
CESC	cis	rs7872515	0.536	rs4302907	chr9:94774086	T/C	cg01248375	chr9:94877805	SPTLC1	0.61	5.31	0.31	2.38e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.61	6.89	0.39	3.99e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs10870270	1.000	rs10870270	chr10:133754334	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.85	-12.55	-0.61	1.19e-28	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs4423214	0.879	rs1792281	chr11:71135496	G/A	cg05163923	chr11:71159392	DHCR7	-0.63	-7.34	-0.41	2.58e-12	Vitamin D levels;
CESC	cis	rs2991971	0.933	rs666720	chr1:46020795	T/C	cg24296786	chr1:45957014	TESK2	0.63	8.23	0.45	8.37e-15	High light scatter reticulocyte count;
CESC	cis	rs17376456	0.877	rs2085960	chr5:93399934	A/G	cg25358565	chr5:93447407	FAM172A	1.11	10.74	0.55	1.41e-22	Diabetic retinopathy;
CESC	cis	rs6543140	0.964	rs6543144	chr2:103092575	A/G	cg04239558	chr2:103089729	SLC9A4	0.5	6.43	0.37	5.76e-10	Blood protein levels;
CESC	cis	rs916888	0.610	rs142167	chr17:44795234	C/T	cg17911788	chr17:44343683	NA	0.44	6.89	0.39	4.07e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg07520141	chr5:10564205	ANKRD33B	0.48	6.52	0.37	3.44e-10	Systemic lupus erythematosus;
CESC	trans	rs1005277	0.579	rs2749616	chr10:38510993	A/T	cg27523141	chr10:43048294	ZNF37B	0.46	6.02	0.35	5.91e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs28386778	0.704	rs1051688	chr17:62006433	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.55	-6.96	-0.39	2.68e-11	Prudent dietary pattern;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg22824265	chr14:39901331	FBXO33	-0.48	-6.17	-0.35	2.52e-9	Asthma;
CESC	cis	rs8177253	0.829	rs9882812	chr3:133506127	A/G	cg12373951	chr3:133503437	NA	0.53	7.59	0.42	5.4e-13	Iron status biomarkers;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg09348431	chr8:144898112	SCRIB	-0.48	-6.76	-0.38	8.53e-11	Fibrinogen levels;
CESC	cis	rs5769765	0.955	rs7511159	chr22:50307896	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.48	-5.42	-0.32	1.35e-7	Schizophrenia;
CESC	cis	rs9311474	0.508	rs12629701	chr3:52619836	T/C	cg18099408	chr3:52552593	STAB1	-0.35	-5.94	-0.34	8.7e-9	Electroencephalogram traits;
CESC	cis	rs56399783	0.901	rs7803944	chr7:2809087	G/A	cg19731401	chr7:2775893	GNA12	0.63	5.69	0.33	3.39e-8	Childhood ear infection;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15919258	chr14:90849921	NA	-0.73	-8.86	-0.48	1.18e-16	Gut microbiome composition (summer);
CESC	trans	rs2109514	0.505	rs1633714	chr7:116022538	C/T	cg19981660	chr12:132434166	EP400	0.45	6.01	0.35	6.02e-9	Prevalent atrial fibrillation;
CESC	cis	rs1878931	0.501	rs37800	chr16:3423648	T/G	cg22508957	chr16:3507546	NAT15	0.38	5.46	0.32	1.09e-7	Body mass index (adult);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27426447	chr16:83947913	MLYCD	-0.55	-6.11	-0.35	3.48e-9	Gut microbiome composition (summer);
CESC	cis	rs6087990	0.568	rs853854	chr20:31420757	T/A	cg13636640	chr20:31349939	DNMT3B	0.74	11.29	0.57	2.18e-24	Ulcerative colitis;
CESC	cis	rs9581857	0.579	rs76657892	chr13:27997604	A/G	cg01674679	chr13:27998804	GTF3A	-0.67	-5.63	-0.33	4.51e-8	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
CESC	cis	rs2243480	1.000	rs451396	chr7:65484074	T/A	cg25894440	chr7:65020034	NA	-0.65	-5.63	-0.33	4.5e-8	Diabetic kidney disease;
CESC	cis	rs6674176	0.542	rs2906468	chr1:44319007	A/G	cg12908607	chr1:44402522	ARTN	-0.4	-5.49	-0.32	9.61e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs4835473	0.897	rs4835119	chr4:144903363	G/C	cg25736465	chr4:144833511	NA	0.4	6.12	0.35	3.42e-9	Immature fraction of reticulocytes;
CESC	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg09177884	chr7:1199841	ZFAND2A	-0.69	-9.75	-0.51	2.12e-19	Longevity;Endometriosis;
CESC	cis	rs2425143	1.000	rs8116836	chr20:34453362	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.74	-6.98	-0.39	2.3e-11	Blood protein levels;
CESC	cis	rs763121	0.853	rs5750626	chr22:38977890	G/C	cg14440974	chr22:39074834	NA	-0.4	-5.26	-0.31	2.98e-7	Menopause (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12271800	chr19:59028764	ZBTB45	-0.62	-7.17	-0.4	7.67e-12	Gut microbiome composition (summer);
CESC	cis	rs4664308	0.618	rs6722275	chr2:160893260	C/T	cg03641300	chr2:160917029	PLA2R1	-0.59	-8.51	-0.46	1.33e-15	Idiopathic membranous nephropathy;
CESC	cis	rs7809950	1.000	rs4730245	chr7:107087294	C/T	cg23024343	chr7:107201750	COG5	-0.42	-5.91	-0.34	1.06e-8	Coronary artery disease;
CESC	cis	rs9611565	0.659	rs28530678	chr22:41934961	G/C	cg17376030	chr22:41985996	PMM1	0.77	7.96	0.44	4.91e-14	Vitiligo;
CESC	trans	rs11098499	0.954	rs12499324	chr4:120393786	C/T	cg25214090	chr10:38739885	LOC399744	0.71	10.23	0.53	6.54e-21	Corneal astigmatism;
CESC	cis	rs10464366	0.544	rs6952466	chr7:39155032	A/T	cg18850127	chr7:39170497	POU6F2	0.37	5.15	0.3	4.98e-7	IgG glycosylation;
CESC	cis	rs9457247	0.935	rs401260	chr6:167405888	T/C	cg25258033	chr6:167368657	RNASET2	0.39	5.89	0.34	1.15e-8	Crohn's disease;
CESC	cis	rs4148883	0.689	rs1154415	chr4:99999033	T/C	cg12011299	chr4:100065546	ADH4	0.61	8.78	0.47	2.02e-16	Alcohol dependence;
CESC	cis	rs7607369	0.609	rs13391398	chr2:219282429	A/G	cg02176678	chr2:219576539	TTLL4	0.34	5.53	0.32	7.73e-8	Red blood cell count;Amyotrophic lateral sclerosis;
CESC	cis	rs9329289	0.510	rs12359941	chr10:2547015	G/A	cg15501526	chr10:2543763	NA	0.49	7.99	0.44	4.12e-14	Age-related hearing impairment;
CESC	cis	rs6693567	0.565	rs1313570	chr1:150342642	T/C	cg09579323	chr1:150459698	TARS2	0.46	6.05	0.35	4.93e-9	Migraine;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07404466	chr20:56064128	HMGB1L1	-0.59	-7.24	-0.41	4.76e-12	Gut microbiome composition (summer);
CESC	cis	rs1552244	1.000	rs7615646	chr3:10089773	A/C	cg00166722	chr3:10149974	C3orf24	0.52	6.38	0.36	7.91e-10	Alzheimer's disease;
CESC	cis	rs9929218	0.817	rs3114400	chr16:68719430	C/T	cg02972257	chr16:68554789	NA	0.56	6.36	0.36	8.69e-10	Colorectal cancer;
CESC	cis	rs7618915	0.547	rs13085895	chr3:52678270	G/C	cg18099408	chr3:52552593	STAB1	-0.3	-5.04	-0.3	8.71e-7	Bipolar disorder;
CESC	cis	rs9329289	1.000	rs9329289	chr10:2542389	A/G	cg18171855	chr10:2543474	NA	0.36	5.7	0.33	3.12e-8	Age-related hearing impairment;
CESC	cis	rs11758351	0.660	rs16891443	chr6:26221937	A/C	cg01420254	chr6:26195488	NA	0.77	8.49	0.46	1.48e-15	Gout;Renal underexcretion gout;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14995492	chr5:122971951	NA	-0.45	-6.02	-0.35	5.84e-9	Gut microbiome composition (summer);
CESC	cis	rs2130392	1.000	rs873686	chr4:185638876	A/G	cg21366198	chr4:185655624	MLF1IP	0.47	6.33	0.36	1.05e-9	Kawasaki disease;
CESC	cis	rs11098499	1.000	rs1011054	chr4:120202387	A/G	cg24375607	chr4:120327624	NA	-0.44	-5.23	-0.31	3.41e-7	Corneal astigmatism;
CESC	cis	rs9916302	0.851	rs11078907	chr17:37662954	C/T	cg07936489	chr17:37558343	FBXL20	-0.81	-11.96	-0.59	1.17e-26	Glomerular filtration rate (creatinine);
CESC	cis	rs7666738	0.515	rs13118898	chr4:98792893	T/A	cg05340658	chr4:99064831	C4orf37	0.58	7.25	0.41	4.5e-12	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11153306	0.818	rs1476043	chr6:111944979	G/A	cg22127309	chr6:111907043	TRAF3IP2	-0.4	-6.09	-0.35	3.87e-9	Tonsillectomy;
CESC	cis	rs2243480	0.908	rs1532573	chr7:65798802	A/G	cg12463550	chr7:65579703	CRCP	-0.73	-5.71	-0.33	3.01e-8	Diabetic kidney disease;
CESC	cis	rs13191362	0.935	rs67337490	chr6:162953961	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.77	7.22	0.41	5.52e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs875971	0.862	rs1968126	chr7:66057004	A/G	cg12463550	chr7:65579703	CRCP	-0.52	-6.62	-0.38	1.94e-10	Aortic root size;
CESC	trans	rs561341	0.941	rs550213	chr17:30317518	C/G	cg20587970	chr11:113659929	NA	-1.1	-13.92	-0.65	1.93e-33	Hip circumference adjusted for BMI;
CESC	cis	rs2303745	0.589	rs891018	chr19:17396761	C/T	cg04248312	chr19:17393744	ANKLE1	0.94	15.09	0.68	1.46e-37	Systemic lupus erythematosus;
CESC	cis	rs10504229	1.000	rs58371676	chr8:58189382	G/A	cg24829409	chr8:58192753	C8orf71	-0.76	-9.93	-0.52	5.87e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs6951245	0.882	rs10256720	chr7:1210825	C/G	cg18402987	chr7:1209562	NA	0.81	8.43	0.46	2.27e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs4566357	0.595	rs6707159	chr2:227909339	T/A	cg11843606	chr2:227700838	RHBDD1	-0.49	-6.64	-0.38	1.73e-10	Coronary artery disease;
CESC	trans	rs11098499	0.789	rs9991166	chr4:120237851	G/A	cg25214090	chr10:38739885	LOC399744	0.61	8.51	0.46	1.33e-15	Corneal astigmatism;
CESC	cis	rs12950390	0.853	rs10445375	chr17:45864314	C/T	cg00777063	chr17:45855553	NA	0.37	5.5	0.32	9.02e-8	IgG glycosylation;
CESC	cis	rs965469	0.724	rs2007022	chr20:3237674	C/A	cg25506879	chr20:3388711	C20orf194	-0.51	-5.57	-0.32	6.1e-8	IFN-related cytopenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09681706	chr7:75703103	NA	-0.57	-6.13	-0.35	3.17e-9	Gut microbiome composition (summer);
CESC	cis	rs10028773	0.666	rs35231872	chr4:120248376	A/T	cg09307838	chr4:120376055	NA	0.74	9.42	0.5	2.28e-18	Educational attainment;
CESC	cis	rs873946	0.590	rs12783478	chr10:134550700	A/G	cg26818010	chr10:134567672	INPP5A	-0.81	-10.03	-0.52	2.81e-20	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs3096299	0.967	rs2911255	chr16:89487137	C/T	cg16743903	chr16:89593216	SPG7	-0.43	-5.62	-0.33	4.73e-8	Multiple myeloma (IgH translocation);
CESC	cis	rs1552244	0.748	rs9862221	chr3:10059658	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.83	10.26	0.53	5.28e-21	Alzheimer's disease;
CESC	cis	rs7116495	0.609	rs7113520	chr11:71691946	G/A	cg10381502	chr11:71823885	C11orf51	-1.17	-7.41	-0.41	1.74e-12	Severe influenza A (H1N1) infection;
CESC	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg23978390	chr7:1156363	C7orf50	0.54	7.42	0.41	1.61e-12	Longevity;Endometriosis;
CESC	cis	rs4819052	0.851	rs2838865	chr21:46712299	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.92	13.69	0.64	1.29e-32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs820218	0.926	rs820209	chr17:73649954	C/G	cg01592526	chr17:73663357	RECQL5;SAP30BP	0.4	5.34	0.31	2.04e-7	Rotator cuff tears;
CESC	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg26338869	chr17:61819248	STRADA	0.69	9.2	0.49	1.1e-17	Prudent dietary pattern;
CESC	cis	rs9311474	0.632	rs6445528	chr3:52572447	C/T	cg07507251	chr3:52567010	NT5DC2	-0.36	-6.51	-0.37	3.84e-10	Electroencephalogram traits;
CESC	cis	rs4566357	0.615	rs1800517	chr2:227915832	G/A	cg05526886	chr2:227700861	RHBDD1	-0.5	-6.54	-0.37	3.14e-10	Coronary artery disease;
CESC	cis	rs796364	0.570	rs4673491	chr2:200669108	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.62	5.29	0.31	2.52e-7	Schizophrenia;
CESC	cis	rs10129255	0.912	rs35468694	chr14:107192436	A/C	cg23076370	chr14:107095027	NA	-0.47	-5.92	-0.34	9.93e-9	Kawasaki disease;
CESC	cis	rs1729951	0.575	rs2163896	chr3:136691177	G/A	cg25687071	chr3:136751404	NA	0.39	5.19	0.3	4.27e-7	Neuroticism;
CESC	cis	rs7927771	0.524	rs4752865	chr11:47759841	G/A	cg20307385	chr11:47447363	PSMC3	-0.58	-8.05	-0.44	2.77e-14	Subjective well-being;
CESC	cis	rs963731	0.649	rs378698	chr2:39316301	T/C	cg04010122	chr2:39346883	SOS1	-0.74	-5.39	-0.31	1.54e-7	Corticobasal degeneration;
CESC	cis	rs116095464	0.867	rs7726582	chr5:215349	C/G	cg22857025	chr5:266934	NA	-1.25	-17.87	-0.74	2.1e-47	Breast cancer;
CESC	cis	rs34286592	1.000	rs7201519	chr16:29859977	A/G	cg27338089	chr16:29820515	MAZ	0.48	5.04	0.3	8.68e-7	Multiple sclerosis;
CESC	cis	rs7618915	0.571	rs17264436	chr3:52610651	T/A	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.38	6.74	0.38	9.58e-11	Bipolar disorder;
CESC	cis	rs9796	0.621	rs28737302	chr15:41469943	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.44	-6.44	-0.37	5.52e-10	Menopause (age at onset);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg06057141	chr7:45026417	SNORA9;C7orf40	0.39	6.03	0.35	5.54e-9	Gambling;
CESC	cis	rs1008375	1.000	rs7673500	chr4:17621383	C/T	cg15017067	chr4:17643749	FAM184B	0.41	5.9	0.34	1.12e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs1862618	0.525	rs2662016	chr5:56269047	A/G	cg24549020	chr5:56110836	MAP3K1	-0.54	-5.88	-0.34	1.2e-8	Initial pursuit acceleration;
CESC	cis	rs7481584	0.624	rs451060	chr11:3056389	G/A	cg08508325	chr11:3079039	CARS	0.29	5.15	0.3	5.15e-7	Calcium levels;
CESC	cis	rs9611565	0.512	rs8141103	chr22:42136930	T/C	cg06634786	chr22:41940651	POLR3H	0.68	6.72	0.38	1.13e-10	Vitiligo;
CESC	cis	rs9291683	0.595	rs13150928	chr4:10052961	G/T	cg11266682	chr4:10021025	SLC2A9	0.68	13.68	0.64	1.38e-32	Bone mineral density;
CESC	cis	rs6740322	0.748	rs6727631	chr2:43470408	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.77	-8.36	-0.46	3.56e-15	Coronary artery disease;
CESC	cis	rs780096	0.546	rs1260320	chr2:27722416	A/G	cg24768116	chr2:27665128	KRTCAP3	0.31	5.92	0.34	9.98e-9	Total body bone mineral density;
CESC	cis	rs270601	0.770	rs932019	chr5:131599370	T/C	cg18301423	chr5:131593218	PDLIM4	0.41	5.96	0.34	8e-9	Acylcarnitine levels;
CESC	cis	rs9457247	0.579	rs2181059	chr6:167441624	T/C	cg25258033	chr6:167368657	RNASET2	0.37	5.4	0.31	1.51e-7	Crohn's disease;
CESC	cis	rs6089584	0.566	rs7274240	chr20:60622004	C/T	cg24733560	chr20:60626293	TAF4	0.48	7.2	0.4	6.09e-12	Body mass index;
CESC	cis	rs10927875	0.632	rs6699394	chr1:16145143	C/A	cg21385522	chr1:16154831	NA	-1.01	-16.43	-0.71	2.59e-42	Dilated cardiomyopathy;
CESC	trans	rs5769765	0.773	rs9616382	chr22:50312979	C/T	cg09872104	chr7:134855509	C7orf49	-0.55	-6.31	-0.36	1.19e-9	Schizophrenia;
CESC	cis	rs6460942	0.915	rs62448594	chr7:12442229	C/G	cg02935154	chr7:12443704	VWDE	-0.59	-6.31	-0.36	1.14e-9	Coronary artery disease;
CESC	cis	rs3733585	0.699	rs2018643	chr4:9947121	C/T	cg02734326	chr4:10020555	SLC2A9	0.4	5.61	0.33	5.2e-8	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs17401966	1.000	rs58549151	chr1:10314657	A/C	cg15208524	chr1:10270712	KIF1B	0.5	6.47	0.37	4.65e-10	Hepatocellular carcinoma;
CESC	cis	rs782590	0.694	rs2627775	chr2:55877113	C/T	cg18811423	chr2:55921094	PNPT1	0.71	10.47	0.54	1.06e-21	Metabolic syndrome;
CESC	cis	rs6674176	0.628	rs3791119	chr1:44431362	C/G	cg12908607	chr1:44402522	ARTN	-0.49	-6.93	-0.39	3.18e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs2836950	0.527	rs2836948	chr21:40599677	T/C	cg11890956	chr21:40555474	PSMG1	-0.6	-8.25	-0.45	7.41e-15	Menarche (age at onset);
CESC	cis	rs7395581	0.918	rs7124955	chr11:47315274	A/T	cg25783544	chr11:47291846	MADD	0.59	7.61	0.42	4.89e-13	HDL cholesterol;
CESC	cis	rs4654899	0.895	rs10916865	chr1:21136610	C/T	cg05370193	chr1:21551575	ECE1	-0.35	-5.05	-0.3	8.17e-7	Superior frontal gyrus grey matter volume;
CESC	cis	rs728616	0.510	rs35671072	chr10:82172255	A/G	cg05935833	chr10:81318306	SFTPA2	-0.41	-5.2	-0.3	4.04e-7	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs9916302	0.904	rs4357971	chr17:37717280	C/T	cg00129232	chr17:37814104	STARD3	-0.57	-7.46	-0.42	1.22e-12	Glomerular filtration rate (creatinine);
CESC	cis	rs6546550	0.901	rs11126251	chr2:70163434	A/C	cg02498382	chr2:70120550	SNRNP27	-0.41	-7.12	-0.4	1.04e-11	Prevalent atrial fibrillation;
CESC	cis	rs2797160	1.000	rs2797154	chr6:126005197	A/G	cg05901451	chr6:126070800	HEY2	-0.45	-6.53	-0.37	3.43e-10	Endometrial cancer;
CESC	cis	rs1552244	0.554	rs3732963	chr3:10048885	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.62	7.95	0.44	5.32e-14	Alzheimer's disease;
CESC	cis	rs2576037	0.526	rs2571027	chr18:44561516	C/G	cg19077165	chr18:44547161	KATNAL2	0.54	8.01	0.44	3.56e-14	Personality dimensions;
CESC	cis	rs875971	0.862	rs10240949	chr7:65804417	A/G	cg11764359	chr7:65958608	NA	-0.8	-11.89	-0.59	2.01e-26	Aortic root size;
CESC	trans	rs10518765	1.000	rs67810220	chr15:54673819	A/T	cg09098624	chr8:11558334	NA	-0.56	-6.02	-0.35	5.75e-9	Select biomarker traits;
CESC	cis	rs2243480	1.000	rs2257790	chr7:65600450	C/T	cg18252515	chr7:66147081	NA	-1.34	-13.39	-0.64	1.45e-31	Diabetic kidney disease;
CESC	trans	rs7980799	0.649	rs2389218	chr12:33680929	C/A	cg26384229	chr12:38710491	ALG10B	0.57	8.03	0.44	3.14e-14	Heart rate;Heart rate variability traits (RMSSD);
CESC	cis	rs1801251	1.000	rs6437074	chr2:233712296	C/T	cg08000102	chr2:233561755	GIGYF2	-0.68	-9.69	-0.51	3.29e-19	Coronary artery disease;
CESC	cis	rs9911578	0.934	rs58092632	chr17:57111101	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	-0.39	-5.04	-0.3	8.43e-7	Intelligence (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04072768	chr2:54683502	SPTBN1	0.52	6.18	0.35	2.36e-9	Gut microbiome composition (summer);
CESC	cis	rs2070488	0.766	rs6808093	chr3:38498160	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.79	12.54	0.61	1.2e-28	Electrocardiographic conduction measures;
CESC	cis	rs9314323	0.798	rs12682345	chr8:26218332	A/G	cg11498726	chr8:26250323	BNIP3L	0.44	6.36	0.36	8.65e-10	Red cell distribution width;
CESC	cis	rs614226	0.938	rs7963543	chr12:120923948	C/A	cg01236616	chr12:121019343	POP5	1.45	17.93	0.74	1.25e-47	Type 1 diabetes nephropathy;
CESC	cis	rs1670533	1.000	rs4690212	chr4:1054898	T/C	cg27284194	chr4:1044797	NA	0.48	6.06	0.35	4.7e-9	Recombination rate (females);
CESC	cis	rs9787249	0.957	rs1046988	chr1:40219065	A/G	cg02773041	chr1:40204384	PPIE	-0.51	-7.1	-0.4	1.14e-11	Blood protein levels;
CESC	cis	rs9303401	0.659	rs7223708	chr17:56896398	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	1.01	12.5	0.61	1.71e-28	Cognitive test performance;
CESC	cis	rs7666738	0.753	rs7659724	chr4:98944063	C/T	cg18180107	chr4:99064573	C4orf37	0.4	5.07	0.3	7.33e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9611565	0.694	rs5758389	chr22:41941749	T/C	cg03806693	chr22:41940476	POLR3H	-0.87	-11.03	-0.56	1.53e-23	Vitiligo;
CESC	cis	rs9581857	0.547	rs4612914	chr13:28049128	A/G	cg22138327	chr13:27999177	GTF3A	0.63	5.12	0.3	5.88e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
CESC	cis	rs6504663	0.596	rs7208018	chr17:48557863	C/T	cg03611598	chr17:48586076	MYCBPAP	-0.52	-6.05	-0.35	4.83e-9	Visceral fat;
CESC	cis	rs6088580	0.634	rs6142164	chr20:33006597	C/T	cg06115741	chr20:33292138	TP53INP2	-0.47	-6.02	-0.35	5.66e-9	Glomerular filtration rate (creatinine);
CESC	trans	rs814141	1.000	rs9559427	chr13:109512417	C/T	cg06824394	chr7:86846535	C7orf23	-0.63	-6.1	-0.35	3.68e-9	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
CESC	cis	rs6912958	0.712	rs4707383	chr6:88330602	T/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.32	-5.38	-0.31	1.67e-7	Monocyte percentage of white cells;
CESC	cis	rs2204008	0.806	rs11520229	chr12:38246448	C/A	cg26384229	chr12:38710491	ALG10B	0.71	10.11	0.53	1.52e-20	Bladder cancer;
CESC	cis	rs3820928	0.874	rs10177995	chr2:227781600	T/C	cg11843606	chr2:227700838	RHBDD1	-0.49	-6.59	-0.38	2.33e-10	Pulmonary function;
CESC	cis	rs13242816	1.000	rs56298491	chr7:116116687	C/T	cg04696780	chr7:116139425	CAV2	-0.58	-5.16	-0.3	4.76e-7	P wave duration;
CESC	cis	rs1800469	1.000	rs1800469	chr19:41860296	A/G	cg09537434	chr19:41945824	ATP5SL	-0.7	-8.54	-0.46	1.03e-15	Colorectal cancer;
CESC	cis	rs34172651	0.517	rs34172679	chr16:24840381	C/T	cg06028605	chr16:24865363	SLC5A11	0.55	7.81	0.43	1.34e-13	Intelligence (multi-trait analysis);
CESC	cis	rs7134594	0.677	rs2075432	chr12:109874230	A/G	cg19025524	chr12:109796872	NA	-0.39	-5.66	-0.33	3.88e-8	HDL cholesterol;
CESC	trans	rs7077164	0.607	rs1227771	chr10:71577902	C/T	cg01481902	chr6:167791153	TCP10	-0.38	-6.11	-0.35	3.52e-9	Non-alcoholic fatty liver disease histology (lobular);
CESC	cis	rs999943	0.774	rs12205634	chr6:33611667	C/G	cg14003231	chr6:33640908	ITPR3	0.74	13.79	0.65	5.63e-33	Obesity (extreme);
CESC	cis	rs1707322	1.000	rs12077974	chr1:46384141	G/A	cg03146154	chr1:46216737	IPP	0.69	8.99	0.48	4.88e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg11494091	chr17:61959527	GH2	0.72	12.39	0.61	4.12e-28	Prudent dietary pattern;
CESC	cis	rs9815354	0.767	rs73069245	chr3:41951452	G/A	cg03022575	chr3:42003672	ULK4	0.68	5.92	0.34	9.9e-9	Pulse pressure;Diastolic blood pressure;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12381575	chr19:36485972	SDHAF1	-0.67	-7.68	-0.43	2.99e-13	Gut microbiome composition (summer);
CESC	cis	rs62229266	0.563	rs6517325	chr21:37434978	T/C	cg12218747	chr21:37451666	NA	-0.37	-5.09	-0.3	6.84e-7	Mitral valve prolapse;
CESC	cis	rs6860806	0.661	rs2171247	chr5:131580234	G/T	cg09877947	chr5:131593287	PDLIM4	0.46	5.96	0.34	8.2e-9	Breast cancer;
CESC	cis	rs11122272	0.735	rs10489611	chr1:231517854	A/T	cg06096015	chr1:231504339	EGLN1	0.43	6.18	0.35	2.46e-9	Hemoglobin concentration;
CESC	cis	rs9400271	0.632	rs9400262	chr6:109591433	T/C	cg01475377	chr6:109611718	NA	-0.46	-7.18	-0.4	7.24e-12	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
CESC	cis	rs873946	0.517	rs7071784	chr10:134559980	T/C	cg26818010	chr10:134567672	INPP5A	-0.8	-9.99	-0.52	3.86e-20	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs2573652	1.000	rs1469828	chr15:100517210	A/C	cg00587665	chr15:100533223	ADAMTS17	-0.35	-5.53	-0.32	7.83e-8	Height;
CESC	cis	rs514406	0.893	rs1242326	chr1:53399104	C/A	cg16325326	chr1:53192061	ZYG11B	0.89	14.59	0.67	8.76e-36	Monocyte count;
CESC	cis	rs6912958	0.678	rs9450744	chr6:88280529	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-6.58	-0.37	2.55e-10	Monocyte percentage of white cells;
CESC	cis	rs597539	0.652	rs10792001	chr11:68637737	G/C	cg01988459	chr11:68622903	NA	-0.39	-5.21	-0.3	3.76e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs1355223	1.000	rs1355221	chr11:34758609	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.48	-6.35	-0.36	9.2e-10	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.64	7.25	0.41	4.65e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs3733585	0.673	rs4455410	chr4:9953297	C/T	cg11266682	chr4:10021025	SLC2A9	0.57	10.62	0.55	3.48e-22	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs10256972	0.521	rs871019	chr7:1105230	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.52	-6.73	-0.38	1.06e-10	Longevity;Endometriosis;
CESC	cis	rs4704187	0.687	rs6889372	chr5:74531150	A/T	cg03227963	chr5:74354835	NA	0.28	5.17	0.3	4.61e-7	Response to amphetamines;
CESC	cis	rs3806843	0.741	rs2563293	chr5:140110536	T/C	cg16179182	chr5:140090404	VTRNA1-1	0.44	5.77	0.33	2.25e-8	Depressive symptoms (multi-trait analysis);
CESC	cis	rs61008539	0.893	rs11765528	chr7:861952	C/T	cg00934597	chr7:893267	UNC84A	-0.49	-6.68	-0.38	1.39e-10	Perceived unattractiveness to mosquitoes;
CESC	cis	rs9911578	0.757	rs4793954	chr17:56629527	G/T	cg12560992	chr17:57184187	TRIM37	-0.88	-11.4	-0.57	9.56e-25	Intelligence (multi-trait analysis);
CESC	cis	rs2732480	0.538	rs2468943	chr12:48747249	G/T	cg04545296	chr12:48745243	ZNF641	-0.35	-5.78	-0.33	2.04e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs10851478	0.872	rs12591317	chr15:49945675	A/G	cg08060515	chr15:49448048	GALK2;COPS2	0.43	5.29	0.31	2.52e-7	Oral cavity cancer;
CESC	cis	rs2180341	0.961	rs7774468	chr6:127592501	G/C	cg27446573	chr6:127587934	RNF146	1.07	15.89	0.7	2.11e-40	Breast cancer;
CESC	cis	rs7552167	0.925	rs4489498	chr1:24512055	A/G	cg01960748	chr1:24522592	NA	0.46	6.58	0.37	2.5e-10	Psoriasis vulgaris;
CESC	cis	rs4819052	0.851	rs2838829	chr21:46664040	A/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.9	13.14	0.63	1.07e-30	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs7618915	0.501	rs3733041	chr3:52731598	T/C	cg05564831	chr3:52568323	NT5DC2	0.46	7.29	0.41	3.58e-12	Bipolar disorder;
CESC	cis	rs4867766	0.585	rs6878032	chr5:173950070	A/G	cg20434911	chr5:173954559	NA	0.55	5.04	0.3	8.66e-7	Stroke;
CESC	cis	rs7666738	0.830	rs28515641	chr4:98726419	G/A	cg24818145	chr4:99064322	C4orf37	0.39	5.1	0.3	6.51e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2288327	0.643	rs16866334	chr2:179336672	A/G	cg11548914	chr2:179343871	FKBP7;PLEKHA3;MIR548N	0.54	5.83	0.34	1.65e-8	Atrial fibrillation;
CESC	cis	rs11098499	0.863	rs10034450	chr4:120455649	A/G	cg24375607	chr4:120327624	NA	0.43	5.21	0.3	3.82e-7	Corneal astigmatism;
CESC	cis	rs9911578	0.935	rs9911753	chr17:56983174	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.29	0.31	2.52e-7	Intelligence (multi-trait analysis);
CESC	cis	rs5769765	0.704	rs138837	chr22:50180714	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.46	-5.14	-0.3	5.34e-7	Schizophrenia;
CESC	cis	rs4423214	1.000	rs4944955	chr11:71167677	C/T	cg05163923	chr11:71159392	DHCR7	0.84	11.56	0.58	2.73e-25	Vitamin D levels;
CESC	cis	rs2120019	1.000	rs2083731	chr15:75368538	A/C	cg17294928	chr15:75287854	SCAMP5	-0.59	-6.62	-0.38	1.97e-10	Blood trace element (Zn levels);
CESC	cis	rs7223966	1.000	rs9747164	chr17:61864787	T/C	cg11494091	chr17:61959527	GH2	0.38	5.06	0.3	7.94e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs7772486	0.686	rs1004752	chr6:146037822	G/A	cg23711669	chr6:146136114	FBXO30	-0.87	-12.9	-0.62	7e-30	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs34375054	0.724	rs4517581	chr12:125667394	A/G	cg25124228	chr12:125621409	AACS	-0.46	-5.25	-0.31	3.08e-7	Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs1568889	1.000	rs12802157	chr11:28060285	A/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.78	10.96	0.56	2.77e-23	Bipolar disorder;
CESC	cis	rs9905704	0.647	rs8077332	chr17:57105223	A/G	cg12560992	chr17:57184187	TRIM37	0.62	7.7	0.43	2.69e-13	Testicular germ cell tumor;
CESC	cis	rs875971	0.862	rs35378740	chr7:65987712	C/A	cg10691866	chr7:65817282	TPST1	-0.33	-5.39	-0.31	1.58e-7	Aortic root size;
CESC	cis	rs9322193	0.962	rs9688940	chr6:150110113	G/A	cg13206674	chr6:150067644	NUP43	0.42	5.89	0.34	1.19e-8	Lung cancer;
CESC	cis	rs617791	0.530	rs735942	chr11:65749337	A/G	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.38	-5.15	-0.3	5.05e-7	Breast cancer;
CESC	cis	rs73001065	0.901	rs739846	chr19:19419071	G/A	cg03709012	chr19:19516395	GATAD2A	0.92	6.15	0.35	2.82e-9	LDL cholesterol;
CESC	cis	rs3785574	0.927	rs2854160	chr17:61977248	C/T	cg06420487	chr17:61919686	SMARCD2	0.43	5.24	0.31	3.26e-7	Height;
CESC	cis	rs3858526	0.523	rs10742818	chr11:5882535	T/C	cg19445457	chr11:5799446	OR52N5	-0.39	-5.12	-0.3	5.77e-7	DNA methylation (variation);
CESC	cis	rs10791323	0.592	rs2851115	chr11:133705381	C/A	cg15485101	chr11:133734466	NA	0.41	6.63	0.38	1.85e-10	Childhood ear infection;
CESC	cis	rs11112613	0.713	rs12307351	chr12:105955634	T/A	cg03607813	chr12:105948248	NA	0.57	6.39	0.37	7.59e-10	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CESC	cis	rs7943191	0.805	rs12226821	chr11:62369018	C/G	cg23462726	chr11:62437636	C11orf83;C11orf48	-0.45	-5.91	-0.34	1.02e-8	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
CESC	cis	rs6951245	0.810	rs117800627	chr7:1081075	G/C	cg18402987	chr7:1209562	NA	0.71	7.16	0.4	7.98e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7259376	0.936	rs12151261	chr19:22587929	C/T	cg02657401	chr19:22469223	NA	0.26	5.12	0.3	5.76e-7	Menopause (age at onset);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg00699235	chr12:49962218	MCRS1	0.49	6.35	0.36	9.1e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs10752881	0.967	rs8179361	chr1:182974572	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.83	13.12	0.63	1.19e-30	Colorectal cancer;
CESC	cis	rs9322193	0.923	rs9767123	chr6:149981459	A/G	cg04369109	chr6:150039330	LATS1	-0.38	-5.26	-0.31	2.91e-7	Lung cancer;
CESC	cis	rs6940638	0.688	rs1028308	chr6:27129757	G/A	cg12826209	chr6:26865740	GUSBL1	0.39	5.07	0.3	7.42e-7	Intelligence (multi-trait analysis);
CESC	cis	rs6942756	1.000	rs7803052	chr7:128959427	A/G	cg02491457	chr7:128862824	NA	-0.66	-8.95	-0.48	6.38e-17	White matter hyperintensity burden;
CESC	cis	rs941873	0.805	rs8837	chr10:81114813	C/G	cg08514558	chr10:81106712	PPIF	0.35	5.92	0.34	9.89e-9	Height;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg07782113	chr6:12012564	HIVEP1	-0.5	-6.47	-0.37	4.76e-10	Asthma;
CESC	cis	rs4563143	0.675	rs73025085	chr19:29247018	C/A	cg14983838	chr19:29218262	NA	0.5	6.16	0.35	2.67e-9	Methadone dose in opioid dependence;
CESC	cis	rs7584330	0.910	rs6713555	chr2:238398182	A/G	cg14458575	chr2:238380390	NA	-0.7	-9.17	-0.49	1.38e-17	Prostate cancer;
CESC	cis	rs698833	0.961	rs1223162	chr2:44737704	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.45	5.07	0.3	7.46e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs116095464	0.558	rs7703803	chr5:292311	A/G	cg22496380	chr5:211416	CCDC127	-0.75	-8.55	-0.46	1.03e-15	Breast cancer;
CESC	cis	rs3806843	1.000	rs2240692	chr5:140183585	A/G	cg16179182	chr5:140090404	VTRNA1-1	-0.41	-5.26	-0.31	2.95e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs12618769	0.597	rs72819987	chr2:99046253	A/G	cg10123293	chr2:99228465	UNC50	0.4	5.28	0.31	2.67e-7	Bipolar disorder;
CESC	cis	rs11723261	0.582	rs116471062	chr4:163522	A/G	cg12746427	chr4:53362	ZNF718;ZNF595	0.45	5.66	0.33	3.9e-8	Immune response to smallpox vaccine (IL-6);
CESC	cis	rs1552244	0.882	rs55840655	chr3:10042690	C/T	cg00166722	chr3:10149974	C3orf24	0.48	5.92	0.34	1.01e-8	Alzheimer's disease;
CESC	cis	rs9733	0.596	rs6690725	chr1:150632322	T/C	cg17724175	chr1:150552817	MCL1	0.44	7.21	0.41	5.75e-12	Tonsillectomy;
CESC	cis	rs2075371	0.637	rs13245165	chr7:133951492	A/T	cg11752832	chr7:134001865	SLC35B4	0.53	6.79	0.38	7.51e-11	Mean platelet volume;
CESC	cis	rs2228479	0.850	rs17227263	chr16:89810598	G/A	cg14709524	chr16:89940631	TCF25	0.94	7.08	0.4	1.27e-11	Skin colour saturation;
CESC	cis	rs4563143	0.675	rs73029050	chr19:29276554	G/T	cg14983838	chr19:29218262	NA	0.48	5.7	0.33	3.26e-8	Methadone dose in opioid dependence;
CESC	cis	rs9611565	0.649	rs139553	chr22:42187199	A/G	cg06634786	chr22:41940651	POLR3H	0.45	5.08	0.3	7.27e-7	Vitiligo;
CESC	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.54	6.73	0.38	1.05e-10	Prudent dietary pattern;
CESC	cis	rs8114671	0.967	rs6088747	chr20:33754604	G/T	cg24642439	chr20:33292090	TP53INP2	0.42	5.36	0.31	1.79e-7	Height;
CESC	cis	rs360798	0.512	rs6545973	chr2:63089434	C/T	cg17519650	chr2:63277830	OTX1	0.47	5.75	0.33	2.51e-8	Coronary artery disease;
CESC	cis	rs769267	0.931	rs2965193	chr19:19454828	G/A	cg03709012	chr19:19516395	GATAD2A	-0.96	-14.12	-0.66	3.81e-34	Tonsillectomy;
CESC	cis	rs8005677	1.000	rs8006396	chr14:23380850	A/G	cg01529538	chr14:23388837	RBM23	0.51	6.87	0.39	4.64e-11	Cognitive ability (multi-trait analysis);
CESC	cis	rs10883723	0.810	rs3818470	chr10:104263675	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.54	7.43	0.42	1.49e-12	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs7523050	0.730	rs72984612	chr1:109434826	T/C	cg08274380	chr1:109419600	GPSM2	0.91	6.41	0.37	6.51e-10	Fat distribution (HIV);
CESC	cis	rs10504229	0.953	rs114806125	chr8:58182416	C/T	cg22535103	chr8:58192502	C8orf71	-0.88	-11.43	-0.57	7.29e-25	Developmental language disorder (linguistic errors);
CESC	cis	rs12477438	0.765	rs56167745	chr2:99600478	T/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.64	-8.91	-0.48	8.52e-17	Chronic sinus infection;
CESC	cis	rs7666738	0.830	rs62321587	chr4:98997958	T/C	cg05340658	chr4:99064831	C4orf37	0.8	12.33	0.6	6.73e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6088590	0.901	rs6087631	chr20:33403509	T/C	cg06115741	chr20:33292138	TP53INP2	0.6	7.37	0.41	2.11e-12	Coronary artery disease;
CESC	cis	rs7666738	0.791	rs13127542	chr4:98949159	C/T	cg03676636	chr4:99064102	C4orf37	0.33	5.1	0.3	6.4e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg05309454	chr17:79791505	FAM195B;DYSFIP1	-0.49	-7.26	-0.41	4.38e-12	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs11696501	0.694	rs6073827	chr20:44265556	T/C	cg11783356	chr20:44313418	WFDC10B	-0.33	-5.12	-0.3	5.9e-7	Brain structure;
CESC	cis	rs9660992	0.700	rs7547565	chr1:205259402	G/A	cg21643547	chr1:205240462	TMCC2	0.5	7.22	0.41	5.67e-12	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs6835098	1.000	rs10011724	chr4:174088865	A/G	cg08422745	chr4:174089978	GALNT7	-0.83	-12.26	-0.6	1.16e-27	Dementia and core Alzheimer's disease neuropathologic changes;
CESC	cis	rs4474465	0.790	rs10793325	chr11:78252575	T/C	cg27205649	chr11:78285834	NARS2	0.43	5.34	0.31	2.05e-7	Alzheimer's disease (survival time);
CESC	trans	rs6572548	0.504	rs1956082	chr14:49665496	A/C	cg17608500	chr1:154955711	FLAD1	-0.54	-6.17	-0.35	2.55e-9	Subjective well-being;
CESC	cis	rs897080	0.515	rs698767	chr2:44576417	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.52	6.16	0.35	2.64e-9	Height;
CESC	cis	rs10754283	0.967	rs7515375	chr1:90109854	T/C	cg21401794	chr1:90099060	LRRC8C	0.69	9.34	0.5	4.06e-18	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs662064	0.963	rs10864459	chr1:10563609	C/T	cg07384165	chr1:10488281	NA	0.42	5.56	0.32	6.51e-8	Asthma;
CESC	cis	rs921968	0.565	rs35189512	chr2:219628759	T/C	cg02176678	chr2:219576539	TTLL4	-0.44	-7.59	-0.42	5.38e-13	Mean corpuscular hemoglobin concentration;
CESC	cis	rs2637266	0.777	rs2637253	chr10:78311287	A/C	cg18941641	chr10:78392320	NA	-0.31	-5.73	-0.33	2.8e-8	Pulmonary function;
CESC	cis	rs829661	0.532	rs2363073	chr2:30796008	A/C	cg12454169	chr2:30669597	LCLAT1	-0.43	-5.37	-0.31	1.73e-7	Midgestational circulating levels of PBDEs (fetal genetic effect);
CESC	cis	rs270601	0.913	rs273899	chr5:131695178	G/A	cg24060327	chr5:131705240	SLC22A5	-0.75	-10.36	-0.54	2.45e-21	Acylcarnitine levels;
CESC	cis	rs8077577	0.671	rs4925177	chr17:18252868	C/G	cg16794390	chr17:18148240	FLII	0.38	6.25	0.36	1.59e-9	Obesity-related traits;
CESC	cis	rs796364	0.806	rs74771155	chr2:200913743	C/T	cg23649088	chr2:200775458	C2orf69	-0.55	-5.05	-0.3	8.29e-7	Schizophrenia;
CESC	cis	rs7202877	0.610	rs11646418	chr16:75367585	G/C	cg04384234	chr16:75411784	CFDP1	-0.54	-5.59	-0.32	5.71e-8	Type 2 diabetes;Type 1 diabetes;
CESC	cis	rs3008870	0.583	rs17497947	chr1:67457199	G/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.99	-11.11	-0.56	8.58e-24	Lymphocyte percentage of white cells;
CESC	cis	rs765787	0.530	rs12915804	chr15:45512562	T/C	cg24006582	chr15:45444508	DUOX1	0.52	6.32	0.36	1.13e-9	Uric acid levels;
CESC	cis	rs2228479	0.850	rs17226966	chr16:89825338	A/G	cg04013166	chr16:89971882	TCF25	0.79	6.75	0.38	9.14e-11	Skin colour saturation;
CESC	cis	rs875971	1.000	rs1182882	chr7:65562063	C/T	cg12463550	chr7:65579703	CRCP	-0.62	-7.78	-0.43	1.65e-13	Aortic root size;
CESC	cis	rs116161686	0.500	rs76610459	chr1:210050756	T/G	cg21951975	chr1:209979733	IRF6	0.56	6.37	0.36	8.42e-10	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26311208	chr1:59012484	OMA1	0.66	7.97	0.44	4.8e-14	Gut microbiome composition (summer);
CESC	cis	rs7772486	0.875	rs9399572	chr6:146362945	T/G	cg23711669	chr6:146136114	FBXO30	0.83	12.12	0.6	3.46e-27	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7927771	0.524	rs4752865	chr11:47759841	G/A	cg18512352	chr11:47633146	NA	-0.37	-5.75	-0.33	2.43e-8	Subjective well-being;
CESC	cis	rs9902453	1.000	rs4465649	chr17:28394747	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.62	-7.87	-0.44	9.18e-14	Coffee consumption (cups per day);
CESC	cis	rs2303745	0.589	rs891018	chr19:17396761	C/T	cg22549504	chr19:17448937	GTPBP3	-0.5	-5.53	-0.32	7.59e-8	Systemic lupus erythematosus;
CESC	cis	rs7116495	0.609	rs2845860	chr11:71716661	C/T	cg10381502	chr11:71823885	C11orf51	-1.13	-7.56	-0.42	6.78e-13	Severe influenza A (H1N1) infection;
CESC	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.69	-9.75	-0.51	2.12e-19	Longevity;Endometriosis;
CESC	cis	rs4654899	1.000	rs6426668	chr1:21396596	T/C	cg05370193	chr1:21551575	ECE1	0.39	5.84	0.34	1.55e-8	Superior frontal gyrus grey matter volume;
CESC	cis	rs9902453	0.808	rs8069669	chr17:28239502	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.78	10.37	0.54	2.25e-21	Coffee consumption (cups per day);
CESC	cis	rs55788414	0.932	rs9936302	chr16:81190790	C/T	cg06400318	chr16:81190750	PKD1L2	-0.68	-7.57	-0.42	6.2800000000000005e-13	Left ventricular obstructive tract defect (maternal effect);
CESC	cis	rs7178572	0.889	rs11857450	chr15:77802791	C/G	cg22256960	chr15:77711686	NA	0.57	7.6	0.42	4.97e-13	Type 2 diabetes;
CESC	trans	rs61931739	0.500	rs7306435	chr12:34482933	A/G	cg26384229	chr12:38710491	ALG10B	-0.7	-10.4	-0.54	1.86e-21	Morning vs. evening chronotype;
CESC	cis	rs35306767	0.714	rs67205460	chr10:1090366	C/T	cg26597838	chr10:835615	NA	0.63	5.98	0.34	7.22e-9	Eosinophil percentage of granulocytes;
CESC	cis	rs9486715	0.867	rs2499774	chr6:97006581	C/G	cg06623918	chr6:96969491	KIAA0776	-0.96	-15.21	-0.68	5.36e-38	Headache;
CESC	cis	rs9814567	1.000	rs4955555	chr3:134286427	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.45	-6.05	-0.35	4.79e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs854765	0.547	rs9897761	chr17:17912011	A/T	cg09796270	chr17:17721594	SREBF1	0.39	5.47	0.32	1.06e-7	Total body bone mineral density;
CESC	cis	rs9399135	1.000	rs1014021	chr6:135334600	C/T	cg22676075	chr6:135203613	NA	-0.48	-6.81	-0.39	6.44e-11	Red blood cell count;
CESC	cis	rs8067354	0.958	rs8081468	chr17:57836924	A/G	cg02344993	chr17:57696989	CLTC	0.48	6.29	0.36	1.29e-9	Hemoglobin concentration;
CESC	cis	rs7129220	0.512	rs7936409	chr11:10086260	A/C	cg01453529	chr11:10209919	SBF2	-0.47	-5.27	-0.31	2.79e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CESC	cis	rs853679	0.546	rs200954	chr6:27838764	C/G	cg26587870	chr6:27730563	NA	-0.57	-5.14	-0.3	5.29e-7	Depression;
CESC	cis	rs9905704	0.756	rs302860	chr17:56695008	C/A	cg12560992	chr17:57184187	TRIM37	0.62	7.73	0.43	2.17e-13	Testicular germ cell tumor;
CESC	cis	rs4975709	0.569	rs2353583	chr5:1858834	G/C	cg10800226	chr5:1850261	NA	0.36	5.74	0.33	2.64e-8	Cardiovascular disease risk factors;
CESC	cis	rs1018836	0.828	rs10086462	chr8:91558089	A/G	cg16814680	chr8:91681699	NA	-0.64	-9.15	-0.49	1.58e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs6142102	0.625	rs4012234	chr20:32553047	T/G	cg08999081	chr20:33150536	PIGU	0.34	5.1	0.3	6.63e-7	Skin pigmentation;
CESC	cis	rs11098499	0.909	rs1809406	chr4:120377122	G/A	cg09307838	chr4:120376055	NA	0.96	13.95	0.65	1.6e-33	Corneal astigmatism;
CESC	cis	rs8067354	0.540	rs1051424	chr17:58024324	A/G	cg13753209	chr17:57696993	CLTC	0.52	5.49	0.32	9.51e-8	Hemoglobin concentration;
CESC	cis	rs7560272	0.501	rs12713789	chr2:73945600	A/G	cg20560298	chr2:73613845	ALMS1	0.41	5.69	0.33	3.43e-8	Schizophrenia;
CESC	cis	rs7208859	0.623	rs7212991	chr17:29143749	T/C	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.1e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs10832963	1.000	rs4757676	chr11:18640477	C/T	cg09201001	chr11:18656081	SPTY2D1	0.82	12.36	0.6	5.21e-28	Breast cancer;
CESC	cis	rs6831352	0.877	rs28987101	chr4:100049253	T/G	cg12011299	chr4:100065546	ADH4	-0.59	-6.52	-0.37	3.62e-10	Alcohol dependence;
CESC	cis	rs2842992	0.714	rs2495278	chr6:160123674	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.72	9.18	0.49	1.27e-17	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs10851478	0.500	rs10519225	chr15:49720778	G/A	cg08060515	chr15:49448048	GALK2;COPS2	0.52	6.7	0.38	1.23e-10	Oral cavity cancer;
CESC	cis	rs7827545	1.000	rs4909909	chr8:135564627	T/C	cg17885191	chr8:135476712	NA	0.48	6.28	0.36	1.39e-9	Hypertension (SNP x SNP interaction);
CESC	cis	rs7216064	0.911	rs12449442	chr17:65947640	G/A	cg07042672	chr17:66097459	LOC651250	-0.54	-5.84	-0.34	1.55e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs763121	0.853	rs5750664	chr22:39072769	C/T	cg21395723	chr22:39101663	GTPBP1	0.42	5.32	0.31	2.17e-7	Menopause (age at onset);
CESC	cis	rs2933343	0.951	rs789220	chr3:128592135	A/G	cg25356066	chr3:128598488	ACAD9	-0.52	-6.89	-0.39	4.17e-11	IgG glycosylation;
CESC	cis	rs9430161	0.579	rs10864486	chr1:11040979	A/G	cg02454025	chr1:11042201	C1orf127	0.87	13.55	0.64	3.81e-32	Ewing sarcoma;
CESC	cis	rs208520	0.634	rs3909071	chr6:66836947	T/C	cg07460842	chr6:66804631	NA	-0.97	-13.05	-0.63	2.22e-30	Exhaled nitric oxide output;
CESC	cis	rs4474465	0.850	rs10793329	chr11:78265655	G/C	cg27205649	chr11:78285834	NARS2	0.43	5.47	0.32	1.07e-7	Alzheimer's disease (survival time);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27013765	chr3:197402007	MIR922;KIAA0226	-0.56	-6.01	-0.35	6.19e-9	Gut microbiome composition (summer);
CESC	cis	rs727505	1.000	rs6943653	chr7:124512249	G/A	cg23710748	chr7:124431027	NA	-0.48	-7.52	-0.42	8.73e-13	Lewy body disease;
CESC	cis	rs425277	0.606	rs12082939	chr1:2078922	C/T	cg12718519	chr1:2058417	PRKCZ	0.26	5.59	0.32	5.72e-8	Height;
CESC	trans	rs7618501	1.000	rs9855505	chr3:49792158	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.59	-8.4	-0.46	2.72e-15	Intelligence (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18159230	chr1:169076004	ATP1B1	0.56	6.32	0.36	1.11e-9	Gut microbiome composition (summer);
CESC	cis	rs7635838	0.859	rs9826803	chr3:11461863	G/A	cg00170343	chr3:11313890	ATG7	0.46	6.02	0.35	5.77e-9	HDL cholesterol;
CESC	cis	rs1552244	0.572	rs68013239	chr3:10165711	G/T	cg00149659	chr3:10157352	C3orf10	1.0	11.96	0.59	1.22e-26	Alzheimer's disease;
CESC	cis	rs7777484	0.534	rs2533888	chr7:2831083	T/C	cg19717773	chr7:2847554	GNA12	-0.7	-12.08	-0.6	4.61e-27	Height;
CESC	cis	rs854765	0.547	rs7209003	chr17:17907393	T/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.54	7.72	0.43	2.32e-13	Total body bone mineral density;
CESC	cis	rs34779708	0.966	rs11010102	chr10:35411066	T/A	cg04310649	chr10:35416472	CREM	-0.55	-6.76	-0.38	8.85e-11	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs7809950	1.000	rs4727680	chr7:107087407	T/G	cg23024343	chr7:107201750	COG5	-0.41	-5.87	-0.34	1.27e-8	Coronary artery disease;
CESC	cis	rs7772486	0.720	rs6901888	chr6:146023144	A/G	cg23711669	chr6:146136114	FBXO30	-1.0	-15.54	-0.69	3.89e-39	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2180341	0.782	rs4897214	chr6:127723625	G/T	cg24812749	chr6:127587940	RNF146	0.83	12.07	0.6	5.14e-27	Breast cancer;
CESC	cis	rs854765	0.927	rs12943914	chr17:17980671	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.43	5.86	0.34	1.4e-8	Total body bone mineral density;
CESC	cis	rs6460942	0.591	rs4721078	chr7:12334657	T/A	cg20607287	chr7:12443886	VWDE	-0.63	-6.83	-0.39	5.83e-11	Coronary artery disease;
CESC	cis	rs7666738	0.800	rs28427190	chr4:98989106	A/G	cg18180107	chr4:99064573	C4orf37	0.4	5.2	0.3	3.92e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs8073060	0.586	rs35542792	chr17:33903886	A/G	cg19694781	chr19:47549865	TMEM160	0.71	6.81	0.39	6.34e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg06873352	chr17:61820015	STRADA	0.73	13.07	0.63	1.78e-30	Prudent dietary pattern;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg21159473	chr9:15510228	PSIP1	-0.41	-6.03	-0.35	5.38e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs10504229	0.953	rs57669205	chr8:58172253	T/C	cg24829409	chr8:58192753	C8orf71	-0.76	-9.91	-0.52	6.75e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs926392	0.965	rs6129167	chr20:37689228	C/T	cg16355469	chr20:37678765	NA	-0.4	-5.17	-0.3	4.56e-7	Dialysis-related mortality;
CESC	trans	rs561341	1.000	rs535151	chr17:30317405	C/T	cg27661571	chr11:113659931	NA	-0.55	-6.17	-0.35	2.52e-9	Hip circumference adjusted for BMI;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25101327	chr2:119981142	STEAP3	0.63	7.31	0.41	3.14e-12	Gut microbiome composition (summer);
CESC	cis	rs1008375	1.000	rs7661631	chr4:17679751	T/C	cg16339924	chr4:17578868	LAP3	-0.56	-6.93	-0.39	3.14e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs7772486	0.846	rs2748499	chr6:146315002	T/C	cg23711669	chr6:146136114	FBXO30	0.83	12.06	0.6	5.43e-27	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7520050	0.807	rs3013595	chr1:46153203	G/A	cg06784218	chr1:46089804	CCDC17	0.32	5.8	0.34	1.88e-8	Red blood cell count;Reticulocyte count;
CESC	cis	rs9487051	0.872	rs1521908	chr6:109613986	T/C	cg12927641	chr6:109611667	NA	-0.43	-6.81	-0.39	6.43e-11	Reticulocyte fraction of red cells;
CESC	cis	rs911555	0.504	rs8021368	chr14:104074810	G/A	cg12935359	chr14:103987150	CKB	-0.52	-7.55	-0.42	6.85e-13	Intelligence (multi-trait analysis);
CESC	cis	rs798554	0.759	rs1636255	chr7:2892804	A/C	cg19717773	chr7:2847554	GNA12	0.46	6.52	0.37	3.55e-10	Height;
CESC	cis	rs4819052	0.766	rs4819035	chr21:46645715	A/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.69	8.16	0.45	1.34e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs2303759	1.000	rs2303759	chr19:49869051	T/G	cg22590775	chr19:49891494	CCDC155	0.58	6.97	0.39	2.46e-11	Multiple sclerosis;
CESC	cis	rs2050392	0.624	rs2489842	chr10:30721991	T/C	cg02070205	chr10:30722105	MAP3K8	-0.47	-5.5	-0.32	8.84e-8	Inflammatory bowel disease;
CESC	cis	rs12617721	0.874	rs3754890	chr2:99088624	C/T	cg10123293	chr2:99228465	UNC50	0.39	5.13	0.3	5.6e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	trans	rs11088226	0.681	rs9622	chr21:33951068	T/C	cg09050820	chr6:167586206	TCP10L2	0.96	10.26	0.53	5.13e-21	Gastritis;
CESC	cis	rs2072499	0.865	rs2758608	chr1:156202860	A/T	cg24450063	chr1:156163899	SLC25A44	0.8	11.95	0.59	1.24e-26	Testicular germ cell tumor;
CESC	cis	rs7044106	0.791	rs10818473	chr9:123484155	A/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.38	6.22	0.36	1.9e-9	Hip circumference adjusted for BMI;
CESC	cis	rs1461503	0.934	rs7121840	chr11:122845360	A/G	cg27398637	chr11:122830231	C11orf63	-0.55	-8.03	-0.44	3.2e-14	Menarche (age at onset);
CESC	cis	rs6951245	0.507	rs10227709	chr7:1180515	T/G	cg03188948	chr7:1209495	NA	0.45	5.17	0.3	4.66e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs9914544	0.966	rs7210746	chr17:18798593	T/C	cg26378065	chr17:18585709	ZNF286B	0.46	5.7	0.33	3.25e-8	Educational attainment (years of education);
CESC	cis	rs1348850	0.914	rs4893961	chr2:178411075	A/G	cg23306229	chr2:178417860	TTC30B	0.62	7.94	0.44	5.89e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs10911251	0.528	rs10911263	chr1:183115018	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.87	13.8	0.65	5.11e-33	Colorectal cancer;
CESC	trans	rs1814175	0.645	rs847630	chr11:49926360	C/T	cg03929089	chr4:120376271	NA	-0.92	-15.2	-0.68	6e-38	Height;
CESC	cis	rs9303280	0.901	rs12103884	chr17:38045725	C/T	cg19468946	chr17:37922297	IKZF3	-0.42	-5.63	-0.33	4.63e-8	Self-reported allergy;
CESC	cis	rs514406	0.861	rs7417821	chr1:53295117	A/G	cg25767906	chr1:53392781	SCP2	-0.42	-5.86	-0.34	1.37e-8	Monocyte count;
CESC	cis	rs523516	0.645	rs16527	chr17:37322080	T/C	cg20555674	chr17:37321631	ARL5C	0.37	6.25	0.36	1.6e-9	IgG glycosylation;
CESC	cis	rs9303401	0.659	rs11079357	chr17:56902778	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	1.01	12.45	0.61	2.57e-28	Cognitive test performance;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg27138727	chr3:107150777	NA	-0.47	-6.12	-0.35	3.26e-9	Height;
CESC	cis	rs11792861	0.926	rs17628095	chr9:111889172	A/G	cg05043794	chr9:111880884	C9orf5	0.38	6.07	0.35	4.37e-9	Menarche (age at onset);
CESC	cis	rs8092503	1.000	rs12956220	chr18:52481750	A/T	cg12377874	chr18:52495404	RAB27B	0.39	6.38	0.36	8.04e-10	Childhood body mass index;
CESC	cis	rs7613875	0.620	rs13079006	chr3:49996924	G/T	cg24110177	chr3:50126178	RBM5	-0.56	-7.62	-0.42	4.63e-13	Body mass index;
CESC	cis	rs798554	0.679	rs2527681	chr7:2892384	A/T	cg13628971	chr7:2884303	GNA12	0.65	8.78	0.47	2.04e-16	Height;
CESC	cis	rs4727027	0.716	rs4727020	chr7:148837317	C/T	cg23158103	chr7:148848205	ZNF398	-0.35	-5.29	-0.31	2.52e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs13191362	0.935	rs34141091	chr6:162953893	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.8	7.66	0.43	3.61e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs9916302	0.861	rs11078912	chr17:37671490	A/G	cg07936489	chr17:37558343	FBXL20	-0.78	-11.94	-0.59	1.45e-26	Glomerular filtration rate (creatinine);
CESC	cis	rs9318086	0.935	rs9652081	chr13:24435510	C/T	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.39	-5.32	-0.31	2.19e-7	Myopia (pathological);
CESC	cis	rs116095464	0.558	rs10052012	chr5:231908	T/C	cg22496380	chr5:211416	CCDC127	-0.74	-8.57	-0.47	8.98e-16	Breast cancer;
CESC	trans	rs916888	0.610	rs199529	chr17:44837217	A/C	cg22433210	chr17:43662623	NA	0.77	9.59	0.51	6.84e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs1124376	1.000	rs6771941	chr3:20157077	G/T	cg05072819	chr3:20081367	KAT2B	0.44	5.63	0.33	4.56e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs965513	1.000	rs1561962	chr9:100546219	C/T	cg13688889	chr9:100608707	NA	-0.59	-8.34	-0.46	4.03e-15	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
CESC	cis	rs12079745	0.590	rs75967403	chr1:169173497	T/G	cg09363564	chr1:169337483	NME7;BLZF1	-1.1	-6.5	-0.37	3.95e-10	QT interval;
CESC	cis	rs12971120	0.891	rs3794953	chr18:72180519	C/T	cg26446133	chr18:72167187	CNDP2	-0.75	-9.12	-0.49	1.95e-17	Refractive error;
CESC	cis	rs7267979	0.966	rs2387885	chr20:25415224	G/A	cg08601574	chr20:25228251	PYGB	-0.35	-5.04	-0.3	8.82e-7	Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg19507727	chr1:233086292	C1orf57	-0.53	-7.1	-0.4	1.12e-11	Fibrinogen levels;
CESC	cis	rs2404602	0.669	rs1875884	chr15:76638161	C/T	cg22467129	chr15:76604101	ETFA	-0.38	-5.71	-0.33	3.1e-8	Blood metabolite levels;
CESC	cis	rs875971	0.619	rs2302918	chr7:66000932	A/G	cg14393609	chr7:65229607	NA	0.47	6.26	0.36	1.51e-9	Aortic root size;
CESC	cis	rs950776	0.518	rs12906284	chr15:78825105	C/T	cg06917634	chr15:78832804	PSMA4	0.8	12.12	0.6	3.34e-27	Sudden cardiac arrest;
CESC	cis	rs9788333	0.962	rs61951450	chr13:21886354	G/A	cg25811766	chr13:21894605	NA	0.76	10.27	0.53	4.91e-21	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs1008375	0.966	rs3733576	chr4:17586703	T/C	cg02297831	chr4:17616191	MED28	0.52	5.97	0.34	7.56e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs826838	0.904	rs1554550	chr12:39208889	G/A	cg26384229	chr12:38710491	ALG10B	0.78	12.94	0.62	4.96e-30	Heart rate;
CESC	cis	rs853679	0.550	rs1233701	chr6:28168726	C/G	cg20151795	chr6:28129481	ZNF389	-0.43	-5.82	-0.34	1.73e-8	Depression;
CESC	cis	rs12497850	0.931	rs9846123	chr3:49088112	C/T	cg03060546	chr3:49711283	APEH	-0.47	-5.84	-0.34	1.56e-8	Parkinson's disease;
CESC	cis	rs34779708	0.897	rs9787566	chr10:35279455	T/A	cg03585969	chr10:35415529	CREM	0.77	10.16	0.53	1.05e-20	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs1670533	1.000	rs2045068	chr4:1052212	G/A	cg27284194	chr4:1044797	NA	0.45	5.68	0.33	3.56e-8	Recombination rate (females);
CESC	cis	rs1552244	0.882	rs35056669	chr3:10014171	C/T	cg00166722	chr3:10149974	C3orf24	0.48	5.93	0.34	9.18e-9	Alzheimer's disease;
CESC	cis	rs17401966	0.931	rs11584023	chr1:10302596	A/G	cg15208524	chr1:10270712	KIF1B	0.41	5.34	0.31	1.95e-7	Hepatocellular carcinoma;
CESC	cis	rs875971	0.862	rs9791713	chr7:66105198	C/A	cg19163074	chr7:65112434	INTS4L2	0.43	5.37	0.31	1.71e-7	Aortic root size;
CESC	cis	rs875971	0.830	rs587360	chr7:65522698	C/A	cg11764359	chr7:65958608	NA	0.89	13.11	0.63	1.31e-30	Aortic root size;
CESC	cis	rs7208859	0.673	rs7211776	chr17:29120196	T/G	cg13385521	chr17:29058706	SUZ12P	0.59	5.49	0.32	9.51e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs7264396	0.622	rs3787165	chr20:34228946	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.86	-11.84	-0.59	3.02e-26	Total cholesterol levels;
CESC	cis	rs7829975	0.714	rs11777085	chr8:8672429	G/C	cg17143192	chr8:8559678	CLDN23	0.43	5.31	0.31	2.35e-7	Mood instability;
CESC	cis	rs2576037	0.526	rs10853545	chr18:44475220	A/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.43	6.98	0.39	2.43e-11	Personality dimensions;
CESC	cis	rs887829	0.569	rs4148326	chr2:234673462	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.54	-6.92	-0.39	3.46e-11	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg13446235	chr16:90039146	AFG3L1;CENPBD1	-0.55	-7.13	-0.4	9.32e-12	Fibrinogen levels;
CESC	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg12034118	chr1:209979487	IRF6	0.8	14.38	0.66	4.65e-35	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
CESC	cis	rs734999	0.545	rs10910106	chr1:2538886	G/T	cg18854424	chr1:2615690	NA	0.3	5.83	0.34	1.65e-8	Ulcerative colitis;
CESC	cis	rs11785693	0.909	rs62489558	chr8:4968620	G/A	cg26367366	chr8:4980734	NA	0.86	7.35	0.41	2.48e-12	Neuroticism (multi-trait analysis);Neuroticism;
CESC	cis	rs1577917	0.959	rs16876540	chr6:86612519	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.49	-6.29	-0.36	1.3e-9	Response to antipsychotic treatment;
CESC	cis	rs910316	0.726	rs12882664	chr14:75446778	C/T	cg11812906	chr14:75593930	NEK9	0.79	12.28	0.6	9.31e-28	Height;
CESC	cis	rs2730245	0.527	rs2788470	chr7:158649801	G/T	cg24397884	chr7:158709396	WDR60	0.78	8.03	0.44	3.25e-14	Height;
CESC	cis	rs4727027	0.865	rs12154368	chr7:148862041	C/T	cg23583168	chr7:148888333	NA	-0.81	-12.68	-0.61	4.05e-29	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs834811	0.505	rs7789711	chr7:135938979	C/T	cg01726295	chr7:135938950	NA	-0.36	-6.45	-0.37	5.28e-10	Post-traumatic stress disorder;
CESC	cis	rs2841277	0.770	rs10149193	chr14:105403474	C/T	cg14403583	chr14:105418241	AHNAK2	-0.57	-7.86	-0.44	9.41e-14	Rheumatoid arthritis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26794364	chr3:9691143	MTMR14	0.55	6.05	0.35	5e-9	Gut microbiome composition (summer);
CESC	cis	rs6088590	0.687	rs73106933	chr20:33287425	T/C	cg24642439	chr20:33292090	TP53INP2	0.67	8.95	0.48	6.36e-17	Coronary artery disease;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg06549955	chr12:110434341	GIT2	0.49	6.59	0.38	2.31e-10	Thyroid stimulating hormone;
CESC	cis	rs2439831	0.850	rs28595038	chr15:44044859	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.71	6.68	0.38	1.43e-10	Lung cancer in ever smokers;
CESC	cis	rs4665809	0.590	rs6730317	chr2:26419482	C/T	cg08470875	chr2:26401718	FAM59B	-0.72	-7.98	-0.44	4.44e-14	Gut microbiome composition (summer);
CESC	trans	rs3942852	0.568	rs10838800	chr11:48094879	C/T	cg03929089	chr4:120376271	NA	-0.64	-7.94	-0.44	5.67e-14	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs4843747	0.605	rs4072779	chr16:88107290	C/T	cg06374794	chr16:88002281	BANP	0.39	5.16	0.3	4.78e-7	Menopause (age at onset);
CESC	cis	rs4568518	0.616	rs10950691	chr7:18006134	G/C	cg03009463	chr7:17980271	SNX13	0.44	5.79	0.34	1.98e-8	Measles;
CESC	cis	rs875971	0.862	rs35034167	chr7:65580166	C/G	cg18876405	chr7:65276391	NA	-0.55	-7.4	-0.41	1.75e-12	Aortic root size;
CESC	cis	rs1552244	1.000	rs7619340	chr3:10108178	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.8	-10.46	-0.54	1.15e-21	Alzheimer's disease;
CESC	cis	rs7267979	0.932	rs6115214	chr20:25557426	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.74	-12.84	-0.62	1.1e-29	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs1348850	0.526	rs7588049	chr2:178390778	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.71	-6.52	-0.37	3.49e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs7818688	0.697	rs11781757	chr8:95987891	A/T	cg16049864	chr8:95962084	TP53INP1	0.56	5.66	0.33	3.98e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs9905704	0.918	rs304283	chr17:56785725	C/T	cg12560992	chr17:57184187	TRIM37	0.59	7.06	0.4	1.45e-11	Testicular germ cell tumor;
CESC	cis	rs4665809	0.590	rs7586047	chr2:26447335	A/G	cg22920501	chr2:26401640	FAM59B	-0.92	-10.46	-0.54	1.19e-21	Gut microbiome composition (summer);
CESC	cis	rs738322	0.967	rs133021	chr22:38573338	T/C	cg25457927	chr22:38595422	NA	-0.35	-6.43	-0.37	6.04e-10	Cutaneous nevi;
CESC	cis	rs7824557	0.767	rs3808513	chr8:11157460	G/T	cg21775007	chr8:11205619	TDH	-0.52	-7.88	-0.44	8.28e-14	Retinal vascular caliber;
CESC	cis	rs7829975	0.846	rs7005216	chr8:8547110	C/G	cg06636001	chr8:8085503	FLJ10661	-0.48	-6.4	-0.37	6.97e-10	Mood instability;
CESC	cis	rs9527	0.590	rs10786741	chr10:104939182	G/A	cg04362960	chr10:104952993	NT5C2	0.42	5.25	0.31	3.09e-7	Arsenic metabolism;
CESC	cis	rs798502	0.522	rs7790322	chr7:2830498	C/T	cg13628971	chr7:2884303	GNA12	0.39	5.03	0.3	8.97e-7	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Inflammatory bowel disease;Waist circumference adjusted for BMI in non-smokers;Ulcerative colitis;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
CESC	cis	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg03188948	chr7:1209495	NA	0.7	6.77	0.38	8.37e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7216064	0.734	rs11653507	chr17:65892064	A/T	cg12091567	chr17:66097778	LOC651250	-0.62	-6.98	-0.39	2.31e-11	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs7223966	1.000	rs7223672	chr17:61720565	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.46	-5.26	-0.31	2.96e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs6728642	0.908	rs10203833	chr2:98017363	G/A	cg26665480	chr2:98280029	ACTR1B	-0.83	-8.16	-0.45	1.32e-14	Bipolar disorder lithium response (continuous) or schizophrenia;
CESC	cis	rs9911578	0.839	rs7208505	chr17:57187729	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.4	5.2	0.3	3.92e-7	Intelligence (multi-trait analysis);
CESC	cis	rs6088580	0.634	rs6088475	chr20:32964987	T/C	cg08999081	chr20:33150536	PIGU	-0.64	-11.19	-0.57	4.76e-24	Glomerular filtration rate (creatinine);
CESC	cis	rs9291683	0.692	rs1558489	chr4:10325489	T/A	cg11266682	chr4:10021025	SLC2A9	-0.46	-8.19	-0.45	1.12e-14	Bone mineral density;
CESC	cis	rs9910055	0.762	rs227579	chr17:42223134	A/T	cg08499158	chr17:42289980	UBTF	0.56	7.35	0.41	2.48e-12	Total body bone mineral density;
CESC	cis	rs853679	0.517	rs17711344	chr6:28077602	A/G	cg23161317	chr6:28129485	ZNF389	-0.45	-5.72	-0.33	2.89e-8	Depression;
CESC	cis	rs9916302	0.904	rs755500	chr17:37409865	C/T	cg00129232	chr17:37814104	STARD3	-0.52	-6.61	-0.38	2.06e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg10862848	chr6:42927986	GNMT	-0.26	-6.6	-0.38	2.17e-10	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs6723226	0.699	rs376914	chr2:32508393	G/C	cg02381751	chr2:32503542	YIPF4	0.82	11.74	0.59	6.4e-26	Intelligence (multi-trait analysis);
CESC	cis	rs896854	0.846	rs13254283	chr8:95914103	G/T	cg09323728	chr8:95962352	TP53INP1	-0.41	-8.96	-0.48	5.8e-17	Type 2 diabetes;
CESC	cis	rs3862260	0.509	rs1045827	chr1:120162442	C/T	cg11530693	chr1:120165357	ZNF697	-0.69	-10.51	-0.54	7.7e-22	Systemic lupus erythematosus;
CESC	cis	rs2228479	0.717	rs12917681	chr16:89810941	C/A	cg06558623	chr16:89946397	TCF25	0.78	7.41	0.41	1.69e-12	Skin colour saturation;
CESC	cis	rs2797160	1.000	rs6933302	chr6:126016951	T/C	cg05901451	chr6:126070800	HEY2	0.46	6.63	0.38	1.86e-10	Endometrial cancer;
CESC	cis	rs2439831	0.850	rs28476182	chr15:44139643	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.66	6.03	0.35	5.4e-9	Lung cancer in ever smokers;
CESC	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg24503407	chr1:205819492	PM20D1	0.93	17.07	0.72	1.4e-44	Menarche (age at onset);
CESC	cis	rs9325144	0.560	rs7304568	chr12:38632408	G/A	cg26384229	chr12:38710491	ALG10B	-0.58	-8.9	-0.48	9.2e-17	Morning vs. evening chronotype;
CESC	cis	rs2637266	0.627	rs2013238	chr10:78476272	A/C	cg18941641	chr10:78392320	NA	0.41	7.69	0.43	2.89e-13	Pulmonary function;
CESC	cis	rs597539	0.652	rs674654	chr11:68698762	G/T	cg18350739	chr11:68623251	NA	-0.44	-6.73	-0.38	1.02e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs13108904	0.967	rs11727167	chr4:1285521	A/G	cg00684032	chr4:1343700	KIAA1530	0.4	5.46	0.32	1.1e-7	Obesity-related traits;
CESC	cis	rs1008375	1.000	rs10939750	chr4:17692422	C/G	cg16339924	chr4:17578868	LAP3	0.62	7.73	0.43	2.21e-13	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs2576037	0.583	rs11660085	chr18:44529603	A/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.33	-5.13	-0.3	5.64e-7	Personality dimensions;
CESC	cis	rs7647973	0.925	rs4955439	chr3:49245645	G/T	cg06212747	chr3:49208901	KLHDC8B	-0.56	-7.06	-0.4	1.46e-11	Menarche (age at onset);
CESC	cis	rs7615952	0.576	rs1127717	chr3:125826059	T/C	cg02772935	chr3:125709198	NA	-0.45	-5.04	-0.3	8.78e-7	Blood pressure (smoking interaction);
CESC	trans	rs7937682	0.924	rs489783	chr11:111520522	A/G	cg18187862	chr3:45730750	SACM1L	0.51	6.47	0.37	4.81e-10	Primary sclerosing cholangitis;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg02059047	chr12:57634677	NDUFA4L2	-0.44	-6.09	-0.35	3.93e-9	Asthma;
CESC	cis	rs3750965	0.959	rs11228490	chr11:68860872	C/G	cg01403660	chr11:68851641	TPCN2	-0.4	-5.48	-0.32	9.88e-8	Hair color;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21915639	chr1:46769308	LRRC41;UQCRH	0.66	7.59	0.42	5.57e-13	Gut microbiome composition (summer);
CESC	cis	rs7208859	0.673	rs216418	chr17:28936537	G/A	cg04154034	chr17:28927549	LRRC37B2	0.67	6.03	0.35	5.4e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	trans	rs1728785	1.000	rs4783657	chr16:68586322	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.61	7.29	0.41	3.49e-12	Ulcerative colitis;
CESC	cis	rs12780046	0.536	rs10883315	chr10:101061053	C/T	cg27143070	chr10:101087766	CNNM1	-0.36	-5.38	-0.31	1.61e-7	Non-glioblastoma glioma;
CESC	cis	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg06080402	chr16:57481519	CIAPIN1;COQ9	-0.34	-5.06	-0.3	7.88e-7	Gambling;
CESC	cis	rs2299587	0.554	rs2283106	chr8:17754330	G/A	cg08627089	chr8:17753878	FGL1	-0.39	-5.5	-0.32	8.87e-8	Economic and political preferences;
CESC	cis	rs2836974	0.897	rs8128102	chr21:40606414	G/A	cg27266027	chr21:40555129	PSMG1	0.44	5.2	0.3	3.91e-7	Cognitive function;
CESC	cis	rs2836974	0.931	rs13625	chr21:40669083	G/T	cg27266027	chr21:40555129	PSMG1	0.44	5.18	0.3	4.48e-7	Cognitive function;
CESC	cis	rs7799006	0.606	rs4721527	chr7:2306655	G/A	cg08027265	chr7:2291960	NA	-0.58	-9.91	-0.52	6.91e-20	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg21954346	chr16:68271489	ESRP2	-0.45	-6.24	-0.36	1.73e-9	Gambling;
CESC	cis	rs3858526	0.959	rs10838901	chr11:5959128	G/A	cg13902645	chr11:5959945	NA	-0.67	-7.42	-0.41	1.56e-12	DNA methylation (variation);
CESC	trans	rs7944735	0.517	rs74763661	chr11:48233772	T/C	cg15704280	chr7:45808275	SEPT13	0.72	6.77	0.38	8.37e-11	Intraocular pressure;
CESC	cis	rs1448094	0.511	rs61930074	chr12:86218759	G/C	cg02569458	chr12:86230093	RASSF9	0.48	7.3	0.41	3.39e-12	Major depressive disorder;
CESC	cis	rs9303401	0.659	rs12940212	chr17:56674474	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.02	11.55	0.58	2.86e-25	Cognitive test performance;
CESC	cis	rs10206020	0.921	rs9678719	chr2:1549628	A/G	cg01028140	chr2:1542097	TPO	-0.47	-5.93	-0.34	9.62e-9	IgG glycosylation;
CESC	cis	rs9324022	0.790	rs7156824	chr14:101171480	C/A	cg18089426	chr14:101175970	NA	0.57	6.08	0.35	4.18e-9	Plateletcrit;
CESC	cis	rs9715521	0.677	rs4490528	chr4:59854572	T/G	cg11281224	chr4:60001000	NA	-0.51	-7.15	-0.4	8.65e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	trans	rs1814175	0.817	rs10839351	chr11:49758153	C/T	cg03929089	chr4:120376271	NA	-0.93	-15.39	-0.69	1.28e-38	Height;
CESC	cis	rs9815354	0.812	rs73069203	chr3:41938767	T/C	cg03022575	chr3:42003672	ULK4	0.71	6.44	0.37	5.46e-10	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs2294693	0.945	rs2073015	chr6:41008747	A/G	cg14769373	chr6:40998127	UNC5CL	-0.45	-5.81	-0.34	1.8e-8	Gastric cancer;Non-cardia gastric cancer;
CESC	cis	rs7084402	0.935	rs10763564	chr10:60360423	C/A	cg07615347	chr10:60278583	BICC1	0.54	8.25	0.45	7.48e-15	Refractive error;
CESC	cis	rs7640424	0.618	rs35798995	chr3:107914313	G/A	cg09227934	chr3:107805635	CD47	-0.45	-5.82	-0.34	1.66e-8	Body mass index;
CESC	cis	rs3749237	0.595	rs11130192	chr3:49467206	C/G	cg02487422	chr3:49467188	NICN1	0.56	8.1	0.45	2.02e-14	Resting heart rate;
CESC	cis	rs9611565	0.649	rs738422	chr22:42123399	C/T	cg06634786	chr22:41940651	POLR3H	0.45	5.04	0.3	8.76e-7	Vitiligo;
CESC	cis	rs3806843	1.000	rs2879089	chr5:140191893	A/T	cg26395211	chr5:140044315	WDR55	-0.41	-5.13	-0.3	5.72e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs11577318	0.853	rs7541333	chr1:26622889	C/T	cg00813993	chr1:26644493	UBXN11;CD52	-0.38	-6.1	-0.35	3.69e-9	Granulocyte percentage of myeloid white cells;
CESC	cis	rs9300255	0.509	rs641760	chr12:123518866	T/C	cg05973401	chr12:123451056	ABCB9	0.58	6.4	0.37	7.21e-10	Neutrophil percentage of white cells;
CESC	cis	rs77106637	0.769	rs11603313	chr11:72588177	G/A	cg04827223	chr11:72435913	ARAP1	-0.52	-5.53	-0.32	7.58e-8	Type 2 diabetes;
CESC	cis	rs9611565	0.918	rs9538	chr22:41755857	G/T	cg06481639	chr22:41940642	POLR3H	-0.7	-7.34	-0.41	2.63e-12	Vitiligo;
CESC	cis	rs7412746	0.658	rs1546376	chr1:150937661	A/G	cg17724175	chr1:150552817	MCL1	0.38	5.79	0.34	1.95e-8	Melanoma;
CESC	cis	rs7937682	0.824	rs539524	chr11:111477325	A/G	cg22437258	chr11:111473054	SIK2	0.71	9.54	0.51	9.65e-19	Primary sclerosing cholangitis;
CESC	cis	rs11031096	0.678	rs11031219	chr11:4197578	G/A	cg18678763	chr11:4115507	RRM1	-0.4	-5.18	-0.3	4.46e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	cis	rs801193	0.844	rs2244022	chr7:66202430	A/G	cg06456125	chr7:65229604	NA	0.41	5.73	0.33	2.71e-8	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00801868	chr3:155588370	GMPS	0.57	6.25	0.36	1.64e-9	Gut microbiome composition (summer);
CESC	cis	rs9322193	0.923	rs6913486	chr6:150026196	C/T	cg07701084	chr6:150067640	NUP43	-0.41	-5.51	-0.32	8.39e-8	Lung cancer;
CESC	trans	rs2727020	0.533	rs10839195	chr11:48973460	C/T	cg00717180	chr2:96193071	NA	-0.46	-6.17	-0.35	2.49e-9	Coronary artery disease;
CESC	cis	rs7666738	0.830	rs10009943	chr4:99021475	G/A	cg05340658	chr4:99064831	C4orf37	0.82	12.99	0.62	3.34e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6687430	0.532	rs67488812	chr1:10614804	A/G	cg20482658	chr1:10539492	PEX14	0.39	8.02	0.44	3.37e-14	Hand grip strength;
CESC	trans	rs931812	0.895	rs7831714	chr8:101913987	C/T	cg20993868	chr7:22813445	NA	0.5	6.99	0.39	2.23e-11	Attention deficit hyperactivity disorder and conduct disorder;
CESC	cis	rs75477785	0.590	rs1109430	chr1:209992501	G/A	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.93	6.05	0.35	4.8e-9	Cleft lip with or without cleft palate;
CESC	cis	rs72717009	0.825	rs867624	chr1:161467837	A/T	cg15358701	chr1:161410459	NA	-0.7	-5.65	-0.33	4.15e-8	Rheumatoid arthritis;
CESC	trans	rs6572548	0.504	rs1956082	chr14:49665496	A/C	cg12843872	chr7:90894352	FZD1	-0.58	-6.75	-0.38	9.28e-11	Subjective well-being;
CESC	cis	rs11190604	1.000	rs12219789	chr10:102213778	A/G	cg07080220	chr10:102295463	HIF1AN	0.55	5.51	0.32	8.5e-8	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs13191362	1.000	rs13213408	chr6:162998049	A/T	cg21926612	chr6:163149169	PACRG;PARK2	0.84	8.78	0.47	2.01e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs561341	1.000	rs8064843	chr17:30245744	A/G	cg13647721	chr17:30228624	UTP6	0.6	6.06	0.35	4.66e-9	Hip circumference adjusted for BMI;
CESC	cis	rs7103648	0.669	rs7927445	chr11:47780754	G/T	cg10504702	chr11:47789108	FNBP4	0.43	5.47	0.32	1.03e-7	Diastolic blood pressure;Systolic blood pressure;
CESC	cis	rs2732480	0.577	rs2732479	chr12:48736260	A/C	cg24011408	chr12:48396354	COL2A1	0.44	5.95	0.34	8.54e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs362272	0.524	rs13150241	chr4:3367281	A/G	cg08886695	chr4:3369023	RGS12	-0.43	-5.86	-0.34	1.35e-8	Serum sulfate level;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22498987	chr12:120427182	CCDC64	0.55	6.91	0.39	3.58e-11	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.791	rs13146909	chr4:98934198	C/T	cg17366294	chr4:99064904	C4orf37	0.61	8.56	0.47	9.36e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs8062405	0.573	rs8045689	chr16:28988269	C/T	cg08761264	chr16:28874980	SH2B1	0.47	5.47	0.32	1.03e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13344237	chr2:25565575	DNMT3A	0.58	6.41	0.37	6.54e-10	Gut microbiome composition (summer);
CESC	cis	rs4713118	0.662	rs469228	chr6:27970704	A/G	cg23161317	chr6:28129485	ZNF389	0.46	6.04	0.35	5.25e-9	Parkinson's disease;
CESC	cis	rs2228479	0.764	rs11641201	chr16:89983276	T/C	cg06558623	chr16:89946397	TCF25	0.75	7.06	0.4	1.46e-11	Skin colour saturation;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg14475554	chr1:209799191	LAMB3	0.54	7.81	0.43	1.31e-13	Fibrinogen levels;
CESC	cis	rs6582630	0.555	rs11182422	chr12:38522833	A/G	cg26384229	chr12:38710491	ALG10B	0.66	10.32	0.54	3.36e-21	Drug-induced liver injury (flucloxacillin);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20935025	chr14:35874013	NFKBIA	-0.61	-6.74	-0.38	9.63e-11	Gut microbiome composition (summer);
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg22783598	chr5:133747613	CDKN2AIPNL	0.47	6.11	0.35	3.55e-9	Thyroid stimulating hormone;
CESC	cis	rs6460942	0.915	rs62448619	chr7:12457743	C/T	cg10578991	chr7:12443926	VWDE	-0.5	-5.52	-0.32	7.93e-8	Coronary artery disease;
CESC	cis	rs3785574	0.962	rs2955235	chr17:61966950	A/C	cg11494091	chr17:61959527	GH2	0.41	5.66	0.33	4e-8	Height;
CESC	cis	rs7824557	0.510	rs4841524	chr8:11243126	C/G	cg21775007	chr8:11205619	TDH	-0.51	-7.53	-0.42	7.87e-13	Retinal vascular caliber;
CESC	cis	rs7072216	0.763	rs4475861	chr10:100164989	C/T	cg26618903	chr10:100175079	PYROXD2	-0.33	-5.07	-0.3	7.59e-7	Metabolite levels;
CESC	cis	rs10504229	0.683	rs55986917	chr8:58137210	C/T	cg02725872	chr8:58115012	NA	-0.45	-7.05	-0.4	1.52e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs4844614	0.904	rs4844388	chr1:207842900	G/A	cg21110645	chr1:207815933	NA	0.36	5.31	0.31	2.37e-7	LDL cholesterol;
CESC	cis	rs9300255	0.539	rs1969355	chr12:123742061	G/A	cg19016782	chr12:123741754	C12orf65	-0.36	-5.46	-0.32	1.12e-7	Neutrophil percentage of white cells;
CESC	cis	rs2777491	0.540	rs7164684	chr15:41705008	G/T	cg18705301	chr15:41695430	NDUFAF1	-1.07	-17.07	-0.72	1.45e-44	Ulcerative colitis;
CESC	cis	rs57506017	0.585	rs5011437	chr7:12268792	A/T	cg23422036	chr7:12250390	TMEM106B	0.38	5.13	0.3	5.62e-7	Neuroticism;
CESC	cis	rs6752107	0.967	rs56049444	chr2:234157688	C/T	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.38	5.78	0.33	2.07e-8	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs3096299	0.933	rs2965823	chr16:89454924	G/A	cg02187348	chr16:89574699	SPG7	0.54	7.14	0.4	8.81e-12	Multiple myeloma (IgH translocation);
CESC	cis	rs853679	0.517	rs9348793	chr6:28084189	G/A	cg26335602	chr6:28129616	ZNF389	0.53	7.06	0.4	1.48e-11	Depression;
CESC	cis	rs2777491	1.000	rs316609	chr15:41743828	T/A	cg20272979	chr15:41787780	ITPKA	0.44	6.52	0.37	3.5e-10	Ulcerative colitis;
CESC	cis	rs11696501	0.789	rs1487319	chr20:44295943	A/G	cg11783356	chr20:44313418	WFDC10B	-0.32	-5.05	-0.3	8.26e-7	Brain structure;
CESC	cis	rs9527	0.590	rs1807298	chr10:104870218	G/A	cg04362960	chr10:104952993	NT5C2	0.44	5.54	0.32	7.12e-8	Arsenic metabolism;
CESC	cis	rs2717559	0.542	rs2717560	chr8:143881670	G/A	cg17252645	chr8:143867129	LY6D	-0.32	-5.56	-0.32	6.67e-8	Urinary tract infection frequency;
CESC	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.69	-9.54	-0.51	1.01e-18	Longevity;Endometriosis;
CESC	cis	rs1728785	0.818	rs11075684	chr16:68582365	C/T	cg02972257	chr16:68554789	NA	-0.55	-6.21	-0.36	2.01e-9	Ulcerative colitis;
CESC	cis	rs34734847	1.000	rs56273049	chr12:121156041	A/T	cg21892295	chr12:121157589	UNC119B	-0.42	-6.65	-0.38	1.66e-10	Mean corpuscular volume;
CESC	cis	rs12220238	0.908	rs11000893	chr10:75905996	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.65	6.16	0.35	2.63e-9	Soluble interleukin-2 receptor subunit alpha;
CESC	cis	rs2455799	0.613	rs12485852	chr3:15914511	G/C	cg16303742	chr3:15540471	COLQ	-0.37	-5.67	-0.33	3.7e-8	Mean platelet volume;
CESC	cis	rs9549367	0.789	rs7317558	chr13:113893625	G/A	cg18105134	chr13:113819100	PROZ	-0.69	-8.64	-0.47	5.29e-16	Platelet distribution width;
CESC	trans	rs1493916	1.000	rs1493916	chr18:31392577	T/G	cg27147174	chr7:100797783	AP1S1	-0.52	-7.04	-0.4	1.62e-11	Life satisfaction;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg09825030	chr2:85568866	NA	-0.49	-6.11	-0.35	3.59e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs4971059	0.629	rs9297	chr1:155106550	A/G	cg22049894	chr1:155113146	DPM3	0.46	5.89	0.34	1.18e-8	Breast cancer;
CESC	cis	rs4604732	0.631	rs12039642	chr1:247624898	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.57	7.17	0.4	7.39e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs1008375	0.932	rs11935124	chr4:17668200	G/A	cg16339924	chr4:17578868	LAP3	-0.61	-7.19	-0.4	6.68e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs698833	0.852	rs698761	chr2:44547574	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	-0.47	-5.82	-0.34	1.66e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs250677	0.522	rs11954893	chr5:148392362	A/G	cg18129178	chr5:148520854	ABLIM3	-0.47	-5.22	-0.31	3.63e-7	Breast cancer;
CESC	cis	rs4604732	0.578	rs12036417	chr1:247624805	T/C	cg12754571	chr1:247694271	LOC148824;OR2C3	0.44	5.44	0.32	1.21e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs7772486	0.624	rs9485018	chr6:146025731	T/C	cg05347473	chr6:146136440	FBXO30	-0.52	-6.85	-0.39	5e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7103648	1.000	rs10838709	chr11:47447346	C/T	cg20307385	chr11:47447363	PSMC3	0.96	15.96	0.7	1.23e-40	Diastolic blood pressure;Systolic blood pressure;
CESC	cis	rs7089973	0.584	rs4752322	chr10:116613258	A/C	cg23260525	chr10:116636907	FAM160B1	0.41	7.83	0.43	1.17e-13	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs6570726	0.935	rs388394	chr6:145852689	C/T	cg05347473	chr6:146136440	FBXO30	0.46	6.12	0.35	3.29e-9	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs672059	0.513	rs627064	chr1:183165716	C/T	cg06211724	chr1:183155437	LAMC2	-0.35	-5.64	-0.33	4.27e-8	Hypertriglyceridemia;
CESC	cis	rs6121246	0.529	rs6060296	chr20:30198480	T/C	cg13852791	chr20:30311386	BCL2L1	0.66	6.54	0.37	3.19e-10	Mean corpuscular hemoglobin;
CESC	cis	rs9916302	0.706	rs9891892	chr17:37479856	A/C	cg07936489	chr17:37558343	FBXL20	0.89	9.66	0.51	4.24e-19	Glomerular filtration rate (creatinine);
CESC	cis	rs2180341	0.960	rs3756996	chr6:127664258	G/C	cg27446573	chr6:127587934	RNF146	1.08	15.59	0.69	2.58e-39	Breast cancer;
CESC	cis	rs17756712	0.527	rs1747586	chr6:614375	A/C	cg14374089	chr6:596013	EXOC2	0.48	5.12	0.3	5.83e-7	Vertical cup-disc ratio;
CESC	cis	rs873946	0.557	rs4880427	chr10:134591389	T/C	cg27297192	chr10:134578999	INPP5A	0.42	5.44	0.32	1.23e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs796364	1.000	rs281783	chr2:200751582	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.86	8.21	0.45	9.89e-15	Schizophrenia;
CESC	cis	rs172166	0.694	rs1631552	chr6:28089699	C/A	cg23281280	chr6:28129359	ZNF389	0.43	6.57	0.37	2.61e-10	Cardiac Troponin-T levels;
CESC	cis	rs2549003	0.966	rs839	chr5:131819126	C/T	cg21138405	chr5:131827807	IRF1	0.54	9.24	0.49	8.12e-18	Asthma (sex interaction);
CESC	trans	rs78579285	0.545	rs113385327	chr16:88785242	A/C	cg15076811	chr1:11001038	NA	0.72	6.2	0.36	2.13e-9	Joint mobility (Beighton score);
CESC	cis	rs7635838	0.684	rs2594966	chr3:11325276	A/G	cg00170343	chr3:11313890	ATG7	-0.54	-7.92	-0.44	6.42e-14	HDL cholesterol;
CESC	cis	rs763014	0.898	rs8050792	chr16:656033	T/C	cg00802000	chr16:706648	WDR90	-0.39	-6.0	-0.35	6.61e-9	Height;
CESC	cis	rs11785400	0.793	rs4336593	chr8:143739647	A/C	cg24634471	chr8:143751801	JRK	-0.47	-5.93	-0.34	9.18e-9	Schizophrenia;
CESC	cis	rs2952156	0.883	rs2941505	chr17:37832704	A/G	cg20243544	chr17:37824526	PNMT	0.63	8.01	0.44	3.74e-14	Asthma;
CESC	cis	rs7633857	0.512	rs1868109	chr3:160682500	G/A	cg03342759	chr3:160939853	NMD3	-0.39	-5.03	-0.3	9.17e-7	Educational attainment (years of education);
CESC	cis	rs1801251	1.000	rs2044449	chr2:233718808	G/A	cg25237894	chr2:233734115	C2orf82	-0.48	-8.37	-0.46	3.46e-15	Coronary artery disease;
CESC	cis	rs3105593	1.000	rs3109879	chr15:50837618	A/G	cg08437265	chr15:50716283	USP8	0.43	5.62	0.33	4.77e-8	QT interval;
CESC	cis	rs11235843	0.853	rs55910552	chr11:73525917	A/T	cg03538470	chr11:73498718	MRPL48	-0.53	-5.03	-0.3	8.92e-7	Hand grip strength;
CESC	trans	rs10934447	0.512	rs1696528	chr3:118043411	T/C	cg24652809	chr6:168813688	NA	-0.49	-6.05	-0.35	4.91e-9	Neuroticism;
CESC	cis	rs35146811	0.586	rs10267231	chr7:99595480	T/C	cg22906224	chr7:99728672	NA	0.45	5.36	0.31	1.79e-7	Coronary artery disease;
CESC	trans	rs10242455	0.571	rs11972210	chr7:99206943	A/C	cg09045935	chr12:6379348	NA	0.73	6.03	0.35	5.47e-9	Blood metabolite levels;
CESC	cis	rs875971	0.540	rs781152	chr7:65479572	T/A	cg14393609	chr7:65229607	NA	0.46	6.04	0.35	5.09e-9	Aortic root size;
CESC	cis	rs780096	0.526	rs1406295	chr2:27689700	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.3	-5.57	-0.32	6.2e-8	Total body bone mineral density;
CESC	cis	rs2342371	0.545	rs7646174	chr3:196210808	T/C	cg15048948	chr3:196158458	UBXN7	-0.39	-5.5	-0.32	9.12e-8	Fat distribution (HIV);
CESC	cis	rs9831754	0.756	rs13084140	chr3:78426004	G/A	cg06138941	chr3:78371609	NA	-0.49	-6.27	-0.36	1.5e-9	Calcium levels;
CESC	cis	rs1371867	0.846	rs1788194	chr8:101277916	T/C	cg11906718	chr8:101322791	RNF19A	0.5	6.39	0.37	7.26e-10	Atrioventricular conduction;
CESC	cis	rs7680126	0.596	rs17418533	chr4:10316941	T/C	cg00071950	chr4:10020882	SLC2A9	-0.48	-5.34	-0.31	2.03e-7	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg02737830	chr12:64616354	C12orf66	0.49	6.47	0.37	4.81e-10	Tetralogy of Fallot;
CESC	cis	rs853679	0.517	rs2275508	chr6:28094731	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.53	-6.19	-0.36	2.27e-9	Depression;
CESC	cis	rs4819052	0.851	rs8134392	chr21:46663790	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.75	-10.0	-0.52	3.38e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs7552404	1.000	rs11161511	chr1:76210477	A/G	cg03433033	chr1:76189801	ACADM	-0.61	-7.34	-0.41	2.67e-12	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs6788895	0.661	rs16862837	chr3:150469858	A/C	cg09723797	chr3:150481914	SIAH2	-0.65	-5.75	-0.33	2.42e-8	Breast cancer;
CESC	cis	rs7714584	1.000	rs13361189	chr5:150223387	A/G	cg22134413	chr5:150180641	NA	0.52	5.5	0.32	8.85e-8	Crohn's disease;
CESC	trans	rs4942242	0.663	rs1472330	chr13:44209628	A/G	cg19169023	chr15:41853346	TYRO3	0.56	7.12	0.4	1.03e-11	Response to tocilizumab in rheumatoid arthritis;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg13486387	chr9:94124044	AUH	-0.51	-6.36	-0.36	8.9e-10	Ulcerative colitis;
CESC	cis	rs4835473	0.897	rs13135627	chr4:144612252	G/A	cg25736465	chr4:144833511	NA	-0.41	-5.97	-0.34	7.63e-9	Immature fraction of reticulocytes;
CESC	cis	rs8114671	0.562	rs4911163	chr20:33470694	C/T	cg06115741	chr20:33292138	TP53INP2	0.48	5.8	0.34	1.91e-8	Height;
CESC	cis	rs929354	0.685	rs7807856	chr7:156934498	T/C	cg05182265	chr7:156933206	UBE3C	-0.49	-7.04	-0.4	1.69e-11	Body mass index;
CESC	cis	rs1847202	0.762	rs13093504	chr3:72949855	T/C	cg10804678	chr3:72788309	NA	-0.4	-5.32	-0.31	2.26e-7	Motion sickness;
CESC	cis	rs714031	1.000	rs5750869	chr22:40065332	T/C	cg21377881	chr22:40064566	CACNA1I	-0.37	-6.04	-0.35	5.21e-9	Schizophrenia;
CESC	cis	rs6032067	0.777	rs13038275	chr20:43780988	A/T	cg11264863	chr20:43835661	SEMG1	0.5	5.39	0.31	1.54e-7	Blood protein levels;
CESC	cis	rs3791556	1.000	rs3791558	chr2:240113255	G/A	cg03281426	chr2:240109471	HDAC4	0.49	5.64	0.33	4.44e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs7424096	0.613	rs17332671	chr2:37244124	C/G	cg14987922	chr2:37194071	STRN	0.49	5.4	0.32	1.45e-7	High light scatter reticulocyte percentage of red cells;
CESC	cis	rs9308731	0.644	rs1837369	chr2:111874276	C/T	cg04202892	chr2:111875749	ACOXL	0.51	7.66	0.43	3.41e-13	Chronic lymphocytic leukemia;
CESC	cis	rs5769707	1.000	rs5769707	chr22:50013402	G/T	cg05373962	chr22:49881684	NA	-0.38	-6.75	-0.38	9.34e-11	Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs6088590	1.000	rs6058111	chr20:33310999	T/C	cg06115741	chr20:33292138	TP53INP2	0.57	7.05	0.4	1.59e-11	Coronary artery disease;
CESC	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg18337363	chr3:52569053	NT5DC2	0.36	7.11	0.4	1.07e-11	Electroencephalogram traits;
CESC	cis	rs7666738	0.830	rs9994346	chr4:99037986	A/G	cg03467027	chr4:99064603	C4orf37	0.51	6.37	0.36	8.37e-10	Colonoscopy-negative controls vs population controls;
CESC	cis	rs56235845	0.964	rs11741640	chr5:176792743	G/A	cg17509989	chr5:176798049	RGS14	0.72	8.01	0.44	3.6e-14	Hemoglobin concentration;Hematocrit;
CESC	cis	rs6089584	0.927	rs2296081	chr20:60572663	G/T	cg13770153	chr20:60521292	NA	-0.44	-5.88	-0.34	1.21e-8	Body mass index;
CESC	cis	rs6662572	0.950	rs11579176	chr1:46050561	G/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.51	5.69	0.33	3.39e-8	Blood protein levels;
CESC	cis	rs9660180	0.934	rs12729990	chr1:1812035	T/A	cg05132306	chr1:1846340	CALML6	-0.31	-6.45	-0.37	5.43e-10	Body mass index;
CESC	cis	rs60871478	0.636	rs4719520	chr7:875216	C/G	cg13798912	chr7:905769	UNC84A	-0.57	-5.67	-0.33	3.76e-8	Cerebrospinal P-tau181p levels;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg05785653	chr15:45695817	SPATA5L1	-0.49	-6.1	-0.35	3.75e-9	Ulcerative colitis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16625000	chr3:184081092	POLR2H	0.63	7.3	0.41	3.28e-12	Gut microbiome composition (summer);
CESC	cis	rs910316	0.737	rs175049	chr14:75481368	C/T	cg11812906	chr14:75593930	NEK9	-0.8	-12.88	-0.62	8.29e-30	Height;
CESC	cis	rs7020830	0.931	rs7034554	chr9:37081301	A/G	cg14294708	chr9:37120828	ZCCHC7	1.28	25.5	0.84	2.85e-73	Schizophrenia;
CESC	cis	rs72945132	0.882	rs12294540	chr11:70118973	A/T	cg00319359	chr11:70116639	PPFIA1	0.79	7.83	0.43	1.15e-13	Coronary artery disease;
CESC	cis	rs9811920	0.609	rs17174947	chr3:99598884	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.59	7.22	0.41	5.61e-12	Axial length;
CESC	cis	rs3947	0.687	rs1736065	chr8:11685453	A/G	cg00262122	chr8:11665843	FDFT1	-0.5	-5.14	-0.3	5.23e-7	Blood protein levels;
CESC	cis	rs11030122	0.673	rs11030660	chr11:4043268	T/C	cg18678763	chr11:4115507	RRM1	-0.49	-6.63	-0.38	1.91e-10	Mean platelet volume;Platelet distribution width;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09573809	chr19:58874563	ZNF497	0.53	6.16	0.35	2.69e-9	Gut microbiome composition (summer);
CESC	cis	rs6860806	0.695	rs11952099	chr5:131576772	A/G	cg22638593	chr5:131593259	PDLIM4	0.4	5.24	0.31	3.26e-7	Breast cancer;
CESC	cis	rs6502050	0.528	rs12942561	chr17:80116639	G/A	cg23985595	chr17:80112537	CCDC57	-0.41	-6.46	-0.37	4.88e-10	Life satisfaction;
CESC	trans	rs7690543	0.579	rs12498828	chr4:67996799	C/T	cg05505961	chr17:66375071	ARSG	-0.53	-6.17	-0.35	2.6e-9	Glucose homeostasis traits;
CESC	cis	rs875971	0.540	rs1723268	chr7:65473080	A/C	cg26939375	chr7:64535504	NA	0.75	10.67	0.55	2.37e-22	Aortic root size;
CESC	cis	rs270601	0.770	rs10463891	chr5:131597392	C/T	cg04518342	chr5:131593106	PDLIM4	-0.42	-6.39	-0.37	7.57e-10	Acylcarnitine levels;
CESC	cis	rs763121	0.853	rs5750633	chr22:38993467	A/G	cg06544989	chr22:39130855	UNC84B	0.5	9.21	0.49	1e-17	Menopause (age at onset);
CESC	trans	rs7937682	0.961	rs4935790	chr11:111633014	T/C	cg18187862	chr3:45730750	SACM1L	-0.56	-6.16	-0.35	2.67e-9	Primary sclerosing cholangitis;
CESC	trans	rs9929218	0.871	rs1862748	chr16:68832943	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.64	-8.32	-0.46	4.57e-15	Colorectal cancer;
CESC	cis	rs6866344	0.570	rs1071881	chr5:178135917	C/T	cg03877680	chr5:178157825	ZNF354A	0.83	10.2	0.53	8.29e-21	Neutrophil percentage of white cells;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg19512021	chr11:95524497	CEP57	0.46	6.58	0.37	2.51e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs412050	0.696	rs76843711	chr22:22262093	C/A	cg17089214	chr22:22089827	YPEL1	0.74	6.09	0.35	3.88e-9	Attention deficit hyperactivity disorder;
CESC	cis	rs7100689	0.556	rs946893	chr10:82023524	A/G	cg00277334	chr10:82204260	NA	-0.51	-6.49	-0.37	4.22e-10	Post bronchodilator FEV1;
CESC	trans	rs916888	0.531	rs183211	chr17:44788310	G/A	cg22968622	chr17:43663579	NA	0.79	10.7	0.55	1.92e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs1514687	0.534	rs11694726	chr2:1460220	C/T	cg13703866	chr2:1479523	TPO	-0.76	-5.15	-0.3	5.08e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);
CESC	cis	rs2380220	0.606	rs4559095	chr6:95994154	A/C	cg15832292	chr6:96025679	MANEA	0.63	7.09	0.4	1.22e-11	Behavioural disinhibition (generation interaction);
CESC	cis	rs951366	1.000	rs4951261	chr1:205717823	A/C	cg14159672	chr1:205819179	PM20D1	-0.46	-6.24	-0.36	1.76e-9	Menarche (age at onset);
CESC	cis	rs116095464	0.510	rs7714944	chr5:231765	C/T	cg22857025	chr5:266934	NA	-1.27	-18.09	-0.74	3.37e-48	Breast cancer;
CESC	cis	rs3785574	0.582	rs62072238	chr17:61948841	A/T	cg06873352	chr17:61820015	STRADA	0.49	7.1	0.4	1.12e-11	Height;
CESC	cis	rs1218582	0.772	rs11264282	chr1:154867370	G/A	cg24250549	chr1:154909240	PMVK	0.73	10.85	0.55	6.18e-23	Prostate cancer;
CESC	cis	rs4889855	0.556	rs61096326	chr17:78543796	G/C	cg16591659	chr17:78472290	NA	0.38	6.32	0.36	1.08e-9	Fractional excretion of uric acid;
CESC	cis	rs2839186	0.814	rs2839167	chr21:47661587	A/G	cg11766577	chr21:47581405	C21orf56	-0.45	-6.11	-0.35	3.59e-9	Testicular germ cell tumor;
CESC	cis	rs801193	0.967	rs2420827	chr7:66147101	G/A	cg18876405	chr7:65276391	NA	-0.59	-7.87	-0.44	9.13e-14	Aortic root size;
CESC	cis	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg22963979	chr7:1858916	MAD1L1	0.42	5.73	0.33	2.69e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs7659604	0.539	rs7699776	chr4:122753885	A/G	cg06713675	chr4:122721982	EXOSC9	-0.51	-6.96	-0.39	2.71e-11	Type 2 diabetes;
CESC	cis	rs763121	0.853	rs2267394	chr22:39101633	T/C	cg21395723	chr22:39101663	GTPBP1	0.49	6.76	0.38	8.89e-11	Menopause (age at onset);
CESC	cis	rs10851478	0.872	rs34414487	chr15:49783775	A/G	cg08060515	chr15:49448048	GALK2;COPS2	0.42	5.19	0.3	4.12e-7	Oral cavity cancer;
CESC	cis	rs898097	0.585	rs9892342	chr17:80893029	C/T	cg15664640	chr17:80829946	TBCD	0.4	5.73	0.33	2.69e-8	Breast cancer;
CESC	cis	rs9322193	0.884	rs12528279	chr6:150072028	A/C	cg07701084	chr6:150067640	NUP43	0.47	6.58	0.37	2.47e-10	Lung cancer;
CESC	cis	rs9910055	0.512	rs7209801	chr17:42323376	G/A	cg19774624	chr17:42201019	HDAC5	-0.47	-5.92	-0.34	9.73e-9	Total body bone mineral density;
CESC	cis	rs1957429	0.520	rs72625645	chr14:65343431	G/C	cg23373153	chr14:65346875	NA	-0.84	-6.3	-0.36	1.22e-9	Pediatric areal bone mineral density (radius);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19650814	chr6:100016539	CCNC	0.59	7.15	0.4	8.46e-12	Gut microbiome composition (summer);
CESC	cis	rs892961	0.932	rs7208336	chr17:75412932	T/C	cg05865280	chr17:75406074	SEPT9	0.62	12.67	0.61	4.57e-29	Airflow obstruction;
CESC	cis	rs10256972	0.621	rs10951594	chr7:1088607	C/G	cg07308232	chr7:1071921	C7orf50	-0.56	-8.07	-0.44	2.4e-14	Longevity;Endometriosis;
CESC	trans	rs2321882	0.881	rs7990810	chr13:59393390	T/C	cg20914879	chr14:56566808	NA	-0.43	-6.17	-0.35	2.51e-9	Body mass index;
CESC	cis	rs7116495	0.609	rs7121080	chr11:71703935	G/A	cg07596299	chr11:71824057	C11orf51	-0.8	-5.35	-0.31	1.92e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs10992471	1.000	rs10992471	chr9:95559505	A/G	cg13798575	chr9:95087839	CENPP;NOL8	0.4	5.18	0.3	4.42e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CESC	cis	rs1003719	0.715	rs2835640	chr21:38537380	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.59	-8.06	-0.44	2.72e-14	Eye color traits;
CESC	cis	rs6546550	0.901	rs10167142	chr2:70062360	T/C	cg02498382	chr2:70120550	SNRNP27	-0.39	-6.78	-0.38	7.75e-11	Prevalent atrial fibrillation;
CESC	cis	rs9522267	0.535	rs2039915	chr13:112238794	C/T	cg10483660	chr13:112241077	NA	-0.32	-5.63	-0.33	4.64e-8	Hepatitis;
CESC	cis	rs798554	0.757	rs2533879	chr7:2859847	G/A	cg19717773	chr7:2847554	GNA12	-0.56	-7.87	-0.44	9.12e-14	Height;
CESC	cis	rs473651	0.935	rs472357	chr2:239355454	A/G	cg18131467	chr2:239335373	ASB1	-0.97	-20.36	-0.78	3.98e-56	Multiple system atrophy;
CESC	cis	rs9322193	0.847	rs56103941	chr6:150137231	A/G	cg04369109	chr6:150039330	LATS1	-0.48	-6.59	-0.38	2.33e-10	Lung cancer;
CESC	cis	rs3105593	0.555	rs3131560	chr15:50775562	T/C	cg05456662	chr15:50716270	USP8	0.38	5.12	0.3	5.74e-7	QT interval;
CESC	cis	rs3096299	0.933	rs28608022	chr16:89454292	C/T	cg00750074	chr16:89608354	SPG7	-0.37	-5.31	-0.31	2.33e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs12477438	0.798	rs13393860	chr2:99590397	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.7	-10.22	-0.53	6.79e-21	Chronic sinus infection;
CESC	cis	rs8014204	0.804	rs7154845	chr14:75247746	A/G	cg08847533	chr14:75593920	NEK9	0.46	5.88	0.34	1.2e-8	Caffeine consumption;
CESC	trans	rs35110281	0.782	rs9981291	chr21:45031458	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.53	6.99	0.39	2.2e-11	Mean corpuscular volume;
CESC	cis	rs2635047	0.967	rs9960264	chr18:44606996	T/C	cg19077165	chr18:44547161	KATNAL2	-0.53	-7.12	-0.4	9.94e-12	Educational attainment;
CESC	cis	rs36051895	0.623	rs7870536	chr9:5245493	C/T	cg02405213	chr9:5042618	JAK2	-0.53	-6.61	-0.38	2.09e-10	Pediatric autoimmune diseases;
CESC	cis	rs5753618	0.504	rs5753661	chr22:31899797	C/A	cg02404636	chr22:31891804	SFI1	0.42	5.85	0.34	1.47e-8	Colorectal cancer;
CESC	trans	rs61931739	0.534	rs1387789	chr12:34056304	C/A	cg26384229	chr12:38710491	ALG10B	0.53	7.12	0.4	9.92e-12	Morning vs. evening chronotype;
CESC	cis	rs10876993	0.890	rs1092472	chr12:58036688	G/T	cg18357645	chr12:58087776	OS9	0.59	9.02	0.48	3.89e-17	Celiac disease or Rheumatoid arthritis;
CESC	trans	rs2121875	0.667	rs12518129	chr5:44171952	A/G	cg07292773	chr6:156718177	NA	-0.48	-6.12	-0.35	3.38e-9	Prostate cancer;
CESC	cis	rs752010	0.806	rs10890148	chr1:42091517	T/C	cg06885757	chr1:42089581	HIVEP3	0.49	8.24	0.45	8.1e-15	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg06873352	chr17:61820015	STRADA	0.72	12.88	0.62	8.42e-30	Prudent dietary pattern;
CESC	cis	rs514406	0.729	rs534070	chr1:53308858	T/G	cg08736216	chr1:53307985	ZYG11A	-0.41	-7.3	-0.41	3.45e-12	Monocyte count;
CESC	cis	rs7264396	0.635	rs6060675	chr20:34493614	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.81	-11.08	-0.56	1.08e-23	Total cholesterol levels;
CESC	cis	rs2839186	0.616	rs4819213	chr21:47619300	G/A	cg10351095	chr21:47802916	PCNT	0.43	5.55	0.32	7.02e-8	Testicular germ cell tumor;
CESC	cis	rs4819052	0.851	rs4819038	chr21:46659393	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.46	5.79	0.34	2e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs4481887	0.927	rs12744455	chr1:248479960	A/G	cg00666640	chr1:248458726	OR2T12	0.35	5.79	0.34	1.95e-8	Common traits (Other);
CESC	cis	rs4737010	0.570	rs2111804	chr8:41644266	A/T	cg08923054	chr8:41654455	ANK1	0.55	6.87	0.39	4.58e-11	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
CESC	cis	rs477692	0.583	rs2008387	chr10:131448764	C/T	cg05714579	chr10:131428358	MGMT	-0.75	-11.37	-0.57	1.15e-24	Response to temozolomide;
CESC	cis	rs7828089	0.934	rs12544427	chr8:22263115	C/T	cg12081754	chr8:22256438	SLC39A14	-0.42	-5.53	-0.32	7.82e-8	Verbal declarative memory;
CESC	cis	rs7259376	0.902	rs10409947	chr19:22512518	G/A	cg02657401	chr19:22469223	NA	-0.26	-5.24	-0.31	3.22e-7	Menopause (age at onset);
CESC	cis	rs9322193	0.962	rs3805753	chr6:150116798	C/T	cg04369109	chr6:150039330	LATS1	-0.38	-5.14	-0.3	5.4e-7	Lung cancer;
CESC	cis	rs4595586	0.525	rs6580891	chr12:39370127	C/T	cg26384229	chr12:38710491	ALG10B	0.54	7.53	0.42	7.85e-13	Morning vs. evening chronotype;
CESC	cis	rs2034088	0.833	rs4968120	chr17:431364	T/G	cg06217071	chr17:408420	NA	0.48	9.14	0.49	1.7e-17	Hip circumference adjusted for BMI;
CESC	cis	rs2635047	0.615	rs2576052	chr18:44690107	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.4	5.04	0.3	8.84e-7	Educational attainment;
CESC	cis	rs4654899	1.000	rs4654896	chr1:21356930	T/C	cg05370193	chr1:21551575	ECE1	0.41	6.26	0.36	1.55e-9	Superior frontal gyrus grey matter volume;
CESC	cis	rs2243480	1.000	rs56291018	chr7:65390339	G/A	cg12463550	chr7:65579703	CRCP	0.71	5.5	0.32	8.79e-8	Diabetic kidney disease;
CESC	cis	rs16854884	0.582	rs35211123	chr3:143640171	A/T	cg06585982	chr3:143692056	C3orf58	0.54	7.06	0.4	1.47e-11	Economic and political preferences (feminism/equality);
CESC	cis	rs7267979	0.816	rs8115257	chr20:25207931	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.67	11.49	0.58	4.6e-25	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs11608355	0.515	rs34038572	chr12:109901657	A/G	cg05360138	chr12:110035743	NA	0.81	8.84	0.48	1.41e-16	Neuroticism;
CESC	cis	rs763121	0.853	rs5750622	chr22:38956464	C/G	cg14440974	chr22:39074834	NA	-0.4	-5.31	-0.31	2.32e-7	Menopause (age at onset);
CESC	cis	rs3785574	1.000	rs7223257	chr17:61787684	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.57	7.04	0.4	1.63e-11	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23959119	chr19:42806179	PRR19;PAFAH1B3	0.57	6.06	0.35	4.54e-9	Gut microbiome composition (summer);
CESC	cis	rs4595586	0.545	rs6580888	chr12:39369704	C/T	cg26384229	chr12:38710491	ALG10B	0.54	7.53	0.42	7.85e-13	Morning vs. evening chronotype;
CESC	cis	rs921968	0.509	rs3856548	chr2:219398164	C/T	cg02176678	chr2:219576539	TTLL4	-0.54	-9.78	-0.51	1.78e-19	Mean corpuscular hemoglobin concentration;
CESC	cis	rs734999	0.588	rs3748817	chr1:2525665	T/C	cg18854424	chr1:2615690	NA	0.27	5.46	0.32	1.12e-7	Ulcerative colitis;
CESC	cis	rs483180	0.859	rs478093	chr1:120255126	C/T	cg19096424	chr1:120255104	PHGDH	-0.77	-9.17	-0.49	1.33e-17	Macular telangiectasia type 2;
CESC	cis	rs7666738	0.830	rs28878289	chr4:98855181	C/T	cg05340658	chr4:99064831	C4orf37	0.75	11.16	0.57	5.89e-24	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6963495	0.818	rs1355614	chr7:105179176	A/G	cg13798780	chr7:105162888	PUS7	0.6	6.99	0.39	2.2e-11	Bipolar disorder (body mass index interaction);
CESC	cis	rs1799949	1.000	rs16942	chr17:41244000	T/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.46	6.4	0.37	6.98e-10	Menopause (age at onset);
CESC	trans	rs2727020	0.729	rs588458	chr11:49214048	C/A	cg03929089	chr4:120376271	NA	0.78	11.9	0.59	1.91e-26	Coronary artery disease;
CESC	cis	rs10479542	0.503	rs12719865	chr5:178993566	C/T	cg26516362	chr5:178986906	RUFY1	0.47	7.31	0.41	3.11e-12	Lung cancer;
CESC	cis	rs1008375	0.966	rs10006317	chr4:17702525	A/G	cg16339924	chr4:17578868	LAP3	0.62	7.64	0.42	4.03e-13	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg20586607	chr14:50235780	KLHDC2	-0.45	-6.02	-0.35	5.72e-9	Height;
CESC	cis	rs2576037	0.899	rs2576035	chr18:44587654	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.61	-8.67	-0.47	4.54e-16	Personality dimensions;
CESC	cis	rs1355223	0.833	rs286885	chr11:34687346	G/T	cg11058730	chr11:34937778	PDHX;APIP	0.44	5.78	0.33	2.11e-8	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs4253772	0.575	rs74879643	chr22:46660014	T/C	cg24881330	chr22:46731750	TRMU	0.74	5.63	0.33	4.6e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs2576037	0.526	rs1789152	chr18:44433092	G/T	cg19077165	chr18:44547161	KATNAL2	-0.53	-7.83	-0.43	1.17e-13	Personality dimensions;
CESC	cis	rs910316	1.000	rs12590452	chr14:75548756	T/C	cg11812906	chr14:75593930	NEK9	0.91	16.04	0.7	6.55e-41	Height;
CESC	cis	rs2415984	0.622	rs11846013	chr14:46932291	A/C	cg14871534	chr14:47121158	RPL10L	0.35	5.26	0.31	3.02e-7	Number of children ever born;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg09133386	chr6:20404188	E2F3	-0.45	-6.02	-0.35	5.94e-9	Height;
CESC	cis	rs1707322	0.721	rs10789470	chr1:46158331	T/G	cg05343316	chr1:45956843	TESK2	0.51	6.2	0.36	2.19e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs698833	0.886	rs2927433	chr2:44580737	T/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.48	5.87	0.34	1.33e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs13082711	0.911	rs3755652	chr3:27472936	A/G	cg02860705	chr3:27208620	NA	-0.56	-5.91	-0.34	1.02e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CESC	cis	rs9303401	0.614	rs12947982	chr17:57140301	A/G	cg12560992	chr17:57184187	TRIM37	0.5	5.22	0.31	3.67e-7	Cognitive test performance;
CESC	cis	rs2276314	0.802	rs9963714	chr18:33592056	T/C	cg19628046	chr18:33552617	C18orf21	0.51	5.58	0.32	5.92e-8	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs3791406	0.654	rs3791409	chr2:240030606	C/G	cg13090969	chr2:240043331	HDAC4	-0.48	-5.75	-0.33	2.42e-8	Skin aging (microtopography measurement);
CESC	cis	rs909674	0.775	rs8138462	chr22:39839670	G/C	cg05872129	chr22:39784769	NA	-0.77	-10.35	-0.54	2.59e-21	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs854765	0.647	rs712267	chr17:18021607	G/A	cg16928487	chr17:17741425	SREBF1	-0.46	-7.14	-0.4	9.06e-12	Total body bone mineral density;
CESC	trans	rs6964833	1.000	rs4717906	chr7:74086247	G/A	cg07504079	chr7:72649617	NCF1B	-0.55	-6.23	-0.36	1.79e-9	Menarche (age at onset);
CESC	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg24846343	chr22:24311635	DDTL	0.61	10.31	0.54	3.42e-21	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs6963495	0.818	rs73192107	chr7:105168095	G/A	cg02135003	chr7:105160482	PUS7	-0.46	-5.5	-0.32	9.1e-8	Bipolar disorder (body mass index interaction);
CESC	cis	rs2295499	0.674	rs34626871	chr4:2637560	C/T	cg08330972	chr4:2403930	ZFYVE28	-0.34	-5.4	-0.32	1.46e-7	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
CESC	cis	rs6088580	0.634	rs6087579	chr20:32985155	A/G	cg24642439	chr20:33292090	TP53INP2	-0.54	-7.09	-0.4	1.21e-11	Glomerular filtration rate (creatinine);
CESC	trans	rs13098911	0.540	rs13079869	chr3:46008087	G/A	cg10236987	chr1:228114221	WNT9A	0.57	6.14	0.35	2.95e-9	Celiac disease;
CESC	cis	rs950169	0.922	rs12906983	chr15:84931022	G/A	cg17507749	chr15:85114479	UBE2QP1	0.59	6.46	0.37	5e-10	Schizophrenia;
CESC	cis	rs1552244	1.000	rs4269070	chr3:10126083	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	12.92	0.62	6.2e-30	Alzheimer's disease;
CESC	cis	rs875971	0.862	rs6971059	chr7:66067032	A/G	cg11764359	chr7:65958608	NA	-0.78	-11.32	-0.57	1.76e-24	Aortic root size;
CESC	cis	rs7191439	0.657	rs3826076	chr16:88780518	C/T	cg27087555	chr16:88793112	FAM38A	1.05	9.3	0.5	5.62e-18	Plateletcrit;
CESC	cis	rs2404602	0.692	rs67570291	chr15:77020502	T/C	cg26408565	chr15:76604113	ETFA	-0.38	-5.52	-0.32	8.03e-8	Blood metabolite levels;
CESC	cis	rs7089973	0.624	rs1359080	chr10:116582419	C/A	cg25233709	chr10:116636983	FAM160B1	0.35	5.42	0.32	1.35e-7	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg11522767	chr6:157342961	ARID1B	-0.42	-6.03	-0.35	5.46e-9	Gambling;
CESC	cis	rs910316	1.000	rs10136948	chr14:75511075	C/T	cg08847533	chr14:75593920	NEK9	1.02	19.36	0.77	1.26e-52	Height;
CESC	cis	rs2180341	0.961	rs3798857	chr6:127659473	A/T	cg27446573	chr6:127587934	RNF146	1.09	16.35	0.71	5.12e-42	Breast cancer;
CESC	cis	rs9549367	0.789	rs2287247	chr13:113889212	A/G	cg18105134	chr13:113819100	PROZ	-0.68	-8.29	-0.45	5.77e-15	Platelet distribution width;
CESC	trans	rs7615952	0.551	rs6438945	chr3:125634473	G/A	cg07211511	chr3:129823064	LOC729375	-1.1	-13.63	-0.64	2.03e-32	Blood pressure (smoking interaction);
CESC	trans	rs12599106	0.715	rs34006830	chr16:34878550	C/A	cg03395511	chr6:291903	DUSP22	-0.7	-8.58	-0.47	8.27e-16	Menopause (age at onset);
CESC	cis	rs11098499	0.955	rs35197422	chr4:120169314	T/G	cg24375607	chr4:120327624	NA	0.43	5.22	0.31	3.66e-7	Corneal astigmatism;
CESC	trans	rs7937682	0.883	rs568038	chr11:111432161	A/C	cg18187862	chr3:45730750	SACM1L	-0.55	-6.75	-0.38	9.09e-11	Primary sclerosing cholangitis;
CESC	cis	rs832540	0.519	rs1445998	chr5:56268205	A/G	cg24531977	chr5:56204891	C5orf35	-0.41	-5.11	-0.3	6.22e-7	Coronary artery disease;
CESC	cis	rs2857078	0.627	rs1476512	chr17:42330122	C/T	cg19774624	chr17:42201019	HDAC5	0.42	5.69	0.33	3.38e-8	Red cell distribution width;Reticulocyte count;
CESC	cis	rs965469	0.947	rs6037578	chr20:3345911	T/C	cg25506879	chr20:3388711	C20orf194	-0.55	-5.85	-0.34	1.43e-8	IFN-related cytopenia;
CESC	cis	rs2070433	1.000	rs2839306	chr21:47954219	G/T	cg12379764	chr21:47803548	PCNT	-0.56	-6.66	-0.38	1.57e-10	Lymphocyte counts;
CESC	cis	rs739401	0.595	rs2237903	chr11:2967901	C/T	cg25174290	chr11:3078921	CARS	0.59	7.79	0.43	1.53e-13	Longevity;
CESC	cis	rs3733585	0.699	rs1079128	chr4:9951221	T/C	cg11266682	chr4:10021025	SLC2A9	-0.59	-11.3	-0.57	1.99e-24	Cleft plate (environmental tobacco smoke interaction);
CESC	trans	rs4038131	0.818	rs11096484	chr2:17985852	A/G	cg12680326	chr20:2821316	VPS16;FAM113A	0.88	6.04	0.35	5.28e-9	Psychosis and Alzheimer's disease;
CESC	cis	rs11958404	1.000	rs72816532	chr5:157413130	C/T	cg05962755	chr5:157440814	NA	0.52	5.95	0.34	8.38e-9	IgG glycosylation;
CESC	trans	rs4650994	0.525	rs2493860	chr1:178541492	A/G	cg05059571	chr16:84539110	KIAA1609	-0.39	-6.01	-0.35	5.99e-9	HDL cholesterol levels;HDL cholesterol;
CESC	cis	rs2624839	0.629	rs2526397	chr3:50187790	A/C	cg08283408	chr3:49949060	MON1A	0.39	5.1	0.3	6.43e-7	Intelligence (multi-trait analysis);
CESC	trans	rs11039798	0.512	rs28453037	chr11:49006929	C/A	cg03929089	chr4:120376271	NA	0.59	6.09	0.35	3.97e-9	Axial length;
CESC	cis	rs9467711	0.606	rs9348709	chr6:26360311	G/A	cg14345882	chr6:26364793	BTN3A2	0.59	6.06	0.35	4.66e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg11494091	chr17:61959527	GH2	0.72	12.28	0.6	1e-27	Prudent dietary pattern;
CESC	trans	rs2727020	0.595	rs10769583	chr11:49483193	G/A	cg15704280	chr7:45808275	SEPT13	-0.95	-16.88	-0.72	6.55e-44	Coronary artery disease;
CESC	cis	rs7666738	0.716	rs6817529	chr4:99023213	T/C	cg18180107	chr4:99064573	C4orf37	0.41	5.39	0.31	1.57e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2243480	0.803	rs423187	chr7:65509499	G/C	cg12463550	chr7:65579703	CRCP	0.7	5.41	0.32	1.41e-7	Diabetic kidney disease;
CESC	cis	rs4237845	0.844	rs4630335	chr12:58302258	A/G	cg02175503	chr12:58329896	NA	0.59	7.98	0.44	4.34e-14	Intelligence (multi-trait analysis);
CESC	cis	rs117623576	0.618	rs211413	chr10:32396902	C/A	cg03047570	chr10:32398778	NA	0.69	7.67	0.43	3.33e-13	Anti-saccade response;
CESC	cis	rs597539	0.690	rs497149	chr11:68626639	A/T	cg04772025	chr11:68637568	NA	0.59	6.81	0.39	6.62e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	trans	rs11098499	0.909	rs10020034	chr4:120294331	A/G	cg25214090	chr10:38739885	LOC399744	0.68	9.23	0.49	8.9e-18	Corneal astigmatism;
CESC	cis	rs317689	0.690	rs570256	chr12:69662929	A/T	cg20891283	chr12:69753455	YEATS4	0.48	5.28	0.31	2.76e-7	Response to diuretic therapy;
CESC	cis	rs4588572	0.774	rs4072853	chr5:77656402	G/C	cg11547950	chr5:77652471	NA	0.47	6.2	0.36	2.21e-9	Triglycerides;
CESC	cis	rs116095464	0.558	rs13354585	chr5:242263	G/C	cg20965017	chr5:231967	SDHA	-0.47	-5.35	-0.31	1.88e-7	Breast cancer;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg15422050	chr6:88412138	NCRNA00120;AKIRIN2	-0.52	-6.26	-0.36	1.52e-9	Ulcerative colitis;
CESC	trans	rs2823962	0.759	rs4485640	chr21:18018262	A/T	cg06419850	chr17:4688683	VMO1	-0.42	-6.11	-0.35	3.45e-9	Amyotrophic lateral sclerosis;
CESC	cis	rs854765	0.551	rs12600546	chr17:17867614	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.59	8.22	0.45	9.43e-15	Total body bone mineral density;
CESC	cis	rs4803468	1.000	rs284663	chr19:41932612	C/T	cg08639244	chr19:41945921	ATP5SL	-0.43	-5.21	-0.3	3.89e-7	Height;
CESC	cis	rs7666738	0.830	rs35235971	chr4:98999833	G/T	cg17366294	chr4:99064904	C4orf37	0.6	8.61	0.47	6.47e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4631830	0.540	rs2843562	chr10:51496796	A/G	cg20129853	chr10:51489980	NA	0.29	5.28	0.31	2.64e-7	Prostate-specific antigen levels;
CESC	trans	rs2488856	0.624	rs7151863	chr14:43614110	A/G	cg14326805	chr9:71737756	TJP2	0.37	6.03	0.35	5.51e-9	Osteoprotegerin levels;
CESC	cis	rs7937682	0.924	rs11213968	chr11:111527629	G/C	cg09085632	chr11:111637200	PPP2R1B	-1.0	-16.13	-0.7	3.03e-41	Primary sclerosing cholangitis;
CESC	cis	rs2342371	0.848	rs9864836	chr3:196200737	C/T	cg15048948	chr3:196158458	UBXN7	0.42	5.58	0.32	5.9e-8	Fat distribution (HIV);
CESC	cis	rs1348850	0.668	rs13010396	chr2:178492934	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.46	5.4	0.31	1.48e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs6952808	0.692	rs59619245	chr7:2068630	C/T	cg23048001	chr7:2026167	MAD1L1	0.47	6.14	0.35	2.93e-9	Bipolar disorder and schizophrenia;
CESC	trans	rs7107217	1.000	rs1873872	chr11:129473993	A/T	cg21843114	chr4:26334859	RBPJ	-0.45	-6.19	-0.36	2.32e-9	Breast cancer;Type 2 diabetes;
CESC	trans	rs459571	0.959	rs465535	chr9:136910905	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.57	-7.48	-0.42	1.12e-12	Platelet distribution width;
CESC	cis	rs72781680	0.898	rs72796152	chr2:23933626	G/A	cg20701182	chr2:24300061	SF3B14	0.66	5.92	0.34	1.01e-8	Lymphocyte counts;
CESC	cis	rs590820	0.712	rs4846913	chr1:230294715	A/C	cg20703242	chr1:230279135	GALNT2	-0.31	-5.15	-0.3	5e-7	Metabolite levels (lipoprotein measures);
CESC	cis	rs360798	0.512	rs11893131	chr2:63079528	C/A	cg17519650	chr2:63277830	OTX1	0.5	6.38	0.36	7.78e-10	Coronary artery disease;
CESC	cis	rs2108622	0.727	rs7256877	chr19:15980683	T/C	cg13772218	chr19:15982569	NA	0.3	5.87	0.34	1.27e-8	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CESC	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg05025164	chr4:1340916	KIAA1530	0.89	12.06	0.6	5.43e-27	Longevity;
CESC	cis	rs863345	0.564	rs1418844	chr1:158457569	A/T	cg12129480	chr1:158549410	OR10X1	-0.36	-7.14	-0.4	9.13e-12	Pneumococcal bacteremia;
CESC	cis	rs654950	0.783	rs668359	chr1:42003425	A/C	cg06885757	chr1:42089581	HIVEP3	-0.49	-8.13	-0.45	1.61e-14	Airway imaging phenotypes;
CESC	cis	rs10870270	0.830	rs10781571	chr10:133774316	G/C	cg17892150	chr10:133769511	PPP2R2D	-0.86	-12.57	-0.61	9.6e-29	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs2070488	0.930	rs928813	chr3:38528537	G/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.96	18.05	0.74	4.84e-48	Electrocardiographic conduction measures;
CESC	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg24642844	chr7:1081250	C7orf50	-0.78	-9.49	-0.5	1.38e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs477692	0.673	rs579325	chr10:131363688	C/T	cg24747557	chr10:131355152	MGMT	-0.38	-5.17	-0.3	4.67e-7	Response to temozolomide;
CESC	cis	rs13336428	0.730	rs3946124	chr16:1525779	A/G	cg07835181	chr16:1525278	CLCN7	-0.72	-9.98	-0.52	4e-20	Bone mineral density;
CESC	cis	rs7267979	1.000	rs1888998	chr20:25291826	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.84	-16.08	-0.7	4.65e-41	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs1863918	0.807	rs4701049	chr5:178545214	G/T	cg21905437	chr5:178450457	ZNF879	0.36	5.04	0.3	8.55e-7	Depression in response to interferon-based therapy in chronic hepatitis C;
CESC	cis	rs4835473	0.868	rs1828503	chr4:144914507	A/G	cg25736465	chr4:144833511	NA	-0.46	-7.04	-0.4	1.69e-11	Immature fraction of reticulocytes;
CESC	cis	rs3096299	0.967	rs16965692	chr16:89471482	C/T	cg02187348	chr16:89574699	SPG7	0.52	7.04	0.4	1.68e-11	Multiple myeloma (IgH translocation);
CESC	cis	rs4862750	0.872	rs6836781	chr4:187899701	G/A	cg22105103	chr4:187893119	NA	0.51	7.69	0.43	2.88e-13	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6938	0.618	rs11072514	chr15:75221865	T/A	cg14664628	chr15:75095509	CSK	-0.53	-6.91	-0.39	3.64e-11	Breast cancer;
CESC	cis	rs4566357	0.615	rs10178098	chr2:227914425	C/T	cg05526886	chr2:227700861	RHBDD1	-0.45	-5.93	-0.34	9.37e-9	Coronary artery disease;
CESC	cis	rs270601	0.770	rs10463891	chr5:131597392	C/T	cg18758796	chr5:131593413	PDLIM4	-0.5	-7.22	-0.41	5.5e-12	Acylcarnitine levels;
CESC	cis	rs11958404	0.932	rs72816540	chr5:157414500	T/C	cg05962755	chr5:157440814	NA	0.52	6.01	0.35	6.19e-9	IgG glycosylation;
CESC	cis	rs1008375	1.000	rs6818639	chr4:17633049	A/G	cg16339924	chr4:17578868	LAP3	0.56	7.13	0.4	9.83e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs4481887	0.893	rs10888355	chr1:248457180	G/A	cg00666640	chr1:248458726	OR2T12	0.4	6.62	0.38	1.97e-10	Common traits (Other);
CESC	trans	rs9329221	0.506	rs17689674	chr8:9981854	C/A	cg06636001	chr8:8085503	FLJ10661	0.49	6.06	0.35	4.59e-9	Neuroticism;
CESC	cis	rs17401966	1.000	rs11578788	chr1:10422958	A/G	cg15208524	chr1:10270712	KIF1B	0.49	6.21	0.36	2.06e-9	Hepatocellular carcinoma;
CESC	cis	rs826838	0.900	rs9739128	chr12:38948960	A/T	cg26384229	chr12:38710491	ALG10B	0.82	14.8	0.67	1.54e-36	Heart rate;
CESC	cis	rs875971	0.545	rs316323	chr7:65610989	C/T	cg25405998	chr7:65216604	CCT6P1	-0.45	-5.06	-0.3	7.71e-7	Aortic root size;
CESC	cis	rs514406	0.698	rs522259	chr1:53365481	A/G	cg24675658	chr1:53192096	ZYG11B	-0.67	-9.24	-0.49	8.49e-18	Monocyte count;
CESC	trans	rs11039798	1.000	rs7479655	chr11:48576714	G/T	cg15704280	chr7:45808275	SEPT13	0.68	6.45	0.37	5.36e-10	Axial length;
CESC	cis	rs888194	0.677	rs10774696	chr12:109875753	C/T	cg19025524	chr12:109796872	NA	-0.4	-6.13	-0.35	3.19e-9	Neuroticism;
CESC	cis	rs2929278	0.588	rs1975364	chr15:44150189	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.5	6.38	0.37	7.72e-10	Schizophrenia;
CESC	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg26668828	chr6:292823	DUSP22	-0.72	-9.68	-0.51	3.54e-19	Menopause (age at onset);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg00429618	chr9:99962350	ZNF322B	-0.45	-6.45	-0.37	5.2400000000000005e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs2295359	1.000	rs736197	chr1:67607135	G/T	cg03340356	chr1:67600835	NA	0.32	5.46	0.32	1.11e-7	Psoriasis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17449403	chr12:48357323	TMEM106C	0.6	6.73	0.38	1.05e-10	Gut microbiome composition (summer);
CESC	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg18402987	chr7:1209562	NA	0.75	8.6	0.47	7.24e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7385804	0.761	rs568733	chr7:100311662	G/T	cg20848291	chr7:100343083	ZAN	0.47	6.3	0.36	1.24e-9	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
CESC	cis	rs9611519	0.929	rs2064560	chr22:41530040	A/G	cg03806693	chr22:41940476	POLR3H	-0.58	-5.93	-0.34	9.4e-9	Neuroticism;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg10255097	chr10:114711603	TCF7L2	0.49	6.11	0.35	3.46e-9	Thyroid stimulating hormone;
CESC	cis	rs7666738	0.830	rs7664305	chr4:99037691	G/A	cg05340658	chr4:99064831	C4orf37	0.82	12.87	0.62	9.38e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs763121	0.853	rs4821812	chr22:39075235	G/C	cg06022373	chr22:39101656	GTPBP1	0.9	14.15	0.66	2.99e-34	Menopause (age at onset);
CESC	cis	rs60871478	0.636	rs4721834	chr7:896142	C/T	cg05535760	chr7:792225	HEATR2	-0.78	-8.24	-0.45	8.16e-15	Cerebrospinal P-tau181p levels;
CESC	cis	rs7208859	0.623	rs216445	chr17:28933576	A/G	cg14008862	chr17:28927542	LRRC37B2	0.73	5.52	0.32	8.23e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs7116495	0.609	rs2508860	chr11:71805052	C/T	cg10381502	chr11:71823885	C11orf51	1.04	6.47	0.37	4.61e-10	Severe influenza A (H1N1) infection;
CESC	cis	rs611744	0.647	rs615126	chr8:109247619	C/T	cg21045802	chr8:109455806	TTC35	0.49	6.06	0.35	4.71e-9	Dupuytren's disease;
CESC	cis	rs2708240	1.000	rs2710139	chr7:147570807	G/A	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.34	-5.53	-0.32	7.72e-8	QT interval (drug interaction);
CESC	cis	rs2066819	1.000	rs2306694	chr12:56680636	C/T	cg26734620	chr12:56694298	CS	-1.07	-6.58	-0.37	2.56e-10	Psoriasis vulgaris;
CESC	cis	rs10504229	0.683	rs66893068	chr8:58144238	A/G	cg21724239	chr8:58056113	NA	0.56	5.96	0.34	8.22e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs7116495	1.000	rs6592448	chr11:71670044	C/T	cg10381502	chr11:71823885	C11orf51	0.7	6.16	0.35	2.67e-9	Severe influenza A (H1N1) infection;
CESC	cis	rs6540559	0.673	rs17015361	chr1:210018901	C/G	cg23283495	chr1:209979779	IRF6	0.48	5.61	0.33	5.1e-8	Cleft lip with or without cleft palate;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22817039	chr5:60628030	ZSWIM6	0.59	6.8	0.39	6.72e-11	Gut microbiome composition (summer);
CESC	cis	rs807669	0.548	rs9605957	chr22:19187375	G/A	cg02655711	chr22:19163373	SLC25A1	0.6	9.14	0.49	1.73e-17	Metabolite levels;
CESC	cis	rs7772486	0.790	rs2485632	chr6:146193228	A/G	cg05347473	chr6:146136440	FBXO30	0.58	7.45	0.42	1.31e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs66887589	0.967	rs56173225	chr4:120509972	G/A	cg09307838	chr4:120376055	NA	-0.53	-7.07	-0.4	1.35e-11	Diastolic blood pressure;
CESC	cis	rs72781680	0.611	rs55788848	chr2:24268721	C/T	cg06627628	chr2:24431161	ITSN2	-0.65	-6.21	-0.36	2.08e-9	Lymphocyte counts;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23260190	chr10:101419318	ENTPD7	0.58	7.08	0.4	1.27e-11	Gut microbiome composition (summer);
CESC	cis	rs863345	0.967	rs10797016	chr1:158468413	T/C	cg12129480	chr1:158549410	OR10X1	-0.31	-6.23	-0.36	1.78e-9	Pneumococcal bacteremia;
CESC	cis	rs763121	0.853	rs8140617	chr22:38970439	A/G	cg06544989	chr22:39130855	UNC84B	-0.47	-7.47	-0.42	1.17e-12	Menopause (age at onset);
CESC	cis	rs12497850	0.866	rs6791234	chr3:48996137	A/G	cg03060546	chr3:49711283	APEH	0.5	6.03	0.35	5.57e-9	Parkinson's disease;
CESC	cis	rs17818399	0.547	rs7607308	chr2:46759104	T/C	cg02822958	chr2:46747628	ATP6V1E2	0.44	5.34	0.31	1.97e-7	Height;
CESC	cis	rs10504229	0.906	rs73607868	chr8:58172482	T/C	cg24829409	chr8:58192753	C8orf71	-0.76	-10.0	-0.52	3.53e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs2742234	0.590	rs2075912	chr10:43622217	T/C	cg07801480	chr10:43725741	RASGEF1A	0.4	5.2	0.3	4e-7	Hirschsprung disease;
CESC	cis	rs12701220	0.604	rs34904312	chr7:1135883	G/A	cg23978390	chr7:1156363	C7orf50	0.67	6.57	0.37	2.64e-10	Bronchopulmonary dysplasia;
CESC	cis	rs483180	0.512	rs1163251	chr1:120209755	T/C	cg19096424	chr1:120255104	PHGDH	-0.43	-5.24	-0.31	3.26e-7	Macular telangiectasia type 2;
CESC	cis	rs12824058	0.831	rs11608406	chr12:130805866	G/C	cg24838063	chr12:130822603	PIWIL1	0.6	8.01	0.44	3.7e-14	Menopause (age at onset);
CESC	trans	rs61148964	0.826	rs11913459	chr22:37228603	G/A	cg26037026	chr7:1641922	NA	0.53	6.15	0.35	2.88e-9	Scarlet fever;
CESC	cis	rs3857536	0.776	rs9363560	chr6:66949686	T/G	cg07460842	chr6:66804631	NA	-0.42	-5.29	-0.31	2.55e-7	Blood trace element (Cu levels);
CESC	cis	rs1008375	0.931	rs1860592	chr4:17577028	C/G	cg27347728	chr4:17578864	LAP3	0.43	5.11	0.3	6.18e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs10504229	0.593	rs17192845	chr8:58053339	C/T	cg05313129	chr8:58192883	C8orf71	-0.53	-5.27	-0.31	2.86e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs2651899	0.934	rs10909887	chr1:3087373	A/T	cg07622451	chr1:3079886	PRDM16	-0.31	-5.41	-0.32	1.43e-7	Migraine;
CESC	cis	rs782590	0.783	rs7594279	chr2:55812073	T/G	cg18811423	chr2:55921094	PNPT1	0.8	12.72	0.62	2.9e-29	Metabolic syndrome;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg25356086	chr21:33764900	C21orf119;URB1	-0.5	-7.19	-0.4	6.69e-12	Gambling;
CESC	cis	rs4835473	0.712	rs12498218	chr4:144658053	A/G	cg25736465	chr4:144833511	NA	-0.33	-5.11	-0.3	6.26e-7	Immature fraction of reticulocytes;
CESC	cis	rs7618915	0.508	rs11717043	chr3:52656092	A/T	cg05564831	chr3:52568323	NT5DC2	0.44	6.76	0.38	8.84e-11	Bipolar disorder;
CESC	cis	rs1799949	1.000	rs11654731	chr17:41326940	G/A	cg23758822	chr17:41437982	NA	1.04	15.71	0.69	9.05e-40	Menopause (age at onset);
CESC	cis	rs2204008	0.539	rs2703682	chr12:38107969	A/G	cg26384229	chr12:38710491	ALG10B	0.41	5.43	0.32	1.25e-7	Bladder cancer;
CESC	cis	rs941408	0.515	rs878893	chr19:2781325	A/G	cg06609049	chr19:2785107	THOP1	0.95	14.55	0.67	1.16e-35	Total cholesterol levels;
CESC	cis	rs2011503	1.000	rs2916070	chr19:19524105	C/T	cg11584989	chr19:19387371	SF4	0.59	6.62	0.38	1.95e-10	Bipolar disorder;
CESC	cis	rs4523957	0.671	rs12103726	chr17:2192839	C/T	cg16513277	chr17:2031491	SMG6	-0.49	-5.65	-0.33	4.2e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs6964587	0.869	rs7810391	chr7:91520227	G/A	cg17063962	chr7:91808500	NA	-0.53	-6.97	-0.39	2.58e-11	Breast cancer;
CESC	cis	rs9911578	0.817	rs304264	chr17:56749628	A/G	cg12560992	chr17:57184187	TRIM37	0.93	15.07	0.68	1.7e-37	Intelligence (multi-trait analysis);
CESC	cis	rs2204008	0.837	rs4312131	chr12:38181087	G/T	cg13010199	chr12:38710504	ALG10B	0.54	6.69	0.38	1.28e-10	Bladder cancer;
CESC	cis	rs9400271	0.632	rs9398191	chr6:109586561	C/T	cg01475377	chr6:109611718	NA	-0.46	-7.21	-0.4	5.96e-12	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
CESC	cis	rs72781680	0.756	rs2551337	chr2:24006886	C/T	cg08917208	chr2:24149416	ATAD2B	0.7	6.76	0.38	8.54e-11	Lymphocyte counts;
CESC	cis	rs12142240	0.698	rs56049453	chr1:46835468	A/G	cg10495392	chr1:46806563	NSUN4	0.58	6.24	0.36	1.68e-9	Menopause (age at onset);
CESC	cis	rs11723261	0.582	rs4634177	chr4:136837	C/T	cg12746427	chr4:53362	ZNF718;ZNF595	0.49	6.36	0.36	8.91e-10	Immune response to smallpox vaccine (IL-6);
CESC	cis	rs7178572	0.568	rs12912050	chr15:77689423	C/T	cg22256960	chr15:77711686	NA	-0.54	-6.95	-0.39	2.9e-11	Type 2 diabetes;
CESC	cis	rs13108904	0.604	rs11946375	chr4:1313488	T/C	cg22903657	chr4:1355424	KIAA1530	-0.36	-5.11	-0.3	6.11e-7	Obesity-related traits;
CESC	cis	rs1832871	0.711	rs62439861	chr6:158700531	A/G	cg07165851	chr6:158734300	TULP4	0.59	6.32	0.36	1.08e-9	Height;
CESC	cis	rs875971	0.862	rs778684	chr7:65836403	A/T	cg12463550	chr7:65579703	CRCP	0.49	6.26	0.36	1.56e-9	Aortic root size;
CESC	cis	rs3820928	0.845	rs13384342	chr2:227805010	G/A	cg11843606	chr2:227700838	RHBDD1	-0.48	-6.39	-0.37	7.55e-10	Pulmonary function;
CESC	cis	rs6541297	1.000	rs4846839	chr1:230284924	A/G	cg20703242	chr1:230279135	GALNT2	0.74	11.07	0.56	1.18e-23	Coronary artery disease;
CESC	cis	rs597539	0.652	rs516425	chr11:68715675	G/A	cg21963583	chr11:68658836	MRPL21	0.4	5.75	0.33	2.41e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13944219	chr5:65440479	SFRS12	0.58	6.99	0.39	2.28e-11	Gut microbiome composition (summer);
CESC	cis	rs10905065	0.930	rs7096742	chr10:5735648	C/T	cg11519256	chr10:5708881	ASB13	0.45	5.87	0.34	1.32e-8	Menopause (age at onset);
CESC	cis	rs6061231	0.556	rs6121571	chr20:60977323	T/G	cg22601191	chr20:60968625	CABLES2	0.38	5.18	0.3	4.3e-7	Colorectal cancer;
CESC	cis	rs1401999	0.714	rs7646621	chr3:183640865	A/C	cg01324343	chr3:183735012	ABCC5	-0.45	-9.34	-0.5	3.97e-18	Anterior chamber depth;
CESC	cis	rs10504229	0.679	rs6995378	chr8:58113933	C/T	cg21724239	chr8:58056113	NA	0.58	5.93	0.34	9.45e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs2124969	0.562	rs13393480	chr2:161058790	G/T	cg03641300	chr2:160917029	PLA2R1	-0.4	-5.76	-0.33	2.36e-8	Waist circumference adjusted for body mass index;
CESC	cis	rs61931739	0.500	rs11836198	chr12:34552782	T/C	cg06521331	chr12:34319734	NA	-0.36	-5.03	-0.3	9.12e-7	Morning vs. evening chronotype;
CESC	cis	rs9916302	0.904	rs4511574	chr17:37532916	A/G	cg15445000	chr17:37608096	MED1	0.36	5.77	0.33	2.18e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs3741404	0.791	rs7112960	chr11:63907079	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.9	13.31	0.63	2.68e-31	Platelet count;
CESC	cis	rs3768617	0.510	rs6424889	chr1:183091796	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.89	14.39	0.66	4.39e-35	Fuchs's corneal dystrophy;
CESC	cis	rs4819052	0.819	rs34818688	chr21:46672416	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.92	13.57	0.64	3.24e-32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs7116495	1.000	rs7124000	chr11:71754338	T/C	cg10381502	chr11:71823885	C11orf51	-0.58	-5.16	-0.3	4.75e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs7582720	1.000	rs72926802	chr2:203830228	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.36	0.41	2.34e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs3768617	0.811	rs11590958	chr1:183023636	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.66	8.99	0.48	4.82e-17	Fuchs's corneal dystrophy;
CESC	cis	rs4849845	0.925	rs4100690	chr2:121027361	T/G	cg24070213	chr2:121070622	NA	0.39	5.04	0.3	8.71e-7	Mean platelet volume;
CESC	cis	rs1348850	0.757	rs2166554	chr2:178455824	A/G	cg23306229	chr2:178417860	TTC30B	0.49	6.21	0.36	2.04e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	trans	rs9325144	0.510	rs6582599	chr12:38715965	T/G	cg23762105	chr12:34175262	ALG10	-0.49	-6.38	-0.36	8.01e-10	Morning vs. evening chronotype;
CESC	cis	rs2573652	0.698	rs12916269	chr15:100530216	A/T	cg00587665	chr15:100533223	ADAMTS17	0.42	6.79	0.39	7.18e-11	Height;
CESC	cis	rs7659604	1.000	rs28640980	chr4:122664284	T/C	cg19671926	chr4:122722719	EXOSC9	-0.44	-5.2	-0.3	4.01e-7	Type 2 diabetes;
CESC	cis	rs1552244	1.000	rs7615764	chr3:10082592	C/T	cg00166722	chr3:10149974	C3orf24	0.47	5.97	0.34	7.56e-9	Alzheimer's disease;
CESC	cis	rs2243480	1.000	rs313813	chr7:65503500	C/T	cg12463550	chr7:65579703	CRCP	0.69	5.47	0.32	1.04e-7	Diabetic kidney disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01902939	chr1:54304230	TMEM48	0.58	7.14	0.4	9.06e-12	Gut microbiome composition (summer);
CESC	cis	rs637571	0.522	rs1151512	chr11:65757533	G/A	cg04055107	chr11:65626734	MUS81;CFL1	0.42	5.18	0.3	4.38e-7	Eosinophil percentage of white cells;
CESC	cis	rs7998202	0.667	rs282584	chr13:113349819	C/T	cg02820901	chr13:113351484	ATP11A	-0.52	-5.14	-0.3	5.45e-7	Glycated hemoglobin levels;
CESC	cis	rs3768617	0.811	rs10911233	chr1:183052585	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.67	9.27	0.49	6.9e-18	Fuchs's corneal dystrophy;
CESC	cis	rs2228479	0.681	rs10153196	chr16:89967397	A/C	cg06558623	chr16:89946397	TCF25	0.55	5.28	0.31	2.71e-7	Skin colour saturation;
CESC	cis	rs2180341	0.961	rs910720	chr6:127619070	T/C	cg27446573	chr6:127587934	RNF146	1.08	16.13	0.7	3.14e-41	Breast cancer;
CESC	cis	rs6062302	0.522	rs2297428	chr20:62221766	C/T	cg09650180	chr20:62225654	GMEB2	-0.8	-9.04	-0.49	3.38e-17	Glioblastoma;
CESC	cis	rs9875589	0.509	rs6783645	chr3:14024542	T/C	cg19554555	chr3:13937349	NA	-0.44	-5.69	-0.33	3.33e-8	Ovarian reserve;
CESC	cis	rs6504249	0.893	rs2521827	chr17:62692728	T/G	cg02598441	chr17:62777298	LOC146880	-0.48	-5.06	-0.3	7.85e-7	Joint mobility (Beighton score);
CESC	cis	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23151353	chr4:100867933	DNAJB14	0.52	6.18	0.35	2.42e-9	Gut microbiome composition (summer);
CESC	cis	rs11992186	0.505	rs7845203	chr8:8145440	A/G	cg06636001	chr8:8085503	FLJ10661	0.42	5.16	0.3	4.74e-7	Neuroticism;
CESC	cis	rs9649213	0.593	rs6947208	chr7:97912204	C/T	cg24562669	chr7:97807699	LMTK2	0.47	6.52	0.37	3.51e-10	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7916697	0.520	rs12265247	chr10:70038398	A/G	cg06988349	chr10:69991859	ATOH7	0.34	5.29	0.31	2.6e-7	Optic disc area;
CESC	cis	rs1552244	0.935	rs4441636	chr3:10083876	G/A	cg00149659	chr3:10157352	C3orf10	0.77	9.67	0.51	3.91e-19	Alzheimer's disease;
CESC	cis	rs9399137	0.507	rs7761964	chr6:135314265	T/C	cg22676075	chr6:135203613	NA	0.53	7.09	0.4	1.22e-11	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	cis	rs7927592	0.913	rs7123564	chr11:68362164	C/T	cg20283391	chr11:68216788	NA	-0.61	-7.28	-0.41	3.86e-12	Total body bone mineral density;
CESC	cis	rs9894429	1.000	rs7213129	chr17:79581573	C/T	cg21984481	chr17:79567631	NPLOC4	-0.49	-8.04	-0.44	2.97e-14	Eye color traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19947233	chr4:90032727	TIGD2	0.66	7.09	0.4	1.23e-11	Gut microbiome composition (summer);
CESC	cis	rs9462846	0.959	rs7750915	chr6:42882067	C/T	cg05552183	chr6:42928497	GNMT	0.46	5.3	0.31	2.43e-7	Blood protein levels;
CESC	cis	rs9858542	0.953	rs6766131	chr3:49538932	T/C	cg07274523	chr3:49395745	GPX1	0.66	8.05	0.44	2.82e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg17050100	chr2:27852231	GPN1;CCDC121	0.46	6.21	0.36	2.04e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs6088590	0.561	rs2295444	chr20:33173883	C/T	cg08999081	chr20:33150536	PIGU	0.7	12.43	0.61	3.03e-28	Coronary artery disease;
CESC	trans	rs9693444	0.898	rs4732697	chr8:29519861	A/G	cg16931877	chr3:32726605	CNOT10	-0.44	-6.53	-0.37	3.41e-10	Breast cancer;
CESC	cis	rs6499255	1.000	rs4580150	chr16:69814953	G/A	cg15192750	chr16:69999425	NA	0.46	5.64	0.33	4.46e-8	IgE levels;
CESC	cis	rs6570726	0.791	rs9322029	chr6:145906683	A/G	cg23711669	chr6:146136114	FBXO30	0.93	13.88	0.65	2.77e-33	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1799949	1.000	rs2070834	chr17:41242285	T/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.45	6.4	0.37	7.12e-10	Menopause (age at onset);
CESC	cis	rs12765878	1.000	rs11191843	chr10:105648651	G/C	cg24587175	chr10:105670608	OBFC1	0.32	5.22	0.31	3.58e-7	Coronary artery disease;
CESC	cis	rs8133932	0.701	rs2839054	chr21:47328449	A/G	cg14185626	chr21:47401492	COL6A1	0.46	5.17	0.3	4.51e-7	Schizophrenia;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg16365729	chr1:244998894	FAM36A	-0.45	-6.07	-0.35	4.48e-9	Ulcerative colitis;
CESC	cis	rs34779708	0.931	rs4934721	chr10:35377715	A/G	cg03585969	chr10:35415529	CREM	0.78	10.05	0.53	2.38e-20	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs12500824	0.564	rs72657839	chr4:77335916	G/T	cg20311846	chr4:77356250	SHROOM3	0.39	7.5	0.42	9.73e-13	Coronary artery disease;
CESC	cis	rs1005277	0.522	rs9418276	chr10:37940116	G/T	cg00409905	chr10:38381863	ZNF37A	-0.49	-6.68	-0.38	1.4e-10	Extrinsic epigenetic age acceleration;
CESC	cis	rs56399783	0.901	rs56007918	chr7:2826205	A/G	cg19731401	chr7:2775893	GNA12	0.64	5.73	0.33	2.67e-8	Childhood ear infection;
CESC	cis	rs9311474	1.000	rs7629072	chr3:52305633	C/T	cg18337363	chr3:52569053	NT5DC2	0.3	5.63	0.33	4.64e-8	Electroencephalogram traits;
CESC	cis	rs8070740	0.891	rs4790264	chr17:5336791	G/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.56	6.38	0.36	7.92e-10	Menopause (age at onset);
CESC	cis	rs2032447	0.517	rs7767546	chr6:25904067	T/C	cg03517284	chr6:25882590	NA	-0.62	-8.88	-0.48	1.06e-16	Intelligence (multi-trait analysis);
CESC	cis	rs787274	0.867	rs786969	chr9:115449556	C/G	cg13803584	chr9:115635662	SNX30	0.68	5.1	0.3	6.49e-7	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs7618915	0.501	rs1468638	chr3:52748058	T/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	5.84	0.34	1.51e-8	Bipolar disorder;
CESC	cis	rs4563143	0.647	rs73029014	chr19:29257655	G/C	cg12756686	chr19:29218302	NA	0.56	7.3	0.41	3.44e-12	Methadone dose in opioid dependence;
CESC	cis	rs9611565	0.729	rs9611570	chr22:41782721	G/T	cg06634786	chr22:41940651	POLR3H	-0.65	-6.97	-0.39	2.47e-11	Vitiligo;
CESC	cis	rs7771547	0.542	rs597153	chr6:36395997	C/T	cg04289385	chr6:36355825	ETV7	0.38	5.57	0.32	6.41e-8	Platelet distribution width;
CESC	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.65	0.38	1.71e-10	Prudent dietary pattern;
CESC	cis	rs2806561	0.734	rs2806564	chr1:23506685	T/C	cg12483005	chr1:23474871	LUZP1	0.39	6.15	0.35	2.85e-9	Height;
CESC	cis	rs1799949	1.000	rs35330014	chr17:41212547	C/T	cg05368731	chr17:41323189	NBR1	0.77	10.63	0.55	3.23e-22	Menopause (age at onset);
CESC	cis	rs854765	0.547	rs2955359	chr17:17946730	T/C	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.5	-6.33	-0.36	1.03e-9	Total body bone mineral density;
CESC	cis	rs1538970	0.924	rs11211117	chr1:45930246	C/T	cg06784218	chr1:46089804	CCDC17	0.34	5.45	0.32	1.14e-7	Platelet count;
CESC	trans	rs208520	0.955	rs9453664	chr6:66976079	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.7	7.87	0.44	9.16e-14	Exhaled nitric oxide output;
CESC	cis	rs7116495	0.609	rs10793014	chr11:71698838	A/G	cg07596299	chr11:71824057	C11orf51	-0.85	-5.48	-0.32	9.86e-8	Severe influenza A (H1N1) infection;
CESC	trans	rs2963826	0.589	rs298091	chr5:58996603	A/T	cg07628558	chr20:56964831	VAPB	0.48	6.0	0.35	6.36e-9	Obesity-related traits;
CESC	cis	rs7236492	0.748	rs78531995	chr18:77198370	C/T	cg15644404	chr18:77186268	NFATC1	-0.69	-5.4	-0.31	1.49e-7	Inflammatory bowel disease;Crohn's disease;
CESC	trans	rs4927850	0.918	rs4361313	chr3:195752260	A/G	cg16724585	chr3:197361211	NA	-0.56	-7.17	-0.4	7.33e-12	Pancreatic cancer;
CESC	cis	rs2637266	0.739	rs2583040	chr10:78439388	A/C	cg18941641	chr10:78392320	NA	0.4	7.32	0.41	2.98e-12	Pulmonary function;
CESC	cis	rs11785400	1.000	rs3735999	chr8:143746069	T/C	cg24634471	chr8:143751801	JRK	0.47	6.23	0.36	1.87e-9	Schizophrenia;
CESC	cis	rs3026101	0.671	rs2309372	chr17:5298396	G/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.43	5.68	0.33	3.57e-8	Body mass index;
CESC	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg11905131	chr22:24372483	LOC391322	-0.8	-12.03	-0.59	7.02e-27	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs2932538	0.846	rs7546203	chr1:113154529	C/A	cg22162597	chr1:113214053	CAPZA1	0.59	7.46	0.42	1.28e-12	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg02520729	chr12:122261552	SETD1B	0.5	6.59	0.38	2.3e-10	Fibrinogen levels;
CESC	cis	rs757110	0.866	rs5215	chr11:17408630	C/T	cg11839944	chr11:17409644	KCNJ11	0.41	5.38	0.31	1.67e-7	Type 2 diabetes;
CESC	cis	rs7395581	0.918	rs3816725	chr11:47305669	T/G	cg25783544	chr11:47291846	MADD	0.61	8.12	0.45	1.74e-14	HDL cholesterol;
CESC	cis	rs9649213	0.593	rs6465662	chr7:97917801	A/T	cg08684580	chr7:98029266	BAIAP2L1	-0.33	-5.26	-0.31	2.92e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7917772	0.503	rs7896841	chr10:104294665	C/T	cg22532475	chr10:104410764	TRIM8	-0.35	-6.02	-0.35	5.75e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs919433	0.926	rs787996	chr2:198216805	A/G	cg10820045	chr2:198174542	NA	0.39	5.78	0.33	2.05e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs8050907	0.744	rs17887050	chr16:4524584	C/A	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.89	5.66	0.33	3.84e-8	Obesity-related traits;
CESC	cis	rs943466	0.513	rs755497	chr6:33734419	C/T	cg25922239	chr6:33757077	LEMD2	-0.43	-5.68	-0.33	3.56e-8	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
CESC	cis	rs10927875	0.562	rs10803401	chr1:16147377	G/A	cg05821634	chr1:16164109	FLJ37453	0.35	5.04	0.3	8.7e-7	Dilated cardiomyopathy;
CESC	cis	rs892961	0.867	rs6501955	chr17:75414443	A/G	cg05865280	chr17:75406074	SEPT9	0.63	12.75	0.62	2.36e-29	Airflow obstruction;
CESC	cis	rs796364	0.951	rs13029537	chr2:200998950	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.7	-6.78	-0.38	7.71e-11	Schizophrenia;
CESC	cis	rs6800768	0.633	rs57144868	chr3:24144965	G/C	cg10674438	chr3:24145617	LOC152024	-0.46	-6.19	-0.36	2.23e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs2637266	0.935	rs751770	chr10:78393956	A/G	cg18941641	chr10:78392320	NA	0.43	8.09	0.45	2.14e-14	Pulmonary function;
CESC	cis	rs17401966	0.838	rs1538557	chr1:10297230	T/C	cg15208524	chr1:10270712	KIF1B	0.4	5.24	0.31	3.33e-7	Hepatocellular carcinoma;
CESC	cis	rs9303401	0.538	rs12603174	chr17:56489279	T/C	cg25039879	chr17:56429692	SUPT4H1	0.6	6.33	0.36	1.05e-9	Cognitive test performance;
CESC	trans	rs7980799	0.649	rs1601003	chr12:33689436	A/T	cg26384229	chr12:38710491	ALG10B	0.55	7.85	0.43	1.05e-13	Heart rate;Heart rate variability traits (RMSSD);
CESC	cis	rs17125944	0.506	rs7151491	chr14:53313711	C/G	cg00686598	chr14:53173677	PSMC6	-0.56	-5.09	-0.3	6.79e-7	Alzheimer's disease (late onset);
CESC	cis	rs13242816	1.000	rs62471198	chr7:116107963	T/C	cg04696780	chr7:116139425	CAV2	-0.62	-5.69	-0.33	3.31e-8	P wave duration;
CESC	cis	rs61542988	0.532	rs12673996	chr7:22833400	C/T	cg13679077	chr7:22862647	TOMM7	0.48	5.62	0.33	4.92e-8	Fibrinogen levels;
CESC	cis	rs6973256	0.569	rs13246174	chr7:133395004	C/T	cg10665199	chr7:133106180	EXOC4	0.44	6.0	0.35	6.41e-9	Intelligence (multi-trait analysis);
CESC	cis	rs2276314	0.857	rs16967327	chr18:33587036	C/T	cg05985134	chr18:33552581	C18orf21	0.61	7.24	0.41	4.75e-12	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs7772486	0.875	rs2814876	chr6:146304030	C/T	cg05347473	chr6:146136440	FBXO30	0.56	7.33	0.41	2.74e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7914558	0.966	rs2297786	chr10:104679978	C/T	cg04362960	chr10:104952993	NT5C2	0.43	5.52	0.32	8.02e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs853679	0.517	rs17774663	chr6:28120898	G/A	cg17949981	chr6:28129498	ZNF389	0.46	5.51	0.32	8.48e-8	Depression;
CESC	cis	rs6752107	1.000	rs6431654	chr2:234161769	C/T	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.39	6.04	0.35	5.27e-9	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs2425143	1.000	rs6058325	chr20:34388806	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.79	-7.16	-0.4	7.72e-12	Blood protein levels;
CESC	cis	rs9311474	0.508	rs17052256	chr3:52593119	A/G	cg18404041	chr3:52824283	ITIH1	-0.38	-6.45	-0.37	5.31e-10	Electroencephalogram traits;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg08722104	chr11:47448306	PSMC3	0.45	6.0	0.35	6.56e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs10465746	0.687	rs6576954	chr1:84323701	C/T	cg10977910	chr1:84465055	TTLL7	-0.43	-5.54	-0.32	7.13e-8	Obesity-related traits;
CESC	cis	rs722599	0.961	rs2359239	chr14:75326771	C/T	cg11812906	chr14:75593930	NEK9	-0.4	-5.08	-0.3	7.29e-7	IgG glycosylation;
CESC	cis	rs6076065	1.000	rs2424547	chr20:23392690	A/G	cg12062639	chr20:23401060	NAPB	0.42	5.17	0.3	4.64e-7	Facial morphology (factor 15, philtrum width);
CESC	cis	rs763014	0.898	rs1981484	chr16:630710	A/G	cg00908189	chr16:619842	PIGQ	0.66	9.26	0.49	7.42e-18	Height;
CESC	cis	rs7178909	0.732	rs57163265	chr15:90400650	A/T	cg19708238	chr15:90437601	AP3S2	0.38	5.09	0.3	6.64e-7	Common traits (Other);
CESC	cis	rs4803468	1.000	rs13344563	chr19:41945904	G/C	cg14132834	chr19:41945861	ATP5SL	0.6	7.5	0.42	9.48e-13	Height;
CESC	cis	rs36715	1.000	rs36702	chr5:127552723	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.55	6.3	0.36	1.23e-9	Breast cancer;
CESC	cis	rs7267979	0.745	rs6132845	chr20:25547767	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.7	11.61	0.58	1.77e-25	Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg09378111	chr2:211036309	C2orf67	0.48	6.08	0.35	4.13e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs9837602	1.000	rs13069311	chr3:99801628	A/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.51	7.05	0.4	1.55e-11	Breast cancer;
CESC	cis	rs684232	0.666	rs425961	chr17:573714	G/A	cg12384639	chr17:618140	VPS53	0.4	5.14	0.3	5.27e-7	Prostate cancer;
CESC	cis	rs9549367	0.713	rs2476328	chr13:113829350	C/T	cg18105134	chr13:113819100	PROZ	0.57	7.02	0.4	1.89e-11	Platelet distribution width;
CESC	cis	rs9322193	0.923	rs4354168	chr6:150017778	C/T	cg13206674	chr6:150067644	NUP43	0.45	6.48	0.37	4.57e-10	Lung cancer;
CESC	cis	rs1707322	0.827	rs12125508	chr1:46246010	A/G	cg03146154	chr1:46216737	IPP	0.8	11.14	0.56	6.98e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs34172651	0.517	rs2287783	chr16:24831727	C/T	cg02428538	chr16:24856791	SLC5A11	-0.48	-5.05	-0.3	8.04e-7	Intelligence (multi-trait analysis);
CESC	cis	rs9914544	0.933	rs11871889	chr17:18771425	T/C	cg26378065	chr17:18585709	ZNF286B	0.45	5.54	0.32	7.46e-8	Educational attainment (years of education);
CESC	cis	rs4253772	0.530	rs9615955	chr22:46743931	A/G	cg00784671	chr22:46762841	CELSR1	-0.65	-6.19	-0.36	2.31e-9	LDL cholesterol;Cholesterol, total;
CESC	cis	rs8020095	0.571	rs2144909	chr14:67325444	G/C	cg19548862	chr14:67692701	FAM71D	-0.49	-5.94	-0.34	8.74e-9	Depression (quantitative trait);
CESC	cis	rs57506017	0.585	rs10950395	chr7:12264467	T/C	cg23422036	chr7:12250390	TMEM106B	0.39	5.23	0.31	3.37e-7	Neuroticism;
CESC	cis	rs7809950	1.000	rs7793613	chr7:107250484	C/T	cg23024343	chr7:107201750	COG5	-0.43	-5.93	-0.34	9.53e-9	Coronary artery disease;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg07949612	chr2:69664562	NFU1	-0.45	-6.28	-0.36	1.41e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs4268898	0.662	rs2891380	chr2:24525830	G/A	cg08917208	chr2:24149416	ATAD2B	0.51	5.14	0.3	5.27e-7	Asthma;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04453488	chr8:145619577	CPSF1;MIR939	-0.49	-6.29	-0.36	1.33e-9	Gut microbiome composition (summer);
CESC	cis	rs317689	0.513	rs317659	chr12:69686132	T/A	cg20891283	chr12:69753455	YEATS4	0.58	7.3	0.41	3.45e-12	Response to diuretic therapy;
CESC	cis	rs4523957	0.928	rs216202	chr17:2197387	T/C	cg16513277	chr17:2031491	SMG6	0.6	8.31	0.45	5.14e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs854765	0.927	rs12943914	chr17:17980671	A/G	cg16928487	chr17:17741425	SREBF1	-0.51	-8.45	-0.46	2.01e-15	Total body bone mineral density;
CESC	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg07677032	chr17:61819896	STRADA	0.49	6.42	0.37	6.41e-10	Prudent dietary pattern;
CESC	cis	rs35110281	0.641	rs4818861	chr21:45123807	A/G	cg04455712	chr21:45112962	RRP1B	0.49	7.1	0.4	1.16e-11	Mean corpuscular volume;
CESC	cis	rs2742417	0.624	rs2673068	chr3:45768981	G/A	cg04837898	chr3:45731254	SACM1L	-0.48	-6.28	-0.36	1.4e-9	Response to anti-depressant treatment in major depressive disorder;
CESC	cis	rs5769765	0.954	rs5770709	chr22:50245196	G/T	cg22709217	chr22:50311962	ALG12;CRELD2	0.47	5.44	0.32	1.18e-7	Schizophrenia;
CESC	cis	rs897984	0.762	rs7206511	chr16:30950352	G/A	cg02466173	chr16:30829666	NA	0.48	8.01	0.44	3.58e-14	Dementia with Lewy bodies;
CESC	cis	rs1707322	0.721	rs11211157	chr1:46132844	T/C	cg03146154	chr1:46216737	IPP	0.82	11.52	0.58	3.64e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg20972342	chr5:235327	SDHA	0.43	6.12	0.35	3.38e-9	Fibrinogen levels;
CESC	cis	rs7618915	0.547	rs62253733	chr3:52653414	A/G	cg17372223	chr3:52568218	NT5DC2	0.42	6.29	0.36	1.32e-9	Bipolar disorder;
CESC	cis	rs514406	0.793	rs12402415	chr1:53218539	G/T	cg16325326	chr1:53192061	ZYG11B	-0.73	-12.08	-0.6	4.76e-27	Monocyte count;
CESC	cis	rs11997175	0.603	rs7016580	chr8:33824135	G/A	ch.8.33884649F	chr8:33765107	NA	0.49	5.84	0.34	1.53e-8	Body mass index;
CESC	cis	rs780094	0.544	rs780108	chr2:27684957	T/C	cg02592271	chr2:27665507	KRTCAP3	-0.26	-5.6	-0.33	5.49e-8	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27056436	chr7:5569463	ACTB	0.57	6.69	0.38	1.33e-10	Gut microbiome composition (summer);
CESC	cis	rs2839186	0.709	rs2839176	chr21:47678173	A/G	cg00815214	chr21:47717953	NA	-0.35	-5.17	-0.3	4.58e-7	Testicular germ cell tumor;
CESC	cis	rs7811142	0.830	rs705866	chr7:99965285	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.07	10.34	0.54	2.91e-21	Platelet count;
CESC	cis	rs9287719	0.967	rs6755548	chr2:10746126	A/G	cg00105475	chr2:10696890	NA	0.38	5.55	0.32	6.76e-8	Prostate cancer;
CESC	cis	rs7666738	0.830	rs35685312	chr4:98858521	G/A	cg05340658	chr4:99064831	C4orf37	0.75	11.16	0.57	5.89e-24	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1707322	0.686	rs3014236	chr1:46091305	T/C	cg05343316	chr1:45956843	TESK2	-0.52	-6.4	-0.37	7.03e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9549260	0.755	rs9549252	chr13:41230141	A/G	cg21288729	chr13:41239152	FOXO1	0.55	6.78	0.38	7.64e-11	Red blood cell count;
CESC	cis	rs7091068	0.671	rs591392	chr10:95406081	G/A	cg20715218	chr10:95462985	C10orf4	-0.54	-5.76	-0.33	2.31e-8	Urinary tract infection frequency;
CESC	cis	rs56235845	0.694	rs6876677	chr5:176755342	T/C	cg17509989	chr5:176798049	RGS14	0.51	6.56	0.37	2.76e-10	Hemoglobin concentration;Hematocrit;
CESC	cis	rs7084402	0.515	rs12262629	chr10:60265656	G/A	cg07615347	chr10:60278583	BICC1	-0.56	-7.97	-0.44	4.75e-14	Refractive error;
CESC	cis	rs6426558	0.621	rs7521639	chr1:227223736	T/C	cg10327440	chr1:227177885	CDC42BPA	0.83	11.74	0.58	6.81e-26	Neutrophil percentage of white cells;
CESC	trans	rs916888	0.773	rs199447	chr17:44812188	C/T	cg07870213	chr5:140052090	DND1	0.64	6.87	0.39	4.48e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg02543249	chr2:176867176	KIAA1715	0.51	6.25	0.36	1.66e-9	Thyroid stimulating hormone;
CESC	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.09	21.15	0.79	7.85e-59	Prudent dietary pattern;
CESC	cis	rs950169	0.922	rs8037078	chr15:84818871	A/G	cg17507749	chr15:85114479	UBE2QP1	-0.55	-6.25	-0.36	1.66e-9	Schizophrenia;
CESC	cis	rs10088262	0.527	rs3911939	chr8:124793744	T/G	cg15047889	chr8:124780837	FAM91A1	-0.55	-6.67	-0.38	1.49e-10	Pancreatic cancer;
CESC	cis	rs4665809	1.000	rs10048648	chr2:26320315	T/C	cg08470875	chr2:26401718	FAM59B	-0.47	-5.29	-0.31	2.56e-7	Gut microbiome composition (summer);
CESC	trans	rs916888	0.610	rs142167	chr17:44795234	C/T	cg10053473	chr17:62856997	LRRC37A3	0.67	9.22	0.49	9.43e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs9303401	0.659	rs12935851	chr17:56600244	C/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.03	12.7	0.62	3.54e-29	Cognitive test performance;
CESC	cis	rs9463078	0.739	rs1293467	chr6:44769204	C/G	cg25276700	chr6:44698697	NA	0.34	5.2	0.3	4.04e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CESC	cis	rs11098499	0.863	rs3775844	chr4:120428033	G/A	cg24375607	chr4:120327624	NA	0.44	5.23	0.31	3.48e-7	Corneal astigmatism;
CESC	cis	rs13108904	0.557	rs1250098	chr4:1238256	A/T	cg05025164	chr4:1340916	KIAA1530	-0.64	-8.8	-0.48	1.8e-16	Obesity-related traits;
CESC	cis	rs7940866	0.834	rs10894298	chr11:130840571	C/A	cg12179176	chr11:130786555	SNX19	0.66	10.11	0.53	1.52e-20	Schizophrenia;
CESC	cis	rs2637266	0.703	rs2583061	chr10:78558475	G/A	cg18941641	chr10:78392320	NA	0.4	7.53	0.42	7.91e-13	Pulmonary function;
CESC	cis	rs868036	0.718	rs3784710	chr15:68072458	T/C	cg03210257	chr15:68118127	LBXCOR1	-0.28	-5.11	-0.3	6.25e-7	Restless legs syndrome;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	ch.6.215100R	chr6:7903714	TXNDC5	-0.45	-6.21	-0.36	2.09e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs854765	0.520	rs7219324	chr17:17909775	C/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.51	-6.71	-0.38	1.15e-10	Total body bone mineral density;
CESC	cis	rs9733	0.519	rs11800855	chr1:150800995	G/A	cg17724175	chr1:150552817	MCL1	0.33	5.23	0.31	3.49e-7	Tonsillectomy;
CESC	cis	rs11158198	0.643	rs7151771	chr14:58580310	C/T	cg15908186	chr14:58618357	C14orf37	0.35	5.09	0.3	6.67e-7	Dementia and core Alzheimer's disease neuropathologic changes;
CESC	trans	rs55704346	0.566	rs9991246	chr4:25385320	T/C	cg01822600	chr1:245751692	KIF26B	0.43	6.27	0.36	1.44e-9	Tonsillectomy;
CESC	cis	rs72781680	0.898	rs72782106	chr2:24022009	A/G	cg08917208	chr2:24149416	ATAD2B	1.13	10.18	0.53	9.42e-21	Lymphocyte counts;
CESC	cis	rs4253772	0.530	rs11090865	chr22:46731689	G/T	cg18190219	chr22:46762943	CELSR1	-0.66	-7.03	-0.4	1.72e-11	LDL cholesterol;Cholesterol, total;
CESC	cis	rs4986172	0.726	rs12946454	chr17:43208121	A/T	cg10701640	chr17:43249399	NA	0.39	6.13	0.35	3.25e-9	Height;
CESC	cis	rs8114671	0.836	rs13042358	chr20:33634479	G/A	cg24642439	chr20:33292090	TP53INP2	-0.45	-5.44	-0.32	1.19e-7	Height;
CESC	cis	rs6912958	0.754	rs10755484	chr6:88244648	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-6.5	-0.37	3.99e-10	Monocyte percentage of white cells;
CESC	trans	rs7617773	0.817	rs3731534	chr3:48211777	C/T	cg02094337	chr17:80542118	FOXK2	0.43	6.17	0.35	2.5e-9	Coronary artery disease;
CESC	cis	rs2075371	0.829	rs9641970	chr7:134004887	C/A	cg00033643	chr7:134001901	SLC35B4	0.41	5.23	0.31	3.38e-7	Mean platelet volume;
CESC	cis	rs7811142	1.000	rs11766752	chr7:100073292	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.95	10.19	0.53	8.92e-21	Platelet count;
CESC	cis	rs763121	0.962	rs5757130	chr22:38937794	G/A	cg06544989	chr22:39130855	UNC84B	0.44	7.89	0.44	8.13e-14	Menopause (age at onset);
CESC	cis	rs116095464	0.558	rs6881920	chr5:222411	T/C	cg10591111	chr5:226296	SDHA	-0.51	-6.35	-0.36	9.22e-10	Breast cancer;
CESC	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.63	7.15	0.4	8.37e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs72634258	0.732	rs6577464	chr1:8171302	T/C	cg00042356	chr1:8021962	PARK7	-0.52	-5.64	-0.33	4.36e-8	Inflammatory bowel disease;
CESC	cis	rs8077889	0.672	rs1230397	chr17:41844689	A/G	cg26893861	chr17:41843967	DUSP3	1.09	22.94	0.82	7.04e-65	Triglycerides;
CESC	cis	rs7100689	0.646	rs1290317	chr10:82062531	C/A	cg00277334	chr10:82204260	NA	-0.61	-8.08	-0.44	2.35e-14	Post bronchodilator FEV1;
CESC	trans	rs931812	1.000	rs931812	chr8:101919321	A/G	cg20993868	chr7:22813445	NA	-0.44	-6.17	-0.35	2.51e-9	Attention deficit hyperactivity disorder and conduct disorder;
CESC	cis	rs5750830	0.594	rs6001587	chr22:39819008	T/C	cg02038168	chr22:39784481	NA	-0.62	-7.66	-0.43	3.51e-13	Intelligence (multi-trait analysis);
CESC	cis	rs57506017	0.585	rs6460899	chr7:12253050	A/C	cg23422036	chr7:12250390	TMEM106B	0.39	5.21	0.3	3.76e-7	Neuroticism;
CESC	cis	rs6461049	0.646	rs3778970	chr7:2143208	C/A	cg23048001	chr7:2026167	MAD1L1	0.45	5.72	0.33	2.84e-8	Schizophrenia;
CESC	cis	rs11997175	0.902	rs7009022	chr8:33700404	A/G	ch.8.33884649F	chr8:33765107	NA	0.61	7.89	0.44	8.22e-14	Body mass index;
CESC	cis	rs1008375	0.966	rs6832962	chr4:17652133	T/C	cg02297831	chr4:17616191	MED28	0.66	8.05	0.44	2.75e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs12410462	0.581	rs35141785	chr1:227553496	G/C	cg10327440	chr1:227177885	CDC42BPA	-0.62	-5.2	-0.3	3.97e-7	Major depressive disorder;
CESC	cis	rs9318086	0.935	rs9652080	chr13:24435426	A/C	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.39	-5.31	-0.31	2.3e-7	Myopia (pathological);
CESC	cis	rs9611565	0.765	rs132906	chr22:41799767	G/C	cg06634786	chr22:41940651	POLR3H	0.44	5.15	0.3	5.08e-7	Vitiligo;
CESC	cis	rs4969178	0.600	rs4969184	chr17:76393413	G/A	cg05887092	chr17:76393375	PGS1	0.69	11.47	0.58	5.36e-25	HDL cholesterol levels;
CESC	cis	rs6460942	0.915	rs6968695	chr7:12443878	G/C	cg13733410	chr7:12443478	VWDE	-0.53	-5.45	-0.32	1.17e-7	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07272677	chr4:186741447	SORBS2	-0.53	-6.04	-0.35	5.22e-9	Gut microbiome composition (summer);
CESC	cis	rs2576037	0.901	rs6507719	chr18:44581310	A/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.45	5.86	0.34	1.4e-8	Personality dimensions;
CESC	cis	rs1670533	0.929	rs6599280	chr4:1063818	A/G	cg27284194	chr4:1044797	NA	0.47	5.83	0.34	1.57e-8	Recombination rate (females);
CESC	cis	rs12142240	0.698	rs72677594	chr1:46824371	A/C	cg00530320	chr1:46809349	NSUN4	0.6	8.04	0.44	2.96e-14	Menopause (age at onset);
CESC	cis	rs2629540	0.793	rs10794180	chr10:126449306	T/A	cg08799069	chr10:126477246	METTL10	-0.67	-9.16	-0.49	1.44e-17	Cocaine dependence;
CESC	cis	rs4728302	0.574	rs7804463	chr7:133447651	T/C	cg10665199	chr7:133106180	EXOC4	0.42	5.64	0.33	4.35e-8	Intelligence;Intelligence (multi-trait analysis);
CESC	cis	rs3738443	0.594	rs60050650	chr1:247376776	T/C	cg07706540	chr1:247373924	NA	-0.46	-5.45	-0.32	1.15e-7	Alcohol dependence;
CESC	cis	rs853679	0.517	rs9380052	chr6:28064623	A/G	cg17949981	chr6:28129498	ZNF389	0.42	5.17	0.3	4.72e-7	Depression;
CESC	cis	rs2901656	0.502	rs9425308	chr1:172383265	A/C	cg03748243	chr1:172413542	C1orf105;PIGC	0.38	5.16	0.3	4.75e-7	Red cell distribution width;Platelet distribution width;
CESC	trans	rs561341	0.831	rs11658469	chr17:30206426	T/C	cg20587970	chr11:113659929	NA	0.99	11.72	0.58	7.58e-26	Hip circumference adjusted for BMI;
CESC	cis	rs13256369	0.802	rs2280560	chr8:8560602	C/T	cg17143192	chr8:8559678	CLDN23	0.76	8.64	0.47	5.49e-16	Obesity-related traits;
CESC	cis	rs2576037	0.583	rs10070	chr18:44388899	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.51	-6.87	-0.39	4.63e-11	Personality dimensions;
CESC	cis	rs453301	0.624	rs2979265	chr8:8858717	G/C	cg06636001	chr8:8085503	FLJ10661	0.45	5.93	0.34	9.22e-9	Joint mobility (Beighton score);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12598099	chr18:60189407	ZCCHC2	-0.61	-7.22	-0.41	5.42e-12	Gut microbiome composition (summer);
CESC	cis	rs1862618	0.853	rs832565	chr5:56150803	T/G	cg18230493	chr5:56204884	C5orf35	-0.74	-8.73	-0.47	2.85e-16	Initial pursuit acceleration;
CESC	cis	rs6460942	0.841	rs17443848	chr7:12443688	A/G	cg16278512	chr7:12443529	VWDE	-0.52	-6.47	-0.37	4.63e-10	Coronary artery disease;
CESC	cis	rs514406	0.570	rs1332776	chr1:53189816	C/T	cg27535305	chr1:53392650	SCP2	-0.31	-5.4	-0.31	1.5e-7	Monocyte count;
CESC	trans	rs11098499	0.863	rs6534139	chr4:120449456	A/G	cg25214090	chr10:38739885	LOC399744	-0.68	-8.98	-0.48	5.25e-17	Corneal astigmatism;
CESC	cis	rs6429082	0.683	rs868815	chr1:235584543	C/G	cg26050004	chr1:235667680	B3GALNT2	-0.54	-6.76	-0.38	8.66e-11	Adiposity;
CESC	cis	rs72781680	0.848	rs6748727	chr2:24041058	G/A	cg08917208	chr2:24149416	ATAD2B	0.95	8.71	0.47	3.45e-16	Lymphocyte counts;
CESC	cis	rs3824867	0.920	rs7108143	chr11:47453722	T/G	cg20307385	chr11:47447363	PSMC3	-0.49	-5.9	-0.34	1.12e-8	Mean corpuscular hemoglobin;
CESC	cis	rs514406	0.644	rs7552663	chr1:53204352	C/T	cg25767906	chr1:53392781	SCP2	0.43	5.85	0.34	1.42e-8	Monocyte count;
CESC	cis	rs965469	0.779	rs6037548	chr20:3299299	G/A	cg25506879	chr20:3388711	C20orf194	-0.49	-5.41	-0.32	1.44e-7	IFN-related cytopenia;
CESC	cis	rs10751667	0.600	rs10751665	chr11:941300	G/A	cg06064525	chr11:970664	AP2A2	-0.52	-10.43	-0.54	1.43e-21	Alzheimer's disease (late onset);
CESC	cis	rs17376456	0.877	rs35075119	chr5:93385457	T/C	cg21475434	chr5:93447410	FAM172A	0.77	6.93	0.39	3.23e-11	Diabetic retinopathy;
CESC	cis	rs11155671	0.530	rs4869764	chr6:150211828	T/C	cg09699651	chr6:150184138	LRP11	0.55	7.7	0.43	2.78e-13	Testicular germ cell tumor;
CESC	cis	rs11249608	0.548	rs12152869	chr5:178462520	A/G	cg21905437	chr5:178450457	ZNF879	0.58	8.1	0.45	2.04e-14	Pubertal anthropometrics;
CESC	cis	rs7193541	0.646	rs4888267	chr16:74687906	A/G	cg01733217	chr16:74700730	RFWD3	1.05	20.16	0.78	2e-55	Multiple myeloma;
CESC	cis	rs1808579	0.935	rs1623060	chr18:21143183	C/T	cg14672496	chr18:21087552	C18orf8	0.38	5.43	0.32	1.29e-7	Hip circumference;Body mass index;BMI (adjusted for smoking behaviour);
CESC	cis	rs7927592	0.763	rs10791982	chr11:68337664	T/G	cg01657329	chr11:68192670	LRP5	0.5	6.72	0.38	1.11e-10	Total body bone mineral density;
CESC	cis	rs1799949	0.602	rs8176235	chr17:41219560	C/T	cg05368731	chr17:41323189	NBR1	0.71	8.2	0.45	1.06e-14	Menopause (age at onset);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg07970400	chr15:40650285	DISP2	-0.43	-6.08	-0.35	4.07e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs3806843	0.735	rs801183	chr5:140091115	C/T	cg26395211	chr5:140044315	WDR55	-0.47	-6.16	-0.35	2.68e-9	Depressive symptoms (multi-trait analysis);
CESC	cis	rs829883	0.646	rs1641638	chr12:98891031	A/G	cg25150519	chr12:98850993	NA	0.41	5.34	0.31	2.01e-7	Colorectal adenoma (advanced);
CESC	cis	rs6831352	0.879	rs2851255	chr4:100042103	C/G	cg12011299	chr4:100065546	ADH4	0.52	5.9	0.34	1.11e-8	Alcohol dependence;
CESC	cis	rs4665809	0.941	rs1434079	chr2:26284670	C/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.67	-7.6	-0.42	4.99e-13	Gut microbiome composition (summer);
CESC	cis	rs8177179	0.967	rs10935085	chr3:133459735	C/T	cg16262614	chr3:133464971	TF	0.4	7.96	0.44	4.99e-14	Iron status biomarkers (transferrin levels);
CESC	cis	rs9549367	0.789	rs6577031	chr13:113878182	T/C	cg18105134	chr13:113819100	PROZ	0.62	8.25	0.45	7.66e-15	Platelet distribution width;
CESC	cis	rs1483890	0.723	rs6783070	chr3:69411596	A/C	cg22125112	chr3:69402811	FRMD4B	-0.39	-5.24	-0.31	3.26e-7	Resting heart rate;
CESC	cis	rs80130819	0.688	rs11168455	chr12:48592792	G/A	cg05342945	chr12:48394962	COL2A1	-0.53	-6.1	-0.35	3.76e-9	Prostate cancer;
CESC	cis	rs902774	0.597	rs7299694	chr12:53352572	A/C	cg16329197	chr12:53359506	NA	-0.54	-7.74	-0.43	2.15e-13	Prostate cancer;
CESC	cis	rs698833	0.501	rs10194161	chr2:44507213	A/G	cg04920474	chr2:44395004	PPM1B	-0.46	-6.7	-0.38	1.25e-10	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg22506413	chr7:54902079	NA	-0.42	-6.15	-0.35	2.86e-9	Gut microbiota (bacterial taxa);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg04025244	chr7:32766748	LOC441208	-0.36	-6.09	-0.35	3.89e-9	Gambling;
CESC	cis	rs7412746	0.611	rs7556661	chr1:150892009	C/T	cg22823121	chr1:150693482	HORMAD1	0.4	5.64	0.33	4.46e-8	Melanoma;
CESC	cis	rs12142240	0.698	rs10158236	chr1:46820896	G/T	cg10495392	chr1:46806563	NSUN4	0.58	6.32	0.36	1.09e-9	Menopause (age at onset);
CESC	cis	rs7216064	1.000	rs62084249	chr17:65874998	A/G	cg07042672	chr17:66097459	LOC651250	-0.52	-5.4	-0.31	1.5e-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs8177179	0.967	rs4078166	chr3:133435979	C/A	cg17775713	chr3:133465469	TF	0.34	6.03	0.35	5.54e-9	Iron status biomarkers (transferrin levels);
CESC	cis	rs7264396	0.528	rs7273880	chr20:34551507	A/G	cg17201900	chr20:34330562	RBM39	0.5	5.22	0.31	3.71e-7	Total cholesterol levels;
CESC	cis	rs938554	0.578	rs7663032	chr4:9993838	C/T	cg02734326	chr4:10020555	SLC2A9	0.45	5.42	0.32	1.35e-7	Blood metabolite levels;
CESC	cis	rs72781680	1.000	rs12623496	chr2:24181583	C/T	cg20701182	chr2:24300061	SF3B14	0.64	5.74	0.33	2.63e-8	Lymphocyte counts;
CESC	cis	rs10883723	0.962	rs1056740	chr10:104236552	C/T	cg22532475	chr10:104410764	TRIM8	-0.34	-5.67	-0.33	3.77e-8	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs644799	0.687	rs3748252	chr11:95519195	A/T	cg25622487	chr11:95524042	FAM76B;CEP57	-0.76	-10.68	-0.55	2.2e-22	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs7267979	1.000	rs2424712	chr20:25416942	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.87	18.11	0.74	3e-48	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs34779708	0.733	rs12254018	chr10:35550641	T/A	cg03585969	chr10:35415529	CREM	0.54	6.14	0.35	2.97e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs734999	0.588	rs10910098	chr1:2533250	C/A	cg18854424	chr1:2615690	NA	0.28	5.41	0.32	1.43e-7	Ulcerative colitis;
CESC	cis	rs3796352	1.000	rs4478072	chr3:53106125	G/T	cg07884673	chr3:53033167	SFMBT1	0.53	5.3	0.31	2.47e-7	Immune reponse to smallpox (secreted IL-2);
CESC	cis	rs9660180	1.000	rs3737628	chr1:1722932	C/T	cg17747265	chr1:1875780	NA	-0.58	-9.2	-0.49	1.14e-17	Body mass index;
CESC	trans	rs1814175	0.616	rs1722001	chr11:49894427	A/G	cg03929089	chr4:120376271	NA	-0.9	-14.75	-0.67	2.44e-36	Height;
CESC	cis	rs7659604	0.521	rs4833235	chr4:122695136	C/A	cg20573242	chr4:122745356	CCNA2	-0.39	-5.03	-0.3	8.9e-7	Type 2 diabetes;
CESC	cis	rs2066819	1.000	rs77131854	chr12:56664231	C/T	cg26734620	chr12:56694298	CS	1.04	6.71	0.38	1.18e-10	Psoriasis vulgaris;
CESC	cis	rs6088580	0.634	rs6088484	chr20:32985961	T/C	cg08999081	chr20:33150536	PIGU	-0.65	-11.34	-0.57	1.5e-24	Glomerular filtration rate (creatinine);
CESC	cis	rs9300255	0.602	rs1106241	chr12:123627016	T/C	cg19016782	chr12:123741754	C12orf65	-0.37	-5.07	-0.3	7.56e-7	Neutrophil percentage of white cells;
CESC	cis	rs765787	0.530	rs2413785	chr15:45530381	T/C	cg24006582	chr15:45444508	DUOX1	-0.6	-7.3	-0.41	3.34e-12	Uric acid levels;
CESC	cis	rs2948294	0.588	rs4840913	chr8:8116906	A/C	cg06636001	chr8:8085503	FLJ10661	0.43	5.28	0.31	2.66e-7	Red cell distribution width;
CESC	cis	rs514406	0.679	rs12563825	chr1:53238324	G/T	cg24675658	chr1:53192096	ZYG11B	0.74	11.37	0.57	1.15e-24	Monocyte count;
CESC	cis	rs7512552	0.839	rs834231	chr1:150389392	A/T	cg15654264	chr1:150340011	RPRD2	-0.42	-5.63	-0.33	4.48e-8	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CESC	trans	rs61931739	0.517	rs7486246	chr12:34526419	T/G	cg26384229	chr12:38710491	ALG10B	0.54	7.53	0.42	8.03e-13	Morning vs. evening chronotype;
CESC	cis	rs4665809	0.556	rs6730311	chr2:26419474	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.99	-12.0	-0.59	8.9e-27	Gut microbiome composition (summer);
CESC	cis	rs9419702	0.614	rs9419567	chr10:133535149	C/G	cg04492858	chr10:133558786	NA	0.39	5.52	0.32	7.87e-8	Survival in rectal cancer;
CESC	cis	rs4073582	0.555	rs521109	chr11:66030948	G/A	cg14036092	chr11:66035641	RAB1B	0.56	7.87	0.44	9.14e-14	Gout;
CESC	cis	rs2569991	0.588	rs14191	chr3:12940346	G/A	cg22481960	chr3:13008800	IQSEC1	-0.57	-6.76	-0.38	8.53e-11	Periodontitis (DPAL);
CESC	cis	rs4975709	0.589	rs4975744	chr5:1860049	A/G	cg17650747	chr5:1873721	NA	0.43	6.1	0.35	3.77e-9	Cardiovascular disease risk factors;
CESC	cis	rs6577655	0.517	rs6996991	chr8:135589255	G/A	cg17885191	chr8:135476712	NA	0.47	5.24	0.31	3.26e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CESC	cis	rs7508679	1.000	rs10401485	chr19:7222234	T/C	cg09779027	chr19:7224513	INSR	0.53	8.58	0.47	7.92e-16	Hypothyroidism;
CESC	cis	rs7582720	1.000	rs75869289	chr2:203806724	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.38	0.41	1.99e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs11997175	0.766	rs6983113	chr8:33699513	G/A	ch.8.33884649F	chr8:33765107	NA	0.44	5.61	0.33	5.22e-8	Body mass index;
CESC	cis	rs2404602	0.692	rs58361452	chr15:76973372	T/C	cg22467129	chr15:76604101	ETFA	-0.34	-5.15	-0.3	5.13e-7	Blood metabolite levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13402217	chr1:151584375	SNX27	0.61	7.56	0.42	6.81e-13	Gut microbiome composition (summer);
CESC	cis	rs9322193	0.962	rs9322206	chr6:149962617	T/C	cg07701084	chr6:150067640	NUP43	0.42	5.82	0.34	1.7e-8	Lung cancer;
CESC	trans	rs765547	1.000	rs920588	chr8:19854267	C/T	cg12649343	chr22:47023005	GRAMD4	-0.3	-6.21	-0.36	2.08e-9	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
CESC	cis	rs7662987	0.517	rs1311615	chr4:100012261	G/A	cg12011299	chr4:100065546	ADH4	0.59	6.45	0.37	5.25e-10	Smoking initiation;
CESC	cis	rs2479724	0.905	rs2251274	chr6:41839438	T/G	cg17623882	chr6:41773611	USP49	-0.42	-6.19	-0.36	2.29e-9	Menarche (age at onset);
CESC	cis	rs4727027	0.870	rs1568945	chr7:148874112	T/G	cg23583168	chr7:148888333	NA	-0.77	-11.19	-0.57	4.52e-24	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs7520050	0.966	rs10890363	chr1:46356148	C/T	cg24296786	chr1:45957014	TESK2	-0.43	-5.34	-0.31	2e-7	Red blood cell count;Reticulocyte count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14666069	chr1:155145896	TRIM46;KRTCAP2	0.56	6.12	0.35	3.34e-9	Gut microbiome composition (summer);
CESC	cis	rs10979	1.000	rs9484768	chr6:143887928	C/T	cg25407410	chr6:143891975	LOC285740	-0.61	-9.2	-0.49	1.11e-17	Hypospadias;
CESC	cis	rs7666738	0.830	rs17550610	chr4:99008273	T/C	cg05340658	chr4:99064831	C4orf37	0.8	12.44	0.61	2.83e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9322193	0.962	rs9688412	chr6:150124283	A/G	cg07701084	chr6:150067640	NUP43	-0.44	-5.97	-0.34	7.79e-9	Lung cancer;
CESC	cis	rs9910055	0.540	rs609292	chr17:42180436	G/A	cg19774624	chr17:42201019	HDAC5	0.62	8.84	0.48	1.33e-16	Total body bone mineral density;
CESC	cis	rs938554	0.571	rs12509955	chr4:10024303	C/T	cg11266682	chr4:10021025	SLC2A9	-0.49	-6.89	-0.39	4.17e-11	Blood metabolite levels;
CESC	cis	rs1559088	0.847	rs3760891	chr19:33599708	C/T	cg27124370	chr19:33622961	WDR88	0.45	5.86	0.34	1.34e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs10504229	0.861	rs59873610	chr8:58172290	T/A	cg05313129	chr8:58192883	C8orf71	-0.54	-6.28	-0.36	1.4e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs2180341	1.000	rs6910763	chr6:127630925	T/C	cg24812749	chr6:127587940	RNF146	1.07	15.48	0.69	6e-39	Breast cancer;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg19199483	chr13:111483035	NA	0.45	6.48	0.37	4.37e-10	Fibrinogen levels;
CESC	cis	rs7659604	0.539	rs7686084	chr4:122764725	A/C	cg06713675	chr4:122721982	EXOSC9	-0.51	-6.96	-0.39	2.71e-11	Type 2 diabetes;
CESC	cis	rs2108622	0.683	rs112571591	chr19:15977445	G/A	cg13772218	chr19:15982569	NA	0.29	5.69	0.33	3.28e-8	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CESC	cis	rs10504229	0.500	rs9772760	chr8:57986999	G/C	cg24829409	chr8:58192753	C8orf71	-0.36	-5.08	-0.3	7.21e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs8114671	0.836	rs6120778	chr20:33565169	T/C	cg06115741	chr20:33292138	TP53INP2	0.46	5.45	0.32	1.14e-7	Height;
CESC	cis	rs6582630	0.555	rs1829583	chr12:38423161	T/C	cg26384229	chr12:38710491	ALG10B	-0.63	-9.48	-0.5	1.55e-18	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs10949834	1.000	rs8326	chr7:73483689	G/C	cg07137043	chr7:73588983	EIF4H	-0.65	-5.99	-0.35	6.97e-9	Verbal memory performance (residualized delayed recall change);
CESC	cis	rs7818688	0.929	rs73276439	chr8:96035892	C/A	cg16049864	chr8:95962084	TP53INP1	0.6	5.76	0.33	2.27e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs35110281	0.517	rs11089020	chr21:44939991	C/T	cg04455712	chr21:45112962	RRP1B	0.34	5.09	0.3	6.86e-7	Mean corpuscular volume;
CESC	trans	rs61931739	0.658	rs4476006	chr12:34237154	A/C	cg26384229	chr12:38710491	ALG10B	0.49	6.73	0.38	1.02e-10	Morning vs. evening chronotype;
CESC	cis	rs3733585	0.699	rs7437120	chr4:9967683	T/A	cg11266682	chr4:10021025	SLC2A9	-0.58	-10.89	-0.56	4.5e-23	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs72829446	0.530	rs7210292	chr17:7380305	G/T	cg02795151	chr17:7402630	POLR2A	0.55	5.82	0.34	1.72e-8	Androgen levels;
CESC	cis	rs11792861	0.888	rs75543406	chr9:111816903	A/T	cg13535736	chr9:111863775	C9orf5	-0.52	-6.91	-0.39	3.63e-11	Menarche (age at onset);
CESC	cis	rs34779708	0.733	rs7070778	chr10:35541688	T/C	cg03585969	chr10:35415529	CREM	0.56	6.42	0.37	6.15e-10	Inflammatory bowel disease;Crohn's disease;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg08928321	chr10:70748447	KIAA1279	-0.44	-6.27	-0.36	1.42e-9	Asthma;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24148044	chr16:85061578	KIAA0513	0.61	7.21	0.4	5.95e-12	Gut microbiome composition (summer);
CESC	cis	rs7833790	0.660	rs10091077	chr8:82705464	A/G	cg17211192	chr8:82754475	SNX16	-0.6	-7.75	-0.43	1.92e-13	Diastolic blood pressure;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09546895	chr5:32174322	GOLPH3	0.57	7.04	0.4	1.65e-11	Gut microbiome composition (summer);
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg01632260	chr4:89183583	PPM1K	0.4	6.01	0.35	6.2e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg15487600	chr1:155113158	DPM3	-0.49	-6.17	-0.35	2.56e-9	Ulcerative colitis;
CESC	cis	rs4665809	0.941	rs1470096	chr2:26311482	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.82	-9.22	-0.49	9.78e-18	Gut microbiome composition (summer);
CESC	cis	rs17253792	0.545	rs12893610	chr14:56016347	C/T	cg01858014	chr14:56050164	KTN1	-0.86	-6.4	-0.37	7.2e-10	Putamen volume;
CESC	cis	rs1538970	0.748	rs11211137	chr1:46013892	T/A	cg05343316	chr1:45956843	TESK2	0.91	11.59	0.58	2.07e-25	Platelet count;
CESC	cis	rs7811142	0.830	rs6965458	chr7:99973402	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.99	9.38	0.5	3.07e-18	Platelet count;
CESC	cis	rs4919087	1.000	rs10882898	chr10:99087330	G/A	cg25902810	chr10:99078978	FRAT1	-0.66	-8.61	-0.47	6.57e-16	Monocyte count;
CESC	cis	rs4481887	0.927	rs12039929	chr1:248482018	G/A	cg00666640	chr1:248458726	OR2T12	0.36	5.9	0.34	1.11e-8	Common traits (Other);
CESC	cis	rs17666538	0.585	rs336437	chr8:636251	A/C	cg02524346	chr8:600233	NA	0.85	6.42	0.37	6.23e-10	IgG glycosylation;
CESC	cis	rs12497850	0.644	rs11928552	chr3:48739883	T/C	cg07636037	chr3:49044803	WDR6	0.94	15.05	0.68	2.07e-37	Parkinson's disease;
CESC	cis	rs6429082	0.668	rs291395	chr1:235652049	A/C	cg26050004	chr1:235667680	B3GALNT2	-0.64	-9.62	-0.51	5.38e-19	Adiposity;
CESC	cis	rs4930561	0.765	rs1894204	chr11:67929671	C/T	cg16338278	chr11:67432957	ALDH3B2	0.41	5.18	0.3	4.32e-7	Breast cancer in childhood cancer survivors;IgG glycosylation;
CESC	cis	rs6879260	1.000	rs7706951	chr5:179733407	C/T	cg23221052	chr5:179740743	GFPT2	-0.55	-7.36	-0.41	2.32e-12	Height;
CESC	cis	rs6662572	1.000	rs7541935	chr1:46217493	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.51	5.62	0.33	4.83e-8	Blood protein levels;
CESC	cis	rs7116495	0.609	rs2155142	chr11:71642524	A/G	cg10381502	chr11:71823885	C11orf51	0.9	6.15	0.35	2.92e-9	Severe influenza A (H1N1) infection;
CESC	cis	rs28489187	0.706	rs4949890	chr1:85830632	T/C	cg16011679	chr1:85725395	C1orf52	0.57	6.38	0.36	7.83e-10	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg08024316	chr17:73401273	GRB2	-0.49	-7.05	-0.4	1.59e-11	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs2549003	1.000	rs2070727	chr5:131820275	C/A	cg02551604	chr5:131831745	NA	-0.37	-5.22	-0.31	3.53e-7	Asthma (sex interaction);
CESC	cis	rs4919687	0.550	rs12775883	chr10:104485301	G/A	cg04362960	chr10:104952993	NT5C2	0.48	5.45	0.32	1.18e-7	Colorectal cancer;
CESC	cis	rs1559088	0.895	rs1974784	chr19:33551563	T/G	cg17764715	chr19:33622953	WDR88	0.45	5.66	0.33	3.86e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs10489202	0.683	rs202260	chr1:167956167	G/T	cg24449463	chr1:168025552	DCAF6	-0.45	-5.76	-0.33	2.36e-8	Schizophrenia;
CESC	cis	rs1799949	0.930	rs56729776	chr17:41422131	C/T	cg23758822	chr17:41437982	NA	1.05	15.64	0.69	1.68e-39	Menopause (age at onset);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg15230273	chr5:107006413	EFNA5	0.44	6.0	0.35	6.4e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs9902453	0.817	rs4794861	chr17:28183174	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.64	8.19	0.45	1.09e-14	Coffee consumption (cups per day);
CESC	cis	rs73206853	0.764	rs57033697	chr12:110550992	G/A	cg12870014	chr12:110450643	ANKRD13A	0.65	5.63	0.33	4.52e-8	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs12464559	0.522	rs4316939	chr2:152525120	C/T	cg01189475	chr2:152685088	ARL5A	-0.56	-5.2	-0.3	3.98e-7	Response to cognitive-behavioural therapy in anxiety disorder;
CESC	cis	rs6032067	0.641	rs13042991	chr20:43767178	A/G	cg10761708	chr20:43804764	PI3	0.54	6.11	0.35	3.62e-9	Blood protein levels;
CESC	cis	rs7772486	0.754	rs4896838	chr6:146015451	T/C	cg05347473	chr6:146136440	FBXO30	-0.58	-6.9	-0.39	3.9e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1348850	0.668	rs4893972	chr2:178496874	T/C	cg22681709	chr2:178499509	PDE11A	-0.41	-5.9	-0.34	1.09e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs6982240	0.514	rs10088801	chr8:142275801	T/C	cg00131261	chr8:142287264	NA	-0.54	-7.43	-0.42	1.5e-12	Tonsillectomy;
CESC	trans	rs9329221	0.510	rs4841282	chr8:9975604	C/A	cg15556689	chr8:8085844	FLJ10661	0.5	6.29	0.36	1.3e-9	Neuroticism;
CESC	cis	rs7592578	0.771	rs75579212	chr2:191376575	C/T	cg27211696	chr2:191398769	TMEM194B	-0.62	-5.63	-0.33	4.7e-8	Diastolic blood pressure;
CESC	cis	rs4460629	0.742	rs7366355	chr1:155076734	C/T	cg01019262	chr1:155095195	NA	-0.3	-5.06	-0.3	7.71e-7	Serum magnesium levels;
CESC	cis	rs3820928	0.900	rs6754155	chr2:227784961	A/G	cg11843606	chr2:227700838	RHBDD1	-0.49	-6.59	-0.38	2.33e-10	Pulmonary function;
CESC	cis	rs7212590	0.748	rs7213697	chr17:57903041	G/C	cg20303301	chr17:57937339	TUBD1	-0.59	-5.57	-0.32	6.14e-8	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs2276314	0.762	rs3826600	chr18:33609053	A/G	cg19628046	chr18:33552617	C18orf21	0.51	5.76	0.33	2.3e-8	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs854765	0.583	rs62064156	chr17:17822480	C/T	cg09796270	chr17:17721594	SREBF1	0.46	6.39	0.37	7.35e-10	Total body bone mineral density;
CESC	cis	rs10191773	0.584	rs72831633	chr2:112945932	T/G	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.71	-6.95	-0.39	2.88e-11	Yeast infection;
CESC	cis	rs7084402	0.967	rs1649041	chr10:60328782	T/C	cg07615347	chr10:60278583	BICC1	0.59	9.18	0.49	1.26e-17	Refractive error;
CESC	cis	rs6502050	0.835	rs3924780	chr17:80112978	G/A	cg11859384	chr17:80120422	CCDC57	-0.39	-5.37	-0.31	1.76e-7	Life satisfaction;
CESC	cis	rs2243480	0.803	rs36127118	chr7:65565505	A/G	cg18252515	chr7:66147081	NA	-1.32	-12.9	-0.62	6.93e-30	Diabetic kidney disease;
CESC	cis	rs1865760	0.566	rs9348706	chr6:26065481	G/C	cg17691542	chr6:26056736	HIST1H1C	0.42	5.76	0.33	2.36e-8	Height;
CESC	cis	rs9309473	0.539	rs7574268	chr2:73904872	C/T	cg20560298	chr2:73613845	ALMS1	0.52	7.19	0.4	6.46e-12	Metabolite levels;
CESC	cis	rs11122272	0.735	rs2808595	chr1:231526238	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.56	-7.59	-0.42	5.44e-13	Hemoglobin concentration;
CESC	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg18402987	chr7:1209562	NA	0.75	7.52	0.42	8.71e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2228479	0.850	rs12599473	chr16:89827435	A/C	cg14709524	chr16:89940631	TCF25	0.91	6.75	0.38	9.26e-11	Skin colour saturation;
CESC	cis	rs2415984	0.622	rs61993303	chr14:46949716	G/C	cg14871534	chr14:47121158	RPL10L	-0.38	-5.67	-0.33	3.72e-8	Number of children ever born;
CESC	cis	rs9611519	1.000	rs2057070	chr22:41564287	T/C	cg03806693	chr22:41940476	POLR3H	-0.56	-5.74	-0.33	2.63e-8	Neuroticism;
CESC	cis	rs11997175	0.574	rs12156280	chr8:33650277	C/T	ch.8.33884649F	chr8:33765107	NA	0.65	8.33	0.46	4.44e-15	Body mass index;
CESC	cis	rs36051895	0.659	rs7046077	chr9:5045328	C/G	cg02405213	chr9:5042618	JAK2	-0.43	-5.34	-0.31	2.01e-7	Pediatric autoimmune diseases;
CESC	cis	rs7666738	0.830	rs34164616	chr4:99015251	G/A	cg17366294	chr4:99064904	C4orf37	0.6	8.62	0.47	6.37e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3760982	0.585	rs62116964	chr19:44291986	T/C	cg11993925	chr19:44307056	LYPD5	0.33	5.68	0.33	3.62e-8	Breast cancer (estrogen-receptor negative);Breast cancer;
CESC	cis	rs714031	0.934	rs5757764	chr22:40067818	C/T	cg21377881	chr22:40064566	CACNA1I	-0.33	-5.3	-0.31	2.48e-7	Schizophrenia;
CESC	cis	rs2197308	0.643	rs1842597	chr12:37862142	C/G	cg26384229	chr12:38710491	ALG10B	-0.53	-7.57	-0.42	6.06e-13	Morning vs. evening chronotype;
CESC	cis	rs7552404	0.696	rs10518521	chr1:76461214	G/A	cg22875332	chr1:76189707	ACADM	0.57	5.27	0.31	2.87e-7	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs7937682	0.575	rs34888817	chr11:111756455	C/T	cg09085632	chr11:111637200	PPP2R1B	0.92	12.04	0.59	6.56e-27	Primary sclerosing cholangitis;
CESC	cis	rs7208859	0.510	rs216402	chr17:28917126	A/T	cg13385521	chr17:29058706	SUZ12P	0.75	5.46	0.32	1.09e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	trans	rs10435719	0.902	rs7459983	chr8:11807221	T/C	cg15556689	chr8:8085844	FLJ10661	0.52	6.46	0.37	4.92e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
CESC	cis	rs3820068	0.581	rs58425551	chr1:15922518	A/G	cg13390004	chr1:15929781	NA	0.34	5.3	0.31	2.41e-7	Systolic blood pressure;
CESC	cis	rs3733585	0.699	rs4588456	chr4:9963895	A/T	cg02734326	chr4:10020555	SLC2A9	-0.43	-6.01	-0.35	6.1e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs12477438	1.000	rs12053372	chr2:99810055	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.69	-8.4	-0.46	2.74e-15	Chronic sinus infection;
CESC	cis	rs9611565	0.649	rs5751108	chr22:41858035	T/C	cg06481639	chr22:41940642	POLR3H	0.64	6.5	0.37	3.86e-10	Vitiligo;
CESC	cis	rs6061231	0.631	rs2427318	chr20:60975727	G/T	cg06197360	chr20:60970103	CABLES2	-0.4	-5.72	-0.33	2.89e-8	Colorectal cancer;
CESC	cis	rs858239	0.539	rs6945510	chr7:23192240	C/T	cg23682824	chr7:23144976	KLHL7	0.51	6.79	0.38	7.41e-11	Cerebrospinal fluid biomarker levels;
CESC	cis	rs5769707	0.967	rs9616701	chr22:50025546	G/A	cg20744362	chr22:50050164	C22orf34	0.47	8.14	0.45	1.59e-14	Monocyte count;Monocyte percentage of white cells;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg22478328	chr22:32340140	C22orf24;YWHAH	-0.42	-6.06	-0.35	4.56e-9	Gambling;
CESC	cis	rs7520050	0.966	rs4376778	chr1:46288846	C/G	cg03146154	chr1:46216737	IPP	-0.48	-6.3	-0.36	1.25e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs11690935	0.655	rs1028127	chr2:172530036	T/C	cg13550731	chr2:172543902	DYNC1I2	0.57	7.98	0.44	4.34e-14	Schizophrenia;
CESC	cis	rs10979	0.965	rs9496674	chr6:143886106	G/T	cg25407410	chr6:143891975	LOC285740	-0.62	-9.52	-0.51	1.1e-18	Hypospadias;
CESC	cis	rs4704187	0.640	rs7721018	chr5:74492978	C/T	cg03227963	chr5:74354835	NA	0.28	5.1	0.3	6.6e-7	Response to amphetamines;
CESC	cis	rs4822044	0.680	rs8138780	chr22:42097462	A/T	cg06634786	chr22:41940651	POLR3H	0.65	6.47	0.37	4.73e-10	Cannabis dependence symptom count;
CESC	cis	rs1129187	0.837	rs4714634	chr6:42901120	G/A	cg10862848	chr6:42927986	GNMT	-0.24	-5.64	-0.33	4.32e-8	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs2456568	0.775	rs1607404	chr11:93660449	C/G	cg26875233	chr11:93583750	C11orf90	-0.29	-5.09	-0.3	6.65e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
CESC	cis	rs34779708	0.766	rs16935949	chr10:35551815	T/C	cg03585969	chr10:35415529	CREM	0.55	6.19	0.36	2.25e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs6460942	0.597	rs17448913	chr7:12533984	T/C	cg02935154	chr7:12443704	VWDE	-0.57	-5.7	-0.33	3.23e-8	Coronary artery disease;
CESC	cis	rs13256369	0.760	rs7839473	chr8:8575836	C/T	cg18904891	chr8:8559673	CLDN23	0.69	8.06	0.44	2.63e-14	Obesity-related traits;
CESC	cis	rs1784581	0.894	rs1626020	chr6:162383379	G/A	cg17173639	chr6:162384350	PARK2	-0.83	-13.83	-0.65	4.07e-33	Itch intensity from mosquito bite;
CESC	cis	rs4665809	1.000	rs4665298	chr2:26256378	G/A	cg27170947	chr2:26402098	FAM59B	-0.58	-6.91	-0.39	3.63e-11	Gut microbiome composition (summer);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg13248847	chr17:7137857	DVL2	-0.46	-6.19	-0.36	2.3e-9	Ulcerative colitis;
CESC	cis	rs2836633	0.929	rs4514962	chr21:40041753	C/T	cg05519781	chr21:40033154	ERG	0.79	13.54	0.64	4.34e-32	Coronary artery disease;
CESC	cis	rs2243480	1.000	rs160639	chr7:65579987	C/G	cg12463550	chr7:65579703	CRCP	0.75	5.89	0.34	1.19e-8	Diabetic kidney disease;
CESC	cis	rs7829975	0.714	rs4840362	chr8:8670082	C/G	cg06636001	chr8:8085503	FLJ10661	-0.41	-5.46	-0.32	1.08e-7	Mood instability;
CESC	cis	rs875971	0.660	rs801193	chr7:66030612	A/C	cg11764359	chr7:65958608	NA	-0.73	-9.87	-0.52	8.76e-20	Aortic root size;
CESC	cis	rs4629180	0.586	rs7583526	chr2:102124665	G/A	cg04415270	chr2:102091202	RFX8	-0.31	-5.39	-0.31	1.57e-7	Chronic rhinosinusitis with nasal polyps;
CESC	cis	rs4253772	0.637	rs11703173	chr22:46660367	G/A	cg01287605	chr22:46663522	TTC38	0.54	5.11	0.3	6.28e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg24642844	chr7:1081250	C7orf50	-0.77	-9.63	-0.51	5.27e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs3892630	0.878	rs2903759	chr19:33195947	A/G	cg22980127	chr19:33182716	NUDT19	1.01	11.5	0.58	4.33e-25	Red blood cell traits;
CESC	cis	rs6570726	0.526	rs4896805	chr6:145735429	C/A	cg23711669	chr6:146136114	FBXO30	-0.54	-7.01	-0.4	2e-11	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg11799704	chr12:117187868	RNFT2	-0.44	-6.65	-0.38	1.68e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg15023313	chr10:37414759	ANKRD30A	0.45	7.45	0.42	1.36e-12	Fibrinogen levels;
CESC	cis	rs9916302	0.904	rs9892055	chr17:37510402	C/T	cg15445000	chr17:37608096	MED1	-0.41	-6.74	-0.38	9.82e-11	Glomerular filtration rate (creatinine);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg03822003	chr16:30569878	ZNF764	-0.44	-6.3	-0.36	1.22e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs959260	0.925	rs1108355	chr17:73383913	A/T	cg12999837	chr17:73267436	MIF4GD	-0.52	-5.94	-0.34	8.69e-9	Systemic lupus erythematosus;
CESC	cis	rs55871839	0.708	rs10098750	chr8:59813205	T/G	cg07426533	chr8:59803705	TOX	-0.47	-7.01	-0.4	1.95e-11	Pneumonia;
CESC	cis	rs8067354	0.540	rs12600680	chr17:58037374	T/C	cg13753209	chr17:57696993	CLTC	0.54	5.66	0.33	3.83e-8	Hemoglobin concentration;
CESC	cis	rs6922893	0.961	rs2504735	chr6:71623655	C/G	cg10766373	chr6:71666121	B3GAT2	0.33	5.15	0.3	5.17e-7	Obesity-related traits;
CESC	cis	rs4665809	0.531	rs34081866	chr2:26475940	C/T	cg27170947	chr2:26402098	FAM59B	0.87	10.16	0.53	1.05e-20	Gut microbiome composition (summer);
CESC	cis	rs478304	0.651	rs10896038	chr11:65505528	G/C	cg10518572	chr11:65560635	OVOL1	-0.32	-6.19	-0.36	2.31e-9	Acne (severe);
CESC	cis	rs12476592	0.571	rs6546005	chr2:63672071	G/A	cg17519650	chr2:63277830	OTX1	-0.47	-5.28	-0.31	2.75e-7	Childhood ear infection;
CESC	cis	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg09177884	chr7:1199841	ZFAND2A	-0.49	-6.21	-0.36	2.04e-9	Longevity;Endometriosis;
CESC	cis	rs1468333	0.538	rs13182414	chr5:137639838	T/G	cg24847829	chr5:136834464	SPOCK1	0.27	5.05	0.3	8.37e-7	Resting heart rate;
CESC	cis	rs2267137	0.903	rs5752903	chr22:29769306	G/T	cg07256473	chr22:29710276	RASL10A	0.39	5.79	0.33	2.02e-8	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	cis	rs34779708	0.966	rs12769575	chr10:35435927	A/T	cg04310649	chr10:35416472	CREM	-0.51	-6.21	-0.36	2.08e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs9818941	0.740	rs11713363	chr3:157828322	A/G	cg08654915	chr3:157813417	NA	0.43	7.08	0.4	1.31e-11	Height;
CESC	cis	rs10504229	0.861	rs116964504	chr8:58185354	A/C	cg05313129	chr8:58192883	C8orf71	-0.55	-6.29	-0.36	1.34e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs9303401	1.000	rs6503882	chr17:56915761	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.72	9.41	0.5	2.58e-18	Cognitive test performance;
CESC	cis	rs2635047	0.901	rs2684837	chr18:44749884	A/C	cg19077165	chr18:44547161	KATNAL2	-0.4	-5.36	-0.31	1.82e-7	Educational attainment;
CESC	cis	rs476633	0.708	rs28629856	chr15:41446950	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.61	-8.87	-0.48	1.08e-16	Glomerular filtration rate (creatinine);
CESC	cis	rs8064299	0.584	rs2384957	chr17:72784630	A/G	cg25054828	chr17:72772726	NAT9;TMEM104	0.82	13.93	0.65	1.87e-33	Monocyte count;
CESC	cis	rs1152591	0.562	rs872227	chr14:64656165	T/C	cg23250157	chr14:64679961	SYNE2	0.41	5.88	0.34	1.21e-8	Atrial fibrillation;
CESC	cis	rs514406	0.929	rs564273	chr1:53332445	G/C	cg08859206	chr1:53392774	SCP2	-0.61	-8.04	-0.44	3e-14	Monocyte count;
CESC	cis	rs875971	0.862	rs28491091	chr7:65669064	G/T	cg18252515	chr7:66147081	NA	0.46	5.98	0.34	7.28e-9	Aortic root size;
CESC	cis	rs61931739	0.500	rs7979482	chr12:34542877	C/A	cg19457237	chr12:34500585	NA	-0.37	-5.14	-0.3	5.27e-7	Morning vs. evening chronotype;
CESC	cis	rs2839186	0.770	rs2839984	chr21:47671690	A/G	cg13012494	chr21:47604986	C21orf56	0.49	6.56	0.37	2.78e-10	Testicular germ cell tumor;
CESC	cis	rs10129255	0.500	rs8021941	chr14:107189727	C/T	cg23076370	chr14:107095027	NA	-0.71	-11.07	-0.56	1.12e-23	Kawasaki disease;
CESC	cis	rs28374715	0.635	rs8023530	chr15:41647775	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.78	-11.79	-0.59	4.63e-26	Ulcerative colitis;
CESC	cis	rs7586673	0.866	rs747003	chr2:161916409	C/T	cg22496339	chr2:162101262	NA	-0.49	-6.52	-0.37	3.48e-10	Intelligence (multi-trait analysis);
CESC	cis	rs7178909	0.902	rs8033554	chr15:90441569	C/A	cg19708238	chr15:90437601	AP3S2	0.46	6.58	0.37	2.48e-10	Common traits (Other);
CESC	cis	rs921968	0.565	rs4672897	chr2:219588134	A/G	cg02176678	chr2:219576539	TTLL4	-0.43	-7.63	-0.42	4.22e-13	Mean corpuscular hemoglobin concentration;
CESC	cis	rs6088590	1.000	rs1998028	chr20:33344595	A/T	cg06115741	chr20:33292138	TP53INP2	0.59	7.29	0.41	3.51e-12	Coronary artery disease;
CESC	cis	rs6060717	0.610	rs6058393	chr20:34608664	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.55	-6.73	-0.38	1.07e-10	Hip circumference adjusted for BMI;
CESC	cis	rs2014572	0.967	rs11084492	chr19:57756026	A/T	cg24459738	chr19:57751996	ZNF805	-0.54	-7.78	-0.43	1.67e-13	Hyperactive-impulsive symptoms;
CESC	cis	rs9733	0.596	rs6587518	chr1:150661787	T/C	cg22823121	chr1:150693482	HORMAD1	0.47	6.98	0.39	2.34e-11	Tonsillectomy;
CESC	cis	rs9322193	0.962	rs952165	chr6:150120036	T/C	cg13206674	chr6:150067644	NUP43	0.41	5.78	0.33	2.05e-8	Lung cancer;
CESC	cis	rs4722166	0.630	rs1829927	chr7:22779918	G/A	cg13104385	chr7:22767384	IL6	0.48	6.43	0.37	5.96e-10	Lung cancer;
CESC	cis	rs2732480	0.577	rs2634678	chr12:48735538	C/G	cg24011408	chr12:48396354	COL2A1	0.44	5.94	0.34	9.12e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs7660520	0.524	rs6839881	chr4:183729137	A/T	cg03209412	chr4:183728196	NA	0.55	5.28	0.31	2.63e-7	Pediatric autoimmune diseases;
CESC	cis	rs11098499	0.954	rs4309825	chr4:120314881	C/T	cg24375607	chr4:120327624	NA	-0.4	-5.03	-0.3	9.03e-7	Corneal astigmatism;
CESC	trans	rs1814175	0.654	rs7482446	chr11:49779020	A/G	cg03929089	chr4:120376271	NA	-0.9	-14.66	-0.67	4.99e-36	Height;
CESC	cis	rs6121246	0.529	rs6060291	chr20:30198043	T/G	cg13852791	chr20:30311386	BCL2L1	0.57	5.43	0.32	1.26e-7	Mean corpuscular hemoglobin;
CESC	cis	rs4563143	0.647	rs117946634	chr19:29256822	G/T	cg12667521	chr19:29218732	NA	0.48	6.28	0.36	1.37e-9	Methadone dose in opioid dependence;
CESC	cis	rs1801251	1.000	rs12987513	chr2:233622066	A/G	cg08000102	chr2:233561755	GIGYF2	0.65	9.21	0.49	1.01e-17	Coronary artery disease;
CESC	cis	rs7666738	0.830	rs6846739	chr4:99016647	G/A	cg03676636	chr4:99064102	C4orf37	0.33	5.14	0.3	5.3e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7089973	0.604	rs10885618	chr10:116617718	A/G	cg03647239	chr10:116582469	FAM160B1	0.47	6.05	0.35	4.79e-9	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs8177253	1.000	rs3811647	chr3:133484029	G/A	cg11941060	chr3:133502564	NA	-0.47	-6.5	-0.37	3.96e-10	Iron status biomarkers;
CESC	cis	rs9311474	0.508	rs12629701	chr3:52619836	T/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.52	0.37	3.46e-10	Electroencephalogram traits;
CESC	cis	rs9815354	0.951	rs55835726	chr3:41763049	C/T	cg03022575	chr3:42003672	ULK4	0.51	5.1	0.3	6.62e-7	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs10256972	0.900	rs7812072	chr7:1053862	A/G	cg23978390	chr7:1156363	C7orf50	0.45	6.05	0.35	5.04e-9	Longevity;Endometriosis;
CESC	cis	rs3820068	0.705	rs4646031	chr1:15834648	A/G	cg18192808	chr1:15853278	DNAJC16	0.46	5.65	0.33	4.16e-8	Systolic blood pressure;
CESC	trans	rs2530545	0.851	rs2609231	chr7:34692376	G/C	cg14080982	chr15:71736038	THSD4	-0.48	-6.27	-0.36	1.43e-9	IgG glycosylation;
CESC	cis	rs3785574	0.962	rs2665842	chr17:61878535	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.58	7.15	0.4	8.48e-12	Height;
CESC	cis	rs116095464	1.000	rs2015774	chr5:312958	G/T	cg12570787	chr5:219185	SDHA;CCDC127	0.64	5.17	0.3	4.7e-7	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17143303	chr17:33734764	NA	-0.65	-6.78	-0.38	7.58e-11	Gut microbiome composition (summer);
CESC	cis	rs863345	0.901	rs1117126	chr1:158509383	A/G	cg12129480	chr1:158549410	OR10X1	-0.32	-6.49	-0.37	4.3e-10	Pneumococcal bacteremia;
CESC	cis	rs644148	0.785	rs2140111	chr19:44973019	A/C	cg15540054	chr19:45004280	ZNF180	-0.6	-6.46	-0.37	4.86e-10	Personality dimensions;
CESC	cis	rs300703	0.719	rs446488	chr2:195365	T/C	cg21211680	chr2:198530	NA	1.07	12.54	0.61	1.25e-28	Blood protein levels;
CESC	cis	rs4888262	0.526	rs8056718	chr16:74612030	G/C	cg01733217	chr16:74700730	RFWD3	0.83	11.46	0.58	5.96e-25	Testicular germ cell tumor;
CESC	cis	rs7809950	0.637	rs2701685	chr7:107299584	A/G	cg23024343	chr7:107201750	COG5	0.39	5.31	0.31	2.27e-7	Coronary artery disease;
CESC	cis	rs4948102	0.731	rs4689	chr7:56067016	G/T	cg09872392	chr7:56161020	PHKG1	-0.44	-6.7	-0.38	1.23e-10	Plasma homocysteine levels (post-methionine load test);
CESC	cis	rs2797160	0.967	rs8180614	chr6:126000599	G/C	cg05901451	chr6:126070800	HEY2	-0.45	-6.67	-0.38	1.44e-10	Endometrial cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07312552	chr22:24819968	NA	0.54	6.28	0.36	1.39e-9	Gut microbiome composition (summer);
CESC	cis	rs6500395	1.000	rs12447645	chr16:48694440	A/G	cg04672837	chr16:48644449	N4BP1	-0.51	-6.36	-0.36	8.64e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	trans	rs1945213	0.694	rs10895985	chr11:55831595	T/C	cg15704280	chr7:45808275	SEPT13	0.76	7.31	0.41	3.2e-12	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs1843834	0.505	rs4674911	chr2:225345254	A/G	cg22455342	chr2:225449267	CUL3	0.69	9.77	0.51	1.84e-19	IgE levels in asthmatics (D.p. specific);
CESC	cis	rs8072100	0.840	rs12452796	chr17:45479733	G/T	cg08085267	chr17:45401833	C17orf57	0.51	6.8	0.39	6.81e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs1552244	1.000	rs56394721	chr3:10150795	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-10.84	-0.55	6.85e-23	Alzheimer's disease;
CESC	cis	rs2839186	0.814	rs2839167	chr21:47661587	A/G	cg10351095	chr21:47802916	PCNT	-0.49	-6.85	-0.39	5.2e-11	Testicular germ cell tumor;
CESC	trans	rs681383	0.826	rs669168	chr18:8328770	G/A	cg27042584	chr16:51168485	NA	-0.5	-6.11	-0.35	3.55e-9	Sitting height ratio;
CESC	cis	rs6893300	0.524	rs12374446	chr5:179131143	A/G	cg14593053	chr5:179126677	CANX	0.47	6.64	0.38	1.74e-10	Resting heart rate;
CESC	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.16	11.93	0.59	1.55e-26	Platelet count;
CESC	cis	rs13256369	0.708	rs10903310	chr8:8589687	A/C	cg18904891	chr8:8559673	CLDN23	-0.55	-5.9	-0.34	1.08e-8	Obesity-related traits;
CESC	cis	rs36051895	0.664	rs62543877	chr9:5093465	C/A	cg02405213	chr9:5042618	JAK2	-0.54	-6.57	-0.37	2.58e-10	Pediatric autoimmune diseases;
CESC	cis	rs2235649	0.798	rs9922462	chr16:1848011	C/T	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.43	-5.3	-0.31	2.43e-7	Blood metabolite levels;
CESC	cis	rs12681288	0.523	rs11137122	chr8:954702	A/G	cg04851639	chr8:1020857	NA	-0.32	-6.32	-0.36	1.1e-9	Schizophrenia;
CESC	cis	rs9322193	0.923	rs1413654	chr6:150105092	G/A	cg04369109	chr6:150039330	LATS1	-0.4	-5.4	-0.31	1.48e-7	Lung cancer;
CESC	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg21280719	chr6:42927975	GNMT	0.3	7.08	0.4	1.26e-11	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs116095464	0.614	rs10061564	chr5:271329	T/C	cg12570787	chr5:219185	SDHA;CCDC127	0.52	5.42	0.32	1.31e-7	Breast cancer;
CESC	cis	rs6694270	0.913	rs3935030	chr1:19116956	C/T	cg19637330	chr1:19110922	NA	-0.48	-6.12	-0.35	3.42e-9	Drug-induced liver injury (nitrofurantoin);
CESC	trans	rs9929218	0.953	rs2902323	chr16:68736292	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.76	-9.26	-0.49	7.21e-18	Colorectal cancer;
CESC	cis	rs35110281	0.744	rs162396	chr21:44947807	T/C	cg21573476	chr21:45109991	RRP1B	-0.37	-5.22	-0.31	3.65e-7	Mean corpuscular volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11309891	chr11:73388802	RAB6A	-0.59	-6.99	-0.39	2.17e-11	Gut microbiome composition (summer);
CESC	cis	rs9905704	0.681	rs1860262	chr17:56580997	T/C	cg12560992	chr17:57184187	TRIM37	-0.65	-5.99	-0.35	6.72e-9	Testicular germ cell tumor;
CESC	cis	rs6714710	0.580	rs11690737	chr2:98461953	C/T	cg26665480	chr2:98280029	ACTR1B	0.56	7.92	0.44	6.74e-14	Posterior cortical atrophy and Alzheimer's disease;
CESC	cis	rs660498	0.507	rs17681969	chr10:27734691	A/G	cg25705717	chr10:27608719	NA	0.47	5.88	0.34	1.23e-8	Asthma (childhood onset);
CESC	cis	rs7666738	0.830	rs13121558	chr4:99002848	G/A	cg18180107	chr4:99064573	C4orf37	0.4	5.23	0.31	3.41e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2576037	0.583	rs593340	chr18:44418346	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.78	13.0	0.62	3.18e-30	Personality dimensions;
CESC	cis	rs7945705	0.967	rs2568090	chr11:8849495	T/C	cg21881798	chr11:8931708	C11orf17;ST5	0.37	5.66	0.33	4.01e-8	Hemoglobin concentration;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg02331450	chr3:33155354	CRTAP	-0.47	-6.31	-0.36	1.14e-9	Ulcerative colitis;
CESC	cis	rs3096299	0.606	rs2965946	chr16:89516612	T/C	cg16743903	chr16:89593216	SPG7	-0.51	-6.21	-0.36	2.03e-9	Multiple myeloma (IgH translocation);
CESC	cis	rs6866344	0.570	rs1079487	chr5:178136005	G/A	cg03877680	chr5:178157825	ZNF354A	0.82	10.03	0.52	2.8e-20	Neutrophil percentage of white cells;
CESC	cis	rs12887734	0.546	rs4900597	chr14:104266664	A/G	cg01849466	chr14:104193079	ZFYVE21	0.45	5.7	0.33	3.13e-8	Schizophrenia;Autism spectrum disorder or schizophrenia;
CESC	cis	rs7071206	0.891	rs10824559	chr10:79409222	A/G	cg07817648	chr10:79422355	NA	-0.86	-10.32	-0.54	3.28e-21	Bone mineral density;
CESC	cis	rs709400	0.663	rs62007681	chr14:103884651	G/A	cg12935359	chr14:103987150	CKB	-0.56	-8.18	-0.45	1.21e-14	Body mass index;
CESC	cis	rs412050	0.502	rs75034650	chr22:22177949	C/T	cg17089214	chr22:22089827	YPEL1	0.67	5.26	0.31	2.9e-7	Attention deficit hyperactivity disorder;
CESC	cis	rs2836974	0.932	rs6517527	chr21:40581751	G/A	cg17971929	chr21:40555470	PSMG1	1.07	16.31	0.71	7.07e-42	Cognitive function;
CESC	cis	rs7772486	0.686	rs1011596	chr6:146076433	A/G	cg23711669	chr6:146136114	FBXO30	0.88	13.09	0.63	1.56e-30	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9916302	0.861	rs11078913	chr17:37671714	G/T	cg19468946	chr17:37922297	IKZF3	-0.4	-5.24	-0.31	3.31e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs6701037	0.512	rs2285216	chr1:175133012	C/T	cg00321850	chr1:175162397	KIAA0040	0.44	6.32	0.36	1.11e-9	Alcohol dependence;
CESC	cis	rs10208940	0.920	rs10164780	chr2:68766250	A/T	cg12452813	chr2:68675892	NA	0.51	5.11	0.3	6.17e-7	Urate levels in lean individuals;
CESC	cis	rs367615	0.642	rs439182	chr5:108952367	A/G	cg17395555	chr5:108820864	NA	-0.42	-5.66	-0.33	4e-8	Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs9611565	0.592	rs5996037	chr22:41965292	A/G	cg06634786	chr22:41940651	POLR3H	-0.62	-6.75	-0.38	9.16e-11	Vitiligo;
CESC	cis	rs57502260	0.651	rs3781586	chr11:68199393	C/A	cg20283391	chr11:68216788	NA	-0.58	-5.35	-0.31	1.95e-7	Total body bone mineral density (age 45-60);
CESC	cis	rs17780086	0.529	rs7406406	chr17:30220153	T/G	cg13647721	chr17:30228624	UTP6	0.83	10.88	0.56	5.03e-23	Height;
CESC	cis	rs2075371	0.931	rs1646697	chr7:133999930	G/A	cg11752832	chr7:134001865	SLC35B4	0.54	7.0	0.4	2.04e-11	Mean platelet volume;
CESC	cis	rs6088580	0.634	rs2378133	chr20:32919505	C/G	cg08999081	chr20:33150536	PIGU	-0.65	-11.29	-0.57	2.07e-24	Glomerular filtration rate (creatinine);
CESC	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg06873352	chr17:61820015	STRADA	0.73	12.98	0.62	3.9e-30	Prudent dietary pattern;
CESC	cis	rs6461049	0.638	rs3778994	chr7:2175855	G/T	cg23048001	chr7:2026167	MAD1L1	0.41	5.44	0.32	1.22e-7	Schizophrenia;
CESC	cis	rs12477438	0.520	rs11689265	chr2:99799267	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.87	16.01	0.7	7.88e-41	Chronic sinus infection;
CESC	trans	rs4843747	0.749	rs72818535	chr16:88074039	G/A	cg26811252	chr16:29126840	RRN3P2	0.69	9.65	0.51	4.35e-19	Menopause (age at onset);
CESC	cis	rs9911578	0.967	rs1267542	chr17:56654690	T/C	cg12560992	chr17:57184187	TRIM37	-0.93	-15.46	-0.69	7.17e-39	Intelligence (multi-trait analysis);
CESC	cis	rs10411936	0.692	rs3810196	chr19:16601154	T/C	cg10248733	chr19:16607483	C19orf44;CALR3	0.53	6.52	0.37	3.6e-10	White blood cell count;Multiple sclerosis;
CESC	cis	rs1808579	0.904	rs1652348	chr18:21147509	C/T	cg14672496	chr18:21087552	C18orf8	0.4	5.58	0.32	5.91e-8	Hip circumference;Body mass index;BMI (adjusted for smoking behaviour);
CESC	cis	rs11958404	0.932	rs72816572	chr5:157429818	T/C	cg05962755	chr5:157440814	NA	0.62	6.53	0.37	3.41e-10	IgG glycosylation;
CESC	cis	rs2276314	0.947	rs16967319	chr18:33573525	A/G	cg05985134	chr18:33552581	C18orf21	0.64	7.22	0.41	5.46e-12	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs13102973	0.897	rs10434068	chr4:135840331	A/G	cg14419869	chr4:135874104	NA	0.34	5.38	0.31	1.6e-7	Subjective well-being;
CESC	cis	rs4955124	0.558	rs12485595	chr3:32018354	C/T	cg05935571	chr3:32023257	ZNF860;OSBPL10	0.98	8.8	0.48	1.77e-16	Schizophrenia;
CESC	cis	rs7335046	0.536	rs7992229	chr13:100040979	G/A	cg21788972	chr13:99853209	UBAC2	-0.43	-5.59	-0.32	5.66e-8	Basal cell carcinoma;
CESC	cis	rs9796	0.674	rs6492978	chr15:41317702	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.41	-6.17	-0.35	2.5e-9	Menopause (age at onset);
CESC	cis	rs2228479	0.850	rs11639788	chr16:89807543	G/A	cg06558623	chr16:89946397	TCF25	1.14	9.11	0.49	2.11e-17	Skin colour saturation;
CESC	trans	rs9325144	0.555	rs28738714	chr12:38706912	G/A	cg23762105	chr12:34175262	ALG10	0.49	6.35	0.36	9.17e-10	Morning vs. evening chronotype;
CESC	cis	rs4888262	0.526	rs7193423	chr16:74626340	A/C	cg01733217	chr16:74700730	RFWD3	0.86	11.16	0.57	5.72e-24	Testicular germ cell tumor;
CESC	cis	rs4555082	0.834	rs2816651	chr14:105708470	A/G	cg27165867	chr14:105738592	BRF1	-0.54	-6.1	-0.35	3.81e-9	Mean platelet volume;Platelet distribution width;
CESC	cis	rs853679	0.517	rs9380058	chr6:28127444	T/C	cg20151795	chr6:28129481	ZNF389	0.46	5.9	0.34	1.1e-8	Depression;
CESC	cis	rs4862750	0.832	rs6836076	chr4:187899660	A/C	cg11301795	chr4:187892539	NA	-0.75	-12.33	-0.6	6.74e-28	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs113835537	0.529	rs2298806	chr11:66282095	G/A	cg22134325	chr11:66188745	NPAS4	0.37	5.81	0.34	1.77e-8	Airway imaging phenotypes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06431905	chr5:148931119	CSNK1A1	0.67	8.55	0.46	9.88e-16	Gut microbiome composition (summer);
CESC	cis	rs10492096	0.947	rs10849484	chr12:6637941	C/T	cg13857086	chr12:6580257	VAMP1	0.56	5.44	0.32	1.18e-7	Hip geometry;
CESC	cis	rs7412746	0.658	rs2864869	chr1:150734655	G/A	cg04414720	chr1:150670196	GOLPH3L	0.58	7.57	0.42	6.07e-13	Melanoma;
CESC	cis	rs8060686	0.516	rs8062085	chr16:68289313	C/A	cg26727032	chr16:67993705	SLC12A4	-0.56	-7.31	-0.41	3.15e-12	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs12600856	1	rs12600856	chr17:38163295	T/C	cg17467752	chr17:38218738	THRA	0.69	10.55	0.54	5.78e-22	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
CESC	cis	rs7474896	0.537	rs1022449	chr10:38279467	T/A	cg25427524	chr10:38739819	LOC399744	0.49	5.42	0.32	1.35e-7	Obesity (extreme);
CESC	cis	rs7659604	0.539	rs7660548	chr4:122730821	G/C	cg06713675	chr4:122721982	EXOSC9	-0.51	-6.99	-0.39	2.2e-11	Type 2 diabetes;
CESC	cis	rs2290720	0.930	rs10778112	chr12:101713020	T/C	cg22051763	chr12:101673672	UTP20	-0.47	-5.78	-0.33	2.09e-8	Brain structure (hippocampal volume);
CESC	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg22764044	chr5:178986830	RUFY1	-0.47	-7.24	-0.41	4.81e-12	Lung cancer;
CESC	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg03452623	chr4:187889614	NA	-0.94	-18.76	-0.76	1.57e-50	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7605827	0.930	rs1549017	chr2:15617017	T/C	cg19274914	chr2:15703543	NA	0.35	6.13	0.35	3.19e-9	Educational attainment (years of education);
CESC	cis	rs4700695	0.719	rs27584	chr5:65445232	G/A	cg21114390	chr5:65439923	SFRS12	-0.51	-6.22	-0.36	1.96e-9	Facial morphology (factor 19);
CESC	cis	rs2721195	0.967	rs748195	chr8:145682514	T/C	cg15857475	chr8:145742913	RECQL4;LRRC14	0.71	9.69	0.51	3.46e-19	Age at first birth;
CESC	cis	rs801193	0.569	rs4717315	chr7:66178325	C/T	cg18876405	chr7:65276391	NA	0.44	6.06	0.35	4.76e-9	Aortic root size;
CESC	cis	rs4566357	1.000	rs6721237	chr2:227923357	T/A	cg11843606	chr2:227700838	RHBDD1	-0.42	-5.28	-0.31	2.76e-7	Coronary artery disease;
CESC	cis	rs4689388	0.926	rs4688987	chr4:6287329	C/T	cg00701064	chr4:6280414	WFS1	0.73	12.84	0.62	1.11e-29	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs2243480	1.000	rs313824	chr7:65581207	C/T	cg12463550	chr7:65579703	CRCP	0.74	5.77	0.33	2.23e-8	Diabetic kidney disease;
CESC	cis	rs7208859	0.573	rs8070182	chr17:29135594	A/C	cg13385521	chr17:29058706	SUZ12P	0.76	6.26	0.36	1.53e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs4547160	0.606	rs12828712	chr12:63475233	G/C	cg26727693	chr12:63544175	AVPR1A	-0.38	-5.42	-0.32	1.31e-7	Morning vs. evening chronotype;
CESC	cis	rs1865721	0.656	rs724765	chr18:73139794	A/G	cg26385618	chr18:73139727	C18orf62	-0.45	-7.25	-0.41	4.49e-12	Intelligence;
CESC	cis	rs617791	0.508	rs2276132	chr11:65770545	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.44	-5.12	-0.3	6.02e-7	Breast cancer;
CESC	cis	rs11098499	0.618	rs28491261	chr4:120294900	C/A	cg09307838	chr4:120376055	NA	0.92	12.42	0.61	3.18e-28	Corneal astigmatism;
CESC	trans	rs9329221	0.537	rs6986911	chr8:9978523	C/T	cg15556689	chr8:8085844	FLJ10661	0.49	6.14	0.35	3.03e-9	Neuroticism;
CESC	cis	rs7208859	0.623	rs11650973	chr17:29214045	G/A	cg19761014	chr17:28927070	LRRC37B2	0.63	5.31	0.31	2.38e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs17376456	0.877	rs12153501	chr5:93360866	T/G	cg21475434	chr5:93447410	FAM172A	0.77	6.93	0.39	3.17e-11	Diabetic retinopathy;
CESC	cis	rs8070624	0.543	rs7219320	chr17:17880877	A/G	cg04398451	chr17:18023971	MYO15A	-0.69	-9.6	-0.51	6.26e-19	Total body bone mineral density;
CESC	cis	rs7274811	0.744	rs3746460	chr20:32248163	C/T	cg21523528	chr20:32077966	CBFA2T2	0.56	6.28	0.36	1.36e-9	Height;
CESC	cis	rs4819052	1.000	rs733739	chr21:46666210	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.88	11.7	0.58	9.02e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs11792861	0.926	rs59904140	chr9:111910051	C/T	cg13535736	chr9:111863775	C9orf5	-0.41	-5.3	-0.31	2.47e-7	Menarche (age at onset);
CESC	cis	rs1983891	0.706	rs3800285	chr6:41558443	C/T	cg20194872	chr6:41519635	FOXP4	-0.46	-6.67	-0.38	1.48e-10	Prostate cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15985338	chr7:6048868	PMS2;AIMP2	0.58	6.8	0.39	6.73e-11	Gut microbiome composition (summer);
CESC	cis	rs854765	0.663	rs3744115	chr17:17749822	G/A	cg09796270	chr17:17721594	SREBF1	-0.46	-6.59	-0.38	2.37e-10	Total body bone mineral density;
CESC	cis	rs2243480	1.000	rs316307	chr7:65570171	C/T	cg13147721	chr7:65941812	NA	-0.99	-9.31	-0.5	5.19e-18	Diabetic kidney disease;
CESC	cis	rs7666738	0.606	rs28481322	chr4:99086638	T/C	cg17366294	chr4:99064904	C4orf37	0.43	5.77	0.33	2.15e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg23978390	chr7:1156363	C7orf50	0.55	7.52	0.42	8.34e-13	Longevity;Endometriosis;
CESC	cis	rs10751667	0.643	rs10751666	chr11:941933	C/T	cg20946044	chr11:1010712	AP2A2	-0.39	-5.44	-0.32	1.23e-7	Alzheimer's disease (late onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02235289	chr2:27852069	GPN1;CCDC121	-0.55	-6.48	-0.37	4.54e-10	Gut microbiome composition (summer);
CESC	cis	rs6424115	0.743	rs2229580	chr1:24201109	C/T	cg10978503	chr1:24200527	CNR2	0.33	6.64	0.38	1.73e-10	Immature fraction of reticulocytes;
CESC	trans	rs4824093	0.610	rs73441787	chr22:50269646	A/G	cg09872104	chr7:134855509	C7orf49	-0.97	-6.92	-0.39	3.45e-11	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs28374715	0.578	rs13313520	chr15:41629127	T/G	cg18705301	chr15:41695430	NDUFAF1	-1.05	-15.76	-0.7	6.06e-40	Ulcerative colitis;
CESC	cis	rs4253772	0.872	rs14843	chr22:46639462	A/T	cg18190219	chr22:46762943	CELSR1	-0.61	-5.82	-0.34	1.66e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs13095912	1.000	rs4686666	chr3:185342847	T/C	cg11274856	chr3:185301563	NA	0.34	5.49	0.32	9.19e-8	Systolic blood pressure;
CESC	cis	rs514406	0.861	rs4926932	chr1:53247495	C/T	cg24675658	chr1:53192096	ZYG11B	0.53	6.73	0.38	1.04e-10	Monocyte count;
CESC	cis	rs704795	0.805	rs1728926	chr2:27612937	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.29	-5.36	-0.31	1.85e-7	Menopause (age at onset);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg00097940	chr3:197476561	KIAA0226;FYTTD1	-0.44	-6.14	-0.35	3.05e-9	Gambling;
CESC	cis	rs9399135	0.967	rs9373122	chr6:135373534	G/A	cg22676075	chr6:135203613	NA	0.52	7.32	0.41	2.89e-12	Red blood cell count;
CESC	cis	rs9611565	0.559	rs9611619	chr22:41986714	C/T	cg03806693	chr22:41940476	POLR3H	-1.16	-13.06	-0.63	1.99e-30	Vitiligo;
CESC	cis	rs10159302	0.714	rs11809894	chr1:57796019	A/G	cg23691223	chr1:57785036	DAB1	-0.45	-5.34	-0.31	2.03e-7	HIV-1 control;
CESC	cis	rs6088590	0.930	rs6087618	chr20:33288407	C/T	cg06115741	chr20:33292138	TP53INP2	0.6	7.45	0.42	1.29e-12	Coronary artery disease;
CESC	cis	rs6964587	1.000	rs12531366	chr7:91683849	C/G	cg17063962	chr7:91808500	NA	0.56	7.61	0.42	4.83e-13	Breast cancer;
CESC	cis	rs875971	1.000	rs1167612	chr7:65567976	C/A	cg10691866	chr7:65817282	TPST1	0.33	5.2	0.3	4.02e-7	Aortic root size;
CESC	cis	rs3806843	0.706	rs1089305	chr5:140066306	T/C	cg16179182	chr5:140090404	VTRNA1-1	0.39	5.11	0.3	6.21e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs13256369	1.000	rs1109619	chr8:8571616	G/T	cg00074818	chr8:8560427	CLDN23	0.34	5.03	0.3	9.11e-7	Obesity-related traits;
CESC	cis	rs6831352	1.000	rs6837685	chr4:100049145	G/A	cg21548116	chr4:100009993	ADH5	0.48	5.15	0.3	4.98e-7	Alcohol dependence;
CESC	cis	rs763014	0.898	rs4984897	chr16:632180	G/C	cg09263875	chr16:632152	PIGQ	0.67	11.24	0.57	3.15e-24	Height;
CESC	trans	rs2727020	0.823	rs7102374	chr11:49261795	G/A	cg03929089	chr4:120376271	NA	0.75	9.66	0.51	4.18e-19	Coronary artery disease;
CESC	cis	rs4975709	0.589	rs1684967	chr5:1863055	G/C	cg07747251	chr5:1868357	NA	0.33	5.59	0.32	5.71e-8	Cardiovascular disease risk factors;
CESC	cis	rs7666738	0.791	rs7660866	chr4:98961335	G/A	cg17366294	chr4:99064904	C4orf37	0.6	8.52	0.46	1.2e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs514406	0.607	rs11206000	chr1:53205923	A/C	cg08736216	chr1:53307985	ZYG11A	0.3	5.05	0.3	8.16e-7	Monocyte count;
CESC	cis	rs3126085	1.000	rs114304428	chr1:152254010	T/C	cg03465714	chr1:152285911	FLG	0.49	5.43	0.32	1.24e-7	Atopic dermatitis;
CESC	cis	rs911555	0.504	rs61995761	chr14:104075712	T/C	cg24130564	chr14:104152367	KLC1	-0.82	-13.38	-0.63	1.58e-31	Intelligence (multi-trait analysis);
CESC	cis	rs6032067	0.929	rs6017503	chr20:43815103	G/A	cg11264863	chr20:43835661	SEMG1	0.49	5.32	0.31	2.21e-7	Blood protein levels;
CESC	cis	rs911555	0.723	rs2273701	chr14:103923225	G/T	cg24130564	chr14:104152367	KLC1	0.5	6.6	0.38	2.27e-10	Intelligence (multi-trait analysis);
CESC	cis	rs4692589	0.772	rs34642369	chr4:170973469	G/A	cg19918862	chr4:170955249	NA	0.39	5.26	0.31	2.92e-7	Anxiety disorder;
CESC	cis	rs6089829	0.962	rs6062393	chr20:61663230	G/A	cg08564027	chr20:61660810	NA	0.9	15.42	0.69	9.97e-39	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs17826219	0.706	rs609472	chr17:28951427	T/C	cg19761014	chr17:28927070	LRRC37B2	0.81	7.5	0.42	9.82e-13	Body mass index;
CESC	cis	rs763014	0.932	rs4984898	chr16:641164	G/T	cg09263875	chr16:632152	PIGQ	0.68	11.14	0.56	6.77e-24	Height;
CESC	cis	rs2243480	1.000	rs316325	chr7:65609518	G/A	cg13147721	chr7:65941812	NA	-0.97	-9.14	-0.49	1.7e-17	Diabetic kidney disease;
CESC	cis	rs787274	0.718	rs4979173	chr9:115627699	A/C	cg13803584	chr9:115635662	SNX30	-0.66	-6.1	-0.35	3.77e-9	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs6752107	1.000	rs34123137	chr2:234167881	T/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.46	6.33	0.36	1.03e-9	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs2072499	0.750	rs55910626	chr1:156159909	C/G	cg25208724	chr1:156163844	SLC25A44	1.0	12.82	0.62	1.34e-29	Testicular germ cell tumor;
CESC	cis	rs2228479	0.850	rs9282681	chr16:89805914	T/C	cg06558623	chr16:89946397	TCF25	1.07	8.36	0.46	3.66e-15	Skin colour saturation;
CESC	cis	rs8114671	0.552	rs2024635	chr20:33422614	G/A	cg08999081	chr20:33150536	PIGU	0.38	5.34	0.31	2.05e-7	Height;
CESC	cis	rs910316	0.967	rs12147532	chr14:75651858	T/G	cg11812906	chr14:75593930	NEK9	-0.85	-13.68	-0.64	1.4e-32	Height;
CESC	cis	rs7666738	0.791	rs34437628	chr4:99029232	C/G	cg24818145	chr4:99064322	C4orf37	0.39	5.09	0.3	6.95e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6815814	0.898	rs6848423	chr4:38887933	C/T	cg02016764	chr4:38805732	TLR1	-0.56	-6.63	-0.38	1.85e-10	Breast cancer;
CESC	cis	rs6088580	0.634	rs6059905	chr20:33126946	T/C	cg08999081	chr20:33150536	PIGU	0.67	11.59	0.58	2.17e-25	Glomerular filtration rate (creatinine);
CESC	cis	rs9790314	0.905	rs4856739	chr3:160986710	A/C	cg03342759	chr3:160939853	NMD3	-0.48	-6.29	-0.36	1.28e-9	Morning vs. evening chronotype;
CESC	cis	rs7666738	0.830	rs13112037	chr4:98976986	A/T	cg05340658	chr4:99064831	C4orf37	0.79	12.26	0.6	1.12e-27	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2576037	0.583	rs578451	chr18:44404525	T/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.33	5.3	0.31	2.43e-7	Personality dimensions;
CESC	cis	rs9640161	0.750	rs11769348	chr7:150026753	C/T	cg10018233	chr7:150070692	REPIN1	-0.42	-6.42	-0.37	6.22e-10	Blood protein levels;Circulating chemerin levels;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg16823105	chr6:97372572	KLHL32	0.44	6.19	0.36	2.26e-9	Systemic lupus erythematosus;
CESC	trans	rs561341	1.000	rs113676348	chr17:30244327	A/G	cg27661571	chr11:113659931	NA	-0.7	-7.09	-0.4	1.19e-11	Hip circumference adjusted for BMI;
CESC	cis	rs116095464	0.558	rs6872854	chr5:209038	G/T	cg12570787	chr5:219185	SDHA;CCDC127	0.51	5.55	0.32	7.07e-8	Breast cancer;
CESC	cis	rs35306767	0.903	rs7077278	chr10:911291	A/G	cg26597838	chr10:835615	NA	-0.86	-9.09	-0.49	2.44e-17	Eosinophil percentage of granulocytes;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg16432235	chr1:41976593	HIVEP3	0.49	6.95	0.39	2.88e-11	Fibrinogen levels;
CESC	cis	rs9487051	0.802	rs9487039	chr6:109610163	A/T	cg12927641	chr6:109611667	NA	-0.43	-6.7	-0.38	1.22e-10	Reticulocyte fraction of red cells;
CESC	cis	rs4253772	0.550	rs6008601	chr22:46705326	C/G	cg24881330	chr22:46731750	TRMU	0.81	6.95	0.39	2.82e-11	LDL cholesterol;Cholesterol, total;
CESC	cis	rs2836974	0.565	rs2836939	chr21:40578546	C/T	cg11890956	chr21:40555474	PSMG1	0.83	9.01	0.48	4.34e-17	Cognitive function;
CESC	cis	rs9611565	0.559	rs5758428	chr22:42106216	G/A	cg06481639	chr22:41940642	POLR3H	0.6	6.04	0.35	5.18e-9	Vitiligo;
CESC	cis	rs1801251	0.778	rs812383	chr2:233737132	C/A	cg25237894	chr2:233734115	C2orf82	-0.5	-8.95	-0.48	6.53e-17	Coronary artery disease;
CESC	cis	rs17376456	0.877	rs9314092	chr5:93326362	A/G	cg25358565	chr5:93447407	FAM172A	1.06	10.35	0.54	2.67e-21	Diabetic retinopathy;
CESC	cis	rs1799949	1.000	rs1060915	chr17:41234470	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.42	5.72	0.33	2.94e-8	Menopause (age at onset);
CESC	cis	rs636291	0.517	rs2781233	chr1:10529194	T/C	cg07384165	chr1:10488281	NA	-0.58	-8.37	-0.46	3.38e-15	Prostate cancer;
CESC	cis	rs4819052	0.851	rs28676615	chr21:46676576	G/C	cg11663144	chr21:46675770	NA	-0.63	-9.75	-0.51	2.19e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs734999	0.545	rs10910111	chr1:2542653	A/G	cg18854424	chr1:2615690	NA	0.3	6.09	0.35	3.96e-9	Ulcerative colitis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01518846	chr6:26246970	HIST1H4G	-0.63	-6.78	-0.38	7.98e-11	Gut microbiome composition (summer);
CESC	cis	rs7914558	0.966	rs1971589	chr10:104744406	A/G	cg04362960	chr10:104952993	NT5C2	0.45	5.74	0.33	2.65e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs875971	0.862	rs778707	chr7:65857027	G/A	cg11764359	chr7:65958608	NA	0.78	11.31	0.57	1.86e-24	Aortic root size;
CESC	cis	rs8072100	0.840	rs56952963	chr17:45493826	T/C	cg08085267	chr17:45401833	C17orf57	-0.53	-7.22	-0.41	5.35e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs3858526	0.523	rs10838750	chr11:5886246	C/T	cg05234568	chr11:5960015	NA	0.65	9.92	0.52	6.21e-20	DNA methylation (variation);
CESC	cis	rs244293	0.831	rs2111097	chr17:53090474	A/C	cg19360675	chr17:53046073	COX11;STXBP4	0.4	5.06	0.3	7.99e-7	Menarche (age at onset);
CESC	cis	rs911555	0.504	rs4444269	chr14:104072724	G/C	cg24130564	chr14:104152367	KLC1	-0.78	-12.61	-0.61	7.33e-29	Intelligence (multi-trait analysis);
CESC	cis	rs10504073	0.584	rs74457150	chr8:49890753	C/G	cg00325661	chr8:49890786	NA	0.56	8.52	0.46	1.26e-15	Blood metabolite ratios;
CESC	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg26354017	chr1:205819088	PM20D1	0.7	10.99	0.56	2.19e-23	Monocyte percentage of white cells;
CESC	cis	rs5750830	0.594	rs1010170	chr22:39778327	C/T	cg01416388	chr22:39784598	NA	0.5	5.98	0.35	7.03e-9	Intelligence (multi-trait analysis);
CESC	cis	rs2948294	0.588	rs12544596	chr8:8116346	A/T	cg06636001	chr8:8085503	FLJ10661	0.45	5.39	0.31	1.57e-7	Red cell distribution width;
CESC	cis	rs6088580	0.634	rs1890000	chr20:32968312	G/T	cg06115741	chr20:33292138	TP53INP2	-0.46	-5.93	-0.34	9.51e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs7306456	0.623	rs10902513	chr12:132693487	A/G	cg19601865	chr12:132687172	GALNT9	0.32	5.03	0.3	9.19e-7	Anti-saccade response;
CESC	cis	rs10754283	0.967	rs10801760	chr1:90113824	G/A	cg21401794	chr1:90099060	LRRC8C	0.69	9.34	0.5	4.06e-18	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs7818345	0.967	rs12678336	chr8:19280552	C/A	cg11303988	chr8:19266685	CSGALNACT1	0.34	6.11	0.35	3.47e-9	Language performance in older adults (adjusted for episodic memory);
CESC	cis	rs34172651	0.517	rs36113933	chr16:24838862	A/G	cg00339695	chr16:24857497	SLC5A11	0.52	6.84	0.39	5.54e-11	Intelligence (multi-trait analysis);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg13620366	chr9:138839624	UBAC1	0.52	7.09	0.4	1.24e-11	Fibrinogen levels;
CESC	cis	rs7216064	0.953	rs4790905	chr17:65863350	C/A	cg07042672	chr17:66097459	LOC651250	-0.57	-6.57	-0.37	2.69e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs6460942	0.915	rs7803051	chr7:12306904	A/T	cg20607287	chr7:12443886	VWDE	-0.49	-6.77	-0.38	8.08e-11	Coronary artery disease;
CESC	cis	rs7786877	0.626	rs11770389	chr7:100221218	T/G	cg20848291	chr7:100343083	ZAN	-0.67	-6.94	-0.39	2.94e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs6686643	1.000	rs6686643	chr1:165616588	T/C	cg19407955	chr1:165599744	MGST3	-0.51	-5.3	-0.31	2.47e-7	Total ventricular volume;
CESC	cis	rs7412746	0.634	rs4451553	chr1:150937329	C/T	cg22823121	chr1:150693482	HORMAD1	0.42	5.81	0.34	1.77e-8	Melanoma;
CESC	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg18538332	chr22:24372958	LOC391322	-0.68	-9.7	-0.51	3.17e-19	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs36051895	0.589	rs2224571	chr9:5196253	A/C	cg02405213	chr9:5042618	JAK2	-0.52	-6.0	-0.35	6.34e-9	Pediatric autoimmune diseases;
CESC	cis	rs13191362	0.935	rs34347104	chr6:163055716	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.52	5.41	0.32	1.44e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs4332037	0.624	rs11764124	chr7:1891723	C/G	cg23422044	chr7:1970798	MAD1L1	-0.49	-5.34	-0.31	1.95e-7	Bipolar disorder;
CESC	cis	rs1552244	0.882	rs17050699	chr3:10037167	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	10.87	0.56	5.21e-23	Alzheimer's disease;
CESC	cis	rs17376456	0.825	rs10079708	chr5:93261796	G/C	cg21475434	chr5:93447410	FAM172A	0.74	6.16	0.35	2.67e-9	Diabetic retinopathy;
CESC	cis	rs2251381	0.523	rs2832306	chr21:30754468	C/T	cg24692254	chr21:30365293	RNF160	-0.39	-5.07	-0.3	7.63e-7	Selective IgA deficiency;
CESC	cis	rs80130819	0.515	rs1793912	chr12:48387052	A/C	cg05342945	chr12:48394962	COL2A1	-0.49	-5.97	-0.34	7.7e-9	Prostate cancer;
CESC	cis	rs12497850	0.897	rs9850134	chr3:48957147	A/G	cg03060546	chr3:49711283	APEH	0.45	5.62	0.33	4.84e-8	Parkinson's disease;
CESC	cis	rs780096	0.546	rs1060525	chr2:27635582	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.35	-6.34	-0.36	9.61e-10	Total body bone mineral density;
CESC	cis	rs67311347	1.000	rs12494022	chr3:40426652	A/C	cg09455208	chr3:40491958	NA	0.51	8.27	0.45	6.59e-15	Renal cell carcinoma;
CESC	cis	rs60154123	0.730	rs12403947	chr1:210456524	A/G	cg22029157	chr1:209979665	IRF6	-0.52	-6.1	-0.35	3.71e-9	Coronary artery disease;
CESC	cis	rs10208940	0.920	rs7580719	chr2:68833572	A/G	cg12452813	chr2:68675892	NA	-0.53	-5.33	-0.31	2.08e-7	Urate levels in lean individuals;
CESC	cis	rs7666738	0.830	rs6846739	chr4:99016647	G/A	cg03467027	chr4:99064603	C4orf37	0.46	5.83	0.34	1.62e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2820292	0.740	rs12137232	chr1:201885446	G/T	cg11586189	chr1:201857591	SHISA4	-0.34	-5.54	-0.32	7.21e-8	Waist circumference;Body mass index (joint analysis main effects and smoking interaction);Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23085882	chr19:893253	MED16	-0.6	-6.83	-0.39	5.92e-11	Gut microbiome composition (summer);
CESC	cis	rs72901758	0.810	rs61740716	chr17:76244648	G/A	cg26068271	chr17:76253126	NA	0.49	7.25	0.41	4.52e-12	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
CESC	cis	rs2749592	0.588	rs2505192	chr10:38395023	G/A	cg00409905	chr10:38381863	ZNF37A	-0.54	-6.97	-0.39	2.46e-11	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs10927875	0.722	rs1763606	chr1:16338282	A/G	cg21214613	chr1:16344536	HSPB7	0.37	5.34	0.31	2.03e-7	Dilated cardiomyopathy;
CESC	cis	rs2075371	0.830	rs2077671	chr7:133951204	C/T	cg11752832	chr7:134001865	SLC35B4	0.51	6.52	0.37	3.54e-10	Mean platelet volume;
CESC	cis	rs7586879	0.662	rs2384059	chr2:25100338	C/T	cg01884057	chr2:25150051	NA	0.37	7.09	0.4	1.21e-11	Body mass index;
CESC	cis	rs832540	0.864	rs832576	chr5:56163255	C/A	cg14703610	chr5:56206110	C5orf35	0.44	5.78	0.33	2.11e-8	Coronary artery disease;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03079549	chr15:45879223	PLDN	0.48	6.27	0.36	1.46e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs4819052	0.765	rs2838868	chr21:46714641	A/G	cg11663144	chr21:46675770	NA	0.52	7.02	0.4	1.87e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs3892630	0.824	rs7247264	chr19:33239846	T/G	cg13157960	chr19:33183277	NUDT19	0.55	5.12	0.3	5.91e-7	Red blood cell traits;
CESC	cis	rs7949030	0.653	rs2849030	chr11:62366986	G/A	cg22862634	chr11:62369728	EML3;MTA2	-0.53	-7.43	-0.42	1.47e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs875971	0.862	rs10950043	chr7:65988610	T/C	cg19163074	chr7:65112434	INTS4L2	-0.43	-5.34	-0.31	2e-7	Aortic root size;
CESC	cis	rs10504229	1.000	rs72650900	chr8:58185675	T/A	cg05313129	chr8:58192883	C8orf71	-0.55	-6.29	-0.36	1.34e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs67311347	1.000	rs11720360	chr3:40448397	G/A	cg09455208	chr3:40491958	NA	0.5	8.27	0.45	6.47e-15	Renal cell carcinoma;
CESC	cis	rs6963495	0.818	rs6956234	chr7:105149707	A/G	cg19920283	chr7:105172520	RINT1	0.66	6.28	0.36	1.36e-9	Bipolar disorder (body mass index interaction);
CESC	cis	rs17818399	0.962	rs2122715	chr2:46845849	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.45	5.59	0.32	5.57e-8	Height;
CESC	cis	rs4919087	1.000	rs10786333	chr10:99090390	A/G	cg25902810	chr10:99078978	FRAT1	-0.68	-8.96	-0.48	5.86e-17	Monocyte count;
CESC	cis	rs637571	0.522	rs493899	chr11:65747952	A/C	cg02427764	chr11:65769310	BANF1;EIF1AD	0.73	10.63	0.55	3.17e-22	Eosinophil percentage of white cells;
CESC	cis	rs9911578	1.000	rs2333332	chr17:56631054	A/G	cg12560992	chr17:57184187	TRIM37	-0.93	-15.47	-0.69	6.42e-39	Intelligence (multi-trait analysis);
CESC	cis	rs698833	0.548	rs8410	chr2:44546016	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.54	5.6	0.33	5.28e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs4862750	0.872	rs13101380	chr4:187894744	G/A	cg10295955	chr4:187884368	NA	-1.02	-20.11	-0.78	2.9e-55	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4835473	0.932	rs1450233	chr4:144695863	T/A	cg25736465	chr4:144833511	NA	-0.33	-5.18	-0.3	4.39e-7	Immature fraction of reticulocytes;
CESC	cis	rs3008870	0.755	rs2815355	chr1:67485034	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.61	7.91	0.44	7.21e-14	Lymphocyte percentage of white cells;
CESC	cis	rs7296418	0.961	rs10848428	chr12:123572495	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.33	-5.18	-0.3	4.43e-7	Platelet count;
CESC	cis	rs67478160	0.595	rs12889993	chr14:104274294	A/G	cg08213375	chr14:104286397	PPP1R13B	0.54	10.76	0.55	1.22e-22	Schizophrenia;
CESC	cis	rs10504229	0.906	rs113745779	chr8:58191301	C/G	cg05313129	chr8:58192883	C8orf71	-0.55	-6.29	-0.36	1.34e-9	Developmental language disorder (linguistic errors);
CESC	trans	rs2727020	0.533	rs10839195	chr11:48973460	C/T	cg15704280	chr7:45808275	SEPT13	-0.55	-6.65	-0.38	1.68e-10	Coronary artery disease;
CESC	cis	rs10883723	0.810	rs1884929	chr10:104275418	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.55	7.58	0.42	5.73e-13	Allergic disease (asthma, hay fever or eczema);
CESC	trans	rs2235573	0.527	rs139887	chr22:38371396	G/C	cg19894588	chr14:64061835	NA	0.57	7.43	0.42	1.5e-12	Glioblastoma;Glioma;
CESC	cis	rs9926296	0.533	rs12102290	chr16:89812617	C/T	cg07648498	chr16:89883185	FANCA	0.49	6.21	0.36	1.99e-9	Vitiligo;
CESC	cis	rs7666738	0.830	rs7662199	chr4:99019766	G/A	cg03676636	chr4:99064102	C4orf37	0.33	5.08	0.3	7.23e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7666738	0.830	rs60411337	chr4:99046617	T/C	cg18180107	chr4:99064573	C4orf37	0.41	5.29	0.31	2.51e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7666738	0.830	rs11931166	chr4:99054187	A/T	cg05340658	chr4:99064831	C4orf37	0.82	12.88	0.62	8.44e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1862618	0.613	rs252889	chr5:56227069	C/A	cg18230493	chr5:56204884	C5orf35	-0.62	-8.31	-0.45	4.87e-15	Initial pursuit acceleration;
CESC	cis	rs9611565	0.625	rs9611606	chr22:41931074	A/G	cg06481639	chr22:41940642	POLR3H	-0.61	-6.39	-0.37	7.34e-10	Vitiligo;
CESC	cis	rs757110	0.745	rs10734252	chr11:17404839	G/A	cg15432903	chr11:17409602	KCNJ11	0.62	8.64	0.47	5.32e-16	Type 2 diabetes;
CESC	cis	rs17376456	0.825	rs17314797	chr5:93234845	T/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.62	5.24	0.31	3.31e-7	Diabetic retinopathy;
CESC	trans	rs61931739	0.534	rs4931775	chr12:34050729	G/A	cg26384229	chr12:38710491	ALG10B	0.6	8.36	0.46	3.68e-15	Morning vs. evening chronotype;
CESC	cis	rs9611565	0.765	rs202659	chr22:41811620	T/C	cg06634786	chr22:41940651	POLR3H	0.71	7.47	0.42	1.16e-12	Vitiligo;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg15959319	chr5:32174494	GOLPH3	-0.45	-6.13	-0.35	3.12e-9	Fibrinogen levels;
CESC	cis	rs11650494	0.710	rs2119935	chr17:47471334	T/C	cg08112188	chr17:47440006	ZNF652	0.84	6.39	0.37	7.58e-10	Prostate cancer;
CESC	cis	rs1562975	0.609	rs55707402	chr4:109418264	T/A	cg16022748	chr4:109541635	LOC285456;RPL34	0.42	5.38	0.31	1.66e-7	Height;
CESC	cis	rs2180341	1.000	rs9285460	chr6:127640190	A/G	cg27446573	chr6:127587934	RNF146	1.09	16.38	0.71	3.79e-42	Breast cancer;
CESC	cis	rs1552244	0.572	rs41464050	chr3:10158393	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.72	-8.19	-0.45	1.08e-14	Alzheimer's disease;
CESC	cis	rs238295	0.805	rs6053486	chr20:5530767	T/G	cg24001556	chr20:5591874	RP5-1022P6.2	-0.44	-5.09	-0.3	6.66e-7	Occipital cortical area (total cortical area interaction);
CESC	cis	rs765787	0.505	rs11630884	chr15:45532246	C/T	cg24006582	chr15:45444508	DUOX1	-0.55	-6.81	-0.39	6.47e-11	Uric acid levels;
CESC	cis	rs10484885	0.878	rs17763820	chr6:90569634	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.77	-7.37	-0.41	2.17e-12	QRS interval (sulfonylurea treatment interaction);
CESC	cis	rs7618915	0.501	rs3852066	chr3:52621839	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	7.55	0.42	7.15e-13	Bipolar disorder;
CESC	cis	rs6460942	0.915	rs1595802	chr7:12439672	C/T	cg17427002	chr7:12443146	VWDE	-0.58	-6.01	-0.35	6.16e-9	Coronary artery disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg03570498	chr10:131566727	NA	0.52	6.75	0.38	9.09e-11	Fibrinogen levels;
CESC	cis	rs875971	0.862	rs6460293	chr7:65810192	C/A	cg18252515	chr7:66147081	NA	0.45	5.88	0.34	1.22e-8	Aortic root size;
CESC	cis	rs8103278	0.507	rs7260651	chr19:46260245	G/A	cg06577658	chr19:46296270	DMWD	0.43	5.27	0.31	2.76e-7	Coronary artery disease;
CESC	cis	rs2070488	0.775	rs2186457	chr3:38553965	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.75	11.85	0.59	2.86e-26	Electrocardiographic conduction measures;
CESC	cis	rs1045902	0.583	rs36106493	chr2:73442339	C/T	cg01422370	chr2:73384389	NA	0.35	5.52	0.32	8.23e-8	Intelligence (multi-trait analysis);
CESC	cis	rs9287719	0.935	rs10803723	chr2:10722877	C/T	cg02196655	chr2:10830764	NOL10	-0.36	-5.57	-0.32	6.1e-8	Prostate cancer;
CESC	cis	rs9393777	0.513	rs9379905	chr6:26630990	G/A	cg12292205	chr6:26970375	C6orf41	-0.5	-5.67	-0.33	3.8e-8	Intelligence (multi-trait analysis);
CESC	cis	rs853679	0.513	rs9468296	chr6:28113730	A/G	cg26335602	chr6:28129616	ZNF389	0.53	6.85	0.39	5.12e-11	Depression;
CESC	cis	rs7917772	0.503	rs2031601	chr10:104308064	T/G	cg22532475	chr10:104410764	TRIM8	-0.33	-5.74	-0.33	2.65e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs790123	1.000	rs790116	chr3:122380923	G/C	cg17380795	chr3:122379686	NA	0.34	5.14	0.3	5.37e-7	Response to angiotensin II receptor blocker therapy;
CESC	cis	rs34779708	0.742	rs35912711	chr10:35312996	T/C	cg03585969	chr10:35415529	CREM	0.75	9.74	0.51	2.4e-19	Inflammatory bowel disease;Crohn's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04935666	chr14:105817407	PACS2	-0.51	-6.23	-0.36	1.81e-9	Gut microbiome composition (summer);
CESC	cis	rs7824557	0.591	rs2736283	chr8:11225910	A/G	cg21775007	chr8:11205619	TDH	-0.52	-8.27	-0.45	6.57e-15	Retinal vascular caliber;
CESC	cis	rs4654899	1.000	rs6683542	chr1:21369610	T/C	cg05370193	chr1:21551575	ECE1	0.38	5.78	0.33	2.1e-8	Superior frontal gyrus grey matter volume;
CESC	cis	rs4604732	0.631	rs7546720	chr1:247627229	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.57	7.17	0.4	7.39e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs875971	0.862	rs4236208	chr7:65749078	C/T	cg11764359	chr7:65958608	NA	-0.82	-12.43	-0.61	2.88e-28	Aortic root size;
CESC	cis	rs6732160	0.932	rs13417029	chr2:73380423	T/G	cg01422370	chr2:73384389	NA	0.51	8.77	0.47	2.15e-16	Intelligence (multi-trait analysis);
CESC	cis	rs514406	0.571	rs11206004	chr1:53210958	G/A	cg24675658	chr1:53192096	ZYG11B	0.64	8.96	0.48	5.99e-17	Monocyte count;
CESC	cis	rs7621025	0.500	rs9845460	chr3:136587117	A/G	cg15507776	chr3:136538369	TMEM22	0.77	9.63	0.51	5.14e-19	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
CESC	cis	rs10463316	0.925	rs6877344	chr5:150742650	C/T	cg03212797	chr5:150827313	SLC36A1	-0.43	-5.04	-0.3	8.73e-7	Metabolite levels (Pyroglutamine);
CESC	cis	rs7666738	0.830	rs1124253	chr4:98949682	C/T	cg03467027	chr4:99064603	C4orf37	0.45	5.67	0.33	3.69e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10504229	0.953	rs57131327	chr8:58171895	T/C	cg22535103	chr8:58192502	C8orf71	-1.05	-13.27	-0.63	3.63e-31	Developmental language disorder (linguistic errors);
CESC	cis	rs155076	1.000	rs261431	chr13:21865738	A/G	cg23743428	chr13:21893420	NA	-0.38	-5.09	-0.3	6.83e-7	White matter hyperintensity burden;
CESC	cis	rs7918232	0.830	rs9833	chr10:27400861	G/A	cg14240646	chr10:27532245	ACBD5	-0.66	-6.3	-0.36	1.21e-9	Breast cancer;
CESC	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg11494091	chr17:61959527	GH2	0.74	12.74	0.62	2.54e-29	Prudent dietary pattern;
CESC	cis	rs9388451	0.626	rs1739384	chr6:126099246	C/A	cg05901451	chr6:126070800	HEY2	-0.57	-8.3	-0.45	5.26e-15	Brugada syndrome;
CESC	cis	rs1552244	0.935	rs35586456	chr3:10116938	A/G	cg00166722	chr3:10149974	C3orf24	0.55	6.83	0.39	5.64e-11	Alzheimer's disease;
CESC	cis	rs875971	0.505	rs1167386	chr7:65513096	G/A	cg08632164	chr7:65971372	NA	0.31	5.1	0.3	6.37e-7	Aortic root size;
CESC	cis	rs8062405	0.823	rs7202948	chr16:28558289	T/A	cg08761264	chr16:28874980	SH2B1	-0.41	-5.03	-0.3	8.87e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs4665809	0.590	rs1056389	chr2:26502875	T/C	cg26314531	chr2:26401878	FAM59B	0.83	8.36	0.46	3.57e-15	Gut microbiome composition (summer);
CESC	trans	rs123509	0.913	rs339661	chr3:42753904	G/A	cg22035501	chr5:112073398	APC	0.58	6.28	0.36	1.35e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	trans	rs7945705	0.935	rs2653567	chr11:8889630	T/C	cg10637292	chr12:52960529	KRT74	0.35	6.11	0.35	3.56e-9	Hemoglobin concentration;
CESC	cis	rs7267979	1.000	rs13038834	chr20:25441433	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.82	15.34	0.69	1.94e-38	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs6088590	1.000	rs3787222	chr20:33333040	T/A	cg24642439	chr20:33292090	TP53INP2	0.85	11.75	0.59	5.97e-26	Coronary artery disease;
CESC	cis	rs7296418	0.961	rs61955196	chr12:123451018	G/C	cg00376283	chr12:123451042	ABCB9	0.73	10.27	0.53	4.75e-21	Platelet count;
CESC	cis	rs916888	0.697	rs199516	chr17:44856485	C/T	cg15921436	chr17:44337874	NA	-0.71	-8.05	-0.44	2.83e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07505695	chr15:65281854	SPG21	-0.56	-6.48	-0.37	4.48e-10	Gut microbiome composition (summer);
CESC	cis	rs9325144	0.560	rs11183150	chr12:38674698	A/G	cg26384229	chr12:38710491	ALG10B	-0.6	-8.5	-0.46	1.44e-15	Morning vs. evening chronotype;
CESC	cis	rs2425143	0.908	rs11697087	chr20:34427583	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.71	-6.06	-0.35	4.71e-9	Blood protein levels;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg02120071	chr2:114737129	NA	0.46	6.1	0.35	3.76e-9	Fibrinogen levels;
CESC	cis	rs367943	0.665	rs4705560	chr5:112977073	T/G	cg12552261	chr5:112820674	MCC	0.44	5.67	0.33	3.72e-8	Type 2 diabetes;
CESC	cis	rs1005224	0.889	rs9323617	chr14:76158638	A/G	cg25116370	chr14:76127843	TTLL5;C14orf1	-0.44	-6.15	-0.35	2.87e-9	Large artery stroke;
CESC	cis	rs854765	0.547	rs2955359	chr17:17946730	T/C	cg16928487	chr17:17741425	SREBF1	0.55	9.13	0.49	1.86e-17	Total body bone mineral density;
CESC	cis	rs1865721	0.804	rs3826652	chr18:73142153	C/T	cg26385618	chr18:73139727	C18orf62	0.47	7.87	0.44	8.87e-14	Intelligence;
CESC	cis	rs17253792	0.822	rs17685053	chr14:56125771	T/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.72	5.82	0.34	1.69e-8	Putamen volume;
CESC	cis	rs909002	0.830	rs1356803	chr1:32131163	C/G	cg13919466	chr1:32135498	COL16A1	-0.5	-9.08	-0.49	2.49e-17	Intelligence (multi-trait analysis);
CESC	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	21.45	0.8	7.43e-60	Prudent dietary pattern;
CESC	cis	rs59918340	1.000	rs59918340	chr8:142232256	A/G	cg23750338	chr8:142222470	SLC45A4	0.43	6.7	0.38	1.26e-10	Immature fraction of reticulocytes;
CESC	cis	rs7618915	0.501	rs55678971	chr3:52717229	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	7.57	0.42	6.19e-13	Bipolar disorder;
CESC	cis	rs8002861	0.846	rs12428112	chr13:44475821	C/A	cg19180546	chr13:44453867	C13orf31;CCDC122	-0.45	-5.79	-0.34	1.94e-8	Leprosy;
CESC	cis	rs2236918	0.965	rs2488472	chr1:242019919	T/C	cg17736920	chr1:242011382	EXO1	0.73	9.67	0.51	3.87e-19	Menopause (age at onset);
CESC	cis	rs1670533	1.000	rs6822863	chr4:1055606	G/A	cg04106633	chr4:1044584	NA	0.4	5.12	0.3	6.01e-7	Recombination rate (females);
CESC	cis	rs3768617	0.510	rs10797839	chr1:183077797	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.89	14.21	0.66	1.9e-34	Fuchs's corneal dystrophy;
CESC	cis	rs7666738	0.830	rs7691864	chr4:98971376	G/C	cg03467027	chr4:99064603	C4orf37	0.42	5.32	0.31	2.25e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs34172651	0.517	rs12927710	chr16:24790282	A/C	cg06505273	chr16:24850292	NA	0.51	5.87	0.34	1.27e-8	Intelligence (multi-trait analysis);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg01956158	chr8:132916947	EFR3A	-0.44	-6.23	-0.36	1.86e-9	Gambling;
CESC	cis	rs1707322	0.721	rs10789470	chr1:46158331	T/G	cg06784218	chr1:46089804	CCDC17	0.43	7.58	0.42	5.65e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs1707322	0.717	rs12023439	chr1:46104636	C/T	cg06784218	chr1:46089804	CCDC17	0.4	6.99	0.39	2.23e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2109514	0.840	rs2402080	chr7:116135016	G/C	cg12739419	chr7:116140593	CAV2	-0.38	-6.74	-0.38	1.01e-10	Prevalent atrial fibrillation;
CESC	cis	rs4660261	0.545	rs803682	chr1:44362623	G/A	cg12908607	chr1:44402522	ARTN	-0.49	-7.49	-0.42	1.04e-12	Intelligence (multi-trait analysis);
CESC	cis	rs9287719	0.967	rs10203664	chr2:10752377	T/C	cg02196655	chr2:10830764	NOL10	-0.37	-5.69	-0.33	3.39e-8	Prostate cancer;
CESC	cis	rs12824058	0.831	rs1390849	chr12:130811547	A/G	cg23887609	chr12:130822674	PIWIL1	0.45	5.82	0.34	1.69e-8	Menopause (age at onset);
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg17789542	chr5:71604139	MRPS27	-0.49	-6.33	-0.36	1.04e-9	Asthma;
CESC	cis	rs72634258	0.945	rs12727642	chr1:8046672	C/A	cg00042356	chr1:8021962	PARK7	0.79	6.93	0.39	3.15e-11	Inflammatory bowel disease;
CESC	cis	rs2295359	0.963	rs12030867	chr1:67627620	T/C	cg03340356	chr1:67600835	NA	0.33	5.34	0.31	1.96e-7	Psoriasis;
CESC	cis	rs56104184	0.775	rs55756106	chr19:49403055	A/G	cg15549821	chr19:49342101	PLEKHA4	-0.6	-5.99	-0.35	6.95e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg23275840	chr4:47708675	CORIN	-0.34	-6.41	-0.37	6.81e-10	Thyroid stimulating hormone;
CESC	trans	rs853679	0.545	rs35949109	chr6:28025926	T/C	cg06606381	chr12:133084897	FBRSL1	-0.76	-6.59	-0.38	2.31e-10	Depression;
CESC	cis	rs9929218	0.551	rs3785133	chr16:68728611	C/T	cg01251360	chr16:68772225	CDH1	-0.23	-5.24	-0.31	3.23e-7	Colorectal cancer;
CESC	cis	rs4604732	0.588	rs7549955	chr1:247628321	G/A	cg12758973	chr1:247694275	LOC148824;OR2C3	0.48	6.01	0.35	6.07e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs897080	0.552	rs698793	chr2:44685685	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.46	5.33	0.31	2.09e-7	Height;
CESC	cis	rs7772486	0.875	rs6914813	chr6:146397798	A/G	cg23711669	chr6:146136114	FBXO30	0.86	12.76	0.62	2.12e-29	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7107174	1.000	rs2512550	chr11:77943848	C/T	cg02023728	chr11:77925099	USP35	0.39	5.54	0.32	7.31e-8	Testicular germ cell tumor;
CESC	cis	rs2070488	0.804	rs1817364	chr3:38474513	T/G	cg24069376	chr3:38537580	EXOG	0.35	5.92	0.34	9.72e-9	Electrocardiographic conduction measures;
CESC	cis	rs11264213	0.786	rs72659676	chr1:36254032	C/T	cg27506609	chr1:36549197	TEKT2	0.61	5.04	0.3	8.54e-7	Schizophrenia;
CESC	cis	rs2839186	0.558	rs2968	chr21:47608580	C/T	cg12516959	chr21:47718080	NA	0.41	5.98	0.34	7.14e-9	Testicular germ cell tumor;
CESC	cis	rs875971	0.825	rs6951503	chr7:65718936	T/G	cg12463550	chr7:65579703	CRCP	-0.48	-6.14	-0.35	2.99e-9	Aortic root size;
CESC	cis	rs2290720	1.000	rs7312071	chr12:101698982	A/G	cg22051763	chr12:101673672	UTP20	-0.42	-5.08	-0.3	7.02e-7	Brain structure (hippocampal volume);
CESC	cis	rs5760092	0.618	rs4461358	chr22:24260106	T/C	cg23131131	chr22:24373011	LOC391322	0.62	7.5	0.42	9.49e-13	Urinary 1,3-butadiene metabolite levels in smokers;
CESC	cis	rs367615	0.537	rs17161729	chr5:108660528	C/G	cg17395555	chr5:108820864	NA	-0.5	-8.07	-0.44	2.49e-14	Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs8077577	0.945	rs11655731	chr17:18107525	G/T	cg16794390	chr17:18148240	FLII	0.46	5.78	0.33	2.12e-8	Obesity-related traits;
CESC	cis	rs763121	0.651	rs738249	chr22:39037979	T/C	cg14440974	chr22:39074834	NA	-0.39	-5.18	-0.3	4.49e-7	Menopause (age at onset);
CESC	cis	rs6951245	0.580	rs10257426	chr7:1213694	G/A	cg24642844	chr7:1081250	C7orf50	-0.53	-6.86	-0.39	4.83e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs7107217	1.000	rs1873872	chr11:129473993	A/T	cg05518842	chr16:1823291	MRPS34;EME2	0.47	6.17	0.35	2.48e-9	Breast cancer;Type 2 diabetes;
CESC	cis	rs6598955	0.543	rs12122527	chr1:26549748	C/T	cg04990556	chr1:26633338	UBXN11	0.8	9.15	0.49	1.57e-17	Obesity-related traits;
CESC	cis	rs2050392	0.858	rs306583	chr10:30710057	C/T	cg25182066	chr10:30743637	MAP3K8	0.42	5.77	0.33	2.21e-8	Inflammatory bowel disease;
CESC	cis	rs208520	1.000	rs72884025	chr6:66994185	T/C	cg07460842	chr6:66804631	NA	0.88	9.99	0.52	3.87e-20	Exhaled nitric oxide output;
CESC	cis	rs61931739	0.500	rs11836207	chr12:34315177	G/A	cg06521331	chr12:34319734	NA	-0.46	-6.18	-0.35	2.41e-9	Morning vs. evening chronotype;
CESC	cis	rs4253772	0.515	rs8142080	chr22:46647429	G/T	cg00784671	chr22:46762841	CELSR1	-0.56	-5.8	-0.34	1.84e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs13385	0.728	rs10055141	chr5:139616609	T/C	cg26211634	chr5:139558579	C5orf32	0.48	5.24	0.31	3.28e-7	Atrial fibrillation;
CESC	cis	rs3733585	0.781	rs57250714	chr4:9984529	C/T	cg00071950	chr4:10020882	SLC2A9	0.69	11.21	0.57	4.08e-24	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs1799949	0.894	rs36062488	chr17:41337472	C/T	cg25072359	chr17:41440525	NA	-0.5	-7.33	-0.41	2.72e-12	Menopause (age at onset);
CESC	trans	rs650950	0.528	rs646660	chr11:35528452	C/T	cg12758922	chr20:37101595	RALGAPB	0.45	6.0	0.35	6.61e-9	Bronchopulmonary dysplasia;
CESC	trans	rs2347503	0.510	rs16879344	chr8:32262521	A/G	cg00536910	chr8:1319507	NA	-0.68	-6.3	-0.36	1.27e-9	Cognitive function;
CESC	cis	rs3785574	0.924	rs2727292	chr17:61893747	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.57	6.99	0.39	2.29e-11	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14195823	chr19:39926698	RPS16	0.62	7.02	0.4	1.85e-11	Gut microbiome composition (summer);
CESC	cis	rs6580649	0.943	rs1990029	chr12:48407987	C/T	cg05342945	chr12:48394962	COL2A1	-0.55	-6.27	-0.36	1.46e-9	Lung cancer;
CESC	cis	rs3820068	0.581	rs58567918	chr1:15925823	A/G	cg13390004	chr1:15929781	NA	0.35	5.58	0.32	5.83e-8	Systolic blood pressure;
CESC	cis	rs2066819	0.786	rs116934693	chr12:56696545	T/G	cg26714650	chr12:56694279	CS	-1.52	-10.39	-0.54	1.95e-21	Psoriasis vulgaris;
CESC	cis	rs9916302	0.904	rs2338755	chr17:37419317	C/T	cg00129232	chr17:37814104	STARD3	0.55	7.23	0.41	5.14e-12	Glomerular filtration rate (creatinine);
CESC	cis	rs1008375	1.000	rs10805359	chr4:17684886	A/G	cg15017067	chr4:17643749	FAM184B	0.34	5.05	0.3	8.24e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs72781680	0.898	rs55841168	chr2:24007926	T/C	cg08917208	chr2:24149416	ATAD2B	0.95	8.71	0.47	3.45e-16	Lymphocyte counts;
CESC	cis	rs7208859	0.673	rs216440	chr17:28928309	A/T	cg19761014	chr17:28927070	LRRC37B2	0.73	7.27	0.41	3.98e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs7680126	0.633	rs4697975	chr4:10209966	A/T	cg11266682	chr4:10021025	SLC2A9	-0.4	-5.31	-0.31	2.32e-7	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	cis	rs4805272	0.512	rs12373558	chr19:29337692	A/G	cg12756686	chr19:29218302	NA	0.41	5.39	0.31	1.58e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
CESC	cis	rs9916302	0.904	rs2303316	chr17:37704217	A/G	cg19468946	chr17:37922297	IKZF3	-0.39	-5.12	-0.3	5.78e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs12579753	0.917	rs11115029	chr12:82202219	C/G	cg24719984	chr12:82153464	PPFIA2	-0.33	-5.04	-0.3	8.55e-7	Resting heart rate;
CESC	cis	rs9911578	1.000	rs2643119	chr17:56827760	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.21	0.3	3.88e-7	Intelligence (multi-trait analysis);
CESC	cis	rs9916302	0.861	rs10491129	chr17:37461643	T/G	cg07936489	chr17:37558343	FBXL20	0.76	10.63	0.55	3.3e-22	Glomerular filtration rate (creatinine);
CESC	cis	rs13191362	1.000	rs34931503	chr6:163003876	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.83	8.39	0.46	3.02e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11353064	chr12:57472281	TMEM194A	0.57	6.66	0.38	1.55e-10	Gut microbiome composition (summer);
CESC	cis	rs2836974	0.932	rs6517527	chr21:40581751	G/A	cg27266027	chr21:40555129	PSMG1	0.45	5.3	0.31	2.47e-7	Cognitive function;
CESC	cis	rs10911232	0.507	rs5022057	chr1:182997761	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.84	13.19	0.63	6.74e-31	Hypertriglyceridemia;
CESC	cis	rs9388451	0.531	rs9321057	chr6:126156943	G/A	cg05901451	chr6:126070800	HEY2	-0.44	-5.97	-0.34	7.44e-9	Brugada syndrome;
CESC	cis	rs4808199	0.895	rs6511036	chr19:19582651	A/G	cg03709012	chr19:19516395	GATAD2A	1.16	13.34	0.63	2.07e-31	Nonalcoholic fatty liver disease;
CESC	cis	rs10504229	0.683	rs11784908	chr8:58131472	T/C	cg02725872	chr8:58115012	NA	-0.45	-7.05	-0.4	1.52e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs4713118	0.662	rs156744	chr6:27967274	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.59	-6.96	-0.39	2.71e-11	Parkinson's disease;
CESC	cis	rs10791097	0.690	rs12286234	chr11:130730528	T/C	cg09137382	chr11:130731461	NA	0.39	5.86	0.34	1.36e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg23708337	chr7:1209742	NA	0.53	5.34	0.31	1.98e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs28489187	0.706	rs1498375	chr1:85787323	T/A	cg16011679	chr1:85725395	C1orf52	0.56	6.55	0.37	3.05e-10	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	cis	rs1799949	1.000	rs16941	chr17:41244435	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	8.65	0.47	5.16e-16	Menopause (age at onset);
CESC	cis	rs718433	0.584	rs2204935	chr14:22212463	A/G	cg02257791	chr14:22217085	NA	-0.32	-5.09	-0.3	6.83e-7	Intraocular pressure;
CESC	cis	rs4319547	0.695	rs1803290	chr12:122865029	T/C	cg05707623	chr12:122985044	ZCCHC8	0.53	5.92	0.34	1.01e-8	Body mass index;
CESC	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg18099408	chr3:52552593	STAB1	-0.43	-8.07	-0.44	2.45e-14	Electroencephalogram traits;
CESC	cis	rs1707322	0.963	rs11211238	chr1:46449415	G/A	cg06784218	chr1:46089804	CCDC17	0.33	5.63	0.33	4.7e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs17711722	0.522	rs4642526	chr7:65216742	G/T	cg05332525	chr7:65337924	VKORC1L1	0.45	5.74	0.33	2.54e-8	Calcium levels;
CESC	cis	rs2836974	0.644	rs2836986	chr21:40702136	A/C	cg22974920	chr21:40686053	BRWD1	-0.45	-5.57	-0.32	6.21e-8	Cognitive function;
CESC	cis	rs9611565	0.512	rs1983576	chr22:42166486	G/A	cg17376030	chr22:41985996	PMM1	-0.79	-8.37	-0.46	3.43e-15	Vitiligo;
CESC	cis	rs11098499	0.909	rs28714195	chr4:120316950	A/T	cg24375607	chr4:120327624	NA	0.47	5.62	0.33	4.74e-8	Corneal astigmatism;
CESC	cis	rs2816062	0.786	rs742486	chr1:18900829	G/A	cg18795169	chr1:18902165	NA	-0.93	-18.14	-0.74	2.24e-48	Urate levels in lean individuals;
CESC	cis	rs11658309	1	rs11658309	chr17:17762247	T/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.54	-7.75	-0.43	1.97e-13	Strep throat;
CESC	cis	rs769267	0.895	rs2916069	chr19:19520358	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.57	7.48	0.42	1.09e-12	Tonsillectomy;
CESC	cis	rs7714584	1.000	rs9324660	chr5:150257054	C/G	cg22134413	chr5:150180641	NA	0.5	5.81	0.34	1.81e-8	Crohn's disease;
CESC	cis	rs9399401	0.667	rs6922607	chr6:142703483	A/G	cg04461802	chr6:142623433	GPR126	0.37	5.55	0.32	6.88e-8	Chronic obstructive pulmonary disease;
CESC	cis	rs3015497	0.753	rs12881776	chr14:51136330	T/G	cg09863266	chr14:51125203	SAV1	-0.35	-5.39	-0.31	1.59e-7	Mean platelet volume;
CESC	cis	rs853679	0.517	rs9468286	chr6:28079428	C/T	cg19592336	chr6:28129416	ZNF389	0.6	7.98	0.44	4.4e-14	Depression;
CESC	cis	rs4253772	0.550	rs9615953	chr22:46731024	C/G	cg24881330	chr22:46731750	TRMU	0.8	5.7	0.33	3.13e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs738322	0.805	rs2016755	chr22:38539604	A/G	cg25457927	chr22:38595422	NA	-0.28	-5.18	-0.3	4.37e-7	Cutaneous nevi;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg06059318	chr7:72936700	BAZ1B	0.48	6.08	0.35	4.27e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs12618769	0.597	rs7585939	chr2:99219206	T/A	cg10123293	chr2:99228465	UNC50	0.4	5.19	0.3	4.2e-7	Bipolar disorder;
CESC	cis	rs4665809	0.589	rs4665841	chr2:26448950	G/A	cg26314531	chr2:26401878	FAM59B	-0.85	-9.49	-0.5	1.45e-18	Gut microbiome composition (summer);
CESC	trans	rs2502399	0.689	rs7752798	chr6:113492470	G/A	cg00285294	chr7:1089767	C7orf50	-0.33	-6.2	-0.36	2.2e-9	Plasma clusterin levels;
CESC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg19603075	chr15:89010536	MRPS11;MRPL46	-0.55	-6.27	-0.36	1.47e-9	Lung cancer in ever smokers;
CESC	cis	rs896854	0.684	rs10099941	chr8:95987008	C/T	cg16049864	chr8:95962084	TP53INP1	-0.65	-11.59	-0.58	2.1e-25	Type 2 diabetes;
CESC	cis	rs9611565	0.649	rs202614	chr22:41822150	A/C	cg03806693	chr22:41940476	POLR3H	1.2	14.5	0.67	1.86e-35	Vitiligo;
CESC	cis	rs6736093	0.966	rs4848899	chr2:112710111	G/A	cg12686935	chr2:112915763	FBLN7	-0.42	-5.46	-0.32	1.1e-7	Coronary artery disease;
CESC	cis	rs72802342	0.541	rs185052	chr16:75467063	C/T	cg04384234	chr16:75411784	CFDP1	0.5	5.93	0.34	9.67e-9	Advanced age-related macular degeneration;
CESC	cis	rs6540556	0.643	rs2282739	chr1:209883001	C/T	cg05527609	chr1:210001259	C1orf107	-0.48	-5.59	-0.32	5.56e-8	Red blood cell count;
CESC	cis	rs7811142	0.943	rs66958101	chr7:100074020	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.78	6.81	0.39	6.56e-11	Platelet count;
CESC	cis	rs7666738	0.830	rs13125432	chr4:98961253	G/A	cg03467027	chr4:99064603	C4orf37	0.44	5.57	0.32	6.41e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7208859	0.673	rs216409	chr17:28906269	C/T	cg04154034	chr17:28927549	LRRC37B2	-0.65	-5.9	-0.34	1.09e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs62064224	0.902	rs17732573	chr17:30627664	C/T	cg25809561	chr17:30822961	MYO1D	-0.39	-5.27	-0.31	2.84e-7	Schizophrenia;
CESC	cis	rs10870270	1.000	rs10159746	chr10:133742677	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.62	-8.06	-0.44	2.63e-14	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs7084402	0.967	rs1658418	chr10:60333003	G/A	cg07615347	chr10:60278583	BICC1	0.59	9.23	0.49	9.22e-18	Refractive error;
CESC	cis	rs9925964	0.967	rs2855475	chr16:31147548	G/A	cg02466173	chr16:30829666	NA	-0.33	-5.15	-0.3	5.02e-7	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs4919694	0.572	rs4917995	chr10:104845443	A/T	cg04362960	chr10:104952993	NT5C2	-0.65	-6.22	-0.36	1.94e-9	Arsenic metabolism;
CESC	cis	rs6120849	0.802	rs6087681	chr20:33752896	G/C	cg24642439	chr20:33292090	TP53INP2	0.61	6.49	0.37	4.21e-10	Protein C levels;
CESC	cis	rs911555	0.755	rs8016676	chr14:103904842	C/A	cg24130564	chr14:104152367	KLC1	0.5	6.52	0.37	3.62e-10	Intelligence (multi-trait analysis);
CESC	cis	rs6120849	0.754	rs11167253	chr20:33614449	T/C	cg24642439	chr20:33292090	TP53INP2	0.68	6.77	0.38	8.46e-11	Protein C levels;
CESC	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.44	0.37	5.54e-10	Prudent dietary pattern;
CESC	cis	rs7786808	0.579	rs4045391	chr7:158181826	T/C	cg01191920	chr7:158217561	PTPRN2	-0.34	-5.57	-0.32	6.15e-8	Obesity-related traits;
CESC	cis	rs2645694	0.532	rs2645706	chr4:77829606	A/C	cg10057126	chr4:77819792	ANKRD56	0.58	8.31	0.45	4.97e-15	Emphysema distribution in smoking;
CESC	cis	rs829883	0.934	rs1641642	chr12:98898726	A/G	cg25150519	chr12:98850993	NA	0.7	9.63	0.51	5.03e-19	Colorectal adenoma (advanced);
CESC	cis	rs2721195	0.719	rs4925811	chr8:145802447	G/T	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.77	-11.75	-0.59	6.15e-26	Age at first birth;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04691540	chr1:179198414	ABL2	0.5	6.59	0.38	2.32e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs853679	0.517	rs3757185	chr6:28107776	T/A	cg22143856	chr6:28129313	ZNF389	0.53	6.86	0.39	4.9e-11	Depression;
CESC	cis	rs909002	0.800	rs968335	chr1:32085776	G/A	cg13919466	chr1:32135498	COL16A1	-0.46	-8.22	-0.45	8.97e-15	Intelligence (multi-trait analysis);
CESC	cis	rs13102973	0.933	rs7656595	chr4:135875693	G/A	cg14419869	chr4:135874104	NA	0.36	5.67	0.33	3.64e-8	Subjective well-being;
CESC	cis	rs1348850	0.768	rs57681892	chr2:178357645	G/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.81	11.65	0.58	1.3e-25	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs2243480	1.000	rs313799	chr7:65494330	A/G	cg18252515	chr7:66147081	NA	-1.13	-10.9	-0.56	4.18e-23	Diabetic kidney disease;
CESC	cis	rs13102973	0.932	rs7656273	chr4:135852678	G/A	cg14419869	chr4:135874104	NA	0.33	5.13	0.3	5.56e-7	Subjective well-being;
CESC	cis	rs4805272	0.512	rs7245724	chr19:29341679	C/T	cg12756686	chr19:29218302	NA	0.43	5.86	0.34	1.37e-8	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
CESC	cis	rs733592	1.000	rs1859440	chr12:48427329	T/C	cg24011408	chr12:48396354	COL2A1	-0.51	-8.17	-0.45	1.27e-14	Plateletcrit;
CESC	cis	rs7216064	1.000	rs7214758	chr17:65880538	T/C	cg12091567	chr17:66097778	LOC651250	-0.87	-8.96	-0.48	6.1e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs12190007	0.547	rs2981944	chr6:169801753	T/G	cg15038512	chr6:170123185	PHF10	-0.48	-6.81	-0.39	6.6e-11	Obesity-related traits;
CESC	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.52	6.46	0.37	4.96e-10	Prudent dietary pattern;
CESC	cis	rs3820928	1.000	rs9288617	chr2:227762815	G/C	cg11843606	chr2:227700838	RHBDD1	-0.42	-5.72	-0.33	2.92e-8	Pulmonary function;
CESC	cis	rs13031619	0.517	rs10183413	chr2:3684342	T/C	cg01268866	chr2:3683757	COLEC11	-0.64	-6.87	-0.39	4.68e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CESC	cis	rs11098499	0.754	rs4107728	chr4:120253910	G/A	cg09307838	chr4:120376055	NA	0.8	10.77	0.55	1.16e-22	Corneal astigmatism;
CESC	cis	rs10504229	0.593	rs2317990	chr8:58024168	G/T	cg24829409	chr8:58192753	C8orf71	-0.5	-6.08	-0.35	4.13e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs9296095	0.632	rs6914422	chr6:33534880	A/G	cg14003231	chr6:33640908	ITPR3	-0.32	-5.53	-0.32	7.81e-8	Platelet count;
CESC	trans	rs634534	0.561	rs655744	chr11:65776585	G/T	cg17712092	chr4:129076599	LARP1B	-0.69	-9.49	-0.5	1.44e-18	Sum eosinophil basophil counts;Eosinophil counts;
CESC	cis	rs4955124	0.558	rs78465094	chr3:32019016	T/C	cg05935571	chr3:32023257	ZNF860;OSBPL10	0.97	8.8	0.48	1.83e-16	Schizophrenia;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg06227920	chr15:65477998	CLPX	-0.47	-6.31	-0.36	1.13e-9	Fibrinogen levels;
CESC	cis	rs6460942	0.597	rs13227809	chr7:12525557	G/A	cg20607287	chr7:12443886	VWDE	-0.71	-7.67	-0.43	3.19e-13	Coronary artery disease;
CESC	cis	rs8103278	1.000	rs1548029	chr19:46309203	A/C	cg11657440	chr19:46296263	DMWD	-0.59	-7.24	-0.41	4.94e-12	Coronary artery disease;
CESC	cis	rs7312933	0.703	rs12370778	chr12:42599696	T/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.49	6.4	0.37	6.94e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs12220238	1.000	rs12358614	chr10:75906173	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.63	6.15	0.35	2.9e-9	Soluble interleukin-2 receptor subunit alpha;
CESC	cis	rs28386778	0.669	rs12603821	chr17:62006432	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	-0.54	-6.65	-0.38	1.63e-10	Prudent dietary pattern;
CESC	cis	rs9324022	0.722	rs17099613	chr14:101164715	T/A	cg18089426	chr14:101175970	NA	0.59	5.34	0.31	2e-7	Plateletcrit;
CESC	cis	rs6575793	0.512	rs6575791	chr14:101029203	A/G	cg18516195	chr14:101012996	BEGAIN	-0.42	-5.32	-0.31	2.19e-7	Menarche (age at onset);
CESC	cis	rs10504229	0.683	rs7459958	chr8:58111905	G/T	cg21724239	chr8:58056113	NA	0.58	5.93	0.34	9.45e-9	Developmental language disorder (linguistic errors);
CESC	trans	rs11992162	0.551	rs59191504	chr8:11785081	A/G	cg15556689	chr8:8085844	FLJ10661	-0.51	-6.11	-0.35	3.59e-9	Monocyte count;
CESC	trans	rs4942242	1.000	rs7335094	chr13:44223936	T/C	cg19169023	chr15:41853346	TYRO3	-0.45	-6.49	-0.37	4.12e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg03311606	chr2:173292277	ITGA6	-0.44	-6.28	-0.36	1.4e-9	Gambling;
CESC	cis	rs8092503	1.000	rs12456731	chr18:52500292	C/T	cg12377874	chr18:52495404	RAB27B	0.32	5.41	0.32	1.41e-7	Childhood body mass index;
CESC	cis	rs6920965	0.507	rs7754833	chr6:126190894	A/G	cg05901451	chr6:126070800	HEY2	-0.41	-5.29	-0.31	2.52e-7	High light scatter reticulocyte count;
CESC	cis	rs9488822	0.676	rs12196579	chr6:116351724	G/T	cg26893134	chr6:116381904	FRK	0.25	6.1	0.35	3.71e-9	Cholesterol, total;LDL cholesterol;
CESC	cis	rs11638352	1.000	rs8038096	chr15:44367290	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	-0.62	-5.96	-0.34	8.14e-9	Lipoprotein phospholipase A2 activity in cardiovascular disease;
CESC	cis	rs116095464	0.558	rs9312978	chr5:221930	C/G	cg22857025	chr5:266934	NA	-1.28	-14.18	-0.66	2.32e-34	Breast cancer;
CESC	cis	rs727505	1.000	rs68091803	chr7:124526331	C/T	cg23710748	chr7:124431027	NA	-0.48	-7.52	-0.42	8.49e-13	Lewy body disease;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg07399355	chr1:155163013	MUC1	-0.51	-7.06	-0.4	1.48e-11	Height;
CESC	cis	rs10504229	0.683	rs66893068	chr8:58144238	A/G	cg02725872	chr8:58115012	NA	-0.42	-6.61	-0.38	2.1e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs4665809	0.878	rs6720312	chr2:26364934	A/G	cg08470875	chr2:26401718	FAM59B	0.57	6.6	0.38	2.26e-10	Gut microbiome composition (summer);
CESC	cis	rs67311347	1.000	rs1466236	chr3:40462162	C/T	cg24209194	chr3:40518798	ZNF619	0.48	6.42	0.37	6.11e-10	Renal cell carcinoma;
CESC	cis	rs561341	1.000	rs757009	chr17:30243937	A/G	cg19193384	chr17:30244184	NA	-0.49	-5.56	-0.32	6.53e-8	Hip circumference adjusted for BMI;
CESC	cis	rs7666738	0.830	rs6818045	chr4:99049374	G/A	cg03676636	chr4:99064102	C4orf37	0.34	5.13	0.3	5.5e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3096299	0.935	rs3114890	chr16:89449546	C/G	cg08392591	chr16:89556376	ANKRD11	0.43	5.41	0.32	1.41e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs34172651	0.917	rs8043962	chr16:24781372	A/G	cg06028605	chr16:24865363	SLC5A11	0.35	5.5	0.32	8.72e-8	Intelligence (multi-trait analysis);
CESC	cis	rs2228479	0.717	rs2270460	chr16:89972416	C/A	cg00800038	chr16:89945340	TCF25	-0.76	-7.12	-0.4	9.88e-12	Skin colour saturation;
CESC	cis	rs9929218	0.551	rs2296408	chr16:68713823	A/C	cg02972257	chr16:68554789	NA	0.44	5.51	0.32	8.36e-8	Colorectal cancer;
CESC	cis	rs7208859	0.623	rs56018041	chr17:29059985	G/A	cg19761014	chr17:28927070	LRRC37B2	0.76	6.25	0.36	1.66e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs7568498	0.564	rs9287807	chr2:161915361	T/C	cg21518248	chr2:162101506	NA	-0.48	-5.23	-0.31	3.52e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);
CESC	cis	rs1448094	0.512	rs7953318	chr12:86245929	G/A	cg00310523	chr12:86230176	RASSF9	0.35	5.46	0.32	1.1e-7	Major depressive disorder;
CESC	cis	rs12136530	0.577	rs4912002	chr1:19793402	G/T	cg01832549	chr1:19774989	CAPZB	-0.42	-5.82	-0.34	1.68e-8	Lead levels in blood;
CESC	cis	rs2576037	0.526	rs8095373	chr18:44527895	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.32	5.05	0.3	8.14e-7	Personality dimensions;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg21830480	chr12:72057690	THAP2;ZFC3H1	0.46	6.1	0.35	3.74e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs1045714	0.895	rs4721867	chr7:2643352	A/G	cg20813462	chr7:2646259	IQCE	-0.65	-5.68	-0.33	3.58e-8	Urate levels in lean individuals;
CESC	cis	rs170557	0.597	rs6664500	chr1:210096295	C/T	cg21951975	chr1:209979733	IRF6	-0.36	-5.05	-0.3	8.37e-7	Alopecia areata;
CESC	cis	rs9287719	0.837	rs4331474	chr2:10755583	G/A	cg00105475	chr2:10696890	NA	0.37	5.17	0.3	4.54e-7	Prostate cancer;
CESC	trans	rs11039798	1.000	rs7131020	chr11:48642132	A/G	cg15704280	chr7:45808275	SEPT13	0.66	6.3	0.36	1.24e-9	Axial length;
CESC	cis	rs7666738	0.830	rs17484966	chr4:99014432	T/C	cg03676636	chr4:99064102	C4orf37	0.33	5.16	0.3	4.86e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2980439	0.870	rs2945230	chr8:8109936	A/G	cg15556689	chr8:8085844	FLJ10661	0.61	7.42	0.41	1.57e-12	Neuroticism;
CESC	cis	rs761746	0.960	rs5753680	chr22:31930972	A/G	cg25791279	chr22:32026902	PISD	-0.54	-6.17	-0.35	2.52e-9	Intelligence;
CESC	cis	rs10751667	0.961	rs7479171	chr11:926809	G/A	cg06064525	chr11:970664	AP2A2	-0.44	-7.77	-0.43	1.72e-13	Alzheimer's disease (late onset);
CESC	cis	rs1799949	1.000	rs8176269	chr17:41213626	G/T	cg05368731	chr17:41323189	NBR1	0.75	9.93	0.52	5.94e-20	Menopause (age at onset);
CESC	cis	rs10242455	0.702	rs73713507	chr7:99138603	G/A	cg25640893	chr7:99214727	ZNF498	0.79	5.58	0.32	6.05e-8	Blood metabolite levels;
CESC	trans	rs9693444	0.898	rs4732697	chr8:29519861	A/G	cg09426994	chr11:118478258	PHLDB1	-0.4	-6.09	-0.35	4.02e-9	Breast cancer;
CESC	cis	rs6466055	0.720	rs1204060	chr7:104963064	T/C	cg04380332	chr7:105027541	SRPK2	0.43	5.61	0.33	5.17e-8	Schizophrenia;
CESC	cis	rs8028182	0.636	rs8030802	chr15:75813153	A/G	cg20655648	chr15:75932815	IMP3	0.48	5.9	0.34	1.08e-8	Sudden cardiac arrest;
CESC	cis	rs791888	0.760	rs10788561	chr10:89423245	A/G	cg13926569	chr10:89418898	PAPSS2	0.55	7.83	0.43	1.2e-13	Magnesium levels;
CESC	cis	rs9323205	0.953	rs11623710	chr14:51694261	C/T	cg23942311	chr14:51606299	NA	-0.42	-5.13	-0.3	5.57e-7	Cancer;
CESC	cis	rs921968	0.591	rs13421421	chr2:219519286	A/G	cg02176678	chr2:219576539	TTLL4	0.41	7.22	0.41	5.65e-12	Mean corpuscular hemoglobin concentration;
CESC	cis	rs7095944	0.584	rs4962692	chr10:126424823	G/A	cg08799069	chr10:126477246	METTL10	-0.39	-5.55	-0.32	6.81e-8	Asthma;
CESC	cis	rs4975616	0.836	rs460073	chr5:1336459	T/C	cg06550200	chr5:1325588	CLPTM1L	-0.69	-10.71	-0.55	1.76e-22	Lung cancer;
CESC	cis	rs66530629	0.874	rs6692599	chr1:25094714	T/C	cg22509179	chr1:25234806	RUNX3	-0.44	-5.64	-0.33	4.27e-8	Plateletcrit;
CESC	cis	rs1552244	0.572	rs6783705	chr3:10164783	A/G	cg00149659	chr3:10157352	C3orf10	1.0	11.96	0.59	1.22e-26	Alzheimer's disease;
CESC	cis	rs965469	1.000	rs6037526	chr20:3251248	T/C	cg25506879	chr20:3388711	C20orf194	-0.59	-6.27	-0.36	1.48e-9	IFN-related cytopenia;
CESC	cis	rs67311347	0.544	rs4974040	chr3:40331059	G/A	cg24209194	chr3:40518798	ZNF619	0.38	5.25	0.31	3.05e-7	Renal cell carcinoma;
CESC	cis	rs17021463	0.807	rs6847989	chr4:95277099	A/C	cg11021082	chr4:95130006	SMARCAD1	0.42	6.52	0.37	3.49e-10	Testicular germ cell tumor;
CESC	cis	rs9322193	0.962	rs4552	chr6:150132319	A/T	cg04369109	chr6:150039330	LATS1	-0.41	-5.54	-0.32	7.36e-8	Lung cancer;
CESC	cis	rs4595586	0.545	rs7958118	chr12:39376685	C/T	cg26384229	chr12:38710491	ALG10B	0.54	7.53	0.42	7.85e-13	Morning vs. evening chronotype;
CESC	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.59	-9.39	-0.5	2.78e-18	Longevity;Endometriosis;
CESC	cis	rs208520	0.526	rs9351542	chr6:66788571	A/G	cg07460842	chr6:66804631	NA	-1.11	-26.93	-0.86	8.11e-78	Exhaled nitric oxide output;
CESC	cis	rs3741798	1.000	rs73277486	chr12:12494761	T/C	cg08615371	chr12:12503544	MANSC1	0.81	5.83	0.34	1.59e-8	Cerebrospinal fluid biomarker levels;
CESC	cis	rs9796	0.621	rs1659228	chr15:41471978	A/G	cg12386646	chr15:41787261	ITPKA	0.33	5.08	0.3	7.11e-7	Menopause (age at onset);
CESC	cis	rs6542838	0.609	rs13028500	chr2:99528296	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.49	-6.28	-0.36	1.41e-9	Fear of minor pain;
CESC	cis	rs4555082	0.915	rs79048296	chr14:105754944	G/A	cg06808227	chr14:105710500	BRF1	-0.58	-6.52	-0.37	3.47e-10	Mean platelet volume;Platelet distribution width;
CESC	cis	rs926938	0.520	rs4140445	chr1:115291978	T/C	cg12756093	chr1:115239321	AMPD1	-0.55	-6.73	-0.38	1.04e-10	Autism;
CESC	cis	rs4727027	0.866	rs35599790	chr7:148806012	C/T	cg23158103	chr7:148848205	ZNF398	-0.42	-6.84	-0.39	5.49e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs1355223	0.844	rs12809046	chr11:34748261	T/A	cg11058730	chr11:34937778	PDHX;APIP	-0.46	-5.94	-0.34	8.84e-9	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs17376456	1.000	rs67150649	chr5:93292377	A/G	cg25358565	chr5:93447407	FAM172A	1.11	10.3	0.53	3.78e-21	Diabetic retinopathy;
CESC	cis	rs12791968	0.917	rs11038238	chr11:45002010	A/G	cg11846598	chr11:44996168	LOC221122	-0.56	-7.44	-0.42	1.37e-12	Inhibitory control;
CESC	cis	rs1552244	0.572	rs6783705	chr3:10164783	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.68	-7.55	-0.42	6.87e-13	Alzheimer's disease;
CESC	cis	rs7615952	0.641	rs12488180	chr3:125782236	C/T	cg06494592	chr3:125709126	NA	-0.46	-5.19	-0.3	4.25e-7	Blood pressure (smoking interaction);
CESC	cis	rs6060717	0.536	rs6060676	chr20:34498551	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.75	-6.7	-0.38	1.22e-10	Hip circumference adjusted for BMI;
CESC	cis	rs2730245	0.550	rs2709860	chr7:158651156	A/T	cg24397884	chr7:158709396	WDR60	0.79	12.79	0.62	1.69e-29	Height;
CESC	cis	rs1864400	0.690	rs2565200	chr10:43622933	A/G	cg15436174	chr10:43711423	RASGEF1A	-0.44	-5.28	-0.31	2.75e-7	Hirschsprung disease;
CESC	cis	rs10504073	0.565	rs974780	chr8:49930976	G/A	cg00325661	chr8:49890786	NA	0.56	8.46	0.46	1.8e-15	Blood metabolite ratios;
CESC	cis	rs916888	0.779	rs430685	chr17:44859148	T/C	cg15921436	chr17:44337874	NA	-0.71	-8.07	-0.44	2.47e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs10791097	0.694	rs7942621	chr11:130751308	C/G	cg12179176	chr11:130786555	SNX19	0.66	10.42	0.54	1.61e-21	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs9858542	0.953	rs11711485	chr3:49491983	G/T	cg03060546	chr3:49711283	APEH	-0.54	-6.05	-0.35	4.83e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	trans	rs637571	0.557	rs1204649	chr11:65702776	A/C	cg17712092	chr4:129076599	LARP1B	0.74	10.19	0.53	8.94e-21	Eosinophil percentage of white cells;
CESC	cis	rs1552244	0.882	rs7633769	chr3:10020622	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.87	11.21	0.57	3.99e-24	Alzheimer's disease;
CESC	cis	rs6089584	1.000	rs6089587	chr20:60564829	C/T	cg13770153	chr20:60521292	NA	-0.45	-5.9	-0.34	1.12e-8	Body mass index;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16261398	chr11:1410750	BRSK2	0.56	6.0	0.35	6.38e-9	Gut microbiome composition (summer);
CESC	cis	rs1862618	0.853	rs252910	chr5:56192983	G/A	cg22800045	chr5:56110881	MAP3K1	0.83	9.46	0.5	1.7e-18	Initial pursuit acceleration;
CESC	cis	rs7647973	0.580	rs11716334	chr3:49230096	G/A	cg07636037	chr3:49044803	WDR6	0.78	12.95	0.62	4.62e-30	Menarche (age at onset);
CESC	cis	rs1395	0.778	rs11693660	chr2:27468856	T/C	cg22903471	chr2:27725779	GCKR	-0.43	-5.2	-0.3	4.04e-7	Blood metabolite levels;
CESC	cis	rs17818399	0.716	rs62134741	chr2:46782189	G/A	cg26688816	chr2:46740690	ATP6V1E2	-0.5	-5.38	-0.31	1.62e-7	Height;
CESC	cis	rs73110464	0.562	rs2363634	chr12:53354683	A/G	cg05393297	chr12:53359155	NA	-0.7	-9.94	-0.52	5.35e-20	Cancer (pleiotropy);
CESC	cis	rs1552244	0.554	rs6443275	chr3:10008819	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.56	-7.32	-0.41	2.93e-12	Alzheimer's disease;
CESC	cis	rs4713118	0.629	rs149899	chr6:28019979	C/T	cg26335602	chr6:28129616	ZNF389	0.44	5.66	0.33	3.97e-8	Parkinson's disease;
CESC	cis	rs7116495	1.000	rs11235440	chr11:71826644	A/G	cg26138937	chr11:71823887	C11orf51	0.79	6.6	0.38	2.2e-10	Severe influenza A (H1N1) infection;
CESC	cis	rs72781680	0.898	rs72786270	chr2:24059049	G/A	cg08917208	chr2:24149416	ATAD2B	0.95	8.74	0.47	2.69e-16	Lymphocyte counts;
CESC	cis	rs3096299	0.754	rs3102382	chr16:89409742	C/G	cg08822215	chr16:89438651	ANKRD11	-0.34	-5.05	-0.3	8.07e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs2742234	0.590	rs1254960	chr10:43699657	C/T	cg07801480	chr10:43725741	RASGEF1A	-0.41	-5.33	-0.31	2.14e-7	Hirschsprung disease;
CESC	cis	rs270601	0.913	rs273899	chr5:131695178	G/A	cg07395648	chr5:131743802	NA	-0.4	-5.22	-0.31	3.67e-7	Acylcarnitine levels;
CESC	cis	rs8067545	0.586	rs2526459	chr17:20090042	G/T	cg13482628	chr17:19912719	NA	-0.41	-5.68	-0.33	3.5e-8	Schizophrenia;
CESC	cis	rs9640161	0.711	rs60268791	chr7:150023800	G/T	cg13722127	chr7:150037890	RARRES2	0.34	5.17	0.3	4.68e-7	Blood protein levels;Circulating chemerin levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12072290	chr12:124018993	RILPL1	-0.67	-8.48	-0.46	1.63e-15	Gut microbiome composition (summer);
CESC	cis	rs7618915	0.547	rs13085331	chr3:52627486	G/C	cg18099408	chr3:52552593	STAB1	-0.31	-5.09	-0.3	6.68e-7	Bipolar disorder;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg08052428	chr9:135996421	RALGDS	0.47	6.33	0.36	1.03e-9	Systemic lupus erythematosus;
CESC	trans	rs1945213	0.694	rs7129022	chr11:55876132	A/G	cg03929089	chr4:120376271	NA	0.78	7.5	0.42	9.59e-13	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs67340775	0.541	rs200966	chr6:27862152	T/C	cg17221315	chr6:27791827	HIST1H4J	0.53	5.07	0.3	7.52e-7	Lung cancer in ever smokers;
CESC	cis	rs9948	0.655	rs76653480	chr2:97375549	C/T	cg01990225	chr2:97406019	LMAN2L	-0.92	-7.07	-0.4	1.36e-11	Erectile dysfunction and prostate cancer treatment;
CESC	cis	rs6089829	0.962	rs6062778	chr20:61663959	A/G	cg16240275	chr20:61666158	NCRNA00029	0.5	8.97	0.48	5.67e-17	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs875971	0.522	rs2008188	chr7:65429013	G/C	cg18876405	chr7:65276391	NA	0.69	9.58	0.51	7.2e-19	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09392819	chr2:26568944	SELI;GPR113	0.62	6.92	0.39	3.38e-11	Gut microbiome composition (summer);
CESC	cis	rs4919694	0.536	rs12256506	chr10:104963618	T/A	cg04362960	chr10:104952993	NT5C2	0.69	6.87	0.39	4.53e-11	Arsenic metabolism;
CESC	cis	rs4704187	0.687	rs6891023	chr5:74500755	G/A	cg03227963	chr5:74354835	NA	0.29	5.27	0.31	2.77e-7	Response to amphetamines;
CESC	cis	rs3015497	0.631	rs17718908	chr14:51005213	A/G	cg26011998	chr14:51135199	SAV1	0.48	5.54	0.32	7.41e-8	Mean platelet volume;
CESC	cis	rs60843830	1.000	rs60149603	chr2:285421	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.89	11.9	0.59	1.88e-26	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs1799949	1.000	rs34059614	chr17:41303071	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.64	8.64	0.47	5.23e-16	Menopause (age at onset);
CESC	cis	rs12410462	0.681	rs79461024	chr1:227568783	G/T	cg04117972	chr1:227635322	NA	0.75	6.21	0.36	2e-9	Major depressive disorder;
CESC	cis	rs6831352	0.918	rs13127582	chr4:100058194	G/A	cg12011299	chr4:100065546	ADH4	-0.6	-6.62	-0.38	2.04e-10	Alcohol dependence;
CESC	cis	rs2836974	0.799	rs13047550	chr21:40515495	T/C	cg17971929	chr21:40555470	PSMG1	0.92	12.26	0.6	1.16e-27	Cognitive function;
CESC	trans	rs61931739	0.517	rs12816252	chr12:34067693	G/A	cg26384229	chr12:38710491	ALG10B	0.6	8.38	0.46	3.12e-15	Morning vs. evening chronotype;
CESC	cis	rs4588572	0.644	rs10942856	chr5:77746199	A/G	cg11547950	chr5:77652471	NA	0.39	5.37	0.31	1.72e-7	Triglycerides;
CESC	cis	rs9399135	0.933	rs4559100	chr6:135324085	T/C	cg24558204	chr6:135376177	HBS1L	0.53	7.28	0.41	3.85e-12	Red blood cell count;
CESC	cis	rs10129255	0.536	rs17113249	chr14:107134290	A/G	cg23076370	chr14:107095027	NA	-0.64	-9.84	-0.52	1.15e-19	Kawasaki disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21828663	chr7:6198703	USP42	-0.56	-6.31	-0.36	1.2e-9	Gut microbiome composition (summer);
CESC	cis	rs1348850	0.914	rs1348849	chr2:178358072	C/T	cg22681709	chr2:178499509	PDE11A	-0.42	-6.06	-0.35	4.65e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs12291225	0.679	rs11605531	chr11:14291594	A/G	cg19336497	chr11:14380999	RRAS2	-0.37	-5.37	-0.31	1.68e-7	Sense of smell;
CESC	cis	rs909674	0.690	rs5750823	chr22:39829973	C/T	cg05872129	chr22:39784769	NA	-0.75	-10.19	-0.53	8.35e-21	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs10504229	0.724	rs16922734	chr8:58111192	C/T	cg21724239	chr8:58056113	NA	0.58	5.93	0.34	9.45e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs9513593	1.000	rs9513593	chr13:99950260	G/A	cg21788972	chr13:99853209	UBAC2	-0.56	-6.73	-0.38	1.02e-10	Psoriasis;
CESC	cis	rs6500395	0.962	rs1115759	chr16:48599530	A/G	cg04672837	chr16:48644449	N4BP1	0.44	5.28	0.31	2.66e-7	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs2180341	0.618	rs12210968	chr6:127596985	A/G	cg24812749	chr6:127587940	RNF146	0.59	8.02	0.44	3.42e-14	Breast cancer;
CESC	cis	rs3931020	0.548	rs969435	chr1:75273866	A/G	cg00121533	chr1:75199117	CRYZ;TYW3	-0.52	-7.06	-0.4	1.43e-11	Resistin levels;
CESC	trans	rs1285495	0.627	rs10912059	chr1:187354887	C/T	cg08078366	chr3:50375349	RASSF1	-0.47	-6.09	-0.35	3.99e-9	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
CESC	cis	rs3858526	0.523	rs10769290	chr11:5886947	T/A	cg13902645	chr11:5959945	NA	-0.68	-10.46	-0.54	1.14e-21	DNA methylation (variation);
CESC	cis	rs941873	0.803	rs5015119	chr10:81101609	G/C	cg08514558	chr10:81106712	PPIF	0.36	6.13	0.35	3.2e-9	Height;
CESC	trans	rs3780486	1.000	rs12342831	chr9:33124872	A/G	cg04842962	chr6:43655489	MRPS18A	0.9	13.75	0.65	7.82e-33	IgG glycosylation;
CESC	cis	rs4141404	0.923	rs2413046	chr22:31665909	C/A	cg13145458	chr22:31556086	RNF185	0.48	5.35	0.31	1.88e-7	Paclitaxel-induced neuropathy;
CESC	cis	rs17253792	0.822	rs10483643	chr14:56089931	G/C	cg01858014	chr14:56050164	KTN1	-0.85	-6.99	-0.39	2.22e-11	Putamen volume;
CESC	cis	rs826838	0.967	rs826870	chr12:39120250	G/A	cg13010199	chr12:38710504	ALG10B	-0.46	-6.44	-0.37	5.5e-10	Heart rate;
CESC	cis	rs7618501	1.000	rs3811696	chr3:49761605	C/T	cg24308560	chr3:49941425	MST1R	0.51	7.06	0.4	1.48e-11	Intelligence (multi-trait analysis);
CESC	cis	rs7726839	0.540	rs72703083	chr5:595365	C/T	cg16447950	chr5:562315	NA	-0.6	-6.04	-0.35	5.24e-9	Obesity-related traits;
CESC	cis	rs9916302	0.706	rs7212621	chr17:37527911	T/G	cg07936489	chr17:37558343	FBXL20	0.88	9.52	0.5	1.1e-18	Glomerular filtration rate (creatinine);
CESC	cis	rs4253772	0.591	rs7286155	chr22:46714735	A/G	cg24881330	chr22:46731750	TRMU	0.78	6.83	0.39	5.79e-11	LDL cholesterol;Cholesterol, total;
CESC	cis	rs1448094	0.522	rs12313658	chr12:86271063	C/T	cg02569458	chr12:86230093	RASSF9	0.47	6.95	0.39	2.79e-11	Major depressive disorder;
CESC	cis	rs637571	0.726	rs689274	chr11:65665988	A/G	cg04055107	chr11:65626734	MUS81;CFL1	-0.64	-8.3	-0.45	5.35e-15	Eosinophil percentage of white cells;
CESC	cis	rs1799949	1.000	rs2070834	chr17:41242285	T/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.66	9.34	0.5	4.25e-18	Menopause (age at onset);
CESC	cis	rs12930096	1.000	rs8050192	chr16:11678582	C/T	cg07439791	chr16:11680400	LITAF	0.61	5.64	0.33	4.42e-8	QT interval;
CESC	cis	rs738322	0.934	rs133016	chr22:38572582	C/T	cg25457927	chr22:38595422	NA	-0.3	-5.46	-0.32	1.1e-7	Cutaneous nevi;
CESC	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg06873352	chr17:61820015	STRADA	0.72	12.67	0.61	4.43e-29	Prudent dietary pattern;
CESC	cis	rs9910055	0.821	rs4473241	chr17:42281282	G/T	cg13607699	chr17:42295918	UBTF	0.55	6.73	0.38	1.07e-10	Total body bone mineral density;
CESC	cis	rs10870270	1.000	rs10430617	chr10:133748889	T/C	cg08754478	chr10:133766260	PPP2R2D	-0.61	-7.98	-0.44	4.32e-14	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs5769765	0.865	rs4824108	chr22:50271428	A/G	cg02269571	chr22:50332266	NA	0.46	6.28	0.36	1.39e-9	Schizophrenia;
CESC	cis	rs9910055	0.762	rs2240226	chr17:42266218	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	0.42	6.18	0.35	2.44e-9	Total body bone mineral density;
CESC	cis	rs9868809	0.881	rs13063312	chr3:48661985	G/A	cg07636037	chr3:49044803	WDR6	-0.64	-5.29	-0.31	2.55e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs9581857	0.685	rs10467687	chr13:28036516	G/A	cg01674679	chr13:27998804	GTF3A	-0.68	-5.52	-0.32	7.95e-8	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
CESC	cis	rs7216064	0.953	rs4791300	chr17:65930772	A/G	cg07042672	chr17:66097459	LOC651250	-0.59	-7.11	-0.4	1.09e-11	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19606431	chr6:131949205	MED23	0.54	6.64	0.38	1.79e-10	Gut microbiome composition (summer);
CESC	cis	rs644799	0.511	rs12791736	chr11:95475399	C/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.48	6.11	0.35	3.57e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs896854	0.818	rs896855	chr8:95959808	A/G	cg16049864	chr8:95962084	TP53INP1	-0.67	-12.02	-0.59	7.22e-27	Type 2 diabetes;
CESC	cis	rs1799949	1.000	rs11655505	chr17:41278377	G/A	cg25072359	chr17:41440525	NA	0.43	5.78	0.33	2.04e-8	Menopause (age at onset);
CESC	cis	rs2624839	0.629	rs2526397	chr3:50187790	A/C	cg24110177	chr3:50126178	RBM5	0.46	5.85	0.34	1.44e-8	Intelligence (multi-trait analysis);
CESC	trans	rs1545843	0.593	rs10862854	chr12:84773155	C/A	cg03015433	chr16:56623111	MT3	-0.33	-6.0	-0.35	6.34e-9	Major depressive disorder;
CESC	cis	rs13108904	0.967	rs900028	chr4:1279162	A/T	cg22903657	chr4:1355424	KIAA1530	-0.38	-5.23	-0.31	3.51e-7	Obesity-related traits;
CESC	trans	rs11992162	0.636	rs13265816	chr8:11797485	G/A	cg15556689	chr8:8085844	FLJ10661	0.51	6.35	0.36	9.34e-10	Monocyte count;
CESC	trans	rs10209086	0.736	rs1584436	chr2:138298878	A/G	cg26879696	chr10:114206778	VTI1A;ZDHHC6	0.49	6.18	0.35	2.44e-9	Multiple system atrophy;
CESC	cis	rs617791	0.530	rs10791835	chr11:65750924	C/A	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.38	-5.14	-0.3	5.29e-7	Breast cancer;
CESC	cis	rs1348850	0.651	rs1901824	chr2:178225466	T/C	cg23306229	chr2:178417860	TTC30B	0.54	6.99	0.39	2.2e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs8114671	0.527	rs6060112	chr20:33489276	A/T	cg07148914	chr20:33460835	GGT7	0.52	6.79	0.39	7.24e-11	Height;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg19092105	chr15:85383079	ALPK3	0.47	6.3	0.36	1.26e-9	Fibrinogen levels;
CESC	cis	rs11642862	0.685	rs79974799	chr16:30996795	C/T	cg02466173	chr16:30829666	NA	-0.57	-5.21	-0.3	3.81e-7	Tonsillectomy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10424330	chr16:71894309	ZNF821;ATXN1L	-0.7	-7.56	-0.42	6.76e-13	Gut microbiome composition (summer);
CESC	cis	rs4727963	0.846	rs1525484	chr7:122702980	G/T	cg03640110	chr7:122635026	TAS2R16	-0.37	-5.7	-0.33	3.11e-8	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
CESC	cis	rs7618915	0.547	rs3774365	chr3:52642487	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.48	6.81	0.39	6.61e-11	Bipolar disorder;
CESC	cis	rs3015497	0.789	rs2356457	chr14:51116863	C/T	cg09863266	chr14:51125203	SAV1	-0.34	-5.34	-0.31	2.05e-7	Mean platelet volume;
CESC	cis	rs6121246	0.529	rs6060195	chr20:30185638	C/T	cg13852791	chr20:30311386	BCL2L1	0.58	5.56	0.32	6.65e-8	Mean corpuscular hemoglobin;
CESC	cis	rs75804782	0.521	rs56373856	chr2:239437926	C/T	cg18131467	chr2:239335373	ASB1	-0.68	-5.18	-0.3	4.38e-7	Morning vs. evening chronotype;Chronotype;
CESC	cis	rs4862750	0.914	rs11943333	chr4:187872455	A/G	cg10295955	chr4:187884368	NA	-0.72	-11.18	-0.57	5.02e-24	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs769267	0.899	rs3934667	chr19:19431423	T/G	cg03709012	chr19:19516395	GATAD2A	-0.95	-13.98	-0.65	1.22e-33	Tonsillectomy;
CESC	cis	rs12497850	0.931	rs13064911	chr3:48952385	A/G	cg03060546	chr3:49711283	APEH	0.45	5.48	0.32	9.77e-8	Parkinson's disease;
CESC	cis	rs9815354	0.680	rs10510730	chr3:41849013	C/G	cg03022575	chr3:42003672	ULK4	0.7	6.04	0.35	5.26e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs116095464	0.558	rs60251075	chr5:245292	T/C	cg22857025	chr5:266934	NA	-1.27	-18.37	-0.75	3.49e-49	Breast cancer;
CESC	cis	rs769267	0.740	rs2965185	chr19:19525792	T/C	cg03709012	chr19:19516395	GATAD2A	0.89	12.31	0.6	7.6e-28	Tonsillectomy;
CESC	cis	rs7216064	1.000	rs11869819	chr17:65868669	A/C	cg07042672	chr17:66097459	LOC651250	-0.54	-5.59	-0.32	5.61e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs10899021	0.920	rs7112384	chr11:74348205	T/G	cg25880958	chr11:74394337	NA	-0.75	-7.78	-0.43	1.6e-13	Response to metformin (IC50);
CESC	cis	rs4853012	0.887	rs2280642	chr2:74358252	T/A	cg05776053	chr2:74358815	NA	0.43	5.07	0.3	7.45e-7	Gestational age at birth (maternal effect);
CESC	cis	rs7208859	0.623	rs216434	chr17:28922335	G/C	cg19761014	chr17:28927070	LRRC37B2	0.87	6.7	0.38	1.21e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs2243480	1.000	rs464895	chr7:65527106	A/G	cg13147721	chr7:65941812	NA	-0.91	-9.0	-0.48	4.55e-17	Diabetic kidney disease;
CESC	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	22.15	0.81	3.07e-62	Prudent dietary pattern;
CESC	cis	rs9311474	1.000	rs7629072	chr3:52305633	C/T	cg07507251	chr3:52567010	NT5DC2	0.33	5.74	0.33	2.65e-8	Electroencephalogram traits;
CESC	cis	rs3806843	1.000	rs1030164	chr5:140185272	A/G	cg16179182	chr5:140090404	VTRNA1-1	-0.41	-5.28	-0.31	2.74e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs780096	0.526	rs1260341	chr2:27663215	T/A	cg24768116	chr2:27665128	KRTCAP3	-0.3	-5.57	-0.32	6.2e-8	Total body bone mineral density;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg14703032	chr6:3140546	BPHL	0.46	6.42	0.37	6.12e-10	Fibrinogen levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09526122	chr4:1828794	LETM1	-0.53	-6.31	-0.36	1.17e-9	Gut microbiome composition (summer);
CESC	trans	rs12356475	0.710	rs10822686	chr10:67733250	C/T	cg26040332	chr1:27960788	FGR	0.52	6.31	0.36	1.15e-9	Psoriatic arthritis;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg22654940	chr2:54856752	SPTBN1	0.53	7.36	0.41	2.3e-12	Fibrinogen levels;
CESC	cis	rs10927875	0.722	rs945425	chr1:16348412	T/C	cg22431228	chr1:16359049	CLCNKA	-0.51	-8.37	-0.46	3.39e-15	Dilated cardiomyopathy;
CESC	cis	rs4665809	1.000	rs10048648	chr2:26320315	T/C	cg25036284	chr2:26402008	FAM59B	-0.57	-6.58	-0.37	2.57e-10	Gut microbiome composition (summer);
CESC	cis	rs2795502	1.000	rs2795496	chr10:43337842	G/A	cg20628663	chr10:43360327	NA	-0.63	-7.43	-0.42	1.5e-12	Blood protein levels;
CESC	cis	rs9611565	0.573	rs9306355	chr22:42111896	A/T	cg06481639	chr22:41940642	POLR3H	0.48	5.58	0.32	6.02e-8	Vitiligo;
CESC	cis	rs1048238	0.506	rs598371	chr1:16212739	G/A	cg22431228	chr1:16359049	CLCNKA	0.36	6.21	0.36	2.03e-9	Systolic blood pressure;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10272801	chr16:14013773	ERCC4	0.58	6.49	0.37	4.28e-10	Gut microbiome composition (summer);
CESC	cis	rs2066819	1.000	rs77768890	chr12:56725121	A/G	cg26804944	chr12:56660921	COQ10A	-0.85	-5.12	-0.3	5.95e-7	Psoriasis vulgaris;
CESC	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg02475777	chr4:1388615	CRIPAK	0.75	9.38	0.5	3.03e-18	Longevity;
CESC	trans	rs11989744	0.597	rs2033788	chr8:23574847	G/T	cg03492747	chr16:86543808	FOXF1	-0.82	-13.05	-0.63	2.17e-30	Waist-hip ratio;
CESC	cis	rs7799006	0.606	rs12669625	chr7:2315950	C/T	cg08027265	chr7:2291960	NA	-0.57	-9.66	-0.51	4.16e-19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs597539	0.652	rs546382	chr11:68704264	C/T	cg04772025	chr11:68637568	NA	0.51	6.21	0.36	2.09e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs898097	0.625	rs6502017	chr17:80891135	C/T	cg19046167	chr17:80928561	B3GNTL1	0.41	5.42	0.32	1.33e-7	Breast cancer;
CESC	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.43	-5.78	-0.33	2.08e-8	Longevity;Endometriosis;
CESC	cis	rs16854884	0.586	rs4561830	chr3:143735572	C/T	cg06585982	chr3:143692056	C3orf58	0.5	6.64	0.38	1.73e-10	Economic and political preferences (feminism/equality);
CESC	cis	rs250677	0.917	rs36066	chr5:148419771	A/G	cg18129178	chr5:148520854	ABLIM3	-0.5	-5.45	-0.32	1.14e-7	Breast cancer;
CESC	cis	rs1322639	0.614	rs6903921	chr6:169563957	C/T	cg04662567	chr6:169592167	NA	-0.5	-5.26	-0.31	2.93e-7	Pulse pressure;
CESC	cis	rs1005277	0.579	rs2474574	chr10:38387295	C/T	cg25517755	chr10:38738941	LOC399744	-0.47	-6.05	-0.35	4.86e-9	Extrinsic epigenetic age acceleration;
CESC	trans	rs9325144	0.560	rs10785573	chr12:38654166	G/A	cg23762105	chr12:34175262	ALG10	0.48	6.31	0.36	1.15e-9	Morning vs. evening chronotype;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01694628	chr15:25478725	SNORD115-35	-0.54	-6.85	-0.39	5.18e-11	Gut microbiome composition (summer);
CESC	cis	rs798554	0.757	rs1182185	chr7:2872233	A/G	cg13628971	chr7:2884303	GNA12	0.62	8.51	0.46	1.27e-15	Height;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg05808815	chr1:54666250	CYB5RL;MRPL37	-0.37	-6.07	-0.35	4.5e-9	Gambling;
CESC	cis	rs7236492	0.748	rs11663658	chr18:77197555	T/C	cg15644404	chr18:77186268	NFATC1	-0.69	-5.39	-0.31	1.55e-7	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs1005277	0.522	rs289649	chr10:37975384	T/C	cg25517755	chr10:38738941	LOC399744	-0.41	-5.35	-0.31	1.88e-7	Extrinsic epigenetic age acceleration;
CESC	cis	rs7264396	0.512	rs2425072	chr20:34293686	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.64	6.87	0.39	4.6e-11	Total cholesterol levels;
CESC	cis	rs1448094	0.512	rs6539925	chr12:86244358	A/G	cg19622623	chr12:86230825	RASSF9	-0.46	-5.88	-0.34	1.22e-8	Major depressive disorder;
CESC	cis	rs8072100	0.905	rs9901869	chr17:45575206	G/A	cg08085267	chr17:45401833	C17orf57	-0.47	-6.22	-0.36	1.94e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs1062177	1.000	rs2915887	chr5:151205504	C/T	cg12924095	chr5:151150029	G3BP1	0.5	6.43	0.37	5.81e-10	Preschool internalizing problems;
CESC	cis	rs2032447	0.670	rs198848	chr6:26106325	A/G	cg12310025	chr6:25882481	NA	-0.44	-6.43	-0.37	5.77e-10	Intelligence (multi-trait analysis);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg00622658	chr8:10469796	RP1L1	0.43	6.41	0.37	6.74e-10	Fibrinogen levels;
CESC	cis	rs854765	0.583	rs11650890	chr17:17790882	C/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.49	-6.25	-0.36	1.6e-9	Total body bone mineral density;
CESC	cis	rs2832191	0.791	rs2832178	chr21:30479858	T/G	cg08807101	chr21:30365312	RNF160	-0.77	-11.15	-0.56	6.51e-24	Dental caries;
CESC	cis	rs7617480	0.648	rs9864243	chr3:48982732	G/A	cg06212747	chr3:49208901	KLHDC8B	0.54	5.97	0.34	7.63e-9	Subjective well-being (multi-trait analysis);Menarche (age at onset);
CESC	cis	rs9733	0.596	rs2175615	chr1:150624101	A/G	cg09365446	chr1:150670422	GOLPH3L	0.42	5.98	0.34	7.35e-9	Tonsillectomy;
CESC	cis	rs35110281	0.693	rs3819161	chr21:45092653	A/G	cg01579765	chr21:45077557	HSF2BP	-0.55	-8.72	-0.47	3.14e-16	Mean corpuscular volume;
CESC	cis	rs2204008	0.811	rs8189445	chr12:38276295	T/C	cg13010199	chr12:38710504	ALG10B	0.48	6.04	0.35	5.23e-9	Bladder cancer;
CESC	cis	rs713587	1.000	rs713587	chr2:25158281	C/T	cg01884057	chr2:25150051	NA	0.42	7.97	0.44	4.67e-14	Body mass index in non-asthmatics;
CESC	cis	rs10504229	1.000	rs73607875	chr8:58173522	T/C	cg24829409	chr8:58192753	C8orf71	-0.76	-10.0	-0.52	3.53e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs11112613	0.775	rs7299470	chr12:105961773	G/A	cg03607813	chr12:105948248	NA	0.61	7.42	0.41	1.56e-12	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CESC	cis	rs9488822	0.676	rs10456902	chr6:116333742	C/G	cg18764771	chr6:116381957	FRK	-0.22	-5.53	-0.32	7.61e-8	Cholesterol, total;LDL cholesterol;
CESC	cis	rs1546924	0.570	rs197415	chr1:112311593	C/T	cg23955903	chr1:112298873	DDX20;C1orf183	0.43	5.55	0.32	6.95e-8	Body mass index;
CESC	cis	rs4242434	0.927	rs2272718	chr8:22457388	G/A	cg03733263	chr8:22462867	KIAA1967	0.97	13.98	0.65	1.18e-33	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CESC	cis	rs1577917	1.000	rs1337850	chr6:86729103	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-6.17	-0.35	2.58e-9	Response to antipsychotic treatment;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08668662	chr20:30539908	PDRG1	0.56	6.73	0.38	1.05e-10	Gut microbiome composition (summer);
CESC	cis	rs9635726	0.638	rs2952155	chr17:37861718	T/C	cg20243544	chr17:37824526	PNMT	0.66	7.05	0.4	1.59e-11	Primary biliary cholangitis;
CESC	cis	rs9487051	0.872	rs9487043	chr6:109610474	C/T	cg12927641	chr6:109611667	NA	-0.41	-6.17	-0.35	2.49e-9	Reticulocyte fraction of red cells;
CESC	cis	rs2712431	0.554	rs2010054	chr3:128305302	A/G	cg16766828	chr3:128327626	NA	-0.36	-5.96	-0.34	8.1e-9	Monocyte chemoattractant protein-1 levels;
CESC	cis	rs11645898	0.935	rs72787094	chr16:72192613	C/A	cg14768367	chr16:72042858	DHODH	-0.79	-6.58	-0.37	2.51e-10	Blood protein levels;
CESC	cis	rs11148252	0.574	rs9536247	chr13:53279542	T/C	cg00495681	chr13:53174319	NA	0.62	8.56	0.47	9.42e-16	Lewy body disease;
CESC	cis	rs11871801	0.718	rs34967087	chr17:40576816	A/C	cg21433558	chr17:40837037	CNTNAP1	0.48	5.33	0.31	2.11e-7	Crohn's disease;
CESC	cis	rs8038465	0.615	rs6495076	chr15:73982965	G/A	cg15420318	chr15:73925796	NPTN	0.52	7.94	0.44	5.93e-14	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs875971	1.000	rs4718357	chr7:65960878	A/G	cg11764359	chr7:65958608	NA	0.96	15.25	0.68	3.95e-38	Aortic root size;
CESC	cis	rs4481887	1.000	rs10788775	chr1:248471945	C/G	cg00666640	chr1:248458726	OR2T12	0.38	6.32	0.36	1.11e-9	Common traits (Other);
CESC	cis	rs35306767	0.903	rs11253488	chr10:922482	G/C	cg10556349	chr10:835070	NA	0.56	5.26	0.31	2.9e-7	Eosinophil percentage of granulocytes;
CESC	cis	rs9311474	0.508	rs2878628	chr3:52584715	C/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	-0.32	-5.84	-0.34	1.52e-8	Electroencephalogram traits;
CESC	cis	rs13034020	0.522	rs12996059	chr2:61245551	G/C	cg18625361	chr2:61244694	PEX13;PUS10	0.66	5.9	0.34	1.13e-8	Hodgkin's lymphoma;
CESC	cis	rs11252926	0.604	rs2050970	chr10:515870	C/T	cg18196295	chr10:418757	DIP2C	0.4	5.38	0.31	1.67e-7	Psychosis in Alzheimer's disease;
CESC	cis	rs10504229	0.683	rs56208052	chr8:58130207	A/T	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs1008375	1.000	rs4698641	chr4:17642630	C/T	cg02297831	chr4:17616191	MED28	0.6	7.51	0.42	9.14e-13	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs7044106	0.718	rs10616	chr9:123363533	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.78	11.64	0.58	1.48e-25	Hip circumference adjusted for BMI;
CESC	cis	rs7089973	0.872	rs12773943	chr10:116631184	G/A	cg25233709	chr10:116636983	FAM160B1	0.34	5.06	0.3	7.68e-7	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs2295359	0.892	rs72676069	chr1:67658954	T/C	cg03340356	chr1:67600835	NA	0.32	5.26	0.31	2.93e-7	Psoriasis;
CESC	cis	rs6736093	0.966	rs13013340	chr2:112694988	C/A	cg12686935	chr2:112915763	FBLN7	-0.43	-5.56	-0.32	6.75e-8	Coronary artery disease;
CESC	cis	rs727563	0.569	rs73178647	chr22:41964168	G/A	cg17376030	chr22:41985996	PMM1	0.75	7.88	0.44	8.52e-14	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs4803468	1.000	rs2241708	chr19:41912270	C/T	cg09537434	chr19:41945824	ATP5SL	-1.04	-18.47	-0.75	1.65e-49	Height;
CESC	cis	rs9902453	0.619	rs2617866	chr17:28076217	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.78	-10.44	-0.54	1.34e-21	Coffee consumption (cups per day);
CESC	cis	rs2859741	0.587	rs510969	chr1:37475061	T/C	cg09363841	chr1:37513479	NA	-0.49	-6.75	-0.38	9.25e-11	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
CESC	cis	rs8060686	0.641	rs116821144	chr16:68081341	A/G	cg26727032	chr16:67993705	SLC12A4	-0.54	-6.12	-0.35	3.44e-9	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs7264396	0.635	rs3827030	chr20:34474947	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	-0.63	-7.2	-0.4	6.07e-12	Total cholesterol levels;
CESC	cis	rs3857536	0.611	rs6927407	chr6:66870010	T/C	cg07460842	chr6:66804631	NA	-0.54	-7.02	-0.4	1.89e-11	Blood trace element (Cu levels);
CESC	cis	rs59698941	0.943	rs57880964	chr5:132210674	G/C	cg02081065	chr5:132209139	LEAP2	-0.52	-5.11	-0.3	6.08e-7	Apolipoprotein A-IV levels;
CESC	cis	rs2549003	1.000	rs2070722	chr5:131824486	A/C	cg21138405	chr5:131827807	IRF1	0.54	9.64	0.51	4.83e-19	Asthma (sex interaction);
CESC	cis	rs35110281	0.712	rs8133523	chr21:45062403	A/G	cg04455712	chr21:45112962	RRP1B	0.38	5.59	0.32	5.78e-8	Mean corpuscular volume;
CESC	cis	rs10876993	0.784	rs1871417	chr12:58018979	C/T	cg18357645	chr12:58087776	OS9	-0.55	-8.5	-0.46	1.39e-15	Celiac disease or Rheumatoid arthritis;
CESC	cis	rs2439831	0.867	rs4583210	chr15:43660925	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	13.19	0.63	6.83e-31	Lung cancer in ever smokers;
CESC	cis	rs12995491	0.933	rs13023008	chr2:88530933	G/A	cg18490616	chr2:88469792	THNSL2	-0.53	-7.91	-0.44	6.92e-14	Response to metformin (IC50);
CESC	cis	rs34779708	0.733	rs7083266	chr10:35541632	C/A	cg03585969	chr10:35415529	CREM	0.56	6.42	0.37	6.15e-10	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs7216064	1.000	rs1976054	chr17:65833224	T/G	cg12091567	chr17:66097778	LOC651250	-0.78	-8.85	-0.48	1.31e-16	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	trans	rs1994135	0.647	rs67243558	chr12:33695383	T/C	cg26384229	chr12:38710491	ALG10B	0.46	6.37	0.36	8.12e-10	Resting heart rate;
CESC	cis	rs6460942	0.915	rs7802454	chr7:12454508	A/G	cg02935154	chr7:12443704	VWDE	-0.58	-6.16	-0.35	2.73e-9	Coronary artery disease;
CESC	cis	rs11650494	0.710	rs73987294	chr17:47474730	T/C	cg08112188	chr17:47440006	ZNF652	0.83	6.31	0.36	1.17e-9	Prostate cancer;
CESC	cis	rs910316	1.000	rs11623413	chr14:75588824	C/T	cg11812906	chr14:75593930	NEK9	-0.87	-14.17	-0.66	2.62e-34	Height;
CESC	cis	rs9300255	0.537	rs1618679	chr12:123650714	A/G	cg19016782	chr12:123741754	C12orf65	-0.4	-5.77	-0.33	2.27e-8	Neutrophil percentage of white cells;
CESC	cis	rs796364	0.806	rs79053279	chr2:201057443	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.78	-6.47	-0.37	4.64e-10	Schizophrenia;
CESC	cis	rs875971	1.000	rs6460295	chr7:65882728	T/C	cg10691866	chr7:65817282	TPST1	-0.34	-5.47	-0.32	1.06e-7	Aortic root size;
CESC	cis	rs3858526	0.834	rs7128847	chr11:6003111	C/T	cg05234568	chr11:5960015	NA	-0.43	-5.07	-0.3	7.64e-7	DNA methylation (variation);
CESC	cis	rs7512552	0.839	rs698916	chr1:150388385	A/G	cg15654264	chr1:150340011	RPRD2	0.4	5.3	0.31	2.4e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs832540	0.931	rs2591960	chr5:56238811	A/T	cg18230493	chr5:56204884	C5orf35	0.43	5.03	0.3	9.04e-7	Coronary artery disease;
CESC	cis	rs11785400	0.793	rs11785012	chr8:143748355	G/A	cg10596483	chr8:143751796	JRK	0.43	5.37	0.31	1.69e-7	Schizophrenia;
CESC	cis	rs2797160	0.651	rs6569437	chr6:126034540	T/G	cg05901451	chr6:126070800	HEY2	0.51	7.47	0.42	1.19e-12	Endometrial cancer;
CESC	cis	rs4253772	0.550	rs9615953	chr22:46731024	C/G	cg10541313	chr22:46663664	TTC38	0.73	5.21	0.3	3.86e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs2404602	0.583	rs2176623	chr15:76568579	C/T	cg26408565	chr15:76604113	ETFA	-0.41	-6.21	-0.36	2e-9	Blood metabolite levels;
CESC	trans	rs7819412	0.645	rs4841508	chr8:11065003	C/A	cg06636001	chr8:8085503	FLJ10661	-0.57	-6.58	-0.37	2.57e-10	Triglycerides;
CESC	cis	rs3820068	0.603	rs72647118	chr1:15956535	G/T	cg16988262	chr1:15930761	NA	0.34	5.43	0.32	1.24e-7	Systolic blood pressure;
CESC	cis	rs60871478	1.000	rs4397290	chr7:828493	T/C	cg05729249	chr7:766119	PRKAR1B;HEATR2	-0.53	-5.34	-0.31	2.01e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs2243480	1.000	rs4718316	chr7:65648731	A/G	cg12463550	chr7:65579703	CRCP	-0.73	-5.66	-0.33	4.03e-8	Diabetic kidney disease;
CESC	cis	rs9649465	0.561	rs600081	chr7:123414591	A/T	cg03229431	chr7:123269106	ASB15	0.4	5.58	0.32	5.96e-8	Migraine;
CESC	cis	rs72781680	0.566	rs6713979	chr2:23899876	A/G	cg20701182	chr2:24300061	SF3B14	0.64	6.54	0.37	3.13e-10	Lymphocyte counts;
CESC	cis	rs7666738	0.830	rs7667796	chr4:99071415	G/T	cg03467027	chr4:99064603	C4orf37	-0.48	-5.91	-0.34	1.04e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9291683	0.561	rs3733584	chr4:10036506	T/C	cg11266682	chr4:10021025	SLC2A9	0.7	13.81	0.65	4.81e-33	Bone mineral density;
CESC	cis	rs9900062	0.560	rs11656678	chr17:62681505	G/A	cg02598441	chr17:62777298	LOC146880	-0.63	-6.97	-0.39	2.5e-11	QT interval;
CESC	cis	rs11031096	0.568	rs10767891	chr11:4234524	A/G	cg18678763	chr11:4115507	RRM1	-0.37	-5.07	-0.3	7.36e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	cis	rs72945132	0.882	rs7942613	chr11:70210675	C/T	cg00319359	chr11:70116639	PPFIA1	0.71	6.85	0.39	5.11e-11	Coronary artery disease;
CESC	cis	rs6546550	0.901	rs13015457	chr2:70125763	G/T	cg02498382	chr2:70120550	SNRNP27	-0.4	-7.03	-0.4	1.71e-11	Prevalent atrial fibrillation;
CESC	trans	rs208520	0.690	rs851459	chr6:66813989	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.97	-12.84	-0.62	1.19e-29	Exhaled nitric oxide output;
CESC	cis	rs4819052	1.000	rs3746980	chr21:46711580	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.88	11.34	0.57	1.46e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs9362426	0.503	rs6454609	chr6:88106028	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.42	5.05	0.3	8.34e-7	Depressive episodes in bipolar disorder;
CESC	cis	rs7255436	0.965	rs11668346	chr19:8450854	A/T	cg10174797	chr19:8464628	RAB11B	0.39	5.57	0.32	6.11e-8	HDL cholesterol;
CESC	cis	rs1552244	0.882	rs13062917	chr3:10017032	T/A	cg00149659	chr3:10157352	C3orf10	0.71	8.4	0.46	2.72e-15	Alzheimer's disease;
CESC	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg16590910	chr6:42928470	GNMT	0.36	5.06	0.3	7.99e-7	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs4268898	1.000	rs4268898	chr2:24490413	C/T	cg06627628	chr2:24431161	ITSN2	0.68	8.24	0.45	7.99e-15	Asthma;
CESC	cis	rs651907	0.557	rs7629753	chr3:101371922	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.51	-6.93	-0.39	3.1e-11	Colorectal cancer;
CESC	cis	rs17039065	0.920	rs1595198	chr4:109472351	A/C	cg16022748	chr4:109541635	LOC285456;RPL34	0.66	5.78	0.33	2.11e-8	Gut microbiome composition (summer);
CESC	cis	rs3091242	0.967	rs3091240	chr1:25676935	G/T	cg02931644	chr1:25747376	RHCE	0.47	7.99	0.44	4.14e-14	Erythrocyte sedimentation rate;
CESC	cis	rs6500602	0.702	rs6500606	chr16:4502514	A/G	cg08645402	chr16:4508243	NA	-0.49	-7.84	-0.43	1.07e-13	Schizophrenia;
CESC	cis	rs4474465	0.790	rs10899541	chr11:78245573	A/G	cg27205649	chr11:78285834	NARS2	-0.47	-5.92	-0.34	9.7e-9	Alzheimer's disease (survival time);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18165186	chr3:50314180	SEMA3B	-0.65	-7.06	-0.4	1.47e-11	Gut microbiome composition (summer);
CESC	cis	rs60154123	0.615	rs701943	chr1:210425727	A/G	cg23283495	chr1:209979779	IRF6	-0.43	-5.68	-0.33	3.48e-8	Coronary artery disease;
CESC	cis	rs4654899	0.758	rs2874367	chr1:21324491	A/C	cg05370193	chr1:21551575	ECE1	-0.38	-5.71	-0.33	3.04e-8	Superior frontal gyrus grey matter volume;
CESC	cis	rs1005277	0.522	rs289645	chr10:37943642	T/C	cg25427524	chr10:38739819	LOC399744	-0.63	-8.98	-0.48	5.02e-17	Extrinsic epigenetic age acceleration;
CESC	cis	rs3806843	0.735	rs778597	chr5:140040665	A/G	cg26395211	chr5:140044315	WDR55	-0.48	-6.21	-0.36	2.09e-9	Depressive symptoms (multi-trait analysis);
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg04279939	chr12:10876163	CSDA	-0.43	-6.01	-0.35	6.17e-9	Height;
CESC	cis	rs977987	0.832	rs37597	chr16:75500275	T/G	cg03315344	chr16:75512273	CHST6	-0.48	-6.7	-0.38	1.24e-10	Dupuytren's disease;
CESC	cis	rs4713118	0.527	rs9461433	chr6:28095172	C/T	cg23281280	chr6:28129359	ZNF389	0.58	8.05	0.44	2.72e-14	Parkinson's disease;
CESC	cis	rs875971	1.000	rs2087647	chr7:65593188	C/A	cg18876405	chr7:65276391	NA	-0.5	-6.78	-0.38	7.91e-11	Aortic root size;
CESC	cis	rs4253772	0.550	rs6007779	chr22:46678615	A/C	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.78	9.39	0.5	2.94e-18	LDL cholesterol;Cholesterol, total;
CESC	cis	rs11734570	0.581	rs76682731	chr4:38586045	T/C	cg18361445	chr4:38666374	KLF3;FLJ13197	0.59	6.78	0.38	7.63e-11	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs9911578	1.000	rs6503870	chr17:56659018	C/T	cg05425664	chr17:57184151	TRIM37	-0.49	-6.83	-0.39	5.7e-11	Intelligence (multi-trait analysis);
CESC	cis	rs2228479	0.850	rs1800344	chr16:89816367	T/G	cg19635926	chr16:89946313	TCF25	0.67	5.09	0.3	6.82e-7	Skin colour saturation;
CESC	cis	rs1707322	0.752	rs6703748	chr1:46095976	G/A	cg06784218	chr1:46089804	CCDC17	0.4	6.97	0.39	2.52e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs8111998	0.826	rs10421310	chr19:22768069	G/A	cg19914732	chr19:22715077	NA	-0.37	-5.18	-0.3	4.45e-7	Corneal structure;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg06943149	chr12:77157476	ZDHHC17	0.44	6.06	0.35	4.57e-9	Systemic lupus erythematosus;
CESC	cis	rs798554	1.000	rs798540	chr7:2764130	G/A	cg18446336	chr7:2847575	GNA12	-0.4	-6.15	-0.35	2.86e-9	Height;
CESC	cis	rs523522	0.962	rs11065149	chr12:120956963	G/A	cg27279351	chr12:120934652	DYNLL1	0.69	9.11	0.49	2.02e-17	High light scatter reticulocyte count;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg10089324	chr1:51984752	EPS15	-0.43	-6.22	-0.36	1.91e-9	Gambling;
CESC	cis	rs826838	0.510	rs10876149	chr12:39228083	C/G	cg26384229	chr12:38710491	ALG10B	-0.68	-10.12	-0.53	1.44e-20	Heart rate;
CESC	cis	rs10751667	0.643	rs10751666	chr11:941933	C/T	cg06064525	chr11:970664	AP2A2	-0.5	-10.04	-0.52	2.7e-20	Alzheimer's disease (late onset);
CESC	trans	rs35110281	0.748	rs2838322	chr21:44998615	G/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.56	7.42	0.41	1.59e-12	Mean corpuscular volume;
CESC	cis	rs12681288	0.676	rs4565481	chr8:1001944	C/T	cg15309053	chr8:964076	NA	0.4	6.68	0.38	1.36e-10	Schizophrenia;
CESC	cis	rs7917772	0.582	rs11191352	chr10:104372244	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.39	5.41	0.32	1.43e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs41271473	0.500	rs4440831	chr1:228887522	C/T	cg00850481	chr1:228891306	NA	0.48	6.81	0.39	6.7e-11	Chronic lymphocytic leukemia;
CESC	cis	rs1348850	0.567	rs1405714	chr2:178538584	A/G	cg23306229	chr2:178417860	TTC30B	-0.52	-6.59	-0.38	2.38e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs2404602	0.735	rs11638767	chr15:76655938	T/C	cg23625390	chr15:77176239	SCAPER	-0.42	-5.66	-0.33	3.94e-8	Blood metabolite levels;
CESC	cis	rs9361491	0.580	rs13204088	chr6:79757438	A/C	cg05283184	chr6:79620031	NA	-0.38	-5.6	-0.33	5.47e-8	Intelligence (multi-trait analysis);
CESC	cis	rs7927771	0.524	rs12226431	chr11:47805856	G/A	cg18512352	chr11:47633146	NA	0.34	5.27	0.31	2.8e-7	Subjective well-being;
CESC	cis	rs2635047	0.747	rs9956387	chr18:44773382	A/T	cg24371990	chr18:44770781	NA	0.39	6.33	0.36	1.07e-9	Educational attainment;
CESC	cis	rs1862618	0.853	rs2113079	chr5:56157951	A/G	cg22800045	chr5:56110881	MAP3K1	0.82	9.94	0.52	5.44e-20	Initial pursuit acceleration;
CESC	cis	rs1372520	0.532	rs2583972	chr4:90747411	T/G	cg15133208	chr4:90757351	SNCA	-0.39	-5.25	-0.31	3.09e-7	Neuroticism;
CESC	cis	rs4253772	0.550	rs6008615	chr22:46707928	G/A	cg09491104	chr22:46646882	C22orf40	-0.5	-5.93	-0.34	9.22e-9	LDL cholesterol;Cholesterol, total;
CESC	cis	rs7336332	0.511	rs7998978	chr13:27999457	T/C	cg01674679	chr13:27998804	GTF3A	-0.59	-5.98	-0.34	7.12e-9	Weight;
CESC	cis	rs12142240	0.698	rs72886911	chr1:46814352	G/A	cg10495392	chr1:46806563	NSUN4	0.57	6.28	0.36	1.39e-9	Menopause (age at onset);
CESC	cis	rs7408868	1.000	rs10406754	chr19:15274201	T/A	cg14696996	chr19:15285081	NOTCH3	1.11	11.47	0.58	5.57e-25	Pulse pressure;
CESC	cis	rs7179456	0.545	rs605928	chr15:59046163	C/G	cg05156742	chr15:59063176	FAM63B	0.57	7.38	0.41	2.09e-12	Asperger disorder;
CESC	cis	rs5750830	0.621	rs743838	chr22:39824707	T/G	cg01416388	chr22:39784598	NA	-0.57	-6.93	-0.39	3.19e-11	Intelligence (multi-trait analysis);
CESC	cis	rs1799949	1.000	rs8176120	chr17:41261233	C/T	cg05368731	chr17:41323189	NBR1	0.79	11.2	0.57	4.19e-24	Menopause (age at onset);
CESC	cis	rs6537837	1.000	rs3768486	chr1:110123971	A/G	cg05049280	chr1:110155535	GNAT2	0.39	5.55	0.32	6.86e-8	Major depressive disorder;
CESC	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.15	12.2	0.6	1.84e-27	Platelet count;
CESC	cis	rs11098499	0.954	rs10006877	chr4:120242793	C/T	cg09307838	chr4:120376055	NA	0.91	12.62	0.61	6.43e-29	Corneal astigmatism;
CESC	cis	rs8031584	0.678	rs4779790	chr15:31164595	T/C	cg14298792	chr15:30685198	CHRFAM7A	-0.46	-5.53	-0.32	7.81e-8	Huntington's disease progression;
CESC	cis	rs7542091	0.704	rs7550330	chr1:210044587	G/A	cg23283495	chr1:209979779	IRF6	0.35	5.8	0.34	1.84e-8	Monobrow;
CESC	cis	rs3741151	0.773	rs7115055	chr11:73227827	T/C	cg17517138	chr11:73019481	ARHGEF17	1.0	7.33	0.41	2.76e-12	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs9905704	0.718	rs758377	chr17:56607124	T/C	cg12560992	chr17:57184187	TRIM37	-0.63	-5.99	-0.35	6.89e-9	Testicular germ cell tumor;
CESC	cis	rs798554	0.591	rs1182193	chr7:2869240	A/G	cg13628971	chr7:2884303	GNA12	0.45	5.93	0.34	9.59e-9	Height;
CESC	cis	rs9394438	0.628	rs4714080	chr6:37544618	A/G	cg00985040	chr6:37553208	NA	0.39	6.71	0.38	1.16e-10	IgG glycosylation;
CESC	cis	rs9287719	0.601	rs12996735	chr2:10716716	C/A	cg00105475	chr2:10696890	NA	0.4	5.4	0.32	1.46e-7	Prostate cancer;
CESC	cis	rs6504663	0.558	rs7627	chr17:48552154	G/C	cg03168497	chr17:48586147	MYCBPAP	0.47	5.62	0.33	4.72e-8	Visceral fat;
CESC	cis	rs2832191	0.935	rs11910475	chr21:30519702	T/C	cg24692254	chr21:30365293	RNF160	-0.72	-10.69	-0.55	2.14e-22	Dental caries;
CESC	cis	rs2742417	0.603	rs2673055	chr3:45772772	G/A	cg04837898	chr3:45731254	SACM1L	-0.47	-6.17	-0.35	2.54e-9	Response to anti-depressant treatment in major depressive disorder;
CESC	cis	rs919433	0.926	rs787997	chr2:198216271	A/G	cg20885578	chr2:198174922	NA	0.39	5.33	0.31	2.09e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs71277158	0.688	rs7615039	chr3:169806170	G/A	cg04067573	chr3:169899625	PHC3	0.67	6.71	0.38	1.17e-10	Prostate cancer;
CESC	cis	rs7980687	0.628	rs1609520	chr12:123735937	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	0.33	5.05	0.3	8.37e-7	Height;Educational attainment;Head circumference (infant);
CESC	cis	rs1218582	0.772	rs2174507	chr1:154887949	C/T	cg06221963	chr1:154839813	KCNN3	-0.66	-11.27	-0.57	2.42e-24	Prostate cancer;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg06867543	chr15:77271730	NA	0.49	6.38	0.36	7.95e-10	Ulcerative colitis;
CESC	cis	rs4888262	0.526	rs13330282	chr16:74572373	C/T	cg01733217	chr16:74700730	RFWD3	0.81	11.33	0.57	1.58e-24	Testicular germ cell tumor;
CESC	trans	rs11098499	0.826	rs12511640	chr4:120251248	T/C	cg25214090	chr10:38739885	LOC399744	0.62	8.7	0.47	3.58e-16	Corneal astigmatism;
CESC	cis	rs9303401	0.592	rs12936771	chr17:56725052	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.04	13.0	0.62	3.27e-30	Cognitive test performance;
CESC	cis	rs2072732	0.687	rs10489588	chr1:2951834	C/T	cg03976712	chr1:2946727	NA	0.33	5.58	0.32	5.96e-8	Plateletcrit;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03522216	chr5:32174578	GOLPH3	0.56	6.07	0.35	4.46e-9	Gut microbiome composition (summer);
CESC	cis	rs539096	0.500	rs2367804	chr1:44314266	C/T	cg12908607	chr1:44402522	ARTN	-0.49	-7.38	-0.41	1.98e-12	Intelligence (multi-trait analysis);
CESC	cis	rs12477438	0.501	rs13000731	chr2:99795231	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.75	12.51	0.61	1.6e-28	Chronic sinus infection;
CESC	cis	rs7246657	0.943	rs8109038	chr19:38015709	A/G	cg23950597	chr19:37808831	NA	0.57	5.94	0.34	9.05e-9	Coronary artery calcification;
CESC	cis	rs897984	0.542	rs3751855	chr16:31091209	T/C	cg02466173	chr16:30829666	NA	-0.4	-6.88	-0.39	4.38e-11	Dementia with Lewy bodies;
CESC	cis	rs365132	1.000	rs353464	chr5:176403023	A/G	cg16309518	chr5:176445507	NA	-0.39	-5.76	-0.33	2.31e-8	Menarche and menopause (age at onset);Menopause (age at onset);
CESC	cis	rs7666738	0.830	rs11097598	chr4:98946057	T/C	cg03676636	chr4:99064102	C4orf37	0.34	5.25	0.31	3.2e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs875971	0.522	rs781144	chr7:65440344	C/G	cg11764359	chr7:65958608	NA	0.66	8.18	0.45	1.16e-14	Aortic root size;
CESC	cis	rs909674	0.818	rs8136980	chr22:39844574	G/A	cg01416388	chr22:39784598	NA	-0.58	-7.04	-0.4	1.67e-11	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs1506636	1.000	rs2259457	chr7:123424350	A/G	cg03229431	chr7:123269106	ASB15	0.49	6.54	0.37	3.11e-10	Plateletcrit;Platelet count;
CESC	cis	rs7267979	1.000	rs6050564	chr20:25344231	G/A	cg08601574	chr20:25228251	PYGB	-0.38	-5.46	-0.32	1.12e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs6502050	0.799	rs6502066	chr17:80103737	T/C	cg23985595	chr17:80112537	CCDC57	-0.42	-6.57	-0.37	2.72e-10	Life satisfaction;
CESC	cis	rs514406	0.929	rs557847	chr1:53333116	A/G	cg08736216	chr1:53307985	ZYG11A	-0.42	-7.02	-0.4	1.86e-11	Monocyte count;
CESC	cis	rs858239	0.600	rs13438188	chr7:23144197	C/T	cg23682824	chr7:23144976	KLHL7	-0.51	-6.95	-0.39	2.84e-11	Cerebrospinal fluid biomarker levels;
CESC	cis	rs9457247	1.000	rs385113	chr6:167403971	A/G	cg25258033	chr6:167368657	RNASET2	0.39	5.88	0.34	1.26e-8	Crohn's disease;
CESC	cis	rs7666738	0.830	rs13148913	chr4:99009732	C/T	cg18180107	chr4:99064573	C4orf37	0.4	5.3	0.31	2.48e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6741892	0.536	rs13024840	chr2:38895920	T/A	cg01546378	chr2:38892901	GALM	-0.52	-7.04	-0.4	1.68e-11	5-HTT brain serotonin transporter levels;
CESC	cis	rs9787249	0.957	rs12086750	chr1:40210468	G/C	cg19912559	chr1:40204330	PPIE	0.43	6.57	0.37	2.63e-10	Blood protein levels;
CESC	cis	rs40363	0.645	rs1690446	chr16:3519009	T/C	cg05754148	chr16:3507555	NAT15	0.57	8.2	0.45	1.02e-14	Tuberculosis;
CESC	cis	rs11792861	0.926	rs56899598	chr9:111867271	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.42	5.17	0.3	4.6e-7	Menarche (age at onset);
CESC	cis	rs710865	0.541	rs12567768	chr1:19568603	T/A	cg13387374	chr1:19411106	UBR4	0.45	5.5	0.32	9.11e-8	Brain structure;
CESC	cis	rs1005277	0.522	rs11011343	chr10:38002698	A/G	cg25517755	chr10:38738941	LOC399744	-0.39	-5.06	-0.3	7.79e-7	Extrinsic epigenetic age acceleration;
CESC	cis	rs916888	0.647	rs199524	chr17:44848438	G/T	cg15921436	chr17:44337874	NA	-0.48	-6.06	-0.35	4.62e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs4927850	0.752	rs7618864	chr3:195749561	G/A	cg01181863	chr3:195395398	SDHAP2	-0.55	-6.59	-0.38	2.33e-10	Pancreatic cancer;
CESC	cis	rs1799949	1.000	rs11654452	chr17:41189383	G/T	cg05368731	chr17:41323189	NBR1	0.8	10.6	0.55	3.93e-22	Menopause (age at onset);
CESC	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg18402987	chr7:1209562	NA	0.59	7.0	0.4	2.06e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs853679	0.517	rs4713148	chr6:28115921	G/A	cg26335602	chr6:28129616	ZNF389	0.53	6.75	0.38	9.35e-11	Depression;
CESC	cis	rs698833	0.852	rs698761	chr2:44547574	A/G	cg04920474	chr2:44395004	PPM1B	-0.37	-5.09	-0.3	6.77e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs9311474	0.508	rs6786043	chr3:52604861	A/G	cg18099408	chr3:52552593	STAB1	-0.32	-5.43	-0.32	1.28e-7	Electroencephalogram traits;
CESC	cis	rs7552404	0.731	rs7523573	chr1:76372020	G/T	cg22875332	chr1:76189707	ACADM	0.59	5.73	0.33	2.78e-8	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs72772090	0.539	rs56213813	chr5:96112284	A/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.6	-5.05	-0.3	8.29e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs3858526	0.883	rs1453429	chr11:5933478	C/T	cg02574844	chr11:5959923	NA	-0.42	-5.32	-0.31	2.18e-7	DNA methylation (variation);
CESC	cis	rs11997175	0.766	rs7387133	chr8:33727045	C/G	ch.8.33884649F	chr8:33765107	NA	-0.44	-5.83	-0.34	1.64e-8	Body mass index;
CESC	cis	rs748404	0.586	rs2584700	chr15:43685332	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.62	7.8	0.43	1.4e-13	Lung cancer;
CESC	cis	rs7000551	0.675	rs2469758	chr8:22363032	C/T	cg12081754	chr8:22256438	SLC39A14	0.41	5.42	0.32	1.36e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CESC	cis	rs1904096	0.506	rs2632412	chr4:95149319	A/C	cg11021082	chr4:95130006	SMARCAD1	0.65	9.62	0.51	5.54e-19	Type 2 diabetes;
CESC	trans	rs11098499	0.604	rs2389882	chr4:120566733	A/C	cg25214090	chr10:38739885	LOC399744	0.6	8.01	0.44	3.56e-14	Corneal astigmatism;
CESC	cis	rs9291683	0.588	rs17247314	chr4:10004743	C/G	cg02734326	chr4:10020555	SLC2A9	0.45	6.46	0.37	4.94e-10	Bone mineral density;
CESC	cis	rs17376456	0.877	rs10213956	chr5:93460839	C/T	cg21475434	chr5:93447410	FAM172A	0.85	7.6	0.42	5.01e-13	Diabetic retinopathy;
CESC	cis	rs9611565	0.607	rs132792	chr22:42062822	C/T	cg06481639	chr22:41940642	POLR3H	0.47	5.53	0.32	7.78e-8	Vitiligo;
CESC	cis	rs10789491	1.000	rs7516616	chr1:47186274	A/G	cg15501359	chr1:47185051	KIAA0494	-0.78	-8.07	-0.44	2.45e-14	Response to hepatitis C treatment;
CESC	cis	rs1878931	0.580	rs7194596	chr16:3404408	T/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.97	14.77	0.67	1.96e-36	Body mass index (adult);
CESC	cis	rs9291683	0.507	rs3775940	chr4:10025163	A/T	cg00071950	chr4:10020882	SLC2A9	0.8	13.98	0.65	1.25e-33	Bone mineral density;
CESC	cis	rs6543140	0.964	rs4851592	chr2:103087641	C/T	cg04239558	chr2:103089729	SLC9A4	0.47	6.23	0.36	1.83e-9	Blood protein levels;
CESC	cis	rs453301	0.507	rs2929306	chr8:9084909	C/T	cg15556689	chr8:8085844	FLJ10661	-0.52	-6.6	-0.38	2.29e-10	Joint mobility (Beighton score);
CESC	cis	rs400736	0.740	rs225129	chr1:8094164	T/A	cg25007680	chr1:8021821	PARK7	0.71	9.96	0.52	4.56e-20	Response to antidepressants and depression;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12957096	chr22:41777779	TEF	0.62	6.98	0.39	2.31e-11	Gut microbiome composition (summer);
CESC	cis	rs870825	0.616	rs4264873	chr4:185624336	C/T	cg04058563	chr4:185651563	MLF1IP	0.64	7.05	0.4	1.59e-11	Blood protein levels;
CESC	cis	rs7089973	0.624	rs10885614	chr10:116609098	C/T	cg03647239	chr10:116582469	FAM160B1	0.43	5.35	0.31	1.94e-7	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	trans	rs61931739	0.500	rs3924705	chr12:34557825	A/T	cg26384229	chr12:38710491	ALG10B	0.53	7.41	0.41	1.74e-12	Morning vs. evening chronotype;
CESC	cis	rs8002861	0.905	rs12874535	chr13:44433565	A/G	cg14210620	chr13:44453864	C13orf31;CCDC122	-0.42	-5.35	-0.31	1.9e-7	Leprosy;
CESC	cis	rs11785400	0.793	rs2280879	chr8:143722228	T/C	cg10596483	chr8:143751796	JRK	0.4	5.14	0.3	5.32e-7	Schizophrenia;
CESC	cis	rs2303745	0.589	rs6512182	chr19:17399476	G/T	cg10664184	chr19:17420304	DDA1	0.44	5.18	0.3	4.35e-7	Systemic lupus erythematosus;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22779765	chr14:103369786	TRAF3	-0.58	-6.34	-0.36	9.73e-10	Gut microbiome composition (summer);
CESC	cis	rs9300255	0.602	rs2682434	chr12:123694724	C/T	cg05973401	chr12:123451056	ABCB9	0.49	5.63	0.33	4.63e-8	Neutrophil percentage of white cells;
CESC	cis	rs1008375	1.000	rs28497813	chr4:17685503	A/G	cg02297831	chr4:17616191	MED28	0.42	5.44	0.32	1.2e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs3540	0.513	rs2601154	chr15:90894284	T/C	cg10434728	chr15:90938212	IQGAP1	0.41	7.18	0.4	7.06e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs3820068	0.705	rs4646103	chr1:15819827	T/A	cg17385448	chr1:15911702	AGMAT	0.39	6.09	0.35	3.91e-9	Systolic blood pressure;
CESC	cis	rs1642645	0.831	rs2886564	chr1:42496924	G/A	cg16685388	chr1:42384056	HIVEP3	0.37	5.61	0.33	5.2e-8	Left ventricular obstructive tract defect (maternal effect);
CESC	cis	rs1355223	0.902	rs1539251	chr11:34742772	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.48	-6.44	-0.37	5.45e-10	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs6987853	0.563	rs7004796	chr8:42450170	T/G	cg09913449	chr8:42400586	C8orf40	0.34	5.48	0.32	1.01e-7	Mean corpuscular hemoglobin concentration;
CESC	cis	rs34172651	0.517	rs3803716	chr16:24802325	C/T	cg06505273	chr16:24850292	NA	0.53	6.51	0.37	3.7e-10	Intelligence (multi-trait analysis);
CESC	cis	rs6088580	0.634	rs6059867	chr20:33078103	C/T	cg24642439	chr20:33292090	TP53INP2	0.54	7.04	0.4	1.68e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs11690935	0.921	rs4668414	chr2:172704291	A/C	cg13550731	chr2:172543902	DYNC1I2	-0.96	-14.15	-0.66	2.96e-34	Schizophrenia;
CESC	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg03188948	chr7:1209495	NA	0.72	6.91	0.39	3.61e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7943191	0.768	rs34065644	chr11:62371938	C/T	cg23462726	chr11:62437636	C11orf83;C11orf48	-0.45	-5.86	-0.34	1.39e-8	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25345767	chr1:226070210	TMEM63A	0.55	6.38	0.36	7.97e-10	Gut microbiome composition (summer);
CESC	trans	rs1814175	0.647	rs28456013	chr11:50047629	T/C	cg15704280	chr7:45808275	SEPT13	-0.85	-11.66	-0.58	1.2e-25	Height;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg23260799	chr11:451101	PTDSS2	-0.44	-6.22	-0.36	1.97e-9	Gambling;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03770877	chr3:73046015	PPP4R2	0.48	6.1	0.35	3.83e-9	Gut microbiome composition (summer);
CESC	cis	rs2243480	1.000	rs35046236	chr7:65408613	T/C	cg13147721	chr7:65941812	NA	-0.85	-8.1	-0.45	2e-14	Diabetic kidney disease;
CESC	cis	rs9311474	0.508	rs7625743	chr3:52606366	C/G	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.38	6.95	0.39	2.86e-11	Electroencephalogram traits;
CESC	cis	rs477692	1.000	rs548390	chr10:131417427	G/A	cg05714579	chr10:131428358	MGMT	0.48	6.46	0.37	5.02e-10	Response to temozolomide;
CESC	trans	rs9693444	0.898	rs4732697	chr8:29519861	A/G	cg10047026	chr17:4613992	ARRB2	-0.41	-6.18	-0.35	2.43e-9	Breast cancer;
CESC	cis	rs9733	0.566	rs11204675	chr1:150570985	A/C	cg17724175	chr1:150552817	MCL1	-0.31	-5.15	-0.3	5.19e-7	Tonsillectomy;
CESC	cis	rs7552404	1.000	rs9662166	chr1:76235906	C/A	cg10523679	chr1:76189770	ACADM	0.54	6.13	0.35	3.18e-9	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs1552244	1.000	rs61052895	chr3:10147516	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	12.39	0.61	4.17e-28	Alzheimer's disease;
CESC	cis	rs12142240	0.659	rs72677591	chr1:46818219	T/G	cg00530320	chr1:46809349	NSUN4	0.58	7.89	0.44	8.15e-14	Menopause (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00093900	chr1:204381012	PPP1R15B	-0.54	-6.5	-0.37	3.92e-10	Gut microbiome composition (summer);
CESC	cis	rs2737618	0.674	rs2260033	chr1:200086074	G/A	cg21825944	chr1:200113062	NR5A2	-0.45	-6.77	-0.38	8.12e-11	Uric acid levels;
CESC	cis	rs644799	0.525	rs3016206	chr11:95536724	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.75	10.51	0.54	8.07e-22	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg14777817	chr13:80055594	NDFIP2	-0.42	-6.02	-0.35	5.88e-9	Fibrinogen levels;
CESC	cis	rs483180	0.512	rs594400	chr1:120214275	G/T	cg19096424	chr1:120255104	PHGDH	-0.43	-5.21	-0.31	3.72e-7	Macular telangiectasia type 2;
CESC	cis	rs7412746	0.611	rs4319334	chr1:150766822	G/A	cg17724175	chr1:150552817	MCL1	0.34	5.26	0.31	2.91e-7	Melanoma;
CESC	cis	rs8044868	0.586	rs12917999	chr16:72089451	T/C	cg16558253	chr16:72132732	DHX38	-0.41	-6.49	-0.37	4.12e-10	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CESC	cis	rs9393777	0.623	rs7756567	chr6:26481642	T/G	cg12826209	chr6:26865740	GUSBL1	0.65	6.85	0.39	5.16e-11	Intelligence (multi-trait analysis);
CESC	cis	rs748404	0.690	rs1079309	chr15:43783164	C/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.5	7.74	0.43	2.06e-13	Lung cancer;
CESC	cis	rs11945232	1.000	rs28630962	chr4:88336386	C/T	cg23841344	chr4:88312519	HSD17B11	-0.64	-7.97	-0.44	4.78e-14	Intelligence (multi-trait analysis);
CESC	cis	rs6963495	0.745	rs2392749	chr7:105182605	A/G	cg13798780	chr7:105162888	PUS7	0.63	7.31	0.41	3.16e-12	Bipolar disorder (body mass index interaction);
CESC	cis	rs7072216	0.763	rs12763326	chr10:100167396	A/G	cg26618903	chr10:100175079	PYROXD2	0.37	5.69	0.33	3.28e-8	Metabolite levels;
CESC	cis	rs868036	0.609	rs3784707	chr15:68043878	A/C	cg08079166	chr15:68083412	MAP2K5	0.4	5.32	0.31	2.25e-7	Restless legs syndrome;
CESC	cis	rs2933343	0.672	rs1872545	chr3:128645039	G/C	cg25356066	chr3:128598488	ACAD9	0.6	8.4	0.46	2.72e-15	IgG glycosylation;
CESC	trans	rs10780944	0.620	rs17535600	chr9:73130529	G/A	cg06462780	chr16:1843741	IGFALS	0.43	6.08	0.35	4.11e-9	Pubertal anthropometrics;
CESC	cis	rs10504229	0.679	rs111843870	chr8:58126798	A/G	cg22535103	chr8:58192502	C8orf71	-0.84	-9.44	-0.5	2.04e-18	Developmental language disorder (linguistic errors);
CESC	cis	rs1862618	0.853	rs252904	chr5:56118733	A/T	cg24531977	chr5:56204891	C5orf35	-0.87	-10.92	-0.56	3.64e-23	Initial pursuit acceleration;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03503634	chr11:36531973	TRAF6	0.56	6.18	0.35	2.37e-9	Gut microbiome composition (summer);
CESC	cis	rs798554	0.757	rs2533878	chr7:2878707	A/G	cg19346786	chr7:2764209	NA	0.45	6.65	0.38	1.68e-10	Height;
CESC	cis	rs12618769	0.597	rs3754886	chr2:99107677	A/G	cg10123293	chr2:99228465	UNC50	0.39	5.13	0.3	5.6e-7	Bipolar disorder;
CESC	cis	rs2243480	1.000	rs906134	chr7:65444288	G/C	cg13147721	chr7:65941812	NA	-0.9	-8.65	-0.47	4.98e-16	Diabetic kidney disease;
CESC	cis	rs798554	0.679	rs11973498	chr7:2886873	C/A	cg04166393	chr7:2884313	GNA12	0.59	8.08	0.44	2.29e-14	Height;
CESC	cis	rs4664304	0.966	rs925407	chr2:160767502	A/C	cg03641300	chr2:160917029	PLA2R1	-0.48	-6.88	-0.39	4.42e-11	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs7516138	1.000	rs4240895	chr1:9713386	C/T	cg26573321	chr1:9711663	PIK3CD	0.61	9.33	0.5	4.49e-18	Monocyte count;
CESC	cis	rs12618769	0.597	rs3769719	chr2:99124404	T/C	cg10123293	chr2:99228465	UNC50	0.4	5.38	0.31	1.64e-7	Bipolar disorder;
CESC	cis	rs3105593	1.000	rs3109878	chr15:50836243	T/G	cg08437265	chr15:50716283	USP8	0.44	5.69	0.33	3.44e-8	QT interval;
CESC	cis	rs8180040	0.701	rs1079276	chr3:47045739	C/G	cg27129171	chr3:47204927	SETD2	0.68	9.96	0.52	4.81e-20	Colorectal cancer;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg11066750	chr2:120125096	C2orf76;DBI	-0.44	-6.01	-0.35	5.96e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs2820292	1.000	rs2644128	chr1:201793440	C/G	cg11586189	chr1:201857591	SHISA4	-0.31	-5.35	-0.31	1.86e-7	Waist circumference;Body mass index (joint analysis main effects and smoking interaction);Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);
CESC	cis	rs2797160	1.000	rs926853	chr6:126021435	A/T	cg05901451	chr6:126070800	HEY2	0.45	6.46	0.37	5.01e-10	Endometrial cancer;
CESC	cis	rs12995491	0.933	rs12995212	chr2:88527184	C/T	cg04511125	chr2:88470314	THNSL2	-0.49	-6.98	-0.39	2.43e-11	Response to metformin (IC50);
CESC	cis	rs9399135	0.967	rs2183709	chr6:135377091	C/T	cg22676075	chr6:135203613	NA	0.52	7.29	0.41	3.61e-12	Red blood cell count;
CESC	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.16	12.35	0.6	5.74e-28	Platelet count;
CESC	cis	rs4423214	0.610	rs12789253	chr11:71125765	G/A	cg05163923	chr11:71159392	DHCR7	0.6	7.94	0.44	5.72e-14	Vitamin D levels;
CESC	cis	rs1595825	0.838	rs58576043	chr2:198524149	C/T	cg10820045	chr2:198174542	NA	0.41	5.21	0.3	3.79e-7	Ulcerative colitis;
CESC	cis	rs6860806	0.631	rs7736284	chr5:131588151	T/C	cg12564285	chr5:131593104	PDLIM4	0.4	6.09	0.35	3.99e-9	Breast cancer;
CESC	cis	rs6500602	0.727	rs7193136	chr16:4580034	C/T	cg08645402	chr16:4508243	NA	0.5	7.97	0.44	4.66e-14	Schizophrenia;
CESC	cis	rs4589502	0.800	rs1498499	chr15:67202620	C/T	cg12317470	chr15:67143691	NA	-0.68	-7.97	-0.44	4.68e-14	Lung cancer (smoking interaction);
CESC	trans	rs11039798	0.920	rs11500574	chr11:48713986	A/T	cg15704280	chr7:45808275	SEPT13	0.7	6.31	0.36	1.15e-9	Axial length;
CESC	trans	rs3808502	0.574	rs4841559	chr8:11416885	C/T	cg15556689	chr8:8085844	FLJ10661	-0.57	-6.81	-0.39	6.39e-11	Neuroticism;
CESC	cis	rs6032067	0.777	rs56191952	chr20:43802487	A/G	cg10761708	chr20:43804764	PI3	0.56	6.65	0.38	1.7e-10	Blood protein levels;
CESC	cis	rs1552244	1.000	rs9849434	chr3:10133710	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.9	-12.56	-0.61	1.07e-28	Alzheimer's disease;
CESC	cis	rs4253772	0.550	rs9615347	chr22:46728153	A/G	cg18190219	chr22:46762943	CELSR1	-0.59	-5.25	-0.31	3.06e-7	LDL cholesterol;Cholesterol, total;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04031383	chr16:84088007	MBTPS1	-0.56	-6.23	-0.36	1.81e-9	Gut microbiome composition (summer);
CESC	cis	rs12780046	0.505	rs10883307	chr10:101038249	G/A	cg27143070	chr10:101087766	CNNM1	0.36	5.26	0.31	3.03e-7	Non-glioblastoma glioma;
CESC	cis	rs7590720	1.000	rs1991533	chr2:216908910	T/C	cg12620499	chr2:216877984	MREG	0.9	12.13	0.6	3.27e-27	Alcohol dependence;
CESC	cis	rs1505368	0.781	rs10197836	chr2:213274278	T/C	cg16329650	chr2:213403929	ERBB4	0.38	5.24	0.31	3.28e-7	Symmetrical dimethylarginine levels;
CESC	cis	rs4718428	0.607	rs66954441	chr7:66369209	T/C	cg12165864	chr7:66369176	NA	-0.67	-7.8	-0.43	1.41e-13	Corneal structure;
CESC	cis	rs6701037	1.000	rs11580331	chr1:175123288	T/C	cg00321850	chr1:175162397	KIAA0040	-0.42	-5.86	-0.34	1.37e-8	Alcohol dependence;
CESC	trans	rs116095464	0.558	rs13356367	chr5:242395	C/T	cg00938859	chr5:1591904	SDHAP3	0.64	6.98	0.39	2.36e-11	Breast cancer;
CESC	cis	rs9309711	0.623	rs4641971	chr2:3481857	A/C	cg15506890	chr2:3487001	NA	0.47	5.78	0.33	2.07e-8	Neurofibrillary tangles;
CESC	cis	rs7178572	0.568	rs4886515	chr15:77686886	G/A	cg22256960	chr15:77711686	NA	-0.54	-6.95	-0.39	2.9e-11	Type 2 diabetes;
CESC	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.52	-6.62	-0.38	1.95e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs6728642	0.901	rs10179966	chr2:97845100	C/T	cg26665480	chr2:98280029	ACTR1B	-0.74	-7.26	-0.41	4.32e-12	Bipolar disorder lithium response (continuous) or schizophrenia;
CESC	cis	rs919433	0.889	rs6711624	chr2:198207607	C/G	cg03934865	chr2:198174659	NA	-0.46	-6.59	-0.38	2.34e-10	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs9300255	0.639	rs941306	chr12:123715113	C/T	cg19016782	chr12:123741754	C12orf65	-0.5	-7.08	-0.4	1.33e-11	Neutrophil percentage of white cells;
CESC	cis	rs7586879	0.687	rs11892869	chr2:25096692	A/T	cg01884057	chr2:25150051	NA	0.38	7.4	0.41	1.85e-12	Body mass index;
CESC	cis	rs2228479	0.850	rs11649162	chr16:89807131	C/A	cg19635926	chr16:89946313	TCF25	0.67	5.09	0.3	6.89e-7	Skin colour saturation;
CESC	cis	rs10779751	1.000	rs2300093	chr1:11266392	G/C	cg08854313	chr1:11322531	MTOR	0.91	14.23	0.66	1.56e-34	Body mass index;
CESC	cis	rs113835537	0.529	rs61561111	chr11:66275923	T/C	cg22134325	chr11:66188745	NPAS4	0.36	5.64	0.33	4.35e-8	Airway imaging phenotypes;
CESC	cis	rs7851660	0.839	rs10113884	chr9:100624622	C/T	cg13688889	chr9:100608707	NA	-0.64	-8.89	-0.48	9.61e-17	Strep throat;
CESC	cis	rs7589728	0.514	rs12465706	chr2:88467459	C/A	cg04511125	chr2:88470314	THNSL2	0.69	6.76	0.38	8.71e-11	Plasma clusterin levels;
CESC	cis	rs7824557	0.564	rs11781637	chr8:11214972	C/T	cg21775007	chr8:11205619	TDH	-0.51	-7.85	-0.43	1.04e-13	Retinal vascular caliber;
CESC	cis	rs801193	0.569	rs881285	chr7:66119420	A/G	cg18876405	chr7:65276391	NA	-0.45	-6.21	-0.36	2e-9	Aortic root size;
CESC	cis	rs2243480	1.000	rs35283677	chr7:65359233	C/T	cg18252515	chr7:66147081	NA	-1.18	-11.4	-0.57	9.2e-25	Diabetic kidney disease;
CESC	cis	rs367943	0.637	rs6859521	chr5:113007423	C/T	cg12552261	chr5:112820674	MCC	0.45	5.33	0.31	2.05e-7	Type 2 diabetes;
CESC	cis	rs9470366	0.509	rs4714001	chr6:36638175	G/A	cg08179530	chr6:36648295	CDKN1A	-0.63	-9.36	-0.5	3.54e-18	QRS duration;
CESC	cis	rs9611565	0.559	rs6002408	chr22:41967870	C/T	cg17376030	chr22:41985996	PMM1	0.52	5.58	0.32	6.06e-8	Vitiligo;
CESC	cis	rs514406	0.758	rs532242	chr1:53308665	C/G	cg08736216	chr1:53307985	ZYG11A	-0.44	-7.4	-0.41	1.77e-12	Monocyte count;
CESC	cis	rs4423214	0.592	rs10898191	chr11:71194601	G/A	cg05163923	chr11:71159392	DHCR7	-0.59	-6.16	-0.35	2.73e-9	Vitamin D levels;
CESC	cis	rs72772090	0.539	rs11747148	chr5:96112863	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.6	-5.05	-0.3	8.29e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs7666738	0.800	rs1559858	chr4:99024075	A/G	cg03467027	chr4:99064603	C4orf37	0.47	5.85	0.34	1.47e-8	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05705089	chr20:42839217	C20orf111	0.63	7.16	0.4	8.12e-12	Gut microbiome composition (summer);
CESC	cis	rs9326248	0.590	rs2542063	chr11:116684767	C/T	cg16524733	chr11:117070046	TAGLN	0.28	5.18	0.3	4.39e-7	Blood protein levels;
CESC	cis	rs854765	0.547	rs4365348	chr17:17912548	C/T	cg16928487	chr17:17741425	SREBF1	-0.58	-10.31	-0.53	3.65e-21	Total body bone mineral density;
CESC	trans	rs12356475	0.710	rs10822686	chr10:67733250	C/T	cg26994227	chr5:130971071	RAPGEF6	0.53	6.4	0.37	7.1e-10	Psoriatic arthritis;
CESC	cis	rs73195822	0.506	rs61440260	chr12:111142855	G/T	cg12870014	chr12:110450643	ANKRD13A	0.65	5.65	0.33	4.05e-8	Itch intensity from mosquito bite;
CESC	cis	rs6987853	0.966	rs1901282	chr8:42392942	C/G	cg09913449	chr8:42400586	C8orf40	0.39	6.13	0.35	3.15e-9	Mean corpuscular hemoglobin concentration;
CESC	cis	rs6665290	0.904	rs10916075	chr1:227184074	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.2	-31.28	-0.89	6.16e-91	Myeloid white cell count;
CESC	cis	rs6502050	0.835	rs4789666	chr17:80162276	C/T	cg11859384	chr17:80120422	CCDC57	-0.37	-5.15	-0.3	4.98e-7	Life satisfaction;
CESC	cis	rs6032067	1.000	rs6032042	chr20:43815949	T/C	cg11264863	chr20:43835661	SEMG1	0.49	5.29	0.31	2.5e-7	Blood protein levels;
CESC	cis	rs9910055	0.762	rs1135215	chr17:42253519	T/C	cg13607699	chr17:42295918	UBTF	0.63	8.35	0.46	3.84e-15	Total body bone mineral density;
CESC	cis	rs2228479	0.867	rs62052187	chr16:89973071	G/A	cg00800038	chr16:89945340	TCF25	-0.75	-7.11	-0.4	1.1e-11	Skin colour saturation;
CESC	cis	rs9660992	0.710	rs1668864	chr1:205248799	T/C	cg21643547	chr1:205240462	TMCC2	-0.46	-6.16	-0.35	2.67e-9	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs11785693	0.862	rs11774842	chr8:4979769	A/C	cg26367366	chr8:4980734	NA	0.81	7.32	0.41	2.88e-12	Neuroticism (multi-trait analysis);Neuroticism;
CESC	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg18765753	chr7:1198926	ZFAND2A	-0.45	-6.53	-0.37	3.27e-10	Longevity;Endometriosis;
CESC	trans	rs10463316	0.894	rs6579862	chr5:150761717	T/G	cg24389359	chr12:111284228	CCDC63	-0.34	-6.08	-0.35	4.1e-9	Metabolite levels (Pyroglutamine);
CESC	cis	rs4423214	0.524	rs4944046	chr11:71123794	C/G	cg05163923	chr11:71159392	DHCR7	0.43	5.46	0.32	1.11e-7	Vitamin D levels;
CESC	cis	rs1005224	0.927	rs1981899	chr14:76175594	G/A	cg25116370	chr14:76127843	TTLL5;C14orf1	-0.43	-5.83	-0.34	1.57e-8	Large artery stroke;
CESC	cis	rs6540559	0.546	rs735694	chr1:210034029	T/C	cg22029157	chr1:209979665	IRF6	0.72	7.16	0.4	8.04e-12	Cleft lip with or without cleft palate;
CESC	cis	rs11997175	0.574	rs4236733	chr8:33655582	G/A	ch.8.33884649F	chr8:33765107	NA	0.66	8.38	0.46	3.14e-15	Body mass index;
CESC	cis	rs9311474	0.508	rs11720243	chr3:52618018	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.6	8.55	0.46	9.94e-16	Electroencephalogram traits;
CESC	cis	rs9660180	0.967	rs61422524	chr1:1767565	C/A	cg20999797	chr1:1681921	NA	0.26	5.13	0.3	5.64e-7	Body mass index;
CESC	cis	rs763121	0.819	rs5757160	chr22:38989646	T/C	cg06022373	chr22:39101656	GTPBP1	0.94	17.17	0.73	5.98e-45	Menopause (age at onset);
CESC	cis	rs739401	0.595	rs2237903	chr11:2967901	C/T	cg08508325	chr11:3079039	CARS	-0.46	-7.9	-0.44	7.55e-14	Longevity;
CESC	cis	rs7819412	0.740	rs11250119	chr8:11037034	C/T	cg14752069	chr8:11977206	FAM66D	-0.32	-5.41	-0.32	1.4e-7	Triglycerides;
CESC	cis	rs1697139	0.583	rs1428474	chr5:66544015	C/A	cg11553311	chr5:66541588	NA	0.38	5.25	0.31	3.1e-7	Breast cancer;
CESC	cis	rs11514810	1.000	rs4076699	chr7:1435521	C/T	cg24899294	chr7:1481343	MICALL2	-0.67	-5.54	-0.32	7.25e-8	Executive inhibition (Stroop WIT and CIT) in attention deficit hyperactivity disorder;
CESC	cis	rs7044106	0.791	rs3904196	chr9:123480369	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.38	6.13	0.35	3.25e-9	Hip circumference adjusted for BMI;
CESC	cis	rs6062302	0.522	rs2297428	chr20:62221766	C/T	cg06363034	chr20:62225388	GMEB2	-0.52	-6.63	-0.38	1.91e-10	Glioblastoma;
CESC	cis	rs2991971	0.934	rs11211129	chr1:45983080	C/T	cg05343316	chr1:45956843	TESK2	-0.5	-6.52	-0.37	3.59e-10	High light scatter reticulocyte count;
CESC	cis	rs7647973	1.000	rs12583	chr3:49571462	G/T	cg02487422	chr3:49467188	NICN1	-0.42	-5.39	-0.31	1.53e-7	Menarche (age at onset);
CESC	cis	rs1008375	1.000	rs2872959	chr4:17677163	G/A	cg02297831	chr4:17616191	MED28	-0.49	-5.8	-0.34	1.89e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs854765	0.583	rs8070722	chr17:17813562	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.57	8.19	0.45	1.1e-14	Total body bone mineral density;
CESC	cis	rs10744422	1.000	rs936083	chr12:123338964	A/G	cg25930673	chr12:123319894	HIP1R	-0.76	-5.88	-0.34	1.26e-8	Schizophrenia;
CESC	cis	rs7666738	0.546	rs11097591	chr4:98910173	G/A	cg05340658	chr4:99064831	C4orf37	0.54	6.47	0.37	4.73e-10	Colonoscopy-negative controls vs population controls;
CESC	cis	rs12048904	0.505	rs10493936	chr1:101213335	A/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.65	-7.96	-0.44	5.17e-14	Multiple sclerosis;
CESC	cis	rs76917914	0.780	rs2417727	chr9:100846475	T/C	cg03040243	chr9:100819229	NANS	0.47	5.19	0.3	4.27e-7	Immature fraction of reticulocytes;
CESC	cis	rs3862260	0.509	rs10754416	chr1:120163531	A/G	cg16322792	chr1:120165303	ZNF697	0.58	11.03	0.56	1.53e-23	Systemic lupus erythematosus;
CESC	cis	rs2228479	0.850	rs11648689	chr16:89806732	G/A	cg14709524	chr16:89940631	TCF25	0.93	6.87	0.39	4.68e-11	Skin colour saturation;
CESC	cis	rs4076764	0.801	rs4571944	chr1:163367975	T/C	cg24596788	chr1:163392923	NA	-0.42	-5.94	-0.34	8.9e-9	Motion sickness;
CESC	cis	rs7953249	0.502	rs1169294	chr12:121426594	G/A	cg25281562	chr12:121454272	C12orf43	0.57	7.18	0.4	7.24e-12	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
CESC	cis	rs3858526	0.584	rs10769274	chr11:5866925	T/C	cg19445457	chr11:5799446	OR52N5	-0.38	-5.06	-0.3	8.01e-7	DNA methylation (variation);
CESC	trans	rs12310956	0.532	rs11052933	chr12:33969881	G/A	cg26384229	chr12:38710491	ALG10B	0.58	8.12	0.45	1.8e-14	Morning vs. evening chronotype;
CESC	cis	rs10416265	0.502	rs7245411	chr19:33543029	A/T	cg03563238	chr19:33554763	RHPN2	-0.3	-5.2	-0.3	4.07e-7	Bone properties (heel);
CESC	cis	rs34779708	0.897	rs34481177	chr10:35380913	C/T	cg03585969	chr10:35415529	CREM	0.77	10.07	0.53	2.06e-20	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs8050907	0.744	rs55810554	chr16:4524392	C/T	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.9	6.28	0.36	1.39e-9	Obesity-related traits;
CESC	cis	rs6500602	0.627	rs2270363	chr16:4526292	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.42	5.77	0.33	2.22e-8	Schizophrenia;
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg10541813	chr2:85839361	C2orf68	-0.41	-6.53	-0.37	3.36e-10	Vertical cup-disc ratio;
CESC	cis	rs4919087	0.651	rs12240590	chr10:99072066	C/G	cg25902810	chr10:99078978	FRAT1	-0.48	-5.43	-0.32	1.29e-7	Monocyte count;
CESC	cis	rs2292884	0.505	rs11889660	chr2:238438395	C/T	cg14458575	chr2:238380390	NA	0.6	5.91	0.34	1.07e-8	Prostate cancer;
CESC	trans	rs61931739	0.500	rs73103774	chr12:34482279	C/T	cg13010199	chr12:38710504	ALG10B	0.5	6.52	0.37	3.54e-10	Morning vs. evening chronotype;
CESC	cis	rs7824557	0.767	rs7003241	chr8:11169075	A/G	cg21775007	chr8:11205619	TDH	0.49	7.08	0.4	1.28e-11	Retinal vascular caliber;
CESC	cis	rs9217	0.513	rs7216801	chr17:7386811	A/T	cg02795151	chr17:7402630	POLR2A	0.55	5.86	0.34	1.41e-8	Height;
CESC	cis	rs7833790	0.724	rs12676336	chr8:82771008	C/T	cg17211192	chr8:82754475	SNX16	0.53	6.72	0.38	1.14e-10	Diastolic blood pressure;
CESC	cis	rs6088590	0.561	rs6059934	chr20:33178324	G/T	cg24642439	chr20:33292090	TP53INP2	0.61	8.14	0.45	1.56e-14	Coronary artery disease;
CESC	cis	rs2455799	0.573	rs2174172	chr3:15768579	C/A	cg16303742	chr3:15540471	COLQ	-0.39	-6.19	-0.36	2.32e-9	Mean platelet volume;
CESC	cis	rs921968	0.565	rs3821035	chr2:219620223	T/G	cg02176678	chr2:219576539	TTLL4	-0.44	-7.67	-0.43	3.29e-13	Mean corpuscular hemoglobin concentration;
CESC	cis	rs7659604	1.000	rs7689714	chr4:122665943	T/A	cg19671926	chr4:122722719	EXOSC9	-0.49	-5.92	-0.34	9.92e-9	Type 2 diabetes;
CESC	cis	rs597539	0.652	rs557625	chr11:68634722	G/A	cg18350739	chr11:68623251	NA	-0.46	-7.02	-0.4	1.88e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs1865760	0.566	rs9295686	chr6:26081983	G/C	cg17691542	chr6:26056736	HIST1H1C	0.42	5.57	0.32	6.13e-8	Height;
CESC	cis	rs9660992	0.624	rs72745217	chr1:205261482	C/G	cg00857998	chr1:205179979	DSTYK	0.49	5.51	0.32	8.52e-8	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs765787	0.530	rs28414644	chr15:45536721	G/C	cg24006582	chr15:45444508	DUOX1	-0.59	-7.32	-0.41	3.04e-12	Uric acid levels;
CESC	cis	rs9768139	0.733	rs56205111	chr7:158121055	T/C	cg27057461	chr7:158136379	PTPRN2	-0.33	-5.17	-0.3	4.6e-7	Calcium levels;
CESC	cis	rs853679	0.517	rs9380065	chr6:28144751	A/G	cg12963246	chr6:28129442	ZNF389	0.54	7.18	0.4	6.92e-12	Depression;
CESC	cis	rs10949834	0.504	rs12539781	chr7:73568425	C/T	cg07137043	chr7:73588983	EIF4H	-0.63	-6.98	-0.39	2.36e-11	Verbal memory performance (residualized delayed recall change);
CESC	cis	rs523522	0.962	rs4767912	chr12:120981202	A/G	cg27279351	chr12:120934652	DYNLL1	0.69	9.11	0.49	2.02e-17	High light scatter reticulocyte count;
CESC	cis	rs7918232	0.941	rs1753415	chr10:27395102	T/C	cg14442939	chr10:27389572	ANKRD26	0.68	6.47	0.37	4.78e-10	Breast cancer;
CESC	cis	rs1062177	1.000	rs2964576	chr5:151150602	T/G	cg00977110	chr5:151150581	G3BP1	0.67	7.15	0.4	8.3e-12	Preschool internalizing problems;
CESC	cis	rs853679	0.517	rs1904841	chr6:28108085	C/T	cg23161317	chr6:28129485	ZNF389	0.53	6.84	0.39	5.36e-11	Depression;
CESC	cis	rs7666738	0.791	rs10010438	chr4:99022177	C/T	cg03467027	chr4:99064603	C4orf37	0.46	5.81	0.34	1.8e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1552244	1.000	rs3895942	chr3:10108745	G/C	cg00149659	chr3:10157352	C3orf10	0.7	8.38	0.46	3.2e-15	Alzheimer's disease;
CESC	cis	rs4604732	0.527	rs79329288	chr1:247626513	T/C	cg12758973	chr1:247694275	LOC148824;OR2C3	0.51	6.36	0.36	8.65e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs1538970	0.669	rs3219476	chr1:45802670	A/C	cg24296786	chr1:45957014	TESK2	0.5	6.57	0.37	2.65e-10	Platelet count;
CESC	cis	rs72945132	0.882	rs7121012	chr11:70214421	A/T	cg00319359	chr11:70116639	PPFIA1	0.72	6.89	0.39	4.01e-11	Coronary artery disease;
CESC	cis	rs6539267	0.741	rs2279759	chr12:106694988	T/C	cg00173435	chr12:106696525	TCP11L2	0.68	8.0	0.44	3.88e-14	Tourette syndrome;
CESC	cis	rs28374715	0.528	rs28492932	chr15:41624397	G/C	cg18705301	chr15:41695430	NDUFAF1	-1.05	-15.34	-0.69	1.9e-38	Ulcerative colitis;
CESC	cis	rs10493773	0.609	rs10873716	chr1:86178347	G/T	cg17807903	chr1:86174739	ZNHIT6	-0.44	-6.53	-0.37	3.43e-10	Urate levels in overweight individuals;
CESC	cis	rs2652834	0.904	rs7175602	chr15:63367032	T/C	cg05507819	chr15:63340323	TPM1	-0.67	-6.95	-0.39	2.84e-11	HDL cholesterol;
CESC	cis	rs780096	0.546	rs1060525	chr2:27635582	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.35	-7.12	-0.4	9.89e-12	Total body bone mineral density;
CESC	cis	rs7223966	0.960	rs2319990	chr17:61705397	T/C	cg11494091	chr17:61959527	GH2	0.4	5.63	0.33	4.49e-8	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs6688613	0.765	rs56229522	chr1:166816108	T/A	cg07049167	chr1:166818506	POGK	0.48	5.99	0.35	6.88e-9	Refractive astigmatism;
CESC	cis	rs1799949	1.000	rs4793190	chr17:41200109	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.64	8.65	0.47	4.88e-16	Menopause (age at onset);
CESC	cis	rs6951245	0.706	rs1133116	chr7:1195215	A/C	cg04025307	chr7:1156635	C7orf50	0.42	5.15	0.3	5.16e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2243480	1.000	rs4718317	chr7:65648901	A/G	cg13147721	chr7:65941812	NA	0.92	8.72	0.47	3.02e-16	Diabetic kidney disease;
CESC	cis	rs7772486	0.790	rs1832362	chr6:146179955	C/T	cg05347473	chr6:146136440	FBXO30	0.55	7.26	0.41	4.4e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1008375	0.618	rs13129002	chr4:17567513	A/G	cg16339924	chr4:17578868	LAP3	0.6	7.28	0.41	3.84e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs2243480	1.000	rs313803	chr7:65514731	G/A	cg13147721	chr7:65941812	NA	-0.88	-8.52	-0.46	1.19e-15	Diabetic kidney disease;
CESC	cis	rs7829975	0.688	rs6995407	chr8:8384647	C/G	cg06636001	chr8:8085503	FLJ10661	0.56	6.67	0.38	1.45e-10	Mood instability;
CESC	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg23978390	chr7:1156363	C7orf50	0.55	7.54	0.42	7.57e-13	Longevity;Endometriosis;
CESC	cis	rs3806843	0.676	rs778591	chr5:140025484	G/A	cg26395211	chr5:140044315	WDR55	0.49	6.21	0.36	2.07e-9	Depressive symptoms (multi-trait analysis);
CESC	cis	rs1008375	0.966	rs28750296	chr4:17685826	A/T	cg16339924	chr4:17578868	LAP3	0.51	6.66	0.38	1.58e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs9815354	0.767	rs73081335	chr3:41895177	A/G	cg03022575	chr3:42003672	ULK4	0.71	6.23	0.36	1.84e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs7811142	0.887	rs4074838	chr7:100032665	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.06	10.39	0.54	1.98e-21	Platelet count;
CESC	cis	rs6570726	0.818	rs437978	chr6:145809134	A/G	cg05347473	chr6:146136440	FBXO30	0.51	6.71	0.38	1.16e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1059312	0.932	rs11059916	chr12:129287609	C/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.7	-9.54	-0.51	9.53e-19	Systemic lupus erythematosus;
CESC	cis	rs3136441	0.892	rs898604	chr11:46917983	A/G	cg25783544	chr11:47291846	MADD	0.51	5.46	0.32	1.11e-7	HDL cholesterol;
CESC	cis	rs9303401	0.614	rs8081058	chr17:57160513	G/C	cg25039879	chr17:56429692	SUPT4H1	0.5	5.29	0.31	2.58e-7	Cognitive test performance;
CESC	cis	rs12926788	0.546	rs200537	chr16:24747787	G/C	cg06028605	chr16:24865363	SLC5A11	-0.54	-8.12	-0.45	1.77e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs1023500	0.551	rs133371	chr22:42465574	G/A	cg15557168	chr22:42548783	NA	-0.45	-6.5	-0.37	3.87e-10	Schizophrenia;
CESC	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg26338869	chr17:61819248	STRADA	-0.69	-9.06	-0.49	2.99e-17	Prudent dietary pattern;
CESC	cis	rs910316	0.967	rs4384542	chr14:75658013	A/C	cg08847533	chr14:75593920	NEK9	-0.94	-16.69	-0.72	3.23e-43	Height;
CESC	cis	rs6570726	0.791	rs427128	chr6:145865917	T/C	cg23711669	chr6:146136114	FBXO30	1.02	15.62	0.69	2.01e-39	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01327474	chr16:28223637	XPO6	-0.65	-7.79	-0.43	1.52e-13	Gut microbiome composition (summer);
CESC	cis	rs7223966	1.000	rs9891018	chr17:61827856	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.57	6.74	0.38	9.83e-11	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs660498	0.507	rs2020155	chr10:27740194	C/T	cg25705717	chr10:27608719	NA	0.47	5.66	0.33	3.87e-8	Asthma (childhood onset);
CESC	cis	rs477895	0.713	rs12787852	chr11:63954648	G/A	cg04317338	chr11:64019027	PLCB3	0.9	9.42	0.5	2.3e-18	Mean platelet volume;
CESC	cis	rs7264396	0.733	rs6060515	chr20:34211779	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.87	-11.51	-0.58	3.98e-25	Total cholesterol levels;
CESC	trans	rs11165623	0.792	rs6701031	chr1:96975515	C/T	cg10631902	chr5:14652156	NA	-0.48	-7.0	-0.4	2.14e-11	Hip circumference;Waist circumference;
CESC	cis	rs3818285	0.610	rs642938	chr10:111633025	A/C	cg00817464	chr10:111662876	XPNPEP1	0.44	6.7	0.38	1.21e-10	Superior crus of antihelix expression;
CESC	cis	rs7666738	0.830	rs10007872	chr4:99001904	T/C	cg05340658	chr4:99064831	C4orf37	0.78	11.87	0.59	2.5e-26	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1983891	0.673	rs9369296	chr6:41570251	A/G	cg20194872	chr6:41519635	FOXP4	0.43	6.09	0.35	3.86e-9	Prostate cancer;
CESC	trans	rs61931739	0.500	rs11053272	chr12:34547020	C/G	cg26384229	chr12:38710491	ALG10B	0.72	10.84	0.55	6.43e-23	Morning vs. evening chronotype;
CESC	cis	rs8141529	0.748	rs132533	chr22:29299571	A/G	cg02153584	chr22:29168773	CCDC117	-0.57	-7.19	-0.4	6.52e-12	Lymphocyte counts;
CESC	cis	rs9467711	0.606	rs9379875	chr6:26444732	C/T	cg14345882	chr6:26364793	BTN3A2	0.63	5.85	0.34	1.42e-8	Autism spectrum disorder or schizophrenia;
CESC	cis	rs3820928	0.845	rs13415319	chr2:227878936	G/C	cg05526886	chr2:227700861	RHBDD1	-0.43	-5.21	-0.3	3.85e-7	Pulmonary function;
CESC	cis	rs35306767	0.953	rs10904581	chr10:964685	A/T	cg10556349	chr10:835070	NA	0.53	5.75	0.33	2.5e-8	Eosinophil percentage of granulocytes;
CESC	cis	rs2051211	0.947	rs60479981	chr3:38568611	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.66	-7.44	-0.42	1.37e-12	QRS duration;
CESC	cis	rs9549260	0.755	rs7989711	chr13:41215696	C/T	cg21288729	chr13:41239152	FOXO1	0.65	8.62	0.47	6.27e-16	Red blood cell count;
CESC	cis	rs9733	0.628	rs72700895	chr1:150626029	C/T	cg04414720	chr1:150670196	GOLPH3L	0.63	9.04	0.49	3.47e-17	Tonsillectomy;
CESC	cis	rs875971	0.964	rs778721	chr7:65845397	C/G	cg11764359	chr7:65958608	NA	0.98	15.79	0.7	4.82e-40	Aortic root size;
CESC	cis	rs889312	0.500	rs832580	chr5:56172646	T/C	cg14703610	chr5:56206110	C5orf35	0.48	6.19	0.36	2.29e-9	Breast cancer;Breast cancer (early onset);
CESC	cis	rs7949030	0.688	rs2849031	chr11:62365665	G/A	cg13298116	chr11:62369859	EML3;MTA2	-0.62	-9.16	-0.49	1.43e-17	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs2228479	0.850	rs62056103	chr16:89942781	G/A	cg06558623	chr16:89946397	TCF25	1.13	8.89	0.48	9.9900000000000006e-17	Skin colour saturation;
CESC	cis	rs3126085	0.935	rs74129461	chr1:152285099	C/T	cg03465714	chr1:152285911	FLG	0.5	5.71	0.33	2.96e-8	Atopic dermatitis;
CESC	cis	rs506597	1.000	rs564449	chr7:100321138	G/T	cg10426581	chr7:100472382	SRRT	0.61	5.1	0.3	6.36e-7	Pursuit maintenance gain in psychotic disorders;
CESC	cis	rs875971	0.964	rs60193905	chr7:65971260	A/G	cg18876405	chr7:65276391	NA	0.49	6.52	0.37	3.49e-10	Aortic root size;
CESC	cis	rs60843830	1.000	rs62114501	chr2:231741	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.88	11.69	0.58	9.5e-26	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs5753037	0.702	rs249398	chr22:30214704	G/C	cg01021169	chr22:30184971	ASCC2	-0.47	-6.72	-0.38	1.13e-10	Type 1 diabetes;
CESC	cis	rs3026101	0.671	rs1065482	chr17:5284719	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.44	5.89	0.34	1.18e-8	Body mass index;
CESC	cis	rs7100689	0.646	rs6585967	chr10:82139791	A/G	cg00277334	chr10:82204260	NA	0.56	7.24	0.41	4.89e-12	Post bronchodilator FEV1;
CESC	trans	rs7615952	0.551	rs12695470	chr3:125635718	C/A	cg07211511	chr3:129823064	LOC729375	-1.1	-13.63	-0.64	2.03e-32	Blood pressure (smoking interaction);
CESC	cis	rs6546537	0.869	rs35024605	chr2:69820332	A/G	cg10773587	chr2:69614142	GFPT1	-0.55	-6.78	-0.38	7.79e-11	Serum thyroid-stimulating hormone levels;
CESC	cis	rs4595586	0.545	rs12813151	chr12:39363405	C/G	cg26384229	chr12:38710491	ALG10B	-0.52	-7.09	-0.4	1.19e-11	Morning vs. evening chronotype;
CESC	cis	rs2832191	0.755	rs2832193	chr21:30493589	T/C	cg24692254	chr21:30365293	RNF160	-0.79	-11.89	-0.59	2e-26	Dental caries;
CESC	cis	rs875971	0.830	rs778715	chr7:65849209	C/T	cg18252515	chr7:66147081	NA	-0.43	-5.59	-0.32	5.73e-8	Aortic root size;
CESC	cis	rs9527	0.830	rs11191442	chr10:104643596	T/A	cg04362960	chr10:104952993	NT5C2	0.44	5.18	0.3	4.38e-7	Arsenic metabolism;
CESC	cis	rs10504229	0.861	rs57942497	chr8:58171239	G/T	cg05313129	chr8:58192883	C8orf71	-0.55	-6.37	-0.36	8.42e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs12497850	0.931	rs4974079	chr3:48906469	T/G	cg03060546	chr3:49711283	APEH	0.45	5.5	0.32	9e-8	Parkinson's disease;
CESC	trans	rs9693444	0.898	rs4732697	chr8:29519861	A/G	cg11122148	chr13:45150705	TSC22D1	-0.42	-6.31	-0.36	1.13e-9	Breast cancer;
CESC	cis	rs4689388	0.926	rs10937720	chr4:6295451	A/G	cg14416269	chr4:6271139	WFS1	0.46	7.76	0.43	1.79e-13	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs7833790	0.927	rs61020899	chr8:82757090	C/T	cg17211192	chr8:82754475	SNX16	0.69	8.29	0.45	5.83e-15	Diastolic blood pressure;
CESC	cis	rs6547741	0.717	rs2178197	chr2:27860551	C/T	cg27432699	chr2:27873401	GPN1	0.57	8.46	0.46	1.81e-15	Oral cavity cancer;
CESC	cis	rs2797160	0.515	rs9375409	chr6:125972798	A/G	cg05901451	chr6:126070800	HEY2	-0.38	-5.27	-0.31	2.83e-7	Endometrial cancer;
CESC	cis	rs116095464	0.558	rs13354585	chr5:242263	G/C	cg12570787	chr5:219185	SDHA;CCDC127	0.5	5.33	0.31	2.15e-7	Breast cancer;
CESC	cis	rs7100689	0.556	rs10788541	chr10:82016530	T/G	cg09936400	chr10:82049201	MAT1A	0.35	5.2	0.3	4.02e-7	Post bronchodilator FEV1;
CESC	cis	rs561341	1.000	rs55736640	chr17:30333848	G/A	cg00745463	chr17:30367425	LRRC37B	-0.88	-7.77	-0.43	1.78e-13	Hip circumference adjusted for BMI;
CESC	cis	rs1808579	0.904	rs1618725	chr18:21126952	C/T	cg14672496	chr18:21087552	C18orf8	0.41	5.94	0.34	8.82e-9	Hip circumference;Body mass index;BMI (adjusted for smoking behaviour);
CESC	cis	rs7809950	0.530	rs34021916	chr7:106817901	A/G	cg23024343	chr7:107201750	COG5	-0.5	-6.33	-0.36	1.05e-9	Coronary artery disease;
CESC	trans	rs11098499	0.779	rs6815934	chr4:120267310	T/C	cg25214090	chr10:38739885	LOC399744	0.59	8.14	0.45	1.55e-14	Corneal astigmatism;
CESC	trans	rs864643	0.773	rs11129837	chr3:39589963	A/G	cg06237717	chr12:95467511	NR2C1	0.49	6.35	0.36	9.17e-10	Attention deficit hyperactivity disorder;
CESC	cis	rs7666738	0.893	rs11729640	chr4:99052699	C/T	cg03467027	chr4:99064603	C4orf37	0.47	5.98	0.34	7.19e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7208859	0.673	rs11657270	chr17:29214387	A/G	cg19761014	chr17:28927070	LRRC37B2	0.73	5.75	0.33	2.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs651907	0.535	rs17347156	chr3:101504674	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.45	5.98	0.34	7.14e-9	Colorectal cancer;
CESC	cis	rs634534	0.622	rs593525	chr11:65727799	T/C	cg02427764	chr11:65769310	BANF1;EIF1AD	0.67	9.39	0.5	2.89e-18	Sum eosinophil basophil counts;Eosinophil counts;
CESC	cis	rs3754214	0.823	rs496203	chr1:150270025	A/G	cg09579323	chr1:150459698	TARS2	-0.47	-6.18	-0.35	2.44e-9	Cerebrospinal fluid biomarker levels;
CESC	cis	rs17125944	0.505	rs75296244	chr14:53233218	G/A	cg13660082	chr14:53194042	PSMC6	-0.67	-5.83	-0.34	1.58e-8	Alzheimer's disease (late onset);
CESC	cis	rs7208859	0.524	rs73263982	chr17:28920624	T/C	cg19761014	chr17:28927070	LRRC37B2	0.8	7.38	0.41	2.04e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs875971	0.545	rs6961853	chr7:66002022	G/A	cg18876405	chr7:65276391	NA	0.5	5.89	0.34	1.16e-8	Aortic root size;
CESC	cis	rs909674	0.818	rs5750833	chr22:39843091	C/A	cg02038168	chr22:39784481	NA	-0.65	-8.1	-0.45	2.03e-14	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs853679	0.550	rs1233704	chr6:28166923	A/G	cg23281280	chr6:28129359	ZNF389	-0.48	-6.82	-0.39	6.24e-11	Depression;
CESC	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.42	-6.33	-0.36	1.02e-9	Longevity;Endometriosis;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg16303825	chr3:10362878	SEC13	-0.45	-6.25	-0.36	1.6e-9	Fibrinogen levels;
CESC	cis	rs2985684	0.894	rs4900932	chr14:50022928	A/G	cg02151108	chr14:50098012	C14orf104	-0.39	-5.31	-0.31	2.36e-7	Carotid intima media thickness;
CESC	cis	rs2408955	0.501	rs8716	chr12:48539482	T/G	cg24011408	chr12:48396354	COL2A1	0.5	7.6	0.42	5.27e-13	Glycated hemoglobin levels;
CESC	trans	rs916888	0.773	rs199457	chr17:44795469	C/T	cg07870213	chr5:140052090	DND1	0.65	6.81	0.39	6.37e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs6459804	1.000	rs6459804	chr7:157510195	C/T	cg05731713	chr7:157510257	PTPRN2	0.39	6.61	0.38	2.06e-10	Bipolar disorder and schizophrenia;
CESC	cis	rs9611565	0.765	rs132915	chr22:41805782	T/C	cg17376030	chr22:41985996	PMM1	-0.59	-6.24	-0.36	1.69e-9	Vitiligo;
CESC	trans	rs10776614	0.799	rs1965170	chr10:49764417	C/A	cg19218067	chr2:181235115	NA	0.49	6.0	0.35	6.35e-9	Self-employment;
CESC	cis	rs769267	0.929	rs2905431	chr19:19482882	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.59	-7.67	-0.43	3.25e-13	Tonsillectomy;
CESC	cis	rs7824557	0.652	rs12677504	chr8:11133175	G/A	cg21775007	chr8:11205619	TDH	-0.47	-6.95	-0.39	2.78e-11	Retinal vascular caliber;
CESC	cis	rs7811142	0.830	rs77861211	chr7:99962096	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.69	6.31	0.36	1.14e-9	Platelet count;
CESC	cis	rs67478160	0.679	rs7156834	chr14:104211180	G/A	cg08213375	chr14:104286397	PPP1R13B	0.54	10.85	0.55	6.32e-23	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11331422	chr19:10491258	TYK2	0.54	6.47	0.37	4.72e-10	Gut microbiome composition (summer);
CESC	cis	rs9649465	0.935	rs3807636	chr7:123368488	G/A	cg04330084	chr7:123175371	IQUB	-0.39	-5.23	-0.31	3.47e-7	Migraine;
CESC	cis	rs2933343	0.700	rs1680788	chr3:128625318	C/T	cg24203234	chr3:128598194	ACAD9	0.39	5.25	0.31	3.19e-7	IgG glycosylation;
CESC	cis	rs3096299	0.685	rs4238830	chr16:89540241	C/T	cg02034447	chr16:89574710	SPG7	0.52	6.66	0.38	1.6e-10	Multiple myeloma (IgH translocation);
CESC	cis	rs35160687	0.623	rs13005014	chr2:86487216	T/C	cg01119172	chr2:86362222	SNORD94;PTCD3	-0.39	-5.18	-0.3	4.34e-7	Night sleep phenotypes;
CESC	cis	rs9733	0.596	rs2867300	chr1:150666990	C/G	cg22823121	chr1:150693482	HORMAD1	0.47	6.84	0.39	5.33e-11	Tonsillectomy;
CESC	cis	rs9303401	0.614	rs34550282	chr17:57092788	G/A	cg12560992	chr17:57184187	TRIM37	0.5	5.26	0.31	2.91e-7	Cognitive test performance;
CESC	cis	rs9457247	1.000	rs430097	chr6:167405073	A/G	cg25258033	chr6:167368657	RNASET2	0.39	5.88	0.34	1.26e-8	Crohn's disease;
CESC	cis	rs35110281	0.744	rs162395	chr21:44945759	T/C	cg01579765	chr21:45077557	HSF2BP	-0.55	-9.54	-0.51	9.94e-19	Mean corpuscular volume;
CESC	cis	rs6032067	0.929	rs2233895	chr20:43850143	T/A	cg10761708	chr20:43804764	PI3	0.5	6.12	0.35	3.3e-9	Blood protein levels;
CESC	cis	rs7666738	0.830	rs1025203	chr4:99023073	G/A	cg03467027	chr4:99064603	C4orf37	0.46	5.66	0.33	3.91e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs8114671	0.562	rs6087651	chr20:33518353	C/T	cg24642439	chr20:33292090	TP53INP2	0.43	5.19	0.3	4.19e-7	Height;
CESC	cis	rs4474465	1.000	rs7131199	chr11:78192148	T/G	cg02023728	chr11:77925099	USP35	0.39	5.06	0.3	7.93e-7	Alzheimer's disease (survival time);
CESC	cis	rs9308433	0.505	rs958304	chr1:214474241	C/T	cg06198575	chr1:214491504	SMYD2	0.5	5.94	0.34	8.72e-9	IgG glycosylation;
CESC	cis	rs921968	0.643	rs545460	chr2:219392159	A/G	cg02176678	chr2:219576539	TTLL4	0.4	6.93	0.39	3.22e-11	Mean corpuscular hemoglobin concentration;
CESC	cis	rs7618915	0.571	rs6778844	chr3:52596398	C/T	cg05564831	chr3:52568323	NT5DC2	-0.46	-6.82	-0.39	6.21e-11	Bipolar disorder;
CESC	cis	rs3768617	0.510	rs3768622	chr1:183090011	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.86	13.3	0.63	2.81e-31	Fuchs's corneal dystrophy;
CESC	cis	rs11676348	0.791	rs6726126	chr2:218952233	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.42	-5.59	-0.32	5.59e-8	Ulcerative colitis;
CESC	cis	rs736408	0.522	rs6445535	chr3:52771468	T/C	cg18337363	chr3:52569053	NT5DC2	0.28	5.13	0.3	5.59e-7	Bipolar disorder;
CESC	cis	rs875971	0.862	rs6978028	chr7:65886300	G/C	cg10691866	chr7:65817282	TPST1	-0.33	-5.43	-0.32	1.3e-7	Aortic root size;
CESC	cis	rs2832077	1.000	rs2832077	chr21:30141021	G/A	cg03476357	chr21:30257390	N6AMT1	-0.5	-5.43	-0.32	1.3e-7	Cognitive test performance;
CESC	cis	rs1538970	0.781	rs11211139	chr1:46015751	G/T	cg24296786	chr1:45957014	TESK2	-0.48	-5.14	-0.3	5.38e-7	Platelet count;
CESC	cis	rs2933343	0.729	rs813732	chr3:128619357	C/T	cg24203234	chr3:128598194	ACAD9	0.4	5.26	0.31	3.05e-7	IgG glycosylation;
CESC	cis	rs35146811	0.807	rs6953441	chr7:99617067	G/A	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.49	6.06	0.35	4.59e-9	Coronary artery disease;
CESC	cis	rs35306767	0.903	rs11812523	chr10:915638	C/T	cg25019033	chr10:957182	NA	-0.59	-6.34	-0.36	9.88e-10	Eosinophil percentage of granulocytes;
CESC	cis	rs7429990	0.965	rs9811277	chr3:48011638	A/G	cg11946769	chr3:48343235	NME6	0.44	5.36	0.31	1.83e-7	Educational attainment (years of education);
CESC	cis	rs3820068	0.705	rs2145396	chr1:15875184	A/G	cg17385448	chr1:15911702	AGMAT	0.36	5.62	0.33	4.77e-8	Systolic blood pressure;
CESC	cis	rs4727963	0.846	rs11772178	chr7:122707928	C/G	cg03640110	chr7:122635026	TAS2R16	-0.37	-5.7	-0.33	3.11e-8	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
CESC	trans	rs637571	0.522	rs493899	chr11:65747952	A/C	cg17712092	chr4:129076599	LARP1B	0.72	9.97	0.52	4.26e-20	Eosinophil percentage of white cells;
CESC	cis	rs11785400	0.793	rs2976399	chr8:143746050	C/T	cg10596483	chr8:143751796	JRK	0.42	5.26	0.31	2.94e-7	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05312278	chr15:43803195	TP53BP1	0.61	7.0	0.4	2.1e-11	Gut microbiome composition (summer);
CESC	cis	rs898097	0.607	rs2199111	chr17:80823203	A/G	cg10494973	chr17:80897199	TBCD	0.42	5.07	0.3	7.45e-7	Breast cancer;
CESC	trans	rs561341	0.883	rs2074102	chr17:30228884	G/A	cg20587970	chr11:113659929	NA	-1.08	-13.07	-0.63	1.8e-30	Hip circumference adjusted for BMI;
CESC	cis	rs7666738	0.830	rs7686456	chr4:99019695	T/C	cg18180107	chr4:99064573	C4orf37	0.41	5.39	0.31	1.57e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2806561	0.765	rs641032	chr1:23513980	C/T	cg12483005	chr1:23474871	LUZP1	-0.38	-5.97	-0.34	7.77e-9	Height;
CESC	cis	rs734999	0.566	rs6664969	chr1:2534978	G/A	cg20673091	chr1:2541236	MMEL1	0.45	7.53	0.42	8.17e-13	Ulcerative colitis;
CESC	cis	rs7264396	0.580	rs2425181	chr20:34447709	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.85	-9.39	-0.5	2.81e-18	Total cholesterol levels;
CESC	cis	rs4665809	0.627	rs35461456	chr2:26482361	C/G	cg26119090	chr2:26468346	HADHA;HADHB	1.1	12.71	0.62	3.31e-29	Gut microbiome composition (summer);
CESC	cis	rs1552244	0.935	rs7618815	chr3:10151045	A/G	cg00149659	chr3:10157352	C3orf10	0.73	8.81	0.48	1.65e-16	Alzheimer's disease;
CESC	cis	rs5769765	1.000	rs5770741	chr22:50270215	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.46	5.32	0.31	2.21e-7	Schizophrenia;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg10704137	chr6:25732153	NA	0.46	6.58	0.37	2.5e-10	Fibrinogen levels;
CESC	cis	rs5769765	0.565	rs8137232	chr22:50256885	G/C	cg02269571	chr22:50332266	NA	0.46	5.46	0.32	1.08e-7	Schizophrenia;
CESC	cis	rs514406	0.825	rs1242328	chr1:53396869	A/G	cg25767906	chr1:53392781	SCP2	-0.44	-5.51	-0.32	8.62e-8	Monocyte count;
CESC	cis	rs8114671	0.562	rs6120757	chr20:33488771	C/T	cg07148914	chr20:33460835	GGT7	0.48	6.31	0.36	1.18e-9	Height;
CESC	cis	rs6570726	0.791	rs6923074	chr6:145893332	T/C	cg05347473	chr6:146136440	FBXO30	0.59	7.63	0.42	4.24e-13	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2243480	1.000	rs2465120	chr7:65620974	C/G	cg12463550	chr7:65579703	CRCP	0.73	5.71	0.33	3.1e-8	Diabetic kidney disease;
CESC	cis	rs660899	0.595	rs37455	chr1:44294228	A/G	cg19743044	chr1:44115203	KDM4A	0.47	6.0	0.35	6.4e-9	Hypertension risk in short sleep duration;
CESC	cis	rs60843830	0.633	rs1078763	chr2:113763	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	-0.47	-5.71	-0.33	3.07e-8	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs17039065	1.000	rs72889372	chr4:109387298	A/G	cg16022748	chr4:109541635	LOC285456;RPL34	0.6	5.07	0.3	7.55e-7	Gut microbiome composition (summer);
CESC	cis	rs1799949	0.930	rs2298861	chr17:41176831	G/A	cg23758822	chr17:41437982	NA	1.03	14.68	0.67	3.99e-36	Menopause (age at onset);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg00358220	chr18:3247473	MYL12A	-0.47	-6.41	-0.37	6.48e-10	Fibrinogen levels;
CESC	cis	rs977987	0.843	rs6564259	chr16:75447393	T/G	cg03315344	chr16:75512273	CHST6	0.41	5.83	0.34	1.59e-8	Dupuytren's disease;
CESC	cis	rs910316	1.000	rs11159117	chr14:75584867	C/T	cg11812906	chr14:75593930	NEK9	0.9	15.46	0.69	7.06e-39	Height;
CESC	cis	rs10256972	0.524	rs6945202	chr7:1116558	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.39	-5.65	-0.33	4.23e-8	Longevity;Endometriosis;
CESC	cis	rs61656020	1	rs61656020	chr16:1882221	C/G	cg03013636	chr16:1946785	NA	0.4	5.52	0.32	8.17e-8	Ankle injury;
CESC	cis	rs6142102	0.625	rs4243974	chr20:32547868	T/C	cg08999081	chr20:33150536	PIGU	0.34	5.11	0.3	6.04e-7	Skin pigmentation;
CESC	cis	rs9359856	0.529	rs56352205	chr6:90439272	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.62	-5.88	-0.34	1.23e-8	Bipolar disorder;
CESC	cis	rs1153858	0.945	rs1974981	chr15:45729123	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.37	-5.05	-0.3	8.25e-7	Homoarginine levels;
CESC	cis	rs7542091	1.000	rs7542091	chr1:210031948	G/C	cg23283495	chr1:209979779	IRF6	0.32	5.07	0.3	7.37e-7	Monobrow;
CESC	cis	rs6089829	0.962	rs4997812	chr20:61663153	T/G	cg03213289	chr20:61660250	NA	0.4	6.13	0.35	3.1e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs40363	0.645	rs250629	chr16:3525431	C/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.55	-7.1	-0.4	1.13e-11	Tuberculosis;
CESC	cis	rs8017423	0.647	rs4904674	chr14:90817412	G/A	cg14092571	chr14:90743983	NA	0.44	6.62	0.38	1.93e-10	Mortality in heart failure;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg05135541	chr1:150039387	VPS45	-0.45	-7.21	-0.4	5.92e-12	Gambling;
CESC	cis	rs12136530	0.550	rs10753560	chr1:19708577	T/C	cg01832549	chr1:19774989	CAPZB	0.46	6.06	0.35	4.62e-9	Lead levels in blood;
CESC	cis	rs9926296	0.533	rs12102290	chr16:89812617	C/T	cg04287289	chr16:89883240	FANCA	0.92	16.38	0.71	3.91e-42	Vitiligo;
CESC	cis	rs5769765	0.773	rs9616395	chr22:50317803	A/G	cg02269571	chr22:50332266	NA	-0.63	-6.78	-0.38	7.82e-11	Schizophrenia;
CESC	cis	rs9790314	0.902	rs9863590	chr3:161116445	T/C	cg03342759	chr3:160939853	NMD3	-0.43	-5.5	-0.32	9.09e-8	Morning vs. evening chronotype;
CESC	cis	rs80033912	0.713	rs7629936	chr3:49836707	G/A	cg03060546	chr3:49711283	APEH	0.61	6.68	0.38	1.43e-10	Intelligence (multi-trait analysis);
CESC	cis	rs67311347	1.000	rs11707278	chr3:40487075	A/T	cg24209194	chr3:40518798	ZNF619	0.5	6.31	0.36	1.18e-9	Renal cell carcinoma;
CESC	cis	rs4722166	0.695	rs56061963	chr7:22800397	T/C	cg05472934	chr7:22766657	IL6	0.63	8.29	0.45	5.71e-15	Lung cancer;
CESC	cis	rs4919044	0.808	rs835256	chr10:94779550	C/T	cg16508068	chr10:94451736	HHEX	-0.5	-5.49	-0.32	9.61e-8	Coronary artery disease;
CESC	trans	rs650950	0.528	rs646660	chr11:35528452	C/T	cg12121965	chr21:46293563	PTTG1IP	0.52	7.05	0.4	1.51e-11	Bronchopulmonary dysplasia;
CESC	trans	rs11039798	1.000	rs11039978	chr11:48760237	A/G	cg15704280	chr7:45808275	SEPT13	0.7	6.42	0.37	6.38e-10	Axial length;
CESC	cis	rs7084402	0.967	rs1658470	chr10:60292383	A/G	cg07615347	chr10:60278583	BICC1	0.6	9.41	0.5	2.54e-18	Refractive error;
CESC	cis	rs2286503	1.000	rs2286498	chr7:22857504	C/T	cg13679077	chr7:22862647	TOMM7	-0.39	-5.08	-0.3	7.24e-7	Fibrinogen;
CESC	cis	rs875971	0.545	rs313830	chr7:65551931	T/C	cg19163074	chr7:65112434	INTS4L2	0.52	5.35	0.31	1.87e-7	Aortic root size;
CESC	cis	rs7666738	0.753	rs10004827	chr4:99037953	A/C	cg17366294	chr4:99064904	C4orf37	0.61	8.77	0.47	2.27e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs644799	0.635	rs10831428	chr11:95508404	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.78	11.68	0.58	1.03e-25	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs6456156	0.586	rs12525855	chr6:167480013	T/G	cg07741184	chr6:167504864	NA	0.35	6.11	0.35	3.53e-9	Primary biliary cholangitis;
CESC	cis	rs9911578	1.000	rs2531734	chr17:56550804	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	-0.41	-5.41	-0.32	1.38e-7	Intelligence (multi-trait analysis);
CESC	cis	rs703842	0.928	rs724834	chr12:58180416	G/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.71	8.89	0.48	9.48e-17	Multiple sclerosis;
CESC	cis	rs3892630	0.817	rs35408716	chr19:33187961	A/C	cg13157960	chr19:33183277	NUDT19	0.55	5.39	0.31	1.58e-7	Red blood cell traits;
CESC	cis	rs5743618	0.537	rs10470854	chr4:38768533	A/G	cg02016764	chr4:38805732	TLR1	-0.32	-5.1	-0.3	6.49e-7	Asthma;Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs769267	0.965	rs2074303	chr19:19381755	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	7.36	0.41	2.27e-12	Tonsillectomy;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg02607779	chr2:208030673	KLF7	0.46	6.46	0.37	5e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs11077998	0.933	rs2291395	chr17:80526139	A/G	cg10255544	chr17:80519551	FOXK2	0.54	8.65	0.47	4.87e-16	Reticulocyte fraction of red cells;
CESC	cis	rs12477438	0.520	rs11677247	chr2:99756358	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.85	15.81	0.7	4.17e-40	Chronic sinus infection;
CESC	cis	rs4665809	1.000	rs6704930	chr2:26325705	G/A	cg25036284	chr2:26402008	FAM59B	-0.59	-6.77	-0.38	8.41e-11	Gut microbiome composition (summer);
CESC	cis	rs1552244	0.882	rs13063098	chr3:10009919	G/A	cg08888203	chr3:10149979	C3orf24	0.47	5.82	0.34	1.7e-8	Alzheimer's disease;
CESC	cis	rs6582630	0.537	rs66855609	chr12:38299029	T/C	cg26384229	chr12:38710491	ALG10B	0.63	9.25	0.49	7.58e-18	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs597539	0.652	rs646586	chr11:68681653	C/T	cg21963583	chr11:68658836	MRPL21	-0.36	-5.18	-0.3	4.37e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04876968	chr17:30771485	PSMD11	0.54	6.18	0.35	2.36e-9	Gut microbiome composition (summer);
CESC	cis	rs1218582	0.774	rs1007170	chr1:154881461	G/A	cg06221963	chr1:154839813	KCNN3	-0.7	-12.07	-0.6	4.9e-27	Prostate cancer;
CESC	cis	rs7959452	0.530	rs12811632	chr12:69755003	G/A	cg20891283	chr12:69753455	YEATS4	0.87	13.83	0.65	3.99e-33	Blood protein levels;
CESC	cis	rs35306767	0.903	rs12264711	chr10:929525	T/C	cg10556349	chr10:835070	NA	0.57	5.58	0.32	6.05e-8	Eosinophil percentage of granulocytes;
CESC	cis	rs9811920	0.570	rs1021102	chr3:99603780	T/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.64	10.11	0.53	1.53e-20	Axial length;
CESC	cis	rs4665809	1.000	rs10202478	chr2:26276049	T/C	cg27170947	chr2:26402098	FAM59B	-0.68	-7.96	-0.44	5.12e-14	Gut microbiome composition (summer);
CESC	cis	rs2295359	1.000	rs10889661	chr1:67625309	T/A	cg03340356	chr1:67600835	NA	0.33	5.42	0.32	1.37e-7	Psoriasis;
CESC	cis	rs7666738	0.791	rs2903142	chr4:99040071	C/T	cg03676636	chr4:99064102	C4orf37	0.33	5.12	0.3	5.93e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4713118	0.587	rs61471148	chr6:28037032	T/A	cg12963246	chr6:28129442	ZNF389	0.55	6.89	0.39	4.12e-11	Parkinson's disease;
CESC	cis	rs870825	0.616	rs6552806	chr4:185638231	C/T	cg04058563	chr4:185651563	MLF1IP	0.62	6.86	0.39	4.91e-11	Blood protein levels;
CESC	cis	rs10504229	0.683	rs67077711	chr8:58139769	G/T	cg24829409	chr8:58192753	C8orf71	-0.59	-7.31	-0.41	3.16e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs4737010	0.501	rs2111805	chr8:41643457	G/C	cg08923054	chr8:41654455	ANK1	0.63	7.73	0.43	2.23e-13	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03651904	chr19:2807229	THOP1	-0.61	-6.71	-0.38	1.17e-10	Gut microbiome composition (summer);
CESC	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.4	5.05	0.3	8.12e-7	Lymphocyte counts;
CESC	cis	rs2456568	0.709	rs12806128	chr11:93634972	C/T	cg26875233	chr11:93583750	C11orf90	0.28	5.03	0.3	8.9e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
CESC	cis	rs7116495	1.000	rs607446	chr11:71789252	G/A	cg26138937	chr11:71823887	C11orf51	-0.84	-6.79	-0.38	7.37e-11	Severe influenza A (H1N1) infection;
CESC	cis	rs1371867	0.846	rs1660353	chr8:101250907	C/T	cg11906718	chr8:101322791	RNF19A	-0.41	-5.24	-0.31	3.29e-7	Atrioventricular conduction;
CESC	cis	rs12701220	0.590	rs1881124	chr7:1096766	A/C	cg26769984	chr7:1090371	C7orf50	0.57	5.89	0.34	1.19e-8	Bronchopulmonary dysplasia;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg01934962	chr17:19881077	AKAP10	-0.49	-6.28	-0.36	1.41e-9	Asthma;
CESC	cis	rs9486719	0.895	rs12195315	chr6:96905711	T/G	cg18709589	chr6:96969512	KIAA0776	-0.56	-6.11	-0.35	3.51e-9	Migraine;Coronary artery disease;
CESC	cis	rs6460942	1.000	rs7808819	chr7:12297440	C/T	cg06484146	chr7:12443880	VWDE	-0.77	-8.1	-0.45	2.06e-14	Coronary artery disease;
CESC	cis	rs8077577	0.747	rs11078415	chr17:18255498	C/T	cg16794390	chr17:18148240	FLII	0.41	6.31	0.36	1.17e-9	Obesity-related traits;
CESC	cis	rs4237845	0.537	rs11172367	chr12:58272486	T/G	cg02175503	chr12:58329896	NA	0.5	6.04	0.35	5.06e-9	Intelligence (multi-trait analysis);
CESC	cis	rs9584850	0.834	rs7334078	chr13:99120484	C/T	cg20750642	chr13:99100586	FARP1	0.36	5.45	0.32	1.18e-7	Neuroticism;
CESC	cis	rs11645898	0.935	rs4788615	chr16:72192372	G/A	cg14768367	chr16:72042858	DHODH	-0.79	-6.58	-0.37	2.51e-10	Blood protein levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17563338	chr3:125093799	ZNF148	0.63	7.06	0.4	1.42e-11	Gut microbiome composition (summer);
CESC	cis	rs2479106	0.549	rs7862469	chr9:126391268	T/G	cg16191174	chr9:126692580	DENND1A	0.39	5.49	0.32	9.18e-8	Polycystic ovary syndrome;
CESC	cis	rs35306767	0.855	rs11253499	chr10:944090	A/C	cg25019033	chr10:957182	NA	-0.57	-5.99	-0.35	6.93e-9	Eosinophil percentage of granulocytes;
CESC	cis	rs7615952	0.599	rs6803160	chr3:125709554	G/T	cg02807482	chr3:125708958	NA	-0.38	-5.08	-0.3	7.16e-7	Blood pressure (smoking interaction);
CESC	cis	rs2573652	1.000	rs2573650	chr15:100514097	A/G	cg09918751	chr15:100517450	ADAMTS17	0.39	7.51	0.42	8.89e-13	Height;
CESC	cis	rs6502050	0.529	rs35585236	chr17:80116641	T/C	cg11859384	chr17:80120422	CCDC57	-0.38	-5.17	-0.3	4.51e-7	Life satisfaction;
CESC	cis	rs2576037	0.526	rs2051292	chr18:44484372	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.64	-8.9	-0.48	9.08e-17	Personality dimensions;
CESC	cis	rs17253792	0.822	rs8018142	chr14:56173288	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.69	5.92	0.34	9.97e-9	Putamen volume;
CESC	trans	rs7726839	0.540	rs56325086	chr5:640728	G/A	cg25482853	chr8:67687455	SGK3	1.01	10.3	0.53	3.96e-21	Obesity-related traits;
CESC	trans	rs10242455	0.702	rs73713507	chr7:99138603	G/A	cg09045935	chr12:6379348	NA	0.9	7.0	0.4	2.04e-11	Blood metabolite levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05115182	chr10:99496889	ZFYVE27	0.62	7.59	0.42	5.52e-13	Gut microbiome composition (summer);
CESC	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg27588902	chr6:42928151	GNMT	-0.27	-5.04	-0.3	8.61e-7	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs17376456	0.825	rs10054903	chr5:93281491	C/A	cg25358565	chr5:93447407	FAM172A	1.12	10.36	0.54	2.45e-21	Diabetic retinopathy;
CESC	cis	rs4423214	0.879	rs1792277	chr11:71138918	C/T	cg05163923	chr11:71159392	DHCR7	-0.63	-7.28	-0.41	3.75e-12	Vitamin D levels;
CESC	cis	rs4689388	0.889	rs4629534	chr4:6294124	G/T	cg25554036	chr4:6271136	WFS1	0.51	8.34	0.46	4.21e-15	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	trans	rs747782	0.536	rs10838873	chr11:48337765	T/C	cg15704280	chr7:45808275	SEPT13	0.68	6.22	0.36	1.93e-9	Intraocular pressure;
CESC	cis	rs60871478	1.000	rs4720930	chr7:808073	G/A	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.54	5.34	0.31	1.98e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs3106136	0.967	rs72665658	chr4:95144761	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.46	-7.01	-0.4	1.94e-11	Capecitabine sensitivity;
CESC	cis	rs367615	0.506	rs2914684	chr5:108775110	C/T	cg17395555	chr5:108820864	NA	-0.58	-9.8	-0.52	1.46e-19	Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs6968419	0.755	rs2896180	chr7:115897871	A/G	cg02561103	chr7:115862891	TES	-0.44	-5.89	-0.34	1.14e-8	Intraocular pressure;
CESC	cis	rs1707322	0.682	rs10890335	chr1:46100394	G/C	cg05343316	chr1:45956843	TESK2	0.51	6.35	0.36	9.44e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs1670533	0.872	rs11727135	chr4:1051803	G/C	cg27284194	chr4:1044797	NA	0.42	5.17	0.3	4.53e-7	Recombination rate (females);
CESC	cis	rs10492096	0.947	rs61918020	chr12:6605514	C/T	cg13857086	chr12:6580257	VAMP1	0.61	6.14	0.35	3.03e-9	Hip geometry;
CESC	cis	rs9584850	0.834	rs9584855	chr13:99119000	G/T	cg20750642	chr13:99100586	FARP1	0.37	5.73	0.33	2.68e-8	Neuroticism;
CESC	trans	rs2075371	0.932	rs1862048	chr7:133978167	C/G	cg26182263	chr8:22224973	SLC39A14	0.48	6.24	0.36	1.72e-9	Mean platelet volume;
CESC	cis	rs344364	0.511	rs337284	chr16:1954799	A/C	cg26617929	chr16:1858877	NA	-0.51	-5.41	-0.32	1.44e-7	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs875971	0.545	rs1796217	chr7:66085918	A/G	cg11764359	chr7:65958608	NA	-0.8	-9.57	-0.51	7.7e-19	Aortic root size;
CESC	cis	rs10492096	0.947	rs11064227	chr12:6598043	A/G	cg13857086	chr12:6580257	VAMP1	0.62	6.19	0.36	2.24e-9	Hip geometry;
CESC	cis	rs8031584	0.560	rs1056118	chr15:31203786	G/A	cg19680485	chr15:31195859	MTMR15	0.47	5.66	0.33	3.92e-8	Huntington's disease progression;
CESC	cis	rs116095464	0.558	rs9654452	chr5:299561	C/T	cg20965017	chr5:231967	SDHA	-0.48	-5.41	-0.32	1.41e-7	Breast cancer;
CESC	cis	rs9910055	0.762	rs7213436	chr17:42252163	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	-0.37	-5.44	-0.32	1.19e-7	Total body bone mineral density;
CESC	cis	rs644799	0.544	rs1527450	chr11:95467777	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.49	6.38	0.37	7.7e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs514406	0.760	rs475969	chr1:53292607	T/A	cg08859206	chr1:53392774	SCP2	-0.69	-10.44	-0.54	1.33e-21	Monocyte count;
CESC	cis	rs4253772	0.550	rs6008615	chr22:46707928	G/A	cg18190219	chr22:46762943	CELSR1	-0.59	-6.62	-0.38	1.94e-10	LDL cholesterol;Cholesterol, total;
CESC	cis	rs1552244	1.000	rs56394721	chr3:10150795	A/G	cg16606324	chr3:10149918	C3orf24	0.43	5.35	0.31	1.91e-7	Alzheimer's disease;
CESC	cis	rs6502050	0.835	rs9900072	chr17:80114360	C/G	cg11859384	chr17:80120422	CCDC57	-0.39	-5.34	-0.31	1.97e-7	Life satisfaction;
CESC	cis	rs738322	0.753	rs2267372	chr22:38598234	A/G	cg25457927	chr22:38595422	NA	0.32	5.83	0.34	1.57e-8	Cutaneous nevi;
CESC	cis	rs2239547	0.657	rs7620706	chr3:52891756	A/T	cg11645453	chr3:52864694	ITIH4	0.33	5.86	0.34	1.37e-8	Schizophrenia;
CESC	cis	rs11792861	0.851	rs17552292	chr9:111891954	C/T	cg13535736	chr9:111863775	C9orf5	-0.5	-6.61	-0.38	2.12e-10	Menarche (age at onset);
CESC	cis	rs35306767	0.903	rs12762228	chr10:880854	G/A	cg10556349	chr10:835070	NA	0.76	6.35	0.36	9.42e-10	Eosinophil percentage of granulocytes;
CESC	cis	rs7000551	0.688	rs2948145	chr8:22367792	T/C	cg12081754	chr8:22256438	SLC39A14	0.39	5.2	0.3	4.06e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CESC	cis	rs4713118	0.513	rs149954	chr6:28035246	G/A	cg23281280	chr6:28129359	ZNF389	0.4	5.8	0.34	1.88e-8	Parkinson's disease;
CESC	cis	rs11792861	0.926	rs12686736	chr9:111888739	A/G	cg13535736	chr9:111863775	C9orf5	-0.5	-6.5	-0.37	4.04e-10	Menarche (age at onset);
CESC	cis	rs37004	0.748	rs380145	chr5:1328897	C/T	cg07493874	chr5:1342172	CLPTM1L	-0.43	-5.54	-0.32	7.17e-8	Prostate-specific antigen levels;
CESC	cis	rs6964587	1.000	rs4265	chr7:91719608	A/G	cg17063962	chr7:91808500	NA	-0.56	-7.8	-0.43	1.39e-13	Breast cancer;
CESC	trans	rs9929218	0.954	rs4420522	chr16:68822971	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.62	-8.13	-0.45	1.69e-14	Colorectal cancer;
CESC	cis	rs11649653	0.502	rs4889490	chr16:30823047	A/C	cg02466173	chr16:30829666	NA	-0.42	-6.64	-0.38	1.81e-10	Triglycerides;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18146300	chr17:17184632	COPS3	-0.59	-6.78	-0.38	7.67e-11	Gut microbiome composition (summer);
CESC	cis	rs7395581	0.918	rs3847502	chr11:47333685	C/A	cg25783544	chr11:47291846	MADD	0.61	8.04	0.44	2.9e-14	HDL cholesterol;
CESC	cis	rs4423214	1.000	rs2002063	chr11:71163476	T/C	cg05163923	chr11:71159392	DHCR7	0.75	10.18	0.53	9.28e-21	Vitamin D levels;
CESC	cis	rs7927592	0.513	rs901823	chr11:68205578	T/C	cg01657329	chr11:68192670	LRP5	-0.56	-7.24	-0.41	4.81e-12	Total body bone mineral density;
CESC	cis	rs13191362	1.000	rs36113695	chr6:163004733	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.82	8.35	0.46	3.97e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs7580658	0.963	rs2090574	chr2:128131391	C/A	cg10021288	chr2:128175891	PROC	-0.41	-6.47	-0.37	4.66e-10	Protein C levels;
CESC	cis	rs2075371	1.000	rs432487	chr7:133990114	T/G	cg20476274	chr7:133979776	SLC35B4	0.65	9.41	0.5	2.53e-18	Mean platelet volume;
CESC	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	10.34	0.54	2.83e-21	Prudent dietary pattern;
CESC	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.52	6.52	0.37	3.49e-10	Prudent dietary pattern;
CESC	cis	rs9902453	0.791	rs28492945	chr17:28223982	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.7	9.07	0.49	2.73e-17	Coffee consumption (cups per day);
CESC	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg07677032	chr17:61819896	STRADA	0.5	6.7	0.38	1.27e-10	Prudent dietary pattern;
CESC	cis	rs703842	0.963	rs2069506	chr12:58142854	C/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.7	8.87	0.48	1.09e-16	Multiple sclerosis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26581886	chr22:17090862	psiTPTE22	-0.55	-7.1	-0.4	1.18e-11	Gut microbiome composition (summer);
CESC	cis	rs4803468	0.901	rs3745292	chr19:41888506	A/G	cg14132834	chr19:41945861	ATP5SL	-0.61	-7.79	-0.43	1.56e-13	Height;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg18045461	chr22:29601862	EMID1	-0.46	-6.14	-0.35	3.08e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs782590	0.608	rs10207590	chr2:55921782	G/C	cg18811423	chr2:55921094	PNPT1	-0.73	-11.35	-0.57	1.37e-24	Metabolic syndrome;
CESC	cis	rs73110464	0.609	rs727266	chr12:53356411	C/T	cg25025879	chr12:53359317	NA	-0.58	-7.72	-0.43	2.43e-13	Cancer (pleiotropy);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13047596	chr2:233735017	C2orf82	-0.6	-6.84	-0.39	5.41e-11	Gut microbiome composition (summer);
CESC	cis	rs2228479	0.717	rs1007932	chr16:89838541	C/T	cg04287289	chr16:89883240	FANCA	0.72	6.14	0.35	3.05e-9	Skin colour saturation;
CESC	cis	rs4819052	0.765	rs2838868	chr21:46714641	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.7	-8.1	-0.45	1.99e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs4704187	0.687	rs12653162	chr5:74391666	C/T	cg03227963	chr5:74354835	NA	0.32	5.93	0.34	9.57e-9	Response to amphetamines;
CESC	cis	rs2842992	0.789	rs2842969	chr6:160145364	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.72	8.98	0.48	5.29e-17	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs801193	1.000	rs2707856	chr7:66211010	A/T	cg25985355	chr7:65971099	NA	-0.31	-5.14	-0.3	5.4e-7	Aortic root size;
CESC	cis	rs7586673	0.866	rs747003	chr2:161916409	C/T	cg16506815	chr2:162101123	NA	-0.43	-5.96	-0.34	8.23e-9	Intelligence (multi-trait analysis);
CESC	cis	rs425277	0.585	rs3107143	chr1:2045372	G/C	cg23803603	chr1:2058230	PRKCZ	-0.35	-6.12	-0.35	3.38e-9	Height;
CESC	cis	rs7412746	0.611	rs2864873	chr1:150814174	A/G	cg04414720	chr1:150670196	GOLPH3L	0.56	7.41	0.41	1.68e-12	Melanoma;
CESC	cis	rs2645694	0.626	rs2703136	chr4:77828957	T/A	cg10057126	chr4:77819792	ANKRD56	0.6	8.46	0.46	1.79e-15	Emphysema distribution in smoking;
CESC	cis	rs941408	0.515	rs878893	chr19:2781325	A/G	cg02580895	chr19:2754563	NA	-0.41	-5.2	-0.3	3.97e-7	Total cholesterol levels;
CESC	cis	rs79839061	0.520	rs11730111	chr4:942833	C/T	cg07828340	chr4:882639	GAK	1.09	7.84	0.43	1.13e-13	Intelligence (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23561859	chr2:96931676	CIAO1;TMEM127	0.58	6.57	0.37	2.66e-10	Gut microbiome composition (summer);
CESC	cis	rs752010	0.630	rs11210507	chr1:42105488	T/C	cg06885757	chr1:42089581	HIVEP3	0.48	7.76	0.43	1.8e-13	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs1862618	0.853	rs2548665	chr5:56131805	T/A	cg03609598	chr5:56110824	MAP3K1	-0.54	-5.69	-0.33	3.42e-8	Initial pursuit acceleration;
CESC	cis	rs589448	0.902	rs315113	chr12:69786543	G/T	cg14784868	chr12:69753453	YEATS4	-0.74	-11.21	-0.57	3.99e-24	Cerebrospinal fluid biomarker levels;
CESC	trans	rs864643	0.773	rs11129837	chr3:39589963	A/G	cg14245309	chr7:75677153	STYXL1;MDH2	0.5	6.38	0.36	7.91e-10	Attention deficit hyperactivity disorder;
CESC	cis	rs1348850	0.915	rs10930798	chr2:178446141	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.61	8.31	0.45	5.02e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs769267	0.931	rs15622	chr19:19468734	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.43	-5.38	-0.31	1.64e-7	Tonsillectomy;
CESC	cis	rs1348850	0.958	rs4243390	chr2:178468008	G/A	cg23306229	chr2:178417860	TTC30B	0.61	8.12	0.45	1.76e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs6500395	0.962	rs9923371	chr16:48628015	C/T	cg04672837	chr16:48644449	N4BP1	0.52	6.64	0.38	1.81e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs7666738	0.830	rs6831219	chr4:98993576	C/A	cg18180107	chr4:99064573	C4orf37	0.4	5.23	0.31	3.41e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs875971	0.862	rs9791712	chr7:66105163	C/G	cg10691866	chr7:65817282	TPST1	0.31	5.07	0.3	7.31e-7	Aortic root size;
CESC	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg05025164	chr4:1340916	KIAA1530	0.87	11.81	0.59	3.81e-26	Longevity;
CESC	trans	rs1945213	0.694	rs7131381	chr11:55858158	T/G	cg03929089	chr4:120376271	NA	0.77	7.35	0.41	2.48e-12	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs7659604	0.540	rs67150579	chr4:122704331	T/A	cg19671926	chr4:122722719	EXOSC9	0.67	8.91	0.48	8.57e-17	Type 2 diabetes;
CESC	cis	rs9902453	1.000	rs4075623	chr17:28386526	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.62	-7.84	-0.43	1.08e-13	Coffee consumption (cups per day);
CESC	cis	rs7940866	0.838	rs12790299	chr11:130803634	A/G	cg12179176	chr11:130786555	SNX19	0.66	9.98	0.52	3.99e-20	Schizophrenia;
CESC	cis	rs17253792	0.822	rs10142757	chr14:56074211	C/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.79	5.91	0.34	1.06e-8	Putamen volume;
CESC	cis	rs8126001	0.573	rs7271530	chr20:62727915	A/G	cg07246713	chr20:62722933	OPRL1	-0.31	-5.15	-0.3	5.02e-7	Pulse pressure;Mean corpuscular volume;
CESC	cis	rs7618915	0.524	rs10433615	chr3:52638482	C/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	5.62	0.33	4.92e-8	Bipolar disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20070536	chr11:9335581	TMEM41B	-0.53	-6.35	-0.36	9.24e-10	Gut microbiome composition (summer);
CESC	cis	rs6840258	0.941	rs72667757	chr4:87946994	C/A	cg08197287	chr4:87952173	AFF1	-0.4	-5.12	-0.3	6.02e-7	Mean corpuscular volume;Basophil percentage of granulocytes;
CESC	cis	rs1862618	0.853	rs832553	chr5:56114786	A/G	cg22800045	chr5:56110881	MAP3K1	0.82	10.34	0.54	2.87e-21	Initial pursuit acceleration;
CESC	cis	rs2415984	0.562	rs12882684	chr14:46931802	C/T	cg14871534	chr14:47121158	RPL10L	0.4	5.74	0.33	2.63e-8	Number of children ever born;
CESC	cis	rs2230307	0.572	rs11166408	chr1:100641350	A/T	cg24955406	chr1:100503596	HIAT1	-0.5	-5.03	-0.3	9.2e-7	Carotid intima media thickness;
CESC	cis	rs897984	0.762	rs1870293	chr16:30970941	T/C	cg02466173	chr16:30829666	NA	0.52	8.55	0.46	1e-15	Dementia with Lewy bodies;
CESC	cis	rs6460942	0.915	rs62447640	chr7:12488282	A/T	cg20607287	chr7:12443886	VWDE	-0.77	-8.71	-0.47	3.35e-16	Coronary artery disease;
CESC	trans	rs1814175	0.534	rs1983448	chr11:49933856	C/A	cg03929089	chr4:120376271	NA	-0.92	-14.95	-0.68	4.61e-37	Height;
CESC	cis	rs4803468	1.000	rs17318666	chr19:41940342	T/G	cg14132834	chr19:41945861	ATP5SL	0.69	8.61	0.47	6.75e-16	Height;
CESC	cis	rs1023500	0.596	rs133352	chr22:42434022	C/A	cg15557168	chr22:42548783	NA	-0.44	-6.15	-0.35	2.8e-9	Schizophrenia;
CESC	cis	rs4588572	0.643	rs6874309	chr5:77774498	A/T	cg11547950	chr5:77652471	NA	0.46	5.78	0.33	2.11e-8	Triglycerides;
CESC	cis	rs9399135	0.967	rs6909975	chr6:135315570	C/T	cg22676075	chr6:135203613	NA	0.5	6.87	0.39	4.48e-11	Red blood cell count;
CESC	cis	rs6060717	0.536	rs8125393	chr20:34496162	G/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.64	5.45	0.32	1.15e-7	Hip circumference adjusted for BMI;
CESC	cis	rs4986811	1.000	rs7936152	chr11:32453622	A/G	cg27409910	chr11:32454216	WT1	-0.45	-6.04	-0.35	5.12e-9	Rubella-specific interleukin-6 secretion;
CESC	cis	rs4474465	0.679	rs10899537	chr11:78222424	C/G	cg27205649	chr11:78285834	NARS2	0.44	5.27	0.31	2.83e-7	Alzheimer's disease (survival time);
CESC	cis	rs6952808	0.689	rs58227534	chr7:2046328	A/G	cg08027265	chr7:2291960	NA	-0.36	-5.47	-0.32	1.05e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs1862618	0.511	rs2591952	chr5:56120769	T/A	cg22800045	chr5:56110881	MAP3K1	0.81	10.03	0.52	2.74e-20	Initial pursuit acceleration;
CESC	cis	rs36051895	0.632	rs7849717	chr9:5170080	G/A	cg02405213	chr9:5042618	JAK2	-0.51	-5.89	-0.34	1.17e-8	Pediatric autoimmune diseases;
CESC	cis	rs9733	0.596	rs1336898	chr1:150665050	G/A	cg22823121	chr1:150693482	HORMAD1	0.48	7.1	0.4	1.14e-11	Tonsillectomy;
CESC	cis	rs9837602	0.630	rs73138610	chr3:99683653	C/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.49	5.08	0.3	7.05e-7	Breast cancer;
CESC	cis	rs4780401	0.609	rs11639945	chr16:11824056	T/G	cg01061890	chr16:11836724	TXNDC11	-0.56	-7.71	-0.43	2.51e-13	Rheumatoid arthritis;
CESC	cis	rs7246865	0.510	rs3816549	chr19:17173937	G/A	cg16202187	chr19:17186497	HAUS8;MYO9B	0.48	6.28	0.36	1.38e-9	Reticulocyte fraction of red cells;
CESC	cis	rs3126085	0.935	rs877776	chr1:152178018	C/G	cg26876637	chr1:152193138	HRNR	0.46	5.33	0.31	2.06e-7	Atopic dermatitis;
CESC	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg07677032	chr17:61819896	STRADA	0.46	6.21	0.36	2.06e-9	Prudent dietary pattern;
CESC	trans	rs116095464	0.558	rs6874745	chr5:264527	A/G	cg00938859	chr5:1591904	SDHAP3	0.63	6.77	0.38	8.38e-11	Breast cancer;
CESC	cis	rs2404602	0.583	rs2469542	chr15:76557476	A/G	cg22467129	chr15:76604101	ETFA	0.38	5.95	0.34	8.43e-9	Blood metabolite levels;
CESC	cis	rs2963155	0.518	rs862489	chr5:142634355	T/C	cg17617527	chr5:142782415	NR3C1	0.84	7.84	0.43	1.08e-13	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17436476	chr1:62120002	NA	-0.5	-6.14	-0.35	3.06e-9	Gut microbiome composition (summer);
CESC	cis	rs7819412	0.807	rs10105315	chr8:10932203	G/C	cg21775007	chr8:11205619	TDH	-0.43	-6.04	-0.35	5.25e-9	Triglycerides;
CESC	cis	rs1862618	0.756	rs832548	chr5:56183637	G/C	cg12311346	chr5:56204834	C5orf35	-0.74	-8.81	-0.48	1.71e-16	Initial pursuit acceleration;
CESC	cis	rs13191362	0.935	rs67084568	chr6:162988548	C/A	cg21926612	chr6:163149169	PACRG;PARK2	0.86	8.98	0.48	5.03e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs9911578	1.000	rs4793950	chr17:56593111	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	-0.42	-5.63	-0.33	4.54e-8	Intelligence (multi-trait analysis);
CESC	trans	rs61931739	0.500	rs11053280	chr12:34559297	G/T	cg13010199	chr12:38710504	ALG10B	0.51	6.58	0.37	2.47e-10	Morning vs. evening chronotype;
CESC	cis	rs1348850	0.914	rs10170667	chr2:178336878	A/G	cg22681709	chr2:178499509	PDE11A	-0.44	-6.21	-0.36	2.1e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs9790314	0.875	rs336582	chr3:161082659	C/T	cg04691961	chr3:161091175	C3orf57	-0.39	-5.08	-0.3	7.17e-7	Morning vs. evening chronotype;
CESC	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg11494091	chr17:61959527	GH2	0.73	12.52	0.61	1.43e-28	Prudent dietary pattern;
CESC	cis	rs7296418	0.885	rs1716184	chr12:123637509	G/C	cg00376283	chr12:123451042	ABCB9	0.68	9.5	0.5	1.29e-18	Platelet count;
CESC	cis	rs11190604	1.000	rs2295770	chr10:102239829	G/A	cg07080220	chr10:102295463	HIF1AN	0.56	5.59	0.32	5.61e-8	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs7917772	0.599	rs2863717	chr10:104519829	A/G	cg04362960	chr10:104952993	NT5C2	0.46	5.27	0.31	2.86e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs9768139	0.566	rs729099	chr7:158114152	C/T	cg06219351	chr7:158114137	PTPRN2	-0.72	-12.01	-0.59	8.22e-27	Calcium levels;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg02838608	chr17:47438799	ZNF652	0.44	6.48	0.37	4.56e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	10.23	0.53	6.6e-21	Prudent dietary pattern;
CESC	cis	rs1215050	0.782	rs6532693	chr4:98655815	T/C	cg05340658	chr4:99064831	C4orf37	-0.47	-6.04	-0.35	5.08e-9	Waist-to-hip ratio adjusted for body mass index;
CESC	trans	rs17764205	0.777	rs10424519	chr19:3253532	C/G	cg12868887	chr11:70244470	CTTN	-0.75	-6.27	-0.36	1.43e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs7618915	0.571	rs34115864	chr3:52612178	A/G	cg17372223	chr3:52568218	NT5DC2	0.43	6.34	0.36	1e-9	Bipolar disorder;
CESC	cis	rs6690583	0.623	rs6700723	chr1:85514234	C/T	cg22488158	chr1:85528044	WDR63	0.53	5.38	0.31	1.63e-7	Serum sulfate level;
CESC	cis	rs763014	0.931	rs2071982	chr16:630405	T/G	cg09263875	chr16:632152	PIGQ	0.67	11.07	0.56	1.14e-23	Height;
CESC	cis	rs3096299	0.685	rs4329923	chr16:89560178	C/T	cg00750074	chr16:89608354	SPG7	-0.46	-6.85	-0.39	5.16e-11	Multiple myeloma (IgH translocation);
CESC	cis	rs853679	0.517	rs9380047	chr6:28037893	G/T	cg26335602	chr6:28129616	ZNF389	0.53	7.0	0.4	2.1e-11	Depression;
CESC	cis	rs12497850	1.000	rs6788650	chr3:48749543	T/C	cg07636037	chr3:49044803	WDR6	0.94	16.14	0.7	2.75e-41	Parkinson's disease;
CESC	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg24503407	chr1:205819492	PM20D1	0.81	13.38	0.63	1.55e-31	Menarche (age at onset);
CESC	cis	rs769267	0.864	rs7245983	chr19:19657632	A/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.45	5.76	0.33	2.34e-8	Tonsillectomy;
CESC	cis	rs1005277	0.579	rs2472176	chr10:38382921	T/C	cg25427524	chr10:38739819	LOC399744	-0.65	-9.48	-0.5	1.51e-18	Extrinsic epigenetic age acceleration;
CESC	cis	rs4727027	0.866	rs7778766	chr7:148806729	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.42	5.25	0.31	3.12e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg24098762	chr5:137667672	CDC25C	-0.54	-6.81	-0.39	6.48e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs9733	0.596	rs11582840	chr1:150688487	A/G	cg22823121	chr1:150693482	HORMAD1	0.48	7.11	0.4	1.11e-11	Tonsillectomy;
CESC	cis	rs6460942	1.000	rs73053531	chr7:12317474	T/C	cg02935154	chr7:12443704	VWDE	-0.59	-5.84	-0.34	1.5e-8	Coronary artery disease;
CESC	trans	rs11098499	0.863	rs7695620	chr4:120452776	G/A	cg25214090	chr10:38739885	LOC399744	0.7	9.62	0.51	5.47e-19	Corneal astigmatism;
CESC	trans	rs61931739	0.500	rs11052990	chr12:34058647	T/A	cg26384229	chr12:38710491	ALG10B	0.6	8.36	0.46	3.68e-15	Morning vs. evening chronotype;
CESC	cis	rs4727963	0.846	rs2140854	chr7:122718310	G/A	cg03640110	chr7:122635026	TAS2R16	-0.36	-5.48	-0.32	9.74e-8	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
CESC	cis	rs4077515	1.000	rs11145763	chr9:139263596	A/C	cg14169450	chr9:139327907	INPP5E	0.35	5.08	0.3	7.21e-7	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs17209837	0.607	rs17149644	chr7:87086218	T/C	cg00919237	chr7:87102261	ABCB4	-0.51	-6.58	-0.37	2.45e-10	Gallbladder cancer;
CESC	trans	rs916888	0.779	rs430685	chr17:44859148	T/C	cg22433210	chr17:43662623	NA	-0.91	-10.77	-0.55	1.15e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs11098499	1.000	rs28419773	chr4:120211061	T/C	cg24375607	chr4:120327624	NA	0.42	5.03	0.3	8.94e-7	Corneal astigmatism;
CESC	cis	rs7089973	0.872	rs36036948	chr10:116631649	A/G	cg23260525	chr10:116636907	FAM160B1	0.38	6.41	0.37	6.7e-10	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs911555	0.504	rs745079	chr14:104073551	G/A	cg12935359	chr14:103987150	CKB	-0.5	-7.3	-0.41	3.29e-12	Intelligence (multi-trait analysis);
CESC	cis	rs9815354	1.000	rs3774372	chr3:41877414	A/G	cg03022575	chr3:42003672	ULK4	0.6	6.06	0.35	4.57e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs8067354	0.872	rs2645483	chr17:57848184	T/G	cg02344993	chr17:57696989	CLTC	0.48	6.21	0.36	2.06e-9	Hemoglobin concentration;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22902534	chr3:183892754	AP2M1	0.58	6.81	0.39	6.33e-11	Gut microbiome composition (summer);
CESC	cis	rs13108904	0.557	rs1250097	chr4:1238338	C/T	cg20887711	chr4:1340912	KIAA1530	-0.61	-8.28	-0.45	6.08e-15	Obesity-related traits;
CESC	cis	rs6701037	0.555	rs10912898	chr1:175120469	A/G	cg08873628	chr1:175162347	KIAA0040	-0.4	-5.24	-0.31	3.31e-7	Alcohol dependence;
CESC	trans	rs17508449	0.819	rs74524050	chr1:114231207	T/C	cg23028848	chr11:57092561	TNKS1BP1	-0.79	-6.25	-0.36	1.63e-9	Leprosy;
CESC	cis	rs2243480	0.901	rs13237344	chr7:66022256	T/A	cg13147721	chr7:65941812	NA	-0.94	-8.88	-0.48	1.06e-16	Diabetic kidney disease;
CESC	cis	rs17253792	0.822	rs74053651	chr14:56125366	C/T	cg01858014	chr14:56050164	KTN1	-0.71	-6.19	-0.36	2.22e-9	Putamen volume;
CESC	cis	rs909002	0.789	rs56074668	chr1:32123801	T/C	cg13919466	chr1:32135498	COL16A1	-0.49	-8.9	-0.48	8.83e-17	Intelligence (multi-trait analysis);
CESC	trans	rs2983496	0.901	rs3008023	chr6:166033557	G/A	cg21896720	chr4:4673378	NA	0.62	6.06	0.35	4.64e-9	Cortisol levels (saliva);
CESC	cis	rs1799949	1.000	rs34534709	chr17:41302940	C/G	cg25072359	chr17:41440525	NA	0.46	6.1	0.35	3.77e-9	Menopause (age at onset);
CESC	cis	rs2836974	0.666	rs1888487	chr21:40683259	A/G	cg11644478	chr21:40555479	PSMG1	-0.81	-11.65	-0.58	1.35e-25	Cognitive function;
CESC	cis	rs941873	0.900	rs4979861	chr10:81131595	A/G	cg11057378	chr10:81107060	PPIF	0.35	5.51	0.32	8.54e-8	Height;
CESC	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg15147215	chr3:52552868	STAB1	-0.38	-6.91	-0.39	3.57e-11	Electroencephalogram traits;
CESC	cis	rs3096299	0.503	rs4785677	chr16:89555101	A/G	cg08392591	chr16:89556376	ANKRD11	0.64	8.68	0.47	4.24e-16	Multiple myeloma (IgH translocation);
CESC	cis	rs1552244	1.000	rs113522867	chr3:10154503	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.88	12.09	0.6	4.15e-27	Alzheimer's disease;
CESC	cis	rs2213920	0.516	rs13301972	chr9:118158086	C/T	cg13918206	chr9:118159781	DEC1	-0.69	-5.52	-0.32	8.06e-8	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
CESC	cis	rs6662572	0.901	rs58692133	chr1:46067269	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.51	5.69	0.33	3.39e-8	Blood protein levels;
CESC	cis	rs7216064	0.531	rs62084683	chr17:66031725	A/G	cg12091567	chr17:66097778	LOC651250	0.87	11.37	0.57	1.14e-24	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05008406	chr3:118959563	B4GALT4	0.53	6.0	0.35	6.42e-9	Gut microbiome composition (summer);
CESC	cis	rs11583043	1.000	rs7541397	chr1:101322866	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.53	-6.2	-0.36	2.18e-9	Ulcerative colitis;Inflammatory bowel disease;
CESC	cis	rs6570726	0.643	rs9403735	chr6:145936591	C/T	cg05347473	chr6:146136440	FBXO30	0.57	7.27	0.41	4.11e-12	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg03834592	chr13:113534800	ATP11A	0.46	6.11	0.35	3.59e-9	Fibrinogen levels;
CESC	cis	rs9916302	0.904	rs13341996	chr17:37536862	C/T	cg19468946	chr17:37922297	IKZF3	0.39	5.07	0.3	7.62e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs3741798	1.000	rs61922047	chr12:12496471	C/A	cg08615371	chr12:12503544	MANSC1	0.79	5.65	0.33	4.22e-8	Cerebrospinal fluid biomarker levels;
CESC	cis	rs7208859	0.673	rs216420	chr17:28938508	C/T	cg19761014	chr17:28927070	LRRC37B2	0.79	7.2	0.4	6.29e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs875971	0.862	rs12698526	chr7:65969105	T/C	cg11764359	chr7:65958608	NA	0.79	11.17	0.57	5.2e-24	Aortic root size;
CESC	cis	rs72634258	0.699	rs2493214	chr1:7994420	A/G	cg25007680	chr1:8021821	PARK7	0.44	5.1	0.3	6.63e-7	Inflammatory bowel disease;
CESC	cis	rs7618915	0.547	rs34610142	chr3:52708429	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	6.93	0.39	3.13e-11	Bipolar disorder;
CESC	cis	rs3749237	0.595	rs3924462	chr3:49524236	T/G	cg03060546	chr3:49711283	APEH	0.77	11.82	0.59	3.5e-26	Resting heart rate;
CESC	cis	rs72781680	1.000	rs56104215	chr2:24133590	T/C	cg08917208	chr2:24149416	ATAD2B	0.93	8.42	0.46	2.35e-15	Lymphocyte counts;
CESC	cis	rs1728785	1.000	rs1728792	chr16:68596534	G/C	cg02972257	chr16:68554789	NA	-0.59	-6.75	-0.38	9.22e-11	Ulcerative colitis;
CESC	cis	rs2304069	0.526	rs6863283	chr5:149402448	C/A	cg12661370	chr5:149340060	SLC26A2	0.43	5.62	0.33	4.77e-8	HIV-1 control;
CESC	cis	rs9611565	0.765	rs132914	chr22:41805749	T/C	cg17376030	chr22:41985996	PMM1	-0.59	-6.24	-0.36	1.69e-9	Vitiligo;
CESC	cis	rs1062177	0.855	rs919263	chr5:151265853	A/G	cg12924095	chr5:151150029	G3BP1	0.45	6.26	0.36	1.52e-9	Preschool internalizing problems;
CESC	trans	rs7246760	0.867	rs66464474	chr19:9795149	T/C	cg02900749	chr2:68251473	NA	-0.85	-7.53	-0.42	8.04e-13	Pursuit maintenance gain;
CESC	cis	rs561341	0.883	rs72821942	chr17:30234460	C/T	cg19193384	chr17:30244184	NA	-0.56	-5.74	-0.33	2.61e-8	Hip circumference adjusted for BMI;
CESC	cis	rs597539	0.652	rs482172	chr11:68668437	C/A	cg21963583	chr11:68658836	MRPL21	0.36	5.08	0.3	7.2e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs7940866	0.804	rs10894289	chr11:130808685	C/T	cg12179176	chr11:130786555	SNX19	0.67	10.35	0.54	2.63e-21	Schizophrenia;
CESC	cis	rs2549003	0.966	rs2070730	chr5:131819800	G/A	cg02551604	chr5:131831745	NA	-0.37	-5.22	-0.31	3.53e-7	Asthma (sex interaction);
CESC	cis	rs36051895	0.632	rs7022901	chr9:5177680	C/G	cg02405213	chr9:5042618	JAK2	-0.51	-6.55	-0.37	2.92e-10	Pediatric autoimmune diseases;
CESC	cis	rs7264396	0.836	rs1886695	chr20:34180535	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	0.6	7.1	0.4	1.15e-11	Total cholesterol levels;
CESC	cis	rs1008375	1.000	rs10011865	chr4:17645710	G/A	cg16339924	chr4:17578868	LAP3	0.56	7.02	0.4	1.9e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	trans	rs6572548	0.504	rs1956082	chr14:49665496	A/C	cg00761755	chr17:1531579	SLC43A2	-0.53	-6.11	-0.35	3.61e-9	Subjective well-being;
CESC	cis	rs1511802	0.666	rs62350519	chr4:187119701	G/A	cg24794857	chr4:187113578	CYP4V2	0.44	5.72	0.33	2.83e-8	Blood protein levels;
CESC	cis	rs854765	0.533	rs2955354	chr17:17948716	G/C	cg16928487	chr17:17741425	SREBF1	0.55	9.13	0.49	1.86e-17	Total body bone mineral density;
CESC	cis	rs2732480	0.538	rs1387259	chr12:48703522	C/T	cg04545296	chr12:48745243	ZNF641	-0.43	-7.15	-0.4	8.3e-12	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs11122272	0.677	rs2808615	chr1:231550171	G/A	cg06096015	chr1:231504339	EGLN1	-0.41	-5.78	-0.33	2.13e-8	Hemoglobin concentration;
CESC	cis	rs7772486	0.782	rs7747576	chr6:146277827	C/T	cg23711669	chr6:146136114	FBXO30	-0.92	-13.15	-0.63	9.83e-31	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1538970	0.924	rs11211117	chr1:45930246	C/T	cg03146154	chr1:46216737	IPP	0.45	5.24	0.31	3.31e-7	Platelet count;
CESC	cis	rs3126085	0.935	rs1390490	chr1:152161354	T/C	cg03465714	chr1:152285911	FLG	-0.45	-5.39	-0.31	1.59e-7	Atopic dermatitis;
CESC	cis	rs35955747	0.811	rs9606835	chr22:31766960	A/C	cg25791279	chr22:32026902	PISD	0.48	5.79	0.34	1.97e-8	Neutrophil count;Sum basophil neutrophil counts;
CESC	cis	rs1008375	0.900	rs12650220	chr4:17595365	A/T	cg16339924	chr4:17578868	LAP3	0.66	8.49	0.46	1.47e-15	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs4665809	0.590	rs962217	chr2:26438276	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.09	-12.43	-0.61	2.89e-28	Gut microbiome composition (summer);
CESC	cis	rs4713118	0.513	rs9368547	chr6:28028067	A/G	cg23281280	chr6:28129359	ZNF389	0.37	5.42	0.32	1.33e-7	Parkinson's disease;
CESC	cis	rs3806843	1.000	rs10477033	chr5:140169603	G/C	cg26395211	chr5:140044315	WDR55	-0.42	-5.59	-0.32	5.6e-8	Depressive symptoms (multi-trait analysis);
CESC	cis	rs1865721	1.000	rs62089509	chr18:73194519	G/A	cg26385618	chr18:73139727	C18orf62	-0.51	-7.6	-0.42	5.1e-13	Intelligence;
CESC	cis	rs977987	0.815	rs11149821	chr16:75422817	C/T	cg03315344	chr16:75512273	CHST6	0.4	5.74	0.33	2.62e-8	Dupuytren's disease;
CESC	cis	rs3947	1.000	rs1736081	chr8:11702840	T/G	cg00262122	chr8:11665843	FDFT1	-0.51	-5.13	-0.3	5.47e-7	Blood protein levels;
CESC	cis	rs7312933	0.558	rs11181502	chr12:42823833	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.5	6.41	0.37	6.61e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs5167	0.586	rs4803774	chr19:45450872	A/G	cg09555818	chr19:45449301	APOC2	0.43	6.72	0.38	1.08e-10	Blood protein levels;
CESC	cis	rs11785400	0.793	rs3735993	chr8:143741170	G/A	cg24634471	chr8:143751801	JRK	0.44	5.55	0.32	7.02e-8	Schizophrenia;
CESC	cis	rs9311474	0.508	rs6786043	chr3:52604861	A/G	cg18337363	chr3:52569053	NT5DC2	0.3	5.57	0.32	6.38e-8	Electroencephalogram traits;
CESC	cis	rs832540	0.564	rs33329	chr5:56145068	T/C	cg12311346	chr5:56204834	C5orf35	-0.45	-5.49	-0.32	9.29e-8	Coronary artery disease;
CESC	cis	rs2204008	0.805	rs11522896	chr12:38234427	T/C	cg26384229	chr12:38710491	ALG10B	0.73	10.35	0.54	2.55e-21	Bladder cancer;
CESC	cis	rs34779708	0.931	rs11592404	chr10:35273476	G/A	cg03585969	chr10:35415529	CREM	0.77	10.16	0.53	1.05e-20	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg23708337	chr7:1209742	NA	0.54	5.38	0.31	1.61e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7223966	1.000	rs16947014	chr17:61719032	C/T	cg11494091	chr17:61959527	GH2	0.38	5.03	0.3	9.02e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs11048434	0.666	rs12371786	chr12:9090086	G/A	cg04155231	chr12:9217510	LOC144571	0.33	5.35	0.31	1.93e-7	Sjögren's syndrome;
CESC	cis	rs2952156	0.920	rs2934951	chr17:37833328	A/G	cg07936489	chr17:37558343	FBXL20	-0.58	-7.28	-0.41	3.77e-12	Asthma;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg15961887	chr4:71554203	UTP3	-0.48	-6.32	-0.36	1.11e-9	Ulcerative colitis;
CESC	cis	rs6831352	0.918	rs13129488	chr4:100053025	G/T	cg13256891	chr4:100009986	ADH5	-0.77	-8.43	-0.46	2.27e-15	Alcohol dependence;
CESC	cis	rs34172651	0.617	rs9922436	chr16:24704490	C/G	cg04756594	chr16:24857601	SLC5A11	0.53	6.73	0.38	1.04e-10	Intelligence (multi-trait analysis);
CESC	cis	rs4665809	0.590	rs1368902	chr2:26440576	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.1	-12.68	-0.61	4e-29	Gut microbiome composition (summer);
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg27360527	chr16:85722694	GINS2	0.45	6.0	0.35	6.56e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs2797160	0.935	rs926855	chr6:126021782	A/G	cg05901451	chr6:126070800	HEY2	0.45	6.48	0.37	4.36e-10	Endometrial cancer;
CESC	cis	rs362272	0.505	rs3129310	chr4:3301388	T/G	cg14583973	chr4:3374767	RGS12	0.3	5.13	0.3	5.52e-7	Serum sulfate level;
CESC	cis	rs4665809	1.000	rs10182857	chr2:26344411	C/T	cg22920501	chr2:26401640	FAM59B	-0.67	-8.09	-0.44	2.22e-14	Gut microbiome composition (summer);
CESC	cis	rs7208859	0.573	rs73267865	chr17:29064204	C/G	cg14008862	chr17:28927542	LRRC37B2	0.65	5.12	0.3	5.86e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs2836974	0.583	rs9636957	chr21:40705847	G/A	cg22974920	chr21:40686053	BRWD1	-0.42	-5.19	-0.3	4.13e-7	Cognitive function;
CESC	cis	rs644799	0.509	rs561635	chr11:95634232	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	-0.4	-5.19	-0.3	4.14e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs11078597	0.731	rs62090051	chr17:1640640	C/G	cg18436246	chr17:1640651	WDR81	0.62	7.59	0.42	5.36e-13	Serum albumin level;
CESC	cis	rs2281558	0.876	rs2281562	chr20:25273362	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.62	8.23	0.45	8.83e-15	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;
CESC	cis	rs853679	0.825	rs8180562	chr6:28141460	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.75	-6.42	-0.37	6.32e-10	Depression;
CESC	cis	rs7589728	0.514	rs74426843	chr2:88459388	C/T	cg07952391	chr2:88470173	THNSL2	0.62	6.03	0.35	5.61e-9	Plasma clusterin levels;
CESC	cis	rs6800768	0.663	rs12492765	chr3:24091865	C/T	cg10674438	chr3:24145617	LOC152024	-0.4	-5.48	-0.32	1.01e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg18865796	chr19:11457210	TMEM205;CCDC159	-0.43	-6.02	-0.35	5.74e-9	Fibrinogen levels;
CESC	cis	rs17125944	0.505	rs77433996	chr14:53212263	G/A	cg00686598	chr14:53173677	PSMC6	1.33	11.43	0.57	7.31e-25	Alzheimer's disease (late onset);
CESC	cis	rs7666738	0.712	rs34043080	chr4:99008748	G/C	cg03467027	chr4:99064603	C4orf37	0.43	5.4	0.31	1.49e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2952156	0.883	rs2941505	chr17:37832704	A/G	cg00129232	chr17:37814104	STARD3	-0.74	-10.19	-0.53	8.45e-21	Asthma;
CESC	cis	rs807669	0.903	rs1771540	chr22:19173933	T/A	cg02655711	chr22:19163373	SLC25A1	0.96	14.54	0.67	1.32e-35	Metabolite levels;
CESC	cis	rs8077577	0.671	rs9910090	chr17:18250399	A/C	cg16794390	chr17:18148240	FLII	0.38	6.29	0.36	1.34e-9	Obesity-related traits;
CESC	trans	rs17508449	0.819	rs6678422	chr1:114204700	A/G	cg04711050	chr9:4490757	SLC1A1	-0.68	-6.18	-0.35	2.41e-9	Leprosy;
CESC	cis	rs7833790	0.676	rs7834555	chr8:82697625	A/G	cg06027949	chr8:82754900	SNX16	-0.43	-5.22	-0.31	3.66e-7	Diastolic blood pressure;
CESC	trans	rs55728055	0.661	rs5753700	chr22:31971258	C/T	cg09557462	chr8:26721736	ADRA1A	-0.56	-6.25	-0.36	1.62e-9	Age-related hearing impairment;
CESC	cis	rs11122272	0.701	rs1009227	chr1:231480507	A/G	cg06096015	chr1:231504339	EGLN1	0.43	6.41	0.37	6.78e-10	Hemoglobin concentration;
CESC	cis	rs514406	0.505	rs387436	chr1:53179376	C/T	cg24675658	chr1:53192096	ZYG11B	0.5	6.18	0.36	2.34e-9	Monocyte count;
CESC	cis	rs17253792	0.822	rs9323289	chr14:56106784	G/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.79	6.04	0.35	5.13e-9	Putamen volume;
CESC	cis	rs9486719	1.000	rs1303852	chr6:96864523	C/T	cg06623918	chr6:96969491	KIAA0776	0.81	8.29	0.45	5.61e-15	Migraine;Coronary artery disease;
CESC	cis	rs2204008	0.658	rs12371956	chr12:38298010	A/T	cg13010199	chr12:38710504	ALG10B	0.45	5.65	0.33	4.06e-8	Bladder cancer;
CESC	cis	rs10905065	0.965	rs2244755	chr10:5754611	G/A	cg11519256	chr10:5708881	ASB13	0.44	5.85	0.34	1.43e-8	Menopause (age at onset);
CESC	cis	rs11098499	0.863	rs3775847	chr4:120447642	A/C	cg09307838	chr4:120376055	NA	0.92	12.61	0.61	7.4e-29	Corneal astigmatism;
CESC	cis	rs10791323	0.569	rs1119852	chr11:133743022	C/A	cg15485101	chr11:133734466	NA	0.3	5.22	0.31	3.6e-7	Childhood ear infection;
CESC	cis	rs4820539	1.000	rs4822360	chr22:23482460	A/G	cg14186256	chr22:23484241	RTDR1	0.79	13.92	0.65	1.96e-33	Bone mineral density;
CESC	cis	rs258892	0.947	rs266448	chr5:72182229	G/A	cg21869765	chr5:72125136	TNPO1	0.44	5.57	0.32	6.25e-8	Small cell lung carcinoma;
CESC	cis	rs611744	0.538	rs2298605	chr8:109272006	T/C	cg21045802	chr8:109455806	TTC35	0.56	6.95	0.39	2.89e-11	Dupuytren's disease;
CESC	cis	rs11098499	0.954	rs11098526	chr4:120390359	C/T	cg24375607	chr4:120327624	NA	0.45	5.55	0.32	6.9e-8	Corneal astigmatism;
CESC	cis	rs6499129	0.558	rs60626639	chr16:67625797	A/G	cg26727032	chr16:67993705	SLC12A4	-0.6	-7.3	-0.41	3.36e-12	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs4820294	1.000	rs929039	chr22:38071511	T/C	cg21798802	chr22:38057573	PDXP	0.47	8.03	0.44	3.15e-14	Fat distribution (HIV);
CESC	cis	rs60871478	0.735	rs4721501	chr7:862166	G/T	cg15782153	chr7:917662	C7orf20	0.53	5.61	0.33	5.06e-8	Cerebrospinal P-tau181p levels;
CESC	cis	rs9549367	0.713	rs3024747	chr13:113821787	C/G	cg18105134	chr13:113819100	PROZ	-0.66	-8.35	-0.46	3.82e-15	Platelet distribution width;
CESC	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg15383120	chr6:291909	DUSP22	0.66	8.42	0.46	2.34e-15	Menopause (age at onset);
CESC	cis	rs6546537	1.000	rs6727435	chr2:69864236	C/A	cg10773587	chr2:69614142	GFPT1	-0.58	-7.09	-0.4	1.25e-11	Serum thyroid-stimulating hormone levels;
CESC	cis	rs1461503	0.932	rs10892934	chr11:122837950	C/T	cg27398637	chr11:122830231	C11orf63	-0.57	-8.68	-0.47	4.17e-16	Menarche (age at onset);
CESC	cis	rs9916302	0.904	rs587343	chr17:37440603	C/T	cg20243544	chr17:37824526	PNMT	-0.43	-5.27	-0.31	2.81e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs4319547	1.000	rs6489071	chr12:123025576	C/G	cg23029597	chr12:123009494	RSRC2	-0.46	-5.21	-0.3	3.86e-7	Body mass index;
CESC	cis	rs7116495	0.609	rs3750907	chr11:71822560	T/C	cg18441811	chr11:71824068	C11orf51	0.83	5.17	0.3	4.55e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs3806843	0.966	rs6891559	chr5:140145206	G/A	cg16179182	chr5:140090404	VTRNA1-1	-0.43	-5.61	-0.33	5.03e-8	Depressive symptoms (multi-trait analysis);
CESC	cis	rs853679	0.550	rs1233699	chr6:28169158	A/T	cg23281280	chr6:28129359	ZNF389	0.49	6.97	0.39	2.57e-11	Depression;
CESC	cis	rs11155671	0.530	rs6933882	chr6:150210802	A/G	cg09699651	chr6:150184138	LRP11	0.55	7.7	0.43	2.78e-13	Testicular germ cell tumor;
CESC	cis	rs4595586	0.525	rs17467376	chr12:39377551	T/G	cg26384229	chr12:38710491	ALG10B	0.62	8.69	0.47	3.89e-16	Morning vs. evening chronotype;
CESC	cis	rs4604732	0.536	rs12037221	chr1:247631212	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.52	6.44	0.37	5.54e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs11785400	0.793	rs7007891	chr8:143749228	C/T	cg10596483	chr8:143751796	JRK	-0.42	-5.26	-0.31	3e-7	Schizophrenia;
CESC	cis	rs875971	1.000	rs875971	chr7:65617595	A/G	cg18876405	chr7:65276391	NA	-0.5	-6.8	-0.39	6.78e-11	Aortic root size;
CESC	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg02353165	chr6:42928485	GNMT	0.83	13.12	0.63	1.19e-30	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs950027	0.620	rs1145077	chr15:45683795	A/C	cg21132104	chr15:45694354	SPATA5L1	-0.65	-8.18	-0.45	1.16e-14	Response to fenofibrate (adiponectin levels);
CESC	trans	rs8073060	0.586	rs225278	chr17:33974170	C/T	cg19694781	chr19:47549865	TMEM160	-0.73	-7.32	-0.41	3.05e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	cis	rs853679	0.517	rs12174753	chr6:28042465	C/G	cg08968635	chr6:28129556	ZNF389	0.39	5.22	0.31	3.64e-7	Depression;
CESC	cis	rs2576037	0.526	rs2576051	chr18:44557884	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.66	-10.03	-0.52	2.78e-20	Personality dimensions;
CESC	trans	rs7922314	0.571	rs61282002	chr10:64738038	C/T	cg06935979	chr1:232941706	KIAA1383	-0.63	-6.09	-0.35	3.89e-9	Cutaneous psoriasis;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg11857025	chr1:109633344	TMEM167B	-0.45	-6.31	-0.36	1.14e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs1801251	1.000	rs12474040	chr2:233615345	T/G	cg08000102	chr2:233561755	GIGYF2	0.66	9.46	0.5	1.72e-18	Coronary artery disease;
CESC	cis	rs1448094	0.512	rs10863086	chr12:86244225	G/A	cg02569458	chr12:86230093	RASSF9	0.49	7.21	0.4	5.91e-12	Major depressive disorder;
CESC	cis	rs7264396	0.690	rs2425157	chr20:34419083	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.77	-8.34	-0.46	4.18e-15	Total cholesterol levels;
CESC	cis	rs933688	1.000	rs2839728	chr5:90727412	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.91	11.74	0.58	6.66e-26	Smoking behavior;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg13451882	chr2:139256702	NA	0.42	6.18	0.35	2.35e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs7208859	0.673	rs216418	chr17:28936537	G/A	cg17105886	chr17:28927953	LRRC37B2	0.63	5.7	0.33	3.26e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs6860806	0.631	rs6863548	chr5:131575920	G/A	cg11843238	chr5:131593191	PDLIM4	0.35	5.16	0.3	4.86e-7	Breast cancer;
CESC	cis	rs6754311	0.509	rs3820794	chr2:136505546	C/T	cg07169764	chr2:136633963	MCM6	-0.72	-9.31	-0.5	5.24e-18	Mosquito bite size;
CESC	cis	rs514406	0.584	rs7524702	chr1:53197830	G/A	cg08859206	chr1:53392774	SCP2	0.56	7.09	0.4	1.21e-11	Monocyte count;
CESC	cis	rs965513	0.901	rs1877431	chr9:100534147	C/T	cg13688889	chr9:100608707	NA	0.47	6.47	0.37	4.67e-10	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
CESC	cis	rs8060686	0.641	rs13816	chr16:68055495	G/C	cg26727032	chr16:67993705	SLC12A4	-0.52	-6.46	-0.37	4.91e-10	HDL cholesterol;Metabolic syndrome;
CESC	trans	rs1728785	1.000	rs1645935	chr16:68563791	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.61	7.42	0.41	1.57e-12	Ulcerative colitis;
CESC	cis	rs7659604	0.967	rs28529384	chr4:122664215	T/C	cg19671926	chr4:122722719	EXOSC9	-0.44	-5.18	-0.3	4.35e-7	Type 2 diabetes;
CESC	cis	rs875971	1.000	rs2036264	chr7:65799904	G/A	cg12463550	chr7:65579703	CRCP	-0.54	-6.96	-0.39	2.67e-11	Aortic root size;
CESC	cis	rs12142240	0.698	rs3991877	chr1:46853749	C/A	cg00530320	chr1:46809349	NSUN4	0.6	8.3	0.45	5.19e-15	Menopause (age at onset);
CESC	cis	rs72781680	0.846	rs55707417	chr2:24029928	G/A	cg20701182	chr2:24300061	SF3B14	0.78	6.7	0.38	1.22e-10	Lymphocyte counts;
CESC	cis	rs6460942	0.749	rs62448592	chr7:12435985	A/T	cg02935154	chr7:12443704	VWDE	-0.59	-6.31	-0.36	1.14e-9	Coronary artery disease;
CESC	cis	rs10197940	0.686	rs12616688	chr2:152242099	C/G	cg19508488	chr2:152266495	RIF1	0.61	6.94	0.39	2.99e-11	Lung cancer;
CESC	cis	rs7927771	0.507	rs1483988	chr11:47899030	C/T	cg20307385	chr11:47447363	PSMC3	0.61	8.44	0.46	2.09e-15	Subjective well-being;
CESC	cis	rs8103278	1.000	rs35302007	chr19:46219145	G/C	cg11657440	chr19:46296263	DMWD	-0.54	-6.82	-0.39	6.09e-11	Coronary artery disease;
CESC	cis	rs6951245	0.882	rs11764817	chr7:1064610	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.43	5.12	0.3	6.02e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs523522	0.962	rs11065145	chr12:120947419	A/G	cg27279351	chr12:120934652	DYNLL1	0.69	9.11	0.49	2.02e-17	High light scatter reticulocyte count;
CESC	cis	rs7274811	0.681	rs291670	chr20:31945861	G/A	cg21523528	chr20:32077966	CBFA2T2	-0.43	-5.18	-0.3	4.39e-7	Height;
CESC	cis	rs9911578	0.935	rs304261	chr17:56813782	A/G	cg12560992	chr17:57184187	TRIM37	0.91	14.71	0.67	3.24e-36	Intelligence (multi-trait analysis);
CESC	cis	rs9910055	0.762	rs2526020	chr17:42216588	G/T	cg13607699	chr17:42295918	UBTF	0.7	9.52	0.5	1.15e-18	Total body bone mineral density;
CESC	cis	rs367943	0.712	rs7731465	chr5:112687385	A/G	cg12552261	chr5:112820674	MCC	-0.41	-5.08	-0.3	7.03e-7	Type 2 diabetes;
CESC	cis	rs7662987	1.000	rs7683802	chr4:99995138	T/G	cg13256891	chr4:100009986	ADH5	-0.82	-6.06	-0.35	4.59e-9	Smoking initiation;
CESC	cis	rs2629540	0.847	rs12762597	chr10:126387043	G/A	cg08799069	chr10:126477246	METTL10	0.58	7.23	0.41	5.03e-12	Cocaine dependence;
CESC	cis	rs875971	0.862	rs1860469	chr7:66106875	A/G	cg12463550	chr7:65579703	CRCP	-0.5	-6.41	-0.37	6.59e-10	Aortic root size;
CESC	trans	rs116095464	0.558	rs6879656	chr5:264428	T/C	cg00938859	chr5:1591904	SDHAP3	0.62	6.05	0.35	5.01e-9	Breast cancer;
CESC	cis	rs7592578	0.639	rs13417431	chr2:191293055	A/G	cg27211696	chr2:191398769	TMEM194B	-0.56	-5.83	-0.34	1.64e-8	Diastolic blood pressure;
CESC	cis	rs7508679	1.000	rs10410204	chr19:7224350	C/T	cg09779027	chr19:7224513	INSR	0.55	8.86	0.48	1.21e-16	Hypothyroidism;
CESC	cis	rs6987853	0.830	rs12542919	chr8:42356035	C/T	cg09913449	chr8:42400586	C8orf40	-0.34	-5.3	-0.31	2.41e-7	Mean corpuscular hemoglobin concentration;
CESC	cis	rs6088580	0.634	rs6087577	chr20:32955423	C/T	cg08999081	chr20:33150536	PIGU	0.58	9.7	0.51	3.01e-19	Glomerular filtration rate (creatinine);
CESC	cis	rs7727544	0.735	rs273914	chr5:131660431	A/T	cg07395648	chr5:131743802	NA	-0.48	-6.37	-0.36	8.23e-10	Blood metabolite levels;
CESC	cis	rs79839061	0.610	rs3775130	chr4:875144	G/A	cg07828340	chr4:882639	GAK	1.07	8.24	0.45	7.96e-15	Intelligence (multi-trait analysis);
CESC	cis	rs9322193	0.962	rs4869966	chr6:150084850	A/G	cg05861140	chr6:150128134	PCMT1	-0.38	-5.43	-0.32	1.29e-7	Lung cancer;
CESC	cis	rs35520189	0.845	rs13021862	chr2:113641944	G/A	cg06156847	chr2:113672199	IL1F7	0.36	5.47	0.32	1.04e-7	Obstructive sleep apnea trait (apnea hypopnea index);
CESC	cis	rs910316	0.737	rs175043	chr14:75471803	G/A	cg11812906	chr14:75593930	NEK9	-0.81	-12.62	-0.61	6.47e-29	Height;
CESC	cis	rs921968	0.541	rs3755042	chr2:219317248	T/C	cg02176678	chr2:219576539	TTLL4	-0.53	-9.28	-0.5	6.12e-18	Mean corpuscular hemoglobin concentration;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg19850565	chr19:35168394	ZNF302	0.46	6.24	0.36	1.69e-9	Systemic lupus erythematosus;
CESC	cis	rs7666738	0.830	rs34244876	chr4:99031336	G/A	cg03467027	chr4:99064603	C4orf37	0.49	6.18	0.35	2.44e-9	Colonoscopy-negative controls vs population controls;
CESC	trans	rs637571	0.544	rs617791	chr11:65702523	C/G	cg17712092	chr4:129076599	LARP1B	0.68	8.98	0.48	5.29e-17	Eosinophil percentage of white cells;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg23352145	chr13:21751331	MRP63;SKA3	0.48	6.55	0.37	3.02e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs2180341	0.782	rs6912750	chr6:127723081	A/T	cg24812749	chr6:127587940	RNF146	0.83	12.07	0.6	5.14e-27	Breast cancer;
CESC	cis	rs6460942	1.000	rs17191008	chr7:12417690	T/G	cg02935154	chr7:12443704	VWDE	-0.61	-6.32	-0.36	1.08e-9	Coronary artery disease;
CESC	cis	rs951366	1.000	rs4951261	chr1:205717823	A/C	cg26354017	chr1:205819088	PM20D1	-0.47	-6.3	-0.36	1.26e-9	Menarche (age at onset);
CESC	cis	rs561341	1.000	rs542132	chr17:30307193	A/T	cg00745463	chr17:30367425	LRRC37B	-0.78	-7.09	-0.4	1.2e-11	Hip circumference adjusted for BMI;
CESC	cis	rs4862750	0.914	rs1863405	chr4:187874528	G/T	cg11301795	chr4:187892539	NA	0.71	11.36	0.57	1.23e-24	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs116095464	0.558	rs1541822	chr5:269234	A/C	cg00938859	chr5:1591904	SDHAP3	-0.64	-7.05	-0.4	1.52e-11	Breast cancer;
CESC	cis	rs9916302	0.904	rs7221875	chr17:37543328	G/A	cg07936489	chr17:37558343	FBXL20	0.79	11.47	0.58	5.25e-25	Glomerular filtration rate (creatinine);
CESC	cis	rs2732480	0.500	rs12828309	chr12:48641160	C/T	cg04545296	chr12:48745243	ZNF641	0.39	6.71	0.38	1.18e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	trans	rs687914	0.710	rs938662	chr2:45864578	A/G	cg15993674	chr20:4667405	PRNP	0.54	6.0	0.35	6.5e-9	Diastolic blood pressure;
CESC	cis	rs2228479	0.850	rs62054611	chr16:89817017	T/C	cg14709524	chr16:89940631	TCF25	0.93	6.94	0.39	3.03e-11	Skin colour saturation;
CESC	cis	rs4268898	0.662	rs714531	chr2:24399877	G/A	cg08917208	chr2:24149416	ATAD2B	0.62	5.7	0.33	3.21e-8	Asthma;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg19065773	chr10:98469552	PIK3AP1	-0.4	-6.12	-0.35	3.4e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs9611565	0.592	rs1811113	chr22:42073134	C/T	cg06634786	chr22:41940651	POLR3H	0.62	6.25	0.36	1.67e-9	Vitiligo;
CESC	cis	rs72781680	1.000	rs7594510	chr2:24173377	A/G	cg20701182	chr2:24300061	SF3B14	0.64	5.74	0.33	2.63e-8	Lymphocyte counts;
CESC	cis	rs1267303	0.562	rs2476162	chr1:47007324	G/A	cg25110126	chr1:46999211	NA	0.76	9.07	0.49	2.66e-17	Monobrow;
CESC	cis	rs12477438	0.765	rs13390672	chr2:99589829	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.62	-8.67	-0.47	4.43e-16	Chronic sinus infection;
CESC	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg23708337	chr7:1209742	NA	0.52	5.16	0.3	4.88e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs34779708	0.733	rs59287215	chr10:35543994	C/T	cg03585969	chr10:35415529	CREM	0.56	6.54	0.37	3.22e-10	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs4268898	0.571	rs1986478	chr2:24468545	G/A	cg20701182	chr2:24300061	SF3B14	0.63	6.84	0.39	5.33e-11	Asthma;
CESC	cis	rs2070997	0.756	rs3824400	chr9:133734075	A/G	cg11464064	chr9:133710261	ABL1	-0.55	-6.04	-0.35	5.13e-9	Response to amphetamines;
CESC	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg07157834	chr1:205819609	PM20D1	-0.64	-8.49	-0.46	1.51e-15	Menarche (age at onset);
CESC	cis	rs7666738	0.830	rs11947578	chr4:98930462	T/G	cg05340658	chr4:99064831	C4orf37	0.82	12.17	0.6	2.24e-27	Colonoscopy-negative controls vs population controls;
CESC	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg01516881	chr6:292596	DUSP22	-0.84	-11.66	-0.58	1.27e-25	Menopause (age at onset);
CESC	cis	rs769267	0.896	rs7250893	chr19:19625547	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.45	5.82	0.34	1.71e-8	Tonsillectomy;
CESC	cis	rs1538970	0.816	rs10789464	chr1:45959102	C/T	cg05343316	chr1:45956843	TESK2	0.93	12.71	0.62	3.33e-29	Platelet count;
CESC	cis	rs12121840	0.790	rs7535829	chr1:165518876	C/A	cg16553119	chr1:165599451	MGST3	-0.46	-5.22	-0.31	3.69e-7	Interleukin-1-receptor antagonist levels;
CESC	cis	rs116095464	0.558	rs10057299	chr5:242135	C/T	cg12570787	chr5:219185	SDHA;CCDC127	0.5	5.27	0.31	2.9e-7	Breast cancer;
CESC	cis	rs7772486	0.641	rs2748489	chr6:146331287	T/G	cg23711669	chr6:146136114	FBXO30	0.84	10.91	0.56	3.89e-23	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs3106136	0.967	rs282449	chr4:95141228	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.46	-7.01	-0.4	1.94e-11	Capecitabine sensitivity;
CESC	cis	rs10129255	0.500	rs10131875	chr14:107201036	T/C	cg23076370	chr14:107095027	NA	-0.64	-9.33	-0.5	4.36e-18	Kawasaki disease;
CESC	cis	rs11792861	0.816	rs2275637	chr9:111696043	C/G	cg05043794	chr9:111880884	C9orf5	-0.37	-6.05	-0.35	5e-9	Menarche (age at onset);
CESC	cis	rs7129220	0.512	rs16907504	chr11:10169531	C/G	cg01453529	chr11:10209919	SBF2	-0.43	-5.07	-0.3	7.32e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CESC	cis	rs60843830	1.000	rs2290911	chr2:224919	A/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.78	9.89	0.52	7.58e-20	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs698833	0.859	rs1302175	chr2:44657024	G/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.47	5.98	0.34	7.17e-9	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs4665809	0.590	rs4665837	chr2:26434022	C/A	cg26314531	chr2:26401878	FAM59B	-0.85	-8.88	-0.48	1e-16	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26270411	chr20:43514327	YWHAB	0.65	7.93	0.44	6.31e-14	Gut microbiome composition (summer);
CESC	cis	rs2180341	0.960	rs7766802	chr6:127709871	T/G	cg24812749	chr6:127587940	RNF146	1.02	13.91	0.65	2.08e-33	Breast cancer;
CESC	cis	rs9916302	0.904	rs588193	chr17:37440439	A/C	cg07936489	chr17:37558343	FBXL20	0.77	10.91	0.56	4.02e-23	Glomerular filtration rate (creatinine);
CESC	cis	rs10492096	1.000	rs10849462	chr12:6575992	C/T	cg13857086	chr12:6580257	VAMP1	0.64	6.31	0.36	1.18e-9	Hip geometry;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg05095230	chr13:50367060	KPNA3	0.51	7.0	0.4	2.08e-11	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs12220238	1.000	rs11000901	chr10:75919971	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.65	6.16	0.35	2.66e-9	Soluble interleukin-2 receptor subunit alpha;
CESC	cis	rs1144333	1.000	rs1340684	chr1:76471146	T/C	cg22875332	chr1:76189707	ACADM	0.54	5.16	0.3	4.8e-7	Attention function in attention deficit hyperactive disorder;
CESC	cis	rs1372520	0.684	rs1837891	chr4:90736131	C/G	cg15133208	chr4:90757351	SNCA	0.41	5.61	0.33	5.17e-8	Neuroticism;
CESC	trans	rs4374383	0.631	rs10175316	chr2:112669874	A/G	cg12127991	chr1:228870637	RHOU	0.4	6.07	0.35	4.35e-9	Hepatitis C induced liver fibrosis;
CESC	cis	rs78456975	1.000	rs13413356	chr2:1553849	G/T	cg01028140	chr2:1542097	TPO	-0.51	-5.44	-0.32	1.24e-7	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs965469	0.779	rs57373308	chr20:3314715	G/C	cg25506879	chr20:3388711	C20orf194	-0.47	-5.13	-0.3	5.51e-7	IFN-related cytopenia;
CESC	trans	rs1945213	0.694	rs7122627	chr11:55862565	A/G	cg03929089	chr4:120376271	NA	0.77	7.35	0.41	2.48e-12	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs6089829	0.890	rs6062775	chr20:61663650	T/C	cg16240275	chr20:61666158	NCRNA00029	0.5	8.97	0.48	5.67e-17	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs10129255	0.518	rs2006284	chr14:107132201	G/A	cg07958169	chr14:107095056	NA	-0.54	-8.81	-0.48	1.67e-16	Kawasaki disease;
CESC	cis	rs911555	0.755	rs10148970	chr14:103892000	G/A	cg09975044	chr14:104007538	NA	0.45	5.63	0.33	4.63e-8	Intelligence (multi-trait analysis);
CESC	cis	rs4711336	1.000	rs764752	chr6:33658066	G/C	cg14003231	chr6:33640908	ITPR3	0.32	5.46	0.32	1.07e-7	Height;
CESC	cis	rs965513	1.000	rs10983701	chr9:100537577	G/A	cg13688889	chr9:100608707	NA	-0.61	-8.64	-0.47	5.56e-16	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
CESC	cis	rs3008870	0.583	rs11208985	chr1:67464666	G/A	cg08660285	chr1:67390436	MIER1;WDR78	-0.99	-11.11	-0.56	8.58e-24	Lymphocyte percentage of white cells;
CESC	cis	rs7666738	0.830	rs62321569	chr4:98984250	T/A	cg18180107	chr4:99064573	C4orf37	0.4	5.19	0.3	4.29e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4835473	0.932	rs4308330	chr4:144695914	A/G	cg25736465	chr4:144833511	NA	-0.33	-5.18	-0.3	4.39e-7	Immature fraction of reticulocytes;
CESC	cis	rs6690583	0.623	rs1371142	chr1:85455373	A/T	cg22153463	chr1:85462885	MCOLN2	0.72	7.18	0.4	7.13e-12	Serum sulfate level;
CESC	cis	rs8177179	0.666	rs4075352	chr3:133468012	A/G	cg24879335	chr3:133465180	TF	0.31	5.37	0.31	1.75e-7	Iron status biomarkers (transferrin levels);
CESC	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg23034840	chr1:205782522	SLC41A1	-0.58	-6.31	-0.36	1.19e-9	Menarche (age at onset);
CESC	cis	rs8070128	0.601	rs8080602	chr17:17954728	G/C	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.5	-6.33	-0.36	1.03e-9	Total body bone mineral density;
CESC	cis	rs7714584	1.000	rs7709388	chr5:150246539	C/G	cg22134413	chr5:150180641	NA	0.5	5.76	0.33	2.3e-8	Crohn's disease;
CESC	cis	rs6502050	0.835	rs7221451	chr17:80089785	A/G	cg11859384	chr17:80120422	CCDC57	-0.37	-5.12	-0.3	5.87e-7	Life satisfaction;
CESC	cis	rs9304742	0.962	rs1044467	chr19:53452769	A/G	cg09915433	chr19:53449742	NA	-0.38	-5.13	-0.3	5.48e-7	Psoriasis;
CESC	cis	rs10504229	0.609	rs56289889	chr8:58116276	G/C	cg24829409	chr8:58192753	C8orf71	-0.58	-7.2	-0.4	6.31e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs72615157	0.561	rs113844570	chr7:99873778	A/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.72	6.91	0.39	3.57e-11	Lung function (FEV1/FVC);
CESC	cis	rs77741769	0.549	rs57697145	chr12:121333552	T/G	cg02419362	chr12:121203948	SPPL3	0.35	5.6	0.33	5.33e-8	Mean corpuscular volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04228553	chr3:15247818	DVWA;CAPN7	0.63	7.65	0.43	3.71e-13	Gut microbiome composition (summer);
CESC	cis	rs2279817	0.735	rs71644063	chr1:17987274	A/G	cg21791023	chr1:18019539	ARHGEF10L	-0.66	-8.06	-0.44	2.67e-14	Neuroticism;
CESC	cis	rs875971	0.862	rs778697	chr7:65870426	G/A	cg10691866	chr7:65817282	TPST1	-0.33	-5.43	-0.32	1.3e-7	Aortic root size;
CESC	cis	rs6460942	0.732	rs73677576	chr7:12286535	G/A	cg20607287	chr7:12443886	VWDE	-0.59	-6.43	-0.37	5.83e-10	Coronary artery disease;
CESC	cis	rs897984	0.770	rs3813020	chr16:30934075	G/A	cg00531865	chr16:30841666	NA	0.51	7.12	0.4	1.01e-11	Dementia with Lewy bodies;
CESC	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.61	7.86	0.43	9.58e-14	Prudent dietary pattern;
CESC	cis	rs728616	0.558	rs12414691	chr10:82156982	A/T	cg05935833	chr10:81318306	SFTPA2	-0.46	-5.67	-0.33	3.63e-8	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs67311347	1.000	rs66841330	chr3:40531123	G/A	cg24209194	chr3:40518798	ZNF619	0.47	5.76	0.33	2.36e-8	Renal cell carcinoma;
CESC	cis	rs6582630	0.576	rs2387836	chr12:38560070	A/G	cg26384229	chr12:38710491	ALG10B	0.43	5.7	0.33	3.26e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs17376456	0.935	rs13156002	chr5:93508931	G/A	cg21475434	chr5:93447410	FAM172A	0.88	7.77	0.43	1.71e-13	Diabetic retinopathy;
CESC	cis	rs7917772	0.582	rs4917976	chr10:104360518	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.4	-5.54	-0.32	7.23e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs2645694	0.603	rs2703123	chr4:77821154	C/T	cg10057126	chr4:77819792	ANKRD56	0.59	8.61	0.47	6.84e-16	Emphysema distribution in smoking;
CESC	cis	rs870825	0.616	rs7678616	chr4:185648714	T/G	cg04058563	chr4:185651563	MLF1IP	0.63	6.96	0.39	2.59e-11	Blood protein levels;
CESC	cis	rs4629180	1.000	rs908133	chr2:102092374	A/C	cg01388757	chr2:102091195	RFX8	-0.38	-5.86	-0.34	1.37e-8	Chronic rhinosinusitis with nasal polyps;
CESC	cis	rs938554	0.806	rs4447862	chr4:9931645	C/G	cg00071950	chr4:10020882	SLC2A9	-0.44	-5.96	-0.34	8.01e-9	Blood metabolite levels;
CESC	cis	rs9660992	0.736	rs55673946	chr1:205250475	T/C	cg21643547	chr1:205240462	TMCC2	-0.48	-7.1	-0.4	1.15e-11	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs910316	1.000	rs9805979	chr14:75566209	G/A	cg08847533	chr14:75593920	NEK9	0.99	18.74	0.75	1.84e-50	Height;
CESC	cis	rs34779708	0.898	rs11595898	chr10:35326263	T/C	cg04310649	chr10:35416472	CREM	-0.48	-5.8	-0.34	1.85e-8	Inflammatory bowel disease;Crohn's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01172785	chr16:50092553	NA	-0.76	-8.52	-0.46	1.25e-15	Gut microbiome composition (summer);
CESC	cis	rs36096196	0.891	rs12082516	chr1:2251160	C/T	cg17974515	chr1:2252516	NA	-0.45	-7.85	-0.43	1e-13	Coronary artery disease;
CESC	cis	rs9649213	0.593	rs13246942	chr7:97915021	C/T	cg24562669	chr7:97807699	LMTK2	0.51	7.35	0.41	2.45e-12	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs4268898	1.000	rs1203	chr2:24443330	A/G	cg20701182	chr2:24300061	SF3B14	-0.43	-5.23	-0.31	3.4e-7	Asthma;
CESC	trans	rs875971	0.638	rs801205	chr7:66022144	C/A	cg26939375	chr7:64535504	NA	-0.64	-8.7	-0.47	3.62e-16	Aortic root size;
CESC	cis	rs258892	0.895	rs57787613	chr5:72047278	C/A	cg21869765	chr5:72125136	TNPO1	-0.4	-5.13	-0.3	5.56e-7	Small cell lung carcinoma;
CESC	cis	rs1005277	0.522	rs289645	chr10:37943642	T/C	cg00409905	chr10:38381863	ZNF37A	-0.48	-6.54	-0.37	3.13e-10	Extrinsic epigenetic age acceleration;
CESC	cis	rs6502050	0.604	rs9897355	chr17:80078095	G/A	cg23985595	chr17:80112537	CCDC57	0.41	6.54	0.37	3.19e-10	Life satisfaction;
CESC	trans	rs7944735	1.000	rs7944735	chr11:47955608	G/C	cg15704280	chr7:45808275	SEPT13	0.61	6.36	0.36	8.65e-10	Intraocular pressure;
CESC	cis	rs6502050	0.805	rs9898326	chr17:80119582	C/T	cg23985595	chr17:80112537	CCDC57	-0.41	-6.57	-0.37	2.6e-10	Life satisfaction;
CESC	trans	rs459571	0.920	rs455073	chr9:136909141	G/C	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.65	-8.58	-0.47	8.08e-16	Platelet distribution width;
CESC	cis	rs854765	0.583	rs8075965	chr17:17853180	A/T	cg16928487	chr17:17741425	SREBF1	-0.57	-9.58	-0.51	7.39e-19	Total body bone mineral density;
CESC	cis	rs3096299	0.685	rs12935112	chr16:89542858	C/T	cg08392591	chr16:89556376	ANKRD11	-0.52	-7.05	-0.4	1.56e-11	Multiple myeloma (IgH translocation);
CESC	cis	rs7429990	0.930	rs13075457	chr3:48054553	A/G	cg11946769	chr3:48343235	NME6	-0.43	-5.18	-0.3	4.46e-7	Educational attainment (years of education);
CESC	cis	rs5769765	0.955	rs9616368	chr22:50303533	C/G	cg26441486	chr22:50317300	CRELD2	0.42	5.28	0.31	2.66e-7	Schizophrenia;
CESC	cis	rs727563	0.593	rs5758461	chr22:42162189	G/C	cg06481639	chr22:41940642	POLR3H	0.6	5.97	0.34	7.49e-9	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs9916302	0.904	rs1077715	chr17:37683548	A/T	cg15445000	chr17:37608096	MED1	0.4	6.6	0.38	2.19e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs8070624	0.543	rs8068175	chr17:17874486	C/T	cg04398451	chr17:18023971	MYO15A	-0.69	-9.51	-0.5	1.19e-18	Total body bone mineral density;
CESC	cis	rs854765	0.624	rs9899634	chr17:17727943	A/T	cg04398451	chr17:18023971	MYO15A	0.57	7.71	0.43	2.58e-13	Total body bone mineral density;
CESC	cis	rs7264396	0.790	rs761825	chr20:34194054	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.6	-8.29	-0.45	5.67e-15	Total cholesterol levels;
CESC	cis	rs6679073	1.000	rs6679073	chr1:205756484	A/C	cg14893161	chr1:205819251	PM20D1	0.43	5.99	0.35	6.82e-9	Prostate-specific antigen levels;
CESC	cis	rs2777491	0.957	rs6493002	chr15:41709195	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.65	-9.87	-0.52	8.9e-20	Ulcerative colitis;
CESC	cis	rs875971	0.862	rs10263690	chr7:65766453	G/C	cg18876405	chr7:65276391	NA	-0.5	-6.92	-0.39	3.36e-11	Aortic root size;
CESC	cis	rs2073300	0.609	rs17830281	chr20:23350525	C/T	cg16736954	chr20:23401023	NAPB	0.77	5.74	0.33	2.6e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	trans	rs116095464	0.558	rs10055405	chr5:265666	C/T	cg00938859	chr5:1591904	SDHAP3	0.64	6.9	0.39	3.8e-11	Breast cancer;
CESC	cis	rs9467711	0.659	rs35304979	chr6:26356347	C/A	cg14345882	chr6:26364793	BTN3A2	0.59	6.06	0.35	4.66e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs2635047	0.615	rs2571007	chr18:44645610	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.43	-5.4	-0.31	1.5e-7	Educational attainment;
CESC	cis	rs75920871	0.562	rs68137714	chr11:117025357	A/G	cg01368799	chr11:117014884	PAFAH1B2	-0.57	-5.14	-0.3	5.26e-7	Subjective well-being;
CESC	cis	rs67478160	0.634	rs1955660	chr14:104229985	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.52	-7.56	-0.42	6.69e-13	Schizophrenia;
CESC	cis	rs10504229	1.000	rs66495524	chr8:58187365	C/T	cg22535103	chr8:58192502	C8orf71	-1.05	-13.08	-0.63	1.71e-30	Developmental language disorder (linguistic errors);
CESC	cis	rs61931739	0.534	rs11053073	chr12:34202412	C/T	cg19457237	chr12:34500585	NA	-0.38	-5.33	-0.31	2.12e-7	Morning vs. evening chronotype;
CESC	cis	rs7824557	0.564	rs2736288	chr8:11228100	G/A	cg21775007	chr8:11205619	TDH	-0.53	-7.78	-0.43	1.63e-13	Retinal vascular caliber;
CESC	cis	rs909002	0.772	rs6681414	chr1:32070234	G/A	cg13919466	chr1:32135498	COL16A1	-0.47	-8.6	-0.47	6.88e-16	Intelligence (multi-trait analysis);
CESC	cis	rs853679	0.517	rs9368555	chr6:28108967	T/C	cg12963246	chr6:28129442	ZNF389	0.57	7.67	0.43	3.36e-13	Depression;
CESC	cis	rs2742234	0.541	rs60845448	chr10:43721462	C/T	cg15436174	chr10:43711423	RASGEF1A	0.47	5.58	0.32	5.81e-8	Hirschsprung disease;
CESC	cis	rs2625529	0.526	rs8031386	chr15:72508799	C/A	cg16672083	chr15:72433130	SENP8	-0.44	-6.1	-0.35	3.76e-9	Red blood cell count;
CESC	cis	rs1707322	0.721	rs10890343	chr1:46157922	C/T	cg03146154	chr1:46216737	IPP	0.77	10.66	0.55	2.5e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs1814175	0.754	rs10839453	chr11:49955815	A/T	cg03929089	chr4:120376271	NA	-0.93	-16.29	-0.71	8.13e-42	Height;
CESC	cis	rs1443512	0.812	rs1975470	chr12:54336841	G/A	cg12374095	chr12:54320830	NA	-0.46	-6.37	-0.36	8.26e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
CESC	cis	rs2425143	1.000	rs11907811	chr20:34428078	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.73	-6.78	-0.38	7.94e-11	Blood protein levels;
CESC	cis	rs7666738	0.830	rs34273190	chr4:99004568	C/T	cg17366294	chr4:99064904	C4orf37	0.6	8.61	0.47	6.47e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9487051	0.872	rs9386791	chr6:109608497	C/T	cg01475377	chr6:109611718	NA	-0.51	-8.36	-0.46	3.66e-15	Reticulocyte fraction of red cells;
CESC	cis	rs9457247	0.602	rs12209395	chr6:167463914	C/T	cg23791538	chr6:167370224	RNASET2	-0.49	-6.39	-0.37	7.62e-10	Crohn's disease;
CESC	cis	rs9309473	1.000	rs7604682	chr2:73788026	G/A	cg20560298	chr2:73613845	ALMS1	-0.47	-6.37	-0.36	8.47e-10	Metabolite levels;
CESC	cis	rs1511802	0.579	rs7682918	chr4:187115841	C/T	cg24794857	chr4:187113578	CYP4V2	0.42	5.42	0.32	1.36e-7	Blood protein levels;
CESC	cis	rs367943	1.000	rs367943	chr5:112809728	C/T	cg12552261	chr5:112820674	MCC	0.6	7.35	0.41	2.42e-12	Type 2 diabetes;
CESC	cis	rs854765	0.547	rs4584886	chr17:17896205	C/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.47	6.07	0.35	4.52e-9	Total body bone mineral density;
CESC	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.49	-5.2	-0.3	4.06e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs10504229	0.679	rs12375285	chr8:58040084	G/A	cg22535103	chr8:58192502	C8orf71	-0.67	-7.23	-0.41	5.31e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs1707322	1.000	rs10890378	chr1:46410657	A/G	cg05343316	chr1:45956843	TESK2	-0.44	-5.42	-0.32	1.36e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9926296	0.632	rs7206546	chr16:89799079	C/T	cg04287289	chr16:89883240	FANCA	-0.65	-8.72	-0.47	3.11e-16	Vitiligo;
CESC	cis	rs3096299	0.719	rs2965817	chr16:89513234	C/T	cg16743903	chr16:89593216	SPG7	-0.41	-5.23	-0.31	3.4e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs10504229	0.683	rs72649192	chr8:58110490	T/C	cg21724239	chr8:58056113	NA	0.6	5.55	0.32	6.93e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs9311474	0.652	rs411457	chr3:52228150	A/T	cg07507251	chr3:52567010	NT5DC2	-0.37	-6.44	-0.37	5.55e-10	Electroencephalogram traits;
CESC	cis	rs4423214	1.000	rs1044482	chr11:71155171	C/T	cg24826892	chr11:71159390	DHCR7	0.49	5.84	0.34	1.49e-8	Vitamin D levels;
CESC	cis	rs73195822	0.773	rs10849903	chr12:111112319	T/C	cg12870014	chr12:110450643	ANKRD13A	0.76	7.62	0.42	4.46e-13	Itch intensity from mosquito bite;
CESC	cis	rs34779708	0.966	rs4934537	chr10:35441512	C/T	cg04310649	chr10:35416472	CREM	-0.51	-6.21	-0.36	2.08e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs7917772	0.636	rs2863718	chr10:104519631	G/C	cg04362960	chr10:104952993	NT5C2	0.46	5.24	0.31	3.21e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs8177253	0.761	rs12490148	chr3:133523973	C/T	cg18769074	chr3:133464867	TF	0.29	5.12	0.3	6.02e-7	Iron status biomarkers;
CESC	cis	rs10129255	0.518	rs8009594	chr14:107185733	G/T	cg23076370	chr14:107095027	NA	-0.67	-10.02	-0.52	3.08e-20	Kawasaki disease;
CESC	cis	rs1413885	0.502	rs7545397	chr1:65856282	C/A	cg14976592	chr1:65886160	LEPROT;LEPR	0.49	6.41	0.37	6.53e-10	Anticoagulant levels;
CESC	cis	rs4689592	0.503	rs2292461	chr4:7058473	C/T	cg26116260	chr4:7069785	GRPEL1	0.74	8.82	0.48	1.54e-16	Monocyte percentage of white cells;
CESC	cis	rs1552244	1.000	rs6807846	chr3:10134491	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.84	-11.53	-0.58	3.5e-25	Alzheimer's disease;
CESC	trans	rs1814175	0.565	rs4881721	chr11:49761851	G/A	cg15704280	chr7:45808275	SEPT13	-0.81	-11.18	-0.57	4.85e-24	Height;
CESC	cis	rs10504229	0.728	rs17804335	chr8:58151428	G/T	cg22535103	chr8:58192502	C8orf71	0.86	9.66	0.51	4.12e-19	Developmental language disorder (linguistic errors);
CESC	cis	rs8103278	0.507	rs8112282	chr19:46265029	C/T	cg06577658	chr19:46296270	DMWD	0.43	5.27	0.31	2.77e-7	Coronary artery disease;
CESC	cis	rs2066819	1.000	rs2306693	chr12:56680531	T/C	cg26734620	chr12:56694298	CS	1.07	6.58	0.37	2.56e-10	Psoriasis vulgaris;
CESC	cis	rs9910055	0.530	rs2269908	chr17:42294198	G/C	cg19774624	chr17:42201019	HDAC5	-0.59	-8.54	-0.46	1.04e-15	Total body bone mineral density;
CESC	cis	rs2243480	1.000	rs10247526	chr7:65780696	T/G	cg13147721	chr7:65941812	NA	0.97	9.19	0.49	1.21e-17	Diabetic kidney disease;
CESC	cis	rs453301	0.686	rs7814328	chr8:8876229	T/C	cg15556689	chr8:8085844	FLJ10661	-0.47	-5.72	-0.33	2.93e-8	Joint mobility (Beighton score);
CESC	cis	rs9325144	0.647	rs1386018	chr12:39104360	C/T	cg26384229	chr12:38710491	ALG10B	-0.5	-7.06	-0.4	1.47e-11	Morning vs. evening chronotype;
CESC	cis	rs9858542	1.000	rs1131095	chr3:49714225	T/C	cg07274523	chr3:49395745	GPX1	0.66	8.53	0.46	1.13e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg01100864	chr12:122750645	VPS33A	0.45	6.23	0.36	1.8e-9	Systemic lupus erythematosus;
CESC	cis	rs3784262	0.935	rs4646563	chr15:58353335	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.33	-5.37	-0.31	1.76e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
CESC	cis	rs1218582	0.741	rs10908446	chr1:154869559	G/A	cg06221963	chr1:154839813	KCNN3	-0.67	-11.38	-0.57	1.05e-24	Prostate cancer;
CESC	cis	rs2228479	0.850	rs11644804	chr16:89976224	G/A	cg00800038	chr16:89945340	TCF25	-0.79	-7.7	-0.43	2.8e-13	Skin colour saturation;
CESC	cis	rs4819052	0.851	rs2838844	chr21:46670733	A/C	cg11663144	chr21:46675770	NA	-0.64	-10.02	-0.52	2.95e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs9309473	0.898	rs6546852	chr2:73833431	G/A	cg20560298	chr2:73613845	ALMS1	-0.45	-6.03	-0.35	5.44e-9	Metabolite levels;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg07115558	chr19:3029503	TLE2	-0.48	-6.12	-0.35	3.41e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs3749237	0.595	rs1050088	chr3:49570882	C/T	cg02487422	chr3:49467188	NICN1	-0.52	-7.55	-0.42	6.85e-13	Resting heart rate;
CESC	cis	rs4835473	0.864	rs17018131	chr4:144658800	G/T	cg25736465	chr4:144833511	NA	-0.34	-5.3	-0.31	2.46e-7	Immature fraction of reticulocytes;
CESC	cis	rs9611565	0.532	rs4401299	chr22:42156517	A/G	cg06634786	chr22:41940651	POLR3H	0.5	5.61	0.33	5.08e-8	Vitiligo;
CESC	cis	rs7412746	0.658	rs3768015	chr1:150812954	C/T	cg22823121	chr1:150693482	HORMAD1	0.46	6.49	0.37	4.22e-10	Melanoma;
CESC	cis	rs2836974	0.604	rs2854727	chr21:40713787	A/G	cg11890956	chr21:40555474	PSMG1	0.67	9.32	0.5	4.7e-18	Cognitive function;
CESC	cis	rs12725198	1.000	rs12725694	chr1:16080501	G/A	cg18133145	chr1:16060689	PLEKHM2	-0.52	-5.66	-0.33	4e-8	Cardiac Troponin-T levels;
CESC	cis	rs1545257	0.505	rs958352	chr2:24634240	A/G	cg06627628	chr2:24431161	ITSN2	-0.47	-5.72	-0.33	2.84e-8	Sjögren's syndrome;
CESC	cis	rs55871839	0.708	rs13261666	chr8:59814666	G/T	cg07426533	chr8:59803705	TOX	-0.51	-7.41	-0.41	1.71e-12	Pneumonia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05842370	chr22:41682224	RANGAP1	0.61	7.15	0.4	8.47e-12	Gut microbiome composition (summer);
CESC	cis	rs1862618	0.853	rs832568	chr5:56153776	G/A	cg03609598	chr5:56110824	MAP3K1	-0.53	-5.57	-0.32	6.1e-8	Initial pursuit acceleration;
CESC	cis	rs7143963	0.580	rs6575931	chr14:103301574	A/G	cg24154132	chr14:103367632	TRAF3	0.31	5.64	0.33	4.28e-8	Body mass index;
CESC	cis	rs1799949	1.000	rs33946455	chr17:41321846	C/T	cg23758822	chr17:41437982	NA	1.05	16.24	0.71	1.24e-41	Menopause (age at onset);
CESC	cis	rs35955747	0.869	rs5753576	chr22:31757735	C/T	cg25791279	chr22:32026902	PISD	0.48	5.97	0.34	7.59e-9	Neutrophil count;Sum basophil neutrophil counts;
CESC	cis	rs9487051	0.768	rs398944	chr6:109523444	T/G	cg01475377	chr6:109611718	NA	-0.46	-6.95	-0.39	2.75e-11	Reticulocyte fraction of red cells;
CESC	cis	rs17376456	0.877	rs10476526	chr5:93461916	G/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.62	5.44	0.32	1.23e-7	Diabetic retinopathy;
CESC	cis	rs7223966	1.000	rs8067431	chr17:61817048	T/C	cg11494091	chr17:61959527	GH2	0.4	5.31	0.31	2.3e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs7258465	1.000	rs8103622	chr19:18572834	C/T	cg25828334	chr19:18545568	ISYNA1	-0.33	-5.34	-0.31	2.04e-7	Breast cancer;
CESC	cis	rs12410462	0.681	rs4614224	chr1:227574966	C/T	cg23173402	chr1:227635558	NA	0.68	5.71	0.33	2.96e-8	Major depressive disorder;
CESC	cis	rs1983891	0.673	rs912883	chr6:41552040	T/C	cg20194872	chr6:41519635	FOXP4	0.46	6.54	0.37	3.14e-10	Prostate cancer;
CESC	cis	rs7474896	0.583	rs1208770	chr10:38044683	C/T	cg25427524	chr10:38739819	LOC399744	-0.48	-5.26	-0.31	3.05e-7	Obesity (extreme);
CESC	cis	rs9291683	0.632	rs11734786	chr4:10041499	A/C	cg11266682	chr4:10021025	SLC2A9	0.67	13.02	0.62	2.72e-30	Bone mineral density;
CESC	cis	rs11098499	0.599	rs3864142	chr4:120266191	A/T	cg09307838	chr4:120376055	NA	0.75	9.66	0.51	4.11e-19	Corneal astigmatism;
CESC	cis	rs12497850	0.931	rs7431710	chr3:48935583	G/A	cg06212747	chr3:49208901	KLHDC8B	0.66	9.13	0.49	1.8e-17	Parkinson's disease;
CESC	cis	rs7301826	1.000	rs10773822	chr12:131289107	C/G	cg11011512	chr12:131303247	STX2	0.4	5.08	0.3	7.16e-7	Plasma plasminogen activator levels;
CESC	cis	rs798554	0.757	rs960273	chr7:2857876	T/C	cg13628971	chr7:2884303	GNA12	0.64	8.03	0.44	3.22e-14	Height;
CESC	cis	rs853679	0.517	rs9380050	chr6:28048538	A/G	cg12963246	chr6:28129442	ZNF389	0.55	7.35	0.41	2.46e-12	Depression;
CESC	trans	rs11818084	0.664	rs12573789	chr10:126002644	A/G	cg19462022	chr13:114810756	RASA3	0.37	6.02	0.35	5.73e-9	Clozapine-induced cytotoxicity;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22708233	chr11:47198576	ARFGAP2	0.62	7.48	0.42	1.11e-12	Gut microbiome composition (summer);
CESC	cis	rs9649213	0.574	rs6961790	chr7:98007993	C/G	cg00277769	chr7:97922759	BAIAP2L1	-0.33	-5.52	-0.32	8.02e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs4604732	0.588	rs12045675	chr1:247623915	C/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.57	7.05	0.4	1.54e-11	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs9733	0.596	rs72702556	chr1:150680115	C/T	cg04414720	chr1:150670196	GOLPH3L	0.62	8.85	0.48	1.24e-16	Tonsillectomy;
CESC	cis	rs727505	1.000	rs7806680	chr7:124433079	G/A	cg23710748	chr7:124431027	NA	-0.39	-6.5	-0.37	4.07e-10	Lewy body disease;
CESC	cis	rs2637266	0.703	rs846643	chr10:78516889	T/G	cg18941641	chr10:78392320	NA	0.39	7.46	0.42	1.25e-12	Pulmonary function;
CESC	cis	rs9457247	0.967	rs430145	chr6:167410369	C/T	cg23791538	chr6:167370224	RNASET2	-0.61	-8.81	-0.48	1.71e-16	Crohn's disease;
CESC	cis	rs9462846	0.919	rs12202901	chr6:42828550	A/T	cg05552183	chr6:42928497	GNMT	0.43	5.11	0.3	6.07e-7	Blood protein levels;
CESC	trans	rs12310956	0.532	rs11052948	chr12:33981973	T/C	cg26384229	chr12:38710491	ALG10B	0.6	8.23	0.45	8.51e-15	Morning vs. evening chronotype;
CESC	cis	rs7219021	0.892	rs66866087	chr17:46849323	C/T	cg16584676	chr17:46985605	UBE2Z	-0.52	-5.91	-0.34	1.04e-8	Schizophrenia or bipolar disorder;
CESC	cis	rs4595586	0.545	rs12811619	chr12:39392196	T/C	cg26384229	chr12:38710491	ALG10B	0.54	7.64	0.42	3.96e-13	Morning vs. evening chronotype;
CESC	trans	rs9929218	0.508	rs6499194	chr16:68744100	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.9	14.6	0.67	8.11e-36	Colorectal cancer;
CESC	trans	rs916888	0.773	rs199448	chr17:44809001	A/G	cg10053473	chr17:62856997	LRRC37A3	-0.73	-8.1	-0.45	2.06e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg21944557	chr1:179923876	CEP350	-0.49	-6.42	-0.37	6.16e-10	Ulcerative colitis;
CESC	cis	rs9796	0.689	rs13329537	chr15:41449211	C/G	cg12426344	chr15:41135900	SPINT1	0.23	5.04	0.3	8.65e-7	Menopause (age at onset);
CESC	cis	rs1499972	0.715	rs1463403	chr3:117623116	C/T	cg07612923	chr3:117604196	NA	-0.45	-5.09	-0.3	6.95e-7	Schizophrenia;
CESC	cis	rs7727544	0.735	rs272860	chr5:131684175	C/G	cg07395648	chr5:131743802	NA	-0.43	-5.68	-0.33	3.56e-8	Blood metabolite levels;
CESC	cis	rs7412746	0.658	rs6656535	chr1:150940357	G/T	cg17724175	chr1:150552817	MCL1	0.38	5.85	0.34	1.42e-8	Melanoma;
CESC	trans	rs116095464	0.558	rs6555055	chr5:226160	A/C	cg00938859	chr5:1591904	SDHAP3	0.61	6.84	0.39	5.52e-11	Breast cancer;
CESC	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg06873352	chr17:61820015	STRADA	0.72	12.76	0.62	2.21e-29	Prudent dietary pattern;
CESC	cis	rs34375054	0.526	rs2343638	chr12:125677122	G/C	cg25124228	chr12:125621409	AACS	-0.5	-5.84	-0.34	1.49e-8	Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs2576037	0.545	rs9948405	chr18:44494527	C/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.39	6.26	0.36	1.53e-9	Personality dimensions;
CESC	cis	rs3096299	0.933	rs2965934	chr16:89481229	C/G	cg08392591	chr16:89556376	ANKRD11	0.41	5.37	0.31	1.71e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs868036	1.000	rs4776376	chr15:68093435	G/A	cg08079166	chr15:68083412	MAP2K5	0.44	6.94	0.39	2.94e-11	Restless legs syndrome;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26618056	chr16:25043323	NA	0.62	7.11	0.4	1.06e-11	Gut microbiome composition (summer);
CESC	cis	rs35096708	1.000	rs35096708	chr16:89887249	G/A	cg27130406	chr16:89901659	SPIRE2	-0.4	-5.19	-0.3	4.29e-7	Skin aging (microtopography measurement);
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg14443380	chr15:74725882	SEMA7A	-0.43	-6.54	-0.37	3.19e-10	Vertical cup-disc ratio;
CESC	cis	rs10129255	0.785	rs10150044	chr14:107183934	T/A	cg07958169	chr14:107095056	NA	-0.41	-5.79	-0.33	2.01e-8	Kawasaki disease;
CESC	cis	rs6831352	0.589	rs1133483	chr4:100023923	G/C	cg12011299	chr4:100065546	ADH4	0.72	10.96	0.56	2.76e-23	Alcohol dependence;
CESC	cis	rs3741151	1.000	rs79078097	chr11:73049771	G/A	cg17517138	chr11:73019481	ARHGEF17	0.69	5.46	0.32	1.07e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs7811142	0.943	rs67483801	chr7:100031758	G/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.82	8.2	0.45	1.06e-14	Platelet count;
CESC	cis	rs1395	0.677	rs113353646	chr2:27492674	C/T	cg22903471	chr2:27725779	GCKR	-0.45	-5.46	-0.32	1.11e-7	Blood metabolite levels;
CESC	cis	rs7927771	0.929	rs12787646	chr11:47669665	T/C	cg20307385	chr11:47447363	PSMC3	-0.51	-6.28	-0.36	1.35e-9	Subjective well-being;
CESC	cis	rs7811142	0.830	rs11769057	chr7:99964661	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.69	6.31	0.36	1.14e-9	Platelet count;
CESC	cis	rs7267979	0.966	rs6037097	chr20:25347221	C/T	cg08601574	chr20:25228251	PYGB	0.38	5.47	0.32	1.05e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7000551	0.751	rs2443494	chr8:22372262	C/G	cg12081754	chr8:22256438	SLC39A14	0.42	5.63	0.33	4.69e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CESC	cis	rs3936840	0.539	rs11850701	chr14:102983857	G/A	cg18135206	chr14:102964638	TECPR2	0.44	5.63	0.33	4.67e-8	Plateletcrit;
CESC	cis	rs7089973	0.604	rs7919649	chr10:116609576	T/C	cg25233709	chr10:116636983	FAM160B1	0.37	5.92	0.34	9.85e-9	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs55883249	1.000	rs62119391	chr2:9712272	A/G	cg23886495	chr2:9695866	ADAM17	0.59	5.52	0.32	7.91e-8	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
CESC	cis	rs61542988	0.532	rs12673996	chr7:22833400	C/T	cg11367502	chr7:22862612	TOMM7	0.46	5.71	0.33	3.08e-8	Fibrinogen levels;
CESC	cis	rs57083693	0.551	rs10860709	chr12:101723363	G/T	cg22051763	chr12:101673672	UTP20	-0.49	-6.06	-0.35	4.55e-9	Alcohol dependence (age at onset);
CESC	cis	rs763121	0.853	rs3747172	chr22:39067524	A/G	cg21395723	chr22:39101663	GTPBP1	0.42	5.32	0.31	2.17e-7	Menopause (age at onset);
CESC	cis	rs919433	0.927	rs13032495	chr2:198189346	C/T	cg03934865	chr2:198174659	NA	-0.49	-7.07	-0.4	1.34e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs9303401	0.659	rs62081314	chr17:56778328	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	1.03	12.82	0.62	1.31e-29	Cognitive test performance;
CESC	cis	rs13256369	0.851	rs12541477	chr8:8563895	G/A	cg17143192	chr8:8559678	CLDN23	0.78	8.81	0.48	1.63e-16	Obesity-related traits;
CESC	cis	rs7618915	0.501	rs2336146	chr3:52626646	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.6	8.56	0.47	9.4e-16	Bipolar disorder;
CESC	cis	rs4665809	1.000	rs4233708	chr2:26291345	C/T	cg08470875	chr2:26401718	FAM59B	-0.46	-5.14	-0.3	5.45e-7	Gut microbiome composition (summer);
CESC	cis	rs1062177	1.000	rs72802204	chr5:151183183	T/C	cg12924095	chr5:151150029	G3BP1	0.49	6.5	0.37	3.86e-10	Preschool internalizing problems;
CESC	cis	rs3820928	0.874	rs3752895	chr2:227886773	A/G	cg05526886	chr2:227700861	RHBDD1	-0.44	-5.7	-0.33	3.24e-8	Pulmonary function;
CESC	trans	rs9296661	0.522	rs1326587	chr6:51673684	C/T	cg15101985	chr10:85961501	PCDH21	-0.49	-6.09	-0.35	3.86e-9	Weight loss (gastric bypass surgery);
CESC	cis	rs3768617	0.510	rs2296294	chr1:183095596	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.89	14.39	0.66	4.39e-35	Fuchs's corneal dystrophy;
CESC	cis	rs7618915	0.571	rs34115864	chr3:52612178	A/G	cg18337363	chr3:52569053	NT5DC2	0.29	5.08	0.3	7.02e-7	Bipolar disorder;
CESC	cis	rs2404602	0.618	rs12442266	chr15:76567142	T/C	cg26408565	chr15:76604113	ETFA	-0.4	-5.86	-0.34	1.39e-8	Blood metabolite levels;
CESC	cis	rs4835473	0.864	rs13135472	chr4:144910618	T/C	cg25736465	chr4:144833511	NA	0.42	6.43	0.37	6.02e-10	Immature fraction of reticulocytes;
CESC	cis	rs10089	0.909	rs7732599	chr5:127370421	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.76	9.55	0.51	8.83e-19	Ileal carcinoids;
CESC	cis	rs10504229	0.636	rs77290284	chr8:58055269	G/T	cg24829409	chr8:58192753	C8orf71	-0.61	-6.7	-0.38	1.24e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs561341	0.941	rs2428341	chr17:30317295	C/T	cg19193384	chr17:30244184	NA	-0.53	-6.19	-0.36	2.23e-9	Hip circumference adjusted for BMI;
CESC	cis	rs66573146	0.656	rs111560662	chr4:6952766	C/T	cg26116260	chr4:7069785	GRPEL1	-0.83	-5.2	-0.3	3.95e-7	Granulocyte percentage of myeloid white cells;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg16011583	chr17:59489182	C17orf82	-0.57	-7.39	-0.41	1.91e-12	Ulcerative colitis;
CESC	cis	rs10489525	0.556	rs11102882	chr1:115612222	T/A	cg01522456	chr1:115632236	TSPAN2	0.39	5.11	0.3	6.3e-7	Autism;
CESC	cis	rs17001868	0.568	rs9611311	chr22:40733951	T/C	cg07138101	chr22:40742427	ADSL	0.54	5.18	0.3	4.49e-7	Mammographic density (dense area);
CESC	cis	rs4568518	0.619	rs4470902	chr7:18008310	A/G	cg03009463	chr7:17980271	SNX13	-0.42	-5.59	-0.32	5.65e-8	Measles;
CESC	cis	rs6570726	0.967	rs441364	chr6:145853662	G/C	cg23711669	chr6:146136114	FBXO30	0.75	10.73	0.55	1.55e-22	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs11098499	0.780	rs12504773	chr4:120562149	G/C	cg24375607	chr4:120327624	NA	0.43	5.29	0.31	2.58e-7	Corneal astigmatism;
CESC	cis	rs1983891	1.000	rs913074	chr6:41538545	T/C	cg20194872	chr6:41519635	FOXP4	0.51	6.95	0.39	2.87e-11	Prostate cancer;
CESC	trans	rs11098499	0.818	rs7688802	chr4:120451668	G/A	cg25214090	chr10:38739885	LOC399744	0.7	9.62	0.51	5.47e-19	Corneal astigmatism;
CESC	cis	rs4268898	1.000	rs1203	chr2:24443330	A/G	cg06627628	chr2:24431161	ITSN2	0.67	8.13	0.45	1.67e-14	Asthma;
CESC	cis	rs7647973	0.626	rs1586827	chr3:49671224	T/C	cg13072238	chr3:49761600	GMPPB	-0.45	-5.49	-0.32	9.57e-8	Menarche (age at onset);
CESC	cis	rs17711722	0.522	rs62469933	chr7:65265639	G/A	cg14393609	chr7:65229607	NA	0.44	6.06	0.35	4.67e-9	Calcium levels;
CESC	cis	rs11077998	0.844	rs12185254	chr17:80498972	C/T	cg10255544	chr17:80519551	FOXK2	0.55	8.85	0.48	1.27e-16	Reticulocyte fraction of red cells;
CESC	cis	rs36051895	0.632	rs62541945	chr9:5161571	T/C	cg02405213	chr9:5042618	JAK2	-0.49	-5.55	-0.32	6.82e-8	Pediatric autoimmune diseases;
CESC	cis	rs7412746	0.611	rs10888395	chr1:150762171	C/T	cg17724175	chr1:150552817	MCL1	0.4	5.98	0.35	7.05e-9	Melanoma;
CESC	cis	rs936229	1.000	rs936229	chr15:75132319	A/G	cg14664628	chr15:75095509	CSK	-0.84	-11.11	-0.56	8.71e-24	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CESC	cis	rs4319547	0.915	rs7966094	chr12:123115771	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.59	-6.91	-0.39	3.56e-11	Body mass index;
CESC	cis	rs34734847	0.787	rs1814851	chr12:121128633	C/G	cg26008908	chr12:120799332	MSI1	0.35	5.31	0.31	2.33e-7	Mean corpuscular volume;
CESC	cis	rs13242816	1.000	rs2191498	chr7:116138569	C/T	cg04696780	chr7:116139425	CAV2	-0.61	-5.51	-0.32	8.44e-8	P wave duration;
CESC	cis	rs7819412	0.668	rs2409721	chr8:11038244	A/T	cg21775007	chr8:11205619	TDH	-0.36	-5.07	-0.3	7.4e-7	Triglycerides;
CESC	cis	rs694739	0.536	rs11231740	chr11:64046641	C/T	cg23796481	chr11:64053134	BAD;GPR137	-0.44	-5.33	-0.31	2.08e-7	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CESC	cis	rs947211	0.948	rs1775143	chr1:205755550	C/T	cg17178900	chr1:205818956	PM20D1	0.4	5.31	0.31	2.36e-7	Parkinson's disease;
CESC	cis	rs6088590	1.000	rs2295354	chr20:33356541	T/C	cg06115741	chr20:33292138	TP53INP2	0.6	7.28	0.41	3.73e-12	Coronary artery disease;
CESC	cis	rs9443189	0.813	rs2133191	chr6:76440761	C/T	cg01950844	chr6:76311363	SENP6	-0.65	-7.14	-0.4	8.95e-12	Prostate cancer;
CESC	cis	rs1348850	0.651	rs4893931	chr2:178228212	T/C	cg23306229	chr2:178417860	TTC30B	0.5	6.67	0.38	1.46e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs853679	0.607	rs17763089	chr6:27835218	G/A	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.93	6.78	0.38	7.9e-11	Depression;
CESC	cis	rs34172651	0.517	rs12927710	chr16:24790282	A/C	cg04756594	chr16:24857601	SLC5A11	0.49	5.7	0.33	3.11e-8	Intelligence (multi-trait analysis);
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg27415969	chr3:186500848	EIF4A2	-0.47	-6.05	-0.35	5.02e-9	Height;
CESC	cis	rs35306767	0.903	rs12763396	chr10:927357	C/A	cg10556349	chr10:835070	NA	0.54	5.39	0.31	1.56e-7	Eosinophil percentage of granulocytes;
CESC	cis	rs3096299	0.967	rs2965937	chr16:89488779	A/T	cg08392591	chr16:89556376	ANKRD11	0.44	5.69	0.33	3.28e-8	Multiple myeloma (IgH translocation);
CESC	cis	rs360798	0.512	rs34104251	chr2:62995183	A/G	cg17519650	chr2:63277830	OTX1	-0.57	-7.51	-0.42	8.98e-13	Coronary artery disease;
CESC	cis	rs6499129	1.000	rs7185709	chr16:67529349	T/G	cg26727032	chr16:67993705	SLC12A4	-0.55	-5.79	-0.34	1.99e-8	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs2228479	0.850	rs11076624	chr16:89855749	T/C	cg04013166	chr16:89971882	TCF25	0.78	6.67	0.38	1.44e-10	Skin colour saturation;
CESC	trans	rs116095464	0.614	rs56299325	chr5:220594	C/T	cg00938859	chr5:1591904	SDHAP3	0.6	6.66	0.38	1.55e-10	Breast cancer;
CESC	cis	rs763014	1.000	rs7205409	chr16:642610	A/G	cg00802000	chr16:706648	WDR90	-0.46	-7.12	-0.4	1.02e-11	Height;
CESC	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	10.23	0.53	6.6e-21	Prudent dietary pattern;
CESC	cis	rs7818688	0.697	rs112411609	chr8:95980854	C/A	cg16049864	chr8:95962084	TP53INP1	0.55	5.55	0.32	6.92e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs9388451	0.839	rs3757217	chr6:126069636	G/C	cg05901451	chr6:126070800	HEY2	-0.65	-9.17	-0.49	1.34e-17	Brugada syndrome;
CESC	cis	rs722599	0.748	rs7145173	chr14:75351647	G/A	cg11812906	chr14:75593930	NEK9	-0.47	-5.68	-0.33	3.49e-8	IgG glycosylation;
CESC	cis	rs9420	0.961	rs527528	chr11:57433327	C/T	cg23127183	chr11:57508653	C11orf31	-0.47	-5.54	-0.32	7.28e-8	Schizophrenia;
CESC	cis	rs9309473	1.000	rs1403284	chr2:73726662	A/G	cg20560298	chr2:73613845	ALMS1	0.52	6.43	0.37	5.85e-10	Metabolite levels;
CESC	cis	rs35995292	0.500	rs1019065	chr7:38939775	C/T	cg19327137	chr7:38886074	VPS41	0.65	10.88	0.56	4.95e-23	Subjective well-being (multi-trait analysis);
CESC	cis	rs7264396	0.635	rs6058346	chr20:34481043	G/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.6	6.96	0.39	2.6e-11	Total cholesterol levels;
CESC	cis	rs68170813	0.559	rs7798223	chr7:106829223	T/C	cg02696742	chr7:106810147	HBP1	-0.53	-5.06	-0.3	7.95e-7	Coronary artery disease;
CESC	cis	rs17401966	0.931	rs3748577	chr1:10357406	C/T	cg15208524	chr1:10270712	KIF1B	-0.43	-5.55	-0.32	6.92e-8	Hepatocellular carcinoma;
CESC	trans	rs3780486	0.881	rs10738906	chr9:33135634	T/C	cg20290983	chr6:43655470	MRPS18A	0.98	18.17	0.74	1.8e-48	IgG glycosylation;
CESC	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	10.25	0.53	5.71e-21	Prudent dietary pattern;
CESC	cis	rs9951602	0.920	rs28639710	chr18:76679847	G/A	cg00806245	chr18:76673096	NA	-0.55	-5.94	-0.34	9.03e-9	Obesity-related traits;
CESC	cis	rs9549367	0.826	rs2287249	chr13:113889355	A/G	cg00898013	chr13:113819073	PROZ	-0.5	-6.86	-0.39	4.95e-11	Platelet distribution width;
CESC	trans	rs2018683	0.707	rs4722877	chr7:28972906	A/G	cg19402173	chr7:128379420	CALU	-0.51	-6.73	-0.38	1.06e-10	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CESC	cis	rs965469	1.000	rs6139088	chr20:3329063	G/A	cg25506879	chr20:3388711	C20orf194	-0.54	-5.78	-0.33	2.14e-8	IFN-related cytopenia;
CESC	cis	rs7631605	0.905	rs11720073	chr3:37018991	C/T	cg22985146	chr3:37219077	LRRFIP2	-0.33	-5.09	-0.3	6.91e-7	Cerebrospinal P-tau181p levels;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg23283474	chr11:46450417	AMBRA1	-0.4	-6.4	-0.37	7.03e-10	Gut microbiota (bacterial taxa);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09254969	chr5:141303622	KIAA0141	0.57	6.3	0.36	1.24e-9	Gut microbiome composition (summer);
CESC	cis	rs9611565	0.921	rs6002333	chr22:41719469	C/T	cg17376030	chr22:41985996	PMM1	0.58	6.17	0.35	2.58e-9	Vitiligo;
CESC	cis	rs9768139	1.000	rs9768139	chr7:158120731	G/A	cg25566285	chr7:158114605	PTPRN2	-0.51	-8.75	-0.47	2.61e-16	Calcium levels;
CESC	cis	rs7122539	0.734	rs2513658	chr11:66628249	G/A	cg24851651	chr11:66362959	CCS	-0.48	-6.92	-0.39	3.32e-11	HIV-1 susceptibility;
CESC	cis	rs7296418	0.961	rs1790122	chr12:123606739	G/A	cg00376283	chr12:123451042	ABCB9	0.72	10.11	0.53	1.55e-20	Platelet count;
CESC	cis	rs35110281	0.776	rs229357	chr21:44982717	T/C	cg21573476	chr21:45109991	RRP1B	-0.46	-6.25	-0.36	1.63e-9	Mean corpuscular volume;
CESC	cis	rs9311474	0.508	rs7652191	chr3:52610415	T/C	cg18337363	chr3:52569053	NT5DC2	0.3	5.46	0.32	1.07e-7	Electroencephalogram traits;
CESC	cis	rs9910055	0.747	rs2905981	chr17:42238625	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	0.45	6.86	0.39	4.75e-11	Total body bone mineral density;
CESC	cis	rs7666738	0.830	rs114722517	chr4:99042061	G/A	cg24818145	chr4:99064322	C4orf37	0.38	5.04	0.3	8.49e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7818688	0.697	rs76215523	chr8:95987015	T/C	cg16049864	chr8:95962084	TP53INP1	0.55	5.6	0.33	5.32e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs863345	0.604	rs4584390	chr1:158505975	T/A	cg12129480	chr1:158549410	OR10X1	-0.34	-6.82	-0.39	6.1e-11	Pneumococcal bacteremia;
CESC	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg06873352	chr17:61820015	STRADA	0.72	12.39	0.61	4.13e-28	Prudent dietary pattern;
CESC	cis	rs6541297	1.000	rs7543050	chr1:230278291	C/G	cg20703242	chr1:230279135	GALNT2	0.68	10.7	0.55	1.96e-22	Coronary artery disease;
CESC	cis	rs1865760	0.566	rs9366634	chr6:26072396	C/G	cg16482183	chr6:26056742	HIST1H1C	0.39	5.33	0.31	2.12e-7	Height;
CESC	cis	rs514406	0.893	rs1242317	chr1:53414766	T/C	cg08859206	chr1:53392774	SCP2	-0.57	-7.35	-0.41	2.42e-12	Monocyte count;
CESC	trans	rs9987353	0.840	rs329994	chr8:9123233	A/G	cg03560053	chr19:9946083	PIN1	-0.46	-6.09	-0.35	4e-9	Recombination measurement;
CESC	cis	rs2243480	0.901	rs35087093	chr7:65405208	C/T	cg18252515	chr7:66147081	NA	-1.06	-9.79	-0.52	1.67e-19	Diabetic kidney disease;
CESC	cis	rs4474465	0.850	rs10751294	chr11:78253303	T/A	cg27205649	chr11:78285834	NARS2	0.43	5.34	0.31	2.05e-7	Alzheimer's disease (survival time);
CESC	cis	rs909002	0.849	rs10914456	chr1:32088171	T/C	cg13919466	chr1:32135498	COL16A1	-0.47	-8.26	-0.45	7.22e-15	Intelligence (multi-trait analysis);
CESC	cis	rs6032067	0.852	rs17333103	chr20:43803613	C/T	cg11264863	chr20:43835661	SEMG1	0.5	5.41	0.32	1.41e-7	Blood protein levels;
CESC	cis	rs28489187	0.617	rs11161606	chr1:85853902	T/C	cg16011679	chr1:85725395	C1orf52	0.43	5.08	0.3	7.05e-7	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	cis	rs2404602	0.563	rs12914005	chr15:76765667	A/G	cg22467129	chr15:76604101	ETFA	-0.38	-5.86	-0.34	1.38e-8	Blood metabolite levels;
CESC	cis	rs1008375	0.931	rs6831211	chr4:17697009	G/A	cg16339924	chr4:17578868	LAP3	0.65	8.07	0.44	2.45e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12504415	chr17:74722752	JMJD6;C17orf95	0.58	6.69	0.38	1.32e-10	Gut microbiome composition (summer);
CESC	cis	rs40363	0.523	rs757270	chr16:3534451	C/T	cg22508957	chr16:3507546	NAT15	-0.49	-7.86	-0.43	9.92e-14	Tuberculosis;
CESC	cis	rs7089973	0.604	rs1924034	chr10:116578539	C/T	cg25233709	chr10:116636983	FAM160B1	0.36	5.89	0.34	1.2e-8	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs2228479	0.557	rs11641726	chr16:89891619	G/A	cg00800038	chr16:89945340	TCF25	-0.89	-6.88	-0.39	4.34e-11	Skin colour saturation;
CESC	cis	rs35146811	0.844	rs12705070	chr7:99656927	A/G	cg22906224	chr7:99728672	NA	0.49	5.95	0.34	8.58e-9	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25595571	chr14:104029029	BAG5;C14orf153	0.59	7.18	0.4	7.12e-12	Gut microbiome composition (summer);
CESC	cis	rs6448317	0.954	rs12186333	chr4:24919774	T/C	cg21108841	chr4:24914750	CCDC149	-0.56	-6.63	-0.38	1.85e-10	Heschl's gyrus morphology;
CESC	cis	rs6060717	0.536	rs8125966	chr20:34511823	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.65	5.61	0.33	4.97e-8	Hip circumference adjusted for BMI;
CESC	cis	rs1799949	1.000	rs8176273	chr17:41211653	A/G	cg25072359	chr17:41440525	NA	0.48	6.27	0.36	1.43e-9	Menopause (age at onset);
CESC	cis	rs7191439	0.522	rs8060640	chr16:88744430	G/C	cg27087555	chr16:88793112	FAM38A	-1.11	-6.75	-0.38	9.45e-11	Plateletcrit;
CESC	cis	rs6933660	0.646	rs9397051	chr6:151778325	C/T	cg17179660	chr6:151773299	C6orf211;RMND1	-0.42	-5.28	-0.31	2.67e-7	Menarche (age at onset);
CESC	trans	rs7246657	0.943	rs7255996	chr19:37971699	G/A	cg24637308	chr11:6592297	DNHD1	0.54	6.24	0.36	1.75e-9	Coronary artery calcification;
CESC	cis	rs3824344	0.507	rs10814501	chr9:37019304	C/T	cg14294708	chr9:37120828	ZCCHC7	0.39	5.17	0.3	4.61e-7	Intelligence;
CESC	cis	rs9649213	0.613	rs2286074	chr7:97952011	G/A	cg24562669	chr7:97807699	LMTK2	0.48	7.1	0.4	1.13e-11	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs13191362	0.935	rs34709632	chr6:163048380	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.91	9.13	0.49	1.81e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs6142102	0.602	rs4911395	chr20:32579901	T/G	cg08999081	chr20:33150536	PIGU	0.33	5.03	0.3	9.07e-7	Skin pigmentation;
CESC	cis	rs4689592	0.513	rs3857177	chr4:7066332	G/A	cg06697600	chr4:7070879	GRPEL1	-0.49	-7.34	-0.41	2.55e-12	Monocyte percentage of white cells;
CESC	cis	rs34233420	1	rs34233420	chr17:38004929	GATTT/G	cg20243544	chr17:37824526	PNMT	0.53	7.17	0.4	7.65e-12	Lymphocyte counts;
CESC	cis	rs9311474	0.607	rs4475032	chr3:52560021	C/T	cg15147215	chr3:52552868	STAB1	-0.31	-5.26	-0.31	2.96e-7	Electroencephalogram traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00106744	chr21:27106928	ATP5J;GABPA	0.64	6.93	0.39	3.15e-11	Gut microbiome composition (summer);
CESC	cis	rs9796	0.870	rs12905926	chr15:41283408	G/A	cg18705301	chr15:41695430	NDUFAF1	0.44	6.5	0.37	4.03e-10	Menopause (age at onset);
CESC	cis	rs35110281	0.667	rs4819288	chr21:45120173	C/G	cg04455712	chr21:45112962	RRP1B	0.48	7.35	0.41	2.5e-12	Mean corpuscular volume;
CESC	cis	rs57506017	0.585	rs13230513	chr7:12268243	C/A	cg23422036	chr7:12250390	TMEM106B	0.38	5.13	0.3	5.64e-7	Neuroticism;
CESC	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg09177884	chr7:1199841	ZFAND2A	0.54	7.12	0.4	1e-11	Longevity;Endometriosis;
CESC	cis	rs6667605	0.527	rs6673993	chr1:2552071	T/C	cg18854424	chr1:2615690	NA	0.31	6.32	0.36	1.09e-9	Inflammatory bowel disease;Ulcerative colitis;
CESC	cis	rs67311347	1.000	rs34762643	chr3:40475433	C/T	cg24209194	chr3:40518798	ZNF619	0.46	5.99	0.35	6.9e-9	Renal cell carcinoma;
CESC	cis	rs965469	0.744	rs6139093	chr20:3334838	A/G	cg17110299	chr20:3385021	C20orf194	0.4	5.24	0.31	3.22e-7	IFN-related cytopenia;
CESC	cis	rs7914558	0.966	rs10748835	chr10:104660256	C/T	cg04362960	chr10:104952993	NT5C2	0.42	5.37	0.31	1.72e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs7223966	1.000	rs11658175	chr17:61923838	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.53	6.26	0.36	1.51e-9	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs10540	1.000	rs71487292	chr11:486076	G/A	cg03352830	chr11:487213	PTDSS2	0.72	6.69	0.38	1.33e-10	Body mass index;
CESC	cis	rs2191566	1.000	rs369106	chr19:44506930	C/T	cg20607764	chr19:44506953	ZNF230	0.62	8.22	0.45	9.24e-15	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs7044106	0.690	rs10739569	chr9:123361027	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.55	7.29	0.41	3.5e-12	Hip circumference adjusted for BMI;
CESC	cis	rs1881797	1.000	rs12081895	chr1:247686666	C/G	cg05639522	chr1:247681581	NA	0.46	6.02	0.35	5.84e-9	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs8031584	0.918	rs35396566	chr15:31263057	T/C	cg14829155	chr15:31115871	NA	-0.76	-9.75	-0.51	2.17e-19	Huntington's disease progression;
CESC	cis	rs1642645	0.793	rs4660211	chr1:42484294	T/C	cg16685388	chr1:42384056	HIVEP3	0.38	5.68	0.33	3.57e-8	Left ventricular obstructive tract defect (maternal effect);
CESC	cis	rs9311474	0.508	rs1570	chr3:52586682	T/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.57	7.81	0.43	1.38e-13	Electroencephalogram traits;
CESC	cis	rs9914988	0.943	rs9891925	chr17:27104540	A/T	cg20469991	chr17:27169893	C17orf63	-0.48	-5.25	-0.31	3.18e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CESC	cis	rs1983891	0.706	rs913077	chr6:41569157	G/A	cg20194872	chr6:41519635	FOXP4	0.43	5.95	0.34	8.39e-9	Prostate cancer;
CESC	trans	rs875971	0.642	rs35526611	chr7:66094008	C/T	cg26939375	chr7:64535504	NA	-0.62	-8.25	-0.45	7.44e-15	Aortic root size;
CESC	cis	rs1348850	0.914	rs3902850	chr2:178315899	G/A	cg23306229	chr2:178417860	TTC30B	0.65	8.25	0.45	7.69e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs8180040	0.966	rs12486969	chr3:47429003	G/C	cg27129171	chr3:47204927	SETD2	-0.64	-9.82	-0.52	1.29e-19	Colorectal cancer;
CESC	cis	rs2243480	1.000	rs160648	chr7:65543384	C/A	cg13147721	chr7:65941812	NA	-0.93	-8.86	-0.48	1.16e-16	Diabetic kidney disease;
CESC	cis	rs11997175	0.704	rs11775534	chr8:33695232	G/A	ch.8.33884649F	chr8:33765107	NA	0.44	5.6	0.33	5.26e-8	Body mass index;
CESC	cis	rs2760061	0.819	rs708114	chr1:228197496	G/A	cg18477163	chr1:228402036	OBSCN	0.32	5.62	0.33	4.75e-8	Diastolic blood pressure;
CESC	cis	rs2576037	0.796	rs2247221	chr18:44580082	C/T	cg19077165	chr18:44547161	KATNAL2	0.52	7.26	0.41	4.23e-12	Personality dimensions;
CESC	cis	rs4819052	1.000	rs13052356	chr21:46663588	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.57	6.82	0.39	6.1e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs9486719	0.843	rs1009597	chr6:96843540	A/T	cg18709589	chr6:96969512	KIAA0776	0.55	5.64	0.33	4.26e-8	Migraine;Coronary artery disease;
CESC	cis	rs10504229	0.683	rs67492041	chr8:58140077	G/A	cg21724239	chr8:58056113	NA	0.58	5.95	0.34	8.37e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs10504229	0.683	rs55881798	chr8:58106406	T/C	cg02725872	chr8:58115012	NA	-0.43	-6.81	-0.39	6.53e-11	Developmental language disorder (linguistic errors);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07209141	chr11:68171070	LRP5	-0.56	-6.72	-0.38	1.1e-10	Gut microbiome composition (summer);
CESC	cis	rs2710642	0.564	rs6545963	chr2:62822891	C/T	cg17519650	chr2:63277830	OTX1	-0.5	-6.59	-0.38	2.41e-10	LDL cholesterol levels;LDL cholesterol;
CESC	trans	rs11098499	0.820	rs13128602	chr4:120459366	C/T	cg25214090	chr10:38739885	LOC399744	-0.69	-9.8	-0.52	1.51e-19	Corneal astigmatism;
CESC	trans	rs163030	0.902	rs406068	chr5:76740605	G/A	cg26150533	chr8:82396069	FABP4	-0.39	-6.09	-0.35	4.02e-9	Caudate nucleus volume;
CESC	trans	rs8073060	0.586	rs225288	chr17:33929291	G/A	cg19694781	chr19:47549865	TMEM160	-0.73	-7.01	-0.4	1.96e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	cis	rs9658691	0.607	rs12415680	chr10:90780737	A/T	cg03111039	chr10:90751583	FAS;ACTA2	-0.58	-5.25	-0.31	3.08e-7	Mosquito bite size;
CESC	cis	rs116979167	0.575	rs1728649	chr7:105170570	A/G	cg19920283	chr7:105172520	RINT1	0.54	6.29	0.36	1.3e-9	Bipolar disorder (body mass index interaction);
CESC	cis	rs7481584	0.624	rs397919	chr11:3063094	A/C	cg25174290	chr11:3078921	CARS	-0.52	-7.2	-0.4	6.11e-12	Calcium levels;
CESC	cis	rs7666738	0.830	rs1559859	chr4:99024325	C/T	cg24818145	chr4:99064322	C4orf37	0.4	5.24	0.31	3.29e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7553864	0.667	rs1886633	chr1:87610356	G/A	cg17420885	chr1:87600446	LOC339524	-0.44	-6.0	-0.35	6.35e-9	Smoking behavior;
CESC	cis	rs2439831	0.867	rs8041132	chr15:43635136	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.83	12.31	0.6	7.84e-28	Lung cancer in ever smokers;
CESC	cis	rs9902453	1.000	rs4074170	chr17:28381141	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.62	-7.84	-0.43	1.09e-13	Coffee consumption (cups per day);
CESC	cis	rs425277	0.606	rs424079	chr1:2071340	C/A	cg24578937	chr1:2090814	PRKCZ	-0.36	-6.28	-0.36	1.37e-9	Height;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg13179880	chr1:46016123	AKR1A1	0.4	6.1	0.35	3.8e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs1559088	0.948	rs9304844	chr19:33579935	G/T	cg27124370	chr19:33622961	WDR88	0.48	6.33	0.36	1.06e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs2795502	0.873	rs3121327	chr10:43388285	G/A	cg20628663	chr10:43360327	NA	0.54	6.07	0.35	4.48e-9	Blood protein levels;
CESC	cis	rs875971	0.928	rs6970357	chr7:65968878	T/C	cg10691866	chr7:65817282	TPST1	-0.34	-5.59	-0.32	5.57e-8	Aortic root size;
CESC	cis	rs910316	0.967	rs12890371	chr14:75593839	T/C	cg16144293	chr14:75469539	EIF2B2	-0.39	-5.12	-0.3	5.79e-7	Height;
CESC	cis	rs7512552	0.839	rs4581308	chr1:150276872	A/G	cg15654264	chr1:150340011	RPRD2	-0.41	-5.27	-0.31	2.77e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs6582630	0.538	rs12305104	chr12:38336353	C/T	cg26384229	chr12:38710491	ALG10B	-0.41	-5.33	-0.31	2.09e-7	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs736408	0.507	rs6445531	chr3:52717282	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.53	8.02	0.44	3.41e-14	Bipolar disorder;
CESC	cis	rs116095464	0.558	rs3213838	chr5:223890	G/C	cg22857025	chr5:266934	NA	-1.27	-18.88	-0.76	5.63e-51	Breast cancer;
CESC	cis	rs8020095	0.571	rs8022328	chr14:67253035	A/G	cg19548862	chr14:67692701	FAM71D	0.47	5.77	0.33	2.26e-8	Depression (quantitative trait);
CESC	cis	rs12477438	0.501	rs34272114	chr2:99737443	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.78	12.89	0.62	7.58e-30	Chronic sinus infection;
CESC	cis	rs7666738	0.830	rs36047842	chr4:99004902	C/A	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.62e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4604732	0.527	rs77361748	chr1:247626475	C/T	cg12758973	chr1:247694275	LOC148824;OR2C3	0.51	6.36	0.36	8.65e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs4862750	0.914	rs9995391	chr4:187873749	A/T	cg10295955	chr4:187884368	NA	0.93	15.13	0.68	1.07e-37	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs34779708	0.966	rs4934736	chr10:35496868	G/A	cg04310649	chr10:35416472	CREM	-0.52	-6.31	-0.36	1.18e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs7647973	0.626	rs1996663	chr3:49878264	C/G	cg13072238	chr3:49761600	GMPPB	0.47	5.88	0.34	1.23e-8	Menarche (age at onset);
CESC	cis	rs4713118	0.621	rs4713134	chr6:28034121	T/C	cg20151795	chr6:28129481	ZNF389	0.4	5.09	0.3	6.94e-7	Parkinson's disease;
CESC	cis	rs2243480	0.901	rs34807232	chr7:65965133	G/A	cg12463550	chr7:65579703	CRCP	0.71	5.5	0.32	8.86e-8	Diabetic kidney disease;
CESC	cis	rs61841072	0.961	rs6697552	chr1:243126352	C/T	cg02356786	chr1:243265016	LOC731275	0.4	5.07	0.3	7.42e-7	Schizophrenia;
CESC	cis	rs854765	0.618	rs8068820	chr17:17834119	A/G	cg09796270	chr17:17721594	SREBF1	0.43	6.05	0.35	4.9e-9	Total body bone mineral density;
CESC	cis	rs1878931	0.520	rs12447807	chr16:3413896	A/G	cg00484396	chr16:3507460	NAT15	-0.38	-5.8	-0.34	1.85e-8	Body mass index (adult);
CESC	cis	rs7824557	0.527	rs2572448	chr8:11239352	G/A	cg21775007	chr8:11205619	TDH	-0.51	-7.7	-0.43	2.64e-13	Retinal vascular caliber;
CESC	cis	rs7666738	0.830	rs7678557	chr4:99057329	A/G	cg03467027	chr4:99064603	C4orf37	0.47	5.9	0.34	1.09e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs710216	0.917	rs710223	chr1:43411038	C/G	cg07803811	chr1:43423981	SLC2A1	0.5	5.21	0.3	3.84e-7	Red cell distribution width;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07663789	chr5:32711429	NPR3	-0.53	-6.66	-0.38	1.56e-10	Gut microbiome composition (summer);
CESC	cis	rs2228479	0.850	rs1800339	chr16:89839637	C/A	cg00800038	chr16:89945340	TCF25	-0.92	-7.64	-0.42	4.02e-13	Skin colour saturation;
CESC	cis	rs16937	0.711	rs10751431	chr1:205128059	C/T	cg00857998	chr1:205179979	DSTYK	0.4	5.29	0.31	2.59e-7	Schizophrenia;
CESC	cis	rs2075371	1.000	rs1862051	chr7:133981021	G/A	cg00033643	chr7:134001901	SLC35B4	0.44	5.66	0.33	4.01e-8	Mean platelet volume;
CESC	cis	rs4654899	0.931	rs4654730	chr1:21229286	A/T	cg05370193	chr1:21551575	ECE1	0.37	5.52	0.32	8.22e-8	Superior frontal gyrus grey matter volume;
CESC	cis	rs155076	0.711	rs9550724	chr13:21885030	G/T	cg06138931	chr13:21896616	NA	0.52	5.46	0.32	1.1e-7	White matter hyperintensity burden;
CESC	cis	rs3820068	0.603	rs6429768	chr1:15963531	G/A	cg16988262	chr1:15930761	NA	0.34	5.45	0.32	1.16e-7	Systolic blood pressure;
CESC	cis	rs8060686	0.516	rs2290699	chr16:68289059	C/T	cg26727032	chr16:67993705	SLC12A4	-0.57	-7.36	-0.41	2.28e-12	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs9287719	0.967	rs728134	chr2:10745187	A/G	cg02196655	chr2:10830764	NOL10	-0.38	-5.78	-0.33	2.05e-8	Prostate cancer;
CESC	cis	rs116979167	0.575	rs1728649	chr7:105170570	A/G	cg13798780	chr7:105162888	PUS7	0.52	6.3	0.36	1.22e-9	Bipolar disorder (body mass index interaction);
CESC	cis	rs3540	0.512	rs8033595	chr15:91083353	G/A	cg10434728	chr15:90938212	IQGAP1	-0.4	-7.16	-0.4	7.74e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19099234	chr5:137911120	HSPA9	0.58	6.65	0.38	1.65e-10	Gut microbiome composition (summer);
CESC	cis	rs7799006	0.527	rs2159045	chr7:2207401	T/C	cg08027265	chr7:2291960	NA	-0.35	-5.11	-0.3	6.23e-7	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs4975616	0.869	rs380286	chr5:1320247	G/A	cg26373071	chr5:1325741	CLPTM1L	0.43	6.94	0.39	3.1e-11	Lung cancer;
CESC	cis	rs1348850	0.918	rs12622298	chr2:178450651	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.59	8.01	0.44	3.76e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs8177253	0.665	rs9869535	chr3:133451581	G/A	cg16262614	chr3:133464971	TF	0.3	5.46	0.32	1.11e-7	Iron status biomarkers;
CESC	cis	rs7618501	0.633	rs6446189	chr3:50008566	A/G	cg24308560	chr3:49941425	MST1R	-0.63	-9.04	-0.49	3.45e-17	Intelligence (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00304072	chr15:49338551	SECISBP2L	0.59	6.87	0.39	4.54e-11	Gut microbiome composition (summer);
CESC	cis	rs832540	0.931	rs832536	chr5:56212595	C/T	cg14703610	chr5:56206110	C5orf35	0.55	7.24	0.41	4.82e-12	Coronary artery disease;
CESC	cis	rs8017423	0.935	rs9944124	chr14:90791501	T/C	cg14092571	chr14:90743983	NA	-0.54	-8.24	-0.45	8.15e-15	Mortality in heart failure;
CESC	cis	rs4253772	0.513	rs6008700	chr22:46722560	C/T	cg00784671	chr22:46762841	CELSR1	-0.4	-5.31	-0.31	2.27e-7	LDL cholesterol;Cholesterol, total;
CESC	trans	rs765547	1.000	rs4922117	chr8:19852586	A/G	cg12649343	chr22:47023005	GRAMD4	-0.3	-6.14	-0.35	3.04e-9	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
CESC	cis	rs7772486	0.875	rs7766463	chr6:146364453	A/G	cg05347473	chr6:146136440	FBXO30	0.47	6.2	0.36	2.21e-9	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9487051	0.676	rs4406271	chr6:109598213	G/A	cg01475377	chr6:109611718	NA	-0.45	-7.04	-0.4	1.6e-11	Reticulocyte fraction of red cells;
CESC	cis	rs7618915	0.547	rs11130317	chr3:52731483	C/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	5.7	0.33	3.26e-8	Bipolar disorder;
CESC	cis	rs1008375	0.897	rs1006723	chr4:17618524	G/A	cg04450456	chr4:17643702	FAM184B	0.36	5.15	0.3	5.01e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs67478160	0.643	rs12880167	chr14:104300829	C/T	cg08213375	chr14:104286397	PPP1R13B	0.53	10.37	0.54	2.23e-21	Schizophrenia;
CESC	cis	rs3096299	0.933	rs2965939	chr16:89493043	G/A	cg02034447	chr16:89574710	SPG7	0.42	5.23	0.31	3.45e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs7202877	0.706	rs1074961	chr16:75389484	C/T	cg04384234	chr16:75411784	CFDP1	-0.47	-5.73	-0.33	2.72e-8	Type 2 diabetes;Type 1 diabetes;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg06419568	chr12:46776835	NA	-0.46	-6.24	-0.36	1.76e-9	Height;
CESC	cis	rs7666738	0.830	rs34870112	chr4:99045815	T/G	cg05340658	chr4:99064831	C4orf37	0.82	12.88	0.62	8.44e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs425277	1.000	rs385039	chr1:2077409	C/T	cg16545954	chr1:2118288	C1orf86	-0.33	-5.57	-0.32	6.3e-8	Height;
CESC	cis	rs3812762	0.871	rs3844100	chr11:8817808	A/G	cg03980550	chr11:8754370	ST5	0.36	5.16	0.3	4.92e-7	Hypospadias;
CESC	cis	rs796364	0.806	rs79725795	chr2:201083534	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.75	-6.74	-0.38	9.79e-11	Schizophrenia;
CESC	cis	rs2836974	0.568	rs419469	chr21:40537234	C/T	cg11890956	chr21:40555474	PSMG1	0.96	15.98	0.7	9.91e-41	Cognitive function;
CESC	cis	rs7786877	0.723	rs11764045	chr7:100212754	C/T	cg20848291	chr7:100343083	ZAN	-0.59	-6.0	-0.35	6.36e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs9467711	0.559	rs13208916	chr6:26601940	G/A	cg21479132	chr6:26055353	NA	0.58	5.18	0.3	4.44e-7	Autism spectrum disorder or schizophrenia;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg18085206	chr17:1359243	CRK	-0.48	-6.16	-0.35	2.66e-9	Asthma;
CESC	cis	rs7666738	0.830	rs28417577	chr4:99053007	T/C	cg05340658	chr4:99064831	C4orf37	0.82	12.88	0.62	8.44e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9322193	0.923	rs10782318	chr6:150075273	A/G	cg07701084	chr6:150067640	NUP43	0.44	5.94	0.34	9.04e-9	Lung cancer;
CESC	cis	rs9560113	0.509	rs4771759	chr13:112209217	A/G	cg10483660	chr13:112241077	NA	-0.44	-7.66	-0.43	3.53e-13	Menarche (age at onset);
CESC	cis	rs9322193	0.923	rs12174716	chr6:149965623	C/T	cg13206674	chr6:150067644	NUP43	0.41	5.76	0.33	2.3e-8	Lung cancer;
CESC	cis	rs6674176	0.660	rs12726706	chr1:44399942	G/A	cg13606994	chr1:44402422	ARTN	-0.4	-6.23	-0.36	1.84e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs2243480	1.000	rs437889	chr7:65509234	G/A	cg12463550	chr7:65579703	CRCP	0.69	5.37	0.31	1.75e-7	Diabetic kidney disease;
CESC	cis	rs4975709	0.569	rs2353583	chr5:1858834	G/C	cg11168104	chr5:1857477	NA	-0.39	-5.54	-0.32	7.22e-8	Cardiovascular disease risk factors;
CESC	cis	rs8067545	0.967	rs4924801	chr17:19921070	T/C	cg13482628	chr17:19912719	NA	0.46	6.2	0.36	2.19e-9	Schizophrenia;
CESC	cis	rs9302635	0.513	rs7198572	chr16:72183220	G/A	cg16558253	chr16:72132732	DHX38	-0.42	-5.15	-0.3	5.18e-7	Blood protein levels;
CESC	trans	rs1351696	1	rs1351696	chr11:48382471	A/G	cg15704280	chr7:45808275	SEPT13	-0.68	-6.25	-0.36	1.61e-9	D-dimer levels;
CESC	cis	rs55986470	0.763	rs6713788	chr2:239456932	T/A	cg18131467	chr2:239335373	ASB1	-0.56	-6.27	-0.36	1.47e-9	Chronotype;
CESC	cis	rs9911578	1.000	rs9902994	chr17:56948722	T/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.16	0.3	4.87e-7	Intelligence (multi-trait analysis);
CESC	cis	rs7927771	0.524	rs11039415	chr11:47845814	A/G	cg18512352	chr11:47633146	NA	0.35	5.33	0.31	2.05e-7	Subjective well-being;
CESC	cis	rs10540	1.000	rs35255804	chr11:492617	G/A	cg03934478	chr11:495069	RNH1	0.55	5.36	0.31	1.86e-7	Body mass index;
CESC	cis	rs425277	1.000	rs425277	chr1:2069172	C/T	cg23803603	chr1:2058230	PRKCZ	0.33	5.06	0.3	7.86e-7	Height;
CESC	cis	rs4713118	0.662	rs149969	chr6:27977737	A/G	cg23281280	chr6:28129359	ZNF389	0.53	7.62	0.42	4.57e-13	Parkinson's disease;
CESC	cis	rs4722166	0.630	rs6969258	chr7:22782528	C/T	cg05265849	chr7:22767390	IL6	0.57	7.11	0.4	1.06e-11	Lung cancer;
CESC	cis	rs736408	0.509	rs1108842	chr3:52720080	A/C	cg07507251	chr3:52567010	NT5DC2	0.39	7.32	0.41	2.94e-12	Bipolar disorder;
CESC	cis	rs3026101	0.671	rs1806222	chr17:5289676	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.44	5.8	0.34	1.9e-8	Body mass index;
CESC	cis	rs801193	1.000	rs13239306	chr7:66136017	T/G	cg18876405	chr7:65276391	NA	-0.59	-7.84	-0.43	1.11e-13	Aortic root size;
CESC	cis	rs113835537	0.935	rs117480267	chr11:66398596	C/T	cg22134325	chr11:66188745	NPAS4	0.51	5.89	0.34	1.17e-8	Airway imaging phenotypes;
CESC	cis	rs8141529	0.748	rs9620841	chr22:29290981	C/T	cg15103426	chr22:29168792	CCDC117	0.61	7.95	0.44	5.34e-14	Lymphocyte counts;
CESC	trans	rs2727020	0.521	rs7101761	chr11:49598178	G/A	cg03929089	chr4:120376271	NA	-0.76	-8.02	-0.44	3.35e-14	Coronary artery disease;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg03149719	chr17:1358724	CRK	0.46	6.05	0.35	5.04e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs9733	0.596	rs11204697	chr1:150658971	C/T	cg17724175	chr1:150552817	MCL1	0.44	7.23	0.41	5.25e-12	Tonsillectomy;
CESC	cis	rs896854	0.596	rs7823059	chr8:95974961	T/C	cg13393036	chr8:95962371	TP53INP1	-0.49	-10.52	-0.54	7.38e-22	Type 2 diabetes;
CESC	cis	rs63406760	1	rs63406760	chr12:123742692	TG/T	cg19016782	chr12:123741754	C12orf65	-0.48	-6.9	-0.39	3.71e-11	Allergic disease (asthma, hay fever or eczema);
CESC	trans	rs2727020	0.590	rs7949936	chr11:49378902	G/A	cg03929089	chr4:120376271	NA	-0.65	-7.11	-0.4	1.07e-11	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15133824	chr2:97523823	ANKRD39	0.53	6.61	0.38	2.11e-10	Gut microbiome composition (summer);
CESC	cis	rs780096	0.526	rs1406295	chr2:27689700	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.32	-5.97	-0.34	7.45e-9	Total body bone mineral density;
CESC	cis	rs4665809	0.878	rs6720312	chr2:26364934	A/G	cg26314531	chr2:26401878	FAM59B	0.65	7.61	0.42	4.86e-13	Gut microbiome composition (summer);
CESC	trans	rs9467711	0.538	rs35934643	chr6:26355094	G/A	cg06606381	chr12:133084897	FBRSL1	-0.77	-7.0	-0.4	2.04e-11	Autism spectrum disorder or schizophrenia;
CESC	cis	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg04519918	chr16:57278807	ARL2BP	-0.39	-5.81	-0.34	1.75e-8	Gambling;
CESC	cis	rs6430585	0.528	rs309166	chr2:136667487	C/T	cg07169764	chr2:136633963	MCM6	1.03	14.65	0.67	5.12e-36	Corneal structure;
CESC	cis	rs7927771	0.864	rs10838724	chr11:47527052	G/T	cg20307385	chr11:47447363	PSMC3	-0.47	-5.66	-0.33	3.94e-8	Subjective well-being;
CESC	cis	rs12136530	0.593	rs881248	chr1:19733961	C/T	cg01832549	chr1:19774989	CAPZB	0.44	6.15	0.35	2.77e-9	Lead levels in blood;
CESC	cis	rs7247513	0.930	rs28368916	chr19:12701577	T/G	cg01871581	chr19:12707946	ZNF490	-0.89	-15.13	-0.68	1.1e-37	Bipolar disorder;
CESC	cis	rs7249142	0.597	rs759999	chr19:19281207	A/C	cg27384695	chr19:19271486	LOC729991-MEF2B;MEF2B	0.28	5.16	0.3	4.77e-7	IgG glycosylation;
CESC	cis	rs10870270	0.830	rs11146269	chr10:133761820	G/A	cg26149184	chr10:133730230	NA	0.37	5.07	0.3	7.58e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs12142240	0.738	rs41293277	chr1:46806550	C/T	cg00530320	chr1:46809349	NSUN4	0.59	7.85	0.43	1.02e-13	Menopause (age at onset);
CESC	cis	rs3136441	0.892	rs11039024	chr11:46923168	C/T	cg25783544	chr11:47291846	MADD	0.52	5.27	0.31	2.88e-7	HDL cholesterol;
CESC	trans	rs4843747	0.671	rs28451517	chr16:88109127	A/C	cg26811252	chr16:29126840	RRN3P2	0.69	9.55	0.51	9.45e-19	Menopause (age at onset);
CESC	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg23708337	chr7:1209742	NA	0.54	5.38	0.31	1.61e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs1538970	0.851	rs61788285	chr1:45919234	A/C	cg05343316	chr1:45956843	TESK2	0.91	12.32	0.6	7.03e-28	Platelet count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07639963	chr12:77157760	ZDHHC17	0.5	6.04	0.35	5.08e-9	Gut microbiome composition (summer);
CESC	cis	rs62064224	0.748	rs72813015	chr17:30693331	T/C	cg18200150	chr17:30822561	MYO1D	0.68	10.43	0.54	1.45e-21	Schizophrenia;
CESC	trans	rs916888	0.773	rs199534	chr17:44824213	T/G	cg01341218	chr17:43662625	NA	0.92	10.72	0.55	1.65e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs6665290	0.904	rs3795451	chr1:227181923	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.21	-33.56	-0.9	2.09e-97	Myeloid white cell count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14505161	chr7:30544458	GGCT	0.57	6.16	0.35	2.71e-9	Gut microbiome composition (summer);
CESC	cis	rs8017423	1.000	rs11622075	chr14:90669894	G/T	cg14092571	chr14:90743983	NA	-0.56	-8.31	-0.45	4.98e-15	Mortality in heart failure;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg17444015	chr1:2322981	MORN1;RER1	-0.45	-6.15	-0.35	2.78e-9	Fibrinogen levels;
CESC	cis	rs9303280	0.719	rs56750287	chr17:38062944	A/C	cg20243544	chr17:37824526	PNMT	0.52	6.76	0.38	8.67e-11	Self-reported allergy;
CESC	cis	rs17711722	0.510	rs73142128	chr7:65331109	A/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.37	5.07	0.3	7.31e-7	Calcium levels;
CESC	cis	rs9790314	0.747	rs6789244	chr3:160866230	A/C	cg03342759	chr3:160939853	NMD3	-0.42	-6.02	-0.35	5.77e-9	Morning vs. evening chronotype;
CESC	cis	rs2075371	1.000	rs2598286	chr7:133976029	G/A	cg20476274	chr7:133979776	SLC35B4	0.68	10.16	0.53	1.04e-20	Mean platelet volume;
CESC	cis	rs853679	0.517	rs9348794	chr6:28117757	T/A	cg17949981	chr6:28129498	ZNF389	0.45	5.49	0.32	9.35e-8	Depression;
CESC	cis	rs1843834	0.539	rs2047135	chr2:225427302	G/C	cg22455342	chr2:225449267	CUL3	0.71	9.77	0.51	1.92e-19	IgE levels in asthmatics (D.p. specific);
CESC	cis	rs7208859	0.673	rs1347359	chr17:28914529	T/C	cg17105886	chr17:28927953	LRRC37B2	0.58	5.06	0.3	7.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs1005277	0.579	rs1780145	chr10:38537070	A/G	cg25517755	chr10:38738941	LOC399744	-0.49	-6.39	-0.37	7.49e-10	Extrinsic epigenetic age acceleration;
CESC	cis	rs7811142	0.720	rs7795656	chr7:99950297	A/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.05	10.75	0.55	1.31e-22	Platelet count;
CESC	trans	rs6794880	0.778	rs113110726	chr3:84420854	G/A	cg03554283	chr8:76319451	NA	0.57	6.07	0.35	4.44e-9	Body mass index (joint analysis main effects and smoking interaction);BMI in non-smokers;BMI (adjusted for smoking behaviour);
CESC	cis	rs3749237	0.595	rs1568661	chr3:49520958	A/G	cg07636037	chr3:49044803	WDR6	0.65	9.47	0.5	1.67e-18	Resting heart rate;
CESC	cis	rs796364	0.951	rs7586320	chr2:201068209	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.61	5.74	0.33	2.56e-8	Schizophrenia;
CESC	cis	rs9488822	0.676	rs1338667	chr6:116323910	T/A	cg26893134	chr6:116381904	FRK	0.25	6.04	0.35	5.06e-9	Cholesterol, total;LDL cholesterol;
CESC	cis	rs870825	0.616	rs7659101	chr4:185632158	C/T	cg04058563	chr4:185651563	MLF1IP	0.63	6.84	0.39	5.54e-11	Blood protein levels;
CESC	cis	rs537626	0.848	rs624797	chr11:69308575	G/T	cg08353955	chr11:69289746	NA	0.48	6.02	0.35	5.86e-9	Breast cancer (early onset);
CESC	cis	rs2191566	0.821	rs59756444	chr19:44513656	C/G	cg20607764	chr19:44506953	ZNF230	-0.62	-8.18	-0.45	1.17e-14	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs4746818	0.711	rs2491024	chr10:70847084	T/C	cg11621586	chr10:70884670	VPS26A	0.62	7.09	0.4	1.2e-11	Left atrial antero-posterior diameter;
CESC	cis	rs1788820	0.917	rs4800489	chr18:21125942	A/G	cg14672496	chr18:21087552	C18orf8	0.55	7.55	0.42	6.97e-13	Body mass index;
CESC	cis	rs244293	0.729	rs2332313	chr17:53018825	T/G	cg19360675	chr17:53046073	COX11;STXBP4	-0.44	-5.69	-0.33	3.3e-8	Menarche (age at onset);
CESC	cis	rs34172651	0.606	rs7194189	chr16:24703484	G/T	cg04756594	chr16:24857601	SLC5A11	-0.53	-6.87	-0.39	4.58e-11	Intelligence (multi-trait analysis);
CESC	cis	rs1218582	0.596	rs906595	chr1:154822907	C/T	cg24250549	chr1:154909240	PMVK	0.48	6.13	0.35	3.22e-9	Prostate cancer;
CESC	cis	rs9916302	0.861	rs33933929	chr17:37426441	A/C	cg00129232	chr17:37814104	STARD3	-0.55	-7.26	-0.41	4.23e-12	Glomerular filtration rate (creatinine);
CESC	cis	rs12497850	0.931	rs1134591	chr3:48972892	C/T	cg06212747	chr3:49208901	KLHDC8B	0.74	10.01	0.52	3.14e-20	Parkinson's disease;
CESC	cis	rs8031584	0.541	rs2959037	chr15:31218164	T/C	cg08704250	chr15:31115839	NA	0.63	8.65	0.47	5.15e-16	Huntington's disease progression;
CESC	cis	rs4953318	0.619	rs12105417	chr2:46361255	A/C	cg12428440	chr2:46370979	PRKCE	0.5	6.7	0.38	1.25e-10	Red blood cell count;Hematocrit;Red blood cell traits;
CESC	cis	rs9443189	0.615	rs618239	chr6:76350038	A/G	cg01950844	chr6:76311363	SENP6	0.87	9.2	0.49	1.1e-17	Prostate cancer;
CESC	cis	rs9908102	0.740	rs73981608	chr17:12903928	C/T	cg26162695	chr17:12921313	ELAC2	0.5	5.49	0.32	9.61e-8	Schizophrenia;
CESC	cis	rs1577917	1.000	rs1018184	chr6:86648475	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.42	5.58	0.32	5.98e-8	Response to antipsychotic treatment;
CESC	cis	rs10887741	0.606	rs3824722	chr10:89435723	C/G	cg13926569	chr10:89418898	PAPSS2	0.47	7.15	0.4	8.25e-12	Exercise (leisure time);
CESC	cis	rs644799	0.562	rs1313288	chr11:95520695	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.49	6.47	0.37	4.68e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs11630290	0.592	rs11634436	chr15:64158394	T/G	cg12036633	chr15:63758958	NA	0.44	5.32	0.31	2.19e-7	Iris characteristics;
CESC	cis	rs13095912	0.752	rs62291883	chr3:185313842	T/C	cg11274856	chr3:185301563	NA	0.41	6.36	0.36	8.6e-10	Systolic blood pressure;
CESC	cis	rs6732160	0.691	rs7599223	chr2:73427103	A/G	cg01422370	chr2:73384389	NA	0.44	7.38	0.41	1.99e-12	Intelligence (multi-trait analysis);
CESC	cis	rs9916302	0.861	rs593480	chr17:37453780	A/C	cg00129232	chr17:37814104	STARD3	0.56	7.29	0.41	3.49e-12	Glomerular filtration rate (creatinine);
CESC	cis	rs1448094	0.512	rs6539932	chr12:86247497	T/C	cg02569458	chr12:86230093	RASSF9	0.51	7.53	0.42	7.74e-13	Major depressive disorder;
CESC	cis	rs425277	0.959	rs77665022	chr1:2065958	C/T	cg24578937	chr1:2090814	PRKCZ	0.53	9.07	0.49	2.78e-17	Height;
CESC	trans	rs3857536	0.505	rs208459	chr6:66911055	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.57	-6.7	-0.38	1.23e-10	Blood trace element (Cu levels);
CESC	cis	rs8180040	1.000	rs11714294	chr3:47339723	G/A	cg27129171	chr3:47204927	SETD2	-0.66	-10.18	-0.53	9.2e-21	Colorectal cancer;
CESC	trans	rs3942852	0.910	rs11603850	chr11:48140900	G/A	cg15704280	chr7:45808275	SEPT13	-0.59	-6.53	-0.37	3.33e-10	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs644799	0.648	rs1255178	chr11:95471908	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.43	5.98	0.34	7.37e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs12188164	1.000	rs34453673	chr5:434722	G/C	cg17553881	chr5:443987	EXOC3;C5orf55	-0.34	-5.58	-0.32	5.97e-8	Cystic fibrosis severity;
CESC	cis	rs801193	0.967	rs2707853	chr7:66214010	G/A	cg11764359	chr7:65958608	NA	0.7	9.23	0.49	8.79e-18	Aortic root size;
CESC	cis	rs6502050	0.835	rs35192339	chr17:80119106	G/A	cg23985595	chr17:80112537	CCDC57	-0.41	-6.57	-0.37	2.6200000000000003e-10	Life satisfaction;
CESC	cis	rs7945705	0.905	rs2568054	chr11:8876029	A/G	cg12365402	chr11:9010492	NRIP3	-0.31	-5.06	-0.3	8.03e-7	Hemoglobin concentration;
CESC	cis	rs2625529	0.591	rs7172158	chr15:72405313	T/C	cg16672083	chr15:72433130	SENP8	0.46	6.76	0.38	8.83e-11	Red blood cell count;
CESC	cis	rs3806933	0.522	rs34962120	chr5:110446091	G/A	cg04022379	chr5:110408740	TSLP	0.46	7.43	0.42	1.49e-12	Eosinophilic esophagitis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24683561	chr1:154934703	PYGO2	0.58	6.18	0.35	2.34e-9	Gut microbiome composition (summer);
CESC	cis	rs2239547	0.562	rs35380116	chr3:52979178	A/G	cg11645453	chr3:52864694	ITIH4	-0.32	-5.43	-0.32	1.26e-7	Schizophrenia;
CESC	cis	rs7647973	0.580	rs35218722	chr3:49275805	A/G	cg02487422	chr3:49467188	NICN1	0.39	5.43	0.32	1.27e-7	Menarche (age at onset);
CESC	cis	rs8114671	0.562	rs6087643	chr20:33474462	C/T	cg07148914	chr20:33460835	GGT7	0.46	6.11	0.35	3.46e-9	Height;
CESC	cis	rs889398	0.771	rs1566454	chr16:69900083	C/T	cg09409435	chr16:70099608	PDXDC2	0.4	5.11	0.3	6.15e-7	Body mass index;
CESC	cis	rs6570726	0.791	rs7765675	chr6:145915077	A/C	cg05347473	chr6:146136440	FBXO30	0.57	7.24	0.41	4.72e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4253772	0.550	rs9615913	chr22:46668515	A/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	-0.72	-8.71	-0.47	3.28e-16	LDL cholesterol;Cholesterol, total;
CESC	cis	rs3936840	0.565	rs8006911	chr14:102975265	A/G	cg18135206	chr14:102964638	TECPR2	0.46	5.86	0.34	1.38e-8	Plateletcrit;
CESC	cis	rs7552404	0.731	rs931507	chr1:76401577	G/A	cg03433033	chr1:76189801	ACADM	-0.56	-6.06	-0.35	4.61e-9	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs873946	0.689	rs2803993	chr10:134550606	T/C	cg26818010	chr10:134567672	INPP5A	-0.74	-9.04	-0.49	3.37e-17	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs6662572	0.737	rs4388641	chr1:46522326	A/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.47	5.25	0.31	3.12e-7	Blood protein levels;
CESC	cis	rs4900538	0.819	rs72698591	chr14:102838896	G/A	cg18135206	chr14:102964638	TECPR2	-0.74	-9.24	-0.49	8.19e-18	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	trans	rs2727020	0.521	rs10839296	chr11:49537617	T/C	cg15704280	chr7:45808275	SEPT13	0.82	9.9	0.52	7.22e-20	Coronary artery disease;
CESC	cis	rs7107174	0.901	rs7110387	chr11:78117875	A/G	cg02023728	chr11:77925099	USP35	0.41	5.41	0.32	1.42e-7	Testicular germ cell tumor;
CESC	cis	rs2290416	0.584	rs3816477	chr8:144685271	T/C	cg17524265	chr8:144659883	NAPRT1	-0.52	-5.51	-0.32	8.57e-8	Attention deficit hyperactivity disorder;
CESC	trans	rs7937682	0.855	rs11213985	chr11:111581521	C/A	cg18187862	chr3:45730750	SACM1L	0.51	6.54	0.37	3.12e-10	Primary sclerosing cholangitis;
CESC	cis	rs447	1.000	rs7781923	chr7:83747200	T/G	cg22846510	chr7:83753280	SEMA3A	-0.48	-5.87	-0.34	1.27e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs9790314	0.871	rs336561	chr3:161125305	C/T	cg03342759	chr3:160939853	NMD3	-0.44	-5.94	-0.34	8.85e-9	Morning vs. evening chronotype;
CESC	cis	rs4148883	0.651	rs4147547	chr4:100127311	G/T	cg12011299	chr4:100065546	ADH4	0.64	9.31	0.5	5.14e-18	Alcohol dependence;
CESC	cis	rs270601	0.683	rs81598	chr5:131587960	C/G	cg18301423	chr5:131593218	PDLIM4	0.4	5.49	0.32	9.62e-8	Acylcarnitine levels;
CESC	cis	rs9926296	0.605	rs6500453	chr16:89858657	C/G	cg04287289	chr16:89883240	FANCA	0.87	14.87	0.67	8.69e-37	Vitiligo;
CESC	cis	rs7542091	0.704	rs9429825	chr1:210052133	C/G	cg23283495	chr1:209979779	IRF6	0.34	5.56	0.32	6.66e-8	Monobrow;
CESC	cis	rs6736093	0.862	rs79798002	chr2:112733978	G/A	cg12686935	chr2:112915763	FBLN7	-0.44	-5.72	-0.33	2.86e-8	Coronary artery disease;
CESC	cis	rs7666738	0.830	rs13108422	chr4:99059267	G/A	cg05340658	chr4:99064831	C4orf37	0.81	12.43	0.61	3.07e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9581857	0.615	rs9581848	chr13:28003997	C/T	cg01674679	chr13:27998804	GTF3A	-0.71	-5.67	-0.33	3.72e-8	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
CESC	cis	rs77741769	0.571	rs4454799	chr12:121317075	A/C	cg02419362	chr12:121203948	SPPL3	-0.34	-5.53	-0.32	7.48e-8	Mean corpuscular volume;
CESC	cis	rs4423214	1.000	rs909217	chr11:71146577	G/A	cg05163923	chr11:71159392	DHCR7	0.75	10.16	0.53	1.07e-20	Vitamin D levels;
CESC	cis	rs9796	0.870	rs3986311	chr15:41264339	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.47	-7.0	-0.4	2.08e-11	Menopause (age at onset);
CESC	cis	rs2228479	0.850	rs17226966	chr16:89825338	A/G	cg06558623	chr16:89946397	TCF25	1.17	9.38	0.5	3.19e-18	Skin colour saturation;
CESC	cis	rs2204008	0.652	rs11513964	chr12:37998214	C/G	cg13010199	chr12:38710504	ALG10B	0.53	6.63	0.38	1.87e-10	Bladder cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00442658	chr21:18885041	CXADR	0.57	6.04	0.35	5.17e-9	Gut microbiome composition (summer);
CESC	cis	rs12188164	0.931	rs115554641	chr5:443236	C/G	cg26850624	chr5:429559	AHRR	-0.49	-6.62	-0.38	1.94e-10	Cystic fibrosis severity;
CESC	cis	rs8002861	0.846	rs12428314	chr13:44476011	C/T	cg14210620	chr13:44453864	C13orf31;CCDC122	-0.42	-5.39	-0.31	1.58e-7	Leprosy;
CESC	cis	rs11122272	0.735	rs2250749	chr1:231485763	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.53	-7.43	-0.42	1.53e-12	Hemoglobin concentration;
CESC	cis	rs2050392	0.624	rs303444	chr10:30729347	C/T	cg25182066	chr10:30743637	MAP3K8	-0.45	-5.95	-0.34	8.61e-9	Inflammatory bowel disease;
CESC	cis	rs4819052	0.851	rs7276591	chr21:46680156	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.45	5.6	0.33	5.26e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs13191362	0.938	rs28360532	chr6:162997477	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.83	8.39	0.46	3.02e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs7208859	0.623	rs56163556	chr17:29101868	G/C	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.17e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs10751667	0.621	rs7396107	chr11:970029	C/T	cg06064525	chr11:970664	AP2A2	-0.47	-9.13	-0.49	1.8e-17	Alzheimer's disease (late onset);
CESC	cis	rs72627123	0.867	rs73301485	chr14:74468643	T/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.8	5.77	0.33	2.2e-8	Morning vs. evening chronotype;
CESC	cis	rs9611565	0.838	rs4239894	chr22:41745548	C/G	cg03806693	chr22:41940476	POLR3H	-1.0	-11.63	-0.58	1.52e-25	Vitiligo;
CESC	cis	rs868036	1.000	rs1026733	chr15:68095122	G/A	cg08079166	chr15:68083412	MAP2K5	0.44	6.94	0.39	2.94e-11	Restless legs syndrome;
CESC	trans	rs561341	0.769	rs12941700	chr17:30185022	A/G	cg27661571	chr11:113659931	NA	0.71	7.04	0.4	1.67e-11	Hip circumference adjusted for BMI;
CESC	cis	rs9287719	0.967	rs6432113	chr2:10744889	C/T	cg02196655	chr2:10830764	NOL10	0.36	5.55	0.32	6.89e-8	Prostate cancer;
CESC	cis	rs9875589	0.509	rs9824910	chr3:14040136	C/T	cg19554555	chr3:13937349	NA	-0.44	-5.61	-0.33	4.98e-8	Ovarian reserve;
CESC	cis	rs55882075	0.723	rs56227602	chr5:179179472	A/G	cg14593053	chr5:179126677	CANX	0.55	8.07	0.44	2.51e-14	Monocyte percentage of white cells;
CESC	cis	rs13242816	1.000	rs2024209	chr7:116135336	T/C	cg04696780	chr7:116139425	CAV2	-0.61	-5.51	-0.32	8.44e-8	P wave duration;
CESC	cis	rs1879734	0.636	rs1879733	chr1:54175971	T/C	cg23596471	chr1:54105337	GLIS1	0.32	5.17	0.3	4.7e-7	Mitral valve prolapse;
CESC	cis	rs11785693	0.862	rs11774044	chr8:4988035	C/G	cg26367366	chr8:4980734	NA	0.96	8.72	0.47	3.19e-16	Neuroticism (multi-trait analysis);Neuroticism;
CESC	cis	rs7666738	0.791	rs28579101	chr4:98843203	T/C	cg05340658	chr4:99064831	C4orf37	0.71	10.22	0.53	7.06e-21	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9649213	0.593	rs3801254	chr7:98010811	G/A	cg21770322	chr7:97807741	LMTK2	0.57	8.63	0.47	5.93e-16	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs3857067	0.806	rs7654565	chr4:95112939	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.6	-9.02	-0.48	3.78e-17	QT interval;
CESC	cis	rs2296225	0.722	rs900038	chr1:21057552	C/A	cg24673385	chr1:21051448	SH2D5	0.36	5.66	0.33	3.85e-8	Eosinophilic esophagitis;
CESC	trans	rs9951602	0.512	rs6506874	chr18:76653467	G/T	cg02800362	chr5:177631904	HNRNPAB	0.66	8.63	0.47	5.9e-16	Obesity-related traits;
CESC	cis	rs7312933	1.000	rs7957213	chr12:42475438	T/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.38	5.05	0.3	8.32e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs10927875	0.793	rs1763619	chr1:16326935	A/G	cg21385522	chr1:16154831	NA	0.65	7.88	0.44	8.69e-14	Dilated cardiomyopathy;
CESC	cis	rs7927771	0.864	rs2293580	chr11:47440283	T/A	cg05585544	chr11:47624801	NA	0.41	6.14	0.35	3.01e-9	Subjective well-being;
CESC	cis	rs853679	0.517	rs9357065	chr6:28129580	T/C	cg26335602	chr6:28129616	ZNF389	0.52	6.75	0.38	9.54e-11	Depression;
CESC	cis	rs875971	1.000	rs9986696	chr7:65704576	C/A	cg12463550	chr7:65579703	CRCP	-0.57	-7.44	-0.42	1.43e-12	Aortic root size;
CESC	cis	rs4665809	1.000	rs1470097	chr2:26312840	A/G	cg27170947	chr2:26402098	FAM59B	-0.58	-6.91	-0.39	3.69e-11	Gut microbiome composition (summer);
CESC	cis	rs644799	0.710	rs666398	chr11:95551136	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.76	10.93	0.56	3.47e-23	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs9549367	0.789	rs7994324	chr13:113906497	T/C	cg00898013	chr13:113819073	PROZ	-0.53	-7.31	-0.41	3.07e-12	Platelet distribution width;
CESC	cis	rs9660180	0.837	rs915292	chr1:1792157	A/C	cg17747265	chr1:1875780	NA	-0.6	-9.76	-0.51	2.01e-19	Body mass index;
CESC	cis	rs798554	0.679	rs1614791	chr7:2888057	G/T	cg19717773	chr7:2847554	GNA12	-0.46	-6.48	-0.37	4.36e-10	Height;
CESC	cis	rs7267979	1.000	rs6050559	chr20:25329915	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.84	16.6	0.71	6.47e-43	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs9875589	0.509	rs4685051	chr3:13981760	A/G	cg19554555	chr3:13937349	NA	-0.43	-5.5	-0.32	8.87e-8	Ovarian reserve;
CESC	cis	rs2839186	0.616	rs4819213	chr21:47619300	G/A	cg00815214	chr21:47717953	NA	0.43	6.27	0.36	1.49e-9	Testicular germ cell tumor;
CESC	cis	rs2836974	0.568	rs452377	chr21:40537183	T/C	cg11890956	chr21:40555474	PSMG1	0.97	16.62	0.71	5.65e-43	Cognitive function;
CESC	cis	rs7267979	1.000	rs6076339	chr20:25348712	T/C	cg08601574	chr20:25228251	PYGB	-0.36	-5.19	-0.3	4.1e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs3780486	0.881	rs10738906	chr9:33135634	T/C	cg13443165	chr9:33130375	B4GALT1	0.46	6.78	0.38	7.98e-11	IgG glycosylation;
CESC	cis	rs72781680	0.611	rs7596820	chr2:24335036	G/C	cg08917208	chr2:24149416	ATAD2B	0.56	5.49	0.32	9.59e-8	Lymphocyte counts;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg27013455	chr14:102483114	DYNC1H1	0.44	6.01	0.35	6.21e-9	Fibrinogen levels;
CESC	cis	rs7274811	0.656	rs293736	chr20:31925189	A/C	cg21523528	chr20:32077966	CBFA2T2	-0.5	-5.62	-0.33	4.71e-8	Height;
CESC	cis	rs10638925	1	rs10638925	chr3:194119749	C/CCATAAA	cg00834899	chr3:194121120	GP5	0.58	9.65	0.51	4.34e-19	Platelet distribution width;
CESC	cis	rs8072100	0.713	rs9895776	chr17:45486003	A/G	cg25173405	chr17:45401733	C17orf57	-0.44	-5.48	-0.32	9.7e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs9901225	1	rs9901225	chr17:40755811	C/T	cg23622369	chr17:40706682	HSD17B1	-0.52	-7.68	-0.43	3.09e-13	Colorectal or endometrial cancer;
CESC	cis	rs523522	0.962	rs10849754	chr12:120940418	A/C	cg27279351	chr12:120934652	DYNLL1	0.69	9.11	0.49	2.02e-17	High light scatter reticulocyte count;
CESC	cis	rs763014	0.931	rs10903017	chr16:627920	T/C	cg00908189	chr16:619842	PIGQ	0.67	9.39	0.5	2.81e-18	Height;
CESC	cis	rs10411936	0.712	rs8103486	chr19:16603107	A/G	cg10248733	chr19:16607483	C19orf44;CALR3	0.57	6.74	0.38	9.66e-11	White blood cell count;Multiple sclerosis;
CESC	trans	rs61931739	0.500	rs11053222	chr12:34481100	C/A	cg26384229	chr12:38710491	ALG10B	0.7	10.6	0.55	3.94e-22	Morning vs. evening chronotype;
CESC	cis	rs13256369	0.802	rs11995449	chr8:8559898	G/A	cg00074818	chr8:8560427	CLDN23	0.38	5.32	0.31	2.24e-7	Obesity-related traits;
CESC	cis	rs1005277	0.579	rs2474571	chr10:38384639	T/G	cg25427524	chr10:38739819	LOC399744	-0.66	-9.51	-0.5	1.22e-18	Extrinsic epigenetic age acceleration;
CESC	trans	rs9467711	0.720	rs9348716	chr6:26375658	G/A	cg06606381	chr12:133084897	FBRSL1	-0.76	-6.67	-0.38	1.48e-10	Autism spectrum disorder or schizophrenia;
CESC	cis	rs1670533	0.818	rs585735	chr4:1080391	G/C	cg27284194	chr4:1044797	NA	0.48	6.07	0.35	4.52e-9	Recombination rate (females);
CESC	trans	rs17685	0.753	rs2302438	chr7:75677065	C/A	cg19862616	chr7:65841803	NCRNA00174	0.82	11.95	0.59	1.27e-26	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs909674	0.514	rs7423	chr22:39781429	C/T	cg05872129	chr22:39784769	NA	-0.73	-10.5	-0.54	8.56e-22	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs1153858	1.000	rs7179743	chr15:45638331	G/C	cg21132104	chr15:45694354	SPATA5L1	0.82	11.02	0.56	1.72e-23	Homoarginine levels;
CESC	cis	rs9314323	0.767	rs13271042	chr8:26190212	T/G	cg13160058	chr8:26243215	BNIP3L	-0.35	-5.25	-0.31	3.15e-7	Red cell distribution width;
CESC	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.86	12.8	0.62	1.6e-29	Prudent dietary pattern;
CESC	cis	rs6502050	0.799	rs4789680	chr17:80100547	C/A	cg11859384	chr17:80120422	CCDC57	-0.38	-5.11	-0.3	6.21e-7	Life satisfaction;
CESC	cis	rs7927771	1.000	rs1317149	chr11:47486885	C/T	cg20307385	chr11:47447363	PSMC3	-0.54	-6.4	-0.37	7.03e-10	Subjective well-being;
CESC	cis	rs7809950	0.731	rs4730238	chr7:107054787	G/A	cg23024343	chr7:107201750	COG5	-0.58	-7.43	-0.42	1.49e-12	Coronary artery disease;
CESC	cis	rs1008375	1.000	rs10027755	chr4:17615954	G/C	cg02297831	chr4:17616191	MED28	0.53	6.66	0.38	1.6e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs6952808	0.630	rs10239050	chr7:2158390	A/G	cg02951883	chr7:2050386	MAD1L1	-0.49	-6.34	-0.36	1e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs12995491	0.933	rs34366691	chr2:88537451	G/A	cg07952391	chr2:88470173	THNSL2	-0.55	-8.4	-0.46	2.72e-15	Response to metformin (IC50);
CESC	cis	rs4819052	0.851	rs2838832	chr21:46664904	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.89	-12.56	-0.61	1.02e-28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs4843747	0.708	rs11866437	chr16:88072279	A/G	cg17633681	chr16:88106987	BANP	-0.61	-8.22	-0.45	9.07e-15	Menopause (age at onset);
CESC	cis	rs2075371	0.932	rs2241333	chr7:133970750	C/T	cg00033643	chr7:134001901	SLC35B4	0.4	5.03	0.3	9.21e-7	Mean platelet volume;
CESC	cis	rs11146838	1	rs11146838	chr10:39149977	A/T	cg25517755	chr10:38738941	LOC399744	-0.46	-5.88	-0.34	1.22e-8	Breast cancer;
CESC	cis	rs644799	1.000	rs474442	chr11:95583995	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.92	14.15	0.66	3.04e-34	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs8114671	0.562	rs6058120	chr20:33402829	A/G	cg07148914	chr20:33460835	GGT7	0.44	5.73	0.33	2.68e-8	Height;
CESC	cis	rs3857067	1.000	rs7694820	chr4:95017026	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.52	-8.04	-0.44	3.05e-14	QT interval;
CESC	cis	rs12893668	0.645	rs35229468	chr14:104052057	C/T	cg24130564	chr14:104152367	KLC1	-0.48	-6.01	-0.35	6.16e-9	Reticulocyte count;
CESC	cis	rs7666738	0.830	rs13124904	chr4:98856973	T/C	cg17366294	chr4:99064904	C4orf37	0.55	7.72	0.43	2.38e-13	Colonoscopy-negative controls vs population controls;
CESC	cis	rs8058578	1.000	rs7187359	chr16:30703155	G/A	cg00531865	chr16:30841666	NA	-0.44	-5.84	-0.34	1.51e-8	Multiple myeloma;
CESC	cis	rs7100689	0.646	rs10749581	chr10:82141651	A/G	cg00277334	chr10:82204260	NA	0.55	7.1	0.4	1.12e-11	Post bronchodilator FEV1;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg02957340	chr14:100070899	CCDC85C	-0.46	-6.26	-0.36	1.56e-9	Fibrinogen levels;
CESC	cis	rs3540	0.554	rs34650360	chr15:91059017	T/C	cg22089800	chr15:90895588	ZNF774	-0.61	-8.09	-0.44	2.17e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs7044106	0.708	rs991121	chr9:123370345	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.78	11.61	0.58	1.85e-25	Hip circumference adjusted for BMI;
CESC	cis	rs2228479	0.850	rs11639906	chr16:89798183	T/C	cg00800038	chr16:89945340	TCF25	-0.74	-5.68	-0.33	3.6e-8	Skin colour saturation;
CESC	cis	rs17376456	0.741	rs7718842	chr5:93480568	G/A	cg25358565	chr5:93447407	FAM172A	1.2	10.97	0.56	2.47e-23	Diabetic retinopathy;
CESC	cis	rs1124376	1.000	rs12488369	chr3:20154059	G/T	cg05072819	chr3:20081367	KAT2B	-0.46	-5.09	-0.3	6.86e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs7208859	0.573	rs56031503	chr17:29075665	T/C	cg19761014	chr17:28927070	LRRC37B2	0.76	6.33	0.36	1.02e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs9926296	0.605	rs6500449	chr16:89856393	T/C	cg01097406	chr16:89675127	NA	-0.33	-5.06	-0.3	7.88e-7	Vitiligo;
CESC	cis	rs875971	0.862	rs778724	chr7:65829291	T/C	cg10691866	chr7:65817282	TPST1	-0.31	-5.1	-0.3	6.47e-7	Aortic root size;
CESC	cis	rs7615952	0.576	rs6780025	chr3:125815624	A/C	cg06494592	chr3:125709126	NA	-0.52	-5.56	-0.32	6.58e-8	Blood pressure (smoking interaction);
CESC	trans	rs9929218	1.000	rs17772363	chr16:68788909	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.72	-9.18	-0.49	1.29e-17	Colorectal cancer;
CESC	cis	rs2180341	0.782	rs6569490	chr6:127729615	C/T	cg24812749	chr6:127587940	RNF146	0.84	12.05	0.59	5.93e-27	Breast cancer;
CESC	cis	rs6460942	0.841	rs17443848	chr7:12443688	A/G	cg20607287	chr7:12443886	VWDE	-0.67	-9.67	-0.51	3.97e-19	Coronary artery disease;
CESC	cis	rs11864453	0.647	rs7194397	chr16:72128299	C/T	cg01557791	chr16:72042693	DHODH	-0.43	-5.49	-0.32	9.35e-8	Fibrinogen levels;
CESC	cis	rs477692	0.967	rs519690	chr10:131424033	G/A	cg05714579	chr10:131428358	MGMT	0.48	6.49	0.37	4.29e-10	Response to temozolomide;
CESC	cis	rs7246657	0.941	rs10418729	chr19:37737065	A/C	cg23950597	chr19:37808831	NA	-0.6	-6.43	-0.37	5.86e-10	Coronary artery calcification;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27605355	chr17:74472963	RHBDF2	-0.6	-7.52	-0.42	8.73e-13	Gut microbiome composition (summer);
CESC	trans	rs6445797	0.821	rs11714897	chr3:56666148	G/C	cg15444621	chr13:113611794	NA	0.32	6.01	0.35	6.11e-9	Gastritis;
CESC	trans	rs1814175	0.619	rs10769623	chr11:49865926	C/T	cg15704280	chr7:45808275	SEPT13	-0.98	-18.32	-0.75	5.46e-49	Height;
CESC	cis	rs8005677	0.926	rs34344888	chr14:23387585	A/G	cg25600027	chr14:23388339	RBM23	-0.43	-5.33	-0.31	2.08e-7	Cognitive ability (multi-trait analysis);
CESC	cis	rs7714584	1.000	rs73282255	chr5:150223647	A/T	cg22134413	chr5:150180641	NA	0.53	5.75	0.33	2.47e-8	Crohn's disease;
CESC	cis	rs2836974	0.526	rs1888488	chr21:40686521	C/T	cg17971929	chr21:40555470	PSMG1	-0.85	-12.27	-0.6	1.02e-27	Cognitive function;
CESC	cis	rs1005277	0.579	rs932538	chr10:38381314	T/C	cg25517755	chr10:38738941	LOC399744	-0.44	-5.76	-0.33	2.29e-8	Extrinsic epigenetic age acceleration;
CESC	cis	rs704795	0.836	rs1647281	chr2:27612938	G/C	cg02592271	chr2:27665507	KRTCAP3	-0.28	-5.64	-0.33	4.41e-8	Menopause (age at onset);
CESC	cis	rs8141529	0.509	rs7287124	chr22:29239157	A/G	cg02153584	chr22:29168773	CCDC117	0.59	7.66	0.43	3.42e-13	Lymphocyte counts;
CESC	cis	rs711245	0.573	rs3770796	chr2:36799515	T/C	cg01206211	chr2:36825736	FEZ2	0.32	5.15	0.3	5.02e-7	Height;
CESC	cis	rs758324	0.947	rs72793241	chr5:131240885	C/T	cg06307176	chr5:131281290	NA	-0.43	-5.16	-0.3	4.84e-7	Alzheimer's disease in APOE e4- carriers;
CESC	cis	rs561341	1.000	rs537166	chr17:30326827	C/T	cg00745463	chr17:30367425	LRRC37B	-0.68	-6.81	-0.39	6.34e-11	Hip circumference adjusted for BMI;
CESC	cis	rs2839186	0.814	rs12482209	chr21:47664275	C/G	cg13126279	chr21:47581558	C21orf56	0.47	6.41	0.37	6.65e-10	Testicular germ cell tumor;
CESC	cis	rs672059	0.806	rs3754524	chr1:183153267	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.49	5.97	0.34	7.45e-9	Hypertriglyceridemia;
CESC	trans	rs9951602	1.000	rs1903723	chr18:76646571	A/G	cg02800362	chr5:177631904	HNRNPAB	0.61	6.74	0.38	9.92e-11	Obesity-related traits;
CESC	cis	rs10504229	1.000	rs17217033	chr8:58180061	G/T	cg14926445	chr8:58193284	C8orf71	-0.51	-5.47	-0.32	1.03e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs344364	0.518	rs1657129	chr16:1945826	G/A	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.55	-6.2	-0.36	2.15e-9	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs6754311	0.638	rs2322659	chr2:136555659	A/G	cg15123519	chr2:136567270	LCT	0.29	5.03	0.3	9.15e-7	Mosquito bite size;
CESC	cis	rs11679564	0.714	rs4016031	chr2:37184754	C/T	cg14987922	chr2:37194071	STRN	0.42	5.26	0.31	3.02e-7	Immature fraction of reticulocytes;
CESC	cis	rs8114671	0.836	rs13042358	chr20:33634479	G/A	cg07148914	chr20:33460835	GGT7	-0.41	-5.31	-0.31	2.28e-7	Height;
CESC	cis	rs5769765	0.837	rs4824110	chr22:50271631	T/A	cg02269571	chr22:50332266	NA	0.46	6.28	0.36	1.39e-9	Schizophrenia;
CESC	trans	rs9354308	0.933	rs2022856	chr6:66568235	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.71	7.96	0.44	5.21e-14	Metabolite levels;
CESC	cis	rs10504229	0.861	rs57942497	chr8:58171239	G/T	cg14926445	chr8:58193284	C8orf71	-0.51	-5.47	-0.32	1.03e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs1448094	0.512	rs6539924	chr12:86236935	T/C	cg19622623	chr12:86230825	RASSF9	-0.47	-6.04	-0.35	5.17e-9	Major depressive disorder;
CESC	cis	rs11864453	0.647	rs2550035	chr16:72113416	C/G	cg16558253	chr16:72132732	DHX38	-0.51	-8.02	-0.44	3.35e-14	Fibrinogen levels;
CESC	cis	rs16895831	0.519	rs4379287	chr6:42592486	T/C	cg10605015	chr6:42532144	UBR2	0.52	5.91	0.34	1.07e-8	Granulocyte percentage of myeloid white cells;Neutrophil percentage of white cells;Eosinophil percentage of white cells;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Neutrophil count;Sum basophil neutrophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
CESC	cis	rs853679	0.550	rs1233707	chr6:28172953	G/A	cg23281280	chr6:28129359	ZNF389	0.5	6.97	0.39	2.44e-11	Depression;
CESC	cis	rs6120849	0.707	rs6088690	chr20:33633326	A/G	cg06115741	chr20:33292138	TP53INP2	0.53	5.05	0.3	8.15e-7	Protein C levels;
CESC	cis	rs34779708	0.966	rs12775548	chr10:35479504	G/T	cg04310649	chr10:35416472	CREM	-0.49	-5.81	-0.34	1.82e-8	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs13253111	0.624	rs35990565	chr8:28107815	C/T	cg26534493	chr8:28060551	NA	0.45	6.73	0.38	1.06e-10	Childhood body mass index;
CESC	cis	rs1832871	0.672	rs7745596	chr6:158732991	T/A	cg07165851	chr6:158734300	TULP4	0.6	6.58	0.37	2.57e-10	Height;
CESC	cis	rs9303401	0.659	rs17822807	chr17:56687190	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.0	11.58	0.58	2.27e-25	Cognitive test performance;
CESC	cis	rs2836974	0.897	rs35064900	chr21:40555492	A/G	cg11890956	chr21:40555474	PSMG1	1.21	24.6	0.83	2.29e-70	Cognitive function;
CESC	cis	rs4595586	0.546	rs10876163	chr12:39244915	G/A	cg26384229	chr12:38710491	ALG10B	0.68	10.21	0.53	7.56e-21	Morning vs. evening chronotype;
CESC	cis	rs9611565	0.659	rs12483786	chr22:41938536	A/G	cg06481639	chr22:41940642	POLR3H	-0.62	-6.49	-0.37	4.27e-10	Vitiligo;
CESC	cis	rs6430585	0.702	rs2015532	chr2:136555525	G/T	cg07169764	chr2:136633963	MCM6	-1.24	-16.85	-0.72	8.49e-44	Corneal structure;
CESC	cis	rs3820928	1.000	rs6723774	chr2:227770592	C/T	cg11843606	chr2:227700838	RHBDD1	0.42	5.5	0.32	9e-8	Pulmonary function;
CESC	cis	rs9303401	0.580	rs2013166	chr17:56637630	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.02	12.93	0.62	5.59e-30	Cognitive test performance;
CESC	cis	rs7613875	0.537	rs6446195	chr3:50070853	A/G	cg24308560	chr3:49941425	MST1R	0.58	8.31	0.45	5.15e-15	Body mass index;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02670133	chr5:65440111	SFRS12	0.56	6.4	0.37	7.2e-10	Gut microbiome composition (summer);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg06476606	chr10:91061728	IFIT2	-0.44	-6.43	-0.37	6.06e-10	Gambling;
CESC	cis	rs11711311	1.000	rs12636577	chr3:113497507	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.73	10.3	0.53	3.78e-21	IgG glycosylation;
CESC	cis	rs62229266	0.804	rs880221	chr21:37420785	C/T	cg12218747	chr21:37451666	NA	-0.43	-6.09	-0.35	3.99e-9	Mitral valve prolapse;
CESC	cis	rs4843747	0.671	rs8053377	chr16:88106465	A/G	cg03395651	chr16:88107091	BANP	0.47	5.46	0.32	1.1e-7	Menopause (age at onset);
CESC	cis	rs7085104	0.632	rs7096475	chr10:104609676	A/G	cg15744005	chr10:104629667	AS3MT	-0.32	-5.19	-0.3	4.1e-7	Immature fraction of reticulocytes;Schizophrenia;
CESC	cis	rs10479542	0.929	rs10078796	chr5:178978883	T/A	cg14820908	chr5:178986412	RUFY1	0.47	7.18	0.4	6.86e-12	Lung cancer;
CESC	cis	rs4665809	1.000	rs4233708	chr2:26291345	C/T	cg25036284	chr2:26402008	FAM59B	-0.59	-6.9	-0.39	3.85e-11	Gut microbiome composition (summer);
CESC	cis	rs4925386	0.559	rs2427291	chr20:60921324	G/A	cg22601191	chr20:60968625	CABLES2	0.53	5.26	0.31	2.92e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CESC	trans	rs9329221	0.683	rs688491	chr8:9884823	C/G	cg15556689	chr8:8085844	FLJ10661	-0.54	-6.97	-0.39	2.49e-11	Neuroticism;
CESC	trans	rs7246760	0.748	rs73006398	chr19:9723447	A/G	cg02900749	chr2:68251473	NA	-0.79	-6.02	-0.35	5.78e-9	Pursuit maintenance gain;
CESC	cis	rs7671266	0.668	rs6834055	chr4:10158511	A/T	cg11266682	chr4:10021025	SLC2A9	-0.47	-5.96	-0.34	7.83e-9	Cardiovascular disease risk factors;
CESC	cis	rs12477438	0.501	rs6751927	chr2:99740175	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	15.18	0.68	6.85e-38	Chronic sinus infection;
CESC	cis	rs6142102	0.602	rs4911380	chr20:32546224	C/T	cg08999081	chr20:33150536	PIGU	0.34	5.12	0.3	5.93e-7	Skin pigmentation;
CESC	cis	rs11958404	0.860	rs72818114	chr5:157440207	A/C	cg05962755	chr5:157440814	NA	0.59	6.52	0.37	3.45e-10	IgG glycosylation;
CESC	cis	rs2204008	0.744	rs11168870	chr12:37973333	A/G	cg26384229	chr12:38710491	ALG10B	0.74	10.84	0.55	6.46e-23	Bladder cancer;
CESC	cis	rs4665809	0.590	rs3806514	chr2:26466772	C/T	cg26314531	chr2:26401878	FAM59B	0.85	9.23	0.49	8.65e-18	Gut microbiome composition (summer);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03747177	chr16:23568683	EARS2;UBFD1	0.48	6.04	0.35	5.22e-9	Gut microbiota (bacterial taxa);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg05655935	chr10:93683722	BTAF1	-0.51	-7.09	-0.4	1.24e-11	Fibrinogen levels;
CESC	cis	rs425277	0.583	rs1467217	chr1:2045165	G/A	cg16545954	chr1:2118288	C1orf86	-0.32	-6.17	-0.35	2.55e-9	Height;
CESC	cis	rs6933660	0.800	rs9383893	chr6:151757327	T/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.65	9.43	0.5	2.1e-18	Menarche (age at onset);
CESC	cis	rs35146811	0.586	rs6946168	chr7:99598286	C/T	cg14163444	chr7:99595348	NA	-0.39	-5.13	-0.3	5.57e-7	Coronary artery disease;
CESC	cis	rs6674176	0.660	rs6680421	chr1:44408969	A/C	cg13606994	chr1:44402422	ARTN	0.4	6.17	0.35	2.52e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs9649213	0.593	rs36017146	chr7:97974617	C/T	cg00277769	chr7:97922759	BAIAP2L1	-0.34	-5.55	-0.32	6.9e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs9790314	0.934	rs461638	chr3:161103166	A/G	cg03342759	chr3:160939853	NMD3	-0.45	-5.87	-0.34	1.29e-8	Morning vs. evening chronotype;
CESC	cis	rs875971	1.000	rs778710	chr7:65854834	T/C	cg11764359	chr7:65958608	NA	0.96	15.23	0.68	4.78e-38	Aortic root size;
CESC	cis	rs9443645	0.527	rs3902856	chr6:79699837	C/T	cg05283184	chr6:79620031	NA	-0.37	-5.26	-0.31	2.91e-7	Intelligence (multi-trait analysis);
CESC	cis	rs5758659	1.000	rs5758660	chr22:42623718	C/A	cg04733989	chr22:42467013	NAGA	0.41	5.67	0.33	3.8e-8	Cognitive function;
CESC	cis	rs4595586	0.525	rs11612680	chr12:39344443	A/G	cg13010199	chr12:38710504	ALG10B	0.45	5.65	0.33	4.2e-8	Morning vs. evening chronotype;
CESC	cis	rs2228479	0.702	rs62053702	chr16:89860688	G/T	cg19635926	chr16:89946313	TCF25	0.68	5.17	0.3	4.65e-7	Skin colour saturation;
CESC	cis	rs2439831	0.702	rs7175032	chr15:44060236	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.72	6.81	0.39	6.65e-11	Lung cancer in ever smokers;
CESC	cis	rs35110281	0.840	rs2838331	chr21:45026728	A/G	cg21573476	chr21:45109991	RRP1B	0.46	6.4	0.37	6.98e-10	Mean corpuscular volume;
CESC	cis	rs7267979	0.586	rs6037057	chr20:25182089	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.67	10.88	0.56	4.73e-23	Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs10242455	0.702	rs73405247	chr7:99159174	C/G	cg09045935	chr12:6379348	NA	0.91	6.98	0.39	2.36e-11	Blood metabolite levels;
CESC	cis	rs9611565	0.765	rs767593	chr22:41779971	G/T	cg03806693	chr22:41940476	POLR3H	-1.14	-14.12	-0.66	3.81e-34	Vitiligo;
CESC	cis	rs863345	1.000	rs863345	chr1:158534982	A/G	cg12129480	chr1:158549410	OR10X1	0.32	6.42	0.37	6.09e-10	Pneumococcal bacteremia;
CESC	trans	rs1814175	0.745	rs7483456	chr11:49774613	C/T	cg03929089	chr4:120376271	NA	-0.9	-14.97	-0.68	4.06e-37	Height;
CESC	cis	rs769267	0.930	rs892022	chr19:19613381	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.59	7.42	0.41	1.61e-12	Tonsillectomy;
CESC	cis	rs1862618	0.853	rs832584	chr5:56179212	A/G	cg22800045	chr5:56110881	MAP3K1	-0.8	-9.64	-0.51	4.78e-19	Initial pursuit acceleration;
CESC	cis	rs4835473	0.897	rs1450246	chr4:144624107	A/T	cg25736465	chr4:144833511	NA	0.36	5.48	0.32	9.68e-8	Immature fraction of reticulocytes;
CESC	cis	rs7100689	0.577	rs2282367	chr10:82040346	A/G	cg09936400	chr10:82049201	MAT1A	0.4	6.18	0.36	2.36e-9	Post bronchodilator FEV1;
CESC	cis	rs40363	0.723	rs757269	chr16:3538003	A/G	cg05754148	chr16:3507555	NAT15	-0.64	-6.36	-0.36	8.93e-10	Tuberculosis;
CESC	cis	rs1707322	0.717	rs1972410	chr1:46080947	G/T	cg06784218	chr1:46089804	CCDC17	0.41	7.14	0.4	9.22e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs10927875	1.000	rs12138117	chr1:16305279	T/C	cg22431228	chr1:16359049	CLCNKA	0.37	5.73	0.33	2.74e-8	Dilated cardiomyopathy;
CESC	trans	rs11148252	0.500	rs342768	chr13:53208882	C/T	cg18335740	chr13:41363409	SLC25A15	0.56	7.96	0.44	4.95e-14	Lewy body disease;
CESC	cis	rs7944584	0.655	rs11039183	chr11:47346940	G/A	cg20307385	chr11:47447363	PSMC3	0.69	8.84	0.48	1.39e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);
CESC	cis	rs1545257	0.505	rs7583687	chr2:24634003	C/G	cg06627628	chr2:24431161	ITSN2	-0.47	-5.76	-0.33	2.38e-8	Sjögren's syndrome;
CESC	trans	rs116095464	0.558	rs13357299	chr5:242211	T/C	cg00938859	chr5:1591904	SDHAP3	0.63	6.98	0.39	2.3e-11	Breast cancer;
CESC	cis	rs684232	0.602	rs331008	chr17:544617	C/T	cg15660573	chr17:549704	VPS53	-0.8	-11.67	-0.58	1.16e-25	Prostate cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06725705	chr16:9058264	USP7	0.6	6.91	0.39	3.65e-11	Gut microbiome composition (summer);
CESC	cis	rs9858542	1.000	rs13085791	chr3:49721798	C/A	cg03060546	chr3:49711283	APEH	-0.58	-6.87	-0.39	4.44e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs4237845	0.537	rs12312955	chr12:58265223	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.49	5.46	0.32	1.12e-7	Intelligence (multi-trait analysis);
CESC	cis	rs853679	0.550	rs1150692	chr6:28173957	A/G	cg26335602	chr6:28129616	ZNF389	0.48	6.52	0.37	3.56e-10	Depression;
CESC	cis	rs6430585	0.528	rs309172	chr2:136674028	A/G	cg07169764	chr2:136633963	MCM6	1.16	16.89	0.72	5.92e-44	Corneal structure;
CESC	trans	rs1814175	0.791	rs1722011	chr11:49899340	G/C	cg15704280	chr7:45808275	SEPT13	-1.03	-21.02	-0.79	2.09e-58	Height;
CESC	cis	rs6938	0.662	rs12487	chr15:75136694	A/G	cg17294928	chr15:75287854	SCAMP5	0.52	6.66	0.38	1.62e-10	Breast cancer;
CESC	cis	rs1983891	0.955	rs4714480	chr6:41520891	T/C	cg20194872	chr6:41519635	FOXP4	0.57	8.19	0.45	1.12e-14	Prostate cancer;
CESC	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg22535103	chr8:58192502	C8orf71	-0.95	-9.78	-0.51	1.78e-19	Developmental language disorder (linguistic errors);
CESC	cis	rs2228479	1.000	rs11642267	chr16:89957635	T/C	cg04013166	chr16:89971882	TCF25	0.76	6.53	0.37	3.28e-10	Skin colour saturation;
CESC	cis	rs116095464	0.558	rs1812843	chr5:267658	A/G	cg20965017	chr5:231967	SDHA	-0.48	-5.43	-0.32	1.25e-7	Breast cancer;
CESC	cis	rs72781680	0.716	rs7564732	chr2:24034178	C/T	cg08917208	chr2:24149416	ATAD2B	0.65	6.34	0.36	9.82e-10	Lymphocyte counts;
CESC	cis	rs897984	0.762	rs2305880	chr16:30999462	T/C	cg00531865	chr16:30841666	NA	0.5	6.87	0.39	4.7e-11	Dementia with Lewy bodies;
CESC	cis	rs7811142	0.830	rs6948685	chr7:99970188	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.1	11.2	0.57	4.36e-24	Platelet count;
CESC	cis	rs9549367	0.713	rs1755690	chr13:113824266	T/C	cg00898013	chr13:113819073	PROZ	0.45	6.62	0.38	1.97e-10	Platelet distribution width;
CESC	cis	rs16937	0.518	rs1172149	chr1:205224758	A/G	cg21643547	chr1:205240462	TMCC2	-0.32	-5.04	-0.3	8.5e-7	Schizophrenia;
CESC	cis	rs17253792	0.822	rs10145687	chr14:56124384	T/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.71	5.78	0.33	2.08e-8	Putamen volume;
CESC	cis	rs9815354	0.951	rs1619558	chr3:41914213	C/G	cg03022575	chr3:42003672	ULK4	0.44	5.16	0.3	4.85e-7	Pulse pressure;Diastolic blood pressure;
CESC	trans	rs6460942	0.556	rs2287067	chr7:12370533	T/C	cg16269144	chr1:2003326	PRKCZ	0.51	6.21	0.36	2e-9	Coronary artery disease;
CESC	cis	rs9311474	0.508	rs17052259	chr3:52593138	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.49	7.16	0.4	8.18e-12	Electroencephalogram traits;
CESC	cis	rs1862618	0.853	rs252921	chr5:56137787	G/A	cg12311346	chr5:56204834	C5orf35	-0.72	-8.75	-0.47	2.48e-16	Initial pursuit acceleration;
CESC	cis	rs9790314	1.000	rs336590	chr3:161079583	G/A	cg03342759	chr3:160939853	NMD3	-0.5	-6.45	-0.37	5.33e-10	Morning vs. evening chronotype;
CESC	cis	rs6912958	0.781	rs9444522	chr6:88309705	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-5.07	-0.3	7.4e-7	Monocyte percentage of white cells;
CESC	cis	rs12188164	0.930	rs72717436	chr5:448291	C/A	cg17553881	chr5:443987	EXOC3;C5orf55	-0.38	-6.14	-0.35	2.97e-9	Cystic fibrosis severity;
CESC	cis	rs79349575	0.691	rs28528789	chr17:46986616	C/T	cg16584676	chr17:46985605	UBE2Z	-0.71	-9.25	-0.49	8.03e-18	Type 2 diabetes;
CESC	cis	rs1348850	0.526	rs10497504	chr2:178370040	T/C	cg22681709	chr2:178499509	PDE11A	-0.5	-5.16	-0.3	4.97e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs75229567	0.618	rs1599745	chr12:70186029	A/G	cg10114359	chr12:70132523	RAB3IP	0.78	6.08	0.35	4.08e-9	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
CESC	cis	rs17401966	1.000	rs17411502	chr1:10431158	T/C	cg15208524	chr1:10270712	KIF1B	0.46	5.77	0.33	2.2e-8	Hepatocellular carcinoma;
CESC	cis	rs9322193	0.632	rs3828700	chr6:150112169	C/G	cg07701084	chr6:150067640	NUP43	0.43	5.77	0.33	2.2e-8	Lung cancer;
CESC	cis	rs896543	0.702	rs12692190	chr2:237496190	C/T	cg25295825	chr2:237489920	CXCR7	0.7	9.68	0.51	3.57e-19	Alcohol dependence (age at onset);
CESC	trans	rs1728785	0.792	rs1111502	chr16:68581209	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.61	7.49	0.42	1.04e-12	Ulcerative colitis;
CESC	cis	rs561341	1.000	rs15654	chr17:30326360	A/C	cg00745463	chr17:30367425	LRRC37B	-0.82	-7.51	-0.42	9.09e-13	Hip circumference adjusted for BMI;
CESC	cis	rs9902453	0.967	rs4473252	chr17:28454423	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.62	8.02	0.44	3.41e-14	Coffee consumption (cups per day);
CESC	cis	rs701145	0.586	rs181443	chr3:153959028	G/T	cg16511985	chr3:153974050	SGEF	0.46	6.25	0.36	1.66e-9	Coronary artery disease;
CESC	trans	rs853679	0.546	rs175597	chr6:27810626	T/C	cg06606381	chr12:133084897	FBRSL1	-0.82	-7.72	-0.43	2.38e-13	Depression;
CESC	cis	rs4689388	0.926	rs5018648	chr4:6292818	C/G	cg00701064	chr4:6280414	WFS1	-0.69	-12.24	-0.6	1.34e-27	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs6088590	0.550	rs12624640	chr20:32952125	G/A	cg08999081	chr20:33150536	PIGU	0.56	8.53	0.46	1.15e-15	Coronary artery disease;
CESC	cis	rs6987853	0.686	rs10087350	chr8:42359484	G/A	cg09913449	chr8:42400586	C8orf40	-0.36	-5.92	-0.34	9.91e-9	Mean corpuscular hemoglobin concentration;
CESC	cis	rs7647973	0.580	rs2334958	chr3:49252364	C/T	cg02487422	chr3:49467188	NICN1	0.38	5.26	0.31	2.98e-7	Menarche (age at onset);
CESC	trans	rs2502399	0.652	rs2502370	chr6:113509611	G/A	cg00285294	chr7:1089767	C7orf50	-0.34	-6.33	-0.36	1.06e-9	Plasma clusterin levels;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg00320862	chr3:170588302	RPL22L1	-0.5	-6.5	-0.37	4.02e-10	Ulcerative colitis;
CESC	cis	rs12586317	0.547	rs77780729	chr14:35496176	C/A	cg05294307	chr14:35346193	BAZ1A	-0.58	-5.96	-0.34	7.85e-9	Psoriasis;
CESC	cis	rs7267979	0.933	rs1130694	chr20:25276297	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.86	16.93	0.72	4.47e-44	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7100689	0.646	rs1953972	chr10:82145666	A/G	cg00277334	chr10:82204260	NA	-0.58	-7.62	-0.42	4.52e-13	Post bronchodilator FEV1;
CESC	cis	rs763121	0.853	rs5757196	chr22:39039855	G/C	cg06544989	chr22:39130855	UNC84B	0.5	8.66	0.47	4.63e-16	Menopause (age at onset);
CESC	cis	rs9905704	0.681	rs7225128	chr17:56636854	T/C	cg12560992	chr17:57184187	TRIM37	-0.63	-5.87	-0.34	1.3e-8	Testicular germ cell tumor;
CESC	cis	rs208520	0.690	rs1776365	chr6:66834474	G/T	cg07460842	chr6:66804631	NA	-0.98	-13.25	-0.63	4.4e-31	Exhaled nitric oxide output;
CESC	cis	rs9649213	0.593	rs13246843	chr7:98002661	G/T	cg24562669	chr7:97807699	LMTK2	0.51	7.63	0.42	4.29e-13	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.08	11.23	0.57	3.45e-24	Platelet count;
CESC	cis	rs72615157	0.539	rs4729575	chr7:99686873	G/T	cg22004693	chr7:99632812	ZKSCAN1	0.43	5.31	0.31	2.3e-7	Lung function (FEV1/FVC);
CESC	cis	rs6087990	0.735	rs2064350	chr20:31390533	T/C	cg13636640	chr20:31349939	DNMT3B	0.8	12.86	0.62	9.44e-30	Ulcerative colitis;
CESC	cis	rs8060686	0.545	rs3826164	chr16:68280317	A/G	cg26727032	chr16:67993705	SLC12A4	0.51	5.49	0.32	9.44e-8	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs801193	0.569	rs2707824	chr7:66189243	A/G	cg12463550	chr7:65579703	CRCP	0.49	6.35	0.36	9.51e-10	Aortic root size;
CESC	cis	rs10504229	0.683	rs56058640	chr8:58128862	C/T	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs477895	0.713	rs11601024	chr11:63943074	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.93	10.19	0.53	8.92e-21	Mean platelet volume;
CESC	cis	rs1552244	0.935	rs28815328	chr3:10062227	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.8	-10.5	-0.54	8.72e-22	Alzheimer's disease;
CESC	cis	rs295140	0.546	rs842830	chr2:201131124	C/T	cg23649088	chr2:200775458	C2orf69	-0.46	-6.14	-0.35	3.06e-9	QT interval;
CESC	cis	rs6933660	0.800	rs2046371	chr6:151754744	G/A	cg10883421	chr6:151773342	RMND1;C6orf211	0.8	12.3	0.6	7.99e-28	Menarche (age at onset);
CESC	trans	rs875971	1.000	rs7781698	chr7:65896312	A/T	cg26939375	chr7:64535504	NA	0.48	6.24	0.36	1.68e-9	Aortic root size;
CESC	cis	rs7666738	0.830	rs13133355	chr4:98919415	A/G	cg17366294	chr4:99064904	C4orf37	0.57	8.0	0.44	3.83e-14	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2777491	0.957	rs7163788	chr15:41704789	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.65	-9.82	-0.52	1.26e-19	Ulcerative colitis;
CESC	cis	rs274567	0.501	rs274571	chr5:131712125	A/G	cg04518342	chr5:131593106	PDLIM4	-0.36	-5.21	-0.3	3.8e-7	Blood metabolite levels;
CESC	cis	rs3820928	0.874	rs1114562	chr2:227788592	T/C	cg11843606	chr2:227700838	RHBDD1	-0.49	-6.59	-0.38	2.33e-10	Pulmonary function;
CESC	cis	rs116095464	1.000	rs56075848	chr5:308352	T/C	cg22857025	chr5:266934	NA	-1.2	-10.27	-0.53	4.88e-21	Breast cancer;
CESC	cis	rs2836633	1.000	rs2836633	chr21:40067445	C/T	cg05519781	chr21:40033154	ERG	-0.61	-9.74	-0.51	2.33e-19	Coronary artery disease;
CESC	cis	rs7267979	0.903	rs6107015	chr20:25216764	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.82	14.91	0.68	6.25e-37	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs763121	0.853	rs3788545	chr22:39065172	A/G	cg06022373	chr22:39101656	GTPBP1	0.88	13.88	0.65	2.66e-33	Menopause (age at onset);
CESC	cis	rs514406	0.505	rs374849	chr1:53185631	G/A	cg24675658	chr1:53192096	ZYG11B	-0.5	-6.23	-0.36	1.79e-9	Monocyte count;
CESC	cis	rs6752107	0.967	rs3816234	chr2:234185999	G/A	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.39	5.91	0.34	1.07e-8	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs6460942	1.000	rs118083671	chr7:12466036	C/T	cg20607287	chr7:12443886	VWDE	-0.78	-9.15	-0.49	1.61e-17	Coronary artery disease;
CESC	cis	rs2836974	0.568	rs429955	chr21:40539760	G/A	cg17971929	chr21:40555470	PSMG1	0.86	12.8	0.62	1.53e-29	Cognitive function;
CESC	cis	rs2797160	1.000	rs1739367	chr6:126004720	G/T	cg05901451	chr6:126070800	HEY2	-0.45	-6.53	-0.37	3.43e-10	Endometrial cancer;
CESC	cis	rs875971	1.000	rs3735148	chr7:65971009	T/G	cg10691866	chr7:65817282	TPST1	-0.34	-5.6	-0.33	5.45e-8	Aortic root size;
CESC	cis	rs7219021	0.961	rs7215901	chr17:46858083	A/C	cg16584676	chr17:46985605	UBE2Z	-0.71	-7.92	-0.44	6.57e-14	Schizophrenia or bipolar disorder;
CESC	cis	rs7772486	0.875	rs9373485	chr6:146401429	A/T	cg23711669	chr6:146136114	FBXO30	0.84	12.73	0.62	2.75e-29	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9916302	0.904	rs650106	chr17:37451559	A/G	cg15445000	chr17:37608096	MED1	-0.4	-6.54	-0.37	3.14e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs6460942	0.841	rs6968277	chr7:12443795	C/A	cg06484146	chr7:12443880	VWDE	-0.66	-9.48	-0.5	1.53e-18	Coronary artery disease;
CESC	cis	rs477895	0.713	rs3802933	chr11:63988102	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.93	10.2	0.53	7.77e-21	Mean platelet volume;
CESC	cis	rs72792276	1.000	rs17164395	chr5:127395526	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.68	5.25	0.31	3.14e-7	Red cell distribution width;
CESC	cis	rs897984	0.683	rs12926237	chr16:30837596	C/T	cg02466173	chr16:30829666	NA	0.59	11.07	0.56	1.17e-23	Dementia with Lewy bodies;
CESC	cis	rs7618915	0.547	rs34173654	chr3:52634605	T/C	cg18404041	chr3:52824283	ITIH1	-0.4	-6.71	-0.38	1.19e-10	Bipolar disorder;
CESC	cis	rs7044106	0.718	rs10616	chr9:123363533	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.69	9.88	0.52	8.58e-20	Hip circumference adjusted for BMI;
CESC	cis	rs2295499	0.673	rs73189408	chr4:2705644	T/A	cg27239842	chr4:2403781	ZFYVE28	-0.33	-5.6	-0.33	5.29e-8	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
CESC	cis	rs763121	0.853	rs2072794	chr22:39150543	G/T	cg06022373	chr22:39101656	GTPBP1	0.93	15.31	0.69	2.49e-38	Menopause (age at onset);
CESC	cis	rs6088580	0.634	rs4911419	chr20:32995873	G/A	cg08999081	chr20:33150536	PIGU	-0.65	-11.29	-0.57	2.22e-24	Glomerular filtration rate (creatinine);
CESC	cis	rs763121	0.853	rs2294296	chr22:39053049	T/C	cg21395723	chr22:39101663	GTPBP1	0.43	5.37	0.31	1.76e-7	Menopause (age at onset);
CESC	cis	rs2952156	0.834	rs903503	chr17:37829571	C/A	cg07936489	chr17:37558343	FBXL20	-0.59	-7.52	-0.42	8.39e-13	Asthma;
CESC	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg11494091	chr17:61959527	GH2	0.73	12.48	0.61	2.02e-28	Prudent dietary pattern;
CESC	cis	rs55883249	0.957	rs17362839	chr2:9754439	T/C	cg23886495	chr2:9695866	ADAM17	0.65	5.89	0.34	1.19e-8	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
CESC	cis	rs6089584	0.854	rs8117075	chr20:60613766	T/C	cg13770153	chr20:60521292	NA	-0.47	-6.01	-0.35	6.03e-9	Body mass index;
CESC	cis	rs6570726	0.935	rs380883	chr6:145822992	A/G	cg23711669	chr6:146136114	FBXO30	0.79	11.45	0.58	6.2e-25	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2425143	0.818	rs11700299	chr20:34548865	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.79	-7.13	-0.4	9.32e-12	Blood protein levels;
CESC	cis	rs4555082	0.834	rs2816651	chr14:105708470	A/G	cg06808227	chr14:105710500	BRF1	-0.6	-7.15	-0.4	8.26e-12	Mean platelet volume;Platelet distribution width;
CESC	cis	rs2777491	0.872	rs7176588	chr15:41588872	C/T	cg20272979	chr15:41787780	ITPKA	0.34	5.05	0.3	8.08e-7	Ulcerative colitis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25371950	chr2:242786524	NA	0.58	6.63	0.38	1.91e-10	Gut microbiome composition (summer);
CESC	cis	rs1008375	0.966	rs6839660	chr4:17667987	C/T	cg02297831	chr4:17616191	MED28	0.46	5.81	0.34	1.81e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs1552244	0.938	rs7625049	chr3:10115619	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-11.04	-0.56	1.41e-23	Alzheimer's disease;
CESC	cis	rs72792276	1.000	rs10519971	chr5:127379216	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.74	-5.97	-0.34	7.57e-9	Red cell distribution width;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg24623068	chr5:154317667	GEMIN5	-0.41	-6.2	-0.36	2.19e-9	Gambling;
CESC	cis	rs889312	0.500	rs252906	chr5:56119190	G/T	cg14703610	chr5:56206110	C5orf35	0.46	6.15	0.35	2.86e-9	Breast cancer;Breast cancer (early onset);
CESC	cis	rs6121246	0.865	rs6089055	chr20:30324045	C/T	cg13852791	chr20:30311386	BCL2L1	0.82	7.64	0.42	3.91e-13	Mean corpuscular hemoglobin;
CESC	cis	rs2228479	0.717	rs2270460	chr16:89972416	C/A	cg06558623	chr16:89946397	TCF25	0.91	8.02	0.44	3.45e-14	Skin colour saturation;
CESC	cis	rs965469	0.779	rs6133034	chr20:3337661	A/G	cg17110299	chr20:3385021	C20orf194	0.4	5.26	0.31	3.02e-7	IFN-related cytopenia;
CESC	cis	rs796364	0.806	rs203769	chr2:200900866	C/T	cg23649088	chr2:200775458	C2orf69	-0.58	-5.35	-0.31	1.86e-7	Schizophrenia;
CESC	trans	rs1814175	0.645	rs1721997	chr11:49916653	T/C	cg03929089	chr4:120376271	NA	-0.92	-15.2	-0.68	6e-38	Height;
CESC	cis	rs1707322	0.721	rs11211157	chr1:46132844	T/C	cg05343316	chr1:45956843	TESK2	0.5	6.12	0.35	3.43e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs1552244	1.000	rs7622966	chr3:10139833	C/T	cg00149659	chr3:10157352	C3orf10	0.7	8.64	0.47	5.25e-16	Alzheimer's disease;
CESC	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg24642844	chr7:1081250	C7orf50	-0.77	-9.41	-0.5	2.48e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs12926788	0.546	rs200537	chr16:24747787	G/C	cg04756594	chr16:24857601	SLC5A11	-0.45	-5.55	-0.32	7.01e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs10504229	0.683	rs16921823	chr8:58108612	G/C	cg02725872	chr8:58115012	NA	-0.43	-6.81	-0.39	6.53e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs17253792	0.545	rs75276278	chr14:56024341	C/T	cg01858014	chr14:56050164	KTN1	-0.88	-6.38	-0.36	7.78e-10	Putamen volume;
CESC	cis	rs9951602	0.607	rs3017651	chr18:76668622	T/C	cg00806245	chr18:76673096	NA	-0.56	-8.1	-0.45	1.98e-14	Obesity-related traits;
CESC	cis	rs6088580	0.634	rs1890000	chr20:32968312	G/T	cg24642439	chr20:33292090	TP53INP2	-0.53	-6.99	-0.39	2.23e-11	Glomerular filtration rate (creatinine);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16620766	chr12:122268197	SETD1B	-0.55	-6.19	-0.36	2.28e-9	Gut microbiome composition (summer);
CESC	cis	rs6736093	0.966	rs6743523	chr2:112693875	G/A	cg12686935	chr2:112915763	FBLN7	-0.44	-5.72	-0.33	2.86e-8	Coronary artery disease;
CESC	cis	rs72781680	0.611	rs7596060	chr2:24334361	A/G	cg08917208	chr2:24149416	ATAD2B	-0.55	-5.41	-0.32	1.42e-7	Lymphocyte counts;
CESC	cis	rs7385804	0.727	rs221790	chr7:100278282	G/C	cg16850897	chr7:100343110	ZAN	0.52	7.19	0.4	6.68e-12	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
CESC	cis	rs10256972	0.933	rs35696159	chr7:1047194	A/G	cg23978390	chr7:1156363	C7orf50	0.46	6.17	0.35	2.49e-9	Longevity;Endometriosis;
CESC	cis	rs736408	0.609	rs2336545	chr3:52787603	C/T	cg18337363	chr3:52569053	NT5DC2	-0.3	-5.34	-0.31	2.03e-7	Bipolar disorder;
CESC	cis	rs965513	1.000	rs10759927	chr9:100542176	A/G	cg13688889	chr9:100608707	NA	-0.61	-8.6	-0.47	7.29e-16	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
CESC	cis	rs965469	1.000	rs6051831	chr20:3373712	G/T	cg25506879	chr20:3388711	C20orf194	0.54	5.68	0.33	3.62e-8	IFN-related cytopenia;
CESC	cis	rs559928	0.606	rs12419038	chr11:63912736	A/G	cg18225595	chr11:63971243	STIP1	0.65	6.39	0.37	7.54e-10	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CESC	cis	rs1862618	0.853	rs33325	chr5:56142547	G/C	cg12311346	chr5:56204834	C5orf35	-0.72	-8.75	-0.47	2.48e-16	Initial pursuit acceleration;
CESC	cis	rs3096299	0.719	rs12934708	chr16:89523790	C/T	cg02034447	chr16:89574710	SPG7	0.51	6.44	0.37	5.73e-10	Multiple myeloma (IgH translocation);
CESC	cis	rs10504229	1.000	rs61998259	chr8:58192290	T/C	cg14926445	chr8:58193284	C8orf71	-0.51	-5.52	-0.32	8.28e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs4481887	0.927	rs4341391	chr1:248475720	A/G	cg00666640	chr1:248458726	OR2T12	0.34	5.48	0.32	9.82e-8	Common traits (Other);
CESC	cis	rs854765	0.693	rs12936037	chr17:17777245	A/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.46	-5.96	-0.34	8.19e-9	Total body bone mineral density;
CESC	cis	rs9430161	0.644	rs34365965	chr1:11034442	G/A	cg27631724	chr1:11040367	C1orf127	0.38	6.14	0.35	2.99e-9	Ewing sarcoma;
CESC	cis	rs597539	0.652	rs622082	chr11:68703959	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.81	10.75	0.55	1.29e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg04025307	chr7:1156635	C7orf50	0.58	10.54	0.54	6.57e-22	Longevity;Endometriosis;
CESC	cis	rs34779708	0.966	rs2045918	chr10:35418517	T/G	cg03585969	chr10:35415529	CREM	0.75	9.82	0.52	1.29e-19	Inflammatory bowel disease;Crohn's disease;
CESC	trans	rs208520	0.526	rs6913344	chr6:66754285	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.99	-18.8	-0.76	1.15e-50	Exhaled nitric oxide output;
CESC	cis	rs1707322	0.717	rs28396194	chr1:46213227	C/T	cg03146154	chr1:46216737	IPP	0.82	11.53	0.58	3.39e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs4072980	0.524	rs16824514	chr1:38395947	A/T	cg04673462	chr1:38461896	NA	0.36	5.21	0.3	3.84e-7	Coronary artery disease;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg13412395	chr9:102583693	NR4A3	0.48	6.83	0.39	5.84e-11	Systemic lupus erythematosus;
CESC	cis	rs938554	0.513	rs10939650	chr4:9998440	C/T	cg11266682	chr4:10021025	SLC2A9	0.48	7.42	0.41	1.62e-12	Blood metabolite levels;
CESC	cis	rs36051895	0.659	rs1575285	chr9:5267440	A/G	cg02405213	chr9:5042618	JAK2	-0.5	-6.12	-0.35	3.44e-9	Pediatric autoimmune diseases;
CESC	cis	rs10979	1.000	rs1416208	chr6:143889241	T/A	cg25407410	chr6:143891975	LOC285740	-0.61	-9.14	-0.49	1.72e-17	Hypospadias;
CESC	cis	rs3091242	0.866	rs11249249	chr1:25758134	A/G	cg27572855	chr1:25598939	RHD	0.49	8.37	0.46	3.36e-15	Erythrocyte sedimentation rate;
CESC	cis	rs7129220	0.512	rs1867136	chr11:10228843	C/T	cg01453529	chr11:10209919	SBF2	-0.45	-5.55	-0.32	6.79e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CESC	cis	rs6998277	1.000	rs16869658	chr8:103633762	C/T	cg10187029	chr8:103597600	NA	0.57	6.51	0.37	3.68e-10	Migraine;
CESC	cis	rs7589728	1.000	rs75181745	chr2:88520408	C/T	cg04511125	chr2:88470314	THNSL2	0.58	5.64	0.33	4.33e-8	Plasma clusterin levels;
CESC	cis	rs1218582	0.772	rs877343	chr1:154910012	A/G	cg24250549	chr1:154909240	PMVK	0.72	10.45	0.54	1.26e-21	Prostate cancer;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg24394865	chr11:66206319	MRPL11	-0.44	-6.16	-0.35	2.72e-9	Gambling;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03511402	chr16:30583225	ZNF688	-0.66	-7.03	-0.4	1.8e-11	Gut microbiome composition (summer);
CESC	cis	rs892961	0.965	rs312856	chr17:75401598	A/G	cg05865280	chr17:75406074	SEPT9	0.66	13.5	0.64	5.81e-32	Airflow obstruction;
CESC	cis	rs9611565	0.659	rs4822035	chr22:41935912	A/G	cg06481639	chr22:41940642	POLR3H	0.59	6.19	0.36	2.27e-9	Vitiligo;
CESC	cis	rs514406	0.727	rs61768342	chr1:53217028	G/A	cg16325326	chr1:53192061	ZYG11B	-0.72	-11.9	-0.59	1.88e-26	Monocyte count;
CESC	cis	rs7523050	0.558	rs35926243	chr1:109407712	T/A	cg08274380	chr1:109419600	GPSM2	0.91	5.92	0.34	9.78e-9	Fat distribution (HIV);
CESC	cis	rs7819412	0.668	rs4841507	chr8:11046394	C/G	cg14752069	chr8:11977206	FAM66D	-0.3	-5.11	-0.3	6.21e-7	Triglycerides;
CESC	cis	rs4290604	1.000	rs4290604	chr2:238070885	A/G	cg23555395	chr2:238036564	NA	-0.54	-5.33	-0.31	2.08e-7	Asthma;
CESC	cis	rs10080237	0.564	rs2490230	chr6:80812464	G/A	cg08355045	chr6:80787529	NA	0.33	5.09	0.3	6.73e-7	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
CESC	cis	rs2652834	0.861	rs4774472	chr15:63353760	C/A	cg05507819	chr15:63340323	TPM1	0.62	6.31	0.36	1.14e-9	HDL cholesterol;
CESC	cis	rs76878669	0.561	rs4930179	chr11:66157432	C/T	cg18002602	chr11:66138449	SLC29A2	0.4	6.76	0.38	8.68e-11	Educational attainment (years of education);
CESC	cis	rs28830936	0.966	rs1107858	chr15:41968226	G/A	cg11010575	chr15:42129464	JMJD7-PLA2G4B;JMJD7	-0.41	-5.7	-0.33	3.24e-8	Diastolic blood pressure;
CESC	cis	rs6860806	0.661	rs4705929	chr5:131584178	G/T	cg12564285	chr5:131593104	PDLIM4	0.38	5.75	0.33	2.45e-8	Breast cancer;
CESC	cis	rs2427308	0.607	rs1741635	chr20:60938197	C/G	cg24112000	chr20:60950667	NA	0.52	6.1	0.35	3.82e-9	Colorectal cancer;
CESC	trans	rs9929218	0.906	rs4783565	chr16:68750190	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.78	-10.24	-0.53	6.05e-21	Colorectal cancer;
CESC	cis	rs853679	0.517	rs9468297	chr6:28118874	G/T	cg26335602	chr6:28129616	ZNF389	0.53	6.75	0.38	9.35e-11	Depression;
CESC	cis	rs1577917	0.958	rs12196175	chr6:86779370	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.47	-6.14	-0.35	3.04e-9	Response to antipsychotic treatment;
CESC	cis	rs7917772	0.510	rs2001389	chr10:104375258	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.39	5.41	0.32	1.43e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs2262909	0.962	rs2017521	chr19:22126138	T/C	cg11619707	chr19:22235551	ZNF257	-0.33	-5.52	-0.32	7.97e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
CESC	cis	rs897984	0.770	rs3813020	chr16:30934075	G/A	cg02466173	chr16:30829666	NA	0.49	8.46	0.46	1.82e-15	Dementia with Lewy bodies;
CESC	cis	rs854765	0.693	rs35451946	chr17:17764061	C/G	cg16928487	chr17:17741425	SREBF1	0.59	10.71	0.55	1.79e-22	Total body bone mineral density;
CESC	cis	rs4253772	0.515	rs74766656	chr22:46662497	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.6	5.29	0.31	2.61e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs7412746	0.611	rs12085336	chr1:150775780	A/T	cg09365446	chr1:150670422	GOLPH3L	0.42	5.71	0.33	3.04e-8	Melanoma;
CESC	cis	rs9858542	0.953	rs7648841	chr3:49416825	G/A	cg07274523	chr3:49395745	GPX1	0.67	8.37	0.46	3.46e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs4319547	0.915	rs7966094	chr12:123115771	A/G	cg23029597	chr12:123009494	RSRC2	-0.48	-5.35	-0.31	1.94e-7	Body mass index;
CESC	cis	rs704795	0.805	rs1728926	chr2:27612937	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.32	-5.94	-0.34	8.84e-9	Menopause (age at onset);
CESC	cis	rs875971	0.862	rs949930	chr7:65766822	C/G	cg12463550	chr7:65579703	CRCP	-0.45	-5.72	-0.33	2.86e-8	Aortic root size;
CESC	cis	rs4819052	0.851	rs28622522	chr21:46676599	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.77	10.14	0.53	1.23e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs643506	0.845	rs2850245	chr11:111760738	G/T	cg17089665	chr11:111648010	NA	-0.39	-5.64	-0.33	4.26e-8	Breast cancer;
CESC	cis	rs9487051	0.652	rs6568559	chr6:109592751	C/T	cg12927641	chr6:109611667	NA	-0.37	-5.56	-0.32	6.55e-8	Reticulocyte fraction of red cells;
CESC	cis	rs7202877	0.706	rs247436	chr16:75445971	T/G	cg04384234	chr16:75411784	CFDP1	0.51	5.83	0.34	1.6e-8	Type 2 diabetes;Type 1 diabetes;
CESC	cis	rs752010	0.695	rs12123834	chr1:42105727	T/C	cg06885757	chr1:42089581	HIVEP3	0.48	7.77	0.43	1.73e-13	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs561341	1.000	rs757009	chr17:30243937	A/G	cg13647721	chr17:30228624	UTP6	0.71	7.56	0.42	6.5e-13	Hip circumference adjusted for BMI;
CESC	cis	rs4665809	0.549	rs3828255	chr2:26413252	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.02	11.6	0.58	1.95e-25	Gut microbiome composition (summer);
CESC	cis	rs1775715	0.870	rs1419168	chr10:32257332	A/C	cg18675610	chr10:32216311	ARHGAP12	0.35	5.54	0.32	7.38e-8	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs1003719	0.715	rs8126941	chr21:38551542	T/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.51	-6.72	-0.38	1.14e-10	Eye color traits;
CESC	cis	rs11098499	0.863	rs1155576	chr4:120450159	A/C	cg24375607	chr4:120327624	NA	0.42	5.04	0.3	8.63e-7	Corneal astigmatism;
CESC	cis	rs597539	0.617	rs686348	chr11:68636996	A/G	cg21963583	chr11:68658836	MRPL21	0.4	5.52	0.32	8.06e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18364576	chr14:53417060	FERMT2	-0.51	-6.16	-0.35	2.68e-9	Gut microbiome composition (summer);
CESC	cis	rs3747547	0.792	rs72726052	chr9:38056290	C/T	cg13774184	chr9:37916125	SHB	-0.71	-5.6	-0.33	5.44e-8	Metabolite levels (Dihydroxy docosatrienoic acid);
CESC	cis	rs2486288	0.656	rs11639349	chr15:45568260	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.62	-7.26	-0.41	4.26e-12	Glomerular filtration rate;
CESC	cis	rs826838	1.000	rs1095575	chr12:39110284	C/G	cg13010199	chr12:38710504	ALG10B	-0.41	-5.76	-0.33	2.35e-8	Heart rate;
CESC	cis	rs6570726	0.902	rs9390326	chr6:145791222	A/G	cg23711669	chr6:146136114	FBXO30	-0.72	-10.54	-0.54	6.43e-22	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07586489	chr16:3013227	KREMEN2	0.56	6.35	0.36	9.52e-10	Gut microbiome composition (summer);
CESC	cis	rs8180040	0.627	rs6442059	chr3:47187075	C/G	cg27129171	chr3:47204927	SETD2	0.67	9.81	0.52	1.36e-19	Colorectal cancer;
CESC	cis	rs6089584	0.816	rs4134440	chr20:60624296	A/G	cg06108461	chr20:60628389	TAF4	-0.9	-13.85	-0.65	3.57e-33	Body mass index;
CESC	cis	rs9911578	1.000	rs2567911	chr17:56734977	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.27	0.31	2.87e-7	Intelligence (multi-trait analysis);
CESC	cis	rs2549003	0.966	rs2706386	chr5:131832687	C/T	cg02551604	chr5:131831745	NA	0.4	5.62	0.33	4.9e-8	Asthma (sex interaction);
CESC	trans	rs1908814	0.516	rs7833079	chr8:11792129	A/G	cg15556689	chr8:8085844	FLJ10661	0.52	6.39	0.37	7.33e-10	Neuroticism;
CESC	cis	rs7267979	1.000	rs6050547	chr20:25326012	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.88	-18.21	-0.75	1.29e-48	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs9303401	0.659	rs34275691	chr17:56736640	A/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.04	13.0	0.62	3.27e-30	Cognitive test performance;
CESC	cis	rs9611565	0.694	rs5758411	chr22:42079734	G/A	cg17376030	chr22:41985996	PMM1	-0.45	-5.21	-0.3	3.81e-7	Vitiligo;
CESC	cis	rs514406	0.798	rs576650	chr1:53327207	C/T	cg08859206	chr1:53392774	SCP2	-0.68	-9.49	-0.5	1.38e-18	Monocyte count;
CESC	trans	rs9467711	0.606	rs9393706	chr6:26361500	G/A	cg06606381	chr12:133084897	FBRSL1	-0.77	-7.01	-0.4	1.94e-11	Autism spectrum disorder or schizophrenia;
CESC	cis	rs870825	0.655	rs1527870	chr4:185616631	T/C	cg04058563	chr4:185651563	MLF1IP	0.64	7.05	0.4	1.59e-11	Blood protein levels;
CESC	cis	rs17253792	0.822	rs10139905	chr14:56170031	T/C	cg01858014	chr14:56050164	KTN1	-0.62	-5.67	-0.33	3.78e-8	Putamen volume;
CESC	cis	rs7552404	0.731	rs11161857	chr1:76370228	G/C	cg22875332	chr1:76189707	ACADM	0.59	5.76	0.33	2.34e-8	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs662064	0.852	rs1411402	chr1:10579545	G/T	cg20482658	chr1:10539492	PEX14	0.37	7.64	0.42	4e-13	Asthma;
CESC	cis	rs514406	0.798	rs504816	chr1:53307957	T/G	cg08736216	chr1:53307985	ZYG11A	-0.44	-7.61	-0.42	4.82e-13	Monocyte count;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05989625	chr8:145661381	NFKBIL2	-0.43	-6.62	-0.38	2.02e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs796364	0.951	rs281793	chr2:200847990	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.84	8.14	0.45	1.53e-14	Schizophrenia;
CESC	cis	rs8177253	0.761	rs1830083	chr3:133508551	G/A	cg11941060	chr3:133502564	NA	-0.49	-6.7	-0.38	1.23e-10	Iron status biomarkers;
CESC	cis	rs8072100	0.905	rs8077106	chr17:45653291	T/G	cg08085267	chr17:45401833	C17orf57	0.44	5.9	0.34	1.12e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg12879727	chr14:75061268	LTBP2	0.41	6.01	0.35	6.18e-9	Thyroid stimulating hormone;
CESC	cis	rs1448094	0.512	rs12309296	chr12:86241566	T/C	cg00310523	chr12:86230176	RASSF9	0.36	5.63	0.33	4.6e-8	Major depressive disorder;
CESC	cis	rs1799949	0.965	rs12947782	chr17:41279882	A/G	cg06001716	chr17:41278141	BRCA1;NBR2	0.39	5.28	0.31	2.75e-7	Menopause (age at onset);
CESC	cis	rs4423214	0.879	rs1790330	chr11:71147825	C/T	cg05163923	chr11:71159392	DHCR7	-0.61	-7.24	-0.41	4.76e-12	Vitamin D levels;
CESC	cis	rs634534	0.561	rs655744	chr11:65776585	G/T	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.44	-6.58	-0.37	2.53e-10	Sum eosinophil basophil counts;Eosinophil counts;
CESC	cis	rs11871801	0.517	rs646123	chr17:40720632	G/A	cg21433558	chr17:40837037	CNTNAP1	0.49	5.96	0.34	8.14e-9	Crohn's disease;
CESC	cis	rs7618915	0.501	rs2109634	chr3:52752075	T/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.6	8.47	0.46	1.74e-15	Bipolar disorder;
CESC	cis	rs7666738	0.830	rs1349757	chr4:99058763	C/G	cg18180107	chr4:99064573	C4orf37	0.4	5.16	0.3	4.84e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs8028182	0.636	rs4886703	chr15:75730366	C/T	cg20655648	chr15:75932815	IMP3	0.49	6.2	0.36	2.13e-9	Sudden cardiac arrest;
CESC	cis	rs7662987	0.517	rs1311617	chr4:100012425	T/G	cg13256891	chr4:100009986	ADH5	0.74	7.97	0.44	4.75e-14	Smoking initiation;
CESC	cis	rs2637266	0.783	rs846583	chr10:78495658	T/A	cg18941641	chr10:78392320	NA	0.4	7.69	0.43	2.87e-13	Pulmonary function;
CESC	cis	rs1799949	0.965	rs33925201	chr17:41280682	A/G	cg05368731	chr17:41323189	NBR1	0.8	11.32	0.57	1.66e-24	Menopause (age at onset);
CESC	cis	rs782590	0.902	rs782601	chr2:55848244	T/C	cg18811423	chr2:55921094	PNPT1	0.79	12.15	0.6	2.79e-27	Metabolic syndrome;
CESC	cis	rs9486719	1.000	rs2472897	chr6:96870569	G/T	cg18709589	chr6:96969512	KIAA0776	0.54	5.91	0.34	1.07e-8	Migraine;Coronary artery disease;
CESC	cis	rs2070433	0.752	rs60290737	chr21:47837630	C/A	cg12379764	chr21:47803548	PCNT	0.67	7.31	0.41	3.08e-12	Lymphocyte counts;
CESC	cis	rs933688	0.532	rs11740007	chr5:90545498	C/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	-0.46	-5.33	-0.31	2.12e-7	Smoking behavior;
CESC	cis	rs662064	0.962	rs1188525	chr1:10550877	A/G	cg20482658	chr1:10539492	PEX14	-0.39	-8.0	-0.44	3.93e-14	Asthma;
CESC	cis	rs7605827	0.930	rs6728145	chr2:15573489	C/G	cg19274914	chr2:15703543	NA	0.36	6.45	0.37	5.41e-10	Educational attainment (years of education);
CESC	cis	rs4665809	0.878	rs35709953	chr2:26334997	G/A	cg25036284	chr2:26402008	FAM59B	0.68	7.34	0.41	2.54e-12	Gut microbiome composition (summer);
CESC	cis	rs7917772	0.636	rs2249845	chr10:104512095	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.45	-5.3	-0.31	2.45e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs9399135	0.967	rs34546690	chr6:135369709	T/C	cg24558204	chr6:135376177	HBS1L	0.5	6.8	0.39	6.92e-11	Red blood cell count;
CESC	cis	rs798554	0.679	rs1636250	chr7:2884433	T/C	cg18446336	chr7:2847575	GNA12	-0.35	-5.56	-0.32	6.7e-8	Height;
CESC	cis	rs7618915	0.571	rs1961958	chr3:52585990	A/G	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.29	5.05	0.3	8.05e-7	Bipolar disorder;
CESC	cis	rs7666738	0.791	rs10033994	chr4:98969582	C/T	cg05340658	chr4:99064831	C4orf37	0.79	12.28	0.6	9.45e-28	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04089111	chr2:74942655	NA	0.66	8.04	0.44	3.07e-14	Gut microbiome composition (summer);
CESC	cis	rs10504229	0.683	rs2318148	chr8:58114955	G/A	cg21724239	chr8:58056113	NA	0.58	5.95	0.34	8.29e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs763121	0.853	rs4821811	chr22:39075145	C/T	cg06022373	chr22:39101656	GTPBP1	0.9	14.07	0.65	5.86e-34	Menopause (age at onset);
CESC	cis	rs2247341	0.965	rs2236787	chr4:1718883	A/T	cg07465881	chr4:1713556	SLBP	-0.51	-6.34	-0.36	9.71e-10	Hip circumference adjusted for BMI;Height;
CESC	cis	rs72772090	0.539	rs11750934	chr5:96118487	A/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.57	-5.21	-0.3	3.74e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs10927875	0.631	rs28579893	chr1:16347534	A/G	cg22431228	chr1:16359049	CLCNKA	-0.51	-8.41	-0.46	2.57e-15	Dilated cardiomyopathy;
CESC	cis	rs7851660	0.874	rs1955145	chr9:100634751	A/C	cg13688889	chr9:100608707	NA	0.62	8.73	0.47	2.94e-16	Strep throat;
CESC	cis	rs77956314	0.515	rs4767490	chr12:117435016	A/G	cg02017074	chr12:117425053	FBXW8	0.79	8.45	0.46	1.96e-15	Subcortical brain region volumes;Hippocampal volume;
CESC	cis	rs4665809	0.878	rs892448	chr2:26366205	A/G	cg22920501	chr2:26401640	FAM59B	-0.65	-7.79	-0.43	1.51e-13	Gut microbiome composition (summer);
CESC	cis	rs35740288	0.545	rs12916187	chr15:86326124	A/C	cg20737812	chr15:86336631	KLHL25	-0.47	-5.44	-0.32	1.19e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
CESC	cis	rs4665809	1.000	rs11126364	chr2:26314515	A/G	cg08470875	chr2:26401718	FAM59B	-0.48	-5.27	-0.31	2.79e-7	Gut microbiome composition (summer);
CESC	trans	rs9951602	0.512	rs4799245	chr18:76653397	T/C	cg02800362	chr5:177631904	HNRNPAB	0.66	8.63	0.47	5.9e-16	Obesity-related traits;
CESC	cis	rs6570726	0.764	rs9399553	chr6:145873664	A/T	cg05347473	chr6:146136440	FBXO30	0.58	7.34	0.41	2.64e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs16957304	1.000	rs13334364	chr16:67332365	T/C	cg26727032	chr16:67993705	SLC12A4	-0.52	-5.12	-0.3	5.79e-7	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
CESC	cis	rs8058578	0.832	rs7500719	chr16:30840877	C/T	cg02466173	chr16:30829666	NA	-0.48	-7.66	-0.43	3.54e-13	Multiple myeloma;
CESC	cis	rs12971120	0.947	rs8083001	chr18:72165058	A/G	cg26446133	chr18:72167187	CNDP2	-0.68	-10.0	-0.52	3.47e-20	Refractive error;
CESC	cis	rs2404602	0.619	rs7342603	chr15:76982625	C/T	cg26408565	chr15:76604113	ETFA	-0.39	-5.56	-0.32	6.68e-8	Blood metabolite levels;
CESC	cis	rs72634258	0.945	rs12753070	chr1:8114319	C/G	cg00042356	chr1:8021962	PARK7	0.8	7.14	0.4	9.2e-12	Inflammatory bowel disease;
CESC	cis	rs801193	1.000	rs4279493	chr7:66226620	C/T	cg14393609	chr7:65229607	NA	0.48	6.38	0.37	7.71e-10	Aortic root size;
CESC	cis	rs3785574	0.962	rs2665799	chr17:61919723	A/G	cg06873352	chr17:61820015	STRADA	0.48	7.0	0.4	2.08e-11	Height;
CESC	cis	rs7589342	0.839	rs6747023	chr2:106431856	A/G	cg16077055	chr2:106428750	NCK2	0.52	7.44	0.42	1.42e-12	Addiction;
CESC	cis	rs2760061	0.626	rs596675	chr1:228117892	G/A	cg02753203	chr1:228287806	NA	-0.5	-7.15	-0.4	8.25e-12	Diastolic blood pressure;
CESC	trans	rs17508449	0.865	rs76308249	chr1:114147681	A/G	cg23028848	chr11:57092561	TNKS1BP1	-0.77	-6.14	-0.35	2.98e-9	Leprosy;
CESC	cis	rs116095464	0.558	rs7714335	chr5:263513	T/C	cg10591111	chr5:226296	SDHA	-0.54	-6.11	-0.35	3.55e-9	Breast cancer;
CESC	cis	rs11229555	0.957	rs10896796	chr11:58394256	A/G	cg15696309	chr11:58395628	NA	-0.43	-5.63	-0.33	4.63e-8	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs7824557	0.767	rs6985460	chr8:11171087	A/C	cg21775007	chr8:11205619	TDH	0.46	6.67	0.38	1.49e-10	Retinal vascular caliber;
CESC	cis	rs60871478	0.635	rs4311567	chr7:792295	T/C	cg27478167	chr7:817139	HEATR2	-0.53	-5.67	-0.33	3.82e-8	Cerebrospinal P-tau181p levels;
CESC	cis	rs7618501	0.601	rs2624825	chr3:50154989	G/A	cg24308560	chr3:49941425	MST1R	0.61	9.04	0.49	3.45e-17	Intelligence (multi-trait analysis);
CESC	cis	rs4077515	0.577	rs10870165	chr9:139316601	C/T	cg14169450	chr9:139327907	INPP5E	0.47	6.9	0.39	3.72e-11	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs7539409	0.651	rs910182	chr1:84297117	A/G	cg10977910	chr1:84465055	TTLL7	0.76	7.29	0.41	3.56e-12	Alzheimer's disease;
CESC	cis	rs2576037	0.562	rs13381557	chr18:44513371	A/G	cg19077165	chr18:44547161	KATNAL2	-0.62	-9.31	-0.5	5.06e-18	Personality dimensions;
CESC	cis	rs8018808	0.935	rs8005759	chr14:77880493	C/T	cg20045696	chr14:77926864	AHSA1	0.42	5.84	0.34	1.49e-8	Myeloid white cell count;
CESC	cis	rs6963495	0.818	rs73190151	chr7:105152887	C/T	cg13798780	chr7:105162888	PUS7	0.78	8.0	0.44	4.02e-14	Bipolar disorder (body mass index interaction);
CESC	cis	rs7216064	0.684	rs7406031	chr17:66021753	C/T	cg12091567	chr17:66097778	LOC651250	0.85	11.08	0.56	1.08e-23	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs7086627	0.515	rs11202957	chr10:82209592	A/G	cg00277334	chr10:82204260	NA	-0.91	-15.92	-0.7	1.67e-40	Post bronchodilator FEV1;
CESC	cis	rs6088590	0.710	rs6059992	chr20:33282275	T/C	cg06115741	chr20:33292138	TP53INP2	0.45	5.57	0.32	6.09e-8	Coronary artery disease;
CESC	trans	rs3942852	0.568	rs10769312	chr11:48094769	C/T	cg03929089	chr4:120376271	NA	0.63	7.64	0.42	4.01e-13	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg16405210	chr4:1374714	KIAA1530	-0.95	-12.85	-0.62	1.03e-29	Longevity;
CESC	cis	rs72945132	0.882	rs7945389	chr11:70158876	C/A	cg00319359	chr11:70116639	PPFIA1	0.78	7.71	0.43	2.52e-13	Coronary artery disease;
CESC	cis	rs4851551	0.619	rs34722443	chr2:102840319	T/G	cg09363443	chr2:102758946	NA	0.65	5.28	0.31	2.74e-7	Blood protein levels;
CESC	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.7	-11.11	-0.56	8.87e-24	Longevity;Endometriosis;
CESC	cis	rs6500602	0.702	rs3761680	chr16:4524060	C/A	cg08645402	chr16:4508243	NA	0.57	9.37	0.5	3.26e-18	Schizophrenia;
CESC	cis	rs4253772	0.550	rs11703564	chr22:46722194	G/A	cg10541313	chr22:46663664	TTC38	0.68	5.11	0.3	6.11e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs9322193	0.923	rs2297928	chr6:150039720	G/C	cg13206674	chr6:150067644	NUP43	0.46	6.59	0.38	2.43e-10	Lung cancer;
CESC	cis	rs7932354	0.655	rs6485690	chr11:46798631	A/G	cg25783544	chr11:47291846	MADD	-0.4	-5.14	-0.3	5.22e-7	Bone mineral density (hip);Bone mineral density;
CESC	cis	rs6582630	0.538	rs7971292	chr12:38498151	A/G	cg26384229	chr12:38710491	ALG10B	-0.44	-5.94	-0.34	8.88e-9	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs2075371	0.965	rs1862049	chr7:133978344	A/T	cg20476274	chr7:133979776	SLC35B4	0.68	10.07	0.53	2.04e-20	Mean platelet volume;
CESC	cis	rs9486719	1.000	rs12191653	chr6:96903898	T/C	cg18709589	chr6:96969512	KIAA0776	-0.54	-5.97	-0.34	7.42e-9	Migraine;Coronary artery disease;
CESC	cis	rs76878669	0.515	rs947978	chr11:66108660	C/T	cg18002602	chr11:66138449	SLC29A2	0.41	6.75	0.38	9.45e-11	Educational attainment (years of education);
CESC	cis	rs2439831	0.850	rs7174208	chr15:44052682	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.7	8.05	0.44	2.82e-14	Lung cancer in ever smokers;
CESC	cis	rs832540	0.898	rs252890	chr5:56226410	T/C	cg12311346	chr5:56204834	C5orf35	-0.42	-5.29	-0.31	2.51e-7	Coronary artery disease;
CESC	cis	rs853679	0.517	rs4713135	chr6:28039586	G/A	cg19592336	chr6:28129416	ZNF389	0.6	7.88	0.44	8.73e-14	Depression;
CESC	trans	rs2900976	0.739	rs13016025	chr2:72003083	A/G	cg01646268	chr11:14367071	RRAS2	-0.47	-6.37	-0.36	8.52e-10	Protein quantitative trait loci;
CESC	trans	rs55863869	0.748	rs77841333	chr2:179624788	A/T	cg24136754	chr22:37403978	C22orf33	0.44	6.07	0.35	4.34e-9	QT interval;
CESC	cis	rs704795	0.836	rs1647281	chr2:27612938	G/C	cg21248554	chr2:27665150	KRTCAP3	-0.34	-6.98	-0.39	2.43e-11	Menopause (age at onset);
CESC	cis	rs854765	0.583	rs62064156	chr17:17822480	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.52	7.22	0.41	5.4e-12	Total body bone mineral density;
CESC	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg11301795	chr4:187892539	NA	-0.8	-14.23	-0.66	1.54e-34	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9611565	0.559	rs1006407	chr22:41972032	T/C	cg06634786	chr22:41940651	POLR3H	-0.69	-6.64	-0.38	1.79e-10	Vitiligo;
CESC	cis	rs35079168	0.923	rs10858276	chr9:137287913	C/T	cg13941235	chr9:137270186	RXRA	-0.31	-5.65	-0.33	4.08e-8	Intelligence;
CESC	cis	rs7666738	0.830	rs7680909	chr4:98934604	A/G	cg17366294	chr4:99064904	C4orf37	0.61	8.56	0.47	9.36e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs13108904	0.870	rs1564508	chr4:1244879	A/G	cg00684032	chr4:1343700	KIAA1530	0.37	5.54	0.32	7.28e-8	Obesity-related traits;
CESC	cis	rs8067354	0.681	rs9907923	chr17:57824927	C/T	cg02344993	chr17:57696989	CLTC	0.68	8.08	0.44	2.34e-14	Hemoglobin concentration;
CESC	cis	rs7937682	1.000	rs10789843	chr11:111576158	C/T	cg09085632	chr11:111637200	PPP2R1B	1.05	14.75	0.67	2.39e-36	Primary sclerosing cholangitis;
CESC	cis	rs7618915	0.501	rs2109634	chr3:52752075	T/G	cg18404041	chr3:52824283	ITIH1	-0.4	-6.73	-0.38	1.04e-10	Bipolar disorder;
CESC	cis	rs9400271	0.632	rs9372205	chr6:109588401	A/T	cg01475377	chr6:109611718	NA	-0.46	-7.18	-0.4	7.24e-12	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
CESC	cis	rs36051895	0.659	rs12351277	chr9:5061405	A/C	cg02405213	chr9:5042618	JAK2	-0.51	-6.15	-0.35	2.87e-9	Pediatric autoimmune diseases;
CESC	cis	rs9322193	0.887	rs3734295	chr6:149915053	C/T	cg07701084	chr6:150067640	NUP43	0.41	5.74	0.33	2.65e-8	Lung cancer;
CESC	cis	rs1801251	1.000	rs1446311	chr2:233705071	G/A	cg08000102	chr2:233561755	GIGYF2	-0.7	-10.11	-0.53	1.51e-20	Coronary artery disease;
CESC	cis	rs60154123	0.772	rs628908	chr1:210428002	C/T	cg22029157	chr1:209979665	IRF6	0.45	5.24	0.31	3.29e-7	Coronary artery disease;
CESC	cis	rs9291683	0.588	rs6857693	chr4:10018435	G/A	cg02734326	chr4:10020555	SLC2A9	0.52	7.43	0.42	1.51e-12	Bone mineral density;
CESC	cis	rs9910055	0.531	rs6503490	chr17:42246656	A/G	cg08499158	chr17:42289980	UBTF	-0.49	-6.15	-0.35	2.83e-9	Total body bone mineral density;
CESC	cis	rs763014	0.593	rs28455838	chr16:681966	T/C	cg07343612	chr16:622815	PIGQ	-0.52	-7.53	-0.42	8.09e-13	Height;
CESC	cis	rs17401966	0.838	rs34565762	chr1:10300119	T/C	cg15208524	chr1:10270712	KIF1B	0.4	5.2	0.3	4.06e-7	Hepatocellular carcinoma;
CESC	cis	rs853679	0.517	rs9380047	chr6:28037893	G/T	cg19592336	chr6:28129416	ZNF389	0.59	7.88	0.44	8.48e-14	Depression;
CESC	cis	rs4253772	0.530	rs55653327	chr22:46682976	C/T	cg18190219	chr22:46762943	CELSR1	-0.59	-5.52	-0.32	8.08e-8	LDL cholesterol;Cholesterol, total;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16601444	chr19:47214184	PRKD2	-0.54	-6.18	-0.35	2.35e-9	Gut microbiome composition (summer);
CESC	cis	rs6502050	0.814	rs9894554	chr17:80073423	C/G	cg11859384	chr17:80120422	CCDC57	0.39	5.38	0.31	1.64e-7	Life satisfaction;
CESC	cis	rs7656342	0.653	rs1401439	chr4:9832622	G/C	cg11266682	chr4:10021025	SLC2A9	0.33	5.26	0.31	3e-7	Gut microbiota (bacterial taxa);
CESC	cis	rs7412746	0.611	rs1889741	chr1:150869045	T/C	cg04414720	chr1:150670196	GOLPH3L	0.44	5.84	0.34	1.49e-8	Melanoma;
CESC	cis	rs4665809	0.590	rs1560865	chr2:26452197	C/A	cg22920501	chr2:26401640	FAM59B	-0.93	-10.89	-0.56	4.54e-23	Gut microbiome composition (summer);
CESC	cis	rs644799	1.000	rs514170	chr11:95556696	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	14.27	0.66	1.19e-34	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs12586317	0.513	rs17102962	chr14:35478782	A/T	cg05294307	chr14:35346193	BAZ1A	-0.51	-5.45	-0.32	1.16e-7	Psoriasis;
CESC	cis	rs2304069	0.954	rs9324640	chr5:149413186	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.86	-11.11	-0.56	8.8e-24	HIV-1 control;
CESC	cis	rs9291683	0.561	rs3733584	chr4:10036506	T/C	cg00071950	chr4:10020882	SLC2A9	0.87	15.5	0.69	5.06e-39	Bone mineral density;
CESC	cis	rs13118159	0.550	rs10016557	chr4:1363628	C/T	cg19318889	chr4:1322082	MAEA	-0.56	-7.09	-0.4	1.22e-11	Longevity;
CESC	cis	rs9733	0.519	rs72704603	chr1:150707992	C/T	cg09365446	chr1:150670422	GOLPH3L	0.38	5.27	0.31	2.88e-7	Tonsillectomy;
CESC	cis	rs96067	0.805	rs7522400	chr1:36613380	A/G	cg24686825	chr1:36642396	MAP7D1	-0.5	-5.6	-0.33	5.35e-8	Corneal structure;
CESC	cis	rs12586317	0.586	rs74243590	chr14:35513246	G/A	cg05294307	chr14:35346193	BAZ1A	-0.57	-5.82	-0.34	1.71e-8	Psoriasis;
CESC	cis	rs7605827	0.866	rs9710962	chr2:15533884	C/A	cg19274914	chr2:15703543	NA	0.36	6.59	0.38	2.3e-10	Educational attainment (years of education);
CESC	cis	rs2797685	1.000	rs1689904	chr1:7890801	C/T	cg04725166	chr1:7887271	PER3	-0.47	-6.42	-0.37	6.44e-10	Crohn's disease;
CESC	cis	rs34779708	0.931	rs67261877	chr10:35386340	T/A	cg03585969	chr10:35415529	CREM	0.77	10.07	0.53	2.06e-20	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs4713118	0.629	rs203888	chr6:28021589	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.47	-5.49	-0.32	9.34e-8	Parkinson's disease;
CESC	cis	rs4964805	0.657	rs4964813	chr12:104189554	T/C	cg02344784	chr12:104178138	NT5DC3	0.45	6.38	0.36	7.88e-10	Attention deficit hyperactivity disorder;
CESC	cis	rs12497850	0.931	rs7628719	chr3:48995487	C/T	cg03060546	chr3:49711283	APEH	0.52	6.45	0.37	5.33e-10	Parkinson's disease;
CESC	cis	rs2204008	0.570	rs12318341	chr12:38251087	T/C	cg26384229	chr12:38710491	ALG10B	-0.47	-6.09	-0.35	4.03e-9	Bladder cancer;
CESC	cis	rs7666738	0.962	rs4699596	chr4:99012924	C/T	cg18180107	chr4:99064573	C4orf37	0.42	5.31	0.31	2.28e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7044106	0.791	rs10985008	chr9:123492960	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.87	14.04	0.65	7.75e-34	Hip circumference adjusted for BMI;
CESC	cis	rs9649213	0.537	rs35997266	chr7:97965566	T/C	cg24562669	chr7:97807699	LMTK2	0.51	7.64	0.42	4.09e-13	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7568498	0.564	rs9287807	chr2:161915361	T/C	cg22496339	chr2:162101262	NA	-0.52	-5.51	-0.32	8.44e-8	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);
CESC	cis	rs7937682	0.883	rs1784776	chr11:111472392	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.94	-13.87	-0.65	2.84e-33	Primary sclerosing cholangitis;
CESC	cis	rs11785400	0.762	rs7017931	chr8:143726728	A/G	cg10596483	chr8:143751796	JRK	0.42	5.36	0.31	1.77e-7	Schizophrenia;
CESC	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg14159672	chr1:205819179	PM20D1	0.46	6.6	0.38	2.27e-10	Menarche (age at onset);
CESC	cis	rs4237845	0.735	rs11172375	chr12:58291574	G/C	cg02175503	chr12:58329896	NA	0.64	7.9	0.44	7.24e-14	Intelligence (multi-trait analysis);
CESC	cis	rs9894429	1.000	rs11652797	chr17:79574124	A/G	cg21984481	chr17:79567631	NPLOC4	-0.49	-8.04	-0.44	2.93e-14	Eye color traits;
CESC	cis	rs193541	0.632	rs168913	chr5:122225793	G/A	cg19412675	chr5:122181750	SNX24	0.46	5.4	0.31	1.5e-7	Glucose homeostasis traits;
CESC	cis	rs10870270	0.956	rs67378218	chr10:133752420	A/C	cg26149184	chr10:133730230	NA	0.37	5.07	0.3	7.46e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs61996546	0.622	rs1426219	chr15:26855799	C/T	cg15066197	chr15:26874202	GABRB3	-0.35	-5.19	-0.3	4.1e-7	Response to methotrexate in juvenile idiopathic arthritis;
CESC	cis	rs7149337	1.000	rs8006432	chr14:51731306	A/T	cg23942311	chr14:51606299	NA	0.43	7.22	0.41	5.35e-12	Cancer;
CESC	cis	rs7216064	1.000	rs7221651	chr17:65832390	A/G	cg12091567	chr17:66097778	LOC651250	0.79	8.86	0.48	1.18e-16	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs478304	0.934	rs517115	chr11:65526988	C/T	cg08755490	chr11:65554678	OVOL1	0.49	6.5	0.37	3.95e-10	Acne (severe);
CESC	cis	rs623323	1.000	rs623323	chr17:700020	A/G	cg02666820	chr17:700054	NA	0.95	11.06	0.56	1.3e-23	Type 2 diabetes;
CESC	cis	rs2070677	0.736	rs7895560	chr10:135431038	G/A	cg20169779	chr10:135381914	SYCE1	-0.79	-8.98	-0.48	5.18e-17	Gout;
CESC	cis	rs875971	0.545	rs316316	chr7:65614257	C/T	cg11764359	chr7:65958608	NA	-0.79	-9.47	-0.5	1.62e-18	Aortic root size;
CESC	cis	rs6942756	0.715	rs6467242	chr7:129001173	T/A	cg02491457	chr7:128862824	NA	-0.6	-8.34	-0.46	4.23e-15	White matter hyperintensity burden;
CESC	cis	rs8177253	1.000	rs8177262	chr3:133480652	A/G	cg11941060	chr3:133502564	NA	0.49	6.78	0.38	7.87e-11	Iron status biomarkers;
CESC	cis	rs8062405	0.964	rs7187333	chr16:28865916	G/A	cg08761264	chr16:28874980	SH2B1	-0.45	-5.49	-0.32	9.61e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs738322	0.839	rs2413505	chr22:38592967	G/A	cg25457927	chr22:38595422	NA	0.35	6.59	0.38	2.41e-10	Cutaneous nevi;
CESC	cis	rs769267	0.965	rs735273	chr19:19385411	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	7.34	0.41	2.56e-12	Tonsillectomy;
CESC	cis	rs7208859	0.623	rs9899268	chr17:29150255	T/C	cg19761014	chr17:28927070	LRRC37B2	0.79	6.45	0.37	5.22e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs2652834	0.808	rs11071723	chr15:63355275	A/T	cg05507819	chr15:63340323	TPM1	0.62	6.08	0.35	4.22e-9	HDL cholesterol;
CESC	cis	rs6582630	0.555	rs10880520	chr12:38464111	C/T	cg26384229	chr12:38710491	ALG10B	0.71	10.82	0.55	7.82e-23	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs10791097	0.967	rs10791099	chr11:130718813	G/C	cg14779329	chr11:130786720	SNX19	0.4	6.25	0.36	1.67e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs10504229	0.863	rs75954631	chr8:58166194	C/A	cg24829409	chr8:58192753	C8orf71	-0.67	-7.97	-0.44	4.6e-14	Developmental language disorder (linguistic errors);
CESC	cis	rs7560272	0.512	rs2421677	chr2:73965917	G/T	cg20560298	chr2:73613845	ALMS1	0.4	5.42	0.32	1.35e-7	Schizophrenia;
CESC	cis	rs9296736	1.000	rs7450517	chr6:53902843	G/A	cg04374786	chr6:53939321	C6orf142	0.36	5.68	0.33	3.59e-8	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs3096299	0.719	rs2353581	chr16:89518908	T/C	cg00750074	chr16:89608354	SPG7	-0.45	-6.49	-0.37	4.22e-10	Multiple myeloma (IgH translocation);
CESC	cis	rs7772486	0.790	rs2247206	chr6:146216184	C/T	cg23711669	chr6:146136114	FBXO30	0.82	11.64	0.58	1.47e-25	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs514406	0.505	rs856721	chr1:53162156	C/A	cg08859206	chr1:53392774	SCP2	-0.57	-7.53	-0.42	8.07e-13	Monocyte count;
CESC	cis	rs4253772	0.550	rs6008600	chr22:46704676	A/G	cg09491104	chr22:46646882	C22orf40	-0.52	-6.43	-0.37	5.82e-10	LDL cholesterol;Cholesterol, total;
CESC	cis	rs4834770	1.000	rs878375	chr4:120237574	T/C	cg09307838	chr4:120376055	NA	0.44	5.31	0.31	2.29e-7	Blood protein levels;
CESC	cis	rs593982	0.925	rs3953806	chr11:65505153	C/T	cg08755490	chr11:65554678	OVOL1	-1.26	-10.56	-0.54	5.65e-22	Atopic dermatitis;
CESC	cis	rs2274273	0.774	rs17128440	chr14:55861912	C/T	cg04306507	chr14:55594613	LGALS3	0.3	5.94	0.34	9.13e-9	Protein biomarker;
CESC	cis	rs1983170	0.736	rs13447495	chr1:91974965	A/G	cg02896835	chr1:92012615	NA	0.56	6.03	0.35	5.56e-9	Eosinophil percentage of white cells;
CESC	cis	rs6964587	0.740	rs2020360	chr7:91439506	G/C	cg17063962	chr7:91808500	NA	0.49	6.31	0.36	1.15e-9	Breast cancer;
CESC	trans	rs4332037	0.539	rs55790766	chr7:2021248	C/T	cg11693508	chr17:37793320	STARD3	0.67	6.73	0.38	1.07e-10	Bipolar disorder;
CESC	cis	rs10751667	0.666	rs7395823	chr11:942701	T/C	cg06064525	chr11:970664	AP2A2	-0.5	-10.04	-0.52	2.7e-20	Alzheimer's disease (late onset);
CESC	cis	rs2479106	0.591	rs1475526	chr9:126396659	G/A	cg16191174	chr9:126692580	DENND1A	0.38	5.33	0.31	2.09e-7	Polycystic ovary syndrome;
CESC	cis	rs826838	0.967	rs10875979	chr12:39095149	G/A	cg13010199	chr12:38710504	ALG10B	0.47	6.56	0.37	2.74e-10	Heart rate;
CESC	cis	rs7666738	0.688	rs4632667	chr4:98748299	A/G	cg03676636	chr4:99064102	C4orf37	0.43	5.17	0.3	4.66e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7656342	0.622	rs2102872	chr4:9831358	T/C	cg11266682	chr4:10021025	SLC2A9	0.32	5.15	0.3	5.11e-7	Gut microbiota (bacterial taxa);
CESC	cis	rs7674212	0.570	rs6810571	chr4:104086787	G/T	cg16532752	chr4:104119610	CENPE	-0.44	-5.96	-0.34	8.1e-9	Type 2 diabetes;
CESC	cis	rs765787	0.530	rs28524974	chr15:45543528	C/T	cg24006582	chr15:45444508	DUOX1	-0.55	-6.93	-0.39	3.22e-11	Uric acid levels;
CESC	cis	rs7640424	0.649	rs62262371	chr3:107896108	C/T	cg09227934	chr3:107805635	CD47	-0.45	-5.82	-0.34	1.66e-8	Body mass index;
CESC	cis	rs916888	0.610	rs199530	chr17:44836653	C/T	cg15921436	chr17:44337874	NA	-0.48	-6.25	-0.36	1.63e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg04902049	chr1:36622448	MAP7D1	0.51	6.95	0.39	2.78e-11	Systemic lupus erythematosus;
CESC	cis	rs66561647	0.634	rs7821856	chr8:128939499	A/G	cg05480350	chr8:128972681	MIR1205;PVT1	0.39	5.2	0.3	3.95e-7	Hemoglobin concentration;
CESC	cis	rs7615952	0.599	rs7631268	chr3:125755664	T/A	cg06494592	chr3:125709126	NA	-0.48	-5.09	-0.3	6.89e-7	Blood pressure (smoking interaction);
CESC	cis	rs483180	0.512	rs598685	chr1:120215269	G/A	cg19096424	chr1:120255104	PHGDH	0.42	5.13	0.3	5.49e-7	Macular telangiectasia type 2;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg05898629	chr16:3812688	CREBBP	0.43	6.14	0.35	3.01e-9	Fibrinogen levels;
CESC	cis	rs10504229	0.593	rs12216730	chr8:58003894	C/T	cg22535103	chr8:58192502	C8orf71	-0.64	-7.04	-0.4	1.63e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs929596	0.755	rs3771341	chr2:234673239	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.71	-9.26	-0.49	7.28e-18	Total bilirubin levels in HIV-1 infection;
CESC	cis	rs6032067	0.929	rs17424356	chr20:43804190	A/G	cg11264863	chr20:43835661	SEMG1	0.5	5.39	0.31	1.56e-7	Blood protein levels;
CESC	cis	rs9739070	1	rs9739070	chr12:123771032	A/G	cg19016782	chr12:123741754	C12orf65	-0.44	-5.93	-0.34	9.36e-9	Allergy;
CESC	cis	rs172166	0.694	rs1770131	chr6:28086413	C/T	cg20151795	chr6:28129481	ZNF389	0.36	5.23	0.31	3.44e-7	Cardiac Troponin-T levels;
CESC	cis	rs300703	0.719	rs437853	chr2:196973	C/T	cg21211680	chr2:198530	NA	-1.03	-11.83	-0.59	3.23e-26	Blood protein levels;
CESC	cis	rs8017423	0.647	rs11623736	chr14:90746471	G/T	cg14092571	chr14:90743983	NA	0.55	8.18	0.45	1.18e-14	Mortality in heart failure;
CESC	trans	rs11098499	0.708	rs11732686	chr4:120252330	C/A	cg25214090	chr10:38739885	LOC399744	0.62	8.7	0.47	3.58e-16	Corneal astigmatism;
CESC	cis	rs736408	0.609	rs2230535	chr3:52800284	T/C	cg18404041	chr3:52824283	ITIH1	-0.44	-7.28	-0.41	3.85e-12	Bipolar disorder;
CESC	cis	rs11792861	0.962	rs11789624	chr9:111796231	T/C	cg14384093	chr9:111878565	C9orf5	-0.4	-5.03	-0.3	8.95e-7	Menarche (age at onset);
CESC	cis	rs6502050	0.835	rs7222057	chr17:80087647	C/A	cg11859384	chr17:80120422	CCDC57	-0.38	-5.11	-0.3	6.03e-7	Life satisfaction;
CESC	cis	rs896854	0.654	rs2011566	chr8:95971921	G/A	cg16049864	chr8:95962084	TP53INP1	-0.64	-11.23	-0.57	3.53e-24	Type 2 diabetes;
CESC	trans	rs4650994	0.525	rs4076563	chr1:178516901	C/T	cg05059571	chr16:84539110	KIAA1609	-0.4	-6.22	-0.36	1.93e-9	HDL cholesterol levels;HDL cholesterol;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg09656405	chr15:69745057	RPLP1	0.54	7.17	0.4	7.63e-12	Systemic lupus erythematosus;
CESC	cis	rs4523957	0.553	rs2131702	chr17:2025458	T/C	cg16513277	chr17:2031491	SMG6	-0.77	-11.34	-0.57	1.43e-24	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs6076065	0.748	rs2424542	chr20:23386800	C/T	cg11657817	chr20:23433608	CST11	0.41	6.24	0.36	1.69e-9	Facial morphology (factor 15, philtrum width);
CESC	cis	rs10129255	0.500	rs10142931	chr14:107190525	A/C	cg23076370	chr14:107095027	NA	-0.71	-10.97	-0.56	2.43e-23	Kawasaki disease;
CESC	cis	rs7828089	0.935	rs2293144	chr8:22262418	A/G	cg12081754	chr8:22256438	SLC39A14	0.45	6.04	0.35	5.24e-9	Verbal declarative memory;
CESC	cis	rs3768617	0.966	rs10797850	chr1:183094802	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.65	9.03	0.49	3.63e-17	Fuchs's corneal dystrophy;
CESC	cis	rs10504229	0.861	rs114700910	chr8:58170642	C/T	cg05313129	chr8:58192883	C8orf71	-0.56	-6.45	-0.37	5.31e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs68170813	0.559	rs75154004	chr7:106903326	C/T	cg02696742	chr7:106810147	HBP1	-0.52	-5.09	-0.3	6.84e-7	Coronary artery disease;
CESC	cis	rs798766	1.000	rs798741	chr4:1712413	A/G	cg05874882	chr4:1763078	NA	-0.58	-8.42	-0.46	2.39e-15	Bladder cancer;Urinary bladder cancer;
CESC	cis	rs7666738	0.791	rs1527516	chr4:98967937	A/C	cg17366294	chr4:99064904	C4orf37	0.58	8.25	0.45	7.46e-15	Colonoscopy-negative controls vs population controls;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg24881159	chr15:31284219	MTMR10	-0.45	-6.26	-0.36	1.51e-9	Gambling;
CESC	cis	rs7809799	1.000	rs6969313	chr7:98754007	G/A	cg05967295	chr7:98741636	SMURF1	-0.75	-5.21	-0.3	3.86e-7	Ulcerative colitis;
CESC	cis	rs6831352	0.734	rs3018046	chr4:100030388	C/T	cg13256891	chr4:100009986	ADH5	0.69	8.13	0.45	1.61e-14	Alcohol dependence;
CESC	cis	rs9611565	0.559	rs8139993	chr22:41995335	T/C	cg03806693	chr22:41940476	POLR3H	-0.85	-10.05	-0.53	2.41e-20	Vitiligo;
CESC	cis	rs6502050	0.835	rs3935129	chr17:80113381	G/C	cg11859384	chr17:80120422	CCDC57	-0.4	-5.39	-0.31	1.52e-7	Life satisfaction;
CESC	cis	rs4819052	0.851	rs2838843	chr21:46669284	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.74	9.64	0.51	4.66e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs9457247	1.000	rs416131	chr6:167406544	A/C	cg23791538	chr6:167370224	RNASET2	0.58	8.18	0.45	1.21e-14	Crohn's disease;
CESC	trans	rs7902708	0.920	rs12416665	chr10:54430631	C/T	cg26219051	chr22:43739629	SCUBE1	0.5	6.26	0.36	1.56e-9	Bone properties (heel);
CESC	cis	rs1799949	1.000	rs4793190	chr17:41200109	T/C	cg25072359	chr17:41440525	NA	0.45	5.96	0.34	7.83e-9	Menopause (age at onset);
CESC	cis	rs1256061	0.624	rs944046	chr14:64700299	G/A	cg23250157	chr14:64679961	SYNE2	0.52	7.38	0.41	2.1e-12	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs11122272	0.735	rs2808583	chr1:231512587	G/C	cg06096015	chr1:231504339	EGLN1	0.43	6.16	0.35	2.62e-9	Hemoglobin concentration;
CESC	cis	rs10751667	0.643	rs11246344	chr11:933783	A/C	cg20946044	chr11:1010712	AP2A2	-0.4	-5.43	-0.32	1.26e-7	Alzheimer's disease (late onset);
CESC	cis	rs6466055	0.720	rs2040914	chr7:104972174	A/G	cg04380332	chr7:105027541	SRPK2	0.41	5.54	0.32	7.47e-8	Schizophrenia;
CESC	cis	rs1707322	0.685	rs6690926	chr1:46134978	T/C	cg03146154	chr1:46216737	IPP	0.82	11.52	0.58	3.64e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs796364	1.000	rs10178177	chr2:200829993	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.9	9.16	0.49	1.48e-17	Schizophrenia;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg25649200	chr17:79233120	SLC38A10	0.47	6.56	0.37	2.86e-10	Fibrinogen levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19547976	chr4:1737009	TACC3	-0.55	-6.29	-0.36	1.29e-9	Gut microbiome composition (summer);
CESC	cis	rs11785400	1.000	rs6995314	chr8:143749718	A/G	cg10596483	chr8:143751796	JRK	-0.43	-5.64	-0.33	4.32e-8	Schizophrenia;
CESC	cis	rs10464366	0.544	rs4723824	chr7:39153698	T/C	cg18850127	chr7:39170497	POU6F2	0.36	5.12	0.3	5.98e-7	IgG glycosylation;
CESC	cis	rs9522267	0.502	rs9515450	chr13:112234262	T/C	cg10483660	chr13:112241077	NA	-0.32	-5.69	-0.33	3.32e-8	Hepatitis;
CESC	cis	rs7072216	0.763	rs12763044	chr10:100167451	C/G	cg26618903	chr10:100175079	PYROXD2	-0.36	-5.49	-0.32	9.42e-8	Metabolite levels;
CESC	cis	rs425277	0.583	rs1467217	chr1:2045165	G/A	cg19257562	chr1:2043853	PRKCZ	0.35	5.74	0.33	2.54e-8	Height;
CESC	cis	rs875971	0.862	rs4149461	chr7:65744732	T/C	cg10691866	chr7:65817282	TPST1	0.31	5.32	0.31	2.25e-7	Aortic root size;
CESC	cis	rs9790314	0.645	rs9879687	chr3:160874938	A/G	cg03342759	chr3:160939853	NMD3	-0.41	-5.79	-0.34	1.96e-8	Morning vs. evening chronotype;
CESC	cis	rs950169	1.000	rs12916348	chr15:84765527	C/T	cg17507749	chr15:85114479	UBE2QP1	0.61	6.73	0.38	1.05e-10	Schizophrenia;
CESC	cis	rs8014204	0.935	rs10141438	chr14:75354600	A/G	cg26191576	chr14:75389716	RPS6KL1	0.35	5.03	0.3	9.15e-7	Caffeine consumption;
CESC	cis	rs7212590	0.655	rs34687426	chr17:57997857	A/G	cg20303301	chr17:57937339	TUBD1	-0.52	-5.28	-0.31	2.76e-7	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs801193	0.844	rs732465	chr7:65998450	T/C	cg14393609	chr7:65229607	NA	0.41	5.77	0.33	2.21e-8	Aortic root size;
CESC	trans	rs8073060	0.505	rs225270	chr17:33968871	A/T	cg19694781	chr19:47549865	TMEM160	-0.73	-7.03	-0.4	1.79e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	cis	rs4665809	1.000	rs7573118	chr2:26308086	A/G	cg27170947	chr2:26402098	FAM59B	-0.6	-7.25	-0.41	4.7e-12	Gut microbiome composition (summer);
CESC	cis	rs3204270	0.759	rs62075725	chr17:79611510	A/G	cg18367735	chr17:79674897	NA	0.62	5.11	0.3	6.13e-7	Dental caries;
CESC	cis	rs9649213	0.593	rs3801254	chr7:98010811	G/A	cg08684580	chr7:98029266	BAIAP2L1	-0.35	-5.67	-0.33	3.8e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs9831754	0.906	rs7621811	chr3:78388816	G/A	cg06138941	chr3:78371609	NA	-0.64	-7.66	-0.43	3.46e-13	Calcium levels;
CESC	cis	rs7940866	0.801	rs2113929	chr11:130835974	G/A	cg12179176	chr11:130786555	SNX19	0.67	10.29	0.53	4.16e-21	Schizophrenia;
CESC	cis	rs6582630	0.519	rs4002438	chr12:38484880	C/T	cg13010199	chr12:38710504	ALG10B	0.46	5.95	0.34	8.55e-9	Drug-induced liver injury (flucloxacillin);
CESC	trans	rs9325144	0.600	rs1825807	chr12:38737007	T/C	cg23762105	chr12:34175262	ALG10	-0.48	-6.49	-0.37	4.19e-10	Morning vs. evening chronotype;
CESC	cis	rs9733	0.519	rs11807450	chr1:150677719	C/T	cg04414720	chr1:150670196	GOLPH3L	0.58	8.2	0.45	1.01e-14	Tonsillectomy;
CESC	cis	rs2836633	0.929	rs8130434	chr21:40036243	C/T	cg05519781	chr21:40033154	ERG	-0.8	-14.38	-0.66	4.92e-35	Coronary artery disease;
CESC	cis	rs3857067	0.506	rs282450	chr4:95139598	G/C	cg11021082	chr4:95130006	SMARCAD1	-0.7	-11.56	-0.58	2.74e-25	QT interval;
CESC	cis	rs1799949	1.000	rs35330014	chr17:41212547	C/T	cg23758822	chr17:41437982	NA	1.02	15.27	0.68	3.45e-38	Menopause (age at onset);
CESC	cis	rs4713118	0.629	rs203889	chr6:28021775	T/G	cg23281280	chr6:28129359	ZNF389	0.49	6.48	0.37	4.42e-10	Parkinson's disease;
CESC	cis	rs6547741	0.904	rs2384659	chr2:27856793	G/A	cg21248554	chr2:27665150	KRTCAP3	0.26	5.34	0.31	2.01e-7	Oral cavity cancer;
CESC	cis	rs2276314	1.000	rs2276314	chr18:33557466	C/T	cg19628046	chr18:33552617	C18orf21	-0.59	-6.76	-0.38	8.57e-11	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs9902453	0.967	rs9904336	chr17:28357080	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.62	-7.84	-0.43	1.1e-13	Coffee consumption (cups per day);
CESC	cis	rs7923609	0.905	rs7092784	chr10:65214749	C/T	cg01631684	chr10:65280961	REEP3	-0.43	-5.41	-0.32	1.4e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00116463	chr17:19266443	B9D1	0.63	6.76	0.38	8.88e-11	Gut microbiome composition (summer);
CESC	cis	rs7572263	0.724	rs6704765	chr2:209054267	C/G	cg23998903	chr2:209048830	C2orf80	-0.39	-5.14	-0.3	5.4e-7	Glioma;Non-glioblastoma glioma;
CESC	cis	rs7726839	0.574	rs11134148	chr5:637107	C/T	cg16447950	chr5:562315	NA	-0.58	-6.05	-0.35	5e-9	Obesity-related traits;
CESC	cis	rs4704187	0.687	rs1477934	chr5:74423243	A/T	cg03227963	chr5:74354835	NA	0.31	5.68	0.33	3.52e-8	Response to amphetamines;
CESC	cis	rs1050631	0.564	rs559289	chr18:33752890	A/C	cg25426722	chr18:33708991	SLC39A6;ELP2	0.59	8.23	0.45	8.37e-15	Esophageal squamous cell cancer (length of survival);
CESC	cis	rs763014	0.833	rs3743904	chr16:632767	A/G	cg00802000	chr16:706648	WDR90	-0.4	-6.02	-0.35	5.85e-9	Height;
CESC	cis	rs7618915	0.571	rs6805539	chr3:52609710	T/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	6.85	0.39	5.17e-11	Bipolar disorder;
CESC	cis	rs3733585	0.699	rs12498150	chr4:9950537	C/T	cg02734326	chr4:10020555	SLC2A9	-0.4	-5.63	-0.33	4.67e-8	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs11690935	0.959	rs3770452	chr2:172668682	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.93	-14.4	-0.66	3.98e-35	Schizophrenia;
CESC	cis	rs12188164	0.965	rs72717438	chr5:448663	C/T	cg21144161	chr5:423903	AHRR	0.37	5.98	0.34	7.12e-9	Cystic fibrosis severity;
CESC	cis	rs28595532	0.748	rs17594978	chr4:119336398	T/C	cg21605333	chr4:119757512	SEC24D	1.01	5.58	0.32	5.98e-8	Cannabis dependence symptom count;
CESC	cis	rs875971	0.862	rs7798630	chr7:65771479	G/C	cg10691866	chr7:65817282	TPST1	0.32	5.53	0.32	7.79e-8	Aortic root size;
CESC	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg04234412	chr22:24373322	LOC391322	-0.52	-7.28	-0.41	3.7e-12	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs34375054	0.525	rs1080910	chr12:125608492	T/C	cg25124228	chr12:125621409	AACS	-0.58	-7.32	-0.41	2.97e-12	Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs2380220	0.576	rs4368819	chr6:96031109	T/G	cg04719120	chr6:96025338	MANEA	0.65	6.93	0.39	3.18e-11	Behavioural disinhibition (generation interaction);
CESC	cis	rs7560272	0.723	rs6729468	chr2:73765253	C/A	cg20560298	chr2:73613845	ALMS1	-0.48	-6.88	-0.39	4.22e-11	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13137891	chr2:60779450	BCL11A	-0.54	-6.39	-0.37	7.35e-10	Gut microbiome composition (summer);
CESC	cis	rs9457247	0.765	rs9457252	chr6:167433925	A/G	cg07741184	chr6:167504864	NA	-0.36	-6.56	-0.37	2.76e-10	Crohn's disease;
CESC	cis	rs8020095	0.528	rs10149615	chr14:67824290	T/C	cg19548862	chr14:67692701	FAM71D	-0.45	-5.34	-0.31	2.04e-7	Depression (quantitative trait);
CESC	cis	rs6800768	0.633	rs6769403	chr3:24148622	T/C	cg10674438	chr3:24145617	LOC152024	-0.47	-6.46	-0.37	5.08e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs514406	0.893	rs512723	chr1:53343880	C/T	cg27535305	chr1:53392650	SCP2	0.32	5.26	0.31	3.03e-7	Monocyte count;
CESC	cis	rs7084402	0.967	rs7079648	chr10:60273155	C/A	cg07615347	chr10:60278583	BICC1	-0.57	-8.84	-0.48	1.41e-16	Refractive error;
CESC	cis	rs853679	0.517	rs9380059	chr6:28132358	A/C	cg23281280	chr6:28129359	ZNF389	0.59	7.9	0.44	7.47e-14	Depression;
CESC	cis	rs637571	0.522	rs493899	chr11:65747952	A/C	cg17985854	chr11:65770987	BANF1;EIF1AD	0.44	6.56	0.37	2.77e-10	Eosinophil percentage of white cells;
CESC	cis	rs10504229	0.636	rs77290284	chr8:58055269	G/T	cg22535103	chr8:58192502	C8orf71	-0.85	-8.38	-0.46	3.08e-15	Developmental language disorder (linguistic errors);
CESC	cis	rs4975709	0.589	rs1466606	chr5:1865055	C/T	cg14773178	chr5:1868261	NA	0.33	5.84	0.34	1.55e-8	Cardiovascular disease risk factors;
CESC	cis	rs853679	0.517	rs1904840	chr6:28108232	C/T	cg20151795	chr6:28129481	ZNF389	0.45	5.84	0.34	1.5e-8	Depression;
CESC	cis	rs17641971	0.662	rs13268440	chr8:50000873	C/T	cg00325661	chr8:49890786	NA	0.37	5.25	0.31	3.14e-7	Blood metabolite levels;
CESC	cis	rs4853012	0.838	rs2177707	chr2:74356850	A/G	cg20891558	chr2:74357851	NA	0.84	11.48	0.58	4.88e-25	Gestational age at birth (maternal effect);
CESC	cis	rs7085104	0.572	rs284857	chr10:104574063	C/T	cg04362960	chr10:104952993	NT5C2	-0.47	-6.36	-0.36	8.93e-10	Immature fraction of reticulocytes;Schizophrenia;
CESC	cis	rs896854	0.654	rs28591375	chr8:95973637	C/G	cg09323728	chr8:95962352	TP53INP1	-0.4	-8.68	-0.47	4.05e-16	Type 2 diabetes;
CESC	cis	rs66573146	0.656	rs41410847	chr4:6957332	C/T	cg00086871	chr4:6988644	TBC1D14	0.93	7.59	0.42	5.57e-13	Granulocyte percentage of myeloid white cells;
CESC	cis	rs5758659	0.714	rs133373	chr22:42465788	G/A	cg15557168	chr22:42548783	NA	-0.45	-6.97	-0.39	2.44e-11	Cognitive function;
CESC	cis	rs7615952	0.599	rs12486459	chr3:125741465	T/G	cg04553112	chr3:125709451	NA	-0.51	-5.36	-0.31	1.78e-7	Blood pressure (smoking interaction);
CESC	cis	rs875971	0.964	rs697969	chr7:65558478	C/A	cg12463550	chr7:65579703	CRCP	-0.62	-7.78	-0.43	1.65e-13	Aortic root size;
CESC	cis	rs2243480	1.000	rs2420170	chr7:65656053	T/C	cg18252515	chr7:66147081	NA	1.36	13.62	0.64	2.24e-32	Diabetic kidney disease;
CESC	cis	rs3091242	0.933	rs61775167	chr1:25780893	A/G	cg27572855	chr1:25598939	RHD	-0.44	-7.36	-0.41	2.34e-12	Erythrocyte sedimentation rate;
CESC	cis	rs55794721	0.509	rs11249248	chr1:25753051	T/C	cg12412775	chr1:25698385	RHCE	-0.29	-5.18	-0.3	4.39e-7	Plateletcrit;Mean corpuscular volume;
CESC	cis	rs3785574	0.962	rs62077483	chr17:61806380	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.58	7.21	0.4	5.88e-12	Height;
CESC	cis	rs769267	0.895	rs1000237	chr19:19518316	T/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.46	6.05	0.35	4.83e-9	Tonsillectomy;
CESC	cis	rs875971	1.000	rs697970	chr7:65560052	G/C	cg10691866	chr7:65817282	TPST1	0.34	5.32	0.31	2.17e-7	Aortic root size;
CESC	cis	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg21782813	chr7:2030301	MAD1L1	0.44	6.15	0.35	2.79e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs3126085	0.935	rs11584427	chr1:152299788	A/G	cg03465714	chr1:152285911	FLG	0.49	5.46	0.32	1.11e-7	Atopic dermatitis;
CESC	cis	rs3762637	0.943	rs78429050	chr3:122252428	T/C	cg24169773	chr3:122142474	KPNA1	-0.59	-6.85	-0.39	5.17e-11	LDL cholesterol levels;
CESC	cis	rs10504229	1.000	rs60454728	chr8:58173781	G/A	cg24829409	chr8:58192753	C8orf71	-0.76	-10.0	-0.52	3.53e-20	Developmental language disorder (linguistic errors);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21815083	chr11:69458002	CCND1	0.57	6.28	0.36	1.37e-9	Gut microbiome composition (summer);
CESC	cis	rs950169	0.881	rs34591918	chr15:84950833	C/T	cg17507749	chr15:85114479	UBE2QP1	0.59	6.54	0.37	3.11e-10	Schizophrenia;
CESC	cis	rs1799949	1.000	rs11652332	chr17:41295489	G/A	cg05368731	chr17:41323189	NBR1	0.79	10.91	0.56	4.06e-23	Menopause (age at onset);
CESC	cis	rs2836974	0.932	rs6517523	chr21:40557332	T/C	cg17971929	chr21:40555470	PSMG1	1.06	16.52	0.71	1.26e-42	Cognitive function;
CESC	cis	rs1784581	0.674	rs1789990	chr6:162406957	G/T	cg17173639	chr6:162384350	PARK2	-0.62	-9.8	-0.52	1.45e-19	Itch intensity from mosquito bite;
CESC	cis	rs7809950	0.954	rs2520242	chr7:107136320	G/T	cg23024343	chr7:107201750	COG5	0.43	6.12	0.35	3.33e-9	Coronary artery disease;
CESC	cis	rs889398	0.802	rs9940315	chr16:69876164	A/G	cg09409435	chr16:70099608	PDXDC2	0.41	5.2	0.3	4e-7	Body mass index;
CESC	cis	rs6430585	0.941	rs10496737	chr2:136540083	A/G	cg07169764	chr2:136633963	MCM6	0.97	12.27	0.6	1.02e-27	Corneal structure;
CESC	cis	rs7552404	0.960	rs61797339	chr1:76189946	G/T	cg22875332	chr1:76189707	ACADM	0.65	7.68	0.43	3.04e-13	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs116095464	0.558	rs62344345	chr5:257420	C/T	cg20965017	chr5:231967	SDHA	-0.47	-5.22	-0.31	3.61e-7	Breast cancer;
CESC	cis	rs9914578	0.943	rs3760231	chr17:2014984	T/C	cg16513277	chr17:2031491	SMG6	-0.62	-7.02	-0.4	1.86e-11	Body mass index;
CESC	cis	rs6570726	0.935	rs436212	chr6:145849400	G/A	cg05347473	chr6:146136440	FBXO30	0.49	6.62	0.38	1.96e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2370759	1.000	rs11599522	chr10:32568434	G/C	cg05361325	chr10:32636312	EPC1	-0.54	-5.14	-0.3	5.34e-7	Sexual dysfunction (female);
CESC	cis	rs367615	0.959	rs17161951	chr5:108930590	A/G	cg17395555	chr5:108820864	NA	-0.45	-6.84	-0.39	5.5e-11	Colorectal cancer (SNP x SNP interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15335805	chr11:10880038	ZBED5	0.52	6.0	0.35	6.4e-9	Gut microbiome composition (summer);
CESC	cis	rs1552244	0.572	rs66514627	chr3:10166632	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.78	8.92	0.48	7.63e-17	Alzheimer's disease;
CESC	cis	rs10504229	0.683	rs56235637	chr8:58106008	T/C	cg24829409	chr8:58192753	C8orf71	-0.59	-7.32	-0.41	3.05e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs4843747	0.671	rs4072871	chr16:88106614	C/T	cg17633681	chr16:88106987	BANP	0.76	10.51	0.54	8.29e-22	Menopause (age at onset);
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg02079880	chr6:157802436	ZDHHC14	0.52	6.59	0.38	2.31e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs113835537	0.935	rs57043177	chr11:66423147	A/G	cg22134325	chr11:66188745	NPAS4	0.51	5.84	0.34	1.55e-8	Airway imaging phenotypes;
CESC	cis	rs4843747	0.749	rs12102841	chr16:88072574	C/G	cg17633681	chr16:88106987	BANP	-0.69	-9.54	-0.51	9.94e-19	Menopause (age at onset);
CESC	cis	rs9325144	0.647	rs11169189	chr12:39097078	A/T	cg26384229	chr12:38710491	ALG10B	-0.5	-6.94	-0.39	2.95e-11	Morning vs. evening chronotype;
CESC	cis	rs1005277	0.540	rs11011351	chr10:38030525	A/G	cg00409905	chr10:38381863	ZNF37A	-0.5	-6.82	-0.39	6.27e-11	Extrinsic epigenetic age acceleration;
CESC	cis	rs7223966	1.000	rs6504169	chr17:61709145	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.57	0.37	2.58e-10	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs704010	0.543	rs10762841	chr10:80835684	G/C	cg11504511	chr10:80827333	ZMIZ1;LOC283050	0.49	6.4	0.37	7.17e-10	Breast cancer;
CESC	cis	rs7647973	0.626	rs4855845	chr3:49687043	T/C	cg13072238	chr3:49761600	GMPPB	-0.44	-5.4	-0.32	1.45e-7	Menarche (age at onset);
CESC	cis	rs7666738	0.830	rs10001701	chr4:98918871	G/C	cg17366294	chr4:99064904	C4orf37	0.56	7.7	0.43	2.65e-13	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9910055	0.529	rs170637	chr17:42186868	C/T	cg13607699	chr17:42295918	UBTF	-0.56	-7.36	-0.41	2.3e-12	Total body bone mineral density;
CESC	cis	rs2836974	0.565	rs2836939	chr21:40578546	C/T	cg11644478	chr21:40555479	PSMG1	0.72	7.71	0.43	2.56e-13	Cognitive function;
CESC	cis	rs7264396	0.635	rs6119672	chr20:34479767	A/G	cg17201900	chr20:34330562	RBM39	0.49	5.14	0.3	5.46e-7	Total cholesterol levels;
CESC	cis	rs826838	1.000	rs826888	chr12:39104719	C/G	cg26384229	chr12:38710491	ALG10B	-0.62	-10.2	-0.53	7.78e-21	Heart rate;
CESC	cis	rs2337406	0.866	rs4773949	chr14:107216306	C/T	cg23076370	chr14:107095027	NA	0.5	5.18	0.3	4.35e-7	Alzheimer's disease (late onset);
CESC	cis	rs2243480	1.000	rs316326	chr7:65609453	T/C	cg18252515	chr7:66147081	NA	-1.41	-14.48	-0.66	2.11e-35	Diabetic kidney disease;
CESC	cis	rs863345	0.967	rs11264989	chr1:158469271	A/G	cg12129480	chr1:158549410	OR10X1	-0.31	-6.19	-0.36	2.34e-9	Pneumococcal bacteremia;
CESC	cis	rs9611565	0.838	rs4239894	chr22:41745548	C/G	cg06634786	chr22:41940651	POLR3H	-0.67	-6.99	-0.39	2.17e-11	Vitiligo;
CESC	trans	rs4424809	0.614	rs76432167	chr13:85573798	C/T	cg05918002	chr17:5019452	ZNF232	-0.63	-6.08	-0.35	4.29e-9	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs9311474	0.652	rs614288	chr3:52220203	T/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.32	5.66	0.33	3.89e-8	Electroencephalogram traits;
CESC	cis	rs8027181	1.000	rs4777542	chr15:73082366	C/T	cg25632853	chr15:73088954	NA	-0.36	-6.21	-0.36	2.04e-9	Triglyceride levels;
CESC	cis	rs4727027	0.899	rs4727025	chr7:148862863	A/G	cg23158103	chr7:148848205	ZNF398	-0.42	-6.92	-0.39	3.45e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs854765	0.647	rs2056842	chr17:18009028	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.61	8.51	0.46	1.27e-15	Total body bone mineral density;
CESC	cis	rs2635047	1.000	rs2635049	chr18:44687303	C/T	cg19077165	chr18:44547161	KATNAL2	0.45	6.14	0.35	2.95e-9	Educational attainment;
CESC	cis	rs61935443	0.832	rs11107771	chr12:95276844	A/G	cg21533806	chr12:95267307	NA	0.58	7.13	0.4	9.52e-12	Schizophrenia;
CESC	cis	rs7772486	0.875	rs9399573	chr6:146403255	A/T	cg23711669	chr6:146136114	FBXO30	0.78	11.53	0.58	3.45e-25	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg03355190	chr15:40886188	CASC5	-0.48	-6.03	-0.35	5.55e-9	Asthma;
CESC	cis	rs4722166	0.630	rs7781534	chr7:22778592	A/C	cg13104385	chr7:22767384	IL6	0.48	6.43	0.37	5.96e-10	Lung cancer;
CESC	cis	rs7524258	0.868	rs11120885	chr1:7306755	C/G	cg07173049	chr1:7289937	CAMTA1	0.38	5.88	0.34	1.2e-8	Tourette's syndrome or obsessive-compulsive disorder;
CESC	cis	rs7666738	0.830	rs4443293	chr4:99063120	G/A	cg03467027	chr4:99064603	C4orf37	0.48	5.95	0.34	8.67e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs12545109	0.800	rs970838	chr8:57414806	A/G	cg09654669	chr8:57350985	NA	-0.46	-6.25	-0.36	1.67e-9	Obesity-related traits;
CESC	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg11494091	chr17:61959527	GH2	0.73	12.56	0.61	1.07e-28	Prudent dietary pattern;
CESC	cis	rs3785574	0.962	rs62077509	chr17:61848973	A/G	cg07677032	chr17:61819896	STRADA	0.42	5.25	0.31	3.15e-7	Height;
CESC	cis	rs5167	0.504	rs3760628	chr19:45457225	G/A	cg20090143	chr19:45452003	APOC2	0.37	6.39	0.37	7.51e-10	Blood protein levels;
CESC	cis	rs1949733	1.000	rs2688233	chr4:8491885	T/C	cg11789530	chr4:8429930	ACOX3	0.8	11.25	0.57	2.93e-24	Response to antineoplastic agents;
CESC	cis	rs11098499	0.754	rs9999724	chr4:120239944	C/T	cg09307838	chr4:120376055	NA	0.8	11.03	0.56	1.55e-23	Corneal astigmatism;
CESC	cis	rs801193	0.967	rs1110414	chr7:66205582	A/G	cg14393609	chr7:65229607	NA	0.47	6.31	0.36	1.17e-9	Aortic root size;
CESC	cis	rs77861329	0.702	rs7644325	chr3:52081136	A/G	cg08692210	chr3:52188851	WDR51A	0.47	5.55	0.32	6.88e-8	Macrophage inflammatory protein 1b levels;
CESC	trans	rs4332037	0.950	rs56403963	chr7:1946130	C/G	cg11693508	chr17:37793320	STARD3	0.69	6.55	0.37	2.95e-10	Bipolar disorder;
CESC	cis	rs4689388	0.926	rs10010131	chr4:6292915	A/G	cg25554036	chr4:6271136	WFS1	0.52	8.6	0.47	7.07e-16	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs7772486	0.727	rs10447449	chr6:146138707	A/G	cg23711669	chr6:146136114	FBXO30	0.94	14.33	0.66	7.07e-35	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg20566420	chr12:122327043	PSMD9	0.55	7.21	0.4	5.96e-12	Gut microbiota (bacterial taxa);
CESC	cis	rs4319547	0.956	rs7316149	chr12:123063912	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.59	-6.81	-0.39	6.63e-11	Body mass index;
CESC	cis	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg22963979	chr7:1858916	MAD1L1	-0.43	-5.87	-0.34	1.31e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs801193	0.569	rs881285	chr7:66119420	A/G	cg10691866	chr7:65817282	TPST1	0.31	5.33	0.31	2.06e-7	Aortic root size;
CESC	cis	rs8005677	1.000	rs4981449	chr14:23388871	C/G	cg25600027	chr14:23388339	RBM23	-0.43	-5.33	-0.31	2.08e-7	Cognitive ability (multi-trait analysis);
CESC	cis	rs35740288	0.539	rs4843100	chr15:86339210	G/C	cg20737812	chr15:86336631	KLHL25	-0.48	-5.48	-0.32	9.96e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
CESC	cis	rs2562784	0.638	rs2585056	chr15:84282215	C/G	cg17507749	chr15:85114479	UBE2QP1	0.58	5.37	0.31	1.7e-7	Height;
CESC	cis	rs67460515	0.892	rs16832082	chr3:161043571	A/G	cg03342759	chr3:160939853	NMD3	-0.55	-7.9	-0.44	7.51e-14	Parkinson's disease;
CESC	cis	rs56804039	1.000	rs7017341	chr8:8381664	C/A	cg15556689	chr8:8085844	FLJ10661	-0.49	-5.28	-0.31	2.66e-7	Cervical cancer;
CESC	cis	rs9549367	0.713	rs3024761	chr13:113824090	C/G	cg00898013	chr13:113819073	PROZ	0.52	7.17	0.4	7.7e-12	Platelet distribution width;
CESC	cis	rs329122	0.528	rs6891328	chr5:133851526	G/C	cg26284174	chr5:133860141	NA	0.46	5.27	0.31	2.79e-7	Body mass index;Type 2 diabetes;
CESC	cis	rs9287719	0.934	rs6432115	chr2:10748343	G/T	cg00105475	chr2:10696890	NA	0.38	5.57	0.32	6.34e-8	Prostate cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25447359	chr22:30790057	NA	-0.66	-7.99	-0.44	4.21e-14	Gut microbiome composition (summer);
CESC	cis	rs12926788	0.689	rs1862450	chr16:24856775	A/G	cg06028605	chr16:24865363	SLC5A11	-0.53	-7.49	-0.42	1.03e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	trans	rs11098499	0.865	rs28753180	chr4:120405367	A/T	cg25214090	chr10:38739885	LOC399744	0.72	10.18	0.53	9.16e-21	Corneal astigmatism;
CESC	cis	rs7208859	0.623	rs7223404	chr17:29107363	C/T	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.17e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs4727027	0.625	rs75129390	chr7:148846775	T/A	cg23158103	chr7:148848205	ZNF398	-0.4	-6.4	-0.37	7.14e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs1950500	0.545	rs724165	chr14:24806229	G/A	cg16194253	chr14:24768981	DHRS1;C14orf21	0.57	7.03	0.4	1.71e-11	Height;
CESC	cis	rs7617773	0.779	rs77957078	chr3:48331286	G/C	cg11946769	chr3:48343235	NME6	0.86	11.63	0.58	1.52e-25	Coronary artery disease;
CESC	cis	rs3008870	0.755	rs4486425	chr1:67460791	T/C	cg08660285	chr1:67390436	MIER1;WDR78	-0.63	-8.34	-0.46	4.16e-15	Lymphocyte percentage of white cells;
CESC	cis	rs6460942	0.915	rs7803002	chr7:12306738	C/T	cg20607287	chr7:12443886	VWDE	-0.42	-5.98	-0.35	7.02e-9	Coronary artery disease;
CESC	cis	rs9911578	1.000	rs302848	chr17:56686454	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.4	5.24	0.31	3.21e-7	Intelligence (multi-trait analysis);
CESC	cis	rs4722166	0.695	rs56061963	chr7:22800397	T/C	cg05265849	chr7:22767390	IL6	0.45	6.24	0.36	1.71e-9	Lung cancer;
CESC	trans	rs208520	0.802	rs851600	chr6:66893754	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.91	-11.17	-0.57	5.31e-24	Exhaled nitric oxide output;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg07472647	chr5:149380356	HMGXB3;TIGD6	-0.45	-6.23	-0.36	1.85e-9	Fibrinogen levels;
CESC	cis	rs6088580	0.634	rs6059905	chr20:33126946	T/C	cg24642439	chr20:33292090	TP53INP2	0.52	6.8	0.39	6.84e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs2439831	0.850	rs16965120	chr15:44100342	T/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.67	7.66	0.43	3.45e-13	Lung cancer in ever smokers;
CESC	cis	rs1975974	0.549	rs4889746	chr17:21745187	T/C	cg18423549	chr17:21743878	NA	-0.68	-9.74	-0.51	2.31e-19	Psoriasis;
CESC	trans	rs2530545	0.851	rs1458549	chr7:34686792	A/C	cg14080982	chr15:71736038	THSD4	0.45	6.03	0.35	5.56e-9	IgG glycosylation;
CESC	cis	rs7077164	0.846	rs1227773	chr10:71579347	C/A	cg20696214	chr10:71583771	COL13A1	-0.47	-6.44	-0.37	5.62e-10	Non-alcoholic fatty liver disease histology (lobular);
CESC	cis	rs1790761	0.505	rs7106423	chr11:67314144	A/G	cg00290607	chr11:67383545	NA	-0.36	-5.31	-0.31	2.3e-7	Mean corpuscular volume;
CESC	trans	rs1814175	0.817	rs1996982	chr11:49972619	G/T	cg15704280	chr7:45808275	SEPT13	-1.03	-21.34	-0.8	1.71e-59	Height;
CESC	cis	rs6500395	1.000	rs1909765	chr16:48597358	A/G	cg04672837	chr16:48644449	N4BP1	0.49	6.15	0.35	2.86e-9	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs763121	0.524	rs760645	chr22:39032270	C/T	cg06022373	chr22:39101656	GTPBP1	0.56	7.28	0.41	3.71e-12	Menopause (age at onset);
CESC	cis	rs875971	1.000	rs6979382	chr7:65886375	C/T	cg10691866	chr7:65817282	TPST1	-0.35	-5.77	-0.33	2.18e-8	Aortic root size;
CESC	cis	rs4237845	0.773	rs6650217	chr12:58289072	T/G	cg00677455	chr12:58241039	CTDSP2	0.44	5.78	0.33	2.09e-8	Intelligence (multi-trait analysis);
CESC	cis	rs2075371	0.637	rs2544165	chr7:133920443	A/G	cg20476274	chr7:133979776	SLC35B4	-0.62	-8.88	-0.48	1.05e-16	Mean platelet volume;
CESC	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg03647317	chr4:187891568	NA	-0.37	-5.56	-0.32	6.44e-8	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1682361	1	rs1682361	chr3:136734014	G/C	cg25687071	chr3:136751404	NA	0.4	5.37	0.31	1.73e-7	Schizophrenia;
CESC	cis	rs6541297	0.938	rs1555289	chr1:230292499	C/T	cg20703242	chr1:230279135	GALNT2	-0.67	-9.1	-0.49	2.25e-17	Coronary artery disease;
CESC	cis	rs9733	0.650	rs1971378	chr1:150597261	C/T	cg22823121	chr1:150693482	HORMAD1	-0.39	-5.85	-0.34	1.45e-8	Tonsillectomy;
CESC	cis	rs7605827	0.930	rs2111448	chr2:15599073	T/G	cg19274914	chr2:15703543	NA	0.32	5.67	0.33	3.71e-8	Educational attainment (years of education);
CESC	cis	rs2952156	0.652	rs11869286	chr17:37813856	C/G	cg00129232	chr17:37814104	STARD3	-0.8	-12.06	-0.6	5.51e-27	Asthma;
CESC	trans	rs9951602	0.512	rs3859325	chr18:76652175	A/G	cg02800362	chr5:177631904	HNRNPAB	0.66	8.64	0.47	5.41e-16	Obesity-related traits;
CESC	cis	rs514406	0.793	rs12081018	chr1:53217542	C/A	cg08736216	chr1:53307985	ZYG11A	0.32	5.53	0.32	7.58e-8	Monocyte count;
CESC	cis	rs9788333	0.962	rs12584792	chr13:21887208	C/T	cg25811766	chr13:21894605	NA	0.76	10.27	0.53	4.91e-21	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs17021463	0.673	rs1609424	chr4:95301887	G/A	cg11021082	chr4:95130006	SMARCAD1	0.49	6.15	0.35	2.79e-9	Testicular germ cell tumor;
CESC	trans	rs877282	0.583	rs7072970	chr10:822757	G/A	cg22713356	chr15:30763199	NA	1.07	9.68	0.51	3.6e-19	Uric acid levels;
CESC	cis	rs977987	0.806	rs1364077	chr16:75396991	C/T	cg03315344	chr16:75512273	CHST6	0.39	5.63	0.33	4.61e-8	Dupuytren's disease;
CESC	trans	rs1728785	1.000	rs1170428	chr16:68603988	C/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.71	8.42	0.46	2.43e-15	Ulcerative colitis;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg16741889	chr21:44280710	WDR4	-0.39	-6.18	-0.35	2.36e-9	Gambling;
CESC	cis	rs8072100	0.967	rs3760370	chr17:45695832	C/T	cg08085267	chr17:45401833	C17orf57	0.39	5.03	0.3	8.87e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs561341	0.882	rs111484028	chr17:30287701	G/A	cg00745463	chr17:30367425	LRRC37B	-0.7	-7.02	-0.4	1.85e-11	Hip circumference adjusted for BMI;
CESC	cis	rs250677	0.522	rs55732303	chr5:148392538	C/T	cg18129178	chr5:148520854	ABLIM3	-0.47	-5.22	-0.31	3.57e-7	Breast cancer;
CESC	cis	rs853679	0.517	rs35227624	chr6:28132726	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.57	-6.49	-0.37	4.32e-10	Depression;
CESC	cis	rs34779708	0.931	rs7923217	chr10:35309589	A/G	cg04310649	chr10:35416472	CREM	-0.53	-6.41	-0.37	6.57e-10	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs936229	0.749	rs7497201	chr15:75190690	A/G	cg14664628	chr15:75095509	CSK	-0.72	-9.02	-0.48	3.93e-17	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CESC	cis	rs1799949	0.965	rs8176323	chr17:41195711	G/C	cg05368731	chr17:41323189	NBR1	0.75	10.32	0.54	3.35e-21	Menopause (age at onset);
CESC	cis	rs9309473	0.950	rs13431529	chr2:73876041	G/C	cg20560298	chr2:73613845	ALMS1	-0.53	-6.77	-0.38	8.13e-11	Metabolite levels;
CESC	cis	rs7212590	0.655	rs8072050	chr17:58010972	G/A	cg20303301	chr17:57937339	TUBD1	-0.55	-5.57	-0.32	6.25e-8	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs6456156	0.586	rs10946208	chr6:167459596	C/T	cg07741184	chr6:167504864	NA	0.34	5.88	0.34	1.21e-8	Primary biliary cholangitis;
CESC	cis	rs4862750	0.872	rs6852907	chr4:187897094	A/C	cg22105103	chr4:187893119	NA	0.5	7.32	0.41	2.98e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7726839	0.718	rs6887972	chr5:597274	C/G	cg16447950	chr5:562315	NA	-0.49	-5.72	-0.33	2.88e-8	Obesity-related traits;
CESC	cis	rs7100689	0.622	rs4933378	chr10:82147057	T/C	cg00277334	chr10:82204260	NA	-0.58	-7.62	-0.42	4.52e-13	Post bronchodilator FEV1;
CESC	cis	rs875971	0.862	rs10263690	chr7:65766453	G/C	cg11764359	chr7:65958608	NA	-0.78	-11.64	-0.58	1.47e-25	Aortic root size;
CESC	cis	rs853679	0.517	rs9295761	chr6:28147987	A/G	cg19592336	chr6:28129416	ZNF389	0.59	7.73	0.43	2.24e-13	Depression;
CESC	cis	rs2425143	1.000	rs11167275	chr20:34340275	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.82	-7.45	-0.42	1.33e-12	Blood protein levels;
CESC	cis	rs7809950	0.862	rs62482502	chr7:106987810	A/C	cg23024343	chr7:107201750	COG5	-0.37	-5.15	-0.3	5.09e-7	Coronary artery disease;
CESC	cis	rs13108904	0.935	rs1732100	chr4:1281761	C/T	cg16405210	chr4:1374714	KIAA1530	0.45	5.64	0.33	4.35e-8	Obesity-related traits;
CESC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg01258499	chr20:30540016	PDRG1	0.48	6.27	0.36	1.45e-9	Tetralogy of Fallot;
CESC	cis	rs3008870	1.000	rs2755256	chr1:67471692	A/T	cg08660285	chr1:67390436	MIER1;WDR78	1.03	14.0	0.65	1e-33	Lymphocyte percentage of white cells;
CESC	cis	rs11690935	0.959	rs10166005	chr2:172607294	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.97	-14.98	-0.68	3.73e-37	Schizophrenia;
CESC	cis	rs6460942	0.915	rs62448593	chr7:12436845	G/C	cg20607287	chr7:12443886	VWDE	-0.77	-9.04	-0.49	3.38e-17	Coronary artery disease;
CESC	cis	rs2073300	0.609	rs6137927	chr20:23372513	A/G	cg12062639	chr20:23401060	NAPB	1.07	8.85	0.48	1.29e-16	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs7666738	0.830	rs6819177	chr4:99040907	T/C	cg03676636	chr4:99064102	C4orf37	0.33	5.12	0.3	5.93e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1401999	1.000	rs1533684	chr3:183635815	A/G	cg01324343	chr3:183735012	ABCC5	0.63	13.45	0.64	8.71e-32	Anterior chamber depth;
CESC	cis	rs1799949	0.965	rs11650913	chr17:41331597	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.59	7.71	0.43	2.62e-13	Menopause (age at onset);
CESC	cis	rs736408	0.609	rs2230535	chr3:52800284	T/C	cg07507251	chr3:52567010	NT5DC2	0.42	7.15	0.4	8.2e-12	Bipolar disorder;
CESC	cis	rs1600249	0.562	rs17153419	chr8:11394233	C/T	cg21775007	chr8:11205619	TDH	-0.39	-5.09	-0.3	6.74e-7	Rheumatoid arthritis;
CESC	cis	rs35849525	1.000	rs35849525	chr3:50067350	T/C	cg24308560	chr3:49941425	MST1R	-0.56	-6.83	-0.39	5.8e-11	Intelligence (multi-trait analysis);
CESC	cis	rs12497850	0.931	rs7647813	chr3:48833348	G/T	cg03060546	chr3:49711283	APEH	0.43	5.34	0.31	2.05e-7	Parkinson's disease;
CESC	cis	rs780096	0.546	rs12473776	chr2:27636474	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.29	-5.36	-0.31	1.82e-7	Total body bone mineral density;
CESC	cis	rs7044106	0.791	rs3904196	chr9:123480369	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.84	13.61	0.64	2.42e-32	Hip circumference adjusted for BMI;
CESC	cis	rs710216	0.917	rs2297977	chr1:43415288	G/T	cg03128534	chr1:43423976	SLC2A1	0.56	6.54	0.37	3.2e-10	Red cell distribution width;
CESC	cis	rs4253772	0.513	rs6008700	chr22:46722560	C/T	cg10231785	chr22:46692440	CN5H6.4;GTSE1	0.5	5.19	0.3	4.27e-7	LDL cholesterol;Cholesterol, total;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg10077144	chr16:3199858	NA	-0.41	-6.39	-0.37	7.42e-10	Gambling;
CESC	cis	rs16866061	1.000	rs16866061	chr2:225439844	A/G	cg12698349	chr2:225449008	CUL3	0.77	11.29	0.57	2.16e-24	Acute graft versus host disease in bone marrow transplantation (recipient effect);
CESC	cis	rs875971	0.522	rs2949690	chr7:65483242	C/T	cg14393609	chr7:65229607	NA	-0.52	-7.14	-0.4	8.84e-12	Aortic root size;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg00515312	chr12:77158614	ZDHHC17	0.47	6.5	0.37	3.87e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs9611565	0.592	rs8779	chr22:42070276	T/C	cg17376030	chr22:41985996	PMM1	-0.79	-8.55	-0.47	9.65e-16	Vitiligo;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25300318	chr2:200527297	NA	-0.54	-6.0	-0.35	6.47e-9	Gut microbiome composition (summer);
CESC	cis	rs2032447	0.839	rs6901039	chr6:26000885	A/C	cg18357526	chr6:26021779	HIST1H4A	0.66	8.67	0.47	4.36e-16	Intelligence (multi-trait analysis);
CESC	cis	rs2249625	0.904	rs2496514	chr6:72904071	A/G	cg18830697	chr6:72922368	RIMS1	-0.39	-5.58	-0.32	5.81e-8	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CESC	cis	rs7771547	0.573	rs544267	chr6:36398302	A/G	cg07856975	chr6:36356162	ETV7	0.36	5.38	0.31	1.67e-7	Platelet distribution width;
CESC	cis	rs7786877	0.500	rs2272572	chr7:100285888	C/T	cg20848291	chr7:100343083	ZAN	-0.81	-10.03	-0.52	2.88e-20	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24596729	chr1:165345813	NA	0.62	7.12	0.4	9.97e-12	Gut microbiome composition (summer);
CESC	cis	rs6088580	0.660	rs6059893	chr20:33105897	T/G	cg08999081	chr20:33150536	PIGU	0.66	11.5	0.58	4.31e-25	Glomerular filtration rate (creatinine);
CESC	trans	rs1814175	0.817	rs10769613	chr11:49769692	G/A	cg15704280	chr7:45808275	SEPT13	-1.02	-19.93	-0.77	1.26e-54	Height;
CESC	cis	rs7208859	0.673	rs11652370	chr17:29097223	G/A	cg13385521	chr17:29058706	SUZ12P	0.59	5.46	0.32	1.09e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs911555	0.755	rs2756135	chr14:103962579	G/A	cg12935359	chr14:103987150	CKB	0.67	9.78	0.52	1.73e-19	Intelligence (multi-trait analysis);
CESC	cis	rs7223966	1.000	rs11870797	chr17:61804622	C/T	cg11494091	chr17:61959527	GH2	0.38	5.19	0.3	4.28e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs2708240	0.515	rs2708269	chr7:147595615	T/A	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.32	-5.68	-0.33	3.46e-8	QT interval (drug interaction);
CESC	cis	rs9611565	0.918	rs7290404	chr22:41749796	C/T	cg03806693	chr22:41940476	POLR3H	-1.02	-11.89	-0.59	2.03e-26	Vitiligo;
CESC	cis	rs7188697	0.922	rs1981961	chr16:58597291	A/T	cg21335942	chr16:58549945	SETD6	-0.45	-5.2	-0.3	4.06e-7	QT interval;
CESC	cis	rs2302190	0.882	rs7221464	chr17:56552353	A/T	cg25885038	chr17:56607967	SEPT4	-0.41	-5.55	-0.32	6.92e-8	Vitamin D levels;
CESC	cis	rs9911578	1.000	rs7216680	chr17:56988243	G/C	cg05425664	chr17:57184151	TRIM37	-0.5	-6.83	-0.39	5.94e-11	Intelligence (multi-trait analysis);
CESC	cis	rs10089	1.000	rs4836360	chr5:127458161	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.79	10.74	0.55	1.38e-22	Ileal carcinoids;
CESC	cis	rs7937682	0.883	rs1613778	chr11:111456105	G/C	cg09085632	chr11:111637200	PPP2R1B	-0.93	-13.47	-0.64	7.49e-32	Primary sclerosing cholangitis;
CESC	cis	rs6912958	0.559	rs242267	chr6:88061837	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.48	-8.26	-0.45	6.9e-15	Monocyte percentage of white cells;
CESC	cis	rs790123	0.933	rs812596	chr3:122382301	A/T	cg17380795	chr3:122379686	NA	0.45	6.85	0.39	5.16e-11	Response to angiotensin II receptor blocker therapy;
CESC	cis	rs7074356	0.523	rs7087728	chr10:82033470	G/A	cg27171509	chr10:82033454	MAT1A	-0.33	-5.1	-0.3	6.52e-7	Borderline personality disorder;
CESC	cis	rs868036	0.609	rs28742003	chr15:68127769	C/T	cg08079166	chr15:68083412	MAP2K5	0.41	5.58	0.32	5.86e-8	Restless legs syndrome;
CESC	trans	rs3934047	0.869	rs12909073	chr15:82065902	A/G	cg19098314	chr17:28804347	GOSR1	-0.43	-6.02	-0.35	5.83e-9	Response to paliperidone in schizophrenia (positive Marder score);
CESC	cis	rs6693567	0.507	rs4970964	chr1:150458029	A/G	cg09579323	chr1:150459698	TARS2	0.46	5.69	0.33	3.42e-8	Migraine;
CESC	cis	rs2228479	0.850	rs2286393	chr16:89809548	C/A	cg14709524	chr16:89940631	TCF25	0.84	6.38	0.36	7.86e-10	Skin colour saturation;
CESC	cis	rs4243830	0.850	rs10779790	chr1:6608435	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.85	-8.45	-0.46	1.93e-15	Body mass index;
CESC	cis	rs1023500	0.505	rs2143139	chr22:42614401	G/C	cg04733989	chr22:42467013	NAGA	0.68	10.01	0.52	3.26e-20	Schizophrenia;
CESC	cis	rs1552244	1.000	rs3846177	chr3:10068572	G/T	cg00166722	chr3:10149974	C3orf24	0.5	6.31	0.36	1.19e-9	Alzheimer's disease;
CESC	cis	rs9649213	0.593	rs1468338	chr7:97951118	T/C	cg24562669	chr7:97807699	LMTK2	0.48	7.1	0.4	1.13e-11	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs116095464	0.558	rs7703803	chr5:292311	A/G	cg10591111	chr5:226296	SDHA	-0.53	-6.45	-0.37	5.35e-10	Breast cancer;
CESC	cis	rs4332037	0.586	rs62442944	chr7:2015047	T/G	cg23422044	chr7:1970798	MAD1L1	-0.49	-5.29	-0.31	2.6e-7	Bipolar disorder;
CESC	cis	rs7537660	1.000	rs10888256	chr1:248004775	C/T	cg12080717	chr1:248004886	OR11L1	-0.46	-5.71	-0.33	2.99e-8	Platelet distribution width;
CESC	cis	rs8072100	0.840	rs1912482	chr17:45454883	G/A	cg25173405	chr17:45401733	C17orf57	-0.43	-5.64	-0.33	4.46e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs1559088	1.000	rs28803235	chr19:33561804	G/A	cg17764715	chr19:33622953	WDR88	0.45	5.55	0.32	6.8e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs2839186	0.770	rs2280956	chr21:47642323	C/G	cg11766577	chr21:47581405	C21orf56	0.47	6.48	0.37	4.36e-10	Testicular germ cell tumor;
CESC	cis	rs3126085	0.935	rs1353436	chr1:152172658	G/A	cg03465714	chr1:152285911	FLG	-0.43	-5.28	-0.31	2.72e-7	Atopic dermatitis;
CESC	cis	rs7829975	0.714	rs6994038	chr8:8660538	C/A	cg17143192	chr8:8559678	CLDN23	0.42	5.11	0.3	6.11e-7	Mood instability;
CESC	cis	rs35110281	0.774	rs2838321	chr21:44995488	A/T	cg21573476	chr21:45109991	RRP1B	-0.42	-5.91	-0.34	1.04e-8	Mean corpuscular volume;
CESC	cis	rs9311474	0.713	rs352165	chr3:52242902	A/G	cg18099408	chr3:52552593	STAB1	-0.32	-5.44	-0.32	1.22e-7	Electroencephalogram traits;
CESC	cis	rs4332037	0.664	rs73046334	chr7:1887037	T/C	cg23422044	chr7:1970798	MAD1L1	-0.55	-5.93	-0.34	9.42e-9	Bipolar disorder;
CESC	cis	rs2710642	0.540	rs11893614	chr2:62861661	A/G	cg17519650	chr2:63277830	OTX1	0.47	5.54	0.32	7.36e-8	LDL cholesterol levels;LDL cholesterol;
CESC	cis	rs362296	0.511	rs2051558	chr4:3324886	G/A	cg08886695	chr4:3369023	RGS12	-0.42	-6.12	-0.35	3.4e-9	Parental longevity (mother's age at death);
CESC	cis	rs2075371	0.796	rs1978504	chr7:134006933	C/T	cg20476274	chr7:133979776	SLC35B4	-0.6	-8.35	-0.46	3.73e-15	Mean platelet volume;
CESC	cis	rs9733	0.744	rs2039590	chr1:150813315	G/A	cg22823121	chr1:150693482	HORMAD1	-0.4	-6.11	-0.35	3.6e-9	Tonsillectomy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12171159	chr11:72504902	STARD10	0.64	6.94	0.39	3.03e-11	Gut microbiome composition (summer);
CESC	trans	rs9399401	1.000	rs972982	chr6:142666861	A/G	cg02046995	chr22:41487740	EP300;MIR1281	-0.42	-6.06	-0.35	4.76e-9	Chronic obstructive pulmonary disease;
CESC	cis	rs1799949	0.602	rs4600503	chr17:41414324	C/G	cg06001716	chr17:41278141	BRCA1;NBR2	0.38	5.13	0.3	5.72e-7	Menopause (age at onset);
CESC	cis	rs2742417	0.603	rs2742458	chr3:45767602	C/T	cg04837898	chr3:45731254	SACM1L	-0.47	-6.17	-0.35	2.54e-9	Response to anti-depressant treatment in major depressive disorder;
CESC	trans	rs916888	0.773	rs199443	chr17:44819565	C/T	cg04282206	chr17:62833786	PLEKHM1P	0.54	6.41	0.37	6.78e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs4975709	0.589	rs1684967	chr5:1863055	G/C	cg11168104	chr5:1857477	NA	-0.38	-5.72	-0.33	2.85e-8	Cardiovascular disease risk factors;
CESC	cis	rs2645694	0.626	rs2703126	chr4:77819842	T/C	cg10057126	chr4:77819792	ANKRD56	0.58	8.45	0.46	2.02e-15	Emphysema distribution in smoking;
CESC	cis	rs959260	1.000	rs4788889	chr17:73389126	A/G	cg12999837	chr17:73267436	MIF4GD	-0.47	-5.48	-0.32	9.82e-8	Systemic lupus erythematosus;
CESC	cis	rs7726839	0.561	rs72703050	chr5:582917	A/C	cg16447950	chr5:562315	NA	-0.55	-6.14	-0.35	3.06e-9	Obesity-related traits;
CESC	cis	rs6693567	0.565	rs834234	chr1:150352494	C/G	cg09579323	chr1:150459698	TARS2	-0.44	-6.0	-0.35	6.52e-9	Migraine;
CESC	cis	rs801193	0.935	rs11772264	chr7:66176387	T/C	cg14393609	chr7:65229607	NA	0.45	6.15	0.35	2.86e-9	Aortic root size;
CESC	cis	rs12477438	0.798	rs7606635	chr2:99644782	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.62	-8.67	-0.47	4.43e-16	Chronic sinus infection;
CESC	trans	rs877282	0.945	rs12767287	chr10:787310	A/G	cg22713356	chr15:30763199	NA	1.31	13.31	0.63	2.78e-31	Uric acid levels;
CESC	cis	rs898097	0.783	rs11650335	chr17:80835111	A/G	cg15369054	chr17:80825471	TBCD	0.53	7.25	0.41	4.62e-12	Breast cancer;
CESC	cis	rs67460515	0.563	rs16831886	chr3:160799830	A/C	cg03342759	chr3:160939853	NMD3	-0.51	-6.31	-0.36	1.18e-9	Parkinson's disease;
CESC	cis	rs17023223	0.537	rs6677107	chr1:119708765	C/T	cg05756136	chr1:119680316	WARS2	-0.47	-5.69	-0.33	3.34e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CESC	cis	rs853679	0.517	rs6922063	chr6:28094366	G/A	cg23161317	chr6:28129485	ZNF389	0.53	6.97	0.39	2.54e-11	Depression;
CESC	cis	rs4689388	0.926	rs5018648	chr4:6292818	C/G	cg25554036	chr4:6271136	WFS1	-0.51	-8.5	-0.46	1.38e-15	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs728616	0.558	rs12772945	chr10:82154496	C/T	cg05935833	chr10:81318306	SFTPA2	-0.46	-5.67	-0.33	3.63e-8	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs80130819	0.688	rs10783239	chr12:48616801	G/C	cg05342945	chr12:48394962	COL2A1	-0.54	-5.61	-0.33	5.08e-8	Prostate cancer;
CESC	cis	rs365132	0.934	rs149307	chr5:176471591	C/T	cg16309518	chr5:176445507	NA	-0.43	-6.32	-0.36	1.11e-9	Menarche and menopause (age at onset);Menopause (age at onset);
CESC	cis	rs2404602	0.692	rs35077207	chr15:76935306	A/G	cg26408565	chr15:76604113	ETFA	-0.38	-5.44	-0.32	1.21e-7	Blood metabolite levels;
CESC	cis	rs6461049	0.800	rs3800913	chr7:2163237	A/G	cg21782813	chr7:2030301	MAD1L1	0.44	6.2	0.36	2.16e-9	Schizophrenia;
CESC	cis	rs9926296	0.512	rs11076626	chr16:89865103	T/A	cg27121462	chr16:89883253	FANCA	0.79	11.83	0.59	3.38e-26	Vitiligo;
CESC	cis	rs7666738	0.861	rs13139309	chr4:99020916	A/G	cg18180107	chr4:99064573	C4orf37	0.41	5.39	0.31	1.57e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg02725872	chr8:58115012	NA	-0.43	-5.8	-0.34	1.9e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs911555	0.755	rs12436729	chr14:103929889	G/C	cg12935359	chr14:103987150	CKB	0.65	9.46	0.5	1.73e-18	Intelligence (multi-trait analysis);
CESC	cis	rs3820068	0.705	rs72645803	chr1:15868232	G/A	cg18192808	chr1:15853278	DNAJC16	0.46	5.44	0.32	1.2e-7	Systolic blood pressure;
CESC	cis	rs11123610	0.520	rs66557864	chr2:3720812	C/A	cg19052272	chr2:3704530	ALLC	-0.47	-5.73	-0.33	2.72e-8	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CESC	trans	rs61931739	0.534	rs10844729	chr12:34022919	A/G	cg26384229	chr12:38710491	ALG10B	0.58	8.04	0.44	2.91e-14	Morning vs. evening chronotype;
CESC	cis	rs7208859	0.623	rs609063	chr17:28951513	A/G	cg13385521	chr17:29058706	SUZ12P	0.79	5.73	0.33	2.74e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs3768617	0.510	rs10797842	chr1:183081867	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.86	13.7	0.64	1.14e-32	Fuchs's corneal dystrophy;
CESC	cis	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg02951883	chr7:2050386	MAD1L1	-0.51	-6.85	-0.39	5.02e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs1775715	0.677	rs2491272	chr10:32186783	A/G	cg18675610	chr10:32216311	ARHGAP12	0.34	5.21	0.3	3.84e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03933756	chr16:86565719	MTHFSD	-0.56	-6.46	-0.37	4.95e-10	Gut microbiome composition (summer);
CESC	cis	rs10242455	0.702	rs79878591	chr7:99082928	C/T	cg25640893	chr7:99214727	ZNF498	1.15	7.03	0.4	1.74e-11	Blood metabolite levels;
CESC	cis	rs9488822	0.676	rs6918059	chr6:116349041	C/T	cg15226275	chr6:116381976	FRK	0.25	6.43	0.37	5.95e-10	Cholesterol, total;LDL cholesterol;
CESC	cis	rs55728055	0.661	rs73162112	chr22:32045449	G/A	cg01338084	chr22:32026380	PISD	1.29	8.72	0.47	3.17e-16	Age-related hearing impairment;
CESC	cis	rs7818345	0.967	rs11786847	chr8:19277200	T/C	cg11303988	chr8:19266685	CSGALNACT1	0.33	6.0	0.35	6.48e-9	Language performance in older adults (adjusted for episodic memory);
CESC	cis	rs11098499	0.863	rs6858777	chr4:120475966	A/G	cg24375607	chr4:120327624	NA	0.45	5.51	0.32	8.55e-8	Corneal astigmatism;
CESC	cis	rs4819052	0.851	rs4819044	chr21:46660118	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.45	5.58	0.32	5.81e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs12477438	0.501	rs2632260	chr2:99771590	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.86	15.04	0.68	2.28e-37	Chronic sinus infection;
CESC	cis	rs2985684	0.948	rs7143010	chr14:50081803	T/C	cg04989706	chr14:50066350	PPIL5	-0.47	-5.12	-0.3	5.98e-7	Carotid intima media thickness;
CESC	cis	rs13191362	0.938	rs13192618	chr6:163132822	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.59	6.38	0.37	7.69e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs11252926	0.661	rs7077209	chr10:484159	A/G	cg18196295	chr10:418757	DIP2C	-0.4	-5.49	-0.32	9.19e-8	Psychosis in Alzheimer's disease;
CESC	cis	rs10504229	0.683	rs16921819	chr8:58107936	G/T	cg21724239	chr8:58056113	NA	0.57	5.9	0.34	1.08e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs644799	0.687	rs3748252	chr11:95519195	A/T	cg03916912	chr11:95522834	CEP57;FAM76B	-0.76	-10.79	-0.55	9.49e-23	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs910316	0.687	rs11627442	chr14:75669649	A/G	cg16144293	chr14:75469539	EIF2B2	0.39	5.04	0.3	8.49e-7	Height;
CESC	cis	rs9910055	0.571	rs10208	chr17:42300278	C/T	cg13607699	chr17:42295918	UBTF	0.92	15.36	0.69	1.59e-38	Total body bone mineral density;
CESC	cis	rs2841277	0.708	rs28454709	chr14:105405942	G/A	cg17340268	chr14:105411764	AHNAK2	-0.52	-6.91	-0.39	3.56e-11	Rheumatoid arthritis;
CESC	trans	rs6759922	1.000	rs11124322	chr2:22442392	G/A	cg21162304	chr4:80247171	NAA11	0.37	6.04	0.35	5.2e-9	Subjective well-being (multi-trait analysis);
CESC	cis	rs8180040	0.932	rs12490058	chr3:47529063	T/C	cg27129171	chr3:47204927	SETD2	0.62	9.22	0.49	9.43e-18	Colorectal cancer;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg23039201	chr2:27851887	GPN1;CCDC121	-0.44	-6.4	-0.37	7.04e-10	Fibrinogen levels;
CESC	cis	rs11214589	0.905	rs12804573	chr11:113241726	G/A	cg14159747	chr11:113255604	NA	0.32	5.6	0.33	5.38e-8	Neuroticism;
CESC	cis	rs7618915	0.501	rs3733041	chr3:52731598	T/C	cg18404041	chr3:52824283	ITIH1	-0.39	-6.69	-0.38	1.3e-10	Bipolar disorder;
CESC	cis	rs7927592	0.956	rs12271290	chr11:68326236	A/G	cg16797656	chr11:68205561	LRP5	-0.39	-5.47	-0.32	1.03e-7	Total body bone mineral density;
CESC	cis	rs8180040	0.676	rs11130114	chr3:47154651	T/G	cg27129171	chr3:47204927	SETD2	0.73	11.38	0.57	1.09e-24	Colorectal cancer;
CESC	cis	rs711245	0.573	rs11899523	chr2:36800918	T/C	cg09467607	chr2:36825704	FEZ2	0.6	10.46	0.54	1.12e-21	Height;
CESC	cis	rs7662987	0.517	rs2602883	chr4:100040914	A/T	cg12011299	chr4:100065546	ADH4	0.6	6.57	0.37	2.59e-10	Smoking initiation;
CESC	cis	rs7927771	0.698	rs34467936	chr11:47915299	A/G	cg05585544	chr11:47624801	NA	-0.46	-6.93	-0.39	3.23e-11	Subjective well-being;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg02396668	chr19:50528878	VRK3;ZNF473	0.53	7.13	0.4	9.34e-12	Systemic lupus erythematosus;
CESC	cis	rs6543140	0.964	rs6736135	chr2:103064924	A/G	cg04239558	chr2:103089729	SLC9A4	0.45	5.58	0.32	6.06e-8	Blood protein levels;
CESC	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg17541715	chr7:1216824	NA	-0.39	-5.29	-0.31	2.63e-7	Longevity;Endometriosis;
CESC	cis	rs950027	0.620	rs1145084	chr15:45675440	G/A	cg21132104	chr15:45694354	SPATA5L1	0.67	8.55	0.46	1.01e-15	Response to fenofibrate (adiponectin levels);
CESC	cis	rs12477438	0.798	rs13409996	chr2:99575497	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-10.4	-0.54	1.79e-21	Chronic sinus infection;
CESC	cis	rs9479482	1.000	rs5017316	chr6:150333489	A/T	cg25797454	chr6:150327115	RAET1K	0.27	5.23	0.31	3.43e-7	Alopecia areata;
CESC	cis	rs9902453	0.740	rs1382391	chr17:28111986	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-10.34	-0.54	2.82e-21	Coffee consumption (cups per day);
CESC	cis	rs6088580	0.524	rs6088552	chr20:33226491	A/G	cg08999081	chr20:33150536	PIGU	-0.46	-6.47	-0.37	4.84e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs12822507	0.831	rs34975957	chr12:12786190	G/A	cg11838227	chr12:12764436	CREBL2	-0.4	-5.19	-0.3	4.2e-7	Systemic lupus erythematosus;
CESC	cis	rs4927850	0.752	rs7624460	chr3:195748530	C/T	cg12923728	chr3:195709715	SDHAP1	-0.69	-9.25	-0.49	7.99e-18	Pancreatic cancer;
CESC	cis	rs2294693	0.947	rs742492	chr6:40996381	G/A	cg14769373	chr6:40998127	UNC5CL	-0.47	-6.58	-0.37	2.5e-10	Gastric cancer;Non-cardia gastric cancer;
CESC	cis	rs1707322	1.000	rs11211239	chr1:46451947	A/G	cg06784218	chr1:46089804	CCDC17	0.33	5.63	0.33	4.7e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs290268	0.838	rs1319677	chr9:93565999	A/G	cg02608019	chr9:93564028	SYK	0.66	10.19	0.53	8.52e-21	Platelet count;
CESC	trans	rs877282	1.000	rs11253361	chr10:770387	T/C	cg22713356	chr15:30763199	NA	1.11	11.26	0.57	2.79e-24	Uric acid levels;
CESC	cis	rs7107174	1.000	rs2511186	chr11:77984306	C/G	cg02023728	chr11:77925099	USP35	0.48	6.86	0.39	4.75e-11	Testicular germ cell tumor;
CESC	cis	rs6460942	0.778	rs74993124	chr7:12462917	A/G	cg20607287	chr7:12443886	VWDE	-0.76	-10.63	-0.55	3.23e-22	Coronary artery disease;
CESC	cis	rs2404602	0.692	rs1116535	chr15:77009514	C/G	cg26408565	chr15:76604113	ETFA	0.39	5.76	0.33	2.29e-8	Blood metabolite levels;
CESC	cis	rs909002	0.830	rs10914461	chr1:32113217	G/A	cg13919466	chr1:32135498	COL16A1	-0.47	-8.51	-0.46	1.28e-15	Intelligence (multi-trait analysis);
CESC	trans	rs1814175	0.541	rs12287397	chr11:49819799	G/A	cg15704280	chr7:45808275	SEPT13	-1.03	-20.12	-0.78	2.71e-55	Height;
CESC	cis	rs7678296	1.000	rs7669536	chr4:37185787	C/T	cg06805348	chr4:37245195	KIAA1239	0.45	5.18	0.3	4.45e-7	3-hydroxypropylmercapturic acid levels in smokers;
CESC	cis	rs1030877	0.515	rs17030766	chr2:105911905	G/A	cg02079111	chr2:105885981	TGFBRAP1	-0.43	-5.67	-0.33	3.67e-8	Obesity-related traits;
CESC	cis	rs66530629	0.917	rs4648879	chr1:25175246	A/G	cg22509179	chr1:25234806	RUNX3	-0.45	-5.83	-0.34	1.62e-8	Plateletcrit;
CESC	cis	rs7618501	1.000	rs7374183	chr3:49785133	G/A	cg24308560	chr3:49941425	MST1R	0.51	6.96	0.39	2.69e-11	Intelligence (multi-trait analysis);
CESC	cis	rs172166	0.694	rs1150666	chr6:28123928	T/C	cg12963246	chr6:28129442	ZNF389	0.43	6.11	0.35	3.59e-9	Cardiac Troponin-T levels;
CESC	cis	rs7824557	0.564	rs2736295	chr8:11234780	C/G	cg21775007	chr8:11205619	TDH	0.52	7.55	0.42	7.08e-13	Retinal vascular caliber;
CESC	cis	rs7429990	0.965	rs13074973	chr3:48028144	T/A	cg11946769	chr3:48343235	NME6	-0.44	-5.37	-0.31	1.75e-7	Educational attainment (years of education);
CESC	cis	rs721399	0.924	rs1115784	chr8:18255410	C/T	cg18736775	chr8:18248649	NAT2	0.38	5.03	0.3	9.22e-7	Blood metabolite levels;
CESC	cis	rs9487051	0.836	rs9487036	chr6:109607449	C/T	cg21918786	chr6:109611834	NA	-0.4	-6.01	-0.35	6.17e-9	Reticulocyte fraction of red cells;
CESC	cis	rs1707322	1.000	rs34694458	chr1:46332696	G/A	cg06784218	chr1:46089804	CCDC17	0.32	5.47	0.32	1.02e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs929596	0.785	rs6714634	chr2:234664765	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.62	7.73	0.43	2.22e-13	Total bilirubin levels in HIV-1 infection;
CESC	cis	rs36051895	0.664	rs7852755	chr9:5100862	C/T	cg02405213	chr9:5042618	JAK2	-0.52	-6.46	-0.37	5.04e-10	Pediatric autoimmune diseases;
CESC	cis	rs514406	0.929	rs11206035	chr1:53323571	T/C	cg16325326	chr1:53192061	ZYG11B	0.82	12.7	0.62	3.43e-29	Monocyte count;
CESC	cis	rs896854	0.624	rs9297949	chr8:95969445	A/C	cg16049864	chr8:95962084	TP53INP1	-0.64	-11.1	-0.56	9.32e-24	Type 2 diabetes;
CESC	cis	rs12681288	0.862	rs7814070	chr8:1020991	A/G	cg15309053	chr8:964076	NA	0.32	5.42	0.32	1.33e-7	Schizophrenia;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg06057208	chr16:30535933	ZNF768	0.46	6.69	0.38	1.3100000000000001e-10	Fibrinogen levels;
CESC	cis	rs1005277	0.522	rs11011343	chr10:38002698	A/G	cg25427524	chr10:38739819	LOC399744	-0.66	-9.74	-0.51	2.4e-19	Extrinsic epigenetic age acceleration;
CESC	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg03395511	chr6:291903	DUSP22	-0.72	-9.23	-0.49	9.24e-18	Menopause (age at onset);
CESC	cis	rs9858542	0.953	rs9862080	chr3:49674458	A/G	cg07274523	chr3:49395745	GPX1	0.68	8.72	0.47	3.23e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs7208859	0.623	rs9914499	chr17:29107588	G/A	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.17e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs2070488	0.965	rs9877282	chr3:38541452	A/G	cg24069376	chr3:38537580	EXOG	-0.48	-8.85	-0.48	1.31e-16	Electrocardiographic conduction measures;
CESC	cis	rs9322193	0.923	rs12195866	chr6:150014470	A/G	cg07701084	chr6:150067640	NUP43	0.43	5.83	0.34	1.62e-8	Lung cancer;
CESC	cis	rs9900062	0.546	rs2676294	chr17:62710764	A/G	cg02598441	chr17:62777298	LOC146880	0.5	5.28	0.31	2.63e-7	QT interval;
CESC	cis	rs2243480	1.000	rs56291018	chr7:65390339	G/A	cg25894440	chr7:65020034	NA	-0.62	-5.16	-0.3	4.73e-7	Diabetic kidney disease;
CESC	cis	rs6545883	0.894	rs778148	chr2:61606866	G/A	cg15711740	chr2:61764176	XPO1	0.42	5.39	0.31	1.57e-7	Tuberculosis;
CESC	cis	rs6088580	0.668	rs1205340	chr20:32923871	G/A	cg06115741	chr20:33292138	TP53INP2	-0.45	-5.67	-0.33	3.65e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs7520050	0.966	rs7539932	chr1:46292354	C/T	cg03146154	chr1:46216737	IPP	-0.48	-6.3	-0.36	1.25e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs7116495	0.609	rs60054591	chr11:71825687	G/A	cg07596299	chr11:71824057	C11orf51	0.79	5.03	0.3	9.06e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs5758659	0.657	rs5758587	chr22:42517636	C/G	cg15557168	chr22:42548783	NA	0.43	6.72	0.38	1.11e-10	Cognitive function;
CESC	cis	rs7615952	0.866	rs6438949	chr3:125650064	G/C	cg05084668	chr3:125655381	ALG1L	-0.54	-6.45	-0.37	5.41e-10	Blood pressure (smoking interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08498485	chr3:49711383	APEH	0.57	6.61	0.38	2.16e-10	Gut microbiome composition (summer);
CESC	cis	rs4819052	0.808	rs2838825	chr21:46655651	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.47	5.78	0.33	2.12e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs116095464	0.558	rs56127718	chr5:270273	G/T	cg22496380	chr5:211416	CCDC127	-0.75	-8.61	-0.47	6.58e-16	Breast cancer;
CESC	cis	rs847851	0.617	rs9394267	chr6:34960760	C/T	cg13137465	chr6:34857473	ANKS1A	-0.69	-7.19	-0.4	6.64e-12	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7144547	0.950	rs8004137	chr14:81884857	A/G	cg02996355	chr14:81879375	NA	-0.81	-9.23	-0.49	9e-18	Prudent dietary pattern;
CESC	cis	rs796364	0.951	rs769952	chr2:200734368	C/T	cg23649088	chr2:200775458	C2orf69	0.54	5.1	0.3	6.38e-7	Schizophrenia;
CESC	cis	rs9291683	0.609	rs12507050	chr4:10007305	G/T	cg00071950	chr4:10020882	SLC2A9	0.86	16.57	0.71	8.63e-43	Bone mineral density;
CESC	cis	rs6922893	1.000	rs7449748	chr6:71660328	C/T	cg10766373	chr6:71666121	B3GAT2	-0.34	-5.28	-0.31	2.7e-7	Obesity-related traits;
CESC	cis	rs8067545	0.611	rs2158472	chr17:20171524	C/T	cg13482628	chr17:19912719	NA	-0.42	-5.62	-0.33	4.93e-8	Schizophrenia;
CESC	cis	rs12681288	0.782	rs2123055	chr8:1029500	T/G	cg04851639	chr8:1020857	NA	-0.42	-8.74	-0.47	2.69e-16	Schizophrenia;
CESC	cis	rs412050	0.947	rs239915	chr22:22316631	G/A	cg17089214	chr22:22089827	YPEL1	0.65	6.03	0.35	5.37e-9	Attention deficit hyperactivity disorder;
CESC	cis	rs9300255	0.544	rs2049114	chr12:123657338	T/C	cg19016782	chr12:123741754	C12orf65	-0.43	-5.97	-0.34	7.66e-9	Neutrophil percentage of white cells;
CESC	cis	rs9790314	1.000	rs336590	chr3:161079583	G/A	cg04691961	chr3:161091175	C3orf57	-0.4	-5.04	-0.3	8.47e-7	Morning vs. evening chronotype;
CESC	cis	rs7264396	0.836	rs2010565	chr20:34182517	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.6	-7.1	-0.4	1.15e-11	Total cholesterol levels;
CESC	trans	rs35110281	0.782	rs2329442	chr21:45041790	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.53	6.9	0.39	3.75e-11	Mean corpuscular volume;
CESC	cis	rs8016982	0.698	rs8021385	chr14:81704682	G/A	cg01989461	chr14:81687754	GTF2A1	0.68	10.36	0.54	2.42e-21	Schizophrenia;
CESC	cis	rs7777484	0.534	rs2533890	chr7:2828743	C/T	cg18446336	chr7:2847575	GNA12	-0.4	-6.51	-0.37	3.66e-10	Height;
CESC	cis	rs9611565	0.765	rs132909	chr22:41802031	G/A	cg06481639	chr22:41940642	POLR3H	0.62	6.52	0.37	3.49e-10	Vitiligo;
CESC	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	7.73	0.43	2.29e-13	Prudent dietary pattern;
CESC	trans	rs7618501	1.000	rs695238	chr3:49869158	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.59	8.32	0.46	4.72e-15	Intelligence (multi-trait analysis);
CESC	cis	rs7520050	0.966	rs4660898	chr1:46402171	A/G	cg24296786	chr1:45957014	TESK2	0.43	5.39	0.31	1.59e-7	Red blood cell count;Reticulocyte count;
CESC	trans	rs11098499	0.954	rs11729521	chr4:120416788	T/C	cg25214090	chr10:38739885	LOC399744	0.72	10.09	0.53	1.85e-20	Corneal astigmatism;
CESC	cis	rs3733418	0.860	rs13124015	chr4:165930282	G/A	cg10852876	chr4:165953100	TRIM60	-0.5	-5.87	-0.34	1.29e-8	Obesity-related traits;
CESC	cis	rs6762477	0.748	rs11717349	chr3:50223977	C/T	cg24308560	chr3:49941425	MST1R	0.39	5.1	0.3	6.47e-7	Menarche (age at onset);
CESC	cis	rs2425143	1.000	rs6060588	chr20:34337480	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.82	-7.51	-0.42	9.19e-13	Blood protein levels;
CESC	cis	rs7872515	0.536	rs10820938	chr9:94841980	C/T	cg01248375	chr9:94877805	SPTLC1	0.65	5.25	0.31	3.15e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs3740713	1.000	rs73440614	chr11:18466700	C/G	cg23797887	chr11:18477753	LDHAL6A	-0.54	-5.24	-0.31	3.31e-7	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs28647808	1.000	rs13940	chr9:136271546	T/C	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.9	5.73	0.33	2.75e-8	Blood protein levels;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg06134410	chr7:1705349	NA	-0.42	-6.36	-0.36	8.81e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs7762018	0.891	rs12529402	chr6:170147675	A/T	cg13891659	chr6:170190454	C6orf122;C6orf208	0.67	6.53	0.37	3.28e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	trans	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg13565492	chr6:43139072	SRF	-0.76	-9.09	-0.49	2.43e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs826838	0.967	rs7970069	chr12:38810631	T/C	cg26384229	chr12:38710491	ALG10B	0.83	14.57	0.67	1.05e-35	Heart rate;
CESC	cis	rs10089	1.000	rs9968597	chr5:127455383	C/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.78	10.67	0.55	2.37e-22	Ileal carcinoids;
CESC	trans	rs7615952	0.641	rs6805074	chr3:125772274	T/A	cg07211511	chr3:129823064	LOC729375	-0.59	-6.53	-0.37	3.37e-10	Blood pressure (smoking interaction);
CESC	trans	rs7246760	0.867	rs8112764	chr19:9748907	G/A	cg02900749	chr2:68251473	NA	-0.85	-7.53	-0.42	8.04e-13	Pursuit maintenance gain;
CESC	cis	rs864537	0.676	rs1773560	chr1:167421763	A/G	cg22356347	chr1:167427500	CD247	-0.39	-8.13	-0.45	1.61e-14	Celiac disease or Rheumatoid arthritis;Celiac disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06521597	chr19:2783551	SGTA	0.58	6.52	0.37	3.47e-10	Gut microbiome composition (summer);
CESC	cis	rs9467711	0.516	rs1324087	chr6:25841408	A/G	cg08501292	chr6:25962987	TRIM38	-0.55	-5.79	-0.34	1.97e-8	Autism spectrum disorder or schizophrenia;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg01250699	chr8:22225185	SLC39A14	-0.51	-6.51	-0.37	3.75e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25772039	chr12:132329240	MMP17	-0.55	-6.38	-0.36	8.04e-10	Gut microbiome composition (summer);
CESC	cis	rs1974653	0.781	rs175162	chr22:20113253	A/C	cg12670310	chr22:20071307	DGCR8	-0.33	-5.04	-0.3	8.49e-7	Schizophrenia;
CESC	cis	rs7617773	0.539	rs12486944	chr3:48390016	G/A	cg11946769	chr3:48343235	NME6	0.62	7.86	0.43	9.99e-14	Coronary artery disease;
CESC	cis	rs3733585	0.699	rs28837683	chr4:9959808	C/T	cg11266682	chr4:10021025	SLC2A9	-0.6	-11.22	-0.57	3.77e-24	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs9322193	0.847	rs9383844	chr6:150037404	T/C	cg07701084	chr6:150067640	NUP43	0.47	6.77	0.38	8.49e-11	Lung cancer;
CESC	cis	rs2735413	0.918	rs12925605	chr16:78071715	G/A	cg04733911	chr16:78082701	NA	-0.54	-9.16	-0.49	1.47e-17	Systolic blood pressure (alcohol consumption interaction);
CESC	cis	rs9457247	0.544	rs6920858	chr6:167464630	G/A	cg07741184	chr6:167504864	NA	0.37	6.49	0.37	4.2e-10	Crohn's disease;
CESC	cis	rs3105593	1.000	rs57002197	chr15:50873760	C/T	cg08437265	chr15:50716283	USP8	0.42	5.33	0.31	2.09e-7	QT interval;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17322163	chr12:51632344	DAZAP2	0.61	6.86	0.39	4.87e-11	Gut microbiome composition (summer);
CESC	cis	rs2011503	1.000	rs8110250	chr19:19559989	G/A	cg11584989	chr19:19387371	SF4	0.62	7.22	0.41	5.51e-12	Bipolar disorder;
CESC	cis	rs1799949	0.864	rs60309406	chr17:41435665	C/T	cg23758822	chr17:41437982	NA	1.05	16.11	0.7	3.64e-41	Menopause (age at onset);
CESC	cis	rs2412819	0.597	rs78282429	chr15:43922003	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.51	6.46	0.37	4.98e-10	Lung cancer;
CESC	cis	rs2404602	0.583	rs2139190	chr15:76555539	G/C	cg22467129	chr15:76604101	ETFA	-0.39	-6.0	-0.35	6.37e-9	Blood metabolite levels;
CESC	cis	rs11122272	0.735	rs2739513	chr1:231515201	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.59	-8.04	-0.44	3.04e-14	Hemoglobin concentration;
CESC	cis	rs941873	0.772	rs1892498	chr10:81103862	A/G	cg11057378	chr10:81107060	PPIF	0.34	5.37	0.31	1.75e-7	Height;
CESC	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg11494091	chr17:61959527	GH2	0.73	12.52	0.61	1.45e-28	Prudent dietary pattern;
CESC	cis	rs863345	1.000	rs863352	chr1:158539006	A/G	cg12129480	chr1:158549410	OR10X1	-0.32	-6.38	-0.36	7.97e-10	Pneumococcal bacteremia;
CESC	cis	rs10504229	0.683	rs11786523	chr8:58131319	G/C	cg24829409	chr8:58192753	C8orf71	-0.58	-7.2	-0.4	6.31e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs73206853	0.764	rs73206868	chr12:110816835	G/T	cg12870014	chr12:110450643	ANKRD13A	0.63	5.23	0.31	3.48e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs2204008	0.658	rs12371956	chr12:38298010	A/T	cg26384229	chr12:38710491	ALG10B	0.7	10.34	0.54	2.92e-21	Bladder cancer;
CESC	cis	rs875971	0.545	rs11770063	chr7:65783016	G/A	cg18876405	chr7:65276391	NA	0.47	5.3	0.31	2.45e-7	Aortic root size;
CESC	cis	rs9467160	1.000	rs9461011	chr6:24440351	C/T	cg20631270	chr6:24437470	GPLD1	-0.46	-5.84	-0.34	1.56e-8	Liver enzyme levels;
CESC	cis	rs7296418	0.885	rs1716184	chr12:123637509	G/C	cg05973401	chr12:123451056	ABCB9	0.53	6.75	0.38	9.03e-11	Platelet count;
CESC	cis	rs2243480	1.000	rs13247184	chr7:65358928	A/G	cg13147721	chr7:65941812	NA	-0.9	-8.76	-0.47	2.35e-16	Diabetic kidney disease;
CESC	cis	rs4665809	0.590	rs1560865	chr2:26452197	C/A	cg08470875	chr2:26401718	FAM59B	-0.76	-8.06	-0.44	2.69e-14	Gut microbiome composition (summer);
CESC	cis	rs9457247	1.000	rs448060	chr6:167382622	A/G	cg07741184	chr6:167504864	NA	0.31	5.53	0.32	7.76e-8	Crohn's disease;
CESC	cis	rs763014	0.865	rs4006748	chr16:632225	T/C	cg07256732	chr16:621771	PIGQ	-0.3	-5.14	-0.3	5.22e-7	Height;
CESC	cis	rs10097731	0.901	rs28505206	chr8:82044410	A/G	cg25230327	chr8:82042993	NA	-0.56	-6.29	-0.36	1.32e-9	Serum total protein level;
CESC	cis	rs7666738	0.830	rs4401456	chr4:98959902	C/T	cg03467027	chr4:99064603	C4orf37	0.44	5.57	0.32	6.41e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs853679	0.517	rs9380061	chr6:28132803	T/C	cg12963246	chr6:28129442	ZNF389	0.56	7.38	0.41	1.99e-12	Depression;
CESC	cis	rs10089	0.904	rs2195921	chr5:127489754	A/C	cg19767477	chr5:127420684	SLC12A2	-0.39	-5.08	-0.3	7.15e-7	Ileal carcinoids;
CESC	cis	rs5167	0.504	rs3760629	chr19:45458146	A/C	cg13119609	chr19:45449297	APOC2	0.45	7.36	0.41	2.29e-12	Blood protein levels;
CESC	cis	rs7666738	0.830	rs11723283	chr4:99001617	C/T	cg17366294	chr4:99064904	C4orf37	0.6	8.61	0.47	6.47e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11871801	0.517	rs645692	chr17:40701073	C/T	cg16308533	chr17:40838983	CNTNAP1	0.4	5.21	0.3	3.85e-7	Crohn's disease;
CESC	trans	rs66573146	1.000	rs9942188	chr4:6984181	C/T	cg07817883	chr1:32538562	TMEM39B	1.36	8.97	0.48	5.47e-17	Granulocyte percentage of myeloid white cells;
CESC	cis	rs4722166	0.630	rs1581497	chr7:22779503	C/A	cg05265849	chr7:22767390	IL6	0.57	7.11	0.4	1.06e-11	Lung cancer;
CESC	cis	rs897984	0.806	rs11640534	chr16:30949515	G/A	cg00531865	chr16:30841666	NA	0.5	6.92	0.39	3.43e-11	Dementia with Lewy bodies;
CESC	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg21724239	chr8:58056113	NA	0.67	9.03	0.49	3.58e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs3741798	1.000	rs78807762	chr12:12484136	G/A	cg08615371	chr12:12503544	MANSC1	0.89	6.41	0.37	6.53e-10	Cerebrospinal fluid biomarker levels;
CESC	cis	rs9457247	1.000	rs364283	chr6:167383750	C/T	cg23791538	chr6:167370224	RNASET2	-0.6	-8.65	-0.47	5.12e-16	Crohn's disease;
CESC	cis	rs1552244	0.816	rs17050701	chr3:10041554	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.74	-9.37	-0.5	3.42e-18	Alzheimer's disease;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg02430089	chr12:100661568	SCYL2;DEPDC4	-0.49	-6.7	-0.38	1.28e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs644799	1.000	rs12786522	chr11:95522858	G/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.55	6.89	0.39	4e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs896854	0.654	rs1453377	chr8:95969947	C/T	cg16049864	chr8:95962084	TP53INP1	-0.65	-11.35	-0.57	1.35e-24	Type 2 diabetes;
CESC	trans	rs7188861	0.681	rs12927773	chr16:11403963	G/T	cg22142858	chr6:6004804	NRN1	-0.43	-6.17	-0.35	2.6e-9	HDL cholesterol;
CESC	cis	rs1799949	1.000	rs8176242	chr17:41217874	C/T	cg25072359	chr17:41440525	NA	0.48	6.44	0.37	5.69e-10	Menopause (age at onset);
CESC	cis	rs3020736	0.500	rs6002603	chr22:42492362	C/G	cg12850546	chr22:42539477	CYP2D7P1	0.44	5.23	0.31	3.44e-7	Autism spectrum disorder or schizophrenia;
CESC	trans	rs61931739	0.534	rs2625897	chr12:34064295	G/A	cg26384229	chr12:38710491	ALG10B	0.52	6.96	0.39	2.64e-11	Morning vs. evening chronotype;
CESC	cis	rs8020095	0.528	rs6573765	chr14:67756236	T/C	cg19548862	chr14:67692701	FAM71D	-0.49	-6.04	-0.35	5.3300000000000004e-09	Depression (quantitative trait);
CESC	cis	rs7904368	0.754	rs7076955	chr10:16852781	G/A	cg23933602	chr10:16859644	RSU1	0.74	7.29	0.41	3.68e-12	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
CESC	cis	rs896854	0.517	rs10112447	chr8:95955701	C/T	cg23172400	chr8:95962367	TP53INP1	-0.4	-7.31	-0.41	3.18e-12	Type 2 diabetes;
CESC	cis	rs1348850	0.914	rs10194648	chr2:178337031	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.83	11.66	0.58	1.27e-25	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs2576037	0.583	rs541634	chr18:44420271	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.78	13.0	0.62	3.18e-30	Personality dimensions;
CESC	cis	rs2180341	0.618	rs6683	chr6:127610021	G/A	cg24812749	chr6:127587940	RNF146	0.6	8.1	0.45	2.05e-14	Breast cancer;
CESC	trans	rs2018683	1.000	rs160837	chr7:29012732	C/G	cg19402173	chr7:128379420	CALU	-0.7	-9.52	-0.5	1.11e-18	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CESC	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg18765753	chr7:1198926	ZFAND2A	-0.47	-5.86	-0.34	1.34e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs60843830	1.000	rs7566279	chr2:281178	C/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.88	11.87	0.59	2.33e-26	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs7647973	0.677	rs11130211	chr3:49645209	C/T	cg06212747	chr3:49208901	KLHDC8B	0.68	8.05	0.44	2.84e-14	Menarche (age at onset);
CESC	cis	rs1018836	0.892	rs13267237	chr8:91550820	T/C	cg16814680	chr8:91681699	NA	-0.66	-9.41	-0.5	2.41e-18	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs7811142	0.943	rs66958101	chr7:100074020	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.0	9.6	0.51	6.43e-19	Platelet count;
CESC	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg17178900	chr1:205818956	PM20D1	0.91	16.02	0.7	7.38e-41	Menarche (age at onset);
CESC	cis	rs1005277	0.541	rs2263163	chr10:38389887	G/A	cg25427524	chr10:38739819	LOC399744	-0.64	-9.23	-0.49	8.69e-18	Extrinsic epigenetic age acceleration;
CESC	cis	rs1957429	0.614	rs73279823	chr14:65351315	A/G	cg23373153	chr14:65346875	NA	-0.92	-6.7	-0.38	1.21e-10	Pediatric areal bone mineral density (radius);
CESC	cis	rs6693567	0.545	rs6664703	chr1:150459087	G/C	cg09579323	chr1:150459698	TARS2	0.44	5.52	0.32	8.21e-8	Migraine;
CESC	trans	rs864643	0.773	rs11129837	chr3:39589963	A/G	cg05310071	chr17:16120569	PIGL	0.44	6.28	0.36	1.4e-9	Attention deficit hyperactivity disorder;
CESC	cis	rs710216	0.827	rs841850	chr1:43402054	T/C	cg03128534	chr1:43423976	SLC2A1	0.44	5.13	0.3	5.73e-7	Red cell distribution width;
CESC	cis	rs9911578	1.000	rs9902994	chr17:56948722	T/A	cg05425664	chr17:57184151	TRIM37	-0.5	-6.96	-0.39	2.6e-11	Intelligence (multi-trait analysis);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg17809632	chr2:27435717	SLC5A6;C2orf28	0.45	6.37	0.36	8.2e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25798026	chr22:32149910	DEPDC5	0.59	6.69	0.38	1.35e-10	Gut microbiome composition (summer);
CESC	cis	rs3760982	0.585	rs61013802	chr19:44292142	A/T	cg11993925	chr19:44307056	LYPD5	0.33	5.48	0.32	9.7e-8	Breast cancer (estrogen-receptor negative);Breast cancer;
CESC	cis	rs7811142	1.000	rs11763511	chr7:100081944	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.86	8.83	0.48	1.43e-16	Platelet count;
CESC	cis	rs3806843	0.966	rs11958868	chr5:140201420	T/C	cg16179182	chr5:140090404	VTRNA1-1	-0.4	-5.15	-0.3	4.97e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs2415984	0.562	rs34368760	chr14:46928532	T/A	cg14871534	chr14:47121158	RPL10L	0.39	5.73	0.33	2.76e-8	Number of children ever born;
CESC	cis	rs116095464	0.510	rs60844864	chr5:267000	A/G	cg12570787	chr5:219185	SDHA;CCDC127	0.51	5.29	0.31	2.58e-7	Breast cancer;
CESC	cis	rs2073300	0.609	rs6137945	chr20:23406136	C/T	cg12062639	chr20:23401060	NAPB	1.06	8.23	0.45	8.54e-15	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs35123781	0.696	rs356433	chr5:139071193	C/T	cg10513866	chr5:139070639	NA	0.43	6.09	0.35	3.88e-9	Schizophrenia;
CESC	cis	rs116095464	0.614	rs56299325	chr5:220594	C/T	cg12570787	chr5:219185	SDHA;CCDC127	0.53	5.74	0.33	2.63e-8	Breast cancer;
CESC	cis	rs41271473	0.526	rs72765760	chr1:228743222	G/A	cg10167378	chr1:228756711	NA	0.51	5.28	0.31	2.73e-7	Chronic lymphocytic leukemia;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg07905888	chr1:36023245	NCDN;KIAA0319L	-0.47	-6.04	-0.35	5.23e-9	Ulcerative colitis;
CESC	cis	rs561341	1.000	rs4795669	chr17:30244701	C/T	cg00745463	chr17:30367425	LRRC37B	-0.6	-5.81	-0.34	1.8e-8	Hip circumference adjusted for BMI;
CESC	cis	rs3733585	0.781	rs6449183	chr4:9970691	C/A	cg11266682	chr4:10021025	SLC2A9	-0.61	-12.17	-0.6	2.26e-27	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs7937682	0.889	rs1784787	chr11:111486125	T/A	cg22437258	chr11:111473054	SIK2	0.72	9.66	0.51	4.24e-19	Primary sclerosing cholangitis;
CESC	cis	rs7208859	0.673	rs216424	chr17:28943064	T/G	cg14008862	chr17:28927542	LRRC37B2	0.79	7.07	0.4	1.34e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs7089973	0.604	rs55759483	chr10:116573423	T/C	cg25233709	chr10:116636983	FAM160B1	0.36	5.86	0.34	1.39e-8	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs2294693	0.947	rs6924722	chr6:41002195	C/T	cg14769373	chr6:40998127	UNC5CL	0.4	5.79	0.34	1.99e-8	Gastric cancer;Non-cardia gastric cancer;
CESC	cis	rs2197308	0.692	rs1904964	chr12:37933241	T/A	cg13010199	chr12:38710504	ALG10B	0.5	6.45	0.37	5.2e-10	Morning vs. evening chronotype;
CESC	cis	rs9467711	0.539	rs34436535	chr6:26370365	G/C	cg12826209	chr6:26865740	GUSBL1	0.62	5.22	0.31	3.66e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs36093924	0.646	rs4822069	chr22:42351481	T/C	cg15557168	chr22:42548783	NA	0.37	5.39	0.31	1.58e-7	Intelligence;
CESC	cis	rs854765	0.964	rs854810	chr17:18006421	G/C	cg04398451	chr17:18023971	MYO15A	0.67	9.35	0.5	3.75e-18	Total body bone mineral density;
CESC	cis	rs2637266	1.000	rs755824	chr10:78381348	A/G	cg18941641	chr10:78392320	NA	0.43	8.31	0.45	4.85e-15	Pulmonary function;
CESC	cis	rs9649213	0.593	rs62478177	chr7:97964611	G/A	cg08684580	chr7:98029266	BAIAP2L1	-0.35	-5.77	-0.33	2.2e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs863345	0.967	rs7512117	chr1:158532064	C/T	cg12129480	chr1:158549410	OR10X1	-0.33	-6.65	-0.38	1.62e-10	Pneumococcal bacteremia;
CESC	cis	rs77861329	0.920	rs9860982	chr3:52096432	T/C	cg08692210	chr3:52188851	WDR51A	0.8	7.04	0.4	1.61e-11	Macrophage inflammatory protein 1b levels;
CESC	cis	rs807669	0.802	rs762528	chr22:19166680	A/G	cg02655711	chr22:19163373	SLC25A1	0.99	14.8	0.67	1.54e-36	Metabolite levels;
CESC	cis	rs1401999	1.000	rs6805913	chr3:183662924	T/G	cg01324343	chr3:183735012	ABCC5	0.63	13.49	0.64	6.42e-32	Anterior chamber depth;
CESC	cis	rs875971	0.767	rs61348003	chr7:66005934	C/T	cg10691866	chr7:65817282	TPST1	-0.33	-5.39	-0.31	1.58e-7	Aortic root size;
CESC	cis	rs4243830	0.850	rs7536908	chr1:6607814	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.78	-7.77	-0.43	1.78e-13	Body mass index;
CESC	cis	rs910316	0.967	rs175498	chr14:75536369	G/A	cg08847533	chr14:75593920	NEK9	-0.96	-17.69	-0.74	8.96e-47	Height;
CESC	cis	rs798554	0.836	rs798500	chr7:2790685	C/T	cg19346786	chr7:2764209	NA	0.49	7.12	0.4	9.94e-12	Height;
CESC	cis	rs1799949	0.683	rs55737636	chr17:41264739	C/T	cg25072359	chr17:41440525	NA	0.49	7.15	0.4	8.55e-12	Menopause (age at onset);
CESC	cis	rs5753618	0.561	rs4141404	chr22:31675185	A/C	cg00478049	chr22:31556069	RNF185	0.46	5.21	0.3	3.75e-7	Colorectal cancer;
CESC	cis	rs4853012	0.838	rs59570457	chr2:74344282	T/C	cg05890377	chr2:74357713	NA	0.77	10.5	0.54	8.77e-22	Gestational age at birth (maternal effect);
CESC	cis	rs8067545	0.611	rs1373146	chr17:20206675	G/A	cg13482628	chr17:19912719	NA	-0.42	-5.61	-0.33	5.2e-8	Schizophrenia;
CESC	cis	rs4481887	0.708	rs6696691	chr1:248539720	T/C	cg26353448	chr1:248524236	OR2T4	-0.37	-5.27	-0.31	2.78e-7	Common traits (Other);
CESC	cis	rs6893300	0.961	rs62406219	chr5:179211629	G/A	cg14593053	chr5:179126677	CANX	-0.53	-5.94	-0.34	9.17e-9	Resting heart rate;
CESC	cis	rs1538970	0.748	rs11211137	chr1:46013892	T/A	cg06784218	chr1:46089804	CCDC17	0.41	6.36	0.36	8.76e-10	Platelet count;
CESC	cis	rs4713118	0.662	rs149947	chr6:27972433	A/T	cg23161317	chr6:28129485	ZNF389	0.51	6.53	0.37	3.27e-10	Parkinson's disease;
CESC	cis	rs875971	0.660	rs801192	chr7:66031952	C/G	cg25985355	chr7:65971099	NA	0.33	5.52	0.32	7.94e-8	Aortic root size;
CESC	cis	rs992157	0.697	rs13384682	chr2:219069137	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.68	9.56	0.51	8.5e-19	Colorectal cancer;
CESC	cis	rs2289583	0.517	rs2004278	chr15:75264363	C/T	cg14664628	chr15:75095509	CSK	0.52	6.07	0.35	4.51e-9	Systemic lupus erythematosus;
CESC	cis	rs2011503	0.882	rs10423874	chr19:19359500	C/G	cg11584989	chr19:19387371	SF4	0.54	6.53	0.37	3.31e-10	Bipolar disorder;
CESC	cis	rs1218582	0.772	rs7528532	chr1:154874440	C/T	cg16680214	chr1:154839983	KCNN3	-0.44	-6.76	-0.38	8.73e-11	Prostate cancer;
CESC	cis	rs561341	0.609	rs4795659	chr17:30187139	C/G	cg13647721	chr17:30228624	UTP6	-0.74	-8.56	-0.47	9.61e-16	Hip circumference adjusted for BMI;
CESC	cis	rs11864453	0.647	rs10492814	chr16:72126514	G/A	cg16558253	chr16:72132732	DHX38	-0.55	-8.54	-0.46	1.08e-15	Fibrinogen levels;
CESC	cis	rs4474465	0.850	rs10899539	chr11:78243743	T/C	cg27205649	chr11:78285834	NARS2	0.43	5.41	0.32	1.41e-7	Alzheimer's disease (survival time);
CESC	cis	rs1451375	0.617	rs10267323	chr7:50591424	A/G	cg14593290	chr7:50529359	DDC	0.49	5.9	0.34	1.12e-8	Malaria;
CESC	cis	rs6540556	0.723	rs12090931	chr1:209889601	A/G	cg05527609	chr1:210001259	C1orf107	-0.67	-7.36	-0.41	2.32e-12	Red blood cell count;
CESC	trans	rs2207136	0.835	rs11970011	chr6:50845787	T/C	cg06522515	chr3:184090630	THPO	-0.37	-6.48	-0.37	4.51e-10	Myopia;
CESC	cis	rs11723261	0.546	rs4315728	chr4:141021	T/C	cg12746427	chr4:53362	ZNF718;ZNF595	0.43	5.11	0.3	6.24e-7	Immune response to smallpox vaccine (IL-6);
CESC	cis	rs2790457	0.958	rs2807754	chr10:28887192	C/T	cg04045419	chr10:28823091	WAC	-0.43	-5.2	-0.3	4.07e-7	Multiple myeloma;
CESC	cis	rs3105593	1.000	rs12438305	chr15:50912454	G/C	cg08437265	chr15:50716283	USP8	0.41	5.34	0.31	2.05e-7	QT interval;
CESC	cis	rs6088580	0.634	rs6141471	chr20:33006730	A/G	cg06115741	chr20:33292138	TP53INP2	-0.47	-6.03	-0.35	5.36e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs5758659	0.652	rs133347	chr22:42423645	A/T	cg05082376	chr22:42548792	NA	-0.38	-5.65	-0.33	4.06e-8	Cognitive function;
CESC	cis	rs1538970	0.961	rs884962	chr1:45847981	G/A	cg06784218	chr1:46089804	CCDC17	0.34	5.76	0.33	2.3e-8	Platelet count;
CESC	cis	rs1322639	0.614	rs9364356	chr6:169567108	G/A	cg03254818	chr6:169586852	NA	0.54	5.55	0.32	6.83e-8	Pulse pressure;
CESC	cis	rs10254118	0.757	rs13241123	chr7:133135507	A/T	cg10665199	chr7:133106180	EXOC4	0.58	7.77	0.43	1.68e-13	Intelligence (multi-trait analysis);
CESC	cis	rs9858542	0.953	rs9811982	chr3:49624377	A/C	cg07274523	chr3:49395745	GPX1	0.64	8.15	0.45	1.42e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs7666738	0.830	rs34313689	chr4:99013689	T/C	cg17366294	chr4:99064904	C4orf37	0.59	8.44	0.46	2.17e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6089829	0.962	rs6122347	chr20:61661866	C/T	cg08564027	chr20:61660810	NA	0.9	15.42	0.69	9.97e-39	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs4888262	0.526	rs4887777	chr16:74637821	A/G	cg01733217	chr16:74700730	RFWD3	0.86	11.9	0.59	1.96e-26	Testicular germ cell tumor;
CESC	cis	rs1008375	0.898	rs9998130	chr4:17593905	A/G	cg27347728	chr4:17578864	LAP3	0.49	5.54	0.32	7.34e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs9584850	0.834	rs3803253	chr13:99117149	G/A	cg22223119	chr13:99095684	FARP1	-0.36	-5.11	-0.3	6.19e-7	Neuroticism;
CESC	cis	rs2576037	0.583	rs8096263	chr18:44515216	C/T	cg19077165	chr18:44547161	KATNAL2	-0.6	-9.17	-0.49	1.4e-17	Personality dimensions;
CESC	cis	rs2242116	0.796	rs2290546	chr3:46965197	C/G	cg27129171	chr3:47204927	SETD2	0.53	6.75	0.38	9.29e-11	Birth weight;
CESC	cis	rs6087990	0.899	rs1003521	chr20:31366598	T/C	cg13636640	chr20:31349939	DNMT3B	0.9	15.74	0.7	7.54e-40	Ulcerative colitis;
CESC	cis	rs7178572	0.568	rs4886862	chr15:77652368	T/C	cg22256960	chr15:77711686	NA	-0.52	-6.55	-0.37	3.02e-10	Type 2 diabetes;
CESC	cis	rs2980439	0.525	rs2945238	chr8:8170136	A/C	cg06636001	chr8:8085503	FLJ10661	0.52	6.45	0.37	5.27e-10	Neuroticism;
CESC	cis	rs1953600	0.645	rs7071579	chr10:81910278	A/G	cg04850286	chr10:81895943	PLAC9	0.3	5.2	0.3	3.98e-7	Sarcoidosis;
CESC	trans	rs459571	1.000	rs2810489	chr9:136922700	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.66	-8.63	-0.47	5.61e-16	Platelet distribution width;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg20354231	chr13:53171401	NA	0.4	6.22	0.36	1.89e-9	Gambling;
CESC	cis	rs1881797	1.000	rs12063141	chr1:247688343	G/A	cg18198730	chr1:247681584	NA	0.62	7.73	0.43	2.22e-13	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs7084402	0.967	rs1658439	chr10:60325986	A/G	cg07615347	chr10:60278583	BICC1	0.61	9.55	0.51	8.96e-19	Refractive error;
CESC	cis	rs4803468	0.967	rs4803461	chr19:41908871	G/A	cg14132834	chr19:41945861	ATP5SL	-0.56	-7.01	-0.4	2.03e-11	Height;
CESC	cis	rs28647808	1.000	rs4962143	chr9:136275137	G/A	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.9	5.73	0.33	2.75e-8	Blood protein levels;
CESC	cis	rs4889855	0.556	rs4890043	chr17:78526831	C/T	cg16591659	chr17:78472290	NA	0.35	5.82	0.34	1.71e-8	Fractional excretion of uric acid;
CESC	cis	rs477692	0.870	rs532248	chr10:131414156	T/A	cg05714579	chr10:131428358	MGMT	0.5	7.01	0.4	2.02e-11	Response to temozolomide;
CESC	cis	rs6575793	0.553	rs7140556	chr14:101036458	G/T	cg18516195	chr14:101012996	BEGAIN	0.42	5.25	0.31	3.05e-7	Menarche (age at onset);
CESC	cis	rs1506636	0.962	rs2456551	chr7:123394610	C/G	cg03229431	chr7:123269106	ASB15	0.52	6.99	0.39	2.25e-11	Plateletcrit;Platelet count;
CESC	trans	rs1814175	0.765	rs1794141	chr11:49914135	G/C	cg03929089	chr4:120376271	NA	-0.93	-16.26	-0.71	1.03e-41	Height;
CESC	cis	rs2249625	0.545	rs2463743	chr6:72874741	C/T	cg18830697	chr6:72922368	RIMS1	-0.48	-7.16	-0.4	7.86e-12	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CESC	cis	rs7017914	0.934	rs17689585	chr8:71818801	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.45	-5.78	-0.33	2.1e-8	Bone mineral density;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00597555	chr15:90177036	KIF7	-0.6	-6.52	-0.37	3.64e-10	Gut microbiome composition (summer);
CESC	cis	rs9611565	0.729	rs203320	chr22:41913477	T/C	cg06634786	chr22:41940651	POLR3H	-0.45	-5.21	-0.3	3.76e-7	Vitiligo;
CESC	cis	rs9916302	0.861	rs2338801	chr17:37490780	G/T	cg15445000	chr17:37608096	MED1	-0.39	-6.45	-0.37	5.31e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs10899021	0.915	rs11236198	chr11:74372200	G/T	cg25880958	chr11:74394337	NA	-0.73	-7.26	-0.41	4.38e-12	Response to metformin (IC50);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg15450734	chr14:103541957	NA	-0.51	-7.46	-0.42	1.26e-12	Gambling;
CESC	cis	rs4906332	0.901	rs4900575	chr14:103899169	G/C	cg09975044	chr14:104007538	NA	0.47	6.4	0.37	6.89e-10	Coronary artery disease;
CESC	cis	rs7811142	0.830	rs11769057	chr7:99964661	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.07	11.24	0.57	3.07e-24	Platelet count;
CESC	cis	rs10771431	0.935	rs1988852	chr12:9372862	G/A	cg08997352	chr12:9597637	DDX12	-0.67	-8.9	-0.48	9.17e-17	Breast size;
CESC	cis	rs1577917	0.538	rs7755996	chr6:86423720	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.35	5.25	0.31	3.19e-7	Response to antipsychotic treatment;
CESC	cis	rs7216064	1.000	rs1976053	chr17:65833002	C/G	cg12091567	chr17:66097778	LOC651250	-0.81	-9.7	-0.51	3.18e-19	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs722599	0.748	rs17093914	chr14:75363641	A/G	cg11812906	chr14:75593930	NEK9	0.48	5.79	0.33	2.02e-8	IgG glycosylation;
CESC	cis	rs7618915	0.501	rs7624716	chr3:52751534	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.53	7.89	0.44	7.99e-14	Bipolar disorder;
CESC	cis	rs7829975	0.774	rs1039915	chr8:8679614	T/C	cg06636001	chr8:8085503	FLJ10661	0.46	5.98	0.34	7.1e-9	Mood instability;
CESC	cis	rs9487051	0.872	rs9386793	chr6:109610002	C/A	cg01475377	chr6:109611718	NA	-0.51	-8.36	-0.46	3.66e-15	Reticulocyte fraction of red cells;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg03399598	chr4:174091002	GALNT7	-0.46	-6.89	-0.39	4.15e-11	Gambling;
CESC	cis	rs7249142	0.549	rs3787040	chr19:19297292	A/G	cg27384695	chr19:19271486	LOC729991-MEF2B;MEF2B	0.3	5.37	0.31	1.75e-7	IgG glycosylation;
CESC	cis	rs7618501	0.521	rs11130222	chr3:49901060	A/T	cg24308560	chr3:49941425	MST1R	-0.64	-8.99	-0.48	4.68e-17	Intelligence (multi-trait analysis);
CESC	cis	rs7208859	0.623	rs57486336	chr17:29085731	G/T	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.91e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs9581857	0.685	rs9319370	chr13:28042493	G/T	cg01674679	chr13:27998804	GTF3A	-0.69	-5.52	-0.32	8.1e-8	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
CESC	cis	rs7100689	0.646	rs7081889	chr10:82165427	C/A	cg00277334	chr10:82204260	NA	-0.46	-6.25	-0.36	1.67e-9	Post bronchodilator FEV1;
CESC	cis	rs7586673	1.000	rs7586673	chr2:161923520	C/A	cg08807892	chr2:162101083	NA	0.46	6.24	0.36	1.68e-9	Intelligence (multi-trait analysis);
CESC	cis	rs13108904	0.557	rs1680030	chr4:1245500	A/T	cg19318889	chr4:1322082	MAEA	-0.5	-6.46	-0.37	5.05e-10	Obesity-related traits;
CESC	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg04025307	chr7:1156635	C7orf50	0.47	6.51	0.37	3.75e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs9612	1.000	rs28446957	chr19:44246600	T/A	cg08581076	chr19:44259116	C19orf61	0.58	6.62	0.38	1.95e-10	Exhaled nitric oxide output;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg17502267	chr15:59981239	BNIP2	-0.56	-7.35	-0.41	2.5e-12	Gut microbiota (bacterial taxa);
CESC	cis	rs7208859	0.623	rs73271842	chr17:29137155	T/C	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.1e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs12476592	0.602	rs262479	chr2:63872479	C/T	cg17519650	chr2:63277830	OTX1	-0.44	-5.05	-0.3	8.32e-7	Childhood ear infection;
CESC	cis	rs6493487	0.512	rs28430533	chr15:51256012	T/C	cg02338191	chr15:51200825	AP4E1	0.63	5.84	0.34	1.49e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs1552244	1.000	rs112847840	chr3:10101652	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.8	-10.46	-0.54	1.15e-21	Alzheimer's disease;
CESC	cis	rs2836974	0.897	rs13047678	chr21:40708853	C/T	cg17971929	chr21:40555470	PSMG1	0.9	11.81	0.59	3.7e-26	Cognitive function;
CESC	cis	rs854765	0.583	rs7214002	chr17:17852104	G/C	cg16928487	chr17:17741425	SREBF1	-0.52	-8.66	-0.47	4.86e-16	Total body bone mineral density;
CESC	cis	rs1005277	0.529	rs1780125	chr10:38531376	A/G	cg25427524	chr10:38739819	LOC399744	-0.72	-10.76	-0.55	1.2e-22	Extrinsic epigenetic age acceleration;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20972342	chr5:235327	SDHA	-0.59	-7.09	-0.4	1.21e-11	Gut microbiome composition (summer);
CESC	cis	rs12618769	0.597	rs17032120	chr2:99082938	A/G	cg10123293	chr2:99228465	UNC50	-0.39	-5.17	-0.3	4.71e-7	Bipolar disorder;
CESC	cis	rs4975616	0.836	rs13178866	chr5:1323212	C/T	cg06550200	chr5:1325588	CLPTM1L	-0.71	-11.17	-0.57	5.29e-24	Lung cancer;
CESC	cis	rs7927771	0.832	rs10838698	chr11:47385923	G/A	cg18512352	chr11:47633146	NA	0.53	7.51	0.42	8.89e-13	Subjective well-being;
CESC	cis	rs6991838	0.584	rs10957361	chr8:66531861	C/G	cg13398993	chr8:66546079	ARMC1	0.46	5.65	0.33	4.19e-8	Intelligence (multi-trait analysis);
CESC	cis	rs2191566	1.000	rs7256908	chr19:44528898	C/T	cg20607764	chr19:44506953	ZNF230	-0.63	-8.19	-0.45	1.15e-14	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs2119480	0.559	rs381835	chr13:111300957	A/T	cg16216153	chr13:111290848	CARKD	-0.36	-5.46	-0.32	1.1e-7	Diastolic blood pressure;
CESC	cis	rs2404602	0.692	rs58889902	chr15:77173070	A/C	cg26408565	chr15:76604113	ETFA	-0.39	-5.68	-0.33	3.6e-8	Blood metabolite levels;
CESC	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg10150615	chr22:24372951	LOC391322	-0.58	-8.04	-0.44	2.96e-14	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs7264396	0.563	rs2425131	chr20:34337074	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.63	6.74	0.38	9.75e-11	Total cholesterol levels;
CESC	cis	rs3096299	0.685	rs4238830	chr16:89540241	C/T	cg00750074	chr16:89608354	SPG7	-0.44	-6.36	-0.36	8.85e-10	Multiple myeloma (IgH translocation);
CESC	cis	rs832540	0.695	rs702686	chr5:56201350	A/G	cg22800045	chr5:56110881	MAP3K1	0.59	7.6	0.42	5.08e-13	Coronary artery disease;
CESC	cis	rs9911578	1.000	rs9901114	chr17:56575208	G/A	cg05425664	chr17:57184151	TRIM37	0.48	6.63	0.38	1.92e-10	Intelligence (multi-trait analysis);
CESC	cis	rs916888	0.821	rs199507	chr17:44858855	A/G	cg15921436	chr17:44337874	NA	-0.7	-7.95	-0.44	5.35e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs897080	0.516	rs1067361	chr2:44661217	G/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	5.76	0.33	2.3e-8	Height;
CESC	cis	rs7071206	0.853	rs66786803	chr10:79429941	A/G	cg23888215	chr10:79422304	NA	-0.53	-5.96	-0.34	8.03e-9	Bone mineral density;
CESC	cis	rs8177253	0.829	rs9882812	chr3:133506127	A/G	cg24879335	chr3:133465180	TF	0.33	5.33	0.31	2.07e-7	Iron status biomarkers;
CESC	cis	rs861020	0.630	rs628300	chr1:209998298	C/T	cg05527609	chr1:210001259	C1orf107	0.84	11.26	0.57	2.8e-24	Orofacial clefts;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20853569	chr17:79247697	SLC38A10	-0.56	-6.06	-0.35	4.58e-9	Gut microbiome composition (summer);
CESC	cis	rs6741892	0.536	rs13024840	chr2:38895920	T/A	cg05275752	chr2:38892887	GALM	-0.49	-6.77	-0.38	8.5e-11	5-HTT brain serotonin transporter levels;
CESC	cis	rs6541297	0.703	rs638116	chr1:230310740	C/T	cg20703242	chr1:230279135	GALNT2	-0.43	-5.56	-0.32	6.46e-8	Coronary artery disease;
CESC	trans	rs2085496	0.764	rs1596751	chr2:193807860	A/G	cg07414097	chr2:232646663	PDE6D	0.47	6.09	0.35	4.06e-9	Neuroticism;
CESC	cis	rs6964587	1.000	rs1859114	chr7:91682848	T/C	cg17063962	chr7:91808500	NA	0.58	8.03	0.44	3.17e-14	Breast cancer;
CESC	cis	rs1707322	1.000	rs1768817	chr1:46514534	C/G	cg06784218	chr1:46089804	CCDC17	-0.33	-5.65	-0.33	4.08e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs889312	0.500	rs832552	chr5:56113850	A/C	cg14703610	chr5:56206110	C5orf35	-0.45	-6.34	-0.36	1.01e-9	Breast cancer;Breast cancer (early onset);
CESC	cis	rs10504229	0.679	rs72649109	chr8:58031274	A/T	cg21724239	chr8:58056113	NA	0.56	5.04	0.3	8.84e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs644799	0.965	rs545342	chr11:95545369	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.53	6.41	0.37	6.77e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs71403859	0.502	rs7195767	chr16:71464943	A/G	cg08717414	chr16:71523259	ZNF19	-0.86	-8.58	-0.47	7.96e-16	Post bronchodilator FEV1;
CESC	cis	rs10504073	0.647	rs6997703	chr8:49998364	T/C	cg00325661	chr8:49890786	NA	0.58	8.52	0.46	1.19e-15	Blood metabolite ratios;
CESC	cis	rs1799949	1.000	rs8176077	chr17:41276348	T/C	cg05368731	chr17:41323189	NBR1	0.8	11.32	0.57	1.66e-24	Menopause (age at onset);
CESC	trans	rs3780486	0.846	rs7865745	chr9:33140976	A/G	cg04842962	chr6:43655489	MRPS18A	-1.0	-19.5	-0.77	3.8e-53	IgG glycosylation;
CESC	cis	rs3008870	1.000	rs2985811	chr1:67377722	G/T	cg08660285	chr1:67390436	MIER1;WDR78	1.05	14.57	0.67	9.8e-36	Lymphocyte percentage of white cells;
CESC	cis	rs7917772	0.536	rs11191361	chr10:104411958	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.58	7.1	0.4	1.16e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs9916302	0.851	rs12947620	chr17:37605364	T/C	cg20243544	chr17:37824526	PNMT	0.51	6.5	0.37	3.97e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs208515	0.525	rs12215007	chr6:66671008	C/T	cg07460842	chr6:66804631	NA	-0.87	-11.02	-0.56	1.7e-23	Exhaled nitric oxide levels;
CESC	cis	rs35306767	0.904	rs35667562	chr10:950630	G/A	cg10556349	chr10:835070	NA	0.72	6.05	0.35	4.94e-9	Eosinophil percentage of granulocytes;
CESC	cis	rs8014204	0.604	rs11159109	chr14:75389074	G/A	cg11812906	chr14:75593930	NEK9	0.54	6.68	0.38	1.44e-10	Caffeine consumption;
CESC	cis	rs6964587	1.000	rs7806184	chr7:91601978	A/G	cg17063962	chr7:91808500	NA	0.57	7.82	0.43	1.22e-13	Breast cancer;
CESC	cis	rs7412746	0.611	rs4509581	chr1:150774465	A/G	cg04414720	chr1:150670196	GOLPH3L	0.57	7.44	0.42	1.43e-12	Melanoma;
CESC	cis	rs4853012	0.793	rs6707619	chr2:74344656	G/A	cg05890377	chr2:74357713	NA	0.76	10.21	0.53	7.42e-21	Gestational age at birth (maternal effect);
CESC	cis	rs2717559	0.542	rs2717590	chr8:143900712	A/G	cg17252645	chr8:143867129	LY6D	-0.32	-5.23	-0.31	3.44e-7	Urinary tract infection frequency;
CESC	cis	rs8062405	0.755	rs12445823	chr16:28588049	A/C	cg07382826	chr16:28625726	SULT1A1	0.4	6.52	0.37	3.49e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	trans	rs72681920	0.881	rs12504321	chr4:100202705	G/T	cg22948791	chr15:71404101	CT62	-0.54	-6.14	-0.35	2.96e-9	Alcohol dependence;
CESC	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg18402987	chr7:1209562	NA	0.72	7.1	0.4	1.15e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs4727027	0.901	rs7794500	chr7:148819519	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	-0.43	-5.41	-0.32	1.39e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs13256369	0.901	rs12681327	chr8:8566414	G/T	cg17143192	chr8:8559678	CLDN23	0.71	8.17	0.45	1.27e-14	Obesity-related traits;
CESC	cis	rs7845219	0.597	rs7002058	chr8:95873993	G/C	cg23172400	chr8:95962367	TP53INP1	-0.33	-6.07	-0.35	4.39e-9	Type 2 diabetes;
CESC	cis	rs875971	0.508	rs6947808	chr7:66045082	A/G	cg18252515	chr7:66147081	NA	0.39	5.18	0.3	4.4e-7	Aortic root size;
CESC	cis	rs4662945	0.603	rs2406981	chr2:130305487	A/G	cg05903289	chr2:130345205	NA	-0.43	-6.39	-0.37	7.5e-10	Response to cytidine analogues (gemcitabine);
CESC	cis	rs71403859	0.570	rs77809998	chr16:71430687	C/T	cg08717414	chr16:71523259	ZNF19	-1.1	-8.98	-0.48	5.21e-17	Post bronchodilator FEV1;
CESC	cis	rs9902453	0.542	rs3809789	chr17:27955761	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.51	6.4	0.37	6.97e-10	Coffee consumption (cups per day);
CESC	cis	rs589448	0.867	rs623853	chr12:69753830	G/A	cg20891283	chr12:69753455	YEATS4	1.0	17.27	0.73	2.72e-45	Cerebrospinal fluid biomarker levels;
CESC	cis	rs10504229	0.683	rs16921843	chr8:58113338	T/C	cg02725872	chr8:58115012	NA	-0.45	-7.04	-0.4	1.66e-11	Developmental language disorder (linguistic errors);
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg17608500	chr1:154955711	FLAD1	0.46	6.25	0.36	1.67e-9	Systemic lupus erythematosus;
CESC	cis	rs11711311	1.000	rs62268168	chr3:113489447	A/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.71	10.02	0.52	3.12e-20	IgG glycosylation;
CESC	cis	rs78456975	1.000	rs13416881	chr2:1554808	G/A	cg26248373	chr2:1572462	NA	-0.58	-5.22	-0.31	3.68e-7	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs2404602	0.647	rs2404604	chr15:76991105	A/G	cg23625390	chr15:77176239	SCAPER	-0.4	-5.21	-0.3	3.85e-7	Blood metabolite levels;
CESC	cis	rs2072499	0.833	rs2842870	chr1:156200671	T/C	cg25208724	chr1:156163844	SLC25A44	0.84	13.54	0.64	4.32e-32	Testicular germ cell tumor;
CESC	cis	rs12042052	0.590	rs16858252	chr1:232949224	A/C	cg06935979	chr1:232941706	KIAA1383	0.71	5.9	0.34	1.09e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CESC	cis	rs7618915	0.547	rs6976	chr3:52728804	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	6.47	0.37	4.75e-10	Bipolar disorder;
CESC	cis	rs2836974	0.897	rs2836944	chr21:40593539	G/A	cg11644478	chr21:40555479	PSMG1	1.05	17.05	0.72	1.61e-44	Cognitive function;
CESC	cis	rs34172651	0.917	rs11074654	chr16:24813743	A/G	cg06028605	chr16:24865363	SLC5A11	0.34	5.32	0.31	2.24e-7	Intelligence (multi-trait analysis);
CESC	cis	rs34779708	0.966	rs12257770	chr10:35517234	A/G	cg04310649	chr10:35416472	CREM	-0.51	-6.11	-0.35	3.6e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs4664308	0.870	rs2198918	chr2:161015052	C/T	cg03641300	chr2:160917029	PLA2R1	-0.62	-9.13	-0.49	1.82e-17	Idiopathic membranous nephropathy;
CESC	cis	rs7829975	0.774	rs13259216	chr8:8673601	A/C	cg17143192	chr8:8559678	CLDN23	0.42	5.18	0.3	4.5e-7	Mood instability;
CESC	cis	rs9611565	0.649	rs79009	chr22:41860864	C/A	cg17376030	chr22:41985996	PMM1	-0.75	-8.08	-0.44	2.34e-14	Vitiligo;
CESC	cis	rs1712517	0.525	rs2271751	chr10:105175131	A/G	cg04362960	chr10:104952993	NT5C2	-0.46	-5.53	-0.32	7.83e-8	Migraine;
CESC	cis	rs4332037	0.624	rs56256289	chr7:1892529	C/T	cg23422044	chr7:1970798	MAD1L1	-0.49	-5.36	-0.31	1.82e-7	Bipolar disorder;
CESC	cis	rs7845219	0.544	rs9643351	chr8:95917290	C/T	cg23172400	chr8:95962367	TP53INP1	-0.38	-6.92	-0.39	3.35e-11	Type 2 diabetes;
CESC	cis	rs11630290	0.736	rs7174738	chr15:64144813	A/T	cg12036633	chr15:63758958	NA	-0.57	-6.1	-0.35	3.65e-9	Iris characteristics;
CESC	cis	rs9467711	0.659	rs66941101	chr6:26530376	C/T	cg14345882	chr6:26364793	BTN3A2	0.61	5.24	0.31	3.27e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs12136530	0.509	rs2268812	chr1:19666928	A/G	cg01832549	chr1:19774989	CAPZB	-0.39	-5.34	-0.31	2.05e-7	Lead levels in blood;
CESC	cis	rs250677	0.522	rs6872172	chr5:148359529	G/C	cg18129178	chr5:148520854	ABLIM3	0.47	5.16	0.3	4.93e-7	Breast cancer;
CESC	cis	rs4713118	0.662	rs149961	chr6:28015569	A/C	cg22143856	chr6:28129313	ZNF389	0.42	5.24	0.31	3.31e-7	Parkinson's disease;
CESC	cis	rs734999	0.967	rs4486391	chr1:2513055	A/T	cg20673091	chr1:2541236	MMEL1	0.31	5.1	0.3	6.6e-7	Ulcerative colitis;
CESC	cis	rs748404	0.697	rs546170	chr15:43564849	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.5	7.7	0.43	2.73e-13	Lung cancer;
CESC	cis	rs9910055	0.718	rs2526022	chr17:42213216	C/T	cg08499158	chr17:42289980	UBTF	-0.56	-7.32	-0.41	2.94e-12	Total body bone mineral density;
CESC	cis	rs1799949	0.965	rs4793230	chr17:41427403	A/C	cg05368731	chr17:41323189	NBR1	0.56	7.62	0.42	4.53e-13	Menopause (age at onset);
CESC	cis	rs2228479	0.557	rs11648881	chr16:89862434	T/C	cg14709524	chr16:89940631	TCF25	0.93	6.92	0.39	3.35e-11	Skin colour saturation;
CESC	cis	rs13118159	0.767	rs2141656	chr4:1317192	C/T	cg00684032	chr4:1343700	KIAA1530	0.38	5.69	0.33	3.43e-8	Longevity;
CESC	cis	rs2841277	0.646	rs3742935	chr14:105405599	G/C	cg15352829	chr14:105391018	PLD4	-0.6	-10.53	-0.54	6.87e-22	Rheumatoid arthritis;
CESC	cis	rs6912958	0.781	rs6916732	chr6:88259225	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-6.55	-0.37	3.03e-10	Monocyte percentage of white cells;
CESC	cis	rs7098414	0.530	rs10749572	chr10:82136664	G/T	cg00277334	chr10:82204260	NA	-0.52	-7.67	-0.43	3.38e-13	Post bronchodilator FEV1;
CESC	cis	rs1775715	0.835	rs1419169	chr10:32257204	C/G	cg04359828	chr10:32216031	ARHGAP12	0.35	5.13	0.3	5.49e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	trans	rs7107217	1.000	rs1873872	chr11:129473993	A/T	cg01083584	chr19:14629193	DNAJB1	0.43	6.06	0.35	4.7e-9	Breast cancer;Type 2 diabetes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08944080	chr1:156675950	CRABP2	0.6	6.59	0.38	2.35e-10	Gut microbiome composition (summer);
CESC	cis	rs2228479	0.850	rs17226666	chr16:89835401	G/A	cg04013166	chr16:89971882	TCF25	0.78	6.69	0.38	1.3e-10	Skin colour saturation;
CESC	cis	rs875971	0.545	rs4718335	chr7:65804606	C/T	cg11764359	chr7:65958608	NA	0.82	9.56	0.51	8.23e-19	Aortic root size;
CESC	cis	rs3026101	0.624	rs60691290	chr17:5318503	C/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.4	5.22	0.31	3.64e-7	Body mass index;
CESC	cis	rs4664304	0.789	rs7595388	chr2:160756345	G/A	cg03641300	chr2:160917029	PLA2R1	-0.43	-5.82	-0.34	1.7e-8	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs9733	0.527	rs11204694	chr1:150653391	G/A	cg22823121	chr1:150693482	HORMAD1	0.47	6.95	0.39	2.77e-11	Tonsillectomy;
CESC	cis	rs1552244	1.000	rs17032283	chr3:10081545	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	13.44	0.64	9.78e-32	Alzheimer's disease;
CESC	trans	rs4942242	0.512	rs9533551	chr13:44187120	G/C	cg19169023	chr15:41853346	TYRO3	-0.67	-8.34	-0.46	4.11e-15	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs3753275	0.690	rs301809	chr1:8519070	C/T	cg00120948	chr1:8484417	RERE	-0.41	-5.08	-0.3	7.08e-7	Educational attainment;
CESC	cis	rs7605827	0.897	rs7564514	chr2:15654808	G/A	cg19274914	chr2:15703543	NA	0.37	6.65	0.38	1.7e-10	Educational attainment (years of education);
CESC	cis	rs72634258	0.786	rs4268374	chr1:8174083	G/T	cg00042356	chr1:8021962	PARK7	-0.47	-5.21	-0.3	3.76e-7	Inflammatory bowel disease;
CESC	cis	rs798554	0.610	rs2251491	chr7:2852835	T/C	cg13628971	chr7:2884303	GNA12	0.43	5.74	0.33	2.58e-8	Height;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg21482489	chr5:121414366	LOX	-0.48	-6.62	-0.38	1.99e-10	Asthma;
CESC	cis	rs3126085	0.935	rs2152862	chr1:152259742	T/C	cg03465714	chr1:152285911	FLG	0.45	5.54	0.32	7.12e-8	Atopic dermatitis;
CESC	cis	rs2228479	0.850	rs1800344	chr16:89816367	T/G	cg06558623	chr16:89946397	TCF25	1.16	9.28	0.5	6.08e-18	Skin colour saturation;
CESC	cis	rs12995849	0.905	rs12712218	chr2:106451751	G/T	cg16077055	chr2:106428750	NCK2	0.39	6.23	0.36	1.85e-9	Addiction;
CESC	cis	rs60154123	0.730	rs652241	chr1:210465029	A/T	cg22029157	chr1:209979665	IRF6	0.48	5.88	0.34	1.21e-8	Coronary artery disease;
CESC	trans	rs7089973	0.549	rs7094440	chr10:116745408	T/C	cg17463145	chr7:79084011	MAGI2	0.32	6.36	0.36	8.92e-10	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs4474465	0.688	rs4457782	chr11:78284733	A/G	cg27205649	chr11:78285834	NARS2	0.39	5.09	0.3	6.7e-7	Alzheimer's disease (survival time);
CESC	cis	rs752010	0.574	rs6671999	chr1:42120416	G/A	cg06885757	chr1:42089581	HIVEP3	0.47	7.64	0.43	3.89e-13	Lupus nephritis in systemic lupus erythematosus;
CESC	trans	rs561341	0.941	rs112569713	chr17:30271738	C/T	cg20587970	chr11:113659929	NA	-1.12	-14.14	-0.66	3.28e-34	Hip circumference adjusted for BMI;
CESC	cis	rs9911578	1.000	rs9898626	chr17:56698219	C/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.27	0.31	2.87e-7	Intelligence (multi-trait analysis);
CESC	cis	rs12142240	0.698	rs17357635	chr1:46808668	G/A	cg10495392	chr1:46806563	NSUN4	0.59	6.34	0.36	9.65e-10	Menopause (age at onset);
CESC	cis	rs826838	0.967	rs980572	chr12:39127673	A/C	cg26384229	chr12:38710491	ALG10B	0.63	9.67	0.51	3.75e-19	Heart rate;
CESC	cis	rs4843747	0.749	rs12102841	chr16:88072574	C/G	cg06915872	chr16:87998081	BANP	-0.48	-6.07	-0.35	4.33e-9	Menopause (age at onset);
CESC	cis	rs4891159	0.790	rs4891018	chr18:74127082	A/T	cg24786174	chr18:74118243	ZNF516	-0.74	-11.98	-0.59	9.92e-27	Longevity;
CESC	cis	rs9348729	1	rs9348729	chr6:26664268	T/C	cg14345882	chr6:26364793	BTN3A2	0.41	5.25	0.31	3.16e-7	Intelligence (multi-trait analysis);
CESC	cis	rs4975709	0.589	rs4975746	chr5:1861069	G/A	cg10800226	chr5:1850261	NA	0.35	5.65	0.33	4.18e-8	Cardiovascular disease risk factors;
CESC	cis	rs17039065	0.920	rs17039103	chr4:109434995	A/G	cg16022748	chr4:109541635	LOC285456;RPL34	0.67	6.15	0.35	2.81e-9	Gut microbiome composition (summer);
CESC	cis	rs1499972	0.941	rs1093464	chr3:117726256	C/T	cg07612923	chr3:117604196	NA	-0.8	-5.97	-0.34	7.5e-9	Schizophrenia;
CESC	cis	rs910316	0.712	rs175015	chr14:75457075	A/C	cg08847533	chr14:75593920	NEK9	-0.87	-14.67	-0.67	4.68e-36	Height;
CESC	cis	rs7615952	0.641	rs4422257	chr3:125774363	A/G	cg04553112	chr3:125709451	NA	-0.52	-5.47	-0.32	1.03e-7	Blood pressure (smoking interaction);
CESC	cis	rs10949834	0.878	rs2527839	chr7:73510891	G/C	cg07137043	chr7:73588983	EIF4H	-0.65	-5.65	-0.33	4.1e-8	Verbal memory performance (residualized delayed recall change);
CESC	cis	rs1008375	1.000	rs2058337	chr4:17678649	C/T	cg16339924	chr4:17578868	LAP3	0.47	6.03	0.35	5.4e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25955816	chr1:228612876	HIST3H3	-0.69	-7.64	-0.42	3.86e-13	Gut microbiome composition (summer);
CESC	cis	rs9311474	0.607	rs13076398	chr3:52573096	G/A	cg07507251	chr3:52567010	NT5DC2	0.45	8.24	0.45	7.76e-15	Electroencephalogram traits;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg17979991	chr7:43769177	C7orf44	-0.42	-6.55	-0.37	3.05e-10	Gambling;
CESC	cis	rs7666738	0.830	rs4443293	chr4:99063120	G/A	cg18180107	chr4:99064573	C4orf37	0.4	5.14	0.3	5.21e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4909189	0.957	rs71547529	chr7:158135469	G/T	cg24154853	chr7:158122151	PTPRN2	0.48	6.22	0.36	1.94e-9	Response to amphetamines;
CESC	cis	rs9814567	1.000	rs7432268	chr3:134242051	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.47	-6.37	-0.36	8.41e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs4319547	0.695	rs10846699	chr12:122853073	A/G	cg05707623	chr12:122985044	ZCCHC8	0.55	6.43	0.37	5.88e-10	Body mass index;
CESC	cis	rs1062177	0.756	rs2964587	chr5:151119972	C/T	cg00977110	chr5:151150581	G3BP1	-0.62	-6.36	-0.36	8.62e-10	Preschool internalizing problems;
CESC	cis	rs3845702	0.736	rs12465592	chr2:180862654	C/G	cg01881094	chr2:180872142	CWC22	1.08	9.4	0.5	2.75e-18	Schizophrenia;
CESC	cis	rs13118159	0.714	rs6843025	chr4:1334418	C/G	cg20887711	chr4:1340912	KIAA1530	0.55	7.84	0.43	1.08e-13	Longevity;
CESC	cis	rs2549003	1.000	rs2548999	chr5:131831058	G/T	cg02551604	chr5:131831745	NA	0.39	5.54	0.32	7.14e-8	Asthma (sex interaction);
CESC	cis	rs6024905	0.551	rs2425364	chr20:36969340	G/T	cg07053727	chr20:36965646	BPI	0.5	7.65	0.43	3.68e-13	Bipolar disorder and schizophrenia;
CESC	cis	rs7666738	0.791	rs4440223	chr4:99044796	G/A	cg17366294	chr4:99064904	C4orf37	0.61	8.78	0.47	2.13e-16	Colonoscopy-negative controls vs population controls;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg09581281	chr1:15853227	DNAJC16	0.49	6.31	0.36	1.13e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs1032355	0.722	rs13139650	chr4:100513580	G/C	cg05468953	chr4:100565104	NA	0.34	5.11	0.3	6.23e-7	Celiac disease;
CESC	trans	rs9467711	0.790	rs13195401	chr6:26463574	G/T	cg01620082	chr3:125678407	NA	-0.79	-6.2	-0.36	2.13e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs816535	1	rs816535	chr20:26255996	C/T	cg04150495	chr20:26190328	MIR663	0.3	5.73	0.33	2.67e-8	Parkinson disease and lewy body pathology;
CESC	cis	rs2718058	0.601	rs2709104	chr7:37762810	A/G	cg15028436	chr7:37888078	TXNDC3	-0.44	-6.24	-0.36	1.69e-9	Alzheimer's disease (late onset);
CESC	cis	rs6580649	0.941	rs57380031	chr12:48452237	C/T	cg05342945	chr12:48394962	COL2A1	0.5	5.85	0.34	1.47e-8	Lung cancer;
CESC	cis	rs854765	0.547	rs2955385	chr17:17939247	C/T	cg04398451	chr17:18023971	MYO15A	-0.72	-10.57	-0.54	5.17e-22	Total body bone mineral density;
CESC	cis	rs6467136	0.765	rs17715255	chr7:127195850	C/T	cg25922125	chr7:127225783	GCC1	-0.37	-5.11	-0.3	6.03e-7	Type 2 diabetes;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg14778137	chr11:66336132	CTSF	-0.4	-6.16	-0.35	2.65e-9	Gambling;
CESC	cis	rs2836974	0.568	rs2142111	chr21:40549289	G/C	cg11890956	chr21:40555474	PSMG1	0.94	15.36	0.69	1.56e-38	Cognitive function;
CESC	cis	rs6598163	0.517	rs11246827	chr12:132296423	G/A	cg22244940	chr12:132335942	MMP17	0.53	7.22	0.41	5.5e-12	Migraine;
CESC	cis	rs6089829	0.926	rs7273917	chr20:61665975	G/A	cg03213289	chr20:61660250	NA	0.39	6.1	0.35	3.69e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs9389248	0.690	rs1028314	chr6:135255710	A/C	cg22676075	chr6:135203613	NA	-0.6	-8.48	-0.46	1.57e-15	High light scatter reticulocyte percentage of red cells;
CESC	cis	rs7927771	0.965	rs17788930	chr11:47752775	A/G	cg18512352	chr11:47633146	NA	-0.6	-9.45	-0.5	1.91e-18	Subjective well-being;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg23260255	chr3:187871479	LPP	-0.45	-6.54	-0.37	3.16e-10	Gambling;
CESC	cis	rs35306767	0.903	rs11253485	chr10:919362	C/T	cg10556349	chr10:835070	NA	0.59	5.59	0.32	5.54e-8	Eosinophil percentage of granulocytes;
CESC	trans	rs3925158	0.510	rs34886276	chr3:38291717	A/C	cg23247845	chr10:3679085	NA	0.66	6.06	0.35	4.74e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs1691799	0.806	rs1168319	chr12:66744857	T/A	cg16791601	chr12:66731901	HELB	-0.79	-14.34	-0.66	6.63e-35	White blood cell count (basophil);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04542817	chr3:15116352	ZFYVE20	-0.56	-6.64	-0.38	1.81e-10	Gut microbiome composition (summer);
CESC	cis	rs7959452	0.868	rs10784774	chr12:69737879	C/T	cg20891283	chr12:69753455	YEATS4	-0.6	-8.38	-0.46	3.23e-15	Blood protein levels;
CESC	cis	rs10779751	0.734	rs1130683	chr1:11132217	G/A	cg08854313	chr1:11322531	MTOR	0.76	10.24	0.53	5.91e-21	Body mass index;
CESC	cis	rs4727027	0.645	rs12704072	chr7:148904888	G/A	cg23583168	chr7:148888333	NA	-0.93	-16.96	-0.72	3.33e-44	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs2070677	0.935	rs12245634	chr10:135420002	A/G	cg20169779	chr10:135381914	SYCE1	-0.73	-9.56	-0.51	8.51e-19	Gout;
CESC	cis	rs2836633	0.929	rs4514962	chr21:40041753	C/T	cg12884169	chr21:40033163	ERG	0.39	6.21	0.36	2.06e-9	Coronary artery disease;
CESC	cis	rs17376456	0.877	rs12374488	chr5:93481407	A/G	cg25358565	chr5:93447407	FAM172A	1.17	10.96	0.56	2.63e-23	Diabetic retinopathy;
CESC	cis	rs477895	0.652	rs72920332	chr11:63947071	G/T	cg18225595	chr11:63971243	STIP1	0.52	5.14	0.3	5.26e-7	Mean platelet volume;
CESC	cis	rs17711722	0.701	rs781145	chr7:65440370	A/C	cg11987759	chr7:65425863	GUSB	-0.47	-6.37	-0.36	8.52e-10	Calcium levels;
CESC	cis	rs7666738	0.830	rs2865981	chr4:99031493	G/A	cg18180107	chr4:99064573	C4orf37	0.41	5.35	0.31	1.95e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs853679	1.000	rs1679732	chr6:28221264	G/A	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	-0.8	-8.47	-0.46	1.76e-15	Depression;
CESC	cis	rs752010	0.714	rs6664708	chr1:42083070	G/A	cg12614395	chr1:42085415	HIVEP3	0.29	5.04	0.3	8.66e-7	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs1862618	0.853	rs10051747	chr5:56083289	C/A	cg03609598	chr5:56110824	MAP3K1	-0.52	-5.45	-0.32	1.18e-7	Initial pursuit acceleration;
CESC	cis	rs7208859	0.673	rs75142521	chr17:29240537	G/A	cg19761014	chr17:28927070	LRRC37B2	0.62	5.22	0.31	3.55e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs7666738	0.830	rs28465658	chr4:99035866	T/C	cg24818145	chr4:99064322	C4orf37	0.38	5.04	0.3	8.81e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6594499	0.872	rs10051830	chr5:110452845	G/A	cg04022379	chr5:110408740	TSLP	0.33	5.7	0.33	3.24e-8	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs7100689	0.784	rs10749578	chr10:82139115	A/G	cg00277334	chr10:82204260	NA	0.59	7.5	0.42	9.45e-13	Post bronchodilator FEV1;
CESC	cis	rs1552244	1.000	rs12152515	chr3:10143976	C/T	cg24633833	chr3:10029261	TMEM111	0.45	5.17	0.3	4.55e-7	Alzheimer's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11437374	chr5:169010780	CCDC99	0.59	6.94	0.39	3.07e-11	Gut microbiome composition (summer);
CESC	cis	rs1506636	1.000	rs2429617	chr7:123418027	A/G	cg03229431	chr7:123269106	ASB15	0.49	6.59	0.38	2.41e-10	Plateletcrit;Platelet count;
CESC	cis	rs7833986	0.501	rs72653978	chr8:57018393	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.62	7.54	0.42	7.58e-13	Height;
CESC	cis	rs6424115	0.830	rs2502992	chr1:24201919	T/C	cg10978503	chr1:24200527	CNR2	0.34	6.62	0.38	2.01e-10	Immature fraction of reticulocytes;
CESC	cis	rs1008375	0.932	rs6845288	chr4:17665498	A/T	cg02297831	chr4:17616191	MED28	-0.53	-6.06	-0.35	4.65e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs561341	1.000	rs2344312	chr17:30243583	G/T	cg19193384	chr17:30244184	NA	-0.46	-5.19	-0.3	4.15e-7	Hip circumference adjusted for BMI;
CESC	cis	rs4629710	0.545	rs3777477	chr6:131534374	T/C	cg12606694	chr6:131520996	AKAP7	0.38	5.05	0.3	8.18e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg06877462	chr1:205807181	PM20D1	0.38	5.41	0.32	1.43e-7	Menarche (age at onset);
CESC	cis	rs12701220	0.655	rs10241018	chr7:1144774	G/C	cg26769984	chr7:1090371	C7orf50	0.54	6.25	0.36	1.65e-9	Bronchopulmonary dysplasia;
CESC	cis	rs4604732	0.631	rs12031694	chr1:247623653	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.51	6.61	0.38	2.14e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs2276314	0.857	rs9960670	chr18:33577712	A/G	cg05985134	chr18:33552581	C18orf21	0.61	7.03	0.4	1.72e-11	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs2760061	0.598	rs849904	chr1:228137145	G/C	cg02753203	chr1:228287806	NA	-0.5	-7.22	-0.41	5.54e-12	Diastolic blood pressure;
CESC	cis	rs2832191	0.671	rs2409332	chr21:30512779	G/A	cg24692254	chr21:30365293	RNF160	-0.6	-7.62	-0.42	4.44e-13	Dental caries;
CESC	cis	rs7412746	0.611	rs4509581	chr1:150774465	A/G	cg09365446	chr1:150670422	GOLPH3L	0.4	5.27	0.31	2.86e-7	Melanoma;
CESC	cis	rs910316	1.000	rs175426	chr14:75624134	C/T	cg11812906	chr14:75593930	NEK9	-0.88	-15.31	-0.68	2.55e-38	Height;
CESC	cis	rs2228479	0.850	rs11639788	chr16:89807543	G/A	cg00800038	chr16:89945340	TCF25	-0.87	-7.27	-0.41	4.07e-12	Skin colour saturation;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg13325346	chr17:37353483	CACNB1	0.44	6.33	0.36	1.03e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs1256061	0.603	rs960069	chr14:64745002	C/T	cg23250157	chr14:64679961	SYNE2	0.53	7.49	0.42	1.03e-12	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	10.23	0.53	6.6e-21	Prudent dietary pattern;
CESC	cis	rs6539267	0.741	rs10861572	chr12:106688576	A/G	cg00173435	chr12:106696525	TCP11L2	-0.67	-7.78	-0.43	1.6e-13	Tourette syndrome;
CESC	cis	rs453301	0.571	rs2929305	chr8:9085217	G/A	cg06636001	chr8:8085503	FLJ10661	-0.52	-6.85	-0.39	5.07e-11	Joint mobility (Beighton score);
CESC	cis	rs7555523	0.779	rs2790049	chr1:165743523	A/G	cg24409356	chr1:165738333	TMCO1	1.03	8.91	0.48	8.27e-17	Intraocular pressure;Glaucoma (high intraocular pressure);
CESC	cis	rs7811142	0.830	rs11765869	chr7:99964789	T/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.71	6.1	0.35	3.74e-9	Platelet count;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg26468274	chr6:43544000	XPO5;POLH	-0.49	-6.74	-0.38	1e-10	Fibrinogen levels;
CESC	cis	rs8060686	0.641	rs2418737	chr16:68122726	T/C	cg26727032	chr16:67993705	SLC12A4	-0.53	-6.32	-0.36	1.13e-9	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs769267	0.965	rs2074299	chr19:19380646	T/C	cg03709012	chr19:19516395	GATAD2A	0.96	14.1	0.65	4.66e-34	Tonsillectomy;
CESC	cis	rs79057730	0.527	rs34519158	chr7:811114	G/A	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.91	7.84	0.43	1.1e-13	Initial pursuit acceleration;
CESC	cis	rs7666738	0.830	rs7663924	chr4:99037679	A/G	cg17366294	chr4:99064904	C4orf37	-0.6	-8.33	-0.46	4.42e-15	Colonoscopy-negative controls vs population controls;
CESC	trans	rs2727020	0.729	rs6485965	chr11:49166730	C/T	cg03929089	chr4:120376271	NA	0.77	11.55	0.58	2.9e-25	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23538755	chr19:2774549	SGTA	0.5	6.27	0.36	1.48e-9	Gut microbiome composition (summer);
CESC	cis	rs1048238	0.506	rs7525608	chr1:16141901	A/G	cg22431228	chr1:16359049	CLCNKA	-0.35	-6.14	-0.35	2.97e-9	Systolic blood pressure;
CESC	cis	rs131777	0.577	rs5770928	chr22:51029091	G/C	cg00083937	chr22:51039805	MAPK8IP2	0.38	5.34	0.31	2.02e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	cis	rs7274811	0.711	rs657040	chr20:32001292	A/G	cg21523528	chr20:32077966	CBFA2T2	-0.48	-5.6	-0.33	5.31e-8	Height;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg18970754	chr14:74079533	NA	-0.45	-6.41	-0.37	6.65e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs1865760	0.532	rs1061482	chr6:26086699	G/T	cg17691542	chr6:26056736	HIST1H1C	0.39	5.08	0.3	7.26e-7	Height;
CESC	cis	rs7909074	1.000	rs4948925	chr10:45392455	C/T	cg05187965	chr10:45406764	TMEM72	-0.35	-5.41	-0.32	1.38e-7	Mean corpuscular volume;
CESC	cis	rs10540	1.000	rs12419766	chr11:503710	C/T	cg03934478	chr11:495069	RNH1	0.56	5.39	0.31	1.54e-7	Body mass index;
CESC	trans	rs10411161	0.702	rs1433081	chr19:52390710	A/C	cg22319618	chr22:45562946	NUP50	-0.75	-7.39	-0.41	1.94e-12	Breast cancer;
CESC	cis	rs9929218	1.000	rs12921546	chr16:68780069	G/A	cg02972257	chr16:68554789	NA	0.54	6.32	0.36	1.12e-9	Colorectal cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21638108	chr19:19431283	KIAA0892;SF4	0.57	6.96	0.39	2.74e-11	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16072655	chr12:10086277	CLEC2A	-0.58	-7.03	-0.4	1.71e-11	Gut microbiome composition (summer);
CESC	cis	rs9303401	0.614	rs35308719	chr17:57163501	C/T	cg25039879	chr17:56429692	SUPT4H1	0.5	5.28	0.31	2.75e-7	Cognitive test performance;
CESC	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg23708337	chr7:1209742	NA	0.54	5.25	0.31	3.13e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs13191362	0.935	rs13215748	chr6:163010710	A/C	cg14584255	chr6:163149320	PACRG;PARK2	0.5	5.17	0.3	4.63e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs4819052	0.851	rs8127834	chr21:46696109	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.48	5.93	0.34	9.54e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs9733	0.519	rs1134067	chr1:150721175	G/T	cg17724175	chr1:150552817	MCL1	0.46	7.09	0.4	1.18e-11	Tonsillectomy;
CESC	cis	rs1799949	1.000	rs11658754	chr17:41292739	G/A	cg05368731	chr17:41323189	NBR1	0.8	11.27	0.57	2.51e-24	Menopause (age at onset);
CESC	cis	rs7918232	0.943	rs6482593	chr10:27371437	A/G	cg14240646	chr10:27532245	ACBD5	-0.69	-6.39	-0.37	7.29e-10	Breast cancer;
CESC	cis	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg04267008	chr7:1944627	MAD1L1	-0.58	-7.01	-0.4	1.99e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs79057730	0.599	rs79272827	chr7:807015	C/G	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.92	7.89	0.44	7.75e-14	Initial pursuit acceleration;
CESC	cis	rs7520050	0.966	rs6700597	chr1:46284246	G/A	cg24296786	chr1:45957014	TESK2	0.43	5.41	0.32	1.38e-7	Red blood cell count;Reticulocyte count;
CESC	cis	rs66573146	1.000	rs28729690	chr4:6962061	C/T	cg00086871	chr4:6988644	TBC1D14	1.09	6.61	0.38	2.14e-10	Granulocyte percentage of myeloid white cells;
CESC	cis	rs763121	0.785	rs5750646	chr22:39013830	T/C	cg21395723	chr22:39101663	GTPBP1	0.52	6.92	0.39	3.42e-11	Menopause (age at onset);
CESC	cis	rs733592	0.504	rs2261608	chr12:48721634	A/T	cg24011408	chr12:48396354	COL2A1	0.44	6.86	0.39	4.82e-11	Plateletcrit;
CESC	trans	rs35110281	0.720	rs162374	chr21:44927089	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.54	-7.3	-0.41	3.43e-12	Mean corpuscular volume;
CESC	cis	rs9457247	0.934	rs2345571	chr6:167403400	T/G	cg25258033	chr6:167368657	RNASET2	0.39	5.92	0.34	9.82e-9	Crohn's disease;
CESC	cis	rs959260	0.925	rs9901434	chr17:73388770	A/G	cg20590849	chr17:73267439	MIF4GD	-0.57	-6.41	-0.37	6.55e-10	Systemic lupus erythematosus;
CESC	cis	rs4665809	0.590	rs35532350	chr2:26441605	T/C	cg27170947	chr2:26402098	FAM59B	-0.87	-9.89	-0.52	7.6e-20	Gut microbiome composition (summer);
CESC	cis	rs1799949	1.000	rs11658754	chr17:41292739	G/A	cg23758822	chr17:41437982	NA	1.02	15.64	0.69	1.65e-39	Menopause (age at onset);
CESC	cis	rs854765	0.547	rs4584886	chr17:17896205	C/T	cg16928487	chr17:17741425	SREBF1	-0.51	-8.5	-0.46	1.39e-15	Total body bone mineral density;
CESC	cis	rs10791097	0.694	rs11222370	chr11:130744767	T/G	cg12179176	chr11:130786555	SNX19	0.64	9.86	0.52	9.69e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs514406	0.760	rs475969	chr1:53292607	T/A	cg16325326	chr1:53192061	ZYG11B	0.65	9.89	0.52	7.87e-20	Monocyte count;
CESC	trans	rs7246760	0.867	rs12461215	chr19:9782461	G/A	cg02900749	chr2:68251473	NA	-0.85	-7.53	-0.42	8.04e-13	Pursuit maintenance gain;
CESC	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.42	-5.51	-0.32	8.44e-8	Longevity;Endometriosis;
CESC	cis	rs1692580	0.870	rs590367	chr1:2162944	C/T	cg24578937	chr1:2090814	PRKCZ	0.33	5.19	0.3	4.11e-7	Coronary artery disease;
CESC	cis	rs780096	0.506	rs8395	chr2:27715207	T/A	cg17158414	chr2:27665306	KRTCAP3	-0.31	-5.67	-0.33	3.74e-8	Total body bone mineral density;
CESC	cis	rs7811142	1.000	rs67239991	chr7:100046504	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.13	13.23	0.63	5.21e-31	Platelet count;
CESC	cis	rs61931739	0.500	rs7965679	chr12:34542494	T/C	cg06521331	chr12:34319734	NA	-0.36	-5.03	-0.3	9.01e-7	Morning vs. evening chronotype;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg19729279	chr5:133861951	PHF15	0.49	6.44	0.37	5.6e-10	Systemic lupus erythematosus;
CESC	cis	rs7666738	0.830	rs35433756	chr4:99070555	C/T	cg03467027	chr4:99064603	C4orf37	0.48	5.9	0.34	1.11e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1215050	0.791	rs6813619	chr4:98830768	C/T	cg05340658	chr4:99064831	C4orf37	-0.48	-6.31	-0.36	1.15e-9	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs11608355	0.705	rs4766601	chr12:109890080	C/G	cg05360138	chr12:110035743	NA	0.57	6.97	0.39	2.58e-11	Neuroticism;
CESC	cis	rs8180040	0.783	rs11710121	chr3:47351501	T/G	cg27129171	chr3:47204927	SETD2	-0.63	-9.12	-0.49	1.97e-17	Colorectal cancer;
CESC	cis	rs7618915	0.547	rs13065019	chr3:52685244	T/C	cg07507251	chr3:52567010	NT5DC2	0.4	7.06	0.4	1.5e-11	Bipolar disorder;
CESC	cis	rs7772486	0.875	rs2777479	chr6:146309178	C/A	cg23711669	chr6:146136114	FBXO30	0.84	11.72	0.58	7.63e-26	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6933660	0.721	rs2128945	chr6:151767907	A/G	cg14262678	chr6:151773367	RMND1;C6orf211	0.64	9.03	0.49	3.53e-17	Menarche (age at onset);
CESC	cis	rs10927875	0.578	rs10927859	chr1:16141862	C/T	cg18973939	chr1:16164122	FLJ37453	0.37	5.58	0.32	6e-8	Dilated cardiomyopathy;
CESC	cis	rs7605827	0.930	rs11893303	chr2:15613715	G/A	cg19274914	chr2:15703543	NA	0.35	6.13	0.35	3.19e-9	Educational attainment (years of education);
CESC	cis	rs2243480	1.000	rs57057549	chr7:65405738	A/G	cg18252515	chr7:66147081	NA	-1.23	-11.37	-0.57	1.14e-24	Diabetic kidney disease;
CESC	cis	rs2576037	0.583	rs541634	chr18:44420271	C/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.33	5.33	0.31	2.11e-7	Personality dimensions;
CESC	cis	rs1862618	0.853	rs33326	chr5:56142601	G/A	cg24549020	chr5:56110836	MAP3K1	0.68	7.72	0.43	2.37e-13	Initial pursuit acceleration;
CESC	cis	rs9467711	0.516	rs548987	chr6:25869371	C/G	cg08501292	chr6:25962987	TRIM38	0.54	5.93	0.34	9.22e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs4925386	0.625	rs3810550	chr20:60912117	C/T	cg12382846	chr20:60892121	LAMA5	0.41	6.43	0.37	6.06e-10	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs920590	0.876	rs3907478	chr8:19657753	G/T	cg17834443	chr8:19674713	INTS10	0.49	5.78	0.33	2.13e-8	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg02353165	chr6:42928485	GNMT	0.84	13.21	0.63	6.05e-31	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs4664304	0.900	rs17231993	chr2:160741415	C/T	cg03641300	chr2:160917029	PLA2R1	-0.47	-6.57	-0.37	2.64e-10	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs10465746	0.935	rs11163878	chr1:84442654	G/A	cg10977910	chr1:84465055	TTLL7	0.47	6.45	0.37	5.23e-10	Obesity-related traits;
CESC	cis	rs6788895	1.000	rs16862842	chr3:150484844	A/G	cg09723797	chr3:150481914	SIAH2	0.7	5.22	0.31	3.67e-7	Breast cancer;
CESC	cis	rs36051895	0.623	rs62541541	chr9:5040817	G/C	cg02405213	chr9:5042618	JAK2	-0.47	-5.56	-0.32	6.71e-8	Pediatric autoimmune diseases;
CESC	cis	rs920590	0.684	rs57837509	chr8:19670088	A/G	cg01411142	chr8:19674711	INTS10	0.56	6.24	0.36	1.77e-9	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs7666738	0.893	rs11729640	chr4:99052699	C/T	cg03676636	chr4:99064102	C4orf37	0.33	5.12	0.3	5.93e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6499255	0.904	rs7187653	chr16:69562838	G/C	cg15192750	chr16:69999425	NA	0.58	6.79	0.38	7.41e-11	IgE levels;
CESC	cis	rs863345	0.967	rs10908664	chr1:158492629	G/A	cg12129480	chr1:158549410	OR10X1	-0.31	-6.04	-0.35	5.08e-9	Pneumococcal bacteremia;
CESC	cis	rs1862618	0.853	rs2548665	chr5:56131805	T/A	cg24549020	chr5:56110836	MAP3K1	0.68	7.76	0.43	1.85e-13	Initial pursuit acceleration;
CESC	cis	rs9611565	0.546	rs739134	chr22:42089623	T/C	cg03806693	chr22:41940476	POLR3H	1.04	12.31	0.6	7.65e-28	Vitiligo;
CESC	cis	rs2635047	0.967	rs1355593	chr18:44746460	A/T	cg19077165	chr18:44547161	KATNAL2	-0.43	-5.64	-0.33	4.42e-8	Educational attainment;
CESC	cis	rs4523957	0.928	rs749240	chr17:2186100	A/G	cg16513277	chr17:2031491	SMG6	0.56	6.93	0.39	3.24e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs11893307	0.507	rs1465305	chr2:191585392	C/G	cg10560079	chr2:191398806	TMEM194B	-0.45	-5.59	-0.32	5.55e-8	Mean platelet volume;
CESC	cis	rs1707322	1.000	rs6687301	chr1:46382852	T/C	cg03146154	chr1:46216737	IPP	0.72	9.82	0.52	1.29e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs17508449	0.819	rs4839329	chr1:114135705	G/A	cg23028848	chr11:57092561	TNKS1BP1	-0.79	-6.26	-0.36	1.54e-9	Leprosy;
CESC	cis	rs6748734	0.894	rs4675869	chr2:241827696	A/G	cg04034577	chr2:241836375	C2orf54	-0.47	-7.96	-0.44	5.1e-14	Urinary metabolites;
CESC	cis	rs1005277	0.579	rs1614236	chr10:38502996	C/T	cg00409905	chr10:38381863	ZNF37A	-0.51	-6.8	-0.39	6.98e-11	Extrinsic epigenetic age acceleration;
CESC	cis	rs12042938	1.000	rs823158	chr1:231782650	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.48	6.63	0.38	1.84e-10	Neuranatomic and neurocognitive phenotypes;
CESC	cis	rs6460942	0.915	rs62447639	chr7:12486803	T/C	cg02935154	chr7:12443704	VWDE	-0.57	-5.94	-0.34	9.02e-9	Coronary artery disease;
CESC	cis	rs9796	0.870	rs2306083	chr15:41347658	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.45	-6.82	-0.39	6.24e-11	Menopause (age at onset);
CESC	cis	rs473651	0.935	rs483166	chr2:239346641	C/T	cg18131467	chr2:239335373	ASB1	-1.0	-20.86	-0.79	7.88e-58	Multiple system atrophy;
CESC	cis	rs483180	0.532	rs561931	chr1:120254506	A/G	cg19096424	chr1:120255104	PHGDH	0.5	6.29	0.36	1.31e-9	Macular telangiectasia type 2;
CESC	cis	rs67478160	0.572	rs8015603	chr14:104293678	C/G	cg01849466	chr14:104193079	ZFYVE21	-0.51	-7.11	-0.4	1.1e-11	Schizophrenia;
CESC	cis	rs2414059	0.548	rs3098177	chr15:50783777	A/G	cg08437265	chr15:50716283	USP8	-0.51	-6.86	-0.39	4.87e-11	QT interval;
CESC	cis	rs1790761	0.667	rs4147581	chr11:67351585	C/G	cg08355456	chr11:67383691	NA	0.34	5.22	0.31	3.6e-7	Mean corpuscular volume;
CESC	cis	rs7659604	0.676	rs6855269	chr4:122697418	T/G	cg20573242	chr4:122745356	CCNA2	0.54	6.78	0.38	7.9e-11	Type 2 diabetes;
CESC	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg21226059	chr5:178986404	RUFY1	-0.51	-7.74	-0.43	2.11e-13	Lung cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05397629	chr11:3848986	RHOG	-0.57	-6.69	-0.38	1.3100000000000001e-10	Gut microbiome composition (summer);
CESC	cis	rs7116495	1.000	rs7949480	chr11:71697588	T/C	cg26138937	chr11:71823887	C11orf51	-0.81	-6.63	-0.38	1.93e-10	Severe influenza A (H1N1) infection;
CESC	cis	rs9322193	0.923	rs10872645	chr6:150063976	G/A	cg07701084	chr6:150067640	NUP43	0.43	5.81	0.34	1.77e-8	Lung cancer;
CESC	cis	rs12701220	0.655	rs6463317	chr7:1159243	G/A	cg23978390	chr7:1156363	C7orf50	0.65	6.73	0.38	1.06e-10	Bronchopulmonary dysplasia;
CESC	cis	rs7927771	0.524	rs7939420	chr11:47723938	A/G	cg20307385	chr11:47447363	PSMC3	-0.58	-7.95	-0.44	5.41e-14	Subjective well-being;
CESC	cis	rs644799	0.648	rs1255178	chr11:95471908	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.49	6.91	0.39	3.66e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs4862750	0.832	rs10007858	chr4:187877492	A/G	cg07414643	chr4:187882934	NA	0.52	7.4	0.41	1.83e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7666738	0.830	rs28818218	chr4:98880575	A/C	cg03467027	chr4:99064603	C4orf37	0.42	5.28	0.31	2.72e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs12476592	0.516	rs4671503	chr2:63637091	A/T	cg17519650	chr2:63277830	OTX1	-0.47	-5.19	-0.3	4.21e-7	Childhood ear infection;
CESC	cis	rs1881797	0.872	rs12408686	chr1:247691141	C/T	cg18198730	chr1:247681584	NA	0.63	8.15	0.45	1.42e-14	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs79349575	0.783	rs4793996	chr17:47019597	T/C	cg16584676	chr17:46985605	UBE2Z	0.54	6.67	0.38	1.46e-10	Type 2 diabetes;
CESC	cis	rs2797160	1.000	rs1935773	chr6:125996475	A/G	cg05901451	chr6:126070800	HEY2	-0.46	-6.72	-0.38	1.1e-10	Endometrial cancer;
CESC	cis	rs67460515	0.892	rs4856756	chr3:160999414	G/A	cg03342759	chr3:160939853	NMD3	-0.53	-7.52	-0.42	8.34e-13	Parkinson's disease;
CESC	cis	rs11098499	0.909	rs7681978	chr4:120383775	T/C	cg24375607	chr4:120327624	NA	0.45	5.52	0.32	8.05e-8	Corneal astigmatism;
CESC	cis	rs11785693	0.817	rs62491199	chr8:4997878	G/A	cg26367366	chr8:4980734	NA	0.81	7.68	0.43	3.05e-13	Neuroticism (multi-trait analysis);Neuroticism;
CESC	cis	rs4862750	0.872	rs6821507	chr4:187876829	G/T	cg06074448	chr4:187884817	NA	0.38	5.48	0.32	1e-7	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs17376456	0.877	rs17083462	chr5:93462401	T/G	cg25358565	chr5:93447407	FAM172A	1.15	11.75	0.59	5.96e-26	Diabetic retinopathy;
CESC	cis	rs62344088	1.000	rs10065373	chr5:106819	C/T	cg22857025	chr5:266934	NA	-1.01	-5.45	-0.32	1.14e-7	Asthma (childhood onset);
CESC	cis	rs9611565	0.580	rs5758449	chr22:42140160	C/T	cg03806693	chr22:41940476	POLR3H	0.78	9.54	0.51	9.81e-19	Vitiligo;
CESC	cis	rs7208859	0.623	rs8081299	chr17:29104296	G/A	cg19761014	chr17:28927070	LRRC37B2	0.74	6.05	0.35	4.88e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs6088590	0.523	rs6088536	chr20:33189106	T/C	cg06115741	chr20:33292138	TP53INP2	0.53	6.69	0.38	1.3100000000000001e-10	Coronary artery disease;
CESC	cis	rs8177179	0.967	rs6439436	chr3:133453779	C/T	cg24879335	chr3:133465180	TF	-0.43	-8.19	-0.45	1.14e-14	Iron status biomarkers (transferrin levels);
CESC	cis	rs8180040	0.726	rs2305634	chr3:47043538	A/G	cg27129171	chr3:47204927	SETD2	-0.67	-9.09	-0.49	2.38e-17	Colorectal cancer;
CESC	cis	rs17039065	0.920	rs7672020	chr4:109436064	T/C	cg16022748	chr4:109541635	LOC285456;RPL34	0.67	6.4	0.37	7.14e-10	Gut microbiome composition (summer);
CESC	cis	rs8060686	0.920	rs3809630	chr16:67879400	G/A	cg26727032	chr16:67993705	SLC12A4	-0.58	-6.26	-0.36	1.55e-9	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs514406	0.729	rs534070	chr1:53308858	T/G	cg25767906	chr1:53392781	SCP2	-0.5	-7.06	-0.4	1.49e-11	Monocyte count;
CESC	cis	rs875971	1.000	rs2420168	chr7:65630631	C/G	cg10691866	chr7:65817282	TPST1	0.33	5.51	0.32	8.45e-8	Aortic root size;
CESC	cis	rs1580019	0.885	rs1610141	chr7:32498435	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.89	12.7	0.62	3.54e-29	Cognitive ability;
CESC	cis	rs73206853	0.563	rs4073472	chr12:111176494	A/G	cg04375036	chr12:111181819	PPP1CC	-0.64	-5.11	-0.3	6.21e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs796364	0.950	rs188146	chr2:200750444	C/T	cg23649088	chr2:200775458	C2orf69	0.56	5.29	0.31	2.54e-7	Schizophrenia;
CESC	cis	rs6942756	1.000	rs7778277	chr7:128978805	C/T	cg02491457	chr7:128862824	NA	-0.68	-9.24	-0.49	8.31e-18	White matter hyperintensity burden;
CESC	cis	rs947211	0.948	rs1775143	chr1:205755550	C/T	cg26354017	chr1:205819088	PM20D1	0.44	5.68	0.33	3.49e-8	Parkinson's disease;
CESC	cis	rs2242073	0.627	rs13007922	chr2:209004186	G/A	cg10392614	chr2:208977121	NA	-0.37	-5.05	-0.3	8.4e-7	Attention deficit hyperactivity disorder;
CESC	cis	rs1799949	1.000	rs8176318	chr17:41197274	G/T	cg23758822	chr17:41437982	NA	0.98	14.49	0.66	1.97e-35	Menopause (age at onset);
CESC	cis	rs17331151	0.573	rs11718060	chr3:52875546	G/A	cg04865290	chr3:52927548	TMEM110	-0.49	-5.1	-0.3	6.44e-7	Immune reponse to smallpox (secreted IL-2);
CESC	cis	rs651907	0.557	rs3806654	chr3:101396529	G/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	7.0	0.39	2.15e-11	Colorectal cancer;
CESC	trans	rs1814175	0.645	rs1851850	chr11:50012168	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.41	-6.0	-0.35	6.53e-9	Height;
CESC	cis	rs2243480	1.000	rs6970243	chr7:65388490	C/A	cg25894440	chr7:65020034	NA	-0.59	-5.07	-0.3	7.57e-7	Diabetic kidney disease;
CESC	cis	rs4472734	1.000	rs4275425	chr1:214612500	C/A	cg00063699	chr1:214624242	PTPN14	-0.32	-5.04	-0.3	8.6e-7	Height;
CESC	cis	rs11122272	0.735	rs2739509	chr1:231526765	C/T	cg06096015	chr1:231504339	EGLN1	0.43	6.13	0.35	3.23e-9	Hemoglobin concentration;
CESC	cis	rs425277	0.628	rs10797427	chr1:2060732	C/T	cg19257562	chr1:2043853	PRKCZ	0.36	5.95	0.34	8.48e-9	Height;
CESC	trans	rs17508449	0.819	rs79667495	chr1:114191329	T/G	cg23028848	chr11:57092561	TNKS1BP1	-0.75	-6.02	-0.35	5.69e-9	Leprosy;
CESC	cis	rs7666738	0.830	rs9996098	chr4:98867740	T/C	cg05340658	chr4:99064831	C4orf37	0.74	10.7	0.55	1.97e-22	Colonoscopy-negative controls vs population controls;
CESC	cis	rs941873	0.772	rs1316312	chr10:81110417	G/C	cg11057378	chr10:81107060	PPIF	0.35	5.49	0.32	9.18e-8	Height;
CESC	trans	rs9467711	0.606	rs35307327	chr6:26370474	C/T	cg06606381	chr12:133084897	FBRSL1	-0.76	-6.86	-0.39	4.71e-11	Autism spectrum disorder or schizophrenia;
CESC	cis	rs9815354	0.638	rs75687617	chr3:42044664	C/T	cg03022575	chr3:42003672	ULK4	0.76	6.68	0.38	1.39e-10	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs6062302	0.548	rs6089940	chr20:62252695	C/T	cg06363034	chr20:62225388	GMEB2	-0.5	-6.41	-0.37	6.66e-10	Glioblastoma;
CESC	cis	rs9633740	1.000	rs1870138	chr10:82269611	A/G	cg00277334	chr10:82204260	NA	-0.5	-5.11	-0.3	6.19e-7	Post bronchodilator FEV1;
CESC	trans	rs1814175	0.529	rs1988417	chr11:49932430	A/G	cg03929089	chr4:120376271	NA	-0.8	-10.63	-0.55	3.2e-22	Height;
CESC	cis	rs2276314	0.857	rs28530656	chr18:33588700	C/T	cg05985134	chr18:33552581	C18orf21	-0.6	-7.39	-0.41	1.98e-12	Endometriosis;Drug-induced torsades de pointes;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg13409248	chr3:40428643	ENTPD3	-0.46	-6.03	-0.35	5.52e-9	Fibrinogen levels;
CESC	cis	rs6502050	0.749	rs7209948	chr17:80086804	T/G	cg23985595	chr17:80112537	CCDC57	0.42	6.61	0.38	2.14e-10	Life satisfaction;
CESC	cis	rs12926788	0.542	rs11862971	chr16:24767574	C/A	cg02428538	chr16:24856791	SLC5A11	-0.47	-5.03	-0.3	9.12e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.77	0.38	8.24e-11	Prudent dietary pattern;
CESC	cis	rs6582630	0.502	rs1115515	chr12:38279830	C/T	cg26384229	chr12:38710491	ALG10B	0.68	9.7	0.51	3.2e-19	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs7872515	0.887	rs58129324	chr9:94839105	T/C	cg01248375	chr9:94877805	SPTLC1	0.56	6.1	0.35	3.81e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs4780401	0.678	rs7189287	chr16:11764608	A/G	cg01061890	chr16:11836724	TXNDC11	-0.39	-5.06	-0.3	7.71e-7	Rheumatoid arthritis;
CESC	cis	rs2710642	0.721	rs1487074	chr2:62890551	T/C	cg17519650	chr2:63277830	OTX1	0.55	6.64	0.38	1.82e-10	LDL cholesterol levels;LDL cholesterol;
CESC	cis	rs1707322	1.000	rs12133129	chr1:46373348	C/T	cg03146154	chr1:46216737	IPP	0.71	9.86	0.52	9.69e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs8044868	0.530	rs7201866	chr16:72086534	A/T	cg16558253	chr16:72132732	DHX38	-0.39	-6.15	-0.35	2.89e-9	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CESC	cis	rs17384381	0.734	rs12129013	chr1:85891709	A/C	cg16011679	chr1:85725395	C1orf52	0.6	6.74	0.38	1.01e-10	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs6513791	0.663	rs1883269	chr20:41044482	C/T	cg20844924	chr4:15328821	NA	0.61	6.06	0.35	4.71e-9	Microalbuminuria;
CESC	cis	rs10504229	0.683	rs7838958	chr8:58136968	T/C	cg02725872	chr8:58115012	NA	-0.45	-7.05	-0.4	1.52e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg04025307	chr7:1156635	C7orf50	0.41	5.21	0.31	3.71e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7618915	0.547	rs11177	chr3:52721305	G/A	cg18099408	chr3:52552593	STAB1	-0.31	-5.18	-0.3	4.29e-7	Bipolar disorder;
CESC	cis	rs6952808	0.729	rs35797753	chr7:1954914	G/A	cg00106254	chr7:1943704	MAD1L1	-0.49	-6.2	-0.36	2.18e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs7666738	0.830	rs7673385	chr4:99024922	T/G	cg24818145	chr4:99064322	C4orf37	0.38	5.04	0.3	8.61e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7208859	0.623	rs8067035	chr17:29102188	T/C	cg13385521	chr17:29058706	SUZ12P	0.78	6.41	0.37	6.55e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs6570726	0.935	rs416987	chr6:145847005	G/C	cg23711669	chr6:146136114	FBXO30	0.8	11.89	0.59	2e-26	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs8014204	0.967	rs2359240	chr14:75328247	T/C	cg26191576	chr14:75389716	RPS6KL1	0.36	5.18	0.3	4.44e-7	Caffeine consumption;
CESC	cis	rs9322193	0.923	rs2880436	chr6:150180259	T/C	cg04369109	chr6:150039330	LATS1	-0.41	-5.47	-0.32	1.03e-7	Lung cancer;
CESC	cis	rs1511802	0.666	rs4862662	chr4:187118662	A/C	cg24794857	chr4:187113578	CYP4V2	-0.44	-5.81	-0.34	1.77e-8	Blood protein levels;
CESC	cis	rs1881797	1.000	rs68059491	chr1:247683070	C/T	cg18198730	chr1:247681584	NA	0.62	7.76	0.43	1.9e-13	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs2742234	0.504	rs10899780	chr10:43725796	T/C	cg15436174	chr10:43711423	RASGEF1A	0.47	5.5	0.32	8.97e-8	Hirschsprung disease;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg08577743	chr9:38621011	C9orf122;ANKRD18A	0.46	6.23	0.36	1.87e-9	Systemic lupus erythematosus;
CESC	cis	rs875971	0.895	rs12698520	chr7:65918707	C/A	cg12463550	chr7:65579703	CRCP	0.56	7.09	0.4	1.19e-11	Aortic root size;
CESC	trans	rs11098499	1.000	rs11098499	chr4:120187611	C/T	cg25214090	chr10:38739885	LOC399744	0.67	9.18	0.49	1.26e-17	Corneal astigmatism;
CESC	cis	rs736408	0.609	rs2268025	chr3:52795224	A/T	cg07507251	chr3:52567010	NT5DC2	0.43	7.38	0.41	2.01e-12	Bipolar disorder;
CESC	cis	rs12822507	0.811	rs34946234	chr12:12781812	A/G	cg09462578	chr12:12878428	APOLD1	-0.44	-5.51	-0.32	8.36e-8	Systemic lupus erythematosus;
CESC	cis	rs8005677	1.000	rs11157930	chr14:23403171	T/G	cg25600027	chr14:23388339	RBM23	-0.43	-5.23	-0.31	3.43e-7	Cognitive ability (multi-trait analysis);
CESC	cis	rs1538970	0.816	rs61788356	chr1:46006675	C/T	cg03146154	chr1:46216737	IPP	0.49	5.6	0.33	5.25e-8	Platelet count;
CESC	cis	rs9311474	0.508	rs4687629	chr3:52615227	G/C	cg17372223	chr3:52568218	NT5DC2	0.42	6.35	0.36	9.09e-10	Electroencephalogram traits;
CESC	cis	rs9487051	0.872	rs9487032	chr6:109605323	G/T	cg12927641	chr6:109611667	NA	-0.42	-6.4	-0.37	7.18e-10	Reticulocyte fraction of red cells;
CESC	trans	rs1814175	0.645	rs7119101	chr11:49955665	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.43	-6.26	-0.36	1.53e-9	Height;
CESC	cis	rs10206020	0.921	rs72778009	chr2:1573322	G/T	cg26248373	chr2:1572462	NA	-0.6	-7.09	-0.4	1.21e-11	IgG glycosylation;
CESC	cis	rs4919087	1.000	rs4919091	chr10:99088682	A/T	cg25902810	chr10:99078978	FRAT1	-0.65	-8.52	-0.46	1.2e-15	Monocyte count;
CESC	cis	rs7267979	1.000	rs6107046	chr20:25442049	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.83	15.81	0.7	4.28e-40	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs208520	1.000	rs72882102	chr6:66983408	C/A	cg07460842	chr6:66804631	NA	0.88	10.14	0.53	1.22e-20	Exhaled nitric oxide output;
CESC	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg06873352	chr17:61820015	STRADA	0.73	13.15	0.63	9.34e-31	Prudent dietary pattern;
CESC	cis	rs1552244	0.882	rs112621205	chr3:10017916	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.86	11.09	0.56	9.7e-24	Alzheimer's disease;
CESC	cis	rs7618915	0.547	rs11720432	chr3:52672742	T/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.3	5.33	0.31	2.14e-7	Bipolar disorder;
CESC	cis	rs10463316	0.894	rs7729438	chr5:150762197	G/A	cg03212797	chr5:150827313	SLC36A1	-0.46	-6.02	-0.35	5.83e-9	Metabolite levels (Pyroglutamine);
CESC	cis	rs875971	0.965	rs9969301	chr7:65781655	G/A	cg11764359	chr7:65958608	NA	-0.94	-15.61	-0.69	2.16e-39	Aortic root size;
CESC	cis	rs611744	0.647	rs11774904	chr8:109273435	G/A	cg21045802	chr8:109455806	TTC35	0.52	6.45	0.37	5.39e-10	Dupuytren's disease;
CESC	cis	rs1670533	0.932	rs13140571	chr4:1054358	T/C	cg04106633	chr4:1044584	NA	0.41	5.23	0.31	3.36e-7	Recombination rate (females);
CESC	cis	rs2075371	0.932	rs1035328	chr7:133978419	T/C	cg20476274	chr7:133979776	SLC35B4	0.64	9.4	0.5	2.72e-18	Mean platelet volume;
CESC	cis	rs9311474	0.508	rs17052259	chr3:52593138	A/G	cg07507251	chr3:52567010	NT5DC2	0.34	5.8	0.34	1.85e-8	Electroencephalogram traits;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg10268125	chr7:120590544	ING3	0.51	6.7	0.38	1.23e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs875971	0.862	rs10282433	chr7:65721439	G/A	cg12463550	chr7:65579703	CRCP	-0.45	-5.85	-0.34	1.41e-8	Aortic root size;
CESC	cis	rs113835537	0.529	rs7943327	chr11:66256581	G/C	cg24851651	chr11:66362959	CCS	0.45	5.82	0.34	1.67e-8	Airway imaging phenotypes;
CESC	cis	rs2576037	0.796	rs2247021	chr18:44578794	A/C	cg19077165	chr18:44547161	KATNAL2	-0.5	-6.99	-0.39	2.18e-11	Personality dimensions;
CESC	cis	rs7618915	0.547	rs10780035	chr3:52764624	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	6.64	0.38	1.81e-10	Bipolar disorder;
CESC	cis	rs763014	0.932	rs4984898	chr16:641164	G/T	cg00908189	chr16:619842	PIGQ	0.64	8.48	0.46	1.63e-15	Height;
CESC	cis	rs1005277	0.505	rs200937	chr10:38135772	T/C	cg25427524	chr10:38739819	LOC399744	-0.68	-10.02	-0.52	3.01e-20	Extrinsic epigenetic age acceleration;
CESC	cis	rs7208859	0.673	rs9899349	chr17:29200122	C/T	cg19761014	chr17:28927070	LRRC37B2	0.72	5.71	0.33	3.06e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs9814567	1.000	rs9990351	chr3:134239191	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.43	5.95	0.34	8.44e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs1775148	1	rs1775148	chr1:205757824	C/T	cg11965913	chr1:205819406	PM20D1	0.45	6.59	0.38	2.34e-10	Prostate cancer;
CESC	cis	rs1799949	1.000	rs8176289	chr17:41206056	T/C	cg05368731	chr17:41323189	NBR1	0.75	10.35	0.54	2.72e-21	Menopause (age at onset);
CESC	cis	rs1552244	1.000	rs58275763	chr3:10143274	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.8	-10.93	-0.56	3.47e-23	Alzheimer's disease;
CESC	cis	rs763121	0.853	rs1062687	chr22:39134715	T/C	cg21395723	chr22:39101663	GTPBP1	0.49	6.7	0.38	1.23e-10	Menopause (age at onset);
CESC	cis	rs1044826	0.692	rs184155	chr3:139229772	G/A	cg00490450	chr3:139108681	COPB2	-0.44	-5.43	-0.32	1.31e-7	Obesity-related traits;
CESC	cis	rs4268898	0.662	rs714531	chr2:24399877	G/A	cg06627628	chr2:24431161	ITSN2	-0.98	-9.85	-0.52	1.06e-19	Asthma;
CESC	cis	rs2204008	0.604	rs2320521	chr12:38253789	A/G	cg26384229	chr12:38710491	ALG10B	0.68	9.7	0.51	3.2e-19	Bladder cancer;
CESC	cis	rs4604732	0.631	rs12031721	chr1:247623773	G/A	cg12754571	chr1:247694271	LOC148824;OR2C3	0.41	5.1	0.3	6.5e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs6484504	0.600	rs972714	chr11:31358875	T/G	cg14844989	chr11:31128820	NA	0.38	5.16	0.3	4.92e-7	Red blood cell count;
CESC	cis	rs1983891	1.000	rs6458228	chr6:41543793	C/A	cg20194872	chr6:41519635	FOXP4	0.55	7.76	0.43	1.88e-13	Prostate cancer;
CESC	cis	rs35110281	0.807	rs9976441	chr21:45046591	G/A	cg21573476	chr21:45109991	RRP1B	-0.46	-6.4	-0.37	7.1e-10	Mean corpuscular volume;
CESC	cis	rs798554	0.757	rs1182187	chr7:2870454	T/G	cg19346786	chr7:2764209	NA	-0.42	-5.91	-0.34	1.02e-8	Height;
CESC	cis	rs2032447	0.714	rs129129	chr6:25961029	A/G	cg03264133	chr6:25882463	NA	-0.49	-7.22	-0.41	5.49e-12	Intelligence (multi-trait analysis);
CESC	cis	rs597539	0.652	rs686390	chr11:68656077	T/C	cg04772025	chr11:68637568	NA	0.51	6.04	0.35	5.22e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs35955747	0.871	rs5994392	chr22:31783906	T/A	cg25791279	chr22:32026902	PISD	-0.44	-5.37	-0.31	1.76e-7	Neutrophil count;Sum basophil neutrophil counts;
CESC	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg06877462	chr1:205807181	PM20D1	-0.4	-5.99	-0.35	6.7e-9	Menarche (age at onset);
CESC	cis	rs7647973	0.580	rs35218722	chr3:49275805	A/G	cg07636037	chr3:49044803	WDR6	0.81	13.66	0.64	1.62e-32	Menarche (age at onset);
CESC	cis	rs7618915	0.501	rs7622694	chr3:52663882	G/A	cg18099408	chr3:52552593	STAB1	-0.3	-5.03	-0.3	8.99e-7	Bipolar disorder;
CESC	cis	rs1707322	0.721	rs4330955	chr1:46217485	G/C	cg06784218	chr1:46089804	CCDC17	0.43	7.58	0.42	5.65e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs4073405	0.584	rs6485607	chr11:45306531	G/A	cg27235148	chr11:45376932	NA	0.29	5.03	0.3	9.19e-7	Schizophrenia;
CESC	cis	rs4780401	0.609	rs4781142	chr16:11808806	T/C	cg01061890	chr16:11836724	TXNDC11	-0.56	-7.59	-0.42	5.59e-13	Rheumatoid arthritis;
CESC	cis	rs67478160	0.619	rs11160759	chr14:104231542	C/T	cg08213375	chr14:104286397	PPP1R13B	0.55	11.09	0.56	9.71e-24	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01516466	chr9:3526944	RFX3	-0.58	-6.48	-0.37	4.37e-10	Gut microbiome composition (summer);
CESC	cis	rs1538970	0.884	rs61788261	chr1:45899114	G/A	cg05343316	chr1:45956843	TESK2	0.9	12.61	0.61	7.33e-29	Platelet count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10827434	chr1:84944976	RPF1	0.66	7.44	0.42	1.41e-12	Gut microbiome composition (summer);
CESC	trans	rs4332037	0.950	rs7807014	chr7:1939021	T/C	cg11693508	chr17:37793320	STARD3	0.67	6.4	0.37	6.96e-10	Bipolar disorder;
CESC	cis	rs9902453	0.904	rs11654983	chr17:28370042	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.67	-8.69	-0.47	3.8e-16	Coffee consumption (cups per day);
CESC	trans	rs2727020	0.619	rs11040300	chr11:49269984	C/A	cg15704280	chr7:45808275	SEPT13	0.79	10.11	0.53	1.51e-20	Coronary artery disease;
CESC	cis	rs875971	0.862	rs908915	chr7:65614651	G/T	cg10691866	chr7:65817282	TPST1	0.31	5.21	0.3	3.81e-7	Aortic root size;
CESC	trans	rs453301	0.624	rs330058	chr8:9089809	G/A	cg15556689	chr8:8085844	FLJ10661	-0.53	-6.6	-0.38	2.25e-10	Joint mobility (Beighton score);
CESC	trans	rs10411161	0.702	rs8110546	chr19:52383556	C/A	cg22319618	chr22:45562946	NUP50	-0.69	-6.75	-0.38	9.37e-11	Breast cancer;
CESC	cis	rs2576037	0.796	rs2571018	chr18:44585344	T/A	cg19077165	chr18:44547161	KATNAL2	0.54	7.57	0.42	6.29e-13	Personality dimensions;
CESC	cis	rs853679	0.517	rs35227624	chr6:28132726	A/G	cg23161317	chr6:28129485	ZNF389	0.52	6.48	0.37	4.37e-10	Depression;
CESC	cis	rs3785574	0.924	rs2584641	chr17:61862889	A/G	cg07677032	chr17:61819896	STRADA	0.41	5.15	0.3	4.97e-7	Height;
CESC	cis	rs875971	0.522	rs1917563	chr7:65415647	C/T	cg18876405	chr7:65276391	NA	-0.65	-8.93	-0.48	7.45e-17	Aortic root size;
CESC	cis	rs763121	0.853	rs5757226	chr22:39070550	T/C	cg21395723	chr22:39101663	GTPBP1	0.42	5.32	0.31	2.17e-7	Menopause (age at onset);
CESC	cis	rs796364	0.806	rs11688194	chr2:200916239	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.84	-7.75	-0.43	1.94e-13	Schizophrenia;
CESC	cis	rs11112613	0.713	rs871220	chr12:105938558	G/A	cg03607813	chr12:105948248	NA	0.65	7.98	0.44	4.53e-14	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CESC	trans	rs916888	0.773	rs199443	chr17:44819565	C/T	cg04703951	chr17:43578652	NA	0.5	6.0	0.35	6.62e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs12477438	0.765	rs10181344	chr2:99692829	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.64	-8.73	-0.47	2.94e-16	Chronic sinus infection;
CESC	cis	rs13191362	1.000	rs35583420	chr6:163214327	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.96	8.86	0.48	1.2e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs826838	0.967	rs4768330	chr12:39129399	T/C	cg13010199	chr12:38710504	ALG10B	-0.45	-6.26	-0.36	1.51e-9	Heart rate;
CESC	cis	rs6460942	0.591	rs62451464	chr7:12363059	C/A	cg06484146	chr7:12443880	VWDE	-0.62	-6.74	-0.38	9.67e-11	Coronary artery disease;
CESC	cis	rs965469	0.779	rs6133039	chr20:3385006	C/T	cg17110299	chr20:3385021	C20orf194	0.38	5.12	0.3	5.97e-7	IFN-related cytopenia;
CESC	cis	rs1218582	0.711	rs4845677	chr1:154838050	C/T	cg06221963	chr1:154839813	KCNN3	-0.7	-12.23	-0.6	1.49e-27	Prostate cancer;
CESC	cis	rs4689592	0.513	rs3857177	chr4:7066332	G/A	cg26116260	chr4:7069785	GRPEL1	0.98	14.35	0.66	5.85e-35	Monocyte percentage of white cells;
CESC	cis	rs5758659	0.623	rs133328	chr22:42408079	T/C	cg04733989	chr22:42467013	NAGA	0.47	6.37	0.36	8.53e-10	Cognitive function;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21164723	chr1:214776304	CENPF	0.59	6.97	0.39	2.46e-11	Gut microbiome composition (summer);
CESC	cis	rs17345786	1.000	rs3804778	chr3:101294572	C/T	cg12386194	chr3:101231763	SENP7	0.6	6.65	0.38	1.68e-10	Colonoscopy-negative controls vs population controls;
CESC	cis	rs597539	0.690	rs608810	chr11:68624118	G/C	cg04772025	chr11:68637568	NA	0.55	6.25	0.36	1.67e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs9419702	0.568	rs9419635	chr10:133546164	C/T	cg04492858	chr10:133558786	NA	0.46	6.73	0.38	1.06e-10	Survival in rectal cancer;
CESC	cis	rs9325144	0.560	rs11183090	chr12:38662293	G/C	cg13010199	chr12:38710504	ALG10B	-0.45	-6.1	-0.35	3.79e-9	Morning vs. evening chronotype;
CESC	cis	rs6952808	0.595	rs3778983	chr7:2166319	T/G	cg21782813	chr7:2030301	MAD1L1	0.49	7.07	0.4	1.4e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs10504229	0.679	rs12679941	chr8:58051812	G/T	cg22535103	chr8:58192502	C8orf71	-0.69	-7.61	-0.42	4.76e-13	Developmental language disorder (linguistic errors);
CESC	cis	rs7777484	0.500	rs2533885	chr7:2835655	C/T	cg18446336	chr7:2847575	GNA12	-0.38	-6.45	-0.37	5.17e-10	Height;
CESC	cis	rs7212590	0.581	rs8081710	chr17:57838040	G/A	cg20303301	chr17:57937339	TUBD1	-0.55	-5.18	-0.3	4.34e-7	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs9815354	0.767	rs73077375	chr3:41853058	C/T	cg03022575	chr3:42003672	ULK4	0.7	6.32	0.36	1.08e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs4474465	0.790	rs4492845	chr11:78260161	C/T	cg27205649	chr11:78285834	NARS2	0.42	5.27	0.31	2.88e-7	Alzheimer's disease (survival time);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg15273368	chr10:104221031	TMEM180	-0.48	-6.77	-0.38	8.39e-11	Fibrinogen levels;
CESC	trans	rs61931739	0.517	rs34760282	chr12:34153711	G/T	cg26384229	chr12:38710491	ALG10B	0.64	9.06	0.49	2.9e-17	Morning vs. evening chronotype;
CESC	cis	rs7618915	0.547	rs13085895	chr3:52678270	G/C	cg07507251	chr3:52567010	NT5DC2	0.4	7.06	0.4	1.49e-11	Bipolar disorder;
CESC	cis	rs4713118	0.512	rs2622319	chr6:28120401	G/C	cg12963246	chr6:28129442	ZNF389	0.43	6.3	0.36	1.25e-9	Parkinson's disease;
CESC	cis	rs6089584	0.888	rs6061979	chr20:60617141	C/G	cg24733560	chr20:60626293	TAF4	0.45	6.44	0.37	5.45e-10	Body mass index;
CESC	cis	rs9814567	1.000	rs7428326	chr3:134251184	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.45	-6.15	-0.35	2.87e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs2733201	1.000	rs2623019	chr15:44399628	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	-0.63	-5.83	-0.34	1.61e-8	Lipoprotein phospholipase A2 activity in cardiovascular disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15164871	chr12:123380523	VPS37B	0.61	7.25	0.41	4.58e-12	Gut microbiome composition (summer);
CESC	cis	rs7618915	0.501	rs2164885	chr3:52731269	T/C	cg07507251	chr3:52567010	NT5DC2	0.32	5.53	0.32	7.76e-8	Bipolar disorder;
CESC	cis	rs1218582	0.772	rs4240875	chr1:154885782	G/A	cg03351412	chr1:154909251	PMVK	0.69	9.25	0.49	7.88e-18	Prostate cancer;
CESC	trans	rs637571	0.654	rs1058068	chr11:65667796	G/A	cg17712092	chr4:129076599	LARP1B	0.95	13.56	0.64	3.71e-32	Eosinophil percentage of white cells;
CESC	trans	rs6572548	0.504	rs1956082	chr14:49665496	A/C	cg09365624	chr1:87597710	LOC339524	-0.53	-6.09	-0.35	3.96e-9	Subjective well-being;
CESC	cis	rs9916302	0.904	rs6503506	chr17:37524653	C/A	cg19468946	chr17:37922297	IKZF3	0.39	5.12	0.3	5.95e-7	Glomerular filtration rate (creatinine);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18279994	chr2:54950960	EML6	0.62	6.77	0.38	8.43e-11	Gut microbiome composition (summer);
CESC	cis	rs7267979	0.586	rs6083776	chr20:25186116	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.66	10.94	0.56	3.16e-23	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs9926296	0.593	rs6500456	chr16:89888341	T/C	cg27121462	chr16:89883253	FANCA	0.56	6.87	0.39	4.59e-11	Vitiligo;
CESC	cis	rs72781680	0.898	rs17462558	chr2:24020812	T/C	cg08917208	chr2:24149416	ATAD2B	0.95	8.71	0.47	3.45e-16	Lymphocyte counts;
CESC	cis	rs2408955	0.522	rs4760612	chr12:48421856	C/T	cg04545296	chr12:48745243	ZNF641	-0.35	-6.1	-0.35	3.79e-9	Glycated hemoglobin levels;
CESC	cis	rs2011503	0.882	rs72999030	chr19:19364240	A/T	cg11584989	chr19:19387371	SF4	0.53	6.41	0.37	6.52e-10	Bipolar disorder;
CESC	cis	rs9398803	0.673	rs1262557	chr6:127054588	C/T	cg19875578	chr6:126661172	C6orf173	-0.42	-5.52	-0.32	8.13e-8	Male-pattern baldness;
CESC	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	7.79	0.43	1.49e-13	Prudent dietary pattern;
CESC	cis	rs4974559	0.501	rs1250129	chr4:1254930	C/T	cg05025164	chr4:1340916	KIAA1530	0.53	5.6	0.33	5.35e-8	Systolic blood pressure;
CESC	cis	rs1223245	0.740	rs360063	chr1:226036309	A/G	cg27179622	chr1:226127290	LEFTY2	-0.35	-5.26	-0.31	2.95e-7	Preschool internalizing problems;
CESC	cis	rs801193	0.569	rs2659908	chr7:66160822	G/A	cg11764359	chr7:65958608	NA	0.73	10.55	0.54	5.73e-22	Aortic root size;
CESC	cis	rs9649213	0.593	rs35941058	chr7:97918159	T/C	cg21770322	chr7:97807741	LMTK2	0.55	8.08	0.44	2.32e-14	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7412746	0.611	rs10788794	chr1:150728676	T/C	cg17724175	chr1:150552817	MCL1	0.42	6.42	0.37	6.31e-10	Melanoma;
CESC	cis	rs4604732	0.631	rs10925043	chr1:247627001	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.57	7.17	0.4	7.39e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	trans	rs6991952	0.845	rs7822766	chr8:25742279	A/T	cg01353569	chr7:106810328	HBP1	-0.5	-6.2	-0.36	2.11e-9	Inguinal hernia;
CESC	cis	rs826838	0.967	rs1684411	chr12:39128494	C/T	cg13010199	chr12:38710504	ALG10B	-0.44	-5.97	-0.34	7.74e-9	Heart rate;
CESC	cis	rs6933660	0.683	rs8180642	chr6:151756612	A/G	cg14262678	chr6:151773367	RMND1;C6orf211	0.61	8.47	0.46	1.76e-15	Menarche (age at onset);
CESC	cis	rs7116495	1.000	rs73539532	chr11:71815684	C/A	cg26138937	chr11:71823887	C11orf51	0.85	6.85	0.39	5.03e-11	Severe influenza A (H1N1) infection;
CESC	cis	rs10504229	0.954	rs114134184	chr8:58181969	G/A	cg14926445	chr8:58193284	C8orf71	-0.51	-5.52	-0.32	8.28e-8	Developmental language disorder (linguistic errors);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg08989921	chr17:76836740	USP36	-0.52	-6.73	-0.38	1.04e-10	Ulcerative colitis;
CESC	cis	rs8067354	0.574	rs2531898	chr17:58012351	G/C	cg02344993	chr17:57696989	CLTC	0.53	5.47	0.32	1.03e-7	Hemoglobin concentration;
CESC	cis	rs6088580	0.634	rs6088471	chr20:32932643	C/A	cg06115741	chr20:33292138	TP53INP2	-0.46	-5.85	-0.34	1.45e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs769267	1.000	rs1009136	chr19:19440428	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.43	-5.52	-0.32	8.26e-8	Tonsillectomy;
CESC	cis	rs780096	0.546	rs4425043	chr2:27733452	G/A	cg12648201	chr2:27665141	KRTCAP3	-0.36	-6.38	-0.36	7.97e-10	Total body bone mineral density;
CESC	cis	rs9611565	0.649	rs5758344	chr22:41817685	G/A	cg06634786	chr22:41940651	POLR3H	0.73	7.3	0.41	3.43e-12	Vitiligo;
CESC	cis	rs897984	0.542	rs11864806	chr16:31095204	G/C	cg00531865	chr16:30841666	NA	-0.39	-5.42	-0.32	1.33e-7	Dementia with Lewy bodies;
CESC	trans	rs35146811	0.700	rs858513	chr7:99825558	G/A	cg13215871	chr17:75784724	NA	-0.34	-6.39	-0.37	7.46e-10	Coronary artery disease;
CESC	cis	rs2859741	0.967	rs494157	chr1:37512995	C/T	cg09363841	chr1:37513479	NA	0.7	11.79	0.59	4.34e-26	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
CESC	cis	rs4268898	0.662	rs2891380	chr2:24525830	G/A	cg06627628	chr2:24431161	ITSN2	-0.98	-11.27	-0.57	2.51e-24	Asthma;
CESC	cis	rs10883723	0.773	rs11191303	chr10:104255158	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.54	7.43	0.42	1.49e-12	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs9814567	0.896	rs7653807	chr3:134345724	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.42	-5.67	-0.33	3.63e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs9549367	0.789	rs2287248	chr13:113889226	T/C	cg18105134	chr13:113819100	PROZ	-0.65	-7.73	-0.43	2.24e-13	Platelet distribution width;
CESC	cis	rs4805272	0.512	rs8106166	chr19:29339578	A/G	cg12756686	chr19:29218302	NA	-0.44	-5.86	-0.34	1.35e-8	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
CESC	cis	rs4727027	0.865	rs13236754	chr7:148845773	G/A	cg23158103	chr7:148848205	ZNF398	-0.43	-7.01	-0.4	1.96e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs6460942	0.915	rs6945067	chr7:12444731	A/C	cg16278512	chr7:12443529	VWDE	-0.55	-5.87	-0.34	1.27e-8	Coronary artery disease;
CESC	cis	rs3754214	0.823	rs494041	chr1:150270026	T/C	cg09579323	chr1:150459698	TARS2	-0.47	-6.18	-0.35	2.44e-9	Cerebrospinal fluid biomarker levels;
CESC	cis	rs1448094	0.512	rs7299285	chr12:86244959	A/T	cg00310523	chr12:86230176	RASSF9	0.35	5.46	0.32	1.1e-7	Major depressive disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16256719	chr1:228613082	HIST3H3	-0.59	-6.52	-0.37	3.6e-10	Gut microbiome composition (summer);
CESC	cis	rs9322193	0.962	rs62441335	chr6:150113794	G/A	cg07701084	chr6:150067640	NUP43	0.42	5.78	0.33	2.07e-8	Lung cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22692790	chr10:70748415	KIAA1279	-0.62	-7.08	-0.4	1.33e-11	Gut microbiome composition (summer);
CESC	cis	rs11997175	0.583	rs17780571	chr8:33817821	G/C	ch.8.33884649F	chr8:33765107	NA	0.46	5.75	0.33	2.44e-8	Body mass index;
CESC	cis	rs7481584	0.962	rs11024766	chr11:2984645	C/G	cg25174290	chr11:3078921	CARS	-0.5	-6.01	-0.35	6.01e-9	Calcium levels;
CESC	cis	rs514406	0.929	rs555741	chr1:53318851	T/G	cg08736216	chr1:53307985	ZYG11A	-0.41	-6.9	-0.39	3.83e-11	Monocyte count;
CESC	cis	rs611744	0.967	rs655722	chr8:109197541	A/T	cg21045802	chr8:109455806	TTC35	0.42	5.32	0.31	2.19e-7	Dupuytren's disease;
CESC	cis	rs763121	0.853	rs5757162	chr22:38993370	C/T	cg06022373	chr22:39101656	GTPBP1	0.84	12.24	0.6	1.36e-27	Menopause (age at onset);
CESC	cis	rs7917772	0.582	rs10786683	chr10:104320476	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.42	5.71	0.33	3.08e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs5760092	0.618	rs4461358	chr22:24260106	T/C	cg12419862	chr22:24373484	LOC391322	0.81	10.51	0.54	8.1e-22	Urinary 1,3-butadiene metabolite levels in smokers;
CESC	cis	rs7264396	0.790	rs6058297	chr20:34271861	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.86	-11.84	-0.59	2.93e-26	Total cholesterol levels;
CESC	cis	rs2235642	0.893	rs2143285	chr16:1593171	A/G	cg07639376	chr16:1584516	IFT140;TMEM204	-0.33	-5.26	-0.31	3.04e-7	Coronary artery disease;
CESC	cis	rs738322	0.726	rs5750561	chr22:38595260	A/T	cg17652424	chr22:38574118	PLA2G6	0.31	5.39	0.31	1.53e-7	Cutaneous nevi;
CESC	cis	rs9914988	0.943	rs9890155	chr17:27125467	A/G	cg20469991	chr17:27169893	C17orf63	-0.48	-5.25	-0.31	3.18e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CESC	cis	rs9649213	0.593	rs13246868	chr7:97986453	T/C	cg24562669	chr7:97807699	LMTK2	0.51	7.63	0.42	4.29e-13	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs4243830	0.850	rs4908915	chr1:6601607	T/C	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.93	-8.7	-0.47	3.49e-16	Body mass index;
CESC	cis	rs9916302	0.821	rs11078916	chr17:37746307	T/C	cg00129232	chr17:37814104	STARD3	-0.7	-9.13	-0.49	1.86e-17	Glomerular filtration rate (creatinine);
CESC	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.45	-6.48	-0.37	4.36e-10	Longevity;Endometriosis;
CESC	cis	rs9457247	0.637	rs9459846	chr6:167441023	T/G	cg23791538	chr6:167370224	RNASET2	-0.57	-7.71	-0.43	2.6e-13	Crohn's disease;
CESC	cis	rs6598955	0.671	rs17257176	chr1:26578233	G/A	cg19743891	chr1:26644573	UBXN11;CD52	0.37	5.19	0.3	4.16e-7	Obesity-related traits;
CESC	cis	rs2637266	0.628	rs846632	chr10:78535759	C/A	cg18941641	chr10:78392320	NA	0.42	8.34	0.46	4.01e-15	Pulmonary function;
CESC	cis	rs3785574	0.962	rs2727331	chr17:61926990	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.57	7.1	0.4	1.11e-11	Height;
CESC	cis	rs36051895	0.589	rs11790596	chr9:5198335	T/C	cg02405213	chr9:5042618	JAK2	-0.56	-6.85	-0.39	5.09e-11	Pediatric autoimmune diseases;
CESC	cis	rs9916302	0.752	rs6503513	chr17:37561613	A/G	cg00129232	chr17:37814104	STARD3	0.56	6.5	0.37	3.99e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs7666738	0.791	rs2903151	chr4:99027218	T/C	cg24818145	chr4:99064322	C4orf37	0.39	5.09	0.3	6.95e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7914558	1.000	rs7077097	chr10:104945463	G/A	cg04362960	chr10:104952993	NT5C2	0.46	6.16	0.35	2.74e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs9811920	0.599	rs61148087	chr3:99539891	C/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.58	-9.13	-0.49	1.79e-17	Axial length;
CESC	cis	rs6860806	0.603	rs112300250	chr5:131583292	G/A	cg09877947	chr5:131593287	PDLIM4	0.46	6.15	0.35	2.84e-9	Breast cancer;
CESC	cis	rs870825	0.746	rs1107908	chr4:185620113	T/C	cg04058563	chr4:185651563	MLF1IP	0.64	7.05	0.4	1.59e-11	Blood protein levels;
CESC	cis	rs947211	0.950	rs1775145	chr1:205756143	C/A	cg26354017	chr1:205819088	PM20D1	0.43	5.58	0.32	5.98e-8	Parkinson's disease;
CESC	cis	rs60843830	0.964	rs17713568	chr2:242132	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.79	10.3	0.53	3.78e-21	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs4450131	0.522	rs35645049	chr10:126368119	C/G	cg20435097	chr10:126320824	FAM53B	0.29	5.26	0.31	2.94e-7	White blood cell count (basophil);
CESC	cis	rs12701220	0.522	rs868833	chr7:1054973	C/G	cg20821713	chr7:1055600	C7orf50	-0.5	-6.5	-0.37	4.04e-10	Bronchopulmonary dysplasia;
CESC	cis	rs798554	0.591	rs1182156	chr7:2901084	G/T	cg19717773	chr7:2847554	GNA12	-0.5	-7.53	-0.42	8.18e-13	Height;
CESC	cis	rs8014204	0.935	rs8010840	chr14:75355203	T/C	cg26191576	chr14:75389716	RPS6KL1	0.36	5.19	0.3	4.2e-7	Caffeine consumption;
CESC	cis	rs1538970	0.816	rs10789464	chr1:45959102	C/T	cg24296786	chr1:45957014	TESK2	-0.47	-5.2	-0.3	4e-7	Platelet count;
CESC	cis	rs13256369	1.000	rs10103769	chr8:8573036	G/T	cg18904891	chr8:8559673	CLDN23	0.71	8.29	0.45	5.61e-15	Obesity-related traits;
CESC	cis	rs80130819	0.688	rs4760692	chr12:48587549	T/C	cg07561017	chr12:48398056	COL2A1	0.38	5.13	0.3	5.71e-7	Prostate cancer;
CESC	cis	rs853679	0.517	rs9295761	chr6:28147987	A/G	cg23281280	chr6:28129359	ZNF389	0.56	7.6	0.42	5.19e-13	Depression;
CESC	cis	rs7089973	0.836	rs12765350	chr10:116635305	G/A	cg25233709	chr10:116636983	FAM160B1	0.34	5.03	0.3	9.07e-7	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	trans	rs11039798	1.000	rs6485848	chr11:48541517	G/T	cg15704280	chr7:45808275	SEPT13	0.7	6.6	0.38	2.27e-10	Axial length;
CESC	cis	rs561341	1.000	rs560132	chr17:30320019	C/T	cg12193833	chr17:30244370	NA	-0.76	-6.99	-0.39	2.21e-11	Hip circumference adjusted for BMI;
CESC	trans	rs62140779	0.524	rs76045944	chr2:58618545	T/C	cg16116203	chr12:6876922	PTMS	0.51	6.04	0.35	5.19e-9	Neuroticism;
CESC	cis	rs2950393	0.929	rs2958155	chr12:57064545	A/C	cg05584118	chr12:57595605	LRP1	-0.37	-5.23	-0.31	3.44e-7	Platelet distribution width;
CESC	cis	rs9486715	0.867	rs9386500	chr6:96889845	A/C	cg06623918	chr6:96969491	KIAA0776	0.93	14.47	0.66	2.36e-35	Headache;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg12227505	chr17:78194145	SLC26A11;SGSH	-0.43	-6.14	-0.35	3.01e-9	Fibrinogen levels;
CESC	cis	rs7697216	0.668	rs28465148	chr4:175850605	T/G	cg14561282	chr4:175839468	ADAM29	0.49	5.48	0.32	1e-7	Breast cancer;
CESC	cis	rs4665809	1.000	rs7588802	chr2:26277789	A/G	cg04944784	chr2:26401820	FAM59B	-0.74	-8.28	-0.45	6.01e-15	Gut microbiome composition (summer);
CESC	cis	rs7793239	0.550	rs10246191	chr7:130029811	G/A	cg04743876	chr7:130013617	NA	0.32	5.97	0.34	7.57e-9	Antipsychotic drug-induced QTc interval change in schizophrenia;
CESC	cis	rs514406	0.825	rs6693210	chr1:53223398	A/G	cg24675658	chr1:53192096	ZYG11B	0.52	6.52	0.37	3.55e-10	Monocyte count;
CESC	cis	rs1983170	0.736	rs12127718	chr1:91997490	A/T	cg25838465	chr1:92012736	NA	0.44	5.08	0.3	7.1e-7	Eosinophil percentage of white cells;
CESC	cis	rs11920090	0.860	rs7643425	chr3:170737395	A/G	cg09710316	chr3:170744871	SLC2A2	0.45	5.35	0.31	1.94e-7	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
CESC	cis	rs6987853	0.901	rs2923429	chr8:42389743	A/G	cg09913449	chr8:42400586	C8orf40	0.39	6.13	0.35	3.15e-9	Mean corpuscular hemoglobin concentration;
CESC	cis	rs7811142	1.000	rs67315960	chr7:100015124	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.09	10.81	0.55	8.61e-23	Platelet count;
CESC	trans	rs916888	0.773	rs199439	chr17:44793503	A/G	cg22968622	chr17:43663579	NA	1.32	18.48	0.75	1.44e-49	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs7208859	0.623	rs79607958	chr17:28934548	T/G	cg13385521	chr17:29058706	SUZ12P	0.78	5.67	0.33	3.78e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs7904368	0.806	rs7899853	chr10:16857603	A/T	cg23933602	chr10:16859644	RSU1	0.68	6.32	0.36	1.08e-9	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
CESC	cis	rs67311347	1.000	rs9874006	chr3:40471596	G/A	cg09455208	chr3:40491958	NA	0.44	7.56	0.42	6.79e-13	Renal cell carcinoma;
CESC	cis	rs116095464	0.558	rs1541822	chr5:269234	A/C	cg20965017	chr5:231967	SDHA	0.45	5.05	0.3	8.36e-7	Breast cancer;
CESC	cis	rs2228479	0.850	rs12599473	chr16:89827435	A/C	cg00800038	chr16:89945340	TCF25	-0.92	-7.62	-0.42	4.38e-13	Skin colour saturation;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg16811695	chr10:115999009	VWA2	0.45	6.36	0.36	9.04e-10	Systemic lupus erythematosus;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20412726	chr6:167412529	FGFR1OP	0.57	6.82	0.39	5.97e-11	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.830	rs34890015	chr4:99023769	A/T	cg18180107	chr4:99064573	C4orf37	0.42	5.44	0.32	1.2e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9486719	1.000	rs2472888	chr6:96865501	T/C	cg18709589	chr6:96969512	KIAA0776	0.53	5.81	0.34	1.75e-8	Migraine;Coronary artery disease;
CESC	cis	rs7811142	0.830	rs7792959	chr7:99972403	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.09	12.96	0.62	4.51e-30	Platelet count;
CESC	cis	rs3008870	0.755	rs2208577	chr1:67513574	A/C	cg02640540	chr1:67518911	SLC35D1	0.71	9.11	0.49	2.03e-17	Lymphocyte percentage of white cells;
CESC	cis	rs780096	0.506	rs8395	chr2:27715207	T/A	cg12648201	chr2:27665141	KRTCAP3	-0.36	-6.64	-0.38	1.76e-10	Total body bone mineral density;
CESC	trans	rs220324	1.000	rs220324	chr21:43586699	C/T	cg08141495	chr18:31739521	NOL4	0.29	6.06	0.35	4.58e-9	Idiopathic osteonecrosis of the femoral head;
CESC	cis	rs4722166	0.508	rs1474348	chr7:22767908	C/G	cg05472934	chr7:22766657	IL6	0.83	11.08	0.56	1.04e-23	Lung cancer;
CESC	cis	rs72634258	0.554	rs68024107	chr1:7914066	G/C	cg26816564	chr1:7831052	VAMP3	0.49	5.16	0.3	4.9e-7	Inflammatory bowel disease;
CESC	cis	rs875971	0.862	rs1612452	chr7:65573896	T/A	cg19163074	chr7:65112434	INTS4L2	0.42	5.13	0.3	5.63e-7	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02031769	chr6:161695303	AGPAT4	-0.55	-6.04	-0.35	5.12e-9	Gut microbiome composition (summer);
CESC	cis	rs7949030	0.626	rs7930896	chr11:62325272	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.57	7.88	0.44	8.65e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg10150615	chr22:24372951	LOC391322	0.57	7.78	0.43	1.59e-13	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs2075371	0.966	rs1901204	chr7:133985896	A/G	cg11752832	chr7:134001865	SLC35B4	0.58	7.62	0.42	4.5e-13	Mean platelet volume;
CESC	cis	rs116095464	0.558	rs10075018	chr5:239175	G/A	cg22496380	chr5:211416	CCDC127	-0.74	-8.58	-0.47	8.28e-16	Breast cancer;
CESC	cis	rs3820068	0.608	rs10927831	chr1:16028373	T/G	cg17385448	chr1:15911702	AGMAT	0.38	6.08	0.35	4.28e-9	Systolic blood pressure;
CESC	cis	rs4423214	0.592	rs7120029	chr11:71198957	G/A	cg05163923	chr11:71159392	DHCR7	-0.55	-6.01	-0.35	6.09e-9	Vitamin D levels;
CESC	cis	rs10875943	0.751	rs56222401	chr12:49672714	A/G	cg14846292	chr12:49726500	C1QL4	-0.37	-5.14	-0.3	5.31e-7	Prostate cancer;
CESC	cis	rs4268898	0.932	rs7577964	chr2:24598279	A/G	cg06627628	chr2:24431161	ITSN2	0.64	7.48	0.42	1.1e-12	Asthma;
CESC	cis	rs2204008	0.837	rs11495722	chr12:38337245	G/A	cg26384229	chr12:38710491	ALG10B	0.75	10.74	0.55	1.42e-22	Bladder cancer;
CESC	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg24829409	chr8:58192753	C8orf71	-0.67	-8.18	-0.45	1.19e-14	Developmental language disorder (linguistic errors);
CESC	cis	rs1799949	0.894	rs8176160	chr17:41241503	T/C	cg06001716	chr17:41278141	BRCA1;NBR2	0.38	5.22	0.31	3.62e-7	Menopause (age at onset);
CESC	cis	rs9900062	0.507	rs7225993	chr17:62708284	C/G	cg02598441	chr17:62777298	LOC146880	-0.59	-6.52	-0.37	3.56e-10	QT interval;
CESC	cis	rs3749237	0.595	rs4855873	chr3:49459114	A/C	cg03060546	chr3:49711283	APEH	0.76	11.67	0.58	1.11e-25	Resting heart rate;
CESC	cis	rs7267979	1.000	rs6050573	chr20:25366065	C/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.88	18.14	0.74	2.36e-48	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs2832191	1.000	rs2832184	chr21:30483265	C/T	cg08807101	chr21:30365312	RNF160	-0.67	-9.26	-0.49	7.29e-18	Dental caries;
CESC	cis	rs11785400	0.793	rs1056012	chr8:143740167	A/G	cg10596483	chr8:143751796	JRK	0.42	5.31	0.31	2.32e-7	Schizophrenia;
CESC	cis	rs4888262	0.508	rs7193583	chr16:74649589	C/G	cg01733217	chr16:74700730	RFWD3	0.87	12.3	0.6	8.07e-28	Testicular germ cell tumor;
CESC	cis	rs2576037	0.526	rs538221	chr18:44375111	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.55	-7.7	-0.43	2.68e-13	Personality dimensions;
CESC	cis	rs5753618	0.504	rs7284622	chr22:31907985	G/A	cg02404636	chr22:31891804	SFI1	0.43	5.96	0.34	7.98e-9	Colorectal cancer;
CESC	cis	rs7666738	0.830	rs9999200	chr4:99030690	A/C	cg24818145	chr4:99064322	C4orf37	0.39	5.09	0.3	6.95e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs12995491	0.731	rs55705009	chr2:88500718	T/G	cg18490616	chr2:88469792	THNSL2	-0.52	-7.74	-0.43	2.04e-13	Response to metformin (IC50);
CESC	cis	rs10905065	0.930	rs7909988	chr10:5736388	A/T	cg11519256	chr10:5708881	ASB13	0.44	5.62	0.33	4.95e-8	Menopause (age at onset);
CESC	cis	rs4566357	0.521	rs78411533	chr2:227910807	G/A	cg11843606	chr2:227700838	RHBDD1	-0.47	-6.49	-0.37	4.32e-10	Coronary artery disease;
CESC	cis	rs4974559	0.739	rs28573879	chr4:1285910	C/T	cg02980000	chr4:1222292	CTBP1	0.81	7.39	0.41	1.88e-12	Systolic blood pressure;
CESC	cis	rs8180040	0.966	rs2062278	chr3:47416761	C/T	cg27129171	chr3:47204927	SETD2	0.61	9.39	0.5	2.95e-18	Colorectal cancer;
CESC	cis	rs12911832	1.000	rs12911832	chr15:58985904	A/T	cg05156742	chr15:59063176	FAM63B	0.51	6.13	0.35	3.13e-9	Schizophrenia;
CESC	cis	rs7618501	0.633	rs13060128	chr3:50025028	A/G	cg24110177	chr3:50126178	RBM5	-0.53	-7.36	-0.41	2.33e-12	Intelligence (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07522190	chr16:28925877	RABEP2	-0.54	-6.34	-0.36	9.77e-10	Gut microbiome composition (summer);
CESC	cis	rs950169	0.579	rs62027818	chr15:84661145	T/C	cg17507749	chr15:85114479	UBE2QP1	0.63	6.07	0.35	4.33e-9	Schizophrenia;
CESC	cis	rs6088580	0.634	rs6087587	chr20:33058628	G/T	cg24642439	chr20:33292090	TP53INP2	0.52	6.9	0.39	3.73e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs4660306	0.848	rs1088099	chr1:45946654	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.62	7.71	0.43	2.56e-13	Homocysteine levels;
CESC	cis	rs2315504	0.626	rs2957100	chr17:39004145	A/G	cg05063374	chr17:38953512	KRT28	0.38	5.27	0.31	2.78e-7	Height;
CESC	cis	rs4077515	0.967	rs4266763	chr9:139289825	C/T	cg14169450	chr9:139327907	INPP5E	-0.36	-5.15	-0.3	5.13e-7	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
CESC	trans	rs4332037	0.539	rs62444881	chr7:2052318	C/T	cg11693508	chr17:37793320	STARD3	0.68	6.85	0.39	5.01e-11	Bipolar disorder;
CESC	cis	rs2072499	0.833	rs2758605	chr1:156200445	G/C	cg24450063	chr1:156163899	SLC25A44	0.82	12.64	0.61	5.76e-29	Testicular germ cell tumor;
CESC	cis	rs13191362	0.935	rs35537826	chr6:163145867	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.68	7.21	0.41	5.82e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs644799	0.965	rs598876	chr11:95560853	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.55	6.76	0.38	8.51e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs2439831	0.681	rs511673	chr15:43618863	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.85	12.74	0.62	2.55e-29	Lung cancer in ever smokers;
CESC	cis	rs597539	0.580	rs7935851	chr11:68731122	A/G	cg18350739	chr11:68623251	NA	-0.46	-6.9	-0.39	3.76e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs7666738	0.830	rs28417577	chr4:99053007	T/C	cg24818145	chr4:99064322	C4orf37	0.38	5.04	0.3	8.49e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs72627123	0.656	rs77660260	chr14:74569573	T/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.74	5.12	0.3	5.89e-7	Morning vs. evening chronotype;
CESC	cis	rs1375194	0.606	rs10188817	chr2:33815471	A/G	cg04131969	chr2:33951647	MYADML	-0.52	-6.6	-0.38	2.28e-10	Response to antidepressants in depression;
CESC	cis	rs11864453	0.612	rs11862813	chr16:72132356	C/T	cg01557791	chr16:72042693	DHODH	-0.43	-5.65	-0.33	4.15e-8	Fibrinogen levels;
CESC	cis	rs7580658	0.929	rs4150496	chr2:128029503	C/T	cg10021288	chr2:128175891	PROC	-0.4	-6.25	-0.36	1.6e-9	Protein C levels;
CESC	cis	rs6502050	0.835	rs9900128	chr17:80087920	A/T	cg01763666	chr17:80159506	CCDC57	-0.37	-5.1	-0.3	6.55e-7	Life satisfaction;
CESC	cis	rs11122272	0.701	rs2790894	chr1:231505587	T/A	cg06096015	chr1:231504339	EGLN1	0.4	5.74	0.33	2.58e-8	Hemoglobin concentration;
CESC	cis	rs8051149	0.688	rs12444670	chr16:87870312	C/T	cg03408354	chr16:87871219	SLC7A5	-0.45	-5.6	-0.33	5.3e-8	Blood metabolite levels;
CESC	cis	rs11098499	0.863	rs13149407	chr4:120437825	A/G	cg24375607	chr4:120327624	NA	0.43	5.13	0.3	5.73e-7	Corneal astigmatism;
CESC	cis	rs2180341	0.920	rs6916990	chr6:127698759	G/A	cg24812749	chr6:127587940	RNF146	1.04	14.79	0.67	1.71e-36	Breast cancer;
CESC	cis	rs1799949	1.000	rs8176077	chr17:41276348	T/C	cg25072359	chr17:41440525	NA	0.43	5.78	0.33	2.04e-8	Menopause (age at onset);
CESC	cis	rs919433	0.783	rs2565165	chr2:198233575	T/G	cg10820045	chr2:198174542	NA	0.41	5.93	0.34	9.6e-9	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs2404602	0.716	rs17364076	chr15:76760891	C/T	cg26408565	chr15:76604113	ETFA	-0.44	-6.54	-0.37	3.15e-10	Blood metabolite levels;
CESC	cis	rs57506017	0.585	rs12667950	chr7:12268468	G/T	cg23422036	chr7:12250390	TMEM106B	0.38	5.13	0.3	5.58e-7	Neuroticism;
CESC	trans	rs4824093	0.610	rs4141437	chr22:50243719	C/G	cg09872104	chr7:134855509	C7orf49	0.9	6.4	0.37	6.9e-10	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs4654899	0.643	rs2053981	chr1:21227083	G/A	cg05370193	chr1:21551575	ECE1	0.36	5.46	0.32	1.08e-7	Superior frontal gyrus grey matter volume;
CESC	cis	rs644799	0.625	rs1255177	chr11:95471495	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.45	6.03	0.35	5.6e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs9815354	0.812	rs73071343	chr3:41826877	G/C	cg03022575	chr3:42003672	ULK4	0.7	6.04	0.35	5.26e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs6690583	0.623	rs6679539	chr1:85479457	G/T	cg11262906	chr1:85462892	MCOLN2	-0.53	-5.12	-0.3	5.75e-7	Serum sulfate level;
CESC	cis	rs4822044	0.560	rs7284839	chr22:42010902	C/T	cg06481639	chr22:41940642	POLR3H	0.6	6.14	0.35	2.95e-9	Cannabis dependence symptom count;
CESC	cis	rs735539	1.000	rs6490606	chr13:21285096	C/G	cg04906043	chr13:21280425	IL17D	0.39	6.12	0.35	3.32e-9	Dental caries;
CESC	cis	rs1008375	1.000	rs4698635	chr4:17630242	C/A	cg02297831	chr4:17616191	MED28	0.55	6.92	0.39	3.33e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs854765	0.583	rs9913724	chr17:17819101	A/G	cg09796270	chr17:17721594	SREBF1	0.42	5.95	0.34	8.29e-9	Total body bone mineral density;
CESC	cis	rs654950	0.875	rs600109	chr1:41998246	A/G	cg06885757	chr1:42089581	HIVEP3	-0.48	-7.36	-0.41	2.36e-12	Airway imaging phenotypes;
CESC	cis	rs2108225	0.714	rs929393	chr7:107437048	C/T	cg18560240	chr7:107437656	SLC26A3	-0.49	-6.9	-0.39	3.89e-11	Ulcerative colitis;
CESC	cis	rs7927592	0.956	rs11228258	chr11:68254328	A/C	cg20283391	chr11:68216788	NA	0.51	6.42	0.37	6.43e-10	Total body bone mineral density;
CESC	cis	rs10504229	0.679	rs6995378	chr8:58113933	C/T	cg02725872	chr8:58115012	NA	-0.45	-7.04	-0.4	1.66e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs3936840	0.548	rs1190545	chr14:102904179	G/C	cg18135206	chr14:102964638	TECPR2	-0.43	-5.34	-0.31	1.99e-7	Plateletcrit;
CESC	cis	rs6582630	0.555	rs4601853	chr12:38435569	G/A	cg13010199	chr12:38710504	ALG10B	0.46	6.05	0.35	5.01e-9	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs644799	0.965	rs11021317	chr11:95517576	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	14.66	0.67	4.93e-36	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs4253772	0.591	rs9615938	chr22:46689468	G/A	cg24881330	chr22:46731750	TRMU	0.73	5.24	0.31	3.32e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs2228479	0.850	rs45524643	chr16:89815824	G/A	cg19635926	chr16:89946313	TCF25	0.67	5.09	0.3	6.82e-7	Skin colour saturation;
CESC	cis	rs7647973	1.000	rs9871024	chr3:49554241	T/C	cg07636037	chr3:49044803	WDR6	-0.72	-10.34	-0.54	2.85e-21	Menarche (age at onset);
CESC	cis	rs12971120	0.838	rs747176	chr18:72154931	G/A	cg26446133	chr18:72167187	CNDP2	-0.67	-9.01	-0.48	4.21e-17	Refractive error;
CESC	cis	rs1008375	0.866	rs12233712	chr4:17570063	T/A	cg02297831	chr4:17616191	MED28	0.45	5.41	0.32	1.41e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs1711745	0.702	rs2995805	chr9:115454618	T/C	cg13803584	chr9:115635662	SNX30	0.53	5.1	0.3	6.48e-7	Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
CESC	cis	rs870825	0.616	rs4623060	chr4:185642943	A/G	cg04058563	chr4:185651563	MLF1IP	0.65	7.16	0.4	8e-12	Blood protein levels;
CESC	cis	rs35306767	0.903	rs11253494	chr10:937047	C/T	cg26597838	chr10:835615	NA	0.87	9.23	0.49	9.18e-18	Eosinophil percentage of granulocytes;
CESC	cis	rs13118159	0.801	rs1128427	chr4:1330759	T/C	cg20887711	chr4:1340912	KIAA1530	0.53	7.32	0.41	2.94e-12	Longevity;
CESC	cis	rs9426691	1	rs9426691	chr1:23484904	A/G	cg12483005	chr1:23474871	LUZP1	0.51	7.83	0.43	1.17e-13	Coenzyme Q10 levels;
CESC	cis	rs10242455	0.702	rs28460612	chr7:98993205	C/G	cg25640893	chr7:99214727	ZNF498	1.04	6.31	0.36	1.15e-9	Blood metabolite levels;
CESC	cis	rs6461049	0.765	rs4719432	chr7:2140330	A/G	cg02951883	chr7:2050386	MAD1L1	-0.41	-5.35	-0.31	1.88e-7	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10623043	chr11:67211318	CORO1B	-0.62	-7.49	-0.42	1.01e-12	Gut microbiome composition (summer);
CESC	cis	rs1577917	1.000	rs12201571	chr6:86609750	A/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-5.91	-0.34	1.05e-8	Response to antipsychotic treatment;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20340149	chr2:122407145	CLASP1	0.61	7.4	0.41	1.77e-12	Gut microbiome composition (summer);
CESC	cis	rs4604732	0.588	rs12045675	chr1:247623915	C/A	cg12754571	chr1:247694271	LOC148824;OR2C3	0.42	5.13	0.3	5.67e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs801193	0.844	rs7779971	chr7:66161790	T/C	cg14393609	chr7:65229607	NA	0.47	6.31	0.36	1.17e-9	Aortic root size;
CESC	cis	rs1552244	1.000	rs35741213	chr3:10087661	A/G	cg00149659	chr3:10157352	C3orf10	0.74	8.85	0.48	1.3e-16	Alzheimer's disease;
CESC	cis	rs751728	1.000	rs6920075	chr6:33731797	C/T	cg25922239	chr6:33757077	LEMD2	0.52	7.24	0.41	4.84e-12	Crohn's disease;
CESC	cis	rs7216064	0.953	rs4791048	chr17:65848994	G/A	cg12091567	chr17:66097778	LOC651250	-0.81	-9.25	-0.49	7.53e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg17543123	chr19:30155994	PLEKHF1	-0.43	-6.0	-0.35	6.58e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs736408	0.716	rs2300149	chr3:52822921	C/T	cg18337363	chr3:52569053	NT5DC2	0.3	5.24	0.31	3.34e-7	Bipolar disorder;
CESC	cis	rs897984	0.683	rs8046001	chr16:30833321	C/T	cg02466173	chr16:30829666	NA	-0.61	-11.63	-0.58	1.55e-25	Dementia with Lewy bodies;
CESC	cis	rs992157	0.798	rs2382819	chr2:219155909	G/T	cg00012203	chr2:219082015	ARPC2	-0.74	-9.58	-0.51	7.54e-19	Colorectal cancer;
CESC	cis	rs11166927	0.548	rs4736099	chr8:140828745	T/C	cg16909799	chr8:140841666	TRAPPC9	-0.63	-9.91	-0.52	6.75e-20	Pediatric non-alcoholic fatty liver disease activity score;
CESC	cis	rs4242434	0.819	rs2291230	chr8:22463697	C/G	cg03733263	chr8:22462867	KIAA1967	0.88	15.37	0.69	1.51e-38	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CESC	cis	rs1129187	0.837	rs3763236	chr6:42902508	C/T	cg09436375	chr6:42928200	GNMT	0.26	5.54	0.32	7.11e-8	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs875971	1.000	rs6956179	chr7:65806659	C/T	cg10691866	chr7:65817282	TPST1	0.32	5.13	0.3	5.51e-7	Aortic root size;
CESC	cis	rs7980687	0.628	rs1609520	chr12:123735937	A/G	cg19016782	chr12:123741754	C12orf65	0.37	5.43	0.32	1.29e-7	Height;Educational attainment;Head circumference (infant);
CESC	trans	rs57221529	0.709	rs72707023	chr5:667620	G/A	cg25482853	chr8:67687455	SGK3	1.03	10.01	0.52	3.23e-20	Lung disease severity in cystic fibrosis;
CESC	cis	rs8114671	0.562	rs1060615	chr20:33478381	C/T	cg06115741	chr20:33292138	TP53INP2	-0.48	-5.82	-0.34	1.7e-8	Height;
CESC	cis	rs9300255	0.679	rs4759420	chr12:123794871	G/C	cg00376283	chr12:123451042	ABCB9	0.59	6.86	0.39	4.85e-11	Neutrophil percentage of white cells;
CESC	trans	rs7618501	0.602	rs2624853	chr3:50128893	A/G	cg21659725	chr3:3221576	CRBN	-0.51	-7.04	-0.4	1.67e-11	Intelligence (multi-trait analysis);
CESC	cis	rs7607369	0.596	rs56304256	chr2:219276138	T/C	cg02176678	chr2:219576539	TTLL4	-0.41	-6.33	-0.36	1.06e-9	Red blood cell count;Amyotrophic lateral sclerosis;
CESC	cis	rs73001065	0.591	rs57962361	chr19:19425025	C/T	cg03709012	chr19:19516395	GATAD2A	0.92	6.45	0.37	5.41e-10	LDL cholesterol;
CESC	cis	rs4665809	0.652	rs10779956	chr2:26405985	A/G	cg08470875	chr2:26401718	FAM59B	-0.73	-7.82	-0.43	1.27e-13	Gut microbiome composition (summer);
CESC	cis	rs67311347	0.955	rs73078170	chr3:40483947	C/T	cg09455208	chr3:40491958	NA	0.51	8.08	0.44	2.35e-14	Renal cell carcinoma;
CESC	cis	rs10242455	0.702	rs28668326	chr7:98998153	G/A	cg18809830	chr7:99032528	PTCD1	-0.91	-6.3	-0.36	1.22e-9	Blood metabolite levels;
CESC	cis	rs4713118	0.629	rs203888	chr6:28021589	C/T	cg26335602	chr6:28129616	ZNF389	0.45	6.01	0.35	6.07e-9	Parkinson's disease;
CESC	cis	rs2549003	1.000	rs2070723	chr5:131823187	A/G	cg21138405	chr5:131827807	IRF1	0.54	9.17	0.49	1.36e-17	Asthma (sex interaction);
CESC	cis	rs72945132	0.882	rs67093918	chr11:70198999	C/A	cg14191688	chr11:70257035	CTTN	0.41	5.12	0.3	6.02e-7	Coronary artery disease;
CESC	cis	rs1005224	0.819	rs10147492	chr14:76155309	T/G	cg25116370	chr14:76127843	TTLL5;C14orf1	-0.43	-5.88	-0.34	1.21e-8	Large artery stroke;
CESC	cis	rs40363	0.671	rs4786425	chr16:3537650	A/G	cg21433313	chr16:3507492	NAT15	-0.61	-6.53	-0.37	3.24e-10	Tuberculosis;
CESC	cis	rs6570726	0.846	rs9399559	chr6:145945778	C/T	cg05347473	chr6:146136440	FBXO30	0.53	6.89	0.39	4.01e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7799006	0.606	rs4721527	chr7:2306655	G/A	cg12745145	chr7:2261452	MAD1L1	-0.33	-5.24	-0.31	3.21e-7	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs4268898	0.662	rs58971404	chr2:24403753	G/A	cg08917208	chr2:24149416	ATAD2B	0.62	5.75	0.33	2.46e-8	Asthma;
CESC	cis	rs71277158	0.688	rs2241292	chr3:169798962	C/G	cg04067573	chr3:169899625	PHC3	0.71	6.97	0.39	2.52e-11	Prostate cancer;
CESC	cis	rs4919087	0.683	rs7091162	chr10:99071242	G/T	cg25902810	chr10:99078978	FRAT1	-0.5	-5.62	-0.33	4.79e-8	Monocyte count;
CESC	cis	rs1595825	0.891	rs79745588	chr2:198516835	G/A	cg10820045	chr2:198174542	NA	0.4	5.04	0.3	8.74e-7	Ulcerative colitis;
CESC	cis	rs7523050	0.643	rs35438081	chr1:109402831	G/T	cg08274380	chr1:109419600	GPSM2	0.86	5.69	0.33	3.36e-8	Fat distribution (HIV);
CESC	cis	rs875971	0.522	rs7784623	chr7:65395034	T/G	cg06456125	chr7:65229604	NA	0.44	5.77	0.33	2.22e-8	Aortic root size;
CESC	cis	rs829883	0.738	rs249854	chr12:98862772	G/A	cg25150519	chr12:98850993	NA	0.85	14.18	0.66	2.46e-34	Colorectal adenoma (advanced);
CESC	cis	rs677665	0.537	rs12121476	chr1:9335327	C/G	cg25755851	chr1:9335794	NA	0.95	13.99	0.65	1.11e-33	Eosinophil percentage of white cells;
CESC	cis	rs9488822	0.596	rs6568921	chr6:116373616	C/T	cg26893134	chr6:116381904	FRK	0.22	5.22	0.31	3.58e-7	Cholesterol, total;LDL cholesterol;
CESC	cis	rs12079745	0.590	rs7544446	chr1:169256524	T/C	cg09363564	chr1:169337483	NME7;BLZF1	-0.94	-6.2	-0.36	2.13e-9	QT interval;
CESC	cis	rs2273669	0.667	rs6899723	chr6:109362749	T/G	cg05315195	chr6:109294784	ARMC2	-0.67	-6.32	-0.36	1.13e-9	Prostate cancer;
CESC	cis	rs35306767	0.903	rs11253462	chr10:889323	T/G	cg20503657	chr10:835505	NA	0.76	7.62	0.42	4.63e-13	Eosinophil percentage of granulocytes;
CESC	cis	rs8141529	0.748	rs132533	chr22:29299571	A/G	cg15103426	chr22:29168792	CCDC117	-0.6	-7.55	-0.42	7.06e-13	Lymphocyte counts;
CESC	cis	rs9325144	0.560	rs61929893	chr12:38653366	G/A	cg26384229	chr12:38710491	ALG10B	-0.6	-8.49	-0.46	1.45e-15	Morning vs. evening chronotype;
CESC	cis	rs58688157	0.592	rs12803048	chr11:584243	C/T	cg02461776	chr11:598696	PHRF1	0.5	5.39	0.31	1.55e-7	Systemic lupus erythematosus;
CESC	cis	rs1552244	0.882	rs13100734	chr3:10022878	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.87	11.18	0.57	4.82e-24	Alzheimer's disease;
CESC	cis	rs9486715	0.867	rs4598081	chr6:96975227	A/G	cg06623918	chr6:96969491	KIAA0776	0.96	15.06	0.68	1.84e-37	Headache;
CESC	cis	rs782590	0.818	rs2627782	chr2:55825352	A/G	cg18811423	chr2:55921094	PNPT1	0.77	12.1	0.6	4.01e-27	Metabolic syndrome;
CESC	cis	rs597539	0.727	rs632984	chr11:68620271	C/T	cg18350739	chr11:68623251	NA	-0.46	-6.63	-0.38	1.91e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs9916302	0.904	rs8070695	chr17:37478062	C/T	cg15445000	chr17:37608096	MED1	-0.42	-6.65	-0.38	1.69e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg26338869	chr17:61819248	STRADA	0.69	9.12	0.49	1.91e-17	Prudent dietary pattern;
CESC	cis	rs959260	0.748	rs4789178	chr17:73368242	C/G	cg12999837	chr17:73267436	MIF4GD	-0.47	-5.45	-0.32	1.17e-7	Systemic lupus erythematosus;
CESC	cis	rs9287719	0.967	rs4405729	chr2:10755779	A/G	cg02196655	chr2:10830764	NOL10	-0.37	-5.69	-0.33	3.39e-8	Prostate cancer;
CESC	cis	rs10089	0.680	rs3805616	chr5:127520897	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.6	5.32	0.31	2.19e-7	Ileal carcinoids;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17046977	chr15:63796567	USP3	0.56	6.18	0.35	2.41e-9	Gut microbiome composition (summer);
CESC	trans	rs9369898	0.963	rs9381789	chr6:49413391	G/C	cg15934674	chr1:150266645	MRPS21	-0.37	-6.03	-0.35	5.37e-9	Homocysteine levels;
CESC	cis	rs4481887	0.927	rs9651176	chr1:248447343	A/G	cg00666640	chr1:248458726	OR2T12	0.39	6.67	0.38	1.47e-10	Common traits (Other);
CESC	cis	rs6963495	0.818	rs6956249	chr7:105149743	A/T	cg02135003	chr7:105160482	PUS7	-0.47	-5.61	-0.33	5.12e-8	Bipolar disorder (body mass index interaction);
CESC	cis	rs897984	0.542	rs11864806	chr16:31095204	G/C	cg02466173	chr16:30829666	NA	-0.4	-6.75	-0.38	9.46e-11	Dementia with Lewy bodies;
CESC	cis	rs910316	0.763	rs175047	chr14:75479039	C/G	cg11812906	chr14:75593930	NEK9	-0.81	-13.24	-0.63	4.78e-31	Height;
CESC	cis	rs1775715	0.677	rs2808105	chr10:32110907	C/T	cg18675610	chr10:32216311	ARHGAP12	0.34	5.27	0.31	2.85e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs733592	0.507	rs7138917	chr12:48455255	G/A	cg24011408	chr12:48396354	COL2A1	-0.5	-8.32	-0.45	4.78e-15	Plateletcrit;
CESC	cis	rs6860806	0.631	rs4705931	chr5:131588345	T/C	cg11843238	chr5:131593191	PDLIM4	0.37	5.4	0.31	1.47e-7	Breast cancer;
CESC	cis	rs4233802	1.000	rs10165225	chr2:151121736	C/T	cg25300694	chr2:151184358	NA	0.9	7.5	0.42	9.95e-13	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
CESC	cis	rs2425143	0.730	rs6058354	chr20:34491110	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-6.93	-0.39	3.22e-11	Blood protein levels;
CESC	cis	rs4665809	0.887	rs4665825	chr2:26333100	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.67	-7.53	-0.42	7.92e-13	Gut microbiome composition (summer);
CESC	cis	rs7746199	0.736	rs6904596	chr6:27491299	G/A	cg02228804	chr6:27775720	HIST1H2AI;HIST1H2BL	0.69	5.18	0.3	4.36e-7	Gait speed in old age;Autism spectrum disorder or schizophrenia;
CESC	cis	rs2836974	0.644	rs61300849	chr21:40680194	G/A	cg11644478	chr21:40555479	PSMG1	-0.84	-12.51	-0.61	1.57e-28	Cognitive function;
CESC	cis	rs12824058	0.799	rs4759656	chr12:130815804	G/A	cg26677194	chr12:130822605	PIWIL1	0.52	6.82	0.39	6.23e-11	Menopause (age at onset);
CESC	cis	rs9911578	1.000	rs2531729	chr17:56539890	C/T	cg12560992	chr17:57184187	TRIM37	0.92	15.31	0.69	2.4e-38	Intelligence (multi-trait analysis);
CESC	cis	rs4713118	0.621	rs10484403	chr6:28033523	A/G	cg12963246	chr6:28129442	ZNF389	0.51	6.83	0.39	5.78e-11	Parkinson's disease;
CESC	cis	rs666930	0.519	rs483180	chr1:120267505	C/G	cg19096424	chr1:120255104	PHGDH	-0.72	-8.33	-0.46	4.47e-15	Breast cancer;
CESC	cis	rs6964587	0.626	rs2188841	chr7:91522641	A/G	cg17063962	chr7:91808500	NA	-0.46	-6.47	-0.37	4.65e-10	Breast cancer;
CESC	cis	rs7598759	0.712	rs6727372	chr2:232331906	T/G	cg19187155	chr2:232395269	NMUR1	0.4	6.27	0.36	1.42e-9	Noise-induced hearing loss;
CESC	cis	rs4665809	0.590	rs4665321	chr2:26433801	A/C	cg26314531	chr2:26401878	FAM59B	-0.85	-8.88	-0.48	1e-16	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.861	rs13139309	chr4:99020916	A/G	cg03676636	chr4:99064102	C4orf37	0.33	5.15	0.3	5.05e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11148252	0.574	rs73186430	chr13:53232891	T/C	cg00495681	chr13:53174319	NA	0.62	8.55	0.47	9.89e-16	Lewy body disease;
CESC	cis	rs1167827	0.680	rs1167796	chr7:75173180	C/T	cg04681579	chr7:75027559	TRIM73;TRIM74	0.47	5.88	0.34	1.21e-8	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs1580019	0.587	rs1597555	chr7:32546118	T/G	cg06627557	chr7:32535165	LSM5;AVL9	1.06	18.8	0.76	1.12e-50	Cognitive ability;
CESC	cis	rs651907	0.557	rs13066768	chr3:101486920	A/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.44	-5.94	-0.34	9.01e-9	Colorectal cancer;
CESC	cis	rs6570726	0.935	rs365658	chr6:145844588	C/T	cg23711669	chr6:146136114	FBXO30	0.79	11.85	0.59	2.77e-26	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs736408	0.774	rs4687551	chr3:52823448	C/T	cg18404041	chr3:52824283	ITIH1	0.47	7.78	0.43	1.62e-13	Bipolar disorder;
CESC	cis	rs7605827	0.897	rs11674618	chr2:15593035	T/C	cg19274914	chr2:15703543	NA	0.32	5.69	0.33	3.38e-8	Educational attainment (years of education);
CESC	cis	rs2976388	0.566	rs4736373	chr8:143792357	G/C	cg24634471	chr8:143751801	JRK	-0.45	-5.4	-0.31	1.5e-7	Urinary tract infection frequency;
CESC	cis	rs79057730	0.599	rs9458	chr7:825494	A/G	cg06242242	chr7:766104	PRKAR1B;HEATR2	-0.85	-7.58	-0.42	5.99e-13	Initial pursuit acceleration;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27223758	chr11:64491106	NRXN2	0.46	6.26	0.36	1.51e-9	Gut microbiome composition (summer);
CESC	cis	rs2742234	0.590	rs2257767	chr10:43657811	T/G	cg07801480	chr10:43725741	RASGEF1A	0.46	5.76	0.33	2.3e-8	Hirschsprung disease;
CESC	cis	rs881375	0.678	rs7037195	chr9:123684000	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.45	6.51	0.37	3.65e-10	Rheumatoid arthritis;
CESC	cis	rs8064299	0.597	rs6501736	chr17:72775358	G/A	cg25054828	chr17:72772726	NAT9;TMEM104	0.87	14.93	0.68	5.45e-37	Monocyte count;
CESC	cis	rs4555082	0.915	rs66527719	chr14:105750523	C/G	cg13114125	chr14:105738426	BRF1	-0.74	-9.21	-0.49	1.06e-17	Mean platelet volume;Platelet distribution width;
CESC	cis	rs4132509	0.744	rs12031994	chr1:243917309	T/C	cg21452805	chr1:244014465	NA	0.64	7.03	0.4	1.71e-11	RR interval (heart rate);
CESC	cis	rs7342306	0.709	rs4290286	chr12:6290541	A/G	cg23019886	chr12:6277045	NA	0.22	5.05	0.3	8.22e-7	Platelet count;
CESC	cis	rs853679	0.517	rs9368557	chr6:28131537	T/C	cg08968635	chr6:28129556	ZNF389	0.4	5.22	0.31	3.69e-7	Depression;
CESC	cis	rs2282802	0.685	rs2337138	chr5:139691664	A/C	cg26211634	chr5:139558579	C5orf32	0.44	6.32	0.36	1.13e-9	Intelligence (multi-trait analysis);
CESC	cis	rs6952808	1.000	rs6953693	chr7:1886388	C/G	cg13880726	chr7:1868755	MAD1L1	0.51	6.9	0.39	3.91e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs8114671	0.869	rs1407202	chr20:33651967	C/T	cg24642439	chr20:33292090	TP53INP2	-0.49	-5.93	-0.34	9.34e-9	Height;
CESC	cis	rs61542988	0.606	rs4722185	chr7:22832711	G/A	cg11367502	chr7:22862612	TOMM7	0.54	6.42	0.37	6.29e-10	Fibrinogen levels;
CESC	cis	rs7833790	1.000	rs7460277	chr8:82709777	T/C	cg27398817	chr8:82754497	SNX16	-0.55	-6.39	-0.37	7.62e-10	Diastolic blood pressure;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg08269037	chr1:11751616	MAD2L2;C1orf187	0.49	6.7	0.38	1.27e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs7264396	0.563	rs6058312	chr20:34324484	A/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.63	6.86	0.39	4.77e-11	Total cholesterol levels;
CESC	cis	rs10791097	0.653	rs11222362	chr11:130731425	T/C	cg09137382	chr11:130731461	NA	0.39	5.84	0.34	1.51e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs5769765	0.862	rs138897	chr22:50231067	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.47	-5.22	-0.31	3.55e-7	Schizophrenia;
CESC	cis	rs6831352	0.703	rs2602854	chr4:100028651	C/T	cg12011299	chr4:100065546	ADH4	0.57	6.87	0.39	4.58e-11	Alcohol dependence;
CESC	cis	rs4253772	0.872	rs4253776	chr22:46629479	C/T	cg09491104	chr22:46646882	C22orf40	0.49	6.58	0.37	2.46e-10	LDL cholesterol;Cholesterol, total;
CESC	cis	rs4555082	0.834	rs2735826	chr14:105710866	G/A	cg13114125	chr14:105738426	BRF1	-0.81	-9.8	-0.52	1.56e-19	Mean platelet volume;Platelet distribution width;
CESC	cis	rs965469	0.779	rs6051770	chr20:3327014	A/G	cg17110299	chr20:3385021	C20orf194	0.4	5.25	0.31	3.1e-7	IFN-related cytopenia;
CESC	cis	rs7582720	1.000	rs72932572	chr2:203859391	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.36	0.41	2.34e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	trans	rs3780486	0.718	rs73645257	chr9:33132354	C/T	cg20290983	chr6:43655470	MRPS18A	0.71	8.4	0.46	2.68e-15	IgG glycosylation;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22209105	chr20:16710841	SNRPB2	0.63	7.02	0.4	1.84e-11	Gut microbiome composition (summer);
CESC	cis	rs67311347	1.000	rs4973878	chr3:40407565	C/T	cg09455208	chr3:40491958	NA	0.45	7.8	0.43	1.42e-13	Renal cell carcinoma;
CESC	cis	rs77741769	0.571	rs11065283	chr12:121266453	A/G	cg02419362	chr12:121203948	SPPL3	0.36	5.79	0.33	2.03e-8	Mean corpuscular volume;
CESC	cis	rs7089973	0.604	rs11196929	chr10:116582080	G/C	cg23260525	chr10:116636907	FAM160B1	0.37	6.52	0.37	3.48e-10	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs7917772	0.604	rs4917977	chr10:104363119	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.42	5.66	0.33	4.02e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs710216	0.879	rs710218	chr1:43427218	A/T	cg03128534	chr1:43423976	SLC2A1	0.62	7.94	0.44	5.89e-14	Red cell distribution width;
CESC	cis	rs12681288	0.748	rs2701935	chr8:1028618	T/A	cg04851639	chr8:1020857	NA	-0.42	-8.98	-0.48	5.33e-17	Schizophrenia;
CESC	cis	rs9399135	0.967	rs4895436	chr6:135295001	G/A	cg24558204	chr6:135376177	HBS1L	0.5	6.75	0.38	9.09e-11	Red blood cell count;
CESC	cis	rs8017423	0.740	rs8003095	chr14:90680643	A/T	cg14092571	chr14:90743983	NA	-0.58	-8.73	-0.47	2.97e-16	Mortality in heart failure;
CESC	cis	rs11167764	1.000	rs7722567	chr5:141483178	C/T	cg08523384	chr5:141488047	NDFIP1	-0.37	-5.43	-0.32	1.3e-7	Crohn's disease;
CESC	cis	rs6088580	0.634	rs6059896	chr20:33111783	T/C	cg06115741	chr20:33292138	TP53INP2	0.45	5.74	0.33	2.53e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs6502050	0.835	rs35192339	chr17:80119106	G/A	cg11859384	chr17:80120422	CCDC57	-0.39	-5.34	-0.31	1.98e-7	Life satisfaction;
CESC	cis	rs826838	0.510	rs17523988	chr12:39222785	A/C	cg26384229	chr12:38710491	ALG10B	0.7	10.51	0.54	7.69e-22	Heart rate;
CESC	cis	rs9894429	1.000	rs7213129	chr17:79581573	C/T	cg18240062	chr17:79603768	NPLOC4	0.72	10.27	0.53	4.71e-21	Eye color traits;
CESC	cis	rs7666738	0.822	rs6815312	chr4:99058220	T/C	cg05340658	chr4:99064831	C4orf37	0.83	12.92	0.62	5.96e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6674176	0.569	rs34830883	chr1:44405339	T/C	cg23954153	chr1:44402353	ARTN	-0.35	-5.51	-0.32	8.39e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs7818688	0.929	rs7812312	chr8:96020400	T/C	cg16049864	chr8:95962084	TP53INP1	0.61	5.74	0.33	2.56e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs1832871	0.672	rs62437159	chr6:158697705	C/T	cg07165851	chr6:158734300	TULP4	0.59	6.32	0.36	1.08e-9	Height;
CESC	cis	rs36051895	0.625	rs11792531	chr9:5152203	T/C	cg02405213	chr9:5042618	JAK2	-0.49	-5.55	-0.32	7.04e-8	Pediatric autoimmune diseases;
CESC	cis	rs11792861	0.926	rs58795279	chr9:111851902	A/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.41	5.09	0.3	6.65e-7	Menarche (age at onset);
CESC	cis	rs6461049	0.638	rs1859993	chr7:2183702	A/G	cg05863683	chr7:1912471	MAD1L1	0.35	5.29	0.31	2.51e-7	Schizophrenia;
CESC	cis	rs12618769	0.625	rs3769717	chr2:99124817	G/A	cg10123293	chr2:99228465	UNC50	0.39	5.13	0.3	5.6e-7	Bipolar disorder;
CESC	cis	rs919433	1.000	rs6761919	chr2:198163328	A/G	cg10820045	chr2:198174542	NA	-0.42	-6.46	-0.37	4.95e-10	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs73001065	0.901	rs3794991	chr19:19610596	C/T	cg03709012	chr19:19516395	GATAD2A	0.96	5.93	0.34	9.6e-9	LDL cholesterol;
CESC	cis	rs853679	0.517	rs4713150	chr6:28136212	G/A	cg20151795	chr6:28129481	ZNF389	0.41	5.3	0.31	2.46e-7	Depression;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg25005433	chr10:38146040	ZNF248	-0.41	-6.15	-0.35	2.88e-9	Gambling;
CESC	cis	rs4862750	0.794	rs7672272	chr4:187896774	T/G	cg03452623	chr4:187889614	NA	-0.88	-16.16	-0.7	2.28e-41	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs7615952	0.512	rs2979336	chr3:125357470	G/A	cg21747405	chr11:67723411	NA	-0.44	-6.72	-0.38	1.12e-10	Blood pressure (smoking interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06728098	chr8:80942046	MRPS28	-0.5	-6.22	-0.36	1.95e-9	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.546	rs1456207	chr4:98676911	G/A	cg05340658	chr4:99064831	C4orf37	0.54	6.55	0.37	2.96e-10	Colonoscopy-negative controls vs population controls;
CESC	trans	rs61931739	0.517	rs56308002	chr12:34016021	C/G	cg26384229	chr12:38710491	ALG10B	0.59	8.24	0.45	8.19e-15	Morning vs. evening chronotype;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25001845	chr14:75201709	FCF1	-0.66	-7.75	-0.43	2e-13	Gut microbiome composition (summer);
CESC	cis	rs6496667	0.779	rs8027211	chr15:90983706	A/G	cg13834112	chr15:90361639	NA	0.39	5.07	0.3	7.63e-7	Rheumatoid arthritis;
CESC	cis	rs6834538	0.597	rs9991830	chr4:113485372	T/C	cg05166686	chr4:113558556	LARP7;C4orf21	0.43	5.3	0.31	2.43e-7	Free thyroxine concentration;
CESC	cis	rs875971	0.830	rs427973	chr7:65526648	C/A	cg12463550	chr7:65579703	CRCP	0.57	7.18	0.4	7.04e-12	Aortic root size;
CESC	cis	rs2836974	0.897	rs35391055	chr21:40525516	G/A	cg27266027	chr21:40555129	PSMG1	0.49	6.01	0.35	6.14e-9	Cognitive function;
CESC	cis	rs365132	0.967	rs353471	chr5:176363429	T/C	cg16309518	chr5:176445507	NA	-0.37	-5.37	-0.31	1.76e-7	Menarche and menopause (age at onset);Menopause (age at onset);
CESC	cis	rs4253772	0.513	rs9615345	chr22:46713631	C/T	cg24881330	chr22:46731750	TRMU	0.84	8.76	0.47	2.31e-16	LDL cholesterol;Cholesterol, total;
CESC	cis	rs6598955	0.694	rs6659387	chr1:26634307	G/A	cg00852783	chr1:26633632	UBXN11	0.43	6.18	0.36	2.35e-9	Obesity-related traits;
CESC	cis	rs896854	0.625	rs13281709	chr8:95972819	T/A	cg26343298	chr8:95960752	TP53INP1	0.36	5.96	0.34	7.8e-9	Type 2 diabetes;
CESC	cis	rs35110281	0.720	rs162393	chr21:44942692	G/A	cg01579765	chr21:45077557	HSF2BP	-0.54	-9.19	-0.49	1.15e-17	Mean corpuscular volume;
CESC	cis	rs8017423	0.967	rs11626011	chr14:90693572	A/G	cg14092571	chr14:90743983	NA	-0.51	-7.61	-0.42	4.78e-13	Mortality in heart failure;
CESC	cis	rs10504229	0.953	rs59034808	chr8:58185337	T/C	cg05313129	chr8:58192883	C8orf71	-0.46	-5.71	-0.33	3.1e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs9457247	1.000	rs2149085	chr6:167371110	T/C	cg23791538	chr6:167370224	RNASET2	0.61	8.65	0.47	5.15e-16	Crohn's disease;
CESC	cis	rs473651	0.904	rs10929275	chr2:239323169	A/G	cg18131467	chr2:239335373	ASB1	1.0	20.02	0.78	6.05e-55	Multiple system atrophy;
CESC	cis	rs853679	0.517	rs9295759	chr6:28124469	C/T	cg23281280	chr6:28129359	ZNF389	0.6	7.95	0.44	5.53e-14	Depression;
CESC	cis	rs7520050	0.966	rs6661910	chr1:46290632	A/T	cg24296786	chr1:45957014	TESK2	0.43	5.4	0.31	1.47e-7	Red blood cell count;Reticulocyte count;
CESC	cis	rs4819052	0.851	rs2838832	chr21:46664904	A/G	cg11663144	chr21:46675770	NA	0.63	9.77	0.51	1.93e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs9814567	1.000	rs9809619	chr3:134280948	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.45	-6.09	-0.35	3.9e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs796364	0.806	rs203766	chr2:200902672	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.87	-8.14	-0.45	1.58e-14	Schizophrenia;
CESC	cis	rs7666738	0.715	rs116787789	chr4:98718720	G/A	cg24818145	chr4:99064322	C4orf37	0.39	5.09	0.3	6.79e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1385374	0.858	rs10847696	chr12:129297153	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.58	5.22	0.31	3.55e-7	Systemic lupus erythematosus;
CESC	cis	rs5750830	0.594	rs6001587	chr22:39819008	T/C	cg24399712	chr22:39784796	NA	-0.81	-10.81	-0.55	8.51e-23	Intelligence (multi-trait analysis);
CESC	trans	rs7618501	0.932	rs4855850	chr3:49761571	G/A	cg21659725	chr3:3221576	CRBN	-0.83	-13.7	-0.64	1.17e-32	Intelligence (multi-trait analysis);
CESC	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg03188948	chr7:1209495	NA	0.72	6.98	0.39	2.42e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2658782	0.789	rs2605574	chr11:93136444	T/G	cg15737290	chr11:93063684	CCDC67	0.4	5.25	0.31	3.12e-7	Pulmonary function decline;
CESC	trans	rs10751667	1.000	rs6597972	chr11:928402	C/T	cg11748187	chr10:114713108	TCF7L2	-0.4	-6.15	-0.35	2.88e-9	Alzheimer's disease (late onset);
CESC	cis	rs9457247	0.529	rs6907666	chr6:167523395	A/G	cg23791538	chr6:167370224	RNASET2	0.46	6.11	0.35	3.46e-9	Crohn's disease;
CESC	cis	rs6088580	0.634	rs6120642	chr20:33012531	A/G	cg08999081	chr20:33150536	PIGU	0.65	11.43	0.57	7.26e-25	Glomerular filtration rate (creatinine);
CESC	cis	rs11690935	0.959	rs10184866	chr2:172608956	T/G	cg13550731	chr2:172543902	DYNC1I2	-1.02	-16.95	-0.72	3.78e-44	Schizophrenia;
CESC	cis	rs9926296	0.712	rs258332	chr16:89727683	G/A	cg27121462	chr16:89883253	FANCA	-0.47	-5.52	-0.32	8.24e-8	Vitiligo;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20851790	chr17:78330477	RNF213;LOC100294362	-0.61	-7.71	-0.43	2.55e-13	Gut microbiome composition (summer);
CESC	cis	rs798766	1.000	rs798766	chr4:1734239	C/T	cg05874882	chr4:1763078	NA	0.57	7.64	0.42	3.99e-13	Bladder cancer;Urinary bladder cancer;
CESC	cis	rs4722166	0.630	rs2091115	chr7:22810166	G/T	cg26061582	chr7:22766209	IL6	0.53	6.11	0.35	3.58e-9	Lung cancer;
CESC	cis	rs9457247	0.663	rs9459835	chr6:167417551	G/T	cg23791538	chr6:167370224	RNASET2	-0.58	-7.96	-0.44	5.09e-14	Crohn's disease;
CESC	cis	rs10170846	0.893	rs11692810	chr2:223544096	A/C	cg25565276	chr2:223520875	FARSB	-0.57	-7.96	-0.44	4.98e-14	Schizophrenia (inflammation and infection response interaction);
CESC	cis	rs6087990	0.899	rs6058893	chr20:31392777	C/T	cg13636640	chr20:31349939	DNMT3B	0.88	15.22	0.68	5.13e-38	Ulcerative colitis;
CESC	cis	rs7607369	0.536	rs6436091	chr2:219669141	T/C	cg02176678	chr2:219576539	TTLL4	-0.36	-6.16	-0.35	2.75e-9	Red blood cell count;Amyotrophic lateral sclerosis;
CESC	cis	rs6460942	1.000	rs118083671	chr7:12466036	C/T	cg10578991	chr7:12443926	VWDE	-0.5	-5.52	-0.32	7.93e-8	Coronary artery disease;
CESC	cis	rs2836950	0.565	rs2150413	chr21:40614878	C/T	cg11644478	chr21:40555479	PSMG1	-0.55	-7.46	-0.42	1.24e-12	Menarche (age at onset);
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg11956111	chr2:74710460	TTC31;CCDC142	0.5	6.74	0.38	9.6e-11	Systemic lupus erythematosus;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09730017	chr11:118955708	HMBS	-0.66	-7.54	-0.42	7.65e-13	Gut microbiome composition (summer);
CESC	cis	rs2295499	0.727	rs9762293	chr4:2729158	C/G	cg08330972	chr4:2403930	ZFYVE28	-0.31	-5.04	-0.3	8.52e-7	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04686114	chr12:57081832	PTGES3	0.54	6.58	0.37	2.53e-10	Gut microbiome composition (summer);
CESC	cis	rs9863	0.861	rs3789967	chr12:124447339	T/G	cg17562584	chr12:124393655	DNAH10	0.32	5.55	0.32	6.96e-8	White blood cell count;
CESC	cis	rs3540	0.512	rs3862433	chr15:91076028	G/A	cg22089800	chr15:90895588	ZNF774	-0.64	-8.73	-0.47	2.85e-16	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs9611565	0.546	rs739134	chr22:42089623	T/C	cg06481639	chr22:41940642	POLR3H	0.62	6.5	0.37	3.95e-10	Vitiligo;
CESC	cis	rs3540	0.576	rs12907587	chr15:91045851	G/C	cg22089800	chr15:90895588	ZNF774	-0.65	-8.94	-0.48	6.86e-17	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs397969	0.607	rs169413	chr17:19849745	G/A	cg12073167	chr17:19770448	ULK2	-0.44	-5.11	-0.3	6.17e-7	Platelet count;
CESC	cis	rs7267979	1.000	rs448396	chr20:25440269	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.86	17.57	0.73	2.33e-46	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs13256369	0.708	rs10903310	chr8:8589687	A/C	cg17143192	chr8:8559678	CLDN23	-0.6	-6.53	-0.37	3.37e-10	Obesity-related traits;
CESC	cis	rs9611565	0.525	rs1883827	chr22:41703579	A/G	cg06481639	chr22:41940642	POLR3H	-0.49	-5.57	-0.32	6.21e-8	Vitiligo;
CESC	trans	rs7945705	0.935	rs2568061	chr11:8886260	A/G	cg10637292	chr12:52960529	KRT74	0.36	6.19	0.36	2.27e-9	Hemoglobin concentration;
CESC	cis	rs12079745	1.000	rs72637225	chr1:169129320	T/G	cg09363564	chr1:169337483	NME7;BLZF1	-0.71	-5.47	-0.32	1.06e-7	QT interval;
CESC	cis	rs9300255	0.602	rs1727314	chr12:123640664	C/A	cg19016782	chr12:123741754	C12orf65	-0.4	-5.77	-0.33	2.27e-8	Neutrophil percentage of white cells;
CESC	cis	rs597539	0.652	rs553875	chr11:68695144	T/G	cg21963583	chr11:68658836	MRPL21	0.38	5.11	0.3	6.19e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs4665809	0.938	rs35844686	chr2:26304949	A/G	cg27170947	chr2:26402098	FAM59B	0.66	7.37	0.41	2.12e-12	Gut microbiome composition (summer);
CESC	cis	rs9322193	0.851	rs9322194	chr6:149920249	C/T	cg07701084	chr6:150067640	NUP43	0.41	5.73	0.33	2.67e-8	Lung cancer;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg24441383	chr12:19459574	PLEKHA5	0.53	6.93	0.39	3.25e-11	Fibrinogen levels;
CESC	cis	rs270601	0.739	rs1979981	chr5:131601720	G/A	cg09877947	chr5:131593287	PDLIM4	0.48	6.32	0.36	1.11e-9	Acylcarnitine levels;
CESC	cis	rs4150161	0.591	rs3785036	chr16:84219810	T/G	cg10106505	chr16:84220380	TAF1C	-0.76	-5.53	-0.32	7.76e-8	Systolic blood pressure response to hydrochlorothiazide in hypertension;
CESC	trans	rs11039798	0.925	rs6485831	chr11:48455031	A/T	cg15704280	chr7:45808275	SEPT13	0.68	6.37	0.36	8.22e-10	Axial length;
CESC	cis	rs17655565	0.508	rs1548303	chr12:52737642	C/T	cg00777198	chr12:52828273	KRT75	0.37	5.48	0.32	9.85e-8	Plasma amyloid beta peptide concentrations (ABx-42);
CESC	cis	rs6540559	1.000	rs17015259	chr1:209982923	G/A	cg12034118	chr1:209979487	IRF6	0.42	5.31	0.31	2.37e-7	Cleft lip with or without cleft palate;
CESC	cis	rs7116495	0.881	rs7930722	chr11:71737484	C/G	cg26138937	chr11:71823887	C11orf51	-0.77	-6.19	-0.36	2.3e-9	Severe influenza A (H1N1) infection;
CESC	cis	rs7255436	0.928	rs7250870	chr19:8453682	C/T	cg10174797	chr19:8464628	RAB11B	0.39	5.55	0.32	7.06e-8	HDL cholesterol;
CESC	cis	rs2832191	0.791	rs8134407	chr21:30476586	G/A	cg08807101	chr21:30365312	RNF160	0.74	10.56	0.54	5.33e-22	Dental caries;
CESC	trans	rs561341	0.941	rs2470236	chr17:30304940	G/C	cg20587970	chr11:113659929	NA	-1.1	-13.93	-0.65	1.88e-33	Hip circumference adjusted for BMI;
CESC	cis	rs854765	0.647	rs854770	chr17:18019048	A/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.49	6.25	0.36	1.65e-9	Total body bone mineral density;
CESC	trans	rs7618501	0.633	rs11925192	chr3:50038664	G/A	cg21659725	chr3:3221576	CRBN	0.49	6.89	0.39	3.95e-11	Intelligence (multi-trait analysis);
CESC	trans	rs6828577	0.819	rs1064034	chr4:119631992	A/T	cg05098011	chr1:151736092	OAZ3;MRPL9	0.49	6.13	0.35	3.25e-9	Perioperative myocardial infarction in coronary artery bypass surgery;
CESC	cis	rs13343954	0.518	rs2216594	chr19:33533258	G/A	cg03563238	chr19:33554763	RHPN2	-0.31	-5.44	-0.32	1.21e-7	Colorectal cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15739997	chr20:48729771	UBE2V1;TMEM189-UBE2V1	0.58	6.24	0.36	1.75e-9	Gut microbiome composition (summer);
CESC	cis	rs8044868	0.586	rs6499564	chr16:72189655	G/A	cg01557791	chr16:72042693	DHODH	-0.41	-5.47	-0.32	1.02e-7	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CESC	cis	rs2243480	1.000	rs4718333	chr7:65772758	T/C	cg18252515	chr7:66147081	NA	1.41	14.3	0.66	9.43e-35	Diabetic kidney disease;
CESC	cis	rs11711311	0.955	rs9823423	chr3:113419741	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.57	7.51	0.42	9.29e-13	IgG glycosylation;
CESC	cis	rs2072732	0.861	rs67289919	chr1:2954208	G/A	cg03976712	chr1:2946727	NA	0.33	5.53	0.32	7.83e-8	Plateletcrit;
CESC	cis	rs798554	0.836	rs798500	chr7:2790685	C/T	cg13628971	chr7:2884303	GNA12	-0.61	-7.84	-0.43	1.07e-13	Height;
CESC	cis	rs7580658	0.929	rs2276583	chr2:128014684	G/A	cg10021288	chr2:128175891	PROC	-0.41	-6.47	-0.37	4.79e-10	Protein C levels;
CESC	cis	rs11098499	0.775	rs67281037	chr4:120281157	G/C	cg09307838	chr4:120376055	NA	0.87	12.16	0.6	2.41e-27	Corneal astigmatism;
CESC	cis	rs3126085	0.935	rs4634913	chr1:152249932	T/C	cg03465714	chr1:152285911	FLG	-0.46	-5.75	-0.33	2.42e-8	Atopic dermatitis;
CESC	cis	rs9914988	0.943	rs12453504	chr17:27119524	C/A	cg20469991	chr17:27169893	C17orf63	-0.48	-5.25	-0.31	3.18e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CESC	cis	rs1371867	0.875	rs7830342	chr8:101327738	T/A	cg11906718	chr8:101322791	RNF19A	0.46	5.92	0.34	1.02e-8	Atrioventricular conduction;
CESC	cis	rs8050907	0.744	rs78538387	chr16:4523167	G/A	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.9	6.28	0.36	1.39e-9	Obesity-related traits;
CESC	cis	rs597583	0.715	rs11216437	chr11:117394685	A/G	cg27161313	chr11:117392002	DSCAML1	0.46	6.03	0.35	5.46e-9	Putamen volume;
CESC	cis	rs11792861	0.589	rs75742991	chr9:111929624	C/G	cg13535736	chr9:111863775	C9orf5	-0.5	-6.15	-0.35	2.89e-9	Menarche (age at onset);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg03161587	chr2:220405163	CHPF	0.47	7.12	0.4	1.02e-11	Gambling;
CESC	cis	rs644799	1.000	rs623191	chr11:95548359	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.53	6.41	0.37	6.77e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs9911578	1.000	rs12449365	chr17:56600660	C/G	cg02118635	chr17:56770003	RAD51C;TEX14	-0.41	-5.53	-0.32	7.63e-8	Intelligence (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02327464	chr16:88871102	CDT1	0.56	6.37	0.36	8.28e-10	Gut microbiome composition (summer);
CESC	cis	rs10206020	0.836	rs10202105	chr2:1553301	C/T	cg26248373	chr2:1572462	NA	-0.55	-6.12	-0.35	3.31e-9	IgG glycosylation;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09038155	chr4:139937227	CCRN4L	0.55	6.04	0.35	5.29e-9	Gut microbiome composition (summer);
CESC	cis	rs714031	0.785	rs11704439	chr22:40069493	T/G	cg21377881	chr22:40064566	CACNA1I	-0.37	-6.03	-0.35	5.62e-9	Schizophrenia;
CESC	cis	rs66731853	0.769	rs657624	chr1:20888348	C/T	cg04087271	chr1:20915334	CDA	-0.45	-6.28	-0.36	1.38e-9	Mean corpuscular volume;
CESC	cis	rs4595586	0.546	rs2056159	chr12:39270417	C/G	cg26384229	chr12:38710491	ALG10B	0.69	10.4	0.54	1.82e-21	Morning vs. evening chronotype;
CESC	cis	rs3091242	0.933	rs10903130	chr1:25769221	A/T	cg02931644	chr1:25747376	RHCE	0.39	6.6	0.38	2.19e-10	Erythrocyte sedimentation rate;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg02698620	chr7:45026579	C7orf40;SNORA9	0.51	6.57	0.37	2.68e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs6460942	1.000	rs77010200	chr7:12290724	G/A	cg10578991	chr7:12443926	VWDE	-0.56	-5.76	-0.33	2.27e-8	Coronary artery disease;
CESC	cis	rs10754283	0.967	rs10754285	chr1:90116587	A/G	cg21401794	chr1:90099060	LRRC8C	0.54	7.2	0.4	6.35e-12	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs7666738	0.581	rs34205844	chr4:98887494	C/A	cg05340658	chr4:99064831	C4orf37	0.71	10.09	0.53	1.79e-20	Colonoscopy-negative controls vs population controls;
CESC	trans	rs79976124	0.800	rs10944857	chr6:66637078	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.68	7.73	0.43	2.2e-13	Type 2 diabetes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06397510	chr1:32403634	PTP4A2	0.57	6.79	0.38	7.4e-11	Gut microbiome composition (summer);
CESC	cis	rs4665809	0.590	rs35746418	chr2:26455002	C/G	cg27170947	chr2:26402098	FAM59B	0.87	9.89	0.52	7.6e-20	Gut microbiome composition (summer);
CESC	cis	rs6665290	0.935	rs12403236	chr1:227196502	C/G	cg10327440	chr1:227177885	CDC42BPA	-1.23	-31.46	-0.89	1.89e-91	Myeloid white cell count;
CESC	cis	rs2120019	1.000	rs2415253	chr15:75375699	A/G	cg17294928	chr15:75287854	SCAMP5	-0.6	-6.81	-0.39	6.44e-11	Blood trace element (Zn levels);
CESC	trans	rs9929218	0.817	rs3114402	chr16:68719607	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.84	-11.16	-0.57	5.74e-24	Colorectal cancer;
CESC	cis	rs3540	0.597	rs7498113	chr15:91051192	C/G	cg22089800	chr15:90895588	ZNF774	-0.63	-8.41	-0.46	2.65e-15	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs1552244	0.882	rs34779351	chr3:10021801	A/G	cg08888203	chr3:10149979	C3orf24	0.49	6.14	0.35	3.07e-9	Alzheimer's disease;
CESC	cis	rs4919087	0.748	rs701816	chr10:98977250	C/T	cg25902810	chr10:99078978	FRAT1	-0.51	-5.73	-0.33	2.66e-8	Monocyte count;
CESC	cis	rs9291683	0.595	rs35250962	chr4:10048271	C/T	cg02734326	chr4:10020555	SLC2A9	0.47	6.6	0.38	2.23e-10	Bone mineral density;
CESC	cis	rs6032067	1.000	rs6032052	chr20:43829883	C/A	cg10761708	chr20:43804764	PI3	0.52	6.32	0.36	1.07e-9	Blood protein levels;
CESC	cis	rs9640161	0.830	rs76741564	chr7:150059529	A/T	cg17279839	chr7:150038598	RARRES2	0.41	5.33	0.31	2.07e-7	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs453301	0.658	rs6983877	chr8:8904639	T/C	cg15556689	chr8:8085844	FLJ10661	-0.51	-6.27	-0.36	1.47e-9	Joint mobility (Beighton score);
CESC	cis	rs7666738	0.546	rs13105521	chr4:98734419	C/T	cg05340658	chr4:99064831	C4orf37	0.58	7.22	0.41	5.63e-12	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9916302	0.861	rs8079590	chr17:37426201	T/C	cg07936489	chr17:37558343	FBXL20	-0.8	-11.48	-0.58	5.11e-25	Glomerular filtration rate (creatinine);
CESC	cis	rs798554	0.679	rs1614791	chr7:2888057	G/T	cg04166393	chr7:2884313	GNA12	0.62	8.1	0.45	2.08e-14	Height;
CESC	cis	rs9611565	0.694	rs5758365	chr22:41858657	A/G	cg06481639	chr22:41940642	POLR3H	0.64	6.52	0.37	3.61e-10	Vitiligo;
CESC	cis	rs7618915	0.547	rs34610142	chr3:52708429	G/A	cg05564831	chr3:52568323	NT5DC2	0.44	6.68	0.38	1.37e-10	Bipolar disorder;
CESC	cis	rs1044826	0.642	rs4607068	chr3:139162994	A/G	cg00490450	chr3:139108681	COPB2	0.41	5.05	0.3	8.21e-7	Obesity-related traits;
CESC	cis	rs35306767	0.903	rs11812523	chr10:915638	C/T	cg20503657	chr10:835505	NA	0.79	7.89	0.44	8.13e-14	Eosinophil percentage of granulocytes;
CESC	cis	rs67311347	1.000	rs9882171	chr3:40518821	G/A	cg24209194	chr3:40518798	ZNF619	0.57	7.75	0.43	2.03e-13	Renal cell carcinoma;
CESC	cis	rs9911578	0.842	rs12450766	chr17:56832965	G/C	cg05425664	chr17:57184151	TRIM37	0.46	5.73	0.33	2.72e-8	Intelligence (multi-trait analysis);
CESC	cis	rs7552404	0.924	rs1303169	chr1:76195041	T/C	cg22875332	chr1:76189707	ACADM	0.7	9.5	0.5	1.27e-18	Blood metabolite levels;Acylcarnitine levels;
CESC	trans	rs12599106	0.715	rs34006830	chr16:34878550	C/A	cg11235426	chr6:292522	DUSP22	-0.72	-9.09	-0.49	2.39e-17	Menopause (age at onset);
CESC	cis	rs7216064	1.000	rs3206817	chr17:65892834	A/G	cg07042672	chr17:66097459	LOC651250	-0.54	-5.81	-0.34	1.79e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg02217955	chr22:50941799	LMF2	0.43	6.8	0.39	6.91e-11	Fibrinogen levels;
CESC	cis	rs9549260	0.753	rs9549246	chr13:41220755	G/A	cg21288729	chr13:41239152	FOXO1	0.53	5.04	0.3	8.53e-7	Red blood cell count;
CESC	cis	rs4704187	0.553	rs116188801	chr5:74398141	A/G	cg03227963	chr5:74354835	NA	0.32	5.91	0.34	1.03e-8	Response to amphetamines;
CESC	trans	rs116095464	0.614	rs10059220	chr5:242813	C/T	cg00938859	chr5:1591904	SDHAP3	0.7	6.66	0.38	1.54e-10	Breast cancer;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg26782824	chr11:82867961	PCF11	0.43	6.0	0.35	6.29e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs72781680	0.898	rs55846516	chr2:24158003	T/C	cg08917208	chr2:24149416	ATAD2B	0.94	8.66	0.47	4.66e-16	Lymphocyte counts;
CESC	cis	rs6433857	0.594	rs17455575	chr2:181524487	G/A	cg23363182	chr2:181467187	NA	-0.47	-6.56	-0.37	2.78e-10	Body mass index;
CESC	cis	rs1448094	0.534	rs974818	chr12:86144307	T/C	cg02569458	chr12:86230093	RASSF9	-0.42	-6.44	-0.37	5.67e-10	Major depressive disorder;
CESC	cis	rs2576037	0.526	rs564113	chr18:44364389	A/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.42	6.89	0.39	4.17e-11	Personality dimensions;
CESC	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	22.16	0.81	2.75e-62	Prudent dietary pattern;
CESC	cis	rs801193	1.000	rs2659912	chr7:66157999	G/C	cg18876405	chr7:65276391	NA	0.54	7.27	0.41	3.98e-12	Aortic root size;
CESC	cis	rs1552244	1.000	rs12374115	chr3:10134766	A/G	cg00149659	chr3:10157352	C3orf10	-0.7	-9.07	-0.49	2.76e-17	Alzheimer's disease;
CESC	cis	rs597539	0.690	rs11228383	chr11:68623228	T/G	cg04772025	chr11:68637568	NA	0.53	5.95	0.34	8.3e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs9649213	0.555	rs6948346	chr7:97959956	A/G	cg24562669	chr7:97807699	LMTK2	0.5	7.25	0.41	4.62e-12	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7818345	0.845	rs7821446	chr8:19268822	A/G	cg11303988	chr8:19266685	CSGALNACT1	-0.39	-6.92	-0.39	3.4e-11	Language performance in older adults (adjusted for episodic memory);
CESC	cis	rs34779708	0.966	rs6481941	chr10:35440141	G/A	cg04310649	chr10:35416472	CREM	-0.54	-6.57	-0.37	2.61e-10	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs3857067	1.000	rs1588382	chr4:95017589	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.52	-7.99	-0.44	4.12e-14	QT interval;
CESC	cis	rs910316	0.967	rs11159116	chr14:75550584	G/T	cg08847533	chr14:75593920	NEK9	1.0	18.73	0.75	1.97e-50	Height;
CESC	cis	rs3749237	0.595	rs1568661	chr3:49520958	A/G	cg02487422	chr3:49467188	NICN1	0.57	8.17	0.45	1.23e-14	Resting heart rate;
CESC	cis	rs9303280	0.806	rs10852936	chr17:38031714	C/T	cg20243544	chr17:37824526	PNMT	0.49	6.31	0.36	1.15e-9	Self-reported allergy;
CESC	cis	rs9611565	0.503	rs5996062	chr22:42167464	C/G	cg06481639	chr22:41940642	POLR3H	0.6	5.92	0.34	9.88e-9	Vitiligo;
CESC	trans	rs561341	0.739	rs6505267	chr17:30225950	A/C	cg20587970	chr11:113659929	NA	-0.62	-7.94	-0.44	5.93e-14	Hip circumference adjusted for BMI;
CESC	trans	rs7937682	0.883	rs659529	chr11:111436896	T/A	cg18187862	chr3:45730750	SACM1L	0.57	7.18	0.4	7.14e-12	Primary sclerosing cholangitis;
CESC	cis	rs4689388	0.890	rs1801206	chr4:6302707	C/T	cg00701064	chr4:6280414	WFS1	0.7	11.8	0.59	4.03e-26	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs4704187	0.687	rs1363579	chr5:74510353	G/T	cg03227963	chr5:74354835	NA	0.28	5.04	0.3	8.66e-7	Response to amphetamines;
CESC	cis	rs4132509	0.779	rs3006936	chr1:243674772	A/G	cg21452805	chr1:244014465	NA	0.42	5.17	0.3	4.58e-7	RR interval (heart rate);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg04534504	chr10:62704143	RHOBTB1	-0.44	-6.08	-0.35	4.13e-9	Fibrinogen levels;
CESC	cis	rs7481584	0.624	rs440130	chr11:3051476	A/G	cg25174290	chr11:3078921	CARS	-0.45	-6.27	-0.36	1.48e-9	Calcium levels;
CESC	cis	rs9486719	0.948	rs11152952	chr6:96894303	A/G	cg18709589	chr6:96969512	KIAA0776	-0.53	-5.81	-0.34	1.75e-8	Migraine;Coronary artery disease;
CESC	cis	rs10089	1.000	rs4836363	chr5:127462737	G/C	cg19767477	chr5:127420684	SLC12A2	-0.4	-5.32	-0.31	2.18e-7	Ileal carcinoids;
CESC	cis	rs12476592	0.602	rs7576316	chr2:63741122	G/A	cg17519650	chr2:63277830	OTX1	-0.48	-5.55	-0.32	6.83e-8	Childhood ear infection;
CESC	cis	rs853679	0.517	rs67878650	chr6:28142587	G/C	cg23161317	chr6:28129485	ZNF389	0.47	5.88	0.34	1.21e-8	Depression;
CESC	trans	rs877282	0.898	rs11253350	chr10:765968	G/A	cg22713356	chr15:30763199	NA	1.16	11.35	0.57	1.37e-24	Uric acid levels;
CESC	cis	rs2576037	0.583	rs593340	chr18:44418346	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.51	-7.04	-0.4	1.68e-11	Personality dimensions;
CESC	cis	rs9911578	1.000	rs2643119	chr17:56827760	G/T	cg05425664	chr17:57184151	TRIM37	-0.49	-6.72	-0.38	1.11e-10	Intelligence (multi-trait analysis);
CESC	cis	rs4474465	0.646	rs10751297	chr11:78278567	C/T	cg27205649	chr11:78285834	NARS2	0.49	6.42	0.37	6.14e-10	Alzheimer's disease (survival time);
CESC	cis	rs7918232	0.830	rs7911024	chr10:27433636	A/C	cg14240646	chr10:27532245	ACBD5	-0.68	-6.49	-0.37	4.12e-10	Breast cancer;
CESC	cis	rs2882667	0.858	rs11951899	chr5:138374310	A/G	cg04439458	chr5:138467593	SIL1	-0.42	-6.47	-0.37	4.7e-10	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs7635838	0.827	rs9826044	chr3:11458075	A/G	cg00170343	chr3:11313890	ATG7	0.43	5.73	0.33	2.72e-8	HDL cholesterol;
CESC	cis	rs7615952	0.599	rs1044215	chr3:125725559	C/G	cg06494592	chr3:125709126	NA	-0.44	-5.05	-0.3	8.41e-7	Blood pressure (smoking interaction);
CESC	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg05313129	chr8:58192883	C8orf71	-0.49	-5.32	-0.31	2.23e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs4704187	0.687	rs1363577	chr5:74463185	T/G	cg03227963	chr5:74354835	NA	0.29	5.32	0.31	2.25e-7	Response to amphetamines;
CESC	cis	rs7618915	0.547	rs6762813	chr3:52726695	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	6.89	0.39	4.03e-11	Bipolar disorder;
CESC	cis	rs854765	0.624	rs9899634	chr17:17727943	A/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.49	-6.25	-0.36	1.62e-9	Total body bone mineral density;
CESC	cis	rs763121	0.853	rs6001191	chr22:39074452	T/C	cg14440974	chr22:39074834	NA	-0.42	-5.89	-0.34	1.14e-8	Menopause (age at onset);
CESC	cis	rs2282802	0.758	rs739954	chr5:139701920	C/T	cg26211634	chr5:139558579	C5orf32	0.36	5.23	0.31	3.51e-7	Intelligence (multi-trait analysis);
CESC	cis	rs13191362	0.935	rs34603926	chr6:163266793	A/T	cg06582575	chr6:163149167	PACRG;PARK2	0.69	6.41	0.37	6.47e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs7727544	0.571	rs12521097	chr5:131575338	G/A	cg12564285	chr5:131593104	PDLIM4	0.36	5.15	0.3	5.01e-7	Blood metabolite levels;
CESC	cis	rs7084402	0.967	rs1658468	chr10:60292664	A/G	cg07615347	chr10:60278583	BICC1	0.6	9.41	0.5	2.54e-18	Refractive error;
CESC	cis	rs1862618	0.853	rs10051747	chr5:56083289	C/A	cg18230493	chr5:56204884	C5orf35	-0.72	-8.39	-0.46	2.96e-15	Initial pursuit acceleration;
CESC	cis	rs7188697	0.922	rs9924805	chr16:58615659	T/C	cg21335942	chr16:58549945	SETD6	-0.45	-5.24	-0.31	3.34e-7	QT interval;
CESC	cis	rs7772486	0.875	rs7739418	chr6:146359188	G/A	cg05347473	chr6:146136440	FBXO30	0.48	6.5	0.37	4.02e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1707322	0.721	rs6429574	chr1:46134054	A/G	cg06784218	chr1:46089804	CCDC17	0.41	7.41	0.41	1.67e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9303401	0.659	rs11495824	chr17:56918882	C/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.01	12.45	0.61	2.57e-28	Cognitive test performance;
CESC	cis	rs832540	0.898	rs331498	chr5:56249842	C/G	cg24531977	chr5:56204891	C5orf35	0.45	5.4	0.31	1.47e-7	Coronary artery disease;
CESC	cis	rs262150	0.567	rs2527177	chr7:158804737	T/C	cg19418458	chr7:158789849	NA	-0.42	-6.36	-0.36	8.92e-10	Facial morphology (factor 20);
CESC	cis	rs4434138	0.683	rs13063160	chr3:52602274	T/C	cg05564831	chr3:52568323	NT5DC2	0.48	7.73	0.43	2.18e-13	Intelligence (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15421363	chr5:131826865	IRF1	0.53	6.34	0.36	9.96e-10	Gut microbiome composition (summer);
CESC	cis	rs801193	1.000	rs10252765	chr7:66228732	C/G	cg14393609	chr7:65229607	NA	0.44	5.66	0.33	3.88e-8	Aortic root size;
CESC	cis	rs4665809	1.000	rs6546727	chr2:26275282	C/T	cg25036284	chr2:26402008	FAM59B	-0.58	-6.53	-0.37	3.26e-10	Gut microbiome composition (summer);
CESC	cis	rs4819052	0.851	rs34101026	chr21:46662200	C/T	cg11663144	chr21:46675770	NA	-0.63	-10.04	-0.53	2.57e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs7520050	0.966	rs12409773	chr1:46358831	A/G	cg24296786	chr1:45957014	TESK2	0.42	5.26	0.31	2.92e-7	Red blood cell count;Reticulocyte count;
CESC	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg10862848	chr6:42927986	GNMT	-0.3	-7.47	-0.42	1.14e-12	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs9354352	0.935	rs7766730	chr6:66697003	C/A	cg07460842	chr6:66804631	NA	0.66	9.67	0.51	3.82e-19	Initial pursuit acceleration in psychotic disorders;
CESC	cis	rs9513593	1.000	rs723090	chr13:100017105	A/G	cg21788972	chr13:99853209	UBAC2	0.62	7.01	0.4	1.93e-11	Psoriasis;
CESC	cis	rs7618915	0.571	rs6805539	chr3:52609710	T/A	cg07507251	chr3:52567010	NT5DC2	0.41	7.2	0.4	6.34e-12	Bipolar disorder;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg13030586	chr4:186347098	UFSP2	-0.43	-6.08	-0.35	4.28e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg21280719	chr6:42927975	GNMT	-0.3	-6.8	-0.39	7.12e-11	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs9910055	0.530	rs11652651	chr17:42302907	A/G	cg13607699	chr17:42295918	UBTF	-0.82	-12.74	-0.62	2.52e-29	Total body bone mineral density;
CESC	cis	rs12079745	0.590	rs10919100	chr1:169190401	C/T	cg09363564	chr1:169337483	NME7;BLZF1	-1.1	-6.51	-0.37	3.77e-10	QT interval;
CESC	cis	rs7618501	0.572	rs4688756	chr3:50040194	T/A	cg24110177	chr3:50126178	RBM5	-0.51	-7.1	-0.4	1.16e-11	Intelligence (multi-trait analysis);
CESC	cis	rs2073300	0.609	rs6137907	chr20:23344511	C/T	cg16736954	chr20:23401023	NAPB	0.77	5.74	0.33	2.6e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg27132391	chr11:6341850	PRKCDBP	0.48	6.18	0.35	2.4e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs1790761	0.587	rs4930430	chr11:67294198	A/G	cg00290607	chr11:67383545	NA	0.4	5.95	0.34	8.6e-9	Mean corpuscular volume;
CESC	cis	rs4523957	0.583	rs9303251	chr17:2047214	C/T	cg16513277	chr17:2031491	SMG6	-0.75	-10.79	-0.55	9.49e-23	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs7666738	0.830	rs10017557	chr4:98983969	G/A	cg05340658	chr4:99064831	C4orf37	0.8	12.42	0.61	3.31e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7786808	0.707	rs11770299	chr7:158228822	G/A	cg01191920	chr7:158217561	PTPRN2	-0.45	-8.07	-0.44	2.4e-14	Obesity-related traits;
CESC	cis	rs684232	0.563	rs12939528	chr17:524391	C/T	cg12384639	chr17:618140	VPS53	0.42	5.42	0.32	1.32e-7	Prostate cancer;
CESC	cis	rs4919087	0.620	rs1253427	chr10:98981092	G/A	cg25902810	chr10:99078978	FRAT1	-0.53	-5.2	-0.3	3.98e-7	Monocyte count;
CESC	cis	rs9303401	0.614	rs34678056	chr17:57177549	G/A	cg25039879	chr17:56429692	SUPT4H1	0.5	5.29	0.31	2.58e-7	Cognitive test performance;
CESC	cis	rs9796	0.505	rs28665387	chr15:41532869	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.45	-6.43	-0.37	5.82e-10	Menopause (age at onset);
CESC	cis	rs4819052	0.679	rs4819053	chr21:46711357	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	-0.5	-6.58	-0.37	2.51e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs10883723	0.773	rs2296578	chr10:104240974	C/G	ch.10.2196322F	chr10:104248062	ACTR1A	0.43	5.22	0.31	3.57e-7	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs2576037	0.526	rs626217	chr18:44429182	T/G	cg19077165	chr18:44547161	KATNAL2	-0.53	-7.83	-0.43	1.17e-13	Personality dimensions;
CESC	cis	rs796364	1.000	rs769950	chr2:200730028	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.85	8.19	0.45	1.12e-14	Schizophrenia;
CESC	cis	rs1475911	0.708	rs66994219	chr21:43521647	G/A	cg19766460	chr21:43528205	UMODL1;C21orf128	0.93	12.29	0.6	9.2e-28	IgG glycosylation;
CESC	cis	rs2242073	0.660	rs4289171	chr2:209000144	G/A	cg10392614	chr2:208977121	NA	-0.38	-5.12	-0.3	5.92e-7	Attention deficit hyperactivity disorder;
CESC	cis	rs11098499	0.863	rs2127823	chr4:120485670	G/T	cg09307838	chr4:120376055	NA	0.9	12.2	0.6	1.77e-27	Corneal astigmatism;
CESC	cis	rs7552404	1.000	rs7534754	chr1:76185308	G/A	cg22875332	chr1:76189707	ACADM	0.65	7.61	0.42	4.8e-13	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs3806843	0.900	rs2563279	chr5:140131535	G/A	cg26395211	chr5:140044315	WDR55	0.4	5.16	0.3	4.86e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs28830936	0.510	rs7174099	chr15:42099059	A/G	cg17847044	chr15:42102381	MAPKBP1	-0.46	-8.18	-0.45	1.23e-14	Diastolic blood pressure;
CESC	cis	rs10129255	0.536	rs6576223	chr14:107184687	C/T	cg07958169	chr14:107095056	NA	-0.54	-8.51	-0.46	1.33e-15	Kawasaki disease;
CESC	cis	rs36051895	0.632	rs1590803	chr9:5177533	T/C	cg02405213	chr9:5042618	JAK2	-0.51	-6.62	-0.38	2.03e-10	Pediatric autoimmune diseases;
CESC	cis	rs4073582	0.595	rs1151540	chr11:66041807	A/C	cg14036092	chr11:66035641	RAB1B	0.56	7.89	0.44	8.15e-14	Gout;
CESC	cis	rs4665809	0.680	rs3955310	chr2:26290828	T/G	cg08470875	chr2:26401718	FAM59B	-0.46	-5.14	-0.3	5.45e-7	Gut microbiome composition (summer);
CESC	cis	rs854765	0.583	rs28428991	chr17:17827649	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.57	8.18	0.45	1.22e-14	Total body bone mineral density;
CESC	cis	rs9926296	0.712	rs258330	chr16:89729574	T/G	cg03605463	chr16:89740564	NA	0.64	7.82	0.43	1.3e-13	Vitiligo;
CESC	cis	rs2228479	0.717	rs62052210	chr16:89980158	A/G	cg00800038	chr16:89945340	TCF25	-0.75	-7.09	-0.4	1.23e-11	Skin colour saturation;
CESC	cis	rs10504229	0.683	rs56211106	chr8:58113497	A/G	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs2228479	0.850	rs17226498	chr16:89840631	T/C	cg06558623	chr16:89946397	TCF25	1.17	9.29	0.5	5.84e-18	Skin colour saturation;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg16757658	chr11:126138769	SRPR;FOXRED1	-0.49	-6.59	-0.38	2.37e-10	Ulcerative colitis;
CESC	cis	rs7264396	0.747	rs73283043	chr20:34383863	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.84	-11.45	-0.58	6.33e-25	Total cholesterol levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17106536	chr1:227127636	CABC1	0.6	6.6	0.38	2.29e-10	Gut microbiome composition (summer);
CESC	cis	rs6893300	0.785	rs55654737	chr5:179218842	G/A	cg14593053	chr5:179126677	CANX	-0.5	-5.89	-0.34	1.15e-8	Resting heart rate;
CESC	cis	rs17854409	0.803	rs1048109	chr20:61472120	G/A	cg05147244	chr20:61493195	TCFL5	0.97	6.5	0.37	4e-10	Obesity-related traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15084921	chr5:14143207	TRIO	0.55	6.16	0.35	2.71e-9	Gut microbiome composition (summer);
CESC	cis	rs9311474	0.629	rs13081028	chr3:52555316	G/A	cg18404041	chr3:52824283	ITIH1	-0.38	-6.75	-0.38	9.05e-11	Electroencephalogram traits;
CESC	trans	rs2832077	0.527	rs2705690	chr21:30239245	T/A	cg14791747	chr16:20752902	THUMPD1	-0.48	-6.53	-0.37	3.26e-10	Cognitive test performance;
CESC	cis	rs796364	0.789	rs176008	chr2:200814720	A/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.87	8.5	0.46	1.36e-15	Schizophrenia;
CESC	cis	rs9457247	1.000	rs436707	chr6:167388843	T/C	cg25258033	chr6:167368657	RNASET2	0.39	5.87	0.34	1.31e-8	Crohn's disease;
CESC	cis	rs875971	0.723	rs28391294	chr7:65654315	T/C	cg12463550	chr7:65579703	CRCP	-0.49	-6.21	-0.36	2.06e-9	Aortic root size;
CESC	cis	rs1957429	0.614	rs61012404	chr14:65347649	C/T	cg23373153	chr14:65346875	NA	-0.9	-6.61	-0.38	2.11e-10	Pediatric areal bone mineral density (radius);
CESC	cis	rs3008870	1.000	rs1137656	chr1:67451602	A/C	cg08660285	chr1:67390436	MIER1;WDR78	-1.06	-15.19	-0.68	6.65e-38	Lymphocyte percentage of white cells;
CESC	cis	rs1670533	1.000	rs13134921	chr4:1054177	A/G	cg27284194	chr4:1044797	NA	0.46	5.8	0.34	1.84e-8	Recombination rate (females);
CESC	cis	rs6570726	0.935	rs371744	chr6:145841024	C/T	cg05347473	chr6:146136440	FBXO30	0.44	6.04	0.35	5.25e-9	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs3820068	0.705	rs2042369	chr1:15843244	A/G	cg18192808	chr1:15853278	DNAJC16	-0.46	-5.62	-0.33	4.85e-8	Systolic blood pressure;
CESC	cis	rs1552244	0.935	rs7618815	chr3:10151045	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.82	-10.94	-0.56	3.04e-23	Alzheimer's disease;
CESC	cis	rs7828089	0.582	rs3817445	chr8:22266054	G/T	cg12081754	chr8:22256438	SLC39A14	0.62	8.67	0.47	4.54e-16	Verbal declarative memory;
CESC	cis	rs4819052	0.851	rs2330012	chr21:46658592	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.46	5.79	0.34	2e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs9470366	0.545	rs6930083	chr6:36634156	A/G	cg08179530	chr6:36648295	CDKN1A	-0.58	-8.26	-0.45	7.05e-15	QRS duration;
CESC	cis	rs68170813	0.641	rs79328953	chr7:106901557	C/T	cg02696742	chr7:106810147	HBP1	-0.53	-5.13	-0.3	5.74e-7	Coronary artery disease;
CESC	cis	rs796364	1.000	rs1509835	chr2:200814809	C/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.8	8.16	0.45	1.39e-14	Schizophrenia;
CESC	cis	rs514406	0.505	rs6703127	chr1:53180565	C/T	cg27535305	chr1:53392650	SCP2	-0.32	-5.32	-0.31	2.25e-7	Monocyte count;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg19138900	chr10:3826266	KLF6	0.43	6.01	0.35	5.99e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01915076	chr12:49393228	DDN	0.54	6.32	0.36	1.12e-9	Gut microbiome composition (summer);
CESC	trans	rs9784649	0.760	rs72755820	chr5:25066181	G/A	cg08600765	chr20:34638493	LOC647979	-0.55	-6.24	-0.36	1.69e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs72945132	0.882	rs6592537	chr11:70172975	C/T	cg00319359	chr11:70116639	PPFIA1	0.76	7.4	0.41	1.86e-12	Coronary artery disease;
CESC	cis	rs9733	0.744	rs12126004	chr1:150889877	T/C	cg22823121	chr1:150693482	HORMAD1	-0.35	-5.04	-0.3	8.72e-7	Tonsillectomy;
CESC	cis	rs3091242	0.902	rs36003018	chr1:25784318	A/G	cg12412775	chr1:25698385	RHCE	0.28	5.11	0.3	6.04e-7	Erythrocyte sedimentation rate;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	ch.14.1513839R	chr14:93819181	KIAA1409	-0.59	-6.6	-0.38	2.23e-10	Gut microbiome composition (summer);
CESC	cis	rs75477785	0.590	rs17015565	chr1:210244688	A/G	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.92	6.23	0.36	1.82e-9	Cleft lip with or without cleft palate;
CESC	cis	rs7264396	0.563	rs11698796	chr20:34248134	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.59	5.78	0.33	2.11e-8	Total cholesterol levels;
CESC	cis	rs4555082	0.915	rs2816632	chr14:105741355	C/T	cg06808227	chr14:105710500	BRF1	0.49	6.38	0.36	7.9e-10	Mean platelet volume;Platelet distribution width;
CESC	cis	rs941873	0.868	rs12780295	chr10:81115438	G/A	cg09469691	chr10:81107165	PPIF	0.55	7.6	0.42	5.14e-13	Height;
CESC	cis	rs897080	0.552	rs1067320	chr2:44633122	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	5.91	0.34	1.07e-8	Height;
CESC	trans	rs7618501	0.633	rs13060128	chr3:50025028	A/G	cg21659725	chr3:3221576	CRBN	0.5	6.87	0.39	4.44e-11	Intelligence (multi-trait analysis);
CESC	cis	rs7474896	0.537	rs1208587	chr10:38207759	A/G	cg00409905	chr10:38381863	ZNF37A	0.44	5.07	0.3	7.5e-7	Obesity (extreme);
CESC	cis	rs933688	0.941	rs2887007	chr5:90740531	A/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.91	11.96	0.59	1.22e-26	Smoking behavior;
CESC	cis	rs854765	0.583	rs11078405	chr17:17824978	G/T	cg09796270	chr17:17721594	SREBF1	0.46	6.42	0.37	6.23e-10	Total body bone mineral density;
CESC	cis	rs2294693	0.945	rs9369253	chr6:40986538	A/G	cg14769373	chr6:40998127	UNC5CL	-0.48	-6.36	-0.36	8.73e-10	Gastric cancer;Non-cardia gastric cancer;
CESC	cis	rs2075371	0.863	rs9641966	chr7:133961205	G/A	cg20476274	chr7:133979776	SLC35B4	0.62	8.86	0.48	1.15e-16	Mean platelet volume;
CESC	cis	rs9926296	0.533	rs9938865	chr16:89867797	A/G	cg21285383	chr16:89894308	SPIRE2	0.29	5.22	0.31	3.65e-7	Vitiligo;
CESC	trans	rs6572548	0.504	rs1956082	chr14:49665496	A/C	cg19292611	chr13:114288232	TFDP1	0.5	6.05	0.35	4.83e-9	Subjective well-being;
CESC	cis	rs2290720	0.930	rs7314205	chr12:101722293	A/G	cg22051763	chr12:101673672	UTP20	-0.49	-6.02	-0.35	5.86e-9	Brain structure (hippocampal volume);
CESC	cis	rs2243480	1.000	rs7792391	chr7:65773429	A/G	cg13147721	chr7:65941812	NA	0.98	9.24	0.49	8.25e-18	Diabetic kidney disease;
CESC	cis	rs4692589	0.743	rs3806825	chr4:170948619	T/C	cg19918862	chr4:170955249	NA	0.44	6.77	0.38	8.1e-11	Anxiety disorder;
CESC	cis	rs4665809	1.000	rs750450	chr2:26324631	A/G	cg27170947	chr2:26402098	FAM59B	-0.61	-7.31	-0.41	3.25e-12	Gut microbiome composition (summer);
CESC	cis	rs718433	0.584	rs4982492	chr14:22212818	A/G	cg02257791	chr14:22217085	NA	-0.32	-5.09	-0.3	6.83e-7	Intraocular pressure;
CESC	cis	rs3820928	0.648	rs1997484	chr2:227898962	T/A	cg05526886	chr2:227700861	RHBDD1	-0.44	-5.59	-0.32	5.64e-8	Pulmonary function;
CESC	trans	rs208520	0.690	rs2797693	chr6:66868985	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.99	-13.06	-0.63	1.94e-30	Exhaled nitric oxide output;
CESC	cis	rs113835537	0.529	rs57724777	chr11:66236431	G/A	cg22134325	chr11:66188745	NPAS4	0.45	6.8	0.39	6.87e-11	Airway imaging phenotypes;
CESC	cis	rs9467711	0.659	rs13220261	chr6:26499185	C/T	cg21479132	chr6:26055353	NA	0.78	5.36	0.31	1.84e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs7607369	0.580	rs7568196	chr2:219652373	G/A	cg02176678	chr2:219576539	TTLL4	-0.49	-8.42	-0.46	2.45e-15	Red blood cell count;Amyotrophic lateral sclerosis;
CESC	cis	rs5758659	0.714	rs5758574	chr22:42481400	G/C	cg04733989	chr22:42467013	NAGA	-0.44	-6.21	-0.36	2e-9	Cognitive function;
CESC	cis	rs1707322	1.000	rs785484	chr1:46574015	T/C	cg06784218	chr1:46089804	CCDC17	-0.36	-5.93	-0.34	9.35e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9611565	0.592	rs4822040	chr22:41963553	C/G	cg03806693	chr22:41940476	POLR3H	-0.97	-11.95	-0.59	1.26e-26	Vitiligo;
CESC	cis	rs7300001	0.538	rs7968848	chr12:110941059	T/A	cg12870014	chr12:110450643	ANKRD13A	0.65	5.59	0.32	5.78e-8	Headache;
CESC	cis	rs853679	0.517	rs4713150	chr6:28136212	G/A	cg22143856	chr6:28129313	ZNF389	0.46	5.83	0.34	1.58e-8	Depression;
CESC	cis	rs1218582	0.772	rs12095061	chr1:154912968	A/T	cg24250549	chr1:154909240	PMVK	0.71	10.45	0.54	1.29e-21	Prostate cancer;
CESC	cis	rs736801	0.740	rs17622378	chr5:131778452	A/G	cg21138405	chr5:131827807	IRF1	-0.38	-5.53	-0.32	7.68e-8	Breast cancer;Mosquito bite size;
CESC	cis	rs7179456	0.557	rs446126	chr15:59113102	A/G	cg05156742	chr15:59063176	FAM63B	0.72	10.04	0.52	2.61e-20	Asperger disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14909795	chr11:64851572	CDCA5;ZFPL1	0.6	6.43	0.37	5.9e-10	Gut microbiome composition (summer);
CESC	cis	rs12200560	0.505	rs1988040	chr6:97076271	G/A	cg06623918	chr6:96969491	KIAA0776	0.51	6.46	0.37	5.04e-10	Coronary heart disease;
CESC	cis	rs9611565	0.512	rs964899	chr22:42142386	G/A	cg06634786	chr22:41940651	POLR3H	0.71	6.92	0.39	3.35e-11	Vitiligo;
CESC	cis	rs9905704	0.918	rs581903	chr17:56719197	C/T	cg12560992	chr17:57184187	TRIM37	0.59	6.98	0.39	2.34e-11	Testicular germ cell tumor;
CESC	cis	rs2710642	0.962	rs7557501	chr2:63086639	C/T	cg17519650	chr2:63277830	OTX1	0.51	6.63	0.38	1.92e-10	LDL cholesterol levels;LDL cholesterol;
CESC	cis	rs6121246	0.865	rs77130187	chr20:30269060	G/A	cg13852791	chr20:30311386	BCL2L1	0.71	5.85	0.34	1.43e-8	Mean corpuscular hemoglobin;
CESC	cis	rs13343954	0.518	rs8106293	chr19:33536376	C/T	cg27124370	chr19:33622961	WDR88	0.51	7.07	0.4	1.39e-11	Colorectal cancer;
CESC	cis	rs12893668	0.703	rs4906336	chr14:104033265	C/G	cg24130564	chr14:104152367	KLC1	-0.48	-5.87	-0.34	1.31e-8	Reticulocyte count;
CESC	cis	rs11252926	0.966	rs11252923	chr10:566195	G/A	cg08603382	chr10:743973	NA	-0.59	-7.52	-0.42	8.45e-13	Psychosis in Alzheimer's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05881776	chr2:235860554	SH3BP4	0.55	6.09	0.35	3.99e-9	Gut microbiome composition (summer);
CESC	cis	rs959260	0.688	rs1369299	chr17:73347325	T/C	cg20590849	chr17:73267439	MIF4GD	-0.56	-6.27	-0.36	1.49e-9	Systemic lupus erythematosus;
CESC	cis	rs7959452	0.527	rs4761157	chr12:69780907	A/G	cg14784868	chr12:69753453	YEATS4	0.84	13.21	0.63	6.15e-31	Blood protein levels;
CESC	cis	rs2991971	0.967	rs11211130	chr1:45986852	G/C	cg05343316	chr1:45956843	TESK2	-0.52	-6.76	-0.38	8.52e-11	High light scatter reticulocyte count;
CESC	cis	rs7666738	0.753	rs2903143	chr4:99040480	C/T	cg05340658	chr4:99064831	C4orf37	0.8	12.39	0.61	3.91e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11098499	0.909	rs78332141	chr4:120375782	C/T	cg09307838	chr4:120376055	NA	0.93	13.29	0.63	3.24e-31	Corneal astigmatism;
CESC	cis	rs13108904	0.967	rs13150571	chr4:1278636	C/G	cg22903657	chr4:1355424	KIAA1530	-0.38	-5.23	-0.31	3.48e-7	Obesity-related traits;
CESC	cis	rs115344852	0.598	rs2531815	chr6:28436060	C/T	cg14547644	chr6:28411285	ZSCAN23	-0.32	-5.07	-0.3	7.31e-7	Epithelial ovarian cancer;
CESC	cis	rs12476592	0.602	rs4671068	chr2:63798333	C/T	cg17519650	chr2:63277830	OTX1	-0.48	-5.59	-0.32	5.56e-8	Childhood ear infection;
CESC	cis	rs72627123	0.867	rs73301477	chr14:74463560	C/T	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.74	5.1	0.3	6.34e-7	Morning vs. evening chronotype;
CESC	trans	rs9987353	0.840	rs329994	chr8:9123233	A/G	cg00231006	chr5:130599637	CDC42SE2	-0.47	-6.32	-0.36	1.13e-9	Recombination measurement;
CESC	cis	rs72772090	0.539	rs10515249	chr5:96125259	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.57	-5.26	-0.31	3.01e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs2988277	0.737	rs2949668	chr1:167434721	T/C	cg22356347	chr1:167427500	CD247	-0.32	-6.43	-0.37	6.01e-10	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs17021463	0.617	rs12499187	chr4:95323917	A/G	cg11021082	chr4:95130006	SMARCAD1	0.5	6.69	0.38	1.29e-10	Testicular germ cell tumor;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg09578018	chr15:60883649	RORA	0.52	7.42	0.41	1.56e-12	Systemic lupus erythematosus;
CESC	cis	rs367943	0.672	rs6594712	chr5:112715211	T/G	cg12552261	chr5:112820674	MCC	0.38	5.07	0.3	7.31e-7	Type 2 diabetes;
CESC	cis	rs7264396	0.790	rs2425125	chr20:34330954	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	-0.63	-7.66	-0.43	3.51e-13	Total cholesterol levels;
CESC	cis	rs11098499	0.908	rs28499576	chr4:120386677	G/A	cg24375607	chr4:120327624	NA	0.44	5.44	0.32	1.19e-7	Corneal astigmatism;
CESC	cis	rs9325144	0.505	rs901635	chr12:38646572	A/C	cg13010199	chr12:38710504	ALG10B	-0.46	-6.32	-0.36	1.08e-9	Morning vs. evening chronotype;
CESC	cis	rs12681288	0.550	rs12549204	chr8:959085	G/T	cg15309053	chr8:964076	NA	0.48	8.23	0.45	8.5e-15	Schizophrenia;
CESC	cis	rs2836974	0.584	rs34436313	chr21:40685246	A/G	cg11644478	chr21:40555479	PSMG1	-0.8	-11.75	-0.59	6.13e-26	Cognitive function;
CESC	cis	rs9300255	0.602	rs1626899	chr12:123708063	A/G	cg05973401	chr12:123451056	ABCB9	0.5	5.68	0.33	3.48e-8	Neutrophil percentage of white cells;
CESC	cis	rs9399137	0.507	rs28384513	chr6:135376209	T/G	cg22676075	chr6:135203613	NA	0.53	7.03	0.4	1.73e-11	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	cis	rs2302190	1.000	rs7207286	chr17:56514458	A/C	cg25885038	chr17:56607967	SEPT4	0.43	6.04	0.35	5.3e-9	Vitamin D levels;
CESC	cis	rs1552244	1.000	rs7628448	chr3:10146828	G/A	cg08888203	chr3:10149979	C3orf24	0.44	5.39	0.31	1.57e-7	Alzheimer's disease;
CESC	cis	rs2404602	0.583	rs3759853	chr15:76587777	C/T	cg05617483	chr15:76483344	C15orf27	0.38	5.13	0.3	5.49e-7	Blood metabolite levels;
CESC	cis	rs7223966	1.000	rs13380863	chr17:61780793	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.53	6.16	0.35	2.74e-9	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs4819052	0.851	rs4819041	chr21:46659955	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.83	12.05	0.59	6.05e-27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs7826238	0.623	rs2976893	chr8:8338219	G/T	cg15556689	chr8:8085844	FLJ10661	-0.47	-5.94	-0.34	8.81e-9	Systolic blood pressure;
CESC	cis	rs7833790	0.685	rs13255262	chr8:82728024	T/G	cg17211192	chr8:82754475	SNX16	-0.58	-7.38	-0.41	2.05e-12	Diastolic blood pressure;
CESC	cis	rs763121	0.706	rs3827356	chr22:39064806	G/T	cg06022373	chr22:39101656	GTPBP1	-0.79	-12.61	-0.61	7.04e-29	Menopause (age at onset);
CESC	cis	rs11711311	0.955	rs78029398	chr3:113421321	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.51	6.6	0.38	2.27e-10	IgG glycosylation;
CESC	cis	rs1670533	1.000	rs13135215	chr4:1054364	A/G	cg27284194	chr4:1044797	NA	0.46	5.83	0.34	1.61e-8	Recombination rate (females);
CESC	cis	rs17384381	1.000	rs71652696	chr1:85831792	A/C	cg16011679	chr1:85725395	C1orf52	0.83	8.29	0.45	5.92e-15	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2576037	0.899	rs12955429	chr18:44585484	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.63	-8.83	-0.48	1.42e-16	Personality dimensions;
CESC	cis	rs7044106	0.648	rs2031369	chr9:123360294	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.33	5.22	0.31	3.62e-7	Hip circumference adjusted for BMI;
CESC	cis	rs60154123	0.772	rs664072	chr1:210422160	G/A	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.49	5.1	0.3	6.34e-7	Coronary artery disease;
CESC	cis	rs4523957	0.855	rs216172	chr17:2126504	G/C	cg16513277	chr17:2031491	SMG6	-0.59	-8.03	-0.44	3.23e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs5769765	0.728	rs6520064	chr22:50294469	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.45	-5.21	-0.3	3.79e-7	Schizophrenia;
CESC	cis	rs6963495	0.818	rs711430	chr7:105167969	A/G	cg19920283	chr7:105172520	RINT1	0.72	8.05	0.44	2.75e-14	Bipolar disorder (body mass index interaction);
CESC	trans	rs8057939	0.593	rs11860577	chr16:49435600	C/T	cg15532236	chr6:170188124	NA	0.49	6.1	0.35	3.68e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs11958404	0.932	rs72816556	chr5:157424412	C/G	cg05962755	chr5:157440814	NA	0.58	6.4	0.37	7.16e-10	IgG glycosylation;
CESC	cis	rs2645694	0.626	rs2703121	chr4:77822328	C/G	cg18351406	chr4:77819688	ANKRD56	0.54	6.74	0.38	1.01e-10	Emphysema distribution in smoking;
CESC	cis	rs478304	0.651	rs4930312	chr11:65499719	G/A	cg10518572	chr11:65560635	OVOL1	-0.33	-6.61	-0.38	2.09e-10	Acne (severe);
CESC	cis	rs6502050	0.799	rs6502066	chr17:80103737	T/C	cg11859384	chr17:80120422	CCDC57	-0.38	-5.11	-0.3	6.21e-7	Life satisfaction;
CESC	cis	rs7216064	1.000	rs8082512	chr17:65837059	T/C	cg12091567	chr17:66097778	LOC651250	-0.86	-8.83	-0.48	1.49e-16	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs4819052	1.000	rs2838830	chr21:46664227	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.87	11.36	0.57	1.3e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs1008375	1.000	rs4698641	chr4:17642630	C/T	cg15017067	chr4:17643749	FAM184B	0.39	5.47	0.32	1.02e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs2742417	0.609	rs2673066	chr3:45771200	C/T	cg04837898	chr3:45731254	SACM1L	-0.47	-6.17	-0.35	2.54e-9	Response to anti-depressant treatment in major depressive disorder;
CESC	cis	rs10504229	0.871	rs10504226	chr8:58159283	A/G	cg24829409	chr8:58192753	C8orf71	-0.63	-8.2	-0.45	1.04e-14	Developmental language disorder (linguistic errors);
CESC	cis	rs9399135	0.967	rs4896125	chr6:135342569	C/T	cg24558204	chr6:135376177	HBS1L	0.52	7.29	0.41	3.48e-12	Red blood cell count;
CESC	cis	rs7208859	0.573	rs216442	chr17:28931197	T/G	cg19761014	chr17:28927070	LRRC37B2	0.85	6.59	0.38	2.33e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs9457247	0.663	rs9295384	chr6:167448113	T/A	cg07741184	chr6:167504864	NA	0.34	6.02	0.35	5.87e-9	Crohn's disease;
CESC	cis	rs4132509	1.000	rs12116882	chr1:243959106	G/A	cg21452805	chr1:244014465	NA	0.49	5.95	0.34	8.28e-9	RR interval (heart rate);
CESC	cis	rs897984	0.683	rs8050330	chr16:30824970	C/T	cg02466173	chr16:30829666	NA	-0.64	-12.49	-0.61	1.77e-28	Dementia with Lewy bodies;
CESC	cis	rs7647973	0.516	rs4308307	chr3:49193216	C/T	cg06212747	chr3:49208901	KLHDC8B	0.77	11.49	0.58	4.66e-25	Menarche (age at onset);
CESC	cis	rs7927592	0.913	rs10896347	chr11:68353127	G/A	cg20283391	chr11:68216788	NA	-0.61	-7.29	-0.41	3.48e-12	Total body bone mineral density;
CESC	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg11301795	chr4:187892539	NA	-0.8	-14.13	-0.66	3.5e-34	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs10883723	0.669	rs2001595	chr10:104395085	C/T	ch.10.2196322F	chr10:104248062	ACTR1A	0.51	5.54	0.32	7.29e-8	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs1008375	0.966	rs2191504	chr4:17675592	C/G	cg02297831	chr4:17616191	MED28	0.45	5.64	0.33	4.42e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs13272623	0.502	rs268562	chr8:71494780	G/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.49	-6.11	-0.35	3.57e-9	IgG glycosylation;
CESC	cis	rs858239	0.601	rs10278776	chr7:23169759	C/T	cg23682824	chr7:23144976	KLHL7	0.55	7.73	0.43	2.27e-13	Cerebrospinal fluid biomarker levels;
CESC	cis	rs7927771	0.832	rs896816	chr11:47394338	T/C	cg18512352	chr11:47633146	NA	0.49	6.89	0.39	4.11e-11	Subjective well-being;
CESC	cis	rs2279817	0.863	rs12023877	chr1:18025633	A/C	cg21791023	chr1:18019539	ARHGEF10L	0.54	7.88	0.44	8.25e-14	Neuroticism;
CESC	cis	rs4563143	0.514	rs73029081	chr19:29295583	C/G	cg12756686	chr19:29218302	NA	0.54	6.27	0.36	1.46e-9	Methadone dose in opioid dependence;
CESC	cis	rs4332037	0.624	rs11764124	chr7:1891723	C/G	cg13880726	chr7:1868755	MAD1L1	-0.48	-5.08	-0.3	7.17e-7	Bipolar disorder;
CESC	cis	rs11098499	0.566	rs17051356	chr4:120585308	C/T	cg24375607	chr4:120327624	NA	0.43	5.25	0.31	3.11e-7	Corneal astigmatism;
CESC	cis	rs6587515	0.901	rs10888396	chr1:150777514	T/C	cg13175981	chr1:150552382	MCL1	0.61	5.06	0.3	7.99e-7	Pericardial adipose tissue adjusted for height and weight;
CESC	cis	rs2274273	0.870	rs1952087	chr14:55683211	A/C	cg04306507	chr14:55594613	LGALS3	0.29	5.83	0.34	1.64e-8	Protein biomarker;
CESC	cis	rs6748734	0.625	rs4295000	chr2:241821237	C/T	cg04034577	chr2:241836375	C2orf54	-0.29	-5.25	-0.31	3.05e-7	Urinary metabolites;
CESC	cis	rs4423214	0.879	rs10898144	chr11:71151540	A/T	cg05163923	chr11:71159392	DHCR7	-0.65	-7.95	-0.44	5.37e-14	Vitamin D levels;
CESC	cis	rs5769765	0.874	rs4624	chr22:50281917	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.46	5.32	0.31	2.21e-7	Schizophrenia;
CESC	cis	rs6543140	0.964	rs2080288	chr2:103022166	G/A	cg04239558	chr2:103089729	SLC9A4	0.49	6.15	0.35	2.83e-9	Blood protein levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19519331	chr10:91403645	PANK1	-0.57	-6.84	-0.39	5.37e-11	Gut microbiome composition (summer);
CESC	cis	rs4888262	0.526	rs4888253	chr16:74583146	C/T	cg01733217	chr16:74700730	RFWD3	0.81	11.45	0.58	6.4e-25	Testicular germ cell tumor;
CESC	cis	rs896854	0.846	rs7845219	chr8:95937502	T/C	cg16049864	chr8:95962084	TP53INP1	-0.67	-11.87	-0.59	2.36e-26	Type 2 diabetes;
CESC	cis	rs7212590	0.881	rs7214032	chr17:57885828	T/C	cg20303301	chr17:57937339	TUBD1	-0.55	-5.28	-0.31	2.67e-7	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs7429990	0.932	rs6803741	chr3:48123540	C/T	cg11946769	chr3:48343235	NME6	-0.5	-6.26	-0.36	1.53e-9	Educational attainment (years of education);
CESC	cis	rs7615952	0.673	rs16834637	chr3:125605471	C/T	cg05084668	chr3:125655381	ALG1L	-0.58	-6.39	-0.37	7.5e-10	Blood pressure (smoking interaction);
CESC	cis	rs6952809	0.532	rs10227362	chr7:2456799	A/G	cg23289794	chr7:2394357	EIF3B	-0.74	-7.04	-0.4	1.62e-11	Multiple sclerosis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13094338	chr20:62258937	GMEB2	-0.59	-6.63	-0.38	1.86e-10	Gut microbiome composition (summer);
CESC	cis	rs60843830	1.000	rs17713729	chr2:249092	A/C	cg00108164	chr2:264199	ACP1;SH3YL1	0.8	10.42	0.54	1.55e-21	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs9322193	0.884	rs9383864	chr6:150173105	T/C	cg07701084	chr6:150067640	NUP43	0.4	5.23	0.31	3.41e-7	Lung cancer;
CESC	cis	rs1799949	1.000	rs4793194	chr17:41218333	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.66	9.08	0.49	2.51e-17	Menopause (age at onset);
CESC	cis	rs7659604	0.521	rs6822155	chr4:122673274	C/A	cg19671926	chr4:122722719	EXOSC9	0.59	7.44	0.42	1.44e-12	Type 2 diabetes;
CESC	cis	rs4819052	0.851	rs2838829	chr21:46664040	A/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.75	9.94	0.52	5.59e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs9322193	0.809	rs9479808	chr6:150072464	A/T	cg04369109	chr6:150039330	LATS1	-0.43	-5.91	-0.34	1.05e-8	Lung cancer;
CESC	cis	rs6860806	0.631	rs4705931	chr5:131588345	T/C	cg09877947	chr5:131593287	PDLIM4	0.48	6.28	0.36	1.39e-9	Breast cancer;
CESC	cis	rs6964587	0.869	rs406	chr7:91546526	C/A	cg01689657	chr7:91764605	CYP51A1	-0.28	-5.06	-0.3	7.76e-7	Breast cancer;
CESC	trans	rs208520	0.690	rs207118	chr6:66788948	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.0	-12.83	-0.62	1.2e-29	Exhaled nitric oxide output;
CESC	cis	rs9361491	0.621	rs12196457	chr6:79627743	A/T	cg05283184	chr6:79620031	NA	-0.37	-5.23	-0.31	3.45e-7	Intelligence (multi-trait analysis);
CESC	cis	rs9325144	0.560	rs11182930	chr12:38633693	A/T	cg26384229	chr12:38710491	ALG10B	-0.61	-8.58	-0.47	8.35e-16	Morning vs. evening chronotype;
CESC	cis	rs863345	0.967	rs10908680	chr1:158521961	T/C	cg12129480	chr1:158549410	OR10X1	-0.31	-6.18	-0.36	2.35e-9	Pneumococcal bacteremia;
CESC	cis	rs4727027	0.866	rs12666477	chr7:148812322	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.42	5.23	0.31	3.41e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs546131	0.928	rs516228	chr11:34838823	C/T	cg06937548	chr11:34938143	PDHX;APIP	0.51	6.42	0.37	6.29e-10	Lung disease severity in cystic fibrosis;
CESC	cis	rs524281	0.861	rs9736673	chr11:65924024	T/A	cg14036092	chr11:66035641	RAB1B	-0.49	-5.17	-0.3	4.67e-7	Electroencephalogram traits;
CESC	cis	rs4481887	0.830	rs4474289	chr1:248474972	T/A	cg00666640	chr1:248458726	OR2T12	0.34	5.62	0.33	4.8e-8	Common traits (Other);
CESC	cis	rs9905704	0.633	rs2632518	chr17:56512236	T/C	cg12560992	chr17:57184187	TRIM37	0.6	5.62	0.33	4.8e-8	Testicular germ cell tumor;
CESC	cis	rs4595586	0.679	rs7131749	chr12:39405462	A/G	cg26384229	chr12:38710491	ALG10B	-0.42	-6.19	-0.36	2.23e-9	Morning vs. evening chronotype;
CESC	cis	rs6938	0.514	rs35556055	chr15:75253414	G/A	cg17294928	chr15:75287854	SCAMP5	0.49	6.2	0.36	2.17e-9	Breast cancer;
CESC	cis	rs7503807	0.935	rs7215534	chr17:78612119	C/T	cg09596252	chr17:78655493	RPTOR	0.47	6.87	0.39	4.51e-11	Obesity;
CESC	cis	rs4555082	0.830	rs2816614	chr14:105727359	C/T	cg13114125	chr14:105738426	BRF1	-0.85	-10.46	-0.54	1.18e-21	Mean platelet volume;Platelet distribution width;
CESC	cis	rs13191362	1.000	rs36042757	chr6:163004744	A/C	cg21926612	chr6:163149169	PACRG;PARK2	0.82	8.8	0.48	1.79e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs9837602	1.000	rs35844878	chr3:99796626	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.49	6.84	0.39	5.32e-11	Breast cancer;
CESC	cis	rs854765	0.964	rs854764	chr17:18011750	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.46	-5.81	-0.34	1.82e-8	Total body bone mineral density;
CESC	cis	rs17384381	0.953	rs2076699	chr1:85817295	G/A	cg16011679	chr1:85725395	C1orf52	0.8	8.13	0.45	1.69e-14	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9649213	0.555	rs6956686	chr7:97997945	T/C	cg08684580	chr7:98029266	BAIAP2L1	-0.35	-5.72	-0.33	2.81e-8	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12781834	chr17:40169085	DNAJC7;NKIRAS2	0.57	6.25	0.36	1.59e-9	Gut microbiome composition (summer);
CESC	cis	rs4523957	0.893	rs12950555	chr17:2156910	C/G	cg16513277	chr17:2031491	SMG6	0.6	8.27	0.45	6.71e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs1348850	0.567	rs3770012	chr2:178538023	A/G	cg22681709	chr2:178499509	PDE11A	0.49	7.4	0.41	1.78e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs2066819	1.000	rs2020854	chr12:56743367	T/C	cg26734620	chr12:56694298	CS	0.88	8.73	0.47	2.85e-16	Psoriasis vulgaris;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg09386619	chr6:125420923	NA	-0.57	-7.11	-0.4	1.05e-11	Ulcerative colitis;
CESC	cis	rs8005677	1.000	rs8006396	chr14:23380850	A/G	cg25600027	chr14:23388339	RBM23	-0.43	-5.33	-0.31	2.08e-7	Cognitive ability (multi-trait analysis);
CESC	cis	rs4819052	0.851	rs28676615	chr21:46676576	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.95	14.1	0.65	4.6e-34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs735396	1.000	rs2259816	chr12:121435587	A/C	cg02403541	chr12:121454288	C12orf43	-0.61	-8.91	-0.48	8.13e-17	N-glycan levels;
CESC	cis	rs9948	0.521	rs62156207	chr2:97359236	C/A	cg01990225	chr2:97406019	LMAN2L	-0.79	-6.42	-0.37	6.44e-10	Erectile dysfunction and prostate cancer treatment;
CESC	cis	rs6565180	0.632	rs8050812	chr16:30385837	C/T	cg17640201	chr16:30407289	ZNF48	-0.85	-11.53	-0.58	3.45e-25	Tonsillectomy;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg03191116	chr12:72058171	ZFC3H1;THAP2	0.47	6.25	0.36	1.61e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs67311347	1.000	rs4973997	chr3:40460145	G/A	cg24209194	chr3:40518798	ZNF619	0.46	6.0	0.35	6.33e-9	Renal cell carcinoma;
CESC	cis	rs2882667	0.858	rs35812969	chr5:138377550	G/C	cg04439458	chr5:138467593	SIL1	-0.4	-6.15	-0.35	2.89e-9	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs7044106	0.791	rs10984997	chr9:123481206	T/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.63	8.64	0.47	5.31e-16	Hip circumference adjusted for BMI;
CESC	cis	rs933688	1.000	rs12651840	chr5:90729592	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.01	13.73	0.64	8.84e-33	Smoking behavior;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05867387	chr4:170679069	C4orf27	0.52	6.01	0.35	6.05e-9	Gut microbiome composition (summer);
CESC	cis	rs4253772	0.591	rs6008365	chr22:46652929	G/A	cg09491104	chr22:46646882	C22orf40	-0.6	-9.25	-0.49	7.56e-18	LDL cholesterol;Cholesterol, total;
CESC	cis	rs875971	0.862	rs11769079	chr7:65842128	G/A	cg18876405	chr7:65276391	NA	0.5	6.84	0.39	5.47e-11	Aortic root size;
CESC	cis	rs7666738	0.830	rs11097608	chr4:99011693	T/C	cg18180107	chr4:99064573	C4orf37	0.41	5.3	0.31	2.47e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs637571	0.544	rs12361552	chr11:65701204	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.63	-8.24	-0.45	8.11e-15	Eosinophil percentage of white cells;
CESC	cis	rs939574	1.000	rs56927225	chr2:220100922	A/G	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.82	7.21	0.41	5.76e-12	Platelet distribution width;
CESC	cis	rs12477438	0.520	rs13023744	chr2:99738224	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.87	16.09	0.7	4.08e-41	Chronic sinus infection;
CESC	cis	rs7674212	0.541	rs2251322	chr4:104079424	C/T	cg16532752	chr4:104119610	CENPE	-0.45	-6.18	-0.36	2.37e-9	Type 2 diabetes;
CESC	cis	rs7267979	1.000	rs7267979	chr20:25298087	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.86	16.91	0.72	5.14e-44	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs10540	1.000	rs61876333	chr11:487136	G/A	cg03576123	chr11:487126	PTDSS2	-1.1	-10.38	-0.54	2.07e-21	Body mass index;
CESC	cis	rs1707322	0.717	rs28396194	chr1:46213227	C/T	cg05343316	chr1:45956843	TESK2	0.51	6.32	0.36	1.09e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs11626933	1.000	rs11621007	chr14:90743967	G/A	cg14092571	chr14:90743983	NA	-1.01	-16.28	-0.71	8.56e-42	Gut microbiota (bacterial taxa);
CESC	cis	rs1538970	1.000	rs2050884	chr1:45830824	A/G	cg05343316	chr1:45956843	TESK2	0.76	10.54	0.54	6.54e-22	Platelet count;
CESC	cis	rs7267979	1.000	rs2257496	chr20:25279315	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	18.72	0.75	2.09e-50	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7659604	0.846	rs35986491	chr4:122664528	A/T	cg19671926	chr4:122722719	EXOSC9	-0.45	-5.26	-0.31	2.96e-7	Type 2 diabetes;
CESC	cis	rs7923609	0.967	rs10761729	chr10:64995604	G/C	cg01631684	chr10:65280961	REEP3	-0.45	-5.56	-0.32	6.57e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25621096	chr1:151032116	CDC42SE1;MLLT11	0.6	6.81	0.39	6.47e-11	Gut microbiome composition (summer);
CESC	cis	rs1552244	1.000	rs9809061	chr3:10085130	C/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-10.99	-0.56	2.15e-23	Alzheimer's disease;
CESC	cis	rs7786808	0.505	rs67537656	chr7:158192646	C/T	cg09998033	chr7:158218633	PTPRN2	0.35	5.31	0.31	2.32e-7	Obesity-related traits;
CESC	cis	rs425277	0.606	rs2257684	chr1:2077872	A/G	cg16545954	chr1:2118288	C1orf86	0.35	6.55	0.37	2.95e-10	Height;
CESC	cis	rs6952808	0.601	rs3800882	chr7:2120758	G/A	cg04267008	chr7:1944627	MAD1L1	-0.58	-7.04	-0.4	1.67e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs9549367	0.713	rs3024746	chr13:113821777	G/A	cg18105134	chr13:113819100	PROZ	-0.66	-8.35	-0.46	3.82e-15	Platelet distribution width;
CESC	cis	rs1707322	0.717	rs3014249	chr1:46079493	A/G	cg06784218	chr1:46089804	CCDC17	-0.41	-7.07	-0.4	1.34e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2228479	0.717	rs1800358	chr16:89809319	T/C	cg04287289	chr16:89883240	FANCA	0.71	6.53	0.37	3.42e-10	Skin colour saturation;
CESC	cis	rs921968	0.565	rs7599365	chr2:219620566	G/A	cg02176678	chr2:219576539	TTLL4	-0.44	-7.74	-0.43	2.08e-13	Mean corpuscular hemoglobin concentration;
CESC	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.64	7.2	0.4	6.15e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2243480	1.000	rs6460260	chr7:65215455	T/C	cg12463550	chr7:65579703	CRCP	-0.7	-5.35	-0.31	1.89e-7	Diabetic kidney disease;
CESC	cis	rs2243480	1.000	rs1638734	chr7:66097539	A/C	cg18252515	chr7:66147081	NA	-1.4	-14.2	-0.66	2.03e-34	Diabetic kidney disease;
CESC	cis	rs7927592	0.913	rs4988291	chr11:68381607	G/A	cg20283391	chr11:68216788	NA	-0.61	-7.37	-0.41	2.24e-12	Total body bone mineral density;
CESC	cis	rs909674	0.818	rs5750833	chr22:39843091	C/A	cg11247378	chr22:39784982	NA	-0.64	-9.23	-0.49	9.24e-18	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs7580658	0.895	rs4662580	chr2:128102806	C/A	cg10021288	chr2:128175891	PROC	-0.41	-6.46	-0.37	5.11e-10	Protein C levels;
CESC	cis	rs10504229	0.954	rs903717	chr8:58167856	A/G	cg22535103	chr8:58192502	C8orf71	-0.83	-10.91	-0.56	3.89e-23	Developmental language disorder (linguistic errors);
CESC	cis	rs7264396	0.511	rs2425102	chr20:34312303	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.64	6.86	0.39	4.78e-11	Total cholesterol levels;
CESC	cis	rs10791097	0.748	rs4937580	chr11:130734270	T/C	cg12179176	chr11:130786555	SNX19	0.63	9.81	0.52	1.39e-19	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs2180341	0.640	rs11154395	chr6:127629138	T/C	cg24812749	chr6:127587940	RNF146	0.62	8.22	0.45	8.91e-15	Breast cancer;
CESC	cis	rs7582720	1.000	rs72936838	chr2:203772984	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.39	0.41	1.96e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs4588572	0.606	rs2362828	chr5:77718835	C/T	cg11547950	chr5:77652471	NA	-0.4	-5.58	-0.32	5.84e-8	Triglycerides;
CESC	cis	rs6933660	0.683	rs8180642	chr6:151756612	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.8	12.41	0.61	3.4e-28	Menarche (age at onset);
CESC	cis	rs4237845	0.837	rs7963992	chr12:58295949	G/C	cg00677455	chr12:58241039	CTDSP2	0.43	5.39	0.31	1.52e-7	Intelligence (multi-trait analysis);
CESC	cis	rs875971	0.522	rs9530	chr7:65425894	A/G	cg11764359	chr7:65958608	NA	0.7	8.8	0.48	1.84e-16	Aortic root size;
CESC	cis	rs9660992	0.573	rs12125276	chr1:205199440	C/T	cg21643547	chr1:205240462	TMCC2	-0.39	-5.37	-0.31	1.76e-7	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs67311347	0.911	rs9863737	chr3:40439836	C/T	cg24209194	chr3:40518798	ZNF619	0.51	6.42	0.37	6.35e-10	Renal cell carcinoma;
CESC	trans	rs2530545	0.851	rs59297232	chr7:34692183	C/T	cg14080982	chr15:71736038	THSD4	-0.48	-6.27	-0.36	1.43e-9	IgG glycosylation;
CESC	cis	rs919433	0.963	rs10153881	chr2:198171098	T/C	cg10820045	chr2:198174542	NA	-0.36	-5.08	-0.3	7.09e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs9926296	0.605	rs886951	chr16:89836865	A/G	cg04287289	chr16:89883240	FANCA	0.89	15.36	0.69	1.58e-38	Vitiligo;
CESC	cis	rs1348850	0.519	rs1527407	chr2:178525630	T/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.57	7.05	0.4	1.57e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs1775715	0.870	rs11008696	chr10:32218614	G/A	cg04359828	chr10:32216031	ARHGAP12	0.38	5.23	0.31	3.5e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs4680	0.737	rs4818	chr22:19951207	C/G	cg23601416	chr22:19950040	COMT	-0.28	-5.25	-0.31	3.06e-7	Blood metabolite levels;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg19796955	chr12:64895570	TBK1	0.37	6.36	0.36	8.76e-10	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs17253792	0.822	rs75049893	chr14:56089158	A/G	cg01858014	chr14:56050164	KTN1	-0.91	-7.19	-0.4	6.49e-12	Putamen volume;
CESC	cis	rs9583531	0.689	rs9521913	chr13:111382058	C/T	cg15841412	chr13:111365552	ING1	-0.42	-5.15	-0.3	5.08e-7	Coronary artery disease;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg10002088	chr19:9271911	ZNF317	-0.49	-6.39	-0.37	7.55e-10	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs896854	0.654	rs896846	chr8:95972453	G/A	cg13393036	chr8:95962371	TP53INP1	-0.48	-10.36	-0.54	2.51e-21	Type 2 diabetes;
CESC	cis	rs9291683	0.509	rs998676	chr4:9948564	T/C	cg02734326	chr4:10020555	SLC2A9	-0.45	-6.73	-0.38	1.06e-10	Bone mineral density;
CESC	cis	rs6460942	0.841	rs6968277	chr7:12443795	C/A	cg19099843	chr7:12443191	VWDE	-0.51	-6.26	-0.36	1.52e-9	Coronary artery disease;
CESC	cis	rs2235544	0.639	rs72664117	chr1:54476931	A/G	cg25741118	chr1:54482237	LDLRAD1	-0.26	-6.32	-0.36	1.09e-9	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
CESC	cis	rs7647973	0.626	rs4855846	chr3:49683526	G/A	cg07636037	chr3:49044803	WDR6	0.53	6.41	0.37	6.49e-10	Menarche (age at onset);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg24863706	chr4:120549163	PDE5A	-0.48	-6.26	-0.36	1.56e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs7666738	0.830	rs13102369	chr4:99045912	A/G	cg18180107	chr4:99064573	C4orf37	0.41	5.29	0.31	2.51e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs34375054	0.526	rs883315	chr12:125676889	T/C	cg25124228	chr12:125621409	AACS	-0.5	-5.84	-0.34	1.49e-8	Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs12347191	0.500	rs973473	chr9:100620730	T/G	cg13688889	chr9:100608707	NA	-0.91	-13.42	-0.64	1.07e-31	Orofacial clefts;
CESC	cis	rs4664308	0.840	rs1870102	chr2:161070582	A/G	cg03641300	chr2:160917029	PLA2R1	-0.62	-8.88	-0.48	1.04e-16	Idiopathic membranous nephropathy;
CESC	cis	rs9487051	0.676	rs9398193	chr6:109593134	G/T	cg12927641	chr6:109611667	NA	-0.37	-5.56	-0.32	6.55e-8	Reticulocyte fraction of red cells;
CESC	cis	rs68170813	0.559	rs3815148	chr7:106938420	G/T	cg02696742	chr7:106810147	HBP1	0.55	5.57	0.32	6.21e-8	Coronary artery disease;
CESC	cis	rs1448094	0.511	rs17345299	chr12:86166005	C/G	cg00310523	chr12:86230176	RASSF9	0.35	5.71	0.33	3.01e-8	Major depressive disorder;
CESC	cis	rs10504073	0.647	rs4873314	chr8:50011656	A/C	cg00325661	chr8:49890786	NA	0.57	8.56	0.47	9.52e-16	Blood metabolite ratios;
CESC	cis	rs780094	0.585	rs7586601	chr2:27584666	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.26	-5.34	-0.31	1.97e-7	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
CESC	cis	rs4853012	0.838	rs2177707	chr2:74356850	A/G	cg05890377	chr2:74357713	NA	0.74	9.2	0.49	1.1e-17	Gestational age at birth (maternal effect);
CESC	cis	rs6141600	0.760	rs2590991	chr20:34716238	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.38	-5.12	-0.3	5.83e-7	Height;Hip circumference;
CESC	cis	rs965469	0.779	rs6133031	chr20:3300857	A/C	cg25506879	chr20:3388711	C20orf194	-0.49	-5.41	-0.32	1.44e-7	IFN-related cytopenia;
CESC	cis	rs7264396	0.676	rs6058380	chr20:34552900	T/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.52	6.1	0.35	3.72e-9	Total cholesterol levels;
CESC	trans	rs916888	0.773	rs199535	chr17:44822662	A/G	cg04703951	chr17:43578652	NA	0.51	6.16	0.35	2.63e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs7666738	0.830	rs7674095	chr4:99048158	T/A	cg05340658	chr4:99064831	C4orf37	0.82	12.88	0.62	8.44e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs593982	0.920	rs487264	chr11:65481465	A/C	cg08755490	chr11:65554678	OVOL1	1.15	10.39	0.54	2.01e-21	Atopic dermatitis;
CESC	cis	rs1395	0.778	rs12465084	chr2:27414203	G/C	cg22903471	chr2:27725779	GCKR	-0.42	-5.21	-0.3	3.81e-7	Blood metabolite levels;
CESC	cis	rs7312933	0.558	rs55702525	chr12:42814309	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.5	-6.72	-0.38	1.08e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs6762	0.748	rs5030780	chr11:838110	C/T	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.7	-9.31	-0.5	5.22e-18	Mean platelet volume;
CESC	cis	rs61931739	0.517	rs7313663	chr12:34417058	T/C	cg06521331	chr12:34319734	NA	-0.37	-5.12	-0.3	5.75e-7	Morning vs. evening chronotype;
CESC	cis	rs992157	0.735	rs12990082	chr2:219102332	C/T	cg00012203	chr2:219082015	ARPC2	0.85	12.27	0.6	1.07e-27	Colorectal cancer;
CESC	cis	rs12464559	0.649	rs10754989	chr2:152642235	T/C	cg01189475	chr2:152685088	ARL5A	0.72	6.22	0.36	1.95e-9	Response to cognitive-behavioural therapy in anxiety disorder;
CESC	cis	rs8060686	0.920	rs73591976	chr16:67811590	C/A	cg26727032	chr16:67993705	SLC12A4	-0.59	-6.16	-0.35	2.69e-9	HDL cholesterol;Metabolic syndrome;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04407579	chr13:99228509	STK24	0.55	6.36	0.36	8.82e-10	Gut microbiome composition (summer);
CESC	cis	rs2749592	0.611	rs2505199	chr10:38392457	G/A	cg00409905	chr10:38381863	ZNF37A	-0.54	-6.97	-0.39	2.46e-11	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs362272	0.545	rs2749783	chr4:3326098	A/C	cg08886695	chr4:3369023	RGS12	-0.42	-5.84	-0.34	1.52e-8	Serum sulfate level;
CESC	trans	rs57221529	0.766	rs28563961	chr5:554498	C/G	cg25482853	chr8:67687455	SGK3	1.12	10.9	0.56	4.19e-23	Lung disease severity in cystic fibrosis;
CESC	cis	rs7274811	0.711	rs291669	chr20:31945364	C/T	cg21523528	chr20:32077966	CBFA2T2	-0.44	-5.64	-0.33	4.32e-8	Height;
CESC	cis	rs780094	0.544	rs780110	chr2:27685388	G/A	cg12648201	chr2:27665141	KRTCAP3	-0.29	-5.73	-0.33	2.72e-8	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
CESC	cis	rs9831754	1.000	rs1028024	chr3:78371577	A/C	cg06138941	chr3:78371609	NA	-0.76	-8.76	-0.47	2.34e-16	Calcium levels;
CESC	cis	rs1506636	1.000	rs659416	chr7:123401764	A/G	cg03229431	chr7:123269106	ASB15	-0.5	-6.53	-0.37	3.34e-10	Plateletcrit;Platelet count;
CESC	cis	rs1957429	0.634	rs59000318	chr14:65419473	C/A	cg23373153	chr14:65346875	NA	-0.8	-8.13	-0.45	1.7e-14	Pediatric areal bone mineral density (radius);
CESC	cis	rs1799949	0.894	rs8176160	chr17:41241503	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.65	9.25	0.49	7.64e-18	Menopause (age at onset);
CESC	cis	rs4450798	0.793	rs9831150	chr3:13740916	C/T	cg23332027	chr3:13681764	NA	0.4	5.36	0.31	1.81e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs9733	0.596	rs12089731	chr1:150647798	T/C	cg18016565	chr1:150552671	MCL1	0.33	5.16	0.3	4.96e-7	Tonsillectomy;
CESC	cis	rs344364	0.511	rs1742460	chr16:1945441	G/C	cg03013636	chr16:1946785	NA	0.5	6.43	0.37	5.92e-10	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs1124376	0.810	rs6807771	chr3:20160634	C/A	cg05072819	chr3:20081367	KAT2B	0.5	5.59	0.32	5.7e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs3858526	0.834	rs10839166	chr11:6002464	T/C	cg13902645	chr11:5959945	NA	-0.47	-5.45	-0.32	1.13e-7	DNA methylation (variation);
CESC	cis	rs73001065	0.636	rs10415849	chr19:19505087	C/T	cg03709012	chr19:19516395	GATAD2A	0.89	7.25	0.41	4.66e-12	LDL cholesterol;
CESC	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	-0.86	-12.57	-0.61	9.53e-29	Prudent dietary pattern;
CESC	cis	rs9914578	1.000	rs4061660	chr17:2004377	C/T	cg16513277	chr17:2031491	SMG6	-0.6	-7.02	-0.4	1.89e-11	Body mass index;
CESC	cis	rs2806561	0.765	rs681395	chr1:23500314	G/A	cg12483005	chr1:23474871	LUZP1	0.39	6.21	0.36	2.05e-9	Height;
CESC	cis	rs853679	0.517	rs9380047	chr6:28037893	G/T	cg18032046	chr6:28092343	ZSCAN16	-0.53	-6.03	-0.35	5.5e-9	Depression;
CESC	trans	rs9858542	0.953	rs7622302	chr3:49547561	T/C	cg21659725	chr3:3221576	CRBN	-0.55	-6.49	-0.37	4.26e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs7937682	0.855	rs11213985	chr11:111581521	C/A	cg09085632	chr11:111637200	PPP2R1B	-1.02	-17.06	-0.72	1.51e-44	Primary sclerosing cholangitis;
CESC	cis	rs35110281	1.000	rs35110281	chr21:45068947	T/A	cg21573476	chr21:45109991	RRP1B	-0.51	-7.01	-0.4	1.93e-11	Mean corpuscular volume;
CESC	cis	rs9916302	0.904	rs35335692	chr17:37710006	A/G	cg20243544	chr17:37824526	PNMT	0.52	6.56	0.37	2.77e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs4713118	0.662	rs149948	chr6:27974817	C/G	cg12963246	chr6:28129442	ZNF389	0.42	5.68	0.33	3.48e-8	Parkinson's disease;
CESC	cis	rs4642101	0.824	rs9852222	chr3:12848491	G/T	cg05775895	chr3:12838266	CAND2	0.39	5.78	0.33	2.1e-8	QRS complex (12-leadsum);
CESC	cis	rs875971	0.862	rs778697	chr7:65870426	G/A	cg18876405	chr7:65276391	NA	0.53	7.32	0.41	3.01e-12	Aortic root size;
CESC	cis	rs4474465	0.850	rs4565922	chr11:78260699	A/G	cg27205649	chr11:78285834	NARS2	0.41	5.22	0.31	3.61e-7	Alzheimer's disease (survival time);
CESC	cis	rs2486288	0.587	rs12899942	chr15:45547280	T/C	cg21132104	chr15:45694354	SPATA5L1	-0.54	-6.54	-0.37	3.21e-10	Glomerular filtration rate;
CESC	cis	rs2032447	0.507	rs478349	chr6:25894057	T/C	cg18357526	chr6:26021779	HIST1H4A	0.46	5.59	0.32	5.76e-8	Intelligence (multi-trait analysis);
CESC	cis	rs112158604	1	rs112158604	chr1:150696792	TCTTCTGCAG/T	cg04414720	chr1:150670196	GOLPH3L	-0.37	-5.17	-0.3	4.64e-7	Lymphocyte counts;
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg05793409	chr1:35658810	SFPQ	-0.46	-6.66	-0.38	1.61e-10	Vertical cup-disc ratio;
CESC	cis	rs9611565	0.918	rs2281333	chr22:41749630	T/C	cg03806693	chr22:41940476	POLR3H	-0.77	-9.39	-0.5	2.97e-18	Vitiligo;
CESC	cis	rs3858526	0.508	rs10838734	chr11:5876325	T/G	cg13902645	chr11:5959945	NA	-0.59	-7.36	-0.41	2.36e-12	DNA methylation (variation);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg24725560	chr11:32605793	EIF3M	-0.45	-6.35	-0.36	9.17e-10	Gambling;
CESC	cis	rs3020736	0.500	rs6002618	chr22:42507859	G/C	cg04733989	chr22:42467013	NAGA	-0.78	-11.9	-0.59	1.87e-26	Autism spectrum disorder or schizophrenia;
CESC	cis	rs1355223	0.867	rs7944030	chr11:34691738	A/T	cg11058730	chr11:34937778	PDHX;APIP	-0.53	-6.88	-0.39	4.42e-11	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs2836974	0.644	rs11088472	chr21:40699376	A/C	cg11644478	chr21:40555479	PSMG1	-0.79	-11.61	-0.58	1.77e-25	Cognitive function;
CESC	cis	rs35306767	0.761	rs11253557	chr10:1043667	C/T	cg20503657	chr10:835505	NA	0.71	6.4	0.37	6.85e-10	Eosinophil percentage of granulocytes;
CESC	cis	rs478304	0.934	rs506853	chr11:65521247	C/T	cg08755490	chr11:65554678	OVOL1	0.46	6.15	0.35	2.85e-9	Acne (severe);
CESC	cis	rs34172651	0.517	rs11862923	chr16:24767303	G/T	cg04756594	chr16:24857601	SLC5A11	0.45	5.52	0.32	8.21e-8	Intelligence (multi-trait analysis);
CESC	cis	rs858239	0.600	rs4409314	chr7:23127952	T/C	cg23682824	chr7:23144976	KLHL7	0.51	6.92	0.39	3.47e-11	Cerebrospinal fluid biomarker levels;
CESC	cis	rs898097	0.783	rs11650335	chr17:80835111	A/G	cg20271620	chr17:80763330	TBCD	0.46	5.39	0.31	1.59e-7	Breast cancer;
CESC	cis	rs9916302	0.706	rs667239	chr17:37442241	A/G	cg00129232	chr17:37814104	STARD3	0.49	5.42	0.32	1.31e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs76917914	0.820	rs7020081	chr9:100823360	C/A	cg03040243	chr9:100819229	NANS	0.46	5.14	0.3	5.36e-7	Immature fraction of reticulocytes;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg06134974	chr12:51477539	CSRNP2	0.49	6.64	0.38	1.78e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs4844614	1.000	rs12038371	chr1:207821046	A/G	cg21110645	chr1:207815933	NA	0.37	5.68	0.33	3.61e-8	LDL cholesterol;
CESC	cis	rs66573146	1.000	rs6838042	chr4:6973049	G/T	cg00086871	chr4:6988644	TBC1D14	0.89	5.77	0.33	2.22e-8	Granulocyte percentage of myeloid white cells;
CESC	cis	rs12681288	0.676	rs34435811	chr8:990630	T/A	cg04851639	chr8:1020857	NA	-0.31	-6.66	-0.38	1.59e-10	Schizophrenia;
CESC	cis	rs7100689	0.516	rs10887711	chr10:82034842	A/G	cg00277334	chr10:82204260	NA	-0.46	-5.76	-0.33	2.28e-8	Post bronchodilator FEV1;
CESC	cis	rs8077577	0.689	rs2273029	chr17:18236339	G/A	cg16794390	chr17:18148240	FLII	0.41	6.45	0.37	5.33e-10	Obesity-related traits;
CESC	cis	rs514406	0.607	rs6665324	chr1:53201610	G/A	cg25767906	chr1:53392781	SCP2	0.43	5.94	0.34	9.04e-9	Monocyte count;
CESC	cis	rs227584	0.663	rs2040810	chr17:42243771	C/T	cg19774624	chr17:42201019	HDAC5	0.69	10.27	0.53	4.8e-21	Bone mineral density (hip);Bone mineral density;
CESC	cis	rs10256972	0.626	rs62433138	chr7:1050877	T/C	cg00431813	chr7:1051703	C7orf50	-0.56	-9.46	-0.5	1.8e-18	Longevity;Endometriosis;
CESC	cis	rs6460942	1.000	rs62448563	chr7:12400040	G/A	cg02935154	chr7:12443704	VWDE	-0.57	-6.15	-0.35	2.77e-9	Coronary artery disease;
CESC	cis	rs11098499	0.863	rs12508173	chr4:120318526	T/C	cg24375607	chr4:120327624	NA	0.47	5.73	0.33	2.74e-8	Corneal astigmatism;
CESC	cis	rs10504229	0.689	rs17801390	chr8:58054768	T/C	cg02725872	chr8:58115012	NA	-0.44	-6.08	-0.35	4.08e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs9633740	1.000	rs1870137	chr10:82269848	C/G	cg00277334	chr10:82204260	NA	-0.58	-5.78	-0.33	2.15e-8	Post bronchodilator FEV1;
CESC	cis	rs1448094	0.511	rs10506918	chr12:86227913	A/G	cg02569458	chr12:86230093	RASSF9	-0.44	-6.62	-0.38	2.02e-10	Major depressive disorder;
CESC	cis	rs1008375	0.932	rs6845288	chr4:17665498	A/T	cg16339924	chr4:17578868	LAP3	-0.66	-7.59	-0.42	5.58e-13	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs1003719	0.788	rs9974286	chr21:38456832	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.58	-8.09	-0.45	2.14e-14	Eye color traits;
CESC	cis	rs10504229	0.683	rs11786527	chr8:58131344	G/C	cg02725872	chr8:58115012	NA	-0.45	-7.05	-0.4	1.52e-11	Developmental language disorder (linguistic errors);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg01517940	chr14:69865233	SLC39A9;ERH	-0.45	-6.3	-0.36	1.2e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs2243480	1.000	rs160633	chr7:65528228	T/C	cg12463550	chr7:65579703	CRCP	0.65	5.26	0.31	3.04e-7	Diabetic kidney disease;
CESC	cis	rs3126085	0.935	rs12726613	chr1:152185500	C/G	cg26876637	chr1:152193138	HRNR	-0.44	-5.03	-0.3	9.04e-7	Atopic dermatitis;
CESC	cis	rs6582630	0.537	rs3942440	chr12:38459672	A/G	cg13010199	chr12:38710504	ALG10B	0.47	6.11	0.35	3.63e-9	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs7714584	1.000	rs6875011	chr5:150182710	G/A	cg22134413	chr5:150180641	NA	0.62	5.79	0.34	1.96e-8	Crohn's disease;
CESC	cis	rs854765	0.647	rs8066764	chr17:17974668	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.61	8.64	0.47	5.3e-16	Total body bone mineral density;
CESC	cis	rs12188164	0.686	rs72711365	chr5:416672	G/A	cg15813090	chr5:442598	EXOC3;C5orf55	0.39	5.86	0.34	1.41e-8	Cystic fibrosis severity;
CESC	cis	rs6502050	0.769	rs8079122	chr17:80120427	G/T	cg23985595	chr17:80112537	CCDC57	-0.4	-6.17	-0.35	2.56e-9	Life satisfaction;
CESC	cis	rs67311347	0.822	rs9826847	chr3:40345312	A/T	cg09455208	chr3:40491958	NA	0.43	7.02	0.4	1.81e-11	Renal cell carcinoma;
CESC	cis	rs11098499	0.954	rs11098525	chr4:120390152	G/A	cg24375607	chr4:120327624	NA	0.45	5.61	0.33	5.1e-8	Corneal astigmatism;
CESC	cis	rs2991971	0.967	rs2275276	chr1:45973928	C/T	cg15605315	chr1:45957053	TESK2	0.48	6.41	0.37	6.69e-10	High light scatter reticulocyte count;
CESC	cis	rs898097	0.627	rs3785514	chr17:80888905	A/G	cg15664640	chr17:80829946	TBCD	0.65	9.57	0.51	7.85e-19	Breast cancer;
CESC	cis	rs10504229	0.600	rs6987243	chr8:58115406	T/C	cg02725872	chr8:58115012	NA	-0.44	-6.87	-0.39	4.48e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs17711722	0.585	rs6942660	chr7:65302406	C/T	cg06456125	chr7:65229604	NA	0.43	5.61	0.33	5.03e-8	Calcium levels;
CESC	cis	rs1499972	0.878	rs817513	chr3:117733823	A/T	cg07612923	chr3:117604196	NA	-0.8	-5.97	-0.34	7.5e-9	Schizophrenia;
CESC	cis	rs2019216	0.564	rs907707	chr17:21910083	G/C	cg22648282	chr17:21454238	C17orf51	-0.44	-5.96	-0.34	7.89e-9	Pelvic organ prolapse;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19245296	chr20:10015646	ANKRD5	0.62	6.93	0.39	3.17e-11	Gut microbiome composition (summer);
CESC	trans	rs561341	1.000	rs530715	chr17:30320544	T/G	cg27661571	chr11:113659931	NA	-0.71	-7.33	-0.41	2.83e-12	Hip circumference adjusted for BMI;
CESC	cis	rs2204008	0.870	rs12369578	chr12:38444227	C/T	cg26384229	chr12:38710491	ALG10B	0.69	10.28	0.53	4.42e-21	Bladder cancer;
CESC	cis	rs2576037	0.526	rs998819	chr18:44564181	C/T	cg19077165	chr18:44547161	KATNAL2	0.54	7.97	0.44	4.82e-14	Personality dimensions;
CESC	cis	rs9311474	0.508	rs6805156	chr3:52609362	T/C	cg18099408	chr3:52552593	STAB1	-0.32	-5.42	-0.32	1.37e-7	Electroencephalogram traits;
CESC	cis	rs2303759	0.918	rs7251704	chr19:49890873	T/G	cg22307029	chr19:49891270	CCDC155	0.74	8.79	0.48	1.88e-16	Multiple sclerosis;
CESC	cis	rs644799	1.000	rs472231	chr11:95532166	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.92	13.87	0.65	2.93e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs684232	0.602	rs379998	chr17:556884	A/G	cg12384639	chr17:618140	VPS53	0.41	5.23	0.31	3.42e-7	Prostate cancer;
CESC	cis	rs10949834	0.652	rs2269082	chr7:73519875	A/G	cg07137043	chr7:73588983	EIF4H	-0.69	-7.58	-0.42	5.98e-13	Verbal memory performance (residualized delayed recall change);
CESC	cis	rs7618915	0.547	rs2286800	chr3:52778051	C/T	cg18099408	chr3:52552593	STAB1	-0.31	-5.13	-0.3	5.6e-7	Bipolar disorder;
CESC	cis	rs6831352	0.959	rs6532796	chr4:100042242	C/T	cg12011299	chr4:100065546	ADH4	-0.69	-8.26	-0.45	6.95e-15	Alcohol dependence;
CESC	cis	rs1862618	0.713	rs832549	chr5:56183542	C/T	cg12311346	chr5:56204834	C5orf35	-0.73	-8.79	-0.48	1.93e-16	Initial pursuit acceleration;
CESC	cis	rs7940866	0.903	rs1347283	chr11:130868583	T/G	cg12179176	chr11:130786555	SNX19	0.61	8.52	0.46	1.21e-15	Schizophrenia;
CESC	cis	rs7829975	0.514	rs2945873	chr8:8260445	C/T	cg15556689	chr8:8085844	FLJ10661	0.6	7.84	0.43	1.09e-13	Mood instability;
CESC	cis	rs9910055	0.530	rs7222349	chr17:42304644	C/T	cg13607699	chr17:42295918	UBTF	0.83	12.93	0.62	5.67e-30	Total body bone mineral density;
CESC	cis	rs7552404	0.961	rs448710	chr1:76116554	T/C	cg10523679	chr1:76189770	ACADM	-0.71	-8.24	-0.45	7.75e-15	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs1799949	1.000	rs11653460	chr17:41331306	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.59	7.71	0.43	2.62e-13	Menopause (age at onset);
CESC	cis	rs506597	0.920	rs221786	chr7:100266081	T/C	cg10426581	chr7:100472382	SRRT	-0.78	-5.55	-0.32	7.07e-8	Pursuit maintenance gain in psychotic disorders;
CESC	cis	rs17854409	0.803	rs1063247	chr20:61472118	C/G	cg05147244	chr20:61493195	TCFL5	0.97	6.5	0.37	4e-10	Obesity-related traits;
CESC	cis	rs6582630	0.537	rs2204006	chr12:38407098	A/G	cg26384229	chr12:38710491	ALG10B	0.68	10.35	0.54	2.71e-21	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs116095464	0.558	rs9688136	chr5:229348	T/C	cg12570787	chr5:219185	SDHA;CCDC127	0.53	5.69	0.33	3.34e-8	Breast cancer;
CESC	cis	rs611744	0.647	rs1448150	chr8:109276161	T/C	cg21045802	chr8:109455806	TTC35	0.47	5.81	0.34	1.76e-8	Dupuytren's disease;
CESC	trans	rs11644601	1	rs11644601	chr16:15172118	T/C	cg04146151	chr16:2155961	PKD1	-0.6	-6.73	-0.38	1.07e-10	Metabolite levels (lipid measures);
CESC	cis	rs1801516	0.948	rs55949629	chr11:108226399	T/C	cg04514998	chr11:108680123	DDX10	0.46	5.04	0.3	8.55e-7	Melanoma;
CESC	cis	rs9911578	1.000	rs304292	chr17:56824123	G/A	cg05425664	chr17:57184151	TRIM37	-0.49	-6.72	-0.38	1.11e-10	Intelligence (multi-trait analysis);
CESC	cis	rs10905065	0.965	rs7100576	chr10:5784649	G/A	cg11519256	chr10:5708881	ASB13	0.44	5.86	0.34	1.36e-8	Menopause (age at onset);
CESC	cis	rs2302190	0.769	rs7215531	chr17:56493374	A/T	cg25885038	chr17:56607967	SEPT4	-0.4	-5.15	-0.3	5.03e-7	Vitamin D levels;
CESC	cis	rs6952808	0.862	rs4721167	chr7:1933224	C/T	cg05863683	chr7:1912471	MAD1L1	0.48	7.32	0.41	2.95e-12	Bipolar disorder and schizophrenia;
CESC	trans	rs28549925	0.590	rs17136905	chr7:16985642	T/C	cg12639933	chr12:57626296	SHMT2	0.89	6.04	0.35	5.23e-9	Congenital heart disease (maternal effect);Conotruncal heart defects (maternal effects);
CESC	cis	rs10465746	0.967	rs7531537	chr1:84414924	C/T	cg10977910	chr1:84465055	TTLL7	0.47	6.39	0.37	7.37e-10	Obesity-related traits;
CESC	cis	rs6088580	0.634	rs6059856	chr20:33057954	G/C	cg08999081	chr20:33150536	PIGU	0.66	11.67	0.58	1.16e-25	Glomerular filtration rate (creatinine);
CESC	cis	rs11153147	0.730	rs2798646	chr6:109310596	C/A	cg05315195	chr6:109294784	ARMC2	0.65	5.95	0.34	8.24e-9	Mean corpuscular volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25421043	chr12:122124840	NA	-0.58	-6.85	-0.39	5.08e-11	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18485729	chr3:113774958	QTRTD1;KIAA1407	-0.53	-6.11	-0.35	3.62e-9	Gut microbiome composition (summer);
CESC	cis	rs896854	0.654	rs10104909	chr8:95977973	C/T	cg26343298	chr8:95960752	TP53INP1	0.37	6.22	0.36	1.91e-9	Type 2 diabetes;
CESC	cis	rs9457247	1.000	rs365189	chr6:167384545	G/A	cg07741184	chr6:167504864	NA	0.31	5.53	0.32	7.76e-8	Crohn's disease;
CESC	cis	rs2694528	0.686	rs7729781	chr5:59872406	C/T	cg11474532	chr5:59995715	DEPDC1B	0.91	6.37	0.36	8.39e-10	Parkinson's disease;
CESC	cis	rs1799949	0.965	rs9897425	chr17:41430179	C/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.56	7.97	0.44	4.86e-14	Menopause (age at onset);
CESC	trans	rs7726839	0.540	rs72703083	chr5:595365	C/T	cg25482853	chr8:67687455	SGK3	1.04	10.1	0.53	1.69e-20	Obesity-related traits;
CESC	cis	rs9325144	0.560	rs1843910	chr12:38677408	T/C	cg26384229	chr12:38710491	ALG10B	-0.6	-9.35	-0.5	3.86e-18	Morning vs. evening chronotype;
CESC	cis	rs13064411	0.735	rs6438158	chr3:113217290	C/T	cg18753928	chr3:113234510	CCDC52	-0.51	-6.22	-0.36	1.9e-9	Response to simvastatin treatment (PCSK9 protein level change);
CESC	cis	rs57709857	0.957	rs6996860	chr8:38243865	G/T	cg01506891	chr8:38243824	LETM2	-0.46	-5.1	-0.3	6.42e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs11997175	0.583	rs7460295	chr8:33812288	C/T	ch.8.33884649F	chr8:33765107	NA	0.45	5.69	0.33	3.31e-8	Body mass index;
CESC	cis	rs6991838	0.584	rs7463649	chr8:66485995	C/T	cg13398993	chr8:66546079	ARMC1	-0.45	-5.54	-0.32	7.3900000000000007e-08	Intelligence (multi-trait analysis);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg25175887	chr12:3274880	TSPAN9	-0.43	-6.49	-0.37	4.26e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs3617	0.573	rs2336668	chr3:52919096	G/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	-0.33	-5.54	-0.32	7.3900000000000007e-08	Red blood cell count;Autism spectrum disorder or schizophrenia;
CESC	cis	rs61990749	0.544	rs176979	chr14:78198072	A/C	cg23188588	chr14:78226832	SNW1;C14orf178	0.47	5.09	0.3	6.84e-7	Fibroblast growth factor basic levels;
CESC	cis	rs60871478	0.898	rs62432897	chr7:825429	A/G	cg13798912	chr7:905769	UNC84A	0.52	5.16	0.3	4.86e-7	Cerebrospinal P-tau181p levels;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg17482706	chr9:77643371	C9orf41	0.48	6.19	0.36	2.25e-9	Systemic lupus erythematosus;
CESC	cis	rs3105593	1.000	rs4775897	chr15:50944066	G/A	cg08437265	chr15:50716283	USP8	0.44	5.81	0.34	1.79e-8	QT interval;
CESC	cis	rs2242663	0.798	rs607736	chr11:66328877	G/A	cg24851651	chr11:66362959	CCS	0.4	5.16	0.3	4.75e-7	Bipolar disorder;
CESC	cis	rs9815354	0.812	rs73077360	chr3:41850054	C/T	cg03022575	chr3:42003672	ULK4	0.7	6.04	0.35	5.26e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs9911578	1.000	rs8076121	chr17:57041699	G/A	cg05425664	chr17:57184151	TRIM37	-0.5	-6.96	-0.39	2.66e-11	Intelligence (multi-trait analysis);
CESC	cis	rs2072732	0.861	rs10489589	chr1:2951244	T/C	cg15211996	chr1:2936768	ACTRT2	0.34	5.95	0.34	8.31e-9	Plateletcrit;
CESC	cis	rs6860806	0.507	rs274572	chr5:131710917	T/G	cg04518342	chr5:131593106	PDLIM4	-0.36	-5.21	-0.3	3.8e-7	Breast cancer;
CESC	cis	rs1364705	1.000	rs61600037	chr8:120225613	T/C	cg09273054	chr8:120220131	MAL2	0.52	5.98	0.34	7.35e-9	Hippocampal atrophy;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg02760553	chr17:73975121	ACOX1;C17orf106	0.51	6.49	0.37	4.16e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs7640424	0.620	rs71321252	chr3:107813107	A/C	cg09227934	chr3:107805635	CD47	-0.45	-5.58	-0.32	5.86e-8	Body mass index;
CESC	cis	rs57221529	0.766	rs17497684	chr5:558307	T/C	cg09021430	chr5:549028	NA	-0.42	-5.26	-0.31	2.92e-7	Lung disease severity in cystic fibrosis;
CESC	cis	rs920590	0.758	rs62496731	chr8:19659543	C/G	cg01411142	chr8:19674711	INTS10	0.53	5.88	0.34	1.22e-8	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs4665809	0.590	rs7604564	chr2:26501953	C/A	cg27170947	chr2:26402098	FAM59B	0.82	9.18	0.49	1.23e-17	Gut microbiome composition (summer);
CESC	cis	rs920590	0.758	rs2898491	chr8:19661883	C/T	cg03894339	chr8:19674705	INTS10	0.63	7.26	0.41	4.24e-12	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs4566357	0.595	rs10201538	chr2:227914449	A/G	cg05526886	chr2:227700861	RHBDD1	-0.45	-5.93	-0.34	9.37e-9	Coronary artery disease;
CESC	cis	rs875971	0.895	rs6460278	chr7:65662736	T/C	cg12463550	chr7:65579703	CRCP	-0.51	-6.5	-0.37	3.9e-10	Aortic root size;
CESC	trans	rs9325144	0.647	rs61930266	chr12:38922048	A/G	cg23762105	chr12:34175262	ALG10	0.47	6.17	0.35	2.6e-9	Morning vs. evening chronotype;
CESC	cis	rs10504229	0.683	rs10504224	chr8:58143735	A/G	cg24829409	chr8:58192753	C8orf71	-0.62	-7.16	-0.4	7.75e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs6089829	0.889	rs6090206	chr20:61668363	G/A	cg03213289	chr20:61660250	NA	0.39	6.06	0.35	4.68e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs6952808	0.689	rs4719391	chr7:2048136	T/C	cg23048001	chr7:2026167	MAD1L1	0.48	6.29	0.36	1.33e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs13191362	0.935	rs34587258	chr6:162945580	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.69	5.96	0.34	8.22e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs6061231	0.740	rs11698650	chr20:60958374	A/T	cg24112000	chr20:60950667	NA	-0.55	-8.62	-0.47	6.17e-16	Colorectal cancer;
CESC	cis	rs6439153	0.933	rs6769662	chr3:128721310	A/C	cg25356066	chr3:128598488	ACAD9	0.53	6.92	0.39	3.33e-11	Pneumococcal bacteremia;
CESC	cis	rs3020736	0.500	rs5996110	chr22:42493767	A/G	cg04733989	chr22:42467013	NAGA	-0.79	-12.03	-0.59	6.75e-27	Autism spectrum disorder or schizophrenia;
CESC	cis	rs9303280	0.806	rs9904624	chr17:38036586	A/G	cg20243544	chr17:37824526	PNMT	0.5	6.54	0.37	3.21e-10	Self-reported allergy;
CESC	cis	rs4835473	0.897	rs17693768	chr4:144658656	G/A	cg25736465	chr4:144833511	NA	-0.33	-5.24	-0.31	3.3e-7	Immature fraction of reticulocytes;
CESC	cis	rs67311347	0.955	rs6773383	chr3:40377412	A/T	cg24209194	chr3:40518798	ZNF619	0.45	5.87	0.34	1.3e-8	Renal cell carcinoma;
CESC	cis	rs2652822	0.550	rs11853804	chr15:63528256	C/A	cg02713581	chr15:63449717	RPS27L	0.49	6.07	0.35	4.47e-9	Metabolic traits;
CESC	cis	rs3862260	0.509	rs3795663	chr1:120165187	G/A	cg11530693	chr1:120165357	ZNF697	0.69	10.58	0.55	4.58e-22	Systemic lupus erythematosus;
CESC	cis	rs798554	1.000	rs798545	chr7:2762386	C/T	cg04166393	chr7:2884313	GNA12	0.56	7.01	0.4	1.93e-11	Height;
CESC	cis	rs853679	0.542	rs6934769	chr6:28090931	A/G	cg23161317	chr6:28129485	ZNF389	0.51	6.5	0.37	3.98e-10	Depression;
CESC	cis	rs8077577	0.747	rs62072509	chr17:18182393	G/A	cg16794390	chr17:18148240	FLII	0.42	6.58	0.37	2.5e-10	Obesity-related traits;
CESC	cis	rs7165102	1.000	rs7163482	chr15:65739683	C/T	cg11441148	chr15:65824328	PTPLAD1	0.31	5.18	0.3	4.29e-7	Mean corpuscular hemoglobin;
CESC	cis	rs6582630	0.519	rs11495376	chr12:38284957	A/C	cg13010199	chr12:38710504	ALG10B	0.45	5.65	0.33	4.06e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs36051895	0.530	rs4142064	chr9:5221818	C/T	cg02405213	chr9:5042618	JAK2	-0.48	-5.6	-0.33	5.23e-8	Pediatric autoimmune diseases;
CESC	cis	rs2832077	0.527	rs2776210	chr21:30268558	A/G	cg03476357	chr21:30257390	N6AMT1	0.41	5.13	0.3	5.56e-7	Cognitive test performance;
CESC	cis	rs9611565	0.918	rs9611566	chr22:41768625	A/G	cg06634786	chr22:41940651	POLR3H	0.69	7.17	0.4	7.68e-12	Vitiligo;
CESC	cis	rs1799949	1.000	rs11649954	chr17:41420035	A/G	cg05368731	chr17:41323189	NBR1	0.79	10.92	0.56	3.52e-23	Menopause (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18622001	chr10:126150304	LHPP	0.55	6.43	0.37	5.94e-10	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05797093	chr3:58109301	FLNB	-0.59	-6.73	-0.38	1.03e-10	Gut microbiome composition (summer);
CESC	cis	rs3126085	1.000	rs3120662	chr1:152302865	G/T	cg03465714	chr1:152285911	FLG	0.43	5.22	0.31	3.62e-7	Atopic dermatitis;
CESC	cis	rs4975709	0.569	rs931509	chr5:1858821	A/T	cg17650747	chr5:1873721	NA	0.45	6.07	0.35	4.34e-9	Cardiovascular disease risk factors;
CESC	cis	rs7089973	0.604	rs61596353	chr10:116597763	T/C	cg23260525	chr10:116636907	FAM160B1	0.4	7.38	0.41	2.03e-12	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs959260	1.000	rs930298	chr17:73404666	T/G	cg20590849	chr17:73267439	MIF4GD	-0.57	-6.55	-0.37	2.97e-10	Systemic lupus erythematosus;
CESC	cis	rs11764590	0.724	rs62444917	chr7:2107262	A/C	cg21782813	chr7:2030301	MAD1L1	-0.4	-5.16	-0.3	4.81e-7	Neuroticism;
CESC	cis	rs13102973	0.965	rs28826933	chr4:135876644	T/A	cg14419869	chr4:135874104	NA	-0.37	-5.7	-0.33	3.19e-8	Subjective well-being;
CESC	cis	rs9309473	1.000	rs9653557	chr2:73795962	A/C	cg20560298	chr2:73613845	ALMS1	-0.55	-7.17	-0.4	7.7e-12	Metabolite levels;
CESC	cis	rs4423214	1.000	rs11600569	chr11:71173747	C/G	cg05163923	chr11:71159392	DHCR7	0.79	10.44	0.54	1.35e-21	Vitamin D levels;
CESC	cis	rs7312933	0.703	rs7957471	chr12:42545591	G/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.47	6.02	0.35	5.72e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs10540	1.000	rs35255804	chr11:492617	G/A	cg21784768	chr11:537496	LRRC56	-0.55	-5.21	-0.3	3.76e-7	Body mass index;
CESC	cis	rs9303401	0.659	rs34382037	chr17:56643550	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.02	12.93	0.62	5.59e-30	Cognitive test performance;
CESC	trans	rs11624776	1.000	rs11624776	chr14:93595591	A/C	cg24799795	chr11:5959658	NA	-0.37	-6.0	-0.35	6.43e-9	Migraine;Thyroid hormone levels;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg03241502	chr19:7505149	ARHGEF18	0.48	6.25	0.36	1.67e-9	Fibrinogen levels;
CESC	cis	rs2228479	0.850	rs11641552	chr16:89838700	C/A	cg00800038	chr16:89945340	TCF25	-0.92	-7.64	-0.42	4.02e-13	Skin colour saturation;
CESC	cis	rs1256061	0.603	rs1152579	chr14:64695087	A/G	cg21174375	chr14:64681225	SYNE2	0.49	6.47	0.37	4.73e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs113835537	0.529	rs17495838	chr11:66196265	T/C	cg22134325	chr11:66188745	NPAS4	0.47	6.97	0.39	2.5e-11	Airway imaging phenotypes;
CESC	trans	rs9650657	0.529	rs10108618	chr8:10953092	A/G	cg06636001	chr8:8085503	FLJ10661	-0.47	-6.12	-0.35	3.43e-9	Neuroticism;
CESC	cis	rs73019876	0.869	rs1859093	chr19:22143339	T/G	cg11619707	chr19:22235551	ZNF257	-0.27	-5.1	-0.3	6.32e-7	Testicular germ cell tumor;
CESC	cis	rs10078	0.571	rs890973	chr5:471494	T/C	cg08916839	chr5:415575	AHRR	0.58	6.76	0.38	8.54e-11	Fat distribution (HIV);
CESC	cis	rs4819052	0.851	rs1006779	chr21:46670752	A/G	cg11663144	chr21:46675770	NA	-0.57	-8.81	-0.48	1.66e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs11864453	0.713	rs12708926	chr16:72126063	T/C	cg01557791	chr16:72042693	DHODH	-0.46	-5.92	-0.34	9.98e-9	Fibrinogen levels;
CESC	cis	rs58688157	0.705	rs12803132	chr11:586696	A/G	cg02461776	chr11:598696	PHRF1	0.51	5.58	0.32	6.09e-8	Systemic lupus erythematosus;
CESC	cis	rs763014	0.898	rs916414	chr16:632073	C/T	cg07343612	chr16:622815	PIGQ	-0.57	-8.23	-0.45	8.47e-15	Height;
CESC	cis	rs597539	0.616	rs72945243	chr11:68633358	T/C	cg21963583	chr11:68658836	MRPL21	0.42	5.88	0.34	1.21e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs10979	1.000	rs1416207	chr6:143889275	G/A	cg25407410	chr6:143891975	LOC285740	-0.61	-9.14	-0.49	1.72e-17	Hypospadias;
CESC	cis	rs10089	1.000	rs9968597	chr5:127455383	C/G	cg19767477	chr5:127420684	SLC12A2	-0.4	-5.47	-0.32	1.04e-7	Ileal carcinoids;
CESC	cis	rs79349575	0.749	rs2270574	chr17:47022270	C/T	cg26022315	chr17:47021804	SNF8	0.39	5.16	0.3	4.94e-7	Type 2 diabetes;
CESC	cis	rs7512552	0.839	rs12042229	chr1:150447398	A/G	cg15654264	chr1:150340011	RPRD2	0.39	5.15	0.3	5.16e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs7818688	1.000	rs28616734	chr8:96021443	C/T	cg16049864	chr8:95962084	TP53INP1	0.61	5.77	0.33	2.17e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs3741798	1.000	rs61922028	chr12:12487096	A/C	cg08615371	chr12:12503544	MANSC1	0.9	6.56	0.37	2.79e-10	Cerebrospinal fluid biomarker levels;
CESC	cis	rs4713118	0.621	rs4713132	chr6:28034035	A/G	cg23281280	chr6:28129359	ZNF389	0.53	7.06	0.4	1.5e-11	Parkinson's disease;
CESC	cis	rs6542838	0.641	rs4850890	chr2:99535426	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.5	-6.46	-0.37	5e-10	Fear of minor pain;
CESC	cis	rs735396	0.595	rs1169279	chr12:121455873	C/T	cg25281562	chr12:121454272	C12orf43	0.55	7.01	0.4	1.93e-11	N-glycan levels;
CESC	cis	rs2842992	0.872	rs2758315	chr6:160158640	T/C	cg26839252	chr6:160211577	TCP1;MRPL18	0.46	5.46	0.32	1.12e-7	Age-related macular degeneration (geographic atrophy);
CESC	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg07332563	chr6:291687	DUSP22	-0.69	-9.04	-0.49	3.5e-17	Menopause (age at onset);
CESC	cis	rs12579753	0.917	rs12316644	chr12:82205497	C/T	cg23701643	chr12:82153290	PPFIA2	0.35	5.24	0.31	3.26e-7	Resting heart rate;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg02205746	chr16:2732724	KCTD5	-0.43	-6.15	-0.35	2.91e-9	Fibrinogen levels;
CESC	cis	rs698833	0.962	rs698830	chr2:44730863	G/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.46	5.34	0.31	2.03e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs10479542	0.544	rs7706275	chr5:178990305	A/G	cg26516362	chr5:178986906	RUFY1	0.46	7.14	0.4	8.75e-12	Lung cancer;
CESC	cis	rs367943	0.698	rs2115207	chr5:112998285	C/T	cg12552261	chr5:112820674	MCC	0.45	5.77	0.33	2.18e-8	Type 2 diabetes;
CESC	cis	rs4705952	1.000	rs4705952	chr5:131839618	A/G	cg13365209	chr5:132202351	UQCRQ	0.41	5.31	0.31	2.29e-7	C-reactive protein levels;
CESC	trans	rs35146811	0.695	rs858508	chr7:99821381	C/G	cg13215871	chr17:75784724	NA	-0.34	-6.39	-0.37	7.46e-10	Coronary artery disease;
CESC	cis	rs875971	0.660	rs3857686	chr7:66036191	C/T	cg06456125	chr7:65229604	NA	-0.4	-5.27	-0.31	2.8e-7	Aortic root size;
CESC	cis	rs7927592	0.513	rs653056	chr11:68203625	T/C	cg16797656	chr11:68205561	LRP5	0.63	9.82	0.52	1.27e-19	Total body bone mineral density;
CESC	cis	rs6964587	1.000	rs2188155	chr7:91599825	A/C	cg17063962	chr7:91808500	NA	0.57	7.74	0.43	2.11e-13	Breast cancer;
CESC	cis	rs7666738	0.830	rs13121558	chr4:99002848	G/A	cg17366294	chr4:99064904	C4orf37	0.6	8.61	0.47	6.47e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9814567	1.000	rs10804632	chr3:134294501	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.41	-5.47	-0.32	1.03e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs644799	1.000	rs11021319	chr11:95523123	C/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.71	9.37	0.5	3.31e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs17384381	1.000	rs12132677	chr1:85879613	A/C	cg16011679	chr1:85725395	C1orf52	0.76	7.79	0.43	1.51e-13	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7615952	0.576	rs4646763	chr3:125822129	G/A	cg15145296	chr3:125709740	NA	-0.56	-5.91	-0.34	1.06e-8	Blood pressure (smoking interaction);
CESC	cis	rs7527798	0.571	rs12045913	chr1:207844625	A/G	cg21110645	chr1:207815933	NA	-0.33	-5.75	-0.33	2.4e-8	Erythrocyte sedimentation rate;
CESC	cis	rs4423214	0.921	rs11603330	chr11:71153459	C/A	cg24826892	chr11:71159390	DHCR7	0.45	5.32	0.31	2.22e-7	Vitamin D levels;
CESC	cis	rs11723261	0.582	rs4582104	chr4:136942	A/T	cg12746427	chr4:53362	ZNF718;ZNF595	0.51	6.82	0.39	6.07e-11	Immune response to smallpox vaccine (IL-6);
CESC	trans	rs17685	0.712	rs59659102	chr7:75710114	G/A	cg19862616	chr7:65841803	NCRNA00174	0.83	11.94	0.59	1.36e-26	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs9399135	0.967	rs4142299	chr6:135377186	G/T	cg22676075	chr6:135203613	NA	0.52	7.29	0.41	3.61e-12	Red blood cell count;
CESC	cis	rs2857078	0.720	rs9906669	chr17:42305706	A/G	cg13607699	chr17:42295918	UBTF	0.78	11.36	0.57	1.25e-24	Red cell distribution width;Reticulocyte count;
CESC	cis	rs854765	0.583	rs9904163	chr17:17830553	C/T	cg04398451	chr17:18023971	MYO15A	-0.67	-9.6	-0.51	6.42e-19	Total body bone mineral density;
CESC	cis	rs4654899	0.833	rs10127757	chr1:21490045	A/G	cg05370193	chr1:21551575	ECE1	0.46	7.11	0.4	1.08e-11	Superior frontal gyrus grey matter volume;
CESC	cis	rs7208859	0.623	rs7208441	chr17:29143863	C/T	cg19761014	chr17:28927070	LRRC37B2	0.77	6.35	0.36	9.2e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs13118159	0.742	rs7679860	chr4:1333987	C/T	cg16405210	chr4:1374714	KIAA1530	-0.65	-8.48	-0.46	1.56e-15	Longevity;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07835809	chr10:85899104	GHITM	-0.57	-6.38	-0.36	7.86e-10	Gut microbiome composition (summer);
CESC	trans	rs941207	0.542	rs12370142	chr12:57184585	G/T	cg26462586	chr2:11164677	NA	0.38	6.02	0.35	5.82e-9	Platelet count;
CESC	cis	rs3862030	0.720	rs11595149	chr10:104235978	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.37	-5.1	-0.3	6.39e-7	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
CESC	cis	rs17711722	0.522	rs62469933	chr7:65265639	G/A	cg11764359	chr7:65958608	NA	0.47	5.84	0.34	1.53e-8	Calcium levels;
CESC	cis	rs7017914	0.967	rs12680988	chr8:71695890	T/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.42	-5.3	-0.31	2.38e-7	Bone mineral density;
CESC	cis	rs1538970	0.816	rs10789464	chr1:45959102	C/T	cg03146154	chr1:46216737	IPP	0.49	5.52	0.32	8.01e-8	Platelet count;
CESC	cis	rs4595586	0.545	rs3914596	chr12:39388538	T/C	cg26384229	chr12:38710491	ALG10B	0.54	7.58	0.42	5.91e-13	Morning vs. evening chronotype;
CESC	cis	rs7927592	0.763	rs10896351	chr11:68386896	G/A	cg16797656	chr11:68205561	LRP5	0.46	6.77	0.38	8.45e-11	Total body bone mineral density;
CESC	cis	rs8114671	0.836	rs2104083	chr20:33649133	G/A	cg24642439	chr20:33292090	TP53INP2	-0.47	-5.71	-0.33	3.09e-8	Height;
CESC	cis	rs3768617	0.903	rs10911251	chr1:183081194	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.66	9.4	0.5	2.74e-18	Fuchs's corneal dystrophy;
CESC	cis	rs2985684	1.000	rs3007030	chr14:50086563	C/T	cg10008539	chr14:50087325	RPL36AL;MGAT2	-0.46	-5.4	-0.31	1.49e-7	Carotid intima media thickness;
CESC	cis	rs6460942	0.908	rs73677559	chr7:12270819	A/C	cg06484146	chr7:12443880	VWDE	-0.54	-5.66	-0.33	3.93e-8	Coronary artery disease;
CESC	cis	rs9943753	0.525	rs7952909	chr12:109808573	A/T	cg19025524	chr12:109796872	NA	0.48	7.03	0.4	1.71e-11	HDL cholesterol;
CESC	cis	rs9916302	0.851	rs11657899	chr17:37626963	G/A	cg07936489	chr17:37558343	FBXL20	-0.81	-11.96	-0.59	1.17e-26	Glomerular filtration rate (creatinine);
CESC	cis	rs9910055	0.614	rs12944572	chr17:42245241	T/C	cg10896456	chr17:42255109	ASB16;C17orf65	0.49	7.21	0.41	5.7e-12	Total body bone mineral density;
CESC	cis	rs12586317	0.582	rs731906	chr14:35604543	C/T	cg16230307	chr14:35515116	FAM177A1	0.96	10.35	0.54	2.58e-21	Psoriasis;
CESC	cis	rs4834770	1.000	rs6857641	chr4:120243511	T/C	cg09307838	chr4:120376055	NA	0.45	5.39	0.31	1.52e-7	Blood protein levels;
CESC	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg07308232	chr7:1071921	C7orf50	-0.5	-7.0	-0.39	2.12e-11	Longevity;Endometriosis;
CESC	cis	rs1348850	0.526	rs7588049	chr2:178390778	C/T	cg23306229	chr2:178417860	TTC30B	-0.77	-6.94	-0.39	3.08e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	trans	rs1545843	0.537	rs11836792	chr12:84793080	C/T	cg03015433	chr16:56623111	MT3	-0.34	-6.12	-0.35	3.37e-9	Major depressive disorder;
CESC	cis	rs7666738	0.830	rs10034330	chr4:99064849	G/A	cg03467027	chr4:99064603	C4orf37	0.48	5.95	0.34	8.67e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9896933	0.775	rs79299098	chr17:80830944	G/A	cg20578329	chr17:80767326	TBCD	-0.75	-7.78	-0.43	1.62e-13	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
CESC	cis	rs9443645	0.507	rs9352633	chr6:79462623	C/G	cg05283184	chr6:79620031	NA	-0.39	-6.1	-0.35	3.68e-9	Intelligence (multi-trait analysis);
CESC	cis	rs2479106	1.000	rs2479106	chr9:126525212	A/G	cg16191174	chr9:126692580	DENND1A	0.5	6.98	0.39	2.3e-11	Polycystic ovary syndrome;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg13837942	chr14:69260273	ZFP36L1	-0.5	-6.22	-0.36	1.96e-9	Ulcerative colitis;
CESC	cis	rs875971	0.545	rs35459055	chr7:65944386	G/A	cg11764359	chr7:65958608	NA	0.81	9.93	0.52	5.9e-20	Aortic root size;
CESC	cis	rs2070677	1.000	rs1329149	chr10:135349801	T/C	cg20169779	chr10:135381914	SYCE1	0.71	8.48	0.46	1.63e-15	Gout;
CESC	cis	rs6831352	0.734	rs2602857	chr4:100030318	G/A	cg12011299	chr4:100065546	ADH4	0.56	6.67	0.38	1.44e-10	Alcohol dependence;
CESC	cis	rs12701220	0.655	rs6463317	chr7:1159243	G/A	cg26769984	chr7:1090371	C7orf50	0.53	6.2	0.36	2.16e-9	Bronchopulmonary dysplasia;
CESC	cis	rs7829975	0.714	rs4841042	chr8:8664622	A/G	cg15556689	chr8:8085844	FLJ10661	-0.5	-6.35	-0.36	9.36e-10	Mood instability;
CESC	cis	rs2070488	0.804	rs4678605	chr3:38444489	T/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.83	13.25	0.63	4.47e-31	Electrocardiographic conduction measures;
CESC	cis	rs9916302	0.904	rs6503519	chr17:37706578	A/G	cg00129232	chr17:37814104	STARD3	-0.56	-7.25	-0.41	4.69e-12	Glomerular filtration rate (creatinine);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21168982	chr1:28559030	DNAJC8	-0.59	-6.99	-0.39	2.24e-11	Gut microbiome composition (summer);
CESC	trans	rs9949291	0.565	rs10469258	chr18:61362156	C/A	cg18704691	chr1:221052468	HLX	-0.39	-6.11	-0.35	3.46e-9	Eosinophil percentage of white cells;
CESC	cis	rs3105593	0.965	rs62017203	chr15:50950590	C/T	cg08437265	chr15:50716283	USP8	0.42	5.36	0.31	1.85e-7	QT interval;
CESC	cis	rs735539	0.718	rs7985552	chr13:21280738	A/T	cg04906043	chr13:21280425	IL17D	0.37	5.34	0.31	2.04e-7	Dental caries;
CESC	cis	rs959260	0.800	rs9895739	chr17:73399916	C/T	cg20590849	chr17:73267439	MIF4GD	-0.55	-6.39	-0.37	7.49e-10	Systemic lupus erythematosus;
CESC	cis	rs2832191	0.935	rs11910475	chr21:30519702	T/C	cg08807101	chr21:30365312	RNF160	-0.64	-8.5	-0.46	1.4e-15	Dental caries;
CESC	cis	rs3859192	0.561	rs12451547	chr17:38181168	T/C	cg17467752	chr17:38218738	THRA	-0.47	-6.34	-0.36	9.92e-10	White blood cell count;
CESC	cis	rs4237845	0.780	rs3751331	chr12:58290278	G/A	cg00677455	chr12:58241039	CTDSP2	0.63	7.68	0.43	3.1400000000000003e-13	Intelligence (multi-trait analysis);
CESC	cis	rs6815814	0.904	rs73236628	chr4:38825443	C/T	cg02016764	chr4:38805732	TLR1	-0.58	-6.34	-0.36	9.93e-10	Breast cancer;
CESC	trans	rs7246657	0.882	rs28623164	chr19:37913453	G/A	cg01833234	chr11:6592585	DNHD1	0.52	6.0	0.35	6.5e-9	Coronary artery calcification;
CESC	cis	rs9660180	0.967	rs2272908	chr1:1721479	A/G	cg13866156	chr1:1669148	SLC35E2	0.49	6.66	0.38	1.59e-10	Body mass index;
CESC	cis	rs7666738	0.830	rs6532719	chr4:99043691	A/G	cg03676636	chr4:99064102	C4orf37	0.33	5.08	0.3	7.13e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs12579753	0.917	rs11115032	chr12:82205073	T/C	cg24719984	chr12:82153464	PPFIA2	-0.33	-5.04	-0.3	8.55e-7	Resting heart rate;
CESC	cis	rs5753618	0.583	rs5753631	chr22:31863022	A/C	cg13145458	chr22:31556086	RNF185	-0.49	-5.8	-0.34	1.88e-8	Colorectal cancer;
CESC	cis	rs1008375	0.931	rs7672369	chr4:17604825	A/G	cg02297831	chr4:17616191	MED28	0.56	7.08	0.4	1.29e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs7412746	0.611	rs111905669	chr1:150777565	T/C	cg04414720	chr1:150670196	GOLPH3L	0.57	7.58	0.42	5.74e-13	Melanoma;
CESC	cis	rs2075371	1.000	rs2598285	chr7:133971153	A/T	cg11752832	chr7:134001865	SLC35B4	0.52	6.77	0.38	8.06e-11	Mean platelet volume;
CESC	cis	rs10276381	0.786	rs740261	chr7:28241276	A/G	cg23620719	chr7:28220237	JAZF1	0.7	6.81	0.39	6.66e-11	Crohn's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09569258	chr4:57844912	POLR2B;C4orf14	0.61	6.97	0.39	2.45e-11	Gut microbiome composition (summer);
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg04958252	chr8:87517638	FAM82B	0.47	6.65	0.38	1.64e-10	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs113835537	0.735	rs519380	chr11:66409409	G/A	cg22134325	chr11:66188745	NPAS4	0.46	6.63	0.38	1.9e-10	Airway imaging phenotypes;
CESC	cis	rs6540556	0.723	rs10863783	chr1:209889802	T/C	cg05527609	chr1:210001259	C1orf107	-0.67	-7.36	-0.41	2.32e-12	Red blood cell count;
CESC	cis	rs116095464	0.558	rs6869925	chr5:264036	A/G	cg22857025	chr5:266934	NA	-1.3	-18.55	-0.75	8.05e-50	Breast cancer;
CESC	cis	rs7570971	0.617	rs1869829	chr2:135877562	C/T	cg07169764	chr2:136633963	MCM6	-0.67	-7.98	-0.44	4.34e-14	Blood metabolite levels;Body mass index;Cholesterol, total;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg10324013	chr2:48809499	STON1-GTF2A1L;STON1	-0.44	-6.07	-0.35	4.34e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs9549367	0.789	rs9549701	chr13:113881752	G/C	cg18105134	chr13:113819100	PROZ	-0.64	-7.7	-0.43	2.8e-13	Platelet distribution width;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg27657525	chr19:30432971	C19orf2	-0.45	-6.25	-0.36	1.62e-9	Ulcerative colitis;
CESC	cis	rs13064411	0.735	rs722392	chr3:113228294	A/G	cg18753928	chr3:113234510	CCDC52	-0.48	-5.72	-0.33	2.92e-8	Response to simvastatin treatment (PCSK9 protein level change);
CESC	cis	rs5769765	0.955	rs5769767	chr22:50276909	G/A	cg26441486	chr22:50317300	CRELD2	-0.39	-5.5	-0.32	8.72e-8	Schizophrenia;
CESC	cis	rs1801251	1.000	rs283475	chr2:233654381	A/C	cg25237894	chr2:233734115	C2orf82	-0.48	-8.5	-0.46	1.35e-15	Coronary artery disease;
CESC	cis	rs7249921	0.833	rs6510469	chr19:35672008	G/T	cg15419183	chr19:35660584	FXYD5	0.54	8.15	0.45	1.44e-14	Platelet count;
CESC	cis	rs2979489	0.699	rs7840356	chr8:30406251	G/A	cg26383811	chr8:30366931	RBPMS	0.78	9.91	0.52	6.64e-20	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CESC	cis	rs1348850	0.567	rs3821006	chr2:178537694	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.54	7.16	0.4	7.91e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg09428623	chr2:68480128	PPP3R1	0.48	6.03	0.35	5.4e-9	Gut microbiota (bacterial taxa);
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg11338345	chr3:136052698	NA	0.39	6.08	0.35	4.2e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs9549367	0.601	rs558869	chr13:113849932	G/T	cg18105134	chr13:113819100	PROZ	0.54	7.14	0.4	9.19e-12	Platelet distribution width;
CESC	cis	rs68092024	0.731	rs793479	chr3:99488232	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.43	-6.78	-0.38	7.81e-11	Cleft lip with or without cleft palate;
CESC	cis	rs9399137	0.507	rs4289677	chr6:135275485	A/G	cg24558204	chr6:135376177	HBS1L	0.66	8.77	0.47	2.18e-16	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04229103	chr2:145090268	GTDC1	0.61	6.76	0.38	8.74e-11	Gut microbiome composition (summer);
CESC	cis	rs7188697	0.922	rs37061	chr16:58566671	A/G	cg21335942	chr16:58549945	SETD6	0.46	5.37	0.31	1.7e-7	QT interval;
CESC	cis	rs9494145	0.680	rs9389269	chr6:135427159	T/C	cg22676075	chr6:135203613	NA	0.46	5.55	0.32	7.04e-8	Mean platelet volume;Platelet count;Fetal hemoglobin levels in sickle cell anemia;Red blood cell traits;
CESC	cis	rs7249142	0.549	rs1858846	chr19:19281187	T/G	cg27384695	chr19:19271486	LOC729991-MEF2B;MEF2B	0.29	5.21	0.3	3.74e-7	IgG glycosylation;
CESC	cis	rs4481887	0.893	rs4275482	chr1:248473506	T/C	cg00666640	chr1:248458726	OR2T12	0.36	6.12	0.35	3.33e-9	Common traits (Other);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08370718	chr15:49913307	DTWD1;C15orf33	0.57	6.76	0.38	8.52e-11	Gut microbiome composition (summer);
CESC	cis	rs7296418	0.961	rs61955196	chr12:123451018	G/C	cg05973401	chr12:123451056	ABCB9	0.58	7.38	0.41	2.04e-12	Platelet count;
CESC	cis	rs34779708	0.966	rs17500582	chr10:35498788	T/A	cg04310649	chr10:35416472	CREM	-0.52	-6.33	-0.36	1.06e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs7264396	0.635	rs6058355	chr20:34491343	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.81	-11.23	-0.57	3.44e-24	Total cholesterol levels;
CESC	cis	rs4563143	0.675	rs55976444	chr19:29265214	G/C	cg04546413	chr19:29218101	NA	0.56	7.91	0.44	6.84e-14	Methadone dose in opioid dependence;
CESC	cis	rs2204008	0.743	rs11182052	chr12:38450421	T/C	cg13010199	chr12:38710504	ALG10B	0.44	5.84	0.34	1.52e-8	Bladder cancer;
CESC	trans	rs916888	0.779	rs199528	chr17:44843136	C/T	cg27125505	chr17:43679177	LOC644172	0.51	6.75	0.38	9.27e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	trans	rs12599106	0.680	rs34728702	chr16:34896584	A/G	cg21548813	chr6:291882	DUSP22	-0.74	-9.91	-0.52	6.8e-20	Menopause (age at onset);
CESC	cis	rs801193	0.569	rs11761542	chr7:66218196	G/A	cg12463550	chr7:65579703	CRCP	0.48	6.23	0.36	1.86e-9	Aortic root size;
CESC	cis	rs7635838	0.855	rs9816564	chr3:11475297	T/C	cg00170343	chr3:11313890	ATG7	0.43	5.71	0.33	2.99e-8	HDL cholesterol;
CESC	cis	rs4975709	0.610	rs4975705	chr5:1860359	T/C	cg14773178	chr5:1868261	NA	0.32	5.78	0.33	2.06e-8	Cardiovascular disease risk factors;
CESC	cis	rs1729951	0.575	rs1682357	chr3:136692009	G/A	cg03617693	chr3:136751559	NA	0.39	5.46	0.32	1.08e-7	Neuroticism;
CESC	trans	rs7922314	0.571	rs61865717	chr10:64739190	G/A	cg06935979	chr1:232941706	KIAA1383	-0.69	-6.38	-0.36	7.94e-10	Cutaneous psoriasis;
CESC	cis	rs4665809	0.590	rs4665840	chr2:26444962	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-1.1	-12.68	-0.61	4e-29	Gut microbiome composition (summer);
CESC	cis	rs6952808	0.531	rs3779003	chr7:2184902	C/T	cg23048001	chr7:2026167	MAD1L1	0.43	5.5	0.32	8.88e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs2228479	0.702	rs62056087	chr16:89920383	C/A	cg14709524	chr16:89940631	TCF25	0.88	6.04	0.35	5.27e-9	Skin colour saturation;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15535636	chr19:41284070	RAB4B	0.58	6.55	0.37	3.03e-10	Gut microbiome composition (summer);
CESC	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg18402987	chr7:1209562	NA	0.76	7.55	0.42	7.26e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27381216	chr5:7869428	MTRR;FASTKD3	0.76	8.82	0.48	1.57e-16	Gut microbiome composition (summer);
CESC	cis	rs4665809	0.941	rs7602922	chr2:26265782	C/T	cg08470875	chr2:26401718	FAM59B	-0.63	-6.72	-0.38	1.09e-10	Gut microbiome composition (summer);
CESC	cis	rs13191362	0.935	rs34035978	chr6:163165336	G/C	cg21926612	chr6:163149169	PACRG;PARK2	0.68	7.28	0.41	3.79e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19855366	chr13:111267979	CARKD	0.53	6.27	0.36	1.47e-9	Gut microbiome composition (summer);
CESC	cis	rs9911578	1.000	rs12940681	chr17:56933622	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.26	0.31	2.94e-7	Intelligence (multi-trait analysis);
CESC	cis	rs2075371	0.966	rs2544224	chr7:133995832	A/G	cg20476274	chr7:133979776	SLC35B4	0.65	9.44	0.5	2e-18	Mean platelet volume;
CESC	cis	rs9733	0.596	rs1415148	chr1:150705755	G/A	cg22823121	chr1:150693482	HORMAD1	0.47	6.96	0.39	2.6e-11	Tonsillectomy;
CESC	trans	rs17685	0.671	rs60303271	chr7:75760008	A/G	cg19862616	chr7:65841803	NCRNA00174	0.85	12.41	0.61	3.51e-28	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs7264396	0.623	rs78949029	chr20:34384964	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.86	-9.4	-0.5	2.67e-18	Total cholesterol levels;
CESC	cis	rs6912958	1.000	rs9450701	chr6:88173167	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.57	-8.02	-0.44	3.39e-14	Monocyte percentage of white cells;
CESC	cis	rs10540	1.000	rs67912009	chr11:495057	G/T	cg03352830	chr11:487213	PTDSS2	0.67	6.76	0.38	8.54e-11	Body mass index;
CESC	cis	rs2797160	1.000	rs6569435	chr6:125998186	T/C	cg05901451	chr6:126070800	HEY2	-0.45	-6.68	-0.38	1.38e-10	Endometrial cancer;
CESC	cis	rs7666738	0.716	rs114187620	chr4:98819534	T/A	cg05340658	chr4:99064831	C4orf37	0.73	10.48	0.54	1.02e-21	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7223966	0.621	rs28571160	chr17:61638723	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.47	5.4	0.31	1.48e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs7208859	0.623	rs3752019	chr17:29151705	C/T	cg13385521	chr17:29058706	SUZ12P	0.75	6.0	0.35	6.29e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs826838	0.616	rs7977357	chr12:38626008	C/G	cg26384229	chr12:38710491	ALG10B	-0.43	-5.65	-0.33	4.09e-8	Heart rate;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05930370	chr1:224545104	CNIH4	0.58	6.05	0.35	4.99e-9	Gut microbiome composition (summer);
CESC	cis	rs7552404	0.590	rs1565717	chr1:76320441	T/C	cg22875332	chr1:76189707	ACADM	-0.63	-6.66	-0.38	1.6e-10	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs28830936	1.000	rs112896623	chr15:42001845	C/T	cg11010575	chr15:42129464	JMJD7-PLA2G4B;JMJD7	-0.37	-5.39	-0.31	1.54e-7	Diastolic blood pressure;
CESC	cis	rs7943191	0.810	rs7942991	chr11:62337203	A/G	cg02375832	chr11:62437615	C11orf48	0.37	5.46	0.32	1.08e-7	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
CESC	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg07092213	chr7:1199455	ZFAND2A	-0.49	-5.33	-0.31	2.15e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7100689	0.516	rs3862532	chr10:82015725	A/C	cg00277334	chr10:82204260	NA	-0.51	-6.45	-0.37	5.38e-10	Post bronchodilator FEV1;
CESC	cis	rs644148	0.730	rs2686766	chr19:44991595	T/G	cg15540054	chr19:45004280	ZNF180	-0.57	-6.05	-0.35	4.92e-9	Personality dimensions;
CESC	cis	rs1348850	0.632	rs12467363	chr2:178502512	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.6	7.71	0.43	2.58e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs8180040	0.966	rs13064843	chr3:47415467	C/T	cg27129171	chr3:47204927	SETD2	0.64	9.85	0.52	1.05e-19	Colorectal cancer;
CESC	cis	rs6580649	1.000	rs6580649	chr12:48410517	A/G	cg05342945	chr12:48394962	COL2A1	-0.5	-5.66	-0.33	3.84e-8	Lung cancer;
CESC	cis	rs698813	0.851	rs698807	chr2:44701659	G/C	cg04920474	chr2:44395004	PPM1B	0.39	5.06	0.3	7.77e-7	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
CESC	cis	rs548181	0.621	rs2912098	chr11:125528569	C/T	cg03464685	chr11:125439445	EI24	0.96	8.11	0.45	1.92e-14	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs208520	0.661	rs4710566	chr6:66848538	G/A	cg07460842	chr6:66804631	NA	-0.99	-13.5	-0.64	5.96e-32	Exhaled nitric oxide output;
CESC	trans	rs677673	0.904	rs675365	chr20:10480889	T/C	cg16021678	chr13:55475951	NA	0.51	6.41	0.37	6.76e-10	Body mass index (change over time) in chronic obstructive pulmonary disease;
CESC	cis	rs8062405	1.000	rs62036622	chr16:28837203	T/G	cg08761264	chr16:28874980	SH2B1	-0.44	-5.4	-0.31	1.46e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs7264396	0.623	rs2425127	chr20:34332037	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.88	-10.7	-0.55	1.96e-22	Total cholesterol levels;
CESC	cis	rs2302190	0.882	rs9901693	chr17:56606915	C/T	cg25885038	chr17:56607967	SEPT4	-0.42	-5.7	-0.33	3.22e-8	Vitamin D levels;
CESC	cis	rs780096	0.526	rs4582	chr2:27604279	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.34	-7.01	-0.4	1.97e-11	Total body bone mineral density;
CESC	cis	rs523522	0.962	rs4767902	chr12:120910004	C/T	cg12219531	chr12:120966889	COQ5	0.73	9.48	0.5	1.51e-18	High light scatter reticulocyte count;
CESC	cis	rs1538970	0.816	rs12029322	chr1:45970446	C/T	cg05343316	chr1:45956843	TESK2	0.93	12.78	0.62	1.91e-29	Platelet count;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg19244826	chr22:19466934	UFD1L;CDC45L	-0.44	-6.12	-0.35	3.32e-9	Gut microbiota (bacterial taxa);
CESC	trans	rs10411161	0.702	rs10414472	chr19:52398597	C/T	cg22319618	chr22:45562946	NUP50	-0.6	-6.22	-0.36	1.97e-9	Breast cancer;
CESC	cis	rs854765	0.616	rs8070624	chr17:17843396	G/A	cg04398451	chr17:18023971	MYO15A	-0.62	-8.25	-0.45	7.27e-15	Total body bone mineral density;
CESC	cis	rs10484885	0.775	rs72919985	chr6:90534641	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.76	-7.15	-0.4	8.35e-12	QRS interval (sulfonylurea treatment interaction);
CESC	cis	rs4563143	0.663	rs10406794	chr19:29228056	C/T	cg12756686	chr19:29218302	NA	0.47	6.64	0.38	1.77e-10	Methadone dose in opioid dependence;
CESC	cis	rs6860806	0.507	rs272868	chr5:131680751	C/G	cg24060327	chr5:131705240	SLC22A5	-0.77	-10.85	-0.55	6.31e-23	Breast cancer;
CESC	cis	rs6088590	0.610	rs6120663	chr20:33081906	A/C	cg24642439	chr20:33292090	TP53INP2	-0.63	-8.58	-0.47	7.98e-16	Coronary artery disease;
CESC	cis	rs2688608	0.530	rs71507081	chr10:75493136	G/A	cg23231163	chr10:75533350	FUT11	-0.35	-5.27	-0.31	2.81e-7	Inflammatory bowel disease;
CESC	cis	rs11997175	0.511	rs4613957	chr8:33673130	C/T	ch.8.33884649F	chr8:33765107	NA	-0.55	-7.47	-0.42	1.16e-12	Body mass index;
CESC	cis	rs1799949	0.965	rs8176310	chr17:41199913	T/C	cg25072359	chr17:41440525	NA	0.48	7.22	0.41	5.65e-12	Menopause (age at onset);
CESC	cis	rs80130819	0.688	rs7305418	chr12:48586112	A/G	cg05342945	chr12:48394962	COL2A1	-0.52	-5.88	-0.34	1.26e-8	Prostate cancer;
CESC	cis	rs1707322	0.752	rs28550303	chr1:46188914	G/T	cg05343316	chr1:45956843	TESK2	0.51	6.29	0.36	1.29e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs698833	0.819	rs1372078	chr2:44543389	A/T	cg04920474	chr2:44395004	PPM1B	-0.37	-5.03	-0.3	9.19e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs10870270	1.000	rs11146354	chr10:133774757	A/G	cg26149184	chr10:133730230	NA	0.38	5.14	0.3	5.22e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs12478296	1.000	rs55717005	chr2:243041071	T/A	cg06360820	chr2:242988706	NA	-0.67	-7.61	-0.42	4.78e-13	Obesity-related traits;
CESC	cis	rs13108904	0.967	rs2293635	chr4:1291791	A/G	cg22903657	chr4:1355424	KIAA1530	-0.37	-5.13	-0.3	5.71e-7	Obesity-related traits;
CESC	cis	rs6933660	0.760	rs6904364	chr6:151754273	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.8	12.3	0.6	7.99e-28	Menarche (age at onset);
CESC	cis	rs4566357	0.615	rs10198406	chr2:227913539	A/G	cg05526886	chr2:227700861	RHBDD1	-0.46	-6.15	-0.35	2.88e-9	Coronary artery disease;
CESC	cis	rs11252926	0.770	rs4880736	chr10:680133	C/G	cg16386425	chr10:429943	DIP2C	-0.46	-5.75	-0.33	2.4e-8	Psychosis in Alzheimer's disease;
CESC	cis	rs1707322	1.000	rs12097799	chr1:46459886	C/A	cg03146154	chr1:46216737	IPP	0.75	10.29	0.53	4.13e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs629535	0.814	rs549643	chr8:70062884	C/T	cg21567404	chr3:27674614	NA	0.82	9.72	0.51	2.63e-19	Dupuytren's disease;
CESC	cis	rs6540559	1.000	rs6659367	chr1:209982408	G/T	cg10074409	chr1:209979377	IRF6	0.35	5.68	0.33	3.46e-8	Cleft lip with or without cleft palate;
CESC	cis	rs7666738	0.830	rs11727235	chr4:98946331	T/C	cg03676636	chr4:99064102	C4orf37	0.34	5.11	0.3	6.15e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20217938	chr19:3958344	NA	-0.5	-6.14	-0.35	3.03e-9	Gut microbiome composition (summer);
CESC	cis	rs2839186	0.526	rs59977673	chr21:47922091	C/T	cg10351095	chr21:47802916	PCNT	-0.38	-5.09	-0.3	6.71e-7	Testicular germ cell tumor;
CESC	cis	rs9311474	0.508	rs6786043	chr3:52604861	A/G	cg05564831	chr3:52568323	NT5DC2	0.48	7.73	0.43	2.18e-13	Electroencephalogram traits;
CESC	cis	rs3741404	0.537	rs1123251	chr11:63917601	G/T	cg05555928	chr11:63887634	MACROD1	0.56	8.66	0.47	4.68e-16	Platelet count;
CESC	cis	rs35306767	0.953	rs1539174	chr10:974870	C/G	cg26597838	chr10:835615	NA	0.7	8.11	0.45	1.9e-14	Eosinophil percentage of granulocytes;
CESC	cis	rs1552244	1.000	rs9881859	chr3:10072814	A/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.8	-10.69	-0.55	2e-22	Alzheimer's disease;
CESC	trans	rs10028773	0.506	rs12374346	chr4:120281705	G/A	cg25214090	chr10:38739885	LOC399744	0.65	9.11	0.49	2.04e-17	Educational attainment;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg00905354	chr6:170059414	WDR27	0.39	6.05	0.35	4.98e-9	Gambling;
CESC	cis	rs4919694	0.901	rs74376228	chr10:104677662	G/C	cg04362960	chr10:104952993	NT5C2	0.76	5.99	0.35	6.7e-9	Arsenic metabolism;
CESC	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg10862848	chr6:42927986	GNMT	-0.29	-7.18	-0.4	6.93e-12	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs2576037	0.521	rs4986227	chr18:44595031	G/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.48	-6.06	-0.35	4.77e-9	Personality dimensions;
CESC	cis	rs28735056	0.509	rs4799094	chr18:77621727	T/C	cg17174613	chr18:77631625	KCNG2	0.29	5.16	0.3	4.78e-7	Schizophrenia;
CESC	cis	rs7552404	0.727	rs7521344	chr1:76318325	C/T	cg10523679	chr1:76189770	ACADM	-0.65	-6.63	-0.38	1.85e-10	Blood metabolite levels;Acylcarnitine levels;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg11694641	chr12:98987961	SLC25A3	0.47	6.14	0.35	3.07e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs6964587	1.000	rs9690778	chr7:91735299	A/G	cg17063962	chr7:91808500	NA	0.56	7.69	0.43	2.96e-13	Breast cancer;
CESC	cis	rs6860806	0.631	rs6863548	chr5:131575920	G/A	cg12564285	chr5:131593104	PDLIM4	0.39	6.15	0.35	2.84e-9	Breast cancer;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg22982014	chr19:39322497	ECH1	-0.51	-6.59	-0.38	2.33e-10	Ulcerative colitis;
CESC	trans	rs281288	0.666	rs653749	chr15:47644528	A/G	cg00990635	chr19:19745667	GMIP	-0.48	-6.22	-0.36	1.93e-9	Positive affect;
CESC	cis	rs12188164	0.930	rs72717436	chr5:448291	C/A	cg21144161	chr5:423903	AHRR	0.37	5.98	0.34	7.12e-9	Cystic fibrosis severity;
CESC	cis	rs6723226	0.881	rs10181198	chr2:32686582	A/G	cg02381751	chr2:32503542	YIPF4	0.83	11.72	0.58	7.51e-26	Intelligence (multi-trait analysis);
CESC	cis	rs9311474	0.597	rs6778735	chr3:52565100	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.35	5.12	0.3	5.75e-7	Electroencephalogram traits;
CESC	cis	rs873946	0.586	rs12782567	chr10:134576709	C/G	cg26818010	chr10:134567672	INPP5A	0.93	11.51	0.58	4e-25	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs11122272	0.735	rs2790886	chr1:231529491	A/C	cg06096015	chr1:231504339	EGLN1	0.43	6.15	0.35	2.9e-9	Hemoglobin concentration;
CESC	cis	rs9815354	0.812	rs10510732	chr3:42007339	C/T	cg03022575	chr3:42003672	ULK4	0.7	6.29	0.36	1.3e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs919433	0.929	rs10931779	chr2:198166825	A/G	cg10820045	chr2:198174542	NA	-0.43	-6.83	-0.39	5.72e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs2228479	0.850	rs17226980	chr16:89825065	G/A	cg14709524	chr16:89940631	TCF25	0.91	6.75	0.38	9.34e-11	Skin colour saturation;
CESC	cis	rs7834588	0.523	rs7014483	chr8:63833074	C/A	cg20602954	chr8:63776762	NKAIN3	0.3	5.03	0.3	9.14e-7	Response to Vitamin E supplementation;
CESC	cis	rs7552404	0.690	rs7549863	chr1:76327923	T/C	cg03433033	chr1:76189801	ACADM	-0.62	-6.52	-0.37	3.45e-10	Blood metabolite levels;Acylcarnitine levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09868359	chr21:43230669	PRDM15	-0.56	-6.19	-0.36	2.32e-9	Gut microbiome composition (summer);
CESC	cis	rs11098499	0.954	rs6846442	chr4:120326323	G/A	cg24375607	chr4:120327624	NA	0.47	5.89	0.34	1.14e-8	Corneal astigmatism;
CESC	cis	rs478304	0.651	rs11227279	chr11:65495211	G/A	cg27068330	chr11:65405492	SIPA1	-0.45	-5.46	-0.32	1.08e-7	Acne (severe);
CESC	cis	rs7044106	0.762	rs10739570	chr9:123381222	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.37	5.96	0.34	7.88e-9	Hip circumference adjusted for BMI;
CESC	cis	rs6831352	1.000	rs1126671	chr4:100048414	T/C	cg12011299	chr4:100065546	ADH4	0.69	8.43	0.46	2.17e-15	Alcohol dependence;
CESC	cis	rs9486715	0.867	rs9480700	chr6:96965056	A/G	cg06623918	chr6:96969491	KIAA0776	0.95	14.61	0.67	7.22e-36	Headache;
CESC	cis	rs6582630	0.593	rs12816835	chr12:38533304	C/T	cg26384229	chr12:38710491	ALG10B	-0.41	-5.44	-0.32	1.18e-7	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs853679	0.517	rs4713150	chr6:28136212	G/A	cg26335602	chr6:28129616	ZNF389	0.52	6.84	0.39	5.58e-11	Depression;
CESC	cis	rs2832191	0.935	rs67287920	chr21:30523519	C/A	cg24692254	chr21:30365293	RNF160	-0.74	-11.14	-0.56	6.98e-24	Dental caries;
CESC	cis	rs8062405	0.720	rs9926245	chr16:28555706	T/A	cg08761264	chr16:28874980	SH2B1	-0.41	-5.05	-0.3	8.41e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs826838	0.900	rs11169301	chr12:39128497	C/A	cg26384229	chr12:38710491	ALG10B	0.79	12.71	0.62	3.35e-29	Heart rate;
CESC	cis	rs7259376	0.875	rs9304996	chr19:22486535	A/G	cg02657401	chr19:22469223	NA	-0.26	-5.32	-0.31	2.19e-7	Menopause (age at onset);
CESC	cis	rs9457247	0.967	rs2015864	chr6:167381476	T/C	cg25258033	chr6:167368657	RNASET2	-0.4	-6.07	-0.35	4.52e-9	Crohn's disease;
CESC	cis	rs3096299	0.692	rs4785565	chr16:89515759	T/C	cg16743903	chr16:89593216	SPG7	-0.46	-6.02	-0.35	5.64e-9	Multiple myeloma (IgH translocation);
CESC	cis	rs9322193	0.923	rs62441303	chr6:150088683	A/G	cg04369109	chr6:150039330	LATS1	-0.39	-5.27	-0.31	2.82e-7	Lung cancer;
CESC	cis	rs17401966	1.000	rs12407992	chr1:10311983	A/C	cg15208524	chr1:10270712	KIF1B	0.44	5.91	0.34	1.04e-8	Hepatocellular carcinoma;
CESC	cis	rs6540559	0.546	rs59435160	chr1:210030730	C/A	cg23283495	chr1:209979779	IRF6	0.45	5.03	0.3	8.95e-7	Cleft lip with or without cleft palate;
CESC	cis	rs3785574	0.962	rs2727280	chr17:61918082	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.58	6.92	0.39	3.37e-11	Height;
CESC	cis	rs72781680	0.716	rs6718631	chr2:24036086	A/G	cg08917208	chr2:24149416	ATAD2B	-0.64	-6.34	-0.36	9.79e-10	Lymphocyte counts;
CESC	cis	rs6570726	0.818	rs9399555	chr6:145877554	T/C	cg05347473	chr6:146136440	FBXO30	0.5	6.5	0.37	3.87e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs754466	0.874	rs55910200	chr10:79665173	T/C	cg17075019	chr10:79541650	NA	-0.76	-9.37	-0.5	3.24e-18	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs172166	0.637	rs1233691	chr6:28153897	T/G	cg12963246	chr6:28129442	ZNF389	0.39	5.88	0.34	1.22e-8	Cardiac Troponin-T levels;
CESC	cis	rs736408	0.677	rs678	chr3:52820981	A/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.1	0.35	3.66e-9	Bipolar disorder;
CESC	cis	rs7824557	0.628	rs3779891	chr8:11183505	G/A	cg21775007	chr8:11205619	TDH	0.54	8.56	0.47	9.54e-16	Retinal vascular caliber;
CESC	cis	rs667920	0.573	rs9682783	chr3:136539689	T/C	cg15507776	chr3:136538369	TMEM22	0.79	9.88	0.52	8.41e-20	Coronary artery disease;
CESC	cis	rs7223966	0.961	rs112709843	chr17:61836936	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.56	6.53	0.37	3.33e-10	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs4077515	0.874	rs3812560	chr9:139269905	T/C	cg14169450	chr9:139327907	INPP5E	0.4	5.76	0.33	2.35e-8	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs2204008	0.807	rs11182461	chr12:38539288	T/C	cg26384229	chr12:38710491	ALG10B	0.74	11.17	0.57	5.31e-24	Bladder cancer;
CESC	cis	rs727505	0.789	rs66756015	chr7:124740641	C/A	cg23710748	chr7:124431027	NA	-0.39	-6.27	-0.36	1.44e-9	Lewy body disease;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg09685500	chr17:40333380	KCNH4	-0.39	-6.43	-0.37	5.98e-10	Gambling;
CESC	cis	rs1059312	0.778	rs4760594	chr12:129296865	T/A	cg09035930	chr12:129282057	SLC15A4	0.69	9.2	0.49	1.1e-17	Systemic lupus erythematosus;
CESC	cis	rs2243480	0.708	rs13242216	chr7:65898277	T/C	cg12463550	chr7:65579703	CRCP	0.71	5.46	0.32	1.08e-7	Diabetic kidney disease;
CESC	cis	rs67311347	1.000	rs73080137	chr3:40516412	A/G	cg09455208	chr3:40491958	NA	0.51	8.7	0.47	3.65e-16	Renal cell carcinoma;
CESC	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg26338869	chr17:61819248	STRADA	-0.66	-8.52	-0.46	1.23e-15	Prudent dietary pattern;
CESC	cis	rs2404602	0.692	rs60658665	chr15:77042508	T/C	cg26408565	chr15:76604113	ETFA	-0.38	-5.52	-0.32	8.03e-8	Blood metabolite levels;
CESC	cis	rs1256061	0.603	rs1256036	chr14:64743332	C/T	cg21174375	chr14:64681225	SYNE2	0.51	6.77	0.38	8.38e-11	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg09311052	chr1:154531418	UBE2Q1	0.47	6.3	0.36	1.2e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs7949030	0.620	rs2428551	chr11:62329758	T/A	cg02375832	chr11:62437615	C11orf48	-0.35	-5.07	-0.3	7.59e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs12477438	0.748	rs6712773	chr2:99585781	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-10.57	-0.54	5.22e-22	Chronic sinus infection;
CESC	cis	rs1552244	0.748	rs113890152	chr3:10085986	A/G	cg00149659	chr3:10157352	C3orf10	0.77	9.68	0.51	3.58e-19	Alzheimer's disease;
CESC	cis	rs7726839	0.540	rs57306627	chr5:597643	T/C	cg16447950	chr5:562315	NA	-0.59	-6.01	-0.35	6.18e-9	Obesity-related traits;
CESC	cis	rs9915657	0.803	rs12449851	chr17:70099002	C/T	cg09344028	chr17:70110421	NA	-0.38	-7.58	-0.42	5.9e-13	Thyroid hormone levels;
CESC	cis	rs17376456	0.825	rs10078941	chr5:93279029	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.67	5.45	0.32	1.13e-7	Diabetic retinopathy;
CESC	cis	rs9309473	0.607	rs12478346	chr2:73584360	C/T	cg20560298	chr2:73613845	ALMS1	-0.48	-6.39	-0.37	7.59e-10	Metabolite levels;
CESC	cis	rs72781680	0.611	rs72781699	chr2:24277709	G/A	cg20701182	chr2:24300061	SF3B14	0.93	10.68	0.55	2.27e-22	Lymphocyte counts;
CESC	cis	rs514406	0.929	rs557920	chr1:53338757	C/A	cg16325326	chr1:53192061	ZYG11B	0.9	14.71	0.67	3.12e-36	Monocyte count;
CESC	trans	rs561341	1.000	rs510264	chr17:30323414	A/G	cg20587970	chr11:113659929	NA	-1.48	-19.58	-0.77	2.15e-53	Hip circumference adjusted for BMI;
CESC	cis	rs7605827	0.897	rs13017859	chr2:15537641	T/C	cg19274914	chr2:15703543	NA	0.36	6.55	0.37	2.91e-10	Educational attainment (years of education);
CESC	cis	rs10504229	0.610	rs6987118	chr8:58147851	G/T	cg22535103	chr8:58192502	C8orf71	-0.76	-9.04	-0.49	3.45e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs7584330	0.554	rs77380873	chr2:238426551	C/T	cg14458575	chr2:238380390	NA	0.72	6.82	0.39	6.16e-11	Prostate cancer;
CESC	cis	rs2070997	0.756	rs3808820	chr9:133726956	A/T	cg11464064	chr9:133710261	ABL1	0.54	5.83	0.34	1.6e-8	Response to amphetamines;
CESC	cis	rs13095912	1.000	rs13340181	chr3:185325612	T/C	cg11274856	chr3:185301563	NA	0.36	5.95	0.34	8.39e-9	Systolic blood pressure;
CESC	cis	rs7089973	0.604	rs10885620	chr10:116630048	A/T	cg23260525	chr10:116636907	FAM160B1	0.42	8.21	0.45	1.01e-14	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs11650494	0.908	rs117853079	chr17:47421593	G/C	cg08112188	chr17:47440006	ZNF652	1.31	8.51	0.46	1.33e-15	Prostate cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09701880	chr2:112252254	LOC541471	-0.55	-6.41	-0.37	6.61e-10	Gut microbiome composition (summer);
CESC	cis	rs60871478	0.947	rs62432239	chr7:794576	C/T	cg27478167	chr7:817139	HEATR2	-0.5	-6.02	-0.35	5.83e-9	Cerebrospinal P-tau181p levels;
CESC	cis	rs703842	0.616	rs10877024	chr12:58226709	C/T	cg02175503	chr12:58329896	NA	0.47	5.87	0.34	1.32e-8	Multiple sclerosis;
CESC	cis	rs3015469	0.724	rs11850340	chr14:51213555	A/G	cg26011998	chr14:51135199	SAV1	0.55	6.26	0.36	1.51e-9	Plasma amyloid beta peptide concentrations (ABx-40);
CESC	cis	rs360798	0.512	rs2710642	chr2:63149557	G/A	cg17519650	chr2:63277830	OTX1	0.53	6.48	0.37	4.56e-10	Coronary artery disease;
CESC	cis	rs2073300	0.609	rs6137920	chr20:23363436	C/T	cg16736954	chr20:23401023	NAPB	0.8	6.09	0.35	3.89e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12277122	chr19:12902277	JUNB	0.56	6.36	0.36	9.03e-10	Gut microbiome composition (summer);
CESC	cis	rs6831352	0.918	rs17218560	chr4:100060794	C/T	cg12011299	chr4:100065546	ADH4	0.52	6.19	0.36	2.29e-9	Alcohol dependence;
CESC	cis	rs12477438	0.798	rs2084987	chr2:99587885	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.75	-10.87	-0.56	5.17e-23	Chronic sinus infection;
CESC	cis	rs2710642	0.586	rs6545961	chr2:62814166	A/T	cg17519650	chr2:63277830	OTX1	0.43	5.58	0.32	6.03e-8	LDL cholesterol levels;LDL cholesterol;
CESC	cis	rs9911578	1.000	rs11079365	chr17:56945430	T/C	cg12560992	chr17:57184187	TRIM37	0.94	15.65	0.69	1.5e-39	Intelligence (multi-trait analysis);
CESC	cis	rs1799949	1.000	rs11079056	chr17:41300799	C/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.67	9.36	0.5	3.44e-18	Menopause (age at onset);
CESC	cis	rs7267979	0.966	rs2261790	chr20:25262789	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	18.61	0.75	5.02e-50	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs9649213	0.593	rs34534766	chr7:97920871	G/C	cg08684580	chr7:98029266	BAIAP2L1	-0.34	-5.41	-0.32	1.44e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs34375054	0.526	rs34764657	chr12:125679639	A/G	cg00522288	chr12:125625016	AACS	-0.33	-5.16	-0.3	4.81e-7	Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs7100689	0.577	rs10749550	chr10:82031197	A/G	cg00277334	chr10:82204260	NA	-0.53	-6.64	-0.38	1.81e-10	Post bronchodilator FEV1;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg10122252	chr11:67269539	PITPNM1	-0.42	-6.08	-0.35	4.07e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs10779751	1.000	rs2300092	chr1:11266464	T/C	cg08854313	chr1:11322531	MTOR	0.88	13.52	0.64	5.1e-32	Body mass index;
CESC	cis	rs4253772	0.550	rs12165597	chr22:46705584	A/G	cg24881330	chr22:46731750	TRMU	0.84	7.55	0.42	7.21e-13	LDL cholesterol;Cholesterol, total;
CESC	cis	rs2242116	0.932	rs4683301	chr3:46931478	A/T	cg02527881	chr3:46936655	PTH1R	0.56	9.47	0.5	1.63e-18	Birth weight;
CESC	cis	rs6088590	1.000	rs910870	chr20:33292893	T/C	cg06115741	chr20:33292138	TP53INP2	0.49	5.83	0.34	1.57e-8	Coronary artery disease;
CESC	cis	rs4665809	1.000	rs4665811	chr2:26260017	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.7	-7.86	-0.43	9.43e-14	Gut microbiome composition (summer);
CESC	cis	rs8072100	0.713	rs4968228	chr17:45497548	T/C	cg25173405	chr17:45401733	C17orf57	-0.43	-5.43	-0.32	1.26e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs4568518	0.740	rs11535159	chr7:18010309	T/C	cg03009463	chr7:17980271	SNX13	0.47	6.16	0.35	2.72e-9	Measles;
CESC	cis	rs10189230	0.967	rs12990760	chr2:222354725	G/T	cg14652038	chr2:222343519	EPHA4	0.34	7.01	0.4	1.99e-11	Urate levels in lean individuals;
CESC	cis	rs7520050	0.778	rs3014238	chr1:46090214	A/G	cg06784218	chr1:46089804	CCDC17	-0.34	-6.11	-0.35	3.49e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs722599	0.748	rs61978932	chr14:75342954	C/T	cg08847533	chr14:75593920	NEK9	-0.46	-5.67	-0.33	3.65e-8	IgG glycosylation;
CESC	cis	rs7927592	0.763	rs7119422	chr11:68331154	C/T	cg01657329	chr11:68192670	LRP5	0.49	6.63	0.38	1.83e-10	Total body bone mineral density;
CESC	cis	rs12142240	0.698	rs1057535	chr1:46815898	T/C	cg10495392	chr1:46806563	NSUN4	0.57	6.28	0.36	1.39e-9	Menopause (age at onset);
CESC	cis	rs12530845	0.887	rs4492299	chr7:135315690	T/G	cg23117316	chr7:135346802	PL-5283	-0.48	-5.83	-0.34	1.58e-8	Red blood cell traits;
CESC	cis	rs7605827	0.930	rs4668925	chr2:15703576	C/T	cg19274914	chr2:15703543	NA	0.36	6.5	0.37	4.08e-10	Educational attainment (years of education);
CESC	cis	rs5758659	0.623	rs133328	chr22:42408079	T/C	cg19513890	chr22:42538836	CYP2D7P1	-0.38	-5.39	-0.31	1.55e-7	Cognitive function;
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg07115558	chr19:3029503	TLE2	-0.42	-6.01	-0.35	6.17e-9	Vertical cup-disc ratio;
CESC	cis	rs6696846	0.715	rs61822659	chr1:205142847	G/A	cg00857998	chr1:205179979	DSTYK	0.56	7.2	0.4	6.3e-12	Red blood cell count;
CESC	cis	rs5750830	0.649	rs5750815	chr22:39798449	T/C	cg24399712	chr22:39784796	NA	-0.83	-11.17	-0.57	5.4e-24	Intelligence (multi-trait analysis);
CESC	cis	rs9814567	0.752	rs9848254	chr3:134330374	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.4	-5.09	-0.3	6.84e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs668210	0.793	rs619701	chr11:65772080	G/A	cg02202077	chr11:65769826	EIF1AD;BANF1	-0.66	-6.55	-0.37	3.06e-10	Cerebrospinal fluid biomarker levels;
CESC	cis	rs2950393	0.929	rs7980835	chr12:57070631	G/A	cg05584118	chr12:57595605	LRP1	-0.38	-5.47	-0.32	1.06e-7	Platelet distribution width;
CESC	cis	rs868036	1.000	rs4776974	chr15:68095927	G/A	cg08079166	chr15:68083412	MAP2K5	0.44	6.94	0.39	2.94e-11	Restless legs syndrome;
CESC	cis	rs4727027	0.870	rs1568945	chr7:148874112	T/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.43	5.39	0.31	1.52e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs9584850	0.540	rs61969457	chr13:99176742	C/T	cg20750642	chr13:99100586	FARP1	-0.46	-6.15	-0.35	2.91e-9	Neuroticism;
CESC	cis	rs3008870	1.000	rs2985821	chr1:67403787	G/A	cg02640540	chr1:67518911	SLC35D1	0.51	5.58	0.32	5.89e-8	Lymphocyte percentage of white cells;
CESC	cis	rs889398	0.771	rs1500337	chr16:69901884	C/T	cg09409435	chr16:70099608	PDXDC2	-0.39	-5.09	-0.3	6.67e-7	Body mass index;
CESC	cis	rs7264396	0.635	rs6060709	chr20:34536022	A/G	cg17201900	chr20:34330562	RBM39	0.5	5.26	0.31	2.96e-7	Total cholesterol levels;
CESC	cis	rs10838687	0.736	rs1449626	chr11:47290759	A/C	cg25783544	chr11:47291846	MADD	0.56	6.52	0.37	3.53e-10	Proinsulin levels;
CESC	cis	rs546131	0.642	rs568529	chr11:34842506	C/A	cg06937548	chr11:34938143	PDHX;APIP	0.42	5.06	0.3	8e-7	Lung disease severity in cystic fibrosis;
CESC	cis	rs4865169	0.783	rs7668814	chr4:57825190	A/G	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.4	-5.16	-0.3	4.88e-7	Breast cancer;
CESC	cis	rs11098499	0.774	rs73842616	chr4:120290683	G/A	cg24375607	chr4:120327624	NA	0.42	5.19	0.3	4.19e-7	Corneal astigmatism;
CESC	cis	rs765787	0.530	rs12903149	chr15:45539076	G/A	cg24006582	chr15:45444508	DUOX1	0.58	6.95	0.39	2.9100000000000002e-11	Uric acid levels;
CESC	cis	rs11723261	0.621	rs11733385	chr4:140461	T/G	cg12746427	chr4:53362	ZNF718;ZNF595	0.43	5.11	0.3	6.24e-7	Immune response to smallpox vaccine (IL-6);
CESC	cis	rs11958404	0.932	rs55943686	chr5:157439591	G/C	cg05962755	chr5:157440814	NA	0.62	6.66	0.38	1.57e-10	IgG glycosylation;
CESC	cis	rs9894429	0.869	rs9748184	chr17:79596280	A/G	cg18240062	chr17:79603768	NPLOC4	0.73	10.27	0.53	4.66e-21	Eye color traits;
CESC	cis	rs4595586	0.505	rs12826314	chr12:39379435	A/C	cg26384229	chr12:38710491	ALG10B	0.54	7.53	0.42	7.85e-13	Morning vs. evening chronotype;
CESC	cis	rs911555	0.723	rs6575991	chr14:103908433	C/T	cg24130564	chr14:104152367	KLC1	0.5	6.5	0.37	4.05e-10	Intelligence (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24083067	chr19:48972665	CYTH2	0.57	6.15	0.35	2.81e-9	Gut microbiome composition (summer);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg21893394	chr19:10342123	S1PR2	-0.48	-6.1	-0.35	3.69e-9	Ulcerative colitis;
CESC	cis	rs796364	0.715	rs11688872	chr2:201052418	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.72	-6.05	-0.35	4.99e-9	Schizophrenia;
CESC	cis	rs1008375	0.932	rs4698627	chr4:17605959	T/C	cg02297831	chr4:17616191	MED28	0.52	6.61	0.38	2.1e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs7617773	0.817	rs6801801	chr3:48326433	T/C	cg11946769	chr3:48343235	NME6	0.8	10.77	0.55	1.16e-22	Coronary artery disease;
CESC	cis	rs3741404	0.791	rs7112960	chr11:63907079	A/G	cg04317338	chr11:64019027	PLCB3	0.47	5.62	0.33	4.95e-8	Platelet count;
CESC	cis	rs9818758	0.607	rs12185979	chr3:49651970	C/G	cg00383909	chr3:49044727	WDR6	0.89	5.16	0.3	4.96e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CESC	cis	rs2243480	1.000	rs778704	chr7:65863467	T/C	cg12463550	chr7:65579703	CRCP	0.71	5.49	0.32	9.37e-8	Diabetic kidney disease;
CESC	cis	rs9649213	0.555	rs34695842	chr7:97931062	G/T	cg24562669	chr7:97807699	LMTK2	0.51	7.54	0.42	7.27e-13	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs875971	0.545	rs2279757	chr7:65828663	T/C	cg11764359	chr7:65958608	NA	0.82	9.37	0.5	3.25e-18	Aortic root size;
CESC	cis	rs9486719	0.947	rs12213375	chr6:96902134	A/G	cg06623918	chr6:96969491	KIAA0776	-0.8	-8.17	-0.45	1.23e-14	Migraine;Coronary artery disease;
CESC	cis	rs2635047	0.967	rs2247784	chr18:44746997	G/A	cg24371990	chr18:44770781	NA	0.33	5.21	0.3	3.74e-7	Educational attainment;
CESC	cis	rs9487051	0.714	rs6927569	chr6:109621494	T/C	cg21918786	chr6:109611834	NA	-0.36	-5.26	-0.31	2.99e-7	Reticulocyte fraction of red cells;
CESC	cis	rs61776719	0.738	rs7555461	chr1:38444749	T/C	cg18451016	chr1:38461880	NA	-0.5	-7.43	-0.42	1.47e-12	Coronary artery disease;
CESC	trans	rs7618501	1.000	rs7634902	chr3:49762662	G/T	cg21659725	chr3:3221576	CRBN	-0.83	-13.62	-0.64	2.29e-32	Intelligence (multi-trait analysis);
CESC	cis	rs524023	0.915	rs531763	chr11:64352063	A/G	cg07220939	chr11:64358617	SLC22A12	0.35	5.46	0.32	1.08e-7	Urate levels in obese individuals;
CESC	cis	rs6752107	1.000	rs2289474	chr2:234181848	C/T	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.37	5.58	0.32	5.94e-8	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs7818688	1.000	rs4323442	chr8:96022986	T/C	cg16049864	chr8:95962084	TP53INP1	0.6	5.77	0.33	2.19e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs2243480	1.000	rs7456042	chr7:65299778	T/C	cg18252515	chr7:66147081	NA	-1.07	-10.28	-0.53	4.28e-21	Diabetic kidney disease;
CESC	cis	rs10927875	0.864	rs12744578	chr1:16173110	A/T	cg21385522	chr1:16154831	NA	-0.95	-12.46	-0.61	2.25e-28	Dilated cardiomyopathy;
CESC	cis	rs11683229	0.704	rs35881827	chr2:63132482	G/A	cg17519650	chr2:63277830	OTX1	-0.66	-5.32	-0.31	2.17e-7	Protein quantitative trait loci;
CESC	cis	rs9611565	0.879	rs5758307	chr22:41750219	A/G	cg06481639	chr22:41940642	POLR3H	-0.44	-5.08	-0.3	7.18e-7	Vitiligo;
CESC	cis	rs2708240	0.666	rs2708257	chr7:147592449	C/A	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.37	-6.16	-0.35	2.71e-9	QT interval (drug interaction);
CESC	cis	rs8103278	0.793	rs59093775	chr19:46374037	G/A	cg14061069	chr19:46274453	DMPK	-0.38	-5.08	-0.3	7.17e-7	Coronary artery disease;
CESC	cis	rs7937682	0.924	rs1784782	chr11:111525764	A/C	cg09085632	chr11:111637200	PPP2R1B	-0.99	-16.01	-0.7	8.36e-41	Primary sclerosing cholangitis;
CESC	cis	rs11577318	0.853	rs17645	chr1:26646730	A/G	cg18121669	chr1:26560928	CCDC21	0.42	5.07	0.3	7.54e-7	Granulocyte percentage of myeloid white cells;
CESC	cis	rs4728302	0.869	rs889826	chr7:133595871	A/G	cg10665199	chr7:133106180	EXOC4	0.39	5.51	0.32	8.43e-8	Intelligence;Intelligence (multi-trait analysis);
CESC	cis	rs9811920	0.638	rs796977	chr3:99549723	T/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.61	-9.71	-0.51	2.81e-19	Axial length;
CESC	cis	rs2519796	0.531	rs2519109	chr9:136807770	A/G	cg13751417	chr9:136814406	VAV2	-0.4	-5.18	-0.3	4.48e-7	Hematocrit;Hemoglobin concentration;
CESC	cis	rs854765	0.534	rs7207461	chr17:17949789	T/G	cg16928487	chr17:17741425	SREBF1	0.56	9.25	0.49	7.81e-18	Total body bone mineral density;
CESC	cis	rs11690935	0.550	rs6730085	chr2:172864845	C/A	cg13550731	chr2:172543902	DYNC1I2	0.44	6.03	0.35	5.45e-9	Schizophrenia;
CESC	cis	rs6963495	0.799	rs73190201	chr7:105165891	A/C	cg02135003	chr7:105160482	PUS7	-0.47	-5.59	-0.33	5.51e-8	Bipolar disorder (body mass index interaction);
CESC	trans	rs13394619	0.935	rs6746291	chr2:11728381	T/C	cg18984002	chr17:36876514	MLLT6	-0.43	-6.43	-0.37	5.75e-10	Endometriosis;
CESC	trans	rs804280	0.542	rs36100659	chr8:11791653	A/T	cg15556689	chr8:8085844	FLJ10661	0.52	6.41	0.37	6.53e-10	Myopia (pathological);
CESC	cis	rs798554	0.644	rs7783400	chr7:2894434	A/C	cg19717773	chr7:2847554	GNA12	0.47	6.24	0.36	1.74e-9	Height;
CESC	cis	rs9393777	0.623	rs9358944	chr6:26469875	A/C	cg12826209	chr6:26865740	GUSBL1	0.68	7.43	0.42	1.51e-12	Intelligence (multi-trait analysis);
CESC	cis	rs780096	0.526	rs2010087	chr2:27637235	C/T	cg24768116	chr2:27665128	KRTCAP3	-0.29	-5.33	-0.31	2.07e-7	Total body bone mineral density;
CESC	cis	rs9788682	1.000	rs12441354	chr15:78821016	G/A	cg06917634	chr15:78832804	PSMA4	-0.55	-6.48	-0.37	4.52e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs12451471	0.529	rs2278620	chr17:78083565	G/A	cg06718696	chr17:78121285	EIF4A3	0.81	9.77	0.51	1.84e-19	Plateletcrit;Mean corpuscular hemoglobin concentration;
CESC	cis	rs2901656	0.967	rs4916186	chr1:172396020	A/G	cg03748243	chr1:172413542	C1orf105;PIGC	0.44	6.41	0.37	6.55e-10	Red cell distribution width;Platelet distribution width;
CESC	cis	rs7191439	0.858	rs8050715	chr16:88780923	C/G	cg02389323	chr16:88786976	FAM38A	0.84	7.38	0.41	2.08e-12	Plateletcrit;
CESC	cis	rs9457247	1.000	rs429083	chr6:167383972	T/C	cg25258033	chr6:167368657	RNASET2	0.39	5.87	0.34	1.27e-8	Crohn's disease;
CESC	cis	rs7727544	0.735	rs272867	chr5:131681057	G/A	cg24060327	chr5:131705240	SLC22A5	-0.67	-9.0	-0.48	4.57e-17	Blood metabolite levels;
CESC	cis	rs684232	0.602	rs331010	chr17:547124	G/A	cg15660573	chr17:549704	VPS53	-0.8	-11.67	-0.58	1.16e-25	Prostate cancer;
CESC	cis	rs7618915	0.570	rs2336145	chr3:52629750	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.47	6.57	0.37	2.61e-10	Bipolar disorder;
CESC	trans	rs916888	0.773	rs199533	chr17:44828931	G/A	cg23590916	chr17:43697445	MGC57346	0.65	6.72	0.38	1.12e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs2455799	0.593	rs2470544	chr3:15727234	A/G	cg16303742	chr3:15540471	COLQ	-0.38	-5.8	-0.34	1.88e-8	Mean platelet volume;
CESC	cis	rs9486719	0.857	rs2983897	chr6:97033780	C/T	cg06623918	chr6:96969491	KIAA0776	-0.86	-10.06	-0.53	2.27e-20	Migraine;Coronary artery disease;
CESC	cis	rs10504229	1.000	rs67913746	chr8:58177825	A/G	cg22535103	chr8:58192502	C8orf71	-1.05	-13.27	-0.63	3.63e-31	Developmental language disorder (linguistic errors);
CESC	cis	rs7917772	0.503	rs7087665	chr10:104282418	T/C	cg22532475	chr10:104410764	TRIM8	-0.33	-5.67	-0.33	3.77e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs7552404	1.000	rs7516226	chr1:76234257	G/A	cg10523679	chr1:76189770	ACADM	0.66	7.34	0.41	2.64e-12	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs1215050	0.740	rs6855827	chr4:99065706	G/A	cg05340658	chr4:99064831	C4orf37	0.59	7.84	0.43	1.12e-13	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs561341	0.700	rs2074101	chr17:30228656	G/A	cg13647721	chr17:30228624	UTP6	0.83	10.81	0.55	8.66e-23	Hip circumference adjusted for BMI;
CESC	cis	rs7811142	1.000	rs2406253	chr7:100077273	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.12	12.83	0.62	1.23e-29	Platelet count;
CESC	cis	rs9911578	1.000	rs1494977	chr17:56863064	C/T	cg12560992	chr17:57184187	TRIM37	0.92	15.11	0.68	1.28e-37	Intelligence (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19760249	chr17:79254595	SLC38A10	-0.58	-7.18	-0.4	6.92e-12	Gut microbiome composition (summer);
CESC	cis	rs7582720	1.000	rs72936353	chr2:204070956	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.84	7.17	0.4	7.7e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs4803468	0.967	rs1077856	chr19:41885221	T/C	cg14132834	chr19:41945861	ATP5SL	-0.6	-7.49	-0.42	1.02e-12	Height;
CESC	cis	rs9894429	0.546	rs9906979	chr17:79608765	A/G	cg13777783	chr17:79615861	NA	-0.36	-5.83	-0.34	1.62e-8	Eye color traits;
CESC	cis	rs514406	0.621	rs928452	chr1:53195926	G/C	cg16325326	chr1:53192061	ZYG11B	-1.0	-17.81	-0.74	3.35e-47	Monocyte count;
CESC	cis	rs9611565	0.649	rs738422	chr22:42123399	C/T	cg03806693	chr22:41940476	POLR3H	0.76	9.28	0.5	6.17e-18	Vitiligo;
CESC	cis	rs7250872	0.568	rs749109	chr19:1819736	G/A	cg10370574	chr19:1840461	REXO1	-0.44	-5.95	-0.34	8.27e-9	Bipolar disorder;
CESC	cis	rs10992471	0.627	rs4744138	chr9:95291909	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.43	-5.06	-0.3	7.72e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
CESC	cis	rs4268898	0.662	rs2303292	chr2:24432138	C/T	cg08917208	chr2:24149416	ATAD2B	0.55	5.27	0.31	2.89e-7	Asthma;
CESC	cis	rs4689592	0.554	rs3951346	chr4:7073321	C/T	cg06697600	chr4:7070879	GRPEL1	-0.46	-7.03	-0.4	1.7e-11	Monocyte percentage of white cells;
CESC	cis	rs12477438	0.765	rs7591992	chr2:99668954	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.62	-8.67	-0.47	4.43e-16	Chronic sinus infection;
CESC	cis	rs6500602	0.627	rs6500610	chr16:4529613	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.41	5.81	0.34	1.83e-8	Schizophrenia;
CESC	trans	rs9858213	1	rs9858213	chr3:49731861	G/T	cg21659725	chr3:3221576	CRBN	-0.55	-6.69	-0.38	1.35e-10	Educational attainment;
CESC	cis	rs10754283	0.967	rs10801761	chr1:90115269	C/T	cg21401794	chr1:90099060	LRRC8C	0.7	9.29	0.5	5.98e-18	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs2839186	0.500	rs13052701	chr21:47660045	A/T	cg10351095	chr21:47802916	PCNT	-0.5	-5.98	-0.34	7.35e-9	Testicular germ cell tumor;
CESC	cis	rs9303401	0.659	rs8074016	chr17:56840587	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.98	12.12	0.6	3.53e-27	Cognitive test performance;
CESC	cis	rs2404602	0.692	rs7169663	chr15:77192843	A/C	cg22467129	chr15:76604101	ETFA	-0.35	-5.24	-0.31	3.34e-7	Blood metabolite levels;
CESC	cis	rs9649213	0.593	rs7778015	chr7:97920270	T/C	cg08684580	chr7:98029266	BAIAP2L1	-0.34	-5.41	-0.32	1.44e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs3736485	0.966	rs10467923	chr15:51767265	A/C	cg08986416	chr15:51914746	DMXL2	-0.42	-5.32	-0.31	2.23e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs9911578	0.967	rs9894274	chr17:56977919	G/A	cg05425664	chr17:57184151	TRIM37	-0.5	-6.81	-0.39	6.5500000000000006e-11	Intelligence (multi-trait analysis);
CESC	cis	rs9291683	0.632	rs11734375	chr4:10046298	A/G	cg11266682	chr4:10021025	SLC2A9	0.68	13.29	0.63	3.1e-31	Bone mineral density;
CESC	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.43	-5.99	-0.35	6.66e-9	Longevity;Endometriosis;
CESC	cis	rs2243480	1.000	rs6964245	chr7:65718717	G/A	cg12463550	chr7:65579703	CRCP	-0.74	-5.73	-0.33	2.74e-8	Diabetic kidney disease;
CESC	cis	rs9549367	0.826	rs35306827	chr13:113869045	G/A	cg00898013	chr13:113819073	PROZ	-0.52	-7.3	-0.41	3.38e-12	Platelet distribution width;
CESC	cis	rs66573146	0.901	rs55882710	chr4:7030704	G/A	cg12726927	chr4:7941431	AFAP1	-0.88	-5.25	-0.31	3.09e-7	Granulocyte percentage of myeloid white cells;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00722097	chr6:111195976	AMD1	0.51	6.39	0.37	7.4e-10	Gut microbiome composition (summer);
CESC	cis	rs17711722	0.727	rs1880555	chr7:65432567	T/C	cg11764359	chr7:65958608	NA	0.68	8.82	0.48	1.52e-16	Calcium levels;
CESC	cis	rs9815354	0.638	rs17284933	chr3:42029835	T/C	cg03022575	chr3:42003672	ULK4	0.75	6.64	0.38	1.72e-10	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs7940866	0.834	rs7939417	chr11:130853832	T/A	cg14779329	chr11:130786720	SNX19	0.33	5.1	0.3	6.46e-7	Schizophrenia;
CESC	cis	rs854765	0.654	rs11078400	chr17:17757728	A/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.43	-5.68	-0.33	3.55e-8	Total body bone mineral density;
CESC	cis	rs61931739	0.500	rs10844844	chr12:34380350	G/T	cg19457237	chr12:34500585	NA	-0.35	-5.07	-0.3	7.6e-7	Morning vs. evening chronotype;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg09593402	chr5:96270297	LNPEP	0.52	6.65	0.38	1.72e-10	Gut microbiota (bacterial taxa);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg06211794	chr20:48330587	B4GALT5	-0.49	-6.78	-0.38	7.97e-11	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs10189230	0.868	rs5002064	chr2:222353508	G/A	cg14652038	chr2:222343519	EPHA4	0.35	7.22	0.41	5.49e-12	Urate levels in lean individuals;
CESC	trans	rs9325144	0.647	rs61931899	chr12:38892422	A/G	cg23762105	chr12:34175262	ALG10	0.47	6.13	0.35	3.2e-9	Morning vs. evening chronotype;
CESC	cis	rs7412746	0.658	rs3768016	chr1:150809919	T/C	cg09365446	chr1:150670422	GOLPH3L	0.4	5.35	0.31	1.89e-7	Melanoma;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12122041	chr4:3234814	HTT	-0.58	-7.13	-0.4	9.57e-12	Gut microbiome composition (summer);
CESC	cis	rs7084402	0.967	rs1649066	chr10:60305916	G/C	cg07615347	chr10:60278583	BICC1	0.59	9.34	0.5	4.23e-18	Refractive error;
CESC	cis	rs7953249	0.514	rs1169312	chr12:121441461	G/T	cg02403541	chr12:121454288	C12orf43	0.64	9.22	0.49	9.44e-18	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
CESC	cis	rs4891159	0.790	rs9950025	chr18:74113596	C/G	cg24786174	chr18:74118243	ZNF516	0.76	12.11	0.6	3.83e-27	Longevity;
CESC	cis	rs13256369	0.851	rs13255061	chr8:8563834	G/A	cg18904891	chr8:8559673	CLDN23	0.73	8.12	0.45	1.74e-14	Obesity-related traits;
CESC	trans	rs11252926	0.673	rs7096559	chr10:499188	C/T	cg00953403	chr17:74099816	EXOC7	0.53	6.71	0.38	1.2e-10	Psychosis in Alzheimer's disease;
CESC	cis	rs9902453	0.904	rs12103671	chr17:28408217	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.69	-8.89	-0.48	9.34e-17	Coffee consumption (cups per day);
CESC	cis	rs7937682	0.889	rs493810	chr11:111491888	G/T	cg09085632	chr11:111637200	PPP2R1B	-0.95	-14.6	-0.67	8.26e-36	Primary sclerosing cholangitis;
CESC	cis	rs1559088	0.625	rs10411739	chr19:33616327	T/C	cg17764715	chr19:33622953	WDR88	0.59	8.53	0.46	1.17e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs4243830	0.737	rs7552172	chr1:6612269	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.85	-8.42	-0.46	2.41e-15	Body mass index;
CESC	cis	rs17023223	0.553	rs11484962	chr1:119725186	G/A	cg05756136	chr1:119680316	WARS2	-0.47	-5.69	-0.33	3.34e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CESC	cis	rs801193	1.000	rs6958520	chr7:66151453	T/C	cg14393609	chr7:65229607	NA	0.47	6.31	0.36	1.15e-9	Aortic root size;
CESC	cis	rs7301826	0.651	rs10744485	chr12:131298550	A/G	cg11011512	chr12:131303247	STX2	0.45	5.48	0.32	9.73e-8	Plasma plasminogen activator levels;
CESC	cis	rs79387448	0.626	rs80256362	chr2:103025501	A/G	cg09003973	chr2:102972529	NA	1.0	7.8	0.43	1.41e-13	Gut microbiota (bacterial taxa);
CESC	cis	rs9787249	0.874	rs7520588	chr1:40214525	T/A	cg02773041	chr1:40204384	PPIE	0.53	7.56	0.42	6.49e-13	Blood protein levels;
CESC	cis	rs11078917	1	rs11078917	chr17:37746359	A/C	cg00129232	chr17:37814104	STARD3	-0.69	-9.09	-0.49	2.44e-17	Mean corpuscular volume;
CESC	cis	rs9640161	0.702	rs3735175	chr7:150020457	C/T	cg10018233	chr7:150070692	REPIN1	0.45	7.08	0.4	1.3e-11	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs801193	0.527	rs2707837	chr7:66181073	G/C	cg11764359	chr7:65958608	NA	0.73	10.55	0.54	5.73e-22	Aortic root size;
CESC	cis	rs6866344	0.561	rs55974982	chr5:178141421	G/A	cg03877680	chr5:178157825	ZNF354A	0.82	10.14	0.53	1.28e-20	Neutrophil percentage of white cells;
CESC	trans	rs74054849	0.850	rs41270289	chr1:15993905	C/T	cg06826283	chr7:600452	PRKAR1B	0.74	6.17	0.35	2.55e-9	Alcoholic chronic pancreatitis;
CESC	cis	rs9322193	0.607	rs12209310	chr6:150226018	G/A	cg01145232	chr6:150245071	RAET1G	0.53	6.68	0.38	1.36e-10	Lung cancer;
CESC	cis	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg02951883	chr7:2050386	MAD1L1	0.52	6.99	0.39	2.18e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs2228479	0.850	rs62056068	chr16:89909737	C/T	cg00800038	chr16:89945340	TCF25	-0.89	-6.89	-0.39	4.13e-11	Skin colour saturation;
CESC	trans	rs7866350	0.604	rs1935389	chr9:100994470	A/G	cg15921012	chr3:15919793	NA	-0.44	-6.02	-0.35	5.87e-9	Post-traumatic stress disorder;
CESC	cis	rs7255436	0.965	rs12981318	chr19:8451430	G/A	cg16745616	chr19:8428856	ANGPTL4	-0.36	-5.49	-0.32	9.22e-8	HDL cholesterol;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg07031243	chr17:40976230	BECN1	-0.52	-6.27	-0.36	1.44e-9	Ulcerative colitis;
CESC	cis	rs12950390	0.893	rs12325760	chr17:45840886	C/T	cg00777063	chr17:45855553	NA	-0.41	-6.12	-0.35	3.4e-9	IgG glycosylation;
CESC	cis	rs17253792	0.822	rs75936910	chr14:56149351	T/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.81	5.68	0.33	3.46e-8	Putamen volume;
CESC	cis	rs6714710	0.603	rs11681535	chr2:98488949	G/C	cg26665480	chr2:98280029	ACTR1B	0.56	7.86	0.43	9.67e-14	Posterior cortical atrophy and Alzheimer's disease;
CESC	cis	rs829883	0.664	rs829864	chr12:98850195	C/T	cg25150519	chr12:98850993	NA	0.87	14.77	0.67	2.01e-36	Colorectal adenoma (advanced);
CESC	cis	rs2404602	0.536	rs7163946	chr15:76766049	C/G	cg22467129	chr15:76604101	ETFA	-0.38	-5.86	-0.34	1.38e-8	Blood metabolite levels;
CESC	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg17372223	chr3:52568218	NT5DC2	0.54	9.29	0.5	5.98e-18	Electroencephalogram traits;
CESC	cis	rs2859741	0.546	rs2102087	chr1:37482849	G/A	cg09363841	chr1:37513479	NA	-0.49	-7.18	-0.4	6.92e-12	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
CESC	cis	rs7072216	0.770	rs1061115	chr10:100177049	G/A	cg26618903	chr10:100175079	PYROXD2	-0.33	-5.06	-0.3	7.97e-7	Metabolite levels;
CESC	cis	rs2303759	0.918	rs10405465	chr19:49869298	C/T	cg22590775	chr19:49891494	CCDC155	0.46	5.66	0.33	3.96e-8	Multiple sclerosis;
CESC	cis	rs514406	0.893	rs512723	chr1:53343880	C/T	cg25767906	chr1:53392781	SCP2	0.42	5.37	0.31	1.7e-7	Monocyte count;
CESC	cis	rs868036	1.000	rs1026736	chr15:68101813	T/C	cg08079166	chr15:68083412	MAP2K5	0.44	6.94	0.39	2.94e-11	Restless legs syndrome;
CESC	cis	rs477692	0.673	rs579325	chr10:131363688	C/T	cg05714579	chr10:131428358	MGMT	0.41	5.31	0.31	2.29e-7	Response to temozolomide;
CESC	cis	rs992157	0.798	rs10932772	chr2:219177148	C/T	cg00012203	chr2:219082015	ARPC2	0.76	10.09	0.53	1.84e-20	Colorectal cancer;
CESC	trans	rs4689592	0.619	rs3796908	chr4:7061378	G/A	cg07817883	chr1:32538562	TMEM39B	-0.6	-6.66	-0.38	1.62e-10	Monocyte percentage of white cells;
CESC	cis	rs4718428	0.607	rs66954441	chr7:66369209	T/C	cg25985355	chr7:65971099	NA	-0.34	-5.04	-0.3	8.74e-7	Corneal structure;
CESC	cis	rs1552244	0.935	rs7649243	chr3:10089470	T/A	cg08888203	chr3:10149979	C3orf24	0.51	6.39	0.37	7.29e-10	Alzheimer's disease;
CESC	cis	rs35110281	0.777	rs7276215	chr21:44990697	A/G	cg01579765	chr21:45077557	HSF2BP	-0.55	-9.26	-0.49	7.26e-18	Mean corpuscular volume;
CESC	cis	rs7312933	0.558	rs7305397	chr12:42850058	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.49	6.22	0.36	1.93e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs4642101	0.793	rs13320486	chr3:12822069	C/A	cg05775895	chr3:12838266	CAND2	0.39	5.93	0.34	9.32e-9	QRS complex (12-leadsum);
CESC	cis	rs9322193	0.923	rs66516768	chr6:149993135	C/T	cg13206674	chr6:150067644	NUP43	0.44	6.37	0.36	8.34e-10	Lung cancer;
CESC	cis	rs4253772	0.938	rs9626814	chr22:46637254	C/T	cg09491104	chr22:46646882	C22orf40	-0.46	-6.56	-0.37	2.89e-10	LDL cholesterol;Cholesterol, total;
CESC	cis	rs1799949	1.000	rs8176318	chr17:41197274	G/T	cg05368731	chr17:41323189	NBR1	0.73	9.81	0.52	1.4e-19	Menopause (age at onset);
CESC	cis	rs9788682	0.655	rs578776	chr15:78888400	G/A	cg24631222	chr15:78858424	CHRNA5	0.66	7.83	0.43	1.15e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs116095464	0.681	rs10060016	chr5:241100	T/C	cg20965017	chr5:231967	SDHA	-0.47	-5.38	-0.31	1.65e-7	Breast cancer;
CESC	cis	rs2760061	0.583	rs708118	chr1:228201801	A/G	cg02753203	chr1:228287806	NA	-0.72	-11.52	-0.58	3.57e-25	Diastolic blood pressure;
CESC	cis	rs1008375	0.931	rs3796814	chr4:17602033	G/C	cg02297831	chr4:17616191	MED28	0.53	6.55	0.37	3.03e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs36051895	0.632	rs10974969	chr9:5125336	G/A	cg02405213	chr9:5042618	JAK2	-0.51	-6.08	-0.35	4.27e-9	Pediatric autoimmune diseases;
CESC	cis	rs72781680	0.848	rs72780199	chr2:24016269	A/C	cg08917208	chr2:24149416	ATAD2B	0.95	8.71	0.47	3.45e-16	Lymphocyte counts;
CESC	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg26668828	chr6:292823	DUSP22	-0.72	-9.61	-0.51	6.02e-19	Menopause (age at onset);
CESC	cis	rs7188861	0.768	rs1794025	chr16:11380945	C/T	cg01510278	chr16:11456238	NA	0.33	5.12	0.3	5.81e-7	HDL cholesterol;
CESC	cis	rs6430585	0.583	rs78364332	chr2:136640101	T/C	cg07169764	chr2:136633963	MCM6	1.3	20.96	0.79	3.59e-58	Corneal structure;
CESC	cis	rs2425143	1.000	rs1056196	chr20:34327159	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.8	-7.51	-0.42	9.02e-13	Blood protein levels;
CESC	trans	rs7246657	0.943	rs10420754	chr19:37959372	C/G	cg01833234	chr11:6592585	DNHD1	0.52	6.0	0.35	6.5e-9	Coronary artery calcification;
CESC	cis	rs1878931	0.582	rs4785933	chr16:3419741	T/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.67	8.1	0.45	2.07e-14	Body mass index (adult);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19715471	chr10:13344246	NA	0.54	6.24	0.36	1.72e-9	Gut microbiome composition (summer);
CESC	cis	rs7772486	0.875	rs2814876	chr6:146304030	C/T	cg23711669	chr6:146136114	FBXO30	0.89	12.95	0.62	4.73e-30	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs524281	0.861	rs10750778	chr11:65948648	T/C	cg14036092	chr11:66035641	RAB1B	-0.58	-5.92	-0.34	9.93e-9	Electroencephalogram traits;
CESC	trans	rs2816958	0.708	rs2816972	chr1:200085004	A/G	cg16196175	chr7:27289120	NA	0.61	6.13	0.35	3.16e-9	Ulcerative colitis;Inflammatory bowel disease;
CESC	cis	rs2878628	0.650	rs56098033	chr3:52758571	T/A	cg05564831	chr3:52568323	NT5DC2	0.46	7.19	0.4	6.63e-12	Intelligence (multi-trait analysis);
CESC	cis	rs116095464	0.510	rs7723883	chr5:270798	T/C	cg20965017	chr5:231967	SDHA	-0.45	-5.1	-0.3	6.6e-7	Breast cancer;
CESC	cis	rs9908102	0.740	rs55825263	chr17:12905743	G/A	cg26162695	chr17:12921313	ELAC2	0.5	5.49	0.32	9.61e-8	Schizophrenia;
CESC	cis	rs7659604	0.540	rs116452657	chr4:122674147	A/G	cg19671926	chr4:122722719	EXOSC9	0.53	6.71	0.38	1.2e-10	Type 2 diabetes;
CESC	cis	rs963731	0.649	rs297159	chr2:39328827	C/T	cg04010122	chr2:39346883	SOS1	-0.75	-5.53	-0.32	7.73e-8	Corticobasal degeneration;
CESC	cis	rs208520	0.754	rs851594	chr6:66876695	A/G	cg07460842	chr6:66804631	NA	-1.0	-12.97	-0.62	3.95e-30	Exhaled nitric oxide output;
CESC	cis	rs2576037	0.583	rs641366	chr18:44430326	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.78	13.27	0.63	3.73e-31	Personality dimensions;
CESC	cis	rs9486719	1.000	rs2472888	chr6:96865501	T/C	cg06623918	chr6:96969491	KIAA0776	0.81	8.29	0.45	5.61e-15	Migraine;Coronary artery disease;
CESC	cis	rs2479106	0.892	rs7849665	chr9:126697865	C/T	cg16191174	chr9:126692580	DENND1A	0.51	6.83	0.39	5.88e-11	Polycystic ovary syndrome;
CESC	cis	rs12200560	0.505	rs211179	chr6:97074103	A/G	cg06623918	chr6:96969491	KIAA0776	0.52	6.65	0.38	1.71e-10	Coronary heart disease;
CESC	cis	rs1801251	1.000	rs895430	chr2:233725483	C/A	cg08000102	chr2:233561755	GIGYF2	-0.7	-9.96	-0.52	4.76e-20	Coronary artery disease;
CESC	cis	rs9322193	0.923	rs9688517	chr6:150061791	T/C	cg13206674	chr6:150067644	NUP43	0.45	6.43	0.37	5.76e-10	Lung cancer;
CESC	trans	rs7107217	1.000	rs1873872	chr11:129473993	A/T	cg09373211	chr1:154193749	C1orf43;UBAP2L	0.48	6.09	0.35	3.89e-9	Breast cancer;Type 2 diabetes;
CESC	trans	rs997295	0.529	rs12592315	chr15:68040266	A/G	cg05052335	chr5:130970657	RAPGEF6	0.47	6.12	0.35	3.33e-9	Motion sickness;
CESC	cis	rs6547741	0.904	rs1528403	chr2:27846645	C/G	cg27432699	chr2:27873401	GPN1	0.38	5.41	0.32	1.4e-7	Oral cavity cancer;
CESC	cis	rs10871290	0.881	rs4099290	chr16:74468889	A/G	cg01733217	chr16:74700730	RFWD3	-0.7	-9.29	-0.5	6.06e-18	Breast cancer;
CESC	cis	rs6089584	0.508	rs6061988	chr20:60626300	C/T	cg06108461	chr20:60628389	TAF4	-0.6	-8.04	-0.44	3.01e-14	Body mass index;
CESC	cis	rs9311474	0.597	rs13303	chr3:52558008	T/C	cg05564831	chr3:52568323	NT5DC2	0.54	9.27	0.49	6.88e-18	Electroencephalogram traits;
CESC	cis	rs9660180	0.934	rs34849348	chr1:1762757	C/T	cg13866156	chr1:1669148	SLC35E2	-0.51	-6.75	-0.38	9.36e-11	Body mass index;
CESC	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg03180552	chr7:157981849	PTPRN2	0.43	6.84	0.39	5.34e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CESC	cis	rs2290159	0.615	rs7610956	chr3:12677158	A/G	cg23032965	chr3:12705835	RAF1	0.52	5.46	0.32	1.12e-7	Cholesterol, total;
CESC	cis	rs5498	0.809	rs1056538	chr19:10402938	G/A	cg10604476	chr19:10403908	ICAM5	0.45	6.36	0.36	8.97e-10	Lymphocyte counts;Soluble ICAM-1;Blood protein levels;
CESC	cis	rs17253792	0.822	rs17746106	chr14:56069168	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.77	6.53	0.37	3.27e-10	Putamen volume;
CESC	cis	rs5769707	0.967	rs9616327	chr22:50010891	G/A	cg05373962	chr22:49881684	NA	-0.38	-6.54	-0.37	3.16e-10	Monocyte count;Monocyte percentage of white cells;
CESC	trans	rs4942242	1.000	rs9594987	chr13:44230994	C/T	cg19169023	chr15:41853346	TYRO3	0.48	7.14	0.4	9.01e-12	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs9905704	0.633	rs2531727	chr17:56502264	C/T	cg12560992	chr17:57184187	TRIM37	0.59	5.74	0.33	2.54e-8	Testicular germ cell tumor;
CESC	cis	rs3960554	0.867	rs79359354	chr7:75702597	G/A	cg17325771	chr7:75508891	RHBDD2	-0.33	-5.06	-0.3	8.03e-7	Eotaxin levels;
CESC	cis	rs116095464	0.764	rs10069197	chr5:230822	G/C	cg22496380	chr5:211416	CCDC127	-0.74	-8.65	-0.47	5.2e-16	Breast cancer;
CESC	cis	rs7762018	0.943	rs11546265	chr6:170108363	G/A	cg13891659	chr6:170190454	C6orf122;C6orf208	0.54	5.64	0.33	4.46e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs2880765	0.835	rs4280192	chr15:86043020	G/A	cg10818794	chr15:86012489	AKAP13	-0.34	-5.27	-0.31	2.77e-7	Coronary artery disease;
CESC	cis	rs709400	0.827	rs2274269	chr14:104029246	G/A	cg12935359	chr14:103987150	CKB	-0.5	-6.59	-0.38	2.4e-10	Body mass index;
CESC	cis	rs13064411	0.696	rs1486894	chr3:113211513	G/A	cg18753928	chr3:113234510	CCDC52	-0.52	-6.31	-0.36	1.17e-9	Response to simvastatin treatment (PCSK9 protein level change);
CESC	trans	rs8056446	0.710	rs8059793	chr16:78189298	A/C	cg06134974	chr12:51477539	CSRNP2	0.47	6.26	0.36	1.52e-9	Pulmonary function (smoking interaction);
CESC	cis	rs10751667	1.000	rs7394449	chr11:962190	T/C	cg01483505	chr11:975446	AP2A2	0.39	5.27	0.31	2.82e-7	Alzheimer's disease (late onset);
CESC	cis	rs6860806	0.507	rs156322	chr5:131653925	C/T	cg18758796	chr5:131593413	PDLIM4	0.46	6.24	0.36	1.75e-9	Breast cancer;
CESC	cis	rs6540559	0.740	rs2064163	chr1:210048819	G/T	cg22442454	chr1:209979470	IRF6	0.41	5.26	0.31	3.04e-7	Cleft lip with or without cleft palate;
CESC	cis	rs2933343	1.000	rs1680784	chr3:128644458	A/G	cg25356066	chr3:128598488	ACAD9	0.61	7.45	0.42	1.3e-12	IgG glycosylation;
CESC	cis	rs6842047	1.000	rs1877320	chr4:187131279	G/A	cg09526685	chr4:187126073	CYP4V2	0.7	5.81	0.34	1.83e-8	Blood protein levels;
CESC	cis	rs2404602	0.692	rs4383105	chr15:77055510	T/C	cg26408565	chr15:76604113	ETFA	-0.38	-5.52	-0.32	8.03e-8	Blood metabolite levels;
CESC	cis	rs2404602	0.684	rs2454451	chr15:76861461	G/T	cg23625390	chr15:77176239	SCAPER	0.41	5.81	0.34	1.83e-8	Blood metabolite levels;
CESC	cis	rs6570726	0.935	rs380883	chr6:145822992	A/G	cg05347473	chr6:146136440	FBXO30	0.5	6.58	0.37	2.5e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7666738	0.830	rs1426672	chr4:98923984	T/C	cg03467027	chr4:99064603	C4orf37	0.46	5.59	0.32	5.78e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3026101	0.671	rs1544399	chr17:5305887	C/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.42	5.6	0.33	5.31e-8	Body mass index;
CESC	cis	rs4689388	0.890	rs4688989	chr4:6290594	T/C	cg25554036	chr4:6271136	WFS1	0.53	8.69	0.47	3.8e-16	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs2204008	0.837	rs12581130	chr12:38319387	A/G	cg26384229	chr12:38710491	ALG10B	0.66	9.76	0.51	2.04e-19	Bladder cancer;
CESC	cis	rs17253792	0.822	rs2296181	chr14:56107051	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.79	6.04	0.35	5.13e-9	Putamen volume;
CESC	cis	rs35110281	0.616	rs2236666	chr21:45109856	T/C	cg04455712	chr21:45112962	RRP1B	0.48	7.19	0.4	6.79e-12	Mean corpuscular volume;
CESC	cis	rs6540559	1.000	rs6540559	chr1:209982025	G/A	cg10074409	chr1:209979377	IRF6	0.35	5.67	0.33	3.73e-8	Cleft lip with or without cleft palate;
CESC	cis	rs9300255	0.602	rs2851435	chr12:123712416	G/A	cg00376283	chr12:123451042	ABCB9	0.58	6.36	0.36	8.8e-10	Neutrophil percentage of white cells;
CESC	cis	rs11025559	0.812	rs10766678	chr11:20507180	A/G	cg19653624	chr11:20408972	PRMT3	-0.45	-5.08	-0.3	7.09e-7	Pursuit maintenance gain;
CESC	cis	rs4665809	1.000	rs12471809	chr2:26307140	A/G	cg27170947	chr2:26402098	FAM59B	-0.59	-7.06	-0.4	1.46e-11	Gut microbiome composition (summer);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg27056175	chr8:141556352	EIF2C2	0.47	6.06	0.35	4.68e-9	Fibrinogen levels;
CESC	cis	rs7824557	0.872	rs1347410	chr8:11111242	G/A	cg21775007	chr8:11205619	TDH	-0.37	-5.29	-0.31	2.51e-7	Retinal vascular caliber;
CESC	cis	rs11252926	0.537	rs4881274	chr10:459940	G/A	cg18196295	chr10:418757	DIP2C	0.51	6.96	0.39	2.68e-11	Psychosis in Alzheimer's disease;
CESC	cis	rs7917772	0.503	rs56397707	chr10:104302693	T/C	cg22532475	chr10:104410764	TRIM8	-0.35	-5.97	-0.34	7.47e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs6137287	0.668	rs6047255	chr20:21095936	A/G	cg13880779	chr20:21376337	NKX2-4	0.33	5.19	0.3	4.18e-7	Height;
CESC	cis	rs6582630	0.502	rs4559747	chr12:38436235	G/A	cg13010199	chr12:38710504	ALG10B	0.42	5.55	0.32	6.77e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs6951245	0.706	rs28522260	chr7:1183964	C/A	cg03188948	chr7:1209495	NA	0.72	7.77	0.43	1.75e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7264396	0.635	rs6058365	chr20:34508092	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.82	-11.07	-0.56	1.19e-23	Total cholesterol levels;
CESC	cis	rs425277	0.917	rs78609670	chr1:2045886	G/T	cg04315214	chr1:2043799	PRKCZ	-0.43	-6.01	-0.35	6.26e-9	Height;
CESC	cis	rs2033711	0.870	rs6510152	chr19:58953319	C/T	cg26874164	chr19:58962979	ZNF324B	0.55	7.66	0.43	3.59e-13	Uric acid clearance;
CESC	cis	rs12900413	0.687	rs28650972	chr15:90311941	C/T	cg24249390	chr15:90295951	MESP1	-0.41	-5.57	-0.32	6.32e-8	Coronary artery aneurysm in Kawasaki disease;
CESC	cis	rs6963495	0.818	rs56251768	chr7:105165591	A/G	cg13798780	chr7:105162888	PUS7	0.78	8.06	0.44	2.68e-14	Bipolar disorder (body mass index interaction);
CESC	cis	rs853679	0.517	rs9380062	chr6:28137569	G/A	cg19592336	chr6:28129416	ZNF389	0.58	7.71	0.43	2.54e-13	Depression;
CESC	cis	rs6598955	0.670	rs6676619	chr1:26539035	T/G	cg04990556	chr1:26633338	UBXN11	-0.75	-10.6	-0.55	4.14e-22	Obesity-related traits;
CESC	cis	rs7577696	0.524	rs12991444	chr2:32265125	G/T	cg02381751	chr2:32503542	YIPF4	-0.43	-5.15	-0.3	5e-7	Inflammatory biomarkers;
CESC	cis	rs116095464	0.558	rs56127718	chr5:270273	G/T	cg10591111	chr5:226296	SDHA	-0.52	-6.36	-0.36	8.59e-10	Breast cancer;
CESC	cis	rs8141529	0.748	rs715531	chr22:29282679	A/G	cg02153584	chr22:29168773	CCDC117	0.6	7.92	0.44	6.37e-14	Lymphocyte counts;
CESC	cis	rs798554	0.591	rs1713913	chr7:2895627	C/T	cg19717773	chr7:2847554	GNA12	-0.49	-7.51	-0.42	9.16e-13	Height;
CESC	cis	rs672059	1.000	rs575474	chr1:183158599	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.54	6.97	0.39	2.51e-11	Hypertriglyceridemia;
CESC	cis	rs965513	1.000	rs7021576	chr9:100540541	C/T	cg13688889	chr9:100608707	NA	-0.6	-8.46	-0.46	1.86e-15	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
CESC	cis	rs5769765	0.874	rs4624	chr22:50281917	A/G	cg26441486	chr22:50317300	CRELD2	-0.39	-5.5	-0.32	8.72e-8	Schizophrenia;
CESC	cis	rs454510	0.726	rs838989	chr1:120182906	G/A	cg16322792	chr1:120165303	ZNF697	0.41	6.47	0.37	4.68e-10	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
CESC	trans	rs9467711	0.606	rs28360517	chr6:26602453	A/G	cg06606381	chr12:133084897	FBRSL1	-0.74	-7.14	-0.4	8.79e-12	Autism spectrum disorder or schizophrenia;
CESC	cis	rs7833790	0.660	rs10091077	chr8:82705464	A/G	cg07697082	chr8:82753677	SNX16	0.38	5.8	0.34	1.85e-8	Diastolic blood pressure;
CESC	trans	rs208520	0.690	rs207107	chr6:66794385	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.0	-12.83	-0.62	1.2e-29	Exhaled nitric oxide output;
CESC	cis	rs4268898	0.636	rs76172309	chr2:24458911	G/C	cg20701182	chr2:24300061	SF3B14	0.64	6.91	0.39	3.56e-11	Asthma;
CESC	cis	rs10504229	0.683	rs7820302	chr8:58142502	C/T	cg22535103	chr8:58192502	C8orf71	-0.74	-8.52	-0.46	1.25e-15	Developmental language disorder (linguistic errors);
CESC	cis	rs7605827	0.930	rs3805103	chr2:15518352	A/G	cg19274914	chr2:15703543	NA	-0.35	-6.13	-0.35	3.19e-9	Educational attainment (years of education);
CESC	cis	rs1008375	0.966	rs12503540	chr4:17698781	C/G	cg02297831	chr4:17616191	MED28	-0.45	-5.33	-0.31	2.06e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs2836950	0.565	rs2836934	chr21:40564885	A/C	cg11890956	chr21:40555474	PSMG1	-0.62	-8.65	-0.47	5.07e-16	Menarche (age at onset);
CESC	cis	rs13256369	1.000	rs13266699	chr8:8570313	A/T	cg18904891	chr8:8559673	CLDN23	-0.67	-7.51	-0.42	8.91e-13	Obesity-related traits;
CESC	cis	rs10504229	0.906	rs56130194	chr8:58197061	C/A	cg22535103	chr8:58192502	C8orf71	-1.03	-10.87	-0.56	5.14e-23	Developmental language disorder (linguistic errors);
CESC	cis	rs7618501	0.602	rs2071207	chr3:50159844	T/C	cg24308560	chr3:49941425	MST1R	0.59	8.45	0.46	1.93e-15	Intelligence (multi-trait analysis);
CESC	cis	rs1799949	1.000	rs8176265	chr17:41213996	C/T	cg05368731	chr17:41323189	NBR1	0.75	9.96	0.52	4.74e-20	Menopause (age at onset);
CESC	cis	rs10791097	0.694	rs10894275	chr11:130756251	C/T	cg09137382	chr11:130731461	NA	0.34	5.1	0.3	6.52e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg25107717	chr1:94312368	MIR760	-0.45	-6.3	-0.36	1.26e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19436804	chr8:8560866	CLDN23	-0.56	-6.4	-0.37	6.92e-10	Gut microbiome composition (summer);
CESC	cis	rs12541335	0.639	rs13257108	chr8:22165043	T/C	cg26039829	chr8:22132926	PIWIL2	0.37	5.69	0.33	3.29e-8	Hypertriglyceridemia;
CESC	cis	rs4481887	0.927	rs4564179	chr1:248472422	T/C	cg00666640	chr1:248458726	OR2T12	0.35	5.93	0.34	9.43e-9	Common traits (Other);
CESC	trans	rs877282	0.898	rs11253341	chr10:765008	G/C	cg22713356	chr15:30763199	NA	1.16	11.35	0.57	1.37e-24	Uric acid levels;
CESC	cis	rs7618915	0.547	rs3755806	chr3:52643685	C/T	cg18337363	chr3:52569053	NT5DC2	-0.29	-5.13	-0.3	5.58e-7	Bipolar disorder;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg21308919	chr4:140619560	MGST2	0.43	6.2	0.36	2.11e-9	Fibrinogen levels;
CESC	cis	rs11122272	0.735	rs2790890	chr1:231514567	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.54	-7.28	-0.41	3.86e-12	Hemoglobin concentration;
CESC	cis	rs11264213	0.681	rs72659694	chr1:36301803	G/A	cg27506609	chr1:36549197	TEKT2	0.64	5.24	0.31	3.21e-7	Schizophrenia;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg25793566	chr3:196467045	PAK2	-0.44	-6.0	-0.35	6.38e-9	Ulcerative colitis;
CESC	cis	rs651907	0.557	rs35117343	chr3:101445126	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.44	5.64	0.33	4.29e-8	Colorectal cancer;
CESC	cis	rs7264396	0.570	rs1970576	chr20:34336720	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.86	-11.72	-0.58	7.6e-26	Total cholesterol levels;
CESC	trans	rs561341	0.943	rs508566	chr17:30289861	G/C	cg20587970	chr11:113659929	NA	-1.44	-17.64	-0.73	1.34e-46	Hip circumference adjusted for BMI;
CESC	cis	rs9815354	0.857	rs6796078	chr3:42017820	A/T	cg03022575	chr3:42003672	ULK4	-0.48	-5.52	-0.32	8.27e-8	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs10463316	0.963	rs10463315	chr5:150745615	T/A	cg03212797	chr5:150827313	SLC36A1	-0.44	-5.24	-0.31	3.34e-7	Metabolite levels (Pyroglutamine);
CESC	cis	rs7949030	0.653	rs17773169	chr11:62318530	G/T	cg22862634	chr11:62369728	EML3;MTA2	0.54	7.73	0.43	2.21e-13	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs6032067	0.777	rs73907811	chr20:43801395	T/A	cg11264863	chr20:43835661	SEMG1	0.5	5.36	0.31	1.77e-7	Blood protein levels;
CESC	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg24846343	chr22:24311635	DDTL	0.61	10.24	0.53	6.07e-21	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs7208859	0.673	rs8077116	chr17:29140162	A/G	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.1e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg16887890	chr2:219745233	WNT10A	-0.43	-6.07	-0.35	4.47e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs1801251	1.000	rs283468	chr2:233658309	C/T	cg08000102	chr2:233561755	GIGYF2	0.68	9.67	0.51	3.76e-19	Coronary artery disease;
CESC	cis	rs3784262	1.000	rs4646640	chr15:58247563	C/G	cg12031962	chr15:58353849	ALDH1A2	0.3	5.04	0.3	8.53e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
CESC	cis	rs514406	0.505	rs440871	chr1:53173052	C/T	cg24675658	chr1:53192096	ZYG11B	-0.5	-6.23	-0.36	1.79e-9	Monocyte count;
CESC	cis	rs853679	0.517	rs9368557	chr6:28131537	T/C	cg22143856	chr6:28129313	ZNF389	0.49	6.24	0.36	1.73e-9	Depression;
CESC	trans	rs11112613	0.938	rs2374513	chr12:106007300	C/T	cg20363022	chr13:111909300	ARHGEF7	0.56	6.17	0.35	2.58e-9	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CESC	cis	rs3768617	0.510	rs10752904	chr1:183101038	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.89	14.39	0.66	4.39e-35	Fuchs's corneal dystrophy;
CESC	trans	rs687914	0.710	rs938662	chr2:45864578	A/G	cg25018755	chr22:43506952	BIK	0.6	6.22	0.36	1.89e-9	Diastolic blood pressure;
CESC	cis	rs796364	0.806	rs11694236	chr2:200916230	T/C	cg23649088	chr2:200775458	C2orf69	-0.55	-5.05	-0.3	8.29e-7	Schizophrenia;
CESC	cis	rs761746	0.920	rs5753662	chr22:31901432	G/A	cg25791279	chr22:32026902	PISD	-0.5	-5.54	-0.32	7.33e-8	Intelligence;
CESC	cis	rs7772486	0.659	rs9376957	chr6:146011064	C/T	cg05347473	chr6:146136440	FBXO30	-0.51	-6.55	-0.37	2.92e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg24642844	chr7:1081250	C7orf50	-0.77	-9.41	-0.5	2.48e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs4689388	0.889	rs13101355	chr4:6293446	T/C	cg14416269	chr4:6271139	WFS1	0.46	7.76	0.43	1.79e-13	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs4642101	0.512	rs12629892	chr3:12818920	A/G	cg24848339	chr3:12840334	CAND2	0.43	6.78	0.38	7.98e-11	QRS complex (12-leadsum);
CESC	cis	rs9815354	0.723	rs12152489	chr3:42060402	T/C	cg03022575	chr3:42003672	ULK4	0.76	6.86	0.39	4.88e-11	Pulse pressure;Diastolic blood pressure;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg05041045	chr14:31091339	SCFD1	-0.43	-6.17	-0.35	2.56e-9	Thyroid stimulating hormone;
CESC	trans	rs9325144	0.647	rs7957185	chr12:38909710	G/A	cg23762105	chr12:34175262	ALG10	0.46	6.05	0.35	4.99e-9	Morning vs. evening chronotype;
CESC	cis	rs9611565	0.592	rs5751101	chr22:41828111	C/T	cg06634786	chr22:41940651	POLR3H	0.71	7.17	0.4	7.54e-12	Vitiligo;
CESC	cis	rs10242455	0.867	rs2687135	chr7:99326309	T/G	cg07715041	chr7:99302981	CYP3A7	-0.43	-5.43	-0.32	1.28e-7	Blood metabolite levels;
CESC	cis	rs9300255	0.602	rs1402274	chr12:123686224	T/C	cg05973401	chr12:123451056	ABCB9	0.5	5.74	0.33	2.53e-8	Neutrophil percentage of white cells;
CESC	cis	rs780094	0.544	rs780110	chr2:27685388	G/A	cg17158414	chr2:27665306	KRTCAP3	-0.27	-5.4	-0.31	1.51e-7	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
CESC	cis	rs6460942	0.908	rs78374554	chr7:12242285	G/A	cg20607287	chr7:12443886	VWDE	-0.62	-6.03	-0.35	5.41e-9	Coronary artery disease;
CESC	cis	rs2243480	0.901	rs2949697	chr7:65464236	A/G	cg18252515	chr7:66147081	NA	-1.13	-10.9	-0.56	4.18e-23	Diabetic kidney disease;
CESC	cis	rs9314323	0.964	rs2304300	chr8:26249018	G/A	cg13160058	chr8:26243215	BNIP3L	-0.32	-5.16	-0.3	4.79e-7	Red cell distribution width;
CESC	cis	rs7551222	0.752	rs4951075	chr1:204464446	C/A	cg20240347	chr1:204465584	NA	-0.27	-5.53	-0.32	7.5e-8	Schizophrenia;
CESC	cis	rs6088580	0.634	rs6141465	chr20:32967314	T/C	cg08999081	chr20:33150536	PIGU	-0.64	-11.25	-0.57	2.81e-24	Glomerular filtration rate (creatinine);
CESC	trans	rs6794880	0.778	rs78141845	chr3:84417405	C/T	cg03554283	chr8:76319451	NA	0.57	6.07	0.35	4.44e-9	Body mass index (joint analysis main effects and smoking interaction);BMI in non-smokers;BMI (adjusted for smoking behaviour);
CESC	cis	rs7267979	0.934	rs2482913	chr20:25405086	T/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.81	-15.41	-0.69	1.07e-38	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs8177179	0.967	rs4078166	chr3:133435979	C/A	cg24879335	chr3:133465180	TF	0.46	8.71	0.47	3.36e-16	Iron status biomarkers (transferrin levels);
CESC	cis	rs72945132	0.660	rs67433166	chr11:70121604	T/A	cg00319359	chr11:70116639	PPFIA1	0.78	7.78	0.43	1.6e-13	Coronary artery disease;
CESC	trans	rs1005277	0.579	rs1780137	chr10:38501475	C/G	cg27523141	chr10:43048294	ZNF37B	0.46	6.02	0.35	5.91e-9	Extrinsic epigenetic age acceleration;
CESC	trans	rs875971	0.929	rs12673810	chr7:65923853	T/A	cg26939375	chr7:64535504	NA	0.46	6.0	0.35	6.4e-9	Aortic root size;
CESC	cis	rs9611519	0.531	rs1967708	chr22:41444444	G/C	cg03806693	chr22:41940476	POLR3H	-0.5	-5.96	-0.34	7.8e-9	Neuroticism;
CESC	cis	rs35306767	0.903	rs12250936	chr10:870109	C/T	cg10556349	chr10:835070	NA	0.6	5.71	0.33	3.1e-8	Eosinophil percentage of granulocytes;
CESC	cis	rs12476592	0.571	rs964903	chr2:63741548	C/T	cg17519650	chr2:63277830	OTX1	-0.49	-5.51	-0.32	8.61e-8	Childhood ear infection;
CESC	cis	rs780096	0.506	rs8395	chr2:27715207	T/A	cg02592271	chr2:27665507	KRTCAP3	-0.3	-5.97	-0.34	7.49e-9	Total body bone mineral density;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg04135372	chr2:99061383	INPP4A	-0.41	-6.49	-0.37	4.09e-10	Gambling;
CESC	cis	rs1879734	0.731	rs12041221	chr1:54164165	A/G	cg23596471	chr1:54105337	GLIS1	0.35	5.58	0.32	5.97e-8	Mitral valve prolapse;
CESC	cis	rs9325144	0.678	rs7315271	chr12:39164731	A/G	cg26384229	chr12:38710491	ALG10B	-0.52	-7.09	-0.4	1.19e-11	Morning vs. evening chronotype;
CESC	cis	rs6942756	0.876	rs7789697	chr7:129060386	T/A	cg02491457	chr7:128862824	NA	-0.53	-7.26	-0.41	4.34e-12	White matter hyperintensity burden;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02601626	chr11:889231	CHID1	-0.52	-6.01	-0.35	5.99e-9	Gut microbiome composition (summer);
CESC	cis	rs2688608	0.592	rs10762563	chr10:75524802	C/A	cg23231163	chr10:75533350	FUT11	-0.36	-5.5	-0.32	8.89e-8	Inflammatory bowel disease;
CESC	cis	rs9470366	0.545	rs2395655	chr6:36645696	C/T	cg08179530	chr6:36648295	CDKN1A	-0.77	-13.01	-0.62	3.01e-30	QRS duration;
CESC	cis	rs2072499	0.966	rs2842865	chr1:156159532	G/A	cg24450063	chr1:156163899	SLC25A44	1.11	23.64	0.82	3.21e-67	Testicular germ cell tumor;
CESC	cis	rs7618915	0.571	rs12632381	chr3:52607685	G/A	cg07507251	chr3:52567010	NT5DC2	0.42	7.37	0.41	2.11e-12	Bipolar disorder;
CESC	cis	rs514406	0.798	rs575138	chr1:53328394	C/G	cg08736216	chr1:53307985	ZYG11A	-0.44	-7.39	-0.41	1.95e-12	Monocyte count;
CESC	cis	rs2404602	0.692	rs2304920	chr15:76993867	T/C	cg22467129	chr15:76604101	ETFA	-0.34	-5.11	-0.3	6.27e-7	Blood metabolite levels;
CESC	cis	rs7801375	0.515	rs2058968	chr7:131560452	C/T	cg26572488	chr7:132299669	PLXNA4	-0.45	-5.06	-0.3	7.81e-7	Schizophrenia;Autism spectrum disorder or schizophrenia;
CESC	cis	rs965469	0.779	rs2236114	chr20:3296040	A/G	cg25506879	chr20:3388711	C20orf194	-0.48	-5.23	-0.31	3.4e-7	IFN-related cytopenia;
CESC	cis	rs6541297	0.645	rs4846918	chr1:230300586	A/G	cg20703242	chr1:230279135	GALNT2	-0.52	-6.22	-0.36	1.92e-9	Coronary artery disease;
CESC	cis	rs9787249	0.915	rs6664570	chr1:40206298	G/A	cg02773041	chr1:40204384	PPIE	0.54	7.74	0.43	2.16e-13	Blood protein levels;
CESC	trans	rs12681287	0.547	rs9942823	chr8:87509177	A/G	cg27317242	chr8:23145699	R3HCC1	-0.53	-6.35	-0.36	9.05e-10	Caudate activity during reward;
CESC	cis	rs2820292	0.678	rs4494199	chr1:201884668	C/T	cg06775570	chr1:201857621	SHISA4	0.31	5.4	0.31	1.51e-7	Waist circumference;Body mass index (joint analysis main effects and smoking interaction);Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);
CESC	cis	rs10504229	0.683	rs56192850	chr8:58135356	A/G	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs400736	0.930	rs408320	chr1:8085328	T/C	cg25007680	chr1:8021821	PARK7	0.71	10.24	0.53	5.87e-21	Response to antidepressants and depression;
CESC	trans	rs7615952	0.512	rs2922175	chr3:125361360	T/C	cg00769240	chr8:12517080	NA	-0.44	-6.02	-0.35	5.7e-9	Blood pressure (smoking interaction);
CESC	cis	rs801193	1.000	rs7789184	chr7:66210195	A/T	cg14393609	chr7:65229607	NA	0.47	6.31	0.36	1.17e-9	Aortic root size;
CESC	cis	rs910316	0.967	rs4899549	chr14:75647494	G/A	cg11812906	chr14:75593930	NEK9	-0.84	-13.44	-0.64	9.06e-32	Height;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg18879991	chr6:27861393	HIST1H2AM;HIST1H2BO	0.47	6.14	0.35	3.03e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs2228479	0.702	rs17177891	chr16:89799950	C/T	cg06558623	chr16:89946397	TCF25	1.03	8.03	0.44	3.28e-14	Skin colour saturation;
CESC	cis	rs1008375	1.000	rs17507481	chr4:17620066	A/G	cg04450456	chr4:17643702	FAM184B	0.39	5.57	0.32	6.19e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs9287719	0.967	rs4669598	chr2:10757838	T/C	cg00105475	chr2:10696890	NA	0.37	5.4	0.31	1.52e-7	Prostate cancer;
CESC	cis	rs7828089	0.935	rs896378	chr8:22262321	T/C	cg12081754	chr8:22256438	SLC39A14	0.43	5.84	0.34	1.52e-8	Verbal declarative memory;
CESC	cis	rs1670533	1.000	rs11247971	chr4:1053580	A/G	cg27284194	chr4:1044797	NA	0.46	5.86	0.34	1.35e-8	Recombination rate (females);
CESC	cis	rs10504229	0.679	rs75402323	chr8:58136227	A/G	cg02725872	chr8:58115012	NA	-0.45	-7.05	-0.4	1.52e-11	Developmental language disorder (linguistic errors);
CESC	trans	rs637571	0.522	rs542332	chr11:65744421	C/T	cg17712092	chr4:129076599	LARP1B	0.72	9.97	0.52	4.26e-20	Eosinophil percentage of white cells;
CESC	cis	rs9640161	0.711	rs3735170	chr7:150034184	T/C	cg10018233	chr7:150070692	REPIN1	0.46	6.86	0.39	4.92e-11	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs7945705	0.902	rs2568059	chr11:8884161	T/C	cg09997546	chr11:8931473	C11orf17;ST5	-0.38	-6.51	-0.37	3.85e-10	Hemoglobin concentration;
CESC	cis	rs8114671	0.562	rs6088640	chr20:33472509	C/T	cg06115741	chr20:33292138	TP53INP2	0.48	5.8	0.34	1.91e-8	Height;
CESC	cis	rs17711722	0.727	rs2658585	chr7:65461941	A/T	cg14393609	chr7:65229607	NA	0.54	7.23	0.41	5.3e-12	Calcium levels;
CESC	cis	rs1552244	1.000	rs6793396	chr3:10110927	T/C	cg00149659	chr3:10157352	C3orf10	0.72	8.61	0.47	6.41e-16	Alzheimer's disease;
CESC	cis	rs17253792	0.915	rs28375514	chr14:56179941	G/A	cg01858014	chr14:56050164	KTN1	-0.91	-7.03	-0.4	1.8e-11	Putamen volume;
CESC	cis	rs875971	0.862	rs778736	chr7:65813848	C/T	cg12463550	chr7:65579703	CRCP	0.48	6.17	0.35	2.6e-9	Aortic root size;
CESC	cis	rs10883723	0.773	rs1326193	chr10:104271674	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.54	7.41	0.41	1.65e-12	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs523522	0.962	rs4766969	chr12:120988238	A/G	cg27279351	chr12:120934652	DYNLL1	0.68	8.7	0.47	3.47e-16	High light scatter reticulocyte count;
CESC	cis	rs787274	1.000	rs72768411	chr9:115502670	C/A	cg13803584	chr9:115635662	SNX30	0.58	5.05	0.3	8.31e-7	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs7210086	0.768	rs72849444	chr17:70637805	G/A	cg04206342	chr17:70636940	NA	-0.31	-5.98	-0.34	7.18e-9	Ulcerative colitis;
CESC	cis	rs4595586	0.525	rs12825567	chr12:39386621	C/T	cg26384229	chr12:38710491	ALG10B	0.52	7.32	0.41	3.06e-12	Morning vs. evening chronotype;
CESC	cis	rs9837602	1.000	rs2291494	chr3:99781805	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.5	7.18	0.4	6.88e-12	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17113216	chr4:83821792	THAP9	0.58	6.65	0.38	1.68e-10	Gut microbiome composition (summer);
CESC	cis	rs258324	0.720	rs154663	chr16:89726035	T/C	cg04240660	chr16:89714849	CHMP1A	0.55	5.62	0.33	4.93e-8	Height;
CESC	cis	rs1878931	0.597	rs37814	chr16:3455247	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.76	-9.04	-0.49	3.32e-17	Body mass index (adult);
CESC	cis	rs853679	1.000	rs10456362	chr6:28221816	A/G	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	-0.72	-8.17	-0.45	1.24e-14	Depression;
CESC	cis	rs7020830	0.861	rs6476622	chr9:37308049	T/A	cg14294708	chr9:37120828	ZCCHC7	1.12	19.76	0.77	4.99e-54	Schizophrenia;
CESC	cis	rs5753618	0.583	rs8138596	chr22:31786961	T/A	cg02404636	chr22:31891804	SFI1	0.38	5.15	0.3	5.1e-7	Colorectal cancer;
CESC	cis	rs7264396	0.635	rs6060709	chr20:34536022	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.57	6.99	0.39	2.23e-11	Total cholesterol levels;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg00744550	chr2:242609941	ATG4B	0.46	6.51	0.37	3.73e-10	Fibrinogen levels;
CESC	cis	rs17209837	1.000	rs17149641	chr7:87086090	T/C	cg00919237	chr7:87102261	ABCB4	-0.5	-5.83	-0.34	1.6e-8	Gallbladder cancer;
CESC	cis	rs9715521	0.900	rs6819160	chr4:59834879	A/G	cg11281224	chr4:60001000	NA	-0.52	-6.76	-0.38	8.63e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	trans	rs877282	0.947	rs7475589	chr10:767479	C/G	cg22713356	chr15:30763199	NA	1.19	11.74	0.58	6.81e-26	Uric acid levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20064231	chr18:74608296	ZNF236	-0.71	-8.15	-0.45	1.42e-14	Gut microbiome composition (summer);
CESC	cis	rs950169	0.579	rs12912716	chr15:84664263	A/T	cg17507749	chr15:85114479	UBE2QP1	0.63	6.17	0.35	2.59e-9	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20675196	chr20:2854059	PTPRA	0.58	6.48	0.37	4.48e-10	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.830	rs3846444	chr4:99032888	T/C	cg05340658	chr4:99064831	C4orf37	0.83	13.1	0.63	1.43e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7914558	1.000	rs7071373	chr10:104771922	A/G	cg04362960	chr10:104952993	NT5C2	0.44	5.84	0.34	1.53e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs644799	0.965	rs3789960	chr11:95509037	C/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.71	9.5	0.5	1.28e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs3733585	0.746	rs4318650	chr4:10016868	T/C	cg11266682	chr4:10021025	SLC2A9	0.68	13.13	0.63	1.13e-30	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs7568458	0.660	rs6547623	chr2:85801964	T/A	cg02493740	chr2:85810744	VAMP5	-0.57	-8.52	-0.46	1.26e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CESC	cis	rs4891159	0.756	rs8084155	chr18:74134952	A/G	cg24786174	chr18:74118243	ZNF516	-0.77	-13.18	-0.63	7.72e-31	Longevity;
CESC	cis	rs61931739	0.500	rs7489130	chr12:34539674	C/A	cg19457237	chr12:34500585	NA	-0.37	-5.08	-0.3	6.97e-7	Morning vs. evening chronotype;
CESC	cis	rs6032067	0.929	rs876835	chr20:43827241	T/C	cg10761708	chr20:43804764	PI3	0.53	6.36	0.36	8.83e-10	Blood protein levels;
CESC	cis	rs6912958	0.559	rs451829	chr6:88041919	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.74	11.38	0.57	1.11e-24	Monocyte percentage of white cells;
CESC	cis	rs6088580	0.634	rs6059897	chr20:33113224	A/G	cg24642439	chr20:33292090	TP53INP2	0.5	6.55	0.37	2.92e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs4332037	0.707	rs73046323	chr7:1882795	G/A	cg13880726	chr7:1868755	MAD1L1	-0.5	-5.25	-0.31	3.06e-7	Bipolar disorder;
CESC	cis	rs7666738	1.000	rs13106934	chr4:99028685	C/T	cg05340658	chr4:99064831	C4orf37	0.64	8.35	0.46	3.77e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs12220238	1.000	rs11000922	chr10:75969305	T/G	cg19889307	chr10:75911429	ADK;AP3M1	0.6	5.03	0.3	9.09e-7	Soluble interleukin-2 receptor subunit alpha;
CESC	cis	rs801193	0.591	rs2707839	chr7:66193084	A/G	cg12463550	chr7:65579703	CRCP	0.56	7.28	0.41	3.73e-12	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22458401	chr7:72742115	TRIM50;FKBP6	-0.51	-6.59	-0.38	2.33e-10	Gut microbiome composition (summer);
CESC	trans	rs208520	0.545	rs10944874	chr6:66752080	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.99	-18.67	-0.75	3.17e-50	Exhaled nitric oxide output;
CESC	cis	rs10129255	0.500	rs1024350	chr14:107141122	C/T	cg07958169	chr14:107095056	NA	-0.52	-8.4	-0.46	2.68e-15	Kawasaki disease;
CESC	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg11235426	chr6:292522	DUSP22	-0.73	-9.82	-0.52	1.27e-19	Menopause (age at onset);
CESC	cis	rs3747547	0.818	rs7859715	chr9:37948322	A/C	cg13774184	chr9:37916125	SHB	-0.61	-6.22	-0.36	1.92e-9	Metabolite levels (Dihydroxy docosatrienoic acid);
CESC	cis	rs7918232	0.941	rs788210	chr10:27476948	T/C	cg14240646	chr10:27532245	ACBD5	0.64	6.11	0.35	3.46e-9	Breast cancer;
CESC	cis	rs365132	0.875	rs547798	chr5:176326721	C/A	cg16309518	chr5:176445507	NA	-0.38	-5.54	-0.32	7.31e-8	Menarche and menopause (age at onset);Menopause (age at onset);
CESC	cis	rs1218582	0.741	rs883718	chr1:154846274	C/T	cg09359103	chr1:154839909	KCNN3	-0.69	-13.74	-0.65	8.09e-33	Prostate cancer;
CESC	cis	rs1218582	0.774	rs4845681	chr1:154868055	G/T	cg06221963	chr1:154839813	KCNN3	-0.64	-11.23	-0.57	3.53e-24	Prostate cancer;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg16071359	chr2:169312933	LASS6	-0.46	-6.58	-0.37	2.57e-10	Gambling;
CESC	cis	rs959260	1.000	rs930299	chr17:73404668	A/C	cg20590849	chr17:73267439	MIF4GD	-0.57	-6.55	-0.37	2.97e-10	Systemic lupus erythematosus;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03383472	chr7:2314947	SNX8	-0.56	-6.23	-0.36	1.8e-9	Gut microbiome composition (summer);
CESC	trans	rs11945798	1.000	rs16887512	chr4:12734271	C/T	cg22784836	chr11:1219516	NA	0.55	6.19	0.36	2.24e-9	Word reading;
CESC	cis	rs7086627	0.515	rs7078254	chr10:82212193	C/T	cg03267442	chr10:82210566	NA	-0.34	-5.57	-0.32	6.21e-8	Post bronchodilator FEV1;
CESC	cis	rs28386778	0.965	rs2854154	chr17:61981696	C/A	cg07677032	chr17:61819896	STRADA	-0.44	-5.71	-0.33	2.99e-8	Prudent dietary pattern;
CESC	cis	rs6967414	0.605	rs7786706	chr7:6747267	C/T	cg09896999	chr7:6746977	ZNF12	-0.44	-6.31	-0.36	1.16e-9	Hematocrit;Hemoglobin concentration;
CESC	cis	rs873946	0.586	rs12770021	chr10:134562021	G/A	cg27297192	chr10:134578999	INPP5A	0.42	5.47	0.32	1.02e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs3784262	1.000	rs3784262	chr15:58253106	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.31	-5.19	-0.3	4.29e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
CESC	cis	rs2281845	0.533	rs10753891	chr1:201100482	A/G	cg06714761	chr1:201096289	NA	0.32	5.72	0.33	2.85e-8	Permanent tooth development;
CESC	cis	rs6502050	0.765	rs6502075	chr17:80121813	G/A	cg11859384	chr17:80120422	CCDC57	-0.39	-5.34	-0.31	1.98e-7	Life satisfaction;
CESC	cis	rs2735413	0.750	rs75500355	chr16:78075396	A/T	cg04733911	chr16:78082701	NA	0.4	5.25	0.31	3.07e-7	Systolic blood pressure (alcohol consumption interaction);
CESC	cis	rs801193	1.000	rs1553610	chr7:66197233	T/C	cg14393609	chr7:65229607	NA	0.47	6.31	0.36	1.17e-9	Aortic root size;
CESC	cis	rs12618769	0.597	rs55900716	chr2:99109132	G/A	cg10123293	chr2:99228465	UNC50	0.39	5.13	0.3	5.6e-7	Bipolar disorder;
CESC	cis	rs35110281	0.805	rs4818855	chr21:45038951	C/T	cg01579765	chr21:45077557	HSF2BP	-0.52	-8.9	-0.48	8.79e-17	Mean corpuscular volume;
CESC	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	13.76	0.65	7.41e-33	Prudent dietary pattern;
CESC	cis	rs3858526	0.628	rs1840177	chr11:5944627	T/G	cg25319279	chr11:5960081	NA	0.38	5.41	0.32	1.41e-7	DNA methylation (variation);
CESC	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg22907277	chr7:1156413	C7orf50	0.44	6.27	0.36	1.43e-9	Longevity;Endometriosis;
CESC	cis	rs2625529	0.668	rs8192386	chr15:72513148	A/C	cg16672083	chr15:72433130	SENP8	0.39	5.06	0.3	7.84e-7	Red blood cell count;
CESC	cis	rs9649213	0.593	rs6968144	chr7:97915697	G/A	cg00277769	chr7:97922759	BAIAP2L1	-0.34	-5.54	-0.32	7.11e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs4481887	0.893	rs7515080	chr1:248494073	A/G	cg00666640	chr1:248458726	OR2T12	0.41	6.71	0.38	1.17e-10	Common traits (Other);
CESC	cis	rs11719291	0.504	rs71324924	chr3:48865444	G/A	cg00383909	chr3:49044727	WDR6	0.92	6.66	0.38	1.62e-10	Cognitive function;
CESC	cis	rs780094	0.606	rs6729709	chr2:27583156	G/A	cg02592271	chr2:27665507	KRTCAP3	-0.26	-5.39	-0.31	1.57e-7	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
CESC	cis	rs3820928	1.000	rs7561378	chr2:227772248	T/C	cg05526886	chr2:227700861	RHBDD1	-0.42	-5.54	-0.32	7.19e-8	Pulmonary function;
CESC	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg10862848	chr6:42927986	GNMT	-0.3	-7.8	-0.43	1.44e-13	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs6815814	0.731	rs10776483	chr4:38775040	A/G	cg02016764	chr4:38805732	TLR1	-0.44	-6.08	-0.35	4.24e-9	Breast cancer;
CESC	trans	rs4927850	0.957	rs4927851	chr3:195751853	A/G	cg16724585	chr3:197361211	NA	-0.56	-7.17	-0.4	7.33e-12	Pancreatic cancer;
CESC	cis	rs1551570	0.819	rs11666402	chr19:10219076	A/G	cg00593900	chr19:10206746	ANGPTL6	0.32	5.42	0.32	1.33e-7	Narcolepsy;
CESC	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	13.67	0.64	1.44e-32	Prudent dietary pattern;
CESC	cis	rs7086627	0.515	rs11202957	chr10:82209592	A/G	cg03267442	chr10:82210566	NA	-0.34	-5.6	-0.33	5.45e-8	Post bronchodilator FEV1;
CESC	cis	rs8050907	0.590	rs17883666	chr16:4550153	G/A	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.8	5.41	0.32	1.44e-7	Obesity-related traits;
CESC	trans	rs13098911	0.540	rs36122610	chr3:46022833	G/A	cg10236987	chr1:228114221	WNT9A	0.6	6.17	0.35	2.61e-9	Celiac disease;
CESC	cis	rs1799949	0.965	rs11656945	chr17:41330265	A/G	cg25072359	chr17:41440525	NA	0.51	6.83	0.39	5.9e-11	Menopause (age at onset);
CESC	cis	rs28374715	0.528	rs28492932	chr15:41624397	G/C	cg02330683	chr15:41787940	ITPKA	0.49	5.77	0.33	2.23e-8	Ulcerative colitis;
CESC	cis	rs7523875	0.516	rs6682599	chr1:211522427	G/A	cg26515805	chr1:211431828	RCOR3	0.38	5.23	0.31	3.49e-7	Mean corpuscular volume;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg06219926	chr3:196669402	NCBP2;LOC152217	-0.44	-6.49	-0.37	4.09e-10	Gambling;
CESC	cis	rs117623576	0.680	rs12269122	chr10:32367864	C/T	cg03047570	chr10:32398778	NA	-0.62	-6.74	-0.38	9.86e-11	Anti-saccade response;
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg11328405	chr15:49170157	SHC4;EID1	-0.41	-6.05	-0.35	4.95e-9	Vertical cup-disc ratio;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26806188	chr12:108908720	FICD	0.6	6.27	0.36	1.47e-9	Gut microbiome composition (summer);
CESC	cis	rs12497850	0.864	rs3212	chr3:49145741	T/C	cg02487422	chr3:49467188	NICN1	0.45	5.69	0.33	3.32e-8	Parkinson's disease;
CESC	cis	rs8114671	0.585	rs2236271	chr20:33523840	G/T	cg07148914	chr20:33460835	GGT7	-0.49	-6.22	-0.36	1.92e-9	Height;
CESC	cis	rs1215050	0.791	rs165247	chr4:98692399	A/G	cg05340658	chr4:99064831	C4orf37	0.49	6.33	0.36	1.02e-9	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs57221529	0.766	rs72706610	chr5:561111	G/A	cg16447950	chr5:562315	NA	-0.71	-7.83	-0.43	1.2e-13	Lung disease severity in cystic fibrosis;
CESC	trans	rs6572548	0.504	rs1956082	chr14:49665496	A/C	cg09068198	chr2:65357064	RAB1A	-0.56	-6.4	-0.37	6.88e-10	Subjective well-being;
CESC	cis	rs12541635	0.966	rs62527363	chr8:107024258	A/G	cg10147462	chr8:107024639	NA	0.42	6.04	0.35	5.06e-9	Age of smoking initiation;
CESC	cis	rs7618915	0.571	rs33964154	chr3:52596914	A/G	cg17372223	chr3:52568218	NT5DC2	0.43	6.37	0.36	8.33e-10	Bipolar disorder;
CESC	cis	rs6570726	0.791	rs1509214	chr6:145784606	A/C	cg05347473	chr6:146136440	FBXO30	-0.51	-6.3	-0.36	1.23e-9	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2404602	0.716	rs8030411	chr15:76699855	A/G	cg22467129	chr15:76604101	ETFA	-0.4	-5.97	-0.34	7.64e-9	Blood metabolite levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05043431	chr1:229406934	RAB4A	0.61	7.02	0.4	1.86e-11	Gut microbiome composition (summer);
CESC	cis	rs910316	0.874	rs61980828	chr14:75630378	G/A	cg11812906	chr14:75593930	NEK9	-0.9	-14.84	-0.67	1.12e-36	Height;
CESC	trans	rs10743315	0.557	rs74669613	chr12:19313696	T/C	cg09562322	chr12:119419143	SRRM4	-0.47	-6.08	-0.35	4.07e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs4664308	0.837	rs56172865	chr2:160967333	C/T	cg03641300	chr2:160917029	PLA2R1	-0.64	-9.44	-0.5	2.04e-18	Idiopathic membranous nephropathy;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg11310629	chr13:45991975	SLC25A30	-0.43	-6.54	-0.37	3.21e-10	Gambling;
CESC	cis	rs4803468	1.000	rs10417311	chr19:41902038	G/A	cg14132834	chr19:41945861	ATP5SL	-0.65	-8.13	-0.45	1.69e-14	Height;
CESC	cis	rs910316	0.789	rs175444	chr14:75601782	G/C	cg11812906	chr14:75593930	NEK9	-0.82	-13.27	-0.63	3.72e-31	Height;
CESC	trans	rs12659622	0.703	rs74655962	chr5:15680745	G/A	cg22457238	chr19:58570995	ZNF135	-0.59	-6.41	-0.37	6.65e-10	Obesity-related traits;
CESC	cis	rs72829446	0.530	rs9891297	chr17:7385204	T/C	cg02795151	chr17:7402630	POLR2A	0.55	5.86	0.34	1.41e-8	Androgen levels;
CESC	cis	rs7666738	0.830	rs3857217	chr4:99034347	T/C	cg05340658	chr4:99064831	C4orf37	0.83	12.92	0.62	5.86e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7259965	0.920	rs10853744	chr19:41521939	G/T	cg27089200	chr19:41531976	NA	0.35	5.31	0.31	2.31e-7	Midgestational circulating levels of PBDEs;Midgestational circulating levels of organochlorine pesticides;
CESC	cis	rs736408	0.609	rs13061423	chr3:52790213	T/C	cg18099408	chr3:52552593	STAB1	-0.31	-5.07	-0.3	7.49e-7	Bipolar disorder;
CESC	cis	rs9488822	0.676	rs12154016	chr6:116355188	C/T	cg05304507	chr6:116381966	FRK	0.26	6.71	0.38	1.2e-10	Cholesterol, total;LDL cholesterol;
CESC	cis	rs6087990	0.965	rs742630	chr20:31350664	C/G	cg13636640	chr20:31349939	DNMT3B	0.93	16.67	0.72	3.77e-43	Ulcerative colitis;
CESC	cis	rs7615952	0.673	rs3811677	chr3:125648080	G/A	cg05084668	chr3:125655381	ALG1L	-0.51	-5.99	-0.35	6.79e-9	Blood pressure (smoking interaction);
CESC	cis	rs2032447	0.714	rs129129	chr6:25961029	A/G	cg12310025	chr6:25882481	NA	-0.45	-6.74	-0.38	9.75e-11	Intelligence (multi-trait analysis);
CESC	cis	rs4819052	0.851	rs875621	chr21:46682295	A/G	cg11663144	chr21:46675770	NA	-0.61	-9.55	-0.51	9.13e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs35110281	0.782	rs2838329	chr21:45023329	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.53	6.92	0.39	3.33e-11	Mean corpuscular volume;
CESC	cis	rs34779708	0.931	rs10466072	chr10:35402756	C/T	cg04310649	chr10:35416472	CREM	-0.54	-6.47	-0.37	4.62e-10	Inflammatory bowel disease;Crohn's disease;
CESC	trans	rs8135828	0.770	rs5763306	chr22:29930578	C/A	cg17961835	chr3:126195582	ZXDC	-0.45	-6.03	-0.35	5.35e-9	Lipid traits;
CESC	cis	rs2228479	0.681	rs7199685	chr16:89959805	G/C	cg04013166	chr16:89971882	TCF25	0.72	8.83	0.48	1.51e-16	Skin colour saturation;
CESC	cis	rs7973683	0.541	rs12309481	chr12:124389150	C/A	cg00084347	chr12:124393913	DNAH10	0.28	5.71	0.33	3.09e-8	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
CESC	cis	rs863345	0.604	rs1873509	chr1:158461563	A/G	cg12129480	chr1:158549410	OR10X1	0.35	7.07	0.4	1.38e-11	Pneumococcal bacteremia;
CESC	cis	rs2730245	0.550	rs2709860	chr7:158651156	A/T	cg01943577	chr7:158741284	NA	-0.43	-5.71	-0.33	2.95e-8	Height;
CESC	cis	rs9911578	0.835	rs9904993	chr17:56468569	G/T	cg12560992	chr17:57184187	TRIM37	-0.87	-14.29	-0.66	9.86e-35	Intelligence (multi-trait analysis);
CESC	cis	rs477895	0.838	rs1058735	chr11:64000410	C/G	cg04317338	chr11:64019027	PLCB3	0.9	10.09	0.53	1.82e-20	Mean platelet volume;
CESC	cis	rs1862618	0.853	rs832578	chr5:56164223	C/T	cg18230493	chr5:56204884	C5orf35	-0.73	-8.89	-0.48	9.77e-17	Initial pursuit acceleration;
CESC	cis	rs55883249	1.000	rs75139639	chr2:9763905	A/T	cg23886495	chr2:9695866	ADAM17	0.61	5.51	0.32	8.64e-8	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
CESC	cis	rs910316	0.737	rs175072	chr14:75502827	T/C	cg16144293	chr14:75469539	EIF2B2	0.4	5.36	0.31	1.8e-7	Height;
CESC	cis	rs854765	0.583	rs28428991	chr17:17827649	C/T	cg09796270	chr17:17721594	SREBF1	0.43	6.05	0.35	4.93e-9	Total body bone mineral density;
CESC	cis	rs793571	0.568	rs6494029	chr15:58923206	T/C	cg05156742	chr15:59063176	FAM63B	0.75	10.68	0.55	2.23e-22	Schizophrenia;
CESC	cis	rs2708240	1.000	rs7806519	chr7:147574574	C/T	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.35	-5.78	-0.33	2.06e-8	QT interval (drug interaction);
CESC	cis	rs853679	0.766	rs9368561	chr6:28168343	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.75	-6.47	-0.37	4.62e-10	Depression;
CESC	cis	rs1165640	0.522	rs554880	chr3:193552879	G/A	cg21197336	chr3:193587490	NA	-0.49	-5.31	-0.31	2.31e-7	Smoking cessation in chronic obstructive pulmonary disease;
CESC	cis	rs6502050	0.835	rs62078306	chr17:80085341	A/G	cg23985595	chr17:80112537	CCDC57	0.42	6.63	0.38	1.9e-10	Life satisfaction;
CESC	cis	rs7772486	0.754	rs6915718	chr6:146100676	A/G	cg23711669	chr6:146136114	FBXO30	-0.99	-15.26	-0.68	3.83e-38	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2841277	0.738	rs1036713	chr14:105396693	C/G	cg15352829	chr14:105391018	PLD4	0.4	6.29	0.36	1.33e-9	Rheumatoid arthritis;
CESC	cis	rs2180341	1.000	rs6904520	chr6:127629802	T/C	cg27446573	chr6:127587934	RNF146	1.09	16.33	0.71	5.73e-42	Breast cancer;
CESC	trans	rs4689592	0.546	rs10937784	chr4:7060935	G/C	cg07817883	chr1:32538562	TMEM39B	-0.53	-6.3	-0.36	1.24e-9	Monocyte percentage of white cells;
CESC	cis	rs10129255	0.500	rs2027903	chr14:107215283	A/C	cg23076370	chr14:107095027	NA	-0.71	-10.98	-0.56	2.23e-23	Kawasaki disease;
CESC	cis	rs992157	0.767	rs2014615	chr2:219171191	A/G	cg00012203	chr2:219082015	ARPC2	0.73	9.89	0.52	7.98e-20	Colorectal cancer;
CESC	cis	rs12893668	0.542	rs12884809	chr14:104095320	G/A	cg19000871	chr14:103996768	TRMT61A	-0.33	-5.09	-0.3	6.69e-7	Reticulocyte count;
CESC	cis	rs2594989	0.837	rs2454497	chr3:11501597	T/C	cg00170343	chr3:11313890	ATG7	0.56	5.1	0.3	6.55e-7	Circulating chemerin levels;
CESC	cis	rs7582720	1.000	rs77931721	chr2:203763076	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.39	0.41	1.96e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs1728785	1.000	rs864742	chr16:68575309	T/C	cg02972257	chr16:68554789	NA	-0.55	-6.31	-0.36	1.17e-9	Ulcerative colitis;
CESC	cis	rs2075371	1.000	rs1421485	chr7:133985181	C/T	cg20476274	chr7:133979776	SLC35B4	0.65	9.41	0.5	2.53e-18	Mean platelet volume;
CESC	cis	rs6933660	0.745	rs3778608	chr6:151738131	A/G	cg14262678	chr6:151773367	RMND1;C6orf211	0.66	9.43	0.5	2.09e-18	Menarche (age at onset);
CESC	trans	rs6572548	0.504	rs1956082	chr14:49665496	A/C	cg11594892	chr1:150849332	ARNT	-0.53	-6.28	-0.36	1.38e-9	Subjective well-being;
CESC	cis	rs9894429	1.000	rs7406003	chr17:79597597	C/T	cg13777783	chr17:79615861	NA	-0.34	-5.65	-0.33	4.22e-8	Eye color traits;
CESC	cis	rs2652822	0.571	rs62012880	chr15:63527162	A/G	cg02713581	chr15:63449717	RPS27L	0.45	5.56	0.32	6.53e-8	Metabolic traits;
CESC	cis	rs35110281	0.687	rs4819284	chr21:45084548	C/T	cg01579765	chr21:45077557	HSF2BP	-0.48	-8.03	-0.44	3.1e-14	Mean corpuscular volume;
CESC	cis	rs28374715	0.532	rs7164211	chr15:41705041	A/T	cg20272979	chr15:41787780	ITPKA	0.44	5.64	0.33	4.34e-8	Ulcerative colitis;
CESC	cis	rs11122272	0.735	rs2739515	chr1:231514681	G/A	cg06096015	chr1:231504339	EGLN1	0.43	6.18	0.35	2.46e-9	Hemoglobin concentration;
CESC	cis	rs9488822	0.636	rs11153592	chr6:116330574	T/C	cg18764771	chr6:116381957	FRK	0.22	5.37	0.31	1.68e-7	Cholesterol, total;LDL cholesterol;
CESC	cis	rs2625529	0.617	rs2128112	chr15:72186286	A/T	cg16672083	chr15:72433130	SENP8	0.46	6.79	0.38	7.52e-11	Red blood cell count;
CESC	cis	rs7084402	1.000	rs34774248	chr10:60269691	A/G	cg07615347	chr10:60278583	BICC1	-0.57	-8.71	-0.47	3.43e-16	Refractive error;
CESC	cis	rs6120849	0.901	rs6060273	chr20:33744323	G/C	cg24642439	chr20:33292090	TP53INP2	0.6	6.4	0.37	6.87e-10	Protein C levels;
CESC	trans	rs916888	0.821	rs199506	chr17:44859031	A/G	cg10053473	chr17:62856997	LRRC37A3	0.64	6.98	0.39	2.43e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs2522056	0.935	rs757104	chr5:131795229	T/C	cg07395648	chr5:131743802	NA	0.44	5.08	0.3	6.96e-7	Lymphocyte counts;Fibrinogen;
CESC	cis	rs4253772	0.938	rs41427746	chr22:46637239	T/C	cg24881330	chr22:46731750	TRMU	0.6	5.44	0.32	1.18e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs9287719	0.934	rs6727884	chr2:10757557	C/T	cg02196655	chr2:10830764	NOL10	0.35	5.35	0.31	1.95e-7	Prostate cancer;
CESC	cis	rs4481887	0.790	rs7546964	chr1:248414960	A/G	cg00666640	chr1:248458726	OR2T12	0.34	5.9	0.34	1.08e-8	Common traits (Other);
CESC	cis	rs3785574	0.743	rs2727334	chr17:61969063	A/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.03	16.25	0.71	1.1e-41	Height;
CESC	cis	rs1670533	1.000	rs10084849	chr4:1053586	T/C	cg04106633	chr4:1044584	NA	0.41	5.2	0.3	3.94e-7	Recombination rate (females);
CESC	cis	rs7107174	0.901	rs2510053	chr11:77959435	T/C	cg02023728	chr11:77925099	USP35	0.39	5.69	0.33	3.4e-8	Testicular germ cell tumor;
CESC	cis	rs2404602	0.692	rs57178708	chr15:76904069	T/C	cg22467129	chr15:76604101	ETFA	-0.36	-5.29	-0.31	2.53e-7	Blood metabolite levels;
CESC	cis	rs6088590	0.687	rs13044899	chr20:33287078	G/A	cg24642439	chr20:33292090	TP53INP2	0.66	8.4	0.46	2.74e-15	Coronary artery disease;
CESC	cis	rs1348850	0.918	rs12463893	chr2:178448559	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.61	8.41	0.46	2.51e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs72781680	0.611	rs2303289	chr2:24342242	C/G	cg06627628	chr2:24431161	ITSN2	0.66	6.25	0.36	1.62e-9	Lymphocyte counts;
CESC	trans	rs877282	0.898	rs12356709	chr10:763365	A/G	cg22713356	chr15:30763199	NA	1.16	11.35	0.57	1.37e-24	Uric acid levels;
CESC	cis	rs2933343	0.700	rs789238	chr3:128636715	A/G	cg25356066	chr3:128598488	ACAD9	0.58	7.93	0.44	6.33e-14	IgG glycosylation;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg12857786	chr4:83934023	LIN54	-0.48	-6.09	-0.35	4.01e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs713587	0.935	rs11676272	chr2:25141538	A/G	cg01884057	chr2:25150051	NA	0.42	7.91	0.44	6.96e-14	Body mass index in non-asthmatics;
CESC	cis	rs2635047	0.600	rs2635056	chr18:44710568	G/A	cg24371990	chr18:44770781	NA	0.32	5.15	0.3	5.03e-7	Educational attainment;
CESC	cis	rs9583531	0.600	rs9521909	chr13:111362170	A/G	cg24331049	chr13:111365604	ING1	0.75	10.98	0.56	2.28e-23	Coronary artery disease;
CESC	cis	rs17095355	0.901	rs9783184	chr10:111760499	T/G	cg00817464	chr10:111662876	XPNPEP1	-0.52	-5.99	-0.35	6.73e-9	Biliary atresia;
CESC	cis	rs875971	0.862	rs6971059	chr7:66067032	A/G	cg18252515	chr7:66147081	NA	0.47	6.17	0.35	2.57e-9	Aortic root size;
CESC	cis	rs1800469	1.000	rs1800469	chr19:41860296	A/G	cg08477640	chr19:41863820	B9D2	0.63	8.36	0.46	3.6e-15	Colorectal cancer;
CESC	cis	rs7103648	0.897	rs3758675	chr11:47400602	G/A	cg03711944	chr11:47377212	SPI1	-0.39	-6.06	-0.35	4.76e-9	Diastolic blood pressure;Systolic blood pressure;
CESC	cis	rs2576037	0.583	rs9304336	chr18:44461687	T/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.33	5.28	0.31	2.71e-7	Personality dimensions;
CESC	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg18402987	chr7:1209562	NA	0.75	7.57	0.42	6.17e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2120019	0.938	rs2289582	chr15:75310394	T/C	cg17294928	chr15:75287854	SCAMP5	-0.73	-8.52	-0.46	1.18e-15	Blood trace element (Zn levels);
CESC	cis	rs2235642	0.893	rs2076445	chr16:1592266	A/T	cg07639376	chr16:1584516	IFT140;TMEM204	-0.34	-5.51	-0.32	8.57e-8	Coronary artery disease;
CESC	cis	rs6594499	0.872	rs6859041	chr5:110435231	G/A	cg04022379	chr5:110408740	TSLP	0.34	6.2	0.36	2.15e-9	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs739401	0.572	rs12276060	chr11:3015572	A/T	cg08508325	chr11:3079039	CARS	-0.54	-10.31	-0.53	3.66e-21	Longevity;
CESC	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	10.55	0.54	6.12e-22	Prudent dietary pattern;
CESC	cis	rs9549367	0.865	rs9549366	chr13:113907644	G/A	cg00898013	chr13:113819073	PROZ	-0.52	-7.45	-0.42	1.31e-12	Platelet distribution width;
CESC	cis	rs6987853	0.736	rs35295075	chr8:42428852	A/G	cg09913449	chr8:42400586	C8orf40	0.47	7.89	0.44	8.14e-14	Mean corpuscular hemoglobin concentration;
CESC	cis	rs7208859	0.623	rs216423	chr17:28942109	G/C	cg14008862	chr17:28927542	LRRC37B2	0.7	6.36	0.36	8.84e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01181084	chr8:43059863	NA	-0.56	-6.07	-0.35	4.38e-9	Gut microbiome composition (summer);
CESC	cis	rs35123781	1.000	rs601728	chr5:139057076	T/C	cg10513866	chr5:139070639	NA	0.37	5.37	0.31	1.75e-7	Schizophrenia;
CESC	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	22.36	0.81	6.07e-63	Prudent dietary pattern;
CESC	cis	rs2286503	0.780	rs929464	chr7:22874770	T/C	cg13679077	chr7:22862647	TOMM7	0.59	7.55	0.42	7.17e-13	Fibrinogen;
CESC	cis	rs11098499	0.865	rs11098513	chr4:120316075	A/G	cg24375607	chr4:120327624	NA	0.46	5.59	0.32	5.52e-8	Corneal astigmatism;
CESC	cis	rs10911232	0.507	rs4266836	chr1:183029070	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.86	13.28	0.63	3.52e-31	Hypertriglyceridemia;
CESC	cis	rs6500395	0.928	rs4553627	chr16:48708801	A/T	cg04672837	chr16:48644449	N4BP1	-0.52	-6.64	-0.38	1.75e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs4803468	0.935	rs12602	chr19:41889748	T/C	cg09537434	chr19:41945824	ATP5SL	-1.07	-18.75	-0.76	1.72e-50	Height;
CESC	cis	rs2066819	1.000	rs57279772	chr12:56698960	G/A	cg26714650	chr12:56694279	CS	-1.52	-10.39	-0.54	1.95e-21	Psoriasis vulgaris;
CESC	cis	rs1005277	0.579	rs1780121	chr10:38529437	C/A	cg00409905	chr10:38381863	ZNF37A	-0.51	-6.77	-0.38	8.46e-11	Extrinsic epigenetic age acceleration;
CESC	cis	rs736408	0.812	rs1075653	chr3:52825528	T/C	cg18404041	chr3:52824283	ITIH1	-0.5	-8.26	-0.45	7.16e-15	Bipolar disorder;
CESC	cis	rs8067545	0.586	rs2526478	chr17:20130452	A/G	cg13482628	chr17:19912719	NA	0.43	5.65	0.33	4.18e-8	Schizophrenia;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg16406212	chr2:24163862	UBXN2A	0.45	6.15	0.35	2.87e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs7666738	0.830	rs28852677	chr4:99039509	T/G	cg03467027	chr4:99064603	C4orf37	0.47	5.98	0.34	7.19e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.64	7.45	0.42	1.33e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg07308232	chr7:1071921	C7orf50	-0.45	-6.04	-0.35	5.3e-9	Longevity;Endometriosis;
CESC	cis	rs9399135	0.935	rs6908681	chr6:135337733	A/G	cg24558204	chr6:135376177	HBS1L	0.52	7.18	0.4	7.05e-12	Red blood cell count;
CESC	cis	rs13118159	0.550	rs10016557	chr4:1363628	C/T	cg02475777	chr4:1388615	CRIPAK	-0.56	-7.05	-0.4	1.53e-11	Longevity;
CESC	cis	rs2731664	0.756	rs2545796	chr5:176864269	T/C	cg23176889	chr5:176863531	GRK6	-0.64	-11.1	-0.56	9.37e-24	Intelligence (multi-trait analysis);
CESC	cis	rs17253792	0.822	rs75509578	chr14:56133493	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.81	6.25	0.36	1.67e-9	Putamen volume;
CESC	cis	rs853679	0.517	rs4713135	chr6:28039586	G/A	cg26335602	chr6:28129616	ZNF389	0.53	6.89	0.39	4.07e-11	Depression;
CESC	cis	rs853679	0.546	rs200989	chr6:27816442	A/G	cg26587870	chr6:27730563	NA	-0.59	-5.24	-0.31	3.26e-7	Depression;
CESC	cis	rs1185460	1.000	rs7127212	chr11:118953202	A/G	cg23280166	chr11:118938394	VPS11	-0.5	-6.62	-0.38	1.95e-10	Coronary artery disease;
CESC	cis	rs2576037	0.526	rs642897	chr18:44396917	T/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.42	6.89	0.39	3.96e-11	Personality dimensions;
CESC	cis	rs875971	0.830	rs6976714	chr7:65891461	G/A	cg18876405	chr7:65276391	NA	0.52	7.09	0.4	1.24e-11	Aortic root size;
CESC	cis	rs8180040	0.726	rs13094672	chr3:47149439	C/T	cg27129171	chr3:47204927	SETD2	0.7	10.5	0.54	8.74e-22	Colorectal cancer;
CESC	cis	rs875971	0.862	rs10950033	chr7:65739673	A/G	cg12463550	chr7:65579703	CRCP	-0.45	-5.72	-0.33	2.86e-8	Aortic root size;
CESC	cis	rs35123781	0.696	rs10067965	chr5:139071353	T/C	cg10513866	chr5:139070639	NA	0.44	6.35	0.36	9.27e-10	Schizophrenia;
CESC	cis	rs6582630	0.638	rs10880620	chr12:38517467	A/G	cg26384229	chr12:38710491	ALG10B	-0.44	-5.97	-0.34	7.7e-9	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs748404	0.650	rs556851	chr15:43571219	A/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.6	7.99	0.44	4.21e-14	Lung cancer;
CESC	cis	rs4604732	0.631	rs10754561	chr1:247622800	A/G	cg12758973	chr1:247694275	LOC148824;OR2C3	0.45	6.46	0.37	5e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs10504229	0.817	rs114173899	chr8:58170640	G/T	cg24829409	chr8:58192753	C8orf71	-0.76	-10.0	-0.52	3.39e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs965469	0.779	rs2236103	chr20:3276821	A/G	cg25506879	chr20:3388711	C20orf194	0.47	5.11	0.3	6.12e-7	IFN-related cytopenia;
CESC	trans	rs1814175	0.645	rs847639	chr11:49919603	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.43	-6.36	-0.36	8.98e-10	Height;
CESC	cis	rs476633	0.708	rs28656781	chr15:41447440	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.61	-9.0	-0.48	4.54e-17	Glomerular filtration rate (creatinine);
CESC	cis	rs7666738	0.830	rs35951881	chr4:98999474	A/C	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.62e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4563143	0.675	rs56293553	chr19:29270455	A/G	cg04546413	chr19:29218101	NA	0.56	7.91	0.44	6.84e-14	Methadone dose in opioid dependence;
CESC	cis	rs1153858	1.000	rs2461701	chr15:45703391	G/A	cg21132104	chr15:45694354	SPATA5L1	0.76	10.15	0.53	1.12e-20	Homoarginine levels;
CESC	cis	rs7615952	0.599	rs6438955	chr3:125730333	C/A	cg15145296	chr3:125709740	NA	-0.46	-5.19	-0.3	4.14e-7	Blood pressure (smoking interaction);
CESC	trans	rs1547374	0.694	rs225349	chr21:43776890	C/T	cg09521743	chr10:75415752	SYNPO2L	0.5	6.93	0.39	3.12e-11	Pancreatic cancer;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg20552752	chr15:90895281	ZNF774	-0.45	-6.33	-0.36	1.03e-9	Height;
CESC	cis	rs1707322	0.964	rs785509	chr1:46527300	G/A	cg05343316	chr1:45956843	TESK2	-0.42	-5.05	-0.3	8.16e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs4984778	0.750	rs7198064	chr16:1272472	C/T	cg07748719	chr16:1272498	TPSG1	0.81	12.6	0.61	7.74e-29	Blood protein levels;
CESC	cis	rs668210	0.739	rs543952	chr11:65744275	T/C	cg02202077	chr11:65769826	EIF1AD;BANF1	0.68	7.36	0.41	2.3e-12	Cerebrospinal fluid biomarker levels;
CESC	trans	rs2270927	1.000	rs4546360	chr5:75577563	T/C	cg13563193	chr19:33072644	PDCD5	0.76	6.27	0.36	1.45e-9	Mean corpuscular volume;
CESC	cis	rs523522	0.962	rs2393590	chr12:120913900	G/A	cg27279351	chr12:120934652	DYNLL1	0.67	8.73	0.47	2.89e-16	High light scatter reticulocyte count;
CESC	cis	rs853679	0.517	rs9357065	chr6:28129580	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.57	-6.47	-0.37	4.74e-10	Depression;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00171578	chr1:147789747	NA	-0.68	-8.67	-0.47	4.34e-16	Gut microbiome composition (summer);
CESC	cis	rs12534701	1.000	rs12534701	chr7:154680910	A/C	cg24255201	chr7:154684926	DPP6	-0.47	-6.56	-0.37	2.88e-10	Colorectal cancer (diet interaction);
CESC	cis	rs12476592	0.602	rs262472	chr2:63833616	G/A	cg17519650	chr2:63277830	OTX1	-0.45	-5.12	-0.3	5.75e-7	Childhood ear infection;
CESC	cis	rs875971	0.660	rs801193	chr7:66030612	A/C	cg14393609	chr7:65229607	NA	-0.5	-6.83	-0.39	5.81e-11	Aortic root size;
CESC	cis	rs9457247	0.967	rs1794696	chr6:167396174	T/C	cg23791538	chr6:167370224	RNASET2	-0.58	-8.22	-0.45	9.24e-15	Crohn's disease;
CESC	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg11965913	chr1:205819406	PM20D1	0.79	12.71	0.62	3.15e-29	Menarche (age at onset);
CESC	cis	rs2425143	0.818	rs7272684	chr20:34424692	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.63	5.22	0.31	3.67e-7	Blood protein levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18073423	chr4:9514864	NA	-0.5	-6.14	-0.35	3e-9	Gut microbiome composition (summer);
CESC	cis	rs7772486	0.743	rs9403742	chr6:146060193	A/C	cg05347473	chr6:146136440	FBXO30	0.5	6.57	0.37	2.73e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2635047	0.875	rs2635040	chr18:44640972	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.49	6.5	0.37	3.9e-10	Educational attainment;
CESC	cis	rs11122272	0.735	rs2790886	chr1:231529491	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.56	-7.66	-0.43	3.45e-13	Hemoglobin concentration;
CESC	cis	rs9300255	0.602	rs1716177	chr12:123655457	C/T	cg05973401	chr12:123451056	ABCB9	0.54	6.04	0.35	5.31e-9	Neutrophil percentage of white cells;
CESC	cis	rs11209002	0.592	rs4655672	chr1:67553543	C/T	cg02640540	chr1:67518911	SLC35D1	0.45	5.13	0.3	5.47e-7	Crohn's disease;
CESC	cis	rs1546924	0.570	rs197412	chr1:112308953	T/C	cg23955903	chr1:112298873	DDX20;C1orf183	0.43	5.55	0.32	6.88e-8	Body mass index;
CESC	cis	rs769267	0.899	rs3934667	chr19:19431423	T/G	cg17414380	chr19:19431394	KIAA0892;SF4	-0.47	-5.81	-0.34	1.77e-8	Tonsillectomy;
CESC	cis	rs1401999	1.000	rs6804242	chr3:183659463	A/T	cg01324343	chr3:183735012	ABCC5	0.64	13.44	0.64	9.36e-32	Anterior chamber depth;
CESC	trans	rs61931739	1.000	rs1852223	chr12:34013251	C/T	cg26384229	chr12:38710491	ALG10B	-0.45	-6.23	-0.36	1.87e-9	Morning vs. evening chronotype;
CESC	cis	rs3796352	1.000	rs13092352	chr3:52969697	C/T	cg12962167	chr3:53033115	SFMBT1	0.6	5.09	0.3	6.95e-7	Immune reponse to smallpox (secreted IL-2);
CESC	cis	rs782590	0.764	rs2054728	chr2:55818419	C/T	cg18811423	chr2:55921094	PNPT1	0.76	12.05	0.59	6.03e-27	Metabolic syndrome;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24103461	chr1:205091125	RBBP5	0.58	6.66	0.38	1.59e-10	Gut microbiome composition (summer);
CESC	cis	rs17711722	0.522	rs6957759	chr7:65271785	A/G	cg12143784	chr7:64541923	NA	0.37	5.13	0.3	5.63e-7	Calcium levels;
CESC	cis	rs752010	0.619	rs10789406	chr1:42105182	G/T	cg06885757	chr1:42089581	HIVEP3	-0.48	-7.98	-0.44	4.53e-14	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs6496667	0.533	rs2074584	chr15:91009381	C/T	cg22089800	chr15:90895588	ZNF774	0.44	5.63	0.33	4.61e-8	Rheumatoid arthritis;
CESC	cis	rs875971	1.000	rs2036264	chr7:65799904	G/A	cg18876405	chr7:65276391	NA	-0.5	-6.83	-0.39	5.93e-11	Aortic root size;
CESC	cis	rs7503807	1.000	rs12936076	chr17:78601195	C/T	cg09596252	chr17:78655493	RPTOR	0.54	7.96	0.44	5.16e-14	Obesity;
CESC	cis	rs2345546	1	rs2345546	chr16:25427472	C/T	cg08360281	chr16:25269390	ZKSCAN2	1.05	10.13	0.53	1.33e-20	Major depression and alcohol dependence;
CESC	trans	rs7615952	1.000	rs7616044	chr3:125649354	G/C	cg07211511	chr3:129823064	LOC729375	-1.11	-15.63	-0.69	1.81e-39	Blood pressure (smoking interaction);
CESC	cis	rs9287719	0.781	rs6714795	chr2:10759134	C/T	cg02196655	chr2:10830764	NOL10	-0.36	-5.59	-0.32	5.58e-8	Prostate cancer;
CESC	cis	rs1670533	1.000	rs6839931	chr4:1053172	A/G	cg04106633	chr4:1044584	NA	0.41	5.32	0.31	2.25e-7	Recombination rate (females);
CESC	cis	rs12586317	0.547	rs10130773	chr14:35445299	G/A	cg16230307	chr14:35515116	FAM177A1	0.96	10.66	0.55	2.55e-22	Psoriasis;
CESC	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg10351095	chr21:47802916	PCNT	-0.45	-6.22	-0.36	1.9e-9	Testicular germ cell tumor;
CESC	cis	rs2274273	0.840	rs66486619	chr14:55869555	T/G	cg04306507	chr14:55594613	LGALS3	0.27	5.3	0.31	2.44e-7	Protein biomarker;
CESC	cis	rs6831352	0.918	rs17218073	chr4:100055739	G/A	cg13256891	chr4:100009986	ADH5	-0.77	-8.45	-0.46	1.97e-15	Alcohol dependence;
CESC	cis	rs861020	0.630	rs628300	chr1:209998298	C/T	cg09163369	chr1:210001066	C1orf107	0.4	5.2	0.3	3.91e-7	Orofacial clefts;
CESC	cis	rs7833790	0.660	rs1451995	chr8:82746123	G/C	cg17211192	chr8:82754475	SNX16	0.52	6.64	0.38	1.73e-10	Diastolic blood pressure;
CESC	cis	rs10744422	0.858	rs10773627	chr12:123311853	A/G	cg25930673	chr12:123319894	HIP1R	-0.65	-5.28	-0.31	2.72e-7	Schizophrenia;
CESC	cis	rs2070433	0.756	rs9637220	chr21:47887436	T/C	cg12379764	chr21:47803548	PCNT	0.52	6.31	0.36	1.18e-9	Lymphocyte counts;
CESC	cis	rs7707921	0.671	rs2406911	chr5:81312256	A/G	cg15871215	chr5:81402204	ATG10	0.38	5.49	0.32	9.54e-8	Breast cancer;
CESC	cis	rs6429082	0.715	rs2291687	chr1:235594182	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.54	-6.91	-0.39	3.65e-11	Adiposity;
CESC	cis	rs13223928	0.651	rs4722426	chr7:3150697	C/T	cg19214707	chr7:3157722	NA	0.44	6.02	0.35	5.65e-9	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
CESC	cis	rs3818285	0.679	rs2475275	chr10:111633979	C/T	cg00817464	chr10:111662876	XPNPEP1	0.43	6.61	0.38	2.16e-10	Superior crus of antihelix expression;
CESC	cis	rs5995756	0.761	rs6001637	chr22:40001083	A/G	cg03390717	chr22:39966585	CACNA1I	-0.35	-6.15	-0.35	2.79e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs7267979	0.866	rs2424699	chr20:25257462	G/A	cg08601574	chr20:25228251	PYGB	0.38	5.35	0.31	1.9e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs9581857	0.685	rs9319369	chr13:28042323	A/T	cg01674679	chr13:27998804	GTF3A	-0.69	-5.53	-0.32	7.63e-8	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
CESC	cis	rs17761864	0.762	rs11658881	chr17:2072949	A/G	cg16513277	chr17:2031491	SMG6	0.42	5.28	0.31	2.75e-7	Esophageal cancer (squamous cell);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12056857	chr12:100593408	ACTR6	0.55	6.54	0.37	3.13e-10	Gut microbiome composition (summer);
CESC	cis	rs17433780	0.808	rs12122780	chr1:89508916	T/C	cg09516651	chr1:89888402	LOC400759	0.7	10.7	0.55	1.94e-22	Carotid intima media thickness;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg12970008	chr11:3186095	OSBPL5	0.43	6.07	0.35	4.41e-9	Systemic lupus erythematosus;
CESC	cis	rs12497850	0.829	rs12636030	chr3:49182237	A/G	cg07636037	chr3:49044803	WDR6	1.06	18.4	0.75	2.81e-49	Parkinson's disease;
CESC	cis	rs2279817	0.865	rs35255680	chr1:17981184	A/C	cg21791023	chr1:18019539	ARHGEF10L	-0.55	-7.13	-0.4	9.39e-12	Neuroticism;
CESC	cis	rs9302635	0.513	rs12444701	chr16:72155240	C/T	cg16558253	chr16:72132732	DHX38	-0.46	-6.04	-0.35	5.09e-9	Blood protein levels;
CESC	cis	rs10927875	0.793	rs1763619	chr1:16326935	A/G	cg22431228	chr1:16359049	CLCNKA	-0.49	-8.17	-0.45	1.27e-14	Dilated cardiomyopathy;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg21810621	chr11:1331345	LOC255512;TOLLIP	-0.45	-6.33	-0.36	1.04e-9	Fibrinogen levels;
CESC	cis	rs9311474	0.539	rs12489828	chr3:52567014	G/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.34	6.58	0.37	2.55e-10	Electroencephalogram traits;
CESC	cis	rs2273669	0.667	rs10457187	chr6:109336051	G/A	cg05315195	chr6:109294784	ARMC2	-0.67	-6.32	-0.36	1.13e-9	Prostate cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26567788	chr11:118401236	TMEM25;TTC36	-0.64	-7.5	-0.42	9.81e-13	Gut microbiome composition (summer);
CESC	cis	rs9300255	0.537	rs2682429	chr12:123642955	C/G	cg19016782	chr12:123741754	C12orf65	-0.4	-5.77	-0.33	2.27e-8	Neutrophil percentage of white cells;
CESC	trans	rs1814175	0.669	rs11040473	chr11:49703813	C/T	cg15704280	chr7:45808275	SEPT13	-0.83	-11.53	-0.58	3.31e-25	Height;
CESC	cis	rs662064	0.925	rs597438	chr1:10554505	A/G	cg20482658	chr1:10539492	PEX14	-0.4	-8.37	-0.46	3.4e-15	Asthma;
CESC	cis	rs6089584	0.893	rs6089306	chr20:60574868	G/A	cg13770153	chr20:60521292	NA	-0.46	-6.0	-0.35	6.55e-9	Body mass index;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09391093	chr10:38265555	ZNF25	-0.62	-6.9	-0.39	3.88e-11	Gut microbiome composition (summer);
CESC	trans	rs6495367	1.000	rs3851677	chr15:79380869	C/T	cg01071459	chr5:92939654	NA	0.38	6.13	0.35	3.25e-9	Spherical equivalent (joint analysis main effects and education interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20715365	chr17:73900573	MRPL38	0.53	6.02	0.35	5.9e-9	Gut microbiome composition (summer);
CESC	cis	rs8177179	0.967	rs4443173	chr3:133439378	A/G	cg16262614	chr3:133464971	TF	0.4	7.83	0.43	1.18e-13	Iron status biomarkers (transferrin levels);
CESC	cis	rs72781680	0.848	rs56371415	chr2:23932603	C/G	cg08917208	chr2:24149416	ATAD2B	1.09	10.09	0.53	1.85e-20	Lymphocyte counts;
CESC	cis	rs12477438	0.798	rs10202452	chr2:99569409	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-10.65	-0.55	2.75e-22	Chronic sinus infection;
CESC	cis	rs2072732	0.861	rs6692292	chr1:2959610	C/T	cg03976712	chr1:2946727	NA	-0.31	-5.25	-0.31	3.13e-7	Plateletcrit;
CESC	cis	rs35306767	0.903	rs61833260	chr10:975148	T/G	cg20503657	chr10:835505	NA	0.84	8.61	0.47	6.52e-16	Eosinophil percentage of granulocytes;
CESC	cis	rs7953249	0.656	rs2178463	chr12:121389721	A/G	cg25281562	chr12:121454272	C12orf43	-0.46	-5.78	-0.33	2.12e-8	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
CESC	cis	rs769267	0.899	rs67720221	chr19:19440864	C/T	cg03709012	chr19:19516395	GATAD2A	-0.95	-13.78	-0.65	6.29e-33	Tonsillectomy;
CESC	cis	rs704795	0.867	rs7566052	chr2:27628635	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.34	-6.24	-0.36	1.68e-9	Menopause (age at onset);
CESC	cis	rs1799949	0.930	rs3765640	chr17:41276247	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.67	9.34	0.5	3.98e-18	Menopause (age at onset);
CESC	cis	rs9649213	0.593	rs13246942	chr7:97915021	C/T	cg08684580	chr7:98029266	BAIAP2L1	-0.33	-5.13	-0.3	5.56e-7	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11942548	chr13:22248814	FGF9	-0.57	-6.19	-0.36	2.31e-9	Gut microbiome composition (summer);
CESC	cis	rs6831352	0.918	rs29001231	chr4:100046680	T/C	cg13256891	chr4:100009986	ADH5	-0.77	-8.43	-0.46	2.27e-15	Alcohol dependence;
CESC	cis	rs6460942	0.908	rs77799203	chr7:12264432	C/G	cg06484146	chr7:12443880	VWDE	-0.58	-6.08	-0.35	4.22e-9	Coronary artery disease;
CESC	cis	rs7772486	0.846	rs2892453	chr6:146377717	C/A	cg05347473	chr6:146136440	FBXO30	0.49	6.67	0.38	1.51e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg05313129	chr8:58192883	C8orf71	-0.48	-5.27	-0.31	2.89e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs11696501	0.739	rs6073822	chr20:44251880	A/G	cg11783356	chr20:44313418	WFDC10B	-0.35	-5.42	-0.32	1.35e-7	Brain structure;
CESC	cis	rs7786877	0.723	rs62482239	chr7:100217810	C/T	cg20848291	chr7:100343083	ZAN	-0.66	-7.08	-0.4	1.31e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	trans	rs1814175	0.765	rs1794141	chr11:49914135	G/C	cg15704280	chr7:45808275	SEPT13	-1.03	-21.21	-0.79	4.77e-59	Height;
CESC	cis	rs6952808	0.792	rs11771973	chr7:1950440	C/G	cg05863683	chr7:1912471	MAD1L1	0.44	6.62	0.38	1.95e-10	Bipolar disorder and schizophrenia;
CESC	cis	rs13256369	0.756	rs13282580	chr8:8562903	C/T	cg00074818	chr8:8560427	CLDN23	0.38	5.46	0.32	1.1e-7	Obesity-related traits;
CESC	cis	rs4900538	0.927	rs8005804	chr14:102957803	A/G	cg18135206	chr14:102964638	TECPR2	0.84	11.44	0.58	6.53e-25	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	cis	rs7618915	0.524	rs2028216	chr3:52680823	C/T	cg18099408	chr3:52552593	STAB1	-0.31	-5.09	-0.3	6.72e-7	Bipolar disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08861270	chr19:3700656	PIP5K1C	-0.65	-7.92	-0.44	6.39e-14	Gut microbiome composition (summer);
CESC	cis	rs11098499	0.535	rs7671759	chr4:120248094	A/C	cg09307838	chr4:120376055	NA	0.76	9.93	0.52	5.9e-20	Corneal astigmatism;
CESC	cis	rs854765	0.893	rs712265	chr17:18008447	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.44	-5.74	-0.33	2.6e-8	Total body bone mineral density;
CESC	cis	rs9649465	0.935	rs1605285	chr7:123374412	A/G	cg04330084	chr7:123175371	IQUB	-0.38	-5.13	-0.3	5.72e-7	Migraine;
CESC	cis	rs1862618	0.853	rs2113078	chr5:56087190	C/T	cg24531977	chr5:56204891	C5orf35	-0.87	-10.68	-0.55	2.24e-22	Initial pursuit acceleration;
CESC	cis	rs4713118	0.515	rs9368549	chr6:28050047	T/A	cg08968635	chr6:28129556	ZNF389	0.39	5.22	0.31	3.64e-7	Parkinson's disease;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg10387458	chr1:93645817	TMED5;CCDC18	-0.43	-6.22	-0.36	1.88e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs9911578	1.000	rs12453459	chr17:56624291	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.39	-5.16	-0.3	4.83e-7	Intelligence (multi-trait analysis);
CESC	cis	rs7586879	0.575	rs6712981	chr2:25126230	A/G	cg01884057	chr2:25150051	NA	0.36	7.01	0.4	2.02e-11	Body mass index;
CESC	cis	rs6032067	0.929	rs6032063	chr20:43854475	C/T	cg10761708	chr20:43804764	PI3	0.5	6.15	0.35	2.83e-9	Blood protein levels;
CESC	cis	rs11055008	0.935	rs10845601	chr12:12820134	A/G	cg09462578	chr12:12878428	APOLD1	0.63	8.08	0.44	2.33e-14	Pulse pressure;
CESC	cis	rs853679	0.517	rs12332979	chr6:28141548	T/G	cg23161317	chr6:28129485	ZNF389	0.47	5.88	0.34	1.21e-8	Depression;
CESC	cis	rs2228479	0.717	rs1007932	chr16:89838541	C/T	cg00800038	chr16:89945340	TCF25	-0.78	-7.56	-0.42	6.7e-13	Skin colour saturation;
CESC	cis	rs7259376	0.775	rs7257134	chr19:22540857	A/T	cg02657401	chr19:22469223	NA	-0.28	-5.5	-0.32	9.08e-8	Menopause (age at onset);
CESC	cis	rs4819052	0.885	rs9980676	chr21:46665430	A/G	cg11663144	chr21:46675770	NA	-0.62	-9.86	-0.52	9.62e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs561341	1.000	rs55962687	chr17:30260369	C/T	cg12193833	chr17:30244370	NA	-0.67	-6.13	-0.35	3.14e-9	Hip circumference adjusted for BMI;
CESC	cis	rs631288	0.557	rs4534444	chr1:146679283	T/C	cg25205988	chr1:146714368	CHD1L	1.02	6.44	0.37	5.5e-10	PR interval in Tripanosoma cruzi seropositivity;
CESC	cis	rs4862750	0.872	rs56389997	chr4:187894796	A/C	cg11301795	chr4:187892539	NA	-0.75	-12.18	-0.6	2.18e-27	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg08781755	chr2:44172074	LRPPRC	0.4	6.3	0.36	1.25e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs6502050	0.799	rs58538819	chr17:80107153	G/C	cg11859384	chr17:80120422	CCDC57	-0.4	-5.44	-0.32	1.22e-7	Life satisfaction;
CESC	cis	rs1881744	1.000	rs55647411	chr12:47815942	T/G	cg18786123	chr12:47787067	NA	0.67	5.07	0.3	7.66e-7	Metabolite levels (HVA/5-HIAA ratio);
CESC	cis	rs514406	0.893	rs1242315	chr1:53417181	A/G	cg25767906	chr1:53392781	SCP2	-0.43	-5.37	-0.31	1.75e-7	Monocyte count;
CESC	cis	rs9768139	0.634	rs56389048	chr7:158121368	T/A	cg27057461	chr7:158136379	PTPRN2	-0.34	-5.26	-0.31	2.91e-7	Calcium levels;
CESC	cis	rs514406	0.861	rs11206011	chr1:53235910	T/C	cg08859206	chr1:53392774	SCP2	0.6	8.96	0.48	5.76e-17	Monocyte count;
CESC	cis	rs208520	0.779	rs208446	chr6:66903515	T/C	cg07460842	chr6:66804631	NA	-0.86	-10.11	-0.53	1.55e-20	Exhaled nitric oxide output;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg22145576	chr8:144897413	SCRIB	-0.45	-5.99	-0.35	6.67e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs7692995	1.000	rs7663887	chr4:17902920	G/T	cg08925142	chr4:18023851	LCORL	-0.46	-5.28	-0.31	2.75e-7	Height;
CESC	trans	rs34117943	1	rs34117943	chr16:68819642	C/CT	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.65	-8.51	-0.46	1.27e-15	Mean corpuscular volume;
CESC	cis	rs11723261	0.621	rs6599307	chr4:143777	C/T	cg12746427	chr4:53362	ZNF718;ZNF595	0.46	6.14	0.35	2.98e-9	Immune response to smallpox vaccine (IL-6);
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg04100724	chr12:92539208	BTG1	0.46	6.21	0.36	2.06e-9	Systemic lupus erythematosus;
CESC	cis	rs72945132	0.882	rs1061328	chr11:70185325	C/T	cg14191688	chr11:70257035	CTTN	0.43	5.51	0.32	8.64e-8	Coronary artery disease;
CESC	cis	rs769267	0.965	rs13964	chr19:19468710	C/G	cg17414380	chr19:19431394	KIAA0892;SF4	-0.5	-6.23	-0.36	1.78e-9	Tonsillectomy;
CESC	cis	rs711830	0.965	rs2857532	chr2:177033283	A/G	cg13092806	chr2:177043255	NA	0.87	11.85	0.59	2.73e-26	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
CESC	cis	rs6831352	0.819	rs13832	chr4:99993075	C/A	cg21548116	chr4:100009993	ADH5	0.5	5.49	0.32	9.3e-8	Alcohol dependence;
CESC	trans	rs1814175	0.616	rs1722001	chr11:49894427	A/G	cg15704280	chr7:45808275	SEPT13	-1.0	-18.78	-0.76	1.35e-50	Height;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg09391705	chr13:26828746	CDK8	0.46	6.16	0.35	2.63e-9	Systemic lupus erythematosus;
CESC	cis	rs3785574	0.924	rs2727292	chr17:61893747	A/G	cg07677032	chr17:61819896	STRADA	0.42	5.36	0.31	1.78e-7	Height;
CESC	cis	rs3087591	0.960	rs9898664	chr17:29567152	T/C	cg24425628	chr17:29625626	OMG;NF1	-0.42	-5.25	-0.31	3.12e-7	Hip circumference;
CESC	cis	rs9828933	0.938	rs9809432	chr3:64002953	G/A	cg16258503	chr3:63850278	ATXN7;THOC7	-0.61	-6.18	-0.35	2.43e-9	Type 2 diabetes;
CESC	cis	rs1499972	0.590	rs1456196	chr3:117654553	C/A	cg07612923	chr3:117604196	NA	0.69	6.3	0.36	1.22e-9	Schizophrenia;
CESC	cis	rs2120019	0.935	rs8042409	chr15:75350433	G/A	cg09165964	chr15:75287851	SCAMP5	-0.73	-8.56	-0.47	9.11e-16	Blood trace element (Zn levels);
CESC	cis	rs2274273	1.000	rs10149435	chr14:55627489	C/T	cg04306507	chr14:55594613	LGALS3	0.28	5.28	0.31	2.71e-7	Protein biomarker;
CESC	cis	rs1552244	1.000	rs7652935	chr3:10151138	T/C	cg00166722	chr3:10149974	C3orf24	0.46	5.78	0.33	2.08e-8	Alzheimer's disease;
CESC	cis	rs748404	0.631	rs7163288	chr15:43671355	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.64	8.25	0.45	7.36e-15	Lung cancer;
CESC	cis	rs3806843	1.000	rs6898906	chr5:140169299	C/G	cg26395211	chr5:140044315	WDR55	-0.42	-5.43	-0.32	1.26e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs854765	0.552	rs11078407	chr17:17841083	T/C	cg09796270	chr17:17721594	SREBF1	0.41	5.79	0.34	2e-8	Total body bone mineral density;
CESC	cis	rs868036	0.609	rs2045960	chr15:68092079	G/A	cg08079166	chr15:68083412	MAP2K5	0.38	5.41	0.32	1.42e-7	Restless legs syndrome;
CESC	trans	rs17248895	0.803	rs8004267	chr14:67883129	A/G	cg05725531	chr6:46097441	ENPP4	0.51	6.04	0.35	5.26e-9	Immature fraction of reticulocytes;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	cis	rs28374715	0.578	rs17730589	chr15:41600878	T/C	cg02330683	chr15:41787940	ITPKA	0.48	5.54	0.32	7.36e-8	Ulcerative colitis;
CESC	cis	rs9814567	0.929	rs1534027	chr3:134284662	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.46	-6.12	-0.35	3.4e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs2594989	0.887	rs2454498	chr3:11500953	A/G	cg00170343	chr3:11313890	ATG7	0.56	5.1	0.3	6.55e-7	Circulating chemerin levels;
CESC	cis	rs9359856	0.510	rs2748298	chr6:90436877	A/C	cg13799429	chr6:90582589	CASP8AP2	-0.68	-7.65	-0.43	3.72e-13	Bipolar disorder;
CESC	cis	rs3008870	0.755	rs2755271	chr1:67474977	C/T	cg02640540	chr1:67518911	SLC35D1	0.45	5.51	0.32	8.51e-8	Lymphocyte percentage of white cells;
CESC	cis	rs80282103	0.618	rs11818314	chr10:1148157	G/C	cg08668510	chr10:1095578	IDI1	0.77	6.35	0.36	9.51e-10	Glomerular filtration rate (creatinine);
CESC	trans	rs9650657	0.644	rs4395858	chr8:10521021	C/T	cg15556689	chr8:8085844	FLJ10661	0.5	6.28	0.36	1.38e-9	Neuroticism;
CESC	cis	rs820218	0.743	rs4789223	chr17:73641899	G/A	cg01592526	chr17:73663357	RECQL5;SAP30BP	-0.39	-5.25	-0.31	3.05e-7	Rotator cuff tears;
CESC	cis	rs7647973	0.600	rs35174559	chr3:49287759	T/C	cg02487422	chr3:49467188	NICN1	0.38	5.24	0.31	3.24e-7	Menarche (age at onset);
CESC	cis	rs6570726	0.935	rs409725	chr6:145840340	G/A	cg05347473	chr6:146136440	FBXO30	0.49	6.74	0.38	1e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1670533	1.000	rs6812596	chr4:1069866	A/G	cg27284194	chr4:1044797	NA	0.45	5.73	0.33	2.78e-8	Recombination rate (females);
CESC	trans	rs208520	0.545	rs6899712	chr6:66749670	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.99	18.48	0.75	1.53e-49	Exhaled nitric oxide output;
CESC	cis	rs9354308	0.899	rs1938059	chr6:66539291	G/A	cg07460842	chr6:66804631	NA	0.58	6.59	0.38	2.37e-10	Metabolite levels;
CESC	cis	rs763121	0.819	rs5757133	chr22:38947835	A/G	cg06544989	chr22:39130855	UNC84B	-0.46	-7.78	-0.43	1.58e-13	Menopause (age at onset);
CESC	cis	rs1008375	0.931	rs2109519	chr4:17695453	A/G	cg16339924	chr4:17578868	LAP3	0.6	7.47	0.42	1.16e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs9322193	0.847	rs12210605	chr6:150138403	A/G	cg09699651	chr6:150184138	LRP11	0.41	5.13	0.3	5.51e-7	Lung cancer;
CESC	cis	rs1348850	0.632	rs10167783	chr2:178519041	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.6	7.55	0.42	6.83e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs1707322	1.000	rs7547189	chr1:46319514	C/A	cg05343316	chr1:45956843	TESK2	0.44	5.55	0.32	7.05e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2569991	0.588	rs2596909	chr3:12928672	G/C	cg22481960	chr3:13008800	IQSEC1	-0.56	-6.71	-0.38	1.17e-10	Periodontitis (DPAL);
CESC	cis	rs77956314	0.515	rs9804817	chr12:117440220	G/A	cg02017074	chr12:117425053	FBXW8	-0.79	-8.42	-0.46	2.34e-15	Subcortical brain region volumes;Hippocampal volume;
CESC	cis	rs3747547	0.584	rs1887879	chr9:38079565	G/C	cg13774184	chr9:37916125	SHB	-0.64	-5.49	-0.32	9.57e-8	Metabolite levels (Dihydroxy docosatrienoic acid);
CESC	cis	rs9787249	0.874	rs12094291	chr1:40226046	G/A	cg24920358	chr1:40204285	PPIE	0.4	5.84	0.34	1.52e-8	Blood protein levels;
CESC	cis	rs17039065	0.920	rs73838438	chr4:109451248	G/T	cg16022748	chr4:109541635	LOC285456;RPL34	0.62	5.61	0.33	5.08e-8	Gut microbiome composition (summer);
CESC	cis	rs1799949	1.000	rs35956818	chr17:41422985	T/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.4	5.38	0.31	1.6e-7	Menopause (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00340921	chr19:7600526	PNPLA6	0.6	6.76	0.38	8.87e-11	Gut microbiome composition (summer);
CESC	cis	rs7267979	1.000	rs2387880	chr20:25377787	T/C	cg08601574	chr20:25228251	PYGB	-0.38	-5.55	-0.32	6.92e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs9660992	0.710	rs1668872	chr1:205236069	G/A	cg00857998	chr1:205179979	DSTYK	0.47	5.35	0.31	1.87e-7	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs10504229	0.636	rs77753517	chr8:58115897	C/T	cg02725872	chr8:58115012	NA	-0.45	-7.05	-0.4	1.52e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs2415984	0.622	rs2817568	chr14:46940986	C/G	cg14871534	chr14:47121158	RPL10L	0.38	5.93	0.34	9.18e-9	Number of children ever born;
CESC	cis	rs6460942	0.749	rs79221452	chr7:12202897	T/C	cg06484146	chr7:12443880	VWDE	-0.58	-5.55	-0.32	7.03e-8	Coronary artery disease;
CESC	cis	rs832540	0.801	rs7731700	chr5:56111927	C/T	cg22800045	chr5:56110881	MAP3K1	0.45	5.53	0.32	7.57e-8	Coronary artery disease;
CESC	cis	rs11252926	0.528	rs11252090	chr10:436547	C/T	cg03684893	chr10:554711	DIP2C	0.35	5.19	0.3	4.14e-7	Psychosis in Alzheimer's disease;
CESC	cis	rs7666738	0.724	rs28451676	chr4:98966990	C/T	cg17366294	chr4:99064904	C4orf37	0.59	8.45	0.46	1.94e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7618915	0.547	rs35211965	chr3:52685305	C/G	cg05564831	chr3:52568323	NT5DC2	0.44	6.72	0.38	1.13e-10	Bipolar disorder;
CESC	cis	rs7618915	0.501	rs11714030	chr3:52765882	C/T	cg18337363	chr3:52569053	NT5DC2	0.29	5.22	0.31	3.59e-7	Bipolar disorder;
CESC	cis	rs875971	0.522	rs10807697	chr7:65416170	A/G	cg26939375	chr7:64535504	NA	0.76	10.89	0.56	4.67e-23	Aortic root size;
CESC	trans	rs11098499	0.909	rs78332141	chr4:120375782	C/T	cg25214090	chr10:38739885	LOC399744	0.69	9.59	0.51	6.76e-19	Corneal astigmatism;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg03846288	chr15:59279849	RNF111	-0.46	-6.09	-0.35	3.89e-9	Height;
CESC	cis	rs10924309	0.765	rs1122735	chr1:245853299	G/A	cg00036263	chr1:245852353	KIF26B	-0.49	-6.12	-0.35	3.33e-9	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
CESC	cis	rs9487051	0.621	rs351726	chr6:109548304	C/T	cg01475377	chr6:109611718	NA	-0.38	-5.18	-0.3	4.49e-7	Reticulocyte fraction of red cells;
CESC	cis	rs2777491	0.574	rs11635906	chr15:41779260	A/G	cg20272979	chr15:41787780	ITPKA	0.44	5.24	0.31	3.22e-7	Ulcerative colitis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07666984	chr4:153858209	NA	-0.54	-6.08	-0.35	4.22e-9	Gut microbiome composition (summer);
CESC	cis	rs5769765	0.773	rs9616382	chr22:50312979	C/T	cg26441486	chr22:50317300	CRELD2	0.41	5.22	0.31	3.7e-7	Schizophrenia;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg11750080	chr17:74379913	SPHK1	-0.53	-6.71	-0.38	1.2e-10	Asthma;
CESC	cis	rs6693567	0.586	rs12031973	chr1:150485566	T/G	cg09579323	chr1:150459698	TARS2	0.47	5.75	0.33	2.47e-8	Migraine;
CESC	trans	rs9354352	0.967	rs9354351	chr6:66696271	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.68	9.93	0.52	5.77e-20	Initial pursuit acceleration in psychotic disorders;
CESC	cis	rs6831352	0.918	rs29001214	chr4:100051733	A/G	cg13256891	chr4:100009986	ADH5	-0.77	-8.43	-0.46	2.27e-15	Alcohol dependence;
CESC	cis	rs959260	1.000	rs4789188	chr17:73397871	A/C	cg12999837	chr17:73267436	MIF4GD	-0.45	-5.21	-0.3	3.8e-7	Systemic lupus erythematosus;
CESC	cis	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg01152906	chr10:7861152	TAF3	0.48	6.07	0.35	4.34e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.55	-6.09	-0.35	3.98e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs10504073	0.669	rs818558	chr8:50030855	A/G	cg00325661	chr8:49890786	NA	0.51	7.52	0.42	8.73e-13	Blood metabolite ratios;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12849807	chr6:90348187	LYRM2	0.57	6.81	0.39	6.54e-11	Gut microbiome composition (summer);
CESC	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg11965913	chr1:205819406	PM20D1	0.91	16.7	0.72	2.84e-43	Menarche (age at onset);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg04135372	chr2:99061383	INPP4A	-0.47	-6.21	-0.36	2.02e-9	Ulcerative colitis;
CESC	cis	rs514406	0.547	rs377808	chr1:53190359	T/G	cg08736216	chr1:53307985	ZYG11A	-0.39	-6.13	-0.35	3.13e-9	Monocyte count;
CESC	cis	rs1218582	0.596	rs11264275	chr1:154825270	G/T	cg06221963	chr1:154839813	KCNN3	0.48	7.47	0.42	1.15e-12	Prostate cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13357178	chr17:41623362	ETV4	0.54	6.21	0.36	2.01e-9	Gut microbiome composition (summer);
CESC	cis	rs6502050	0.835	rs34867501	chr17:80121358	T/C	cg11859384	chr17:80120422	CCDC57	-0.39	-5.34	-0.31	1.98e-7	Life satisfaction;
CESC	cis	rs12148488	0.763	rs2304902	chr15:75340727	G/T	cg17294928	chr15:75287854	SCAMP5	0.56	7.03	0.4	1.74e-11	Caffeine consumption;
CESC	cis	rs7666738	0.830	rs6834014	chr4:98951431	G/A	cg03676636	chr4:99064102	C4orf37	0.33	5.09	0.3	6.71e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs72634258	0.554	rs1012477	chr1:7858135	C/G	cg26816564	chr1:7831052	VAMP3	-0.59	-5.7	-0.33	3.14e-8	Inflammatory bowel disease;
CESC	cis	rs3820068	0.581	rs1122386	chr1:15946877	C/T	cg17385448	chr1:15911702	AGMAT	0.42	6.83	0.39	5.64e-11	Systolic blood pressure;
CESC	cis	rs4785763	0.570	rs4785759	chr16:90050880	G/T	cg08547343	chr16:90038815	CENPBD1;AFG3L1	-0.53	-6.93	-0.39	3.22e-11	Melanoma;
CESC	cis	rs2180341	0.960	rs1543432	chr6:127698018	T/C	cg27446573	chr6:127587934	RNF146	1.05	15.29	0.68	2.96e-38	Breast cancer;
CESC	cis	rs6977660	0.652	rs10486362	chr7:19755224	A/G	cg05791153	chr7:19748676	TWISTNB	-0.83	-7.3	-0.41	3.39e-12	Thyroid stimulating hormone;
CESC	cis	rs780096	0.546	rs4665976	chr2:27640325	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.35	-7.19	-0.4	6.72e-12	Total body bone mineral density;
CESC	cis	rs10504229	0.683	rs7459925	chr8:58111771	G/A	cg21724239	chr8:58056113	NA	0.57	5.86	0.34	1.39e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs7714584	1.000	rs4958424	chr5:150225036	C/T	cg22134413	chr5:150180641	NA	0.52	5.64	0.33	4.31e-8	Crohn's disease;
CESC	cis	rs6502050	0.835	rs8065565	chr17:80115399	A/G	cg11859384	chr17:80120422	CCDC57	-0.38	-5.17	-0.3	4.68e-7	Life satisfaction;
CESC	cis	rs6541297	0.703	rs677990	chr1:230320428	G/A	cg20703242	chr1:230279135	GALNT2	-0.41	-5.35	-0.31	1.94e-7	Coronary artery disease;
CESC	trans	rs1814175	0.645	rs10839448	chr11:49938930	G/A	cg15704280	chr7:45808275	SEPT13	-0.98	-18.48	-0.75	1.48e-49	Height;
CESC	cis	rs10479542	0.503	rs12719865	chr5:178993566	C/T	cg19626725	chr5:178986131	RUFY1	0.35	5.45	0.32	1.17e-7	Lung cancer;
CESC	cis	rs787274	1.000	rs2796037	chr9:115511826	C/T	cg13803584	chr9:115635662	SNX30	0.52	5.44	0.32	1.21e-7	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs8062405	1.000	rs7198606	chr16:28875122	T/G	cg08761264	chr16:28874980	SH2B1	-0.47	-5.85	-0.34	1.42e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs938554	0.784	rs4481233	chr4:9956079	A/G	cg11266682	chr4:10021025	SLC2A9	0.42	5.19	0.3	4.28e-7	Blood metabolite levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06138422	chr12:133338013	ANKLE2	0.55	6.47	0.37	4.63e-10	Gut microbiome composition (summer);
CESC	cis	rs7216064	1.000	rs56393562	chr17:65933918	C/T	cg07042672	chr17:66097459	LOC651250	-0.54	-5.87	-0.34	1.3e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs921968	0.541	rs585185	chr2:219457741	G/A	cg02176678	chr2:219576539	TTLL4	0.48	8.27	0.45	6.46e-15	Mean corpuscular hemoglobin concentration;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg10887309	chr12:49412603	PRKAG1	-0.39	-6.0	-0.35	6.56e-9	Gambling;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg04190776	chr16:89614921	SPG7	0.51	6.95	0.39	2.89e-11	Fibrinogen levels;
CESC	cis	rs7267979	1.000	rs6076345	chr20:25381895	T/G	cg08601574	chr20:25228251	PYGB	-0.38	-5.45	-0.32	1.13e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs2072499	0.966	rs11587860	chr1:156156951	G/C	cg24450063	chr1:156163899	SLC25A44	1.08	21.39	0.8	1.2e-59	Testicular germ cell tumor;
CESC	cis	rs7208859	0.673	rs73265633	chr17:29236306	G/T	cg19761014	chr17:28927070	LRRC37B2	0.71	5.63	0.33	4.48e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs7212590	0.529	rs60283440	chr17:57994248	T/C	cg20303301	chr17:57937339	TUBD1	-0.56	-5.55	-0.32	6.81e-8	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs8070740	0.838	rs57745425	chr17:5327528	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.52	5.7	0.33	3.23e-8	Menopause (age at onset);
CESC	cis	rs4243830	0.850	rs4908904	chr1:6580250	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	0.76	8.63	0.47	5.93e-16	Body mass index;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16339435	chr6:146285414	SHPRH	0.54	6.31	0.36	1.18e-9	Gut microbiome composition (summer);
CESC	cis	rs2235642	0.750	rs1894649	chr16:1657284	C/G	cg03715980	chr16:1756201	MAPK8IP3	0.39	5.25	0.31	3.18e-7	Coronary artery disease;
CESC	trans	rs9929218	0.551	rs1886697	chr16:68716179	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.97	16.93	0.72	4.4e-44	Colorectal cancer;
CESC	cis	rs9837602	0.507	rs793452	chr3:99529523	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.4	-5.39	-0.31	1.59e-7	Breast cancer;
CESC	trans	rs78049276	0.736	rs10305838	chr4:148400256	T/C	cg13149281	chr14:23389818	RBM23;PRMT5	-0.69	-7.55	-0.42	6.94e-13	Pulse pressure;
CESC	cis	rs459571	0.959	rs2810491	chr9:136923331	C/T	cg13789015	chr9:136890014	NCRNA00094	-0.53	-7.34	-0.41	2.67e-12	Platelet distribution width;
CESC	cis	rs10479542	0.784	rs7702303	chr5:178986436	G/A	cg22764044	chr5:178986830	RUFY1	0.49	7.24	0.41	4.85e-12	Lung cancer;
CESC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg07415687	chr6:7910841	TXNDC5	0.51	6.06	0.35	4.78e-9	Breast cancer;
CESC	cis	rs6598955	0.724	rs12726972	chr1:26639634	A/G	cg04990556	chr1:26633338	UBXN11	0.64	8.9	0.48	8.75e-17	Obesity-related traits;
CESC	cis	rs2576037	0.526	rs4890703	chr18:44522037	A/G	cg07643061	chr18:44555308	TCEB3C;TCEB3CL;KATNAL2	-0.35	-5.16	-0.3	4.82e-7	Personality dimensions;
CESC	cis	rs2404602	0.692	rs67010831	chr15:76965308	T/G	cg22467129	chr15:76604101	ETFA	-0.34	-5.08	-0.3	7.27e-7	Blood metabolite levels;
CESC	cis	rs11640533	0.901	rs11862250	chr16:53415038	C/A	cg10144400	chr16:53407678	NA	0.42	5.44	0.32	1.22e-7	Intelligence (multi-trait analysis);
CESC	cis	rs12477438	0.834	rs10179043	chr2:99687490	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.75	-10.73	-0.55	1.54e-22	Chronic sinus infection;
CESC	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg11905131	chr22:24372483	LOC391322	-0.7	-10.05	-0.53	2.39e-20	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs10504229	0.681	rs11779172	chr8:58045538	A/G	cg22535103	chr8:58192502	C8orf71	-0.65	-6.98	-0.39	2.38e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs4665809	0.590	rs1469523	chr2:26474631	T/A	cg25036284	chr2:26402008	FAM59B	0.86	9.36	0.5	3.44e-18	Gut microbiome composition (summer);
CESC	cis	rs9611565	0.512	rs139573	chr22:42214785	G/A	cg06634786	chr22:41940651	POLR3H	-0.66	-6.51	-0.37	3.7e-10	Vitiligo;
CESC	cis	rs2404602	0.598	rs11634019	chr15:76634680	A/G	cg00316803	chr15:76480434	C15orf27	0.49	6.73	0.38	1.03e-10	Blood metabolite levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09925987	chr7:2629300	IQCE	-0.6	-7.01	-0.4	2.01e-11	Gut microbiome composition (summer);
CESC	cis	rs10823500	0.748	rs12355080	chr10:71963608	G/A	cg04118878	chr10:71993077	PPA1	0.47	5.54	0.32	7.27e-8	Blood protein levels;
CESC	cis	rs1005277	0.522	rs200943	chr10:38148730	A/G	cg00409905	chr10:38381863	ZNF37A	-0.56	-7.73	-0.43	2.23e-13	Extrinsic epigenetic age acceleration;
CESC	cis	rs4819052	0.788	rs9978857	chr21:46705155	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.87	11.97	0.59	1.07e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs11098499	0.954	rs4345162	chr4:120312959	G/A	cg25214090	chr10:38739885	LOC399744	0.68	9.2	0.49	1.14e-17	Corneal astigmatism;
CESC	cis	rs453301	0.598	rs2921383	chr8:8892221	C/T	cg15556689	chr8:8085844	FLJ10661	0.49	6.09	0.35	3.86e-9	Joint mobility (Beighton score);
CESC	cis	rs7980687	0.638	rs7299943	chr12:123593485	A/T	cg05973401	chr12:123451056	ABCB9	0.56	6.14	0.35	3.05e-9	Height;Educational attainment;Head circumference (infant);
CESC	cis	rs9399137	0.507	rs4895437	chr6:135317354	G/A	cg22676075	chr6:135203613	NA	0.53	7.09	0.4	1.22e-11	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	cis	rs644799	1.000	rs557079	chr11:95530125	C/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.69	8.94	0.48	6.65e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs11785693	0.865	rs11784227	chr8:4970485	A/C	cg26367366	chr8:4980734	NA	0.81	7.25	0.41	4.53e-12	Neuroticism (multi-trait analysis);Neuroticism;
CESC	cis	rs72781680	0.611	rs72781692	chr2:24263319	T/G	cg08917208	chr2:24149416	ATAD2B	0.67	6.42	0.37	6.2e-10	Lymphocyte counts;
CESC	cis	rs1862618	0.671	rs2591958	chr5:56239369	C/G	cg12311346	chr5:56204834	C5orf35	0.64	8.66	0.47	4.55e-16	Initial pursuit acceleration;
CESC	cis	rs7071206	0.947	rs11002226	chr10:79399656	T/A	cg07817648	chr10:79422355	NA	-0.89	-11.2	-0.57	4.27e-24	Bone mineral density;
CESC	cis	rs6500395	0.928	rs723807	chr16:48691443	A/G	cg04672837	chr16:48644449	N4BP1	-0.51	-6.36	-0.36	8.64e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs8072100	0.840	rs9912311	chr17:45547132	T/C	cg25173405	chr17:45401733	C17orf57	-0.43	-5.77	-0.33	2.25e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs1801251	0.778	rs809639	chr2:233731244	C/G	cg08000102	chr2:233561755	GIGYF2	0.6	8.01	0.44	3.62e-14	Coronary artery disease;
CESC	cis	rs7618915	0.501	rs11714030	chr3:52765882	C/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	5.78	0.33	2.11e-8	Bipolar disorder;
CESC	cis	rs367943	0.698	rs4336355	chr5:113000368	C/T	cg12552261	chr5:112820674	MCC	0.46	5.88	0.34	1.26e-8	Type 2 diabetes;
CESC	cis	rs4689388	0.819	rs12649341	chr4:6294759	G/A	cg25554036	chr4:6271136	WFS1	0.51	8.37	0.46	3.31e-15	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs1728785	0.901	rs1645974	chr16:68564774	C/G	cg02972257	chr16:68554789	NA	-0.55	-6.37	-0.36	8.21e-10	Ulcerative colitis;
CESC	cis	rs12145833	0.596	rs12123491	chr1:243297924	C/G	cg02356786	chr1:243265016	LOC731275	0.76	6.38	0.36	8.08e-10	Obesity (early onset extreme);
CESC	cis	rs3749237	0.595	rs885592	chr3:49497883	T/G	cg02487422	chr3:49467188	NICN1	0.56	8.19	0.45	1.11e-14	Resting heart rate;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01267274	chr14:90864532	CALM1	0.56	6.1	0.35	3.7e-9	Gut microbiome composition (summer);
CESC	cis	rs3806843	1.000	rs10223116	chr5:140192643	C/T	cg26395211	chr5:140044315	WDR55	-0.39	-5.1	-0.3	6.52e-7	Depressive symptoms (multi-trait analysis);
CESC	trans	rs877282	0.945	rs71489301	chr10:770191	A/G	cg22713356	chr15:30763199	NA	1.14	11.22	0.57	3.6e-24	Uric acid levels;
CESC	cis	rs6032067	0.929	rs2267864	chr20:43805279	C/G	cg11264863	chr20:43835661	SEMG1	0.44	5.06	0.3	7.82e-7	Blood protein levels;
CESC	cis	rs13118159	0.836	rs2276903	chr4:1343405	A/G	cg05025164	chr4:1340916	KIAA1530	0.6	8.3	0.45	5.4e-15	Longevity;
CESC	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg07092213	chr7:1199455	ZFAND2A	-0.45	-5.2	-0.3	3.98e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs28498503	0.573	rs9955010	chr18:76654038	G/A	cg00806245	chr18:76673096	NA	-0.69	-5.66	-0.33	3.92e-8	Attention function in attention deficit hyperactive disorder;
CESC	cis	rs1044826	0.692	rs176987	chr3:139233001	G/A	cg00490450	chr3:139108681	COPB2	-0.44	-5.45	-0.32	1.13e-7	Obesity-related traits;
CESC	cis	rs8060686	0.920	rs55661503	chr16:67836552	T/A	cg26727032	chr16:67993705	SLC12A4	-0.58	-6.26	-0.36	1.51e-9	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs9549367	0.789	rs2025247	chr13:113882564	C/G	cg18105134	chr13:113819100	PROZ	-0.63	-7.55	-0.42	6.88e-13	Platelet distribution width;
CESC	cis	rs1018836	0.628	rs6471085	chr8:91463783	G/A	cg16814680	chr8:91681699	NA	-0.55	-7.24	-0.41	4.86e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs2836974	0.568	rs11910906	chr21:40685662	T/C	cg11890956	chr21:40555474	PSMG1	-0.94	-14.76	-0.67	2.14e-36	Cognitive function;
CESC	cis	rs514406	0.708	rs480299	chr1:53320274	G/T	cg25767906	chr1:53392781	SCP2	-0.57	-8.09	-0.44	2.23e-14	Monocyte count;
CESC	cis	rs7552404	0.920	rs2788654	chr1:76219569	C/T	cg10523679	chr1:76189770	ACADM	0.75	10.09	0.53	1.8e-20	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs12142240	0.698	rs17357759	chr1:46832534	A/G	cg10495392	chr1:46806563	NSUN4	0.55	6.1	0.35	3.84e-9	Menopause (age at onset);
CESC	cis	rs9549260	0.755	rs17061491	chr13:41228210	T/A	cg21288729	chr13:41239152	FOXO1	0.65	8.53	0.46	1.16e-15	Red blood cell count;
CESC	cis	rs4728142	0.738	rs3807306	chr7:128580680	A/C	cg06630958	chr7:128577819	IRF5	0.34	5.38	0.31	1.64e-7	Inflammatory bowel disease;Systemic lupus erythematosus;Ulcerative colitis;
CESC	cis	rs9611565	0.512	rs5758439	chr22:42131762	C/T	cg17376030	chr22:41985996	PMM1	-0.78	-8.33	-0.46	4.43e-15	Vitiligo;
CESC	cis	rs637571	0.522	rs550435	chr11:65732651	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.44	6.65	0.38	1.71e-10	Eosinophil percentage of white cells;
CESC	trans	rs6600671	1.000	rs2319969	chr1:121207335	A/G	cg17023122	chr1:144479586	NA	0.48	6.57	0.37	2.58e-10	Hip geometry;
CESC	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg17178900	chr1:205818956	PM20D1	-0.69	-9.46	-0.5	1.75e-18	Menarche (age at onset);
CESC	cis	rs798554	0.660	rs2527687	chr7:2838485	G/A	cg19717773	chr7:2847554	GNA12	-0.59	-9.06	-0.49	3.02e-17	Height;
CESC	cis	rs7512552	0.839	rs1260405	chr1:150304781	A/G	cg15654264	chr1:150340011	RPRD2	0.39	5.23	0.31	3.42e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs67478160	0.608	rs34066659	chr14:104263427	A/C	cg01849466	chr14:104193079	ZFYVE21	-0.51	-7.09	-0.4	1.2e-11	Schizophrenia;
CESC	cis	rs1413885	0.516	rs6588138	chr1:65838366	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.46	5.98	0.34	7.15e-9	Anticoagulant levels;
CESC	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg23034840	chr1:205782522	SLC41A1	0.65	7.99	0.44	4.13e-14	Menarche (age at onset);
CESC	cis	rs10465746	0.935	rs2389647	chr1:84403041	C/T	cg10977910	chr1:84465055	TTLL7	0.47	6.21	0.36	2.09e-9	Obesity-related traits;
CESC	cis	rs7772486	0.875	rs9322045	chr6:146384950	C/G	cg23711669	chr6:146136114	FBXO30	0.85	12.56	0.61	1.08e-28	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs67460515	0.563	rs73023235	chr3:160864123	G/A	cg03342759	chr3:160939853	NMD3	-0.52	-6.51	-0.37	3.68e-10	Parkinson's disease;
CESC	cis	rs36051895	0.623	rs62541543	chr9:5042082	G/A	cg02405213	chr9:5042618	JAK2	-0.48	-5.64	-0.33	4.29e-8	Pediatric autoimmune diseases;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg05393424	chr1:91403111	ZNF644	0.4	6.3	0.36	1.21e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs7818382	1.000	rs7818382	chr8:96054000	C/T	cg09323728	chr8:95962352	TP53INP1	-0.33	-7.02	-0.4	1.83e-11	Alzheimer's disease (late onset);
CESC	cis	rs2204008	0.580	rs11520047	chr12:38051778	T/A	cg26384229	chr12:38710491	ALG10B	0.74	10.7	0.55	1.96e-22	Bladder cancer;
CESC	cis	rs9399137	0.507	rs6904897	chr6:135382980	T/G	cg22676075	chr6:135203613	NA	0.52	6.85	0.39	5.13e-11	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	trans	rs561341	0.941	rs17780080	chr17:30343146	G/A	cg27661571	chr11:113659931	NA	-0.85	-7.51	-0.42	9.26e-13	Hip circumference adjusted for BMI;
CESC	cis	rs7659604	0.539	rs11098648	chr4:122759872	C/T	cg20573242	chr4:122745356	CCNA2	0.65	8.05	0.44	2.81e-14	Type 2 diabetes;
CESC	cis	rs10905065	0.829	rs2246399	chr10:5799286	T/A	cg11519256	chr10:5708881	ASB13	-0.39	-5.11	-0.3	6.23e-7	Menopause (age at onset);
CESC	cis	rs1801251	1.000	rs283477	chr2:233649427	A/G	cg25237894	chr2:233734115	C2orf82	0.47	7.93	0.44	6.29e-14	Coronary artery disease;
CESC	cis	rs6831352	0.879	rs29001196	chr4:100054116	C/T	cg12011299	chr4:100065546	ADH4	-0.6	-6.62	-0.38	2.04e-10	Alcohol dependence;
CESC	cis	rs7917772	0.636	rs1475644	chr10:104491164	G/A	cg04362960	chr10:104952993	NT5C2	-0.5	-5.79	-0.34	2e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs1953600	0.870	rs12770550	chr10:81953451	G/T	cg04850286	chr10:81895943	PLAC9	0.29	5.06	0.3	7.95e-7	Sarcoidosis;
CESC	cis	rs853679	0.517	rs2275508	chr6:28094731	T/C	cg23281280	chr6:28129359	ZNF389	0.61	8.7	0.47	3.53e-16	Depression;
CESC	cis	rs6580649	0.824	rs1635534	chr12:48386553	A/G	cg05342945	chr12:48394962	COL2A1	-0.51	-6.1	-0.35	3.71e-9	Lung cancer;
CESC	cis	rs11792861	0.926	rs72607174	chr9:111899132	A/T	cg05043794	chr9:111880884	C9orf5	-0.42	-6.94	-0.39	3.04e-11	Menarche (age at onset);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg00252332	chr13:73633178	KLF5	-0.4	-6.14	-0.35	3.07e-9	Gambling;
CESC	cis	rs8005677	1.000	rs1951119	chr14:23388326	A/C	cg25600027	chr14:23388339	RBM23	-0.43	-5.32	-0.31	2.25e-7	Cognitive ability (multi-trait analysis);
CESC	cis	rs9790314	1.000	rs163328	chr3:161073599	A/G	cg03342759	chr3:160939853	NMD3	-0.47	-6.15	-0.35	2.79e-9	Morning vs. evening chronotype;
CESC	cis	rs13064411	0.696	rs6787026	chr3:113162117	A/G	cg18753928	chr3:113234510	CCDC52	-0.49	-5.27	-0.31	2.88e-7	Response to simvastatin treatment (PCSK9 protein level change);
CESC	cis	rs5769707	0.609	rs2007024	chr22:49988815	C/T	cg05373962	chr22:49881684	NA	-0.35	-5.22	-0.31	3.64e-7	Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs72634258	0.945	rs12745223	chr1:8094978	C/T	cg00042356	chr1:8021962	PARK7	0.82	7.32	0.41	3.04e-12	Inflammatory bowel disease;
CESC	cis	rs6500395	1.000	rs9930365	chr16:48682154	A/C	cg04672837	chr16:48644449	N4BP1	0.51	6.36	0.36	8.64e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs3768617	0.510	rs3768620	chr1:183092237	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.89	14.39	0.66	4.39e-35	Fuchs's corneal dystrophy;
CESC	cis	rs28647808	1.000	rs7857017	chr9:136271101	A/C	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.9	5.73	0.33	2.75e-8	Blood protein levels;
CESC	cis	rs2836974	0.897	rs2836924	chr21:40525639	C/T	cg17971929	chr21:40555470	PSMG1	1.05	16.62	0.71	5.49e-43	Cognitive function;
CESC	cis	rs829883	0.659	rs12366275	chr12:98920276	G/C	cg25150519	chr12:98850993	NA	-0.65	-7.97	-0.44	4.6e-14	Colorectal adenoma (advanced);
CESC	cis	rs533123	0.818	rs527931	chr1:29167161	T/C	cg08366446	chr1:29138936	OPRD1	0.51	5.78	0.33	2.07e-8	Schizophrenia;
CESC	cis	rs854765	0.647	rs854808	chr17:18006634	C/T	cg09796270	chr17:17721594	SREBF1	0.4	5.39	0.31	1.56e-7	Total body bone mineral density;
CESC	cis	rs6539267	0.847	rs12831519	chr12:106682917	A/G	cg02476566	chr12:106696527	TCP11L2	0.67	6.85	0.39	5.05e-11	Tourette syndrome;
CESC	cis	rs4727027	0.901	rs4727018	chr7:148822247	G/C	cg23583168	chr7:148888333	NA	-0.74	-10.66	-0.55	2.51e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs2204008	0.580	rs11520047	chr12:38051778	T/A	cg13010199	chr12:38710504	ALG10B	0.54	6.69	0.38	1.28e-10	Bladder cancer;
CESC	cis	rs11264213	0.591	rs274745	chr1:36538282	G/A	cg27506609	chr1:36549197	TEKT2	-0.77	-7.45	-0.42	1.34e-12	Schizophrenia;
CESC	cis	rs10504073	0.609	rs17644494	chr8:50019679	T/C	cg00325661	chr8:49890786	NA	0.52	7.96	0.44	4.91e-14	Blood metabolite ratios;
CESC	cis	rs2842992	0.915	rs2758350	chr6:160118056	A/G	cg11366901	chr6:160182831	ACAT2	0.76	9.68	0.51	3.64e-19	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs6466055	0.666	rs12671047	chr7:104999535	C/A	cg04380332	chr7:105027541	SRPK2	-0.43	-5.62	-0.33	4.95e-8	Schizophrenia;
CESC	cis	rs12477438	0.765	rs1115756	chr2:99659845	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.64	-8.73	-0.47	2.94e-16	Chronic sinus infection;
CESC	cis	rs2276314	1.000	rs4799834	chr18:33566243	T/C	cg19628046	chr18:33552617	C18orf21	0.54	5.96	0.34	7.82e-9	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs1577917	1.000	rs12190604	chr6:86716215	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-6.25	-0.36	1.66e-9	Response to antipsychotic treatment;
CESC	cis	rs9905704	0.596	rs2526367	chr17:56470750	C/T	cg12560992	chr17:57184187	TRIM37	-0.61	-5.75	-0.33	2.49e-8	Testicular germ cell tumor;
CESC	cis	rs6982240	0.514	rs10089212	chr8:142265380	T/A	cg00131261	chr8:142287264	NA	-0.53	-7.31	-0.41	3.25e-12	Tonsillectomy;
CESC	cis	rs17376456	0.877	rs10213956	chr5:93460839	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.6	5.11	0.3	6.27e-7	Diabetic retinopathy;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg16857181	chr7:32931955	KBTBD2	-0.5	-7.15	-0.4	8.38e-12	Gambling;
CESC	cis	rs7520050	0.743	rs61789988	chr1:46085242	G/C	cg06784218	chr1:46089804	CCDC17	-0.31	-5.63	-0.33	4.69e-8	Red blood cell count;Reticulocyte count;
CESC	cis	rs11252926	0.545	rs1551508	chr10:555469	A/G	cg16386425	chr10:429943	DIP2C	-0.4	-5.13	-0.3	5.63e-7	Psychosis in Alzheimer's disease;
CESC	cis	rs9858542	1.000	rs2172252	chr3:49678307	A/T	cg03060546	chr3:49711283	APEH	-0.58	-6.81	-0.39	6.68e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	trans	rs1814175	0.647	rs28456013	chr11:50047629	T/C	cg03929089	chr4:120376271	NA	-0.76	-9.77	-0.51	1.88e-19	Height;
CESC	cis	rs67311347	1.000	rs12638199	chr3:40475285	A/G	cg09455208	chr3:40491958	NA	0.44	7.53	0.42	8.04e-13	Renal cell carcinoma;
CESC	cis	rs863345	0.967	rs9804005	chr1:158520414	A/G	cg12129480	chr1:158549410	OR10X1	-0.33	-6.6	-0.38	2.19e-10	Pneumococcal bacteremia;
CESC	cis	rs72781680	1.000	rs17762782	chr2:24126493	A/G	cg08917208	chr2:24149416	ATAD2B	0.93	8.42	0.46	2.35e-15	Lymphocyte counts;
CESC	cis	rs523522	1.000	rs523522	chr12:121020250	A/T	cg12219531	chr12:120966889	COQ5	0.77	10.22	0.53	7.1e-21	High light scatter reticulocyte count;
CESC	trans	rs7819412	0.521	rs10110684	chr8:11039159	G/C	cg06636001	chr8:8085503	FLJ10661	-0.53	-6.16	-0.35	2.7e-9	Triglycerides;
CESC	cis	rs9399137	0.507	rs13064	chr6:135287533	A/G	cg24558204	chr6:135376177	HBS1L	0.7	9.64	0.51	4.87e-19	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	cis	rs12497850	0.931	rs11924597	chr3:48937790	T/C	cg07636037	chr3:49044803	WDR6	1.03	19.67	0.77	1.02e-53	Parkinson's disease;
CESC	cis	rs5750830	0.649	rs5750814	chr22:39797987	T/C	cg11247378	chr22:39784982	NA	-0.64	-9.76	-0.51	1.96e-19	Intelligence (multi-trait analysis);
CESC	trans	rs9467711	0.659	rs66757203	chr6:26454956	C/T	cg01620082	chr3:125678407	NA	-0.81	-6.27	-0.36	1.44e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs4242434	0.892	rs11776549	chr8:22493124	C/T	cg03733263	chr8:22462867	KIAA1967	1.01	13.25	0.63	4.38e-31	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CESC	cis	rs2737618	0.651	rs2816976	chr1:200081021	A/T	cg21825944	chr1:200113062	NR5A2	-0.47	-7.23	-0.41	5.26e-12	Uric acid levels;
CESC	cis	rs7618915	0.547	rs2268027	chr3:52766606	G/A	cg17372223	chr3:52568218	NT5DC2	0.44	6.55	0.37	2.98e-10	Bipolar disorder;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg12344600	chr6:89769123	NA	-0.52	-7.44	-0.42	1.41e-12	Gut microbiota (bacterial taxa);
CESC	cis	rs3091242	0.933	rs4649084	chr1:25752617	A/G	cg03538708	chr1:25844672	NA	-0.42	-6.4	-0.37	6.96e-10	Erythrocyte sedimentation rate;
CESC	cis	rs7621025	0.662	rs3856637	chr3:136391195	C/T	cg15507776	chr3:136538369	TMEM22	0.42	5.47	0.32	1.06e-7	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
CESC	cis	rs2243480	1.000	rs1873494	chr7:65649899	T/C	cg12463550	chr7:65579703	CRCP	-0.73	-5.66	-0.33	4.03e-8	Diabetic kidney disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg01181084	chr8:43059863	NA	0.5	6.64	0.38	1.75e-10	Fibrinogen levels;
CESC	cis	rs7542091	0.704	rs2142907	chr1:210039505	T/C	cg09509183	chr1:209979624	IRF6	0.4	5.61	0.33	5.13e-8	Monobrow;
CESC	cis	rs7914558	1.000	rs11191542	chr10:104824324	T/A	cg04362960	chr10:104952993	NT5C2	0.48	6.45	0.37	5.35e-10	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg06336792	chr10:35415599	CREM	-0.41	-6.07	-0.35	4.47e-9	Gambling;
CESC	cis	rs1707322	0.752	rs7529699	chr1:46134634	C/T	cg05343316	chr1:45956843	TESK2	0.51	6.24	0.36	1.7e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2070488	0.775	rs9838614	chr3:38537671	A/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.75	-11.59	-0.58	2.15e-25	Electrocardiographic conduction measures;
CESC	cis	rs1707322	0.686	rs2152078	chr1:46055600	C/T	cg03146154	chr1:46216737	IPP	-0.77	-10.4	-0.54	1.77e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg24037629	chr17:48226544	PPP1R9B	-0.45	-6.53	-0.37	3.39e-10	Gambling;
CESC	cis	rs4664308	0.694	rs4665140	chr2:160890710	T/A	cg03641300	chr2:160917029	PLA2R1	-0.59	-8.54	-0.46	1.04e-15	Idiopathic membranous nephropathy;
CESC	cis	rs7666738	0.830	rs10017557	chr4:98983969	G/A	cg18180107	chr4:99064573	C4orf37	0.4	5.19	0.3	4.29e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs1557351	0.569	rs1942347	chr18:54724458	A/T	cg11433624	chr6:7146702	RREB1	0.37	6.19	0.36	2.29e-9	Multiple sclerosis (age of onset);
CESC	cis	rs9733	0.650	rs6698495	chr1:150564476	T/C	cg18016565	chr1:150552671	MCL1	-0.43	-7.13	-0.4	9.74e-12	Tonsillectomy;
CESC	cis	rs933688	1.000	rs2367526	chr5:90740525	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.1	12.13	0.6	3.17e-27	Smoking behavior;
CESC	cis	rs3845702	0.668	rs3856415	chr2:180807367	G/A	cg01881094	chr2:180872142	CWC22	-1.05	-9.21	-0.49	9.96e-18	Schizophrenia;
CESC	cis	rs8060686	0.641	rs12447931	chr16:68179195	C/T	cg26727032	chr16:67993705	SLC12A4	-0.53	-6.02	-0.35	5.67e-9	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs6570726	0.791	rs11155426	chr6:145817130	T/C	cg23711669	chr6:146136114	FBXO30	1.02	16.0	0.7	8.93e-41	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg01698708	chr1:28100000	STX12	0.52	7.02	0.4	1.82e-11	Systemic lupus erythematosus;
CESC	cis	rs9322193	0.923	rs9688938	chr6:150110077	G/A	cg04369109	chr6:150039330	LATS1	-0.4	-5.4	-0.31	1.48e-7	Lung cancer;
CESC	cis	rs8060686	0.546	rs7188350	chr16:68149316	T/C	cg26727032	chr16:67993705	SLC12A4	-0.6	-8.17	-0.45	1.25e-14	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs9868809	0.881	rs3821876	chr3:48668394	G/T	cg07636037	chr3:49044803	WDR6	-0.63	-5.15	-0.3	5.14e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CESC	trans	rs1908814	0.516	rs10112958	chr8:11793140	A/G	cg15556689	chr8:8085844	FLJ10661	0.54	6.58	0.37	2.47e-10	Neuroticism;
CESC	cis	rs400736	0.602	rs6694154	chr1:8163520	G/A	cg25007680	chr1:8021821	PARK7	-0.58	-7.78	-0.43	1.61e-13	Response to antidepressants and depression;
CESC	cis	rs933688	1.000	rs60513756	chr5:90727692	A/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.17	13.81	0.65	4.68e-33	Smoking behavior;
CESC	cis	rs7916697	0.520	rs10762201	chr10:70040111	A/G	cg06988349	chr10:69991859	ATOH7	-0.31	-5.04	-0.3	8.45e-7	Optic disc area;
CESC	cis	rs765787	0.530	rs2554457	chr15:45520926	G/A	cg24006582	chr15:45444508	DUOX1	-0.57	-6.88	-0.39	4.36e-11	Uric acid levels;
CESC	cis	rs4843747	0.605	rs4072779	chr16:88107290	C/T	cg03395651	chr16:88107091	BANP	0.46	5.36	0.31	1.85e-7	Menopause (age at onset);
CESC	cis	rs9584850	0.834	rs12869627	chr13:99120452	G/A	cg22223119	chr13:99095684	FARP1	-0.36	-5.14	-0.3	5.29e-7	Neuroticism;
CESC	cis	rs12142240	0.698	rs6684274	chr1:46810842	A/G	cg00530320	chr1:46809349	NSUN4	-0.58	-7.83	-0.43	1.2e-13	Menopause (age at onset);
CESC	cis	rs7618915	0.547	rs11177	chr3:52721305	G/A	cg05564831	chr3:52568323	NT5DC2	0.44	6.66	0.38	1.6e-10	Bipolar disorder;
CESC	cis	rs3820068	0.705	rs11589076	chr1:15827027	C/T	cg18192808	chr1:15853278	DNAJC16	0.47	5.56	0.32	6.42e-8	Systolic blood pressure;
CESC	cis	rs9814567	0.679	rs1880379	chr3:134330612	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.4	-5.09	-0.3	6.84e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs72945132	0.660	rs7121703	chr11:70140296	C/T	cg00319359	chr11:70116639	PPFIA1	0.78	7.67	0.43	3.32e-13	Coronary artery disease;
CESC	cis	rs7666738	0.830	rs62318504	chr4:98935558	T/G	cg05340658	chr4:99064831	C4orf37	0.82	12.54	0.61	1.29e-28	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13755630	chr13:27949051	NA	-0.53	-6.15	-0.35	2.79e-9	Gut microbiome composition (summer);
CESC	cis	rs662064	0.544	rs12402967	chr1:10617924	T/C	cg20482658	chr1:10539492	PEX14	0.35	5.81	0.34	1.82e-8	Asthma;
CESC	trans	rs11039798	1.000	rs9667626	chr11:48485877	T/C	cg15704280	chr7:45808275	SEPT13	0.69	6.59	0.38	2.31e-10	Axial length;
CESC	cis	rs6446731	0.517	rs2157093	chr4:3270913	C/G	cg08886695	chr4:3369023	RGS12	0.38	5.49	0.32	9.46e-8	Mean platelet volume;
CESC	cis	rs7246657	0.882	rs4803539	chr19:37897522	A/C	cg23950597	chr19:37808831	NA	-0.54	-6.02	-0.35	5.69e-9	Coronary artery calcification;
CESC	cis	rs2204008	0.744	rs11519905	chr12:38222959	G/A	cg13010199	chr12:38710504	ALG10B	0.54	6.69	0.38	1.35e-10	Bladder cancer;
CESC	cis	rs873946	0.586	rs12774727	chr10:134569910	T/C	cg27297192	chr10:134578999	INPP5A	0.4	5.13	0.3	5.54e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs703842	1.000	rs11172342	chr12:58187758	G/T	cg00677455	chr12:58241039	CTDSP2	0.52	6.55	0.37	3.04e-10	Multiple sclerosis;
CESC	cis	rs72781680	0.611	rs72783619	chr2:24311607	G/A	cg08917208	chr2:24149416	ATAD2B	0.55	5.22	0.31	3.56e-7	Lymphocyte counts;
CESC	cis	rs863345	0.967	rs10908685	chr1:158524436	T/A	cg12129480	chr1:158549410	OR10X1	-0.32	-6.53	-0.37	3.28e-10	Pneumococcal bacteremia;
CESC	trans	rs61931739	0.534	rs1352206	chr12:34036668	G/A	cg26384229	chr12:38710491	ALG10B	0.53	7.22	0.41	5.44e-12	Morning vs. evening chronotype;
CESC	cis	rs6502050	0.835	rs8078950	chr17:80122327	T/G	cg11859384	chr17:80120422	CCDC57	-0.39	-5.34	-0.31	1.98e-7	Life satisfaction;
CESC	cis	rs11760633	0.672	rs10950377	chr7:1835894	C/G	cg23422044	chr7:1970798	MAD1L1	0.45	5.32	0.31	2.26e-7	Coronary artery disease;
CESC	cis	rs568617	0.859	rs1204650	chr11:65645580	A/C	cg19792802	chr11:65647270	CTSW	-0.35	-5.31	-0.31	2.33e-7	Crohn's disease;
CESC	trans	rs2727020	0.615	rs35423199	chr11:49514914	T/C	cg15704280	chr7:45808275	SEPT13	-0.95	-17.2	-0.73	5e-45	Coronary artery disease;
CESC	cis	rs13256369	0.851	rs13258283	chr8:8563630	T/C	cg17143192	chr8:8559678	CLDN23	0.78	8.81	0.48	1.65e-16	Obesity-related traits;
CESC	cis	rs9325144	0.836	rs7489197	chr12:38750065	C/T	cg26384229	chr12:38710491	ALG10B	-0.48	-5.87	-0.34	1.28e-8	Morning vs. evening chronotype;
CESC	cis	rs2742234	0.518	rs1254967	chr10:43690391	G/A	cg15436174	chr10:43711423	RASGEF1A	0.5	5.87	0.34	1.27e-8	Hirschsprung disease;
CESC	cis	rs1799949	0.526	rs4352088	chr17:41414679	A/G	cg25072359	chr17:41440525	NA	0.5	6.65	0.38	1.63e-10	Menopause (age at onset);
CESC	cis	rs9649213	0.555	rs6956686	chr7:97997945	T/C	cg21770322	chr7:97807741	LMTK2	0.57	8.7	0.47	3.62e-16	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs1957429	0.808	rs2357866	chr14:65336517	C/T	cg23373153	chr14:65346875	NA	0.85	7.82	0.43	1.26e-13	Pediatric areal bone mineral density (radius);
CESC	cis	rs2404602	0.716	rs67920045	chr15:76800084	G/A	cg22467129	chr15:76604101	ETFA	-0.36	-5.38	-0.31	1.64e-7	Blood metabolite levels;
CESC	cis	rs9911578	0.900	rs717828	chr17:56535932	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.41	5.52	0.32	7.9e-8	Intelligence (multi-trait analysis);
CESC	cis	rs2932538	0.885	rs6661642	chr1:113090109	T/C	cg22162597	chr1:113214053	CAPZA1	0.55	6.91	0.39	3.58e-11	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CESC	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	7.64	0.43	3.85e-13	Prudent dietary pattern;
CESC	cis	rs6032067	0.777	rs35476703	chr20:43802875	C/G	cg11264863	chr20:43835661	SEMG1	0.5	5.38	0.31	1.62e-7	Blood protein levels;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg03729288	chr17:7232752	NEURL4	-0.48	-6.1	-0.35	3.67e-9	Ulcerative colitis;
CESC	cis	rs7656342	0.653	rs1401439	chr4:9832622	G/C	cg00071950	chr4:10020882	SLC2A9	0.41	5.54	0.32	7.34e-8	Gut microbiota (bacterial taxa);
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg22110569	chr1:161009463	TSTD1;USF1	-0.46	-6.37	-0.36	8.29e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs2243480	1.000	rs313798	chr7:65493031	A/G	cg13147721	chr7:65941812	NA	-0.91	-8.69	-0.47	3.87e-16	Diabetic kidney disease;
CESC	cis	rs11264213	0.901	rs72661616	chr1:36370512	G/A	cg27506609	chr1:36549197	TEKT2	0.66	5.59	0.32	5.62e-8	Schizophrenia;
CESC	cis	rs7666738	0.830	rs11940273	chr4:98979965	T/A	cg17366294	chr4:99064904	C4orf37	0.59	8.46	0.46	1.87e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2204008	0.641	rs66876045	chr12:38205713	G/A	cg13010199	chr12:38710504	ALG10B	0.51	6.45	0.37	5.18e-10	Bladder cancer;
CESC	cis	rs2486288	0.656	rs8039153	chr15:45579813	T/C	cg21132104	chr15:45694354	SPATA5L1	-0.59	-7.1	-0.4	1.12e-11	Glomerular filtration rate;
CESC	cis	rs853679	0.517	rs9393898	chr6:28130376	G/T	cg23281280	chr6:28129359	ZNF389	0.61	8.26	0.45	6.87e-15	Depression;
CESC	cis	rs7959452	1.000	rs7959452	chr12:69735492	A/G	cg22834771	chr12:69754056	YEATS4	-0.43	-5.62	-0.33	4.89e-8	Blood protein levels;
CESC	cis	rs3008870	0.755	rs2815380	chr1:67510857	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-0.52	-6.55	-0.37	2.89e-10	Lymphocyte percentage of white cells;
CESC	cis	rs875971	1.000	rs2087647	chr7:65593188	C/A	cg11764359	chr7:65958608	NA	-0.93	-14.62	-0.67	6.62e-36	Aortic root size;
CESC	cis	rs4853012	0.887	rs77148265	chr2:74339519	C/T	cg19729930	chr2:74357872	NA	0.83	11.32	0.57	1.77e-24	Gestational age at birth (maternal effect);
CESC	cis	rs6582630	0.502	rs11522899	chr12:38270637	T/C	cg13010199	chr12:38710504	ALG10B	0.52	6.38	0.36	8.04e-10	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs798554	0.757	rs1182172	chr7:2878103	G/A	cg04166393	chr7:2884313	GNA12	0.58	6.96	0.39	2.73e-11	Height;
CESC	cis	rs9911578	1.000	rs2009948	chr17:56611920	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	-0.39	-5.16	-0.3	4.83e-7	Intelligence (multi-trait analysis);
CESC	cis	rs10911232	0.507	rs10911234	chr1:183053001	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.85	13.7	0.64	1.21e-32	Hypertriglyceridemia;
CESC	cis	rs4253772	0.591	rs6008595	chr22:46703860	A/T	cg18190219	chr22:46762943	CELSR1	-0.56	-6.44	-0.37	5.69e-10	LDL cholesterol;Cholesterol, total;
CESC	cis	rs9388451	0.869	rs7764016	chr6:126070789	T/G	cg05901451	chr6:126070800	HEY2	-0.63	-8.82	-0.48	1.55e-16	Brugada syndrome;
CESC	cis	rs2576037	0.583	rs9304336	chr18:44461687	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.79	13.18	0.63	7.6e-31	Personality dimensions;
CESC	cis	rs9911578	0.967	rs8182277	chr17:57144367	C/T	cg05425664	chr17:57184151	TRIM37	-0.53	-7.36	-0.41	2.28e-12	Intelligence (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11656663	chr1:202976539	TMEM183A;TMEM183B	0.57	6.09	0.35	3.92e-9	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.830	rs11097609	chr4:99011707	C/T	cg03467027	chr4:99064603	C4orf37	0.44	5.63	0.33	4.57e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg16405210	chr4:1374714	KIAA1530	-0.9	-12.06	-0.6	5.62e-27	Longevity;
CESC	cis	rs7937682	0.924	rs875258	chr11:111530607	C/A	cg09085632	chr11:111637200	PPP2R1B	-1.0	-16.56	-0.71	9.02e-43	Primary sclerosing cholangitis;
CESC	cis	rs7552404	0.924	rs114752222	chr1:76180878	C/T	cg03433033	chr1:76189801	ACADM	0.7	9.42	0.5	2.34e-18	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs5758511	0.680	rs5758682	chr22:42645202	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.58	8.64	0.47	5.58e-16	Birth weight;
CESC	cis	rs11608355	0.576	rs1477117	chr12:109888779	A/G	cg05360138	chr12:110035743	NA	-0.75	-7.75	-0.43	2.03e-13	Neuroticism;
CESC	cis	rs2204008	0.599	rs2320526	chr12:38220405	T/A	cg26384229	chr12:38710491	ALG10B	0.67	9.49	0.5	1.38e-18	Bladder cancer;
CESC	cis	rs7524258	0.900	rs7551574	chr1:7314363	G/T	cg07173049	chr1:7289937	CAMTA1	0.36	5.61	0.33	5.2e-8	Tourette's syndrome or obsessive-compulsive disorder;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg14528756	chr2:176862893	KIAA1715	0.41	6.66	0.38	1.56e-10	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs9322193	0.961	rs9027	chr6:149916057	T/A	cg13206674	chr6:150067644	NUP43	0.38	5.42	0.32	1.31e-7	Lung cancer;
CESC	cis	rs4481887	0.927	rs7524700	chr1:248472816	A/G	cg00666640	chr1:248458726	OR2T12	0.36	6.12	0.35	3.33e-9	Common traits (Other);
CESC	cis	rs965469	0.779	rs6051717	chr20:3270242	C/T	cg25506879	chr20:3388711	C20orf194	-0.48	-5.29	-0.31	2.52e-7	IFN-related cytopenia;
CESC	cis	rs4704187	0.663	rs4404659	chr5:74422119	T/C	cg03227963	chr5:74354835	NA	0.31	5.7	0.33	3.22e-8	Response to amphetamines;
CESC	cis	rs4927850	0.881	rs7624638	chr3:195748729	C/T	cg01181863	chr3:195395398	SDHAP2	-0.48	-5.57	-0.32	6.34e-8	Pancreatic cancer;
CESC	cis	rs4722166	0.630	rs13311155	chr7:22789789	A/C	cg05472934	chr7:22766657	IL6	0.83	10.33	0.54	3.1e-21	Lung cancer;
CESC	cis	rs7923609	0.967	rs7909269	chr10:65177766	G/A	cg01631684	chr10:65280961	REEP3	-0.43	-5.32	-0.31	2.25e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs2841277	0.708	rs4465542	chr14:105407798	A/G	cg15352829	chr14:105391018	PLD4	-0.6	-10.49	-0.54	9.33e-22	Rheumatoid arthritis;
CESC	cis	rs13191362	1.000	rs34398656	chr6:162999612	G/T	cg21926612	chr6:163149169	PACRG;PARK2	0.83	8.86	0.48	1.15e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs10504073	0.647	rs10435574	chr8:49996028	G/A	cg00325661	chr8:49890786	NA	0.55	8.17	0.45	1.29e-14	Blood metabolite ratios;
CESC	cis	rs116095464	0.558	rs6875291	chr5:264192	T/C	cg22496380	chr5:211416	CCDC127	-0.74	-8.46	-0.46	1.86e-15	Breast cancer;
CESC	cis	rs35306767	0.903	rs11253488	chr10:922482	G/C	cg20503657	chr10:835505	NA	0.77	7.56	0.42	6.6e-13	Eosinophil percentage of granulocytes;
CESC	cis	rs11785693	0.862	rs17435612	chr8:4987896	C/T	cg26367366	chr8:4980734	NA	-0.6	-6.25	-0.36	1.62e-9	Neuroticism (multi-trait analysis);Neuroticism;
CESC	cis	rs7914558	0.966	rs4532960	chr10:104667406	C/T	cg08650961	chr10:104748594	CNNM2	0.32	5.09	0.3	6.95e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs2404602	0.532	rs12591100	chr15:76700801	C/A	cg00316803	chr15:76480434	C15orf27	0.37	5.54	0.32	7.33e-8	Blood metabolite levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08912058	chr1:6313858	GPR153	-0.52	-6.06	-0.35	4.68e-9	Gut microbiome composition (summer);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg06819704	chr5:159707559	CCNJL	0.44	6.01	0.35	6.27e-9	Fibrinogen levels;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg08496016	chr9:99181722	ZNF367	0.47	6.29	0.36	1.3e-9	Gut microbiota (bacterial taxa);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg03242101	chr16:67143792	C16orf70	-0.46	-6.07	-0.35	4.38e-9	Ulcerative colitis;
CESC	trans	rs853679	0.607	rs13203816	chr6:28079598	T/C	cg06606381	chr12:133084897	FBRSL1	-1.1	-8.36	-0.46	3.51e-15	Depression;
CESC	cis	rs9790314	0.967	rs460165	chr3:161087710	G/A	cg04691961	chr3:161091175	C3orf57	-0.4	-5.11	-0.3	6.19e-7	Morning vs. evening chronotype;
CESC	cis	rs733592	0.524	rs10875741	chr12:48492922	A/C	cg24011408	chr12:48396354	COL2A1	-0.5	-8.33	-0.46	4.47e-15	Plateletcrit;
CESC	cis	rs847577	0.609	rs11768309	chr7:97773812	G/T	cg21770322	chr7:97807741	LMTK2	0.87	15.35	0.69	1.77e-38	Breast cancer;
CESC	cis	rs2267137	0.747	rs1963292	chr22:29805867	T/C	cg07256473	chr22:29710276	RASL10A	0.38	5.53	0.32	7.68e-8	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	trans	rs6054906	0.710	rs6117744	chr20:7265038	A/C	cg02086952	chr17:54911499	DGKE	0.46	6.04	0.35	5.27e-9	Response to amphetamines;
CESC	cis	rs12681288	0.644	rs2123058	chr8:1000304	A/G	cg04851639	chr8:1020857	NA	-0.32	-6.83	-0.39	5.89e-11	Schizophrenia;
CESC	cis	rs9287719	0.934	rs6710033	chr2:10757677	C/T	cg00105475	chr2:10696890	NA	0.37	5.4	0.31	1.52e-7	Prostate cancer;
CESC	cis	rs2425143	1.000	rs73905926	chr20:34251982	G/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.61	5.17	0.3	4.59e-7	Blood protein levels;
CESC	cis	rs651907	0.557	rs1056579	chr3:101397877	T/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.46	5.91	0.34	1.07e-8	Colorectal cancer;
CESC	cis	rs9322193	0.923	rs9767554	chr6:149937996	T/C	cg13206674	chr6:150067644	NUP43	0.43	6.32	0.36	1.11e-9	Lung cancer;
CESC	cis	rs2732480	0.557	rs2732454	chr12:48719677	T/C	cg24011408	chr12:48396354	COL2A1	0.4	5.76	0.33	2.31e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs34172651	0.517	rs8059004	chr16:24837905	G/A	cg06028605	chr16:24865363	SLC5A11	0.53	7.87	0.44	9.04e-14	Intelligence (multi-trait analysis);
CESC	cis	rs67311347	1.000	rs13324109	chr3:40460767	T/C	cg09455208	chr3:40491958	NA	0.45	7.58	0.42	5.66e-13	Renal cell carcinoma;
CESC	cis	rs1144333	1.000	rs78223982	chr1:76465203	T/C	cg10523679	chr1:76189770	ACADM	0.55	5.14	0.3	5.24e-7	Attention function in attention deficit hyperactive disorder;
CESC	cis	rs55794721	0.509	rs7554255	chr1:25778106	C/T	cg03538708	chr1:25844672	NA	-0.41	-6.27	-0.36	1.48e-9	Plateletcrit;Mean corpuscular volume;
CESC	cis	rs793571	0.614	rs347117	chr15:59000957	C/T	cg05156742	chr15:59063176	FAM63B	0.58	7.66	0.43	3.42e-13	Schizophrenia;
CESC	cis	rs7100689	0.646	rs1815650	chr10:82157464	C/T	cg00277334	chr10:82204260	NA	-0.46	-6.31	-0.36	1.19e-9	Post bronchodilator FEV1;
CESC	trans	rs11989744	0.956	rs35693687	chr8:23575746	A/G	cg03492747	chr16:86543808	FOXF1	0.68	7.53	0.42	7.9e-13	Waist-hip ratio;
CESC	cis	rs2262909	0.962	rs411020	chr19:22231102	G/A	cg11619707	chr19:22235551	ZNF257	-0.32	-5.26	-0.31	2.94e-7	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
CESC	cis	rs6831352	0.879	rs29001229	chr4:100046823	A/G	cg12011299	chr4:100065546	ADH4	-0.58	-6.41	-0.37	6.57e-10	Alcohol dependence;
CESC	cis	rs7312933	0.702	rs10785333	chr12:42586470	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.5	-6.54	-0.37	3.15e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs72781680	0.898	rs116113042	chr2:23960194	G/T	cg20701182	chr2:24300061	SF3B14	0.62	5.49	0.32	9.46e-8	Lymphocyte counts;
CESC	cis	rs6860806	0.695	rs11952099	chr5:131576772	A/G	cg04518342	chr5:131593106	PDLIM4	0.4	6.15	0.35	2.9e-9	Breast cancer;
CESC	cis	rs2439831	0.850	rs16950562	chr15:44036364	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.68	7.97	0.44	4.64e-14	Lung cancer in ever smokers;
CESC	cis	rs11608355	0.515	rs2241204	chr12:109972037	G/A	cg05360138	chr12:110035743	NA	0.82	8.92	0.48	7.9e-17	Neuroticism;
CESC	cis	rs875971	0.505	rs1723275	chr7:65504633	G/C	cg06456125	chr7:65229604	NA	-0.47	-6.28	-0.36	1.36e-9	Aortic root size;
CESC	cis	rs13256369	0.951	rs10503394	chr8:8565775	A/G	cg17143192	chr8:8559678	CLDN23	0.75	8.75	0.47	2.58e-16	Obesity-related traits;
CESC	cis	rs10504229	0.817	rs55949560	chr8:58167603	T/C	cg24829409	chr8:58192753	C8orf71	-0.63	-8.99	-0.48	4.81e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs6540559	0.673	rs1073150	chr1:210017083	G/A	cg21951975	chr1:209979733	IRF6	0.55	6.64	0.38	1.75e-10	Cleft lip with or without cleft palate;
CESC	cis	rs3785574	0.962	rs7219920	chr17:61811642	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.81	10.83	0.55	6.96e-23	Height;
CESC	cis	rs875971	0.660	rs79009421	chr7:66068509	G/C	cg06456125	chr7:65229604	NA	-0.4	-5.18	-0.3	4.45e-7	Aortic root size;
CESC	cis	rs7927592	0.731	rs7108376	chr11:68347870	A/G	cg16797656	chr11:68205561	LRP5	-0.48	-7.32	-0.41	2.97e-12	Total body bone mineral density;
CESC	cis	rs60843830	0.661	rs6755432	chr2:106692	T/C	cg00108164	chr2:264199	ACP1;SH3YL1	0.44	5.14	0.3	5.34e-7	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs4665809	1.000	rs1560868	chr2:26281459	A/T	cg22920501	chr2:26401640	FAM59B	0.81	9.89	0.52	7.79e-20	Gut microbiome composition (summer);
CESC	cis	rs9486719	0.857	rs4346856	chr6:96880270	C/T	cg06623918	chr6:96969491	KIAA0776	0.88	10.92	0.56	3.63e-23	Migraine;Coronary artery disease;
CESC	cis	rs7666738	0.822	rs13110418	chr4:99046963	G/A	cg03467027	chr4:99064603	C4orf37	0.47	5.98	0.34	7.19e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7772486	0.875	rs10872583	chr6:146396699	G/T	cg23711669	chr6:146136114	FBXO30	-0.83	-11.96	-0.59	1.24e-26	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7412746	0.611	rs16827671	chr1:150738759	T/C	cg22823121	chr1:150693482	HORMAD1	0.47	6.58	0.37	2.48e-10	Melanoma;
CESC	cis	rs4555082	0.957	rs3000073	chr14:105729792	G/A	cg27165867	chr14:105738592	BRF1	-0.53	-6.2	-0.36	2.13e-9	Mean platelet volume;Platelet distribution width;
CESC	cis	rs7246657	0.882	rs10422667	chr19:37937876	T/C	cg23950597	chr19:37808831	NA	-0.62	-6.3	-0.36	1.24e-9	Coronary artery calcification;
CESC	cis	rs9872999	1	rs9872999	chr3:133457514	C/T	cg17775713	chr3:133465469	TF	0.33	5.91	0.34	1.04e-8	Iron status biomarkers;
CESC	cis	rs9486715	0.867	rs6568428	chr6:96903604	A/G	cg06623918	chr6:96969491	KIAA0776	0.93	14.44	0.66	2.86e-35	Headache;
CESC	cis	rs3796352	0.892	rs58515094	chr3:52995575	C/T	cg12962167	chr3:53033115	SFMBT1	0.62	5.13	0.3	5.63e-7	Immune reponse to smallpox (secreted IL-2);
CESC	cis	rs3820068	0.705	rs4645983	chr1:15850603	G/A	cg18192808	chr1:15853278	DNAJC16	0.47	5.81	0.34	1.75e-8	Systolic blood pressure;
CESC	cis	rs9488822	0.702	rs6909746	chr6:116352750	C/T	cg15226275	chr6:116381976	FRK	0.25	6.36	0.36	8.99e-10	Cholesterol, total;LDL cholesterol;
CESC	cis	rs875971	0.660	rs12698534	chr7:65986845	C/T	cg25985355	chr7:65971099	NA	-0.31	-5.05	-0.3	8.31e-7	Aortic root size;
CESC	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.38	5.25	0.31	3.16e-7	Lymphocyte counts;
CESC	cis	rs854765	0.583	rs11869536	chr17:17826528	T/A	cg09796270	chr17:17721594	SREBF1	0.43	6.05	0.35	4.93e-9	Total body bone mineral density;
CESC	cis	rs7635838	0.617	rs346076	chr3:11292682	A/G	cg00170343	chr3:11313890	ATG7	-0.63	-9.38	-0.5	3.07e-18	HDL cholesterol;
CESC	cis	rs12477438	0.520	rs13018891	chr2:99755099	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.85	15.81	0.7	4.17e-40	Chronic sinus infection;
CESC	cis	rs7666738	0.830	rs11726604	chr4:99000969	T/C	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.62e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs225245	0.817	rs1476553	chr17:33994566	C/T	cg05299278	chr17:33885742	SLFN14	0.36	5.14	0.3	5.34e-7	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
CESC	cis	rs10751667	0.666	rs4074231	chr11:978219	G/C	cg06064525	chr11:970664	AP2A2	-0.47	-9.12	-0.49	1.9e-17	Alzheimer's disease (late onset);
CESC	cis	rs9611565	0.918	rs9611566	chr22:41768625	A/G	cg03806693	chr22:41940476	POLR3H	1.04	12.12	0.6	3.49e-27	Vitiligo;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg17099815	chr15:31217407	MTMR15	-0.48	-6.4	-0.37	7.15e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs7937682	0.632	rs11214015	chr11:111719417	A/T	cg22437258	chr11:111473054	SIK2	0.51	5.74	0.33	2.57e-8	Primary sclerosing cholangitis;
CESC	cis	rs754466	0.651	rs10762767	chr10:79645070	C/A	cg17075019	chr10:79541650	NA	-0.84	-12.55	-0.61	1.15e-28	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs7811142	1.000	rs112317829	chr7:100043173	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.03	11.46	0.58	5.9e-25	Platelet count;
CESC	cis	rs1552244	0.882	rs17050660	chr3:10001772	A/G	cg08888203	chr3:10149979	C3orf24	-0.44	-5.86	-0.34	1.36e-8	Alzheimer's disease;
CESC	cis	rs10788264	0.538	rs1998344	chr10:124030137	A/G	cg09507567	chr10:124027408	NA	0.39	5.78	0.33	2.08e-8	Total body bone mineral density;
CESC	cis	rs514406	0.584	rs12095247	chr1:53193796	A/C	cg08736216	chr1:53307985	ZYG11A	0.4	6.33	0.36	1.04e-9	Monocyte count;
CESC	cis	rs9322193	0.923	rs11155677	chr6:150078089	C/G	cg07701084	chr6:150067640	NUP43	0.49	6.81	0.39	6.47e-11	Lung cancer;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg02978827	chr13:48877687	RB1	-0.49	-6.51	-0.37	3.73e-10	Asthma;
CESC	trans	rs72766638	1.000	rs72766638	chr9:136931778	C/A	cg10765909	chr12:53715428	AAAS	-0.73	-6.51	-0.37	3.82e-10	Mosquito bite size;
CESC	cis	rs2361718	1.000	rs2361718	chr17:78103466	C/T	cg20811857	chr17:78079795	GAA	-0.32	-5.03	-0.3	8.96e-7	Yeast infection;
CESC	cis	rs2243480	0.901	rs73148097	chr7:65431787	A/C	cg13147721	chr7:65941812	NA	-0.9	-8.65	-0.47	4.98e-16	Diabetic kidney disease;
CESC	cis	rs17125944	0.505	rs77433996	chr14:53212263	G/A	cg13660082	chr14:53194042	PSMC6	-0.66	-6.03	-0.35	5.46e-9	Alzheimer's disease (late onset);
CESC	cis	rs96067	0.652	rs274132	chr1:36581978	C/T	cg27506609	chr1:36549197	TEKT2	0.33	5.21	0.3	3.78e-7	Corneal structure;
CESC	cis	rs7618501	1.000	rs7618501	chr3:49772647	A/G	cg24308560	chr3:49941425	MST1R	0.5	6.81	0.39	6.38e-11	Intelligence (multi-trait analysis);
CESC	cis	rs6088580	0.634	rs6087579	chr20:32985155	A/G	cg08999081	chr20:33150536	PIGU	-0.65	-11.43	-0.57	7.18e-25	Glomerular filtration rate (creatinine);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03428881	chr7:150725579	ABCB8	0.6	6.9	0.39	3.79e-11	Gut microbiome composition (summer);
CESC	cis	rs4642101	0.737	rs6767504	chr3:12826667	C/T	cg05775895	chr3:12838266	CAND2	0.38	5.69	0.33	3.38e-8	QRS complex (12-leadsum);
CESC	cis	rs8014204	0.935	rs4903267	chr14:75360419	G/T	cg08847533	chr14:75593920	NEK9	-0.46	-5.68	-0.33	3.46e-8	Caffeine consumption;
CESC	cis	rs10504229	1.000	rs116444534	chr8:58181915	A/G	cg24829409	chr8:58192753	C8orf71	-0.69	-9.06	-0.49	2.93e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg26338869	chr17:61819248	STRADA	0.69	9.18	0.49	1.31e-17	Prudent dietary pattern;
CESC	cis	rs9894429	0.789	rs6565611	chr17:79598319	T/C	cg18240062	chr17:79603768	NPLOC4	0.9	13.13	0.63	1.15e-30	Eye color traits;
CESC	cis	rs7267979	0.932	rs431579	chr20:25470056	T/C	cg08601574	chr20:25228251	PYGB	0.37	5.37	0.31	1.76e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7666738	0.606	rs4577589	chr4:99087858	A/G	cg05340658	chr4:99064831	C4orf37	0.65	8.94	0.48	6.63e-17	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2836974	0.563	rs997147	chr21:40695325	A/G	cg17971929	chr21:40555470	PSMG1	-0.85	-12.26	-0.6	1.12e-27	Cognitive function;
CESC	cis	rs12765878	1.000	rs1980653	chr10:105654164	A/G	cg24587175	chr10:105670608	OBFC1	0.34	5.54	0.32	7.37e-8	Coronary artery disease;
CESC	cis	rs13223928	0.554	rs13438334	chr7:3156956	G/A	cg19214707	chr7:3157722	NA	-0.43	-5.78	-0.33	2.09e-8	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
CESC	cis	rs4423214	0.592	rs3829251	chr11:71194559	G/A	cg05163923	chr11:71159392	DHCR7	-0.62	-6.12	-0.35	3.29e-9	Vitamin D levels;
CESC	cis	rs15676	0.838	rs2280841	chr9:131600111	T/C	cg00228799	chr9:131580591	ENDOG	0.55	7.06	0.4	1.43e-11	Blood metabolite levels;
CESC	cis	rs9311474	0.508	rs1570	chr3:52586682	T/A	cg18099408	chr3:52552593	STAB1	-0.36	-6.12	-0.35	3.3e-9	Electroencephalogram traits;
CESC	cis	rs7264396	0.563	rs2425089	chr20:34304036	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.63	6.7	0.38	1.23e-10	Total cholesterol levels;
CESC	cis	rs3785574	0.638	rs2854182	chr17:61969062	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.03	16.25	0.71	1.1e-41	Height;
CESC	cis	rs7020830	0.830	rs12554976	chr9:37244505	G/T	cg14294708	chr9:37120828	ZCCHC7	1.2	22.49	0.81	2.13e-63	Schizophrenia;
CESC	cis	rs4819052	0.851	rs35871601	chr21:46675214	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.77	10.14	0.53	1.23e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs10078	0.898	rs2241598	chr5:438564	C/T	cg08916839	chr5:415575	AHRR	-0.41	-5.32	-0.31	2.22e-7	Fat distribution (HIV);
CESC	cis	rs4555082	0.830	rs2816614	chr14:105727359	C/T	cg10792982	chr14:105748885	BRF1	0.41	5.26	0.31	2.96e-7	Mean platelet volume;Platelet distribution width;
CESC	cis	rs736408	0.509	rs3774349	chr3:52722335	A/C	cg18337363	chr3:52569053	NT5DC2	0.31	6.1	0.35	3.71e-9	Bipolar disorder;
CESC	cis	rs2637266	0.703	rs846639	chr10:78524428	A/G	cg18941641	chr10:78392320	NA	0.38	7.56	0.42	6.56e-13	Pulmonary function;
CESC	cis	rs1580019	0.961	rs2392056	chr7:32498953	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.73	10.11	0.53	1.5e-20	Cognitive ability;
CESC	cis	rs7649275	0.882	rs877257	chr3:53784503	A/G	cg21503701	chr3:53781065	CACNA1D	-0.39	-5.19	-0.3	4.28e-7	Trans fatty acid levels;
CESC	cis	rs6499255	1.000	rs4497676	chr16:69814950	G/A	cg15192750	chr16:69999425	NA	0.44	5.41	0.32	1.41e-7	IgE levels;
CESC	cis	rs6815814	0.950	rs5743557	chr4:38806827	G/A	cg02016764	chr4:38805732	TLR1	-0.63	-7.2	-0.4	6.39e-12	Breast cancer;
CESC	cis	rs644799	0.542	rs10831415	chr11:95466159	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.65	9.13	0.49	1.83e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs9612	1.000	rs346526	chr19:44259565	A/G	cg08581076	chr19:44259116	C19orf61	0.52	6.14	0.35	2.96e-9	Exhaled nitric oxide output;
CESC	cis	rs10256972	0.967	rs7799110	chr7:1039065	A/G	cg00431813	chr7:1051703	C7orf50	-0.39	-6.06	-0.35	4.71e-9	Longevity;Endometriosis;
CESC	cis	rs2228479	0.867	rs73276534	chr16:89950557	A/G	cg04013166	chr16:89971882	TCF25	0.73	8.84	0.48	1.38e-16	Skin colour saturation;
CESC	cis	rs3008870	0.883	rs2755249	chr1:67493662	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.01	13.63	0.64	1.99e-32	Lymphocyte percentage of white cells;
CESC	cis	rs34172651	0.517	rs1465423	chr16:24772680	C/G	cg06028605	chr16:24865363	SLC5A11	-0.53	-7.96	-0.44	5.15e-14	Intelligence (multi-trait analysis);
CESC	cis	rs561341	1.000	rs508192	chr17:30315147	C/T	cg12193833	chr17:30244370	NA	0.68	6.08	0.35	4.11e-9	Hip circumference adjusted for BMI;
CESC	cis	rs72781680	1.000	rs72796327	chr2:24140372	T/C	cg08917208	chr2:24149416	ATAD2B	1.02	9.22	0.49	9.42e-18	Lymphocyte counts;
CESC	cis	rs7584330	0.910	rs880932	chr2:238396963	A/G	cg11271282	chr2:238384023	NA	0.48	5.7	0.33	3.22e-8	Prostate cancer;
CESC	cis	rs9911578	0.967	rs9894274	chr17:56977919	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.41	5.41	0.32	1.38e-7	Intelligence (multi-trait analysis);
CESC	cis	rs7953249	0.618	rs2650000	chr12:121388962	G/T	cg02403541	chr12:121454288	C12orf43	0.51	6.73	0.38	1.04e-10	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
CESC	cis	rs72781680	0.848	rs72798057	chr2:23976731	T/C	cg20701182	chr2:24300061	SF3B14	0.63	5.54	0.32	7.13e-8	Lymphocyte counts;
CESC	cis	rs7598759	0.527	rs7571691	chr2:232369401	C/T	cg19187155	chr2:232395269	NMUR1	0.61	10.12	0.53	1.46e-20	Noise-induced hearing loss;
CESC	cis	rs6674176	0.932	rs7412307	chr1:44433864	C/G	cg12908607	chr1:44402522	ARTN	0.46	6.32	0.36	1.11e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs9322193	0.923	rs14314	chr6:150141531	A/C	cg07701084	chr6:150067640	NUP43	0.44	5.91	0.34	1.04e-8	Lung cancer;
CESC	cis	rs9910055	0.529	rs425038	chr17:42182028	T/C	cg19774624	chr17:42201019	HDAC5	0.66	9.1	0.49	2.22e-17	Total body bone mineral density;
CESC	cis	rs3008870	0.755	rs11208974	chr1:67398119	A/T	cg02640540	chr1:67518911	SLC35D1	0.46	5.56	0.32	6.52e-8	Lymphocyte percentage of white cells;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg10593459	chr1:44447478	B4GALT2	0.44	6.41	0.37	6.63e-10	Fibrinogen levels;
CESC	cis	rs3858526	0.839	rs10466484	chr11:5943696	A/G	cg02574844	chr11:5959923	NA	-0.43	-5.41	-0.32	1.42e-7	DNA methylation (variation);
CESC	cis	rs7605827	0.930	rs7568459	chr2:15691026	C/T	cg19274914	chr2:15703543	NA	0.37	6.7	0.38	1.22e-10	Educational attainment (years of education);
CESC	cis	rs514406	0.627	rs485128	chr1:53344583	T/C	cg25767906	chr1:53392781	SCP2	-0.57	-7.56	-0.42	6.52e-13	Monocyte count;
CESC	cis	rs5769765	1.000	rs761879	chr22:50241210	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	0.51	5.9	0.34	1.11e-8	Schizophrenia;
CESC	cis	rs910316	0.967	rs2010678	chr14:75567178	C/T	cg08847533	chr14:75593920	NEK9	1.01	19.43	0.77	6.73e-53	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12035827	chr1:10855226	CASZ1	0.66	7.56	0.42	6.42e-13	Gut microbiome composition (summer);
CESC	cis	rs3096299	0.967	rs28575874	chr16:89469890	C/T	cg08822215	chr16:89438651	ANKRD11	-0.39	-5.9	-0.34	1.13e-8	Multiple myeloma (IgH translocation);
CESC	cis	rs672059	0.565	rs525410	chr1:183176430	C/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.52	-6.98	-0.39	2.36e-11	Hypertriglyceridemia;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg21149582	chr1:10532838	DFFA	-0.51	-7.42	-0.41	1.59e-12	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs2281727	0.500	rs2169356	chr17:2138016	A/T	cg16513277	chr17:2031491	SMG6	-0.63	-8.88	-0.48	1.06e-16	Coronary artery disease;Body mass index;
CESC	cis	rs2075371	0.829	rs35897242	chr7:134004041	G/A	cg11752832	chr7:134001865	SLC35B4	0.52	6.64	0.38	1.76e-10	Mean platelet volume;
CESC	cis	rs2455799	0.573	rs2455836	chr3:15754538	A/G	cg09340198	chr3:15902540	ANKRD28	-0.32	-5.09	-0.3	6.67e-7	Mean platelet volume;
CESC	cis	rs4867766	0.871	rs2242419	chr5:173959332	C/T	cg20434911	chr5:173954559	NA	0.56	6.16	0.35	2.72e-9	Stroke;
CESC	cis	rs7666738	0.830	rs10031292	chr4:99056877	A/G	cg05340658	chr4:99064831	C4orf37	0.82	13.07	0.63	1.82e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7666738	0.830	rs10014284	chr4:98681951	G/C	cg03467027	chr4:99064603	C4orf37	0.44	5.39	0.31	1.52e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4953318	0.694	rs3768747	chr2:46352058	G/T	cg12428440	chr2:46370979	PRKCE	-0.48	-6.83	-0.39	5.66e-11	Red blood cell count;Hematocrit;Red blood cell traits;
CESC	cis	rs863345	0.625	rs10908655	chr1:158460899	C/T	cg12129480	chr1:158549410	OR10X1	-0.36	-7.15	-0.4	8.67e-12	Pneumococcal bacteremia;
CESC	cis	rs7274811	0.652	rs293732	chr20:31975090	G/A	cg21523528	chr20:32077966	CBFA2T2	-0.55	-6.42	-0.37	6.26e-10	Height;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg13445258	chr3:128369860	RPN1	-0.45	-6.52	-0.37	3.52e-10	Gambling;
CESC	cis	rs10411936	0.692	rs62118141	chr19:16602808	T/C	cg10248733	chr19:16607483	C19orf44;CALR3	0.53	6.5	0.37	3.88e-10	White blood cell count;Multiple sclerosis;
CESC	cis	rs3091242	0.933	rs909833	chr1:25754140	C/G	cg27572855	chr1:25598939	RHD	0.43	7.14	0.4	9.07e-12	Erythrocyte sedimentation rate;
CESC	cis	rs9733	0.596	rs56058687	chr1:150635066	C/T	cg04414720	chr1:150670196	GOLPH3L	0.63	9.08	0.49	2.58e-17	Tonsillectomy;
CESC	cis	rs5769707	0.609	rs739247	chr22:49996657	T/C	cg20744362	chr22:50050164	C22orf34	0.37	5.39	0.31	1.53e-7	Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs778371	1.000	rs778371	chr2:233743109	A/G	cg08000102	chr2:233561755	GIGYF2	-0.8	-11.14	-0.56	6.71e-24	Schizophrenia;
CESC	cis	rs2760061	0.583	rs1636195	chr1:228211589	T/C	cg02753203	chr1:228287806	NA	0.79	10.96	0.56	2.59e-23	Diastolic blood pressure;
CESC	cis	rs2404602	0.716	rs17460201	chr15:76673627	C/T	cg26408565	chr15:76604113	ETFA	0.44	6.44	0.37	5.72e-10	Blood metabolite levels;
CESC	cis	rs9929218	0.906	rs33965787	chr16:68828173	G/A	cg02972257	chr16:68554789	NA	0.44	5.25	0.31	3.2e-7	Colorectal cancer;
CESC	cis	rs11792861	0.816	rs28361186	chr9:111704064	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.52	6.67	0.38	1.49e-10	Menarche (age at onset);
CESC	cis	rs597539	0.654	rs655816	chr11:68626405	A/G	cg04772025	chr11:68637568	NA	0.58	6.73	0.38	1.06e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs7666738	0.830	rs10029849	chr4:99059362	T/C	cg18180107	chr4:99064573	C4orf37	0.42	5.3	0.31	2.44e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs57506017	0.585	rs6460898	chr7:12252893	A/G	cg23422036	chr7:12250390	TMEM106B	0.38	5.12	0.3	5.88e-7	Neuroticism;
CESC	cis	rs4665809	0.531	rs10199898	chr2:26445485	T/G	cg22920501	chr2:26401640	FAM59B	-0.91	-10.33	-0.54	3.07e-21	Gut microbiome composition (summer);
CESC	cis	rs7599312	0.532	rs16848751	chr2:213389346	A/G	cg16329650	chr2:213403929	ERBB4	0.41	5.43	0.32	1.3e-7	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs9583531	0.600	rs4773241	chr13:111363021	A/G	cg15841412	chr13:111365552	ING1	0.53	6.72	0.38	1.1e-10	Coronary artery disease;
CESC	cis	rs10479542	0.784	rs7703730	chr5:178986632	C/A	cg00080972	chr5:178986291	RUFY1	-0.44	-6.93	-0.39	3.24e-11	Lung cancer;
CESC	cis	rs6952808	0.595	rs3778984	chr7:2166514	T/C	cg02951883	chr7:2050386	MAD1L1	-0.46	-5.89	-0.34	1.14e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs10779751	0.922	rs11121708	chr1:11307253	G/C	cg08854313	chr1:11322531	MTOR	0.8	10.83	0.55	6.99e-23	Body mass index;
CESC	cis	rs1008375	1.000	rs10939740	chr4:17617490	T/C	cg04450456	chr4:17643702	FAM184B	0.41	5.77	0.33	2.18e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs9611565	0.649	rs202614	chr22:41822150	A/C	cg17376030	chr22:41985996	PMM1	-0.76	-8.01	-0.44	3.71e-14	Vitiligo;
CESC	cis	rs13095912	0.785	rs6444076	chr3:185321405	T/C	cg11274856	chr3:185301563	NA	0.4	5.99	0.35	6.69e-9	Systolic blood pressure;
CESC	cis	rs7044106	0.615	rs10818470	chr9:123359204	A/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.75	11.1	0.56	9.3e-24	Hip circumference adjusted for BMI;
CESC	cis	rs2836974	0.897	rs2836944	chr21:40593539	G/A	cg17971929	chr21:40555470	PSMG1	1.08	16.45	0.71	2.24e-42	Cognitive function;
CESC	cis	rs4974559	1.000	rs4974559	chr4:1380848	C/T	cg02980000	chr4:1222292	CTBP1	-0.71	-8.95	-0.48	6.25e-17	Systolic blood pressure;
CESC	cis	rs17253792	0.822	rs17685078	chr14:56127202	T/C	cg01858014	chr14:56050164	KTN1	-0.97	-7.54	-0.42	7.36e-13	Putamen volume;
CESC	cis	rs3126085	0.935	rs12027807	chr1:152253726	C/G	cg03465714	chr1:152285911	FLG	-0.46	-5.75	-0.33	2.42e-8	Atopic dermatitis;
CESC	cis	rs1953600	1.000	rs2789679	chr10:81907884	A/T	cg00277334	chr10:82204260	NA	-0.51	-7.23	-0.41	5.11e-12	Sarcoidosis;
CESC	cis	rs77106637	0.860	rs7129793	chr11:72455885	C/T	cg03713592	chr11:72463424	ARAP1	1.3	11.0	0.56	2e-23	Type 2 diabetes;
CESC	cis	rs741677	0.663	rs405203	chr17:491009	A/G	cg15660573	chr17:549704	VPS53	0.43	5.65	0.33	4.24e-8	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
CESC	cis	rs9467711	0.606	rs9393714	chr6:26373740	G/T	cg12826209	chr6:26865740	GUSBL1	0.62	5.34	0.31	1.96e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs1862618	0.853	rs1862619	chr5:56098256	T/A	cg12311346	chr5:56204834	C5orf35	-0.64	-7.96	-0.44	4.98e-14	Initial pursuit acceleration;
CESC	cis	rs1218582	0.772	rs6683557	chr1:154852307	C/G	cg09359103	chr1:154839909	KCNN3	-0.66	-12.64	-0.61	5.4e-29	Prostate cancer;
CESC	cis	rs12142240	0.698	rs41294476	chr1:46818374	C/A	cg00530320	chr1:46809349	NSUN4	0.58	7.89	0.44	8.15e-14	Menopause (age at onset);
CESC	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.55	-6.17	-0.35	2.48e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7178909	0.872	rs7174330	chr15:90434579	C/T	cg19708238	chr15:90437601	AP3S2	-0.4	-5.65	-0.33	4.15e-8	Common traits (Other);
CESC	cis	rs2032447	0.802	rs199755	chr6:25990367	G/A	cg12310025	chr6:25882481	NA	-0.45	-6.26	-0.36	1.57e-9	Intelligence (multi-trait analysis);
CESC	cis	rs897984	0.542	rs11865038	chr16:31095171	C/T	cg02466173	chr16:30829666	NA	-0.4	-6.75	-0.38	9.46e-11	Dementia with Lewy bodies;
CESC	cis	rs7223966	1.000	rs8073373	chr17:61703320	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.45	-5.46	-0.32	1.1e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs2797160	1.000	rs1935774	chr6:125996661	A/G	cg05901451	chr6:126070800	HEY2	0.41	6.09	0.35	4e-9	Endometrial cancer;
CESC	cis	rs1878931	0.597	rs37814	chr16:3455247	C/T	cg22508957	chr16:3507546	NAT15	0.4	5.29	0.31	2.57e-7	Body mass index (adult);
CESC	cis	rs79387448	0.638	rs78123896	chr2:103075417	T/C	cg09003973	chr2:102972529	NA	0.78	6.46	0.37	5e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs7116495	1.000	rs17161966	chr11:71815308	T/C	cg26138937	chr11:71823887	C11orf51	0.85	6.85	0.39	5.03e-11	Severe influenza A (H1N1) infection;
CESC	cis	rs7618915	0.501	rs2164885	chr3:52731269	T/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	5.86	0.34	1.41e-8	Bipolar disorder;
CESC	cis	rs7267979	0.833	rs4619688	chr20:25244101	C/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.82	15.09	0.68	1.41e-37	Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs9325144	0.647	rs11168741	chr12:38989120	C/T	cg23762105	chr12:34175262	ALG10	0.48	6.33	0.36	1.03e-9	Morning vs. evening chronotype;
CESC	cis	rs17376456	0.809	rs10476602	chr5:93445255	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.57	5.08	0.3	7.18e-7	Diabetic retinopathy;
CESC	cis	rs4789693	0.938	rs4789694	chr17:80428099	A/C	cg04308225	chr17:80449738	NA	-0.45	-5.23	-0.31	3.52e-7	Glucocorticoid-induced osteonecrosis;
CESC	cis	rs4409675	0.576	rs11247706	chr1:28213983	G/C	cg23691781	chr1:28212827	C1orf38	0.29	5.69	0.33	3.41e-8	Corneal astigmatism;
CESC	cis	rs9486719	1.000	rs2499816	chr6:96878206	C/T	cg18709589	chr6:96969512	KIAA0776	0.53	5.81	0.34	1.75e-8	Migraine;Coronary artery disease;
CESC	cis	rs11249608	0.548	rs17078991	chr5:178459426	A/C	cg21905437	chr5:178450457	ZNF879	0.58	8.09	0.45	2.16e-14	Pubertal anthropometrics;
CESC	cis	rs1256061	0.624	rs1152578	chr14:64697037	T/C	cg23250157	chr14:64679961	SYNE2	0.52	7.37	0.41	2.22e-12	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs875971	0.638	rs7793569	chr7:66116633	T/G	cg18876405	chr7:65276391	NA	-0.54	-7.06	-0.4	1.46e-11	Aortic root size;
CESC	cis	rs60871478	0.636	rs10245785	chr7:894422	T/C	cg00475322	chr7:917719	C7orf20	0.46	5.1	0.3	6.42e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs17376456	0.877	rs7701974	chr5:93311417	C/T	cg25358565	chr5:93447407	FAM172A	1.07	10.61	0.55	3.7e-22	Diabetic retinopathy;
CESC	cis	rs9814567	1.000	rs4334685	chr3:134304335	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.4	-5.47	-0.32	1.07e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs2766692	1.000	rs4905941	chr14:100725438	A/G	cg14866419	chr14:100704911	YY1	0.62	8.4	0.46	2.7e-15	Electroencephalographic traits in alcoholism;
CESC	cis	rs896854	0.967	rs10956933	chr8:95967688	C/G	cg09323728	chr8:95962352	TP53INP1	-0.42	-9.2	-0.49	1.09e-17	Type 2 diabetes;
CESC	cis	rs5769765	0.955	rs5770750	chr22:50276828	A/G	cg02269571	chr22:50332266	NA	0.46	6.28	0.36	1.39e-9	Schizophrenia;
CESC	trans	rs561341	0.941	rs72825736	chr17:30330286	G/A	cg27661571	chr11:113659931	NA	-0.82	-7.6	-0.42	5.24e-13	Hip circumference adjusted for BMI;
CESC	cis	rs4563143	0.663	rs10417671	chr19:29235335	T/C	cg12756686	chr19:29218302	NA	0.44	6.49	0.37	4.09e-10	Methadone dose in opioid dependence;
CESC	cis	rs208520	0.909	rs62414636	chr6:67015723	T/G	cg07460842	chr6:66804631	NA	0.84	8.13	0.45	1.67e-14	Exhaled nitric oxide output;
CESC	cis	rs34779708	0.966	rs4934539	chr10:35472199	A/G	cg03585969	chr10:35415529	CREM	0.77	10.56	0.54	5.56e-22	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs4689592	0.619	rs2359011	chr4:7066052	T/G	cg26116260	chr4:7069785	GRPEL1	0.99	14.52	0.67	1.52e-35	Monocyte percentage of white cells;
CESC	cis	rs12145833	0.596	rs1060643	chr1:243429976	G/C	cg02356786	chr1:243265016	LOC731275	0.74	5.59	0.32	5.53e-8	Obesity (early onset extreme);
CESC	cis	rs853679	0.517	rs9380050	chr6:28048538	A/G	cg22143856	chr6:28129313	ZNF389	0.49	6.3	0.36	1.2e-9	Depression;
CESC	cis	rs61841072	0.602	rs11589245	chr1:243131106	C/T	cg02356786	chr1:243265016	LOC731275	0.41	5.26	0.31	2.97e-7	Schizophrenia;
CESC	cis	rs6951245	0.882	rs56048221	chr7:1092533	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.49	-5.89	-0.34	1.15e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs796364	0.616	rs2689762	chr2:200687204	G/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.57	5.25	0.31	3.09e-7	Schizophrenia;
CESC	cis	rs9311474	0.508	rs4687629	chr3:52615227	G/C	cg18099408	chr3:52552593	STAB1	-0.32	-5.41	-0.32	1.43e-7	Electroencephalogram traits;
CESC	cis	rs2576037	0.583	rs530205	chr18:44385150	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.52	-7.09	-0.4	1.25e-11	Personality dimensions;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg12784241	chr6:158402508	SYNJ2	-0.41	-6.21	-0.36	2.09e-9	Fibrinogen levels;
CESC	cis	rs2404602	0.716	rs7164813	chr15:76708066	T/C	cg26408565	chr15:76604113	ETFA	-0.42	-6.08	-0.35	4.19e-9	Blood metabolite levels;
CESC	cis	rs7208859	0.673	rs216420	chr17:28938508	C/T	cg04154034	chr17:28927549	LRRC37B2	0.67	5.93	0.34	9.32e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs853679	0.550	rs9295762	chr6:28155418	C/T	cg23281280	chr6:28129359	ZNF389	-0.47	-6.61	-0.38	2.13e-10	Depression;
CESC	cis	rs367943	0.501	rs960691	chr5:112971654	G/C	cg12552261	chr5:112820674	MCC	0.44	5.63	0.33	4.63e-8	Type 2 diabetes;
CESC	cis	rs4965006	1.000	rs4965006	chr12:132419533	A/G	cg00588090	chr12:132412438	PUS1	-0.51	-7.17	-0.4	7.48e-12	Posterior cortical atrophy and Alzheimer's disease;
CESC	cis	rs61784830	0.710	rs61783251	chr1:46368087	G/C	cg06784218	chr1:46089804	CCDC17	0.48	5.42	0.32	1.37e-7	Iron status biomarkers (total iron binding capacity);
CESC	cis	rs7412746	0.658	rs3843843	chr1:150918084	C/T	cg22823121	chr1:150693482	HORMAD1	0.4	5.7	0.33	3.2e-8	Melanoma;
CESC	cis	rs2235642	0.821	rs2281234	chr16:1602938	A/G	cg03771183	chr16:1608904	IFT140	0.4	5.9	0.34	1.12e-8	Coronary artery disease;
CESC	cis	rs7666738	0.830	rs7662948	chr4:99020132	G/C	cg18180107	chr4:99064573	C4orf37	0.41	5.35	0.31	1.92e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7917772	0.582	rs7899004	chr10:104341435	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.4	-5.44	-0.32	1.19e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs57506017	0.585	rs5011436	chr7:12268758	A/C	cg23422036	chr7:12250390	TMEM106B	0.38	5.16	0.3	4.76e-7	Neuroticism;
CESC	cis	rs1465370	0.720	rs2402995	chr7:130016595	C/T	cg04743876	chr7:130013617	NA	0.31	5.88	0.34	1.23e-8	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24582500	chr10:131934763	GLRX3	0.54	6.49	0.37	4.18e-10	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01077841	chr13:99228499	STK24	0.56	6.35	0.36	9.36e-10	Gut microbiome composition (summer);
CESC	cis	rs12477438	0.798	rs12473029	chr2:99637961	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.73	-11.02	-0.56	1.73e-23	Chronic sinus infection;
CESC	cis	rs597539	0.616	rs473997	chr11:68639481	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.79	9.54	0.51	1.02e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs1707322	0.963	rs4508055	chr1:46257731	A/T	cg05343316	chr1:45956843	TESK2	0.51	6.25	0.36	1.59e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2425143	1.000	rs78877130	chr20:34344947	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.84	-7.66	-0.43	3.49e-13	Blood protein levels;
CESC	cis	rs9768139	0.708	rs896780	chr7:158113972	C/T	cg06219351	chr7:158114137	PTPRN2	-0.56	-8.83	-0.48	1.49e-16	Calcium levels;
CESC	cis	rs734999	0.545	rs7368072	chr1:2556125	C/T	cg18854424	chr1:2615690	NA	0.3	5.88	0.34	1.2e-8	Ulcerative colitis;
CESC	cis	rs8077577	0.747	rs62072507	chr17:18172335	G/A	cg16794390	chr17:18148240	FLII	0.43	6.54	0.37	3.16e-10	Obesity-related traits;
CESC	cis	rs2836974	0.897	rs2836925	chr21:40532353	T/C	cg17971929	chr21:40555470	PSMG1	1.04	15.93	0.7	1.5e-40	Cognitive function;
CESC	cis	rs2070488	0.775	rs7647657	chr3:38573746	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.76	-11.21	-0.57	3.97e-24	Electrocardiographic conduction measures;
CESC	cis	rs12477438	0.501	rs11688004	chr2:99735052	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.78	13.44	0.64	9.76e-32	Chronic sinus infection;
CESC	cis	rs2303759	0.874	rs10411630	chr19:49891314	C/A	cg22590775	chr19:49891494	CCDC155	0.6	6.99	0.39	2.19e-11	Multiple sclerosis;
CESC	cis	rs2228479	0.867	rs34272502	chr16:89949000	G/C	cg14709524	chr16:89940631	TCF25	0.74	5.75	0.33	2.43e-8	Skin colour saturation;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg15754109	chr8:67974431	COPS5	-0.51	-6.81	-0.39	6.6e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs2840044	0.534	rs2124246	chr17:33885431	G/A	cg05299278	chr17:33885742	SLFN14	0.42	5.95	0.34	8.31e-9	Response to radiotherapy in cancer (late toxicity);
CESC	cis	rs6685188	0.920	rs6676110	chr1:205662977	G/A	cg14159672	chr1:205819179	PM20D1	-0.4	-5.22	-0.31	3.58e-7	White blood cell count (basophil);Basophil percentage of white cells;
CESC	cis	rs7666738	0.830	rs11097606	chr4:99011486	C/T	cg03676636	chr4:99064102	C4orf37	0.33	5.2	0.3	4.07e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11112613	0.775	rs10507194	chr12:105959488	G/A	cg03607813	chr12:105948248	NA	0.57	6.35	0.36	9.12e-10	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CESC	cis	rs12824058	0.831	rs12829373	chr12:130814114	G/C	cg24838063	chr12:130822603	PIWIL1	0.62	8.55	0.47	9.78e-16	Menopause (age at onset);
CESC	cis	rs2303759	0.676	rs10426452	chr19:49907690	G/A	cg22590775	chr19:49891494	CCDC155	0.51	6.16	0.35	2.67e-9	Multiple sclerosis;
CESC	cis	rs13242816	1.000	rs56275709	chr7:116108489	A/G	cg04696780	chr7:116139425	CAV2	-0.62	-5.69	-0.33	3.31e-8	P wave duration;
CESC	cis	rs2262909	0.962	rs11669110	chr19:22296485	A/G	cg11619707	chr19:22235551	ZNF257	0.35	5.61	0.33	5.04e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
CESC	cis	rs1881797	1.000	rs10925069	chr1:247681313	C/T	cg21399703	chr1:247681439	NA	-0.6	-8.04	-0.44	2.95e-14	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs6582630	0.519	rs8189623	chr12:38351436	G/A	cg13010199	chr12:38710504	ALG10B	0.48	6.06	0.35	4.62e-9	Drug-induced liver injury (flucloxacillin);
CESC	trans	rs10463316	0.894	rs7707745	chr5:150765198	G/T	cg24389359	chr12:111284228	CCDC63	-0.34	-6.14	-0.35	3.06e-9	Metabolite levels (Pyroglutamine);
CESC	cis	rs9300255	0.739	rs1402275	chr12:123750895	A/G	cg19016782	chr12:123741754	C12orf65	-0.49	-7.09	-0.4	1.22e-11	Neutrophil percentage of white cells;
CESC	cis	rs11758351	0.518	rs79922979	chr6:26224975	A/G	cg01420254	chr6:26195488	NA	0.77	8.49	0.46	1.48e-15	Gout;Renal underexcretion gout;
CESC	cis	rs2302190	0.882	rs1974586	chr17:56640731	C/T	cg25885038	chr17:56607967	SEPT4	-0.4	-5.43	-0.32	1.27e-7	Vitamin D levels;
CESC	cis	rs113835537	0.529	rs2305535	chr11:66272237	A/G	cg22134325	chr11:66188745	NPAS4	-0.33	-5.05	-0.3	8.22e-7	Airway imaging phenotypes;
CESC	cis	rs7824557	0.527	rs2736298	chr8:11235136	C/G	cg21775007	chr8:11205619	TDH	-0.53	-7.87	-0.44	8.89e-14	Retinal vascular caliber;
CESC	cis	rs6662572	0.737	rs11584814	chr1:46504389	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.46	5.2	0.3	4.05e-7	Blood protein levels;
CESC	cis	rs1008375	0.966	rs4698642	chr4:17679174	A/T	cg02297831	chr4:17616191	MED28	0.44	5.66	0.33	4.03e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs9733	0.596	rs11582840	chr1:150688487	A/G	cg18016565	chr1:150552671	MCL1	0.35	5.36	0.31	1.86e-7	Tonsillectomy;
CESC	cis	rs8017423	0.669	rs7153190	chr14:90703904	T/G	cg14092571	chr14:90743983	NA	-0.56	-8.3	-0.45	5.2e-15	Mortality in heart failure;
CESC	cis	rs2933343	0.601	rs1680758	chr3:128594897	T/C	cg24203234	chr3:128598194	ACAD9	0.43	5.88	0.34	1.23e-8	IgG glycosylation;
CESC	cis	rs2243480	1.000	rs35421653	chr7:65363429	C/A	cg13147721	chr7:65941812	NA	-0.88	-8.2	-0.45	1.03e-14	Diabetic kidney disease;
CESC	cis	rs6439153	0.933	rs9822511	chr3:128705567	G/A	cg25356066	chr3:128598488	ACAD9	0.54	7.0	0.39	2.12e-11	Pneumococcal bacteremia;
CESC	cis	rs9926296	0.585	rs8045232	chr16:89857548	A/G	cg03388025	chr16:89894329	SPIRE2	0.41	7.99	0.44	4.07e-14	Vitiligo;
CESC	cis	rs2075371	0.966	rs2544223	chr7:133995787	A/G	cg11752832	chr7:134001865	SLC35B4	0.54	6.89	0.39	3.94e-11	Mean platelet volume;
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg23912435	chr1:150601613	ENSA	-0.37	-6.1	-0.35	3.84e-9	Vertical cup-disc ratio;
CESC	cis	rs7671266	0.747	rs6827946	chr4:10151335	T/C	cg11266682	chr4:10021025	SLC2A9	-0.43	-5.43	-0.32	1.26e-7	Cardiovascular disease risk factors;
CESC	cis	rs4253772	0.515	rs6008591	chr22:46703664	T/C	cg00784671	chr22:46762841	CELSR1	-0.48	-5.59	-0.32	5.72e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs1580019	0.961	rs4460271	chr7:32496503	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.73	10.15	0.53	1.14e-20	Cognitive ability;
CESC	cis	rs35110281	0.591	rs86138	chr21:44932398	G/A	cg01579765	chr21:45077557	HSF2BP	-0.52	-9.14	-0.49	1.64e-17	Mean corpuscular volume;
CESC	cis	rs826838	0.967	rs826879	chr12:39088999	A/C	cg26384229	chr12:38710491	ALG10B	-0.62	-10.22	-0.53	6.67e-21	Heart rate;
CESC	cis	rs9443645	0.901	rs1984195	chr6:79657391	G/A	cg05283184	chr6:79620031	NA	-0.42	-6.43	-0.37	5.8e-10	Intelligence (multi-trait analysis);
CESC	trans	rs801193	1.000	rs2420824	chr7:66131116	G/A	cg26939375	chr7:64535504	NA	-0.65	-8.64	-0.47	5.39e-16	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12458179	chr2:238969828	SCLY	0.56	6.73	0.38	1.06e-10	Gut microbiome composition (summer);
CESC	cis	rs910316	0.737	rs398896	chr14:75482827	C/A	cg16144293	chr14:75469539	EIF2B2	0.39	5.12	0.3	5.81e-7	Height;
CESC	cis	rs6582630	0.502	rs2204008	chr12:38439203	C/T	cg13010199	chr12:38710504	ALG10B	0.45	5.66	0.33	3.84e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs13191362	1.000	rs67487119	chr6:163102657	A/C	cg06582575	chr6:163149167	PACRG;PARK2	1.02	10.2	0.53	7.92e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs4853012	0.838	rs58759652	chr2:74344902	A/T	cg05776053	chr2:74358815	NA	0.4	5.05	0.3	8.18e-7	Gestational age at birth (maternal effect);
CESC	cis	rs6089584	0.816	rs4925336	chr20:60627180	A/G	cg13770153	chr20:60521292	NA	-0.48	-6.17	-0.35	2.56e-9	Body mass index;
CESC	cis	rs137699	0.687	rs4821887	chr22:39756985	C/T	cg01416388	chr22:39784598	NA	-0.53	-6.09	-0.35	3.86e-9	IgG glycosylation;
CESC	cis	rs2236521	0.714	rs6062210	chr20:60890375	A/G	cg12382846	chr20:60892121	LAMA5	0.38	7.03	0.4	1.8e-11	Pelvic organ prolapse;
CESC	cis	rs12545109	0.800	rs1530217	chr8:57408097	C/T	cg09654669	chr8:57350985	NA	-0.56	-6.65	-0.38	1.67e-10	Obesity-related traits;
CESC	cis	rs59698941	0.943	rs60545802	chr5:132204577	T/G	cg02081065	chr5:132209139	LEAP2	-0.52	-5.12	-0.3	5.8e-7	Apolipoprotein A-IV levels;
CESC	cis	rs34779708	0.966	rs34296409	chr10:35404613	C/G	cg04310649	chr10:35416472	CREM	-0.52	-6.25	-0.36	1.62e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs909341	0.710	rs6010998	chr20:62294402	A/T	cg03999872	chr20:62272968	STMN3	0.55	5.38	0.31	1.66e-7	Atopic dermatitis;
CESC	cis	rs1915146	0.546	rs1715862	chr10:126856255	C/T	cg05090351	chr10:126851162	NA	-0.6	-9.51	-0.5	1.23e-18	Menarche (age at onset);
CESC	cis	rs4523957	0.786	rs9897624	chr17:2121745	A/G	cg16513277	chr17:2031491	SMG6	-0.63	-8.77	-0.47	2.29e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs11155671	0.530	rs9371215	chr6:150194298	C/T	cg09699651	chr6:150184138	LRP11	0.52	6.95	0.39	2.88e-11	Testicular germ cell tumor;
CESC	cis	rs9660992	0.573	rs7368327	chr1:205214792	C/T	cg00857998	chr1:205179979	DSTYK	0.56	6.86	0.39	4.99e-11	Mean corpuscular volume;Mean platelet volume;
CESC	trans	rs3780486	0.846	rs3824458	chr9:33144809	C/T	cg04842962	chr6:43655489	MRPS18A	0.99	18.1	0.74	3.15e-48	IgG glycosylation;
CESC	cis	rs7592578	0.771	rs4258824	chr2:191395027	C/T	cg27211696	chr2:191398769	TMEM194B	-0.57	-5.31	-0.31	2.37e-7	Diastolic blood pressure;
CESC	cis	rs7666738	0.830	rs6532721	chr4:99048015	G/A	cg05340658	chr4:99064831	C4orf37	0.82	12.88	0.62	8.44e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4268898	0.662	rs17733015	chr2:24509370	A/G	cg20701182	chr2:24300061	SF3B14	0.6	6.76	0.38	8.99e-11	Asthma;
CESC	cis	rs11608355	0.552	rs2304549	chr12:109794875	A/G	cg19025524	chr12:109796872	NA	-0.54	-7.99	-0.44	4.03e-14	Neuroticism;
CESC	cis	rs875971	0.895	rs12531677	chr7:65769086	G/A	cg10691866	chr7:65817282	TPST1	0.32	5.53	0.32	7.79e-8	Aortic root size;
CESC	cis	rs8092503	1.000	rs12957162	chr18:52484299	T/A	cg12377874	chr18:52495404	RAB27B	0.41	6.49	0.37	4.22e-10	Childhood body mass index;
CESC	cis	rs7552404	1.000	rs7533888	chr1:76160449	A/C	cg22875332	chr1:76189707	ACADM	0.66	7.81	0.43	1.31e-13	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs7811142	1.000	rs11766752	chr7:100073292	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.13	13.28	0.63	3.38e-31	Platelet count;
CESC	cis	rs936229	0.861	rs7176022	chr15:75107880	G/T	cg14664628	chr15:75095509	CSK	1.01	16.08	0.7	4.69e-41	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CESC	cis	rs4268898	0.560	rs2384007	chr2:24514841	A/G	cg06627628	chr2:24431161	ITSN2	-0.9	-9.95	-0.52	5.1e-20	Asthma;
CESC	cis	rs7089973	0.604	rs55759483	chr10:116573423	T/C	cg03647239	chr10:116582469	FAM160B1	0.42	5.39	0.31	1.59e-7	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs6121246	0.512	rs6058384	chr20:30276409	A/T	cg13852791	chr20:30311386	BCL2L1	0.81	10.51	0.54	8.04e-22	Mean corpuscular hemoglobin;
CESC	cis	rs1499614	1.000	rs2659913	chr7:66157336	T/A	cg13147721	chr7:65941812	NA	-0.94	-8.9	-0.48	9.08e-17	Gout;
CESC	cis	rs5769765	0.908	rs9627788	chr22:50300438	T/C	cg26441486	chr22:50317300	CRELD2	0.39	5.45	0.32	1.13e-7	Schizophrenia;
CESC	cis	rs240764	0.764	rs6910391	chr6:100925774	T/C	cg21058520	chr6:100914733	NA	0.37	5.76	0.33	2.34e-8	Neuroticism;
CESC	cis	rs10089	1.000	rs77086350	chr5:127494431	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.72	9.43	0.5	2.17e-18	Ileal carcinoids;
CESC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg27022615	chr11:70049105	FADD	-0.51	-6.59	-0.38	2.42e-10	Age-related hearing impairment (SNP x SNP interaction);
CESC	trans	rs8073060	0.586	rs225305	chr17:33921160	C/T	cg19694781	chr19:47549865	TMEM160	-0.7	-6.84	-0.39	5.46e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	cis	rs1801251	0.963	rs6739638	chr2:233576015	G/A	cg08000102	chr2:233561755	GIGYF2	0.68	9.27	0.49	6.98e-18	Coronary artery disease;
CESC	cis	rs1499614	0.803	rs1796229	chr7:66119661	G/A	cg13147721	chr7:65941812	NA	-0.93	-8.6	-0.47	7.11e-16	Gout;
CESC	cis	rs4974559	0.501	rs1250096	chr4:1238836	G/C	cg02980000	chr4:1222292	CTBP1	-0.77	-7.95	-0.44	5.45e-14	Systolic blood pressure;
CESC	cis	rs7296418	0.663	rs4553407	chr12:123750748	G/C	cg05973401	chr12:123451056	ABCB9	0.46	5.93	0.34	9.46e-9	Platelet count;
CESC	cis	rs400736	0.628	rs12758337	chr1:8145294	C/T	cg25007680	chr1:8021821	PARK7	-0.65	-8.88	-0.48	1.01e-16	Response to antidepressants and depression;
CESC	cis	rs2282802	0.685	rs7715538	chr5:139665181	T/C	cg26211634	chr5:139558579	C5orf32	0.51	7.42	0.41	1.55e-12	Intelligence (multi-trait analysis);
CESC	cis	rs10097731	0.901	rs10464931	chr8:82042664	A/G	cg25230327	chr8:82042993	NA	0.52	5.71	0.33	2.95e-8	Serum total protein level;
CESC	cis	rs832540	0.931	rs33319	chr5:56206675	C/A	cg24531977	chr5:56204891	C5orf35	-0.42	-5.33	-0.31	2.1e-7	Coronary artery disease;
CESC	cis	rs12597458	0.752	rs8051239	chr16:72036257	T/A	cg01557791	chr16:72042693	DHODH	0.82	12.63	0.61	6.2e-29	Prostate cancer;
CESC	cis	rs2439831	0.850	rs28564774	chr15:44125475	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.68	7.43	0.42	1.45e-12	Lung cancer in ever smokers;
CESC	cis	rs6922893	1.000	rs1320315	chr6:71666146	T/C	cg10766373	chr6:71666121	B3GAT2	-0.34	-5.36	-0.31	1.78e-7	Obesity-related traits;
CESC	cis	rs425277	0.958	rs262639	chr1:2107061	G/T	cg04315214	chr1:2043799	PRKCZ	-0.38	-5.34	-0.31	1.96e-7	Height;
CESC	cis	rs10791097	0.690	rs12284487	chr11:130729705	T/C	cg12179176	chr11:130786555	SNX19	0.58	8.5	0.46	1.41e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs7799006	0.757	rs2398668	chr7:2298227	A/G	cg12745145	chr7:2261452	MAD1L1	0.33	5.45	0.32	1.17e-7	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs9303401	0.703	rs8077052	chr17:57208921	T/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.68	8.6	0.47	7e-16	Cognitive test performance;
CESC	cis	rs644799	0.710	rs10831429	chr11:95508524	C/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.75	11.15	0.57	6.35e-24	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs5769765	0.913	rs2319462	chr22:50263370	C/T	cg26441486	chr22:50317300	CRELD2	-0.39	-5.5	-0.32	8.72e-8	Schizophrenia;
CESC	cis	rs9916302	0.800	rs8069451	chr17:37504933	C/T	cg07936489	chr17:37558343	FBXL20	-0.78	-10.96	-0.56	2.63e-23	Glomerular filtration rate (creatinine);
CESC	cis	rs6598955	0.671	rs11247908	chr1:26638222	G/A	cg19743891	chr1:26644573	UBXN11;CD52	0.39	5.38	0.31	1.62e-7	Obesity-related traits;
CESC	cis	rs763121	0.853	rs4820345	chr22:39091151	T/C	cg14440974	chr22:39074834	NA	-0.43	-5.71	-0.33	2.98e-8	Menopause (age at onset);
CESC	cis	rs7917772	0.619	rs2801050	chr10:104509393	T/A	cg04362960	chr10:104952993	NT5C2	-0.48	-5.45	-0.32	1.16e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs798554	0.959	rs798557	chr7:2758982	G/A	cg13628971	chr7:2884303	GNA12	0.58	7.31	0.41	3.23e-12	Height;
CESC	cis	rs36051895	0.589	rs16922772	chr9:5194521	C/A	cg02405213	chr9:5042618	JAK2	-0.53	-6.15	-0.35	2.82e-9	Pediatric autoimmune diseases;
CESC	cis	rs71277158	0.688	rs7638400	chr3:169837787	A/G	cg04067573	chr3:169899625	PHC3	0.71	7.06	0.4	1.45e-11	Prostate cancer;
CESC	cis	rs2425143	0.915	rs2378408	chr20:34367732	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	0.8	7.75	0.43	1.96e-13	Blood protein levels;
CESC	cis	rs7208859	0.573	rs8070182	chr17:29135594	A/C	cg19761014	chr17:28927070	LRRC37B2	0.77	6.52	0.37	3.61e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs7727544	0.716	rs6863213	chr5:131575932	C/T	cg14196790	chr5:131705035	SLC22A5	0.36	5.28	0.31	2.64e-7	Blood metabolite levels;
CESC	cis	rs1163251	0.837	rs658442	chr1:120244858	T/G	cg19096424	chr1:120255104	PHGDH	0.52	6.67	0.38	1.52e-10	Blood metabolite levels;
CESC	cis	rs709400	0.567	rs1961600	chr14:103862144	G/A	cg12935359	chr14:103987150	CKB	-0.52	-7.62	-0.42	4.4e-13	Body mass index;
CESC	cis	rs9925964	0.622	rs8046707	chr16:30916233	G/A	cg02466173	chr16:30829666	NA	0.36	5.43	0.32	1.26e-7	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs7666738	0.830	rs10470893	chr4:99038756	C/T	cg24818145	chr4:99064322	C4orf37	0.38	5.04	0.3	8.49e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3105593	0.563	rs539383	chr15:50878478	C/T	cg08437265	chr15:50716283	USP8	0.42	5.33	0.31	2.09e-7	QT interval;
CESC	cis	rs9287719	0.967	rs6432126	chr2:10757101	A/G	cg00105475	chr2:10696890	NA	0.37	5.4	0.31	1.52e-7	Prostate cancer;
CESC	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg07167872	chr1:205819463	PM20D1	0.77	12.43	0.61	3.03e-28	Menarche (age at onset);
CESC	cis	rs10129255	0.518	rs8009594	chr14:107185733	G/T	cg07958169	chr14:107095056	NA	-0.55	-8.62	-0.47	6.1e-16	Kawasaki disease;
CESC	cis	rs17376456	0.825	rs35426871	chr5:93291613	C/T	cg21475434	chr5:93447410	FAM172A	0.74	6.26	0.36	1.54e-9	Diabetic retinopathy;
CESC	cis	rs3105593	1.000	rs3109892	chr15:50877011	A/T	cg08437265	chr15:50716283	USP8	0.39	5.1	0.3	6.41e-7	QT interval;
CESC	cis	rs9660180	0.935	rs2180311	chr1:1748734	T/C	cg20999797	chr1:1681921	NA	0.27	5.21	0.31	3.71e-7	Body mass index;
CESC	cis	rs798554	0.759	rs1636255	chr7:2892804	A/C	cg18446336	chr7:2847575	GNA12	0.34	5.31	0.31	2.34e-7	Height;
CESC	cis	rs2276314	1.000	rs4573997	chr18:33552568	C/T	cg05985134	chr18:33552581	C18orf21	0.67	7.86	0.44	9.41e-14	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs6860806	0.531	rs2631359	chr5:131707892	C/T	cg04518342	chr5:131593106	PDLIM4	-0.36	-5.25	-0.31	3.13e-7	Breast cancer;
CESC	cis	rs36051895	0.632	rs12343038	chr9:5178579	A/G	cg02405213	chr9:5042618	JAK2	0.51	6.55	0.37	2.98e-10	Pediatric autoimmune diseases;
CESC	cis	rs73206853	0.841	rs57299791	chr12:110954021	G/A	cg12870014	chr12:110450643	ANKRD13A	0.63	5.22	0.31	3.56e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs9322193	0.923	rs12211511	chr6:150066342	G/C	cg04369109	chr6:150039330	LATS1	-0.38	-5.2	-0.3	4.06e-7	Lung cancer;
CESC	cis	rs2836974	0.931	rs8132285	chr21:40655752	T/C	cg17971929	chr21:40555470	PSMG1	1.08	16.28	0.71	9.03e-42	Cognitive function;
CESC	cis	rs4819052	1.000	rs4819052	chr21:46699777	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.88	11.34	0.57	1.46e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs617791	0.508	rs747526	chr11:65776071	C/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.46	-5.28	-0.31	2.65e-7	Breast cancer;
CESC	cis	rs10504229	0.683	rs61306359	chr8:58134646	G/A	cg24829409	chr8:58192753	C8orf71	-0.58	-7.2	-0.4	6.31e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs7264396	0.790	rs6058288	chr20:34228680	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	-0.6	-7.4	-0.41	1.84e-12	Total cholesterol levels;
CESC	cis	rs9650657	0.529	rs10108618	chr8:10953092	A/G	cg21775007	chr8:11205619	TDH	-0.38	-5.52	-0.32	8.13e-8	Neuroticism;
CESC	cis	rs1005277	0.579	rs1740732	chr10:38491385	C/T	cg25427524	chr10:38739819	LOC399744	-0.71	-10.63	-0.55	3.34e-22	Extrinsic epigenetic age acceleration;
CESC	cis	rs919433	0.783	rs2565165	chr2:198233575	T/G	cg03934865	chr2:198174659	NA	0.43	6.21	0.36	2.01e-9	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs9611565	0.532	rs202627	chr22:41847367	A/T	cg06481639	chr22:41940642	POLR3H	0.52	5.58	0.32	5.84e-8	Vitiligo;
CESC	cis	rs2075371	0.966	rs1901204	chr7:133985896	A/G	cg00033643	chr7:134001901	SLC35B4	0.43	5.61	0.33	5.13e-8	Mean platelet volume;
CESC	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.7	-11.1	-0.56	8.95e-24	Longevity;Endometriosis;
CESC	cis	rs722599	0.715	rs61978928	chr14:75321714	T/C	cg11812906	chr14:75593930	NEK9	-0.46	-5.63	-0.33	4.49e-8	IgG glycosylation;
CESC	cis	rs10504073	0.506	rs7007271	chr8:49941897	T/C	cg00325661	chr8:49890786	NA	0.56	8.42	0.46	2.33e-15	Blood metabolite ratios;
CESC	cis	rs4242434	0.787	rs1545837	chr8:22477807	T/C	cg03733263	chr8:22462867	KIAA1967	0.77	10.0	0.52	3.44e-20	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CESC	cis	rs7618501	0.815	rs3819325	chr3:49843723	T/C	cg24308560	chr3:49941425	MST1R	-0.53	-7.12	-0.4	1.04e-11	Intelligence (multi-trait analysis);
CESC	cis	rs7116495	0.786	rs4479013	chr11:71673732	C/G	cg10381502	chr11:71823885	C11orf51	-0.68	-5.67	-0.33	3.64e-8	Severe influenza A (H1N1) infection;
CESC	cis	rs4595586	0.525	rs11613788	chr12:39390710	T/C	cg26384229	chr12:38710491	ALG10B	0.54	7.64	0.42	3.96e-13	Morning vs. evening chronotype;
CESC	cis	rs524281	0.861	rs11227426	chr11:65971951	T/C	cg14036092	chr11:66035641	RAB1B	-0.49	-5.29	-0.31	2.56e-7	Electroencephalogram traits;
CESC	cis	rs561341	0.941	rs8066156	chr17:30361629	A/G	cg19193384	chr17:30244184	NA	-0.52	-5.63	-0.33	4.55e-8	Hip circumference adjusted for BMI;
CESC	cis	rs2075371	0.830	rs1421478	chr7:133922793	T/A	cg11752832	chr7:134001865	SLC35B4	0.53	6.89	0.39	4.15e-11	Mean platelet volume;
CESC	cis	rs412050	0.547	rs5999842	chr22:22214889	G/A	cg17089214	chr22:22089827	YPEL1	0.75	6.3	0.36	1.22e-9	Attention deficit hyperactivity disorder;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg00145979	chr1:155057785	EFNA3	-0.44	-6.12	-0.35	3.28e-9	Gambling;
CESC	cis	rs710216	0.718	rs841852	chr1:43401499	C/T	cg03128534	chr1:43423976	SLC2A1	0.44	5.13	0.3	5.62e-7	Red cell distribution width;
CESC	cis	rs7223966	1.000	rs992416	chr17:61745905	A/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.44	-5.16	-0.3	4.73e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs3106136	0.934	rs2902979	chr4:95177874	C/G	cg11021082	chr4:95130006	SMARCAD1	-0.45	-6.72	-0.38	1.14e-10	Capecitabine sensitivity;
CESC	cis	rs1371867	0.846	rs2439460	chr8:101312665	C/T	cg11906718	chr8:101322791	RNF19A	0.46	5.92	0.34	1.02e-8	Atrioventricular conduction;
CESC	cis	rs12995491	0.731	rs34991383	chr2:88500337	T/G	cg04169830	chr2:88471460	THNSL2	0.33	5.13	0.3	5.56e-7	Response to metformin (IC50);
CESC	cis	rs7666738	0.830	rs4699591	chr4:98974171	A/G	cg17366294	chr4:99064904	C4orf37	0.59	8.43	0.46	2.31e-15	Colonoscopy-negative controls vs population controls;
CESC	trans	rs7615952	0.515	rs4441610	chr3:125681307	C/G	cg07211511	chr3:129823064	LOC729375	-0.64	-6.94	-0.39	3.1e-11	Blood pressure (smoking interaction);
CESC	cis	rs3820068	0.705	rs6656907	chr1:15896984	A/G	cg18192808	chr1:15853278	DNAJC16	0.43	5.13	0.3	5.68e-7	Systolic blood pressure;
CESC	trans	rs1814175	0.904	rs7924371	chr11:49620595	C/T	cg03929089	chr4:120376271	NA	-0.87	-13.32	-0.63	2.44e-31	Height;
CESC	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg07677032	chr17:61819896	STRADA	0.44	5.88	0.34	1.23e-8	Prudent dietary pattern;
CESC	cis	rs2204008	0.840	rs7136347	chr12:38453531	G/A	cg26384229	chr12:38710491	ALG10B	0.72	10.64	0.55	3.12e-22	Bladder cancer;
CESC	trans	rs9578106	0.703	rs76717881	chr13:30155738	G/A	cg08144675	chr16:73097057	NA	-0.58	-6.05	-0.35	4.81e-9	Breast cancer;
CESC	cis	rs61931739	0.658	rs4476006	chr12:34237154	A/C	cg19457237	chr12:34500585	NA	-0.38	-5.45	-0.32	1.15e-7	Morning vs. evening chronotype;
CESC	cis	rs3857536	0.544	rs208453	chr6:66906841	A/T	cg07460842	chr6:66804631	NA	-0.65	-8.0	-0.44	3.79e-14	Blood trace element (Cu levels);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18783047	chr19:10420351	ZGLP1	-0.58	-6.35	-0.36	9.35e-10	Gut microbiome composition (summer);
CESC	cis	rs2637266	0.655	rs861744	chr10:78519132	T/G	cg18941641	chr10:78392320	NA	0.41	7.76	0.43	1.89e-13	Pulmonary function;
CESC	cis	rs1030268	0.608	rs12707106	chr7:133311350	A/T	cg10665199	chr7:133106180	EXOC4	0.51	5.38	0.31	1.6e-7	Intelligence (multi-trait analysis);
CESC	cis	rs6952808	0.656	rs12699646	chr7:2093162	T/G	cg02951883	chr7:2050386	MAD1L1	0.49	6.34	0.36	9.96e-10	Bipolar disorder and schizophrenia;
CESC	cis	rs57506017	0.585	rs10234805	chr7:12253543	T/C	cg23422036	chr7:12250390	TMEM106B	0.39	5.21	0.3	3.76e-7	Neuroticism;
CESC	cis	rs7618915	0.547	rs11130314	chr3:52697082	T/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.71	0.38	1.17e-10	Bipolar disorder;
CESC	cis	rs57506017	0.585	rs28549831	chr7:12268117	C/T	cg23422036	chr7:12250390	TMEM106B	0.38	5.13	0.3	5.58e-7	Neuroticism;
CESC	trans	rs3942852	0.806	rs4752807	chr11:48128751	T/G	cg03929089	chr4:120376271	NA	-0.56	-6.34	-0.36	1.01e-9	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs17376456	0.825	rs12153021	chr5:93073913	A/G	cg25358565	chr5:93447407	FAM172A	1.1	10.54	0.54	6.5e-22	Diabetic retinopathy;
CESC	cis	rs1005277	0.579	rs2505237	chr10:38438898	T/G	cg00409905	chr10:38381863	ZNF37A	-0.45	-5.96	-0.34	7.89e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs992157	0.835	rs2045434	chr2:219144498	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.67	-8.69	-0.47	3.72e-16	Colorectal cancer;
CESC	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg01238044	chr22:24384105	GSTT1	-0.66	-8.63	-0.47	5.75e-16	Liver enzyme levels (gamma-glutamyl transferase);
CESC	trans	rs875971	0.666	rs13242072	chr7:65765988	A/G	cg26939375	chr7:64535504	NA	-0.64	-8.48	-0.46	1.64e-15	Aortic root size;
CESC	cis	rs8092503	1.000	rs3764515	chr18:52494397	G/T	cg12377874	chr18:52495404	RAB27B	0.37	6.14	0.35	3.02e-9	Childhood body mass index;
CESC	cis	rs6831352	0.918	rs13107558	chr4:100050200	C/A	cg13256891	chr4:100009986	ADH5	-0.75	-8.6	-0.47	7.31e-16	Alcohol dependence;
CESC	cis	rs5769765	0.908	rs138891	chr22:50227741	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.47	-5.26	-0.31	3e-7	Schizophrenia;
CESC	cis	rs9393777	0.623	rs7773938	chr6:26474044	C/T	cg14345882	chr6:26364793	BTN3A2	0.44	5.36	0.31	1.81e-7	Intelligence (multi-trait analysis);
CESC	cis	rs7811142	1.000	rs7809801	chr7:100072031	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.83	8.4	0.46	2.81e-15	Platelet count;
CESC	cis	rs1865721	0.771	rs8093397	chr18:73136217	C/G	cg26385618	chr18:73139727	C18orf62	-0.51	-8.36	-0.46	3.47e-15	Intelligence;
CESC	cis	rs17125944	0.556	rs12588482	chr14:53311552	G/A	cg00686598	chr14:53173677	PSMC6	-0.67	-5.84	-0.34	1.52e-8	Alzheimer's disease (late onset);
CESC	cis	rs1799949	1.000	rs2175957	chr17:41286822	T/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.45	6.3	0.36	1.24e-9	Menopause (age at onset);
CESC	cis	rs12912251	1.000	rs71403553	chr15:38989121	C/A	cg01338139	chr15:38987640	C15orf53	-0.47	-5.43	-0.32	1.26e-7	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
CESC	cis	rs2932538	0.922	rs61818800	chr1:113148571	A/G	cg22162597	chr1:113214053	CAPZA1	0.57	7.39	0.41	1.92e-12	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CESC	cis	rs769267	0.895	rs2965183	chr19:19545696	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.57	7.33	0.41	2.84e-12	Tonsillectomy;
CESC	cis	rs6558174	1.000	rs6558174	chr8:22492129	A/G	cg03733263	chr8:22462867	KIAA1967	0.5	6.19	0.36	2.3e-9	Breast cancer;
CESC	cis	rs7829975	0.807	rs519019	chr8:8595104	A/T	cg06636001	chr8:8085503	FLJ10661	-0.43	-5.62	-0.33	4.8e-8	Mood instability;
CESC	cis	rs763121	0.853	rs5757200	chr22:39043491	T/G	cg06022373	chr22:39101656	GTPBP1	0.88	13.79	0.65	5.43e-33	Menopause (age at onset);
CESC	trans	rs1003719	0.715	rs762139	chr21:38568475	A/T	cg23660064	chr1:223395288	SUSD4	0.43	6.05	0.35	4.89e-9	Eye color traits;
CESC	cis	rs2637266	0.905	rs10824428	chr10:78346041	G/A	cg18941641	chr10:78392320	NA	0.4	7.38	0.41	1.98e-12	Pulmonary function;
CESC	cis	rs3096299	0.900	rs4785666	chr16:89462771	C/G	cg08822215	chr16:89438651	ANKRD11	-0.43	-6.77	-0.38	8.06e-11	Multiple myeloma (IgH translocation);
CESC	cis	rs765787	0.530	rs2413776	chr15:45544170	A/G	cg24006582	chr15:45444508	DUOX1	-0.59	-7.37	-0.41	2.19e-12	Uric acid levels;
CESC	cis	rs13256369	0.802	rs12681326	chr8:8566389	G/A	cg18904891	chr8:8559673	CLDN23	0.7	7.89	0.44	7.96e-14	Obesity-related traits;
CESC	cis	rs6089584	1.000	rs6089583	chr20:60563624	G/A	cg06108461	chr20:60628389	TAF4	-0.78	-11.24	-0.57	3.19e-24	Body mass index;
CESC	cis	rs4835473	0.900	rs35419968	chr4:144655736	G/A	cg25736465	chr4:144833511	NA	-0.33	-5.23	-0.31	3.44e-7	Immature fraction of reticulocytes;
CESC	cis	rs2637266	0.783	rs846627	chr10:78539556	A/G	cg18941641	chr10:78392320	NA	0.42	8.44	0.46	2.13e-15	Pulmonary function;
CESC	cis	rs2463822	0.920	rs28678254	chr11:62151875	G/C	cg06239285	chr11:62104954	ASRGL1	-0.98	-8.69	-0.47	3.86e-16	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs80282103	0.867	rs74117668	chr10:1076620	C/T	cg08668510	chr10:1095578	IDI1	0.66	5.24	0.31	3.24e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs875971	0.964	rs6945032	chr7:65922486	C/T	cg18876405	chr7:65276391	NA	0.51	6.82	0.39	6.05e-11	Aortic root size;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg05048922	chr8:6565434	AGPAT5	-0.45	-6.27	-0.36	1.45e-9	Gambling;
CESC	cis	rs870825	0.549	rs10015956	chr4:185614705	T/C	cg04058563	chr4:185651563	MLF1IP	0.64	7.05	0.4	1.59e-11	Blood protein levels;
CESC	cis	rs3733585	0.699	rs62294331	chr4:9959889	A/G	cg02734326	chr4:10020555	SLC2A9	-0.43	-6.01	-0.35	6.1e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs13191362	0.507	rs2846536	chr6:163033492	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.51	6.4	0.37	6.98e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs887829	0.569	rs6711351	chr2:234634916	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.54	-7.44	-0.42	1.4e-12	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CESC	cis	rs6732160	0.588	rs1430345	chr2:73370682	A/G	cg01422370	chr2:73384389	NA	0.52	8.36	0.46	3.58e-15	Intelligence (multi-trait analysis);
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg18876457	chr1:160071037	NA	-0.46	-7.15	-0.4	8.69e-12	Vertical cup-disc ratio;
CESC	cis	rs4689388	0.679	rs1046316	chr4:6304087	A/G	cg14416269	chr4:6271139	WFS1	0.44	6.65	0.38	1.64e-10	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg13101948	chr6:4056654	PRPF4B	0.47	6.24	0.36	1.68e-9	Thyroid stimulating hormone;
CESC	cis	rs2425143	1.000	rs111597121	chr20:34371913	A/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.69	5.95	0.34	8.54e-9	Blood protein levels;
CESC	cis	rs7833790	0.929	rs10958048	chr8:82792914	C/T	cg07697082	chr8:82753677	SNX16	-0.39	-5.4	-0.31	1.47e-7	Diastolic blood pressure;
CESC	cis	rs7666738	0.830	rs1593570	chr4:99017058	T/C	cg03467027	chr4:99064603	C4orf37	0.46	5.83	0.34	1.62e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2120019	1.000	rs12185102	chr15:75352201	G/A	cg09165964	chr15:75287851	SCAMP5	-0.73	-8.56	-0.47	9.11e-16	Blood trace element (Zn levels);
CESC	cis	rs2479724	0.811	rs6905726	chr6:41750812	T/C	cg08135965	chr6:41755394	TOMM6	-0.41	-5.28	-0.31	2.72e-7	Menarche (age at onset);
CESC	cis	rs524281	0.817	rs10896092	chr11:65958046	A/C	cg14036092	chr11:66035641	RAB1B	-0.5	-5.48	-0.32	1.01e-7	Electroencephalogram traits;
CESC	cis	rs3820928	0.934	rs4675117	chr2:227769794	A/G	cg11843606	chr2:227700838	RHBDD1	0.43	5.36	0.31	1.84e-7	Pulmonary function;
CESC	cis	rs2836974	0.568	rs2183573	chr21:40574305	A/G	cg11644478	chr21:40555479	PSMG1	-0.82	-12.36	-0.6	5.25e-28	Cognitive function;
CESC	cis	rs6089584	0.888	rs6587283	chr20:60613727	A/C	cg13770153	chr20:60521292	NA	-0.47	-6.07	-0.35	4.44e-9	Body mass index;
CESC	cis	rs4253772	0.938	rs78336060	chr22:46641597	C/T	cg00784671	chr22:46762841	CELSR1	-0.57	-5.62	-0.33	4.95e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs4862750	0.872	rs6811837	chr4:187898162	G/A	cg03647317	chr4:187891568	NA	-0.39	-5.83	-0.34	1.57e-8	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9815354	0.638	rs12634670	chr3:41875299	G/C	cg03022575	chr3:42003672	ULK4	0.71	6.23	0.36	1.84e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs668210	0.793	rs506873	chr11:65767215	A/C	cg02202077	chr11:65769826	EIF1AD;BANF1	-0.71	-7.77	-0.43	1.78e-13	Cerebrospinal fluid biomarker levels;
CESC	trans	rs7741085	1.000	rs7741085	chr6:44636919	C/T	cg04735960	chr13:21006388	CRYL1	-0.47	-6.37	-0.36	8.55e-10	Total body bone mineral density;
CESC	cis	rs1728785	0.901	rs11075688	chr16:68655924	A/G	cg02972257	chr16:68554789	NA	0.68	7.46	0.42	1.25e-12	Ulcerative colitis;
CESC	cis	rs17376456	0.825	rs13164315	chr5:93147421	A/G	cg25358565	chr5:93447407	FAM172A	1.11	10.65	0.55	2.72e-22	Diabetic retinopathy;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg05013783	chr12:56652058	ANKRD52	0.46	6.31	0.36	1.14e-9	Systemic lupus erythematosus;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg21255605	chr3:14989131	NR2C2	-0.52	-7.03	-0.4	1.7e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs651907	0.557	rs13081846	chr3:101383321	T/C	cg12386194	chr3:101231763	SENP7	0.44	5.48	0.32	9.88e-8	Colorectal cancer;
CESC	cis	rs12893668	0.637	rs4525427	chr14:104072793	C/A	cg24130564	chr14:104152367	KLC1	-0.51	-6.4	-0.37	7.05e-10	Reticulocyte count;
CESC	cis	rs6545883	0.929	rs7563678	chr2:61741811	C/T	cg15711740	chr2:61764176	XPO1	0.42	5.19	0.3	4.24e-7	Tuberculosis;
CESC	cis	rs4835473	0.932	rs1849120	chr4:144906490	A/T	cg25736465	chr4:144833511	NA	0.41	6.29	0.36	1.28e-9	Immature fraction of reticulocytes;
CESC	cis	rs2832077	0.527	rs2738953	chr21:30238363	G/C	cg03476357	chr21:30257390	N6AMT1	0.46	5.87	0.34	1.27e-8	Cognitive test performance;
CESC	cis	rs9611565	0.681	rs5751094	chr22:41803279	C/T	cg06634786	chr22:41940651	POLR3H	0.71	7.47	0.42	1.16e-12	Vitiligo;
CESC	cis	rs34375054	0.526	rs7302475	chr12:125677886	T/C	cg00522288	chr12:125625016	AACS	-0.34	-5.21	-0.3	3.84e-7	Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs514406	0.708	rs536621	chr1:53309097	A/G	cg25767906	chr1:53392781	SCP2	-0.5	-7.01	-0.4	1.92e-11	Monocyte count;
CESC	cis	rs2243480	0.831	rs57294491	chr7:65684901	T/A	cg13147721	chr7:65941812	NA	0.98	9.23	0.49	9.21e-18	Diabetic kidney disease;
CESC	cis	rs6912958	0.712	rs6454641	chr6:88371060	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.35	-5.68	-0.33	3.46e-8	Monocyte percentage of white cells;
CESC	cis	rs703842	1.000	rs3825079	chr12:58203354	C/T	cg00677455	chr12:58241039	CTDSP2	0.52	6.7	0.38	1.23e-10	Multiple sclerosis;
CESC	cis	rs4727963	0.511	rs846655	chr7:122645560	A/G	cg03640110	chr7:122635026	TAS2R16	-0.52	-8.23	-0.45	8.33e-15	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
CESC	cis	rs2637266	0.783	rs2588334	chr10:78518504	C/T	cg18941641	chr10:78392320	NA	0.38	7.4	0.41	1.84e-12	Pulmonary function;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg16594066	chr16:30569726	ZNF764	-0.42	-6.1	-0.35	3.82e-9	Fibrinogen levels;
CESC	cis	rs7267979	0.934	rs4815423	chr20:25387521	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.83	-16.38	-0.71	3.84e-42	Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs35110281	0.807	rs1598206	chr21:45058776	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.52	6.85	0.39	5.3e-11	Mean corpuscular volume;
CESC	cis	rs2228479	0.717	rs12917681	chr16:89810941	C/A	cg04287289	chr16:89883240	FANCA	0.71	6.55	0.37	3.01e-10	Skin colour saturation;
CESC	cis	rs6987853	0.933	rs6474401	chr8:42367068	T/C	cg09913449	chr8:42400586	C8orf40	-0.42	-6.72	-0.38	1.1e-10	Mean corpuscular hemoglobin concentration;
CESC	cis	rs1904096	0.506	rs28522293	chr4:95167087	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.63	-10.06	-0.53	2.19e-20	Type 2 diabetes;
CESC	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	22.58	0.81	1.09e-63	Prudent dietary pattern;
CESC	cis	rs6582630	0.548	rs1607870	chr12:38385964	G/T	cg26384229	chr12:38710491	ALG10B	-0.47	-6.27	-0.36	1.45e-9	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs7264396	0.563	rs2425146	chr20:34355268	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.86	-10.2	-0.53	7.89e-21	Total cholesterol levels;
CESC	cis	rs763121	0.853	rs1569716	chr22:38998519	C/A	cg06544989	chr22:39130855	UNC84B	0.49	8.97	0.48	5.72e-17	Menopause (age at onset);
CESC	cis	rs9815354	0.812	rs73077386	chr3:41857652	A/G	cg03022575	chr3:42003672	ULK4	0.7	6.34	0.36	1.01e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs2070488	0.775	rs13098946	chr3:38517784	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.82	13.23	0.63	5.09e-31	Electrocardiographic conduction measures;
CESC	cis	rs1799949	0.965	rs35954893	chr17:41333786	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.62	8.39	0.46	2.99e-15	Menopause (age at onset);
CESC	cis	rs12458462	0.859	rs35493271	chr18:77448793	G/T	cg23301140	chr18:77439876	CTDP1	0.57	7.7	0.43	2.65e-13	Monocyte count;
CESC	cis	rs4964805	0.657	rs11111787	chr12:104189499	C/T	cg02344784	chr12:104178138	NT5DC3	0.46	6.57	0.37	2.73e-10	Attention deficit hyperactivity disorder;
CESC	cis	rs10504229	0.906	rs67389108	chr8:58193718	G/A	cg24829409	chr8:58192753	C8orf71	-0.74	-9.68	-0.51	3.6e-19	Developmental language disorder (linguistic errors);
CESC	cis	rs8141529	0.702	rs469990	chr22:29304200	A/T	cg15103426	chr22:29168792	CCDC117	0.62	8.1	0.45	2.05e-14	Lymphocyte counts;
CESC	cis	rs870825	0.581	rs28602720	chr4:185630598	T/C	cg04058563	chr4:185651563	MLF1IP	0.64	7.0	0.4	2.05e-11	Blood protein levels;
CESC	cis	rs798766	1.000	rs3099555	chr4:1725651	T/C	cg05874882	chr4:1763078	NA	-0.61	-8.56	-0.47	9.25e-16	Bladder cancer;Urinary bladder cancer;
CESC	cis	rs9311474	0.967	rs11717383	chr3:52287468	G/T	cg18099408	chr3:52552593	STAB1	-0.31	-5.31	-0.31	2.3e-7	Electroencephalogram traits;
CESC	cis	rs9611565	0.659	rs9611604	chr22:41916001	C/G	cg03806693	chr22:41940476	POLR3H	-1.22	-15.34	-0.69	1.99e-38	Vitiligo;
CESC	cis	rs12824058	0.831	rs11060826	chr12:130809931	G/C	cg23887609	chr12:130822674	PIWIL1	0.45	5.82	0.34	1.69e-8	Menopause (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17484976	chr20:60982411	CABLES2	0.56	6.83	0.39	5.86e-11	Gut microbiome composition (summer);
CESC	cis	rs9660180	0.839	rs12040826	chr1:1705287	A/C	cg03396347	chr1:1875803	NA	-0.41	-6.34	-0.36	1.01e-9	Body mass index;
CESC	cis	rs2274273	0.870	rs10142547	chr14:55763963	T/C	cg04306507	chr14:55594613	LGALS3	0.31	6.09	0.35	4.01e-9	Protein biomarker;
CESC	cis	rs34779708	0.741	rs34397613	chr10:35550313	A/G	cg03585969	chr10:35415529	CREM	0.54	6.12	0.35	3.34e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs4835473	0.932	rs12512649	chr4:144657898	A/G	cg25736465	chr4:144833511	NA	-0.33	-5.23	-0.31	3.4e-7	Immature fraction of reticulocytes;
CESC	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg05564831	chr3:52568323	NT5DC2	0.49	8.27	0.45	6.76e-15	Electroencephalogram traits;
CESC	cis	rs8141529	0.778	rs763073	chr22:29215542	G/A	cg15103426	chr22:29168792	CCDC117	0.67	9.75	0.51	2.24e-19	Lymphocyte counts;
CESC	cis	rs514406	0.758	rs532242	chr1:53308665	C/G	cg16325326	chr1:53192061	ZYG11B	0.89	15.1	0.68	1.38e-37	Monocyte count;
CESC	cis	rs12079745	0.623	rs12091844	chr1:169433273	C/T	cg09363564	chr1:169337483	NME7;BLZF1	-1.16	-6.88	-0.39	4.39e-11	QT interval;
CESC	cis	rs57244997	0.582	rs73030432	chr6:162439864	G/A	cg17173639	chr6:162384350	PARK2	-0.45	-5.19	-0.3	4.15e-7	Mosquito bite size;
CESC	cis	rs1552244	1.000	rs9845756	chr3:10067548	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.88	11.96	0.59	1.2e-26	Alzheimer's disease;
CESC	cis	rs873946	0.648	rs35417213	chr10:134553749	A/G	cg06453172	chr10:134556979	INPP5A	-0.42	-5.51	-0.32	8.32e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs7020830	0.898	rs2790063	chr9:37287405	G/A	cg14294708	chr9:37120828	ZCCHC7	1.11	20.53	0.78	1.06e-56	Schizophrenia;
CESC	cis	rs698813	0.642	rs1837702	chr2:44492444	T/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.49	5.43	0.32	1.3e-7	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
CESC	cis	rs2404602	0.692	rs2120108	chr15:76869929	G/T	cg26408565	chr15:76604113	ETFA	0.37	5.38	0.31	1.62e-7	Blood metabolite levels;
CESC	cis	rs1153858	1.000	rs2453541	chr15:45645378	G/A	cg21132104	chr15:45694354	SPATA5L1	0.76	10.17	0.53	1.03e-20	Homoarginine levels;
CESC	cis	rs10504229	1.000	rs55787104	chr8:58178519	C/T	cg24829409	chr8:58192753	C8orf71	-0.76	-9.94	-0.52	5.53e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs472402	0.580	rs3733773	chr5:6652252	G/A	cg10789808	chr5:6633262	NSUN2;SRD5A1	-0.55	-7.06	-0.4	1.43e-11	Response to amphetamines;
CESC	cis	rs67311347	1.000	rs7631893	chr3:40440869	C/T	cg09455208	chr3:40491958	NA	0.45	8.07	0.44	2.44e-14	Renal cell carcinoma;
CESC	cis	rs7647973	0.626	rs4855845	chr3:49687043	T/C	cg03060546	chr3:49711283	APEH	0.68	8.35	0.46	3.86e-15	Menarche (age at onset);
CESC	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg24829409	chr8:58192753	C8orf71	-0.67	-7.99	-0.44	4.08e-14	Developmental language disorder (linguistic errors);
CESC	cis	rs2842992	1.000	rs2842992	chr6:160071159	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.62	7.55	0.42	6.95e-13	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs12145833	0.596	rs10737887	chr1:243424146	T/C	cg02356786	chr1:243265016	LOC731275	-0.6	-5.18	-0.3	4.3e-7	Obesity (early onset extreme);
CESC	cis	rs5750830	0.649	rs5750818	chr22:39820885	A/G	cg01416388	chr22:39784598	NA	-0.6	-7.51	-0.42	9.01e-13	Intelligence (multi-trait analysis);
CESC	cis	rs6060717	0.653	rs2590962	chr20:34615363	G/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.49	6.23	0.36	1.86e-9	Hip circumference adjusted for BMI;
CESC	cis	rs9660180	0.967	rs11260623	chr1:1781456	G/T	cg03396347	chr1:1875803	NA	-0.42	-6.63	-0.38	1.82e-10	Body mass index;
CESC	cis	rs8114671	0.562	rs6087642	chr20:33468306	T/C	cg06115741	chr20:33292138	TP53INP2	0.43	5.28	0.31	2.72e-7	Height;
CESC	cis	rs6831352	1.000	rs6837685	chr4:100049145	G/A	cg12011299	chr4:100065546	ADH4	0.69	8.43	0.46	2.17e-15	Alcohol dependence;
CESC	cis	rs9457247	1.000	rs439553	chr6:167391212	A/G	cg07741184	chr6:167504864	NA	0.33	5.98	0.34	7.1e-9	Crohn's disease;
CESC	cis	rs12477438	0.765	rs6740054	chr2:99576631	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.63	-8.76	-0.47	2.41e-16	Chronic sinus infection;
CESC	trans	rs7246760	0.867	rs16981648	chr19:9804424	A/C	cg02900749	chr2:68251473	NA	-0.82	-7.19	-0.4	6.54e-12	Pursuit maintenance gain;
CESC	cis	rs698813	0.604	rs1596010	chr2:44491804	A/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.51	5.68	0.33	3.49e-8	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
CESC	cis	rs9911578	1.000	rs12938772	chr17:56776320	T/C	cg12560992	chr17:57184187	TRIM37	0.9	15.1	0.68	1.36e-37	Intelligence (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06331185	chr16:23689892	PLK1	0.57	6.57	0.37	2.7e-10	Gut microbiome composition (summer);
CESC	cis	rs10858096	0.608	rs413582	chr1:109851126	C/T	cg08367326	chr1:110052010	AMIGO1	0.42	5.14	0.3	5.26e-7	Intelligence (multi-trait analysis);
CESC	cis	rs9911578	1.000	rs9911578	chr17:56953147	C/T	cg12560992	chr17:57184187	TRIM37	0.94	15.65	0.69	1.5e-39	Intelligence (multi-trait analysis);
CESC	cis	rs4253772	0.872	rs45552534	chr22:46638171	G/A	cg00784671	chr22:46762841	CELSR1	-0.51	-5.27	-0.31	2.87e-7	LDL cholesterol;Cholesterol, total;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18444519	chr5:134210458	TXNDC15	0.49	6.2	0.36	2.18e-9	Gut microbiome composition (summer);
CESC	cis	rs853679	0.517	rs9468298	chr6:28122345	A/G	cg26335602	chr6:28129616	ZNF389	0.53	6.74	0.38	9.91e-11	Depression;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09378105	chr7:100895380	NA	0.61	7.17	0.4	7.46e-12	Gut microbiome composition (summer);
CESC	cis	rs4268898	0.662	rs17733015	chr2:24509370	A/G	cg06627628	chr2:24431161	ITSN2	-0.96	-11.37	-0.57	1.15e-24	Asthma;
CESC	cis	rs5769765	0.955	rs9616367	chr22:50303515	A/C	cg02269571	chr22:50332266	NA	-0.55	-6.8	-0.39	6.73e-11	Schizophrenia;
CESC	cis	rs10791097	0.765	rs4622274	chr11:130729486	C/T	cg12179176	chr11:130786555	SNX19	0.57	8.25	0.45	7.65e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs9916302	0.904	rs4794814	chr17:37696852	G/A	cg00129232	chr17:37814104	STARD3	-0.57	-7.53	-0.42	7.83e-13	Glomerular filtration rate (creatinine);
CESC	cis	rs875971	0.660	rs3857686	chr7:66036191	C/T	cg18876405	chr7:65276391	NA	-0.59	-7.97	-0.44	4.6e-14	Aortic root size;
CESC	cis	rs6500395	1.000	rs8052196	chr16:48691644	C/T	cg04672837	chr16:48644449	N4BP1	-0.51	-6.36	-0.36	8.64e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs34375054	0.526	rs7302475	chr12:125677886	T/C	cg05341575	chr12:125625032	AACS	-0.37	-5.27	-0.31	2.81e-7	Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs854765	0.686	rs8065497	chr17:17782649	A/G	cg04398451	chr17:18023971	MYO15A	0.62	8.32	0.45	4.84e-15	Total body bone mineral density;
CESC	cis	rs9916302	0.706	rs8182252	chr17:37727950	T/C	cg07936489	chr17:37558343	FBXL20	0.94	12.28	0.6	9.67e-28	Glomerular filtration rate (creatinine);
CESC	cis	rs11098499	0.645	rs72676059	chr4:120290828	C/G	cg24375607	chr4:120327624	NA	0.42	5.19	0.3	4.19e-7	Corneal astigmatism;
CESC	cis	rs6740322	0.895	rs13384080	chr2:43557363	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.69	-7.44	-0.42	1.45e-12	Coronary artery disease;
CESC	cis	rs9929218	0.954	rs12928043	chr16:68828885	G/A	cg02972257	chr16:68554789	NA	0.45	5.37	0.31	1.74e-7	Colorectal cancer;
CESC	cis	rs11785400	1.000	rs4736342	chr8:143735190	A/G	cg24634471	chr8:143751801	JRK	0.47	6.02	0.35	5.81e-9	Schizophrenia;
CESC	cis	rs722599	0.683	rs17102847	chr14:75324780	A/G	cg08847533	chr14:75593920	NEK9	-0.48	-5.97	-0.34	7.73e-9	IgG glycosylation;
CESC	trans	rs1814175	0.817	rs4084376	chr11:49831160	T/C	cg15704280	chr7:45808275	SEPT13	-1.03	-20.7	-0.79	2.81e-57	Height;
CESC	cis	rs16857609	0.600	rs10932715	chr2:218259783	A/G	cg15335768	chr2:218268053	DIRC3	-0.37	-5.8	-0.34	1.92e-8	Breast cancer;Breast cancer (estrogen-receptor negative);
CESC	cis	rs4648845	0.777	rs2477686	chr1:2392648	C/G	cg13556452	chr1:2391241	NA	-0.35	-6.13	-0.35	3.09e-9	Schizophrenia;
CESC	trans	rs7839040	0.698	rs7836498	chr8:82928782	A/G	cg14472086	chr9:107730925	NA	-0.47	-6.33	-0.36	1.02e-9	Response to methotrexate in juvenile idiopathic arthritis;
CESC	cis	rs7834588	0.523	rs1378521	chr8:63834621	T/C	cg20602954	chr8:63776762	NKAIN3	0.3	5.03	0.3	9.14e-7	Response to Vitamin E supplementation;
CESC	cis	rs9399401	0.710	rs6900087	chr6:142717303	A/T	cg03128060	chr6:142623767	GPR126	0.38	6.4	0.37	7.02e-10	Chronic obstructive pulmonary disease;
CESC	cis	rs12711979	0.765	rs6715805	chr2:3821117	T/C	cg17052675	chr2:3827356	NA	-0.41	-6.47	-0.37	4.82e-10	Itch intensity from mosquito bite adjusted by bite size;
CESC	cis	rs1862618	0.853	rs252898	chr5:56188931	T/C	cg18230493	chr5:56204884	C5orf35	-0.75	-9.01	-0.48	4.28e-17	Initial pursuit acceleration;
CESC	cis	rs1707322	0.964	rs785483	chr1:46559171	T/C	cg06784218	chr1:46089804	CCDC17	-0.33	-5.63	-0.33	4.67e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs1945213	0.694	rs34390414	chr11:55863367	T/G	cg03929089	chr4:120376271	NA	0.72	6.85	0.39	5.25e-11	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs7412746	0.658	rs7521719	chr1:150913134	G/A	cg04414720	chr1:150670196	GOLPH3L	0.52	6.88	0.39	4.32e-11	Melanoma;
CESC	cis	rs8028182	0.636	rs7163451	chr15:75861076	G/T	cg20655648	chr15:75932815	IMP3	0.5	6.17	0.35	2.57e-9	Sudden cardiac arrest;
CESC	cis	rs4253772	0.550	rs11703564	chr22:46722194	G/A	cg18190219	chr22:46762943	CELSR1	-0.59	-5.79	-0.33	2.02e-8	LDL cholesterol;Cholesterol, total;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16116244	chr1:16939841	NBPF1	0.63	7.1	0.4	1.13e-11	Gut microbiome composition (summer);
CESC	cis	rs11785400	0.762	rs7460801	chr8:143730972	C/A	cg10596483	chr8:143751796	JRK	0.42	5.33	0.31	2.06e-7	Schizophrenia;
CESC	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg23034840	chr1:205782522	SLC41A1	0.7	8.66	0.47	4.66e-16	Menarche (age at onset);
CESC	cis	rs4819052	0.765	rs2838852	chr21:46677037	C/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.47	5.87	0.34	1.27e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg04238871	chr10:126431886	FAM53B	0.51	7.32	0.41	3.01e-12	Systemic lupus erythematosus;
CESC	cis	rs1008375	1.000	rs10939738	chr4:17604295	G/C	cg02297831	chr4:17616191	MED28	0.52	6.61	0.38	2.1e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs858239	0.539	rs870476	chr7:23193271	C/T	cg23682824	chr7:23144976	KLHL7	0.47	6.36	0.36	8.93e-10	Cerebrospinal fluid biomarker levels;
CESC	cis	rs7618915	0.547	rs11130315	chr3:52697163	A/G	cg05564831	chr3:52568323	NT5DC2	0.44	6.72	0.38	1.08e-10	Bipolar disorder;
CESC	cis	rs12136530	0.593	rs12403041	chr1:19730927	A/G	cg01832549	chr1:19774989	CAPZB	-0.46	-6.3	-0.36	1.23e-9	Lead levels in blood;
CESC	cis	rs2439831	0.850	rs67541383	chr15:44172548	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.66	6.48	0.37	4.38e-10	Lung cancer in ever smokers;
CESC	cis	rs2274273	0.588	rs58296156	chr14:55828327	C/T	cg04306507	chr14:55594613	LGALS3	0.3	5.26	0.31	2.92e-7	Protein biomarker;
CESC	cis	rs1152591	0.505	rs1152601	chr14:64667337	T/C	cg21174375	chr14:64681225	SYNE2	0.59	8.42	0.46	2.32e-15	Atrial fibrillation;
CESC	cis	rs4555082	0.874	rs11625098	chr14:105756891	A/G	cg13114125	chr14:105738426	BRF1	-0.9	-10.61	-0.55	3.82e-22	Mean platelet volume;Platelet distribution width;
CESC	cis	rs7580658	0.963	rs12479003	chr2:128118553	C/T	cg10021288	chr2:128175891	PROC	-0.41	-6.47	-0.37	4.66e-10	Protein C levels;
CESC	cis	rs3785574	0.924	rs2584641	chr17:61862889	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.58	7.25	0.41	4.59e-12	Height;
CESC	cis	rs4665809	0.590	rs2289019	chr2:26420809	G/C	cg25036284	chr2:26402008	FAM59B	-0.84	-9.66	-0.51	4.19e-19	Gut microbiome composition (summer);
CESC	cis	rs847577	0.651	rs10464490	chr7:97715319	T/G	cg24562669	chr7:97807699	LMTK2	0.63	10.15	0.53	1.13e-20	Breast cancer;
CESC	cis	rs1728785	1.000	rs7192341	chr16:68569224	G/C	cg02972257	chr16:68554789	NA	-0.62	-6.93	-0.39	3.14e-11	Ulcerative colitis;
CESC	cis	rs7818345	1.000	rs7011602	chr8:19308915	T/C	cg11303988	chr8:19266685	CSGALNACT1	0.34	5.87	0.34	1.29e-8	Language performance in older adults (adjusted for episodic memory);
CESC	cis	rs9311474	1.000	rs2276834	chr3:52325759	A/G	cg05564831	chr3:52568323	NT5DC2	0.47	7.42	0.41	1.62e-12	Electroencephalogram traits;
CESC	trans	rs61931739	0.500	rs11053212	chr12:34466116	T/G	cg26384229	chr12:38710491	ALG10B	0.71	10.64	0.55	3.04e-22	Morning vs. evening chronotype;
CESC	cis	rs4243830	0.737	rs11122085	chr1:6597861	T/C	cg22792644	chr1:6614718	TAS1R1;NOL9	0.85	7.42	0.41	1.63e-12	Body mass index;
CESC	cis	rs13118159	0.550	rs4974617	chr4:1373658	T/C	cg19318889	chr4:1322082	MAEA	0.59	7.21	0.41	5.72e-12	Longevity;
CESC	cis	rs7894051	1.000	rs7074435	chr10:135190570	G/T	cg12428399	chr10:135191333	PAOX	0.62	5.25	0.31	3.11e-7	Lifespan;
CESC	cis	rs8014204	0.836	rs888413	chr14:75267396	C/T	cg08847533	chr14:75593920	NEK9	0.5	6.25	0.36	1.62e-9	Caffeine consumption;
CESC	cis	rs9287719	0.967	rs2010073	chr2:10736478	C/T	cg00105475	chr2:10696890	NA	0.39	5.61	0.33	4.96e-8	Prostate cancer;
CESC	cis	rs4665809	0.590	rs9309474	chr2:26448830	T/A	cg25036284	chr2:26402008	FAM59B	-0.86	-9.4	-0.5	2.74e-18	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06032540	chr15:43941563	CATSPER2	-0.66	-8.0	-0.44	3.92e-14	Gut microbiome composition (summer);
CESC	cis	rs6933660	0.800	rs13201167	chr6:151773504	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.83	13.45	0.64	8.71e-32	Menarche (age at onset);
CESC	cis	rs4727027	0.870	rs11525060	chr7:148801091	G/A	cg23583168	chr7:148888333	NA	-0.73	-10.77	-0.55	1.16e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs919433	0.927	rs7592748	chr2:198170688	G/A	cg10820045	chr2:198174542	NA	-0.38	-5.16	-0.3	4.87e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs8014204	0.743	rs35809608	chr14:75254762	A/G	cg08847533	chr14:75593920	NEK9	0.47	5.97	0.34	7.75e-9	Caffeine consumption;
CESC	cis	rs67311347	0.568	rs57287242	chr3:40335538	T/C	cg09455208	chr3:40491958	NA	0.37	6.67	0.38	1.48e-10	Renal cell carcinoma;
CESC	cis	rs8031584	0.679	rs34017474	chr15:31230611	T/C	cg08109568	chr15:31115862	NA	-0.5	-6.76	-0.38	8.56e-11	Huntington's disease progression;
CESC	cis	rs9611565	0.694	rs79011	chr22:41866938	A/G	cg06481639	chr22:41940642	POLR3H	0.55	6.05	0.35	4.91e-9	Vitiligo;
CESC	cis	rs7666738	0.962	rs13147921	chr4:99069296	C/G	cg05340658	chr4:99064831	C4orf37	0.7	9.08	0.49	2.6e-17	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3785574	0.962	rs2584628	chr17:61894578	T/C	cg06420487	chr17:61919686	SMARCD2	0.45	5.43	0.32	1.3e-7	Height;
CESC	cis	rs832540	0.656	rs832567	chr5:56152416	C/A	cg24531977	chr5:56204891	C5orf35	-0.48	-5.86	-0.34	1.38e-8	Coronary artery disease;
CESC	cis	rs6669072	0.647	rs1335727	chr1:91238652	C/T	cg08895590	chr1:91227319	NA	-0.34	-5.86	-0.34	1.39e-8	Cognitive function;
CESC	cis	rs6089584	0.853	rs1740367	chr20:60574834	C/T	cg18761221	chr20:60518478	NA	0.38	5.06	0.3	7.89e-7	Body mass index;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg26462404	chr19:2270807	OAZ1	-0.42	-6.11	-0.35	3.58e-9	Gambling;
CESC	cis	rs7949030	0.626	rs61296092	chr11:62320838	T/C	cg23462726	chr11:62437636	C11orf83;C11orf48	-0.39	-5.05	-0.3	8.14e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs73206853	0.620	rs28720928	chr12:111126609	C/T	cg12870014	chr12:110450643	ANKRD13A	0.73	5.37	0.31	1.69e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs57506017	0.585	rs5011434	chr7:12268717	C/T	cg23422036	chr7:12250390	TMEM106B	0.39	5.19	0.3	4.14e-7	Neuroticism;
CESC	cis	rs10838687	0.736	rs3781619	chr11:47255317	C/T	cg25783544	chr11:47291846	MADD	0.57	6.55	0.37	3.01e-10	Proinsulin levels;
CESC	cis	rs10493773	0.775	rs2069208	chr1:86117583	T/C	cg17807903	chr1:86174739	ZNHIT6	-0.37	-5.03	-0.3	9.19e-7	Urate levels in overweight individuals;
CESC	cis	rs12148488	0.816	rs4886655	chr15:75385568	C/T	cg17294928	chr15:75287854	SCAMP5	0.52	6.48	0.37	4.42e-10	Caffeine consumption;
CESC	cis	rs1594829	0.500	rs2046223	chr8:26210178	C/T	cg11498726	chr8:26250323	BNIP3L	0.38	5.53	0.32	7.63e-8	Height;
CESC	cis	rs13385	0.769	rs13353859	chr5:139620455	A/G	cg26211634	chr5:139558579	C5orf32	0.48	5.27	0.31	2.79e-7	Atrial fibrillation;
CESC	cis	rs1062177	0.855	rs919262	chr5:151266084	C/T	cg00977110	chr5:151150581	G3BP1	-0.52	-5.82	-0.34	1.69e-8	Preschool internalizing problems;
CESC	cis	rs55986470	0.763	rs11888775	chr2:239424876	C/T	cg18131467	chr2:239335373	ASB1	0.54	6.02	0.35	5.82e-9	Chronotype;
CESC	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg04025307	chr7:1156635	C7orf50	0.54	9.05	0.49	3.14e-17	Longevity;Endometriosis;
CESC	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg06873352	chr17:61820015	STRADA	-0.73	-12.33	-0.6	6.62e-28	Prudent dietary pattern;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13985271	chr9:97140681	HIATL1	-0.57	-6.19	-0.36	2.25e-9	Gut microbiome composition (summer);
CESC	cis	rs4819052	0.851	rs7279182	chr21:46656112	G/A	cg11663144	chr21:46675770	NA	-0.62	-9.43	-0.5	2.14e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs35955747	0.902	rs7287402	chr22:31654823	A/G	cg25791279	chr22:32026902	PISD	0.48	5.81	0.34	1.78e-8	Neutrophil count;Sum basophil neutrophil counts;
CESC	cis	rs6879260	1.000	rs7725605	chr5:179732678	T/G	cg13944838	chr5:179740914	GFPT2	-0.74	-10.05	-0.53	2.34e-20	Height;
CESC	cis	rs1879734	0.731	rs11206196	chr1:54165624	A/G	cg23596471	chr1:54105337	GLIS1	0.32	5.46	0.32	1.07e-7	Mitral valve prolapse;
CESC	cis	rs2243480	1.000	rs34560516	chr7:65404092	A/T	cg18252515	chr7:66147081	NA	-1.18	-10.88	-0.56	5.02e-23	Diabetic kidney disease;
CESC	cis	rs7666738	0.830	rs969048	chr4:98988921	T/C	cg05340658	chr4:99064831	C4orf37	0.8	12.42	0.61	3.09e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7618915	0.571	rs6762457	chr3:52609157	G/A	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.38	6.74	0.38	9.76e-11	Bipolar disorder;
CESC	trans	rs17508449	0.865	rs76112502	chr1:114149696	T/C	cg23028848	chr11:57092561	TNKS1BP1	-0.77	-6.14	-0.35	2.98e-9	Leprosy;
CESC	cis	rs3741151	0.773	rs79915238	chr11:73272947	C/T	cg17517138	chr11:73019481	ARHGEF17	1.03	7.57	0.42	6.07e-13	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00776782	chr1:12677088	DHRS3	0.63	6.78	0.38	8e-11	Gut microbiome composition (summer);
CESC	cis	rs561341	0.883	rs886224	chr17:30229902	T/C	cg12193833	chr17:30244370	NA	-0.62	-6.22	-0.36	1.97e-9	Hip circumference adjusted for BMI;
CESC	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg05025164	chr4:1340916	KIAA1530	0.93	12.43	0.61	2.85e-28	Longevity;
CESC	cis	rs7666738	0.791	rs1967978	chr4:98966152	T/C	cg18180107	chr4:99064573	C4orf37	0.4	5.14	0.3	5.26e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2361710	1.000	rs2361710	chr17:78111877	C/T	cg06718696	chr17:78121285	EIF4A3	-0.46	-5.85	-0.34	1.42e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
CESC	trans	rs7246657	0.943	rs7248733	chr19:37996361	A/C	cg01833234	chr11:6592585	DNHD1	0.51	6.14	0.35	3.08e-9	Coronary artery calcification;
CESC	cis	rs6701037	0.748	rs11585368	chr1:175135448	G/A	cg00321850	chr1:175162397	KIAA0040	-0.41	-5.97	-0.34	7.39e-9	Alcohol dependence;
CESC	cis	rs11734570	0.581	rs73808504	chr4:38600593	T/C	cg18361445	chr4:38666374	KLF3;FLJ13197	0.6	7.34	0.41	2.7e-12	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs2066819	1.000	rs79750959	chr12:56702012	C/A	cg26714650	chr12:56694279	CS	-1.48	-9.9	-0.52	7.03e-20	Psoriasis vulgaris;
CESC	cis	rs3820068	0.655	rs11587521	chr1:15839206	T/C	cg17385448	chr1:15911702	AGMAT	0.38	5.92	0.34	9.72e-9	Systolic blood pressure;
CESC	cis	rs896854	0.715	rs12548874	chr8:95935164	A/C	cg13393036	chr8:95962371	TP53INP1	0.45	9.2	0.49	1.08e-17	Type 2 diabetes;
CESC	cis	rs7116495	0.609	rs2511120	chr11:71786211	C/T	cg10381502	chr11:71823885	C11orf51	-1.1	-6.81	-0.39	6.36e-11	Severe influenza A (H1N1) infection;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26988692	chr8:37756473	RAB11FIP1	0.55	6.21	0.36	2.06e-9	Gut microbiome composition (summer);
CESC	cis	rs2380220	0.576	rs4368819	chr6:96031109	T/G	cg23517279	chr6:96025343	MANEA	0.54	5.28	0.31	2.66e-7	Behavioural disinhibition (generation interaction);
CESC	cis	rs28489187	0.730	rs12140103	chr1:85849489	G/A	cg16011679	chr1:85725395	C1orf52	0.48	5.67	0.33	3.68e-8	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	7.85	0.43	1.05e-13	Prudent dietary pattern;
CESC	cis	rs748404	0.697	rs498227	chr15:43573052	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.53	8.08	0.44	2.26e-14	Lung cancer;
CESC	cis	rs208520	0.690	rs10944872	chr6:66708239	T/G	cg07460842	chr6:66804631	NA	0.94	12.61	0.61	7.28e-29	Exhaled nitric oxide output;
CESC	cis	rs12682352	0.602	rs1473029	chr8:8668917	A/C	cg06636001	chr8:8085503	FLJ10661	0.42	5.23	0.31	3.43e-7	Neuroticism;
CESC	cis	rs72781680	0.898	rs72780191	chr2:24007122	T/C	cg20701182	chr2:24300061	SF3B14	0.78	6.7	0.38	1.22e-10	Lymphocyte counts;
CESC	cis	rs2522056	1.000	rs1003533	chr5:131755651	C/T	cg24060327	chr5:131705240	SLC22A5	0.64	7.3	0.41	3.44e-12	Lymphocyte counts;Fibrinogen;
CESC	cis	rs1552244	0.572	rs73117481	chr3:10160132	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.68	-7.55	-0.42	6.87e-13	Alzheimer's disease;
CESC	trans	rs916888	0.610	rs199436	chr17:44789285	C/T	cg22968622	chr17:43663579	NA	-0.79	-10.63	-0.55	3.19e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs1552244	1.000	rs67852463	chr3:10157205	G/C	cg16606324	chr3:10149918	C3orf24	0.41	5.1	0.3	6.38e-7	Alzheimer's disease;
CESC	cis	rs1552244	0.706	rs279545	chr3:9972493	A/G	cg00166722	chr3:10149974	C3orf24	0.42	5.85	0.34	1.45e-8	Alzheimer's disease;
CESC	cis	rs10208940	0.764	rs6737302	chr2:68782837	A/G	cg12452813	chr2:68675892	NA	0.52	5.16	0.3	4.88e-7	Urate levels in lean individuals;
CESC	cis	rs6952808	0.531	rs1107351	chr7:2177093	G/A	cg04267008	chr7:1944627	MAD1L1	-0.57	-6.76	-0.38	9.02e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs4523957	0.553	rs2476355	chr17:2029559	A/G	cg16513277	chr17:2031491	SMG6	-0.79	-11.71	-0.58	8.09e-26	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs3858526	0.959	rs4758219	chr11:5951846	G/C	cg13902645	chr11:5959945	NA	-0.66	-7.99	-0.44	4.21e-14	DNA methylation (variation);
CESC	cis	rs56804039	1.000	rs59620654	chr8:8382632	A/G	cg15556689	chr8:8085844	FLJ10661	-0.48	-5.2	-0.3	4.05e-7	Cervical cancer;
CESC	cis	rs4555082	0.718	rs28513571	chr14:105709592	C/A	cg13114125	chr14:105738426	BRF1	-0.77	-9.49	-0.5	1.4e-18	Mean platelet volume;Platelet distribution width;
CESC	cis	rs921968	0.643	rs552882	chr2:219401726	G/A	cg02176678	chr2:219576539	TTLL4	0.42	7.44	0.42	1.43e-12	Mean corpuscular hemoglobin concentration;
CESC	cis	rs7666738	0.830	rs1834647	chr4:98882915	G/A	cg05340658	chr4:99064831	C4orf37	0.75	10.97	0.56	2.53e-23	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.39	5.11	0.3	6.29e-7	Lymphocyte counts;
CESC	cis	rs1847202	0.563	rs13095184	chr3:72951008	A/G	cg25664220	chr3:72788482	NA	-0.38	-5.57	-0.32	6.3e-8	Motion sickness;
CESC	cis	rs4722166	0.695	rs4722177	chr7:22798531	T/C	cg05265849	chr7:22767390	IL6	0.46	6.31	0.36	1.17e-9	Lung cancer;
CESC	cis	rs7084402	0.967	rs11006170	chr10:60276369	T/C	cg07615347	chr10:60278583	BICC1	-0.59	-9.45	-0.5	1.94e-18	Refractive error;
CESC	trans	rs17685	0.712	rs60721456	chr7:75743820	T/A	cg19862616	chr7:65841803	NCRNA00174	0.75	10.73	0.55	1.51e-22	Coffee consumption;Coffee consumption (cups per day);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg12351856	chr18:19192308	SNRPD1	-0.45	-6.33	-0.36	1.03e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs3820068	0.705	rs7533125	chr1:15883744	T/C	cg17385448	chr1:15911702	AGMAT	0.37	5.81	0.34	1.8e-8	Systolic blood pressure;
CESC	cis	rs4919694	0.901	rs10509763	chr10:104776391	G/A	cg04362960	chr10:104952993	NT5C2	0.74	6.38	0.37	7.75e-10	Arsenic metabolism;
CESC	cis	rs875971	0.767	rs61348003	chr7:66005934	C/T	cg12463550	chr7:65579703	CRCP	0.51	6.36	0.36	8.66e-10	Aortic root size;
CESC	trans	rs916888	0.610	rs199453	chr17:44800946	C/T	cg01341218	chr17:43662625	NA	0.53	7.07	0.4	1.4e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs75804782	0.641	rs11885523	chr2:239344263	G/A	cg18131467	chr2:239335373	ASB1	-0.68	-5.91	-0.34	1.03e-8	Morning vs. evening chronotype;Chronotype;
CESC	cis	rs10504229	0.953	rs6990806	chr8:58183113	G/A	cg24829409	chr8:58192753	C8orf71	-0.76	-9.93	-0.52	5.87e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs796364	0.806	rs10445792	chr2:201078821	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.72	-5.97	-0.34	7.44e-9	Schizophrenia;
CESC	cis	rs2243480	1.000	rs419603	chr7:65597341	C/T	cg13147721	chr7:65941812	NA	-0.99	-9.4	-0.5	2.68e-18	Diabetic kidney disease;
CESC	cis	rs12477438	0.798	rs4324365	chr2:99623845	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-10.57	-0.54	5.22e-22	Chronic sinus infection;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18216292	chr1:155920810	ARHGEF2	-0.57	-6.54	-0.37	3.18e-10	Gut microbiome composition (summer);
CESC	trans	rs2235573	0.527	rs139885	chr22:38371039	C/T	cg19894588	chr14:64061835	NA	0.59	7.63	0.42	4.24e-13	Glioblastoma;Glioma;
CESC	cis	rs12824058	0.831	rs4759657	chr12:130815818	G/A	cg23887609	chr12:130822674	PIWIL1	0.45	5.86	0.34	1.38e-8	Menopause (age at onset);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg01877967	chr7:56148907	PHKG1	0.54	7.2	0.4	6.23e-12	Fibrinogen levels;
CESC	cis	rs919433	0.854	rs787994	chr2:198223121	T/C	cg10820045	chr2:198174542	NA	0.39	5.78	0.33	2.08e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs4665809	0.590	rs62128455	chr2:26466530	G/A	cg08470875	chr2:26401718	FAM59B	0.75	7.79	0.43	1.49e-13	Gut microbiome composition (summer);
CESC	cis	rs2228479	1.000	rs12596492	chr16:89957169	T/G	cg04013166	chr16:89971882	TCF25	0.76	6.53	0.37	3.28e-10	Skin colour saturation;
CESC	cis	rs3820068	0.559	rs6675334	chr1:15923580	A/T	cg17385448	chr1:15911702	AGMAT	0.44	7.29	0.41	3.67e-12	Systolic blood pressure;
CESC	cis	rs2006771	0.818	rs8142376	chr22:32001037	C/T	cg25791279	chr22:32026902	PISD	-0.46	-5.7	-0.33	3.2e-8	Nonsyndromic cleft lip with cleft palate;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg03729288	chr17:7232752	NEURL4	-0.49	-6.72	-0.38	1.08e-10	Fibrinogen levels;
CESC	cis	rs7044106	0.791	rs2416799	chr9:123480866	G/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.38	6.24	0.36	1.77e-9	Hip circumference adjusted for BMI;
CESC	cis	rs2243480	1.000	rs427044	chr7:65508545	G/A	cg25894440	chr7:65020034	NA	-0.61	-5.12	-0.3	5.89e-7	Diabetic kidney disease;
CESC	cis	rs7084402	0.935	rs1896246	chr10:60276068	A/G	cg07615347	chr10:60278583	BICC1	-0.59	-9.42	-0.5	2.33e-18	Refractive error;
CESC	cis	rs477895	0.653	rs72918475	chr11:63878644	G/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.88	9.6	0.51	6.39e-19	Mean platelet volume;
CESC	cis	rs796364	0.806	rs78037592	chr2:201105734	G/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.76	-6.21	-0.36	2.09e-9	Schizophrenia;
CESC	cis	rs9287719	0.967	rs6432117	chr2:10749359	G/C	cg00105475	chr2:10696890	NA	0.38	5.57	0.32	6.34e-8	Prostate cancer;
CESC	cis	rs3820068	0.705	rs4646091	chr1:15822043	T/C	cg18192808	chr1:15853278	DNAJC16	0.47	5.78	0.33	2.05e-8	Systolic blood pressure;
CESC	cis	rs13191362	0.808	rs13217502	chr6:163231414	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.59	5.88	0.34	1.22e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs7264396	0.635	rs6060710	chr20:34536055	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.82	-11.3	-0.57	1.94e-24	Total cholesterol levels;
CESC	cis	rs4237845	0.844	rs7306124	chr12:58303349	A/T	cg00677455	chr12:58241039	CTDSP2	0.55	7.11	0.4	1.06e-11	Intelligence (multi-trait analysis);
CESC	cis	rs7772486	0.875	rs6914813	chr6:146397798	A/G	cg05347473	chr6:146136440	FBXO30	0.51	6.68	0.38	1.36e-10	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13369981	chr7:100027501	MEPCE;ZCWPW1	0.57	6.77	0.38	8.15e-11	Gut microbiome composition (summer);
CESC	cis	rs7937682	0.847	rs583032	chr11:111432757	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.95	-13.83	-0.65	3.96e-33	Primary sclerosing cholangitis;
CESC	cis	rs7605827	0.897	rs6431713	chr2:15691382	C/T	cg19274914	chr2:15703543	NA	0.36	6.39	0.37	7.29e-10	Educational attainment (years of education);
CESC	cis	rs6714710	0.603	rs34373359	chr2:98442202	G/A	cg26665480	chr2:98280029	ACTR1B	0.6	8.23	0.45	8.31e-15	Posterior cortical atrophy and Alzheimer's disease;
CESC	cis	rs1023500	0.596	rs5751209	chr22:42451603	A/G	cg15557168	chr22:42548783	NA	-0.41	-5.31	-0.31	2.32e-7	Schizophrenia;
CESC	cis	rs6088580	0.634	rs6088475	chr20:32964987	T/C	cg24642439	chr20:33292090	TP53INP2	-0.53	-7.01	-0.4	2.01e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs9309711	0.961	rs35067331	chr2:3474085	C/T	cg10845886	chr2:3471009	TTC15	-0.84	-11.45	-0.58	6.34e-25	Neurofibrillary tangles;
CESC	cis	rs7762018	0.660	rs41265385	chr6:170068086	C/T	cg05834625	chr6:170176447	C6orf70	0.51	5.53	0.32	7.75e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs561341	0.883	rs2074102	chr17:30228884	G/A	cg19193384	chr17:30244184	NA	-0.55	-5.62	-0.33	4.73e-8	Hip circumference adjusted for BMI;
CESC	cis	rs9322193	0.962	rs9765929	chr6:150090816	T/C	cg05861140	chr6:150128134	PCMT1	-0.37	-5.33	-0.31	2.15e-7	Lung cancer;
CESC	cis	rs9926296	0.585	rs6500450	chr16:89858024	A/G	cg07648498	chr16:89883185	FANCA	0.44	5.44	0.32	1.2e-7	Vitiligo;
CESC	cis	rs7107174	0.892	rs2512529	chr11:77977351	C/T	cg02023728	chr11:77925099	USP35	0.48	6.6	0.38	2.28e-10	Testicular germ cell tumor;
CESC	cis	rs12682352	0.602	rs635594	chr8:8613387	C/T	cg18904891	chr8:8559673	CLDN23	-0.43	-5.07	-0.3	7.34e-7	Neuroticism;
CESC	cis	rs4253772	0.591	rs8135363	chr22:46651713	T/C	cg09491104	chr22:46646882	C22orf40	-0.59	-9.15	-0.49	1.58e-17	LDL cholesterol;Cholesterol, total;
CESC	cis	rs4835473	0.932	rs1849118	chr4:144910975	T/C	cg25736465	chr4:144833511	NA	0.42	6.39	0.37	7.37e-10	Immature fraction of reticulocytes;
CESC	cis	rs10504229	0.815	rs16921955	chr8:58164553	C/T	cg02725872	chr8:58115012	NA	-0.34	-5.31	-0.31	2.36e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs72781680	0.898	rs72788212	chr2:24087385	G/A	cg20701182	chr2:24300061	SF3B14	0.62	5.68	0.33	3.54e-8	Lymphocyte counts;
CESC	cis	rs2806561	0.765	rs668234	chr1:23515467	G/A	cg12483005	chr1:23474871	LUZP1	0.38	6.0	0.35	6.44e-9	Height;
CESC	cis	rs6558174	0.965	rs2009212	chr8:22491496	G/A	cg03733263	chr8:22462867	KIAA1967	0.47	6.32	0.36	1.1e-9	Breast cancer;
CESC	cis	rs4665809	0.590	rs5001914	chr2:26415429	A/G	cg08470875	chr2:26401718	FAM59B	-0.73	-7.97	-0.44	4.87e-14	Gut microbiome composition (summer);
CESC	cis	rs6460942	0.915	rs62448596	chr7:12446869	C/T	cg20607287	chr7:12443886	VWDE	-0.7	-8.49	-0.46	1.46e-15	Coronary artery disease;
CESC	cis	rs801193	1.000	rs3800812	chr7:66223461	T/C	cg10691866	chr7:65817282	TPST1	-0.32	-5.04	-0.3	8.78e-7	Aortic root size;
CESC	cis	rs9796	0.804	rs28688742	chr15:41403638	G/A	cg12426344	chr15:41135900	SPINT1	-0.24	-5.28	-0.31	2.69e-7	Menopause (age at onset);
CESC	cis	rs16858210	0.874	rs34113436	chr3:183573836	G/A	cg25686905	chr3:183603175	PARL	-0.34	-6.45	-0.37	5.41e-10	Menopause (age at onset);
CESC	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg11494091	chr17:61959527	GH2	0.72	12.33	0.6	6.37e-28	Prudent dietary pattern;
CESC	cis	rs2204008	0.713	rs12366709	chr12:38210179	G/A	cg26384229	chr12:38710491	ALG10B	0.74	10.7	0.55	1.96e-22	Bladder cancer;
CESC	cis	rs3820068	0.581	rs6693694	chr1:15980135	G/T	cg18133145	chr1:16060689	PLEKHM2	-0.4	-5.15	-0.3	5.15e-7	Systolic blood pressure;
CESC	cis	rs7618915	1.000	rs34569561	chr3:52287293	T/C	cg05315796	chr3:52349193	DNAH1	0.37	6.14	0.35	3.01e-9	Bipolar disorder;
CESC	cis	rs11098499	0.697	rs10016448	chr4:120298845	A/G	cg24375607	chr4:120327624	NA	0.46	5.55	0.32	6.98e-8	Corneal astigmatism;
CESC	cis	rs1552244	0.816	rs17050701	chr3:10041554	A/G	cg00166722	chr3:10149974	C3orf24	0.48	5.98	0.34	7.06e-9	Alzheimer's disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg14716208	chr3:52089752	DUSP7	-0.44	-6.0	-0.35	6.41e-9	Fibrinogen levels;
CESC	cis	rs2842992	0.724	rs1128670	chr6:160211636	G/A	cg26839252	chr6:160211577	TCP1;MRPL18	0.49	6.15	0.35	2.83e-9	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs9287719	0.566	rs34595606	chr2:10722518	G/A	cg00105475	chr2:10696890	NA	0.4	5.35	0.31	1.94e-7	Prostate cancer;
CESC	cis	rs847577	0.722	rs7790736	chr7:97713039	G/A	cg24562669	chr7:97807699	LMTK2	0.63	10.27	0.53	4.67e-21	Breast cancer;
CESC	cis	rs4282054	0.631	rs13081155	chr3:52732429	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.48	7.54	0.42	7.64e-13	Cognitive function;
CESC	cis	rs3741404	0.609	rs635139	chr11:63872210	A/G	cg18225595	chr11:63971243	STIP1	0.5	6.59	0.38	2.39e-10	Platelet count;
CESC	cis	rs7618915	0.524	rs12488461	chr3:52698417	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	6.95	0.39	2.84e-11	Bipolar disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20781241	chr15:74907290	CLK3	0.59	6.61	0.38	2.1e-10	Gut microbiome composition (summer);
CESC	cis	rs826838	1.000	rs1095575	chr12:39110284	C/G	cg26384229	chr12:38710491	ALG10B	-0.62	-9.91	-0.52	6.55e-20	Heart rate;
CESC	cis	rs523522	0.962	rs3213565	chr12:120992401	C/T	cg12219531	chr12:120966889	COQ5	0.74	9.75	0.51	2.17e-19	High light scatter reticulocyte count;
CESC	cis	rs9916302	0.904	rs4794807	chr17:37531718	T/A	cg00129232	chr17:37814104	STARD3	0.6	8.04	0.44	3.04e-14	Glomerular filtration rate (creatinine);
CESC	cis	rs9796	0.611	rs691672	chr15:41444438	A/C	cg12426344	chr15:41135900	SPINT1	-0.24	-5.31	-0.31	2.35e-7	Menopause (age at onset);
CESC	cis	rs4253772	0.614	rs11090859	chr22:46687460	T/G	cg18190219	chr22:46762943	CELSR1	-0.46	-5.81	-0.34	1.82e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs2735413	0.709	rs9938043	chr16:78091426	A/G	cg04733911	chr16:78082701	NA	-0.47	-7.31	-0.41	3.12e-12	Systolic blood pressure (alcohol consumption interaction);
CESC	trans	rs4349753	0.640	rs10037082	chr5:144075537	T/C	cg22407458	chr6:35109121	TCP11	0.5	6.29	0.36	1.31e-9	Photic sneeze reflex;
CESC	cis	rs9911578	0.785	rs10853008	chr17:56993407	T/C	cg12560992	chr17:57184187	TRIM37	-0.9	-12.25	-0.6	1.26e-27	Intelligence (multi-trait analysis);
CESC	cis	rs35955747	0.533	rs5998004	chr22:31881829	C/T	cg25791279	chr22:32026902	PISD	-0.43	-5.09	-0.3	6.72e-7	Neutrophil count;Sum basophil neutrophil counts;
CESC	cis	rs727505	1.000	rs10244817	chr7:124467470	T/C	cg23710748	chr7:124431027	NA	-0.48	-7.55	-0.42	6.85e-13	Lewy body disease;
CESC	cis	rs7249142	0.549	rs7260127	chr19:19280499	C/T	cg27384695	chr19:19271486	LOC729991-MEF2B;MEF2B	-0.28	-5.08	-0.3	7.14e-7	IgG glycosylation;
CESC	cis	rs1878931	0.696	rs35175748	chr16:3445427	C/G	cg00484396	chr16:3507460	NAT15	-0.43	-6.68	-0.38	1.41e-10	Body mass index (adult);
CESC	cis	rs10823500	0.748	rs7072230	chr10:71978144	A/G	cg04118878	chr10:71993077	PPA1	0.47	5.56	0.32	6.61e-8	Blood protein levels;
CESC	cis	rs12586317	0.547	rs28577270	chr14:35498443	G/A	cg16230307	chr14:35515116	FAM177A1	0.99	10.61	0.55	3.72e-22	Psoriasis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12853981	chr14:58862714	TOMM20L	0.57	6.32	0.36	1.09e-9	Gut microbiome composition (summer);
CESC	cis	rs2742234	0.590	rs2503863	chr10:43667398	G/A	cg07801480	chr10:43725741	RASGEF1A	0.41	5.29	0.31	2.56e-7	Hirschsprung disease;
CESC	cis	rs1799949	0.930	rs66499067	chr17:41248484	G/C	cg25072359	chr17:41440525	NA	0.47	6.3	0.36	1.23e-9	Menopause (age at onset);
CESC	cis	rs4716602	0.898	rs10249494	chr7:156159448	G/T	cg04090468	chr7:156181990	NA	0.4	5.11	0.3	6.28e-7	Anti-saccade response;
CESC	cis	rs875971	0.895	rs10447522	chr7:65796074	A/G	cg12463550	chr7:65579703	CRCP	-0.48	-6.17	-0.35	2.6e-9	Aortic root size;
CESC	cis	rs10870270	0.957	rs7074604	chr10:133740373	G/C	cg08754478	chr10:133766260	PPP2R2D	-0.62	-8.06	-0.44	2.63e-14	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs1580019	0.885	rs4580942	chr7:32496435	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.73	9.88	0.52	8.14e-20	Cognitive ability;
CESC	cis	rs9660992	0.700	rs1172125	chr1:205258442	A/T	cg21643547	chr1:205240462	TMCC2	-0.48	-7.08	-0.4	1.29e-11	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs7089973	0.872	rs17092497	chr10:116612628	G/A	cg23260525	chr10:116636907	FAM160B1	0.37	6.22	0.36	1.95e-9	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs9733	0.566	rs72702554	chr1:150678234	A/G	cg17724175	chr1:150552817	MCL1	0.45	7.31	0.41	3.22e-12	Tonsillectomy;
CESC	cis	rs12893668	0.703	rs2403197	chr14:104053764	C/T	cg24130564	chr14:104152367	KLC1	-0.48	-6.01	-0.35	6.16e-9	Reticulocyte count;
CESC	cis	rs2652822	0.967	rs1472631	chr15:63423739	A/G	cg02713581	chr15:63449717	RPS27L	0.56	7.16	0.4	7.96e-12	Metabolic traits;
CESC	cis	rs8114671	0.562	rs1018447	chr20:33401707	A/G	cg24642439	chr20:33292090	TP53INP2	-0.42	-5.16	-0.3	4.94e-7	Height;
CESC	cis	rs11867934	0.577	rs9893676	chr17:17054951	C/G	cg26176665	chr17:16994978	MPRIP	0.4	5.4	0.32	1.46e-7	Diabetic retinopathy;
CESC	cis	rs703842	0.963	rs923829	chr12:58174306	T/C	cg00677455	chr12:58241039	CTDSP2	0.52	6.86	0.39	4.72e-11	Multiple sclerosis;
CESC	cis	rs4974559	0.947	rs10000012	chr4:1357325	C/G	cg02980000	chr4:1222292	CTBP1	-0.67	-6.27	-0.36	1.46e-9	Systolic blood pressure;
CESC	cis	rs7618915	0.547	rs4687548	chr3:52666650	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.48	6.89	0.39	4.13e-11	Bipolar disorder;
CESC	cis	rs911555	0.755	rs7148567	chr14:103882234	C/T	cg24130564	chr14:104152367	KLC1	-0.52	-7.05	-0.4	1.56e-11	Intelligence (multi-trait analysis);
CESC	cis	rs6089584	0.850	rs6089634	chr20:60632566	T/C	cg13770153	chr20:60521292	NA	-0.53	-6.89	-0.39	4.06e-11	Body mass index;
CESC	cis	rs1008375	0.933	rs10939757	chr4:17694125	T/C	cg16339924	chr4:17578868	LAP3	0.58	7.08	0.4	1.33e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs8060686	0.516	rs7189794	chr16:68277727	T/C	cg26727032	chr16:67993705	SLC12A4	-0.53	-7.07	-0.4	1.35e-11	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs7945705	0.902	rs10743093	chr11:8869129	A/G	cg09997546	chr11:8931473	C11orf17;ST5	0.35	5.63	0.33	4.67e-8	Hemoglobin concentration;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19189310	chr6:34393779	RPS10	0.6	6.75	0.38	9.37e-11	Gut microbiome composition (summer);
CESC	cis	rs9926296	0.605	rs6500453	chr16:89858657	C/G	cg07648498	chr16:89883185	FANCA	0.44	5.56	0.32	6.59e-8	Vitiligo;
CESC	cis	rs10744422	0.920	rs10773657	chr12:123327900	C/A	cg22842854	chr12:123319900	HIP1R	-0.62	-5.1	-0.3	6.33e-7	Schizophrenia;
CESC	cis	rs4654899	1.000	rs4654902	chr1:21435056	T/G	cg05370193	chr1:21551575	ECE1	0.4	6.03	0.35	5.41e-9	Superior frontal gyrus grey matter volume;
CESC	cis	rs7044106	0.537	rs10818474	chr9:123489964	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.67	8.49	0.46	1.48e-15	Hip circumference adjusted for BMI;
CESC	cis	rs12220238	1.000	rs10824114	chr10:75970503	T/A	cg19889307	chr10:75911429	ADK;AP3M1	0.6	5.45	0.32	1.13e-7	Soluble interleukin-2 receptor subunit alpha;
CESC	cis	rs10979	1.000	rs6570565	chr6:143899531	C/T	cg25407410	chr6:143891975	LOC285740	-0.61	-9.03	-0.48	3.7e-17	Hypospadias;
CESC	cis	rs7809950	0.911	rs1015411	chr7:107135612	C/T	cg23024343	chr7:107201750	COG5	-0.43	-5.97	-0.34	7.72e-9	Coronary artery disease;
CESC	cis	rs4555082	0.834	rs11849607	chr14:105745383	G/A	cg27165867	chr14:105738592	BRF1	-0.52	-5.65	-0.33	4.2e-8	Mean platelet volume;Platelet distribution width;
CESC	cis	rs6963495	0.674	rs75880756	chr7:105163821	G/C	cg02135003	chr7:105160482	PUS7	-0.47	-5.59	-0.33	5.51e-8	Bipolar disorder (body mass index interaction);
CESC	cis	rs597539	0.654	rs619727	chr11:68627535	A/G	cg18350739	chr11:68623251	NA	-0.45	-6.63	-0.38	1.92e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs916888	0.773	rs199439	chr17:44793503	A/G	cg01570182	chr17:44337453	NA	0.9	10.27	0.53	4.95e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs4843747	0.803	rs72818522	chr16:88059144	C/T	cg17633681	chr16:88106987	BANP	0.69	8.74	0.47	2.68e-16	Menopause (age at onset);
CESC	cis	rs17376456	0.569	rs35878747	chr5:93094070	C/A	cg25358565	chr5:93447407	FAM172A	0.67	7.16	0.4	7.97e-12	Diabetic retinopathy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21650900	chr2:235405122	ARL4C	0.54	6.2	0.36	2.19e-9	Gut microbiome composition (summer);
CESC	cis	rs2124969	0.548	rs72982036	chr2:161031590	G/A	cg03641300	chr2:160917029	PLA2R1	-0.57	-5.99	-0.35	6.83e-9	Waist circumference adjusted for body mass index;
CESC	cis	rs77741769	0.529	rs12579868	chr12:121207147	C/T	cg02419362	chr12:121203948	SPPL3	0.36	5.77	0.33	2.26e-8	Mean corpuscular volume;
CESC	cis	rs9443189	0.570	rs6903448	chr6:76173832	C/T	cg01950844	chr6:76311363	SENP6	0.56	5.31	0.31	2.29e-7	Prostate cancer;
CESC	trans	rs2216164	0.966	rs12315837	chr12:68573003	C/A	cg27495728	chr7:99067116	NA	-0.35	-6.26	-0.36	1.56e-9	Alopecia areata;
CESC	cis	rs10504229	1.000	rs17217047	chr8:58180296	G/A	cg24829409	chr8:58192753	C8orf71	-0.76	-10.0	-0.52	3.53e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs7617773	0.817	rs3731497	chr3:48226553	T/G	cg11946769	chr3:48343235	NME6	0.8	10.29	0.53	4.08e-21	Coronary artery disease;
CESC	cis	rs6701037	0.875	rs6929	chr1:175126721	A/G	cg00321850	chr1:175162397	KIAA0040	-0.4	-5.6	-0.33	5.46e-8	Alcohol dependence;
CESC	trans	rs73568641	0.546	rs12524666	chr6:154088541	A/T	cg08374472	chr16:87445639	ZCCHC14	-0.47	-6.25	-0.36	1.66e-9	Methadone dose in opioid dependence;
CESC	cis	rs1729951	0.546	rs361246	chr3:136695667	G/A	cg04103450	chr3:136751342	NA	0.41	5.44	0.32	1.19e-7	Neuroticism;
CESC	cis	rs4900538	0.855	rs762105	chr14:102830175	A/G	cg18135206	chr14:102964638	TECPR2	-0.75	-9.43	-0.5	2.18e-18	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	cis	rs8077889	0.750	rs76557360	chr17:41936842	G/A	cg26893861	chr17:41843967	DUSP3	0.86	8.47	0.46	1.77e-15	Triglycerides;
CESC	cis	rs6088590	1.000	rs6088615	chr20:33400474	C/T	cg24642439	chr20:33292090	TP53INP2	-0.77	-10.27	-0.53	4.77e-21	Coronary artery disease;
CESC	cis	rs875971	0.862	rs778720	chr7:65846275	A/C	cg18876405	chr7:65276391	NA	-0.49	-6.72	-0.38	1.11e-10	Aortic root size;
CESC	cis	rs7829975	0.774	rs13259216	chr8:8673601	A/C	cg06636001	chr8:8085503	FLJ10661	0.46	6.07	0.35	4.45e-9	Mood instability;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg06867543	chr15:77271730	NA	0.49	7.07	0.4	1.39e-11	Fibrinogen levels;
CESC	cis	rs6963495	0.818	rs73190167	chr7:105160418	A/G	cg19920283	chr7:105172520	RINT1	0.69	6.56	0.37	2.85e-10	Bipolar disorder (body mass index interaction);
CESC	cis	rs7178572	1.000	rs2055901	chr15:77759295	G/A	cg22256960	chr15:77711686	NA	-0.59	-7.96	-0.44	5e-14	Type 2 diabetes;
CESC	cis	rs6540559	1.000	rs6696825	chr1:209982372	A/G	cg10074409	chr1:209979377	IRF6	0.34	5.57	0.32	6.28e-8	Cleft lip with or without cleft palate;
CESC	cis	rs2288073	0.801	rs10176347	chr2:24367994	G/A	cg06627628	chr2:24431161	ITSN2	-0.71	-9.07	-0.49	2.8e-17	Venous thromboembolism (SNP x SNP interaction);
CESC	cis	rs12477438	0.798	rs12468419	chr2:99579680	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.64	-9.2	-0.49	1.14e-17	Chronic sinus infection;
CESC	cis	rs17711722	0.740	rs7809991	chr7:65406218	A/G	cg11764359	chr7:65958608	NA	0.67	8.62	0.47	6.29e-16	Calcium levels;
CESC	cis	rs6570726	0.935	rs429306	chr6:145827016	T/C	cg05347473	chr6:146136440	FBXO30	0.49	6.69	0.38	1.3100000000000001e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs734999	0.588	rs2843403	chr1:2529097	T/C	cg20673091	chr1:2541236	MMEL1	-0.43	-7.33	-0.41	2.76e-12	Ulcerative colitis;
CESC	cis	rs57506017	0.585	rs1054168	chr7:12273413	C/T	cg23422036	chr7:12250390	TMEM106B	0.39	5.17	0.3	4.57e-7	Neuroticism;
CESC	cis	rs11190604	1.000	rs7099913	chr10:102314777	T/C	cg07080220	chr10:102295463	HIF1AN	0.57	5.52	0.32	8.11e-8	Palmitoleic acid (16:1n-7) levels;
CESC	trans	rs2115172	0.836	rs4835799	chr5:122762229	A/G	cg06184463	chr3:11888509	C3orf31	0.45	6.15	0.35	2.88e-9	Weight;
CESC	cis	rs763014	0.898	rs2017567	chr16:637212	T/C	cg00908189	chr16:619842	PIGQ	0.65	9.08	0.49	2.49e-17	Height;
CESC	cis	rs7267979	0.966	rs6037083	chr20:25290543	T/C	cg08601574	chr20:25228251	PYGB	-0.39	-5.58	-0.32	6.03e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs1348850	0.598	rs1405717	chr2:178500101	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.57	7.38	0.41	2.1e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs9287719	0.967	rs4470306	chr2:10743998	C/T	cg00105475	chr2:10696890	NA	0.39	5.63	0.33	4.6e-8	Prostate cancer;
CESC	cis	rs11871801	0.517	rs665268	chr17:40722029	A/G	cg14558262	chr17:40713999	COASY	0.5	5.85	0.34	1.46e-8	Crohn's disease;
CESC	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg06873352	chr17:61820015	STRADA	0.72	12.83	0.62	1.2e-29	Prudent dietary pattern;
CESC	cis	rs10504229	0.645	rs56670121	chr8:58138872	C/T	cg21724239	chr8:58056113	NA	0.58	5.95	0.34	8.37e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs1799949	1.000	rs1399323	chr17:41332330	T/C	cg05368731	chr17:41323189	NBR1	0.77	10.72	0.55	1.69e-22	Menopause (age at onset);
CESC	cis	rs2832191	0.791	rs2832179	chr21:30480366	C/T	cg08807101	chr21:30365312	RNF160	-0.76	-10.82	-0.55	7.78e-23	Dental caries;
CESC	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	7.74	0.43	2.06e-13	Prudent dietary pattern;
CESC	cis	rs1387259	0.790	rs2732445	chr12:48645533	C/T	cg04545296	chr12:48745243	ZNF641	0.41	6.85	0.39	5.09e-11	Obstructive sleep apnea trait (apnea hypopnea index);
CESC	cis	rs10788264	0.504	rs4751883	chr10:124018027	A/C	cg09507567	chr10:124027408	NA	0.38	5.25	0.31	3.13e-7	Total body bone mineral density;
CESC	cis	rs524281	0.731	rs10791841	chr11:65808587	T/C	cg14036092	chr11:66035641	RAB1B	-0.58	-5.36	-0.31	1.84e-7	Electroencephalogram traits;
CESC	cis	rs8092503	1.000	rs12966541	chr18:52481402	C/G	cg12377874	chr18:52495404	RAB27B	0.38	6.2	0.36	2.13e-9	Childhood body mass index;
CESC	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg07677032	chr17:61819896	STRADA	0.5	6.7	0.38	1.24e-10	Prudent dietary pattern;
CESC	cis	rs9322193	1.000	rs9377228	chr6:149921998	G/A	cg13206674	chr6:150067644	NUP43	0.42	6.18	0.36	2.37e-9	Lung cancer;
CESC	cis	rs4925386	0.840	rs6142738	chr20:60919960	C/T	cg22307297	chr20:60903441	LAMA5	-0.36	-5.17	-0.3	4.54e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs1881797	1.000	rs10925069	chr1:247681313	C/T	cg05639522	chr1:247681581	NA	-0.52	-7.0	-0.39	2.14e-11	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs7726839	0.561	rs56410216	chr5:583216	C/A	cg16447950	chr5:562315	NA	-0.55	-6.19	-0.36	2.29e-9	Obesity-related traits;
CESC	cis	rs1372520	0.564	rs356196	chr4:90682803	A/T	cg15133208	chr4:90757351	SNCA	0.43	5.12	0.3	5.78e-7	Neuroticism;
CESC	cis	rs614226	1.000	rs1167726	chr12:120967364	A/C	cg01236616	chr12:121019343	POP5	-1.51	-19.53	-0.77	3e-53	Type 1 diabetes nephropathy;
CESC	cis	rs1728785	1.000	rs8058314	chr16:68584151	G/A	cg02972257	chr16:68554789	NA	-0.54	-6.27	-0.36	1.45e-9	Ulcerative colitis;
CESC	cis	rs898097	1.000	rs898097	chr17:80904310	C/T	cg15369054	chr17:80825471	TBCD	-0.44	-6.0	-0.35	6.45e-9	Breast cancer;
CESC	cis	rs7618501	1.000	rs34451146	chr3:49813013	C/T	cg24308560	chr3:49941425	MST1R	-0.49	-6.74	-0.38	9.66e-11	Intelligence (multi-trait analysis);
CESC	cis	rs4919687	0.550	rs12259058	chr10:104484799	A/G	cg04362960	chr10:104952993	NT5C2	0.48	5.45	0.32	1.18e-7	Colorectal cancer;
CESC	cis	rs10870270	0.957	rs3829156	chr10:133789386	C/G	cg08754478	chr10:133766260	PPP2R2D	-0.57	-7.42	-0.41	1.64e-12	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs7845219	0.544	rs4735332	chr8:95923660	C/T	cg23172400	chr8:95962367	TP53INP1	-0.38	-7.21	-0.4	5.89e-12	Type 2 diabetes;
CESC	cis	rs11608355	0.545	rs2302708	chr12:109893726	A/C	cg05360138	chr12:110035743	NA	0.82	8.92	0.48	7.93e-17	Neuroticism;
CESC	cis	rs476633	0.691	rs28735224	chr15:41537539	C/T	cg12386646	chr15:41787261	ITPKA	0.36	5.44	0.32	1.22e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs9733	0.503	rs7556451	chr1:150913142	A/G	cg22823121	chr1:150693482	HORMAD1	0.36	5.12	0.3	5.88e-7	Tonsillectomy;
CESC	cis	rs208520	0.690	rs3899423	chr6:66835285	A/G	cg07460842	chr6:66804631	NA	-0.94	-13.3	-0.63	2.87e-31	Exhaled nitric oxide output;
CESC	cis	rs1008375	1.000	rs2286771	chr4:17643848	G/A	cg16339924	chr4:17578868	LAP3	0.56	7.02	0.4	1.9e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs2991971	0.933	rs12568144	chr1:45965307	G/A	cg15605315	chr1:45957053	TESK2	0.48	6.43	0.37	5.79e-10	High light scatter reticulocyte count;
CESC	cis	rs12458462	0.892	rs35928863	chr18:77438956	A/G	cg11879182	chr18:77439856	CTDP1	0.85	13.03	0.63	2.43e-30	Monocyte count;
CESC	cis	rs1005277	0.579	rs2474587	chr10:38420666	C/T	cg25517755	chr10:38738941	LOC399744	-0.47	-6.04	-0.35	5.28e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs2932538	0.583	rs2279500	chr1:113244433	T/C	cg22162597	chr1:113214053	CAPZA1	-0.49	-5.17	-0.3	4.61e-7	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CESC	cis	rs72627123	0.867	rs73303107	chr14:74477284	A/G	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.79	5.8	0.34	1.92e-8	Morning vs. evening chronotype;
CESC	cis	rs7714584	1.000	rs10051924	chr5:150226639	T/C	cg22134413	chr5:150180641	NA	0.52	5.64	0.33	4.31e-8	Crohn's disease;
CESC	cis	rs3741151	0.773	rs61345051	chr11:73112305	T/C	cg17517138	chr11:73019481	ARHGEF17	0.98	7.14	0.4	8.91e-12	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21124756	chr1:1447564	ATAD3A	0.54	6.24	0.36	1.71e-9	Gut microbiome composition (summer);
CESC	trans	rs7628583	0.696	rs12488626	chr3:64071952	C/A	cg17243659	chr21:48055224	PRMT2	-0.56	-6.01	-0.35	6.14e-9	Parental extreme longevity (95 years and older);
CESC	cis	rs4957048	0.891	rs11960196	chr5:568857	C/A	cg09021430	chr5:549028	NA	-0.48	-6.57	-0.37	2.6e-10	Ulcerative colitis;
CESC	cis	rs1448094	0.511	rs11117042	chr12:86207547	G/T	cg02569458	chr12:86230093	RASSF9	0.51	7.63	0.42	4.33e-13	Major depressive disorder;
CESC	cis	rs4660261	0.526	rs803680	chr1:44364370	G/C	cg15962314	chr1:44399869	ARTN	0.27	5.11	0.3	6.04e-7	Intelligence (multi-trait analysis);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg12737030	chr10:73975246	ASCC1;C10orf104	0.4	6.08	0.35	4.21e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19102404	chr1:116941269	C1orf203;ATP1A1	-0.53	-6.56	-0.37	2.86e-10	Gut microbiome composition (summer);
CESC	cis	rs7552404	0.696	rs12140121	chr1:76455001	A/G	cg22875332	chr1:76189707	ACADM	0.55	5.39	0.31	1.55e-7	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs7772486	0.846	rs9376976	chr6:146355605	T/C	cg05347473	chr6:146136440	FBXO30	0.5	6.51	0.37	3.72e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2439831	0.702	rs2788	chr15:44064886	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.7	6.72	0.38	1.14e-10	Lung cancer in ever smokers;
CESC	cis	rs9976767	0.637	rs2277799	chr21:43824123	G/C	cg23042151	chr21:43824109	UBASH3A	-0.36	-6.79	-0.38	7.32e-11	Type 1 diabetes;
CESC	cis	rs736408	0.522	rs11130310	chr3:52674667	C/T	cg18099408	chr3:52552593	STAB1	-0.3	-5.03	-0.3	9.18e-7	Bipolar disorder;
CESC	cis	rs9300255	0.543	rs655293	chr12:123528405	G/A	cg05973401	chr12:123451056	ABCB9	0.59	6.43	0.37	5.84e-10	Neutrophil percentage of white cells;
CESC	cis	rs72781680	0.800	rs72790306	chr2:24111311	T/G	cg08917208	chr2:24149416	ATAD2B	1.11	10.15	0.53	1.13e-20	Lymphocyte counts;
CESC	cis	rs12995491	0.933	rs34366691	chr2:88537451	G/A	cg14558114	chr2:88469736	THNSL2	-0.49	-7.13	-0.4	9.46e-12	Response to metformin (IC50);
CESC	cis	rs7560272	0.723	rs1083923	chr2:73703374	A/G	cg20560298	chr2:73613845	ALMS1	0.49	7.09	0.4	1.21e-11	Schizophrenia;
CESC	cis	rs4969178	0.965	rs11653305	chr17:76386918	T/C	cg05887092	chr17:76393375	PGS1	0.59	9.27	0.49	6.61e-18	HDL cholesterol levels;
CESC	cis	rs7937682	0.602	rs4936804	chr11:111743851	A/C	cg09085632	chr11:111637200	PPP2R1B	0.9	11.72	0.58	8.02e-26	Primary sclerosing cholangitis;
CESC	cis	rs117623576	0.941	rs72778753	chr10:32426579	A/T	cg03047570	chr10:32398778	NA	-0.57	-5.57	-0.32	6.11e-8	Anti-saccade response;
CESC	cis	rs12887734	0.569	rs66953418	chr14:104271470	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.44	-5.63	-0.33	4.71e-8	Schizophrenia;Autism spectrum disorder or schizophrenia;
CESC	cis	rs13191362	1.000	rs73016459	chr6:163066323	C/A	cg21926612	chr6:163149169	PACRG;PARK2	0.93	9.75	0.51	2.1e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs60154123	0.772	rs614167	chr1:210425895	T/C	cg21951975	chr1:209979733	IRF6	0.48	6.03	0.35	5.35e-9	Coronary artery disease;
CESC	cis	rs9926296	0.682	rs258328	chr16:89730314	C/T	cg03605463	chr16:89740564	NA	0.64	7.81	0.43	1.34e-13	Vitiligo;
CESC	cis	rs11683229	0.704	rs12991414	chr2:63103597	C/A	cg17519650	chr2:63277830	OTX1	-0.68	-5.46	-0.32	1.11e-7	Protein quantitative trait loci;
CESC	cis	rs7980687	0.527	rs28533432	chr12:123873242	C/T	cg00376283	chr12:123451042	ABCB9	0.5	6.38	0.36	8e-10	Height;Educational attainment;Head circumference (infant);
CESC	cis	rs1707322	1.000	rs785510	chr1:46528618	T/C	cg05343316	chr1:45956843	TESK2	-0.48	-5.68	-0.33	3.62e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs10504229	0.683	rs55986917	chr8:58137210	C/T	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs67311347	1.000	rs7625736	chr3:40441345	C/G	cg24209194	chr3:40518798	ZNF619	-0.5	-6.72	-0.38	1.1e-10	Renal cell carcinoma;
CESC	cis	rs7666738	0.830	rs2865978	chr4:99017946	G/T	cg03467027	chr4:99064603	C4orf37	0.46	5.81	0.34	1.8e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs62064224	0.703	rs62065493	chr17:30822620	C/G	cg12855166	chr17:30846586	MYO1D	0.4	5.11	0.3	6.15e-7	Schizophrenia;
CESC	cis	rs8114671	0.562	rs1018447	chr20:33401707	A/G	cg08999081	chr20:33150536	PIGU	-0.4	-5.87	-0.34	1.3e-8	Height;
CESC	cis	rs17253792	0.822	rs9972178	chr14:56073480	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.79	5.91	0.34	1.06e-8	Putamen volume;
CESC	cis	rs9300255	0.602	rs949142	chr12:123634043	T/C	cg05973401	chr12:123451056	ABCB9	0.51	5.72	0.33	2.81e-8	Neutrophil percentage of white cells;
CESC	cis	rs2841277	0.770	rs10149193	chr14:105403474	C/T	cg17340268	chr14:105411764	AHNAK2	-0.52	-6.92	-0.39	3.36e-11	Rheumatoid arthritis;
CESC	cis	rs60871478	1.000	rs4721124	chr7:823761	T/C	cg05535760	chr7:792225	HEATR2	0.87	10.87	0.56	5.18e-23	Cerebrospinal P-tau181p levels;
CESC	cis	rs7666738	0.830	rs35915560	chr4:98978649	C/T	cg03467027	chr4:99064603	C4orf37	0.42	5.26	0.31	3.01e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs12142240	0.621	rs66828173	chr1:46818166	G/A	cg00530320	chr1:46809349	NSUN4	0.58	7.89	0.44	8.15e-14	Menopause (age at onset);
CESC	cis	rs17807624	1.000	rs17807624	chr8:11463015	A/G	cg12395012	chr8:11607386	GATA4	0.36	5.33	0.31	2.11e-7	Systemic lupus erythematosus;
CESC	cis	rs11122272	0.701	rs743120	chr1:231531232	C/T	cg06096015	chr1:231504339	EGLN1	0.43	6.15	0.35	2.9e-9	Hemoglobin concentration;
CESC	trans	rs11098499	1.000	rs35643470	chr4:120184948	T/C	cg25214090	chr10:38739885	LOC399744	0.68	9.17	0.49	1.32e-17	Corneal astigmatism;
CESC	cis	rs897984	0.683	rs72799316	chr16:30827205	A/G	cg02466173	chr16:30829666	NA	-0.6	-11.61	-0.58	1.8e-25	Dementia with Lewy bodies;
CESC	cis	rs896854	0.738	rs527234	chr8:95963798	C/G	cg09323728	chr8:95962352	TP53INP1	0.36	7.02	0.4	1.88e-11	Type 2 diabetes;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg25010622	chr20:32700257	EIF2S2	0.43	6.12	0.35	3.33e-9	Gut microbiota (bacterial taxa);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg09248284	chr2:27851818	CCDC121;GPN1	-0.47	-6.61	-0.38	2.11e-10	Fibrinogen levels;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg23975144	chr12:120875872	COX6A1	0.45	6.01	0.35	5.96e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs801193	0.904	rs4718405	chr7:66254646	A/G	cg26939375	chr7:64535504	NA	0.65	8.61	0.47	6.45e-16	Aortic root size;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg15716185	chr18:60190644	ZCCHC2	-0.44	-6.39	-0.37	7.6e-10	Gambling;
CESC	cis	rs6963495	0.818	rs114865717	chr7:105158526	C/T	cg13798780	chr7:105162888	PUS7	0.78	8.04	0.44	2.99e-14	Bipolar disorder (body mass index interaction);
CESC	cis	rs1483890	0.723	rs12629229	chr3:69411222	A/G	cg22125112	chr3:69402811	FRMD4B	0.42	5.57	0.32	6.32e-8	Resting heart rate;
CESC	cis	rs897984	0.542	rs750952	chr16:31093954	C/T	cg02466173	chr16:30829666	NA	-0.42	-7.21	-0.4	5.83e-12	Dementia with Lewy bodies;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07674403	chr19:13068176	GADD45GIP1	-0.61	-6.85	-0.39	5.27e-11	Gut microbiome composition (summer);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05232081	chr2:10567526	HPCAL1	0.42	6.09	0.35	4e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs9457247	0.663	rs12526548	chr6:167431147	C/T	cg25258033	chr6:167368657	RNASET2	0.36	5.21	0.3	3.87e-7	Crohn's disease;
CESC	cis	rs11864453	0.614	rs12445586	chr16:72126276	C/T	cg16558253	chr16:72132732	DHX38	-0.56	-8.7	-0.47	3.62e-16	Fibrinogen levels;
CESC	cis	rs9596863	1.000	rs9316669	chr13:54401836	C/G	ch.13.53330881F	chr13:54432880	NA	0.65	5.45	0.32	1.13e-7	Epilepsy and lamotrigine-induced maculopapular eruptions;
CESC	cis	rs2645694	0.626	rs2645709	chr4:77824474	G/A	cg10057126	chr4:77819792	ANKRD56	0.58	8.42	0.46	2.44e-15	Emphysema distribution in smoking;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16427743	chr14:65210080	PLEKHG3	-0.58	-6.72	-0.38	1.12e-10	Gut microbiome composition (summer);
CESC	cis	rs6066835	0.572	rs11698365	chr20:47259527	C/T	cg18078177	chr20:47281410	PREX1	0.68	5.06	0.3	8.03e-7	Multiple myeloma;
CESC	cis	rs10540	1.000	rs79808876	chr11:465763	C/A	cg03352830	chr11:487213	PTDSS2	0.71	7.25	0.41	4.71e-12	Body mass index;
CESC	cis	rs35110281	0.667	rs914197	chr21:45117439	A/G	cg01579765	chr21:45077557	HSF2BP	-0.51	-8.35	-0.46	3.74e-15	Mean corpuscular volume;
CESC	cis	rs7927771	0.560	rs4752858	chr11:47685829	C/T	cg18512352	chr11:47633146	NA	-0.36	-5.65	-0.33	4.18e-8	Subjective well-being;
CESC	cis	rs9926296	0.715	rs467035	chr16:89740285	C/G	cg27121462	chr16:89883253	FANCA	0.41	5.08	0.3	7.04e-7	Vitiligo;
CESC	trans	rs3749237	1.000	rs11710675	chr3:49751900	C/A	cg21659725	chr3:3221576	CRBN	0.56	6.65	0.38	1.62e-10	Resting heart rate;
CESC	cis	rs3820928	0.874	rs4675133	chr2:227843010	A/G	cg11843606	chr2:227700838	RHBDD1	0.43	5.58	0.32	6e-8	Pulmonary function;
CESC	cis	rs2637266	0.505	rs10824434	chr10:78441162	T/C	cg18941641	chr10:78392320	NA	-0.32	-5.19	-0.3	4.11e-7	Pulmonary function;
CESC	trans	rs916888	0.773	rs199448	chr17:44809001	A/G	cg07870213	chr5:140052090	DND1	0.61	6.73	0.38	1.07e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs28374715	0.662	rs13329579	chr15:41467435	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.79	-10.4	-0.54	1.81e-21	Ulcerative colitis;
CESC	cis	rs1559088	0.847	rs10416265	chr19:33605300	A/G	cg17764715	chr19:33622953	WDR88	0.42	5.16	0.3	4.91e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs34779708	0.966	rs1148245	chr10:35511894	C/T	cg04310649	chr10:35416472	CREM	-0.55	-6.45	-0.37	5.2e-10	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs3768617	0.706	rs4129858	chr1:183004334	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.68	9.54	0.51	9.93e-19	Fuchs's corneal dystrophy;
CESC	cis	rs4148883	0.628	rs34195655	chr4:100073795	C/T	cg13256891	chr4:100009986	ADH5	0.53	7.0	0.4	2.1e-11	Alcohol dependence;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg27613076	chr10:121484944	INPP5F	0.44	6.1	0.35	3.72e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs1448094	0.512	rs12313775	chr12:86241197	G/A	cg02569458	chr12:86230093	RASSF9	0.5	7.51	0.42	9.29e-13	Major depressive disorder;
CESC	cis	rs6500602	1.000	rs12447826	chr16:4464617	T/C	cg08645402	chr16:4508243	NA	0.49	7.76	0.43	1.89e-13	Schizophrenia;
CESC	cis	rs2302777	0.507	rs9889711	chr17:38108292	A/T	cg17467752	chr17:38218738	THRA	0.41	5.11	0.3	6.17e-7	Multiple myeloma (hyperdiploidy);
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg02364793	chr5:175964512	RNF44	-0.44	-6.01	-0.35	6.1e-9	Asthma;
CESC	cis	rs738322	1.000	rs4381	chr22:38570791	T/C	cg17652424	chr22:38574118	PLA2G6	-0.34	-6.04	-0.35	5.08e-9	Cutaneous nevi;
CESC	cis	rs1862618	0.853	rs2113079	chr5:56157951	A/G	cg24531977	chr5:56204891	C5orf35	-0.89	-11.41	-0.57	8.38e-25	Initial pursuit acceleration;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02852436	chr20:2821472	FAM113A;VPS16	0.6	7.51	0.42	9.15e-13	Gut microbiome composition (summer);
CESC	cis	rs875971	0.830	rs4718358	chr7:65973668	T/C	cg10691866	chr7:65817282	TPST1	-0.35	-5.81	-0.34	1.82e-8	Aortic root size;
CESC	cis	rs3820068	0.581	rs16851841	chr1:15922713	A/G	cg17385448	chr1:15911702	AGMAT	0.41	6.7	0.38	1.24e-10	Systolic blood pressure;
CESC	trans	rs629535	0.862	rs2472141	chr8:70054216	T/C	cg21567404	chr3:27674614	NA	0.93	11.14	0.56	6.94e-24	Dupuytren's disease;
CESC	cis	rs7615952	0.641	rs61048217	chr3:125807905	G/T	cg02807482	chr3:125708958	NA	-0.39	-5.07	-0.3	7.59e-7	Blood pressure (smoking interaction);
CESC	cis	rs7666738	0.791	rs1115615	chr4:99006614	G/A	cg18180107	chr4:99064573	C4orf37	0.4	5.23	0.31	3.41e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11122272	0.735	rs2572263	chr1:231509408	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.57	-7.82	-0.43	1.29e-13	Hemoglobin concentration;
CESC	cis	rs4704187	0.687	rs6888707	chr5:74442920	A/G	cg03227963	chr5:74354835	NA	0.3	5.58	0.32	5.99e-8	Response to amphetamines;
CESC	trans	rs35110281	0.720	rs162393	chr21:44942692	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.55	7.41	0.41	1.69e-12	Mean corpuscular volume;
CESC	cis	rs780096	0.506	rs780100	chr2:27652153	G/T	cg21248554	chr2:27665150	KRTCAP3	-0.35	-7.33	-0.41	2.74e-12	Total body bone mineral density;
CESC	cis	rs12893668	0.637	rs12892038	chr14:104068629	G/A	cg24130564	chr14:104152367	KLC1	-0.51	-6.4	-0.37	7.05e-10	Reticulocyte count;
CESC	cis	rs208520	0.690	rs3846808	chr6:66818604	A/G	cg07460842	chr6:66804631	NA	-0.95	-12.85	-0.62	1.07e-29	Exhaled nitric oxide output;
CESC	trans	rs11098499	0.820	rs11737395	chr4:120520704	C/G	cg25214090	chr10:38739885	LOC399744	0.68	9.19	0.49	1.2e-17	Corneal astigmatism;
CESC	cis	rs537626	1.000	rs537626	chr11:69307695	C/G	cg08353955	chr11:69289746	NA	0.55	6.09	0.35	4.02e-9	Breast cancer (early onset);
CESC	cis	rs11828289	0.660	rs17306433	chr11:23223034	C/G	cg20040320	chr11:23191996	NA	-0.68	-5.65	-0.33	4.04e-8	Cancer;
CESC	cis	rs6540559	0.673	rs6540561	chr1:209982255	C/T	cg21951975	chr1:209979733	IRF6	0.61	7.52	0.42	8.54e-13	Cleft lip with or without cleft palate;
CESC	cis	rs875971	0.929	rs10950041	chr7:65973875	T/C	cg18876405	chr7:65276391	NA	0.49	6.51	0.37	3.76e-10	Aortic root size;
CESC	cis	rs7824557	0.767	rs6985146	chr8:11170721	A/C	cg21775007	chr8:11205619	TDH	0.48	6.78	0.38	7.88e-11	Retinal vascular caliber;
CESC	cis	rs875971	0.862	rs6960446	chr7:65733259	A/G	cg19163074	chr7:65112434	INTS4L2	0.4	5.07	0.3	7.58e-7	Aortic root size;
CESC	cis	rs35110281	0.782	rs1584917	chr21:45042365	A/G	cg01579765	chr21:45077557	HSF2BP	-0.58	-9.96	-0.52	4.8e-20	Mean corpuscular volume;
CESC	cis	rs2439831	0.850	rs28476182	chr15:44139643	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.67	7.46	0.42	1.21e-12	Lung cancer in ever smokers;
CESC	cis	rs6815814	0.898	rs1873195	chr4:38891173	C/T	cg02016764	chr4:38805732	TLR1	-0.57	-6.62	-0.38	2e-10	Breast cancer;
CESC	cis	rs4665809	0.590	rs11897162	chr2:26503654	T/C	cg04944784	chr2:26401820	FAM59B	0.84	9.0	0.48	4.44e-17	Gut microbiome composition (summer);
CESC	cis	rs2274273	0.870	rs946059	chr14:55847466	A/G	cg04306507	chr14:55594613	LGALS3	0.31	6.09	0.35	4.04e-9	Protein biomarker;
CESC	cis	rs9914988	0.887	rs11652710	chr17:27145075	C/T	cg20469991	chr17:27169893	C17orf63	-0.48	-5.25	-0.31	3.18e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CESC	cis	rs9309473	0.607	rs6716776	chr2:73587713	T/C	cg20560298	chr2:73613845	ALMS1	-0.44	-5.63	-0.33	4.52e-8	Metabolite levels;
CESC	cis	rs7666738	0.830	rs28485415	chr4:99060340	G/A	cg18180107	chr4:99064573	C4orf37	0.41	5.23	0.31	3.41e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs117623576	0.680	rs72777120	chr10:32367608	A/G	cg03047570	chr10:32398778	NA	-0.62	-6.74	-0.38	9.83e-11	Anti-saccade response;
CESC	cis	rs7089973	0.624	rs17586888	chr10:116598121	T/C	cg23260525	chr10:116636907	FAM160B1	0.4	7.38	0.41	2.03e-12	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs875971	0.522	rs7784623	chr7:65395034	T/G	cg26939375	chr7:64535504	NA	0.77	11.07	0.56	1.15e-23	Aortic root size;
CESC	cis	rs6540556	0.723	rs7539852	chr1:209898539	A/G	cg05527609	chr1:210001259	C1orf107	-0.56	-6.21	-0.36	2.01e-9	Red blood cell count;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg02429398	chr16:53536813	AKTIP	-0.42	-6.01	-0.35	6.09e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs4654899	0.567	rs9426735	chr1:21505472	A/T	cg05370193	chr1:21551575	ECE1	0.35	5.18	0.3	4.4e-7	Superior frontal gyrus grey matter volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08466385	chr6:18368294	NA	-0.54	-6.62	-0.38	2.03e-10	Gut microbiome composition (summer);
CESC	cis	rs9611565	0.659	rs73178632	chr22:41934573	C/T	cg17376030	chr22:41985996	PMM1	0.72	7.81	0.43	1.35e-13	Vitiligo;
CESC	cis	rs965469	1.000	rs6139103	chr20:3361140	T/C	cg25506879	chr20:3388711	C20orf194	-0.57	-6.01	-0.35	6.27e-9	IFN-related cytopenia;
CESC	cis	rs7312933	0.501	rs3810793	chr12:42729407	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.47	5.84	0.34	1.54e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs897984	0.684	rs6950	chr16:30995669	T/C	cg02466173	chr16:30829666	NA	0.48	8.09	0.44	2.18e-14	Dementia with Lewy bodies;
CESC	cis	rs9915657	0.773	rs9912974	chr17:70095963	C/T	cg09344028	chr17:70110421	NA	0.41	8.29	0.45	5.69e-15	Thyroid hormone levels;
CESC	cis	rs12477438	0.520	rs1133978	chr2:99741964	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.79	12.63	0.61	6.22e-29	Chronic sinus infection;
CESC	cis	rs752010	0.619	rs6702659	chr1:42112236	T/C	cg06885757	chr1:42089581	HIVEP3	0.65	10.05	0.53	2.44e-20	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs6732160	0.588	rs62151795	chr2:73376840	G/A	cg01422370	chr2:73384389	NA	0.57	9.17	0.49	1.4e-17	Intelligence (multi-trait analysis);
CESC	cis	rs4909189	1.000	rs62493650	chr7:158135570	G/T	cg06219351	chr7:158114137	PTPRN2	-0.6	-8.1	-0.45	2e-14	Response to amphetamines;
CESC	cis	rs6460942	0.591	rs80311633	chr7:12339690	G/C	cg20607287	chr7:12443886	VWDE	-0.61	-6.7	-0.38	1.24e-10	Coronary artery disease;
CESC	cis	rs9486719	1.000	rs2472880	chr6:96860130	G/A	cg06623918	chr6:96969491	KIAA0776	0.81	8.08	0.44	2.38e-14	Migraine;Coronary artery disease;
CESC	cis	rs55728055	1.000	rs8142355	chr22:32081681	C/T	cg01338084	chr22:32026380	PISD	1.25	8.17	0.45	1.31e-14	Age-related hearing impairment;
CESC	cis	rs11690935	0.550	rs62183785	chr2:172866976	G/A	cg13550731	chr2:172543902	DYNC1I2	0.49	6.75	0.38	9.18e-11	Schizophrenia;
CESC	cis	rs9660992	0.762	rs1668871	chr1:205237137	T/C	cg21643547	chr1:205240462	TMCC2	-0.46	-6.7	-0.38	1.22e-10	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs13256369	1.000	rs10098234	chr8:8576692	G/A	cg18904891	chr8:8559673	CLDN23	0.66	7.63	0.42	4.23e-13	Obesity-related traits;
CESC	cis	rs10504229	0.683	rs34804288	chr8:58117570	C/A	cg02725872	chr8:58115012	NA	-0.45	-7.05	-0.4	1.52e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg18099408	chr3:52552593	STAB1	-0.44	-8.37	-0.46	3.28e-15	Electroencephalogram traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01505312	chr11:56258856	OR5M8;OR8U8	-0.43	-6.44	-0.37	5.74e-10	Gut microbiome composition (summer);
CESC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg25270252	chr3:130745615	NEK11;ASTE1	0.48	6.28	0.36	1.36e-9	Tetralogy of Fallot;
CESC	cis	rs4975709	0.589	rs4975746	chr5:1861069	G/A	cg11168104	chr5:1857477	NA	-0.37	-5.38	-0.31	1.62e-7	Cardiovascular disease risk factors;
CESC	cis	rs67311347	0.956	rs7640228	chr3:40516190	G/A	cg24209194	chr3:40518798	ZNF619	-0.53	-6.87	-0.39	4.67e-11	Renal cell carcinoma;
CESC	cis	rs9926296	0.605	rs886951	chr16:89836865	A/G	cg21285383	chr16:89894308	SPIRE2	0.32	5.89	0.34	1.18e-8	Vitiligo;
CESC	trans	rs4662834	0.872	rs12996713	chr2:129483106	A/G	cg12497543	chr10:97515377	ENTPD1	-0.38	-6.32	-0.36	1.08e-9	Response to bleomycin (chromatid breaks);
CESC	cis	rs1799949	0.930	rs35292991	chr17:41334016	C/A	cg23758822	chr17:41437982	NA	1.03	15.5	0.69	5.3e-39	Menopause (age at onset);
CESC	cis	rs8031584	0.918	rs35784593	chr15:31254588	G/A	cg08704250	chr15:31115839	NA	-0.63	-8.2	-0.45	1.05e-14	Huntington's disease progression;
CESC	cis	rs8002861	0.905	rs12853286	chr13:44446817	A/G	cg19180546	chr13:44453867	C13orf31;CCDC122	-0.48	-5.98	-0.34	7.07e-9	Leprosy;
CESC	trans	rs11098499	0.955	rs35434465	chr4:120169378	C/G	cg25214090	chr10:38739885	LOC399744	0.62	8.25	0.45	7.27e-15	Corneal astigmatism;
CESC	cis	rs8180040	0.701	rs62248439	chr3:46996448	A/G	cg27129171	chr3:47204927	SETD2	-0.64	-9.06	-0.49	2.9e-17	Colorectal cancer;
CESC	cis	rs11648796	0.757	rs6600231	chr16:766485	A/G	cg27144592	chr16:783916	NARFL	-0.44	-6.27	-0.36	1.44e-9	Height;
CESC	cis	rs3785574	0.962	rs4480868	chr17:61788859	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.77	10.11	0.53	1.56e-20	Height;
CESC	cis	rs7829975	0.742	rs1533059	chr8:8684953	A/G	cg17143192	chr8:8559678	CLDN23	-0.46	-5.49	-0.32	9.49e-8	Mood instability;
CESC	cis	rs7680126	0.596	rs11722185	chr4:10317482	C/G	cg11266682	chr4:10021025	SLC2A9	-0.41	-5.38	-0.31	1.64e-7	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg12771118	chr3:138067402	MRAS	-0.49	-6.36	-0.36	8.79e-10	Asthma;
CESC	cis	rs875971	0.508	rs10253883	chr7:66061138	T/C	cg06456125	chr7:65229604	NA	-0.4	-5.59	-0.32	5.76e-8	Aortic root size;
CESC	cis	rs2066819	1.000	rs76466034	chr12:56719450	G/A	cg26734620	chr12:56694298	CS	1.03	6.25	0.36	1.65e-9	Psoriasis vulgaris;
CESC	cis	rs801193	0.660	rs2659897	chr7:66187715	A/G	cg10691866	chr7:65817282	TPST1	0.34	5.75	0.33	2.42e-8	Aortic root size;
CESC	cis	rs9287719	0.578	rs7598541	chr2:10700516	G/A	cg00105475	chr2:10696890	NA	0.41	5.65	0.33	4.24e-8	Prostate cancer;
CESC	cis	rs6547741	0.967	rs4665999	chr2:27834444	T/C	cg21248554	chr2:27665150	KRTCAP3	0.24	5.09	0.3	6.94e-7	Oral cavity cancer;
CESC	cis	rs7917772	0.636	rs7911747	chr10:104528890	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.45	-5.29	-0.31	2.59e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs738322	0.839	rs133015	chr22:38572526	C/G	cg17652424	chr22:38574118	PLA2G6	-0.34	-5.87	-0.34	1.29e-8	Cutaneous nevi;
CESC	cis	rs7107174	1.000	rs2510039	chr11:77944480	G/A	cg02023728	chr11:77925099	USP35	0.55	6.87	0.39	4.69e-11	Testicular germ cell tumor;
CESC	cis	rs7918232	0.607	rs1755401	chr10:27405763	A/C	cg14442939	chr10:27389572	ANKRD26	0.68	5.2	0.3	3.93e-7	Breast cancer;
CESC	cis	rs3091242	0.728	rs706845	chr1:25730713	G/A	cg02931644	chr1:25747376	RHCE	0.38	6.24	0.36	1.7e-9	Erythrocyte sedimentation rate;
CESC	cis	rs6728642	0.908	rs6731522	chr2:97647997	A/G	cg26665480	chr2:98280029	ACTR1B	-0.71	-7.64	-0.42	4.04e-13	Bipolar disorder lithium response (continuous) or schizophrenia;
CESC	cis	rs710216	0.843	rs710214	chr1:43439282	C/T	cg22176566	chr1:43424700	SLC2A1	0.47	5.12	0.3	5.98e-7	Red cell distribution width;
CESC	cis	rs2635047	1.000	rs2277717	chr18:44702718	C/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.5	6.81	0.39	6.52e-11	Educational attainment;
CESC	cis	rs7618915	0.547	rs3755806	chr3:52643685	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.46	-6.36	-0.36	8.6e-10	Bipolar disorder;
CESC	cis	rs2108622	0.727	rs12609468	chr19:15977814	A/G	cg13772218	chr19:15982569	NA	0.29	5.69	0.33	3.28e-8	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CESC	cis	rs7552404	0.727	rs5745390	chr1:76306591	A/C	cg10523679	chr1:76189770	ACADM	0.68	6.63	0.38	1.86e-10	Blood metabolite levels;Acylcarnitine levels;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg04650786	chr6:108395545	OSTM1	0.47	6.13	0.35	3.25e-9	Systemic lupus erythematosus;
CESC	cis	rs853679	0.517	rs55747925	chr6:28044337	T/C	cg08968635	chr6:28129556	ZNF389	0.39	5.22	0.31	3.64e-7	Depression;
CESC	cis	rs11630290	0.592	rs12594446	chr15:64156674	G/T	cg12036633	chr15:63758958	NA	0.45	5.46	0.32	1.12e-7	Iris characteristics;
CESC	cis	rs7918232	0.941	rs10741128	chr10:27411509	G/A	cg14442939	chr10:27389572	ANKRD26	0.68	6.73	0.38	1.04e-10	Breast cancer;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg07899956	chr17:74261249	FAM100B	0.45	6.54	0.37	3.19e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs6674176	0.597	rs6671164	chr1:44403489	G/T	cg12908607	chr1:44402522	ARTN	-0.49	-7.33	-0.41	2.84e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs7077164	0.607	rs1227771	chr10:71577902	C/T	cg07630274	chr10:71583235	COL13A1	-0.33	-5.93	-0.34	9.17e-9	Non-alcoholic fatty liver disease histology (lobular);
CESC	cis	rs8058578	0.832	rs3812999	chr16:30773605	G/T	cg00531865	chr16:30841666	NA	-0.46	-6.22	-0.36	1.94e-9	Multiple myeloma;
CESC	trans	rs561341	0.941	rs2470236	chr17:30304940	G/C	cg27661571	chr11:113659931	NA	-0.72	-7.45	-0.42	1.31e-12	Hip circumference adjusted for BMI;
CESC	cis	rs5750830	0.594	rs9611166	chr22:39775268	T/C	cg24399712	chr22:39784796	NA	-0.77	-11.05	-0.56	1.34e-23	Intelligence (multi-trait analysis);
CESC	cis	rs2749592	0.550	rs7081464	chr10:37883937	C/T	cg00409905	chr10:38381863	ZNF37A	0.41	5.36	0.31	1.85e-7	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs17826219	0.561	rs4085382	chr17:29071202	T/C	cg19761014	chr17:28927070	LRRC37B2	0.72	6.21	0.36	2.07e-9	Body mass index;
CESC	cis	rs67460515	0.563	rs6441362	chr3:160877613	G/A	cg03342759	chr3:160939853	NMD3	-0.49	-6.36	-0.36	8.8e-10	Parkinson's disease;
CESC	cis	rs7605827	0.930	rs10929374	chr2:15676884	T/A	cg19274914	chr2:15703543	NA	0.3	5.39	0.31	1.57e-7	Educational attainment (years of education);
CESC	cis	rs2797160	1.000	rs13328298	chr6:126016580	G/A	cg05901451	chr6:126070800	HEY2	0.46	6.63	0.38	1.86e-10	Endometrial cancer;
CESC	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg24642844	chr7:1081250	C7orf50	-0.64	-8.58	-0.47	8.21e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs6582630	0.502	rs11520276	chr12:38359216	C/T	cg26384229	chr12:38710491	ALG10B	0.72	10.81	0.55	8.31e-23	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs698833	0.828	rs786623	chr2:44606171	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.45	5.74	0.33	2.64e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs17401966	1.000	rs6700866	chr1:10306038	A/G	cg15208524	chr1:10270712	KIF1B	0.43	5.8	0.34	1.93e-8	Hepatocellular carcinoma;
CESC	cis	rs2404602	1.000	rs2404741	chr15:76851735	C/T	cg22467129	chr15:76604101	ETFA	-0.35	-5.25	-0.31	3.16e-7	Blood metabolite levels;
CESC	cis	rs7678296	1.000	rs1342999	chr4:37217990	A/G	cg06805348	chr4:37245195	KIAA1239	0.47	5.2	0.3	4.07e-7	3-hydroxypropylmercapturic acid levels in smokers;
CESC	cis	rs2073300	0.609	rs6137914	chr20:23358364	C/T	cg16736954	chr20:23401023	NAPB	0.8	6.09	0.35	3.89e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs1008375	1.000	rs6449319	chr4:17640283	T/A	cg16339924	chr4:17578868	LAP3	0.66	8.38	0.46	3.23e-15	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs9916302	0.904	rs650106	chr17:37451559	A/G	cg00129232	chr17:37814104	STARD3	0.54	7.03	0.4	1.75e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs8067545	0.611	rs2703771	chr17:20130154	C/G	cg13482628	chr17:19912719	NA	-0.42	-5.59	-0.33	5.51e-8	Schizophrenia;
CESC	cis	rs7647973	0.710	rs2029591	chr3:49646981	C/T	cg07636037	chr3:49044803	WDR6	-0.57	-6.59	-0.38	2.31e-10	Menarche (age at onset);
CESC	cis	rs7666738	0.791	rs34437628	chr4:99029232	C/G	cg05340658	chr4:99064831	C4orf37	0.83	13.1	0.63	1.43e-30	Colonoscopy-negative controls vs population controls;
CESC	trans	rs2219968	0.683	rs4607596	chr8:78902651	C/T	cg23454517	chr17:77917772	TBC1D16	0.38	6.02	0.35	5.64e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs2243480	0.901	rs2900904	chr7:65204264	C/G	cg25894440	chr7:65020034	NA	-0.66	-5.49	-0.32	9.63e-8	Diabetic kidney disease;
CESC	cis	rs7188697	0.922	rs2090727	chr16:58604161	A/G	cg02549819	chr16:58548995	SETD6	0.43	5.4	0.31	1.51e-7	QT interval;
CESC	cis	rs736408	0.774	rs4687551	chr3:52823448	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.51	-6.6	-0.38	2.17e-10	Bipolar disorder;
CESC	cis	rs11264213	0.901	rs72661646	chr1:36454954	A/T	cg27506609	chr1:36549197	TEKT2	0.67	5.56	0.32	6.59e-8	Schizophrenia;
CESC	cis	rs10206020	0.921	rs72778009	chr2:1573322	G/T	cg12573674	chr2:1569213	NA	-0.48	-5.48	-0.32	9.85e-8	IgG glycosylation;
CESC	cis	rs3845702	0.673	rs12468986	chr2:180862320	T/G	cg01881094	chr2:180872142	CWC22	1.08	9.4	0.5	2.75e-18	Schizophrenia;
CESC	cis	rs2576037	0.526	rs3892820	chr18:44479558	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.58	-7.96	-0.44	5.04e-14	Personality dimensions;
CESC	cis	rs9790314	1.000	rs1382426	chr3:161045933	G/A	cg04691961	chr3:161091175	C3orf57	-0.42	-5.31	-0.31	2.3e-7	Morning vs. evening chronotype;
CESC	cis	rs929354	0.772	rs2051876	chr7:157009037	A/G	cg05182265	chr7:156933206	UBE3C	0.46	6.78	0.38	7.7e-11	Body mass index;
CESC	cis	rs56104184	0.775	rs73061694	chr19:49399978	T/C	cg21252483	chr19:49399788	TULP2	-0.52	-5.69	-0.33	3.36e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	cis	rs7662987	0.540	rs2851257	chr4:100039499	G/C	cg13256891	chr4:100009986	ADH5	0.75	8.03	0.44	3.29e-14	Smoking initiation;
CESC	cis	rs9660992	0.626	rs61823972	chr1:205201325	A/C	cg00857998	chr1:205179979	DSTYK	0.51	6.65	0.38	1.69e-10	Mean corpuscular volume;Mean platelet volume;
CESC	trans	rs6951245	0.744	rs1133122	chr7:1192572	C/A	cg13565492	chr6:43139072	SRF	-0.61	-6.23	-0.36	1.79e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2839186	0.709	rs2156117	chr21:47669300	C/A	cg05896524	chr21:47604654	C21orf56	0.43	5.57	0.32	6.11e-8	Testicular germ cell tumor;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg22218536	chr3:40518595	ZNF619	-0.41	-6.09	-0.35	3.9e-9	Gambling;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11911399	chr1:108742837	SLC25A24	0.56	6.49	0.37	4.12e-10	Gut microbiome composition (summer);
CESC	cis	rs73206853	0.688	rs57837519	chr12:110961082	C/T	cg12870014	chr12:110450643	ANKRD13A	0.65	5.8	0.34	1.91e-8	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs4601790	0.601	rs4930295	chr11:65390554	C/G	cg26668713	chr11:65405903	SIPA1	0.71	7.8	0.43	1.39e-13	Blood pressure (age interaction);
CESC	cis	rs853679	0.517	rs9348797	chr6:28137533	G/C	cg22143856	chr6:28129313	ZNF389	0.46	5.83	0.34	1.58e-8	Depression;
CESC	cis	rs10479542	0.544	rs10056863	chr5:179005100	G/A	cg05457628	chr5:178986728	RUFY1	0.49	7.04	0.4	1.68e-11	Lung cancer;
CESC	cis	rs78366141	0.649	rs112818517	chr4:89653103	G/A	cg01026744	chr4:89619053	NAP1L5;HERC3	0.88	5.86	0.34	1.34e-8	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
CESC	cis	rs2055729	0.500	rs1396186	chr8:9875204	T/C	cg21625330	chr8:9911636	MSRA	-0.51	-5.26	-0.31	2.92e-7	Multiple myeloma (hyperdiploidy);
CESC	cis	rs7998202	0.667	rs665813	chr13:113355765	A/G	cg02820901	chr13:113351484	ATP11A	0.64	5.7	0.33	3.25e-8	Glycated hemoglobin levels;
CESC	cis	rs4700695	0.719	rs27588	chr5:65459360	C/A	cg21114390	chr5:65439923	SFRS12	-0.49	-5.98	-0.34	7.35e-9	Facial morphology (factor 19);
CESC	cis	rs875971	1.000	rs4718307	chr7:65610988	A/G	cg12463550	chr7:65579703	CRCP	-0.57	-7.4	-0.41	1.79e-12	Aortic root size;
CESC	cis	rs36051895	0.632	rs117896567	chr9:5141281	C/G	cg02405213	chr9:5042618	JAK2	-0.5	-6.02	-0.35	5.93e-9	Pediatric autoimmune diseases;
CESC	cis	rs2625529	0.824	rs7182776	chr15:72462831	A/G	cg16672083	chr15:72433130	SENP8	0.41	5.82	0.34	1.66e-8	Red blood cell count;
CESC	cis	rs10504229	0.911	rs77203035	chr8:58175458	C/A	cg24829409	chr8:58192753	C8orf71	-0.76	-10.0	-0.52	3.53e-20	Developmental language disorder (linguistic errors);
CESC	trans	rs61931739	0.534	rs7310499	chr12:34212112	G/A	cg26384229	chr12:38710491	ALG10B	0.65	9.28	0.5	6.46e-18	Morning vs. evening chronotype;
CESC	cis	rs9300255	0.602	rs1727315	chr12:123638930	A/G	cg05973401	chr12:123451056	ABCB9	-0.51	-5.85	-0.34	1.46e-8	Neutrophil percentage of white cells;
CESC	cis	rs213032	1.000	rs213027	chr1:21651660	G/T	cg16416158	chr1:21652298	ECE1	0.33	5.48	0.32	9.99e-8	Obesity-related traits;
CESC	trans	rs11098499	0.697	rs6832410	chr4:120296800	A/G	cg25214090	chr10:38739885	LOC399744	0.68	9.2	0.49	1.14e-17	Corneal astigmatism;
CESC	cis	rs9322193	0.962	rs9688809	chr6:150109056	C/T	cg07701084	chr6:150067640	NUP43	0.43	5.85	0.34	1.45e-8	Lung cancer;
CESC	cis	rs9649213	0.593	rs2394854	chr7:98027306	A/G	cg21770322	chr7:97807741	LMTK2	0.56	8.55	0.47	9.65e-16	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs4689592	0.523	rs6446565	chr4:7074027	A/G	cg19539972	chr4:7069911	GRPEL1	0.78	9.98	0.52	3.98e-20	Monocyte percentage of white cells;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25503565	chr17:38264529	NA	0.55	6.26	0.36	1.54e-9	Gut microbiome composition (summer);
CESC	cis	rs713587	1.000	rs2384054	chr2:25156773	T/C	cg01884057	chr2:25150051	NA	0.43	8.06	0.44	2.71e-14	Body mass index in non-asthmatics;
CESC	cis	rs67460515	0.892	rs1478566	chr3:161030335	A/T	cg03342759	chr3:160939853	NMD3	-0.54	-7.68	-0.43	3.01e-13	Parkinson's disease;
CESC	cis	rs965469	1.000	rs6037532	chr20:3267911	T/C	cg25506879	chr20:3388711	C20orf194	-0.55	-5.96	-0.34	7.97e-9	IFN-related cytopenia;
CESC	cis	rs4604732	0.631	rs10925043	chr1:247627001	G/A	cg12754571	chr1:247694271	LOC148824;OR2C3	0.44	5.44	0.32	1.21e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs7937682	0.889	rs551825	chr11:111480116	C/G	cg22437258	chr11:111473054	SIK2	0.72	9.69	0.51	3.38e-19	Primary sclerosing cholangitis;
CESC	cis	rs73206853	0.925	rs61106808	chr12:110876009	C/G	cg12870014	chr12:110450643	ANKRD13A	0.66	5.9	0.34	1.13e-8	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs1005277	0.579	rs1740735	chr10:38497777	A/C	cg25427524	chr10:38739819	LOC399744	-0.71	-10.71	-0.55	1.78e-22	Extrinsic epigenetic age acceleration;
CESC	cis	rs9300255	0.544	rs1716175	chr12:123658388	A/T	cg19016782	chr12:123741754	C12orf65	-0.43	-5.89	-0.34	1.16e-8	Neutrophil percentage of white cells;
CESC	cis	rs9611565	0.649	rs5758466	chr22:42176059	G/A	cg06481639	chr22:41940642	POLR3H	0.47	5.28	0.31	2.67e-7	Vitiligo;
CESC	cis	rs1055129	0.537	rs1135640	chr17:73949540	C/G	cg08125733	chr17:73851984	WBP2	-0.49	-6.63	-0.38	1.86e-10	White matter hyperintensity burden;
CESC	cis	rs9929218	0.559	rs11642362	chr16:68811307	T/C	cg02972257	chr16:68554789	NA	-0.42	-5.26	-0.31	2.92e-7	Colorectal cancer;
CESC	cis	rs910316	0.967	rs1071989	chr14:75564659	G/T	cg08847533	chr14:75593920	NEK9	0.99	18.74	0.75	1.84e-50	Height;
CESC	cis	rs35306767	0.903	rs12778891	chr10:950130	T/A	cg20503657	chr10:835505	NA	0.82	8.4	0.46	2.81e-15	Eosinophil percentage of granulocytes;
CESC	cis	rs4595586	0.545	rs12816776	chr12:39375817	A/G	cg26384229	chr12:38710491	ALG10B	0.54	7.53	0.42	7.85e-13	Morning vs. evening chronotype;
CESC	trans	rs7839040	0.698	rs10106364	chr8:82920659	A/G	cg14472086	chr9:107730925	NA	-0.46	-6.29	-0.36	1.29e-9	Response to methotrexate in juvenile idiopathic arthritis;
CESC	cis	rs523522	0.962	rs12309824	chr12:120990582	A/C	cg12219531	chr12:120966889	COQ5	0.74	9.75	0.51	2.17e-19	High light scatter reticulocyte count;
CESC	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg24829409	chr8:58192753	C8orf71	-0.69	-7.68	-0.43	3.13e-13	Developmental language disorder (linguistic errors);
CESC	cis	rs17666538	0.535	rs896522	chr8:616991	A/G	cg07234876	chr8:600039	NA	0.84	5.94	0.34	9.04e-9	IgG glycosylation;
CESC	cis	rs2832191	0.740	rs2012645	chr21:30445961	G/A	cg24692254	chr21:30365293	RNF160	0.99	17.29	0.73	2.32e-45	Dental caries;
CESC	cis	rs769267	0.895	rs1000237	chr19:19518316	T/A	cg03709012	chr19:19516395	GATAD2A	0.99	15.8	0.7	4.37e-40	Tonsillectomy;
CESC	cis	rs2985684	1.000	rs7142457	chr14:50097862	C/T	cg02151108	chr14:50098012	C14orf104	-0.42	-5.48	-0.32	9.97e-8	Carotid intima media thickness;
CESC	cis	rs1790761	0.692	rs611663	chr11:67312221	C/T	cg08355456	chr11:67383691	NA	0.33	5.15	0.3	5.01e-7	Mean corpuscular volume;
CESC	cis	rs7412746	0.611	rs111905669	chr1:150777565	T/C	cg17724175	chr1:150552817	MCL1	0.41	6.16	0.35	2.64e-9	Melanoma;
CESC	trans	rs9929218	0.953	rs11075696	chr16:68731365	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.76	-10.56	-0.54	5.67e-22	Colorectal cancer;
CESC	cis	rs920590	0.684	rs57462676	chr8:19670848	G/C	cg01411142	chr8:19674711	INTS10	0.5	5.44	0.32	1.19e-7	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs654950	0.792	rs625448	chr1:41988541	A/T	cg06885757	chr1:42089581	HIVEP3	0.4	6.29	0.36	1.34e-9	Airway imaging phenotypes;
CESC	cis	rs6088590	0.901	rs6087631	chr20:33403509	T/C	cg08999081	chr20:33150536	PIGU	0.58	8.88	0.48	1.04e-16	Coronary artery disease;
CESC	cis	rs2430307	0.556	rs3905501	chr7:76542080	C/T	cg15770687	chr7:76625569	PMS2L11	-0.53	-5.31	-0.31	2.37e-7	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
CESC	cis	rs10504229	0.636	rs77290284	chr8:58055269	G/T	cg02725872	chr8:58115012	NA	-0.44	-6.1	-0.35	3.84e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs11031096	0.621	rs11031159	chr11:4179695	T/G	cg18678763	chr11:4115507	RRM1	-0.46	-6.24	-0.36	1.76e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	cis	rs854765	0.547	rs9912096	chr17:17896673	A/C	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.53	7.06	0.4	1.46e-11	Total body bone mineral density;
CESC	cis	rs2963155	0.518	rs865482	chr5:142640317	C/A	cg17617527	chr5:142782415	NR3C1	0.84	7.16	0.4	7.87e-12	Breast cancer;
CESC	cis	rs473651	0.935	rs1103770	chr2:239339281	G/C	cg21699342	chr2:239360505	ASB1	0.41	5.72	0.33	2.92e-8	Multiple system atrophy;
CESC	cis	rs4803468	1.000	rs11670668	chr19:41920454	G/C	cg14132834	chr19:41945861	ATP5SL	-0.67	-8.23	-0.45	8.57e-15	Height;
CESC	cis	rs6952808	0.564	rs55865401	chr7:2145720	G/C	cg04267008	chr7:1944627	MAD1L1	-0.53	-6.38	-0.36	8e-10	Bipolar disorder and schizophrenia;
CESC	cis	rs5758511	0.680	rs5758699	chr22:42688034	C/G	cg00645731	chr22:42541494	CYP2D7P1	0.54	8.23	0.45	8.4e-15	Birth weight;
CESC	cis	rs6752107	0.936	rs1045100	chr2:234203597	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.49	6.65	0.38	1.7e-10	Crohn's disease;Inflammatory bowel disease;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg25425078	chr12:4381777	CCND2	-0.49	-7.34	-0.41	2.68e-12	Gut microbiota (bacterial taxa);
CESC	cis	rs7666738	0.791	rs62318907	chr4:99037120	C/T	cg18180107	chr4:99064573	C4orf37	0.41	5.31	0.31	2.36e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs470119	1.000	rs2782	chr22:50961854	T/C	cg12969734	chr22:50962224	SCO2	0.41	6.29	0.36	1.32e-9	Mean corpuscular hemoglobin;
CESC	cis	rs798554	0.680	rs2533889	chr7:2900309	G/C	cg18446336	chr7:2847575	GNA12	-0.38	-5.8	-0.34	1.9e-8	Height;
CESC	cis	rs1267303	0.642	rs7542296	chr1:46998009	A/G	cg25110126	chr1:46999211	NA	0.97	12.5	0.61	1.7e-28	Monobrow;
CESC	cis	rs12479064	0.724	rs112900993	chr2:99948805	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.6	-7.2	-0.4	6.39e-12	Chronic sinus infection;
CESC	cis	rs4704187	0.663	rs7735057	chr5:74403857	T/A	cg03227963	chr5:74354835	NA	0.32	5.94	0.34	8.7e-9	Response to amphetamines;
CESC	cis	rs12497850	0.931	rs11920534	chr3:48937761	G/T	cg02487422	chr3:49467188	NICN1	0.38	5.04	0.3	8.65e-7	Parkinson's disease;
CESC	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.42	-5.35	-0.31	1.91e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs4713118	0.662	rs464312	chr6:27967591	T/A	cg17949981	chr6:28129498	ZNF389	0.39	5.1	0.3	6.36e-7	Parkinson's disease;
CESC	cis	rs10751667	0.666	rs7483273	chr11:951127	T/C	cg06064525	chr11:970664	AP2A2	-0.47	-9.17	-0.49	1.33e-17	Alzheimer's disease (late onset);
CESC	cis	rs1364705	0.910	rs13274578	chr8:120314864	T/C	cg09273054	chr8:120220131	MAL2	0.63	7.1	0.4	1.15e-11	Hippocampal atrophy;
CESC	cis	rs875971	0.545	rs221986	chr7:65570310	T/C	cg19163074	chr7:65112434	INTS4L2	0.51	5.33	0.31	2.12e-7	Aortic root size;
CESC	cis	rs780096	0.545	rs2280737	chr2:27589810	A/G	cg22903471	chr2:27725779	GCKR	-0.5	-7.38	-0.41	2.04e-12	Total body bone mineral density;
CESC	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg24846343	chr22:24311635	DDTL	0.66	11.37	0.57	1.2e-24	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs9931543	0.504	rs4784651	chr16:56311774	A/G	cg02433656	chr16:56322654	GNAO1	-0.4	-5.29	-0.31	2.54e-7	Subjective well-being;
CESC	cis	rs34638657	0.732	rs4889477	chr16:82201302	C/T	cg09439754	chr16:82129088	HSD17B2	-0.36	-6.24	-0.36	1.71e-9	Lung adenocarcinoma;
CESC	cis	rs7666738	0.830	rs10005120	chr4:99038200	A/G	cg03467027	chr4:99064603	C4orf37	0.47	5.99	0.35	6.71e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2120019	0.938	rs1867150	chr15:75321139	T/C	cg09165964	chr15:75287851	SCAMP5	-0.81	-10.13	-0.53	1.34e-20	Blood trace element (Zn levels);
CESC	cis	rs1728785	1.000	rs1645927	chr16:68589300	T/G	cg02972257	chr16:68554789	NA	-0.59	-6.79	-0.38	7.32e-11	Ulcerative colitis;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg12475106	chr4:503275	PIGG	-0.48	-6.17	-0.35	2.61e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs34779708	0.966	rs12260130	chr10:35467671	C/T	cg03585969	chr10:35415529	CREM	0.77	10.56	0.54	5.56e-22	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs1371867	0.817	rs1788185	chr8:101335529	T/C	cg11906718	chr8:101322791	RNF19A	0.53	6.86	0.39	4.86e-11	Atrioventricular conduction;
CESC	cis	rs2839186	0.504	rs4347941	chr21:47938239	T/C	cg10657630	chr21:48055338	PRMT2	0.45	5.69	0.33	3.38e-8	Testicular germ cell tumor;
CESC	cis	rs2486288	0.656	rs2413773	chr15:45549442	C/A	cg21132104	chr15:45694354	SPATA5L1	-0.54	-6.55	-0.37	3.03e-10	Glomerular filtration rate;
CESC	cis	rs3733585	0.660	rs13122290	chr4:9933832	A/G	cg02734326	chr4:10020555	SLC2A9	-0.41	-5.99	-0.35	6.74e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs7586673	0.893	rs889925	chr2:161971597	T/C	cg21518248	chr2:162101506	NA	0.46	6.24	0.36	1.73e-9	Intelligence (multi-trait analysis);
CESC	cis	rs780096	0.546	rs1260320	chr2:27722416	A/G	cg12648201	chr2:27665141	KRTCAP3	0.36	6.94	0.39	3.07e-11	Total body bone mineral density;
CESC	cis	rs9309473	0.950	rs6740766	chr2:73780913	A/G	cg20560298	chr2:73613845	ALMS1	-0.54	-7.08	-0.4	1.31e-11	Metabolite levels;
CESC	cis	rs3750082	0.852	rs7786669	chr7:32898338	A/G	cg08946731	chr7:32981826	RP9P	0.35	5.04	0.3	8.55e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs875971	0.545	rs1796226	chr7:66087710	C/T	cg25405998	chr7:65216604	CCT6P1	0.48	5.57	0.32	6.4e-8	Aortic root size;
CESC	cis	rs7618915	0.571	rs17264436	chr3:52610651	T/A	cg18404041	chr3:52824283	ITIH1	-0.41	-6.77	-0.38	8.16e-11	Bipolar disorder;
CESC	cis	rs7552404	0.924	rs67757078	chr1:76169456	G/A	cg10523679	chr1:76189770	ACADM	0.76	10.05	0.53	2.4e-20	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs4665809	1.000	rs12469163	chr2:26283587	T/C	cg27170947	chr2:26402098	FAM59B	-0.59	-7.05	-0.4	1.59e-11	Gut microbiome composition (summer);
CESC	cis	rs873946	0.648	rs1543593	chr10:134553185	A/T	cg27286337	chr10:134555280	INPP5A	0.69	8.04	0.44	2.95e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs6570726	0.791	rs6913727	chr6:145899826	A/G	cg05347473	chr6:146136440	FBXO30	0.59	7.78	0.43	1.59e-13	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg03395511	chr6:291903	DUSP22	0.7	9.0	0.48	4.55e-17	Menopause (age at onset);
CESC	cis	rs7107174	1.000	rs2511178	chr11:77923220	C/T	cg02023728	chr11:77925099	USP35	0.49	6.56	0.37	2.89e-10	Testicular germ cell tumor;
CESC	cis	rs6461049	0.800	rs2398706	chr7:2156338	A/T	cg23048001	chr7:2026167	MAD1L1	0.45	5.79	0.33	2.01e-8	Schizophrenia;
CESC	cis	rs9322193	0.962	rs9393175	chr6:149998723	A/G	cg13206674	chr6:150067644	NUP43	0.4	5.43	0.32	1.25e-7	Lung cancer;
CESC	cis	rs6502050	0.805	rs6502057	chr17:80082060	A/G	cg11859384	chr17:80120422	CCDC57	0.37	5.12	0.3	5.88e-7	Life satisfaction;
CESC	cis	rs9303401	0.659	rs16943326	chr17:57050365	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.0	12.47	0.61	2.1e-28	Cognitive test performance;
CESC	cis	rs4665809	0.652	rs2384360	chr2:26405016	C/G	cg04944784	chr2:26401820	FAM59B	-0.91	-10.38	-0.54	2.12e-21	Gut microbiome composition (summer);
CESC	cis	rs2637266	0.935	rs2579719	chr10:78400026	A/G	cg18941641	chr10:78392320	NA	0.45	8.65	0.47	5e-16	Pulmonary function;
CESC	cis	rs12325245	0.536	rs12931124	chr16:58620063	G/A	cg05725404	chr16:58534157	NDRG4	-0.64	-5.37	-0.31	1.76e-7	Schizophrenia;
CESC	cis	rs2204008	0.640	rs11520199	chr12:38211026	T/C	cg13010199	chr12:38710504	ALG10B	0.54	6.69	0.38	1.28e-10	Bladder cancer;
CESC	cis	rs3780486	0.846	rs2209948	chr9:33138247	G/A	cg13443165	chr9:33130375	B4GALT1	0.45	6.49	0.37	4.1e-10	IgG glycosylation;
CESC	trans	rs7090925	1.000	rs2646424	chr10:8463115	G/C	cg02275004	chr12:976007	WNK1;HSN2	0.46	6.04	0.35	5.17e-9	Systemic lupus erythematosus;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11993436	chr7:155437098	RBM33	0.51	6.07	0.35	4.39e-9	Gut microbiome composition (summer);
CESC	cis	rs1355223	0.506	rs7947848	chr11:34866220	T/C	cg11622362	chr11:34938112	PDHX;APIP	0.44	5.29	0.31	2.52e-7	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs769267	0.930	rs10419912	chr19:19597055	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.59	-7.56	-0.42	6.46e-13	Tonsillectomy;
CESC	cis	rs977987	0.843	rs60730309	chr16:75431769	C/G	cg03315344	chr16:75512273	CHST6	0.39	5.71	0.33	2.98e-8	Dupuytren's disease;
CESC	cis	rs2735413	0.875	rs4888737	chr16:78083819	A/G	cg04733911	chr16:78082701	NA	-0.53	-8.89	-0.48	9.44e-17	Systolic blood pressure (alcohol consumption interaction);
CESC	cis	rs11655198	1	rs11655198	chr17:38026169	C/T	cg20243544	chr17:37824526	PNMT	0.53	7.05	0.4	1.57e-11	Asthma;
CESC	cis	rs9611565	0.592	rs5751139	chr22:42099981	G/C	cg03806693	chr22:41940476	POLR3H	1.15	13.67	0.64	1.42e-32	Vitiligo;
CESC	cis	rs1878931	0.668	rs11643983	chr16:3438865	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	1.02	17.06	0.72	1.5e-44	Body mass index (adult);
CESC	cis	rs9303401	0.659	rs12946852	chr17:57013337	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.98	11.93	0.59	1.56e-26	Cognitive test performance;
CESC	cis	rs7605827	0.930	rs2241236	chr2:15655480	A/G	cg19274914	chr2:15703543	NA	0.37	6.65	0.38	1.65e-10	Educational attainment (years of education);
CESC	cis	rs9733	0.596	rs34600506	chr1:150687808	C/G	cg18016565	chr1:150552671	MCL1	0.35	5.36	0.31	1.86e-7	Tonsillectomy;
CESC	cis	rs7666738	0.830	rs11729753	chr4:98803267	T/A	cg03467027	chr4:99064603	C4orf37	0.44	5.43	0.32	1.26e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10504229	0.953	rs66815941	chr8:58187306	C/T	cg24829409	chr8:58192753	C8orf71	-0.76	-9.93	-0.52	5.87e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs9457247	1.000	rs430477	chr6:167389851	T/C	cg25258033	chr6:167368657	RNASET2	0.39	5.87	0.34	1.31e-8	Crohn's disease;
CESC	cis	rs9660180	0.620	rs34298494	chr1:1663402	A/C	cg27541892	chr1:1571801	CDK11B	-0.61	-8.05	-0.44	2.83e-14	Body mass index;
CESC	cis	rs4843747	0.605	rs28399183	chr16:88107277	G/A	cg06915872	chr16:87998081	BANP	0.44	5.31	0.31	2.32e-7	Menopause (age at onset);
CESC	cis	rs6500395	1.000	rs7191028	chr16:48626023	T/C	cg04672837	chr16:48644449	N4BP1	0.53	6.65	0.38	1.63e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs4689592	0.503	rs59640165	chr4:7051661	G/A	cg06697600	chr4:7070879	GRPEL1	0.52	6.07	0.35	4.51e-9	Monocyte percentage of white cells;
CESC	cis	rs28386778	0.669	rs12603821	chr17:62006432	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.66	-8.82	-0.48	1.54e-16	Prudent dietary pattern;
CESC	cis	rs2425143	0.818	rs35448195	chr20:34542365	C/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.65	5.59	0.32	5.74e-8	Blood protein levels;
CESC	cis	rs736801	0.607	rs11739135	chr5:131733397	C/G	cg07395648	chr5:131743802	NA	-0.45	-5.68	-0.33	3.61e-8	Breast cancer;Mosquito bite size;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg15097968	chr15:63449935	RPS27L	-0.49	-7.01	-0.4	1.93e-11	Gambling;
CESC	cis	rs9487051	0.714	rs9487058	chr6:109631060	A/C	cg01475377	chr6:109611718	NA	-0.46	-7.2	-0.4	6.15e-12	Reticulocyte fraction of red cells;
CESC	cis	rs9325144	0.532	rs1352121	chr12:39130696	A/G	cg26384229	chr12:38710491	ALG10B	-0.51	-7.05	-0.4	1.58e-11	Morning vs. evening chronotype;
CESC	trans	rs941207	0.542	rs7311381	chr12:57194070	G/A	cg26462586	chr2:11164677	NA	0.38	6.1	0.35	3.74e-9	Platelet count;
CESC	cis	rs6967414	0.786	rs3757482	chr7:6748927	A/G	cg00387323	chr7:6746715	ZNF12	0.66	6.25	0.36	1.65e-9	Hematocrit;Hemoglobin concentration;
CESC	trans	rs61931739	0.500	rs11053212	chr12:34466116	T/G	cg13010199	chr12:38710504	ALG10B	0.49	6.29	0.36	1.3e-9	Morning vs. evening chronotype;
CESC	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg26354017	chr1:205819088	PM20D1	0.84	13.04	0.63	2.31e-30	Menarche (age at onset);
CESC	cis	rs1256061	0.603	rs1256041	chr14:64738029	A/G	cg23250157	chr14:64679961	SYNE2	0.53	7.64	0.42	4.09e-13	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs2243480	0.901	rs778693	chr7:65872345	T/G	cg18252515	chr7:66147081	NA	-1.39	-14.18	-0.66	2.5e-34	Diabetic kidney disease;
CESC	cis	rs2299587	0.604	rs11203933	chr8:17901910	G/T	cg18067069	chr8:17937731	ASAH1	-0.37	-5.09	-0.3	6.95e-7	Economic and political preferences;
CESC	trans	rs2908835	0.705	rs12425902	chr12:11643114	T/C	cg09915232	chr8:1879280	ARHGEF10	-0.64	-6.29	-0.36	1.31e-9	Information processing speed;
CESC	cis	rs2777491	0.957	rs8027626	chr15:41711514	T/G	cg18705301	chr15:41695430	NDUFAF1	-0.65	-9.76	-0.51	1.95e-19	Ulcerative colitis;
CESC	cis	rs7953249	0.656	rs2243616	chr12:121406370	G/T	cg02403541	chr12:121454288	C12orf43	-0.55	-7.05	-0.4	1.52e-11	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
CESC	cis	rs7811142	0.830	rs6979910	chr7:99940630	A/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.91	10.16	0.53	1.07e-20	Platelet count;
CESC	cis	rs425277	0.561	rs11584491	chr1:2042543	A/G	cg12718519	chr1:2058417	PRKCZ	-0.24	-5.2	-0.3	4e-7	Height;
CESC	cis	rs6460942	0.915	rs72584550	chr7:12304990	G/A	cg20607287	chr7:12443886	VWDE	-0.42	-5.92	-0.34	1.02e-8	Coronary artery disease;
CESC	cis	rs8067354	0.645	rs7215180	chr17:57822354	A/G	cg02344993	chr17:57696989	CLTC	0.68	8.07	0.44	2.5e-14	Hemoglobin concentration;
CESC	cis	rs8114671	0.562	rs6119545	chr20:33522869	T/C	cg24642439	chr20:33292090	TP53INP2	0.43	5.19	0.3	4.19e-7	Height;
CESC	cis	rs7216064	1.000	rs2365468	chr17:65841318	C/T	cg12091567	chr17:66097778	LOC651250	-0.81	-9.35	-0.5	3.74e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26934072	chr16:2033910	GFER	0.53	6.39	0.37	7.37e-10	Gut microbiome composition (summer);
CESC	cis	rs10771431	1.000	rs11611670	chr12:9385535	C/T	cg08997352	chr12:9597637	DDX12	-0.66	-8.78	-0.47	2.07e-16	Breast size;
CESC	cis	rs10129255	0.518	rs10150460	chr14:107133196	C/G	cg23076370	chr14:107095027	NA	0.63	9.86	0.52	9.63e-20	Kawasaki disease;
CESC	cis	rs1008375	0.966	rs10939755	chr4:17693755	T/C	cg16339924	chr4:17578868	LAP3	0.61	7.58	0.42	5.98e-13	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs9910055	0.664	rs433610	chr17:42197281	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	-0.43	-6.34	-0.36	9.82e-10	Total body bone mineral density;
CESC	cis	rs9322193	0.847	rs12234128	chr6:149948689	T/C	cg07701084	chr6:150067640	NUP43	0.44	6.12	0.35	3.33e-9	Lung cancer;
CESC	cis	rs11809207	0.574	rs2783631	chr1:26504756	C/T	cg00147160	chr1:26503991	CNKSR1	0.27	5.16	0.3	4.81e-7	Height;
CESC	cis	rs801193	0.839	rs6968619	chr7:66068867	T/C	cg14393609	chr7:65229607	NA	-0.42	-5.86	-0.34	1.35e-8	Aortic root size;
CESC	cis	rs939658	0.805	rs35462901	chr15:79442201	C/T	cg17916960	chr15:79447300	NA	-0.35	-5.98	-0.34	7.25e-9	Refractive error;
CESC	cis	rs9549367	0.789	rs9577218	chr13:113894911	A/G	cg00898013	chr13:113819073	PROZ	-0.53	-7.54	-0.42	7.53e-13	Platelet distribution width;
CESC	cis	rs3105593	0.965	rs8029073	chr15:50913148	T/A	cg08437265	chr15:50716283	USP8	0.4	5.12	0.3	6.02e-7	QT interval;
CESC	cis	rs4132509	0.515	rs76243949	chr1:243674094	G/A	cg21452805	chr1:244014465	NA	0.48	5.33	0.31	2.08e-7	RR interval (heart rate);
CESC	cis	rs3733585	0.753	rs12500805	chr4:10017979	C/T	cg02734326	chr4:10020555	SLC2A9	0.49	6.91	0.39	3.54e-11	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs7089973	0.604	rs2420069	chr10:116605103	A/G	cg23260525	chr10:116636907	FAM160B1	0.4	7.2	0.4	6.31e-12	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs4975616	0.843	rs4975615	chr5:1315343	C/T	cg06550200	chr5:1325588	CLPTM1L	0.65	9.7	0.51	3.09e-19	Lung cancer;
CESC	cis	rs7520050	0.807	rs4274104	chr1:46217941	T/C	cg03146154	chr1:46216737	IPP	0.5	6.71	0.38	1.16e-10	Red blood cell count;Reticulocyte count;
CESC	cis	rs4665809	0.531	rs12987980	chr2:26462093	A/T	cg08470875	chr2:26401718	FAM59B	0.75	7.78	0.43	1.63e-13	Gut microbiome composition (summer);
CESC	cis	rs4665809	0.590	rs3806514	chr2:26466772	C/T	cg25036284	chr2:26402008	FAM59B	0.88	9.99	0.52	3.79e-20	Gut microbiome composition (summer);
CESC	cis	rs7811142	1.000	rs11559117	chr7:100076614	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.87	9.07	0.49	2.8e-17	Platelet count;
CESC	cis	rs4242434	0.927	rs720746	chr8:22471399	T/C	cg03733263	chr8:22462867	KIAA1967	0.92	13.81	0.65	4.86e-33	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CESC	cis	rs7618501	1.000	rs7372725	chr3:49790544	C/A	cg24308560	chr3:49941425	MST1R	0.51	6.95	0.39	2.89e-11	Intelligence (multi-trait analysis);
CESC	cis	rs73019876	0.869	rs2522096	chr19:22123417	C/A	cg11619707	chr19:22235551	ZNF257	-0.31	-5.78	-0.33	2.14e-8	Testicular germ cell tumor;
CESC	cis	rs11098499	0.863	rs7664986	chr4:120429952	A/C	cg24375607	chr4:120327624	NA	0.44	5.28	0.31	2.67e-7	Corneal astigmatism;
CESC	trans	rs9693444	0.898	rs4732697	chr8:29519861	A/G	cg04151612	chr3:9932217	JAGN1	-0.42	-6.17	-0.35	2.48e-9	Breast cancer;
CESC	cis	rs17376456	0.597	rs6869110	chr5:93355531	G/A	cg25358565	chr5:93447407	FAM172A	-0.46	-5.45	-0.32	1.17e-7	Diabetic retinopathy;
CESC	cis	rs2929278	0.617	rs524908	chr15:44187991	G/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.44	-6.05	-0.35	4.92e-9	Schizophrenia;
CESC	trans	rs4424809	0.614	rs7336959	chr13:85571724	C/G	cg05918002	chr17:5019452	ZNF232	-0.64	-6.08	-0.35	4.2e-9	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs7666738	0.791	rs1830231	chr4:99026185	A/C	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.58e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	ch.3.1042801R	chr3:49084142	QRICH1	0.44	6.01	0.35	6.16e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg13633754	chr9:95858523	C9orf89	-0.44	-6.19	-0.36	2.33e-9	Fibrinogen levels;
CESC	cis	rs2204008	0.782	rs11514339	chr12:38236670	G/A	cg13010199	chr12:38710504	ALG10B	0.52	6.43	0.37	5.91e-10	Bladder cancer;
CESC	cis	rs425277	1.000	rs262647	chr1:2095699	C/T	cg04315214	chr1:2043799	PRKCZ	-0.37	-5.28	-0.31	2.74e-7	Height;
CESC	cis	rs11122272	0.735	rs2437148	chr1:231513979	A/G	cg06096015	chr1:231504339	EGLN1	0.43	6.18	0.35	2.46e-9	Hemoglobin concentration;
CESC	cis	rs2191566	0.691	rs56320525	chr19:44587879	C/T	cg20607764	chr19:44506953	ZNF230	-0.4	-5.17	-0.3	4.53e-7	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs6426558	0.537	rs1320494	chr1:227241300	A/T	cg10327440	chr1:227177885	CDC42BPA	0.48	6.0	0.35	6.39e-9	Neutrophil percentage of white cells;
CESC	cis	rs7659604	0.539	rs11731917	chr4:122783233	G/A	cg20573242	chr4:122745356	CCNA2	0.65	8.05	0.44	2.81e-14	Type 2 diabetes;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg16739247	chr1:76252438	SNORD45C;SNORD45A;RABGGTB	0.49	6.23	0.36	1.81e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs7818345	0.967	rs6990357	chr8:19276681	C/G	cg11303988	chr8:19266685	CSGALNACT1	0.33	5.99	0.35	6.77e-9	Language performance in older adults (adjusted for episodic memory);
CESC	cis	rs4975709	0.569	rs4975743	chr5:1859941	G/T	cg11168104	chr5:1857477	NA	-0.36	-5.17	-0.3	4.55e-7	Cardiovascular disease risk factors;
CESC	cis	rs9611565	0.592	rs9611613	chr22:41961831	T/C	cg06481639	chr22:41940642	POLR3H	-0.58	-6.42	-0.37	6.32e-10	Vitiligo;
CESC	cis	rs11640533	0.901	rs11862250	chr16:53415038	C/A	cg04653913	chr16:53407753	NA	0.47	6.2	0.36	2.21e-9	Intelligence (multi-trait analysis);
CESC	trans	rs9929218	0.906	rs9932679	chr16:68751904	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.78	-10.11	-0.53	1.52e-20	Colorectal cancer;
CESC	cis	rs2304069	0.545	rs7728248	chr5:149394965	A/G	cg12661370	chr5:149340060	SLC26A2	0.43	5.67	0.33	3.75e-8	HIV-1 control;
CESC	cis	rs7520050	0.966	rs12139630	chr1:46350935	A/G	cg24296786	chr1:45957014	TESK2	0.43	5.41	0.32	1.42e-7	Red blood cell count;Reticulocyte count;
CESC	cis	rs78456975	1.000	rs11883965	chr2:1560062	T/C	cg01028140	chr2:1542097	TPO	-0.5	-5.37	-0.31	1.69e-7	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs4889855	0.556	rs11547301	chr17:78518780	C/T	cg16591659	chr17:78472290	NA	0.38	6.03	0.35	5.35e-9	Fractional excretion of uric acid;
CESC	trans	rs78049276	0.736	rs17612742	chr4:148414651	C/T	cg13149281	chr14:23389818	RBM23;PRMT5	0.62	6.32	0.36	1.13e-9	Pulse pressure;
CESC	trans	rs28549925	0.590	rs9690470	chr7:16987440	G/C	cg12639933	chr12:57626296	SHMT2	0.91	6.18	0.35	2.42e-9	Congenital heart disease (maternal effect);Conotruncal heart defects (maternal effects);
CESC	cis	rs921968	0.565	rs12612395	chr2:219621642	G/C	cg02176678	chr2:219576539	TTLL4	-0.43	-7.56	-0.42	6.81e-13	Mean corpuscular hemoglobin concentration;
CESC	cis	rs34638657	0.789	rs2303264	chr16:82203711	G/T	cg09439754	chr16:82129088	HSD17B2	-0.35	-5.83	-0.34	1.64e-8	Lung adenocarcinoma;
CESC	cis	rs736408	0.608	rs6445534	chr3:52743384	G/A	cg17372223	chr3:52568218	NT5DC2	0.43	6.54	0.37	3.21e-10	Bipolar disorder;
CESC	cis	rs769267	0.965	rs2315281	chr19:19480099	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.44	-5.76	-0.33	2.36e-8	Tonsillectomy;
CESC	cis	rs757110	0.526	rs757081	chr11:17351683	C/G	cg15432903	chr11:17409602	KCNJ11	-0.48	-6.62	-0.38	1.97e-10	Type 2 diabetes;
CESC	cis	rs35079168	0.923	rs10858277	chr9:137287959	G/A	cg13941235	chr9:137270186	RXRA	-0.31	-5.66	-0.33	3.86e-8	Intelligence;
CESC	cis	rs929354	0.651	rs6951298	chr7:156949149	T/C	cg05182265	chr7:156933206	UBE3C	-0.5	-7.29	-0.41	3.49e-12	Body mass index;
CESC	cis	rs55788414	0.932	rs12716908	chr16:81186245	T/C	cg06400318	chr16:81190750	PKD1L2	-0.59	-6.58	-0.37	2.44e-10	Left ventricular obstructive tract defect (maternal effect);
CESC	cis	rs9527	0.590	rs11191540	chr10:104822809	G/C	cg04362960	chr10:104952993	NT5C2	0.45	5.76	0.33	2.34e-8	Arsenic metabolism;
CESC	cis	rs7223966	1.000	rs9901112	chr17:61730617	C/G	cg11494091	chr17:61959527	GH2	0.38	5.1	0.3	6.42e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs1552244	1.000	rs2272125	chr3:10138069	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	12.57	0.61	9.49e-29	Alzheimer's disease;
CESC	cis	rs1048238	0.506	rs698890	chr1:16267371	C/G	cg21385522	chr1:16154831	NA	-0.45	-5.7	-0.33	3.22e-8	Systolic blood pressure;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05160409	chr11:60681264	TMEM109	-0.54	-6.54	-0.37	3.21e-10	Gut microbiome composition (summer);
CESC	trans	rs758324	0.606	rs247276	chr5:131469004	C/T	cg26954464	chr16:67472862	ATP6V0D1	0.45	6.14	0.35	2.92e-9	Alzheimer's disease in APOE e4- carriers;
CESC	cis	rs67311347	1.000	rs12492035	chr3:40467110	G/A	cg09455208	chr3:40491958	NA	0.49	8.14	0.45	1.52e-14	Renal cell carcinoma;
CESC	cis	rs3540	0.533	rs1869179	chr15:90895564	A/C	cg22089800	chr15:90895588	ZNF774	0.77	10.97	0.56	2.43e-23	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs9486715	0.838	rs7452350	chr6:96883326	C/A	cg06623918	chr6:96969491	KIAA0776	0.91	14.05	0.65	6.83e-34	Headache;
CESC	cis	rs6963495	0.651	rs3892298	chr7:105152187	A/G	cg13798780	chr7:105162888	PUS7	0.76	7.77	0.43	1.79e-13	Bipolar disorder (body mass index interaction);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg16583193	chr19:3652060	PIP5K1C	0.49	6.27	0.36	1.5e-9	Fibrinogen levels;
CESC	cis	rs7615952	0.688	rs12485622	chr3:125710739	T/C	cg15145296	chr3:125709740	NA	-0.48	-5.24	-0.31	3.22e-7	Blood pressure (smoking interaction);
CESC	cis	rs9733	0.596	rs6678013	chr1:150623285	T/G	cg22823121	chr1:150693482	HORMAD1	0.48	7.12	0.4	1.03e-11	Tonsillectomy;
CESC	cis	rs61996546	0.622	rs61998698	chr15:26868306	G/C	cg15066197	chr15:26874202	GABRB3	-0.34	-5.06	-0.3	8.04e-7	Response to methotrexate in juvenile idiopathic arthritis;
CESC	cis	rs7208859	0.673	rs216420	chr17:28938508	C/T	cg17105886	chr17:28927953	LRRC37B2	0.59	5.14	0.3	5.26e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01213128	chr5:138629571	MATR3	0.54	6.34	0.36	9.84e-10	Gut microbiome composition (summer);
CESC	cis	rs4423214	1.000	rs12808368	chr11:71170817	C/T	cg05163923	chr11:71159392	DHCR7	0.78	10.34	0.54	2.91e-21	Vitamin D levels;
CESC	cis	rs17818399	0.890	rs34752561	chr2:46850150	G/A	cg02822958	chr2:46747628	ATP6V1E2	0.46	5.51	0.32	8.47e-8	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10460643	chr3:53205536	PRKCD	-0.56	-6.84	-0.39	5.43e-11	Gut microbiome composition (summer);
CESC	trans	rs3741489	1.000	rs3741489	chr12:133417802	A/G	cg24132527	chr5:140019269	TMCO6	1.11	7.52	0.42	8.38e-13	Cognitive function;
CESC	cis	rs34779708	0.733	rs7086715	chr10:35541840	A/G	cg03585969	chr10:35415529	CREM	0.56	6.42	0.37	6.15e-10	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs6831352	0.734	rs1311620	chr4:100013091	C/T	cg13256891	chr4:100009986	ADH5	0.69	8.16	0.45	1.32e-14	Alcohol dependence;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg01622965	chr7:98476371	TRRAP	0.49	6.38	0.36	8.08e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs7666738	0.512	rs165251	chr4:98758490	C/G	cg05340658	chr4:99064831	C4orf37	0.51	6.65	0.38	1.63e-10	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9787249	0.957	rs10888958	chr1:40211737	T/C	cg19912559	chr1:40204330	PPIE	0.43	6.57	0.37	2.63e-10	Blood protein levels;
CESC	cis	rs9901225	1	rs9901225	chr17:40755811	C/T	cg21433558	chr17:40837037	CNTNAP1	0.72	11.77	0.59	5.35e-26	Colorectal or endometrial cancer;
CESC	cis	rs8180040	0.620	rs9845728	chr3:47103376	C/T	cg27129171	chr3:47204927	SETD2	0.66	9.71	0.51	2.81e-19	Colorectal cancer;
CESC	cis	rs4971059	0.654	rs7364524	chr1:155121922	A/G	cg22049894	chr1:155113146	DPM3	0.47	6.07	0.35	4.32e-9	Breast cancer;
CESC	cis	rs10872587	0.657	rs11155459	chr6:146578751	A/G	cg23711669	chr6:146136114	FBXO30	-0.63	-7.46	-0.42	1.24e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs11098499	0.909	rs73842633	chr4:120375464	G/A	cg24375607	chr4:120327624	NA	0.46	5.39	0.31	1.57e-7	Corneal astigmatism;
CESC	cis	rs7615952	0.641	rs2365019	chr3:125808135	T/C	cg18479299	chr3:125709523	NA	-0.48	-5.06	-0.3	7.98e-7	Blood pressure (smoking interaction);
CESC	cis	rs9322193	0.923	rs9767554	chr6:149937996	T/C	cg07701084	chr6:150067640	NUP43	0.45	6.47	0.37	4.76e-10	Lung cancer;
CESC	cis	rs28374715	0.578	rs7165914	chr15:41632451	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.06	-15.45	-0.69	7.91e-39	Ulcerative colitis;
CESC	cis	rs10504229	0.683	rs56741275	chr8:58136108	C/G	cg21724239	chr8:58056113	NA	0.58	5.95	0.34	8.29e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs4888262	0.545	rs7195499	chr16:74693973	C/G	cg01733217	chr16:74700730	RFWD3	0.91	12.21	0.6	1.62e-27	Testicular germ cell tumor;
CESC	cis	rs9910055	0.683	rs7220138	chr17:42254011	C/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.5	7.5	0.42	9.57e-13	Total body bone mineral density;
CESC	cis	rs765787	0.505	rs4439707	chr15:45524216	G/A	cg24006582	chr15:45444508	DUOX1	0.57	6.82	0.39	6.17e-11	Uric acid levels;
CESC	cis	rs896854	0.846	rs7845219	chr8:95937502	T/C	cg23172400	chr8:95962367	TP53INP1	-0.43	-8.98	-0.48	5.05e-17	Type 2 diabetes;
CESC	cis	rs1862618	0.627	rs744023	chr5:56197078	C/T	cg24549020	chr5:56110836	MAP3K1	0.62	6.49	0.37	4.21e-10	Initial pursuit acceleration;
CESC	cis	rs7605827	0.930	rs2890487	chr2:15594938	A/G	cg19274914	chr2:15703543	NA	0.32	5.69	0.33	3.38e-8	Educational attainment (years of education);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26399201	chr5:132149404	ANKRD43	0.59	6.15	0.35	2.9e-9	Gut microbiome composition (summer);
CESC	cis	rs2108225	0.837	rs6959729	chr7:107446180	A/C	cg18560240	chr7:107437656	SLC26A3	-0.4	-5.38	-0.31	1.64e-7	Ulcerative colitis;
CESC	cis	rs3785574	0.962	rs2665835	chr17:61903258	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.57	7.05	0.4	1.57e-11	Height;
CESC	cis	rs1975974	0.935	rs67979358	chr17:21723834	G/C	cg18423549	chr17:21743878	NA	-0.51	-7.12	-0.4	1.04e-11	Psoriasis;
CESC	cis	rs8177253	1.000	rs8177271	chr3:133482230	G/A	cg11941060	chr3:133502564	NA	-0.46	-6.12	-0.35	3.36e-9	Iron status biomarkers;
CESC	cis	rs763014	0.865	rs2018789	chr16:632051	T/C	cg00802000	chr16:706648	WDR90	-0.41	-6.12	-0.35	3.33e-9	Height;
CESC	cis	rs12497850	0.897	rs7373778	chr3:48836392	C/G	cg07636037	chr3:49044803	WDR6	1.01	18.31	0.75	5.7e-49	Parkinson's disease;
CESC	cis	rs7917772	0.582	rs12782153	chr10:104368294	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.4	-5.39	-0.31	1.59e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs10760279	0.584	rs10760280	chr9:126112812	A/G	cg14503395	chr9:126128745	CRB2	0.48	5.86	0.34	1.35e-8	Body mass index;
CESC	cis	rs9300255	0.602	rs1727306	chr12:123665695	A/G	cg05973401	chr12:123451056	ABCB9	0.49	5.49	0.32	9.51e-8	Neutrophil percentage of white cells;
CESC	cis	rs40363	0.672	rs1617722	chr16:3520806	C/T	cg22508957	chr16:3507546	NAT15	-0.56	-9.04	-0.49	3.28e-17	Tuberculosis;
CESC	cis	rs9462846	0.691	rs7744454	chr6:42914041	C/G	cg05552183	chr6:42928497	GNMT	0.52	6.02	0.35	5.77e-9	Blood protein levels;
CESC	cis	rs7809950	0.678	rs2237659	chr7:106847492	G/T	cg23024343	chr7:107201750	COG5	0.49	5.88	0.34	1.2e-8	Coronary artery disease;
CESC	cis	rs360071	0.841	rs1223246	chr1:226093362	T/C	cg17950169	chr1:226067900	TMEM63A	0.32	5.07	0.3	7.32e-7	Response to radiotherapy in prostate cancer (toxicity, rectal bleeding);
CESC	cis	rs9733	0.596	rs12072339	chr1:150686099	A/G	cg17724175	chr1:150552817	MCL1	0.45	7.31	0.41	3.23e-12	Tonsillectomy;
CESC	cis	rs4889855	0.511	rs9908700	chr17:78466594	A/G	cg16591659	chr17:78472290	NA	-0.53	-7.71	-0.43	2.56e-13	Fractional excretion of uric acid;
CESC	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.43	-5.8	-0.34	1.93e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs9584850	0.794	rs9630321	chr13:99106979	C/G	cg20750642	chr13:99100586	FARP1	-0.39	-5.86	-0.34	1.39e-8	Neuroticism;
CESC	cis	rs709400	0.567	rs28496120	chr14:103897899	C/T	cg12935359	chr14:103987150	CKB	-0.49	-7.09	-0.4	1.24e-11	Body mass index;
CESC	cis	rs12477438	0.677	rs12475034	chr2:99699464	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.66	-8.0	-0.44	3.96e-14	Chronic sinus infection;
CESC	cis	rs7149337	0.805	rs71422017	chr14:51612417	A/T	cg23942311	chr14:51606299	NA	0.48	8.24	0.45	8.16e-15	Cancer;
CESC	cis	rs2033711	0.870	rs11084545	chr19:58951693	G/C	cg00825309	chr19:58991885	ZNF446	-0.58	-8.31	-0.45	5.12e-15	Uric acid clearance;
CESC	cis	rs7666738	0.830	rs10017557	chr4:98983969	G/A	cg03467027	chr4:99064603	C4orf37	0.44	5.54	0.32	7.12e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6460942	0.915	rs7809263	chr7:12450589	C/G	cg06484146	chr7:12443880	VWDE	-0.7	-8.69	-0.47	3.72e-16	Coronary artery disease;
CESC	cis	rs644799	1.000	rs680134	chr11:95559517	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.54	6.73	0.38	1.06e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs7618915	0.547	rs11130313	chr3:52676190	A/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.5	0.37	3.92e-10	Bipolar disorder;
CESC	cis	rs5743618	0.537	rs7694115	chr4:38779094	A/G	cg02016764	chr4:38805732	TLR1	-0.32	-5.13	-0.3	5.66e-7	Asthma;Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs75804782	0.521	rs58568091	chr2:239430582	G/A	cg18131467	chr2:239335373	ASB1	-0.7	-5.44	-0.32	1.18e-7	Morning vs. evening chronotype;Chronotype;
CESC	cis	rs4077515	0.967	rs4078099	chr9:139267533	G/A	cg14169450	chr9:139327907	INPP5E	0.36	5.21	0.3	3.84e-7	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs6032067	0.929	rs2143944	chr20:43819370	G/A	cg11264863	chr20:43835661	SEMG1	0.49	5.29	0.31	2.5e-7	Blood protein levels;
CESC	trans	rs7615952	0.932	rs13321217	chr3:125631771	G/A	cg07211511	chr3:129823064	LOC729375	-1.09	-15.57	-0.69	2.97e-39	Blood pressure (smoking interaction);
CESC	cis	rs13385	0.723	rs28722951	chr5:139609952	T/G	cg26211634	chr5:139558579	C5orf32	0.47	5.19	0.3	4.23e-7	Atrial fibrillation;
CESC	cis	rs3806843	0.676	rs778594	chr5:140027304	T/C	cg16179182	chr5:140090404	VTRNA1-1	0.44	5.57	0.32	6.19e-8	Depressive symptoms (multi-trait analysis);
CESC	cis	rs6540559	0.808	rs11119358	chr1:210042456	T/C	cg09509183	chr1:209979624	IRF6	0.44	5.07	0.3	7.39e-7	Cleft lip with or without cleft palate;
CESC	cis	rs3740909	1.000	rs3740911	chr11:125889755	C/T	cg10589353	chr11:126294637	KIRREL3	0.49	5.66	0.33	3.99e-8	Blood protein levels;
CESC	cis	rs853679	0.513	rs9468296	chr6:28113730	A/G	cg20151795	chr6:28129481	ZNF389	0.45	5.72	0.33	2.9e-8	Depression;
CESC	cis	rs10504229	1.000	rs66886949	chr8:58187613	A/G	cg24829409	chr8:58192753	C8orf71	-0.76	-9.93	-0.52	5.87e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs12477438	0.700	rs12467679	chr2:99654449	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-10.57	-0.54	5.22e-22	Chronic sinus infection;
CESC	trans	rs10506458	0.834	rs12426893	chr12:63388120	G/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.31	-17.59	-0.73	2.03e-46	Hemostatic factors and hematological phenotypes;
CESC	cis	rs6430585	0.528	rs114760827	chr2:136661110	G/A	cg07169764	chr2:136633963	MCM6	1.23	16.5	0.71	1.49e-42	Corneal structure;
CESC	cis	rs1799949	1.000	rs11652332	chr17:41295489	G/A	cg23758822	chr17:41437982	NA	1.01	15.2	0.68	5.81e-38	Menopause (age at onset);
CESC	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg23708337	chr7:1209742	NA	0.53	5.34	0.31	1.98e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2479106	0.509	rs4836938	chr9:126367435	G/T	cg16191174	chr9:126692580	DENND1A	0.38	5.19	0.3	4.28e-7	Polycystic ovary syndrome;
CESC	trans	rs1814175	0.867	rs7926002	chr11:49616018	A/G	cg15704280	chr7:45808275	SEPT13	-0.98	-16.77	-0.72	1.6700000000000001e-43	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23838375	chr17:72732946	RAB37	0.52	6.06	0.35	4.67e-9	Gut microbiome composition (summer);
CESC	cis	rs4835473	0.736	rs6851661	chr4:144771740	T/G	cg25736465	chr4:144833511	NA	0.45	6.65	0.38	1.67e-10	Immature fraction of reticulocytes;
CESC	trans	rs561341	0.824	rs1978115	chr17:30220776	A/C	cg27661571	chr11:113659931	NA	-0.62	-6.35	-0.36	9.13e-10	Hip circumference adjusted for BMI;
CESC	cis	rs9300255	0.602	rs1626899	chr12:123708063	A/G	cg19016782	chr12:123741754	C12orf65	-0.45	-6.55	-0.37	2.97e-10	Neutrophil percentage of white cells;
CESC	cis	rs72781680	1.000	rs12616985	chr2:24165511	A/C	cg08917208	chr2:24149416	ATAD2B	0.94	8.58	0.47	7.87e-16	Lymphocyte counts;
CESC	cis	rs3820068	0.581	rs6669417	chr1:15922371	G/T	cg16988262	chr1:15930761	NA	0.33	5.29	0.31	2.52e-7	Systolic blood pressure;
CESC	cis	rs4604732	0.678	rs74154674	chr1:247625685	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.57	7.17	0.4	7.39e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs514406	0.644	rs7529978	chr1:53204705	G/A	cg08736216	chr1:53307985	ZYG11A	0.3	5.05	0.3	8.16e-7	Monocyte count;
CESC	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg05313129	chr8:58192883	C8orf71	-0.49	-5.32	-0.31	2.23e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs7312933	1.000	rs11181328	chr12:42504679	T/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.44	5.72	0.33	2.94e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs9926296	0.605	rs886952	chr16:89836781	G/A	cg04287289	chr16:89883240	FANCA	0.89	15.41	0.69	1.1e-38	Vitiligo;
CESC	cis	rs61931739	0.517	rs7958856	chr12:34294737	T/C	cg19457237	chr12:34500585	NA	-0.38	-5.19	-0.3	4.19e-7	Morning vs. evening chronotype;
CESC	cis	rs2836974	0.931	rs12151994	chr21:40690397	A/C	cg11644478	chr21:40555479	PSMG1	0.99	15.22	0.68	5.25e-38	Cognitive function;
CESC	trans	rs60843830	1.000	rs11553746	chr2:272203	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.68	8.45	0.46	1.94e-15	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg23131131	chr22:24373011	LOC391322	-0.7	-9.86	-0.52	9.82e-20	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs2243480	1.000	rs34136756	chr7:65381256	A/G	cg12463550	chr7:65579703	CRCP	0.7	5.58	0.32	5.87e-8	Diabetic kidney disease;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg15027563	chr16:11038165	CLEC16A	0.52	6.95	0.39	2.85e-11	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs911555	0.673	rs7144271	chr14:103890674	A/G	cg12935359	chr14:103987150	CKB	-0.54	-7.83	-0.43	1.2e-13	Intelligence (multi-trait analysis);
CESC	cis	rs12545109	0.800	rs1837620	chr8:57399473	C/A	cg09654669	chr8:57350985	NA	-0.57	-7.22	-0.41	5.35e-12	Obesity-related traits;
CESC	cis	rs4889855	0.530	rs4890052	chr17:78564245	G/T	cg16591659	chr17:78472290	NA	0.34	5.62	0.33	4.9e-8	Fractional excretion of uric acid;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg20510080	chr22:51021491	LOC100144603;CHKB-CPT1B;CHKB	-0.5	-6.2	-0.36	2.21e-9	Asthma;
CESC	cis	rs4665809	0.652	rs10779956	chr2:26405985	A/G	cg25036284	chr2:26402008	FAM59B	-0.84	-9.51	-0.5	1.19e-18	Gut microbiome composition (summer);
CESC	cis	rs4280164	0.945	rs2281472	chr14:24775846	C/T	cg16194253	chr14:24768981	DHRS1;C14orf21	0.51	5.77	0.33	2.26e-8	Parent of origin effect on language impairment (paternal);
CESC	cis	rs10504229	1.000	rs59797486	chr8:58174435	T/C	cg22535103	chr8:58192502	C8orf71	-0.96	-12.41	-0.61	3.38e-28	Developmental language disorder (linguistic errors);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01198338	chr7:75508496	RHBDD2	0.53	6.15	0.35	2.78e-9	Gut microbiome composition (summer);
CESC	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg04234412	chr22:24373322	LOC391322	-0.66	-9.7	-0.51	3.04e-19	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs9894429	0.789	rs7213849	chr17:79567610	C/T	cg18240062	chr17:79603768	NPLOC4	-0.89	-13.32	-0.63	2.53e-31	Eye color traits;
CESC	cis	rs11677416	1.000	rs17561	chr2:113537223	C/A	cg27083787	chr2:113543245	IL1A	0.6	7.49	0.42	1.01e-12	Response to antipsychotic treatment in schizophrenia (working memory);
CESC	cis	rs4409675	0.597	rs1000431	chr1:28225114	C/T	cg23691781	chr1:28212827	C1orf38	0.28	5.63	0.33	4.7e-8	Corneal astigmatism;
CESC	cis	rs875971	0.660	rs801192	chr7:66031952	C/G	cg10691866	chr7:65817282	TPST1	0.31	5.06	0.3	7.76e-7	Aortic root size;
CESC	cis	rs17666538	0.535	rs168062	chr8:632444	T/A	cg13264159	chr8:625131	ERICH1	-0.71	-5.68	-0.33	3.47e-8	IgG glycosylation;
CESC	cis	rs2929278	0.562	rs8033846	chr15:44035363	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	-0.47	-7.48	-0.42	1.09e-12	Schizophrenia;
CESC	cis	rs7551222	0.716	rs4951078	chr1:204491802	A/G	cg20240347	chr1:204465584	NA	-0.28	-5.57	-0.32	6.31e-8	Schizophrenia;
CESC	cis	rs1799949	0.602	rs4600503	chr17:41414324	C/G	cg05368731	chr17:41323189	NBR1	0.79	10.96	0.56	2.64e-23	Menopause (age at onset);
CESC	cis	rs62158211	0.955	rs1823125	chr2:114090412	C/T	cg17784749	chr2:114082611	LOC440839	-0.76	-9.17	-0.49	1.32e-17	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;
CESC	cis	rs7586673	0.930	rs6432667	chr2:161905001	T/C	cg16506815	chr2:162101123	NA	0.47	6.17	0.35	2.54e-9	Intelligence (multi-trait analysis);
CESC	cis	rs2797160	1.000	rs1777225	chr6:126018270	T/C	cg05901451	chr6:126070800	HEY2	0.46	6.48	0.37	4.56e-10	Endometrial cancer;
CESC	cis	rs9488822	0.702	rs10872141	chr6:116323246	C/A	cg18764771	chr6:116381957	FRK	0.22	5.44	0.32	1.21e-7	Cholesterol, total;LDL cholesterol;
CESC	cis	rs7618915	0.501	rs3852066	chr3:52621839	C/T	cg18099408	chr3:52552593	STAB1	-0.3	-5.11	-0.3	6.18e-7	Bipolar disorder;
CESC	cis	rs4253772	0.872	rs45576140	chr22:46638216	C/G	cg00784671	chr22:46762841	CELSR1	-0.51	-5.27	-0.31	2.87e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs881375	0.715	rs10985073	chr9:123643855	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.52	7.71	0.43	2.59e-13	Rheumatoid arthritis;
CESC	cis	rs6502050	0.835	rs10163482	chr17:80110394	C/A	cg23985595	chr17:80112537	CCDC57	-0.41	-6.41	-0.37	6.76e-10	Life satisfaction;
CESC	cis	rs4713118	0.662	rs9468277	chr6:28028390	C/A	cg23161317	chr6:28129485	ZNF389	0.49	6.19	0.36	2.28e-9	Parkinson's disease;
CESC	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg07677032	chr17:61819896	STRADA	0.44	5.9	0.34	1.1e-8	Prudent dietary pattern;
CESC	cis	rs3858526	0.959	rs4758219	chr11:5951846	G/C	cg02574844	chr11:5959923	NA	-0.44	-5.53	-0.32	7.81e-8	DNA methylation (variation);
CESC	cis	rs6840360	0.593	rs3805356	chr4:152680701	C/T	cg22705602	chr4:152727874	NA	0.35	5.03	0.3	9.23e-7	Intelligence (multi-trait analysis);
CESC	cis	rs74181299	0.819	rs2723087	chr2:65298282	T/A	cg05010058	chr2:65284262	CEP68	0.34	5.7	0.33	3.14e-8	Pulse pressure;
CESC	cis	rs7552404	1.000	rs11161521	chr1:76216330	T/C	cg03433033	chr1:76189801	ACADM	0.64	7.52	0.42	8.69e-13	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs35306767	0.903	rs4522091	chr10:874116	G/T	cg20503657	chr10:835505	NA	0.82	8.12	0.45	1.71e-14	Eosinophil percentage of granulocytes;
CESC	cis	rs2072499	0.750	rs72708291	chr1:156177285	A/T	cg25208724	chr1:156163844	SLC25A44	0.92	11.76	0.59	5.87e-26	Testicular germ cell tumor;
CESC	cis	rs10129255	0.518	rs7143784	chr14:107143294	A/G	cg07958169	chr14:107095056	NA	-0.53	-8.7	-0.47	3.54e-16	Kawasaki disease;
CESC	cis	rs7589342	0.899	rs11885225	chr2:106486548	T/C	cg16077055	chr2:106428750	NCK2	0.5	7.22	0.41	5.51e-12	Addiction;
CESC	cis	rs9611565	0.512	rs7291736	chr22:42124874	C/A	cg06481639	chr22:41940642	POLR3H	0.59	5.91	0.34	1.07e-8	Vitiligo;
CESC	cis	rs9811920	0.809	rs4928235	chr3:99706870	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.47	-7.66	-0.43	3.42e-13	Axial length;
CESC	cis	rs2836974	0.899	rs34978594	chr21:40580003	C/T	cg11644478	chr21:40555479	PSMG1	1.02	16.31	0.71	7.16e-42	Cognitive function;
CESC	cis	rs3741404	0.584	rs645461	chr11:63893694	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.76	-10.98	-0.56	2.34e-23	Platelet count;
CESC	cis	rs34172651	0.537	rs8049014	chr16:24698903	A/G	cg06028605	chr16:24865363	SLC5A11	0.45	6.74	0.38	9.92e-11	Intelligence (multi-trait analysis);
CESC	cis	rs2625529	0.775	rs62023342	chr15:72161305	A/C	cg16672083	chr15:72433130	SENP8	-0.4	-5.17	-0.3	4.53e-7	Red blood cell count;
CESC	cis	rs2243480	1.000	rs1723267	chr7:65473314	G/A	cg12463550	chr7:65579703	CRCP	0.72	5.81	0.34	1.8e-8	Diabetic kidney disease;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg09196146	chr14:90042364	PRO1768;FOXN3	-0.54	-7.49	-0.42	1.03e-12	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs9311474	0.659	rs1133415	chr3:52575831	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.39	5.69	0.33	3.29e-8	Electroencephalogram traits;
CESC	cis	rs514406	0.560	rs1889033	chr1:53211887	A/G	cg16325326	chr1:53192061	ZYG11B	-0.98	-17.59	-0.73	1.95e-46	Monocyte count;
CESC	cis	rs868036	0.681	rs28688285	chr15:68110297	T/C	cg08079166	chr15:68083412	MAP2K5	0.41	5.6	0.33	5.49e-8	Restless legs syndrome;
CESC	cis	rs16910800	0.689	rs7128636	chr11:23164689	C/T	cg20040320	chr11:23191996	NA	-0.64	-6.08	-0.35	4.07e-9	Cancer;
CESC	cis	rs9311474	0.508	rs2878628	chr3:52584715	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.57	-7.87	-0.44	9.06e-14	Electroencephalogram traits;
CESC	cis	rs4862750	0.914	rs11945845	chr4:187874136	T/C	cg22105103	chr4:187893119	NA	0.46	6.48	0.37	4.54e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs11098499	0.863	rs1010739	chr4:120463471	C/T	cg09307838	chr4:120376055	NA	0.92	12.91	0.62	6.68e-30	Corneal astigmatism;
CESC	cis	rs5750830	0.649	rs5757657	chr22:39798429	G/T	cg05872129	chr22:39784769	NA	-0.84	-11.68	-0.58	1.03e-25	Intelligence (multi-trait analysis);
CESC	cis	rs875971	0.964	rs9691480	chr7:65944306	A/C	cg12463550	chr7:65579703	CRCP	0.56	7.09	0.4	1.2e-11	Aortic root size;
CESC	cis	rs11677416	1.000	rs3783555	chr2:113531093	T/C	cg27083787	chr2:113543245	IL1A	0.41	5.17	0.3	4.53e-7	Response to antipsychotic treatment in schizophrenia (working memory);
CESC	cis	rs644799	0.672	rs61902245	chr11:95517737	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.78	11.75	0.59	6.11e-26	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs6496667	0.557	rs2601203	chr15:90958129	T/G	cg22089800	chr15:90895588	ZNF774	0.45	5.77	0.33	2.25e-8	Rheumatoid arthritis;
CESC	cis	rs4955124	0.730	rs58048871	chr3:32060067	G/A	cg05935571	chr3:32023257	ZNF860;OSBPL10	0.84	5.81	0.34	1.78e-8	Schizophrenia;
CESC	cis	rs3806843	0.900	rs2563254	chr5:140142701	T/C	cg26395211	chr5:140044315	WDR55	0.39	5.17	0.3	4.51e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs7100689	0.784	rs11202699	chr10:82131453	A/G	cg00277334	chr10:82204260	NA	-0.59	-7.45	-0.42	1.36e-12	Post bronchodilator FEV1;
CESC	cis	rs4665809	0.590	rs4665318	chr2:26424517	C/T	cg27170947	chr2:26402098	FAM59B	0.79	9.1	0.49	2.2e-17	Gut microbiome composition (summer);
CESC	cis	rs4604732	0.631	rs74154673	chr1:247625629	G/A	cg12758973	chr1:247694275	LOC148824;OR2C3	0.51	6.36	0.36	8.65e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs6942756	0.531	rs4731569	chr7:128930828	C/T	cg02491457	chr7:128862824	NA	0.45	6.39	0.37	7.43e-10	White matter hyperintensity burden;
CESC	cis	rs3785574	0.962	rs8079161	chr17:61808561	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.1	19.08	0.76	1.12e-51	Height;
CESC	cis	rs11252926	0.599	rs11252213	chr10:454694	C/T	cg03684893	chr10:554711	DIP2C	-0.37	-5.36	-0.31	1.79e-7	Psychosis in Alzheimer's disease;
CESC	cis	rs9322193	0.962	rs9322223	chr6:150122645	G/A	cg05861140	chr6:150128134	PCMT1	-0.35	-5.07	-0.3	7.45e-7	Lung cancer;
CESC	cis	rs7666738	0.830	rs13101352	chr4:98957544	C/T	cg03676636	chr4:99064102	C4orf37	0.33	5.11	0.3	6.05e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4969178	0.930	rs12452576	chr17:76386037	A/C	cg05887092	chr17:76393375	PGS1	0.57	9.02	0.48	3.85e-17	HDL cholesterol levels;
CESC	cis	rs9291683	0.527	rs3822247	chr4:10094671	G/A	cg00071950	chr4:10020882	SLC2A9	-0.66	-10.55	-0.54	6.11e-22	Bone mineral density;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26985912	chr7:76179317	LOC100133091	-0.53	-6.23	-0.36	1.86e-9	Gut microbiome composition (summer);
CESC	cis	rs6598955	0.670	rs7531518	chr1:26539749	T/C	cg04990556	chr1:26633338	UBXN11	-0.75	-10.63	-0.55	3.15e-22	Obesity-related traits;
CESC	cis	rs4727027	0.870	rs11525060	chr7:148801091	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.42	5.25	0.31	3.08e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs11792861	0.781	rs28361152	chr9:111727529	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.51	6.64	0.38	1.79e-10	Menarche (age at onset);
CESC	cis	rs875971	1.000	rs6963646	chr7:65685767	T/C	cg10691866	chr7:65817282	TPST1	0.33	5.5	0.32	8.76e-8	Aortic root size;
CESC	cis	rs6120849	0.754	rs6088667	chr20:33566722	A/C	cg24642439	chr20:33292090	TP53INP2	0.63	6.55	0.37	2.89e-10	Protein C levels;
CESC	trans	rs11098499	0.908	rs28559989	chr4:120386627	C/T	cg25214090	chr10:38739885	LOC399744	0.7	9.93	0.52	5.63e-20	Corneal astigmatism;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00219956	chr16:30794205	ZNF629	-0.64	-7.63	-0.42	4.27e-13	Gut microbiome composition (summer);
CESC	trans	rs453301	0.624	rs330056	chr8:9089695	A/T	cg06636001	chr8:8085503	FLJ10661	-0.52	-6.7	-0.38	1.24e-10	Joint mobility (Beighton score);
CESC	cis	rs34779708	0.966	rs4934736	chr10:35496868	G/A	cg03585969	chr10:35415529	CREM	0.75	9.92	0.52	6.22e-20	Inflammatory bowel disease;Crohn's disease;
CESC	trans	rs9951602	1.000	rs9949784	chr18:76649994	A/G	cg02800362	chr5:177631904	HNRNPAB	0.63	6.87	0.39	4.65e-11	Obesity-related traits;
CESC	cis	rs863345	0.933	rs1418843	chr1:158450382	A/G	cg12129480	chr1:158549410	OR10X1	0.31	6.3	0.36	1.25e-9	Pneumococcal bacteremia;
CESC	cis	rs1580019	0.587	rs6972365	chr7:32548931	T/A	cg06627557	chr7:32535165	LSM5;AVL9	1.06	18.8	0.76	1.12e-50	Cognitive ability;
CESC	cis	rs7208859	0.524	rs73988172	chr17:29086332	A/C	cg13385521	chr17:29058706	SUZ12P	0.81	6.44	0.37	5.52e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs75229567	0.618	rs11177853	chr12:70184924	A/G	cg10114359	chr12:70132523	RAB3IP	1.34	8.39	0.46	3.03e-15	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
CESC	cis	rs13096760	1	rs13096760	chr3:49476806	T/C	cg02487422	chr3:49467188	NICN1	0.56	8.15	0.45	1.49e-14	Intelligence (multi-trait analysis);
CESC	cis	rs17125944	0.505	rs75194546	chr14:53212069	A/C	cg13660082	chr14:53194042	PSMC6	-0.68	-5.94	-0.34	8.96e-9	Alzheimer's disease (late onset);
CESC	cis	rs55882075	0.967	rs59666900	chr5:179147641	C/T	cg14593053	chr5:179126677	CANX	0.45	5.99	0.35	6.99e-9	Monocyte percentage of white cells;
CESC	cis	rs34172651	0.517	rs3803716	chr16:24802325	C/T	cg06028605	chr16:24865363	SLC5A11	0.55	8.13	0.45	1.62e-14	Intelligence (multi-trait analysis);
CESC	cis	rs7605827	0.930	rs1035247	chr2:15617846	T/A	cg19274914	chr2:15703543	NA	0.36	6.42	0.37	6.38e-10	Educational attainment (years of education);
CESC	trans	rs5756813	0.727	rs4239889	chr22:38140352	T/G	cg19894588	chr14:64061835	NA	-0.66	-7.81	-0.43	1.35e-13	Optic cup area;Vertical cup-disc ratio;
CESC	cis	rs10392	0.543	rs4300896	chr20:37580130	A/C	cg27552599	chr20:37590471	DHX35	0.39	5.69	0.33	3.39e-8	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
CESC	cis	rs3126085	0.935	rs11204947	chr1:152218257	G/T	cg26876637	chr1:152193138	HRNR	-0.45	-5.11	-0.3	6.14e-7	Atopic dermatitis;
CESC	cis	rs4664304	1.000	rs3806603	chr2:160761808	T/C	cg03641300	chr2:160917029	PLA2R1	-0.48	-6.78	-0.38	8.02e-11	Crohn's disease;Inflammatory bowel disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09447007	chr7:43769356	C7orf44	-0.58	-6.55	-0.37	2.9e-10	Gut microbiome composition (summer);
CESC	trans	rs2727020	0.615	rs10128582	chr11:49447424	C/T	cg03929089	chr4:120376271	NA	-0.81	-12.59	-0.61	8.43e-29	Coronary artery disease;
CESC	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.6	0.38	2.17e-10	Prudent dietary pattern;
CESC	cis	rs4835473	0.897	rs7687317	chr4:144630163	T/A	cg25736465	chr4:144833511	NA	0.4	6.17	0.35	2.59e-9	Immature fraction of reticulocytes;
CESC	cis	rs7520050	0.966	rs7522601	chr1:46419021	G/A	cg24296786	chr1:45957014	TESK2	0.44	5.49	0.32	9.54e-8	Red blood cell count;Reticulocyte count;
CESC	cis	rs72634258	0.554	rs4908704	chr1:7918904	A/G	cg00042356	chr1:8021962	PARK7	0.58	5.55	0.32	6.83e-8	Inflammatory bowel disease;
CESC	cis	rs8141529	0.584	rs58004020	chr22:29257050	A/T	cg02153584	chr22:29168773	CCDC117	0.61	8.55	0.46	1.03e-15	Lymphocyte counts;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg06812225	chr1:204485782	MDM4	0.46	6.49	0.37	4.15e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs7208859	0.673	rs9912122	chr17:29140716	C/A	cg19761014	chr17:28927070	LRRC37B2	0.68	6.72	0.38	1.11e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs6460942	1.000	rs7796485	chr7:12405676	G/A	cg06484146	chr7:12443880	VWDE	-0.79	-8.75	-0.47	2.47e-16	Coronary artery disease;
CESC	cis	rs853679	0.517	rs9393896	chr6:28127703	C/T	cg22143856	chr6:28129313	ZNF389	0.49	6.21	0.36	2.02e-9	Depression;
CESC	cis	rs611744	0.647	rs589347	chr8:109253929	T/A	cg21045802	chr8:109455806	TTC35	0.49	6.06	0.35	4.71e-9	Dupuytren's disease;
CESC	cis	rs875971	0.545	rs2420612	chr7:66001812	G/A	cg11764359	chr7:65958608	NA	0.84	9.72	0.51	2.63e-19	Aortic root size;
CESC	cis	rs7927771	0.832	rs1317164	chr11:47419757	G/T	cg18512352	chr11:47633146	NA	-0.52	-7.57	-0.42	6.2e-13	Subjective well-being;
CESC	cis	rs2228479	0.850	rs2238532	chr16:89863672	T/C	cg04013166	chr16:89971882	TCF25	0.76	6.49	0.37	4.31e-10	Skin colour saturation;
CESC	cis	rs9913156	0.707	rs72835625	chr17:4560274	G/A	cg00122941	chr17:4613640	ARRB2	0.85	9.99	0.52	3.79e-20	Lymphocyte counts;
CESC	cis	rs7044106	0.791	rs7036766	chr9:123479621	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.84	13.61	0.64	2.42e-32	Hip circumference adjusted for BMI;
CESC	cis	rs7666738	0.830	rs13113899	chr4:99050422	T/C	cg03676636	chr4:99064102	C4orf37	0.33	5.04	0.3	8.51e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6460942	0.915	rs6460907	chr7:12304449	G/A	cg02935154	chr7:12443704	VWDE	-0.4	-5.54	-0.32	7.17e-8	Coronary artery disease;
CESC	cis	rs2276314	1.000	rs16967317	chr18:33573400	A/G	cg19628046	chr18:33552617	C18orf21	0.53	5.87	0.34	1.31e-8	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs7208859	0.623	rs9916725	chr17:29107471	A/C	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.91e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs2963155	0.518	rs853184	chr5:142640901	C/T	cg17617527	chr5:142782415	NR3C1	0.85	7.47	0.42	1.2e-12	Breast cancer;
CESC	cis	rs4819052	0.851	rs13052344	chr21:46676101	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.76	10.1	0.53	1.62e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs6696846	0.936	rs6662930	chr1:205041465	T/C	cg00857998	chr1:205179979	DSTYK	0.55	7.15	0.4	8.5e-12	Red blood cell count;
CESC	cis	rs477895	0.938	rs28395875	chr11:64024048	G/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.73	6.41	0.37	6.72e-10	Mean platelet volume;
CESC	trans	rs10488821	0.648	rs544625	chr11:30516496	A/G	cg04407762	chr4:113442791	NA	-0.39	-6.33	-0.36	1.04e-9	QRS complex (12-leadsum);
CESC	cis	rs9291683	0.588	rs35099040	chr4:10018839	T/C	cg00071950	chr4:10020882	SLC2A9	0.9	16.87	0.72	7.08e-44	Bone mineral density;
CESC	cis	rs4927850	1.000	rs7630875	chr3:195753766	A/G	cg01181863	chr3:195395398	SDHAP2	-0.46	-5.34	-0.31	2.01e-7	Pancreatic cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19062112	chr14:103059054	RCOR1	0.59	6.18	0.35	2.41e-9	Gut microbiome composition (summer);
CESC	cis	rs62103177	0.608	rs34383580	chr18:77833263	A/G	cg12964065	chr18:77638022	KCNG2	-0.45	-5.28	-0.31	2.72e-7	Opioid sensitivity;
CESC	cis	rs7618501	0.699	rs2681781	chr3:49898273	A/G	cg24110177	chr3:50126178	RBM5	-0.45	-6.04	-0.35	5.06e-9	Intelligence (multi-trait analysis);
CESC	cis	rs9916302	0.904	rs8066704	chr17:37477218	C/T	cg19468946	chr17:37922297	IKZF3	0.41	5.25	0.31	3.18e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs9443189	0.570	rs276684	chr6:76427065	A/G	cg01950844	chr6:76311363	SENP6	-0.85	-8.25	-0.45	7.63e-15	Prostate cancer;
CESC	cis	rs2576037	0.583	rs616900	chr18:44410849	T/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.34	5.51	0.32	8.39e-8	Personality dimensions;
CESC	cis	rs17253792	0.822	rs77408754	chr14:56082047	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.79	5.73	0.33	2.77e-8	Putamen volume;
CESC	cis	rs1832871	0.683	rs11752399	chr6:158711188	G/A	cg07165851	chr6:158734300	TULP4	0.6	6.59	0.38	2.33e-10	Height;
CESC	cis	rs2274273	0.870	rs6573009	chr14:55682324	A/C	cg04306507	chr14:55594613	LGALS3	0.29	5.85	0.34	1.47e-8	Protein biomarker;
CESC	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg01516881	chr6:292596	DUSP22	-0.84	-11.53	-0.58	3.34e-25	Menopause (age at onset);
CESC	cis	rs11031096	0.678	rs12222136	chr11:4180148	T/C	cg18678763	chr11:4115507	RRM1	-0.43	-5.95	-0.34	8.24e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	cis	rs6088580	0.634	rs4911418	chr20:32994257	G/A	cg24642439	chr20:33292090	TP53INP2	-0.53	-6.99	-0.39	2.17e-11	Glomerular filtration rate (creatinine);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19201477	chr8:21776851	XPO7	-0.57	-6.21	-0.36	2.02e-9	Gut microbiome composition (summer);
CESC	cis	rs2404602	0.608	rs12439484	chr15:76602937	A/C	cg26408565	chr15:76604113	ETFA	-0.4	-5.81	-0.34	1.76e-8	Blood metabolite levels;
CESC	cis	rs765787	0.530	rs12904331	chr15:45518293	C/T	cg24006582	chr15:45444508	DUOX1	0.52	6.19	0.36	2.33e-9	Uric acid levels;
CESC	cis	rs5997397	0.934	rs6005863	chr22:29156448	A/G	cg02153584	chr22:29168773	CCDC117	0.55	7.4	0.41	1.76e-12	Red cell distribution width;
CESC	cis	rs77956314	0.515	rs4767490	chr12:117435016	A/G	cg25972092	chr12:117363249	FBXW8	0.55	6.04	0.35	5.22e-9	Subcortical brain region volumes;Hippocampal volume;
CESC	cis	rs2415984	0.579	rs10140977	chr14:46955156	T/A	cg14871534	chr14:47121158	RPL10L	-0.35	-5.33	-0.31	2.05e-7	Number of children ever born;
CESC	trans	rs7618501	0.602	rs2240327	chr3:50113034	C/T	cg21659725	chr3:3221576	CRBN	0.55	7.93	0.44	5.99e-14	Intelligence (multi-trait analysis);
CESC	cis	rs7236492	0.532	rs3786184	chr18:77195885	A/C	cg15644404	chr18:77186268	NFATC1	-0.49	-5.57	-0.32	6.16e-8	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs870825	0.616	rs2696037	chr4:185610940	C/T	cg04058563	chr4:185651563	MLF1IP	-0.58	-6.29	-0.36	1.3e-9	Blood protein levels;
CESC	cis	rs763121	0.853	rs11704021	chr22:39074716	G/A	cg21395723	chr22:39101663	GTPBP1	0.42	5.3	0.31	2.39e-7	Menopause (age at onset);
CESC	cis	rs11645898	0.810	rs11646364	chr16:72108687	A/T	cg14768367	chr16:72042858	DHODH	-0.81	-6.78	-0.38	7.74e-11	Blood protein levels;
CESC	cis	rs2991971	0.776	rs12139364	chr1:45890155	T/C	cg24296786	chr1:45957014	TESK2	0.58	8.21	0.45	9.72e-15	High light scatter reticulocyte count;
CESC	cis	rs7949030	0.688	rs2849031	chr11:62365665	G/A	cg02375832	chr11:62437615	C11orf48	0.36	5.2	0.3	3.99e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15933130	chr5:137089362	HNRNPA0	0.62	7.38	0.41	2.05e-12	Gut microbiome composition (summer);
CESC	cis	rs858239	0.601	rs2141307	chr7:23191424	G/C	cg23682824	chr7:23144976	KLHL7	0.43	5.38	0.31	1.61e-7	Cerebrospinal fluid biomarker levels;
CESC	cis	rs35306767	0.903	rs11253458	chr10:882843	T/C	cg25019033	chr10:957182	NA	-0.57	-6.13	-0.35	3.22e-9	Eosinophil percentage of granulocytes;
CESC	trans	rs459571	0.629	rs441233	chr9:136876021	A/G	cg09836344	chr4:1243392	C4orf42;CTBP1	0.77	10.52	0.54	7.2e-22	Platelet distribution width;
CESC	cis	rs425277	0.606	rs12082939	chr1:2078922	C/T	cg23803603	chr1:2058230	PRKCZ	0.32	5.67	0.33	3.8e-8	Height;
CESC	cis	rs2072499	0.750	rs57056972	chr1:156159064	C/A	cg24450063	chr1:156163899	SLC25A44	0.98	11.99	0.59	9.64e-27	Testicular germ cell tumor;
CESC	cis	rs1799949	1.000	rs4793215	chr17:41318932	G/A	cg23758822	chr17:41437982	NA	1.04	15.84	0.7	3.15e-40	Menopause (age at onset);
CESC	cis	rs4819052	0.819	rs8134084	chr21:46693295	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.75	10.02	0.52	2.97e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs6570726	0.935	rs419850	chr6:145827281	A/G	cg05347473	chr6:146136440	FBXO30	0.49	6.71	0.38	1.21e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6500395	1.000	rs1872655	chr16:48670883	A/C	cg04672837	chr16:48644449	N4BP1	0.51	6.43	0.37	6.06e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs6460942	0.841	rs6968277	chr7:12443795	C/A	cg10578991	chr7:12443926	VWDE	-0.41	-5.48	-0.32	1.01e-7	Coronary artery disease;
CESC	cis	rs875971	0.660	rs1860468	chr7:66107252	T/C	cg06456125	chr7:65229604	NA	-0.4	-5.36	-0.31	1.84e-7	Aortic root size;
CESC	cis	rs9916302	0.610	rs11078902	chr17:37631883	C/G	cg15445000	chr17:37608096	MED1	0.41	6.77	0.38	8.24e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs589448	0.902	rs315124	chr12:69771727	G/A	cg20891283	chr12:69753455	YEATS4	0.98	16.88	0.72	6.74e-44	Cerebrospinal fluid biomarker levels;
CESC	cis	rs896854	0.625	rs13281709	chr8:95972819	T/A	cg16049864	chr8:95962084	TP53INP1	-0.65	-11.35	-0.57	1.31e-24	Type 2 diabetes;
CESC	cis	rs10504229	0.683	rs16921937	chr8:58145010	A/G	cg22535103	chr8:58192502	C8orf71	-0.78	-8.81	-0.48	1.69e-16	Developmental language disorder (linguistic errors);
CESC	cis	rs7772486	0.754	rs697055	chr6:146003790	C/G	cg05347473	chr6:146136440	FBXO30	0.51	6.05	0.35	5.03e-9	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9915657	0.870	rs4140902	chr17:70133750	A/G	cg09344028	chr17:70110421	NA	0.35	6.16	0.35	2.71e-9	Thyroid hormone levels;
CESC	cis	rs611744	0.870	rs2212703	chr8:109198401	G/C	cg21045802	chr8:109455806	TTC35	0.47	5.7	0.33	3.26e-8	Dupuytren's disease;
CESC	cis	rs9916302	0.904	rs12452880	chr17:37591149	G/C	cg15445000	chr17:37608096	MED1	0.41	6.81	0.39	6.45e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs6831352	0.959	rs6848050	chr4:100053733	T/C	cg13256891	chr4:100009986	ADH5	0.73	8.48	0.46	1.62e-15	Alcohol dependence;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03317280	chr1:228675123	RNF187	0.57	6.14	0.35	2.92e-9	Gut microbiome composition (summer);
CESC	cis	rs1707322	0.963	rs10890371	chr1:46390897	T/G	cg06784218	chr1:46089804	CCDC17	0.33	5.63	0.33	4.7e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs10479542	0.721	rs6894113	chr5:178974789	G/C	cg09060608	chr5:178986726	RUFY1	0.43	6.23	0.36	1.82e-9	Lung cancer;
CESC	cis	rs2070677	0.736	rs4498943	chr10:135422505	A/T	cg20169779	chr10:135381914	SYCE1	0.79	8.91	0.48	8.63e-17	Gout;
CESC	cis	rs2731664	0.819	rs449351	chr5:176872591	T/C	cg23176889	chr5:176863531	GRK6	-0.65	-11.37	-0.57	1.17e-24	Intelligence (multi-trait analysis);
CESC	trans	rs9467711	0.606	rs66823108	chr6:26377939	G/A	cg06606381	chr12:133084897	FBRSL1	-0.74	-6.44	-0.37	5.45e-10	Autism spectrum disorder or schizophrenia;
CESC	cis	rs7552404	0.960	rs61797339	chr1:76189946	G/T	cg03433033	chr1:76189801	ACADM	0.68	8.2	0.45	1.06e-14	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs9916302	0.904	rs10221223	chr17:37489100	T/G	cg20243544	chr17:37824526	PNMT	-0.46	-5.63	-0.33	4.6e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs11190604	1.000	rs7100386	chr10:102301417	C/T	cg07080220	chr10:102295463	HIF1AN	0.66	6.04	0.35	5.08e-9	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs1707322	1.000	rs7519181	chr1:46387829	G/C	cg06784218	chr1:46089804	CCDC17	0.33	5.63	0.33	4.7e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs1799949	1.000	rs4534897	chr17:41431808	A/G	cg23758822	chr17:41437982	NA	1.03	15.87	0.7	2.47e-40	Menopause (age at onset);
CESC	cis	rs2295359	0.824	rs4655679	chr1:67599657	A/G	cg17031739	chr1:67600172	NA	-0.45	-6.21	-0.36	2e-9	Psoriasis;
CESC	cis	rs1552244	1.000	rs9834980	chr3:10065528	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.89	11.97	0.59	1.14e-26	Alzheimer's disease;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg06713297	chr1:242011104	EXO1	0.52	6.77	0.38	8.21e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs5753618	0.539	rs695438	chr22:31811876	G/C	cg02404636	chr22:31891804	SFI1	0.41	6.11	0.35	3.61e-9	Colorectal cancer;
CESC	cis	rs2154427	0.938	rs2833967	chr21:34191308	G/A	cg03746930	chr21:34165763	C21orf62;C21orf49	-0.52	-5.26	-0.31	2.94e-7	Bilirubin levels;
CESC	trans	rs6084875	0.600	rs2093387	chr20:4724223	C/A	cg10192164	chr16:30419175	ZNF771	-0.51	-6.18	-0.35	2.46e-9	Systemic lupus erythematosus;
CESC	cis	rs2235544	0.565	rs664848	chr1:54468321	C/T	cg25741118	chr1:54482237	LDLRAD1	0.23	5.66	0.33	4.02e-8	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
CESC	cis	rs7828089	0.715	rs11136029	chr8:22253485	A/G	cg12081754	chr8:22256438	SLC39A14	-0.57	-8.35	-0.46	3.79e-15	Verbal declarative memory;
CESC	cis	rs2075371	0.897	rs12667905	chr7:134000812	A/C	cg00033643	chr7:134001901	SLC35B4	0.41	5.26	0.31	2.91e-7	Mean platelet volume;
CESC	cis	rs3820928	0.874	rs7563644	chr2:227846932	A/G	cg11843606	chr2:227700838	RHBDD1	-0.45	-5.81	-0.34	1.77e-8	Pulmonary function;
CESC	cis	rs7474896	0.559	rs1212108	chr10:38094322	A/C	cg25427524	chr10:38739819	LOC399744	-0.48	-5.16	-0.3	4.76e-7	Obesity (extreme);
CESC	cis	rs17818399	0.962	rs7565274	chr2:46841861	G/T	cg06386533	chr2:46925753	SOCS5	0.49	5.66	0.33	3.97e-8	Height;
CESC	cis	rs9308731	0.591	rs10439381	chr2:111936459	A/G	cg04202892	chr2:111875749	ACOXL	0.41	5.66	0.33	3.94e-8	Chronic lymphocytic leukemia;
CESC	cis	rs12681366	0.564	rs2165405	chr8:95454307	A/T	cg13257157	chr8:95487014	RAD54B	0.43	5.14	0.3	5.45e-7	Nonsyndromic cleft lip with cleft palate;
CESC	cis	rs10504229	0.683	rs2318143	chr8:58114660	C/T	cg21724239	chr8:58056113	NA	0.58	5.95	0.34	8.29e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs40363	0.645	rs250633	chr16:3523002	C/T	cg05754148	chr16:3507555	NAT15	0.57	8.63	0.47	5.67e-16	Tuberculosis;
CESC	trans	rs10435719	0.753	rs9694940	chr8:11789858	G/C	cg15556689	chr8:8085844	FLJ10661	0.52	6.49	0.37	4.16e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
CESC	cis	rs78456975	0.527	rs11885279	chr2:1560633	T/C	cg26248373	chr2:1572462	NA	-0.58	-6.93	-0.39	3.29e-11	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs7833790	0.963	rs2400473	chr8:82703403	C/T	cg07697082	chr8:82753677	SNX16	0.37	5.18	0.3	4.36e-7	Diastolic blood pressure;
CESC	cis	rs8077577	0.945	rs8069094	chr17:18096528	C/T	cg16794390	chr17:18148240	FLII	0.42	5.87	0.34	1.32e-8	Obesity-related traits;
CESC	cis	rs7582720	1.000	rs72936847	chr2:203774748	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.39	0.41	1.96e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22542702	chr2:132384461	NA	-0.47	-6.59	-0.38	2.42e-10	Gut microbiome composition (summer);
CESC	cis	rs7312774	0.748	rs4964191	chr12:107306497	G/A	cg16260113	chr12:107380972	MTERFD3	0.64	6.13	0.35	3.11e-9	Severe influenza A (H1N1) infection;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13942016	chr11:47447463	PSMC3	0.6	7.51	0.42	8.99e-13	Gut microbiome composition (summer);
CESC	cis	rs9929218	0.954	rs10163398	chr16:68823124	C/G	cg02972257	chr16:68554789	NA	0.45	5.39	0.31	1.58e-7	Colorectal cancer;
CESC	trans	rs2727020	1.000	rs2727020	chr11:49111407	C/G	cg15704280	chr7:45808275	SEPT13	0.77	10.53	0.54	6.76e-22	Coronary artery disease;
CESC	cis	rs36051895	0.632	rs10815171	chr9:5172567	G/A	cg02405213	chr9:5042618	JAK2	-0.51	-6.41	-0.37	6.63e-10	Pediatric autoimmune diseases;
CESC	cis	rs3768617	0.510	rs4491025	chr1:183065183	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.88	14.24	0.66	1.45e-34	Fuchs's corneal dystrophy;
CESC	cis	rs9543976	0.920	rs9543972	chr13:76121675	T/C	cg01531495	chr13:76123901	UCHL3	0.5	5.14	0.3	5.41e-7	Diabetic retinopathy;
CESC	cis	rs7044106	0.791	rs10984998	chr9:123481516	G/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.38	6.14	0.35	3.06e-9	Hip circumference adjusted for BMI;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09516144	chr16:15982637	C16orf63	0.62	6.96	0.39	2.69e-11	Gut microbiome composition (summer);
CESC	cis	rs2576037	0.796	rs6507718	chr18:44581284	G/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.45	5.88	0.34	1.24e-8	Personality dimensions;
CESC	cis	rs9911578	0.967	rs9894274	chr17:56977919	G/A	cg12560992	chr17:57184187	TRIM37	0.93	15.26	0.68	3.55e-38	Intelligence (multi-trait analysis);
CESC	cis	rs1790761	0.505	rs7927657	chr11:67346988	T/C	cg14500267	chr11:67383377	NA	-0.31	-5.12	-0.3	5.81e-7	Mean corpuscular volume;
CESC	trans	rs1814175	0.935	rs1827017	chr11:49632592	C/G	cg15704280	chr7:45808275	SEPT13	-1.0	-17.77	-0.74	4.61e-47	Height;
CESC	cis	rs7208859	0.623	rs216436	chr17:28922900	G/A	cg19761014	chr17:28927070	LRRC37B2	0.88	6.7	0.38	1.22e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs7089973	0.525	rs11196945	chr10:116600424	G/A	cg25233709	chr10:116636983	FAM160B1	0.38	6.08	0.35	4.13e-9	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	trans	rs916888	0.697	rs199516	chr17:44856485	C/T	cg01341218	chr17:43662625	NA	-0.86	-10.66	-0.55	2.59e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs28830936	0.510	rs12440605	chr15:42102285	A/G	cg17847044	chr15:42102381	MAPKBP1	0.43	7.48	0.42	1.12e-12	Diastolic blood pressure;
CESC	cis	rs4711336	0.935	rs3818525	chr6:33660779	A/G	cg14003231	chr6:33640908	ITPR3	0.31	5.29	0.31	2.56e-7	Height;
CESC	cis	rs10504229	0.593	rs16921589	chr8:58024387	C/A	cg24829409	chr8:58192753	C8orf71	-0.5	-6.08	-0.35	4.13e-9	Developmental language disorder (linguistic errors);
CESC	trans	rs55704346	0.534	rs17605302	chr4:25396907	C/T	cg01822600	chr1:245751692	KIF26B	0.42	6.12	0.35	3.41e-9	Tonsillectomy;
CESC	cis	rs7666738	0.830	rs1025203	chr4:99023073	G/A	cg17366294	chr4:99064904	C4orf37	0.6	8.39	0.46	2.99e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7264396	0.635	rs6058363	chr20:34505054	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.7	-9.89	-0.52	7.98e-20	Total cholesterol levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24034412	chr19:49122294	RPL18;SPHK2	0.59	7.22	0.41	5.37e-12	Gut microbiome composition (summer);
CESC	cis	rs7772486	0.654	rs702321	chr6:146006695	A/G	cg23711669	chr6:146136114	FBXO30	-0.9	-13.01	-0.62	2.84e-30	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4819052	0.851	rs28676615	chr21:46676576	G/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.47	5.84	0.34	1.49e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs1595825	0.891	rs2045244	chr2:198506466	C/T	cg10820045	chr2:198174542	NA	0.42	5.15	0.3	5.02e-7	Ulcerative colitis;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg02685945	chr6:22570146	HDGFL1	-0.53	-6.7	-0.38	1.26e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs9611565	0.879	rs4820437	chr22:41761290	T/C	cg03806693	chr22:41940476	POLR3H	-0.73	-8.87	-0.48	1.12e-16	Vitiligo;
CESC	cis	rs1005277	0.579	rs2472173	chr10:38374638	G/A	cg25517755	chr10:38738941	LOC399744	-0.48	-6.22	-0.36	1.94e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs9911578	0.967	rs4132925	chr17:56938016	C/G	cg05425664	chr17:57184151	TRIM37	0.49	6.83	0.39	5.89e-11	Intelligence (multi-trait analysis);
CESC	trans	rs7839040	0.698	rs4529421	chr8:82921979	A/G	cg14472086	chr9:107730925	NA	-0.49	-6.4	-0.37	6.9e-10	Response to methotrexate in juvenile idiopathic arthritis;
CESC	trans	rs9929218	0.679	rs9924886	chr16:68743939	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.79	-10.18	-0.53	9.51e-21	Colorectal cancer;
CESC	cis	rs1862618	0.853	rs252902	chr5:56116085	A/G	cg24549020	chr5:56110836	MAP3K1	0.64	7.41	0.41	1.65e-12	Initial pursuit acceleration;
CESC	cis	rs362272	0.524	rs10937924	chr4:3374898	T/C	cg08886695	chr4:3369023	RGS12	-0.39	-5.4	-0.31	1.48e-7	Serum sulfate level;
CESC	cis	rs9309473	1.000	rs10169714	chr2:73808773	T/G	cg20560298	chr2:73613845	ALMS1	-0.54	-7.03	-0.4	1.71e-11	Metabolite levels;
CESC	cis	rs10789491	0.951	rs35050319	chr1:47103886	C/A	cg15501359	chr1:47185051	KIAA0494	-0.77	-8.1	-0.45	2.02e-14	Response to hepatitis C treatment;
CESC	cis	rs4253772	0.637	rs56017104	chr22:46651982	A/G	cg00784671	chr22:46762841	CELSR1	-0.52	-5.49	-0.32	9.2e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs7202877	0.706	rs37602	chr16:75505046	C/T	cg04384234	chr16:75411784	CFDP1	0.46	5.5	0.32	9e-8	Type 2 diabetes;Type 1 diabetes;
CESC	cis	rs9796	0.870	rs4244584	chr15:41259523	A/G	cg18705301	chr15:41695430	NDUFAF1	0.39	5.89	0.34	1.19e-8	Menopause (age at onset);
CESC	cis	rs2797160	1.000	rs4897152	chr6:126002400	A/G	cg05901451	chr6:126070800	HEY2	-0.46	-6.62	-0.38	1.94e-10	Endometrial cancer;
CESC	cis	rs61996546	0.622	rs12900771	chr15:26835235	G/A	cg15066197	chr15:26874202	GABRB3	-0.35	-5.07	-0.3	7.55e-7	Response to methotrexate in juvenile idiopathic arthritis;
CESC	cis	rs853679	0.517	rs1904841	chr6:28108085	C/T	cg12963246	chr6:28129442	ZNF389	0.6	8.3	0.45	5.21e-15	Depression;
CESC	cis	rs9393777	0.513	rs11967852	chr6:26612870	G/T	cg14345882	chr6:26364793	BTN3A2	0.41	5.36	0.31	1.78e-7	Intelligence (multi-trait analysis);
CESC	cis	rs769267	0.965	rs2074296	chr19:19373689	A/G	cg03709012	chr19:19516395	GATAD2A	0.93	13.21	0.63	6e-31	Tonsillectomy;
CESC	cis	rs4474465	0.688	rs7927494	chr11:78280578	G/A	cg27205649	chr11:78285834	NARS2	0.49	6.27	0.36	1.47e-9	Alzheimer's disease (survival time);
CESC	cis	rs7662987	0.517	rs2851260	chr4:100033574	C/T	cg12011299	chr4:100065546	ADH4	0.6	6.56	0.37	2.83e-10	Smoking initiation;
CESC	cis	rs875971	0.545	rs801212	chr7:66015630	C/G	cg18876405	chr7:65276391	NA	-0.5	-5.91	-0.34	1.05e-8	Aortic root size;
CESC	cis	rs4665809	0.590	rs6749046	chr2:26429451	C/G	cg26119090	chr2:26468346	HADHA;HADHB	1.09	13.26	0.63	4.06e-31	Gut microbiome composition (summer);
CESC	cis	rs12701220	0.696	rs12112029	chr7:1137889	G/A	cg26769984	chr7:1090371	C7orf50	0.65	7.25	0.41	4.53e-12	Bronchopulmonary dysplasia;
CESC	cis	rs7927592	0.673	rs498782	chr11:68275851	A/G	cg01657329	chr11:68192670	LRP5	-0.48	-6.37	-0.36	8.48e-10	Total body bone mineral density;
CESC	cis	rs67311347	1.000	rs954589	chr3:40444545	C/T	cg24209194	chr3:40518798	ZNF619	0.51	6.42	0.37	6.35e-10	Renal cell carcinoma;
CESC	cis	rs826838	0.967	rs7965656	chr12:38807244	G/A	cg13010199	chr12:38710504	ALG10B	0.6	8.24	0.45	8.03e-15	Heart rate;
CESC	cis	rs483180	0.512	rs597308	chr1:120214953	G/A	cg19096424	chr1:120255104	PHGDH	0.42	5.13	0.3	5.49e-7	Macular telangiectasia type 2;
CESC	cis	rs2635047	0.967	rs2684843	chr18:44726260	T/A	cg24371990	chr18:44770781	NA	0.34	5.39	0.31	1.58e-7	Educational attainment;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg14965979	chr2:44588995	PREPL;C2orf34	-0.46	-6.0	-0.35	6.46e-9	Fibrinogen levels;
CESC	cis	rs2066819	1.000	rs77032009	chr12:56679971	A/G	cg26804944	chr12:56660921	COQ10A	-0.85	-5.19	-0.3	4.22e-7	Psoriasis vulgaris;
CESC	cis	rs2204008	0.536	rs12368354	chr12:38042798	G/A	cg26384229	chr12:38710491	ALG10B	0.75	10.72	0.55	1.61e-22	Bladder cancer;
CESC	cis	rs72781680	1.000	rs56205282	chr2:24221317	C/T	cg08917208	chr2:24149416	ATAD2B	1.1	9.67	0.51	3.96e-19	Lymphocyte counts;
CESC	cis	rs763121	0.819	rs3747173	chr22:39069045	A/G	cg06544989	chr22:39130855	UNC84B	0.5	8.88	0.48	1.05e-16	Menopause (age at onset);
CESC	cis	rs10883723	0.810	rs2296582	chr10:104244139	G/T	ch.10.2196322F	chr10:104248062	ACTR1A	0.43	5.43	0.32	1.29e-7	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs2463822	0.583	rs17709552	chr11:62040519	A/G	cg06239285	chr11:62104954	ASRGL1	-1.06	-8.68	-0.47	4.09e-16	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs73001065	0.711	rs58489806	chr19:19456917	C/T	cg03709012	chr19:19516395	GATAD2A	0.99	6.91	0.39	3.51e-11	LDL cholesterol;
CESC	cis	rs7195044	0.538	rs78001411	chr16:7267998	C/T	cg07283511	chr16:7352896	A2BP1	-0.76	-5.32	-0.31	2.2e-7	Brain volume in infants (cerebrospinal fluid);
CESC	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg11905131	chr22:24372483	LOC391322	-0.72	-10.56	-0.54	5.46e-22	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs28386778	0.799	rs12450683	chr17:61984299	C/G	cg26338869	chr17:61819248	STRADA	0.64	8.7	0.47	3.66e-16	Prudent dietary pattern;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg15351736	chr11:111808104	DIXDC1	0.55	7.59	0.42	5.58e-13	Systemic lupus erythematosus;
CESC	cis	rs72781680	0.560	rs72781698	chr2:24271506	C/T	cg20701182	chr2:24300061	SF3B14	0.94	10.48	0.54	1.01e-21	Lymphocyte counts;
CESC	cis	rs2070488	0.965	rs1046048	chr3:38524742	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.94	17.48	0.73	5.01e-46	Electrocardiographic conduction measures;
CESC	trans	rs4950322	0.580	rs972368	chr1:146582724	C/G	cg04954894	chr8:38089920	DDHD2	-0.59	-6.23	-0.36	1.82e-9	Protein quantitative trait loci;
CESC	cis	rs13191362	1.000	rs34398656	chr6:162999612	G/T	cg06582575	chr6:163149167	PACRG;PARK2	0.79	8.31	0.45	5.17e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs958025	1	rs958025	chr15:78759348	C/T	cg24631222	chr15:78858424	CHRNA5	0.64	7.58	0.42	5.76e-13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
CESC	cis	rs7246865	0.906	rs11666569	chr19:17214073	A/G	cg19418318	chr19:17219073	MYO9B	-0.35	-5.94	-0.34	9e-9	Reticulocyte fraction of red cells;
CESC	cis	rs2845885	0.744	rs56271783	chr11:64004723	G/C	cg24431193	chr11:63883947	FLRT1;MACROD1	0.79	5.1	0.3	6.56e-7	Body mass index;
CESC	cis	rs7666738	0.830	rs13149346	chr4:99009933	C/T	cg05340658	chr4:99064831	C4orf37	0.8	12.51	0.61	1.52e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs8005677	0.828	rs2295682	chr14:23374862	C/T	cg01529538	chr14:23388837	RBM23	0.43	5.78	0.33	2.08e-8	Cognitive ability (multi-trait analysis);
CESC	cis	rs7208859	0.725	rs6505215	chr17:29189903	C/A	cg19761014	chr17:28927070	LRRC37B2	0.57	5.71	0.33	2.96e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs2243480	0.708	rs35310401	chr7:65390359	A/G	cg25894440	chr7:65020034	NA	-0.59	-5.07	-0.3	7.57e-7	Diabetic kidney disease;
CESC	cis	rs2236918	1.000	rs1635515	chr1:242017009	A/G	cg17736920	chr1:242011382	EXO1	0.74	10.16	0.53	1.04e-20	Menopause (age at onset);
CESC	cis	rs6815814	0.950	rs5743565	chr4:38805983	T/C	cg02016764	chr4:38805732	TLR1	-0.63	-7.26	-0.41	4.22e-12	Breast cancer;
CESC	cis	rs11958404	0.932	rs56204919	chr5:157431084	C/T	cg05962755	chr5:157440814	NA	0.62	6.56	0.37	2.74e-10	IgG glycosylation;
CESC	cis	rs2243480	1.000	rs35421653	chr7:65363429	C/A	cg25894440	chr7:65020034	NA	-0.61	-5.12	-0.3	5.87e-7	Diabetic kidney disease;
CESC	cis	rs2073300	0.609	rs17757228	chr20:23351288	A/T	cg16736954	chr20:23401023	NAPB	0.77	5.74	0.33	2.6e-8	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs2806561	0.704	rs2746560	chr1:23526279	G/A	cg12483005	chr1:23474871	LUZP1	0.43	6.55	0.37	2.93e-10	Height;
CESC	cis	rs8016982	0.633	rs7160342	chr14:81713427	G/C	cg01989461	chr14:81687754	GTF2A1	0.72	11.27	0.57	2.52e-24	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02266452	chr11:82905235	ANKRD42	0.57	6.17	0.35	2.59e-9	Gut microbiome composition (summer);
CESC	cis	rs9300255	0.602	rs1790095	chr12:123681222	G/A	cg05973401	chr12:123451056	ABCB9	0.49	5.44	0.32	1.2e-7	Neutrophil percentage of white cells;
CESC	cis	rs3096299	0.503	rs4785677	chr16:89555101	A/G	cg02034447	chr16:89574710	SPG7	0.43	5.2	0.3	4.09e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs10791323	0.572	rs10750551	chr11:133737462	G/A	cg03690763	chr11:133734501	NA	-0.31	-5.14	-0.3	5.36e-7	Childhood ear infection;
CESC	cis	rs7666738	0.791	rs2865958	chr4:99040732	G/T	cg03676636	chr4:99064102	C4orf37	0.33	5.12	0.3	5.93e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7267979	0.866	rs2424698	chr20:25256106	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.83	15.24	0.68	4.21e-38	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs3105593	1.000	rs11070805	chr15:50964192	G/A	cg08437265	chr15:50716283	USP8	0.45	5.93	0.34	9.66e-9	QT interval;
CESC	cis	rs4704187	0.687	rs6894048	chr5:74456838	A/G	cg03227963	chr5:74354835	NA	0.3	5.49	0.32	9.27e-8	Response to amphetamines;
CESC	cis	rs8099014	0.906	rs4940693	chr18:56101171	T/G	cg19312305	chr18:56117016	MIR122	-0.3	-5.55	-0.32	6.75e-8	Platelet count;
CESC	cis	rs7818345	0.967	rs6999786	chr8:19277817	G/A	cg11303988	chr8:19266685	CSGALNACT1	0.34	6.25	0.36	1.64e-9	Language performance in older adults (adjusted for episodic memory);
CESC	cis	rs916888	0.821	rs199514	chr17:44856881	G/A	cg15921436	chr17:44337874	NA	-0.72	-7.88	-0.44	8.53e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs3858526	0.755	rs10769368	chr11:5962084	C/T	cg13902645	chr11:5959945	NA	0.48	6.02	0.35	5.9e-9	DNA methylation (variation);
CESC	cis	rs1552244	0.748	rs9862221	chr3:10059658	G/T	cg08888203	chr3:10149979	C3orf24	0.51	6.21	0.36	2.07e-9	Alzheimer's disease;
CESC	cis	rs13191362	0.872	rs13215538	chr6:163037975	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.54	6.07	0.35	4.34e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs6496667	0.779	rs2107436	chr15:91042921	A/T	cg13834112	chr15:90361639	NA	0.4	5.31	0.31	2.27e-7	Rheumatoid arthritis;
CESC	cis	rs17376456	1.000	rs9968749	chr5:93509559	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.6	5.05	0.3	8.13e-7	Diabetic retinopathy;
CESC	cis	rs514406	0.661	rs562641	chr1:53374666	C/T	cg06600287	chr1:53387719	ECHDC2	-0.27	-5.05	-0.3	8.13e-7	Monocyte count;
CESC	cis	rs698833	0.886	rs698775	chr2:44588941	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.56	7.11	0.4	1.07e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs74781061	1.000	rs6495117	chr15:74899500	T/C	cg17294928	chr15:75287854	SCAMP5	-0.51	-5.46	-0.32	1.11e-7	Endometriosis;
CESC	cis	rs7107174	1.000	rs2512544	chr11:77986371	A/T	cg02023728	chr11:77925099	USP35	0.47	6.49	0.37	4.19e-10	Testicular germ cell tumor;
CESC	cis	rs875971	0.895	rs7782806	chr7:65657897	C/T	cg12463550	chr7:65579703	CRCP	-0.49	-6.21	-0.36	2.06e-9	Aortic root size;
CESC	cis	rs2073300	0.609	rs3827086	chr20:23357331	C/T	cg12062639	chr20:23401060	NAPB	1.08	8.67	0.47	4.32e-16	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs4268898	1.000	rs10165445	chr2:24441698	C/T	cg06627628	chr2:24431161	ITSN2	0.66	8.08	0.44	2.26e-14	Asthma;
CESC	cis	rs763121	0.853	rs5757211	chr22:39051705	C/T	cg21395723	chr22:39101663	GTPBP1	0.43	5.33	0.31	2.09e-7	Menopause (age at onset);
CESC	cis	rs5769707	0.967	rs1018812	chr22:50010073	C/T	cg20744362	chr22:50050164	C22orf34	0.46	7.99	0.44	4.04e-14	Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs34734847	0.787	rs695948	chr12:121149596	A/G	cg21892295	chr12:121157589	UNC119B	-0.4	-6.43	-0.37	5.96e-10	Mean corpuscular volume;
CESC	cis	rs7618501	0.602	rs2245365	chr3:50097319	C/A	cg24110177	chr3:50126178	RBM5	0.52	7.18	0.4	6.85e-12	Intelligence (multi-trait analysis);
CESC	cis	rs2120019	1.000	rs12185102	chr15:75352201	G/A	cg17294928	chr15:75287854	SCAMP5	-0.65	-7.04	-0.4	1.67e-11	Blood trace element (Zn levels);
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg12732814	chr3:14220329	LSM3;XPC	0.47	6.11	0.35	3.54e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs5758659	0.652	rs133349	chr22:42428727	A/T	cg15557168	chr22:42548783	NA	-0.48	-7.54	-0.42	7.54e-13	Cognitive function;
CESC	cis	rs9487051	0.676	rs6568568	chr6:109597048	C/T	cg01475377	chr6:109611718	NA	-0.45	-7.04	-0.4	1.6e-11	Reticulocyte fraction of red cells;
CESC	cis	rs801193	0.569	rs11761542	chr7:66218196	G/A	cg18876405	chr7:65276391	NA	0.44	6.02	0.35	5.82e-9	Aortic root size;
CESC	cis	rs9549367	0.737	rs9549712	chr13:113902355	G/A	cg00898013	chr13:113819073	PROZ	-0.53	-7.21	-0.41	5.74e-12	Platelet distribution width;
CESC	cis	rs8114671	0.967	rs4911478	chr20:33782625	A/C	cg06115741	chr20:33292138	TP53INP2	-0.42	-5.11	-0.3	6.06e-7	Height;
CESC	cis	rs7267979	0.764	rs2474767	chr20:25246733	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.78	14.09	0.65	4.79e-34	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs372883	0.638	rs117213	chr21:30720536	G/A	cg24692254	chr21:30365293	RNF160	-0.53	-6.67	-0.38	1.5e-10	Pancreatic cancer;
CESC	cis	rs8180040	0.620	rs9844122	chr3:47108330	C/T	cg27129171	chr3:47204927	SETD2	0.66	9.71	0.51	2.81e-19	Colorectal cancer;
CESC	cis	rs6089584	0.888	rs6061982	chr20:60620673	C/T	cg13770153	chr20:60521292	NA	-0.44	-5.7	-0.33	3.2e-8	Body mass index;
CESC	cis	rs10927875	0.562	rs10803401	chr1:16147377	G/A	cg18973939	chr1:16164122	FLJ37453	0.38	5.66	0.33	3.9e-8	Dilated cardiomyopathy;
CESC	cis	rs116095464	0.558	rs9688045	chr5:254035	T/C	cg12570787	chr5:219185	SDHA;CCDC127	0.51	5.28	0.31	2.76e-7	Breast cancer;
CESC	trans	rs650950	0.528	rs646660	chr11:35528452	C/T	cg19905880	chr11:67049324	ADRBK1	-0.47	-6.41	-0.37	6.63e-10	Bronchopulmonary dysplasia;
CESC	cis	rs2637266	0.739	rs2583041	chr10:78439219	C/T	cg18941641	chr10:78392320	NA	-0.4	-7.36	-0.41	2.38e-12	Pulmonary function;
CESC	cis	rs4889855	0.614	rs7208670	chr17:78494220	T/G	cg16591659	chr17:78472290	NA	-0.49	-6.84	-0.39	5.35e-11	Fractional excretion of uric acid;
CESC	cis	rs67311347	1.000	rs11914297	chr3:40410070	T/C	cg09455208	chr3:40491958	NA	0.52	8.83	0.48	1.45e-16	Renal cell carcinoma;
CESC	cis	rs35110281	0.744	rs162373	chr21:44927107	C/A	cg04455712	chr21:45112962	RRP1B	-0.36	-5.57	-0.32	6.4e-8	Mean corpuscular volume;
CESC	trans	rs8057939	0.593	rs1437110	chr16:49404789	C/G	cg15532236	chr6:170188124	NA	-0.55	-6.43	-0.37	5.91e-10	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs12356475	0.710	rs10822686	chr10:67733250	C/T	cg17546822	chr22:41865178	ACO2;PHF5A	0.47	6.01	0.35	6.24e-9	Psoriatic arthritis;
CESC	cis	rs2235544	0.565	rs681660	chr1:54471189	G/A	cg25741118	chr1:54482237	LDLRAD1	0.23	5.88	0.34	1.25e-8	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
CESC	cis	rs7666738	0.830	rs11725095	chr4:99009711	T/A	cg03467027	chr4:99064603	C4orf37	0.44	5.63	0.33	4.57e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1580019	0.563	rs10486509	chr7:32585443	C/G	cg07520158	chr7:32535189	LSM5;AVL9	-0.54	-6.65	-0.38	1.66e-10	Cognitive ability;
CESC	cis	rs2439831	0.867	rs28461955	chr15:43661459	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	13.19	0.63	6.83e-31	Lung cancer in ever smokers;
CESC	cis	rs12699921	0.935	rs6461363	chr7:17992150	A/T	cg03009463	chr7:17980271	SNX13	0.42	5.45	0.32	1.16e-7	Fibrinogen levels;
CESC	cis	rs4065321	0.522	rs34648856	chr17:38149411	G/A	cg17344932	chr17:38183730	MED24;SNORD124	0.6	8.97	0.48	5.57e-17	White blood cell count (basophil);White blood cell count;
CESC	cis	rs7089973	0.584	rs4752255	chr10:116576790	C/T	cg23260525	chr10:116636907	FAM160B1	0.38	6.97	0.39	2.57e-11	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs10899021	1.000	rs11236201	chr11:74375633	A/G	cg25880958	chr11:74394337	NA	-0.73	-6.74	-0.38	9.58e-11	Response to metformin (IC50);
CESC	cis	rs2243480	1.000	rs34703416	chr7:65300642	A/G	cg18252515	chr7:66147081	NA	-1.06	-10.24	-0.53	6.08e-21	Diabetic kidney disease;
CESC	cis	rs6430585	0.591	rs75223002	chr2:136525309	G/T	cg07169764	chr2:136633963	MCM6	1.26	16.5	0.71	1.45e-42	Corneal structure;
CESC	cis	rs7666738	0.830	rs28594127	chr4:99001121	T/G	cg17366294	chr4:99064904	C4orf37	0.6	8.61	0.47	6.47e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7894051	1.000	rs11101721	chr10:135190358	C/G	cg20534287	chr10:135191450	PAOX	0.51	5.12	0.3	5.94e-7	Lifespan;
CESC	cis	rs986417	1.000	rs10130267	chr14:60944527	A/G	cg00859478	chr14:60978094	SIX6	0.45	5.06	0.3	7.79e-7	Gut microbiota (bacterial taxa);
CESC	cis	rs12410462	0.681	rs79461024	chr1:227568783	G/T	cg23173402	chr1:227635558	NA	0.68	5.72	0.33	2.88e-8	Major depressive disorder;
CESC	cis	rs10870270	1.000	rs7078692	chr10:133775370	T/A	cg26149184	chr10:133730230	NA	0.38	5.14	0.3	5.22e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs3892630	0.878	rs66788054	chr19:33190146	G/T	cg13157960	chr19:33183277	NUDT19	0.56	5.46	0.32	1.08e-7	Red blood cell traits;
CESC	cis	rs6429082	0.749	rs291362	chr1:235686690	T/A	cg26050004	chr1:235667680	B3GALNT2	0.66	8.77	0.47	2.23e-16	Adiposity;
CESC	cis	rs6952808	0.929	rs12667688	chr7:1931030	C/T	cg21782813	chr7:2030301	MAD1L1	0.44	6.17	0.35	2.54e-9	Bipolar disorder and schizophrenia;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg19006050	chr10:131904236	NA	0.45	6.05	0.35	4.96e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs1800469	1.000	rs1982072	chr19:41864509	T/A	cg08477640	chr19:41863820	B9D2	0.63	8.38	0.46	3.16e-15	Colorectal cancer;
CESC	cis	rs28829049	0.731	rs7537573	chr1:19373605	C/T	cg13387374	chr1:19411106	UBR4	0.46	5.78	0.33	2.06e-8	QRS duration in Tripanosoma cruzi seropositivity;
CESC	cis	rs11696501	0.739	rs6104252	chr20:44254323	G/A	cg11783356	chr20:44313418	WFDC10B	-0.35	-5.42	-0.32	1.35e-7	Brain structure;
CESC	cis	rs9733	0.596	rs72702536	chr1:150662574	C/T	cg18016565	chr1:150552671	MCL1	0.33	5.16	0.3	4.85e-7	Tonsillectomy;
CESC	cis	rs6582630	0.555	rs12828034	chr12:38274249	C/T	cg26384229	chr12:38710491	ALG10B	-0.46	-6.05	-0.35	4.85e-9	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg09177884	chr7:1199841	ZFAND2A	-0.5	-6.23	-0.36	1.83e-9	Longevity;Endometriosis;
CESC	cis	rs644799	1.000	rs505220	chr11:95563228	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	14.27	0.66	1.19e-34	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs950169	0.922	rs11630760	chr15:85113337	G/T	cg17507749	chr15:85114479	UBE2QP1	0.54	6.11	0.35	3.61e-9	Schizophrenia;
CESC	cis	rs9649213	0.613	rs10953256	chr7:97951886	G/C	cg24562669	chr7:97807699	LMTK2	0.48	7.1	0.4	1.13e-11	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs17125944	0.505	rs10483617	chr14:53202605	A/G	cg13660082	chr14:53194042	PSMC6	0.58	5.13	0.3	5.67e-7	Alzheimer's disease (late onset);
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg16218377	chr11:34073324	CAPRIN1	-0.47	-6.31	-0.36	1.19e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs2299587	0.762	rs62500086	chr8:17787808	T/A	cg08627089	chr8:17753878	FGL1	-0.37	-5.13	-0.3	5.63e-7	Economic and political preferences;
CESC	cis	rs7520050	0.966	rs4073846	chr1:46462881	C/T	cg03146154	chr1:46216737	IPP	0.46	5.95	0.34	8.28e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs10504229	1.000	rs17805549	chr8:58179653	T/C	cg22535103	chr8:58192502	C8orf71	-1.05	-13.27	-0.63	3.63e-31	Developmental language disorder (linguistic errors);
CESC	cis	rs61931739	0.559	rs4385974	chr12:34313128	G/C	cg19457237	chr12:34500585	NA	-0.42	-5.62	-0.33	4.83e-8	Morning vs. evening chronotype;
CESC	cis	rs6580649	1.000	rs7305954	chr12:48403530	C/T	cg24011408	chr12:48396354	COL2A1	0.38	5.09	0.3	6.71e-7	Lung cancer;
CESC	cis	rs11864453	0.645	rs7194668	chr16:72128207	G/C	cg16558253	chr16:72132732	DHX38	-0.53	-7.73	-0.43	2.27e-13	Fibrinogen levels;
CESC	cis	rs9768139	0.935	rs116290351	chr7:158119712	T/A	cg24154853	chr7:158122151	PTPRN2	-0.37	-5.8	-0.34	1.85e-8	Calcium levels;
CESC	cis	rs2281558	0.876	rs6115135	chr20:25279878	C/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.62	8.38	0.46	3.08e-15	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;
CESC	trans	rs1814175	0.616	rs28417656	chr11:50040152	C/T	cg15704280	chr7:45808275	SEPT13	-1.0	-18.7	-0.75	2.39e-50	Height;
CESC	cis	rs6570726	0.935	rs384806	chr6:145814889	C/G	cg23711669	chr6:146136114	FBXO30	0.82	12.29	0.6	8.74e-28	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7959452	0.535	rs11615712	chr12:69619736	A/T	cg20891283	chr12:69753455	YEATS4	-0.7	-9.87	-0.52	9.11e-20	Blood protein levels;
CESC	cis	rs35110281	0.837	rs12627667	chr21:45071396	A/C	cg21573476	chr21:45109991	RRP1B	-0.48	-6.7	-0.38	1.27e-10	Mean corpuscular volume;
CESC	cis	rs68170813	0.559	rs10953530	chr7:106827796	A/C	cg02696742	chr7:106810147	HBP1	-0.54	-5.09	-0.3	6.64e-7	Coronary artery disease;
CESC	trans	rs11039798	0.512	rs1588069	chr11:48694871	A/G	cg15704280	chr7:45808275	SEPT13	0.65	6.5	0.37	4.05e-10	Axial length;
CESC	cis	rs514406	0.644	rs1855127	chr1:53199594	A/G	cg08859206	chr1:53392774	SCP2	0.65	9.62	0.51	5.62e-19	Monocyte count;
CESC	cis	rs826838	1.000	rs10875991	chr12:39108886	G/C	cg13010199	chr12:38710504	ALG10B	0.58	8.08	0.44	2.24e-14	Heart rate;
CESC	cis	rs637571	0.557	rs1204649	chr11:65702776	A/C	cg02427764	chr11:65769310	BANF1;EIF1AD	0.7	9.7	0.51	3.16e-19	Eosinophil percentage of white cells;
CESC	cis	rs853679	0.517	rs2275508	chr6:28094731	T/C	cg19592336	chr6:28129416	ZNF389	0.63	8.71	0.47	3.29e-16	Depression;
CESC	cis	rs35110281	0.720	rs162375	chr21:44927015	C/T	cg21573476	chr21:45109991	RRP1B	0.44	6.28	0.36	1.37e-9	Mean corpuscular volume;
CESC	cis	rs763121	0.853	rs6001173	chr22:39015302	A/G	cg06544989	chr22:39130855	UNC84B	0.5	9.14	0.49	1.65e-17	Menopause (age at onset);
CESC	cis	rs7647973	1.000	rs2312462	chr3:49601255	A/G	cg06212747	chr3:49208901	KLHDC8B	0.52	6.96	0.39	2.59e-11	Menarche (age at onset);
CESC	cis	rs7618915	0.501	rs62253740	chr3:52684128	A/T	cg05564831	chr3:52568323	NT5DC2	0.46	7.38	0.41	2.06e-12	Bipolar disorder;
CESC	cis	rs71403859	0.685	rs12927044	chr16:71930105	C/A	cg08717414	chr16:71523259	ZNF19	-0.83	-5.2	-0.3	3.96e-7	Post bronchodilator FEV1;
CESC	cis	rs6456156	0.846	rs10946211	chr6:167515489	G/A	cg07741184	chr6:167504864	NA	-0.35	-6.04	-0.35	5.2e-9	Primary biliary cholangitis;
CESC	cis	rs896854	0.530	rs10956934	chr8:95992473	C/A	cg16049864	chr8:95962084	TP53INP1	-0.6	-10.24	-0.53	5.78e-21	Type 2 diabetes;
CESC	cis	rs113835537	0.935	rs15969	chr11:66394387	C/T	cg24851651	chr11:66362959	CCS	0.62	5.6	0.33	5.26e-8	Airway imaging phenotypes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19385725	chr18:21166173	NPC1	0.6	6.86	0.39	4.84e-11	Gut microbiome composition (summer);
CESC	cis	rs2204008	0.558	rs66545149	chr12:38204694	A/G	cg13010199	chr12:38710504	ALG10B	0.53	6.43	0.37	5.94e-10	Bladder cancer;
CESC	cis	rs7249142	0.526	rs7256811	chr19:19283551	A/G	cg27384695	chr19:19271486	LOC729991-MEF2B;MEF2B	0.29	5.21	0.3	3.75e-7	IgG glycosylation;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15651152	chr8:141297750	TRAPPC9	-0.57	-6.28	-0.36	1.34e-9	Gut microbiome composition (summer);
CESC	cis	rs16854884	0.657	rs35067746	chr3:143747147	T/A	cg06585982	chr3:143692056	C3orf58	0.5	6.71	0.38	1.18e-10	Economic and political preferences (feminism/equality);
CESC	cis	rs9287719	0.601	rs9287718	chr2:10701629	A/T	cg00105475	chr2:10696890	NA	-0.41	-5.61	-0.33	5.1e-8	Prostate cancer;
CESC	cis	rs7618915	0.501	rs35526119	chr3:52749334	C/T	cg05564831	chr3:52568323	NT5DC2	0.46	7.22	0.41	5.37e-12	Bipolar disorder;
CESC	trans	rs561341	0.769	rs9899093	chr17:30191954	C/G	cg27661571	chr11:113659931	NA	-0.65	-6.25	-0.36	1.66e-9	Hip circumference adjusted for BMI;
CESC	cis	rs9715521	0.677	rs17493148	chr4:59861895	T/C	cg11281224	chr4:60001000	NA	-0.56	-7.71	-0.43	2.58e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	trans	rs7943203	1.000	rs4754322	chr11:108311655	T/C	cg01416241	chr5:148737479	PCYOX1L	-0.48	-6.07	-0.35	4.52e-9	Red blood cell count;Mean corpuscular volume;
CESC	cis	rs2576037	0.526	rs8095373	chr18:44527895	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.7	10.93	0.56	3.27e-23	Personality dimensions;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg06110578	chr6:43597079	MAD2L1BP;GTPBP2	-0.47	-6.59	-0.38	2.38e-10	Gambling;
CESC	cis	rs4481887	0.927	rs9651177	chr1:248445702	A/G	cg00666640	chr1:248458726	OR2T12	0.33	5.81	0.34	1.83e-8	Common traits (Other);
CESC	cis	rs7089973	0.604	rs3758603	chr10:116605368	T/C	cg03647239	chr10:116582469	FAM160B1	0.43	5.35	0.31	1.94e-7	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs4810685	0.509	rs8114940	chr20:46411490	T/C	cg08288986	chr20:46415360	SULF2	0.51	5.81	0.34	1.75e-8	Attention deficit hyperactivity disorder (time to onset);
CESC	cis	rs722599	0.683	rs10144845	chr14:75237770	C/T	cg11812906	chr14:75593930	NEK9	0.4	5.08	0.3	7.15e-7	IgG glycosylation;
CESC	cis	rs7647973	0.587	rs10452032	chr3:49680973	G/A	cg07636037	chr3:49044803	WDR6	0.53	6.34	0.36	9.78e-10	Menarche (age at onset);
CESC	cis	rs4664304	0.966	rs1397707	chr2:160760972	C/T	cg03641300	chr2:160917029	PLA2R1	-0.46	-6.35	-0.36	9.12e-10	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs818427	0.929	rs153550	chr5:112234957	C/T	cg07820702	chr5:112228657	REEP5	-0.4	-5.06	-0.3	7.9e-7	Total body bone mineral density;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02546618	chr19:19431379	KIAA0892;SF4	-0.57	-6.14	-0.35	3.05e-9	Gut microbiome composition (summer);
CESC	trans	rs1814175	0.645	rs4598671	chr11:50003191	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.42	-6.12	-0.35	3.32e-9	Height;
CESC	cis	rs11690935	0.694	rs312921	chr2:172567225	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.96	-14.72	-0.67	2.89e-36	Schizophrenia;
CESC	cis	rs6831352	0.918	rs29001201	chr4:100053861	T/C	cg13256891	chr4:100009986	ADH5	-0.77	-8.29	-0.45	5.73e-15	Alcohol dependence;
CESC	cis	rs6748734	0.894	rs4675869	chr2:241827696	A/G	cg07537917	chr2:241836409	C2orf54	-0.24	-5.05	-0.3	8.42e-7	Urinary metabolites;
CESC	cis	rs9393777	0.513	rs9379907	chr6:26654318	C/T	cg14345882	chr6:26364793	BTN3A2	0.41	5.12	0.3	5.79e-7	Intelligence (multi-trait analysis);
CESC	cis	rs9649213	0.593	rs6465677	chr7:98003552	C/T	cg21770322	chr7:97807741	LMTK2	0.54	8.21	0.45	9.94e-15	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs1552244	1.000	rs9845756	chr3:10067548	G/C	cg08888203	chr3:10149979	C3orf24	0.49	6.29	0.36	1.3e-9	Alzheimer's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04213338	chr7:6144367	USP42	0.59	6.88	0.39	4.42e-11	Gut microbiome composition (summer);
CESC	cis	rs4665809	0.878	rs4143538	chr2:26290178	A/C	cg27170947	chr2:26402098	FAM59B	-0.71	-8.11	-0.45	1.84e-14	Gut microbiome composition (summer);
CESC	cis	rs2073300	1.000	rs78000067	chr20:23439507	A/G	cg12062639	chr20:23401060	NAPB	0.91	6.41	0.37	6.71e-10	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs9399135	0.935	rs9376086	chr6:135371329	T/C	cg22676075	chr6:135203613	NA	0.52	7.3	0.41	3.39e-12	Red blood cell count;
CESC	cis	rs959260	0.557	rs12936583	chr17:73304710	A/C	cg14668889	chr17:73230827	NUP85	0.39	5.38	0.31	1.6e-7	Systemic lupus erythematosus;
CESC	cis	rs8177253	1.000	rs8177272	chr3:133482870	C/T	cg12373951	chr3:133503437	NA	0.39	5.53	0.32	7.86e-8	Iron status biomarkers;
CESC	cis	rs12586317	0.547	rs60152856	chr14:35421373	G/A	cg16230307	chr14:35515116	FAM177A1	0.96	10.36	0.54	2.4e-21	Psoriasis;
CESC	cis	rs2439831	0.850	rs28684672	chr15:44107662	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.65	5.9	0.34	1.13e-8	Lung cancer in ever smokers;
CESC	cis	rs71636778	0.543	rs17162333	chr1:27236757	C/G	cg12203394	chr1:27248618	NUDC	0.66	5.55	0.32	6.85e-8	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
CESC	cis	rs7084402	0.934	rs1658426	chr10:60331542	A/T	cg07615347	chr10:60278583	BICC1	0.59	9.22	0.49	9.62e-18	Refractive error;
CESC	cis	rs13343954	0.518	rs2216594	chr19:33533258	G/A	cg17764715	chr19:33622953	WDR88	0.54	7.23	0.41	5.16e-12	Colorectal cancer;
CESC	cis	rs793571	0.669	rs28864995	chr15:58945671	T/G	cg05156742	chr15:59063176	FAM63B	0.63	8.45	0.46	1.94e-15	Schizophrenia;
CESC	cis	rs3820068	0.581	rs2861387	chr1:15951296	G/A	cg13390004	chr1:15929781	NA	0.37	5.8	0.34	1.9e-8	Systolic blood pressure;
CESC	cis	rs117623576	0.941	rs67225815	chr10:32408946	C/T	cg03047570	chr10:32398778	NA	-0.76	-7.88	-0.44	8.62e-14	Anti-saccade response;
CESC	cis	rs10504229	1.000	rs56740825	chr8:58175617	A/G	cg05313129	chr8:58192883	C8orf71	-0.55	-6.37	-0.36	8.42e-10	Developmental language disorder (linguistic errors);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17522466	chr8:23386187	SLC25A37	-0.55	-6.07	-0.35	4.34e-9	Gut microbiome composition (summer);
CESC	cis	rs11676348	0.818	rs7425447	chr2:218980183	T/C	cg00012203	chr2:219082015	ARPC2	-0.57	-7.47	-0.42	1.14e-12	Ulcerative colitis;
CESC	cis	rs4819052	0.851	rs4819044	chr21:46660118	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.89	13.04	0.63	2.35e-30	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs79349575	0.715	rs1058018	chr17:47000251	C/T	cg16584676	chr17:46985605	UBE2Z	0.66	8.83	0.48	1.49e-16	Type 2 diabetes;
CESC	cis	rs6952808	0.792	rs12536261	chr7:1953571	G/A	cg04267008	chr7:1944627	MAD1L1	-0.74	-10.0	-0.52	3.37e-20	Bipolar disorder and schizophrenia;
CESC	cis	rs9814567	0.762	rs13071852	chr3:134223217	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.44	5.68	0.33	3.53e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs11098499	0.954	rs17006190	chr4:120418838	C/G	cg24375607	chr4:120327624	NA	0.48	5.97	0.34	7.47e-9	Corneal astigmatism;
CESC	cis	rs4780401	0.573	rs8045673	chr16:11804385	C/A	cg01061890	chr16:11836724	TXNDC11	-0.56	-7.65	-0.43	3.84e-13	Rheumatoid arthritis;
CESC	cis	rs8033133	0.957	rs3742952	chr15:25351026	A/G	cg14481604	chr15:25334117	SNORD116-22	-0.38	-5.67	-0.33	3.69e-8	Blood osmolality (transformed sodium);
CESC	cis	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.56	-7.1	-0.4	1.14e-11	Bipolar disorder;
CESC	cis	rs35306767	0.807	rs34982663	chr10:852521	C/G	cg20503657	chr10:835505	NA	1.1	10.47	0.54	1.12e-21	Eosinophil percentage of granulocytes;
CESC	cis	rs4072980	0.545	rs11210870	chr1:38449910	T/C	cg26528311	chr1:38462546	FHL3	-0.35	-5.26	-0.31	2.95e-7	Coronary artery disease;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg01485165	chr20:49411421	BCAS4	0.45	6.34	0.36	1.01e-9	Systemic lupus erythematosus;
CESC	cis	rs769267	0.930	rs4808957	chr19:19567248	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.47	5.87	0.34	1.28e-8	Tonsillectomy;
CESC	cis	rs748404	0.690	rs1079309	chr15:43783164	C/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.57	7.35	0.41	2.53e-12	Lung cancer;
CESC	cis	rs7605827	0.930	rs11679632	chr2:15605659	G/A	cg19274914	chr2:15703543	NA	0.35	6.13	0.35	3.19e-9	Educational attainment (years of education);
CESC	cis	rs8058578	1.000	rs8058578	chr16:30726248	C/T	cg00531865	chr16:30841666	NA	-0.43	-5.62	-0.33	4.95e-8	Multiple myeloma;
CESC	trans	rs11098499	0.954	rs66506550	chr4:120371445	T/A	cg25214090	chr10:38739885	LOC399744	0.7	9.92	0.52	6.5e-20	Corneal astigmatism;
CESC	cis	rs2732480	0.577	rs2634681	chr12:48733084	C/T	cg04545296	chr12:48745243	ZNF641	-0.34	-5.98	-0.34	7.35e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs7649275	0.882	rs2612025	chr3:53778314	T/C	cg21503701	chr3:53781065	CACNA1D	-0.38	-5.08	-0.3	7.14e-7	Trans fatty acid levels;
CESC	cis	rs17253792	0.822	rs28513551	chr14:56094993	G/A	cg01858014	chr14:56050164	KTN1	-0.85	-6.99	-0.39	2.22e-11	Putamen volume;
CESC	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg24642844	chr7:1081250	C7orf50	-0.75	-9.1	-0.49	2.29e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs933688	0.938	rs6869048	chr5:90664322	G/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.16	15.56	0.69	3.24e-39	Smoking behavior;
CESC	cis	rs9322193	0.923	rs55849538	chr6:149956466	T/C	cg04369109	chr6:150039330	LATS1	-0.39	-5.38	-0.31	1.62e-7	Lung cancer;
CESC	cis	rs75477785	1.000	rs12064211	chr1:210050518	A/C	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.79	5.15	0.3	5.08e-7	Cleft lip with or without cleft palate;
CESC	cis	rs4665809	0.887	rs28699126	chr2:26357294	C/T	cg22920501	chr2:26401640	FAM59B	-0.64	-7.7	-0.43	2.73e-13	Gut microbiome composition (summer);
CESC	cis	rs6032067	0.714	rs35770435	chr20:43788804	C/T	cg10761708	chr20:43804764	PI3	0.54	6.31	0.36	1.14e-9	Blood protein levels;
CESC	cis	rs2243480	1.000	rs316330	chr7:65605372	C/A	cg13147721	chr7:65941812	NA	-0.97	-9.14	-0.49	1.7e-17	Diabetic kidney disease;
CESC	cis	rs9926296	0.528	rs4785721	chr16:89839997	G/A	cg04287289	chr16:89883240	FANCA	0.88	14.55	0.67	1.23e-35	Vitiligo;
CESC	cis	rs116095464	0.558	rs62346526	chr5:220614	T/C	cg12570787	chr5:219185	SDHA;CCDC127	0.53	5.74	0.33	2.63e-8	Breast cancer;
CESC	cis	rs10463316	0.784	rs906678	chr5:150779040	T/C	cg03212797	chr5:150827313	SLC36A1	-0.44	-5.54	-0.32	7.2e-8	Metabolite levels (Pyroglutamine);
CESC	cis	rs258892	0.895	rs155432	chr5:72138608	G/T	cg21869765	chr5:72125136	TNPO1	0.44	5.68	0.33	3.61e-8	Small cell lung carcinoma;
CESC	cis	rs7666738	0.791	rs4440223	chr4:99044796	G/A	cg05340658	chr4:99064831	C4orf37	0.82	12.88	0.62	8.44e-30	Colonoscopy-negative controls vs population controls;
CESC	trans	rs7107217	1.000	rs1873872	chr11:129473993	A/T	cg22532736	chr15:64126641	HERC1	0.47	6.03	0.35	5.55e-9	Breast cancer;Type 2 diabetes;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg22541143	chr4:84377292	HELQ;MRPS18C	-0.45	-6.47	-0.37	4.75e-10	Fibrinogen levels;
CESC	cis	rs7914558	1.000	rs7914558	chr10:104775908	G/A	cg04362960	chr10:104952993	NT5C2	0.43	5.77	0.33	2.19e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs12681288	0.782	rs12549337	chr8:1030187	A/G	cg04851639	chr8:1020857	NA	-0.42	-8.67	-0.47	4.48e-16	Schizophrenia;
CESC	cis	rs950027	0.620	rs1617984	chr15:45622662	A/G	cg21132104	chr15:45694354	SPATA5L1	0.67	8.6	0.47	7.08e-16	Response to fenofibrate (adiponectin levels);
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg00902396	chr2:135679280	CCNT2	0.48	7.03	0.4	1.8e-11	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs4819052	0.851	rs7275870	chr21:46671214	C/T	cg11663144	chr21:46675770	NA	-0.64	-10.05	-0.53	2.34e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg02951883	chr7:2050386	MAD1L1	0.41	5.58	0.32	5.89e-8	Bipolar disorder and schizophrenia;
CESC	trans	rs2075371	0.932	rs1862048	chr7:133978167	C/G	cg10929213	chr11:66056787	YIF1A	0.53	6.18	0.35	2.42e-9	Mean platelet volume;
CESC	cis	rs863345	0.604	rs949398	chr1:158461983	A/G	cg12129480	chr1:158549410	OR10X1	-0.36	-7.29	-0.41	3.49e-12	Pneumococcal bacteremia;
CESC	cis	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.46	5.36	0.31	1.77e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs10779751	0.770	rs11121696	chr1:11238063	A/G	cg08854313	chr1:11322531	MTOR	-0.7	-8.35	-0.46	3.95e-15	Body mass index;
CESC	cis	rs832540	0.931	rs832529	chr5:56229288	C/T	cg24531977	chr5:56204891	C5orf35	-0.43	-5.42	-0.32	1.33e-7	Coronary artery disease;
CESC	cis	rs4481887	0.800	rs10788780	chr1:248483598	G/A	cg00666640	chr1:248458726	OR2T12	0.35	5.88	0.34	1.23e-8	Common traits (Other);
CESC	cis	rs748404	0.631	rs3809482	chr15:43661802	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.56	8.8	0.48	1.82e-16	Lung cancer;
CESC	cis	rs62244186	0.541	rs3804583	chr3:44884647	G/T	cg15225532	chr3:44803084	KIF15;KIAA1143	0.43	5.68	0.33	3.51e-8	Depressive symptoms;
CESC	cis	rs9486715	0.867	rs1855533	chr6:97050265	T/C	cg06623918	chr6:96969491	KIAA0776	-0.96	-15.13	-0.68	1.08e-37	Headache;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg07398558	chr1:28879201	TRNAU1AP	-0.49	-6.39	-0.37	7.34e-10	Asthma;
CESC	cis	rs2637266	0.935	rs2583059	chr10:78395178	G/C	cg18941641	chr10:78392320	NA	0.45	8.6	0.47	7.12e-16	Pulmonary function;
CESC	cis	rs62244186	0.545	rs7640654	chr3:44763037	A/C	cg15225532	chr3:44803084	KIF15;KIAA1143	0.48	6.29	0.36	1.33e-9	Depressive symptoms;
CESC	cis	rs1461503	0.534	rs4293127	chr11:122804263	G/C	cg27398637	chr11:122830231	C11orf63	-0.48	-6.66	-0.38	1.57e-10	Menarche (age at onset);
CESC	cis	rs2228479	0.571	rs62052183	chr16:89966921	C/A	cg00800038	chr16:89945340	TCF25	-0.84	-7.29	-0.41	3.49e-12	Skin colour saturation;
CESC	cis	rs6762	0.748	rs1130719	chr11:838760	T/A	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.68	-8.7	-0.47	3.52e-16	Mean platelet volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03849660	chr7:102098214	ALKBH4	-0.55	-6.52	-0.37	3.44e-10	Gut microbiome composition (summer);
CESC	cis	rs2625529	0.689	rs10851847	chr15:72111760	T/C	cg16672083	chr15:72433130	SENP8	-0.5	-7.3	-0.41	3.42e-12	Red blood cell count;
CESC	cis	rs1008375	0.966	rs6449313	chr4:17588320	A/G	cg16339924	chr4:17578868	LAP3	0.8	10.51	0.54	8.03e-22	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs1499614	1.000	rs2659903	chr7:66180931	G/A	cg12463550	chr7:65579703	CRCP	0.73	5.73	0.33	2.78e-8	Gout;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg03153775	chr3:45185028	CDCP1	0.43	6.15	0.35	2.81e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs6540559	0.673	rs17015218	chr1:209967915	A/G	cg25204440	chr1:209979598	IRF6	0.63	6.57	0.37	2.64e-10	Cleft lip with or without cleft palate;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg05364211	chr1:213188787	ANGEL2	-0.52	-6.11	-0.35	3.58e-9	Ulcerative colitis;
CESC	cis	rs6690583	0.623	rs55721024	chr1:85454447	A/C	cg22153463	chr1:85462885	MCOLN2	0.71	7.12	0.4	1.01e-11	Serum sulfate level;
CESC	cis	rs2191566	0.639	rs7260075	chr19:44566766	T/C	cg20607764	chr19:44506953	ZNF230	-0.44	-5.64	-0.33	4.34e-8	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs16854884	0.710	rs1530479	chr3:143819653	C/T	cg06585982	chr3:143692056	C3orf58	0.44	5.94	0.34	8.85e-9	Economic and political preferences (feminism/equality);
CESC	cis	rs9457247	0.967	rs2757054	chr6:167380501	A/G	cg23791538	chr6:167370224	RNASET2	0.6	8.56	0.47	9.4e-16	Crohn's disease;
CESC	cis	rs2439831	0.867	rs2447196	chr15:43893818	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.68	-8.17	-0.45	1.25e-14	Lung cancer in ever smokers;
CESC	trans	rs17508449	0.819	rs77551704	chr1:114235186	G/C	cg23028848	chr11:57092561	TNKS1BP1	-0.79	-6.28	-0.36	1.38e-9	Leprosy;
CESC	cis	rs2070997	0.607	rs13294646	chr9:133715206	C/G	cg11464064	chr9:133710261	ABL1	0.68	7.26	0.41	4.36e-12	Response to amphetamines;
CESC	cis	rs6952808	0.630	rs4719443	chr7:2161099	A/G	cg02951883	chr7:2050386	MAD1L1	-0.46	-5.85	-0.34	1.47e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs2836974	0.897	rs2836944	chr21:40593539	G/A	cg11890956	chr21:40555474	PSMG1	1.21	23.11	0.82	1.81e-65	Cognitive function;
CESC	cis	rs6460942	0.915	rs62448620	chr7:12458170	C/T	cg20607287	chr7:12443886	VWDE	-0.78	-9.15	-0.49	1.61e-17	Coronary artery disease;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg16282910	chr9:112296723	NA	-0.48	-6.52	-0.37	3.6e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs11249608	0.511	rs58827878	chr5:178481936	C/G	cg01312482	chr5:178451176	ZNF879	-0.42	-5.31	-0.31	2.34e-7	Pubertal anthropometrics;
CESC	cis	rs6912958	0.781	rs2300906	chr6:88207155	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	-0.33	-5.25	-0.31	3.05e-7	Monocyte percentage of white cells;
CESC	cis	rs1862618	0.756	rs9292125	chr5:56107200	C/T	cg12311346	chr5:56204834	C5orf35	-0.7	-8.58	-0.47	8.32e-16	Initial pursuit acceleration;
CESC	cis	rs2404602	0.647	rs7165053	chr15:76978918	A/G	cg23625390	chr15:77176239	SCAPER	-0.42	-5.69	-0.33	3.27e-8	Blood metabolite levels;
CESC	cis	rs1552244	0.572	rs113406084	chr3:10170190	T/C	cg00149659	chr3:10157352	C3orf10	0.98	11.92	0.59	1.59e-26	Alzheimer's disease;
CESC	cis	rs7520050	0.966	rs10890363	chr1:46356148	C/T	cg03146154	chr1:46216737	IPP	0.48	6.24	0.36	1.7e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs892961	0.932	rs11650011	chr17:75412334	A/G	cg05865280	chr17:75406074	SEPT9	0.61	12.34	0.6	5.8e-28	Airflow obstruction;
CESC	cis	rs711245	0.545	rs848617	chr2:36811298	G/C	cg01206211	chr2:36825736	FEZ2	0.34	5.92	0.34	1e-8	Height;
CESC	cis	rs2479106	0.591	rs6478629	chr9:126442550	A/G	cg16191174	chr9:126692580	DENND1A	0.39	5.3	0.31	2.38e-7	Polycystic ovary syndrome;
CESC	cis	rs55728055	0.661	rs62237763	chr22:31947392	C/G	cg01338084	chr22:32026380	PISD	1.26	8.11	0.45	1.91e-14	Age-related hearing impairment;
CESC	cis	rs763014	1.000	rs2269558	chr16:682250	C/T	cg00802000	chr16:706648	WDR90	-0.4	-6.14	-0.35	3.03e-9	Height;
CESC	cis	rs1878931	0.543	rs1129568	chr16:3483475	G/A	cg00484396	chr16:3507460	NAT15	-0.42	-6.61	-0.38	2.07e-10	Body mass index (adult);
CESC	cis	rs17431357	0.867	rs73225213	chr12:120946237	C/T	cg25045489	chr12:120971538	RNF10	-0.93	-5.46	-0.32	1.1e-7	Insulin resistance/response;
CESC	cis	rs13191362	0.810	rs28360533	chr6:162996742	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.83	8.39	0.46	3.02e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs9916302	0.784	rs34473775	chr17:37396201	G/T	cg20243544	chr17:37824526	PNMT	0.48	5.99	0.35	6.77e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	21.45	0.8	7.14e-60	Prudent dietary pattern;
CESC	trans	rs523522	0.923	rs2235217	chr12:120884328	C/T	cg02849695	chr1:159869960	CCDC19	0.33	6.05	0.35	5e-9	High light scatter reticulocyte count;
CESC	cis	rs644799	0.603	rs1255180	chr11:95472134	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.51	7.05	0.4	1.58e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs34779708	0.966	rs4934730	chr10:35415555	A/G	cg04310649	chr10:35416472	CREM	-0.51	-6.16	-0.35	2.62e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs67311347	1.000	rs28707772	chr3:40504666	G/A	cg09455208	chr3:40491958	NA	0.51	8.03	0.44	3.17e-14	Renal cell carcinoma;
CESC	cis	rs35306767	0.855	rs61830900	chr10:871481	C/G	cg20503657	chr10:835505	NA	1.09	10.01	0.52	3.32e-20	Eosinophil percentage of granulocytes;
CESC	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg06873352	chr17:61820015	STRADA	0.71	12.33	0.6	6.72e-28	Prudent dietary pattern;
CESC	trans	rs629535	0.665	rs2433331	chr8:70041943	T/C	cg21567404	chr3:27674614	NA	0.95	11.48	0.58	4.92e-25	Dupuytren's disease;
CESC	cis	rs798554	0.660	rs1182175	chr7:2875026	C/T	cg19717773	chr7:2847554	GNA12	0.52	8.14	0.45	1.59e-14	Height;
CESC	cis	rs11792861	0.926	rs1333344	chr9:111776224	C/T	cg05043794	chr9:111880884	C9orf5	-0.38	-6.27	-0.36	1.43e-9	Menarche (age at onset);
CESC	cis	rs6952808	0.500	rs3778996	chr7:2177190	G/A	cg04267008	chr7:1944627	MAD1L1	-0.57	-6.82	-0.39	6.04e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs7017914	0.967	rs7825446	chr8:71664174	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.2	-0.3	3.94e-7	Bone mineral density;
CESC	cis	rs6964587	1.000	rs733957	chr7:91707197	C/T	cg17063962	chr7:91808500	NA	0.59	8.09	0.45	2.1e-14	Breast cancer;
CESC	cis	rs939658	0.805	rs36068099	chr15:79438598	G/C	cg17916960	chr15:79447300	NA	-0.35	-5.96	-0.34	8.11e-9	Refractive error;
CESC	cis	rs1144333	0.655	rs11162053	chr1:76470267	A/C	cg22875332	chr1:76189707	ACADM	0.54	5.18	0.3	4.47e-7	Attention function in attention deficit hyperactive disorder;
CESC	cis	rs514406	0.793	rs4500255	chr1:53213279	A/G	cg16325326	chr1:53192061	ZYG11B	-0.71	-11.68	-0.58	1.05e-25	Monocyte count;
CESC	cis	rs11169225	0.724	rs7305290	chr12:50341465	A/G	cg23855989	chr12:50355821	AQP5	0.49	6.75	0.38	9.42e-11	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs4654899	0.931	rs10753506	chr1:21141022	A/G	cg05370193	chr1:21551575	ECE1	-0.37	-5.38	-0.31	1.66e-7	Superior frontal gyrus grey matter volume;
CESC	cis	rs6754311	0.731	rs3754686	chr2:136603276	T/C	cg07169764	chr2:136633963	MCM6	-0.69	-8.49	-0.46	1.51e-15	Mosquito bite size;
CESC	cis	rs4665809	1.000	rs6729757	chr2:26285102	A/G	cg22920501	chr2:26401640	FAM59B	-0.69	-8.44	-0.46	2.06e-15	Gut microbiome composition (summer);
CESC	cis	rs35146811	0.807	rs6953441	chr7:99617067	G/A	cg22906224	chr7:99728672	NA	0.49	5.77	0.33	2.23e-8	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26912078	chr2:97523308	ANKRD39	-0.59	-6.33	-0.36	1.03e-9	Gut microbiome composition (summer);
CESC	cis	rs10504229	1.000	rs67384205	chr8:58180348	C/G	cg24829409	chr8:58192753	C8orf71	-0.76	-10.0	-0.52	3.53e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs11166927	0.524	rs10092101	chr8:140830697	C/T	cg16909799	chr8:140841666	TRAPPC9	-0.59	-9.45	-0.5	1.83e-18	Pediatric non-alcoholic fatty liver disease activity score;
CESC	cis	rs2197308	0.655	rs1971964	chr12:37870474	C/T	cg13010199	chr12:38710504	ALG10B	0.52	6.64	0.38	1.8e-10	Morning vs. evening chronotype;
CESC	cis	rs2635047	0.934	rs11663321	chr18:44622704	T/C	cg19077165	chr18:44547161	KATNAL2	-0.5	-6.84	-0.39	5.45e-11	Educational attainment;
CESC	cis	rs2857078	0.745	rs4793085	chr17:42320732	A/C	cg09913183	chr17:42254507	C17orf65;ASB16	-0.42	-5.14	-0.3	5.21e-7	Red cell distribution width;Reticulocyte count;
CESC	trans	rs7307889	0.793	rs73047609	chr12:5996588	G/A	cg18407955	chr7:158110685	PTPRN2	-0.73	-6.22	-0.36	1.89e-9	Obesity-related traits;
CESC	cis	rs2274273	1.000	rs15870	chr14:55619311	A/G	cg04306507	chr14:55594613	LGALS3	0.28	5.23	0.31	3.42e-7	Protein biomarker;
CESC	cis	rs6540556	0.954	rs643118	chr1:209934841	C/T	cg05527609	chr1:210001259	C1orf107	-0.42	-5.28	-0.31	2.71e-7	Red blood cell count;
CESC	cis	rs8031584	0.918	rs1425292	chr15:31285422	G/A	cg08704250	chr15:31115839	NA	-0.64	-8.21	-0.45	9.71e-15	Huntington's disease progression;
CESC	cis	rs6502050	0.835	rs6502069	chr17:80112599	G/T	cg11859384	chr17:80120422	CCDC57	-0.39	-5.37	-0.31	1.76e-7	Life satisfaction;
CESC	cis	rs5750830	0.597	rs4821889	chr22:39777254	T/C	cg01416388	chr22:39784598	NA	-0.49	-6.68	-0.38	1.38e-10	Intelligence (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01747036	chr13:113140125	TUBGCP3	-0.65	-8.0	-0.44	3.94e-14	Gut microbiome composition (summer);
CESC	cis	rs2991971	0.933	rs12568144	chr1:45965307	G/A	cg24296786	chr1:45957014	TESK2	0.66	9.05	0.49	3.15e-17	High light scatter reticulocyte count;
CESC	cis	rs2985684	1.000	rs3007031	chr14:50102269	G/C	cg02151108	chr14:50098012	C14orf104	-0.42	-5.48	-0.32	9.97e-8	Carotid intima media thickness;
CESC	cis	rs921968	0.607	rs529474	chr2:219463283	C/T	cg02176678	chr2:219576539	TTLL4	0.42	7.12	0.4	1.01e-11	Mean corpuscular hemoglobin concentration;
CESC	cis	rs8103278	1.000	rs35302007	chr19:46219145	G/C	cg14061069	chr19:46274453	DMPK	-0.38	-5.38	-0.31	1.62e-7	Coronary artery disease;
CESC	cis	rs9811920	0.809	rs4577503	chr3:99657922	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.48	-7.82	-0.43	1.28e-13	Axial length;
CESC	cis	rs72634258	0.554	rs4908699	chr1:7905274	G/A	cg26816564	chr1:7831052	VAMP3	0.58	5.15	0.3	5.18e-7	Inflammatory bowel disease;
CESC	cis	rs79349575	0.749	rs8182364	chr17:47018025	A/G	cg16584676	chr17:46985605	UBE2Z	0.54	6.67	0.38	1.46e-10	Type 2 diabetes;
CESC	cis	rs936229	0.813	rs7085	chr15:75095483	T/C	cg14664628	chr15:75095509	CSK	-1.0	-15.17	-0.68	7.63e-38	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CESC	cis	rs3820928	0.874	rs2276593	chr2:227898434	A/G	cg11843606	chr2:227700838	RHBDD1	0.48	6.23	0.36	1.77e-9	Pulmonary function;
CESC	cis	rs10838687	0.867	rs2957873	chr11:47249294	G/A	cg25783544	chr11:47291846	MADD	-0.59	-7.45	-0.42	1.3e-12	Proinsulin levels;
CESC	cis	rs4867766	0.871	rs113284505	chr5:173954800	A/G	cg20434911	chr5:173954559	NA	-0.58	-6.42	-0.37	6.37e-10	Stroke;
CESC	cis	rs11155671	0.530	rs7768665	chr6:150208024	G/A	cg09699651	chr6:150184138	LRP11	0.56	7.79	0.43	1.56e-13	Testicular germ cell tumor;
CESC	cis	rs12220238	1.000	rs8255	chr10:75879750	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.66	6.58	0.37	2.49e-10	Soluble interleukin-2 receptor subunit alpha;
CESC	cis	rs7666738	0.830	rs10012167	chr4:99048579	T/C	cg24818145	chr4:99064322	C4orf37	0.38	5.04	0.3	8.49e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1005277	0.579	rs2474595	chr10:38426782	C/G	cg00409905	chr10:38381863	ZNF37A	0.45	5.94	0.34	8.9e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs6665290	0.904	rs3738729	chr1:227191227	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.22	-32.74	-0.9	3.97e-95	Myeloid white cell count;
CESC	cis	rs2075371	0.830	rs12669960	chr7:133931782	A/G	cg11752832	chr7:134001865	SLC35B4	0.52	6.74	0.38	1.01e-10	Mean platelet volume;
CESC	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg18402987	chr7:1209562	NA	0.76	7.57	0.42	6.04e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs13191362	1.000	rs34443622	chr6:163208214	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.06	10.27	0.53	4.91e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs1552244	1.000	rs4260416	chr3:10125283	C/T	cg00149659	chr3:10157352	C3orf10	0.7	8.63	0.47	5.68e-16	Alzheimer's disease;
CESC	cis	rs7914558	1.000	rs4917380	chr10:104775335	C/G	cg04362960	chr10:104952993	NT5C2	0.43	5.77	0.33	2.19e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs16867321	0.627	rs7571765	chr2:181590328	G/A	cg23363182	chr2:181467187	NA	0.44	6.57	0.37	2.71e-10	Obesity;
CESC	cis	rs11785400	1.000	rs10108059	chr8:143750028	G/T	cg10596483	chr8:143751796	JRK	-0.44	-5.6	-0.33	5.29e-8	Schizophrenia;
CESC	trans	rs72991	0.793	rs10790443	chr11:121234131	G/T	cg26394191	chr3:123459423	MYLK	0.28	6.62	0.38	1.94e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs11583043	0.918	rs56402739	chr1:101397133	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.46	5.17	0.3	4.71e-7	Ulcerative colitis;Inflammatory bowel disease;
CESC	cis	rs9815354	0.680	rs75308766	chr3:42031894	G/A	cg03022575	chr3:42003672	ULK4	0.75	6.64	0.38	1.72e-10	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs9902453	0.967	rs1906450	chr17:28515744	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	7.68	0.43	3.18e-13	Coffee consumption (cups per day);
CESC	cis	rs9311474	0.508	rs4687546	chr3:52605943	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.49	7.18	0.4	6.94e-12	Electroencephalogram traits;
CESC	cis	rs78707713	0.841	rs7475662	chr10:71210744	G/C	cg12610070	chr10:71211762	TSPAN15	-0.36	-6.48	-0.37	4.36e-10	Venous thromboembolism;
CESC	cis	rs5750830	0.620	rs1007337	chr22:39781585	C/T	cg24399712	chr22:39784796	NA	-0.77	-11.15	-0.57	6.39e-24	Intelligence (multi-trait analysis);
CESC	cis	rs1862618	0.853	rs832569	chr5:56154584	T/A	cg12311346	chr5:56204834	C5orf35	-0.74	-8.75	-0.47	2.61e-16	Initial pursuit acceleration;
CESC	cis	rs6502050	0.799	rs58538819	chr17:80107153	G/C	cg01763666	chr17:80159506	CCDC57	-0.38	-5.17	-0.3	4.61e-7	Life satisfaction;
CESC	cis	rs7613875	0.580	rs2624819	chr3:50010571	G/T	cg24110177	chr3:50126178	RBM5	-0.58	-8.07	-0.44	2.48e-14	Body mass index;
CESC	trans	rs2727020	0.658	rs10839269	chr11:49385596	A/G	cg03929089	chr4:120376271	NA	-0.81	-12.68	-0.61	4.19e-29	Coronary artery disease;
CESC	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg07414643	chr4:187882934	NA	0.55	7.97	0.44	4.6e-14	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9487051	0.676	rs6910119	chr6:109599263	A/G	cg01475377	chr6:109611718	NA	-0.43	-6.82	-0.39	6.19e-11	Reticulocyte fraction of red cells;
CESC	cis	rs6964587	0.967	rs10279943	chr7:91587477	G/C	cg17063962	chr7:91808500	NA	0.58	7.92	0.44	6.66e-14	Breast cancer;
CESC	cis	rs11098499	0.739	rs9996382	chr4:120151012	C/T	cg09307838	chr4:120376055	NA	0.63	8.03	0.44	3.16e-14	Corneal astigmatism;
CESC	cis	rs769267	0.930	rs1047361	chr19:19606634	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.46	5.93	0.34	9.24e-9	Tonsillectomy;
CESC	cis	rs7927592	0.956	rs2510384	chr11:68391837	C/A	cg20283391	chr11:68216788	NA	-0.47	-5.48	-0.32	1e-7	Total body bone mineral density;
CESC	cis	rs7264396	0.563	rs2425081	chr20:34299733	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.88	-10.64	-0.55	3.06e-22	Total cholesterol levels;
CESC	cis	rs1475911	0.708	rs56109792	chr21:43520060	A/G	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.46	-7.06	-0.4	1.46e-11	IgG glycosylation;
CESC	cis	rs11252926	0.770	rs4880736	chr10:680133	C/G	cg08603382	chr10:743973	NA	0.41	5.68	0.33	3.55e-8	Psychosis in Alzheimer's disease;
CESC	cis	rs1348850	0.914	rs4341974	chr2:178324879	A/C	cg22681709	chr2:178499509	PDE11A	-0.39	-5.69	-0.33	3.29e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs7208859	0.623	rs9891166	chr17:29111902	G/A	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.91e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs10504229	0.906	rs7003285	chr8:58173108	A/G	cg24829409	chr8:58192753	C8orf71	-0.76	-10.0	-0.52	3.53e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs1348850	0.540	rs10172355	chr2:178443225	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.52	5.11	0.3	6.11e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs962856	0.604	rs2035566	chr2:67616273	G/C	cg09028215	chr2:67624308	ETAA1	-0.44	-5.26	-0.31	3.04e-7	Pancreatic cancer;
CESC	cis	rs1008375	0.931	rs10008337	chr4:17593849	G/C	cg27347728	chr4:17578864	LAP3	0.44	5.24	0.31	3.33e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14472251	chr14:55493991	SOCS4;WDHD1	0.58	6.24	0.36	1.73e-9	Gut microbiome composition (summer);
CESC	cis	rs2274273	0.840	rs6573014	chr14:55735892	C/T	cg04306507	chr14:55594613	LGALS3	-0.28	-5.46	-0.32	1.1e-7	Protein biomarker;
CESC	cis	rs1046896	0.520	rs8074086	chr17:80818460	A/C	cg19500275	chr17:80737654	TBCD	0.49	5.6	0.33	5.23e-8	Glycated hemoglobin levels;
CESC	cis	rs72781680	1.000	rs17762782	chr2:24126493	A/G	cg20701182	chr2:24300061	SF3B14	0.63	5.67	0.33	3.79e-8	Lymphocyte counts;
CESC	cis	rs763121	0.853	rs10135	chr22:39082174	C/T	cg06022373	chr22:39101656	GTPBP1	-0.93	-17.03	-0.72	1.95e-44	Menopause (age at onset);
CESC	cis	rs2742234	0.915	rs2742233	chr10:43610558	C/T	cg07801480	chr10:43725741	RASGEF1A	0.39	5.39	0.31	1.56e-7	Hirschsprung disease;
CESC	cis	rs17826219	0.706	rs57698184	chr17:29064918	T/C	cg19761014	chr17:28927070	LRRC37B2	0.77	6.31	0.36	1.17e-9	Body mass index;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg03823108	chr20:1099106	PSMF1	-0.5	-6.89	-0.39	3.94e-11	Fibrinogen levels;
CESC	cis	rs9322193	0.923	rs9505826	chr6:149955048	A/G	cg07701084	chr6:150067640	NUP43	0.45	6.39	0.37	7.37e-10	Lung cancer;
CESC	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg06873352	chr17:61820015	STRADA	0.74	13.19	0.63	7.17e-31	Prudent dietary pattern;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03092603	chr22:38712210	CSNK1E	0.44	6.35	0.36	9.3e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs875971	0.545	rs316305	chr7:65617971	G/A	cg11764359	chr7:65958608	NA	-0.79	-9.51	-0.5	1.18e-18	Aortic root size;
CESC	cis	rs9325144	0.602	rs10785590	chr12:38694145	C/T	cg26384229	chr12:38710491	ALG10B	0.58	8.47	0.46	1.67e-15	Morning vs. evening chronotype;
CESC	cis	rs1832871	0.683	rs62437360	chr6:158720162	G/A	cg07165851	chr6:158734300	TULP4	0.6	6.59	0.38	2.33e-10	Height;
CESC	cis	rs1152591	0.562	rs1262242	chr14:64653869	C/T	cg21174375	chr14:64681225	SYNE2	0.56	8.07	0.44	2.49e-14	Atrial fibrillation;
CESC	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.63	0.38	1.89e-10	Prudent dietary pattern;
CESC	cis	rs6032067	0.641	rs35882692	chr20:43763968	T/C	cg10761708	chr20:43804764	PI3	0.54	5.85	0.34	1.45e-8	Blood protein levels;
CESC	cis	rs40363	0.620	rs1137454	chr16:3533577	C/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.51	6.39	0.37	7.37e-10	Tuberculosis;
CESC	cis	rs11792861	0.926	rs72607169	chr9:111832471	A/T	cg13535736	chr9:111863775	C9orf5	-0.51	-6.84	-0.39	5.58e-11	Menarche (age at onset);
CESC	cis	rs9311474	0.659	rs1133415	chr3:52575831	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.45	6.16	0.35	2.7e-9	Electroencephalogram traits;
CESC	cis	rs6952808	0.595	rs2398705	chr7:2164995	G/A	cg23048001	chr7:2026167	MAD1L1	0.45	5.88	0.34	1.24e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs6815814	0.851	rs17582893	chr4:38886420	G/A	cg02016764	chr4:38805732	TLR1	-0.56	-6.33	-0.36	1.07e-9	Breast cancer;
CESC	cis	rs7714584	0.793	rs11958146	chr5:150254158	A/G	cg22134413	chr5:150180641	NA	0.51	5.92	0.34	9.88e-9	Crohn's disease;
CESC	trans	rs6572548	0.504	rs1956082	chr14:49665496	A/C	cg23667933	chr9:71650719	FXN	-0.58	-6.42	-0.37	6.29e-10	Subjective well-being;
CESC	trans	rs7618501	0.966	rs7372966	chr3:49788969	T/C	cg21659725	chr3:3221576	CRBN	-0.83	-13.42	-0.64	1.08e-31	Intelligence (multi-trait analysis);
CESC	cis	rs769267	1.000	rs2074089	chr19:19449603	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.64	-8.23	-0.45	8.51e-15	Tonsillectomy;
CESC	cis	rs921968	0.565	rs7599945	chr2:219641528	G/T	cg02176678	chr2:219576539	TTLL4	-0.43	-7.67	-0.43	3.39e-13	Mean corpuscular hemoglobin concentration;
CESC	trans	rs7618501	1.000	rs1049256	chr3:49763338	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.58	-8.39	-0.46	2.92e-15	Intelligence (multi-trait analysis);
CESC	cis	rs2011503	1.000	rs80007081	chr19:19626734	A/G	cg11584989	chr19:19387371	SF4	0.61	7.06	0.4	1.45e-11	Bipolar disorder;
CESC	cis	rs34172651	0.617	rs9922436	chr16:24704490	C/G	cg06028605	chr16:24865363	SLC5A11	0.44	6.45	0.37	5.41e-10	Intelligence (multi-trait analysis);
CESC	cis	rs6912958	0.754	rs2268994	chr6:88185386	A/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.44	-5.84	-0.34	1.52e-8	Monocyte percentage of white cells;
CESC	cis	rs1775715	0.737	rs2799031	chr10:32173168	C/T	cg18675610	chr10:32216311	ARHGAP12	0.35	5.38	0.31	1.65e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg12243255	chr3:39194549	CSRNP1	0.47	6.24	0.36	1.68e-9	Systemic lupus erythematosus;
CESC	cis	rs950027	0.620	rs1145089	chr15:45652054	G/C	cg21132104	chr15:45694354	SPATA5L1	0.66	8.52	0.46	1.22e-15	Response to fenofibrate (adiponectin levels);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg10459717	chr5:6633577	NSUN2;SRD5A1	-0.48	-6.3	-0.36	1.22e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs2072732	0.861	rs12042403	chr1:2950872	T/C	cg03976712	chr1:2946727	NA	0.33	5.45	0.32	1.17e-7	Plateletcrit;
CESC	cis	rs3008870	1.000	rs1118393	chr1:67366668	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.02	14.09	0.65	4.84e-34	Lymphocyte percentage of white cells;
CESC	cis	rs7017914	0.967	rs34558600	chr8:71586152	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.09	-0.3	6.93e-7	Bone mineral density;
CESC	cis	rs752010	0.715	rs4660551	chr1:42099979	T/C	cg06885757	chr1:42089581	HIVEP3	0.7	10.94	0.56	3.02e-23	Lupus nephritis in systemic lupus erythematosus;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00504134	chr3:152552530	P2RY1	0.52	6.14	0.35	2.93e-9	Gut microbiome composition (summer);
CESC	cis	rs7829975	0.688	rs7837587	chr8:8378992	T/C	cg06636001	chr8:8085503	FLJ10661	0.51	6.35	0.36	9.5e-10	Mood instability;
CESC	trans	rs2755237	0.656	rs2721051	chr13:41110884	C/T	cg16029875	chr1:204320179	PLEKHA6	-0.66	-6.04	-0.35	5.11e-9	Central corneal thickness;
CESC	cis	rs7937682	0.632	rs4441050	chr11:111772506	C/T	cg22437258	chr11:111473054	SIK2	-0.5	-5.5	-0.32	8.78e-8	Primary sclerosing cholangitis;
CESC	cis	rs7666738	0.962	rs2865991	chr4:99067369	C/A	cg05340658	chr4:99064831	C4orf37	0.69	9.2	0.49	1.08e-17	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7666738	0.791	rs4699324	chr4:98967496	G/A	cg05340658	chr4:99064831	C4orf37	0.79	12.33	0.6	6.78e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs16854884	0.586	rs7639366	chr3:143752034	T/G	cg01302019	chr3:143689584	C3orf58	-0.32	-5.07	-0.3	7.32e-7	Economic and political preferences (feminism/equality);
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg17213616	chr1:5933044	NPHP4	0.45	6.09	0.35	3.86e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs13064411	0.696	rs9814395	chr3:113188885	C/T	cg18753928	chr3:113234510	CCDC52	-0.46	-5.45	-0.32	1.13e-7	Response to simvastatin treatment (PCSK9 protein level change);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06936779	chr1:151171405	PIP5K1A	0.58	6.57	0.37	2.7e-10	Gut microbiome composition (summer);
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg19990977	chr19:10654446	ATG4D	-0.48	-6.02	-0.35	5.86e-9	Asthma;
CESC	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg06074448	chr4:187884817	NA	-0.38	-5.31	-0.31	2.3e-7	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs1814175	0.645	rs28447324	chr11:50046629	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.42	-6.1	-0.35	3.76e-9	Height;
CESC	cis	rs6750795	0.602	rs1667317	chr2:232412036	T/C	cg19187155	chr2:232395269	NMUR1	0.59	7.53	0.42	7.74e-13	Height;
CESC	cis	rs7044106	0.791	rs7036196	chr9:123479457	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.73	10.79	0.55	9.56e-23	Hip circumference adjusted for BMI;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg08912860	chr12:132863782	GALNT9	0.29	6.05	0.35	4.81e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg24044651	chr1:24105262	C1orf128	0.46	6.06	0.35	4.69e-9	Systemic lupus erythematosus;
CESC	cis	rs17253792	0.545	rs71412688	chr14:56021539	A/G	cg01858014	chr14:56050164	KTN1	-0.87	-6.37	-0.36	8.34e-10	Putamen volume;
CESC	cis	rs7953249	0.594	rs11065384	chr12:121423285	T/C	cg25281562	chr12:121454272	C12orf43	-0.55	-6.95	-0.39	2.81e-11	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
CESC	cis	rs367943	0.712	rs10053654	chr5:112724314	G/C	cg12552261	chr5:112820674	MCC	0.38	5.15	0.3	5.04e-7	Type 2 diabetes;
CESC	cis	rs8060686	0.516	rs7193701	chr16:68185160	A/G	cg26727032	chr16:67993705	SLC12A4	0.48	6.85	0.39	5.14e-11	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs1218582	0.772	rs10796935	chr1:154891363	G/T	cg16680214	chr1:154839983	KCNN3	-0.44	-6.78	-0.38	7.71e-11	Prostate cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19898828	chr8:110346621	NUDCD1;ENY2	0.51	6.17	0.35	2.56e-9	Gut microbiome composition (summer);
CESC	cis	rs6087990	0.735	rs2424914	chr20:31374520	A/G	cg13636640	chr20:31349939	DNMT3B	0.81	13.19	0.63	6.87e-31	Ulcerative colitis;
CESC	cis	rs3857067	0.934	rs899132	chr4:95040022	A/C	cg11021082	chr4:95130006	SMARCAD1	0.5	7.61	0.42	4.95e-13	QT interval;
CESC	cis	rs763014	0.833	rs3743904	chr16:632767	A/G	cg09263875	chr16:632152	PIGQ	0.67	11.21	0.57	3.99e-24	Height;
CESC	cis	rs2243480	1.000	rs34193460	chr7:65393110	A/G	cg25894440	chr7:65020034	NA	-0.64	-5.31	-0.31	2.33e-7	Diabetic kidney disease;
CESC	cis	rs780096	0.546	rs1104	chr2:27599875	T/G	cg22903471	chr2:27725779	GCKR	-0.51	-7.17	-0.4	7.47e-12	Total body bone mineral density;
CESC	cis	rs5769765	0.908	rs138891	chr22:50227741	G/A	cg02269571	chr22:50332266	NA	-0.46	-5.95	-0.34	8.65e-9	Schizophrenia;
CESC	cis	rs1915146	0.546	rs1715862	chr10:126856255	C/T	cg00406319	chr10:126851303	NA	-0.38	-6.11	-0.35	3.46e-9	Menarche (age at onset);
CESC	cis	rs9467711	0.606	rs9379899	chr6:26603015	T/A	cg21479132	chr6:26055353	NA	0.65	5.69	0.33	3.29e-8	Autism spectrum disorder or schizophrenia;
CESC	cis	rs3892630	0.588	rs28787932	chr19:33226229	T/C	cg22980127	chr19:33182716	NUDT19	1.14	14.45	0.66	2.72e-35	Red blood cell traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00840257	chr16:8963031	CARHSP1	0.64	7.49	0.42	1.03e-12	Gut microbiome composition (summer);
CESC	cis	rs897984	0.683	rs12447534	chr16:30804257	C/T	cg00531865	chr16:30841666	NA	0.55	8.01	0.44	3.66e-14	Dementia with Lewy bodies;
CESC	cis	rs763121	0.853	rs1062687	chr22:39134715	T/C	cg06022373	chr22:39101656	GTPBP1	0.92	17.03	0.72	1.87e-44	Menopause (age at onset);
CESC	cis	rs561341	0.609	rs739800	chr17:30190083	T/A	cg13647721	chr17:30228624	UTP6	-0.74	-8.56	-0.47	9.61e-16	Hip circumference adjusted for BMI;
CESC	cis	rs9527	0.637	rs12219247	chr10:104613361	A/G	cg15744005	chr10:104629667	AS3MT	-0.37	-5.66	-0.33	3.95e-8	Arsenic metabolism;
CESC	cis	rs10883723	0.641	rs80146619	chr10:104405850	G/A	ch.10.2196322F	chr10:104248062	ACTR1A	0.62	6.03	0.35	5.39e-9	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs2485892	0.581	rs2484032	chr1:210317225	G/A	cg23283495	chr1:209979779	IRF6	0.44	5.54	0.32	7.24e-8	Manic episodes in bipolar disorder;
CESC	cis	rs454510	0.816	rs838987	chr1:120176127	A/G	cg11530693	chr1:120165357	ZNF697	0.43	5.48	0.32	9.71e-8	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
CESC	cis	rs193541	0.632	rs62377425	chr5:122332625	C/G	cg19412675	chr5:122181750	SNX24	-0.46	-5.38	-0.31	1.67e-7	Glucose homeostasis traits;
CESC	cis	rs270601	0.690	rs162904	chr5:131595784	C/T	cg04518342	chr5:131593106	PDLIM4	-0.37	-5.13	-0.3	5.55e-7	Acylcarnitine levels;
CESC	cis	rs35110281	0.667	rs4818859	chr21:45117120	G/A	cg01579765	chr21:45077557	HSF2BP	-0.51	-8.35	-0.46	3.74e-15	Mean corpuscular volume;
CESC	cis	rs796364	0.806	rs1605900	chr2:200870197	C/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.83	7.5	0.42	9.65e-13	Schizophrenia;
CESC	cis	rs2249694	0.960	rs4556495	chr10:135422209	C/T	cg19469447	chr10:135341870	CYP2E1	0.36	5.17	0.3	4.65e-7	Obesity-related traits;
CESC	cis	rs910316	0.737	rs175049	chr14:75481368	C/T	cg08847533	chr14:75593920	NEK9	-0.89	-15.25	-0.68	4.09e-38	Height;
CESC	cis	rs9303401	0.614	rs34843288	chr17:57103140	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.96	11.01	0.56	1.87e-23	Cognitive test performance;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg24688926	chr19:6737877	GPR108	-0.49	-6.48	-0.37	4.41e-10	Asthma;
CESC	cis	rs2479724	0.818	rs9357369	chr6:41818202	A/C	cg08135965	chr6:41755394	TOMM6	0.4	5.57	0.32	6.33e-8	Menarche (age at onset);
CESC	cis	rs7937682	0.855	rs7109592	chr11:111533105	C/A	cg09085632	chr11:111637200	PPP2R1B	-0.99	-16.33	-0.71	5.97e-42	Primary sclerosing cholangitis;
CESC	cis	rs910316	1.000	rs175436	chr14:75608683	C/G	cg08847533	chr14:75593920	NEK9	-0.96	-18.37	-0.75	3.6e-49	Height;
CESC	cis	rs17376456	0.877	rs10476601	chr5:93402522	G/A	cg25358565	chr5:93447407	FAM172A	1.13	10.9	0.56	4.33e-23	Diabetic retinopathy;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	ch.12.2922115F	chr12:133248407	POLE	0.52	6.83	0.39	5.66e-11	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs12995491	0.731	rs17435433	chr2:88509616	A/G	cg04511125	chr2:88470314	THNSL2	-0.52	-7.48	-0.42	1.1e-12	Response to metformin (IC50);
CESC	cis	rs2991971	0.933	rs2356553	chr1:46009313	G/C	cg24296786	chr1:45957014	TESK2	0.63	8.37	0.46	3.36e-15	High light scatter reticulocyte count;
CESC	trans	rs17685	0.753	rs1104878	chr7:75685593	G/T	cg19862616	chr7:65841803	NCRNA00174	0.83	12.38	0.61	4.45e-28	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs4835473	0.932	rs35017645	chr4:144681349	A/G	cg25736465	chr4:144833511	NA	-0.43	-6.52	-0.37	3.62e-10	Immature fraction of reticulocytes;
CESC	cis	rs763121	0.886	rs1013339	chr22:38974680	C/T	cg21395723	chr22:39101663	GTPBP1	0.43	5.6	0.33	5.44e-8	Menopause (age at onset);
CESC	cis	rs11871801	0.517	rs6963	chr17:40731597	A/T	cg21433558	chr17:40837037	CNTNAP1	-0.48	-5.8	-0.34	1.84e-8	Crohn's disease;
CESC	cis	rs9868809	0.881	rs3806694	chr3:48672334	G/C	cg07636037	chr3:49044803	WDR6	-0.63	-5.15	-0.3	5.14e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs2228479	0.867	rs62052168	chr16:89947203	G/A	cg04013166	chr16:89971882	TCF25	0.76	6.47	0.37	4.59e-10	Skin colour saturation;
CESC	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.53	-5.93	-0.34	9.61e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs6456156	0.586	rs9457266	chr6:167482555	T/C	cg07741184	chr6:167504864	NA	0.37	6.36	0.36	8.83e-10	Primary biliary cholangitis;
CESC	cis	rs617219	0.889	rs1622238	chr5:78437340	A/G	cg22188827	chr5:78429774	NA	-0.43	-5.1	-0.3	6.62e-7	Betaine levels in individuals undergoing cardiac evaluation;
CESC	cis	rs41271473	0.526	rs72765760	chr1:228743222	G/A	cg16512390	chr1:228756714	NA	0.55	5.66	0.33	3.84e-8	Chronic lymphocytic leukemia;
CESC	cis	rs9649213	0.593	rs12704989	chr7:98029438	G/T	cg08684580	chr7:98029266	BAIAP2L1	-0.35	-5.69	-0.33	3.28e-8	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07318073	chr4:74904359	CXCL3	0.6	6.39	0.37	7.28e-10	Gut microbiome composition (summer);
CESC	cis	rs372883	0.648	rs1153288	chr21:30686091	A/G	cg08807101	chr21:30365312	RNF160	0.45	5.31	0.31	2.32e-7	Pancreatic cancer;
CESC	cis	rs12765878	1.000	rs11191846	chr10:105649813	A/G	cg11005552	chr10:105648138	OBFC1	0.34	5.05	0.3	8.35e-7	Coronary artery disease;
CESC	cis	rs4971059	0.654	rs4971076	chr1:155124772	C/A	cg22049894	chr1:155113146	DPM3	0.47	6.06	0.35	4.62e-9	Breast cancer;
CESC	cis	rs708547	0.647	rs781668	chr4:57825140	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.6	-8.07	-0.44	2.49e-14	Response to bleomycin (chromatid breaks);
CESC	cis	rs7772486	0.902	rs2748500	chr6:146314852	C/A	cg05347473	chr6:146136440	FBXO30	0.49	6.6	0.38	2.28e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9311474	0.508	rs6788887	chr3:52605005	T/C	cg18099408	chr3:52552593	STAB1	-0.36	-6.09	-0.35	4.06e-9	Electroencephalogram traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00264380	chr18:48405387	ME2	0.58	6.61	0.38	2.07e-10	Gut microbiome composition (summer);
CESC	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg18402987	chr7:1209562	NA	0.76	7.56	0.42	6.59e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs67257959	0.586	rs8105085	chr19:17159962	G/A	cg16202187	chr19:17186497	HAUS8;MYO9B	0.52	6.78	0.38	7.69e-11	Selective IgA deficiency;
CESC	cis	rs2732480	0.577	rs2450994	chr12:48721832	G/A	cg24011408	chr12:48396354	COL2A1	0.4	5.76	0.33	2.31e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs1862618	0.853	rs33326	chr5:56142601	G/A	cg03609598	chr5:56110824	MAP3K1	-0.53	-5.62	-0.33	4.78e-8	Initial pursuit acceleration;
CESC	cis	rs116095464	0.558	rs59113266	chr5:279965	T/C	cg22496380	chr5:211416	CCDC127	-0.74	-8.46	-0.46	1.77e-15	Breast cancer;
CESC	cis	rs8040855	0.627	rs4980356	chr15:85608132	G/A	cg08123816	chr15:85640762	PDE8A	-0.41	-6.07	-0.35	4.31e-9	Bulimia nervosa;
CESC	cis	rs854765	0.547	rs2955356	chr17:17964717	G/A	cg04398451	chr17:18023971	MYO15A	0.72	10.46	0.54	1.15e-21	Total body bone mineral density;
CESC	cis	rs34734847	1.000	rs56179458	chr12:121157535	G/A	cg21892295	chr12:121157589	UNC119B	-0.42	-6.65	-0.38	1.66e-10	Mean corpuscular volume;
CESC	cis	rs1580019	0.522	rs10951340	chr7:32562408	G/A	cg07520158	chr7:32535189	LSM5;AVL9	0.51	6.51	0.37	3.72e-10	Cognitive ability;
CESC	cis	rs7520050	0.966	rs4076006	chr1:46438076	C/T	cg03146154	chr1:46216737	IPP	-0.47	-6.03	-0.35	5.46e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs34779708	0.966	rs17499247	chr10:35426755	A/G	cg03585969	chr10:35415529	CREM	0.76	10.3	0.53	3.72e-21	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs977987	0.806	rs1895490	chr16:75392806	G/A	cg03315344	chr16:75512273	CHST6	0.39	5.63	0.33	4.61e-8	Dupuytren's disease;
CESC	trans	rs4927850	0.881	rs7624638	chr3:195748729	C/T	cg16724585	chr3:197361211	NA	-0.56	-7.07	-0.4	1.39e-11	Pancreatic cancer;
CESC	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg18110333	chr6:292329	DUSP22	-0.75	-10.06	-0.53	2.21e-20	Menopause (age at onset);
CESC	cis	rs11760633	0.672	rs7811019	chr7:1843541	C/G	cg23422044	chr7:1970798	MAD1L1	-0.48	-5.54	-0.32	7.14e-8	Coronary artery disease;
CESC	cis	rs10876993	0.890	rs1678516	chr12:58047458	G/A	cg18357645	chr12:58087776	OS9	0.59	9.02	0.48	3.88e-17	Celiac disease or Rheumatoid arthritis;
CESC	cis	rs116095464	0.558	rs56081398	chr5:247318	C/T	cg22496380	chr5:211416	CCDC127	-0.98	-10.28	-0.53	4.47e-21	Breast cancer;
CESC	cis	rs875971	0.660	rs28698552	chr7:66005018	A/G	cg06456125	chr7:65229604	NA	0.39	5.07	0.3	7.38e-7	Aortic root size;
CESC	cis	rs9796	0.870	rs1001341	chr15:41261491	T/A	cg18705301	chr15:41695430	NDUFAF1	0.43	6.28	0.36	1.41e-9	Menopause (age at onset);
CESC	cis	rs3845702	1.000	rs3845697	chr2:180798553	C/T	cg01881094	chr2:180872142	CWC22	0.65	6.73	0.38	1.07e-10	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26304119	chr11:67265369	PITPNM1	-0.57	-7.11	-0.4	1.08e-11	Gut microbiome composition (summer);
CESC	cis	rs11048434	0.649	rs11613650	chr12:9060396	T/C	cg04155231	chr12:9217510	LOC144571	0.33	5.36	0.31	1.77e-7	Sjögren's syndrome;
CESC	cis	rs2370759	1.000	rs79487858	chr10:32616405	T/C	cg01819863	chr10:32635814	EPC1	1.16	12.42	0.61	3.2e-28	Sexual dysfunction (female);
CESC	cis	rs35306767	0.909	rs12264390	chr10:959111	T/C	cg26597838	chr10:835615	NA	0.77	9.03	0.49	3.62e-17	Eosinophil percentage of granulocytes;
CESC	cis	rs1552244	0.882	rs67762674	chr3:10014485	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.77	-9.88	-0.52	8.65e-20	Alzheimer's disease;
CESC	cis	rs4523957	0.890	rs9908888	chr17:2102453	G/C	cg16513277	chr17:2031491	SMG6	-0.67	-9.26	-0.49	7.04e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs2204008	0.774	rs3910796	chr12:38230660	G/T	cg13010199	chr12:38710504	ALG10B	0.54	6.69	0.38	1.28e-10	Bladder cancer;
CESC	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg01238044	chr22:24384105	GSTT1	-0.5	-6.21	-0.36	2.08e-9	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs3809863	0.602	rs2317677	chr17:45393407	G/A	cg25173405	chr17:45401733	C17orf57	-0.54	-6.98	-0.39	2.34e-11	Glaucoma (primary open-angle);
CESC	cis	rs1568889	1.000	rs7951681	chr11:28273894	G/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.8	10.99	0.56	2.09e-23	Bipolar disorder;
CESC	trans	rs1945213	0.694	rs67394518	chr11:55855303	G/A	cg03929089	chr4:120376271	NA	0.73	6.63	0.38	1.85e-10	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs67311347	1.000	rs12633431	chr3:40505740	C/T	cg24209194	chr3:40518798	ZNF619	-0.54	-7.1	-0.4	1.13e-11	Renal cell carcinoma;
CESC	cis	rs7267979	1.000	rs6050561	chr20:25334855	C/T	cg08601574	chr20:25228251	PYGB	-0.38	-5.55	-0.32	6.85e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs6456156	0.792	rs9366089	chr6:167512896	A/G	cg23791538	chr6:167370224	RNASET2	-0.41	-5.3	-0.31	2.45e-7	Primary biliary cholangitis;
CESC	cis	rs1185460	0.967	rs1784302	chr11:118940957	C/G	cg23280166	chr11:118938394	VPS11	0.57	7.85	0.43	1.04e-13	Coronary artery disease;
CESC	cis	rs7618915	0.524	rs10433615	chr3:52638482	C/T	cg18404041	chr3:52824283	ITIH1	-0.39	-6.55	-0.37	2.91e-10	Bipolar disorder;
CESC	trans	rs7937682	0.889	rs558736	chr11:111500760	C/G	cg18187862	chr3:45730750	SACM1L	0.52	6.55	0.37	2.95e-10	Primary sclerosing cholangitis;
CESC	cis	rs8092503	1.000	rs12960467	chr18:52492951	C/G	cg12377874	chr18:52495404	RAB27B	0.38	5.95	0.34	8.67e-9	Childhood body mass index;
CESC	cis	rs2235649	0.592	rs2429186	chr16:1969939	C/T	cg03715980	chr16:1756201	MAPK8IP3	0.45	5.11	0.3	6.31e-7	Blood metabolite levels;
CESC	cis	rs5995756	0.697	rs713865	chr22:39997630	C/T	cg03390717	chr22:39966585	CACNA1I	-0.32	-5.41	-0.32	1.38e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs9611565	0.527	rs2234053	chr22:41777315	G/T	cg03806693	chr22:41940476	POLR3H	-1.12	-13.95	-0.65	1.55e-33	Vitiligo;
CESC	cis	rs7089973	0.604	rs2181563	chr10:116604344	T/C	cg25233709	chr10:116636983	FAM160B1	0.38	6.44	0.37	5.46e-10	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs11792861	0.816	rs7027263	chr9:111699569	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.51	6.59	0.38	2.3e-10	Menarche (age at onset);
CESC	cis	rs854765	0.547	rs2955377	chr17:17932818	G/A	cg09796270	chr17:17721594	SREBF1	0.37	5.08	0.3	7.17e-7	Total body bone mineral density;
CESC	cis	rs9322193	0.923	rs9479494	chr6:150060244	A/G	cg04369109	chr6:150039330	LATS1	-0.42	-5.95	-0.34	8.52e-9	Lung cancer;
CESC	trans	rs17764205	0.777	rs17696630	chr19:3261995	A/G	cg13921652	chr1:144931966	PDE4DIP	-0.75	-6.15	-0.35	2.81e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs12137294	0.866	rs1172151	chr1:205221659	A/C	cg21643547	chr1:205240462	TMCC2	-0.35	-5.71	-0.33	3.04e-8	Red cell distribution width;
CESC	cis	rs9560113	0.509	rs28608633	chr13:112206880	G/A	cg10483660	chr13:112241077	NA	0.42	7.14	0.4	9e-12	Menarche (age at onset);
CESC	cis	rs9611565	0.921	rs4822021	chr22:41726053	G/A	cg06634786	chr22:41940651	POLR3H	-0.63	-6.75	-0.38	9.25e-11	Vitiligo;
CESC	cis	rs7666738	0.830	rs7674095	chr4:99048158	T/A	cg03676636	chr4:99064102	C4orf37	0.33	5.12	0.3	5.93e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2708240	1.000	rs2538979	chr7:147582719	C/T	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	0.32	5.25	0.31	3.12e-7	QT interval (drug interaction);
CESC	cis	rs875971	1.000	rs6961990	chr7:65888570	C/A	cg18876405	chr7:65276391	NA	0.49	6.42	0.37	6.43e-10	Aortic root size;
CESC	cis	rs3924048	0.559	rs6541039	chr1:12626261	T/C	cg00291366	chr1:12616550	NA	0.36	6.26	0.36	1.5e-9	Optic cup area;
CESC	cis	rs4665809	1.000	rs4665820	chr2:26309150	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.7	-8.01	-0.44	3.69e-14	Gut microbiome composition (summer);
CESC	cis	rs2180341	0.711	rs4371861	chr6:127568447	G/T	cg27446573	chr6:127587934	RNF146	0.67	9.9	0.52	7.15e-20	Breast cancer;
CESC	cis	rs7044106	0.791	rs2416799	chr9:123480866	G/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.72	10.87	0.56	5.43e-23	Hip circumference adjusted for BMI;
CESC	cis	rs8044868	0.530	rs2287999	chr16:72059149	A/G	cg16558253	chr16:72132732	DHX38	-0.37	-5.67	-0.33	3.8e-8	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CESC	trans	rs9467711	0.659	rs3823158	chr6:26463271	T/A	cg06606381	chr12:133084897	FBRSL1	-0.95	-7.31	-0.41	3.06e-12	Autism spectrum disorder or schizophrenia;
CESC	cis	rs7945705	0.935	rs1883098	chr11:8890594	G/A	cg12365402	chr11:9010492	NRIP3	-0.31	-5.16	-0.3	4.76e-7	Hemoglobin concentration;
CESC	cis	rs6582630	0.502	rs7312212	chr12:38274760	T/G	cg26384229	chr12:38710491	ALG10B	0.65	9.03	0.49	3.55e-17	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs9875589	0.509	rs2129888	chr3:14013826	A/T	cg19554555	chr3:13937349	NA	-0.42	-5.35	-0.31	1.86e-7	Ovarian reserve;
CESC	cis	rs4692589	0.606	rs12645495	chr4:170933909	T/C	cg19918862	chr4:170955249	NA	0.41	5.32	0.31	2.22e-7	Anxiety disorder;
CESC	cis	rs854765	0.552	rs6502624	chr17:17847936	G/A	cg16928487	chr17:17741425	SREBF1	-0.57	-9.57	-0.51	7.66e-19	Total body bone mineral density;
CESC	cis	rs72772090	0.539	rs116360011	chr5:96117797	T/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.57	-5.18	-0.3	4.41e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs4072980	0.545	rs16824518	chr1:38415315	A/C	cg18451016	chr1:38461880	NA	-0.37	-5.04	-0.3	8.5e-7	Coronary artery disease;
CESC	cis	rs12618769	0.543	rs4851132	chr2:99042782	T/C	cg10123293	chr2:99228465	UNC50	0.4	5.34	0.31	1.97e-7	Bipolar disorder;
CESC	cis	rs561341	1.000	rs8070262	chr17:30262467	A/G	cg19193384	chr17:30244184	NA	-0.48	-5.52	-0.32	8.2e-8	Hip circumference adjusted for BMI;
CESC	cis	rs6565180	0.507	rs4471699	chr16:30320307	G/T	cg17640201	chr16:30407289	ZNF48	-0.67	-9.33	-0.5	4.28e-18	Tonsillectomy;
CESC	cis	rs2243480	0.803	rs36004293	chr7:65416512	T/C	cg13147721	chr7:65941812	NA	-0.86	-8.49	-0.46	1.47e-15	Diabetic kidney disease;
CESC	cis	rs698813	0.674	rs713447	chr2:44505185	T/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.48	5.18	0.3	4.32e-7	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
CESC	cis	rs5750830	0.649	rs6001588	chr22:39819049	G/C	cg11247378	chr22:39784982	NA	-0.62	-9.06	-0.49	2.88e-17	Intelligence (multi-trait analysis);
CESC	cis	rs875971	0.862	rs4718319	chr7:65652784	C/A	cg10691866	chr7:65817282	TPST1	0.31	5.24	0.31	3.34e-7	Aortic root size;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg27453922	chr7:148922355	ZNF282	0.5	6.45	0.37	5.22e-10	Fibrinogen levels;
CESC	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg07092213	chr7:1199455	ZFAND2A	-0.43	-5.57	-0.32	6.36e-8	Longevity;Endometriosis;
CESC	cis	rs7666738	0.830	rs11931166	chr4:99054187	A/T	cg03467027	chr4:99064603	C4orf37	0.47	5.98	0.34	7.19e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4819052	0.851	rs34101026	chr21:46662200	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.9	13.15	0.63	1e-30	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs7615952	0.688	rs7624806	chr3:125599074	G/A	cg07211511	chr3:129823064	LOC729375	-1.03	-13.07	-0.63	1.76e-30	Blood pressure (smoking interaction);
CESC	cis	rs6695640	0.820	rs6678862	chr1:17744852	G/A	cg01904812	chr1:17746340	RCC2	0.36	5.29	0.31	2.51e-7	Mean platelet volume;
CESC	cis	rs172166	0.694	rs203876	chr6:28046673	T/C	cg12963246	chr6:28129442	ZNF389	0.41	6.0	0.35	6.29e-9	Cardiac Troponin-T levels;
CESC	cis	rs7809950	0.817	rs58052742	chr7:107210003	A/G	cg23024343	chr7:107201750	COG5	0.57	7.24	0.41	4.92e-12	Coronary artery disease;
CESC	cis	rs116095464	0.558	rs6875291	chr5:264192	T/C	cg10591111	chr5:226296	SDHA	-0.52	-6.35	-0.36	9.51e-10	Breast cancer;
CESC	cis	rs6690583	0.623	rs75918067	chr1:85453413	T/C	cg22153463	chr1:85462885	MCOLN2	0.71	7.12	0.4	1.01e-11	Serum sulfate level;
CESC	cis	rs7412746	0.658	rs12097963	chr1:150870450	T/C	cg18016565	chr1:150552671	MCL1	0.34	5.07	0.3	7.52e-7	Melanoma;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01394034	chr12:98909208	TMPO;LOC100128191	0.61	6.67	0.38	1.51e-10	Gut microbiome composition (summer);
CESC	cis	rs7552404	0.727	rs12093623	chr1:76256232	T/G	cg10523679	chr1:76189770	ACADM	0.68	6.77	0.38	8.41e-11	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs2841277	0.708	rs10083496	chr14:105402786	G/A	cg17340268	chr14:105411764	AHNAK2	-0.5	-6.75	-0.38	9.45e-11	Rheumatoid arthritis;
CESC	cis	rs6582630	0.519	rs11520262	chr12:38333051	A/G	cg13010199	chr12:38710504	ALG10B	0.48	6.11	0.35	3.53e-9	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs35306767	0.903	rs12764024	chr10:922861	A/G	cg10556349	chr10:835070	NA	0.55	5.54	0.32	7.41e-8	Eosinophil percentage of granulocytes;
CESC	cis	rs752010	0.905	rs4525030	chr1:42091307	G/C	cg06885757	chr1:42089581	HIVEP3	0.46	7.42	0.41	1.64e-12	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs8016982	0.609	rs8009519	chr14:81702503	C/G	cg01989461	chr14:81687754	GTF2A1	0.75	11.77	0.59	5.41e-26	Schizophrenia;
CESC	cis	rs7923609	1.000	rs10822163	chr10:65124098	C/G	cg01631684	chr10:65280961	REEP3	-0.41	-5.15	-0.3	5.05e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg22702420	chr1:213031749	FLVCR1;LQK1	-0.55	-6.5	-0.37	3.94e-10	Ulcerative colitis;
CESC	cis	rs7085104	0.514	rs284855	chr10:104574422	A/G	cg04362960	chr10:104952993	NT5C2	-0.47	-6.37	-0.36	8.3e-10	Immature fraction of reticulocytes;Schizophrenia;
CESC	cis	rs12681366	0.734	rs16916788	chr8:95399618	C/T	cg13257157	chr8:95487014	RAD54B	0.38	5.14	0.3	5.22e-7	Nonsyndromic cleft lip with cleft palate;
CESC	trans	rs17685	0.712	rs6464994	chr7:75784668	C/T	cg19862616	chr7:65841803	NCRNA00174	0.8	11.44	0.57	6.89e-25	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs7542091	0.669	rs7540534	chr1:210044824	A/T	cg25204440	chr1:209979598	IRF6	0.37	5.1	0.3	6.55e-7	Monobrow;
CESC	cis	rs4253772	0.591	rs11704614	chr22:46691936	A/G	cg00784671	chr22:46762841	CELSR1	-0.58	-5.61	-0.33	4.99e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs769267	0.896	rs7253807	chr19:19631444	A/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.49	6.0	0.35	6.47e-9	Tonsillectomy;
CESC	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	20.7	0.79	2.79e-57	Prudent dietary pattern;
CESC	cis	rs514406	0.825	rs6693210	chr1:53223398	A/G	cg08736216	chr1:53307985	ZYG11A	0.41	6.86	0.39	4.94e-11	Monocyte count;
CESC	trans	rs7726839	0.574	rs12517345	chr5:628294	G/A	cg25482853	chr8:67687455	SGK3	1.01	9.87	0.52	8.86e-20	Obesity-related traits;
CESC	cis	rs10208940	0.920	rs72903979	chr2:68813938	C/T	cg12452813	chr2:68675892	NA	0.53	5.29	0.31	2.54e-7	Urate levels in lean individuals;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg25560965	chr12:12510064	LOH12CR1;LOH12CR2	-0.44	-6.21	-0.36	2.09e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs853679	0.517	rs9393893	chr6:28109262	T/C	cg26335602	chr6:28129616	ZNF389	0.54	7.14	0.4	8.92e-12	Depression;
CESC	cis	rs4319547	0.698	rs10773178	chr12:122944752	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.57	-7.03	-0.4	1.75e-11	Body mass index;
CESC	cis	rs1005277	0.565	rs2474565	chr10:38380828	A/G	cg25427524	chr10:38739819	LOC399744	-0.65	-9.48	-0.5	1.51e-18	Extrinsic epigenetic age acceleration;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05712126	chr22:29601860	EMID1	0.57	6.11	0.35	3.54e-9	Gut microbiome composition (summer);
CESC	cis	rs735396	0.770	rs1169300	chr12:121431225	G/A	cg02403541	chr12:121454288	C12orf43	0.72	9.79	0.52	1.56e-19	N-glycan levels;
CESC	cis	rs2576037	0.526	rs2510444	chr18:44376849	G/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.54	-7.48	-0.42	1.08e-12	Personality dimensions;
CESC	trans	rs116095464	0.558	rs10077076	chr5:231940	C/T	cg00938859	chr5:1591904	SDHAP3	0.63	6.87	0.39	4.49e-11	Breast cancer;
CESC	cis	rs360071	0.528	rs360100	chr1:226067382	G/A	cg17950169	chr1:226067900	TMEM63A	0.42	6.42	0.37	6.42e-10	Response to radiotherapy in prostate cancer (toxicity, rectal bleeding);
CESC	cis	rs7903847	0.642	rs1537645	chr10:99149914	T/C	cg20016023	chr10:99160130	RRP12	-0.3	-5.15	-0.3	5.04e-7	Granulocyte percentage of myeloid white cells;
CESC	cis	rs2070997	0.702	rs3780284	chr9:133733961	A/G	cg11464064	chr9:133710261	ABL1	0.55	5.98	0.34	7.32e-9	Response to amphetamines;
CESC	cis	rs9815354	1.000	rs9875107	chr3:41822313	A/T	cg03022575	chr3:42003672	ULK4	0.49	5.38	0.31	1.66e-7	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs11195062	0.521	rs6584977	chr10:111954970	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.51	-6.89	-0.39	3.99e-11	Multiple myeloma;
CESC	cis	rs9311474	0.652	rs614288	chr3:52220203	T/C	cg05315796	chr3:52349193	DNAH1	0.32	5.66	0.33	3.84e-8	Electroencephalogram traits;
CESC	cis	rs4474465	0.688	rs4945300	chr11:78282632	T/C	cg27205649	chr11:78285834	NARS2	0.52	7.25	0.41	4.65e-12	Alzheimer's disease (survival time);
CESC	trans	rs2727020	0.521	rs7946190	chr11:49521964	T/A	cg03929089	chr4:120376271	NA	0.69	7.89	0.44	8.11e-14	Coronary artery disease;
CESC	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.48	-5.08	-0.3	7.1e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs62103177	0.810	rs62103194	chr18:77629482	G/A	cg12964065	chr18:77638022	KCNG2	0.58	5.46	0.32	1.07e-7	Opioid sensitivity;
CESC	cis	rs2075371	0.897	rs1646702	chr7:134000177	C/G	cg20476274	chr7:133979776	SLC35B4	0.65	9.4	0.5	2.76e-18	Mean platelet volume;
CESC	trans	rs11098499	0.739	rs9884728	chr4:120127079	C/T	cg25214090	chr10:38739885	LOC399744	-0.54	-7.16	-0.4	8.19e-12	Corneal astigmatism;
CESC	cis	rs875971	0.502	rs6460311	chr7:66111873	C/T	cg19163074	chr7:65112434	INTS4L2	0.51	5.25	0.31	3.05e-7	Aortic root size;
CESC	cis	rs3096299	0.719	rs2965817	chr16:89513234	C/T	cg00750074	chr16:89608354	SPG7	-0.42	-6.17	-0.35	2.6e-9	Multiple myeloma (IgH translocation);
CESC	cis	rs12477438	0.798	rs6740267	chr2:99561867	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.75	-10.81	-0.55	8.66e-23	Chronic sinus infection;
CESC	trans	rs1944866	0.764	rs1944865	chr11:134479371	A/T	cg26534871	chr5:108064185	NA	-1.04	-6.0	-0.35	6.61e-9	Myopia (pathological);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05151241	chr15:90808880	NGRN	0.55	6.03	0.35	5.46e-9	Gut microbiome composition (summer);
CESC	cis	rs2243480	0.803	rs403089	chr7:65517723	T/C	cg25894440	chr7:65020034	NA	-0.61	-5.3	-0.31	2.42e-7	Diabetic kidney disease;
CESC	cis	rs1797885	0.934	rs709162	chr3:12521180	T/G	cg26432171	chr3:12704882	RAF1	-0.49	-6.26	-0.36	1.57e-9	Immature fraction of reticulocytes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04203298	chr11:59521722	STX3	0.56	6.91	0.39	3.53e-11	Gut microbiome composition (summer);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg17408923	chr2:109335769	RANBP2	-0.44	-6.4	-0.37	6.94e-10	Gambling;
CESC	cis	rs34779708	0.931	rs10508815	chr10:35332621	A/C	cg04310649	chr10:35416472	CREM	-0.53	-6.4	-0.37	6.96e-10	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs34779708	0.931	rs2505631	chr10:35368385	A/T	cg04310649	chr10:35416472	CREM	0.51	6.22	0.36	1.93e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs3857536	0.813	rs6931701	chr6:66940905	T/C	cg07460842	chr6:66804631	NA	-0.42	-5.34	-0.31	1.96e-7	Blood trace element (Cu levels);
CESC	cis	rs9929218	1.000	rs7200690	chr16:68778457	C/T	cg02972257	chr16:68554789	NA	0.55	6.39	0.37	7.36e-10	Colorectal cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15622551	chr19:11039538	C19orf52;YIPF2	0.56	6.14	0.35	3e-9	Gut microbiome composition (summer);
CESC	cis	rs9488822	0.676	rs1999929	chr6:116381994	T/C	cg05304507	chr6:116381966	FRK	0.26	6.79	0.38	7.51e-11	Cholesterol, total;LDL cholesterol;
CESC	trans	rs28549925	0.590	rs28507245	chr7:16990447	G/C	cg12639933	chr12:57626296	SHMT2	0.95	6.1	0.35	3.83e-9	Congenital heart disease (maternal effect);Conotruncal heart defects (maternal effects);
CESC	cis	rs11864453	0.514	rs2269918	chr16:72134831	C/A	cg01557791	chr16:72042693	DHODH	-0.43	-5.62	-0.33	4.93e-8	Fibrinogen levels;
CESC	cis	rs7085104	0.700	rs3740397	chr10:104592675	G/C	cg04362960	chr10:104952993	NT5C2	0.48	6.12	0.35	3.31e-9	Immature fraction of reticulocytes;Schizophrenia;
CESC	cis	rs9300255	0.722	rs34997336	chr12:123829116	G/A	cg19016782	chr12:123741754	C12orf65	0.44	6.2	0.36	2.22e-9	Neutrophil percentage of white cells;
CESC	cis	rs854765	0.547	rs4584886	chr17:17896205	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.65	9.61	0.51	6.12e-19	Total body bone mineral density;
CESC	cis	rs801193	0.569	rs11772819	chr7:66217970	T/C	cg18876405	chr7:65276391	NA	0.45	6.18	0.35	2.39e-9	Aortic root size;
CESC	cis	rs7208859	0.673	rs2433	chr17:29226228	T/C	cg19761014	chr17:28927070	LRRC37B2	0.73	5.78	0.33	2.06e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs7618501	0.571	rs2240329	chr3:50107512	G/A	cg24110177	chr3:50126178	RBM5	0.52	7.28	0.41	3.76e-12	Intelligence (multi-trait analysis);
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg19161053	chr7:99036702	CPSF4;PTCD1	0.47	6.3	0.36	1.22e-9	Systemic lupus erythematosus;
CESC	cis	rs270601	0.661	rs10036208	chr5:131571323	T/C	cg18758796	chr5:131593413	PDLIM4	0.42	5.61	0.33	5.13e-8	Acylcarnitine levels;
CESC	cis	rs7267979	0.932	rs6115200	chr20:25487377	G/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.76	13.57	0.64	3.43e-32	Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08591886	chr16:81111003	C16orf46	0.52	6.13	0.35	3.18e-9	Gut microbiome composition (summer);
CESC	cis	rs6009527	0.711	rs8141990	chr22:49570455	T/G	cg12746016	chr22:49560550	NA	0.44	7.54	0.42	7.27e-13	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);
CESC	cis	rs9535495	0.833	rs7320482	chr13:51367489	C/G	cg07818422	chr13:52301946	WDFY2	0.36	5.25	0.31	3.11e-7	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	cis	rs12545109	0.800	rs2118261	chr8:57393286	A/G	cg09654669	chr8:57350985	NA	0.56	7.32	0.41	2.9e-12	Obesity-related traits;
CESC	cis	rs7680126	0.633	rs11728093	chr4:10296407	A/C	cg11266682	chr4:10021025	SLC2A9	-0.46	-5.96	-0.34	7.88e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	cis	rs3026101	0.554	rs1806259	chr17:5315502	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.41	5.36	0.31	1.8e-7	Body mass index;
CESC	cis	rs9900062	0.535	rs753917	chr17:62673136	C/T	cg02097616	chr17:62675921	NA	0.46	5.52	0.32	8.01e-8	QT interval;
CESC	cis	rs9311474	0.502	rs4687624	chr3:52563572	C/T	cg18099408	chr3:52552593	STAB1	-0.38	-6.48	-0.37	4.41e-10	Electroencephalogram traits;
CESC	cis	rs9486719	0.857	rs11759769	chr6:97065212	G/A	cg06623918	chr6:96969491	KIAA0776	-0.83	-8.95	-0.48	6.52e-17	Migraine;Coronary artery disease;
CESC	cis	rs6089584	0.888	rs6061983	chr20:60621202	T/C	cg24733560	chr20:60626293	TAF4	0.45	6.44	0.37	5.45e-10	Body mass index;
CESC	cis	rs8020095	0.528	rs73284892	chr14:67832820	A/G	cg19548862	chr14:67692701	FAM71D	-0.45	-5.3	-0.31	2.41e-7	Depression (quantitative trait);
CESC	cis	rs7703051	0.901	rs5744680	chr5:74879890	C/T	cg03227963	chr5:74354835	NA	0.29	5.22	0.31	3.7e-7	LDL cholesterol;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
CESC	cis	rs9467711	0.606	rs9379901	chr6:26603866	T/C	cg21479132	chr6:26055353	NA	0.65	5.69	0.33	3.29e-8	Autism spectrum disorder or schizophrenia;
CESC	cis	rs12681288	0.782	rs2600500	chr8:1029031	G/C	cg15309053	chr8:964076	NA	0.37	5.77	0.33	2.15e-8	Schizophrenia;
CESC	cis	rs7100689	0.646	rs10400045	chr10:82077032	A/G	cg00277334	chr10:82204260	NA	-0.6	-7.96	-0.44	4.91e-14	Post bronchodilator FEV1;
CESC	cis	rs6460942	0.915	rs62448621	chr7:12459941	G/A	cg20607287	chr7:12443886	VWDE	-0.79	-9.27	-0.49	6.78e-18	Coronary artery disease;
CESC	cis	rs4555082	0.834	rs28489970	chr14:105748862	T/C	cg27165867	chr14:105738592	BRF1	-0.48	-5.1	-0.3	6.44e-7	Mean platelet volume;Platelet distribution width;
CESC	cis	rs9916302	0.718	rs7219909	chr17:37706243	C/T	cg07936489	chr17:37558343	FBXL20	-0.81	-11.66	-0.58	1.24e-25	Glomerular filtration rate (creatinine);
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg04334108	chr4:148555806	TMEM184C	0.41	6.22	0.36	1.95e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg08945467	chr1:58522070	DAB1	0.47	6.0	0.35	6.33e-9	Ulcerative colitis;
CESC	cis	rs9837602	1.000	rs1688772	chr3:99503366	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.52	-7.18	-0.4	6.88e-12	Breast cancer;
CESC	cis	rs7937682	0.924	rs875258	chr11:111530607	C/A	cg22437258	chr11:111473054	SIK2	0.69	9.29	0.5	5.71e-18	Primary sclerosing cholangitis;
CESC	trans	rs12599106	0.715	rs34006830	chr16:34878550	C/A	cg18110333	chr6:292329	DUSP22	-0.74	-9.46	-0.5	1.77e-18	Menopause (age at onset);
CESC	cis	rs3026101	0.624	rs1806255	chr17:5314263	G/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.49	6.29	0.36	1.27e-9	Body mass index;
CESC	cis	rs921968	0.541	rs933994	chr2:219650616	C/T	cg02176678	chr2:219576539	TTLL4	-0.45	-7.83	-0.43	1.19e-13	Mean corpuscular hemoglobin concentration;
CESC	cis	rs1707322	1.000	rs10890360	chr1:46338444	C/T	cg03146154	chr1:46216737	IPP	0.71	9.86	0.52	9.69e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs826838	0.935	rs3886109	chr12:39189243	C/T	cg13010199	chr12:38710504	ALG10B	0.58	8.05	0.44	2.77e-14	Heart rate;
CESC	cis	rs7618915	0.547	rs3774365	chr3:52642487	T/C	cg07507251	chr3:52567010	NT5DC2	0.4	6.95	0.39	2.85e-11	Bipolar disorder;
CESC	cis	rs7208859	0.623	rs216433	chr17:28921860	T/C	cg14008862	chr17:28927542	LRRC37B2	0.69	6.16	0.35	2.63e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs1218582	0.803	rs7531728	chr1:154840516	C/A	cg16680214	chr1:154839983	KCNN3	-0.52	-7.97	-0.44	4.67e-14	Prostate cancer;
CESC	cis	rs3617	0.625	rs2240915	chr3:52859526	T/A	cg11645453	chr3:52864694	ITIH4	0.25	5.2	0.3	3.93e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
CESC	cis	rs7959452	0.532	rs2291005	chr12:69764388	A/G	cg20891283	chr12:69753455	YEATS4	0.9	14.79	0.67	1.71e-36	Blood protein levels;
CESC	cis	rs2249694	0.810	rs2987785	chr10:135365003	C/T	cg19469447	chr10:135341870	CYP2E1	-0.36	-5.04	-0.3	8.61e-7	Obesity-related traits;
CESC	cis	rs523522	0.885	rs524735	chr12:121022099	T/C	cg12219531	chr12:120966889	COQ5	0.76	9.91	0.52	6.54e-20	High light scatter reticulocyte count;
CESC	cis	rs12348691	0.503	rs7046645	chr9:100617375	T/C	cg13688889	chr9:100608707	NA	-0.9	-13.65	-0.64	1.78e-32	Alopecia areata;
CESC	cis	rs2777491	1.000	rs7168177	chr15:41715585	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.65	-9.76	-0.51	1.94e-19	Ulcerative colitis;
CESC	cis	rs7084402	1.000	rs717452	chr10:60268270	A/G	cg07615347	chr10:60278583	BICC1	0.6	9.17	0.49	1.41e-17	Refractive error;
CESC	cis	rs16854884	0.657	rs7610378	chr3:143711298	G/A	cg06585982	chr3:143692056	C3orf58	0.5	6.44	0.37	5.45e-10	Economic and political preferences (feminism/equality);
CESC	cis	rs5758659	0.737	rs10854749	chr22:42447341	G/T	cg15557168	chr22:42548783	NA	-0.45	-6.66	-0.38	1.55e-10	Cognitive function;
CESC	cis	rs7178909	0.902	rs3853638	chr15:90443140	C/T	cg19708238	chr15:90437601	AP3S2	-0.43	-6.16	-0.35	2.65e-9	Common traits (Other);
CESC	cis	rs798554	0.610	rs2644297	chr7:2858906	A/C	cg19717773	chr7:2847554	GNA12	-0.53	-8.33	-0.46	4.37e-15	Height;
CESC	cis	rs9916302	0.904	rs12600751	chr17:37553651	G/C	cg07936489	chr17:37558343	FBXL20	0.78	10.32	0.54	3.4e-21	Glomerular filtration rate (creatinine);
CESC	cis	rs9354308	0.866	rs2814092	chr6:66547346	C/G	cg07460842	chr6:66804631	NA	0.58	6.53	0.37	3.29e-10	Metabolite levels;
CESC	cis	rs4975616	0.869	rs452384	chr5:1330840	T/C	cg06550200	chr5:1325588	CLPTM1L	-0.7	-11.17	-0.57	5.42e-24	Lung cancer;
CESC	cis	rs2625529	0.652	rs2278987	chr15:72409769	T/C	cg16672083	chr15:72433130	SENP8	0.45	7.06	0.4	1.49e-11	Red blood cell count;
CESC	cis	rs4924935	0.770	rs4924946	chr17:18846525	A/T	cg26378065	chr17:18585709	ZNF286B	-0.46	-5.74	-0.33	2.64e-8	Pancreatic cancer;
CESC	cis	rs4563143	0.675	rs34113156	chr19:29270822	G/A	cg14983838	chr19:29218262	NA	0.5	6.16	0.35	2.67e-9	Methadone dose in opioid dependence;
CESC	cis	rs2075371	1.000	rs2058976	chr7:133981379	G/T	cg11752832	chr7:134001865	SLC35B4	0.54	7.06	0.4	1.5e-11	Mean platelet volume;
CESC	cis	rs6893300	0.961	rs7447159	chr5:179177676	G/C	cg14593053	chr5:179126677	CANX	-0.47	-5.04	-0.3	8.65e-7	Resting heart rate;
CESC	cis	rs1451375	0.617	rs7790758	chr7:50561544	G/A	cg14593290	chr7:50529359	DDC	-0.5	-6.33	-0.36	1.04e-9	Malaria;
CESC	trans	rs3749237	0.964	rs13084243	chr3:49821878	G/C	cg21659725	chr3:3221576	CRBN	0.53	6.33	0.36	1.04e-9	Resting heart rate;
CESC	cis	rs7605827	0.823	rs11689269	chr2:15621917	C/G	cg19274914	chr2:15703543	NA	0.36	6.52	0.37	3.44e-10	Educational attainment (years of education);
CESC	cis	rs2404602	0.647	rs11072636	chr15:77185786	A/G	cg23625390	chr15:77176239	SCAPER	-0.45	-6.24	-0.36	1.69e-9	Blood metabolite levels;
CESC	cis	rs2072732	0.904	rs2993481	chr1:2973433	A/T	cg15211996	chr1:2936768	ACTRT2	0.31	5.32	0.31	2.2e-7	Plateletcrit;
CESC	trans	rs116095464	0.558	rs7730700	chr5:264713	G/A	cg00938859	chr5:1591904	SDHAP3	0.63	6.77	0.38	8.38e-11	Breast cancer;
CESC	cis	rs27434	0.583	rs26653	chr5:96139250	C/G	cg16492584	chr5:96139282	ERAP1	-0.37	-5.38	-0.31	1.66e-7	Ankylosing spondylitis;
CESC	cis	rs12142240	0.660	rs6679080	chr1:46819779	A/T	cg00530320	chr1:46809349	NSUN4	0.58	7.89	0.44	8.15e-14	Menopause (age at onset);
CESC	cis	rs56235845	0.694	rs11748912	chr5:176765395	G/A	cg06060754	chr5:176797920	RGS14	0.42	5.26	0.31	3.04e-7	Hemoglobin concentration;Hematocrit;
CESC	cis	rs2425143	1.000	rs11696527	chr20:34245379	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.61	5.14	0.3	5.43e-7	Blood protein levels;
CESC	cis	rs2836974	0.897	rs2026265	chr21:40595517	G/A	cg27266027	chr21:40555129	PSMG1	0.45	5.37	0.31	1.72e-7	Cognitive function;
CESC	cis	rs7666738	0.648	rs33988750	chr4:98985386	T/C	cg05340658	chr4:99064831	C4orf37	0.52	5.52	0.32	8.06e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3820068	0.705	rs1800616	chr1:15832229	G/A	cg18192808	chr1:15853278	DNAJC16	0.47	5.74	0.33	2.59e-8	Systolic blood pressure;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14783567	chr1:244211067	NA	0.53	6.05	0.35	4.95e-9	Gut microbiome composition (summer);
CESC	cis	rs9916302	0.904	rs55689507	chr17:37404436	G/C	cg20243544	chr17:37824526	PNMT	0.49	5.98	0.35	7.02e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs7772486	0.875	rs1331645	chr6:146398407	C/G	cg23711669	chr6:146136114	FBXO30	0.76	10.99	0.56	2.07e-23	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4523957	0.855	rs12603057	chr17:2112567	T/C	cg16513277	chr17:2031491	SMG6	-0.65	-8.99	-0.48	4.99e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs4867766	0.711	rs76632055	chr5:173976272	C/T	cg20434911	chr5:173954559	NA	-0.59	-5.06	-0.3	7.86e-7	Stroke;
CESC	cis	rs4906332	0.782	rs2236281	chr14:104000518	G/T	cg04998671	chr14:104000505	TRMT61A	-0.46	-5.54	-0.32	7.16e-8	Coronary artery disease;
CESC	cis	rs1707322	0.686	rs3014235	chr1:46091512	A/G	cg05343316	chr1:45956843	TESK2	-0.52	-6.53	-0.37	3.41e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20258083	chr10:93976192	CPEB3	-0.56	-6.02	-0.35	5.71e-9	Gut microbiome composition (summer);
CESC	cis	rs1218582	0.774	rs4845679	chr1:154861187	G/T	cg16680214	chr1:154839983	KCNN3	-0.52	-8.13	-0.45	1.64e-14	Prostate cancer;
CESC	cis	rs2050392	0.590	rs2065723	chr10:30720462	A/T	cg02070205	chr10:30722105	MAP3K8	-0.46	-5.39	-0.31	1.59e-7	Inflammatory bowel disease;
CESC	trans	rs9929218	0.954	rs12928043	chr16:68828885	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.62	-8.02	-0.44	3.46e-14	Colorectal cancer;
CESC	cis	rs9611565	0.921	rs4822021	chr22:41726053	G/A	cg03806693	chr22:41940476	POLR3H	-0.87	-9.9	-0.52	7.2e-20	Vitiligo;
CESC	cis	rs2836974	0.897	rs68090597	chr21:40535633	A/G	cg27266027	chr21:40555129	PSMG1	0.47	5.81	0.34	1.75e-8	Cognitive function;
CESC	cis	rs137699	0.687	rs4821887	chr22:39756985	C/T	cg24399712	chr22:39784796	NA	-0.61	-7.13	-0.4	9.54e-12	IgG glycosylation;
CESC	trans	rs6445797	0.821	rs10212341	chr3:56669148	C/T	cg15444621	chr13:113611794	NA	0.32	6.01	0.35	6.11e-9	Gastritis;
CESC	trans	rs17742757	0.522	rs899364	chr8:11329544	G/T	cg15556689	chr8:8085844	FLJ10661	-0.56	-6.31	-0.36	1.2e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs2932538	0.922	rs6681371	chr1:113101168	A/C	cg22162597	chr1:113214053	CAPZA1	0.59	7.13	0.4	9.49e-12	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CESC	cis	rs9522267	0.535	rs9522296	chr13:112234340	C/T	cg10483660	chr13:112241077	NA	0.33	5.79	0.33	2.04e-8	Hepatitis;
CESC	cis	rs9393777	0.623	rs3734544	chr6:26468660	G/A	cg14345882	chr6:26364793	BTN3A2	0.44	5.46	0.32	1.11e-7	Intelligence (multi-trait analysis);
CESC	cis	rs7940866	0.834	rs10791108	chr11:130849354	T/A	cg12179176	chr11:130786555	SNX19	0.68	10.34	0.54	2.83e-21	Schizophrenia;
CESC	cis	rs2479106	0.892	rs549779	chr9:126613028	A/G	cg16191174	chr9:126692580	DENND1A	-0.42	-5.32	-0.31	2.24e-7	Polycystic ovary syndrome;
CESC	cis	rs2404602	0.669	rs1875884	chr15:76638161	C/T	cg26408565	chr15:76604113	ETFA	-0.42	-5.98	-0.34	7.26e-9	Blood metabolite levels;
CESC	cis	rs6964587	0.692	rs4729018	chr7:91644613	C/T	cg17063962	chr7:91808500	NA	0.46	6.55	0.37	2.91e-10	Breast cancer;
CESC	cis	rs2637266	1.000	rs17384253	chr10:78342391	A/G	cg18941641	chr10:78392320	NA	0.42	7.79	0.43	1.54e-13	Pulmonary function;
CESC	cis	rs11583043	0.874	rs72734253	chr1:101380718	A/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.48	5.51	0.32	8.66e-8	Ulcerative colitis;Inflammatory bowel disease;
CESC	cis	rs897984	0.542	rs11864839	chr16:31095251	G/C	cg02466173	chr16:30829666	NA	-0.41	-7.07	-0.4	1.4e-11	Dementia with Lewy bodies;
CESC	cis	rs6582630	0.555	rs10880625	chr12:38526612	A/C	cg26384229	chr12:38710491	ALG10B	0.74	11.16	0.57	6e-24	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs7680126	0.633	rs4698023	chr4:10304726	A/G	cg11266682	chr4:10021025	SLC2A9	-0.38	-5.13	-0.3	5.57e-7	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11129439	chr14:104029859	BAG5;C14orf153	-0.59	-7.68	-0.43	3.06e-13	Gut microbiome composition (summer);
CESC	trans	rs34421088	0.560	rs2248315	chr8:11397086	T/A	cg15556689	chr8:8085844	FLJ10661	-0.51	-6.0	-0.35	6.33e-9	Neuroticism;
CESC	cis	rs11997175	0.580	rs34398087	chr8:33813800	A/G	ch.8.33884649F	chr8:33765107	NA	-0.49	-5.84	-0.34	1.5e-8	Body mass index;
CESC	cis	rs10129255	0.957	rs8014696	chr14:107177994	A/C	cg07958169	chr14:107095056	NA	0.37	5.13	0.3	5.64e-7	Kawasaki disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26475180	chr22:41742086	ZC3H7B	-0.61	-6.92	-0.39	3.43e-11	Gut microbiome composition (summer);
CESC	cis	rs10504229	0.683	rs16921831	chr8:58111142	G/A	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs4901869	0.966	rs12148052	chr14:59338970	C/T	cg02291164	chr14:59296302	NA	0.45	7.81	0.43	1.3e-13	Panic disorder;
CESC	cis	rs763121	0.853	rs6001184	chr22:39052116	C/T	cg06544989	chr22:39130855	UNC84B	0.49	8.52	0.46	1.22e-15	Menopause (age at onset);
CESC	cis	rs1218582	0.772	rs2174507	chr1:154887949	C/T	cg24250549	chr1:154909240	PMVK	0.75	11.19	0.57	4.8e-24	Prostate cancer;
CESC	cis	rs1862618	0.671	rs2591966	chr5:56233688	T/G	cg12311346	chr5:56204834	C5orf35	0.64	8.9	0.48	8.96e-17	Initial pursuit acceleration;
CESC	cis	rs4642101	0.686	rs13085726	chr3:12832672	A/C	cg05775895	chr3:12838266	CAND2	0.39	5.99	0.35	6.78e-9	QRS complex (12-leadsum);
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg21087902	chr17:79234955	SLC38A10	0.4	6.11	0.35	3.52e-9	Thyroid stimulating hormone;
CESC	cis	rs561341	0.941	rs72825736	chr17:30330286	G/A	cg12193833	chr17:30244370	NA	-0.73	-6.71	-0.38	1.14e-10	Hip circumference adjusted for BMI;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03115649	chr1:179851535	TOR1AIP1	0.53	6.18	0.35	2.47e-9	Gut microbiome composition (summer);
CESC	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg18404041	chr3:52824283	ITIH1	-0.33	-6.0	-0.35	6.5e-9	Bipolar disorder;
CESC	cis	rs56104184	0.775	rs73063505	chr19:49402765	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.6	-5.99	-0.35	6.95e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	cis	rs3796352	1.000	rs35576914	chr3:53092270	G/A	cg07884673	chr3:53033167	SFMBT1	0.68	5.79	0.34	1.99e-8	Immune reponse to smallpox (secreted IL-2);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg06310300	chr7:100076089	TSC22D4	0.49	6.54	0.37	3.13e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs873946	0.590	rs12259699	chr10:134549692	A/G	cg27286337	chr10:134555280	INPP5A	0.64	7.64	0.42	4.1e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs9435341	0.896	rs1730851	chr1:107596443	A/G	cg09367891	chr1:107599246	PRMT6	-0.62	-7.49	-0.42	1.01e-12	Facial morphology (factor 21, depth of nasal alae);
CESC	cis	rs10791097	0.935	rs4601795	chr11:130729430	T/C	cg12179176	chr11:130786555	SNX19	0.56	7.97	0.44	4.59e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	trans	rs17685	0.884	rs8565	chr7:75630274	T/C	cg19862616	chr7:65841803	NCRNA00174	-0.67	-8.84	-0.48	1.38e-16	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs1775715	0.737	rs2799015	chr10:32107712	C/T	cg18675610	chr10:32216311	ARHGAP12	0.33	5.1	0.3	6.52e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs7674212	0.541	rs2720471	chr4:104023840	A/G	cg16532752	chr4:104119610	CENPE	-0.43	-5.8	-0.34	1.87e-8	Type 2 diabetes;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg26434548	chr7:129074607	FAM40B	-0.44	-6.33	-0.36	1.02e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs61931739	0.517	rs12815556	chr12:34319670	G/A	cg19457237	chr12:34500585	NA	-0.37	-5.06	-0.3	7.75e-7	Morning vs. evening chronotype;
CESC	cis	rs2880765	0.566	rs12911430	chr15:86011264	A/T	cg10818794	chr15:86012489	AKAP13	-0.36	-5.04	-0.3	8.8e-7	Coronary artery disease;
CESC	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg14893161	chr1:205819251	PM20D1	0.88	14.76	0.67	2.08e-36	Menarche (age at onset);
CESC	cis	rs3820068	0.580	rs12746773	chr1:16001588	C/T	cg17385448	chr1:15911702	AGMAT	0.42	6.58	0.37	2.55e-10	Systolic blood pressure;
CESC	cis	rs7584330	0.518	rs74003103	chr2:238446699	G/A	cg14458575	chr2:238380390	NA	0.67	6.31	0.36	1.16e-9	Prostate cancer;
CESC	cis	rs4132509	0.793	rs7522883	chr1:243803022	C/T	cg21452805	chr1:244014465	NA	0.63	6.63	0.38	1.85e-10	RR interval (heart rate);
CESC	cis	rs10504229	1.000	rs58053450	chr8:58173348	T/C	cg05313129	chr8:58192883	C8orf71	-0.55	-6.37	-0.36	8.42e-10	Developmental language disorder (linguistic errors);
CESC	trans	rs1814175	0.817	rs4881648	chr11:49812901	A/G	cg15704280	chr7:45808275	SEPT13	-1.02	-20.13	-0.78	2.46e-55	Height;
CESC	cis	rs3091242	0.967	rs3093614	chr1:25677844	T/A	cg03538708	chr1:25844672	NA	0.36	5.42	0.32	1.36e-7	Erythrocyte sedimentation rate;
CESC	cis	rs654950	1.000	rs654950	chr1:41987868	G/C	cg06885757	chr1:42089581	HIVEP3	-0.54	-8.29	-0.45	5.91e-15	Airway imaging phenotypes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26612563	chr11:4115769	RRM1	0.55	6.02	0.35	5.7e-9	Gut microbiome composition (summer);
CESC	cis	rs1372520	0.684	rs2619355	chr4:90748374	A/C	cg15133208	chr4:90757351	SNCA	-0.4	-5.34	-0.31	2.01e-7	Neuroticism;
CESC	cis	rs9649213	0.574	rs12873	chr7:97922773	T/C	cg21770322	chr7:97807741	LMTK2	0.55	8.08	0.44	2.33e-14	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs4423214	1.000	rs2282621	chr11:71183474	C/T	cg05163923	chr11:71159392	DHCR7	0.82	10.82	0.55	7.47e-23	Vitamin D levels;
CESC	cis	rs4253772	0.938	rs77378083	chr22:46639386	G/A	cg18190219	chr22:46762943	CELSR1	-0.61	-5.83	-0.34	1.64e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs9300255	0.739	rs10846491	chr12:123753492	C/G	cg19016782	chr12:123741754	C12orf65	-0.49	-7.07	-0.4	1.35e-11	Neutrophil percentage of white cells;
CESC	cis	rs478304	0.934	rs570954	chr11:65498261	A/G	cg08755490	chr11:65554678	OVOL1	0.47	6.21	0.36	2.06e-9	Acne (severe);
CESC	cis	rs4660306	0.677	rs781062	chr1:45932738	T/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.47	5.2	0.3	4.02e-7	Homocysteine levels;
CESC	cis	rs71277158	0.688	rs73879180	chr3:169874968	T/C	cg04067573	chr3:169899625	PHC3	0.7	6.91	0.39	3.51e-11	Prostate cancer;
CESC	cis	rs9543976	0.623	rs7982517	chr13:76162039	A/G	cg01531495	chr13:76123901	UCHL3	0.51	5.14	0.3	5.32e-7	Diabetic retinopathy;
CESC	cis	rs4713118	0.621	rs4713133	chr6:28034041	T/C	cg19592336	chr6:28129416	ZNF389	0.57	7.34	0.41	2.64e-12	Parkinson's disease;
CESC	trans	rs7944735	0.671	rs7106731	chr11:48003392	T/G	cg15704280	chr7:45808275	SEPT13	0.66	8.15	0.45	1.49e-14	Intraocular pressure;
CESC	cis	rs2832191	0.791	rs7283853	chr21:30498515	G/A	cg24692254	chr21:30365293	RNF160	-0.79	-12.11	-0.6	3.71e-27	Dental caries;
CESC	cis	rs6463523	0.933	rs4724821	chr7:762544	C/T	cg14391382	chr7:866102	UNC84A	0.44	5.49	0.32	9.48e-8	Subjective well-being;
CESC	cis	rs6456156	0.583	rs7748224	chr6:167456860	C/T	cg23791538	chr6:167370224	RNASET2	-0.52	-6.74	-0.38	9.89e-11	Primary biliary cholangitis;
CESC	cis	rs2836974	0.897	rs36113648	chr21:40555497	G/A	cg11890956	chr21:40555474	PSMG1	1.21	24.6	0.83	2.29e-70	Cognitive function;
CESC	cis	rs2710642	0.583	rs7421841	chr2:62880765	G/A	cg17519650	chr2:63277830	OTX1	0.49	5.78	0.33	2.11e-8	LDL cholesterol levels;LDL cholesterol;
CESC	cis	rs3091242	0.935	rs4233043	chr1:25765483	A/G	cg02931644	chr1:25747376	RHCE	0.4	6.68	0.38	1.37e-10	Erythrocyte sedimentation rate;
CESC	trans	rs11039798	0.764	rs4357721	chr11:48354907	G/A	cg15704280	chr7:45808275	SEPT13	-0.67	-6.23	-0.36	1.78e-9	Axial length;
CESC	cis	rs8016982	0.674	rs759939	chr14:81663453	G/C	cg01989461	chr14:81687754	GTF2A1	0.73	11.43	0.57	7.37e-25	Schizophrenia;
CESC	cis	rs13118159	0.801	rs13147602	chr4:1332175	A/G	cg16405210	chr4:1374714	KIAA1530	-0.65	-8.6	-0.47	7.07e-16	Longevity;
CESC	cis	rs6582630	0.555	rs11182429	chr12:38526679	A/C	cg26384229	chr12:38710491	ALG10B	0.67	10.53	0.54	6.77e-22	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs7833790	0.724	rs1054078	chr8:82712153	A/G	cg02079420	chr8:82753780	SNX16	0.55	8.25	0.45	7.73e-15	Diastolic blood pressure;
CESC	cis	rs752010	0.619	rs1123483	chr1:42114198	C/T	cg12614395	chr1:42085415	HIVEP3	-0.32	-5.04	-0.3	8.68e-7	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs17253792	0.545	rs3742571	chr14:56016704	A/G	cg01858014	chr14:56050164	KTN1	-0.82	-5.81	-0.34	1.76e-8	Putamen volume;
CESC	cis	rs763121	0.853	rs2281020	chr22:39064406	A/G	cg06544989	chr22:39130855	UNC84B	0.48	8.4	0.46	2.69e-15	Menopause (age at onset);
CESC	cis	rs2732480	0.500	rs1552550	chr12:48643351	C/A	cg24011408	chr12:48396354	COL2A1	0.44	6.22	0.36	1.95e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs2637266	0.630	rs7095225	chr10:78452623	G/T	cg18941641	chr10:78392320	NA	0.39	6.87	0.39	4.48e-11	Pulmonary function;
CESC	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg07677032	chr17:61819896	STRADA	0.45	5.97	0.34	7.8e-9	Prudent dietary pattern;
CESC	cis	rs7503807	1.000	rs4889775	chr17:78592287	A/G	cg09596252	chr17:78655493	RPTOR	0.49	7.11	0.4	1.06e-11	Obesity;
CESC	cis	rs1862618	0.853	rs252898	chr5:56188931	T/C	cg24549020	chr5:56110836	MAP3K1	0.6	6.65	0.38	1.67e-10	Initial pursuit acceleration;
CESC	cis	rs2816062	0.861	rs2745312	chr1:18904012	T/A	cg18795169	chr1:18902165	NA	-0.86	-15.54	-0.69	3.85e-39	Urate levels in lean individuals;
CESC	cis	rs501120	1.000	rs518594	chr10:44757107	T/C	cg09554077	chr10:44749378	NA	0.54	7.1	0.4	1.12e-11	Coronary artery disease;Coronary heart disease;
CESC	cis	rs3857536	0.741	rs4710582	chr6:66939984	T/G	cg07460842	chr6:66804631	NA	-0.42	-5.34	-0.31	1.96e-7	Blood trace element (Cu levels);
CESC	cis	rs13191362	0.810	rs34714603	chr6:163008078	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.49	5.36	0.31	1.82e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs2932538	0.885	rs6693880	chr1:113110261	A/G	cg22162597	chr1:113214053	CAPZA1	0.55	6.96	0.39	2.59e-11	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CESC	cis	rs2370759	1.000	rs75984055	chr10:32591276	T/C	cg18270830	chr10:32634957	EPC1	0.73	7.22	0.41	5.35e-12	Sexual dysfunction (female);
CESC	cis	rs2243480	0.803	rs35268390	chr7:65416536	C/G	cg18252515	chr7:66147081	NA	-1.05	-10.01	-0.52	3.2e-20	Diabetic kidney disease;
CESC	cis	rs9291683	0.510	rs4318649	chr4:10016815	T/C	cg00071950	chr4:10020882	SLC2A9	0.82	13.82	0.65	4.37e-33	Bone mineral density;
CESC	cis	rs1153858	1.000	rs4774579	chr15:45651803	G/A	cg21132104	chr15:45694354	SPATA5L1	0.85	11.64	0.58	1.47e-25	Homoarginine levels;
CESC	cis	rs10089	1.000	rs13355233	chr5:127425350	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.78	-10.51	-0.54	8.14e-22	Ileal carcinoids;
CESC	cis	rs2839186	0.869	rs17176513	chr21:47682428	A/G	cg10351095	chr21:47802916	PCNT	-0.49	-6.57	-0.37	2.59e-10	Testicular germ cell tumor;
CESC	cis	rs875971	0.895	rs6460278	chr7:65662736	T/C	cg19163074	chr7:65112434	INTS4L2	0.44	5.5	0.32	9.04e-8	Aortic root size;
CESC	cis	rs728616	0.614	rs56080607	chr10:82105964	A/T	cg05935833	chr10:81318306	SFTPA2	-0.37	-5.34	-0.31	1.99e-7	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs243505	0.559	rs10215794	chr7:148478895	C/G	cg09806900	chr7:148480153	CUL1	0.45	5.35	0.31	1.89e-7	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs11792861	0.816	rs3763643	chr9:111695607	T/C	cg13535736	chr9:111863775	C9orf5	-0.47	-6.11	-0.35	3.54e-9	Menarche (age at onset);
CESC	cis	rs6005807	0.543	rs12168849	chr22:29202063	A/G	cg15103426	chr22:29168792	CCDC117	0.49	5.07	0.3	7.34e-7	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
CESC	cis	rs12410462	0.681	rs6681096	chr1:227609720	G/A	cg23173402	chr1:227635558	NA	0.74	6.46	0.37	4.96e-10	Major depressive disorder;
CESC	cis	rs4819052	0.765	rs2838854	chr21:46680364	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.45	5.64	0.33	4.43e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs2708240	0.577	rs851707	chr7:147534049	T/C	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.4	-5.81	-0.34	1.81e-8	QT interval (drug interaction);
CESC	cis	rs12142240	0.660	rs72886903	chr1:46813860	C/T	cg10495392	chr1:46806563	NSUN4	0.57	6.28	0.36	1.39e-9	Menopause (age at onset);
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg11148483	chr3:28393736	NA	0.41	6.07	0.35	4.36e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	trans	rs7866350	0.604	rs1935389	chr9:100994470	A/G	cg09552692	chr15:66274614	MEGF11	0.43	6.2	0.36	2.15e-9	Post-traumatic stress disorder;
CESC	cis	rs1949733	0.701	rs1880024	chr4:8454639	A/G	cg11789530	chr4:8429930	ACOX3	0.76	11.12	0.56	8.15e-24	Response to antineoplastic agents;
CESC	cis	rs2033711	0.870	rs7409473	chr19:58939165	A/G	cg26874164	chr19:58962979	ZNF324B	0.54	7.47	0.42	1.2e-12	Uric acid clearance;
CESC	cis	rs4561483	0.583	rs1019814	chr16:11940764	T/C	cg08843971	chr16:11963173	GSPT1	0.45	6.28	0.36	1.4e-9	Testicular germ cell tumor;
CESC	trans	rs1908814	0.516	rs60176945	chr8:11796674	T/C	cg15556689	chr8:8085844	FLJ10661	0.52	6.37	0.36	8.4e-10	Neuroticism;
CESC	cis	rs2354432	0.556	rs7525622	chr1:146774116	G/A	cg25205988	chr1:146714368	CHD1L	-0.95	-8.25	-0.45	7.34e-15	Mitochondrial DNA levels;
CESC	cis	rs1799949	0.550	rs2343818	chr17:41409774	G/A	cg23758822	chr17:41437982	NA	1.04	15.72	0.69	8.6e-40	Menopause (age at onset);
CESC	cis	rs61008539	0.893	rs4719460	chr7:859610	C/T	cg00475322	chr7:917719	C7orf20	-0.47	-7.18	-0.4	7.01e-12	Perceived unattractiveness to mosquitoes;
CESC	cis	rs11638352	1.000	rs8035212	chr15:44304636	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	-0.49	-5.17	-0.3	4.51e-7	Lipoprotein phospholipase A2 activity in cardiovascular disease;
CESC	cis	rs4925386	1.000	rs4925386	chr20:60921044	C/T	cg24112000	chr20:60950667	NA	-0.44	-6.35	-0.36	9.2e-10	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs4808199	0.948	rs2301671	chr19:19466269	C/T	cg03709012	chr19:19516395	GATAD2A	1.08	12.28	0.6	9.85e-28	Nonalcoholic fatty liver disease;
CESC	cis	rs10883723	0.810	rs3818470	chr10:104263675	T/C	ch.10.2196322F	chr10:104248062	ACTR1A	0.42	5.08	0.3	6.99e-7	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs801193	1.000	rs7783924	chr7:66209057	A/C	cg11764359	chr7:65958608	NA	0.69	9.1	0.49	2.27e-17	Aortic root size;
CESC	cis	rs853679	0.550	rs1150692	chr6:28173957	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.48	-5.66	-0.33	3.97e-8	Depression;
CESC	cis	rs55882075	0.634	rs11249657	chr5:179111637	G/C	cg14593053	chr5:179126677	CANX	0.46	5.91	0.34	1.07e-8	Monocyte percentage of white cells;
CESC	cis	rs13118159	0.550	rs4974614	chr4:1373489	A/G	cg05025164	chr4:1340916	KIAA1530	0.88	11.92	0.59	1.61e-26	Longevity;
CESC	cis	rs61931739	0.500	rs11053249	chr12:34518834	A/T	cg19457237	chr12:34500585	NA	-0.37	-5.09	-0.3	6.86e-7	Morning vs. evening chronotype;
CESC	cis	rs875971	0.545	rs1638735	chr7:66095738	C/T	cg18876405	chr7:65276391	NA	0.48	5.64	0.33	4.35e-8	Aortic root size;
CESC	cis	rs4253772	0.530	rs6008616	chr22:46707954	A/G	cg10541313	chr22:46663664	TTC38	0.59	5.05	0.3	8.15e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs5750830	0.645	rs4821890	chr22:39777523	G/A	cg05872129	chr22:39784769	NA	-0.72	-10.51	-0.54	7.81e-22	Intelligence (multi-trait analysis);
CESC	cis	rs73129298	0.551	rs6012787	chr20:48594615	C/A	cg25655593	chr20:48599521	SNAI1	0.46	5.15	0.3	5.05e-7	Inflammatory skin disease;
CESC	cis	rs2274273	0.870	rs10149420	chr14:55854257	T/C	cg04306507	chr14:55594613	LGALS3	0.3	5.88	0.34	1.24e-8	Protein biomarker;
CESC	cis	rs910316	0.763	rs175044	chr14:75472109	G/A	cg11812906	chr14:75593930	NEK9	-0.79	-12.34	-0.6	5.81e-28	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03951180	chr7:72742151	TRIM50;FKBP6	-0.57	-6.95	-0.39	2.78e-11	Gut microbiome composition (summer);
CESC	trans	rs561341	0.800	rs7209766	chr17:30234848	T/A	cg20587970	chr11:113659929	NA	-0.65	-8.22	-0.45	8.89e-15	Hip circumference adjusted for BMI;
CESC	cis	rs919433	0.662	rs2043018	chr2:198236958	G/A	cg20885578	chr2:198174922	NA	0.41	5.38	0.31	1.66e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs13191362	1.000	rs67046187	chr6:163068532	C/A	cg21926612	chr6:163149169	PACRG;PARK2	0.93	9.75	0.51	2.1e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs798554	0.610	rs1182173	chr7:2878016	C/G	cg19717773	chr7:2847554	GNA12	-0.51	-8.12	-0.45	1.72e-14	Height;
CESC	cis	rs7523050	0.643	rs35526993	chr1:109405107	A/T	cg08274380	chr1:109419600	GPSM2	0.85	5.82	0.34	1.74e-8	Fat distribution (HIV);
CESC	cis	rs117623576	0.941	rs211423	chr10:32398777	A/G	cg03047570	chr10:32398778	NA	0.84	8.84	0.48	1.33e-16	Anti-saccade response;
CESC	cis	rs8060686	0.516	rs12599238	chr16:68276235	G/A	cg26727032	chr16:67993705	SLC12A4	-0.51	-5.49	-0.32	9.27e-8	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs6912958	0.515	rs381782	chr6:88040649	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.35	5.65	0.33	4.12e-8	Monocyte percentage of white cells;
CESC	cis	rs2050392	0.965	rs2265368	chr10:30690289	G/C	cg25182066	chr10:30743637	MAP3K8	-0.37	-5.04	-0.3	8.77e-7	Inflammatory bowel disease;
CESC	cis	rs2243480	1.000	rs67728539	chr7:65378124	G/A	cg13147721	chr7:65941812	NA	-0.83	-7.92	-0.44	6.77e-14	Diabetic kidney disease;
CESC	trans	rs11098499	0.820	rs28394116	chr4:120524283	T/G	cg25214090	chr10:38739885	LOC399744	0.67	9.36	0.5	3.52e-18	Corneal astigmatism;
CESC	cis	rs4803468	1.000	rs284655	chr19:41928765	C/T	cg14132834	chr19:41945861	ATP5SL	-0.65	-7.95	-0.44	5.44e-14	Height;
CESC	cis	rs11583043	0.874	rs11578366	chr1:101396852	T/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.55	6.34	0.36	9.81e-10	Ulcerative colitis;Inflammatory bowel disease;
CESC	cis	rs763014	0.931	rs1981483	chr16:630665	G/A	cg09263875	chr16:632152	PIGQ	0.67	11.14	0.56	6.6e-24	Height;
CESC	cis	rs6540559	1.000	rs742214	chr1:209960925	T/C	cg25204440	chr1:209979598	IRF6	0.64	8.11	0.45	1.94e-14	Cleft lip with or without cleft palate;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26353957	chr4:47465606	COMMD8	0.57	6.33	0.36	1.04e-9	Gut microbiome composition (summer);
CESC	trans	rs1728785	0.892	rs1170427	chr16:68603852	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.65	7.93	0.44	6e-14	Ulcerative colitis;
CESC	cis	rs6570726	0.791	rs365747	chr6:145866784	C/T	cg23711669	chr6:146136114	FBXO30	1.02	15.62	0.69	2.01e-39	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9291683	0.588	rs6857693	chr4:10018435	G/A	cg11266682	chr4:10021025	SLC2A9	0.72	14.87	0.67	8.73e-37	Bone mineral density;
CESC	cis	rs11098499	0.863	rs11723090	chr4:120490592	T/C	cg24375607	chr4:120327624	NA	0.48	5.95	0.34	8.26e-9	Corneal astigmatism;
CESC	cis	rs9322193	0.923	rs3798761	chr6:150004779	A/G	cg13206674	chr6:150067644	NUP43	0.45	6.54	0.37	3.14e-10	Lung cancer;
CESC	cis	rs7772486	0.754	rs9399561	chr6:145955687	C/G	cg23711669	chr6:146136114	FBXO30	1.02	15.77	0.7	5.6e-40	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs13082711	0.516	rs1492339	chr3:27371526	A/C	cg02860705	chr3:27208620	NA	-0.5	-6.34	-0.36	9.94e-10	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CESC	cis	rs1215050	0.791	rs7688942	chr4:98832048	T/C	cg05340658	chr4:99064831	C4orf37	0.51	6.54	0.37	3.07e-10	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs4555082	1.000	rs4277291	chr14:105759009	A/G	cg13114125	chr14:105738426	BRF1	-0.75	-9.55	-0.51	8.88e-19	Mean platelet volume;Platelet distribution width;
CESC	cis	rs2576037	0.583	rs616900	chr18:44410849	T/A	cg19077165	chr18:44547161	KATNAL2	-0.61	-9.18	-0.49	1.27e-17	Personality dimensions;
CESC	cis	rs2576037	0.526	rs2187092	chr18:44526798	A/C	cg19077165	chr18:44547161	KATNAL2	-0.53	-7.75	-0.43	2.02e-13	Personality dimensions;
CESC	cis	rs35306767	0.903	rs12778891	chr10:950130	T/A	cg10556349	chr10:835070	NA	0.57	5.53	0.32	7.76e-8	Eosinophil percentage of granulocytes;
CESC	cis	rs5747327	0.838	rs35945753	chr22:18156644	A/G	cg19898043	chr22:18121309	BCL2L13	-0.42	-5.29	-0.31	2.62e-7	Myeloid white cell count;Granulocyte count;
CESC	cis	rs2836974	0.965	rs8130984	chr21:40639966	A/C	cg11644478	chr21:40555479	PSMG1	1.01	15.98	0.7	1.06e-40	Cognitive function;
CESC	cis	rs10782582	0.593	rs74090712	chr1:76189098	A/G	cg22875332	chr1:76189707	ACADM	-0.42	-5.1	-0.3	6.52e-7	Daytime sleep phenotypes;
CESC	cis	rs8072100	0.676	rs7221345	chr17:45405144	G/A	cg08085267	chr17:45401833	C17orf57	-0.66	-8.98	-0.48	5.26e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs4843747	0.605	rs28399183	chr16:88107277	G/A	cg17633681	chr16:88106987	BANP	0.76	10.52	0.54	7.38e-22	Menopause (age at onset);
CESC	cis	rs853679	0.517	rs6922063	chr6:28094366	G/A	cg23281280	chr6:28129359	ZNF389	0.61	8.7	0.47	3.53e-16	Depression;
CESC	cis	rs6502050	0.765	rs6502075	chr17:80121813	G/A	cg23985595	chr17:80112537	CCDC57	-0.41	-6.57	-0.37	2.6200000000000003e-10	Life satisfaction;
CESC	cis	rs6570726	0.935	rs421690	chr6:145834594	A/C	cg05347473	chr6:146136440	FBXO30	0.49	6.69	0.38	1.3100000000000001e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1355223	0.525	rs7129533	chr11:34872292	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.55	-6.64	-0.38	1.81e-10	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs17539620	0.624	rs111484697	chr6:154838903	A/G	cg17771515	chr6:154831774	CNKSR3	0.55	5.13	0.3	5.49e-7	Lipoprotein (a) levels;
CESC	cis	rs4927850	1.000	rs10881564	chr3:195750326	C/T	cg00031303	chr3:195681400	NA	0.47	5.91	0.34	1.03e-8	Pancreatic cancer;
CESC	cis	rs9325144	0.600	rs2171405	chr12:38741030	G/T	cg26384229	chr12:38710491	ALG10B	-0.56	-7.86	-0.43	9.84e-14	Morning vs. evening chronotype;
CESC	cis	rs12477438	0.501	rs1133977	chr2:99741984	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.79	-12.88	-0.62	8.43e-30	Chronic sinus infection;
CESC	trans	rs61931739	0.890	rs1705748	chr12:34133171	A/G	cg26384229	chr12:38710491	ALG10B	0.44	6.03	0.35	5.63e-9	Morning vs. evening chronotype;
CESC	cis	rs7107174	1.000	rs10899495	chr11:78123293	C/T	cg02023728	chr11:77925099	USP35	0.43	5.54	0.32	7.31e-8	Testicular germ cell tumor;
CESC	cis	rs929354	0.709	rs1182363	chr7:157019151	A/G	cg05182265	chr7:156933206	UBE3C	0.5	7.32	0.41	2.97e-12	Body mass index;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21649051	chr1:85514340	MCOLN3	0.57	6.38	0.36	7.93e-10	Gut microbiome composition (summer);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg24448245	chr7:66461718	SBDS;TYW1	-0.46	-6.58	-0.37	2.45e-10	Gambling;
CESC	cis	rs7937682	0.883	rs568038	chr11:111432161	A/C	cg09085632	chr11:111637200	PPP2R1B	0.97	13.91	0.65	2.07e-33	Primary sclerosing cholangitis;
CESC	cis	rs765787	0.530	rs12909987	chr15:45512207	C/T	cg24006582	chr15:45444508	DUOX1	-0.45	-5.53	-0.32	7.59e-8	Uric acid levels;
CESC	cis	rs4604732	0.631	rs10802509	chr1:247627158	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.57	7.17	0.4	7.39e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs921968	0.541	rs72965126	chr2:219330189	C/T	cg02176678	chr2:219576539	TTLL4	-0.54	-9.87	-0.52	9.03e-20	Mean corpuscular hemoglobin concentration;
CESC	cis	rs7666738	0.677	rs13120306	chr4:99036099	A/T	cg17366294	chr4:99064904	C4orf37	0.62	8.62	0.47	6.05e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4862750	0.872	rs6553029	chr4:187876470	G/T	cg07414643	chr4:187882934	NA	-0.52	-6.88	-0.39	4.19e-11	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg27401989	chr12:53774447	SP1	-0.48	-6.06	-0.35	4.69e-9	Fibrinogen levels;
CESC	trans	rs11989744	1.000	rs17782111	chr8:23565784	A/G	cg03492747	chr16:86543808	FOXF1	0.65	7.18	0.4	6.94e-12	Waist-hip ratio;
CESC	cis	rs12893668	0.572	rs1606	chr14:104161281	G/A	cg08213375	chr14:104286397	PPP1R13B	0.31	5.2	0.3	4.07e-7	Reticulocyte count;
CESC	cis	rs1670533	1.000	rs6599278	chr4:1058798	C/T	cg27284194	chr4:1044797	NA	0.43	5.46	0.32	1.11e-7	Recombination rate (females);
CESC	cis	rs2276314	1.000	rs4799832	chr18:33559646	T/C	cg05985134	chr18:33552581	C18orf21	0.64	7.52	0.42	8.25e-13	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs11792861	0.530	rs1772047	chr9:111679012	A/G	cg05043794	chr9:111880884	C9orf5	0.31	5.41	0.32	1.42e-7	Menarche (age at onset);
CESC	cis	rs13191362	1.000	rs34228197	chr6:163008232	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.78	8.21	0.45	9.97e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs7100689	0.577	rs873395	chr10:82037215	C/T	cg00277334	chr10:82204260	NA	0.56	6.97	0.39	2.57e-11	Post bronchodilator FEV1;
CESC	cis	rs2576037	0.501	rs7245049	chr18:44528213	G/A	cg19077165	chr18:44547161	KATNAL2	-0.53	-7.79	-0.43	1.54e-13	Personality dimensions;
CESC	cis	rs6714710	0.557	rs17490429	chr2:98449024	G/A	cg26665480	chr2:98280029	ACTR1B	0.6	8.23	0.45	8.31e-15	Posterior cortical atrophy and Alzheimer's disease;
CESC	cis	rs7927771	0.524	rs10838763	chr11:47794802	C/T	cg20307385	chr11:47447363	PSMC3	0.61	8.64	0.47	5.45e-16	Subjective well-being;
CESC	cis	rs2857078	0.772	rs4793086	chr17:42320751	C/T	cg08499158	chr17:42289980	UBTF	0.45	5.49	0.32	9.19e-8	Red cell distribution width;Reticulocyte count;
CESC	cis	rs155076	0.711	rs4770131	chr13:21897468	A/G	cg21970626	chr13:21893289	NA	-0.53	-5.71	-0.33	3.02e-8	White matter hyperintensity burden;
CESC	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg03188948	chr7:1209495	NA	0.72	6.91	0.39	3.61e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7429990	0.965	rs7651237	chr3:48105528	A/G	cg11946769	chr3:48343235	NME6	-0.61	-7.29	-0.41	3.66e-12	Educational attainment (years of education);
CESC	cis	rs1775715	0.707	rs2808094	chr10:32133756	T/C	cg18675610	chr10:32216311	ARHGAP12	0.33	5.09	0.3	6.66e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs6942756	1.000	rs7780886	chr7:128879347	G/A	cg02491457	chr7:128862824	NA	-0.69	-9.88	-0.52	8.42e-20	White matter hyperintensity burden;
CESC	cis	rs1552244	1.000	rs6764168	chr3:10123805	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.8	-10.48	-0.54	9.87e-22	Alzheimer's disease;
CESC	trans	rs35110281	0.782	rs6518309	chr21:45047992	C/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.51	6.13	0.35	3.13e-9	Mean corpuscular volume;
CESC	cis	rs7312774	0.618	rs4964503	chr12:107335937	C/G	cg16260113	chr12:107380972	MTERFD3	-0.74	-6.5	-0.37	4e-10	Severe influenza A (H1N1) infection;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27651003	chr16:67261081	TMEM208;LRRC29	-0.53	-6.42	-0.37	6.11e-10	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11196904	chr1:10491304	APITD1	0.6	6.89	0.39	3.98e-11	Gut microbiome composition (summer);
CESC	cis	rs17376456	0.569	rs10476520	chr5:93058290	A/C	cg25358565	chr5:93447407	FAM172A	0.68	7.38	0.41	2.07e-12	Diabetic retinopathy;
CESC	cis	rs7818688	1.000	rs28496357	chr8:96030511	T/C	cg16049864	chr8:95962084	TP53INP1	0.6	5.78	0.33	2.14e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg18588052	chr6:111408752	SLC16A10	-0.42	-5.99	-0.35	6.7e-9	Fibrinogen levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24219704	chr12:107349641	C12orf23	0.51	6.03	0.35	5.48e-9	Gut microbiome composition (summer);
CESC	trans	rs9951602	0.512	rs61021837	chr18:76648210	A/C	cg02800362	chr5:177631904	HNRNPAB	0.64	8.28	0.45	5.96e-15	Obesity-related traits;
CESC	cis	rs12249377	0.519	rs11186320	chr10:92576448	C/T	cg14313238	chr10:92632228	RPP30	-0.45	-5.85	-0.34	1.44e-8	White matter microstructure (global fractional anisotropy);
CESC	cis	rs6032067	0.777	rs35434469	chr20:43778544	C/T	cg10761708	chr20:43804764	PI3	0.57	6.54	0.37	3.11e-10	Blood protein levels;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg10668512	chr15:42565522	GANC;TMEM87A	0.55	7.28	0.41	3.89e-12	Gut microbiota (bacterial taxa);
CESC	cis	rs2282802	0.685	rs2436391	chr5:139557385	C/T	cg26211634	chr5:139558579	C5orf32	-0.48	-7.04	-0.4	1.68e-11	Intelligence (multi-trait analysis);
CESC	cis	rs80130819	0.688	rs4760698	chr12:48592872	C/T	cg05342945	chr12:48394962	COL2A1	-0.53	-6.1	-0.35	3.76e-9	Prostate cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00482248	chr7:73589137	EIF4H	-0.62	-7.08	-0.4	1.27e-11	Gut microbiome composition (summer);
CESC	cis	rs2519796	0.531	rs2077384	chr9:136808454	C/T	cg13751417	chr9:136814406	VAV2	-0.43	-5.55	-0.32	6.77e-8	Hematocrit;Hemoglobin concentration;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07156929	chr6:34856927	ANKS1A;TAF11	0.65	7.83	0.43	1.21e-13	Gut microbiome composition (summer);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg04618842	chr12:57472555	TMEM194A	0.42	6.09	0.35	3.95e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs4665809	0.556	rs10221814	chr2:26442759	C/T	cg08470875	chr2:26401718	FAM59B	-0.76	-8.06	-0.44	2.6e-14	Gut microbiome composition (summer);
CESC	trans	rs7395662	0.571	rs10838947	chr11:48568693	G/T	cg00717180	chr2:96193071	NA	-0.45	-6.19	-0.36	2.32e-9	HDL cholesterol;
CESC	cis	rs7793919	0.726	rs10261971	chr7:4776547	A/G	cg09789173	chr7:4769017	FOXK1	0.79	12.04	0.59	6.43e-27	Mosquito bite size;
CESC	cis	rs433852	0.718	rs386551	chr19:49138286	C/G	cg06677660	chr19:49140777	SEC1;DBP	-0.43	-5.27	-0.31	2.87e-7	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;
CESC	cis	rs9467773	0.595	rs12525810	chr6:26623511	T/TA	cg12826209	chr6:26865740	GUSBL1	0.78	8.28	0.45	6.3e-15	Intelligence (multi-trait analysis);
CESC	cis	rs933688	0.941	rs6452954	chr5:90735692	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.09	14.15	0.66	2.96e-34	Smoking behavior;
CESC	cis	rs2735413	0.918	rs4888733	chr16:78080523	C/T	cg04733911	chr16:78082701	NA	-0.53	-9.01	-0.48	4.08e-17	Systolic blood pressure (alcohol consumption interaction);
CESC	cis	rs9287719	0.935	rs6751075	chr2:10723546	C/G	cg02196655	chr2:10830764	NOL10	-0.36	-5.57	-0.32	6.1e-8	Prostate cancer;
CESC	cis	rs3815700	0.844	rs444089	chr19:33106991	G/C	cg02997394	chr19:33096574	ANKRD27	0.66	6.53	0.37	3.37e-10	Eosinophilic esophagitis;
CESC	cis	rs2658782	0.547	rs3020054	chr11:93055556	C/T	cg15737290	chr11:93063684	CCDC67	0.53	7.3	0.41	3.37e-12	Pulmonary function decline;
CESC	cis	rs12220238	0.908	rs10824133	chr10:76020585	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.6	5.87	0.34	1.33e-8	Soluble interleukin-2 receptor subunit alpha;
CESC	cis	rs11792861	0.926	rs72607170	chr9:111836941	G/A	cg13535736	chr9:111863775	C9orf5	-0.51	-6.76	-0.38	8.77e-11	Menarche (age at onset);
CESC	cis	rs796364	0.951	rs12613687	chr2:200999256	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.68	-6.65	-0.38	1.7e-10	Schizophrenia;
CESC	cis	rs4843747	0.605	rs4072779	chr16:88107290	C/T	cg06915872	chr16:87998081	BANP	0.44	5.24	0.31	3.36e-7	Menopause (age at onset);
CESC	cis	rs1790761	0.692	rs614080	chr11:67347287	G/A	cg14500267	chr11:67383377	NA	0.36	5.71	0.33	2.99e-8	Mean corpuscular volume;
CESC	cis	rs1065852	0.526	rs8138080	chr22:42396371	A/G	cg22189786	chr22:42395067	WBP2NL	-0.43	-5.34	-0.31	2e-7	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
CESC	cis	rs875971	0.651	rs2420596	chr7:65915983	T/C	cg11764359	chr7:65958608	NA	0.81	11.81	0.59	3.86e-26	Aortic root size;
CESC	cis	rs921968	0.541	rs41461846	chr2:219313354	A/G	cg02176678	chr2:219576539	TTLL4	-0.48	-8.03	-0.44	3.23e-14	Mean corpuscular hemoglobin concentration;
CESC	cis	rs2404602	0.552	rs11636612	chr15:76959530	C/T	cg00316803	chr15:76480434	C15orf27	0.43	5.77	0.33	2.25e-8	Blood metabolite levels;
CESC	cis	rs1218582	0.741	rs6656494	chr1:154839799	A/G	cg16680214	chr1:154839983	KCNN3	-0.46	-7.14	-0.4	9.24e-12	Prostate cancer;
CESC	cis	rs7666738	0.830	rs13102369	chr4:99045912	A/G	cg03467027	chr4:99064603	C4orf37	0.47	5.98	0.34	7.19e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10861342	0.892	rs12227605	chr12:105501100	G/A	cg23923672	chr12:105501055	KIAA1033	0.64	5.2	0.3	4.08e-7	IgG glycosylation;
CESC	cis	rs7923609	0.936	rs10761778	chr10:65273782	A/G	cg01631684	chr10:65280961	REEP3	-0.43	-5.4	-0.31	1.47e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs3540	0.554	rs12900987	chr15:91071776	T/C	cg10434728	chr15:90938212	IQGAP1	-0.4	-7.02	-0.4	1.85e-11	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs7666738	0.830	rs3846443	chr4:99032666	G/A	cg05340658	chr4:99064831	C4orf37	0.84	13.09	0.63	1.51e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9322193	0.962	rs9689242	chr6:150109106	T/C	cg04369109	chr6:150039330	LATS1	-0.4	-5.4	-0.31	1.48e-7	Lung cancer;
CESC	cis	rs295140	0.506	rs295136	chr2:201141002	G/C	cg23649088	chr2:200775458	C2orf69	0.46	6.16	0.35	2.67e-9	QT interval;
CESC	cis	rs4835473	0.831	rs4452380	chr4:144894009	A/G	cg25736465	chr4:144833511	NA	0.4	6.1	0.35	3.74e-9	Immature fraction of reticulocytes;
CESC	cis	rs614226	1.000	rs580016	chr12:120933977	T/C	cg01236616	chr12:121019343	POP5	-1.52	-16.63	-0.71	5.04e-43	Type 1 diabetes nephropathy;
CESC	cis	rs4555082	0.874	rs1008628	chr14:105722726	T/C	cg27165867	chr14:105738592	BRF1	-0.56	-6.26	-0.36	1.51e-9	Mean platelet volume;Platelet distribution width;
CESC	cis	rs8077577	0.895	rs11658477	chr17:18044893	G/A	cg16794390	chr17:18148240	FLII	0.49	6.06	0.35	4.68e-9	Obesity-related traits;
CESC	cis	rs11122272	0.766	rs2739511	chr1:231526490	G/C	cg06096015	chr1:231504339	EGLN1	0.41	5.85	0.34	1.46e-8	Hemoglobin concentration;
CESC	cis	rs1728785	1.000	rs1728781	chr16:68567794	A/T	cg02972257	chr16:68554789	NA	-0.55	-6.36	-0.36	8.6e-10	Ulcerative colitis;
CESC	cis	rs7666738	0.830	rs6827516	chr4:98971740	T/C	cg03467027	chr4:99064603	C4orf37	0.43	5.4	0.31	1.49e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9911578	0.900	rs7214335	chr17:57158840	G/A	cg05425664	chr17:57184151	TRIM37	-0.51	-7.01	-0.4	1.98e-11	Intelligence (multi-trait analysis);
CESC	cis	rs1953600	0.668	rs11201879	chr10:81908573	A/C	cg00277334	chr10:82204260	NA	0.4	5.44	0.32	1.24e-7	Sarcoidosis;
CESC	cis	rs12079745	0.793	rs12071122	chr1:169191749	C/A	cg09363564	chr1:169337483	NME7;BLZF1	-1.01	-6.28	-0.36	1.38e-9	QT interval;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg01938359	chr5:1335135	CLPTM1L	0.54	7.81	0.43	1.35e-13	Fibrinogen levels;
CESC	cis	rs9303401	0.659	rs12946397	chr17:56769979	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.05	12.77	0.62	1.94e-29	Cognitive test performance;
CESC	cis	rs654950	0.875	rs881719	chr1:41991427	C/T	cg06885757	chr1:42089581	HIVEP3	-0.45	-6.89	-0.39	4.07e-11	Airway imaging phenotypes;
CESC	cis	rs7503807	0.935	rs9910745	chr17:78610543	C/T	cg09596252	chr17:78655493	RPTOR	0.49	7.19	0.4	6.53e-12	Obesity;
CESC	cis	rs17253792	0.822	rs74653073	chr14:56079528	T/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.77	5.4	0.31	1.5e-7	Putamen volume;
CESC	cis	rs16895831	0.549	rs1028462	chr6:42616678	G/C	cg10605015	chr6:42532144	UBR2	-0.5	-5.52	-0.32	8.27e-8	Granulocyte percentage of myeloid white cells;Neutrophil percentage of white cells;Eosinophil percentage of white cells;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Neutrophil count;Sum basophil neutrophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
CESC	cis	rs651907	0.514	rs11706494	chr3:101509475	A/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.46	6.05	0.35	4.95e-9	Colorectal cancer;
CESC	cis	rs4665809	1.000	rs4665811	chr2:26260017	A/G	cg04944784	chr2:26401820	FAM59B	-0.67	-7.61	-0.42	4.8e-13	Gut microbiome composition (summer);
CESC	cis	rs6570726	0.791	rs9322029	chr6:145906683	A/G	cg05347473	chr6:146136440	FBXO30	0.58	7.59	0.42	5.51e-13	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6693567	0.565	rs497128	chr1:150269952	A/G	cg09579323	chr1:150459698	TARS2	-0.47	-6.18	-0.35	2.44e-9	Migraine;
CESC	cis	rs2228479	0.717	rs1800358	chr16:89809319	T/C	cg06558623	chr16:89946397	TCF25	0.79	7.45	0.42	1.32e-12	Skin colour saturation;
CESC	trans	rs7618501	0.601	rs2624825	chr3:50154989	G/A	cg21659725	chr3:3221576	CRBN	-0.47	-6.53	-0.37	3.44e-10	Intelligence (multi-trait analysis);
CESC	cis	rs7084402	0.967	rs1658451	chr10:60311527	A/T	cg07615347	chr10:60278583	BICC1	0.62	9.95	0.52	5.08e-20	Refractive error;
CESC	cis	rs1784581	0.674	rs1789989	chr6:162408138	C/T	cg17173639	chr6:162384350	PARK2	0.58	9.21	0.49	1.03e-17	Itch intensity from mosquito bite;
CESC	cis	rs35110281	0.667	rs4818859	chr21:45117120	G/A	cg21573476	chr21:45109991	RRP1B	-0.55	-7.91	-0.44	6.87e-14	Mean corpuscular volume;
CESC	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg14159672	chr1:205819179	PM20D1	0.81	12.25	0.6	1.24e-27	Menarche (age at onset);
CESC	cis	rs861020	1.000	rs622832	chr1:209974232	A/C	cg05527609	chr1:210001259	C1orf107	0.93	11.26	0.57	2.76e-24	Orofacial clefts;
CESC	cis	rs992157	0.710	rs6752254	chr2:219058743	C/T	cg00012203	chr2:219082015	ARPC2	0.85	12.08	0.6	4.56e-27	Colorectal cancer;
CESC	cis	rs80130819	0.636	rs2732451	chr12:48719946	T/C	cg05342945	chr12:48394962	COL2A1	-0.49	-5.34	-0.31	2.03e-7	Prostate cancer;
CESC	cis	rs9309473	1.000	rs6745368	chr2:73809974	C/T	cg20560298	chr2:73613845	ALMS1	-0.54	-7.08	-0.4	1.27e-11	Metabolite levels;
CESC	cis	rs2011503	0.941	rs55762233	chr19:19367319	C/G	cg11584989	chr19:19387371	SF4	0.62	7.38	0.41	1.99e-12	Bipolar disorder;
CESC	cis	rs611744	0.647	rs864166	chr8:109249300	C/G	cg21045802	chr8:109455806	TTC35	0.46	5.67	0.33	3.65e-8	Dupuytren's disease;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg13910983	chr1:28241279	RPA2	-0.43	-6.13	-0.35	3.26e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs4132509	0.948	rs12136624	chr1:243981611	C/A	cg21452805	chr1:244014465	NA	0.5	6.16	0.35	2.66e-9	RR interval (heart rate);
CESC	cis	rs875971	0.755	rs10228885	chr7:65780529	C/G	cg10691866	chr7:65817282	TPST1	0.32	5.45	0.32	1.18e-7	Aortic root size;
CESC	cis	rs6867032	1.000	rs28392808	chr5:2013477	A/G	cg26168224	chr5:2018326	NA	0.91	17.91	0.74	1.45e-47	Gut microbiome composition (winter);
CESC	cis	rs9309473	1.000	rs10179134	chr2:73637519	A/G	cg20560298	chr2:73613845	ALMS1	-0.54	-7.1	-0.4	1.18e-11	Metabolite levels;
CESC	cis	rs6580649	0.941	rs72644844	chr12:48465425	A/C	cg05342945	chr12:48394962	COL2A1	0.51	5.91	0.34	1.07e-8	Lung cancer;
CESC	cis	rs7267979	0.899	rs442834	chr20:25458096	A/G	cg08601574	chr20:25228251	PYGB	0.37	5.36	0.31	1.77e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs2806561	0.929	rs628096	chr1:23537676	C/G	cg12483005	chr1:23474871	LUZP1	0.32	5.15	0.3	4.99e-7	Height;
CESC	cis	rs965513	1.000	rs4743130	chr9:100546040	C/T	cg13688889	chr9:100608707	NA	-0.6	-8.5	-0.46	1.37e-15	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg03304299	chr22:17565742	IL17RA	-0.46	-6.05	-0.35	4.98e-9	Fibrinogen levels;
CESC	cis	rs2625529	0.652	rs2929517	chr15:72332917	T/G	cg16672083	chr15:72433130	SENP8	0.38	5.67	0.33	3.79e-8	Red blood cell count;
CESC	trans	rs116095464	0.614	rs4371799	chr5:268192	C/A	cg00938859	chr5:1591904	SDHAP3	0.63	6.89	0.39	4.18e-11	Breast cancer;
CESC	cis	rs826838	1.000	rs1684416	chr12:39130301	G/A	cg13010199	chr12:38710504	ALG10B	-0.45	-6.26	-0.36	1.51e-9	Heart rate;
CESC	cis	rs798766	0.779	rs3134866	chr4:1723265	A/G	cg10756475	chr4:1757242	NA	0.45	6.2	0.36	2.15e-9	Bladder cancer;Urinary bladder cancer;
CESC	cis	rs9462846	0.959	rs7750915	chr6:42882067	C/T	cg02353165	chr6:42928485	GNMT	0.5	5.64	0.33	4.28e-8	Blood protein levels;
CESC	cis	rs10883723	0.810	rs7079810	chr10:104243883	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.54	7.52	0.42	8.75e-13	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs6461049	0.765	rs3800908	chr7:2159437	C/T	cg23048001	chr7:2026167	MAD1L1	0.45	5.92	0.34	9.84e-9	Schizophrenia;
CESC	cis	rs9863	0.828	rs12303671	chr12:124492610	T/G	cg00084347	chr12:124393913	DNAH10	0.26	5.15	0.3	5.05e-7	White blood cell count;
CESC	cis	rs3820928	0.874	rs67513858	chr2:227804819	A/C	cg05526886	chr2:227700861	RHBDD1	-0.39	-5.04	-0.3	8.54e-7	Pulmonary function;
CESC	cis	rs1862618	0.802	rs7733041	chr5:56107377	A/C	cg24531977	chr5:56204891	C5orf35	-0.75	-9.36	-0.5	3.47e-18	Initial pursuit acceleration;
CESC	cis	rs6582630	0.502	rs1607876	chr12:38355750	T/C	cg13010199	chr12:38710504	ALG10B	0.45	5.77	0.33	2.24e-8	Drug-induced liver injury (flucloxacillin);
CESC	trans	rs11989744	0.957	rs61099147	chr8:23573953	A/G	cg03492747	chr16:86543808	FOXF1	0.68	7.61	0.42	4.92e-13	Waist-hip ratio;
CESC	cis	rs2050392	0.544	rs598672	chr10:30742388	C/T	cg25182066	chr10:30743637	MAP3K8	-0.54	-7.56	-0.42	6.81e-13	Inflammatory bowel disease;
CESC	cis	rs7826238	0.539	rs2945891	chr8:8155475	C/T	cg06636001	chr8:8085503	FLJ10661	0.59	7.27	0.41	4.14e-12	Systolic blood pressure;
CESC	cis	rs694739	0.894	rs887314	chr11:64053157	T/G	cg23796481	chr11:64053134	BAD;GPR137	0.66	8.35	0.46	3.96e-15	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CESC	cis	rs6754311	0.731	rs309134	chr2:136755684	A/G	cg07169764	chr2:136633963	MCM6	-0.72	-9.22	-0.49	9.75e-18	Mosquito bite size;
CESC	cis	rs6540559	0.932	rs764093	chr1:209983331	A/G	cg21951975	chr1:209979733	IRF6	0.6	9.51	0.5	1.25e-18	Cleft lip with or without cleft palate;
CESC	cis	rs116988415	0.584	rs77587730	chr14:65237285	C/A	cg25083366	chr14:65239357	SPTB	0.8	5.68	0.33	3.58e-8	Daytime sleep phenotypes;
CESC	cis	rs13118159	0.836	rs2276903	chr4:1343405	A/G	cg02018176	chr4:1364513	KIAA1530	0.45	6.34	0.36	1.01e-9	Longevity;
CESC	cis	rs2836974	0.897	rs35391055	chr21:40525516	G/A	cg17971929	chr21:40555470	PSMG1	1.05	16.62	0.71	5.49e-43	Cognitive function;
CESC	cis	rs1707322	0.685	rs56177313	chr1:46225806	A/C	cg03146154	chr1:46216737	IPP	0.81	11.44	0.58	6.59e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7923452	0.507	rs612802	chr10:30756441	G/A	cg18806716	chr10:30721971	MAP3K8	-0.54	-8.2	-0.45	1.03e-14	Itch intensity from mosquito bite;
CESC	cis	rs17253792	0.822	rs9972178	chr14:56073480	A/G	cg01858014	chr14:56050164	KTN1	-0.85	-6.99	-0.39	2.22e-11	Putamen volume;
CESC	cis	rs9858542	0.953	rs11711485	chr3:49491983	G/T	cg07274523	chr3:49395745	GPX1	0.65	8.0	0.44	3.84e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs7811142	0.830	rs11765869	chr7:99964789	T/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.91	8.47	0.46	1.68e-15	Platelet count;
CESC	cis	rs4423214	0.840	rs1792234	chr11:71182018	T/C	cg05163923	chr11:71159392	DHCR7	-0.68	-8.01	-0.44	3.74e-14	Vitamin D levels;
CESC	cis	rs561341	1.000	rs521919	chr17:30298039	G/T	cg19193384	chr17:30244184	NA	-0.6	-6.23	-0.36	1.78e-9	Hip circumference adjusted for BMI;
CESC	cis	rs7914558	1.000	rs12255047	chr10:104760752	G/A	cg04362960	chr10:104952993	NT5C2	0.45	6.0	0.35	6.3e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs3008870	0.785	rs10889651	chr1:67463513	A/T	cg02640540	chr1:67518911	SLC35D1	-0.45	-5.5	-0.32	8.85e-8	Lymphocyte percentage of white cells;
CESC	cis	rs6570726	0.846	rs372904	chr6:145887425	T/C	cg23711669	chr6:146136114	FBXO30	0.92	13.93	0.65	1.83e-33	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs644799	0.965	rs3016295	chr11:95554311	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.53	6.42	0.37	6.39e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs1008375	0.966	rs10939736	chr4:17581617	T/A	cg27347728	chr4:17578864	LAP3	0.43	5.12	0.3	5.92e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs10931896	0.531	rs295117	chr2:201146828	C/T	cg23649088	chr2:200775458	C2orf69	0.53	7.34	0.41	2.62e-12	Systolic blood pressure;
CESC	cis	rs7918232	0.882	rs6415983	chr10:27357211	A/G	cg14240646	chr10:27532245	ACBD5	-0.55	-5.1	-0.3	6.51e-7	Breast cancer;
CESC	cis	rs1843834	0.931	rs10170573	chr2:225552916	A/G	cg22455342	chr2:225449267	CUL3	0.53	6.56	0.37	2.86e-10	IgE levels in asthmatics (D.p. specific);
CESC	trans	rs875971	0.660	rs10263935	chr7:66096028	A/G	cg26939375	chr7:64535504	NA	0.53	7.13	0.4	9.73e-12	Aortic root size;
CESC	cis	rs12477438	0.520	rs6542864	chr2:99725223	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.86	16.04	0.7	6.57e-41	Chronic sinus infection;
CESC	cis	rs34779708	0.931	rs72789609	chr10:35306206	C/T	cg04310649	chr10:35416472	CREM	-0.48	-5.84	-0.34	1.53e-8	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs763014	0.932	rs4984898	chr16:641164	G/T	cg00802000	chr16:706648	WDR90	-0.37	-5.31	-0.31	2.35e-7	Height;
CESC	cis	rs9311474	0.508	rs12637627	chr3:52619962	G/T	cg17372223	chr3:52568218	NT5DC2	0.43	6.49	0.37	4.15e-10	Electroencephalogram traits;
CESC	cis	rs4481887	1.000	rs10788782	chr1:248496132	C/A	cg00666640	chr1:248458726	OR2T12	0.41	6.57	0.37	2.64e-10	Common traits (Other);
CESC	cis	rs4969178	0.896	rs11077361	chr17:76397128	A/G	cg20026190	chr17:76395443	PGS1	0.49	7.78	0.43	1.67e-13	HDL cholesterol levels;
CESC	cis	rs514406	0.505	rs6688064	chr1:53165609	C/T	cg08859206	chr1:53392774	SCP2	-0.57	-7.56	-0.42	6.6e-13	Monocyte count;
CESC	cis	rs3784262	0.967	rs11630835	chr15:58269462	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.31	-5.07	-0.3	7.49e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
CESC	cis	rs9467711	0.606	rs13203358	chr6:26590578	A/T	cg12826209	chr6:26865740	GUSBL1	0.66	5.67	0.33	3.73e-8	Autism spectrum disorder or schizophrenia;
CESC	cis	rs262150	0.630	rs2730274	chr7:158796062	C/A	cg19418458	chr7:158789849	NA	-0.47	-7.59	-0.42	5.51e-13	Facial morphology (factor 20);
CESC	cis	rs1879734	0.731	rs11206192	chr1:54158690	A/G	cg23596471	chr1:54105337	GLIS1	-0.32	-5.12	-0.3	5.76e-7	Mitral valve prolapse;
CESC	cis	rs858239	0.601	rs10224327	chr7:23161820	T/C	cg23682824	chr7:23144976	KLHL7	0.49	6.5	0.37	4.06e-10	Cerebrospinal fluid biomarker levels;
CESC	trans	rs7307889	0.546	rs10160866	chr12:6014627	G/T	cg18407955	chr7:158110685	PTPRN2	-0.71	-6.58	-0.37	2.48e-10	Obesity-related traits;
CESC	cis	rs1348850	0.540	rs10172355	chr2:178443225	A/G	cg23306229	chr2:178417860	TTC30B	0.59	5.7	0.33	3.22e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs854765	0.583	rs9890341	chr17:17823175	G/C	cg04398451	chr17:18023971	MYO15A	-0.67	-9.6	-0.51	6.42e-19	Total body bone mineral density;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03794219	chr15:84954280	NA	-0.41	-6.92	-0.39	3.4e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs7103648	0.669	rs7114011	chr11:47811309	A/C	cg20307385	chr11:47447363	PSMC3	0.81	12.27	0.6	1.04e-27	Diastolic blood pressure;Systolic blood pressure;
CESC	cis	rs780096	0.526	rs2911713	chr2:27640980	G/A	cg17158414	chr2:27665306	KRTCAP3	-0.32	-5.99	-0.35	6.73e-9	Total body bone mineral density;
CESC	cis	rs6456156	0.586	rs9459853	chr6:167465774	C/A	cg07741184	chr6:167504864	NA	0.37	6.34	0.36	9.82e-10	Primary biliary cholangitis;
CESC	cis	rs10779751	1.000	rs12124983	chr1:11286178	C/T	cg08854313	chr1:11322531	MTOR	-0.92	-14.48	-0.66	2.19e-35	Body mass index;
CESC	cis	rs5769765	0.778	rs4574208	chr22:50256738	C/T	cg26441486	chr22:50317300	CRELD2	-0.39	-5.5	-0.32	8.79e-8	Schizophrenia;
CESC	cis	rs921968	0.643	rs598701	chr2:219387005	C/G	cg02176678	chr2:219576539	TTLL4	-0.34	-5.91	-0.34	1.06e-8	Mean corpuscular hemoglobin concentration;
CESC	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg07332563	chr6:291687	DUSP22	-0.7	-9.13	-0.49	1.77e-17	Menopause (age at onset);
CESC	cis	rs8180040	0.966	rs6765990	chr3:47542894	G/A	cg27129171	chr3:47204927	SETD2	0.6	8.92	0.48	7.91e-17	Colorectal cancer;
CESC	cis	rs875971	0.545	rs6961853	chr7:66002022	G/A	cg11764359	chr7:65958608	NA	0.82	10.05	0.53	2.44e-20	Aortic root size;
CESC	cis	rs4849845	0.849	rs12711940	chr2:121036386	T/A	cg24070213	chr2:121070622	NA	0.4	5.13	0.3	5.63e-7	Mean platelet volume;
CESC	cis	rs1862618	0.853	rs33325	chr5:56142547	G/C	cg18230493	chr5:56204884	C5orf35	-0.74	-9.05	-0.49	3.27e-17	Initial pursuit acceleration;
CESC	cis	rs9660180	0.967	rs6603802	chr1:1812521	C/T	cg05132306	chr1:1846340	CALML6	-0.29	-6.06	-0.35	4.58e-9	Body mass index;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg17017335	chr3:97540665	NA	-0.47	-6.73	-0.38	1.02e-10	Gambling;
CESC	cis	rs3733585	0.781	rs4292328	chr4:9970962	C/T	cg11266682	chr4:10021025	SLC2A9	-0.62	-12.53	-0.61	1.38e-28	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs514406	0.861	rs11206011	chr1:53235910	T/C	cg24675658	chr1:53192096	ZYG11B	0.54	7.53	0.42	7.86e-13	Monocyte count;
CESC	cis	rs4975709	0.609	rs2232373	chr5:1882280	C/G	cg12288994	chr5:1860383	NA	0.36	5.63	0.33	4.48e-8	Cardiovascular disease risk factors;
CESC	cis	rs4474465	0.850	rs10793327	chr11:78256841	A/C	cg27205649	chr11:78285834	NARS2	0.43	5.42	0.32	1.37e-7	Alzheimer's disease (survival time);
CESC	cis	rs9457247	0.646	rs4710160	chr6:167409241	T/A	cg25258033	chr6:167368657	RNASET2	0.4	6.14	0.35	2.93e-9	Crohn's disease;
CESC	cis	rs2637266	1.000	rs7905033	chr10:78368212	A/C	cg18941641	chr10:78392320	NA	0.43	8.26	0.45	6.94e-15	Pulmonary function;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg05926606	chr21:40685342	BRWD1	-0.44	-6.01	-0.35	6.11e-9	Fibrinogen levels;
CESC	cis	rs2204008	0.720	rs11170774	chr12:38021722	C/T	cg26384229	chr12:38710491	ALG10B	-0.54	-7.65	-0.43	3.79e-13	Bladder cancer;
CESC	cis	rs798554	0.567	rs1182192	chr7:2869274	G/A	cg04166393	chr7:2884313	GNA12	0.4	5.21	0.3	3.81e-7	Height;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg01174859	chr7:128379317	CALU	0.45	6.15	0.35	2.88e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs4237845	0.514	rs4760339	chr12:58268149	G/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.5	5.62	0.33	4.83e-8	Intelligence (multi-trait analysis);
CESC	cis	rs9640161	0.789	rs36035506	chr7:150057843	C/T	cg27494647	chr7:150038898	RARRES2	0.42	5.12	0.3	5.75e-7	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs7680126	0.596	rs10022911	chr4:10140551	A/G	cg11266682	chr4:10021025	SLC2A9	-0.46	-6.08	-0.35	4.14e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	trans	rs1945213	0.694	rs12422168	chr11:55866840	A/G	cg03929089	chr4:120376271	NA	0.73	6.92	0.39	3.43e-11	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs2239547	0.522	rs2581815	chr3:52982159	C/G	cg11645453	chr3:52864694	ITIH4	0.33	5.5	0.32	9.05e-8	Schizophrenia;
CESC	cis	rs748404	0.697	rs475261	chr15:43546456	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	7.87	0.44	8.86e-14	Lung cancer;
CESC	cis	rs12142240	0.698	rs66911505	chr1:46823298	A/G	cg10495392	chr1:46806563	NSUN4	0.58	6.32	0.36	1.09e-9	Menopause (age at onset);
CESC	trans	rs2727020	0.704	rs2988340	chr11:49176057	C/T	cg15704280	chr7:45808275	SEPT13	-0.82	-12.5	-0.61	1.69e-28	Coronary artery disease;
CESC	cis	rs9948	0.881	rs7580942	chr2:97468276	C/G	cg01990225	chr2:97406019	LMAN2L	-0.54	-5.2	-0.3	4.09e-7	Erectile dysfunction and prostate cancer treatment;
CESC	cis	rs10484885	0.878	rs72921937	chr6:90579863	T/G	cg13799429	chr6:90582589	CASP8AP2	-0.79	-7.55	-0.42	7.1e-13	QRS interval (sulfonylurea treatment interaction);
CESC	cis	rs7267979	0.844	rs6107017	chr20:25232300	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.72	11.88	0.59	2.28e-26	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs9287719	0.967	rs4284804	chr2:10722124	C/T	cg00105475	chr2:10696890	NA	0.39	5.69	0.33	3.35e-8	Prostate cancer;
CESC	cis	rs3106136	0.527	rs2632411	chr4:95149434	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.7	-11.58	-0.58	2.35e-25	Capecitabine sensitivity;
CESC	cis	rs7267979	1.000	rs2297496	chr20:25295787	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.89	-18.7	-0.75	2.48e-50	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs9443645	0.527	rs7756996	chr6:79509367	A/C	cg05283184	chr6:79620031	NA	-0.36	-5.29	-0.31	2.62e-7	Intelligence (multi-trait analysis);
CESC	cis	rs6500602	0.626	rs7665	chr16:4562512	A/G	cg08645402	chr16:4508243	NA	0.43	6.3	0.36	1.23e-9	Schizophrenia;
CESC	cis	rs7786808	0.741	rs11767875	chr7:158228923	A/G	cg09998033	chr7:158218633	PTPRN2	-0.43	-6.44	-0.37	5.71e-10	Obesity-related traits;
CESC	trans	rs11992162	0.933	rs10108075	chr8:11832079	A/G	cg15556689	chr8:8085844	FLJ10661	0.54	6.18	0.35	2.39e-9	Monocyte count;
CESC	cis	rs3749237	0.595	rs17595772	chr3:49409704	G/A	cg07636037	chr3:49044803	WDR6	0.62	8.98	0.48	5.18e-17	Resting heart rate;
CESC	cis	rs6500602	0.701	rs4786508	chr16:4568043	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.38	5.48	0.32	9.96e-8	Schizophrenia;
CESC	cis	rs7824557	0.628	rs7815802	chr8:11190647	G/C	cg21775007	chr8:11205619	TDH	0.55	8.63	0.47	5.8e-16	Retinal vascular caliber;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg24162330	chr15:28520159	HERC2	-0.37	-6.19	-0.36	2.24e-9	Gambling;
CESC	trans	rs12356475	0.710	rs10822686	chr10:67733250	C/T	cg19056506	chr17:79633562	CCDC137;C17orf90	0.51	6.24	0.36	1.77e-9	Psoriatic arthritis;
CESC	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg07677032	chr17:61819896	STRADA	0.47	6.31	0.36	1.16e-9	Prudent dietary pattern;
CESC	cis	rs9467711	0.606	rs9358935	chr6:26369587	A/G	cg14345882	chr6:26364793	BTN3A2	0.6	6.21	0.36	2.06e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs818427	0.593	rs3317	chr5:112212151	G/A	cg07820702	chr5:112228657	REEP5	0.39	5.1	0.3	6.36e-7	Total body bone mineral density;
CESC	cis	rs2976388	0.566	rs2585141	chr8:143806343	G/A	cg20862496	chr8:143823734	SLURP1	0.34	5.27	0.31	2.9e-7	Urinary tract infection frequency;
CESC	cis	rs7647973	0.600	rs13064780	chr3:49274826	T/G	cg07636037	chr3:49044803	WDR6	0.8	13.11	0.63	1.37e-30	Menarche (age at onset);
CESC	cis	rs7647973	0.626	rs4855845	chr3:49687043	T/C	cg07636037	chr3:49044803	WDR6	0.54	6.47	0.37	4.79e-10	Menarche (age at onset);
CESC	cis	rs4665809	0.590	rs6730317	chr2:26419482	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-1.06	-13.11	-0.63	1.37e-30	Gut microbiome composition (summer);
CESC	cis	rs780096	0.565	rs11681351	chr2:27743423	G/A	cg12648201	chr2:27665141	KRTCAP3	-0.32	-5.68	-0.33	3.62e-8	Total body bone mineral density;
CESC	cis	rs16866061	0.517	rs7594223	chr2:225472985	T/C	cg12698349	chr2:225449008	CUL3	0.46	5.99	0.35	6.67e-9	Acute graft versus host disease in bone marrow transplantation (recipient effect);
CESC	cis	rs2361718	0.500	rs8068856	chr17:78100731	A/G	cg27427491	chr17:78079615	GAA	-0.39	-5.75	-0.33	2.44e-8	Yeast infection;
CESC	cis	rs9457247	0.756	rs1811123	chr6:167403443	T/C	cg25258033	chr6:167368657	RNASET2	0.39	5.83	0.34	1.59e-8	Crohn's disease;
CESC	cis	rs1775715	0.737	rs11008695	chr10:32216887	T/G	cg26784012	chr10:32216390	ARHGAP12	0.38	5.08	0.3	7.1e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg23978390	chr7:1156363	C7orf50	0.53	7.11	0.4	1.08e-11	Longevity;Endometriosis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08399230	chr16:4665037	FAM100A	0.63	7.53	0.42	7.93e-13	Gut microbiome composition (summer);
CESC	cis	rs3096299	0.509	rs4785691	chr16:89597221	A/G	cg08392591	chr16:89556376	ANKRD11	0.52	6.81	0.39	6.38e-11	Multiple myeloma (IgH translocation);
CESC	cis	rs9910055	0.529	rs228765	chr17:42186422	C/T	cg13607699	chr17:42295918	UBTF	-0.44	-5.51	-0.32	8.36e-8	Total body bone mineral density;
CESC	cis	rs1153858	0.943	rs8038342	chr15:45651537	T/C	cg14582100	chr15:45693742	SPATA5L1	0.42	5.97	0.34	7.62e-9	Homoarginine levels;
CESC	cis	rs3091242	0.933	rs909833	chr1:25754140	C/G	cg03538708	chr1:25844672	NA	-0.41	-6.29	-0.36	1.29e-9	Erythrocyte sedimentation rate;
CESC	cis	rs2370759	1.000	rs76998371	chr10:32631785	A/G	cg05361325	chr10:32636312	EPC1	-0.56	-5.21	-0.3	3.82e-7	Sexual dysfunction (female);
CESC	cis	rs898097	0.841	rs12453162	chr17:80859971	C/T	cg15664640	chr17:80829946	TBCD	-0.68	-9.62	-0.51	5.39e-19	Breast cancer;
CESC	cis	rs3741404	0.609	rs635139	chr11:63872210	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.71	9.9	0.52	7.1e-20	Platelet count;
CESC	cis	rs12477438	0.520	rs13022329	chr2:99731189	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.86	15.87	0.7	2.48e-40	Chronic sinus infection;
CESC	cis	rs9902453	1.000	rs4465650	chr17:28396721	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	8.36	0.46	3.69e-15	Coffee consumption (cups per day);
CESC	cis	rs881375	0.678	rs10818488	chr9:123705087	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.47	6.82	0.39	6.25e-11	Rheumatoid arthritis;
CESC	cis	rs3820928	0.845	rs7570869	chr2:227878818	A/C	cg11843606	chr2:227700838	RHBDD1	-0.48	-6.15	-0.35	2.84e-9	Pulmonary function;
CESC	cis	rs258892	0.895	rs10042574	chr5:72085684	C/G	cg21869765	chr5:72125136	TNPO1	-0.42	-5.42	-0.32	1.36e-7	Small cell lung carcinoma;
CESC	cis	rs8058578	0.614	rs2878304	chr16:30878366	C/T	cg02466173	chr16:30829666	NA	0.45	6.57	0.37	2.65e-10	Multiple myeloma;
CESC	cis	rs11650494	0.710	rs73987293	chr17:47474728	A/G	cg08112188	chr17:47440006	ZNF652	0.83	6.31	0.36	1.17e-9	Prostate cancer;
CESC	cis	rs4308124	0.708	rs10179596	chr2:111970380	G/A	cg04571233	chr2:111982156	NA	-0.62	-6.8	-0.39	6.82e-11	Vitiligo;
CESC	cis	rs3820068	0.559	rs6675334	chr1:15923580	A/T	cg13390004	chr1:15929781	NA	0.33	5.31	0.31	2.33e-7	Systolic blood pressure;
CESC	cis	rs7659604	0.676	rs4516739	chr4:122699741	G/T	cg06713675	chr4:122721982	EXOSC9	-0.45	-6.39	-0.37	7.46e-10	Type 2 diabetes;
CESC	cis	rs13385	0.769	rs13188675	chr5:139606718	G/A	cg26211634	chr5:139558579	C5orf32	0.47	5.16	0.3	4.78e-7	Atrial fibrillation;
CESC	cis	rs9487051	0.872	rs9386790	chr6:109608460	G/T	cg12927641	chr6:109611667	NA	0.44	6.82	0.39	6.1e-11	Reticulocyte fraction of red cells;
CESC	cis	rs6445797	0.855	rs35467279	chr3:56567152	C/A	cg13792233	chr3:56591045	CCDC66	-0.38	-5.18	-0.3	4.44e-7	Gastritis;
CESC	cis	rs6831352	0.734	rs1453872	chr4:100022482	G/A	cg13256891	chr4:100009986	ADH5	0.7	8.18	0.45	1.17e-14	Alcohol dependence;
CESC	cis	rs6987853	0.527	rs2974298	chr8:42376477	T/C	cg09913449	chr8:42400586	C8orf40	-0.35	-5.58	-0.32	5.96e-8	Mean corpuscular hemoglobin concentration;
CESC	cis	rs116095464	0.558	rs13354585	chr5:242263	G/C	cg22496380	chr5:211416	CCDC127	-0.74	-8.68	-0.47	4.09e-16	Breast cancer;
CESC	cis	rs3785574	0.962	rs2665835	chr17:61903258	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.79	10.49	0.54	9.34e-22	Height;
CESC	cis	rs11785400	0.793	rs4581034	chr8:143736968	G/A	cg24634471	chr8:143751801	JRK	0.46	5.91	0.34	1.04e-8	Schizophrenia;
CESC	cis	rs801193	0.613	rs2659900	chr7:66184443	G/C	cg11764359	chr7:65958608	NA	0.89	13.96	0.65	1.41e-33	Aortic root size;
CESC	cis	rs7772486	0.686	rs857877	chr6:145976230	A/C	cg05347473	chr6:146136440	FBXO30	-0.55	-7.1	-0.4	1.12e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs3780486	1.000	rs10813957	chr9:33153527	G/T	cg13443165	chr9:33130375	B4GALT1	0.42	5.23	0.31	3.48e-7	IgG glycosylation;
CESC	cis	rs7666738	0.830	rs6848397	chr4:98946738	A/G	cg03467027	chr4:99064603	C4orf37	0.46	5.82	0.34	1.74e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs523522	0.962	rs509445	chr12:121017243	A/C	cg27279351	chr12:120934652	DYNLL1	0.69	8.92	0.48	7.73e-17	High light scatter reticulocyte count;
CESC	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.52	6.42	0.37	6.2e-10	Prudent dietary pattern;
CESC	cis	rs1552244	1.000	rs67852463	chr3:10157205	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.88	12.21	0.6	1.71e-27	Alzheimer's disease;
CESC	cis	rs2836950	0.565	rs2836934	chr21:40564885	A/C	cg11644478	chr21:40555479	PSMG1	-0.53	-7.17	-0.4	7.64e-12	Menarche (age at onset);
CESC	cis	rs9611565	0.559	rs6002408	chr22:41967870	C/T	cg06634786	chr22:41940651	POLR3H	-0.59	-6.29	-0.36	1.29e-9	Vitiligo;
CESC	cis	rs9733	0.596	rs2275236	chr1:150669952	A/G	cg17724175	chr1:150552817	MCL1	-0.43	-6.96	-0.39	2.6e-11	Tonsillectomy;
CESC	trans	rs28549925	0.590	rs66681092	chr7:16989244	C/T	cg12639933	chr12:57626296	SHMT2	0.95	6.1	0.35	3.83e-9	Congenital heart disease (maternal effect);Conotruncal heart defects (maternal effects);
CESC	cis	rs7618915	0.547	rs62255371	chr3:52747321	A/G	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.31	5.54	0.32	7.45e-8	Bipolar disorder;
CESC	cis	rs425277	0.585	rs3107156	chr1:2060630	T/C	cg16545954	chr1:2118288	C1orf86	-0.34	-6.15	-0.35	2.79e-9	Height;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg02988255	chr11:60621110	GPR44	0.39	6.0	0.35	6.35e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg01570069	chr10:96305623	HELLS	0.46	6.06	0.35	4.68e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs9488822	0.676	rs12524249	chr6:116368813	G/A	cg18764771	chr6:116381957	FRK	0.23	5.72	0.33	2.83e-8	Cholesterol, total;LDL cholesterol;
CESC	cis	rs2070997	0.756	rs7872328	chr9:133727453	T/A	cg11464064	chr9:133710261	ABL1	0.56	6.07	0.35	4.53e-9	Response to amphetamines;
CESC	cis	rs2243480	0.901	rs313808	chr7:65499873	T/G	cg18252515	chr7:66147081	NA	-1.13	-10.91	-0.56	3.9e-23	Diabetic kidney disease;
CESC	cis	rs67478160	0.644	rs7159810	chr14:104294117	T/G	cg08213375	chr14:104286397	PPP1R13B	0.54	10.53	0.54	6.84e-22	Schizophrenia;
CESC	cis	rs1799949	1.000	rs4793192	chr17:41204390	T/C	cg23758822	chr17:41437982	NA	1.0	14.95	0.68	4.7e-37	Menopause (age at onset);
CESC	cis	rs3106136	0.903	rs35361491	chr4:95202492	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.47	-6.94	-0.39	3.03e-11	Capecitabine sensitivity;
CESC	cis	rs7789940	0.857	rs12532935	chr7:75939698	G/C	cg10167463	chr7:75959203	YWHAG	-0.47	-5.64	-0.33	4.42e-8	Multiple sclerosis;
CESC	trans	rs11098499	0.535	rs10005542	chr4:120268302	T/C	cg25214090	chr10:38739885	LOC399744	0.59	8.14	0.45	1.55e-14	Corneal astigmatism;
CESC	cis	rs8099014	0.648	rs4940704	chr18:56115507	A/G	cg12827950	chr18:55968429	NEDD4L	-0.47	-5.06	-0.3	7.79e-7	Platelet count;
CESC	cis	rs6430585	0.527	rs76380759	chr2:136438517	G/A	cg07169764	chr2:136633963	MCM6	1.08	12.35	0.6	5.71e-28	Corneal structure;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg03425468	chr1:155164676	MIR92B	-0.47	-6.25	-0.36	1.67e-9	Ulcerative colitis;
CESC	cis	rs801193	0.548	rs2659891	chr7:66201114	A/G	cg18252515	chr7:66147081	NA	-0.48	-6.45	-0.37	5.25e-10	Aortic root size;
CESC	cis	rs6963495	0.745	rs73190179	chr7:105162812	C/A	cg02135003	chr7:105160482	PUS7	-0.46	-5.55	-0.32	6.92e-8	Bipolar disorder (body mass index interaction);
CESC	cis	rs11048434	0.673	rs2159961	chr12:9061456	G/T	cg04155231	chr12:9217510	LOC144571	0.31	5.08	0.3	7.3e-7	Sjögren's syndrome;
CESC	cis	rs7666738	0.753	rs11932536	chr4:98930105	A/G	cg05340658	chr4:99064831	C4orf37	0.82	12.17	0.6	2.24e-27	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9916302	0.904	rs4795355	chr17:37427382	C/T	cg19468946	chr17:37922297	IKZF3	-0.39	-5.03	-0.3	8.96e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs9527	0.590	rs2148200	chr10:104879847	C/A	cg04362960	chr10:104952993	NT5C2	0.44	5.54	0.32	7.12e-8	Arsenic metabolism;
CESC	cis	rs4891159	0.790	rs72973773	chr18:74115176	T/C	cg24786174	chr18:74118243	ZNF516	-0.72	-11.24	-0.57	3.28e-24	Longevity;
CESC	cis	rs6952808	0.594	rs3778969	chr7:2139990	A/G	cg04267008	chr7:1944627	MAD1L1	0.6	7.16	0.4	7.71e-12	Bipolar disorder and schizophrenia;
CESC	cis	rs7772486	0.875	rs6913797	chr6:146413758	A/G	cg05347473	chr6:146136440	FBXO30	0.49	6.63	0.38	1.83e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2777491	0.874	rs28716108	chr15:41655523	G/C	cg18705301	chr15:41695430	NDUFAF1	-0.67	-10.15	-0.53	1.13e-20	Ulcerative colitis;
CESC	cis	rs787274	0.543	rs10739377	chr9:115631598	A/G	cg13803584	chr9:115635662	SNX30	0.64	5.98	0.34	7.3e-9	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs514406	0.861	rs10888755	chr1:53240829	A/G	cg16325326	chr1:53192061	ZYG11B	-0.84	-14.58	-0.67	9.51e-36	Monocyte count;
CESC	cis	rs4713118	0.662	rs149948	chr6:27974817	C/G	cg18032046	chr6:28092343	ZSCAN16	-0.55	-6.8	-0.39	7.12e-11	Parkinson's disease;
CESC	cis	rs9487051	1.000	rs1008084	chr6:109626965	G/A	cg01475377	chr6:109611718	NA	-0.4	-6.08	-0.35	4.24e-9	Reticulocyte fraction of red cells;
CESC	trans	rs3780486	0.846	rs10971438	chr9:33180308	A/G	cg20290983	chr6:43655470	MRPS18A	0.86	12.64	0.61	5.48e-29	IgG glycosylation;
CESC	cis	rs6942756	1.000	rs6467243	chr7:129001508	A/G	cg02491457	chr7:128862824	NA	-0.67	-9.42	-0.5	2.27e-18	White matter hyperintensity burden;
CESC	cis	rs7666738	0.830	rs17484890	chr4:99013778	T/C	cg03676636	chr4:99064102	C4orf37	0.33	5.07	0.3	7.39e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg06715928	chr10:112257500	DUSP5	0.41	6.02	0.35	5.68e-9	Vertical cup-disc ratio;
CESC	cis	rs2273669	0.667	rs12154092	chr6:109313303	C/T	cg05315195	chr6:109294784	ARMC2	-0.66	-6.28	-0.36	1.36e-9	Prostate cancer;
CESC	cis	rs8020095	0.528	rs10132093	chr14:67847511	G/A	cg19548862	chr14:67692701	FAM71D	-0.45	-5.3	-0.31	2.41e-7	Depression (quantitative trait);
CESC	cis	rs7259376	0.869	rs11671804	chr19:22591216	A/G	cg02657401	chr19:22469223	NA	0.27	5.55	0.32	6.97e-8	Menopause (age at onset);
CESC	cis	rs13191362	0.935	rs4273664	chr6:162955494	T/G	cg06582575	chr6:163149167	PACRG;PARK2	0.76	7.37	0.41	2.13e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs736408	0.507	rs6445531	chr3:52717282	T/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.81	0.39	6.64e-11	Bipolar disorder;
CESC	cis	rs854765	0.583	rs62064156	chr17:17822480	C/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.49	6.36	0.36	8.96e-10	Total body bone mineral density;
CESC	cis	rs9399135	0.967	rs1041480	chr6:135373076	G/T	cg22676075	chr6:135203613	NA	0.52	7.3	0.41	3.39e-12	Red blood cell count;
CESC	cis	rs9733	0.596	rs2867304	chr1:150630995	G/A	cg22823121	chr1:150693482	HORMAD1	0.48	7.12	0.4	1.03e-11	Tonsillectomy;
CESC	cis	rs6570726	0.738	rs4495284	chr6:145916617	T/A	cg23711669	chr6:146136114	FBXO30	0.95	14.33	0.66	7.03e-35	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs8058578	0.945	rs8058961	chr16:30809063	G/A	cg02466173	chr16:30829666	NA	-0.47	-7.49	-0.42	1.03e-12	Multiple myeloma;
CESC	trans	rs2727020	0.731	rs10450572	chr11:49281073	T/C	cg03929089	chr4:120376271	NA	0.8	12.07	0.6	5.09e-27	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15606819	chr19:49661083	TRPM4	0.62	7.3	0.41	3.4e-12	Gut microbiome composition (summer);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg12931616	chr22:38528856	PLA2G6	0.44	6.16	0.35	2.65e-9	Fibrinogen levels;
CESC	cis	rs79349575	0.783	rs962272	chr17:46978283	A/G	cg26022315	chr17:47021804	SNF8	0.38	5.03	0.3	9.14e-7	Type 2 diabetes;
CESC	cis	rs2836950	0.561	rs34705151	chr21:40553344	G/A	cg11890956	chr21:40555474	PSMG1	-0.63	-8.8	-0.48	1.76e-16	Menarche (age at onset);
CESC	cis	rs1018836	0.608	rs7821069	chr8:91465548	C/G	cg16814680	chr8:91681699	NA	-0.5	-6.99	-0.39	2.18e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs9457247	0.967	rs2757054	chr6:167380501	A/G	cg25258033	chr6:167368657	RNASET2	-0.42	-6.24	-0.36	1.77e-9	Crohn's disease;
CESC	cis	rs1003719	0.715	rs6517405	chr21:38560334	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.61	-8.29	-0.45	5.68e-15	Eye color traits;
CESC	cis	rs79349575	0.756	rs3848460	chr17:47047114	A/G	cg16584676	chr17:46985605	UBE2Z	-0.44	-5.48	-0.32	1.01e-7	Type 2 diabetes;
CESC	cis	rs4891159	0.790	rs1787448	chr18:74113179	T/C	cg24786174	chr18:74118243	ZNF516	0.76	12.11	0.6	3.83e-27	Longevity;
CESC	cis	rs9902453	0.808	rs56216220	chr17:28209182	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	8.08	0.44	2.31e-14	Coffee consumption (cups per day);
CESC	cis	rs853679	0.517	rs4713135	chr6:28039586	G/A	cg22143856	chr6:28129313	ZNF389	0.49	6.16	0.35	2.76e-9	Depression;
CESC	cis	rs2228479	0.850	rs11642010	chr16:89845111	T/C	cg04013166	chr16:89971882	TCF25	0.76	6.05	0.35	5.02e-9	Skin colour saturation;
CESC	cis	rs11608355	0.515	rs2287191	chr12:109931741	C/T	cg05360138	chr12:110035743	NA	0.82	8.85	0.48	1.27e-16	Neuroticism;
CESC	cis	rs3806843	0.966	rs2563260	chr5:140137867	C/A	cg26395211	chr5:140044315	WDR55	0.44	5.6	0.33	5.41e-8	Depressive symptoms (multi-trait analysis);
CESC	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg11301795	chr4:187892539	NA	-0.75	-12.3	-0.6	8.03e-28	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs8077577	0.747	rs62072541	chr17:18226699	G/A	cg16794390	chr17:18148240	FLII	0.4	6.34	0.36	9.98e-10	Obesity-related traits;
CESC	cis	rs9612	1.000	rs7246677	chr19:44248625	G/A	cg08581076	chr19:44259116	C19orf61	0.59	6.7	0.38	1.26e-10	Exhaled nitric oxide output;
CESC	cis	rs11997175	0.603	rs7001603	chr8:33680978	T/G	ch.8.33884649F	chr8:33765107	NA	0.57	7.38	0.41	2.01e-12	Body mass index;
CESC	cis	rs10504073	0.647	rs7817571	chr8:50003218	T/C	cg00325661	chr8:49890786	NA	0.51	7.78	0.43	1.65e-13	Blood metabolite ratios;
CESC	cis	rs7216064	0.954	rs4790974	chr17:65951107	A/T	cg12091567	chr17:66097778	LOC651250	0.72	8.17	0.45	1.3e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs643506	0.874	rs634983	chr11:111747427	C/T	cg17089665	chr11:111648010	NA	-0.38	-5.51	-0.32	8.29e-8	Breast cancer;
CESC	cis	rs9388451	0.869	rs7764016	chr6:126070789	T/G	cg10911889	chr6:126070802	HEY2	0.39	5.34	0.31	1.97e-7	Brugada syndrome;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02466933	chr2:9770529	YWHAQ	0.56	6.78	0.38	7.99e-11	Gut microbiome composition (summer);
CESC	cis	rs4950322	0.570	rs945742	chr1:146785157	A/G	cg16700924	chr1:146552102	NA	-0.41	-5.1	-0.3	6.37e-7	Protein quantitative trait loci;
CESC	cis	rs7666738	0.830	rs35685312	chr4:98858521	G/A	cg03467027	chr4:99064603	C4orf37	0.42	5.16	0.3	4.73e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg13009927	chr2:242254519	SEPT2;HDLBP	-0.42	-6.08	-0.35	4.27e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs910316	1.000	rs4322591	chr14:75600697	C/T	cg08847533	chr14:75593920	NEK9	1.01	19.64	0.77	1.26e-53	Height;
CESC	cis	rs919433	0.750	rs788010	chr2:198230949	T/C	cg20885578	chr2:198174922	NA	0.41	5.36	0.31	1.79e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs4604732	0.631	rs12038793	chr1:247624262	C/T	cg12758973	chr1:247694275	LOC148824;OR2C3	-0.52	-6.6	-0.38	2.22e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs2404602	0.692	rs7350777	chr15:76985441	G/A	cg22467129	chr15:76604101	ETFA	-0.34	-5.12	-0.3	5.9e-7	Blood metabolite levels;
CESC	cis	rs3796352	1.000	rs3097417	chr3:53088601	C/G	cg07884673	chr3:53033167	SFMBT1	-0.64	-5.87	-0.34	1.31e-8	Immune reponse to smallpox (secreted IL-2);
CESC	cis	rs2075371	0.932	rs11766132	chr7:133993062	T/C	cg20476274	chr7:133979776	SLC35B4	0.63	8.97	0.48	5.48e-17	Mean platelet volume;
CESC	cis	rs9926296	0.585	rs4785595	chr16:89835521	C/T	cg04287289	chr16:89883240	FANCA	-0.77	-11.54	-0.58	3.18e-25	Vitiligo;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg08701028	chr2:54880931	SPTBN1	0.49	6.43	0.37	5.85e-10	Fibrinogen levels;
CESC	cis	rs4604732	0.578	rs12040725	chr1:247644697	T/A	cg12758973	chr1:247694275	LOC148824;OR2C3	0.45	5.75	0.33	2.48e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs875971	0.508	rs10242423	chr7:66059175	A/G	cg11764359	chr7:65958608	NA	-0.54	-7.08	-0.4	1.31e-11	Aortic root size;
CESC	cis	rs1035144	0.506	rs2371416	chr14:81275672	A/T	cg06600135	chr14:81408086	NA	-0.54	-7.17	-0.4	7.51e-12	Male sexual orientation;
CESC	cis	rs2658782	0.789	rs2259633	chr11:93141580	C/A	cg15737290	chr11:93063684	CCDC67	0.45	5.34	0.31	2.04e-7	Pulmonary function decline;
CESC	cis	rs3857067	0.806	rs6817795	chr4:95127716	T/A	cg11021082	chr4:95130006	SMARCAD1	-0.61	-9.21	-0.49	1.06e-17	QT interval;
CESC	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg07507251	chr3:52567010	NT5DC2	0.37	6.9	0.39	3.85e-11	Bipolar disorder;
CESC	cis	rs5750830	0.594	rs9611169	chr22:39783027	C/T	cg20735954	chr22:39777886	SYNGR1	-0.41	-5.23	-0.31	3.43e-7	Intelligence (multi-trait analysis);
CESC	cis	rs9910055	0.659	rs227584	chr17:42225547	A/C	cg19774624	chr17:42201019	HDAC5	-0.88	-14.07	-0.65	5.68e-34	Total body bone mineral density;
CESC	cis	rs9916302	0.821	rs412430	chr17:37737094	C/G	cg07936489	chr17:37558343	FBXL20	-0.79	-10.99	-0.56	2.18e-23	Glomerular filtration rate (creatinine);
CESC	cis	rs17376456	0.569	rs6556834	chr5:93123067	C/T	cg21475434	chr5:93447410	FAM172A	-0.5	-5.1	-0.3	6.36e-7	Diabetic retinopathy;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg14906455	chr17:2628088	NA	0.48	6.37	0.36	8.23e-10	Systemic lupus erythematosus;
CESC	cis	rs1953600	0.645	rs2819945	chr10:81952956	G/A	cg00277334	chr10:82204260	NA	0.54	7.95	0.44	5.46e-14	Sarcoidosis;
CESC	cis	rs7927771	0.832	rs10838698	chr11:47385923	G/A	cg05585544	chr11:47624801	NA	0.49	7.14	0.4	8.83e-12	Subjective well-being;
CESC	cis	rs1506636	1.000	rs2402669	chr7:123297460	C/G	cg03229431	chr7:123269106	ASB15	-0.52	-6.72	-0.38	1.09e-10	Plateletcrit;Platelet count;
CESC	cis	rs2299587	0.623	rs12718384	chr8:17781112	T/C	cg08627089	chr8:17753878	FGL1	-0.4	-5.37	-0.31	1.7e-7	Economic and political preferences;
CESC	cis	rs11711311	0.955	rs12630833	chr3:113390883	G/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.66	8.62	0.47	6.11e-16	IgG glycosylation;
CESC	cis	rs6570726	1.000	rs444564	chr6:145859795	G/C	cg23711669	chr6:146136114	FBXO30	0.76	11.1	0.56	9.21e-24	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs12497850	0.931	rs13315711	chr3:48986399	A/T	cg06212747	chr3:49208901	KLHDC8B	0.73	9.87	0.52	9.15e-20	Parkinson's disease;
CESC	cis	rs769267	0.930	rs892021	chr19:19613480	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	7.47	0.42	1.14e-12	Tonsillectomy;
CESC	cis	rs28374715	0.578	rs10518717	chr15:41623368	C/G	cg02330683	chr15:41787940	ITPKA	0.46	5.42	0.32	1.36e-7	Ulcerative colitis;
CESC	cis	rs11148252	0.595	rs9526974	chr13:53251040	C/G	cg00495681	chr13:53174319	NA	0.56	7.58	0.42	5.68e-13	Lewy body disease;
CESC	trans	rs1814175	0.817	rs1319547	chr11:49916705	C/T	cg03929089	chr4:120376271	NA	-0.93	-15.69	-0.69	1.12e-39	Height;
CESC	cis	rs2285947	1.000	rs10228845	chr7:21583617	G/A	cg04471919	chr7:21584483	DNAH11	0.31	5.16	0.3	4.73e-7	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
CESC	cis	rs477895	0.653	rs11231701	chr11:63893702	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.93	10.21	0.53	7.43e-21	Mean platelet volume;
CESC	cis	rs9388451	0.839	rs4897155	chr6:126095144	C/A	cg10911889	chr6:126070802	HEY2	0.36	5.09	0.3	6.91e-7	Brugada syndrome;
CESC	cis	rs62229266	0.804	rs11088331	chr21:37421872	T/C	cg12218747	chr21:37451666	NA	-0.43	-6.09	-0.35	3.99e-9	Mitral valve prolapse;
CESC	cis	rs9399135	0.967	rs9399129	chr6:135285148	C/A	cg22676075	chr6:135203613	NA	0.51	7.07	0.4	1.41e-11	Red blood cell count;
CESC	cis	rs7666738	0.830	rs9998682	chr4:98939009	T/C	cg17366294	chr4:99064904	C4orf37	0.61	8.56	0.47	9.36e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7044106	0.762	rs10760115	chr9:123476952	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.37	6.07	0.35	4.38e-9	Hip circumference adjusted for BMI;
CESC	cis	rs7412746	0.611	rs2256355	chr1:150811794	A/G	cg17724175	chr1:150552817	MCL1	0.33	5.24	0.31	3.23e-7	Melanoma;
CESC	trans	rs2018683	0.835	rs7782264	chr7:28978986	A/G	cg19402173	chr7:128379420	CALU	0.55	7.5	0.42	9.72e-13	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CESC	cis	rs938554	0.692	rs4428284	chr4:9996392	A/T	cg11266682	chr4:10021025	SLC2A9	0.5	6.44	0.37	5.74e-10	Blood metabolite levels;
CESC	cis	rs1448094	0.621	rs10863089	chr12:86279699	C/T	cg02569458	chr12:86230093	RASSF9	0.42	6.14	0.35	3.03e-9	Major depressive disorder;
CESC	cis	rs12541335	0.639	rs7834182	chr8:22163112	G/A	cg02463440	chr8:22132932	PIWIL2	0.36	5.46	0.32	1.08e-7	Hypertriglyceridemia;
CESC	cis	rs3733585	0.673	rs4519796	chr4:9955936	A/G	cg00071950	chr4:10020882	SLC2A9	-0.69	-11.31	-0.57	1.83e-24	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs6732160	0.932	rs6546803	chr2:73381315	C/G	cg01422370	chr2:73384389	NA	0.51	8.77	0.47	2.15e-16	Intelligence (multi-trait analysis);
CESC	cis	rs4689388	0.581	rs11727100	chr4:6281458	A/C	cg14416269	chr4:6271139	WFS1	0.41	5.23	0.31	3.47e-7	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs1577917	1.000	rs12665321	chr6:86769289	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.47	-6.14	-0.35	3.04e-9	Response to antipsychotic treatment;
CESC	cis	rs6815814	0.731	rs11735251	chr4:38773057	T/A	cg02016764	chr4:38805732	TLR1	-0.44	-6.08	-0.35	4.24e-9	Breast cancer;
CESC	cis	rs9611565	0.729	rs9611570	chr22:41782721	G/T	cg03806693	chr22:41940476	POLR3H	-1.18	-16.09	-0.7	4.22e-41	Vitiligo;
CESC	cis	rs2933343	0.700	rs789239	chr3:128633808	T/C	cg11901034	chr3:128598214	ACAD9	-0.39	-5.71	-0.33	3.07e-8	IgG glycosylation;
CESC	cis	rs881375	0.967	rs7864019	chr9:123692868	A/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.38	5.14	0.3	5.24e-7	Rheumatoid arthritis;
CESC	cis	rs929354	0.772	rs10229630	chr7:157004790	C/T	cg05182265	chr7:156933206	UBE3C	-0.49	-7.15	-0.4	8.25e-12	Body mass index;
CESC	cis	rs6460942	0.591	rs6945587	chr7:12356992	G/A	cg06484146	chr7:12443880	VWDE	-0.62	-6.64	-0.38	1.72e-10	Coronary artery disease;
CESC	cis	rs270601	0.770	rs4361510	chr5:131599647	C/T	cg04518342	chr5:131593106	PDLIM4	0.4	5.96	0.34	7.99e-9	Acylcarnitine levels;
CESC	cis	rs116095464	0.558	rs6555052	chr5:224268	G/A	cg10591111	chr5:226296	SDHA	-0.52	-6.52	-0.37	3.47e-10	Breast cancer;
CESC	cis	rs7666738	0.649	rs28865589	chr4:98954279	C/A	cg05340658	chr4:99064831	C4orf37	0.79	11.79	0.59	4.35e-26	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4604732	0.631	rs75600450	chr1:247625492	C/T	cg12758973	chr1:247694275	LOC148824;OR2C3	0.5	6.29	0.36	1.29e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs2404602	0.692	rs12595586	chr15:77172210	A/G	cg26408565	chr15:76604113	ETFA	-0.39	-5.68	-0.33	3.63e-8	Blood metabolite levels;
CESC	cis	rs4242434	0.927	rs2291231	chr8:22463912	C/T	cg03733263	chr8:22462867	KIAA1967	0.94	15.78	0.7	5.38e-40	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CESC	cis	rs62432291	0.681	rs388001	chr6:159658459	C/T	cg14500486	chr6:159655392	FNDC1	-0.62	-6.34	-0.36	9.83e-10	Joint mobility (Beighton score);
CESC	cis	rs3820928	0.845	rs10165767	chr2:227781863	G/A	cg11843606	chr2:227700838	RHBDD1	-0.49	-6.55	-0.37	2.93e-10	Pulmonary function;
CESC	cis	rs1005277	0.540	rs289638	chr10:37923731	G/A	cg25517755	chr10:38738941	LOC399744	-0.41	-5.34	-0.31	1.99e-7	Extrinsic epigenetic age acceleration;
CESC	cis	rs2204008	0.628	rs10876106	chr12:37990767	A/G	cg13010199	chr12:38710504	ALG10B	0.46	5.68	0.33	3.46e-8	Bladder cancer;
CESC	cis	rs3105593	1.000	rs2174608	chr15:50871993	T/A	cg08437265	chr15:50716283	USP8	0.4	5.22	0.31	3.57e-7	QT interval;
CESC	cis	rs7620457	1.000	rs7620457	chr3:183747266	A/G	cg01324343	chr3:183735012	ABCC5	-0.47	-6.01	-0.35	6.24e-9	Body mass index;
CESC	cis	rs7618915	0.571	rs12632381	chr3:52607685	G/A	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.38	6.72	0.38	1.13e-10	Bipolar disorder;
CESC	cis	rs3845702	1.000	rs259808	chr2:180791419	T/G	cg01881094	chr2:180872142	CWC22	-0.7	-7.18	-0.4	6.96e-12	Schizophrenia;
CESC	cis	rs524281	0.692	rs11227395	chr11:65829637	A/C	cg14036092	chr11:66035641	RAB1B	-0.56	-6.19	-0.36	2.29e-9	Electroencephalogram traits;
CESC	cis	rs7084402	0.967	rs1649060	chr10:60310480	C/G	cg07615347	chr10:60278583	BICC1	-0.59	-8.88	-0.48	1.07e-16	Refractive error;
CESC	cis	rs7666738	0.546	rs13105521	chr4:98734419	C/T	cg17366294	chr4:99064904	C4orf37	0.53	6.64	0.38	1.78e-10	Colonoscopy-negative controls vs population controls;
CESC	cis	rs875971	0.522	rs1968127	chr7:66056803	C/T	cg18876405	chr7:65276391	NA	-0.57	-7.64	-0.42	3.94e-13	Aortic root size;
CESC	cis	rs4665809	0.549	rs34075014	chr2:26520842	T/C	cg22920501	chr2:26401640	FAM59B	0.78	7.93	0.44	6.01e-14	Gut microbiome composition (summer);
CESC	cis	rs3008870	0.920	rs1925413	chr1:67417101	T/C	cg02640540	chr1:67518911	SLC35D1	0.51	5.54	0.32	7.41e-8	Lymphocyte percentage of white cells;
CESC	cis	rs875971	0.577	rs35072105	chr7:65609817	A/G	cg18876405	chr7:65276391	NA	-0.67	-9.41	-0.5	2.43e-18	Aortic root size;
CESC	cis	rs763014	0.898	rs8060921	chr16:635988	C/A	cg09263875	chr16:632152	PIGQ	0.68	11.61	0.58	1.81e-25	Height;
CESC	cis	rs12701220	0.857	rs869412	chr7:1074134	T/C	cg26769984	chr7:1090371	C7orf50	0.67	7.64	0.42	4.07e-13	Bronchopulmonary dysplasia;
CESC	cis	rs3096299	0.748	rs3102339	chr16:89442711	C/T	cg16743903	chr16:89593216	SPG7	-0.44	-5.57	-0.32	6.32e-8	Multiple myeloma (IgH translocation);
CESC	cis	rs736408	0.716	rs2300149	chr3:52822921	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	6.56	0.37	2.81e-10	Bipolar disorder;
CESC	cis	rs6570726	0.935	rs451349	chr6:145820894	A/G	cg23711669	chr6:146136114	FBXO30	0.81	12.04	0.59	6.44e-27	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4925386	0.681	rs2427296	chr20:60927475	G/A	cg22633769	chr20:60982531	CABLES2	0.56	5.95	0.34	8.51e-9	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs6991838	0.584	rs7463740	chr8:66486185	G/A	cg13398993	chr8:66546079	ARMC1	-0.45	-5.54	-0.32	7.3900000000000007e-08	Intelligence (multi-trait analysis);
CESC	cis	rs1348850	0.567	rs7605609	chr2:178534942	C/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.56	7.01	0.4	2.02e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs3857536	0.740	rs7766407	chr6:66885658	C/A	cg07460842	chr6:66804631	NA	-0.42	-5.39	-0.31	1.53e-7	Blood trace element (Cu levels);
CESC	cis	rs7560272	0.538	rs4852975	chr2:73932465	C/T	cg20560298	chr2:73613845	ALMS1	0.46	6.27	0.36	1.48e-9	Schizophrenia;
CESC	cis	rs7537660	0.929	rs4607924	chr1:248004848	G/C	cg12080717	chr1:248004886	OR11L1	-0.46	-5.69	-0.33	3.29e-8	Platelet distribution width;
CESC	cis	rs4819052	0.851	rs10470246	chr21:46659017	C/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.45	5.58	0.32	5.81e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs8067354	0.958	rs2333563	chr17:57839568	A/G	cg13753209	chr17:57696993	CLTC	0.51	6.85	0.39	5.04e-11	Hemoglobin concentration;
CESC	cis	rs228437	1.000	rs450801	chr6:134905309	T/C	cg24504307	chr6:134963096	NA	0.52	5.52	0.32	8.27e-8	Melanoma;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg02701985	chr7:100888300	FIS1	-0.5	-6.24	-0.36	1.76e-9	Asthma;
CESC	cis	rs5769765	0.908	rs9616370	chr22:50306316	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.59	6.3	0.36	1.27e-9	Schizophrenia;
CESC	cis	rs1215050	0.740	rs783941	chr4:99008235	T/C	cg05340658	chr4:99064831	C4orf37	-0.56	-7.6	-0.42	4.97e-13	Waist-to-hip ratio adjusted for body mass index;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg05514743	chr19:14629124	DNAJB1	-0.54	-6.42	-0.37	6.23e-10	Ulcerative colitis;
CESC	cis	rs798554	0.679	rs7807978	chr7:2814635	C/T	cg19717773	chr7:2847554	GNA12	-0.55	-8.64	-0.47	5.48e-16	Height;
CESC	cis	rs7647973	1.000	rs11928090	chr3:49604904	G/A	cg07636037	chr3:49044803	WDR6	0.71	10.04	0.52	2.62e-20	Menarche (age at onset);
CESC	cis	rs1941023	0.503	rs4939349	chr11:60135880	G/A	cg08716584	chr11:60157161	MS4A7	-0.54	-8.74	-0.47	2.67e-16	Congenital heart disease (maternal effect);
CESC	cis	rs55728055	0.661	rs12168645	chr22:32061014	G/A	cg01338084	chr22:32026380	PISD	1.15	8.18	0.45	1.22e-14	Age-related hearing impairment;
CESC	cis	rs2243480	1.000	rs419603	chr7:65597341	C/T	cg18252515	chr7:66147081	NA	-1.41	-14.36	-0.66	5.44e-35	Diabetic kidney disease;
CESC	cis	rs6456156	0.586	rs2017338	chr6:167471714	G/A	cg07741184	chr6:167504864	NA	0.36	6.21	0.36	2.01e-9	Primary biliary cholangitis;
CESC	cis	rs1562975	0.609	rs60290218	chr4:109409501	A/G	cg16022748	chr4:109541635	LOC285456;RPL34	0.42	5.4	0.32	1.45e-7	Height;
CESC	cis	rs853679	0.517	rs9380058	chr6:28127444	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.56	-6.34	-0.36	9.9e-10	Depression;
CESC	cis	rs1964356	0.967	rs2953802	chr8:8851881	G/A	cg06636001	chr8:8085503	FLJ10661	0.4	5.3	0.31	2.42e-7	Mean corpuscular volume;
CESC	trans	rs1814175	0.559	rs1818892	chr11:49863084	C/A	cg15704280	chr7:45808275	SEPT13	-1.0	-18.78	-0.76	1.35e-50	Height;
CESC	cis	rs501120	1.000	rs522293	chr10:44756703	G/A	cg09554077	chr10:44749378	NA	0.52	6.91	0.39	3.59e-11	Coronary artery disease;Coronary heart disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10145585	chr7:2443058	CHST12	0.62	7.49	0.42	1.04e-12	Gut microbiome composition (summer);
CESC	trans	rs6651255	0.657	rs12679359	chr8:130724556	G/T	cg14074285	chr4:4868908	NA	-0.44	-6.07	-0.35	4.44e-9	Sciatica caused by lumbar disc herniation (treated with microdiscectomy);
CESC	cis	rs9911578	1.000	rs2270097	chr17:56572070	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	-0.41	-5.46	-0.32	1.08e-7	Intelligence (multi-trait analysis);
CESC	trans	rs10028773	0.700	rs7671797	chr4:120248157	A/G	cg25214090	chr10:38739885	LOC399744	0.62	8.69	0.47	3.79e-16	Educational attainment;
CESC	cis	rs34734847	1.000	rs10431385	chr12:121128882	T/C	cg21892295	chr12:121157589	UNC119B	-0.37	-5.84	-0.34	1.5e-8	Mean corpuscular volume;
CESC	cis	rs5995756	0.688	rs11705236	chr22:40010682	G/A	cg03390717	chr22:39966585	CACNA1I	-0.29	-5.05	-0.3	8.27e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs875971	1.000	rs12532998	chr7:65967459	A/C	cg10691866	chr7:65817282	TPST1	-0.34	-5.62	-0.33	4.8e-8	Aortic root size;
CESC	cis	rs372883	0.564	rs766928	chr21:30753606	A/G	cg24692254	chr21:30365293	RNF160	0.5	6.18	0.35	2.43e-9	Pancreatic cancer;
CESC	cis	rs7666738	0.830	rs7678567	chr4:99057346	A/G	cg18180107	chr4:99064573	C4orf37	0.41	5.2	0.3	4.03e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs72634258	0.945	rs36016881	chr1:8051241	A/G	cg00042356	chr1:8021962	PARK7	0.83	7.58	0.42	5.96e-13	Inflammatory bowel disease;
CESC	cis	rs2732480	0.577	rs2634693	chr12:48706498	C/T	cg24011408	chr12:48396354	COL2A1	0.43	5.91	0.34	1.07e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs1707322	0.821	rs10749857	chr1:46248143	C/T	cg05343316	chr1:45956843	TESK2	0.48	5.87	0.34	1.3e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs56011263	0.687	rs4690293	chr4:706101	A/G	cg05835009	chr4:710272	PCGF3	0.42	5.35	0.31	1.92e-7	White blood cell count;
CESC	cis	rs72781680	0.611	rs2111884	chr2:24289472	A/T	cg20701182	chr2:24300061	SF3B14	0.94	10.39	0.54	2.01e-21	Lymphocyte counts;
CESC	cis	rs1552244	0.554	rs6768339	chr3:10006079	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.63	-8.01	-0.44	3.68e-14	Alzheimer's disease;
CESC	cis	rs1879734	0.773	rs1465037	chr1:54135078	C/A	cg23596471	chr1:54105337	GLIS1	0.35	5.44	0.32	1.19e-7	Mitral valve prolapse;
CESC	cis	rs875971	0.862	rs709609	chr7:65560561	A/G	cg19163074	chr7:65112434	INTS4L2	0.48	5.78	0.33	2.06e-8	Aortic root size;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg03341697	chr11:94277138	FUT4	0.49	6.43	0.37	5.8e-10	Systemic lupus erythematosus;
CESC	cis	rs9322193	0.924	rs9322189	chr6:149909933	T/C	cg07701084	chr6:150067640	NUP43	0.45	6.26	0.36	1.54e-9	Lung cancer;
CESC	cis	rs6546550	0.694	rs12467361	chr2:70019127	G/A	cg02498382	chr2:70120550	SNRNP27	-0.34	-5.76	-0.33	2.33e-8	Prevalent atrial fibrillation;
CESC	cis	rs1707322	0.716	rs28370457	chr1:46172062	C/T	cg06784218	chr1:46089804	CCDC17	0.41	7.21	0.41	5.75e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs3213545	0.700	rs10849829	chr12:121470256	A/G	cg15155738	chr12:121454335	C12orf43	-0.47	-5.78	-0.33	2.13e-8	Subjective well-being;Cardiovascular disease risk factors;
CESC	cis	rs875971	0.505	rs1167385	chr7:65513308	G/A	cg11764359	chr7:65958608	NA	-0.7	-9.27	-0.49	6.71e-18	Aortic root size;
CESC	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg06873352	chr17:61820015	STRADA	0.73	12.41	0.61	3.42e-28	Prudent dietary pattern;
CESC	cis	rs10791097	0.690	rs12284540	chr11:130729772	T/C	cg12179176	chr11:130786555	SNX19	0.58	8.5	0.46	1.41e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs2576037	0.583	rs545344	chr18:44367079	A/G	cg19077165	chr18:44547161	KATNAL2	-0.61	-9.1	-0.49	2.27e-17	Personality dimensions;
CESC	cis	rs4268898	0.931	rs55642516	chr2:24502305	A/G	cg06627628	chr2:24431161	ITSN2	-0.7	-8.58	-0.47	7.87e-16	Asthma;
CESC	cis	rs7618915	0.547	rs62253733	chr3:52653414	A/G	cg18404041	chr3:52824283	ITIH1	-0.39	-6.54	-0.37	3.08e-10	Bipolar disorder;
CESC	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg06873352	chr17:61820015	STRADA	0.71	12.15	0.6	2.65e-27	Prudent dietary pattern;
CESC	cis	rs3733585	0.699	rs4588456	chr4:9963895	A/T	cg11266682	chr4:10021025	SLC2A9	-0.6	-11.2	-0.57	4.42e-24	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs6088580	0.524	rs7269596	chr20:33229063	T/C	cg08999081	chr20:33150536	PIGU	-0.45	-6.37	-0.36	8.42e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs72781680	1.000	rs72796339	chr2:24143063	T/C	cg08917208	chr2:24149416	ATAD2B	0.93	8.42	0.46	2.35e-15	Lymphocyte counts;
CESC	cis	rs12048904	0.595	rs10493937	chr1:101342650	A/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.66	-9.5	-0.5	1.33e-18	Multiple sclerosis;
CESC	cis	rs6545883	0.931	rs778768	chr2:61790289	C/G	cg15711740	chr2:61764176	XPO1	-0.43	-5.16	-0.3	4.84e-7	Tuberculosis;
CESC	cis	rs7851660	0.967	rs1443435	chr9:100617583	T/C	cg13688889	chr9:100608707	NA	-0.69	-10.57	-0.54	4.92e-22	Strep throat;
CESC	cis	rs9649213	0.593	rs6967457	chr7:97912221	T/G	cg21770322	chr7:97807741	LMTK2	0.58	8.55	0.47	9.84e-16	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs4253772	0.591	rs6008538	chr22:46685963	G/A	cg10231785	chr22:46692440	CN5H6.4;GTSE1	0.57	5.83	0.34	1.59e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs7208859	0.623	rs7503335	chr17:29073962	G/A	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.79e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs2425143	1.000	rs7273668	chr20:34442731	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.66	5.72	0.33	2.88e-8	Blood protein levels;
CESC	trans	rs1605070	1.000	rs1587922	chr3:51918228	C/T	cg17926940	chr14:97685060	NA	0.35	6.25	0.36	1.66e-9	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs2050392	1.000	rs7077496	chr10:30692028	G/A	cg18806716	chr10:30721971	MAP3K8	0.44	6.25	0.36	1.64e-9	Inflammatory bowel disease;
CESC	cis	rs875971	1.000	rs811880	chr7:65818646	T/C	cg10691866	chr7:65817282	TPST1	-0.33	-5.41	-0.32	1.44e-7	Aortic root size;
CESC	cis	rs40363	0.723	rs4785936	chr16:3535116	A/G	cg22508957	chr16:3507546	NAT15	-0.64	-6.84	-0.39	5.58e-11	Tuberculosis;
CESC	cis	rs7586673	0.930	rs7591506	chr2:161960925	T/G	cg08807892	chr2:162101083	NA	0.47	6.35	0.36	9.31e-10	Intelligence (multi-trait analysis);
CESC	cis	rs4253772	0.530	rs6008662	chr22:46713917	G/A	cg10231785	chr22:46692440	CN5H6.4;GTSE1	0.62	6.5	0.37	4.02e-10	LDL cholesterol;Cholesterol, total;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg12049088	chr22:36784491	MYH9	0.43	6.17	0.35	2.56e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs1707322	0.963	rs10789478	chr1:46350506	C/T	cg06784218	chr1:46089804	CCDC17	0.35	5.91	0.34	1.05e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs4835473	0.932	rs2323417	chr4:144890261	T/C	cg25736465	chr4:144833511	NA	0.4	6.27	0.36	1.49e-9	Immature fraction of reticulocytes;
CESC	cis	rs801193	1.000	rs10274773	chr7:66133578	G/A	cg14393609	chr7:65229607	NA	-0.45	-6.02	-0.35	5.91e-9	Aortic root size;
CESC	cis	rs4523957	0.928	rs394752	chr17:2199749	C/A	cg16513277	chr17:2031491	SMG6	0.63	8.49	0.46	1.48e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs4665809	0.556	rs4665314	chr2:26415912	T/C	cg04944784	chr2:26401820	FAM59B	-0.93	-10.7	-0.55	1.94e-22	Gut microbiome composition (summer);
CESC	cis	rs2742234	0.504	rs7093409	chr10:43740067	A/G	cg07801480	chr10:43725741	RASGEF1A	-0.41	-5.41	-0.32	1.42e-7	Hirschsprung disease;
CESC	cis	rs13191362	0.507	rs2023038	chr6:163119280	C/G	cg21926612	chr6:163149169	PACRG;PARK2	-0.52	-6.32	-0.36	1.08e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs7621025	0.505	rs61789643	chr3:136109752	G/T	cg15507776	chr3:136538369	TMEM22	-0.73	-5.84	-0.34	1.56e-8	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
CESC	cis	rs7666738	0.830	rs10012003	chr4:99064881	A/G	cg03676636	chr4:99064102	C4orf37	0.33	5.04	0.3	8.47e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs735396	0.770	rs2464196	chr12:121435427	G/A	cg25281562	chr12:121454272	C12orf43	0.53	6.79	0.38	7.44e-11	N-glycan levels;
CESC	cis	rs589448	0.867	rs623853	chr12:69753830	G/A	cg22834771	chr12:69754056	YEATS4	-0.55	-7.21	-0.41	5.72e-12	Cerebrospinal fluid biomarker levels;
CESC	cis	rs4319547	0.619	rs10744208	chr12:122931559	C/A	cg05707623	chr12:122985044	ZCCHC8	-0.5	-5.77	-0.33	2.19e-8	Body mass index;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg20506460	chr20:43150682	SERINC3	0.47	6.15	0.35	2.89e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs12971120	0.947	rs8084109	chr18:72168312	T/A	cg26446133	chr18:72167187	CNDP2	-0.74	-11.03	-0.56	1.55e-23	Refractive error;
CESC	cis	rs7264396	0.580	rs2425173	chr20:34445142	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.86	-9.5	-0.5	1.31e-18	Total cholesterol levels;
CESC	cis	rs60843830	1.000	rs57542652	chr2:228088	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.86	11.08	0.56	1.11e-23	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs7945705	0.967	rs1569408	chr11:8909732	G/A	cg21881798	chr11:8931708	C11orf17;ST5	0.51	8.18	0.45	1.2e-14	Hemoglobin concentration;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27481639	chr12:66524651	LLPH	0.57	6.09	0.35	3.99e-9	Gut microbiome composition (summer);
CESC	cis	rs1448094	0.512	rs7308229	chr12:86239849	A/T	cg00310523	chr12:86230176	RASSF9	-0.36	-5.81	-0.34	1.76e-8	Major depressive disorder;
CESC	cis	rs896543	0.702	rs12692188	chr2:237495929	A/G	cg25295825	chr2:237489920	CXCR7	0.7	9.1	0.49	2.19e-17	Alcohol dependence (age at onset);
CESC	cis	rs7666738	0.830	rs17027225	chr4:99028564	C/T	cg24818145	chr4:99064322	C4orf37	0.39	5.09	0.3	6.95e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2070488	0.804	rs35463537	chr3:38498248	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.79	12.54	0.61	1.2e-28	Electrocardiographic conduction measures;
CESC	cis	rs4077515	0.967	rs4075760	chr9:139266697	A/G	cg14169450	chr9:139327907	INPP5E	0.35	5.11	0.3	6.31e-7	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs6500395	1.000	rs3817029	chr16:48584942	C/T	cg04672837	chr16:48644449	N4BP1	0.51	6.32	0.36	1.13e-9	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs1707322	1.000	rs785468	chr1:46521517	G/A	cg05343316	chr1:45956843	TESK2	-0.44	-5.44	-0.32	1.2e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs10129255	0.500	rs8022547	chr14:107190222	A/T	cg07958169	chr14:107095056	NA	-0.53	-8.39	-0.46	2.85e-15	Kawasaki disease;
CESC	cis	rs9905704	0.918	rs304271	chr17:56802458	C/T	cg12560992	chr17:57184187	TRIM37	0.59	7.06	0.4	1.45e-11	Testicular germ cell tumor;
CESC	cis	rs6691722	0.583	rs7535482	chr1:24695114	A/C	cg02336364	chr1:24764700	NIPAL3	0.27	5.65	0.33	4.22e-8	Response to interferon beta in multiple sclerosis;
CESC	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg23978390	chr7:1156363	C7orf50	0.5	6.92	0.39	3.3e-11	Longevity;Endometriosis;
CESC	cis	rs6061231	0.624	rs8668	chr20:60964064	C/T	cg24112000	chr20:60950667	NA	0.47	6.75	0.38	9.47e-11	Colorectal cancer;
CESC	cis	rs11098499	0.866	rs9991221	chr4:120292107	G/C	cg24375607	chr4:120327624	NA	0.42	5.19	0.3	4.19e-7	Corneal astigmatism;
CESC	cis	rs7937682	0.961	rs491937	chr11:111494947	A/T	cg22437258	chr11:111473054	SIK2	0.71	9.73	0.51	2.44e-19	Primary sclerosing cholangitis;
CESC	cis	rs10927875	0.632	rs4481843	chr1:16128205	G/A	cg05821634	chr1:16164109	FLJ37453	0.35	5.04	0.3	8.77e-7	Dilated cardiomyopathy;
CESC	cis	rs4728302	0.869	rs2042456	chr7:133580447	G/A	cg10665199	chr7:133106180	EXOC4	0.4	5.47	0.32	1.03e-7	Intelligence;Intelligence (multi-trait analysis);
CESC	cis	rs9309473	1.000	rs7583255	chr2:73797996	T/G	cg20560298	chr2:73613845	ALMS1	-0.53	-6.96	-0.39	2.6e-11	Metabolite levels;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg05518842	chr16:1823291	MRPS34;EME2	-0.48	-6.5	-0.37	3.96e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs11770686	0.967	rs4728289	chr7:75348505	C/T	cg24179850	chr19:56154938	ZNF581	-0.41	-6.2	-0.36	2.14e-9	Essential tremor;
CESC	cis	rs8141529	0.632	rs5762803	chr22:29193638	G/C	cg15103426	chr22:29168792	CCDC117	0.69	9.43	0.5	2.09e-18	Lymphocyte counts;
CESC	cis	rs2559856	0.935	rs2695287	chr12:102088361	T/C	cg12213457	chr12:102090980	CHPT1	-0.36	-5.33	-0.31	2.07e-7	Blood protein levels;
CESC	cis	rs10189230	0.967	rs10498113	chr2:222352629	C/T	cg14652038	chr2:222343519	EPHA4	0.36	7.52	0.42	8.29e-13	Urate levels in lean individuals;
CESC	cis	rs4595586	0.545	rs2388175	chr12:39389217	A/G	cg26384229	chr12:38710491	ALG10B	0.54	7.58	0.42	5.91e-13	Morning vs. evening chronotype;
CESC	cis	rs2836974	0.897	rs8132568	chr21:40527916	C/T	cg11644478	chr21:40555479	PSMG1	1.03	17.63	0.73	1.46e-46	Cognitive function;
CESC	cis	rs1538970	0.924	rs12097497	chr1:45880669	C/T	cg05343316	chr1:45956843	TESK2	0.87	12.22	0.6	1.54e-27	Platelet count;
CESC	cis	rs10256972	0.527	rs28671326	chr7:1174973	G/A	cg07092213	chr7:1199455	ZFAND2A	-0.42	-5.67	-0.33	3.74e-8	Longevity;Endometriosis;
CESC	cis	rs668210	0.793	rs502363	chr11:65775592	C/T	cg02202077	chr11:65769826	EIF1AD;BANF1	0.65	7.02	0.4	1.82e-11	Cerebrospinal fluid biomarker levels;
CESC	cis	rs11997175	0.545	rs4733457	chr8:33661236	G/A	ch.8.33884649F	chr8:33765107	NA	0.56	7.18	0.4	7.09e-12	Body mass index;
CESC	cis	rs854765	0.583	rs8065970	chr17:17858771	A/G	cg09796270	chr17:17721594	SREBF1	0.45	6.15	0.35	2.87e-9	Total body bone mineral density;
CESC	cis	rs3741404	0.609	rs641378	chr11:63869493	T/C	cg18225595	chr11:63971243	STIP1	0.51	6.7	0.38	1.24e-10	Platelet count;
CESC	cis	rs7666738	0.830	rs62321569	chr4:98984250	T/A	cg05340658	chr4:99064831	C4orf37	0.8	12.42	0.61	3.31e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9457247	1.000	rs444988	chr6:167389674	A/T	cg23791538	chr6:167370224	RNASET2	-0.58	-8.34	-0.46	4.24e-15	Crohn's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14993712	chr7:138720786	ZC3HAV1L	0.58	6.52	0.37	3.47e-10	Gut microbiome composition (summer);
CESC	cis	rs1707322	0.721	rs56255771	chr1:46224319	C/T	cg06784218	chr1:46089804	CCDC17	0.4	7.33	0.41	2.85e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs7618501	0.574	rs6765484	chr3:50041313	C/T	cg21659725	chr3:3221576	CRBN	-0.49	-6.87	-0.39	4.6e-11	Intelligence (multi-trait analysis);
CESC	trans	rs9693444	0.898	rs4732697	chr8:29519861	A/G	cg18287962	chr20:25176437	ENTPD6	-0.43	-6.2	-0.36	2.12e-9	Breast cancer;
CESC	cis	rs7809950	1.000	rs2712215	chr7:107188207	A/G	cg23024343	chr7:107201750	COG5	-0.42	-5.89	-0.34	1.15e-8	Coronary artery disease;
CESC	cis	rs921968	0.565	rs7573999	chr2:219601392	A/G	cg02176678	chr2:219576539	TTLL4	-0.47	-8.36	-0.46	3.68e-15	Mean corpuscular hemoglobin concentration;
CESC	cis	rs7666738	0.761	rs1456210	chr4:98645932	T/G	cg17366294	chr4:99064904	C4orf37	0.54	7.52	0.42	8.55e-13	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1799949	0.965	rs9911630	chr17:41188342	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.47	6.45	0.37	5.2400000000000005e-10	Menopause (age at onset);
CESC	cis	rs7503807	0.688	rs901061	chr17:78595328	G/C	cg09596252	chr17:78655493	RPTOR	0.37	5.21	0.3	3.84e-7	Obesity;
CESC	cis	rs9815354	0.951	rs17063653	chr3:41863817	A/G	cg03022575	chr3:42003672	ULK4	0.49	5.52	0.32	7.99e-8	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs6594499	0.872	rs10050834	chr5:110427328	C/T	cg04022379	chr5:110408740	TSLP	0.31	5.53	0.32	7.59e-8	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs7659604	0.676	rs4077102	chr4:122699830	A/G	cg20573242	chr4:122745356	CCNA2	0.53	6.59	0.38	2.34e-10	Type 2 diabetes;
CESC	cis	rs1153858	1.000	rs4534782	chr15:45652933	G/A	cg21132104	chr15:45694354	SPATA5L1	0.85	11.64	0.58	1.47e-25	Homoarginine levels;
CESC	cis	rs7116495	0.609	rs1548348	chr11:71750917	A/G	cg10381502	chr11:71823885	C11orf51	-1.13	-6.89	-0.39	4.16e-11	Severe influenza A (H1N1) infection;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26040211	chr2:75186107	POLE4	0.6	6.59	0.38	2.33e-10	Gut microbiome composition (summer);
CESC	cis	rs4862750	0.872	rs7672831	chr4:187898882	C/T	cg06074448	chr4:187884817	NA	-0.38	-5.68	-0.33	3.49e-8	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2425143	1.000	rs73902914	chr20:34432882	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.67	5.78	0.33	2.11e-8	Blood protein levels;
CESC	cis	rs6987853	0.686	rs55837592	chr8:42359974	T/C	cg09913449	chr8:42400586	C8orf40	-0.38	-6.24	-0.36	1.72e-9	Mean corpuscular hemoglobin concentration;
CESC	cis	rs2070488	0.804	rs13094715	chr3:38504430	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.83	13.43	0.64	1.05e-31	Electrocardiographic conduction measures;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg09754948	chr16:28834200	ATXN2L	0.46	6.11	0.35	3.52e-9	Asthma;
CESC	trans	rs875971	1.000	rs10257427	chr7:65743208	T/C	cg26939375	chr7:64535504	NA	-0.46	-6.08	-0.35	4.27e-9	Aortic root size;
CESC	cis	rs28830936	0.966	rs890498	chr15:42111298	C/G	cg11010575	chr15:42129464	JMJD7-PLA2G4B;JMJD7	-0.43	-5.94	-0.34	8.93e-9	Diastolic blood pressure;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18425377	chr14:105167727	INF2	-0.55	-6.3	-0.36	1.26e-9	Gut microbiome composition (summer);
CESC	trans	rs4756846	1.000	rs72871402	chr11:16472994	C/G	cg05579622	chr5:10618622	ANKRD33B	0.71	6.21	0.36	2.01e-9	Obesity and osteoporosis;
CESC	cis	rs11997175	0.766	rs4733176	chr8:33685334	A/T	ch.8.33884649F	chr8:33765107	NA	0.45	5.7	0.33	3.19e-8	Body mass index;
CESC	cis	rs72781680	0.821	rs56064672	chr2:24156769	G/T	cg08917208	chr2:24149416	ATAD2B	0.63	6.24	0.36	1.73e-9	Lymphocyte counts;
CESC	trans	rs7615952	0.673	rs115942855	chr3:125601960	G/A	cg07211511	chr3:129823064	LOC729375	-0.96	-8.16	-0.45	1.35e-14	Blood pressure (smoking interaction);
CESC	cis	rs6860806	0.695	rs6867282	chr5:131583120	G/C	cg14196790	chr5:131705035	SLC22A5	0.32	5.06	0.3	7.67e-7	Breast cancer;
CESC	cis	rs853679	0.607	rs35902873	chr6:28058949	G/C	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.83	5.09	0.3	6.76e-7	Depression;
CESC	cis	rs7447593	0.666	rs10866705	chr5:176801131	G/T	cg16006841	chr5:176797999	RGS14	-0.51	-5.82	-0.34	1.74e-8	Urinary electrolytes (magnesium/calcium ratio);
CESC	cis	rs763121	0.853	rs7289855	chr22:39042221	G/T	cg21395723	chr22:39101663	GTPBP1	0.45	5.56	0.32	6.69e-8	Menopause (age at onset);
CESC	cis	rs7927771	0.524	rs10838771	chr11:47831332	A/G	cg18512352	chr11:47633146	NA	-0.36	-5.56	-0.32	6.67e-8	Subjective well-being;
CESC	cis	rs7714584	1.000	rs34156253	chr5:150226230	A/G	cg22134413	chr5:150180641	NA	0.53	5.6	0.33	5.4e-8	Crohn's disease;
CESC	trans	rs11098499	0.954	rs12510138	chr4:120423935	C/G	cg25214090	chr10:38739885	LOC399744	0.67	9.47	0.5	1.64e-18	Corneal astigmatism;
CESC	cis	rs9443189	1.000	rs6906615	chr6:76489774	A/G	cg01950844	chr6:76311363	SENP6	0.65	6.93	0.39	3.12e-11	Prostate cancer;
CESC	cis	rs1707322	0.721	rs12045096	chr1:46114428	A/G	cg06784218	chr1:46089804	CCDC17	0.43	7.48	0.42	1.07e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs875971	1.000	rs697970	chr7:65560052	G/C	cg11764359	chr7:65958608	NA	-0.95	-14.43	-0.66	3.25e-35	Aortic root size;
CESC	cis	rs11958404	0.615	rs7711271	chr5:157452268	C/G	cg05962755	chr5:157440814	NA	0.38	5.63	0.33	4.47e-8	IgG glycosylation;
CESC	cis	rs73206853	0.563	rs57488849	chr12:111181785	C/T	cg04375036	chr12:111181819	PPP1CC	-0.64	-5.16	-0.3	4.82e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs9303280	0.806	rs35736272	chr17:38032680	T/C	cg20243544	chr17:37824526	PNMT	0.53	6.96	0.39	2.6e-11	Self-reported allergy;
CESC	cis	rs11792861	0.851	rs4542004	chr9:111814478	A/G	cg13535736	chr9:111863775	C9orf5	-0.45	-6.2	-0.36	2.14e-9	Menarche (age at onset);
CESC	cis	rs738322	0.934	rs133016	chr22:38572582	C/T	cg17652424	chr22:38574118	PLA2G6	-0.34	-6.04	-0.35	5.08e-9	Cutaneous nevi;
CESC	cis	rs4764487	0.735	rs11612258	chr12:6360683	G/T	cg08284733	chr12:6341482	CD9	0.36	5.33	0.31	2.05e-7	Mean platelet volume;
CESC	cis	rs7843479	0.601	rs4422769	chr8:21844265	A/G	cg17168535	chr8:21777572	XPO7	0.73	11.71	0.58	8.3e-26	Mean corpuscular volume;
CESC	cis	rs1552244	1.000	rs113153120	chr3:10156398	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.86	-11.97	-0.59	1.09e-26	Alzheimer's disease;
CESC	cis	rs4713118	0.621	rs10484403	chr6:28033523	A/G	cg20151795	chr6:28129481	ZNF389	0.4	5.23	0.31	3.51e-7	Parkinson's disease;
CESC	cis	rs60154123	0.730	rs689248	chr1:210463122	A/G	cg22029157	chr1:209979665	IRF6	-0.5	-6.24	-0.36	1.71e-9	Coronary artery disease;
CESC	cis	rs11264213	0.579	rs72659681	chr1:36265565	G/A	cg27506609	chr1:36549197	TEKT2	0.61	5.05	0.3	8.16e-7	Schizophrenia;
CESC	cis	rs7116495	0.609	rs3750907	chr11:71822560	T/C	cg26138937	chr11:71823887	C11orf51	1.36	8.4	0.46	2.8e-15	Severe influenza A (H1N1) infection;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16714605	chr19:10765132	ILF3;LOC147727	0.59	7.06	0.4	1.49e-11	Gut microbiome composition (summer);
CESC	cis	rs35771425	0.509	rs3120782	chr1:211419700	A/T	cg25617285	chr1:211431773	RCOR3	-0.38	-5.72	-0.33	2.85e-8	Educational attainment (years of education);
CESC	trans	rs2727020	0.729	rs10839283	chr11:49490943	T/C	cg15704280	chr7:45808275	SEPT13	0.83	11.46	0.58	5.59e-25	Coronary artery disease;
CESC	cis	rs73001065	0.901	rs73004962	chr19:19713069	A/T	cg03709012	chr19:19516395	GATAD2A	0.95	6.33	0.36	1.06e-9	LDL cholesterol;
CESC	cis	rs1538970	0.781	rs34768551	chr1:46020408	G/A	cg05343316	chr1:45956843	TESK2	0.85	10.86	0.55	5.75e-23	Platelet count;
CESC	cis	rs447	1.000	rs7793598	chr7:83759108	C/T	cg22846510	chr7:83753280	SEMA3A	-0.44	-5.38	-0.31	1.64e-7	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs7267979	0.545	rs6050426	chr20:25178265	C/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.52	7.64	0.42	4.06e-13	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs9733	0.791	rs11800059	chr1:150651175	C/T	cg13175981	chr1:150552382	MCL1	0.62	9.22	0.49	9.44e-18	Tonsillectomy;
CESC	cis	rs13118159	0.801	rs7664474	chr4:1329116	T/A	cg05025164	chr4:1340916	KIAA1530	0.5	6.9	0.39	3.71e-11	Longevity;
CESC	cis	rs9796	0.621	rs28737302	chr15:41469943	G/A	cg20272979	chr15:41787780	ITPKA	0.33	5.07	0.3	7.6e-7	Menopause (age at onset);
CESC	cis	rs2845885	0.793	rs35927325	chr11:63882495	C/T	cg24431193	chr11:63883947	FLRT1;MACROD1	0.7	6.82	0.39	6.02e-11	Body mass index;
CESC	cis	rs12410462	1.000	rs80168344	chr1:227655804	C/T	cg23173402	chr1:227635558	NA	0.56	5.64	0.33	4.28e-8	Major depressive disorder;
CESC	cis	rs6570726	0.764	rs4263604	chr6:145916697	A/G	cg23711669	chr6:146136114	FBXO30	0.94	14.19	0.66	2.3e-34	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1348850	0.793	rs6736390	chr2:178480314	T/C	cg22681709	chr2:178499509	PDE11A	-0.44	-6.49	-0.37	4.11e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs7762018	0.891	rs7764839	chr6:170146351	C/A	cg13891659	chr6:170190454	C6orf122;C6orf208	0.67	6.53	0.37	3.28e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs4819052	0.851	rs1999333	chr21:46670401	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.74	9.76	0.51	1.96e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs57221529	0.713	rs12521091	chr5:590710	G/T	cg16447950	chr5:562315	NA	-0.61	-6.47	-0.37	4.64e-10	Lung disease severity in cystic fibrosis;
CESC	cis	rs6570726	0.905	rs375692	chr6:145840368	A/G	cg23711669	chr6:146136114	FBXO30	0.76	11.32	0.57	1.74e-24	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs853679	0.550	rs1237875	chr6:28173010	A/G	cg21251018	chr6:28226885	NKAPL	-0.37	-5.41	-0.32	1.41e-7	Depression;
CESC	cis	rs870825	0.655	rs28451943	chr4:185645572	C/T	cg04058563	chr4:185651563	MLF1IP	0.63	6.96	0.39	2.59e-11	Blood protein levels;
CESC	cis	rs11190604	0.725	rs9420796	chr10:102323092	G/C	cg07080220	chr10:102295463	HIF1AN	0.56	5.29	0.31	2.52e-7	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs2050392	0.762	rs306587	chr10:30722908	G/C	cg25182066	chr10:30743637	MAP3K8	-0.43	-5.81	-0.34	1.82e-8	Inflammatory bowel disease;
CESC	cis	rs9916302	0.851	rs11078906	chr17:37662767	C/T	cg00129232	chr17:37814104	STARD3	-0.57	-7.57	-0.42	6.31e-13	Glomerular filtration rate (creatinine);
CESC	cis	rs704795	0.775	rs4665975	chr2:27626017	A/T	cg21248554	chr2:27665150	KRTCAP3	-0.31	-6.23	-0.36	1.79e-9	Menopause (age at onset);
CESC	cis	rs9910055	0.593	rs58392387	chr17:42297889	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.42	5.06	0.3	7.72e-7	Total body bone mineral density;
CESC	cis	rs7927771	0.832	rs10838697	chr11:47384484	T/A	cg18512352	chr11:47633146	NA	-0.53	-7.46	-0.42	1.22e-12	Subjective well-being;
CESC	cis	rs6570726	0.620	rs12201226	chr6:145913419	A/T	cg23711669	chr6:146136114	FBXO30	0.91	11.75	0.59	5.92e-26	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs360798	0.532	rs1553832	chr2:63013515	C/G	cg17519650	chr2:63277830	OTX1	-0.56	-7.39	-0.41	1.96e-12	Coronary artery disease;
CESC	cis	rs1552244	1.000	rs9811771	chr3:10133949	A/G	cg08888203	chr3:10149979	C3orf24	0.44	5.57	0.32	6.29e-8	Alzheimer's disease;
CESC	cis	rs853679	0.517	rs9348793	chr6:28084189	G/A	cg12963246	chr6:28129442	ZNF389	0.56	7.63	0.42	4.26e-13	Depression;
CESC	trans	rs11098499	0.865	rs9994730	chr4:120381564	A/C	cg25214090	chr10:38739885	LOC399744	0.71	9.82	0.52	1.33e-19	Corneal astigmatism;
CESC	cis	rs853679	0.517	rs3173443	chr6:28137027	T/G	cg17949981	chr6:28129498	ZNF389	0.42	5.24	0.31	3.27e-7	Depression;
CESC	cis	rs10504229	0.679	rs72649132	chr8:58054615	G/A	cg22535103	chr8:58192502	C8orf71	-0.77	-8.08	-0.44	2.33e-14	Developmental language disorder (linguistic errors);
CESC	cis	rs875971	0.505	rs1167386	chr7:65513096	G/A	cg11764359	chr7:65958608	NA	-0.7	-9.25	-0.49	7.82e-18	Aortic root size;
CESC	cis	rs9291683	0.546	rs13120348	chr4:10053155	C/G	cg02734326	chr4:10020555	SLC2A9	-0.43	-6.25	-0.36	1.61e-9	Bone mineral density;
CESC	cis	rs9309473	0.898	rs9807961	chr2:73694043	A/G	cg20560298	chr2:73613845	ALMS1	-0.5	-6.77	-0.38	8.09e-11	Metabolite levels;
CESC	cis	rs28673728	0.868	rs28380108	chr1:38409103	G/C	cg18451016	chr1:38461880	NA	0.4	5.92	0.34	9.92e-9	Red cell distribution width;
CESC	trans	rs17764205	0.777	rs10424519	chr19:3253532	C/G	cg27384338	chr17:2031545	SMG6	0.76	6.24	0.36	1.7e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs2836974	0.932	rs6517526	chr21:40581530	T/C	cg11644478	chr21:40555479	PSMG1	1.02	16.31	0.71	7.16e-42	Cognitive function;
CESC	cis	rs2228479	0.850	rs17226973	chr16:89825248	T/C	cg04013166	chr16:89971882	TCF25	0.79	6.75	0.38	9.14e-11	Skin colour saturation;
CESC	cis	rs10751667	0.666	rs10902241	chr11:949129	G/A	cg20946044	chr11:1010712	AP2A2	-0.38	-5.24	-0.31	3.23e-7	Alzheimer's disease (late onset);
CESC	cis	rs853679	0.574	rs1233705	chr6:28166447	C/G	cg20151795	chr6:28129481	ZNF389	0.4	5.39	0.31	1.58e-7	Depression;
CESC	cis	rs447735	0.587	rs11647958	chr16:89720909	A/T	cg03605463	chr16:89740564	NA	0.4	5.1	0.3	6.55e-7	Hemoglobin concentration;
CESC	cis	rs9640161	0.750	rs11764936	chr7:150025915	G/T	cg17279839	chr7:150038598	RARRES2	0.43	5.32	0.31	2.18e-7	Blood protein levels;Circulating chemerin levels;
CESC	trans	rs875971	0.660	rs3857686	chr7:66036191	C/T	cg26939375	chr7:64535504	NA	-0.64	-8.8	-0.48	1.77e-16	Aortic root size;
CESC	cis	rs733175	0.855	rs9291640	chr4:10007086	C/T	cg11266682	chr4:10021025	SLC2A9	0.37	5.04	0.3	8.82e-7	Psychosis and Alzheimer's disease;
CESC	cis	rs1865721	0.761	rs7242709	chr18:73222819	T/C	cg26385618	chr18:73139727	C18orf62	-0.53	-7.75	-0.43	2.02e-13	Intelligence;
CESC	cis	rs9581857	0.547	rs75800999	chr13:28055293	A/G	cg01674679	chr13:27998804	GTF3A	-0.65	-5.19	-0.3	4.24e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
CESC	cis	rs501120	0.810	rs683297	chr10:44746140	A/G	cg09554077	chr10:44749378	NA	0.52	6.89	0.39	4.17e-11	Coronary artery disease;Coronary heart disease;
CESC	cis	rs631288	0.557	rs7546434	chr1:146676339	A/G	cg25205988	chr1:146714368	CHD1L	1.05	6.69	0.38	1.28e-10	PR interval in Tripanosoma cruzi seropositivity;
CESC	cis	rs477692	0.544	rs7923750	chr10:131446895	G/C	cg05714579	chr10:131428358	MGMT	-0.71	-9.8	-0.52	1.48e-19	Response to temozolomide;
CESC	cis	rs7202877	0.561	rs2865532	chr16:75350975	A/G	cg04384234	chr16:75411784	CFDP1	-0.48	-5.7	-0.33	3.12e-8	Type 2 diabetes;Type 1 diabetes;
CESC	cis	rs7726839	0.540	rs61580655	chr5:597564	A/G	cg16447950	chr5:562315	NA	-0.59	-6.01	-0.35	6.18e-9	Obesity-related traits;
CESC	cis	rs7412746	0.658	rs10305711	chr1:150802996	T/C	cg17724175	chr1:150552817	MCL1	0.4	6.28	0.36	1.4e-9	Melanoma;
CESC	cis	rs2243480	1.000	rs316327	chr7:65609201	G/T	cg12463550	chr7:65579703	CRCP	-0.79	-6.28	-0.36	1.38e-9	Diabetic kidney disease;
CESC	cis	rs2273669	0.667	rs12196143	chr6:109302372	C/T	cg05315195	chr6:109294784	ARMC2	-0.65	-6.08	-0.35	4.15e-9	Prostate cancer;
CESC	cis	rs2976388	0.578	rs3736010	chr8:143817503	T/C	cg10596483	chr8:143751796	JRK	-0.46	-5.05	-0.3	8.37e-7	Urinary tract infection frequency;
CESC	cis	rs7508	0.694	rs2073572	chr8:17921666	C/T	cg18067069	chr8:17937731	ASAH1	-0.39	-5.19	-0.3	4.21e-7	Atrial fibrillation;
CESC	cis	rs7246657	0.882	rs59224125	chr19:37963205	T/C	cg23950597	chr19:37808831	NA	-0.55	-5.99	-0.35	6.69e-9	Coronary artery calcification;
CESC	cis	rs769267	0.965	rs2965191	chr19:19453521	T/G	cg03709012	chr19:19516395	GATAD2A	-0.96	-14.11	-0.66	4.09e-34	Tonsillectomy;
CESC	cis	rs1620921	0.505	rs1965092	chr6:161204889	C/T	cg01280913	chr6:161186852	NA	-0.36	-5.27	-0.31	2.81e-7	Lipoprotein (a) - cholesterol levels;
CESC	cis	rs1538970	0.884	rs1771551	chr1:45883643	C/G	cg05343316	chr1:45956843	TESK2	0.82	12.03	0.59	6.96e-27	Platelet count;
CESC	cis	rs4523957	0.928	rs9899193	chr17:2156917	G/A	cg16513277	chr17:2031491	SMG6	0.6	8.27	0.45	6.71e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs72772090	0.634	rs72773912	chr5:96107801	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.64	-5.7	-0.33	3.24e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs1552244	0.882	rs7636817	chr3:10014876	G/T	cg00149659	chr3:10157352	C3orf10	0.73	8.54	0.46	1.05e-15	Alzheimer's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12551462	chr6:153304904	FBXO5	0.61	6.95	0.39	2.75e-11	Gut microbiome composition (summer);
CESC	cis	rs873946	0.648	rs12766050	chr10:134549108	G/A	cg27286337	chr10:134555280	INPP5A	0.69	8.1	0.45	2.01e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs2832191	0.720	rs2832200	chr21:30499165	G/A	cg08807101	chr21:30365312	RNF160	-0.72	-9.88	-0.52	8.5e-20	Dental caries;
CESC	cis	rs16857609	0.529	rs74723351	chr2:218288217	G/A	cg15335768	chr2:218268053	DIRC3	-0.37	-5.25	-0.31	3.15e-7	Breast cancer;Breast cancer (estrogen-receptor negative);
CESC	cis	rs6430585	0.527	rs57530667	chr2:136444338	A/G	cg07169764	chr2:136633963	MCM6	1.09	12.56	0.61	1.07e-28	Corneal structure;
CESC	cis	rs9976767	0.608	rs3746923	chr21:43826344	C/T	cg23042151	chr21:43824109	UBASH3A	-0.33	-6.06	-0.35	4.61e-9	Type 1 diabetes;
CESC	cis	rs6121246	0.909	rs6058450	chr20:30343911	G/A	cg13852791	chr20:30311386	BCL2L1	0.81	8.61	0.47	6.48e-16	Mean corpuscular hemoglobin;
CESC	cis	rs9457247	0.579	rs2181059	chr6:167441624	T/C	cg23791538	chr6:167370224	RNASET2	-0.57	-7.7	-0.43	2.7e-13	Crohn's disease;
CESC	cis	rs9322193	0.923	rs9968911	chr6:149978555	A/T	cg04369109	chr6:150039330	LATS1	-0.38	-5.29	-0.31	2.58e-7	Lung cancer;
CESC	cis	rs9611565	0.559	rs132761	chr22:42004371	C/T	cg03806693	chr22:41940476	POLR3H	1.09	12.94	0.62	5.17e-30	Vitiligo;
CESC	cis	rs11690935	0.851	rs10930502	chr2:172890588	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.66	-8.9	-0.48	9.29e-17	Schizophrenia;
CESC	cis	rs10779751	0.879	rs7543400	chr1:11283964	C/G	cg08854313	chr1:11322531	MTOR	0.91	14.25	0.66	1.34e-34	Body mass index;
CESC	cis	rs208520	0.690	rs207102	chr6:66795671	G/A	cg07460842	chr6:66804631	NA	-1.0	-13.33	-0.63	2.21e-31	Exhaled nitric oxide output;
CESC	cis	rs9814567	1.000	rs1498718	chr3:134205920	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.42	-5.76	-0.33	2.32e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs1707322	0.752	rs28623463	chr1:46170758	A/C	cg06784218	chr1:46089804	CCDC17	0.41	7.21	0.41	5.75e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs818427	0.896	rs460832	chr5:112225148	G/A	cg07820702	chr5:112228657	REEP5	-0.43	-5.36	-0.31	1.85e-7	Total body bone mineral density;
CESC	cis	rs2290720	1.000	rs2290720	chr12:101687043	C/T	cg22051763	chr12:101673672	UTP20	-0.43	-5.24	-0.31	3.24e-7	Brain structure (hippocampal volume);
CESC	cis	rs2066819	1.000	rs78149779	chr12:56694817	A/G	cg26804944	chr12:56660921	COQ10A	-0.85	-5.19	-0.3	4.22e-7	Psoriasis vulgaris;
CESC	cis	rs71007656	1	rs71007656	chr10:37970845	CGGCTG/C	cg25517755	chr10:38738941	LOC399744	-0.43	-5.64	-0.33	4.44e-8	Extrinsic epigenetic age acceleration;
CESC	cis	rs727563	0.552	rs4822045	chr22:41985958	C/A	cg03806693	chr22:41940476	POLR3H	-1.16	-13.06	-0.63	1.99e-30	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs1862618	0.853	rs2113079	chr5:56157951	A/G	cg03609598	chr5:56110824	MAP3K1	-0.55	-5.92	-0.34	9.88e-9	Initial pursuit acceleration;
CESC	cis	rs3791406	0.654	rs747787	chr2:240032319	G/A	cg13090969	chr2:240043331	HDAC4	-0.51	-6.01	-0.35	6.06e-9	Skin aging (microtopography measurement);
CESC	cis	rs1862618	0.754	rs252899	chr5:56188569	G/C	cg22800045	chr5:56110881	MAP3K1	0.8	9.57	0.51	8.15e-19	Initial pursuit acceleration;
CESC	cis	rs9430161	0.579	rs7542354	chr1:11040385	G/A	cg27631724	chr1:11040367	C1orf127	0.44	7.63	0.42	4.18e-13	Ewing sarcoma;
CESC	cis	rs863345	0.604	rs11265008	chr1:158498671	C/T	cg12129480	chr1:158549410	OR10X1	-0.34	-6.84	-0.39	5.41e-11	Pneumococcal bacteremia;
CESC	cis	rs17401966	1.000	rs4846208	chr1:10313839	T/C	cg15208524	chr1:10270712	KIF1B	0.5	6.47	0.37	4.65e-10	Hepatocellular carcinoma;
CESC	cis	rs950027	0.549	rs2899375	chr15:45598335	G/A	cg21132104	chr15:45694354	SPATA5L1	-0.58	-6.96	-0.39	2.74e-11	Response to fenofibrate (adiponectin levels);
CESC	cis	rs8114671	0.562	rs6120763	chr20:33506400	C/G	cg24642439	chr20:33292090	TP53INP2	0.44	5.32	0.31	2.18e-7	Height;
CESC	cis	rs7666738	0.830	rs11722272	chr4:99000839	C/T	cg18180107	chr4:99064573	C4orf37	0.43	5.39	0.31	1.55e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs16870629	0.564	rs326050	chr5:1002620	C/T	cg00278107	chr5:1061253	SLC12A7	0.7	11.17	0.57	5.29e-24	QT interval;
CESC	cis	rs7618915	0.547	rs62253733	chr3:52653414	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	6.79	0.39	7.29e-11	Bipolar disorder;
CESC	cis	rs2721195	0.967	rs748193	chr8:145682115	C/T	cg15857475	chr8:145742913	RECQL4;LRRC14	0.67	9.21	0.49	1e-17	Age at first birth;
CESC	cis	rs4665809	1.000	rs7573118	chr2:26308086	A/G	cg04944784	chr2:26401820	FAM59B	-0.67	-7.75	-0.43	2e-13	Gut microbiome composition (summer);
CESC	cis	rs2243480	0.901	rs3813708	chr7:65305632	C/A	cg18252515	chr7:66147081	NA	-1.22	-11.91	-0.59	1.82e-26	Diabetic kidney disease;
CESC	cis	rs9611565	0.649	rs202625	chr22:41827082	G/A	cg06481639	chr22:41940642	POLR3H	0.63	6.29	0.36	1.27e-9	Vitiligo;
CESC	cis	rs7590720	1.000	rs7590720	chr2:216898658	A/G	cg12620499	chr2:216877984	MREG	-0.9	-12.71	-0.62	3.24e-29	Alcohol dependence;
CESC	cis	rs7020830	0.898	rs2047010	chr9:37077947	A/G	cg14294708	chr9:37120828	ZCCHC7	1.28	24.7	0.84	1.03e-70	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20881074	chr2:45236659	SIX2	0.58	6.71	0.38	1.2e-10	Gut microbiome composition (summer);
CESC	cis	rs3820068	0.581	rs61056912	chr1:15926296	A/G	cg16988262	chr1:15930761	NA	0.33	5.35	0.31	1.89e-7	Systolic blood pressure;
CESC	cis	rs7927592	0.956	rs7113287	chr11:68372186	A/T	cg01657329	chr11:68192670	LRP5	-0.39	-5.1	-0.3	6.44e-7	Total body bone mineral density;
CESC	cis	rs2228479	0.850	rs11639925	chr16:89908250	C/T	cg06558623	chr16:89946397	TCF25	1.12	8.25	0.45	7.72e-15	Skin colour saturation;
CESC	cis	rs10779751	0.734	rs2486920	chr1:11125050	T/C	cg08854313	chr1:11322531	MTOR	0.77	10.41	0.54	1.73e-21	Body mass index;
CESC	cis	rs1008375	0.966	rs4235391	chr4:17696409	A/G	cg16339924	chr4:17578868	LAP3	0.59	7.41	0.41	1.69e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07564188	chr1:165667906	ALDH9A1	0.61	7.31	0.41	3.2e-12	Gut microbiome composition (summer);
CESC	cis	rs7089973	0.604	rs11819372	chr10:116594934	A/G	cg23260525	chr10:116636907	FAM160B1	0.4	7.74	0.43	2.1e-13	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs6952808	0.862	rs4721135	chr7:1912222	A/G	cg05863683	chr7:1912471	MAD1L1	0.39	6.0	0.35	6.48e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs933688	0.556	rs4916855	chr5:90596345	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.56	-7.12	-0.4	1e-11	Smoking behavior;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg12694510	chr17:26646013	TMEM97	-0.52	-6.87	-0.39	4.64e-11	Fibrinogen levels;
CESC	trans	rs801193	0.901	rs4273746	chr7:66301111	C/T	cg26939375	chr7:64535504	NA	-0.66	-8.37	-0.46	3.27e-15	Aortic root size;
CESC	cis	rs736408	0.736	rs4687550	chr3:52823430	T/G	cg07507251	chr3:52567010	NT5DC2	0.34	5.47	0.32	1.04e-7	Bipolar disorder;
CESC	cis	rs728616	0.558	rs2343302	chr10:82163186	A/G	cg05935833	chr10:81318306	SFTPA2	-0.46	-5.71	-0.33	3.09e-8	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs9611565	0.649	rs5758442	chr22:42133060	T/C	cg06634786	chr22:41940651	POLR3H	0.49	5.5	0.32	8.83e-8	Vitiligo;
CESC	cis	rs10504229	0.683	rs73605816	chr8:58117167	T/C	cg21724239	chr8:58056113	NA	0.58	5.95	0.34	8.29e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs2243480	0.901	rs13237344	chr7:66022256	T/A	cg12463550	chr7:65579703	CRCP	0.71	5.54	0.32	7.17e-8	Diabetic kidney disease;
CESC	cis	rs55665837	0.524	rs2882128	chr11:14414634	A/C	cg19336497	chr11:14380999	RRAS2	-0.36	-5.33	-0.31	2.12e-7	Vitamin D levels;
CESC	cis	rs4604732	0.631	rs34924545	chr1:247626892	G/T	cg12754571	chr1:247694271	LOC148824;OR2C3	0.44	5.45	0.32	1.17e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs703842	0.616	rs7489290	chr12:58228588	C/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.59	6.86	0.39	4.78e-11	Multiple sclerosis;
CESC	cis	rs6691722	0.503	rs2274167	chr1:24707296	C/T	cg18323236	chr1:24743029	NIPAL3	0.37	5.47	0.32	1.02e-7	Response to interferon beta in multiple sclerosis;
CESC	cis	rs453301	0.682	rs2929451	chr8:9085295	A/T	cg17143192	chr8:8559678	CLDN23	0.4	5.07	0.3	7.6e-7	Joint mobility (Beighton score);
CESC	cis	rs4665809	1.000	rs11126364	chr2:26314515	A/G	cg04944784	chr2:26401820	FAM59B	-0.67	-7.75	-0.43	2e-13	Gut microbiome composition (summer);
CESC	cis	rs4948102	0.731	rs4948099	chr7:56072250	A/C	cg09872392	chr7:56161020	PHKG1	0.41	6.48	0.37	4.44e-10	Plasma homocysteine levels (post-methionine load test);
CESC	cis	rs3768617	0.510	rs10797838	chr1:183077020	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.86	14.19	0.66	2.14e-34	Fuchs's corneal dystrophy;
CESC	cis	rs35306767	0.953	rs35693858	chr10:979813	C/T	cg25019033	chr10:957182	NA	-0.65	-7.92	-0.44	6.62e-14	Eosinophil percentage of granulocytes;
CESC	cis	rs1552244	0.816	rs13059144	chr3:10010197	A/C	cg00149659	chr3:10157352	C3orf10	0.69	8.12	0.45	1.77e-14	Alzheimer's disease;
CESC	trans	rs9937837	0.959	rs9925985	chr16:31305593	A/C	cg04903759	chr3:167238645	WDR49	0.53	6.6	0.38	2.21e-10	Systemic lupus erythematosus;
CESC	cis	rs6942756	0.713	rs691158	chr7:129129982	G/T	cg02491457	chr7:128862824	NA	-0.57	-7.81	-0.43	1.32e-13	White matter hyperintensity burden;
CESC	cis	rs798766	1.000	rs1665362	chr4:1726367	T/A	cg05874882	chr4:1763078	NA	-0.61	-8.63	-0.47	5.74e-16	Bladder cancer;Urinary bladder cancer;
CESC	cis	rs826838	0.510	rs17523988	chr12:39222785	A/C	cg13010199	chr12:38710504	ALG10B	0.58	7.73	0.43	2.17e-13	Heart rate;
CESC	cis	rs12136530	0.774	rs12409301	chr1:19774715	G/A	cg01832549	chr1:19774989	CAPZB	-0.47	-6.84	-0.39	5.52e-11	Lead levels in blood;
CESC	cis	rs962856	0.964	rs1486135	chr2:67596265	T/C	cg09028215	chr2:67624308	ETAA1	-0.41	-5.43	-0.32	1.25e-7	Pancreatic cancer;
CESC	cis	rs7589342	0.895	rs2033008	chr2:106502585	T/A	cg16077055	chr2:106428750	NCK2	0.41	5.85	0.34	1.46e-8	Addiction;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16517634	chr2:8977876	KIDINS220	0.53	6.12	0.35	3.31e-9	Gut microbiome composition (summer);
CESC	cis	rs6570726	0.620	rs12201226	chr6:145913419	A/T	cg05347473	chr6:146136440	FBXO30	0.71	8.87	0.48	1.14e-16	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7666738	0.791	rs2903151	chr4:99027218	T/C	cg03467027	chr4:99064603	C4orf37	0.49	6.18	0.35	2.44e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6502050	0.805	rs62080003	chr17:80078957	C/T	cg11859384	chr17:80120422	CCDC57	0.38	5.16	0.3	4.82e-7	Life satisfaction;
CESC	cis	rs1580019	0.961	rs1580022	chr7:32497712	C/A	cg06627557	chr7:32535165	LSM5;AVL9	0.73	10.13	0.53	1.34e-20	Cognitive ability;
CESC	cis	rs12927205	0.510	rs7185601	chr16:72035082	A/G	cg14768367	chr16:72042858	DHODH	0.71	5.87	0.34	1.28e-8	Cholesterol, total;LDL cholesterol;
CESC	cis	rs5758659	0.967	rs5751250	chr22:42639645	T/G	cg04733989	chr22:42467013	NAGA	0.42	5.78	0.33	2.14e-8	Cognitive function;
CESC	cis	rs4835473	0.897	rs3874	chr4:144889948	A/G	cg25736465	chr4:144833511	NA	0.41	6.26	0.36	1.55e-9	Immature fraction of reticulocytes;
CESC	cis	rs727505	0.866	rs3214004	chr7:124720929	T/C	cg23710748	chr7:124431027	NA	-0.4	-6.52	-0.37	3.56e-10	Lewy body disease;
CESC	cis	rs7618915	0.501	rs6617	chr3:52740182	C/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.61	8.76	0.47	2.33e-16	Bipolar disorder;
CESC	cis	rs10504229	0.861	rs116964504	chr8:58185354	A/C	cg14926445	chr8:58193284	C8orf71	-0.51	-5.52	-0.32	8.28e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs8027181	0.839	rs10459647	chr15:73035241	T/C	cg25632853	chr15:73088954	NA	0.31	5.52	0.32	8.02e-8	Triglyceride levels;
CESC	cis	rs2732480	0.577	rs2732486	chr12:48737834	G/A	cg04545296	chr12:48745243	ZNF641	0.44	7.23	0.41	5.12e-12	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs718433	0.556	rs1569287	chr14:22215593	C/T	cg02257791	chr14:22217085	NA	-0.32	-5.08	-0.3	7.19e-7	Intraocular pressure;
CESC	cis	rs5769765	1.000	rs910800	chr22:50278642	C/T	cg26441486	chr22:50317300	CRELD2	-0.39	-5.5	-0.32	8.72e-8	Schizophrenia;
CESC	trans	rs9467711	0.606	rs9379875	chr6:26444732	C/T	cg06606381	chr12:133084897	FBRSL1	-0.82	-6.76	-0.38	9.01e-11	Autism spectrum disorder or schizophrenia;
CESC	cis	rs7103648	0.966	rs1377416	chr11:47416746	C/T	cg20307385	chr11:47447363	PSMC3	0.96	16.51	0.71	1.41e-42	Diastolic blood pressure;Systolic blood pressure;
CESC	cis	rs6951245	0.882	rs11764817	chr7:1064610	T/C	cg03188948	chr7:1209495	NA	0.56	5.73	0.33	2.65e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2836950	0.502	rs12627205	chr21:40630027	C/T	cg11890956	chr21:40555474	PSMG1	-0.62	-8.45	-0.46	1.95e-15	Menarche (age at onset);
CESC	cis	rs6089584	0.566	rs7274240	chr20:60622004	C/T	cg23463467	chr20:60627584	TAF4	0.35	5.06	0.3	7.96e-7	Body mass index;
CESC	cis	rs868036	0.958	rs3784709	chr15:68072275	C/T	cg08079166	chr15:68083412	MAP2K5	0.39	5.89	0.34	1.16e-8	Restless legs syndrome;
CESC	cis	rs6032067	0.929	rs45461302	chr20:43805274	G/A	cg11264863	chr20:43835661	SEMG1	0.51	5.56	0.32	6.5e-8	Blood protein levels;
CESC	cis	rs7927771	0.524	rs7111576	chr11:47787445	G/A	cg20307385	chr11:47447363	PSMC3	0.61	8.59	0.47	7.41e-16	Subjective well-being;
CESC	cis	rs4588572	0.537	rs7719228	chr5:77730576	G/A	cg11547950	chr5:77652471	NA	-0.39	-5.31	-0.31	2.36e-7	Triglycerides;
CESC	cis	rs2204008	0.774	rs11495520	chr12:38060605	T/G	cg26384229	chr12:38710491	ALG10B	0.74	10.7	0.55	1.96e-22	Bladder cancer;
CESC	cis	rs6484504	0.576	rs208067	chr11:31153578	C/T	cg14844989	chr11:31128820	NA	-0.41	-5.67	-0.33	3.71e-8	Red blood cell count;
CESC	cis	rs10129255	0.912	rs8011090	chr14:107134913	G/A	cg23076370	chr14:107095027	NA	-0.41	-5.16	-0.3	4.85e-7	Kawasaki disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11737246	chr15:40401244	BMF	0.56	6.27	0.36	1.49e-9	Gut microbiome composition (summer);
CESC	cis	rs1552244	0.572	rs3894323	chr3:10168967	G/A	cg00149659	chr3:10157352	C3orf10	0.99	12.05	0.59	6.02e-27	Alzheimer's disease;
CESC	cis	rs919433	0.783	rs2565165	chr2:198233575	T/G	cg20885578	chr2:198174922	NA	0.41	5.36	0.31	1.79e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs858239	0.600	rs7787110	chr7:23138474	C/T	cg23682824	chr7:23144976	KLHL7	0.54	7.82	0.43	1.23e-13	Cerebrospinal fluid biomarker levels;
CESC	cis	rs1797885	0.564	rs2454422	chr3:12603900	C/T	cg26432171	chr3:12704882	RAF1	-0.5	-6.65	-0.38	1.69e-10	Immature fraction of reticulocytes;
CESC	cis	rs597539	0.652	rs636049	chr11:68667198	A/C	cg21963583	chr11:68658836	MRPL21	0.39	5.51	0.32	8.33e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs7914558	1.000	rs7071373	chr10:104771922	A/G	cg08650961	chr10:104748594	CNNM2	0.33	5.52	0.32	8.25e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs12347191	0.500	rs925485	chr9:100619561	G/C	cg13688889	chr9:100608707	NA	-0.91	-13.42	-0.64	1.07e-31	Orofacial clefts;
CESC	cis	rs4253772	0.550	rs6008600	chr22:46704676	A/G	cg10541313	chr22:46663664	TTC38	0.67	5.9	0.34	1.1e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs901683	1.000	rs34285816	chr10:45976851	G/A	cg16031567	chr10:46195673	NA	-0.76	-5.09	-0.3	6.84e-7	Red blood cell traits;Mean corpuscular volume;
CESC	cis	rs11229555	1.000	rs11603890	chr11:58402251	T/C	cg15696309	chr11:58395628	NA	-0.44	-5.72	-0.33	2.82e-8	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs9768139	0.935	rs6953748	chr7:158121184	G/A	cg24154853	chr7:158122151	PTPRN2	-0.37	-5.86	-0.34	1.4e-8	Calcium levels;
CESC	cis	rs6449957	0.607	rs251394	chr5:67512000	C/G	cg23036683	chr5:67512108	NA	0.44	6.07	0.35	4.36e-9	Cleft lip with or without cleft palate;
CESC	cis	rs17021463	0.673	rs12507134	chr4:95283980	C/A	cg11021082	chr4:95130006	SMARCAD1	0.51	6.97	0.39	2.55e-11	Testicular germ cell tumor;
CESC	cis	rs1552244	1.000	rs12152515	chr3:10143976	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.86	-12.3	-0.6	7.95e-28	Alzheimer's disease;
CESC	cis	rs798766	1.000	rs11729657	chr4:1737585	T/C	cg07041428	chr4:1763019	NA	-0.4	-5.7	-0.33	3.11e-8	Bladder cancer;Urinary bladder cancer;
CESC	cis	rs769267	0.864	rs7245983	chr19:19657632	A/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.42	5.11	0.3	6.28e-7	Tonsillectomy;
CESC	cis	rs2228479	0.618	rs62052174	chr16:89950901	G/A	cg14709524	chr16:89940631	TCF25	0.74	5.75	0.33	2.43e-8	Skin colour saturation;
CESC	cis	rs6860806	1.000	rs6860806	chr5:131640536	C/T	cg14196790	chr5:131705035	SLC22A5	-0.34	-5.59	-0.32	5.6e-8	Breast cancer;
CESC	cis	rs763121	0.853	rs7289855	chr22:39042221	G/T	cg06544989	chr22:39130855	UNC84B	0.51	8.67	0.47	4.48e-16	Menopause (age at onset);
CESC	cis	rs7264396	0.580	rs2425173	chr20:34445142	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.67	6.74	0.38	1.01e-10	Total cholesterol levels;
CESC	cis	rs7666738	0.784	rs4699602	chr4:99034903	T/C	cg24818145	chr4:99064322	C4orf37	0.41	5.23	0.31	3.37e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs7715474	0.738	rs10059100	chr5:120100784	A/G	cg12384126	chr1:185285600	IVNS1ABP	-0.46	-6.02	-0.35	5.66e-9	Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs798554	1.000	rs798545	chr7:2762386	C/T	cg09658497	chr7:2847517	GNA12	-0.43	-6.12	-0.35	3.43e-9	Height;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg08926035	chr11:64521052	PYGM	0.42	6.1	0.35	3.65e-9	Fibrinogen levels;
CESC	cis	rs7937682	0.883	rs659529	chr11:111436896	T/A	cg22437258	chr11:111473054	SIK2	0.74	9.62	0.51	5.34e-19	Primary sclerosing cholangitis;
CESC	cis	rs1707322	1.000	rs785490	chr1:46577124	T/C	cg03146154	chr1:46216737	IPP	-0.74	-9.64	-0.51	4.75e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs6860806	0.631	rs6863548	chr5:131575920	G/A	cg18301423	chr5:131593218	PDLIM4	0.37	5.36	0.31	1.78e-7	Breast cancer;
CESC	cis	rs10256972	0.527	rs2949170	chr7:1216438	A/G	cg27094323	chr7:1216898	NA	-0.45	-6.05	-0.35	4.86e-9	Longevity;Endometriosis;
CESC	cis	rs7927771	0.524	rs4752798	chr11:47886364	T/C	cg20307385	chr11:47447363	PSMC3	-0.58	-8.11	-0.45	1.89e-14	Subjective well-being;
CESC	cis	rs7666738	0.830	rs7669407	chr4:98750251	G/A	cg05340658	chr4:99064831	C4orf37	0.76	11.26	0.57	2.63e-24	Colonoscopy-negative controls vs population controls;
CESC	cis	rs12701220	0.689	rs12530960	chr7:1095471	G/A	cg26769984	chr7:1090371	C7orf50	0.58	5.99	0.35	6.9e-9	Bronchopulmonary dysplasia;
CESC	cis	rs7552404	0.655	rs1146646	chr1:76265500	G/A	cg03433033	chr1:76189801	ACADM	0.68	8.35	0.46	3.96e-15	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs55788414	0.932	rs2317123	chr16:81182636	A/T	cg06400318	chr16:81190750	PKD1L2	-0.59	-6.8	-0.39	6.75e-11	Left ventricular obstructive tract defect (maternal effect);
CESC	cis	rs2531992	0.686	rs933392	chr16:4032716	T/G	cg05927578	chr16:4029543	ADCY9	0.54	6.86	0.39	4.82e-11	Waist circumference;
CESC	cis	rs703842	1.000	rs11172349	chr12:58212528	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.71	9.01	0.48	4.25e-17	Multiple sclerosis;
CESC	cis	rs12900413	0.631	rs62023455	chr15:90301999	G/A	cg24249390	chr15:90295951	MESP1	-0.4	-5.36	-0.31	1.79e-7	Coronary artery aneurysm in Kawasaki disease;
CESC	cis	rs523522	0.673	rs643372	chr12:121022640	C/G	cg12219531	chr12:120966889	COQ5	0.76	10.07	0.53	2.15e-20	High light scatter reticulocyte count;
CESC	cis	rs12142240	0.698	rs17357628	chr1:46808462	A/G	cg00530320	chr1:46809349	NSUN4	0.6	7.98	0.44	4.48e-14	Menopause (age at onset);
CESC	cis	rs2279817	1.000	rs1339800	chr1:18020201	C/G	cg21791023	chr1:18019539	ARHGEF10L	-0.58	-8.52	-0.46	1.25e-15	Neuroticism;
CESC	cis	rs734999	0.588	rs3001837	chr1:2532506	G/A	cg20673091	chr1:2541236	MMEL1	-0.45	-7.46	-0.42	1.2e-12	Ulcerative colitis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13997647	chr14:95623841	FLJ45244;DICER1	0.6	6.87	0.39	4.49e-11	Gut microbiome composition (summer);
CESC	cis	rs6121246	0.697	rs6120970	chr20:30232452	C/T	cg13852791	chr20:30311386	BCL2L1	0.67	7.01	0.4	1.94e-11	Mean corpuscular hemoglobin;
CESC	cis	rs79387448	0.655	rs3771167	chr2:102986188	A/G	cg09003973	chr2:102972529	NA	1.22	10.27	0.53	4.91e-21	Gut microbiota (bacterial taxa);
CESC	cis	rs4072980	0.545	rs11210870	chr1:38449910	T/C	cg04673462	chr1:38461896	NA	-0.37	-5.08	-0.3	7.09e-7	Coronary artery disease;
CESC	cis	rs1005277	0.505	rs200939	chr10:38139483	T/C	cg25427524	chr10:38739819	LOC399744	-0.68	-10.03	-0.52	2.86e-20	Extrinsic epigenetic age acceleration;
CESC	cis	rs1568889	0.838	rs10835299	chr11:28277693	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	-0.81	-13.99	-0.65	1.14e-33	Bipolar disorder;
CESC	cis	rs3857536	0.740	rs9354391	chr6:66890183	C/T	cg07460842	chr6:66804631	NA	0.41	5.34	0.31	1.96e-7	Blood trace element (Cu levels);
CESC	cis	rs7666738	0.830	rs13124689	chr4:98961182	A/T	cg18180107	chr4:99064573	C4orf37	0.4	5.14	0.3	5.26e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11098499	0.863	rs3822195	chr4:120471660	C/T	cg24375607	chr4:120327624	NA	0.45	5.5	0.32	9.09e-8	Corneal astigmatism;
CESC	cis	rs763121	0.853	rs138709	chr22:39139216	C/G	cg06022373	chr22:39101656	GTPBP1	0.91	16.86	0.72	7.73e-44	Menopause (age at onset);
CESC	cis	rs9486715	0.830	rs2255552	chr6:96999643	A/G	cg06623918	chr6:96969491	KIAA0776	-0.88	-13.31	-0.63	2.73e-31	Headache;
CESC	trans	rs561341	0.769	rs12941700	chr17:30185022	A/G	cg20587970	chr11:113659929	NA	0.99	11.03	0.56	1.56e-23	Hip circumference adjusted for BMI;
CESC	cis	rs2303759	1.000	rs2303759	chr19:49869051	T/G	cg22307029	chr19:49891270	CCDC155	0.7	8.38	0.46	3.2e-15	Multiple sclerosis;
CESC	cis	rs7193541	0.684	rs8062783	chr16:74691264	C/T	cg05580060	chr16:74700937	RFWD3	0.47	5.96	0.34	8.02e-9	Multiple myeloma;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg24243429	chr4:148653539	ARHGAP10	-0.44	-6.4	-0.37	7.11e-10	Gambling;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg15620385	chr12:26986279	ITPR2	-0.45	-6.17	-0.35	2.5e-9	Fibrinogen levels;
CESC	cis	rs9790314	1.000	rs2218803	chr3:161047973	T/G	cg04691961	chr3:161091175	C3orf57	-0.41	-5.22	-0.31	3.57e-7	Morning vs. evening chronotype;
CESC	cis	rs801193	0.761	rs2659888	chr7:66230171	T/G	cg11764359	chr7:65958608	NA	0.66	8.61	0.47	6.69e-16	Aortic root size;
CESC	cis	rs75064307	0.834	rs4855561	chr3:108116331	T/C	cg03329597	chr3:108125523	MYH15	0.5	5.61	0.33	5.18e-8	Intelligence (multi-trait analysis);
CESC	cis	rs9625935	0.518	rs9625870	chr22:30261219	C/T	cg01021169	chr22:30184971	ASCC2	-0.41	-6.35	-0.36	9.43e-10	Tonsillectomy;
CESC	cis	rs2841277	0.708	rs28600075	chr14:105408315	T/C	cg19901468	chr14:105411992	AHNAK2	-0.6	-8.79	-0.48	1.91e-16	Rheumatoid arthritis;
CESC	cis	rs1552244	1.000	rs17032414	chr3:10158302	C/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.91	-13.59	-0.64	2.71e-32	Alzheimer's disease;
CESC	cis	rs1843834	0.539	rs2047135	chr2:225427302	G/C	cg12698349	chr2:225449008	CUL3	0.63	8.96	0.48	6.05e-17	IgE levels in asthmatics (D.p. specific);
CESC	trans	rs875971	1.000	rs9986696	chr7:65704576	C/A	cg26939375	chr7:64535504	NA	-0.46	-6.16	-0.35	2.64e-9	Aortic root size;
CESC	cis	rs17209837	1.000	rs45546132	chr7:87086140	C/T	cg00919237	chr7:87102261	ABCB4	-0.49	-5.77	-0.33	2.23e-8	Gallbladder cancer;
CESC	cis	rs4148883	0.689	rs1869458	chr4:100024728	C/G	cg13256891	chr4:100009986	ADH5	0.52	6.98	0.39	2.38e-11	Alcohol dependence;
CESC	cis	rs2760061	0.598	rs673726	chr1:228120173	T/C	cg01973587	chr1:228161476	NA	0.38	5.93	0.34	9.18e-9	Diastolic blood pressure;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg20930514	chr14:77499758	NA	-0.43	-6.01	-0.35	6.26e-9	Height;
CESC	cis	rs8005677	0.828	rs12589539	chr14:23396680	A/G	cg01529538	chr14:23388837	RBM23	0.45	6.13	0.35	3.22e-9	Cognitive ability (multi-trait analysis);
CESC	cis	rs4315565	0.541	rs7580085	chr2:69282900	C/A	cg12800200	chr2:69260302	ANTXR1	-0.38	-5.33	-0.31	2.09e-7	Height;
CESC	cis	rs7072216	0.690	rs113195335	chr10:100175532	A/C	cg26618903	chr10:100175079	PYROXD2	-0.38	-5.96	-0.34	8.02e-9	Metabolite levels;
CESC	cis	rs4460629	0.905	rs4971077	chr1:155128717	T/C	cg02153340	chr1:155202674	NA	-0.37	-5.5	-0.32	8.76e-8	Serum magnesium levels;
CESC	cis	rs644799	1.000	rs516551	chr11:95588626	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.69	8.55	0.46	1.01e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs796364	0.806	rs6743396	chr2:200860138	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.85	7.68	0.43	3.06e-13	Schizophrenia;
CESC	cis	rs6952808	0.929	rs12667688	chr7:1931030	C/T	cg08061076	chr7:1943177	MAD1L1	-0.38	-5.09	-0.3	6.68e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs6938	0.618	rs12911254	chr15:75166335	G/A	cg14664628	chr15:75095509	CSK	-0.52	-7.03	-0.4	1.77e-11	Breast cancer;
CESC	cis	rs7811142	0.720	rs7795656	chr7:99950297	A/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.1	11.36	0.57	1.28e-24	Platelet count;
CESC	cis	rs3096299	0.719	rs2911262	chr16:89515041	C/T	cg08392591	chr16:89556376	ANKRD11	0.59	8.1	0.45	2e-14	Multiple myeloma (IgH translocation);
CESC	cis	rs1178968	0.748	rs10248063	chr7:72776008	T/G	cg25889504	chr7:72793014	NA	0.47	5.03	0.3	8.91e-7	Triglyceride levels;
CESC	cis	rs9325144	0.505	rs1906262	chr12:38653605	A/G	cg13010199	chr12:38710504	ALG10B	0.47	6.46	0.37	5e-10	Morning vs. evening chronotype;
CESC	cis	rs6580649	0.941	rs4760614	chr12:48427884	A/G	cg05342945	chr12:48394962	COL2A1	0.5	5.74	0.33	2.59e-8	Lung cancer;
CESC	cis	rs1348850	0.914	rs11893448	chr2:178280013	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.86	12.77	0.62	1.97e-29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs875971	0.505	rs1723275	chr7:65504633	G/C	cg11987759	chr7:65425863	GUSB	0.45	6.18	0.35	2.47e-9	Aortic root size;
CESC	cis	rs7937682	0.562	rs10891276	chr11:111370415	A/C	cg09085632	chr11:111637200	PPP2R1B	-0.64	-8.61	-0.47	6.54e-16	Primary sclerosing cholangitis;
CESC	cis	rs2295499	0.725	rs2298959	chr4:2644311	T/C	cg08330972	chr4:2403930	ZFYVE28	-0.32	-5.13	-0.3	5.62e-7	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
CESC	cis	rs9814567	1.000	rs13081177	chr3:134289860	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.45	6.1	0.35	3.71e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs7044106	0.762	rs10760110	chr9:123412563	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	-0.33	-5.09	-0.3	6.78e-7	Hip circumference adjusted for BMI;
CESC	cis	rs7520050	0.807	rs6656279	chr1:46124088	C/G	cg24296786	chr1:45957014	TESK2	-0.46	-5.96	-0.34	8.19e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs9322193	0.962	rs9322223	chr6:150122645	G/A	cg07701084	chr6:150067640	NUP43	0.4	5.48	0.32	9.87e-8	Lung cancer;
CESC	cis	rs7833790	0.636	rs12544174	chr8:82731477	G/A	cg17211192	chr8:82754475	SNX16	-0.52	-6.64	-0.38	1.73e-10	Diastolic blood pressure;
CESC	cis	rs10779751	1.000	rs12730522	chr1:11284091	G/A	cg08854313	chr1:11322531	MTOR	0.91	14.25	0.66	1.34e-34	Body mass index;
CESC	cis	rs6500602	0.964	rs2896893	chr16:4478559	T/A	cg08645402	chr16:4508243	NA	0.43	6.62	0.38	2.03e-10	Schizophrenia;
CESC	trans	rs7824557	0.527	rs10109537	chr8:11239640	C/T	cg06636001	chr8:8085503	FLJ10661	-0.48	-6.07	-0.35	4.35e-9	Retinal vascular caliber;
CESC	cis	rs1707322	0.890	rs2297883	chr1:46511487	G/C	cg05343316	chr1:45956843	TESK2	-0.44	-5.44	-0.32	1.2e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs57221529	0.766	rs12522303	chr5:555564	A/C	cg09021430	chr5:549028	NA	-0.42	-5.26	-0.31	2.92e-7	Lung disease severity in cystic fibrosis;
CESC	cis	rs10769945	0.679	rs217213	chr11:1979118	C/G	cg23202291	chr11:1979235	NA	-0.37	-5.22	-0.31	3.57e-7	DNA methylation (variation);
CESC	cis	rs7582720	1.000	rs72932558	chr2:203847325	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.36	0.41	2.34e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs9486719	0.895	rs12527021	chr6:97025496	C/T	cg06623918	chr6:96969491	KIAA0776	-0.8	-8.28	-0.45	6.29e-15	Migraine;Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22331096	chr8:128749328	MYC	0.56	6.4	0.37	7.13e-10	Gut microbiome composition (summer);
CESC	trans	rs1506636	0.886	rs6945841	chr7:123266094	G/A	cg12383159	chr11:1262597	MUC5B	0.36	6.14	0.35	3.08e-9	Plateletcrit;Platelet count;
CESC	cis	rs3096299	0.685	rs12935112	chr16:89542858	C/T	cg02187348	chr16:89574699	SPG7	-0.6	-8.53	-0.46	1.1e-15	Multiple myeloma (IgH translocation);
CESC	cis	rs6964587	1.000	rs6967256	chr7:91643219	G/A	cg17063962	chr7:91808500	NA	0.55	7.63	0.42	4.25e-13	Breast cancer;
CESC	cis	rs7188697	0.922	rs173475	chr16:58580530	T/C	cg02549819	chr16:58548995	SETD6	-0.42	-5.26	-0.31	3.04e-7	QT interval;
CESC	cis	rs10504229	0.683	rs6980850	chr8:58127204	A/G	cg02725872	chr8:58115012	NA	-0.45	-6.84	-0.39	5.31e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs870825	0.860	rs2696044	chr4:185595988	C/G	cg04058563	chr4:185651563	MLF1IP	0.54	5.52	0.32	8.11e-8	Blood protein levels;
CESC	cis	rs561341	0.714	rs473535	chr17:30312365	A/G	cg19193384	chr17:30244184	NA	-0.64	-5.99	-0.35	6.79e-9	Hip circumference adjusted for BMI;
CESC	cis	rs4423214	1.000	rs11606612	chr11:71164047	C/A	cg05163923	chr11:71159392	DHCR7	0.76	10.16	0.53	1.05e-20	Vitamin D levels;
CESC	cis	rs6783573	1.000	rs12185926	chr3:46602999	C/G	cg21489266	chr3:46619131	LRRC2;TDGF1	-0.43	-6.23	-0.36	1.8e-9	Cerebrospinal fluid biomarker levels;
CESC	cis	rs2657888	1.000	rs2657901	chr12:56933416	A/G	cg23002907	chr12:56915593	RBMS2	0.39	5.21	0.3	3.78e-7	Adiponectin levels;
CESC	cis	rs854572	0.870	rs757158	chr7:94955528	C/T	cg20119798	chr7:94954144	PON1	-0.41	-6.04	-0.35	5.25e-9	Paraoxonase activity;
CESC	cis	rs875971	0.540	rs1723268	chr7:65473080	A/C	cg08632164	chr7:65971372	NA	-0.32	-5.19	-0.3	4.14e-7	Aortic root size;
CESC	cis	rs7618501	0.735	rs9876508	chr3:49780844	G/A	cg24308560	chr3:49941425	MST1R	0.49	6.74	0.38	9.66e-11	Intelligence (multi-trait analysis);
CESC	trans	rs4927850	1.000	rs7614767	chr3:195753451	C/T	cg16724585	chr3:197361211	NA	-0.56	-7.54	-0.42	7.58e-13	Pancreatic cancer;
CESC	trans	rs393155	0.517	rs330050	chr8:9087679	G/C	cg15556689	chr8:8085844	FLJ10661	-0.52	-6.57	-0.37	2.61e-10	Neuroticism;
CESC	cis	rs71403859	0.502	rs17345863	chr16:71523261	C/T	cg08717414	chr16:71523259	ZNF19	-1.01	-9.55	-0.51	8.95e-19	Post bronchodilator FEV1;
CESC	cis	rs10504229	1.000	rs17805326	chr8:58169533	A/C	cg24829409	chr8:58192753	C8orf71	-0.76	-10.07	-0.53	2.08e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs2204008	0.665	rs11495668	chr12:38221018	C/T	cg26384229	chr12:38710491	ALG10B	0.74	10.65	0.55	2.74e-22	Bladder cancer;
CESC	cis	rs6446731	0.593	rs7674472	chr4:3273538	C/G	cg08886695	chr4:3369023	RGS12	-0.38	-5.51	-0.32	8.38e-8	Mean platelet volume;
CESC	cis	rs7618501	0.633	rs2624843	chr3:49997963	G/A	cg24110177	chr3:50126178	RBM5	-0.54	-7.55	-0.42	7.06e-13	Intelligence (multi-trait analysis);
CESC	cis	rs898097	0.578	rs9906163	chr17:80908174	T/C	cg10494973	chr17:80897199	TBCD	-0.48	-6.09	-0.35	3.92e-9	Breast cancer;
CESC	cis	rs6952808	0.689	rs4719391	chr7:2048136	T/C	cg02951883	chr7:2050386	MAD1L1	-0.56	-7.4	-0.41	1.75e-12	Bipolar disorder and schizophrenia;
CESC	cis	rs1552244	1.000	rs113153120	chr3:10156398	G/A	cg00166722	chr3:10149974	C3orf24	0.45	5.65	0.33	4.12e-8	Alzheimer's disease;
CESC	cis	rs72781680	0.848	rs56021814	chr2:24073437	T/A	cg20701182	chr2:24300061	SF3B14	0.62	5.58	0.32	6.04e-8	Lymphocyte counts;
CESC	cis	rs9457247	1.000	rs2757042	chr6:167371234	A/T	cg23791538	chr6:167370224	RNASET2	0.57	8.13	0.45	1.64e-14	Crohn's disease;
CESC	cis	rs4654899	1.000	rs12133780	chr1:21270808	G/A	cg05370193	chr1:21551575	ECE1	0.39	5.83	0.34	1.6e-8	Superior frontal gyrus grey matter volume;
CESC	cis	rs910316	0.737	rs424120	chr14:75482828	G/T	cg16144293	chr14:75469539	EIF2B2	0.39	5.11	0.3	6.28e-7	Height;
CESC	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.55	-6.17	-0.35	2.48e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs1348850	0.526	rs2178017	chr2:178374788	G/T	cg22681709	chr2:178499509	PDE11A	-0.49	-5.07	-0.3	7.32e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs7772486	0.790	rs1133832	chr6:146205604	C/T	cg05347473	chr6:146136440	FBXO30	-0.51	-6.84	-0.39	5.6e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9660992	0.512	rs12123773	chr1:205122420	C/G	cg00857998	chr1:205179979	DSTYK	0.58	7.45	0.42	1.34e-12	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs2880765	0.835	rs7174323	chr15:86049719	A/C	cg19183879	chr15:85880815	NA	-0.26	-5.29	-0.31	2.52e-7	Coronary artery disease;
CESC	cis	rs6982240	0.514	rs9324543	chr8:142275662	T/C	cg00131261	chr8:142287264	NA	-0.54	-7.51	-0.42	8.94e-13	Tonsillectomy;
CESC	cis	rs35306767	0.953	rs35174953	chr10:961191	C/A	cg26597838	chr10:835615	NA	0.84	9.84	0.52	1.15e-19	Eosinophil percentage of granulocytes;
CESC	cis	rs72792276	0.908	rs3828656	chr5:127487535	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.65	5.71	0.33	3.04e-8	Red cell distribution width;
CESC	trans	rs61931739	0.500	rs7971957	chr12:34477558	C/T	cg26384229	chr12:38710491	ALG10B	0.55	7.59	0.42	5.63e-13	Morning vs. evening chronotype;
CESC	cis	rs425277	0.561	rs925906	chr1:2044054	A/C	cg23803603	chr1:2058230	PRKCZ	-0.34	-5.75	-0.33	2.5e-8	Height;
CESC	cis	rs780096	0.545	rs6716894	chr2:27583273	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.35	-7.09	-0.4	1.24e-11	Total body bone mineral density;
CESC	cis	rs10206020	0.797	rs72778008	chr2:1573182	T/G	cg26248373	chr2:1572462	NA	-0.6	-7.09	-0.4	1.21e-11	IgG glycosylation;
CESC	cis	rs1129187	0.837	rs4714634	chr6:42901120	G/A	cg21280719	chr6:42927975	GNMT	-0.25	-5.56	-0.32	6.46e-8	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs2730245	0.569	rs1188955	chr7:158690866	A/G	cg14689365	chr7:158441557	NCAPG2	0.41	5.05	0.3	8.24e-7	Height;
CESC	cis	rs6570726	0.599	rs4398765	chr6:145935006	C/A	cg23711669	chr6:146136114	FBXO30	0.92	11.94	0.59	1.42e-26	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs7980799	0.682	rs1601007	chr12:33609675	C/G	cg26384229	chr12:38710491	ALG10B	0.5	7.2	0.4	6.33e-12	Heart rate;Heart rate variability traits (RMSSD);
CESC	cis	rs4819052	0.851	rs9974628	chr21:46672647	C/T	cg11663144	chr21:46675770	NA	-0.64	-9.99	-0.52	3.77e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs7666738	0.830	rs11941961	chr4:99065654	G/T	cg17366294	chr4:99064904	C4orf37	0.6	8.52	0.46	1.21e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7666738	0.830	rs2865949	chr4:99039967	A/G	cg03676636	chr4:99064102	C4orf37	0.33	5.12	0.3	5.93e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg26634707	chr19:59030662	ZBTB45	-0.51	-6.31	-0.36	1.17e-9	Ulcerative colitis;
CESC	cis	rs2731664	0.792	rs2544809	chr5:176885499	T/C	cg23176889	chr5:176863531	GRK6	-0.65	-11.42	-0.57	7.74e-25	Intelligence (multi-trait analysis);
CESC	cis	rs1062177	1.000	rs2915882	chr5:151145436	T/C	cg00977110	chr5:151150581	G3BP1	0.67	7.27	0.41	3.98e-12	Preschool internalizing problems;
CESC	cis	rs8040855	0.627	rs12909130	chr15:85590501	T/C	cg08123816	chr15:85640762	PDE8A	-0.38	-5.66	-0.33	4e-8	Bulimia nervosa;
CESC	cis	rs9522267	0.535	rs9515452	chr13:112234553	A/G	cg10483660	chr13:112241077	NA	-0.33	-5.79	-0.33	2.04e-8	Hepatitis;
CESC	cis	rs4664304	0.658	rs2667012	chr2:160867553	G/T	cg03641300	chr2:160917029	PLA2R1	-0.45	-6.4	-0.37	6.82e-10	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs736408	0.716	rs2300149	chr3:52822921	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.34	5.8	0.34	1.89e-8	Bipolar disorder;
CESC	cis	rs727563	0.635	rs713988	chr22:42159072	A/G	cg06481639	chr22:41940642	POLR3H	0.6	5.95	0.34	8.27e-9	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs3126085	0.935	rs4845423	chr1:152184950	T/G	cg26876637	chr1:152193138	HRNR	0.48	5.51	0.32	8.31e-8	Atopic dermatitis;
CESC	cis	rs3806843	0.735	rs6849	chr5:140086191	G/T	cg16179182	chr5:140090404	VTRNA1-1	0.4	5.18	0.3	4.46e-7	Depressive symptoms (multi-trait analysis);
CESC	trans	rs7307889	0.793	rs73047639	chr12:6008285	C/G	cg18407955	chr7:158110685	PTPRN2	-0.67	-6.29	-0.36	1.33e-9	Obesity-related traits;
CESC	cis	rs7833790	0.963	rs1451997	chr8:82774053	A/T	cg07697082	chr8:82753677	SNX16	-0.4	-5.69	-0.33	3.32e-8	Diastolic blood pressure;
CESC	cis	rs9322193	0.884	rs2342858	chr6:150127103	C/T	cg13206674	chr6:150067644	NUP43	0.42	5.83	0.34	1.64e-8	Lung cancer;
CESC	cis	rs7582720	1.000	rs114110842	chr2:203823400	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.36	0.41	2.34e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs9296736	1.000	rs4715438	chr6:53901329	G/A	cg04374786	chr6:53939321	C6orf142	-0.37	-5.69	-0.33	3.34e-8	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs7666738	0.791	rs11097610	chr4:99011795	C/G	cg03467027	chr4:99064603	C4orf37	0.45	5.58	0.32	5.85e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs801193	1.000	rs2707836	chr7:66160435	A/C	cg14393609	chr7:65229607	NA	0.47	6.31	0.36	1.17e-9	Aortic root size;
CESC	cis	rs1062177	0.756	rs2915815	chr5:151115883	G/C	cg12924095	chr5:151150029	G3BP1	-0.46	-5.78	-0.33	2.06e-8	Preschool internalizing problems;
CESC	cis	rs344364	0.511	rs2906912	chr16:1953151	G/A	cg03013636	chr16:1946785	NA	0.47	6.4	0.37	6.98e-10	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs7605827	0.930	rs2049720	chr2:15514982	T/C	cg19274914	chr2:15703543	NA	0.31	5.39	0.31	1.55e-7	Educational attainment (years of education);
CESC	cis	rs644799	0.965	rs11021313	chr11:95506907	G/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.54	6.76	0.38	8.71e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs2274273	0.840	rs11547116	chr14:55738165	T/C	cg04306507	chr14:55594613	LGALS3	0.28	5.42	0.32	1.37e-7	Protein biomarker;
CESC	cis	rs2832191	0.791	rs2065270	chr21:30485420	T/C	cg08807101	chr21:30365312	RNF160	-0.76	-10.9	-0.56	4.29e-23	Dental caries;
CESC	cis	rs11638352	1.000	rs11631340	chr15:44286325	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	-0.63	-5.6	-0.33	5.48e-8	Lipoprotein phospholipase A2 activity in cardiovascular disease;
CESC	cis	rs854765	0.506	rs7210400	chr17:17949957	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.56	-8.0	-0.44	3.85e-14	Total body bone mineral density;
CESC	trans	rs801193	0.967	rs2707849	chr7:66152712	T/C	cg26939375	chr7:64535504	NA	0.64	8.77	0.47	2.19e-16	Aortic root size;
CESC	cis	rs7656342	0.636	rs10012880	chr4:9835480	T/C	cg00071950	chr4:10020882	SLC2A9	-0.42	-5.58	-0.32	5.89e-8	Gut microbiota (bacterial taxa);
CESC	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg03188948	chr7:1209495	NA	0.43	5.37	0.31	1.75e-7	Longevity;Endometriosis;
CESC	cis	rs7188697	0.922	rs37053	chr16:58558707	T/C	cg02549819	chr16:58548995	SETD6	-0.42	-5.23	-0.31	3.45e-7	QT interval;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22663240	chr12:56473408	ERBB3	0.56	6.45	0.37	5.17e-10	Gut microbiome composition (summer);
CESC	cis	rs5753037	0.653	rs131266	chr22:30145717	G/T	cg01021169	chr22:30184971	ASCC2	-0.47	-6.6	-0.38	2.17e-10	Type 1 diabetes;
CESC	trans	rs12505749	1.000	rs12505749	chr4:57334112	C/G	cg09583921	chr3:87101925	NA	0.95	6.15	0.35	2.79e-9	Airflow obstruction;
CESC	cis	rs854765	0.964	rs854813	chr17:18003845	C/T	cg04398451	chr17:18023971	MYO15A	0.67	9.35	0.5	3.75e-18	Total body bone mineral density;
CESC	trans	rs61931739	0.534	rs4539411	chr12:34014807	T/C	cg26384229	chr12:38710491	ALG10B	0.5	6.87	0.39	4.63e-11	Morning vs. evening chronotype;
CESC	cis	rs113835537	0.529	rs4930183	chr11:66255732	C/T	cg24851651	chr11:66362959	CCS	0.45	5.62	0.33	4.87e-8	Airway imaging phenotypes;
CESC	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg22083815	chr1:32666378	CCDC28B	0.46	6.04	0.35	5.27e-9	Myopia (pathological);
CESC	cis	rs60871478	0.636	rs4721600	chr7:871728	C/T	cg15782153	chr7:917662	C7orf20	0.47	5.1	0.3	6.59e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs7666738	0.800	rs10028921	chr4:98962630	G/T	cg17366294	chr4:99064904	C4orf37	0.6	8.52	0.46	1.22e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9322193	0.923	rs10782318	chr6:150075273	A/G	cg13206674	chr6:150067644	NUP43	0.43	6.01	0.35	6.08e-9	Lung cancer;
CESC	cis	rs6502050	0.871	rs6502055	chr17:80070868	G/T	cg11859384	chr17:80120422	CCDC57	0.41	5.53	0.32	7.63e-8	Life satisfaction;
CESC	cis	rs1538970	0.924	rs12037201	chr1:45941349	G/T	cg03146154	chr1:46216737	IPP	0.46	5.3	0.31	2.49e-7	Platelet count;
CESC	cis	rs9325144	0.560	rs1825802	chr12:38650341	C/T	cg26384229	chr12:38710491	ALG10B	-0.62	-9.6	-0.51	6.43e-19	Morning vs. evening chronotype;
CESC	cis	rs1707322	0.721	rs4609469	chr1:46117185	C/T	cg03146154	chr1:46216737	IPP	0.82	11.52	0.58	3.64e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9291683	0.509	rs6849717	chr4:9958719	T/C	cg11266682	chr4:10021025	SLC2A9	-0.62	-12.43	-0.61	2.85e-28	Bone mineral density;
CESC	cis	rs7615952	0.641	rs12488180	chr3:125782236	C/T	cg02807482	chr3:125708958	NA	-0.39	-5.31	-0.31	2.36e-7	Blood pressure (smoking interaction);
CESC	cis	rs1218582	0.688	rs58629129	chr1:154910930	T/C	cg03351412	chr1:154909251	PMVK	0.52	6.38	0.36	7.94e-10	Prostate cancer;
CESC	cis	rs7084402	0.905	rs7914888	chr10:60308558	T/C	cg07615347	chr10:60278583	BICC1	-0.56	-8.49	-0.46	1.46e-15	Refractive error;
CESC	cis	rs10540	1.000	rs61876342	chr11:496193	T/G	cg03934478	chr11:495069	RNH1	0.55	5.36	0.31	1.86e-7	Body mass index;
CESC	cis	rs9323205	0.906	rs11629336	chr14:51686620	A/C	cg23942311	chr14:51606299	NA	0.44	5.61	0.33	5.02e-8	Cancer;
CESC	cis	rs7927771	0.524	rs10838739	chr11:47672743	A/G	cg18512352	chr11:47633146	NA	-0.34	-5.24	-0.31	3.3e-7	Subjective well-being;
CESC	cis	rs73206853	0.925	rs12297709	chr12:110901758	A/G	cg12870014	chr12:110450643	ANKRD13A	0.64	5.8	0.34	1.84e-8	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs9796	0.700	rs2305656	chr15:41279519	T/A	cg18705301	chr15:41695430	NDUFAF1	-0.54	-7.52	-0.42	8.37e-13	Menopause (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16580496	chr1:38156394	C1orf109	0.59	6.3	0.36	1.27e-9	Gut microbiome composition (summer);
CESC	cis	rs412050	0.547	rs112153746	chr22:22138691	G/A	cg17089214	chr22:22089827	YPEL1	0.65	5.36	0.31	1.78e-7	Attention deficit hyperactivity disorder;
CESC	cis	rs2354432	0.607	rs10453880	chr1:146693689	T/C	cg25205988	chr1:146714368	CHD1L	1.18	8.99	0.48	4.8e-17	Mitochondrial DNA levels;
CESC	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg24829409	chr8:58192753	C8orf71	-0.65	-7.84	-0.43	1.13e-13	Developmental language disorder (linguistic errors);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26831488	chr11:114270881	RBM7;C11orf71	0.62	6.55	0.37	3.06e-10	Gut microbiome composition (summer);
CESC	cis	rs5753618	0.583	rs5749270	chr22:31812853	C/T	cg02404636	chr22:31891804	SFI1	0.39	5.37	0.31	1.71e-7	Colorectal cancer;
CESC	cis	rs9894429	0.621	rs9747119	chr17:79607017	A/G	cg13777783	chr17:79615861	NA	-0.37	-6.16	-0.35	2.72e-9	Eye color traits;
CESC	cis	rs977987	0.806	rs4888388	chr16:75394148	G/A	cg03315344	chr16:75512273	CHST6	0.39	5.63	0.33	4.61e-8	Dupuytren's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18727501	chr4:89513542	HERC3	0.55	6.77	0.38	8.11e-11	Gut microbiome composition (summer);
CESC	cis	rs6088580	0.634	rs4277599	chr20:33008905	A/G	cg24642439	chr20:33292090	TP53INP2	-0.55	-7.53	-0.42	8.19e-13	Glomerular filtration rate (creatinine);
CESC	cis	rs6860806	0.661	rs1588263	chr5:131577158	T/C	cg14196790	chr5:131705035	SLC22A5	0.32	5.17	0.3	4.62e-7	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06520258	chr11:118436842	C11orf60	-0.54	-6.48	-0.37	4.45e-10	Gut microbiome composition (summer);
CESC	cis	rs6430585	0.527	rs12465544	chr2:136451676	C/T	cg07169764	chr2:136633963	MCM6	1.09	12.56	0.61	1.07e-28	Corneal structure;
CESC	cis	rs6772849	0.930	rs68090762	chr3:128343907	C/T	cg16766828	chr3:128327626	NA	-0.31	-5.09	-0.3	6.77e-7	Monocyte percentage of white cells;Monocyte count;
CESC	cis	rs208520	0.690	rs2126120	chr6:66742754	A/G	cg07460842	chr6:66804631	NA	0.97	12.84	0.62	1.11e-29	Exhaled nitric oxide output;
CESC	cis	rs3820068	0.705	rs2145396	chr1:15875184	A/G	cg18192808	chr1:15853278	DNAJC16	0.47	5.69	0.33	3.33e-8	Systolic blood pressure;
CESC	cis	rs9309473	0.528	rs11126395	chr2:73564964	A/G	cg20560298	chr2:73613845	ALMS1	-0.47	-6.45	-0.37	5.34e-10	Metabolite levels;
CESC	cis	rs1552244	1.000	rs6772315	chr3:10113644	G/A	cg00149659	chr3:10157352	C3orf10	0.72	8.61	0.47	6.41e-16	Alzheimer's disease;
CESC	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	10.32	0.54	3.32e-21	Prudent dietary pattern;
CESC	cis	rs1552244	1.000	rs9809061	chr3:10085130	C/G	cg00166722	chr3:10149974	C3orf24	0.48	6.16	0.35	2.64e-9	Alzheimer's disease;
CESC	cis	rs1707322	0.721	rs4660883	chr1:46236098	C/T	cg03146154	chr1:46216737	IPP	0.85	12.13	0.6	3.17e-27	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs6860806	0.661	rs2136188	chr5:131577514	A/G	cg04518342	chr5:131593106	PDLIM4	-0.42	-6.29	-0.36	1.28e-9	Breast cancer;
CESC	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg18538332	chr22:24372958	LOC391322	-0.73	-10.92	-0.56	3.57e-23	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs916888	0.779	rs199528	chr17:44843136	C/T	cg01570182	chr17:44337453	NA	0.93	10.7	0.55	1.93e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs1005277	0.579	rs2474594	chr10:38426661	G/C	cg25517755	chr10:38738941	LOC399744	-0.47	-6.16	-0.35	2.76e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs55728055	0.661	rs62237764	chr22:31947393	T/G	cg01338084	chr22:32026380	PISD	1.26	8.11	0.45	1.91e-14	Age-related hearing impairment;
CESC	cis	rs807669	0.525	rs9604934	chr22:19194868	C/T	cg17887427	chr22:19166691	SLC25A1	-0.38	-5.08	-0.3	7.27e-7	Metabolite levels;
CESC	cis	rs1448094	0.842	rs10863159	chr12:86459140	T/C	cg02569458	chr12:86230093	RASSF9	-0.35	-5.31	-0.31	2.33e-7	Major depressive disorder;
CESC	cis	rs727505	1.000	rs67084428	chr7:124499388	G/T	cg23710748	chr7:124431027	NA	-0.48	-7.52	-0.42	8.73e-13	Lewy body disease;
CESC	cis	rs9443189	0.530	rs614065	chr6:76315633	G/A	cg01950844	chr6:76311363	SENP6	0.88	9.44	0.5	2.07e-18	Prostate cancer;
CESC	cis	rs6736093	0.966	rs11674891	chr2:112713116	A/G	cg12686935	chr2:112915763	FBLN7	-0.42	-5.46	-0.32	1.1e-7	Coronary artery disease;
CESC	cis	rs9911578	0.704	rs72628393	chr17:56585314	A/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.42	-5.58	-0.32	5.86e-8	Intelligence (multi-trait analysis);
CESC	cis	rs10870270	1.000	rs10159746	chr10:133742677	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.86	-12.69	-0.61	3.83e-29	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs1881744	1.000	rs7298217	chr12:47809049	A/C	cg18786123	chr12:47787067	NA	0.66	5.27	0.31	2.88e-7	Metabolite levels (HVA/5-HIAA ratio);
CESC	cis	rs1801251	1.000	rs6761324	chr2:233582793	T/G	cg25237894	chr2:233734115	C2orf82	0.51	8.57	0.47	8.75e-16	Coronary artery disease;
CESC	cis	rs798554	0.660	rs798480	chr7:2805597	G/T	cg09658497	chr7:2847517	GNA12	-0.35	-5.13	-0.3	5.56e-7	Height;
CESC	cis	rs385076	0.502	rs13013695	chr2:32391231	G/A	cg02381751	chr2:32503542	YIPF4	-0.56	-6.47	-0.37	4.63e-10	Interleukin-18 levels;
CESC	cis	rs977987	0.778	rs35214308	chr16:75476088	C/T	cg03315344	chr16:75512273	CHST6	0.43	6.13	0.35	3.23e-9	Dupuytren's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24327541	chr19:8570921	NA	0.6	7.55	0.42	7.05e-13	Gut microbiome composition (summer);
CESC	cis	rs4332037	0.508	rs56758848	chr7:1868727	A/G	cg23422044	chr7:1970798	MAD1L1	-0.51	-5.12	-0.3	5.76e-7	Bipolar disorder;
CESC	cis	rs1862618	0.853	rs252909	chr5:56121131	T/C	cg18230493	chr5:56204884	C5orf35	-0.72	-8.57	-0.47	8.6e-16	Initial pursuit acceleration;
CESC	cis	rs2485892	0.553	rs2494191	chr1:210346053	G/C	cg22029157	chr1:209979665	IRF6	0.51	5.73	0.33	2.76e-8	Manic episodes in bipolar disorder;
CESC	trans	rs61931739	0.534	rs11052957	chr12:33995354	G/A	cg26384229	chr12:38710491	ALG10B	0.48	6.63	0.38	1.9e-10	Morning vs. evening chronotype;
CESC	cis	rs7940866	0.801	rs10894288	chr11:130808679	T/C	cg12179176	chr11:130786555	SNX19	0.65	10.04	0.52	2.6e-20	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17854747	chr18:29672535	RNF138	-0.54	-6.14	-0.35	2.99e-9	Gut microbiome composition (summer);
CESC	cis	rs7647973	0.710	rs12637313	chr3:49645458	A/G	cg13072238	chr3:49761600	GMPPB	-0.51	-5.98	-0.35	7.05e-9	Menarche (age at onset);
CESC	cis	rs2836974	0.897	rs2836929	chr21:40543811	T/C	cg11644478	chr21:40555479	PSMG1	1.02	16.64	0.71	4.59e-43	Cognitive function;
CESC	cis	rs2573652	1.000	rs2581363	chr15:100513364	G/A	cg09918751	chr15:100517450	ADAMTS17	-0.38	-7.42	-0.41	1.55e-12	Height;
CESC	cis	rs2836974	0.836	rs8129355	chr21:40579869	A/G	cg11890956	chr21:40555474	PSMG1	1.18	21.95	0.8	1.42e-61	Cognitive function;
CESC	cis	rs2952156	0.684	rs11658786	chr17:37815899	G/A	cg20243544	chr17:37824526	PNMT	0.65	8.83	0.48	1.46e-16	Asthma;
CESC	cis	rs2279817	0.863	rs12139706	chr1:18026435	G/A	cg21791023	chr1:18019539	ARHGEF10L	0.52	7.77	0.43	1.7e-13	Neuroticism;
CESC	cis	rs6580649	1.000	rs9805048	chr12:48403692	C/T	cg24011408	chr12:48396354	COL2A1	0.38	5.11	0.3	6.28e-7	Lung cancer;
CESC	cis	rs9486715	0.929	rs7775721	chr6:97056979	C/T	cg18709589	chr6:96969512	KIAA0776	-0.44	-6.1	-0.35	3.76e-9	Headache;
CESC	cis	rs2243480	1.000	rs2462569	chr7:65474846	C/T	cg25894440	chr7:65020034	NA	0.57	5.04	0.3	8.44e-7	Diabetic kidney disease;
CESC	cis	rs3008870	1.000	rs2985824	chr1:67410171	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-1.05	-15.15	-0.68	9.32e-38	Lymphocyte percentage of white cells;
CESC	cis	rs12413816	0.818	rs35567671	chr10:13769722	C/A	cg16485048	chr10:13749193	FRMD4A	0.47	5.85	0.34	1.42e-8	Red cell distribution width;
CESC	cis	rs1005277	0.565	rs2474565	chr10:38380828	A/G	cg00409905	chr10:38381863	ZNF37A	-0.45	-6.0	-0.35	6.61e-9	Extrinsic epigenetic age acceleration;
CESC	trans	rs9858542	0.953	rs9811982	chr3:49624377	A/C	cg21659725	chr3:3221576	CRBN	-0.53	-6.41	-0.37	6.75e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs2404602	0.735	rs2436994	chr15:76801063	G/C	cg23625390	chr15:77176239	SCAPER	-0.37	-5.16	-0.3	4.73e-7	Blood metabolite levels;
CESC	cis	rs2204008	0.774	rs11615665	chr12:38328162	T/A	cg13010199	chr12:38710504	ALG10B	0.47	6.0	0.35	6.62e-9	Bladder cancer;
CESC	cis	rs6893300	0.961	rs11741570	chr5:179208910	A/G	cg14593053	chr5:179126677	CANX	-0.52	-5.79	-0.33	2.03e-8	Resting heart rate;
CESC	cis	rs9488822	0.651	rs3798228	chr6:116321156	T/C	cg15226275	chr6:116381976	FRK	0.25	6.22	0.36	1.94e-9	Cholesterol, total;LDL cholesterol;
CESC	cis	rs875971	0.545	rs73136346	chr7:65566082	A/G	cg11764359	chr7:65958608	NA	-0.81	-9.0	-0.48	4.57e-17	Aortic root size;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg07236925	chr15:91498269	RCCD1	-0.46	-6.03	-0.35	5.56e-9	Height;
CESC	cis	rs847577	0.609	rs11763970	chr7:97817321	A/G	cg24562669	chr7:97807699	LMTK2	0.83	13.76	0.65	7.13e-33	Breast cancer;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg26869362	chr11:105947257	KBTBD3;AASDHPPT	0.36	6.07	0.35	4.46e-9	Gambling;
CESC	cis	rs7552404	0.924	rs114752222	chr1:76180878	C/T	cg22875332	chr1:76189707	ACADM	0.7	9.26	0.49	7.34e-18	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs11264213	0.786	rs72659696	chr1:36313665	G/A	cg27506609	chr1:36549197	TEKT2	0.65	5.49	0.32	9.31e-8	Schizophrenia;
CESC	cis	rs8114671	0.562	rs6120758	chr20:33492523	C/T	cg24642439	chr20:33292090	TP53INP2	0.43	5.19	0.3	4.19e-7	Height;
CESC	cis	rs909674	0.818	rs7364148	chr22:39842165	T/C	cg11247378	chr22:39784982	NA	-0.63	-8.59	-0.47	7.61e-16	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs367943	0.634	rs2195377	chr5:112973620	G/A	cg12552261	chr5:112820674	MCC	0.44	5.63	0.33	4.63e-8	Type 2 diabetes;
CESC	cis	rs2742234	0.541	rs10899786	chr10:43744583	G/A	cg15436174	chr10:43711423	RASGEF1A	0.46	5.33	0.31	2.14e-7	Hirschsprung disease;
CESC	cis	rs34172651	0.583	rs200541	chr16:24733141	A/G	cg06028605	chr16:24865363	SLC5A11	-0.56	-7.83	-0.43	1.2e-13	Intelligence (multi-trait analysis);
CESC	cis	rs36051895	0.632	rs12344116	chr9:5142216	G/A	cg02405213	chr9:5042618	JAK2	-0.5	-6.27	-0.36	1.49e-9	Pediatric autoimmune diseases;
CESC	cis	rs2836974	0.897	rs4817996	chr21:40525759	G/C	cg11644478	chr21:40555479	PSMG1	1.04	17.8	0.74	3.62e-47	Cognitive function;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24327397	chr15:83478411	WHAMM	0.63	7.19	0.4	6.68e-12	Gut microbiome composition (summer);
CESC	cis	rs1790761	0.692	rs10896179	chr11:67316928	C/A	cg24690094	chr11:67383802	NA	0.36	6.01	0.35	6.22e-9	Mean corpuscular volume;
CESC	cis	rs61931739	0.500	rs11053273	chr12:34547255	C/T	cg19457237	chr12:34500585	NA	-0.37	-5.08	-0.3	6.97e-7	Morning vs. evening chronotype;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg08538778	chr1:115212897	DENND2C	0.42	6.24	0.36	1.71e-9	Systemic lupus erythematosus;
CESC	cis	rs12956009	0.583	rs12965907	chr18:44888455	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.51	6.59	0.38	2.42e-10	Educational attainment (years of education);
CESC	cis	rs8062405	1.000	rs2008514	chr16:28825605	A/G	cg08761264	chr16:28874980	SH2B1	0.46	5.72	0.33	2.85e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs1915146	0.967	rs7086481	chr10:126844523	A/T	cg05090351	chr10:126851162	NA	-0.77	-13.26	-0.63	3.94e-31	Menarche (age at onset);
CESC	cis	rs897984	0.759	rs13708	chr16:31000809	G/A	cg00531865	chr16:30841666	NA	0.5	6.87	0.39	4.7e-11	Dementia with Lewy bodies;
CESC	cis	rs12347191	0.500	rs907580	chr9:100622597	T/C	cg13688889	chr9:100608707	NA	-0.89	-13.0	-0.62	3.11e-30	Orofacial clefts;
CESC	trans	rs11098499	0.618	rs35265692	chr4:120325135	T/C	cg25214090	chr10:38739885	LOC399744	0.7	9.6	0.51	6.27e-19	Corneal astigmatism;
CESC	cis	rs863345	0.604	rs59427353	chr1:158500621	A/C	cg12129480	chr1:158549410	OR10X1	-0.34	-6.76	-0.38	8.6e-11	Pneumococcal bacteremia;
CESC	cis	rs9322193	0.923	rs9968911	chr6:149978555	A/T	cg13206674	chr6:150067644	NUP43	0.45	6.43	0.37	5.79e-10	Lung cancer;
CESC	cis	rs1348850	0.526	rs6723014	chr2:178410586	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.67	6.09	0.35	3.87e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs7084402	0.967	rs1365740	chr10:60277549	A/C	cg07615347	chr10:60278583	BICC1	-0.59	-9.45	-0.5	1.94e-18	Refractive error;
CESC	cis	rs7833986	0.534	rs17814089	chr8:56965563	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	-0.6	-7.45	-0.42	1.29e-12	Height;
CESC	cis	rs2243480	0.901	rs778687	chr7:65835819	G/A	cg12463550	chr7:65579703	CRCP	0.71	5.49	0.32	9.37e-8	Diabetic kidney disease;
CESC	cis	rs4523957	0.928	rs216180	chr17:2172416	C/G	cg16513277	chr17:2031491	SMG6	0.59	7.99	0.44	4.21e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs7666738	0.546	rs9993299	chr4:98815976	G/A	cg17366294	chr4:99064904	C4orf37	0.48	5.8	0.34	1.84e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2243480	0.708	rs35825036	chr7:65986502	T/C	cg12463550	chr7:65579703	CRCP	0.72	5.55	0.32	6.96e-8	Diabetic kidney disease;
CESC	cis	rs6732160	0.631	rs7557285	chr2:73442812	G/A	cg01422370	chr2:73384389	NA	0.43	7.28	0.41	3.72e-12	Intelligence (multi-trait analysis);
CESC	cis	rs12682352	0.602	rs11783966	chr8:8665147	A/G	cg17143192	chr8:8559678	CLDN23	-0.42	-5.07	-0.3	7.58e-7	Neuroticism;
CESC	cis	rs8072100	0.777	rs9914653	chr17:45537395	T/C	cg08085267	chr17:45401833	C17orf57	-0.55	-7.41	-0.41	1.68e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs8177253	0.665	rs9869257	chr3:133451412	G/T	cg18769074	chr3:133464867	TF	0.32	5.89	0.34	1.19e-8	Iron status biomarkers;
CESC	cis	rs2032447	0.869	rs2230655	chr6:26033506	A/G	cg03264133	chr6:25882463	NA	0.47	6.7	0.38	1.27e-10	Intelligence (multi-trait analysis);
CESC	cis	rs875971	0.862	rs6947339	chr7:65888470	T/C	cg10691866	chr7:65817282	TPST1	-0.33	-5.43	-0.32	1.3e-7	Aortic root size;
CESC	cis	rs7078219	0.505	rs6584281	chr10:101286480	A/G	cg09788492	chr10:101292477	NKX2-3	0.33	6.28	0.36	1.37e-9	Dental caries;
CESC	cis	rs1707322	0.963	rs4459051	chr1:46451203	A/G	cg06784218	chr1:46089804	CCDC17	0.33	5.63	0.33	4.7e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs36051895	0.626	rs10283564	chr9:5075628	C/G	cg02405213	chr9:5042618	JAK2	-0.49	-5.97	-0.34	7.79e-9	Pediatric autoimmune diseases;
CESC	cis	rs9911578	0.839	rs7208505	chr17:57187729	C/T	cg05425664	chr17:57184151	TRIM37	-0.49	-6.74	-0.38	1.01e-10	Intelligence (multi-trait analysis);
CESC	cis	rs1799949	1.000	rs2037076	chr17:41305883	G/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.45	6.26	0.36	1.57e-9	Menopause (age at onset);
CESC	cis	rs7412746	0.563	rs3768013	chr1:150815411	G/A	cg04414720	chr1:150670196	GOLPH3L	0.48	6.53	0.37	3.26e-10	Melanoma;
CESC	cis	rs6500602	0.727	rs11644481	chr16:4581002	T/G	cg08645402	chr16:4508243	NA	0.51	8.34	0.46	4.21e-15	Schizophrenia;
CESC	cis	rs11577318	0.853	rs4333841	chr1:26631927	T/C	cg00852783	chr1:26633632	UBXN11	0.5	6.99	0.39	2.17e-11	Granulocyte percentage of myeloid white cells;
CESC	cis	rs10504229	0.683	rs2101864	chr8:58113226	C/T	cg21724239	chr8:58056113	NA	0.58	5.93	0.34	9.45e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs13102973	0.965	rs10434072	chr4:135867883	C/T	cg14419869	chr4:135874104	NA	-0.4	-6.29	-0.36	1.32e-9	Subjective well-being;
CESC	cis	rs6736093	1.000	rs13006203	chr2:112661150	G/A	cg12686935	chr2:112915763	FBLN7	-0.42	-5.17	-0.3	4.56e-7	Coronary artery disease;
CESC	cis	rs6088580	0.634	rs4911153	chr20:32961547	C/T	cg06115741	chr20:33292138	TP53INP2	-0.45	-5.73	-0.33	2.67e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs910316	0.737	rs175424	chr14:75626257	T/C	cg11812906	chr14:75593930	NEK9	-0.79	-12.24	-0.6	1.36e-27	Height;
CESC	cis	rs765787	0.530	rs4331289	chr15:45515338	C/T	cg24006582	chr15:45444508	DUOX1	-0.58	-7.11	-0.4	1.11e-11	Uric acid levels;
CESC	cis	rs4964805	0.657	rs1866294	chr12:104186795	A/G	cg02344784	chr12:104178138	NT5DC3	0.46	6.57	0.37	2.73e-10	Attention deficit hyperactivity disorder;
CESC	cis	rs4713118	0.662	rs149946	chr6:27970031	A/C	cg20151795	chr6:28129481	ZNF389	-0.41	-5.2	-0.3	3.9e-7	Parkinson's disease;
CESC	cis	rs4853012	0.838	rs60705299	chr2:74345370	C/G	cg20891558	chr2:74357851	NA	0.81	12.0	0.59	8.82e-27	Gestational age at birth (maternal effect);
CESC	cis	rs3736485	0.966	rs10467924	chr15:51787579	A/G	cg08986416	chr15:51914746	DMXL2	-0.41	-5.3	-0.31	2.39e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs7927771	0.524	rs7124396	chr11:47787434	T/G	cg18512352	chr11:47633146	NA	-0.35	-5.47	-0.32	1.03e-7	Subjective well-being;
CESC	cis	rs2439831	1.000	rs537115	chr15:43729948	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.89	10.6	0.55	4.2e-22	Lung cancer in ever smokers;
CESC	cis	rs6460942	0.597	rs17448193	chr7:12525641	G/A	cg06484146	chr7:12443880	VWDE	-0.71	-7.69	-0.43	2.88e-13	Coronary artery disease;
CESC	cis	rs763121	0.925	rs4821815	chr22:39105707	G/A	cg06544989	chr22:39130855	UNC84B	0.54	10.36	0.54	2.52e-21	Menopause (age at onset);
CESC	cis	rs10751667	1.000	rs7395632	chr11:958789	C/T	cg01483505	chr11:975446	AP2A2	-0.38	-5.16	-0.3	4.88e-7	Alzheimer's disease (late onset);
CESC	cis	rs8180040	0.966	rs807932	chr3:47354241	C/T	cg27129171	chr3:47204927	SETD2	0.66	10.1	0.53	1.7e-20	Colorectal cancer;
CESC	cis	rs11958404	0.860	rs72818136	chr5:157462866	C/T	cg05962755	chr5:157440814	NA	0.62	7.21	0.4	5.94e-12	IgG glycosylation;
CESC	cis	rs12530845	1.000	rs78186690	chr7:135334991	G/C	cg23117316	chr7:135346802	PL-5283	-0.4	-5.15	-0.3	4.98e-7	Red blood cell traits;
CESC	cis	rs7216064	1.000	rs12600941	chr17:65918807	A/G	cg07042672	chr17:66097459	LOC651250	-0.51	-5.31	-0.31	2.36e-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs9910055	0.550	rs113844752	chr17:42297631	C/A	cg19774624	chr17:42201019	HDAC5	-0.46	-5.9	-0.34	1.08e-8	Total body bone mineral density;
CESC	cis	rs6582630	0.502	rs8186661	chr12:38380781	G/A	cg26384229	chr12:38710491	ALG10B	0.73	10.65	0.55	2.87e-22	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs9640161	0.789	rs10282458	chr7:150045302	C/T	cg17279839	chr7:150038598	RARRES2	0.46	5.65	0.33	4.15e-8	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs6500395	0.962	rs1564979	chr16:48647017	C/A	cg04672837	chr16:48644449	N4BP1	0.47	5.57	0.32	6.4e-8	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs56104184	0.723	rs73063515	chr19:49407715	C/T	cg21252483	chr19:49399788	TULP2	-0.52	-5.72	-0.33	2.94e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	cis	rs9837602	0.938	rs1017968	chr3:99787011	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.5	7.15	0.4	8.2e-12	Breast cancer;
CESC	cis	rs801193	1.000	rs4717310	chr7:66161007	C/T	cg06456125	chr7:65229604	NA	0.39	5.05	0.3	8.06e-7	Aortic root size;
CESC	cis	rs1348850	0.526	rs935426	chr2:178369433	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.68	6.17	0.35	2.52e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs3825932	0.659	rs4778724	chr15:79238406	C/T	cg25744700	chr15:79237217	CTSH	0.49	6.4	0.37	7.01e-10	Type 1 diabetes;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg01662158	chr6:156030265	NA	0.38	6.0	0.35	6.47e-9	Fibrinogen levels;
CESC	cis	rs4713118	0.615	rs9295747	chr6:27736993	G/T	cg17221315	chr6:27791827	HIST1H4J	-0.45	-6.21	-0.36	2.07e-9	Parkinson's disease;
CESC	cis	rs66782572	1	rs66782572	chr3:52567617	A/G	cg18337363	chr3:52569053	NT5DC2	0.33	6.42	0.37	6.27e-10	Hemoglobin concentration;
CESC	cis	rs17021463	0.726	rs62320444	chr4:95261251	C/T	cg11021082	chr4:95130006	SMARCAD1	0.51	7.58	0.42	5.93e-13	Testicular germ cell tumor;
CESC	cis	rs7520050	0.807	rs3013594	chr1:46138000	T/C	cg24296786	chr1:45957014	TESK2	-0.46	-5.68	-0.33	3.5e-8	Red blood cell count;Reticulocyte count;
CESC	trans	rs57221529	0.713	rs72703072	chr5:590626	A/G	cg25482853	chr8:67687455	SGK3	1.0	10.02	0.52	2.99e-20	Lung disease severity in cystic fibrosis;
CESC	cis	rs2075371	1.000	rs2504	chr7:133979545	A/T	cg11752832	chr7:134001865	SLC35B4	0.54	7.02	0.4	1.91e-11	Mean platelet volume;
CESC	cis	rs10979	1.000	rs6905264	chr6:143894378	A/G	cg25407410	chr6:143891975	LOC285740	-0.61	-9.2	-0.49	1.13e-17	Hypospadias;
CESC	cis	rs9894429	0.682	rs7406360	chr17:79591545	G/A	cg18240062	chr17:79603768	NPLOC4	0.9	13.2	0.63	6.66e-31	Eye color traits;
CESC	cis	rs2408955	0.521	rs10875753	chr12:48557141	C/T	cg24011408	chr12:48396354	COL2A1	0.48	7.34	0.41	2.63e-12	Glycated hemoglobin levels;
CESC	cis	rs7666738	0.830	rs7673880	chr4:99057262	A/G	cg05340658	chr4:99064831	C4orf37	0.82	12.66	0.61	4.76e-29	Colonoscopy-negative controls vs population controls;
CESC	cis	rs12973672	0.812	rs2280745	chr19:35756178	T/C	cg12095397	chr19:35769544	USF2	0.5	6.01	0.35	6.19e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs10504229	0.645	rs56670121	chr8:58138872	C/T	cg22535103	chr8:58192502	C8orf71	-0.8	-9.09	-0.49	2.46e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs801193	0.569	rs2707824	chr7:66189243	A/G	cg18876405	chr7:65276391	NA	0.45	6.09	0.35	3.92e-9	Aortic root size;
CESC	cis	rs5753618	0.504	rs9606846	chr22:31897571	C/T	cg02404636	chr22:31891804	SFI1	0.42	5.7	0.33	3.25e-8	Colorectal cancer;
CESC	cis	rs8060686	0.920	rs12448923	chr16:67839128	C/T	cg26727032	chr16:67993705	SLC12A4	-0.58	-6.26	-0.36	1.51e-9	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs208520	1.000	rs208535	chr6:66962286	G/A	cg07460842	chr6:66804631	NA	-0.9	-10.34	-0.54	2.79e-21	Exhaled nitric oxide output;
CESC	cis	rs2836974	0.666	rs11910705	chr21:40685604	C/T	cg11890956	chr21:40555474	PSMG1	-0.94	-14.78	-0.67	1.79e-36	Cognitive function;
CESC	cis	rs6502050	0.764	rs28676462	chr17:80105100	G/C	cg23985595	chr17:80112537	CCDC57	-0.42	-6.57	-0.37	2.72e-10	Life satisfaction;
CESC	cis	rs79349575	0.594	rs1985785	chr17:46967788	T/C	cg16584676	chr17:46985605	UBE2Z	0.55	6.69	0.38	1.29e-10	Type 2 diabetes;
CESC	cis	rs853679	0.517	rs6922063	chr6:28094366	G/A	cg17949981	chr6:28129498	ZNF389	0.48	6.14	0.35	3.05e-9	Depression;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg10822314	chr22:43547440	TSPO	-0.46	-6.46	-0.37	4.9e-10	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs2730245	0.527	rs62476462	chr7:158686619	A/G	cg24397884	chr7:158709396	WDR60	0.85	8.84	0.48	1.41e-16	Height;
CESC	cis	rs753778	0.962	rs2043422	chr8:142236337	C/T	cg23750338	chr8:142222470	SLC45A4	0.36	5.18	0.3	4.41e-7	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	cis	rs2274273	0.837	rs6573010	chr14:55721592	T/C	cg04306507	chr14:55594613	LGALS3	0.29	5.83	0.34	1.65e-8	Protein biomarker;
CESC	cis	rs6912958	0.559	rs242287	chr6:88071825	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.34	5.41	0.32	1.39e-7	Monocyte percentage of white cells;
CESC	cis	rs9926296	0.568	rs886950	chr16:89836872	T/C	cg21285383	chr16:89894308	SPIRE2	0.32	5.77	0.33	2.15e-8	Vitiligo;
CESC	cis	rs2599510	0.703	rs762023	chr2:32713170	G/A	cg02381751	chr2:32503542	YIPF4	0.48	6.09	0.35	3.94e-9	Interleukin-18 levels;
CESC	cis	rs9894429	1.000	rs9894429	chr17:79596811	C/T	cg18240062	chr17:79603768	NPLOC4	0.73	10.27	0.53	4.66e-21	Eye color traits;
CESC	cis	rs801193	1.000	rs3800812	chr7:66223461	T/C	cg14393609	chr7:65229607	NA	0.48	6.38	0.37	7.71e-10	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10058540	chr12:57941150	DCTN2	-0.63	-7.47	-0.42	1.16e-12	Gut microbiome composition (summer);
CESC	cis	rs367943	0.965	rs458044	chr5:112797779	A/G	cg12552261	chr5:112820674	MCC	-0.62	-7.66	-0.43	3.5e-13	Type 2 diabetes;
CESC	cis	rs365132	0.870	rs2454949	chr5:176466011	G/A	cg16309518	chr5:176445507	NA	-0.42	-6.16	-0.35	2.75e-9	Menarche and menopause (age at onset);Menopause (age at onset);
CESC	cis	rs17826219	0.706	rs9893922	chr17:29068425	T/C	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.79e-10	Body mass index;
CESC	cis	rs11203032	0.831	rs10430718	chr10:90937951	A/T	cg16672925	chr10:90967113	CH25H	0.72	7.18	0.4	7.03e-12	Heart failure;
CESC	cis	rs6952808	0.789	rs35729895	chr7:1885069	C/T	cg13880726	chr7:1868755	MAD1L1	0.54	7.25	0.41	4.45e-12	Bipolar disorder and schizophrenia;
CESC	cis	rs2576037	0.583	rs646128	chr18:44397691	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.77	12.94	0.62	5.09e-30	Personality dimensions;
CESC	cis	rs834811	0.831	rs1097147	chr7:135880446	C/T	cg01726295	chr7:135938950	NA	0.36	6.1	0.35	3.65e-9	Post-traumatic stress disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11065262	chr2:191878861	STAT1	0.55	6.1	0.35	3.66e-9	Gut microbiome composition (summer);
CESC	cis	rs7084402	0.934	rs1658441	chr10:60323021	G/C	cg07615347	chr10:60278583	BICC1	0.61	9.62	0.51	5.56e-19	Refractive error;
CESC	cis	rs12618769	0.652	rs3769698	chr2:99233894	T/C	cg10123293	chr2:99228465	UNC50	0.4	5.41	0.32	1.39e-7	Bipolar disorder;
CESC	cis	rs736408	0.609	rs13082960	chr3:52785168	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.49	6.99	0.39	2.22e-11	Bipolar disorder;
CESC	cis	rs4819052	0.851	rs10470247	chr21:46659018	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.89	13.04	0.63	2.35e-30	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs10870270	0.917	rs9971362	chr10:133790150	T/C	cg26149184	chr10:133730230	NA	0.38	5.12	0.3	5.86e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09175718	chr10:97453958	TCTN3	0.52	6.16	0.35	2.68e-9	Gut microbiome composition (summer);
CESC	cis	rs61776719	0.747	rs28428561	chr1:38434306	G/A	cg26528311	chr1:38462546	FHL3	-0.39	-6.35	-0.36	9.31e-10	Coronary artery disease;
CESC	cis	rs10899021	1.000	rs10899021	chr11:74338054	C/T	cg25880958	chr11:74394337	NA	0.71	7.68	0.43	3.15e-13	Response to metformin (IC50);
CESC	cis	rs13102973	0.965	rs4331828	chr4:135849100	C/G	cg14419869	chr4:135874104	NA	0.33	5.19	0.3	4.29e-7	Subjective well-being;
CESC	cis	rs4474465	0.850	rs7112872	chr11:78227396	C/A	cg27205649	chr11:78285834	NARS2	0.46	5.61	0.33	5.18e-8	Alzheimer's disease (survival time);
CESC	cis	rs1712517	0.566	rs7917388	chr10:105054963	C/T	cg04362960	chr10:104952993	NT5C2	-0.46	-5.55	-0.32	6.98e-8	Migraine;
CESC	cis	rs7188697	0.922	rs246196	chr16:58574253	T/C	cg21335942	chr16:58549945	SETD6	0.46	5.36	0.31	1.84e-7	QT interval;
CESC	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg11301795	chr4:187892539	NA	0.73	11.44	0.57	6.89e-25	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs7246760	0.609	rs57889827	chr19:9777459	T/C	cg02900749	chr2:68251473	NA	-0.85	-7.53	-0.42	8.04e-13	Pursuit maintenance gain;
CESC	cis	rs897984	0.572	rs4889526	chr16:31030344	C/A	cg02466173	chr16:30829666	NA	-0.38	-6.48	-0.37	4.36e-10	Dementia with Lewy bodies;
CESC	cis	rs34172651	0.874	rs200534	chr16:24752641	G/A	cg06028605	chr16:24865363	SLC5A11	-0.42	-6.28	-0.36	1.38e-9	Intelligence (multi-trait analysis);
CESC	cis	rs3741404	0.825	rs7111753	chr11:63942189	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.89	13.05	0.63	2.22e-30	Platelet count;
CESC	trans	rs11098499	0.874	rs12509054	chr4:120115075	A/C	cg25214090	chr10:38739885	LOC399744	0.61	8.04	0.44	2.91e-14	Corneal astigmatism;
CESC	cis	rs7017914	0.967	rs13274381	chr8:71765094	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.44	-5.56	-0.32	6.74e-8	Bone mineral density;
CESC	cis	rs7618915	0.501	rs12635140	chr3:52738165	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.54	-8.02	-0.44	3.42e-14	Bipolar disorder;
CESC	cis	rs78456975	0.527	rs72778003	chr2:1571487	G/A	cg26248373	chr2:1572462	NA	-0.57	-6.52	-0.37	3.58e-10	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs3136441	0.901	rs11039002	chr11:46857279	T/C	cg25783544	chr11:47291846	MADD	0.53	5.06	0.3	7.79e-7	HDL cholesterol;
CESC	cis	rs9611565	0.729	rs2413646	chr22:41906325	C/T	cg06481639	chr22:41940642	POLR3H	-0.64	-6.6	-0.38	2.21e-10	Vitiligo;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg08466385	chr6:18368294	NA	0.43	6.26	0.36	1.52e-9	Fibrinogen levels;
CESC	cis	rs6120849	0.707	rs6088690	chr20:33633326	A/G	cg24642439	chr20:33292090	TP53INP2	0.68	6.77	0.38	8.46e-11	Protein C levels;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg24824997	chr2:220507347	NA	-0.44	-6.09	-0.35	3.86e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs597539	0.616	rs631001	chr11:68642974	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.78	9.33	0.5	4.32e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs7666738	0.716	rs13136721	chr4:99085602	G/A	cg03467027	chr4:99064603	C4orf37	0.42	5.04	0.3	8.53e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg11494091	chr17:61959527	GH2	0.72	12.33	0.6	6.37e-28	Prudent dietary pattern;
CESC	cis	rs34779708	0.931	rs35317849	chr10:35285721	C/A	cg03585969	chr10:35415529	CREM	0.77	10.22	0.53	6.85e-21	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs6496667	0.509	rs6496677	chr15:90990358	A/G	cg10434728	chr15:90938212	IQGAP1	0.3	5.26	0.31	2.94e-7	Rheumatoid arthritis;
CESC	cis	rs7044106	0.762	rs13291660	chr9:123392748	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.66	9.27	0.49	6.93e-18	Hip circumference adjusted for BMI;
CESC	cis	rs9733	0.715	rs7534124	chr1:150739073	C/T	cg18016565	chr1:150552671	MCL1	-0.36	-5.95	-0.34	8.45e-9	Tonsillectomy;
CESC	cis	rs10504073	0.584	rs11778863	chr8:49954893	C/T	cg00325661	chr8:49890786	NA	0.59	8.9	0.48	9.3e-17	Blood metabolite ratios;
CESC	cis	rs9467711	0.606	rs9366655	chr6:26377385	C/G	cg14345882	chr6:26364793	BTN3A2	0.6	6.57	0.37	2.64e-10	Autism spectrum disorder or schizophrenia;
CESC	cis	rs6502050	0.835	rs10163496	chr17:80110867	G/A	cg11859384	chr17:80120422	CCDC57	-0.39	-5.31	-0.31	2.34e-7	Life satisfaction;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22660933	chr17:46608355	HOXB1	-0.56	-6.36	-0.36	8.86e-10	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19037388	chr19:19774945	ATP13A1	-0.57	-6.49	-0.37	4.09e-10	Gut microbiome composition (summer);
CESC	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.38	-5.1	-0.3	6.37e-7	Longevity;Endometriosis;
CESC	cis	rs7666738	0.830	rs1593570	chr4:99017058	T/C	cg05340658	chr4:99064831	C4orf37	0.82	13.05	0.63	2.08e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs992157	0.710	rs10167446	chr2:219056866	A/G	cg00012203	chr2:219082015	ARPC2	0.82	11.67	0.58	1.18e-25	Colorectal cancer;
CESC	cis	rs9916302	0.904	rs7503705	chr17:37669704	A/G	cg07936489	chr17:37558343	FBXL20	-0.81	-11.78	-0.59	4.78e-26	Glomerular filtration rate (creatinine);
CESC	cis	rs3820928	0.874	rs10202239	chr2:227901819	C/T	cg05526886	chr2:227700861	RHBDD1	-0.45	-5.7	-0.33	3.25e-8	Pulmonary function;
CESC	cis	rs5758659	1.000	rs5758660	chr22:42623718	C/A	cg15557168	chr22:42548783	NA	-0.48	-7.65	-0.43	3.74e-13	Cognitive function;
CESC	cis	rs3825932	0.778	rs1036938	chr15:79237247	C/G	cg25744700	chr15:79237217	CTSH	0.49	6.46	0.37	5.06e-10	Type 1 diabetes;
CESC	cis	rs9611565	0.649	rs202666	chr22:41814719	T/C	cg06481639	chr22:41940642	POLR3H	0.61	6.41	0.37	6.55e-10	Vitiligo;
CESC	cis	rs6951245	0.744	rs10275401	chr7:1213943	A/C	cg22907277	chr7:1156413	C7orf50	0.45	5.03	0.3	9.22e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs17039065	0.920	rs7671977	chr4:109435999	T/C	cg27151770	chr16:49620536	ZNF423	-0.51	-6.21	-0.36	2.09e-9	Gut microbiome composition (summer);
CESC	cis	rs4660306	0.677	rs781060	chr1:45934166	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.47	5.2	0.3	3.91e-7	Homocysteine levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07944278	chr6:35699425	LOC285847	0.57	6.47	0.37	4.67e-10	Gut microbiome composition (summer);
CESC	cis	rs8072100	0.869	rs4439799	chr17:45781599	C/T	cg08085267	chr17:45401833	C17orf57	-0.39	-5.05	-0.3	8.17e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs1055129	0.560	rs9891076	chr17:73911715	C/T	cg08125733	chr17:73851984	WBP2	0.52	7.12	0.4	9.85e-12	White matter hyperintensity burden;
CESC	cis	rs9549367	0.826	rs1885688	chr13:113894236	G/T	cg18105134	chr13:113819100	PROZ	-0.69	-8.63	-0.47	5.71e-16	Platelet distribution width;
CESC	cis	rs477895	0.838	rs72922039	chr11:64013116	A/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.9	10.01	0.52	3.13e-20	Mean platelet volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10582639	chr11:121526840	NA	0.59	6.55	0.37	2.94e-10	Gut microbiome composition (summer);
CESC	cis	rs2011503	1.000	rs2060275	chr19:19536208	G/C	cg11584989	chr19:19387371	SF4	0.62	7.23	0.41	5.15e-12	Bipolar disorder;
CESC	cis	rs4561483	0.801	rs33649	chr16:11979608	G/C	cg08843971	chr16:11963173	GSPT1	-0.54	-7.99	-0.44	4.22e-14	Testicular germ cell tumor;
CESC	cis	rs7666738	0.791	rs4699324	chr4:98967496	G/A	cg03467027	chr4:99064603	C4orf37	0.43	5.47	0.32	1.03e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs668210	0.643	rs549334	chr11:65774659	C/G	cg02202077	chr11:65769826	EIF1AD;BANF1	0.68	7.46	0.42	1.26e-12	Cerebrospinal fluid biomarker levels;
CESC	cis	rs6430585	0.528	rs6711493	chr2:136692553	A/G	cg07169764	chr2:136633963	MCM6	1.11	16.72	0.72	2.51e-43	Corneal structure;
CESC	cis	rs7086627	0.515	rs10887901	chr10:82210581	G/A	cg00277334	chr10:82204260	NA	-0.91	-15.99	-0.7	9.29e-41	Post bronchodilator FEV1;
CESC	cis	rs2075371	0.829	rs11770521	chr7:133936251	A/C	cg00033643	chr7:134001901	SLC35B4	0.42	5.34	0.31	1.97e-7	Mean platelet volume;
CESC	cis	rs7937682	0.924	rs1784782	chr11:111525764	A/C	cg22437258	chr11:111473054	SIK2	0.7	9.35	0.5	3.83e-18	Primary sclerosing cholangitis;
CESC	cis	rs1707322	0.721	rs4431884	chr1:46101323	C/T	cg03146154	chr1:46216737	IPP	0.76	10.71	0.55	1.75e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs13333054	1.000	rs12232384	chr16:86009760	A/C	cg04454285	chr16:86016317	NA	-0.42	-5.11	-0.3	6.08e-7	Multiple sclerosis;
CESC	cis	rs887829	0.569	rs4663333	chr2:234655303	G/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.48	-6.25	-0.36	1.6e-9	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CESC	cis	rs9894429	0.646	rs6565612	chr17:79602820	C/T	cg18240062	chr17:79603768	NPLOC4	-0.55	-7.17	-0.4	7.36e-12	Eye color traits;
CESC	cis	rs3857536	0.740	rs7773577	chr6:66892124	G/A	cg07460842	chr6:66804631	NA	-0.4	-5.23	-0.31	3.47e-7	Blood trace element (Cu levels);
CESC	cis	rs798766	1.000	rs798766	chr4:1734239	C/T	cg10756475	chr4:1757242	NA	-0.44	-5.74	-0.33	2.57e-8	Bladder cancer;Urinary bladder cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15003434	chr9:136202985	SURF6	0.51	6.02	0.35	5.93e-9	Gut microbiome composition (summer);
CESC	cis	rs7208859	0.623	rs73271869	chr17:29152221	G/A	cg13385521	chr17:29058706	SUZ12P	0.75	6.0	0.35	6.29e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg03188948	chr7:1209495	NA	0.71	7.06	0.4	1.5e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2243480	0.708	rs35825036	chr7:65986502	T/C	cg13147721	chr7:65941812	NA	-0.95	-8.91	-0.48	8.34e-17	Diabetic kidney disease;
CESC	cis	rs13385	0.769	rs7704262	chr5:139611043	T/A	cg26211634	chr5:139558579	C5orf32	0.47	5.19	0.3	4.23e-7	Atrial fibrillation;
CESC	cis	rs1514687	0.534	rs58529796	chr2:1473693	C/T	cg13703866	chr2:1479523	TPO	-0.77	-5.24	-0.31	3.35e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg19871361	chr10:11505280	USP6NL	0.46	6.38	0.36	7.68e-10	Fibrinogen levels;
CESC	cis	rs853679	0.550	rs1233701	chr6:28168726	C/G	cg12963246	chr6:28129442	ZNF389	-0.52	-7.21	-0.4	5.96e-12	Depression;
CESC	cis	rs896854	0.654	rs13281625	chr8:95972738	T/C	cg09323728	chr8:95962352	TP53INP1	-0.39	-8.53	-0.46	1.11e-15	Type 2 diabetes;
CESC	cis	rs1218582	0.772	rs10796935	chr1:154891363	G/T	cg06221963	chr1:154839813	KCNN3	-0.66	-11.27	-0.57	2.42e-24	Prostate cancer;
CESC	cis	rs7762018	0.607	rs77972667	chr6:170130456	G/C	cg19338460	chr6:170058176	WDR27	-1.05	-7.36	-0.41	2.35e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs11864453	0.713	rs6680	chr16:72146570	T/C	cg16558253	chr16:72132732	DHX38	-0.55	-8.77	-0.47	2.24e-16	Fibrinogen levels;
CESC	cis	rs1707322	0.717	rs2275086	chr1:46085879	C/G	cg03146154	chr1:46216737	IPP	-0.78	-10.75	-0.55	1.29e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs7618501	0.699	rs1317154	chr3:49910084	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.48	6.67	0.38	1.47e-10	Intelligence (multi-trait analysis);
CESC	trans	rs9325144	0.534	rs1843887	chr12:38692380	T/C	cg23762105	chr12:34175262	ALG10	-0.46	-6.22	-0.36	1.88e-9	Morning vs. evening chronotype;
CESC	cis	rs3213545	0.700	rs2260445	chr12:121468863	C/A	cg02403541	chr12:121454288	C12orf43	0.69	9.85	0.52	1.05e-19	Subjective well-being;Cardiovascular disease risk factors;
CESC	cis	rs2282802	0.685	rs11750229	chr5:139559014	T/G	cg26211634	chr5:139558579	C5orf32	-0.49	-7.05	-0.4	1.55e-11	Intelligence (multi-trait analysis);
CESC	trans	rs11098499	0.708	rs10005237	chr4:120237897	T/C	cg25214090	chr10:38739885	LOC399744	0.61	8.51	0.46	1.33e-15	Corneal astigmatism;
CESC	cis	rs35110281	0.641	rs4819283	chr21:45083011	T/A	cg04455712	chr21:45112962	RRP1B	0.5	7.86	0.43	9.62e-14	Mean corpuscular volume;
CESC	cis	rs921968	0.541	rs523937	chr2:219437596	G/C	cg02176678	chr2:219576539	TTLL4	0.5	8.89	0.48	9.82e-17	Mean corpuscular hemoglobin concentration;
CESC	cis	rs7833790	0.963	rs1451997	chr8:82774053	A/T	cg02079420	chr8:82753780	SNX16	-0.57	-7.89	-0.44	7.79e-14	Diastolic blood pressure;
CESC	cis	rs2361718	0.500	rs4889818	chr17:78085228	A/G	cg27427491	chr17:78079615	GAA	-0.42	-6.06	-0.35	4.65e-9	Yeast infection;
CESC	cis	rs4906332	1.000	rs2065015	chr14:103904061	G/T	cg09975044	chr14:104007538	NA	-0.47	-6.43	-0.37	5.95e-10	Coronary artery disease;
CESC	cis	rs9322193	0.923	rs11155670	chr6:149966128	C/G	cg07701084	chr6:150067640	NUP43	0.45	6.31	0.36	1.16e-9	Lung cancer;
CESC	trans	rs17685	0.753	rs8200	chr7:75696606	C/G	cg19862616	chr7:65841803	NCRNA00174	-0.86	-12.73	-0.62	2.68e-29	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs10504229	1.000	rs60651159	chr8:58174074	T/C	cg14926445	chr8:58193284	C8orf71	-0.51	-5.47	-0.32	1.03e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs796364	0.951	rs7586284	chr2:201068002	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.61	5.74	0.33	2.56e-8	Schizophrenia;
CESC	cis	rs9581857	0.579	rs77187836	chr13:27998646	C/A	cg01674679	chr13:27998804	GTF3A	-0.66	-5.47	-0.32	1.02e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg24791880	chr19:19616215	GATAD2A	0.43	6.1	0.35	3.67e-9	Fibrinogen levels;
CESC	cis	rs798554	0.757	rs1713919	chr7:2864706	C/A	cg09658497	chr7:2847517	GNA12	-0.41	-5.78	-0.33	2.07e-8	Height;
CESC	cis	rs10870270	1.000	rs4880263	chr10:133787629	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.58	-7.38	-0.41	2.03e-12	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs2576037	0.507	rs2571019	chr18:44585287	A/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.46	6.12	0.35	3.43e-9	Personality dimensions;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg19250579	chr3:75487529	NA	-0.41	-6.34	-0.36	9.6e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs6502050	0.731	rs4789730	chr17:80145983	T/A	cg11859384	chr17:80120422	CCDC57	-0.38	-5.25	-0.31	3.08e-7	Life satisfaction;
CESC	trans	rs163030	0.902	rs367188	chr5:76737930	A/G	cg26150533	chr8:82396069	FABP4	-0.39	-6.0	-0.35	6.49e-9	Caudate nucleus volume;
CESC	cis	rs9916302	0.718	rs7219909	chr17:37706243	C/T	cg15445000	chr17:37608096	MED1	0.42	6.83	0.39	5.67e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs7617773	0.563	rs62263035	chr3:48391569	C/T	cg11946769	chr3:48343235	NME6	0.66	8.41	0.46	2.65e-15	Coronary artery disease;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg14666473	chr12:27091463	FGFR1OP2;C12orf11	-0.37	-6.49	-0.37	4.15e-10	Gambling;
CESC	cis	rs2933343	0.679	rs789221	chr3:128591625	A/G	cg24203234	chr3:128598194	ACAD9	0.39	5.22	0.31	3.62e-7	IgG glycosylation;
CESC	cis	rs9399401	0.593	rs262117	chr6:142807093	G/A	cg03128060	chr6:142623767	GPR126	0.33	5.39	0.31	1.56e-7	Chronic obstructive pulmonary disease;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg23325670	chr19:17337031	OCEL1	-0.45	-6.11	-0.35	3.52e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs8114671	0.562	rs6087653	chr20:33522054	T/C	cg06115741	chr20:33292138	TP53INP2	0.48	5.79	0.34	1.97e-8	Height;
CESC	trans	rs7947523	0.813	rs4999940	chr11:80942337	C/T	cg09378111	chr2:211036309	C2orf67	0.5	6.61	0.38	2.16e-10	Emphysema imaging phenotypes;
CESC	cis	rs4665809	1.000	rs6709595	chr2:26259885	A/G	cg26314531	chr2:26401878	FAM59B	-0.6	-6.79	-0.38	7.45e-11	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.830	rs60994860	chr4:99046753	G/A	cg05340658	chr4:99064831	C4orf37	0.82	12.88	0.62	8.44e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1941023	0.584	rs950803	chr11:60152563	A/T	cg08716584	chr11:60157161	MS4A7	0.57	9.4	0.5	2.61e-18	Congenital heart disease (maternal effect);
CESC	cis	rs12900413	0.687	rs6496602	chr15:90317797	A/G	cg24249390	chr15:90295951	MESP1	-0.43	-5.98	-0.34	7.25e-9	Coronary artery aneurysm in Kawasaki disease;
CESC	cis	rs6912958	0.525	rs242262	chr6:88018057	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.73	10.23	0.53	6.27e-21	Monocyte percentage of white cells;
CESC	trans	rs2727020	0.729	rs10742932	chr11:49173234	T/C	cg03929089	chr4:120376271	NA	-0.77	-11.65	-0.58	1.32e-25	Coronary artery disease;
CESC	cis	rs1707322	0.963	rs11211229	chr1:46400517	A/C	cg06784218	chr1:46089804	CCDC17	0.33	5.63	0.33	4.7e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs875971	0.522	rs56028712	chr7:65466565	C/T	cg11987759	chr7:65425863	GUSB	-0.46	-6.3	-0.36	1.26e-9	Aortic root size;
CESC	cis	rs4843747	0.671	rs8062855	chr16:88106941	T/C	cg06915872	chr16:87998081	BANP	0.44	5.24	0.31	3.36e-7	Menopause (age at onset);
CESC	cis	rs10870270	0.830	rs10781571	chr10:133774316	G/C	cg08754478	chr10:133766260	PPP2R2D	-0.59	-7.61	-0.42	4.72e-13	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs4664308	1.000	rs62175515	chr2:160909524	A/T	cg03641300	chr2:160917029	PLA2R1	-0.68	-10.17	-0.53	9.82e-21	Idiopathic membranous nephropathy;
CESC	cis	rs9527	0.590	rs726010	chr10:104841977	C/T	cg04362960	chr10:104952993	NT5C2	0.44	5.6	0.33	5.24e-8	Arsenic metabolism;
CESC	cis	rs7568458	0.663	rs699664	chr2:85780536	A/G	cg02493740	chr2:85810744	VAMP5	0.6	9.39	0.5	2.97e-18	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CESC	cis	rs56804039	1.000	rs11777086	chr8:8384479	G/T	cg15556689	chr8:8085844	FLJ10661	-0.5	-5.36	-0.31	1.82e-7	Cervical cancer;
CESC	cis	rs854765	0.583	rs6502622	chr17:17834691	A/G	cg09796270	chr17:17721594	SREBF1	0.42	5.95	0.34	8.24e-9	Total body bone mineral density;
CESC	cis	rs709400	0.930	rs57447494	chr14:104034569	G/A	cg12935359	chr14:103987150	CKB	-0.49	-6.39	-0.37	7.55e-10	Body mass index;
CESC	cis	rs60843830	0.964	rs62114538	chr2:256116	G/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.77	10.08	0.53	1.92e-20	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs7618501	1.000	rs11716575	chr3:49744890	A/G	cg24308560	chr3:49941425	MST1R	0.5	6.94	0.39	3.08e-11	Intelligence (multi-trait analysis);
CESC	cis	rs8067545	0.578	rs62066870	chr17:20063758	A/C	cg13482628	chr17:19912719	NA	0.4	5.37	0.31	1.75e-7	Schizophrenia;
CESC	trans	rs687914	0.710	rs938662	chr2:45864578	A/G	cg00679716	chr14:23067188	ABHD4	0.63	6.45	0.37	5.29e-10	Diastolic blood pressure;
CESC	cis	rs894734	0.535	rs2366143	chr12:54323256	G/A	cg12374095	chr12:54320830	NA	-0.41	-5.85	-0.34	1.47e-8	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
CESC	cis	rs8072100	1.000	rs8065437	chr17:45721653	C/T	cg08085267	chr17:45401833	C17orf57	-0.43	-5.66	-0.33	3.85e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs909674	0.524	rs5750821	chr22:39825492	A/T	cg24399712	chr22:39784796	NA	-0.81	-11.1	-0.56	9.09e-24	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs36051895	0.632	rs12337481	chr9:5134599	T/G	cg02405213	chr9:5042618	JAK2	-0.47	-5.85	-0.34	1.42e-8	Pediatric autoimmune diseases;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04590956	chr2:70057467	GMCL1	0.56	7.29	0.41	3.66e-12	Gut microbiota (bacterial taxa);
CESC	cis	rs7089973	0.604	rs11196942	chr10:116596872	G/A	cg03647239	chr10:116582469	FAM160B1	0.42	5.13	0.3	5.5e-7	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg22897353	chr20:18548235	LOC388789	-0.46	-6.14	-0.35	3.04e-9	Asthma;
CESC	cis	rs6570726	0.516	rs9376932	chr6:145729490	T/C	cg23711669	chr6:146136114	FBXO30	0.51	6.48	0.37	4.35e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs910316	0.967	rs175502	chr14:75533679	A/G	cg11812906	chr14:75593930	NEK9	-0.88	-15.0	-0.68	3.17e-37	Height;
CESC	cis	rs3858526	0.959	rs10838795	chr11:5920721	A/G	cg05234568	chr11:5960015	NA	0.54	6.46	0.37	4.98e-10	DNA methylation (variation);
CESC	cis	rs1448094	0.809	rs11117103	chr12:86314431	C/T	cg02569458	chr12:86230093	RASSF9	0.36	5.12	0.3	6.01e-7	Major depressive disorder;
CESC	cis	rs7216064	0.773	rs11867618	chr17:65875587	G/A	cg12091567	chr17:66097778	LOC651250	-0.9	-8.15	-0.45	1.43e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	trans	rs3780486	0.505	rs1411609	chr9:33137303	C/T	cg04842962	chr6:43655489	MRPS18A	0.69	10.59	0.55	4.26e-22	IgG glycosylation;
CESC	cis	rs3785574	0.962	rs7219920	chr17:61811642	C/G	cg06420487	chr17:61919686	SMARCD2	0.47	5.66	0.33	3.87e-8	Height;
CESC	cis	rs4803468	1.000	rs9304593	chr19:41942875	A/C	cg09537434	chr19:41945824	ATP5SL	1.06	19.76	0.77	5e-54	Height;
CESC	cis	rs9916302	0.851	rs11078906	chr17:37662767	C/T	cg07936489	chr17:37558343	FBXL20	-0.82	-12.22	-0.6	1.6e-27	Glomerular filtration rate (creatinine);
CESC	cis	rs7666738	0.887	rs34509663	chr4:98982531	C/T	cg18180107	chr4:99064573	C4orf37	0.41	5.2	0.3	3.93e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs238295	0.602	rs6053458	chr20:5510185	G/T	cg24001556	chr20:5591874	RP5-1022P6.2	0.42	5.12	0.3	5.96e-7	Occipital cortical area (total cortical area interaction);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg16385941	chr7:1579643	MAFK	0.47	6.07	0.35	4.33e-9	Fibrinogen levels;
CESC	cis	rs12530845	0.623	rs77454235	chr7:135341862	T/C	cg23117316	chr7:135346802	PL-5283	-0.58	-6.53	-0.37	3.25e-10	Red blood cell traits;
CESC	cis	rs9649213	0.586	rs55648546	chr7:97960800	G/A	cg09267113	chr7:98030324	BAIAP2L1	-0.45	-6.09	-0.35	4.04e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs6430585	0.583	rs79176913	chr2:136638113	C/A	cg07169764	chr2:136633963	MCM6	1.31	20.73	0.79	2.13e-57	Corneal structure;
CESC	cis	rs1348850	0.567	rs7605609	chr2:178534942	C/G	cg22681709	chr2:178499509	PDE11A	-0.5	-7.37	-0.41	2.24e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs28830936	1.000	rs28444909	chr15:41953105	C/T	cg11010575	chr15:42129464	JMJD7-PLA2G4B;JMJD7	-0.39	-5.35	-0.31	1.9e-7	Diastolic blood pressure;
CESC	cis	rs7247513	0.964	rs4804202	chr19:12718619	T/C	cg01871581	chr19:12707946	ZNF490	-0.86	-14.11	-0.66	4.12e-34	Bipolar disorder;
CESC	cis	rs7089973	0.584	rs4752255	chr10:116576790	C/T	cg03647239	chr10:116582469	FAM160B1	0.44	5.63	0.33	4.56e-8	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs7959452	0.684	rs11177615	chr12:69754189	G/A	cg14784868	chr12:69753453	YEATS4	0.85	13.17	0.63	8.45e-31	Blood protein levels;
CESC	cis	rs3204270	0.759	rs77740144	chr17:79608968	G/A	cg26965718	chr17:79658957	HGS	-0.72	-5.13	-0.3	5.51e-7	Dental caries;
CESC	cis	rs10461617	0.617	rs79742142	chr5:56104377	A/G	cg24549020	chr5:56110836	MAP3K1	0.65	7.3	0.41	3.43e-12	Type 2 diabetes;
CESC	cis	rs561341	1.000	rs554078	chr17:30330109	A/C	cg23018236	chr17:30244563	NA	-0.55	-5.33	-0.31	2.1e-7	Hip circumference adjusted for BMI;
CESC	cis	rs2735413	0.914	rs1922608	chr16:78065139	A/G	cg04733911	chr16:78082701	NA	-0.5	-7.9	-0.44	7.56e-14	Systolic blood pressure (alcohol consumption interaction);
CESC	cis	rs35110281	0.641	rs9978858	chr21:45085552	A/G	cg21573476	chr21:45109991	RRP1B	-0.58	-8.01	-0.44	3.56e-14	Mean corpuscular volume;
CESC	cis	rs4077515	0.901	rs34826348	chr9:139281570	A/C	cg14169450	chr9:139327907	INPP5E	0.38	5.42	0.32	1.31e-7	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs8017423	0.967	rs2277515	chr14:90723000	A/G	cg14092571	chr14:90743983	NA	-0.55	-8.31	-0.45	5.06e-15	Mortality in heart failure;
CESC	cis	rs397969	0.596	rs62066348	chr17:19899913	A/G	cg12073167	chr17:19770448	ULK2	-0.47	-5.34	-0.31	2.04e-7	Platelet count;
CESC	cis	rs1499614	1.000	rs1267818	chr7:66107024	C/T	cg08632164	chr7:65971372	NA	-0.49	-5.15	-0.3	5.03e-7	Gout;
CESC	cis	rs11098499	0.909	rs79704848	chr4:120309351	T/A	cg24375607	chr4:120327624	NA	0.46	5.55	0.32	6.98e-8	Corneal astigmatism;
CESC	cis	rs372883	0.648	rs382732	chr21:30719010	A/G	cg24692254	chr21:30365293	RNF160	0.53	6.68	0.38	1.43e-10	Pancreatic cancer;
CESC	cis	rs35306767	0.807	rs61831436	chr10:837882	G/A	cg20503657	chr10:835505	NA	1.08	10.24	0.53	6.05e-21	Eosinophil percentage of granulocytes;
CESC	trans	rs9987353	0.840	rs329994	chr8:9123233	A/G	cg10927534	chr5:141392688	GNPDA1	-0.49	-6.14	-0.35	2.94e-9	Recombination measurement;
CESC	cis	rs2354432	0.599	rs4950423	chr1:146854539	T/C	cg25205988	chr1:146714368	CHD1L	1.01	8.93	0.48	7.3e-17	Mitochondrial DNA levels;
CESC	cis	rs7208859	0.673	rs9899943	chr17:29223925	G/A	cg19761014	chr17:28927070	LRRC37B2	0.73	5.77	0.33	2.22e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs472109	0.748	rs4910498	chr11:9765503	A/T	cg03108697	chr11:9732066	SWAP70	-0.43	-6.44	-0.37	5.71e-10	Coronary artery disease;
CESC	cis	rs734999	0.505	rs10797437	chr1:2539006	T/C	cg18854424	chr1:2615690	NA	0.3	6.01	0.35	6.23e-9	Ulcerative colitis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00243897	chr12:122326549	PSMD9	0.65	7.46	0.42	1.24e-12	Gut microbiome composition (summer);
CESC	cis	rs68170813	0.559	rs80212020	chr7:106957596	C/T	cg02696742	chr7:106810147	HBP1	-0.53	-5.04	-0.3	8.64e-7	Coronary artery disease;
CESC	cis	rs2242116	0.796	rs2290546	chr3:46965197	C/G	cg02527881	chr3:46936655	PTH1R	-0.5	-6.98	-0.39	2.37e-11	Birth weight;
CESC	cis	rs60871478	1.000	rs62432899	chr7:826542	G/C	cg27478167	chr7:817139	HEATR2	-0.47	-5.05	-0.3	8.35e-7	Cerebrospinal P-tau181p levels;
CESC	trans	rs561341	0.882	rs563539	chr17:30307958	A/G	cg20587970	chr11:113659929	NA	-1.11	-14.04	-0.65	7.35e-34	Hip circumference adjusted for BMI;
CESC	cis	rs34172651	0.517	rs2547040	chr16:24736408	G/C	cg06505273	chr16:24850292	NA	-0.55	-6.58	-0.37	2.52e-10	Intelligence (multi-trait analysis);
CESC	cis	rs7833790	0.660	rs1451995	chr8:82746123	G/C	cg02079420	chr8:82753780	SNX16	-0.54	-8.28	-0.45	6.23e-15	Diastolic blood pressure;
CESC	cis	rs61931739	0.500	rs11053208	chr12:34460029	A/G	cg23762105	chr12:34175262	ALG10	-0.4	-5.1	-0.3	6.52e-7	Morning vs. evening chronotype;
CESC	cis	rs3733585	0.806	rs7375599	chr4:9954918	C/T	cg11266682	chr4:10021025	SLC2A9	0.61	12.36	0.6	5.22e-28	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs6681460	0.966	rs6588215	chr1:67141949	A/G	cg02459107	chr1:67143332	SGIP1	0.37	5.09	0.3	6.64e-7	Presence of antiphospholipid antibodies;
CESC	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg24829409	chr8:58192753	C8orf71	-0.67	-7.99	-0.44	4.08e-14	Developmental language disorder (linguistic errors);
CESC	cis	rs2075371	1.000	rs8134	chr7:133974519	A/G	cg00033643	chr7:134001901	SLC35B4	0.42	5.47	0.32	1.04e-7	Mean platelet volume;
CESC	cis	rs1862618	0.671	rs2255726	chr5:56243128	T/C	cg12311346	chr5:56204834	C5orf35	0.64	8.64	0.47	5.57e-16	Initial pursuit acceleration;
CESC	cis	rs9486719	0.895	rs3734239	chr6:96996244	A/G	cg06623918	chr6:96969491	KIAA0776	-0.8	-8.3	-0.45	5.39e-15	Migraine;Coronary artery disease;
CESC	cis	rs7561273	0.586	rs11902756	chr2:24300932	A/G	cg06627628	chr2:24431161	ITSN2	-0.48	-5.64	-0.33	4.35e-8	Quantitative traits;
CESC	cis	rs7474896	0.537	rs2749586	chr10:38270214	G/C	cg00409905	chr10:38381863	ZNF37A	0.45	5.06	0.3	7.68e-7	Obesity (extreme);
CESC	cis	rs7949030	0.626	rs11231154	chr11:62362293	A/G	cg23462726	chr11:62437636	C11orf83;C11orf48	-0.4	-5.22	-0.31	3.64e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs8053891	0.756	rs12708921	chr16:71999589	G/A	cg04254540	chr16:71951199	KIAA0174	-0.42	-5.3	-0.31	2.48e-7	Coronary artery disease;
CESC	cis	rs1018836	0.847	rs35409073	chr8:91648036	G/T	cg16814680	chr8:91681699	NA	-0.75	-10.44	-0.54	1.34e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs11098499	0.863	rs11098532	chr4:120490726	C/A	cg09307838	chr4:120376055	NA	0.92	12.65	0.61	5.39e-29	Corneal astigmatism;
CESC	cis	rs7635838	0.892	rs12163566	chr3:11483096	T/A	cg00170343	chr3:11313890	ATG7	0.43	5.85	0.34	1.46e-8	HDL cholesterol;
CESC	cis	rs1879734	0.731	rs4927029	chr1:54169455	C/G	cg23596471	chr1:54105337	GLIS1	0.35	5.47	0.32	1.03e-7	Mitral valve prolapse;
CESC	cis	rs9790314	0.936	rs7629987	chr3:161002023	A/C	cg03342759	chr3:160939853	NMD3	-0.45	-5.95	-0.34	8.66e-9	Morning vs. evening chronotype;
CESC	cis	rs7208859	0.623	rs78071511	chr17:29128154	C/T	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.79e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs11690935	0.851	rs6731562	chr2:172798262	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.72	-10.7	-0.55	1.98e-22	Schizophrenia;
CESC	cis	rs6032067	0.526	rs2743347	chr20:43920493	T/C	cg10761708	chr20:43804764	PI3	0.39	5.03	0.3	9.02e-7	Blood protein levels;
CESC	cis	rs17253792	0.822	rs11546	chr14:56146357	G/A	cg01858014	chr14:56050164	KTN1	-0.94	-7.57	-0.42	6.2800000000000005e-13	Putamen volume;
CESC	cis	rs4253772	0.513	rs6008612	chr22:46707907	G/A	cg10231785	chr22:46692440	CN5H6.4;GTSE1	0.58	5.97	0.34	7.57e-9	LDL cholesterol;Cholesterol, total;
CESC	trans	rs10506458	0.915	rs12424908	chr12:63402364	G/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.38	-18.5	-0.75	1.25e-49	Hemostatic factors and hematological phenotypes;
CESC	cis	rs7223966	1.000	rs2665826	chr17:61944924	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.46	-5.41	-0.32	1.43e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	trans	rs10463316	0.894	rs10476980	chr5:150764157	A/G	cg24389359	chr12:111284228	CCDC63	-0.33	-6.02	-0.35	5.68e-9	Metabolite levels (Pyroglutamine);
CESC	cis	rs7666738	0.791	rs34437628	chr4:99029232	C/G	cg17366294	chr4:99064904	C4orf37	0.62	8.95	0.48	6.32e-17	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2573652	1.000	rs2581365	chr15:100513318	A/C	cg00587665	chr15:100533223	ADAMTS17	-0.33	-5.41	-0.32	1.43e-7	Height;
CESC	cis	rs1008375	0.966	rs4698619	chr4:17580955	G/A	cg27347728	chr4:17578864	LAP3	0.43	5.12	0.3	5.92e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs2559856	1.000	rs2695284	chr12:102089318	A/G	cg15068132	chr12:102092402	CHPT1	0.43	5.82	0.34	1.72e-8	Blood protein levels;
CESC	trans	rs3794271	0.706	rs9971816	chr12:20826911	C/T	cg13747066	chr9:74525074	C9orf85;FAM108B1	0.46	6.51	0.37	3.69e-10	Response to TNF-alpha inhibitors in rheumatoid arthritis;
CESC	cis	rs10504229	0.683	rs11786523	chr8:58131319	G/C	cg02725872	chr8:58115012	NA	-0.45	-7.05	-0.4	1.52e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs4862750	0.872	rs6821507	chr4:187876829	G/T	cg10295955	chr4:187884368	NA	1.04	19.76	0.77	5.02e-54	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs17253792	0.822	rs17746106	chr14:56069168	C/T	cg01858014	chr14:56050164	KTN1	-0.71	-6.4	-0.37	7.09e-10	Putamen volume;
CESC	cis	rs2576037	0.796	rs2571020	chr18:44584189	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.61	-8.59	-0.47	7.46e-16	Personality dimensions;
CESC	cis	rs959260	1.000	rs4788889	chr17:73389126	A/G	cg20590849	chr17:73267439	MIF4GD	-0.55	-6.36	-0.36	8.61e-10	Systemic lupus erythematosus;
CESC	cis	rs36051895	0.664	rs3780369	chr9:5095095	A/C	cg02405213	chr9:5042618	JAK2	-0.52	-6.4	-0.37	7.16e-10	Pediatric autoimmune diseases;
CESC	cis	rs11958404	0.932	rs113264420	chr5:157437779	T/C	cg05962755	chr5:157440814	NA	0.59	6.52	0.37	3.45e-10	IgG glycosylation;
CESC	cis	rs2032447	0.670	rs198848	chr6:26106325	A/G	cg03517284	chr6:25882590	NA	-0.43	-5.92	-0.34	9.68e-9	Intelligence (multi-trait analysis);
CESC	cis	rs11630290	1.000	rs72750981	chr15:63983737	A/T	cg12036633	chr15:63758958	NA	-0.54	-5.27	-0.31	2.87e-7	Iris characteristics;
CESC	cis	rs34638657	0.732	rs7205534	chr16:82201618	C/T	cg09439754	chr16:82129088	HSD17B2	-0.35	-6.14	-0.35	3.05e-9	Lung adenocarcinoma;
CESC	cis	rs1062177	0.826	rs1549920	chr5:151140844	A/T	cg00977110	chr5:151150581	G3BP1	0.62	6.93	0.39	3.25e-11	Preschool internalizing problems;
CESC	cis	rs7520050	0.933	rs12045165	chr1:46256022	C/A	cg03146154	chr1:46216737	IPP	-0.49	-6.37	-0.36	8.44e-10	Red blood cell count;Reticulocyte count;
CESC	cis	rs6723226	0.772	rs2366894	chr2:32713706	A/T	cg02381751	chr2:32503542	YIPF4	0.82	12.2	0.6	1.79e-27	Intelligence (multi-trait analysis);
CESC	cis	rs4853012	0.887	rs2280644	chr2:74358411	G/A	cg20891558	chr2:74357851	NA	0.81	11.18	0.57	5.16e-24	Gestational age at birth (maternal effect);
CESC	cis	rs10208940	0.920	rs35002937	chr2:68753240	T/A	cg12452813	chr2:68675892	NA	0.51	5.1	0.3	6.39e-7	Urate levels in lean individuals;
CESC	cis	rs7552404	1.000	rs11161511	chr1:76210477	A/G	cg10523679	chr1:76189770	ACADM	-0.65	-7.57	-0.42	6.15e-13	Blood metabolite levels;Acylcarnitine levels;
CESC	trans	rs10489896	0.541	rs16843220	chr1:234589999	T/C	cg10395685	chr11:86085715	CCDC81	-0.43	-6.15	-0.35	2.9e-9	Cognitive test performance;
CESC	cis	rs561341	1.000	rs7210970	chr17:30262169	G/A	cg13647721	chr17:30228624	UTP6	0.52	5.32	0.31	2.17e-7	Hip circumference adjusted for BMI;
CESC	trans	rs916888	0.821	rs199509	chr17:44858728	G/A	cg22433210	chr17:43662623	NA	-0.91	-10.81	-0.55	8.16e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs362296	0.698	rs3095072	chr4:3263325	G/A	cg08886695	chr4:3369023	RGS12	0.39	5.19	0.3	4.19e-7	Parental longevity (mother's age at death);
CESC	cis	rs2404602	0.692	rs12911902	chr15:77053575	T/C	cg22467129	chr15:76604101	ETFA	-0.34	-5.16	-0.3	4.84e-7	Blood metabolite levels;
CESC	cis	rs4665809	0.590	rs35727620	chr2:26458364	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.1	12.68	0.61	4e-29	Gut microbiome composition (summer);
CESC	cis	rs875971	0.767	rs12668005	chr7:65909021	T/C	cg10691866	chr7:65817282	TPST1	-0.32	-5.26	-0.31	3.02e-7	Aortic root size;
CESC	trans	rs10411161	0.702	rs7251571	chr19:52389057	A/G	cg22319618	chr22:45562946	NUP50	-0.71	-7.13	-0.4	9.41e-12	Breast cancer;
CESC	cis	rs2404602	0.669	rs8036703	chr15:76951040	A/G	cg26408565	chr15:76604113	ETFA	-0.39	-5.58	-0.32	5.95e-8	Blood metabolite levels;
CESC	cis	rs11098499	0.730	rs12505735	chr4:120532956	G/T	cg09307838	chr4:120376055	NA	0.86	11.72	0.58	7.86e-26	Corneal astigmatism;
CESC	cis	rs10540	1.000	rs61876332	chr11:487101	C/T	cg21784768	chr11:537496	LRRC56	-0.57	-5.36	-0.31	1.85e-7	Body mass index;
CESC	cis	rs6460942	0.630	rs62451487	chr7:12390464	G/A	cg06484146	chr7:12443880	VWDE	-0.65	-7.02	-0.4	1.89e-11	Coronary artery disease;
CESC	cis	rs72829446	0.530	rs12325773	chr17:7393871	G/A	cg02795151	chr17:7402630	POLR2A	0.55	5.83	0.34	1.63e-8	Androgen levels;
CESC	cis	rs2455799	0.613	rs4685264	chr3:15858347	G/A	cg16303742	chr3:15540471	COLQ	-0.37	-5.69	-0.33	3.4e-8	Mean platelet volume;
CESC	cis	rs1799949	0.929	rs799905	chr17:41277187	G/C	cg05368731	chr17:41323189	NBR1	0.55	7.57	0.42	6.23e-13	Menopause (age at onset);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg06225133	chr3:44690200	ZNF35	-0.56	-7.12	-0.4	1.04e-11	Ulcerative colitis;
CESC	cis	rs6696846	0.765	rs61822567	chr1:205078725	T/C	cg00857998	chr1:205179979	DSTYK	0.54	7.21	0.41	5.81e-12	Red blood cell count;
CESC	trans	rs804280	0.518	rs34266352	chr8:11791462	G/A	cg15556689	chr8:8085844	FLJ10661	0.52	6.41	0.37	6.53e-10	Myopia (pathological);
CESC	cis	rs7666738	0.830	rs969048	chr4:98988921	T/C	cg03467027	chr4:99064603	C4orf37	0.44	5.56	0.32	6.57e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2180341	0.700	rs4598100	chr6:127565314	G/A	cg24812749	chr6:127587940	RNF146	0.78	10.33	0.54	3.16e-21	Breast cancer;
CESC	cis	rs9596863	0.808	rs9568879	chr13:54225170	C/T	ch.13.53330881F	chr13:54432880	NA	0.63	5.11	0.3	6.3e-7	Epilepsy and lamotrigine-induced maculopapular eruptions;
CESC	cis	rs3931020	0.548	rs969435	chr1:75273866	A/G	cg10128416	chr1:75198403	TYW3;CRYZ	-0.47	-6.27	-0.36	1.49e-9	Resistin levels;
CESC	cis	rs2033711	0.783	rs11671113	chr19:58958087	C/T	cg11952622	chr19:58962976	ZNF324B	0.47	6.49	0.37	4.27e-10	Uric acid clearance;
CESC	cis	rs7833790	0.553	rs9693128	chr8:82706128	A/G	cg06027949	chr8:82754900	SNX16	-0.64	-8.49	-0.46	1.54e-15	Diastolic blood pressure;
CESC	cis	rs9303401	0.614	rs68100606	chr17:56500898	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.95	11.7	0.58	9.24e-26	Cognitive test performance;
CESC	cis	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg20295408	chr7:1910781	MAD1L1	-0.41	-5.27	-0.31	2.82e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs1552244	1.000	rs6764068	chr3:10153842	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.88	12.09	0.6	4.15e-27	Alzheimer's disease;
CESC	cis	rs4595586	0.545	rs1303887	chr12:39366523	C/T	cg26384229	chr12:38710491	ALG10B	0.53	7.51	0.42	9.32e-13	Morning vs. evening chronotype;
CESC	cis	rs9925964	0.933	rs56314408	chr16:31117389	T/C	cg02466173	chr16:30829666	NA	-0.32	-5.19	-0.3	4.18e-7	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs2295499	0.754	rs2285082	chr4:2627698	G/A	cg08330972	chr4:2403930	ZFYVE28	-0.33	-5.4	-0.31	1.51e-7	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
CESC	cis	rs514406	0.861	rs551435	chr1:53260537	G/T	cg16325326	chr1:53192061	ZYG11B	-0.88	-14.98	-0.68	3.69e-37	Monocyte count;
CESC	cis	rs12477438	0.520	rs2171359	chr2:99795360	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.86	15.21	0.68	5.36e-38	Chronic sinus infection;
CESC	cis	rs9611565	0.506	rs7364221	chr22:41650190	C/A	cg03806693	chr22:41940476	POLR3H	-0.72	-7.94	-0.44	5.69e-14	Vitiligo;
CESC	cis	rs80130819	0.688	rs10783232	chr12:48583491	A/G	cg05342945	chr12:48394962	COL2A1	-0.51	-6.02	-0.35	5.77e-9	Prostate cancer;
CESC	cis	rs2404602	0.735	rs2461870	chr15:76813920	T/G	cg23625390	chr15:77176239	SCAPER	-0.4	-5.69	-0.33	3.31e-8	Blood metabolite levels;
CESC	cis	rs2573652	1.000	rs2573625	chr15:100513158	A/G	cg09939229	chr15:100514479	ADAMTS17	0.36	5.22	0.31	3.62e-7	Height;
CESC	cis	rs861020	1.000	rs12134698	chr1:209987801	C/A	cg05527609	chr1:210001259	C1orf107	-1.07	-13.45	-0.64	8.66e-32	Orofacial clefts;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg01768981	chr5:54529226	CCNO	-0.45	-6.24	-0.36	1.68e-9	Fibrinogen levels;
CESC	cis	rs4555082	0.915	rs28594491	chr14:105758018	G/A	cg06808227	chr14:105710500	BRF1	-0.55	-6.3	-0.36	1.22e-9	Mean platelet volume;Platelet distribution width;
CESC	cis	rs875971	0.862	rs7798630	chr7:65771479	G/C	cg19163074	chr7:65112434	INTS4L2	0.41	5.27	0.31	2.89e-7	Aortic root size;
CESC	cis	rs10492096	0.945	rs1045546	chr12:6567907	C/T	cg13857086	chr12:6580257	VAMP1	0.63	5.98	0.34	7.09e-9	Hip geometry;
CESC	cis	rs10129255	1.000	rs4612959	chr14:107175298	A/G	cg23076370	chr14:107095027	NA	-0.44	-5.42	-0.32	1.36e-7	Kawasaki disease;
CESC	cis	rs9486719	0.901	rs760619	chr6:96857431	A/G	cg18709589	chr6:96969512	KIAA0776	0.53	5.54	0.32	7.29e-8	Migraine;Coronary artery disease;
CESC	cis	rs854765	0.927	rs4925138	chr17:17992793	T/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.44	-5.57	-0.32	6.19e-8	Total body bone mineral density;
CESC	cis	rs9467711	0.538	rs35934643	chr6:26355094	G/A	cg12826209	chr6:26865740	GUSBL1	0.62	5.31	0.31	2.36e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs9640161	0.711	rs55881542	chr7:150025734	G/A	cg13722127	chr7:150037890	RARRES2	0.36	5.12	0.3	5.88e-7	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs2463822	0.925	rs72923272	chr11:62166832	G/A	cg06239285	chr11:62104954	ASRGL1	-1.05	-9.05	-0.49	3.22e-17	Chronic obstructive pulmonary disease-related biomarkers;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21075560	chr15:43663139	ZSCAN29;TUBGCP4	0.59	6.72	0.38	1.11e-10	Gut microbiome composition (summer);
CESC	cis	rs12549902	1.000	rs12550613	chr8:41510260	G/C	cg00088007	chr8:41504566	NKX6-3	0.29	5.05	0.3	8.34e-7	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
CESC	cis	rs2522056	1.000	rs2706393	chr5:131796067	G/A	cg24060327	chr5:131705240	SLC22A5	0.59	6.63	0.38	1.85e-10	Lymphocyte counts;Fibrinogen;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg01302669	chr3:49824110	IP6K1	-0.46	-6.26	-0.36	1.55e-9	Height;
CESC	cis	rs897984	0.770	rs12930657	chr16:30931968	C/T	cg02466173	chr16:30829666	NA	0.49	8.46	0.46	1.82e-15	Dementia with Lewy bodies;
CESC	cis	rs11252926	0.931	rs12358336	chr10:566981	A/T	cg18196295	chr10:418757	DIP2C	-0.49	-5.74	-0.33	2.62e-8	Psychosis in Alzheimer's disease;
CESC	cis	rs2463822	1.000	rs2513052	chr11:62108248	C/G	cg06239285	chr11:62104954	ASRGL1	0.87	8.77	0.47	2.28e-16	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs9303401	0.614	rs62084387	chr17:57148027	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.97	11.01	0.56	1.82e-23	Cognitive test performance;
CESC	cis	rs9768139	0.566	rs729099	chr7:158114152	C/T	cg25566285	chr7:158114605	PTPRN2	0.52	8.26	0.45	7.04e-15	Calcium levels;
CESC	cis	rs5763662	1.000	rs13056990	chr22:30534161	G/A	cg21388335	chr22:29999516	NF2	-0.74	-5.03	-0.3	9.22e-7	LDL cholesterol levels;LDL cholesterol;
CESC	cis	rs4253772	0.530	rs9615958	chr22:46751122	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.62	5.16	0.3	4.87e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs1707322	0.717	rs3014237	chr1:46090252	A/G	cg03146154	chr1:46216737	IPP	-0.78	-10.38	-0.54	2.03e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs112790992	1	rs112790992	chr14:105758217	A/C	cg06808227	chr14:105710500	BRF1	-0.54	-6.78	-0.38	7.72e-11	Platelet count;
CESC	cis	rs2860975	1.000	rs2860974	chr10:96779866	A/G	cg09036531	chr10:96991505	NA	-0.41	-5.62	-0.33	4.74e-8	Immune response to smallpox vaccine (IL-6);
CESC	cis	rs4253772	0.638	rs6007845	chr22:46718417	A/T	cg10231785	chr22:46692440	CN5H6.4;GTSE1	-0.56	-6.21	-0.36	2.08e-9	LDL cholesterol;Cholesterol, total;
CESC	cis	rs637571	0.522	rs12792888	chr11:65761446	C/T	cg02202077	chr11:65769826	EIF1AD;BANF1	0.46	6.08	0.35	4.16e-9	Eosinophil percentage of white cells;
CESC	cis	rs6088580	0.634	rs4277599	chr20:33008905	A/G	cg08999081	chr20:33150536	PIGU	-0.59	-10.37	-0.54	2.31e-21	Glomerular filtration rate (creatinine);
CESC	cis	rs10276381	0.901	rs73300638	chr7:28187344	A/C	cg23620719	chr7:28220237	JAZF1	0.74	7.66	0.43	3.44e-13	Crohn's disease;
CESC	cis	rs7659604	0.702	rs58649165	chr4:122693752	C/A	cg20573242	chr4:122745356	CCNA2	0.43	5.35	0.31	1.86e-7	Type 2 diabetes;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg17524151	chr16:475494	RAB11FIP3	-0.54	-7.27	-0.41	4.07e-12	Gut microbiota (bacterial taxa);
CESC	cis	rs9457247	0.663	rs9295384	chr6:167448113	T/A	cg25258033	chr6:167368657	RNASET2	0.36	5.24	0.31	3.33e-7	Crohn's disease;
CESC	cis	rs7618501	1.000	rs6802890	chr3:49832261	A/G	cg24308560	chr3:49941425	MST1R	-0.52	-7.11	-0.4	1.08e-11	Intelligence (multi-trait analysis);
CESC	cis	rs875971	1.000	rs35149210	chr7:65929925	T/C	cg10691866	chr7:65817282	TPST1	-0.34	-5.62	-0.33	4.93e-8	Aortic root size;
CESC	cis	rs1190552	0.846	rs1044503	chr14:102965996	A/G	cg18135206	chr14:102964638	TECPR2	0.42	5.29	0.31	2.52e-7	Blood protein levels;
CESC	cis	rs1790761	0.587	rs4930431	chr11:67294308	C/T	cg14500267	chr11:67383377	NA	-0.33	-5.58	-0.32	5.86e-8	Mean corpuscular volume;
CESC	cis	rs2486288	0.539	rs2433601	chr15:45716425	T/C	cg21132104	chr15:45694354	SPATA5L1	0.66	8.55	0.47	9.63e-16	Glomerular filtration rate;
CESC	cis	rs2243480	1.000	rs59794892	chr7:65415873	G/A	cg12463550	chr7:65579703	CRCP	0.7	5.61	0.33	5e-8	Diabetic kidney disease;
CESC	cis	rs1008375	0.931	rs10939734	chr4:17570709	C/T	cg27347728	chr4:17578864	LAP3	0.43	5.14	0.3	5.22e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs8062405	0.755	rs7186573	chr16:28587389	T/C	cg01378222	chr16:28622494	SULT1A1	0.31	5.32	0.31	2.25e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs7264396	0.635	rs6060719	chr20:34546013	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.81	-11.06	-0.56	1.23e-23	Total cholesterol levels;
CESC	cis	rs35110281	0.633	rs4818860	chr21:45119617	C/T	cg21573476	chr21:45109991	RRP1B	-0.57	-8.24	-0.45	7.86e-15	Mean corpuscular volume;
CESC	cis	rs30380	0.587	rs151940	chr5:96147777	T/C	cg16492584	chr5:96139282	ERAP1	-0.51	-7.02	-0.4	1.86e-11	Cerebrospinal fluid biomarker levels;
CESC	cis	rs2576037	0.526	rs10853545	chr18:44475220	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.68	10.27	0.53	4.67e-21	Personality dimensions;
CESC	cis	rs12477438	0.508	rs2516832	chr2:99771268	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.85	15.81	0.7	4.17e-40	Chronic sinus infection;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg13393195	chr12:113659153	TPCN1;IQCD	0.55	7.19	0.4	6.65e-12	Gut microbiota (bacterial taxa);
CESC	cis	rs6748734	1.000	rs4675874	chr2:241819796	A/G	cg04034577	chr2:241836375	C2orf54	0.51	9.07	0.49	2.67e-17	Urinary metabolites;
CESC	trans	rs9467711	0.606	rs9379859	chr6:26369549	C/T	cg06606381	chr12:133084897	FBRSL1	-0.76	-6.86	-0.39	4.71e-11	Autism spectrum disorder or schizophrenia;
CESC	cis	rs6089829	0.888	rs4809468	chr20:61673566	T/C	cg03213289	chr20:61660250	NA	0.35	5.23	0.31	3.47e-7	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg13132016	chr14:58893740	KIAA0586;TIMM9	-0.47	-6.48	-0.37	4.37e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg23978390	chr7:1156363	C7orf50	0.6	8.45	0.46	1.91e-15	Longevity;Endometriosis;
CESC	cis	rs1218582	0.772	rs10908448	chr1:154882544	A/G	cg16680214	chr1:154839983	KCNN3	0.43	6.71	0.38	1.15e-10	Prostate cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17404403	chr4:110737017	GAR1	0.65	7.6	0.42	5.13e-13	Gut microbiome composition (summer);
CESC	cis	rs60154123	0.505	rs2206043	chr1:210042983	G/A	cg25204440	chr1:209979598	IRF6	0.61	5.95	0.34	8.43e-9	Coronary artery disease;
CESC	cis	rs736408	0.677	rs678	chr3:52820981	A/T	cg17372223	chr3:52568218	NT5DC2	0.38	5.2	0.3	4.05e-7	Bipolar disorder;
CESC	cis	rs1552244	0.882	rs13074282	chr3:10024699	T/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.87	11.29	0.57	2.21e-24	Alzheimer's disease;
CESC	cis	rs722599	0.683	rs2302834	chr14:75279395	T/A	cg08847533	chr14:75593920	NEK9	0.49	5.97	0.34	7.47e-9	IgG glycosylation;
CESC	cis	rs1008375	1.000	rs6449323	chr4:17683916	A/T	cg16339924	chr4:17578868	LAP3	0.54	6.7	0.38	1.27e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs1697139	0.583	rs11739603	chr5:66540687	C/T	cg11553311	chr5:66541588	NA	0.38	5.37	0.31	1.75e-7	Breast cancer;
CESC	cis	rs798554	0.723	rs798518	chr7:2777825	A/G	cg09658497	chr7:2847517	GNA12	-0.42	-6.01	-0.35	6.1e-9	Height;
CESC	cis	rs17711722	0.523	rs365896	chr7:65510697	A/G	cg26939375	chr7:64535504	NA	-0.67	-9.59	-0.51	6.8e-19	Calcium levels;
CESC	cis	rs2979489	0.891	rs6982511	chr8:30355513	G/T	cg26383811	chr8:30366931	RBPMS	-0.79	-10.19	-0.53	8.89e-21	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CESC	cis	rs7149337	0.836	rs34953083	chr14:51672432	A/G	cg23942311	chr14:51606299	NA	0.43	7.19	0.4	6.59e-12	Cancer;
CESC	cis	rs780096	0.526	rs7602534	chr2:27592423	C/T	cg24768116	chr2:27665128	KRTCAP3	-0.3	-5.47	-0.32	1.02e-7	Total body bone mineral density;
CESC	cis	rs6460942	0.915	rs6945067	chr7:12444731	A/C	cg02935154	chr7:12443704	VWDE	-0.6	-6.82	-0.39	6.02e-11	Coronary artery disease;
CESC	cis	rs3106136	0.967	rs12645192	chr4:95181525	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.46	-6.73	-0.38	1.07e-10	Capecitabine sensitivity;
CESC	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg03762994	chr17:6899332	ALOX12	0.4	7.14	0.4	8.85e-12	Tonsillectomy;
CESC	cis	rs4423214	0.592	rs11234027	chr11:71234107	G/A	cg05163923	chr11:71159392	DHCR7	-0.57	-6.03	-0.35	5.49e-9	Vitamin D levels;
CESC	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg07092213	chr7:1199455	ZFAND2A	-0.39	-5.35	-0.31	1.9e-7	Longevity;Endometriosis;
CESC	cis	rs826838	1.000	rs1393537	chr12:38920961	C/T	cg13010199	chr12:38710504	ALG10B	0.6	8.42	0.46	2.34e-15	Heart rate;
CESC	cis	rs11676348	0.712	rs12694426	chr2:218942351	T/G	cg00012203	chr2:219082015	ARPC2	-0.45	-5.52	-0.32	8.2e-8	Ulcerative colitis;
CESC	cis	rs826838	0.935	rs4583043	chr12:38645147	T/G	cg13010199	chr12:38710504	ALG10B	0.59	8.3	0.45	5.22e-15	Heart rate;
CESC	cis	rs514406	0.929	rs12354395	chr1:53327663	A/G	cg16325326	chr1:53192061	ZYG11B	0.82	12.7	0.61	3.6e-29	Monocyte count;
CESC	cis	rs7618915	0.571	rs6762457	chr3:52609157	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.47	6.71	0.38	1.2e-10	Bipolar disorder;
CESC	cis	rs7833986	0.501	rs2667999	chr8:56950474	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.61	7.55	0.42	6.89e-13	Height;
CESC	cis	rs7914558	0.966	rs11191438	chr10:104637864	C/G	cg15744005	chr10:104629667	AS3MT	-0.34	-5.57	-0.32	6.14e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs12050794	0.671	rs7179427	chr15:72516821	G/A	cg16672083	chr15:72433130	SENP8	0.46	6.89	0.39	4.06e-11	Metabolite levels (HVA/MHPG ratio);
CESC	cis	rs7666738	0.830	rs2865949	chr4:99039967	A/G	cg05340658	chr4:99064831	C4orf37	0.82	12.88	0.62	8.44e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9660180	0.935	rs2180311	chr1:1748734	T/C	cg13866156	chr1:1669148	SLC35E2	-0.51	-6.82	-0.39	6.21e-11	Body mass index;
CESC	cis	rs921968	0.643	rs579610	chr2:219327582	C/A	cg02176678	chr2:219576539	TTLL4	0.43	7.66	0.43	3.53e-13	Mean corpuscular hemoglobin concentration;
CESC	cis	rs921968	0.541	rs532425	chr2:219434194	A/G	cg02176678	chr2:219576539	TTLL4	0.5	8.89	0.48	9.82e-17	Mean corpuscular hemoglobin concentration;
CESC	cis	rs12497850	0.931	rs9840050	chr3:49133310	A/G	cg02487422	chr3:49467188	NICN1	0.45	5.67	0.33	3.69e-8	Parkinson's disease;
CESC	cis	rs798554	0.959	rs798528	chr7:2772431	A/C	cg19346786	chr7:2764209	NA	-0.5	-7.44	-0.42	1.44e-12	Height;
CESC	cis	rs7847628	0.551	rs10818476	chr9:123572038	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.45	7.75	0.43	1.92e-13	Birth weight;
CESC	trans	rs9467711	0.790	rs13195402	chr6:26463575	G/T	cg06606381	chr12:133084897	FBRSL1	-1.06	-8.04	-0.44	3.05e-14	Autism spectrum disorder or schizophrenia;
CESC	trans	rs1814175	0.616	rs10769644	chr11:49987676	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.43	-6.26	-0.36	1.53e-9	Height;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg19022476	chr8:145745884	LRRC14	-0.46	-6.49	-0.37	4.16e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12251659	chr12:122018385	KDM2B	0.63	7.02	0.4	1.81e-11	Gut microbiome composition (summer);
CESC	cis	rs10463316	0.894	rs7718085	chr5:150742957	G/C	cg03212797	chr5:150827313	SLC36A1	-0.47	-6.0	-0.35	6.43e-9	Metabolite levels (Pyroglutamine);
CESC	cis	rs67460515	0.563	rs34630898	chr3:160827038	A/G	cg03342759	chr3:160939853	NMD3	-0.47	-6.04	-0.35	5.13e-9	Parkinson's disease;
CESC	cis	rs1800795	0.901	rs2069833	chr7:22767664	C/T	cg05472934	chr7:22766657	IL6	0.84	11.19	0.57	4.68e-24	Cerebrospinal fluid clusterin levels in APOEe4- carriers;
CESC	cis	rs7772486	0.754	rs4896838	chr6:146015451	T/C	cg23711669	chr6:146136114	FBXO30	-1.04	-14.66	-0.67	5.06e-36	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2637266	0.739	rs2579737	chr10:78422546	G/T	cg18941641	chr10:78392320	NA	0.39	7.28	0.41	3.87e-12	Pulmonary function;
CESC	cis	rs7084402	0.967	rs1658424	chr10:60331588	G/A	cg07615347	chr10:60278583	BICC1	0.59	9.15	0.49	1.57e-17	Refractive error;
CESC	cis	rs6674970	0.518	rs6587552	chr1:151018861	C/T	cg03258749	chr1:151040405	MLLT11	0.43	5.95	0.34	8.43e-9	Childhood ear infection;
CESC	cis	rs4253772	0.550	rs9615949	chr22:46722531	C/T	cg00784671	chr22:46762841	CELSR1	-0.54	-5.92	-0.34	1.01e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs7116495	0.609	rs4245463	chr11:71743213	C/A	cg10381502	chr11:71823885	C11orf51	-1.22	-7.42	-0.41	1.64e-12	Severe influenza A (H1N1) infection;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg18501264	chr19:33555827	RHPN2	0.47	6.23	0.36	1.82e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs938554	0.784	rs4481233	chr4:9956079	A/G	cg00071950	chr4:10020882	SLC2A9	0.6	6.39	0.37	7.46e-10	Blood metabolite levels;
CESC	cis	rs875971	0.830	rs6967708	chr7:65657313	A/T	cg11764359	chr7:65958608	NA	-0.78	-11.43	-0.57	7.35e-25	Aortic root size;
CESC	cis	rs12477438	0.798	rs6712338	chr2:99585457	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-10.57	-0.54	5.22e-22	Chronic sinus infection;
CESC	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	7.69	0.43	2.88e-13	Prudent dietary pattern;
CESC	trans	rs60843830	1.000	rs59937473	chr2:271797	G/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.65	8.27	0.45	6.64e-15	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs34779708	0.771	rs12098283	chr10:35478115	G/T	cg03585969	chr10:35415529	CREM	0.72	9.08	0.49	2.61e-17	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs4595586	0.545	rs7976609	chr12:39394317	T/C	cg26384229	chr12:38710491	ALG10B	0.54	7.64	0.42	3.96e-13	Morning vs. evening chronotype;
CESC	cis	rs7666738	0.830	rs13138051	chr4:99050367	C/T	cg18180107	chr4:99064573	C4orf37	0.41	5.29	0.31	2.51e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs112158604	1	rs112158604	chr1:150696792	TCTTCTGCAG/T	cg18016565	chr1:150552671	MCL1	-0.34	-5.69	-0.33	3.43e-8	Lymphocyte counts;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08135278	chr1:226070709	TMEM63A	0.65	7.28	0.41	3.82e-12	Gut microbiome composition (summer);
CESC	cis	rs12541635	0.902	rs62525696	chr8:106968703	C/T	cg10147462	chr8:107024639	NA	0.38	5.21	0.3	3.83e-7	Age of smoking initiation;
CESC	cis	rs4253772	0.591	rs9615938	chr22:46689468	G/A	cg18190219	chr22:46762943	CELSR1	-0.59	-5.45	-0.32	1.14e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs7727544	0.735	rs274557	chr5:131721204	T/C	cg07395648	chr5:131743802	NA	0.48	6.48	0.37	4.48e-10	Blood metabolite levels;
CESC	cis	rs709400	0.628	rs1989565	chr14:103862193	G/A	cg12935359	chr14:103987150	CKB	0.51	7.83	0.43	1.17e-13	Body mass index;
CESC	cis	rs875971	0.895	rs7788984	chr7:65915616	A/G	cg18876405	chr7:65276391	NA	0.51	6.84	0.39	5.61e-11	Aortic root size;
CESC	trans	rs7656342	0.808	rs10003216	chr4:9766749	A/G	cg00727112	chr4:159690372	FNIP2	-0.51	-6.17	-0.35	2.6e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs763121	0.819	rs5757161	chr22:38990662	G/A	cg06022373	chr22:39101656	GTPBP1	0.89	15.08	0.68	1.66e-37	Menopause (age at onset);
CESC	cis	rs854765	0.647	rs721669	chr17:18005073	A/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.48	6.11	0.35	3.58e-9	Total body bone mineral density;
CESC	cis	rs9457247	0.935	rs1794697	chr6:167395410	C/T	cg25258033	chr6:167368657	RNASET2	0.4	5.95	0.34	8.39e-9	Crohn's disease;
CESC	cis	rs9322193	0.566	rs4869768	chr6:150245203	A/G	cg01145232	chr6:150245071	RAET1G	-0.57	-7.19	-0.4	6.69e-12	Lung cancer;
CESC	trans	rs61931739	0.500	rs7312938	chr12:34378708	C/T	cg13010199	chr12:38710504	ALG10B	0.48	6.21	0.36	2.01e-9	Morning vs. evening chronotype;
CESC	trans	rs9650657	0.504	rs10093053	chr8:11037187	T/C	cg06636001	chr8:8085503	FLJ10661	-0.51	-6.58	-0.37	2.48e-10	Neuroticism;
CESC	cis	rs2074585	0.679	rs2601195	chr15:90938232	G/A	cg10434728	chr15:90938212	IQGAP1	0.44	8.23	0.45	8.55e-15	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
CESC	cis	rs3105593	1.000	rs8023644	chr15:50937123	C/T	cg08437265	chr15:50716283	USP8	0.41	5.41	0.32	1.41e-7	QT interval;
CESC	cis	rs734999	0.572	rs3748816	chr1:2526746	A/G	cg18854424	chr1:2615690	NA	0.27	5.43	0.32	1.27e-7	Ulcerative colitis;
CESC	cis	rs35110281	0.591	rs162369	chr21:44931965	G/A	cg01579765	chr21:45077557	HSF2BP	-0.49	-8.43	-0.46	2.25e-15	Mean corpuscular volume;
CESC	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg06873352	chr17:61820015	STRADA	0.72	12.61	0.61	7.18e-29	Prudent dietary pattern;
CESC	cis	rs6952808	0.531	rs3778991	chr7:2172455	G/A	cg23048001	chr7:2026167	MAD1L1	0.41	5.25	0.31	3.07e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs12541635	0.966	rs7819327	chr8:106986003	A/C	cg10147462	chr8:107024639	NA	0.41	5.62	0.33	4.73e-8	Age of smoking initiation;
CESC	cis	rs2637266	1.000	rs2395390	chr10:78357734	C/G	cg18941641	chr10:78392320	NA	0.42	7.73	0.43	2.28e-13	Pulmonary function;
CESC	cis	rs9381040	0.674	rs4711657	chr6:41162715	G/A	cg20398880	chr6:41068722	NFYA;LOC221442	-0.39	-5.06	-0.3	7.8e-7	Alzheimer's disease (late onset);
CESC	cis	rs853679	0.517	rs9368554	chr6:28082711	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.58	-6.75	-0.38	9.45e-11	Depression;
CESC	cis	rs5769765	0.955	rs2295406	chr22:50260169	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	0.45	5.26	0.31	3.05e-7	Schizophrenia;
CESC	cis	rs7546094	1.000	rs6669096	chr1:113132361	T/C	cg22162597	chr1:113214053	CAPZA1	0.38	5.86	0.34	1.35e-8	Platelet distribution width;
CESC	cis	rs1799949	1.000	rs12950607	chr17:41299928	G/C	cg05368731	chr17:41323189	NBR1	0.8	11.27	0.57	2.51e-24	Menopause (age at onset);
CESC	cis	rs4819052	0.851	rs2838828	chr21:46663423	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.9	13.15	0.63	1e-30	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs7618501	1.000	rs34451146	chr3:49813013	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.58	8.4	0.46	2.71e-15	Intelligence (multi-trait analysis);
CESC	cis	rs12220238	1.000	rs10824129	chr10:76008855	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.61	6.02	0.35	5.8e-9	Soluble interleukin-2 receptor subunit alpha;
CESC	cis	rs2742234	0.541	rs11238479	chr10:43717423	C/T	cg15436174	chr10:43711423	RASGEF1A	0.47	5.58	0.32	5.81e-8	Hirschsprung disease;
CESC	cis	rs727505	1.000	rs59294613	chr7:124554267	C/A	cg23710748	chr7:124431027	NA	-0.39	-6.33	-0.36	1.05e-9	Lewy body disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg06505107	chr7:1177883	C7orf50	-0.46	-6.15	-0.35	2.89e-9	Fibrinogen levels;
CESC	cis	rs17253792	0.915	rs28663681	chr14:56178820	A/T	cg01858014	chr14:56050164	KTN1	-0.94	-7.27	-0.41	4.03e-12	Putamen volume;
CESC	cis	rs1448094	0.512	rs7133591	chr12:86239752	G/C	cg02569458	chr12:86230093	RASSF9	0.48	7.26	0.41	4.17e-12	Major depressive disorder;
CESC	cis	rs7845219	0.544	rs7001535	chr8:95921090	C/G	cg16049864	chr8:95962084	TP53INP1	-0.49	-7.22	-0.41	5.48e-12	Type 2 diabetes;
CESC	cis	rs9487051	0.872	rs9480923	chr6:109607369	G/C	cg12927641	chr6:109611667	NA	-0.44	-6.83	-0.39	5.89e-11	Reticulocyte fraction of red cells;
CESC	cis	rs3008870	0.583	rs3008892	chr1:67373558	A/T	cg08660285	chr1:67390436	MIER1;WDR78	1.0	11.28	0.57	2.4e-24	Lymphocyte percentage of white cells;
CESC	cis	rs2066819	1.000	rs77032009	chr12:56679971	A/G	cg26714650	chr12:56694279	CS	-1.52	-10.39	-0.54	1.95e-21	Psoriasis vulgaris;
CESC	cis	rs2836633	0.929	rs2836602	chr21:40039169	A/T	cg05519781	chr21:40033154	ERG	-0.75	-13.05	-0.63	2.17e-30	Coronary artery disease;
CESC	cis	rs7772486	0.754	rs702304	chr6:145990797	A/G	cg05347473	chr6:146136440	FBXO30	-0.53	-6.79	-0.38	7.4e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs11146838	1	rs11146838	chr10:39149977	A/T	cg17219203	chr10:38645113	HSD17B7P2	-0.46	-5.73	-0.33	2.78e-8	Breast cancer;
CESC	cis	rs9323205	0.861	rs55763867	chr14:51608567	G/A	cg23942311	chr14:51606299	NA	-0.46	-6.1	-0.35	3.81e-9	Cancer;
CESC	cis	rs28489187	0.683	rs6576764	chr1:85866411	A/T	cg16011679	chr1:85725395	C1orf52	-0.44	-5.32	-0.31	2.22e-7	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	trans	rs561341	0.769	rs7217004	chr17:30178092	A/G	cg20587970	chr11:113659929	NA	1.02	10.75	0.55	1.29e-22	Hip circumference adjusted for BMI;
CESC	cis	rs4925386	1.000	rs6089351	chr20:60916153	G/A	cg24112000	chr20:60950667	NA	0.51	7.53	0.42	8.09e-13	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs9300255	0.537	rs1716182	chr12:123686127	A/C	cg00376283	chr12:123451042	ABCB9	0.71	8.92	0.48	7.69e-17	Neutrophil percentage of white cells;
CESC	cis	rs9287719	0.934	rs6432110	chr2:10738018	T/A	cg02196655	chr2:10830764	NOL10	-0.37	-5.72	-0.33	2.87e-8	Prostate cancer;
CESC	cis	rs7524258	0.868	rs4908448	chr1:7269283	A/G	cg07173049	chr1:7289937	CAMTA1	-0.32	-5.06	-0.3	7.93e-7	Tourette's syndrome or obsessive-compulsive disorder;
CESC	cis	rs12142240	0.659	rs17361873	chr1:46832686	A/G	cg10495392	chr1:46806563	NSUN4	0.57	6.24	0.36	1.74e-9	Menopause (age at onset);
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg23593986	chr20:33577678	MIR499;MYH7B	-0.46	-6.62	-0.38	1.93e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs4969178	1.000	rs4969178	chr17:76388202	C/T	cg05887092	chr17:76393375	PGS1	-0.56	-8.82	-0.48	1.57e-16	HDL cholesterol levels;
CESC	cis	rs56775891	1.000	rs56775891	chr18:77575613	C/T	cg13263691	chr18:77568018	NA	0.52	7.54	0.42	7.43e-13	Schizophrenia;
CESC	cis	rs9733	0.596	rs72702523	chr1:150650425	G/T	cg17724175	chr1:150552817	MCL1	0.44	7.21	0.41	5.8e-12	Tonsillectomy;
CESC	cis	rs9896933	0.832	rs75552659	chr17:80804630	G/A	cg15664640	chr17:80829946	TBCD	-0.54	-5.81	-0.34	1.76e-8	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
CESC	cis	rs1448094	0.511	rs1993807	chr12:86146833	A/G	cg02569458	chr12:86230093	RASSF9	-0.42	-6.44	-0.37	5.67e-10	Major depressive disorder;
CESC	cis	rs875971	0.964	rs2161065	chr7:65932905	A/G	cg11764359	chr7:65958608	NA	0.94	14.96	0.68	4.3e-37	Aortic root size;
CESC	cis	rs1691799	0.867	rs2172881	chr12:66766039	C/G	cg16791601	chr12:66731901	HELB	-0.76	-13.45	-0.64	8.78e-32	White blood cell count (basophil);
CESC	cis	rs60871478	0.541	rs56964970	chr7:910791	G/C	cg13798912	chr7:905769	UNC84A	-0.57	-5.55	-0.32	6.82e-8	Cerebrospinal P-tau181p levels;
CESC	cis	rs2832191	0.791	rs2832186	chr21:30484151	A/C	cg24692254	chr21:30365293	RNF160	-0.78	-12.16	-0.6	2.57e-27	Dental caries;
CESC	cis	rs941873	0.868	rs7898	chr10:81114959	C/T	cg08514558	chr10:81106712	PPIF	0.33	5.8	0.34	1.85e-8	Height;
CESC	cis	rs12541335	0.639	rs7834182	chr8:22163112	G/A	cg18135555	chr8:22132992	PIWIL2	0.25	5.35	0.31	1.93e-7	Hypertriglyceridemia;
CESC	cis	rs7208859	0.573	rs55661352	chr17:29045628	A/G	cg14008862	chr17:28927542	LRRC37B2	0.67	5.17	0.3	4.7e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs6433857	0.536	rs7557023	chr2:181350474	G/A	cg23363182	chr2:181467187	NA	-0.41	-5.94	-0.34	9.11e-9	Body mass index;
CESC	cis	rs12497850	0.865	rs7649458	chr3:48920127	C/T	cg06212747	chr3:49208901	KLHDC8B	0.65	8.98	0.48	5.35e-17	Parkinson's disease;
CESC	cis	rs10779751	1.000	rs2024627	chr1:11298790	T/C	cg08854313	chr1:11322531	MTOR	0.79	10.78	0.55	1.06e-22	Body mass index;
CESC	cis	rs1005277	0.579	rs2983343	chr10:38383332	A/G	cg25517755	chr10:38738941	LOC399744	-0.48	-6.22	-0.36	1.95e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs11098499	0.954	rs6857105	chr4:120222298	C/G	cg24375607	chr4:120327624	NA	0.45	5.57	0.32	6.19e-8	Corneal astigmatism;
CESC	cis	rs6570726	0.791	rs4335004	chr6:145904764	G/A	cg05347473	chr6:146136440	FBXO30	0.58	7.38	0.41	2.1e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs60154123	0.730	rs12403947	chr1:210456524	A/G	cg21951975	chr1:209979733	IRF6	-0.48	-6.23	-0.36	1.78e-9	Coronary artery disease;
CESC	cis	rs9611565	0.512	rs45500192	chr22:42177899	A/G	cg03806693	chr22:41940476	POLR3H	-1.18	-13.79	-0.65	5.81e-33	Vitiligo;
CESC	cis	rs7605827	0.681	rs63106161	chr2:15537726	T/C	cg19274914	chr2:15703543	NA	0.36	6.55	0.37	2.91e-10	Educational attainment (years of education);
CESC	cis	rs300703	0.719	rs423314	chr2:195372	A/G	cg21211680	chr2:198530	NA	1.07	12.54	0.61	1.25e-28	Blood protein levels;
CESC	cis	rs9733	0.596	rs6685702	chr1:150656307	A/G	cg04414720	chr1:150670196	GOLPH3L	0.63	9.01	0.48	4.11e-17	Tonsillectomy;
CESC	trans	rs7246760	1.000	rs112124298	chr19:9923154	T/C	cg02900749	chr2:68251473	NA	-0.74	-6.84	-0.39	5.62e-11	Pursuit maintenance gain;
CESC	cis	rs4654899	0.802	rs6685306	chr1:21219050	C/T	cg05370193	chr1:21551575	ECE1	0.4	5.72	0.33	2.81e-8	Superior frontal gyrus grey matter volume;
CESC	cis	rs798554	0.757	rs2533879	chr7:2859847	G/A	cg19346786	chr7:2764209	NA	-0.51	-7.34	-0.41	2.69e-12	Height;
CESC	cis	rs12220238	0.908	rs11000937	chr10:75998785	A/C	cg19889307	chr10:75911429	ADK;AP3M1	0.61	5.98	0.35	7.02e-9	Soluble interleukin-2 receptor subunit alpha;
CESC	cis	rs12368653	1.000	rs12371356	chr12:58135420	T/C	cg00677455	chr12:58241039	CTDSP2	-0.42	-5.51	-0.32	8.7e-8	Multiple sclerosis;
CESC	cis	rs9633740	1.000	rs7922621	chr10:82251544	C/A	cg00277334	chr10:82204260	NA	-0.57	-5.73	-0.33	2.69e-8	Post bronchodilator FEV1;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00309178	chr1:242011396	EXO1	0.57	6.19	0.36	2.27e-9	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15034757	chr3:186617939	NA	-0.57	-6.42	-0.37	6.18e-10	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26335430	chr17:73780571	UNK	-0.59	-7.05	-0.4	1.56e-11	Gut microbiome composition (summer);
CESC	cis	rs3785574	0.962	rs2584632	chr17:61880641	G/A	cg06873352	chr17:61820015	STRADA	0.47	6.85	0.39	5.3e-11	Height;
CESC	cis	rs798554	0.704	rs798512	chr7:2782592	C/G	cg13628971	chr7:2884303	GNA12	0.42	5.5	0.32	9.03e-8	Height;
CESC	cis	rs7829975	0.742	rs1533058	chr8:8685190	A/G	cg06636001	chr8:8085503	FLJ10661	0.44	5.56	0.32	6.64e-8	Mood instability;
CESC	cis	rs72781680	0.848	rs55725028	chr2:23966447	A/G	cg08917208	chr2:24149416	ATAD2B	1.09	9.91	0.52	6.96e-20	Lymphocyte counts;
CESC	cis	rs6502050	0.635	rs11867440	chr17:80147185	A/T	cg11859384	chr17:80120422	CCDC57	-0.38	-5.17	-0.3	4.56e-7	Life satisfaction;
CESC	cis	rs11785400	1.000	rs7459630	chr8:143738585	A/C	cg24634471	chr8:143751801	JRK	0.47	6.25	0.36	1.66e-9	Schizophrenia;
CESC	cis	rs9902453	0.619	rs2244585	chr17:28072176	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-10.22	-0.53	6.81e-21	Coffee consumption (cups per day);
CESC	cis	rs6963495	0.745	rs818620	chr7:105172685	G/C	cg02135003	chr7:105160482	PUS7	-0.43	-5.88	-0.34	1.24e-8	Bipolar disorder (body mass index interaction);
CESC	cis	rs909674	0.818	rs7364148	chr22:39842165	T/C	cg01416388	chr22:39784598	NA	-0.62	-7.29	-0.41	3.5e-12	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs7246657	0.943	rs2081096	chr19:37964700	G/A	cg23950597	chr19:37808831	NA	-0.54	-5.93	-0.34	9.47e-9	Coronary artery calcification;
CESC	cis	rs11920090	0.720	rs5394	chr3:170744893	G/A	cg09710316	chr3:170744871	SLC2A2	0.48	5.38	0.31	1.62e-7	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18803079	chr1:64014643	EFCAB7;DLEU2L	-0.7	-8.0	-0.44	3.88e-14	Gut microbiome composition (summer);
CESC	cis	rs72781680	1.000	rs72796357	chr2:24160131	A/G	cg08917208	chr2:24149416	ATAD2B	0.94	8.52	0.46	1.26e-15	Lymphocyte counts;
CESC	cis	rs910316	1.000	rs12435391	chr14:75601737	A/G	cg11812906	chr14:75593930	NEK9	0.89	15.29	0.68	2.96e-38	Height;
CESC	cis	rs644799	0.526	rs542509	chr11:95641602	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.55	7.41	0.41	1.69e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs1008375	1.000	rs4642241	chr4:17617111	T/C	cg02297831	chr4:17616191	MED28	0.53	6.73	0.38	1.04e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs17376456	0.825	rs13361613	chr5:93272176	C/T	cg25358565	chr5:93447407	FAM172A	1.12	10.4	0.54	1.88e-21	Diabetic retinopathy;
CESC	cis	rs12136530	0.625	rs12726614	chr1:19730957	G/C	cg01832549	chr1:19774989	CAPZB	-0.44	-6.25	-0.36	1.59e-9	Lead levels in blood;
CESC	cis	rs4665809	0.793	rs6546715	chr2:26261520	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.69	-7.83	-0.43	1.19e-13	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05863534	chr17:34948351	DHRS11	0.58	6.56	0.37	2.77e-10	Gut microbiome composition (summer);
CESC	cis	rs686320	1.000	rs72643572	chr11:65250967	A/G	cg21890820	chr11:65308645	LTBP3	0.48	5.25	0.31	3.15e-7	Hip circumference adjusted for BMI;
CESC	cis	rs7917772	0.503	rs61871067	chr10:104295382	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.58	7.05	0.4	1.6e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs9837602	0.872	rs1489816	chr3:99769088	C/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.49	-6.91	-0.39	3.51e-11	Breast cancer;
CESC	cis	rs896854	0.517	rs2013597	chr8:95951807	G/A	cg23172400	chr8:95962367	TP53INP1	-0.41	-7.29	-0.41	3.51e-12	Type 2 diabetes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05424782	chr22:42017079	XRCC6;PPPDE2	-0.7	-7.55	-0.42	6.88e-13	Gut microbiome composition (summer);
CESC	cis	rs1475911	0.708	rs11701371	chr21:43523972	C/G	cg03240473	chr21:43526662	UMODL1;C21orf128	-0.54	-7.36	-0.41	2.25e-12	IgG glycosylation;
CESC	cis	rs7560272	0.513	rs7558546	chr2:73937732	A/T	cg20560298	chr2:73613845	ALMS1	0.4	5.57	0.32	6.27e-8	Schizophrenia;
CESC	cis	rs11792861	0.781	rs11789252	chr9:111762010	A/T	cg13535736	chr9:111863775	C9orf5	-0.46	-6.04	-0.35	5.1e-9	Menarche (age at onset);
CESC	cis	rs11098499	0.954	rs10005644	chr4:120298477	T/C	cg24375607	chr4:120327624	NA	0.46	5.55	0.32	6.98e-8	Corneal astigmatism;
CESC	cis	rs1580019	0.539	rs11769109	chr7:32571352	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.5	6.38	0.36	7.89e-10	Cognitive ability;
CESC	cis	rs951366	1.000	rs951366	chr1:205685352	C/T	cg07167872	chr1:205819463	PM20D1	0.37	5.39	0.31	1.56e-7	Menarche (age at onset);
CESC	cis	rs7692995	1.000	rs2085683	chr4:18007435	C/G	cg08925142	chr4:18023851	LCORL	-0.44	-5.08	-0.3	7.07e-7	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22168255	chr1:156627392	BCAN	0.52	6.13	0.35	3.12e-9	Gut microbiome composition (summer);
CESC	cis	rs826838	0.834	rs826874	chr12:39122599	C/A	cg26384229	chr12:38710491	ALG10B	-0.63	-10.32	-0.54	3.31e-21	Heart rate;
CESC	cis	rs6456156	0.603	rs2345754	chr6:167484361	T/C	cg23791538	chr6:167370224	RNASET2	-0.51	-6.44	-0.37	5.67e-10	Primary biliary cholangitis;
CESC	cis	rs11098499	0.866	rs12510451	chr4:120289143	C/T	cg09307838	chr4:120376055	NA	0.87	12.16	0.6	2.41e-27	Corneal astigmatism;
CESC	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg19626725	chr5:178986131	RUFY1	0.41	6.69	0.38	1.34e-10	Lung cancer;
CESC	cis	rs4728302	0.869	rs13233690	chr7:133587328	C/T	cg10665199	chr7:133106180	EXOC4	0.39	5.43	0.32	1.29e-7	Intelligence;Intelligence (multi-trait analysis);
CESC	cis	rs11264213	0.786	rs72659671	chr1:36237762	C/T	cg27506609	chr1:36549197	TEKT2	0.65	5.34	0.31	1.97e-7	Schizophrenia;
CESC	cis	rs13256369	0.853	rs13256216	chr8:8577883	C/T	cg18904891	chr8:8559673	CLDN23	0.65	7.1	0.4	1.16e-11	Obesity-related traits;
CESC	cis	rs9325144	0.555	rs7977200	chr12:38713745	C/T	cg26384229	chr12:38710491	ALG10B	0.59	8.37	0.46	3.43e-15	Morning vs. evening chronotype;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg26007659	chr1:146643600	PRKAB2	-0.49	-6.13	-0.35	3.1e-9	Asthma;
CESC	cis	rs9911578	0.692	rs411988	chr17:56709034	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.41	5.44	0.32	1.21e-7	Intelligence (multi-trait analysis);
CESC	cis	rs4319547	0.695	rs10773152	chr12:122910180	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.54	-6.19	-0.36	2.3e-9	Body mass index;
CESC	cis	rs344364	0.511	rs1742469	chr16:1950244	C/T	cg03013636	chr16:1946785	NA	0.48	6.62	0.38	2.02e-10	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs9911578	0.935	rs2567912	chr17:56731270	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.4	5.29	0.31	2.5e-7	Intelligence (multi-trait analysis);
CESC	cis	rs6500395	1.000	rs3848321	chr16:48620780	A/T	cg04672837	chr16:48644449	N4BP1	0.51	6.5	0.37	3.95e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs7412746	0.622	rs72704654	chr1:150826410	G/A	cg22823121	chr1:150693482	HORMAD1	0.44	6.11	0.35	3.48e-9	Melanoma;
CESC	cis	rs1008375	1.000	rs2058339	chr4:17678456	C/T	cg02297831	chr4:17616191	MED28	0.45	5.82	0.34	1.69e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs7647973	0.593	rs4855885	chr3:49690199	G/A	cg07636037	chr3:49044803	WDR6	0.52	5.93	0.34	9.51e-9	Menarche (age at onset);
CESC	cis	rs6570726	0.791	rs370654	chr6:145879005	C/G	cg23711669	chr6:146136114	FBXO30	0.98	15.12	0.68	1.11e-37	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2599510	0.807	rs176416	chr2:32652223	A/G	cg02381751	chr2:32503542	YIPF4	-0.45	-5.58	-0.32	5.92e-8	Interleukin-18 levels;
CESC	cis	rs9910055	0.552	rs12937114	chr17:42325073	A/G	cg13607699	chr17:42295918	UBTF	0.87	12.61	0.61	7.04e-29	Total body bone mineral density;
CESC	cis	rs7666738	0.830	rs6848397	chr4:98946738	A/G	cg05340658	chr4:99064831	C4orf37	0.82	12.66	0.61	4.8e-29	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9863	0.861	rs4765219	chr12:124440110	G/T	cg17562584	chr12:124393655	DNAH10	0.29	5.06	0.3	7.91e-7	White blood cell count;
CESC	cis	rs12497850	0.864	rs4955410	chr3:49181218	A/G	cg06212747	chr3:49208901	KLHDC8B	0.72	9.73	0.51	2.47e-19	Parkinson's disease;
CESC	cis	rs10771431	1.000	rs10771431	chr12:9380859	C/T	cg00504896	chr12:9437009	LOC642846	-0.38	-5.05	-0.3	8.41e-7	Breast size;
CESC	cis	rs780094	0.564	rs4665978	chr2:27648726	T/C	cg21248554	chr2:27665150	KRTCAP3	-0.28	-5.99	-0.35	6.88e-9	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
CESC	cis	rs2228479	0.850	rs17232910	chr16:89839766	G/C	cg14709524	chr16:89940631	TCF25	0.91	6.74	0.38	1e-10	Skin colour saturation;
CESC	cis	rs79349575	0.783	rs58591767	chr17:47026076	G/A	cg26022315	chr17:47021804	SNF8	0.39	5.16	0.3	4.94e-7	Type 2 diabetes;
CESC	cis	rs3015497	0.603	rs2291672	chr14:51060452	A/G	cg26011998	chr14:51135199	SAV1	-0.48	-5.45	-0.32	1.16e-7	Mean platelet volume;
CESC	cis	rs7789940	0.810	rs12533978	chr7:75943352	T/C	cg10167463	chr7:75959203	YWHAG	-0.51	-5.89	-0.34	1.17e-8	Multiple sclerosis;
CESC	trans	rs11088226	0.681	rs8131384	chr21:33944127	C/T	cg09050820	chr6:167586206	TCP10L2	0.87	8.43	0.46	2.32e-15	Gastritis;
CESC	cis	rs977987	0.778	rs34222958	chr16:75398252	C/T	cg03315344	chr16:75512273	CHST6	0.39	5.63	0.33	4.61e-8	Dupuytren's disease;
CESC	cis	rs875971	1.000	rs1544549	chr7:66090663	T/A	cg12463550	chr7:65579703	CRCP	-0.56	-7.09	-0.4	1.25e-11	Aortic root size;
CESC	cis	rs35306767	0.715	rs11253550	chr10:1028288	C/G	cg26597838	chr10:835615	NA	0.76	7.14	0.4	8.95e-12	Eosinophil percentage of granulocytes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06458679	chr21:46974866	NA	0.58	6.95	0.39	2.75e-11	Gut microbiome composition (summer);
CESC	cis	rs7714584	1.000	rs10463307	chr5:150254620	C/T	cg22134413	chr5:150180641	NA	0.51	5.5	0.32	8.92e-8	Crohn's disease;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg16793757	chr10:62098976	ANK3	-0.44	-6.35	-0.36	9.46e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs4975616	0.869	rs452932	chr5:1330253	T/C	cg06550200	chr5:1325588	CLPTM1L	-0.7	-11.16	-0.57	5.97e-24	Lung cancer;
CESC	cis	rs1577917	0.771	rs2758847	chr6:86349103	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.53	-7.03	-0.4	1.71e-11	Response to antipsychotic treatment;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01759413	chr5:180650114	TRIM41	0.54	6.01	0.35	6.01e-9	Gut microbiome composition (summer);
CESC	cis	rs875971	0.867	rs13227219	chr7:65844062	T/A	cg10691866	chr7:65817282	TPST1	-0.32	-5.06	-0.3	7.94e-7	Aortic root size;
CESC	cis	rs2280018	0.963	rs12928424	chr16:15150773	C/G	cg27102117	chr16:15229624	NA	0.48	7.5	0.42	9.75e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs10504229	0.575	rs78075335	chr8:57997243	A/C	cg22535103	chr8:58192502	C8orf71	-0.56	-6.58	-0.37	2.48e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs2625529	0.668	rs34189331	chr15:72404573	A/T	cg16672083	chr15:72433130	SENP8	-0.36	-5.08	-0.3	7.27e-7	Red blood cell count;
CESC	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg27094323	chr7:1216898	NA	-0.39	-5.28	-0.31	2.64e-7	Longevity;Endometriosis;
CESC	cis	rs1348850	0.914	rs2364854	chr2:178378452	T/A	cg22681709	chr2:178499509	PDE11A	-0.39	-5.72	-0.33	2.8e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs1799949	0.896	rs35908185	chr17:41255111	A/T	cg25072359	chr17:41440525	NA	0.45	6.14	0.35	2.95e-9	Menopause (age at onset);
CESC	cis	rs11828289	0.714	rs1384478	chr11:23243582	T/C	cg20040320	chr11:23191996	NA	0.66	5.75	0.33	2.42e-8	Cancer;
CESC	cis	rs2228479	0.557	rs2293584	chr16:89888686	C/G	cg00800038	chr16:89945340	TCF25	-0.89	-6.88	-0.39	4.34e-11	Skin colour saturation;
CESC	cis	rs2898681	0.618	rs116241740	chr4:53733523	A/G	cg00791764	chr4:53727839	RASL11B	0.51	5.13	0.3	5.53e-7	Optic nerve measurement (cup area);
CESC	cis	rs6120849	0.754	rs6120804	chr20:33623701	C/A	cg06115741	chr20:33292138	TP53INP2	0.53	5.05	0.3	8.15e-7	Protein C levels;
CESC	cis	rs17401966	0.931	rs12137880	chr1:10388620	T/C	cg15208524	chr1:10270712	KIF1B	0.43	5.47	0.32	1.04e-7	Hepatocellular carcinoma;
CESC	cis	rs4700695	0.668	rs253212	chr5:65497553	C/T	cg21114390	chr5:65439923	SFRS12	-0.48	-5.85	-0.34	1.48e-8	Facial morphology (factor 19);
CESC	trans	rs1667255	0.830	rs2034404	chr18:29156302	A/G	cg21942430	chr1:65613385	AK3L1	0.48	6.29	0.36	1.27e-9	Retinol levels;
CESC	cis	rs72781680	0.611	rs78861366	chr2:24354428	A/G	cg20701182	chr2:24300061	SF3B14	0.93	10.43	0.54	1.41e-21	Lymphocyte counts;
CESC	cis	rs9611565	0.649	rs126092	chr22:42178441	A/G	cg03806693	chr22:41940476	POLR3H	0.71	8.08	0.44	2.25e-14	Vitiligo;
CESC	cis	rs12142240	0.698	rs17413694	chr1:46818416	A/C	cg00530320	chr1:46809349	NSUN4	0.58	7.89	0.44	8.15e-14	Menopause (age at onset);
CESC	cis	rs8028182	0.636	rs4451914	chr15:75739824	C/T	cg20655648	chr15:75932815	IMP3	0.48	6.1	0.35	3.67e-9	Sudden cardiac arrest;
CESC	cis	rs9911578	0.934	rs8081967	chr17:57072701	T/C	cg05425664	chr17:57184151	TRIM37	-0.52	-7.09	-0.4	1.21e-11	Intelligence (multi-trait analysis);
CESC	cis	rs11630290	1.000	rs72750986	chr15:63996338	C/A	cg12036633	chr15:63758958	NA	-0.57	-5.34	-0.31	2.04e-7	Iris characteristics;
CESC	cis	rs6570726	0.791	rs6913727	chr6:145899826	A/G	cg23711669	chr6:146136114	FBXO30	0.97	14.97	0.68	4.06e-37	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs769267	1.000	rs769267	chr19:19446936	A/G	cg15052019	chr19:19431593	KIAA0892;SF4	0.43	5.48	0.32	9.84e-8	Tonsillectomy;
CESC	cis	rs4595586	0.546	rs11169801	chr12:39241429	G/A	cg13010199	chr12:38710504	ALG10B	0.57	7.65	0.43	3.78e-13	Morning vs. evening chronotype;
CESC	cis	rs17376456	0.825	rs13156202	chr5:93157721	C/T	cg21475434	chr5:93447410	FAM172A	-0.78	-7.02	-0.4	1.84e-11	Diabetic retinopathy;
CESC	cis	rs6831352	0.918	rs7694646	chr4:100059732	T/A	cg12011299	chr4:100065546	ADH4	-0.59	-6.59	-0.38	2.35e-10	Alcohol dependence;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02661258	chr5:14664470	FAM105B	0.57	6.74	0.38	1.01e-10	Gut microbiome composition (summer);
CESC	cis	rs962856	0.619	rs1027000	chr2:67600789	T/C	cg09028215	chr2:67624308	ETAA1	-0.42	-5.1	-0.3	6.49e-7	Pancreatic cancer;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg20756454	chr17:28951397	LRRC37B2	0.53	6.87	0.39	4.66e-11	Fibrinogen levels;
CESC	cis	rs12477438	0.501	rs11683107	chr2:99759235	T/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.78	13.4	0.64	1.33e-31	Chronic sinus infection;
CESC	cis	rs7811142	1.000	rs1073	chr7:100031612	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.06	10.39	0.54	1.98e-21	Platelet count;
CESC	cis	rs3815700	1.000	rs8109990	chr19:33095636	A/G	cg02997394	chr19:33096574	ANKRD27	0.71	7.09	0.4	1.21e-11	Eosinophilic esophagitis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06733439	chr2:118845890	INSIG2	0.58	6.34	0.36	9.83e-10	Gut microbiome composition (summer);
CESC	cis	rs2204008	0.538	rs11514000	chr12:38067706	A/G	cg26384229	chr12:38710491	ALG10B	0.52	7.59	0.42	5.36e-13	Bladder cancer;
CESC	cis	rs67311347	1.000	rs56992941	chr3:40472434	A/T	cg09455208	chr3:40491958	NA	0.46	8.07	0.44	2.39e-14	Renal cell carcinoma;
CESC	cis	rs6502050	0.835	rs4789754	chr17:80091941	C/T	cg11859384	chr17:80120422	CCDC57	-0.38	-5.21	-0.3	3.8e-7	Life satisfaction;
CESC	trans	rs9325144	0.647	rs1875609	chr12:39018259	C/T	cg23762105	chr12:34175262	ALG10	0.48	6.33	0.36	1.01e-9	Morning vs. evening chronotype;
CESC	cis	rs6982240	0.569	rs6992286	chr8:142279412	G/A	cg00131261	chr8:142287264	NA	-0.52	-7.47	-0.42	1.19e-12	Tonsillectomy;
CESC	cis	rs4713118	0.662	rs149961	chr6:28015569	A/C	cg19592336	chr6:28129416	ZNF389	0.52	6.67	0.38	1.48e-10	Parkinson's disease;
CESC	cis	rs6460942	1.000	rs2053382	chr7:12400587	A/G	cg02935154	chr7:12443704	VWDE	-0.57	-6.16	-0.35	2.7e-9	Coronary artery disease;
CESC	trans	rs11098499	0.708	rs1546506	chr4:120241240	T/C	cg25214090	chr10:38739885	LOC399744	0.62	8.55	0.46	1.01e-15	Corneal astigmatism;
CESC	cis	rs826838	0.935	rs11169508	chr12:39173385	C/T	cg26384229	chr12:38710491	ALG10B	0.78	13.0	0.62	3.24e-30	Heart rate;
CESC	cis	rs7666738	0.515	rs13131874	chr4:98779183	A/G	cg17366294	chr4:99064904	C4orf37	0.5	6.19	0.36	2.34e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10885582	0.774	rs11196782	chr10:116302495	A/G	cg17056676	chr10:116301354	ABLIM1	-0.29	-5.19	-0.3	4.28e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs2842992	0.915	rs2842958	chr6:160108425	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.64	8.1	0.45	2.06e-14	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs3780486	0.846	rs6476402	chr9:33148552	G/A	cg13443165	chr9:33130375	B4GALT1	0.47	6.91	0.39	3.6e-11	IgG glycosylation;
CESC	cis	rs7103648	0.669	rs7131262	chr11:47836302	T/A	cg20307385	chr11:47447363	PSMC3	0.79	11.51	0.58	3.8e-25	Diastolic blood pressure;Systolic blood pressure;
CESC	cis	rs4948102	0.597	rs12669623	chr7:56139179	G/C	cg09872392	chr7:56161020	PHKG1	-0.45	-7.37	-0.41	2.19e-12	Plasma homocysteine levels (post-methionine load test);
CESC	cis	rs3126085	0.877	rs12065368	chr1:152253497	C/T	cg03465714	chr1:152285911	FLG	-0.45	-5.56	-0.32	6.52e-8	Atopic dermatitis;
CESC	cis	rs116095464	0.558	rs60251075	chr5:245292	T/C	cg12570787	chr5:219185	SDHA;CCDC127	0.5	5.27	0.31	2.9e-7	Breast cancer;
CESC	cis	rs853679	0.517	rs12174753	chr6:28042465	C/G	cg22143856	chr6:28129313	ZNF389	0.49	6.3	0.36	1.2e-9	Depression;
CESC	cis	rs7772486	0.686	rs4896833	chr6:145965673	T/G	cg05347473	chr6:146136440	FBXO30	0.53	6.9	0.39	3.92e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4237845	0.591	rs10747788	chr12:58315338	C/T	cg02175503	chr12:58329896	NA	0.8	10.59	0.55	4.42e-22	Intelligence (multi-trait analysis);
CESC	cis	rs11955398	0.625	rs11739209	chr5:59959767	T/C	cg02684056	chr5:59996105	DEPDC1B	0.4	5.09	0.3	6.86e-7	Intelligence (multi-trait analysis);
CESC	cis	rs631288	0.655	rs4245679	chr1:146710504	C/A	cg25205988	chr1:146714368	CHD1L	1.07	6.04	0.35	5.32e-9	PR interval in Tripanosoma cruzi seropositivity;
CESC	cis	rs801193	0.591	rs9986881	chr7:66173040	A/G	cg18876405	chr7:65276391	NA	0.4	5.19	0.3	4.29e-7	Aortic root size;
CESC	cis	rs12048904	0.505	rs10493936	chr1:101213335	A/T	cg15686842	chr1:101360669	SLC30A7;EXTL2	-0.49	-5.5	-0.32	8.82e-8	Multiple sclerosis;
CESC	cis	rs11997175	0.568	rs4733169	chr8:33581855	T/C	ch.8.33884649F	chr8:33765107	NA	0.47	5.65	0.33	4.11e-8	Body mass index;
CESC	cis	rs875971	0.522	rs2008188	chr7:65429013	G/C	cg06456125	chr7:65229604	NA	0.45	5.91	0.34	1.03e-8	Aortic root size;
CESC	cis	rs9649213	0.593	rs6949214	chr7:97960233	G/A	cg00277769	chr7:97922759	BAIAP2L1	-0.33	-5.42	-0.32	1.31e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs372883	0.532	rs388707	chr21:30714776	T/C	cg24692254	chr21:30365293	RNF160	-0.49	-6.46	-0.37	5.04e-10	Pancreatic cancer;
CESC	cis	rs807669	0.544	rs2040771	chr22:19161935	C/T	cg02655711	chr22:19163373	SLC25A1	0.42	6.22	0.36	1.9e-9	Metabolite levels;
CESC	cis	rs4810685	0.816	rs1413146	chr20:46407290	C/T	cg08288986	chr20:46415360	SULF2	0.56	6.99	0.39	2.21e-11	Attention deficit hyperactivity disorder (time to onset);
CESC	cis	rs7592578	0.581	rs59109438	chr2:191287683	A/G	cg27211696	chr2:191398769	TMEM194B	-0.6	-6.15	-0.35	2.88e-9	Diastolic blood pressure;
CESC	cis	rs7843479	0.965	rs1564305	chr8:21803816	A/C	cg17168535	chr8:21777572	XPO7	0.5	6.86	0.39	4.85e-11	Mean corpuscular volume;
CESC	cis	rs73206853	0.764	rs55929416	chr12:110622543	C/T	cg12870014	chr12:110450643	ANKRD13A	0.65	5.62	0.33	4.79e-8	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs826838	0.510	rs10506129	chr12:39224242	A/T	cg13010199	chr12:38710504	ALG10B	0.58	7.73	0.43	2.17e-13	Heart rate;
CESC	cis	rs12479064	0.724	rs10496336	chr2:99996165	A/G	cg09787394	chr2:99771194	LIPT1;TSGA10	0.48	5.03	0.3	8.99e-7	Chronic sinus infection;
CESC	cis	rs6088580	0.634	rs62212172	chr20:32987705	G/A	cg08999081	chr20:33150536	PIGU	-0.64	-11.24	-0.57	3.23e-24	Glomerular filtration rate (creatinine);
CESC	cis	rs3733585	0.605	rs4697710	chr4:10122649	T/C	cg11266682	chr4:10021025	SLC2A9	-0.57	-10.15	-0.53	1.13e-20	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs7666738	0.830	rs6532719	chr4:99043691	A/G	cg03467027	chr4:99064603	C4orf37	0.47	5.96	0.34	8.08e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs875971	0.862	rs801203	chr7:66023012	A/G	cg10691866	chr7:65817282	TPST1	0.33	5.51	0.32	8.51e-8	Aortic root size;
CESC	cis	rs4595586	0.546	rs11609849	chr12:39258090	C/G	cg13010199	chr12:38710504	ALG10B	0.58	7.79	0.43	1.52e-13	Morning vs. evening chronotype;
CESC	cis	rs3008870	1.000	rs2815352	chr1:67482104	A/G	cg02640540	chr1:67518911	SLC35D1	0.48	5.15	0.3	5.14e-7	Lymphocyte percentage of white cells;
CESC	cis	rs782590	0.559	rs12617719	chr2:55915826	G/C	cg18811423	chr2:55921094	PNPT1	-0.71	-10.77	-0.55	1.16e-22	Metabolic syndrome;
CESC	trans	rs8014252	0.667	rs9323536	chr14:70808603	T/C	cg03123320	chr1:229394665	NA	-0.49	-6.27	-0.36	1.45e-9	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
CESC	cis	rs6121246	0.697	rs7269866	chr20:30232504	G/A	cg13852791	chr20:30311386	BCL2L1	0.77	7.91	0.44	7.11e-14	Mean corpuscular hemoglobin;
CESC	cis	rs561341	0.654	rs6505265	chr17:30172580	C/T	cg19193384	chr17:30244184	NA	0.54	5.3	0.31	2.43e-7	Hip circumference adjusted for BMI;
CESC	cis	rs3916	1.000	rs1799958	chr12:121176083	G/A	cg21892295	chr12:121157589	UNC119B	-0.36	-5.24	-0.31	3.24e-7	Urinary metabolites (H-NMR features);
CESC	cis	rs71277158	0.688	rs7618919	chr3:169860239	C/T	cg04067573	chr3:169899625	PHC3	0.67	6.87	0.39	4.66e-11	Prostate cancer;
CESC	cis	rs3105593	1.000	rs3131582	chr15:50879670	C/T	cg08437265	chr15:50716283	USP8	0.41	5.26	0.31	2.94e-7	QT interval;
CESC	cis	rs2576037	0.583	rs8098948	chr18:44512332	C/A	cg19077165	chr18:44547161	KATNAL2	-0.63	-9.53	-0.51	1.06e-18	Personality dimensions;
CESC	cis	rs61008539	0.893	rs4721502	chr7:862186	A/G	cg00934597	chr7:893267	UNC84A	-0.5	-6.72	-0.38	1.08e-10	Perceived unattractiveness to mosquitoes;
CESC	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg24503407	chr1:205819492	PM20D1	0.82	13.96	0.65	1.43e-33	Menarche (age at onset);
CESC	cis	rs4689388	0.926	rs5018648	chr4:6292818	C/G	cg14416269	chr4:6271139	WFS1	-0.46	-8.0	-0.44	4.02e-14	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs1799949	1.000	rs11657053	chr17:41191129	G/T	cg23758822	chr17:41437982	NA	1.03	14.72	0.67	3.07e-36	Menopause (age at onset);
CESC	cis	rs2832077	0.689	rs2832052	chr21:30130073	G/C	cg24692254	chr21:30365293	RNF160	-0.42	-5.15	-0.3	5.01e-7	Cognitive test performance;
CESC	cis	rs832540	0.830	rs252907	chr5:56120646	G/A	cg14703610	chr5:56206110	C5orf35	0.49	6.56	0.37	2.8e-10	Coronary artery disease;
CESC	cis	rs9311474	0.508	rs6786919	chr3:52599789	A/G	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	5.84	0.34	1.53e-8	Electroencephalogram traits;
CESC	cis	rs4665809	0.590	rs2303892	chr2:26461733	C/G	cg08470875	chr2:26401718	FAM59B	0.75	7.78	0.43	1.63e-13	Gut microbiome composition (summer);
CESC	cis	rs9457247	1.000	rs2757042	chr6:167371234	A/T	cg07741184	chr6:167504864	NA	-0.3	-5.45	-0.32	1.18e-7	Crohn's disease;
CESC	cis	rs644799	1.000	rs473155	chr11:95596873	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.66	8.22	0.45	9.21e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs7917772	0.536	rs11191361	chr10:104411958	C/T	ch.10.2196322F	chr10:104248062	ACTR1A	0.5	5.55	0.32	6.81e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs17102884	0.506	rs4899540	chr14:75403408	G/A	cg08847533	chr14:75593920	NEK9	-0.44	-5.49	-0.32	9.41e-8	Neuroticism;
CESC	cis	rs12478296	1.000	rs55777943	chr2:243040686	T/C	cg06360820	chr2:242988706	NA	-0.92	-8.99	-0.48	4.94e-17	Obesity-related traits;
CESC	cis	rs4595586	0.545	rs969469	chr12:39366775	A/C	cg26384229	chr12:38710491	ALG10B	0.5	7.16	0.4	7.88e-12	Morning vs. evening chronotype;
CESC	cis	rs10504229	0.545	rs56394419	chr8:58128982	T/C	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	trans	rs11098499	0.754	rs12509621	chr4:120249660	T/C	cg25214090	chr10:38739885	LOC399744	0.62	8.7	0.47	3.58e-16	Corneal astigmatism;
CESC	cis	rs854765	0.583	rs11650649	chr17:17790319	C/A	cg04398451	chr17:18023971	MYO15A	0.64	8.87	0.48	1.14e-16	Total body bone mineral density;
CESC	cis	rs6460942	0.915	rs62448602	chr7:12457145	T/G	cg06484146	chr7:12443880	VWDE	-0.78	-9.14	-0.49	1.68e-17	Coronary artery disease;
CESC	trans	rs61931739	0.500	rs11053272	chr12:34547020	C/G	cg13010199	chr12:38710504	ALG10B	0.51	6.58	0.37	2.47e-10	Morning vs. evening chronotype;
CESC	trans	rs7107217	1.000	rs1873872	chr11:129473993	A/T	cg26155979	chr10:105110866	PCGF6	0.49	6.38	0.36	8.07e-10	Breast cancer;Type 2 diabetes;
CESC	cis	rs2599510	0.811	rs62136345	chr2:32807223	G/T	cg02381751	chr2:32503542	YIPF4	0.43	5.33	0.31	2.13e-7	Interleukin-18 levels;
CESC	cis	rs4563143	0.647	rs117442062	chr19:29256823	A/T	cg12756686	chr19:29218302	NA	0.59	7.62	0.42	4.52e-13	Methadone dose in opioid dependence;
CESC	cis	rs514406	0.584	rs7548832	chr1:53193576	A/T	cg24675658	chr1:53192096	ZYG11B	-0.69	-8.79	-0.48	1.89e-16	Monocyte count;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg21699506	chr4:80786707	NA	0.41	6.04	0.35	5.3e-9	Ulcerative colitis;
CESC	cis	rs919433	0.783	rs2565155	chr2:198236425	A/G	cg10820045	chr2:198174542	NA	0.41	5.93	0.34	9.6e-9	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs651907	0.535	rs9830943	chr3:101428899	T/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.43	5.52	0.32	8.16e-8	Colorectal cancer;
CESC	cis	rs1371867	0.875	rs1788178	chr8:101332518	A/C	cg11906718	chr8:101322791	RNF19A	0.53	6.86	0.39	4.86e-11	Atrioventricular conduction;
CESC	cis	rs10870270	0.956	rs7915388	chr10:133734972	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.62	-8.06	-0.44	2.63e-14	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs10781543	0.775	rs10870194	chr9:139327034	A/G	cg14019695	chr9:139328340	INPP5E	0.36	5.3	0.31	2.47e-7	Monocyte percentage of white cells;
CESC	cis	rs7208859	0.524	rs73988172	chr17:29086332	A/C	cg19761014	chr17:28927070	LRRC37B2	0.78	6.38	0.36	8.01e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs7552404	0.883	rs77773255	chr1:76217193	G/A	cg03433033	chr1:76189801	ACADM	0.69	8.44	0.46	2.14e-15	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs9911578	0.967	rs9907940	chr17:56663842	A/G	cg05425664	chr17:57184151	TRIM37	-0.48	-6.66	-0.38	1.61e-10	Intelligence (multi-trait analysis);
CESC	cis	rs9291683	0.588	rs35099040	chr4:10018839	T/C	cg11266682	chr4:10021025	SLC2A9	0.71	14.52	0.67	1.5e-35	Bone mineral density;
CESC	cis	rs6912958	0.559	rs2985039	chr6:88041757	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.76	11.12	0.56	7.93e-24	Monocyte percentage of white cells;
CESC	cis	rs9311474	0.508	rs6786919	chr3:52599789	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.57	7.95	0.44	5.42e-14	Electroencephalogram traits;
CESC	cis	rs13191362	0.935	rs34347104	chr6:163055716	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.93	9.63	0.51	5.2e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs7208859	0.623	rs28556733	chr17:29083945	T/G	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.17e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs7945705	0.782	rs2742545	chr11:8884308	C/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.31	-5.12	-0.3	6e-7	Hemoglobin concentration;
CESC	cis	rs7552404	0.731	rs1770885	chr1:76402212	C/T	cg03433033	chr1:76189801	ACADM	-0.58	-6.33	-0.36	1.04e-9	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs2841277	0.676	rs10438247	chr14:105411781	G/A	cg19901468	chr14:105411992	AHNAK2	-0.62	-9.07	-0.49	2.79e-17	Rheumatoid arthritis;
CESC	cis	rs4927850	1.000	rs7630875	chr3:195753766	A/G	cg12923728	chr3:195709715	SDHAP1	-0.67	-8.8	-0.48	1.78e-16	Pancreatic cancer;
CESC	cis	rs6952808	0.825	rs34296663	chr7:1935245	C/T	cg00106254	chr7:1943704	MAD1L1	-0.5	-6.25	-0.36	1.67e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs10461617	0.531	rs2662033	chr5:56213410	T/G	cg22800045	chr5:56110881	MAP3K1	0.68	8.22	0.45	9.26e-15	Type 2 diabetes;
CESC	cis	rs727505	0.721	rs11534064	chr7:124767997	G/T	cg23710748	chr7:124431027	NA	0.32	5.43	0.32	1.26e-7	Lewy body disease;
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg14574726	chr11:809735	RPLP2	-0.39	-6.28	-0.36	1.41e-9	Vertical cup-disc ratio;
CESC	cis	rs854765	0.647	rs712267	chr17:18021607	G/A	cg04398451	chr17:18023971	MYO15A	-0.8	-11.75	-0.59	6.09e-26	Total body bone mineral density;
CESC	cis	rs4713118	0.629	rs203888	chr6:28021589	C/T	cg12963246	chr6:28129442	ZNF389	0.46	6.18	0.36	2.38e-9	Parkinson's disease;
CESC	cis	rs9287719	0.967	rs7587114	chr2:10739963	C/T	cg00105475	chr2:10696890	NA	0.39	5.61	0.33	4.96e-8	Prostate cancer;
CESC	cis	rs16866061	0.962	rs3845840	chr2:225359100	G/A	cg12698349	chr2:225449008	CUL3	0.72	10.55	0.54	5.98e-22	Acute graft versus host disease in bone marrow transplantation (recipient effect);
CESC	cis	rs193541	0.632	rs2910135	chr5:122229790	C/T	cg19412675	chr5:122181750	SNX24	0.48	5.69	0.33	3.39e-8	Glucose homeostasis traits;
CESC	cis	rs76878669	0.561	rs10791872	chr11:66138434	C/G	cg18002602	chr11:66138449	SLC29A2	-0.41	-6.84	-0.39	5.38e-11	Educational attainment (years of education);
CESC	cis	rs1691799	0.899	rs1168327	chr12:66728842	G/A	cg16791601	chr12:66731901	HELB	-0.73	-12.46	-0.61	2.25e-28	White blood cell count (basophil);
CESC	cis	rs2228479	0.850	rs3785279	chr16:89824562	G/C	cg06558623	chr16:89946397	TCF25	1.17	9.38	0.5	3.19e-18	Skin colour saturation;
CESC	cis	rs7927771	0.524	rs754434	chr11:47814280	A/G	cg18512352	chr11:47633146	NA	0.35	5.33	0.31	2.05e-7	Subjective well-being;
CESC	cis	rs2066819	1.000	rs2695789	chr12:56694261	C/A	cg26714650	chr12:56694279	CS	1.29	16.3	0.71	7.7e-42	Psoriasis vulgaris;
CESC	trans	rs7726839	0.561	rs6555357	chr5:560923	A/G	cg25482853	chr8:67687455	SGK3	0.93	10.03	0.52	2.74e-20	Obesity-related traits;
CESC	cis	rs2075371	0.796	rs12672752	chr7:134007382	C/T	cg11752832	chr7:134001865	SLC35B4	0.52	6.58	0.37	2.49e-10	Mean platelet volume;
CESC	cis	rs916888	0.610	rs199530	chr17:44836653	C/T	cg01570182	chr17:44337453	NA	-0.6	-8.25	-0.45	7.42e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs7618915	0.547	rs2878726	chr3:52748271	C/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.49	6.97	0.39	2.44e-11	Bipolar disorder;
CESC	cis	rs854765	0.547	rs4459604	chr17:17888549	A/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.53	6.68	0.38	1.4e-10	Total body bone mineral density;
CESC	cis	rs35110281	0.748	rs2838322	chr21:44998615	G/C	cg04455712	chr21:45112962	RRP1B	0.37	5.52	0.32	7.97e-8	Mean corpuscular volume;
CESC	cis	rs9811920	0.660	rs7619512	chr3:99729132	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.4	-6.51	-0.37	3.79e-10	Axial length;
CESC	trans	rs3942852	0.806	rs10769316	chr11:48119745	C/G	cg15704280	chr7:45808275	SEPT13	-0.63	-7.45	-0.42	1.3e-12	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs7772486	0.790	rs2253764	chr6:146199881	T/A	cg05347473	chr6:146136440	FBXO30	0.55	7.24	0.41	4.76e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6964587	0.869	rs405	chr7:91546327	G/C	cg17063962	chr7:91808500	NA	-0.52	-6.86	-0.39	4.85e-11	Breast cancer;
CESC	cis	rs79057730	0.599	rs6951032	chr7:794092	C/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.91	7.75	0.43	1.92e-13	Initial pursuit acceleration;
CESC	cis	rs2637266	0.935	rs1907299	chr10:78325316	T/C	cg18941641	chr10:78392320	NA	0.38	6.83	0.39	5.66e-11	Pulmonary function;
CESC	cis	rs6546537	0.955	rs35947226	chr2:69845829	C/G	cg10773587	chr2:69614142	GFPT1	-0.59	-7.02	-0.4	1.81e-11	Serum thyroid-stimulating hormone levels;
CESC	cis	rs2576037	0.501	rs7245049	chr18:44528213	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.54	-7.5	-0.42	9.68e-13	Personality dimensions;
CESC	cis	rs7666738	0.830	rs957742	chr4:99029409	C/T	cg18180107	chr4:99064573	C4orf37	0.42	5.43	0.32	1.29e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2303759	0.709	rs8102658	chr19:49828855	C/T	cg22307029	chr19:49891270	CCDC155	0.54	5.97	0.34	7.51e-9	Multiple sclerosis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23921860	chr17:4608406	PELP1	-0.6	-6.98	-0.39	2.3e-11	Gut microbiome composition (summer);
CESC	cis	rs4561483	0.583	rs62038798	chr16:12001569	C/T	cg08843971	chr16:11963173	GSPT1	0.47	6.56	0.37	2.88e-10	Testicular germ cell tumor;
CESC	cis	rs6695640	0.820	rs1535874	chr1:17748027	C/T	cg01904812	chr1:17746340	RCC2	-0.35	-5.17	-0.3	4.65e-7	Mean platelet volume;
CESC	cis	rs12497850	0.931	rs13316620	chr3:49045355	T/C	cg07636037	chr3:49044803	WDR6	1.06	19.52	0.77	3.45e-53	Parkinson's disease;
CESC	cis	rs6662572	0.737	rs6429593	chr1:46505235	T/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.48	5.3	0.31	2.45e-7	Blood protein levels;
CESC	cis	rs672059	1.000	rs547905	chr1:183157924	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.57	7.36	0.41	2.35e-12	Hypertriglyceridemia;
CESC	cis	rs4665809	0.590	rs6749046	chr2:26429451	C/G	cg25036284	chr2:26402008	FAM59B	0.84	9.45	0.5	1.91e-18	Gut microbiome composition (summer);
CESC	cis	rs11785400	1.000	rs754957	chr8:143746416	A/G	cg24634471	chr8:143751801	JRK	0.47	6.23	0.36	1.87e-9	Schizophrenia;
CESC	cis	rs17666538	0.585	rs1669733	chr8:606696	C/T	cg07234876	chr8:600039	NA	-0.88	-6.43	-0.37	5.87e-10	IgG glycosylation;
CESC	cis	rs34638657	0.827	rs11641736	chr16:82206279	G/A	cg09439754	chr16:82129088	HSD17B2	-0.37	-5.22	-0.31	3.56e-7	Lung adenocarcinoma;
CESC	cis	rs4654899	0.802	rs57351360	chr1:21229538	T/A	cg05370193	chr1:21551575	ECE1	0.38	5.52	0.32	8.12e-8	Superior frontal gyrus grey matter volume;
CESC	cis	rs9291683	0.632	rs12508991	chr4:10041104	C/T	cg11266682	chr4:10021025	SLC2A9	0.67	13.02	0.62	2.72e-30	Bone mineral density;
CESC	cis	rs6088590	1.000	rs6088615	chr20:33400474	C/T	cg06115741	chr20:33292138	TP53INP2	-0.54	-6.45	-0.37	5.18e-10	Coronary artery disease;
CESC	cis	rs4319547	0.619	rs10744208	chr12:122931559	C/A	cg23029597	chr12:123009494	RSRC2	-0.45	-5.08	-0.3	7.04e-7	Body mass index;
CESC	cis	rs9487051	0.872	rs9400271	chr6:109607556	G/A	cg12927641	chr6:109611667	NA	-0.43	-6.7	-0.38	1.22e-10	Reticulocyte fraction of red cells;
CESC	cis	rs1008375	1.000	rs10939740	chr4:17617490	T/C	cg02297831	chr4:17616191	MED28	0.58	7.14	0.4	8.79e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs1862618	0.802	rs252900	chr5:56185281	T/A	cg12311346	chr5:56204834	C5orf35	-0.74	-8.81	-0.48	1.71e-16	Initial pursuit acceleration;
CESC	cis	rs2777491	0.874	rs28716108	chr15:41655523	G/C	cg01768344	chr15:41576519	LOC729082	0.41	5.03	0.3	8.98e-7	Ulcerative colitis;
CESC	cis	rs6460942	0.908	rs79175014	chr7:12245378	T/G	cg20607287	chr7:12443886	VWDE	-0.61	-6.14	-0.35	2.93e-9	Coronary artery disease;
CESC	cis	rs3126085	0.935	rs3126072	chr1:152279729	C/T	cg03465714	chr1:152285911	FLG	0.43	5.2	0.3	3.94e-7	Atopic dermatitis;
CESC	cis	rs1005277	0.502	rs2800484	chr10:38542415	C/T	cg25427524	chr10:38739819	LOC399744	-0.72	-10.76	-0.55	1.2e-22	Extrinsic epigenetic age acceleration;
CESC	cis	rs7666738	0.830	rs7698771	chr4:98986479	T/G	cg17366294	chr4:99064904	C4orf37	0.59	8.57	0.47	8.46e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7264396	0.622	rs3787165	chr20:34228946	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.63	7.56	0.42	6.68e-13	Total cholesterol levels;
CESC	cis	rs34375054	0.526	rs4412800	chr12:125674742	C/T	cg05341575	chr12:125625032	AACS	0.35	5.21	0.3	3.79e-7	Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs2635047	0.569	rs9958817	chr18:44786481	G/A	cg24371990	chr18:44770781	NA	0.36	5.82	0.34	1.69e-8	Educational attainment;
CESC	cis	rs7044106	0.791	rs10985009	chr9:123493039	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	-0.37	-5.89	-0.34	1.15e-8	Hip circumference adjusted for BMI;
CESC	cis	rs41271951	0.512	rs11204774	chr1:151062957	C/T	cg11822372	chr1:151115635	SEMA6C	-0.62	-5.36	-0.31	1.8e-7	Blood protein levels;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg10859966	chr14:24898992	CBLN3;KHNYN	-0.52	-6.44	-0.37	5.7e-10	Ulcerative colitis;
CESC	cis	rs11098499	0.909	rs1809406	chr4:120377122	G/A	cg24375607	chr4:120327624	NA	0.44	5.51	0.32	8.65e-8	Corneal astigmatism;
CESC	cis	rs858239	0.600	rs7776644	chr7:23119307	C/T	cg23682824	chr7:23144976	KLHL7	0.55	7.73	0.43	2.24e-13	Cerebrospinal fluid biomarker levels;
CESC	cis	rs909674	0.690	rs5750823	chr22:39829973	C/T	cg02038168	chr22:39784481	NA	-0.61	-7.88	-0.44	8.37e-14	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs7216064	1.000	rs55939964	chr17:65869297	G/A	cg12091567	chr17:66097778	LOC651250	-0.85	-8.7	-0.47	3.61e-16	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23029715	chr19:42363959	RPS19	-0.53	-6.12	-0.35	3.27e-9	Gut microbiome composition (summer);
CESC	cis	rs1799949	1.000	rs4793194	chr17:41218333	G/A	cg06001716	chr17:41278141	BRCA1;NBR2	0.39	5.3	0.31	2.46e-7	Menopause (age at onset);
CESC	cis	rs7116495	0.609	rs949324	chr11:71714526	G/C	cg26138937	chr11:71823887	C11orf51	-1.16	-7.82	-0.43	1.29e-13	Severe influenza A (H1N1) infection;
CESC	cis	rs367943	1.000	rs348956	chr5:112821464	C/T	cg12552261	chr5:112820674	MCC	0.64	8.05	0.44	2.83e-14	Type 2 diabetes;
CESC	cis	rs6754311	0.689	rs192822	chr2:136682274	A/T	cg07169764	chr2:136633963	MCM6	0.71	9.07	0.49	2.8e-17	Mosquito bite size;
CESC	cis	rs4971059	0.629	rs12904	chr1:155106697	G/A	cg22049894	chr1:155113146	DPM3	0.46	5.95	0.34	8.68e-9	Breast cancer;
CESC	cis	rs875971	0.825	rs1000464	chr7:65777909	G/C	cg11764359	chr7:65958608	NA	-0.79	-11.97	-0.59	1.07e-26	Aortic root size;
CESC	cis	rs514406	0.708	rs514881	chr1:53336737	A/G	cg08736216	chr1:53307985	ZYG11A	0.36	6.47	0.37	4.6e-10	Monocyte count;
CESC	cis	rs9916302	0.904	rs8079355	chr17:37473018	G/A	cg07936489	chr17:37558343	FBXL20	0.78	11.03	0.56	1.58e-23	Glomerular filtration rate (creatinine);
CESC	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg16145915	chr7:1198662	ZFAND2A	0.49	7.32	0.41	2.93e-12	Longevity;Endometriosis;
CESC	cis	rs6500395	0.775	rs1968902	chr16:48663974	A/G	cg04672837	chr16:48644449	N4BP1	0.49	6.27	0.36	1.5e-9	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs7208859	0.614	rs9914534	chr17:29202664	G/A	cg19761014	chr17:28927070	LRRC37B2	0.63	5.27	0.31	2.88e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13679837	chr20:21283918	XRN2	0.65	7.28	0.41	3.83e-12	Gut microbiome composition (summer);
CESC	cis	rs933688	0.938	rs7720235	chr5:90659329	A/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.16	15.37	0.69	1.51e-38	Smoking behavior;
CESC	cis	rs9311474	0.508	rs12629701	chr3:52619836	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.57	7.79	0.43	1.49e-13	Electroencephalogram traits;
CESC	trans	rs7107217	1.000	rs1873872	chr11:129473993	A/T	cg25447359	chr22:30790057	NA	-0.47	-6.55	-0.37	3.04e-10	Breast cancer;Type 2 diabetes;
CESC	cis	rs1218582	0.710	rs4845685	chr1:154878300	C/A	cg24250549	chr1:154909240	PMVK	0.74	11.09	0.56	1.01e-23	Prostate cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13107428	chr1:197744541	DENND1B	0.59	6.71	0.38	1.19e-10	Gut microbiome composition (summer);
CESC	cis	rs9322193	0.884	rs9688699	chr6:150054816	A/G	cg00933542	chr6:150070202	PCMT1	0.3	5.23	0.31	3.39e-7	Lung cancer;
CESC	cis	rs514406	0.861	rs1571979	chr1:53237526	G/A	cg16325326	chr1:53192061	ZYG11B	-0.88	-15.0	-0.68	3.14e-37	Monocyte count;
CESC	cis	rs10461617	0.535	rs7709874	chr5:56047451	C/T	cg22800045	chr5:56110881	MAP3K1	0.6	7.53	0.42	8.21e-13	Type 2 diabetes;
CESC	cis	rs8017423	0.967	rs57793584	chr14:90714833	G/A	cg14092571	chr14:90743983	NA	-0.58	-8.66	-0.47	4.57e-16	Mortality in heart failure;
CESC	cis	rs826838	0.900	rs1403523	chr12:39130570	T/A	cg26384229	chr12:38710491	ALG10B	-0.67	-11.03	-0.56	1.63e-23	Heart rate;
CESC	cis	rs1620921	0.524	rs12194271	chr6:161195895	A/G	cg01280913	chr6:161186852	NA	-0.4	-6.12	-0.35	3.42e-9	Lipoprotein (a) - cholesterol levels;
CESC	cis	rs708547	0.830	rs1713983	chr4:57883084	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.66	8.59	0.47	7.72e-16	Response to bleomycin (chromatid breaks);
CESC	cis	rs740474	0.554	rs251041	chr5:141027888	C/G	cg00076195	chr5:140892677	NA	0.39	5.07	0.3	7.35e-7	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs7927771	0.542	rs7108479	chr11:47781460	G/T	cg18512352	chr11:47633146	NA	0.34	5.24	0.31	3.22e-7	Subjective well-being;
CESC	cis	rs10788264	0.621	rs9633733	chr10:124056546	A/G	cg09507567	chr10:124027408	NA	-0.38	-5.7	-0.33	3.15e-8	Total body bone mineral density;
CESC	cis	rs6952808	0.692	rs60755037	chr7:2030104	G/A	cg02951883	chr7:2050386	MAD1L1	-0.58	-7.77	-0.43	1.72e-13	Bipolar disorder and schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05920998	chr6:656504	HUS1B;EXOC2	-0.56	-6.2	-0.36	2.11e-9	Gut microbiome composition (summer);
CESC	cis	rs8067354	0.645	rs2132715	chr17:57858374	A/T	cg13753209	chr17:57696993	CLTC	0.57	6.44	0.37	5.46e-10	Hemoglobin concentration;
CESC	cis	rs4555082	0.872	rs7153832	chr14:105730563	G/T	cg06808227	chr14:105710500	BRF1	-0.58	-7.07	-0.4	1.35e-11	Mean platelet volume;Platelet distribution width;
CESC	cis	rs1707322	1.000	rs10890365	chr1:46359348	C/T	cg03146154	chr1:46216737	IPP	0.72	9.96	0.52	4.71e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs853679	0.517	rs9380060	chr6:28132603	G/A	cg19592336	chr6:28129416	ZNF389	0.61	8.03	0.44	3.13e-14	Depression;
CESC	cis	rs7949030	0.626	rs7943191	chr11:62328551	A/G	cg23462726	chr11:62437636	C11orf83;C11orf48	-0.39	-5.11	-0.3	6.2e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs8014204	0.836	rs7153700	chr14:75268544	C/T	cg08847533	chr14:75593920	NEK9	0.46	5.8	0.34	1.93e-8	Caffeine consumption;
CESC	cis	rs3087591	1.000	rs2854332	chr17:29712378	A/T	cg24425628	chr17:29625626	OMG;NF1	-0.42	-5.11	-0.3	6.08e-7	Hip circumference;
CESC	cis	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.53	-5.91	-0.34	1.06e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs9393777	0.513	rs9393741	chr6:26654189	A/G	cg12292205	chr6:26970375	C6orf41	-0.53	-5.76	-0.33	2.33e-8	Intelligence (multi-trait analysis);
CESC	cis	rs2228479	0.850	rs11644526	chr16:89898660	C/T	cg14709524	chr16:89940631	TCF25	0.88	6.1	0.35	3.82e-9	Skin colour saturation;
CESC	cis	rs62064224	0.589	rs4523973	chr17:30809455	G/A	cg18200150	chr17:30822561	MYO1D	0.42	5.38	0.31	1.64e-7	Schizophrenia;
CESC	cis	rs875971	0.862	rs11765791	chr7:65936574	A/G	cg12463550	chr7:65579703	CRCP	0.51	6.37	0.36	8.13e-10	Aortic root size;
CESC	cis	rs1975974	0.935	rs41361749	chr17:21732693	A/G	cg18423549	chr17:21743878	NA	0.45	6.02	0.35	5.89e-9	Psoriasis;
CESC	cis	rs2742234	0.541	rs1254959	chr10:43700979	C/G	cg07801480	chr10:43725741	RASGEF1A	-0.41	-5.33	-0.31	2.14e-7	Hirschsprung disease;
CESC	cis	rs34779708	0.898	rs4934695	chr10:35280605	C/T	cg04310649	chr10:35416472	CREM	-0.5	-6.06	-0.35	4.78e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs875971	0.755	rs10228885	chr7:65780529	C/G	cg18252515	chr7:66147081	NA	0.42	5.59	0.32	5.6e-8	Aortic root size;
CESC	cis	rs7818345	1.000	rs7823194	chr8:19292528	C/T	cg11303988	chr8:19266685	CSGALNACT1	0.35	6.32	0.36	1.08e-9	Language performance in older adults (adjusted for episodic memory);
CESC	cis	rs1799949	1.000	rs33994002	chr17:41328818	T/A	cg05368731	chr17:41323189	NBR1	0.79	10.98	0.56	2.21e-23	Menopause (age at onset);
CESC	cis	rs6688613	0.685	rs61815130	chr1:166910465	T/C	ch.1.3259774R	chr1:166827647	TADA1	0.57	5.27	0.31	2.9e-7	Refractive astigmatism;
CESC	cis	rs1008375	1.000	rs7436403	chr4:17692685	T/G	cg02297831	chr4:17616191	MED28	-0.54	-6.37	-0.36	8.46e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs6460942	0.556	rs2287067	chr7:12370533	T/C	cg20607287	chr7:12443886	VWDE	-0.52	-7.48	-0.42	1.09e-12	Coronary artery disease;
CESC	cis	rs9487051	0.872	rs1111863	chr6:109611206	C/T	cg01475377	chr6:109611718	NA	0.48	7.63	0.42	4.2e-13	Reticulocyte fraction of red cells;
CESC	cis	rs3733585	0.699	rs6823361	chr4:9963127	A/G	cg11266682	chr4:10021025	SLC2A9	-0.6	-11.22	-0.57	3.77e-24	Cleft plate (environmental tobacco smoke interaction);
CESC	trans	rs9929218	0.954	rs12919719	chr16:68822341	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.61	-7.94	-0.44	5.84e-14	Colorectal cancer;
CESC	cis	rs3733585	0.673	rs6840802	chr4:9965633	C/G	cg11266682	chr4:10021025	SLC2A9	0.59	10.46	0.54	1.14e-21	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs11098499	0.818	rs7688802	chr4:120451668	G/A	cg24375607	chr4:120327624	NA	0.43	5.21	0.3	3.82e-7	Corneal astigmatism;
CESC	cis	rs9611565	0.765	rs132907	chr22:41801268	A/C	cg06634786	chr22:41940651	POLR3H	0.73	7.47	0.42	1.2e-12	Vitiligo;
CESC	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg03188948	chr7:1209495	NA	0.48	6.18	0.35	2.39e-9	Longevity;Endometriosis;
CESC	trans	rs2235573	0.551	rs139897	chr22:38399098	A/G	cg19894588	chr14:64061835	NA	0.58	7.43	0.42	1.51e-12	Glioblastoma;Glioma;
CESC	cis	rs873946	0.586	rs12259688	chr10:134549628	A/G	cg27297192	chr10:134578999	INPP5A	0.37	5.03	0.3	8.85e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs637571	0.522	rs606978	chr11:65711517	A/C	cg02427764	chr11:65769310	BANF1;EIF1AD	0.7	9.76	0.51	2.03e-19	Eosinophil percentage of white cells;
CESC	cis	rs2502731	0.539	rs3003609	chr9:130984755	A/G	cg09976142	chr9:130955436	CIZ1	-0.39	-6.36	-0.36	8.71e-10	Attention deficit hyperactivity disorder;
CESC	cis	rs7512552	0.803	rs2454286	chr1:150355538	G/A	cg15654264	chr1:150340011	RPRD2	0.4	5.27	0.31	2.89e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs769267	0.792	rs4808961	chr19:19577215	C/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.46	5.68	0.33	3.6e-8	Tonsillectomy;
CESC	cis	rs853679	0.546	rs200990	chr6:27815823	T/G	cg17221315	chr6:27791827	HIST1H4J	0.63	5.28	0.31	2.67e-7	Depression;
CESC	cis	rs7618915	0.547	rs34215106	chr3:52659124	T/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.35	6.23	0.36	1.78e-9	Bipolar disorder;
CESC	cis	rs6500395	0.962	rs9934626	chr16:48602761	G/C	cg04672837	chr16:48644449	N4BP1	0.47	5.8	0.34	1.9e-8	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs7124681	0.584	rs7950674	chr11:47871017	T/C	cg20307385	chr11:47447363	PSMC3	0.63	8.8	0.48	1.84e-16	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
CESC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg01510332	chr19:59087201	MGC2752	0.47	5.99	0.35	6.69e-9	Tetralogy of Fallot;
CESC	cis	rs10779751	0.960	rs1883964	chr1:11294942	T/A	cg08854313	chr1:11322531	MTOR	0.79	10.78	0.55	1.06e-22	Body mass index;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04977610	chr16:30366665	CD2BP2	0.65	7.83	0.43	1.14e-13	Gut microbiome composition (summer);
CESC	cis	rs9948	0.748	rs62156223	chr2:97412167	T/C	cg01990225	chr2:97406019	LMAN2L	-0.87	-6.74	-0.38	9.62e-11	Erectile dysfunction and prostate cancer treatment;
CESC	cis	rs4851870	0.560	rs11690510	chr2:106446674	T/C	cg16077055	chr2:106428750	NCK2	-0.36	-5.2	-0.3	3.93e-7	Addiction;
CESC	cis	rs3008870	1.000	rs2985794	chr1:67425311	T/G	cg08660285	chr1:67390436	MIER1;WDR78	1.06	15.19	0.68	6.65e-38	Lymphocyte percentage of white cells;
CESC	cis	rs7605827	0.930	rs4668909	chr2:15607842	T/C	cg19274914	chr2:15703543	NA	0.33	5.96	0.34	8.22e-9	Educational attainment (years of education);
CESC	cis	rs5769765	0.908	rs138880	chr22:50218611	A/C	cg02269571	chr22:50332266	NA	-0.43	-5.49	-0.32	9.29e-8	Schizophrenia;
CESC	cis	rs9926296	0.568	rs4420527	chr16:89814188	C/T	cg07648498	chr16:89883185	FANCA	-0.5	-6.34	-0.36	9.78e-10	Vitiligo;
CESC	cis	rs7772486	0.817	rs2144477	chr6:146406248	C/T	cg23711669	chr6:146136114	FBXO30	0.85	12.48	0.61	2.01e-28	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2197308	0.728	rs7304305	chr12:37932990	T/C	cg26384229	chr12:38710491	ALG10B	-0.54	-7.66	-0.43	3.57e-13	Morning vs. evening chronotype;
CESC	cis	rs3091242	0.904	rs6661533	chr1:25771715	A/G	cg03538708	chr1:25844672	NA	-0.41	-6.17	-0.35	2.53e-9	Erythrocyte sedimentation rate;
CESC	cis	rs896854	0.684	rs10099941	chr8:95987008	C/T	cg26343298	chr8:95960752	TP53INP1	0.36	6.05	0.35	4.98e-9	Type 2 diabetes;
CESC	cis	rs4808199	0.947	rs10401193	chr19:19591066	A/G	cg03709012	chr19:19516395	GATAD2A	1.15	13.17	0.63	8.54e-31	Nonalcoholic fatty liver disease;
CESC	cis	rs17431357	0.867	rs117264981	chr12:120997625	A/C	cg25045489	chr12:120971538	RNF10	-0.93	-5.46	-0.32	1.1e-7	Insulin resistance/response;
CESC	cis	rs6430585	0.528	rs309151	chr2:136661150	C/T	cg07169764	chr2:136633963	MCM6	1.1	14.75	0.67	2.41e-36	Corneal structure;
CESC	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg04267008	chr7:1944627	MAD1L1	-0.57	-6.93	-0.39	3.2e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs10779751	1.000	rs2016559	chr1:11269917	G/T	cg08854313	chr1:11322531	MTOR	0.78	10.59	0.55	4.41e-22	Body mass index;
CESC	cis	rs765787	0.530	rs11634794	chr15:45534492	A/C	cg24006582	chr15:45444508	DUOX1	-0.55	-6.68	-0.38	1.42e-10	Uric acid levels;
CESC	cis	rs4853012	0.838	rs12619982	chr2:74356022	G/A	cg20891558	chr2:74357851	NA	0.87	12.04	0.59	6.34e-27	Gestational age at birth (maternal effect);
CESC	cis	rs7223966	0.921	rs11655493	chr17:61733052	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.44	-5.1	-0.3	6.57e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs7208859	0.524	rs59913838	chr17:29101563	A/T	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.91e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs9902453	0.808	rs12452288	chr17:28235220	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.65	8.2	0.45	1.05e-14	Coffee consumption (cups per day);
CESC	cis	rs4253772	0.550	rs6007818	chr22:46703776	C/T	cg24881330	chr22:46731750	TRMU	0.86	7.93	0.44	6.07e-14	LDL cholesterol;Cholesterol, total;
CESC	cis	rs853679	0.517	rs9357066	chr6:28129831	T/C	cg12963246	chr6:28129442	ZNF389	0.56	7.38	0.41	1.99e-12	Depression;
CESC	cis	rs6964587	1.000	rs2299239	chr7:91654617	C/T	cg17063962	chr7:91808500	NA	0.58	8.02	0.44	3.36e-14	Breast cancer;
CESC	cis	rs4727027	0.901	rs7794500	chr7:148819519	C/T	cg23583168	chr7:148888333	NA	0.73	10.68	0.55	2.23e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs4332037	0.707	rs62435130	chr7:1890002	C/T	cg23422044	chr7:1970798	MAD1L1	-0.5	-5.41	-0.32	1.43e-7	Bipolar disorder;
CESC	cis	rs727505	0.866	rs66650870	chr7:124713194	T/C	cg23710748	chr7:124431027	NA	-0.4	-6.54	-0.37	3.1e-10	Lewy body disease;
CESC	trans	rs916888	0.773	rs199447	chr17:44812188	C/T	cg22433210	chr17:43662623	NA	0.97	10.86	0.55	5.52e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs1559088	0.600	rs7256470	chr19:33558085	C/A	cg03563238	chr19:33554763	RHPN2	-0.32	-5.78	-0.33	2.09e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs10504229	0.679	rs6995378	chr8:58113933	C/T	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs7772486	0.701	rs11155438	chr6:145950112	C/G	cg05347473	chr6:146136440	FBXO30	0.58	7.37	0.41	2.23e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9905704	0.918	rs2611783	chr17:56808530	A/G	cg12560992	chr17:57184187	TRIM37	0.59	7.01	0.4	1.92e-11	Testicular germ cell tumor;
CESC	cis	rs7589728	0.925	rs78829281	chr2:88502293	T/A	cg04511125	chr2:88470314	THNSL2	0.57	5.47	0.32	1.06e-7	Plasma clusterin levels;
CESC	cis	rs2304069	0.545	rs4705404	chr5:149381952	A/C	cg12661370	chr5:149340060	SLC26A2	0.43	5.64	0.33	4.32e-8	HIV-1 control;
CESC	cis	rs72781680	1.000	rs7578969	chr2:24168620	T/C	cg08917208	chr2:24149416	ATAD2B	0.94	8.58	0.47	7.87e-16	Lymphocyte counts;
CESC	cis	rs2070488	0.574	rs57754356	chr3:38488706	C/G	cg24069376	chr3:38537580	EXOG	0.32	5.47	0.32	1.03e-7	Electrocardiographic conduction measures;
CESC	cis	rs5758659	0.504	rs133367	chr22:42463366	A/G	cg15557168	chr22:42548783	NA	0.41	6.29	0.36	1.32e-9	Cognitive function;
CESC	trans	rs7246760	0.867	rs889177	chr19:9846225	C/T	cg02900749	chr2:68251473	NA	-0.82	-7.35	-0.41	2.45e-12	Pursuit maintenance gain;
CESC	cis	rs5753618	0.509	rs5997912	chr22:31593861	A/G	cg13145458	chr22:31556086	RNF185	0.48	5.45	0.32	1.15e-7	Colorectal cancer;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg18490802	chr7:6049303	PMS2;AIMP2	-0.46	-6.87	-0.39	4.65e-11	Gambling;
CESC	cis	rs9929218	0.551	rs9888942	chr16:68727572	A/G	cg01251360	chr16:68772225	CDH1	-0.23	-5.13	-0.3	5.55e-7	Colorectal cancer;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg02958194	chr7:97736036	LMTK2	0.5	6.25	0.36	1.61e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs1814175	0.645	rs1851844	chr11:50021773	T/C	cg15704280	chr7:45808275	SEPT13	-1.0	-18.54	-0.75	9.01e-50	Height;
CESC	cis	rs2933343	0.700	rs1680788	chr3:128625318	C/T	cg25356066	chr3:128598488	ACAD9	0.58	7.92	0.44	6.51e-14	IgG glycosylation;
CESC	cis	rs8099014	0.725	rs10871755	chr18:56094783	C/G	cg12827950	chr18:55968429	NEDD4L	-0.45	-5.07	-0.3	7.51e-7	Platelet count;
CESC	cis	rs12142240	0.659	rs111723629	chr1:46853361	G/T	cg00530320	chr1:46809349	NSUN4	0.6	8.3	0.45	5.19e-15	Menopause (age at onset);
CESC	cis	rs7827290	0.863	rs7014099	chr8:142305766	C/T	cg00131261	chr8:142287264	NA	0.4	5.11	0.3	6.13e-7	Bipolar disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12214665	chr6:138188557	TNFAIP3	0.57	6.36	0.36	8.9e-10	Gut microbiome composition (summer);
CESC	cis	rs6460942	0.591	rs62451461	chr7:12355480	G/A	cg20607287	chr7:12443886	VWDE	-0.59	-6.27	-0.36	1.43e-9	Coronary artery disease;
CESC	cis	rs4665809	0.590	rs1560865	chr2:26452197	C/A	cg25036284	chr2:26402008	FAM59B	-0.88	-9.99	-0.52	3.79e-20	Gut microbiome composition (summer);
CESC	cis	rs910316	0.967	rs175451	chr14:75589729	C/T	cg11812906	chr14:75593930	NEK9	-0.85	-14.31	-0.66	8.38e-35	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27328408	chr15:75615005	NA	-0.6	-6.88	-0.39	4.34e-11	Gut microbiome composition (summer);
CESC	cis	rs9389248	0.737	rs12664956	chr6:135384188	T/C	cg22676075	chr6:135203613	NA	0.54	7.0	0.4	2.06e-11	High light scatter reticulocyte percentage of red cells;
CESC	cis	rs11785400	0.612	rs10110864	chr8:143750072	A/G	cg10596483	chr8:143751796	JRK	0.42	5.2	0.3	3.92e-7	Schizophrenia;
CESC	cis	rs62064224	0.702	rs2302277	chr17:30791509	C/G	cg24550644	chr17:30846204	MYO1D	-0.38	-5.6	-0.33	5.28e-8	Schizophrenia;
CESC	cis	rs317689	0.918	rs581911	chr12:69738293	C/T	cg20891283	chr12:69753455	YEATS4	0.6	6.66	0.38	1.56e-10	Response to diuretic therapy;
CESC	cis	rs3806843	1.000	rs1548699	chr5:140164918	T/C	cg16179182	chr5:140090404	VTRNA1-1	-0.4	-5.18	-0.3	4.31e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs858239	0.600	rs6967419	chr7:23136310	C/T	cg23682824	chr7:23144976	KLHL7	0.55	7.61	0.42	4.84e-13	Cerebrospinal fluid biomarker levels;
CESC	cis	rs1008375	1.000	rs6849704	chr4:17652031	G/C	cg16339924	chr4:17578868	LAP3	0.56	7.02	0.4	1.9e-11	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs6952808	0.609	rs4721190	chr7:1954732	A/G	cg02951883	chr7:2050386	MAD1L1	0.39	5.06	0.3	7.99e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs1552244	1.000	rs9809061	chr3:10085130	C/G	cg00149659	chr3:10157352	C3orf10	0.75	9.44	0.5	2.06e-18	Alzheimer's disease;
CESC	cis	rs10791097	0.694	rs4459316	chr11:130756176	T/C	cg09137382	chr11:130731461	NA	0.35	5.21	0.3	3.81e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs2737618	0.674	rs2816973	chr1:200084743	C/G	cg21825944	chr1:200113062	NR5A2	0.47	7.37	0.41	2.21e-12	Uric acid levels;
CESC	cis	rs1707322	1.000	rs4606257	chr1:46307268	G/A	cg06784218	chr1:46089804	CCDC17	0.35	5.91	0.34	1.05e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs826838	0.935	rs11169511	chr12:39175802	T/C	cg13010199	chr12:38710504	ALG10B	0.58	8.08	0.44	2.27e-14	Heart rate;
CESC	cis	rs7666738	0.830	rs28795113	chr4:98951331	A/G	cg03676636	chr4:99064102	C4orf37	0.33	5.09	0.3	6.71e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2228479	0.850	rs17227057	chr16:89816333	C/T	cg06558623	chr16:89946397	TCF25	1.16	9.28	0.5	6.08e-18	Skin colour saturation;
CESC	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg03188948	chr7:1209495	NA	0.73	7.02	0.4	1.85e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg14530801	chr4:4544016	STX18	-0.49	-6.05	-0.35	4.8e-9	Thyroid stimulating hormone;
CESC	cis	rs12464559	0.649	rs2030588	chr2:152668750	C/A	cg01189475	chr2:152685088	ARL5A	0.66	5.81	0.34	1.74e-8	Response to cognitive-behavioural therapy in anxiety disorder;
CESC	cis	rs561341	1.000	rs72823789	chr17:30284084	G/A	cg23018236	chr17:30244563	NA	-0.55	-5.31	-0.31	2.37e-7	Hip circumference adjusted for BMI;
CESC	cis	rs10504229	0.953	rs67886764	chr8:58187117	T/C	cg14926445	chr8:58193284	C8orf71	-0.51	-5.52	-0.32	8.28e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs826838	1.000	rs7299124	chr12:39002661	T/C	cg13010199	chr12:38710504	ALG10B	0.59	8.22	0.45	8.93e-15	Heart rate;
CESC	cis	rs2576037	0.583	rs8094654	chr18:44527397	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.33	5.2	0.3	4.06e-7	Personality dimensions;
CESC	cis	rs9311474	0.597	rs6778735	chr3:52565100	T/C	cg17372223	chr3:52568218	NT5DC2	0.52	8.67	0.47	4.36e-16	Electroencephalogram traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23009962	chr19:18572435	ELL	-0.62	-6.89	-0.39	4.02e-11	Gut microbiome composition (summer);
CESC	cis	rs3768617	0.510	rs4651139	chr1:183091963	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.89	14.39	0.66	4.39e-35	Fuchs's corneal dystrophy;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg01593421	chr7:65303149	NA	0.45	6.33	0.36	1.02e-9	Fibrinogen levels;
CESC	cis	rs35110281	0.776	rs9306159	chr21:45061839	G/T	cg04455712	chr21:45112962	RRP1B	0.38	5.58	0.32	6.09e-8	Mean corpuscular volume;
CESC	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg11494091	chr17:61959527	GH2	0.72	12.38	0.61	4.46e-28	Prudent dietary pattern;
CESC	cis	rs8078723	0.510	rs11655264	chr17:38138995	G/C	cg17344932	chr17:38183730	MED24;SNORD124	0.39	5.79	0.34	1.96e-8	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CESC	cis	rs12477438	0.520	rs13004491	chr2:99738008	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.88	15.61	0.69	2.15e-39	Chronic sinus infection;
CESC	cis	rs12477438	0.520	rs6708576	chr2:99801308	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.9	15.49	0.69	5.56e-39	Chronic sinus infection;
CESC	cis	rs711245	0.573	rs7570763	chr2:36800589	A/C	cg09467607	chr2:36825704	FEZ2	-0.58	-10.17	-0.53	1.01e-20	Height;
CESC	cis	rs7208859	0.623	rs77009951	chr17:29080650	T/C	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.91e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs12586317	0.547	rs76770287	chr14:35487210	C/A	cg05294307	chr14:35346193	BAZ1A	-0.51	-5.48	-0.32	1.01e-7	Psoriasis;
CESC	trans	rs208520	0.789	rs9351549	chr6:66871851	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.99	-12.67	-0.61	4.31e-29	Exhaled nitric oxide output;
CESC	cis	rs9487051	0.676	rs9398193	chr6:109593134	G/T	cg01475377	chr6:109611718	NA	-0.44	-6.99	-0.39	2.19e-11	Reticulocyte fraction of red cells;
CESC	cis	rs9549260	0.709	rs4943795	chr13:41173433	C/T	cg21288729	chr13:41239152	FOXO1	-0.5	-5.2	-0.3	4e-7	Red blood cell count;
CESC	cis	rs2204008	0.594	rs11531211	chr12:37998007	T/G	cg26384229	chr12:38710491	ALG10B	-0.55	-7.79	-0.43	1.49e-13	Bladder cancer;
CESC	cis	rs853679	0.517	rs868987	chr6:28110148	A/G	cg23161317	chr6:28129485	ZNF389	-0.52	-6.62	-0.38	1.94e-10	Depression;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg25845374	chr2:119981187	STEAP3	-0.37	-6.15	-0.35	2.83e-9	Gambling;
CESC	cis	rs7503807	0.967	rs4889867	chr17:78593058	C/T	cg09596252	chr17:78655493	RPTOR	0.48	7.04	0.4	1.63e-11	Obesity;
CESC	cis	rs4689388	0.853	rs13103357	chr4:6294544	A/G	cg14416269	chr4:6271139	WFS1	0.46	7.76	0.43	1.79e-13	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs2228479	0.850	rs62056069	chr16:89912000	C/T	cg04013166	chr16:89971882	TCF25	0.72	5.75	0.33	2.41e-8	Skin colour saturation;
CESC	cis	rs2290159	0.800	rs11128607	chr3:12673275	A/G	cg23032965	chr3:12705835	RAF1	0.53	5.67	0.33	3.76e-8	Cholesterol, total;
CESC	cis	rs16854884	0.632	rs1466941	chr3:143670131	A/G	cg01302019	chr3:143689584	C3orf58	-0.35	-5.47	-0.32	1.06e-7	Economic and political preferences (feminism/equality);
CESC	cis	rs6582630	0.519	rs11514372	chr12:38308613	T/G	cg13010199	chr12:38710504	ALG10B	0.46	5.88	0.34	1.26e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs75804782	0.521	rs72993034	chr2:239385895	C/T	cg18131467	chr2:239335373	ASB1	-0.73	-5.88	-0.34	1.23e-8	Morning vs. evening chronotype;Chronotype;
CESC	cis	rs4547160	0.606	rs10784329	chr12:63477676	C/T	cg26727693	chr12:63544175	AVPR1A	-0.35	-5.18	-0.3	4.48e-7	Morning vs. evening chronotype;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg07310536	chr10:103892743	PPRC1	-0.51	-6.58	-0.37	2.45e-10	Fibrinogen levels;
CESC	cis	rs1862618	0.853	rs861283	chr5:56184610	C/T	cg24531977	chr5:56204891	C5orf35	-0.87	-10.87	-0.56	5.43e-23	Initial pursuit acceleration;
CESC	cis	rs16895831	0.549	rs12209281	chr6:42615451	G/A	cg10605015	chr6:42532144	UBR2	-0.5	-5.52	-0.32	8.27e-8	Granulocyte percentage of myeloid white cells;Neutrophil percentage of white cells;Eosinophil percentage of white cells;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Neutrophil count;Sum basophil neutrophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
CESC	cis	rs8058578	1.000	rs67456513	chr16:30714828	A/T	cg02466173	chr16:30829666	NA	-0.4	-6.36	-0.36	8.58e-10	Multiple myeloma;
CESC	cis	rs5498	0.869	rs892188	chr19:10409793	A/G	cg10604476	chr19:10403908	ICAM5	-0.46	-6.39	-0.37	7.31e-10	Lymphocyte counts;Soluble ICAM-1;Blood protein levels;
CESC	cis	rs1552244	1.000	rs6442146	chr3:10073544	C/T	cg00166722	chr3:10149974	C3orf24	0.47	6.03	0.35	5.62e-9	Alzheimer's disease;
CESC	cis	rs5758659	0.652	rs129857	chr22:42399686	C/T	cg04733989	chr22:42467013	NAGA	-0.45	-6.09	-0.35	3.87e-9	Cognitive function;
CESC	cis	rs4969178	0.931	rs6501208	chr17:76395038	A/T	cg20026190	chr17:76395443	PGS1	0.49	7.9	0.44	7.44e-14	HDL cholesterol levels;
CESC	cis	rs7666738	0.830	rs28587201	chr4:98991733	C/T	cg17366294	chr4:99064904	C4orf37	0.6	8.61	0.47	6.47e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2425143	1.000	rs73902914	chr20:34432882	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.8	-7.23	-0.41	5.31e-12	Blood protein levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17076397	chr5:10353763	MARCH6	0.55	6.06	0.35	4.69e-9	Gut microbiome composition (summer);
CESC	cis	rs2072499	0.966	rs6427307	chr1:156190083	A/G	cg25208724	chr1:156163844	SLC25A44	0.98	17.46	0.73	5.7200000000000004e-46	Testicular germ cell tumor;
CESC	cis	rs7818688	0.697	rs57890591	chr8:95983130	G/A	cg16049864	chr8:95962084	TP53INP1	0.55	5.55	0.32	6.92e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs5753618	0.504	rs7284622	chr22:31907985	G/A	cg00478049	chr22:31556069	RNF185	-0.46	-5.59	-0.32	5.63e-8	Colorectal cancer;
CESC	cis	rs875971	1.000	rs778722	chr7:65844828	T/C	cg12463550	chr7:65579703	CRCP	0.59	7.42	0.41	1.55e-12	Aortic root size;
CESC	cis	rs601339	1.000	rs1798219	chr12:123180061	A/C	cg11919336	chr12:123188078	GPR109A	0.48	6.49	0.37	4.12e-10	Adiponectin levels;
CESC	cis	rs9325144	0.554	rs1906264	chr12:38739490	A/G	cg26384229	chr12:38710491	ALG10B	0.56	8.09	0.45	2.12e-14	Morning vs. evening chronotype;
CESC	cis	rs4704187	0.687	rs4621540	chr5:74371203	T/G	cg03227963	chr5:74354835	NA	0.31	5.81	0.34	1.74e-8	Response to amphetamines;
CESC	cis	rs4604732	0.527	rs79329288	chr1:247626513	T/C	cg12754571	chr1:247694271	LOC148824;OR2C3	0.44	5.44	0.32	1.21e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs12701220	0.522	rs1881116	chr7:1053958	C/T	cg20821713	chr7:1055600	C7orf50	-0.46	-5.57	-0.32	6.32e-8	Bronchopulmonary dysplasia;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg19586645	chr17:73266642	MIF4GD	0.49	6.61	0.38	2.14e-10	Systemic lupus erythematosus;
CESC	cis	rs965513	0.524	rs1443432	chr9:100583195	C/T	cg13688889	chr9:100608707	NA	-0.53	-7.71	-0.43	2.49e-13	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
CESC	cis	rs9916302	0.752	rs12150047	chr17:37601755	A/G	cg07936489	chr17:37558343	FBXL20	-0.91	-9.97	-0.52	4.37e-20	Glomerular filtration rate (creatinine);
CESC	cis	rs4629710	0.592	rs13205441	chr6:131575069	G/A	cg12606694	chr6:131520996	AKAP7	0.49	5.99	0.35	6.78e-9	Multiple myeloma (IgH translocation);
CESC	cis	rs7586673	0.930	rs2884364	chr2:161977647	G/A	cg16506815	chr2:162101123	NA	0.42	5.83	0.34	1.63e-8	Intelligence (multi-trait analysis);
CESC	cis	rs10751667	0.666	rs7395267	chr11:962326	C/A	cg06064525	chr11:970664	AP2A2	-0.47	-9.32	-0.5	4.88e-18	Alzheimer's disease (late onset);
CESC	cis	rs1801251	1.000	rs1446311	chr2:233705071	G/A	cg25237894	chr2:233734115	C2orf82	-0.46	-8.05	-0.44	2.73e-14	Coronary artery disease;
CESC	trans	rs561341	1.000	rs8064843	chr17:30245744	A/G	cg20587970	chr11:113659929	NA	-0.85	-10.47	-0.54	1.04e-21	Hip circumference adjusted for BMI;
CESC	cis	rs9322193	0.884	rs9397036	chr6:150172923	C/T	cg07701084	chr6:150067640	NUP43	0.4	5.23	0.31	3.41e-7	Lung cancer;
CESC	cis	rs2425143	1.000	rs79035779	chr20:34343004	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.84	-7.55	-0.42	6.87e-13	Blood protein levels;
CESC	cis	rs780096	0.546	rs4425043	chr2:27733452	G/A	cg17158414	chr2:27665306	KRTCAP3	-0.31	-5.48	-0.32	1.01e-7	Total body bone mineral density;
CESC	cis	rs2842992	0.789	rs2475566	chr6:160148741	C/T	cg26839252	chr6:160211577	TCP1;MRPL18	0.44	5.06	0.3	7.95e-7	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs7811142	0.775	rs1636980	chr7:99938864	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	-1.08	-11.42	-0.57	8.16e-25	Platelet count;
CESC	cis	rs11690935	0.595	rs788171	chr2:172921832	A/G	cg13550731	chr2:172543902	DYNC1I2	0.5	6.94	0.39	3e-11	Schizophrenia;
CESC	cis	rs950776	0.518	rs55690619	chr15:78833612	A/G	cg06917634	chr15:78832804	PSMA4	-0.78	-11.9	-0.59	1.92e-26	Sudden cardiac arrest;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08084737	chr7:43965691	URGCP;UBE2D4	-0.7	-8.83	-0.48	1.46e-16	Gut microbiome composition (summer);
CESC	cis	rs2361718	0.500	rs4889818	chr17:78085228	A/G	cg21238619	chr17:78079768	GAA	-0.42	-6.1	-0.35	3.7e-9	Yeast infection;
CESC	cis	rs2247341	0.894	rs61675353	chr4:1720794	T/G	cg07465881	chr4:1713556	SLBP	-0.52	-6.55	-0.37	2.94e-10	Hip circumference adjusted for BMI;Height;
CESC	cis	rs6963495	0.745	rs73192153	chr7:105212418	A/T	cg19920283	chr7:105172520	RINT1	0.7	6.36	0.36	8.94e-10	Bipolar disorder (body mass index interaction);
CESC	cis	rs523522	0.962	rs10849758	chr12:120971149	C/T	cg27279351	chr12:120934652	DYNLL1	0.69	9.11	0.49	2.02e-17	High light scatter reticulocyte count;
CESC	cis	rs3617	0.539	rs9880619	chr3:52953055	G/A	cg07507251	chr3:52567010	NT5DC2	-0.35	-5.62	-0.33	4.91e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
CESC	cis	rs6089584	0.888	rs6061983	chr20:60621202	T/C	cg13770153	chr20:60521292	NA	-0.44	-5.7	-0.33	3.2e-8	Body mass index;
CESC	cis	rs9916302	0.861	rs10491129	chr17:37461643	T/G	cg20243544	chr17:37824526	PNMT	-0.44	-5.47	-0.32	1.06e-7	Glomerular filtration rate (creatinine);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22163445	chr2:101618580	RPL31	0.55	6.02	0.35	5.84e-9	Gut microbiome composition (summer);
CESC	cis	rs28829049	0.597	rs12566296	chr1:19498443	A/C	cg13387374	chr1:19411106	UBR4	0.44	5.53	0.32	7.52e-8	QRS duration in Tripanosoma cruzi seropositivity;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg10673544	chr7:122321539	CADPS2	-0.53	-7.25	-0.41	4.48e-12	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs1538970	1.000	rs1538970	chr1:45847562	G/A	cg06784218	chr1:46089804	CCDC17	0.35	5.96	0.34	7.86e-9	Platelet count;
CESC	cis	rs2952156	0.959	rs2934952	chr17:37832366	G/A	cg00129232	chr17:37814104	STARD3	-0.71	-9.32	-0.5	4.89e-18	Asthma;
CESC	cis	rs9926296	0.656	rs11861084	chr16:89875710	G/T	cg27121462	chr16:89883253	FANCA	-0.57	-7.1	-0.4	1.15e-11	Vitiligo;
CESC	cis	rs477692	1.000	rs531572	chr10:131427569	A/G	cg05714579	chr10:131428358	MGMT	-0.55	-7.59	-0.42	5.38e-13	Response to temozolomide;
CESC	cis	rs3008870	1.000	rs3008848	chr1:67379284	C/T	cg02640540	chr1:67518911	SLC35D1	0.49	5.21	0.3	3.81e-7	Lymphocyte percentage of white cells;
CESC	cis	rs116095464	0.558	rs28418643	chr5:240859	A/G	cg12570787	chr5:219185	SDHA;CCDC127	0.5	5.31	0.31	2.3e-7	Breast cancer;
CESC	cis	rs854765	0.547	rs4368210	chr17:17896090	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.62	-9.02	-0.48	4.02e-17	Total body bone mineral density;
CESC	cis	rs9733	0.596	rs34140753	chr1:150642583	T/C	cg17724175	chr1:150552817	MCL1	0.44	7.23	0.41	5.25e-12	Tonsillectomy;
CESC	cis	rs4889855	0.530	rs7209279	chr17:78598055	T/A	cg16591659	chr17:78472290	NA	-0.33	-5.25	-0.31	3.08e-7	Fractional excretion of uric acid;
CESC	cis	rs736408	0.527	rs2577831	chr3:52628056	C/A	cg17372223	chr3:52568218	NT5DC2	0.45	7.38	0.41	2.09e-12	Bipolar disorder;
CESC	cis	rs1559088	0.847	rs10423531	chr19:33600140	T/C	cg17764715	chr19:33622953	WDR88	0.48	6.2	0.36	2.2e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs8072100	0.875	rs62073966	chr17:45600013	T/A	cg08085267	chr17:45401833	C17orf57	0.46	6.2	0.36	2.21e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs4555082	0.874	rs3000075	chr14:105713219	C/T	cg10792982	chr14:105748885	BRF1	-0.42	-5.69	-0.33	3.3e-8	Mean platelet volume;Platelet distribution width;
CESC	cis	rs2832191	0.791	rs2832187	chr21:30485543	T/C	cg24692254	chr21:30365293	RNF160	-0.8	-12.74	-0.62	2.64e-29	Dental caries;
CESC	cis	rs2625529	0.586	rs7173626	chr15:72186926	C/A	cg16672083	chr15:72433130	SENP8	0.36	5.35	0.31	1.91e-7	Red blood cell count;
CESC	cis	rs7666738	0.830	rs35915560	chr4:98978649	C/T	cg17366294	chr4:99064904	C4orf37	0.58	8.31	0.45	5.14e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1707322	0.964	rs785499	chr1:46592420	G/A	cg03146154	chr1:46216737	IPP	-0.74	-9.64	-0.51	4.75e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7811142	0.830	rs61735533	chr7:99955866	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.08	11.0	0.56	1.98e-23	Platelet count;
CESC	cis	rs2404602	0.552	rs11634428	chr15:77084582	T/C	cg00316803	chr15:76480434	C15orf27	0.42	5.64	0.33	4.39e-8	Blood metabolite levels;
CESC	cis	rs7666738	0.830	rs3857217	chr4:99034347	T/C	cg17366294	chr4:99064904	C4orf37	0.62	8.86	0.48	1.22e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs896854	0.714	rs6471503	chr8:95990283	G/A	cg16049864	chr8:95962084	TP53INP1	-0.65	-11.59	-0.58	2.12e-25	Type 2 diabetes;
CESC	cis	rs6502050	0.835	rs34620191	chr17:80149532	G/A	cg23985595	chr17:80112537	CCDC57	-0.42	-6.57	-0.37	2.59e-10	Life satisfaction;
CESC	cis	rs4319547	1.000	rs7309390	chr12:123110422	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.6	-7.08	-0.4	1.29e-11	Body mass index;
CESC	trans	rs62103177	0.810	rs62103189	chr18:77627815	G/A	cg05926928	chr17:57297772	GDPD1	1.18	10.14	0.53	1.27e-20	Opioid sensitivity;
CESC	cis	rs9894429	0.682	rs7406360	chr17:79591545	G/A	cg13777783	chr17:79615861	NA	-0.33	-5.23	-0.31	3.45e-7	Eye color traits;
CESC	cis	rs2444240	1.000	rs494965	chr11:120053650	C/T	cg04390734	chr11:120039366	NA	-0.28	-5.15	-0.3	5.09e-7	Corneal curvature;
CESC	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	7.6	0.42	5.11e-13	Prudent dietary pattern;
CESC	cis	rs10129255	0.518	rs28378320	chr14:107216845	T/C	cg07958169	chr14:107095056	NA	-0.61	-9.81	-0.52	1.35e-19	Kawasaki disease;
CESC	cis	rs7582720	1.000	rs7560547	chr2:203757916	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.39	0.41	1.96e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs6500395	0.962	rs9941275	chr16:48573428	A/G	cg04672837	chr16:48644449	N4BP1	0.49	6.13	0.35	3.14e-9	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs6748734	1.000	rs4675874	chr2:241819796	A/G	cg07537917	chr2:241836409	C2orf54	0.27	5.95	0.34	8.64e-9	Urinary metabolites;
CESC	cis	rs473651	0.935	rs541128	chr2:239336449	A/G	cg18131467	chr2:239335373	ASB1	1.02	21.09	0.79	1.28e-58	Multiple system atrophy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10358816	chr4:83295331	HNRNPD	0.55	6.28	0.36	1.4e-9	Gut microbiome composition (summer);
CESC	cis	rs919433	0.963	rs1896857	chr2:198164530	A/G	cg10820045	chr2:198174542	NA	-0.39	-5.71	-0.33	3.05e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	trans	rs35110281	0.607	rs4819212	chr21:44977455	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.56	7.4	0.41	1.83e-12	Mean corpuscular volume;
CESC	cis	rs9858542	0.953	rs35115732	chr3:49475155	T/C	cg07274523	chr3:49395745	GPX1	0.66	8.1	0.45	2.07e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs7188697	0.922	rs37057	chr16:58561954	T/C	cg21335942	chr16:58549945	SETD6	0.46	5.41	0.32	1.4e-7	QT interval;
CESC	cis	rs4665809	0.887	rs4665814	chr2:26273687	G/T	cg04944784	chr2:26401820	FAM59B	-0.64	-7.21	-0.41	5.78e-12	Gut microbiome composition (summer);
CESC	cis	rs60843830	0.928	rs55742348	chr2:217563	T/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.77	9.72	0.51	2.66e-19	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs709400	0.627	rs55859054	chr14:103953666	T/A	cg12935359	chr14:103987150	CKB	-0.5	-7.3	-0.41	3.36e-12	Body mass index;
CESC	cis	rs7216064	1.000	rs12602655	chr17:65909442	A/G	cg12091567	chr17:66097778	LOC651250	-0.8	-8.08	-0.44	2.31e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09721380	chr16:69140530	HAS3	-0.56	-6.38	-0.36	7.96e-10	Gut microbiome composition (summer);
CESC	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg23978390	chr7:1156363	C7orf50	0.58	7.93	0.44	6.02e-14	Longevity;Endometriosis;
CESC	cis	rs9818758	0.607	rs35283189	chr3:49113668	T/C	cg00383909	chr3:49044727	WDR6	0.92	6.59	0.38	2.35e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CESC	cis	rs1552244	0.882	rs61429272	chr3:10037320	G/C	cg00166722	chr3:10149974	C3orf24	0.48	5.98	0.34	7.06e-9	Alzheimer's disease;
CESC	cis	rs270601	0.770	rs932019	chr5:131599370	T/C	cg12564285	chr5:131593104	PDLIM4	0.41	6.28	0.36	1.39e-9	Acylcarnitine levels;
CESC	cis	rs116095464	0.681	rs10060016	chr5:241100	T/C	cg10591111	chr5:226296	SDHA	-0.52	-6.38	-0.36	7.94e-10	Breast cancer;
CESC	cis	rs79349575	0.715	rs4793997	chr17:47019672	C/A	cg26022315	chr17:47021804	SNF8	0.39	5.16	0.3	4.94e-7	Type 2 diabetes;
CESC	cis	rs13191362	1.000	rs28360546	chr6:163210973	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.01	9.42	0.5	2.35e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs2880765	0.835	rs4344688	chr15:86043007	A/C	cg10818794	chr15:86012489	AKAP13	-0.34	-5.26	-0.31	3.02e-7	Coronary artery disease;
CESC	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg24829409	chr8:58192753	C8orf71	-0.67	-8.09	-0.44	2.23e-14	Developmental language disorder (linguistic errors);
CESC	cis	rs11997175	0.902	rs7462610	chr8:33693318	A/T	ch.8.33884649F	chr8:33765107	NA	0.61	7.75	0.43	1.91e-13	Body mass index;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14242958	chr11:101785693	KIAA1377;ANGPTL5	0.54	6.23	0.36	1.78e-9	Gut microbiome composition (summer);
CESC	cis	rs6674176	0.628	rs2240447	chr1:44415415	C/T	cg12908607	chr1:44402522	ARTN	-0.46	-6.64	-0.38	1.75e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs35955747	0.902	rs5997938	chr22:31676992	A/G	cg25791279	chr22:32026902	PISD	-0.5	-5.96	-0.34	7.96e-9	Neutrophil count;Sum basophil neutrophil counts;
CESC	cis	rs6540559	1.000	rs742215	chr1:209961023	A/T	cg09509183	chr1:209979624	IRF6	0.47	5.72	0.33	2.93e-8	Cleft lip with or without cleft palate;
CESC	cis	rs11792861	0.926	rs72607171	chr9:111837776	T/C	cg05043794	chr9:111880884	C9orf5	-0.41	-6.74	-0.38	9.83e-11	Menarche (age at onset);
CESC	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.55	-6.17	-0.35	2.48e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg24903794	chr1:220220036	EPRS	-0.51	-6.53	-0.37	3.26e-10	Asthma;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23495556	chr7:44836196	PPIA	0.62	7.35	0.41	2.45e-12	Gut microbiome composition (summer);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg18504358	chr14:23340787	LRP10	0.51	6.61	0.38	2.15e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs9649213	0.593	rs35535338	chr7:97962319	C/T	cg24562669	chr7:97807699	LMTK2	0.52	7.69	0.43	2.85e-13	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs2952156	0.959	rs2941504	chr17:37830900	A/G	cg00129232	chr17:37814104	STARD3	-0.72	-9.62	-0.51	5.62e-19	Asthma;
CESC	cis	rs7639513	0.767	rs7648488	chr3:12708946	T/C	cg23032965	chr3:12705835	RAF1	0.76	10.86	0.55	5.83e-23	Itch intensity from mosquito bite;
CESC	cis	rs847577	0.748	rs940431	chr7:97716495	C/T	cg21770322	chr7:97807741	LMTK2	0.64	10.52	0.54	7.29e-22	Breast cancer;
CESC	cis	rs9303280	0.806	rs4795395	chr17:37962987	T/A	cg19468946	chr17:37922297	IKZF3	-0.41	-5.66	-0.33	3.9e-8	Self-reported allergy;
CESC	cis	rs3087591	1.000	rs7226006	chr17:29650656	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.47	-5.82	-0.34	1.68e-8	Hip circumference;
CESC	cis	rs4253772	0.550	rs6008601	chr22:46705326	C/G	cg10541313	chr22:46663664	TTC38	0.63	5.26	0.31	2.94e-7	LDL cholesterol;Cholesterol, total;
CESC	trans	rs11722228	0.522	rs62286604	chr4:10131161	A/G	cg26043149	chr18:55253948	FECH	1.01	12.66	0.61	4.83e-29	Gout;Urate levels;Serum uric acid levels;
CESC	cis	rs7621025	0.500	rs1965107	chr3:136648643	T/A	cg15507776	chr3:136538369	TMEM22	0.74	8.92	0.48	7.86e-17	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
CESC	cis	rs748404	0.676	rs4401024	chr15:43650335	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.54	8.25	0.45	7.26e-15	Lung cancer;
CESC	cis	rs7927771	0.839	rs59360790	chr11:47669175	T/C	cg05585544	chr11:47624801	NA	-0.41	-6.48	-0.37	4.55e-10	Subjective well-being;
CESC	cis	rs7618915	0.547	rs11709448	chr3:52647449	T/C	cg18404041	chr3:52824283	ITIH1	-0.4	-6.63	-0.38	1.85e-10	Bipolar disorder;
CESC	trans	rs997295	0.570	rs11632574	chr15:67852405	A/C	cg05081167	chr6:156967138	NA	0.27	6.05	0.35	4.99e-9	Motion sickness;
CESC	cis	rs3820068	0.581	rs68052904	chr1:15916714	T/C	cg16988262	chr1:15930761	NA	0.34	5.38	0.31	1.61e-7	Systolic blood pressure;
CESC	cis	rs9915657	0.870	rs759499	chr17:70133177	C/T	cg06234051	chr17:70120541	SOX9	-0.41	-5.97	-0.34	7.75e-9	Thyroid hormone levels;
CESC	cis	rs172166	0.637	rs1225592	chr6:28150242	G/A	cg21251018	chr6:28226885	NKAPL	0.37	6.21	0.36	2.04e-9	Cardiac Troponin-T levels;
CESC	trans	rs7980799	0.935	rs10844582	chr12:33560873	A/G	cg26384229	chr12:38710491	ALG10B	-0.52	-6.69	-0.38	1.29e-10	Heart rate;Heart rate variability traits (RMSSD);
CESC	cis	rs2404602	0.716	rs1946650	chr15:76848463	T/C	cg26408565	chr15:76604113	ETFA	-0.43	-6.18	-0.36	2.37e-9	Blood metabolite levels;
CESC	cis	rs7539409	0.651	rs6576953	chr1:84316946	A/G	cg10977910	chr1:84465055	TTLL7	0.78	7.37	0.41	2.21e-12	Alzheimer's disease;
CESC	cis	rs7927592	0.672	rs10501398	chr11:68331715	C/G	cg01657329	chr11:68192670	LRP5	0.49	6.64	0.38	1.72e-10	Total body bone mineral density;
CESC	cis	rs2180341	1.000	rs4895822	chr6:127642703	T/C	cg24812749	chr6:127587940	RNF146	1.07	15.4	0.69	1.16e-38	Breast cancer;
CESC	cis	rs55871839	0.684	rs10095333	chr8:59815629	G/A	cg07426533	chr8:59803705	TOX	-0.5	-7.39	-0.41	1.87e-12	Pneumonia;
CESC	cis	rs7552404	0.765	rs1251078	chr1:76189488	C/G	cg03433033	chr1:76189801	ACADM	-0.8	-12.69	-0.61	3.85e-29	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs3806843	0.735	rs801185	chr5:140068869	A/G	cg16179182	chr5:140090404	VTRNA1-1	0.39	5.11	0.3	6.21e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs2204008	0.715	rs11525003	chr12:38332359	G/A	cg26384229	chr12:38710491	ALG10B	0.73	10.9	0.56	4.29e-23	Bladder cancer;
CESC	cis	rs34172651	0.517	rs200528	chr16:24759131	A/G	cg06028605	chr16:24865363	SLC5A11	-0.54	-8.07	-0.44	2.39e-14	Intelligence (multi-trait analysis);
CESC	cis	rs6991838	0.584	rs4737747	chr8:66519259	C/T	cg13398993	chr8:66546079	ARMC1	-0.46	-5.45	-0.32	1.14e-7	Intelligence (multi-trait analysis);
CESC	cis	rs6424115	0.800	rs2229583	chr1:24200983	C/T	cg10978503	chr1:24200527	CNR2	0.31	6.02	0.35	5.84e-9	Immature fraction of reticulocytes;
CESC	cis	rs6087990	1.000	rs1007123	chr20:31345840	G/A	cg13636640	chr20:31349939	DNMT3B	0.91	15.84	0.7	3.34e-40	Ulcerative colitis;
CESC	cis	rs4481887	0.927	rs4279879	chr1:248486475	A/G	cg00666640	chr1:248458726	OR2T12	0.36	6.17	0.35	2.56e-9	Common traits (Other);
CESC	cis	rs2361718	0.521	rs2361724	chr17:78099114	G/A	cg21238619	chr17:78079768	GAA	-0.38	-5.63	-0.33	4.51e-8	Yeast infection;
CESC	cis	rs4704187	0.687	rs6858969	chr5:74379281	T/C	cg03227963	chr5:74354835	NA	0.32	5.95	0.34	8.68e-9	Response to amphetamines;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg25616684	chr1:38478508	UTP11L	-0.48	-6.41	-0.37	6.55e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs7584330	0.737	rs937392	chr2:238367130	C/T	cg14458575	chr2:238380390	NA	0.62	8.43	0.46	2.19e-15	Prostate cancer;
CESC	cis	rs875971	0.862	rs801195	chr7:66026115	A/G	cg18252515	chr7:66147081	NA	0.46	5.96	0.34	8.03e-9	Aortic root size;
CESC	cis	rs28830936	0.510	rs11070349	chr15:42085017	A/C	cg17847044	chr15:42102381	MAPKBP1	-0.45	-7.97	-0.44	4.8e-14	Diastolic blood pressure;
CESC	cis	rs763121	0.719	rs9610995	chr22:39057763	C/T	cg14440974	chr22:39074834	NA	-0.4	-5.5	-0.32	9.03e-8	Menopause (age at onset);
CESC	trans	rs3942852	0.550	rs1113480	chr11:48058313	G/T	cg03929089	chr4:120376271	NA	-0.62	-7.5	-0.42	9.35e-13	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs287982	0.932	rs58521916	chr2:9966470	C/T	cg10881225	chr2:9984929	TAF1B	0.41	5.2	0.3	4.01e-7	Nonsyndromic cleft lip with cleft palate;
CESC	cis	rs16854884	0.580	rs7615861	chr3:143860822	A/G	cg06585982	chr3:143692056	C3orf58	0.43	5.39	0.31	1.59e-7	Economic and political preferences (feminism/equality);
CESC	cis	rs2274273	0.870	rs8023197	chr14:55767395	G/T	cg04306507	chr14:55594613	LGALS3	0.32	6.17	0.35	2.53e-9	Protein biomarker;
CESC	cis	rs2573652	0.674	rs11630619	chr15:100543367	G/A	cg00587665	chr15:100533223	ADAMTS17	-0.41	-6.75	-0.38	9.15e-11	Height;
CESC	cis	rs6967385	0.704	rs17149929	chr7:12406080	A/T	cg06484146	chr7:12443880	VWDE	0.37	6.13	0.35	3.17e-9	Response to taxane treatment (placlitaxel);
CESC	cis	rs763014	0.833	rs916415	chr16:632115	G/A	cg07343612	chr16:622815	PIGQ	-0.57	-8.23	-0.45	8.47e-15	Height;
CESC	cis	rs4692589	0.581	rs12646523	chr4:170944698	C/T	cg19918862	chr4:170955249	NA	0.44	5.86	0.34	1.35e-8	Anxiety disorder;
CESC	cis	rs7819412	0.749	rs11991118	chr8:10939273	A/C	cg21775007	chr8:11205619	TDH	0.36	5.24	0.31	3.29e-7	Triglycerides;
CESC	cis	rs9311474	0.713	rs352167	chr3:52238656	C/T	cg05564831	chr3:52568323	NT5DC2	-0.36	-5.6	-0.33	5.46e-8	Electroencephalogram traits;
CESC	cis	rs9399135	0.967	rs7741515	chr6:135374368	C/G	cg24558204	chr6:135376177	HBS1L	-0.5	-6.77	-0.38	8.11e-11	Red blood cell count;
CESC	cis	rs11577318	0.853	rs2276712	chr1:26627478	T/C	cg19743891	chr1:26644573	UBXN11;CD52	-0.28	-5.05	-0.3	8.22e-7	Granulocyte percentage of myeloid white cells;
CESC	cis	rs2637266	0.905	rs1978925	chr10:78399879	C/T	cg18941641	chr10:78392320	NA	0.44	8.42	0.46	2.48e-15	Pulmonary function;
CESC	cis	rs12893668	0.703	rs7148456	chr14:104028270	C/T	cg24130564	chr14:104152367	KLC1	0.47	6.2	0.36	2.16e-9	Reticulocyte count;
CESC	trans	rs66573146	0.572	rs55740475	chr4:6954092	C/G	cg07817883	chr1:32538562	TMEM39B	1.2	8.35	0.46	3.81e-15	Granulocyte percentage of myeloid white cells;
CESC	cis	rs2289583	0.544	rs6495132	chr15:75255322	C/T	cg14664628	chr15:75095509	CSK	0.47	5.57	0.32	6.28e-8	Systemic lupus erythematosus;
CESC	cis	rs1499614	0.803	rs1796229	chr7:66119661	G/A	cg12463550	chr7:65579703	CRCP	0.74	5.71	0.33	3.03e-8	Gout;
CESC	cis	rs8002861	0.765	rs12868462	chr13:44453480	C/T	cg19180546	chr13:44453867	C13orf31;CCDC122	-0.46	-5.84	-0.34	1.5e-8	Leprosy;
CESC	cis	rs4481887	0.741	rs6682957	chr1:248535639	T/G	cg26353448	chr1:248524236	OR2T4	-0.4	-5.6	-0.33	5.41e-8	Common traits (Other);
CESC	cis	rs727563	0.593	rs132770	chr22:42017264	A/G	cg06481639	chr22:41940642	POLR3H	0.62	6.27	0.36	1.47e-9	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs7560272	0.723	rs1052161	chr2:73828538	A/G	cg20560298	chr2:73613845	ALMS1	-0.5	-7.18	-0.4	6.95e-12	Schizophrenia;
CESC	cis	rs9649213	0.614	rs4236537	chr7:97996593	T/C	cg09267113	chr7:98030324	BAIAP2L1	-0.45	-6.07	-0.35	4.46e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs1801251	0.778	rs709934	chr2:233733352	A/G	cg25237894	chr2:233734115	C2orf82	-0.49	-8.62	-0.47	6.2e-16	Coronary artery disease;
CESC	cis	rs763121	0.853	rs3788544	chr22:39064966	C/T	cg21395723	chr22:39101663	GTPBP1	0.42	5.18	0.3	4.45e-7	Menopause (age at onset);
CESC	cis	rs962856	1.000	rs6755797	chr2:67598633	G/A	cg09028215	chr2:67624308	ETAA1	-0.41	-5.42	-0.32	1.33e-7	Pancreatic cancer;
CESC	cis	rs7264396	0.635	rs2024854	chr20:34511189	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.83	-11.07	-0.56	1.17e-23	Total cholesterol levels;
CESC	trans	rs6818288	0.778	rs77441057	chr4:30077134	T/C	cg12528397	chr3:62933670	NA	0.42	6.13	0.35	3.2e-9	Obesity-related traits;
CESC	cis	rs6733011	0.508	rs4851173	chr2:99520608	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.41	-5.11	-0.3	6.13e-7	Bipolar disorder;
CESC	cis	rs8103278	0.507	rs4802276	chr19:46260748	T/C	cg06577658	chr19:46296270	DMWD	0.49	5.86	0.34	1.37e-8	Coronary artery disease;
CESC	trans	rs76747430	0.528	rs5750913	chr22:40640285	A/G	cg02581963	chr10:102133317	C10orf75	0.5	6.47	0.37	4.7e-10	Facial morphology (factor 20);
CESC	cis	rs6964587	1.000	rs10281556	chr7:91660053	C/T	cg17063962	chr7:91808500	NA	-0.56	-7.9	-0.44	7.64e-14	Breast cancer;
CESC	cis	rs9916302	0.851	rs11657899	chr17:37626963	G/A	cg19468946	chr17:37922297	IKZF3	-0.39	-5.08	-0.3	7.08e-7	Glomerular filtration rate (creatinine);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19016110	chr17:36981717	CCDC49	0.56	6.58	0.37	2.55e-10	Gut microbiome composition (summer);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg21926875	chr2:47596410	EPCAM	-0.44	-6.01	-0.35	6.23e-9	Fibrinogen levels;
CESC	cis	rs2204008	0.837	rs11514225	chr12:38076270	G/A	cg26384229	chr12:38710491	ALG10B	0.74	10.75	0.55	1.31e-22	Bladder cancer;
CESC	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg24829409	chr8:58192753	C8orf71	-0.67	-7.99	-0.44	4.08e-14	Developmental language disorder (linguistic errors);
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg08413153	chr17:46185283	SNX11	-0.44	-6.47	-0.37	4.71e-10	Vertical cup-disc ratio;
CESC	cis	rs77741769	0.529	rs2893876	chr12:121245158	T/C	cg02419362	chr12:121203948	SPPL3	0.34	5.55	0.32	6.87e-8	Mean corpuscular volume;
CESC	cis	rs9911578	1.000	rs302854	chr17:56683612	G/A	cg05425664	chr17:57184151	TRIM37	-0.51	-7.21	-0.4	6.03e-12	Intelligence (multi-trait analysis);
CESC	cis	rs959260	1.000	rs9892325	chr17:73394449	A/C	cg20590849	chr17:73267439	MIF4GD	-0.6	-6.77	-0.38	8.44e-11	Systemic lupus erythematosus;
CESC	cis	rs3858526	0.584	rs10769274	chr11:5866925	T/C	cg02574844	chr11:5959923	NA	-0.48	-7.13	-0.4	9.35e-12	DNA methylation (variation);
CESC	cis	rs9815354	0.812	rs73073326	chr3:41834195	G/T	cg03022575	chr3:42003672	ULK4	0.7	6.04	0.35	5.26e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs7666738	0.830	rs11941844	chr4:99042722	A/T	cg03467027	chr4:99064603	C4orf37	0.47	5.98	0.34	7.19e-9	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05070332	chr2:56411072	CCDC85A	0.52	6.02	0.35	5.75e-9	Gut microbiome composition (summer);
CESC	cis	rs9987353	0.620	rs34455383	chr8:9066458	C/T	cg15556689	chr8:8085844	FLJ10661	-0.59	-6.43	-0.37	5.93e-10	Recombination measurement;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg16528926	chr11:94823603	ENDOD1	0.45	6.43	0.37	5.86e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs763121	0.853	rs138705	chr22:39133803	C/T	cg06544989	chr22:39130855	UNC84B	0.47	8.16	0.45	1.33e-14	Menopause (age at onset);
CESC	cis	rs875971	0.522	rs9530	chr7:65425894	A/G	cg26939375	chr7:64535504	NA	0.75	10.17	0.53	1.03e-20	Aortic root size;
CESC	cis	rs11122272	0.735	rs2491405	chr1:231513431	C/A	cg06096015	chr1:231504339	EGLN1	0.43	6.18	0.35	2.46e-9	Hemoglobin concentration;
CESC	trans	rs7618501	1.000	rs11130218	chr3:49752372	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.58	-8.46	-0.46	1.88e-15	Intelligence (multi-trait analysis);
CESC	cis	rs1707322	1.000	rs6676982	chr1:46275401	A/T	cg03146154	chr1:46216737	IPP	0.71	9.86	0.52	9.77e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2243480	1.000	rs387676	chr7:65598220	C/T	cg13147721	chr7:65941812	NA	-0.99	-9.4	-0.5	2.68e-18	Diabetic kidney disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06616775	chr2:202316682	STRADB;TRAK2	0.55	6.02	0.35	5.88e-9	Gut microbiome composition (summer);
CESC	cis	rs6968419	0.755	rs17138483	chr7:115893845	A/C	cg02561103	chr7:115862891	TES	-0.4	-5.26	-0.31	2.92e-7	Intraocular pressure;
CESC	cis	rs35110281	0.807	rs2838328	chr21:45023234	G/C	cg04455712	chr21:45112962	RRP1B	0.41	6.19	0.36	2.3e-9	Mean corpuscular volume;
CESC	cis	rs1322639	0.614	rs9689800	chr6:169572945	T/A	cg04662567	chr6:169592167	NA	0.4	5.64	0.33	4.36e-8	Pulse pressure;
CESC	cis	rs10791323	0.604	rs2723605	chr11:133711241	C/G	cg06766960	chr11:133703094	NA	-0.41	-5.77	-0.33	2.24e-8	Childhood ear infection;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg15929201	chr5:31531945	RNASEN;C5orf22	-0.42	-6.1	-0.35	3.79e-9	Gambling;
CESC	cis	rs35306767	0.903	rs11815185	chr10:923617	T/A	cg25019033	chr10:957182	NA	-0.57	-6.43	-0.37	6e-10	Eosinophil percentage of granulocytes;
CESC	cis	rs875971	0.862	rs6952182	chr7:65683317	T/G	cg19163074	chr7:65112434	INTS4L2	0.44	5.53	0.32	7.83e-8	Aortic root size;
CESC	cis	rs875971	0.522	rs34973832	chr7:65396204	A/G	cg14393609	chr7:65229607	NA	0.53	7.22	0.41	5.48e-12	Aortic root size;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg14819838	chr17:14140124	CDRT15	0.32	6.13	0.35	3.14e-9	Gambling;
CESC	cis	rs11750568	0.935	rs10070609	chr5:178524969	T/C	cg10208897	chr5:178548229	ADAMTS2	0.37	5.25	0.31	3.17e-7	Height;
CESC	cis	rs35082559	1	rs35082559	chr2:23896606	CA/C	cg14009731	chr2:24150123	ATAD2B	0.52	5.37	0.31	1.71e-7	Granulocyte percentage of myeloid white cells;
CESC	cis	rs5750830	0.595	rs4821892	chr22:39795683	G/C	cg11247378	chr22:39784982	NA	-0.63	-9.37	-0.5	3.38e-18	Intelligence (multi-trait analysis);
CESC	cis	rs4888262	0.526	rs7201105	chr16:74590603	A/G	cg01733217	chr16:74700730	RFWD3	0.81	11.35	0.57	1.39e-24	Testicular germ cell tumor;
CESC	cis	rs10911232	0.507	rs10797816	chr1:182998486	A/T	ch.1.3577855R	chr1:183094577	LAMC1	0.8	12.2	0.6	1.85e-27	Hypertriglyceridemia;
CESC	cis	rs10504229	0.953	rs78089850	chr8:58171557	A/G	cg22535103	chr8:58192502	C8orf71	-1.06	-13.13	-0.63	1.17e-30	Developmental language disorder (linguistic errors);
CESC	cis	rs3091242	0.933	rs11802413	chr1:25760920	A/G	cg03538708	chr1:25844672	NA	0.37	5.69	0.33	3.32e-8	Erythrocyte sedimentation rate;
CESC	cis	rs2732480	0.500	rs7315820	chr12:48598938	C/T	cg24011408	chr12:48396354	COL2A1	0.43	6.11	0.35	3.5e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs4835473	0.897	rs11931330	chr4:144891961	G/A	cg25736465	chr4:144833511	NA	0.39	5.99	0.35	6.96e-9	Immature fraction of reticulocytes;
CESC	cis	rs7809950	1.000	rs10273733	chr7:107258121	A/G	cg23024343	chr7:107201750	COG5	0.44	5.88	0.34	1.26e-8	Coronary artery disease;
CESC	cis	rs2816062	0.813	rs6698315	chr1:18895806	A/G	cg18795169	chr1:18902165	NA	-0.91	-17.81	-0.74	3.44e-47	Urate levels in lean individuals;
CESC	cis	rs7811142	1.000	rs11764818	chr7:100043055	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.11	10.93	0.56	3.38e-23	Platelet count;
CESC	cis	rs2204008	0.623	rs1315348	chr12:38163044	G/A	cg26384229	chr12:38710491	ALG10B	-0.43	-5.92	-0.34	9.92e-9	Bladder cancer;
CESC	cis	rs1862618	0.853	rs43184	chr5:56141777	G/C	cg03609598	chr5:56110824	MAP3K1	-0.53	-5.62	-0.33	4.78e-8	Initial pursuit acceleration;
CESC	cis	rs9905704	0.918	rs694720	chr17:56708019	T/C	cg12560992	chr17:57184187	TRIM37	0.59	7.02	0.4	1.86e-11	Testicular germ cell tumor;
CESC	cis	rs8062405	1.000	rs62037371	chr16:28890131	C/A	cg08761264	chr16:28874980	SH2B1	-0.47	-5.85	-0.34	1.42e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg16423265	chr20:60697137	LSM14B	-0.42	-6.08	-0.35	4.12e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs35520189	0.591	rs11690185	chr2:113698136	C/T	cg06156847	chr2:113672199	IL1F7	0.37	5.27	0.31	2.87e-7	Obstructive sleep apnea trait (apnea hypopnea index);
CESC	cis	rs7107174	1.000	rs2510036	chr11:77966788	G/T	cg02023728	chr11:77925099	USP35	0.44	5.76	0.33	2.33e-8	Testicular germ cell tumor;
CESC	cis	rs11676348	0.791	rs4133195	chr2:218951245	A/G	cg00012203	chr2:219082015	ARPC2	0.52	6.83	0.39	5.92e-11	Ulcerative colitis;
CESC	cis	rs853679	0.517	rs4713137	chr6:28083521	C/G	cg18032046	chr6:28092343	ZSCAN16	-0.58	-6.75	-0.38	9.45e-11	Depression;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25485126	chr19:13873471	CCDC130	-0.56	-6.75	-0.38	9.03e-11	Gut microbiome composition (summer);
CESC	trans	rs10411161	0.702	rs2867319	chr19:52397160	T/C	cg22319618	chr22:45562946	NUP50	-0.77	-7.77	-0.43	1.78e-13	Breast cancer;
CESC	cis	rs3862260	0.509	rs3795663	chr1:120165187	G/A	cg16322792	chr1:120165303	ZNF697	0.58	10.95	0.56	2.82e-23	Systemic lupus erythematosus;
CESC	cis	rs2228479	0.850	rs1800339	chr16:89839637	C/A	cg06558623	chr16:89946397	TCF25	1.17	9.29	0.5	5.84e-18	Skin colour saturation;
CESC	cis	rs9300255	0.830	rs28413626	chr12:123861452	G/A	cg00376283	chr12:123451042	ABCB9	-0.66	-7.42	-0.41	1.57e-12	Neutrophil percentage of white cells;
CESC	cis	rs11608355	0.545	rs12823587	chr12:109896390	A/G	cg05360138	chr12:110035743	NA	0.82	8.92	0.48	7.93e-17	Neuroticism;
CESC	cis	rs2933343	0.951	rs796862	chr3:128593040	G/A	cg25356066	chr3:128598488	ACAD9	0.57	7.19	0.4	6.81e-12	IgG glycosylation;
CESC	cis	rs10927875	0.894	rs10927878	chr1:16319957	C/T	cg21385522	chr1:16154831	NA	-0.6	-7.57	-0.42	6.04e-13	Dilated cardiomyopathy;
CESC	trans	rs2121875	0.667	rs56338120	chr5:44215482	C/T	cg09056876	chr6:156718398	NA	-0.47	-6.09	-0.35	4.01e-9	Prostate cancer;
CESC	cis	rs4862750	0.872	rs6553030	chr4:187899234	T/C	cg22105103	chr4:187893119	NA	0.51	7.6	0.42	5.05e-13	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2629540	0.889	rs4962402	chr10:126459114	T/G	cg08799069	chr10:126477246	METTL10	-0.66	-9.2	-0.49	1.13e-17	Cocaine dependence;
CESC	cis	rs875971	0.965	rs7794930	chr7:65778546	A/C	cg12463550	chr7:65579703	CRCP	-0.54	-6.97	-0.39	2.44e-11	Aortic root size;
CESC	cis	rs514406	0.668	rs520281	chr1:53365235	G/C	cg08736216	chr1:53307985	ZYG11A	-0.39	-6.65	-0.38	1.65e-10	Monocyte count;
CESC	cis	rs651907	0.557	rs7629753	chr3:101371922	C/T	cg12386194	chr3:101231763	SENP7	-0.44	-5.6	-0.33	5.35e-8	Colorectal cancer;
CESC	cis	rs6502050	0.835	rs67149434	chr17:80128007	G/A	cg11859384	chr17:80120422	CCDC57	-0.39	-5.34	-0.31	1.97e-7	Life satisfaction;
CESC	cis	rs34172651	0.517	rs2287783	chr16:24831727	C/T	cg06505273	chr16:24850292	NA	0.5	6.06	0.35	4.66e-9	Intelligence (multi-trait analysis);
CESC	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg07677032	chr17:61819896	STRADA	0.45	5.92	0.34	1.01e-8	Prudent dietary pattern;
CESC	cis	rs10426930	0.700	rs8106479	chr19:5003940	G/C	cg18115693	chr19:4968519	KDM4B	-0.42	-5.34	-0.31	2.05e-7	Monocyte percentage of white cells;
CESC	cis	rs6032067	0.929	rs1997892	chr20:43810961	A/T	cg10761708	chr20:43804764	PI3	0.56	6.97	0.39	2.54e-11	Blood protein levels;
CESC	cis	rs7397814	0.558	rs4764447	chr12:9579109	C/T	cg08919224	chr12:9569744	NA	-0.47	-6.03	-0.35	5.51e-9	IgG glycosylation;
CESC	cis	rs6460942	0.915	rs7809263	chr7:12450589	C/G	cg19099843	chr7:12443191	VWDE	-0.49	-5.3	-0.31	2.47e-7	Coronary artery disease;
CESC	cis	rs2637266	0.783	rs1660908	chr10:78494856	T/C	cg18941641	chr10:78392320	NA	0.43	8.46	0.46	1.83e-15	Pulmonary function;
CESC	cis	rs1550582	1.000	rs4909827	chr8:135517576	C/T	cg17885191	chr8:135476712	NA	0.63	7.35	0.41	2.53e-12	Educational attainment;
CESC	cis	rs853679	0.542	rs9393892	chr6:28081394	A/G	cg23281280	chr6:28129359	ZNF389	0.6	8.29	0.45	5.57e-15	Depression;
CESC	cis	rs1552244	1.000	rs58275763	chr3:10143274	C/T	cg08888203	chr3:10149979	C3orf24	0.46	5.9	0.34	1.09e-8	Alzheimer's disease;
CESC	cis	rs17826219	0.568	rs9898097	chr17:29072672	T/G	cg14008862	chr17:28927542	LRRC37B2	0.65	5.14	0.3	5.34e-7	Body mass index;
CESC	cis	rs4595586	0.525	rs11611705	chr12:39426828	C/T	cg13010199	chr12:38710504	ALG10B	0.43	5.17	0.3	4.55e-7	Morning vs. evening chronotype;
CESC	cis	rs7539409	0.833	rs2057083	chr1:84269942	T/G	cg10977910	chr1:84465055	TTLL7	0.66	5.92	0.34	9.98e-9	Alzheimer's disease;
CESC	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg07677032	chr17:61819896	STRADA	0.48	6.47	0.37	4.64e-10	Prudent dietary pattern;
CESC	cis	rs10779751	0.734	rs2791657	chr1:11128001	A/G	cg08854313	chr1:11322531	MTOR	0.77	10.41	0.54	1.73e-21	Body mass index;
CESC	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg04025307	chr7:1156635	C7orf50	0.49	7.97	0.44	4.59e-14	Longevity;Endometriosis;
CESC	cis	rs829883	1.000	rs2908843	chr12:98889332	C/G	cg25150519	chr12:98850993	NA	-0.7	-9.62	-0.51	5.38e-19	Colorectal adenoma (advanced);
CESC	cis	rs801193	0.569	rs3846973	chr7:66120035	T/C	cg10691866	chr7:65817282	TPST1	0.31	5.33	0.31	2.06e-7	Aortic root size;
CESC	cis	rs6831352	0.819	rs896992	chr4:100002372	C/T	cg13256891	chr4:100009986	ADH5	0.67	8.06	0.44	2.68e-14	Alcohol dependence;
CESC	cis	rs7772486	0.534	rs34541797	chr6:146205304	A/G	cg05347473	chr6:146136440	FBXO30	0.77	9.78	0.51	1.78e-19	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs875971	0.505	rs6955582	chr7:65431686	A/G	cg14393609	chr7:65229607	NA	0.51	6.96	0.39	2.61e-11	Aortic root size;
CESC	cis	rs7666738	0.791	rs1896155	chr4:99020948	C/A	cg03467027	chr4:99064603	C4orf37	0.46	5.81	0.34	1.8e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9322193	0.923	rs9371199	chr6:150138662	A/T	cg09699651	chr6:150184138	LRP11	0.41	5.13	0.3	5.51e-7	Lung cancer;
CESC	cis	rs11864453	0.713	rs7190995	chr16:72124157	A/G	cg01557791	chr16:72042693	DHODH	-0.46	-5.92	-0.34	9.98e-9	Fibrinogen levels;
CESC	cis	rs7264396	0.635	rs6060696	chr20:34522060	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.58	6.99	0.39	2.22e-11	Total cholesterol levels;
CESC	cis	rs9611565	0.840	rs9607799	chr22:41777558	A/G	cg17376030	chr22:41985996	PMM1	0.6	6.45	0.37	5.42e-10	Vitiligo;
CESC	cis	rs6496667	0.865	rs13329288	chr15:90897451	C/T	cg22089800	chr15:90895588	ZNF774	0.57	5.76	0.33	2.27e-8	Rheumatoid arthritis;
CESC	cis	rs2012796	0.913	rs8010181	chr14:81820125	T/C	cg02996355	chr14:81879375	NA	0.48	5.77	0.33	2.22e-8	Night sleep phenotypes;
CESC	cis	rs7727544	0.735	rs274568	chr5:131713578	C/T	cg07395648	chr5:131743802	NA	0.48	6.41	0.37	6.73e-10	Blood metabolite levels;
CESC	cis	rs4077515	0.874	rs4498662	chr9:139290251	C/G	cg14169450	chr9:139327907	INPP5E	0.4	5.81	0.34	1.79e-8	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs7851660	0.809	rs7022148	chr9:100660824	T/C	cg13688889	chr9:100608707	NA	-0.62	-8.87	-0.48	1.11e-16	Strep throat;
CESC	cis	rs9649213	0.593	rs2158553	chr7:97951131	G/A	cg24562669	chr7:97807699	LMTK2	0.48	7.1	0.4	1.13e-11	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs9486715	0.867	rs4839828	chr6:96863326	G/A	cg06623918	chr6:96969491	KIAA0776	0.9	14.0	0.65	1.07e-33	Headache;
CESC	cis	rs7582720	1.000	rs72926779	chr2:203805929	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.38	0.41	1.99e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs1707322	0.721	rs12043945	chr1:46106922	T/A	cg05343316	chr1:45956843	TESK2	0.51	6.22	0.36	1.91e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15598754	chr1:21551903	ECE1	-0.61	-6.94	-0.39	3.01e-11	Gut microbiome composition (summer);
CESC	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	21.54	0.8	3.65e-60	Prudent dietary pattern;
CESC	cis	rs6546550	1.000	rs6546550	chr2:70038232	C/G	cg02498382	chr2:70120550	SNRNP27	-0.4	-6.9	-0.39	3.75e-11	Prevalent atrial fibrillation;
CESC	cis	rs796364	0.951	rs36086821	chr2:201067436	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.61	5.71	0.33	3.07e-8	Schizophrenia;
CESC	cis	rs10504229	0.569	rs75466737	chr8:58055034	A/G	cg05313129	chr8:58192883	C8orf71	-0.53	-5.27	-0.31	2.86e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs798554	0.660	rs2527692	chr7:2856533	G/A	cg13628971	chr7:2884303	GNA12	0.41	5.49	0.32	9.4e-8	Height;
CESC	trans	rs11159647	0.636	rs4899848	chr14:84731303	A/T	cg19838074	chr2:242149865	ANO7	0.41	6.01	0.35	6.06e-9	Alzheimer's disease;
CESC	cis	rs2236918	1.000	rs2526701	chr1:242018427	T/C	cg17736920	chr1:242011382	EXO1	0.73	9.84	0.52	1.16e-19	Menopause (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11021810	chr14:89720620	FOXN3	-0.6	-6.81	-0.39	6.68e-11	Gut microbiome composition (summer);
CESC	cis	rs9322193	0.923	rs9377230	chr6:149934743	T/C	cg13206674	chr6:150067644	NUP43	0.43	6.31	0.36	1.16e-9	Lung cancer;
CESC	cis	rs295140	0.526	rs295113	chr2:201197816	C/G	cg23649088	chr2:200775458	C2orf69	0.47	6.36	0.36	8.87e-10	QT interval;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01452438	chr16:4303710	NA	0.55	6.11	0.35	3.54e-9	Gut microbiome composition (summer);
CESC	cis	rs2742234	0.590	rs2435339	chr10:43642173	G/C	cg15436174	chr10:43711423	RASGEF1A	-0.48	-5.61	-0.33	5.11e-8	Hirschsprung disease;
CESC	cis	rs7267979	0.966	rs2500417	chr20:25383287	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.86	-16.62	-0.71	5.52e-43	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs2072732	0.861	rs3795262	chr1:2938697	A/C	cg03976712	chr1:2946727	NA	0.35	5.66	0.33	3.92e-8	Plateletcrit;
CESC	cis	rs3862030	0.503	rs6584505	chr10:104254412	C/A	cg22532475	chr10:104410764	TRIM8	-0.35	-5.92	-0.34	9.74e-9	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
CESC	cis	rs863345	0.967	rs4528114	chr1:158467713	T/C	cg12129480	chr1:158549410	OR10X1	-0.32	-6.27	-0.36	1.42e-9	Pneumococcal bacteremia;
CESC	cis	rs12500824	0.564	rs72657832	chr4:77319523	A/G	cg20311846	chr4:77356250	SHROOM3	0.39	7.46	0.42	1.24e-12	Coronary artery disease;
CESC	cis	rs1461503	0.868	rs7126785	chr11:122839564	C/A	cg27398637	chr11:122830231	C11orf63	-0.55	-8.32	-0.45	4.77e-15	Menarche (age at onset);
CESC	trans	rs4424809	0.614	rs74521004	chr13:85572247	A/G	cg05918002	chr17:5019452	ZNF232	-0.64	-6.06	-0.35	4.77e-9	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs17345786	0.798	rs4257518	chr3:101281709	C/T	cg12386194	chr3:101231763	SENP7	-0.49	-6.14	-0.35	3.08e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1790761	0.520	rs1551884	chr11:67399601	C/G	cg14500267	chr11:67383377	NA	-0.35	-5.48	-0.32	1e-7	Mean corpuscular volume;
CESC	trans	rs1493916	0.905	rs4239383	chr18:31401066	T/C	cg27147174	chr7:100797783	AP1S1	-0.52	-6.93	-0.39	3.22e-11	Life satisfaction;
CESC	cis	rs9309473	0.950	rs7567585	chr2:73751966	G/A	cg20560298	chr2:73613845	ALMS1	-0.45	-6.13	-0.35	3.13e-9	Metabolite levels;
CESC	cis	rs6088590	0.561	rs11167239	chr20:33140472	G/A	cg08999081	chr20:33150536	PIGU	0.7	12.47	0.61	2.17e-28	Coronary artery disease;
CESC	cis	rs9325144	0.532	rs12812406	chr12:38719802	G/A	cg26384229	chr12:38710491	ALG10B	-0.58	-7.99	-0.44	4.15e-14	Morning vs. evening chronotype;
CESC	cis	rs4665809	0.590	rs1560865	chr2:26452197	C/A	cg26314531	chr2:26401878	FAM59B	-0.85	-9.23	-0.49	8.65e-18	Gut microbiome composition (summer);
CESC	cis	rs2991971	0.869	rs2453404	chr1:46014735	A/G	cg15605315	chr1:45957053	TESK2	0.42	5.3	0.31	2.42e-7	High light scatter reticulocyte count;
CESC	cis	rs35306767	0.909	rs12264390	chr10:959111	T/C	cg25019033	chr10:957182	NA	-0.64	-8.06	-0.44	2.66e-14	Eosinophil percentage of granulocytes;
CESC	cis	rs853679	0.517	rs35227624	chr6:28132726	A/G	cg22143856	chr6:28129313	ZNF389	0.49	6.24	0.36	1.73e-9	Depression;
CESC	cis	rs7116495	0.609	rs2276384	chr11:71701523	A/G	cg07596299	chr11:71824057	C11orf51	0.76	5.21	0.3	3.86e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs7917772	0.560	rs11595170	chr10:104339851	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.4	-5.4	-0.31	1.49e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs7903847	0.642	rs10786344	chr10:99165975	T/C	cg20016023	chr10:99160130	RRP12	-0.3	-5.12	-0.3	5.91e-7	Granulocyte percentage of myeloid white cells;
CESC	cis	rs1862618	0.853	rs832584	chr5:56179212	A/G	cg24549020	chr5:56110836	MAP3K1	-0.68	-7.76	-0.43	1.8e-13	Initial pursuit acceleration;
CESC	cis	rs4689388	0.609	rs1046319	chr4:6304286	C/T	cg00701064	chr4:6280414	WFS1	0.56	7.32	0.41	2.89e-12	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	trans	rs4843747	0.636	rs11864872	chr16:88105966	A/G	cg26811252	chr16:29126840	RRN3P2	0.67	9.47	0.5	1.58e-18	Menopause (age at onset);
CESC	cis	rs644799	0.648	rs1016031	chr11:95473365	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	-0.5	-6.91	-0.39	3.54e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs6570726	0.935	rs110289	chr6:145865176	C/G	cg05347473	chr6:146136440	FBXO30	0.48	6.45	0.37	5.27e-10	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg01092528	chr4:76861103	NAAA	-0.41	-6.11	-0.35	3.58e-9	Gambling;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg23260190	chr10:101419318	ENTPD7	-0.44	-6.47	-0.37	4.78e-10	Fibrinogen levels;
CESC	cis	rs7617773	0.780	rs13067450	chr3:48337206	C/T	cg11946769	chr3:48343235	NME6	0.89	12.11	0.6	3.63e-27	Coronary artery disease;
CESC	cis	rs6540559	1.000	rs4844895	chr1:209958580	T/C	cg10074409	chr1:209979377	IRF6	0.36	5.75	0.33	2.46e-8	Cleft lip with or without cleft palate;
CESC	cis	rs2637266	1.000	rs12251434	chr10:78345468	C/A	cg18941641	chr10:78392320	NA	0.43	7.93	0.44	5.97e-14	Pulmonary function;
CESC	cis	rs1448094	0.512	rs6539925	chr12:86244358	A/G	cg02569458	chr12:86230093	RASSF9	0.49	7.21	0.4	5.91e-12	Major depressive disorder;
CESC	cis	rs7940866	0.903	rs11222411	chr11:130838682	A/G	cg12179176	chr11:130786555	SNX19	0.6	8.26	0.45	7e-15	Schizophrenia;
CESC	cis	rs2839186	0.709	rs2156117	chr21:47669300	C/A	cg13012494	chr21:47604986	C21orf56	0.49	6.57	0.37	2.71e-10	Testicular germ cell tumor;
CESC	cis	rs7927592	0.871	rs12360903	chr11:68236314	C/A	cg20283391	chr11:68216788	NA	-0.61	-7.29	-0.41	3.64e-12	Total body bone mineral density;
CESC	cis	rs2841277	0.509	rs11850949	chr14:105408827	A/C	cg15352829	chr14:105391018	PLD4	-0.6	-10.38	-0.54	2.05e-21	Rheumatoid arthritis;
CESC	cis	rs72634258	0.842	rs7545677	chr1:8165619	C/T	cg00042356	chr1:8021962	PARK7	0.46	5.05	0.3	8.29e-7	Inflammatory bowel disease;
CESC	cis	rs2797160	0.967	rs1954360	chr6:126001064	A/G	cg05901451	chr6:126070800	HEY2	-0.45	-6.62	-0.38	1.95e-10	Endometrial cancer;
CESC	cis	rs7116495	1.000	rs671681	chr11:71782812	T/C	cg10381502	chr11:71823885	C11orf51	-0.68	-5.48	-0.32	9.68e-8	Severe influenza A (H1N1) infection;
CESC	cis	rs6456156	0.792	rs2039321	chr6:167516299	C/T	cg23791538	chr6:167370224	RNASET2	-0.4	-5.11	-0.3	6.28e-7	Primary biliary cholangitis;
CESC	cis	rs6088580	0.634	rs6059875	chr20:33086090	T/G	cg06115741	chr20:33292138	TP53INP2	0.45	5.74	0.33	2.53e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs524281	0.861	rs4013917	chr11:65926185	A/G	cg14036092	chr11:66035641	RAB1B	-0.56	-5.57	-0.32	6.24e-8	Electroencephalogram traits;
CESC	cis	rs7586673	0.930	rs2884364	chr2:161977647	G/A	cg21518248	chr2:162101506	NA	0.46	6.24	0.36	1.73e-9	Intelligence (multi-trait analysis);
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg06808967	chr3:38178743	ACAA1;MYD88	-0.46	-6.28	-0.36	1.37e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs10504229	1.000	rs17805326	chr8:58169533	A/C	cg22535103	chr8:58192502	C8orf71	-1.06	-13.36	-0.63	1.72e-31	Developmental language disorder (linguistic errors);
CESC	cis	rs9287719	0.967	rs6432112	chr2:10744874	A/G	cg00105475	chr2:10696890	NA	-0.38	-5.69	-0.33	3.3e-8	Prostate cancer;
CESC	trans	rs150063	0.572	rs150070	chr16:13245367	C/G	cg18016365	chr4:47033634	GABRB1	-0.33	-6.11	-0.35	3.61e-9	Lung function (FEV1/FVC);
CESC	cis	rs8092503	1.000	rs2014237	chr18:52494583	T/C	cg12377874	chr18:52495404	RAB27B	-0.33	-5.75	-0.33	2.4e-8	Childhood body mass index;
CESC	cis	rs6502050	0.835	rs6502065	chr17:80095642	T/C	cg23985595	chr17:80112537	CCDC57	-0.42	-6.6	-0.38	2.18e-10	Life satisfaction;
CESC	cis	rs889312	0.500	rs832570	chr5:56156408	G/A	cg14703610	chr5:56206110	C5orf35	0.45	5.84	0.34	1.5e-8	Breast cancer;Breast cancer (early onset);
CESC	cis	rs9487051	0.802	rs9487039	chr6:109610163	A/T	cg21918786	chr6:109611834	NA	-0.4	-6.01	-0.35	6.17e-9	Reticulocyte fraction of red cells;
CESC	cis	rs2952156	0.920	rs12150298	chr17:37834541	T/C	cg20243544	chr17:37824526	PNMT	0.62	8.21	0.45	9.64e-15	Asthma;
CESC	cis	rs9311474	0.581	rs4687626	chr3:52569098	G/A	cg17372223	chr3:52568218	NT5DC2	0.52	8.16	0.45	1.32e-14	Electroencephalogram traits;
CESC	cis	rs7937682	0.961	rs4936682	chr11:111629743	T/G	cg22437258	chr11:111473054	SIK2	-0.6	-6.53	-0.37	3.27e-10	Primary sclerosing cholangitis;
CESC	cis	rs589448	0.902	rs315138	chr12:69764850	A/T	cg22834771	chr12:69754056	YEATS4	-0.57	-7.68	-0.43	3.15e-13	Cerebrospinal fluid biomarker levels;
CESC	cis	rs3008870	0.755	rs1024230	chr1:67512920	A/C	cg08660285	chr1:67390436	MIER1;WDR78	0.56	7.05	0.4	1.58e-11	Lymphocyte percentage of white cells;
CESC	cis	rs2302190	0.882	rs7210714	chr17:56675666	A/C	cg25885038	chr17:56607967	SEPT4	-0.4	-5.45	-0.32	1.17e-7	Vitamin D levels;
CESC	cis	rs7666738	0.830	rs4699597	chr4:99019031	G/A	cg05340658	chr4:99064831	C4orf37	0.82	12.99	0.62	3.34e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs13256369	1.000	rs9329166	chr8:8576655	C/T	cg18904891	chr8:8559673	CLDN23	0.64	7.22	0.41	5.45e-12	Obesity-related traits;
CESC	trans	rs7107217	1.000	rs1873872	chr11:129473993	A/T	cg10451977	chr15:45507901	NA	-0.49	-6.29	-0.36	1.33e-9	Breast cancer;Type 2 diabetes;
CESC	cis	rs72781680	0.611	rs72781699	chr2:24277709	G/A	cg06627628	chr2:24431161	ITSN2	-0.65	-6.29	-0.36	1.31e-9	Lymphocyte counts;
CESC	cis	rs1256061	0.564	rs1256043	chr14:64734282	A/G	cg23250157	chr14:64679961	SYNE2	0.53	7.64	0.42	4.09e-13	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs910316	0.967	rs175505	chr14:75529619	C/T	cg08847533	chr14:75593920	NEK9	-0.97	-18.2	-0.75	1.38e-48	Height;
CESC	cis	rs1799949	1.000	rs11654731	chr17:41326940	G/A	cg05368731	chr17:41323189	NBR1	0.78	10.62	0.55	3.59e-22	Menopause (age at onset);
CESC	cis	rs1448094	0.512	rs56082822	chr12:86255475	C/T	cg02569458	chr12:86230093	RASSF9	0.51	7.64	0.42	3.9e-13	Major depressive disorder;
CESC	cis	rs67072384	1.000	rs72964181	chr11:72440124	C/G	cg04827223	chr11:72435913	ARAP1	-0.66	-5.98	-0.34	7.28e-9	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
CESC	cis	rs12425791	0.500	rs34336285	chr12:721769	G/T	cg26654770	chr12:740100	NINJ2	-0.52	-5.45	-0.32	1.14e-7	Stroke;Paclitaxel disposition in epithelial ovarian cancer;
CESC	cis	rs2576037	0.526	rs571181	chr18:44376399	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.46	7.83	0.43	1.14e-13	Personality dimensions;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08450091	chr3:82857215	NA	-0.56	-6.5	-0.37	3.9e-10	Gut microbiome composition (summer);
CESC	cis	rs748404	0.660	rs2602141	chr15:43724646	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.57	7.58	0.42	5.77e-13	Lung cancer;
CESC	cis	rs6860806	0.661	rs2136188	chr5:131577514	A/G	cg18301423	chr5:131593218	PDLIM4	-0.4	-5.73	-0.33	2.76e-8	Breast cancer;
CESC	cis	rs6867032	0.570	rs13166888	chr5:1982966	G/T	cg26168224	chr5:2018326	NA	-0.79	-11.71	-0.58	8.14e-26	Gut microbiome composition (winter);
CESC	cis	rs4132509	1.000	rs3766673	chr1:243720473	T/C	cg21452805	chr1:244014465	NA	0.44	5.38	0.31	1.63e-7	RR interval (heart rate);
CESC	cis	rs7618915	0.547	rs2289250	chr3:52682946	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	-0.5	-7.27	-0.41	4e-12	Bipolar disorder;
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg16296724	chr12:123237325	DENR	0.47	7.16	0.4	8.07e-12	Vertical cup-disc ratio;
CESC	cis	rs34779708	0.931	rs11010125	chr10:35502953	A/G	cg04310649	chr10:35416472	CREM	-0.52	-6.34	-0.36	1e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs228437	0.913	rs1535117	chr6:134911816	G/A	cg24504307	chr6:134963096	NA	0.49	5.65	0.33	4.23e-8	Melanoma;
CESC	cis	rs11676348	0.935	rs4674250	chr2:218977531	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.45	-5.82	-0.34	1.7e-8	Ulcerative colitis;
CESC	cis	rs1707322	0.717	rs2275086	chr1:46085879	C/G	cg05343316	chr1:45956843	TESK2	-0.53	-6.58	-0.37	2.49e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7712401	0.502	rs30066	chr5:122293702	A/G	cg19412675	chr5:122181750	SNX24	0.46	5.42	0.32	1.37e-7	Mean platelet volume;
CESC	cis	rs1475911	1.000	rs55645900	chr21:43515728	G/T	cg19766460	chr21:43528205	UMODL1;C21orf128	0.58	6.46	0.37	5.04e-10	IgG glycosylation;
CESC	cis	rs9768139	0.935	rs7800718	chr7:158121878	G/A	cg06219351	chr7:158114137	PTPRN2	0.45	7.0	0.39	2.13e-11	Calcium levels;
CESC	cis	rs66573146	1.000	rs7686186	chr4:6986094	C/T	cg00086871	chr4:6988644	TBC1D14	1.11	6.36	0.36	8.97e-10	Granulocyte percentage of myeloid white cells;
CESC	cis	rs853679	0.517	rs9283884	chr6:28135660	C/G	cg17949981	chr6:28129498	ZNF389	-0.45	-5.51	-0.32	8.35e-8	Depression;
CESC	cis	rs2204008	0.652	rs11520002	chr12:38022179	G/T	cg26384229	chr12:38710491	ALG10B	0.75	10.72	0.55	1.61e-22	Bladder cancer;
CESC	cis	rs644799	0.664	rs603625	chr11:95554283	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.77	11.04	0.56	1.47e-23	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs11711311	0.955	rs12636240	chr3:113391282	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.69	9.04	0.49	3.38e-17	IgG glycosylation;
CESC	cis	rs7107174	1.000	rs4492844	chr11:78026516	A/G	cg02023728	chr11:77925099	USP35	0.46	6.34	0.36	9.69e-10	Testicular germ cell tumor;
CESC	cis	rs9287719	0.967	rs6432119	chr2:10753687	A/T	cg02196655	chr2:10830764	NOL10	-0.37	-5.69	-0.33	3.39e-8	Prostate cancer;
CESC	cis	rs7264396	0.563	rs2425088	chr20:34303902	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.88	-10.64	-0.55	3.06e-22	Total cholesterol levels;
CESC	cis	rs3091242	1.000	rs646867	chr1:25709258	A/C	cg12412775	chr1:25698385	RHCE	-0.32	-5.7	-0.33	3.13e-8	Erythrocyte sedimentation rate;
CESC	cis	rs13118159	0.801	rs1128427	chr4:1330759	T/C	cg19318889	chr4:1322082	MAEA	0.44	6.02	0.35	5.83e-9	Longevity;
CESC	cis	rs769267	0.930	rs4808967	chr19:19640524	A/G	cg03709012	chr19:19516395	GATAD2A	0.98	15.06	0.68	1.85e-37	Tonsillectomy;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg12540815	chr19:45394385	TOMM40	0.52	6.71	0.38	1.21e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07367563	chr1:151032068	CDC42SE1;MLLT11	0.59	6.96	0.39	2.73e-11	Gut microbiome composition (summer);
CESC	cis	rs7618501	1.000	rs7431106	chr3:49808374	G/A	cg24308560	chr3:49941425	MST1R	-0.51	-6.99	-0.39	2.28e-11	Intelligence (multi-trait analysis);
CESC	cis	rs10504229	0.953	rs59034808	chr8:58185337	T/C	cg22535103	chr8:58192502	C8orf71	-0.88	-11.43	-0.57	7.29e-25	Developmental language disorder (linguistic errors);
CESC	cis	rs1801251	1.000	rs283484	chr2:233646505	A/G	cg08000102	chr2:233561755	GIGYF2	0.65	9.33	0.5	4.55e-18	Coronary artery disease;
CESC	trans	rs1728785	0.818	rs11075684	chr16:68582365	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.61	7.35	0.41	2.44e-12	Ulcerative colitis;
CESC	cis	rs1506636	1.000	rs676755	chr7:123439082	A/G	cg03229431	chr7:123269106	ASB15	-0.43	-5.58	-0.32	5.86e-8	Plateletcrit;Platelet count;
CESC	cis	rs6582630	0.555	rs11610015	chr12:38508856	A/G	cg26384229	chr12:38710491	ALG10B	0.65	9.72	0.51	2.77e-19	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs7520050	0.807	rs5021934	chr1:46109304	A/G	cg03146154	chr1:46216737	IPP	-0.52	-7.04	-0.4	1.68e-11	Red blood cell count;Reticulocyte count;
CESC	cis	rs9291683	0.509	rs10939671	chr4:10050815	T/C	cg00071950	chr4:10020882	SLC2A9	0.79	13.76	0.65	7.23e-33	Bone mineral density;
CESC	trans	rs629535	0.911	rs627382	chr8:70014081	C/T	cg21567404	chr3:27674614	NA	-0.91	-10.9	-0.56	4.13e-23	Dupuytren's disease;
CESC	cis	rs270601	0.770	rs4361510	chr5:131599647	C/T	cg18301423	chr5:131593218	PDLIM4	0.38	5.5	0.32	8.83e-8	Acylcarnitine levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03127034	chr6:41561307	FOXP4	-0.52	-6.25	-0.36	1.62e-9	Gut microbiome composition (summer);
CESC	cis	rs1800469	1.000	rs2241712	chr19:41869756	C/T	cg08477640	chr19:41863820	B9D2	0.67	9.24	0.49	8.62e-18	Colorectal cancer;
CESC	cis	rs7147624	0.938	rs10467734	chr14:65913947	C/T	cg03016385	chr14:66212404	NA	-0.49	-5.04	-0.3	8.51e-7	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs11583043	1.000	rs6675353	chr1:101459625	A/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.5	5.56	0.32	6.53e-8	Ulcerative colitis;Inflammatory bowel disease;
CESC	cis	rs4523957	0.548	rs7213756	chr17:2098339	C/A	cg16513277	chr17:2031491	SMG6	-0.49	-6.31	-0.36	1.15e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs735396	1.000	rs2259816	chr12:121435587	A/C	cg25281562	chr12:121454272	C12orf43	-0.38	-5.04	-0.3	8.8e-7	N-glycan levels;
CESC	cis	rs6933660	0.800	rs9383893	chr6:151757327	T/C	cg02564969	chr6:151773285	C6orf211;RMND1	0.61	8.4	0.46	2.82e-15	Menarche (age at onset);
CESC	cis	rs17253792	0.749	rs45458197	chr14:56145018	A/T	cg01858014	chr14:56050164	KTN1	-0.97	-7.54	-0.42	7.36e-13	Putamen volume;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg10942059	chr7:105460221	ATXN7L1	0.47	6.28	0.36	1.37e-9	Fibrinogen levels;
CESC	cis	rs244293	0.831	rs1948000	chr17:53147716	T/G	cg19360675	chr17:53046073	COX11;STXBP4	0.39	5.04	0.3	8.6e-7	Menarche (age at onset);
CESC	cis	rs10788972	0.873	rs11206283	chr1:54576639	A/C	cg25741118	chr1:54482237	LDLRAD1	0.21	5.18	0.3	4.4e-7	Parkinson disease and lewy body pathology;
CESC	cis	rs8114671	0.527	rs6088650	chr20:33514465	C/T	cg24642439	chr20:33292090	TP53INP2	-0.44	-5.38	-0.31	1.67e-7	Height;
CESC	cis	rs1728785	1.000	rs1094282	chr16:68577260	G/A	cg02972257	chr16:68554789	NA	-0.55	-6.31	-0.36	1.17e-9	Ulcerative colitis;
CESC	cis	rs1008375	0.932	rs2302394	chr4:17641188	A/G	cg02297831	chr4:17616191	MED28	0.66	8.05	0.44	2.75e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs2440129	0.611	rs1042356	chr17:6902743	G/A	cg05657792	chr17:6899758	ALOX12	0.41	7.05	0.4	1.58e-11	Tonsillectomy;
CESC	cis	rs238295	0.631	rs6038205	chr20:5549073	T/A	cg24001556	chr20:5591874	RP5-1022P6.2	-0.46	-5.11	-0.3	6.12e-7	Occipital cortical area (total cortical area interaction);
CESC	cis	rs1552244	1.000	rs722509	chr3:10102377	T/A	cg00166722	chr3:10149974	C3orf24	0.53	6.65	0.38	1.64e-10	Alzheimer's disease;
CESC	cis	rs9486719	0.947	rs11153071	chr6:97039741	G/A	cg18709589	chr6:96969512	KIAA0776	-0.5	-5.42	-0.32	1.31e-7	Migraine;Coronary artery disease;
CESC	cis	rs2228479	0.850	rs62054224	chr16:89892071	C/T	cg14709524	chr16:89940631	TCF25	0.89	6.41	0.37	6.61e-10	Skin colour saturation;
CESC	cis	rs611744	0.647	rs647907	chr8:109251374	T/C	cg21045802	chr8:109455806	TTC35	0.48	5.89	0.34	1.17e-8	Dupuytren's disease;
CESC	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.62	0.38	1.94e-10	Prudent dietary pattern;
CESC	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	10.38	0.54	2.06e-21	Prudent dietary pattern;
CESC	cis	rs11030122	0.702	rs10835340	chr11:3960420	A/G	cg18678763	chr11:4115507	RRM1	0.5	6.61	0.38	2.08e-10	Mean platelet volume;Platelet distribution width;
CESC	cis	rs12458462	0.892	rs35928863	chr18:77438956	A/G	cg23301140	chr18:77439876	CTDP1	0.55	7.26	0.41	4.23e-12	Monocyte count;
CESC	cis	rs4704187	0.687	rs4404660	chr5:74422210	T/C	cg03227963	chr5:74354835	NA	0.31	5.7	0.33	3.22e-8	Response to amphetamines;
CESC	cis	rs8017423	0.607	rs10142482	chr14:90848280	G/T	cg14092571	chr14:90743983	NA	0.42	6.24	0.36	1.71e-9	Mortality in heart failure;
CESC	cis	rs9311474	0.632	rs6445528	chr3:52572447	C/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	-0.3	-5.56	-0.32	6.56e-8	Electroencephalogram traits;
CESC	cis	rs9549367	0.789	rs3861720	chr13:113906097	A/G	cg18105134	chr13:113819100	PROZ	-0.68	-8.25	-0.45	7.53e-15	Platelet distribution width;
CESC	cis	rs9487051	0.752	rs9372209	chr6:109601684	T/C	cg12927641	chr6:109611667	NA	-0.36	-5.24	-0.31	3.24e-7	Reticulocyte fraction of red cells;
CESC	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg11494091	chr17:61959527	GH2	0.73	12.71	0.62	3.32e-29	Prudent dietary pattern;
CESC	cis	rs11098499	0.697	rs4560394	chr4:120313435	T/G	cg09307838	chr4:120376055	NA	0.92	12.59	0.61	8.63e-29	Corneal astigmatism;
CESC	cis	rs4919694	0.901	rs12264456	chr10:104830634	C/T	cg04362960	chr10:104952993	NT5C2	0.79	7.08	0.4	1.27e-11	Arsenic metabolism;
CESC	cis	rs858239	0.600	rs6461691	chr7:23139345	G/A	cg23682824	chr7:23144976	KLHL7	0.51	6.82	0.39	6.16e-11	Cerebrospinal fluid biomarker levels;
CESC	cis	rs7809950	0.678	rs7788330	chr7:106985648	G/T	cg23024343	chr7:107201750	COG5	-0.52	-6.73	-0.38	1.02e-10	Coronary artery disease;
CESC	cis	rs738322	0.726	rs5750561	chr22:38595260	A/T	cg25457927	chr22:38595422	NA	0.36	6.83	0.39	5.91e-11	Cutaneous nevi;
CESC	cis	rs1862618	0.671	rs72644088	chr5:56241019	G/A	cg24531977	chr5:56204891	C5orf35	0.69	9.17	0.49	1.4e-17	Initial pursuit acceleration;
CESC	cis	rs9926296	0.568	rs7203907	chr16:89833774	C/G	cg03388025	chr16:89894329	SPIRE2	0.42	8.07	0.44	2.41e-14	Vitiligo;
CESC	cis	rs17253792	0.822	rs17253730	chr14:56157911	A/G	cg01858014	chr14:56050164	KTN1	-0.97	-7.59	-0.42	5.34e-13	Putamen volume;
CESC	cis	rs796364	0.806	rs11679658	chr2:200923081	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.84	-7.66	-0.43	3.54e-13	Schizophrenia;
CESC	cis	rs9300255	0.507	rs1615350	chr12:123650335	C/T	cg00376283	chr12:123451042	ABCB9	0.66	9.14	0.49	1.7e-17	Neutrophil percentage of white cells;
CESC	cis	rs2075371	0.796	rs12154724	chr7:133943443	G/A	cg00033643	chr7:134001901	SLC35B4	0.41	5.22	0.31	3.68e-7	Mean platelet volume;
CESC	cis	rs9926296	0.605	rs12599180	chr16:89839306	C/T	cg04287289	chr16:89883240	FANCA	-0.8	-13.71	-0.64	1.04e-32	Vitiligo;
CESC	cis	rs738322	0.934	rs133019	chr22:38573035	A/G	cg25457927	chr22:38595422	NA	-0.35	-6.41	-0.37	6.52e-10	Cutaneous nevi;
CESC	cis	rs6693567	0.545	rs1260403	chr1:150303666	A/G	cg09579323	chr1:150459698	TARS2	0.5	6.24	0.36	1.75e-9	Migraine;
CESC	cis	rs3820068	0.581	rs58425551	chr1:15922518	A/G	cg16988262	chr1:15930761	NA	0.35	5.69	0.33	3.38e-8	Systolic blood pressure;
CESC	cis	rs7336332	0.574	rs9512699	chr13:28029896	G/A	cg22138327	chr13:27999177	GTF3A	-0.52	-5.04	-0.3	8.48e-7	Weight;
CESC	cis	rs1153858	1.000	rs7169587	chr15:45640379	A/G	cg21132104	chr15:45694354	SPATA5L1	0.82	11.02	0.56	1.72e-23	Homoarginine levels;
CESC	cis	rs2204008	0.774	rs4534658	chr12:38246783	G/A	cg26384229	chr12:38710491	ALG10B	0.66	9.37	0.5	3.3e-18	Bladder cancer;
CESC	cis	rs6060717	0.536	rs11697024	chr20:34546500	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.65	5.58	0.32	5.8e-8	Hip circumference adjusted for BMI;
CESC	cis	rs4561483	0.514	rs33639	chr16:11989499	A/C	cg08843971	chr16:11963173	GSPT1	-0.54	-7.54	-0.42	7.41e-13	Testicular germ cell tumor;
CESC	cis	rs6582630	0.537	rs35336822	chr12:38346251	T/C	cg26384229	chr12:38710491	ALG10B	0.7	10.48	0.54	9.91e-22	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs1045714	0.895	rs73043180	chr7:2645972	C/T	cg20813462	chr7:2646259	IQCE	0.63	5.53	0.32	7.86e-8	Urate levels in lean individuals;
CESC	cis	rs6690583	0.524	rs12030837	chr1:85519383	A/G	cg22488158	chr1:85528044	WDR63	-0.59	-5.61	-0.33	5.05e-8	Serum sulfate level;
CESC	cis	rs45535039	1.000	rs7114172	chr11:119116603	T/C	cg16724696	chr11:118992527	HINFP	0.4	5.16	0.3	4.82e-7	Plateletcrit;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04205485	chr20:32399084	CHMP4B	0.53	6.03	0.35	5.53e-9	Gut microbiome composition (summer);
CESC	cis	rs6693567	0.565	rs10888578	chr1:150260993	A/G	cg09579323	chr1:150459698	TARS2	-0.44	-5.57	-0.32	6.11e-8	Migraine;
CESC	cis	rs826838	0.754	rs2387920	chr12:38626351	A/G	cg13010199	chr12:38710504	ALG10B	0.53	6.89	0.39	4.13e-11	Heart rate;
CESC	cis	rs10504229	0.861	rs116964504	chr8:58185354	A/C	cg24829409	chr8:58192753	C8orf71	-0.76	-9.93	-0.52	5.87e-20	Developmental language disorder (linguistic errors);
CESC	cis	rs11098499	0.863	rs3775841	chr4:120425777	A/C	cg24375607	chr4:120327624	NA	0.44	5.22	0.31	3.58e-7	Corneal astigmatism;
CESC	cis	rs3096299	0.606	rs4785674	chr16:89536613	A/G	cg02187348	chr16:89574699	SPG7	0.44	5.34	0.31	2e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs12142240	0.738	rs17361749	chr1:46806480	C/T	cg00530320	chr1:46809349	NSUN4	0.59	7.85	0.43	1.02e-13	Menopause (age at onset);
CESC	cis	rs7824557	0.527	rs2572369	chr8:11238597	C/T	cg21775007	chr8:11205619	TDH	-0.52	-7.77	-0.43	1.79e-13	Retinal vascular caliber;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01530317	chr1:3566579	WDR8	0.55	6.29	0.36	1.34e-9	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.830	rs13144771	chr4:99026935	G/C	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.58e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2440129	0.611	rs1042356	chr17:6902743	G/A	cg08946332	chr17:6899888	ALOX12	0.44	6.48	0.37	4.45e-10	Tonsillectomy;
CESC	cis	rs1005277	0.579	rs2474608	chr10:38457109	C/T	cg00409905	chr10:38381863	ZNF37A	-0.46	-6.03	-0.35	5.39e-9	Extrinsic epigenetic age acceleration;
CESC	trans	rs2115172	0.836	rs4835799	chr5:122762229	A/G	cg11355319	chr5:89825117	LYSMD3	0.48	6.57	0.37	2.59e-10	Weight;
CESC	cis	rs148803332	1	rs148803332	chr17:65958250	CAAAAGAAA/C	cg12091567	chr17:66097778	LOC651250	0.71	8.03	0.44	3.18e-14	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;
CESC	cis	rs225245	0.817	rs1634684	chr17:33941051	A/G	cg05299278	chr17:33885742	SLFN14	0.38	5.52	0.32	8.21e-8	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08984405	chr17:685103	RNMTL1;GLOD4	-0.68	-7.77	-0.43	1.72e-13	Gut microbiome composition (summer);
CESC	cis	rs7100689	0.646	rs1538823	chr10:82088040	C/A	cg00277334	chr10:82204260	NA	-0.6	-7.96	-0.44	4.91e-14	Post bronchodilator FEV1;
CESC	cis	rs1497406	0.744	rs4661718	chr1:16505908	C/T	cg20430773	chr1:16534157	ARHGEF19	0.33	5.32	0.31	2.22e-7	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs11574514	1.000	rs8052287	chr16:67865073	C/T	cg01866162	chr16:67596514	CTCF	0.94	5.69	0.33	3.28e-8	Crohn's disease;
CESC	cis	rs3820068	0.581	rs56128111	chr1:15928948	T/G	cg13390004	chr1:15929781	NA	0.35	5.58	0.32	5.83e-8	Systolic blood pressure;
CESC	cis	rs921968	0.510	rs2577761	chr2:219462500	G/A	cg02176678	chr2:219576539	TTLL4	0.48	8.45	0.46	2e-15	Mean corpuscular hemoglobin concentration;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03368399	chr8:22102556	POLR3D;MIR320A	0.5	6.16	0.35	2.66e-9	Gut microbiome composition (summer);
CESC	cis	rs17253792	0.545	rs12894368	chr14:56025178	C/A	cg01858014	chr14:56050164	KTN1	-0.88	-6.42	-0.37	6.38e-10	Putamen volume;
CESC	cis	rs270601	0.739	rs1979981	chr5:131601720	G/A	cg18758796	chr5:131593413	PDLIM4	0.48	6.97	0.39	2.55e-11	Acylcarnitine levels;
CESC	cis	rs3820068	0.581	rs78175477	chr1:15948091	C/G	cg17385448	chr1:15911702	AGMAT	0.42	6.83	0.39	5.64e-11	Systolic blood pressure;
CESC	cis	rs2836974	0.931	rs13047663	chr21:40708818	C/T	cg11890956	chr21:40555474	PSMG1	1.03	15.61	0.69	2.04e-39	Cognitive function;
CESC	cis	rs9814567	1.000	rs1534026	chr3:134284767	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.45	-6.07	-0.35	4.51e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs10256972	0.616	rs7806746	chr7:1075573	A/C	cg18765753	chr7:1198926	ZFAND2A	-0.41	-5.67	-0.33	3.66e-8	Longevity;Endometriosis;
CESC	cis	rs55692411	0.537	rs71326904	chr3:49991060	C/T	cg24308560	chr3:49941425	MST1R	-0.53	-6.43	-0.37	6.09e-10	Intelligence (multi-trait analysis);
CESC	cis	rs921968	0.619	rs1554623	chr2:219606177	C/T	cg02176678	chr2:219576539	TTLL4	-0.46	-8.2	-0.45	1.07e-14	Mean corpuscular hemoglobin concentration;
CESC	cis	rs7613875	0.620	rs7430334	chr3:50078221	T/C	cg24110177	chr3:50126178	RBM5	0.58	8.17	0.45	1.28e-14	Body mass index;
CESC	cis	rs60154123	0.505	rs76101197	chr1:210044089	T/C	cg21951975	chr1:209979733	IRF6	0.6	6.65	0.38	1.62e-10	Coronary artery disease;
CESC	cis	rs9487051	0.714	rs7755970	chr6:109602359	A/G	cg21918786	chr6:109611834	NA	-0.38	-5.63	-0.33	4.59e-8	Reticulocyte fraction of red cells;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg19757253	chr2:32853039	TTC27	-0.45	-6.33	-0.36	1.02e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs72781680	1.000	rs12616250	chr2:24211550	T/C	cg20701182	chr2:24300061	SF3B14	0.63	5.58	0.32	6.04e-8	Lymphocyte counts;
CESC	cis	rs6089584	0.888	rs2386555	chr20:60612373	C/T	cg24733560	chr20:60626293	TAF4	0.44	6.24	0.36	1.68e-9	Body mass index;
CESC	cis	rs963731	0.649	rs10439459	chr2:39236983	G/T	cg04010122	chr2:39346883	SOS1	-0.72	-5.65	-0.33	4.12e-8	Corticobasal degeneration;
CESC	cis	rs870825	0.616	rs7678900	chr4:185635249	A/G	cg04058563	chr4:185651563	MLF1IP	0.64	6.83	0.39	5.66e-11	Blood protein levels;
CESC	cis	rs9325144	0.723	rs1586373	chr12:39181582	G/A	cg26384229	chr12:38710491	ALG10B	-0.51	-7.23	-0.41	5.23e-12	Morning vs. evening chronotype;
CESC	cis	rs67311347	1.000	rs9848083	chr3:40466979	A/G	cg09455208	chr3:40491958	NA	-0.44	-7.7	-0.43	2.67e-13	Renal cell carcinoma;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11687679	chr13:37573611	EXOSC8;ALG5	0.58	6.76	0.38	8.82e-11	Gut microbiome composition (summer);
CESC	cis	rs9916302	0.904	rs11654018	chr17:37703740	C/T	cg20243544	chr17:37824526	PNMT	-0.51	-6.41	-0.37	6.5e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs4253772	0.637	rs6008339	chr22:46650846	C/T	cg09491104	chr22:46646882	C22orf40	-0.59	-9.15	-0.49	1.58e-17	LDL cholesterol;Cholesterol, total;
CESC	cis	rs3020736	0.500	rs6002604	chr22:42493081	A/T	cg15557168	chr22:42548783	NA	0.45	6.57	0.37	2.72e-10	Autism spectrum disorder or schizophrenia;
CESC	cis	rs76878669	0.561	rs4930363	chr11:66169676	C/T	cg18002602	chr11:66138449	SLC29A2	0.36	5.89	0.34	1.18e-8	Educational attainment (years of education);
CESC	cis	rs2710642	0.544	rs10204410	chr2:62829979	G/T	cg17519650	chr2:63277830	OTX1	0.49	6.47	0.37	4.69e-10	LDL cholesterol levels;LDL cholesterol;
CESC	cis	rs1784581	0.588	rs10945792	chr6:162423484	C/T	cg17173639	chr6:162384350	PARK2	0.57	8.68	0.47	4.23e-16	Itch intensity from mosquito bite;
CESC	cis	rs7647973	0.677	rs11130211	chr3:49645209	C/T	cg07636037	chr3:49044803	WDR6	0.6	7.17	0.4	7.33e-12	Menarche (age at onset);
CESC	cis	rs67311347	0.544	rs67533651	chr3:40338367	T/A	cg09455208	chr3:40491958	NA	0.36	6.35	0.36	9.37e-10	Renal cell carcinoma;
CESC	cis	rs2115536	0.967	rs3826008	chr15:80189805	G/T	cg00225070	chr15:80189496	MTHFS	0.61	8.58	0.47	7.87e-16	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CESC	cis	rs61776719	0.520	rs72661887	chr1:38416310	C/T	cg17077180	chr1:38461687	NA	0.45	6.89	0.39	3.99e-11	Coronary artery disease;
CESC	cis	rs514406	1.000	rs514406	chr1:53330458	A/G	cg16325326	chr1:53192061	ZYG11B	0.79	11.72	0.58	7.81e-26	Monocyte count;
CESC	cis	rs6088580	0.602	rs6059834	chr20:33019299	A/G	cg06115741	chr20:33292138	TP53INP2	0.48	6.14	0.35	3e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs453301	0.571	rs2929456	chr8:9083416	G/A	cg17143192	chr8:8559678	CLDN23	-0.44	-5.35	-0.31	1.94e-7	Joint mobility (Beighton score);
CESC	cis	rs1413885	0.516	rs6659883	chr1:65838618	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.46	5.95	0.34	8.55e-9	Anticoagulant levels;
CESC	cis	rs3780486	0.874	rs10813955	chr9:33141791	C/T	cg13443165	chr9:33130375	B4GALT1	0.45	6.49	0.37	4.1e-10	IgG glycosylation;
CESC	cis	rs10504229	0.683	rs6980850	chr8:58127204	A/G	cg22535103	chr8:58192502	C8orf71	-0.84	-9.44	-0.5	2.04e-18	Developmental language disorder (linguistic errors);
CESC	cis	rs1577917	0.771	rs2475790	chr6:86368068	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.55	-7.3	-0.41	3.27e-12	Response to antipsychotic treatment;
CESC	cis	rs4819052	0.851	rs1056099	chr21:46678892	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.76	10.4	0.54	1.76e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs7937682	0.587	rs611607	chr11:111349765	C/T	cg22437258	chr11:111473054	SIK2	0.42	5.21	0.3	3.75e-7	Primary sclerosing cholangitis;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg00986762	chr1:36107072	PSMB2	-0.49	-6.78	-0.38	7.75e-11	Height;
CESC	cis	rs853679	0.517	rs4711165	chr6:28115184	T/G	cg20151795	chr6:28129481	ZNF389	0.46	5.83	0.34	1.65e-8	Depression;
CESC	cis	rs9796	0.621	rs2578655	chr15:41462809	T/G	cg18705301	chr15:41695430	NDUFAF1	-0.48	-6.94	-0.39	3.01e-11	Menopause (age at onset);
CESC	cis	rs617791	0.508	rs1047464	chr11:65769456	A/T	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.38	-5.03	-0.3	8.96e-7	Breast cancer;
CESC	cis	rs6867032	0.958	rs4463207	chr5:2017118	G/T	cg26168224	chr5:2018326	NA	0.95	19.24	0.76	3.09e-52	Gut microbiome composition (winter);
CESC	cis	rs7107174	1.000	rs10793295	chr11:77996521	C/G	cg02023728	chr11:77925099	USP35	-0.38	-5.43	-0.32	1.26e-7	Testicular germ cell tumor;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18364779	chr6:26104403	HIST1H4C	-0.53	-6.07	-0.35	4.42e-9	Gut microbiome composition (summer);
CESC	cis	rs9733	0.566	rs11204675	chr1:150570985	A/C	cg22823121	chr1:150693482	HORMAD1	-0.34	-5.07	-0.3	7.5e-7	Tonsillectomy;
CESC	cis	rs863345	0.604	rs1342945	chr1:158512912	C/A	cg12129480	chr1:158549410	OR10X1	-0.35	-7.1	-0.4	1.14e-11	Pneumococcal bacteremia;
CESC	cis	rs35110281	0.837	rs2838342	chr21:45077865	G/A	cg04455712	chr21:45112962	RRP1B	0.39	5.94	0.34	9e-9	Mean corpuscular volume;
CESC	cis	rs7726839	0.561	rs4957050	chr5:579066	A/C	cg09021430	chr5:549028	NA	-0.44	-5.96	-0.34	8.23e-9	Obesity-related traits;
CESC	cis	rs9640161	0.636	rs3735171	chr7:150033882	A/G	cg10018233	chr7:150070692	REPIN1	0.49	7.38	0.41	2.09e-12	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs9611565	0.659	rs12484175	chr22:41953739	A/C	cg17554472	chr22:41940697	POLR3H	-0.49	-5.05	-0.3	8.22e-7	Vitiligo;
CESC	trans	rs916888	0.647	rs199523	chr17:44848517	C/A	cg01341218	chr17:43662625	NA	-0.58	-7.66	-0.43	3.54e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs6502050	0.731	rs9891378	chr17:80116035	T/C	cg23985595	chr17:80112537	CCDC57	-0.41	-6.46	-0.37	4.88e-10	Life satisfaction;
CESC	cis	rs1005277	0.541	rs2263163	chr10:38389887	G/A	cg00409905	chr10:38381863	ZNF37A	-0.45	-5.98	-0.34	7.18e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs34172651	0.545	rs8056132	chr16:24716348	A/G	cg06028605	chr16:24865363	SLC5A11	0.38	6.04	0.35	5.1e-9	Intelligence (multi-trait analysis);
CESC	cis	rs9863	0.828	rs11057412	chr12:124489142	G/C	cg17562584	chr12:124393655	DNAH10	0.3	5.17	0.3	4.68e-7	White blood cell count;
CESC	cis	rs2991971	0.782	rs10789463	chr1:45927848	C/A	cg15605315	chr1:45957053	TESK2	-0.4	-5.56	-0.32	6.56e-8	High light scatter reticulocyte count;
CESC	cis	rs12995491	0.933	rs7590305	chr2:88513131	C/T	cg18490616	chr2:88469792	THNSL2	-0.5	-7.06	-0.4	1.49e-11	Response to metformin (IC50);
CESC	cis	rs919433	0.963	rs1366837	chr2:198160501	T/C	cg10820045	chr2:198174542	NA	-0.43	-6.58	-0.37	2.48e-10	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs6912958	0.781	rs9444512	chr6:88223397	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	-0.32	-5.27	-0.31	2.82e-7	Monocyte percentage of white cells;
CESC	cis	rs2980439	0.525	rs2980508	chr8:8171732	C/T	cg06636001	chr8:8085503	FLJ10661	0.51	6.17	0.35	2.61e-9	Neuroticism;
CESC	cis	rs734999	0.549	rs867436	chr1:2523723	C/T	cg20673091	chr1:2541236	MMEL1	0.42	6.92	0.39	3.48e-11	Ulcerative colitis;
CESC	cis	rs873946	0.648	rs12769533	chr10:134548685	C/T	cg27286337	chr10:134555280	INPP5A	-0.61	-7.31	-0.41	3.25e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs2842992	0.724	rs4709368	chr6:160204127	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	-0.83	-11.73	-0.58	7.13e-26	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs7119038	0.818	rs4936444	chr11:118743338	A/G	cg19308663	chr11:118741387	NA	-0.43	-5.19	-0.3	4.12e-7	Sjögren's syndrome;
CESC	cis	rs9322193	0.923	rs12211511	chr6:150066342	G/C	cg13206674	chr6:150067644	NUP43	0.41	5.72	0.33	2.8e-8	Lung cancer;
CESC	cis	rs2404602	0.716	rs17461634	chr15:76764107	G/A	cg26408565	chr15:76604113	ETFA	-0.42	-6.09	-0.35	3.92e-9	Blood metabolite levels;
CESC	trans	rs8017423	0.740	rs8003095	chr14:90680643	A/T	cg01911440	chr17:78818045	RPTOR	-0.4	-6.03	-0.35	5.43e-9	Mortality in heart failure;
CESC	cis	rs10883723	0.810	rs3781289	chr10:104244991	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.55	7.62	0.42	4.65e-13	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs9815354	1.000	rs73069392	chr3:41787009	C/T	cg03022575	chr3:42003672	ULK4	0.57	5.52	0.32	8.18e-8	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs6484504	0.625	rs6484501	chr11:31373100	G/T	cg14844989	chr11:31128820	NA	0.39	5.25	0.31	3.13e-7	Red blood cell count;
CESC	cis	rs1144333	1.000	rs5745354	chr1:76275178	G/A	cg03433033	chr1:76189801	ACADM	-0.54	-5.59	-0.32	5.62e-8	Attention function in attention deficit hyperactive disorder;
CESC	cis	rs514406	0.825	rs28817407	chr1:53226116	G/A	cg24675658	chr1:53192096	ZYG11B	0.53	6.78	0.38	7.96e-11	Monocyte count;
CESC	cis	rs7267979	1.000	rs6083804	chr20:25317060	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.89	-18.7	-0.75	2.48e-50	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs12995491	1.000	rs12995491	chr2:88527414	C/T	cg04511125	chr2:88470314	THNSL2	0.48	7.03	0.4	1.74e-11	Response to metformin (IC50);
CESC	cis	rs7592578	0.766	rs62181052	chr2:191387858	A/G	cg10560079	chr2:191398806	TMEM194B	-0.65	-5.46	-0.32	1.11e-7	Diastolic blood pressure;
CESC	cis	rs7267979	0.966	rs454723	chr20:25438928	G/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.86	17.28	0.73	2.57e-45	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs2455799	0.613	rs6795100	chr3:15793798	C/T	cg16303742	chr3:15540471	COLQ	-0.39	-6.14	-0.35	3.01e-9	Mean platelet volume;
CESC	cis	rs6032067	0.641	rs761500	chr20:43772272	A/G	cg10761708	chr20:43804764	PI3	-0.58	-6.47	-0.37	4.61e-10	Blood protein levels;
CESC	cis	rs28386778	0.734	rs12946669	chr17:62006007	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.66	8.76	0.47	2.29e-16	Prudent dietary pattern;
CESC	cis	rs8038465	1.000	rs8032727	chr15:73977336	A/G	cg15420318	chr15:73925796	NPTN	0.44	6.23	0.36	1.81e-9	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs4253772	0.591	rs6007726	chr22:46650858	A/C	cg10231785	chr22:46692440	CN5H6.4;GTSE1	0.48	5.11	0.3	6.16e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs1023500	0.573	rs1807494	chr22:42474138	C/G	cg15557168	chr22:42548783	NA	0.45	6.5	0.37	3.87e-10	Schizophrenia;
CESC	cis	rs3820068	0.603	rs67349836	chr1:15966176	T/C	cg17385448	chr1:15911702	AGMAT	0.44	7.14	0.4	8.88e-12	Systolic blood pressure;
CESC	cis	rs9322193	0.923	rs55993747	chr6:149943152	A/G	cg02462569	chr6:150064036	NUP43	-0.34	-5.06	-0.3	7.74e-7	Lung cancer;
CESC	cis	rs6582630	0.519	rs4406888	chr12:38293312	A/C	cg13010199	chr12:38710504	ALG10B	0.46	5.88	0.34	1.26e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs1568889	1.000	rs7933332	chr11:28036392	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.79	11.02	0.56	1.69e-23	Bipolar disorder;
CESC	cis	rs10779751	0.770	rs2261434	chr1:11170131	A/C	cg08854313	chr1:11322531	MTOR	0.84	12.06	0.6	5.27e-27	Body mass index;
CESC	cis	rs7811142	1.000	rs6975729	chr7:100028187	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.11	10.96	0.56	2.75e-23	Platelet count;
CESC	cis	rs6963495	0.818	rs73190187	chr7:105164401	A/T	cg19920283	chr7:105172520	RINT1	0.7	6.66	0.38	1.58e-10	Bipolar disorder (body mass index interaction);
CESC	cis	rs1799949	1.000	rs2037075	chr17:41305826	G/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.64	8.52	0.46	1.18e-15	Menopause (age at onset);
CESC	cis	rs8060686	0.623	rs7204208	chr16:68069416	A/G	cg26727032	chr16:67993705	SLC12A4	-0.59	-8.16	-0.45	1.39e-14	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs1475911	0.708	rs8129075	chr21:43523430	G/T	cg03240473	chr21:43526662	UMODL1;C21orf128	-0.54	-7.21	-0.41	5.73e-12	IgG glycosylation;
CESC	trans	rs7740797	0.967	rs3757291	chr6:155124583	G/T	cg08950929	chr16:58768327	GOT2	0.45	6.0	0.35	6.49e-9	Colorectal or endometrial cancer;
CESC	cis	rs875971	0.522	rs781144	chr7:65440344	C/G	cg06456125	chr7:65229604	NA	0.44	5.6	0.33	5.44e-8	Aortic root size;
CESC	cis	rs2832191	0.791	rs2832202	chr21:30501342	G/A	cg24692254	chr21:30365293	RNF160	-0.8	-12.29	-0.6	9.16e-28	Dental caries;
CESC	cis	rs7666738	0.830	rs13148913	chr4:99009732	C/T	cg03467027	chr4:99064603	C4orf37	0.44	5.63	0.33	4.57e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9303401	0.615	rs7502342	chr17:56922629	C/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.01	12.45	0.61	2.57e-28	Cognitive test performance;
CESC	cis	rs6570726	0.620	rs367693	chr6:145815949	G/A	cg23711669	chr6:146136114	FBXO30	0.93	12.43	0.61	2.96e-28	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs76419734	0.558	rs10019217	chr4:106588509	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	0.73	9.54	0.51	9.69e-19	Post bronchodilator FEV1;
CESC	cis	rs9527	0.614	rs4919691	chr10:104624475	A/C	cg15744005	chr10:104629667	AS3MT	-0.34	-5.34	-0.31	1.96e-7	Arsenic metabolism;
CESC	cis	rs1697139	0.563	rs6859520	chr5:66529020	C/T	cg11553311	chr5:66541588	NA	0.36	5.16	0.3	4.96e-7	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21025089	chr22:42487122	NDUFA6	0.57	6.27	0.36	1.42e-9	Gut microbiome composition (summer);
CESC	cis	rs7582720	0.943	rs115130739	chr2:203725677	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.32	0.41	3.04e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs1976403	0.633	rs1780324	chr1:21821757	A/G	cg02390115	chr1:21767211	NBPF3	0.36	5.05	0.3	8.05e-7	Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01457183	chr3:180707371	DNAJC19	0.59	6.7	0.38	1.23e-10	Gut microbiome composition (summer);
CESC	cis	rs13392177	0.637	rs61041183	chr2:219056380	G/A	cg00012203	chr2:219082015	ARPC2	0.73	9.91	0.52	6.93e-20	Pyoderma gangrenosum in inflammatory bowel disease;
CESC	cis	rs6665290	0.836	rs56029302	chr1:227203390	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.14	-25.05	-0.84	7.67e-72	Myeloid white cell count;
CESC	cis	rs1348850	0.914	rs10497503	chr2:178371739	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.79	11.25	0.57	2.91e-24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs17209837	0.607	rs4148811	chr7:87101486	T/G	cg00919237	chr7:87102261	ABCB4	-0.51	-6.51	-0.37	3.66e-10	Gallbladder cancer;
CESC	cis	rs13118159	0.778	rs12640984	chr4:1338834	G/A	cg00684032	chr4:1343700	KIAA1530	0.42	6.52	0.37	3.57e-10	Longevity;
CESC	cis	rs10089	1.000	rs2409109	chr5:127461471	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.76	10.07	0.53	2.04e-20	Ileal carcinoids;
CESC	trans	rs7618501	1.000	rs7649348	chr3:49772375	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.58	-8.39	-0.46	2.99e-15	Intelligence (multi-trait analysis);
CESC	cis	rs7824557	0.564	rs2572386	chr8:11236975	A/G	cg21775007	chr8:11205619	TDH	-0.54	-8.05	-0.44	2.77e-14	Retinal vascular caliber;
CESC	cis	rs1044826	0.642	rs1080371	chr3:139210894	C/T	cg00490450	chr3:139108681	COPB2	0.43	5.34	0.31	2.03e-7	Obesity-related traits;
CESC	cis	rs208520	0.874	rs208512	chr6:66943869	C/G	cg07460842	chr6:66804631	NA	-0.83	-9.92	-0.52	6.27e-20	Exhaled nitric oxide output;
CESC	cis	rs6952808	0.729	rs35797753	chr7:1954914	G/A	cg02951883	chr7:2050386	MAD1L1	-0.46	-6.17	-0.35	2.57e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs801193	0.660	rs2659897	chr7:66187715	A/G	cg12463550	chr7:65579703	CRCP	-0.56	-7.2	-0.4	6.04e-12	Aortic root size;
CESC	cis	rs4665809	1.000	rs4665306	chr2:26319124	C/T	cg26314531	chr2:26401878	FAM59B	-0.6	-6.82	-0.39	6.24e-11	Gut microbiome composition (summer);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg26257210	chr1:6305348	HES3	-0.47	-6.66	-0.38	1.53e-10	Fibrinogen levels;
CESC	cis	rs73001065	0.901	rs73004951	chr19:19695228	C/T	cg03709012	chr19:19516395	GATAD2A	0.98	5.98	0.34	7.23e-9	LDL cholesterol;
CESC	cis	rs12586317	0.534	rs1568200	chr14:35419592	C/T	cg16230307	chr14:35515116	FAM177A1	0.9	10.77	0.55	1.1e-22	Psoriasis;
CESC	cis	rs6879260	1.000	rs888922	chr5:179731635	C/G	cg02891314	chr5:179741120	GFPT2	-0.7	-9.49	-0.5	1.4e-18	Height;
CESC	cis	rs238295	0.805	rs1056244	chr20:5551034	G/C	cg24001556	chr20:5591874	RP5-1022P6.2	-0.46	-5.11	-0.3	6.12e-7	Occipital cortical area (total cortical area interaction);
CESC	cis	rs3015497	1.000	rs3015495	chr14:51114703	C/T	cg26011998	chr14:51135199	SAV1	-0.41	-5.21	-0.3	3.89e-7	Mean platelet volume;
CESC	cis	rs6087990	0.966	rs2377667	chr20:31346925	A/G	cg13636640	chr20:31349939	DNMT3B	0.91	16.04	0.7	6.22e-41	Ulcerative colitis;
CESC	cis	rs4849845	0.598	rs3889223	chr2:121024432	A/G	cg24070213	chr2:121070622	NA	0.45	6.67	0.38	1.53e-10	Mean platelet volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19104112	chr7:39663043	RALA	0.54	6.0	0.35	6.4e-9	Gut microbiome composition (summer);
CESC	cis	rs5769707	0.837	rs5769709	chr22:50021757	C/T	cg20744362	chr22:50050164	C22orf34	0.44	7.13	0.4	9.27e-12	Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs9660180	0.935	rs9786942	chr1:1759213	A/G	cg13866156	chr1:1669148	SLC35E2	-0.51	-6.77	-0.38	8.38e-11	Body mass index;
CESC	cis	rs2279817	0.954	rs12143113	chr1:18018857	T/C	cg21791023	chr1:18019539	ARHGEF10L	0.57	7.84	0.43	1.14e-13	Neuroticism;
CESC	cis	rs2228479	0.764	rs7186976	chr16:89961593	A/G	cg04013166	chr16:89971882	TCF25	0.69	7.12	0.4	1.04e-11	Skin colour saturation;
CESC	trans	rs7944735	0.517	rs12274550	chr11:48196752	C/A	cg15704280	chr7:45808275	SEPT13	0.7	6.76	0.38	8.86e-11	Intraocular pressure;
CESC	cis	rs2070488	0.695	rs6599201	chr3:38476614	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.79	12.48	0.61	2.05e-28	Electrocardiographic conduction measures;
CESC	cis	rs4555082	0.834	rs2816652	chr14:105712493	C/T	cg27165867	chr14:105738592	BRF1	-0.49	-5.3	-0.31	2.41e-7	Mean platelet volume;Platelet distribution width;
CESC	cis	rs7520050	0.966	rs10890361	chr1:46346234	A/T	cg03146154	chr1:46216737	IPP	-0.48	-6.76	-0.38	8.95e-11	Red blood cell count;Reticulocyte count;
CESC	cis	rs7523050	0.730	rs34254854	chr1:109419875	C/T	cg08274380	chr1:109419600	GPSM2	0.92	6.41	0.37	6.62e-10	Fat distribution (HIV);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22819488	chr3:28390286	AZI2	0.56	6.12	0.35	3.39e-9	Gut microbiome composition (summer);
CESC	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.54	7.1	0.4	1.17e-11	Lymphocyte counts;
CESC	cis	rs1008375	0.966	rs11737844	chr4:17697421	A/C	cg16339924	chr4:17578868	LAP3	0.59	7.4	0.41	1.83e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs9815354	0.767	rs75651509	chr3:41953564	A/G	cg03022575	chr3:42003672	ULK4	0.68	5.94	0.34	8.93e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs9486715	1.000	rs9386670	chr6:97060688	C/A	cg18709589	chr6:96969512	KIAA0776	-0.46	-6.23	-0.36	1.84e-9	Headache;
CESC	cis	rs7666738	0.830	rs4699597	chr4:99019031	G/A	cg17366294	chr4:99064904	C4orf37	0.61	8.76	0.47	2.35e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11690935	0.921	rs10200608	chr2:172597929	G/A	cg13550731	chr2:172543902	DYNC1I2	-0.97	-14.91	-0.68	6.48e-37	Schizophrenia;
CESC	cis	rs11997175	0.624	rs7464055	chr8:33679382	G/A	ch.8.33884649F	chr8:33765107	NA	0.58	7.4	0.41	1.85e-12	Body mass index;
CESC	cis	rs643506	0.874	rs4936786	chr11:111727227	C/T	cg17089665	chr11:111648010	NA	-0.36	-5.2	-0.3	4.07e-7	Breast cancer;
CESC	cis	rs1018836	0.923	rs13254212	chr8:91582355	T/C	cg16814680	chr8:91681699	NA	-0.65	-8.76	-0.47	2.41e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs4604732	0.631	rs11490198	chr1:247625703	A/G	cg12754571	chr1:247694271	LOC148824;OR2C3	0.44	5.44	0.32	1.21e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs4664304	0.802	rs1511224	chr2:160750861	C/T	cg03641300	chr2:160917029	PLA2R1	-0.42	-6.0	-0.35	6.46e-9	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs8062405	0.754	rs151179	chr16:28487056	A/G	cg05966235	chr16:28915196	ATP2A1	0.36	5.22	0.31	3.61e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs10883723	0.810	rs7072351	chr10:104265047	C/T	cg22532475	chr10:104410764	TRIM8	-0.35	-5.94	-0.34	8.94e-9	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs12142240	0.698	rs17361812	chr1:46814008	C/T	cg00530320	chr1:46809349	NSUN4	0.58	7.89	0.44	8.17e-14	Menopause (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26864130	chr11:119187858	MCAM	0.52	6.28	0.36	1.41e-9	Gut microbiome composition (summer);
CESC	cis	rs2963826	0.589	rs298091	chr5:58996603	A/T	cg07145255	chr5:59995354	DEPDC1B	0.44	5.85	0.34	1.42e-8	Obesity-related traits;
CESC	cis	rs854765	0.587	rs4077828	chr17:17833644	A/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.57	8.17	0.45	1.29e-14	Total body bone mineral density;
CESC	cis	rs3091242	0.804	rs631133	chr1:25724146	T/C	cg02931644	chr1:25747376	RHCE	0.38	6.31	0.36	1.16e-9	Erythrocyte sedimentation rate;
CESC	cis	rs644799	0.965	rs11021313	chr11:95506907	G/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.71	9.44	0.5	1.99e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs7917772	0.636	rs4919676	chr10:104524352	C/T	cg04362960	chr10:104952993	NT5C2	0.45	5.11	0.3	6.07e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs6439153	1.000	rs6439153	chr3:128701130	T/C	cg25356066	chr3:128598488	ACAD9	0.51	6.5	0.37	3.9e-10	Pneumococcal bacteremia;
CESC	cis	rs854765	0.583	rs4077198	chr17:17834563	T/C	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.55	7.29	0.41	3.65e-12	Total body bone mineral density;
CESC	cis	rs2243480	0.908	rs313822	chr7:65573939	G/A	cg12463550	chr7:65579703	CRCP	0.73	5.64	0.33	4.33e-8	Diabetic kidney disease;
CESC	cis	rs12464483	0.591	rs67686878	chr2:30895044	C/T	cg07150166	chr2:30669952	LCLAT1	0.52	5.1	0.3	6.52e-7	Pre-treatment pain in head and neck squamous cell carcinoma;
CESC	trans	rs9951602	0.512	rs9953258	chr18:76651199	A/C	cg02800362	chr5:177631904	HNRNPAB	0.66	8.66	0.47	4.55e-16	Obesity-related traits;
CESC	cis	rs911555	0.504	rs8006526	chr14:104075015	T/C	cg12935359	chr14:103987150	CKB	-0.5	-7.26	-0.41	4.31e-12	Intelligence (multi-trait analysis);
CESC	cis	rs13102973	0.932	rs13149380	chr4:135866539	A/C	cg14419869	chr4:135874104	NA	0.36	5.81	0.34	1.8e-8	Subjective well-being;
CESC	cis	rs11098499	0.730	rs78971550	chr4:120281041	C/T	cg09307838	chr4:120376055	NA	0.85	11.06	0.56	1.25e-23	Corneal astigmatism;
CESC	cis	rs4253772	0.938	rs78336060	chr22:46641597	C/T	cg18190219	chr22:46762943	CELSR1	-0.62	-5.89	-0.34	1.19e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs7582720	1.000	rs72936332	chr2:204056678	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.84	7.17	0.4	7.7e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs7727544	0.735	rs272867	chr5:131681057	G/A	cg07395648	chr5:131743802	NA	-0.45	-6.02	-0.35	5.83e-9	Blood metabolite levels;
CESC	cis	rs2425143	1.000	rs7261284	chr20:34244104	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.83	-7.52	-0.42	8.7e-13	Blood protein levels;
CESC	cis	rs523522	0.962	rs1050187	chr12:120902111	A/G	cg12219531	chr12:120966889	COQ5	-0.75	-9.84	-0.52	1.11e-19	High light scatter reticulocyte count;
CESC	cis	rs4665809	1.000	rs2384322	chr2:26291146	C/G	cg26314531	chr2:26401878	FAM59B	-0.77	-8.56	-0.47	9.38e-16	Gut microbiome composition (summer);
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg19767339	chr1:63932041	ITGB3BP	0.39	6.1	0.35	3.77e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs6545883	0.965	rs7421663	chr2:61753786	C/T	cg15711740	chr2:61764176	XPO1	-0.44	-5.32	-0.31	2.25e-7	Tuberculosis;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg18338181	chr19:13044658	FARSA	-0.46	-6.01	-0.35	6.11e-9	Asthma;
CESC	cis	rs780096	0.506	rs2950834	chr2:27627366	G/A	cg22903471	chr2:27725779	GCKR	-0.5	-7.11	-0.4	1.07e-11	Total body bone mineral density;
CESC	cis	rs7568498	0.517	rs197261	chr2:161904823	A/G	cg22496339	chr2:162101262	NA	-0.53	-5.51	-0.32	8.32e-8	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);
CESC	cis	rs2777491	0.574	rs11858812	chr15:41731550	G/A	cg02330683	chr15:41787940	ITPKA	0.42	5.12	0.3	5.92e-7	Ulcerative colitis;
CESC	cis	rs2288073	0.965	rs72789923	chr2:24394504	A/C	cg06627628	chr2:24431161	ITSN2	-0.78	-8.96	-0.48	5.79e-17	Venous thromboembolism (SNP x SNP interaction);
CESC	cis	rs2243480	1.000	rs68189316	chr7:65409169	C/G	cg18252515	chr7:66147081	NA	-1.06	-9.79	-0.52	1.67e-19	Diabetic kidney disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01939212	chr16:85644243	KIAA0182	0.6	6.62	0.38	2.04e-10	Gut microbiome composition (summer);
CESC	cis	rs2635047	1.000	rs2635049	chr18:44687303	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.5	-6.91	-0.39	3.69e-11	Educational attainment;
CESC	cis	rs9322193	0.923	rs62441279	chr6:150042330	G/A	cg04369109	chr6:150039330	LATS1	-0.39	-5.43	-0.32	1.28e-7	Lung cancer;
CESC	cis	rs7772486	0.727	rs2235481	chr6:146056848	T/C	cg05347473	chr6:146136440	FBXO30	-0.69	-8.86	-0.48	1.22e-16	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg14922886	chr7:27239701	HOXA13	-0.39	-6.15	-0.35	2.9e-9	Gambling;
CESC	trans	rs7618501	0.933	rs6809431	chr3:49804119	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.59	8.5	0.46	1.36e-15	Intelligence (multi-trait analysis);
CESC	trans	rs9467711	0.790	rs13195401	chr6:26463574	G/T	cg06606381	chr12:133084897	FBRSL1	-1.06	-8.04	-0.44	3.05e-14	Autism spectrum disorder or schizophrenia;
CESC	cis	rs270601	0.770	rs10463891	chr5:131597392	C/T	cg12564285	chr5:131593104	PDLIM4	-0.4	-6.19	-0.36	2.23e-9	Acylcarnitine levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08950886	chr10:33247484	ITGB1	0.59	7.38	0.41	2.03e-12	Gut microbiome composition (summer);
CESC	cis	rs9611519	0.929	rs4821991	chr22:41440683	T/C	cg03806693	chr22:41940476	POLR3H	-0.56	-5.88	-0.34	1.22e-8	Neuroticism;
CESC	cis	rs3806843	0.735	rs2563333	chr5:140052271	A/G	cg26395211	chr5:140044315	WDR55	0.45	6.0	0.35	6.57e-9	Depressive symptoms (multi-trait analysis);
CESC	cis	rs4253772	0.530	rs6008616	chr22:46707954	A/G	cg24881330	chr22:46731750	TRMU	0.81	7.31	0.41	3.09e-12	LDL cholesterol;Cholesterol, total;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22935501	chr17:78234799	RNF213	0.53	6.24	0.36	1.76e-9	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11886286	chr6:27114864	HIST1H2BK;HIST1H2AH	-0.56	-6.12	-0.35	3.38e-9	Gut microbiome composition (summer);
CESC	cis	rs8067545	0.611	rs2703812	chr17:20114803	A/G	cg13482628	chr17:19912719	NA	-0.42	-5.68	-0.33	3.46e-8	Schizophrenia;
CESC	cis	rs4481887	0.790	rs10888364	chr1:248488387	T/G	cg00666640	chr1:248458726	OR2T12	0.35	5.98	0.35	7.04e-9	Common traits (Other);
CESC	cis	rs2742417	0.603	rs13059502	chr3:45781380	A/G	cg04837898	chr3:45731254	SACM1L	-0.46	-6.04	-0.35	5.31e-9	Response to anti-depressant treatment in major depressive disorder;
CESC	cis	rs1862618	0.853	rs252916	chr5:56121788	G/C	cg12311346	chr5:56204834	C5orf35	-0.72	-8.86	-0.48	1.15e-16	Initial pursuit acceleration;
CESC	trans	rs7584330	0.554	rs77956735	chr2:238399130	C/T	cg06514003	chr17:40330907	KCNH4	-0.74	-6.2	-0.36	2.1e-9	Prostate cancer;
CESC	cis	rs10089	0.953	rs6887674	chr5:127531183	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.73	9.05	0.49	3.19e-17	Ileal carcinoids;
CESC	cis	rs4862750	0.872	rs13101408	chr4:187894777	G/A	cg06074448	chr4:187884817	NA	-0.36	-5.06	-0.3	7.74e-7	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs875971	0.862	rs10950043	chr7:65988610	T/C	cg18252515	chr7:66147081	NA	-0.47	-6.08	-0.35	4.25e-9	Aortic root size;
CESC	cis	rs9486719	1.000	rs2472895	chr6:96870387	A/T	cg06623918	chr6:96969491	KIAA0776	0.81	8.29	0.45	5.61e-15	Migraine;Coronary artery disease;
CESC	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg05552183	chr6:42928497	GNMT	0.76	11.28	0.57	2.39e-24	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg18337363	chr3:52569053	NT5DC2	0.3	5.93	0.34	9.48e-9	Bipolar disorder;
CESC	cis	rs4589502	1.000	rs75502100	chr15:67131417	T/C	cg12317470	chr15:67143691	NA	0.72	5.87	0.34	1.31e-8	Lung cancer (smoking interaction);
CESC	cis	rs1552244	0.882	rs17081288	chr3:10042113	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.87	11.4	0.57	9.22e-25	Alzheimer's disease;
CESC	cis	rs12451471	0.667	rs12942002	chr17:78101629	C/G	cg06718696	chr17:78121285	EIF4A3	0.87	10.99	0.56	2.15e-23	Plateletcrit;Mean corpuscular hemoglobin concentration;
CESC	cis	rs698833	0.926	rs786626	chr2:44604066	C/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.47	6.06	0.35	4.56e-9	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs1799949	1.000	rs11658754	chr17:41292739	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.67	9.36	0.5	3.44e-18	Menopause (age at onset);
CESC	cis	rs7447593	0.518	rs4074995	chr5:176797343	C/T	cg17509989	chr5:176798049	RGS14	0.75	8.44	0.46	2.1e-15	Urinary electrolytes (magnesium/calcium ratio);
CESC	cis	rs796364	0.694	rs1653299	chr2:201075611	A/G	cg23649088	chr2:200775458	C2orf69	0.6	7.38	0.41	1.99e-12	Schizophrenia;
CESC	cis	rs8050907	0.744	rs7191458	chr16:4511752	T/C	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.86	5.97	0.34	7.5e-9	Obesity-related traits;
CESC	cis	rs6860806	0.507	rs274570	chr5:131713226	C/T	cg07395648	chr5:131743802	NA	0.43	5.58	0.32	5.91e-8	Breast cancer;
CESC	cis	rs6011002	0.935	rs41309933	chr20:62311377	G/A	cg15212369	chr20:62274085	STMN3	-0.59	-5.11	-0.3	6.12e-7	Dental caries;
CESC	cis	rs9790314	1.000	rs464766	chr3:161087592	C/G	cg04691961	chr3:161091175	C3orf57	-0.44	-5.66	-0.33	4e-8	Morning vs. evening chronotype;
CESC	cis	rs7312774	0.618	rs28716736	chr12:107364410	A/G	cg16260113	chr12:107380972	MTERFD3	0.79	6.89	0.39	4.15e-11	Severe influenza A (H1N1) infection;
CESC	trans	rs561341	1.000	rs508192	chr17:30315147	C/T	cg27661571	chr11:113659931	NA	0.75	6.68	0.38	1.4e-10	Hip circumference adjusted for BMI;
CESC	cis	rs870825	0.616	rs2090589	chr4:185647731	A/G	cg04058563	chr4:185651563	MLF1IP	0.63	6.96	0.39	2.59e-11	Blood protein levels;
CESC	cis	rs854765	0.619	rs4561528	chr17:17979099	C/T	cg04398451	chr17:18023971	MYO15A	-0.8	-12.02	-0.59	7.2e-27	Total body bone mineral density;
CESC	cis	rs763014	0.838	rs4984670	chr16:641044	A/G	cg09263875	chr16:632152	PIGQ	0.69	11.21	0.57	3.95e-24	Height;
CESC	cis	rs4268898	0.662	rs59996104	chr2:24404064	C/T	cg08917208	chr2:24149416	ATAD2B	0.6	5.56	0.32	6.71e-8	Asthma;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14727059	chr3:53195316	PRKCD	0.57	6.11	0.35	3.49e-9	Gut microbiome composition (summer);
CESC	cis	rs644799	0.965	rs573758	chr11:95539591	G/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.53	6.41	0.37	6.77e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs9311474	0.539	rs12489828	chr3:52567014	G/T	cg07507251	chr3:52567010	NT5DC2	0.54	11.08	0.56	1.11e-23	Electroencephalogram traits;
CESC	cis	rs9660180	0.868	rs12567685	chr1:1806647	T/C	cg13866156	chr1:1669148	SLC35E2	-0.5	-6.53	-0.37	3.26e-10	Body mass index;
CESC	cis	rs829883	0.664	rs829876	chr12:98842138	A/G	cg25150519	chr12:98850993	NA	0.88	15.05	0.68	2e-37	Colorectal adenoma (advanced);
CESC	cis	rs17376456	0.825	rs28705226	chr5:93233135	T/C	cg25358565	chr5:93447407	FAM172A	1.09	10.71	0.55	1.77e-22	Diabetic retinopathy;
CESC	cis	rs11792861	0.926	rs72607169	chr9:111832471	A/T	cg05043794	chr9:111880884	C9orf5	-0.39	-6.39	-0.37	7.25e-10	Menarche (age at onset);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg11371681	chr1:26606896	SH3BGRL3	0.48	6.11	0.35	3.52e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs910316	0.737	rs175084	chr14:75519175	C/T	cg11812906	chr14:75593930	NEK9	-0.83	-13.45	-0.64	9e-32	Height;
CESC	cis	rs10791097	0.568	rs4411284	chr11:130738568	A/C	cg12179176	chr11:130786555	SNX19	0.64	9.95	0.52	4.91e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs4076764	1.000	rs7525643	chr1:163426283	G/A	cg06092702	chr1:163392909	NA	-0.37	-5.38	-0.31	1.63e-7	Motion sickness;
CESC	cis	rs9902453	0.845	rs58606097	chr17:28020379	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	8.53	0.46	1.15e-15	Coffee consumption (cups per day);
CESC	trans	rs12095761	0.515	rs6604648	chr1:217018694	A/G	cg02004048	chr6:109868066	AKD1	-0.39	-6.07	-0.35	4.49e-9	Breast cancer;
CESC	cis	rs2243480	1.000	rs59794892	chr7:65415873	G/A	cg13147721	chr7:65941812	NA	-0.83	-7.94	-0.44	5.77e-14	Diabetic kidney disease;
CESC	cis	rs3796619	1.000	rs11939380	chr4:1086871	C/T	cg27284194	chr4:1044797	NA	-0.37	-5.7	-0.33	3.27e-8	Recombination rate (males);
CESC	cis	rs10504073	0.647	rs56057508	chr8:49982793	G/T	cg00325661	chr8:49890786	NA	0.53	7.77	0.43	1.76e-13	Blood metabolite ratios;
CESC	cis	rs7520050	0.966	rs10749860	chr1:46328210	C/G	cg03146154	chr1:46216737	IPP	-0.49	-6.37	-0.36	8.44e-10	Red blood cell count;Reticulocyte count;
CESC	cis	rs12586317	0.547	rs4982234	chr14:35460106	T/A	cg16230307	chr14:35515116	FAM177A1	0.98	10.57	0.54	5.04e-22	Psoriasis;
CESC	cis	rs9611565	0.513	rs739135	chr22:42090069	A/C	cg06634786	chr22:41940651	POLR3H	0.65	6.47	0.37	4.73e-10	Vitiligo;
CESC	cis	rs6430585	0.527	rs60966546	chr2:136401843	C/T	cg07169764	chr2:136633963	MCM6	1.04	12.32	0.6	7.31e-28	Corneal structure;
CESC	cis	rs1983170	0.935	rs578155	chr1:91976541	G/A	cg02896835	chr1:92012615	NA	-0.53	-5.91	-0.34	1.07e-8	Eosinophil percentage of white cells;
CESC	cis	rs896854	0.654	rs28591375	chr8:95973637	C/G	cg16049864	chr8:95962084	TP53INP1	-0.65	-11.4	-0.57	9.17e-25	Type 2 diabetes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00028918	chr5:159200479	NA	-0.6	-6.35	-0.36	9.54e-10	Gut microbiome composition (summer);
CESC	cis	rs2072732	0.861	rs10909866	chr1:2960372	C/T	cg03976712	chr1:2946727	NA	0.35	5.63	0.33	4.52e-8	Plateletcrit;
CESC	trans	rs7246657	0.943	rs2112923	chr19:37940327	C/T	cg24637308	chr11:6592297	DNHD1	0.54	6.34	0.36	1.01e-9	Coronary artery calcification;
CESC	cis	rs6952808	0.895	rs12669518	chr7:1921429	G/C	cg21782813	chr7:2030301	MAD1L1	0.41	5.86	0.34	1.37e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs7635838	0.859	rs9869423	chr3:11459156	G/T	cg00170343	chr3:11313890	ATG7	0.43	5.73	0.33	2.76e-8	HDL cholesterol;
CESC	cis	rs7615952	0.800	rs13086460	chr3:125646417	C/T	cg05084668	chr3:125655381	ALG1L	-0.51	-5.95	-0.34	8.56e-9	Blood pressure (smoking interaction);
CESC	cis	rs2882667	0.858	rs6882112	chr5:138413735	C/T	cg04439458	chr5:138467593	SIL1	0.37	6.1	0.35	3.78e-9	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs17253792	0.598	rs71413578	chr14:56018651	T/C	cg01858014	chr14:56050164	KTN1	-0.89	-6.36	-0.36	9.03e-10	Putamen volume;
CESC	cis	rs3011225	0.683	rs4660753	chr1:44321044	G/A	cg12908607	chr1:44402522	ARTN	-0.46	-6.6	-0.38	2.26e-10	Amyotrophic lateral sclerosis (age of onset);
CESC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg20053493	chr11:47776175	FNBP4	-0.44	-6.41	-0.37	6.52e-10	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11344626	chr1:14026360	PRDM2	-0.51	-6.1	-0.35	3.65e-9	Gut microbiome composition (summer);
CESC	cis	rs9311474	0.508	rs11714565	chr3:52606292	C/T	cg18099408	chr3:52552593	STAB1	-0.36	-6.09	-0.35	4.06e-9	Electroencephalogram traits;
CESC	cis	rs72781680	0.566	rs72794293	chr2:23898149	A/G	cg08917208	chr2:24149416	ATAD2B	0.7	6.84	0.39	5.48e-11	Lymphocyte counts;
CESC	cis	rs2268241	0.938	rs9978166	chr21:34770516	A/G	cg14850771	chr21:34775459	IFNGR2	0.89	10.99	0.56	2.19e-23	Obesity-related traits;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg04127825	chr1:167503222	NA	0.45	6.01	0.35	6.15e-9	Systemic lupus erythematosus;
CESC	cis	rs7259376	0.936	rs8108630	chr19:22535177	G/T	cg02657401	chr19:22469223	NA	-0.27	-5.31	-0.31	2.28e-7	Menopause (age at onset);
CESC	cis	rs10504229	0.593	rs11781042	chr8:57993056	A/T	cg22535103	chr8:58192502	C8orf71	-0.66	-7.06	-0.4	1.45e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs2204008	0.540	rs1672425	chr12:38122842	G/A	cg26384229	chr12:38710491	ALG10B	-0.46	-6.46	-0.37	4.93e-10	Bladder cancer;
CESC	cis	rs17253792	0.822	rs10147688	chr14:56054642	T/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.82	5.99	0.35	6.73e-9	Putamen volume;
CESC	cis	rs300703	1.000	rs300703	chr2:239416	C/T	cg21211680	chr2:198530	NA	0.96	7.57	0.42	6.12e-13	Blood protein levels;
CESC	cis	rs4730250	0.634	rs257371	chr7:106795043	C/A	cg02696742	chr7:106810147	HBP1	-0.55	-5.18	-0.3	4.44e-7	Osteoarthritis;
CESC	cis	rs4819052	0.765	rs2838868	chr21:46714641	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.9	-11.57	-0.58	2.47e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs7599312	0.534	rs7355673	chr2:213404389	T/C	cg20637307	chr2:213403960	ERBB4	0.57	8.92	0.48	7.78e-17	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs4319547	0.956	rs10773302	chr12:123043145	G/T	cg05707623	chr12:122985044	ZCCHC8	-0.56	-6.69	-0.38	1.3e-10	Body mass index;
CESC	cis	rs6540556	0.637	rs12060922	chr1:209904433	G/A	cg05527609	chr1:210001259	C1orf107	-0.68	-7.5	-0.42	9.46e-13	Red blood cell count;
CESC	cis	rs6582630	0.519	rs12578283	chr12:38325349	A/T	cg26384229	chr12:38710491	ALG10B	0.72	10.83	0.55	7.25e-23	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs6762	0.719	rs28620453	chr11:836971	G/C	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.77	-10.39	-0.54	1.97e-21	Mean platelet volume;
CESC	cis	rs35849525	0.776	rs7615318	chr3:49987475	C/T	cg24110177	chr3:50126178	RBM5	-0.43	-5.1	-0.3	6.39e-7	Intelligence (multi-trait analysis);
CESC	cis	rs7666738	0.830	rs13119913	chr4:98977983	G/T	cg03467027	chr4:99064603	C4orf37	0.42	5.29	0.31	2.5e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs853679	0.517	rs9348797	chr6:28137533	G/C	cg23281280	chr6:28129359	ZNF389	0.56	7.62	0.42	4.55e-13	Depression;
CESC	cis	rs826838	1.000	rs11168217	chr12:38884278	T/C	cg26384229	chr12:38710491	ALG10B	0.83	14.68	0.67	4e-36	Heart rate;
CESC	cis	rs514406	0.607	rs6665324	chr1:53201610	G/A	cg27535305	chr1:53392650	SCP2	0.34	6.03	0.35	5.37e-9	Monocyte count;
CESC	cis	rs6964587	0.967	rs7786031	chr7:91649001	T/G	cg17063962	chr7:91808500	NA	0.57	7.86	0.43	9.58e-14	Breast cancer;
CESC	cis	rs1801251	1.000	rs991873	chr2:233711046	A/G	cg25237894	chr2:233734115	C2orf82	-0.47	-8.28	-0.45	6.12e-15	Coronary artery disease;
CESC	cis	rs10979	1.000	rs9496678	chr6:143896664	C/A	cg25407410	chr6:143891975	LOC285740	-0.61	-9.2	-0.49	1.13e-17	Hypospadias;
CESC	cis	rs6772849	0.930	rs55987729	chr3:128340110	T/C	cg16766828	chr3:128327626	NA	-0.31	-5.13	-0.3	5.62e-7	Monocyte percentage of white cells;Monocyte count;
CESC	cis	rs875971	1.000	rs709595	chr7:65817333	G/C	cg18876405	chr7:65276391	NA	0.51	6.92	0.39	3.39e-11	Aortic root size;
CESC	cis	rs7666738	0.830	rs1967977	chr4:98966141	A/G	cg03676636	chr4:99064102	C4orf37	0.33	5.14	0.3	5.39e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1514687	0.534	rs2138020	chr2:1482093	T/A	cg13703866	chr2:1479523	TPO	-0.79	-6.17	-0.35	2.53e-9	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);
CESC	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg04025307	chr7:1156635	C7orf50	0.49	6.73	0.38	1.02e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs9329221	0.683	rs555200	chr8:9888729	A/G	cg06636001	chr8:8085503	FLJ10661	-0.55	-7.36	-0.41	2.31e-12	Neuroticism;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg18548362	chr4:1857197	LETM1	0.45	6.36	0.36	8.68e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs763121	0.853	rs2076028	chr22:39150450	G/A	cg21395723	chr22:39101663	GTPBP1	0.45	5.75	0.33	2.41e-8	Menopause (age at onset);
CESC	cis	rs9325144	0.513	rs12313652	chr12:38665412	G/A	cg26384229	chr12:38710491	ALG10B	-0.6	-8.49	-0.46	1.45e-15	Morning vs. evening chronotype;
CESC	cis	rs2882667	0.858	rs11959803	chr5:138451315	G/A	cg04439458	chr5:138467593	SIL1	-0.39	-6.02	-0.35	5.74e-9	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs3785574	0.962	rs2584628	chr17:61894578	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	1.1	19.13	0.76	7.67e-52	Height;
CESC	cis	rs10256972	1.000	rs10256972	chr7:1039003	G/T	cg09177884	chr7:1199841	ZFAND2A	0.4	5.03	0.3	8.88e-7	Longevity;Endometriosis;
CESC	cis	rs7129220	0.588	rs61878628	chr11:10128872	T/G	cg01453529	chr11:10209919	SBF2	-0.48	-5.5	-0.32	8.85e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CESC	cis	rs4604732	0.631	rs12038880	chr1:247624603	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.56	7.5	0.42	9.89e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs72627123	0.582	rs62005102	chr14:74500586	T/A	cg05179529	chr14:74551516	LIN52;ALDH6A1	0.56	5.57	0.32	6.34e-8	Morning vs. evening chronotype;
CESC	cis	rs4819052	0.851	rs4819041	chr21:46659955	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.72	9.91	0.52	6.86e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs9815354	0.812	rs59146151	chr3:41949301	T/C	cg03022575	chr3:42003672	ULK4	0.71	6.45	0.37	5.42e-10	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs863345	0.967	rs11264998	chr1:158488766	G/A	cg12129480	chr1:158549410	OR10X1	-0.3	-5.97	-0.34	7.49e-9	Pneumococcal bacteremia;
CESC	cis	rs12497850	0.931	rs9835307	chr3:48857805	T/C	cg03060546	chr3:49711283	APEH	0.45	5.5	0.32	9e-8	Parkinson's disease;
CESC	cis	rs10931896	0.531	rs296801	chr2:201142812	C/T	cg23649088	chr2:200775458	C2orf69	0.55	7.72	0.43	2.42e-13	Systolic blood pressure;
CESC	cis	rs7589728	0.858	rs79992736	chr2:88530575	A/C	cg14558114	chr2:88469736	THNSL2	0.54	6.06	0.35	4.64e-9	Plasma clusterin levels;
CESC	cis	rs2637266	0.538	rs11001852	chr10:78445987	G/C	cg18941641	chr10:78392320	NA	-0.33	-5.22	-0.31	3.63e-7	Pulmonary function;
CESC	cis	rs3820068	0.608	rs12740492	chr1:16048951	A/T	cg17385448	chr1:15911702	AGMAT	0.37	5.67	0.33	3.82e-8	Systolic blood pressure;
CESC	cis	rs35110281	0.782	rs2051407	chr21:45079245	T/C	cg04455712	chr21:45112962	RRP1B	0.4	5.96	0.34	7.97e-9	Mean corpuscular volume;
CESC	cis	rs72781680	1.000	rs72796359	chr2:24160545	T/C	cg08917208	chr2:24149416	ATAD2B	1.12	10.07	0.53	2.16e-20	Lymphocyte counts;
CESC	cis	rs9858542	0.953	rs6997	chr3:49453834	C/T	cg07274523	chr3:49395745	GPX1	0.65	8.57	0.47	8.85e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs367943	0.901	rs463167	chr5:112799369	C/A	cg12552261	chr5:112820674	MCC	-0.62	-7.85	-0.43	1.05e-13	Type 2 diabetes;
CESC	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg14159672	chr1:205819179	PM20D1	0.9	15.91	0.7	1.82e-40	Menarche (age at onset);
CESC	cis	rs3026101	0.624	rs1806261	chr17:5317008	A/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.46	5.97	0.34	7.7e-9	Body mass index;
CESC	cis	rs3096299	0.642	rs12934829	chr16:89523349	T/A	cg08822215	chr16:89438651	ANKRD11	-0.34	-5.13	-0.3	5.54e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs4563143	0.634	rs113736470	chr19:29240125	G/A	cg12667521	chr19:29218732	NA	0.48	6.75	0.38	9.2e-11	Methadone dose in opioid dependence;
CESC	cis	rs1707322	1.000	rs785497	chr1:46591903	G/C	cg03146154	chr1:46216737	IPP	-0.74	-9.64	-0.51	4.75e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs1062177	1.000	rs1062177	chr5:151184701	C/T	cg00977110	chr5:151150581	G3BP1	0.63	6.88	0.39	4.37e-11	Preschool internalizing problems;
CESC	cis	rs7605827	0.930	rs10929365	chr2:15531626	G/A	cg19274914	chr2:15703543	NA	0.35	6.2	0.36	2.14e-9	Educational attainment (years of education);
CESC	cis	rs9308433	0.529	rs55760458	chr1:214491536	G/C	cg06198575	chr1:214491504	SMYD2	0.5	6.02	0.35	5.67e-9	IgG glycosylation;
CESC	cis	rs13242816	1.000	rs6968230	chr7:116137049	G/T	cg04696780	chr7:116139425	CAV2	-0.61	-5.51	-0.32	8.44e-8	P wave duration;
CESC	cis	rs68170813	0.599	rs77878465	chr7:106890996	G/A	cg02696742	chr7:106810147	HBP1	-0.52	-5.14	-0.3	5.32e-7	Coronary artery disease;
CESC	cis	rs3091242	0.933	rs11249250	chr1:25767609	G/A	cg12412775	chr1:25698385	RHCE	-0.29	-5.17	-0.3	4.61e-7	Erythrocyte sedimentation rate;
CESC	cis	rs9894429	1.000	rs9748176	chr17:79584043	C/G	cg18240062	chr17:79603768	NPLOC4	0.72	10.24	0.53	5.94e-21	Eye color traits;
CESC	cis	rs9322193	0.923	rs12176034	chr6:150121693	C/T	cg07701084	chr6:150067640	NUP43	0.41	5.5	0.32	8.83e-8	Lung cancer;
CESC	cis	rs7220401	0.512	rs71371126	chr17:28002642	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.64	-6.64	-0.38	1.78e-10	Coronary artery disease;
CESC	cis	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg08061076	chr7:1943177	MAD1L1	-0.38	-5.07	-0.3	7.38e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs12410462	0.581	rs77837509	chr1:227559873	C/T	cg04117972	chr1:227635322	NA	0.69	5.84	0.34	1.54e-8	Major depressive disorder;
CESC	trans	rs9929218	0.954	rs112225541	chr16:68755165	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.75	-9.77	-0.51	1.8e-19	Colorectal cancer;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg08977639	chr16:1047820	NA	0.44	6.16	0.35	2.67e-9	Systemic lupus erythematosus;
CESC	cis	rs3741404	0.825	rs2515241	chr11:63975331	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.87	12.74	0.62	2.47e-29	Platelet count;
CESC	cis	rs9649465	0.967	rs12537989	chr7:123308195	A/G	cg04330084	chr7:123175371	IQUB	-0.37	-5.05	-0.3	8.09e-7	Migraine;
CESC	cis	rs9623117	0.874	rs7284980	chr22:40474513	C/T	cg05033341	chr22:40419857	FAM83F	-0.46	-5.2	-0.3	4.05e-7	Prostate cancer (SNP x SNP interaction);Prostate cancer;
CESC	cis	rs1707322	1.000	rs12077974	chr1:46384141	G/A	cg05343316	chr1:45956843	TESK2	0.44	5.33	0.31	2.14e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9682041	0.696	rs11709437	chr3:170085568	T/G	cg11886554	chr3:170076028	SKIL	0.7	6.49	0.37	4.1e-10	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg03565437	chr5:14488482	TRIO	0.57	7.87	0.44	9.19e-14	Fibrinogen levels;
CESC	cis	rs9611565	0.729	rs505533	chr22:41864216	A/C	cg03806693	chr22:41940476	POLR3H	0.77	10.01	0.52	3.34e-20	Vitiligo;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13958304	chr1:114354463	RSBN1	-0.58	-6.12	-0.35	3.42e-9	Gut microbiome composition (summer);
CESC	cis	rs1051424	0.642	rs115869798	chr17:57892829	T/A	cg13753209	chr17:57696993	CLTC	0.67	8.48	0.46	1.6e-15	Obesity-related traits;
CESC	cis	rs5769765	0.955	rs6520066	chr22:50294988	C/T	cg02269571	chr22:50332266	NA	-0.45	-6.01	-0.35	6.23e-9	Schizophrenia;
CESC	cis	rs6963495	0.818	rs73192113	chr7:105169603	C/T	cg13798780	chr7:105162888	PUS7	0.77	7.88	0.44	8.3e-14	Bipolar disorder (body mass index interaction);
CESC	cis	rs1552244	1.000	rs7648104	chr3:10073311	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.87	11.84	0.59	2.99e-26	Alzheimer's disease;
CESC	cis	rs752010	0.631	rs4660549	chr1:42088102	A/G	cg06885757	chr1:42089581	HIVEP3	0.7	11.13	0.56	7.59e-24	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs7666738	0.791	rs34152299	chr4:98929862	G/C	cg17366294	chr4:99064904	C4orf37	0.6	8.22	0.45	9.04e-15	Colonoscopy-negative controls vs population controls;
CESC	trans	rs7980799	0.649	rs1994135	chr12:33682405	T/C	cg26384229	chr12:38710491	ALG10B	0.47	6.55	0.37	3.03e-10	Heart rate;Heart rate variability traits (RMSSD);
CESC	cis	rs12325245	0.536	rs3169293	chr16:58552959	A/G	cg02549819	chr16:58548995	SETD6	0.98	6.55	0.37	3.06e-10	Schizophrenia;
CESC	cis	rs2742234	0.503	rs1254968	chr10:43691691	C/T	cg07801480	chr10:43725741	RASGEF1A	-0.41	-5.31	-0.31	2.3e-7	Hirschsprung disease;
CESC	cis	rs1784581	0.507	rs1790020	chr6:162366266	C/T	cg17173639	chr6:162384350	PARK2	-0.6	-8.87	-0.48	1.14e-16	Itch intensity from mosquito bite;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23397427	chr15:51571820	CYP19A1	-0.5	-6.27	-0.36	1.49e-9	Gut microbiome composition (summer);
CESC	cis	rs2011503	0.941	rs56135441	chr19:19371370	A/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.52	5.34	0.31	2.03e-7	Bipolar disorder;
CESC	cis	rs7618915	0.532	rs13060675	chr3:52674300	T/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	7.08	0.4	1.27e-11	Bipolar disorder;
CESC	cis	rs4727027	0.727	rs1568944	chr7:148873497	A/T	cg23583168	chr7:148888333	NA	-0.75	-9.76	-0.51	1.99e-19	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs7116495	0.609	rs60054591	chr11:71825687	G/A	cg10381502	chr11:71823885	C11orf51	1.06	6.8	0.39	6.99e-11	Severe influenza A (H1N1) infection;
CESC	trans	rs1285495	0.627	rs10912059	chr1:187354887	C/T	cg07564188	chr1:165667906	ALDH9A1	-0.46	-6.04	-0.35	5.27e-9	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
CESC	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg02071572	chr4:1403502	NA	0.34	5.05	0.3	8.37e-7	Longevity;
CESC	cis	rs9796	0.621	rs690733	chr15:41476465	G/A	cg12386646	chr15:41787261	ITPKA	0.33	5.12	0.3	5.98e-7	Menopause (age at onset);
CESC	cis	rs7267979	0.932	rs372678	chr20:25465248	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.73	13.31	0.63	2.6e-31	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs6456156	0.586	rs12528323	chr6:167461645	A/G	cg23791538	chr6:167370224	RNASET2	-0.49	-6.37	-0.36	8.2e-10	Primary biliary cholangitis;
CESC	cis	rs12042052	0.793	rs12036759	chr1:232925441	A/G	cg00951395	chr1:232941775	KIAA1383	0.83	7.02	0.4	1.82e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CESC	cis	rs2732480	0.577	rs2732466	chr12:48732459	A/G	cg24011408	chr12:48396354	COL2A1	0.43	5.78	0.33	2.05e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs10779751	0.708	rs2746640	chr1:11292952	T/A	cg08854313	chr1:11322531	MTOR	0.8	10.67	0.55	2.34e-22	Body mass index;
CESC	cis	rs34172651	0.517	rs35560136	chr16:24788915	T/A	cg06028605	chr16:24865363	SLC5A11	0.57	8.09	0.45	2.17e-14	Intelligence (multi-trait analysis);
CESC	cis	rs6912958	0.935	rs6454629	chr6:88165515	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.33	-5.42	-0.32	1.32e-7	Monocyte percentage of white cells;
CESC	trans	rs28551159	1	rs28551159	chr6:26376368	A/G	cg06606381	chr12:133084897	FBRSL1	-0.76	-6.68	-0.38	1.4e-10	Urinary tract infection frequency;
CESC	cis	rs11792861	0.781	rs72607158	chr9:111763010	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.52	6.58	0.37	2.54e-10	Menarche (age at onset);
CESC	cis	rs2549003	1.000	rs2549004	chr5:131827825	C/G	cg00255919	chr5:131827918	IRF1	-0.6	-10.57	-0.54	5.26e-22	Asthma (sex interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24108215	chr1:39174820	NA	-0.58	-7.26	-0.41	4.2e-12	Gut microbiome composition (summer);
CESC	cis	rs2841277	0.708	rs28454709	chr14:105405942	G/A	cg19901468	chr14:105411992	AHNAK2	-0.6	-8.69	-0.47	3.79e-16	Rheumatoid arthritis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25329269	chr9:86432854	GKAP1	-0.59	-7.03	-0.4	1.77e-11	Gut microbiome composition (summer);
CESC	trans	rs61931739	0.853	rs10844751	chr12:34099651	T/G	cg26384229	chr12:38710491	ALG10B	-0.48	-6.62	-0.38	1.95e-10	Morning vs. evening chronotype;
CESC	cis	rs10191773	0.535	rs11685514	chr2:113100014	C/T	cg07905836	chr2:113190072	RGPD8;RGPD5	0.6	5.12	0.3	5.88e-7	Yeast infection;
CESC	cis	rs3820928	1.000	rs7592387	chr2:227777095	A/G	cg11843606	chr2:227700838	RHBDD1	-0.43	-5.81	-0.34	1.74e-8	Pulmonary function;
CESC	cis	rs9388451	0.839	rs3799711	chr6:126075313	C/T	cg10911889	chr6:126070802	HEY2	-0.38	-5.23	-0.31	3.41e-7	Brugada syndrome;
CESC	cis	rs6681460	1.000	rs2872078	chr1:67127367	C/A	cg02459107	chr1:67143332	SGIP1	0.39	5.41	0.32	1.43e-7	Presence of antiphospholipid antibodies;
CESC	cis	rs2415984	0.622	rs2415998	chr14:46930712	A/G	cg14871534	chr14:47121158	RPL10L	-0.34	-5.13	-0.3	5.71e-7	Number of children ever born;
CESC	cis	rs7618915	0.621	rs6788993	chr3:52605136	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.5	7.34	0.41	2.6e-12	Bipolar disorder;
CESC	cis	rs10504229	0.683	rs16921829	chr8:58110950	A/G	cg02725872	chr8:58115012	NA	-0.45	-7.04	-0.4	1.66e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs7811142	0.830	rs28495773	chr7:99943583	A/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.11	11.43	0.57	7.53e-25	Platelet count;
CESC	cis	rs4654899	0.931	rs10799679	chr1:21341776	A/G	cg05370193	chr1:21551575	ECE1	0.38	5.66	0.33	3.96e-8	Superior frontal gyrus grey matter volume;
CESC	cis	rs4835473	0.897	rs35556180	chr4:144658748	G/A	cg25736465	chr4:144833511	NA	-0.34	-5.3	-0.31	2.46e-7	Immature fraction of reticulocytes;
CESC	cis	rs561341	1.000	rs535151	chr17:30317405	C/T	cg00745463	chr17:30367425	LRRC37B	-0.48	-5.23	-0.31	3.42e-7	Hip circumference adjusted for BMI;
CESC	cis	rs2836974	0.863	rs1065242	chr21:40567716	C/G	cg11644478	chr21:40555479	PSMG1	1.04	16.67	0.72	3.61e-43	Cognitive function;
CESC	cis	rs4253772	0.513	rs6008612	chr22:46707907	G/A	cg18190219	chr22:46762943	CELSR1	-0.44	-5.49	-0.32	9.55e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs17666538	0.585	rs6559063	chr8:623051	C/T	cg07234876	chr8:600039	NA	0.86	5.81	0.34	1.79e-8	IgG glycosylation;
CESC	cis	rs9611565	0.729	rs169362	chr22:41827589	G/C	cg03806693	chr22:41940476	POLR3H	0.77	9.78	0.51	1.74e-19	Vitiligo;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg10236037	chr2:9347576	ASAP2	-0.44	-6.52	-0.37	3.56e-10	Gambling;
CESC	cis	rs7772486	0.720	rs6570713	chr6:146075085	G/A	cg23711669	chr6:146136114	FBXO30	-1.01	-15.7	-0.69	1.03e-39	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4268898	0.552	rs11125454	chr2:24373669	T/C	cg20701182	chr2:24300061	SF3B14	-0.38	-5.28	-0.31	2.72e-7	Asthma;
CESC	cis	rs11997175	0.967	rs11993169	chr8:33738004	G/T	ch.8.33884649F	chr8:33765107	NA	0.66	8.42	0.46	2.34e-15	Body mass index;
CESC	cis	rs4654899	0.931	rs58762579	chr1:21257831	G/A	cg05370193	chr1:21551575	ECE1	0.36	5.3	0.31	2.43e-7	Superior frontal gyrus grey matter volume;
CESC	cis	rs61996546	0.622	rs12901009	chr15:26855181	C/G	cg15066197	chr15:26874202	GABRB3	-0.35	-5.19	-0.3	4.1e-7	Response to methotrexate in juvenile idiopathic arthritis;
CESC	cis	rs2635047	0.967	rs2684843	chr18:44726260	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.48	6.65	0.38	1.66e-10	Educational attainment;
CESC	cis	rs17376456	0.825	rs17314797	chr5:93234845	T/A	cg21475434	chr5:93447410	FAM172A	0.77	6.77	0.38	8.36e-11	Diabetic retinopathy;
CESC	cis	rs4523957	0.928	rs216179	chr17:2168878	T/A	cg16513277	chr17:2031491	SMG6	0.59	8.06	0.44	2.6e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs9905704	0.633	rs2526369	chr17:56469113	T/C	cg12560992	chr17:57184187	TRIM37	-0.61	-5.75	-0.33	2.49e-8	Testicular germ cell tumor;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10293422	chr8:17434503	PDGFRL	-0.57	-6.55	-0.37	2.99e-10	Gut microbiome composition (summer);
CESC	cis	rs2075371	0.965	rs2544216	chr7:133987902	G/A	cg00033643	chr7:134001901	SLC35B4	0.44	5.71	0.33	3.05e-8	Mean platelet volume;
CESC	cis	rs12313068	0.709	rs11064912	chr12:110505699	A/T	cg12870014	chr12:110450643	ANKRD13A	-0.8	-9.45	-0.5	1.91e-18	Intelligence (multi-trait analysis);
CESC	cis	rs12500824	0.564	rs7660503	chr4:77319044	A/G	cg20311846	chr4:77356250	SHROOM3	0.39	7.5	0.42	9.73e-13	Coronary artery disease;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg14544983	chr19:47248940	FKRP;STRN4	-0.43	-6.06	-0.35	4.67e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs2274273	1.000	rs1047556	chr14:55600282	A/T	cg04306507	chr14:55594613	LGALS3	0.28	5.28	0.31	2.63e-7	Protein biomarker;
CESC	cis	rs3820928	0.605	rs4281898	chr2:227855493	A/C	cg05526886	chr2:227700861	RHBDD1	-0.48	-6.43	-0.37	5.76e-10	Pulmonary function;
CESC	cis	rs67478160	0.643	rs3742369	chr14:104251276	T/C	cg08213375	chr14:104286397	PPP1R13B	0.55	10.97	0.56	2.52e-23	Schizophrenia;
CESC	cis	rs2842992	0.662	rs2273826	chr6:160211421	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.77	11.06	0.56	1.26e-23	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs561341	1.000	rs483301	chr17:30293398	G/T	cg23018236	chr17:30244563	NA	-0.55	-5.31	-0.31	2.37e-7	Hip circumference adjusted for BMI;
CESC	cis	rs3015497	0.527	rs2934670	chr14:51153409	G/A	cg26011998	chr14:51135199	SAV1	-0.57	-6.36	-0.36	8.78e-10	Mean platelet volume;
CESC	cis	rs7809950	0.954	rs2189839	chr7:107230026	A/G	cg23024343	chr7:107201750	COG5	0.41	5.68	0.33	3.5e-8	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12568633	chr10:73533407	CDH23;C10orf54	0.64	7.8	0.43	1.42e-13	Gut microbiome composition (summer);
CESC	cis	rs7193541	0.673	rs12716769	chr16:74652537	T/C	cg01733217	chr16:74700730	RFWD3	1.06	20.52	0.78	1.11e-56	Multiple myeloma;
CESC	cis	rs4853012	0.838	rs72911122	chr2:74344119	C/G	cg05890377	chr2:74357713	NA	0.77	10.48	0.54	9.95e-22	Gestational age at birth (maternal effect);
CESC	cis	rs4979906	0.920	rs11002239	chr10:79443836	A/C	cg00983440	chr10:79422392	NA	-0.48	-5.1	-0.3	6.57e-7	Mortality in heart failure;
CESC	cis	rs863345	0.526	rs857724	chr1:158607372	C/T	cg12129480	chr1:158549410	OR10X1	-0.29	-5.51	-0.32	8.53e-8	Pneumococcal bacteremia;
CESC	cis	rs9393777	0.920	rs34150729	chr6:27388754	T/C	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.85	5.46	0.32	1.08e-7	Intelligence (multi-trait analysis);
CESC	cis	rs826838	0.967	rs11169169	chr12:39093153	A/C	cg13010199	chr12:38710504	ALG10B	0.57	7.95	0.44	5.42e-14	Heart rate;
CESC	cis	rs10463316	0.894	rs7719630	chr5:150760961	C/T	cg03212797	chr5:150827313	SLC36A1	-0.46	-6.02	-0.35	5.83e-9	Metabolite levels (Pyroglutamine);
CESC	cis	rs9611565	0.659	rs9611609	chr22:41945357	C/A	cg06481639	chr22:41940642	POLR3H	-0.62	-6.61	-0.38	2.12e-10	Vitiligo;
CESC	cis	rs7618915	0.508	rs11717043	chr3:52656092	A/T	cg17372223	chr3:52568218	NT5DC2	0.42	6.35	0.36	9.4e-10	Bipolar disorder;
CESC	cis	rs9790314	0.586	rs11710916	chr3:161130070	A/G	cg03342759	chr3:160939853	NMD3	-0.42	-5.86	-0.34	1.34e-8	Morning vs. evening chronotype;
CESC	cis	rs9611565	0.879	rs2235845	chr22:41729294	T/G	cg06481639	chr22:41940642	POLR3H	-0.46	-5.29	-0.31	2.55e-7	Vitiligo;
CESC	cis	rs10504229	0.683	rs7827014	chr8:58132230	G/A	cg21724239	chr8:58056113	NA	0.58	5.95	0.34	8.29e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs909341	0.629	rs3761124	chr20:62288752	T/C	cg03999872	chr20:62272968	STMN3	0.56	5.43	0.32	1.27e-7	Atopic dermatitis;
CESC	cis	rs11048434	0.761	rs12827055	chr12:9130861	G/T	cg23795048	chr12:9217529	LOC144571	0.34	5.05	0.3	8.31e-7	Sjögren's syndrome;
CESC	cis	rs13108904	0.901	rs6826029	chr4:1307689	A/G	cg16405210	chr4:1374714	KIAA1530	-0.48	-6.11	-0.35	3.56e-9	Obesity-related traits;
CESC	cis	rs736408	0.609	rs2268025	chr3:52795224	A/T	cg05564831	chr3:52568323	NT5DC2	0.42	6.19	0.36	2.26e-9	Bipolar disorder;
CESC	cis	rs12620999	0.941	rs7593758	chr2:237980920	G/T	cg23555395	chr2:238036564	NA	-0.42	-6.05	-0.35	4.97e-9	Systemic lupus erythematosus;
CESC	trans	rs11098499	0.754	rs9991959	chr4:120253773	C/T	cg25214090	chr10:38739885	LOC399744	-0.62	-8.81	-0.48	1.73e-16	Corneal astigmatism;
CESC	cis	rs7811142	0.830	rs11761426	chr7:99956893	A/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.13	11.76	0.59	5.69e-26	Platelet count;
CESC	cis	rs757110	0.745	rs2074311	chr11:17421860	A/G	cg15432903	chr11:17409602	KCNJ11	0.55	7.55	0.42	7.22e-13	Type 2 diabetes;
CESC	cis	rs265548	0.538	rs36688	chr19:17911212	A/C	cg16744531	chr19:17905626	B3GNT3	0.6	8.23	0.45	8.48e-15	Tumor biomarkers;
CESC	trans	rs11098499	0.954	rs6849171	chr4:120409549	G/A	cg25214090	chr10:38739885	LOC399744	0.71	10.21	0.53	7.28e-21	Corneal astigmatism;
CESC	cis	rs10504229	1.000	rs55944282	chr8:58180821	A/G	cg22535103	chr8:58192502	C8orf71	-1.05	-13.27	-0.63	3.63e-31	Developmental language disorder (linguistic errors);
CESC	cis	rs28386778	0.799	rs12450683	chr17:61984299	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.67	9.73	0.51	2.43e-19	Prudent dietary pattern;
CESC	cis	rs7818688	0.697	rs58282276	chr8:95985391	G/A	cg16049864	chr8:95962084	TP53INP1	0.57	5.73	0.33	2.68e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg09122683	chr20:56285701	PMEPA1	-0.48	-6.27	-0.36	1.46e-9	Asthma;
CESC	cis	rs10504073	0.647	rs9643394	chr8:50014427	A/G	cg00325661	chr8:49890786	NA	0.52	7.93	0.44	6.02e-14	Blood metabolite ratios;
CESC	cis	rs9649213	0.593	rs3801256	chr7:97992095	C/G	cg00277769	chr7:97922759	BAIAP2L1	-0.33	-5.41	-0.32	1.41e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7666738	0.830	rs2865951	chr4:99040191	C/T	cg17366294	chr4:99064904	C4orf37	0.6	8.52	0.46	1.23e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs977987	0.843	rs11649638	chr16:75488285	G/A	cg03315344	chr16:75512273	CHST6	0.44	6.44	0.37	5.73e-10	Dupuytren's disease;
CESC	cis	rs4803468	1.000	rs10422956	chr19:41901261	C/T	cg08477640	chr19:41863820	B9D2	0.38	5.05	0.3	8.16e-7	Height;
CESC	cis	rs9733	0.596	rs12086630	chr1:150650955	T/C	cg04414720	chr1:150670196	GOLPH3L	0.63	9.01	0.48	4.11e-17	Tonsillectomy;
CESC	cis	rs6445967	1.000	rs14927	chr3:58305033	G/T	cg23715586	chr3:58305044	RPP14	-0.43	-7.1	-0.4	1.15e-11	Platelet count;
CESC	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg06873352	chr17:61820015	STRADA	0.7	12.33	0.6	6.27e-28	Prudent dietary pattern;
CESC	cis	rs9916302	0.706	rs12947506	chr17:37707592	A/G	cg20243544	chr17:37824526	PNMT	0.5	5.07	0.3	7.55e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs9355610	0.609	rs9366076	chr6:167373708	C/T	cg23791538	chr6:167370224	RNASET2	0.49	5.81	0.34	1.75e-8	Graves' disease;
CESC	cis	rs10870270	1.000	rs10870292	chr10:133770782	G/C	cg17892150	chr10:133769511	PPP2R2D	-0.85	-12.49	-0.61	1.79e-28	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs798554	0.757	rs2533882	chr7:2846894	G/T	cg19346786	chr7:2764209	NA	-0.52	-7.38	-0.41	1.99e-12	Height;
CESC	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg03188948	chr7:1209495	NA	0.7	6.71	0.38	1.2e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs6541297	0.775	rs4846910	chr1:230291441	C/A	cg20703242	chr1:230279135	GALNT2	0.68	9.26	0.49	6.99e-18	Coronary artery disease;
CESC	cis	rs12701220	0.655	rs9638973	chr7:1133678	A/G	cg23978390	chr7:1156363	C7orf50	0.65	6.41	0.37	6.82e-10	Bronchopulmonary dysplasia;
CESC	cis	rs2836950	0.501	rs2070865	chr21:40715519	C/T	cg11890956	chr21:40555474	PSMG1	-0.59	-7.69	-0.43	2.98e-13	Menarche (age at onset);
CESC	cis	rs9361491	0.657	rs9352625	chr6:79454754	G/A	cg05283184	chr6:79620031	NA	-0.34	-5.04	-0.3	8.67e-7	Intelligence (multi-trait analysis);
CESC	cis	rs1348850	0.645	rs10181259	chr2:178428256	C/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.55	5.83	0.34	1.58e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs854765	0.583	rs5002487	chr17:17832460	A/G	cg16928487	chr17:17741425	SREBF1	-0.58	-10.17	-0.53	1e-20	Total body bone mineral density;
CESC	cis	rs34779708	0.931	rs2384275	chr10:35297142	A/G	cg04310649	chr10:35416472	CREM	-0.52	-6.34	-0.36	9.99e-10	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs35362007	0.530	rs10484053	chr14:96011645	C/T	cg13511115	chr14:96000878	GLRX5;SNHG10;SCARNA13	0.66	5.36	0.31	1.81e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	cis	rs6088580	0.634	rs6058052	chr20:33047084	A/G	cg24642439	chr20:33292090	TP53INP2	0.52	6.87	0.39	4.68e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs7666738	0.830	rs28444709	chr4:99028496	A/T	cg24818145	chr4:99064322	C4orf37	0.39	5.09	0.3	6.95e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs617219	0.889	rs1533760	chr5:78438937	A/C	cg22188827	chr5:78429774	NA	-0.43	-5.1	-0.3	6.62e-7	Betaine levels in individuals undergoing cardiac evaluation;
CESC	cis	rs807669	0.903	rs2854643	chr22:19189706	T/C	cg02655711	chr22:19163373	SLC25A1	0.95	14.13	0.66	3.59e-34	Metabolite levels;
CESC	cis	rs763121	0.889	rs6001209	chr22:39121252	C/T	cg06544989	chr22:39130855	UNC84B	-0.46	-7.75	-0.43	1.98e-13	Menopause (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07150772	chr14:90864620	CALM1	-0.58	-6.64	-0.38	1.72e-10	Gut microbiome composition (summer);
CESC	cis	rs9457247	1.000	rs4710147	chr6:167374239	G/A	cg25258033	chr6:167368657	RNASET2	-0.42	-6.29	-0.36	1.31e-9	Crohn's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02164407	chr11:8008755	EIF3F	-0.56	-6.16	-0.35	2.62e-9	Gut microbiome composition (summer);
CESC	cis	rs561341	0.769	rs12941700	chr17:30185022	A/G	cg00745463	chr17:30367425	LRRC37B	0.59	5.62	0.33	4.73e-8	Hip circumference adjusted for BMI;
CESC	cis	rs6540559	0.673	rs6694552	chr1:209976459	A/C	cg10074409	chr1:209979377	IRF6	0.4	5.32	0.31	2.16e-7	Cleft lip with or without cleft palate;
CESC	cis	rs10979	0.965	rs9376758	chr6:143886878	G/A	cg25407410	chr6:143891975	LOC285740	-0.61	-9.2	-0.49	1.08e-17	Hypospadias;
CESC	cis	rs3733418	0.799	rs13151735	chr4:165932516	G/C	cg10852876	chr4:165953100	TRIM60	-0.48	-5.72	-0.33	2.88e-8	Obesity-related traits;
CESC	cis	rs763121	0.706	rs3827356	chr22:39064806	G/T	cg14440974	chr22:39074834	NA	0.35	5.06	0.3	7.98e-7	Menopause (age at onset);
CESC	cis	rs7552404	0.924	rs2275378	chr1:76198436	T/C	cg22875332	chr1:76189707	ACADM	0.71	9.78	0.51	1.76e-19	Blood metabolite levels;Acylcarnitine levels;
CESC	trans	rs2727020	0.521	rs10839299	chr11:49573981	C/T	cg03929089	chr4:120376271	NA	-0.71	-8.18	-0.45	1.21e-14	Coronary artery disease;
CESC	cis	rs9790314	1.000	rs1600209	chr3:161038217	A/T	cg03342759	chr3:160939853	NMD3	-0.48	-6.25	-0.36	1.61e-9	Morning vs. evening chronotype;
CESC	cis	rs8180040	0.932	rs1038394	chr3:47464122	A/G	cg27129171	chr3:47204927	SETD2	0.64	9.68	0.51	3.54e-19	Colorectal cancer;
CESC	cis	rs7927771	0.864	rs2053979	chr11:47439444	A/G	cg18512352	chr11:47633146	NA	-0.5	-7.08	-0.4	1.31e-11	Subjective well-being;
CESC	cis	rs4665809	0.652	rs4665832	chr2:26404775	A/G	cg08470875	chr2:26401718	FAM59B	-0.7	-7.42	-0.41	1.55e-12	Gut microbiome composition (summer);
CESC	cis	rs801193	0.569	rs35070132	chr7:66238083	C/T	cg12463550	chr7:65579703	CRCP	0.49	6.29	0.36	1.29e-9	Aortic root size;
CESC	trans	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg04282206	chr17:62833786	PLEKHM1P	0.57	6.54	0.37	3.22e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs9311474	0.507	rs6787154	chr3:52784416	C/T	cg05564831	chr3:52568323	NT5DC2	0.46	7.21	0.41	5.71e-12	Electroencephalogram traits;
CESC	cis	rs3136441	1.000	rs2290883	chr11:46890197	A/G	cg25783544	chr11:47291846	MADD	-0.55	-5.3	-0.31	2.45e-7	HDL cholesterol;
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg01989157	chr22:40742702	ADSL	-0.4	-6.04	-0.35	5.22e-9	Vertical cup-disc ratio;
CESC	cis	rs701145	0.556	rs355779	chr3:153977253	T/C	cg16511985	chr3:153974050	SGEF	0.44	5.9	0.34	1.1e-8	Coronary artery disease;
CESC	cis	rs4950322	0.570	rs72691102	chr1:146772888	A/T	cg22381352	chr1:146742008	CHD1L	-0.46	-5.05	-0.3	8.32e-7	Protein quantitative trait loci;
CESC	cis	rs7000551	0.715	rs2461477	chr8:22378314	A/G	cg12081754	chr8:22256438	SLC39A14	0.42	5.61	0.33	5.13e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CESC	cis	rs367943	0.712	rs13188946	chr5:112722855	C/T	cg12552261	chr5:112820674	MCC	0.39	5.24	0.31	3.25e-7	Type 2 diabetes;
CESC	cis	rs4665809	1.000	rs2053367	chr2:26293413	T/C	cg22920501	chr2:26401640	FAM59B	-0.69	-8.4	-0.46	2.74e-15	Gut microbiome composition (summer);
CESC	cis	rs9611565	0.694	rs9607816	chr22:41950897	G/A	cg06634786	chr22:41940651	POLR3H	-0.63	-6.61	-0.38	2.1e-10	Vitiligo;
CESC	cis	rs208520	0.690	rs6932475	chr6:66863155	G/A	cg07460842	chr6:66804631	NA	-1.0	-13.46	-0.64	8.08e-32	Exhaled nitric oxide output;
CESC	cis	rs1348850	0.793	rs6736390	chr2:178480314	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.58	7.37	0.41	2.17e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04391736	chr16:69373674	COG8;NIP7	-0.61	-7.3	-0.41	3.28e-12	Gut microbiome composition (summer);
CESC	trans	rs116095464	0.558	rs7356561	chr5:284381	G/C	cg00938859	chr5:1591904	SDHAP3	0.65	7.03	0.4	1.73e-11	Breast cancer;
CESC	cis	rs9311474	0.508	rs7625743	chr3:52606366	C/G	cg18404041	chr3:52824283	ITIH1	-0.39	-6.73	-0.38	1.03e-10	Electroencephalogram traits;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg09008928	chr6:24667597	ACOT13;TTRAP	-0.46	-6.13	-0.35	3.2e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs4595586	0.679	rs35743713	chr12:39318539	C/G	cg26384229	chr12:38710491	ALG10B	0.45	6.69	0.38	1.36e-10	Morning vs. evening chronotype;
CESC	cis	rs6754311	0.731	rs748841	chr2:136558157	C/T	cg07169764	chr2:136633963	MCM6	-0.66	-8.09	-0.45	2.12e-14	Mosquito bite size;
CESC	cis	rs4454254	0.736	rs11779476	chr8:141065953	T/C	cg06693505	chr8:141057453	TRAPPC9	-0.34	-5.83	-0.34	1.57e-8	Pulse pressure;
CESC	cis	rs9311474	0.508	rs11718420	chr3:52611413	T/C	cg18099408	chr3:52552593	STAB1	-0.36	-6.11	-0.35	3.63e-9	Electroencephalogram traits;
CESC	cis	rs7927771	1.000	rs35624992	chr11:47615798	G/C	cg18512352	chr11:47633146	NA	-0.61	-9.33	-0.5	4.47e-18	Subjective well-being;
CESC	cis	rs34172651	0.517	rs11639856	chr16:24788645	A/T	cg06028605	chr16:24865363	SLC5A11	-0.48	-7.12	-0.4	9.85e-12	Intelligence (multi-trait analysis);
CESC	cis	rs7772486	0.875	rs9390371	chr6:146363180	A/G	cg05347473	chr6:146136440	FBXO30	0.48	6.51	0.37	3.73e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4975709	0.589	rs4975744	chr5:1860049	A/G	cg07747251	chr5:1868357	NA	0.31	5.21	0.3	3.89e-7	Cardiovascular disease risk factors;
CESC	cis	rs7631605	0.905	rs9832423	chr3:37176116	A/G	cg22985146	chr3:37219077	LRRFIP2	-0.32	-5.14	-0.3	5.38e-7	Cerebrospinal P-tau181p levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13609937	chr9:133588314	ABL1	0.66	7.36	0.41	2.26e-12	Gut microbiome composition (summer);
CESC	cis	rs7772486	0.790	rs2250387	chr6:146205233	C/T	cg05347473	chr6:146136440	FBXO30	0.56	7.22	0.41	5.39e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9910055	0.659	rs227578	chr17:42210189	C/A	cg10896456	chr17:42255109	ASB16;C17orf65	-0.49	-7.29	-0.41	3.63e-12	Total body bone mineral density;
CESC	cis	rs854765	0.551	rs6502626	chr17:17849450	C/T	cg09796270	chr17:17721594	SREBF1	0.4	5.46	0.32	1.07e-7	Total body bone mineral density;
CESC	trans	rs57221529	0.766	rs17497684	chr5:558307	T/C	cg25482853	chr8:67687455	SGK3	1.11	11.94	0.59	1.39e-26	Lung disease severity in cystic fibrosis;
CESC	cis	rs3857067	0.967	rs899135	chr4:95019816	C/A	cg11021082	chr4:95130006	SMARCAD1	-0.5	-7.53	-0.42	8.12e-13	QT interval;
CESC	cis	rs736408	0.562	rs2072390	chr3:52780509	A/T	cg07507251	chr3:52567010	NT5DC2	0.35	6.12	0.35	3.44e-9	Bipolar disorder;
CESC	cis	rs3820928	0.845	rs13415319	chr2:227878936	G/C	cg11843606	chr2:227700838	RHBDD1	-0.45	-5.62	-0.33	4.9e-8	Pulmonary function;
CESC	cis	rs7589728	0.514	rs12465706	chr2:88467459	C/A	cg07952391	chr2:88470173	THNSL2	0.63	6.17	0.35	2.55e-9	Plasma clusterin levels;
CESC	cis	rs2380220	0.872	rs115871915	chr6:95934180	T/C	cg15832292	chr6:96025679	MANEA	-0.64	-5.71	-0.33	2.99e-8	Behavioural disinhibition (generation interaction);
CESC	cis	rs17253792	0.822	rs75995456	chr14:56073194	A/G	cg01858014	chr14:56050164	KTN1	-0.93	-7.33	-0.41	2.71e-12	Putamen volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05254078	chr15:34502482	C15orf29	0.55	6.04	0.35	5.08e-9	Gut microbiome composition (summer);
CESC	cis	rs11690935	0.959	rs35391289	chr2:172634983	A/C	cg13550731	chr2:172543902	DYNC1I2	-0.96	-14.08	-0.65	5.31e-34	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22295628	chr17:1733433	RPA1;SMYD4	0.54	6.14	0.35	3.06e-9	Gut microbiome composition (summer);
CESC	cis	rs3096299	0.658	rs3934737	chr16:89560209	G/A	cg00750074	chr16:89608354	SPG7	-0.44	-6.39	-0.37	7.45e-10	Multiple myeloma (IgH translocation);
CESC	cis	rs9733	0.596	rs11586422	chr1:150679358	C/T	cg04414720	chr1:150670196	GOLPH3L	0.62	8.86	0.48	1.21e-16	Tonsillectomy;
CESC	trans	rs561341	0.769	rs8074383	chr17:30178793	C/T	cg27661571	chr11:113659931	NA	0.66	6.04	0.35	5.3300000000000004e-09	Hip circumference adjusted for BMI;
CESC	cis	rs17253792	0.822	rs10142497	chr14:56047948	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	-0.85	-6.54	-0.37	3.2e-10	Putamen volume;
CESC	cis	rs708547	0.874	rs1614251	chr4:57891386	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.67	7.71	0.43	2.47e-13	Response to bleomycin (chromatid breaks);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01776877	chr11:86666372	FZD4	0.55	6.56	0.37	2.75e-10	Gut microbiome composition (summer);
CESC	cis	rs9902453	1.000	rs12600855	chr17:28279591	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	8.49	0.46	1.53e-15	Coffee consumption (cups per day);
CESC	trans	rs6987853	0.830	rs4361746	chr8:42355041	C/T	cg27650678	chr11:66636318	PC	-0.46	-6.11	-0.35	3.45e-9	Mean corpuscular hemoglobin concentration;
CESC	cis	rs1395	0.744	rs62130709	chr2:27505782	C/T	cg22903471	chr2:27725779	GCKR	-0.5	-6.08	-0.35	4.12e-9	Blood metabolite levels;
CESC	cis	rs780096	0.546	rs35073769	chr2:27731376	C/T	cg02592271	chr2:27665507	KRTCAP3	-0.32	-6.29	-0.36	1.28e-9	Total body bone mineral density;
CESC	cis	rs929354	0.713	rs7798816	chr7:156940574	A/G	cg05182265	chr7:156933206	UBE3C	-0.49	-7.03	-0.4	1.76e-11	Body mass index;
CESC	cis	rs798554	0.610	rs1182209	chr7:2808595	C/T	cg19717773	chr7:2847554	GNA12	-0.56	-8.77	-0.47	2.14e-16	Height;
CESC	cis	rs3812762	0.912	rs10769953	chr11:8778352	A/G	cg03980550	chr11:8754370	ST5	0.35	5.03	0.3	8.9e-7	Hypospadias;
CESC	cis	rs941873	0.868	rs4980063	chr10:81105844	A/T	cg08514558	chr10:81106712	PPIF	0.33	5.63	0.33	4.5e-8	Height;
CESC	cis	rs35955747	0.871	rs2013254	chr22:31690803	G/A	cg25791279	chr22:32026902	PISD	-0.5	-6.01	-0.35	6.17e-9	Neutrophil count;Sum basophil neutrophil counts;
CESC	cis	rs8062405	1.000	rs28403629	chr16:28854769	A/G	cg08761264	chr16:28874980	SH2B1	-0.47	-5.85	-0.34	1.42e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs9815354	0.812	rs73071328	chr3:41810055	A/C	cg03022575	chr3:42003672	ULK4	0.68	6.06	0.35	4.7e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs4561483	0.864	rs190461	chr16:12005745	A/G	cg08843971	chr16:11963173	GSPT1	-0.42	-5.72	-0.33	2.9e-8	Testicular germ cell tumor;
CESC	cis	rs17433780	0.808	rs12125301	chr1:89508501	G/A	cg09516651	chr1:89888402	LOC400759	0.7	10.59	0.55	4.26e-22	Carotid intima media thickness;
CESC	cis	rs7552404	0.924	rs1251075	chr1:76190569	C/G	cg10523679	chr1:76189770	ACADM	0.75	10.03	0.52	2.82e-20	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs2836950	0.805	rs2836961	chr21:40627020	A/C	cg17971929	chr21:40555470	PSMG1	-0.59	-7.3	-0.41	3.4e-12	Menarche (age at onset);
CESC	cis	rs13191362	0.872	rs67712738	chr6:163245768	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.5	5.24	0.31	3.3e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs4664293	1.000	rs10204535	chr2:160463692	C/T	cg08347373	chr2:160653686	CD302	-0.31	-5.07	-0.3	7.41e-7	Monocyte percentage of white cells;
CESC	cis	rs1707322	0.927	rs6690386	chr1:46253011	C/T	cg06784218	chr1:46089804	CCDC17	0.38	6.59	0.38	2.37e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7178572	1.000	rs952471	chr15:77776498	C/G	cg22256960	chr15:77711686	NA	-0.6	-8.09	-0.44	2.19e-14	Type 2 diabetes;
CESC	cis	rs12476592	0.602	rs6708804	chr2:63807269	G/A	cg17519650	chr2:63277830	OTX1	-0.46	-5.22	-0.31	3.57e-7	Childhood ear infection;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg12049088	chr22:36784491	MYH9	-0.43	-6.06	-0.35	4.65e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs875971	0.862	rs10278014	chr7:66051264	C/T	cg12463550	chr7:65579703	CRCP	-0.5	-6.34	-0.36	9.71e-10	Aortic root size;
CESC	cis	rs2836950	0.565	rs2836942	chr21:40591381	A/G	cg11890956	chr21:40555474	PSMG1	-0.61	-8.43	-0.46	2.25e-15	Menarche (age at onset);
CESC	cis	rs4835473	0.897	rs11100802	chr4:144621199	A/G	cg25736465	chr4:144833511	NA	-0.36	-5.32	-0.31	2.18e-7	Immature fraction of reticulocytes;
CESC	cis	rs2806561	0.808	rs12128178	chr1:23354814	C/T	cg12483005	chr1:23474871	LUZP1	-0.34	-5.33	-0.31	2.06e-7	Height;
CESC	cis	rs4481887	0.741	rs6682953	chr1:248535626	T/C	cg26353448	chr1:248524236	OR2T4	-0.38	-5.38	-0.31	1.67e-7	Common traits (Other);
CESC	cis	rs2635047	0.967	rs2684843	chr18:44726260	T/A	cg19077165	chr18:44547161	KATNAL2	-0.44	-5.98	-0.35	7.03e-9	Educational attainment;
CESC	cis	rs6912958	0.559	rs445434	chr6:88041849	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.76	11.13	0.56	7.1e-24	Monocyte percentage of white cells;
CESC	cis	rs67311347	1.000	rs6599094	chr3:40399593	A/G	cg24209194	chr3:40518798	ZNF619	0.43	5.68	0.33	3.55e-8	Renal cell carcinoma;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21005948	chr18:46065258	KIAA0427	0.56	6.67	0.38	1.48e-10	Gut microbiome composition (summer);
CESC	cis	rs5769765	0.773	rs9616208	chr22:50313359	G/A	cg26441486	chr22:50317300	CRELD2	0.42	5.25	0.31	3.07e-7	Schizophrenia;
CESC	cis	rs11098499	0.863	rs3822190	chr4:120428098	G/A	cg24375607	chr4:120327624	NA	0.44	5.25	0.31	3.13e-7	Corneal astigmatism;
CESC	cis	rs2304069	0.601	rs216143	chr5:149444147	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.88	10.06	0.53	2.2e-20	HIV-1 control;
CESC	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	7.58	0.42	5.78e-13	Prudent dietary pattern;
CESC	cis	rs568617	0.716	rs77779142	chr11:65599656	C/T	cg04055107	chr11:65626734	MUS81;CFL1	0.93	8.33	0.46	4.51e-15	Crohn's disease;
CESC	cis	rs6912958	0.559	rs107690	chr6:88069352	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.73	-11.18	-0.57	4.97e-24	Monocyte percentage of white cells;
CESC	cis	rs4704187	0.687	rs4704196	chr5:74537606	A/G	cg03227963	chr5:74354835	NA	0.27	5.04	0.3	8.67e-7	Response to amphetamines;
CESC	cis	rs854765	0.583	rs8080823	chr17:17864048	T/C	cg04398451	chr17:18023971	MYO15A	-0.67	-9.28	-0.5	6.3e-18	Total body bone mineral density;
CESC	cis	rs911186	0.786	rs3800307	chr6:27185792	A/T	cg12292205	chr6:26970375	C6orf41	-0.55	-6.27	-0.36	1.47e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs2075371	0.966	rs722657	chr7:133994956	T/C	cg11752832	chr7:134001865	SLC35B4	0.54	7.01	0.4	1.96e-11	Mean platelet volume;
CESC	trans	rs1459104	0.571	rs10459012	chr11:55091574	C/A	cg15704280	chr7:45808275	SEPT13	0.58	6.04	0.35	5.24e-9	Body mass index;
CESC	trans	rs801193	0.844	rs7779971	chr7:66161790	T/C	cg26939375	chr7:64535504	NA	0.64	8.77	0.47	2.19e-16	Aortic root size;
CESC	cis	rs7772486	0.875	rs932522	chr6:146374026	A/G	cg05347473	chr6:146136440	FBXO30	-0.53	-6.99	-0.39	2.18e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4141404	0.818	rs5997897	chr22:31570436	G/A	cg13145458	chr22:31556086	RNF185	0.46	5.79	0.34	1.94e-8	Paclitaxel-induced neuropathy;
CESC	cis	rs7618915	0.547	rs62253700	chr3:52625019	T/A	cg07507251	chr3:52567010	NT5DC2	0.41	7.11	0.4	1.05e-11	Bipolar disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12897799	chr12:65175296	NA	-0.56	-6.27	-0.36	1.45e-9	Gut microbiome composition (summer);
CESC	cis	rs3126085	0.935	rs1858479	chr1:152294823	A/T	cg03465714	chr1:152285911	FLG	0.5	5.71	0.33	2.96e-8	Atopic dermatitis;
CESC	cis	rs13256369	0.756	rs13280759	chr8:8562995	G/T	cg00074818	chr8:8560427	CLDN23	0.38	5.46	0.32	1.1e-7	Obesity-related traits;
CESC	cis	rs6860806	0.661	rs4705927	chr5:131578608	C/G	cg22638593	chr5:131593259	PDLIM4	0.4	5.22	0.31	3.69e-7	Breast cancer;
CESC	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg24642844	chr7:1081250	C7orf50	-0.75	-8.99	-0.48	4.94e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs10716881	1	rs10716881	chr12:57038170	GA/G	cg05584118	chr12:57595605	LRP1	0.36	5.13	0.3	5.63e-7	High light scatter reticulocyte count;
CESC	cis	rs12824058	0.831	rs12314111	chr12:130813663	G/T	cg23887609	chr12:130822674	PIWIL1	0.44	5.75	0.33	2.39e-8	Menopause (age at onset);
CESC	cis	rs13191362	1.000	rs34931503	chr6:163003876	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.5	5.17	0.3	4.64e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg27094323	chr7:1216898	NA	-0.37	-5.03	-0.3	8.9e-7	Longevity;Endometriosis;
CESC	cis	rs7818688	1.000	rs6989862	chr8:96027568	T/C	cg16049864	chr8:95962084	TP53INP1	0.6	5.77	0.33	2.25e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs514406	0.763	rs7535088	chr1:53215042	A/G	cg16325326	chr1:53192061	ZYG11B	-0.89	-15.22	-0.68	5.28e-38	Monocyte count;
CESC	cis	rs2066819	1.000	rs79824801	chr12:56728137	T/C	cg26714650	chr12:56694279	CS	-1.39	-9.17	-0.49	1.33e-17	Psoriasis vulgaris;
CESC	trans	rs12356475	0.710	rs10822686	chr10:67733250	C/T	cg02550200	chr17:5389462	MIS12;DERL2	0.54	6.07	0.35	4.52e-9	Psoriatic arthritis;
CESC	cis	rs6800768	0.633	rs59374114	chr3:24112202	G/T	cg10674438	chr3:24145617	LOC152024	-0.43	-5.98	-0.34	7.27e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs7584330	0.704	rs72620820	chr2:238358844	G/A	cg14458575	chr2:238380390	NA	0.88	11.24	0.57	3.14e-24	Prostate cancer;
CESC	cis	rs4563143	0.514	rs55727361	chr19:29300415	A/T	cg12756686	chr19:29218302	NA	0.53	6.18	0.35	2.42e-9	Methadone dose in opioid dependence;
CESC	cis	rs4812048	0.649	rs6070706	chr20:57628239	C/T	cg14073986	chr20:57617431	SLMO2	0.7	5.75	0.33	2.51e-8	Mean platelet volume;
CESC	cis	rs172166	0.637	rs1225592	chr6:28150242	G/A	cg26335602	chr6:28129616	ZNF389	0.37	5.52	0.32	7.92e-8	Cardiac Troponin-T levels;
CESC	cis	rs1395	0.778	rs72810794	chr2:27401260	C/T	cg22903471	chr2:27725779	GCKR	-0.44	-5.41	-0.32	1.38e-7	Blood metabolite levels;
CESC	cis	rs769267	0.965	rs6511026	chr19:19391402	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.43	5.33	0.31	2.11e-7	Tonsillectomy;
CESC	cis	rs9611565	0.512	rs964898	chr22:42142306	C/T	cg06634786	chr22:41940651	POLR3H	-0.67	-6.49	-0.37	4.13e-10	Vitiligo;
CESC	cis	rs2777491	0.915	rs9302109	chr15:41612180	G/T	cg02330683	chr15:41787940	ITPKA	0.45	6.56	0.37	2.73e-10	Ulcerative colitis;
CESC	cis	rs2243480	1.000	rs316334	chr7:65602126	G/T	cg13147721	chr7:65941812	NA	-0.98	-9.24	-0.49	8.33e-18	Diabetic kidney disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19263974	chr12:3103878	TEAD4	-0.62	-7.28	-0.41	3.71e-12	Gut microbiome composition (summer);
CESC	cis	rs4665809	0.793	rs6546715	chr2:26261520	G/A	cg22920501	chr2:26401640	FAM59B	-0.66	-7.9	-0.44	7.42e-14	Gut microbiome composition (summer);
CESC	cis	rs72945132	0.882	rs72947012	chr11:70149472	G/A	cg14191688	chr11:70257035	CTTN	0.47	5.65	0.33	4.1e-8	Coronary artery disease;
CESC	cis	rs9322193	0.962	rs2342764	chr6:150156204	G/A	cg04369109	chr6:150039330	LATS1	-0.47	-6.47	-0.37	4.63e-10	Lung cancer;
CESC	trans	rs875971	0.660	rs10215132	chr7:66054406	C/A	cg26939375	chr7:64535504	NA	-0.63	-8.53	-0.46	1.17e-15	Aortic root size;
CESC	cis	rs12541635	0.934	rs11776139	chr8:106983966	A/G	cg10147462	chr8:107024639	NA	0.41	5.62	0.33	4.83e-8	Age of smoking initiation;
CESC	cis	rs875971	0.862	rs11773628	chr7:65982631	G/T	cg18252515	chr7:66147081	NA	0.43	5.57	0.32	6.1e-8	Aortic root size;
CESC	cis	rs4919694	0.808	rs80020194	chr10:105035954	A/G	cg04362960	chr10:104952993	NT5C2	0.79	5.87	0.34	1.3e-8	Arsenic metabolism;
CESC	cis	rs6598955	0.671	rs11247914	chr1:26648838	G/T	cg19743891	chr1:26644573	UBXN11;CD52	0.37	5.27	0.31	2.88e-7	Obesity-related traits;
CESC	cis	rs7845219	0.544	rs34293080	chr8:95908078	G/T	cg09323728	chr8:95962352	TP53INP1	-0.35	-6.89	-0.39	4.07e-11	Type 2 diabetes;
CESC	cis	rs2050392	0.624	rs303435	chr10:30731491	T/C	cg25182066	chr10:30743637	MAP3K8	-0.49	-6.5	-0.37	3.93e-10	Inflammatory bowel disease;
CESC	trans	rs875971	0.619	rs12533585	chr7:65984605	G/C	cg26939375	chr7:64535504	NA	0.64	8.73	0.47	2.82e-16	Aortic root size;
CESC	cis	rs6665290	0.901	rs3795453	chr1:227205331	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.15	-24.28	-0.83	2.41e-69	Myeloid white cell count;
CESC	trans	rs11039798	0.544	rs114343057	chr11:48558172	C/T	cg15704280	chr7:45808275	SEPT13	0.66	6.67	0.38	1.46e-10	Axial length;
CESC	cis	rs9733	0.596	rs7412396	chr1:150666797	C/T	cg18016565	chr1:150552671	MCL1	0.36	5.35	0.31	1.93e-7	Tonsillectomy;
CESC	cis	rs6813479	0.523	rs2932114	chr4:137744095	G/A	cg16185213	chr4:137733633	NA	0.37	5.05	0.3	8.19e-7	Longevity;
CESC	cis	rs11723261	0.582	rs6599293	chr4:133027	A/G	cg12746427	chr4:53362	ZNF718;ZNF595	0.5	6.49	0.37	4.3e-10	Immune response to smallpox vaccine (IL-6);
CESC	cis	rs6088580	0.634	rs6059905	chr20:33126946	T/C	cg06115741	chr20:33292138	TP53INP2	0.47	5.92	0.34	1.01e-8	Glomerular filtration rate (creatinine);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18358588	chr6:26660131	ZNF322A	0.53	6.56	0.37	2.83e-10	Gut microbiome composition (summer);
CESC	cis	rs3824867	0.879	rs10742806	chr11:47456226	T/A	cg20307385	chr11:47447363	PSMC3	0.5	6.09	0.35	3.87e-9	Mean corpuscular hemoglobin;
CESC	cis	rs9660180	0.967	rs6687065	chr1:1778469	A/G	cg17747265	chr1:1875780	NA	-0.57	-9.18	-0.49	1.24e-17	Body mass index;
CESC	cis	rs7818688	1.000	rs10103841	chr8:96025904	T/G	cg16049864	chr8:95962084	TP53INP1	0.6	5.77	0.33	2.25e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg04025307	chr7:1156635	C7orf50	0.55	9.79	0.52	1.64e-19	Longevity;Endometriosis;
CESC	cis	rs10791097	0.694	rs11222369	chr11:130744670	A/G	cg12179176	chr11:130786555	SNX19	0.64	9.86	0.52	9.69e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs875971	0.825	rs801202	chr7:66023929	C/T	cg18876405	chr7:65276391	NA	-0.53	-7.22	-0.41	5.6e-12	Aortic root size;
CESC	cis	rs17376456	1.000	rs59472588	chr5:93511981	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.65	5.58	0.32	6.01e-8	Diabetic retinopathy;
CESC	cis	rs1153858	0.887	rs7171163	chr15:45636395	A/C	cg21132104	chr15:45694354	SPATA5L1	0.82	11.02	0.56	1.72e-23	Homoarginine levels;
CESC	cis	rs6963495	0.745	rs818620	chr7:105172685	G/C	cg13798780	chr7:105162888	PUS7	0.62	7.14	0.4	8.93e-12	Bipolar disorder (body mass index interaction);
CESC	cis	rs2439831	0.850	rs11070408	chr15:44034788	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.71	6.68	0.38	1.43e-10	Lung cancer in ever smokers;
CESC	cis	rs1950500	0.565	rs3181248	chr14:24808168	G/A	cg16194253	chr14:24768981	DHRS1;C14orf21	0.55	6.75	0.38	9.16e-11	Height;
CESC	cis	rs6942756	0.744	rs2718088	chr7:128927020	C/A	cg02491457	chr7:128862824	NA	0.62	8.66	0.47	4.73e-16	White matter hyperintensity burden;
CESC	trans	rs2727020	0.538	rs61885230	chr11:49128958	T/C	cg00717180	chr2:96193071	NA	-0.52	-7.24	-0.41	4.77e-12	Coronary artery disease;
CESC	cis	rs11098499	0.644	rs6855918	chr4:120546299	C/T	cg09307838	chr4:120376055	NA	0.74	9.88	0.52	8.51e-20	Corneal astigmatism;
CESC	cis	rs35110281	0.748	rs1584918	chr21:45042419	C/T	cg04455712	chr21:45112962	RRP1B	0.4	5.93	0.34	9.32e-9	Mean corpuscular volume;
CESC	cis	rs3733418	0.860	rs72697987	chr4:165953917	G/A	cg10852876	chr4:165953100	TRIM60	-0.47	-5.48	-0.32	1.01e-7	Obesity-related traits;
CESC	cis	rs881375	0.678	rs7021049	chr9:123683982	G/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.5	7.31	0.41	3.22e-12	Rheumatoid arthritis;
CESC	cis	rs11608355	0.545	rs34737994	chr12:109901621	C/T	cg05360138	chr12:110035743	NA	0.81	8.84	0.48	1.41e-16	Neuroticism;
CESC	cis	rs4523957	0.788	rs11078865	chr17:2109109	T/A	cg16513277	chr17:2031491	SMG6	-0.59	-7.94	-0.44	5.92e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs1799949	1.000	rs12952790	chr17:41299607	A/G	cg23758822	chr17:41437982	NA	1.02	15.64	0.69	1.65e-39	Menopause (age at onset);
CESC	cis	rs10838687	0.736	rs2306353	chr11:47256708	C/T	cg25783544	chr11:47291846	MADD	0.56	6.47	0.37	4.81e-10	Proinsulin levels;
CESC	cis	rs12122100	0.507	rs1925343	chr1:146505535	A/T	cg02487331	chr1:146550467	NA	-0.37	-5.75	-0.33	2.47e-8	HIV-1 control;
CESC	trans	rs673604	0.505	rs676614	chr1:36107510	G/T	cg09747232	chr8:103827049	NA	0.55	6.42	0.37	6.27e-10	Endometrial cancer;
CESC	cis	rs7602441	0.521	rs78567942	chr2:14767845	C/A	cg06545361	chr2:14773388	FAM84A	0.71	6.88	0.39	4.38e-11	Visceral adipose tissue adjusted for BMI;
CESC	cis	rs10979	1.000	rs9386032	chr6:143887492	A/G	cg25407410	chr6:143891975	LOC285740	-0.61	-9.14	-0.49	1.72e-17	Hypospadias;
CESC	cis	rs66573146	1.000	rs66573146	chr4:6984464	C/G	cg00086871	chr4:6988644	TBC1D14	1.11	6.36	0.36	8.97e-10	Granulocyte percentage of myeloid white cells;
CESC	cis	rs6860806	0.507	rs273901	chr5:131694360	G/T	cg07395648	chr5:131743802	NA	-0.4	-5.22	-0.31	3.67e-7	Breast cancer;
CESC	cis	rs8027181	0.617	rs12439200	chr15:73086731	A/G	cg25632853	chr15:73088954	NA	0.4	6.14	0.35	3e-9	Triglyceride levels;
CESC	trans	rs7943203	1.000	rs61913875	chr11:108298852	A/G	cg24643211	chr18:11851603	GNAL;CHMP1B	-0.47	-6.05	-0.35	4.93e-9	Red blood cell count;Mean corpuscular volume;
CESC	cis	rs1799949	0.965	rs35521261	chr17:41313612	A/G	cg23758822	chr17:41437982	NA	1.05	16.36	0.71	4.52e-42	Menopause (age at onset);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg09994017	chr10:75118319	TTC18	-0.46	-6.4	-0.37	6.94e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs736408	0.505	rs2083180	chr3:52668119	G/T	cg18099408	chr3:52552593	STAB1	-0.3	-5.03	-0.3	9.03e-7	Bipolar disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08222185	chr21:46494823	ADARB1	0.6	7.05	0.4	1.54e-11	Gut microbiome composition (summer);
CESC	cis	rs11638352	0.661	rs2615269	chr15:44427956	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.56	5.29	0.31	2.53e-7	Lipoprotein phospholipase A2 activity in cardiovascular disease;
CESC	cis	rs684232	0.666	rs2657629	chr17:602261	G/T	cg15660573	chr17:549704	VPS53	-0.67	-9.37	-0.5	3.26e-18	Prostate cancer;
CESC	cis	rs116095464	0.558	rs9312977	chr5:221916	G/C	cg10591111	chr5:226296	SDHA	-0.51	-6.35	-0.36	9.22e-10	Breast cancer;
CESC	cis	rs4665809	0.590	rs62128457	chr2:26467347	C/A	cg26119090	chr2:26468346	HADHA;HADHB	1.1	12.68	0.61	4e-29	Gut microbiome composition (summer);
CESC	cis	rs12971120	0.947	rs8084109	chr18:72168312	T/A	cg25817165	chr18:72167213	CNDP2	-0.56	-7.72	-0.43	2.34e-13	Refractive error;
CESC	cis	rs9302635	0.513	rs3812987	chr16:72158920	C/A	cg01557791	chr16:72042693	DHODH	-0.62	-7.3	-0.41	3.4e-12	Blood protein levels;
CESC	trans	rs9929218	1.000	rs9928847	chr16:68797893	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.63	-8.44	-0.46	2.1e-15	Colorectal cancer;
CESC	cis	rs7937682	0.883	rs1784775	chr11:111472460	T/C	cg09085632	chr11:111637200	PPP2R1B	-0.94	-13.87	-0.65	2.84e-33	Primary sclerosing cholangitis;
CESC	cis	rs7666738	0.830	rs4699588	chr4:98973789	A/G	cg03676636	chr4:99064102	C4orf37	0.34	5.2	0.3	3.93e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs13191362	1.000	rs34443622	chr6:163208214	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.66	6.37	0.36	8.45e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs11098499	0.913	rs10010696	chr4:120164303	T/C	cg24375607	chr4:120327624	NA	0.43	5.18	0.3	4.31e-7	Corneal astigmatism;
CESC	cis	rs853679	0.517	rs56364346	chr6:28050762	T/G	cg17949981	chr6:28129498	ZNF389	0.45	5.62	0.33	4.9e-8	Depression;
CESC	cis	rs72781680	0.898	rs17762651	chr2:24115922	A/G	cg20701182	chr2:24300061	SF3B14	0.63	5.65	0.33	4.07e-8	Lymphocyte counts;
CESC	cis	rs10129255	0.957	rs8005468	chr14:107142448	C/T	cg23076370	chr14:107095027	NA	-0.44	-5.47	-0.32	1.06e-7	Kawasaki disease;
CESC	cis	rs8028182	0.549	rs7402293	chr15:75636137	A/G	cg20655648	chr15:75932815	IMP3	-0.42	-5.29	-0.31	2.52e-7	Sudden cardiac arrest;
CESC	cis	rs6083	0.571	rs41294813	chr15:58847807	T/C	cg05156742	chr15:59063176	FAM63B	-0.7	-9.92	-0.52	6.14e-20	Schizophrenia;
CESC	cis	rs854765	0.616	rs8076747	chr17:17853595	C/T	cg04398451	chr17:18023971	MYO15A	-0.72	-10.51	-0.54	7.97e-22	Total body bone mineral density;
CESC	trans	rs9987353	0.840	rs329994	chr8:9123233	A/G	cg02442412	chr4:83720054	SCD5	-0.43	-6.09	-0.35	3.86e-9	Recombination measurement;
CESC	cis	rs2204008	0.684	rs11514164	chr12:38036494	C/T	cg13010199	chr12:38710504	ALG10B	0.47	5.83	0.34	1.62e-8	Bladder cancer;
CESC	cis	rs68170813	0.559	rs76299183	chr7:106904859	A/G	cg02696742	chr7:106810147	HBP1	-0.54	-5.33	-0.31	2.15e-7	Coronary artery disease;
CESC	cis	rs832540	0.669	rs832539	chr5:56199386	A/C	cg12311346	chr5:56204834	C5orf35	-0.54	-7.23	-0.41	5.33e-12	Coronary artery disease;
CESC	cis	rs6540559	0.808	rs11119358	chr1:210042456	T/C	cg12034118	chr1:209979487	IRF6	0.46	5.37	0.31	1.68e-7	Cleft lip with or without cleft palate;
CESC	cis	rs1577917	0.771	rs9362237	chr6:86409064	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.58	8.01	0.44	3.58e-14	Response to antipsychotic treatment;
CESC	cis	rs7552404	0.727	rs7547056	chr1:76279267	C/T	cg03433033	chr1:76189801	ACADM	0.64	6.49	0.37	4.22e-10	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs56399783	0.901	rs73051415	chr7:2850643	C/T	cg19731401	chr7:2775893	GNA12	0.63	5.42	0.32	1.32e-7	Childhood ear infection;
CESC	cis	rs780096	0.506	rs72819512	chr2:27614449	G/A	cg22903471	chr2:27725779	GCKR	-0.57	-8.18	-0.45	1.2e-14	Total body bone mineral density;
CESC	cis	rs1790761	0.505	rs6591256	chr11:67349899	A/G	cg14500267	chr11:67383377	NA	-0.32	-5.34	-0.31	2.02e-7	Mean corpuscular volume;
CESC	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg05552183	chr6:42928497	GNMT	0.82	13.72	0.64	1.01e-32	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs798554	0.797	rs798493	chr7:2798731	A/G	cg19717773	chr7:2847554	GNA12	-0.56	-7.92	-0.44	6.66e-14	Height;
CESC	cis	rs9324022	0.858	rs1004573	chr14:101178235	G/C	cg18089426	chr14:101175970	NA	0.61	7.68	0.43	3.15e-13	Plateletcrit;
CESC	cis	rs6952808	0.823	rs58222895	chr7:1885064	G/A	cg23102388	chr7:1867652	MAD1L1	-0.33	-5.05	-0.3	8.16e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs5167	0.504	rs4803781	chr19:45459671	C/T	cg09555818	chr19:45449301	APOC2	0.39	6.22	0.36	1.88e-9	Blood protein levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27323088	chr5:89770393	MBLAC2;POLR3G	0.61	7.08	0.4	1.32e-11	Gut microbiome composition (summer);
CESC	cis	rs9457247	1.000	rs405553	chr6:167395058	A/G	cg25258033	chr6:167368657	RNASET2	0.39	5.87	0.34	1.31e-8	Crohn's disease;
CESC	cis	rs941207	0.526	rs7303216	chr12:57074693	A/C	cg05584118	chr12:57595605	LRP1	-0.37	-5.04	-0.3	8.53e-7	Platelet count;
CESC	cis	rs35306767	0.903	rs11253504	chr10:956046	A/G	cg20503657	chr10:835505	NA	0.9	9.27	0.49	6.58e-18	Eosinophil percentage of granulocytes;
CESC	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg11301795	chr4:187892539	NA	-0.75	-11.49	-0.58	4.49e-25	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs17376456	0.569	rs6556834	chr5:93123067	C/T	cg25358565	chr5:93447407	FAM172A	-0.71	-7.57	-0.42	6.39e-13	Diabetic retinopathy;
CESC	cis	rs7208859	0.623	rs11652631	chr17:29060766	A/G	cg19761014	chr17:28927070	LRRC37B2	0.76	6.25	0.36	1.66e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs1862618	0.853	rs1833896	chr5:56097669	C/A	cg24549020	chr5:56110836	MAP3K1	0.59	6.95	0.39	2.75e-11	Initial pursuit acceleration;
CESC	trans	rs61148964	0.826	rs11913459	chr22:37228603	G/A	cg08062273	chr3:45641120	LIMD1	0.59	6.18	0.35	2.41e-9	Scarlet fever;
CESC	cis	rs965469	0.532	rs6115865	chr20:3359303	A/G	cg25506879	chr20:3388711	C20orf194	0.42	5.15	0.3	5.05e-7	IFN-related cytopenia;
CESC	cis	rs514406	0.668	rs1672911	chr1:53340320	T/C	cg08859206	chr1:53392774	SCP2	-0.66	-9.63	-0.51	5.2e-19	Monocyte count;
CESC	cis	rs9649213	0.593	rs13232181	chr7:97935671	C/G	cg24562669	chr7:97807699	LMTK2	0.49	6.87	0.39	4.57e-11	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs4308124	0.708	rs28871990	chr2:111962441	G/A	cg04571233	chr2:111982156	NA	-0.64	-7.06	-0.4	1.47e-11	Vitiligo;
CESC	cis	rs2576037	0.583	rs4890343	chr18:44540969	G/A	cg19077165	chr18:44547161	KATNAL2	-0.65	-9.87	-0.52	8.73e-20	Personality dimensions;
CESC	trans	rs7618501	0.665	rs7621352	chr3:50070763	A/C	cg21659725	chr3:3221576	CRBN	-0.52	-7.37	-0.41	2.22e-12	Intelligence (multi-trait analysis);
CESC	cis	rs9393777	0.546	rs9366673	chr6:26893329	C/G	cg12826209	chr6:26865740	GUSBL1	0.76	8.71	0.47	3.34e-16	Intelligence (multi-trait analysis);
CESC	cis	rs7208859	0.623	rs7217984	chr17:29092766	G/A	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.91e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs1707322	1.000	rs11211236	chr1:46443767	C/A	cg06784218	chr1:46089804	CCDC17	0.33	5.63	0.33	4.7e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7336332	0.628	rs9581854	chr13:28017782	C/T	cg01674679	chr13:27998804	GTF3A	-0.59	-5.25	-0.31	3.08e-7	Weight;
CESC	cis	rs8014204	0.935	rs2300596	chr14:75353855	C/T	cg08847533	chr14:75593920	NEK9	0.43	5.38	0.31	1.65e-7	Caffeine consumption;
CESC	cis	rs7666738	0.546	rs11727151	chr4:98837353	A/C	cg17366294	chr4:99064904	C4orf37	0.49	6.0	0.35	6.32e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9308731	0.591	rs10439396	chr2:111935976	T/A	cg04202892	chr2:111875749	ACOXL	0.38	5.27	0.31	2.76e-7	Chronic lymphocytic leukemia;
CESC	cis	rs2635047	0.811	rs17785603	chr18:44769534	T/A	cg19077165	chr18:44547161	KATNAL2	-0.39	-5.11	-0.3	6.12e-7	Educational attainment;
CESC	cis	rs9911578	0.740	rs368243	chr17:56708979	T/C	cg05425664	chr17:57184151	TRIM37	-0.42	-5.63	-0.33	4.62e-8	Intelligence (multi-trait analysis);
CESC	trans	rs11098499	0.954	rs28685688	chr4:120420334	T/C	cg25214090	chr10:38739885	LOC399744	0.71	9.95	0.52	4.98e-20	Corneal astigmatism;
CESC	cis	rs11190604	1.000	rs2495736	chr10:102338410	T/C	cg07080220	chr10:102295463	HIF1AN	0.64	5.91	0.34	1.07e-8	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs8060686	0.545	rs8057119	chr16:68268836	C/T	cg26727032	chr16:67993705	SLC12A4	-0.49	-5.67	-0.33	3.79e-8	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs3749237	0.595	rs7621003	chr3:49411404	T/C	cg03060546	chr3:49711283	APEH	0.75	11.29	0.57	2.23e-24	Resting heart rate;
CESC	trans	rs17508449	0.775	rs4839336	chr1:114234145	A/T	cg23028848	chr11:57092561	TNKS1BP1	-0.79	-6.28	-0.36	1.38e-9	Leprosy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02984193	chr15:91260561	BLM	0.57	6.94	0.39	3e-11	Gut microbiome composition (summer);
CESC	cis	rs9359856	0.564	rs6914142	chr6:90398903	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.62	-6.13	-0.35	3.11e-9	Bipolar disorder;
CESC	cis	rs40363	0.645	rs6501177	chr16:3523681	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.54	-6.9	-0.39	3.91e-11	Tuberculosis;
CESC	cis	rs12618769	0.597	rs72821907	chr2:99085296	A/G	cg10123293	chr2:99228465	UNC50	0.38	5.04	0.3	8.64e-7	Bipolar disorder;
CESC	cis	rs6570726	0.791	rs2096201	chr6:145934273	C/T	cg05347473	chr6:146136440	FBXO30	0.58	7.43	0.42	1.48e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs478304	0.651	rs948494	chr11:65552118	G/A	cg10518572	chr11:65560635	OVOL1	-0.31	-5.76	-0.33	2.37e-8	Acne (severe);
CESC	cis	rs6502050	0.799	rs6502078	chr17:80124364	G/A	cg11859384	chr17:80120422	CCDC57	-0.39	-5.34	-0.31	1.98e-7	Life satisfaction;
CESC	cis	rs6964587	0.692	rs10236483	chr7:91797296	A/C	cg01689657	chr7:91764605	CYP51A1	0.27	5.37	0.31	1.69e-7	Breast cancer;
CESC	cis	rs7786808	0.782	rs7787923	chr7:158227312	A/G	cg01191920	chr7:158217561	PTPRN2	-0.36	-6.3	-0.36	1.24e-9	Obesity-related traits;
CESC	cis	rs7524258	0.900	rs6577426	chr1:7306451	A/G	cg07173049	chr1:7289937	CAMTA1	0.35	5.38	0.31	1.64e-7	Tourette's syndrome or obsessive-compulsive disorder;
CESC	cis	rs116095464	0.510	rs60844864	chr5:267000	A/G	cg20965017	chr5:231967	SDHA	-0.49	-5.41	-0.32	1.44e-7	Breast cancer;
CESC	cis	rs28647808	1.000	rs4962140	chr9:136272507	T/C	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.9	5.73	0.33	2.75e-8	Blood protein levels;
CESC	cis	rs2502731	1.000	rs2502731	chr9:130976557	A/G	cg13642260	chr9:130955380	CIZ1	-0.58	-9.49	-0.5	1.44e-18	Attention deficit hyperactivity disorder;
CESC	cis	rs6540559	0.673	rs7550857	chr1:209956542	C/A	cg22029157	chr1:209979665	IRF6	0.76	8.86	0.48	1.18e-16	Cleft lip with or without cleft palate;
CESC	cis	rs12956009	0.583	rs11663609	chr18:44862757	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.51	6.6	0.38	2.25e-10	Educational attainment (years of education);
CESC	cis	rs1401999	1.000	rs1402003	chr3:183642879	C/T	cg01324343	chr3:183735012	ABCC5	0.62	13.18	0.63	7.52e-31	Anterior chamber depth;
CESC	cis	rs9488822	0.676	rs12154016	chr6:116355188	C/T	cg15226275	chr6:116381976	FRK	0.25	6.31	0.36	1.16e-9	Cholesterol, total;LDL cholesterol;
CESC	cis	rs1538970	0.774	rs67683090	chr1:45977803	T/G	cg24296786	chr1:45957014	TESK2	-0.46	-5.15	-0.3	4.97e-7	Platelet count;
CESC	cis	rs1008375	0.966	rs2302393	chr4:17654341	G/A	cg15017067	chr4:17643749	FAM184B	0.36	5.1	0.3	6.56e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg07172676	chr8:144997714	PLEC1	0.5	6.94	0.39	2.95e-11	Fibrinogen levels;
CESC	cis	rs72901758	0.768	rs1567237	chr17:76246294	A/G	cg23302638	chr17:76210176	BIRC5	-0.47	-5.33	-0.31	2.13e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
CESC	cis	rs8067354	0.645	rs16943838	chr17:57839604	C/T	cg13753209	chr17:57696993	CLTC	0.56	6.1	0.35	3.83e-9	Hemoglobin concentration;
CESC	cis	rs2249694	0.960	rs4133041	chr10:135408387	G/A	cg19469447	chr10:135341870	CYP2E1	0.37	5.18	0.3	4.42e-7	Obesity-related traits;
CESC	cis	rs7666738	0.822	rs11097599	chr4:98959562	T/A	cg03676636	chr4:99064102	C4orf37	0.33	5.12	0.3	5.76e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2242116	0.796	rs4587	chr3:46963502	T/C	cg27129171	chr3:47204927	SETD2	0.52	6.52	0.37	3.53e-10	Birth weight;
CESC	cis	rs3091242	1.000	rs9689	chr1:25688276	A/G	cg02931644	chr1:25747376	RHCE	0.43	7.29	0.41	3.51e-12	Erythrocyte sedimentation rate;
CESC	cis	rs7100689	0.753	rs1572816	chr10:82137600	A/G	cg00277334	chr10:82204260	NA	-0.58	-7.29	-0.41	3.66e-12	Post bronchodilator FEV1;
CESC	cis	rs7937682	0.889	rs551825	chr11:111480116	C/G	cg09085632	chr11:111637200	PPP2R1B	-0.95	-14.72	-0.67	3.09e-36	Primary sclerosing cholangitis;
CESC	cis	rs7827545	0.545	rs57219802	chr8:135554231	C/T	cg17885191	chr8:135476712	NA	0.58	6.27	0.36	1.42e-9	Hypertension (SNP x SNP interaction);
CESC	cis	rs7666738	0.830	rs11725652	chr4:98878362	G/A	cg17366294	chr4:99064904	C4orf37	0.55	7.72	0.43	2.46e-13	Colonoscopy-negative controls vs population controls;
CESC	cis	rs644799	0.635	rs10831428	chr11:95508404	C/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.75	11.2	0.57	4.24e-24	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs9814567	0.752	rs4955542	chr3:134328740	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.4	-5.08	-0.3	6.97e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs66573146	0.656	rs66517061	chr4:6935163	C/G	cg00086871	chr4:6988644	TBC1D14	0.95	5.18	0.3	4.33e-7	Granulocyte percentage of myeloid white cells;
CESC	cis	rs11126435	0.591	rs10779958	chr2:74755778	A/C	cg11955373	chr2:74710513	TTC31;CCDC142	0.55	5.29	0.31	2.57e-7	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs4555082	0.794	rs2735827	chr14:105710600	T/A	cg06808227	chr14:105710500	BRF1	-0.54	-6.24	-0.36	1.69e-9	Mean platelet volume;Platelet distribution width;
CESC	cis	rs1799949	0.930	rs8176194	chr17:41231221	A/C	cg05368731	chr17:41323189	NBR1	0.77	10.67	0.55	2.32e-22	Menopause (age at onset);
CESC	cis	rs4253772	0.591	rs9627324	chr22:46656511	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.69	8.17	0.45	1.28e-14	LDL cholesterol;Cholesterol, total;
CESC	cis	rs6736093	0.966	rs2271701	chr2:112731173	C/G	cg12686935	chr2:112915763	FBLN7	-0.42	-5.51	-0.32	8.65e-8	Coronary artery disease;
CESC	cis	rs7937682	0.883	rs2212520	chr11:111462096	C/T	cg22437258	chr11:111473054	SIK2	0.71	9.19	0.49	1.16e-17	Primary sclerosing cholangitis;
CESC	trans	rs2727020	0.556	rs2866365	chr11:49390731	A/G	cg15704280	chr7:45808275	SEPT13	-0.82	-9.67	-0.51	3.85e-19	Coronary artery disease;
CESC	trans	rs7937682	0.855	rs521947	chr11:111492616	A/G	cg18187862	chr3:45730750	SACM1L	0.48	6.01	0.35	6.26e-9	Primary sclerosing cholangitis;
CESC	cis	rs7044106	0.762	rs1867254	chr9:123429078	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.65	8.79	0.47	1.99e-16	Hip circumference adjusted for BMI;
CESC	trans	rs2727020	0.729	rs4315497	chr11:49214499	G/A	cg15704280	chr7:45808275	SEPT13	0.85	14.1	0.65	4.49e-34	Coronary artery disease;
CESC	trans	rs9951602	0.512	rs4798994	chr18:76654327	T/G	cg02800362	chr5:177631904	HNRNPAB	0.66	8.63	0.47	5.9e-16	Obesity-related traits;
CESC	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.6	6.75	0.38	9.49e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs6879260	1.000	rs10903252	chr5:179733934	T/C	cg02891314	chr5:179741120	GFPT2	-0.57	-7.77	-0.43	1.78e-13	Height;
CESC	cis	rs68170813	0.559	rs2107319	chr7:106863744	T/C	cg02696742	chr7:106810147	HBP1	-0.54	-5.52	-0.32	7.95e-8	Coronary artery disease;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg22819824	chr10:115618670	NHLRC2	0.42	6.27	0.36	1.47e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs941408	1.000	rs1076447	chr19:2792128	C/G	cg06609049	chr19:2785107	THOP1	0.73	10.39	0.54	2.02e-21	Total cholesterol levels;
CESC	trans	rs7582180	0.700	rs1437971	chr2:100986964	A/C	cg17205461	chr7:27779758	TAX1BP1	0.6	6.02	0.35	5.94e-9	Intelligence (multi-trait analysis);
CESC	cis	rs4722166	0.541	rs1800795	chr7:22766645	C/G	cg13104385	chr7:22767384	IL6	0.42	5.79	0.33	2.01e-8	Lung cancer;
CESC	cis	rs314370	0.855	rs76181418	chr7:100494960	G/T	cg10426581	chr7:100472382	SRRT	0.84	8.18	0.45	1.23e-14	Resting heart rate;
CESC	cis	rs10540	1.000	rs61876334	chr11:487201	T/C	cg03352830	chr11:487213	PTDSS2	0.7	6.71	0.38	1.16e-10	Body mass index;
CESC	cis	rs9549367	0.826	rs9549710	chr13:113898064	A/C	cg00898013	chr13:113819073	PROZ	-0.52	-7.07	-0.4	1.36e-11	Platelet distribution width;
CESC	cis	rs1707322	1.000	rs4660318	chr1:46334876	A/G	cg05343316	chr1:45956843	TESK2	0.44	5.55	0.32	7.05e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs4141404	0.706	rs5753698	chr22:31970054	A/C	cg00478049	chr22:31556069	RNF185	-0.45	-5.34	-0.31	1.98e-7	Paclitaxel-induced neuropathy;
CESC	cis	rs1538970	0.924	rs11211108	chr1:45891152	C/T	cg03146154	chr1:46216737	IPP	0.44	5.09	0.3	6.74e-7	Platelet count;
CESC	cis	rs731174	0.802	rs12123842	chr1:38187989	T/C	cg12339802	chr1:38156545	C1orf109	-0.55	-5.57	-0.32	6.11e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs13191362	0.507	rs2846566	chr6:163059714	G/A	cg21926612	chr6:163149169	PACRG;PARK2	-0.58	-6.91	-0.39	3.68e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs4332037	0.707	rs56070303	chr7:1891015	C/T	cg23422044	chr7:1970798	MAD1L1	-0.5	-5.41	-0.32	1.43e-7	Bipolar disorder;
CESC	cis	rs28489187	0.577	rs729655	chr1:85844617	A/C	cg16011679	chr1:85725395	C1orf52	0.44	5.22	0.31	3.62e-7	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	cis	rs7833986	0.501	rs2953909	chr8:56968200	T/C	cg26371346	chr8:56986568	SNORD54;RPS20	0.57	5.16	0.3	4.9e-7	Height;
CESC	cis	rs1580019	0.961	rs958217	chr7:32493417	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.76	10.45	0.54	1.27e-21	Cognitive ability;
CESC	cis	rs35110281	0.667	rs2070533	chr21:45122753	G/A	cg04455712	chr21:45112962	RRP1B	0.51	7.86	0.43	9.96e-14	Mean corpuscular volume;
CESC	trans	rs7937682	0.889	rs11213969	chr11:111528441	A/G	cg18187862	chr3:45730750	SACM1L	0.48	6.19	0.36	2.22e-9	Primary sclerosing cholangitis;
CESC	cis	rs7605827	0.930	rs7575290	chr2:15597322	C/T	cg19274914	chr2:15703543	NA	0.33	5.97	0.34	7.72e-9	Educational attainment (years of education);
CESC	cis	rs1018836	0.828	rs9297871	chr8:91572731	G/A	cg16814680	chr8:91681699	NA	-0.62	-8.98	-0.48	5.22e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs4665809	1.000	rs7599132	chr2:26279810	A/T	cg26314531	chr2:26401878	FAM59B	0.7	7.94	0.44	5.58e-14	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.830	rs28456179	chr4:98991439	A/G	cg03467027	chr4:99064603	C4orf37	0.44	5.48	0.32	9.95e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs17376456	0.825	rs66564678	chr5:93165894	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.63	5.38	0.31	1.66e-7	Diabetic retinopathy;
CESC	cis	rs875971	0.929	rs778692	chr7:65872449	A/G	cg10691866	chr7:65817282	TPST1	-0.34	-5.47	-0.32	1.06e-7	Aortic root size;
CESC	cis	rs10733682	0.659	rs3906146	chr9:129463613	C/T	cg00232160	chr9:129468157	NA	0.42	6.54	0.37	3.17e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs6430585	0.702	rs73958637	chr2:136546927	C/T	cg07169764	chr2:136633963	MCM6	1.29	17.4	0.73	9.47e-46	Corneal structure;
CESC	trans	rs1814175	0.645	rs1721996	chr11:49915527	G/A	cg03929089	chr4:120376271	NA	-0.92	-15.2	-0.68	6e-38	Height;
CESC	cis	rs9287719	0.967	rs7563816	chr2:10763400	C/T	cg02196655	chr2:10830764	NOL10	-0.37	-5.56	-0.32	6.58e-8	Prostate cancer;
CESC	cis	rs2839186	0.814	rs12482209	chr21:47664275	C/G	cg13012494	chr21:47604986	C21orf56	-0.48	-6.43	-0.37	6.02e-10	Testicular germ cell tumor;
CESC	cis	rs7044106	0.762	rs10760107	chr9:123383630	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.33	5.19	0.3	4.19e-7	Hip circumference adjusted for BMI;
CESC	cis	rs75477785	1.000	rs12063989	chr1:210049893	T/C	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.79	5.15	0.3	5.08e-7	Cleft lip with or without cleft palate;
CESC	cis	rs9399135	0.967	rs6908512	chr6:135367757	A/G	cg24558204	chr6:135376177	HBS1L	0.5	6.85	0.39	5.16e-11	Red blood cell count;
CESC	cis	rs67460515	0.852	rs2404341	chr3:161092405	T/C	cg03342759	chr3:160939853	NMD3	-0.54	-7.64	-0.42	3.94e-13	Parkinson's disease;
CESC	cis	rs9322193	0.923	rs1112729	chr6:150087627	C/A	cg13206674	chr6:150067644	NUP43	0.43	5.98	0.34	7.33e-9	Lung cancer;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg07656391	chr2:32264720	DPY30	0.48	6.6	0.38	2.29e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs11785400	0.793	rs4581034	chr8:143736968	G/A	cg10596483	chr8:143751796	JRK	0.43	5.43	0.32	1.31e-7	Schizophrenia;
CESC	cis	rs1003719	0.715	rs2251952	chr21:38559711	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.51	-6.71	-0.38	1.18e-10	Eye color traits;
CESC	cis	rs8114671	0.562	rs7266550	chr20:33495510	C/T	cg07148914	chr20:33460835	GGT7	0.46	6.13	0.35	3.19e-9	Height;
CESC	cis	rs1552244	1.000	rs35198334	chr3:10104553	G/C	cg00149659	chr3:10157352	C3orf10	0.74	8.67	0.47	4.4e-16	Alzheimer's disease;
CESC	cis	rs736408	0.527	rs2577831	chr3:52628056	C/A	cg18404041	chr3:52824283	ITIH1	-0.37	-6.66	-0.38	1.6e-10	Bipolar disorder;
CESC	cis	rs5769765	0.773	rs4075331	chr22:50302850	A/G	cg26441486	chr22:50317300	CRELD2	0.39	5.19	0.3	4.1e-7	Schizophrenia;
CESC	cis	rs3785574	0.962	rs58131426	chr17:61854375	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.81	10.73	0.55	1.51e-22	Height;
CESC	cis	rs13191362	1.000	rs13195226	chr6:163006421	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.82	8.75	0.47	2.56e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs477895	0.653	rs34089806	chr11:63887987	C/T	cg04317338	chr11:64019027	PLCB3	0.85	8.72	0.47	3.12e-16	Mean platelet volume;
CESC	cis	rs1364505	0.575	rs732490	chr7:132014616	T/C	cg03295361	chr7:131864608	PLXNA4	-0.37	-5.04	-0.3	8.61e-7	Venous thromboembolism (SNP x SNP interaction);
CESC	trans	rs55704346	0.566	rs10027825	chr4:25386599	G/A	cg01822600	chr1:245751692	KIF26B	0.42	6.17	0.35	2.58e-9	Tonsillectomy;
CESC	cis	rs2075371	0.966	rs2244690	chr7:133987039	A/G	cg20476274	chr7:133979776	SLC35B4	0.65	9.41	0.5	2.53e-18	Mean platelet volume;
CESC	cis	rs1008375	0.606	rs6828925	chr4:17561139	C/T	cg02297831	chr4:17616191	MED28	0.43	5.45	0.32	1.13e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs875971	0.545	rs7811204	chr7:65852200	G/A	cg18876405	chr7:65276391	NA	0.49	5.38	0.31	1.63e-7	Aortic root size;
CESC	cis	rs7412746	0.658	rs1546376	chr1:150937661	A/G	cg04414720	chr1:150670196	GOLPH3L	0.51	6.8	0.39	6.73e-11	Melanoma;
CESC	cis	rs10791097	0.694	rs7106973	chr11:130758113	G/A	cg12179176	chr11:130786555	SNX19	0.64	9.86	0.52	9.65e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs7809950	0.817	rs4727678	chr7:107083635	C/G	cg23024343	chr7:107201750	COG5	-0.56	-7.2	-0.4	6.06e-12	Coronary artery disease;
CESC	cis	rs6952808	0.531	rs73039217	chr7:2178731	G/A	cg05863683	chr7:1912471	MAD1L1	0.39	5.67	0.33	3.67e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs1499972	0.618	rs61384494	chr3:117640660	C/T	cg07612923	chr3:117604196	NA	0.68	6.27	0.36	1.45e-9	Schizophrenia;
CESC	cis	rs6500602	0.701	rs4786508	chr16:4568043	G/A	cg08645402	chr16:4508243	NA	0.44	6.43	0.37	6.05e-10	Schizophrenia;
CESC	cis	rs9287719	0.967	rs7593496	chr2:10738176	A/C	cg02196655	chr2:10830764	NOL10	-0.37	-5.72	-0.33	2.87e-8	Prostate cancer;
CESC	cis	rs6831352	0.879	rs1230154	chr4:99988659	C/T	cg13256891	chr4:100009986	ADH5	0.65	7.94	0.44	5.92e-14	Alcohol dependence;
CESC	cis	rs798554	0.797	rs35957220	chr7:2812632	C/G	cg04166393	chr7:2884313	GNA12	0.59	7.33	0.41	2.87e-12	Height;
CESC	cis	rs7474896	0.583	rs1208770	chr10:38044683	C/T	cg00409905	chr10:38381863	ZNF37A	-0.46	-5.03	-0.3	9.04e-7	Obesity (extreme);
CESC	cis	rs61841072	0.808	rs61842502	chr1:243127288	A/G	cg02356786	chr1:243265016	LOC731275	0.4	5.03	0.3	9.1e-7	Schizophrenia;
CESC	cis	rs6598955	0.627	rs12143920	chr1:26575834	A/G	cg19743891	chr1:26644573	UBXN11;CD52	0.37	5.19	0.3	4.16e-7	Obesity-related traits;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg24185116	chr15:52044314	LYSMD2;TMOD2	-0.5	-7.03	-0.4	1.79e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs61008539	0.815	rs6960062	chr7:884665	A/G	cg15782153	chr7:917662	C7orf20	0.56	8.35	0.46	3.95e-15	Perceived unattractiveness to mosquitoes;
CESC	cis	rs7666738	0.830	rs10012003	chr4:99064881	A/G	cg18180107	chr4:99064573	C4orf37	0.4	5.14	0.3	5.21e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7666738	0.830	rs13137808	chr4:99047095	T/C	cg05340658	chr4:99064831	C4orf37	0.82	12.88	0.62	8.44e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4689388	0.856	rs3200	chr4:6304878	C/T	cg14416269	chr4:6271139	WFS1	0.49	8.21	0.45	9.71e-15	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	trans	rs7980799	0.905	rs4244866	chr12:33511983	G/C	cg26384229	chr12:38710491	ALG10B	-0.45	-6.12	-0.35	3.3e-9	Heart rate;Heart rate variability traits (RMSSD);
CESC	cis	rs1729951	0.546	rs12054219	chr3:136677472	G/A	cg03617693	chr3:136751559	NA	0.38	5.26	0.31	3.02e-7	Neuroticism;
CESC	cis	rs16917546	0.935	rs10822050	chr10:64438771	T/C	cg03961010	chr10:64397487	ZNF365	-0.32	-5.34	-0.31	1.97e-7	Basal cell carcinoma;
CESC	cis	rs1707322	0.656	rs2991981	chr1:46057144	A/G	cg05343316	chr1:45956843	TESK2	-0.55	-6.78	-0.38	7.74e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs854765	0.551	rs6502626	chr17:17849450	C/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.48	6.1	0.35	3.78e-9	Total body bone mineral density;
CESC	cis	rs4595586	1.000	rs3803020	chr12:39233771	A/G	cg26384229	chr12:38710491	ALG10B	-0.38	-5.31	-0.31	2.32e-7	Morning vs. evening chronotype;
CESC	cis	rs798554	0.836	rs798526	chr7:2775542	G/C	cg13628971	chr7:2884303	GNA12	0.62	7.99	0.44	4.05e-14	Height;
CESC	trans	rs7448080	0.510	rs1875500	chr5:123246522	A/G	cg10971134	chr1:56877429	NA	-0.91	-6.4	-0.37	7.02e-10	Alcohol dependence (age at onset);
CESC	cis	rs9287719	0.967	rs1541574	chr2:10773508	A/T	cg00105475	chr2:10696890	NA	0.37	5.2	0.3	4.04e-7	Prostate cancer;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg11938120	chr5:56110761	MAP3K1	0.48	6.02	0.35	5.78e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs6952808	0.689	rs12668156	chr7:2019875	G/A	cg21782813	chr7:2030301	MAD1L1	0.49	6.78	0.38	7.76e-11	Bipolar disorder and schizophrenia;
CESC	cis	rs1580019	0.961	rs1868777	chr7:32494076	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.53	5.59	0.32	5.54e-8	Cognitive ability;
CESC	cis	rs1552244	0.882	rs56332224	chr3:10037321	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.76	-9.68	-0.51	3.46e-19	Alzheimer's disease;
CESC	cis	rs875971	1.000	rs778699	chr7:65868290	G/A	cg11764359	chr7:65958608	NA	0.98	15.79	0.7	4.71e-40	Aortic root size;
CESC	cis	rs1552244	0.872	rs6792951	chr3:10119603	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	12.72	0.62	2.99e-29	Alzheimer's disease;
CESC	cis	rs6582630	0.519	rs8189561	chr12:38296178	G/A	cg26384229	chr12:38710491	ALG10B	0.7	10.34	0.54	2.92e-21	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs2304069	0.545	rs12153714	chr5:149395254	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.47	6.36	0.36	8.69e-10	HIV-1 control;
CESC	cis	rs9354308	0.802	rs2814102	chr6:66523230	A/G	cg07460842	chr6:66804631	NA	0.51	5.57	0.32	6.14e-8	Metabolite levels;
CESC	cis	rs9488822	0.702	rs6909746	chr6:116352750	C/T	cg18764771	chr6:116381957	FRK	0.23	5.6	0.33	5.42e-8	Cholesterol, total;LDL cholesterol;
CESC	cis	rs1799949	0.965	rs11658499	chr17:41334749	C/T	cg23758822	chr17:41437982	NA	1.03	15.5	0.69	5.3e-39	Menopause (age at onset);
CESC	cis	rs2204008	0.729	rs2892365	chr12:38446760	G/C	cg26384229	chr12:38710491	ALG10B	-0.63	-9.48	-0.5	1.55e-18	Bladder cancer;
CESC	cis	rs4566357	0.576	rs6750845	chr2:227911037	T/G	cg11843606	chr2:227700838	RHBDD1	-0.47	-6.49	-0.37	4.32e-10	Coronary artery disease;
CESC	cis	rs4665809	0.627	rs7562192	chr2:26469457	C/G	cg04944784	chr2:26401820	FAM59B	0.96	10.83	0.55	7.34e-23	Gut microbiome composition (summer);
CESC	cis	rs2932538	1.000	rs2932538	chr1:113216543	A/G	cg22162597	chr1:113214053	CAPZA1	-0.57	-7.2	-0.4	6.14e-12	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CESC	cis	rs8180040	0.967	rs807935	chr3:47321669	A/G	cg27129171	chr3:47204927	SETD2	0.66	10.09	0.53	1.82e-20	Colorectal cancer;
CESC	cis	rs514406	0.505	rs447581	chr1:53177098	T/C	cg24675658	chr1:53192096	ZYG11B	-0.54	-7.03	-0.4	1.71e-11	Monocyte count;
CESC	trans	rs9650657	0.571	rs11783247	chr8:10788875	C/T	cg15556689	chr8:8085844	FLJ10661	-0.56	-6.87	-0.39	4.7e-11	Neuroticism;
CESC	cis	rs2635047	0.638	rs2571010	chr18:44652130	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.4	5.51	0.32	8.4e-8	Educational attainment;
CESC	cis	rs2109514	0.967	rs4730743	chr7:116145957	A/T	cg12739419	chr7:116140593	CAV2	-0.35	-6.48	-0.37	4.44e-10	Prevalent atrial fibrillation;
CESC	cis	rs7666738	0.830	rs1426668	chr4:98945585	T/A	cg05340658	chr4:99064831	C4orf37	0.82	12.66	0.61	4.8e-29	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9300255	0.602	rs884548	chr12:123634122	A/G	cg05973401	chr12:123451056	ABCB9	0.51	5.72	0.33	2.81e-8	Neutrophil percentage of white cells;
CESC	cis	rs863345	0.625	rs10489833	chr1:158490451	C/T	cg12129480	chr1:158549410	OR10X1	-0.34	-6.85	-0.39	5.17e-11	Pneumococcal bacteremia;
CESC	cis	rs55692411	0.517	rs13095697	chr3:50136463	G/A	cg24308560	chr3:49941425	MST1R	-0.52	-6.39	-0.37	7.28e-10	Intelligence (multi-trait analysis);
CESC	cis	rs4604732	0.631	rs12080860	chr1:247623053	A/G	cg12758973	chr1:247694275	LOC148824;OR2C3	0.48	6.04	0.35	5.19e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs514406	0.825	rs487453	chr1:53271225	T/C	cg16325326	chr1:53192061	ZYG11B	-0.72	-11.75	-0.59	6.36e-26	Monocyte count;
CESC	cis	rs3820928	1.000	rs11692572	chr2:227774503	C/G	cg11843606	chr2:227700838	RHBDD1	-0.45	-5.96	-0.34	7.99e-9	Pulmonary function;
CESC	cis	rs2115630	0.645	rs3825877	chr15:85174631	G/A	cg11189052	chr15:85197271	WDR73	-0.5	-6.84	-0.39	5.31e-11	P wave terminal force;
CESC	cis	rs875971	0.540	rs1723268	chr7:65473080	A/C	cg10691866	chr7:65817282	TPST1	-0.33	-5.3	-0.31	2.43e-7	Aortic root size;
CESC	cis	rs712039	0.652	rs853196	chr17:35848659	A/T	cg16670864	chr17:35848621	DUSP14	0.47	6.02	0.35	5.78e-9	Tuberculosis;
CESC	cis	rs909002	1.000	rs2292993	chr1:32140733	C/T	cg13919466	chr1:32135498	COL16A1	-0.5	-9.02	-0.48	4.04e-17	Intelligence (multi-trait analysis);
CESC	cis	rs1784581	0.761	rs7741581	chr6:162435250	C/T	cg17173639	chr6:162384350	PARK2	0.6	9.33	0.5	4.55e-18	Itch intensity from mosquito bite;
CESC	cis	rs6840258	0.825	rs72667747	chr4:87922063	C/T	cg08197287	chr4:87952173	AFF1	-0.42	-5.33	-0.31	2.12e-7	Mean corpuscular volume;Basophil percentage of granulocytes;
CESC	cis	rs7605827	0.893	rs35123590	chr2:15708639	T/C	cg19274914	chr2:15703543	NA	0.29	5.22	0.31	3.7e-7	Educational attainment (years of education);
CESC	cis	rs798554	0.567	rs1182194	chr7:2868824	C/G	cg13628971	chr7:2884303	GNA12	0.43	5.59	0.32	5.52e-8	Height;
CESC	cis	rs7666738	0.830	rs6532724	chr4:99060993	C/T	cg18180107	chr4:99064573	C4orf37	0.41	5.23	0.31	3.41e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9916302	0.861	rs632202	chr17:37453294	C/A	cg07936489	chr17:37558343	FBXL20	0.75	10.45	0.54	1.24e-21	Glomerular filtration rate (creatinine);
CESC	cis	rs2933343	0.729	rs1680794	chr3:128620390	A/G	cg11901034	chr3:128598214	ACAD9	-0.39	-5.71	-0.33	3.06e-8	IgG glycosylation;
CESC	cis	rs2576037	0.526	rs4258717	chr18:44456954	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.42	6.88	0.39	4.25e-11	Personality dimensions;
CESC	cis	rs7666738	0.830	rs10031292	chr4:99056877	A/G	cg18180107	chr4:99064573	C4orf37	0.43	5.59	0.32	5.69e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11098499	0.863	rs2291185	chr4:120434833	C/A	cg24375607	chr4:120327624	NA	0.43	5.19	0.3	4.27e-7	Corneal astigmatism;
CESC	cis	rs6499255	0.762	rs12325186	chr16:69658807	A/T	cg15192750	chr16:69999425	NA	0.58	6.48	0.37	4.54e-10	IgE levels;
CESC	cis	rs1594829	0.553	rs2046224	chr8:26151604	G/T	cg11498726	chr8:26250323	BNIP3L	-0.41	-6.12	-0.35	3.44e-9	Height;
CESC	cis	rs9309711	0.772	rs9309715	chr2:3492318	C/G	cg10845886	chr2:3471009	TTC15	0.79	10.56	0.54	5.55e-22	Neurofibrillary tangles;
CESC	cis	rs3733585	0.781	rs13103879	chr4:9972879	T/C	cg11266682	chr4:10021025	SLC2A9	-0.61	-12.23	-0.6	1.47e-27	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs5758659	1.000	rs134900	chr22:42683343	C/G	cg15557168	chr22:42548783	NA	-0.46	-7.42	-0.41	1.57e-12	Cognitive function;
CESC	cis	rs1178968	0.818	rs4717084	chr7:72764541	C/T	cg25889504	chr7:72793014	NA	0.48	5.06	0.3	7.68e-7	Triglyceride levels;
CESC	cis	rs9623117	0.915	rs6001765	chr22:40498156	A/T	cg05033341	chr22:40419857	FAM83F	-0.43	-5.1	-0.3	6.47e-7	Prostate cancer (SNP x SNP interaction);Prostate cancer;
CESC	cis	rs9926296	0.681	rs12923946	chr16:89821080	C/T	cg03388025	chr16:89894329	SPIRE2	0.3	5.11	0.3	6.28e-7	Vitiligo;
CESC	cis	rs875971	0.964	rs1643388	chr7:65844562	T/C	cg18876405	chr7:65276391	NA	0.5	6.66	0.38	1.61e-10	Aortic root size;
CESC	cis	rs2282802	0.685	rs1347143	chr5:139669386	A/G	cg26211634	chr5:139558579	C5orf32	-0.5	-7.33	-0.41	2.85e-12	Intelligence (multi-trait analysis);
CESC	cis	rs3747547	0.892	rs3747545	chr9:37916164	C/T	cg13774184	chr9:37916125	SHB	-0.72	-5.96	-0.34	7.81e-9	Metabolite levels (Dihydroxy docosatrienoic acid);
CESC	cis	rs3091242	0.933	rs9438904	chr1:25756860	T/C	cg02931644	chr1:25747376	RHCE	0.4	6.54	0.37	3.15e-10	Erythrocyte sedimentation rate;
CESC	cis	rs3540	0.960	rs8040585	chr15:91026477	T/C	cg22089800	chr15:90895588	ZNF774	0.41	5.09	0.3	6.64e-7	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs6709815	0.841	rs6740004	chr2:219663153	G/A	cg02176678	chr2:219576539	TTLL4	-0.38	-6.62	-0.38	1.93e-10	Reticulocyte count;High light scatter reticulocyte count;
CESC	cis	rs1799949	1.000	rs11654731	chr17:41326940	G/A	cg25072359	chr17:41440525	NA	0.5	6.75	0.38	9.44e-11	Menopause (age at onset);
CESC	cis	rs721399	0.719	rs4646254	chr8:18262059	A/G	cg18736775	chr8:18248649	NAT2	-0.5	-5.5	-0.32	8.82e-8	Blood metabolite levels;
CESC	cis	rs796364	0.806	rs11689664	chr2:201099961	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.78	-6.44	-0.37	5.52e-10	Schizophrenia;
CESC	cis	rs10504229	0.683	rs61201557	chr8:58138370	T/C	cg24829409	chr8:58192753	C8orf71	-0.58	-7.2	-0.4	6.31e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs10504229	0.610	rs6987118	chr8:58147851	G/T	cg24829409	chr8:58192753	C8orf71	-0.53	-6.91	-0.39	3.62e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs4423214	1.000	rs2040323	chr11:71172783	A/C	cg05163923	chr11:71159392	DHCR7	0.86	11.46	0.58	5.92e-25	Vitamin D levels;
CESC	cis	rs67311347	1.000	rs2887995	chr3:40409029	C/G	cg09455208	chr3:40491958	NA	0.45	7.8	0.43	1.45e-13	Renal cell carcinoma;
CESC	trans	rs1223629	1.000	rs56204274	chr10:95941639	A/G	cg16346422	chr11:2920819	SLC22A18;SLC22A18AS	0.67	6.04	0.35	5.08e-9	Glucose homeostasis traits;
CESC	cis	rs1862618	0.853	rs6885541	chr5:56110857	G/C	cg24549020	chr5:56110836	MAP3K1	0.66	7.56	0.42	6.6e-13	Initial pursuit acceleration;
CESC	cis	rs9894429	1.000	rs11651264	chr17:79576394	A/G	cg18240062	chr17:79603768	NPLOC4	-0.72	-10.27	-0.53	4.71e-21	Eye color traits;
CESC	cis	rs2455799	0.613	rs7620787	chr3:15882826	G/A	cg16303742	chr3:15540471	COLQ	-0.37	-5.55	-0.32	6.91e-8	Mean platelet volume;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg12498409	chr7:40174463	C7orf10;C7orf11	-0.44	-6.07	-0.35	4.31e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs2836974	0.897	rs4817996	chr21:40525759	G/C	cg17971929	chr21:40555470	PSMG1	1.05	16.62	0.71	5.49e-43	Cognitive function;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06376129	chr1:205180539	DSTYK	0.53	6.32	0.36	1.12e-9	Gut microbiome composition (summer);
CESC	cis	rs6546537	0.840	rs34743816	chr2:69813345	A/C	cg10773587	chr2:69614142	GFPT1	-0.58	-7.27	-0.41	4.07e-12	Serum thyroid-stimulating hormone levels;
CESC	cis	rs11764590	0.666	rs7787359	chr7:2090849	A/G	cg21782813	chr7:2030301	MAD1L1	-0.42	-5.31	-0.31	2.35e-7	Neuroticism;
CESC	cis	rs11112613	0.713	rs12316204	chr12:105944244	G/A	cg03607813	chr12:105948248	NA	0.65	7.81	0.43	1.33e-13	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CESC	cis	rs853679	0.517	rs17711801	chr6:28092307	C/G	cg20151795	chr6:28129481	ZNF389	0.44	5.74	0.33	2.6e-8	Depression;
CESC	cis	rs9911578	1.000	rs12453049	chr17:56611372	C/T	cg05425664	chr17:57184151	TRIM37	0.5	7.06	0.4	1.5e-11	Intelligence (multi-trait analysis);
CESC	cis	rs9467711	0.584	rs34244947	chr6:26761745	T/C	cg21479132	chr6:26055353	NA	0.71	5.25	0.31	3.1e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs7618501	1.000	rs11130218	chr3:49752372	C/T	cg24308560	chr3:49941425	MST1R	0.51	7.13	0.4	9.72e-12	Intelligence (multi-trait analysis);
CESC	cis	rs4472734	0.813	rs4394613	chr1:214622818	A/G	cg00063699	chr1:214624242	PTPN14	-0.32	-5.08	-0.3	7.05e-7	Height;
CESC	cis	rs4853012	0.838	rs61521879	chr2:74346208	T/C	cg05890377	chr2:74357713	NA	0.78	10.7	0.55	1.9e-22	Gestational age at birth (maternal effect);
CESC	cis	rs8180040	0.966	rs34634681	chr3:47579102	G/A	cg27129171	chr3:47204927	SETD2	-0.62	-9.06	-0.49	2.87e-17	Colorectal cancer;
CESC	cis	rs4665809	1.000	rs6546728	chr2:26276531	G/C	cg27170947	chr2:26402098	FAM59B	-0.72	-8.31	-0.45	5.18e-15	Gut microbiome composition (summer);
CESC	cis	rs12130219	0.500	rs4845737	chr1:152177539	G/A	cg17718321	chr1:152188247	HRNR	-0.53	-8.66	-0.47	4.78e-16	Inflammatory skin disease;
CESC	cis	rs11792861	0.619	rs2289480	chr9:111705501	A/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.61	9.39	0.5	2.83e-18	Menarche (age at onset);
CESC	cis	rs9660180	1.000	rs3737628	chr1:1722932	C/T	cg20999797	chr1:1681921	NA	0.29	5.5	0.32	8.98e-8	Body mass index;
CESC	cis	rs6061231	0.631	rs2427317	chr20:60975725	C/T	cg24112000	chr20:60950667	NA	-0.54	-8.45	-0.46	1.94e-15	Colorectal cancer;
CESC	cis	rs7044106	0.762	rs7044226	chr9:123466328	G/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.36	5.83	0.34	1.61e-8	Hip circumference adjusted for BMI;
CESC	cis	rs1008375	0.932	rs4698629	chr4:17608884	C/G	cg16339924	chr4:17578868	LAP3	0.52	5.85	0.34	1.44e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs2425143	0.687	rs6119649	chr20:34369596	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	-0.72	-6.67	-0.38	1.52e-10	Blood protein levels;
CESC	cis	rs6674176	0.660	rs6801	chr1:44396646	C/G	cg23954153	chr1:44402353	ARTN	0.36	5.64	0.33	4.42e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs9611565	0.918	rs9611561	chr22:41757234	C/G	cg03806693	chr22:41940476	POLR3H	-1.03	-11.79	-0.59	4.34e-26	Vitiligo;
CESC	cis	rs11235843	0.636	rs6592531	chr11:73412354	C/T	cg18195628	chr11:73498948	MRPL48	-0.5	-5.49	-0.32	9.46e-8	Hand grip strength;
CESC	cis	rs1552244	0.882	rs13077641	chr3:10022935	G/A	cg08888203	chr3:10149979	C3orf24	0.49	6.17	0.35	2.49e-9	Alzheimer's disease;
CESC	cis	rs7116495	1.000	rs585228	chr11:71773289	G/C	cg26138937	chr11:71823887	C11orf51	-0.83	-6.95	-0.39	2.81e-11	Severe influenza A (H1N1) infection;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg03542721	chr8:22926253	TNFRSF10B	-0.43	-7.03	-0.4	1.77e-11	Gambling;
CESC	cis	rs10924309	0.882	rs10924305	chr1:245856763	A/G	cg00036263	chr1:245852353	KIF26B	0.47	5.79	0.34	1.97e-8	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
CESC	cis	rs9311474	0.508	rs11720159	chr3:52617802	T/G	cg18099408	chr3:52552593	STAB1	-0.32	-5.4	-0.31	1.47e-7	Electroencephalogram traits;
CESC	cis	rs1799949	1.000	rs4793231	chr17:41427469	A/G	cg23758822	chr17:41437982	NA	1.02	15.36	0.69	1.61e-38	Menopause (age at onset);
CESC	cis	rs875971	0.825	rs1860472	chr7:66082723	T/C	cg18876405	chr7:65276391	NA	-0.53	-7.2	-0.4	6.28e-12	Aortic root size;
CESC	cis	rs7520050	0.966	rs12410071	chr1:46358886	T/C	cg03146154	chr1:46216737	IPP	-0.45	-5.71	-0.33	2.99e-8	Red blood cell count;Reticulocyte count;
CESC	cis	rs921968	0.643	rs596076	chr2:219451015	T/G	cg02176678	chr2:219576539	TTLL4	0.42	7.29	0.41	3.59e-12	Mean corpuscular hemoglobin concentration;
CESC	cis	rs11229555	1.000	rs2276153	chr11:58407740	C/G	cg15696309	chr11:58395628	NA	-0.43	-5.6	-0.33	5.43e-8	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs4853525	0.522	rs6744420	chr2:191589082	A/G	cg10560079	chr2:191398806	TMEM194B	0.45	5.68	0.33	3.62e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg20600704	chr10:85899064	GHITM	0.45	6.15	0.35	2.9e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs7618915	0.547	rs2268027	chr3:52766606	G/A	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.38	6.6	0.38	2.18e-10	Bipolar disorder;
CESC	cis	rs9910055	0.531	rs6503490	chr17:42246656	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.54	8.23	0.45	8.69e-15	Total body bone mineral density;
CESC	cis	rs7208859	0.623	rs56018041	chr17:29059985	G/A	cg14008862	chr17:28927542	LRRC37B2	0.65	5.12	0.3	5.86e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs9362426	1.000	rs9450662	chr6:88088593	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.5	6.32	0.36	1.11e-9	Depressive episodes in bipolar disorder;
CESC	cis	rs2072499	0.838	rs2758619	chr1:156162559	A/G	cg25208724	chr1:156163844	SLC25A44	1.01	19.07	0.76	1.21e-51	Testicular germ cell tumor;
CESC	cis	rs4891159	0.757	rs11665518	chr18:74147054	C/T	cg24786174	chr18:74118243	ZNF516	-0.72	-10.94	-0.56	3.02e-23	Longevity;
CESC	cis	rs9487051	1.000	rs6568570	chr6:109613241	T/G	cg01475377	chr6:109611718	NA	-0.42	-6.43	-0.37	6.01e-10	Reticulocyte fraction of red cells;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg23129613	chr7:150065255	REPIN1	-0.43	-6.3	-0.36	1.23e-9	Gambling;
CESC	cis	rs9457247	1.000	rs9457247	chr6:167392174	C/T	cg25258033	chr6:167368657	RNASET2	0.39	5.87	0.34	1.31e-8	Crohn's disease;
CESC	cis	rs801193	0.569	rs6978178	chr7:66123084	G/A	cg18876405	chr7:65276391	NA	-0.45	-6.18	-0.35	2.43e-9	Aortic root size;
CESC	cis	rs501120	0.925	rs1746052	chr10:44778546	G/T	cg09554077	chr10:44749378	NA	-0.55	-6.62	-0.38	1.98e-10	Coronary artery disease;Coronary heart disease;
CESC	cis	rs9660992	0.573	rs1172147	chr1:205225457	G/A	cg21643547	chr1:205240462	TMCC2	-0.42	-5.83	-0.34	1.57e-8	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs9902453	0.967	rs12150261	chr17:28320473	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.69	-8.69	-0.47	3.76e-16	Coffee consumption (cups per day);
CESC	cis	rs3859192	0.599	rs2302777	chr17:38179492	A/G	cg17467752	chr17:38218738	THRA	-0.44	-5.92	-0.34	1.01e-8	White blood cell count;
CESC	cis	rs9287719	0.967	rs728282	chr2:10750303	A/G	cg02196655	chr2:10830764	NOL10	-0.38	-5.79	-0.34	1.96e-8	Prostate cancer;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg18170098	chr16:71880032	ATXN1L	0.45	6.37	0.36	8.14e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs9611565	0.592	rs57102627	chr22:41987627	T/C	cg03806693	chr22:41940476	POLR3H	-0.87	-10.5	-0.54	8.63e-22	Vitiligo;
CESC	cis	rs1348850	0.558	rs4337505	chr2:178529714	A/T	cg22681709	chr2:178499509	PDE11A	-0.47	-6.85	-0.39	5.19e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs887829	0.609	rs7597496	chr2:234630443	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.46	-5.83	-0.34	1.59e-8	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
CESC	cis	rs1642645	0.831	rs10736422	chr1:42480320	C/T	cg16685388	chr1:42384056	HIVEP3	0.39	5.81	0.34	1.75e-8	Left ventricular obstructive tract defect (maternal effect);
CESC	cis	rs9926296	0.632	rs4785716	chr16:89801127	T/C	cg27121462	chr16:89883253	FANCA	0.64	8.22	0.45	9.36e-15	Vitiligo;
CESC	cis	rs3096299	0.933	rs2965938	chr16:89491336	C/T	cg02034447	chr16:89574710	SPG7	0.4	5.04	0.3	8.84e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs9311474	1.000	rs7614727	chr3:52295895	C/T	cg25934064	chr3:52569026	NT5DC2	0.27	5.68	0.33	3.5e-8	Electroencephalogram traits;
CESC	cis	rs2836974	0.533	rs418298	chr21:40536654	A/T	cg11890956	chr21:40555474	PSMG1	0.98	16.61	0.71	6.1e-43	Cognitive function;
CESC	cis	rs12477438	0.520	rs6739579	chr2:99731552	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.86	15.87	0.7	2.48e-40	Chronic sinus infection;
CESC	trans	rs9467711	0.606	rs1978	chr6:26377573	A/T	cg06606381	chr12:133084897	FBRSL1	-0.72	-6.48	-0.37	4.35e-10	Autism spectrum disorder or schizophrenia;
CESC	cis	rs4835473	0.864	rs1849132	chr4:144879462	C/T	cg25736465	chr4:144833511	NA	0.41	6.11	0.35	3.59e-9	Immature fraction of reticulocytes;
CESC	trans	rs7246760	1.000	rs12462027	chr19:9926860	G/A	cg02900749	chr2:68251473	NA	-0.81	-6.86	-0.39	4.95e-11	Pursuit maintenance gain;
CESC	cis	rs919433	0.783	rs2565155	chr2:198236425	A/G	cg20885578	chr2:198174922	NA	0.41	5.36	0.31	1.79e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs172166	0.637	rs1071893	chr6:28167635	G/C	cg23281280	chr6:28129359	ZNF389	0.4	5.94	0.34	9.03e-9	Cardiac Troponin-T levels;
CESC	cis	rs6430585	0.527	rs7592050	chr2:136459227	C/T	cg07169764	chr2:136633963	MCM6	-1.08	-12.57	-0.61	9.58e-29	Corneal structure;
CESC	cis	rs6570726	0.791	rs418701	chr6:145889992	C/T	cg05347473	chr6:146136440	FBXO30	0.59	7.63	0.42	4.24e-13	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs34779708	0.733	rs3936502	chr10:35549218	C/T	cg04310649	chr10:35416472	CREM	-0.45	-5.14	-0.3	5.34e-7	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs17854409	0.803	rs1048100	chr20:61472073	C/A	cg05147244	chr20:61493195	TCFL5	0.9	6.53	0.37	3.34e-10	Obesity-related traits;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg07792822	chr1:157961914	KIRREL	-0.44	-6.05	-0.35	4.84e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg27221266	chr10:96122679	NOC3L	-0.44	-6.32	-0.36	1.12e-9	Gambling;
CESC	cis	rs9527	0.590	rs34104646	chr10:104896078	T/A	cg04362960	chr10:104952993	NT5C2	0.44	5.54	0.32	7.12e-8	Arsenic metabolism;
CESC	cis	rs10883723	0.810	rs7093028	chr10:104259417	A/G	cg22532475	chr10:104410764	TRIM8	-0.34	-5.73	-0.33	2.77e-8	Allergic disease (asthma, hay fever or eczema);
CESC	trans	rs2727020	0.554	rs2866490	chr11:49425463	A/G	cg03929089	chr4:120376271	NA	-0.67	-7.45	-0.42	1.31e-12	Coronary artery disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg03193865	chr8:145510099	BOP1	0.5	6.64	0.38	1.75e-10	Fibrinogen levels;
CESC	cis	rs2637266	1.000	rs2579750	chr10:78340260	C/G	cg18941641	chr10:78392320	NA	-0.42	-7.88	-0.44	8.29e-14	Pulmonary function;
CESC	cis	rs11148252	0.595	rs4885325	chr13:53171317	C/T	cg00495681	chr13:53174319	NA	0.61	8.44	0.46	2.08e-15	Lewy body disease;
CESC	cis	rs6502050	0.835	rs3924780	chr17:80112978	G/A	cg23985595	chr17:80112537	CCDC57	-0.42	-6.59	-0.38	2.43e-10	Life satisfaction;
CESC	cis	rs2011503	1.000	rs113527843	chr19:19643343	A/T	cg11584989	chr19:19387371	SF4	0.58	6.67	0.38	1.52e-10	Bipolar disorder;
CESC	cis	rs10782582	0.593	rs17647178	chr1:76210524	A/G	cg22875332	chr1:76189707	ACADM	-0.44	-5.24	-0.31	3.32e-7	Daytime sleep phenotypes;
CESC	cis	rs72781680	0.898	rs17462670	chr2:24026579	T/C	cg08917208	chr2:24149416	ATAD2B	0.95	8.71	0.47	3.45e-16	Lymphocyte counts;
CESC	cis	rs478304	0.934	rs498354	chr11:65528213	A/G	cg08755490	chr11:65554678	OVOL1	0.49	6.5	0.37	3.95e-10	Acne (severe);
CESC	cis	rs7336332	0.598	rs76249173	chr13:28010445	A/G	cg22138327	chr13:27999177	GTF3A	0.62	5.82	0.34	1.71e-8	Weight;
CESC	cis	rs17362650	0.653	rs10929581	chr2:9552379	C/T	cg12832956	chr2:9616023	IAH1	-0.55	-6.19	-0.36	2.33e-9	Alcohol dependence (age at onset);
CESC	cis	rs1348850	0.914	rs4341974	chr2:178324879	A/C	cg23306229	chr2:178417860	TTC30B	0.64	8.2	0.45	1.03e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs9443645	0.901	rs13191068	chr6:79714867	T/C	cg05283184	chr6:79620031	NA	-0.43	-6.61	-0.38	2.06e-10	Intelligence (multi-trait analysis);
CESC	cis	rs728616	0.681	rs55838345	chr10:82085120	G/C	cg05935833	chr10:81318306	SFTPA2	-0.46	-5.75	-0.33	2.48e-8	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs9910055	1.000	rs2071167	chr17:42287519	A/G	cg13607699	chr17:42295918	UBTF	-0.66	-8.17	-0.45	1.31e-14	Total body bone mineral density;
CESC	trans	rs1814175	0.817	rs7481230	chr11:49772235	G/A	cg15704280	chr7:45808275	SEPT13	-1.02	-19.93	-0.77	1.26e-54	Height;
CESC	cis	rs9549367	0.756	rs9549702	chr13:113881944	T/G	cg18105134	chr13:113819100	PROZ	-0.67	-8.45	-0.46	1.99e-15	Platelet distribution width;
CESC	cis	rs2108225	0.934	rs4730269	chr7:107455719	T/G	cg18560240	chr7:107437656	SLC26A3	-0.38	-5.05	-0.3	8.34e-7	Ulcerative colitis;
CESC	cis	rs11123610	0.520	rs12996655	chr2:3720900	G/A	cg10645314	chr2:3704589	ALLC	-0.45	-5.06	-0.3	8.01e-7	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
CESC	trans	rs4295623	0.789	rs12541318	chr8:11594970	G/T	cg15556689	chr8:8085844	FLJ10661	-0.55	-6.08	-0.35	4.12e-9	Morning vs. evening chronotype;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg26428032	chr11:67387935	NA	-0.43	-6.95	-0.39	2.87e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs7107174	0.901	rs2512522	chr11:77925855	G/C	cg02023728	chr11:77925099	USP35	0.47	6.43	0.37	5.9e-10	Testicular germ cell tumor;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23064501	chr12:42680748	NA	-0.64	-7.76	-0.43	1.84e-13	Gut microbiome composition (summer);
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg13883984	chr15:83621779	HOMER2	0.46	6.66	0.38	1.59e-10	Systemic lupus erythematosus;
CESC	cis	rs7312933	0.933	rs4534650	chr12:42444222	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.41	5.44	0.32	1.24e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs66887589	0.616	rs11731675	chr4:120212514	T/C	cg09307838	chr4:120376055	NA	0.66	9.12	0.49	1.94e-17	Diastolic blood pressure;
CESC	cis	rs11792861	0.564	rs3816237	chr9:111718348	T/A	cg05043794	chr9:111880884	C9orf5	-0.3	-5.49	-0.32	9.36e-8	Menarche (age at onset);
CESC	cis	rs4925325	1.000	rs4925325	chr20:60514224	G/A	cg13770153	chr20:60521292	NA	0.83	11.74	0.59	6.51e-26	Obesity-related traits;
CESC	cis	rs4319547	0.656	rs2173582	chr12:122824694	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.49	-5.66	-0.33	3.95e-8	Body mass index;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg00140813	chr16:28857836	TUFM	0.5	7.09	0.4	1.21e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs7000551	0.715	rs1879792	chr8:22314029	C/A	cg12081754	chr8:22256438	SLC39A14	0.41	5.27	0.31	2.81e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CESC	cis	rs113835537	0.597	rs4576	chr11:66331000	A/G	cg22134325	chr11:66188745	NPAS4	0.37	5.63	0.33	4.58e-8	Airway imaging phenotypes;
CESC	cis	rs12458462	0.859	rs2242177	chr18:77477379	G/A	cg23301140	chr18:77439876	CTDP1	0.56	7.31	0.41	3.13e-12	Monocyte count;
CESC	cis	rs2841277	0.741	rs9672139	chr14:105408182	T/G	cg21017887	chr14:105400489	NA	0.4	6.48	0.37	4.5e-10	Rheumatoid arthritis;
CESC	cis	rs2303759	0.918	rs1054770	chr19:49878115	G/A	cg22307029	chr19:49891270	CCDC155	0.7	8.41	0.46	2.52e-15	Multiple sclerosis;
CESC	cis	rs4664304	0.658	rs2667016	chr2:160868855	C/T	cg03641300	chr2:160917029	PLA2R1	-0.46	-6.53	-0.37	3.38e-10	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs7932354	0.528	rs10838654	chr11:47095511	G/C	cg25783544	chr11:47291846	MADD	-0.42	-5.63	-0.33	4.62e-8	Bone mineral density (hip);Bone mineral density;
CESC	cis	rs1215050	0.791	rs700738	chr4:98907909	C/A	cg05340658	chr4:99064831	C4orf37	-0.49	-6.37	-0.36	8.15e-10	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs2120019	1.000	rs8033837	chr15:75353975	A/C	cg09165964	chr15:75287851	SCAMP5	-0.73	-8.56	-0.47	9.11e-16	Blood trace element (Zn levels);
CESC	cis	rs3812049	0.826	rs34576922	chr5:127364103	C/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.9	-11.14	-0.56	6.93e-24	Lymphocyte counts;Red cell distribution width;
CESC	cis	rs9322193	0.923	rs10872651	chr6:150089409	A/T	cg07701084	chr6:150067640	NUP43	0.43	5.78	0.33	2.13e-8	Lung cancer;
CESC	cis	rs8070624	0.574	rs9914127	chr17:17875836	A/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.68	9.67	0.51	3.79e-19	Total body bone mineral density;
CESC	cis	rs854765	0.964	rs12943202	chr17:17994332	T/A	cg16928487	chr17:17741425	SREBF1	0.57	9.75	0.51	2.09e-19	Total body bone mineral density;
CESC	cis	rs7666738	0.530	rs2865992	chr4:99067181	A/T	cg17366294	chr4:99064904	C4orf37	0.43	5.62	0.33	4.86e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs40363	0.620	rs1137454	chr16:3533577	C/G	cg22508957	chr16:3507546	NAT15	-0.59	-9.57	-0.51	7.86e-19	Tuberculosis;
CESC	cis	rs4862750	0.872	rs9998172	chr4:187898773	T/C	cg07414643	chr4:187882934	NA	0.54	7.9	0.44	7.51e-14	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs854765	0.583	rs11078406	chr17:17840823	G/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.48	6.3	0.36	1.24e-9	Total body bone mineral density;
CESC	cis	rs6460942	0.659	rs6969309	chr7:12515847	T/C	cg10578991	chr7:12443926	VWDE	-0.48	-5.06	-0.3	7.85e-7	Coronary artery disease;
CESC	cis	rs6088590	0.965	rs6088620	chr20:33412022	A/G	cg24642439	chr20:33292090	TP53INP2	0.84	11.74	0.59	6.4e-26	Coronary artery disease;
CESC	cis	rs854765	0.583	rs4341796	chr17:17839024	C/A	cg04398451	chr17:18023971	MYO15A	-0.66	-9.24	-0.49	8.32e-18	Total body bone mineral density;
CESC	trans	rs7674118	0.850	rs10010647	chr4:166847150	G/A	cg23810282	chr5:43037519	NA	0.67	6.02	0.35	5.77e-9	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs7552404	1.000	rs7513559	chr1:76173744	A/G	cg03433033	chr1:76189801	ACADM	0.65	7.67	0.43	3.3e-13	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs3760982	0.585	rs67773424	chr19:44293994	G/A	cg11993925	chr19:44307056	LYPD5	0.32	5.5	0.32	8.79e-8	Breast cancer (estrogen-receptor negative);Breast cancer;
CESC	cis	rs870825	0.616	rs72705689	chr4:185639894	A/G	cg04058563	chr4:185651563	MLF1IP	0.64	7.09	0.4	1.21e-11	Blood protein levels;
CESC	cis	rs6942756	1.000	rs11763056	chr7:128960871	C/A	cg02491457	chr7:128862824	NA	-0.68	-9.24	-0.49	8.31e-18	White matter hyperintensity burden;
CESC	cis	rs7208859	0.614	rs216412	chr17:28903394	A/G	cg04154034	chr17:28927549	LRRC37B2	-0.65	-6.18	-0.35	2.42e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs9303401	1.000	rs9303401	chr17:56847945	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.73	9.6	0.51	6.34e-19	Cognitive test performance;
CESC	cis	rs4665809	0.590	rs35532350	chr2:26441605	T/C	cg26314531	chr2:26401878	FAM59B	-0.85	-9.04	-0.49	3.44e-17	Gut microbiome composition (summer);
CESC	cis	rs7618915	0.547	rs3774365	chr3:52642487	T/C	cg18099408	chr3:52552593	STAB1	-0.31	-5.05	-0.3	8.09e-7	Bipolar disorder;
CESC	cis	rs2708240	1.000	rs2538974	chr7:147587753	A/T	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.33	-5.33	-0.31	2.06e-7	QT interval (drug interaction);
CESC	cis	rs2124969	0.548	rs62175388	chr2:161019664	G/A	cg03641300	chr2:160917029	PLA2R1	-0.58	-6.01	-0.35	6.14e-9	Waist circumference adjusted for body mass index;
CESC	cis	rs7412746	0.658	rs11582281	chr1:150826831	T/C	cg22823121	chr1:150693482	HORMAD1	0.44	6.11	0.35	3.48e-9	Melanoma;
CESC	cis	rs875971	0.545	rs2707851	chr7:66089165	C/T	cg11764359	chr7:65958608	NA	-0.79	-9.42	-0.5	2.25e-18	Aortic root size;
CESC	cis	rs4819052	0.851	rs2255766	chr21:46683777	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.76	10.15	0.53	1.18e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs425277	0.628	rs262668	chr1:2082602	A/G	cg04315214	chr1:2043799	PRKCZ	-0.44	-7.05	-0.4	1.53e-11	Height;
CESC	cis	rs4722166	0.630	rs6461667	chr7:22796743	A/G	cg13104385	chr7:22767384	IL6	0.43	5.53	0.32	7.75e-8	Lung cancer;
CESC	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg24846343	chr22:24311635	DDTL	-0.59	-9.82	-0.52	1.33e-19	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs77972916	0.609	rs13414381	chr2:43567218	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.56	-5.11	-0.3	6.16e-7	Granulocyte percentage of myeloid white cells;
CESC	cis	rs28386778	0.830	rs7209321	chr17:61855668	A/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.56	0.37	2.83e-10	Prudent dietary pattern;
CESC	cis	rs6570726	0.846	rs441575	chr6:145849205	A/C	cg23711669	chr6:146136114	FBXO30	0.8	11.89	0.59	2e-26	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7949030	0.588	rs2512562	chr11:62312156	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.57	8.62	0.47	6.29e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs9914988	0.832	rs34267753	chr17:27157586	T/C	cg20469991	chr17:27169893	C17orf63	-0.48	-5.25	-0.31	3.18e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CESC	cis	rs910316	0.664	rs2098252	chr14:75492732	T/C	cg11812906	chr14:75593930	NEK9	0.83	13.51	0.64	5.28e-32	Height;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg08568075	chr14:105220026	SIVA1	-0.47	-6.32	-0.36	1.07e-9	Height;
CESC	cis	rs2777491	0.872	rs61037359	chr15:41585926	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.6	-9.19	-0.49	1.19e-17	Ulcerative colitis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08292080	chr16:56398010	AMFR	-0.56	-6.82	-0.39	6.11e-11	Gut microbiome composition (summer);
CESC	cis	rs3008870	1.000	rs3008874	chr1:67431365	A/T	cg02640540	chr1:67518911	SLC35D1	0.51	5.58	0.32	5.89e-8	Lymphocyte percentage of white cells;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14452650	chr2:42396274	EML4	0.6	6.49	0.37	4.27e-10	Gut microbiome composition (summer);
CESC	cis	rs11945232	1.000	rs4314250	chr4:88340969	A/G	cg23841344	chr4:88312519	HSD17B11	0.6	7.41	0.41	1.72e-12	Intelligence (multi-trait analysis);
CESC	cis	rs3825932	0.961	rs10400881	chr15:79234384	G/C	cg25744700	chr15:79237217	CTSH	0.48	6.46	0.37	5.05e-10	Type 1 diabetes;
CESC	cis	rs72945132	0.619	rs34053053	chr11:70260598	C/T	cg00319359	chr11:70116639	PPFIA1	0.62	5.59	0.32	5.67e-8	Coronary artery disease;
CESC	trans	rs2155929	0.660	rs12956304	chr18:26609858	T/C	cg25413575	chr17:80870577	TBCD	-0.38	-6.0	-0.35	6.63e-9	Temperament (bipolar disorder);
CESC	trans	rs60843830	1.000	rs55936726	chr2:258210	T/C	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.68	8.49	0.46	1.51e-15	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs10504229	0.871	rs7002070	chr8:58153817	A/G	cg24829409	chr8:58192753	C8orf71	-0.62	-8.1	-0.45	1.99e-14	Developmental language disorder (linguistic errors);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg15312298	chr8:127570908	FAM84B	-0.41	-6.23	-0.36	1.78e-9	Gambling;
CESC	cis	rs4888262	0.526	rs4404098	chr16:74570050	G/A	cg01733217	chr16:74700730	RFWD3	0.73	9.93	0.52	5.99e-20	Testicular germ cell tumor;
CESC	cis	rs4970988	0.501	rs11204713	chr1:150694623	T/A	cg09365446	chr1:150670422	GOLPH3L	0.41	5.82	0.34	1.73e-8	Urate levels;
CESC	trans	rs7726839	0.507	rs60068988	chr5:597668	T/C	cg25482853	chr8:67687455	SGK3	1.04	10.08	0.53	1.87e-20	Obesity-related traits;
CESC	cis	rs4835473	0.864	rs61427459	chr4:144620758	C/T	cg25736465	chr4:144833511	NA	-0.35	-5.22	-0.31	3.65e-7	Immature fraction of reticulocytes;
CESC	cis	rs7827545	1.000	rs4909910	chr8:135565201	T/C	cg17885191	chr8:135476712	NA	0.48	6.28	0.36	1.39e-9	Hypertension (SNP x SNP interaction);
CESC	cis	rs854765	0.547	rs9897761	chr17:17912011	A/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.54	7.23	0.41	5.11e-12	Total body bone mineral density;
CESC	cis	rs2180341	1.000	rs9388561	chr6:127634921	C/T	cg24812749	chr6:127587940	RNF146	1.07	15.48	0.69	6.31e-39	Breast cancer;
CESC	cis	rs7666738	0.830	rs34412187	chr4:99010454	A/G	cg18180107	chr4:99064573	C4orf37	0.4	5.3	0.31	2.48e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs5753618	0.583	rs5749268	chr22:31809152	G/A	cg02404636	chr22:31891804	SFI1	0.39	5.37	0.31	1.71e-7	Colorectal cancer;
CESC	trans	rs11098499	0.909	rs35111518	chr4:120440682	A/G	cg25214090	chr10:38739885	LOC399744	0.71	9.72	0.51	2.74e-19	Corneal astigmatism;
CESC	cis	rs9908102	0.710	rs8079762	chr17:12910795	T/C	cg26162695	chr17:12921313	ELAC2	0.52	5.71	0.33	3.04e-8	Schizophrenia;
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg03925809	chr19:6393419	GTF2F1	-0.45	-6.98	-0.39	2.37e-11	Vertical cup-disc ratio;
CESC	cis	rs7582720	0.832	rs115194657	chr2:203829284	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.36	0.41	2.34e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs11214589	0.806	rs4551806	chr11:113250540	T/A	cg14159747	chr11:113255604	NA	0.3	5.37	0.31	1.69e-7	Neuroticism;
CESC	cis	rs6540559	0.673	rs58637469	chr1:209971480	T/A	cg21951975	chr1:209979733	IRF6	0.62	7.75	0.43	2.01e-13	Cleft lip with or without cleft palate;
CESC	cis	rs72781680	0.611	rs4149373	chr2:24300023	C/T	cg20701182	chr2:24300061	SF3B14	0.93	10.6	0.55	4.05e-22	Lymphocyte counts;
CESC	cis	rs1348850	0.668	rs2365619	chr2:178497366	A/G	cg23306229	chr2:178417860	TTC30B	-0.6	-7.02	-0.4	1.82e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs763121	0.925	rs1056661	chr22:39080245	A/G	cg21395723	chr22:39101663	GTPBP1	0.38	5.06	0.3	7.7e-7	Menopause (age at onset);
CESC	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg24846343	chr22:24311635	DDTL	0.66	11.31	0.57	1.91e-24	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs7666738	0.830	rs2865949	chr4:99039967	A/G	cg17366294	chr4:99064904	C4orf37	0.61	8.78	0.47	2.13e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7927771	1.000	rs12787330	chr11:47812311	C/T	cg20307385	chr11:47447363	PSMC3	-0.49	-6.04	-0.35	5.24e-9	Subjective well-being;
CESC	cis	rs7618915	0.547	rs8906	chr3:52739520	T/C	cg17372223	chr3:52568218	NT5DC2	0.44	6.56	0.37	2.82e-10	Bipolar disorder;
CESC	cis	rs7618501	0.601	rs2624825	chr3:50154989	G/A	cg24110177	chr3:50126178	RBM5	0.54	7.58	0.42	5.95e-13	Intelligence (multi-trait analysis);
CESC	cis	rs425277	0.606	rs2257182	chr1:2082566	C/T	cg23803603	chr1:2058230	PRKCZ	-0.33	-5.89	-0.34	1.19e-8	Height;
CESC	cis	rs9649213	0.593	rs6465662	chr7:97917801	A/T	cg21770322	chr7:97807741	LMTK2	0.55	8.08	0.44	2.32e-14	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs4919694	1.000	rs17727391	chr10:104836101	C/A	cg04362960	chr10:104952993	NT5C2	0.78	6.93	0.39	3.25e-11	Arsenic metabolism;
CESC	cis	rs5750830	0.594	rs5757650	chr22:39778419	A/G	cg02038168	chr22:39784481	NA	-0.53	-7.02	-0.4	1.84e-11	Intelligence (multi-trait analysis);
CESC	cis	rs9583531	0.527	rs12875067	chr13:111365104	A/G	cg24331049	chr13:111365604	ING1	0.73	10.94	0.56	3.01e-23	Coronary artery disease;
CESC	cis	rs72634258	0.679	rs7523227	chr1:8180097	G/A	cg00042356	chr1:8021962	PARK7	0.5	5.43	0.32	1.29e-7	Inflammatory bowel disease;
CESC	cis	rs2228479	0.867	rs12930606	chr16:89946682	A/G	cg14709524	chr16:89940631	TCF25	0.74	5.75	0.33	2.43e-8	Skin colour saturation;
CESC	cis	rs4629710	0.592	rs749375	chr6:131553692	C/G	cg12606694	chr6:131520996	AKAP7	0.5	6.11	0.35	3.45e-9	Multiple myeloma (IgH translocation);
CESC	cis	rs1862618	0.756	rs832548	chr5:56183637	G/C	cg18230493	chr5:56204884	C5orf35	-0.73	-8.57	-0.47	8.93e-16	Initial pursuit acceleration;
CESC	cis	rs1729951	0.575	rs361245	chr3:136695706	A/G	cg25687071	chr3:136751404	NA	0.39	5.23	0.31	3.47e-7	Neuroticism;
CESC	cis	rs6541297	0.703	rs57992758	chr1:230314396	A/G	cg20703242	chr1:230279135	GALNT2	-0.43	-5.6	-0.33	5.46e-8	Coronary artery disease;
CESC	cis	rs2486288	0.656	rs8039153	chr15:45579813	T/C	cg09092052	chr15:45571596	NA	0.45	5.38	0.31	1.62e-7	Glomerular filtration rate;
CESC	trans	rs6011002	1.000	rs6011014	chr20:62300940	C/T	cg02961472	chr15:70340064	NA	0.57	6.08	0.35	4.24e-9	Dental caries;
CESC	cis	rs1005277	0.579	rs2103938	chr10:38493998	T/G	cg00409905	chr10:38381863	ZNF37A	-0.5	-6.65	-0.38	1.65e-10	Extrinsic epigenetic age acceleration;
CESC	cis	rs2439831	0.867	rs2412779	chr15:43655927	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	13.11	0.63	1.34e-30	Lung cancer in ever smokers;
CESC	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg07677032	chr17:61819896	STRADA	0.45	5.96	0.34	8.19e-9	Prudent dietary pattern;
CESC	cis	rs9443189	0.570	rs7765254	chr6:76398143	T/C	cg01950844	chr6:76311363	SENP6	0.93	8.52	0.46	1.26e-15	Prostate cancer;
CESC	cis	rs1185460	0.967	rs4454730	chr11:118937444	G/A	cg01677386	chr11:118938358	VPS11	-0.44	-5.64	-0.33	4.35e-8	Coronary artery disease;
CESC	cis	rs113835537	0.529	rs60358007	chr11:66222353	G/A	cg24851651	chr11:66362959	CCS	0.53	6.25	0.36	1.62e-9	Airway imaging phenotypes;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg09622504	chr13:74708442	KLF12	-0.44	-6.14	-0.35	3.04e-9	Asthma;
CESC	cis	rs10276381	0.786	rs10281102	chr7:28243473	A/G	cg23620719	chr7:28220237	JAZF1	0.74	7.64	0.43	3.86e-13	Crohn's disease;
CESC	cis	rs7666738	0.830	rs13119913	chr4:98977983	G/T	cg17366294	chr4:99064904	C4orf37	0.58	8.25	0.45	7.41e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6860806	0.661	rs4705929	chr5:131584178	G/T	cg18758796	chr5:131593413	PDLIM4	0.45	6.35	0.36	9.29e-10	Breast cancer;
CESC	cis	rs1448094	0.511	rs11117042	chr12:86207547	G/T	cg19622623	chr12:86230825	RASSF9	-0.46	-5.97	-0.34	7.6e-9	Major depressive disorder;
CESC	cis	rs9649213	0.593	rs6969731	chr7:97924571	T/G	cg08684580	chr7:98029266	BAIAP2L1	-0.34	-5.54	-0.32	7.3900000000000007e-08	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs2294693	0.945	rs68031000	chr6:41008841	G/T	cg14418226	chr6:40996092	UNC5CL	0.5	5.75	0.33	2.42e-8	Gastric cancer;Non-cardia gastric cancer;
CESC	cis	rs10504229	0.683	rs35244711	chr8:58117762	T/G	cg24829409	chr8:58192753	C8orf71	-0.58	-7.2	-0.4	6.31e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs2625529	0.938	rs4238447	chr15:72131880	C/T	cg16672083	chr15:72433130	SENP8	-0.42	-5.34	-0.31	2.01e-7	Red blood cell count;
CESC	cis	rs709400	1.000	rs861538	chr14:104166733	C/T	cg24130564	chr14:104152367	KLC1	-0.43	-5.48	-0.32	9.71e-8	Body mass index;
CESC	cis	rs6582630	0.555	rs35284307	chr12:38509999	T/G	cg26384229	chr12:38710491	ALG10B	0.7	10.5	0.54	8.9e-22	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs1862618	0.853	rs252916	chr5:56121788	G/C	cg24549020	chr5:56110836	MAP3K1	0.65	7.54	0.42	7.42e-13	Initial pursuit acceleration;
CESC	cis	rs6499255	0.951	rs10852457	chr16:69607853	C/T	cg15192750	chr16:69999425	NA	0.49	5.84	0.34	1.55e-8	IgE levels;
CESC	cis	rs9486715	0.867	rs9384602	chr6:96919561	G/A	cg18709589	chr6:96969512	KIAA0776	0.46	6.47	0.37	4.83e-10	Headache;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg12410370	chr1:43296526	ERMAP	0.43	6.22	0.36	1.92e-9	Fibrinogen levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15622697	chr1:201924833	TIMM17A	0.57	6.45	0.37	5.13e-10	Gut microbiome composition (summer);
CESC	cis	rs896854	0.624	rs9297949	chr8:95969445	A/C	cg23172400	chr8:95962367	TP53INP1	-0.43	-8.75	-0.47	2.62e-16	Type 2 diabetes;
CESC	cis	rs73206853	0.841	rs73206870	chr12:110819953	T/C	cg12870014	chr12:110450643	ANKRD13A	0.64	5.11	0.3	6.16e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	trans	rs11088226	0.681	rs11700671	chr21:33938621	T/A	cg09050820	chr6:167586206	TCP10L2	0.83	7.75	0.43	2.01e-13	Gastritis;
CESC	cis	rs796364	0.906	rs281766	chr2:200820505	T/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.9	9.16	0.49	1.48e-17	Schizophrenia;
CESC	cis	rs727505	1.000	rs56321835	chr7:124529622	T/C	cg23710748	chr7:124431027	NA	-0.48	-7.5	-0.42	9.75e-13	Lewy body disease;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg11694641	chr12:98987961	SLC25A3	-0.45	-6.55	-0.37	2.89e-10	Gambling;
CESC	cis	rs7772486	0.727	rs6941429	chr6:145952283	G/A	cg23711669	chr6:146136114	FBXO30	1.01	15.49	0.69	5.86e-39	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs3815700	1.000	rs7248845	chr19:33096718	T/C	cg02997394	chr19:33096574	ANKRD27	0.71	7.32	0.41	2.93e-12	Eosinophilic esophagitis;
CESC	cis	rs35306767	0.904	rs10904584	chr10:983747	A/T	cg25019033	chr10:957182	NA	-0.63	-7.78	-0.43	1.6e-13	Eosinophil percentage of granulocytes;
CESC	cis	rs757110	0.900	rs2074314	chr11:17411821	C/T	cg11839944	chr11:17409644	KCNJ11	0.39	5.14	0.3	5.46e-7	Type 2 diabetes;
CESC	cis	rs4588572	0.644	rs9293751	chr5:77778296	A/G	cg11547950	chr5:77652471	NA	-0.38	-5.44	-0.32	1.23e-7	Triglycerides;
CESC	cis	rs4665809	0.590	rs7582341	chr2:26416301	A/G	cg27170947	chr2:26402098	FAM59B	-0.84	-10.03	-0.52	2.88e-20	Gut microbiome composition (summer);
CESC	cis	rs75477785	0.590	rs115503938	chr1:210151419	C/G	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.89	6.01	0.35	6.09e-9	Cleft lip with or without cleft palate;
CESC	cis	rs79839061	0.610	rs11248051	chr4:858332	C/T	cg07828340	chr4:882639	GAK	1.07	8.29	0.45	5.69e-15	Intelligence (multi-trait analysis);
CESC	cis	rs10504229	1.000	rs17805602	chr8:58179915	A/G	cg22535103	chr8:58192502	C8orf71	-1.05	-13.27	-0.63	3.63e-31	Developmental language disorder (linguistic errors);
CESC	cis	rs1153858	1.000	rs16952714	chr15:45650358	G/A	cg14582100	chr15:45693742	SPATA5L1	0.43	6.15	0.35	2.82e-9	Homoarginine levels;
CESC	cis	rs6835098	1.000	rs2332654	chr4:174088399	C/T	cg08422745	chr4:174089978	GALNT7	-0.83	-12.26	-0.6	1.16e-27	Dementia and core Alzheimer's disease neuropathologic changes;
CESC	cis	rs116095464	1.000	rs55671190	chr5:287422	G/A	cg22857025	chr5:266934	NA	-1.23	-9.26	-0.49	7e-18	Breast cancer;
CESC	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.51	0.37	3.65e-10	Prudent dietary pattern;
CESC	trans	rs2727020	0.754	rs10839226	chr11:49150883	C/G	cg15704280	chr7:45808275	SEPT13	-0.51	-6.07	-0.35	4.36e-9	Coronary artery disease;
CESC	cis	rs8067354	0.507	rs2645478	chr17:58014712	G/A	cg02344993	chr17:57696989	CLTC	0.52	5.52	0.32	8.03e-8	Hemoglobin concentration;
CESC	cis	rs12887734	0.524	rs4906364	chr14:104214342	C/G	cg01849466	chr14:104193079	ZFYVE21	-0.44	-5.52	-0.32	8.26e-8	Schizophrenia;Autism spectrum disorder or schizophrenia;
CESC	cis	rs7116495	0.881	rs1939243	chr11:71742735	A/G	cg26138937	chr11:71823887	C11orf51	0.78	6.11	0.35	3.51e-9	Severe influenza A (H1N1) infection;
CESC	cis	rs66573146	0.831	rs1048009	chr4:6988677	G/A	cg26116260	chr4:7069785	GRPEL1	-0.73	-5.03	-0.3	9.14e-7	Granulocyte percentage of myeloid white cells;
CESC	cis	rs7772486	0.875	rs2814877	chr6:146299763	C/G	cg23711669	chr6:146136114	FBXO30	0.9	13.16	0.63	8.74e-31	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs13035304	0.773	rs7589671	chr2:130507364	T/G	cg18827756	chr15:42130735	JMJD7-PLA2G4B;PLA2G4B	-0.42	-6.43	-0.37	6.06e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
CESC	cis	rs6952808	0.792	rs4721184	chr7:1950784	T/C	cg21782813	chr7:2030301	MAD1L1	0.41	5.83	0.34	1.58e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs1144333	0.737	rs1144331	chr1:76272357	G/A	cg22875332	chr1:76189707	ACADM	-0.53	-5.15	-0.3	5.11e-7	Attention function in attention deficit hyperactive disorder;
CESC	cis	rs703842	1.000	rs11172349	chr12:58212528	G/A	cg18357645	chr12:58087776	OS9	-0.42	-5.84	-0.34	1.55e-8	Multiple sclerosis;
CESC	cis	rs17253792	0.822	rs74968702	chr14:56076818	A/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.77	5.98	0.34	7.23e-9	Putamen volume;
CESC	cis	rs295137	0.752	rs10931892	chr2:201104997	C/T	cg23649088	chr2:200775458	C2orf69	-0.43	-5.71	-0.33	2.97e-8	Asthma (bronchodilator response);
CESC	cis	rs4654899	0.929	rs7552999	chr1:21314454	T/C	cg05370193	chr1:21551575	ECE1	0.39	5.85	0.34	1.45e-8	Superior frontal gyrus grey matter volume;
CESC	trans	rs11088226	0.681	rs1015048	chr21:33949306	T/C	cg09050820	chr6:167586206	TCP10L2	0.94	10.13	0.53	1.36e-20	Gastritis;
CESC	cis	rs8050907	0.744	rs12446765	chr16:4569625	A/G	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.72	5.2	0.3	3.99e-7	Obesity-related traits;
CESC	cis	rs10504229	0.689	rs17801390	chr8:58054768	T/C	cg21724239	chr8:58056113	NA	0.62	5.77	0.33	2.16e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs1552244	1.000	rs35220123	chr3:10083169	C/T	cg08888203	chr3:10149979	C3orf24	0.46	5.9	0.34	1.11e-8	Alzheimer's disease;
CESC	cis	rs7621025	0.690	rs11715257	chr3:136182053	C/T	cg15507776	chr3:136538369	TMEM22	0.44	5.22	0.31	3.56e-7	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
CESC	cis	rs919433	0.783	rs787979	chr2:198242868	A/T	cg03934865	chr2:198174659	NA	0.42	6.09	0.35	3.93e-9	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs875971	0.545	rs17138156	chr7:65714695	C/T	cg11764359	chr7:65958608	NA	0.75	9.44	0.5	2.03e-18	Aortic root size;
CESC	cis	rs7727544	0.901	rs55633655	chr5:131598756	T/G	cg09877947	chr5:131593287	PDLIM4	0.4	5.07	0.3	7.56e-7	Blood metabolite levels;
CESC	cis	rs7851660	0.844	rs6478445	chr9:100624299	A/G	cg13688889	chr9:100608707	NA	-0.64	-8.89	-0.48	9.61e-17	Strep throat;
CESC	trans	rs997295	0.556	rs10468041	chr15:67773203	G/T	cg05081167	chr6:156967138	NA	0.27	6.0	0.35	6.31e-9	Motion sickness;
CESC	cis	rs7116495	0.609	rs7121080	chr11:71703935	G/A	cg18441811	chr11:71824068	C11orf51	-0.78	-5.3	-0.31	2.43e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs2228479	0.850	rs17232910	chr16:89839766	G/C	cg06558623	chr16:89946397	TCF25	1.17	9.29	0.5	5.84e-18	Skin colour saturation;
CESC	cis	rs769267	0.930	rs2099334	chr19:19578450	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	7.4	0.41	1.78e-12	Tonsillectomy;
CESC	cis	rs12477438	0.765	rs13406288	chr2:99589585	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.65	-8.74	-0.47	2.81e-16	Chronic sinus infection;
CESC	cis	rs7605827	0.930	rs1125533	chr2:15617751	C/G	cg19274914	chr2:15703543	NA	0.35	6.12	0.35	3.29e-9	Educational attainment (years of education);
CESC	cis	rs9902453	0.935	rs9909093	chr17:28271207	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	9.16	0.49	1.49e-17	Coffee consumption (cups per day);
CESC	cis	rs60871478	0.636	rs55663559	chr7:884057	G/A	cg05535760	chr7:792225	HEATR2	-0.76	-7.99	-0.44	4.17e-14	Cerebrospinal P-tau181p levels;
CESC	trans	rs5003154	0.905	rs13273982	chr8:82001360	C/G	cg13159566	chr12:82752887	CCDC59;C12orf26	-0.39	-6.48	-0.37	4.41e-10	Bladder cancer;
CESC	cis	rs6460942	0.591	rs80311633	chr7:12339690	G/C	cg02935154	chr7:12443704	VWDE	-0.5	-5.25	-0.31	3.07e-7	Coronary artery disease;
CESC	cis	rs7811142	1.000	rs11761784	chr7:100039970	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.92	9.76	0.51	2.07e-19	Platelet count;
CESC	cis	rs6860806	0.507	rs2631369	chr5:131705266	G/C	cg18758796	chr5:131593413	PDLIM4	-0.42	-5.65	-0.33	4.19e-8	Breast cancer;
CESC	cis	rs9322193	0.923	rs9689716	chr6:149976798	G/A	cg13206674	chr6:150067644	NUP43	0.44	6.42	0.37	6.24e-10	Lung cancer;
CESC	cis	rs10504229	0.683	rs66730544	chr8:58127280	A/T	cg24829409	chr8:58192753	C8orf71	-0.59	-7.24	-0.41	4.79e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.35	5.09	0.3	6.73e-7	Electroencephalogram traits;
CESC	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg23708337	chr7:1209742	NA	0.53	5.34	0.31	1.98e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs916888	0.821	rs70600	chr17:44860021	C/T	cg22968622	chr17:43663579	NA	1.28	17.05	0.72	1.63e-44	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs1878931	0.501	rs9921169	chr16:3421261	A/T	cg22508957	chr16:3507546	NAT15	-0.4	-5.83	-0.34	1.59e-8	Body mass index (adult);
CESC	cis	rs763121	0.853	rs3747172	chr22:39067524	A/G	cg14440974	chr22:39074834	NA	-0.42	-5.89	-0.34	1.14e-8	Menopause (age at onset);
CESC	trans	rs677673	1.000	rs652325	chr20:10476071	C/T	cg16021678	chr13:55475951	NA	0.46	6.09	0.35	3.98e-9	Body mass index (change over time) in chronic obstructive pulmonary disease;
CESC	cis	rs763014	0.966	rs4247097	chr16:654224	G/A	cg00802000	chr16:706648	WDR90	-0.4	-6.19	-0.36	2.33e-9	Height;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg02056921	chr1:901892	PLEKHN1	0.49	6.3	0.36	1.23e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs9640161	0.789	rs11767409	chr7:150058043	C/T	cg27494647	chr7:150038898	RARRES2	0.42	5.12	0.3	5.75e-7	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg03647317	chr4:187891568	NA	-0.37	-5.56	-0.32	6.44e-8	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7772486	0.727	rs11155442	chr6:146140725	T/C	cg23711669	chr6:146136114	FBXO30	0.97	14.46	0.66	2.38e-35	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9660180	0.967	rs6664664	chr1:1751264	G/A	cg03396347	chr1:1875803	NA	-0.43	-6.67	-0.38	1.46e-10	Body mass index;
CESC	cis	rs2839186	0.872	rs13046834	chr21:47701485	T/C	cg10351095	chr21:47802916	PCNT	-0.5	-6.8	-0.39	6.74e-11	Testicular germ cell tumor;
CESC	cis	rs11864453	0.826	rs12708928	chr16:72137227	C/A	cg01557791	chr16:72042693	DHODH	-0.52	-6.78	-0.38	7.81e-11	Fibrinogen levels;
CESC	cis	rs4654899	0.802	rs935918	chr1:21145660	C/T	cg05370193	chr1:21551575	ECE1	0.39	5.7	0.33	3.12e-8	Superior frontal gyrus grey matter volume;
CESC	cis	rs7666738	0.830	rs11729753	chr4:98803267	T/A	cg24818145	chr4:99064322	C4orf37	0.4	5.18	0.3	4.34e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24833071	chr7:75115655	POM121C	0.6	6.71	0.38	1.18e-10	Gut microbiome composition (summer);
CESC	cis	rs2415984	0.622	rs2415997	chr14:46930446	A/C	cg14871534	chr14:47121158	RPL10L	-0.34	-5.13	-0.3	5.71e-7	Number of children ever born;
CESC	cis	rs7586879	0.639	rs2384058	chr2:25100328	A/G	cg01884057	chr2:25150051	NA	0.36	6.93	0.39	3.12e-11	Body mass index;
CESC	cis	rs4665809	1.000	rs6546744	chr2:26302161	A/G	cg25036284	chr2:26402008	FAM59B	-0.6	-6.97	-0.39	2.56e-11	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.830	rs11097609	chr4:99011707	C/T	cg17366294	chr4:99064904	C4orf37	0.6	8.62	0.47	6.37e-16	Colonoscopy-negative controls vs population controls;
CESC	trans	rs9987353	0.840	rs329994	chr8:9123233	A/G	cg24892074	chr4:89444835	PIGY	-0.51	-6.32	-0.36	1.11e-9	Recombination measurement;
CESC	cis	rs1707322	0.929	rs785513	chr1:46538320	T/C	cg05343316	chr1:45956843	TESK2	-0.45	-5.34	-0.31	1.96e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs76878669	0.561	rs56321771	chr11:66161072	C/T	cg18002602	chr11:66138449	SLC29A2	0.39	6.41	0.37	6.45e-10	Educational attainment (years of education);
CESC	cis	rs7264396	0.635	rs6060688	chr20:34516731	C/G	cg23207816	chr20:34252616	CPNE1;RBM12	-0.53	-6.44	-0.37	5.64e-10	Total cholesterol levels;
CESC	cis	rs56046484	0.711	rs71397835	chr15:85530771	C/T	cg08123816	chr15:85640762	PDE8A	-0.46	-5.27	-0.31	2.78e-7	Testicular germ cell tumor;
CESC	cis	rs1005277	0.563	rs2505216	chr10:38482830	T/C	cg25517755	chr10:38738941	LOC399744	-0.49	-6.35	-0.36	9.08e-10	Extrinsic epigenetic age acceleration;
CESC	cis	rs7927592	0.731	rs2156463	chr11:68386311	T/C	cg20283391	chr11:68216788	NA	-0.44	-5.37	-0.31	1.69e-7	Total body bone mineral density;
CESC	cis	rs13108904	0.935	rs1620928	chr4:1279124	C/T	cg16405210	chr4:1374714	KIAA1530	0.44	5.52	0.32	8.05e-8	Obesity-related traits;
CESC	cis	rs875971	0.545	rs73150604	chr7:65945532	T/A	cg18527119	chr7:66119851	NA	-0.48	-5.19	-0.3	4.15e-7	Aortic root size;
CESC	cis	rs12681366	0.537	rs6999976	chr8:95482422	C/T	cg13257157	chr8:95487014	RAD54B	0.44	5.37	0.31	1.69e-7	Nonsyndromic cleft lip with cleft palate;
CESC	cis	rs13253111	1.000	rs13253111	chr8:28061974	C/T	cg26534493	chr8:28060551	NA	-0.62	-10.34	-0.54	2.9e-21	Childhood body mass index;
CESC	cis	rs9733	0.650	rs1971378	chr1:150597261	C/T	cg13175981	chr1:150552382	MCL1	0.72	10.72	0.55	1.6400000000000001e-22	Tonsillectomy;
CESC	cis	rs826838	0.967	rs11183622	chr12:38792849	T/C	cg26384229	chr12:38710491	ALG10B	0.83	14.61	0.67	7.23e-36	Heart rate;
CESC	cis	rs12477438	0.520	rs36071868	chr2:99737120	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	15.18	0.68	6.85e-38	Chronic sinus infection;
CESC	cis	rs7818345	0.967	rs11204039	chr8:19280442	A/C	cg11303988	chr8:19266685	CSGALNACT1	0.32	5.75	0.33	2.51e-8	Language performance in older adults (adjusted for episodic memory);
CESC	cis	rs10870270	0.956	rs10870293	chr10:133771413	G/A	cg26149184	chr10:133730230	NA	0.37	5.08	0.3	7.04e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs7811142	0.830	rs41280971	chr7:99954457	G/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.04	10.52	0.54	7.52e-22	Platelet count;
CESC	cis	rs8044868	0.530	rs8060770	chr16:72155694	C/A	cg16558253	chr16:72132732	DHX38	-0.38	-5.9	-0.34	1.1e-8	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CESC	cis	rs796364	0.806	rs1106400	chr2:201004089	T/C	cg23649088	chr2:200775458	C2orf69	-0.58	-5.71	-0.33	3.07e-8	Schizophrenia;
CESC	cis	rs7872515	1.000	rs10992221	chr9:94832043	A/G	cg01248375	chr9:94877805	SPTLC1	-0.56	-5.7	-0.33	3.2e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs2228479	0.702	rs11076621	chr16:89837927	A/G	cg14709524	chr16:89940631	TCF25	0.91	6.74	0.38	1e-10	Skin colour saturation;
CESC	cis	rs116095464	0.558	rs6555055	chr5:226160	A/C	cg22496380	chr5:211416	CCDC127	-0.74	-8.78	-0.47	2.06e-16	Breast cancer;
CESC	cis	rs9916302	0.752	rs9901219	chr17:37558369	T/G	cg00129232	chr17:37814104	STARD3	0.56	6.5	0.37	3.99e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs6032067	0.929	rs13039083	chr20:43878838	T/A	cg10761708	chr20:43804764	PI3	0.44	5.4	0.31	1.5e-7	Blood protein levels;
CESC	cis	rs113835537	0.529	rs17496250	chr11:66270774	C/G	cg22134325	chr11:66188745	NPAS4	0.46	7.16	0.4	8.01e-12	Airway imaging phenotypes;
CESC	trans	rs9467711	0.606	rs9393708	chr6:26362643	C/T	cg06606381	chr12:133084897	FBRSL1	0.73	7.01	0.4	1.95e-11	Autism spectrum disorder or schizophrenia;
CESC	cis	rs9457247	0.967	rs1794694	chr6:167404751	T/C	cg07741184	chr6:167504864	NA	0.28	5.1	0.3	6.54e-7	Crohn's disease;
CESC	cis	rs9649213	0.593	rs1468341	chr7:97987696	G/A	cg24562669	chr7:97807699	LMTK2	0.52	7.69	0.43	2.87e-13	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs13106227	0.550	rs4859674	chr4:77376813	A/G	cg20311846	chr4:77356250	SHROOM3	-0.31	-5.67	-0.33	3.65e-8	Eosinophilic esophagitis (pediatric);
CESC	trans	rs916888	0.773	rs199534	chr17:44824213	T/G	cg10053473	chr17:62856997	LRRC37A3	-0.72	-7.68	-0.43	3.06e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	trans	rs8073060	0.614	rs72829932	chr17:34055935	A/G	cg19694781	chr19:47549865	TMEM160	0.74	6.72	0.38	1.14e-10	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	cis	rs2832191	0.692	rs2245734	chr21:30359965	C/T	cg08807101	chr21:30365312	RNF160	0.92	14.34	0.66	6.58e-35	Dental caries;
CESC	cis	rs8114671	0.562	rs6088655	chr20:33527838	A/G	cg07148914	chr20:33460835	GGT7	0.47	6.18	0.35	2.4e-9	Height;
CESC	cis	rs6724607	1.000	rs13006708	chr2:191471428	G/A	cg27211696	chr2:191398769	TMEM194B	-0.53	-8.0	-0.44	3.94e-14	Pulse pressure;
CESC	cis	rs7178572	0.568	rs10152181	chr15:77678346	A/G	cg22256960	chr15:77711686	NA	-0.54	-6.95	-0.39	2.9e-11	Type 2 diabetes;
CESC	trans	rs11098499	0.722	rs7673476	chr4:120248683	C/T	cg25214090	chr10:38739885	LOC399744	0.58	8.09	0.45	2.14e-14	Corneal astigmatism;
CESC	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg14159672	chr1:205819179	PM20D1	-0.78	-12.41	-0.61	3.57e-28	Menarche (age at onset);
CESC	cis	rs8072100	0.902	rs12051716	chr17:45582395	G/A	cg08085267	chr17:45401833	C17orf57	0.42	5.6	0.33	5.46e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs9322193	0.923	rs10747275	chr6:149943918	C/T	cg07701084	chr6:150067640	NUP43	0.43	6.0	0.35	6.52e-9	Lung cancer;
CESC	cis	rs853679	0.550	rs1233699	chr6:28169158	A/T	cg20151795	chr6:28129481	ZNF389	0.4	5.44	0.32	1.22e-7	Depression;
CESC	cis	rs4319547	1.000	rs7307735	chr12:123087442	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.57	-6.82	-0.39	6.15e-11	Body mass index;
CESC	cis	rs7412746	0.634	rs12562939	chr1:150951452	A/C	cg04414720	chr1:150670196	GOLPH3L	0.49	6.45	0.37	5.22e-10	Melanoma;
CESC	trans	rs12356475	0.710	rs10822686	chr10:67733250	C/T	cg24508409	chr1:112298175	DDX20;C1orf183	0.5	6.0	0.35	6.63e-9	Psoriatic arthritis;
CESC	cis	rs875971	0.838	rs2173570	chr7:65762963	T/A	cg18876405	chr7:65276391	NA	-0.49	-6.77	-0.38	8.35e-11	Aortic root size;
CESC	cis	rs7267979	0.966	rs2261795	chr20:25263136	T/C	cg08601574	chr20:25228251	PYGB	0.39	5.67	0.33	3.69e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs9527	0.590	rs1935323	chr10:104877035	T/C	cg04362960	chr10:104952993	NT5C2	0.42	5.28	0.31	2.71e-7	Arsenic metabolism;
CESC	cis	rs1775715	0.707	rs2799024	chr10:32166922	A/G	cg18675610	chr10:32216311	ARHGAP12	0.35	5.41	0.32	1.38e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs9733	0.526	rs11204696	chr1:150658721	T/C	cg18016565	chr1:150552671	MCL1	0.33	5.09	0.3	6.65e-7	Tonsillectomy;
CESC	trans	rs35110281	0.840	rs2838331	chr21:45026728	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.54	-7.18	-0.4	7e-12	Mean corpuscular volume;
CESC	cis	rs3008870	1.000	rs2985818	chr1:67398916	G/A	cg08660285	chr1:67390436	MIER1;WDR78	1.06	15.19	0.68	6.65e-38	Lymphocyte percentage of white cells;
CESC	cis	rs7193541	0.684	rs9923145	chr16:74686166	G/A	cg05580060	chr16:74700937	RFWD3	-0.49	-6.3	-0.36	1.26e-9	Multiple myeloma;
CESC	cis	rs651907	0.557	rs3094296	chr3:101400167	A/G	cg12386194	chr3:101231763	SENP7	0.44	5.38	0.31	1.63e-7	Colorectal cancer;
CESC	cis	rs7296418	0.630	rs28419092	chr12:123812629	G/C	cg05973401	chr12:123451056	ABCB9	0.42	5.35	0.31	1.91e-7	Platelet count;
CESC	cis	rs6500602	0.701	rs4786500	chr16:4525265	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.38	-5.59	-0.32	5.59e-8	Schizophrenia;
CESC	cis	rs2070488	0.775	rs6780349	chr3:38555178	C/T	cg24069376	chr3:38537580	EXOG	-0.32	-5.55	-0.32	7.02e-8	Electrocardiographic conduction measures;
CESC	cis	rs897984	0.609	rs4889609	chr16:31026427	A/G	cg02466173	chr16:30829666	NA	-0.38	-6.48	-0.37	4.36e-10	Dementia with Lewy bodies;
CESC	cis	rs11249608	0.548	rs13161528	chr5:178452958	C/G	cg01312482	chr5:178451176	ZNF879	-0.46	-6.48	-0.37	4.52e-10	Pubertal anthropometrics;
CESC	cis	rs1881797	1.000	rs67977965	chr1:247687835	G/A	cg18198730	chr1:247681584	NA	0.59	7.76	0.43	1.84e-13	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs9300255	0.602	rs2851438	chr12:123643689	T/C	cg05973401	chr12:123451056	ABCB9	0.5	5.81	0.34	1.79e-8	Neutrophil percentage of white cells;
CESC	cis	rs2075371	1.000	rs1862050	chr7:133980999	T/C	cg11752832	chr7:134001865	SLC35B4	0.54	7.09	0.4	1.18e-11	Mean platelet volume;
CESC	cis	rs7412746	0.611	rs36008098	chr1:150856806	G/A	cg17724175	chr1:150552817	MCL1	0.33	5.13	0.3	5.51e-7	Melanoma;
CESC	cis	rs1270639	0.778	rs2906934	chr7:157451447	G/A	cg13357408	chr7:157437802	PTPRN2	0.61	6.72	0.38	1.12e-10	Colorectal cancer;
CESC	cis	rs6547741	1.000	rs1528402	chr2:27857517	G/A	cg27432699	chr2:27873401	GPN1	0.46	6.43	0.37	5.87e-10	Oral cavity cancer;
CESC	cis	rs9487051	0.714	rs6902892	chr6:109627601	G/T	cg21918786	chr6:109611834	NA	-0.36	-5.29	-0.31	2.52e-7	Reticulocyte fraction of red cells;
CESC	cis	rs2840044	0.534	rs321596	chr17:33885736	C/T	cg05299278	chr17:33885742	SLFN14	-0.44	-6.32	-0.36	1.08e-9	Response to radiotherapy in cancer (late toxicity);
CESC	cis	rs9611565	0.512	rs4822052	chr22:42193741	G/A	cg06634786	chr22:41940651	POLR3H	-0.68	-6.91	-0.39	3.6e-11	Vitiligo;
CESC	cis	rs8062405	1.000	rs12443881	chr16:28841777	C/T	cg05966235	chr16:28915196	ATP2A1	0.34	5.13	0.3	5.71e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs7552404	0.731	rs10873787	chr1:76367797	G/A	cg03433033	chr1:76189801	ACADM	0.57	5.63	0.33	4.7e-8	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs2294693	0.945	rs68031000	chr6:41008841	G/T	cg14769373	chr6:40998127	UNC5CL	-0.45	-5.78	-0.33	2.09e-8	Gastric cancer;Non-cardia gastric cancer;
CESC	cis	rs858239	0.600	rs10233039	chr7:23143113	G/A	cg23682824	chr7:23144976	KLHL7	0.51	6.86	0.39	4.76e-11	Cerebrospinal fluid biomarker levels;
CESC	cis	rs8058578	1.000	rs2289442	chr16:30739919	A/G	cg00531865	chr16:30841666	NA	-0.41	-5.37	-0.31	1.76e-7	Multiple myeloma;
CESC	cis	rs7945705	0.712	rs61876274	chr11:9019190	A/T	cg12365402	chr11:9010492	NRIP3	0.49	8.24	0.45	8.06e-15	Hemoglobin concentration;
CESC	cis	rs6582630	0.622	rs11831595	chr12:38511489	C/A	cg26384229	chr12:38710491	ALG10B	-0.43	-5.78	-0.33	2.12e-8	Drug-induced liver injury (flucloxacillin);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg06756931	chr17:78820893	RPTOR	0.49	6.95	0.39	2.79e-11	Fibrinogen levels;
CESC	cis	rs3806843	0.933	rs10069930	chr5:140163328	T/A	cg26395211	chr5:140044315	WDR55	-0.41	-5.3	-0.31	2.39e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs7618915	0.547	rs6768697	chr3:52703615	C/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.31	5.59	0.32	5.58e-8	Bipolar disorder;
CESC	cis	rs7264396	1.000	rs224409	chr20:34124920	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.52	-6.47	-0.37	4.78e-10	Total cholesterol levels;
CESC	cis	rs3806843	1.000	rs6898939	chr5:140169355	C/A	cg26395211	chr5:140044315	WDR55	-0.42	-5.3	-0.31	2.39e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs1348850	0.750	rs12997716	chr2:178494629	G/A	cg22681709	chr2:178499509	PDE11A	-0.43	-6.47	-0.37	4.78e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02958167	chr6:170151846	TCTE3;C6orf70	0.61	7.18	0.4	7.13e-12	Gut microbiome composition (summer);
CESC	cis	rs1348850	0.668	rs6734683	chr2:178494012	C/G	cg23306229	chr2:178417860	TTC30B	0.56	6.75	0.38	9.5e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg04297258	chr16:88772664	RNF166;CTU2	-0.48	-6.9	-0.39	3.74e-11	Gambling;
CESC	cis	rs1344694	0.566	rs4672790	chr2:216892446	C/T	cg12620499	chr2:216877984	MREG	0.65	9.63	0.51	5.12e-19	Alcohol dependence;
CESC	cis	rs4665809	0.878	rs6748745	chr2:26364190	C/T	cg27170947	chr2:26402098	FAM59B	-0.65	-7.94	-0.44	5.66e-14	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.830	rs6855393	chr4:99056534	T/C	cg05340658	chr4:99064831	C4orf37	0.83	12.92	0.62	6.18e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9430161	0.564	rs12081176	chr1:11034145	T/C	cg02454025	chr1:11042201	C1orf127	0.99	16.1	0.7	3.84e-41	Ewing sarcoma;
CESC	cis	rs9549367	0.713	rs3024769	chr13:113825601	A/C	cg00898013	chr13:113819073	PROZ	0.46	6.7	0.38	1.25e-10	Platelet distribution width;
CESC	cis	rs870825	0.616	rs79884757	chr4:185621454	A/G	cg04058563	chr4:185651563	MLF1IP	0.64	7.05	0.4	1.59e-11	Blood protein levels;
CESC	cis	rs875971	1.000	rs10244498	chr7:66116056	A/G	cg11764359	chr7:65958608	NA	0.88	13.78	0.65	5.87e-33	Aortic root size;
CESC	cis	rs9902453	0.934	rs8079028	chr17:28484234	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.65	8.43	0.46	2.29e-15	Coffee consumption (cups per day);
CESC	cis	rs9296095	0.747	rs12206050	chr6:33564296	A/T	cg14003231	chr6:33640908	ITPR3	0.43	6.59	0.37	2.43e-10	Platelet count;
CESC	trans	rs561341	0.941	rs501773	chr17:30314435	T/G	cg20587970	chr11:113659929	NA	-1.1	-13.93	-0.65	1.88e-33	Hip circumference adjusted for BMI;
CESC	cis	rs9388451	0.839	rs3757217	chr6:126069636	G/C	cg10911889	chr6:126070802	HEY2	0.41	5.67	0.33	3.64e-8	Brugada syndrome;
CESC	cis	rs2075371	0.796	rs12672752	chr7:134007382	C/T	cg00033643	chr7:134001901	SLC35B4	0.41	5.13	0.3	5.72e-7	Mean platelet volume;
CESC	cis	rs7561273	0.586	rs116650625	chr2:24353212	C/G	cg20701182	chr2:24300061	SF3B14	0.46	6.01	0.35	6.27e-9	Quantitative traits;
CESC	cis	rs950776	0.518	rs2869544	chr15:78839400	G/A	cg24631222	chr15:78858424	CHRNA5	0.39	5.12	0.3	5.79e-7	Sudden cardiac arrest;
CESC	cis	rs763121	0.853	rs6001214	chr22:39149155	C/T	cg06544989	chr22:39130855	UNC84B	0.49	8.7	0.47	3.68e-16	Menopause (age at onset);
CESC	cis	rs12900413	0.603	rs7177841	chr15:90302117	C/A	cg24249390	chr15:90295951	MESP1	-0.4	-5.4	-0.31	1.52e-7	Coronary artery aneurysm in Kawasaki disease;
CESC	cis	rs2991971	0.967	rs937291	chr1:45957039	G/T	cg24296786	chr1:45957014	TESK2	0.68	9.37	0.5	3.33e-18	High light scatter reticulocyte count;
CESC	cis	rs6484504	0.512	rs7940020	chr11:31366453	T/G	cg14844989	chr11:31128820	NA	0.38	5.16	0.3	4.92e-7	Red blood cell count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27367768	chr5:171615456	STK10	0.52	6.0	0.35	6.47e-9	Gut microbiome composition (summer);
CESC	cis	rs644799	1.000	rs586498	chr11:95537828	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.53	6.38	0.37	7.71e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs4282054	0.631	rs13081155	chr3:52732429	A/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.34	-5.07	-0.3	7.39e-7	Cognitive function;
CESC	cis	rs4409675	0.576	rs7520860	chr1:28232952	C/A	cg23691781	chr1:28212827	C1orf38	0.28	5.53	0.32	7.57e-8	Corneal astigmatism;
CESC	cis	rs6964587	0.967	rs34574955	chr7:91847550	A/C	cg17063962	chr7:91808500	NA	0.58	7.86	0.43	9.59e-14	Breast cancer;
CESC	cis	rs262150	0.819	rs6956589	chr7:158769301	C/T	cg19418458	chr7:158789849	NA	-0.5	-7.97	-0.44	4.62e-14	Facial morphology (factor 20);
CESC	cis	rs896854	0.714	rs6471503	chr8:95990283	G/A	cg13393036	chr8:95962371	TP53INP1	-0.49	-10.71	-0.55	1.77e-22	Type 2 diabetes;
CESC	trans	rs12960505	0.506	rs1125627	chr18:51004270	C/T	cg16503797	chr18:19476805	NA	0.42	6.11	0.35	3.54e-9	Intelligence (multi-trait analysis);
CESC	cis	rs7408868	0.520	rs1043994	chr19:15302844	T/C	cg14696996	chr19:15285081	NOTCH3	0.96	9.33	0.5	4.33e-18	Pulse pressure;
CESC	cis	rs922182	0.542	rs7179912	chr15:64263854	C/T	cg24729988	chr15:64271149	DAPK2	0.4	5.32	0.31	2.21e-7	Blood protein levels;
CESC	cis	rs2073300	1.000	rs6132622	chr20:23442240	A/T	cg12062639	chr20:23401060	NAPB	0.91	6.41	0.37	6.71e-10	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs7824557	0.628	rs34237267	chr8:11197301	G/C	cg21775007	chr8:11205619	TDH	0.58	9.28	0.5	6.25e-18	Retinal vascular caliber;
CESC	cis	rs7618915	0.547	rs11714419	chr3:52628816	A/G	cg05564831	chr3:52568323	NT5DC2	0.45	6.9	0.39	3.76e-11	Bipolar disorder;
CESC	cis	rs9733	0.596	rs1136808	chr1:150702717	G/C	cg09365446	chr1:150670422	GOLPH3L	0.42	5.84	0.34	1.55e-8	Tonsillectomy;
CESC	cis	rs2645694	0.626	rs2703122	chr4:77821418	A/C	cg18351406	chr4:77819688	ANKRD56	0.55	6.89	0.39	4.12e-11	Emphysema distribution in smoking;
CESC	cis	rs7267979	1.000	rs2424716	chr20:25423538	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.83	16.43	0.71	2.68e-42	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs826838	0.967	rs1719852	chr12:39128531	A/G	cg26384229	chr12:38710491	ALG10B	-0.66	-10.31	-0.54	3.42e-21	Heart rate;
CESC	cis	rs2228479	0.541	rs12918575	chr16:89811151	A/G	cg00800038	chr16:89945340	TCF25	-0.71	-7.24	-0.41	4.76e-12	Skin colour saturation;
CESC	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg23034840	chr1:205782522	SLC41A1	0.68	8.34	0.46	4.1e-15	Menarche (age at onset);
CESC	cis	rs9399135	0.935	rs2150680	chr6:135347131	G/C	cg22676075	chr6:135203613	NA	0.51	7.36	0.41	2.34e-12	Red blood cell count;
CESC	cis	rs9788682	0.706	rs2568493	chr15:78740233	G/A	cg24631222	chr15:78858424	CHRNA5	-0.61	-7.19	-0.4	6.65e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs7666738	0.830	rs13118945	chr4:98968586	T/G	cg03676636	chr4:99064102	C4orf37	0.34	5.2	0.3	4.04e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs875971	0.964	rs778721	chr7:65845397	C/G	cg12463550	chr7:65579703	CRCP	0.59	7.42	0.41	1.55e-12	Aortic root size;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg06124975	chr6:107810578	SOBP	0.46	6.11	0.35	3.52e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs10779751	0.734	rs1034528	chr1:11249132	G/C	cg08854313	chr1:11322531	MTOR	-0.82	-10.73	-0.55	1.5e-22	Body mass index;
CESC	cis	rs780096	0.587	rs10205219	chr2:27568565	T/C	cg24768116	chr2:27665128	KRTCAP3	-0.3	-5.61	-0.33	5.09e-8	Total body bone mineral density;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13253694	chr11:60609608	CCDC86	0.56	6.39	0.37	7.59e-10	Gut microbiome composition (summer);
CESC	cis	rs1670533	1.000	rs633556	chr4:1092405	A/G	cg27284194	chr4:1044797	NA	0.45	5.84	0.34	1.5e-8	Recombination rate (females);
CESC	cis	rs2066819	1.000	rs1274493	chr12:56682371	C/T	cg26714650	chr12:56694279	CS	1.29	16.3	0.71	7.7e-42	Psoriasis vulgaris;
CESC	cis	rs9916302	0.861	rs4795376	chr17:37669043	T/C	cg07936489	chr17:37558343	FBXL20	-0.8	-11.82	-0.59	3.49e-26	Glomerular filtration rate (creatinine);
CESC	cis	rs7267979	1.000	rs6138575	chr20:25438952	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.82	15.34	0.69	1.94e-38	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs10791097	0.694	rs4937581	chr11:130740335	T/C	cg12179176	chr11:130786555	SNX19	0.64	10.04	0.52	2.69e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs9322193	0.923	rs9322196	chr6:149940781	T/G	cg07701084	chr6:150067640	NUP43	0.43	6.0	0.35	6.52e-9	Lung cancer;
CESC	cis	rs7937682	0.924	rs4630327	chr11:111539327	C/T	cg22437258	chr11:111473054	SIK2	-0.67	-9.17	-0.49	1.34e-17	Primary sclerosing cholangitis;
CESC	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg02725872	chr8:58115012	NA	-0.42	-5.88	-0.34	1.25e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs2735413	0.875	rs12924402	chr16:78083477	C/G	cg04733911	chr16:78082701	NA	-0.53	-8.86	-0.48	1.17e-16	Systolic blood pressure (alcohol consumption interaction);
CESC	cis	rs12142240	0.698	rs17361950	chr1:46864150	C/T	cg00530320	chr1:46809349	NSUN4	0.59	7.98	0.44	4.57e-14	Menopause (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13446525	chr9:128170432	NA	0.56	7.16	0.4	8.09e-12	Gut microbiome composition (summer);
CESC	cis	rs61931739	0.517	rs12367881	chr12:34175508	T/C	cg19457237	chr12:34500585	NA	-0.4	-5.33	-0.31	2.11e-7	Morning vs. evening chronotype;
CESC	cis	rs67311347	1.000	rs73078163	chr3:40479958	C/T	cg09455208	chr3:40491958	NA	0.51	8.35	0.46	3.82e-15	Renal cell carcinoma;
CESC	cis	rs7680126	0.633	rs11730631	chr4:10292968	C/T	cg00071950	chr4:10020882	SLC2A9	0.51	5.82	0.34	1.66e-8	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	cis	rs10870270	1.000	rs3935905	chr10:133758262	A/C	cg26149184	chr10:133730230	NA	0.38	5.2	0.3	4.06e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	trans	rs7618501	1.000	rs7374183	chr3:49785133	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.6	-8.49	-0.46	1.52e-15	Intelligence (multi-trait analysis);
CESC	cis	rs854765	0.693	rs11657074	chr17:17770355	G/A	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.45	-5.83	-0.34	1.58e-8	Total body bone mineral density;
CESC	cis	rs11122272	0.735	rs2246645	chr1:231497393	T/G	cg06096015	chr1:231504339	EGLN1	0.44	6.42	0.37	6.34e-10	Hemoglobin concentration;
CESC	cis	rs42648	0.869	rs1015404	chr7:89913946	G/C	cg23697855	chr7:89950296	NA	0.27	5.05	0.3	8.24e-7	Homocysteine levels;
CESC	cis	rs2576037	0.583	rs641366	chr18:44430326	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.35	5.69	0.33	3.3e-8	Personality dimensions;
CESC	cis	rs4268898	0.931	rs2551121	chr2:24539967	T/C	cg20701182	chr2:24300061	SF3B14	0.49	5.9	0.34	1.1e-8	Asthma;
CESC	cis	rs7772486	0.686	rs1569540	chr6:146069112	A/G	cg05347473	chr6:146136440	FBXO30	-0.53	-6.96	-0.39	2.69e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs12188164	0.965	rs72717430	chr5:444502	T/C	cg21144161	chr5:423903	AHRR	0.37	5.98	0.34	7.12e-9	Cystic fibrosis severity;
CESC	cis	rs60871478	0.636	rs4721834	chr7:896142	C/T	cg13798912	chr7:905769	UNC84A	-0.56	-5.53	-0.32	7.82e-8	Cerebrospinal P-tau181p levels;
CESC	cis	rs8031584	0.918	rs61997138	chr15:31270776	C/T	cg08109568	chr15:31115862	NA	-0.71	-9.43	-0.5	2.19e-18	Huntington's disease progression;
CESC	cis	rs1483890	0.723	rs2007578	chr3:69408982	T/A	cg22125112	chr3:69402811	FRMD4B	0.41	5.53	0.32	7.56e-8	Resting heart rate;
CESC	cis	rs1799949	0.602	rs8176257	chr17:41216205	G/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.57	6.53	0.37	3.36e-10	Menopause (age at onset);
CESC	cis	rs12497850	0.931	rs6414613	chr3:49035885	C/T	cg02487422	chr3:49467188	NICN1	0.43	5.52	0.32	7.91e-8	Parkinson's disease;
CESC	cis	rs2486288	0.656	rs12911186	chr15:45551423	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.54	-6.55	-0.37	3.03e-10	Glomerular filtration rate;
CESC	cis	rs7818345	0.935	rs4633071	chr8:19275852	G/A	cg11303988	chr8:19266685	CSGALNACT1	0.34	6.25	0.36	1.64e-9	Language performance in older adults (adjusted for episodic memory);
CESC	cis	rs71403859	0.502	rs35394108	chr16:71540639	T/C	cg08717414	chr16:71523259	ZNF19	-1.02	-9.82	-0.52	1.29e-19	Post bronchodilator FEV1;
CESC	cis	rs2463822	0.920	rs11828383	chr11:62067818	C/T	cg06239285	chr11:62104954	ASRGL1	-1.08	-9.44	-0.5	2.08e-18	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs597539	0.652	rs569777	chr11:68706848	G/A	cg01988459	chr11:68622903	NA	-0.45	-6.33	-0.36	1.02e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg21394442	chr8:110346440	ENY2;NUDCD1	-0.47	-6.54	-0.37	3.09e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs2832191	0.716	rs1543652	chr21:30448000	G/C	cg08807101	chr21:30365312	RNF160	0.93	14.2	0.66	2.05e-34	Dental caries;
CESC	cis	rs832540	0.695	rs702686	chr5:56201350	A/G	cg24531977	chr5:56204891	C5orf35	-0.59	-7.73	-0.43	2.2e-13	Coronary artery disease;
CESC	cis	rs9611565	0.649	rs5758434	chr22:42116163	G/A	cg06481639	chr22:41940642	POLR3H	0.48	5.58	0.32	6.02e-8	Vitiligo;
CESC	cis	rs2075371	0.897	rs1646733	chr7:134002228	C/A	cg00033643	chr7:134001901	SLC35B4	0.41	5.15	0.3	5.13e-7	Mean platelet volume;
CESC	cis	rs1799949	0.965	rs33988650	chr17:41287880	A/G	cg05368731	chr17:41323189	NBR1	0.8	11.27	0.57	2.51e-24	Menopause (age at onset);
CESC	cis	rs2832191	0.791	rs2832178	chr21:30479858	T/G	cg24692254	chr21:30365293	RNF160	-0.8	-12.76	-0.62	2.24e-29	Dental caries;
CESC	cis	rs6772849	0.896	rs35535737	chr3:128383406	G/A	cg16766828	chr3:128327626	NA	-0.31	-5.12	-0.3	5.93e-7	Monocyte percentage of white cells;Monocyte count;
CESC	cis	rs7528419	1.000	rs629301	chr1:109818306	G/T	cg00908766	chr1:109817496	CELSR2	0.5	7.35	0.41	2.49e-12	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
CESC	cis	rs5750830	0.649	rs6001588	chr22:39819049	G/C	cg05872129	chr22:39784769	NA	-0.81	-10.75	-0.55	1.29e-22	Intelligence (multi-trait analysis);
CESC	cis	rs875971	0.895	rs1833495	chr7:65921595	T/C	cg18876405	chr7:65276391	NA	0.51	6.82	0.39	6.05e-11	Aortic root size;
CESC	cis	rs1577917	0.876	rs66986937	chr6:86532191	A/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.51	-6.61	-0.38	2.11e-10	Response to antipsychotic treatment;
CESC	cis	rs921968	0.565	rs6436069	chr2:219597185	T/C	cg02176678	chr2:219576539	TTLL4	-0.44	-7.76	-0.43	1.79e-13	Mean corpuscular hemoglobin concentration;
CESC	cis	rs9837602	0.872	rs34996634	chr3:99738219	T/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.47	6.07	0.35	4.47e-9	Breast cancer;
CESC	cis	rs9733	0.818	rs7520022	chr1:150659173	C/G	cg18016565	chr1:150552671	MCL1	-0.32	-5.3	-0.31	2.46e-7	Tonsillectomy;
CESC	cis	rs863345	0.604	rs12034004	chr1:158463885	A/G	cg12129480	chr1:158549410	OR10X1	-0.35	-6.97	-0.39	2.46e-11	Pneumococcal bacteremia;
CESC	cis	rs5167	0.789	rs204467	chr19:45491174	A/G	cg09555818	chr19:45449301	APOC2	-0.35	-5.06	-0.3	7.67e-7	Blood protein levels;
CESC	cis	rs6537837	0.838	rs3737182	chr1:110091271	C/T	cg05049280	chr1:110155535	GNAT2	0.4	5.63	0.33	4.68e-8	Major depressive disorder;
CESC	cis	rs7429990	0.932	rs6442101	chr3:48130893	C/T	cg11946769	chr3:48343235	NME6	-0.54	-6.59	-0.38	2.42e-10	Educational attainment (years of education);
CESC	cis	rs4819052	0.851	rs4819041	chr21:46659955	C/T	cg11663144	chr21:46675770	NA	-0.5	-7.64	-0.43	3.86e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs11785400	0.793	rs1137521	chr8:143739162	C/T	cg24634471	chr8:143751801	JRK	0.45	5.69	0.33	3.29e-8	Schizophrenia;
CESC	cis	rs7917772	0.582	rs4408249	chr10:104374653	T/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.39	5.33	0.31	2.11e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs9910055	0.530	rs11656758	chr17:42301541	A/G	cg13607699	chr17:42295918	UBTF	0.82	12.63	0.61	6.1e-29	Total body bone mineral density;
CESC	cis	rs854765	0.505	rs2955358	chr17:17946623	A/G	cg16928487	chr17:17741425	SREBF1	0.57	9.81	0.52	1.36e-19	Total body bone mineral density;
CESC	cis	rs7799006	0.527	rs73039284	chr7:2221583	C/G	cg08027265	chr7:2291960	NA	-0.38	-5.51	-0.32	8.31e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs11098499	0.954	rs4577559	chr4:120404043	T/G	cg09307838	chr4:120376055	NA	0.93	13.07	0.63	1.78e-30	Corneal astigmatism;
CESC	cis	rs1790761	0.554	rs3758938	chr11:67402362	T/G	cg24690094	chr11:67383802	NA	-0.35	-5.48	-0.32	9.74e-8	Mean corpuscular volume;
CESC	cis	rs3741151	0.764	rs73548680	chr11:73271335	T/C	cg17517138	chr11:73019481	ARHGEF17	1.03	7.61	0.42	4.75e-13	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs933688	1.000	rs332531	chr5:90790451	G/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.95	11.97	0.59	1.1e-26	Smoking behavior;
CESC	cis	rs801193	1.000	rs2707854	chr7:66212597	G/A	cg06456125	chr7:65229604	NA	0.4	5.23	0.31	3.51e-7	Aortic root size;
CESC	cis	rs11190604	1.000	rs11190592	chr10:102291059	T/C	cg07080220	chr10:102295463	HIF1AN	0.7	6.48	0.37	4.34e-10	Palmitoleic acid (16:1n-7) levels;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg26240433	chr14:94547826	DDX24;IFI27L1	-0.43	-6.11	-0.35	3.51e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs12410462	1.000	rs1587158	chr1:227658753	G/A	cg23173402	chr1:227635558	NA	-0.56	-5.75	-0.33	2.44e-8	Major depressive disorder;
CESC	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg24829409	chr8:58192753	C8orf71	-0.67	-8.02	-0.44	3.52e-14	Developmental language disorder (linguistic errors);
CESC	cis	rs9818758	0.607	rs9990153	chr3:49291883	C/T	cg00383909	chr3:49044727	WDR6	0.73	6.32	0.36	1.1e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CESC	trans	rs7666738	0.830	rs4292341	chr4:98959724	C/T	cg01369341	chr16:4852941	ROGDI	0.44	6.1	0.35	3.77e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2075371	0.933	rs1421481	chr7:133964380	A/C	cg20476274	chr7:133979776	SLC35B4	0.68	10.15	0.53	1.19e-20	Mean platelet volume;
CESC	cis	rs9303401	0.614	rs34920953	chr17:56589406	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.0	12.26	0.6	1.16e-27	Cognitive test performance;
CESC	trans	rs875971	1.000	rs6961990	chr7:65888570	C/A	cg26939375	chr7:64535504	NA	0.47	6.04	0.35	5.14e-9	Aortic root size;
CESC	cis	rs7683537	0.887	rs7678412	chr4:185648611	T/C	cg04058563	chr4:185651563	MLF1IP	0.63	6.96	0.39	2.59e-11	Systemic lupus erythematosus;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg03503634	chr11:36531973	TRAF6	-0.55	-7.61	-0.42	4.95e-13	Fibrinogen levels;
CESC	cis	rs1270639	0.778	rs2906928	chr7:157444976	T/G	cg13357408	chr7:157437802	PTPRN2	0.62	7.26	0.41	4.32e-12	Colorectal cancer;
CESC	cis	rs10504229	1.000	rs72650892	chr8:58179714	A/G	cg22535103	chr8:58192502	C8orf71	-1.05	-13.27	-0.63	3.63e-31	Developmental language disorder (linguistic errors);
CESC	cis	rs7134594	0.677	rs7137190	chr12:109866108	G/C	cg19025524	chr12:109796872	NA	-0.41	-5.92	-0.34	9.73e-9	HDL cholesterol;
CESC	cis	rs9911578	1.000	rs9897326	chr17:56902297	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.26	0.31	3.04e-7	Intelligence (multi-trait analysis);
CESC	cis	rs4253772	0.638	rs6007845	chr22:46718417	A/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	-0.73	-9.0	-0.48	4.53e-17	LDL cholesterol;Cholesterol, total;
CESC	cis	rs4803468	1.000	rs3810174	chr19:41904165	C/T	cg09537434	chr19:41945824	ATP5SL	-1.02	-18.28	-0.75	7.49e-49	Height;
CESC	cis	rs8067354	0.681	rs76856339	chr17:57800966	G/A	cg13753209	chr17:57696993	CLTC	0.59	6.34	0.36	9.87e-10	Hemoglobin concentration;
CESC	cis	rs736408	0.609	rs2268025	chr3:52795224	A/T	cg18404041	chr3:52824283	ITIH1	-0.45	-7.4	-0.41	1.84e-12	Bipolar disorder;
CESC	cis	rs7084402	0.967	rs1658429	chr10:60330422	T/C	cg07615347	chr10:60278583	BICC1	0.59	9.15	0.49	1.57e-17	Refractive error;
CESC	cis	rs10751667	0.961	rs6597953	chr11:991099	G/A	cg20946044	chr11:1010712	AP2A2	-0.46	-5.89	-0.34	1.17e-8	Alzheimer's disease (late onset);
CESC	cis	rs561341	1.000	rs8070262	chr17:30262467	A/G	cg12193833	chr17:30244370	NA	-0.49	-5.49	-0.32	9.5e-8	Hip circumference adjusted for BMI;
CESC	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg11494091	chr17:61959527	GH2	0.72	12.38	0.61	4.46e-28	Prudent dietary pattern;
CESC	cis	rs6963495	0.538	rs55967123	chr7:105163678	C/A	cg19920283	chr7:105172520	RINT1	0.7	6.66	0.38	1.58e-10	Bipolar disorder (body mass index interaction);
CESC	cis	rs7666738	0.830	rs4699577	chr4:98846513	G/A	cg05340658	chr4:99064831	C4orf37	0.71	10.13	0.53	1.37e-20	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7829975	0.871	rs572307	chr8:8578811	T/C	cg15556689	chr8:8085844	FLJ10661	-0.44	-5.58	-0.32	5.8e-8	Mood instability;
CESC	cis	rs212524	0.544	rs6665399	chr1:21553933	T/C	cg05370193	chr1:21551575	ECE1	0.41	6.43	0.37	5.82e-10	Height;
CESC	cis	rs4665809	0.652	rs6727974	chr2:26524639	A/G	cg22920501	chr2:26401640	FAM59B	0.68	7.89	0.44	8.2e-14	Gut microbiome composition (summer);
CESC	trans	rs11722228	0.549	rs73212863	chr4:10104173	C/T	cg26043149	chr18:55253948	FECH	0.92	10.72	0.55	1.62e-22	Gout;Urate levels;Serum uric acid levels;
CESC	cis	rs736408	0.812	rs1076425	chr3:52825462	A/G	cg18404041	chr3:52824283	ITIH1	-0.49	-8.04	-0.44	2.93e-14	Bipolar disorder;
CESC	cis	rs5753037	0.702	rs36576	chr22:30206291	C/A	cg01021169	chr22:30184971	ASCC2	-0.46	-6.5	-0.37	3.97e-10	Type 1 diabetes;
CESC	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg07677032	chr17:61819896	STRADA	0.46	6.1	0.35	3.83e-9	Prudent dietary pattern;
CESC	cis	rs738322	0.839	rs2413505	chr22:38592967	G/A	cg17652424	chr22:38574118	PLA2G6	0.3	5.23	0.31	3.43e-7	Cutaneous nevi;
CESC	cis	rs875971	0.545	rs313830	chr7:65551931	T/C	cg25405998	chr7:65216604	CCT6P1	-0.5	-5.28	-0.31	2.64e-7	Aortic root size;
CESC	trans	rs9354308	0.899	rs2802055	chr6:66545756	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.59	6.53	0.37	3.39e-10	Metabolite levels;
CESC	cis	rs12995491	0.933	rs7590305	chr2:88513131	C/T	cg04511125	chr2:88470314	THNSL2	-0.5	-6.99	-0.39	2.27e-11	Response to metformin (IC50);
CESC	trans	rs9929218	0.953	rs3118235	chr16:68732977	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.7	8.79	0.48	1.86e-16	Colorectal cancer;
CESC	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	13.82	0.65	4.25e-33	Prudent dietary pattern;
CESC	cis	rs9611565	0.765	rs132905	chr22:41799106	C/A	cg06481639	chr22:41940642	POLR3H	0.62	6.57	0.37	2.65e-10	Vitiligo;
CESC	cis	rs9858542	0.953	rs6446264	chr3:49417243	C/A	cg03060546	chr3:49711283	APEH	-0.53	-6.04	-0.35	5.23e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs7617773	0.817	rs9830016	chr3:48282494	A/G	cg11946769	chr3:48343235	NME6	0.79	11.36	0.57	1.28e-24	Coronary artery disease;
CESC	cis	rs12188164	0.686	rs56279338	chr5:416118	G/A	cg15813090	chr5:442598	EXOC3;C5orf55	0.39	5.86	0.34	1.41e-8	Cystic fibrosis severity;
CESC	cis	rs113835537	0.559	rs11227497	chr11:66269464	T/C	cg22134325	chr11:66188745	NPAS4	0.35	5.59	0.32	5.77e-8	Airway imaging phenotypes;
CESC	cis	rs9814567	1.000	rs9813774	chr3:134227100	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.42	-5.76	-0.33	2.38e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	trans	rs7980799	0.653	rs11052722	chr12:33626530	G/A	cg26384229	chr12:38710491	ALG10B	-0.51	-7.06	-0.4	1.47e-11	Heart rate;Heart rate variability traits (RMSSD);
CESC	trans	rs7980799	0.682	rs7303356	chr12:33633599	C/G	cg26384229	chr12:38710491	ALG10B	-0.53	-7.33	-0.41	2.83e-12	Heart rate;Heart rate variability traits (RMSSD);
CESC	cis	rs7527798	0.592	rs2296159	chr1:207851760	G/A	cg21110645	chr1:207815933	NA	-0.33	-5.76	-0.33	2.39e-8	Erythrocyte sedimentation rate;
CESC	cis	rs7336332	0.598	rs12018313	chr13:28012266	C/A	cg22138327	chr13:27999177	GTF3A	0.62	5.82	0.34	1.71e-8	Weight;
CESC	trans	rs748404	0.578	rs573615	chr15:43614281	C/T	cg24053811	chr14:70265306	SLC10A1	0.41	6.0	0.35	6.61e-9	Lung cancer;
CESC	cis	rs7772486	0.727	rs11155442	chr6:146140725	T/C	cg05347473	chr6:146136440	FBXO30	0.55	7.08	0.4	1.31e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg24829409	chr8:58192753	C8orf71	-0.67	-8.14	-0.45	1.54e-14	Developmental language disorder (linguistic errors);
CESC	cis	rs17608059	0.679	rs9898056	chr17:13951966	C/G	cg11395062	chr17:14139857	CDRT15	0.48	6.28	0.36	1.38e-9	Temperament;
CESC	cis	rs977987	0.843	rs11149824	chr16:75431830	C/G	cg03315344	chr16:75512273	CHST6	0.4	5.71	0.33	3e-8	Dupuytren's disease;
CESC	cis	rs72781680	0.593	rs72797817	chr2:24350569	A/G	cg08917208	chr2:24149416	ATAD2B	0.55	5.36	0.31	1.79e-7	Lymphocyte counts;
CESC	cis	rs13095912	0.785	rs6807927	chr3:185324933	A/G	cg11274856	chr3:185301563	NA	-0.37	-5.68	-0.33	3.5e-8	Systolic blood pressure;
CESC	cis	rs2708240	0.967	rs2710098	chr7:147574672	G/T	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.35	-5.77	-0.33	2.23e-8	QT interval (drug interaction);
CESC	cis	rs6433857	0.594	rs11680811	chr2:181519898	A/G	cg23363182	chr2:181467187	NA	-0.46	-6.24	-0.36	1.69e-9	Body mass index;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg20300707	chr1:1162156	SDF4	0.44	6.2	0.36	2.16e-9	Fibrinogen levels;
CESC	cis	rs7584330	0.784	rs1463795	chr2:238412392	C/G	cg14458575	chr2:238380390	NA	-0.52	-7.35	-0.41	2.51e-12	Prostate cancer;
CESC	cis	rs1670533	1.000	rs11725984	chr4:1087338	C/T	cg04106633	chr4:1044584	NA	0.4	5.08	0.3	6.98e-7	Recombination rate (females);
CESC	cis	rs3768617	0.727	rs12066735	chr1:183101451	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.66	9.16	0.49	1.45e-17	Fuchs's corneal dystrophy;
CESC	cis	rs7301826	0.610	rs36051740	chr12:131292722	G/A	cg11011512	chr12:131303247	STX2	-0.49	-5.94	-0.34	8.85e-9	Plasma plasminogen activator levels;
CESC	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg18765753	chr7:1198926	ZFAND2A	-0.46	-5.71	-0.33	3.07e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs9815354	0.767	rs73079350	chr3:41876310	C/T	cg03022575	chr3:42003672	ULK4	0.71	6.23	0.36	1.84e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs7216064	1.000	rs8074078	chr17:65838743	A/C	cg12091567	chr17:66097778	LOC651250	-0.8	-9.08	-0.49	2.62e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs7666738	0.822	rs9992360	chr4:98937123	T/C	cg17366294	chr4:99064904	C4orf37	0.61	8.56	0.47	9.36e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6500395	0.963	rs2111242	chr16:48708300	T/C	cg04672837	chr16:48644449	N4BP1	-0.51	-6.53	-0.37	3.33e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg03142411	chr4:3375410	RGS12	0.49	6.67	0.38	1.45e-10	Fibrinogen levels;
CESC	cis	rs5753037	0.653	rs140131	chr22:30151716	A/G	cg01021169	chr22:30184971	ASCC2	-0.43	-6.11	-0.35	3.47e-9	Type 1 diabetes;
CESC	cis	rs2637266	0.765	rs2438993	chr10:78414604	A/C	cg18941641	chr10:78392320	NA	0.41	7.62	0.42	4.43e-13	Pulmonary function;
CESC	cis	rs2456568	0.867	rs72962810	chr11:93663619	A/G	cg26875233	chr11:93583750	C11orf90	-0.29	-5.14	-0.3	5.28e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
CESC	cis	rs4665809	1.000	rs4665816	chr2:26305094	G/C	cg26314531	chr2:26401878	FAM59B	-0.6	-6.84	-0.39	5.32e-11	Gut microbiome composition (summer);
CESC	cis	rs2637266	0.777	rs1907302	chr10:78310828	T/C	cg18941641	chr10:78392320	NA	0.31	5.47	0.32	1.03e-7	Pulmonary function;
CESC	cis	rs7618915	0.547	rs2286800	chr3:52778051	C/T	cg07507251	chr3:52567010	NT5DC2	0.43	7.4	0.41	1.84e-12	Bipolar disorder;
CESC	cis	rs7916697	0.626	rs3858144	chr10:70011354	A/G	cg06988349	chr10:69991859	ATOH7	0.31	5.23	0.31	3.43e-7	Optic disc area;
CESC	cis	rs7847628	0.587	rs10760117	chr9:123586737	T/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.82	13.32	0.63	2.43e-31	Birth weight;
CESC	cis	rs7914558	1.000	rs10883824	chr10:104812897	A/G	cg15744005	chr10:104629667	AS3MT	-0.34	-5.58	-0.32	5.99e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs12318506	0.623	rs12313311	chr12:75768327	A/T	cg04728562	chr12:75699417	CAPS2	-1.13	-7.76	-0.43	1.82e-13	Coronary artery calcification;
CESC	cis	rs7116495	0.609	rs10501408	chr11:71680590	C/T	cg18441811	chr11:71824068	C11orf51	-0.86	-5.06	-0.3	7.97e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs1008375	0.966	rs4235391	chr4:17696409	A/G	cg04450456	chr4:17643702	FAM184B	0.36	5.16	0.3	4.93e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs644799	1.000	rs481630	chr11:95582447	G/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.94	13.9	0.65	2.41e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs9926296	0.585	rs8045232	chr16:89857548	A/G	cg27121462	chr16:89883253	FANCA	0.74	10.71	0.55	1.74e-22	Vitiligo;
CESC	cis	rs910316	0.763	rs175042	chr14:75470833	A/T	cg16144293	chr14:75469539	EIF2B2	0.41	5.45	0.32	1.18e-7	Height;
CESC	cis	rs4689388	0.816	rs13147655	chr4:6293474	A/G	cg25554036	chr4:6271136	WFS1	0.51	8.37	0.46	3.31e-15	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs17253792	0.822	rs28831725	chr14:56087569	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.79	5.91	0.34	1.06e-8	Putamen volume;
CESC	cis	rs2502731	0.539	rs3003609	chr9:130984755	A/G	cg13642260	chr9:130955380	CIZ1	-0.44	-6.56	-0.37	2.8e-10	Attention deficit hyperactivity disorder;
CESC	cis	rs722599	0.748	rs61978932	chr14:75342954	C/T	cg11812906	chr14:75593930	NEK9	-0.46	-5.71	-0.33	2.97e-8	IgG glycosylation;
CESC	trans	rs66573146	0.808	rs55942328	chr4:6990960	T/G	cg07817883	chr1:32538562	TMEM39B	1.09	7.0	0.4	2.06e-11	Granulocyte percentage of myeloid white cells;
CESC	cis	rs6456156	0.967	rs150108	chr6:167513153	C/T	cg07741184	chr6:167504864	NA	0.32	5.44	0.32	1.19e-7	Primary biliary cholangitis;
CESC	trans	rs853679	0.546	rs71537572	chr6:27970715	T/C	cg01620082	chr3:125678407	NA	-0.76	-6.18	-0.35	2.42e-9	Depression;
CESC	trans	rs7839040	0.698	rs13267308	chr8:82930285	A/G	cg14472086	chr9:107730925	NA	-0.49	-6.45	-0.37	5.26e-10	Response to methotrexate in juvenile idiopathic arthritis;
CESC	cis	rs1832871	0.711	rs7747669	chr6:158664345	A/G	cg07165851	chr6:158734300	TULP4	0.6	6.41	0.37	6.66e-10	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07359604	chr15:25415763	SNORD115-1	-0.62	-7.64	-0.42	3.95e-13	Gut microbiome composition (summer);
CESC	cis	rs13108904	0.870	rs4493483	chr4:1279916	G/A	cg22903657	chr4:1355424	KIAA1530	-0.38	-5.18	-0.3	4.5e-7	Obesity-related traits;
CESC	cis	rs9486719	0.895	rs3798294	chr6:97049587	G/A	cg18709589	chr6:96969512	KIAA0776	-0.53	-5.76	-0.33	2.28e-8	Migraine;Coronary artery disease;
CESC	trans	rs11098499	0.874	rs13123591	chr4:120105990	T/G	cg25214090	chr10:38739885	LOC399744	0.57	7.53	0.42	7.93e-13	Corneal astigmatism;
CESC	cis	rs2836974	0.644	rs61300849	chr21:40680194	G/A	cg17971929	chr21:40555470	PSMG1	-0.87	-12.38	-0.61	4.33e-28	Cognitive function;
CESC	cis	rs9311474	0.508	rs17052256	chr3:52593119	A/G	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.36	6.47	0.37	4.74e-10	Electroencephalogram traits;
CESC	cis	rs6460942	1.000	rs6948314	chr7:12418363	T/A	cg02935154	chr7:12443704	VWDE	-0.53	-5.99	-0.35	6.68e-9	Coronary artery disease;
CESC	cis	rs9790314	1.000	rs1478565	chr3:161027464	C/T	cg04691961	chr3:161091175	C3orf57	-0.45	-5.85	-0.34	1.44e-8	Morning vs. evening chronotype;
CESC	cis	rs7914558	0.966	rs10786745	chr10:104956827	A/G	cg08650961	chr10:104748594	CNNM2	0.31	5.04	0.3	8.43e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs8103278	0.507	rs4802276	chr19:46260748	T/C	cg11657440	chr19:46296263	DMWD	0.84	12.67	0.61	4.6e-29	Coronary artery disease;
CESC	cis	rs116095464	0.850	rs10055295	chr5:243749	G/A	cg22857025	chr5:266934	NA	-1.27	-18.37	-0.75	3.49e-49	Breast cancer;
CESC	cis	rs3892630	0.818	rs80137870	chr19:33182750	C/T	cg13157960	chr19:33183277	NUDT19	0.52	5.06	0.3	7.77e-7	Red blood cell traits;
CESC	cis	rs4481887	1.000	rs4360555	chr1:248468591	G/T	cg00666640	chr1:248458726	OR2T12	0.39	6.36	0.36	8.71e-10	Common traits (Other);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg13486387	chr9:94124044	AUH	-0.46	-6.16	-0.35	2.75e-9	Fibrinogen levels;
CESC	cis	rs13191362	0.938	rs35760705	chr6:163020637	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.83	8.73	0.47	3.01e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs7618915	0.571	rs11130307	chr3:52607682	G/A	cg07507251	chr3:52567010	NT5DC2	0.42	7.37	0.41	2.11e-12	Bipolar disorder;
CESC	cis	rs7605827	0.930	rs2287273	chr2:15658523	T/C	cg19274914	chr2:15703543	NA	0.37	6.65	0.38	1.65e-10	Educational attainment (years of education);
CESC	cis	rs3741151	0.656	rs11544311	chr11:73106237	A/C	cg17517138	chr11:73019481	ARHGEF17	0.98	7.14	0.4	8.91e-12	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs1152591	0.669	rs2978381	chr14:64766652	T/C	cg23250157	chr14:64679961	SYNE2	0.43	5.68	0.33	3.53e-8	Atrial fibrillation;
CESC	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg23708337	chr7:1209742	NA	0.51	5.15	0.3	4.99e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs2115172	0.836	rs4835799	chr5:122762229	A/G	cg07945480	chr4:2964972	GRK4;NOP14	0.47	6.11	0.35	3.51e-9	Weight;
CESC	cis	rs7527798	0.592	rs11118359	chr1:207858546	T/C	cg21110645	chr1:207815933	NA	-0.33	-5.79	-0.33	2.02e-8	Erythrocyte sedimentation rate;
CESC	cis	rs7607369	0.572	rs629177	chr2:219454801	T/G	cg02176678	chr2:219576539	TTLL4	0.48	8.27	0.45	6.46e-15	Red blood cell count;Amyotrophic lateral sclerosis;
CESC	cis	rs425277	0.500	rs908744	chr1:2038893	G/A	cg12718519	chr1:2058417	PRKCZ	-0.26	-5.57	-0.32	6.26e-8	Height;
CESC	cis	rs6120849	0.707	rs6120798	chr20:33610822	T/G	cg24642439	chr20:33292090	TP53INP2	0.67	6.67	0.38	1.45e-10	Protein C levels;
CESC	cis	rs2797160	1.000	rs77678056	chr6:126019738	A/G	cg05901451	chr6:126070800	HEY2	0.46	6.53	0.37	3.4e-10	Endometrial cancer;
CESC	cis	rs12476592	0.602	rs187801	chr2:63867446	A/C	cg17519650	chr2:63277830	OTX1	0.44	5.06	0.3	7.87e-7	Childhood ear infection;
CESC	cis	rs62408225	1.000	rs62408235	chr6:90978383	T/C	cg06866423	chr6:90926672	BACH2	0.44	5.27	0.31	2.83e-7	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs2120019	0.938	rs13056	chr15:75312187	A/G	cg09165964	chr15:75287851	SCAMP5	-0.77	-9.82	-0.52	1.29e-19	Blood trace element (Zn levels);
CESC	cis	rs12200560	0.505	rs211174	chr6:97071120	C/T	cg06623918	chr6:96969491	KIAA0776	0.45	5.6	0.33	5.31e-8	Coronary heart disease;
CESC	cis	rs5753618	0.583	rs5749279	chr22:31854209	A/G	cg02404636	chr22:31891804	SFI1	0.4	5.89	0.34	1.18e-8	Colorectal cancer;
CESC	trans	rs1814175	0.587	rs7948538	chr11:50021353	A/C	cg03929089	chr4:120376271	NA	-0.9	-14.7	-0.67	3.47e-36	Height;
CESC	cis	rs3785574	0.745	rs2854162	chr17:61975610	T/C	cg11494091	chr17:61959527	GH2	-0.39	-5.38	-0.31	1.67e-7	Height;
CESC	cis	rs6952808	0.609	rs6944877	chr7:1952582	T/G	cg05863683	chr7:1912471	MAD1L1	0.4	6.02	0.35	5.89e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs7772486	0.875	rs2748490	chr6:146329681	G/T	cg05347473	chr6:146136440	FBXO30	0.49	6.56	0.37	2.8e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs3858526	0.584	rs10769271	chr11:5860572	T/C	cg05234568	chr11:5960015	NA	-0.65	-8.8	-0.48	1.77e-16	DNA methylation (variation);
CESC	cis	rs11785400	0.793	rs4371985	chr8:143737279	C/T	cg24634471	chr8:143751801	JRK	0.45	5.61	0.33	5.01e-8	Schizophrenia;
CESC	cis	rs9905704	0.881	rs2611774	chr17:56732304	G/A	cg12560992	chr17:57184187	TRIM37	0.55	6.34	0.36	1e-9	Testicular germ cell tumor;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14965947	chr9:88357129	AGTPBP1	0.58	6.97	0.39	2.51e-11	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.830	rs6832209	chr4:98994120	A/G	cg17366294	chr4:99064904	C4orf37	0.59	8.43	0.46	2.2e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs113835537	0.935	rs3867133	chr11:66451962	A/G	cg22134325	chr11:66188745	NPAS4	-0.51	-5.93	-0.34	9.62e-9	Airway imaging phenotypes;
CESC	cis	rs8114671	0.562	rs2076667	chr20:33506964	G/A	cg07148914	chr20:33460835	GGT7	0.46	6.13	0.35	3.19e-9	Height;
CESC	cis	rs9640161	0.659	rs77354576	chr7:150013300	A/C	cg10018233	chr7:150070692	REPIN1	0.48	7.66	0.43	3.4e-13	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs7044106	0.791	rs7036196	chr9:123479457	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.38	6.13	0.35	3.25e-9	Hip circumference adjusted for BMI;
CESC	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg24846343	chr22:24311635	DDTL	0.64	10.78	0.55	1.09e-22	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs1728785	1.000	rs821167	chr16:68577222	T/G	cg02972257	chr16:68554789	NA	-0.62	-6.88	-0.39	4.41e-11	Ulcerative colitis;
CESC	cis	rs667920	0.575	rs9861150	chr3:136183320	G/T	cg15507776	chr3:136538369	TMEM22	0.58	6.19	0.36	2.32e-9	Coronary artery disease;
CESC	trans	rs561341	0.739	rs1978116	chr17:30220978	A/C	cg20587970	chr11:113659929	NA	-0.63	-8.23	-0.45	8.45e-15	Hip circumference adjusted for BMI;
CESC	cis	rs2933343	1.000	rs789237	chr3:128636961	A/C	cg25356066	chr3:128598488	ACAD9	0.52	6.46	0.37	4.99e-10	IgG glycosylation;
CESC	cis	rs2836974	0.932	rs35571600	chr21:40590624	A/C	cg11890956	chr21:40555474	PSMG1	1.17	21.95	0.8	1.5e-61	Cognitive function;
CESC	cis	rs473651	0.904	rs501333	chr2:239336045	G/A	cg21699342	chr2:239360505	ASB1	0.54	9.23	0.49	8.77e-18	Multiple system atrophy;
CESC	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	7.63	0.42	4.23e-13	Prudent dietary pattern;
CESC	cis	rs1448094	0.511	rs17279133	chr12:86162353	G/A	cg02569458	chr12:86230093	RASSF9	0.49	7.68	0.43	3.15e-13	Major depressive disorder;
CESC	cis	rs3741489	1.000	rs4758889	chr12:133475533	C/T	cg01499426	chr12:133417423	CHFR	0.9	5.59	0.32	5.6e-8	Cognitive function;
CESC	cis	rs5769765	0.913	rs4824111	chr22:50284305	A/G	cg03033257	chr22:50311977	ALG12;CRELD2	-0.5	-5.12	-0.3	5.99e-7	Schizophrenia;
CESC	cis	rs6032067	0.929	rs17424474	chr20:43804797	C/A	cg11264863	chr20:43835661	SEMG1	0.51	5.56	0.32	6.5e-8	Blood protein levels;
CESC	cis	rs1707322	0.685	rs56177313	chr1:46225806	A/C	cg05343316	chr1:45956843	TESK2	0.5	6.16	0.35	2.65e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs6461049	0.800	rs3778977	chr7:2159746	C/T	cg05863683	chr7:1912471	MAD1L1	0.4	5.85	0.34	1.42e-8	Schizophrenia;
CESC	cis	rs7264396	0.563	rs7268195	chr20:34339854	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.63	6.76	0.38	8.61e-11	Total cholesterol levels;
CESC	cis	rs2288073	0.965	rs10469924	chr2:24416230	G/A	cg06627628	chr2:24431161	ITSN2	-0.81	-9.74	-0.51	2.29e-19	Venous thromboembolism (SNP x SNP interaction);
CESC	cis	rs9435341	0.929	rs1762509	chr1:107592959	A/G	cg09367891	chr1:107599246	PRMT6	-0.71	-8.38	-0.46	3.17e-15	Facial morphology (factor 21, depth of nasal alae);
CESC	cis	rs72781680	0.716	rs2551334	chr2:24000396	G/A	cg08917208	chr2:24149416	ATAD2B	0.57	5.66	0.33	3.89e-8	Lymphocyte counts;
CESC	cis	rs926938	0.527	rs360672	chr1:115483836	C/T	cg12756093	chr1:115239321	AMPD1	0.44	6.17	0.35	2.52e-9	Autism;
CESC	cis	rs2732480	0.500	rs2450986	chr12:48661688	G/A	cg24011408	chr12:48396354	COL2A1	0.43	6.07	0.35	4.46e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs7666738	0.925	rs34423396	chr4:99049031	T/A	cg17366294	chr4:99064904	C4orf37	0.54	7.14	0.4	8.72e-12	Colonoscopy-negative controls vs population controls;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg13795627	chr1:157015873	ARHGEF11	-0.45	-6.18	-0.35	2.36e-9	Fibrinogen levels;
CESC	cis	rs597539	0.690	rs7129960	chr11:68622456	A/G	cg21963583	chr11:68658836	MRPL21	0.41	5.55	0.32	6.9e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs7666738	0.830	rs11723283	chr4:99001617	C/T	cg05340658	chr4:99064831	C4orf37	0.8	12.44	0.61	2.83e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9611565	0.659	rs1810460	chr22:41927700	C/T	cg06481639	chr22:41940642	POLR3H	-0.58	-6.16	-0.35	2.74e-9	Vitiligo;
CESC	cis	rs2243480	1.000	rs2420170	chr7:65656053	T/C	cg12463550	chr7:65579703	CRCP	-0.73	-5.66	-0.33	4.03e-8	Diabetic kidney disease;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg14374347	chr1:38158195	CDCA8	-0.44	-6.02	-0.35	5.69e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs6594713	0.679	rs9326890	chr5:112859994	C/T	cg12552261	chr5:112820674	MCC	0.59	5.73	0.33	2.74e-8	Brain cytoarchitecture;
CESC	cis	rs829883	1.000	rs249837	chr12:98876535	A/G	cg25150519	chr12:98850993	NA	0.68	9.06	0.49	2.94e-17	Colorectal adenoma (advanced);
CESC	cis	rs8141529	0.764	rs5762854	chr22:29246278	T/C	cg02153584	chr22:29168773	CCDC117	0.65	9.1	0.49	2.26e-17	Lymphocyte counts;
CESC	cis	rs2479724	0.905	rs2149274	chr6:41839092	T/C	cg17623882	chr6:41773611	USP49	-0.42	-6.19	-0.36	2.29e-9	Menarche (age at onset);
CESC	cis	rs2839186	0.771	rs13049175	chr21:47641326	G/A	cg13012494	chr21:47604986	C21orf56	-0.44	-5.9	-0.34	1.12e-8	Testicular germ cell tumor;
CESC	cis	rs873946	0.586	rs12259688	chr10:134549628	A/G	cg26818010	chr10:134567672	INPP5A	-0.85	-10.49	-0.54	9.45e-22	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs12824058	0.798	rs4759652	chr12:130808771	C/T	cg23887609	chr12:130822674	PIWIL1	0.45	5.81	0.34	1.74e-8	Menopause (age at onset);
CESC	trans	rs4843747	0.671	rs28671027	chr16:88116323	G/A	cg26811252	chr16:29126840	RRN3P2	0.71	9.94	0.52	5.41e-20	Menopause (age at onset);
CESC	cis	rs7666738	0.830	rs890470	chr4:98923435	A/C	cg03467027	chr4:99064603	C4orf37	0.46	5.59	0.32	5.78e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs35110281	0.712	rs8133523	chr21:45062403	A/G	cg01579765	chr21:45077557	HSF2BP	-0.55	-9.15	-0.49	1.58e-17	Mean corpuscular volume;
CESC	cis	rs780096	0.526	rs4582	chr2:27604279	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.34	-6.29	-0.36	1.3e-9	Total body bone mineral density;
CESC	cis	rs73206853	0.764	rs16940909	chr12:111054591	G/C	cg12870014	chr12:110450643	ANKRD13A	0.65	5.77	0.33	2.19e-8	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs9916302	0.851	rs4794810	chr17:37603774	T/C	cg15445000	chr17:37608096	MED1	0.39	6.46	0.37	4.99e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs1862618	0.671	rs2591970	chr5:56232595	T/C	cg24531977	chr5:56204891	C5orf35	0.68	9.39	0.5	2.77e-18	Initial pursuit acceleration;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg10081138	chr17:7604803	WRAP53	0.46	6.11	0.35	3.53e-9	Fibrinogen levels;
CESC	cis	rs13191362	0.935	rs13212137	chr6:163010261	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.5	5.17	0.3	4.63e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs709400	1.000	rs3915733	chr14:104147353	G/A	cg12935359	chr14:103987150	CKB	-0.45	-6.04	-0.35	5.3e-9	Body mass index;
CESC	cis	rs56399783	0.901	rs17132594	chr7:2775102	G/A	cg19731401	chr7:2775893	GNA12	0.7	6.09	0.35	3.91e-9	Childhood ear infection;
CESC	trans	rs643506	0.874	rs10789849	chr11:111716070	A/C	cg11949262	chr7:20816184	NA	-0.26	-6.06	-0.35	4.7e-9	Breast cancer;
CESC	cis	rs2637266	0.538	rs11510986	chr10:78415171	C/T	cg18941641	chr10:78392320	NA	-0.33	-5.2	-0.3	3.99e-7	Pulmonary function;
CESC	cis	rs2440129	0.611	rs11571335	chr17:6904263	C/T	cg03760483	chr17:6899297	ALOX12	0.43	7.77	0.43	1.74e-13	Tonsillectomy;
CESC	cis	rs2880765	0.835	rs6497202	chr15:86021375	T/C	cg19183879	chr15:85880815	NA	-0.25	-5.17	-0.3	4.6e-7	Coronary artery disease;
CESC	cis	rs67460515	0.926	rs11715591	chr3:161043137	C/T	cg03342759	chr3:160939853	NMD3	-0.52	-7.4	-0.41	1.81e-12	Parkinson's disease;
CESC	cis	rs977987	0.806	rs12051326	chr16:75437887	G/A	cg03315344	chr16:75512273	CHST6	0.41	5.86	0.34	1.35e-8	Dupuytren's disease;
CESC	trans	rs10489896	0.541	rs11578044	chr1:234580945	G/T	cg23817893	chr11:86085932	CCDC81	-0.46	-6.5	-0.37	3.93e-10	Cognitive test performance;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg08429943	chr16:29606618	NA	-0.52	-6.93	-0.39	3.26e-11	Fibrinogen levels;
CESC	cis	rs6540559	1.000	rs742215	chr1:209961023	A/T	cg23283495	chr1:209979779	IRF6	0.51	7.32	0.41	2.98e-12	Cleft lip with or without cleft palate;
CESC	cis	rs60154123	0.505	rs1319435	chr1:210047618	C/T	cg23283495	chr1:209979779	IRF6	-0.51	-5.37	-0.31	1.68e-7	Coronary artery disease;
CESC	cis	rs7512552	0.839	rs2873669	chr1:150426224	C/T	cg15654264	chr1:150340011	RPRD2	-0.39	-5.18	-0.3	4.42e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs4253772	0.550	rs739164	chr22:46684558	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	-0.78	-9.2	-0.49	1.09e-17	LDL cholesterol;Cholesterol, total;
CESC	cis	rs826838	1.000	rs7975243	chr12:38849220	C/T	cg13010199	chr12:38710504	ALG10B	0.6	8.53	0.46	1.18e-15	Heart rate;
CESC	cis	rs7666738	0.830	rs6532701	chr4:98745134	C/T	cg17366294	chr4:99064904	C4orf37	0.58	8.03	0.44	3.26e-14	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7937682	0.855	rs527078	chr11:111479713	T/C	cg22437258	chr11:111473054	SIK2	0.72	9.79	0.52	1.59e-19	Primary sclerosing cholangitis;
CESC	trans	rs6572548	0.504	rs1956082	chr14:49665496	A/C	cg10194341	chr6:43027125	KLC4;MRPL2	-0.63	-7.12	-0.4	1.05e-11	Subjective well-being;
CESC	cis	rs763121	0.853	rs2205802	chr22:39046327	T/C	cg14440974	chr22:39074834	NA	-0.4	-5.48	-0.32	9.77e-8	Menopause (age at onset);
CESC	cis	rs5769765	0.908	rs9616390	chr22:50314289	G/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.59	-5.93	-0.34	9.66e-9	Schizophrenia;
CESC	cis	rs7000551	0.556	rs35359294	chr8:22249755	G/A	cg12081754	chr8:22256438	SLC39A14	0.92	12.78	0.62	1.89e-29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CESC	cis	rs9929218	1.000	rs13333528	chr16:68790502	C/T	cg02972257	chr16:68554789	NA	0.54	6.05	0.35	5.02e-9	Colorectal cancer;
CESC	cis	rs10479542	0.702	rs13183521	chr5:178975606	A/G	cg21226059	chr5:178986404	RUFY1	-0.39	-5.51	-0.32	8.69e-8	Lung cancer;
CESC	cis	rs2204008	0.837	rs7974888	chr12:37945215	A/G	cg13010199	chr12:38710504	ALG10B	0.46	5.81	0.34	1.77e-8	Bladder cancer;
CESC	cis	rs2797160	0.651	rs1343121	chr6:126036184	C/T	cg05901451	chr6:126070800	HEY2	0.52	7.49	0.42	1.04e-12	Endometrial cancer;
CESC	cis	rs9311474	0.659	rs1133415	chr3:52575831	G/A	cg18404041	chr3:52824283	ITIH1	-0.33	-5.71	-0.33	3e-8	Electroencephalogram traits;
CESC	cis	rs4555082	0.915	rs66527719	chr14:105750523	C/G	cg06808227	chr14:105710500	BRF1	-0.53	-6.41	-0.37	6.64e-10	Mean platelet volume;Platelet distribution width;
CESC	cis	rs9948	0.786	rs62152765	chr2:97440420	G/A	cg01990225	chr2:97406019	LMAN2L	-0.92	-7.51	-0.42	9.04e-13	Erectile dysfunction and prostate cancer treatment;
CESC	cis	rs6460942	0.597	rs7778131	chr7:12543233	T/G	cg02935154	chr7:12443704	VWDE	-0.57	-5.58	-0.32	6.01e-8	Coronary artery disease;
CESC	cis	rs7071206	0.947	rs1356090	chr10:79395312	T/C	cg07817648	chr10:79422355	NA	-0.89	-11.33	-0.57	1.52e-24	Bone mineral density;
CESC	cis	rs9916302	0.904	rs11869109	chr17:37518205	G/T	cg07936489	chr17:37558343	FBXL20	0.81	11.81	0.59	3.83e-26	Glomerular filtration rate (creatinine);
CESC	cis	rs6570726	0.791	rs4332001	chr6:145934841	T/C	cg05347473	chr6:146136440	FBXO30	0.5	6.54	0.37	3.15e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs10883723	0.810	rs7912901	chr10:104277440	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.55	7.59	0.42	5.46e-13	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs854765	0.929	rs854766	chr17:18012775	A/G	cg09796270	chr17:17721594	SREBF1	0.4	5.29	0.31	2.56e-7	Total body bone mineral density;
CESC	cis	rs7267979	1.000	rs6037099	chr20:25356876	T/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.88	-18.14	-0.74	2.23e-48	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7618915	0.571	rs6805539	chr3:52609710	T/A	cg05564831	chr3:52568323	NT5DC2	0.46	6.93	0.39	3.11e-11	Bipolar disorder;
CESC	cis	rs873946	0.648	rs12782123	chr10:134554662	G/A	cg27286337	chr10:134555280	INPP5A	0.7	8.11	0.45	1.95e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs1862618	0.853	rs832565	chr5:56150803	T/G	cg24549020	chr5:56110836	MAP3K1	0.68	7.69	0.43	2.85e-13	Initial pursuit acceleration;
CESC	cis	rs12893597	0.715	rs71429953	chr14:76819480	C/T	cg20290672	chr14:76816747	NA	-0.41	-5.78	-0.33	2.05e-8	Maximal oxygen uptake response;
CESC	cis	rs4979906	0.920	rs11002239	chr10:79443836	A/C	cg07817648	chr10:79422355	NA	-0.61	-6.5	-0.37	4e-10	Mortality in heart failure;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg22614265	chr7:100425456	EPHB4	-0.45	-6.48	-0.37	4.39e-10	Gambling;
CESC	cis	rs12950390	0.853	rs8078052	chr17:45859434	A/G	cg00777063	chr17:45855553	NA	-0.38	-5.71	-0.33	3e-8	IgG glycosylation;
CESC	cis	rs60871478	0.945	rs62432254	chr7:804175	C/T	cg05535760	chr7:792225	HEATR2	0.85	10.63	0.55	3.21e-22	Cerebrospinal P-tau181p levels;
CESC	cis	rs1008375	1.000	rs11724495	chr4:17621310	G/A	cg15017067	chr4:17643749	FAM184B	0.39	5.62	0.33	4.85e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs501120	1.000	rs493874	chr10:44764077	C/T	cg09554077	chr10:44749378	NA	0.52	6.89	0.39	4.1e-11	Coronary artery disease;Coronary heart disease;
CESC	cis	rs6835098	0.923	rs9997477	chr4:174112543	C/T	cg08422745	chr4:174089978	GALNT7	-0.72	-9.5	-0.5	1.3e-18	Dementia and core Alzheimer's disease neuropathologic changes;
CESC	cis	rs4237845	0.742	rs6650219	chr12:58289100	T/C	cg02175503	chr12:58329896	NA	0.63	9.03	0.49	3.6e-17	Intelligence (multi-trait analysis);
CESC	cis	rs10744422	1.000	rs1587856	chr12:123342229	A/G	cg25930673	chr12:123319894	HIP1R	-0.81	-6.32	-0.36	1.09e-9	Schizophrenia;
CESC	cis	rs4665809	0.652	rs2384360	chr2:26405016	C/G	cg25036284	chr2:26402008	FAM59B	-0.82	-9.33	-0.5	4.31e-18	Gut microbiome composition (summer);
CESC	cis	rs4803468	1.000	rs3810175	chr19:41904396	C/T	cg08477640	chr19:41863820	B9D2	-0.38	-5.07	-0.3	7.33e-7	Height;
CESC	cis	rs459571	0.959	rs455381	chr9:136905577	C/A	cg13789015	chr9:136890014	NCRNA00094	0.54	7.69	0.43	2.98e-13	Platelet distribution width;
CESC	cis	rs72781680	0.611	rs7602797	chr2:24318148	C/T	cg20701182	chr2:24300061	SF3B14	0.92	10.55	0.54	6.09e-22	Lymphocyte counts;
CESC	cis	rs7809799	0.850	rs2894224	chr7:98765616	A/G	cg05967295	chr7:98741636	SMURF1	-0.77	-5.41	-0.32	1.37e-7	Ulcerative colitis;
CESC	cis	rs12677618	1.000	rs10092931	chr8:142307201	A/G	cg27411547	chr8:142287226	NA	-0.41	-5.24	-0.31	3.25e-7	Plateletcrit;
CESC	trans	rs6011002	0.872	rs6010987	chr20:62277675	G/A	cg17720233	chr1:151128310	TNFAIP8L2	0.84	6.21	0.36	2.07e-9	Dental caries;
CESC	cis	rs1862618	0.802	rs42769	chr5:56144152	G/A	cg24531977	chr5:56204891	C5orf35	-0.88	-11.51	-0.58	3.94e-25	Initial pursuit acceleration;
CESC	cis	rs11031096	0.711	rs17283923	chr11:4173841	C/T	cg18678763	chr11:4115507	RRM1	-0.45	-6.27	-0.36	1.44e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	cis	rs3733585	0.605	rs4697708	chr4:10121189	A/G	cg00071950	chr4:10020882	SLC2A9	-0.63	-9.88	-0.52	8.39e-20	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs875971	1.000	rs6961717	chr7:65587537	C/T	cg12463550	chr7:65579703	CRCP	-0.56	-7.23	-0.41	5.19e-12	Aortic root size;
CESC	cis	rs910316	0.783	rs11850751	chr14:75590113	A/T	cg11812906	chr14:75593930	NEK9	0.89	14.79	0.67	1.64e-36	Height;
CESC	cis	rs597539	0.652	rs569777	chr11:68706848	G/A	cg21963583	chr11:68658836	MRPL21	0.4	5.71	0.33	3.04e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs8070128	0.583	rs7406982	chr17:17942613	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.62	8.81	0.48	1.7e-16	Total body bone mineral density;
CESC	cis	rs853679	0.517	rs9380057	chr6:28104634	G/T	cg17949981	chr6:28129498	ZNF389	0.45	5.71	0.33	3.07e-8	Depression;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07141622	chr14:70193793	NA	0.57	7.04	0.4	1.64e-11	Gut microbiome composition (summer);
CESC	cis	rs9616064	0.506	rs2073275	chr22:47070432	G/C	cg25730555	chr22:47059586	GRAMD4	0.5	6.43	0.37	5.9e-10	Urate levels in obese individuals;
CESC	cis	rs9733	0.596	rs6681990	chr1:150695929	A/G	cg18016565	chr1:150552671	MCL1	0.34	5.28	0.31	2.67e-7	Tonsillectomy;
CESC	cis	rs3858526	0.959	rs4559671	chr11:5923419	C/T	cg05234568	chr11:5960015	NA	-0.54	-6.5	-0.37	3.92e-10	DNA methylation (variation);
CESC	cis	rs9916302	0.904	rs585961	chr17:37444036	G/A	cg07936489	chr17:37558343	FBXL20	0.8	11.52	0.58	3.72e-25	Glomerular filtration rate (creatinine);
CESC	cis	rs6502050	0.835	rs7220639	chr17:80146866	G/A	cg11859384	chr17:80120422	CCDC57	-0.38	-5.24	-0.31	3.28e-7	Life satisfaction;
CESC	cis	rs10791097	0.694	rs4937583	chr11:130741606	A/G	cg12179176	chr11:130786555	SNX19	0.65	10.06	0.53	2.26e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs12824058	0.831	rs55726136	chr12:130810312	G/A	cg23887609	chr12:130822674	PIWIL1	0.45	5.82	0.34	1.69e-8	Menopause (age at onset);
CESC	cis	rs9486719	1.000	rs11153023	chr6:96968525	C/T	cg18709589	chr6:96969512	KIAA0776	-0.55	-5.81	-0.34	1.81e-8	Migraine;Coronary artery disease;
CESC	cis	rs1832871	0.683	rs6908487	chr6:158713047	G/T	cg07165851	chr6:158734300	TULP4	0.6	6.59	0.38	2.33e-10	Height;
CESC	cis	rs200895692	1	rs200895692	chr1:43421956	CGCCTGTAATCCCAG/C	cg00102166	chr1:43425337	SLC2A1	-0.58	-6.38	-0.36	7.94e-10	Monocyte count;
CESC	cis	rs7520050	0.966	rs785520	chr1:46568836	T/C	cg03146154	chr1:46216737	IPP	-0.43	-5.57	-0.32	6.38e-8	Red blood cell count;Reticulocyte count;
CESC	cis	rs2235544	0.579	rs1537322	chr1:54482306	G/T	cg09175620	chr1:54484536	LDLRAD1	-0.29	-5.16	-0.3	4.75e-7	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
CESC	cis	rs34375054	0.526	rs7302475	chr12:125677886	T/C	cg25124228	chr12:125621409	AACS	-0.5	-5.86	-0.34	1.39e-8	Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs921968	0.565	rs6436081	chr2:219637884	A/G	cg02176678	chr2:219576539	TTLL4	-0.43	-7.53	-0.42	7.9e-13	Mean corpuscular hemoglobin concentration;
CESC	cis	rs9814567	0.896	rs6790338	chr3:134208167	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.46	-6.29	-0.36	1.33e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs3749237	0.595	rs4855859	chr3:49526300	C/T	cg02487422	chr3:49467188	NICN1	0.56	8.19	0.45	1.09e-14	Resting heart rate;
CESC	cis	rs853679	0.517	rs9468286	chr6:28079428	C/T	cg26335602	chr6:28129616	ZNF389	0.53	7.06	0.4	1.48e-11	Depression;
CESC	cis	rs2637266	0.703	rs4979829	chr10:78457101	G/A	cg18941641	chr10:78392320	NA	0.4	7.21	0.41	5.71e-12	Pulmonary function;
CESC	cis	rs9311474	0.652	rs614288	chr3:52220203	T/C	cg18099408	chr3:52552593	STAB1	-0.35	-5.96	-0.34	7.8e-9	Electroencephalogram traits;
CESC	cis	rs8070740	0.838	rs35491297	chr17:5327481	T/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.51	6.29	0.36	1.34e-9	Menopause (age at onset);
CESC	cis	rs4450798	0.691	rs62234793	chr3:13752409	G/A	cg23332027	chr3:13681764	NA	0.4	5.47	0.32	1.05e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs7666738	0.830	rs11721726	chr4:98996314	T/C	cg18180107	chr4:99064573	C4orf37	0.4	5.23	0.31	3.41e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2882667	0.858	rs13170388	chr5:138436865	A/G	cg04439458	chr5:138467593	SIL1	-0.4	-6.21	-0.36	2.04e-9	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs7809950	0.817	rs2237678	chr7:107203265	T/G	cg23024343	chr7:107201750	COG5	-0.59	-7.48	-0.42	1.07e-12	Coronary artery disease;
CESC	cis	rs9486719	0.656	rs4839826	chr6:96853616	A/G	cg06623918	chr6:96969491	KIAA0776	-0.74	-8.33	-0.46	4.31e-15	Migraine;Coronary artery disease;
CESC	cis	rs4268898	0.662	rs59996104	chr2:24404064	C/T	cg20701182	chr2:24300061	SF3B14	0.73	7.38	0.41	2.1e-12	Asthma;
CESC	cis	rs7666738	0.830	rs10017201	chr4:98983561	G/A	cg03467027	chr4:99064603	C4orf37	0.44	5.54	0.32	7.12e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs75804782	0.557	rs10178728	chr2:239360121	T/A	cg21699342	chr2:239360505	ASB1	-0.41	-5.22	-0.31	3.64e-7	Morning vs. evening chronotype;Chronotype;
CESC	cis	rs3785574	0.962	rs2584628	chr17:61894578	T/C	cg06873352	chr17:61820015	STRADA	0.47	6.85	0.39	5.1e-11	Height;
CESC	trans	rs7809799	0.850	rs6956645	chr7:98764021	C/T	cg25874421	chr14:90527917	KCNK13	0.65	6.03	0.35	5.41e-9	Ulcerative colitis;
CESC	cis	rs11122272	0.735	rs2808597	chr1:231532351	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.56	-7.66	-0.43	3.45e-13	Hemoglobin concentration;
CESC	cis	rs7607369	0.648	rs55983650	chr2:219654932	T/C	cg02176678	chr2:219576539	TTLL4	-0.51	-8.73	-0.47	2.86e-16	Red blood cell count;Amyotrophic lateral sclerosis;
CESC	trans	rs11764590	0.694	rs56072378	chr7:2104364	A/G	cg11693508	chr17:37793320	STARD3	0.54	6.1	0.35	3.8e-9	Neuroticism;
CESC	cis	rs9916302	0.706	rs597069	chr17:37458512	G/T	cg07936489	chr17:37558343	FBXL20	0.95	10.45	0.54	1.24e-21	Glomerular filtration rate (creatinine);
CESC	cis	rs3026101	0.576	rs56188406	chr17:5316769	T/C	cg24500398	chr17:5266808	RABEP1	-0.42	-5.89	-0.34	1.16e-8	Body mass index;
CESC	cis	rs2836974	0.830	rs2735309	chr21:40715313	C/T	cg11890956	chr21:40555474	PSMG1	1.02	15.55	0.69	3.4e-39	Cognitive function;
CESC	cis	rs45535039	1.000	rs7482443	chr11:119110272	C/T	cg16724696	chr11:118992527	HINFP	0.43	5.36	0.31	1.78e-7	Plateletcrit;
CESC	cis	rs73110464	0.562	rs2363634	chr12:53354683	A/G	cg16329197	chr12:53359506	NA	-0.7	-10.05	-0.53	2.36e-20	Cancer (pleiotropy);
CESC	cis	rs6938	0.534	rs11854704	chr15:75221015	C/T	cg17294928	chr15:75287854	SCAMP5	0.47	6.1	0.35	3.69e-9	Breast cancer;
CESC	cis	rs6547741	1.000	rs2384654	chr2:27847364	C/T	cg21248554	chr2:27665150	KRTCAP3	0.25	5.09	0.3	6.73e-7	Oral cavity cancer;
CESC	cis	rs40363	1.000	rs1635393	chr16:3520493	C/T	cg21433313	chr16:3507492	NAT15	0.6	7.45	0.42	1.34e-12	Tuberculosis;
CESC	cis	rs113835537	0.877	rs77239910	chr11:66329639	G/A	cg24851651	chr11:66362959	CCS	0.63	5.69	0.33	3.28e-8	Airway imaging phenotypes;
CESC	cis	rs12579753	0.719	rs10862377	chr12:82270172	C/T	cg21193143	chr12:82153300	PPFIA2	-0.34	-5.16	-0.3	4.75e-7	Resting heart rate;
CESC	cis	rs826838	0.935	rs1843639	chr12:39178919	C/A	cg13010199	chr12:38710504	ALG10B	0.58	8.08	0.44	2.36e-14	Heart rate;
CESC	cis	rs854765	0.575	rs2955357	chr17:17946401	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.6	-8.42	-0.46	2.43e-15	Total body bone mineral density;
CESC	cis	rs9910055	0.676	rs11079983	chr17:42198170	C/T	cg13607699	chr17:42295918	UBTF	0.56	7.46	0.42	1.27e-12	Total body bone mineral density;
CESC	cis	rs1707322	1.000	rs34444543	chr1:46358862	G/A	cg03146154	chr1:46216737	IPP	0.69	9.24	0.49	8.09e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2236918	0.687	rs2797600	chr1:242029331	C/T	cg17736920	chr1:242011382	EXO1	0.55	7.02	0.4	1.89e-11	Menopause (age at onset);
CESC	cis	rs898097	0.812	rs72859941	chr17:80837459	G/A	cg15664640	chr17:80829946	TBCD	-0.63	-9.05	-0.49	3.16e-17	Breast cancer;
CESC	cis	rs2439831	1.000	rs2245908	chr15:43731454	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.82	11.64	0.58	1.4e-25	Lung cancer in ever smokers;
CESC	cis	rs10256972	0.900	rs4388364	chr7:1033045	T/G	cg07308232	chr7:1071921	C7orf50	-0.46	-6.3	-0.36	1.25e-9	Longevity;Endometriosis;
CESC	cis	rs1568889	1.000	rs12791341	chr11:28335452	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.77	10.13	0.53	1.38e-20	Bipolar disorder;
CESC	cis	rs1448094	0.690	rs7132879	chr12:86289864	A/G	cg02569458	chr12:86230093	RASSF9	0.38	5.47	0.32	1.03e-7	Major depressive disorder;
CESC	cis	rs17376456	0.569	rs2045020	chr5:93224466	T/C	cg21475434	chr5:93447410	FAM172A	-0.5	-5.1	-0.3	6.43e-7	Diabetic retinopathy;
CESC	cis	rs1003719	0.715	rs6579	chr21:38568308	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.59	-8.14	-0.45	1.59e-14	Eye color traits;
CESC	cis	rs12136530	0.593	rs12403329	chr1:19735793	G/C	cg01832549	chr1:19774989	CAPZB	-0.48	-6.3	-0.36	1.25e-9	Lead levels in blood;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg07243700	chr1:100731457	RTCD1	-0.49	-6.75	-0.38	9.55e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs7827545	0.961	rs4909482	chr8:135564786	G/T	cg17885191	chr8:135476712	NA	0.48	6.36	0.36	8.96e-10	Hypertension (SNP x SNP interaction);
CESC	cis	rs13118159	0.778	rs12650998	chr4:1338832	T/C	cg16405210	chr4:1374714	KIAA1530	-0.56	-7.58	-0.42	5.79e-13	Longevity;
CESC	cis	rs6831352	0.918	rs29001203	chr4:100053091	A/G	cg12011299	chr4:100065546	ADH4	-0.58	-6.6	-0.38	2.17e-10	Alcohol dependence;
CESC	cis	rs1008375	0.931	rs6449310	chr4:17575530	T/C	cg02297831	chr4:17616191	MED28	0.5	6.08	0.35	4.17e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs6089829	0.855	rs6062781	chr20:61667128	G/A	cg03213289	chr20:61660250	NA	0.39	6.16	0.35	2.7e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg06873352	chr17:61820015	STRADA	0.71	12.6	0.61	7.56e-29	Prudent dietary pattern;
CESC	cis	rs736408	0.509	rs3774349	chr3:52722335	A/C	cg05564831	chr3:52568323	NT5DC2	0.48	8.18	0.45	1.18e-14	Bipolar disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06057141	chr7:45026417	SNORA9;C7orf40	-0.6	-7.15	-0.4	8.65e-12	Gut microbiome composition (summer);
CESC	cis	rs4722166	0.532	rs1880242	chr7:22759607	A/C	cg05472934	chr7:22766657	IL6	-0.49	-6.39	-0.37	7.6e-10	Lung cancer;
CESC	cis	rs2576037	0.526	rs7240239	chr18:44460037	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.57	-7.99	-0.44	4.13e-14	Personality dimensions;
CESC	cis	rs10197940	0.901	rs2290367	chr2:152266731	T/A	cg06191203	chr2:152266755	RIF1	-0.56	-7.99	-0.44	4.15e-14	Lung cancer;
CESC	cis	rs1790761	0.504	rs61894496	chr11:67391907	C/T	cg24690094	chr11:67383802	NA	0.43	7.51	0.42	9.04e-13	Mean corpuscular volume;
CESC	cis	rs858239	0.600	rs10266123	chr7:23136487	G/C	cg23682824	chr7:23144976	KLHL7	0.51	6.74	0.38	9.98e-11	Cerebrospinal fluid biomarker levels;
CESC	trans	rs1728785	1.000	rs1728789	chr16:68595776	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.65	7.84	0.43	1.09e-13	Ulcerative colitis;
CESC	cis	rs7618915	0.547	rs34610878	chr3:52759169	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	7.2	0.4	6.31e-12	Bipolar disorder;
CESC	cis	rs6866344	0.601	rs4419608	chr5:178097049	C/T	cg10224037	chr5:178157518	ZNF354A	0.52	5.44	0.32	1.24e-7	Neutrophil percentage of white cells;
CESC	cis	rs7267979	0.586	rs1007707	chr20:25190598	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.66	10.86	0.56	5.58e-23	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs1558375	0.679	rs31672	chr7:87059699	C/T	cg00919237	chr7:87102261	ABCB4	0.39	5.4	0.31	1.51e-7	Gallbladder cancer;
CESC	trans	rs2823962	0.759	rs2211988	chr21:18016760	T/C	cg06419850	chr17:4688683	VMO1	-0.42	-6.13	-0.35	3.23e-9	Amyotrophic lateral sclerosis;
CESC	cis	rs11098499	0.954	rs4309825	chr4:120314881	C/T	cg09307838	chr4:120376055	NA	-0.87	-12.2	-0.6	1.84e-27	Corneal astigmatism;
CESC	cis	rs11809207	0.523	rs2783628	chr1:26501827	A/C	cg00147160	chr1:26503991	CNKSR1	0.28	5.23	0.31	3.42e-7	Height;
CESC	cis	rs1915146	0.546	rs9422857	chr10:126861278	C/G	cg00406319	chr10:126851303	NA	0.38	5.86	0.34	1.34e-8	Menarche (age at onset);
CESC	cis	rs13108904	0.557	rs1680030	chr4:1245500	A/T	cg05025164	chr4:1340916	KIAA1530	-0.69	-9.46	-0.5	1.72e-18	Obesity-related traits;
CESC	cis	rs2599510	0.811	rs176410	chr2:32643437	C/G	cg02381751	chr2:32503542	YIPF4	-0.5	-6.49	-0.37	4.14e-10	Interleukin-18 levels;
CESC	cis	rs6967414	0.792	rs6954012	chr7:6755724	A/C	cg09896999	chr7:6746977	ZNF12	-0.48	-6.32	-0.36	1.09e-9	Hematocrit;Hemoglobin concentration;
CESC	cis	rs936229	0.813	rs3784790	chr15:75081745	G/C	cg14664628	chr15:75095509	CSK	-0.95	-14.38	-0.66	4.66e-35	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CESC	cis	rs1801251	1.000	rs6747645	chr2:233571033	C/T	cg25237894	chr2:233734115	C2orf82	-0.49	-8.65	-0.47	5.2e-16	Coronary artery disease;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg00626599	chr2:64068905	UGP2	0.48	6.06	0.35	4.74e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs501120	1.000	rs694425	chr10:44761804	C/G	cg09554077	chr10:44749378	NA	0.49	6.06	0.35	4.75e-9	Coronary artery disease;Coronary heart disease;
CESC	cis	rs4481887	0.927	rs6587444	chr1:248438452	C/T	cg00666640	chr1:248458726	OR2T12	-0.39	-6.46	-0.37	4.95e-10	Common traits (Other);
CESC	cis	rs780096	0.527	rs59644396	chr2:27646083	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.34	-6.94	-0.39	3.02e-11	Total body bone mineral density;
CESC	cis	rs1862618	0.671	rs2591966	chr5:56233688	T/G	cg20203395	chr5:56204925	C5orf35	0.38	5.17	0.3	4.63e-7	Initial pursuit acceleration;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01712359	chr16:88783355	FAM38A	-0.54	-6.03	-0.35	5.38e-9	Gut microbiome composition (summer);
CESC	cis	rs10256972	0.758	rs9801444	chr7:1080444	A/C	cg09177884	chr7:1199841	ZFAND2A	0.47	5.8	0.34	1.92e-8	Longevity;Endometriosis;
CESC	cis	rs901683	1.000	rs78913745	chr10:46019911	A/T	cg16031567	chr10:46195673	NA	-0.77	-5.04	-0.3	8.57e-7	Red blood cell traits;Mean corpuscular volume;
CESC	cis	rs17095355	1.000	rs7905306	chr10:111712902	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.45	-5.3	-0.31	2.49e-7	Biliary atresia;
CESC	cis	rs13108904	0.557	rs1250086	chr4:1248051	G/A	cg16405210	chr4:1374714	KIAA1530	0.78	10.72	0.55	1.65e-22	Obesity-related traits;
CESC	cis	rs35306767	0.903	rs12250937	chr10:900209	C/T	cg25019033	chr10:957182	NA	-0.57	-6.08	-0.35	4.24e-9	Eosinophil percentage of granulocytes;
CESC	cis	rs6540556	0.608	rs2884090	chr1:209884059	C/T	cg05527609	chr1:210001259	C1orf107	-0.46	-5.42	-0.32	1.32e-7	Red blood cell count;
CESC	cis	rs4665809	0.590	rs13016300	chr2:26468365	G/C	cg25036284	chr2:26402008	FAM59B	0.86	9.4	0.5	2.74e-18	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.678	rs7670805	chr4:99008763	A/G	cg03467027	chr4:99064603	C4orf37	0.44	5.51	0.32	8.65e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6051080	1	rs6051080	chr20:25975674	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.36	5.56	0.32	6.47e-8	Colorectal or endometrial cancer;
CESC	cis	rs6598955	0.670	rs11247892	chr1:26592727	A/G	cg00852783	chr1:26633632	UBXN11	0.42	6.23	0.36	1.86e-9	Obesity-related traits;
CESC	cis	rs1005224	0.929	rs11625260	chr14:76162293	G/C	cg25116370	chr14:76127843	TTLL5;C14orf1	-0.41	-5.55	-0.32	7.03e-8	Large artery stroke;
CESC	cis	rs1790761	0.505	rs6591256	chr11:67349899	A/G	cg24690094	chr11:67383802	NA	-0.3	-5.08	-0.3	7.19e-7	Mean corpuscular volume;
CESC	cis	rs12410462	0.579	rs116423559	chr1:227575014	A/G	cg04117972	chr1:227635322	NA	0.75	6.11	0.35	3.57e-9	Major depressive disorder;
CESC	cis	rs6568686	0.627	rs403667	chr6:111910604	T/C	cg22127309	chr6:111907043	TRAF3IP2	0.53	5.2	0.3	3.91e-7	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
CESC	cis	rs1005277	0.540	rs7903942	chr10:37929276	C/T	cg00409905	chr10:38381863	ZNF37A	0.48	6.47	0.37	4.62e-10	Extrinsic epigenetic age acceleration;
CESC	cis	rs270601	0.721	rs270621	chr5:131605821	C/A	cg18301423	chr5:131593218	PDLIM4	0.39	5.18	0.3	4.47e-7	Acylcarnitine levels;
CESC	cis	rs35275482	0.541	rs2099584	chr15:60114161	A/T	cg11160654	chr15:60369068	NA	0.34	5.26	0.31	3.04e-7	Gut microbiota (bacterial taxa);
CESC	cis	rs57506017	0.585	rs6460901	chr7:12255434	C/T	cg23422036	chr7:12250390	TMEM106B	0.39	5.23	0.31	3.36e-7	Neuroticism;
CESC	cis	rs4975616	0.869	rs452384	chr5:1330840	T/C	cg07493874	chr5:1342172	CLPTM1L	-0.41	-7.93	-0.44	6.13e-14	Lung cancer;
CESC	trans	rs2115172	0.836	rs4835799	chr5:122762229	A/G	cg13040021	chr20:5093911	C20orf30	0.5	6.7	0.38	1.24e-10	Weight;
CESC	cis	rs10416265	0.503	rs1981818	chr19:33615122	C/T	cg27124370	chr19:33622961	WDR88	-0.51	-7.43	-0.42	1.5e-12	Bone properties (heel);
CESC	cis	rs748404	0.560	rs1060939	chr15:43816917	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.48	7.13	0.4	9.52e-12	Lung cancer;
CESC	cis	rs6089584	0.606	rs7270469	chr20:60577258	G/A	cg06108461	chr20:60628389	TAF4	-0.55	-7.26	-0.41	4.22e-12	Body mass index;
CESC	cis	rs796364	0.806	rs74266490	chr2:201005995	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.75	-6.83	-0.39	5.71e-11	Schizophrenia;
CESC	cis	rs798554	0.610	rs2644297	chr7:2858906	A/C	cg09658497	chr7:2847517	GNA12	-0.34	-5.15	-0.3	5.19e-7	Height;
CESC	cis	rs9324022	0.929	rs17099617	chr14:101170488	A/G	cg18089426	chr14:101175970	NA	0.55	6.7	0.38	1.24e-10	Plateletcrit;
CESC	cis	rs11792861	0.781	rs28361152	chr9:111727529	T/C	cg13535736	chr9:111863775	C9orf5	-0.47	-6.28	-0.36	1.35e-9	Menarche (age at onset);
CESC	cis	rs2243480	0.706	rs34466769	chr7:65453292	A/C	cg08632164	chr7:65971372	NA	-0.42	-5.39	-0.31	1.53e-7	Diabetic kidney disease;
CESC	cis	rs2228479	0.764	rs7186976	chr16:89961593	A/G	cg00800038	chr16:89945340	TCF25	-0.69	-6.6	-0.38	2.24e-10	Skin colour saturation;
CESC	cis	rs10504229	1.000	rs72650887	chr8:58177343	G/A	cg05313129	chr8:58192883	C8orf71	-0.55	-6.37	-0.36	8.42e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs9926296	0.508	rs1558184	chr16:89842374	T/G	cg03388025	chr16:89894329	SPIRE2	0.42	8.0	0.44	3.87e-14	Vitiligo;
CESC	cis	rs6540559	1.000	rs6696825	chr1:209982372	A/G	cg23283495	chr1:209979779	IRF6	0.51	7.49	0.42	1.01e-12	Cleft lip with or without cleft palate;
CESC	cis	rs1348850	0.519	rs1527407	chr2:178525630	T/G	cg22681709	chr2:178499509	PDE11A	-0.49	-7.04	-0.4	1.63e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs7613875	0.620	rs2526747	chr3:50082914	C/G	cg24110177	chr3:50126178	RBM5	-0.55	-7.49	-0.42	1.06e-12	Body mass index;
CESC	cis	rs13191362	1.000	rs73016459	chr6:163066323	C/A	cg06582575	chr6:163149167	PACRG;PARK2	0.88	8.93	0.48	7.4e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs4660306	0.961	rs945179	chr1:45992460	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.6	7.55	0.42	7.14e-13	Homocysteine levels;
CESC	cis	rs514406	0.627	rs485128	chr1:53344583	T/C	cg06600287	chr1:53387719	ECHDC2	-0.31	-5.42	-0.32	1.31e-7	Monocyte count;
CESC	cis	rs780096	0.526	rs780107	chr2:27684734	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.29	-5.79	-0.34	2e-8	Total body bone mineral density;
CESC	cis	rs2243480	1.000	rs427044	chr7:65508545	G/A	cg13147721	chr7:65941812	NA	-0.95	-9.01	-0.48	4.11e-17	Diabetic kidney disease;
CESC	cis	rs9660992	0.639	rs1151786	chr1:205227760	G/C	cg21643547	chr1:205240462	TMCC2	-0.44	-5.97	-0.34	7.53e-9	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.36	5.32	0.31	2.24e-7	Electroencephalogram traits;
CESC	cis	rs10864907	0.614	rs7557537	chr2:113702530	T/C	cg12858261	chr2:113808755	IL1F8	0.45	5.47	0.32	1.03e-7	Pulmonary function;
CESC	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	22.61	0.81	8.52e-64	Prudent dietary pattern;
CESC	cis	rs13191362	1.000	rs34138336	chr6:163144929	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.09	11.08	0.56	1.09e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs1005277	0.528	rs2057228	chr10:38515766	T/C	cg00409905	chr10:38381863	ZNF37A	-0.52	-7.04	-0.4	1.69e-11	Extrinsic epigenetic age acceleration;
CESC	cis	rs896854	0.818	rs13262110	chr8:95926890	C/T	cg16049864	chr8:95962084	TP53INP1	-0.68	-12.07	-0.6	4.85e-27	Type 2 diabetes;
CESC	cis	rs1729951	0.546	rs12054218	chr3:136677496	C/G	cg03617693	chr3:136751559	NA	0.38	5.36	0.31	1.81e-7	Neuroticism;
CESC	cis	rs7618915	0.501	rs2336146	chr3:52626646	A/G	cg18099408	chr3:52552593	STAB1	-0.3	-5.11	-0.3	6.18e-7	Bipolar disorder;
CESC	cis	rs9457247	0.967	rs1187532	chr6:167382020	G/A	cg07741184	chr6:167504864	NA	0.31	5.53	0.32	7.76e-8	Crohn's disease;
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg02912187	chr19:18314776	RAB3A	0.42	6.05	0.35	4.81e-9	Vertical cup-disc ratio;
CESC	cis	rs10504229	1.000	rs68076606	chr8:58191271	A/G	cg05313129	chr8:58192883	C8orf71	-0.55	-6.29	-0.36	1.34e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs60871478	0.838	rs7789321	chr7:800977	A/G	cg00934597	chr7:893267	UNC84A	0.54	5.45	0.32	1.16e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs6061231	0.544	rs2427314	chr20:60973666	C/T	cg06197360	chr20:60970103	CABLES2	-0.38	-5.19	-0.3	4.25e-7	Colorectal cancer;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg08365438	chr10:21683093	NA	-0.45	-6.16	-0.35	2.64e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs2070677	0.935	rs4582924	chr10:135409033	T/G	cg20169779	chr10:135381914	SYCE1	-0.75	-9.82	-0.52	1.26e-19	Gout;
CESC	cis	rs826838	0.935	rs1719855	chr12:39127242	C/T	cg26384229	chr12:38710491	ALG10B	-0.67	-10.95	-0.56	2.81e-23	Heart rate;
CESC	cis	rs1552244	1.000	rs9879080	chr3:10084224	C/T	cg00166722	chr3:10149974	C3orf24	0.49	6.27	0.36	1.47e-9	Alzheimer's disease;
CESC	cis	rs2836974	0.897	rs35391055	chr21:40525516	G/A	cg11890956	chr21:40555474	PSMG1	1.18	23.84	0.83	6.88e-68	Cognitive function;
CESC	cis	rs2228479	0.850	rs11640336	chr16:89941153	T/C	cg14709524	chr16:89940631	TCF25	0.69	5.28	0.31	2.75e-7	Skin colour saturation;
CESC	cis	rs6570726	0.764	rs367065	chr6:145882309	T/G	cg23711669	chr6:146136114	FBXO30	0.98	15.12	0.68	1.11e-37	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1005277	0.579	rs2505248	chr10:38459097	A/G	cg00409905	chr10:38381863	ZNF37A	-0.46	-6.13	-0.35	3.26e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs9894429	0.700	rs113915083	chr17:79552696	G/C	cg21984481	chr17:79567631	NPLOC4	0.57	9.21	0.49	1.01e-17	Eye color traits;
CESC	cis	rs9291683	1.000	rs9291683	chr4:10324160	C/T	cg11266682	chr4:10021025	SLC2A9	0.43	7.49	0.42	1.02e-12	Bone mineral density;
CESC	cis	rs853679	0.546	rs34295134	chr6:27828151	T/A	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.85	7.22	0.41	5.54e-12	Depression;
CESC	cis	rs56046484	0.750	rs62022525	chr15:85523678	G/T	cg08123816	chr15:85640762	PDE8A	-0.47	-5.07	-0.3	7.4e-7	Testicular germ cell tumor;
CESC	cis	rs780096	0.506	rs2303369	chr2:27715416	C/T	cg24768116	chr2:27665128	KRTCAP3	-0.28	-5.07	-0.3	7.42e-7	Total body bone mineral density;
CESC	cis	rs4481887	0.830	rs28581861	chr1:248506028	T/G	cg00666640	chr1:248458726	OR2T12	0.35	6.04	0.35	5.14e-9	Common traits (Other);
CESC	cis	rs6500395	1.000	rs1558815	chr16:48704869	C/A	cg04672837	chr16:48644449	N4BP1	-0.51	-6.43	-0.37	6.05e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs853679	0.546	rs200995	chr6:27813694	C/T	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	-0.86	-7.89	-0.44	8e-14	Depression;
CESC	cis	rs9768139	0.634	rs56389048	chr7:158121368	T/A	cg06219351	chr7:158114137	PTPRN2	-0.49	-7.65	-0.43	3.84e-13	Calcium levels;
CESC	cis	rs9840812	0.691	rs7621025	chr3:136272246	T/C	cg15507776	chr3:136538369	TMEM22	0.42	5.1	0.3	6.62e-7	Fibrinogen levels;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg14431266	chr11:67057003	ANKRD13D	0.45	6.15	0.35	2.84e-9	Systemic lupus erythematosus;
CESC	cis	rs3768617	0.811	rs12120747	chr1:183042531	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.66	9.05	0.49	3.11e-17	Fuchs's corneal dystrophy;
CESC	cis	rs9733	0.596	rs11582840	chr1:150688487	A/G	cg17724175	chr1:150552817	MCL1	0.45	7.31	0.41	3.23e-12	Tonsillectomy;
CESC	cis	rs10791323	0.569	rs2282602	chr11:133714522	G/A	cg06766960	chr11:133703094	NA	-0.39	-5.56	-0.32	6.46e-8	Childhood ear infection;
CESC	cis	rs801193	0.569	rs2013908	chr7:66121069	A/T	cg10691866	chr7:65817282	TPST1	0.31	5.33	0.31	2.06e-7	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16789084	chr11:66234297	PELI3	0.54	6.2	0.36	2.18e-9	Gut microbiome composition (summer);
CESC	cis	rs9323205	0.817	rs56100232	chr14:51699378	A/G	cg23942311	chr14:51606299	NA	-0.46	-5.5	-0.32	8.99e-8	Cancer;
CESC	cis	rs2073300	0.609	rs1936011	chr20:23341912	G/C	cg12062639	chr20:23401060	NAPB	1.0	7.89	0.44	8.19e-14	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg05314606	chr18:46478925	NA	-0.46	-6.0	-0.35	6.49e-9	Height;
CESC	cis	rs875971	0.767	rs1643394	chr7:65836094	A/G	cg18252515	chr7:66147081	NA	-0.43	-5.62	-0.33	4.88e-8	Aortic root size;
CESC	cis	rs1372520	0.684	rs2583978	chr4:90750326	A/C	cg15133208	chr4:90757351	SNCA	-0.4	-5.37	-0.31	1.71e-7	Neuroticism;
CESC	cis	rs7666738	0.822	rs17484018	chr4:98988960	G/A	cg05340658	chr4:99064831	C4orf37	0.8	12.42	0.61	3.09e-28	Colonoscopy-negative controls vs population controls;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg04078658	chr7:2054064	MAD1L1	0.43	6.53	0.37	3.42e-10	Fibrinogen levels;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg11037719	chr6:2999695	NQO2	-0.45	-6.27	-0.36	1.43e-9	Gambling;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg04765098	chr4:184644154	NA	0.45	6.15	0.35	2.91e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg23173032	chr14:50359789	ARF6	-0.4	-6.21	-0.36	2.06e-9	Gambling;
CESC	cis	rs4803468	0.967	rs16975238	chr19:41944985	T/A	cg09537434	chr19:41945824	ATP5SL	1.06	19.88	0.77	1.84e-54	Height;
CESC	trans	rs6952808	0.743	rs4721097	chr7:1877503	G/T	cg24247370	chr13:99142703	STK24	-0.42	-6.27	-0.36	1.45e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs1790761	0.501	rs4930210	chr11:67404726	G/T	cg24690094	chr11:67383802	NA	-0.34	-6.15	-0.35	2.83e-9	Mean corpuscular volume;
CESC	cis	rs3741489	1.000	rs2062162	chr12:133432744	C/T	cg01499426	chr12:133417423	CHFR	0.96	6.41	0.37	6.72e-10	Cognitive function;
CESC	cis	rs3785574	0.962	rs16947051	chr17:61790917	G/C	cg06873352	chr17:61820015	STRADA	0.49	7.33	0.41	2.81e-12	Height;
CESC	cis	rs10463316	0.862	rs11747047	chr5:150777953	C/T	cg03212797	chr5:150827313	SLC36A1	-0.53	-6.77	-0.38	8.16e-11	Metabolite levels (Pyroglutamine);
CESC	cis	rs1552244	0.935	rs35515831	chr3:10071362	G/A	cg08888203	chr3:10149979	C3orf24	0.49	6.29	0.36	1.3e-9	Alzheimer's disease;
CESC	cis	rs617791	0.530	rs7934543	chr11:65752508	G/T	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.38	-5.11	-0.3	6.15e-7	Breast cancer;
CESC	cis	rs7267979	0.604	rs242130	chr20:25594020	C/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.52	-7.97	-0.44	4.67e-14	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs6740322	0.793	rs13414908	chr2:43546658	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.69	-7.5	-0.42	9.55e-13	Coronary artery disease;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg00873521	chr9:95056130	IARS;SNORA84	-0.44	-6.25	-0.36	1.62e-9	Gambling;
CESC	cis	rs12540874	0.542	rs4947581	chr7:50565967	G/A	cg18232548	chr7:50535776	DDC	-0.35	-5.11	-0.3	6.3e-7	Systemic sclerosis;
CESC	cis	rs4974559	0.895	rs10018133	chr4:1338246	C/T	cg02980000	chr4:1222292	CTBP1	0.76	6.9	0.39	3.74e-11	Systolic blood pressure;
CESC	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-6.21	-0.36	2.01e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs959260	1.000	rs7216423	chr17:73365671	T/C	cg20590849	chr17:73267439	MIF4GD	-0.55	-6.4	-0.37	6.95e-10	Systemic lupus erythematosus;
CESC	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg26338869	chr17:61819248	STRADA	0.69	9.21	0.49	1.05e-17	Prudent dietary pattern;
CESC	cis	rs9322193	0.886	rs17672976	chr6:150097343	T/A	cg05861140	chr6:150128134	PCMT1	-0.37	-5.24	-0.31	3.23e-7	Lung cancer;
CESC	cis	rs2250402	0.510	rs6492926	chr15:40325829	T/G	cg16127683	chr15:40268777	EIF2AK4	-0.66	-5.61	-0.33	5.18e-8	Corneal curvature;
CESC	trans	rs1814175	0.791	rs9787917	chr11:49937281	C/T	cg03929089	chr4:120376271	NA	-0.93	-16.26	-0.71	1.03e-41	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14337668	chr9:99883682	NA	-0.72	-8.67	-0.47	4.43e-16	Gut microbiome composition (summer);
CESC	cis	rs12973672	0.812	rs13345192	chr19:35756155	A/C	cg12095397	chr19:35769544	USF2	-0.5	-6.11	-0.35	3.54e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs3008870	0.629	rs12742428	chr1:67426487	A/G	cg02640540	chr1:67518911	SLC35D1	0.46	5.58	0.32	5.81e-8	Lymphocyte percentage of white cells;
CESC	cis	rs7666738	0.716	rs9994641	chr4:99101605	C/T	cg05340658	chr4:99064831	C4orf37	0.75	10.56	0.54	5.64e-22	Colonoscopy-negative controls vs population controls;
CESC	trans	rs9650657	0.506	rs7823296	chr8:10778546	A/G	cg15556689	chr8:8085844	FLJ10661	-0.58	-7.22	-0.41	5.51e-12	Neuroticism;
CESC	cis	rs6582630	0.679	rs7301806	chr12:38596667	G/A	cg26384229	chr12:38710491	ALG10B	0.46	6.56	0.37	2.76e-10	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg14159672	chr1:205819179	PM20D1	0.8	12.64	0.61	5.69e-29	Menarche (age at onset);
CESC	cis	rs9796	0.621	rs690733	chr15:41476465	G/A	cg20272979	chr15:41787780	ITPKA	0.33	5.09	0.3	6.94e-7	Menopause (age at onset);
CESC	cis	rs142518269	1	rs142518269	chr2:24087095	G/A	cg20701182	chr2:24300061	SF3B14	0.78	6.93	0.39	3.11e-11	Mean corpuscular hemoglobin;
CESC	cis	rs875971	0.862	rs10240949	chr7:65804417	A/G	cg18876405	chr7:65276391	NA	-0.51	-7.03	-0.4	1.8e-11	Aortic root size;
CESC	cis	rs6570726	0.791	rs436156	chr6:145874873	A/G	cg23711669	chr6:146136114	FBXO30	1.03	15.86	0.7	2.71e-40	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs910316	0.763	rs175490	chr14:75545685	A/G	cg08847533	chr14:75593920	NEK9	0.91	15.9	0.7	2.01e-40	Height;
CESC	cis	rs2463822	0.507	rs72919442	chr11:62028707	A/G	cg06239285	chr11:62104954	ASRGL1	-1.02	-7.78	-0.43	1.63e-13	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs3087591	0.919	rs9913470	chr17:29566575	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.42	-5.23	-0.31	3.47e-7	Hip circumference;
CESC	cis	rs863345	0.935	rs10908678	chr1:158506223	A/T	cg12129480	chr1:158549410	OR10X1	-0.32	-6.3	-0.36	1.23e-9	Pneumococcal bacteremia;
CESC	cis	rs35110281	0.641	rs4819283	chr21:45083011	T/A	cg21573476	chr21:45109991	RRP1B	-0.59	-8.8	-0.48	1.82e-16	Mean corpuscular volume;
CESC	cis	rs1707322	0.638	rs1416706	chr1:46602844	G/A	cg03146154	chr1:46216737	IPP	-0.6	-7.18	-0.4	7.09e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2637266	1.000	rs12252604	chr10:78352591	T/C	cg18941641	chr10:78392320	NA	0.42	7.64	0.42	3.92e-13	Pulmonary function;
CESC	cis	rs1003719	0.715	rs9981715	chr21:38499610	C/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-8.47	-0.46	1.69e-15	Eye color traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20029003	chr12:6862076	MLF2	0.54	6.16	0.35	2.7e-9	Gut microbiome composition (summer);
CESC	cis	rs8031584	0.958	rs3512	chr15:31235005	G/C	cg08704250	chr15:31115839	NA	-0.62	-8.0	-0.44	3.91e-14	Huntington's disease progression;
CESC	cis	rs798554	0.757	rs1713919	chr7:2864706	C/A	cg18446336	chr7:2847575	GNA12	-0.35	-5.24	-0.31	3.27e-7	Height;
CESC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg17059624	chr11:85358760	TMEM126A	0.47	6.07	0.35	4.43e-9	Tetralogy of Fallot;
CESC	cis	rs4746818	0.901	rs10740317	chr10:70937566	G/A	cg11621586	chr10:70884670	VPS26A	0.86	8.46	0.46	1.83e-15	Left atrial antero-posterior diameter;
CESC	cis	rs7666738	0.830	rs7678557	chr4:99057329	A/G	cg18180107	chr4:99064573	C4orf37	0.41	5.25	0.31	3.18e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1018836	0.608	rs2205150	chr8:91483232	G/A	cg16814680	chr8:91681699	NA	-0.55	-7.7	-0.43	2.7e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs2070488	0.965	rs7373828	chr3:38524311	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.94	16.57	0.71	8.37e-43	Electrocardiographic conduction measures;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05226292	chr8:71520850	TRAM1	0.43	6.09	0.35	3.94e-9	Gut microbiota (bacterial taxa);
CESC	trans	rs163030	0.811	rs179814	chr5:76752518	A/T	cg26150533	chr8:82396069	FABP4	-0.39	-6.06	-0.35	4.57e-9	Caudate nucleus volume;
CESC	cis	rs2243480	1.000	rs67536397	chr7:65947917	G/A	cg13147721	chr7:65941812	NA	-0.94	-8.74	-0.47	2.71e-16	Diabetic kidney disease;
CESC	cis	rs2637266	0.600	rs12770441	chr10:78384983	C/T	cg18941641	chr10:78392320	NA	-0.34	-5.46	-0.32	1.11e-7	Pulmonary function;
CESC	cis	rs10504229	0.593	rs113184543	chr8:58042950	A/G	cg24829409	chr8:58192753	C8orf71	-0.5	-6.36	-0.36	8.93e-10	Developmental language disorder (linguistic errors);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16505808	chr17:26634458	FLJ40504	-0.51	-6.02	-0.35	5.71e-9	Gut microbiome composition (summer);
CESC	cis	rs6860806	0.661	rs2136187	chr5:131577894	T/C	cg09877947	chr5:131593287	PDLIM4	0.45	5.98	0.34	7.23e-9	Breast cancer;
CESC	cis	rs1372520	0.873	rs2736989	chr4:90776257	T/C	cg15133208	chr4:90757351	SNCA	-0.37	-5.44	-0.32	1.18e-7	Neuroticism;
CESC	cis	rs662064	0.852	rs617728	chr1:10566522	C/T	cg20482658	chr1:10539492	PEX14	0.39	7.82	0.43	1.27e-13	Asthma;
CESC	cis	rs7520050	0.966	rs1707321	chr1:46505309	A/G	cg03146154	chr1:46216737	IPP	-0.46	-6.11	-0.35	3.64e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs13108904	0.901	rs12641735	chr4:1304434	G/C	cg16405210	chr4:1374714	KIAA1530	-0.5	-6.15	-0.35	2.79e-9	Obesity-related traits;
CESC	cis	rs2243480	1.000	rs35820085	chr7:65442758	C/T	cg18252515	chr7:66147081	NA	-1.24	-12.17	-0.6	2.31e-27	Diabetic kidney disease;
CESC	cis	rs11792861	0.816	rs11791845	chr9:111683898	G/A	cg05043794	chr9:111880884	C9orf5	-0.36	-5.95	-0.34	8.29e-9	Menarche (age at onset);
CESC	cis	rs4819052	0.851	rs2838866	chr21:46713014	G/C	cg11663144	chr21:46675770	NA	-0.53	-7.86	-0.43	9.58e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs314370	0.951	rs6706	chr7:100471044	C/T	cg10426581	chr7:100472382	SRRT	0.86	8.37	0.46	3.32e-15	Resting heart rate;
CESC	cis	rs10743315	0.557	rs10505840	chr12:19403729	G/T	cg02471346	chr12:19282374	PLEKHA5	0.74	5.39	0.31	1.54e-7	Gut microbiota (bacterial taxa);
CESC	cis	rs708547	0.874	rs1718868	chr4:57881215	G/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.69	7.8	0.43	1.45e-13	Response to bleomycin (chromatid breaks);
CESC	cis	rs763121	0.962	rs909564	chr22:39126508	A/G	cg14440974	chr22:39074834	NA	-0.36	-5.34	-0.31	1.99e-7	Menopause (age at onset);
CESC	cis	rs6089584	0.606	rs2296082	chr20:60573983	A/G	cg06108461	chr20:60628389	TAF4	-0.56	-7.43	-0.42	1.54e-12	Body mass index;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06987936	chr6:74406097	CD109	0.58	7.05	0.4	1.55e-11	Gut microbiome composition (summer);
CESC	cis	rs9911578	0.967	rs9907940	chr17:56663842	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.11	0.3	6.06e-7	Intelligence (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20150972	chr6:13574573	SIRT5	0.52	6.05	0.35	4.89e-9	Gut microbiome composition (summer);
CESC	cis	rs2204008	0.837	rs11611861	chr12:38357459	A/G	cg26384229	chr12:38710491	ALG10B	0.73	10.95	0.56	2.81e-23	Bladder cancer;
CESC	cis	rs9914578	0.943	rs7225843	chr17:2001825	A/G	cg16513277	chr17:2031491	SMG6	-0.6	-6.62	-0.38	2.02e-10	Body mass index;
CESC	cis	rs514406	0.698	rs511599	chr1:53362818	T/C	cg25767906	chr1:53392781	SCP2	-0.54	-7.54	-0.42	7.6e-13	Monocyte count;
CESC	cis	rs9322193	0.962	rs3763163	chr6:150140906	G/T	cg07701084	chr6:150067640	NUP43	0.41	5.6	0.33	5.23e-8	Lung cancer;
CESC	cis	rs826838	0.900	rs9739128	chr12:38948960	A/T	cg13010199	chr12:38710504	ALG10B	0.59	8.5	0.46	1.37e-15	Heart rate;
CESC	cis	rs4704187	0.687	rs4360021	chr5:74421962	A/G	cg03227963	chr5:74354835	NA	0.31	5.7	0.33	3.22e-8	Response to amphetamines;
CESC	cis	rs2072732	0.756	rs77415878	chr1:2954047	C/G	cg03976712	chr1:2946727	NA	0.34	5.63	0.33	4.57e-8	Plateletcrit;
CESC	cis	rs34330	0.562	rs11055023	chr12:12853197	A/G	cg09462578	chr12:12878428	APOLD1	-0.81	-8.63	-0.47	5.89e-16	Systemic lupus erythematosus;
CESC	cis	rs832540	0.669	rs832538	chr5:56200016	C/T	cg18230493	chr5:56204884	C5orf35	-0.58	-7.69	-0.43	2.89e-13	Coronary artery disease;
CESC	cis	rs7264396	0.635	rs6058351	chr20:34486093	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.58	7.11	0.4	1.11e-11	Total cholesterol levels;
CESC	cis	rs9815354	0.812	rs73077373	chr3:41852887	C/T	cg03022575	chr3:42003672	ULK4	0.7	6.32	0.36	1.08e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs9457247	1.000	rs2769352	chr6:167378619	A/G	cg07741184	chr6:167504864	NA	-0.3	-5.38	-0.31	1.66e-7	Crohn's disease;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg11897279	chr19:13044638	FARSA	0.49	6.53	0.37	3.33e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs57221529	0.654	rs77015126	chr5:670909	G/A	cg25482853	chr8:67687455	SGK3	0.94	9.03	0.49	3.52e-17	Lung disease severity in cystic fibrosis;
CESC	cis	rs11864453	1.000	rs7185407	chr16:72034957	A/T	cg16558253	chr16:72132732	DHX38	0.42	5.94	0.34	8.95e-9	Fibrinogen levels;
CESC	cis	rs4253772	0.530	rs9627387	chr22:46684678	A/G	cg24881330	chr22:46731750	TRMU	0.83	9.19	0.49	1.17e-17	LDL cholesterol;Cholesterol, total;
CESC	cis	rs965469	1.000	rs6051737	chr20:3296992	G/A	cg25506879	chr20:3388711	C20orf194	-0.56	-6.03	-0.35	5.44e-9	IFN-related cytopenia;
CESC	cis	rs3096299	0.933	rs28608022	chr16:89454292	C/T	cg02187348	chr16:89574699	SPG7	0.55	7.25	0.41	4.59e-12	Multiple myeloma (IgH translocation);
CESC	cis	rs62064224	0.902	rs35830939	chr17:30627564	A/C	cg18200150	chr17:30822561	MYO1D	0.53	7.49	0.42	1.01e-12	Schizophrenia;
CESC	cis	rs1707322	0.627	rs3014213	chr1:46045522	T/C	cg06784218	chr1:46089804	CCDC17	-0.41	-7.11	-0.4	1.07e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs11252926	0.583	rs2066317	chr10:520309	C/T	cg18196295	chr10:418757	DIP2C	0.41	5.46	0.32	1.08e-7	Psychosis in Alzheimer's disease;
CESC	cis	rs2742234	0.578	rs2435354	chr10:43652445	C/T	cg15436174	chr10:43711423	RASGEF1A	-0.5	-5.71	-0.33	2.97e-8	Hirschsprung disease;
CESC	cis	rs2303745	0.544	rs6512180	chr19:17399153	C/T	cg04248312	chr19:17393744	ANKLE1	-0.92	-14.67	-0.67	4.56e-36	Systemic lupus erythematosus;
CESC	cis	rs6502050	0.723	rs11657069	chr17:80083809	C/T	cg23985595	chr17:80112537	CCDC57	0.42	6.52	0.37	3.56e-10	Life satisfaction;
CESC	cis	rs7666738	0.830	rs10001702	chr4:99065160	T/G	cg17366294	chr4:99064904	C4orf37	0.62	8.8	0.48	1.82e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2836974	0.644	rs2836982	chr21:40689171	C/A	cg22974920	chr21:40686053	BRWD1	-0.46	-5.73	-0.33	2.76e-8	Cognitive function;
CESC	cis	rs6582630	0.519	rs4002440	chr12:38485012	A/G	cg13010199	chr12:38710504	ALG10B	0.46	5.95	0.34	8.55e-9	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs7116495	1.000	rs58991229	chr11:71839878	G/A	cg26138937	chr11:71823887	C11orf51	0.78	6.17	0.35	2.57e-9	Severe influenza A (H1N1) infection;
CESC	cis	rs875971	1.000	rs778685	chr7:65836176	G/T	cg18876405	chr7:65276391	NA	0.5	6.64	0.38	1.75e-10	Aortic root size;
CESC	cis	rs4718428	0.705	rs28648401	chr7:66367132	T/C	cg18252515	chr7:66147081	NA	-0.45	-5.12	-0.3	5.89e-7	Corneal structure;
CESC	cis	rs7927771	0.832	rs4752993	chr11:47410951	T/C	cg05585544	chr11:47624801	NA	0.46	6.91	0.39	3.55e-11	Subjective well-being;
CESC	cis	rs5753618	0.583	rs2273249	chr22:31836486	T/C	cg13145458	chr22:31556086	RNF185	-0.49	-5.85	-0.34	1.47e-8	Colorectal cancer;
CESC	trans	rs3748784	0.584	rs3748785	chr1:97187083	A/C	cg03706951	chr17:39465518	NA	0.34	6.35	0.36	9.51e-10	Headache;
CESC	cis	rs11764590	0.694	rs7797112	chr7:2085165	T/C	cg21782813	chr7:2030301	MAD1L1	-0.4	-5.37	-0.31	1.73e-7	Neuroticism;
CESC	cis	rs7927771	1.000	rs12363232	chr11:47623890	C/T	cg20307385	chr11:47447363	PSMC3	-0.52	-6.18	-0.35	2.39e-9	Subjective well-being;
CESC	cis	rs3091242	0.809	rs660129	chr1:25727438	C/T	cg02931644	chr1:25747376	RHCE	0.38	6.21	0.36	2.06e-9	Erythrocyte sedimentation rate;
CESC	cis	rs13191362	1.000	rs13212608	chr6:163032128	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.51	5.53	0.32	7.85e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs12681288	0.676	rs1562921	chr8:1021986	G/T	cg15309053	chr8:964076	NA	0.41	7.0	0.39	2.12e-11	Schizophrenia;
CESC	cis	rs760805	1.000	rs4649037	chr1:25258301	G/T	cg22509179	chr1:25234806	RUNX3	-0.6	-8.56	-0.47	9.51e-16	Allergic disease (asthma, hay fever or eczema);
CESC	trans	rs877282	0.947	rs4133015	chr10:774131	T/C	cg22713356	chr15:30763199	NA	1.1	10.96	0.56	2.68e-23	Uric acid levels;
CESC	cis	rs9322193	0.884	rs9689702	chr6:150061856	G/A	cg13206674	chr6:150067644	NUP43	0.44	6.45	0.37	5.27e-10	Lung cancer;
CESC	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg05313129	chr8:58192883	C8orf71	-0.49	-5.36	-0.31	1.8e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs4654899	0.865	rs957163	chr1:21416181	G/T	cg05370193	chr1:21551575	ECE1	0.45	6.78	0.38	7.88e-11	Superior frontal gyrus grey matter volume;
CESC	cis	rs7071206	0.947	rs10509391	chr10:79422369	G/A	cg07817648	chr10:79422355	NA	-0.89	-11.3	-0.57	2.03e-24	Bone mineral density;
CESC	cis	rs858239	0.600	rs7784929	chr7:23124277	T/C	cg23682824	chr7:23144976	KLHL7	0.54	7.58	0.42	5.85e-13	Cerebrospinal fluid biomarker levels;
CESC	cis	rs7589342	0.628	rs11893695	chr2:106401300	C/G	cg16077055	chr2:106428750	NCK2	-0.53	-6.75	-0.38	9.15e-11	Addiction;
CESC	trans	rs629535	0.773	rs681534	chr8:70056964	A/C	cg21567404	chr3:27674614	NA	0.89	10.42	0.54	1.56e-21	Dupuytren's disease;
CESC	cis	rs4148883	0.689	rs1869458	chr4:100024728	C/G	cg12011299	chr4:100065546	ADH4	0.68	10.57	0.54	4.94e-22	Alcohol dependence;
CESC	cis	rs7980687	0.627	rs1727325	chr12:123698332	G/C	cg19016782	chr12:123741754	C12orf65	-0.45	-6.51	-0.37	3.65e-10	Height;Educational attainment;Head circumference (infant);
CESC	cis	rs4925386	0.840	rs8124907	chr20:60913127	A/G	cg12382846	chr20:60892121	LAMA5	0.32	5.12	0.3	5.81e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs6120849	0.662	rs6060300	chr20:33780970	T/C	cg24642439	chr20:33292090	TP53INP2	0.57	5.62	0.33	4.91e-8	Protein C levels;
CESC	cis	rs3736485	0.966	rs11070856	chr15:51853817	C/T	cg08986416	chr15:51914746	DMXL2	-0.4	-5.13	-0.3	5.5e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	trans	rs2983496	0.901	rs57522289	chr6:166037874	A/C	cg24191426	chr17:17908098	LRRC48	0.56	6.02	0.35	5.68e-9	Cortisol levels (saliva);
CESC	cis	rs2842992	0.724	rs9347340	chr6:160188891	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	-0.77	-10.88	-0.56	4.85e-23	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs9322193	0.923	rs12529698	chr6:149972087	G/A	cg04369109	chr6:150039330	LATS1	-0.39	-5.61	-0.33	4.97e-8	Lung cancer;
CESC	cis	rs7178572	0.524	rs7163503	chr15:77493505	C/A	cg22256960	chr15:77711686	NA	-0.53	-6.69	-0.38	1.33e-10	Type 2 diabetes;
CESC	cis	rs9322193	0.886	rs10872652	chr6:150096439	C/T	cg13206674	chr6:150067644	NUP43	0.41	5.74	0.33	2.64e-8	Lung cancer;
CESC	cis	rs12681366	0.620	rs2930968	chr8:95462695	C/T	cg13257157	chr8:95487014	RAD54B	0.39	5.34	0.31	2.04e-7	Nonsyndromic cleft lip with cleft palate;
CESC	cis	rs6952808	0.692	rs12666575	chr7:2004421	C/T	cg23048001	chr7:2026167	MAD1L1	0.48	6.14	0.35	3.02e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs722599	0.715	rs12147629	chr14:75307588	A/G	cg08847533	chr14:75593920	NEK9	-0.5	-6.12	-0.35	3.37e-9	IgG glycosylation;
CESC	cis	rs10832963	0.847	rs4237722	chr11:18639363	T/C	cg09201001	chr11:18656081	SPTY2D1	0.75	10.3	0.53	3.81e-21	Breast cancer;
CESC	cis	rs2243480	1.000	rs1392104	chr7:65759107	G/A	cg13147721	chr7:65941812	NA	0.98	9.24	0.49	8.25e-18	Diabetic kidney disease;
CESC	cis	rs6967414	0.681	rs2881352	chr7:6753511	T/A	cg09896999	chr7:6746977	ZNF12	-0.59	-7.11	-0.4	1.05e-11	Hematocrit;Hemoglobin concentration;
CESC	cis	rs9913156	0.793	rs56020376	chr17:4560909	A/G	cg19197139	chr17:4613644	ARRB2	0.92	10.46	0.54	1.18e-21	Lymphocyte counts;
CESC	cis	rs10876993	0.749	rs703832	chr12:58024626	G/C	cg18357645	chr12:58087776	OS9	0.59	8.7	0.47	3.64e-16	Celiac disease or Rheumatoid arthritis;
CESC	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.03	12.0	0.59	8.71e-27	Platelet count;
CESC	cis	rs36051895	0.632	rs7871515	chr9:5175288	A/G	cg02405213	chr9:5042618	JAK2	0.5	6.36	0.36	8.9e-10	Pediatric autoimmune diseases;
CESC	trans	rs8057939	0.528	rs79253352	chr16:49437248	G/T	cg15532236	chr6:170188124	NA	0.49	6.1	0.35	3.68e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs3747547	0.710	rs16934659	chr9:37950604	T/C	cg13774184	chr9:37916125	SHB	-0.56	-5.87	-0.34	1.32e-8	Metabolite levels (Dihydroxy docosatrienoic acid);
CESC	trans	rs7944735	0.607	rs34895872	chr11:48021778	A/G	cg15704280	chr7:45808275	SEPT13	0.68	8.2	0.45	1.02e-14	Intraocular pressure;
CESC	cis	rs9611565	0.512	rs1534932	chr22:42150146	C/T	cg03806693	chr22:41940476	POLR3H	1.19	13.82	0.65	4.33e-33	Vitiligo;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg12868019	chr2:161126642	NA	-0.43	-6.07	-0.35	4.34e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg05313129	chr8:58192883	C8orf71	-0.47	-5.13	-0.3	5.63e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg07157834	chr1:205819609	PM20D1	0.53	7.98	0.44	4.42e-14	Monocyte percentage of white cells;
CESC	cis	rs9815354	0.951	rs1717018	chr3:41913617	G/A	cg03022575	chr3:42003672	ULK4	0.44	5.16	0.3	4.85e-7	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs12464559	0.522	rs10200512	chr2:152626147	T/C	cg01189475	chr2:152685088	ARL5A	0.72	7.14	0.4	8.85e-12	Response to cognitive-behavioural therapy in anxiety disorder;
CESC	cis	rs72615157	0.613	rs56089143	chr7:99819844	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.6	6.8	0.39	6.87e-11	Lung function (FEV1/FVC);
CESC	trans	rs2018683	0.745	rs917217	chr7:28975025	G/T	cg19402173	chr7:128379420	CALU	0.56	7.38	0.41	2.07e-12	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CESC	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg23708337	chr7:1209742	NA	0.54	5.38	0.31	1.61e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs1552244	1.000	rs112509186	chr3:10156533	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.86	-11.97	-0.59	1.09e-26	Alzheimer's disease;
CESC	cis	rs7843479	0.965	rs9314269	chr8:21804989	A/G	cg17168535	chr8:21777572	XPO7	0.5	6.74	0.38	9.83e-11	Mean corpuscular volume;
CESC	cis	rs67478160	0.643	rs12878868	chr14:104233725	G/A	cg08213375	chr14:104286397	PPP1R13B	0.55	11.0	0.56	1.96e-23	Schizophrenia;
CESC	cis	rs1799949	1.000	rs1824889	chr17:41421876	C/G	cg23758822	chr17:41437982	NA	1.05	16.17	0.7	2.15e-41	Menopause (age at onset);
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg05366272	chr2:95831943	ZNF2	-0.48	-6.76	-0.38	8.57e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs2985684	1.000	rs1952012	chr14:50098896	T/A	cg02151108	chr14:50098012	C14orf104	-0.42	-5.48	-0.32	9.97e-8	Carotid intima media thickness;
CESC	cis	rs514406	0.861	rs35517489	chr1:53304062	G/C	cg08736216	chr1:53307985	ZYG11A	-0.42	-7.0	-0.39	2.12e-11	Monocyte count;
CESC	cis	rs7772486	0.806	rs2247317	chr6:146217570	C/T	cg23711669	chr6:146136114	FBXO30	0.77	10.91	0.56	3.81e-23	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7914558	1.000	rs11191542	chr10:104824324	T/A	cg08650961	chr10:104748594	CNNM2	0.31	5.17	0.3	4.67e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	trans	rs7824557	0.527	rs2736298	chr8:11235136	C/G	cg06636001	chr8:8085503	FLJ10661	-0.48	-6.05	-0.35	4.93e-9	Retinal vascular caliber;
CESC	cis	rs1348850	0.747	rs1047884	chr2:178488281	C/G	cg23306229	chr2:178417860	TTC30B	0.49	6.22	0.36	1.95e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg11530914	chr16:67281528	FHOD1;SLC9A5	0.48	6.67	0.38	1.5e-10	Systemic lupus erythematosus;
CESC	cis	rs752010	0.619	rs1123483	chr1:42114198	C/T	cg06885757	chr1:42089581	HIVEP3	-0.62	-9.89	-0.52	7.83e-20	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs12579753	0.879	rs11115007	chr12:82164673	A/T	cg21193143	chr12:82153300	PPFIA2	-0.35	-5.28	-0.31	2.68e-7	Resting heart rate;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg09060588	chr6:88299742	ORC3L;RARS2	-0.54	-6.59	-0.38	2.37e-10	Ulcerative colitis;
CESC	cis	rs6460942	0.591	rs4721082	chr7:12341804	A/G	cg06484146	chr7:12443880	VWDE	-0.62	-6.8	-0.39	6.82e-11	Coronary artery disease;
CESC	cis	rs950776	0.506	rs12915366	chr15:78831753	G/A	cg06917634	chr15:78832804	PSMA4	0.81	12.07	0.6	5.08e-27	Sudden cardiac arrest;
CESC	cis	rs2932538	0.922	rs36029940	chr1:113106444	T/G	cg22162597	chr1:113214053	CAPZA1	0.6	7.33	0.41	2.75e-12	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CESC	cis	rs75804782	0.641	rs77448526	chr2:239353487	A/C	cg18131467	chr2:239335373	ASB1	-0.67	-5.91	-0.34	1.06e-8	Morning vs. evening chronotype;Chronotype;
CESC	cis	rs72627123	0.867	rs113768127	chr14:74467839	T/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.79	5.74	0.33	2.6e-8	Morning vs. evening chronotype;
CESC	cis	rs4474465	0.688	rs7124803	chr11:78280822	T/G	cg01578073	chr11:78285783	NARS2	-0.45	-5.18	-0.3	4.31e-7	Alzheimer's disease (survival time);
CESC	cis	rs9837602	0.872	rs35154249	chr3:99738230	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.47	6.07	0.35	4.47e-9	Breast cancer;
CESC	cis	rs7084402	0.967	rs1658496	chr10:60279909	G/A	cg07615347	chr10:60278583	BICC1	-0.58	-9.3	-0.5	5.46e-18	Refractive error;
CESC	cis	rs2991971	0.967	rs10789465	chr1:45971759	T/C	cg15605315	chr1:45957053	TESK2	0.5	6.64	0.38	1.76e-10	High light scatter reticulocyte count;
CESC	cis	rs7762018	0.505	rs79843499	chr6:170068420	A/G	cg15199489	chr6:170068458	WDR27	0.68	5.2	0.3	4.03e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs909674	0.865	rs5757683	chr22:39850174	G/A	cg05872129	chr22:39784769	NA	-0.81	-10.48	-0.54	9.64e-22	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs10129255	0.957	rs11846893	chr14:107187307	T/C	cg23076370	chr14:107095027	NA	-0.49	-6.36	-0.36	8.9e-10	Kawasaki disease;
CESC	cis	rs4665809	0.590	rs35746418	chr2:26455002	C/G	cg08470875	chr2:26401718	FAM59B	0.75	7.79	0.43	1.49e-13	Gut microbiome composition (summer);
CESC	cis	rs763014	0.932	rs34498660	chr16:666149	A/G	cg00802000	chr16:706648	WDR90	-0.43	-6.59	-0.38	2.32e-10	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14975318	chr11:17298537	NUCB2	0.51	6.26	0.36	1.53e-9	Gut microbiome composition (summer);
CESC	cis	rs3812565	0.506	rs8413	chr9:139323311	T/C	cg14169450	chr9:139327907	INPP5E	0.53	7.98	0.44	4.35e-14	Granulocyte percentage of myeloid white cells;
CESC	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.58	7.51	0.42	8.95e-13	Prudent dietary pattern;
CESC	cis	rs965469	1.000	rs6051809	chr20:3352551	A/C	cg25506879	chr20:3388711	C20orf194	-0.58	-6.14	-0.35	3.03e-9	IFN-related cytopenia;
CESC	cis	rs4803468	1.000	rs4803463	chr19:41911040	C/G	cg09537434	chr19:41945824	ATP5SL	-1.04	-18.7	-0.75	2.39e-50	Height;
CESC	cis	rs6933660	0.745	rs6557138	chr6:151732017	C/T	cg14416726	chr6:151773293	C6orf211;RMND1	-0.55	-7.31	-0.41	3.22e-12	Menarche (age at onset);
CESC	trans	rs10176755	1.000	rs10176755	chr2:171365889	C/T	cg02062816	chr1:163166949	RGS5	-0.67	-6.12	-0.35	3.34e-9	Visceral fat;
CESC	cis	rs782590	0.902	rs7582278	chr2:55742924	C/G	cg18811423	chr2:55921094	PNPT1	0.79	12.44	0.61	2.73e-28	Metabolic syndrome;
CESC	cis	rs7772486	0.754	rs1415747	chr6:146077249	A/G	cg23711669	chr6:146136114	FBXO30	1.02	15.88	0.7	2.3e-40	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2948294	0.588	rs4840913	chr8:8116906	A/C	cg15556689	chr8:8085844	FLJ10661	0.46	5.51	0.32	8.3e-8	Red cell distribution width;
CESC	cis	rs367615	0.661	rs9326775	chr5:108836925	A/T	cg17395555	chr5:108820864	NA	0.62	11.06	0.56	1.27e-23	Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs2540647	0.908	rs2540652	chr22:18973314	G/A	cg12798833	chr22:18958832	DGCR5	0.62	6.46	0.37	5e-10	Blood metabolite ratios;
CESC	cis	rs9916302	0.706	rs12947506	chr17:37707592	A/G	cg00129232	chr17:37814104	STARD3	-0.54	-5.64	-0.33	4.31e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs35995292	0.500	rs6955677	chr7:38933942	C/T	cg19327137	chr7:38886074	VPS41	0.67	11.01	0.56	1.76e-23	Subjective well-being (multi-trait analysis);
CESC	cis	rs6088590	0.687	rs6088582	chr20:33286798	G/A	cg24642439	chr20:33292090	TP53INP2	0.69	9.25	0.49	7.76e-18	Coronary artery disease;
CESC	cis	rs9388451	0.839	rs4897155	chr6:126095144	C/A	cg05901451	chr6:126070800	HEY2	-0.63	-9.26	-0.49	7.05e-18	Brugada syndrome;
CESC	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg26338869	chr17:61819248	STRADA	0.72	9.36	0.5	3.63e-18	Prudent dietary pattern;
CESC	cis	rs3925075	1.000	rs9673405	chr16:31347599	A/C	cg02846316	chr16:31340340	ITGAM	0.41	6.52	0.37	3.54e-10	IgA nephropathy;
CESC	cis	rs4132509	0.793	rs10927047	chr1:243803677	A/T	cg21452805	chr1:244014465	NA	0.66	7.34	0.41	2.57e-12	RR interval (heart rate);
CESC	cis	rs7771547	0.573	rs9470278	chr6:36399239	G/A	cg04289385	chr6:36355825	ETV7	-0.38	-5.57	-0.32	6.41e-8	Platelet distribution width;
CESC	trans	rs61931739	0.500	rs10772163	chr12:34532950	T/C	cg26384229	chr12:38710491	ALG10B	0.54	7.53	0.42	8.03e-13	Morning vs. evening chronotype;
CESC	cis	rs2228479	0.867	rs35542367	chr16:89965825	G/C	cg06558623	chr16:89946397	TCF25	1.06	9.08	0.49	2.48e-17	Skin colour saturation;
CESC	cis	rs7851660	0.527	rs7870795	chr9:100574120	A/G	cg13688889	chr9:100608707	NA	-0.88	-14.05	-0.65	7.06e-34	Strep throat;
CESC	cis	rs5753618	0.519	rs5997939	chr22:31677130	C/G	cg00478049	chr22:31556069	RNF185	0.46	5.21	0.3	3.75e-7	Colorectal cancer;
CESC	trans	rs12356475	0.710	rs10822686	chr10:67733250	C/T	cg01087832	chr11:68039514	C11orf24	0.49	6.04	0.35	5.21e-9	Psoriatic arthritis;
CESC	cis	rs7208859	0.673	rs9915963	chr17:29019643	C/T	cg14008862	chr17:28927542	LRRC37B2	0.59	5.18	0.3	4.49e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	trans	rs9929218	1.000	rs9936621	chr16:68798682	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.63	-8.44	-0.46	2.13e-15	Colorectal cancer;
CESC	cis	rs941873	0.772	rs7920127	chr10:81122914	T/C	cg08514558	chr10:81106712	PPIF	0.34	5.9	0.34	1.13e-8	Height;
CESC	cis	rs7615952	0.599	rs67575510	chr3:125742355	C/G	cg04553112	chr3:125709451	NA	-0.51	-5.36	-0.31	1.78e-7	Blood pressure (smoking interaction);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg25079743	chr16:30441674	DCTPP1	-0.44	-6.52	-0.37	3.47e-10	Gambling;
CESC	cis	rs2737618	0.722	rs2821333	chr1:200093253	A/C	cg21825944	chr1:200113062	NR5A2	-0.38	-5.4	-0.32	1.45e-7	Uric acid levels;
CESC	cis	rs10791323	0.604	rs2257010	chr11:133712348	G/A	cg15485101	chr11:133734466	NA	0.41	6.67	0.38	1.48e-10	Childhood ear infection;
CESC	cis	rs8070740	0.898	rs8078914	chr17:5323924	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.51	6.35	0.36	9.3e-10	Menopause (age at onset);
CESC	cis	rs13102973	0.965	rs28769289	chr4:135878230	T/C	cg14419869	chr4:135874104	NA	-0.37	-5.75	-0.33	2.42e-8	Subjective well-being;
CESC	trans	rs4332037	0.754	rs62436669	chr7:1926636	G/A	cg11693508	chr17:37793320	STARD3	0.64	6.18	0.35	2.43e-9	Bipolar disorder;
CESC	cis	rs873946	0.648	rs12766166	chr10:134556403	G/C	cg27297192	chr10:134578999	INPP5A	0.4	5.29	0.31	2.59e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs523522	0.962	rs12309824	chr12:120990582	A/C	cg27279351	chr12:120934652	DYNLL1	0.68	8.7	0.47	3.47e-16	High light scatter reticulocyte count;
CESC	cis	rs6456156	0.565	rs2181058	chr6:167465330	A/T	cg23791538	chr6:167370224	RNASET2	-0.49	-6.37	-0.36	8.13e-10	Primary biliary cholangitis;
CESC	cis	rs344364	0.511	rs1742469	chr16:1950244	C/T	cg26617929	chr16:1858877	NA	-0.49	-5.15	-0.3	5.09e-7	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs12618769	0.597	rs3769716	chr2:99133305	G/A	cg10123293	chr2:99228465	UNC50	0.39	5.13	0.3	5.6e-7	Bipolar disorder;
CESC	cis	rs61542988	0.570	rs7781074	chr7:22826360	A/G	cg13679077	chr7:22862647	TOMM7	-0.62	-7.1	-0.4	1.17e-11	Fibrinogen levels;
CESC	cis	rs10752881	1.000	rs6697739	chr1:182983333	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.83	13.25	0.63	4.18e-31	Colorectal cancer;
CESC	cis	rs734999	0.588	rs10910099	chr1:2533552	G/T	cg20673091	chr1:2541236	MMEL1	-0.43	-7.1	-0.4	1.12e-11	Ulcerative colitis;
CESC	cis	rs1372520	0.627	rs2737025	chr4:90719192	A/G	cg15133208	chr4:90757351	SNCA	-0.43	-5.74	-0.33	2.63e-8	Neuroticism;
CESC	cis	rs9300255	0.602	rs1106241	chr12:123627016	T/C	cg05973401	chr12:123451056	ABCB9	0.52	5.82	0.34	1.74e-8	Neutrophil percentage of white cells;
CESC	cis	rs7618915	0.501	rs13079063	chr3:52744460	A/G	cg18404041	chr3:52824283	ITIH1	-0.39	-6.64	-0.38	1.81e-10	Bipolar disorder;
CESC	cis	rs4282054	0.631	rs13081155	chr3:52732429	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	7.09	0.4	1.22e-11	Cognitive function;
CESC	cis	rs2204008	0.805	rs4589389	chr12:37946120	C/A	cg26384229	chr12:38710491	ALG10B	-0.56	-8.05	-0.44	2.86e-14	Bladder cancer;
CESC	cis	rs2576037	0.526	rs509647	chr18:44383675	G/T	cg19077165	chr18:44547161	KATNAL2	-0.53	-7.55	-0.42	6.82e-13	Personality dimensions;
CESC	cis	rs35306767	0.807	rs12768348	chr10:899224	T/G	cg26597838	chr10:835615	NA	1.18	11.3	0.57	2e-24	Eosinophil percentage of granulocytes;
CESC	cis	rs6754311	0.773	rs4988183	chr2:136622046	T/C	cg07169764	chr2:136633963	MCM6	0.65	8.31	0.45	5.05e-15	Mosquito bite size;
CESC	cis	rs3858526	0.628	rs4237762	chr11:5956626	A/C	cg02574844	chr11:5959923	NA	-0.48	-6.51	-0.37	3.67e-10	DNA methylation (variation);
CESC	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg22535103	chr8:58192502	C8orf71	-0.92	-10.19	-0.53	8.81e-21	Developmental language disorder (linguistic errors);
CESC	cis	rs514406	0.763	rs7535088	chr1:53215042	A/G	cg24675658	chr1:53192096	ZYG11B	0.54	6.8	0.39	6.96e-11	Monocyte count;
CESC	cis	rs7100689	0.646	rs10736348	chr10:82139244	C/A	cg00277334	chr10:82204260	NA	-0.59	-7.72	-0.43	2.46e-13	Post bronchodilator FEV1;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00196167	chr7:139026058	C7orf55	0.56	6.58	0.37	2.44e-10	Gut microbiome composition (summer);
CESC	cis	rs9287719	0.967	rs12622765	chr2:10728331	T/C	cg00105475	chr2:10696890	NA	0.39	5.69	0.33	3.35e-8	Prostate cancer;
CESC	cis	rs7116495	1.000	rs7101701	chr11:71762155	A/G	cg10381502	chr11:71823885	C11orf51	-0.66	-5.35	-0.31	1.89e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs6500395	0.926	rs1039342	chr16:48577498	G/A	cg04672837	chr16:48644449	N4BP1	0.48	6.03	0.35	5.53e-9	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs4835473	0.932	rs7693772	chr4:144886767	C/G	cg25736465	chr4:144833511	NA	0.42	6.79	0.38	7.41e-11	Immature fraction of reticulocytes;
CESC	cis	rs12711979	0.765	rs897069	chr2:3818947	C/T	cg17052675	chr2:3827356	NA	0.43	6.71	0.38	1.16e-10	Itch intensity from mosquito bite adjusted by bite size;
CESC	cis	rs854765	0.693	rs12936037	chr17:17777245	A/G	cg09796270	chr17:17721594	SREBF1	-0.45	-6.31	-0.36	1.14e-9	Total body bone mineral density;
CESC	cis	rs9399135	0.967	rs2297338	chr6:135375762	G/A	cg22676075	chr6:135203613	NA	0.52	7.31	0.41	3.24e-12	Red blood cell count;
CESC	cis	rs7833790	0.632	rs6473308	chr8:82707708	G/A	cg06027949	chr8:82754900	SNX16	-0.43	-5.14	-0.3	5.37e-7	Diastolic blood pressure;
CESC	cis	rs2337406	0.714	rs7150993	chr14:107226748	A/T	cg07958169	chr14:107095056	NA	-0.48	-5.25	-0.31	3.13e-7	Alzheimer's disease (late onset);
CESC	cis	rs514406	0.505	rs269292	chr1:53187911	T/C	cg16325326	chr1:53192061	ZYG11B	0.89	15.11	0.68	1.2e-37	Monocyte count;
CESC	cis	rs7635838	0.617	rs184700	chr3:11293061	A/G	cg00170343	chr3:11313890	ATG7	0.56	7.69	0.43	2.9e-13	HDL cholesterol;
CESC	cis	rs131777	0.547	rs131753	chr22:51022862	A/G	cg00083937	chr22:51039805	MAPK8IP2	0.4	5.73	0.33	2.69e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	trans	rs7607369	0.679	rs6751527	chr2:219630965	C/G	cg15547669	chr20:2781122	CPXM1	0.37	6.06	0.35	4.58e-9	Red blood cell count;Amyotrophic lateral sclerosis;
CESC	trans	rs931812	0.895	rs4734016	chr8:101910071	C/T	cg20993868	chr7:22813445	NA	0.57	8.08	0.44	2.36e-14	Attention deficit hyperactivity disorder and conduct disorder;
CESC	cis	rs2658782	0.789	rs3020057	chr11:93118515	C/T	cg15737290	chr11:93063684	CCDC67	0.54	6.61	0.38	2.06e-10	Pulmonary function decline;
CESC	cis	rs2980439	0.846	rs2980437	chr8:8094763	C/T	cg15556689	chr8:8085844	FLJ10661	-0.62	-7.81	-0.43	1.36e-13	Neuroticism;
CESC	cis	rs7552404	0.824	rs1251077	chr1:76189745	C/G	cg22875332	chr1:76189707	ACADM	-0.76	-11.73	-0.58	7.41e-26	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs1595825	0.891	rs77946222	chr2:198533251	C/T	cg10820045	chr2:198174542	NA	0.41	5.07	0.3	7.49e-7	Ulcerative colitis;
CESC	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg21280719	chr6:42927975	GNMT	-0.3	-6.94	-0.39	3e-11	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs1862618	0.853	rs832554	chr5:56115036	A/G	cg12311346	chr5:56204834	C5orf35	-0.71	-8.63	-0.47	5.64e-16	Initial pursuit acceleration;
CESC	cis	rs13108904	0.901	rs13119532	chr4:1304505	G/C	cg16405210	chr4:1374714	KIAA1530	-0.42	-5.07	-0.3	7.4e-7	Obesity-related traits;
CESC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg02125191	chr6:41755473	TOMM6	0.5	6.23	0.36	1.78e-9	Tetralogy of Fallot;
CESC	cis	rs72627123	0.867	rs57482759	chr14:74485523	G/A	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.73	5.65	0.33	4.06e-8	Morning vs. evening chronotype;
CESC	cis	rs3733585	0.673	rs4627861	chr4:9954238	T/G	cg02734326	chr4:10020555	SLC2A9	-0.39	-5.64	-0.33	4.45e-8	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs4555082	0.756	rs76863138	chr14:105736379	C/T	cg13114125	chr14:105738426	BRF1	-0.9	-10.88	-0.56	4.79e-23	Mean platelet volume;Platelet distribution width;
CESC	cis	rs12602486	1.000	rs78867692	chr17:42263873	G/C	cg08193365	chr17:42277699	NA	0.88	5.33	0.31	2.13e-7	Glycated hemoglobin levels;
CESC	trans	rs1728785	1.000	rs1645927	chr16:68589300	T/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.65	7.81	0.43	1.32e-13	Ulcerative colitis;
CESC	cis	rs12893668	0.572	rs4900590	chr14:104146421	C/T	cg24130564	chr14:104152367	KLC1	-0.49	-6.46	-0.37	4.96e-10	Reticulocyte count;
CESC	cis	rs17253792	0.822	rs75232282	chr14:56067290	G/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.82	6.15	0.35	2.84e-9	Putamen volume;
CESC	cis	rs6032067	1.000	rs34885285	chr20:43804789	C/A	cg11264863	chr20:43835661	SEMG1	0.51	5.56	0.32	6.5e-8	Blood protein levels;
CESC	cis	rs9811920	0.598	rs793470	chr3:99548274	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.53	9.0	0.48	4.52e-17	Axial length;
CESC	cis	rs4713118	0.527	rs4713151	chr6:28136356	G/A	cg23281280	chr6:28129359	ZNF389	0.56	7.62	0.42	4.55e-13	Parkinson's disease;
CESC	cis	rs7772486	0.875	rs2748502	chr6:146298239	A/G	cg23711669	chr6:146136114	FBXO30	0.78	11.25	0.57	2.92e-24	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7772486	0.597	rs2246132	chr6:146182515	C/G	cg23711669	chr6:146136114	FBXO30	0.88	11.55	0.58	2.79e-25	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2842992	0.830	rs1535475	chr6:160148935	T/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.68	8.82	0.48	1.56e-16	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs67478160	0.643	rs4900600	chr14:104291839	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.51	-7.14	-0.4	8.85e-12	Schizophrenia;
CESC	cis	rs6570726	0.935	rs411641	chr6:145827532	G/A	cg23711669	chr6:146136114	FBXO30	0.8	11.97	0.59	1.1e-26	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1552244	0.882	rs6796419	chr3:10040812	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	10.94	0.56	3.23e-23	Alzheimer's disease;
CESC	cis	rs916888	0.773	rs199443	chr17:44819565	C/T	cg01570182	chr17:44337453	NA	0.86	9.92	0.52	6.21e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs1018836	0.923	rs7826178	chr8:91649592	C/A	cg16814680	chr8:91681699	NA	-0.78	-12.1	-0.6	4.08e-27	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs875971	0.862	rs778720	chr7:65846275	A/C	cg11764359	chr7:65958608	NA	-0.78	-11.54	-0.58	3.08e-25	Aortic root size;
CESC	cis	rs4076764	0.801	rs6675964	chr1:163375960	A/G	cg24596788	chr1:163392923	NA	-0.42	-5.99	-0.35	6.85e-9	Motion sickness;
CESC	cis	rs12042938	0.579	rs980394	chr1:231779507	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.4	-5.17	-0.3	4.59e-7	Neuranatomic and neurocognitive phenotypes;
CESC	cis	rs2180341	1.000	rs2057223	chr6:127637374	T/C	cg24812749	chr6:127587940	RNF146	1.07	15.48	0.69	6.31e-39	Breast cancer;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg03209809	chr3:126422892	CHCHD6	-0.54	-7.25	-0.41	4.63e-12	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs9467711	0.559	rs13208916	chr6:26601940	G/A	cg14345882	chr6:26364793	BTN3A2	0.56	6.06	0.35	4.58e-9	Autism spectrum disorder or schizophrenia;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg11342046	chr2:242641489	ING5	0.46	6.07	0.35	4.32e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs8133932	0.654	rs7410105	chr21:47332181	A/G	cg14185626	chr21:47401492	COL6A1	0.51	5.11	0.3	6.11e-7	Schizophrenia;
CESC	cis	rs2243480	1.000	rs1715235	chr7:65488394	T/C	cg12463550	chr7:65579703	CRCP	0.72	5.81	0.34	1.8e-8	Diabetic kidney disease;
CESC	trans	rs9325144	0.555	rs61929925	chr12:38698828	C/A	cg23762105	chr12:34175262	ALG10	0.49	6.42	0.37	6.4e-10	Morning vs. evening chronotype;
CESC	cis	rs35306767	0.807	rs34527494	chr10:935192	T/C	cg10556349	chr10:835070	NA	0.72	6.12	0.35	3.29e-9	Eosinophil percentage of granulocytes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07701084	chr6:150067640	NUP43	-0.58	-6.78	-0.38	7.98e-11	Gut microbiome composition (summer);
CESC	cis	rs873946	0.586	rs12770021	chr10:134562021	G/A	cg27286337	chr10:134555280	INPP5A	0.68	7.71	0.43	2.62e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs1552244	0.572	rs17032440	chr3:10169819	A/C	cg00149659	chr3:10157352	C3orf10	-0.98	-11.21	-0.57	3.88e-24	Alzheimer's disease;
CESC	cis	rs60154123	0.615	rs701943	chr1:210425727	A/G	cg25204440	chr1:209979598	IRF6	-0.48	-5.48	-0.32	1.01e-7	Coronary artery disease;
CESC	cis	rs7618915	0.547	rs12486847	chr3:52691112	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	6.86	0.39	4.85e-11	Bipolar disorder;
CESC	cis	rs2228479	0.850	rs11645240	chr16:89837326	T/C	cg00800038	chr16:89945340	TCF25	-0.92	-7.64	-0.42	4.02e-13	Skin colour saturation;
CESC	cis	rs6942756	0.531	rs9649531	chr7:128927659	T/C	cg02491457	chr7:128862824	NA	0.46	6.42	0.37	6.22e-10	White matter hyperintensity burden;
CESC	cis	rs2197308	0.765	rs2387436	chr12:37935337	C/T	cg26384229	chr12:38710491	ALG10B	-0.52	-7.31	-0.41	3.08e-12	Morning vs. evening chronotype;
CESC	cis	rs798554	0.686	rs2527690	chr7:2854250	C/T	cg19717773	chr7:2847554	GNA12	-0.54	-8.46	-0.46	1.83e-15	Height;
CESC	cis	rs1799949	1.000	rs4793231	chr17:41427469	A/G	cg25072359	chr17:41440525	NA	0.5	6.83	0.39	5.65e-11	Menopause (age at onset);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg15717853	chr1:182573596	RGS16	-0.4	-6.21	-0.36	2.01e-9	Gambling;
CESC	cis	rs6439153	0.933	rs34193129	chr3:128691407	G/A	cg24203234	chr3:128598194	ACAD9	0.42	5.47	0.32	1.06e-7	Pneumococcal bacteremia;
CESC	cis	rs4665809	0.556	rs10221814	chr2:26442759	C/T	cg25036284	chr2:26402008	FAM59B	-0.88	-9.99	-0.52	3.83e-20	Gut microbiome composition (summer);
CESC	cis	rs72781680	0.611	rs72781695	chr2:24266744	T/C	cg20701182	chr2:24300061	SF3B14	0.94	10.66	0.55	2.67e-22	Lymphocyte counts;
CESC	cis	rs7577696	0.513	rs212685	chr2:32434701	A/G	cg02381751	chr2:32503542	YIPF4	0.46	5.42	0.32	1.31e-7	Inflammatory biomarkers;
CESC	cis	rs1475911	0.708	rs11701371	chr21:43523972	C/G	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.55	-8.65	-0.47	5.1e-16	IgG glycosylation;
CESC	cis	rs5750830	0.649	rs5750818	chr22:39820885	A/G	cg02038168	chr22:39784481	NA	-0.66	-8.29	-0.45	5.63e-15	Intelligence (multi-trait analysis);
CESC	trans	rs2593957	0.503	rs9821382	chr3:108812154	A/G	cg14361641	chr2:70056642	GMCL1	-0.54	-6.17	-0.35	2.57e-9	Colorectal cancer (diet interaction);
CESC	trans	rs17685	0.753	rs1806885	chr7:75785612	T/G	cg19862616	chr7:65841803	NCRNA00174	0.85	12.42	0.61	3.15e-28	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs10504229	0.953	rs72652908	chr8:58191324	G/A	cg14926445	chr8:58193284	C8orf71	-0.51	-5.52	-0.32	8.28e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs17608059	0.504	rs11656981	chr17:13978777	A/G	cg11395062	chr17:14139857	CDRT15	0.57	7.37	0.41	2.12e-12	Temperament;
CESC	cis	rs5753037	0.702	rs5752961	chr22:30188084	C/T	cg01021169	chr22:30184971	ASCC2	-0.46	-6.57	-0.37	2.65e-10	Type 1 diabetes;
CESC	cis	rs72945132	0.882	rs60917762	chr11:70211384	C/T	cg00319359	chr11:70116639	PPFIA1	0.73	6.99	0.39	2.25e-11	Coronary artery disease;
CESC	cis	rs1046896	0.627	rs7225515	chr17:80795783	C/T	cg02398342	chr17:80708632	TBCD;FN3K	0.44	5.3	0.31	2.39e-7	Glycated hemoglobin levels;
CESC	cis	rs4595586	0.525	rs35089392	chr12:39414547	T/G	cg26384229	chr12:38710491	ALG10B	0.61	8.37	0.46	3.29e-15	Morning vs. evening chronotype;
CESC	cis	rs2115630	0.691	rs61322921	chr15:85163638	T/C	cg12501888	chr15:85177176	SCAND2	-0.49	-6.54	-0.37	3.07e-10	P wave terminal force;
CESC	cis	rs12497850	0.931	rs6446253	chr3:48911443	C/T	cg03060546	chr3:49711283	APEH	0.44	5.5	0.32	8.91e-8	Parkinson's disease;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg24415922	chr4:858814	GAK	-0.43	-6.5	-0.37	3.92e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs2074038	1.000	rs2074038	chr11:44087989	G/T	cg00452199	chr11:44088257	ACCS	-0.78	-7.51	-0.42	9.29e-13	IgA nephropathy;
CESC	cis	rs16858210	0.657	rs73177515	chr3:183566825	T/A	cg25686905	chr3:183603175	PARL	-0.33	-5.83	-0.34	1.62e-8	Menopause (age at onset);
CESC	cis	rs9311474	0.607	rs28661185	chr3:52567188	G/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.3	5.35	0.31	1.88e-7	Electroencephalogram traits;
CESC	cis	rs9733	0.596	rs11807058	chr1:150640475	G/A	cg17724175	chr1:150552817	MCL1	0.44	7.24	0.41	4.8e-12	Tonsillectomy;
CESC	cis	rs16867321	0.627	rs1406262	chr2:181585220	A/G	cg23363182	chr2:181467187	NA	-0.44	-6.8	-0.39	7.09e-11	Obesity;
CESC	cis	rs13102973	0.932	rs6858552	chr4:135864734	C/T	cg14419869	chr4:135874104	NA	-0.4	-6.31	-0.36	1.15e-9	Subjective well-being;
CESC	cis	rs9399135	0.660	rs4472368	chr6:135274232	A/G	cg24558204	chr6:135376177	HBS1L	0.55	7.54	0.42	7.45e-13	Red blood cell count;
CESC	trans	rs916888	0.773	rs199451	chr17:44801784	G/A	cg23590916	chr17:43697445	MGC57346	0.65	6.49	0.37	4.28e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs672059	1.000	rs1760624	chr1:183158552	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.54	6.97	0.39	2.51e-11	Hypertriglyceridemia;
CESC	cis	rs8067354	0.645	rs2665403	chr17:57889985	G/A	cg02344993	chr17:57696989	CLTC	0.56	6.04	0.35	5.31e-9	Hemoglobin concentration;
CESC	cis	rs2404602	0.716	rs4079681	chr15:76695230	G/A	cg26408565	chr15:76604113	ETFA	-0.41	-6.02	-0.35	5.85e-9	Blood metabolite levels;
CESC	cis	rs2979489	0.786	rs2915595	chr8:30402817	A/G	cg26383811	chr8:30366931	RBPMS	0.76	9.67	0.51	3.97e-19	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CESC	cis	rs2000999	0.691	rs11648003	chr16:72052348	A/G	cg01557791	chr16:72042693	DHODH	-0.56	-5.63	-0.33	4.57e-8	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
CESC	cis	rs1552244	0.938	rs34750074	chr3:10091740	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.87	11.4	0.57	9.4e-25	Alzheimer's disease;
CESC	cis	rs9916302	0.904	rs9904334	chr17:37468336	G/A	cg20243544	chr17:37824526	PNMT	-0.46	-5.66	-0.33	3.97e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs3760982	0.585	rs11673534	chr19:44298884	G/A	cg11993925	chr19:44307056	LYPD5	0.34	5.85	0.34	1.45e-8	Breast cancer (estrogen-receptor negative);Breast cancer;
CESC	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg03461704	chr1:205818484	PM20D1	0.41	5.12	0.3	5.93e-7	Menarche (age at onset);
CESC	cis	rs9916302	0.861	rs632202	chr17:37453294	C/A	cg00129232	chr17:37814104	STARD3	0.55	7.17	0.4	7.3e-12	Glomerular filtration rate (creatinine);
CESC	cis	rs854765	0.647	rs2974998	chr17:17995619	A/G	cg04398451	chr17:18023971	MYO15A	-0.76	-11.24	-0.57	3.24e-24	Total body bone mineral density;
CESC	cis	rs28830936	0.966	rs1918310	chr15:42065253	A/C	cg17847044	chr15:42102381	MAPKBP1	-0.35	-5.12	-0.3	5.91e-7	Diastolic blood pressure;
CESC	cis	rs10504229	0.683	rs77548248	chr8:58117542	G/A	cg02725872	chr8:58115012	NA	-0.45	-7.05	-0.4	1.51e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs208520	0.754	rs12204635	chr6:66740779	C/A	cg07460842	chr6:66804631	NA	0.97	12.84	0.62	1.11e-29	Exhaled nitric oxide output;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg05847233	chr18:12374049	AFG3L2	0.44	6.46	0.37	4.98e-10	Cleft plate (environmental tobacco smoke interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18704218	chr5:33162408	NA	-0.57	-6.58	-0.37	2.44e-10	Gut microbiome composition (summer);
CESC	cis	rs1595825	0.891	rs16866940	chr2:198509058	C/T	cg10820045	chr2:198174542	NA	0.41	5.14	0.3	5.33e-7	Ulcerative colitis;
CESC	cis	rs72945132	1.000	rs7938912	chr11:70114885	C/T	cg14191688	chr11:70257035	CTTN	0.41	5.04	0.3	8.65e-7	Coronary artery disease;
CESC	cis	rs854765	0.663	rs1052299	chr17:17750419	A/G	cg09796270	chr17:17721594	SREBF1	-0.45	-6.47	-0.37	4.64e-10	Total body bone mineral density;
CESC	cis	rs854765	0.929	rs854766	chr17:18012775	A/G	cg16928487	chr17:17741425	SREBF1	-0.56	-9.13	-0.49	1.75e-17	Total body bone mineral density;
CESC	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg16132339	chr22:24313637	DDTL;DDT	0.4	6.14	0.35	3.07e-9	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs7659604	0.791	rs57316471	chr4:122663939	A/G	cg19748678	chr4:122722346	EXOSC9	0.54	6.2	0.36	2.17e-9	Type 2 diabetes;
CESC	cis	rs4665809	0.590	rs6716858	chr2:26423414	G/A	cg04944784	chr2:26401820	FAM59B	-0.81	-9.84	-0.52	1.1e-19	Gut microbiome composition (summer);
CESC	cis	rs1862618	0.620	rs189695	chr5:56225769	T/C	cg18230493	chr5:56204884	C5orf35	-0.62	-8.3	-0.45	5.39e-15	Initial pursuit acceleration;
CESC	cis	rs10504229	1.000	rs56350499	chr8:58178139	C/T	cg05313129	chr8:58192883	C8orf71	-0.55	-6.37	-0.36	8.42e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs7811142	0.830	rs10085549	chr7:99983135	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.92	10.05	0.53	2.44e-20	Platelet count;
CESC	cis	rs684232	0.623	rs12601935	chr17:519325	G/A	cg15660573	chr17:549704	VPS53	-0.81	-11.88	-0.59	2.24e-26	Prostate cancer;
CESC	cis	rs11650494	0.710	rs11654557	chr17:47390136	A/G	cg08112188	chr17:47440006	ZNF652	1.31	8.51	0.46	1.31e-15	Prostate cancer;
CESC	cis	rs11122272	0.667	rs2244992	chr1:231537220	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.55	-7.44	-0.42	1.38e-12	Hemoglobin concentration;
CESC	cis	rs116095464	0.614	rs28736753	chr5:274081	G/A	cg22857025	chr5:266934	NA	-1.29	-17.75	-0.74	5.57e-47	Breast cancer;
CESC	cis	rs7937682	1.000	rs12363179	chr11:111568091	G/A	cg09085632	chr11:111637200	PPP2R1B	1.03	14.07	0.65	5.86e-34	Primary sclerosing cholangitis;
CESC	cis	rs1707322	0.721	rs61784796	chr1:46163256	A/G	cg03146154	chr1:46216737	IPP	0.82	11.54	0.58	3.18e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs738322	0.870	rs5750558	chr22:38582497	G/A	cg17652424	chr22:38574118	PLA2G6	0.31	5.55	0.32	6.75e-8	Cutaneous nevi;
CESC	cis	rs1005277	0.579	rs2505237	chr10:38438898	T/G	cg25427524	chr10:38739819	LOC399744	-0.67	-9.8	-0.52	1.46e-19	Extrinsic epigenetic age acceleration;
CESC	cis	rs7552404	1.000	rs12091720	chr1:76186949	G/A	cg10523679	chr1:76189770	ACADM	0.71	8.23	0.45	8.39e-15	Blood metabolite levels;Acylcarnitine levels;
CESC	trans	rs7246657	0.943	rs9676967	chr19:37928089	G/C	cg24637308	chr11:6592297	DNHD1	0.54	6.34	0.36	1.01e-9	Coronary artery calcification;
CESC	cis	rs7618915	0.571	rs12487445	chr3:52618319	A/C	cg18404041	chr3:52824283	ITIH1	-0.41	-6.83	-0.39	5.93e-11	Bipolar disorder;
CESC	cis	rs1048238	0.506	rs848194	chr1:16285342	G/A	cg21385522	chr1:16154831	NA	-0.45	-5.59	-0.32	5.76e-8	Systolic blood pressure;
CESC	cis	rs7107174	0.748	rs7105835	chr11:78075725	T/C	cg02023728	chr11:77925099	USP35	0.39	5.57	0.32	6.35e-8	Testicular germ cell tumor;
CESC	cis	rs1559088	0.847	rs6510348	chr19:33601946	G/A	cg27124370	chr19:33622961	WDR88	0.45	5.86	0.34	1.34e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs2836950	0.565	rs7279497	chr21:40531306	A/G	cg17971929	chr21:40555470	PSMG1	0.52	6.79	0.38	7.35e-11	Menarche (age at onset);
CESC	cis	rs9611565	0.802	rs73176692	chr22:41785735	G/A	cg06481639	chr22:41940642	POLR3H	-0.63	-6.6	-0.38	2.22e-10	Vitiligo;
CESC	cis	rs7937682	0.883	rs486038	chr11:111465963	A/C	cg09085632	chr11:111637200	PPP2R1B	-0.9	-12.87	-0.62	9.33e-30	Primary sclerosing cholangitis;
CESC	cis	rs7666738	0.576	rs7660951	chr4:98651581	T/A	cg05340658	chr4:99064831	C4orf37	0.6	7.36	0.41	2.35e-12	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4803468	1.000	rs10413735	chr19:41921071	C/T	cg14132834	chr19:41945861	ATP5SL	-0.68	-8.41	-0.46	2.55e-15	Height;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg13094511	chr2:99061177	INPP4A	-0.47	-6.21	-0.36	2.09e-9	Ulcerative colitis;
CESC	cis	rs3749237	0.595	rs4855877	chr3:49448527	T/C	cg03060546	chr3:49711283	APEH	0.73	10.94	0.56	3.04e-23	Resting heart rate;
CESC	cis	rs28386778	0.669	rs12603821	chr17:62006432	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.55	-6.96	-0.39	2.68e-11	Prudent dietary pattern;
CESC	cis	rs4713118	0.515	rs9368549	chr6:28050047	T/A	cg22143856	chr6:28129313	ZNF389	0.49	6.3	0.36	1.2e-9	Parkinson's disease;
CESC	cis	rs1443512	0.755	rs1373160	chr12:54340383	A/G	cg12374095	chr12:54320830	NA	-0.46	-6.08	-0.35	4.2e-9	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
CESC	cis	rs929354	0.772	rs933344	chr7:157011265	A/T	cg05182265	chr7:156933206	UBE3C	-0.5	-7.39	-0.41	1.88e-12	Body mass index;
CESC	cis	rs477692	1.000	rs7475154	chr10:131440584	C/T	cg05714579	chr10:131428358	MGMT	-0.51	-6.82	-0.39	6.11e-11	Response to temozolomide;
CESC	cis	rs858239	0.600	rs2014768	chr7:23122440	C/A	cg23682824	chr7:23144976	KLHL7	0.55	7.63	0.42	4.21e-13	Cerebrospinal fluid biomarker levels;
CESC	cis	rs875971	0.545	rs11766183	chr7:65839160	G/C	cg18876405	chr7:65276391	NA	0.49	5.38	0.31	1.63e-7	Aortic root size;
CESC	cis	rs2635047	0.756	rs34939493	chr18:44795621	G/T	cg24371990	chr18:44770781	NA	0.42	6.59	0.38	2.37e-10	Educational attainment;
CESC	cis	rs10256972	0.528	rs7784607	chr7:1178694	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.63	-9.69	-0.51	3.3e-19	Longevity;Endometriosis;
CESC	cis	rs72781680	0.898	rs56413706	chr2:24086961	G/A	cg08917208	chr2:24149416	ATAD2B	1.11	10.18	0.53	9.57e-21	Lymphocyte counts;
CESC	cis	rs116095464	0.558	rs1971229	chr5:268187	A/G	cg12570787	chr5:219185	SDHA;CCDC127	0.53	5.49	0.32	9.44e-8	Breast cancer;
CESC	cis	rs2733201	1.000	rs2114420	chr15:44312583	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	-0.65	-5.93	-0.34	9.58e-9	Lipoprotein phospholipase A2 activity in cardiovascular disease;
CESC	trans	rs11098499	0.954	rs4309825	chr4:120314881	C/T	cg25214090	chr10:38739885	LOC399744	-0.61	-8.37	-0.46	3.42e-15	Corneal astigmatism;
CESC	cis	rs1538970	0.962	rs9429158	chr1:45821393	A/G	cg05343316	chr1:45956843	TESK2	0.8	11.16	0.57	5.81e-24	Platelet count;
CESC	cis	rs2836974	0.644	rs4818017	chr21:40690561	G/T	cg11890956	chr21:40555474	PSMG1	-0.91	-14.27	-0.66	1.14e-34	Cognitive function;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01626569	chr16:20911881	LYRM1;DCUN1D3	0.59	7.02	0.4	1.84e-11	Gut microbiome composition (summer);
CESC	cis	rs60871478	0.838	rs7789321	chr7:800977	A/G	cg05535760	chr7:792225	HEATR2	1.0	11.28	0.57	2.3e-24	Cerebrospinal P-tau181p levels;
CESC	cis	rs35306767	0.761	rs34480046	chr10:1027440	A/G	cg25019033	chr10:957182	NA	-0.65	-6.53	-0.37	3.33e-10	Eosinophil percentage of granulocytes;
CESC	trans	rs4950322	0.542	rs3766519	chr1:146686372	C/T	cg04954894	chr8:38089920	DDHD2	-0.62	-6.34	-0.36	9.73e-10	Protein quantitative trait loci;
CESC	cis	rs2243480	1.000	rs6974723	chr7:65637939	C/T	cg18252515	chr7:66147081	NA	1.36	13.62	0.64	2.25e-32	Diabetic kidney disease;
CESC	cis	rs12497850	0.864	rs4513485	chr3:49139966	G/A	cg03060546	chr3:49711283	APEH	0.55	6.78	0.38	7.91e-11	Parkinson's disease;
CESC	cis	rs7727544	0.684	rs274560	chr5:131719450	T/C	cg07395648	chr5:131743802	NA	0.44	5.93	0.34	9.45e-9	Blood metabolite levels;
CESC	cis	rs2836974	0.568	rs429955	chr21:40539760	G/A	cg11890956	chr21:40555474	PSMG1	0.97	16.58	0.71	7.37e-43	Cognitive function;
CESC	cis	rs7618501	0.633	rs2252833	chr3:50004209	C/T	cg24308560	chr3:49941425	MST1R	-0.65	-9.57	-0.51	7.85e-19	Intelligence (multi-trait analysis);
CESC	cis	rs2832191	0.791	rs2832181	chr21:30481371	G/T	cg24692254	chr21:30365293	RNF160	-0.81	-12.75	-0.62	2.33e-29	Dental caries;
CESC	cis	rs9322193	0.926	rs952166	chr6:150119910	A/T	cg13206674	chr6:150067644	NUP43	0.41	5.78	0.33	2.05e-8	Lung cancer;
CESC	cis	rs2836950	0.501	rs2836983	chr21:40689336	G/A	cg17971929	chr21:40555470	PSMG1	-0.6	-7.82	-0.43	1.24e-13	Menarche (age at onset);
CESC	cis	rs6831352	0.734	rs1154400	chr4:100010010	C/T	cg12011299	chr4:100065546	ADH4	0.58	6.97	0.39	2.49e-11	Alcohol dependence;
CESC	cis	rs2836974	0.831	rs34294410	chr21:40555160	C/G	cg11890956	chr21:40555474	PSMG1	1.2	23.14	0.82	1.44e-65	Cognitive function;
CESC	cis	rs72781680	1.000	rs72781648	chr2:24210333	T/C	cg20701182	chr2:24300061	SF3B14	0.63	5.58	0.32	6.04e-8	Lymphocyte counts;
CESC	cis	rs6502050	0.799	rs4132775	chr17:80155412	C/T	cg23985595	chr17:80112537	CCDC57	-0.4	-6.42	-0.37	6.32e-10	Life satisfaction;
CESC	cis	rs9583531	0.657	rs7337126	chr13:111376788	A/G	cg24331049	chr13:111365604	ING1	0.73	10.44	0.54	1.33e-21	Coronary artery disease;
CESC	cis	rs1799949	1.000	rs8176273	chr17:41211653	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.61	7.93	0.44	6.03e-14	Menopause (age at onset);
CESC	cis	rs300703	0.935	rs4241316	chr2:252197	A/G	cg21211680	chr2:198530	NA	-0.89	-7.74	-0.43	2.16e-13	Blood protein levels;
CESC	cis	rs11608355	0.545	rs12819658	chr12:109907670	A/T	cg05360138	chr12:110035743	NA	0.82	8.92	0.48	7.93e-17	Neuroticism;
CESC	cis	rs3825932	0.778	rs11072817	chr15:79236815	G/A	cg25744700	chr15:79237217	CTSH	0.51	6.87	0.39	4.7e-11	Type 1 diabetes;
CESC	cis	rs853679	0.517	rs9368553	chr6:28082265	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.58	-6.75	-0.38	9.45e-11	Depression;
CESC	cis	rs9910055	0.530	rs8072954	chr17:42294722	G/A	cg13607699	chr17:42295918	UBTF	0.82	12.63	0.61	5.85e-29	Total body bone mineral density;
CESC	cis	rs6495122	0.532	rs2472304	chr15:75044238	G/A	cg14664628	chr15:75095509	CSK	-0.61	-7.96	-0.44	5.11e-14	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
CESC	cis	rs9291683	0.507	rs6849273	chr4:10021595	C/T	cg11266682	chr4:10021025	SLC2A9	0.66	13.27	0.63	3.6e-31	Bone mineral density;
CESC	cis	rs7847628	0.587	rs4837796	chr9:123610288	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	-0.46	-8.18	-0.45	1.23e-14	Birth weight;
CESC	cis	rs1003719	0.715	rs2835646	chr21:38546574	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.59	-7.98	-0.44	4.49e-14	Eye color traits;
CESC	cis	rs2710642	0.721	rs58305080	chr2:62895132	C/T	cg17519650	chr2:63277830	OTX1	0.57	6.78	0.38	7.7e-11	LDL cholesterol levels;LDL cholesterol;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04153114	chr8:99129570	POP1;HRSP12	0.59	7.24	0.41	4.85e-12	Gut microbiome composition (summer);
CESC	cis	rs7267979	0.714	rs3787082	chr20:25235736	A/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.71	11.36	0.57	1.22e-24	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs59918340	0.764	rs10107024	chr8:142227592	T/C	cg16341495	chr8:142228727	SLC45A4	-0.44	-5.32	-0.31	2.22e-7	Immature fraction of reticulocytes;
CESC	cis	rs2832191	0.716	rs8132085	chr21:30501389	G/T	cg08807101	chr21:30365312	RNF160	-0.83	-11.51	-0.58	3.87e-25	Dental caries;
CESC	cis	rs7116495	0.609	rs73543612	chr11:71820350	C/T	cg10381502	chr11:71823885	C11orf51	1.05	6.51	0.37	3.78e-10	Severe influenza A (H1N1) infection;
CESC	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	10.29	0.53	4.17e-21	Prudent dietary pattern;
CESC	cis	rs7666738	0.791	rs34088022	chr4:99001508	G/T	cg05340658	chr4:99064831	C4orf37	0.8	12.44	0.61	2.83e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs873946	0.586	rs2001426	chr10:134563871	G/A	cg27297192	chr10:134578999	INPP5A	0.4	5.27	0.31	2.77e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs561341	0.769	rs559228	chr17:30294527	T/C	cg19193384	chr17:30244184	NA	-0.68	-6.43	-0.37	5.9e-10	Hip circumference adjusted for BMI;
CESC	cis	rs7666738	0.830	rs10007261	chr4:98926155	C/T	cg03467027	chr4:99064603	C4orf37	0.46	5.59	0.32	5.78e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2635047	0.682	rs1980055	chr18:44792636	G/A	cg24371990	chr18:44770781	NA	0.39	6.26	0.36	1.5e-9	Educational attainment;
CESC	cis	rs1707322	0.682	rs28508523	chr1:46189625	G/A	cg03146154	chr1:46216737	IPP	0.76	10.9	0.56	4.26e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg25332325	chr10:71906362	TYSND1	-0.44	-6.18	-0.35	2.36e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg11226328	chr1:29213367	EPB41	0.44	6.16	0.35	2.62e-9	Systemic lupus erythematosus;
CESC	cis	rs754466	0.580	rs11002301	chr10:79574078	G/A	cg17075019	chr10:79541650	NA	-0.87	-13.71	-0.64	1.06e-32	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs9611565	0.649	rs202625	chr22:41827082	G/A	cg06634786	chr22:41940651	POLR3H	0.71	7.08	0.4	1.28e-11	Vitiligo;
CESC	cis	rs35110281	0.633	rs4819292	chr21:45125223	A/G	cg21573476	chr21:45109991	RRP1B	-0.57	-8.43	-0.46	2.2e-15	Mean corpuscular volume;
CESC	cis	rs6460942	0.915	rs6966791	chr7:12439714	T/C	cg10578991	chr7:12443926	VWDE	-0.51	-5.67	-0.33	3.75e-8	Coronary artery disease;
CESC	cis	rs644799	1.000	rs473155	chr11:95596873	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.5	5.93	0.34	9.45e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs1215050	0.791	rs2865942	chr4:98737709	G/C	cg05340658	chr4:99064831	C4orf37	0.5	6.34	0.36	9.81e-10	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.97	9.35	0.5	3.75e-18	Platelet count;
CESC	cis	rs10463316	0.862	rs7720582	chr5:150776502	C/T	cg03212797	chr5:150827313	SLC36A1	0.44	5.8	0.34	1.84e-8	Metabolite levels (Pyroglutamine);
CESC	cis	rs9863	0.794	rs7978610	chr12:124468572	C/G	cg17562584	chr12:124393655	DNAH10	-0.31	-5.18	-0.3	4.39e-7	White blood cell count;
CESC	cis	rs427394	0.582	rs274662	chr5:6704860	G/A	cg10857441	chr5:6722123	POLS	-0.42	-5.07	-0.3	7.61e-7	Menopause (age at onset);
CESC	cis	rs7824557	0.614	rs2736277	chr8:11218893	C/T	cg21775007	chr8:11205619	TDH	-0.56	-9.24	-0.49	8.25e-18	Retinal vascular caliber;
CESC	cis	rs7945705	0.747	rs1980428	chr11:9010497	A/G	cg12365402	chr11:9010492	NRIP3	0.41	7.09	0.4	1.18e-11	Hemoglobin concentration;
CESC	cis	rs873946	0.564	rs12242672	chr10:134555609	A/T	cg26818010	chr10:134567672	INPP5A	-0.79	-9.67	-0.51	3.74e-19	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs2839186	0.770	rs2280956	chr21:47642323	C/G	cg13126279	chr21:47581558	C21orf56	0.49	6.68	0.38	1.36e-10	Testicular germ cell tumor;
CESC	cis	rs116095464	0.558	rs6881920	chr5:222411	T/C	cg22857025	chr5:266934	NA	-1.27	-18.89	-0.76	5.51e-51	Breast cancer;
CESC	cis	rs9291683	0.609	rs12500810	chr4:10031068	G/A	cg11266682	chr4:10021025	SLC2A9	0.7	14.13	0.66	3.49e-34	Bone mineral density;
CESC	cis	rs9467711	0.720	rs7749823	chr6:26158079	A/C	cg21479132	chr6:26055353	NA	0.65	6.51	0.37	3.68e-10	Autism spectrum disorder or schizophrenia;
CESC	cis	rs4523957	0.522	rs8081921	chr17:2021490	C/A	cg16513277	chr17:2031491	SMG6	-0.71	-10.1	-0.53	1.62e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg18765753	chr7:1198926	ZFAND2A	-0.44	-6.53	-0.37	3.41e-10	Longevity;Endometriosis;
CESC	cis	rs6502050	0.835	rs4789675	chr17:80123144	G/A	cg11859384	chr17:80120422	CCDC57	-0.39	-5.34	-0.31	1.98e-7	Life satisfaction;
CESC	cis	rs2836974	0.568	rs2142111	chr21:40549289	G/C	cg11644478	chr21:40555479	PSMG1	0.8	11.84	0.59	3.02e-26	Cognitive function;
CESC	cis	rs7666738	0.791	rs7665273	chr4:98997413	C/A	cg03467027	chr4:99064603	C4orf37	0.44	5.51	0.32	8.65e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4975709	0.589	rs1466607	chr5:1864856	A/G	cg15595755	chr5:1867978	NA	0.51	8.17	0.45	1.29e-14	Cardiovascular disease risk factors;
CESC	cis	rs9311474	0.508	rs3796353	chr3:52593230	C/T	cg18404041	chr3:52824283	ITIH1	-0.38	-6.45	-0.37	5.27e-10	Electroencephalogram traits;
CESC	cis	rs4555082	1.000	rs7146643	chr14:105757392	A/G	cg06808227	chr14:105710500	BRF1	-0.55	-7.06	-0.4	1.42e-11	Mean platelet volume;Platelet distribution width;
CESC	cis	rs863345	0.604	rs7533071	chr1:158504479	T/A	cg12129480	chr1:158549410	OR10X1	-0.34	-6.84	-0.39	5.41e-11	Pneumococcal bacteremia;
CESC	cis	rs9549367	0.789	rs3861720	chr13:113906097	A/G	cg00898013	chr13:113819073	PROZ	-0.53	-7.21	-0.41	5.74e-12	Platelet distribution width;
CESC	cis	rs72720396	0.789	rs12022460	chr1:91202257	A/G	cg13456504	chr1:91191583	NA	-0.48	-6.93	-0.39	3.23e-11	Morning vs. evening chronotype;Chronotype;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg10089324	chr1:51984752	EPS15	0.51	6.61	0.38	2.15e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs4820539	1.000	rs885964	chr22:23461003	G/C	cg14186256	chr22:23484241	RTDR1	0.83	15.02	0.68	2.7e-37	Bone mineral density;
CESC	cis	rs8072100	0.967	rs4289035	chr17:45707211	C/T	cg08085267	chr17:45401833	C17orf57	-0.39	-5.03	-0.3	8.86e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs1030877	0.889	rs2576746	chr2:105909559	G/A	cg02079111	chr2:105885981	TGFBRAP1	0.64	10.21	0.53	7.17e-21	Obesity-related traits;
CESC	cis	rs8062405	0.688	rs3924376	chr16:28925978	T/C	cg08761264	chr16:28874980	SH2B1	0.43	5.09	0.3	6.95e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs1538970	0.924	rs11211117	chr1:45930246	C/T	cg24296786	chr1:45957014	TESK2	-0.46	-5.17	-0.3	4.58e-7	Platelet count;
CESC	cis	rs6060717	0.536	rs6060683	chr20:34507921	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.77	-6.96	-0.39	2.63e-11	Hip circumference adjusted for BMI;
CESC	cis	rs3750965	0.959	rs2253658	chr11:68856804	C/G	cg01403660	chr11:68851641	TPCN2	0.4	5.21	0.3	3.74e-7	Hair color;
CESC	cis	rs644799	1.000	rs505220	chr11:95563228	T/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.55	6.76	0.38	8.51e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs9300255	0.602	rs1616181	chr12:123619856	T/A	cg05973401	chr12:123451056	ABCB9	0.53	5.92	0.34	9.71e-9	Neutrophil percentage of white cells;
CESC	cis	rs7085104	0.632	rs6162	chr10:104596981	G/A	cg04362960	chr10:104952993	NT5C2	0.51	6.76	0.38	8.62e-11	Immature fraction of reticulocytes;Schizophrenia;
CESC	cis	rs7223966	1.000	rs11658740	chr17:61751069	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.45	-5.2	-0.3	3.92e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg05112967	chr7:63353492	NA	0.43	6.03	0.35	5.54e-9	Fibrinogen levels;
CESC	cis	rs12142240	0.660	rs6679080	chr1:46819779	A/T	cg10495392	chr1:46806563	NSUN4	0.57	6.27	0.36	1.47e-9	Menopause (age at onset);
CESC	cis	rs1642645	0.793	rs6695748	chr1:42481707	G/T	cg16685388	chr1:42384056	HIVEP3	0.38	5.68	0.33	3.47e-8	Left ventricular obstructive tract defect (maternal effect);
CESC	cis	rs1008375	1.000	rs6854733	chr4:17640526	C/T	cg02297831	chr4:17616191	MED28	0.53	6.71	0.38	1.2e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs2034088	0.965	rs11651340	chr17:425099	A/C	cg13332499	chr17:408570	NA	-0.42	-6.6	-0.38	2.17e-10	Hip circumference adjusted for BMI;
CESC	cis	rs1057239	0.739	rs1014554	chr1:175133626	A/G	cg00321850	chr1:175162397	KIAA0040	0.44	6.32	0.36	1.11e-9	Diastolic blood pressure;
CESC	cis	rs4665809	0.590	rs9309474	chr2:26448830	T/A	cg26119090	chr2:26468346	HADHA;HADHB	-1.1	-12.68	-0.61	4e-29	Gut microbiome composition (summer);
CESC	cis	rs6693567	0.565	rs696615	chr1:150338988	A/C	cg09579323	chr1:150459698	TARS2	0.48	6.09	0.35	4.04e-9	Migraine;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23329303	chr11:46638664	KIAA0652;HARBI1	0.73	7.94	0.44	5.66e-14	Gut microbiome composition (summer);
CESC	cis	rs9910055	0.659	rs2251165	chr17:42234748	T/C	cg08499158	chr17:42289980	UBTF	-0.5	-6.3	-0.36	1.21e-9	Total body bone mineral density;
CESC	cis	rs2576037	0.583	rs4890343	chr18:44540969	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.35	5.53	0.32	7.62e-8	Personality dimensions;
CESC	cis	rs3091242	0.967	rs3091240	chr1:25676935	G/T	cg03538708	chr1:25844672	NA	-0.36	-5.29	-0.31	2.62e-7	Erythrocyte sedimentation rate;
CESC	trans	rs4578769	0.569	rs12955131	chr18:20480387	A/G	cg03552156	chr3:187463844	BCL6	-0.44	-6.12	-0.35	3.28e-9	Eosinophil percentage of white cells;
CESC	cis	rs9611565	0.512	rs715498	chr22:42148467	G/A	cg06634786	chr22:41940651	POLR3H	0.7	7.01	0.4	1.99e-11	Vitiligo;
CESC	cis	rs798554	0.634	rs6978692	chr7:2857411	C/T	cg04166393	chr7:2884313	GNA12	0.39	5.22	0.31	3.68e-7	Height;
CESC	cis	rs12134245	0.776	rs12122066	chr1:92005140	C/T	cg25838465	chr1:92012736	NA	-0.6	-8.69	-0.47	3.96e-16	Breast cancer;
CESC	cis	rs6062302	0.522	rs4809312	chr20:62234240	C/T	cg06363034	chr20:62225388	GMEB2	-0.51	-6.58	-0.37	2.52e-10	Glioblastoma;
CESC	cis	rs27434	0.605	rs2351012	chr5:96191747	A/G	cg16492584	chr5:96139282	ERAP1	-0.54	-6.5	-0.37	3.86e-10	Ankylosing spondylitis;
CESC	cis	rs7692995	1.000	rs7668933	chr4:17988141	A/G	cg08925142	chr4:18023851	LCORL	-0.44	-5.1	-0.3	6.61e-7	Height;
CESC	cis	rs6432018	0.927	rs6734469	chr2:9735900	G/A	cg23886495	chr2:9695866	ADAM17	0.43	5.08	0.3	7.21e-7	Heart rate variability traits;
CESC	cis	rs763121	0.819	rs5757237	chr22:39073835	G/C	cg14440974	chr22:39074834	NA	-0.42	-5.83	-0.34	1.62e-8	Menopause (age at onset);
CESC	cis	rs7224737	1.000	rs8074708	chr17:40286354	A/G	cg02450064	chr17:40260053	DHX58	0.35	5.13	0.3	5.68e-7	Fibrinogen levels;
CESC	cis	rs7618501	0.602	rs9311446	chr3:50092226	G/A	cg24308560	chr3:49941425	MST1R	0.62	9.16	0.49	1.45e-17	Intelligence (multi-trait analysis);
CESC	cis	rs10870270	0.956	rs7904594	chr10:133734671	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.86	-12.69	-0.61	3.83e-29	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs9910055	0.529	rs228746	chr17:42173752	T/C	cg19774624	chr17:42201019	HDAC5	0.6	7.88	0.44	8.58e-14	Total body bone mineral density;
CESC	trans	rs747782	0.528	rs11039669	chr11:48328818	C/T	cg15704280	chr7:45808275	SEPT13	0.68	6.31	0.36	1.19e-9	Intraocular pressure;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg25327233	chr10:99894913	C10orf28	-0.44	-6.35	-0.36	9.38e-10	Ulcerative colitis;
CESC	cis	rs9467773	0.620	rs2504567	chr6:26662920	C/G	cg24633756	chr6:26577808	NA	0.37	5.5	0.32	8.86e-8	Intelligence (multi-trait analysis);
CESC	cis	rs3820068	0.608	rs12091326	chr1:16048005	A/G	cg17385448	chr1:15911702	AGMAT	0.37	5.75	0.33	2.52e-8	Systolic blood pressure;
CESC	cis	rs15676	0.679	rs6478853	chr9:131588813	C/G	cg00228799	chr9:131580591	ENDOG	-0.55	-7.04	-0.4	1.67e-11	Blood metabolite levels;
CESC	cis	rs9487051	0.676	rs7753697	chr6:109593292	A/G	cg21918786	chr6:109611834	NA	-0.37	-5.41	-0.32	1.39e-7	Reticulocyte fraction of red cells;
CESC	cis	rs1559088	0.847	rs3786933	chr19:33602881	C/T	cg17764715	chr19:33622953	WDR88	0.48	6.2	0.36	2.2e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs3106136	0.609	rs28696050	chr4:95136630	G/C	cg11021082	chr4:95130006	SMARCAD1	-0.47	-6.49	-0.37	4.28e-10	Capecitabine sensitivity;
CESC	cis	rs10129255	0.518	rs8009612	chr14:107185749	G/T	cg07958169	chr14:107095056	NA	-0.55	-8.74	-0.47	2.74e-16	Kawasaki disease;
CESC	cis	rs3741151	0.773	rs73542960	chr11:73115946	T/C	cg17517138	chr11:73019481	ARHGEF17	0.98	7.16	0.4	8.01e-12	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs10504229	0.595	rs116490935	chr8:58117531	A/G	cg22535103	chr8:58192502	C8orf71	-0.8	-9.03	-0.49	3.55e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs5769765	0.862	rs9616381	chr22:50312382	G/A	cg26441486	chr22:50317300	CRELD2	0.42	5.24	0.31	3.33e-7	Schizophrenia;
CESC	cis	rs4132509	0.553	rs12140414	chr1:243674387	A/G	cg21452805	chr1:244014465	NA	0.49	5.71	0.33	2.99e-8	RR interval (heart rate);
CESC	cis	rs7618915	0.571	rs33964154	chr3:52596914	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.47	6.72	0.38	1.09e-10	Bipolar disorder;
CESC	cis	rs992157	0.798	rs10932772	chr2:219177148	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.7	9.5	0.5	1.34e-18	Colorectal cancer;
CESC	cis	rs6952808	0.692	rs60755037	chr7:2030104	G/A	cg23048001	chr7:2026167	MAD1L1	0.47	6.11	0.35	3.5e-9	Bipolar disorder and schizophrenia;
CESC	trans	rs4234798	0.546	rs4689667	chr4:7249188	A/T	cg05306006	chr2:210867127	RPE	0.5	6.18	0.35	2.44e-9	Insulin-like growth factors;
CESC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg20069020	chr7:108166782	PNPLA8	0.47	6.42	0.37	6.44e-10	Intelligence (multi-trait analysis);
CESC	cis	rs1799949	1.000	rs2070834	chr17:41242285	T/G	cg06001716	chr17:41278141	BRCA1;NBR2	0.38	5.34	0.31	2.03e-7	Menopause (age at onset);
CESC	cis	rs9322193	0.923	rs2342857	chr6:150130673	G/A	cg04369109	chr6:150039330	LATS1	-0.41	-5.54	-0.32	7.16e-8	Lung cancer;
CESC	cis	rs2806561	0.780	rs12409321	chr1:23398065	C/T	cg12483005	chr1:23474871	LUZP1	-0.34	-5.3	-0.31	2.42e-7	Height;
CESC	cis	rs11098499	0.821	rs28665282	chr4:120384186	C/T	cg09307838	chr4:120376055	NA	0.95	13.79	0.65	5.71e-33	Corneal astigmatism;
CESC	cis	rs7191439	0.858	rs8050715	chr16:88780923	C/G	cg27087555	chr16:88793112	FAM38A	-1.13	-9.84	-0.52	1.13e-19	Plateletcrit;
CESC	cis	rs17376456	0.877	rs7701011	chr5:93311456	G/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.61	5.33	0.31	2.15e-7	Diabetic retinopathy;
CESC	cis	rs7666738	0.830	rs28485415	chr4:99060340	G/A	cg03467027	chr4:99064603	C4orf37	0.48	5.98	0.35	7.05e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs96067	0.772	rs2231318	chr1:36602943	C/T	cg24686825	chr1:36642396	MAP7D1	-0.45	-5.12	-0.3	5.86e-7	Corneal structure;
CESC	cis	rs1538970	0.962	rs2153608	chr1:45813941	C/T	cg05343316	chr1:45956843	TESK2	-0.77	-10.58	-0.55	4.6e-22	Platelet count;
CESC	trans	rs864643	0.773	rs11129837	chr3:39589963	A/G	cg03273382	chr1:205782342	SLC41A1	0.47	6.03	0.35	5.38e-9	Attention deficit hyperactivity disorder;
CESC	trans	rs7980799	0.682	rs61927702	chr12:33631695	A/G	cg26384229	chr12:38710491	ALG10B	-0.56	-7.98	-0.44	4.41e-14	Heart rate;Heart rate variability traits (RMSSD);
CESC	cis	rs4589502	0.925	rs4259997	chr15:67153310	A/G	cg12317470	chr15:67143691	NA	-0.8	-9.93	-0.52	5.86e-20	Lung cancer (smoking interaction);
CESC	cis	rs28374715	0.681	rs28712264	chr15:41588797	T/C	cg18705301	chr15:41695430	NDUFAF1	-1.0	-14.55	-0.67	1.2e-35	Ulcerative colitis;
CESC	cis	rs6831352	0.819	rs896992	chr4:100002372	C/T	cg12011299	chr4:100065546	ADH4	0.64	8.17	0.45	1.29e-14	Alcohol dependence;
CESC	cis	rs4728302	0.869	rs889825	chr7:133596227	A/G	cg10665199	chr7:133106180	EXOC4	0.4	5.57	0.32	6.32e-8	Intelligence;Intelligence (multi-trait analysis);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg22767166	chr8:49833685	SNAI2	0.37	7.24	0.41	4.74e-12	Gambling;
CESC	cis	rs9486715	0.867	rs12207471	chr6:96963782	A/G	cg06623918	chr6:96969491	KIAA0776	0.93	14.38	0.66	4.81e-35	Headache;
CESC	cis	rs9322193	0.962	rs9767122	chr6:150104689	T/G	cg13206674	chr6:150067644	NUP43	0.42	5.89	0.34	1.19e-8	Lung cancer;
CESC	trans	rs9850225	0.764	rs6780379	chr3:80560525	A/G	cg20909656	chr7:14029360	ETV1	-0.42	-6.13	-0.35	3.23e-9	Erectile dysfunction in type 1 diabetes;
CESC	cis	rs10411262	0.935	rs314661	chr19:47172473	C/T	cg13467550	chr19:47212573	PRKD2	0.32	5.29	0.31	2.59e-7	Tonsillectomy;
CESC	cis	rs6831256	0.505	rs11947277	chr4:3473751	C/T	cg04102620	chr4:3473595	DOK7	0.36	5.22	0.31	3.69e-7	LDL cholesterol;Triglyceride levels;Triglycerides;Cholesterol, total;
CESC	cis	rs7296418	0.630	rs7974099	chr12:123771475	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.34	-5.31	-0.31	2.36e-7	Platelet count;
CESC	cis	rs1008375	0.902	rs6844984	chr4:17651304	C/G	cg02297831	chr4:17616191	MED28	0.6	7.51	0.42	9.14e-13	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs9457247	1.000	rs400063	chr6:167386592	C/T	cg25258033	chr6:167368657	RNASET2	0.4	6.06	0.35	4.59e-9	Crohn's disease;
CESC	cis	rs6952809	0.590	rs1468337	chr7:2432211	C/T	cg25507518	chr7:2405875	EIF3B	0.48	5.08	0.3	7.23e-7	Multiple sclerosis;
CESC	cis	rs1799949	0.965	rs33988650	chr17:41287880	A/G	cg23758822	chr17:41437982	NA	1.02	15.64	0.69	1.65e-39	Menopause (age at onset);
CESC	cis	rs9611565	0.512	rs5751153	chr22:42156561	T/C	cg06481639	chr22:41940642	POLR3H	0.6	5.95	0.34	8.27e-9	Vitiligo;
CESC	cis	rs7216064	1.000	rs7208663	chr17:65885171	T/C	cg12091567	chr17:66097778	LOC651250	-0.8	-9.08	-0.49	2.65e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs9649213	0.593	rs6465683	chr7:98026092	C/A	cg24562669	chr7:97807699	LMTK2	0.51	7.54	0.42	7.55e-13	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.64	7.45	0.42	1.33e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs4563143	0.514	rs73029076	chr19:29292032	G/T	cg14983838	chr19:29218262	NA	0.49	5.47	0.32	1.02e-7	Methadone dose in opioid dependence;
CESC	cis	rs9929218	0.954	rs12924033	chr16:68822599	G/A	cg02972257	chr16:68554789	NA	0.44	5.18	0.3	4.35e-7	Colorectal cancer;
CESC	cis	rs4665809	0.887	rs28699126	chr2:26357294	C/T	cg08470875	chr2:26401718	FAM59B	-0.47	-5.22	-0.31	3.59e-7	Gut microbiome composition (summer);
CESC	cis	rs748404	0.631	rs6493083	chr15:43637985	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.53	7.93	0.44	6.29e-14	Lung cancer;
CESC	cis	rs2303745	0.544	rs6512181	chr19:17399213	T/G	cg10664184	chr19:17420304	DDA1	0.44	5.18	0.3	4.35e-7	Systemic lupus erythematosus;
CESC	cis	rs62064224	0.675	rs12150479	chr17:30636200	T/A	cg18200150	chr17:30822561	MYO1D	0.38	5.14	0.3	5.46e-7	Schizophrenia;
CESC	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg05863683	chr7:1912471	MAD1L1	0.42	6.24	0.36	1.69e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs1691799	0.899	rs1168307	chr12:66739539	A/G	cg16791601	chr12:66731901	HELB	-0.8	-14.41	-0.66	3.8e-35	White blood cell count (basophil);
CESC	cis	rs35306767	0.903	rs12240651	chr10:943656	A/G	cg26597838	chr10:835615	NA	0.92	10.01	0.52	3.13e-20	Eosinophil percentage of granulocytes;
CESC	cis	rs265548	0.646	rs36692	chr19:17906839	C/T	cg16744531	chr19:17905626	B3GNT3	0.58	8.23	0.45	8.43e-15	Tumor biomarkers;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg10727759	chr12:50017361	PRPF40B	-0.43	-6.24	-0.36	1.69e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs853679	0.546	rs35744819	chr6:28318331	G/T	cg01620082	chr3:125678407	NA	-0.81	-6.37	-0.36	8.26e-10	Depression;
CESC	trans	rs997295	0.570	rs737226	chr15:67840773	T/C	cg05081167	chr6:156967138	NA	0.27	6.09	0.35	3.87e-9	Motion sickness;
CESC	cis	rs11718455	0.960	rs3843373	chr3:44011053	C/T	cg08738300	chr3:44038990	NA	-0.45	-5.64	-0.33	4.43e-8	Coronary artery disease;
CESC	cis	rs11098499	0.954	rs67265404	chr4:120359270	C/T	cg24375607	chr4:120327624	NA	0.48	5.81	0.34	1.74e-8	Corneal astigmatism;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg23490074	chr19:30433024	C19orf2	0.44	6.02	0.35	5.92e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs2276314	0.857	rs62101379	chr18:33584902	G/A	cg05985134	chr18:33552581	C18orf21	0.61	7.05	0.4	1.55e-11	Endometriosis;Drug-induced torsades de pointes;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg23852354	chr12:47630075	FAM113B	0.45	6.52	0.37	3.56e-10	Thyroid stimulating hormone;
CESC	cis	rs9847710	0.524	rs11712910	chr3:53094194	C/A	cg13284614	chr3:52569169	NT5DC2;LOC440957	-0.34	-5.3	-0.31	2.47e-7	Ulcerative colitis;
CESC	cis	rs9399135	0.933	rs9389262	chr6:135376409	G/T	cg22676075	chr6:135203613	NA	0.52	7.31	0.41	3.2e-12	Red blood cell count;
CESC	cis	rs2963155	0.518	rs72801029	chr5:142625806	T/C	cg17617527	chr5:142782415	NR3C1	0.81	6.37	0.36	8.42e-10	Breast cancer;
CESC	cis	rs9309473	1.000	rs10184268	chr2:73627044	C/T	cg20560298	chr2:73613845	ALMS1	-0.47	-6.34	-0.36	9.83e-10	Metabolite levels;
CESC	cis	rs6493487	0.547	rs2414053	chr15:51129924	T/C	cg02338191	chr15:51200825	AP4E1	0.51	5.17	0.3	4.58e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs1878931	0.582	rs9937267	chr16:3421073	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	0.71	8.83	0.48	1.51e-16	Body mass index (adult);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg02250680	chr11:58346542	LPXN;ZFP91-CNTF;ZFP91	-0.42	-6.38	-0.36	7.81e-10	Gambling;
CESC	cis	rs6496667	0.779	rs16944518	chr15:91035084	A/C	cg13834112	chr15:90361639	NA	0.38	5.09	0.3	6.82e-7	Rheumatoid arthritis;
CESC	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg18402987	chr7:1209562	NA	0.76	7.79	0.43	1.5e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7666738	0.753	rs1527520	chr4:98929164	A/G	cg05340658	chr4:99064831	C4orf37	0.82	12.2	0.6	1.81e-27	Colonoscopy-negative controls vs population controls;
CESC	cis	rs12474201	0.832	rs11695058	chr2:46978349	A/G	cg06386533	chr2:46925753	SOCS5	0.78	10.51	0.54	8.14e-22	Height;
CESC	cis	rs938554	0.784	rs7439210	chr4:9971749	C/G	cg00071950	chr4:10020882	SLC2A9	-0.48	-5.76	-0.33	2.32e-8	Blood metabolite levels;
CESC	cis	rs61524473	1	rs61524473	chr15:45646283	T/C	cg21132104	chr15:45694354	SPATA5L1	0.84	11.4	0.57	9.5e-25	Metabolite levels (small molecules and protein measures);
CESC	trans	rs11039798	0.588	rs11039807	chr11:48549391	T/A	cg03929089	chr4:120376271	NA	0.6	6.03	0.35	5.36e-9	Axial length;
CESC	cis	rs4974559	0.947	rs10006381	chr4:1359309	C/T	cg02980000	chr4:1222292	CTBP1	0.66	5.97	0.34	7.7e-9	Systolic blood pressure;
CESC	cis	rs8103278	1.000	rs7252126	chr19:46302374	T/A	cg11657440	chr19:46296263	DMWD	-0.59	-7.25	-0.41	4.69e-12	Coronary artery disease;
CESC	cis	rs116095464	0.558	rs10057674	chr5:266813	C/T	cg22496380	chr5:211416	CCDC127	-0.74	-8.46	-0.46	1.86e-15	Breast cancer;
CESC	cis	rs2979489	0.533	rs62505279	chr8:30447069	C/T	cg26383811	chr8:30366931	RBPMS	-0.66	-7.76	-0.43	1.88e-13	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
CESC	cis	rs1008375	0.966	rs6832414	chr4:17696866	C/G	cg02297831	chr4:17616191	MED28	0.44	5.4	0.32	1.45e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs9814567	1.000	rs11928499	chr3:134232350	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.45	5.93	0.34	9.22e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs7208859	0.673	rs55904046	chr17:29215391	G/A	cg19761014	chr17:28927070	LRRC37B2	0.73	5.79	0.34	1.95e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs2836974	0.584	rs7276774	chr21:40628725	T/G	cg11644478	chr21:40555479	PSMG1	-0.85	-12.67	-0.61	4.53e-29	Cognitive function;
CESC	cis	rs11098499	0.863	rs6835635	chr4:120458867	A/G	cg09307838	chr4:120376055	NA	0.9	12.3	0.6	7.96e-28	Corneal astigmatism;
CESC	cis	rs875971	0.862	rs7803416	chr7:65954199	A/G	cg12463550	chr7:65579703	CRCP	0.55	6.86	0.39	4.77e-11	Aortic root size;
CESC	cis	rs10791097	0.967	rs10750450	chr11:130719061	G/T	cg12179176	chr11:130786555	SNX19	0.58	8.41	0.46	2.64e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs7828089	0.542	rs7332050	chr8:22265294	G/T	cg13512537	chr8:22265999	SLC39A14	-0.37	-5.1	-0.3	6.41e-7	Verbal declarative memory;
CESC	cis	rs5167	0.505	rs7257468	chr19:45453144	C/T	cg09555818	chr19:45449301	APOC2	0.41	6.55	0.37	3.05e-10	Blood protein levels;
CESC	cis	rs7666738	0.830	rs28802909	chr4:99039410	G/A	cg03676636	chr4:99064102	C4orf37	0.33	5.12	0.3	5.93e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1401999	1.000	rs3805108	chr3:183691650	T/C	cg01324343	chr3:183735012	ABCC5	0.62	13.06	0.63	2.04e-30	Anterior chamber depth;
CESC	cis	rs17376456	0.825	rs1470150	chr5:93138654	C/T	cg25358565	chr5:93447407	FAM172A	-0.88	-8.8	-0.48	1.77e-16	Diabetic retinopathy;
CESC	cis	rs763121	0.853	rs8138996	chr22:39047435	G/T	cg21395723	chr22:39101663	GTPBP1	0.43	5.33	0.31	2.09e-7	Menopause (age at onset);
CESC	cis	rs9487051	1.000	rs9386796	chr6:109618704	C/T	cg01475377	chr6:109611718	NA	-0.41	-6.26	-0.36	1.57e-9	Reticulocyte fraction of red cells;
CESC	cis	rs3812565	0.506	rs8413	chr9:139323311	T/C	cg14019695	chr9:139328340	INPP5E	0.37	5.47	0.32	1.04e-7	Granulocyte percentage of myeloid white cells;
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg09747232	chr8:103827049	NA	-0.48	-7.19	-0.4	6.6e-12	Vertical cup-disc ratio;
CESC	cis	rs4819052	0.766	rs4819035	chr21:46645715	A/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.48	5.6	0.33	5.32e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs7520050	0.933	rs6666743	chr1:46311275	C/T	cg03146154	chr1:46216737	IPP	-0.48	-6.36	-0.36	8.91e-10	Red blood cell count;Reticulocyte count;
CESC	cis	rs7107174	1.000	rs10793311	chr11:78104399	G/C	cg02023728	chr11:77925099	USP35	0.47	6.17	0.35	2.54e-9	Testicular germ cell tumor;
CESC	cis	rs7020830	0.898	rs6476617	chr9:37200103	G/A	cg14294708	chr9:37120828	ZCCHC7	1.21	23.37	0.82	2.5e-66	Schizophrenia;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg15688767	chr3:125093330	ZNF148	0.46	6.09	0.35	3.85e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs7666738	0.830	rs62321570	chr4:98984276	G/A	cg05340658	chr4:99064831	C4orf37	0.8	12.42	0.61	3.31e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9905704	0.918	rs444393	chr17:56709222	A/G	cg12560992	chr17:57184187	TRIM37	0.59	7.05	0.4	1.52e-11	Testicular germ cell tumor;
CESC	cis	rs3806843	0.518	rs2569188	chr5:140008419	G/A	cg26395211	chr5:140044315	WDR55	0.43	5.41	0.32	1.43e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs514406	0.661	rs562641	chr1:53374666	C/T	cg08736216	chr1:53307985	ZYG11A	-0.38	-6.48	-0.37	4.45e-10	Monocyte count;
CESC	trans	rs718857	0.524	rs10820587	chr9:106721207	A/G	cg12446722	chr1:226374380	ACBD3	-0.48	-6.01	-0.35	6.23e-9	Breast cancer;
CESC	cis	rs117623576	0.715	rs11008755	chr10:32360053	C/T	cg03047570	chr10:32398778	NA	0.55	5.84	0.34	1.55e-8	Anti-saccade response;
CESC	cis	rs6089829	0.851	rs4809460	chr20:61661355	T/C	cg16240275	chr20:61666158	NCRNA00029	0.5	8.95	0.48	6.42e-17	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs2243480	1.000	rs316330	chr7:65605372	C/A	cg18252515	chr7:66147081	NA	-1.41	-14.48	-0.66	2.11e-35	Diabetic kidney disease;
CESC	cis	rs1448094	0.512	rs12297441	chr12:86233980	C/T	cg00310523	chr12:86230176	RASSF9	0.35	5.35	0.31	1.94e-7	Major depressive disorder;
CESC	cis	rs7666738	0.800	rs2839836	chr4:98970512	A/G	cg17366294	chr4:99064904	C4orf37	0.59	8.43	0.46	2.22e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7666738	0.830	rs10014986	chr4:99000687	A/C	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.62e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg16145915	chr7:1198662	ZFAND2A	-0.43	-6.01	-0.35	6.23e-9	Longevity;Endometriosis;
CESC	cis	rs3785574	0.962	rs2727332	chr17:61878584	T/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.8	10.57	0.54	4.93e-22	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04791162	chr14:62331287	NA	-0.53	-6.15	-0.35	2.91e-9	Gut microbiome composition (summer);
CESC	cis	rs938554	0.577	rs4591605	chr4:10002719	T/C	cg00071950	chr4:10020882	SLC2A9	0.59	7.2	0.4	6.16e-12	Blood metabolite levels;
CESC	cis	rs875971	0.862	rs1875057	chr7:65731855	A/G	cg10691866	chr7:65817282	TPST1	0.33	5.52	0.32	8.07e-8	Aortic root size;
CESC	cis	rs10504229	0.683	rs2088217	chr8:58113124	C/T	cg02725872	chr8:58115012	NA	-0.45	-7.04	-0.4	1.66e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs2303745	0.544	rs6512180	chr19:17399153	C/T	cg10664184	chr19:17420304	DDA1	0.44	5.16	0.3	4.74e-7	Systemic lupus erythematosus;
CESC	cis	rs7618915	0.547	rs3755806	chr3:52643685	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.52	-6.82	-0.39	6.03e-11	Bipolar disorder;
CESC	cis	rs9303542	0.559	rs1042818	chr17:46620111	T/C	cg04904318	chr17:46607828	HOXB1	-0.57	-5.51	-0.32	8.4e-8	Ovarian cancer;Epithelial ovarian cancer;
CESC	cis	rs72772090	0.539	rs72773922	chr5:96116660	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.57	-5.05	-0.3	8.36e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs6964587	1.000	rs7789492	chr7:91668854	C/T	cg17063962	chr7:91808500	NA	0.56	7.79	0.43	1.54e-13	Breast cancer;
CESC	cis	rs698833	0.562	rs10182045	chr2:44704236	C/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.43	5.55	0.32	6.97e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs760805	0.965	rs4648883	chr1:25261203	T/C	cg22509179	chr1:25234806	RUNX3	-0.6	-8.6	-0.47	6.95e-16	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs1552244	0.938	rs66915020	chr3:10110174	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	12.09	0.6	4.37e-27	Alzheimer's disease;
CESC	cis	rs7799006	0.593	rs12531150	chr7:2289888	C/T	cg12745145	chr7:2261452	MAD1L1	-0.32	-5.16	-0.3	4.9e-7	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs6831352	0.918	rs34876213	chr4:100062216	G/A	cg13256891	chr4:100009986	ADH5	-0.76	-8.3	-0.45	5.34e-15	Alcohol dependence;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20300707	chr1:1162156	SDF4	-0.59	-6.99	-0.39	2.23e-11	Gut microbiome composition (summer);
CESC	trans	rs11098499	0.863	rs3822194	chr4:120471648	A/G	cg25214090	chr10:38739885	LOC399744	0.67	9.27	0.49	6.8e-18	Corneal astigmatism;
CESC	cis	rs3096299	0.967	rs2911255	chr16:89487137	C/T	cg08822215	chr16:89438651	ANKRD11	-0.36	-5.44	-0.32	1.21e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs17401966	0.894	rs12141201	chr1:10454714	G/A	cg15208524	chr1:10270712	KIF1B	0.41	5.22	0.31	3.59e-7	Hepatocellular carcinoma;
CESC	cis	rs6762	0.642	rs28692469	chr11:839675	T/C	cg23754390	chr11:835074	CD151	0.32	5.7	0.33	3.26e-8	Mean platelet volume;
CESC	cis	rs3785574	0.962	rs7215915	chr17:61828385	C/T	cg07677032	chr17:61819896	STRADA	0.42	5.3	0.31	2.48e-7	Height;
CESC	cis	rs801193	0.935	rs2286683	chr7:66129843	G/A	cg18876405	chr7:65276391	NA	-0.54	-7.06	-0.4	1.46e-11	Aortic root size;
CESC	cis	rs4664308	0.967	rs17831329	chr2:160915819	T/C	cg03641300	chr2:160917029	PLA2R1	-0.67	-10.11	-0.53	1.61e-20	Idiopathic membranous nephropathy;
CESC	cis	rs4654899	0.758	rs2320826	chr1:21392096	A/C	cg05370193	chr1:21551575	ECE1	0.35	5.33	0.31	2.05e-7	Superior frontal gyrus grey matter volume;
CESC	cis	rs9733	0.596	rs7418501	chr1:150711896	A/T	cg04414720	chr1:150670196	GOLPH3L	0.57	8.08	0.44	2.36e-14	Tonsillectomy;
CESC	cis	rs875971	0.862	rs10224872	chr7:65759773	T/A	cg18876405	chr7:65276391	NA	-0.49	-6.83	-0.39	5.72e-11	Aortic root size;
CESC	cis	rs4713118	0.662	rs9393881	chr6:28023751	C/G	cg18032046	chr6:28092343	ZSCAN16	-0.5	-5.72	-0.33	2.82e-8	Parkinson's disease;
CESC	trans	rs7824557	0.527	rs2736296	chr8:11234844	G/A	cg06636001	chr8:8085503	FLJ10661	-0.48	-6.06	-0.35	4.78e-9	Retinal vascular caliber;
CESC	cis	rs17407555	0.821	rs80278615	chr4:10143666	G/A	cg00071950	chr4:10020882	SLC2A9	-0.55	-5.19	-0.3	4.16e-7	Schizophrenia (age at onset);
CESC	cis	rs1568889	1.000	rs34337978	chr11:28136746	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.75	9.44	0.5	2.08e-18	Bipolar disorder;
CESC	cis	rs6964587	1.000	rs4644173	chr7:91759597	A/G	cg17063962	chr7:91808500	NA	0.56	7.79	0.43	1.55e-13	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02366844	chr16:31044544	STX4	0.54	6.32	0.36	1.09e-9	Gut microbiome composition (summer);
CESC	cis	rs514406	0.798	rs504816	chr1:53307957	T/G	cg06600287	chr1:53387719	ECHDC2	-0.3	-5.34	-0.31	1.98e-7	Monocyte count;
CESC	cis	rs2997447	0.802	rs75786059	chr1:26449327	A/G	cg24596570	chr1:26146463	FAM54B;LOC646471	0.58	5.07	0.3	7.52e-7	QRS complex (12-leadsum);
CESC	cis	rs4665809	0.627	rs13032756	chr2:26489730	A/T	cg26314531	chr2:26401878	FAM59B	0.86	9.22	0.49	9.81e-18	Gut microbiome composition (summer);
CESC	cis	rs4950322	0.570	rs72691093	chr1:146769662	C/T	cg22381352	chr1:146742008	CHD1L	-0.46	-5.05	-0.3	8.32e-7	Protein quantitative trait loci;
CESC	cis	rs7259376	0.777	rs7247735	chr19:22575488	C/T	cg02657401	chr19:22469223	NA	0.26	5.14	0.3	5.27e-7	Menopause (age at onset);
CESC	cis	rs4975709	0.569	rs4975743	chr5:1859941	G/T	cg17650747	chr5:1873721	NA	0.43	5.96	0.34	8.13e-9	Cardiovascular disease risk factors;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg01852063	chr16:1500567	CLCN7	0.41	6.08	0.35	4.28e-9	Fibrinogen levels;
CESC	cis	rs77106637	0.929	rs77464186	chr11:72460398	A/C	cg04827223	chr11:72435913	ARAP1	-0.57	-5.49	-0.32	9.48e-8	Type 2 diabetes;
CESC	cis	rs651907	0.557	rs3094295	chr3:101401995	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.44	5.54	0.32	7.38e-8	Colorectal cancer;
CESC	trans	rs11250098	0.541	rs6997839	chr8:10766028	T/C	cg15556689	chr8:8085844	FLJ10661	-0.55	-6.36	-0.36	8.91e-10	Morning vs. evening chronotype;
CESC	cis	rs2180341	1.000	rs2326567	chr6:127606160	G/A	cg27446573	chr6:127587934	RNF146	1.08	16.13	0.7	3.14e-41	Breast cancer;
CESC	cis	rs9399137	0.507	rs12664898	chr6:135288663	T/C	cg22676075	chr6:135203613	NA	0.54	7.07	0.4	1.38e-11	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	cis	rs17362650	0.960	rs13011033	chr2:9657312	G/C	cg12832956	chr2:9616023	IAH1	-0.52	-5.09	-0.3	6.69e-7	Alcohol dependence (age at onset);
CESC	cis	rs2617583	0.868	rs2617596	chr5:1446719	C/G	cg07151155	chr5:1473589	LPCAT1	-0.35	-5.32	-0.31	2.24e-7	Breast cancer;
CESC	cis	rs2635047	0.638	rs1434529	chr18:44730142	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.41	5.47	0.32	1.03e-7	Educational attainment;
CESC	cis	rs2477686	0.526	rs1998760	chr1:2397136	C/T	cg07700843	chr1:2391317	NA	-0.42	-7.01	-0.4	1.97e-11	Non-obstructive azoospermia;
CESC	cis	rs7542091	0.635	rs985431	chr1:210043948	A/T	cg25204440	chr1:209979598	IRF6	0.37	5.1	0.3	6.55e-7	Monobrow;
CESC	cis	rs34779708	0.766	rs7913451	chr10:35551525	T/C	cg04310649	chr10:35416472	CREM	-0.48	-5.38	-0.31	1.62e-7	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs9309711	0.961	rs11890651	chr2:3482796	T/G	cg10845886	chr2:3471009	TTC15	-0.88	-12.59	-0.61	8.31e-29	Neurofibrillary tangles;
CESC	cis	rs9287719	0.967	rs4668691	chr2:10740494	C/T	cg02196655	chr2:10830764	NOL10	-0.38	-5.83	-0.34	1.61e-8	Prostate cancer;
CESC	cis	rs9916302	0.706	rs4332770	chr17:37704712	T/C	cg20243544	chr17:37824526	PNMT	0.53	5.26	0.31	3.03e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs12188164	0.931	rs115554641	chr5:443236	C/G	cg15813090	chr5:442598	EXOC3;C5orf55	0.41	6.17	0.35	2.55e-9	Cystic fibrosis severity;
CESC	cis	rs55986470	0.670	rs10204157	chr2:239422669	C/G	cg18131467	chr2:239335373	ASB1	-0.53	-5.93	-0.34	9.51e-9	Chronotype;
CESC	cis	rs7772486	0.641	rs9390374	chr6:146368175	A/T	cg23711669	chr6:146136114	FBXO30	0.79	9.78	0.52	1.7e-19	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs72781680	0.752	rs72796114	chr2:23906133	C/G	cg08917208	chr2:24149416	ATAD2B	1.16	10.42	0.54	1.59e-21	Lymphocyte counts;
CESC	cis	rs863345	0.625	rs12075903	chr1:158458932	A/G	cg12129480	chr1:158549410	OR10X1	-0.36	-7.15	-0.4	8.67e-12	Pneumococcal bacteremia;
CESC	cis	rs3806843	0.705	rs35614340	chr5:140043618	C/G	cg26395211	chr5:140044315	WDR55	0.48	6.15	0.35	2.79e-9	Depressive symptoms (multi-trait analysis);
CESC	cis	rs9611565	0.659	rs9611603	chr22:41912750	A/G	cg03806693	chr22:41940476	POLR3H	-1.25	-16.88	-0.72	6.4e-44	Vitiligo;
CESC	cis	rs977987	0.806	rs4888420	chr16:75462998	G/C	cg03315344	chr16:75512273	CHST6	0.41	5.91	0.34	1.07e-8	Dupuytren's disease;
CESC	cis	rs651907	0.535	rs13094753	chr3:101525082	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.46	6.05	0.35	4.95e-9	Colorectal cancer;
CESC	cis	rs2180341	1.000	rs3798853	chr6:127636823	C/T	cg27446573	chr6:127587934	RNF146	-1.07	-15.06	-0.68	1.94e-37	Breast cancer;
CESC	cis	rs6812193	0.518	rs17236661	chr4:77196476	A/C	cg20311846	chr4:77356250	SHROOM3	0.3	5.2	0.3	3.91e-7	Parkinson's disease;
CESC	cis	rs9910055	0.659	rs7212573	chr17:42254281	A/G	cg19774624	chr17:42201019	HDAC5	-0.83	-12.64	-0.61	5.84e-29	Total body bone mineral density;
CESC	cis	rs7684253	0.565	rs6830774	chr4:57816306	T/C	cg21154227	chr4:57904332	IGFBP7	0.37	5.32	0.31	2.17e-7	Migraine;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg22610194	chr7:77045539	PION	-0.47	-6.13	-0.35	3.17e-9	Fibrinogen levels;
CESC	cis	rs2777491	1.000	rs7167729	chr15:41721042	G/A	cg02330683	chr15:41787940	ITPKA	0.48	7.08	0.4	1.26e-11	Ulcerative colitis;
CESC	cis	rs9303401	0.538	rs3785493	chr17:56472119	G/T	cg25039879	chr17:56429692	SUPT4H1	-0.64	-6.2	-0.36	2.17e-9	Cognitive test performance;
CESC	cis	rs11711311	1.000	rs2603793	chr3:113496418	A/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.68	9.33	0.5	4.28e-18	IgG glycosylation;
CESC	cis	rs8017423	0.904	rs11622257	chr14:90715014	C/T	cg14092571	chr14:90743983	NA	0.55	8.23	0.45	8.44e-15	Mortality in heart failure;
CESC	cis	rs742320	0.756	rs3765263	chr16:840378	A/G	cg07501729	chr16:846077	CHTF18	0.37	5.44	0.32	1.2e-7	Mean corpuscular volume;
CESC	cis	rs7635838	0.892	rs66974661	chr3:11482729	A/G	cg00170343	chr3:11313890	ATG7	0.42	5.69	0.33	3.44e-8	HDL cholesterol;
CESC	cis	rs5758659	0.652	rs133321	chr22:42405322	A/G	cg04733989	chr22:42467013	NAGA	0.44	5.85	0.34	1.41e-8	Cognitive function;
CESC	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	7.83	0.43	1.17e-13	Prudent dietary pattern;
CESC	cis	rs875971	0.862	rs778702	chr7:65864835	G/A	cg12463550	chr7:65579703	CRCP	0.49	6.21	0.36	2.07e-9	Aortic root size;
CESC	cis	rs7937682	0.889	rs516263	chr11:111484719	A/C	cg09085632	chr11:111637200	PPP2R1B	-0.95	-14.63	-0.67	6.08e-36	Primary sclerosing cholangitis;
CESC	cis	rs910316	0.503	rs4903273	chr14:75441795	G/A	cg15467112	chr14:75489610	MLH3	-0.34	-5.16	-0.3	4.85e-7	Height;
CESC	trans	rs7107217	1.000	rs1873872	chr11:129473993	A/T	cg21496518	chr3:15374154	SH3BP5	0.43	6.71	0.38	1.16e-10	Breast cancer;Type 2 diabetes;
CESC	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg11965913	chr1:205819406	PM20D1	0.89	16.15	0.7	2.65e-41	Menarche (age at onset);
CESC	cis	rs61996546	0.622	rs12907116	chr15:26857399	A/G	cg14859324	chr15:26874363	GABRB3	-0.37	-5.03	-0.3	8.93e-7	Response to methotrexate in juvenile idiopathic arthritis;
CESC	cis	rs4471028	0.905	rs12544032	chr8:75291115	A/G	cg17811994	chr8:74332829	STAU2	-0.3	-5.15	-0.3	5e-7	Waist circumference;
CESC	cis	rs7927771	0.524	rs10769299	chr11:47865160	G/T	cg20307385	chr11:47447363	PSMC3	0.63	8.82	0.48	1.53e-16	Subjective well-being;
CESC	cis	rs10899021	0.512	rs10219168	chr11:74374453	A/T	cg25880958	chr11:74394337	NA	0.47	6.03	0.35	5.51e-9	Response to metformin (IC50);
CESC	cis	rs62344088	0.590	rs60845955	chr5:185094	C/T	cg22857025	chr5:266934	NA	-1.06	-7.52	-0.42	8.62e-13	Asthma (childhood onset);
CESC	trans	rs11039798	0.920	rs11040013	chr11:48782862	G/A	cg15704280	chr7:45808275	SEPT13	0.7	6.33	0.36	1.04e-9	Axial length;
CESC	cis	rs12134245	0.742	rs17501381	chr1:92003919	A/G	cg02896835	chr1:92012615	NA	-0.52	-6.76	-0.38	8.69e-11	Breast cancer;
CESC	cis	rs7937682	0.602	rs503905	chr11:111390762	G/C	cg22437258	chr11:111473054	SIK2	0.49	6.1	0.35	3.72e-9	Primary sclerosing cholangitis;
CESC	cis	rs11785693	0.862	rs62491200	chr8:4998001	A/C	cg26367366	chr8:4980734	NA	0.83	7.91	0.44	6.86e-14	Neuroticism (multi-trait analysis);Neuroticism;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06514377	chr2:3320918	TSSC1	-0.58	-6.15	-0.35	2.88e-9	Gut microbiome composition (summer);
CESC	cis	rs13102973	0.931	rs12643821	chr4:135859614	A/G	cg14419869	chr4:135874104	NA	-0.39	-6.11	-0.35	3.49e-9	Subjective well-being;
CESC	cis	rs17125944	0.505	rs75838476	chr14:53242362	G/A	cg13660082	chr14:53194042	PSMC6	-0.68	-5.9	-0.34	1.13e-8	Alzheimer's disease (late onset);
CESC	cis	rs9660180	0.967	rs6664664	chr1:1751264	G/A	cg17747265	chr1:1875780	NA	-0.57	-9.24	-0.49	8.4e-18	Body mass index;
CESC	cis	rs9443645	0.901	rs1572585	chr6:79690576	C/T	cg05283184	chr6:79620031	NA	-0.41	-6.41	-0.37	6.52e-10	Intelligence (multi-trait analysis);
CESC	cis	rs2197308	0.565	rs12809769	chr12:37909968	C/T	cg13010199	chr12:38710504	ALG10B	0.53	6.76	0.38	8.79e-11	Morning vs. evening chronotype;
CESC	cis	rs433852	0.904	rs8102492	chr19:49140809	A/C	cg06530960	chr19:49140787	SEC1;DBP	0.55	6.86	0.39	4.72e-11	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;
CESC	cis	rs4835473	0.897	rs11100812	chr4:144711553	T/C	cg25736465	chr4:144833511	NA	0.33	5.41	0.32	1.41e-7	Immature fraction of reticulocytes;
CESC	cis	rs1355223	0.872	rs913204	chr11:34706224	C/G	cg11058730	chr11:34937778	PDHX;APIP	0.51	6.66	0.38	1.62e-10	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs7589342	0.894	rs7557976	chr2:106435061	C/A	cg16077055	chr2:106428750	NCK2	0.53	7.56	0.42	6.6e-13	Addiction;
CESC	cis	rs1670533	0.585	rs6827206	chr4:1065071	A/T	cg04106633	chr4:1044584	NA	0.41	5.24	0.31	3.23e-7	Recombination rate (females);
CESC	cis	rs7520050	0.966	rs11810993	chr1:46478793	A/G	cg03146154	chr1:46216737	IPP	-0.46	-5.88	-0.34	1.26e-8	Red blood cell count;Reticulocyte count;
CESC	cis	rs4867766	0.585	rs10043212	chr5:173949740	C/T	cg20434911	chr5:173954559	NA	0.57	5.59	0.32	5.54e-8	Stroke;
CESC	cis	rs478304	0.651	rs11227299	chr11:65549570	C/G	cg27068330	chr11:65405492	SIPA1	-0.47	-5.67	-0.33	3.69e-8	Acne (severe);
CESC	cis	rs40363	0.729	rs6501176	chr16:3522197	A/G	cg00484396	chr16:3507460	NAT15	-0.42	-5.91	-0.34	1.06e-8	Tuberculosis;
CESC	trans	rs2472476	0.900	rs4742922	chr9:107520596	G/A	cg14553338	chr2:66689807	MEIS1	0.45	6.33	0.36	1.02e-9	Obesity-related traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00473112	chr11:507177	RNH1	0.68	7.63	0.42	4.14e-13	Gut microbiome composition (summer);
CESC	cis	rs8060686	0.641	rs73612222	chr16:68216072	A/G	cg26727032	chr16:67993705	SLC12A4	-0.52	-6.01	-0.35	6.19e-9	HDL cholesterol;Metabolic syndrome;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg22561380	chr8:42829775	HOOK3	0.46	6.49	0.37	4.27e-10	Fibrinogen levels;
CESC	cis	rs67340775	0.541	rs200975	chr6:27855625	G/T	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.54	5.07	0.3	7.35e-7	Lung cancer in ever smokers;
CESC	cis	rs11650494	0.710	rs8065814	chr17:47470720	T/C	cg08112188	chr17:47440006	ZNF652	0.84	6.39	0.37	7.58e-10	Prostate cancer;
CESC	cis	rs763014	1.000	rs7205409	chr16:642610	A/G	cg09263875	chr16:632152	PIGQ	0.65	10.85	0.55	6.36e-23	Height;
CESC	cis	rs10504229	0.724	rs72650827	chr8:58126884	A/T	cg24829409	chr8:58192753	C8orf71	-0.59	-7.24	-0.41	4.79e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs11270836	1	rs11270836	chr4:38625915	T/TACATTATGTCATTTCACA	cg18361445	chr4:38666374	KLF3;FLJ13197	0.54	7.67	0.43	3.39e-13	Mumps;
CESC	cis	rs9287719	0.967	rs2287062	chr2:10743191	G/A	cg00105475	chr2:10696890	NA	0.39	5.64	0.33	4.44e-8	Prostate cancer;
CESC	cis	rs17666538	0.792	rs7820788	chr8:601846	C/T	cg02524346	chr8:600233	NA	0.81	6.4	0.37	7.21e-10	IgG glycosylation;
CESC	cis	rs4820539	1.000	rs885963	chr22:23460939	G/T	cg14186256	chr22:23484241	RTDR1	0.82	14.91	0.68	6.55e-37	Bone mineral density;
CESC	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.89	13.44	0.64	9.54e-32	Prudent dietary pattern;
CESC	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	13.67	0.64	1.44e-32	Prudent dietary pattern;
CESC	cis	rs7635838	0.619	rs346087	chr3:11274354	A/G	cg00170343	chr3:11313890	ATG7	0.51	7.12	0.4	1.04e-11	HDL cholesterol;
CESC	cis	rs2635047	0.901	rs2684837	chr18:44749884	A/C	cg24371990	chr18:44770781	NA	0.33	5.2	0.3	4.05e-7	Educational attainment;
CESC	cis	rs12188164	0.965	rs72717435	chr5:448202	G/A	cg21144161	chr5:423903	AHRR	0.37	5.99	0.35	6.64e-9	Cystic fibrosis severity;
CESC	cis	rs9911578	1.000	rs2567905	chr17:56782297	T/C	cg12560992	chr17:57184187	TRIM37	0.92	15.46	0.69	7.24e-39	Intelligence (multi-trait analysis);
CESC	cis	rs1008375	0.931	rs6813374	chr4:17649494	T/C	cg16339924	chr4:17578868	LAP3	0.65	8.27	0.45	6.38e-15	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs17711722	0.727	rs781151	chr7:65479878	T/C	cg11987759	chr7:65425863	GUSB	-0.43	-5.75	-0.33	2.46e-8	Calcium levels;
CESC	cis	rs875971	0.798	rs7789615	chr7:65878661	A/G	cg19163074	chr7:65112434	INTS4L2	-0.41	-5.11	-0.3	6.29e-7	Aortic root size;
CESC	cis	rs870825	0.616	rs28375770	chr4:185647395	C/T	cg04058563	chr4:185651563	MLF1IP	0.63	6.96	0.39	2.59e-11	Blood protein levels;
CESC	cis	rs7017914	0.934	rs7009297	chr8:71672366	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.2	-0.3	3.94e-7	Bone mineral density;
CESC	cis	rs3733585	0.773	rs13107466	chr4:10019390	G/A	cg11266682	chr4:10021025	SLC2A9	0.72	14.87	0.67	8.73e-37	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs7107174	1.000	rs2512535	chr11:77971468	C/T	cg02023728	chr11:77925099	USP35	0.42	6.0	0.35	6.49e-9	Testicular germ cell tumor;
CESC	cis	rs3105593	0.547	rs3131559	chr15:50780214	C/A	cg05456662	chr15:50716270	USP8	0.45	6.05	0.35	5.04e-9	QT interval;
CESC	cis	rs262150	0.842	rs2657398	chr7:158784911	T/C	cg19418458	chr7:158789849	NA	-0.48	-7.77	-0.43	1.72e-13	Facial morphology (factor 20);
CESC	cis	rs13385	0.769	rs6871511	chr5:139592314	G/A	cg26211634	chr5:139558579	C5orf32	0.46	5.06	0.3	7.92e-7	Atrial fibrillation;
CESC	cis	rs9913156	0.793	rs11568061	chr17:4546445	G/A	cg00122941	chr17:4613640	ARRB2	0.84	9.37	0.5	3.42e-18	Lymphocyte counts;
CESC	cis	rs6570726	0.791	rs11155435	chr6:145938545	T/C	cg23711669	chr6:146136114	FBXO30	0.99	15.04	0.68	2.25e-37	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1862618	0.802	rs42769	chr5:56144152	G/A	cg18230493	chr5:56204884	C5orf35	-0.74	-9.05	-0.49	3.27e-17	Initial pursuit acceleration;
CESC	cis	rs7274811	0.681	rs291707	chr20:31964256	G/A	cg21523528	chr20:32077966	CBFA2T2	-0.43	-5.13	-0.3	5.7e-7	Height;
CESC	cis	rs35110281	0.715	rs8129601	chr21:45119104	A/G	cg01579765	chr21:45077557	HSF2BP	-0.52	-8.83	-0.48	1.43e-16	Mean corpuscular volume;
CESC	cis	rs854765	0.583	rs4414547	chr17:17859052	G/T	cg16928487	chr17:17741425	SREBF1	-0.57	-9.57	-0.51	7.66e-19	Total body bone mineral density;
CESC	cis	rs2230307	0.536	rs11166385	chr1:100443462	A/G	cg24955406	chr1:100503596	HIAT1	0.55	5.48	0.32	9.85e-8	Carotid intima media thickness;
CESC	cis	rs4713118	0.629	rs149899	chr6:28019979	C/T	cg23281280	chr6:28129359	ZNF389	0.48	6.32	0.36	1.1e-9	Parkinson's disease;
CESC	cis	rs6570726	0.935	rs414646	chr6:145831685	T/C	cg05347473	chr6:146136440	FBXO30	0.49	6.69	0.38	1.3100000000000001e-10	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg09784847	chr2:74692550	MOGS	-0.49	-6.0	-0.35	6.58e-9	Ulcerative colitis;
CESC	trans	rs61931739	0.500	rs11053273	chr12:34547255	C/T	cg13010199	chr12:38710504	ALG10B	0.51	6.58	0.37	2.47e-10	Morning vs. evening chronotype;
CESC	cis	rs6502050	0.835	rs7503111	chr17:80101587	A/T	cg23985595	chr17:80112537	CCDC57	-0.43	-6.63	-0.38	1.88e-10	Life satisfaction;
CESC	cis	rs1707322	0.752	rs10430105	chr1:46138876	G/A	cg05343316	chr1:45956843	TESK2	0.51	6.32	0.36	1.09e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7089973	0.872	rs7923295	chr10:116625159	C/G	cg23260525	chr10:116636907	FAM160B1	-0.37	-6.31	-0.36	1.19e-9	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs9640161	0.830	rs3757423	chr7:150067714	A/G	cg10018233	chr7:150070692	REPIN1	-0.47	-8.71	-0.47	3.32e-16	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs9318086	0.712	rs9318099	chr13:24442462	C/G	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.42	-5.91	-0.34	1.03e-8	Myopia (pathological);
CESC	cis	rs2180341	0.960	rs7751865	chr6:127683040	G/A	cg24812749	chr6:127587940	RNF146	1.05	15.15	0.68	9.37e-38	Breast cancer;
CESC	cis	rs4975709	0.569	rs931509	chr5:1858821	A/T	cg11168104	chr5:1857477	NA	-0.39	-5.57	-0.32	6.25e-8	Cardiovascular disease risk factors;
CESC	cis	rs1448094	0.773	rs11117100	chr12:86310392	A/G	cg02569458	chr12:86230093	RASSF9	0.37	5.25	0.31	3.19e-7	Major depressive disorder;
CESC	cis	rs453301	0.653	rs7005133	chr8:8901222	T/G	cg15556689	chr8:8085844	FLJ10661	0.51	6.38	0.36	8e-10	Joint mobility (Beighton score);
CESC	cis	rs2576037	0.899	rs2060417	chr18:44576486	C/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.5	6.59	0.38	2.42e-10	Personality dimensions;
CESC	cis	rs962856	0.619	rs1601529	chr2:67594837	A/T	cg09028215	chr2:67624308	ETAA1	0.44	5.32	0.31	2.19e-7	Pancreatic cancer;
CESC	cis	rs412050	0.547	rs78907487	chr22:22151939	A/C	cg17089214	chr22:22089827	YPEL1	0.68	5.82	0.34	1.7e-8	Attention deficit hyperactivity disorder;
CESC	trans	rs877282	1.000	rs877282	chr10:771532	G/A	cg22713356	chr15:30763199	NA	1.26	12.77	0.62	2.03e-29	Uric acid levels;
CESC	cis	rs1552244	0.572	rs67227131	chr3:10172744	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.59	-5.98	-0.34	7.15e-9	Alzheimer's disease;
CESC	cis	rs1355223	0.583	rs1396880	chr11:34870552	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.79	-11.95	-0.59	1.33e-26	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs35306767	0.903	rs11813210	chr10:919796	G/A	cg25019033	chr10:957182	NA	-0.58	-6.21	-0.36	2.03e-9	Eosinophil percentage of granulocytes;
CESC	cis	rs7918232	0.800	rs7907981	chr10:27444329	T/C	cg14240646	chr10:27532245	ACBD5	-0.67	-7.25	-0.41	4.55e-12	Breast cancer;
CESC	cis	rs4523957	0.890	rs8076939	chr17:2099931	C/A	cg16513277	chr17:2031491	SMG6	-0.66	-8.99	-0.48	4.8e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs3105593	1.000	rs3131577	chr15:50863516	G/A	cg08437265	chr15:50716283	USP8	0.43	5.56	0.32	6.74e-8	QT interval;
CESC	cis	rs11190604	1.000	rs11190552	chr10:102206607	G/A	cg07080220	chr10:102295463	HIF1AN	0.55	5.51	0.32	8.5e-8	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs9611565	0.802	rs2234058	chr22:41777883	G/A	cg17376030	chr22:41985996	PMM1	0.67	7.26	0.41	4.21e-12	Vitiligo;
CESC	cis	rs13108904	0.557	rs1250097	chr4:1238338	C/T	cg02475777	chr4:1388615	CRIPAK	-0.47	-6.15	-0.35	2.9e-9	Obesity-related traits;
CESC	cis	rs10131894	0.635	rs174997	chr14:75434806	G/A	cg08847533	chr14:75593920	NEK9	-0.77	-12.2	-0.6	1.77e-27	Coronary artery disease;
CESC	cis	rs1008375	1.000	rs55939327	chr4:17642937	T/A	cg02297831	chr4:17616191	MED28	0.53	6.71	0.38	1.2e-10	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs897080	0.515	rs1067343	chr2:44621042	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.46	5.51	0.32	8.58e-8	Height;
CESC	trans	rs11098499	0.775	rs67281037	chr4:120281157	G/C	cg25214090	chr10:38739885	LOC399744	0.65	9.11	0.49	2.04e-17	Corneal astigmatism;
CESC	cis	rs9611519	0.929	rs12484971	chr22:41439304	A/T	cg03806693	chr22:41940476	POLR3H	-0.56	-5.88	-0.34	1.22e-8	Neuroticism;
CESC	cis	rs4835473	0.604	rs11938387	chr4:144905629	T/C	cg25736465	chr4:144833511	NA	0.41	6.25	0.36	1.65e-9	Immature fraction of reticulocytes;
CESC	cis	rs6426558	0.537	rs2813950	chr1:227426072	A/G	cg10327440	chr1:227177885	CDC42BPA	-0.47	-6.17	-0.35	2.54e-9	Neutrophil percentage of white cells;
CESC	cis	rs2197308	0.765	rs68029712	chr12:37906585	T/G	cg26384229	chr12:38710491	ALG10B	0.75	11.12	0.56	7.84e-24	Morning vs. evening chronotype;
CESC	cis	rs8060686	0.858	rs13334918	chr16:67901343	A/G	cg26727032	chr16:67993705	SLC12A4	-0.65	-9.58	-0.51	7.54e-19	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs4665809	1.000	rs4233709	chr2:26291493	C/T	cg26314531	chr2:26401878	FAM59B	0.53	6.0	0.35	6.49e-9	Gut microbiome composition (summer);
CESC	cis	rs7613875	0.600	rs7061	chr3:50114515	C/T	cg24308560	chr3:49941425	MST1R	0.58	8.15	0.45	1.47e-14	Body mass index;
CESC	cis	rs9346455	1.000	rs12055385	chr6:71996789	G/A	cg27238071	chr6:71998145	OGFRL1	0.59	5.14	0.3	5.47e-7	Antipsychotic drug-induced weight gain (time interaction);Antipsychotic drug-induced weight gain;
CESC	cis	rs1124376	0.882	rs6791385	chr3:20136439	A/C	cg05072819	chr3:20081367	KAT2B	0.47	5.38	0.31	1.61e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs6724607	0.905	rs7603849	chr2:191438741	A/C	cg10560079	chr2:191398806	TMEM194B	0.49	6.85	0.39	5.15e-11	Pulse pressure;
CESC	cis	rs7208859	0.623	rs9890862	chr17:29125450	C/A	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.79e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs12142240	0.698	rs1053628	chr1:46827769	C/T	cg10495392	chr1:46806563	NSUN4	0.58	6.32	0.36	1.12e-9	Menopause (age at onset);
CESC	cis	rs17761864	0.579	rs12325821	chr17:2050166	G/T	cg16513277	chr17:2031491	SMG6	0.41	5.27	0.31	2.82e-7	Esophageal cancer (squamous cell);
CESC	cis	rs2273669	0.667	rs12204576	chr6:109318843	A/G	cg05315195	chr6:109294784	ARMC2	-0.66	-6.37	-0.36	8.17e-10	Prostate cancer;
CESC	cis	rs5758659	0.652	rs133347	chr22:42423645	A/T	cg04733989	chr22:42467013	NAGA	0.48	6.67	0.38	1.52e-10	Cognitive function;
CESC	cis	rs736408	0.609	rs13082960	chr3:52785168	A/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.31	5.52	0.32	7.94e-8	Bipolar disorder;
CESC	cis	rs7945705	0.747	rs2568045	chr11:9004060	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.41	-6.88	-0.39	4.26e-11	Hemoglobin concentration;
CESC	cis	rs4808199	0.894	rs10418051	chr19:19397789	C/T	cg03709012	chr19:19516395	GATAD2A	1.03	11.89	0.59	2.05e-26	Nonalcoholic fatty liver disease;
CESC	cis	rs56046484	0.956	rs34889576	chr15:85664676	A/G	cg08123816	chr15:85640762	PDE8A	-0.5	-6.19	-0.36	2.23e-9	Testicular germ cell tumor;
CESC	cis	rs2842992	0.789	rs4709376	chr6:160226337	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.74	9.32	0.5	4.9e-18	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs7647973	1.000	rs9862534	chr3:49598064	A/G	cg07636037	chr3:49044803	WDR6	0.69	9.69	0.51	3.42e-19	Menarche (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05049096	chr10:5855588	GDI2	0.58	6.11	0.35	3.47e-9	Gut microbiome composition (summer);
CESC	cis	rs6893300	0.922	rs62406187	chr5:179185686	C/T	cg14593053	chr5:179126677	CANX	-0.53	-5.76	-0.33	2.29e-8	Resting heart rate;
CESC	cis	rs9487051	0.872	rs7773331	chr6:109609208	C/T	cg21918786	chr6:109611834	NA	-0.4	-6.01	-0.35	6.17e-9	Reticulocyte fraction of red cells;
CESC	cis	rs4664304	1.000	rs4664304	chr2:160794008	A/G	cg03641300	chr2:160917029	PLA2R1	-0.48	-6.62	-0.38	1.99e-10	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs2933343	0.953	rs2933344	chr3:128658715	A/G	cg25356066	chr3:128598488	ACAD9	0.58	7.24	0.41	4.97e-12	IgG glycosylation;
CESC	cis	rs12497850	0.897	rs6781790	chr3:49044767	C/T	cg02487422	chr3:49467188	NICN1	0.43	5.54	0.32	7.11e-8	Parkinson's disease;
CESC	cis	rs4664304	0.629	rs56122507	chr2:160847353	T/C	cg03641300	chr2:160917029	PLA2R1	-0.43	-5.82	-0.34	1.69e-8	Crohn's disease;Inflammatory bowel disease;
CESC	trans	rs2391518	0.587	rs2969002	chr4:130782328	G/T	cg04981619	chr2:43328122	NA	0.38	6.0	0.35	6.59e-9	Body mass index;
CESC	cis	rs1799949	1.000	rs4793215	chr17:41318932	G/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.39	5.2	0.3	4.06e-7	Menopause (age at onset);
CESC	cis	rs6060717	0.529	rs6060535	chr20:34235522	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.61	5.15	0.3	5.03e-7	Hip circumference adjusted for BMI;
CESC	cis	rs7827545	0.644	rs7386524	chr8:135534005	T/C	cg17885191	chr8:135476712	NA	-0.52	-6.95	-0.39	2.92e-11	Hypertension (SNP x SNP interaction);
CESC	cis	rs12325245	0.536	rs71375919	chr16:58547522	C/T	cg01152986	chr16:58549298	SETD6	0.85	5.09	0.3	6.71e-7	Schizophrenia;
CESC	cis	rs4713118	0.662	rs9393881	chr6:28023751	C/G	cg23161317	chr6:28129485	ZNF389	0.49	6.12	0.35	3.33e-9	Parkinson's disease;
CESC	cis	rs6598955	0.671	rs11247880	chr1:26568926	G/A	cg19743891	chr1:26644573	UBXN11;CD52	0.38	5.19	0.3	4.09e-7	Obesity-related traits;
CESC	cis	rs3785574	0.962	rs4480868	chr17:61788859	C/T	cg06873352	chr17:61820015	STRADA	0.49	7.14	0.4	8.86e-12	Height;
CESC	cis	rs11583043	0.708	rs1335745	chr1:101546439	T/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.51	5.48	0.32	9.66e-8	Ulcerative colitis;Inflammatory bowel disease;
CESC	cis	rs6991838	0.584	rs4275254	chr8:66501364	A/G	cg13398993	chr8:66546079	ARMC1	-0.46	-5.58	-0.32	5.82e-8	Intelligence (multi-trait analysis);
CESC	cis	rs7520050	0.966	rs4660910	chr1:46548402	G/T	cg03146154	chr1:46216737	IPP	-0.44	-5.69	-0.33	3.34e-8	Red blood cell count;Reticulocyte count;
CESC	cis	rs8028182	0.636	rs7175852	chr15:75694535	C/T	cg20655648	chr15:75932815	IMP3	0.45	5.52	0.32	8.15e-8	Sudden cardiac arrest;
CESC	cis	rs7107174	0.901	rs10899473	chr11:78042983	A/C	cg02023728	chr11:77925099	USP35	0.41	5.79	0.34	2e-8	Testicular germ cell tumor;
CESC	cis	rs7662987	1.000	rs7658127	chr4:99994622	C/G	cg13256891	chr4:100009986	ADH5	-0.83	-6.1	-0.35	3.82e-9	Smoking initiation;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26449450	chr19:12228348	NA	-0.61	-7.18	-0.4	7.03e-12	Gut microbiome composition (summer);
CESC	cis	rs7927771	0.864	rs4752999	chr11:47428565	C/T	cg20307385	chr11:47447363	PSMC3	-0.61	-7.38	-0.41	2.05e-12	Subjective well-being;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg05793409	chr1:35658810	SFPQ	-0.52	-6.8	-0.39	6.88e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs8062405	0.573	rs8045689	chr16:28988269	C/T	cg05966235	chr16:28915196	ATP2A1	-0.41	-5.81	-0.34	1.82e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs2276314	1.000	rs4799835	chr18:33571268	G/A	cg05985134	chr18:33552581	C18orf21	0.64	7.2	0.4	6.39e-12	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs1163251	0.902	rs511059	chr1:120217081	G/T	cg19096424	chr1:120255104	PHGDH	0.43	5.22	0.31	3.62e-7	Blood metabolite levels;
CESC	cis	rs668210	0.793	rs506873	chr11:65767215	A/C	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.5	-5.08	-0.3	7.29e-7	Cerebrospinal fluid biomarker levels;
CESC	cis	rs3741151	1.000	rs57893472	chr11:73042826	C/T	cg17517138	chr11:73019481	ARHGEF17	0.62	5.15	0.3	5.08e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs875971	0.862	rs10224872	chr7:65759773	T/A	cg12463550	chr7:65579703	CRCP	-0.46	-5.86	-0.34	1.34e-8	Aortic root size;
CESC	cis	rs74181299	0.750	rs12472718	chr2:65327620	G/A	cg05010058	chr2:65284262	CEP68	-0.31	-5.24	-0.31	3.32e-7	Pulse pressure;
CESC	cis	rs12995491	0.933	rs34029976	chr2:88537797	T/C	cg18490616	chr2:88469792	THNSL2	-0.54	-8.06	-0.44	2.59e-14	Response to metformin (IC50);
CESC	trans	rs7618501	0.633	rs2252833	chr3:50004209	C/T	cg21659725	chr3:3221576	CRBN	0.48	6.58	0.37	2.5e-10	Intelligence (multi-trait analysis);
CESC	cis	rs6546537	0.550	rs72837959	chr2:69780762	C/T	cg10773587	chr2:69614142	GFPT1	-0.43	-5.45	-0.32	1.16e-7	Serum thyroid-stimulating hormone levels;
CESC	cis	rs9296736	0.922	rs614956	chr6:53950865	G/A	cg04374786	chr6:53939321	C6orf142	0.36	5.64	0.33	4.28e-8	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs10504229	0.906	rs113745779	chr8:58191301	C/G	cg22535103	chr8:58192502	C8orf71	-1.05	-13.08	-0.63	1.71e-30	Developmental language disorder (linguistic errors);
CESC	cis	rs7116495	0.609	rs949326	chr11:71730306	A/G	cg10381502	chr11:71823885	C11orf51	1.04	7.3	0.41	3.38e-12	Severe influenza A (H1N1) infection;
CESC	cis	rs9896933	0.832	rs77512810	chr17:80804589	C/T	cg15664640	chr17:80829946	TBCD	-0.54	-5.78	-0.33	2.05e-8	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
CESC	cis	rs1953600	0.837	rs3098105	chr10:81953266	C/T	cg00277334	chr10:82204260	NA	0.45	6.28	0.36	1.4e-9	Sarcoidosis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00205436	chr2:132766767	NA	-0.51	-7.16	-0.4	7.76e-12	Gut microbiome composition (summer);
CESC	cis	rs514406	0.698	rs511599	chr1:53362818	T/C	cg06600287	chr1:53387719	ECHDC2	-0.27	-5.05	-0.3	8.13e-7	Monocyte count;
CESC	cis	rs2404602	0.692	rs12437733	chr15:77155562	A/G	cg22467129	chr15:76604101	ETFA	-0.35	-5.27	-0.31	2.8e-7	Blood metabolite levels;
CESC	cis	rs35306767	0.953	rs12259338	chr10:969377	C/T	cg20503657	chr10:835505	NA	0.7	7.89	0.44	7.91e-14	Eosinophil percentage of granulocytes;
CESC	cis	rs12497850	0.829	rs8926	chr3:49052785	T/A	cg02487422	chr3:49467188	NICN1	0.45	5.72	0.33	2.91e-8	Parkinson's disease;
CESC	cis	rs9388451	0.626	rs3799708	chr6:126078530	C/T	cg05901451	chr6:126070800	HEY2	-0.62	-9.44	-0.5	2e-18	Brugada syndrome;
CESC	cis	rs3540	0.512	rs3862434	chr15:91080387	C/T	cg10434728	chr15:90938212	IQGAP1	0.4	7.1	0.4	1.11e-11	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs35146811	0.586	rs6964754	chr7:99589404	G/A	cg22906224	chr7:99728672	NA	0.43	5.18	0.3	4.42e-7	Coronary artery disease;
CESC	cis	rs950169	0.579	rs11633088	chr15:84672181	A/T	cg17507749	chr15:85114479	UBE2QP1	-0.58	-5.8	-0.34	1.84e-8	Schizophrenia;
CESC	cis	rs798554	1.000	rs798548	chr7:2760935	A/G	cg13628971	chr7:2884303	GNA12	0.61	8.35	0.46	3.73e-15	Height;
CESC	cis	rs9649213	0.593	rs7807555	chr7:97957517	G/A	cg08684580	chr7:98029266	BAIAP2L1	-0.34	-5.63	-0.33	4.6e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7618915	0.547	rs2268026	chr3:52778347	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	7.2	0.4	6.31e-12	Bipolar disorder;
CESC	cis	rs9300255	0.602	rs1727294	chr12:123616514	A/G	cg00376283	chr12:123451042	ABCB9	0.69	8.61	0.47	6.6e-16	Neutrophil percentage of white cells;
CESC	cis	rs854765	0.583	rs11078405	chr17:17824978	G/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.48	6.23	0.36	1.86e-9	Total body bone mineral density;
CESC	cis	rs2880765	0.835	rs7168860	chr15:86037030	G/A	cg10818794	chr15:86012489	AKAP13	-0.34	-5.33	-0.31	2.11e-7	Coronary artery disease;
CESC	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.48	-5.2	-0.3	4.05e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs473651	0.935	rs541128	chr2:239336449	A/G	cg21699342	chr2:239360505	ASB1	0.56	9.61	0.51	6.14e-19	Multiple system atrophy;
CESC	cis	rs9486715	0.825	rs211158	chr6:97022938	C/G	cg06623918	chr6:96969491	KIAA0776	-0.8	-11.8	-0.59	4.22e-26	Headache;
CESC	cis	rs820218	0.926	rs820155	chr17:73663778	G/C	cg01592526	chr17:73663357	RECQL5;SAP30BP	0.44	5.65	0.33	4.15e-8	Rotator cuff tears;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16531660	chr3:141457093	RNF7	0.57	6.39	0.37	7.41e-10	Gut microbiome composition (summer);
CESC	cis	rs6938	0.534	rs11636892	chr15:75266049	G/C	cg09165964	chr15:75287851	SCAMP5	0.49	6.49	0.37	4.18e-10	Breast cancer;
CESC	cis	rs35306767	0.671	rs11253473	chr10:906826	A/G	cg26597838	chr10:835615	NA	0.86	8.97	0.48	5.53e-17	Eosinophil percentage of granulocytes;
CESC	cis	rs36051895	0.502	rs10975003	chr9:5213687	T/C	cg02405213	chr9:5042618	JAK2	-0.45	-5.46	-0.32	1.07e-7	Pediatric autoimmune diseases;
CESC	cis	rs34172651	0.917	rs11074651	chr16:24778409	A/G	cg06028605	chr16:24865363	SLC5A11	0.34	5.37	0.31	1.73e-7	Intelligence (multi-trait analysis);
CESC	cis	rs3741151	1.000	rs79794992	chr11:73049352	A/G	cg17517138	chr11:73019481	ARHGEF17	1.07	7.37	0.41	2.12e-12	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs875971	0.862	rs10250544	chr7:65766561	A/G	cg10691866	chr7:65817282	TPST1	0.33	5.55	0.32	6.96e-8	Aortic root size;
CESC	cis	rs9611565	0.918	rs9611562	chr22:41760172	T/G	cg03806693	chr22:41940476	POLR3H	-1.03	-11.75	-0.59	6.25e-26	Vitiligo;
CESC	cis	rs2066819	1.000	rs57137641	chr12:56741228	G/A	cg26734620	chr12:56694298	CS	0.98	5.95	0.34	8.45e-9	Psoriasis vulgaris;
CESC	cis	rs7811142	1.000	rs6975729	chr7:100028187	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.0	9.63	0.51	5.12e-19	Platelet count;
CESC	cis	rs2625529	0.556	rs1552134	chr15:72232898	T/A	cg16672083	chr15:72433130	SENP8	0.43	6.2	0.36	2.1e-9	Red blood cell count;
CESC	cis	rs35110281	0.776	rs2838338	chr21:45075582	T/C	cg21573476	chr21:45109991	RRP1B	-0.51	-7.27	-0.41	3.97e-12	Mean corpuscular volume;
CESC	cis	rs7216064	1.000	rs7210027	chr17:65977053	C/T	cg12091567	chr17:66097778	LOC651250	0.66	7.63	0.42	4.31e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs367615	0.660	rs10477972	chr5:108831951	C/A	cg17395555	chr5:108820864	NA	0.64	11.03	0.56	1.56e-23	Colorectal cancer (SNP x SNP interaction);
CESC	cis	rs60871478	0.730	rs62432226	chr7:792973	T/C	cg05535760	chr7:792225	HEATR2	0.98	11.15	0.57	6.25e-24	Cerebrospinal P-tau181p levels;
CESC	cis	rs2075371	0.966	rs2544223	chr7:133995787	A/G	cg00033643	chr7:134001901	SLC35B4	0.42	5.39	0.31	1.55e-7	Mean platelet volume;
CESC	cis	rs4472734	0.965	rs12074810	chr1:214619101	C/A	cg00063699	chr1:214624242	PTPN14	-0.34	-5.26	-0.31	2.93e-7	Height;
CESC	cis	rs425277	0.585	rs364677	chr1:2071765	A/G	cg16545954	chr1:2118288	C1orf86	-0.37	-7.02	-0.4	1.91e-11	Height;
CESC	cis	rs3812049	0.826	rs17764730	chr5:127357526	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.89	10.96	0.56	2.78e-23	Lymphocyte counts;Red cell distribution width;
CESC	cis	rs2535633	0.631	rs2245424	chr3:53003021	G/C	cg07507251	chr3:52567010	NT5DC2	-0.31	-5.14	-0.3	5.4e-7	Body mass index;
CESC	cis	rs208515	0.560	rs207084	chr6:66776966	T/C	cg07460842	chr6:66804631	NA	-1.04	-22.02	-0.8	8.43e-62	Exhaled nitric oxide levels;
CESC	cis	rs9322193	0.962	rs9765929	chr6:150090816	T/C	cg04369109	chr6:150039330	LATS1	-0.39	-5.31	-0.31	2.3e-7	Lung cancer;
CESC	cis	rs7809950	1.000	rs2237673	chr7:107131580	T/C	cg23024343	chr7:107201750	COG5	-0.42	-5.99	-0.35	6.9e-9	Coronary artery disease;
CESC	cis	rs11031096	0.782	rs11031110	chr11:4162652	G/C	cg18678763	chr11:4115507	RRM1	-0.46	-6.31	-0.36	1.19e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	cis	rs7647973	0.580	rs7652746	chr3:49262307	C/T	cg07636037	chr3:49044803	WDR6	-0.76	-11.82	-0.59	3.57e-26	Menarche (age at onset);
CESC	cis	rs7084402	0.967	rs1649032	chr10:60279701	T/C	cg07615347	chr10:60278583	BICC1	-0.59	-9.45	-0.5	1.83e-18	Refractive error;
CESC	cis	rs9796	0.866	rs1678750	chr15:41410705	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.42	-6.23	-0.36	1.78e-9	Menopause (age at onset);
CESC	trans	rs945270	0.512	rs868200	chr14:56195998	T/G	cg18102697	chr4:83542773	C4orf11	-0.43	-6.55	-0.37	3.06e-10	Subcortical brain region volumes;
CESC	cis	rs7843479	0.601	rs11780532	chr8:21838670	T/A	cg17168535	chr8:21777572	XPO7	0.72	11.42	0.57	8.1e-25	Mean corpuscular volume;
CESC	cis	rs9322193	0.926	rs9689036	chr6:150101699	T/C	cg13206674	chr6:150067644	NUP43	0.39	5.58	0.32	5.93e-8	Lung cancer;
CESC	cis	rs6831352	0.879	rs67311928	chr4:100048999	A/G	cg12011299	chr4:100065546	ADH4	-0.59	-6.52	-0.37	3.62e-10	Alcohol dependence;
CESC	trans	rs28549925	0.590	rs10228868	chr7:16968585	A/G	cg01443946	chr12:5936980	ANO2	0.77	6.1	0.35	3.67e-9	Congenital heart disease (maternal effect);Conotruncal heart defects (maternal effects);
CESC	cis	rs6662572	1.000	rs55951835	chr1:46132442	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.53	5.83	0.34	1.65e-8	Blood protein levels;
CESC	cis	rs4662945	0.603	rs10496678	chr2:130262209	C/T	cg05962382	chr2:130345044	NA	-0.48	-6.82	-0.39	6.31e-11	Response to cytidine analogues (gemcitabine);
CESC	cis	rs7017914	0.967	rs34042354	chr8:71730961	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.44	-5.68	-0.33	3.58e-8	Bone mineral density;
CESC	cis	rs7202877	0.706	rs4993971	chr16:75411634	C/G	cg04384234	chr16:75411784	CFDP1	0.48	5.87	0.34	1.27e-8	Type 2 diabetes;Type 1 diabetes;
CESC	cis	rs9926296	0.715	rs2115401	chr16:89740609	A/G	cg12119029	chr16:89752879	CDK10	-0.32	-5.53	-0.32	7.62e-8	Vitiligo;
CESC	cis	rs3008870	1.000	rs1925412	chr1:67405057	G/A	cg02640540	chr1:67518911	SLC35D1	0.51	5.54	0.32	7.41e-8	Lymphocyte percentage of white cells;
CESC	cis	rs66530629	0.874	rs7528154	chr1:25130083	T/C	cg22509179	chr1:25234806	RUNX3	-0.43	-5.47	-0.32	1.05e-7	Plateletcrit;
CESC	cis	rs875971	1.000	rs875971	chr7:65617595	A/G	cg10691866	chr7:65817282	TPST1	0.34	5.59	0.32	5.7e-8	Aortic root size;
CESC	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.65	0.38	1.71e-10	Prudent dietary pattern;
CESC	cis	rs9660180	0.934	rs34849348	chr1:1762757	C/T	cg23982607	chr1:1823379	GNB1	-0.78	-12.63	-0.61	6.1e-29	Body mass index;
CESC	cis	rs1005277	0.557	rs176887	chr10:38406094	T/C	cg25427524	chr10:38739819	LOC399744	-0.67	-9.69	-0.51	3.27e-19	Extrinsic epigenetic age acceleration;
CESC	cis	rs2404602	0.692	rs34181263	chr15:77065388	C/T	cg26408565	chr15:76604113	ETFA	-0.38	-5.42	-0.32	1.32e-7	Blood metabolite levels;
CESC	cis	rs4132509	0.744	rs59953491	chr1:243894953	C/T	cg21452805	chr1:244014465	NA	0.53	6.34	0.36	9.77e-10	RR interval (heart rate);
CESC	cis	rs875971	0.522	rs709604	chr7:65497434	A/G	cg25985355	chr7:65971099	NA	0.32	5.26	0.31	2.94e-7	Aortic root size;
CESC	cis	rs17655565	0.533	rs12825729	chr12:52706854	G/A	cg08257133	chr12:52711352	KRT83	0.5	8.66	0.47	4.68e-16	Plasma amyloid beta peptide concentrations (ABx-42);
CESC	trans	rs561341	1.000	rs576985	chr17:30323323	C/T	cg20587970	chr11:113659929	NA	-1.44	-18.71	-0.75	2.25e-50	Hip circumference adjusted for BMI;
CESC	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.71	9.9	0.52	7.25e-20	Prudent dietary pattern;
CESC	cis	rs9311474	0.508	rs7614498	chr3:52618941	A/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.38	6.82	0.39	6.31e-11	Electroencephalogram traits;
CESC	cis	rs7772486	0.536	rs9373467	chr6:145955605	C/T	cg23711669	chr6:146136114	FBXO30	0.93	12.15	0.6	2.61e-27	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs1003719	0.715	rs762139	chr21:38568475	A/T	cg08222185	chr21:46494823	ADARB1	-0.42	-6.12	-0.35	3.3e-9	Eye color traits;
CESC	cis	rs6088590	0.735	rs2273684	chr20:33529766	G/T	cg24642439	chr20:33292090	TP53INP2	-0.68	-9.06	-0.49	3.01e-17	Coronary artery disease;
CESC	cis	rs5758659	0.652	rs6519301	chr22:42385967	A/G	cg04733989	chr22:42467013	NAGA	0.42	5.56	0.32	6.71e-8	Cognitive function;
CESC	cis	rs7937682	0.924	rs10891284	chr11:111527737	T/C	cg22437258	chr11:111473054	SIK2	0.69	9.29	0.5	5.71e-18	Primary sclerosing cholangitis;
CESC	cis	rs9733	0.596	rs12063547	chr1:150674053	G/T	cg18016565	chr1:150552671	MCL1	-0.34	-5.16	-0.3	4.74e-7	Tonsillectomy;
CESC	cis	rs2839186	1.000	rs2839181	chr21:47685939	A/G	cg13126279	chr21:47581558	C21orf56	-0.48	-6.41	-0.37	6.67e-10	Testicular germ cell tumor;
CESC	cis	rs736408	0.522	rs11716747	chr3:52748857	C/T	cg18337363	chr3:52569053	NT5DC2	0.29	5.16	0.3	4.73e-7	Bipolar disorder;
CESC	trans	rs9858542	0.953	rs67216675	chr3:49493151	G/T	cg21659725	chr3:3221576	CRBN	-0.56	-6.57	-0.37	2.66e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs9311474	0.713	rs352165	chr3:52242902	A/G	cg05315796	chr3:52349193	DNAH1	0.29	5.15	0.3	5.06e-7	Electroencephalogram traits;
CESC	cis	rs1707322	0.721	rs61784800	chr1:46178112	A/G	cg05343316	chr1:45956843	TESK2	-0.48	-6.09	-0.35	3.85e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	21.04	0.79	1.78e-58	Prudent dietary pattern;
CESC	cis	rs7267979	1.000	rs6050566	chr20:25351071	G/A	cg08601574	chr20:25228251	PYGB	-0.38	-5.49	-0.32	9.43e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs4819052	0.851	rs2838828	chr21:46663423	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.46	5.81	0.34	1.81e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs12410462	0.681	rs74582965	chr1:227610126	C/T	cg23173402	chr1:227635558	NA	0.74	6.46	0.37	4.96e-10	Major depressive disorder;
CESC	cis	rs9649213	0.593	rs6465678	chr7:98004057	T/C	cg08684580	chr7:98029266	BAIAP2L1	-0.35	-5.75	-0.33	2.39e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs1707322	1.000	rs4454479	chr1:46423555	G/A	cg03146154	chr1:46216737	IPP	0.72	9.82	0.52	1.31e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs4555082	0.874	rs113291192	chr14:105738181	C/T	cg10792982	chr14:105748885	BRF1	0.4	5.1	0.3	6.45e-7	Mean platelet volume;Platelet distribution width;
CESC	cis	rs7044106	0.708	rs959558	chr9:123368911	C/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.35	5.65	0.33	4.07e-8	Hip circumference adjusted for BMI;
CESC	cis	rs7666738	0.962	rs4699605	chr4:99064379	A/G	cg03676636	chr4:99064102	C4orf37	0.35	5.05	0.3	8.25e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9902453	1.000	rs4795525	chr17:28388487	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.62	-7.87	-0.44	9.09e-14	Coffee consumption (cups per day);
CESC	cis	rs28595532	0.668	rs58467651	chr4:119349011	T/G	cg21605333	chr4:119757512	SEC24D	0.93	5.35	0.31	1.9e-7	Cannabis dependence symptom count;
CESC	cis	rs3087591	0.960	rs1801052	chr17:29508775	C/T	cg24425628	chr17:29625626	OMG;NF1	0.42	5.16	0.3	4.75e-7	Hip circumference;
CESC	cis	rs9457247	0.565	rs12193698	chr6:167512073	C/A	cg23791538	chr6:167370224	RNASET2	-0.54	-7.06	-0.4	1.48e-11	Crohn's disease;
CESC	cis	rs4604732	0.527	rs77361748	chr1:247626475	C/T	cg12754571	chr1:247694271	LOC148824;OR2C3	0.44	5.44	0.32	1.21e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs798554	0.757	rs2533878	chr7:2878707	A/G	cg19717773	chr7:2847554	GNA12	0.55	7.96	0.44	5.21e-14	Height;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg19602773	chr3:52007747	ABHD14B;ABHD14A	-0.47	-6.55	-0.37	2.94e-10	Fibrinogen levels;
CESC	cis	rs561341	0.883	rs7219239	chr17:30212016	A/G	cg13647721	chr17:30228624	UTP6	-0.61	-5.68	-0.33	3.47e-8	Hip circumference adjusted for BMI;
CESC	cis	rs1691799	0.899	rs1168295	chr12:66734151	G/C	cg16791601	chr12:66731901	HELB	-0.75	-12.9	-0.62	7.25e-30	White blood cell count (basophil);
CESC	cis	rs597539	0.690	rs608810	chr11:68624118	G/C	cg01988459	chr11:68622903	NA	-0.41	-5.29	-0.31	2.53e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs228437	1.000	rs6934385	chr6:134916471	A/G	cg24504307	chr6:134963096	NA	0.57	5.96	0.34	7.93e-9	Melanoma;
CESC	cis	rs2011503	1.000	rs11670687	chr19:19621752	A/G	cg11584989	chr19:19387371	SF4	0.61	7.06	0.4	1.45e-11	Bipolar disorder;
CESC	cis	rs873946	0.648	rs12782123	chr10:134554662	G/A	cg26818010	chr10:134567672	INPP5A	-0.91	-11.21	-0.57	3.85e-24	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	trans	rs7980799	0.935	rs12301124	chr12:33543024	T/C	cg26384229	chr12:38710491	ALG10B	-0.5	-6.73	-0.38	1.03e-10	Heart rate;Heart rate variability traits (RMSSD);
CESC	cis	rs4689388	0.926	rs5018647	chr4:6292799	A/C	cg14416269	chr4:6271139	WFS1	0.47	7.95	0.44	5.57e-14	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	trans	rs17685	0.725	rs1044483	chr7:75659815	T/C	cg19862616	chr7:65841803	NCRNA00174	-0.81	-11.47	-0.58	5.47e-25	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs9436747	0.605	rs7526141	chr1:65975275	C/T	cg14976592	chr1:65886160	LEPROT;LEPR	-0.43	-5.26	-0.31	3e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
CESC	cis	rs2749592	0.611	rs2505199	chr10:38392457	G/A	cg25427524	chr10:38739819	LOC399744	-0.62	-8.3	-0.45	5.37e-15	Age-related hearing impairment (SNP x SNP interaction);
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg15202251	chr7:100183972	FBXO24;LRCH4	-0.47	-6.35	-0.36	9.52e-10	Asthma;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg14546197	chr17:38137043	PSMD3	-0.49	-6.44	-0.37	5.47e-10	Ulcerative colitis;
CESC	cis	rs8017423	0.608	rs12589866	chr14:90820977	T/C	cg14092571	chr14:90743983	NA	0.44	6.6	0.38	2.22e-10	Mortality in heart failure;
CESC	cis	rs7937682	0.632	rs10891294	chr11:111699224	C/T	cg22437258	chr11:111473054	SIK2	-0.52	-5.75	-0.33	2.48e-8	Primary sclerosing cholangitis;
CESC	cis	rs853679	0.517	rs9295758	chr6:28120663	C/G	cg17949981	chr6:28129498	ZNF389	0.46	5.51	0.32	8.48e-8	Depression;
CESC	cis	rs2933343	0.951	rs7648327	chr3:128570708	A/G	cg25356066	chr3:128598488	ACAD9	0.55	7.04	0.4	1.64e-11	IgG glycosylation;
CESC	cis	rs2439831	0.764	rs2447193	chr15:43929733	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.81	8.43	0.46	2.26e-15	Lung cancer in ever smokers;
CESC	cis	rs1862618	0.853	rs832565	chr5:56150803	T/G	cg12311346	chr5:56204834	C5orf35	-0.74	-8.77	-0.47	2.29e-16	Initial pursuit acceleration;
CESC	cis	rs11758351	0.660	rs16891446	chr6:26226996	A/C	cg23601095	chr6:26197514	HIST1H3D	0.91	9.96	0.52	4.64e-20	Gout;Renal underexcretion gout;
CESC	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg23034840	chr1:205782522	SLC41A1	0.54	6.07	0.35	4.46e-9	Menarche (age at onset);
CESC	cis	rs6952808	1.000	rs10233560	chr7:1885415	T/C	cg21782813	chr7:2030301	MAD1L1	0.38	5.26	0.31	2.99e-7	Bipolar disorder and schizophrenia;
CESC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg17179057	chr10:14884691	HSPA14	0.42	6.39	0.37	7.46e-10	Thyroid stimulating hormone;
CESC	cis	rs2180341	1.000	rs9375499	chr6:127618072	T/C	cg24812749	chr6:127587940	RNF146	1.06	15.35	0.69	1.74e-38	Breast cancer;
CESC	trans	rs10506458	1.000	rs11174759	chr12:63444363	A/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.32	-17.48	-0.73	4.95e-46	Hemostatic factors and hematological phenotypes;
CESC	cis	rs2439831	0.867	rs3213990	chr15:43670226	C/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.86	12.85	0.62	1.02e-29	Lung cancer in ever smokers;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg18905668	chr11:18388147	GTF2H1	0.43	6.3	0.36	1.21e-9	Fibrinogen levels;
CESC	trans	rs11098499	0.661	rs10015965	chr4:120268237	A/G	cg25214090	chr10:38739885	LOC399744	0.59	8.11	0.45	1.88e-14	Corneal astigmatism;
CESC	cis	rs17407555	0.865	rs78272916	chr4:10286838	A/G	cg11266682	chr4:10021025	SLC2A9	-0.45	-5.16	-0.3	4.78e-7	Schizophrenia (age at onset);
CESC	cis	rs4664293	0.967	rs7590607	chr2:160545635	T/C	cg08347373	chr2:160653686	CD302	-0.31	-5.13	-0.3	5.61e-7	Monocyte percentage of white cells;
CESC	cis	rs67311347	1.000	rs9968170	chr3:40494274	A/G	cg24209194	chr3:40518798	ZNF619	-0.46	-5.88	-0.34	1.23e-8	Renal cell carcinoma;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18262260	chr14:89029717	ZC3H14	0.58	6.85	0.39	5e-11	Gut microbiome composition (summer);
CESC	cis	rs9322193	0.923	rs2880436	chr6:150180259	T/C	cg07701084	chr6:150067640	NUP43	0.39	5.11	0.3	6.19e-7	Lung cancer;
CESC	cis	rs9831754	0.906	rs9869812	chr3:78385679	G/A	cg06138941	chr3:78371609	NA	-0.66	-7.76	-0.43	1.88e-13	Calcium levels;
CESC	cis	rs4308124	0.708	rs28766030	chr2:111962429	T/C	cg04571233	chr2:111982156	NA	-0.64	-7.06	-0.4	1.47e-11	Vitiligo;
CESC	trans	rs561341	1.000	rs498391	chr17:30328704	G/A	cg27661571	chr11:113659931	NA	-0.77	-7.23	-0.41	5.19e-12	Hip circumference adjusted for BMI;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg05267963	chr11:63952891	STIP1	-0.42	-6.02	-0.35	5.86e-9	Gambling;
CESC	cis	rs208520	0.909	rs55813840	chr6:67012508	A/C	cg07460842	chr6:66804631	NA	0.84	8.13	0.45	1.67e-14	Exhaled nitric oxide output;
CESC	cis	rs9322193	0.923	rs9800686	chr6:149955600	A/C	cg04369109	chr6:150039330	LATS1	-0.39	-5.44	-0.32	1.23e-7	Lung cancer;
CESC	cis	rs9733	0.525	rs11584184	chr1:150695689	A/T	cg04414720	chr1:150670196	GOLPH3L	0.62	8.8	0.48	1.76e-16	Tonsillectomy;
CESC	cis	rs17253792	0.818	rs78393484	chr14:56065802	T/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.84	5.62	0.33	4.81e-8	Putamen volume;
CESC	cis	rs1008375	0.932	rs4235390	chr4:17696378	G/T	cg16339924	chr4:17578868	LAP3	0.59	7.41	0.41	1.69e-12	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs6061231	1.000	rs13043313	chr20:60958269	A/G	cg22601191	chr20:60968625	CABLES2	0.4	5.29	0.31	2.55e-7	Colorectal cancer;
CESC	cis	rs2635047	0.783	rs9952447	chr18:44784700	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.43	5.63	0.33	4.52e-8	Educational attainment;
CESC	cis	rs4819052	0.851	rs9979545	chr21:46679805	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.75	10.07	0.53	2.04e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19558503	chr7:30068084	PLEKHA8	0.57	6.47	0.37	4.62e-10	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20188490	chr12:11080457	PRH2;PRR4;PRH1	-0.58	-6.4	-0.37	6.83e-10	Gut microbiome composition (summer);
CESC	cis	rs9814567	1.000	rs4417907	chr3:134291363	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.47	-6.36	-0.36	8.57e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs9926296	0.605	rs12448860	chr16:89849629	T/A	cg21285383	chr16:89894308	SPIRE2	0.3	5.31	0.31	2.37e-7	Vitiligo;
CESC	cis	rs61931739	0.517	rs7486246	chr12:34526419	T/G	cg06521331	chr12:34319734	NA	-0.37	-5.15	-0.3	5.19e-7	Morning vs. evening chronotype;
CESC	cis	rs2228479	0.850	rs2286393	chr16:89809548	C/A	cg04013166	chr16:89971882	TCF25	0.74	6.51	0.37	3.73e-10	Skin colour saturation;
CESC	cis	rs7084402	0.967	rs1303970	chr10:60298477	G/T	cg07615347	chr10:60278583	BICC1	0.61	9.68	0.51	3.64e-19	Refractive error;
CESC	cis	rs3785574	0.962	rs62077483	chr17:61806380	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.81	10.83	0.55	6.96e-23	Height;
CESC	cis	rs7827545	0.545	rs6998092	chr8:135557449	A/G	cg17885191	chr8:135476712	NA	0.5	5.47	0.32	1.04e-7	Hypertension (SNP x SNP interaction);
CESC	cis	rs950169	0.881	rs62029599	chr15:84956565	A/C	cg17507749	chr15:85114479	UBE2QP1	0.59	6.54	0.37	3.11e-10	Schizophrenia;
CESC	cis	rs4853012	0.838	rs4452177	chr2:74345206	A/G	cg20891558	chr2:74357851	NA	0.81	11.86	0.59	2.57e-26	Gestational age at birth (maternal effect);
CESC	cis	rs600231	0.554	rs1346	chr11:65337251	A/T	cg17120908	chr11:65337727	SSSCA1	-0.73	-6.44	-0.37	5.62e-10	Bone mineral density;
CESC	cis	rs77106637	0.556	rs7123876	chr11:72444583	T/C	cg03713592	chr11:72463424	ARAP1	0.65	7.27	0.41	4.03e-12	Type 2 diabetes;
CESC	cis	rs9399137	0.507	rs13214669	chr6:135299959	T/C	cg22676075	chr6:135203613	NA	0.56	7.31	0.41	3.21e-12	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	trans	rs11098499	0.779	rs7356491	chr4:120381974	C/T	cg25214090	chr10:38739885	LOC399744	0.7	9.91	0.52	6.89e-20	Corneal astigmatism;
CESC	cis	rs826838	1.000	rs11183160	chr12:38676702	T/C	cg13010199	chr12:38710504	ALG10B	0.62	8.86	0.48	1.23e-16	Heart rate;
CESC	cis	rs2576037	0.526	rs2257027	chr18:44566990	A/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.54	7.54	0.42	7.31e-13	Personality dimensions;
CESC	cis	rs12893668	0.572	rs4906350	chr14:104111794	C/T	cg24130564	chr14:104152367	KLC1	-0.5	-6.58	-0.37	2.48e-10	Reticulocyte count;
CESC	cis	rs4972806	0.849	rs2857541	chr2:177029086	C/T	cg14324370	chr2:177042789	NA	0.43	6.15	0.35	2.87e-9	IgG glycosylation;
CESC	cis	rs1801251	1.000	rs991873	chr2:233711046	A/G	cg08000102	chr2:233561755	GIGYF2	-0.7	-10.11	-0.53	1.59e-20	Coronary artery disease;
CESC	cis	rs2243480	1.000	rs160634	chr7:65528664	C/T	cg13147721	chr7:65941812	NA	0.79	8.28	0.45	5.97e-15	Diabetic kidney disease;
CESC	cis	rs7618915	0.501	rs11130308	chr3:52639257	G/C	cg07507251	chr3:52567010	NT5DC2	0.32	5.5	0.32	8.74e-8	Bipolar disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15471079	chr4:89378292	HERC5	0.56	6.13	0.35	3.16e-9	Gut microbiome composition (summer);
CESC	cis	rs2228479	0.867	rs12930606	chr16:89946682	A/G	cg06558623	chr16:89946397	TCF25	1.06	8.98	0.48	5.17e-17	Skin colour saturation;
CESC	cis	rs2033711	0.870	rs6510152	chr19:58953319	C/T	cg11952622	chr19:58962976	ZNF324B	0.47	6.43	0.37	5.9e-10	Uric acid clearance;
CESC	cis	rs77633900	0.803	rs2469215	chr15:76611933	C/T	cg09663584	chr15:77347405	TSPAN3	0.59	5.17	0.3	4.57e-7	Non-glioblastoma glioma;Glioma;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg25850181	chr2:241992580	SNED1	0.44	6.08	0.35	4.26e-9	Fibrinogen levels;
CESC	cis	rs7116495	0.737	rs7126838	chr11:71826237	A/G	cg26138937	chr11:71823887	C11orf51	0.77	6.41	0.37	6.71e-10	Severe influenza A (H1N1) infection;
CESC	cis	rs2742234	0.578	rs2435354	chr10:43652445	C/T	cg07801480	chr10:43725741	RASGEF1A	0.45	5.68	0.33	3.63e-8	Hirschsprung disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02199589	chr7:77428242	PHTF2;TMEM60	0.51	6.14	0.35	3.03e-9	Gut microbiome composition (summer);
CESC	cis	rs7811142	0.830	rs7341507	chr7:99951315	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.74	6.64	0.38	1.75e-10	Platelet count;
CESC	cis	rs1799949	1.000	rs4534897	chr17:41431808	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.65	9.04	0.49	3.33e-17	Menopause (age at onset);
CESC	cis	rs3768617	0.510	rs20557	chr1:183093875	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.89	14.39	0.66	4.39e-35	Fuchs's corneal dystrophy;
CESC	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg04025307	chr7:1156635	C7orf50	0.48	7.76	0.43	1.89e-13	Longevity;Endometriosis;
CESC	cis	rs1372520	0.766	rs2583961	chr4:90779758	A/G	cg15133208	chr4:90757351	SNCA	-0.35	-5.03	-0.3	8.84e-7	Neuroticism;
CESC	trans	rs3808502	0.647	rs7821302	chr8:11236572	T/A	cg06636001	chr8:8085503	FLJ10661	-0.49	-6.15	-0.35	2.9e-9	Neuroticism;
CESC	cis	rs4595586	0.870	rs7962363	chr12:39299703	C/T	cg26384229	chr12:38710491	ALG10B	-0.39	-5.55	-0.32	6.87e-8	Morning vs. evening chronotype;
CESC	cis	rs473651	0.935	rs515412	chr2:239345394	A/T	cg18131467	chr2:239335373	ASB1	0.97	18.59	0.75	5.96e-50	Multiple system atrophy;
CESC	trans	rs6445797	0.603	rs11130536	chr3:56668522	C/T	cg15444621	chr13:113611794	NA	0.34	6.08	0.35	4.13e-9	Gastritis;
CESC	trans	rs11165623	0.792	rs1125358	chr1:96971800	T/C	cg10631902	chr5:14652156	NA	-0.5	-7.39	-0.41	1.98e-12	Hip circumference;Waist circumference;
CESC	cis	rs7927771	1.000	rs34128973	chr11:47851376	C/T	cg20307385	chr11:47447363	PSMC3	-0.5	-6.05	-0.35	4.98e-9	Subjective well-being;
CESC	cis	rs35955747	0.659	rs11704494	chr22:31913271	G/A	cg25791279	chr22:32026902	PISD	-0.44	-5.26	-0.31	2.98e-7	Neutrophil count;Sum basophil neutrophil counts;
CESC	cis	rs7582720	1.000	rs116678869	chr2:203819471	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.36	0.41	2.34e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22517552	chr7:30518520	NOD1	0.58	6.29	0.36	1.32e-9	Gut microbiome composition (summer);
CESC	cis	rs60871478	0.635	rs4311567	chr7:792295	T/C	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.61	5.89	0.34	1.14e-8	Cerebrospinal P-tau181p levels;
CESC	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg07308232	chr7:1071921	C7orf50	-0.5	-7.01	-0.4	1.95e-11	Longevity;Endometriosis;
CESC	trans	rs7866350	0.604	rs1935389	chr9:100994470	A/G	cg08448040	chr3:13521693	HDAC11	0.47	6.03	0.35	5.45e-9	Post-traumatic stress disorder;
CESC	cis	rs752010	0.808	rs7529858	chr1:42086606	G/C	cg06885757	chr1:42089581	HIVEP3	0.51	8.84	0.48	1.39e-16	Lupus nephritis in systemic lupus erythematosus;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18530716	chr17:6947403	SLC16A11	-0.54	-6.15	-0.35	2.82e-9	Gut microbiome composition (summer);
CESC	cis	rs6775745	0.654	rs10470323	chr3:131784987	C/T	cg12213930	chr3:131751605	CPNE4	0.47	5.38	0.31	1.61e-7	Neutrophil count;
CESC	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg15112475	chr7:1198522	ZFAND2A	-0.39	-6.33	-0.36	1.03e-9	Longevity;Endometriosis;
CESC	cis	rs274567	0.550	rs272885	chr5:131667736	A/G	cg18758796	chr5:131593413	PDLIM4	0.38	5.17	0.3	4.69e-7	Blood metabolite levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17818798	chr19:14228473	PRKACA	0.56	6.98	0.39	2.39e-11	Gut microbiome composition (summer);
CESC	cis	rs8017423	0.935	rs59444150	chr14:90767175	T/C	cg14092571	chr14:90743983	NA	-0.57	-8.47	-0.46	1.71e-15	Mortality in heart failure;
CESC	cis	rs9649213	0.593	rs7787858	chr7:98009914	T/C	cg00277769	chr7:97922759	BAIAP2L1	-0.32	-5.32	-0.31	2.25e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs3924048	0.559	rs4075303	chr1:12626593	C/G	cg00291366	chr1:12616550	NA	0.37	6.44	0.37	5.6e-10	Optic cup area;
CESC	cis	rs9527	0.567	rs6584539	chr10:104879402	G/C	cg04362960	chr10:104952993	NT5C2	0.44	5.54	0.32	7.12e-8	Arsenic metabolism;
CESC	cis	rs4665809	1.000	rs4665823	chr2:26312723	A/G	cg27170947	chr2:26402098	FAM59B	-0.6	-7.18	-0.4	7.06e-12	Gut microbiome composition (summer);
CESC	cis	rs11122272	0.735	rs2749723	chr1:231493302	A/G	cg06096015	chr1:231504339	EGLN1	0.44	6.43	0.37	5.89e-10	Hemoglobin concentration;
CESC	cis	rs3815700	1.000	rs7260624	chr19:33096562	A/G	cg24916020	chr19:33096688	ANKRD27	0.6	6.04	0.35	5.09e-9	Eosinophilic esophagitis;
CESC	cis	rs514406	0.825	rs6695819	chr1:53223366	T/C	cg08736216	chr1:53307985	ZYG11A	0.42	7.11	0.4	1.06e-11	Monocyte count;
CESC	cis	rs7605378	1.000	rs769957	chr2:200695524	A/C	cg23649088	chr2:200775458	C2orf69	0.51	6.77	0.38	8.4e-11	Osteoporosis;
CESC	cis	rs7129220	0.588	rs34984386	chr11:10095987	A/C	cg01453529	chr11:10209919	SBF2	-0.47	-5.31	-0.31	2.32e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CESC	cis	rs7395581	0.877	rs10838691	chr11:47341729	T/C	cg25783544	chr11:47291846	MADD	0.59	7.72	0.43	2.45e-13	HDL cholesterol;
CESC	cis	rs7666738	0.800	rs13107147	chr4:99028753	C/T	cg18180107	chr4:99064573	C4orf37	0.41	5.32	0.31	2.16e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs11122272	0.735	rs2572248	chr1:231514942	A/G	cg06096015	chr1:231504339	EGLN1	0.43	6.18	0.35	2.46e-9	Hemoglobin concentration;
CESC	cis	rs916888	0.773	rs199439	chr17:44793503	A/G	cg17911788	chr17:44343683	NA	-0.62	-8.21	-0.45	9.49e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs3820068	0.532	rs78917815	chr1:15920821	A/G	cg13390004	chr1:15929781	NA	0.33	5.04	0.3	8.45e-7	Systolic blood pressure;
CESC	cis	rs7917772	0.503	rs7914389	chr10:104295402	T/C	ch.10.2196322F	chr10:104248062	ACTR1A	0.42	5.17	0.3	4.66e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs644799	0.930	rs631099	chr11:95563482	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.55	6.76	0.38	8.51e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs8005677	1.000	rs7145494	chr14:23399790	T/C	cg25600027	chr14:23388339	RBM23	-0.44	-5.37	-0.31	1.69e-7	Cognitive ability (multi-trait analysis);
CESC	cis	rs7618915	0.571	rs2251219	chr3:52584787	C/T	cg18099408	chr3:52552593	STAB1	0.34	5.35	0.31	1.86e-7	Bipolar disorder;
CESC	cis	rs6009527	0.752	rs7288176	chr22:49568462	A/G	cg12746016	chr22:49560550	NA	-0.43	-7.37	-0.41	2.24e-12	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);
CESC	cis	rs55788414	0.932	rs9921666	chr16:81181669	T/C	cg06400318	chr16:81190750	PKD1L2	-0.59	-7.04	-0.4	1.62e-11	Left ventricular obstructive tract defect (maternal effect);
CESC	cis	rs2228479	0.702	rs62052710	chr16:89854893	C/T	cg14709524	chr16:89940631	TCF25	0.94	7.06	0.4	1.5e-11	Skin colour saturation;
CESC	cis	rs3760982	0.585	rs11083724	chr19:44298988	A/G	cg11993925	chr19:44307056	LYPD5	0.34	5.85	0.34	1.45e-8	Breast cancer (estrogen-receptor negative);Breast cancer;
CESC	cis	rs2249694	0.960	rs7084384	chr10:135412322	A/G	cg19469447	chr10:135341870	CYP2E1	0.36	5.09	0.3	6.96e-7	Obesity-related traits;
CESC	trans	rs7672847	0.547	rs72973032	chr4:170368547	A/G	cg19308436	chr1:237949471	RYR2	0.6	6.27	0.36	1.46e-9	Subjective well-being;
CESC	cis	rs1707322	0.717	rs1547925	chr1:46085356	C/T	cg06784218	chr1:46089804	CCDC17	-0.41	-7.25	-0.41	4.45e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs2180341	0.920	rs6916990	chr6:127698759	G/A	cg27446573	chr6:127587934	RNF146	1.05	15.29	0.68	2.96e-38	Breast cancer;
CESC	cis	rs2644899	0.750	rs2607424	chr19:41275147	C/T	cg24958765	chr19:41283667	RAB4B	-0.56	-6.53	-0.37	3.4e-10	Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs561341	0.783	rs512698	chr17:30292507	G/T	cg23018236	chr17:30244563	NA	-0.52	-5.07	-0.3	7.62e-7	Hip circumference adjusted for BMI;
CESC	cis	rs2425143	1.000	rs6060578	chr20:34305445	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.82	-7.62	-0.42	4.5e-13	Blood protein levels;
CESC	cis	rs1005277	0.579	rs2504140	chr10:38387579	T/G	cg25427524	chr10:38739819	LOC399744	-0.66	-9.5	-0.5	1.29e-18	Extrinsic epigenetic age acceleration;
CESC	cis	rs7149337	0.836	rs11622116	chr14:51670744	C/T	cg23942311	chr14:51606299	NA	0.44	7.4	0.41	1.76e-12	Cancer;
CESC	cis	rs12142240	0.698	rs56130131	chr1:46861306	A/C	cg00530320	chr1:46809349	NSUN4	0.6	8.23	0.45	8.35e-15	Menopause (age at onset);
CESC	cis	rs1215050	0.791	rs6838628	chr4:98809574	A/G	cg05340658	chr4:99064831	C4orf37	0.54	7.13	0.4	9.4e-12	Waist-to-hip ratio adjusted for body mass index;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg09556632	chr1:40839764	SMAP2	-0.5	-7.15	-0.4	8.56e-12	Fibrinogen levels;
CESC	cis	rs2836974	0.897	rs2836928	chr21:40543320	C/T	cg11890956	chr21:40555474	PSMG1	1.11	18.04	0.74	5.19e-48	Cognitive function;
CESC	cis	rs2228479	0.681	rs10153055	chr16:89965842	C/T	cg06558623	chr16:89946397	TCF25	0.62	6.19	0.36	2.29e-9	Skin colour saturation;
CESC	cis	rs1707322	0.752	rs4660880	chr1:46111040	C/T	cg06784218	chr1:46089804	CCDC17	0.41	7.24	0.41	4.85e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg04366385	chr4:78980382	FRAS1	0.48	6.24	0.36	1.74e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs13108904	0.967	rs900029	chr4:1279145	C/T	cg22903657	chr4:1355424	KIAA1530	-0.38	-5.17	-0.3	4.56e-7	Obesity-related traits;
CESC	cis	rs6504663	0.558	rs11871603	chr17:48559037	T/G	cg03168497	chr17:48586147	MYCBPAP	0.49	5.91	0.34	1.05e-8	Visceral fat;
CESC	cis	rs4665809	0.590	rs10197494	chr2:26445550	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.1	-12.68	-0.61	4e-29	Gut microbiome composition (summer);
CESC	cis	rs6933660	0.683	rs8180642	chr6:151756612	A/G	cg02564969	chr6:151773285	C6orf211;RMND1	0.6	8.16	0.45	1.38e-14	Menarche (age at onset);
CESC	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg11301795	chr4:187892539	NA	-0.75	-12.33	-0.6	6.74e-28	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7772486	0.790	rs9376970	chr6:146241472	A/C	cg23711669	chr6:146136114	FBXO30	-0.93	-14.33	-0.66	6.91e-35	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6540559	0.673	rs6698154	chr1:210007777	A/G	cg22029157	chr1:209979665	IRF6	0.7	7.81	0.43	1.36e-13	Cleft lip with or without cleft palate;
CESC	cis	rs7408868	1.000	rs10415431	chr19:15277027	G/A	cg14696996	chr19:15285081	NOTCH3	1.11	11.51	0.58	3.92e-25	Pulse pressure;
CESC	cis	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg01055000	chr16:56763872	NUP93	-0.35	-5.14	-0.3	5.25e-7	Gambling;
CESC	cis	rs7618501	0.602	rs2624816	chr3:50117312	T/G	cg24308560	chr3:49941425	MST1R	0.61	8.83	0.48	1.49e-16	Intelligence (multi-trait analysis);
CESC	cis	rs832540	0.931	rs33318	chr5:56208414	G/T	cg14703610	chr5:56206110	C5orf35	0.53	6.94	0.39	3e-11	Coronary artery disease;
CESC	trans	rs11148252	0.557	rs9536223	chr13:53233194	A/T	cg18335740	chr13:41363409	SLC25A15	0.52	7.02	0.4	1.89e-11	Lewy body disease;
CESC	cis	rs7726839	0.526	rs11960159	chr5:568685	C/T	cg09021430	chr5:549028	NA	-0.46	-6.33	-0.36	1.04e-9	Obesity-related traits;
CESC	cis	rs2832191	0.671	rs2832213	chr21:30512914	A/G	cg24692254	chr21:30365293	RNF160	-0.61	-7.74	-0.43	2.16e-13	Dental caries;
CESC	cis	rs4808199	0.948	rs2074301	chr19:19381715	G/A	cg03709012	chr19:19516395	GATAD2A	1.09	12.01	0.59	7.83e-27	Nonalcoholic fatty liver disease;
CESC	cis	rs16854884	1.000	rs11924473	chr3:143787075	C/G	cg06585982	chr3:143692056	C3orf58	0.44	5.08	0.3	7.07e-7	Economic and political preferences (feminism/equality);
CESC	cis	rs7666738	0.791	rs62318641	chr4:98816964	T/C	cg05340658	chr4:99064831	C4orf37	0.7	9.81	0.52	1.38e-19	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2072499	0.778	rs2842868	chr1:156196407	A/C	cg24450063	chr1:156163899	SLC25A44	0.86	11.49	0.58	4.77e-25	Testicular germ cell tumor;
CESC	cis	rs1062177	0.826	rs2915879	chr5:151147442	A/G	cg12924095	chr5:151150029	G3BP1	0.42	5.55	0.32	6.93e-8	Preschool internalizing problems;
CESC	trans	rs3857536	0.566	rs208463	chr6:66913962	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.56	-6.71	-0.38	1.21e-10	Blood trace element (Cu levels);
CESC	cis	rs3540	0.553	rs4031431	chr15:90990782	G/T	cg10434728	chr15:90938212	IQGAP1	0.41	7.38	0.41	2.03e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs7592578	0.771	rs10432434	chr2:191387079	T/G	cg10560079	chr2:191398806	TMEM194B	-0.69	-6.18	-0.35	2.39e-9	Diastolic blood pressure;
CESC	cis	rs155076	0.666	rs2015241	chr13:21888254	A/G	cg11317459	chr13:21872234	NA	1.21	15.32	0.69	2.21e-38	White matter hyperintensity burden;
CESC	trans	rs11098499	0.690	rs34818745	chr4:120257055	T/C	cg25214090	chr10:38739885	LOC399744	0.67	9.15	0.49	1.54e-17	Corneal astigmatism;
CESC	trans	rs2727020	0.658	rs4980442	chr11:49445016	G/T	cg03929089	chr4:120376271	NA	-0.81	-12.62	-0.61	6.51e-29	Coronary artery disease;
CESC	cis	rs514406	0.708	rs514881	chr1:53336737	A/G	cg16325326	chr1:53192061	ZYG11B	-0.61	-9.42	-0.5	2.35e-18	Monocyte count;
CESC	cis	rs7208859	0.623	rs11651857	chr17:28926362	G/T	cg14008862	chr17:28927542	LRRC37B2	0.73	5.52	0.32	8.23e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs12701220	0.817	rs1058727	chr7:1087095	A/G	cg26769984	chr7:1090371	C7orf50	0.54	6.54	0.37	3.14e-10	Bronchopulmonary dysplasia;
CESC	cis	rs2820292	1.000	rs1032524	chr1:201790826	C/T	cg11586189	chr1:201857591	SHISA4	-0.32	-5.38	-0.31	1.65e-7	Waist circumference;Body mass index (joint analysis main effects and smoking interaction);Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);
CESC	trans	rs208520	0.526	rs9354370	chr6:66808209	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.11	23.98	0.83	2.35e-68	Exhaled nitric oxide output;
CESC	cis	rs9894429	1.000	rs7213129	chr17:79581573	C/T	cg13777783	chr17:79615861	NA	-0.35	-5.79	-0.34	1.99e-8	Eye color traits;
CESC	cis	rs7945705	0.967	rs10840148	chr11:8923528	C/T	cg12365402	chr11:9010492	NRIP3	0.4	6.09	0.35	3.86e-9	Hemoglobin concentration;
CESC	cis	rs76878669	0.561	rs10896112	chr11:66116836	G/C	cg18002602	chr11:66138449	SLC29A2	-0.41	-6.77	-0.38	8.14e-11	Educational attainment (years of education);
CESC	cis	rs2404602	0.692	rs7169663	chr15:77192843	A/C	cg26408565	chr15:76604113	ETFA	-0.39	-5.67	-0.33	3.72e-8	Blood metabolite levels;
CESC	cis	rs4253772	0.938	rs41371446	chr22:46637272	T/C	cg00784671	chr22:46762841	CELSR1	-0.57	-5.63	-0.33	4.54e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs9560113	0.622	rs4773388	chr13:112195250	A/C	cg10483660	chr13:112241077	NA	0.37	6.15	0.35	2.92e-9	Menarche (age at onset);
CESC	cis	rs780096	0.565	rs780104	chr2:27677691	G/A	cg02592271	chr2:27665507	KRTCAP3	-0.29	-5.79	-0.34	2e-8	Total body bone mineral density;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13561339	chr22:27282899	NA	-0.58	-7.09	-0.4	1.2e-11	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.791	rs1830231	chr4:99026185	A/C	cg18180107	chr4:99064573	C4orf37	0.42	5.43	0.32	1.29e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs116095464	0.558	rs10057299	chr5:242135	C/T	cg00938859	chr5:1591904	SDHAP3	0.64	6.98	0.39	2.36e-11	Breast cancer;
CESC	cis	rs5758659	1.000	rs134902	chr22:42683997	C/T	cg15557168	chr22:42548783	NA	-0.44	-7.2	-0.4	6.16e-12	Cognitive function;
CESC	cis	rs780096	0.526	rs780102	chr2:27659491	T/C	cg12648201	chr2:27665141	KRTCAP3	-0.35	-6.56	-0.37	2.79e-10	Total body bone mineral density;
CESC	cis	rs4665809	1.000	rs2891490	chr2:26325927	T/C	cg26314531	chr2:26401878	FAM59B	-0.61	-6.86	-0.39	4.88e-11	Gut microbiome composition (summer);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg21830805	chr14:91087524	TTC7B	0.44	6.16	0.35	2.7e-9	Fibrinogen levels;
CESC	cis	rs6461049	0.800	rs1860831	chr7:2160931	T/C	cg08027265	chr7:2291960	NA	-0.43	-6.62	-0.38	1.94e-10	Schizophrenia;
CESC	cis	rs870825	0.556	rs6552811	chr4:185653351	T/A	cg04058563	chr4:185651563	MLF1IP	-0.63	-6.94	-0.39	3.04e-11	Blood protein levels;
CESC	cis	rs116095464	0.558	rs10475136	chr5:232796	A/G	cg22857025	chr5:266934	NA	-1.29	-18.24	-0.75	1.01e-48	Breast cancer;
CESC	cis	rs7647973	0.580	rs2117938	chr3:49263850	A/G	cg07636037	chr3:49044803	WDR6	-0.82	-14.18	-0.66	2.46e-34	Menarche (age at onset);
CESC	cis	rs2249625	0.874	rs1852705	chr6:72875512	G/T	cg18830697	chr6:72922368	RIMS1	-0.43	-6.23	-0.36	1.85e-9	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CESC	cis	rs748404	0.697	rs513970	chr15:43579566	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.59	7.88	0.44	8.43e-14	Lung cancer;
CESC	cis	rs478222	1.000	rs478222	chr2:25301755	A/T	cg01884057	chr2:25150051	NA	-0.32	-5.54	-0.32	7.11e-8	Type 1 diabetes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12314527	chr22:19110193	DGCR2	0.56	6.33	0.36	1.02e-9	Gut microbiome composition (summer);
CESC	cis	rs846111	1.000	rs846111	chr1:6279370	G/C	cg15892785	chr1:6309343	GPR153	-0.68	-8.39	-0.46	2.89e-15	QT interval;
CESC	cis	rs7666738	0.830	rs7678567	chr4:99057346	A/G	cg17366294	chr4:99064904	C4orf37	0.6	8.4	0.46	2.66e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg26338869	chr17:61819248	STRADA	0.72	9.35	0.5	3.89e-18	Prudent dietary pattern;
CESC	cis	rs10129255	0.957	rs10142918	chr14:107190443	C/A	cg23076370	chr14:107095027	NA	-0.46	-5.79	-0.34	1.96e-8	Kawasaki disease;
CESC	cis	rs2439831	0.867	rs2264876	chr15:43757419	G/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.89	10.57	0.54	5.08e-22	Lung cancer in ever smokers;
CESC	cis	rs875971	0.540	rs736270	chr7:65428822	T/C	cg05332525	chr7:65337924	VKORC1L1	0.52	6.28	0.36	1.36e-9	Aortic root size;
CESC	cis	rs2276314	0.857	rs6507157	chr18:33631703	A/C	cg19628046	chr18:33552617	C18orf21	0.5	5.49	0.32	9.61e-8	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs7208859	0.623	rs58089675	chr17:29196764	C/G	cg19761014	chr17:28927070	LRRC37B2	0.72	5.71	0.33	3.06e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg11905131	chr22:24372483	LOC391322	0.72	10.6	0.55	3.98e-22	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs3820068	0.581	rs34453754	chr1:15993208	G/C	cg17385448	chr1:15911702	AGMAT	0.45	7.37	0.41	2.21e-12	Systolic blood pressure;
CESC	cis	rs72781680	0.566	rs6713865	chr2:23899807	A/G	cg20701182	chr2:24300061	SF3B14	0.71	7.18	0.4	7.24e-12	Lymphocyte counts;
CESC	cis	rs9322193	0.884	rs9688699	chr6:150054816	A/G	cg07701084	chr6:150067640	NUP43	0.44	6.04	0.35	5.26e-9	Lung cancer;
CESC	cis	rs3947	0.789	rs8005	chr8:11701096	A/C	cg00262122	chr8:11665843	FDFT1	0.55	6.55	0.37	3e-10	Blood protein levels;
CESC	cis	rs911555	0.692	rs7140647	chr14:103893465	A/G	cg12935359	chr14:103987150	CKB	0.63	9.4	0.5	2.68e-18	Intelligence (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26599274	chr7:66205733	RABGEF1	0.63	6.85	0.39	5.28e-11	Gut microbiome composition (summer);
CESC	cis	rs6665290	0.868	rs2183836	chr1:227199404	A/T	cg10327440	chr1:227177885	CDC42BPA	-1.21	-29.63	-0.88	4.28e-86	Myeloid white cell count;
CESC	cis	rs875971	0.638	rs7793569	chr7:66116633	T/G	cg25985355	chr7:65971099	NA	0.32	5.23	0.31	3.53e-7	Aortic root size;
CESC	cis	rs17376456	0.825	rs6877030	chr5:93201841	C/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.63	5.37	0.31	1.74e-7	Diabetic retinopathy;
CESC	cis	rs2832191	0.791	rs2832179	chr21:30480366	C/T	cg24692254	chr21:30365293	RNF160	-0.8	-12.52	-0.61	1.4e-28	Dental caries;
CESC	cis	rs1451375	0.572	rs66792686	chr7:50651239	T/C	cg14593290	chr7:50529359	DDC	0.44	5.29	0.31	2.55e-7	Malaria;
CESC	cis	rs644799	0.965	rs573758	chr11:95539591	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	9.15	0.49	1.61e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	7.83	0.43	1.17e-13	Prudent dietary pattern;
CESC	cis	rs1878931	0.501	rs4785934	chr16:3419934	G/T	cg22508957	chr16:3507546	NAT15	-0.38	-5.5	-0.32	9.16e-8	Body mass index (adult);
CESC	cis	rs7666738	0.753	rs7659724	chr4:98944063	C/T	cg05340658	chr4:99064831	C4orf37	0.82	12.52	0.61	1.45e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10949834	0.793	rs810534	chr7:73505045	A/G	cg07137043	chr7:73588983	EIF4H	0.69	7.52	0.42	8.28e-13	Verbal memory performance (residualized delayed recall change);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06558623	chr16:89946397	TCF25	-0.57	-6.62	-0.38	1.94e-10	Gut microbiome composition (summer);
CESC	cis	rs2180341	0.814	rs9401958	chr6:127736357	T/G	cg24812749	chr6:127587940	RNF146	0.84	12.05	0.59	5.93e-27	Breast cancer;
CESC	cis	rs9815354	0.680	rs115754309	chr3:42017246	A/G	cg03022575	chr3:42003672	ULK4	0.74	6.64	0.38	1.79e-10	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs9715521	0.868	rs6856620	chr4:59820960	A/G	cg11281224	chr4:60001000	NA	-0.52	-6.68	-0.38	1.4e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs9443645	0.687	rs6915558	chr6:79769056	A/T	cg05283184	chr6:79620031	NA	-0.44	-6.75	-0.38	9.41e-11	Intelligence (multi-trait analysis);
CESC	cis	rs56235845	0.694	rs11749830	chr5:176766547	G/A	cg16006841	chr5:176797999	RGS14	0.43	5.17	0.3	4.68e-7	Hemoglobin concentration;Hematocrit;
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg01092528	chr4:76861103	NAAA	-0.45	-6.22	-0.36	1.96e-9	Height;
CESC	cis	rs7149242	0.961	rs7142683	chr14:101158882	A/G	cg18089426	chr14:101175970	NA	-0.36	-5.92	-0.34	9.74e-9	Platelet count;
CESC	cis	rs1799949	1.000	rs12944458	chr17:41180772	C/T	cg05368731	chr17:41323189	NBR1	0.8	10.6	0.55	4.09e-22	Menopause (age at onset);
CESC	cis	rs4689388	0.926	rs11725494	chr4:6293855	C/T	cg00701064	chr4:6280414	WFS1	0.73	12.79	0.62	1.69e-29	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs4665809	0.525	rs4665324	chr2:26447147	A/C	cg22920501	chr2:26401640	FAM59B	-0.91	-10.38	-0.54	2.08e-21	Gut microbiome composition (summer);
CESC	cis	rs10416265	0.527	rs11084699	chr19:33538393	A/T	cg03563238	chr19:33554763	RHPN2	-0.31	-5.56	-0.32	6.42e-8	Bone properties (heel);
CESC	cis	rs684232	0.666	rs838371	chr17:609275	T/C	cg15660573	chr17:549704	VPS53	-0.67	-9.32	-0.5	4.84e-18	Prostate cancer;
CESC	trans	rs2727020	0.576	rs10839305	chr11:49598733	T/C	cg15704280	chr7:45808275	SEPT13	-0.96	-17.33	-0.73	1.73e-45	Coronary artery disease;
CESC	cis	rs1568889	0.887	rs7102237	chr11:28344296	A/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.82	13.94	0.65	1.67e-33	Bipolar disorder;
CESC	cis	rs11122272	0.735	rs2486736	chr1:231521478	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.48	6.3	0.36	1.2e-9	Hemoglobin concentration;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19721211	chr15:51058100	SPPL2A	0.58	6.77	0.38	8.48e-11	Gut microbiome composition (summer);
CESC	cis	rs2997447	0.761	rs61776586	chr1:26438933	T/C	cg24596570	chr1:26146463	FAM54B;LOC646471	0.62	5.33	0.31	2.07e-7	QRS complex (12-leadsum);
CESC	cis	rs6951245	0.882	rs56048221	chr7:1092533	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.44	-5.06	-0.3	7.76e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs4563143	0.675	rs56123392	chr19:29255631	A/C	cg14983838	chr19:29218262	NA	0.49	6.01	0.35	6.12e-9	Methadone dose in opioid dependence;
CESC	cis	rs6460942	0.597	rs4721106	chr7:12535053	T/C	cg02935154	chr7:12443704	VWDE	-0.57	-5.7	-0.33	3.23e-8	Coronary artery disease;
CESC	cis	rs736408	0.812	rs1076425	chr3:52825462	A/G	cg05564831	chr3:52568323	NT5DC2	0.46	6.61	0.38	2.14e-10	Bipolar disorder;
CESC	cis	rs7927771	0.965	rs12787112	chr11:47687147	A/G	cg18512352	chr11:47633146	NA	-0.6	-9.47	-0.5	1.58e-18	Subjective well-being;
CESC	cis	rs4665809	1.000	rs6729080	chr2:26301282	G/A	cg25036284	chr2:26402008	FAM59B	-0.61	-7.08	-0.4	1.31e-11	Gut microbiome composition (summer);
CESC	cis	rs10870270	0.957	rs10870307	chr10:133780610	T/C	cg08754478	chr10:133766260	PPP2R2D	-0.59	-7.56	-0.42	6.51e-13	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs832540	0.669	rs173764	chr5:56198920	C/T	cg24531977	chr5:56204891	C5orf35	-0.55	-7.25	-0.41	4.69e-12	Coronary artery disease;
CESC	cis	rs4065321	0.522	rs3744245	chr17:38146542	C/G	cg17344932	chr17:38183730	MED24;SNORD124	0.6	8.97	0.48	5.57e-17	White blood cell count (basophil);White blood cell count;
CESC	cis	rs7539409	0.915	rs1977119	chr1:84275509	A/G	cg10977910	chr1:84465055	TTLL7	0.63	5.8	0.34	1.88e-8	Alzheimer's disease;
CESC	cis	rs559928	0.606	rs60394481	chr11:63909035	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.68	6.06	0.35	4.55e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
CESC	cis	rs12477438	0.798	rs1453562	chr2:99615850	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.75	-10.87	-0.56	5.17e-23	Chronic sinus infection;
CESC	cis	rs10504229	0.609	rs66477547	chr8:58105763	A/C	cg21724239	chr8:58056113	NA	0.57	5.91	0.34	1.02e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs116095464	0.619	rs2303741	chr5:218356	T/C	cg12570787	chr5:219185	SDHA;CCDC127	0.53	5.74	0.33	2.63e-8	Breast cancer;
CESC	cis	rs7208859	0.673	rs450585	chr17:28951039	G/A	cg04154034	chr17:28927549	LRRC37B2	0.68	6.1	0.35	3.76e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs7647973	0.925	rs9881860	chr3:49352522	A/T	cg07636037	chr3:49044803	WDR6	0.66	8.85	0.48	1.27e-16	Menarche (age at onset);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04436474	chr3:49977685	RBM6	0.5	6.44	0.37	5.55e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs7100689	0.599	rs7077847	chr10:82134952	A/G	cg00277334	chr10:82204260	NA	-0.58	-7.52	-0.42	8.77e-13	Post bronchodilator FEV1;
CESC	cis	rs7651039	1.000	rs7651039	chr3:15648004	C/T	cg16303742	chr3:15540471	COLQ	-0.32	-5.03	-0.3	9e-7	Coronary heart disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06159435	chr11:118966351	H2AFX	0.6	7.05	0.4	1.55e-11	Gut microbiome composition (summer);
CESC	cis	rs4803468	1.000	rs2569754	chr19:41936734	A/G	cg09537434	chr19:41945824	ATP5SL	-1.13	-21.98	-0.8	1.19e-61	Height;
CESC	cis	rs7772486	0.875	rs2814866	chr6:146339414	C/A	cg05347473	chr6:146136440	FBXO30	0.5	6.7	0.38	1.23e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs11642862	0.901	rs11642733	chr16:30969061	G/A	cg02466173	chr16:30829666	NA	-0.57	-5.21	-0.3	3.81e-7	Tonsillectomy;
CESC	cis	rs8092503	1.000	rs12956208	chr18:52473167	C/T	cg12377874	chr18:52495404	RAB27B	0.37	6.0	0.35	6.52e-9	Childhood body mass index;
CESC	cis	rs9300255	0.602	rs1716172	chr12:123712712	G/T	cg19016782	chr12:123741754	C12orf65	-0.47	-6.7	-0.38	1.26e-10	Neutrophil percentage of white cells;
CESC	trans	rs12492269	0.702	rs41381644	chr3:178161614	A/G	cg04062383	chr3:179370420	USP13	-0.7	-6.07	-0.35	4.45e-9	Plasma clusterin levels;
CESC	cis	rs9486719	1.000	rs13207333	chr6:96882254	T/C	cg06623918	chr6:96969491	KIAA0776	-0.81	-8.29	-0.45	5.61e-15	Migraine;Coronary artery disease;
CESC	cis	rs7580658	0.891	rs55998967	chr2:128048674	A/C	cg10021288	chr2:128175891	PROC	-0.41	-6.53	-0.37	3.32e-10	Protein C levels;
CESC	cis	rs2836974	0.583	rs2776306	chr21:40713754	A/G	cg11644478	chr21:40555479	PSMG1	0.61	8.3	0.45	5.41e-15	Cognitive function;
CESC	cis	rs6912958	0.559	rs451829	chr6:88041919	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.45	7.86	0.43	9.86e-14	Monocyte percentage of white cells;
CESC	trans	rs2488397	0.750	rs6702421	chr1:197559324	C/T	cg13426224	chr12:133196447	P2RX2	-0.46	-6.0	-0.35	6.37e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs11077998	0.840	rs9910991	chr17:80481193	G/A	cg10255544	chr17:80519551	FOXK2	0.52	8.45	0.46	1.9e-15	Reticulocyte fraction of red cells;
CESC	cis	rs854765	0.583	rs67253360	chr17:17828973	T/C	cg04398451	chr17:18023971	MYO15A	-0.67	-9.6	-0.51	6.42e-19	Total body bone mineral density;
CESC	cis	rs60154123	0.730	rs588197	chr1:210463515	A/T	cg22029157	chr1:209979665	IRF6	0.47	5.95	0.34	8.53e-9	Coronary artery disease;
CESC	cis	rs6089584	0.888	rs2892060	chr20:60617955	G/T	cg13770153	chr20:60521292	NA	-0.44	-5.7	-0.33	3.2e-8	Body mass index;
CESC	cis	rs3092073	0.624	rs34293711	chr20:44587186	C/T	cg17986701	chr20:44574422	PCIF1	0.34	5.31	0.31	2.27e-7	Intelligence (multi-trait analysis);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg12416067	chr10:70231662	DNA2	-0.48	-6.1	-0.35	3.79e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs11122272	0.735	rs2474630	chr1:231535335	G/A	cg06096015	chr1:231504339	EGLN1	0.43	6.15	0.35	2.9e-9	Hemoglobin concentration;
CESC	cis	rs7208859	0.623	rs9899692	chr17:29156939	C/T	cg13385521	chr17:29058706	SUZ12P	0.75	6.0	0.35	6.29e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs7520050	0.966	rs12561806	chr1:46396776	C/T	cg03146154	chr1:46216737	IPP	-0.47	-6.1	-0.35	3.66e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs4660306	0.961	rs11211138	chr1:46015157	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.58	-7.11	-0.4	1.05e-11	Homocysteine levels;
CESC	cis	rs898097	0.585	rs9892342	chr17:80893029	C/T	cg10494973	chr17:80897199	TBCD	-0.48	-6.0	-0.35	6.41e-9	Breast cancer;
CESC	cis	rs2073300	1.000	rs12625804	chr20:23441981	G/A	cg12062639	chr20:23401060	NAPB	0.91	6.41	0.37	6.71e-10	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs10911232	0.507	rs10911196	chr1:182995233	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.84	13.19	0.63	6.74e-31	Hypertriglyceridemia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00529946	chr2:26568848	SELI;GPR113	0.58	6.85	0.39	5.14e-11	Gut microbiome composition (summer);
CESC	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg21280719	chr6:42927975	GNMT	-0.27	-6.32	-0.36	1.07e-9	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs1790761	0.505	rs2370141	chr11:67348529	A/G	cg14500267	chr11:67383377	NA	-0.31	-5.12	-0.3	5.81e-7	Mean corpuscular volume;
CESC	cis	rs6582630	0.537	rs7310749	chr12:38400472	C/T	cg26384229	chr12:38710491	ALG10B	0.72	11.03	0.56	1.58e-23	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs9733	0.519	rs7521898	chr1:150707596	G/A	cg22823121	chr1:150693482	HORMAD1	0.47	6.89	0.39	4.04e-11	Tonsillectomy;
CESC	cis	rs425277	0.606	rs451061	chr1:2075068	C/G	cg24578937	chr1:2090814	PRKCZ	0.36	6.41	0.37	6.69e-10	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09171577	chr7:150778137	FASTK	-0.55	-6.39	-0.37	7.34e-10	Gut microbiome composition (summer);
CESC	cis	rs67478160	0.619	rs12437066	chr14:104236844	A/C	cg08213375	chr14:104286397	PPP1R13B	0.47	9.08	0.49	2.53e-17	Schizophrenia;
CESC	cis	rs7666738	0.515	rs11733968	chr4:98906448	A/C	cg17366294	chr4:99064904	C4orf37	-0.49	-6.56	-0.37	2.76e-10	Colonoscopy-negative controls vs population controls;
CESC	cis	rs372883	0.600	rs2832293	chr21:30738872	C/G	cg24692254	chr21:30365293	RNF160	0.57	7.15	0.4	8.65e-12	Pancreatic cancer;
CESC	cis	rs9457247	1.000	rs400837	chr6:167411008	T/C	cg07741184	chr6:167504864	NA	0.3	5.52	0.32	8.06e-8	Crohn's disease;
CESC	cis	rs35995292	0.534	rs7793692	chr7:38940580	G/C	cg19327137	chr7:38886074	VPS41	0.66	10.8	0.55	9.13e-23	Subjective well-being (multi-trait analysis);
CESC	cis	rs35110281	0.805	rs2838319	chr21:44991901	A/G	cg01579765	chr21:45077557	HSF2BP	-0.58	-10.01	-0.52	3.14e-20	Mean corpuscular volume;
CESC	cis	rs897984	0.806	rs8050588	chr16:30937799	G/A	cg00531865	chr16:30841666	NA	-0.51	-7.1	-0.4	1.12e-11	Dementia with Lewy bodies;
CESC	cis	rs1881797	1.000	rs10158379	chr1:247686352	C/A	cg11166453	chr1:247681781	NA	0.44	5.77	0.33	2.24e-8	Acute lymphoblastic leukemia (childhood);
CESC	trans	rs7555006	0.671	rs11580026	chr1:51476003	A/T	cg20701182	chr2:24300061	SF3B14	0.49	6.2	0.36	2.13e-9	Headache;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.53	-6.01	-0.35	6.18e-9	Gut microbiome composition (summer);
CESC	cis	rs35955747	0.601	rs5749302	chr22:31950618	C/T	cg25791279	chr22:32026902	PISD	0.44	5.16	0.3	4.91e-7	Neutrophil count;Sum basophil neutrophil counts;
CESC	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	7.69	0.43	2.83e-13	Prudent dietary pattern;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg14475772	chr1:150207136	ANP32E	-0.48	-7.87	-0.44	9.14e-14	Gambling;
CESC	cis	rs801193	0.548	rs2109297	chr7:66122384	G/A	cg11764359	chr7:65958608	NA	-0.73	-10.48	-0.54	1.01e-21	Aortic root size;
CESC	cis	rs7605378	0.528	rs1704190	chr2:200760629	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.47	5.1	0.3	6.51e-7	Osteoporosis;
CESC	cis	rs9322193	0.884	rs1108889	chr6:150166569	A/G	cg04369109	chr6:150039330	LATS1	-0.41	-5.39	-0.31	1.56e-7	Lung cancer;
CESC	cis	rs514406	0.861	rs505444	chr1:53251860	C/T	cg16325326	chr1:53192061	ZYG11B	0.86	14.92	0.68	6.06e-37	Monocyte count;
CESC	cis	rs514406	0.929	rs515857	chr1:53336859	A/G	cg24675658	chr1:53192096	ZYG11B	-0.55	-6.84	-0.39	5.33e-11	Monocyte count;
CESC	cis	rs9837602	0.938	rs793457	chr3:99518987	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.56	-7.39	-0.41	1.89e-12	Breast cancer;
CESC	cis	rs7666738	0.830	rs6852015	chr4:99054373	C/A	cg18180107	chr4:99064573	C4orf37	0.41	5.29	0.31	2.51e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10129255	0.500	rs10143385	chr14:107190796	G/A	cg23076370	chr14:107095027	NA	-0.65	-9.64	-0.51	4.66e-19	Kawasaki disease;
CESC	cis	rs10540	1.000	rs61876339	chr11:495283	T/C	cg03934478	chr11:495069	RNH1	0.58	5.58	0.32	6.07e-8	Body mass index;
CESC	cis	rs2795502	0.938	rs2744085	chr10:43341976	C/T	cg27426351	chr10:43362370	NA	0.44	5.62	0.33	4.89e-8	Blood protein levels;
CESC	cis	rs2836974	0.897	rs35064900	chr21:40555492	A/G	cg17971929	chr21:40555470	PSMG1	1.07	16.73	0.72	2.16e-43	Cognitive function;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21983178	chr1:45120676	TMEM53	-0.58	-6.44	-0.37	5.73e-10	Gut microbiome composition (summer);
CESC	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg26338869	chr17:61819248	STRADA	0.69	9.1	0.49	2.2e-17	Prudent dietary pattern;
CESC	cis	rs8177253	1.000	rs8177253	chr3:133480192	A/G	cg01448562	chr3:133502909	NA	0.42	5.89	0.34	1.14e-8	Iron status biomarkers;
CESC	cis	rs6952808	0.501	rs3778999	chr7:2180885	G/A	cg21782813	chr7:2030301	MAD1L1	0.5	7.07	0.4	1.37e-11	Bipolar disorder and schizophrenia;
CESC	trans	rs9850225	0.719	rs4856616	chr3:80466481	A/C	cg13866129	chr11:62623438	SNORD27;SLC3A2;SNORD28;SNORD25;SNORD26;SNHG1	0.38	6.07	0.35	4.39e-9	Erectile dysfunction in type 1 diabetes;
CESC	cis	rs9948	0.786	rs6756482	chr2:97458561	A/G	cg01990225	chr2:97406019	LMAN2L	-0.73	-6.8	-0.39	7.02e-11	Erectile dysfunction and prostate cancer treatment;
CESC	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg24846343	chr22:24311635	DDTL	0.66	11.43	0.57	7.31e-25	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs10751667	0.666	rs7123912	chr11:963936	T/C	cg01483505	chr11:975446	AP2A2	0.36	5.05	0.3	8.13e-7	Alzheimer's disease (late onset);
CESC	cis	rs73110464	0.609	rs6580923	chr12:53358352	A/G	cg05393297	chr12:53359155	NA	-0.72	-10.41	-0.54	1.64e-21	Cancer (pleiotropy);
CESC	cis	rs10479542	0.892	rs7736163	chr5:178980316	G/C	cg22764044	chr5:178986830	RUFY1	0.45	6.78	0.38	7.76e-11	Lung cancer;
CESC	cis	rs9393777	0.588	rs6926677	chr6:26478825	G/C	cg12826209	chr6:26865740	GUSBL1	0.57	6.77	0.38	8.32e-11	Intelligence (multi-trait analysis);
CESC	cis	rs9549260	0.755	rs7317254	chr13:41217849	A/G	cg21288729	chr13:41239152	FOXO1	0.68	8.81	0.48	1.67e-16	Red blood cell count;
CESC	cis	rs2576037	0.583	rs8086286	chr18:44467515	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.53	7.27	0.41	4.02e-12	Personality dimensions;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21194341	chr7:76256835	POMZP3;LOC100133091	-0.57	-6.3	-0.36	1.24e-9	Gut microbiome composition (summer);
CESC	cis	rs9309711	0.883	rs13429373	chr2:3477014	G/A	cg10845886	chr2:3471009	TTC15	-0.86	-12.03	-0.59	6.73e-27	Neurofibrillary tangles;
CESC	cis	rs3820068	0.603	rs932602	chr1:15986087	A/G	cg18133145	chr1:16060689	PLEKHM2	-0.39	-5.04	-0.3	8.55e-7	Systolic blood pressure;
CESC	cis	rs3740713	1.000	rs57311859	chr11:18454410	A/C	cg23797887	chr11:18477753	LDHAL6A	-0.53	-5.27	-0.31	2.89e-7	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs1008375	0.966	rs28441502	chr4:17598384	G/A	cg04450456	chr4:17643702	FAM184B	0.36	5.04	0.3	8.73e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs79349575	0.783	rs17708633	chr17:47011620	C/G	cg16584676	chr17:46985605	UBE2Z	0.54	6.67	0.38	1.46e-10	Type 2 diabetes;
CESC	cis	rs3820928	0.904	rs59135978	chr2:227857763	T/C	cg11843606	chr2:227700838	RHBDD1	-0.4	-5.1	-0.3	6.47e-7	Pulmonary function;
CESC	cis	rs10883723	0.810	rs10786671	chr10:104271303	G/A	cg22532475	chr10:104410764	TRIM8	-0.33	-5.68	-0.33	3.5e-8	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs736408	0.609	rs2230535	chr3:52800284	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	6.64	0.38	1.73e-10	Bipolar disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07518170	chr20:30865285	KIF3B	0.59	6.94	0.39	3.07e-11	Gut microbiome composition (summer);
CESC	cis	rs17376456	0.741	rs12374432	chr5:93481348	C/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.63	5.33	0.31	2.11e-7	Diabetic retinopathy;
CESC	cis	rs6594499	0.872	rs6881147	chr5:110451936	G/C	cg04022379	chr5:110408740	TSLP	0.32	5.63	0.33	4.49e-8	Allergic disease (asthma, hay fever or eczema);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03426840	chr11:118661678	DDX6	0.56	6.81	0.39	6.52e-11	Gut microbiome composition (summer);
CESC	cis	rs3617	0.572	rs2256332	chr3:52855865	A/G	cg07507251	chr3:52567010	NT5DC2	-0.31	-5.17	-0.3	4.62e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
CESC	cis	rs7809950	1.000	rs987391	chr7:107100794	C/G	cg23024343	chr7:107201750	COG5	-0.4	-5.65	-0.33	4.11e-8	Coronary artery disease;
CESC	cis	rs2836974	0.931	rs2776309	chr21:40715791	A/G	cg27266027	chr21:40555129	PSMG1	0.46	5.29	0.31	2.58e-7	Cognitive function;
CESC	trans	rs7618501	0.633	rs9861216	chr3:50059339	A/G	cg21659725	chr3:3221576	CRBN	-0.48	-6.81	-0.39	6.52e-11	Intelligence (multi-trait analysis);
CESC	cis	rs875971	0.505	rs1167385	chr7:65513308	G/A	cg06456125	chr7:65229604	NA	-0.48	-6.33	-0.36	1.04e-9	Aortic root size;
CESC	cis	rs7666738	0.830	rs6817645	chr4:99016054	T/C	cg05340658	chr4:99064831	C4orf37	0.8	12.51	0.61	1.52e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7568458	0.684	rs60012532	chr2:85752474	A/C	cg02493740	chr2:85810744	VAMP5	-0.58	-8.46	-0.46	1.8e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CESC	cis	rs9911578	0.967	rs11079368	chr17:57086473	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.39	-5.15	-0.3	4.97e-7	Intelligence (multi-trait analysis);
CESC	cis	rs2839186	0.814	rs2276257	chr21:47711229	A/G	cg10351095	chr21:47802916	PCNT	-0.5	-6.78	-0.38	7.62e-11	Testicular germ cell tumor;
CESC	cis	rs3091242	0.933	rs61775174	chr1:25787313	G/A	cg02931644	chr1:25747376	RHCE	-0.39	-6.44	-0.37	5.56e-10	Erythrocyte sedimentation rate;
CESC	trans	rs60843830	0.964	rs62114538	chr2:256116	G/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.64	8.04	0.44	2.99e-14	Spherical equivalent (joint analysis main effects and education interaction);
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg12317515	chr5:74063363	GFM2;NSA2	-0.42	-6.28	-0.36	1.42e-9	Vertical cup-disc ratio;
CESC	cis	rs36051895	0.588	rs12340895	chr9:5076691	C/G	cg02405213	chr9:5042618	JAK2	0.5	6.15	0.35	2.85e-9	Pediatric autoimmune diseases;
CESC	cis	rs10411936	1.000	rs7256818	chr19:16558766	C/A	cg10248733	chr19:16607483	C19orf44;CALR3	-0.54	-6.39	-0.37	7.33e-10	White blood cell count;Multiple sclerosis;
CESC	cis	rs8070128	0.601	rs8080602	chr17:17954728	G/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.62	-8.81	-0.48	1.7e-16	Total body bone mineral density;
CESC	trans	rs637571	0.584	rs594689	chr11:65635559	G/A	cg17712092	chr4:129076599	LARP1B	-0.67	-8.41	-0.46	2.64e-15	Eosinophil percentage of white cells;
CESC	cis	rs10883723	0.810	rs7092622	chr10:104249919	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.54	7.44	0.42	1.43e-12	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs1862618	0.853	rs866222	chr5:56184444	T/C	cg22800045	chr5:56110881	MAP3K1	0.81	9.66	0.51	4.1e-19	Initial pursuit acceleration;
CESC	cis	rs7552404	0.924	rs7546641	chr1:76158035	T/C	cg03433033	chr1:76189801	ACADM	0.7	9.38	0.5	2.99e-18	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs6545883	0.929	rs10200055	chr2:61628017	T/A	cg15711740	chr2:61764176	XPO1	0.41	5.21	0.3	3.79e-7	Tuberculosis;
CESC	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg23978390	chr7:1156363	C7orf50	0.53	7.08	0.4	1.33e-11	Longevity;Endometriosis;
CESC	cis	rs2486288	0.656	rs1719232	chr15:45572072	A/G	cg09092052	chr15:45571596	NA	0.5	5.9	0.34	1.09e-8	Glomerular filtration rate;
CESC	cis	rs4268898	0.697	rs6714652	chr2:24383059	C/T	cg06627628	chr2:24431161	ITSN2	0.48	6.31	0.36	1.14e-9	Asthma;
CESC	cis	rs4588572	0.644	rs7714871	chr5:77754268	G/T	cg11547950	chr5:77652471	NA	-0.4	-5.36	-0.31	1.84e-7	Triglycerides;
CESC	cis	rs477692	0.837	rs543454	chr10:131420536	T/C	cg05714579	chr10:131428358	MGMT	0.55	7.87	0.44	9.05e-14	Response to temozolomide;
CESC	cis	rs1707322	0.721	rs6665808	chr1:46162283	C/T	cg06784218	chr1:46089804	CCDC17	0.42	7.58	0.42	5.82e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs1799949	0.965	rs8176087	chr17:41270666	C/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.64	8.61	0.47	6.49e-16	Menopause (age at onset);
CESC	cis	rs478304	0.651	rs11537193	chr11:65500003	A/C	cg10518572	chr11:65560635	OVOL1	-0.33	-6.61	-0.38	2.09e-10	Acne (severe);
CESC	cis	rs9512730	0.553	rs6491211	chr13:28049533	A/G	cg08193333	chr13:27998609	GTF3A	0.45	5.54	0.32	7.27e-8	Schizophrenia;
CESC	cis	rs897984	0.806	rs11150600	chr16:30940331	C/T	cg00531865	chr16:30841666	NA	0.51	7.12	0.4	1.01e-11	Dementia with Lewy bodies;
CESC	cis	rs12368653	0.693	rs2640610	chr12:58037435	T/A	cg18357645	chr12:58087776	OS9	0.43	6.25	0.36	1.66e-9	Multiple sclerosis;
CESC	cis	rs453301	0.658	rs13271797	chr8:8885954	G/A	cg15556689	chr8:8085844	FLJ10661	-0.48	-5.91	-0.34	1.08e-8	Joint mobility (Beighton score);
CESC	cis	rs8180040	0.966	rs12636851	chr3:47463567	C/T	cg27129171	chr3:47204927	SETD2	0.64	9.81	0.52	1.4e-19	Colorectal cancer;
CESC	cis	rs1552244	0.882	rs66559400	chr3:10012551	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.85	10.98	0.56	2.23e-23	Alzheimer's disease;
CESC	cis	rs12541635	0.677	rs2029880	chr8:107024649	T/C	cg10147462	chr8:107024639	NA	0.47	7.19	0.4	6.44e-12	Age of smoking initiation;
CESC	cis	rs875971	0.522	rs6960048	chr7:65408039	A/G	cg05332525	chr7:65337924	VKORC1L1	0.52	6.46	0.37	5e-10	Aortic root size;
CESC	cis	rs12477438	0.798	rs1993230	chr2:99686079	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.75	-10.87	-0.56	5.17e-23	Chronic sinus infection;
CESC	cis	rs10492096	0.853	rs7300092	chr12:6607364	T/C	cg13857086	chr12:6580257	VAMP1	0.53	5.42	0.32	1.33e-7	Hip geometry;
CESC	cis	rs7523050	0.643	rs17621922	chr1:109404454	C/T	cg08274380	chr1:109419600	GPSM2	0.85	6.16	0.35	2.74e-9	Fat distribution (HIV);
CESC	cis	rs8141529	0.732	rs2239815	chr22:29192670	C/T	cg15103426	chr22:29168792	CCDC117	-0.66	-9.67	-0.51	3.87e-19	Lymphocyte counts;
CESC	cis	rs6540559	0.932	rs764093	chr1:209983331	A/G	cg25204440	chr1:209979598	IRF6	0.63	8.13	0.45	1.64e-14	Cleft lip with or without cleft palate;
CESC	cis	rs35160687	0.644	rs1863061	chr2:86512907	C/T	cg01119172	chr2:86362222	SNORD94;PTCD3	-0.39	-5.16	-0.3	4.88e-7	Night sleep phenotypes;
CESC	cis	rs10504229	0.683	rs59679713	chr8:58134370	G/C	cg22535103	chr8:58192502	C8orf71	-0.8	-9.01	-0.48	4.16e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs7727544	0.684	rs272869	chr5:131677997	A/G	cg24060327	chr5:131705240	SLC22A5	-0.61	-8.14	-0.45	1.53e-14	Blood metabolite levels;
CESC	cis	rs854765	0.547	rs2955355	chr17:17948475	G/A	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.55	-7.27	-0.41	4.15e-12	Total body bone mineral density;
CESC	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg02018176	chr4:1364513	KIAA1530	0.62	7.97	0.44	4.61e-14	Longevity;
CESC	cis	rs1594829	0.535	rs1434022	chr8:26153222	G/A	cg11498726	chr8:26250323	BNIP3L	-0.4	-6.06	-0.35	4.68e-9	Height;
CESC	cis	rs539096	0.500	rs2527776	chr1:44345292	G/A	cg13606994	chr1:44402422	ARTN	-0.38	-6.0	-0.35	6.48e-9	Intelligence (multi-trait analysis);
CESC	cis	rs2294693	0.530	rs9394761	chr6:41033640	A/C	cg14769373	chr6:40998127	UNC5CL	-0.42	-5.18	-0.3	4.3e-7	Gastric cancer;Non-cardia gastric cancer;
CESC	cis	rs4478858	0.839	rs10798834	chr1:31708977	G/A	cg00250761	chr1:31883323	NA	-0.29	-5.71	-0.33	2.95e-8	Alcohol dependence;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg26504019	chr21:37528663	NA	-0.39	-6.07	-0.35	4.38e-9	Gambling;
CESC	cis	rs2130392	0.962	rs7660116	chr4:185626542	G/A	cg21366198	chr4:185655624	MLF1IP	-0.42	-5.97	-0.34	7.57e-9	Kawasaki disease;
CESC	cis	rs2243480	1.000	rs4149468	chr7:65825690	T/C	cg12463550	chr7:65579703	CRCP	0.71	5.51	0.32	8.58e-8	Diabetic kidney disease;
CESC	cis	rs7208859	0.623	rs55814012	chr17:29077697	T/A	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.79e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs3096299	0.591	rs748940	chr16:89440757	T/A	cg08392591	chr16:89556376	ANKRD11	0.41	5.15	0.3	5.06e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs79387448	0.701	rs3752659	chr2:103001598	A/G	cg09003973	chr2:102972529	NA	0.95	7.62	0.42	4.39e-13	Gut microbiota (bacterial taxa);
CESC	cis	rs9768139	0.935	rs116290351	chr7:158119712	T/A	cg25566285	chr7:158114605	PTPRN2	-0.51	-8.63	-0.47	5.71e-16	Calcium levels;
CESC	cis	rs10911232	0.507	rs9787327	chr1:182978459	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.83	13.29	0.63	3.24e-31	Hypertriglyceridemia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04631728	chr17:4607671	PELP1	-0.69	-8.03	-0.44	3.21e-14	Gut microbiome composition (summer);
CESC	cis	rs1580019	0.844	rs1037322	chr7:32501857	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.89	12.66	0.61	4.86e-29	Cognitive ability;
CESC	cis	rs820218	0.962	rs820131	chr17:73669915	T/C	cg01592526	chr17:73663357	RECQL5;SAP30BP	0.45	5.81	0.34	1.78e-8	Rotator cuff tears;
CESC	cis	rs6460942	0.915	rs17541242	chr7:12459068	A/G	cg17427002	chr7:12443146	VWDE	-0.52	-5.04	-0.3	8.67e-7	Coronary artery disease;
CESC	cis	rs4665809	0.590	rs11552518	chr2:26455127	G/A	cg08470875	chr2:26401718	FAM59B	0.75	7.78	0.43	1.63e-13	Gut microbiome composition (summer);
CESC	cis	rs9311474	0.508	rs12629701	chr3:52619836	T/C	cg07507251	chr3:52567010	NT5DC2	0.34	5.91	0.34	1.04e-8	Electroencephalogram traits;
CESC	cis	rs916888	0.647	rs199524	chr17:44848438	G/T	cg01570182	chr17:44337453	NA	-0.64	-8.5	-0.46	1.35e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs7617773	0.694	rs13099560	chr3:48204768	C/T	cg11946769	chr3:48343235	NME6	-0.62	-8.53	-0.46	1.16e-15	Coronary artery disease;
CESC	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	10.16	0.53	1.09e-20	Prudent dietary pattern;
CESC	cis	rs3008870	0.755	rs3736905	chr1:67392614	A/G	cg02640540	chr1:67518911	SLC35D1	0.44	5.35	0.31	1.93e-7	Lymphocyte percentage of white cells;
CESC	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.74	-10.7	-0.55	1.87e-22	Prudent dietary pattern;
CESC	cis	rs11122272	0.735	rs1416916	chr1:231533027	A/G	cg06096015	chr1:231504339	EGLN1	0.43	6.15	0.35	2.9e-9	Hemoglobin concentration;
CESC	cis	rs4665809	0.590	rs17528590	chr2:26505858	A/G	cg22920501	chr2:26401640	FAM59B	0.91	9.92	0.52	6.43e-20	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20349076	chr11:118992192	HINFP	0.56	6.5	0.37	3.9e-10	Gut microbiome composition (summer);
CESC	cis	rs1190552	0.846	rs3783381	chr14:102965435	A/G	cg18135206	chr14:102964638	TECPR2	0.42	5.32	0.31	2.22e-7	Blood protein levels;
CESC	cis	rs4665809	0.816	rs2384359	chr2:26371364	T/C	cg04944784	chr2:26401820	FAM59B	-0.87	-10.16	-0.53	1.04e-20	Gut microbiome composition (summer);
CESC	cis	rs826838	1.000	rs7953227	chr12:38946193	G/A	cg26384229	chr12:38710491	ALG10B	0.82	14.87	0.67	9.2e-37	Heart rate;
CESC	cis	rs2228479	0.867	rs12930056	chr16:89946649	C/A	cg14709524	chr16:89940631	TCF25	0.74	5.75	0.33	2.43e-8	Skin colour saturation;
CESC	cis	rs3812762	0.912	rs10769954	chr11:8783713	A/G	cg03980550	chr11:8754370	ST5	0.35	5.03	0.3	8.91e-7	Hypospadias;
CESC	cis	rs9527	0.590	rs12355120	chr10:104852166	T/G	cg04362960	chr10:104952993	NT5C2	0.45	5.75	0.33	2.5e-8	Arsenic metabolism;
CESC	cis	rs950776	0.518	rs952216	chr15:78819202	C/T	cg06917634	chr15:78832804	PSMA4	0.79	12.0	0.59	8.43e-27	Sudden cardiac arrest;
CESC	cis	rs10818894	0.611	rs10117455	chr9:126692599	G/T	cg16191174	chr9:126692580	DENND1A	0.62	8.0	0.44	3.99e-14	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
CESC	cis	rs847577	0.832	rs1799068	chr7:97707069	G/T	cg21770322	chr7:97807741	LMTK2	-0.52	-8.02	-0.44	3.49e-14	Breast cancer;
CESC	cis	rs2075371	0.931	rs1646697	chr7:133999930	G/A	cg20476274	chr7:133979776	SLC35B4	0.65	9.4	0.5	2.76e-18	Mean platelet volume;
CESC	cis	rs6076065	1.000	rs6076065	chr20:23368411	C/A	cg12062639	chr20:23401060	NAPB	0.42	5.2	0.3	3.94e-7	Facial morphology (factor 15, philtrum width);
CESC	cis	rs950027	0.596	rs2467853	chr15:45698793	T/G	cg21132104	chr15:45694354	SPATA5L1	0.65	8.47	0.46	1.66e-15	Response to fenofibrate (adiponectin levels);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14551182	chr11:16626476	NA	0.55	6.46	0.37	4.87e-10	Gut microbiome composition (summer);
CESC	trans	rs35110281	0.548	rs7276316	chr21:45029333	A/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.54	7.13	0.4	9.65e-12	Mean corpuscular volume;
CESC	cis	rs9322193	0.962	rs3805748	chr6:150093678	C/T	cg04369109	chr6:150039330	LATS1	-0.39	-5.31	-0.31	2.29e-7	Lung cancer;
CESC	cis	rs12545109	0.842	rs2670050	chr8:57402914	T/G	cg09654669	chr8:57350985	NA	-0.57	-7.23	-0.41	5.09e-12	Obesity-related traits;
CESC	cis	rs10818894	0.515	rs10818831	chr9:126312791	C/T	cg16191174	chr9:126692580	DENND1A	0.55	5.99	0.35	6.67e-9	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
CESC	cis	rs2011503	0.941	rs72999068	chr19:19380685	A/G	cg11584989	chr19:19387371	SF4	0.61	7.3	0.41	3.41e-12	Bipolar disorder;
CESC	cis	rs9926296	0.605	rs8046243	chr16:89852133	A/G	cg27121462	chr16:89883253	FANCA	0.82	12.03	0.59	6.84e-27	Vitiligo;
CESC	cis	rs6691722	0.503	rs12086212	chr1:24708740	C/T	cg02336364	chr1:24764700	NIPAL3	0.33	6.66	0.38	1.58e-10	Response to interferon beta in multiple sclerosis;
CESC	cis	rs7811142	1.000	rs7794485	chr7:100068936	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.05	9.76	0.51	2.07e-19	Platelet count;
CESC	cis	rs9910055	0.659	rs227578	chr17:42210189	C/A	cg09913183	chr17:42254507	C17orf65;ASB16	-0.66	-8.76	-0.47	2.37e-16	Total body bone mineral density;
CESC	cis	rs8114671	0.647	rs6060267	chr20:33734012	A/G	cg24642439	chr20:33292090	TP53INP2	0.51	6.5	0.37	3.86e-10	Height;
CESC	cis	rs206966	0.935	rs11065094	chr12:120806706	C/G	cg21001641	chr12:120729728	NA	-0.64	-5.14	-0.3	5.37e-7	Breast cancer;
CESC	trans	rs4950322	0.580	rs2014106	chr1:146590081	C/T	cg04954894	chr8:38089920	DDHD2	-0.59	-6.39	-0.37	7.54e-10	Protein quantitative trait loci;
CESC	cis	rs6570726	0.764	rs4263604	chr6:145916697	A/G	cg05347473	chr6:146136440	FBXO30	0.52	6.73	0.38	1.06e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4148883	0.629	rs10009145	chr4:100047929	G/A	cg12011299	chr4:100065546	ADH4	0.71	10.62	0.55	3.4e-22	Alcohol dependence;
CESC	cis	rs858239	0.601	rs6980224	chr7:23149137	C/T	cg23682824	chr7:23144976	KLHL7	0.55	7.63	0.42	4.25e-13	Cerebrospinal fluid biomarker levels;
CESC	cis	rs7927592	0.763	rs10896351	chr11:68386896	G/A	cg20283391	chr11:68216788	NA	-0.42	-5.09	-0.3	6.65e-7	Total body bone mineral density;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg25495775	chr17:46970705	ATP5G1	-0.45	-6.28	-0.36	1.35e-9	Asthma;
CESC	cis	rs9488822	0.676	rs868943	chr6:116337503	G/A	cg26893134	chr6:116381904	FRK	0.25	6.14	0.35	3.03e-9	Cholesterol, total;LDL cholesterol;
CESC	cis	rs9291683	0.595	rs35501905	chr4:10053431	C/T	cg02734326	chr4:10020555	SLC2A9	0.47	6.73	0.38	1.07e-10	Bone mineral density;
CESC	cis	rs7680126	0.596	rs4698009	chr4:10284993	A/G	cg11266682	chr4:10021025	SLC2A9	-0.38	-5.15	-0.3	4.98e-7	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	cis	rs12824058	0.831	rs7979497	chr12:130804706	C/T	cg24838063	chr12:130822603	PIWIL1	0.61	7.96	0.44	5.22e-14	Menopause (age at onset);
CESC	cis	rs60154123	0.505	rs77990373	chr1:210041111	T/C	cg25204440	chr1:209979598	IRF6	0.67	6.11	0.35	3.54e-9	Coronary artery disease;
CESC	cis	rs3960554	0.741	rs10232162	chr7:75702505	C/T	cg17325771	chr7:75508891	RHBDD2	-0.36	-5.37	-0.31	1.72e-7	Eotaxin levels;
CESC	cis	rs3767633	0.925	rs6427633	chr1:161849569	C/T	cg09175582	chr1:161736000	ATF6	0.86	7.02	0.4	1.91e-11	IgG glycosylation;
CESC	cis	rs2688608	0.618	rs28718766	chr10:75489844	C/A	cg23231163	chr10:75533350	FUT11	-0.37	-5.57	-0.32	6.23e-8	Inflammatory bowel disease;
CESC	cis	rs2933343	0.729	rs1683816	chr3:128651195	G/T	cg25356066	chr3:128598488	ACAD9	-0.64	-8.84	-0.48	1.32e-16	IgG glycosylation;
CESC	cis	rs9858542	0.953	rs10640	chr3:49454277	G/A	cg03060546	chr3:49711283	APEH	-0.52	-5.91	-0.34	1.06e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs634534	0.562	rs661335	chr11:65754061	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.74	10.65	0.55	2.7e-22	Sum eosinophil basophil counts;Eosinophil counts;
CESC	cis	rs654950	0.901	rs607586	chr1:42004379	C/T	cg06885757	chr1:42089581	HIVEP3	-0.68	-10.85	-0.55	6e-23	Airway imaging phenotypes;
CESC	cis	rs116095464	1.000	rs7721278	chr5:310530	G/A	cg22857025	chr5:266934	NA	-1.17	-10.45	-0.54	1.22e-21	Breast cancer;
CESC	cis	rs362272	0.545	rs2236052	chr4:3318413	C/T	cg14583973	chr4:3374767	RGS12	-0.31	-5.57	-0.32	6.4e-8	Serum sulfate level;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27449959	chr8:146024786	ZNF517	-0.56	-6.44	-0.37	5.56e-10	Gut microbiome composition (summer);
CESC	cis	rs798554	0.797	rs798497	chr7:2795957	A/G	cg18446336	chr7:2847575	GNA12	-0.4	-6.0	-0.35	6.62e-9	Height;
CESC	cis	rs12586317	0.547	rs112510746	chr14:35491833	T/G	cg16230307	chr14:35515116	FAM177A1	0.99	10.61	0.55	3.72e-22	Psoriasis;
CESC	cis	rs2380220	0.541	rs72928283	chr6:96082490	A/C	cg23517279	chr6:96025343	MANEA	-0.56	-5.46	-0.32	1.1e-7	Behavioural disinhibition (generation interaction);
CESC	cis	rs34638657	0.702	rs62044259	chr16:82199523	A/T	cg09439754	chr16:82129088	HSD17B2	-0.37	-6.42	-0.37	6.31e-10	Lung adenocarcinoma;
CESC	cis	rs3762637	1.000	rs72958458	chr3:122185549	T/C	cg24169773	chr3:122142474	KPNA1	-0.54	-6.33	-0.36	1.04e-9	LDL cholesterol levels;
CESC	cis	rs10504229	0.906	rs58251024	chr8:58172259	G/C	cg05313129	chr8:58192883	C8orf71	-0.54	-6.23	-0.36	1.82e-9	Developmental language disorder (linguistic errors);
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg21939482	chr7:6388130	C7orf70	-0.46	-6.05	-0.35	4.83e-9	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06537257	chr13:41768693	KBTBD7	0.62	6.75	0.38	9.39e-11	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16636271	chr6:139694487	CITED2	0.58	7.07	0.4	1.4e-11	Gut microbiome composition (summer);
CESC	trans	rs79976124	0.879	rs12213669	chr6:66627704	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.74	8.48	0.46	1.58e-15	Type 2 diabetes;
CESC	cis	rs2204008	0.677	rs1581356	chr12:38391467	T/C	cg13010199	chr12:38710504	ALG10B	0.44	5.45	0.32	1.14e-7	Bladder cancer;
CESC	cis	rs12995491	0.933	rs13023008	chr2:88530933	G/A	cg04511125	chr2:88470314	THNSL2	-0.51	-7.36	-0.41	2.35e-12	Response to metformin (IC50);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11240755	chr1:26147348	FAM54B;LOC646471	0.58	6.3	0.36	1.25e-9	Gut microbiome composition (summer);
CESC	cis	rs4843747	0.671	rs13334603	chr16:88116016	T/C	cg06915872	chr16:87998081	BANP	0.43	5.08	0.3	6.99e-7	Menopause (age at onset);
CESC	cis	rs950027	0.549	rs11636114	chr15:45601412	C/G	cg21132104	chr15:45694354	SPATA5L1	0.57	6.84	0.39	5.55e-11	Response to fenofibrate (adiponectin levels);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27502791	chr1:65886279	LEPR;LEPROT	0.62	6.84	0.39	5.59e-11	Gut microbiome composition (summer);
CESC	cis	rs6088590	0.813	rs1884668	chr20:33285514	A/G	cg06115741	chr20:33292138	TP53INP2	0.52	6.49	0.37	4.1e-10	Coronary artery disease;
CESC	cis	rs9894429	0.934	rs35868252	chr17:79575472	C/G	cg13777783	chr17:79615861	NA	0.35	5.79	0.34	1.99e-8	Eye color traits;
CESC	cis	rs7945705	0.902	rs10743095	chr11:8936984	T/C	cg21881798	chr11:8931708	C11orf17;ST5	0.51	8.5	0.46	1.38e-15	Hemoglobin concentration;
CESC	cis	rs10791097	1.000	rs10791097	chr11:130718630	G/T	cg12179176	chr11:130786555	SNX19	-0.56	-7.89	-0.44	8.19e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs9811920	0.603	rs2638948	chr3:99501539	G/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.45	-7.29	-0.41	3.55e-12	Axial length;
CESC	cis	rs7666738	0.822	rs28367231	chr4:98845726	G/T	cg17366294	chr4:99064904	C4orf37	0.52	7.12	0.4	1.03e-11	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6060717	0.571	rs6060761	chr20:34612487	T/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.5	6.3	0.36	1.26e-9	Hip circumference adjusted for BMI;
CESC	cis	rs7223966	0.921	rs2727300	chr17:61965398	G/A	cg25324976	chr17:61989376	CSHL1	0.4	5.59	0.32	5.76e-8	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs7772486	0.720	rs9403757	chr6:146261271	C/T	cg23711669	chr6:146136114	FBXO30	-0.92	-13.3	-0.63	2.94e-31	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs514406	0.644	rs7529978	chr1:53204705	G/A	cg16325326	chr1:53192061	ZYG11B	-0.7	-11.18	-0.57	4.87e-24	Monocyte count;
CESC	cis	rs9916302	0.904	rs6503507	chr17:37525274	C/T	cg20243544	chr17:37824526	PNMT	-0.48	-6.11	-0.35	3.52e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs7412746	0.658	rs11582281	chr1:150826831	T/C	cg09365446	chr1:150670422	GOLPH3L	0.39	5.23	0.31	3.44e-7	Melanoma;
CESC	cis	rs873946	0.586	rs12776770	chr10:134564831	T/C	cg27286337	chr10:134555280	INPP5A	0.61	6.95	0.39	2.81e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs477895	0.653	rs3824854	chr11:63885305	C/T	cg04317338	chr11:64019027	PLCB3	0.84	8.42	0.46	2.35e-15	Mean platelet volume;
CESC	cis	rs6570726	0.905	rs377143	chr6:145834220	C/T	cg23711669	chr6:146136114	FBXO30	0.74	10.77	0.55	1.1e-22	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2625529	0.938	rs4777464	chr15:72131763	C/T	cg16672083	chr15:72433130	SENP8	-0.41	-5.8	-0.34	1.87e-8	Red blood cell count;
CESC	cis	rs514406	0.861	rs7518390	chr1:53233374	A/G	cg16325326	chr1:53192061	ZYG11B	-0.85	-14.8	-0.67	1.59e-36	Monocyte count;
CESC	cis	rs13631	0.928	rs9411308	chr9:140000115	C/T	cg14289826	chr9:140003911	NA	0.34	6.27	0.36	1.42e-9	Cerebrospinal fluid biomarker levels;
CESC	cis	rs4288356	1	rs4288356	chr8:141055724	G/A	cg06693505	chr8:141057453	TRAPPC9	-0.37	-5.98	-0.34	7.19e-9	Pulse pressure;
CESC	cis	rs950169	1.000	rs1818950	chr15:84722521	A/G	cg17507749	chr15:85114479	UBE2QP1	0.63	6.98	0.39	2.31e-11	Schizophrenia;
CESC	cis	rs7255436	0.830	rs4350678	chr19:8447366	A/G	cg10174797	chr19:8464628	RAB11B	0.4	5.67	0.33	3.75e-8	HDL cholesterol;
CESC	cis	rs2479724	0.901	rs6458244	chr6:41790455	C/T	cg17623882	chr6:41773611	USP49	0.39	5.69	0.33	3.43e-8	Menarche (age at onset);
CESC	cis	rs400736	0.930	rs225100	chr1:8066914	C/T	cg25007680	chr1:8021821	PARK7	-0.72	-10.27	-0.53	4.92e-21	Response to antidepressants and depression;
CESC	cis	rs1552244	1.000	rs57631744	chr3:10118962	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	12.72	0.62	2.99e-29	Alzheimer's disease;
CESC	cis	rs1801251	1.000	rs2675971	chr2:233726154	A/G	cg08000102	chr2:233561755	GIGYF2	-0.71	-10.04	-0.53	2.53e-20	Coronary artery disease;
CESC	cis	rs4589502	1.000	rs16950284	chr15:67154184	A/G	cg12317470	chr15:67143691	NA	-0.67	-6.03	-0.35	5.42e-9	Lung cancer (smoking interaction);
CESC	cis	rs61776719	0.520	rs11485595	chr1:38411350	C/T	cg17077180	chr1:38461687	NA	0.45	6.88	0.39	4.33e-11	Coronary artery disease;
CESC	cis	rs10256972	0.616	rs7806746	chr7:1075573	A/C	cg09177884	chr7:1199841	ZFAND2A	-0.56	-6.97	-0.39	2.55e-11	Longevity;Endometriosis;
CESC	cis	rs938554	0.784	rs11722229	chr4:9980697	C/A	cg00071950	chr4:10020882	SLC2A9	0.48	5.76	0.33	2.36e-8	Blood metabolite levels;
CESC	cis	rs3126085	0.935	rs11204976	chr1:152273777	C/T	cg03465714	chr1:152285911	FLG	0.51	5.87	0.34	1.32e-8	Atopic dermatitis;
CESC	cis	rs12541335	0.639	rs7003478	chr8:22201123	A/G	cg26039829	chr8:22132926	PIWIL2	0.39	6.05	0.35	4.84e-9	Hypertriglyceridemia;
CESC	cis	rs12822507	0.868	rs61915599	chr12:12768409	A/G	cg11838227	chr12:12764436	CREBL2	-0.41	-5.23	-0.31	3.39e-7	Systemic lupus erythematosus;
CESC	cis	rs7584330	0.554	rs6760890	chr2:238400645	G/A	cg14458575	chr2:238380390	NA	0.7	6.12	0.35	3.35e-9	Prostate cancer;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg15309264	chr2:58274034	VRK2	0.46	6.08	0.35	4.07e-9	Systemic lupus erythematosus;
CESC	cis	rs7772486	0.790	rs2254288	chr6:146204470	G/A	cg05347473	chr6:146136440	FBXO30	0.53	7.05	0.4	1.59e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs854765	0.964	rs72827413	chr17:17988299	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.43	-5.71	-0.33	2.97e-8	Total body bone mineral density;
CESC	cis	rs12048904	0.505	rs4517368	chr1:101255052	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.59	-7.04	-0.4	1.65e-11	Multiple sclerosis;
CESC	cis	rs4970988	0.640	rs7524734	chr1:150655686	C/T	cg18016565	chr1:150552671	MCL1	0.33	5.14	0.3	5.34e-7	Urate levels;
CESC	cis	rs754466	0.606	rs12356375	chr10:79594514	C/A	cg17075019	chr10:79541650	NA	-0.88	-13.94	-0.65	1.66e-33	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs3768617	0.510	rs3765522	chr1:183077618	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.88	14.11	0.65	4.24e-34	Fuchs's corneal dystrophy;
CESC	cis	rs11608355	0.545	rs12822891	chr12:109896002	A/G	cg05360138	chr12:110035743	NA	0.82	8.92	0.48	7.93e-17	Neuroticism;
CESC	cis	rs617791	0.530	rs735942	chr11:65749337	A/G	cg04055107	chr11:65626734	MUS81;CFL1	-0.45	-5.1	-0.3	6.46e-7	Breast cancer;
CESC	cis	rs7713065	0.531	rs2522051	chr5:131797578	C/T	cg24060327	chr5:131705240	SLC22A5	-0.42	-5.26	-0.31	3e-7	Lung function (FEV1/FVC);
CESC	trans	rs116095464	0.558	rs13354585	chr5:242263	G/C	cg00938859	chr5:1591904	SDHAP3	0.64	7.01	0.4	2.01e-11	Breast cancer;
CESC	cis	rs5167	0.504	rs7258345	chr19:45453151	T/G	cg20090143	chr19:45452003	APOC2	0.37	6.39	0.37	7.54e-10	Blood protein levels;
CESC	cis	rs501120	1.000	rs604674	chr10:44756894	G/T	cg09554077	chr10:44749378	NA	0.52	6.91	0.39	3.59e-11	Coronary artery disease;Coronary heart disease;
CESC	cis	rs4595586	0.545	rs1319791	chr12:39372486	G/T	cg13010199	chr12:38710504	ALG10B	0.44	5.51	0.32	8.37e-8	Morning vs. evening chronotype;
CESC	cis	rs4642101	0.662	rs9840766	chr3:12821870	G/A	cg05775895	chr3:12838266	CAND2	0.37	5.45	0.32	1.17e-7	QRS complex (12-leadsum);
CESC	cis	rs4819052	0.851	rs10470245	chr21:46658912	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.75	9.98	0.52	4.1e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs2440129	0.611	rs1126667	chr17:6902760	C/T	cg05215272	chr17:6899095	ALOX12	-0.44	-8.33	-0.46	4.45e-15	Tonsillectomy;
CESC	cis	rs7666738	0.830	rs4699597	chr4:99019031	G/A	cg03676636	chr4:99064102	C4orf37	0.33	5.15	0.3	5.05e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6831352	0.918	rs17817958	chr4:100061245	A/C	cg13256891	chr4:100009986	ADH5	0.75	7.82	0.43	1.24e-13	Alcohol dependence;
CESC	cis	rs1799949	1.000	rs8176212	chr17:41226601	G/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.45	6.23	0.36	1.87e-9	Menopause (age at onset);
CESC	cis	rs4566357	0.615	rs12621808	chr2:227909522	A/C	cg11843606	chr2:227700838	RHBDD1	-0.46	-6.3	-0.36	1.26e-9	Coronary artery disease;
CESC	cis	rs6570726	0.935	rs428659	chr6:145827039	T/C	cg23711669	chr6:146136114	FBXO30	0.8	12.02	0.59	7.3e-27	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg08273200	chr1:39338480	MYCBP	-0.45	-6.41	-0.37	6.71e-10	Gambling;
CESC	cis	rs6976053	0.541	rs314359	chr7:100411278	T/C	cg20848291	chr7:100343083	ZAN	0.4	5.5	0.32	9.14e-8	Plasminogen activator inhibitor type 1 levels (PAI-1);
CESC	cis	rs6460942	0.915	rs62448594	chr7:12442229	C/G	cg10578991	chr7:12443926	VWDE	-0.51	-5.67	-0.33	3.75e-8	Coronary artery disease;
CESC	cis	rs8070740	0.898	rs11078562	chr17:5326857	A/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.51	6.42	0.37	6.41e-10	Menopause (age at onset);
CESC	cis	rs7945705	0.818	rs2742552	chr11:8876852	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.41	-6.54	-0.37	3.16e-10	Hemoglobin concentration;
CESC	cis	rs2243480	1.000	rs431076	chr7:65600320	A/C	cg13147721	chr7:65941812	NA	-0.98	-9.24	-0.49	8.33e-18	Diabetic kidney disease;
CESC	cis	rs7100689	0.646	rs7089003	chr10:82124155	T/C	cg00277334	chr10:82204260	NA	-0.58	-7.76	-0.43	1.84e-13	Post bronchodilator FEV1;
CESC	cis	rs3093024	1.000	rs3093023	chr6:167534290	A/G	cg07741184	chr6:167504864	NA	-0.33	-5.58	-0.32	5.88e-8	Rheumatoid arthritis;
CESC	cis	rs117623576	0.680	rs16932874	chr10:32358438	T/C	cg03047570	chr10:32398778	NA	-0.58	-6.24	-0.36	1.77e-9	Anti-saccade response;
CESC	cis	rs7618915	1.000	rs3852064	chr3:52349412	G/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.35	5.13	0.3	5.68e-7	Bipolar disorder;
CESC	cis	rs7666738	0.830	rs10022389	chr4:99022229	T/C	cg17366294	chr4:99064904	C4orf37	0.61	8.76	0.47	2.35e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7561273	0.586	rs12477718	chr2:24330539	A/G	cg06627628	chr2:24431161	ITSN2	-0.46	-5.42	-0.32	1.34e-7	Quantitative traits;
CESC	cis	rs4076764	0.801	rs12046142	chr1:163375247	G/A	cg06092702	chr1:163392909	NA	-0.39	-5.58	-0.32	6.08e-8	Motion sickness;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12145289	chr11:65385911	PCNXL3	-0.54	-6.75	-0.38	9.56e-11	Gut microbiome composition (summer);
CESC	cis	rs7524258	0.903	rs763197	chr1:7289959	A/G	cg07173049	chr1:7289937	CAMTA1	0.48	7.23	0.41	5.08e-12	Tourette's syndrome or obsessive-compulsive disorder;
CESC	cis	rs6500395	1.000	rs12598514	chr16:48689319	T/C	cg04672837	chr16:48644449	N4BP1	-0.51	-6.37	-0.36	8.27e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs4711336	0.967	rs4713658	chr6:33667117	C/G	cg14003231	chr6:33640908	ITPR3	0.3	5.31	0.31	2.32e-7	Height;
CESC	cis	rs5758511	0.514	rs5758580	chr22:42493875	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.63	9.78	0.52	1.69e-19	Birth weight;
CESC	cis	rs7618915	0.547	rs6762813	chr3:52726695	C/T	cg07507251	chr3:52567010	NT5DC2	0.42	7.33	0.41	2.77e-12	Bipolar disorder;
CESC	cis	rs7219021	0.926	rs7208848	chr17:46855295	C/T	cg16584676	chr17:46985605	UBE2Z	-0.56	-6.32	-0.36	1.08e-9	Schizophrenia or bipolar disorder;
CESC	cis	rs694739	0.964	rs2510066	chr11:64052447	C/T	cg02228329	chr11:64053129	BAD;GPR137	0.67	8.6	0.47	6.86e-16	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
CESC	cis	rs4780401	0.609	rs8063099	chr16:11806714	T/G	cg01061890	chr16:11836724	TXNDC11	-0.56	-7.59	-0.42	5.59e-13	Rheumatoid arthritis;
CESC	cis	rs57221529	0.600	rs11750269	chr5:666270	G/A	cg09021430	chr5:549028	NA	-0.43	-5.12	-0.3	5.86e-7	Lung disease severity in cystic fibrosis;
CESC	cis	rs637571	0.522	rs1151512	chr11:65757533	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.45	6.68	0.38	1.44e-10	Eosinophil percentage of white cells;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18494018	chr7:148581708	EZH2	0.5	6.05	0.35	4.93e-9	Gut microbiome composition (summer);
CESC	cis	rs561341	1.000	rs498391	chr17:30328704	G/A	cg00745463	chr17:30367425	LRRC37B	-0.79	-7.41	-0.41	1.68e-12	Hip circumference adjusted for BMI;
CESC	trans	rs10411161	0.702	rs79180893	chr19:52395615	A/G	cg22319618	chr22:45562946	NUP50	-0.74	-7.44	-0.42	1.37e-12	Breast cancer;
CESC	cis	rs3740713	1.000	rs73440606	chr11:18464120	C/T	cg23797887	chr11:18477753	LDHAL6A	-0.54	-5.28	-0.31	2.63e-7	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs853679	0.882	rs4713140	chr6:28097193	C/T	cg25108566	chr6:27775657	HIST1H2AI;HIST1H2BL	0.77	7.2	0.4	6.37e-12	Depression;
CESC	cis	rs2559856	1.000	rs2559855	chr12:102090080	A/G	cg24337881	chr12:102091387	CHPT1	-0.41	-5.6	-0.33	5.34e-8	Blood protein levels;
CESC	cis	rs17826219	0.636	rs7221463	chr17:29080551	A/C	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.17e-10	Body mass index;
CESC	cis	rs6537837	0.668	rs12044778	chr1:110084408	C/T	cg05049280	chr1:110155535	GNAT2	0.37	5.18	0.3	4.36e-7	Major depressive disorder;
CESC	cis	rs896854	0.517	rs1011795	chr8:95951073	G/A	cg13393036	chr8:95962371	TP53INP1	-0.46	-8.23	-0.45	8.45e-15	Type 2 diabetes;
CESC	cis	rs4835473	0.932	rs4490412	chr4:144908566	C/G	cg25736465	chr4:144833511	NA	0.38	5.81	0.34	1.83e-8	Immature fraction of reticulocytes;
CESC	cis	rs11608355	0.515	rs2287184	chr12:109970251	T/C	cg05360138	chr12:110035743	NA	0.82	8.91	0.48	8.24e-17	Neuroticism;
CESC	cis	rs12541635	0.966	rs7839195	chr8:107020193	G/A	cg10147462	chr8:107024639	NA	0.4	5.81	0.34	1.8e-8	Age of smoking initiation;
CESC	cis	rs6486730	1.000	rs6486730	chr12:129275027	C/T	cg09035930	chr12:129282057	SLC15A4	0.45	6.22	0.36	1.97e-9	Systemic lupus erythematosus;
CESC	cis	rs7666738	0.830	rs4492007	chr4:98959848	A/T	cg18180107	chr4:99064573	C4orf37	0.4	5.14	0.3	5.32e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7179456	0.515	rs602602	chr15:59057023	T/A	cg05156742	chr15:59063176	FAM63B	0.51	5.9	0.34	1.12e-8	Asperger disorder;
CESC	cis	rs10883723	0.810	rs7092622	chr10:104249919	T/G	cg22532475	chr10:104410764	TRIM8	-0.33	-5.67	-0.33	3.67e-8	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg06074448	chr4:187884817	NA	-0.47	-7.35	-0.41	2.52e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs3820068	0.603	rs72647138	chr1:15980929	C/T	cg18133145	chr1:16060689	PLEKHM2	-0.4	-5.15	-0.3	5.15e-7	Systolic blood pressure;
CESC	trans	rs853679	0.546	rs35744819	chr6:28318331	G/T	cg06606381	chr12:133084897	FBRSL1	-1.11	-8.41	-0.46	2.54e-15	Depression;
CESC	trans	rs1814175	0.791	rs10219223	chr11:49791468	A/T	cg15704280	chr7:45808275	SEPT13	-1.02	-19.87	-0.77	1.97e-54	Height;
CESC	cis	rs514406	0.621	rs881198	chr1:53196440	C/T	cg24675658	chr1:53192096	ZYG11B	0.68	8.67	0.47	4.34e-16	Monocyte count;
CESC	cis	rs1059312	0.808	rs10847693	chr12:129292006	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.82	-12.11	-0.6	3.74e-27	Systemic lupus erythematosus;
CESC	cis	rs2228479	0.850	rs3785279	chr16:89824562	G/C	cg00800038	chr16:89945340	TCF25	-0.92	-7.67	-0.43	3.37e-13	Skin colour saturation;
CESC	cis	rs1552244	0.810	rs4019706	chr3:10112862	G/A	cg00149659	chr3:10157352	C3orf10	0.7	8.38	0.46	3.2e-15	Alzheimer's disease;
CESC	cis	rs9443189	0.570	rs276687	chr6:76429995	G/T	cg01950844	chr6:76311363	SENP6	-0.84	-8.07	-0.44	2.4e-14	Prostate cancer;
CESC	cis	rs9291683	0.530	rs998675	chr4:9948829	A/G	cg02734326	chr4:10020555	SLC2A9	0.43	6.48	0.37	4.49e-10	Bone mineral density;
CESC	cis	rs13385	0.769	rs11538394	chr5:139574050	G/A	cg26211634	chr5:139558579	C5orf32	0.47	5.28	0.31	2.75e-7	Atrial fibrillation;
CESC	cis	rs6460942	0.591	rs7804805	chr7:12332066	C/G	cg20607287	chr7:12443886	VWDE	-0.63	-6.83	-0.39	5.83e-11	Coronary artery disease;
CESC	cis	rs7666738	0.924	rs11097592	chr4:98927532	C/T	cg05340658	chr4:99064831	C4orf37	0.56	7.36	0.41	2.29e-12	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7259376	0.936	rs12983542	chr19:22590585	C/G	cg02657401	chr19:22469223	NA	0.26	5.12	0.3	5.76e-7	Menopause (age at onset);
CESC	cis	rs9527	0.544	rs1572578	chr10:104822431	C/G	cg04362960	chr10:104952993	NT5C2	0.45	5.76	0.33	2.34e-8	Arsenic metabolism;
CESC	cis	rs7124681	0.584	rs4752792	chr11:47815702	G/A	cg18512352	chr11:47633146	NA	-0.36	-5.55	-0.32	6.84e-8	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
CESC	cis	rs4665809	0.590	rs13006973	chr2:26454707	C/T	cg04944784	chr2:26401820	FAM59B	0.96	10.55	0.54	5.79e-22	Gut microbiome composition (summer);
CESC	cis	rs2637266	0.935	rs2583050	chr10:78403615	C/T	cg18941641	chr10:78392320	NA	0.44	8.58	0.47	7.88e-16	Pulmonary function;
CESC	cis	rs7618915	0.501	rs2109634	chr3:52752075	T/G	cg05564831	chr3:52568323	NT5DC2	0.46	7.19	0.4	6.64e-12	Bipolar disorder;
CESC	cis	rs7927771	0.929	rs66749409	chr11:47568074	C/T	cg20307385	chr11:47447363	PSMC3	-0.5	-6.09	-0.35	4.06e-9	Subjective well-being;
CESC	cis	rs2576037	0.566	rs2437854	chr18:44557613	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.48	6.42	0.37	6.36e-10	Personality dimensions;
CESC	cis	rs1843834	0.539	rs1494109	chr2:225441833	G/A	cg22509189	chr2:225307070	NA	-0.42	-5.63	-0.33	4.6e-8	IgE levels in asthmatics (D.p. specific);
CESC	cis	rs6088590	0.561	rs6059932	chr20:33175466	C/T	cg24642439	chr20:33292090	TP53INP2	0.63	8.39	0.46	2.84e-15	Coronary artery disease;
CESC	cis	rs7666738	0.830	rs2114425	chr4:99023967	T/C	cg05340658	chr4:99064831	C4orf37	0.83	12.88	0.62	8.59e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9796	0.558	rs6492993	chr15:41526104	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.45	-6.43	-0.37	5.78e-10	Menopause (age at onset);
CESC	cis	rs644799	0.932	rs572015	chr11:95637416	T/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.61	7.99	0.44	4.2e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs769267	0.931	rs2965193	chr19:19454828	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	-0.49	-6.12	-0.35	3.41e-9	Tonsillectomy;
CESC	cis	rs9487051	0.803	rs11153161	chr6:109541774	A/G	cg01475377	chr6:109611718	NA	-0.37	-5.34	-0.31	2.01e-7	Reticulocyte fraction of red cells;
CESC	cis	rs7613875	0.600	rs1061474	chr3:50144951	T/C	cg24110177	chr3:50126178	RBM5	0.55	7.47	0.42	1.18e-12	Body mass index;
CESC	cis	rs10489525	0.550	rs6659415	chr1:115632211	C/T	cg01522456	chr1:115632236	TSPAN2	0.72	8.88	0.48	1.03e-16	Autism;
CESC	cis	rs801193	1.000	rs2707854	chr7:66212597	G/A	cg11764359	chr7:65958608	NA	0.69	9.1	0.49	2.27e-17	Aortic root size;
CESC	cis	rs7618915	0.571	rs2289249	chr3:52597664	G/A	cg05564831	chr3:52568323	NT5DC2	0.46	6.94	0.39	3.07e-11	Bipolar disorder;
CESC	cis	rs1865760	0.532	rs9295687	chr6:26082710	T/C	cg16482183	chr6:26056742	HIST1H1C	0.38	5.11	0.3	6.19e-7	Height;
CESC	cis	rs17826219	0.706	rs8075357	chr17:29057197	A/C	cg14008862	chr17:28927542	LRRC37B2	0.65	5.12	0.3	5.86e-7	Body mass index;
CESC	cis	rs67311347	1.000	rs9841335	chr3:40475858	G/A	cg09455208	chr3:40491958	NA	0.44	7.53	0.42	8.04e-13	Renal cell carcinoma;
CESC	trans	rs9911652	1.000	rs16957821	chr17:8948104	C/G	cg18132964	chr6:155541562	TIAM2	0.53	6.12	0.35	3.39e-9	Cleft lip with or without cleft palate;
CESC	cis	rs2842992	0.747	rs1547093	chr6:160205991	C/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.76	9.88	0.52	8.23e-20	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs3008870	0.755	rs11208974	chr1:67398119	A/T	cg08660285	chr1:67390436	MIER1;WDR78	0.63	8.38	0.46	3.04e-15	Lymphocyte percentage of white cells;
CESC	cis	rs16854884	0.632	rs10513234	chr3:143670957	A/G	cg06585982	chr3:143692056	C3orf58	-0.53	-6.92	-0.39	3.36e-11	Economic and political preferences (feminism/equality);
CESC	cis	rs17533156	0.612	rs62078287	chr17:75128493	C/T	cg18815765	chr17:75136729	SEC14L1	0.5	5.25	0.31	3.16e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs12079745	0.793	rs11806445	chr1:169219029	C/T	cg09363564	chr1:169337483	NME7;BLZF1	-1.01	-6.28	-0.36	1.36e-9	QT interval;
CESC	cis	rs225245	0.817	rs2301730	chr17:33998683	A/G	cg05299278	chr17:33885742	SLFN14	0.35	5.07	0.3	7.61e-7	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
CESC	cis	rs6542838	0.554	rs4311103	chr2:99538362	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.52	-6.63	-0.38	1.87e-10	Fear of minor pain;
CESC	cis	rs3820928	0.874	rs12105952	chr2:227864521	G/A	cg05526886	chr2:227700861	RHBDD1	-0.41	-5.14	-0.3	5.4e-7	Pulmonary function;
CESC	cis	rs2243480	1.000	rs316334	chr7:65602126	G/T	cg12463550	chr7:65579703	CRCP	0.74	5.75	0.33	2.4e-8	Diabetic kidney disease;
CESC	cis	rs832540	0.603	rs6870175	chr5:56093371	A/G	cg22800045	chr5:56110881	MAP3K1	0.5	5.99	0.35	6.65e-9	Coronary artery disease;
CESC	cis	rs59918340	0.728	rs2304279	chr8:142229891	A/G	cg16341495	chr8:142228727	SLC45A4	-0.42	-5.11	-0.3	6.15e-7	Immature fraction of reticulocytes;
CESC	cis	rs1799949	1.000	rs34059614	chr17:41303071	C/T	cg23758822	chr17:41437982	NA	1.01	15.21	0.68	5.44e-38	Menopause (age at onset);
CESC	cis	rs2228479	0.850	rs2190808	chr16:89840856	C/T	cg04013166	chr16:89971882	TCF25	0.78	6.69	0.38	1.3e-10	Skin colour saturation;
CESC	cis	rs6987853	0.787	rs2923413	chr8:42455308	A/G	cg09913449	chr8:42400586	C8orf40	0.42	7.02	0.4	1.88e-11	Mean corpuscular hemoglobin concentration;
CESC	cis	rs7264396	0.563	rs6060570	chr20:34291166	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.89	-10.78	-0.55	1.03e-22	Total cholesterol levels;
CESC	cis	rs11655198	1	rs11655198	chr17:38026169	C/T	cg19468946	chr17:37922297	IKZF3	-0.43	-5.85	-0.34	1.48e-8	Asthma;
CESC	cis	rs1348850	0.831	rs7606235	chr2:178401288	T/C	cg22681709	chr2:178499509	PDE11A	-0.44	-6.22	-0.36	1.89e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16311803	chr12:88178298	NA	-0.6	-6.83	-0.39	5.63e-11	Gut microbiome composition (summer);
CESC	cis	rs6088580	0.609	rs6059844	chr20:33036482	A/G	cg08999081	chr20:33150536	PIGU	0.65	11.56	0.58	2.68e-25	Glomerular filtration rate (creatinine);
CESC	cis	rs7216064	1.000	rs58551145	chr17:65837235	A/G	cg12091567	chr17:66097778	LOC651250	-0.85	-8.61	-0.47	6.51e-16	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs589448	0.900	rs588493	chr12:69751986	G/A	cg20891283	chr12:69753455	YEATS4	0.99	17.16	0.73	6.54e-45	Cerebrospinal fluid biomarker levels;
CESC	cis	rs864537	0.646	rs1723018	chr1:167433420	A/G	cg09179987	chr1:167433047	CD247	0.5	7.94	0.44	5.78e-14	Celiac disease or Rheumatoid arthritis;Celiac disease;
CESC	cis	rs727505	0.908	rs56155943	chr7:124606346	T/G	cg23710748	chr7:124431027	NA	-0.46	-7.28	-0.41	3.87e-12	Lewy body disease;
CESC	cis	rs2273669	0.667	rs12216104	chr6:109317635	C/T	cg05315195	chr6:109294784	ARMC2	-0.66	-6.28	-0.36	1.36e-9	Prostate cancer;
CESC	cis	rs62005083	0.737	rs56171007	chr14:74502001	A/G	cg05179529	chr14:74551516	LIN52;ALDH6A1	0.7	5.22	0.31	3.68e-7	Mean corpuscular volume;
CESC	cis	rs4689388	0.853	rs6446479	chr4:6291737	G/C	cg25554036	chr4:6271136	WFS1	0.51	8.05	0.44	2.87e-14	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs3096299	0.685	rs3803682	chr16:89544636	C/T	cg16743903	chr16:89593216	SPG7	-0.42	-5.42	-0.32	1.31e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs926938	0.618	rs516985	chr1:115495011	G/A	cg12756093	chr1:115239321	AMPD1	0.53	7.59	0.42	5.32e-13	Autism;
CESC	cis	rs733592	0.599	rs12819124	chr12:48409054	G/T	cg24011408	chr12:48396354	COL2A1	0.44	6.72	0.38	1.09e-10	Plateletcrit;
CESC	cis	rs16973500	0.808	rs72801797	chr16:71975300	A/G	cg09427745	chr16:71932006	KIAA0174	-0.49	-5.12	-0.3	5.86e-7	Response to anti-TNF therapy in rheumatoid arthritis;Attention deficit hyperactivity disorder and conduct disorder;
CESC	cis	rs9486715	0.867	rs4598081	chr6:96975227	A/G	cg18709589	chr6:96969512	KIAA0776	0.47	6.55	0.37	2.95e-10	Headache;
CESC	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg24101359	chr6:42928495	GNMT	0.6	8.91	0.48	8.14e-17	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.65	7.48	0.42	1.09e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs72627123	0.500	rs67852564	chr14:74559920	A/G	cg05179529	chr14:74551516	LIN52;ALDH6A1	0.53	5.78	0.33	2.07e-8	Morning vs. evening chronotype;
CESC	cis	rs651907	0.557	rs11720745	chr3:101441690	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.44	5.64	0.33	4.29e-8	Colorectal cancer;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg09656405	chr15:69745057	RPLP1	0.51	6.56	0.37	2.85e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs9910055	0.659	rs2246287	chr17:42232442	C/G	cg19774624	chr17:42201019	HDAC5	-0.88	-14.32	-0.66	7.95e-35	Total body bone mineral density;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09292873	chr10:111683347	XPNPEP1	0.5	6.24	0.36	1.71e-9	Gut microbiome composition (summer);
CESC	cis	rs2073300	0.609	rs6132610	chr20:23403987	C/T	cg12062639	chr20:23401060	NAPB	1.06	8.23	0.45	8.54e-15	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs7618915	0.501	rs35526119	chr3:52749334	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.6	8.47	0.46	1.69e-15	Bipolar disorder;
CESC	cis	rs10504229	0.683	rs7843919	chr8:58130792	T/C	cg21724239	chr8:58056113	NA	0.58	5.95	0.34	8.29e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs5769707	0.837	rs5769709	chr22:50021757	C/T	cg05373962	chr22:49881684	NA	-0.37	-6.11	-0.35	3.55e-9	Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs10089	1.000	rs4836360	chr5:127458161	T/C	cg19767477	chr5:127420684	SLC12A2	-0.41	-5.5	-0.32	8.94e-8	Ileal carcinoids;
CESC	cis	rs27434	0.539	rs40604	chr5:96155900	G/A	cg16492584	chr5:96139282	ERAP1	-0.36	-5.09	-0.3	6.81e-7	Ankylosing spondylitis;
CESC	cis	rs6570726	0.846	rs6899900	chr6:145883873	T/G	cg05347473	chr6:146136440	FBXO30	0.49	6.43	0.37	6.06e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs561341	0.882	rs2521594	chr17:30302087	C/T	cg23018236	chr17:30244563	NA	-0.52	-5.1	-0.3	6.39e-7	Hip circumference adjusted for BMI;
CESC	cis	rs9837602	1.000	rs9833980	chr3:99767096	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.54	7.56	0.42	6.43e-13	Breast cancer;
CESC	cis	rs798554	0.704	rs798512	chr7:2782592	C/G	cg09658497	chr7:2847517	GNA12	-0.35	-5.26	-0.31	2.92e-7	Height;
CESC	cis	rs868036	0.609	rs3784707	chr15:68043878	A/C	cg24579218	chr15:68104479	NA	-0.37	-5.11	-0.3	6.12e-7	Restless legs syndrome;
CESC	cis	rs2197308	0.740	rs10880619	chr12:37922720	T/C	cg26384229	chr12:38710491	ALG10B	0.75	11.12	0.56	8.21e-24	Morning vs. evening chronotype;
CESC	cis	rs34779708	0.966	rs12769575	chr10:35435927	A/T	cg03585969	chr10:35415529	CREM	0.76	10.0	0.52	3.56e-20	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs6088580	0.609	rs945674	chr20:32964247	G/C	cg08999081	chr20:33150536	PIGU	-0.65	-11.29	-0.57	2.22e-24	Glomerular filtration rate (creatinine);
CESC	cis	rs7264396	0.790	rs8125090	chr20:34360015	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.87	-11.82	-0.59	3.57e-26	Total cholesterol levels;
CESC	cis	rs11098499	0.874	rs10022508	chr4:120115228	A/G	cg09307838	chr4:120376055	NA	0.74	9.24	0.49	8.6e-18	Corneal astigmatism;
CESC	cis	rs9322193	0.923	rs4869812	chr6:149990583	A/G	cg04369109	chr6:150039330	LATS1	-0.38	-5.26	-0.31	3.04e-7	Lung cancer;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg23216004	chr7:23624964	CLK2P	0.38	6.06	0.35	4.73e-9	Fibrinogen levels;
CESC	cis	rs240764	0.764	rs12208241	chr6:100933472	T/C	cg21058520	chr6:100914733	NA	0.39	6.05	0.35	5.04e-9	Neuroticism;
CESC	cis	rs4642101	0.824	rs9825233	chr3:12843368	A/G	cg05775895	chr3:12838266	CAND2	-0.37	-5.67	-0.33	3.66e-8	QRS complex (12-leadsum);
CESC	cis	rs10899021	0.920	rs7112664	chr11:74348426	T/C	cg25880958	chr11:74394337	NA	-0.75	-7.78	-0.43	1.6e-13	Response to metformin (IC50);
CESC	cis	rs9916302	0.904	rs7501488	chr17:37576417	T/G	cg00129232	chr17:37814104	STARD3	-0.58	-7.67	-0.43	3.25e-13	Glomerular filtration rate (creatinine);
CESC	cis	rs367943	0.698	rs6594746	chr5:112995895	A/C	cg12552261	chr5:112820674	MCC	-0.48	-6.2	-0.36	2.1e-9	Type 2 diabetes;
CESC	cis	rs7208859	0.673	rs11658435	chr17:29228561	A/G	cg19761014	chr17:28927070	LRRC37B2	0.73	5.77	0.33	2.22e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs1784581	0.588	rs9295179	chr6:162420546	G/A	cg17173639	chr6:162384350	PARK2	0.58	8.89	0.48	9.89e-17	Itch intensity from mosquito bite;
CESC	cis	rs6089829	0.962	rs6122347	chr20:61661866	C/T	cg03213289	chr20:61660250	NA	0.39	6.07	0.35	4.42e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs1218582	0.772	rs4845694	chr1:154911651	C/G	cg06221963	chr1:154839813	KCNN3	-0.66	-11.17	-0.57	5.33e-24	Prostate cancer;
CESC	cis	rs2836974	0.568	rs428602	chr21:40547004	A/G	cg11890956	chr21:40555474	PSMG1	0.96	15.92	0.7	1.67e-40	Cognitive function;
CESC	cis	rs6667605	0.506	rs10797440	chr1:2541269	A/G	cg20673091	chr1:2541236	MMEL1	0.45	7.79	0.43	1.5e-13	Inflammatory bowel disease;Ulcerative colitis;
CESC	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg26338869	chr17:61819248	STRADA	0.67	8.82	0.48	1.6e-16	Prudent dietary pattern;
CESC	cis	rs10883723	0.668	rs12414407	chr10:104387019	A/G	ch.10.2196322F	chr10:104248062	ACTR1A	-0.42	-5.18	-0.3	4.35e-7	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs1728785	0.901	rs11865339	chr16:68565296	C/T	cg02972257	chr16:68554789	NA	-0.55	-6.37	-0.36	8.21e-10	Ulcerative colitis;
CESC	cis	rs16854884	0.632	rs4535221	chr3:143658607	A/G	cg06585982	chr3:143692056	C3orf58	0.51	6.44	0.37	5.55e-10	Economic and political preferences (feminism/equality);
CESC	cis	rs9287719	0.967	rs4668691	chr2:10740494	C/T	cg00105475	chr2:10696890	NA	0.39	5.64	0.33	4.44e-8	Prostate cancer;
CESC	cis	rs9790314	0.502	rs2404342	chr3:161092562	C/T	cg03342759	chr3:160939853	NMD3	-0.54	-7.64	-0.42	4.04e-13	Morning vs. evening chronotype;
CESC	trans	rs10435719	0.902	rs11250179	chr8:11800332	C/T	cg15556689	chr8:8085844	FLJ10661	0.53	6.55	0.37	3.03e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
CESC	trans	rs7618501	0.602	rs2240327	chr3:50113034	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.43	6.13	0.35	3.11e-9	Intelligence (multi-trait analysis);
CESC	trans	rs1460163	0.685	rs1460162	chr8:80227400	A/C	cg23373626	chr5:141031295	FCHSD1	-0.58	-6.21	-0.36	2.07e-9	Creutzfeldt-Jakob disease;
CESC	cis	rs6912958	0.754	rs1051131	chr6:88221546	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.51	-6.83	-0.39	5.94e-11	Monocyte percentage of white cells;
CESC	cis	rs654950	0.806	rs1535505	chr1:42026152	A/G	cg06885757	chr1:42089581	HIVEP3	0.51	7.73	0.43	2.24e-13	Airway imaging phenotypes;
CESC	cis	rs6540556	0.723	rs12116437	chr1:209897027	G/A	cg05527609	chr1:210001259	C1orf107	-0.66	-7.32	-0.41	2.95e-12	Red blood cell count;
CESC	cis	rs2080501	0.571	rs1861657	chr16:49675807	G/T	cg27618369	chr16:49636483	ZNF423	0.36	5.36	0.31	1.84e-7	IgG glycosylation;
CESC	trans	rs10411161	0.702	rs11878580	chr19:52388485	C/T	cg22319618	chr22:45562946	NUP50	-0.75	-7.58	-0.42	5.85e-13	Breast cancer;
CESC	cis	rs929354	0.713	rs3802129	chr7:156965297	G/A	cg05182265	chr7:156933206	UBE3C	-0.5	-7.3	-0.41	3.28e-12	Body mass index;
CESC	cis	rs7000551	0.663	rs11778831	chr8:22335088	C/T	cg12081754	chr8:22256438	SLC39A14	0.44	6.11	0.35	3.51e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CESC	cis	rs651907	0.535	rs13084113	chr3:101534039	C/G	cg12386194	chr3:101231763	SENP7	0.42	5.19	0.3	4.17e-7	Colorectal cancer;
CESC	cis	rs7828089	0.582	rs13282084	chr8:22266280	T/C	cg12081754	chr8:22256438	SLC39A14	0.64	9.0	0.48	4.4e-17	Verbal declarative memory;
CESC	cis	rs910316	1.000	rs7156105	chr14:75541954	C/A	cg11812906	chr14:75593930	NEK9	0.91	15.5	0.69	5.4e-39	Height;
CESC	cis	rs10504229	0.683	rs10504223	chr8:58140944	G/A	cg21724239	chr8:58056113	NA	0.58	5.95	0.34	8.37e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg24642844	chr7:1081250	C7orf50	-0.77	-9.3	-0.5	5.54e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs9611565	0.592	rs4481089	chr22:41980892	T/C	cg03806693	chr22:41940476	POLR3H	-0.87	-10.5	-0.54	8.63e-22	Vitiligo;
CESC	cis	rs12220238	1.000	rs7083534	chr10:75955672	C/G	cg19889307	chr10:75911429	ADK;AP3M1	0.59	5.35	0.31	1.86e-7	Soluble interleukin-2 receptor subunit alpha;
CESC	cis	rs763014	0.966	rs4984904	chr16:680809	C/G	cg00802000	chr16:706648	WDR90	-0.4	-6.09	-0.35	3.85e-9	Height;
CESC	cis	rs8103278	1.000	rs1548029	chr19:46309203	A/C	cg12641515	chr19:46296257	DMWD	-0.52	-5.71	-0.33	3.07e-8	Coronary artery disease;
CESC	cis	rs9649213	0.593	rs34129434	chr7:97926464	C/T	cg00277769	chr7:97922759	BAIAP2L1	-0.34	-5.62	-0.33	4.89e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs2070488	0.775	rs7374458	chr3:38531211	T/G	cg24069376	chr3:38537580	EXOG	0.36	6.14	0.35	3.02e-9	Electrocardiographic conduction measures;
CESC	cis	rs12136530	0.774	rs12563442	chr1:19786695	T/C	cg01832549	chr1:19774989	CAPZB	-0.44	-6.04	-0.35	5.3e-9	Lead levels in blood;
CESC	cis	rs736408	0.609	rs13087772	chr3:52782274	T/G	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.31	5.44	0.32	1.24e-7	Bipolar disorder;
CESC	cis	rs2932538	0.885	rs6691025	chr1:113177070	G/T	cg22162597	chr1:113214053	CAPZA1	-0.58	-7.35	-0.41	2.46e-12	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
CESC	cis	rs7618915	0.501	rs3774366	chr3:52641255	T/C	cg07507251	chr3:52567010	NT5DC2	0.32	5.48	0.32	1.01e-7	Bipolar disorder;
CESC	cis	rs72627509	0.857	rs781658	chr4:57779567	G/A	cg26694713	chr4:57773883	REST	0.58	5.68	0.33	3.49e-8	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CESC	trans	rs78049276	0.512	rs6855875	chr4:148402737	C/T	cg13149281	chr14:23389818	RBM23;PRMT5	-0.68	-8.83	-0.48	1.47e-16	Pulse pressure;
CESC	cis	rs17826219	0.568	rs59858012	chr17:29078582	C/T	cg14008862	chr17:28927542	LRRC37B2	0.74	5.33	0.31	2.1e-7	Body mass index;
CESC	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg18402987	chr7:1209562	NA	0.76	7.56	0.42	6.59e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs8018808	0.902	rs147316	chr14:77888664	C/T	cg20045696	chr14:77926864	AHSA1	0.42	5.79	0.34	2e-8	Myeloid white cell count;
CESC	cis	rs16866061	1.000	rs2047134	chr2:225347713	A/C	cg12698349	chr2:225449008	CUL3	0.71	10.22	0.53	6.8e-21	Acute graft versus host disease in bone marrow transplantation (recipient effect);
CESC	cis	rs10206020	0.921	rs72776302	chr2:1571383	G/A	cg26248373	chr2:1572462	NA	-0.6	-6.98	-0.39	2.43e-11	IgG glycosylation;
CESC	cis	rs11792861	0.591	rs10979613	chr9:111687584	A/G	cg05043794	chr9:111880884	C9orf5	-0.29	-5.35	-0.31	1.92e-7	Menarche (age at onset);
CESC	cis	rs4819052	0.851	rs7275870	chr21:46671214	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.92	13.57	0.64	3.24e-32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs40363	0.857	rs55989968	chr16:3530658	C/G	cg05754148	chr16:3507555	NAT15	0.69	7.6	0.42	5.28e-13	Tuberculosis;
CESC	cis	rs853679	0.517	rs9468297	chr6:28118874	G/T	cg18032046	chr6:28092343	ZSCAN16	-0.6	-6.84	-0.39	5.51e-11	Depression;
CESC	cis	rs9457247	0.765	rs9457256	chr6:167436461	T/C	cg23791538	chr6:167370224	RNASET2	-0.55	-7.51	-0.42	8.97e-13	Crohn's disease;
CESC	cis	rs193541	0.632	rs415417	chr5:122322884	G/A	cg19412675	chr5:122181750	SNX24	-0.46	-5.39	-0.31	1.58e-7	Glucose homeostasis traits;
CESC	cis	rs7395581	0.959	rs7120118	chr11:47286290	T/C	cg25783544	chr11:47291846	MADD	0.61	7.93	0.44	6.27e-14	HDL cholesterol;
CESC	cis	rs1059312	0.771	rs7974764	chr12:129296588	G/C	cg09035930	chr12:129282057	SLC15A4	0.69	9.2	0.49	1.1e-17	Systemic lupus erythematosus;
CESC	cis	rs2439831	0.850	rs3736180	chr15:44106624	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.69	7.59	0.42	5.34e-13	Lung cancer in ever smokers;
CESC	cis	rs1862618	0.853	rs10461617	chr5:56104308	A/G	cg24549020	chr5:56110836	MAP3K1	0.63	7.27	0.41	4.11e-12	Initial pursuit acceleration;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05640416	chr10:135176430	ECHS1	-0.5	-6.01	-0.35	6e-9	Gut microbiome composition (summer);
CESC	cis	rs6964587	0.839	rs13229273	chr7:91444472	G/A	cg17063962	chr7:91808500	NA	0.5	6.43	0.37	5.84e-10	Breast cancer;
CESC	cis	rs3747547	0.710	rs7864512	chr9:37949638	G/A	cg13774184	chr9:37916125	SHB	-0.57	-5.86	-0.34	1.39e-8	Metabolite levels (Dihydroxy docosatrienoic acid);
CESC	cis	rs56104184	0.775	rs17272700	chr19:49391770	G/A	cg15549821	chr19:49342101	PLEKHA4	-0.59	-5.82	-0.34	1.7e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	7.7	0.43	2.77e-13	Prudent dietary pattern;
CESC	trans	rs35110281	0.748	rs4997353	chr21:45002329	A/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.5	6.71	0.38	1.18e-10	Mean corpuscular volume;
CESC	cis	rs7264396	0.563	rs6058302	chr20:34290037	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.64	6.86	0.39	4.8e-11	Total cholesterol levels;
CESC	cis	rs10911251	0.546	rs1547714	chr1:183114119	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.84	13.22	0.63	5.53e-31	Colorectal cancer;
CESC	cis	rs9660992	0.573	rs12144980	chr1:205185104	C/T	cg00857998	chr1:205179979	DSTYK	0.53	6.59	0.38	2.35e-10	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs9487051	0.621	rs446974	chr6:109525589	A/C	cg01475377	chr6:109611718	NA	-0.39	-5.3	-0.31	2.44e-7	Reticulocyte fraction of red cells;
CESC	cis	rs7776786	0.934	rs17349342	chr7:18815473	A/C	cg13420273	chr7:18810212	HDAC9	0.34	5.18	0.3	4.42e-7	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs3540	0.514	rs2601192	chr15:90936704	G/A	cg22089800	chr15:90895588	ZNF774	0.67	9.33	0.5	4.5e-18	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
CESC	cis	rs13108904	0.901	rs1680073	chr4:1280337	G/A	cg16405210	chr4:1374714	KIAA1530	0.47	5.97	0.34	7.64e-9	Obesity-related traits;
CESC	cis	rs4253772	0.591	rs8135363	chr22:46651713	T/C	cg24881330	chr22:46731750	TRMU	0.89	10.09	0.53	1.86e-20	LDL cholesterol;Cholesterol, total;
CESC	cis	rs992157	0.835	rs6707559	chr2:219142773	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.7	9.32	0.5	4.66e-18	Colorectal cancer;
CESC	cis	rs7666738	0.800	rs10028921	chr4:98962630	G/T	cg03467027	chr4:99064603	C4orf37	0.44	5.55	0.32	6.77e-8	Colonoscopy-negative controls vs population controls;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg22513962	chr8:67976521	CSPP1	-0.46	-6.27	-0.36	1.43e-9	Fibrinogen levels;
CESC	cis	rs3784262	0.934	rs7164408	chr15:58259336	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.31	-5.05	-0.3	8.37e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
CESC	cis	rs11650494	0.908	rs73324308	chr17:47405338	T/G	cg08112188	chr17:47440006	ZNF652	1.11	7.72	0.43	2.31e-13	Prostate cancer;
CESC	cis	rs11077998	0.869	rs6502123	chr17:80532170	T/C	cg10255544	chr17:80519551	FOXK2	0.55	8.73	0.47	2.83e-16	Reticulocyte fraction of red cells;
CESC	cis	rs698833	0.926	rs786407	chr2:44735865	T/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	6.16	0.35	2.68e-9	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs1881797	0.932	rs10925071	chr1:247686521	C/T	cg05639522	chr1:247681581	NA	-0.47	-6.68	-0.38	1.42e-10	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs36051895	0.589	rs1322222	chr9:5190444	A/G	cg02405213	chr9:5042618	JAK2	-0.55	-6.9	-0.39	3.83e-11	Pediatric autoimmune diseases;
CESC	cis	rs72615157	0.664	rs6953580	chr7:99825275	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.52	5.81	0.34	1.75e-8	Lung function (FEV1/FVC);
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg01160766	chr17:72199871	RPL38	-0.42	-6.25	-0.36	1.65e-9	Vertical cup-disc ratio;
CESC	cis	rs17401966	1.000	rs4845934	chr1:10468946	G/A	cg15208524	chr1:10270712	KIF1B	0.44	5.59	0.32	5.66e-8	Hepatocellular carcinoma;
CESC	cis	rs1005277	0.579	rs1780139	chr10:38503018	C/T	cg25427524	chr10:38739819	LOC399744	-0.73	-10.93	-0.56	3.43e-23	Extrinsic epigenetic age acceleration;
CESC	cis	rs4718428	0.705	rs4718422	chr7:66359269	A/G	cg18252515	chr7:66147081	NA	-0.46	-5.17	-0.3	4.51e-7	Corneal structure;
CESC	cis	rs2845885	0.793	rs57779243	chr11:63882363	G/T	cg24431193	chr11:63883947	FLRT1;MACROD1	0.81	9.49	0.5	1.39e-18	Body mass index;
CESC	cis	rs9900062	0.586	rs2676307	chr17:62690713	C/G	cg02598441	chr17:62777298	LOC146880	-0.48	-5.05	-0.3	8.17e-7	QT interval;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg03020000	chr10:63662887	ARID5B	0.47	6.83	0.39	5.9e-11	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs1878047	0.665	rs34589735	chr19:51775380	T/C	cg14884932	chr19:51774451	NA	-0.37	-5.16	-0.3	4.87e-7	Body mass index;
CESC	cis	rs2735413	0.875	rs12923229	chr16:78080302	C/A	cg04733911	chr16:78082701	NA	-0.54	-9.15	-0.49	1.54e-17	Systolic blood pressure (alcohol consumption interaction);
CESC	cis	rs58688157	0.705	rs12419720	chr11:598205	C/G	cg02461776	chr11:598696	PHRF1	0.51	5.92	0.34	1.01e-8	Systemic lupus erythematosus;
CESC	cis	rs2637266	0.739	rs11001838	chr10:78376351	T/G	cg18941641	chr10:78392320	NA	-0.34	-5.46	-0.32	1.1e-7	Pulmonary function;
CESC	cis	rs1801251	1.000	rs283480	chr2:233648742	G/A	cg25237894	chr2:233734115	C2orf82	0.46	7.81	0.43	1.33e-13	Coronary artery disease;
CESC	cis	rs2708240	1.000	rs2538985	chr7:147580902	A/G	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.34	-5.68	-0.33	3.56e-8	QT interval (drug interaction);
CESC	cis	rs12681366	0.734	rs10504936	chr8:95392055	C/T	cg13257157	chr8:95487014	RAD54B	0.38	5.11	0.3	6.3e-7	Nonsyndromic cleft lip with cleft palate;
CESC	cis	rs28386778	0.701	rs2727337	chr17:61991966	G/A	cg07677032	chr17:61819896	STRADA	-0.46	-6.18	-0.35	2.44e-9	Prudent dietary pattern;
CESC	cis	rs897984	0.553	rs2335013	chr16:30877346	T/G	cg02466173	chr16:30829666	NA	0.47	6.77	0.38	8.11e-11	Dementia with Lewy bodies;
CESC	cis	rs7659604	0.540	rs11734075	chr4:122695685	C/T	cg19671926	chr4:122722719	EXOSC9	0.65	8.61	0.47	6.79e-16	Type 2 diabetes;
CESC	cis	rs2599510	0.783	rs13399071	chr2:32793783	C/T	cg02381751	chr2:32503542	YIPF4	0.46	5.73	0.33	2.72e-8	Interleukin-18 levels;
CESC	cis	rs7666738	0.830	rs28687737	chr4:99009226	G/A	cg03676636	chr4:99064102	C4orf37	0.33	5.16	0.3	4.86e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7666738	0.791	rs34088022	chr4:99001508	G/T	cg03467027	chr4:99064603	C4orf37	0.44	5.51	0.32	8.65e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1062177	0.756	rs2964589	chr5:151118189	G/T	cg12924095	chr5:151150029	G3BP1	-0.41	-5.16	-0.3	4.87e-7	Preschool internalizing problems;
CESC	cis	rs9925964	0.967	rs9936329	chr16:31140799	G/T	cg02466173	chr16:30829666	NA	0.34	5.08	0.3	6.96e-7	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs7223966	1.000	rs11654335	chr17:61797579	A/T	cg11494091	chr17:61959527	GH2	0.38	5.19	0.3	4.28e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs2836974	0.932	rs2234543	chr21:40572072	G/A	cg17971929	chr21:40555470	PSMG1	1.06	16.26	0.71	1.02e-41	Cognitive function;
CESC	cis	rs17253792	0.545	rs12879564	chr14:56017694	A/G	cg01858014	chr14:56050164	KTN1	-0.87	-6.37	-0.36	8.34e-10	Putamen volume;
CESC	cis	rs2280018	0.609	rs2941253	chr16:15173746	G/A	cg07549590	chr16:15018862	NA	-0.52	-8.2	-0.45	1.05e-14	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs4835473	0.932	rs4835471	chr4:144903306	C/T	cg25736465	chr4:144833511	NA	0.4	6.12	0.35	3.42e-9	Immature fraction of reticulocytes;
CESC	cis	rs763121	0.853	rs5757232	chr22:39071677	C/T	cg14440974	chr22:39074834	NA	-0.42	-5.89	-0.34	1.14e-8	Menopause (age at onset);
CESC	cis	rs2576037	0.526	rs658756	chr18:44431832	A/G	cg19077165	chr18:44547161	KATNAL2	-0.55	-8.24	-0.45	7.77e-15	Personality dimensions;
CESC	cis	rs8072100	0.875	rs12451409	chr17:45544856	A/G	cg08085267	chr17:45401833	C17orf57	-0.56	-7.43	-0.42	1.51e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs7618915	0.571	rs1961959	chr3:52585760	G/C	cg18404041	chr3:52824283	ITIH1	-0.41	-6.72	-0.38	1.09e-10	Bipolar disorder;
CESC	cis	rs9916302	0.851	rs4794810	chr17:37603774	T/C	cg00129232	chr17:37814104	STARD3	-0.57	-7.72	-0.43	2.35e-13	Glomerular filtration rate (creatinine);
CESC	cis	rs9733	0.596	rs6686525	chr1:150635811	C/T	cg09365446	chr1:150670422	GOLPH3L	0.42	5.93	0.34	9.63e-9	Tonsillectomy;
CESC	cis	rs2404602	0.647	rs11072625	chr15:77084984	A/G	cg23625390	chr15:77176239	SCAPER	0.39	5.25	0.31	3.13e-7	Blood metabolite levels;
CESC	cis	rs6785206	0.667	rs6439139	chr3:128410285	T/C	cg16766828	chr3:128327626	NA	-0.53	-5.05	-0.3	8.16e-7	Lymphocyte percentage of white cells;
CESC	cis	rs9457247	1.000	rs400176	chr6:167406238	T/C	cg25258033	chr6:167368657	RNASET2	0.39	5.89	0.34	1.15e-8	Crohn's disease;
CESC	cis	rs6690583	0.943	rs1837329	chr1:85469614	G/A	cg22153463	chr1:85462885	MCOLN2	-0.76	-8.93	-0.48	7.44e-17	Serum sulfate level;
CESC	cis	rs514406	0.929	rs2607095	chr1:53325639	T/C	cg16325326	chr1:53192061	ZYG11B	0.82	12.7	0.62	3.43e-29	Monocyte count;
CESC	cis	rs13191362	1.000	rs34594856	chr6:163051845	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.91	9.96	0.52	4.74e-20	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs796364	0.806	rs34510964	chr2:201010676	C/G	cg23649088	chr2:200775458	C2orf69	-0.58	-5.71	-0.33	3.07e-8	Schizophrenia;
CESC	cis	rs9929218	0.906	rs9932679	chr16:68751904	A/G	cg02972257	chr16:68554789	NA	0.58	6.65	0.38	1.63e-10	Colorectal cancer;
CESC	cis	rs2731664	0.792	rs335467	chr5:176890642	A/G	cg23176889	chr5:176863531	GRK6	-0.6	-10.19	-0.53	8.43e-21	Intelligence (multi-trait analysis);
CESC	cis	rs875971	0.862	rs4368860	chr7:65608482	C/G	cg18252515	chr7:66147081	NA	0.4	5.13	0.3	5.57e-7	Aortic root size;
CESC	cis	rs13385	0.769	rs56997077	chr5:139558412	C/T	cg26211634	chr5:139558579	C5orf32	0.47	5.16	0.3	4.77e-7	Atrial fibrillation;
CESC	cis	rs13256369	0.802	rs12681326	chr8:8566389	G/A	cg00074818	chr8:8560427	CLDN23	0.38	5.51	0.32	8.52e-8	Obesity-related traits;
CESC	cis	rs3796352	1.000	rs61172708	chr3:52996052	T/G	cg12962167	chr3:53033115	SFMBT1	0.62	5.13	0.3	5.63e-7	Immune reponse to smallpox (secreted IL-2);
CESC	trans	rs208520	0.779	rs208446	chr6:66903515	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.84	-9.54	-0.51	9.64e-19	Exhaled nitric oxide output;
CESC	cis	rs1023500	0.573	rs133374	chr22:42465941	G/A	cg15557168	chr22:42548783	NA	-0.45	-6.5	-0.37	3.87e-10	Schizophrenia;
CESC	cis	rs4930103	0.904	rs59121562	chr11:2025034	A/T	cg23202291	chr11:1979235	NA	0.38	5.73	0.33	2.78e-8	DNA methylation (parent-of-origin);DNA methylation (variation);
CESC	cis	rs909674	0.731	rs6001594	chr22:39837472	C/T	cg05872129	chr22:39784769	NA	-0.8	-10.43	-0.54	1.49e-21	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08877624	chr8:141521446	CHRAC1	0.6	7.15	0.4	8.21e-12	Gut microbiome composition (summer);
CESC	cis	rs3740713	1.000	rs76599129	chr11:18471627	T/A	cg23797887	chr11:18477753	LDHAL6A	-0.54	-5.21	-0.31	3.72e-7	Amyotrophic lateral sclerosis (sporadic);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18386867	chr2:39347986	SOS1	0.5	6.09	0.35	3.99e-9	Gut microbiome composition (summer);
CESC	cis	rs3815700	1.000	rs8108840	chr19:33094452	A/C	cg24916020	chr19:33096688	ANKRD27	0.58	5.37	0.31	1.69e-7	Eosinophilic esophagitis;
CESC	cis	rs10540	1.000	rs61876333	chr11:487136	G/A	cg21784768	chr11:537496	LRRC56	-0.58	-5.29	-0.31	2.62e-7	Body mass index;
CESC	cis	rs7223966	1.000	rs9912904	chr17:61763534	A/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.44	-5.16	-0.3	4.73e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs9393777	0.513	rs9368448	chr6:26649355	T/C	cg12292205	chr6:26970375	C6orf41	-0.53	-5.76	-0.33	2.33e-8	Intelligence (multi-trait analysis);
CESC	cis	rs2276314	0.857	rs62101402	chr18:33629435	A/G	cg19628046	chr18:33552617	C18orf21	0.5	5.66	0.33	3.84e-8	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs3785574	0.962	rs2584630	chr17:61887561	T/A	cg07677032	chr17:61819896	STRADA	0.42	5.33	0.31	2.12e-7	Height;
CESC	cis	rs10851478	0.872	rs11852336	chr15:49948824	T/C	cg08060515	chr15:49448048	GALK2;COPS2	0.43	5.28	0.31	2.69e-7	Oral cavity cancer;
CESC	cis	rs9649213	0.614	rs59120980	chr7:98017730	G/A	cg09267113	chr7:98030324	BAIAP2L1	-0.45	-6.08	-0.35	4.25e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7666738	0.753	rs11097594	chr4:98944486	A/G	cg17366294	chr4:99064904	C4orf37	0.61	8.52	0.46	1.25e-15	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04094107	chr15:73976560	CD276	0.58	6.47	0.37	4.73e-10	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.791	rs34437628	chr4:99029232	C/G	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.58e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs12136530	0.651	rs10753561	chr1:19711939	T/C	cg15026089	chr1:19640712	PQLC2	0.33	5.08	0.3	7.13e-7	Lead levels in blood;
CESC	cis	rs8072100	0.688	rs12602134	chr17:45582136	C/G	cg08085267	chr17:45401833	C17orf57	0.48	6.57	0.37	2.73e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	cis	rs12477438	0.765	rs12470471	chr2:99689141	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.62	8.67	0.47	4.33e-16	Chronic sinus infection;
CESC	trans	rs6089829	0.926	rs7273917	chr20:61665975	G/A	cg23505145	chr19:12996616	KLF1	0.52	6.78	0.38	7.78e-11	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs1448094	0.511	rs17345975	chr12:86202318	T/A	cg00310523	chr12:86230176	RASSF9	0.39	6.12	0.35	3.26e-9	Major depressive disorder;
CESC	cis	rs9660992	0.674	rs17345816	chr1:205262868	A/T	cg21643547	chr1:205240462	TMCC2	0.47	6.26	0.36	1.54e-9	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs12971120	0.891	rs3764510	chr18:72166846	A/G	cg26446133	chr18:72167187	CNDP2	-0.77	-9.41	-0.5	2.5e-18	Refractive error;
CESC	cis	rs28386778	0.701	rs2727337	chr17:61991966	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.99	-17.01	-0.72	2.37e-44	Prudent dietary pattern;
CESC	cis	rs17539620	0.624	rs62432739	chr6:154835926	A/G	cg17771515	chr6:154831774	CNKSR3	0.59	5.85	0.34	1.43e-8	Lipoprotein (a) levels;
CESC	cis	rs977987	0.778	rs2865528	chr16:75455942	T/C	cg03315344	chr16:75512273	CHST6	0.41	5.98	0.34	7.31e-9	Dupuytren's disease;
CESC	cis	rs9463078	0.774	rs4510673	chr6:45350107	A/G	cg25276700	chr6:44698697	NA	0.34	5.06	0.3	8.02e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
CESC	cis	rs9303401	0.661	rs9902820	chr17:56637545	A/C	cg12560992	chr17:57184187	TRIM37	0.56	7.18	0.4	6.88e-12	Cognitive test performance;
CESC	cis	rs67460515	0.567	rs34691229	chr3:160876897	G/T	cg03342759	chr3:160939853	NMD3	-0.54	-6.92	-0.39	3.36e-11	Parkinson's disease;
CESC	cis	rs9611565	0.512	rs1534932	chr22:42150146	C/T	cg06481639	chr22:41940642	POLR3H	0.62	6.14	0.35	2.97e-9	Vitiligo;
CESC	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg21280719	chr6:42927975	GNMT	-0.29	-6.72	-0.38	1.14e-10	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs1153858	0.621	rs2687512	chr15:45581495	T/C	cg14582100	chr15:45693742	SPATA5L1	-0.41	-5.49	-0.32	9.63e-8	Homoarginine levels;
CESC	cis	rs4253772	0.938	rs77378083	chr22:46639386	G/A	cg00784671	chr22:46762841	CELSR1	-0.57	-5.6	-0.33	5.29e-8	LDL cholesterol;Cholesterol, total;
CESC	cis	rs4974559	0.594	rs11946384	chr4:1313566	T/C	cg02980000	chr4:1222292	CTBP1	0.62	7.25	0.41	4.59e-12	Systolic blood pressure;
CESC	cis	rs4555082	0.874	rs2816612	chr14:105723103	C/T	cg13114125	chr14:105738426	BRF1	-0.85	-10.46	-0.54	1.18e-21	Mean platelet volume;Platelet distribution width;
CESC	cis	rs12893668	0.572	rs12590968	chr14:104136633	G/C	cg08213375	chr14:104286397	PPP1R13B	0.33	5.41	0.32	1.4e-7	Reticulocyte count;
CESC	cis	rs7249142	0.512	rs12981160	chr19:19298099	T/A	cg27384695	chr19:19271486	LOC729991-MEF2B;MEF2B	0.29	5.09	0.3	6.78e-7	IgG glycosylation;
CESC	cis	rs10883723	0.773	rs1326193	chr10:104271674	G/T	cg22532475	chr10:104410764	TRIM8	-0.35	-5.9	-0.34	1.13e-8	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs916888	0.773	rs199535	chr17:44822662	A/G	cg15921436	chr17:44337874	NA	0.76	8.49	0.46	1.53e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs6690583	0.562	rs12024977	chr1:85531051	A/C	cg22153463	chr1:85462885	MCOLN2	0.7	6.93	0.39	3.23e-11	Serum sulfate level;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09212610	chr15:90892496	GABARAPL3	-0.6	-6.94	-0.39	3.09e-11	Gut microbiome composition (summer);
CESC	cis	rs10504229	0.683	rs55868006	chr8:58135703	C/T	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs7527798	0.614	rs11118253	chr1:207825469	G/C	cg21110645	chr1:207815933	NA	-0.33	-5.88	-0.34	1.21e-8	Erythrocyte sedimentation rate;
CESC	cis	rs8060686	0.641	rs8059305	chr16:68036666	A/C	cg26727032	chr16:67993705	SLC12A4	-0.52	-7.2	-0.4	6.08e-12	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs7267979	0.903	rs6050482	chr20:25226327	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.8	15.59	0.69	2.47e-39	Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs352242	0.726	rs975097	chr13:69871862	A/T	cg15456293	chr8:2044148	MYOM2	-0.36	-6.02	-0.35	5.76e-9	Life satisfaction;
CESC	cis	rs651907	0.535	rs61396602	chr3:101509046	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.43	5.67	0.33	3.81e-8	Colorectal cancer;
CESC	cis	rs4713118	0.527	rs35949862	chr6:28115367	A/G	cg22143856	chr6:28129313	ZNF389	0.53	6.71	0.38	1.2e-10	Parkinson's disease;
CESC	cis	rs4595586	0.546	rs2056159	chr12:39270417	C/G	cg13010199	chr12:38710504	ALG10B	0.58	7.71	0.43	2.47e-13	Morning vs. evening chronotype;
CESC	cis	rs9584850	0.874	rs3742137	chr13:99102449	C/T	cg20750642	chr13:99100586	FARP1	-0.39	-5.85	-0.34	1.45e-8	Neuroticism;
CESC	cis	rs9611565	0.532	rs202627	chr22:41847367	A/T	cg06634786	chr22:41940651	POLR3H	0.58	6.21	0.36	2.04e-9	Vitiligo;
CESC	cis	rs6540559	1.000	rs2073485	chr1:209962794	G/A	cg23283495	chr1:209979779	IRF6	0.52	7.42	0.41	1.62e-12	Cleft lip with or without cleft palate;
CESC	cis	rs896854	0.654	rs13281625	chr8:95972738	T/C	cg16049864	chr8:95962084	TP53INP1	-0.65	-11.35	-0.57	1.31e-24	Type 2 diabetes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17847749	chr12:116355168	NA	-0.61	-7.03	-0.4	1.71e-11	Gut microbiome composition (summer);
CESC	cis	rs6570726	1.000	rs405622	chr6:145871897	G/T	cg23711669	chr6:146136114	FBXO30	0.77	11.24	0.57	3.15e-24	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs832540	0.629	rs10461616	chr5:56080347	T/C	cg12311346	chr5:56204834	C5orf35	-0.43	-5.38	-0.31	1.64e-7	Coronary artery disease;
CESC	cis	rs11098499	0.874	rs28452522	chr4:120110784	A/G	cg09307838	chr4:120376055	NA	0.65	7.83	0.43	1.17e-13	Corneal astigmatism;
CESC	cis	rs561341	1.000	rs546748	chr17:30324293	A/C	cg12193833	chr17:30244370	NA	-0.53	-6.0	-0.35	6.57e-9	Hip circumference adjusted for BMI;
CESC	cis	rs9325144	0.647	rs12830095	chr12:38864199	C/T	cg26384229	chr12:38710491	ALG10B	-0.56	-7.89	-0.44	8.02e-14	Morning vs. evening chronotype;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04677326	chr19:3557664	C19orf28	0.56	6.86	0.39	4.93e-11	Gut microbiome composition (summer);
CESC	cis	rs798554	0.686	rs7777484	chr7:2814271	A/G	cg19717773	chr7:2847554	GNA12	-0.57	-8.87	-0.48	1.11e-16	Height;
CESC	cis	rs453301	0.686	rs2409120	chr8:8882571	G/C	cg15556689	chr8:8085844	FLJ10661	-0.49	-5.94	-0.34	9.08e-9	Joint mobility (Beighton score);
CESC	cis	rs9549367	0.789	rs2287250	chr13:113889474	C/T	cg18105134	chr13:113819100	PROZ	0.6	7.49	0.42	1.04e-12	Platelet distribution width;
CESC	cis	rs7481584	0.624	rs412842	chr11:3047448	A/G	cg08508325	chr11:3079039	CARS	0.29	5.08	0.3	7.06e-7	Calcium levels;
CESC	cis	rs7640424	0.649	rs13091474	chr3:107877134	A/T	cg09227934	chr3:107805635	CD47	-0.44	-5.67	-0.33	3.75e-8	Body mass index;
CESC	cis	rs1843834	0.539	rs6713629	chr2:225410973	A/T	cg22509189	chr2:225307070	NA	-0.4	-5.39	-0.31	1.58e-7	IgE levels in asthmatics (D.p. specific);
CESC	cis	rs1878931	0.624	rs37810	chr16:3451881	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.81	-9.94	-0.52	5.62e-20	Body mass index (adult);
CESC	cis	rs4974559	0.690	rs28515563	chr4:1315123	G/A	cg02980000	chr4:1222292	CTBP1	0.79	7.35	0.41	2.44e-12	Systolic blood pressure;
CESC	cis	rs2404602	0.583	rs2456076	chr15:76557553	T/G	cg26408565	chr15:76604113	ETFA	0.39	5.91	0.34	1.05e-8	Blood metabolite levels;
CESC	cis	rs7560272	0.512	rs4530394	chr2:73929650	T/C	cg20560298	chr2:73613845	ALMS1	0.45	6.17	0.35	2.52e-9	Schizophrenia;
CESC	cis	rs1144333	1.000	rs60144605	chr1:76359699	A/C	cg10523679	chr1:76189770	ACADM	0.56	5.31	0.31	2.27e-7	Attention function in attention deficit hyperactive disorder;
CESC	cis	rs4819052	0.851	rs2236443	chr21:46678174	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.76	10.33	0.54	3.05e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs1996720	0.958	rs2353254	chr8:113068212	A/G	cg02687417	chr20:43977232	SDC4	0.46	5.99	0.35	6.64e-9	Temperament;
CESC	cis	rs763121	0.962	rs6001193	chr22:39074737	A/G	cg06022373	chr22:39101656	GTPBP1	0.8	13.36	0.63	1.76e-31	Menopause (age at onset);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg23116115	chr4:1004261	FGFRL1	-0.46	-6.12	-0.35	3.4e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs17711722	0.640	rs13237956	chr7:65318029	G/A	cg11764359	chr7:65958608	NA	0.67	8.6	0.47	7.12e-16	Calcium levels;
CESC	cis	rs2075371	1.000	rs2598296	chr7:133992985	C/T	cg11752832	chr7:134001865	SLC35B4	0.55	7.16	0.4	8.05e-12	Mean platelet volume;
CESC	cis	rs62064224	0.720	rs8078837	chr17:30763537	A/G	cg18200150	chr17:30822561	MYO1D	0.73	11.72	0.58	7.69e-26	Schizophrenia;
CESC	cis	rs6867032	0.527	rs13153217	chr5:2012788	G/T	cg26168224	chr5:2018326	NA	-0.6	-9.18	-0.49	1.24e-17	Gut microbiome composition (winter);
CESC	cis	rs9325144	0.505	rs7138977	chr12:38642109	G/A	cg13010199	chr12:38710504	ALG10B	0.46	6.35	0.36	9.31e-10	Morning vs. evening chronotype;
CESC	cis	rs684232	0.623	rs12601935	chr17:519325	G/A	cg12384639	chr17:618140	VPS53	0.43	5.51	0.32	8.37e-8	Prostate cancer;
CESC	cis	rs1005277	0.540	rs2224248	chr10:38451886	A/G	cg25427524	chr10:38739819	LOC399744	-0.67	-9.8	-0.52	1.46e-19	Extrinsic epigenetic age acceleration;
CESC	cis	rs77956314	0.515	rs7302025	chr12:117442902	C/T	cg16111737	chr12:117408163	FBXW8	-0.46	-5.72	-0.33	2.87e-8	Subcortical brain region volumes;Hippocampal volume;
CESC	cis	rs4835473	0.932	rs34617134	chr4:144904759	T/C	cg25736465	chr4:144833511	NA	0.41	6.16	0.35	2.72e-9	Immature fraction of reticulocytes;
CESC	cis	rs3733418	0.860	rs869867	chr4:165930747	C/G	cg10852876	chr4:165953100	TRIM60	-0.51	-6.01	-0.35	6.03e-9	Obesity-related traits;
CESC	cis	rs10838687	0.800	rs3729805	chr11:47352757	C/T	cg25783544	chr11:47291846	MADD	0.55	6.23	0.36	1.8e-9	Proinsulin levels;
CESC	cis	rs6456156	0.586	rs13210649	chr6:167473193	T/G	cg07741184	chr6:167504864	NA	0.37	6.39	0.37	7.28e-10	Primary biliary cholangitis;
CESC	cis	rs4665809	0.590	rs13016300	chr2:26468365	G/C	cg22920501	chr2:26401640	FAM59B	0.91	10.33	0.54	3.07e-21	Gut microbiome composition (summer);
CESC	cis	rs10242455	0.702	rs78080383	chr7:99064465	C/T	cg18809830	chr7:99032528	PTCD1	-0.84	-5.61	-0.33	5e-8	Blood metabolite levels;
CESC	cis	rs28386778	0.701	rs2727337	chr17:61991966	G/A	cg26338869	chr17:61819248	STRADA	-0.63	-8.19	-0.45	1.12e-14	Prudent dietary pattern;
CESC	cis	rs12926788	0.640	rs12924246	chr16:24844629	A/G	cg06028605	chr16:24865363	SLC5A11	0.55	8.35	0.46	3.75e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs7208859	0.623	rs11650271	chr17:29213943	C/T	cg13385521	chr17:29058706	SUZ12P	0.66	5.03	0.3	9.15e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs3126085	0.935	rs12144058	chr1:152170216	C/T	cg26876637	chr1:152193138	HRNR	0.44	5.04	0.3	8.68e-7	Atopic dermatitis;
CESC	cis	rs35110281	0.743	rs230640	chr21:44914815	A/T	cg04455712	chr21:45112962	RRP1B	-0.38	-5.71	-0.33	3.08e-8	Mean corpuscular volume;
CESC	trans	rs61931739	0.500	rs7489132	chr12:34539712	C/T	cg26384229	chr12:38710491	ALG10B	0.72	10.84	0.55	6.43e-23	Morning vs. evening chronotype;
CESC	cis	rs2836974	0.831	rs11911149	chr21:40528375	C/T	cg27266027	chr21:40555129	PSMG1	0.48	5.86	0.34	1.37e-8	Cognitive function;
CESC	cis	rs896854	0.654	rs16893776	chr8:95973604	C/T	cg09323728	chr8:95962352	TP53INP1	-0.37	-7.93	-0.44	6.24e-14	Type 2 diabetes;
CESC	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg14159672	chr1:205819179	PM20D1	0.8	11.64	0.58	1.39e-25	Menarche (age at onset);
CESC	cis	rs933688	1.000	rs6862125	chr5:90724598	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.17	15.64	0.69	1.6e-39	Smoking behavior;
CESC	cis	rs7618915	0.501	rs7611731	chr3:52692721	T/C	cg05564831	chr3:52568323	NT5DC2	0.46	7.38	0.41	2.06e-12	Bipolar disorder;
CESC	cis	rs12477438	0.765	rs7607578	chr2:99669771	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.64	-8.73	-0.47	2.94e-16	Chronic sinus infection;
CESC	cis	rs6141600	0.760	rs2746097	chr20:34672923	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.41	-5.56	-0.32	6.63e-8	Height;Hip circumference;
CESC	trans	rs656319	0.625	rs4526366	chr8:9890179	C/G	cg06636001	chr8:8085503	FLJ10661	-0.55	-6.49	-0.37	4.22e-10	Myopia (pathological);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg18788524	chr1:145096602	SEC22B	-0.47	-6.22	-0.36	1.98e-9	Fibrinogen levels;
CESC	cis	rs2243480	1.000	rs35735127	chr7:65300423	G/T	cg12463550	chr7:65579703	CRCP	0.68	5.74	0.33	2.59e-8	Diabetic kidney disease;
CESC	cis	rs1018836	0.923	rs2105965	chr8:91537690	T/C	cg16814680	chr8:91681699	NA	-0.74	-11.22	-0.57	3.66e-24	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs1594829	0.553	rs2046226	chr8:26152050	G/A	cg11498726	chr8:26250323	BNIP3L	-0.4	-6.06	-0.35	4.68e-9	Height;
CESC	cis	rs7143963	0.666	rs2403102	chr14:103306215	C/T	cg24154132	chr14:103367632	TRAF3	0.35	6.35	0.36	9.56e-10	Body mass index;
CESC	cis	rs1425132	0.642	rs2033044	chr7:37589834	A/C	cg15028436	chr7:37888078	TXNDC3	-0.31	-5.13	-0.3	5.63e-7	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
CESC	cis	rs6912958	0.712	rs2754260	chr6:88397666	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.54	-7.05	-0.4	1.55e-11	Monocyte percentage of white cells;
CESC	cis	rs2204008	0.682	rs2320517	chr12:38259239	A/T	cg13010199	chr12:38710504	ALG10B	0.52	6.38	0.36	8.04e-10	Bladder cancer;
CESC	cis	rs936229	0.749	rs8031937	chr15:75181121	A/G	cg14664628	chr15:75095509	CSK	-0.72	-9.05	-0.49	3.28e-17	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CESC	cis	rs9815354	1.000	rs13325965	chr3:41914942	G/T	cg03022575	chr3:42003672	ULK4	0.59	5.91	0.34	1.08e-8	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs2243480	0.803	rs34004500	chr7:65312178	A/T	cg12463550	chr7:65579703	CRCP	0.68	5.73	0.33	2.72e-8	Diabetic kidney disease;
CESC	cis	rs2576037	0.583	rs2164104	chr18:44567743	G/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.47	6.19	0.36	2.31e-9	Personality dimensions;
CESC	cis	rs12477438	0.748	rs7558239	chr2:99640581	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-10.57	-0.54	5.22e-22	Chronic sinus infection;
CESC	cis	rs9287719	0.746	rs6742448	chr2:10759126	G/A	cg02196655	chr2:10830764	NOL10	-0.36	-5.59	-0.32	5.58e-8	Prostate cancer;
CESC	cis	rs9486719	1.000	rs2472884	chr6:96863965	C/T	cg18709589	chr6:96969512	KIAA0776	0.52	5.67	0.33	3.8e-8	Migraine;Coronary artery disease;
CESC	cis	rs1862618	0.853	rs9283717	chr5:56078659	G/A	cg24549020	chr5:56110836	MAP3K1	0.64	7.32	0.41	3.05e-12	Initial pursuit acceleration;
CESC	cis	rs6032067	0.777	rs35476703	chr20:43802875	C/G	cg10761708	chr20:43804764	PI3	0.56	6.65	0.38	1.7e-10	Blood protein levels;
CESC	cis	rs765787	0.530	rs4514617	chr15:45535439	A/G	cg24006582	chr15:45444508	DUOX1	-0.51	-6.43	-0.37	6.05e-10	Uric acid levels;
CESC	cis	rs9300255	0.602	rs1716172	chr12:123712712	G/T	cg05973401	chr12:123451056	ABCB9	0.5	5.65	0.33	4.1e-8	Neutrophil percentage of white cells;
CESC	cis	rs6570726	0.935	rs447818	chr6:145868996	C/T	cg23711669	chr6:146136114	FBXO30	0.79	11.47	0.58	5.24e-25	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9733	0.519	rs7511673	chr1:150707636	A/T	cg17724175	chr1:150552817	MCL1	0.45	7.41	0.41	1.71e-12	Tonsillectomy;
CESC	trans	rs35110281	0.774	rs9978811	chr21:44998683	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.48	6.49	0.37	4.14e-10	Mean corpuscular volume;
CESC	cis	rs9818758	0.607	rs80170003	chr3:48951640	T/C	cg00383909	chr3:49044727	WDR6	0.93	6.36	0.36	8.7e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CESC	cis	rs2479724	0.840	rs6925777	chr6:41750822	C/T	cg08135965	chr6:41755394	TOMM6	-0.41	-5.54	-0.32	7.45e-8	Menarche (age at onset);
CESC	cis	rs769267	0.931	rs2965193	chr19:19454828	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.63	-8.19	-0.45	1.15e-14	Tonsillectomy;
CESC	cis	rs9811920	0.809	rs6802817	chr3:99779264	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.45	-7.44	-0.42	1.38e-12	Axial length;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg00711596	chr19:2115281	AP3D1	0.45	6.04	0.35	5.26e-9	Fibrinogen levels;
CESC	cis	rs7605827	0.930	rs4668447	chr2:15516166	T/C	cg19274914	chr2:15703543	NA	0.32	5.55	0.32	6.84e-8	Educational attainment (years of education);
CESC	cis	rs9611565	0.681	rs6002372	chr22:41801299	A/T	cg03806693	chr22:41940476	POLR3H	1.09	12.57	0.61	9.68e-29	Vitiligo;
CESC	cis	rs17376456	0.825	rs13361613	chr5:93272176	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.65	5.32	0.31	2.26e-7	Diabetic retinopathy;
CESC	cis	rs10504229	1.000	rs66936919	chr8:58172868	C/G	cg05313129	chr8:58192883	C8orf71	-0.54	-6.22	-0.36	1.94e-9	Developmental language disorder (linguistic errors);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg15043926	chr4:26863112	STIM2	-0.4	-6.45	-0.37	5.23e-10	Gambling;
CESC	cis	rs9549260	0.848	rs966968	chr13:41248037	C/T	cg21288729	chr13:41239152	FOXO1	-0.66	-8.67	-0.47	4.54e-16	Red blood cell count;
CESC	cis	rs61841072	0.961	rs1985630	chr1:243134694	T/C	cg02356786	chr1:243265016	LOC731275	0.43	5.62	0.33	4.85e-8	Schizophrenia;
CESC	cis	rs67478160	0.643	rs6575999	chr14:104250609	C/G	cg08213375	chr14:104286397	PPP1R13B	0.55	10.79	0.55	9.83e-23	Schizophrenia;
CESC	cis	rs4319547	0.656	rs7975747	chr12:122816995	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.5	-5.73	-0.33	2.66e-8	Body mass index;
CESC	trans	rs7824557	0.564	rs2736302	chr8:11236419	T/C	cg06636001	chr8:8085503	FLJ10661	-0.49	-6.15	-0.35	2.9e-9	Retinal vascular caliber;
CESC	cis	rs651907	0.535	rs13094753	chr3:101525082	A/G	cg12386194	chr3:101231763	SENP7	0.41	5.11	0.3	6.03e-7	Colorectal cancer;
CESC	cis	rs9733	0.544	rs72700902	chr1:150633347	C/T	cg18016565	chr1:150552671	MCL1	0.33	5.07	0.3	7.65e-7	Tonsillectomy;
CESC	cis	rs11098499	0.657	rs9996569	chr4:120299004	G/C	cg24375607	chr4:120327624	NA	0.46	5.55	0.32	6.98e-8	Corneal astigmatism;
CESC	cis	rs3785574	0.962	rs13030	chr17:61908556	C/T	cg06420487	chr17:61919686	SMARCD2	0.44	5.31	0.31	2.36e-7	Height;
CESC	cis	rs3785574	0.927	rs2854160	chr17:61977248	C/T	cg06873352	chr17:61820015	STRADA	0.46	6.76	0.38	8.73e-11	Height;
CESC	trans	rs1994135	0.654	rs11052759	chr12:33724126	G/A	cg26384229	chr12:38710491	ALG10B	0.58	7.82	0.43	1.26e-13	Resting heart rate;
CESC	cis	rs763121	0.853	rs2281020	chr22:39064406	A/G	cg21395723	chr22:39101663	GTPBP1	0.43	5.39	0.31	1.58e-7	Menopause (age at onset);
CESC	trans	rs6665290	0.935	rs6704144	chr1:227201030	C/G	cg02597199	chr15:101098829	NA	-0.46	-6.07	-0.35	4.34e-9	Myeloid white cell count;
CESC	cis	rs12900413	0.687	rs12906905	chr15:90315399	A/G	cg24249390	chr15:90295951	MESP1	-0.41	-5.73	-0.33	2.78e-8	Coronary artery aneurysm in Kawasaki disease;
CESC	cis	rs7267979	1.000	rs2257496	chr20:25279315	A/G	cg08601574	chr20:25228251	PYGB	0.39	5.57	0.32	6.14e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs3733585	0.673	rs4580649	chr4:9948461	G/A	cg11266682	chr4:10021025	SLC2A9	-0.59	-11.25	-0.57	2.88e-24	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs9303401	0.646	rs8067682	chr17:57219391	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.56	7.33	0.41	2.74e-12	Cognitive test performance;
CESC	cis	rs7584330	0.910	rs66509917	chr2:238395394	T/G	cg11271282	chr2:238384023	NA	0.43	5.09	0.3	6.66e-7	Prostate cancer;
CESC	cis	rs853679	0.517	rs9380060	chr6:28132603	G/A	cg22143856	chr6:28129313	ZNF389	0.49	6.24	0.36	1.73e-9	Depression;
CESC	cis	rs9733	1.000	rs9733	chr1:150618961	A/C	cg13175981	chr1:150552382	MCL1	0.54	7.35	0.41	2.5e-12	Tonsillectomy;
CESC	cis	rs1153858	1.000	rs7181167	chr15:45686236	C/G	cg14582100	chr15:45693742	SPATA5L1	0.42	5.88	0.34	1.22e-8	Homoarginine levels;
CESC	cis	rs9976767	0.637	rs2156309	chr21:43824529	G/A	cg23042151	chr21:43824109	UBASH3A	-0.34	-6.38	-0.36	8.06e-10	Type 1 diabetes;
CESC	cis	rs1050631	0.592	rs1785921	chr18:33737196	A/C	cg25426722	chr18:33708991	SLC39A6;ELP2	0.54	7.31	0.41	3.24e-12	Esophageal squamous cell cancer (length of survival);
CESC	cis	rs826838	0.935	rs11169508	chr12:39173385	C/T	cg13010199	chr12:38710504	ALG10B	0.57	7.86	0.43	9.51e-14	Heart rate;
CESC	trans	rs116095464	0.558	rs9654452	chr5:299561	C/T	cg00938859	chr5:1591904	SDHAP3	0.65	7.04	0.4	1.67e-11	Breast cancer;
CESC	cis	rs6088590	0.561	rs764597	chr20:33161225	C/T	cg24642439	chr20:33292090	TP53INP2	0.61	8.29	0.45	5.79e-15	Coronary artery disease;
CESC	cis	rs7254114	0.578	rs7246614	chr19:11310538	C/T	cg02815516	chr19:11306319	KANK2	-0.42	-6.77	-0.38	8.32e-11	Immature fraction of reticulocytes;
CESC	cis	rs7659604	0.702	rs58649165	chr4:122693752	C/A	cg19748678	chr4:122722346	EXOSC9	0.65	8.51	0.46	1.27e-15	Type 2 diabetes;
CESC	cis	rs11828289	0.660	rs17306426	chr11:23222079	G/T	cg20040320	chr11:23191996	NA	0.72	6.19	0.36	2.23e-9	Cancer;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg22542702	chr2:132384461	NA	-0.38	-6.29	-0.36	1.3e-9	Asthma;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06710176	chr12:25347973	CASC1;LYRM5	-0.53	-6.11	-0.35	3.61e-9	Gut microbiome composition (summer);
CESC	cis	rs9487051	0.898	rs882072	chr6:109611806	A/G	cg12927641	chr6:109611667	NA	-0.43	-6.62	-0.38	2e-10	Reticulocyte fraction of red cells;
CESC	cis	rs11051970	0.592	rs11051985	chr12:32555090	G/A	cg24626660	chr12:32551988	NA	0.36	5.27	0.31	2.77e-7	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs9359856	0.564	rs56396054	chr6:90360406	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.65	-6.23	-0.36	1.83e-9	Bipolar disorder;
CESC	cis	rs10883723	0.810	rs2281879	chr10:104268877	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.57	8.01	0.44	3.69e-14	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs2576037	0.523	rs1539881	chr18:44477897	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.51	-7.02	-0.4	1.84e-11	Personality dimensions;
CESC	cis	rs2180341	1.000	rs9398837	chr6:127635217	G/A	cg24812749	chr6:127587940	RNF146	1.07	15.48	0.69	6.31e-39	Breast cancer;
CESC	cis	rs780096	0.526	rs2911713	chr2:27640980	G/A	cg21248554	chr2:27665150	KRTCAP3	-0.35	-7.19	-0.4	6.72e-12	Total body bone mineral density;
CESC	cis	rs11792861	0.781	rs838835	chr9:111758590	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	-0.59	-8.18	-0.45	1.18e-14	Menarche (age at onset);
CESC	cis	rs7589342	0.628	rs62152201	chr2:106411664	C/T	cg16077055	chr2:106428750	NCK2	0.55	7.0	0.39	2.12e-11	Addiction;
CESC	cis	rs9399135	0.935	rs4445070	chr6:135309212	C/T	cg24558204	chr6:135376177	HBS1L	0.49	6.5	0.37	4.05e-10	Red blood cell count;
CESC	cis	rs13108904	0.560	rs11247994	chr4:1343720	G/A	cg13395646	chr4:1353034	KIAA1530	-0.53	-6.56	-0.37	2.81e-10	Obesity-related traits;
CESC	trans	rs2727020	0.521	rs7114564	chr11:49571231	C/T	cg15704280	chr7:45808275	SEPT13	0.82	10.08	0.53	2.01e-20	Coronary artery disease;
CESC	cis	rs287982	1.000	rs2656329	chr2:9968344	C/T	cg10881225	chr2:9984929	TAF1B	0.4	5.03	0.3	9.11e-7	Nonsyndromic cleft lip with cleft palate;
CESC	cis	rs1969363	0.509	rs8189633	chr12:38065155	C/G	cg13010199	chr12:38710504	ALG10B	0.54	6.69	0.38	1.28e-10	Morning vs. evening chronotype;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06130365	chr10:135122020	TUBGCP2;ZNF511	0.55	6.05	0.35	5.03e-9	Gut microbiome composition (summer);
CESC	cis	rs7264396	0.676	rs6060727	chr20:34556000	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.52	6.18	0.36	2.37e-9	Total cholesterol levels;
CESC	cis	rs4466137	0.794	rs6869296	chr5:83007333	C/G	cg16102102	chr5:83017553	HAPLN1	0.44	6.33	0.36	1.06e-9	Prostate cancer;
CESC	cis	rs7666738	0.830	rs7696568	chr4:99005333	A/T	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.62e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs72781680	0.716	rs2712068	chr2:23984000	A/G	cg08917208	chr2:24149416	ATAD2B	0.61	5.95	0.34	8.33e-9	Lymphocyte counts;
CESC	cis	rs703842	0.892	rs1021469	chr12:58208164	C/T	cg18357645	chr12:58087776	OS9	-0.42	-5.84	-0.34	1.54e-8	Multiple sclerosis;
CESC	cis	rs7666738	0.830	rs6827516	chr4:98971740	T/C	cg05340658	chr4:99064831	C4orf37	0.79	12.26	0.6	1.12e-27	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4803468	1.000	rs4674	chr19:41930396	A/G	cg14132834	chr19:41945861	ATP5SL	-0.65	-7.92	-0.44	6.5e-14	Height;
CESC	cis	rs13082711	0.911	rs13082777	chr3:27421942	A/G	cg02860705	chr3:27208620	NA	0.51	6.21	0.36	2.02e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CESC	cis	rs7116495	1.000	rs6592453	chr11:71683231	C/G	cg26138937	chr11:71823887	C11orf51	-0.8	-6.51	-0.37	3.81e-10	Severe influenza A (H1N1) infection;
CESC	trans	rs9325144	0.624	rs12231544	chr12:38901956	C/T	cg23762105	chr12:34175262	ALG10	0.47	6.08	0.35	4.1e-9	Morning vs. evening chronotype;
CESC	cis	rs68170813	0.559	rs7803290	chr7:106907353	T/C	cg02696742	chr7:106810147	HBP1	-0.52	-5.09	-0.3	6.84e-7	Coronary artery disease;
CESC	cis	rs7772486	0.790	rs2253654	chr6:146199445	T/C	cg05347473	chr6:146136440	FBXO30	0.6	7.75	0.43	1.94e-13	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs854765	0.619	rs4561528	chr17:17979099	C/T	cg16928487	chr17:17741425	SREBF1	-0.56	-9.3	-0.5	5.51e-18	Total body bone mineral density;
CESC	cis	rs2299587	0.554	rs2073564	chr8:17743341	G/A	cg08627089	chr8:17753878	FGL1	-0.4	-5.75	-0.33	2.42e-8	Economic and political preferences;
CESC	cis	rs769267	0.930	rs4808957	chr19:19567248	A/G	cg03709012	chr19:19516395	GATAD2A	1.01	15.7	0.69	1.02e-39	Tonsillectomy;
CESC	cis	rs897984	0.609	rs57576577	chr16:31036367	G/A	cg00531865	chr16:30841666	NA	-0.4	-5.59	-0.32	5.78e-8	Dementia with Lewy bodies;
CESC	cis	rs113835537	0.935	rs117131621	chr11:66422334	C/T	cg22134325	chr11:66188745	NPAS4	0.51	5.84	0.34	1.55e-8	Airway imaging phenotypes;
CESC	cis	rs6570726	0.791	rs9373466	chr6:145912016	T/C	cg05347473	chr6:146136440	FBXO30	0.57	7.44	0.42	1.37e-12	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs10540	1.000	rs71487296	chr11:500282	G/A	cg21784768	chr11:537496	LRRC56	-0.54	-5.11	-0.3	6.31e-7	Body mass index;
CESC	cis	rs9322193	0.884	rs12528279	chr6:150072028	A/C	cg04369109	chr6:150039330	LATS1	-0.43	-5.91	-0.34	1.05e-8	Lung cancer;
CESC	cis	rs7208859	0.623	rs216434	chr17:28922335	G/C	cg14008862	chr17:28927542	LRRC37B2	0.76	5.68	0.33	3.49e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	-0.91	-13.91	-0.65	2.14e-33	Prudent dietary pattern;
CESC	cis	rs796364	0.951	rs3098341	chr2:200792498	G/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.87	8.72	0.47	3.16e-16	Schizophrenia;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg12819747	chr12:112622701	C12orf51	-0.45	-6.39	-0.37	7.56e-10	Systemic lupus erythematosus;
CESC	cis	rs6540559	1.000	rs6540559	chr1:209982025	G/A	cg09509183	chr1:209979624	IRF6	0.5	6.32	0.36	1.1e-9	Cleft lip with or without cleft palate;
CESC	cis	rs4780401	0.609	rs7205994	chr16:11815964	C/T	cg01061890	chr16:11836724	TXNDC11	-0.56	-7.52	-0.42	8.36e-13	Rheumatoid arthritis;
CESC	cis	rs12541635	0.966	rs12674846	chr8:107007178	A/G	cg10147462	chr8:107024639	NA	0.42	5.96	0.34	7.89e-9	Age of smoking initiation;
CESC	cis	rs7089973	0.872	rs17092542	chr10:116630289	G/A	cg23260525	chr10:116636907	FAM160B1	0.37	6.3	0.36	1.27e-9	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs9916302	0.861	rs2338801	chr17:37490780	G/T	cg07936489	chr17:37558343	FBXL20	0.77	11.23	0.57	3.4e-24	Glomerular filtration rate (creatinine);
CESC	cis	rs17001868	0.568	rs9607699	chr22:40737036	G/A	cg07138101	chr22:40742427	ADSL	0.57	5.38	0.31	1.66e-7	Mammographic density (dense area);
CESC	cis	rs1862618	0.853	rs863840	chr5:56128999	C/G	cg24531977	chr5:56204891	C5orf35	-0.78	-9.72	-0.51	2.74e-19	Initial pursuit acceleration;
CESC	cis	rs2841277	0.676	rs4264326	chr14:105411700	A/G	cg15352829	chr14:105391018	PLD4	-0.6	-10.51	-0.54	7.92e-22	Rheumatoid arthritis;
CESC	cis	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg25730142	chr20:32031702	SNTA1	-0.43	-5.52	-0.32	7.97e-8	Ulcerative colitis;
CESC	cis	rs7811142	1.000	rs7803454	chr7:99991548	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.99	9.32	0.5	4.59e-18	Platelet count;
CESC	trans	rs3749237	1.000	rs11130214	chr3:49735746	C/G	cg21659725	chr3:3221576	CRBN	-0.53	-6.34	-0.36	1e-9	Resting heart rate;
CESC	cis	rs7945705	0.776	rs2316865	chr11:8815470	A/G	cg12365402	chr11:9010492	NRIP3	0.33	5.07	0.3	7.56e-7	Hemoglobin concentration;
CESC	cis	rs35306767	0.807	rs12768348	chr10:899224	T/G	cg10556349	chr10:835070	NA	0.77	6.42	0.37	6.09e-10	Eosinophil percentage of granulocytes;
CESC	cis	rs9291683	0.510	rs4318649	chr4:10016815	T/C	cg11266682	chr4:10021025	SLC2A9	0.68	13.13	0.63	1.13e-30	Bone mineral density;
CESC	cis	rs367615	0.704	rs4320313	chr5:108828687	A/G	cg17395555	chr5:108820864	NA	0.65	11.29	0.57	2.17e-24	Colorectal cancer (SNP x SNP interaction);
CESC	trans	rs2727020	0.729	rs1164666	chr11:49295867	C/T	cg03929089	chr4:120376271	NA	-0.78	-11.94	-0.59	1.38e-26	Coronary artery disease;
CESC	cis	rs10489202	0.955	rs17557162	chr1:167985950	A/T	cg24449463	chr1:168025552	DCAF6	0.48	5.51	0.32	8.47e-8	Schizophrenia;
CESC	cis	rs9300255	0.596	rs1727331	chr12:123718879	C/G	cg05973401	chr12:123451056	ABCB9	-0.44	-5.5	-0.32	9.15e-8	Neutrophil percentage of white cells;
CESC	cis	rs7552404	1.000	rs72686191	chr1:76218319	G/T	cg10523679	chr1:76189770	ACADM	0.67	7.54	0.42	7.39e-13	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs13191362	1.000	rs67094146	chr6:163145412	G/C	cg21926612	chr6:163149169	PACRG;PARK2	0.77	8.1	0.45	1.99e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs4243830	0.850	rs57203351	chr1:6601319	T/C	cg22792644	chr1:6614718	TAS1R1;NOL9	0.99	9.97	0.52	4.34e-20	Body mass index;
CESC	cis	rs1552244	0.882	rs13066757	chr3:10045030	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.76	-9.68	-0.51	3.46e-19	Alzheimer's disease;
CESC	cis	rs9291683	0.609	rs13149985	chr4:10028390	G/A	cg02734326	chr4:10020555	SLC2A9	0.46	6.41	0.37	6.67e-10	Bone mineral density;
CESC	cis	rs3096299	0.719	rs2911262	chr16:89515041	C/T	cg02187348	chr16:89574699	SPG7	0.65	9.03	0.49	3.66e-17	Multiple myeloma (IgH translocation);
CESC	trans	rs3756309	1.000	rs3756309	chr5:149505624	C/T	cg11703470	chr6:99276280	NA	0.38	6.07	0.35	4.46e-9	Blood protein levels;
CESC	cis	rs7084402	1.000	rs7095501	chr10:60271940	T/C	cg07615347	chr10:60278583	BICC1	-0.57	-8.78	-0.47	2.13e-16	Refractive error;
CESC	cis	rs56399783	0.901	rs11971014	chr7:2778444	C/T	cg19731401	chr7:2775893	GNA12	0.64	5.85	0.34	1.43e-8	Childhood ear infection;
CESC	cis	rs9911578	0.935	rs2302189	chr17:56584205	A/C	cg05425664	chr17:57184151	TRIM37	0.51	6.91	0.39	3.63e-11	Intelligence (multi-trait analysis);
CESC	cis	rs10089	1.000	rs4835945	chr5:127526481	C/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.71	9.35	0.5	3.9e-18	Ileal carcinoids;
CESC	cis	rs7607369	0.791	rs12468043	chr2:219354197	C/A	cg02176678	chr2:219576539	TTLL4	0.5	8.98	0.48	5.22e-17	Red blood cell count;Amyotrophic lateral sclerosis;
CESC	cis	rs854765	0.587	rs4077828	chr17:17833644	A/T	cg09796270	chr17:17721594	SREBF1	0.43	6.05	0.35	4.9e-9	Total body bone mineral density;
CESC	cis	rs7647973	0.588	rs9883000	chr3:49667691	A/G	cg06212747	chr3:49208901	KLHDC8B	0.65	7.77	0.43	1.78e-13	Menarche (age at onset);
CESC	cis	rs13256369	0.802	rs34762800	chr8:8559294	G/A	cg00074818	chr8:8560427	CLDN23	0.38	5.34	0.31	2.05e-7	Obesity-related traits;
CESC	cis	rs11098499	0.754	rs17049949	chr4:120255290	A/G	cg09307838	chr4:120376055	NA	0.8	10.88	0.56	5.04e-23	Corneal astigmatism;
CESC	cis	rs35160687	0.623	rs11127021	chr2:86474919	C/T	cg01119172	chr2:86362222	SNORD94;PTCD3	-0.39	-5.18	-0.3	4.5e-7	Night sleep phenotypes;
CESC	trans	rs4596713	0.507	rs10869975	chr9:71795034	C/T	cg16512924	chr15:28394682	HERC2	-0.5	-6.13	-0.35	3.2e-9	Headache;
CESC	cis	rs9788682	0.706	rs924840	chr15:78731808	A/T	cg06917634	chr15:78832804	PSMA4	-0.45	-5.03	-0.3	9.22e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs9640161	0.789	rs1464753	chr7:150021350	G/C	cg21361702	chr7:150065534	REPIN1	0.5	5.72	0.33	2.8e-8	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs701145	0.556	rs355758	chr3:154007682	C/G	cg16511985	chr3:153974050	SGEF	-0.4	-5.53	-0.32	7.76e-8	Coronary artery disease;
CESC	cis	rs858239	0.539	rs2103281	chr7:23194231	A/G	cg23682824	chr7:23144976	KLHL7	0.45	5.87	0.34	1.29e-8	Cerebrospinal fluid biomarker levels;
CESC	cis	rs8177253	1.000	rs8177262	chr3:133480652	A/G	cg01448562	chr3:133502909	NA	0.43	6.02	0.35	5.65e-9	Iron status biomarkers;
CESC	cis	rs61008539	0.893	rs7783487	chr7:860160	A/C	cg00934597	chr7:893267	UNC84A	-0.5	-6.62	-0.38	1.98e-10	Perceived unattractiveness to mosquitoes;
CESC	cis	rs853679	0.517	rs9468292	chr6:28095355	G/A	cg26335602	chr6:28129616	ZNF389	0.53	7.09	0.4	1.19e-11	Depression;
CESC	cis	rs6582630	0.555	rs11182422	chr12:38522833	A/G	cg13010199	chr12:38710504	ALG10B	0.45	5.97	0.34	7.53e-9	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs9649213	0.613	rs7777415	chr7:97959214	A/T	cg08684580	chr7:98029266	BAIAP2L1	-0.36	-5.87	-0.34	1.27e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs896854	0.846	rs2340584	chr8:95916811	A/G	cg23172400	chr8:95962367	TP53INP1	-0.46	-9.59	-0.51	6.82e-19	Type 2 diabetes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13148496	chr14:103430618	CDC42BPB	-0.56	-6.35	-0.36	9.26e-10	Gut microbiome composition (summer);
CESC	cis	rs2836974	1.000	rs12710454	chr21:40656919	A/G	cg17971929	chr21:40555470	PSMG1	1.0	13.79	0.65	5.43e-33	Cognitive function;
CESC	cis	rs6456156	0.586	rs9457261	chr6:167467679	A/G	cg23791538	chr6:167370224	RNASET2	-0.5	-6.47	-0.37	4.66e-10	Primary biliary cholangitis;
CESC	cis	rs6952808	0.825	rs34922657	chr7:1938655	C/T	cg00106254	chr7:1943704	MAD1L1	-0.5	-6.29	-0.36	1.32e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs11249608	0.548	rs10516150	chr5:178459169	G/C	cg21905437	chr5:178450457	ZNF879	0.58	8.09	0.45	2.16e-14	Pubertal anthropometrics;
CESC	cis	rs4853012	0.838	rs6715351	chr2:74346119	G/A	cg05890377	chr2:74357713	NA	0.78	10.7	0.55	1.9e-22	Gestational age at birth (maternal effect);
CESC	cis	rs11792861	0.926	rs72607170	chr9:111836941	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.42	5.18	0.3	4.44e-7	Menarche (age at onset);
CESC	cis	rs9910055	0.762	rs11080007	chr17:42265442	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	-0.37	-5.36	-0.31	1.81e-7	Total body bone mineral density;
CESC	cis	rs9926296	0.605	rs12709094	chr16:89853017	A/G	cg21285383	chr16:89894308	SPIRE2	0.32	5.72	0.33	2.8e-8	Vitiligo;
CESC	cis	rs397969	0.596	rs62066350	chr17:19900042	T/C	cg12073167	chr17:19770448	ULK2	-0.47	-5.34	-0.31	2.04e-7	Platelet count;
CESC	cis	rs2797160	0.547	rs4144549	chr6:125945251	C/G	cg05901451	chr6:126070800	HEY2	0.39	5.3	0.31	2.4e-7	Endometrial cancer;
CESC	cis	rs2637266	0.783	rs10824437	chr10:78469493	C/T	cg18941641	chr10:78392320	NA	0.43	8.19	0.45	1.08e-14	Pulmonary function;
CESC	trans	rs7980799	0.716	rs1601008	chr12:33611352	A/G	cg26384229	chr12:38710491	ALG10B	-0.53	-7.65	-0.43	3.76e-13	Heart rate;Heart rate variability traits (RMSSD);
CESC	cis	rs1178968	1.000	rs4717751	chr7:72750627	G/A	cg25889504	chr7:72793014	NA	0.47	5.05	0.3	8.36e-7	Triglyceride levels;
CESC	cis	rs9914988	0.943	rs9908881	chr17:27100924	T/A	cg20469991	chr17:27169893	C17orf63	-0.48	-5.25	-0.31	3.18e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CESC	cis	rs7592578	0.771	rs10432434	chr2:191387079	T/G	cg27211696	chr2:191398769	TMEM194B	-0.62	-5.64	-0.33	4.26e-8	Diastolic blood pressure;
CESC	cis	rs7561273	0.586	rs11892283	chr2:24317850	T/C	cg20701182	chr2:24300061	SF3B14	0.52	6.63	0.38	1.89e-10	Quantitative traits;
CESC	cis	rs6460942	0.630	rs62448731	chr7:12341174	G/A	cg06484146	chr7:12443880	VWDE	-0.62	-6.8	-0.39	6.82e-11	Coronary artery disease;
CESC	cis	rs879620	1.000	rs2531995	chr16:4013467	C/T	cg05927578	chr16:4029543	ADCY9	0.38	5.29	0.31	2.52e-7	Hip circumference;Body mass index;
CESC	cis	rs832540	1.000	rs192249	chr5:56197514	C/G	cg12311346	chr5:56204834	C5orf35	-0.41	-5.18	-0.3	4.42e-7	Coronary artery disease;
CESC	cis	rs1580019	0.713	rs2167274	chr7:32524844	A/G	cg06627557	chr7:32535165	LSM5;AVL9	1.01	16.42	0.71	2.93e-42	Cognitive ability;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg08536481	chr12:123459152	ABCB9;OGFOD2	-0.4	-6.14	-0.35	2.97e-9	Gambling;
CESC	cis	rs9311474	0.508	rs17052256	chr3:52593119	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.57	7.79	0.43	1.55e-13	Electroencephalogram traits;
CESC	cis	rs34779708	0.897	rs12830	chr10:35302705	C/T	cg03585969	chr10:35415529	CREM	0.76	9.89	0.52	7.97e-20	Inflammatory bowel disease;Crohn's disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06792154	chr17:29157990	ATAD5	-0.61	-6.85	-0.39	5.13e-11	Gut microbiome composition (summer);
CESC	cis	rs959260	1.000	rs2385264	chr17:73364992	C/T	cg12999837	chr17:73267436	MIF4GD	-0.47	-5.46	-0.32	1.1e-7	Systemic lupus erythematosus;
CESC	cis	rs3820068	0.705	rs11583306	chr1:15860803	A/G	cg18192808	chr1:15853278	DNAJC16	-0.46	-5.46	-0.32	1.11e-7	Systolic blood pressure;
CESC	cis	rs4819052	1.000	rs2838847	chr21:46670958	G/C	cg11663144	chr21:46675770	NA	-0.5	-6.97	-0.39	2.45e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27409770	chr7:43965942	URGCP;UBE2D4	0.55	6.23	0.36	1.81e-9	Gut microbiome composition (summer);
CESC	cis	rs3806843	0.838	rs2563289	chr5:140122766	T/A	cg26395211	chr5:140044315	WDR55	0.4	5.12	0.3	5.82e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs7666738	0.830	rs921522	chr4:98841608	C/T	cg05340658	chr4:99064831	C4orf37	0.71	10.47	0.54	1.1e-21	Colonoscopy-negative controls vs population controls;
CESC	cis	rs35146811	0.844	rs34031156	chr7:99677917	T/A	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.44	5.73	0.33	2.69e-8	Coronary artery disease;
CESC	cis	rs7131987	0.868	rs10771508	chr12:29414211	G/A	cg09582351	chr12:29534625	ERGIC2	-0.35	-5.72	-0.33	2.9e-8	QT interval;
CESC	cis	rs2243480	1.000	rs10807701	chr7:65724686	C/A	cg13147721	chr7:65941812	NA	0.98	9.24	0.49	8.25e-18	Diabetic kidney disease;
CESC	cis	rs56104184	0.775	rs73061697	chr19:49400000	C/T	cg15549821	chr19:49342101	PLEKHA4	-0.6	-5.99	-0.35	6.95e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
CESC	cis	rs1372520	0.748	rs1471484	chr4:90754313	C/T	cg15133208	chr4:90757351	SNCA	-0.42	-5.58	-0.32	6.08e-8	Neuroticism;
CESC	cis	rs8053891	0.708	rs8055242	chr16:72006882	C/T	cg04254540	chr16:71951199	KIAA0174	-0.47	-5.5	-0.32	9.16e-8	Coronary artery disease;
CESC	cis	rs2276314	0.947	rs4799831	chr18:33554775	A/G	cg19628046	chr18:33552617	C18orf21	0.55	6.0	0.35	6.59e-9	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs7824557	0.564	rs2572399	chr8:11234520	A/G	cg21775007	chr8:11205619	TDH	-0.54	-8.11	-0.45	1.87e-14	Retinal vascular caliber;
CESC	cis	rs2440129	0.611	rs1126667	chr17:6902760	C/T	cg12262378	chr17:6899522	ALOX12	-0.41	-7.0	-0.4	2.09e-11	Tonsillectomy;
CESC	cis	rs1552244	1.000	rs2272125	chr3:10138069	A/C	cg00166722	chr3:10149974	C3orf24	0.48	6.05	0.35	4.88e-9	Alzheimer's disease;
CESC	cis	rs7618915	0.501	rs3733045	chr3:52643307	A/G	cg18099408	chr3:52552593	STAB1	-0.3	-5.12	-0.3	5.79e-7	Bipolar disorder;
CESC	cis	rs7107174	1.000	rs2511180	chr11:77937255	A/G	cg02023728	chr11:77925099	USP35	0.47	6.57	0.37	2.67e-10	Testicular germ cell tumor;
CESC	cis	rs1707322	1.000	rs6672115	chr1:46272879	T/C	cg06784218	chr1:46089804	CCDC17	0.36	6.04	0.35	5.11e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs763014	0.932	rs2384975	chr16:651115	G/T	cg09263875	chr16:632152	PIGQ	0.69	12.02	0.59	7.31e-27	Height;
CESC	cis	rs10751667	0.600	rs7950955	chr11:1011490	G/A	cg20946044	chr11:1010712	AP2A2	-0.48	-6.24	-0.36	1.73e-9	Alzheimer's disease (late onset);
CESC	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.63	7.16	0.4	7.99e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs561341	0.941	rs17780080	chr17:30343146	G/A	cg00745463	chr17:30367425	LRRC37B	-0.88	-7.7	-0.43	2.74e-13	Hip circumference adjusted for BMI;
CESC	cis	rs17376456	0.877	rs10072592	chr5:93405989	C/G	cg25358565	chr5:93447407	FAM172A	1.16	10.8	0.55	8.82e-23	Diabetic retinopathy;
CESC	cis	rs6964587	1.000	rs28584017	chr7:91719168	G/A	cg17063962	chr7:91808500	NA	0.57	7.99	0.44	4.23e-14	Breast cancer;
CESC	cis	rs6461049	0.800	rs3800909	chr7:2159594	C/G	cg21782813	chr7:2030301	MAD1L1	0.43	6.1	0.35	3.77e-9	Schizophrenia;
CESC	trans	rs16845107	0.826	rs16861032	chr3:113187675	C/G	cg02899788	chr1:47133675	ATPAF1	-0.83	-6.17	-0.35	2.52e-9	Colorectal cancer;
CESC	cis	rs2832191	0.671	rs2832213	chr21:30512914	A/G	cg08807101	chr21:30365312	RNF160	-0.53	-6.27	-0.36	1.42e-9	Dental caries;
CESC	cis	rs6500395	0.775	rs4471681	chr16:48665946	C/T	cg04672837	chr16:48644449	N4BP1	0.49	6.27	0.36	1.46e-9	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs10754283	0.967	rs7513928	chr1:90104834	A/G	cg21401794	chr1:90099060	LRRC8C	0.7	9.42	0.5	2.27e-18	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs1499614	0.803	rs1796229	chr7:66119661	G/A	cg08632164	chr7:65971372	NA	-0.49	-5.12	-0.3	5.92e-7	Gout;
CESC	cis	rs367943	0.608	rs2972662	chr5:112990330	C/T	cg12552261	chr5:112820674	MCC	-0.4	-5.17	-0.3	4.58e-7	Type 2 diabetes;
CESC	cis	rs2197308	0.765	rs12824529	chr12:37931656	T/C	cg26384229	chr12:38710491	ALG10B	0.75	11.19	0.57	4.49e-24	Morning vs. evening chronotype;
CESC	cis	rs12249377	0.519	rs11597471	chr10:92598767	C/G	cg14313238	chr10:92632228	RPP30	0.45	5.43	0.32	1.28e-7	White matter microstructure (global fractional anisotropy);
CESC	cis	rs875971	1.000	rs2420820	chr7:66091907	T/C	cg11764359	chr7:65958608	NA	-0.91	-13.88	-0.65	2.71e-33	Aortic root size;
CESC	cis	rs2576037	0.526	rs10853544	chr18:44474194	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.71	11.44	0.57	6.98e-25	Personality dimensions;
CESC	cis	rs7811142	1.000	rs113738841	chr7:100081306	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.02	11.36	0.57	1.23e-24	Platelet count;
CESC	cis	rs12791968	0.917	rs11038239	chr11:45002012	A/G	cg11846598	chr11:44996168	LOC221122	-0.56	-7.44	-0.42	1.37e-12	Inhibitory control;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg03117819	chr17:48610072	EPN3	0.46	6.05	0.35	4.79e-9	Systemic lupus erythematosus;
CESC	cis	rs854765	0.583	rs7214536	chr17:17852446	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.59	8.26	0.45	7.24e-15	Total body bone mineral density;
CESC	cis	rs4979906	1.000	rs2395494	chr10:79458340	C/T	cg00983440	chr10:79422392	NA	-0.44	-5.09	-0.3	6.92e-7	Mortality in heart failure;
CESC	cis	rs7666738	0.830	rs13101766	chr4:98957696	C/A	cg05340658	chr4:99064831	C4orf37	0.8	12.4	0.61	3.76e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7927592	0.731	rs2840367	chr11:68302101	G/A	cg01657329	chr11:68192670	LRP5	0.49	6.51	0.37	3.72e-10	Total body bone mineral density;
CESC	cis	rs6502050	0.528	rs12942561	chr17:80116639	G/A	cg11859384	chr17:80120422	CCDC57	-0.38	-5.17	-0.3	4.51e-7	Life satisfaction;
CESC	cis	rs9287719	0.967	rs10454738	chr2:10742049	G/A	cg02196655	chr2:10830764	NOL10	-0.38	-5.83	-0.34	1.61e-8	Prostate cancer;
CESC	cis	rs34779708	0.931	rs11593858	chr10:35381373	G/A	cg04310649	chr10:35416472	CREM	-0.51	-6.06	-0.35	4.62e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs736408	0.609	rs62255396	chr3:52782839	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.5	7.05	0.4	1.53e-11	Bipolar disorder;
CESC	cis	rs7618915	0.501	rs767418	chr3:52767427	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.61	8.64	0.47	5.45e-16	Bipolar disorder;
CESC	cis	rs11250464	1.000	rs11250464	chr10:1406364	A/G	cg08668359	chr10:1443807	ADARB2	0.56	6.88	0.39	4.31e-11	Radiation response;
CESC	cis	rs3733585	0.673	rs4459990	chr4:9954005	T/C	cg02734326	chr4:10020555	SLC2A9	-0.39	-5.64	-0.33	4.45e-8	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs11249608	0.548	rs17078988	chr5:178459283	A/G	cg01312482	chr5:178451176	ZNF879	-0.45	-6.09	-0.35	4.02e-9	Pubertal anthropometrics;
CESC	cis	rs10504229	0.636	rs77290284	chr8:58055269	G/T	cg21724239	chr8:58056113	NA	0.64	5.91	0.34	1.05e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs17376456	0.825	rs13155452	chr5:93164449	C/T	cg25358565	chr5:93447407	FAM172A	-1.01	-9.89	-0.52	7.81e-20	Diabetic retinopathy;
CESC	cis	rs643506	0.874	rs609007	chr11:111719593	A/G	cg17089665	chr11:111648010	NA	0.35	5.06	0.3	7.7300000000000005e-07	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23893906	chr12:6798535	ZNF384	0.67	7.99	0.44	4.26e-14	Gut microbiome composition (summer);
CESC	cis	rs9814567	0.896	rs7642266	chr3:134346025	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.42	-5.67	-0.33	3.63e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs7615952	0.733	rs13314847	chr3:125644788	C/T	cg05084668	chr3:125655381	ALG1L	-0.51	-6.1	-0.35	3.68e-9	Blood pressure (smoking interaction);
CESC	cis	rs57024841	0.500	rs10116414	chr9:139831696	C/T	cg00693599	chr9:139836323	FBXW5	0.43	6.37	0.36	8.31e-10	Beta-trace protein levels;
CESC	cis	rs11640734	0.609	rs11647746	chr16:89806343	C/A	cg06558623	chr16:89946397	TCF25	0.81	7.38	0.41	1.99e-12	Interleukin-17 levels;
CESC	cis	rs7520050	0.807	rs6671802	chr1:46124663	A/G	cg06784218	chr1:46089804	CCDC17	0.33	5.95	0.34	8.25e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs597539	0.518	rs35093305	chr11:68730729	A/G	cg04772025	chr11:68637568	NA	0.49	5.63	0.33	4.7e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	trans	rs1887596	0.624	rs9553854	chr13:27131270	T/C	cg19523213	chr12:21927973	KCNJ8	0.38	6.25	0.36	1.64e-9	Facial morphology (factor 3, length of philtrum);
CESC	cis	rs4819052	0.851	rs35871601	chr21:46675214	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.94	14.0	0.65	1.02e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs9400271	0.632	rs9398192	chr6:109587236	C/T	cg01475377	chr6:109611718	NA	-0.46	-7.18	-0.4	7.24e-12	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
CESC	cis	rs1538970	0.924	rs12046816	chr1:45891543	G/T	cg06784218	chr1:46089804	CCDC17	0.33	5.46	0.32	1.11e-7	Platelet count;
CESC	cis	rs9611565	0.681	rs132918	chr22:41808350	C/T	cg17376030	chr22:41985996	PMM1	-0.52	-5.71	-0.33	3e-8	Vitiligo;
CESC	cis	rs4660261	0.526	rs803680	chr1:44364370	G/C	cg13606994	chr1:44402422	ARTN	-0.36	-5.59	-0.32	5.53e-8	Intelligence (multi-trait analysis);
CESC	cis	rs2777491	1.000	rs2777491	chr15:41735710	T/G	cg18705301	chr15:41695430	NDUFAF1	-0.65	-9.98	-0.52	4.09e-20	Ulcerative colitis;
CESC	cis	rs736408	0.736	rs4687550	chr3:52823430	T/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	6.38	0.37	7.74e-10	Bipolar disorder;
CESC	cis	rs9512730	0.553	rs1040986	chr13:28051352	G/T	cg08193333	chr13:27998609	GTF3A	0.46	5.55	0.32	7.01e-8	Schizophrenia;
CESC	cis	rs8177253	0.514	rs6790668	chr3:133442481	T/A	cg24879335	chr3:133465180	TF	0.36	6.71	0.38	1.16e-10	Iron status biomarkers;
CESC	cis	rs8141529	0.702	rs469991	chr22:29307859	G/C	cg15103426	chr22:29168792	CCDC117	-0.6	-7.7	-0.43	2.68e-13	Lymphocyte counts;
CESC	cis	rs736408	0.648	rs3774355	chr3:52817778	G/A	cg05564831	chr3:52568323	NT5DC2	0.44	6.31	0.36	1.18e-9	Bipolar disorder;
CESC	cis	rs4911259	0.513	rs4287835	chr20:31457337	T/C	cg13636640	chr20:31349939	DNMT3B	-0.58	-8.08	-0.44	2.26e-14	Inflammatory bowel disease;
CESC	cis	rs3087591	0.919	rs2953004	chr17:29502723	C/T	cg24425628	chr17:29625626	OMG;NF1	0.45	5.21	0.3	3.86e-7	Hip circumference;
CESC	trans	rs9858542	0.953	rs34588335	chr3:49407660	G/C	cg21659725	chr3:3221576	CRBN	-0.55	-6.52	-0.37	3.62e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs4604732	0.527	rs7539082	chr1:247627260	T/C	cg12754571	chr1:247694271	LOC148824;OR2C3	0.44	5.46	0.32	1.09e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs9916302	0.706	rs903507	chr17:37726423	A/G	cg07936489	chr17:37558343	FBXL20	-0.99	-11.58	-0.58	2.33e-25	Glomerular filtration rate (creatinine);
CESC	cis	rs3733585	0.699	rs10001964	chr4:9959275	C/T	cg02734326	chr4:10020555	SLC2A9	-0.44	-6.15	-0.35	2.85e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs875971	0.660	rs3764903	chr7:66098482	G/A	cg25985355	chr7:65971099	NA	0.32	5.3	0.31	2.42e-7	Aortic root size;
CESC	cis	rs10861342	1.000	rs1345095	chr12:105471577	C/T	cg23923672	chr12:105501055	KIAA1033	0.69	5.09	0.3	6.84e-7	IgG glycosylation;
CESC	cis	rs1707322	0.721	rs10890337	chr1:46124527	C/T	cg06784218	chr1:46089804	CCDC17	0.43	7.48	0.42	1.07e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9322193	0.926	rs9285525	chr6:150122389	C/G	cg05861140	chr6:150128134	PCMT1	-0.37	-5.3	-0.31	2.42e-7	Lung cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18467133	chr12:100661475	SCYL2;DEPDC4	0.59	6.4	0.37	7.02e-10	Gut microbiome composition (summer);
CESC	cis	rs4727027	0.868	rs10952799	chr7:148840772	C/T	cg23583168	chr7:148888333	NA	-0.78	-12.14	-0.6	2.85e-27	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs7267979	0.934	rs2261753	chr20:25262291	G/A	cg08601574	chr20:25228251	PYGB	0.39	5.65	0.33	4.14e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs4308124	0.708	rs56693625	chr2:111965155	G/A	cg04571233	chr2:111982156	NA	-0.63	-6.91	-0.39	3.58e-11	Vitiligo;
CESC	cis	rs5753618	0.583	rs5753628	chr22:31860322	A/G	cg13145458	chr22:31556086	RNF185	-0.49	-5.81	-0.34	1.81e-8	Colorectal cancer;
CESC	cis	rs10779751	0.770	rs12041740	chr1:11236524	G/A	cg08854313	chr1:11322531	MTOR	0.85	12.69	0.61	3.87e-29	Body mass index;
CESC	cis	rs2235642	0.859	rs12599207	chr16:1606445	A/G	cg03715980	chr16:1756201	MAPK8IP3	0.39	5.1	0.3	6.46e-7	Coronary artery disease;
CESC	cis	rs2404602	0.622	rs11632365	chr15:77139080	G/A	cg06336613	chr15:77223807	RCN2	0.42	5.12	0.3	5.79e-7	Blood metabolite levels;
CESC	cis	rs734999	0.545	rs7368105	chr1:2556548	C/T	cg20673091	chr1:2541236	MMEL1	0.47	7.84	0.43	1.11e-13	Ulcerative colitis;
CESC	cis	rs5750830	0.620	rs1007337	chr22:39781585	C/T	cg02038168	chr22:39784481	NA	-0.58	-7.73	-0.43	2.19e-13	Intelligence (multi-trait analysis);
CESC	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	21.26	0.79	3.33e-59	Prudent dietary pattern;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg08730051	chr6:4018948	NA	-0.48	-6.21	-0.36	2.05e-9	Fibrinogen levels;
CESC	cis	rs7666738	0.830	rs4440224	chr4:99044924	G/A	cg18180107	chr4:99064573	C4orf37	0.41	5.29	0.31	2.51e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9303542	0.559	rs12939811	chr17:46607958	A/T	cg04904318	chr17:46607828	HOXB1	-0.62	-6.01	-0.35	6.02e-9	Ovarian cancer;Epithelial ovarian cancer;
CESC	cis	rs9549367	0.826	rs9549713	chr13:113905308	G/T	cg18105134	chr13:113819100	PROZ	-0.68	-8.25	-0.45	7.53e-15	Platelet distribution width;
CESC	trans	rs61931739	0.534	rs11053029	chr12:34131766	G/T	cg26384229	chr12:38710491	ALG10B	0.6	8.37	0.46	3.38e-15	Morning vs. evening chronotype;
CESC	cis	rs78456975	0.739	rs72776248	chr2:1521314	A/G	cg26248373	chr2:1572462	NA	-0.57	-5.07	-0.3	7.51e-7	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs4704187	0.687	rs1477933	chr5:74437153	G/A	cg03227963	chr5:74354835	NA	0.3	5.58	0.32	5.99e-8	Response to amphetamines;
CESC	cis	rs1801251	1.000	rs11555646	chr2:233599904	A/C	cg25237894	chr2:233734115	C2orf82	0.47	8.13	0.45	1.66e-14	Coronary artery disease;
CESC	cis	rs34779708	0.966	rs35777088	chr10:35409048	T/C	cg04310649	chr10:35416472	CREM	-0.52	-6.25	-0.36	1.62e-9	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs763121	0.853	rs4821798	chr22:39021165	T/C	cg21395723	chr22:39101663	GTPBP1	0.5	6.63	0.38	1.83e-10	Menopause (age at onset);
CESC	cis	rs1008375	1.000	rs3815413	chr4:17654648	T/C	cg16339924	chr4:17578868	LAP3	0.65	8.27	0.45	6.38e-15	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs8177179	0.967	rs4994581	chr3:133437563	T/C	cg17775713	chr3:133465469	TF	0.31	5.46	0.32	1.07e-7	Iron status biomarkers (transferrin levels);
CESC	trans	rs875971	0.895	rs7788984	chr7:65915616	A/G	cg26939375	chr7:64535504	NA	0.47	6.11	0.35	3.62e-9	Aortic root size;
CESC	cis	rs9911578	0.835	rs3744093	chr17:56492800	T/C	cg05425664	chr17:57184151	TRIM37	0.46	6.38	0.36	7.88e-10	Intelligence (multi-trait analysis);
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg10165071	chr2:217557160	IGFBP5	0.46	6.23	0.36	1.78e-9	Ulcerative colitis;
CESC	cis	rs10504229	0.683	rs55660024	chr8:58128943	G/A	cg24829409	chr8:58192753	C8orf71	-0.58	-7.2	-0.4	6.31e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs12476592	0.602	rs262477	chr2:63870959	A/C	cg17519650	chr2:63277830	OTX1	-0.44	-5.1	-0.3	6.44e-7	Childhood ear infection;
CESC	cis	rs2712184	0.873	rs1548945	chr2:217665788	T/C	cg05032264	chr2:217675019	NA	-0.42	-6.16	-0.35	2.66e-9	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
CESC	cis	rs11098499	0.618	rs6858383	chr4:120296772	T/C	cg24375607	chr4:120327624	NA	0.46	5.55	0.32	6.98e-8	Corneal astigmatism;
CESC	cis	rs2066819	1.000	rs77447765	chr12:56690662	G/A	cg26804944	chr12:56660921	COQ10A	-0.85	-5.19	-0.3	4.22e-7	Psoriasis vulgaris;
CESC	cis	rs9910055	0.747	rs2905981	chr17:42238625	C/T	cg13607699	chr17:42295918	UBTF	0.63	8.58	0.47	7.92e-16	Total body bone mineral density;
CESC	cis	rs10392	0.543	rs3752290	chr20:37555116	G/C	cg27552599	chr20:37590471	DHX35	0.39	5.82	0.34	1.73e-8	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12165864	chr7:66369176	NA	-0.6	-6.46	-0.37	5.05e-10	Gut microbiome composition (summer);
CESC	cis	rs1371867	0.846	rs1788196	chr8:101290088	C/T	cg11906718	chr8:101322791	RNF19A	0.46	5.91	0.34	1.03e-8	Atrioventricular conduction;
CESC	cis	rs2839186	0.934	rs2839194	chr21:47699437	T/G	cg10351095	chr21:47802916	PCNT	-0.5	-6.79	-0.38	7.45e-11	Testicular germ cell tumor;
CESC	cis	rs910316	1.000	rs10149880	chr14:75633008	A/G	cg11812906	chr14:75593930	NEK9	-0.9	-14.82	-0.67	1.35e-36	Height;
CESC	cis	rs2836974	0.965	rs8130984	chr21:40639966	A/C	cg17971929	chr21:40555470	PSMG1	1.07	16.24	0.71	1.24e-41	Cognitive function;
CESC	cis	rs2180341	0.700	rs4598100	chr6:127565314	G/A	cg27446573	chr6:127587934	RNF146	0.83	11.45	0.58	6.5e-25	Breast cancer;
CESC	cis	rs1008375	1.000	rs10012335	chr4:17628630	C/G	cg16339924	chr4:17578868	LAP3	0.65	8.15	0.45	1.45e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg07798295	chr16:89715839	CHMP1A	0.46	6.33	0.36	1.05e-9	Fibrinogen levels;
CESC	cis	rs344364	0.511	rs2982433	chr16:1954508	A/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.5	-5.65	-0.33	4.1e-8	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs8017423	0.967	rs4904663	chr14:90729565	G/T	cg14092571	chr14:90743983	NA	-0.56	-8.38	-0.46	3.07e-15	Mortality in heart failure;
CESC	cis	rs875971	0.660	rs28698552	chr7:66005018	A/G	cg14393609	chr7:65229607	NA	0.45	6.11	0.35	3.52e-9	Aortic root size;
CESC	cis	rs889398	0.802	rs12921407	chr16:69860933	T/C	cg09409435	chr16:70099608	PDXDC2	-0.42	-5.21	-0.31	3.73e-7	Body mass index;
CESC	cis	rs3858526	0.959	rs10838797	chr11:5920977	A/G	cg05234568	chr11:5960015	NA	-0.55	-6.5	-0.37	3.93e-10	DNA methylation (variation);
CESC	cis	rs58904263	1	rs58904263	chr20:30401406	A/AG	cg13852791	chr20:30311386	BCL2L1	0.78	8.53	0.46	1.13e-15	Monocyte count;
CESC	cis	rs17293817	0.562	rs11250484	chr10:1417599	G/T	cg04271617	chr10:1416546	ADARB2	-0.31	-5.17	-0.3	4.58e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	trans	rs8180040	0.966	rs11130137	chr3:47578838	C/T	cg09317728	chr14:101699148	NA	-0.35	-6.01	-0.35	6.23e-9	Colorectal cancer;
CESC	cis	rs11229555	0.645	rs12797488	chr11:58174653	A/T	cg15696309	chr11:58395628	NA	-0.42	-5.03	-0.3	9.17e-7	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs34779708	0.931	rs4934533	chr10:35359619	A/G	cg03585969	chr10:35415529	CREM	0.76	9.94	0.52	5.37e-20	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs6430585	0.527	rs2289959	chr2:136423904	C/T	cg07169764	chr2:136633963	MCM6	0.96	11.51	0.58	3.91e-25	Corneal structure;
CESC	cis	rs6456156	0.586	rs13195158	chr6:167481392	G/A	cg07741184	chr6:167504864	NA	0.37	6.38	0.36	7.99e-10	Primary biliary cholangitis;
CESC	cis	rs113835537	0.735	rs519380	chr11:66409409	G/A	cg24851651	chr11:66362959	CCS	0.52	5.86	0.34	1.37e-8	Airway imaging phenotypes;
CESC	cis	rs501120	0.925	rs1657345	chr10:44779078	A/G	cg09554077	chr10:44749378	NA	0.62	6.18	0.36	2.35e-9	Coronary artery disease;Coronary heart disease;
CESC	cis	rs3743266	0.507	rs34092508	chr15:60722979	C/T	cg22293140	chr15:60689852	ANXA2	-0.75	-7.76	-0.43	1.82e-13	Menarche (age at onset);
CESC	cis	rs1008375	1.000	rs2315561	chr4:17679695	C/T	cg02297831	chr4:17616191	MED28	0.45	5.77	0.33	2.26e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs9910055	0.509	rs9916444	chr17:42313512	C/G	cg13607699	chr17:42295918	UBTF	0.78	11.14	0.56	6.56e-24	Total body bone mineral density;
CESC	cis	rs644799	1.000	rs680134	chr11:95559517	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.69	8.99	0.48	4.84e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs7072216	0.727	rs10748728	chr10:100171198	C/T	cg26618903	chr10:100175079	PYROXD2	-0.38	-5.79	-0.34	1.99e-8	Metabolite levels;
CESC	trans	rs853679	0.825	rs8180562	chr6:28141460	G/A	cg06606381	chr12:133084897	FBRSL1	-0.66	-6.19	-0.36	2.24e-9	Depression;
CESC	cis	rs3736485	0.934	rs11635592	chr15:51859786	A/T	cg08986416	chr15:51914746	DMXL2	-0.4	-5.12	-0.3	5.86e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs1862618	0.671	rs2591965	chr5:56236176	T/C	cg24549020	chr5:56110836	MAP3K1	-0.49	-6.03	-0.35	5.63e-9	Initial pursuit acceleration;
CESC	cis	rs8180040	0.587	rs62246398	chr3:47066203	A/C	cg27129171	chr3:47204927	SETD2	-0.66	-9.84	-0.52	1.13e-19	Colorectal cancer;
CESC	cis	rs853679	0.517	rs9393885	chr6:28050009	A/T	cg08968635	chr6:28129556	ZNF389	0.39	5.22	0.31	3.64e-7	Depression;
CESC	cis	rs7666738	0.830	rs6833822	chr4:98951354	G/A	cg17366294	chr4:99064904	C4orf37	0.59	8.52	0.46	1.24e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs8031584	0.672	rs17815726	chr15:31313252	C/G	cg08109568	chr15:31115862	NA	0.67	7.34	0.41	2.57e-12	Huntington's disease progression;
CESC	cis	rs2415984	0.519	rs2642102	chr14:46965502	A/G	cg14871534	chr14:47121158	RPL10L	0.35	5.32	0.31	2.24e-7	Number of children ever born;
CESC	cis	rs11690935	0.959	rs1474074	chr2:172659852	G/A	cg13550731	chr2:172543902	DYNC1I2	-0.96	-14.46	-0.66	2.51e-35	Schizophrenia;
CESC	cis	rs727563	0.635	rs5751149	chr22:42139501	A/G	cg06634786	chr22:41940651	POLR3H	0.68	6.72	0.38	1.13e-10	Crohn's disease;Inflammatory bowel disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg21056458	chr19:12817517	SNORD41;TNPO2	0.53	7.4	0.41	1.79e-12	Fibrinogen levels;
CESC	cis	rs75804782	0.521	rs56121087	chr2:239435766	A/G	cg18131467	chr2:239335373	ASB1	-0.68	-5.18	-0.3	4.38e-7	Morning vs. evening chronotype;Chronotype;
CESC	cis	rs34779708	1.000	rs34779708	chr10:35466185	T/G	cg03585969	chr10:35415529	CREM	0.76	10.01	0.52	3.32e-20	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs7089973	0.604	rs7914792	chr10:116591391	T/C	cg03647239	chr10:116582469	FAM160B1	0.43	5.29	0.31	2.6e-7	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	trans	rs2115172	0.836	rs4835799	chr5:122762229	A/G	cg21939482	chr7:6388130	C7orf70	0.47	6.22	0.36	1.97e-9	Weight;
CESC	cis	rs2933343	0.649	rs1683786	chr3:128626952	T/C	cg25356066	chr3:128598488	ACAD9	0.6	8.46	0.46	1.79e-15	IgG glycosylation;
CESC	cis	rs2439831	0.702	rs495175	chr15:43798684	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.88	12.38	0.61	4.47e-28	Lung cancer in ever smokers;
CESC	cis	rs1799949	1.000	rs33994002	chr17:41328818	T/A	cg23758822	chr17:41437982	NA	1.05	16.2	0.71	1.69e-41	Menopause (age at onset);
CESC	cis	rs1062753	0.771	rs932376	chr22:42614362	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.41	6.6	0.38	2.27e-10	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
CESC	trans	rs4332037	0.539	rs11764780	chr7:2020904	G/C	cg11693508	chr17:37793320	STARD3	0.67	6.73	0.38	1.07e-10	Bipolar disorder;
CESC	cis	rs17818399	0.749	rs4142759	chr2:46783890	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.47	5.59	0.32	5.65e-8	Height;
CESC	cis	rs763121	0.814	rs5757212	chr22:39053757	G/C	cg06544989	chr22:39130855	UNC84B	0.5	9.13	0.49	1.87e-17	Menopause (age at onset);
CESC	cis	rs36207871	1	rs36207871	chr12:56684496	TAGGAA/T	cg26734620	chr12:56694298	CS	-0.93	-9.55	-0.51	9.4e-19	Inflammatory skin disease;
CESC	cis	rs3015497	0.616	rs6572678	chr14:51090115	T/G	cg09863266	chr14:51125203	SAV1	-0.32	-5.06	-0.3	7.7300000000000005e-07	Mean platelet volume;
CESC	cis	rs11690935	1.000	rs11678984	chr2:172535848	T/G	cg13550731	chr2:172543902	DYNC1I2	1.01	16.72	0.72	2.4e-43	Schizophrenia;
CESC	cis	rs7618915	0.547	rs11130311	chr3:52675005	T/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.3	5.43	0.32	1.27e-7	Bipolar disorder;
CESC	cis	rs898097	0.812	rs7406011	chr17:80829980	C/T	cg10494973	chr17:80897199	TBCD	0.51	5.8	0.34	1.88e-8	Breast cancer;
CESC	cis	rs7267979	1.000	rs398036	chr20:25439850	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.82	15.9	0.7	1.91e-40	Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22164177	chr12:117013718	MAP1LC3B2	-0.6	-7.08	-0.4	1.28e-11	Gut microbiome composition (summer);
CESC	cis	rs367943	0.799	rs13154055	chr5:112971516	A/T	cg12552261	chr5:112820674	MCC	0.54	6.14	0.35	3.08e-9	Type 2 diabetes;
CESC	cis	rs7107174	1.000	rs7117238	chr11:78040259	G/A	cg02023728	chr11:77925099	USP35	0.38	5.6	0.33	5.26e-8	Testicular germ cell tumor;
CESC	cis	rs7666738	0.830	rs6817645	chr4:99016054	T/C	cg17366294	chr4:99064904	C4orf37	0.6	8.62	0.47	6.37e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6499255	0.951	rs56316408	chr16:69658776	A/G	cg15192750	chr16:69999425	NA	0.51	5.87	0.34	1.33e-8	IgE levels;
CESC	cis	rs6723226	0.557	rs62136260	chr2:32575447	T/C	cg02381751	chr2:32503542	YIPF4	-0.43	-5.32	-0.31	2.21e-7	Intelligence (multi-trait analysis);
CESC	cis	rs941207	0.547	rs56183434	chr12:57069929	G/T	cg05584118	chr12:57595605	LRP1	-0.38	-5.17	-0.3	4.54e-7	Platelet count;
CESC	cis	rs2635047	0.601	rs2684842	chr18:44725289	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.32	-5.07	-0.3	7.61e-7	Educational attainment;
CESC	cis	rs61542988	0.756	rs5013587	chr7:22882660	C/T	cg13679077	chr7:22862647	TOMM7	0.61	7.47	0.42	1.18e-12	Fibrinogen levels;
CESC	cis	rs7666738	0.830	rs28785514	chr4:98959135	G/A	cg03467027	chr4:99064603	C4orf37	0.44	5.54	0.32	7.16e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7607369	0.759	rs10179708	chr2:219390967	T/A	cg02176678	chr2:219576539	TTLL4	-0.54	-9.8	-0.52	1.49e-19	Red blood cell count;Amyotrophic lateral sclerosis;
CESC	cis	rs8141529	0.732	rs6005872	chr22:29172898	T/G	cg02153584	chr22:29168773	CCDC117	0.71	10.07	0.53	2.16e-20	Lymphocyte counts;
CESC	cis	rs7811142	0.943	rs73403312	chr7:100024153	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.11	11.1	0.56	9.54e-24	Platelet count;
CESC	cis	rs1511802	0.591	rs6810892	chr4:187123941	C/T	cg24794857	chr4:187113578	CYP4V2	0.46	6.07	0.35	4.37e-9	Blood protein levels;
CESC	cis	rs10870270	0.956	rs10870293	chr10:133771413	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.87	-12.66	-0.61	4.87e-29	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs763121	0.785	rs5757199	chr22:39040617	T/G	cg21395723	chr22:39101663	GTPBP1	0.43	5.33	0.31	2.09e-7	Menopause (age at onset);
CESC	cis	rs151234	0.741	rs11647881	chr16:28606173	C/A	cg01378222	chr16:28622494	SULT1A1	-0.55	-6.5	-0.37	4.03e-10	Platelet distribution width;
CESC	cis	rs798554	0.797	rs798493	chr7:2798731	A/G	cg19346786	chr7:2764209	NA	-0.5	-7.24	-0.41	4.86e-12	Height;
CESC	cis	rs875971	0.861	rs801215	chr7:66011938	A/T	cg12463550	chr7:65579703	CRCP	-0.51	-6.36	-0.36	8.66e-10	Aortic root size;
CESC	cis	rs6060717	0.610	rs1891154	chr20:34617129	T/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.49	6.22	0.36	1.96e-9	Hip circumference adjusted for BMI;
CESC	cis	rs8005677	0.962	rs10130756	chr14:23396600	C/G	cg25600027	chr14:23388339	RBM23	-0.44	-5.37	-0.31	1.69e-7	Cognitive ability (multi-trait analysis);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg22190090	chr17:36955626	PIP4K2B	0.48	6.12	0.35	3.44e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs9916302	0.904	rs2338797	chr17:37548241	G/A	cg20243544	chr17:37824526	PNMT	-0.51	-6.5	-0.37	4.07e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs12464559	0.649	rs4306714	chr2:152611351	G/A	cg01189475	chr2:152685088	ARL5A	0.66	5.57	0.32	6.14e-8	Response to cognitive-behavioural therapy in anxiety disorder;
CESC	cis	rs7786877	0.723	rs73407376	chr7:100215200	C/T	cg27028030	chr7:100209634	MOSPD3	0.57	5.59	0.32	5.72e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs854765	0.547	rs7224047	chr17:17932931	G/A	cg09796270	chr17:17721594	SREBF1	0.37	5.08	0.3	7.17e-7	Total body bone mineral density;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16437679	chr6:146056419	EPM2A	0.54	6.07	0.35	4.33e-9	Gut microbiome composition (summer);
CESC	cis	rs4132509	0.948	rs7517921	chr1:243856420	T/C	cg21452805	chr1:244014465	NA	0.42	5.03	0.3	9.13e-7	RR interval (heart rate);
CESC	cis	rs7247513	0.790	rs8112964	chr19:12752173	C/T	cg11738485	chr19:12877000	HOOK2	0.46	5.56	0.32	6.48e-8	Bipolar disorder;
CESC	cis	rs1044573	0.526	rs6050422	chr20:25177920	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.5	7.5	0.42	9.9e-13	Allergic rhinitis;
CESC	cis	rs78132593	0.723	rs34593358	chr1:150686633	A/T	cg04414720	chr1:150670196	GOLPH3L	-0.51	-6.01	-0.35	6.17e-9	High light scatter reticulocyte count;
CESC	cis	rs12477438	0.765	rs6750876	chr2:99679673	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.64	-8.73	-0.47	2.94e-16	Chronic sinus infection;
CESC	trans	rs116095464	0.867	rs7726582	chr5:215349	C/G	cg00938859	chr5:1591904	SDHAP3	0.62	6.81	0.39	6.42e-11	Breast cancer;
CESC	cis	rs9291683	0.588	rs3756238	chr4:10013202	C/T	cg11266682	chr4:10021025	SLC2A9	0.72	14.87	0.67	8.7e-37	Bone mineral density;
CESC	trans	rs9325144	0.600	rs12297194	chr12:38735803	A/G	cg23762105	chr12:34175262	ALG10	0.45	6.12	0.35	3.32e-9	Morning vs. evening chronotype;
CESC	cis	rs909002	0.849	rs6663012	chr1:32091779	T/G	cg13919466	chr1:32135498	COL16A1	-0.46	-8.18	-0.45	1.21e-14	Intelligence (multi-trait analysis);
CESC	cis	rs6582630	0.537	rs8189533	chr12:38391068	A/G	cg13010199	chr12:38710504	ALG10B	0.54	6.67	0.38	1.45e-10	Drug-induced liver injury (flucloxacillin);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg24744501	chr2:207024175	NDUFS1;EEF1B2	-0.5	-6.73	-0.38	1.06e-10	Fibrinogen levels;
CESC	cis	rs7100689	0.784	rs17678947	chr10:82136333	T/C	cg00277334	chr10:82204260	NA	-0.58	-7.29	-0.41	3.66e-12	Post bronchodilator FEV1;
CESC	cis	rs2072732	0.656	rs113272167	chr1:2954051	C/T	cg03976712	chr1:2946727	NA	0.34	5.63	0.33	4.57e-8	Plateletcrit;
CESC	cis	rs709400	0.770	rs7142883	chr14:104066645	G/A	cg24130564	chr14:104152367	KLC1	-0.43	-5.19	-0.3	4.27e-7	Body mass index;
CESC	cis	rs6121246	0.560	rs6088854	chr20:30225357	G/A	cg13852791	chr20:30311386	BCL2L1	0.76	6.19	0.36	2.26e-9	Mean corpuscular hemoglobin;
CESC	cis	rs35306767	0.855	rs11253499	chr10:944090	A/C	cg10556349	chr10:835070	NA	0.62	5.91	0.34	1.05e-8	Eosinophil percentage of granulocytes;
CESC	cis	rs34779708	0.733	rs4934740	chr10:35547141	C/T	cg03585969	chr10:35415529	CREM	0.55	6.37	0.36	8.28e-10	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs7179456	0.545	rs507801	chr15:59053345	T/G	cg05156742	chr15:59063176	FAM63B	0.58	7.11	0.4	1.09e-11	Asperger disorder;
CESC	cis	rs116095464	0.510	rs60844864	chr5:267000	A/G	cg10591111	chr5:226296	SDHA	-0.52	-6.16	-0.35	2.62e-9	Breast cancer;
CESC	cis	rs4148883	0.689	rs2602861	chr4:100030896	C/T	cg12011299	chr4:100065546	ADH4	0.69	10.44	0.54	1.38e-21	Alcohol dependence;
CESC	cis	rs10504229	0.531	rs55923836	chr8:57999127	A/G	cg22535103	chr8:58192502	C8orf71	-0.56	-6.58	-0.37	2.48e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs4713118	0.527	rs35949862	chr6:28115367	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.6	-6.84	-0.39	5.51e-11	Parkinson's disease;
CESC	trans	rs561341	1.000	rs561341	chr17:30316385	T/G	cg27661571	chr11:113659931	NA	-0.83	-7.76	-0.43	1.9e-13	Hip circumference adjusted for BMI;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg19575883	chr2:172231724	METTL8	0.46	6.27	0.36	1.45e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg04322344	chr3:131221642	MRPL3	-0.43	-6.3	-0.36	1.26e-9	Gambling;
CESC	cis	rs703842	1.000	rs10783848	chr12:58196528	G/A	cg00599273	chr12:58146742	CDK4	0.33	5.06	0.3	7.92e-7	Multiple sclerosis;
CESC	cis	rs2710642	0.564	rs7583570	chr2:62852926	C/T	cg17519650	chr2:63277830	OTX1	0.49	6.54	0.37	3.2e-10	LDL cholesterol levels;LDL cholesterol;
CESC	trans	rs11098499	0.909	rs10002083	chr4:120311152	C/T	cg25214090	chr10:38739885	LOC399744	0.68	9.2	0.49	1.14e-17	Corneal astigmatism;
CESC	cis	rs7107174	0.892	rs4944196	chr11:78008731	G/A	cg02023728	chr11:77925099	USP35	0.5	6.69	0.38	1.33e-10	Testicular germ cell tumor;
CESC	cis	rs1552244	1.000	rs6807846	chr3:10134491	G/T	cg00149659	chr3:10157352	C3orf10	0.71	8.63	0.47	5.76e-16	Alzheimer's disease;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg17338258	chr17:7533521	SHBG	-0.45	-6.38	-0.36	7.93e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs919433	1.000	rs6741380	chr2:198165121	A/G	cg03934865	chr2:198174659	NA	0.41	6.1	0.35	3.72e-9	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs4727027	0.933	rs12704063	chr7:148827909	T/C	cg23158103	chr7:148848205	ZNF398	-0.41	-6.74	-0.38	9.65e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs1878931	0.545	rs28603	chr16:3449479	A/G	cg21433313	chr16:3507492	NAT15	0.39	5.05	0.3	8.36e-7	Body mass index (adult);
CESC	trans	rs11098499	0.863	rs9997631	chr4:120469995	C/G	cg25214090	chr10:38739885	LOC399744	0.68	9.39	0.5	2.82e-18	Corneal astigmatism;
CESC	cis	rs7178572	1.000	rs62007299	chr15:77711719	G/A	cg22256960	chr15:77711686	NA	-0.58	-7.92	-0.44	6.36e-14	Type 2 diabetes;
CESC	cis	rs10129255	0.500	rs8014529	chr14:107192302	G/A	cg07958169	chr14:107095056	NA	-0.54	-8.32	-0.45	4.77e-15	Kawasaki disease;
CESC	cis	rs7312933	0.533	rs3747557	chr12:42717961	G/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.48	-6.4	-0.37	7.07e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs13720	0.722	rs163791	chr20:57576174	G/A	cg23907860	chr20:57583709	CTSZ	-0.48	-5.92	-0.34	1.01e-8	Platelet distribution width;
CESC	cis	rs4665809	0.878	rs4143538	chr2:26290178	A/C	cg25036284	chr2:26402008	FAM59B	-0.73	-8.24	-0.45	8.07e-15	Gut microbiome composition (summer);
CESC	cis	rs6952808	0.656	rs11764212	chr7:2067593	C/A	cg04267008	chr7:1944627	MAD1L1	-0.65	-7.93	-0.44	5.95e-14	Bipolar disorder and schizophrenia;
CESC	cis	rs3806843	0.735	rs801185	chr5:140068869	A/G	cg26395211	chr5:140044315	WDR55	0.47	6.03	0.35	5.51e-9	Depressive symptoms (multi-trait analysis);
CESC	cis	rs9487051	0.676	rs13195816	chr6:109598624	T/C	cg12927641	chr6:109611667	NA	-0.37	-5.54	-0.32	7.26e-8	Reticulocyte fraction of red cells;
CESC	cis	rs12995491	0.731	rs13019346	chr2:88509321	A/G	cg18490616	chr2:88469792	THNSL2	-0.44	-6.45	-0.37	5.22e-10	Response to metformin (IC50);
CESC	cis	rs9858542	0.903	rs11921590	chr3:49644193	T/C	cg07274523	chr3:49395745	GPX1	0.68	8.71	0.47	3.38e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs734999	0.588	rs2764842	chr1:2529192	A/G	cg20673091	chr1:2541236	MMEL1	-0.44	-7.23	-0.41	5.08e-12	Ulcerative colitis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21768436	chr8:67341108	RRS1	0.59	6.36	0.36	8.96e-10	Gut microbiome composition (summer);
CESC	cis	rs4665809	1.000	rs10048683	chr2:26320519	C/T	cg22920501	chr2:26401640	FAM59B	-0.67	-8.22	-0.45	9.42e-15	Gut microbiome composition (summer);
CESC	cis	rs7552404	0.655	rs5745336	chr1:76273519	G/A	cg22875332	chr1:76189707	ACADM	0.61	6.25	0.36	1.68e-9	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs3796352	0.764	rs11714902	chr3:53101544	G/C	cg15956490	chr3:53032818	SFMBT1	0.63	5.21	0.3	3.88e-7	Immune reponse to smallpox (secreted IL-2);
CESC	cis	rs79976124	0.797	rs77895756	chr6:66626782	C/T	cg07460842	chr6:66804631	NA	0.74	8.58	0.47	7.85e-16	Type 2 diabetes;
CESC	trans	rs7618501	1.000	rs9872864	chr3:49792023	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.59	-8.5	-0.46	1.38e-15	Intelligence (multi-trait analysis);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg03734322	chr17:1532856	SLC43A2	-0.46	-6.81	-0.39	6.64e-11	Gambling;
CESC	cis	rs13191362	0.872	rs13206549	chr6:162978032	T/G	cg21926612	chr6:163149169	PACRG;PARK2	0.75	7.24	0.41	4.83e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs3820068	0.553	rs7545782	chr1:15955227	G/C	cg16988262	chr1:15930761	NA	0.34	5.43	0.32	1.24e-7	Systolic blood pressure;
CESC	cis	rs2404602	0.536	rs7165025	chr15:76766434	G/A	cg26408565	chr15:76604113	ETFA	-0.43	-6.43	-0.37	5.98e-10	Blood metabolite levels;
CESC	cis	rs7000551	0.715	rs2461478	chr8:22378236	A/G	cg12081754	chr8:22256438	SLC39A14	0.42	5.61	0.33	5.13e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CESC	cis	rs9926296	0.533	rs12102297	chr16:89812762	C/A	cg21285383	chr16:89894308	SPIRE2	0.3	5.39	0.31	1.55e-7	Vitiligo;
CESC	cis	rs1729951	0.546	rs835634	chr3:136676303	C/T	cg04103450	chr3:136751342	NA	0.39	5.15	0.3	5.14e-7	Neuroticism;
CESC	cis	rs12220238	1.000	rs10824099	chr10:75943625	T/A	cg19889307	chr10:75911429	ADK;AP3M1	0.61	5.42	0.32	1.34e-7	Soluble interleukin-2 receptor subunit alpha;
CESC	cis	rs867529	0.695	rs335115	chr2:89027647	C/T	cg26627705	chr2:89060884	NA	0.38	5.46	0.32	1.1e-7	Height;
CESC	cis	rs6938	0.534	rs11636892	chr15:75266049	G/C	cg17294928	chr15:75287854	SCAMP5	0.49	6.16	0.35	2.68e-9	Breast cancer;
CESC	cis	rs9790314	1.000	rs336567	chr3:161073046	A/G	cg03342759	chr3:160939853	NMD3	-0.5	-6.45	-0.37	5.33e-10	Morning vs. evening chronotype;
CESC	cis	rs9649213	0.593	rs36017146	chr7:97974617	C/T	cg21770322	chr7:97807741	LMTK2	0.58	8.95	0.48	6.37e-17	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.43	-6.41	-0.37	6.62e-10	Longevity;Endometriosis;
CESC	cis	rs10463316	0.894	rs7723379	chr5:150765025	T/C	cg03212797	chr5:150827313	SLC36A1	-0.46	-6.04	-0.35	5.23e-9	Metabolite levels (Pyroglutamine);
CESC	cis	rs7412746	0.597	rs868751	chr1:150669414	T/G	cg09365446	chr1:150670422	GOLPH3L	0.41	5.76	0.33	2.36e-8	Melanoma;
CESC	cis	rs8141529	0.702	rs469991	chr22:29307859	G/C	cg02153584	chr22:29168773	CCDC117	-0.57	-7.33	-0.41	2.86e-12	Lymphocyte counts;
CESC	cis	rs1799949	1.000	rs2292595	chr17:41290674	G/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.45	6.31	0.36	1.17e-9	Menopause (age at onset);
CESC	cis	rs8177253	1.000	rs8177252	chr3:133480174	C/A	cg11941060	chr3:133502564	NA	-0.49	-6.7	-0.38	1.26e-10	Iron status biomarkers;
CESC	cis	rs9287719	0.601	rs1861299	chr2:10763757	C/G	cg00105475	chr2:10696890	NA	0.37	5.03	0.3	9.03e-7	Prostate cancer;
CESC	cis	rs1775715	0.737	rs11817598	chr10:32206259	A/G	cg04359828	chr10:32216031	ARHGAP12	0.35	5.04	0.3	8.57e-7	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs7512552	0.839	rs698919	chr1:150387000	A/G	cg15654264	chr1:150340011	RPRD2	0.4	5.3	0.31	2.4e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs9325144	0.625	rs11534879	chr12:38968165	A/G	cg26384229	chr12:38710491	ALG10B	-0.54	-7.65	-0.43	3.83e-13	Morning vs. evening chronotype;
CESC	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg05064044	chr6:292385	DUSP22	-0.68	-8.83	-0.48	1.43e-16	Menopause (age at onset);
CESC	cis	rs12995849	0.905	rs7565757	chr2:106452408	T/A	cg16077055	chr2:106428750	NCK2	0.39	6.23	0.36	1.85e-9	Addiction;
CESC	cis	rs736408	0.648	rs3774354	chr3:52817675	G/A	cg18404041	chr3:52824283	ITIH1	-0.46	-7.52	-0.42	8.75e-13	Bipolar disorder;
CESC	cis	rs6860806	0.507	rs272882	chr5:131669161	G/T	cg24060327	chr5:131705240	SLC22A5	-0.77	-10.88	-0.56	4.91e-23	Breast cancer;
CESC	cis	rs13242816	1.000	rs17138767	chr7:116137677	A/G	cg04696780	chr7:116139425	CAV2	-0.61	-5.51	-0.32	8.44e-8	P wave duration;
CESC	cis	rs60871478	0.636	rs55663559	chr7:884057	G/A	cg15782153	chr7:917662	C7orf20	0.52	5.71	0.33	3e-8	Cerebrospinal P-tau181p levels;
CESC	cis	rs897080	0.514	rs1067376	chr2:44648361	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	5.91	0.34	1.07e-8	Height;
CESC	cis	rs9583531	0.689	rs4773244	chr13:111383937	A/T	cg15841412	chr13:111365552	ING1	-0.47	-5.76	-0.33	2.28e-8	Coronary artery disease;
CESC	cis	rs2637266	0.756	rs846621	chr10:78545171	G/T	cg18941641	chr10:78392320	NA	0.39	7.24	0.41	4.76e-12	Pulmonary function;
CESC	cis	rs1670533	1.000	rs6599279	chr4:1058833	G/A	cg27284194	chr4:1044797	NA	0.47	5.99	0.35	6.88e-9	Recombination rate (females);
CESC	cis	rs9910055	0.615	rs189049	chr17:42197213	A/C	cg10896456	chr17:42255109	ASB16;C17orf65	-0.5	-7.58	-0.42	5.97e-13	Total body bone mineral density;
CESC	cis	rs9911578	0.730	rs55759249	chr17:57027135	A/G	cg12560992	chr17:57184187	TRIM37	-0.89	-11.35	-0.57	1.38e-24	Intelligence (multi-trait analysis);
CESC	cis	rs4803468	0.967	rs3786553	chr19:41902746	T/G	cg14132834	chr19:41945861	ATP5SL	-0.57	-7.1	-0.4	1.17e-11	Height;
CESC	cis	rs1448094	0.511	rs34656916	chr12:86154658	G/C	cg00310523	chr12:86230176	RASSF9	0.35	5.49	0.32	9.42e-8	Major depressive disorder;
CESC	cis	rs4148883	0.675	rs28762430	chr4:100119257	C/A	cg13256891	chr4:100009986	ADH5	0.53	6.91	0.39	3.49e-11	Alcohol dependence;
CESC	cis	rs265548	0.646	rs36692	chr19:17906839	C/T	cg00024989	chr19:17902242	NA	0.43	7.57	0.42	6.33e-13	Tumor biomarkers;
CESC	cis	rs1218582	0.772	rs6699043	chr1:154913021	T/C	cg09359103	chr1:154839909	KCNN3	-0.66	-12.34	-0.6	5.93e-28	Prostate cancer;
CESC	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg05313129	chr8:58192883	C8orf71	-0.49	-5.33	-0.31	2.07e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs10791097	0.694	rs7926167	chr11:130745045	T/C	cg12179176	chr11:130786555	SNX19	0.64	9.86	0.52	9.69e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs4665809	0.590	rs7588328	chr2:26469788	G/A	cg25036284	chr2:26402008	FAM59B	0.86	9.36	0.5	3.44e-18	Gut microbiome composition (summer);
CESC	cis	rs4141404	0.737	rs5998067	chr22:32043630	C/T	cg02404636	chr22:31891804	SFI1	-0.37	-5.12	-0.3	5.89e-7	Paclitaxel-induced neuropathy;
CESC	cis	rs477692	1.000	rs473771	chr10:131408155	A/C	cg05714579	chr10:131428358	MGMT	0.5	6.82	0.39	6.27e-11	Response to temozolomide;
CESC	cis	rs6570726	0.935	rs391820	chr6:145821284	C/T	cg23711669	chr6:146136114	FBXO30	0.76	11.32	0.57	1.68e-24	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7412746	0.658	rs59024312	chr1:150909005	T/G	cg22823121	chr1:150693482	HORMAD1	0.4	5.7	0.33	3.2e-8	Melanoma;
CESC	cis	rs6690583	0.697	rs10873684	chr1:85522196	T/C	cg11262906	chr1:85462892	MCOLN2	-0.43	-5.16	-0.3	4.86e-7	Serum sulfate level;
CESC	cis	rs9733	0.596	rs2175615	chr1:150624101	A/G	cg22823121	chr1:150693482	HORMAD1	0.48	7.12	0.4	1.03e-11	Tonsillectomy;
CESC	cis	rs6688613	0.649	rs11584352	chr1:166850372	T/C	cg07049167	chr1:166818506	POGK	0.46	5.4	0.31	1.47e-7	Refractive astigmatism;
CESC	cis	rs2032447	0.714	rs129129	chr6:25961029	A/G	cg03517284	chr6:25882590	NA	-0.45	-6.4	-0.37	7.15e-10	Intelligence (multi-trait analysis);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg16384552	chr7:74938386	SPDYE8P	0.49	6.36	0.36	8.94e-10	Fibrinogen levels;
CESC	cis	rs7829975	0.514	rs2945873	chr8:8260445	C/T	cg06636001	chr8:8085503	FLJ10661	0.53	7.03	0.4	1.79e-11	Mood instability;
CESC	cis	rs7520050	0.931	rs11576305	chr1:46460046	C/T	cg24296786	chr1:45957014	TESK2	0.45	5.65	0.33	4.17e-8	Red blood cell count;Reticulocyte count;
CESC	cis	rs10540	0.908	rs35608427	chr11:498976	T/C	cg03576123	chr11:487126	PTDSS2	-1.12	-11.26	-0.57	2.72e-24	Body mass index;
CESC	cis	rs7618915	0.571	rs67539070	chr3:52711974	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.5	7.27	0.41	4.02e-12	Bipolar disorder;
CESC	cis	rs7312933	0.618	rs6582394	chr12:42686189	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.46	5.98	0.34	7.34e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs4900538	0.819	rs72700604	chr14:102882307	G/A	cg18135206	chr14:102964638	TECPR2	-0.74	-9.44	-0.5	2.05e-18	Mean corpuscular volume;Mean corpuscular hemoglobin;
CESC	cis	rs9911578	1.000	rs304296	chr17:56834229	G/T	cg05425664	chr17:57184151	TRIM37	-0.48	-6.72	-0.38	1.12e-10	Intelligence (multi-trait analysis);
CESC	cis	rs7246865	0.510	rs1551551	chr19:17170541	G/T	cg16202187	chr19:17186497	HAUS8;MYO9B	0.48	6.26	0.36	1.56e-9	Reticulocyte fraction of red cells;
CESC	cis	rs12190007	0.547	rs3006181	chr6:169809117	T/A	cg15038512	chr6:170123185	PHF10	-0.48	-6.81	-0.39	6.6e-11	Obesity-related traits;
CESC	cis	rs9715521	0.935	rs72634625	chr4:59836434	T/A	cg11281224	chr4:60001000	NA	-0.51	-6.6	-0.38	2.29e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs7772486	0.641	rs960385	chr6:146371074	G/A	cg05347473	chr6:146136440	FBXO30	0.63	8.03	0.44	3.29e-14	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9811920	0.609	rs793463	chr3:99620252	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.64	10.11	0.53	1.53e-20	Axial length;
CESC	cis	rs11122272	0.735	rs2790893	chr1:231508976	T/G	cg06096015	chr1:231504339	EGLN1	0.44	6.32	0.36	1.08e-9	Hemoglobin concentration;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg00271154	chr2:113033418	ZC3H6	-0.5	-7.1	-0.4	1.15e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs2878628	0.596	rs57039206	chr3:52758570	T/A	cg17372223	chr3:52568218	NT5DC2	0.44	6.67	0.38	1.47e-10	Intelligence (multi-trait analysis);
CESC	cis	rs7395581	0.959	rs2279239	chr11:47281780	T/C	cg25783544	chr11:47291846	MADD	0.6	7.8	0.43	1.47e-13	HDL cholesterol;
CESC	cis	rs10504229	1.000	rs17216648	chr8:58169429	C/T	cg14926445	chr8:58193284	C8orf71	-0.52	-5.57	-0.32	6.33e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs853679	0.550	rs1225598	chr6:28160799	T/G	cg23161317	chr6:28129485	ZNF389	0.44	5.69	0.33	3.31e-8	Depression;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg06138422	chr12:133338013	ANKLE2	-0.46	-6.07	-0.35	4.47e-9	Ulcerative colitis;
CESC	cis	rs189798	0.592	rs10111263	chr8:8969433	C/G	cg15556689	chr8:8085844	FLJ10661	-0.5	-6.4	-0.37	7.16e-10	Myopia (pathological);
CESC	cis	rs4704187	0.687	rs4361493	chr5:74405097	A/G	cg03227963	chr5:74354835	NA	0.32	5.94	0.34	8.7e-9	Response to amphetamines;
CESC	cis	rs4835473	0.932	rs1849115	chr4:144910840	A/T	cg25736465	chr4:144833511	NA	0.41	6.26	0.36	1.54e-9	Immature fraction of reticulocytes;
CESC	cis	rs453301	0.571	rs2929456	chr8:9083416	G/A	cg06636001	chr8:8085503	FLJ10661	-0.55	-7.11	-0.4	1.08e-11	Joint mobility (Beighton score);
CESC	trans	rs61931739	0.890	rs814663	chr12:34106338	C/T	cg26384229	chr12:38710491	ALG10B	0.44	6.0	0.35	6.52e-9	Morning vs. evening chronotype;
CESC	cis	rs6688613	0.685	rs10800276	chr1:166858941	A/G	ch.1.3259774R	chr1:166827647	TADA1	-0.57	-5.68	-0.33	3.48e-8	Refractive astigmatism;
CESC	cis	rs10504229	0.683	rs7820302	chr8:58142502	C/T	cg24829409	chr8:58192753	C8orf71	-0.53	-6.73	-0.38	1.04e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs3796352	1.000	rs11713859	chr3:53042080	C/A	cg12962167	chr3:53033115	SFMBT1	0.65	5.17	0.3	4.52e-7	Immune reponse to smallpox (secreted IL-2);
CESC	cis	rs61931739	0.534	rs7302688	chr12:34235064	A/G	cg19457237	chr12:34500585	NA	-0.38	-5.29	-0.31	2.63e-7	Morning vs. evening chronotype;
CESC	cis	rs9640161	0.702	rs1962004	chr7:150020381	G/A	cg27494647	chr7:150038898	RARRES2	0.43	5.04	0.3	8.51e-7	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs7020830	0.522	rs10814509	chr9:37111057	A/G	cg14294708	chr9:37120828	ZCCHC7	0.82	11.6	0.58	2e-25	Schizophrenia;
CESC	cis	rs9929218	0.954	rs1981871	chr16:68819007	C/T	cg02972257	chr16:68554789	NA	0.49	5.82	0.34	1.7e-8	Colorectal cancer;
CESC	cis	rs11048434	0.761	rs1805721	chr12:9147569	A/G	cg23795048	chr12:9217529	LOC144571	-0.33	-5.04	-0.3	8.53e-7	Sjögren's syndrome;
CESC	cis	rs1008375	0.966	rs3775924	chr4:17585984	T/C	cg16339924	chr4:17578868	LAP3	0.74	9.65	0.51	4.51e-19	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs6912958	0.781	rs1051148	chr6:88221892	T/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-5.12	-0.3	5.99e-7	Monocyte percentage of white cells;
CESC	cis	rs7618915	0.501	rs2336149	chr3:52692124	G/A	cg05564831	chr3:52568323	NT5DC2	0.46	7.38	0.41	2.06e-12	Bipolar disorder;
CESC	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg07167872	chr1:205819463	PM20D1	0.85	15.13	0.68	1.07e-37	Menarche (age at onset);
CESC	cis	rs17125944	0.505	rs28568967	chr14:53223060	A/G	cg13660082	chr14:53194042	PSMC6	-0.67	-6.07	-0.35	4.39e-9	Alzheimer's disease (late onset);
CESC	cis	rs35306767	0.855	rs34251037	chr10:867884	C/T	cg10556349	chr10:835070	NA	0.76	6.39	0.37	7.22e-10	Eosinophil percentage of granulocytes;
CESC	cis	rs7666738	0.830	rs11935588	chr4:98979862	A/G	cg03676636	chr4:99064102	C4orf37	-0.33	-5.16	-0.3	4.92e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9581857	0.579	rs77187836	chr13:27998646	C/A	cg22138327	chr13:27999177	GTF3A	0.66	5.57	0.32	6.41e-8	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
CESC	cis	rs7777484	0.500	rs757787	chr7:2836355	G/A	cg18446336	chr7:2847575	GNA12	-0.39	-6.52	-0.37	3.45e-10	Height;
CESC	cis	rs2046867	0.862	rs2322612	chr3:72830058	A/G	cg25664220	chr3:72788482	NA	-0.45	-6.69	-0.38	1.28e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
CESC	cis	rs1008375	0.898	rs10008445	chr4:17593978	G/T	cg27347728	chr4:17578864	LAP3	0.44	5.24	0.31	3.33e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs1707322	0.691	rs11211175	chr1:46220884	C/G	cg06784218	chr1:46089804	CCDC17	0.42	7.59	0.42	5.59e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs12478296	0.786	rs55876934	chr2:243033816	C/T	cg06360820	chr2:242988706	NA	-0.7	-7.87	-0.44	9.07e-14	Obesity-related traits;
CESC	cis	rs9443645	0.901	rs9359354	chr6:79590385	A/G	cg05283184	chr6:79620031	NA	-0.43	-6.55	-0.37	2.95e-10	Intelligence (multi-trait analysis);
CESC	cis	rs853679	0.517	rs9380058	chr6:28127444	T/C	cg23161317	chr6:28129485	ZNF389	0.53	6.72	0.38	1.1e-10	Depression;
CESC	cis	rs1707322	1.000	rs11211243	chr1:46455433	G/C	cg05343316	chr1:45956843	TESK2	0.44	5.42	0.32	1.36e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs4523957	0.583	rs2760735	chr17:2036835	A/G	cg16513277	chr17:2031491	SMG6	-0.78	-11.57	-0.58	2.42e-25	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs96067	0.805	rs1033890	chr1:36608414	C/T	cg24686825	chr1:36642396	MAP7D1	-0.51	-5.49	-0.32	9.31e-8	Corneal structure;
CESC	cis	rs6500602	0.564	rs3747584	chr16:4516092	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.41	5.73	0.33	2.72e-8	Schizophrenia;
CESC	cis	rs10129255	1.000	rs10129255	chr14:107176213	A/G	cg23076370	chr14:107095027	NA	0.43	5.18	0.3	4.41e-7	Kawasaki disease;
CESC	cis	rs6977660	0.507	rs72591450	chr7:19775480	A/G	cg05791153	chr7:19748676	TWISTNB	0.75	6.76	0.38	8.75e-11	Thyroid stimulating hormone;
CESC	cis	rs7071206	0.853	rs114936111	chr10:79430143	G/A	cg00983440	chr10:79422392	NA	-0.61	-7.67	-0.43	3.27e-13	Bone mineral density;
CESC	cis	rs6502050	0.835	rs8081949	chr17:80117490	G/A	cg11859384	chr17:80120422	CCDC57	-0.38	-5.18	-0.3	4.42e-7	Life satisfaction;
CESC	trans	rs9354352	0.935	rs7766730	chr6:66697003	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.68	9.93	0.52	5.77e-20	Initial pursuit acceleration in psychotic disorders;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg23329543	chr19:53432372	ZNF321	-0.46	-6.67	-0.38	1.51e-10	Asthma;
CESC	cis	rs7833790	0.553	rs9693128	chr8:82706128	A/G	cg23324259	chr8:82754387	SNX16	-0.43	-5.49	-0.32	9.36e-8	Diastolic blood pressure;
CESC	cis	rs72781680	1.000	rs72796389	chr2:24171761	A/G	cg08917208	chr2:24149416	ATAD2B	0.94	8.58	0.47	7.87e-16	Lymphocyte counts;
CESC	cis	rs4835473	0.863	rs13146607	chr4:144608436	C/T	cg25736465	chr4:144833511	NA	-0.4	-5.77	-0.33	2.17e-8	Immature fraction of reticulocytes;
CESC	cis	rs13102973	0.965	rs4640720	chr4:135850050	G/T	cg14419869	chr4:135874104	NA	0.33	5.19	0.3	4.29e-7	Subjective well-being;
CESC	cis	rs6754311	0.593	rs10186843	chr2:136586958	C/A	cg07169764	chr2:136633963	MCM6	-0.68	-8.29	-0.45	5.57e-15	Mosquito bite size;
CESC	cis	rs7829975	0.714	rs60315134	chr8:8670599	A/G	cg17143192	chr8:8559678	CLDN23	0.42	5.24	0.31	3.28e-7	Mood instability;
CESC	cis	rs8177253	0.829	rs6794945	chr3:133518463	A/G	cg01448562	chr3:133502909	NA	0.51	7.29	0.41	3.66e-12	Iron status biomarkers;
CESC	cis	rs916888	0.773	rs199533	chr17:44828931	G/A	cg01570182	chr17:44337453	NA	0.91	10.63	0.55	3.34e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs3845702	0.733	rs12693217	chr2:180841914	T/G	cg01881094	chr2:180872142	CWC22	-1.06	-9.19	-0.49	1.18e-17	Schizophrenia;
CESC	cis	rs2836974	0.897	rs2026265	chr21:40595517	G/A	cg11890956	chr21:40555474	PSMG1	1.18	21.96	0.8	1.36e-61	Cognitive function;
CESC	cis	rs1178968	1.000	rs3108462	chr7:72739455	T/C	cg25889504	chr7:72793014	NA	0.47	5.03	0.3	8.91e-7	Triglyceride levels;
CESC	trans	rs2965280	0.793	rs111921454	chr19:34819296	C/T	cg05799317	chr6:165723796	C6orf118	0.81	6.0	0.35	6.45e-9	Colorectal cancer;
CESC	cis	rs9311474	0.508	rs2878628	chr3:52584715	C/T	cg18099408	chr3:52552593	STAB1	0.33	5.63	0.33	4.52e-8	Electroencephalogram traits;
CESC	cis	rs1552244	1.000	rs2272125	chr3:10138069	A/C	cg08888203	chr3:10149979	C3orf24	0.48	6.18	0.35	2.43e-9	Alzheimer's disease;
CESC	trans	rs78049276	0.736	rs73855810	chr4:148383424	G/A	cg13149281	chr14:23389818	RBM23;PRMT5	-0.61	-6.6	-0.38	2.24e-10	Pulse pressure;
CESC	cis	rs853679	0.517	rs9380052	chr6:28064623	A/G	cg22143856	chr6:28129313	ZNF389	0.42	5.28	0.31	2.73e-7	Depression;
CESC	cis	rs7116495	0.541	rs579320	chr11:71794954	G/T	cg26138937	chr11:71823887	C11orf51	-0.86	-7.03	-0.4	1.75e-11	Severe influenza A (H1N1) infection;
CESC	cis	rs8002861	0.905	rs12428350	chr13:44446161	G/A	cg19180546	chr13:44453867	C13orf31;CCDC122	-0.47	-5.85	-0.34	1.47e-8	Leprosy;
CESC	cis	rs951366	0.677	rs1775140	chr1:205672107	C/A	cg24503407	chr1:205819492	PM20D1	0.8	12.37	0.61	4.69e-28	Menarche (age at onset);
CESC	cis	rs7188697	0.922	rs37057	chr16:58561954	T/C	cg02549819	chr16:58548995	SETD6	-0.41	-5.21	-0.3	3.79e-7	QT interval;
CESC	cis	rs7020830	0.898	rs13290794	chr9:37183628	C/T	cg14294708	chr9:37120828	ZCCHC7	1.2	23.06	0.82	2.66e-65	Schizophrenia;
CESC	cis	rs9549367	0.774	rs2287246	chr13:113889127	A/G	cg18105134	chr13:113819100	PROZ	-0.68	-8.29	-0.45	5.77e-15	Platelet distribution width;
CESC	cis	rs713587	0.525	rs11687089	chr2:25082926	T/C	cg01884057	chr2:25150051	NA	0.34	6.33	0.36	1.05e-9	Body mass index in non-asthmatics;
CESC	cis	rs4919087	0.962	rs10882889	chr10:99045890	A/G	cg25902810	chr10:99078978	FRAT1	0.71	10.44	0.54	1.3e-21	Monocyte count;
CESC	cis	rs61542988	0.797	rs4329182	chr7:22882621	C/T	cg13679077	chr7:22862647	TOMM7	0.61	7.47	0.42	1.18e-12	Fibrinogen levels;
CESC	cis	rs412050	0.842	rs1530229	chr22:22300678	A/G	cg17089214	chr22:22089827	YPEL1	0.63	6.05	0.35	4.88e-9	Attention deficit hyperactivity disorder;
CESC	cis	rs7618915	0.547	rs62255371	chr3:52747321	A/G	cg07507251	chr3:52567010	NT5DC2	0.41	7.16	0.4	7.79e-12	Bipolar disorder;
CESC	cis	rs9612	1.000	rs3786954	chr19:44272346	A/G	cg08581076	chr19:44259116	C19orf61	0.45	5.47	0.32	1.03e-7	Exhaled nitric oxide output;
CESC	cis	rs9811920	0.609	rs10936005	chr3:99674093	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.55	-6.87	-0.39	4.64e-11	Axial length;
CESC	cis	rs7208859	0.623	rs9915546	chr17:29132144	G/T	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.1e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs798554	0.634	rs6970963	chr7:2821271	C/T	cg19717773	chr7:2847554	GNA12	-0.55	-8.68	-0.47	4.21e-16	Height;
CESC	cis	rs9287719	0.967	rs1541573	chr2:10773385	T/G	cg00105475	chr2:10696890	NA	0.37	5.2	0.3	4.04e-7	Prostate cancer;
CESC	cis	rs12824058	0.737	rs11060829	chr12:130814996	G/T	cg24838063	chr12:130822603	PIWIL1	0.62	8.55	0.47	9.78e-16	Menopause (age at onset);
CESC	cis	rs4253772	0.550	rs6008762	chr22:46736228	T/C	cg18190219	chr22:46762943	CELSR1	-0.56	-5.96	-0.34	8.1e-9	LDL cholesterol;Cholesterol, total;
CESC	cis	rs796364	0.806	rs11688194	chr2:200916239	C/T	cg23649088	chr2:200775458	C2orf69	-0.55	-5.05	-0.3	8.29e-7	Schizophrenia;
CESC	cis	rs56235845	0.694	rs6875461	chr5:176754665	C/T	cg17509989	chr5:176798049	RGS14	-0.51	-6.5	-0.37	3.93e-10	Hemoglobin concentration;Hematocrit;
CESC	cis	rs9894429	0.738	rs8077038	chr17:79577127	T/G	cg13777783	chr17:79615861	NA	0.33	5.24	0.31	3.35e-7	Eye color traits;
CESC	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg18402987	chr7:1209562	NA	0.76	7.57	0.42	6.04e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7851660	0.844	rs10119760	chr9:100624602	G/C	cg13688889	chr9:100608707	NA	-0.63	-8.94	-0.48	6.87e-17	Strep throat;
CESC	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg24846343	chr22:24311635	DDTL	-0.62	-10.56	-0.54	5.59e-22	Liver enzyme levels (gamma-glutamyl transferase);
CESC	trans	rs12310956	0.532	rs11052951	chr12:33986181	T/A	cg26384229	chr12:38710491	ALG10B	0.45	6.22	0.36	1.98e-9	Morning vs. evening chronotype;
CESC	cis	rs1448094	0.512	rs11832992	chr12:86240790	T/C	cg02569458	chr12:86230093	RASSF9	0.5	7.53	0.42	7.91e-13	Major depressive disorder;
CESC	cis	rs1953600	0.668	rs751740	chr10:81912179	T/C	cg04850286	chr10:81895943	PLAC9	0.31	5.35	0.31	1.88e-7	Sarcoidosis;
CESC	cis	rs6991838	0.557	rs67046768	chr8:66489721	A/G	cg13398993	chr8:66546079	ARMC1	-0.46	-5.54	-0.32	7.22e-8	Intelligence (multi-trait analysis);
CESC	cis	rs7590720	0.959	rs2372684	chr2:216884764	C/A	cg12620499	chr2:216877984	MREG	0.95	12.81	0.62	1.5e-29	Alcohol dependence;
CESC	cis	rs514406	0.679	rs61768344	chr1:53229274	G/A	cg24675658	chr1:53192096	ZYG11B	0.77	11.76	0.59	5.48e-26	Monocyte count;
CESC	trans	rs7246760	0.748	rs28384439	chr19:9731965	G/A	cg02900749	chr2:68251473	NA	-0.79	-6.01	-0.35	6.27e-9	Pursuit maintenance gain;
CESC	cis	rs9611565	0.512	rs964898	chr22:42142306	C/T	cg06481639	chr22:41940642	POLR3H	-0.55	-5.31	-0.31	2.31e-7	Vitiligo;
CESC	cis	rs8020095	0.571	rs10136043	chr14:67440238	C/G	cg19548862	chr14:67692701	FAM71D	-0.5	-6.09	-0.35	4.04e-9	Depression (quantitative trait);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg13944219	chr5:65440479	SFRS12	-0.44	-6.36	-0.36	8.72e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs9291683	0.546	rs13120348	chr4:10053155	C/G	cg00071950	chr4:10020882	SLC2A9	-0.81	-14.74	-0.67	2.5e-36	Bone mineral density;
CESC	cis	rs854765	0.505	rs4506969	chr17:17899839	A/G	cg16928487	chr17:17741425	SREBF1	-0.54	-9.09	-0.49	2.4e-17	Total body bone mineral density;
CESC	trans	rs916888	0.773	rs199535	chr17:44822662	A/G	cg10053473	chr17:62856997	LRRC37A3	-0.69	-7.56	-0.42	6.41e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs3741404	0.665	rs594461	chr11:63872543	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.71	9.9	0.52	7.19e-20	Platelet count;
CESC	trans	rs1814175	0.562	rs1794130	chr11:49903764	T/A	cg03929089	chr4:120376271	NA	-0.92	-15.2	-0.68	6e-38	Height;
CESC	cis	rs9914544	1.000	rs67411574	chr17:18797337	A/G	cg26378065	chr17:18585709	ZNF286B	0.46	5.7	0.33	3.25e-8	Educational attainment (years of education);
CESC	cis	rs4970988	0.556	rs6681426	chr1:150586971	G/A	cg04414720	chr1:150670196	GOLPH3L	-0.46	-5.91	-0.34	1.08e-8	Urate levels;
CESC	cis	rs2354432	0.607	rs4314933	chr1:146821386	T/C	cg25205988	chr1:146714368	CHD1L	0.98	9.04	0.49	3.47e-17	Mitochondrial DNA levels;
CESC	cis	rs2991971	0.967	rs937291	chr1:45957039	G/T	cg05343316	chr1:45956843	TESK2	-0.51	-6.75	-0.38	9.49e-11	High light scatter reticulocyte count;
CESC	cis	rs1957429	0.803	rs10873177	chr14:65318228	G/C	cg23373153	chr14:65346875	NA	0.87	10.01	0.52	3.32e-20	Pediatric areal bone mineral density (radius);
CESC	cis	rs2836974	0.932	rs6517526	chr21:40581530	T/C	cg17971929	chr21:40555470	PSMG1	1.07	16.31	0.71	7.07e-42	Cognitive function;
CESC	cis	rs4892230	1	rs4892230	chr18:72155572	G/A	cg25817165	chr18:72167213	CNDP2	-0.44	-5.9	-0.34	1.09e-8	Mononucleosis;
CESC	cis	rs929354	0.605	rs7806314	chr7:156946903	A/T	cg05182265	chr7:156933206	UBE3C	-0.5	-7.18	-0.4	7.24e-12	Body mass index;
CESC	cis	rs7772486	0.875	rs9403770	chr6:146423334	C/T	cg05347473	chr6:146136440	FBXO30	0.51	6.68	0.38	1.37e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7845219	0.597	rs7002058	chr8:95873993	G/C	cg13393036	chr8:95962371	TP53INP1	-0.35	-6.55	-0.37	2.99e-10	Type 2 diabetes;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg14258078	chr17:62051773	SCN4A	-0.4	-7.93	-0.44	6.03e-14	Gut microbiota (bacterial taxa);
CESC	cis	rs4689592	0.503	rs56099074	chr4:7071259	A/G	cg06697600	chr4:7070879	GRPEL1	0.52	6.56	0.37	2.81e-10	Monocyte percentage of white cells;
CESC	cis	rs55986470	0.817	rs11883735	chr2:239407644	G/A	cg18131467	chr2:239335373	ASB1	-0.57	-5.03	-0.3	9.16e-7	Chronotype;
CESC	cis	rs7666738	0.830	rs1426668	chr4:98945585	T/A	cg03467027	chr4:99064603	C4orf37	0.46	5.82	0.34	1.74e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2985684	0.948	rs2883437	chr14:50031666	A/G	cg04989706	chr14:50066350	PPIL5	-0.46	-5.17	-0.3	4.51e-7	Carotid intima media thickness;
CESC	trans	rs4332037	0.624	rs58169303	chr7:1883274	T/C	cg11693508	chr17:37793320	STARD3	0.6	6.01	0.35	6.17e-9	Bipolar disorder;
CESC	cis	rs55728055	0.661	rs7288051	chr22:32013816	C/T	cg01338084	chr22:32026380	PISD	1.22	8.02	0.44	3.48e-14	Age-related hearing impairment;
CESC	cis	rs8014204	0.541	rs35591392	chr14:75157713	G/T	cg08847533	chr14:75593920	NEK9	0.42	5.05	0.3	8.13e-7	Caffeine consumption;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg26309655	chr1:150459725	TARS2	-0.47	-6.34	-0.36	9.85e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs561341	0.769	rs8074383	chr17:30178793	C/T	cg00745463	chr17:30367425	LRRC37B	0.66	5.96	0.34	7.84e-9	Hip circumference adjusted for BMI;
CESC	cis	rs854765	0.647	rs741782	chr17:18019712	T/C	cg04398451	chr17:18023971	MYO15A	-0.77	-11.36	-0.57	1.22e-24	Total body bone mineral density;
CESC	cis	rs17253792	0.822	rs78922774	chr14:56115302	T/A	cg01858014	chr14:56050164	KTN1	-0.96	-7.52	-0.42	8.3e-13	Putamen volume;
CESC	cis	rs1005277	0.563	rs2800550	chr10:38482929	T/C	cg25427524	chr10:38739819	LOC399744	-0.7	-10.24	-0.53	6.01e-21	Extrinsic epigenetic age acceleration;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg12713142	chr12:57081325	PTGES3	0.51	7.28	0.41	3.81e-12	Systemic lupus erythematosus;
CESC	cis	rs9902453	0.730	rs2020939	chr17:28550732	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.56	-6.86	-0.39	4.87e-11	Coffee consumption (cups per day);
CESC	cis	rs7044106	0.791	rs10739572	chr9:123489815	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.85	13.79	0.65	5.75e-33	Hip circumference adjusted for BMI;
CESC	cis	rs9527	0.830	rs12249194	chr10:104643698	T/C	cg04362960	chr10:104952993	NT5C2	0.45	5.28	0.31	2.69e-7	Arsenic metabolism;
CESC	cis	rs546131	0.928	rs572690	chr11:34833614	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.5	6.38	0.37	7.7e-10	Lung disease severity in cystic fibrosis;
CESC	trans	rs7819412	0.703	rs2409713	chr8:11009797	C/T	cg06636001	chr8:8085503	FLJ10661	-0.49	-6.13	-0.35	3.15e-9	Triglycerides;
CESC	cis	rs965469	1.000	rs6051672	chr20:3224819	C/T	cg25506879	chr20:3388711	C20orf194	-0.65	-6.87	-0.39	4.52e-11	IFN-related cytopenia;
CESC	cis	rs9733	0.744	rs12568757	chr1:150729793	C/T	cg18016565	chr1:150552671	MCL1	-0.36	-5.93	-0.34	9.46e-9	Tonsillectomy;
CESC	cis	rs8070740	0.898	rs9895440	chr17:5325643	C/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.51	6.37	0.36	8.36e-10	Menopause (age at onset);
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg22627950	chr7:44622302	TMED4	-0.48	-6.47	-0.37	4.74e-10	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25820224	chr2:95787551	MRPS5	0.53	6.1	0.35	3.69e-9	Gut microbiome composition (summer);
CESC	cis	rs875971	0.545	rs1796226	chr7:66087710	C/T	cg11764359	chr7:65958608	NA	0.8	9.99	0.52	3.89e-20	Aortic root size;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg06944982	chr8:141779353	PTK2	0.44	6.32	0.36	1.09e-9	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs113835537	0.529	rs57634456	chr11:66250838	A/C	cg22134325	chr11:66188745	NPAS4	0.33	5.27	0.31	2.78e-7	Airway imaging phenotypes;
CESC	cis	rs798554	0.680	rs2533889	chr7:2900309	G/C	cg19346786	chr7:2764209	NA	-0.36	-5.13	-0.3	5.57e-7	Height;
CESC	cis	rs7940866	0.903	rs7130842	chr11:130836269	A/G	cg12179176	chr11:130786555	SNX19	0.6	8.36	0.46	3.66e-15	Schizophrenia;
CESC	cis	rs7584330	0.554	rs77180399	chr2:238442951	G/A	cg14458575	chr2:238380390	NA	0.69	6.44	0.37	5.43e-10	Prostate cancer;
CESC	cis	rs514406	0.679	rs545719	chr1:53304922	T/C	cg16325326	chr1:53192061	ZYG11B	0.57	8.46	0.46	1.77e-15	Monocyte count;
CESC	cis	rs7666738	0.800	rs1559858	chr4:99024075	A/G	cg17366294	chr4:99064904	C4orf37	0.6	8.57	0.47	8.69e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4523957	0.651	rs8068642	chr17:2060353	T/C	cg16513277	chr17:2031491	SMG6	-0.72	-10.2	-0.53	8.12e-21	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs7542091	0.666	rs7537070	chr1:210043565	A/G	cg25204440	chr1:209979598	IRF6	0.37	5.1	0.3	6.55e-7	Monobrow;
CESC	cis	rs477895	1.000	rs34292685	chr11:64049021	C/T	cg04317338	chr11:64019027	PLCB3	0.69	5.93	0.34	9.3e-9	Mean platelet volume;
CESC	trans	rs11098499	0.863	rs6858592	chr4:120458692	G/A	cg25214090	chr10:38739885	LOC399744	0.7	9.72	0.51	2.7e-19	Corneal astigmatism;
CESC	cis	rs9457247	1.000	rs376551	chr6:167384923	G/A	cg07741184	chr6:167504864	NA	0.31	5.53	0.32	7.76e-8	Crohn's disease;
CESC	cis	rs854765	0.547	rs6502633	chr17:17941037	G/C	cg04398451	chr17:18023971	MYO15A	-0.73	-10.55	-0.54	6.12e-22	Total body bone mineral density;
CESC	cis	rs7312933	0.701	rs10880260	chr12:42561398	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.46	5.99	0.35	6.93e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs4330281	0.740	rs4349529	chr3:17792118	A/G	cg20981856	chr3:17787350	NA	0.36	5.06	0.3	7.8e-7	Schizophrenia;
CESC	trans	rs997295	0.529	rs12592315	chr15:68040266	A/G	cg02522757	chr12:48298992	VDR	0.47	6.04	0.35	5.09e-9	Motion sickness;
CESC	trans	rs74054849	0.850	rs112167764	chr1:16016551	G/A	cg06826283	chr7:600452	PRKAR1B	0.69	6.12	0.35	3.34e-9	Alcoholic chronic pancreatitis;
CESC	cis	rs9790314	1.000	rs62279921	chr3:161065441	T/C	cg03342759	chr3:160939853	NMD3	-0.45	-5.86	-0.34	1.37e-8	Morning vs. evening chronotype;
CESC	cis	rs2576037	0.561	rs513775	chr18:44396334	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.78	12.99	0.62	3.48e-30	Personality dimensions;
CESC	cis	rs7246657	0.943	rs4803229	chr19:37864682	T/G	cg23950597	chr19:37808831	NA	-0.55	-6.09	-0.35	3.96e-9	Coronary artery calcification;
CESC	cis	rs6963495	0.769	rs117986187	chr7:105167311	G/A	cg13798780	chr7:105162888	PUS7	0.78	8.02	0.44	3.36e-14	Bipolar disorder (body mass index interaction);
CESC	cis	rs10870270	1.000	rs4880263	chr10:133787629	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.86	-12.51	-0.61	1.56e-28	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg11965913	chr1:205819406	PM20D1	0.82	13.95	0.65	1.49e-33	Menarche (age at onset);
CESC	cis	rs7247513	0.790	rs8112964	chr19:12752173	C/T	cg01871581	chr19:12707946	ZNF490	-0.79	-11.89	-0.59	2.06e-26	Bipolar disorder;
CESC	cis	rs7666738	0.830	rs3907020	chr4:99038583	T/C	cg03676636	chr4:99064102	C4orf37	0.33	5.08	0.3	7.13e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9796	0.558	rs11855102	chr15:41513257	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.45	-6.77	-0.38	8.07e-11	Menopause (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21387238	chr1:155829263	SYT11	0.67	7.63	0.42	4.2e-13	Gut microbiome composition (summer);
CESC	cis	rs911555	0.576	rs8015723	chr14:103895909	A/G	cg12935359	chr14:103987150	CKB	0.47	6.33	0.36	1.06e-9	Intelligence (multi-trait analysis);
CESC	cis	rs524281	0.861	rs10791855	chr11:65963737	A/G	cg14036092	chr11:66035641	RAB1B	-0.58	-6.15	-0.35	2.79e-9	Electroencephalogram traits;
CESC	cis	rs888194	0.544	rs2196612	chr12:109849535	A/G	cg19025524	chr12:109796872	NA	-0.46	-6.64	-0.38	1.77e-10	Neuroticism;
CESC	cis	rs425277	0.585	rs3128294	chr1:2065343	G/C	cg24578937	chr1:2090814	PRKCZ	-0.36	-6.11	-0.35	3.46e-9	Height;
CESC	cis	rs17376456	0.877	rs10073039	chr5:93467709	A/G	cg21475434	chr5:93447410	FAM172A	0.85	7.6	0.42	5.01e-13	Diabetic retinopathy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23603076	chr14:24605279	PSME1	0.62	7.1	0.4	1.17e-11	Gut microbiome composition (summer);
CESC	cis	rs708547	0.581	rs13121027	chr4:57813369	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.54	-7.04	-0.4	1.69e-11	Response to bleomycin (chromatid breaks);
CESC	cis	rs7809799	1.000	rs1918019	chr7:98763419	G/A	cg05967295	chr7:98741636	SMURF1	-0.77	-5.41	-0.32	1.37e-7	Ulcerative colitis;
CESC	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	6.51	0.37	3.65e-10	Prudent dietary pattern;
CESC	cis	rs7824557	0.603	rs2250028	chr8:11213589	T/G	cg21775007	chr8:11205619	TDH	0.54	7.73	0.43	2.26e-13	Retinal vascular caliber;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24441975	chr1:39339062	MYCBP	0.54	6.45	0.37	5.37e-10	Gut microbiome composition (summer);
CESC	cis	rs9291683	0.588	rs2240721	chr4:10020564	G/A	cg11266682	chr4:10021025	SLC2A9	0.72	14.84	0.67	1.1e-36	Bone mineral density;
CESC	cis	rs10504229	0.683	rs6980540	chr8:58127022	A/G	cg02725872	chr8:58115012	NA	-0.45	-6.84	-0.39	5.31e-11	Developmental language disorder (linguistic errors);
CESC	cis	rs951366	0.677	rs1775140	chr1:205672107	C/A	cg07167872	chr1:205819463	PM20D1	0.76	11.92	0.59	1.64e-26	Menarche (age at onset);
CESC	cis	rs8017423	0.967	rs8015510	chr14:90729984	C/T	cg14092571	chr14:90743983	NA	-0.56	-8.38	-0.46	3.07e-15	Mortality in heart failure;
CESC	cis	rs9926296	0.632	rs2011925	chr16:89814064	T/G	cg04287289	chr16:89883240	FANCA	0.63	8.1	0.45	2.05e-14	Vitiligo;
CESC	cis	rs5750830	0.594	rs5757650	chr22:39778419	A/G	cg01416388	chr22:39784598	NA	-0.49	-6.46	-0.37	4.91e-10	Intelligence (multi-trait analysis);
CESC	cis	rs17711722	0.701	rs55773927	chr7:65337902	T/C	cg06456125	chr7:65229604	NA	0.43	5.6	0.33	5.49e-8	Calcium levels;
CESC	cis	rs11630290	0.736	rs72752925	chr15:64146100	C/G	cg12036633	chr15:63758958	NA	-0.55	-5.09	-0.3	6.87e-7	Iris characteristics;
CESC	cis	rs7762018	1.000	rs60253563	chr6:170083019	T/C	cg05834625	chr6:170176447	C6orf70	0.62	7.41	0.41	1.7e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs853679	0.546	rs200990	chr6:27815823	T/G	cg02228804	chr6:27775720	HIST1H2AI;HIST1H2BL	0.64	5.58	0.32	6e-8	Depression;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg26400300	chr15:44829086	EIF3J	-0.41	-6.35	-0.36	9.23e-10	Gambling;
CESC	cis	rs13223928	0.538	rs10951042	chr7:3139417	T/C	cg19214707	chr7:3157722	NA	-0.42	-5.77	-0.33	2.25e-8	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
CESC	trans	rs4424809	1.000	rs57685252	chr13:85277355	C/T	cg22095490	chr18:77560089	NA	-0.87	-6.37	-0.36	8.48e-10	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs6867032	0.876	rs1552435	chr5:2018378	A/G	cg26168224	chr5:2018326	NA	1.04	23.88	0.83	5.34e-68	Gut microbiome composition (winter);
CESC	cis	rs8114671	0.562	rs6088622	chr20:33419977	C/A	cg06115741	chr20:33292138	TP53INP2	0.45	5.31	0.31	2.37e-7	Height;
CESC	cis	rs1153858	1.000	rs11852800	chr15:45639131	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.82	-10.88	-0.56	4.84e-23	Homoarginine levels;
CESC	cis	rs3749237	0.595	rs1464566	chr3:49459376	T/C	cg07636037	chr3:49044803	WDR6	0.6	8.8	0.48	1.74e-16	Resting heart rate;
CESC	cis	rs634534	0.562	rs1151505	chr11:65734539	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.64	8.87	0.48	1.12e-16	Sum eosinophil basophil counts;Eosinophil counts;
CESC	cis	rs1401999	0.690	rs6773408	chr3:183716609	G/T	cg01324343	chr3:183735012	ABCC5	0.56	11.27	0.57	2.46e-24	Anterior chamber depth;
CESC	cis	rs6724607	1.000	rs10165399	chr2:191441595	A/G	cg21644426	chr2:191273491	MFSD6	0.46	6.3	0.36	1.26e-9	Pulse pressure;
CESC	cis	rs6461049	0.765	rs4719432	chr7:2140330	A/G	cg21782813	chr7:2030301	MAD1L1	0.37	5.15	0.3	5.05e-7	Schizophrenia;
CESC	cis	rs9611565	0.649	rs79005	chr22:41835544	G/A	cg06481639	chr22:41940642	POLR3H	0.52	5.68	0.33	3.48e-8	Vitiligo;
CESC	cis	rs1862618	0.573	rs185220	chr5:56205357	A/G	cg22800045	chr5:56110881	MAP3K1	0.77	9.06	0.49	2.91e-17	Initial pursuit acceleration;
CESC	cis	rs2463822	0.844	rs72923263	chr11:62161170	C/G	cg06239285	chr11:62104954	ASRGL1	-1.07	-9.26	-0.49	7.43e-18	Chronic obstructive pulmonary disease-related biomarkers;
CESC	cis	rs2760061	0.659	rs708107	chr1:228189495	C/T	cg02753203	chr1:228287806	NA	0.53	7.79	0.43	1.52e-13	Diastolic blood pressure;
CESC	cis	rs12325245	0.536	rs12709002	chr16:58614337	A/C	cg01152986	chr16:58549298	SETD6	0.9	5.47	0.32	1.02e-7	Schizophrenia;
CESC	cis	rs56235845	0.964	rs11741640	chr5:176792743	G/A	cg16006841	chr5:176797999	RGS14	0.59	6.32	0.36	1.13e-9	Hemoglobin concentration;Hematocrit;
CESC	cis	rs4979906	1.000	rs11002241	chr10:79445327	C/T	cg07817648	chr10:79422355	NA	-0.61	-6.46	-0.37	5.08e-10	Mortality in heart failure;
CESC	cis	rs1707322	0.721	rs11211166	chr1:46157942	G/A	cg03146154	chr1:46216737	IPP	0.82	11.58	0.58	2.25e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs514406	0.929	rs483073	chr1:53314084	T/C	cg08859206	chr1:53392774	SCP2	-0.57	-7.38	-0.41	2.02e-12	Monocyte count;
CESC	cis	rs9393777	0.513	rs9368451	chr6:26654333	A/G	cg12826209	chr6:26865740	GUSBL1	0.73	8.13	0.45	1.7e-14	Intelligence (multi-trait analysis);
CESC	trans	rs4843747	0.671	rs13334603	chr16:88116016	T/C	cg26811252	chr16:29126840	RRN3P2	0.72	10.04	0.52	2.53e-20	Menopause (age at onset);
CESC	cis	rs7508	0.668	rs13280	chr8:17921230	G/A	cg18067069	chr8:17937731	ASAH1	-0.4	-5.36	-0.31	1.82e-7	Atrial fibrillation;
CESC	cis	rs644799	1.000	rs546809	chr11:95579938	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	8.76	0.47	2.41e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs4819052	0.851	rs2838855	chr21:46680566	C/G	cg11663144	chr21:46675770	NA	0.59	9.45	0.5	1.91e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs76878669	0.561	rs4930177	chr11:66120784	T/C	cg18002602	chr11:66138449	SLC29A2	0.4	6.65	0.38	1.71e-10	Educational attainment (years of education);
CESC	cis	rs6964587	1.000	rs58965837	chr7:91585258	T/A	cg17063962	chr7:91808500	NA	0.57	7.67	0.43	3.21e-13	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07156820	chr17:54821256	NA	-0.53	-6.08	-0.35	4.16e-9	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.830	rs13122456	chr4:98936011	A/G	cg05340658	chr4:99064831	C4orf37	0.82	12.54	0.61	1.29e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7647973	0.769	rs4974081	chr3:49070499	A/G	cg07636037	chr3:49044803	WDR6	-0.82	-11.49	-0.58	4.46e-25	Menarche (age at onset);
CESC	cis	rs7772486	0.754	rs9399567	chr6:146147295	C/T	cg23711669	chr6:146136114	FBXO30	1.0	14.39	0.66	4.21e-35	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6121246	0.529	rs6060171	chr20:30183269	C/T	cg13852791	chr20:30311386	BCL2L1	0.57	5.5	0.32	9.14e-8	Mean corpuscular hemoglobin;
CESC	cis	rs11148252	0.508	rs11148260	chr13:53162643	A/C	cg00495681	chr13:53174319	NA	0.55	7.55	0.42	6.84e-13	Lewy body disease;
CESC	trans	rs916888	0.773	rs199443	chr17:44819565	C/T	cg22433210	chr17:43662623	NA	0.98	11.32	0.57	1.66e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs9611565	0.694	rs202641	chr22:41833116	C/T	cg17376030	chr22:41985996	PMM1	-0.55	-6.13	-0.35	3.17e-9	Vitiligo;
CESC	cis	rs2708240	0.936	rs2538976	chr7:147585819	T/C	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.33	-5.69	-0.33	3.39e-8	QT interval (drug interaction);
CESC	cis	rs2439831	0.850	rs7163245	chr15:43671294	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.86	13.09	0.63	1.57e-30	Lung cancer in ever smokers;
CESC	trans	rs1667255	0.830	rs2034404	chr18:29156302	A/G	cg19990402	chr19:37019372	ZNF260	0.49	6.22	0.36	1.92e-9	Retinol levels;
CESC	cis	rs9311474	0.632	rs6445528	chr3:52572447	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	-0.36	-6.83	-0.39	5.84e-11	Electroencephalogram traits;
CESC	cis	rs11112613	0.713	rs11112586	chr12:105939816	C/T	cg03607813	chr12:105948248	NA	0.58	6.62	0.38	2e-10	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CESC	cis	rs13108904	0.870	rs13124876	chr4:1247955	T/C	cg00684032	chr4:1343700	KIAA1530	0.41	5.79	0.33	2.03e-8	Obesity-related traits;
CESC	cis	rs2239547	0.618	rs2071041	chr3:52864693	T/G	cg11645453	chr3:52864694	ITIH4	0.39	7.19	0.4	6.45e-12	Schizophrenia;
CESC	cis	rs4268898	0.722	rs6723257	chr2:24391129	A/G	cg06627628	chr2:24431161	ITSN2	0.53	6.97	0.39	2.47e-11	Asthma;
CESC	cis	rs7216064	0.734	rs12942774	chr17:65967562	A/G	cg12091567	chr17:66097778	LOC651250	0.57	7.22	0.41	5.57e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs116095464	0.558	rs6866776	chr5:264495	C/T	cg10591111	chr5:226296	SDHA	-0.52	-6.35	-0.36	9.51e-10	Breast cancer;
CESC	cis	rs11764590	0.694	rs6977161	chr7:2099361	T/C	cg21782813	chr7:2030301	MAD1L1	-0.43	-5.44	-0.32	1.24e-7	Neuroticism;
CESC	cis	rs10504229	0.683	rs1495866	chr8:58141128	T/C	cg22535103	chr8:58192502	C8orf71	-0.8	-9.09	-0.49	2.46e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs7937682	0.602	rs503905	chr11:111390762	G/C	cg09085632	chr11:111637200	PPP2R1B	-0.67	-8.92	-0.48	7.59e-17	Primary sclerosing cholangitis;
CESC	cis	rs752010	0.715	rs11807117	chr1:42101206	C/T	cg06885757	chr1:42089581	HIVEP3	0.7	10.89	0.56	4.45e-23	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs597539	0.652	rs627731	chr11:68698663	A/C	cg21963583	chr11:68658836	MRPL21	0.4	5.5	0.32	8.98e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs116095464	0.558	rs7710005	chr5:233572	A/G	cg10591111	chr5:226296	SDHA	-0.52	-6.35	-0.36	9.15e-10	Breast cancer;
CESC	cis	rs1799949	0.965	rs8176322	chr17:41195773	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.41	5.61	0.33	5.17e-8	Menopause (age at onset);
CESC	cis	rs826838	1.000	rs10880785	chr12:38655405	T/G	cg26384229	chr12:38710491	ALG10B	0.82	14.26	0.66	1.22e-34	Heart rate;
CESC	trans	rs561341	1.000	rs527256	chr17:30321293	C/G	cg27661571	chr11:113659931	NA	-0.82	-7.63	-0.42	4.18e-13	Hip circumference adjusted for BMI;
CESC	cis	rs7937682	0.575	rs34558891	chr11:111737912	C/T	cg09085632	chr11:111637200	PPP2R1B	0.91	11.76	0.59	5.82e-26	Primary sclerosing cholangitis;
CESC	trans	rs2018683	0.600	rs717891	chr7:29000374	C/T	cg19402173	chr7:128379420	CALU	-0.58	-7.23	-0.41	5.21e-12	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CESC	cis	rs9486719	0.749	rs1009596	chr6:96843688	A/G	cg18709589	chr6:96969512	KIAA0776	0.55	5.64	0.33	4.26e-8	Migraine;Coronary artery disease;
CESC	cis	rs9811920	0.809	rs766778	chr3:99751480	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.46	-7.54	-0.42	7.73e-13	Axial length;
CESC	cis	rs7264396	0.563	rs7264869	chr20:34346502	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.87	-10.3	-0.53	3.83e-21	Total cholesterol levels;
CESC	cis	rs9487051	0.676	rs1608041	chr6:109595903	G/A	cg12927641	chr6:109611667	NA	-0.37	-5.5	-0.32	8.91e-8	Reticulocyte fraction of red cells;
CESC	cis	rs7399018	0.643	rs6580810	chr12:51610478	C/T	cg20712883	chr12:51590929	POU6F1	0.44	5.28	0.31	2.72e-7	Cisplatin-induced ototoxicity;
CESC	cis	rs921968	0.565	rs7599568	chr2:219607819	A/G	cg02176678	chr2:219576539	TTLL4	-0.46	-8.25	-0.45	7.26e-15	Mean corpuscular hemoglobin concentration;
CESC	cis	rs2777491	0.915	rs28578057	chr15:41621921	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.6	-8.84	-0.48	1.39e-16	Ulcerative colitis;
CESC	cis	rs6500602	0.727	rs1477123	chr16:4560627	T/A	cg08645402	chr16:4508243	NA	0.43	6.43	0.37	5.93e-10	Schizophrenia;
CESC	trans	rs11098499	0.743	rs11098501	chr4:120252017	T/G	cg25214090	chr10:38739885	LOC399744	0.62	8.7	0.47	3.58e-16	Corneal astigmatism;
CESC	cis	rs5753618	0.555	rs5749286	chr22:31900359	G/T	cg13145458	chr22:31556086	RNF185	-0.48	-5.66	-0.33	3.93e-8	Colorectal cancer;
CESC	cis	rs35110281	0.693	rs11089093	chr21:45121161	C/T	cg21573476	chr21:45109991	RRP1B	-0.58	-8.38	-0.46	3.04e-15	Mean corpuscular volume;
CESC	cis	rs362272	0.524	rs881816	chr4:3365366	A/G	cg14583973	chr4:3374767	RGS12	0.31	5.49	0.32	9.61e-8	Serum sulfate level;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05731991	chr2:60983297	PAPOLG	0.57	6.24	0.36	1.77e-9	Gut microbiome composition (summer);
CESC	cis	rs854765	0.583	rs4341796	chr17:17839024	C/A	cg16928487	chr17:17741425	SREBF1	-0.6	-10.42	-0.54	1.58e-21	Total body bone mineral density;
CESC	cis	rs992157	0.710	rs6719789	chr2:219057810	G/T	cg00012203	chr2:219082015	ARPC2	-0.83	-11.93	-0.59	1.49e-26	Colorectal cancer;
CESC	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.6	-7.84	-0.43	1.11e-13	Prudent dietary pattern;
CESC	cis	rs13343954	0.518	rs8106293	chr19:33536376	C/T	cg03563238	chr19:33554763	RHPN2	-0.3	-5.32	-0.31	2.18e-7	Colorectal cancer;
CESC	cis	rs7772486	0.790	rs9497424	chr6:146225271	C/A	cg23711669	chr6:146136114	FBXO30	-0.83	-11.88	-0.59	2.31e-26	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs11098499	0.913	rs10006304	chr4:120124305	A/G	cg09307838	chr4:120376055	NA	0.79	9.94	0.52	5.23e-20	Corneal astigmatism;
CESC	cis	rs959260	0.588	rs2385263	chr17:73321117	T/C	cg12999837	chr17:73267436	MIF4GD	-0.43	-5.19	-0.3	4.2e-7	Systemic lupus erythematosus;
CESC	trans	rs1116547	0.602	rs112360538	chr5:112913288	A/C	cg10115368	chr14:100435663	NA	0.51	6.01	0.35	6.17e-9	Cerebral amyloid angiopathy;
CESC	cis	rs1144713	0.686	rs1144715	chr12:32261435	A/G	cg01321189	chr12:32259338	BICD1	0.34	5.15	0.3	4.98e-7	Obesity-related traits;
CESC	cis	rs72781680	0.898	rs72796158	chr2:23935727	T/C	cg20701182	chr2:24300061	SF3B14	0.78	6.91	0.39	3.5e-11	Lymphocyte counts;
CESC	cis	rs2950393	0.929	rs10747769	chr12:57070840	G/A	cg05584118	chr12:57595605	LRP1	-0.38	-5.47	-0.32	1.06e-7	Platelet distribution width;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg06872588	chr7:6692873	NA	0.52	6.89	0.39	4.07e-11	Fibrinogen levels;
CESC	cis	rs514406	0.893	rs476108	chr1:53317351	C/T	cg01802117	chr1:53393560	SCP2	-0.4	-5.12	-0.3	5.9e-7	Monocyte count;
CESC	cis	rs34172651	0.917	rs200538	chr16:24735736	C/T	cg06028605	chr16:24865363	SLC5A11	-0.37	-5.67	-0.33	3.75e-8	Intelligence (multi-trait analysis);
CESC	cis	rs6860806	0.507	rs635620	chr5:131720263	A/G	cg07395648	chr5:131743802	NA	0.42	5.52	0.32	7.92e-8	Breast cancer;
CESC	cis	rs73058052	0.597	rs56873913	chr19:50091199	T/G	cg09250473	chr19:50168907	IRF3;BCL2L12	0.47	5.07	0.3	7.65e-7	Fibrinogen levels;
CESC	cis	rs734999	0.545	rs4474198	chr1:2553758	C/T	cg18854424	chr1:2615690	NA	0.3	6.11	0.35	3.52e-9	Ulcerative colitis;
CESC	cis	rs798554	0.634	rs6970963	chr7:2821271	C/T	cg13628971	chr7:2884303	GNA12	0.42	5.64	0.33	4.45e-8	Height;
CESC	cis	rs793571	0.774	rs10851640	chr15:59137870	T/C	cg05156742	chr15:59063176	FAM63B	-0.53	-6.54	-0.37	3.16e-10	Schizophrenia;
CESC	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.48	-5.08	-0.3	7.1e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs7307889	0.793	rs12301255	chr12:6008816	C/G	cg18407955	chr7:158110685	PTPRN2	-0.72	-6.68	-0.38	1.41e-10	Obesity-related traits;
CESC	cis	rs4555082	0.874	rs2015978	chr14:105720134	G/C	cg13114125	chr14:105738426	BRF1	-0.84	-10.37	-0.54	2.25e-21	Mean platelet volume;Platelet distribution width;
CESC	cis	rs9487051	0.872	rs9372211	chr6:109609648	C/T	cg21918786	chr6:109611834	NA	-0.4	-6.01	-0.35	6.17e-9	Reticulocyte fraction of red cells;
CESC	cis	rs1559088	0.947	rs7259879	chr19:33549462	T/C	cg27124370	chr19:33622961	WDR88	0.43	5.49	0.32	9.52e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	cis	rs2506889	0.553	rs11580264	chr1:10605796	C/A	cg07384165	chr1:10488281	NA	-0.6	-8.61	-0.47	6.59e-16	Breast cancer;
CESC	cis	rs7666738	0.830	rs6819177	chr4:99040907	T/C	cg18180107	chr4:99064573	C4orf37	0.41	5.29	0.31	2.51e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9811920	0.609	rs13317017	chr3:99665521	A/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.64	-10.16	-0.53	1.11e-20	Axial length;
CESC	cis	rs3806843	1.000	rs3756340	chr5:140180451	T/G	cg26395211	chr5:140044315	WDR55	-0.42	-5.35	-0.31	1.94e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs1018836	0.923	rs4735268	chr8:91629715	C/T	cg16814680	chr8:91681699	NA	-0.73	-10.54	-0.54	6.47e-22	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs9811920	0.609	rs7636447	chr3:99612677	G/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.59	7.22	0.41	5.61e-12	Axial length;
CESC	cis	rs11098499	0.874	rs9995277	chr4:120108603	G/A	cg09307838	chr4:120376055	NA	0.67	8.27	0.45	6.71e-15	Corneal astigmatism;
CESC	cis	rs2439831	0.618	rs8023508	chr15:44176103	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.61	-7.58	-0.42	5.81e-13	Lung cancer in ever smokers;
CESC	trans	rs2900976	0.773	rs13033431	chr2:71993723	C/T	cg01646268	chr11:14367071	RRAS2	0.51	6.48	0.37	4.54e-10	Protein quantitative trait loci;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05062674	chr16:89882627	FANCA	0.51	6.2	0.36	2.1e-9	Gut microbiome composition (summer);
CESC	cis	rs7044106	0.762	rs7024046	chr9:123419178	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.33	5.1	0.3	6.43e-7	Hip circumference adjusted for BMI;
CESC	cis	rs2235642	0.821	rs2281236	chr16:1603576	G/A	cg03715980	chr16:1756201	MAPK8IP3	0.38	5.04	0.3	8.44e-7	Coronary artery disease;
CESC	cis	rs2637266	0.935	rs2583058	chr10:78396018	T/A	cg18941641	chr10:78392320	NA	0.45	8.5	0.46	1.43e-15	Pulmonary function;
CESC	cis	rs854765	0.964	rs854813	chr17:18003845	C/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.47	-5.98	-0.34	7.09e-9	Total body bone mineral density;
CESC	cis	rs2637266	0.902	rs2583056	chr10:78399498	A/G	cg18941641	chr10:78392320	NA	0.44	8.56	0.47	9.37e-16	Pulmonary function;
CESC	cis	rs7605827	0.930	rs6704723	chr2:15599895	A/G	cg19274914	chr2:15703543	NA	0.34	6.09	0.35	4.01e-9	Educational attainment (years of education);
CESC	cis	rs9768139	0.935	rs7782393	chr7:158120486	G/A	cg06219351	chr7:158114137	PTPRN2	0.48	7.48	0.42	1.12e-12	Calcium levels;
CESC	cis	rs4268898	0.662	rs72795824	chr2:24435837	T/C	cg06627628	chr2:24431161	ITSN2	-1.02	-11.2	-0.57	4.2e-24	Asthma;
CESC	cis	rs9768139	0.733	rs34173461	chr7:158122175	C/G	cg25566285	chr7:158114605	PTPRN2	0.47	7.67	0.43	3.24e-13	Calcium levels;
CESC	cis	rs1707322	0.717	rs3014237	chr1:46090252	A/G	cg06784218	chr1:46089804	CCDC17	-0.41	-7.08	-0.4	1.26e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs1044826	0.518	rs295488	chr3:139239323	C/T	cg15131784	chr3:139108705	COPB2	0.41	5.25	0.31	3.19e-7	Obesity-related traits;
CESC	cis	rs2797160	0.904	rs1777198	chr6:126007416	C/T	cg05901451	chr6:126070800	HEY2	0.46	6.5	0.37	4.07e-10	Endometrial cancer;
CESC	cis	rs763512	0.504	rs853216	chr17:35863008	G/A	cg16670864	chr17:35848621	DUSP14	0.44	5.58	0.32	5.93e-8	3-hydroxypropylmercapturic acid levels in smokers;
CESC	cis	rs6088580	0.601	rs6059827	chr20:33016358	C/T	cg08999081	chr20:33150536	PIGU	0.64	11.3	0.57	1.92e-24	Glomerular filtration rate (creatinine);
CESC	cis	rs7618915	0.547	rs8906	chr3:52739520	T/C	cg07507251	chr3:52567010	NT5DC2	0.42	7.21	0.4	5.85e-12	Bipolar disorder;
CESC	cis	rs7246657	0.943	rs3745765	chr19:37854235	G/T	cg23950597	chr19:37808831	NA	-0.55	-6.04	-0.35	5.1e-9	Coronary artery calcification;
CESC	cis	rs2742417	0.603	rs2742456	chr3:45767176	C/T	cg04837898	chr3:45731254	SACM1L	-0.47	-6.16	-0.35	2.75e-9	Response to anti-depressant treatment in major depressive disorder;
CESC	cis	rs763014	0.833	rs3743903	chr16:632736	T/C	cg07256732	chr16:621771	PIGQ	-0.3	-5.14	-0.3	5.22e-7	Height;
CESC	cis	rs2204008	0.775	rs12369238	chr12:38176051	A/G	cg13010199	chr12:38710504	ALG10B	0.48	5.91	0.34	1.02e-8	Bladder cancer;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg08276543	chr12:124856791	NCOR2	0.46	6.29	0.36	1.29e-9	Fibrinogen levels;
CESC	cis	rs9894429	1.000	rs35435780	chr17:79579602	G/T	cg18240062	chr17:79603768	NPLOC4	0.72	10.27	0.53	4.71e-21	Eye color traits;
CESC	cis	rs7917772	0.503	rs746552	chr10:104342501	A/G	cg22532475	chr10:104410764	TRIM8	-0.36	-6.33	-0.36	1.07e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs3617	0.573	rs9810807	chr3:52924227	C/T	cg07507251	chr3:52567010	NT5DC2	-0.32	-5.39	-0.31	1.54e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
CESC	cis	rs9815354	0.812	rs73069213	chr3:41940590	G/A	cg03022575	chr3:42003672	ULK4	0.71	6.44	0.37	5.46e-10	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs1799949	1.000	rs34534709	chr17:41302940	C/G	cg05368731	chr17:41323189	NBR1	0.78	10.79	0.55	9.37e-23	Menopause (age at onset);
CESC	cis	rs963731	0.737	rs10194374	chr2:39244914	G/A	cg04010122	chr2:39346883	SOS1	-0.69	-5.21	-0.3	3.87e-7	Corticobasal degeneration;
CESC	cis	rs2933343	0.729	rs1680780	chr3:128612659	G/C	cg24203234	chr3:128598194	ACAD9	0.4	5.19	0.3	4.13e-7	IgG glycosylation;
CESC	cis	rs8070624	0.543	rs57728924	chr17:17875342	A/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.6	7.71	0.43	2.59e-13	Total body bone mineral density;
CESC	cis	rs7520050	0.966	rs785495	chr1:46587887	A/G	cg03146154	chr1:46216737	IPP	-0.45	-5.8	-0.34	1.93e-8	Red blood cell count;Reticulocyte count;
CESC	cis	rs2479106	0.963	rs4838074	chr9:126467202	C/T	cg16191174	chr9:126692580	DENND1A	0.47	6.47	0.37	4.59e-10	Polycystic ovary syndrome;
CESC	cis	rs60871478	0.579	rs56109762	chr7:925967	G/A	cg15782153	chr7:917662	C7orf20	0.56	5.36	0.31	1.85e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs2011503	1.000	rs8111093	chr19:19505548	C/T	cg11584989	chr19:19387371	SF4	0.63	7.42	0.41	1.63e-12	Bipolar disorder;
CESC	cis	rs10504229	1.000	rs66731170	chr8:58187895	C/G	cg22535103	chr8:58192502	C8orf71	-1.05	-13.08	-0.63	1.71e-30	Developmental language disorder (linguistic errors);
CESC	cis	rs6502050	0.835	rs12945993	chr17:80129485	T/C	cg23985595	chr17:80112537	CCDC57	-0.41	-6.42	-0.37	6.37e-10	Life satisfaction;
CESC	cis	rs17376456	0.825	rs72786702	chr5:93254656	A/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.65	5.32	0.31	2.22e-7	Diabetic retinopathy;
CESC	cis	rs7539624	0.588	rs1419305	chr1:223912748	C/T	cg10100437	chr1:223903862	CAPN2	0.43	5.57	0.32	6.23e-8	Schizophrenia;
CESC	cis	rs6674176	0.932	rs4660761	chr1:44440146	G/A	cg13606994	chr1:44402422	ARTN	-0.4	-5.73	-0.33	2.75e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs959260	0.925	rs7207506	chr17:73409410	T/C	cg20590849	chr17:73267439	MIF4GD	-0.55	-6.38	-0.37	7.73e-10	Systemic lupus erythematosus;
CESC	cis	rs17431357	1.000	rs73225218	chr12:120952310	T/C	cg25045489	chr12:120971538	RNF10	-0.93	-5.46	-0.32	1.1e-7	Insulin resistance/response;
CESC	cis	rs425277	0.628	rs3107145	chr1:2047547	G/A	cg13918804	chr1:2043761	PRKCZ	0.27	5.04	0.3	8.46e-7	Height;
CESC	cis	rs4665809	0.590	rs66477033	chr2:26472497	T/C	cg27170947	chr2:26402098	FAM59B	0.87	9.85	0.52	1.01e-19	Gut microbiome composition (summer);
CESC	cis	rs2859741	0.967	rs822854	chr1:37485788	A/G	cg09363841	chr1:37513479	NA	-0.55	-8.55	-0.46	1.01e-15	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
CESC	cis	rs4975616	0.869	rs465498	chr5:1325803	A/G	cg07493874	chr5:1342172	CLPTM1L	-0.41	-7.87	-0.44	8.84e-14	Lung cancer;
CESC	cis	rs6500395	0.926	rs11076571	chr16:48598064	A/G	cg04672837	chr16:48644449	N4BP1	0.46	5.54	0.32	7.22e-8	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs4654899	1.000	rs61117207	chr1:21394374	A/C	cg05370193	chr1:21551575	ECE1	0.39	5.84	0.34	1.55e-8	Superior frontal gyrus grey matter volume;
CESC	cis	rs10493773	0.609	rs11161660	chr1:86184066	C/T	cg17807903	chr1:86174739	ZNHIT6	-0.44	-6.59	-0.38	2.4e-10	Urate levels in overweight individuals;
CESC	cis	rs561341	1.000	rs501312	chr17:30329066	A/G	cg23018236	chr17:30244563	NA	-0.53	-5.14	-0.3	5.32e-7	Hip circumference adjusted for BMI;
CESC	cis	rs10256972	0.900	rs7812072	chr7:1053862	A/G	cg07308232	chr7:1071921	C7orf50	-0.46	-6.32	-0.36	1.08e-9	Longevity;Endometriosis;
CESC	cis	rs2882667	0.858	rs6596460	chr5:138414180	G/A	cg04439458	chr5:138467593	SIL1	-0.33	-5.27	-0.31	2.81e-7	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs977987	0.806	rs11149832	chr16:75462713	C/T	cg03315344	chr16:75512273	CHST6	0.41	5.91	0.34	1.07e-8	Dupuytren's disease;
CESC	cis	rs72781680	1.000	rs72781671	chr2:24231123	A/G	cg20701182	chr2:24300061	SF3B14	0.82	7.03	0.4	1.77e-11	Lymphocyte counts;
CESC	cis	rs4803468	1.000	rs2304242	chr19:41944616	G/T	cg14132834	chr19:41945861	ATP5SL	0.69	8.61	0.47	6.75e-16	Height;
CESC	cis	rs965469	0.779	rs2236115	chr20:3296279	G/A	cg25506879	chr20:3388711	C20orf194	-0.48	-5.35	-0.31	1.92e-7	IFN-related cytopenia;
CESC	cis	rs7772486	0.754	rs4566902	chr6:146244128	A/G	cg05347473	chr6:146136440	FBXO30	-0.55	-7.05	-0.4	1.57e-11	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05491930	chr6:99872786	SFRS18	0.53	6.24	0.36	1.75e-9	Gut microbiome composition (summer);
CESC	cis	rs6460942	1.000	rs2053382	chr7:12400587	A/G	cg17427002	chr7:12443146	VWDE	-0.51	-5.08	-0.3	7.26e-7	Coronary artery disease;
CESC	cis	rs1218582	0.772	rs6669791	chr1:154845484	G/T	cg16680214	chr1:154839983	KCNN3	-0.47	-7.26	-0.41	4.36e-12	Prostate cancer;
CESC	cis	rs1008375	0.932	rs10029173	chr4:17659598	C/T	cg16339924	chr4:17578868	LAP3	-0.62	-7.88	-0.44	8.76e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs9911578	1.000	rs4793952	chr17:56608465	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.39	-5.05	-0.3	8.08e-7	Intelligence (multi-trait analysis);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg18022570	chr8:27950479	ELP3	-0.48	-6.19	-0.36	2.24e-9	Fibrinogen levels;
CESC	cis	rs9910055	0.571	rs10208	chr17:42300278	C/T	cg19774624	chr17:42201019	HDAC5	-0.54	-7.62	-0.42	4.47e-13	Total body bone mineral density;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg07590406	chr3:58292066	RPP14	0.48	6.18	0.35	2.41e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs9359856	0.517	rs72919948	chr6:90509389	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.64	-6.11	-0.35	3.61e-9	Bipolar disorder;
CESC	cis	rs17376456	0.877	rs17083462	chr5:93462401	T/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.62	5.43	0.32	1.3e-7	Diabetic retinopathy;
CESC	cis	rs9814567	0.896	rs13089566	chr3:134349710	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.42	5.67	0.33	3.77e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs7714584	0.826	rs34005003	chr5:150225199	C/T	cg22134413	chr5:150180641	NA	0.52	5.64	0.33	4.31e-8	Crohn's disease;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg21863207	chr12:104234989	NT5DC3	-0.45	-6.34	-0.36	9.98e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs10242455	0.867	rs2687075	chr7:99314986	A/G	cg07715041	chr7:99302981	CYP3A7	-0.43	-5.42	-0.32	1.36e-7	Blood metabolite levels;
CESC	cis	rs17407555	1.000	rs17407555	chr4:10274994	A/G	cg00071950	chr4:10020882	SLC2A9	-0.5	-5.26	-0.31	2.96e-7	Schizophrenia (age at onset);
CESC	cis	rs873946	0.586	rs12774727	chr10:134569910	T/C	cg18305652	chr10:134549665	INPP5A	0.45	6.26	0.36	1.53e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs919433	0.783	rs788007	chr2:198233676	T/G	cg10820045	chr2:198174542	NA	0.41	5.93	0.34	9.6e-9	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
CESC	cis	rs6598955	0.543	rs61608823	chr1:26555090	G/A	cg04990556	chr1:26633338	UBXN11	0.83	9.29	0.5	5.95e-18	Obesity-related traits;
CESC	cis	rs5769707	0.642	rs135880	chr22:50018654	T/A	cg20744362	chr22:50050164	C22orf34	0.39	6.07	0.35	4.52e-9	Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs6456156	0.586	rs7762156	chr6:167485831	A/T	cg23791538	chr6:167370224	RNASET2	-0.5	-6.37	-0.36	8.51e-10	Primary biliary cholangitis;
CESC	cis	rs7592578	0.771	rs4439990	chr2:191398353	A/C	cg27211696	chr2:191398769	TMEM194B	-0.59	-5.3	-0.31	2.39e-7	Diastolic blood pressure;
CESC	trans	rs801193	0.844	rs2244022	chr7:66202430	A/G	cg26939375	chr7:64535504	NA	0.54	7.53	0.42	8.04e-13	Aortic root size;
CESC	cis	rs9311474	0.508	rs11718420	chr3:52611413	T/C	cg18337363	chr3:52569053	NT5DC2	0.29	5.29	0.31	2.51e-7	Electroencephalogram traits;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07589201	chr19:9546257	ZNF266	0.63	7.77	0.43	1.77e-13	Gut microbiome composition (summer);
CESC	cis	rs6546550	0.935	rs2872075	chr2:70068635	G/T	cg02498382	chr2:70120550	SNRNP27	-0.37	-6.39	-0.37	7.3e-10	Prevalent atrial fibrillation;
CESC	trans	rs4332037	0.624	rs11764124	chr7:1891723	C/G	cg11693508	chr17:37793320	STARD3	0.6	6.12	0.35	3.27e-9	Bipolar disorder;
CESC	cis	rs941408	0.515	rs7253128	chr19:2776982	C/T	cg00079169	chr19:2811669	THOP1	0.38	5.21	0.3	3.88e-7	Total cholesterol levels;
CESC	cis	rs9399135	0.967	rs17638970	chr6:135320063	A/G	cg22676075	chr6:135203613	NA	0.51	7.23	0.41	5.22e-12	Red blood cell count;
CESC	cis	rs79057730	0.599	rs112891948	chr7:816059	C/T	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.93	7.96	0.44	5.2e-14	Initial pursuit acceleration;
CESC	cis	rs13242816	1.000	rs1018859	chr7:116067347	C/T	cg04696780	chr7:116139425	CAV2	-0.62	-5.58	-0.32	6.03e-8	P wave duration;
CESC	trans	rs7615952	0.546	rs2976733	chr3:125414138	T/C	cg21747405	chr11:67723411	NA	-0.42	-6.62	-0.38	2.03e-10	Blood pressure (smoking interaction);
CESC	trans	rs11674184	0.714	rs9789525	chr2:11724580	G/T	cg14768519	chr17:79870056	SIRT7;PCYT2	-0.41	-6.03	-0.35	5.42e-9	Endometriosis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26926904	chr4:186317539	ANKRD37	0.52	6.15	0.35	2.83e-9	Gut microbiome composition (summer);
CESC	cis	rs9733	0.818	rs4970924	chr1:150633079	A/G	cg13175981	chr1:150552382	MCL1	0.62	9.23	0.49	9.06e-18	Tonsillectomy;
CESC	trans	rs3942852	0.806	rs10769316	chr11:48119745	C/G	cg03929089	chr4:120376271	NA	-0.56	-6.38	-0.36	7.84e-10	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs7267979	0.933	rs2261109	chr20:25259200	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	18.61	0.75	5.21e-50	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7100689	0.577	rs2342813	chr10:82046302	T/G	cg09936400	chr10:82049201	MAT1A	0.38	5.9	0.34	1.12e-8	Post bronchodilator FEV1;
CESC	cis	rs2820292	0.741	rs12086240	chr1:201885791	G/A	cg11586189	chr1:201857591	SHISA4	-0.36	-6.12	-0.35	3.43e-9	Waist circumference;Body mass index (joint analysis main effects and smoking interaction);Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);
CESC	cis	rs9596863	1.000	rs9596855	chr13:54407032	G/A	ch.13.53330881F	chr13:54432880	NA	0.66	5.25	0.31	3.08e-7	Epilepsy and lamotrigine-induced maculopapular eruptions;
CESC	cis	rs6429082	0.660	rs10737818	chr1:235542023	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.54	-6.78	-0.38	7.8e-11	Adiposity;
CESC	cis	rs9527	0.590	rs10883820	chr10:104764661	A/C	cg04362960	chr10:104952993	NT5C2	-0.41	-5.18	-0.3	4.35e-7	Arsenic metabolism;
CESC	cis	rs1862618	0.713	rs832550	chr5:56182589	C/T	cg18230493	chr5:56204884	C5orf35	-0.73	-8.57	-0.47	8.93e-16	Initial pursuit acceleration;
CESC	cis	rs6460942	0.915	rs62447641	chr7:12488764	G/A	cg06484146	chr7:12443880	VWDE	-0.76	-8.53	-0.46	1.11e-15	Coronary artery disease;
CESC	cis	rs13108904	0.650	rs3796618	chr4:1349602	T/A	cg05025164	chr4:1340916	KIAA1530	0.54	7.06	0.4	1.46e-11	Obesity-related traits;
CESC	cis	rs6952808	1.000	rs12540579	chr7:1882227	C/A	cg21782813	chr7:2030301	MAD1L1	0.39	5.51	0.32	8.6e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs6540556	0.769	rs2272867	chr1:209929579	C/A	cg05527609	chr1:210001259	C1orf107	-0.66	-7.57	-0.42	6.37e-13	Red blood cell count;
CESC	cis	rs6951245	0.507	rs10227709	chr7:1180515	T/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.39	-5.29	-0.31	2.61e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs6499255	0.904	rs7194753	chr16:69564364	A/G	cg15192750	chr16:69999425	NA	-0.53	-6.19	-0.36	2.22e-9	IgE levels;
CESC	cis	rs11166629	1.000	rs7818331	chr8:135639653	C/T	cg27224718	chr8:135614730	ZFAT	0.5	6.26	0.36	1.52e-9	Smoking quantity;
CESC	cis	rs17253792	0.822	rs10148983	chr14:56051879	A/G	cg01858014	chr14:56050164	KTN1	-0.87	-6.77	-0.38	8.19e-11	Putamen volume;
CESC	cis	rs8009147	1	rs8009147	chr14:104264662	A/G	cg08213375	chr14:104286397	PPP1R13B	0.54	10.8	0.55	8.68e-23	Autism spectrum disorder or schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02346006	chr17:78897477	RPTOR	-0.55	-6.13	-0.35	3.21e-9	Gut microbiome composition (summer);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg15684116	chr1:153700070	INTS3	0.46	6.02	0.35	5.89e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs7208859	0.623	rs170051	chr17:28914153	G/A	cg19761014	chr17:28927070	LRRC37B2	0.87	6.7	0.38	1.21e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs11690935	0.959	rs10167419	chr2:172649826	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.96	-14.76	-0.67	2.12e-36	Schizophrenia;
CESC	cis	rs1799949	1.000	rs8176083	chr17:41275151	G/C	cg23758822	chr17:41437982	NA	1.03	15.39	0.69	1.24e-38	Menopause (age at onset);
CESC	cis	rs9435341	0.965	rs1730859	chr1:107617707	A/G	cg09367891	chr1:107599246	PRMT6	0.68	8.21	0.45	1e-14	Facial morphology (factor 21, depth of nasal alae);
CESC	cis	rs11650494	0.831	rs7216993	chr17:47454263	A/G	cg08112188	chr17:47440006	ZNF652	0.85	6.9	0.39	3.93e-11	Prostate cancer;
CESC	cis	rs362272	0.524	rs6819202	chr4:3368264	G/A	cg08886695	chr4:3369023	RGS12	-0.42	-5.82	-0.34	1.72e-8	Serum sulfate level;
CESC	cis	rs6582630	0.537	rs11611326	chr12:38547958	C/A	cg13010199	chr12:38710504	ALG10B	0.51	6.56	0.37	2.88e-10	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs17253792	0.822	rs10135426	chr14:56054644	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.82	5.99	0.35	6.73e-9	Putamen volume;
CESC	trans	rs853679	0.546	rs200952	chr6:27836976	C/T	cg06606381	chr12:133084897	FBRSL1	-0.83	-7.8	-0.43	1.44e-13	Depression;
CESC	cis	rs6500395	1.000	rs9925406	chr16:48671436	C/A	cg04672837	chr16:48644449	N4BP1	0.51	6.31	0.36	1.14e-9	Response to tocilizumab in rheumatoid arthritis;
CESC	trans	rs17685	0.725	rs4476928	chr7:75642107	C/A	cg19862616	chr7:65841803	NCRNA00174	-0.86	-12.76	-0.62	2.16e-29	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs372883	0.648	rs2832296	chr21:30741454	C/T	cg24692254	chr21:30365293	RNF160	-0.51	-6.45	-0.37	5.29e-10	Pancreatic cancer;
CESC	cis	rs870825	0.616	rs28490461	chr4:185651638	C/T	cg04058563	chr4:185651563	MLF1IP	0.63	6.96	0.39	2.74e-11	Blood protein levels;
CESC	cis	rs7927771	0.524	rs7932703	chr11:47769936	A/C	cg20307385	chr11:47447363	PSMC3	0.61	8.59	0.47	7.41e-16	Subjective well-being;
CESC	cis	rs748404	0.690	rs2467737	chr15:43737188	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	8.3	0.45	5.23e-15	Lung cancer;
CESC	cis	rs7586879	0.593	rs10198356	chr2:25130592	A/G	cg01884057	chr2:25150051	NA	0.36	7.01	0.4	2.02e-11	Body mass index;
CESC	cis	rs7666738	0.830	rs34916200	chr4:98851593	C/T	cg05340658	chr4:99064831	C4orf37	0.75	11.16	0.57	5.89e-24	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2011503	0.941	rs55822665	chr19:19383298	C/T	cg11584989	chr19:19387371	SF4	0.6	7.19	0.4	6.59e-12	Bipolar disorder;
CESC	cis	rs7527798	0.592	rs11118345	chr1:207854827	A/T	cg21110645	chr1:207815933	NA	-0.33	-5.76	-0.33	2.33e-8	Erythrocyte sedimentation rate;
CESC	cis	rs4862307	0.836	rs6829678	chr4:185001631	C/T	cg06737308	chr4:185021514	ENPP6	-0.43	-5.8	-0.34	1.92e-8	Serum dimethylarginine levels (asymmetric/symetric ratio);
CESC	cis	rs2050392	0.624	rs303450	chr10:30725337	C/A	cg18806716	chr10:30721971	MAP3K8	-0.63	-9.55	-0.51	9.17e-19	Inflammatory bowel disease;
CESC	cis	rs7808935	0.628	rs72598552	chr7:27939961	G/A	cg05786569	chr7:27702416	HIBADH	0.52	5.79	0.34	1.97e-8	Prostate cancer;
CESC	cis	rs597539	0.690	rs608810	chr11:68624118	G/C	cg21963583	chr11:68658836	MRPL21	0.41	5.56	0.32	6.63e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs73058052	0.597	rs7249925	chr19:50093572	A/G	cg09250473	chr19:50168907	IRF3;BCL2L12	0.5	5.62	0.33	4.75e-8	Fibrinogen levels;
CESC	cis	rs12824058	0.549	rs4759453	chr12:130824565	C/G	cg23887609	chr12:130822674	PIWIL1	0.5	6.01	0.35	6.03e-9	Menopause (age at onset);
CESC	cis	rs6088580	0.634	rs6579165	chr20:32994715	A/G	cg24642439	chr20:33292090	TP53INP2	-0.53	-6.99	-0.39	2.17e-11	Glomerular filtration rate (creatinine);
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg18767321	chr22:39096505	JOSD1	0.45	6.13	0.35	3.19e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs2243480	1.000	rs3885839	chr7:65290403	G/T	cg13147721	chr7:65941812	NA	-0.9	-8.67	-0.47	4.31e-16	Diabetic kidney disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19281871	chr6:88411031	NCRNA00120;AKIRIN2	-0.56	-6.01	-0.35	6.18e-9	Gut microbiome composition (summer);
CESC	cis	rs7481584	0.962	rs2001006	chr11:2974912	A/G	cg25174290	chr11:3078921	CARS	-0.46	-5.5	-0.32	8.72e-8	Calcium levels;
CESC	cis	rs780096	0.526	rs11126999	chr2:27670307	G/A	cg24768116	chr2:27665128	KRTCAP3	-0.28	-5.07	-0.3	7.42e-7	Total body bone mineral density;
CESC	cis	rs3820928	1.000	rs10193404	chr2:227777757	A/G	cg05526886	chr2:227700861	RHBDD1	-0.45	-5.9	-0.34	1.13e-8	Pulmonary function;
CESC	cis	rs17826219	0.500	rs61685770	chr17:29085713	G/A	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.17e-10	Body mass index;
CESC	cis	rs9311474	0.508	rs1570	chr3:52586682	T/A	cg05564831	chr3:52568323	NT5DC2	0.47	7.34	0.41	2.57e-12	Electroencephalogram traits;
CESC	cis	rs72945132	0.882	rs59681006	chr11:70179401	T/C	cg00319359	chr11:70116639	PPFIA1	0.75	7.17	0.4	7.52e-12	Coronary artery disease;
CESC	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg15112475	chr7:1198522	ZFAND2A	-0.41	-6.42	-0.37	6.14e-10	Longevity;Endometriosis;
CESC	cis	rs2637266	0.846	rs752006	chr10:78393136	G/T	cg18941641	chr10:78392320	NA	0.41	7.59	0.42	5.56e-13	Pulmonary function;
CESC	cis	rs938554	0.779	rs6449173	chr4:9966105	A/C	cg00071950	chr4:10020882	SLC2A9	-0.52	-6.13	-0.35	3.2e-9	Blood metabolite levels;
CESC	cis	rs1538970	0.739	rs4660863	chr1:45955868	T/C	cg05343316	chr1:45956843	TESK2	0.93	12.78	0.62	1.91e-29	Platelet count;
CESC	cis	rs801193	0.660	rs1016265	chr7:66214567	C/T	cg11764359	chr7:65958608	NA	0.87	13.29	0.63	3.14e-31	Aortic root size;
CESC	cis	rs561341	1.000	rs527256	chr17:30321293	C/G	cg19193384	chr17:30244184	NA	-0.7	-6.58	-0.37	2.49e-10	Hip circumference adjusted for BMI;
CESC	cis	rs4319547	1.000	rs10998	chr12:122989412	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.66	-7.62	-0.42	4.42e-13	Body mass index;
CESC	cis	rs7107174	1.000	rs2511182	chr11:77982130	G/C	cg02023728	chr11:77925099	USP35	0.47	6.49	0.37	4.19e-10	Testicular germ cell tumor;
CESC	cis	rs67311347	1.000	rs12492035	chr3:40467110	G/A	cg24209194	chr3:40518798	ZNF619	0.49	6.14	0.35	3.03e-9	Renal cell carcinoma;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg25750404	chr12:6579648	VAMP1	0.47	6.24	0.36	1.68e-9	Systemic lupus erythematosus;
CESC	cis	rs853679	0.517	rs4713143	chr6:28106759	A/C	cg08968635	chr6:28129556	ZNF389	0.42	5.72	0.33	2.82e-8	Depression;
CESC	cis	rs7243790	0.774	rs7240534	chr18:51885897	C/T	cg04730925	chr18:51795821	POLI	-0.42	-5.57	-0.32	6.24e-8	Diastolic blood pressure;
CESC	cis	rs3091242	0.933	rs9438905	chr1:25764177	A/G	cg02931644	chr1:25747376	RHCE	0.4	6.65	0.38	1.64e-10	Erythrocyte sedimentation rate;
CESC	cis	rs875971	0.965	rs6971509	chr7:65714970	G/T	cg10691866	chr7:65817282	TPST1	0.33	5.69	0.33	3.43e-8	Aortic root size;
CESC	cis	rs113835537	0.597	rs2075792	chr11:66334556	G/A	cg22134325	chr11:66188745	NPAS4	0.37	5.53	0.32	7.86e-8	Airway imaging phenotypes;
CESC	cis	rs6502050	0.835	rs7221451	chr17:80089785	A/G	cg23985595	chr17:80112537	CCDC57	-0.41	-6.4	-0.37	7.06e-10	Life satisfaction;
CESC	cis	rs9929218	0.861	rs8056206	chr16:68802072	G/C	cg02972257	chr16:68554789	NA	0.44	5.33	0.31	2.11e-7	Colorectal cancer;
CESC	cis	rs9287719	0.649	rs12473957	chr2:10717714	C/G	cg00105475	chr2:10696890	NA	-0.37	-5.2	-0.3	3.99e-7	Prostate cancer;
CESC	cis	rs2070997	0.607	rs2772028	chr9:133707940	C/T	cg11464064	chr9:133710261	ABL1	0.68	7.64	0.42	4.03e-13	Response to amphetamines;
CESC	cis	rs854765	0.654	rs9911281	chr17:17762457	G/C	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.43	-5.68	-0.33	3.55e-8	Total body bone mineral density;
CESC	cis	rs17376456	0.778	rs72786662	chr5:93137630	C/T	cg25358565	chr5:93447407	FAM172A	1.15	10.72	0.55	1.63e-22	Diabetic retinopathy;
CESC	cis	rs922182	0.692	rs7162147	chr15:64291500	G/A	cg24729988	chr15:64271149	DAPK2	0.39	5.5	0.32	9.06e-8	Blood protein levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06346138	chr1:17086071	MST1P9	-0.53	-6.23	-0.36	1.79e-9	Gut microbiome composition (summer);
CESC	cis	rs2204008	0.777	rs114096617	chr12:38342557	A/C	cg13010199	chr12:38710504	ALG10B	0.48	6.05	0.35	4.92e-9	Bladder cancer;
CESC	cis	rs2070488	0.775	rs2051214	chr3:38560303	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.76	-11.47	-0.58	5.3e-25	Electrocardiographic conduction measures;
CESC	cis	rs1348850	0.632	rs1405718	chr2:178499809	C/T	cg22681709	chr2:178499509	PDE11A	-0.57	-9.17	-0.49	1.4e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs7824557	0.736	rs10107010	chr8:11132712	C/A	cg21775007	chr8:11205619	TDH	-0.47	-7.04	-0.4	1.65e-11	Retinal vascular caliber;
CESC	cis	rs6665290	0.901	rs11580229	chr1:227210820	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.14	-23.42	-0.82	1.69e-66	Myeloid white cell count;
CESC	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg02725872	chr8:58115012	NA	-0.42	-5.72	-0.33	2.88e-8	Developmental language disorder (linguistic errors);
CESC	trans	rs61931739	0.817	rs10743841	chr12:34252870	T/C	cg26384229	chr12:38710491	ALG10B	0.48	6.63	0.38	1.84e-10	Morning vs. evening chronotype;
CESC	cis	rs8180040	0.629	rs7426969	chr3:47091355	T/C	cg27129171	chr3:47204927	SETD2	0.67	9.83	0.52	1.18e-19	Colorectal cancer;
CESC	cis	rs787274	0.850	rs4979176	chr9:115641181	A/G	cg13803584	chr9:115635662	SNX30	0.64	5.36	0.31	1.79e-7	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs2735413	0.918	rs4887932	chr16:78078350	C/A	cg04733911	chr16:78082701	NA	-0.53	-8.92	-0.48	7.6e-17	Systolic blood pressure (alcohol consumption interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12012699	chr18:46986876	DYM	-0.58	-6.72	-0.38	1.13e-10	Gut microbiome composition (summer);
CESC	cis	rs9322193	0.923	rs1572229	chr6:150064977	T/A	cg07701084	chr6:150067640	NUP43	0.47	6.58	0.37	2.51e-10	Lung cancer;
CESC	cis	rs59918340	0.692	rs6983780	chr8:142231944	G/A	cg16341495	chr8:142228727	SLC45A4	-0.44	-5.29	-0.31	2.54e-7	Immature fraction of reticulocytes;
CESC	cis	rs9768139	0.708	rs921615	chr7:158117935	A/G	cg06219351	chr7:158114137	PTPRN2	-0.5	-7.7	-0.43	2.69e-13	Calcium levels;
CESC	trans	rs9388451	0.626	rs2875881	chr6:126072853	C/G	cg05039488	chr6:79577232	IRAK1BP1	-0.66	-9.27	-0.49	6.69e-18	Brugada syndrome;
CESC	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg03188948	chr7:1209495	NA	0.61	6.91	0.39	3.61e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs7666738	0.830	rs7678911	chr4:99057430	C/T	cg05340658	chr4:99064831	C4orf37	0.83	12.92	0.62	6.2e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7647973	1.000	rs7644148	chr3:49545241	G/A	cg02487422	chr3:49467188	NICN1	-0.41	-5.36	-0.31	1.81e-7	Menarche (age at onset);
CESC	cis	rs752010	0.619	rs6703992	chr1:42115888	G/A	cg06885757	chr1:42089581	HIVEP3	0.62	9.63	0.51	5.16e-19	Lupus nephritis in systemic lupus erythematosus;
CESC	trans	rs916888	0.773	rs199439	chr17:44793503	A/G	cg10053473	chr17:62856997	LRRC37A3	-0.7	-7.58	-0.42	5.96e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs6968419	0.788	rs1317791	chr7:115839721	C/G	cg02561103	chr7:115862891	TES	-0.39	-5.22	-0.31	3.62e-7	Intraocular pressure;
CESC	cis	rs3741151	1.000	rs74776668	chr11:73065909	G/A	cg17517138	chr11:73019481	ARHGEF17	1.05	7.11	0.4	1.09e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
CESC	cis	rs10256972	0.758	rs4723649	chr7:1071905	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.46	-6.41	-0.37	6.59e-10	Longevity;Endometriosis;
CESC	cis	rs1707322	0.721	rs6429574	chr1:46134054	A/G	cg03146154	chr1:46216737	IPP	0.76	10.71	0.55	1.81e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs60154123	0.505	rs115881613	chr1:210040369	C/T	cg21951975	chr1:209979733	IRF6	0.58	6.23	0.36	1.85e-9	Coronary artery disease;
CESC	cis	rs3892630	0.588	rs7245709	chr19:33242755	C/T	cg22980127	chr19:33182716	NUDT19	1.13	14.4	0.66	4.03e-35	Red blood cell traits;
CESC	cis	rs9322193	0.923	rs7740278	chr6:149961252	C/T	cg04369109	chr6:150039330	LATS1	-0.36	-5.03	-0.3	9.18e-7	Lung cancer;
CESC	cis	rs916888	0.773	rs199445	chr17:44817408	C/T	cg15921436	chr17:44337874	NA	0.75	8.25	0.45	7.37e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs12824058	0.831	rs11060825	chr12:130807905	A/G	cg26677194	chr12:130822605	PIWIL1	0.5	6.55	0.37	2.96e-10	Menopause (age at onset);
CESC	cis	rs7224314	1.000	rs62085810	chr17:65372855	G/A	cg01507342	chr17:65387096	PITPNC1	-0.46	-5.27	-0.31	2.86e-7	Diisocyanate-induced asthma;
CESC	cis	rs593982	1.000	rs74638829	chr11:65495571	C/T	cg08755490	chr11:65554678	OVOL1	-1.26	-10.56	-0.54	5.65e-22	Atopic dermatitis;
CESC	cis	rs34658409	1	rs34658409	chr8:42433985	TC/T	cg09913449	chr8:42400586	C8orf40	0.43	7.15	0.4	8.32e-12	Mean corpuscular hemoglobin concentration;
CESC	cis	rs801193	1.000	rs62466793	chr7:66191517	G/A	cg14393609	chr7:65229607	NA	0.47	6.31	0.36	1.17e-9	Aortic root size;
CESC	cis	rs950027	0.620	rs1153860	chr15:45636584	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.65	-8.27	-0.45	6.68e-15	Response to fenofibrate (adiponectin levels);
CESC	cis	rs4909189	1.000	rs62493651	chr7:158135592	T/C	cg06219351	chr7:158114137	PTPRN2	-0.6	-8.1	-0.45	2e-14	Response to amphetamines;
CESC	cis	rs6867032	1.000	rs16902321	chr5:2015148	A/G	cg26168224	chr5:2018326	NA	0.96	20.64	0.79	4.27e-57	Gut microbiome composition (winter);
CESC	cis	rs1862618	0.756	rs13356762	chr5:56110992	G/T	cg22800045	chr5:56110881	MAP3K1	0.82	10.29	0.53	4.07e-21	Initial pursuit acceleration;
CESC	cis	rs344364	0.511	rs62040571	chr16:1948514	C/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.55	-6.2	-0.36	2.15e-9	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs911555	0.755	rs11627446	chr14:103946450	G/C	cg12935359	chr14:103987150	CKB	-0.59	-8.46	-0.46	1.8e-15	Intelligence (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23429981	chr6:97345948	NDUFAF4	0.54	6.09	0.35	3.89e-9	Gut microbiome composition (summer);
CESC	cis	rs6598955	0.670	rs10902734	chr1:26617923	G/T	cg00852783	chr1:26633632	UBXN11	-0.42	-6.03	-0.35	5.35e-9	Obesity-related traits;
CESC	cis	rs6964587	0.839	rs6950538	chr7:91417816	T/C	cg17063962	chr7:91808500	NA	0.48	6.21	0.36	2.03e-9	Breast cancer;
CESC	cis	rs62103177	0.608	rs8088089	chr18:77832154	A/G	cg12964065	chr18:77638022	KCNG2	-0.45	-5.14	-0.3	5.26e-7	Opioid sensitivity;
CESC	cis	rs4835473	0.900	rs13119630	chr4:144695054	T/G	cg25736465	chr4:144833511	NA	-0.33	-5.18	-0.3	4.39e-7	Immature fraction of reticulocytes;
CESC	cis	rs1707322	1.000	rs10789486	chr1:46408667	A/G	cg06784218	chr1:46089804	CCDC17	0.32	5.49	0.32	9.37e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs4665809	1.000	rs7573118	chr2:26308086	A/G	cg08470875	chr2:26401718	FAM59B	-0.48	-5.27	-0.31	2.79e-7	Gut microbiome composition (summer);
CESC	cis	rs6460942	0.915	rs75158182	chr7:12456059	C/T	cg10578991	chr7:12443926	VWDE	-0.5	-5.52	-0.32	7.93e-8	Coronary artery disease;
CESC	cis	rs7605827	0.930	rs2058869	chr2:15679700	T/C	cg19274914	chr2:15703543	NA	0.37	6.7	0.38	1.22e-10	Educational attainment (years of education);
CESC	cis	rs11997175	0.572	rs7836230	chr8:33623250	T/C	ch.8.33884649F	chr8:33765107	NA	0.57	7.35	0.41	2.5e-12	Body mass index;
CESC	cis	rs6952808	0.575	rs6950330	chr7:1953606	T/C	cg03354898	chr7:1950403	MAD1L1	-0.31	-5.18	-0.3	4.49e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs2963155	0.518	rs6196	chr5:142661490	A/G	cg17617527	chr5:142782415	NR3C1	0.76	7.08	0.4	1.28e-11	Breast cancer;
CESC	cis	rs875971	1.000	rs6460292	chr7:65810075	G/A	cg18876405	chr7:65276391	NA	-0.53	-7.19	-0.4	6.46e-12	Aortic root size;
CESC	cis	rs763121	0.853	rs6001191	chr22:39074452	T/C	cg06544989	chr22:39130855	UNC84B	0.5	8.88	0.48	1.05e-16	Menopause (age at onset);
CESC	cis	rs2985684	0.894	rs6572586	chr14:50021941	A/C	cg04989706	chr14:50066350	PPIL5	-0.45	-5.21	-0.3	3.81e-7	Carotid intima media thickness;
CESC	cis	rs72945132	0.882	rs7123602	chr11:70181489	C/T	cg00319359	chr11:70116639	PPFIA1	0.74	7.17	0.4	7.55e-12	Coronary artery disease;
CESC	trans	rs921968	0.541	rs523305	chr2:219402691	T/C	cg15547669	chr20:2781122	CPXM1	0.35	6.0	0.35	6.31e-9	Mean corpuscular hemoglobin concentration;
CESC	cis	rs10504073	0.647	rs62507245	chr8:50006939	A/T	cg00325661	chr8:49890786	NA	0.57	8.45	0.46	1.97e-15	Blood metabolite ratios;
CESC	cis	rs933688	1.000	rs6452951	chr5:90653868	T/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.13	14.96	0.68	4.21e-37	Smoking behavior;
CESC	cis	rs7131987	0.834	rs7139273	chr12:29434650	T/C	cg09582351	chr12:29534625	ERGIC2	-0.31	-5.1	-0.3	6.42e-7	QT interval;
CESC	cis	rs2963155	0.518	rs258748	chr5:142656454	C/G	cg17617527	chr5:142782415	NR3C1	0.83	7.48	0.42	1.1e-12	Breast cancer;
CESC	trans	rs7618501	0.602	rs2245365	chr3:50097319	C/A	cg21659725	chr3:3221576	CRBN	-0.53	-7.42	-0.41	1.59e-12	Intelligence (multi-trait analysis);
CESC	cis	rs2439831	0.867	rs12323999	chr15:43683115	T/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.91	11.03	0.56	1.59e-23	Lung cancer in ever smokers;
CESC	cis	rs7772486	0.875	rs1929523	chr6:146339989	T/A	cg23711669	chr6:146136114	FBXO30	0.86	12.53	0.61	1.39e-28	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2439831	0.867	rs11856184	chr15:43919162	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.81	8.35	0.46	3.84e-15	Lung cancer in ever smokers;
CESC	cis	rs10851478	0.872	rs12901680	chr15:49880905	T/C	cg08060515	chr15:49448048	GALK2;COPS2	0.43	5.24	0.31	3.24e-7	Oral cavity cancer;
CESC	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg26354017	chr1:205819088	PM20D1	0.93	16.28	0.71	8.56e-42	Menarche (age at onset);
CESC	cis	rs2073300	0.609	rs6132615	chr20:23413200	T/C	cg12062639	chr20:23401060	NAPB	1.06	8.19	0.45	1.14e-14	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs35110281	0.641	rs4818861	chr21:45123807	A/G	cg01579765	chr21:45077557	HSF2BP	-0.53	-8.3	-0.45	5.49e-15	Mean corpuscular volume;
CESC	cis	rs2832077	0.527	rs2705690	chr21:30239245	T/A	cg08807101	chr21:30365312	RNF160	0.53	6.45	0.37	5.32e-10	Cognitive test performance;
CESC	cis	rs1448094	0.512	rs60986162	chr12:86247054	T/G	cg19622623	chr12:86230825	RASSF9	-0.46	-5.89	-0.34	1.14e-8	Major depressive disorder;
CESC	cis	rs2180341	1.000	rs7453272	chr6:127633959	C/T	cg27446573	chr6:127587934	RNF146	-0.97	-12.78	-0.62	1.79e-29	Breast cancer;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg04319218	chr19:11307663	KANK2	-0.43	-6.17	-0.35	2.52e-9	Fibrinogen levels;
CESC	cis	rs10504229	0.610	rs6999661	chr8:58127391	C/G	cg21724239	chr8:58056113	NA	0.57	5.76	0.33	2.29e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs9611565	0.659	rs12484694	chr22:41919330	A/G	cg06481639	chr22:41940642	POLR3H	-0.64	-6.64	-0.38	1.78e-10	Vitiligo;
CESC	cis	rs7772486	0.875	rs6930975	chr6:146387111	C/T	cg23711669	chr6:146136114	FBXO30	0.79	11.75	0.59	6.03e-26	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs73001065	0.818	rs58847337	chr19:19726022	G/A	cg03709012	chr19:19516395	GATAD2A	0.95	6.37	0.36	8.22e-10	LDL cholesterol;
CESC	cis	rs4665809	0.590	rs10495756	chr2:26485586	A/G	cg22920501	chr2:26401640	FAM59B	0.91	10.34	0.54	2.94e-21	Gut microbiome composition (summer);
CESC	cis	rs798554	0.796	rs2158694	chr7:2863443	T/G	cg04166393	chr7:2884313	GNA12	0.63	8.13	0.45	1.71e-14	Height;
CESC	cis	rs9303280	0.806	rs8069176	chr17:38057197	G/A	cg20243544	chr17:37824526	PNMT	0.49	6.28	0.36	1.37e-9	Self-reported allergy;
CESC	cis	rs2072732	0.768	rs57893585	chr1:2944671	T/A	cg03976712	chr1:2946727	NA	0.34	5.35	0.31	1.9e-7	Plateletcrit;
CESC	cis	rs7666738	0.753	rs2865957	chr4:99040725	G/A	cg03467027	chr4:99064603	C4orf37	0.47	5.96	0.34	8.08e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9815354	1.000	rs1716987	chr3:41970516	A/G	cg03022575	chr3:42003672	ULK4	-0.46	-5.37	-0.31	1.74e-7	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs1538970	0.816	rs11211123	chr1:45957609	G/A	cg05343316	chr1:45956843	TESK2	0.93	12.78	0.62	1.91e-29	Platelet count;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg21063480	chr14:78082891	SPTLC2	0.47	6.0	0.35	6.41e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs6752107	1.000	rs3792112	chr2:234176609	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.49	6.76	0.38	8.81e-11	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs7089973	0.872	rs7094072	chr10:116627160	T/G	cg23260525	chr10:116636907	FAM160B1	0.38	6.42	0.37	6.35e-10	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs875971	0.520	rs160645	chr7:65556307	A/G	cg19163074	chr7:65112434	INTS4L2	0.52	5.35	0.31	1.87e-7	Aortic root size;
CESC	cis	rs2637266	1.000	rs7475686	chr10:78358761	T/C	cg18941641	chr10:78392320	NA	0.42	7.91	0.44	7.15e-14	Pulmonary function;
CESC	cis	rs4713118	0.629	rs203889	chr6:28021775	T/G	cg26335602	chr6:28129616	ZNF389	0.44	5.7	0.33	3.25e-8	Parkinson's disease;
CESC	cis	rs642803	1.000	rs557675	chr11:65566719	G/T	cg02870584	chr11:65547924	DKFZp761E198	-0.41	-5.14	-0.3	5.26e-7	Urate levels;
CESC	cis	rs4665809	1.000	rs4665817	chr2:26305167	G/A	cg22920501	chr2:26401640	FAM59B	-0.79	-9.3	-0.5	5.61e-18	Gut microbiome composition (summer);
CESC	cis	rs67311347	0.955	rs2085114	chr3:40497437	T/A	cg09455208	chr3:40491958	NA	0.5	7.92	0.44	6.41e-14	Renal cell carcinoma;
CESC	cis	rs12618769	0.601	rs56118505	chr2:99139832	T/G	cg10123293	chr2:99228465	UNC50	0.38	5.04	0.3	8.64e-7	Bipolar disorder;
CESC	cis	rs4808199	0.895	rs10421505	chr19:19459554	C/T	cg03709012	chr19:19516395	GATAD2A	1.07	12.42	0.61	3.25e-28	Nonalcoholic fatty liver disease;
CESC	cis	rs873946	0.586	rs12767391	chr10:134573844	A/G	cg27286337	chr10:134555280	INPP5A	-0.67	-7.9	-0.44	7.49e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs6831352	0.918	rs2851253	chr4:100043505	G/T	cg13256891	chr4:100009986	ADH5	-0.74	-8.47	-0.46	1.71e-15	Alcohol dependence;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg05992875	chr8:144621330	ZC3H3	0.49	6.4	0.37	6.89e-10	Fibrinogen levels;
CESC	cis	rs4665809	0.590	rs7604564	chr2:26501953	C/A	cg26314531	chr2:26401878	FAM59B	0.81	8.44	0.46	2.06e-15	Gut microbiome composition (summer);
CESC	cis	rs9911578	1.000	rs11870671	chr17:56605360	A/G	cg12560992	chr17:57184187	TRIM37	-0.93	-15.59	-0.69	2.43e-39	Intelligence (multi-trait analysis);
CESC	cis	rs651907	0.535	rs11717638	chr3:101505468	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.46	6.1	0.35	3.71e-9	Colorectal cancer;
CESC	cis	rs62103177	0.733	rs62096747	chr18:77619568	A/G	cg12964065	chr18:77638022	KCNG2	0.58	5.68	0.33	3.5e-8	Opioid sensitivity;
CESC	cis	rs977987	0.806	rs8050059	chr16:75388731	C/T	cg03315344	chr16:75512273	CHST6	0.4	5.78	0.33	2.05e-8	Dupuytren's disease;
CESC	cis	rs10751667	0.961	rs7943115	chr11:973885	T/C	cg20946044	chr11:1010712	AP2A2	-0.42	-5.63	-0.33	4.63e-8	Alzheimer's disease (late onset);
CESC	cis	rs9796	0.870	rs2925346	chr15:41315695	G/A	cg18705301	chr15:41695430	NDUFAF1	0.42	6.32	0.36	1.13e-9	Menopause (age at onset);
CESC	cis	rs3096299	0.967	rs2911257	chr16:89484134	C/G	cg08392591	chr16:89556376	ANKRD11	0.41	5.32	0.31	2.26e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs853679	0.517	rs4713145	chr6:28106827	T/C	cg23161317	chr6:28129485	ZNF389	0.52	6.66	0.38	1.59e-10	Depression;
CESC	cis	rs7666738	0.830	rs7686456	chr4:99019695	T/C	cg17366294	chr4:99064904	C4orf37	0.61	8.76	0.47	2.35e-16	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10540	0.908	rs71487293	chr11:486414	G/A	cg21784768	chr11:537496	LRRC56	-0.57	-5.36	-0.31	1.85e-7	Body mass index;
CESC	cis	rs7188697	0.922	rs37061	chr16:58566671	A/G	cg02549819	chr16:58548995	SETD6	-0.42	-5.25	-0.31	3.1e-7	QT interval;
CESC	cis	rs780096	0.546	rs6547626	chr2:27646770	C/T	cg02592271	chr2:27665507	KRTCAP3	-0.28	-5.7	-0.33	3.25e-8	Total body bone mineral density;
CESC	cis	rs4604732	0.631	rs12031694	chr1:247623653	C/T	cg12754571	chr1:247694271	LOC148824;OR2C3	0.41	5.39	0.31	1.53e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs7692995	0.920	rs16896155	chr4:17962935	A/T	cg08925142	chr4:18023851	LCORL	-0.45	-5.13	-0.3	5.66e-7	Height;
CESC	cis	rs34779708	0.931	rs12268745	chr10:35305989	C/G	cg03585969	chr10:35415529	CREM	0.75	10.02	0.52	2.93e-20	Inflammatory bowel disease;Crohn's disease;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg05221349	chr4:100870488	LOC256880;H2AFZ	0.43	6.48	0.37	4.37e-10	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs2842992	0.872	rs2758330	chr6:160104844	G/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.64	8.09	0.44	2.22e-14	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs853679	0.517	rs4711165	chr6:28115184	T/G	cg17949981	chr6:28129498	ZNF389	0.45	5.49	0.32	9.35e-8	Depression;
CESC	cis	rs7267979	1.000	rs4813562	chr20:25352588	G/A	cg08601574	chr20:25228251	PYGB	-0.38	-5.55	-0.32	6.88e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs2658782	0.526	rs3020062	chr11:93061159	T/C	cg15737290	chr11:93063684	CCDC67	0.55	7.61	0.42	4.71e-13	Pulmonary function decline;
CESC	cis	rs3806843	0.676	rs2245643	chr5:140029780	C/T	cg16179182	chr5:140090404	VTRNA1-1	0.43	5.68	0.33	3.48e-8	Depressive symptoms (multi-trait analysis);
CESC	cis	rs9354308	0.901	rs55832318	chr6:66560086	A/G	cg07460842	chr6:66804631	NA	0.67	7.56	0.42	6.51e-13	Metabolite levels;
CESC	cis	rs6688613	0.685	rs4657613	chr1:166870878	A/G	cg07049167	chr1:166818506	POGK	0.45	5.38	0.31	1.61e-7	Refractive astigmatism;
CESC	cis	rs7089973	0.872	rs41284358	chr10:116622339	A/G	cg23260525	chr10:116636907	FAM160B1	0.38	6.42	0.37	6.35e-10	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	trans	rs10074525	0.885	rs34381536	chr5:90257392	A/G	cg22855255	chr17:50237267	CA10	-0.37	-6.38	-0.36	7.97e-10	Obesity-related traits;
CESC	cis	rs4237845	0.586	rs4760174	chr12:58320436	G/A	cg00677455	chr12:58241039	CTDSP2	0.43	5.4	0.31	1.47e-7	Intelligence (multi-trait analysis);
CESC	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.52	7.13	0.4	9.29e-12	Lymphocyte counts;
CESC	cis	rs2296225	0.722	rs12403580	chr1:21049518	C/T	cg24673385	chr1:21051448	SH2D5	0.33	5.28	0.31	2.72e-7	Eosinophilic esophagitis;
CESC	cis	rs6502050	0.835	rs8070014	chr17:80115247	T/G	cg11859384	chr17:80120422	CCDC57	-0.38	-5.18	-0.3	4.47e-7	Life satisfaction;
CESC	cis	rs7666738	0.830	rs4699594	chr4:98980775	T/C	cg18180107	chr4:99064573	C4orf37	0.39	5.07	0.3	7.39e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7847628	0.587	rs1060817	chr9:123583192	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.94	17.46	0.73	5.92e-46	Birth weight;
CESC	cis	rs3096299	0.606	rs2965946	chr16:89516612	T/C	cg08392591	chr16:89556376	ANKRD11	0.44	5.22	0.31	3.64e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs898097	0.805	rs60233158	chr17:80896612	A/G	cg19046167	chr17:80928561	B3GNTL1	0.4	5.03	0.3	9.23e-7	Breast cancer;
CESC	cis	rs4332037	0.664	rs73046334	chr7:1887037	T/C	cg13880726	chr7:1868755	MAD1L1	-0.49	-5.16	-0.3	4.83e-7	Bipolar disorder;
CESC	cis	rs9399137	0.507	rs7748708	chr6:135275142	G/A	cg24558204	chr6:135376177	HBS1L	0.72	9.68	0.51	3.5e-19	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
CESC	cis	rs7811142	0.830	rs6975660	chr7:99975266	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.83	8.82	0.48	1.58e-16	Platelet count;
CESC	cis	rs9399135	0.967	rs6923765	chr6:135335176	C/G	cg22676075	chr6:135203613	NA	-0.5	-7.06	-0.4	1.44e-11	Red blood cell count;
CESC	cis	rs4664293	1.000	rs13014418	chr2:160483685	T/G	cg08347373	chr2:160653686	CD302	-0.32	-5.08	-0.3	7.08e-7	Monocyte percentage of white cells;
CESC	cis	rs9612	1.000	rs2074634	chr19:44238347	C/T	cg08581076	chr19:44259116	C19orf61	-0.53	-6.12	-0.35	3.3e-9	Exhaled nitric oxide output;
CESC	cis	rs9488822	0.676	rs12154016	chr6:116355188	C/T	cg18764771	chr6:116381957	FRK	0.22	5.59	0.32	5.54e-8	Cholesterol, total;LDL cholesterol;
CESC	cis	rs11190604	1.000	rs1417823	chr10:102227886	C/T	cg07080220	chr10:102295463	HIF1AN	-0.5	-5.16	-0.3	4.94e-7	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs2204008	0.749	rs10880692	chr12:38592918	C/G	cg13010199	chr12:38710504	ALG10B	-0.54	-6.96	-0.39	2.66e-11	Bladder cancer;
CESC	cis	rs1707322	1.000	rs7547284	chr1:46319565	C/G	cg06784218	chr1:46089804	CCDC17	0.32	5.57	0.32	6.35e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7833790	0.676	rs7834555	chr8:82697625	A/G	cg07697082	chr8:82753677	SNX16	0.36	5.54	0.32	7.16e-8	Diastolic blood pressure;
CESC	trans	rs13360092	0.881	rs9291724	chr5:50561870	A/G	cg03200537	chr16:87022121	NA	0.69	6.01	0.35	6.15e-9	Verbal declarative memory;
CESC	cis	rs801193	1.000	rs4717310	chr7:66161007	C/T	cg11764359	chr7:65958608	NA	0.71	9.39	0.5	2.85e-18	Aortic root size;
CESC	cis	rs4835473	0.932	rs4092718	chr4:144720790	A/G	cg25736465	chr4:144833511	NA	-0.42	-6.36	-0.36	9.01e-10	Immature fraction of reticulocytes;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg21012729	chr14:51297401	NIN	-0.4	-6.08	-0.35	4.09e-9	Gambling;
CESC	cis	rs13108904	0.870	rs11727987	chr4:1261435	A/G	cg00684032	chr4:1343700	KIAA1530	0.42	5.93	0.34	9.41e-9	Obesity-related traits;
CESC	cis	rs79349575	0.783	rs12602933	chr17:47029280	G/C	cg26022315	chr17:47021804	SNF8	0.39	5.16	0.3	4.94e-7	Type 2 diabetes;
CESC	cis	rs35306767	0.903	rs12260800	chr10:927933	T/C	cg20503657	chr10:835505	NA	0.74	7.57	0.42	6.23e-13	Eosinophil percentage of granulocytes;
CESC	cis	rs2486288	0.656	rs6493144	chr15:45573489	C/G	cg21132104	chr15:45694354	SPATA5L1	0.59	7.19	0.4	6.61e-12	Glomerular filtration rate;
CESC	cis	rs709400	0.832	rs55864158	chr14:104068579	G/A	cg12935359	chr14:103987150	CKB	-0.47	-5.98	-0.34	7.27e-9	Body mass index;
CESC	cis	rs5769765	0.955	rs9616366	chr22:50301178	C/T	cg26441486	chr22:50317300	CRELD2	0.4	5.38	0.31	1.6e-7	Schizophrenia;
CESC	cis	rs9815354	0.767	rs60943892	chr3:41852307	T/C	cg03022575	chr3:42003672	ULK4	0.71	6.36	0.36	8.91e-10	Pulse pressure;Diastolic blood pressure;
CESC	trans	rs7839040	0.698	rs13262552	chr8:82932653	T/C	cg14472086	chr9:107730925	NA	-0.48	-6.45	-0.37	5.4e-10	Response to methotrexate in juvenile idiopathic arthritis;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg09410845	chr2:203241870	BMPR2	0.52	6.85	0.39	5.04e-11	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs2033711	0.870	rs1051500	chr19:58944402	A/G	cg11952622	chr19:58962976	ZNF324B	0.46	6.14	0.35	3.06e-9	Uric acid clearance;
CESC	cis	rs4132509	1.000	rs12049228	chr1:243995271	C/A	cg21452805	chr1:244014465	NA	0.5	6.17	0.35	2.52e-9	RR interval (heart rate);
CESC	cis	rs10924970	0.625	rs3806394	chr1:235489850	C/T	cg26050004	chr1:235667680	B3GALNT2	0.44	5.09	0.3	6.77e-7	Asthma;
CESC	cis	rs1552244	1.000	rs6791810	chr3:10124444	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.9	-13.26	-0.63	4.07e-31	Alzheimer's disease;
CESC	cis	rs2011503	0.941	rs56278919	chr19:19367190	A/G	cg11584989	chr19:19387371	SF4	0.63	7.52	0.42	8.34e-13	Bipolar disorder;
CESC	cis	rs9649213	0.593	rs7778015	chr7:97920270	T/C	cg00277769	chr7:97922759	BAIAP2L1	-0.34	-5.57	-0.32	6.1e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs2404602	0.692	rs4886829	chr15:77091182	G/T	cg26408565	chr15:76604113	ETFA	-0.38	-5.54	-0.32	7.27e-8	Blood metabolite levels;
CESC	cis	rs3857536	0.740	rs7751095	chr6:66891318	A/G	cg07460842	chr6:66804631	NA	-0.4	-5.23	-0.31	3.47e-7	Blood trace element (Cu levels);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03195600	chr16:11350371	SOCS1	0.55	6.41	0.37	6.7e-10	Gut microbiome composition (summer);
CESC	cis	rs36051895	0.589	rs7038763	chr9:5076399	T/C	cg02405213	chr9:5042618	JAK2	-0.49	-6.07	-0.35	4.35e-9	Pediatric autoimmune diseases;
CESC	cis	rs763121	0.889	rs1043402	chr22:38879688	G/A	cg06022373	chr22:39101656	GTPBP1	0.8	11.31	0.57	1.87e-24	Menopause (age at onset);
CESC	cis	rs4595586	0.545	rs3858554	chr12:39381460	C/T	cg26384229	chr12:38710491	ALG10B	0.54	7.53	0.42	7.85e-13	Morning vs. evening chronotype;
CESC	cis	rs2243480	0.803	rs35268390	chr7:65416536	C/G	cg13147721	chr7:65941812	NA	-0.86	-8.49	-0.46	1.47e-15	Diabetic kidney disease;
CESC	cis	rs7395581	0.959	rs7129661	chr11:47268550	T/G	cg25783544	chr11:47291846	MADD	0.59	7.73	0.43	2.22e-13	HDL cholesterol;
CESC	cis	rs6060717	0.536	rs6058364	chr20:34507890	G/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.65	5.61	0.33	4.97e-8	Hip circumference adjusted for BMI;
CESC	cis	rs7100689	0.784	rs3802638	chr10:82179689	T/C	cg00277334	chr10:82204260	NA	-0.61	-7.42	-0.41	1.57e-12	Post bronchodilator FEV1;
CESC	trans	rs1814175	0.645	rs28634872	chr11:50042175	T/A	cg03929089	chr4:120376271	NA	-0.91	-14.82	-0.67	1.29e-36	Height;
CESC	cis	rs4713118	0.662	rs149961	chr6:28015569	A/C	cg18032046	chr6:28092343	ZSCAN16	-0.52	-5.84	-0.34	1.49e-8	Parkinson's disease;
CESC	cis	rs763014	0.865	rs710924	chr16:633353	T/C	cg09263875	chr16:632152	PIGQ	0.67	11.24	0.57	3.15e-24	Height;
CESC	cis	rs244293	0.730	rs12165058	chr17:53022049	T/C	cg19360675	chr17:53046073	COX11;STXBP4	-0.44	-5.85	-0.34	1.48e-8	Menarche (age at onset);
CESC	cis	rs3857536	0.813	rs7757118	chr6:66946661	T/C	cg07460842	chr6:66804631	NA	-0.42	-5.29	-0.31	2.55e-7	Blood trace element (Cu levels);
CESC	cis	rs9457247	1.000	rs2769347	chr6:167371737	T/A	cg23791538	chr6:167370224	RNASET2	0.59	8.47	0.46	1.75e-15	Crohn's disease;
CESC	cis	rs959260	1.000	rs7226070	chr17:73372811	T/C	cg12999837	chr17:73267436	MIF4GD	-0.47	-5.5	-0.32	8.8e-8	Systemic lupus erythematosus;
CESC	cis	rs9926296	0.744	rs164746	chr16:89709019	C/T	cg03605463	chr16:89740564	NA	0.57	6.51	0.37	3.67e-10	Vitiligo;
CESC	cis	rs2273669	0.667	rs12205053	chr6:109338110	T/C	cg05315195	chr6:109294784	ARMC2	-0.67	-6.32	-0.36	1.13e-9	Prostate cancer;
CESC	cis	rs67311347	1.000	rs11714912	chr3:40494065	A/G	cg24209194	chr3:40518798	ZNF619	-0.47	-6.28	-0.36	1.4e-9	Renal cell carcinoma;
CESC	trans	rs3780486	0.505	rs959749	chr9:33147858	T/C	cg04842962	chr6:43655489	MRPS18A	0.68	10.27	0.53	4.66e-21	IgG glycosylation;
CESC	cis	rs9322193	0.810	rs62439811	chr6:149961552	C/T	cg13206674	chr6:150067644	NUP43	0.39	5.55	0.32	7.04e-8	Lung cancer;
CESC	cis	rs798554	0.679	rs2533870	chr7:2885274	C/G	cg18446336	chr7:2847575	GNA12	0.33	5.32	0.31	2.24e-7	Height;
CESC	cis	rs7216064	0.773	rs74541577	chr17:65853651	C/T	cg12091567	chr17:66097778	LOC651250	-0.85	-8.71	-0.47	3.45e-16	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs12681366	0.537	rs9297939	chr8:95480189	A/C	cg13257157	chr8:95487014	RAD54B	0.45	5.47	0.32	1.05e-7	Nonsyndromic cleft lip with cleft palate;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12759597	chr1:155181615	MTX1	-0.61	-7.22	-0.41	5.56e-12	Gut microbiome composition (summer);
CESC	cis	rs7617773	0.539	rs17593974	chr3:48387334	G/T	cg11946769	chr3:48343235	NME6	0.65	8.35	0.46	3.86e-15	Coronary artery disease;
CESC	cis	rs2294693	0.945	rs11756893	chr6:41010058	A/C	cg14769373	chr6:40998127	UNC5CL	-0.45	-5.78	-0.33	2.09e-8	Gastric cancer;Non-cardia gastric cancer;
CESC	cis	rs1580019	0.922	rs1466147	chr7:32486262	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.88	12.35	0.6	5.7e-28	Cognitive ability;
CESC	cis	rs17376456	0.569	rs10050364	chr5:93064127	T/C	cg25358565	chr5:93447407	FAM172A	0.67	7.24	0.41	4.81e-12	Diabetic retinopathy;
CESC	cis	rs8180040	0.620	rs11707736	chr3:47069504	G/T	cg27129171	chr3:47204927	SETD2	-0.67	-9.93	-0.52	5.93e-20	Colorectal cancer;
CESC	cis	rs4718428	0.705	rs12536410	chr7:66254290	G/A	cg18252515	chr7:66147081	NA	-0.46	-5.1	-0.3	6.63e-7	Corneal structure;
CESC	cis	rs10979	0.965	rs9403508	chr6:143887857	G/A	cg25407410	chr6:143891975	LOC285740	-0.61	-9.14	-0.49	1.72e-17	Hypospadias;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06955158	chr5:10249878	FAM173B;CCT5	0.69	8.3	0.45	5.4e-15	Gut microbiome composition (summer);
CESC	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg22535103	chr8:58192502	C8orf71	-0.93	-10.31	-0.53	3.63e-21	Developmental language disorder (linguistic errors);
CESC	cis	rs8067545	0.604	rs55705283	chr17:20027138	G/A	cg13482628	chr17:19912719	NA	0.39	5.23	0.31	3.45e-7	Schizophrenia;
CESC	cis	rs2243480	1.000	rs6964530	chr7:65718851	G/C	cg18252515	chr7:66147081	NA	1.39	14.1	0.65	4.44e-34	Diabetic kidney disease;
CESC	cis	rs8072100	0.840	rs1912482	chr17:45454883	G/A	cg08085267	chr17:45401833	C17orf57	-0.54	-7.22	-0.41	5.38e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
CESC	trans	rs11098499	0.954	rs6848389	chr4:120402622	A/G	cg25214090	chr10:38739885	LOC399744	0.68	9.28	0.5	6.19e-18	Corneal astigmatism;
CESC	cis	rs9660992	0.710	rs55671824	chr1:205249814	G/A	cg21643547	chr1:205240462	TMCC2	-0.46	-6.16	-0.35	2.67e-9	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs7520050	0.933	rs12565042	chr1:46299110	C/A	cg03146154	chr1:46216737	IPP	-0.48	-6.36	-0.36	8.91e-10	Red blood cell count;Reticulocyte count;
CESC	cis	rs72781680	0.800	rs56398785	chr2:24091515	T/A	cg20701182	chr2:24300061	SF3B14	0.78	6.91	0.39	3.59e-11	Lymphocyte counts;
CESC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg11133979	chr8:110548574	NA	0.41	6.39	0.37	7.35e-10	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs7618915	0.570	rs11130312	chr3:52675055	A/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.3	5.39	0.31	1.54e-7	Bipolar disorder;
CESC	cis	rs9733	0.519	rs11800855	chr1:150800995	G/A	cg22823121	chr1:150693482	HORMAD1	0.38	5.58	0.32	5.92e-8	Tonsillectomy;
CESC	cis	rs3785574	0.638	rs2854182	chr17:61969062	G/A	cg07677032	chr17:61819896	STRADA	0.43	5.42	0.32	1.35e-7	Height;
CESC	cis	rs798554	0.797	rs798487	chr7:2802943	G/A	cg13628971	chr7:2884303	GNA12	0.65	8.39	0.46	2.85e-15	Height;
CESC	cis	rs754466	1.000	rs12220311	chr10:79681507	C/T	cg17075019	chr10:79541650	NA	-0.76	-9.61	-0.51	5.75e-19	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg24642844	chr7:1081250	C7orf50	-0.65	-8.68	-0.47	4.11e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs6933660	0.760	rs1825368	chr6:151775259	C/A	cg14262678	chr6:151773367	RMND1;C6orf211	0.63	8.85	0.48	1.23e-16	Menarche (age at onset);
CESC	cis	rs2070677	0.935	rs4300354	chr10:135415890	C/T	cg20169779	chr10:135381914	SYCE1	-0.74	-9.71	-0.51	2.99e-19	Gout;
CESC	cis	rs6752107	1.000	rs13009506	chr2:234175706	A/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	-0.46	-6.2	-0.36	2.13e-9	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs9911578	0.765	rs66954617	chr17:56999427	A/G	cg12560992	chr17:57184187	TRIM37	0.93	15.49	0.69	5.42e-39	Intelligence (multi-trait analysis);
CESC	cis	rs4919087	0.923	rs12357266	chr10:98978045	G/A	cg25902810	chr10:99078978	FRAT1	0.72	10.45	0.54	1.25e-21	Monocyte count;
CESC	cis	rs7605827	0.930	rs6761904	chr2:15599658	A/G	cg19274914	chr2:15703543	NA	0.34	6.1	0.35	3.79e-9	Educational attainment (years of education);
CESC	cis	rs12188164	0.965	rs72717430	chr5:444502	T/C	cg17553881	chr5:443987	EXOC3;C5orf55	-0.38	-6.14	-0.35	2.97e-9	Cystic fibrosis severity;
CESC	cis	rs10857712	0.754	rs7921041	chr10:135229239	G/C	cg01444801	chr10:135216882	MTG1	-0.44	-5.23	-0.31	3.53e-7	Systemic lupus erythematosus;
CESC	cis	rs9859260	0.555	rs9877493	chr3:195832147	T/C	cg12923728	chr3:195709715	SDHAP1	-0.5	-5.91	-0.34	1.05e-8	Mean corpuscular volume;
CESC	cis	rs4713118	0.662	rs13218430	chr6:28029837	T/C	cg26335602	chr6:28129616	ZNF389	0.44	5.61	0.33	5.19e-8	Parkinson's disease;
CESC	cis	rs4253772	0.550	rs11703564	chr22:46722194	G/A	cg24881330	chr22:46731750	TRMU	0.78	5.94	0.34	8.8e-9	LDL cholesterol;Cholesterol, total;
CESC	cis	rs10504229	1.000	rs60651159	chr8:58174074	T/C	cg05313129	chr8:58192883	C8orf71	-0.55	-6.37	-0.36	8.42e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs1465370	0.750	rs3807136	chr7:130019481	C/T	cg04743876	chr7:130013617	NA	0.31	5.93	0.34	9.5e-9	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
CESC	trans	rs7628583	0.628	rs79157151	chr3:64073123	C/T	cg07702853	chr1:150254280	C1orf51	-0.55	-6.0	-0.35	6.46e-9	Parental extreme longevity (95 years and older);
CESC	cis	rs477895	0.713	rs35095324	chr11:63948412	G/A	cg04317338	chr11:64019027	PLCB3	0.9	9.42	0.5	2.3e-18	Mean platelet volume;
CESC	cis	rs9916302	0.861	rs33933929	chr17:37426441	A/C	cg19468946	chr17:37922297	IKZF3	-0.39	-5.03	-0.3	8.96e-7	Glomerular filtration rate (creatinine);
CESC	cis	rs6502050	0.799	rs34795957	chr17:80118013	G/A	cg11859384	chr17:80120422	CCDC57	-0.38	-5.18	-0.3	4.43e-7	Life satisfaction;
CESC	cis	rs951366	0.649	rs7522056	chr1:205735891	A/G	cg14159672	chr1:205819179	PM20D1	0.5	6.59	0.38	2.43e-10	Menarche (age at onset);
CESC	trans	rs2018683	0.739	rs10233884	chr7:28972307	A/G	cg19402173	chr7:128379420	CALU	-0.51	-6.77	-0.38	8.38e-11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CESC	cis	rs9549260	0.755	rs4943800	chr13:41216831	A/G	cg21288729	chr13:41239152	FOXO1	0.67	8.77	0.47	2.28e-16	Red blood cell count;
CESC	cis	rs9815354	0.812	rs73081361	chr3:41912535	G/A	cg03022575	chr3:42003672	ULK4	0.7	6.18	0.36	2.38e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs12142240	0.698	rs41294456	chr1:46809782	T/C	cg10495392	chr1:46806563	NSUN4	0.59	6.34	0.36	9.65e-10	Menopause (age at onset);
CESC	trans	rs11098499	0.731	rs9995026	chr4:120490499	T/A	cg25214090	chr10:38739885	LOC399744	0.64	8.69	0.47	3.86e-16	Corneal astigmatism;
CESC	cis	rs4699052	1.000	rs7661702	chr4:104140129	C/G	cg16532752	chr4:104119610	CENPE	-0.41	-5.55	-0.32	6.98e-8	Testicular germ cell tumor;
CESC	cis	rs1670533	1.000	rs4690213	chr4:1054868	C/T	cg04106633	chr4:1044584	NA	0.4	5.09	0.3	6.7e-7	Recombination rate (females);
CESC	cis	rs1949733	0.701	rs2631754	chr4:8449233	A/G	cg11789530	chr4:8429930	ACOX3	0.76	10.94	0.56	3.06e-23	Response to antineoplastic agents;
CESC	cis	rs2236918	1.000	rs1635509	chr1:242028027	C/T	cg17736920	chr1:242011382	EXO1	0.68	9.18	0.49	1.28e-17	Menopause (age at onset);
CESC	cis	rs13102973	0.965	rs4437307	chr4:135861598	C/T	cg14419869	chr4:135874104	NA	-0.39	-6.11	-0.35	3.51e-9	Subjective well-being;
CESC	cis	rs78456975	0.527	rs7590742	chr2:1575049	A/T	cg12573674	chr2:1569213	NA	-0.46	-5.2	-0.3	3.96e-7	Placebo response in major depressive disorder (% change in symptom score);
CESC	cis	rs933688	0.532	rs10072084	chr5:90539203	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.47	5.86	0.34	1.37e-8	Smoking behavior;
CESC	cis	rs5750830	0.594	rs5757648	chr22:39775156	G/A	cg24399712	chr22:39784796	NA	-0.77	-11.05	-0.56	1.34e-23	Intelligence (multi-trait analysis);
CESC	cis	rs9611565	0.694	rs202664	chr22:41813886	C/T	cg06634786	chr22:41940651	POLR3H	0.7	7.5	0.42	9.63e-13	Vitiligo;
CESC	cis	rs56399783	0.901	rs73047393	chr7:2775879	C/T	cg19731401	chr7:2775893	GNA12	0.7	6.33	0.36	1.02e-9	Childhood ear infection;
CESC	cis	rs7647973	0.710	rs2029591	chr3:49646981	C/T	cg03060546	chr3:49711283	APEH	-0.62	-6.99	-0.39	2.26e-11	Menarche (age at onset);
CESC	cis	rs4665809	0.531	rs10199898	chr2:26445485	T/G	cg08470875	chr2:26401718	FAM59B	-0.75	-7.79	-0.43	1.49e-13	Gut microbiome composition (summer);
CESC	cis	rs7259376	0.818	rs8101997	chr19:22568432	A/T	cg02657401	chr19:22469223	NA	-0.25	-5.1	-0.3	6.58e-7	Menopause (age at onset);
CESC	cis	rs9911578	1.000	rs2611782	chr17:56717956	T/C	cg12560992	chr17:57184187	TRIM37	0.93	15.58	0.69	2.6e-39	Intelligence (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08130813	chr19:46195655	QPCTL;SNRPD2	0.52	6.15	0.35	2.79e-9	Gut microbiome composition (summer);
CESC	cis	rs9640161	0.830	rs3757424	chr7:150067679	C/A	cg10018233	chr7:150070692	REPIN1	0.49	8.94	0.48	6.79e-17	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs1153858	0.621	rs1706824	chr15:45579948	C/T	cg09092052	chr15:45571596	NA	-0.46	-5.16	-0.3	4.76e-7	Homoarginine levels;
CESC	cis	rs644799	1.000	rs644799	chr11:95564259	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	13.92	0.65	1.91e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs6496667	1.000	rs8026533	chr15:90893228	A/C	cg22089800	chr15:90895588	ZNF774	0.57	5.76	0.33	2.27e-8	Rheumatoid arthritis;
CESC	cis	rs9858542	0.953	rs6809216	chr3:49412559	G/A	cg07274523	chr3:49395745	GPX1	0.68	8.44	0.46	2.17e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs12142240	0.698	rs6695043	chr1:46844530	A/G	cg10495392	chr1:46806563	NSUN4	-0.53	-5.86	-0.34	1.35e-8	Menopause (age at onset);
CESC	cis	rs1568889	0.838	rs11030229	chr11:28173634	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.81	13.43	0.64	1.02e-31	Bipolar disorder;
CESC	cis	rs72781680	0.566	rs72794293	chr2:23898149	A/G	cg20701182	chr2:24300061	SF3B14	0.65	6.59	0.38	2.4e-10	Lymphocyte counts;
CESC	cis	rs6679073	1.000	rs10494874	chr1:205754688	C/G	cg07167872	chr1:205819463	PM20D1	0.41	5.91	0.34	1.03e-8	Prostate-specific antigen levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24043307	chr12:51157954	ATF1	-0.63	-7.1	-0.4	1.12e-11	Gut microbiome composition (summer);
CESC	cis	rs854765	0.583	rs28428991	chr17:17827649	C/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.55	7.28	0.41	3.9e-12	Total body bone mineral density;
CESC	cis	rs7412746	0.658	rs2275235	chr1:150730279	A/G	cg09365446	chr1:150670422	GOLPH3L	0.39	5.1	0.3	6.59e-7	Melanoma;
CESC	cis	rs4713118	0.662	rs9380046	chr6:28030499	T/C	cg12963246	chr6:28129442	ZNF389	0.49	6.31	0.36	1.18e-9	Parkinson's disease;
CESC	cis	rs1799949	1.000	rs4793194	chr17:41218333	G/A	cg23758822	chr17:41437982	NA	1.02	15.55	0.69	3.45e-39	Menopause (age at onset);
CESC	cis	rs6460942	1.000	rs77494477	chr7:12315302	A/T	cg02935154	chr7:12443704	VWDE	-0.59	-5.84	-0.34	1.5e-8	Coronary artery disease;
CESC	cis	rs7560272	0.538	rs4852976	chr2:73936322	T/C	cg20560298	chr2:73613845	ALMS1	0.45	6.18	0.35	2.43e-9	Schizophrenia;
CESC	cis	rs41271473	0.500	rs10916366	chr1:228894575	T/C	cg00850481	chr1:228891306	NA	-0.51	-7.84	-0.43	1.11e-13	Chronic lymphocytic leukemia;
CESC	cis	rs2832191	0.791	rs4817270	chr21:30480368	G/A	cg24692254	chr21:30365293	RNF160	-0.8	-12.52	-0.61	1.4e-28	Dental caries;
CESC	cis	rs7193541	0.694	rs8061942	chr16:74691362	C/T	cg05580060	chr16:74700937	RFWD3	-0.47	-6.01	-0.35	6.11e-9	Multiple myeloma;
CESC	cis	rs10823500	0.777	rs10509321	chr10:71985733	A/G	cg02100629	chr10:71892760	AIFM2	0.33	5.24	0.31	3.36e-7	Blood protein levels;
CESC	cis	rs3785574	0.962	rs57553639	chr17:61848499	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.59	7.21	0.41	5.72e-12	Height;
CESC	cis	rs11078597	0.731	rs4989024	chr17:1639719	A/G	cg18436246	chr17:1640651	WDR81	0.62	7.54	0.42	7.44e-13	Serum albumin level;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg23359706	chr19:11491839	EPOR	-0.42	-6.05	-0.35	4.94e-9	Gambling;
CESC	cis	rs6121246	0.542	rs6059761	chr20:30110522	G/C	cg13852791	chr20:30311386	BCL2L1	0.65	6.87	0.39	4.61e-11	Mean corpuscular hemoglobin;
CESC	cis	rs6580649	0.941	rs11613485	chr12:48462455	T/C	cg05342945	chr12:48394962	COL2A1	0.51	5.91	0.34	1.07e-8	Lung cancer;
CESC	cis	rs1808579	0.904	rs2960578	chr18:21143739	A/C	cg14672496	chr18:21087552	C18orf8	0.39	5.72	0.33	2.83e-8	Hip circumference;Body mass index;BMI (adjusted for smoking behaviour);
CESC	cis	rs561341	1.000	rs72825712	chr17:30316119	A/T	cg23018236	chr17:30244563	NA	-0.55	-5.31	-0.31	2.37e-7	Hip circumference adjusted for BMI;
CESC	cis	rs9611565	0.765	rs132905	chr22:41799106	C/A	cg03806693	chr22:41940476	POLR3H	1.04	12.34	0.6	6.13e-28	Vitiligo;
CESC	cis	rs9287719	0.649	rs58633964	chr2:10736382	T/G	cg02196655	chr2:10830764	NOL10	-0.38	-5.74	-0.33	2.53e-8	Prostate cancer;
CESC	cis	rs769267	0.965	rs2905425	chr19:19475717	G/C	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.44	-5.58	-0.32	5.92e-8	Tonsillectomy;
CESC	cis	rs2370759	0.945	rs74625866	chr10:32597618	A/T	cg01819863	chr10:32635814	EPC1	1.16	13.32	0.63	2.38e-31	Sexual dysfunction (female);
CESC	cis	rs769267	0.930	rs7254748	chr19:19397479	A/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.43	5.24	0.31	3.29e-7	Tonsillectomy;
CESC	cis	rs62344088	1.000	rs6880143	chr5:137516	C/T	cg22857025	chr5:266934	NA	-0.93	-5.86	-0.34	1.34e-8	Asthma (childhood onset);
CESC	cis	rs761746	0.960	rs5998042	chr22:31953962	T/C	cg25791279	chr22:32026902	PISD	0.52	6.15	0.35	2.78e-9	Intelligence;
CESC	cis	rs9910055	0.529	rs228748	chr17:42174390	G/A	cg08499158	chr17:42289980	UBTF	0.41	5.06	0.3	8.02e-7	Total body bone mineral density;
CESC	cis	rs7301826	0.627	rs4325342	chr12:131312482	G/A	cg11011512	chr12:131303247	STX2	0.46	5.75	0.33	2.48e-8	Plasma plasminogen activator levels;
CESC	cis	rs1801251	1.000	rs9653383	chr2:233670380	A/C	cg25237894	chr2:233734115	C2orf82	-0.46	-8.0	-0.44	4.02e-14	Coronary artery disease;
CESC	cis	rs7945705	0.875	rs2568065	chr11:8889648	C/T	cg09997546	chr11:8931473	C11orf17;ST5	-0.39	-6.78	-0.38	8e-11	Hemoglobin concentration;
CESC	cis	rs7508	0.711	rs3810	chr8:17914117	T/G	cg18067069	chr8:17937731	ASAH1	-0.43	-5.54	-0.32	7.22e-8	Atrial fibrillation;
CESC	cis	rs7833986	0.501	rs2976012	chr8:56974343	T/C	cg26371346	chr8:56986568	SNORD54;RPS20	0.57	5.16	0.3	4.9e-7	Height;
CESC	cis	rs6500395	1.000	rs6500398	chr16:48650332	C/T	cg04672837	chr16:48644449	N4BP1	0.51	6.21	0.36	2.08e-9	Response to tocilizumab in rheumatoid arthritis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19628164	chr3:143689916	C3orf58	0.58	6.54	0.37	3.15e-10	Gut microbiome composition (summer);
CESC	cis	rs597539	0.616	rs631001	chr11:68642974	C/T	cg21963583	chr11:68658836	MRPL21	0.42	5.7	0.33	3.21e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs11264213	0.786	rs72659698	chr1:36314688	G/A	cg27506609	chr1:36549197	TEKT2	0.65	5.49	0.32	9.31e-8	Schizophrenia;
CESC	cis	rs9815354	0.812	rs809930	chr3:42065005	A/G	cg03022575	chr3:42003672	ULK4	0.46	5.38	0.31	1.67e-7	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs9487051	0.734	rs56214745	chr6:109536748	G/T	cg01475377	chr6:109611718	NA	-0.44	-6.69	-0.38	1.32e-10	Reticulocyte fraction of red cells;
CESC	cis	rs801193	0.613	rs2659900	chr7:66184443	G/C	cg12463550	chr7:65579703	CRCP	0.56	7.24	0.41	4.94e-12	Aortic root size;
CESC	cis	rs1797885	0.564	rs2596820	chr3:12601941	G/A	cg26432171	chr3:12704882	RAF1	-0.49	-6.48	-0.37	4.45e-10	Immature fraction of reticulocytes;
CESC	cis	rs4853012	0.941	rs7571083	chr2:74342260	C/G	cg20891558	chr2:74357851	NA	0.69	9.14	0.49	1.7e-17	Gestational age at birth (maternal effect);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg16609855	chr10:91011618	LIPA	-0.44	-6.33	-0.36	1.07e-9	Gambling;
CESC	cis	rs7129220	0.545	rs61520995	chr11:10139467	C/T	cg01453529	chr11:10209919	SBF2	-0.48	-5.63	-0.33	4.67e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CESC	cis	rs7520050	0.931	rs6688365	chr1:46329884	G/C	cg03146154	chr1:46216737	IPP	-0.48	-6.22	-0.36	1.98e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs7647973	0.592	rs6774202	chr3:49687779	T/G	cg07636037	chr3:49044803	WDR6	0.54	6.59	0.38	2.39e-10	Menarche (age at onset);
CESC	cis	rs7666738	0.830	rs79075162	chr4:98960674	A/T	cg17366294	chr4:99064904	C4orf37	0.6	8.52	0.46	1.2e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6952808	0.792	rs11771973	chr7:1950440	C/G	cg04267008	chr7:1944627	MAD1L1	-0.75	-9.97	-0.52	4.38e-20	Bipolar disorder and schizophrenia;
CESC	cis	rs4654899	1.000	rs6426669	chr1:21430584	C/A	cg05370193	chr1:21551575	ECE1	0.38	5.63	0.33	4.52e-8	Superior frontal gyrus grey matter volume;
CESC	cis	rs832540	0.669	rs832538	chr5:56200016	C/T	cg24531977	chr5:56204891	C5orf35	-0.55	-7.25	-0.41	4.69e-12	Coronary artery disease;
CESC	cis	rs9325144	0.600	rs10880934	chr12:38730455	C/T	cg26384229	chr12:38710491	ALG10B	-0.56	-7.85	-0.43	1.03e-13	Morning vs. evening chronotype;
CESC	cis	rs9733	0.596	rs7549795	chr1:150656873	G/A	cg04414720	chr1:150670196	GOLPH3L	0.63	9.01	0.48	4.11e-17	Tonsillectomy;
CESC	cis	rs1808579	0.870	rs11665096	chr18:21118025	G/C	cg14672496	chr18:21087552	C18orf8	0.4	6.11	0.35	3.59e-9	Hip circumference;Body mass index;BMI (adjusted for smoking behaviour);
CESC	cis	rs7512552	0.839	rs1498308	chr1:150295131	G/T	cg15654264	chr1:150340011	RPRD2	0.38	5.11	0.3	6.14e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs910316	0.737	rs175424	chr14:75626257	T/C	cg16144293	chr14:75469539	EIF2B2	0.39	5.04	0.3	8.77e-7	Height;
CESC	cis	rs561341	1.000	rs550923	chr17:30327013	G/C	cg19193384	chr17:30244184	NA	-0.7	-6.58	-0.37	2.49e-10	Hip circumference adjusted for BMI;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18367020	chr2:73461259	CCT7;C2orf7	0.65	7.09	0.4	1.19e-11	Gut microbiome composition (summer);
CESC	cis	rs7945705	0.967	rs10769973	chr11:8928615	C/G	cg09997546	chr11:8931473	C11orf17;ST5	0.38	6.0	0.35	6.57e-9	Hemoglobin concentration;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg23285320	chr19:36546349	THAP8;WDR62	0.48	6.13	0.35	3.2e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs78707713	0.841	rs77784890	chr10:71199295	G/C	cg12610070	chr10:71211762	TSPAN15	-0.43	-7.33	-0.41	2.71e-12	Venous thromboembolism;
CESC	cis	rs7647973	0.769	rs11130181	chr3:49109919	G/A	cg06212747	chr3:49208901	KLHDC8B	0.52	6.23	0.36	1.81e-9	Menarche (age at onset);
CESC	cis	rs2070488	0.965	rs7642472	chr3:38525567	T/C	cg24069376	chr3:38537580	EXOG	0.49	9.06	0.49	3.04e-17	Electrocardiographic conduction measures;
CESC	cis	rs3096299	0.967	rs753853	chr16:89446525	G/T	cg16743903	chr16:89593216	SPG7	-0.46	-5.85	-0.34	1.43e-8	Multiple myeloma (IgH translocation);
CESC	cis	rs9403521	1.000	rs9403521	chr6:143994199	C/T	cg18240653	chr6:144019428	PHACTR2	0.49	5.57	0.32	6.12e-8	Obesity-related traits;
CESC	cis	rs1799949	0.965	rs12950779	chr17:41306523	C/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.45	6.21	0.36	2.01e-9	Menopause (age at onset);
CESC	cis	rs16858210	0.520	rs10460892	chr3:183546124	C/T	cg03417191	chr3:183542750	MAP6D1	-0.72	-8.48	-0.46	1.64e-15	Menopause (age at onset);
CESC	cis	rs704	0.585	rs2227735	chr17:26693258	C/T	cg10342447	chr17:26645325	TMEM97	-0.43	-5.93	-0.34	9.49e-9	Osteoprotegerin levels;
CESC	cis	rs1707322	0.721	rs6429575	chr1:46134216	G/C	cg05343316	chr1:45956843	TESK2	0.5	6.12	0.35	3.43e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7267979	0.932	rs449703	chr20:25458559	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.78	14.78	0.67	1.87e-36	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs910316	0.789	rs175457	chr14:75584507	C/T	cg11812906	chr14:75593930	NEK9	-0.82	-13.29	-0.63	3.25e-31	Height;
CESC	cis	rs1218582	0.774	rs4845683	chr1:154877407	T/C	cg03351412	chr1:154909251	PMVK	0.6	7.72	0.43	2.4e-13	Prostate cancer;
CESC	cis	rs7605827	0.704	rs2160695	chr2:15673478	T/A	cg19274914	chr2:15703543	NA	0.38	6.8	0.39	7.12e-11	Educational attainment (years of education);
CESC	cis	rs933688	1.000	rs4382199	chr5:90744228	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.95	10.98	0.56	2.38e-23	Smoking behavior;
CESC	cis	rs2637266	1.000	rs7914880	chr10:78363693	A/G	cg18941641	chr10:78392320	NA	0.44	8.3	0.45	5.27e-15	Pulmonary function;
CESC	cis	rs3091242	0.933	rs35530120	chr1:25785451	A/G	cg02931644	chr1:25747376	RHCE	-0.39	-6.43	-0.37	5.82e-10	Erythrocyte sedimentation rate;
CESC	cis	rs561341	1.000	rs501957	chr17:30314504	C/T	cg23018236	chr17:30244563	NA	-0.52	-5.11	-0.3	6.22e-7	Hip circumference adjusted for BMI;
CESC	cis	rs28830936	1.000	rs17677199	chr15:41954613	C/G	cg11010575	chr15:42129464	JMJD7-PLA2G4B;JMJD7	-0.37	-5.32	-0.31	2.16e-7	Diastolic blood pressure;
CESC	cis	rs7503807	0.664	rs9913181	chr17:78573872	A/C	cg09596252	chr17:78655493	RPTOR	0.39	5.27	0.31	2.87e-7	Obesity;
CESC	trans	rs4824093	0.610	rs77128035	chr22:50241024	C/T	cg09872104	chr7:134855509	C7orf49	-0.95	-6.69	-0.38	1.32e-10	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs9309473	1.000	rs2901438	chr2:73665656	G/A	cg20560298	chr2:73613845	ALMS1	-0.46	-6.25	-0.36	1.62e-9	Metabolite levels;
CESC	cis	rs2204008	0.728	rs11495375	chr12:38282631	G/A	cg13010199	chr12:38710504	ALG10B	0.52	6.38	0.36	8.04e-10	Bladder cancer;
CESC	cis	rs3733585	0.699	rs7663079	chr4:9966771	T/C	cg11266682	chr4:10021025	SLC2A9	-0.58	-10.94	-0.56	3.08e-23	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs11901793	0.505	rs11688053	chr2:237494289	A/T	cg25295825	chr2:237489920	CXCR7	0.66	5.86	0.34	1.38e-8	Total mean fractional anisotropy measurement in first episode schizophrenia;
CESC	cis	rs909674	0.818	rs5757681	chr22:39845547	A/G	cg01416388	chr22:39784598	NA	-0.56	-6.57	-0.37	2.58e-10	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	trans	rs1728785	0.901	rs7194664	chr16:68643313	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	7.71	0.43	2.5e-13	Ulcerative colitis;
CESC	cis	rs9303280	0.901	rs883770	chr17:38063381	C/T	cg19468946	chr17:37922297	IKZF3	-0.41	-5.53	-0.32	7.55e-8	Self-reported allergy;
CESC	cis	rs7945705	0.935	rs10769971	chr11:8925276	C/T	cg09997546	chr11:8931473	C11orf17;ST5	0.38	6.0	0.35	6.57e-9	Hemoglobin concentration;
CESC	cis	rs7953508	0.711	rs11107117	chr12:93979419	T/C	cg18151635	chr12:93972918	NA	-0.37	-5.08	-0.3	7.18e-7	Pubertal anthropometrics;
CESC	cis	rs8114671	0.562	rs6058120	chr20:33402829	A/G	cg24642439	chr20:33292090	TP53INP2	0.44	5.24	0.31	3.24e-7	Height;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg09169215	chr1:120839390	FAM72B	-0.49	-6.4	-0.37	6.88e-10	Fibrinogen levels;
CESC	cis	rs3892630	0.824	rs12976069	chr19:33280084	G/A	cg22980127	chr19:33182716	NUDT19	1.03	11.61	0.58	1.79e-25	Red blood cell traits;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg24553691	chr21:47706090	MCM3AP;C21orf57	-0.4	-6.0	-0.35	6.31e-9	Gambling;
CESC	trans	rs35110281	0.659	rs73367822	chr21:45024252	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.5	6.53	0.37	3.38e-10	Mean corpuscular volume;
CESC	cis	rs9322193	0.923	rs1413654	chr6:150105092	G/A	cg13206674	chr6:150067644	NUP43	0.42	5.89	0.34	1.19e-8	Lung cancer;
CESC	cis	rs8067545	0.611	rs757494	chr17:20150340	C/T	cg13482628	chr17:19912719	NA	-0.43	-5.63	-0.33	4.59e-8	Schizophrenia;
CESC	cis	rs3749237	0.964	rs7431078	chr3:49808190	G/A	cg03060546	chr3:49711283	APEH	0.64	7.46	0.42	1.21e-12	Resting heart rate;
CESC	cis	rs7927771	0.929	rs66749409	chr11:47568074	C/T	cg18512352	chr11:47633146	NA	-0.6	-9.28	-0.5	6.06e-18	Subjective well-being;
CESC	trans	rs7786808	0.712	rs2335167	chr7:158213948	A/C	cg03441993	chr4:55093323	NA	0.4	6.22	0.36	1.97e-9	Obesity-related traits;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg08370882	chr2:219522648	ZNF142	0.41	6.01	0.35	6.08e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs921968	0.541	rs576901	chr2:219424364	A/G	cg02176678	chr2:219576539	TTLL4	0.5	8.97	0.48	5.39e-17	Mean corpuscular hemoglobin concentration;
CESC	trans	rs116095464	0.558	rs7703803	chr5:292311	A/G	cg00938859	chr5:1591904	SDHAP3	0.65	7.04	0.4	1.67e-11	Breast cancer;
CESC	cis	rs9611565	0.570	rs12159188	chr22:42121125	A/T	cg03806693	chr22:41940476	POLR3H	0.89	10.32	0.54	3.36e-21	Vitiligo;
CESC	cis	rs11792861	0.851	rs4542004	chr9:111814478	A/G	cg05043794	chr9:111880884	C9orf5	-0.38	-6.46	-0.37	5.1e-10	Menarche (age at onset);
CESC	cis	rs8133932	0.654	rs7277632	chr21:47327542	A/G	cg14185626	chr21:47401492	COL6A1	0.45	5.19	0.3	4.28e-7	Schizophrenia;
CESC	cis	rs9291683	0.609	rs13149985	chr4:10028390	G/A	cg00071950	chr4:10020882	SLC2A9	0.88	16.02	0.7	7.4e-41	Bone mineral density;
CESC	cis	rs739401	0.595	rs6578304	chr11:2998279	A/G	cg25174290	chr11:3078921	CARS	-0.52	-7.05	-0.4	1.56e-11	Longevity;
CESC	cis	rs11785693	0.862	rs13281354	chr8:4987756	G/T	cg26367366	chr8:4980734	NA	0.96	8.72	0.47	3.19e-16	Neuroticism (multi-trait analysis);Neuroticism;
CESC	cis	rs6502050	0.799	rs34448080	chr17:80121275	A/G	cg23985595	chr17:80112537	CCDC57	-0.41	-6.57	-0.37	2.6200000000000003e-10	Life satisfaction;
CESC	cis	rs7818688	0.697	rs3802192	chr8:95987471	C/T	cg16049864	chr8:95962084	TP53INP1	0.55	5.6	0.33	5.32e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs2228479	0.850	rs62052711	chr16:89855100	C/A	cg04013166	chr16:89971882	TCF25	0.78	6.67	0.38	1.44e-10	Skin colour saturation;
CESC	cis	rs1552244	1.000	rs7648104	chr3:10073311	C/A	cg00149659	chr3:10157352	C3orf10	0.77	9.66	0.51	4.22e-19	Alzheimer's disease;
CESC	cis	rs1707322	0.686	rs3014236	chr1:46091305	T/C	cg06784218	chr1:46089804	CCDC17	-0.42	-7.37	-0.41	2.13e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7116495	1.000	rs2511079	chr11:71804154	C/T	cg10381502	chr11:71823885	C11orf51	-0.62	-5.55	-0.32	6.83e-8	Severe influenza A (H1N1) infection;
CESC	cis	rs12220238	1.000	rs11000930	chr10:75982982	C/G	cg19889307	chr10:75911429	ADK;AP3M1	-0.64	-5.53	-0.32	7.72e-8	Soluble interleukin-2 receptor subunit alpha;
CESC	trans	rs7902708	0.841	rs10824766	chr10:54428297	C/T	cg26219051	chr22:43739629	SCUBE1	-0.48	-6.19	-0.36	2.25e-9	Bone properties (heel);
CESC	cis	rs1018836	0.828	rs10956730	chr8:91597428	T/G	cg16814680	chr8:91681699	NA	-0.72	-10.81	-0.55	8.12e-23	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs3785574	0.886	rs62077504	chr17:61837734	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.11	19.45	0.77	6.01e-53	Height;
CESC	cis	rs7267979	1.000	rs4815406	chr20:25341316	C/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.88	-18.07	-0.74	3.95e-48	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs9549367	0.737	rs71446680	chr13:113894846	C/T	cg00898013	chr13:113819073	PROZ	-0.54	-7.38	-0.41	2.03e-12	Platelet distribution width;
CESC	cis	rs72627123	0.867	rs59892091	chr14:74417609	T/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.77	5.13	0.3	5.7e-7	Morning vs. evening chronotype;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg04135372	chr2:99061383	INPP4A	-0.43	-6.17	-0.35	2.56e-9	Fibrinogen levels;
CESC	cis	rs853679	0.517	rs9348794	chr6:28117757	T/A	cg18032046	chr6:28092343	ZSCAN16	-0.6	-6.84	-0.39	5.51e-11	Depression;
CESC	cis	rs6750795	0.746	rs1667301	chr2:232423717	C/T	cg09339159	chr2:232260559	B3GNT7	0.41	5.05	0.3	8.15e-7	Height;
CESC	cis	rs7917772	0.503	rs6584510	chr10:104299868	T/G	cg22532475	chr10:104410764	TRIM8	-0.35	-5.97	-0.34	7.47e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg23935330	chr11:66807597	SYT12	0.45	6.01	0.35	6.01e-9	Ulcerative colitis;
CESC	cis	rs11190604	1.000	rs10883505	chr10:102280772	C/T	cg07080220	chr10:102295463	HIF1AN	0.7	6.48	0.37	4.34e-10	Palmitoleic acid (16:1n-7) levels;
CESC	cis	rs1355223	0.902	rs286862	chr11:34718779	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.49	6.73	0.38	1.05e-10	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs875971	0.830	rs7799834	chr7:65880694	A/C	cg12463550	chr7:65579703	CRCP	0.59	7.52	0.42	8.29e-13	Aortic root size;
CESC	cis	rs6964587	0.869	rs11769294	chr7:91549937	C/T	cg01689657	chr7:91764605	CYP51A1	0.31	5.65	0.33	4.06e-8	Breast cancer;
CESC	cis	rs17253792	0.571	rs112129578	chr14:56028415	T/C	cg01858014	chr14:56050164	KTN1	-0.97	-7.1	-0.4	1.17e-11	Putamen volume;
CESC	cis	rs4332037	0.802	rs73048106	chr7:1929019	G/T	cg23422044	chr7:1970798	MAD1L1	-0.57	-5.97	-0.34	7.76e-9	Bipolar disorder;
CESC	cis	rs1577917	0.917	rs2197651	chr6:86495442	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.5	-6.65	-0.38	1.68e-10	Response to antipsychotic treatment;
CESC	cis	rs5753037	0.653	rs131273	chr22:30153721	T/C	cg01021169	chr22:30184971	ASCC2	-0.45	-6.16	-0.35	2.7e-9	Type 1 diabetes;
CESC	cis	rs1862618	0.620	rs2591967	chr5:56233551	C/G	cg22800045	chr5:56110881	MAP3K1	-0.6	-7.95	-0.44	5.25e-14	Initial pursuit acceleration;
CESC	cis	rs7100689	0.577	rs4934038	chr10:82057334	C/A	cg00277334	chr10:82204260	NA	-0.51	-6.55	-0.37	3.03e-10	Post bronchodilator FEV1;
CESC	trans	rs61931739	0.517	rs11513519	chr12:34075077	G/A	cg26384229	chr12:38710491	ALG10B	0.6	8.38	0.46	3.22e-15	Morning vs. evening chronotype;
CESC	cis	rs7618915	0.501	rs2336149	chr3:52692124	G/A	cg17372223	chr3:52568218	NT5DC2	0.42	6.47	0.37	4.6e-10	Bipolar disorder;
CESC	cis	rs1707322	0.721	rs10890333	chr1:46100322	T/C	cg06784218	chr1:46089804	CCDC17	0.42	7.28	0.41	3.75e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7635838	0.596	rs347599	chr3:11258191	C/T	cg00170343	chr3:11313890	ATG7	-0.5	-6.85	-0.39	5.09e-11	HDL cholesterol;
CESC	cis	rs875971	0.862	rs709596	chr7:65825913	A/G	cg11764359	chr7:65958608	NA	0.79	11.52	0.58	3.66e-25	Aortic root size;
CESC	cis	rs4820294	1.000	rs62236665	chr22:38059847	C/A	cg21798802	chr22:38057573	PDXP	0.46	7.88	0.44	8.53e-14	Fat distribution (HIV);
CESC	cis	rs4555082	0.830	rs2816614	chr14:105727359	C/T	cg06808227	chr14:105710500	BRF1	-0.58	-6.77	-0.38	8.26e-11	Mean platelet volume;Platelet distribution width;
CESC	cis	rs7617773	1.000	rs9832957	chr3:48185266	A/G	cg11946769	chr3:48343235	NME6	-0.67	-8.76	-0.47	2.43e-16	Coronary artery disease;
CESC	cis	rs1552244	1.000	rs4269070	chr3:10126083	C/G	cg15117754	chr3:10150083	C3orf24	0.38	5.03	0.3	9.19e-7	Alzheimer's disease;
CESC	cis	rs2303759	0.874	rs8108669	chr19:49845895	C/T	cg22590775	chr19:49891494	CCDC155	0.52	6.15	0.35	2.92e-9	Multiple sclerosis;
CESC	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg06873352	chr17:61820015	STRADA	0.72	12.67	0.61	4.43e-29	Prudent dietary pattern;
CESC	cis	rs6502050	0.842	rs6502053	chr17:80066714	C/T	cg23985595	chr17:80112537	CCDC57	0.41	6.34	0.36	9.73e-10	Life satisfaction;
CESC	cis	rs7216064	1.000	rs6504548	chr17:65886048	T/C	cg12091567	chr17:66097778	LOC651250	-0.83	-9.49	-0.5	1.38e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs6543140	0.964	rs11903551	chr2:103084181	C/G	cg04239558	chr2:103089729	SLC9A4	0.47	6.23	0.36	1.83e-9	Blood protein levels;
CESC	cis	rs1499614	0.831	rs3800822	chr7:66147149	A/G	cg13147721	chr7:65941812	NA	0.96	9.03	0.49	3.53e-17	Gout;
CESC	cis	rs875971	0.964	rs6945019	chr7:65922458	C/G	cg18876405	chr7:65276391	NA	0.54	7.16	0.4	7.89e-12	Aortic root size;
CESC	cis	rs9303401	0.614	rs3087762	chr17:56568680	C/T	cg12560992	chr17:57184187	TRIM37	0.53	5.24	0.31	3.32e-7	Cognitive test performance;
CESC	cis	rs2842992	0.724	rs15982	chr6:160199687	T/C	cg11366901	chr6:160182831	ACAT2	0.63	8.02	0.44	3.33e-14	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs2842992	0.789	rs2342446	chr6:160220687	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.78	9.64	0.51	4.81e-19	Age-related macular degeneration (geographic atrophy);
CESC	cis	rs9814567	1.000	rs7630874	chr3:134293291	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.45	6.1	0.35	3.71e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs796364	0.587	rs7588746	chr2:200986345	A/G	cg23649088	chr2:200775458	C2orf69	0.55	6.36	0.36	8.85e-10	Schizophrenia;
CESC	cis	rs4862750	0.872	rs56389997	chr4:187894796	A/C	cg10295955	chr4:187884368	NA	-1.08	-22.04	-0.8	7.03e-62	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs60733400	0.817	rs4648657	chr1:2560735	A/G	cg18854424	chr1:2615690	NA	-0.29	-5.61	-0.33	4.98e-8	Multiple sclerosis;
CESC	trans	rs62103177	0.714	rs28691615	chr18:77612254	C/T	cg05926928	chr17:57297772	GDPD1	0.76	7.87	0.44	8.91e-14	Opioid sensitivity;
CESC	cis	rs7631605	0.935	rs4678945	chr3:37239324	G/C	cg22985146	chr3:37219077	LRRFIP2	-0.32	-5.11	-0.3	6.31e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs7659604	0.702	rs6826506	chr4:122710865	T/G	cg19748678	chr4:122722346	EXOSC9	0.75	9.6	0.51	6.53e-19	Type 2 diabetes;
CESC	cis	rs6088580	0.624	rs6120645	chr20:33025171	C/T	cg24642439	chr20:33292090	TP53INP2	0.52	6.79	0.39	7.18e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs10644111	1	rs10644111	chr7:91652178	A/AAAC	cg17063962	chr7:91808500	NA	0.56	7.69	0.43	2.84e-13	Breast cancer;
CESC	cis	rs8064299	0.597	rs9893035	chr17:72783798	A/C	cg25054828	chr17:72772726	NAT9;TMEM104	0.82	13.4	0.64	1.29e-31	Monocyte count;
CESC	cis	rs2032447	0.869	rs199752	chr6:26012875	C/T	cg03517284	chr6:25882590	NA	-0.47	-6.26	-0.36	1.56e-9	Intelligence (multi-trait analysis);
CESC	cis	rs7089973	0.604	rs7923693	chr10:116619566	A/G	cg03647239	chr10:116582469	FAM160B1	0.47	6.05	0.35	4.79e-9	Bipolar disorder or attention deficit hyperactivity disorder;
CESC	cis	rs7116495	1.000	rs7930721	chr11:71737481	C/A	cg10381502	chr11:71823885	C11orf51	-0.64	-5.21	-0.3	3.81e-7	Severe influenza A (H1N1) infection;
CESC	cis	rs910316	0.737	rs175048	chr14:75479894	A/T	cg16144293	chr14:75469539	EIF2B2	0.4	5.32	0.31	2.24e-7	Height;
CESC	cis	rs6582630	0.576	rs3900594	chr12:38272429	C/T	cg26384229	chr12:38710491	ALG10B	-0.46	-6.05	-0.35	4.85e-9	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs6952808	0.689	rs1107591	chr7:2041638	G/A	cg21782813	chr7:2030301	MAD1L1	0.52	7.64	0.42	3.96e-13	Bipolar disorder and schizophrenia;
CESC	cis	rs9863	0.861	rs34878139	chr12:124446253	T/C	cg00084347	chr12:124393913	DNAH10	0.27	5.28	0.31	2.71e-7	White blood cell count;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg24397552	chr15:40226086	EIF2AK4	-0.46	-6.37	-0.36	8.37e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs698833	0.819	rs1372078	chr2:44543389	A/T	cg18685995	chr2:44588913	PREPL;C2orf34	-0.46	-5.58	-0.32	6.04e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs739401	0.611	rs401707	chr11:3050965	T/C	cg05729581	chr11:3078854	CARS	-0.4	-5.28	-0.31	2.67e-7	Longevity;
CESC	cis	rs11098499	0.954	rs17005535	chr4:120411562	C/T	cg24375607	chr4:120327624	NA	0.46	5.72	0.33	2.83e-8	Corneal astigmatism;
CESC	cis	rs7208859	0.524	rs60114476	chr17:29097667	A/T	cg13385521	chr17:29058706	SUZ12P	0.81	6.54	0.37	3.17e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs9399135	0.967	rs6929661	chr6:135328792	G/A	cg24558204	chr6:135376177	HBS1L	0.53	7.28	0.41	3.85e-12	Red blood cell count;
CESC	cis	rs6089584	0.888	rs6061966	chr20:60607936	C/G	cg24733560	chr20:60626293	TAF4	0.44	6.18	0.36	2.38e-9	Body mass index;
CESC	cis	rs4713118	0.662	rs9468278	chr6:28028482	C/T	cg19592336	chr6:28129416	ZNF389	0.54	6.94	0.39	3e-11	Parkinson's disease;
CESC	cis	rs7618501	0.602	rs2013208	chr3:50129399	C/T	cg24308560	chr3:49941425	MST1R	0.62	8.94	0.48	6.79e-17	Intelligence (multi-trait analysis);
CESC	cis	rs875971	0.862	rs3926380	chr7:66080645	G/T	cg18252515	chr7:66147081	NA	0.47	6.17	0.35	2.57e-9	Aortic root size;
CESC	trans	rs61931739	0.890	rs1197560	chr12:34121447	G/C	cg26384229	chr12:38710491	ALG10B	0.44	6.05	0.35	4.95e-9	Morning vs. evening chronotype;
CESC	trans	rs2637266	0.505	rs11001808	chr10:78293852	A/G	cg07899263	chr13:99293508	NA	-0.39	-6.04	-0.35	5.08e-9	Pulmonary function;
CESC	cis	rs863345	0.527	rs10797019	chr1:158490221	A/T	cg12129480	chr1:158549410	OR10X1	-0.34	-6.85	-0.39	5.17e-11	Pneumococcal bacteremia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12639324	chr10:92617735	HTR7	0.58	7.47	0.42	1.14e-12	Gut microbiome composition (summer);
CESC	cis	rs763014	0.898	rs916416	chr16:632198	T/A	cg07343612	chr16:622815	PIGQ	-0.57	-8.23	-0.45	8.47e-15	Height;
CESC	trans	rs7849270	1.000	rs3118632	chr9:131901284	G/A	cg05583848	chr6:35265411	DEF6	0.45	6.19	0.36	2.29e-9	Blood metabolite ratios;
CESC	cis	rs9457247	1.000	rs422694	chr6:167406074	G/T	cg23791538	chr6:167370224	RNASET2	-0.59	-8.54	-0.46	1.09e-15	Crohn's disease;
CESC	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg02725872	chr8:58115012	NA	-0.41	-5.82	-0.34	1.69e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs7116495	0.609	rs10736783	chr11:71654143	G/A	cg10381502	chr11:71823885	C11orf51	-1.1	-7.6	-0.42	5.21e-13	Severe influenza A (H1N1) infection;
CESC	cis	rs854765	0.551	rs56886154	chr17:17831473	C/A	cg04398451	chr17:18023971	MYO15A	-0.65	-9.11	-0.49	2.08e-17	Total body bone mineral density;
CESC	cis	rs7208487	0.684	rs12449852	chr17:37632088	A/G	cg07936489	chr17:37558343	FBXL20	-0.91	-9.97	-0.52	4.37e-20	Primary biliary cholangitis;Glomerular filtration rate in non diabetics (creatinine);
CESC	cis	rs3091242	0.934	rs686631	chr1:25719599	A/T	cg27572855	chr1:25598939	RHD	0.42	7.0	0.4	2.06e-11	Erythrocyte sedimentation rate;
CESC	cis	rs9311474	0.502	rs4687624	chr3:52563572	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.38	6.77	0.38	8.27e-11	Electroencephalogram traits;
CESC	cis	rs2070997	0.816	rs1800609	chr9:133731184	A/G	cg11464064	chr9:133710261	ABL1	0.63	6.23	0.36	1.81e-9	Response to amphetamines;
CESC	cis	rs2346177	0.542	rs718849	chr2:46698116	G/A	cg02822958	chr2:46747628	ATP6V1E2	0.44	5.5	0.32	9e-8	HDL cholesterol;
CESC	cis	rs6502050	0.835	rs3935129	chr17:80113381	G/C	cg23985595	chr17:80112537	CCDC57	-0.42	-6.53	-0.37	3.31e-10	Life satisfaction;
CESC	cis	rs875971	0.522	rs1880556	chr7:65432544	T/C	cg11987759	chr7:65425863	GUSB	-0.47	-6.22	-0.36	1.94e-9	Aortic root size;
CESC	cis	rs3008870	1.000	rs35365746	chr1:67438900	G/A	cg02640540	chr1:67518911	SLC35D1	-0.51	-5.54	-0.32	7.41e-8	Lymphocyte percentage of white cells;
CESC	cis	rs1499972	0.878	rs817512	chr3:117734787	T/C	cg07612923	chr3:117604196	NA	-0.8	-5.97	-0.34	7.5e-9	Schizophrenia;
CESC	cis	rs6933660	0.800	rs963193	chr6:151789355	G/T	cg14262678	chr6:151773367	RMND1;C6orf211	-0.63	-8.97	-0.48	5.57e-17	Menarche (age at onset);
CESC	cis	rs7918232	0.941	rs10829195	chr10:27431564	G/A	cg14442939	chr10:27389572	ANKRD26	0.68	6.73	0.38	1.04e-10	Breast cancer;
CESC	cis	rs7179456	0.517	rs7167872	chr15:59271375	T/C	cg05156742	chr15:59063176	FAM63B	0.57	7.79	0.43	1.53e-13	Asperger disorder;
CESC	cis	rs4975616	0.869	rs401681	chr5:1322087	C/T	cg06550200	chr5:1325588	CLPTM1L	-0.64	-9.81	-0.52	1.35e-19	Lung cancer;
CESC	cis	rs2243480	1.000	rs60683927	chr7:65394768	T/C	cg13147721	chr7:65941812	NA	-0.83	-7.92	-0.44	6.77e-14	Diabetic kidney disease;
CESC	cis	rs754466	1.000	rs56256440	chr10:79698207	A/G	cg17075019	chr10:79541650	NA	-0.73	-8.97	-0.48	5.61e-17	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs992157	0.764	rs10932774	chr2:219191569	A/G	cg00012203	chr2:219082015	ARPC2	0.59	7.4	0.41	1.82e-12	Colorectal cancer;
CESC	cis	rs9611565	0.559	rs739136	chr22:42100275	C/T	cg03806693	chr22:41940476	POLR3H	-1.15	-13.65	-0.64	1.77e-32	Vitiligo;
CESC	cis	rs962856	0.619	rs6721534	chr2:67574662	G/A	cg09028215	chr2:67624308	ETAA1	-0.44	-5.32	-0.31	2.2e-7	Pancreatic cancer;
CESC	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg23708337	chr7:1209742	NA	0.53	5.34	0.31	1.98e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs12971120	0.947	rs3764509	chr18:72167124	C/G	cg25817165	chr18:72167213	CNDP2	-0.56	-7.72	-0.43	2.34e-13	Refractive error;
CESC	cis	rs12541635	0.677	rs11781331	chr8:107066936	G/A	cg10147462	chr8:107024639	NA	-0.36	-5.06	-0.3	7.76e-7	Age of smoking initiation;
CESC	cis	rs12477438	0.520	rs2969379	chr2:99776686	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.87	16.26	0.71	1.06e-41	Chronic sinus infection;
CESC	cis	rs13191362	1.000	rs67487119	chr6:163102657	A/C	cg18825119	chr6:163149453	PACRG;PARK2	0.54	5.2	0.3	4.01e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs10743315	0.732	rs17271857	chr12:19458136	C/T	cg02471346	chr12:19282374	PLEKHA5	-0.66	-5.87	-0.34	1.32e-8	Gut microbiota (bacterial taxa);
CESC	cis	rs2708240	1.000	rs2538986	chr7:147580726	A/G	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.36	-5.97	-0.34	7.69e-9	QT interval (drug interaction);
CESC	cis	rs36229146	1	rs36229146	chr7:22784486	TTATATATAAATATATATATATATATA/T	cg05265849	chr7:22767390	IL6	0.55	6.69	0.38	1.32e-10	Eosinophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;
CESC	trans	rs629535	0.814	rs545720	chr8:70063370	T/C	cg21567404	chr3:27674614	NA	0.88	10.49	0.54	9.21e-22	Dupuytren's disease;
CESC	cis	rs7786808	0.705	rs1377373	chr7:158215549	A/C	cg01191920	chr7:158217561	PTPRN2	0.32	5.36	0.31	1.78e-7	Obesity-related traits;
CESC	cis	rs34286592	1.000	rs3815824	chr16:29852860	C/T	cg27338089	chr16:29820515	MAZ	0.48	5.04	0.3	8.68e-7	Multiple sclerosis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03833794	chr17:78190983	SGSH	-0.61	-6.49	-0.37	4.12e-10	Gut microbiome composition (summer);
CESC	cis	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11570347	chr4:99850390	EIF4E	0.59	6.64	0.38	1.81e-10	Gut microbiome composition (summer);
CESC	cis	rs2439831	0.681	rs2278858	chr15:43632755	G/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.83	7.68	0.43	3.1400000000000003e-13	Lung cancer in ever smokers;
CESC	cis	rs35306767	0.953	rs10904583	chr10:983498	T/C	cg20503657	chr10:835505	NA	0.66	7.2	0.4	6.1e-12	Eosinophil percentage of granulocytes;
CESC	cis	rs2730245	1.000	rs2527199	chr7:158737113	G/A	cg15303052	chr7:158526867	ESYT2	0.43	5.22	0.31	3.68e-7	Height;
CESC	cis	rs1538970	0.924	rs1826691	chr1:45881262	A/G	cg03146154	chr1:46216737	IPP	-0.43	-5.13	-0.3	5.73e-7	Platelet count;
CESC	cis	rs2235642	0.785	rs1057983	chr16:1660274	A/G	cg03715980	chr16:1756201	MAPK8IP3	0.41	5.5	0.32	8.91e-8	Coronary artery disease;
CESC	cis	rs17376456	0.825	rs13357713	chr5:93145423	T/C	cg21475434	chr5:93447410	FAM172A	0.83	7.35	0.41	2.41e-12	Diabetic retinopathy;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg07343429	chr11:1785120	HCCA2;CTSD	-0.47	-6.43	-0.37	5.93e-10	Fibrinogen levels;
CESC	cis	rs7537052	0.669	rs6686192	chr1:36642991	C/T	cg24686825	chr1:36642396	MAP7D1	-0.57	-8.29	-0.45	5.68e-15	Schizophrenia;
CESC	trans	rs1545843	0.593	rs61562209	chr12:84793389	A/G	cg03015433	chr16:56623111	MT3	-0.34	-6.12	-0.35	3.37e-9	Major depressive disorder;
CESC	cis	rs60871478	1.000	rs62432860	chr7:807522	G/C	cg05535760	chr7:792225	HEATR2	0.88	11.01	0.56	1.78e-23	Cerebrospinal P-tau181p levels;
CESC	cis	rs7618915	0.547	rs62253703	chr3:52632357	T/C	cg17372223	chr3:52568218	NT5DC2	0.44	6.53	0.37	3.36e-10	Bipolar disorder;
CESC	cis	rs1881797	1.000	rs10925069	chr1:247681313	C/T	cg11166453	chr1:247681781	NA	-0.49	-6.48	-0.37	4.55e-10	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs780096	0.526	rs1647266	chr2:27693485	T/C	cg22903471	chr2:27725779	GCKR	-0.52	-7.39	-0.41	1.88e-12	Total body bone mineral density;
CESC	cis	rs765787	0.530	rs11854294	chr15:45527996	A/G	cg24006582	chr15:45444508	DUOX1	-0.59	-7.23	-0.41	5.15e-12	Uric acid levels;
CESC	cis	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg24642844	chr7:1081250	C7orf50	-0.41	-5.36	-0.31	1.82e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs17253792	0.822	rs10137885	chr14:56173590	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.65	5.35	0.31	1.9e-7	Putamen volume;
CESC	cis	rs798554	0.757	rs1183085	chr7:2875570	G/A	cg19346786	chr7:2764209	NA	-0.46	-6.63	-0.38	1.93e-10	Height;
CESC	cis	rs738322	0.967	rs2092180	chr22:38571563	A/G	cg17652424	chr22:38574118	PLA2G6	-0.34	-6.04	-0.35	5.08e-9	Cutaneous nevi;
CESC	cis	rs2573652	1.000	rs2581365	chr15:100513318	A/C	cg09918751	chr15:100517450	ADAMTS17	-0.4	-7.81	-0.43	1.37e-13	Height;
CESC	cis	rs5753037	0.543	rs131284	chr22:30157589	T/C	cg01021169	chr22:30184971	ASCC2	-0.55	-7.84	-0.43	1.13e-13	Type 1 diabetes;
CESC	cis	rs2070488	0.965	rs7433277	chr3:38529818	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.96	18.05	0.74	4.84e-48	Electrocardiographic conduction measures;
CESC	cis	rs28830936	1.000	rs9672298	chr15:41912368	A/C	cg11010575	chr15:42129464	JMJD7-PLA2G4B;JMJD7	-0.36	-5.14	-0.3	5.26e-7	Diastolic blood pressure;
CESC	cis	rs9611565	0.592	rs5751129	chr22:42015765	C/T	cg06481639	chr22:41940642	POLR3H	0.56	6.26	0.36	1.51e-9	Vitiligo;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg06937829	chr11:554920	C11orf35	-0.47	-6.08	-0.35	4.26e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs6963495	1.000	rs6963495	chr7:105166853	T/C	cg19920283	chr7:105172520	RINT1	0.64	5.35	0.31	1.89e-7	Bipolar disorder (body mass index interaction);
CESC	cis	rs6973256	0.605	rs7792396	chr7:133345526	T/C	cg10665199	chr7:133106180	EXOC4	0.46	6.17	0.35	2.51e-9	Intelligence (multi-trait analysis);
CESC	cis	rs35955747	0.869	rs5753576	chr22:31757735	C/T	cg02404636	chr22:31891804	SFI1	0.36	5.2	0.3	3.91e-7	Neutrophil count;Sum basophil neutrophil counts;
CESC	trans	rs9944275	0.860	rs34405613	chr15:97188362	A/T	cg26794346	chr6:16472305	ATXN1	0.75	6.06	0.35	4.65e-9	Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
CESC	cis	rs2228479	0.850	rs62052711	chr16:89855100	C/A	cg00800038	chr16:89945340	TCF25	-0.9	-7.5	-0.42	9.55e-13	Skin colour saturation;
CESC	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg16405210	chr4:1374714	KIAA1530	-0.93	-11.81	-0.59	3.74e-26	Longevity;
CESC	cis	rs4665809	0.627	rs13014338	chr2:26463024	C/T	cg25036284	chr2:26402008	FAM59B	0.86	9.4	0.5	2.74e-18	Gut microbiome composition (summer);
CESC	cis	rs9611565	0.572	rs139569	chr22:42211141	A/G	cg06481639	chr22:41940642	POLR3H	-0.45	-5.22	-0.31	3.53e-7	Vitiligo;
CESC	cis	rs11690935	0.959	rs4667694	chr2:172605399	G/A	cg13550731	chr2:172543902	DYNC1I2	-0.96	-14.06	-0.65	6.1e-34	Schizophrenia;
CESC	cis	rs10089	1.000	rs10478796	chr5:127436187	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.77	10.67	0.55	2.39e-22	Ileal carcinoids;
CESC	cis	rs6460942	0.841	rs62448597	chr7:12449110	G/C	cg06484146	chr7:12443880	VWDE	-0.73	-8.75	-0.47	2.6e-16	Coronary artery disease;
CESC	cis	rs9419702	0.526	rs9419637	chr10:133548059	T/C	cg04492858	chr10:133558786	NA	0.45	6.62	0.38	2.02e-10	Survival in rectal cancer;
CESC	cis	rs2929278	0.617	rs4617832	chr15:44030579	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	-0.49	-7.82	-0.43	1.27e-13	Schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04135372	chr2:99061383	INPP4A	0.61	7.3	0.41	3.45e-12	Gut microbiome composition (summer);
CESC	cis	rs2243480	1.000	rs7456042	chr7:65299778	T/C	cg13147721	chr7:65941812	NA	-0.87	-8.61	-0.47	6.64e-16	Diabetic kidney disease;
CESC	cis	rs11122272	0.735	rs910824	chr1:231498773	C/G	cg06096015	chr1:231504339	EGLN1	0.43	6.26	0.36	1.57e-9	Hemoglobin concentration;
CESC	cis	rs7959452	0.868	rs10784774	chr12:69737879	C/T	cg14784868	chr12:69753453	YEATS4	-0.6	-8.37	-0.46	3.34e-15	Blood protein levels;
CESC	cis	rs67478160	0.584	rs2295147	chr14:104195664	A/G	cg08213375	chr14:104286397	PPP1R13B	-0.37	-6.84	-0.39	5.33e-11	Schizophrenia;
CESC	trans	rs17685	0.753	rs2286830	chr7:75693963	C/T	cg19862616	chr7:65841803	NCRNA00174	-0.81	-11.9	-0.59	1.92e-26	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs3892630	0.824	rs7247264	chr19:33239846	T/G	cg22980127	chr19:33182716	NUDT19	1.03	11.34	0.57	1.42e-24	Red blood cell traits;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg13894748	chr10:102107266	SCD	-0.43	-6.16	-0.35	2.64e-9	Gambling;
CESC	trans	rs10411161	0.702	rs8110531	chr19:52383510	C/T	cg22319618	chr22:45562946	NUP50	-0.69	-6.75	-0.38	9.37e-11	Breast cancer;
CESC	cis	rs7811142	0.830	rs78256546	chr7:99952970	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.72	6.41	0.37	6.71e-10	Platelet count;
CESC	cis	rs875971	1.000	rs6957199	chr7:65978519	T/C	cg12463550	chr7:65579703	CRCP	0.56	7.07	0.4	1.39e-11	Aortic root size;
CESC	cis	rs1538970	0.924	rs10890327	chr1:45891458	C/T	cg06784218	chr1:46089804	CCDC17	0.33	5.46	0.32	1.11e-7	Platelet count;
CESC	cis	rs7589342	0.839	rs12995333	chr2:106436366	A/C	cg16077055	chr2:106428750	NCK2	-0.52	-7.38	-0.41	2.05e-12	Addiction;
CESC	cis	rs1595825	1.000	rs79508374	chr2:198864568	G/A	cg00982548	chr2:198649783	BOLL	-0.44	-5.05	-0.3	8.32e-7	Ulcerative colitis;
CESC	cis	rs2075371	1.000	rs2598291	chr7:133988313	C/G	cg11752832	chr7:134001865	SLC35B4	0.55	7.12	0.4	9.94e-12	Mean platelet volume;
CESC	trans	rs1908814	0.516	rs10113145	chr8:11793295	A/G	cg15556689	chr8:8085844	FLJ10661	0.5	6.13	0.35	3.13e-9	Neuroticism;
CESC	cis	rs6456156	0.586	rs911632	chr6:167471461	T/C	cg07741184	chr6:167504864	NA	0.36	6.17	0.35	2.48e-9	Primary biliary cholangitis;
CESC	cis	rs2832191	0.791	rs2832182	chr21:30481612	G/A	cg08807101	chr21:30365312	RNF160	-0.76	-10.82	-0.55	7.78e-23	Dental caries;
CESC	cis	rs9649213	0.593	rs10808107	chr7:97951671	T/C	cg24562669	chr7:97807699	LMTK2	0.48	7.1	0.4	1.13e-11	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7528419	1.000	rs646776	chr1:109818530	C/T	cg00908766	chr1:109817496	CELSR2	0.47	6.65	0.38	1.64e-10	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
CESC	cis	rs9359856	0.623	rs1179906	chr6:90323624	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.56	-6.44	-0.37	5.45e-10	Bipolar disorder;
CESC	cis	rs10504229	0.906	rs59336968	chr8:58176857	T/C	cg22535103	chr8:58192502	C8orf71	-1.05	-13.27	-0.63	3.63e-31	Developmental language disorder (linguistic errors);
CESC	cis	rs9311474	0.652	rs614288	chr3:52220203	T/C	cg05564831	chr3:52568323	NT5DC2	0.39	5.94	0.34	9e-9	Electroencephalogram traits;
CESC	trans	rs3087243	0.729	rs231810	chr2:204712143	A/G	cg01841312	chr10:38069945	NA	0.38	6.19	0.36	2.31e-9	Rheumatoid arthritis;Hypothyroidism;Type 1 diabetes;
CESC	cis	rs7666738	0.830	rs3907021	chr4:99038668	C/T	cg18180107	chr4:99064573	C4orf37	0.41	5.29	0.31	2.51e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs12701220	0.655	rs34344742	chr7:1149288	C/G	cg23978390	chr7:1156363	C7orf50	0.57	5.85	0.34	1.45e-8	Bronchopulmonary dysplasia;
CESC	cis	rs2073300	0.609	rs3827085	chr20:23356985	A/T	cg12062639	chr20:23401060	NAPB	1.06	8.38	0.46	3.24e-15	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs5769765	1.000	rs5769765	chr22:50271176	G/A	cg02269571	chr22:50332266	NA	0.46	6.28	0.36	1.39e-9	Schizophrenia;
CESC	cis	rs7914558	0.933	rs1538204	chr10:104733893	T/A	cg15744005	chr10:104629667	AS3MT	-0.34	-5.31	-0.31	2.32e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs17376456	0.877	rs10476597	chr5:93367172	C/T	cg25358565	chr5:93447407	FAM172A	-1.14	-10.65	-0.55	2.82e-22	Diabetic retinopathy;
CESC	cis	rs8014204	0.804	rs35641442	chr14:75207263	G/A	cg08847533	chr14:75593920	NEK9	0.48	5.98	0.34	7.26e-9	Caffeine consumption;
CESC	cis	rs7084402	0.967	rs1649084	chr10:60292117	T/A	cg07615347	chr10:60278583	BICC1	0.6	9.41	0.5	2.54e-18	Refractive error;
CESC	cis	rs765787	0.530	rs12439643	chr15:45529767	A/G	cg24006582	chr15:45444508	DUOX1	0.58	6.9	0.39	3.91e-11	Uric acid levels;
CESC	cis	rs1003719	0.762	rs11088381	chr21:38478429	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.63	8.77	0.47	2.14e-16	Eye color traits;
CESC	cis	rs7560272	0.501	rs2006997	chr2:73947846	G/A	cg20560298	chr2:73613845	ALMS1	0.43	5.83	0.34	1.57e-8	Schizophrenia;
CESC	cis	rs1707322	0.964	rs785516	chr1:46564758	T/G	cg03146154	chr1:46216737	IPP	-0.74	-9.64	-0.51	4.75e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs9733	0.596	rs2065900	chr1:150652202	A/G	cg04414720	chr1:150670196	GOLPH3L	0.63	9.01	0.48	4.11e-17	Tonsillectomy;
CESC	cis	rs12765878	0.967	rs11598018	chr10:105661315	C/A	cg11005552	chr10:105648138	OBFC1	0.35	5.06	0.3	7.79e-7	Coronary artery disease;
CESC	cis	rs929354	0.742	rs1182396	chr7:157031831	A/C	cg05182265	chr7:156933206	UBE3C	0.49	7.27	0.41	4.04e-12	Body mass index;
CESC	cis	rs6460942	0.597	rs17448913	chr7:12533984	T/C	cg20607287	chr7:12443886	VWDE	-0.72	-7.71	-0.43	2.51e-13	Coronary artery disease;
CESC	cis	rs4835937	0.590	rs6871743	chr5:127310093	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.57	5.36	0.31	1.79e-7	Cancer;
CESC	trans	rs7618501	0.699	rs2681780	chr3:49897830	C/T	cg21659725	chr3:3221576	CRBN	0.58	8.17	0.45	1.29e-14	Intelligence (multi-trait analysis);
CESC	cis	rs2228479	0.541	rs13335395	chr16:89952843	T/A	cg06558623	chr16:89946397	TCF25	0.58	5.66	0.33	3.93e-8	Skin colour saturation;
CESC	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg07167872	chr1:205819463	PM20D1	0.78	12.49	0.61	1.78e-28	Menarche (age at onset);
CESC	cis	rs1018836	0.923	rs10808615	chr8:91569704	A/T	cg16814680	chr8:91681699	NA	-0.72	-10.29	-0.53	4.01e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs3008870	1.000	rs3008871	chr1:67419089	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-1.02	-14.0	-0.65	1.03e-33	Lymphocyte percentage of white cells;
CESC	cis	rs3008870	0.755	rs2815374	chr1:67507387	G/A	cg02640540	chr1:67518911	SLC35D1	0.46	5.52	0.32	8.04e-8	Lymphocyte percentage of white cells;
CESC	cis	rs35306767	0.903	rs12264711	chr10:929525	T/C	cg20503657	chr10:835505	NA	0.79	8.07	0.44	2.53e-14	Eosinophil percentage of granulocytes;
CESC	cis	rs36051895	0.632	rs11791350	chr9:5172907	G/T	cg02405213	chr9:5042618	JAK2	-0.48	-5.45	-0.32	1.14e-7	Pediatric autoimmune diseases;
CESC	cis	rs2072499	0.750	rs55675376	chr1:156165881	C/T	cg25208724	chr1:156163844	SLC25A44	0.98	12.72	0.62	2.94e-29	Testicular germ cell tumor;
CESC	cis	rs7264396	0.513	rs2425092	chr20:34306815	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.63	6.75	0.38	9.35e-11	Total cholesterol levels;
CESC	cis	rs72829446	0.530	rs2301609	chr17:7399866	G/A	cg02795151	chr17:7402630	POLR2A	0.58	6.14	0.35	3.05e-9	Androgen levels;
CESC	cis	rs826838	0.809	rs11169666	chr12:39211300	T/C	cg26384229	chr12:38710491	ALG10B	0.79	13.11	0.63	1.3e-30	Heart rate;
CESC	cis	rs9858542	0.953	rs6766131	chr3:49538932	T/C	cg03060546	chr3:49711283	APEH	-0.55	-6.28	-0.36	1.34e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs6933660	0.646	rs9397051	chr6:151778325	C/T	cg02564969	chr6:151773285	C6orf211;RMND1	0.67	9.42	0.5	2.33e-18	Menarche (age at onset);
CESC	cis	rs7666738	0.830	rs35939134	chr4:98980311	A/G	cg17366294	chr4:99064904	C4orf37	0.59	8.46	0.46	1.8e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs5821446	1	rs5821446	chr17:65962538	A/AT	cg07042672	chr17:66097459	LOC651250	0.64	8.07	0.44	2.44e-14	Eosinophil percentage of granulocytes;
CESC	cis	rs854765	0.547	rs28537385	chr17:17902135	G/A	cg16928487	chr17:17741425	SREBF1	-0.54	-9.23	-0.49	8.96e-18	Total body bone mineral density;
CESC	cis	rs561341	1.000	rs55978022	chr17:30275937	T/C	cg23018236	chr17:30244563	NA	-0.57	-5.56	-0.32	6.63e-8	Hip circumference adjusted for BMI;
CESC	trans	rs637571	0.522	rs679581	chr11:65746653	A/G	cg17712092	chr4:129076599	LARP1B	0.75	10.37	0.54	2.26e-21	Eosinophil percentage of white cells;
CESC	cis	rs9815354	0.680	rs73073262	chr3:42018443	G/T	cg03022575	chr3:42003672	ULK4	0.74	6.64	0.38	1.79e-10	Pulse pressure;Diastolic blood pressure;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27641051	chr5:137911203	HSPA9	0.66	7.93	0.44	6.07e-14	Gut microbiome composition (summer);
CESC	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg05313129	chr8:58192883	C8orf71	-0.48	-5.27	-0.31	2.89e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs2249625	0.584	rs2463744	chr6:72875936	C/T	cg18830697	chr6:72922368	RIMS1	-0.48	-7.18	-0.4	6.94e-12	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
CESC	cis	rs8060686	0.516	rs4640173	chr16:68163602	C/A	cg26727032	chr16:67993705	SLC12A4	-0.52	-7.06	-0.4	1.42e-11	HDL cholesterol;Metabolic syndrome;
CESC	cis	rs10883723	0.810	rs7094751	chr10:104274818	G/A	ch.10.2196322F	chr10:104248062	ACTR1A	0.42	5.16	0.3	4.76e-7	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs1062177	0.694	rs2915816	chr5:151115857	G/A	cg12924095	chr5:151150029	G3BP1	-0.41	-5.5	-0.32	8.78e-8	Preschool internalizing problems;
CESC	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg19318889	chr4:1322082	MAEA	0.6	7.09	0.4	1.2e-11	Longevity;
CESC	cis	rs7223966	1.000	rs8067064	chr17:61825984	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.56	6.66	0.38	1.6e-10	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs2901656	0.546	rs9425598	chr1:172371922	A/G	cg03748243	chr1:172413542	C1orf105;PIGC	0.48	7.6	0.42	5.27e-13	Red cell distribution width;Platelet distribution width;
CESC	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg21724239	chr8:58056113	NA	0.6	5.44	0.32	1.21e-7	Developmental language disorder (linguistic errors);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09152490	chr1:160098579	ATP1A2	-0.61	-7.83	-0.43	1.19e-13	Gut microbiome composition (summer);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg00482020	chr16:25026850	ARHGAP17	-0.45	-6.63	-0.38	1.84e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs9611565	0.802	rs73176694	chr22:41786788	C/T	cg06634786	chr22:41940651	POLR3H	-0.72	-7.51	-0.42	9.19e-13	Vitiligo;
CESC	cis	rs9311474	0.659	rs1133415	chr3:52575831	G/A	cg18099408	chr3:52552593	STAB1	-0.39	-7.02	-0.4	1.83e-11	Electroencephalogram traits;
CESC	cis	rs9486719	1.000	rs11152968	chr6:96908653	A/G	cg06623918	chr6:96969491	KIAA0776	0.78	7.87	0.44	9.05e-14	Migraine;Coronary artery disease;
CESC	cis	rs11122272	0.735	rs2491408	chr1:231519248	C/G	cg06096015	chr1:231504339	EGLN1	0.43	6.18	0.35	2.46e-9	Hemoglobin concentration;
CESC	cis	rs28829049	0.597	rs2313509	chr1:19437860	C/T	cg13387374	chr1:19411106	UBR4	0.42	5.32	0.31	2.26e-7	QRS duration in Tripanosoma cruzi seropositivity;
CESC	trans	rs9929218	0.507	rs62057805	chr16:68742390	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.9	14.6	0.67	8.11e-36	Colorectal cancer;
CESC	cis	rs10504229	0.683	rs10504225	chr8:58145121	A/T	cg02725872	chr8:58115012	NA	-0.42	-6.61	-0.38	2.1e-10	Developmental language disorder (linguistic errors);
CESC	trans	rs17772222	0.696	rs28666030	chr14:88977807	A/G	cg16524936	chr4:1340807	KIAA1530	-0.5	-6.01	-0.35	5.96e-9	Coronary artery calcification;
CESC	cis	rs4595586	0.505	rs6580897	chr12:39372254	A/G	cg26384229	chr12:38710491	ALG10B	0.5	7.13	0.4	9.33e-12	Morning vs. evening chronotype;
CESC	cis	rs6456156	0.774	rs2022001	chr6:167529509	C/T	cg07741184	chr6:167504864	NA	-0.31	-5.12	-0.3	5.75e-7	Primary biliary cholangitis;
CESC	cis	rs7520050	0.966	rs10789487	chr1:46420221	G/A	cg03146154	chr1:46216737	IPP	-0.47	-6.1	-0.35	3.74e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs6840258	1.000	rs56050898	chr4:87945375	A/G	cg08197287	chr4:87952173	AFF1	-0.4	-5.45	-0.32	1.17e-7	Mean corpuscular volume;Basophil percentage of granulocytes;
CESC	cis	rs34172651	0.537	rs8049014	chr16:24698903	A/G	cg04756594	chr16:24857601	SLC5A11	0.53	6.83	0.39	5.93e-11	Intelligence (multi-trait analysis);
CESC	cis	rs12291225	0.535	rs11023203	chr11:14409815	G/A	cg19336497	chr11:14380999	RRAS2	-0.37	-5.38	-0.31	1.67e-7	Sense of smell;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg26988692	chr8:37756473	RAB11FIP1	-0.48	-6.13	-0.35	3.16e-9	Ulcerative colitis;
CESC	cis	rs9894429	0.634	rs9709130	chr17:79583948	C/T	cg13777783	chr17:79615861	NA	-0.36	-6.12	-0.35	3.36e-9	Eye color traits;
CESC	cis	rs9660180	0.967	rs61422524	chr1:1767565	C/A	cg17747265	chr1:1875780	NA	-0.56	-9.05	-0.49	3.07e-17	Body mass index;
CESC	cis	rs854765	0.583	rs11078406	chr17:17840823	G/T	cg09796270	chr17:17721594	SREBF1	0.4	5.57	0.32	6.21e-8	Total body bone mineral density;
CESC	cis	rs6696846	0.515	rs11240364	chr1:205105917	C/G	cg00857998	chr1:205179979	DSTYK	0.39	5.23	0.31	3.41e-7	Red blood cell count;
CESC	cis	rs4481887	0.927	rs4916121	chr1:248432003	C/T	cg00666640	chr1:248458726	OR2T12	0.41	6.81	0.39	6.53e-11	Common traits (Other);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27539746	chr10:118764201	KIAA1598	0.54	6.53	0.37	3.35e-10	Gut microbiome composition (summer);
CESC	cis	rs3749237	1.000	rs4768	chr3:49758764	A/G	cg03060546	chr3:49711283	APEH	0.64	7.51	0.42	9.34e-13	Resting heart rate;
CESC	cis	rs7851660	0.809	rs7044799	chr9:100665393	A/T	cg13688889	chr9:100608707	NA	-0.63	-8.95	-0.48	6.33e-17	Strep throat;
CESC	cis	rs3820928	0.874	rs1996998	chr2:227840294	C/A	cg11843606	chr2:227700838	RHBDD1	-0.45	-5.8	-0.34	1.86e-8	Pulmonary function;
CESC	cis	rs2075371	1.000	rs2075373	chr7:133984683	A/C	cg11752832	chr7:134001865	SLC35B4	0.54	7.02	0.4	1.88e-11	Mean platelet volume;
CESC	cis	rs3087591	0.960	rs8080679	chr17:29602610	A/G	cg24425628	chr17:29625626	OMG;NF1	0.41	5.13	0.3	5.59e-7	Hip circumference;
CESC	cis	rs7264396	0.635	rs6060720	chr20:34548336	A/C	cg17201900	chr20:34330562	RBM39	0.5	5.22	0.31	3.71e-7	Total cholesterol levels;
CESC	cis	rs7680126	0.633	rs4697975	chr4:10209966	A/T	cg00071950	chr4:10020882	SLC2A9	-0.46	-5.23	-0.31	3.38e-7	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	cis	rs6964587	0.839	rs62466809	chr7:91472801	A/G	cg17063962	chr7:91808500	NA	0.5	6.46	0.37	4.98e-10	Breast cancer;
CESC	cis	rs11677416	1.000	rs1800794	chr2:113543273	G/A	cg27083787	chr2:113543245	IL1A	0.68	8.06	0.44	2.66e-14	Response to antipsychotic treatment in schizophrenia (working memory);
CESC	cis	rs72781680	0.948	rs113530757	chr2:24142500	G/A	cg20701182	chr2:24300061	SF3B14	0.63	5.67	0.33	3.79e-8	Lymphocyte counts;
CESC	cis	rs459571	0.635	rs379471	chr9:136890649	G/A	cg13789015	chr9:136890014	NCRNA00094	0.55	7.9	0.44	7.61e-14	Platelet distribution width;
CESC	cis	rs7095944	0.614	rs10901816	chr10:126440395	G/A	cg08799069	chr10:126477246	METTL10	-0.37	-5.28	-0.31	2.66e-7	Asthma;
CESC	cis	rs10751667	0.666	rs10902243	chr11:949900	T/C	cg20946044	chr11:1010712	AP2A2	-0.38	-5.24	-0.31	3.23e-7	Alzheimer's disease (late onset);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg12037538	chr1:25664880	TMEM50A	-0.48	-6.36	-0.36	8.66e-10	Gut microbiota (bacterial taxa);
CESC	trans	rs9354352	0.935	rs9345749	chr6:66699892	G/T	cg15322624	chr12:2922039	ITFG2	0.47	6.01	0.35	6.05e-9	Initial pursuit acceleration in psychotic disorders;
CESC	cis	rs11229555	0.645	rs11530830	chr11:58252992	C/G	cg15696309	chr11:58395628	NA	0.46	5.17	0.3	4.6e-7	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs6543140	0.964	rs6734203	chr2:103080066	G/C	cg04239558	chr2:103089729	SLC9A4	0.47	6.16	0.35	2.64e-9	Blood protein levels;
CESC	cis	rs2841277	0.708	rs28454709	chr14:105405942	G/A	cg15352829	chr14:105391018	PLD4	-0.6	-10.51	-0.54	8.09e-22	Rheumatoid arthritis;
CESC	cis	rs3785574	0.962	rs2584630	chr17:61887561	T/A	cg06873352	chr17:61820015	STRADA	0.47	6.89	0.39	4.14e-11	Height;
CESC	cis	rs11997175	0.624	rs7016783	chr8:33696831	A/G	ch.8.33884649F	chr8:33765107	NA	0.57	7.52	0.42	8.28e-13	Body mass index;
CESC	cis	rs1062177	0.826	rs2915822	chr5:151130901	G/T	cg12924095	chr5:151150029	G3BP1	-0.44	-5.71	-0.33	3.05e-8	Preschool internalizing problems;
CESC	cis	rs9733	0.519	rs7529194	chr1:150622620	A/T	cg22823121	chr1:150693482	HORMAD1	0.44	6.59	0.38	2.31e-10	Tonsillectomy;
CESC	cis	rs9300255	0.568	rs1790102	chr12:123704890	G/A	cg19016782	chr12:123741754	C12orf65	-0.45	-6.55	-0.37	2.97e-10	Neutrophil percentage of white cells;
CESC	cis	rs13242816	1.000	rs34652384	chr7:116157011	T/C	cg04696780	chr7:116139425	CAV2	-0.61	-5.55	-0.32	7.01e-8	P wave duration;
CESC	cis	rs3093024	1.000	rs3093024	chr6:167532793	C/T	cg07741184	chr6:167504864	NA	0.32	5.51	0.32	8.65e-8	Rheumatoid arthritis;
CESC	cis	rs2836974	0.931	rs2776307	chr21:40713833	C/G	cg17971929	chr21:40555470	PSMG1	-0.92	-12.85	-0.62	1.08e-29	Cognitive function;
CESC	cis	rs7847628	0.587	rs4837796	chr9:123610288	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.84	-14.69	-0.67	3.82e-36	Birth weight;
CESC	trans	rs931812	0.757	rs35569317	chr8:101907971	T/C	cg20993868	chr7:22813445	NA	0.41	6.27	0.36	1.44e-9	Attention deficit hyperactivity disorder and conduct disorder;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg01151424	chr11:17411006	KCNJ11	-0.46	-6.41	-0.37	6.82e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs7851660	0.844	rs10123699	chr9:100637859	A/G	cg13688889	chr9:100608707	NA	-0.62	-8.66	-0.47	4.67e-16	Strep throat;
CESC	cis	rs1018836	0.828	rs756568	chr8:91557038	G/C	cg16814680	chr8:91681699	NA	-0.64	-9.32	-0.5	4.86e-18	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs17253792	0.822	rs75999534	chr14:56036413	A/T	cg01858014	chr14:56050164	KTN1	-0.94	-6.83	-0.39	5.75e-11	Putamen volume;
CESC	cis	rs10504229	0.683	rs6999984	chr8:58115079	G/A	cg21724239	chr8:58056113	NA	0.58	5.95	0.34	8.29e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs9818758	0.607	rs35060561	chr3:49255503	T/C	cg00383909	chr3:49044727	WDR6	0.79	6.01	0.35	5.98e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg03637622	chr5:179334771	TBC1D9B	0.46	6.19	0.36	2.28e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs1109430	0.661	rs77959785	chr1:209891813	G/A	cg02304930	chr1:210405566	SERTAD4;C1orf133	0.85	5.21	0.3	3.82e-7	Orofacial clefts;
CESC	cis	rs11792861	0.926	rs7855282	chr9:111802614	T/A	cg13535736	chr9:111863775	C9orf5	-0.49	-6.51	-0.37	3.85e-10	Menarche (age at onset);
CESC	cis	rs4268898	0.965	rs13033241	chr2:24476118	G/C	cg20701182	chr2:24300061	SF3B14	-0.41	-5.03	-0.3	9.04e-7	Asthma;
CESC	cis	rs1670533	0.932	rs4690347	chr4:1057328	A/G	cg04106633	chr4:1044584	NA	0.41	5.19	0.3	4.11e-7	Recombination rate (females);
CESC	cis	rs6582630	0.555	rs10785454	chr12:38476260	C/T	cg26384229	chr12:38710491	ALG10B	0.71	10.82	0.55	7.82e-23	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs561341	0.739	rs6505267	chr17:30225950	A/C	cg13647721	chr17:30228624	UTP6	0.8	9.74	0.51	2.41e-19	Hip circumference adjusted for BMI;
CESC	cis	rs4563143	0.514	rs73030738	chr19:29312328	G/A	cg04546413	chr19:29218101	NA	0.49	6.22	0.36	1.91e-9	Methadone dose in opioid dependence;
CESC	cis	rs9309473	0.950	rs6546854	chr2:73834034	A/G	cg20560298	chr2:73613845	ALMS1	-0.53	-6.97	-0.39	2.47e-11	Metabolite levels;
CESC	cis	rs7586879	0.639	rs6713978	chr2:25120851	T/C	cg01884057	chr2:25150051	NA	0.36	7.01	0.4	2.02e-11	Body mass index;
CESC	cis	rs8067354	0.645	rs2173119	chr17:57859705	C/T	cg13753209	chr17:57696993	CLTC	0.57	6.44	0.37	5.46e-10	Hemoglobin concentration;
CESC	cis	rs9911578	0.933	rs74370218	chr17:57095212	C/T	cg05425664	chr17:57184151	TRIM37	0.52	7.19	0.4	6.69e-12	Intelligence (multi-trait analysis);
CESC	cis	rs7208859	0.573	rs73277974	chr17:29189869	A/G	cg19761014	chr17:28927070	LRRC37B2	0.72	5.71	0.33	3.06e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	trans	rs61931739	0.500	rs11052994	chr12:34065843	C/T	cg26384229	chr12:38710491	ALG10B	0.6	8.38	0.46	3.12e-15	Morning vs. evening chronotype;
CESC	cis	rs727505	1.000	rs10241173	chr7:124453258	A/G	cg23710748	chr7:124431027	NA	-0.39	-6.4	-0.37	7.02e-10	Lewy body disease;
CESC	cis	rs3733585	0.605	rs4235355	chr4:10123078	C/A	cg02734326	chr4:10020555	SLC2A9	-0.37	-5.07	-0.3	7.36e-7	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs7980687	0.628	rs2851443	chr12:123694250	C/T	cg19016782	chr12:123741754	C12orf65	-0.34	-5.1	-0.3	6.4e-7	Height;Educational attainment;Head circumference (infant);
CESC	cis	rs1005277	0.541	rs1740741	chr10:38515334	C/T	cg00409905	chr10:38381863	ZNF37A	-0.52	-7.04	-0.4	1.69e-11	Extrinsic epigenetic age acceleration;
CESC	cis	rs1023500	0.551	rs61665536	chr22:42512613	A/G	cg04733989	chr22:42467013	NAGA	-0.78	-11.9	-0.59	1.87e-26	Schizophrenia;
CESC	cis	rs72772090	0.634	rs10515246	chr5:96099265	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.63	-5.8	-0.34	1.85e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs9443189	0.526	rs10943255	chr6:76225928	T/A	cg01950844	chr6:76311363	SENP6	0.89	9.14	0.49	1.73e-17	Prostate cancer;
CESC	cis	rs7586673	0.930	rs2884364	chr2:161977647	G/A	cg08807892	chr2:162101083	NA	0.46	6.27	0.36	1.48e-9	Intelligence (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03758523	chr6:151773469	C6orf211;RMND1	0.58	6.7	0.38	1.24e-10	Gut microbiome composition (summer);
CESC	cis	rs258892	0.947	rs266435	chr5:72174432	C/G	cg21869765	chr5:72125136	TNPO1	0.45	5.62	0.33	4.9e-8	Small cell lung carcinoma;
CESC	cis	rs2243480	1.000	rs1723270	chr7:65469830	T/G	cg25894440	chr7:65020034	NA	-0.66	-5.69	-0.33	3.42e-8	Diabetic kidney disease;
CESC	cis	rs1707322	1.000	rs10890350	chr1:46262378	G/A	cg05343316	chr1:45956843	TESK2	0.45	5.6	0.33	5.36e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16238933	chr4:668052	ATP5I	0.65	6.84	0.39	5.6e-11	Gut microbiome composition (summer);
CESC	cis	rs4975709	0.610	rs1531994	chr5:1859297	T/C	cg07747251	chr5:1868357	NA	0.33	5.47	0.32	1.05e-7	Cardiovascular disease risk factors;
CESC	cis	rs10751667	0.666	rs7395321	chr11:940280	C/T	cg20946044	chr11:1010712	AP2A2	-0.39	-5.44	-0.32	1.23e-7	Alzheimer's disease (late onset);
CESC	cis	rs909674	0.818	rs5757680	chr22:39844793	C/T	cg05872129	chr22:39784769	NA	0.72	9.25	0.49	7.7e-18	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs17345786	0.798	rs9817043	chr3:101281852	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.46	-5.99	-0.35	6.92e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9309711	0.666	rs6723126	chr2:3484500	T/C	cg15506890	chr2:3487001	NA	-0.48	-6.03	-0.35	5.51e-9	Neurofibrillary tangles;
CESC	cis	rs28374715	0.681	rs28728213	chr15:41653602	T/A	cg02330683	chr15:41787940	ITPKA	0.47	6.17	0.35	2.56e-9	Ulcerative colitis;
CESC	cis	rs6665290	0.870	rs1045289	chr1:227178713	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.23	-34.55	-0.9	3.8e-100	Myeloid white cell count;
CESC	cis	rs4535700	0.501	rs10245725	chr7:55976548	C/T	cg09872392	chr7:56161020	PHKG1	-0.37	-5.47	-0.32	1.02e-7	Macular telangiectasia type 2;
CESC	cis	rs4862750	0.914	rs1863405	chr4:187874528	G/T	cg22105103	chr4:187893119	NA	-0.47	-6.79	-0.38	7.32e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1538970	0.816	rs11211124	chr1:45962409	T/C	cg24296786	chr1:45957014	TESK2	-0.46	-5.15	-0.3	4.97e-7	Platelet count;
CESC	cis	rs6546550	0.901	rs7598283	chr2:70128717	A/G	cg02498382	chr2:70120550	SNRNP27	-0.38	-6.6	-0.38	2.17e-10	Prevalent atrial fibrillation;
CESC	cis	rs7020830	0.898	rs308521	chr9:37367094	T/C	cg14294708	chr9:37120828	ZCCHC7	1.01	16.33	0.71	5.67e-42	Schizophrenia;
CESC	trans	rs7615952	0.576	rs4646763	chr3:125822129	G/A	cg07211511	chr3:129823064	LOC729375	-0.57	-6.28	-0.36	1.38e-9	Blood pressure (smoking interaction);
CESC	trans	rs2643217	0.953	rs2643207	chr15:38999745	G/T	cg02017892	chr8:103550807	NA	-0.41	-6.01	-0.35	5.96e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs61990749	0.597	rs4903643	chr14:78254791	C/T	cg21497246	chr14:78225524	SNW1;C14orf178	-0.47	-5.09	-0.3	6.77e-7	Fibroblast growth factor basic levels;
CESC	cis	rs7618915	0.501	rs3755798	chr3:52741160	G/A	cg18337363	chr3:52569053	NT5DC2	0.28	5.15	0.3	5.08e-7	Bipolar disorder;
CESC	cis	rs1355223	0.902	rs1773910	chr11:34741253	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.48	-6.44	-0.37	5.45e-10	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs10256972	0.528	rs7784607	chr7:1178694	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.42	-5.56	-0.32	6.66e-8	Longevity;Endometriosis;
CESC	cis	rs72615157	0.613	rs56089143	chr7:99819844	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.52	5.81	0.34	1.75e-8	Lung function (FEV1/FVC);
CESC	cis	rs826838	1.000	rs860400	chr12:39081279	A/G	cg26384229	chr12:38710491	ALG10B	-0.62	-9.75	-0.51	2.14e-19	Heart rate;
CESC	cis	rs2228479	0.850	rs62056102	chr16:89941438	T/C	cg04013166	chr16:89971882	TCF25	0.75	6.39	0.37	7.38e-10	Skin colour saturation;
CESC	cis	rs11030122	0.702	rs11030276	chr11:3946134	A/G	cg18678763	chr11:4115507	RRM1	-0.45	-6.05	-0.35	4.94e-9	Mean platelet volume;Platelet distribution width;
CESC	cis	rs140364877	1	rs140364877	chr7:1885178	C/T	cg05863683	chr7:1912471	MAD1L1	0.35	5.12	0.3	5.76e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs939658	0.776	rs11631411	chr15:79445816	C/T	cg17916960	chr15:79447300	NA	-0.36	-5.94	-0.34	8.77e-9	Refractive error;
CESC	cis	rs4819052	0.885	rs28576202	chr21:46674684	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.77	10.14	0.53	1.23e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs4253772	0.550	rs6007830	chr22:46711323	C/T	cg24881330	chr22:46731750	TRMU	0.81	7.25	0.41	4.61e-12	LDL cholesterol;Cholesterol, total;
CESC	cis	rs752010	0.811	rs10749836	chr1:42086860	G/C	cg06885757	chr1:42089581	HIVEP3	0.46	7.58	0.42	5.74e-13	Lupus nephritis in systemic lupus erythematosus;
CESC	cis	rs57083693	0.518	rs10860710	chr12:101723467	A/G	cg22051763	chr12:101673672	UTP20	-0.45	-5.59	-0.32	5.71e-8	Alcohol dependence (age at onset);
CESC	cis	rs853679	0.517	rs4713141	chr6:28101678	G/C	cg08968635	chr6:28129556	ZNF389	0.42	5.77	0.33	2.15e-8	Depression;
CESC	cis	rs12464559	0.522	rs13016166	chr2:152624144	G/A	cg01189475	chr2:152685088	ARL5A	0.72	7.26	0.41	4.26e-12	Response to cognitive-behavioural therapy in anxiety disorder;
CESC	cis	rs61996546	0.622	rs12900771	chr15:26835235	G/A	cg14859324	chr15:26874363	GABRB3	-0.38	-5.12	-0.3	6e-7	Response to methotrexate in juvenile idiopathic arthritis;
CESC	cis	rs854765	0.663	rs3744115	chr17:17749822	G/A	cg16928487	chr17:17741425	SREBF1	0.59	10.3	0.53	3.77e-21	Total body bone mineral density;
CESC	cis	rs35110281	0.720	rs230647	chr21:44919654	C/T	cg21573476	chr21:45109991	RRP1B	0.45	5.87	0.34	1.27e-8	Mean corpuscular volume;
CESC	cis	rs61776719	0.875	rs10890238	chr1:38445654	A/T	cg04673462	chr1:38461896	NA	0.43	6.63	0.38	1.84e-10	Coronary artery disease;
CESC	cis	rs3857067	0.967	rs1355240	chr4:95019353	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.52	-8.04	-0.44	3.05e-14	QT interval;
CESC	cis	rs7917772	0.582	rs10786695	chr10:104368756	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.4	5.51	0.32	8.5e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs6460942	0.908	rs6956500	chr7:12232120	T/C	cg20607287	chr7:12443886	VWDE	-0.47	-5.06	-0.3	7.96e-7	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04393675	chr16:28986095	SPNS1	0.55	6.32	0.36	1.12e-9	Gut microbiome composition (summer);
CESC	cis	rs77216612	1.000	rs77216612	chr12:12877983	A/G	cg24098013	chr12:12878779	APOLD1	0.57	6.87	0.39	4.45e-11	Lymphocyte counts;
CESC	cis	rs6460942	1.000	rs2053378	chr7:12405564	C/G	cg06484146	chr7:12443880	VWDE	-0.79	-8.75	-0.47	2.47e-16	Coronary artery disease;
CESC	cis	rs2952156	0.684	rs1877031	chr17:37814080	G/A	cg07936489	chr17:37558343	FBXL20	-0.6	-7.82	-0.43	1.27e-13	Asthma;
CESC	cis	rs7542091	0.704	rs4133950	chr1:210044393	C/G	cg21951975	chr1:209979733	IRF6	0.46	8.11	0.45	1.88e-14	Monobrow;
CESC	cis	rs10927875	0.541	rs1763601	chr1:16340460	G/T	cg22431228	chr1:16359049	CLCNKA	-0.52	-9.96	-0.52	4.74e-20	Dilated cardiomyopathy;
CESC	cis	rs9790314	0.967	rs6762645	chr3:160948349	T/G	cg03342759	chr3:160939853	NMD3	-0.49	-6.41	-0.37	6.65e-10	Morning vs. evening chronotype;
CESC	cis	rs4665809	0.590	rs1049987	chr2:26413817	C/T	cg26314531	chr2:26401878	FAM59B	0.84	9.2	0.49	1.13e-17	Gut microbiome composition (summer);
CESC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg13789711	chr9:139743225	PHPT1	-0.54	-6.19	-0.36	2.33e-9	Lung cancer in ever smokers;
CESC	cis	rs12824058	0.831	rs12314111	chr12:130813663	G/T	cg26677194	chr12:130822605	PIWIL1	0.52	6.86	0.39	4.77e-11	Menopause (age at onset);
CESC	cis	rs4835473	0.897	rs6537171	chr4:144630375	G/A	cg25736465	chr4:144833511	NA	0.4	6.17	0.35	2.59e-9	Immature fraction of reticulocytes;
CESC	cis	rs6754311	0.731	rs12615624	chr2:136721603	A/G	cg07169764	chr2:136633963	MCM6	0.71	9.02	0.48	3.89e-17	Mosquito bite size;
CESC	cis	rs10752881	1.000	rs10797813	chr1:182989366	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.84	13.31	0.63	2.66e-31	Colorectal cancer;
CESC	cis	rs1448094	0.512	rs6539931	chr12:86247473	C/T	cg00310523	chr12:86230176	RASSF9	0.35	5.46	0.32	1.1e-7	Major depressive disorder;
CESC	cis	rs72634258	0.554	rs12092614	chr1:7865710	C/T	cg26816564	chr1:7831052	VAMP3	0.64	5.96	0.34	7.92e-9	Inflammatory bowel disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06812651	chr1:234746099	IRF2BP2	0.59	6.33	0.36	1.04e-9	Gut microbiome composition (summer);
CESC	cis	rs1799949	1.000	rs11654452	chr17:41189383	G/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.4	5.15	0.3	4.99e-7	Menopause (age at onset);
CESC	cis	rs1538970	0.847	rs1771550	chr1:45883565	C/T	cg05343316	chr1:45956843	TESK2	-0.8	-11.39	-0.57	9.77e-25	Platelet count;
CESC	cis	rs2120019	0.938	rs35911108	chr15:75322179	G/A	cg17294928	chr15:75287854	SCAMP5	-0.76	-8.79	-0.48	1.96e-16	Blood trace element (Zn levels);
CESC	cis	rs9467711	0.606	rs12176317	chr6:26372786	A/G	cg12826209	chr6:26865740	GUSBL1	0.62	5.24	0.31	3.25e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs17711722	0.503	rs453835	chr7:65511159	T/A	cg06456125	chr7:65229604	NA	-0.41	-5.4	-0.32	1.45e-7	Calcium levels;
CESC	cis	rs2573652	1.000	rs2581345	chr15:100514291	A/G	cg00587665	chr15:100533223	ADAMTS17	-0.34	-5.53	-0.32	7.65e-8	Height;
CESC	trans	rs2075371	0.932	rs1862048	chr7:133978167	C/G	cg08692210	chr3:52188851	WDR51A	0.54	6.5	0.37	3.9e-10	Mean platelet volume;
CESC	cis	rs875971	0.862	rs4718377	chr7:66049678	C/T	cg12463550	chr7:65579703	CRCP	-0.5	-6.34	-0.36	9.71e-10	Aortic root size;
CESC	cis	rs7584330	0.740	rs11896232	chr2:238438124	T/C	cg06639874	chr2:238417703	MLPH	-0.37	-5.32	-0.31	2.2e-7	Prostate cancer;
CESC	cis	rs4911259	0.552	rs13041458	chr20:31467376	G/T	cg13636640	chr20:31349939	DNMT3B	-0.54	-7.44	-0.42	1.45e-12	Inflammatory bowel disease;
CESC	cis	rs2295499	0.754	rs4690052	chr4:2736567	C/T	cg08330972	chr4:2403930	ZFYVE28	-0.33	-5.21	-0.3	3.89e-7	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
CESC	cis	rs853679	0.513	rs13437444	chr6:28070998	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.56	-5.43	-0.32	1.29e-7	Depression;
CESC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg21735491	chr11:66749665	NA	-0.54	-6.2	-0.36	2.2e-9	Lung cancer in ever smokers;
CESC	cis	rs2404602	0.684	rs4886816	chr15:76874707	A/C	cg23625390	chr15:77176239	SCAPER	-0.43	-5.81	-0.34	1.76e-8	Blood metabolite levels;
CESC	cis	rs644799	1.000	rs474442	chr11:95583995	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.56	6.93	0.39	3.11e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs10504229	0.679	rs56040464	chr8:58131603	G/A	cg21724239	chr8:58056113	NA	0.58	5.95	0.34	8.29e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs2404602	0.716	rs67204011	chr15:76846555	C/T	cg22467129	chr15:76604101	ETFA	-0.36	-5.35	-0.31	1.92e-7	Blood metabolite levels;
CESC	cis	rs9359856	0.673	rs2039053	chr6:90303760	G/A	cg13799429	chr6:90582589	CASP8AP2	0.48	5.31	0.31	2.33e-7	Bipolar disorder;
CESC	cis	rs9581857	0.547	rs76971629	chr13:28051031	C/T	cg01674679	chr13:27998804	GTF3A	-0.67	-5.33	-0.31	2.07e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
CESC	cis	rs1862618	0.529	rs978406	chr5:56259808	A/T	cg12311346	chr5:56204834	C5orf35	0.75	9.33	0.5	4.51e-18	Initial pursuit acceleration;
CESC	cis	rs853679	0.517	rs4713135	chr6:28039586	G/A	cg17949981	chr6:28129498	ZNF389	0.45	5.48	0.32	9.77e-8	Depression;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg15039414	chr2:43454687	ZFP36L2;LOC100129726	0.45	6.02	0.35	5.88e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs561341	0.769	rs7217004	chr17:30178092	A/G	cg00745463	chr17:30367425	LRRC37B	0.66	5.96	0.34	7.84e-9	Hip circumference adjusted for BMI;
CESC	cis	rs9457247	1.000	rs398278	chr6:167388169	A/G	cg07741184	chr6:167504864	NA	0.32	5.59	0.32	5.74e-8	Crohn's disease;
CESC	cis	rs2797160	1.000	rs2747719	chr6:126009214	C/T	cg05901451	chr6:126070800	HEY2	0.45	6.59	0.38	2.39e-10	Endometrial cancer;
CESC	cis	rs7786808	0.741	rs11765319	chr7:158226790	A/G	cg09998033	chr7:158218633	PTPRN2	-0.36	-5.45	-0.32	1.15e-7	Obesity-related traits;
CESC	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg24642844	chr7:1081250	C7orf50	-0.75	-9.03	-0.49	3.61e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs1559088	1.000	rs8106453	chr19:33557412	C/T	cg17764715	chr19:33622953	WDR88	0.45	5.63	0.33	4.66e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	trans	rs1814175	0.645	rs11040535	chr11:49808669	C/T	cg15704280	chr7:45808275	SEPT13	-0.96	-16.96	-0.72	3.4e-44	Height;
CESC	cis	rs7786877	0.680	rs28584500	chr7:100216341	G/A	cg20848291	chr7:100343083	ZAN	-0.64	-6.73	-0.38	1.02e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs769267	0.930	rs7254748	chr19:19397479	A/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	7.33	0.41	2.7e-12	Tonsillectomy;
CESC	cis	rs2836950	0.501	rs4818018	chr21:40694072	C/T	cg11890956	chr21:40555474	PSMG1	-0.65	-8.96	-0.48	5.97e-17	Menarche (age at onset);
CESC	cis	rs7666738	0.791	rs2865953	chr4:99040319	C/T	cg18180107	chr4:99064573	C4orf37	0.41	5.34	0.31	2.03e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2302190	0.882	rs11650710	chr17:56583547	C/T	cg25885038	chr17:56607967	SEPT4	-0.4	-5.47	-0.32	1.02e-7	Vitamin D levels;
CESC	cis	rs4466137	0.868	rs6866067	chr5:83022369	A/G	cg16102102	chr5:83017553	HAPLN1	-0.51	-7.22	-0.41	5.5e-12	Prostate cancer;
CESC	cis	rs7552404	1.000	rs1498316	chr1:76159198	G/A	cg03433033	chr1:76189801	ACADM	0.65	7.67	0.43	3.3e-13	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs4692589	0.606	rs13127322	chr4:170935169	C/T	cg19918862	chr4:170955249	NA	0.43	5.69	0.33	3.37e-8	Anxiety disorder;
CESC	cis	rs10504073	0.584	rs11786103	chr8:49904077	A/G	cg00325661	chr8:49890786	NA	0.53	8.09	0.45	2.12e-14	Blood metabolite ratios;
CESC	cis	rs478304	0.651	rs4930313	chr11:65500428	C/T	cg10518572	chr11:65560635	OVOL1	-0.33	-6.61	-0.38	2.09e-10	Acne (severe);
CESC	cis	rs11122272	0.735	rs2474634	chr1:231487017	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.51	-7.0	-0.39	2.15e-11	Hemoglobin concentration;
CESC	cis	rs9815354	0.767	rs17281182	chr3:41817263	C/T	cg03022575	chr3:42003672	ULK4	0.7	6.19	0.36	2.3e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs9916302	0.904	rs4357971	chr17:37717280	C/T	cg07936489	chr17:37558343	FBXL20	-0.81	-11.66	-0.58	1.24e-25	Glomerular filtration rate (creatinine);
CESC	cis	rs7777484	0.534	rs2533890	chr7:2828743	C/T	cg19717773	chr7:2847554	GNA12	-0.69	-11.69	-0.58	1.01e-25	Height;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg21047528	chr22:42915898	RRP7A	-0.53	-6.68	-0.38	1.42e-10	Asthma;
CESC	cis	rs12136530	0.774	rs10799810	chr1:19764032	G/A	cg01832549	chr1:19774989	CAPZB	-0.46	-6.42	-0.37	6.2e-10	Lead levels in blood;
CESC	cis	rs4253772	0.638	rs6007845	chr22:46718417	A/T	cg07012999	chr22:46692446	CN5H6.4;GTSE1	-0.47	-5.07	-0.3	7.63e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs863345	0.967	rs17630699	chr1:158463086	C/T	cg12129480	chr1:158549410	OR10X1	0.31	6.12	0.35	3.37e-9	Pneumococcal bacteremia;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg22335246	chr12:120763591	PLA2G1B	-0.48	-6.57	-0.37	2.69e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs2302190	0.882	rs3744111	chr17:56607959	G/A	cg25885038	chr17:56607967	SEPT4	-0.41	-5.61	-0.33	5.13e-8	Vitamin D levels;
CESC	cis	rs524281	0.773	rs2236652	chr11:66002681	G/A	cg14036092	chr11:66035641	RAB1B	-0.53	-5.31	-0.31	2.38e-7	Electroencephalogram traits;
CESC	cis	rs6500395	1.000	rs9938633	chr16:48682093	G/C	cg04672837	chr16:48644449	N4BP1	0.51	6.36	0.36	8.64e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs1371867	0.846	rs2439458	chr8:101297984	T/C	cg11906718	chr8:101322791	RNF19A	0.46	5.91	0.34	1.03e-8	Atrioventricular conduction;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10825850	chr5:176944593	DDX41	-0.63	-7.57	-0.42	6.17e-13	Gut microbiome composition (summer);
CESC	cis	rs4819052	0.851	rs2255774	chr21:46683851	A/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.56	7.66	0.43	3.41e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs7666738	0.716	rs11721453	chr4:99045485	G/T	cg03676636	chr4:99064102	C4orf37	0.33	5.12	0.3	5.93e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs12995491	0.763	rs1914735	chr2:88511953	A/T	cg04169830	chr2:88471460	THNSL2	0.35	5.38	0.31	1.65e-7	Response to metformin (IC50);
CESC	cis	rs6540556	0.723	rs6672256	chr1:209894043	A/T	cg05527609	chr1:210001259	C1orf107	0.55	5.86	0.34	1.34e-8	Red blood cell count;
CESC	cis	rs875971	0.965	rs697968	chr7:65535033	G/A	cg11764359	chr7:65958608	NA	-0.95	-14.12	-0.66	3.94e-34	Aortic root size;
CESC	cis	rs4481887	0.927	rs4578248	chr1:248434069	G/A	cg00666640	chr1:248458726	OR2T12	0.38	6.38	0.37	7.73e-10	Common traits (Other);
CESC	cis	rs7618501	0.633	rs2526751	chr3:50064867	T/C	cg24308560	chr3:49941425	MST1R	0.61	8.92	0.48	8e-17	Intelligence (multi-trait analysis);
CESC	cis	rs910316	0.967	rs4903292	chr14:75656245	A/G	cg08847533	chr14:75593920	NEK9	0.93	17.1	0.72	1.07e-44	Height;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg11674844	chr1:27216367	GPN2	-0.49	-6.2	-0.36	2.21e-9	Asthma;
CESC	cis	rs62408225	1.000	rs2089126	chr6:90970212	A/G	cg06866423	chr6:90926672	BACH2	0.43	5.13	0.3	5.61e-7	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	trans	rs3008870	0.583	rs2147838	chr1:67399466	T/C	cg19754094	chr2:74055942	STAMBP	0.62	6.0	0.35	6.49e-9	Lymphocyte percentage of white cells;
CESC	cis	rs36051895	0.632	rs12340617	chr9:5164492	G/C	cg02405213	chr9:5042618	JAK2	-0.54	-6.42	-0.37	6.43e-10	Pediatric autoimmune diseases;
CESC	trans	rs35160687	0.644	rs10204589	chr2:86493223	A/G	ch.2.2367852R	chr2:113497768	CKAP2L	-0.48	-6.1	-0.35	3.7e-9	Night sleep phenotypes;
CESC	cis	rs782590	0.935	rs62165197	chr2:55801812	C/T	cg18811423	chr2:55921094	PNPT1	0.8	12.91	0.62	6.32e-30	Metabolic syndrome;
CESC	cis	rs6973256	0.605	rs6467499	chr7:133348922	G/T	cg10665199	chr7:133106180	EXOC4	-0.43	-5.84	-0.34	1.52e-8	Intelligence (multi-trait analysis);
CESC	cis	rs208520	1.000	rs12199876	chr6:66989469	A/G	cg07460842	chr6:66804631	NA	0.89	10.18	0.53	9.11e-21	Exhaled nitric oxide output;
CESC	cis	rs2012796	0.957	rs8011477	chr14:81815587	C/T	cg02996355	chr14:81879375	NA	0.49	5.75	0.33	2.51e-8	Night sleep phenotypes;
CESC	cis	rs6088590	1.000	rs6087626	chr20:33347328	C/T	cg06115741	chr20:33292138	TP53INP2	0.59	7.32	0.41	2.95e-12	Coronary artery disease;
CESC	cis	rs270601	0.770	rs4361510	chr5:131599647	C/T	cg18758796	chr5:131593413	PDLIM4	0.48	6.97	0.39	2.55e-11	Acylcarnitine levels;
CESC	cis	rs992157	0.735	rs12990082	chr2:219102332	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.69	9.55	0.51	8.88e-19	Colorectal cancer;
CESC	cis	rs6793245	0.810	rs7429945	chr3:38591689	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.45	-5.91	-0.34	1.03e-8	QT interval;
CESC	cis	rs2625529	0.938	rs2723343	chr15:72108269	C/T	cg16672083	chr15:72433130	SENP8	-0.48	-5.68	-0.33	3.52e-8	Red blood cell count;
CESC	cis	rs3858526	0.920	rs10742832	chr11:5926020	C/G	cg05234568	chr11:5960015	NA	-0.55	-6.41	-0.37	6.48e-10	DNA methylation (variation);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg26339992	chr1:28241106	RPA2	-0.47	-6.04	-0.35	5.3e-9	Fibrinogen levels;
CESC	cis	rs6137287	0.668	rs6047258	chr20:21098277	A/C	cg13880779	chr20:21376337	NKX2-4	0.35	5.57	0.32	6.31e-8	Height;
CESC	cis	rs4665809	0.941	rs11126336	chr2:26245931	C/T	cg04944784	chr2:26401820	FAM59B	-0.65	-7.18	-0.4	6.92e-12	Gut microbiome composition (summer);
CESC	cis	rs12477438	0.520	rs6743355	chr2:99732360	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.86	15.87	0.7	2.48e-40	Chronic sinus infection;
CESC	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	7.52	0.42	8.3e-13	Prudent dietary pattern;
CESC	cis	rs7959452	0.590	rs56054057	chr12:69775972	C/T	cg20891283	chr12:69753455	YEATS4	0.9	14.99	0.68	3.32e-37	Blood protein levels;
CESC	trans	rs11039798	1.000	rs7125913	chr11:48984318	G/A	cg15704280	chr7:45808275	SEPT13	0.71	6.65	0.38	1.7e-10	Axial length;
CESC	cis	rs9733	0.519	rs12095002	chr1:150649249	G/A	cg18016565	chr1:150552671	MCL1	0.33	5.14	0.3	5.34e-7	Tonsillectomy;
CESC	cis	rs1569175	0.655	rs3115414	chr2:200913244	A/C	cg19045956	chr2:200819837	C2orf60;C2orf47	0.64	5.41	0.32	1.44e-7	Response to treatment for acute lymphoblastic leukemia;
CESC	cis	rs7412746	0.611	rs10888394	chr1:150749913	C/T	cg17724175	chr1:150552817	MCL1	0.42	6.34	0.36	1e-9	Melanoma;
CESC	cis	rs17253792	0.915	rs75862063	chr14:56177769	G/T	cg01858014	chr14:56050164	KTN1	-0.94	-7.27	-0.41	4.03e-12	Putamen volume;
CESC	cis	rs1008375	1.000	rs1860596	chr4:17660082	C/T	cg15017067	chr4:17643749	FAM184B	0.37	5.18	0.3	4.34e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs798766	0.953	rs13123646	chr4:1740539	T/C	cg05874882	chr4:1763078	NA	-0.58	-8.03	-0.44	3.23e-14	Bladder cancer;Urinary bladder cancer;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg14121103	chr3:43731973	ABHD5	0.5	7.41	0.41	1.69e-12	Systemic lupus erythematosus;
CESC	trans	rs8029989	0.869	rs8039162	chr15:38740829	A/G	cg05218311	chr11:79151791	ODZ4	0.37	6.12	0.35	3.3e-9	Psychosis (atypical);
CESC	cis	rs16917546	1.000	rs10995258	chr10:64408787	C/T	cg03961010	chr10:64397487	ZNF365	-0.37	-6.11	-0.35	3.55e-9	Basal cell carcinoma;
CESC	cis	rs2180341	1.000	rs6937287	chr6:127645719	T/A	cg24812749	chr6:127587940	RNF146	1.07	15.4	0.69	1.16e-38	Breast cancer;
CESC	cis	rs6493487	0.512	rs71471523	chr15:51197324	G/A	cg02338191	chr15:51200825	AP4E1	0.6	5.58	0.32	5.79e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs7208859	0.623	rs56095789	chr17:29060170	A/G	cg14008862	chr17:28927542	LRRC37B2	0.65	5.12	0.3	5.86e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs477895	0.653	rs11603212	chr11:63927810	C/T	cg04317338	chr11:64019027	PLCB3	-0.79	-7.5	-0.42	9.5e-13	Mean platelet volume;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg00745463	chr17:30367425	LRRC37B	0.45	6.04	0.35	5.14e-9	Fibrinogen levels;
CESC	cis	rs8044868	0.586	rs7200854	chr16:72083318	G/A	cg01557791	chr16:72042693	DHODH	-0.43	-5.89	-0.34	1.17e-8	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CESC	cis	rs7662987	0.517	rs2924580	chr4:100032168	C/G	cg12011299	chr4:100065546	ADH4	0.62	6.95	0.39	2.9e-11	Smoking initiation;
CESC	cis	rs1401999	0.628	rs1520195	chr3:183736882	G/A	cg01324343	chr3:183735012	ABCC5	0.55	10.8	0.55	8.98e-23	Anterior chamber depth;
CESC	cis	rs10465746	0.725	rs6694752	chr1:84389960	C/T	cg10977910	chr1:84465055	TTLL7	0.55	7.46	0.42	1.24e-12	Obesity-related traits;
CESC	cis	rs2243480	1.000	rs778691	chr7:65873092	G/C	cg18252515	chr7:66147081	NA	-1.39	-14.18	-0.66	2.5e-34	Diabetic kidney disease;
CESC	cis	rs798554	0.836	rs798502	chr7:2789880	G/T	cg19717773	chr7:2847554	GNA12	0.56	8.15	0.45	1.43e-14	Height;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19777992	chr5:52856773	NDUFS4	-0.56	-6.23	-0.36	1.84e-9	Gut microbiome composition (summer);
CESC	cis	rs2996428	0.667	rs7511793	chr1:3744249	A/G	cg13057898	chr1:3703894	LRRC47	0.45	6.19	0.36	2.29e-9	Red cell distribution width;
CESC	cis	rs11683229	0.704	rs17850223	chr2:63283178	C/G	cg17519650	chr2:63277830	OTX1	-0.73	-5.73	-0.33	2.71e-8	Protein quantitative trait loci;
CESC	cis	rs9291683	0.530	rs882223	chr4:9981625	A/C	cg11266682	chr4:10021025	SLC2A9	0.62	12.69	0.61	3.76e-29	Bone mineral density;
CESC	cis	rs28647808	0.881	rs41316982	chr9:136259117	C/T	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.85	5.74	0.33	2.59e-8	Blood protein levels;
CESC	cis	rs898097	0.528	rs2243523	chr17:80680449	G/T	cg15369054	chr17:80825471	TBCD	0.38	5.52	0.32	8.04e-8	Breast cancer;
CESC	cis	rs9486719	1.000	rs2179126	chr6:96871350	A/G	cg18709589	chr6:96969512	KIAA0776	0.53	5.81	0.34	1.75e-8	Migraine;Coronary artery disease;
CESC	cis	rs2370759	0.891	rs76164690	chr10:32590362	T/G	cg18270830	chr10:32634957	EPC1	0.66	5.72	0.33	2.86e-8	Sexual dysfunction (female);
CESC	cis	rs1355223	0.506	rs7130678	chr11:34869181	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.62	-8.06	-0.44	2.71e-14	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs897984	0.721	rs4889525	chr16:30989858	T/C	cg00531865	chr16:30841666	NA	0.5	6.85	0.39	5.2e-11	Dementia with Lewy bodies;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg25536300	chr19:797459	PTBP1	-0.47	-6.15	-0.35	2.82e-9	Ulcerative colitis;
CESC	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg16132339	chr22:24313637	DDTL;DDT	0.38	5.72	0.33	2.83e-8	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs7618915	0.547	rs10780035	chr3:52764624	C/T	cg05564831	chr3:52568323	NT5DC2	0.44	6.69	0.38	1.33e-10	Bipolar disorder;
CESC	cis	rs875971	0.522	rs6960048	chr7:65408039	A/G	cg11987759	chr7:65425863	GUSB	-0.48	-6.55	-0.37	3.04e-10	Aortic root size;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg13134662	chr9:136858680	VAV2	-0.44	-6.48	-0.37	4.55e-10	Gambling;
CESC	cis	rs832540	0.593	rs96844	chr5:56196604	G/A	cg12311346	chr5:56204834	C5orf35	-0.45	-5.59	-0.32	5.61e-8	Coronary artery disease;
CESC	cis	rs113835537	0.529	rs12099041	chr11:66232773	C/T	cg24851651	chr11:66362959	CCS	0.46	5.68	0.33	3.57e-8	Airway imaging phenotypes;
CESC	cis	rs1348850	0.914	rs7565022	chr2:178320222	A/T	cg23306229	chr2:178417860	TTC30B	0.6	7.69	0.43	2.98e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs8077889	0.750	rs231539	chr17:41942109	T/C	cg26893861	chr17:41843967	DUSP3	-0.82	-7.92	-0.44	6.7e-14	Triglycerides;
CESC	cis	rs7927771	0.931	rs4752801	chr11:47907641	A/G	cg05585544	chr11:47624801	NA	-0.42	-6.79	-0.38	7.41e-11	Subjective well-being;
CESC	cis	rs4450798	0.793	rs28541501	chr3:13757636	G/T	cg05589046	chr3:13742034	LOC285375	0.36	5.63	0.33	4.69e-8	Bipolar disorder with mood-incongruent psychosis;
CESC	cis	rs6570726	0.846	rs6919684	chr6:145883801	A/G	cg05347473	chr6:146136440	FBXO30	0.51	6.63	0.38	1.82e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg26304593	chr6:42947056	PEX6	-0.42	-5.39	-0.31	1.56e-7	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs7131987	0.903	rs7970390	chr12:29398655	A/G	cg09582351	chr12:29534625	ERGIC2	-0.34	-5.39	-0.31	1.57e-7	QT interval;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00900124	chr2:69969033	ANXA4	0.53	6.21	0.36	1.99e-9	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.791	rs6851549	chr4:99029827	G/A	cg03676636	chr4:99064102	C4orf37	0.34	5.2	0.3	4.06e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2243480	1.000	rs73142162	chr7:65374296	A/T	cg13147721	chr7:65941812	NA	-0.88	-8.15	-0.45	1.5e-14	Diabetic kidney disease;
CESC	cis	rs7631605	0.905	rs11717310	chr3:37175150	C/T	cg22985146	chr3:37219077	LRRFIP2	-0.32	-5.2	-0.3	3.92e-7	Cerebrospinal P-tau181p levels;
CESC	cis	rs2228479	0.850	rs2190808	chr16:89840856	C/T	cg14709524	chr16:89940631	TCF25	0.91	6.74	0.38	1e-10	Skin colour saturation;
CESC	cis	rs7666738	1.000	rs13124102	chr4:98990696	G/A	cg03676636	chr4:99064102	C4orf37	0.34	5.07	0.3	7.65e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6060717	0.610	rs2244883	chr20:34620896	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.49	6.26	0.36	1.54e-9	Hip circumference adjusted for BMI;
CESC	cis	rs8020095	0.528	rs13379476	chr14:67411733	T/C	cg19548862	chr14:67692701	FAM71D	-0.48	-5.86	-0.34	1.4e-8	Depression (quantitative trait);
CESC	cis	rs533123	0.701	rs204054	chr1:29160462	T/C	cg08366446	chr1:29138936	OPRD1	0.54	5.54	0.32	7.4e-8	Schizophrenia;
CESC	cis	rs4595586	0.563	rs11169769	chr12:39233134	C/G	cg26384229	chr12:38710491	ALG10B	0.68	10.21	0.53	7.67e-21	Morning vs. evening chronotype;
CESC	cis	rs9311474	0.967	rs11717383	chr3:52287468	G/T	cg07507251	chr3:52567010	NT5DC2	0.32	5.78	0.33	2.15e-8	Electroencephalogram traits;
CESC	cis	rs35146811	0.586	rs12705067	chr7:99594726	T/C	cg22906224	chr7:99728672	NA	0.44	5.22	0.31	3.59e-7	Coronary artery disease;
CESC	cis	rs4722166	0.573	rs35436671	chr7:22775508	G/A	cg05265849	chr7:22767390	IL6	0.57	7.02	0.4	1.84e-11	Lung cancer;
CESC	cis	rs116095464	0.681	rs9687745	chr5:229309	C/T	cg10591111	chr5:226296	SDHA	-0.54	-6.75	-0.38	9.52e-11	Breast cancer;
CESC	cis	rs1832871	0.711	rs9459829	chr6:158680799	C/T	cg07165851	chr6:158734300	TULP4	0.59	6.36	0.36	8.84e-10	Height;
CESC	cis	rs780096	0.506	rs1647285	chr2:27714511	A/C	cg02592271	chr2:27665507	KRTCAP3	-0.28	-5.73	-0.33	2.78e-8	Total body bone mineral density;
CESC	cis	rs17253792	0.732	rs10146604	chr14:56045770	C/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.81	5.95	0.34	8.68e-9	Putamen volume;
CESC	cis	rs67311347	1.000	rs9817142	chr3:40425774	C/A	cg24209194	chr3:40518798	ZNF619	0.49	6.15	0.35	2.83e-9	Renal cell carcinoma;
CESC	cis	rs4728302	0.869	rs958404	chr7:133597186	G/T	cg10665199	chr7:133106180	EXOC4	-0.45	-6.22	-0.36	1.88e-9	Intelligence;Intelligence (multi-trait analysis);
CESC	cis	rs4843747	0.605	rs28399183	chr16:88107277	G/A	cg06374794	chr16:88002281	BANP	0.39	5.14	0.3	5.43e-7	Menopause (age at onset);
CESC	trans	rs61931739	0.929	rs1844524	chr12:34094709	A/T	cg26384229	chr12:38710491	ALG10B	-0.47	-6.61	-0.38	2.07e-10	Morning vs. evening chronotype;
CESC	cis	rs1552244	1.000	rs67006488	chr3:10152993	T/C	cg08888203	chr3:10149979	C3orf24	0.48	6.24	0.36	1.72e-9	Alzheimer's disease;
CESC	cis	rs36051895	0.632	rs57698263	chr9:5143262	G/A	cg02405213	chr9:5042618	JAK2	-0.5	-6.28	-0.36	1.39e-9	Pediatric autoimmune diseases;
CESC	cis	rs11098499	0.865	rs28845498	chr4:120405186	G/A	cg09307838	chr4:120376055	NA	0.93	13.07	0.63	1.78e-30	Corneal astigmatism;
CESC	cis	rs1799949	1.000	rs12944458	chr17:41180772	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	8.22	0.45	9.28e-15	Menopause (age at onset);
CESC	cis	rs1927790	0.727	rs9556551	chr13:96947223	T/A	cg02571835	chr13:96230311	CLDN10	-0.36	-5.35	-0.31	1.88e-7	Body mass index;
CESC	cis	rs2732480	0.577	rs2634680	chr12:48734564	T/C	cg04545296	chr12:48745243	ZNF641	0.43	7.15	0.4	8.63e-12	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs7923609	0.967	rs7915779	chr10:65244244	G/C	cg01631684	chr10:65280961	REEP3	-0.43	-5.4	-0.31	1.47e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs67311347	1.000	rs7636719	chr3:40432084	C/T	cg01475735	chr3:40494733	NA	-0.41	-5.22	-0.31	3.64e-7	Renal cell carcinoma;
CESC	cis	rs4654899	0.758	rs6693055	chr1:21421813	C/T	cg05370193	chr1:21551575	ECE1	0.36	5.47	0.32	1.02e-7	Superior frontal gyrus grey matter volume;
CESC	cis	rs9611519	0.894	rs13053242	chr22:41459486	G/A	cg03806693	chr22:41940476	POLR3H	-0.57	-5.96	-0.34	7.83e-9	Neuroticism;
CESC	cis	rs7845219	0.539	rs713113	chr8:95877787	C/T	cg16049864	chr8:95962084	TP53INP1	0.52	7.88	0.44	8.64e-14	Type 2 diabetes;
CESC	cis	rs67311347	1.000	rs7642552	chr3:40424816	T/C	cg24209194	chr3:40518798	ZNF619	0.51	6.64	0.38	1.74e-10	Renal cell carcinoma;
CESC	cis	rs1443512	0.812	rs4759058	chr12:54339052	C/A	cg17410650	chr12:54324560	NA	-0.47	-7.79	-0.43	1.54e-13	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
CESC	cis	rs4803468	0.905	rs284662	chr19:41932275	T/C	cg08639244	chr19:41945921	ATP5SL	-0.47	-5.66	-0.33	3.84e-8	Height;
CESC	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg18402987	chr7:1209562	NA	0.46	6.11	0.35	3.57e-9	Longevity;Endometriosis;
CESC	cis	rs7296418	0.636	rs11057261	chr12:123797567	T/C	cg05973401	chr12:123451056	ABCB9	0.43	5.46	0.32	1.07e-7	Platelet count;
CESC	cis	rs2985684	0.948	rs12886130	chr14:50082753	T/C	cg10008539	chr14:50087325	RPL36AL;MGAT2	-0.48	-5.7	-0.33	3.12e-8	Carotid intima media thickness;
CESC	cis	rs7264396	0.563	rs6060592	chr20:34352414	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.86	-10.2	-0.53	7.89e-21	Total cholesterol levels;
CESC	cis	rs6860806	0.507	rs2631364	chr5:131706914	C/G	cg04518342	chr5:131593106	PDLIM4	-0.36	-5.27	-0.31	2.88e-7	Breast cancer;
CESC	cis	rs17401966	0.838	rs4623	chr1:10366692	C/G	cg15208524	chr1:10270712	KIF1B	0.43	5.5	0.32	8.98e-8	Hepatocellular carcinoma;
CESC	cis	rs2204008	0.805	rs4882575	chr12:37940573	G/A	cg26384229	chr12:38710491	ALG10B	-0.53	-7.52	-0.42	8.68e-13	Bladder cancer;
CESC	cis	rs896854	0.608	rs6991067	chr8:95875676	A/G	cg16049864	chr8:95962084	TP53INP1	-0.59	-9.94	-0.52	5.23e-20	Type 2 diabetes;
CESC	cis	rs3820928	0.605	rs6718767	chr2:227800776	A/G	cg11843606	chr2:227700838	RHBDD1	-0.56	-7.96	-0.44	4.9e-14	Pulmonary function;
CESC	cis	rs1595825	0.891	rs16823148	chr2:198584209	G/A	cg00982548	chr2:198649783	BOLL	-0.52	-5.71	-0.33	3.1e-8	Ulcerative colitis;
CESC	trans	rs208520	0.690	rs207112	chr6:66792092	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.0	-12.83	-0.62	1.2e-29	Exhaled nitric oxide output;
CESC	cis	rs6460942	0.591	rs75804221	chr7:12364319	C/T	cg06484146	chr7:12443880	VWDE	-0.64	-6.99	-0.39	2.27e-11	Coronary artery disease;
CESC	cis	rs11649653	0.502	rs62057232	chr16:30820866	T/C	cg02466173	chr16:30829666	NA	0.44	6.81	0.39	6.43e-11	Triglycerides;
CESC	cis	rs8031584	0.652	rs2691683	chr15:31135060	A/G	cg14298792	chr15:30685198	CHRFAM7A	0.46	5.54	0.32	7.38e-8	Huntington's disease progression;
CESC	cis	rs4901869	0.966	rs12878614	chr14:59339477	A/C	cg02291164	chr14:59296302	NA	0.45	7.78	0.43	1.6e-13	Panic disorder;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg19250764	chr7:66461952	TYW1;SBDS	-0.45	-6.38	-0.36	7.94e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs965469	0.947	rs1854834	chr20:3376619	C/T	cg25506879	chr20:3388711	C20orf194	-0.57	-6.12	-0.35	3.38e-9	IFN-related cytopenia;
CESC	cis	rs4728302	0.807	rs10226267	chr7:133601862	G/A	cg10665199	chr7:133106180	EXOC4	0.42	5.84	0.34	1.56e-8	Intelligence;Intelligence (multi-trait analysis);
CESC	cis	rs6121246	0.647	rs6088855	chr20:30225792	C/T	cg13852791	chr20:30311386	BCL2L1	0.7	7.13	0.4	9.75e-12	Mean corpuscular hemoglobin;
CESC	trans	rs7618501	1.000	rs7372725	chr3:49790544	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.6	-8.49	-0.46	1.55e-15	Intelligence (multi-trait analysis);
CESC	cis	rs2841277	0.509	rs11850949	chr14:105408827	A/C	cg14403583	chr14:105418241	AHNAK2	-0.61	-8.36	-0.46	3.59e-15	Rheumatoid arthritis;
CESC	cis	rs6087990	0.669	rs2424929	chr20:31389518	A/G	cg13636640	chr20:31349939	DNMT3B	0.79	12.92	0.62	6.22e-30	Ulcerative colitis;
CESC	trans	rs3780486	0.846	rs10813954	chr9:33137596	A/C	cg04842962	chr6:43655489	MRPS18A	1.0	19.15	0.76	6.75e-52	IgG glycosylation;
CESC	cis	rs524281	0.773	rs2236651	chr11:66001418	C/T	cg14036092	chr11:66035641	RAB1B	-0.53	-5.31	-0.31	2.38e-7	Electroencephalogram traits;
CESC	cis	rs7216064	1.000	rs12451707	chr17:65871598	G/A	cg07042672	chr17:66097459	LOC651250	-0.53	-5.45	-0.32	1.14e-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs10489525	0.599	rs2335724	chr1:115608444	T/C	cg12756093	chr1:115239321	AMPD1	-0.43	-5.35	-0.31	1.94e-7	Autism;
CESC	cis	rs7216064	1.000	rs62084214	chr17:65843325	C/G	cg07042672	chr17:66097459	LOC651250	-0.54	-5.67	-0.33	3.73e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs815815	0.608	rs815809	chr2:47380203	T/C	cg27223769	chr2:47403360	CALM2	-0.48	-5.55	-0.32	6.82e-8	Dialysis-related mortality;
CESC	cis	rs2737618	0.651	rs2248967	chr1:200084893	A/G	cg21825944	chr1:200113062	NR5A2	0.44	6.87	0.39	4.64e-11	Uric acid levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06688875	chr20:1424325	NSFL1C	-0.65	-7.7	-0.43	2.64e-13	Gut microbiome composition (summer);
CESC	cis	rs1372520	0.684	rs2583968	chr4:90745395	C/G	cg15133208	chr4:90757351	SNCA	-0.39	-5.23	-0.31	3.44e-7	Neuroticism;
CESC	cis	rs1348850	0.567	rs3770012	chr2:178538023	A/G	cg23306229	chr2:178417860	TTC30B	-0.53	-6.5	-0.37	3.94e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs1568889	1.000	rs12796293	chr11:28177723	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	-0.76	-10.36	-0.54	2.5e-21	Bipolar disorder;
CESC	cis	rs35306767	0.903	rs11253493	chr10:936931	T/C	cg20503657	chr10:835505	NA	0.82	8.47	0.46	1.66e-15	Eosinophil percentage of granulocytes;
CESC	cis	rs1808579	0.935	rs2435307	chr18:21127910	A/G	cg14672496	chr18:21087552	C18orf8	-0.38	-5.74	-0.33	2.62e-8	Hip circumference;Body mass index;BMI (adjusted for smoking behaviour);
CESC	cis	rs9393777	0.513	rs11967852	chr6:26612870	G/T	cg11502198	chr6:26597334	ABT1	0.53	5.43	0.32	1.26e-7	Intelligence (multi-trait analysis);
CESC	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.45	-6.05	-0.35	4.97e-9	Longevity;Endometriosis;
CESC	cis	rs1348850	0.789	rs13027959	chr2:178275887	G/A	cg22681709	chr2:178499509	PDE11A	-0.4	-6.03	-0.35	5.36e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs1552244	0.572	rs58862481	chr3:10164308	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.8	8.82	0.48	1.62e-16	Alzheimer's disease;
CESC	cis	rs6575793	1.000	rs7141087	chr14:101036052	T/C	cg18516195	chr14:101012996	BEGAIN	0.46	6.38	0.36	7.77e-10	Menarche (age at onset);
CESC	cis	rs7918232	0.698	rs6482586	chr10:27297829	A/C	cg14240646	chr10:27532245	ACBD5	-0.49	-5.26	-0.31	2.91e-7	Breast cancer;
CESC	cis	rs2637266	0.935	rs7918777	chr10:78394375	A/G	cg18941641	chr10:78392320	NA	0.45	8.6	0.47	6.93e-16	Pulmonary function;
CESC	cis	rs11640734	0.619	rs2293586	chr16:89962394	A/G	cg06558623	chr16:89946397	TCF25	0.54	5.29	0.31	2.61e-7	Interleukin-17 levels;
CESC	cis	rs7618915	0.508	rs11717043	chr3:52656092	A/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.35	6.23	0.36	1.78e-9	Bipolar disorder;
CESC	cis	rs3008870	0.583	rs11208978	chr1:67442210	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.99	-11.11	-0.56	8.58e-24	Lymphocyte percentage of white cells;
CESC	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.57	7.45	0.42	1.32e-12	Prudent dietary pattern;
CESC	cis	rs2859741	0.587	rs580029	chr1:37471609	C/A	cg09363841	chr1:37513479	NA	-0.48	-6.6	-0.38	2.27e-10	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
CESC	cis	rs826838	0.586	rs10785554	chr12:38628749	T/A	cg26384229	chr12:38710491	ALG10B	0.47	6.93	0.39	3.18e-11	Heart rate;
CESC	cis	rs672059	0.548	rs607332	chr1:183253213	G/A	ch.1.3577855R	chr1:183094577	LAMC1	-0.5	-5.9	-0.34	1.1e-8	Hypertriglyceridemia;
CESC	cis	rs12950390	0.853	rs11658511	chr17:45856918	T/C	cg00777063	chr17:45855553	NA	-0.39	-5.77	-0.33	2.26e-8	IgG glycosylation;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03044510	chr21:27107978	ATP5J;GABPA	0.56	6.25	0.36	1.65e-9	Gut microbiome composition (summer);
CESC	cis	rs2952156	0.959	rs1495102	chr17:37832093	T/C	cg20243544	chr17:37824526	PNMT	0.6	7.38	0.41	2.01e-12	Asthma;
CESC	cis	rs56399783	0.803	rs7811164	chr7:2822416	G/A	cg19731401	chr7:2775893	GNA12	0.6	5.6	0.33	5.4e-8	Childhood ear infection;
CESC	trans	rs916888	0.773	rs169201	chr17:44790203	A/G	cg23590916	chr17:43697445	MGC57346	0.65	6.48	0.37	4.51e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs7481584	1.000	rs3814964	chr11:2999507	G/T	cg25174290	chr11:3078921	CARS	-0.45	-5.54	-0.32	7.47e-8	Calcium levels;
CESC	cis	rs2073300	0.609	rs6137927	chr20:23372513	A/G	cg16736954	chr20:23401023	NAPB	0.8	6.25	0.36	1.67e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs6460942	0.591	rs4721079	chr7:12337742	A/G	cg06484146	chr7:12443880	VWDE	-0.63	-7.02	-0.4	1.91e-11	Coronary artery disease;
CESC	cis	rs7246657	0.943	rs35540940	chr19:38008235	G/A	cg23950597	chr19:37808831	NA	-0.6	-6.18	-0.35	2.42e-9	Coronary artery calcification;
CESC	cis	rs950776	0.518	rs952215	chr15:78819153	C/T	cg24631222	chr15:78858424	CHRNA5	0.41	5.2	0.3	3.99e-7	Sudden cardiac arrest;
CESC	cis	rs4699052	0.625	rs10212959	chr4:104300935	C/G	cg16532752	chr4:104119610	CENPE	0.4	5.68	0.33	3.48e-8	Testicular germ cell tumor;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12994003	chr1:225616475	LBR	-0.55	-6.29	-0.36	1.29e-9	Gut microbiome composition (summer);
CESC	cis	rs10504229	1.000	rs55944282	chr8:58180821	A/G	cg14926445	chr8:58193284	C8orf71	-0.51	-5.47	-0.32	1.03e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs55883249	1.000	rs62119429	chr2:9743585	G/C	cg23886495	chr2:9695866	ADAM17	0.61	5.52	0.32	8.11e-8	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
CESC	cis	rs1005277	0.602	rs1831315	chr10:38473353	T/C	cg25427524	chr10:38739819	LOC399744	-0.69	-10.21	-0.53	7.18e-21	Extrinsic epigenetic age acceleration;
CESC	cis	rs769267	0.929	rs2905421	chr19:19457908	G/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.4	5.03	0.3	8.97e-7	Tonsillectomy;
CESC	cis	rs3806843	0.868	rs2563281	chr5:140131219	T/A	cg26395211	chr5:140044315	WDR55	0.39	5.09	0.3	6.79e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs9527	0.590	rs12785223	chr10:104844011	C/T	cg04362960	chr10:104952993	NT5C2	-0.43	-5.41	-0.32	1.41e-7	Arsenic metabolism;
CESC	cis	rs514406	0.621	rs928452	chr1:53195926	G/C	cg08859206	chr1:53392774	SCP2	0.56	7.11	0.4	1.1e-11	Monocyte count;
CESC	trans	rs11250097	0.535	rs11250086	chr8:10769783	A/G	cg15556689	chr8:8085844	FLJ10661	-0.55	-6.72	-0.38	1.13e-10	Neuroticism;
CESC	cis	rs769267	0.930	rs892021	chr19:19613480	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.48	6.05	0.35	4.97e-9	Tonsillectomy;
CESC	cis	rs7552404	1.000	rs7518038	chr1:76154430	G/A	cg22875332	chr1:76189707	ACADM	0.66	7.81	0.43	1.31e-13	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs11148252	0.532	rs9526975	chr13:53255804	C/T	cg00495681	chr13:53174319	NA	0.63	8.41	0.46	2.55e-15	Lewy body disease;
CESC	cis	rs736801	0.780	rs11951091	chr5:131786595	G/A	cg07395648	chr5:131743802	NA	-0.42	-5.26	-0.31	2.93e-7	Breast cancer;Mosquito bite size;
CESC	cis	rs9815354	0.812	rs73071222	chr3:41986896	C/T	cg03022575	chr3:42003672	ULK4	0.68	6.1	0.35	3.75e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs7833986	0.501	rs72653962	chr8:56997505	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.62	7.54	0.42	7.58e-13	Height;
CESC	cis	rs965469	1.000	rs6037533	chr20:3268817	T/C	cg25506879	chr20:3388711	C20orf194	-0.55	-5.96	-0.34	7.97e-9	IFN-related cytopenia;
CESC	cis	rs2797685	1.000	rs2797685	chr1:7879063	C/T	cg04725166	chr1:7887271	PER3	-0.45	-6.24	-0.36	1.72e-9	Crohn's disease;
CESC	cis	rs2635047	0.565	rs2571004	chr18:44710302	T/A	cg24371990	chr18:44770781	NA	0.32	5.15	0.3	5.03e-7	Educational attainment;
CESC	cis	rs7666738	0.753	rs7657644	chr4:99057734	T/A	cg05340658	chr4:99064831	C4orf37	0.83	12.92	0.62	5.96e-30	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6951245	0.580	rs10257426	chr7:1213694	G/A	cg23708337	chr7:1209742	NA	0.48	5.4	0.31	1.46e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs74781061	0.858	rs58473469	chr15:74885063	C/T	cg17294928	chr15:75287854	SCAMP5	-0.49	-5.09	-0.3	6.74e-7	Endometriosis;
CESC	cis	rs1348850	0.958	rs1548067	chr2:178462914	C/T	cg23306229	chr2:178417860	TTC30B	0.54	7.19	0.4	6.5e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs4588572	0.686	rs4470742	chr5:77657957	T/G	cg11547950	chr5:77652471	NA	0.46	5.81	0.34	1.76e-8	Triglycerides;
CESC	cis	rs7223966	1.000	rs7223412	chr17:61808172	T/C	cg11494091	chr17:61959527	GH2	0.38	5.19	0.3	4.28e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.42	8.36	0.46	3.6e-15	Electroencephalogram traits;
CESC	cis	rs7264396	0.623	rs2590984	chr20:34597031	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.49	5.71	0.33	2.98e-8	Total cholesterol levels;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg04309227	chr1:26561027	CCDC21	-0.44	-6.21	-0.36	2.02e-9	Gambling;
CESC	cis	rs4689388	0.926	rs10937717	chr4:6295087	T/A	cg25554036	chr4:6271136	WFS1	0.49	7.87	0.44	8.81e-14	Type 2 diabetes and other traits;Type 2 diabetes;
CESC	cis	rs1799949	0.896	rs8176098	chr17:41268206	A/C	cg25072359	chr17:41440525	NA	0.44	5.91	0.34	1.06e-8	Menopause (age at onset);
CESC	cis	rs4665809	0.549	rs72809635	chr2:26411674	G/A	cg22920501	chr2:26401640	FAM59B	0.78	8.6	0.47	7.14e-16	Gut microbiome composition (summer);
CESC	cis	rs5167	0.525	rs11083752	chr19:45454363	G/A	cg09555818	chr19:45449301	APOC2	0.41	6.54	0.37	3.08e-10	Blood protein levels;
CESC	cis	rs116095464	0.614	rs28736753	chr5:274081	G/A	cg08858540	chr5:346238	AHRR	0.41	5.06	0.3	7.93e-7	Breast cancer;
CESC	trans	rs7095944	0.614	rs4962697	chr10:126447545	G/C	cg27222157	chr11:66382978	RBM14	0.38	6.11	0.35	3.57e-9	Asthma;
CESC	cis	rs2882667	0.861	rs11242445	chr5:138417054	G/T	cg04439458	chr5:138467593	SIL1	-0.3	-5.1	-0.3	6.45e-7	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs3096299	0.667	rs2965947	chr16:89518670	T/C	cg16743903	chr16:89593216	SPG7	-0.43	-5.62	-0.33	4.87e-8	Multiple myeloma (IgH translocation);
CESC	cis	rs55794721	0.509	rs2982358	chr1:25745204	G/T	cg02931644	chr1:25747376	RHCE	0.39	6.52	0.37	3.6e-10	Plateletcrit;Mean corpuscular volume;
CESC	cis	rs1879734	0.636	rs4927031	chr1:54183191	C/T	cg23596471	chr1:54105337	GLIS1	0.31	5.06	0.3	7.86e-7	Mitral valve prolapse;
CESC	cis	rs12545109	0.775	rs10093388	chr8:57318799	C/T	cg09654669	chr8:57350985	NA	-0.61	-8.25	-0.45	7.67e-15	Obesity-related traits;
CESC	cis	rs863345	0.625	rs12119672	chr1:158500285	G/A	cg12129480	chr1:158549410	OR10X1	-0.34	-6.84	-0.39	5.41e-11	Pneumococcal bacteremia;
CESC	cis	rs7918232	0.882	rs788237	chr10:27457932	C/T	cg14240646	chr10:27532245	ACBD5	0.68	6.43	0.37	5.91e-10	Breast cancer;
CESC	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg05313129	chr8:58192883	C8orf71	-0.48	-5.27	-0.31	2.89e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs896854	0.738	rs527234	chr8:95963798	C/G	cg23172400	chr8:95962367	TP53INP1	0.4	7.48	0.42	1.1e-12	Type 2 diabetes;
CESC	trans	rs60380162	0.928	rs1411705	chr1:87728263	C/G	cg20163645	chr8:1900353	ARHGEF10	0.43	6.02	0.35	5.85e-9	Loneliness (linear analysis);
CESC	cis	rs1552244	0.935	rs35515831	chr3:10071362	G/A	cg00149659	chr3:10157352	C3orf10	0.74	9.14	0.49	1.63e-17	Alzheimer's disease;
CESC	cis	rs7254114	0.578	rs3745682	chr19:11313256	C/T	cg02815516	chr19:11306319	KANK2	-0.44	-7.13	-0.4	9.68e-12	Immature fraction of reticulocytes;
CESC	cis	rs13256369	1.000	rs12550762	chr8:8576535	T/A	cg18904891	chr8:8559673	CLDN23	0.65	7.59	0.42	5.56e-13	Obesity-related traits;
CESC	cis	rs2228479	0.850	rs62056066	chr16:89906563	G/A	cg04013166	chr16:89971882	TCF25	0.72	5.75	0.33	2.41e-8	Skin colour saturation;
CESC	cis	rs514406	0.505	rs269286	chr1:53169018	C/T	cg25767906	chr1:53392781	SCP2	0.39	5.24	0.31	3.31e-7	Monocyte count;
CESC	cis	rs9399135	0.967	rs7741626	chr6:135314182	C/T	cg24558204	chr6:135376177	HBS1L	0.53	7.28	0.41	3.85e-12	Red blood cell count;
CESC	cis	rs9322193	0.923	rs7767622	chr6:150002902	T/C	cg00933542	chr6:150070202	PCMT1	0.29	5.06	0.3	7.67e-7	Lung cancer;
CESC	cis	rs709400	1.000	rs709400	chr14:104149475	A/G	cg24130564	chr14:104152367	KLC1	-0.43	-5.48	-0.32	9.93e-8	Body mass index;
CESC	cis	rs7107174	1.000	rs2512546	chr11:77957276	T/C	cg02023728	chr11:77925099	USP35	0.43	6.11	0.35	3.48e-9	Testicular germ cell tumor;
CESC	cis	rs765787	0.530	rs12440238	chr15:45512905	T/C	cg24006582	chr15:45444508	DUOX1	0.52	6.32	0.36	1.13e-9	Uric acid levels;
CESC	cis	rs7243790	0.777	rs3826583	chr18:51932991	G/A	cg04730925	chr18:51795821	POLI	-0.41	-5.3	-0.31	2.46e-7	Diastolic blood pressure;
CESC	cis	rs1048238	0.506	rs848210	chr1:16259813	A/G	cg22431228	chr1:16359049	CLCNKA	0.35	6.07	0.35	4.47e-9	Systolic blood pressure;
CESC	cis	rs11122272	0.701	rs2883799	chr1:231531166	C/G	cg06096015	chr1:231504339	EGLN1	0.43	6.15	0.35	2.9e-9	Hemoglobin concentration;
CESC	cis	rs7937682	1.000	rs7121011	chr11:111568681	C/T	cg09085632	chr11:111637200	PPP2R1B	1.03	14.07	0.65	5.86e-34	Primary sclerosing cholangitis;
CESC	trans	rs6572548	0.504	rs1956082	chr14:49665496	A/C	cg13412003	chr19:35455007	ZNF792	0.52	6.0	0.35	6.51e-9	Subjective well-being;
CESC	cis	rs9611565	0.570	rs12159188	chr22:42121125	A/T	cg06634786	chr22:41940651	POLR3H	0.52	5.53	0.32	7.55e-8	Vitiligo;
CESC	cis	rs7503807	0.935	rs62068348	chr17:78608575	T/C	cg09596252	chr17:78655493	RPTOR	0.49	7.21	0.4	5.93e-12	Obesity;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg10586903	chr19:41221192	ADCK4	-0.43	-6.03	-0.35	5.58e-9	Gambling;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg11321298	chr22:40766510	SGSM3	-0.49	-6.55	-0.37	3.04e-10	Asthma;
CESC	cis	rs11122272	0.735	rs2247132	chr1:231493359	G/A	cg06096015	chr1:231504339	EGLN1	0.46	6.77	0.38	8.33e-11	Hemoglobin concentration;
CESC	cis	rs270601	0.721	rs162894	chr5:131611872	T/G	cg18758796	chr5:131593413	PDLIM4	0.43	5.77	0.33	2.25e-8	Acylcarnitine levels;
CESC	trans	rs10862688	0.716	rs7316185	chr12:83862134	G/T	cg25858261	chr10:12085058	UPF2	-0.42	-6.0	-0.35	6.3e-9	Vertical cup-disc ratio;
CESC	cis	rs2286503	0.752	rs2286504	chr7:22854847	G/T	cg11367502	chr7:22862612	TOMM7	0.39	5.14	0.3	5.45e-7	Fibrinogen;
CESC	cis	rs2242194	0.816	rs11264296	chr1:154994750	T/C	cg06221963	chr1:154839813	KCNN3	-0.38	-5.71	-0.33	3.04e-8	Schizophrenia;
CESC	cis	rs4595586	0.545	rs12819186	chr12:39356912	C/T	cg26384229	chr12:38710491	ALG10B	0.54	7.63	0.42	4.31e-13	Morning vs. evening chronotype;
CESC	cis	rs2066819	1.000	rs2695782	chr12:56722830	C/T	cg26734620	chr12:56694298	CS	-0.94	-8.74	-0.47	2.67e-16	Psoriasis vulgaris;
CESC	cis	rs7618915	0.571	rs7623199	chr3:52605974	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.47	6.59	0.38	2.33e-10	Bipolar disorder;
CESC	cis	rs9322193	0.962	rs7740784	chr6:150154500	C/T	cg09699651	chr6:150184138	LRP11	0.41	5.14	0.3	5.46e-7	Lung cancer;
CESC	cis	rs5769765	0.862	rs9616384	chr22:50313082	C/T	cg26441486	chr22:50317300	CRELD2	0.41	5.22	0.31	3.7e-7	Schizophrenia;
CESC	cis	rs12530845	1.000	rs4291211	chr7:135335373	C/T	cg23117316	chr7:135346802	PL-5283	-0.43	-5.44	-0.32	1.24e-7	Red blood cell traits;
CESC	cis	rs1005277	0.579	rs2023351	chr10:38378814	A/G	cg00409905	chr10:38381863	ZNF37A	-0.45	-6.0	-0.35	6.52e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg15112475	chr7:1198522	ZFAND2A	-0.39	-6.16	-0.35	2.7e-9	Longevity;Endometriosis;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg03607946	chr20:34203965	SPAG4	-0.45	-6.01	-0.35	6.09e-9	Asthma;
CESC	cis	rs77741769	0.571	rs10849807	chr12:121314056	T/C	cg02419362	chr12:121203948	SPPL3	0.34	5.58	0.32	5.97e-8	Mean corpuscular volume;
CESC	trans	rs9951602	0.512	rs4799248	chr18:76653459	G/A	cg02800362	chr5:177631904	HNRNPAB	0.65	8.6	0.47	7.27e-16	Obesity-related traits;
CESC	cis	rs17253792	0.822	rs12100949	chr14:56040787	T/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.81	6.32	0.36	1.08e-9	Putamen volume;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg03228602	chr6:7888995	TXNDC5	0.51	6.64	0.38	1.81e-10	Fibrinogen levels;
CESC	cis	rs1862618	0.671	rs2591965	chr5:56236176	T/C	cg24531977	chr5:56204891	C5orf35	0.7	9.46	0.5	1.71e-18	Initial pursuit acceleration;
CESC	cis	rs250677	0.522	rs2217638	chr5:148364355	A/G	cg18129178	chr5:148520854	ABLIM3	0.46	5.07	0.3	7.47e-7	Breast cancer;
CESC	cis	rs7808935	0.768	rs757138	chr7:27989403	T/G	cg05786569	chr7:27702416	HIBADH	0.42	5.24	0.31	3.2e-7	Prostate cancer;
CESC	cis	rs2795502	1.000	rs3121278	chr10:43375646	G/T	cg20628663	chr10:43360327	NA	0.54	5.67	0.33	3.66e-8	Blood protein levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13300911	chr15:42119951	JMJD7;MAPKBP1;JMJD7-PLA2G4B	-0.57	-6.68	-0.38	1.44e-10	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26468274	chr6:43544000	XPO5;POLH	0.57	6.42	0.37	6.43e-10	Gut microbiome composition (summer);
CESC	cis	rs2073300	1.000	rs79255223	chr20:23443559	G/T	cg12062639	chr20:23401060	NAPB	0.91	6.41	0.37	6.71e-10	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs9926296	0.585	rs6500441	chr16:89828669	C/G	cg21285383	chr16:89894308	SPIRE2	0.28	5.08	0.3	7.09e-7	Vitiligo;
CESC	cis	rs9902453	0.765	rs2264303	chr17:28055348	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-10.33	-0.54	3.03e-21	Coffee consumption (cups per day);
CESC	trans	rs453301	0.571	rs330048	chr8:9087278	A/C	cg06636001	chr8:8085503	FLJ10661	-0.52	-6.74	-0.38	1.01e-10	Joint mobility (Beighton score);
CESC	cis	rs9399135	0.967	rs34546690	chr6:135369709	T/C	cg22676075	chr6:135203613	NA	0.52	7.32	0.41	2.89e-12	Red blood cell count;
CESC	cis	rs10779751	0.770	rs2275527	chr1:11190646	A/G	cg08854313	chr1:11322531	MTOR	0.68	8.16	0.45	1.37e-14	Body mass index;
CESC	cis	rs10771431	0.967	rs7137443	chr12:9372029	C/T	cg00504896	chr12:9437009	LOC642846	-0.41	-5.44	-0.32	1.19e-7	Breast size;
CESC	cis	rs4836694	0.574	rs4837476	chr9:132937533	T/C	cg05251000	chr9:132935664	FREQ	0.42	5.64	0.33	4.33e-8	Alzheimer's disease (cognitive decline);
CESC	cis	rs17433780	0.836	rs61798917	chr1:89506093	G/A	cg09516651	chr1:89888402	LOC400759	0.66	9.66	0.51	4.07e-19	Carotid intima media thickness;
CESC	cis	rs6088590	1.000	rs2236270	chr20:33523155	G/T	cg08999081	chr20:33150536	PIGU	0.58	8.49	0.46	1.46e-15	Coronary artery disease;
CESC	cis	rs1348850	0.872	rs7559521	chr2:178452328	A/G	cg23306229	chr2:178417860	TTC30B	-0.45	-5.66	-0.33	4.01e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs1552244	0.882	rs2030564	chr3:10039044	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.74	-9.36	-0.5	3.67e-18	Alzheimer's disease;
CESC	cis	rs11166629	1.000	rs4909332	chr8:135646340	T/C	cg27224718	chr8:135614730	ZFAT	0.54	6.74	0.38	9.99e-11	Smoking quantity;
CESC	cis	rs6032067	0.777	rs34163611	chr20:43778990	T/C	cg10761708	chr20:43804764	PI3	0.53	6.27	0.36	1.48e-9	Blood protein levels;
CESC	cis	rs1983891	0.909	rs4714482	chr6:41528199	G/A	cg20194872	chr6:41519635	FOXP4	0.56	8.09	0.45	2.16e-14	Prostate cancer;
CESC	cis	rs9649213	0.574	rs3801257	chr7:97991792	A/G	cg08684580	chr7:98029266	BAIAP2L1	-0.36	-5.86	-0.34	1.4e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs11098499	0.863	rs1383532	chr4:120434404	A/T	cg24375607	chr4:120327624	NA	-0.42	-5.1	-0.3	6.6e-7	Corneal astigmatism;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg06361278	chr17:25783929	NA	-0.48	-6.29	-0.36	1.29e-9	Ulcerative colitis;
CESC	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg12419862	chr22:24373484	LOC391322	-0.7	-9.66	-0.51	4.02e-19	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs17253792	0.822	rs10083303	chr14:56068521	T/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.79	5.91	0.34	1.06e-8	Putamen volume;
CESC	cis	rs829883	0.867	rs1641640	chr12:98896017	A/G	cg25150519	chr12:98850993	NA	0.71	9.74	0.51	2.31e-19	Colorectal adenoma (advanced);
CESC	cis	rs9660992	0.573	rs12140703	chr1:205182865	G/C	cg00857998	chr1:205179979	DSTYK	0.54	6.73	0.38	1.06e-10	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs6696846	0.765	rs61822568	chr1:205081166	C/G	cg00857998	chr1:205179979	DSTYK	0.54	7.12	0.4	9.98e-12	Red blood cell count;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg02654935	chr6:12514489	NA	-0.41	-6.11	-0.35	3.54e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs514406	0.929	rs12410420	chr1:53323754	T/C	cg08859206	chr1:53392774	SCP2	-0.64	-8.55	-0.47	9.9e-16	Monocyte count;
CESC	trans	rs931812	0.757	rs4734015	chr8:101909258	C/G	cg20993868	chr7:22813445	NA	0.42	6.48	0.37	4.38e-10	Attention deficit hyperactivity disorder and conduct disorder;
CESC	cis	rs1552244	0.751	rs12715665	chr3:10021601	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.87	11.21	0.57	3.99e-24	Alzheimer's disease;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg20898078	chr7:150773226	SLC4A2	0.49	6.62	0.38	1.97e-10	Fibrinogen levels;
CESC	cis	rs72781680	0.699	rs72794291	chr2:23897935	C/T	cg20701182	chr2:24300061	SF3B14	0.81	7.06	0.4	1.5e-11	Lymphocyte counts;
CESC	cis	rs11750568	1.000	rs1136377	chr5:178513141	C/T	cg10208897	chr5:178548229	ADAMTS2	0.39	5.45	0.32	1.15e-7	Height;
CESC	cis	rs9611565	0.765	rs132920	chr22:41810170	T/C	cg06634786	chr22:41940651	POLR3H	0.71	7.47	0.42	1.16e-12	Vitiligo;
CESC	cis	rs1538970	0.924	rs11211111	chr1:45908782	C/T	cg06784218	chr1:46089804	CCDC17	0.35	5.54	0.32	7.26e-8	Platelet count;
CESC	cis	rs60843830	0.550	rs300751	chr2:209063	A/C	cg00108164	chr2:264199	ACP1;SH3YL1	0.48	6.09	0.35	3.91e-9	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs2243480	1.000	rs6964245	chr7:65718717	G/A	cg13147721	chr7:65941812	NA	0.98	9.24	0.49	8.25e-18	Diabetic kidney disease;
CESC	cis	rs2637266	0.655	rs7902535	chr10:78460889	C/T	cg18941641	chr10:78392320	NA	0.42	7.53	0.42	7.81e-13	Pulmonary function;
CESC	cis	rs6800768	0.663	rs62253424	chr3:24093919	C/A	cg10674438	chr3:24145617	LOC152024	-0.4	-5.48	-0.32	1.01e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs4819052	0.851	rs13047104	chr21:46673562	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.94	14.0	0.65	1.02e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs2933343	0.700	rs2630257	chr3:128644015	T/C	cg24203234	chr3:128598194	ACAD9	0.43	5.8	0.34	1.93e-8	IgG glycosylation;
CESC	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg23708337	chr7:1209742	NA	0.55	5.47	0.32	1.04e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs6582630	0.519	rs11181998	chr12:38439970	C/A	cg13010199	chr12:38710504	ALG10B	0.46	6.0	0.35	6.56e-9	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs9814567	1.000	rs1357762	chr3:134264859	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.43	-5.85	-0.34	1.42e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs1577917	1.000	rs12205336	chr6:86722367	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-6.17	-0.35	2.58e-9	Response to antipsychotic treatment;
CESC	cis	rs8114671	0.935	rs35193912	chr20:33785050	C/T	cg06115741	chr20:33292138	TP53INP2	-0.42	-5.11	-0.3	6.06e-7	Height;
CESC	cis	rs2243480	1.000	rs2257790	chr7:65600450	C/T	cg13147721	chr7:65941812	NA	-0.95	-9.01	-0.48	4.12e-17	Diabetic kidney disease;
CESC	cis	rs2290159	0.800	rs3730269	chr3:12653233	G/T	cg23032965	chr3:12705835	RAF1	0.54	5.86	0.34	1.35e-8	Cholesterol, total;
CESC	cis	rs9309473	1.000	rs11901272	chr2:73720444	A/G	cg20560298	chr2:73613845	ALMS1	-0.45	-6.12	-0.35	3.42e-9	Metabolite levels;
CESC	cis	rs12497850	0.864	rs12493001	chr3:49181885	A/G	cg03060546	chr3:49711283	APEH	0.55	6.66	0.38	1.6e-10	Parkinson's disease;
CESC	cis	rs3768617	0.510	rs4651140	chr1:183096952	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.89	14.39	0.66	4.39e-35	Fuchs's corneal dystrophy;
CESC	cis	rs875971	0.895	rs12698520	chr7:65918707	C/A	cg11764359	chr7:65958608	NA	0.97	15.48	0.69	6.16e-39	Aortic root size;
CESC	cis	rs17401966	0.931	rs3748579	chr1:10420937	C/T	cg15208524	chr1:10270712	KIF1B	0.4	5.12	0.3	6e-7	Hepatocellular carcinoma;
CESC	cis	rs7666738	0.924	rs13124368	chr4:99039615	T/C	cg03467027	chr4:99064603	C4orf37	0.47	5.98	0.34	7.19e-9	Colonoscopy-negative controls vs population controls;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg07050647	chr2:122287957	CLASP1;RNU4ATAC	-0.48	-6.07	-0.35	4.48e-9	Ulcerative colitis;
CESC	cis	rs3768617	1.000	rs12026314	chr1:183104527	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.65	9.62	0.51	5.56e-19	Fuchs's corneal dystrophy;
CESC	cis	rs4665809	0.590	rs35615763	chr2:26468778	C/G	cg27170947	chr2:26402098	FAM59B	0.87	9.89	0.52	7.6e-20	Gut microbiome composition (summer);
CESC	cis	rs9616064	0.889	rs5767287	chr22:46996179	G/A	cg05621596	chr22:47072043	GRAMD4	-0.49	-6.97	-0.39	2.58e-11	Urate levels in obese individuals;
CESC	cis	rs6460942	0.555	rs7803268	chr7:12306793	G/A	cg02935154	chr7:12443704	VWDE	-0.59	-5.9	-0.34	1.11e-8	Coronary artery disease;
CESC	cis	rs798554	0.679	rs1636254	chr7:2885724	T/C	cg09658497	chr7:2847517	GNA12	-0.35	-5.09	-0.3	6.67e-7	Height;
CESC	cis	rs1797885	0.585	rs2255655	chr3:12598839	C/G	cg26432171	chr3:12704882	RAF1	-0.5	-6.5	-0.37	4e-10	Immature fraction of reticulocytes;
CESC	cis	rs9926296	0.572	rs8047581	chr16:89884502	C/T	cg27121462	chr16:89883253	FANCA	0.64	8.54	0.46	1.05e-15	Vitiligo;
CESC	cis	rs1552244	0.748	rs9862221	chr3:10059658	G/T	cg00149659	chr3:10157352	C3orf10	0.66	7.46	0.42	1.23e-12	Alzheimer's disease;
CESC	cis	rs2361718	0.500	rs8064429	chr17:78096187	A/C	cg20811857	chr17:78079795	GAA	-0.44	-6.31	-0.36	1.18e-9	Yeast infection;
CESC	cis	rs2988277	0.713	rs10800313	chr1:167429985	C/T	cg22356347	chr1:167427500	CD247	0.26	5.31	0.31	2.29e-7	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs7918232	0.882	rs2149413	chr10:27430311	C/T	cg14240646	chr10:27532245	ACBD5	0.67	6.36	0.36	8.93e-10	Breast cancer;
CESC	cis	rs9287719	0.810	rs1990612	chr2:10781944	A/G	cg02196655	chr2:10830764	NOL10	-0.37	-5.66	-0.33	3.86e-8	Prostate cancer;
CESC	cis	rs11711311	1.000	rs2603789	chr3:113470479	T/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.58	7.68	0.43	3.1400000000000003e-13	IgG glycosylation;
CESC	cis	rs7267979	0.934	rs2500399	chr20:25354694	T/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.84	-15.92	-0.7	1.72e-40	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7829975	0.711	rs12682352	chr8:8646246	A/G	cg17143192	chr8:8559678	CLDN23	0.43	5.29	0.31	2.63e-7	Mood instability;
CESC	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.42	-5.6	-0.33	5.23e-8	Lymphocyte counts;
CESC	cis	rs9788682	0.747	rs12910984	chr15:78891627	G/A	cg24631222	chr15:78858424	CHRNA5	-0.83	-10.5	-0.54	8.35e-22	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24877558	chr1:42801138	FOXJ3	0.59	6.47	0.37	4.76e-10	Gut microbiome composition (summer);
CESC	cis	rs925228	0.504	rs7568176	chr2:24313758	T/A	cg01493198	chr2:24299560	SF3B14	0.68	5.91	0.34	1.04e-8	Reticulocyte fraction of red cells;Reticulocyte count;
CESC	cis	rs1670533	1.000	rs1670533	chr4:1078187	G/A	cg04106633	chr4:1044584	NA	0.4	5.09	0.3	6.88e-7	Recombination rate (females);
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg12964741	chr18:77160221	NFATC1	0.41	6.02	0.35	5.79e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs6540559	0.546	rs59435160	chr1:210030730	C/A	cg21951975	chr1:209979733	IRF6	0.54	6.34	0.36	1.01e-9	Cleft lip with or without cleft palate;
CESC	cis	rs9925964	0.967	rs1978487	chr16:31129942	C/T	cg02466173	chr16:30829666	NA	-0.32	-5.13	-0.3	5.71e-7	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs6446731	0.517	rs2858087	chr4:3268892	A/T	cg08886695	chr4:3369023	RGS12	0.35	5.28	0.31	2.74e-7	Mean platelet volume;
CESC	cis	rs6570726	0.738	rs6925594	chr6:145898454	T/C	cg23711669	chr6:146136114	FBXO30	0.97	14.97	0.68	4.06e-37	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs9649213	0.593	rs6465678	chr7:98004057	T/C	cg00277769	chr7:97922759	BAIAP2L1	-0.33	-5.43	-0.32	1.29e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs2836974	0.831	rs2836921	chr21:40516070	C/T	cg17971929	chr21:40555470	PSMG1	0.97	12.95	0.62	4.63e-30	Cognitive function;
CESC	cis	rs11723261	0.621	rs7692530	chr4:123445	G/C	cg12746427	chr4:53362	ZNF718;ZNF595	0.48	6.5	0.37	3.9e-10	Immune response to smallpox vaccine (IL-6);
CESC	cis	rs16854884	0.660	rs990320	chr3:143796305	T/C	cg06585982	chr3:143692056	C3orf58	0.45	5.85	0.34	1.47e-8	Economic and political preferences (feminism/equality);
CESC	cis	rs1003719	0.715	rs7282195	chr21:38508619	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-8.56	-0.47	9.46e-16	Eye color traits;
CESC	cis	rs5769707	0.839	rs73176988	chr22:49989649	G/T	cg20744362	chr22:50050164	C22orf34	0.41	6.89	0.39	4.09e-11	Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs12979813	1.000	rs8101802	chr19:11336182	G/C	cg00586551	chr19:11347513	LOC55908;DOCK6	0.38	5.05	0.3	8.34e-7	HDL cholesterol;
CESC	cis	rs1336900	0.641	rs6587756	chr1:150546865	A/T	cg13175981	chr1:150552382	MCL1	0.44	5.27	0.31	2.86e-7	Blood protein levels;
CESC	cis	rs9457247	0.935	rs427824	chr6:167403918	T/G	cg07741184	chr6:167504864	NA	0.28	5.08	0.3	7.24e-7	Crohn's disease;
CESC	cis	rs7412746	0.658	rs2864869	chr1:150734655	G/A	cg17724175	chr1:150552817	MCL1	0.42	6.45	0.37	5.2400000000000005e-10	Melanoma;
CESC	cis	rs6540556	0.954	rs7548219	chr1:209936466	A/G	cg05527609	chr1:210001259	C1orf107	-0.46	-5.74	-0.33	2.65e-8	Red blood cell count;
CESC	cis	rs78456975	0.550	rs10197874	chr2:1545310	A/G	cg26248373	chr2:1572462	NA	-0.57	-6.42	-0.37	6.13e-10	Placebo response in major depressive disorder (% change in symptom score);
CESC	trans	rs9325144	0.647	rs17518186	chr12:38883665	T/C	cg10679878	chr6:156759499	NA	-0.33	-6.03	-0.35	5.46e-9	Morning vs. evening chronotype;
CESC	cis	rs6570726	0.738	rs7746330	chr6:145899257	A/C	cg23711669	chr6:146136114	FBXO30	1.0	15.5	0.69	5.39e-39	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs72627123	0.867	rs11848920	chr14:74476866	A/G	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.73	5.63	0.33	4.49e-8	Morning vs. evening chronotype;
CESC	cis	rs6087771	0.747	rs6058261	chr20:30235470	C/A	cg13852791	chr20:30311386	BCL2L1	0.77	9.66	0.51	4.05e-19	Subcortical brain region volumes;Putamen volume;
CESC	cis	rs11122272	0.735	rs2790878	chr1:231534390	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.5	-6.6	-0.38	2.17e-10	Hemoglobin concentration;
CESC	cis	rs2479106	0.591	rs10283413	chr9:126395188	A/T	cg16191174	chr9:126692580	DENND1A	0.42	5.65	0.33	4.11e-8	Polycystic ovary syndrome;
CESC	cis	rs4423214	0.547	rs11234030	chr11:71236967	G/A	cg05163923	chr11:71159392	DHCR7	-0.54	-5.84	-0.34	1.55e-8	Vitamin D levels;
CESC	cis	rs7552404	0.924	rs1146581	chr1:76213024	T/G	cg22875332	chr1:76189707	ACADM	0.69	9.26	0.49	7.06e-18	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs4604732	0.578	rs7525209	chr1:247627404	C/T	cg12754571	chr1:247694271	LOC148824;OR2C3	0.44	5.44	0.32	1.21e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
CESC	cis	rs7592578	0.679	rs62181018	chr2:191323295	C/T	cg10560079	chr2:191398806	TMEM194B	-0.59	-5.74	-0.33	2.57e-8	Diastolic blood pressure;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg13205571	chr12:50135324	TMBIM6	-0.43	-6.02	-0.35	5.86e-9	Gambling;
CESC	cis	rs4665809	0.531	rs12987980	chr2:26462093	A/T	cg22920501	chr2:26401640	FAM59B	0.91	10.38	0.54	2.08e-21	Gut microbiome composition (summer);
CESC	cis	rs2075371	1.000	rs2544218	chr7:133992315	C/A	cg11752832	chr7:134001865	SLC35B4	0.55	7.23	0.41	5.27e-12	Mean platelet volume;
CESC	cis	rs9487051	1.000	rs6568571	chr6:109613252	A/T	cg01475377	chr6:109611718	NA	-0.39	-5.89	-0.34	1.19e-8	Reticulocyte fraction of red cells;
CESC	cis	rs11166927	1.000	rs11778622	chr8:140805582	A/G	cg16909799	chr8:140841666	TRAPPC9	0.61	9.0	0.48	4.52e-17	Pediatric non-alcoholic fatty liver disease activity score;
CESC	cis	rs8017423	0.935	rs7144070	chr14:90753047	T/C	cg14092571	chr14:90743983	NA	-0.6	-9.06	-0.49	2.86e-17	Mortality in heart failure;
CESC	cis	rs72781680	1.000	rs72781683	chr2:24247423	T/C	cg08917208	chr2:24149416	ATAD2B	1.07	9.36	0.5	3.66e-18	Lymphocyte counts;
CESC	cis	rs11098499	0.954	rs6849561	chr4:120409694	C/G	cg24375607	chr4:120327624	NA	-0.47	-5.82	-0.34	1.66e-8	Corneal astigmatism;
CESC	cis	rs9527	0.590	rs3781282	chr10:104852419	C/T	cg04362960	chr10:104952993	NT5C2	-0.43	-5.37	-0.31	1.72e-7	Arsenic metabolism;
CESC	cis	rs2635047	0.811	rs9965170	chr18:44788274	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.4	5.36	0.31	1.85e-7	Educational attainment;
CESC	cis	rs2832191	0.550	rs66484040	chr21:30511691	G/A	cg24692254	chr21:30365293	RNF160	-0.61	-7.69	-0.43	2.86e-13	Dental caries;
CESC	cis	rs2273669	0.667	rs11751295	chr6:109334458	C/G	cg05315195	chr6:109294784	ARMC2	-0.67	-6.41	-0.37	6.73e-10	Prostate cancer;
CESC	cis	rs7927592	0.871	rs12941	chr11:68382193	C/T	cg20283391	chr11:68216788	NA	-0.61	-7.37	-0.41	2.24e-12	Total body bone mineral density;
CESC	cis	rs763121	0.853	rs4820345	chr22:39091151	T/C	cg06544989	chr22:39130855	UNC84B	0.51	8.52	0.46	1.21e-15	Menopause (age at onset);
CESC	cis	rs7191439	0.858	rs4238685	chr16:88775220	T/C	cg02389323	chr16:88786976	FAM38A	1.08	8.84	0.48	1.36e-16	Plateletcrit;
CESC	cis	rs4481887	1.000	rs7527822	chr1:248467301	A/G	cg01631408	chr1:248437212	OR2T33	-0.35	-5.15	-0.3	5.08e-7	Common traits (Other);
CESC	cis	rs2274273	0.870	rs4597235	chr14:55851987	A/G	cg04306507	chr14:55594613	LGALS3	0.3	5.88	0.34	1.24e-8	Protein biomarker;
CESC	cis	rs10744422	0.920	rs10773657	chr12:123327900	C/A	cg25930673	chr12:123319894	HIP1R	-0.72	-5.64	-0.33	4.46e-8	Schizophrenia;
CESC	cis	rs9611565	0.512	rs4822052	chr22:42193741	G/A	cg17376030	chr22:41985996	PMM1	0.71	7.52	0.42	8.45e-13	Vitiligo;
CESC	cis	rs3096299	0.719	rs2353581	chr16:89518908	T/C	cg08392591	chr16:89556376	ANKRD11	0.6	8.1	0.45	2.08e-14	Multiple myeloma (IgH translocation);
CESC	cis	rs155076	1.000	rs261430	chr13:21865242	C/T	cg11317459	chr13:21872234	NA	-1.08	-12.33	-0.6	6.43e-28	White matter hyperintensity burden;
CESC	cis	rs9322193	0.923	rs12211511	chr6:150066342	G/C	cg05861140	chr6:150128134	PCMT1	-0.35	-5.11	-0.3	6.2e-7	Lung cancer;
CESC	cis	rs1552244	1.000	rs66797209	chr3:10078526	G/A	cg00149659	chr3:10157352	C3orf10	0.77	9.66	0.51	4.22e-19	Alzheimer's disease;
CESC	cis	rs6461049	0.765	rs3800908	chr7:2159437	C/T	cg05863683	chr7:1912471	MAD1L1	0.4	5.87	0.34	1.31e-8	Schizophrenia;
CESC	cis	rs79349575	0.783	rs4793992	chr17:47008207	A/G	cg16584676	chr17:46985605	UBE2Z	0.54	6.68	0.38	1.38e-10	Type 2 diabetes;
CESC	cis	rs6493487	0.512	rs35496548	chr15:51139135	T/C	cg02338191	chr15:51200825	AP4E1	0.6	5.89	0.34	1.18e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs1008375	0.966	rs3775924	chr4:17585984	T/C	cg27347728	chr4:17578864	LAP3	0.46	5.48	0.32	9.65e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs6693567	0.565	rs696617	chr1:150376311	G/T	cg09579323	chr1:150459698	TARS2	0.47	5.88	0.34	1.23e-8	Migraine;
CESC	cis	rs933688	1.000	rs1035476	chr5:90745976	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.94	11.05	0.56	1.37e-23	Smoking behavior;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg07704502	chr1:153914740	DENND4B	0.39	6.33	0.36	1.06e-9	Fibrinogen levels;
CESC	cis	rs1005277	0.579	rs2474594	chr10:38426661	G/C	cg25427524	chr10:38739819	LOC399744	-0.67	-9.68	-0.51	3.49e-19	Extrinsic epigenetic age acceleration;
CESC	cis	rs2455799	0.613	rs12491914	chr3:15808672	A/C	cg16303742	chr3:15540471	COLQ	-0.39	-6.13	-0.35	3.09e-9	Mean platelet volume;
CESC	cis	rs7560272	0.538	rs3980695	chr2:73939552	A/G	cg20560298	chr2:73613845	ALMS1	0.43	5.89	0.34	1.19e-8	Schizophrenia;
CESC	cis	rs17023223	0.537	rs12085308	chr1:119677553	T/C	cg05756136	chr1:119680316	WARS2	-0.46	-5.65	-0.33	4.24e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CESC	cis	rs854765	0.583	rs67253360	chr17:17828973	T/C	cg09796270	chr17:17721594	SREBF1	0.43	6.05	0.35	4.93e-9	Total body bone mineral density;
CESC	trans	rs875971	0.638	rs35986979	chr7:66088990	G/A	cg26939375	chr7:64535504	NA	-0.63	-8.47	-0.46	1.68e-15	Aortic root size;
CESC	cis	rs1552244	0.882	rs112621205	chr3:10017916	G/A	cg00149659	chr3:10157352	C3orf10	0.73	8.54	0.46	1.05e-15	Alzheimer's disease;
CESC	cis	rs977987	0.872	rs3743609	chr16:75467021	G/C	cg03315344	chr16:75512273	CHST6	0.41	5.98	0.34	7.35e-9	Dupuytren's disease;
CESC	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg07677032	chr17:61819896	STRADA	0.45	5.92	0.34	1.01e-8	Prudent dietary pattern;
CESC	cis	rs977987	0.806	rs7188604	chr16:75451170	T/G	cg03315344	chr16:75512273	CHST6	0.41	5.84	0.34	1.56e-8	Dupuytren's disease;
CESC	cis	rs4073582	0.595	rs708472	chr11:65930990	A/G	cg14036092	chr11:66035641	RAB1B	0.54	7.53	0.42	7.89e-13	Gout;
CESC	cis	rs7833790	0.632	rs6415653	chr8:82702536	A/G	cg06027949	chr8:82754900	SNX16	-0.43	-5.22	-0.31	3.66e-7	Diastolic blood pressure;
CESC	cis	rs853679	0.517	rs1947862	chr6:28105196	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.54	-6.19	-0.36	2.25e-9	Depression;
CESC	cis	rs9649213	0.593	rs3801264	chr7:97950620	A/G	cg21770322	chr7:97807741	LMTK2	0.54	8.15	0.45	1.45e-14	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs4975709	0.589	rs4975744	chr5:1860049	A/G	cg12288994	chr5:1860383	NA	0.35	5.9	0.34	1.09e-8	Cardiovascular disease risk factors;
CESC	cis	rs8114671	0.967	rs4911476	chr20:33780768	A/C	cg06115741	chr20:33292138	TP53INP2	-0.42	-5.12	-0.3	6.02e-7	Height;
CESC	cis	rs4237845	0.591	rs4760344	chr12:58320783	A/T	cg00677455	chr12:58241039	CTDSP2	0.52	6.2	0.36	2.19e-9	Intelligence (multi-trait analysis);
CESC	cis	rs524281	0.861	rs11227415	chr11:65885459	C/T	cg14036092	chr11:66035641	RAB1B	0.55	5.66	0.33	3.94e-8	Electroencephalogram traits;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04498971	chr17:56084468	SFRS1	0.51	6.7	0.38	1.27e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs3749237	0.595	rs4855861	chr3:49525962	G/T	cg03060546	chr3:49711283	APEH	0.77	11.82	0.59	3.5e-26	Resting heart rate;
CESC	cis	rs472402	0.560	rs2288447	chr5:6626091	C/T	cg10789808	chr5:6633262	NSUN2;SRD5A1	-0.5	-6.65	-0.38	1.65e-10	Response to amphetamines;
CESC	cis	rs6693567	0.565	rs543179	chr1:150274610	G/A	cg09579323	chr1:150459698	TARS2	-0.44	-5.83	-0.34	1.61e-8	Migraine;
CESC	cis	rs6665290	0.904	rs1343743	chr1:227183125	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.21	-33.33	-0.9	8.91e-97	Myeloid white cell count;
CESC	cis	rs2072499	0.898	rs2736609	chr1:156202640	C/T	cg24450063	chr1:156163899	SLC25A44	0.8	11.95	0.59	1.24e-26	Testicular germ cell tumor;
CESC	cis	rs10927875	0.619	rs28537253	chr1:16148600	A/C	cg21385522	chr1:16154831	NA	-0.69	-9.72	-0.51	2.65e-19	Dilated cardiomyopathy;
CESC	cis	rs561341	0.941	rs550213	chr17:30317518	C/G	cg00745463	chr17:30367425	LRRC37B	-0.67	-6.82	-0.39	6.17e-11	Hip circumference adjusted for BMI;
CESC	cis	rs7605827	0.930	rs4668911	chr2:15610650	A/C	cg19274914	chr2:15703543	NA	0.35	6.13	0.35	3.19e-9	Educational attainment (years of education);
CESC	cis	rs6540559	0.611	rs76766079	chr1:209997731	C/T	cg23283495	chr1:209979779	IRF6	0.49	5.35	0.31	1.89e-7	Cleft lip with or without cleft palate;
CESC	cis	rs7666738	0.830	rs10012271	chr4:99065154	A/C	cg03676636	chr4:99064102	C4orf37	0.33	5.04	0.3	8.47e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg13921956	chr2:12858555	TRIB2	-0.4	-5.39	-0.31	1.53e-7	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs2228479	0.850	rs62052660	chr16:89847420	T/A	cg04013166	chr16:89971882	TCF25	0.77	6.65	0.38	1.65e-10	Skin colour saturation;
CESC	cis	rs761746	0.960	rs5753667	chr22:31905703	G/A	cg25791279	chr22:32026902	PISD	-0.49	-5.52	-0.32	7.93e-8	Intelligence;
CESC	cis	rs10242455	0.702	rs45451992	chr7:99041416	C/A	cg25640893	chr7:99214727	ZNF498	1.26	7.12	0.4	1.02e-11	Blood metabolite levels;
CESC	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.4	5.29	0.31	2.6e-7	Lymphocyte counts;
CESC	cis	rs6570726	0.693	rs450921	chr6:145864260	C/T	cg23711669	chr6:146136114	FBXO30	1.02	15.62	0.69	2.01e-39	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7914558	1.000	rs7911789	chr10:104756374	T/C	cg04362960	chr10:104952993	NT5C2	0.45	6.09	0.35	4.01e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs832540	0.618	rs41106	chr5:56145057	G/T	cg12311346	chr5:56204834	C5orf35	-0.45	-5.49	-0.32	9.29e-8	Coronary artery disease;
CESC	cis	rs9287719	0.967	rs6759740	chr2:10747271	A/G	cg00105475	chr2:10696890	NA	0.38	5.57	0.32	6.34e-8	Prostate cancer;
CESC	cis	rs853679	0.517	rs12332979	chr6:28141548	T/G	cg17949981	chr6:28129498	ZNF389	0.42	5.23	0.31	3.39e-7	Depression;
CESC	cis	rs690037	0.673	rs690573	chr3:16376440	G/T	cg23474789	chr3:16306055	DPH3;OXNAD1	-0.49	-6.64	-0.38	1.75e-10	Optic nerve measurement (cup-to-disc ratio);Optic nerve measurement (cup area);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05052335	chr5:130970657	RAPGEF6	0.46	6.01	0.35	6.11e-9	Gut microbiota (bacterial taxa);
CESC	trans	rs875971	0.508	rs6947808	chr7:66045082	A/G	cg26939375	chr7:64535504	NA	-0.53	-7.31	-0.41	3.22e-12	Aortic root size;
CESC	cis	rs10504229	0.593	rs10504216	chr8:57981470	G/A	cg22535103	chr8:58192502	C8orf71	-0.89	-8.76	-0.47	2.45e-16	Developmental language disorder (linguistic errors);
CESC	cis	rs6500395	0.925	rs16946342	chr16:48668542	G/A	cg04672837	chr16:48644449	N4BP1	0.52	6.52	0.37	3.6e-10	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs763014	0.966	rs4984675	chr16:670117	T/C	cg00802000	chr16:706648	WDR90	-0.41	-6.21	-0.36	2.02e-9	Height;
CESC	cis	rs10979	1.000	rs9484767	chr6:143887912	C/A	cg25407410	chr6:143891975	LOC285740	-0.61	-9.2	-0.49	1.11e-17	Hypospadias;
CESC	cis	rs425277	0.606	rs2257182	chr1:2082566	C/T	cg12718519	chr1:2058417	PRKCZ	-0.26	-5.56	-0.32	6.72e-8	Height;
CESC	cis	rs7412746	0.658	rs2230061	chr1:150727539	G/A	cg04414720	chr1:150670196	GOLPH3L	0.56	7.36	0.41	2.26e-12	Melanoma;
CESC	cis	rs2880765	0.835	rs4842886	chr15:86035773	G/A	cg19183879	chr15:85880815	NA	-0.25	-5.3	-0.31	2.49e-7	Coronary artery disease;
CESC	cis	rs2519796	0.531	rs2263807	chr9:136807021	A/C	cg13751417	chr9:136814406	VAV2	-0.43	-5.74	-0.33	2.59e-8	Hematocrit;Hemoglobin concentration;
CESC	cis	rs10896135	0.526	rs624561	chr11:66414915	C/T	cg15964523	chr11:66469143	SPTBN2	0.41	5.34	0.31	2.02e-7	Bipolar disorder;
CESC	trans	rs9929218	0.906	rs34565494	chr16:68741769	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.77	-9.6	-0.51	6.39e-19	Colorectal cancer;
CESC	cis	rs10883723	0.773	rs2296578	chr10:104240974	C/G	cg22532475	chr10:104410764	TRIM8	-0.32	-5.43	-0.32	1.27e-7	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs3857067	1.000	rs1588384	chr4:95001354	T/G	cg11021082	chr4:95130006	SMARCAD1	-0.5	-7.6	-0.42	5.29e-13	QT interval;
CESC	cis	rs514406	0.722	rs7552139	chr1:53387379	G/C	cg08859206	chr1:53392774	SCP2	-0.62	-8.27	-0.45	6.63e-15	Monocyte count;
CESC	cis	rs2760061	0.819	rs1745416	chr1:228204497	G/A	cg18477163	chr1:228402036	OBSCN	0.33	5.75	0.33	2.4e-8	Diastolic blood pressure;
CESC	cis	rs6580649	0.825	rs4760611	chr12:48421449	A/G	cg24011408	chr12:48396354	COL2A1	0.4	5.18	0.3	4.39e-7	Lung cancer;
CESC	cis	rs2204008	0.743	rs11495614	chr12:38156358	C/T	cg26384229	chr12:38710491	ALG10B	0.72	9.78	0.52	1.71e-19	Bladder cancer;
CESC	cis	rs875971	0.964	rs60193905	chr7:65971260	A/G	cg12463550	chr7:65579703	CRCP	0.57	7.17	0.4	7.53e-12	Aortic root size;
CESC	cis	rs6570726	0.935	rs430561	chr6:145813140	C/T	cg23711669	chr6:146136114	FBXO30	0.81	12.75	0.62	2.41e-29	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2180341	0.960	rs7756884	chr6:127684018	A/G	cg27446573	chr6:127587934	RNF146	1.06	15.51	0.69	4.62e-39	Breast cancer;
CESC	cis	rs35306767	0.953	rs35174953	chr10:961191	C/A	cg20503657	chr10:835505	NA	0.75	8.33	0.46	4.53e-15	Eosinophil percentage of granulocytes;
CESC	cis	rs6121246	0.529	rs6120862	chr20:30199459	T/C	cg13852791	chr20:30311386	BCL2L1	0.55	5.13	0.3	5.66e-7	Mean corpuscular hemoglobin;
CESC	cis	rs9595066	0.627	rs9562536	chr13:44731588	G/A	cg04068111	chr13:44716778	NA	-0.44	-6.01	-0.35	6.17e-9	Schizophrenia;
CESC	cis	rs6456156	0.565	rs6456153	chr6:167472167	T/C	cg23791538	chr6:167370224	RNASET2	-0.5	-6.44	-0.37	5.46e-10	Primary biliary cholangitis;
CESC	cis	rs1185460	0.967	rs4545564	chr11:118937518	T/C	cg01677386	chr11:118938358	VPS11	-0.44	-5.64	-0.33	4.35e-8	Coronary artery disease;
CESC	cis	rs7552404	1.000	rs4559448	chr1:76203456	A/G	cg03433033	chr1:76189801	ACADM	0.7	8.56	0.47	9.39e-16	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs5758659	0.845	rs5758645	chr22:42598951	T/G	cg05082376	chr22:42548792	NA	-0.37	-5.41	-0.32	1.4e-7	Cognitive function;
CESC	cis	rs7520050	0.966	rs6677007	chr1:46400590	A/G	cg24296786	chr1:45957014	TESK2	0.44	5.49	0.32	9.64e-8	Red blood cell count;Reticulocyte count;
CESC	cis	rs3820068	0.705	rs4646022	chr1:15839112	G/A	cg18192808	chr1:15853278	DNAJC16	0.46	5.7	0.33	3.23e-8	Systolic blood pressure;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg26085966	chr14:64319812	SYNE2	-0.49	-6.24	-0.36	1.69e-9	Fibrinogen levels;
CESC	cis	rs6570726	0.967	rs373527	chr6:145801861	C/T	cg05347473	chr6:146136440	FBXO30	0.42	5.76	0.33	2.38e-8	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7481584	0.624	rs369461	chr11:3061992	A/G	cg25174290	chr11:3078921	CARS	-0.54	-7.58	-0.42	5.79e-13	Calcium levels;
CESC	cis	rs12586317	0.547	rs112138868	chr14:35444385	C/T	cg16230307	chr14:35515116	FAM177A1	0.96	10.66	0.55	2.55e-22	Psoriasis;
CESC	cis	rs5750830	0.649	rs5750822	chr22:39826788	C/T	cg01416388	chr22:39784598	NA	-0.57	-6.9	-0.39	3.89e-11	Intelligence (multi-trait analysis);
CESC	cis	rs8031584	0.958	rs3512	chr15:31235005	G/C	cg14298792	chr15:30685198	CHRFAM7A	-0.46	-5.51	-0.32	8.45e-8	Huntington's disease progression;
CESC	cis	rs7580658	0.676	rs4662717	chr2:128013504	C/T	cg10021288	chr2:128175891	PROC	-0.33	-5.35	-0.31	1.9e-7	Protein C levels;
CESC	cis	rs12500824	0.564	rs62300856	chr4:77282063	C/T	cg20311846	chr4:77356250	SHROOM3	0.37	6.88	0.39	4.32e-11	Coronary artery disease;
CESC	cis	rs9346455	0.614	rs9364151	chr6:71997071	T/C	cg27238071	chr6:71998145	OGFRL1	0.6	5.93	0.34	9.65e-9	Antipsychotic drug-induced weight gain (time interaction);Antipsychotic drug-induced weight gain;
CESC	cis	rs62458065	0.713	rs28421905	chr7:32489501	G/A	cg20159608	chr7:32802032	NA	-0.53	-5.08	-0.3	7.29e-7	Metabolite levels (HVA/MHPG ratio);
CESC	cis	rs2243480	1.000	rs316329	chr7:65608416	A/C	cg12463550	chr7:65579703	CRCP	0.76	5.82	0.34	1.69e-8	Diabetic kidney disease;
CESC	cis	rs11098499	0.954	rs6822679	chr4:120402702	A/C	cg09307838	chr4:120376055	NA	0.93	13.0	0.62	3.14e-30	Corneal astigmatism;
CESC	cis	rs6500395	0.962	rs9922356	chr16:48640025	C/T	cg04672837	chr16:48644449	N4BP1	0.47	5.57	0.32	6.4e-8	Response to tocilizumab in rheumatoid arthritis;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg15330255	chr10:103454985	FBXW4	-0.45	-6.1	-0.35	3.75e-9	Asthma;
CESC	cis	rs4555082	0.645	rs2816605	chr14:105715515	C/T	cg06808227	chr14:105710500	BRF1	-0.52	-5.69	-0.33	3.44e-8	Mean platelet volume;Platelet distribution width;
CESC	cis	rs7927771	0.524	rs4752860	chr11:47705015	C/A	cg18512352	chr11:47633146	NA	-0.36	-5.65	-0.33	4.17e-8	Subjective well-being;
CESC	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.5	-7.45	-0.42	1.33e-12	Longevity;Endometriosis;
CESC	cis	rs910316	0.737	rs175510	chr14:75524839	G/A	cg11812906	chr14:75593930	NEK9	-0.84	-13.7	-0.64	1.13e-32	Height;
CESC	cis	rs853679	0.550	rs1225598	chr6:28160799	T/G	cg17949981	chr6:28129498	ZNF389	0.42	5.38	0.31	1.6e-7	Depression;
CESC	cis	rs10871290	0.507	rs3851731	chr16:74485788	C/T	cg01733217	chr16:74700730	RFWD3	0.62	7.66	0.43	3.52e-13	Breast cancer;
CESC	cis	rs8067545	0.611	rs9898080	chr17:20035257	A/G	cg13482628	chr17:19912719	NA	0.4	5.21	0.3	3.75e-7	Schizophrenia;
CESC	cis	rs34779708	0.931	rs11010130	chr10:35513307	T/C	cg03585969	chr10:35415529	CREM	0.75	9.3	0.5	5.36e-18	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs524281	0.861	rs3825067	chr11:65878419	A/G	cg14036092	chr11:66035641	RAB1B	0.6	6.27	0.36	1.47e-9	Electroencephalogram traits;
CESC	cis	rs2880765	0.835	rs4843063	chr15:86048748	G/T	cg10818794	chr15:86012489	AKAP13	-0.34	-5.22	-0.31	3.68e-7	Coronary artery disease;
CESC	cis	rs9649213	0.593	rs13246725	chr7:97914898	C/G	cg24562669	chr7:97807699	LMTK2	0.47	6.73	0.38	1.07e-10	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs1511802	0.501	rs7661323	chr4:187115996	T/G	cg24794857	chr4:187113578	CYP4V2	0.41	5.14	0.3	5.31e-7	Blood protein levels;
CESC	cis	rs473651	0.935	rs559579	chr2:239339501	G/C	cg21699342	chr2:239360505	ASB1	0.41	5.72	0.33	2.92e-8	Multiple system atrophy;
CESC	cis	rs67460515	0.563	rs13071892	chr3:160817877	A/C	cg03342759	chr3:160939853	NMD3	-0.51	-6.44	-0.37	5.65e-10	Parkinson's disease;
CESC	cis	rs11785693	0.862	rs73183633	chr8:4994543	G/A	cg26367366	chr8:4980734	NA	0.84	8.09	0.45	2.16e-14	Neuroticism (multi-trait analysis);Neuroticism;
CESC	cis	rs17253792	0.822	rs78261053	chr14:56061784	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.84	5.62	0.33	4.81e-8	Putamen volume;
CESC	cis	rs941207	0.507	rs1107479	chr12:57030686	C/T	cg05584118	chr12:57595605	LRP1	0.38	5.35	0.31	1.92e-7	Platelet count;
CESC	cis	rs7666738	0.830	rs1115616	chr4:99006603	A/C	cg18180107	chr4:99064573	C4orf37	0.4	5.23	0.31	3.41e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11722228	0.508	rs3756227	chr4:10087995	C/A	cg26043149	chr18:55253948	FECH	0.88	10.88	0.56	4.95e-23	Gout;Urate levels;Serum uric acid levels;
CESC	cis	rs12986413	0.624	rs2108825	chr19:2136515	T/C	cg09261902	chr19:2140048	AP3D1	0.35	5.53	0.32	7.79e-8	Height;
CESC	cis	rs6736093	0.966	rs11676040	chr2:112713115	T/C	cg12686935	chr2:112915763	FBLN7	-0.42	-5.46	-0.32	1.1e-7	Coronary artery disease;
CESC	cis	rs4423214	0.840	rs1790341	chr11:71177578	T/C	cg05163923	chr11:71159392	DHCR7	-0.65	-7.55	-0.42	6.91e-13	Vitamin D levels;
CESC	cis	rs1707322	0.721	rs10789471	chr1:46215619	G/A	cg03146154	chr1:46216737	IPP	0.82	11.53	0.58	3.39e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs74181299	0.964	rs2723065	chr2:65279414	A/G	cg05010058	chr2:65284262	CEP68	0.33	5.79	0.34	1.98e-8	Pulse pressure;
CESC	cis	rs3747547	0.818	rs7027227	chr9:37929809	C/G	cg13774184	chr9:37916125	SHB	0.48	5.21	0.3	3.84e-7	Metabolite levels (Dihydroxy docosatrienoic acid);
CESC	trans	rs11098499	0.604	rs17051352	chr4:120581427	G/A	cg25214090	chr10:38739885	LOC399744	0.61	8.03	0.44	3.12e-14	Corneal astigmatism;
CESC	cis	rs7582720	1.000	rs7605484	chr2:203724495	T/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	7.32	0.41	3.04e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
CESC	cis	rs1448094	0.511	rs10863080	chr12:86153149	C/T	cg02569458	chr12:86230093	RASSF9	-0.46	-7.15	-0.4	8.28e-12	Major depressive disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06166242	chr6:148663498	SASH1	-0.59	-7.33	-0.41	2.85e-12	Gut microbiome composition (summer);
CESC	cis	rs4664304	0.658	rs2667015	chr2:160868586	T/C	cg03641300	chr2:160917029	PLA2R1	-0.46	-6.53	-0.37	3.38e-10	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs9902453	0.904	rs8071742	chr17:28361669	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.62	-7.84	-0.43	1.11e-13	Coffee consumption (cups per day);
CESC	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	10.5	0.54	8.84e-22	Prudent dietary pattern;
CESC	cis	rs11098499	0.863	rs17050695	chr4:120489527	G/T	cg09307838	chr4:120376055	NA	0.88	11.81	0.59	3.78e-26	Corneal astigmatism;
CESC	cis	rs61931739	0.500	rs11053066	chr12:34185318	G/A	cg19457237	chr12:34500585	NA	-0.39	-5.39	-0.31	1.53e-7	Morning vs. evening chronotype;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09983252	chr4:119555556	NA	-0.59	-7.48	-0.42	1.1e-12	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19009323	chr9:132935030	FREQ	-0.57	-6.03	-0.35	5.41e-9	Gut microbiome composition (summer);
CESC	cis	rs3020736	0.500	rs6002616	chr22:42504679	A/G	cg15557168	chr22:42548783	NA	0.45	6.3	0.36	1.25e-9	Autism spectrum disorder or schizophrenia;
CESC	cis	rs9660992	0.710	rs1180721	chr1:205232696	T/C	cg21643547	chr1:205240462	TMCC2	-0.49	-6.84	-0.39	5.31e-11	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs9457247	0.602	rs17615336	chr6:167506734	A/G	cg23791538	chr6:167370224	RNASET2	-0.54	-6.79	-0.38	7.52e-11	Crohn's disease;
CESC	cis	rs3096299	0.509	rs4785691	chr16:89597221	A/G	cg00750074	chr16:89608354	SPG7	-0.41	-5.75	-0.33	2.44e-8	Multiple myeloma (IgH translocation);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15141371	chr3:39195098	CSRNP1	0.5	6.02	0.35	5.7e-9	Gut microbiome composition (summer);
CESC	cis	rs644799	0.610	rs1255179	chr11:95472097	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.49	6.91	0.39	3.66e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs727505	0.866	rs56216989	chr7:124729068	T/A	cg23710748	chr7:124431027	NA	-0.4	-6.52	-0.37	3.56e-10	Lewy body disease;
CESC	cis	rs514406	0.679	rs11585495	chr1:53244331	T/C	cg08859206	chr1:53392774	SCP2	0.72	11.25	0.57	2.95e-24	Monocyte count;
CESC	cis	rs807669	0.934	rs762523	chr22:19180589	A/G	cg02655711	chr22:19163373	SLC25A1	0.97	15.0	0.68	2.98e-37	Metabolite levels;
CESC	cis	rs10876993	0.928	rs10877008	chr12:58103592	A/G	cg18357645	chr12:58087776	OS9	0.64	10.52	0.54	7.31e-22	Celiac disease or Rheumatoid arthritis;
CESC	trans	rs2415984	0.846	rs35563644	chr14:46850583	A/G	cg14945696	chr3:52713679	PBRM1	-0.4	-6.02	-0.35	5.85e-9	Number of children ever born;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20947082	chr1:233749643	KCNK1	0.52	6.11	0.35	3.54e-9	Gut microbiome composition (summer);
CESC	cis	rs9300255	0.620	rs1727311	chr12:123660716	T/G	cg00376283	chr12:123451042	ABCB9	0.61	6.2	0.36	2.2e-9	Neutrophil percentage of white cells;
CESC	trans	rs17685	0.712	rs7785025	chr7:75628101	C/T	cg19862616	chr7:65841803	NCRNA00174	-0.82	-11.82	-0.59	3.56e-26	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs9902453	1.000	rs4533340	chr17:28277951	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.64	8.28	0.45	6.2e-15	Coffee consumption (cups per day);
CESC	cis	rs965469	0.817	rs16988490	chr20:3335431	C/T	cg17110299	chr20:3385021	C20orf194	-0.41	-5.3	-0.31	2.42e-7	IFN-related cytopenia;
CESC	cis	rs9649213	0.593	rs6465666	chr7:97937258	C/T	cg00277769	chr7:97922759	BAIAP2L1	0.32	5.2	0.3	4.05e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs7208859	0.573	rs73267873	chr17:29068457	C/T	cg19761014	chr17:28927070	LRRC37B2	0.72	6.21	0.36	2.07e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs77106637	0.860	rs11603334	chr11:72432985	G/A	cg03713592	chr11:72463424	ARAP1	1.22	11.1	0.56	9.43e-24	Type 2 diabetes;
CESC	cis	rs2637266	0.967	rs12246436	chr10:78352914	C/T	cg18941641	chr10:78392320	NA	0.41	7.55	0.42	7.02e-13	Pulmonary function;
CESC	cis	rs4642101	0.737	rs4447735	chr3:12825513	C/T	cg24848339	chr3:12840334	CAND2	0.38	5.92	0.34	1.01e-8	QRS complex (12-leadsum);
CESC	cis	rs829883	0.724	rs11109508	chr12:98905985	T/C	cg25150519	chr12:98850993	NA	-0.64	-7.91	-0.44	7.1e-14	Colorectal adenoma (advanced);
CESC	cis	rs597539	0.616	rs72945243	chr11:68633358	T/C	cg01988459	chr11:68622903	NA	-0.38	-5.19	-0.3	4.26e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs1953600	0.754	rs2573348	chr10:81925785	C/T	cg00277334	chr10:82204260	NA	-0.42	-5.89	-0.34	1.16e-8	Sarcoidosis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20543431	chr6:34857162	ANKS1A;TAF11	0.55	6.0	0.35	6.3e-9	Gut microbiome composition (summer);
CESC	trans	rs2018683	1.000	rs4719962	chr7:28999237	G/A	cg19402173	chr7:128379420	CALU	-0.65	-8.51	-0.46	1.33e-15	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
CESC	cis	rs10883723	0.810	rs7074343	chr10:104283165	G/A	cg22532475	chr10:104410764	TRIM8	-0.33	-5.67	-0.33	3.77e-8	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs7129220	0.512	rs1867137	chr11:10228809	G/A	cg01453529	chr11:10209919	SBF2	-0.45	-5.55	-0.32	6.79e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CESC	cis	rs9303280	0.934	rs56380902	chr17:38066372	T/C	cg20243544	chr17:37824526	PNMT	0.51	6.96	0.39	2.67e-11	Self-reported allergy;
CESC	cis	rs6540559	0.673	rs114467813	chr1:210017785	G/A	cg23283495	chr1:209979779	IRF6	0.5	5.32	0.31	2.16e-7	Cleft lip with or without cleft palate;
CESC	trans	rs2688325	0.699	rs13251994	chr8:3757722	G/C	cg00283030	chr2:132056444	LOC440910	-0.31	-6.24	-0.36	1.72e-9	Menarche (age at onset);
CESC	cis	rs684232	0.666	rs838372	chr17:566428	C/T	cg12384639	chr17:618140	VPS53	0.4	5.2	0.3	3.92e-7	Prostate cancer;
CESC	cis	rs2836950	0.501	rs2836984	chr21:40700949	A/C	cg17971929	chr21:40555470	PSMG1	-0.6	-7.87	-0.44	9.13e-14	Menarche (age at onset);
CESC	cis	rs7412746	0.658	rs10305714	chr1:150800655	C/T	cg22823121	chr1:150693482	HORMAD1	-0.45	-6.36	-0.36	9e-10	Melanoma;
CESC	trans	rs629535	0.814	rs72654071	chr8:70079484	A/G	cg21567404	chr3:27674614	NA	-0.89	-10.53	-0.54	6.98e-22	Dupuytren's disease;
CESC	cis	rs6952808	0.895	rs4513875	chr7:1928159	C/T	cg08027265	chr7:2291960	NA	-0.35	-5.26	-0.31	2.91e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs9914544	0.689	rs8073236	chr17:18787182	C/G	cg26378065	chr17:18585709	ZNF286B	0.45	5.99	0.35	6.73e-9	Educational attainment (years of education);
CESC	cis	rs2836974	0.897	rs2836932	chr21:40546717	G/A	cg17971929	chr21:40555470	PSMG1	1.05	16.19	0.71	1.86e-41	Cognitive function;
CESC	cis	rs637571	0.615	rs10160792	chr11:65667149	C/G	cg02202077	chr11:65769826	EIF1AD;BANF1	0.42	5.19	0.3	4.18e-7	Eosinophil percentage of white cells;
CESC	cis	rs4919694	1.000	rs17787717	chr10:104695699	T/G	cg04362960	chr10:104952993	NT5C2	0.76	5.99	0.35	6.7e-9	Arsenic metabolism;
CESC	cis	rs2479106	0.656	rs7857196	chr9:126465958	A/G	cg16191174	chr9:126692580	DENND1A	-0.42	-5.1	-0.3	6.37e-7	Polycystic ovary syndrome;
CESC	cis	rs12048904	0.505	rs11166508	chr1:101233511	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.73	-9.12	-0.49	1.93e-17	Multiple sclerosis;
CESC	cis	rs2228479	0.867	rs34604714	chr16:89948985	A/G	cg00800038	chr16:89945340	TCF25	-0.88	-7.85	-0.43	1.01e-13	Skin colour saturation;
CESC	cis	rs2072732	0.756	rs55949537	chr1:2936746	A/T	cg03976712	chr1:2946727	NA	0.33	5.15	0.3	5.01e-7	Plateletcrit;
CESC	cis	rs3806843	1.000	rs3733707	chr5:140181892	T/C	cg16179182	chr5:140090404	VTRNA1-1	-0.4	-5.16	-0.3	4.96e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs1801251	0.727	rs283482	chr2:233646920	A/T	cg25237894	chr2:233734115	C2orf82	0.36	6.18	0.35	2.46e-9	Coronary artery disease;
CESC	cis	rs858239	0.600	rs6956595	chr7:23134256	A/G	cg23682824	chr7:23144976	KLHL7	0.54	7.34	0.41	2.63e-12	Cerebrospinal fluid biomarker levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23819836	chr6:15663134	DTNBP1	0.6	7.32	0.41	2.88e-12	Gut microbiome composition (summer);
CESC	cis	rs7243790	0.805	rs12604412	chr18:51899292	A/G	cg04730925	chr18:51795821	POLI	-0.42	-5.56	-0.32	6.66e-8	Diastolic blood pressure;
CESC	cis	rs9611565	0.877	rs3817999	chr22:41747717	A/G	cg03806693	chr22:41940476	POLR3H	0.8	10.05	0.53	2.49e-20	Vitiligo;
CESC	trans	rs12310956	0.532	rs1906134	chr12:33957135	A/C	cg26384229	chr12:38710491	ALG10B	0.59	8.35	0.46	3.79e-15	Morning vs. evening chronotype;
CESC	cis	rs4713118	0.587	rs9393899	chr6:28133528	G/C	cg08968635	chr6:28129556	ZNF389	0.4	5.22	0.31	3.69e-7	Parkinson's disease;
CESC	cis	rs713587	0.521	rs6545766	chr2:25077856	C/T	cg01884057	chr2:25150051	NA	0.35	6.61	0.38	2.09e-10	Body mass index in non-asthmatics;
CESC	cis	rs2153904	0.793	rs1772145	chr1:205695695	C/T	cg23034840	chr1:205782522	SLC41A1	0.54	5.91	0.34	1.06e-8	Prostate-specific antigen levels;
CESC	cis	rs8062405	0.755	rs55792032	chr16:28599411	A/G	cg07382826	chr16:28625726	SULT1A1	0.4	6.72	0.38	1.11e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs6938	0.618	rs2044157	chr15:75225808	G/C	cg17294928	chr15:75287854	SCAMP5	0.51	6.65	0.38	1.66e-10	Breast cancer;
CESC	cis	rs7267979	1.000	rs2474777	chr20:25272633	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.8	15.92	0.7	1.64e-40	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs9910055	0.593	rs58392387	chr17:42297889	A/G	cg13607699	chr17:42295918	UBTF	0.86	12.51	0.61	1.53e-28	Total body bone mineral density;
CESC	cis	rs7100689	0.753	rs1856773	chr10:82060484	T/A	cg09936400	chr10:82049201	MAT1A	0.37	5.3	0.31	2.41e-7	Post bronchodilator FEV1;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg17371487	chr19:9789027	NA	0.37	6.41	0.37	6.61e-10	Gambling;
CESC	cis	rs6598955	0.543	rs112752634	chr1:26534217	G/A	cg04990556	chr1:26633338	UBXN11	0.81	9.12	0.49	1.92e-17	Obesity-related traits;
CESC	cis	rs2996428	0.628	rs6667526	chr1:3774603	G/A	cg22529645	chr1:3704559	LRRC47	0.4	5.06	0.3	7.7e-7	Red cell distribution width;
CESC	cis	rs736408	0.609	rs13061423	chr3:52790213	T/C	cg17372223	chr3:52568218	NT5DC2	0.44	6.49	0.37	4.23e-10	Bipolar disorder;
CESC	cis	rs17253792	0.822	rs28478195	chr14:56047851	G/A	cg01858014	chr14:56050164	KTN1	-0.96	-7.65	-0.43	3.84e-13	Putamen volume;
CESC	cis	rs853679	0.517	rs868987	chr6:28110148	A/G	cg08968635	chr6:28129556	ZNF389	-0.42	-5.62	-0.33	4.9e-8	Depression;
CESC	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.57	-6.82	-0.39	6.12e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs1003719	0.788	rs8133549	chr21:38447489	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.62	8.71	0.47	3.4e-16	Eye color traits;
CESC	cis	rs5769765	0.773	rs6520065	chr22:50294470	A/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.45	-5.21	-0.3	3.79e-7	Schizophrenia;
CESC	cis	rs4722166	0.695	rs7793125	chr7:22809160	A/G	cg13104385	chr7:22767384	IL6	0.38	5.62	0.33	4.78e-8	Lung cancer;
CESC	cis	rs6693567	0.507	rs863862	chr1:150352361	T/A	cg09579323	chr1:150459698	TARS2	0.48	6.12	0.35	3.27e-9	Migraine;
CESC	cis	rs9815354	0.812	rs73073355	chr3:41842332	G/A	cg03022575	chr3:42003672	ULK4	0.7	6.04	0.35	5.26e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs7959452	0.590	rs11177643	chr12:69785712	T/G	cg20891283	chr12:69753455	YEATS4	0.9	14.98	0.68	3.63e-37	Blood protein levels;
CESC	cis	rs16854884	0.657	rs6791078	chr3:143736876	A/G	cg06585982	chr3:143692056	C3orf58	0.5	6.7	0.38	1.26e-10	Economic and political preferences (feminism/equality);
CESC	cis	rs11901793	0.505	rs34446892	chr2:237495452	C/T	cg25295825	chr2:237489920	CXCR7	0.66	5.86	0.34	1.38e-8	Total mean fractional anisotropy measurement in first episode schizophrenia;
CESC	cis	rs2425143	1.000	rs6058303	chr20:34290281	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.63	5.54	0.32	7.37e-8	Blood protein levels;
CESC	cis	rs5769707	0.632	rs135871	chr22:50008969	A/G	cg20744362	chr22:50050164	C22orf34	0.37	5.24	0.31	3.23e-7	Monocyte count;Monocyte percentage of white cells;
CESC	cis	rs1448094	0.511	rs61930035	chr12:86153695	G/A	cg02569458	chr12:86230093	RASSF9	0.51	7.7	0.43	2.65e-13	Major depressive disorder;
CESC	cis	rs7580658	0.864	rs1566823	chr2:128018192	A/G	cg10021288	chr2:128175891	PROC	-0.38	-6.1	-0.35	3.64e-9	Protein C levels;
CESC	cis	rs2576037	0.899	rs7233515	chr18:44585955	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.37	5.63	0.33	4.52e-8	Personality dimensions;
CESC	cis	rs9837602	1.000	rs6790877	chr3:99779658	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.5	7.11	0.4	1.1e-11	Breast cancer;
CESC	cis	rs2066819	1.000	rs2695788	chr12:56697110	G/A	cg26316697	chr12:56727976	PAN2	-0.69	-6.64	-0.38	1.74e-10	Psoriasis vulgaris;
CESC	cis	rs7247513	0.930	rs34321000	chr19:12713088	C/T	cg11738485	chr19:12877000	HOOK2	0.42	5.16	0.3	4.77e-7	Bipolar disorder;
CESC	cis	rs1218582	0.745	rs1580943	chr1:154865125	G/A	cg24250549	chr1:154909240	PMVK	0.72	10.85	0.55	6.34e-23	Prostate cancer;
CESC	cis	rs6964587	0.935	rs9770444	chr7:91783162	T/G	cg17063962	chr7:91808500	NA	0.59	8.24	0.45	8.03e-15	Breast cancer;
CESC	cis	rs6973256	0.637	rs1362739	chr7:133430934	C/A	cg10665199	chr7:133106180	EXOC4	0.43	6.0	0.35	6.45e-9	Intelligence (multi-trait analysis);
CESC	cis	rs853679	0.550	rs1233701	chr6:28168726	C/G	cg17949981	chr6:28129498	ZNF389	-0.43	-5.66	-0.33	4.02e-8	Depression;
CESC	trans	rs7618501	0.602	rs34831713	chr3:50118748	T/C	cg21659725	chr3:3221576	CRBN	-0.5	-7.0	-0.4	2.12e-11	Intelligence (multi-trait analysis);
CESC	trans	rs2963826	0.589	rs298091	chr5:58996603	A/T	cg03705947	chr1:68152081	GADD45A	0.5	6.81	0.39	6.38e-11	Obesity-related traits;
CESC	cis	rs6912958	0.967	rs6914299	chr6:88149176	T/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.33	-5.51	-0.32	8.64e-8	Monocyte percentage of white cells;
CESC	trans	rs975752	0.850	rs10883450	chr10:101923421	C/T	cg16450097	chr8:101348467	NA	-0.47	-6.18	-0.35	2.38e-9	Schizophrenia;
CESC	cis	rs67460515	0.563	rs11720263	chr3:160848293	T/C	cg03342759	chr3:160939853	NMD3	-0.53	-6.82	-0.39	6.24e-11	Parkinson's disease;
CESC	cis	rs2075371	1.000	rs2544221	chr7:133993014	G/C	cg00033643	chr7:134001901	SLC35B4	0.43	5.52	0.32	7.93e-8	Mean platelet volume;
CESC	cis	rs2302190	0.882	rs8068135	chr17:56654210	A/C	cg25885038	chr17:56607967	SEPT4	-0.4	-5.43	-0.32	1.27e-7	Vitamin D levels;
CESC	cis	rs2204008	0.774	rs11514062	chr12:38332297	A/C	cg26384229	chr12:38710491	ALG10B	0.65	9.65	0.51	4.47e-19	Bladder cancer;
CESC	cis	rs10870270	1.000	rs10781564	chr10:133757922	A/G	cg08754478	chr10:133766260	PPP2R2D	-0.58	-7.58	-0.42	5.74e-13	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
CESC	cis	rs11098499	0.821	rs3775852	chr4:120454556	A/G	cg09307838	chr4:120376055	NA	0.91	12.54	0.61	1.24e-28	Corneal astigmatism;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg24596729	chr1:165345813	NA	-0.49	-6.67	-0.38	1.48e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs1707322	0.721	rs61784796	chr1:46163256	A/G	cg05343316	chr1:45956843	TESK2	0.51	6.2	0.36	2.19e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs4849845	0.598	rs4848586	chr2:121061291	C/T	cg24070213	chr2:121070622	NA	0.42	6.08	0.35	4.29e-9	Mean platelet volume;
CESC	cis	rs5758659	0.714	rs5751220	chr22:42516205	A/C	cg05082376	chr22:42548792	NA	0.35	5.11	0.3	6.08e-7	Cognitive function;
CESC	cis	rs10791323	0.604	rs2257010	chr11:133712348	G/A	cg06766960	chr11:133703094	NA	-0.38	-5.38	-0.31	1.61e-7	Childhood ear infection;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg15533809	chr19:2076775	MOBKL2A	0.44	6.09	0.35	4.04e-9	Fibrinogen levels;
CESC	cis	rs9584850	0.574	rs60492361	chr13:99172653	T/C	cg20750642	chr13:99100586	FARP1	-0.36	-5.18	-0.3	4.32e-7	Neuroticism;
CESC	cis	rs7647973	1.000	rs12583	chr3:49571462	G/T	cg06212747	chr3:49208901	KLHDC8B	-0.6	-7.74	-0.43	2.09e-13	Menarche (age at onset);
CESC	cis	rs9733	0.596	rs72702536	chr1:150662574	C/T	cg04414720	chr1:150670196	GOLPH3L	0.63	9.03	0.49	3.64e-17	Tonsillectomy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27665823	chr16:460516	DECR2	-0.63	-7.1	-0.4	1.16e-11	Gut microbiome composition (summer);
CESC	cis	rs2404602	0.536	rs17364330	chr15:76765385	A/T	cg26408565	chr15:76604113	ETFA	-0.43	-6.41	-0.37	6.6e-10	Blood metabolite levels;
CESC	cis	rs933688	1.000	rs10059163	chr5:90742444	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.15	15.71	0.69	9.34e-40	Smoking behavior;
CESC	cis	rs7267979	1.000	rs4815408	chr20:25346678	C/T	cg08601574	chr20:25228251	PYGB	-0.38	-5.44	-0.32	1.21e-7	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs2933343	0.859	rs789245	chr3:128583580	C/A	cg25356066	chr3:128598488	ACAD9	0.55	6.75	0.38	9.52e-11	IgG glycosylation;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05402854	chr6:111408840	SLC16A10	0.53	6.54	0.37	3.15e-10	Gut microbiome composition (summer);
CESC	cis	rs734999	0.566	rs4648658	chr1:2560882	G/A	cg20673091	chr1:2541236	MMEL1	-0.47	-8.15	-0.45	1.49e-14	Ulcerative colitis;
CESC	cis	rs2569991	0.636	rs361221	chr3:12922767	A/C	cg22481960	chr3:13008800	IQSEC1	0.54	6.59	0.38	2.43e-10	Periodontitis (DPAL);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg20269352	chr1:44483206	SLC6A9	-0.38	-6.52	-0.37	3.52e-10	Gambling;
CESC	cis	rs7772486	0.875	rs2777484	chr6:146334162	A/G	cg23711669	chr6:146136114	FBXO30	0.81	11.71	0.58	8.24e-26	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs10504229	0.861	rs67042991	chr8:58191749	G/C	cg05313129	chr8:58192883	C8orf71	-0.55	-6.29	-0.36	1.34e-9	Developmental language disorder (linguistic errors);
CESC	cis	rs60154123	0.730	rs652241	chr1:210465029	A/T	cg25204440	chr1:209979598	IRF6	0.45	5.05	0.3	8.23e-7	Coronary artery disease;
CESC	cis	rs962856	0.756	rs13016812	chr2:67624302	C/T	cg09028215	chr2:67624308	ETAA1	0.43	5.38	0.31	1.67e-7	Pancreatic cancer;
CESC	cis	rs7412746	0.611	rs111842513	chr1:150712926	G/A	cg22823121	chr1:150693482	HORMAD1	0.47	6.86	0.39	4.77e-11	Melanoma;
CESC	cis	rs3784262	0.757	rs74655564	chr15:58325512	G/C	cg12031962	chr15:58353849	ALDH1A2	-0.35	-5.3	-0.31	2.39e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
CESC	cis	rs593982	0.858	rs537385	chr11:65504900	G/A	cg08755490	chr11:65554678	OVOL1	1.31	20.14	0.78	2.41e-55	Atopic dermatitis;
CESC	cis	rs11792861	0.926	rs72607166	chr9:111821530	A/C	cg05043794	chr9:111880884	C9orf5	-0.39	-6.38	-0.37	7.75e-10	Menarche (age at onset);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg23248324	chr6:80714171	TTK	-0.42	-6.01	-0.35	5.97e-9	Gut microbiota (bacterial taxa);
CESC	trans	rs7107217	1.000	rs1873872	chr11:129473993	A/T	cg01708236	chr6:44233446	NFKBIE	0.49	6.32	0.36	1.08e-9	Breast cancer;Type 2 diabetes;
CESC	cis	rs1670533	1.000	rs6852155	chr4:1067638	T/G	cg04106633	chr4:1044584	NA	0.42	5.35	0.31	1.94e-7	Recombination rate (females);
CESC	cis	rs6991838	0.584	rs66467166	chr8:66486400	C/A	cg13398993	chr8:66546079	ARMC1	-0.45	-5.54	-0.32	7.3900000000000007e-08	Intelligence (multi-trait analysis);
CESC	cis	rs10744422	1.000	rs2292135	chr12:123334075	G/A	cg25930673	chr12:123319894	HIP1R	-0.72	-5.73	-0.33	2.79e-8	Schizophrenia;
CESC	trans	rs7863342	0.766	rs28508550	chr9:71423303	T/C	cg09576762	chr15:99548859	LOC145814	-0.32	-6.18	-0.35	2.47e-9	Cancer;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg26652484	chr3:57582327	ARF4	-0.44	-6.2	-0.36	2.13e-9	Asthma;
CESC	trans	rs9329221	0.868	rs7831557	chr8:10280228	C/T	cg15556689	chr8:8085844	FLJ10661	-0.55	-6.42	-0.37	6.19e-10	Neuroticism;
CESC	cis	rs780096	0.526	rs7602534	chr2:27592423	C/T	cg22903471	chr2:27725779	GCKR	-0.57	-8.2	-0.45	1.04e-14	Total body bone mineral density;
CESC	cis	rs28386778	0.701	rs2727337	chr17:61991966	G/A	cg11494091	chr17:61959527	GH2	-0.8	-14.94	-0.68	5e-37	Prudent dietary pattern;
CESC	cis	rs11997175	0.603	rs7464072	chr8:33776973	G/A	ch.8.33884649F	chr8:33765107	NA	0.53	6.85	0.39	5.24e-11	Body mass index;
CESC	cis	rs7617773	1.000	rs12496784	chr3:48186267	C/T	cg11946769	chr3:48343235	NME6	-0.61	-8.11	-0.45	1.84e-14	Coronary artery disease;
CESC	cis	rs7618915	0.501	rs2079929	chr3:52765646	C/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.31	5.57	0.32	6.31e-8	Bipolar disorder;
CESC	cis	rs7618915	0.501	rs2336146	chr3:52626646	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	7.55	0.42	7.15e-13	Bipolar disorder;
CESC	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.41	-5.33	-0.31	2.09e-7	Longevity;Endometriosis;
CESC	cis	rs9287719	0.967	rs4669599	chr2:10758029	T/C	cg02196655	chr2:10830764	NOL10	-0.37	-5.67	-0.33	3.73e-8	Prostate cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17979991	chr7:43769177	C7orf44	0.62	7.28	0.41	3.75e-12	Gut microbiome composition (summer);
CESC	cis	rs9611565	0.659	rs12483786	chr22:41938536	A/G	cg03806693	chr22:41940476	POLR3H	-1.19	-15.04	-0.68	2.19e-37	Vitiligo;
CESC	cis	rs7223966	1.000	rs6504173	chr17:61735056	T/C	cg11494091	chr17:61959527	GH2	0.38	5.42	0.32	1.34e-7	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs863345	0.967	rs7511912	chr1:158531808	C/T	cg12129480	chr1:158549410	OR10X1	-0.33	-6.64	-0.38	1.74e-10	Pneumococcal bacteremia;
CESC	cis	rs2836974	0.831	rs2836964	chr21:40631006	T/C	cg17971929	chr21:40555470	PSMG1	1.08	16.22	0.71	1.49e-41	Cognitive function;
CESC	cis	rs1448094	0.512	rs7970081	chr12:86243392	G/T	cg19622623	chr12:86230825	RASSF9	-0.46	-5.89	-0.34	1.2e-8	Major depressive disorder;
CESC	cis	rs250677	0.641	rs2915807	chr5:148450950	A/G	cg18129178	chr5:148520854	ABLIM3	-0.6	-6.05	-0.35	4.91e-9	Breast cancer;
CESC	cis	rs10944	0.584	rs1422086	chr5:78374865	G/T	cg22188827	chr5:78429774	NA	-0.4	-5.44	-0.32	1.18e-7	Blood and toenail selenium levels;
CESC	cis	rs3806843	0.966	rs10053945	chr5:140160127	C/T	cg16179182	chr5:140090404	VTRNA1-1	-0.4	-5.18	-0.3	4.31e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs1336900	0.637	rs35967040	chr1:150555588	A/C	cg13175981	chr1:150552382	MCL1	0.44	5.31	0.31	2.31e-7	Blood protein levels;
CESC	cis	rs4654899	0.758	rs6426667	chr1:21396216	C/A	cg05370193	chr1:21551575	ECE1	0.35	5.33	0.31	2.05e-7	Superior frontal gyrus grey matter volume;
CESC	cis	rs8031584	0.918	rs61997139	chr15:31273602	C/G	cg08704250	chr15:31115839	NA	-0.63	-8.15	-0.45	1.48e-14	Huntington's disease progression;
CESC	cis	rs1008375	0.966	rs10939758	chr4:17698255	C/T	cg15017067	chr4:17643749	FAM184B	0.36	5.12	0.3	5.83e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs9457247	0.871	rs1811121	chr6:167403539	T/C	cg25258033	chr6:167368657	RNASET2	0.39	5.83	0.34	1.58e-8	Crohn's disease;
CESC	cis	rs17655565	0.636	rs59951029	chr12:52716607	G/T	cg08257133	chr12:52711352	KRT83	0.37	5.22	0.31	3.58e-7	Plasma amyloid beta peptide concentrations (ABx-42);
CESC	cis	rs4595586	0.545	rs3858553	chr12:39381291	A/C	cg26384229	chr12:38710491	ALG10B	0.62	8.69	0.47	3.89e-16	Morning vs. evening chronotype;
CESC	cis	rs936229	0.861	rs3935077	chr15:75120211	C/G	cg14664628	chr15:75095509	CSK	-0.99	-15.48	-0.69	5.95e-39	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
CESC	cis	rs13256369	0.802	rs13281933	chr8:8562665	C/A	cg17143192	chr8:8559678	CLDN23	0.76	8.71	0.47	3.26e-16	Obesity-related traits;
CESC	cis	rs6831352	0.918	rs13140423	chr4:100050400	T/C	cg12011299	chr4:100065546	ADH4	-0.59	-6.52	-0.37	3.62e-10	Alcohol dependence;
CESC	trans	rs2727020	0.521	rs10839285	chr11:49496852	T/G	cg15704280	chr7:45808275	SEPT13	0.81	10.48	0.54	9.66e-22	Coronary artery disease;
CESC	cis	rs9868809	0.881	rs7620853	chr3:48666503	G/A	cg07636037	chr3:49044803	WDR6	-0.64	-5.32	-0.31	2.21e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg18402987	chr7:1209562	NA	0.4	5.18	0.3	4.48e-7	Longevity;Endometriosis;
CESC	cis	rs2836974	0.931	rs7283569	chr21:40644062	T/G	cg17971929	chr21:40555470	PSMG1	1.08	16.28	0.71	9.03e-42	Cognitive function;
CESC	cis	rs6500395	0.962	rs11647046	chr16:48623217	T/C	cg04672837	chr16:48644449	N4BP1	0.47	5.82	0.34	1.72e-8	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs4700695	0.719	rs27078	chr5:65445331	G/C	cg21114390	chr5:65439923	SFRS12	-0.5	-6.14	-0.35	2.99e-9	Facial morphology (factor 19);
CESC	cis	rs6456156	0.819	rs7765739	chr6:167518472	C/T	cg07741184	chr6:167504864	NA	0.36	6.42	0.37	6.34e-10	Primary biliary cholangitis;
CESC	cis	rs7692995	1.000	rs12506752	chr4:17948352	G/A	cg08925142	chr4:18023851	LCORL	-0.44	-5.1	-0.3	6.36e-7	Height;
CESC	cis	rs9467711	0.606	rs9379897	chr6:26601526	T/C	cg21479132	chr6:26055353	NA	0.58	5.18	0.3	4.44e-7	Autism spectrum disorder or schizophrenia;
CESC	cis	rs904092	0.720	rs1229967	chr4:100207578	G/C	cg12011299	chr4:100065546	ADH4	-0.54	-6.16	-0.35	2.76e-9	Alcohol dependence;
CESC	cis	rs11792861	0.926	rs72607170	chr9:111836941	G/A	cg05043794	chr9:111880884	C9orf5	-0.41	-6.74	-0.38	9.83e-11	Menarche (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26381918	chr2:99225517	C2orf64;UNC50	-0.52	-6.1	-0.35	3.7e-9	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.791	rs7678564	chr4:99057341	A/G	cg05340658	chr4:99064831	C4orf37	0.83	12.74	0.62	2.5e-29	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7116495	1.000	rs2298457	chr11:71734211	T/C	cg26138937	chr11:71823887	C11orf51	-0.77	-6.19	-0.36	2.3e-9	Severe influenza A (H1N1) infection;
CESC	cis	rs765787	0.530	rs2668737	chr15:45522799	C/T	cg24006582	chr15:45444508	DUOX1	-0.59	-7.11	-0.4	1.09e-11	Uric acid levels;
CESC	cis	rs7666738	0.830	rs1426664	chr4:98988264	A/C	cg03676636	chr4:99064102	C4orf37	0.34	5.22	0.31	3.6e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9488822	0.676	rs11757115	chr6:116362619	C/T	cg18764771	chr6:116381957	FRK	0.23	5.73	0.33	2.66e-8	Cholesterol, total;LDL cholesterol;
CESC	cis	rs9549328	0.885	rs3011547	chr13:113635963	C/T	cg22951483	chr13:113628068	MCF2L	0.33	5.27	0.31	2.89e-7	Systolic blood pressure;
CESC	cis	rs7959452	0.558	rs1478464	chr12:69779789	G/C	cg14784868	chr12:69753453	YEATS4	0.84	13.09	0.63	1.52e-30	Blood protein levels;
CESC	cis	rs1215050	0.743	rs6532692	chr4:98648005	C/A	cg05340658	chr4:99064831	C4orf37	-0.48	-6.22	-0.36	1.89e-9	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs250677	0.522	rs10042466	chr5:148393634	T/C	cg18129178	chr5:148520854	ABLIM3	-0.47	-5.33	-0.31	2.08e-7	Breast cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09549848	chr9:113800279	LPAR1	-0.51	-6.08	-0.35	4.2e-9	Gut microbiome composition (summer);
CESC	cis	rs2617583	0.599	rs2975226	chr5:1445616	A/T	cg07151155	chr5:1473589	LPCAT1	-0.34	-5.28	-0.31	2.76e-7	Breast cancer;
CESC	cis	rs1348850	0.632	rs13008857	chr2:178514468	G/A	cg22681709	chr2:178499509	PDE11A	-0.58	-9.09	-0.49	2.35e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs425277	0.606	rs262653	chr1:2090095	T/G	cg12718519	chr1:2058417	PRKCZ	0.25	5.24	0.31	3.23e-7	Height;
CESC	cis	rs9322193	0.923	rs9968911	chr6:149978555	A/T	cg07701084	chr6:150067640	NUP43	0.47	6.61	0.38	2.06e-10	Lung cancer;
CESC	cis	rs2295499	0.643	rs4690088	chr4:2698865	C/T	cg27239842	chr4:2403781	ZFYVE28	-0.32	-5.27	-0.31	2.82e-7	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
CESC	cis	rs5769765	1.000	rs910800	chr22:50278642	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	0.46	5.32	0.31	2.21e-7	Schizophrenia;
CESC	cis	rs911555	0.662	rs4906322	chr14:103879032	A/G	cg12935359	chr14:103987150	CKB	0.6	8.91	0.48	8.49e-17	Intelligence (multi-trait analysis);
CESC	cis	rs769267	0.965	rs2905425	chr19:19475717	G/C	cg17414380	chr19:19431394	KIAA0892;SF4	-0.46	-5.79	-0.33	2.01e-8	Tonsillectomy;
CESC	cis	rs597539	0.616	rs10896386	chr11:68722694	C/T	cg21963583	chr11:68658836	MRPL21	0.39	5.39	0.31	1.58e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs9733	0.596	rs3087960	chr1:150620569	C/G	cg17724175	chr1:150552817	MCL1	0.45	7.19	0.4	6.49e-12	Tonsillectomy;
CESC	cis	rs2933343	1.000	rs1680795	chr3:128620388	T/C	cg25356066	chr3:128598488	ACAD9	0.6	7.25	0.41	4.55e-12	IgG glycosylation;
CESC	cis	rs8067354	0.574	rs2531898	chr17:58012351	G/C	cg13753209	chr17:57696993	CLTC	0.54	5.76	0.33	2.28e-8	Hemoglobin concentration;
CESC	cis	rs2204008	0.745	rs8189516	chr12:38239084	C/T	cg13010199	chr12:38710504	ALG10B	0.49	6.1	0.35	3.78e-9	Bladder cancer;
CESC	cis	rs13034020	0.522	rs35976602	chr2:61241582	G/C	cg18625361	chr2:61244694	PEX13;PUS10	0.66	5.9	0.34	1.13e-8	Hodgkin's lymphoma;
CESC	cis	rs9467773	0.595	rs7767847	chr6:26597893	A/T	cg26531700	chr6:26746687	NA	-0.42	-6.43	-0.37	6.02e-10	Intelligence (multi-trait analysis);
CESC	cis	rs12618769	0.597	rs3769740	chr2:99069208	A/G	cg10123293	chr2:99228465	UNC50	-0.4	-5.44	-0.32	1.18e-7	Bipolar disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08187083	chr17:30186506	C17orf79	0.63	7.03	0.4	1.77e-11	Gut microbiome composition (summer);
CESC	cis	rs7208859	0.673	rs56846352	chr17:29119188	C/T	cg19761014	chr17:28927070	LRRC37B2	0.68	6.72	0.38	1.11e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs2073300	1.000	rs79169006	chr20:23443535	A/T	cg12062639	chr20:23401060	NAPB	0.91	6.41	0.37	6.71e-10	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs801193	1.000	rs2420824	chr7:66131116	G/A	cg14393609	chr7:65229607	NA	-0.45	-5.88	-0.34	1.24e-8	Aortic root size;
CESC	trans	rs4942242	0.602	rs61960076	chr13:44217784	T/C	cg19169023	chr15:41853346	TYRO3	-0.61	-7.72	-0.43	2.46e-13	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs6938	0.563	rs12917376	chr15:75116167	C/T	cg09165964	chr15:75287851	SCAMP5	0.53	7.18	0.4	7.12e-12	Breast cancer;
CESC	cis	rs875971	0.543	rs801191	chr7:66032955	G/A	cg19163074	chr7:65112434	INTS4L2	0.43	5.51	0.32	8.54e-8	Aortic root size;
CESC	cis	rs12618769	0.597	rs2278206	chr2:99172244	A/G	cg10123293	chr2:99228465	UNC50	0.4	5.27	0.31	2.77e-7	Bipolar disorder;
CESC	cis	rs10744422	0.858	rs12426809	chr12:123327143	C/T	cg25930673	chr12:123319894	HIP1R	-0.65	-5.28	-0.31	2.72e-7	Schizophrenia;
CESC	cis	rs8180040	0.966	rs13079098	chr3:47442863	A/G	cg27129171	chr3:47204927	SETD2	0.65	10.14	0.53	1.22e-20	Colorectal cancer;
CESC	cis	rs12145833	0.596	rs61833913	chr1:243440028	C/G	cg02356786	chr1:243265016	LOC731275	0.75	5.66	0.33	3.99e-8	Obesity (early onset extreme);
CESC	cis	rs736801	0.740	rs12515180	chr5:131785684	C/T	cg07395648	chr5:131743802	NA	-0.43	-5.27	-0.31	2.77e-7	Breast cancer;Mosquito bite size;
CESC	cis	rs9303401	0.614	rs28651036	chr17:57080471	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.89	11.09	0.56	9.68e-24	Cognitive test performance;
CESC	cis	rs1008375	0.932	rs4235390	chr4:17696378	G/T	cg02297831	chr4:17616191	MED28	0.44	5.34	0.31	1.99e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs2276314	0.947	rs4799831	chr18:33554775	A/G	cg05985134	chr18:33552581	C18orf21	0.65	7.5	0.42	9.76e-13	Endometriosis;Drug-induced torsades de pointes;
CESC	cis	rs17376456	0.877	rs28633397	chr5:93447048	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.62	5.44	0.32	1.23e-7	Diabetic retinopathy;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg09292409	chr16:15461083	NA	-0.37	-6.14	-0.35	2.95e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs6032067	0.561	rs2743317	chr20:43936931	C/T	cg10761708	chr20:43804764	PI3	0.44	5.37	0.31	1.69e-7	Blood protein levels;
CESC	trans	rs3780486	0.718	rs73645257	chr9:33132354	C/T	cg04842962	chr6:43655489	MRPS18A	0.76	9.1	0.49	2.28e-17	IgG glycosylation;
CESC	cis	rs11809207	0.523	rs12565756	chr1:26498196	G/T	cg00147160	chr1:26503991	CNKSR1	0.27	5.23	0.31	3.39e-7	Height;
CESC	cis	rs7618915	0.547	rs13085895	chr3:52678270	G/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.37	6.5	0.37	3.92e-10	Bipolar disorder;
CESC	cis	rs12410462	0.502	rs78101727	chr1:227732069	C/T	cg04117972	chr1:227635322	NA	0.75	5.13	0.3	5.66e-7	Major depressive disorder;
CESC	cis	rs6500395	1.000	rs11640463	chr16:48644434	A/T	cg04672837	chr16:48644449	N4BP1	0.5	6.07	0.35	4.3e-9	Response to tocilizumab in rheumatoid arthritis;
CESC	cis	rs3820068	0.603	rs3795763	chr1:15959977	C/T	cg13390004	chr1:15929781	NA	0.37	5.89	0.34	1.18e-8	Systolic blood pressure;
CESC	cis	rs9322193	0.923	rs9505982	chr6:149939601	G/A	cg13206674	chr6:150067644	NUP43	0.41	5.77	0.33	2.21e-8	Lung cancer;
CESC	cis	rs6460942	0.643	rs7780093	chr7:12233661	C/G	cg06484146	chr7:12443880	VWDE	-0.47	-5.22	-0.31	3.54e-7	Coronary artery disease;
CESC	cis	rs9309473	0.583	rs6709853	chr2:73576065	T/A	cg20560298	chr2:73613845	ALMS1	-0.45	-6.38	-0.36	8.06e-10	Metabolite levels;
CESC	cis	rs28374715	0.681	rs7168307	chr15:41620534	A/G	cg02330683	chr15:41787940	ITPKA	0.5	6.79	0.39	7.21e-11	Ulcerative colitis;
CESC	cis	rs10905065	0.931	rs6602240	chr10:5816751	C/A	cg11519256	chr10:5708881	ASB13	-0.43	-5.42	-0.32	1.34e-7	Menopause (age at onset);
CESC	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg07167872	chr1:205819463	PM20D1	0.59	9.59	0.51	6.88e-19	Monocyte percentage of white cells;
CESC	cis	rs7264396	0.635	rs6060656	chr20:34466382	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.84	-11.47	-0.58	5.38e-25	Total cholesterol levels;
CESC	cis	rs634534	0.622	rs593525	chr11:65727799	T/C	cg04055107	chr11:65626734	MUS81;CFL1	0.44	5.5	0.32	8.98e-8	Sum eosinophil basophil counts;Eosinophil counts;
CESC	cis	rs12137294	0.761	rs1172150	chr1:205221861	A/G	cg21643547	chr1:205240462	TMCC2	-0.34	-5.46	-0.32	1.09e-7	Red cell distribution width;
CESC	cis	rs17539620	0.624	rs74551216	chr6:154840524	T/C	cg17771515	chr6:154831774	CNKSR3	0.55	5.25	0.31	3.1e-7	Lipoprotein (a) levels;
CESC	cis	rs2040771	0.745	rs361956	chr22:19265799	C/T	cg02655711	chr22:19163373	SLC25A1	0.4	5.8	0.34	1.93e-8	Metabolite levels (small molecules and protein measures);
CESC	cis	rs477692	0.699	rs576175	chr10:131386408	A/T	cg05714579	chr10:131428358	MGMT	0.42	5.51	0.32	8.29e-8	Response to temozolomide;
CESC	cis	rs17253792	0.822	rs12100949	chr14:56040787	T/C	cg01858014	chr14:56050164	KTN1	-0.88	-7.51	-0.42	9.24e-13	Putamen volume;
CESC	cis	rs7520050	0.966	rs785488	chr1:46576095	G/A	cg03146154	chr1:46216737	IPP	-0.43	-5.57	-0.32	6.33e-8	Red blood cell count;Reticulocyte count;
CESC	cis	rs9300255	0.568	rs1790090	chr12:123633424	G/A	cg05973401	chr12:123451056	ABCB9	0.51	5.72	0.33	2.81e-8	Neutrophil percentage of white cells;
CESC	cis	rs7044106	0.791	rs10760116	chr9:123494681	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.88	14.59	0.67	8.79e-36	Hip circumference adjusted for BMI;
CESC	cis	rs9300255	0.739	rs1969354	chr12:123741776	T/C	cg05973401	chr12:123451056	ABCB9	0.49	5.52	0.32	8.03e-8	Neutrophil percentage of white cells;
CESC	cis	rs4132509	1.000	rs73128287	chr1:243952150	T/G	cg21452805	chr1:244014465	NA	0.53	6.55	0.37	2.97e-10	RR interval (heart rate);
CESC	cis	rs3857067	0.901	rs965807	chr4:95045567	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.52	-7.87	-0.44	9.02e-14	QT interval;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg01089097	chr15:37110495	CSNK1A1P	-0.5	-6.41	-0.37	6.81e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs6860806	0.507	rs273915	chr5:131660119	G/C	cg24060327	chr5:131705240	SLC22A5	-0.78	-10.98	-0.56	2.29e-23	Breast cancer;
CESC	cis	rs12101261	0.580	rs3783949	chr14:81448382	A/C	cg06600135	chr14:81408086	NA	0.39	5.3	0.31	2.49e-7	Graves' disease;
CESC	cis	rs4434138	0.664	rs62255364	chr3:52701502	C/T	cg05564831	chr3:52568323	NT5DC2	0.44	6.72	0.38	1.08e-10	Intelligence (multi-trait analysis);
CESC	trans	rs9929218	0.953	rs34909703	chr16:68740097	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.8	-10.54	-0.54	6.34e-22	Colorectal cancer;
CESC	cis	rs67311347	0.869	rs6790495	chr3:40366770	C/T	cg24209194	chr3:40518798	ZNF619	0.4	5.03	0.3	9.09e-7	Renal cell carcinoma;
CESC	cis	rs9818941	1.000	rs9845687	chr3:157682536	T/C	cg08654915	chr3:157813417	NA	-0.46	-7.74	-0.43	2.07e-13	Height;
CESC	cis	rs1008375	0.932	rs1008894	chr4:17704667	C/T	cg27347728	chr4:17578864	LAP3	-0.45	-5.27	-0.31	2.76e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs6942756	0.688	rs2718089	chr7:128927022	G/T	cg02491457	chr7:128862824	NA	0.62	8.66	0.47	4.73e-16	White matter hyperintensity burden;
CESC	cis	rs12824058	0.831	rs11060825	chr12:130807905	A/G	cg24838063	chr12:130822603	PIWIL1	0.61	8.34	0.46	4.03e-15	Menopause (age at onset);
CESC	cis	rs116095464	0.558	rs10057674	chr5:266813	C/T	cg12570787	chr5:219185	SDHA;CCDC127	0.53	5.49	0.32	9.44e-8	Breast cancer;
CESC	cis	rs7208859	0.673	rs9899525	chr17:29120296	T/A	cg19761014	chr17:28927070	LRRC37B2	0.77	6.38	0.36	7.79e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs9814567	0.752	rs7623567	chr3:134330976	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.4	-5.09	-0.3	6.84e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
CESC	cis	rs916888	0.821	rs199512	chr17:44857352	T/C	cg14517863	chr17:44321492	NA	-0.4	-5.16	-0.3	4.82e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg24034477	chr20:35202059	TGIF2	-0.44	-6.25	-0.36	1.61e-9	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs2249694	1.000	rs2480259	chr10:135352076	A/G	cg20169779	chr10:135381914	SYCE1	0.39	5.2	0.3	3.9e-7	Obesity-related traits;
CESC	cis	rs4665809	1.000	rs4665304	chr2:26313406	C/T	cg04944784	chr2:26401820	FAM59B	-0.63	-7.27	-0.41	3.93e-12	Gut microbiome composition (summer);
CESC	cis	rs3096299	0.967	rs2965935	chr16:89481274	C/T	cg16743903	chr16:89593216	SPG7	0.4	5.3	0.31	2.41e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs6543140	0.964	rs6748390	chr2:103062175	A/G	cg04239558	chr2:103089729	SLC9A4	0.46	5.59	0.32	5.62e-8	Blood protein levels;
CESC	cis	rs155076	0.711	rs4770131	chr13:21897468	A/G	cg11317459	chr13:21872234	NA	1.31	15.08	0.68	1.61e-37	White matter hyperintensity burden;
CESC	cis	rs7618915	0.501	rs2289247	chr3:52727257	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.5	7.24	0.41	4.76e-12	Bipolar disorder;
CESC	cis	rs250677	0.522	rs4431331	chr5:148353574	A/C	cg18129178	chr5:148520854	ABLIM3	-0.46	-5.22	-0.31	3.67e-7	Breast cancer;
CESC	cis	rs8103278	1.000	rs9676288	chr19:46292060	G/T	cg14061069	chr19:46274453	DMPK	-0.38	-5.26	-0.31	2.92e-7	Coronary artery disease;
CESC	cis	rs854765	0.547	rs9912096	chr17:17896673	A/C	cg09796270	chr17:17721594	SREBF1	0.4	5.57	0.32	6.1e-8	Total body bone mineral density;
CESC	cis	rs9322193	0.923	rs7753812	chr6:150011286	C/T	cg07701084	chr6:150067640	NUP43	0.43	5.83	0.34	1.62e-8	Lung cancer;
CESC	cis	rs2242194	0.816	rs2242193	chr1:154995503	A/G	cg09359103	chr1:154839909	KCNN3	0.4	6.35	0.36	9.15e-10	Schizophrenia;
CESC	cis	rs2599510	0.934	rs2710634	chr2:32808804	T/C	cg02381751	chr2:32503542	YIPF4	0.6	8.21	0.45	9.63e-15	Interleukin-18 levels;
CESC	cis	rs13191362	1.000	rs66529337	chr6:163005662	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.82	8.75	0.47	2.56e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs12142240	0.698	rs61519400	chr1:46855298	A/G	cg00530320	chr1:46809349	NSUN4	0.6	8.3	0.45	5.19e-15	Menopause (age at onset);
CESC	cis	rs9611565	0.840	rs2234059	chr22:41777913	T/C	cg06634786	chr22:41940651	POLR3H	-0.7	-7.4	-0.41	1.85e-12	Vitiligo;
CESC	cis	rs1577917	0.958	rs12199832	chr6:86652748	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.45	-5.86	-0.34	1.4e-8	Response to antipsychotic treatment;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg03564166	chr16:70380888	DDX19A	-0.5	-6.6	-0.38	2.2e-10	Fibrinogen levels;
CESC	cis	rs36051895	0.664	rs62541915	chr9:5151275	A/T	cg02405213	chr9:5042618	JAK2	-0.48	-5.49	-0.32	9.46e-8	Pediatric autoimmune diseases;
CESC	cis	rs17001868	0.568	rs9607701	chr22:40739116	A/G	cg07138101	chr22:40742427	ADSL	0.57	5.38	0.31	1.66e-7	Mammographic density (dense area);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg26120617	chr12:6603256	NCAPD2;MRPL51	0.48	6.12	0.35	3.39e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs17376456	0.825	rs36042718	chr5:93180997	C/T	cg21475434	chr5:93447410	FAM172A	0.84	7.45	0.42	1.35e-12	Diabetic retinopathy;
CESC	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg19318889	chr4:1322082	MAEA	0.65	7.77	0.43	1.77e-13	Longevity;
CESC	cis	rs9354308	0.770	rs2802048	chr6:66525044	C/G	cg07460842	chr6:66804631	NA	0.51	5.57	0.32	6.27e-8	Metabolite levels;
CESC	cis	rs6952808	0.893	rs35487994	chr7:1920171	G/A	cg22963979	chr7:1858916	MAD1L1	-0.38	-5.12	-0.3	6e-7	Bipolar disorder and schizophrenia;
CESC	cis	rs2832191	0.791	rs2832196	chr21:30497412	G/A	cg08807101	chr21:30365312	RNF160	-0.72	-9.88	-0.52	8.5e-20	Dental caries;
CESC	cis	rs854765	0.618	rs9908017	chr17:17774422	C/T	cg16928487	chr17:17741425	SREBF1	0.59	10.61	0.55	3.78e-22	Total body bone mineral density;
CESC	cis	rs1707322	0.638	rs9429095	chr1:46603348	A/C	cg03146154	chr1:46216737	IPP	-0.59	-7.13	-0.4	9.48e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs10733682	0.659	rs13292976	chr9:129467340	C/T	cg00232160	chr9:129468157	NA	0.37	5.99	0.35	6.91e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs780096	0.546	rs2293572	chr2:27728777	C/G	cg21248554	chr2:27665150	KRTCAP3	0.33	6.59	0.38	2.43e-10	Total body bone mineral density;
CESC	cis	rs67478160	0.643	rs8003653	chr14:104298836	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.51	-7.21	-0.41	5.78e-12	Schizophrenia;
CESC	cis	rs10276381	0.786	rs28430601	chr7:28238811	A/G	cg23620719	chr7:28220237	JAZF1	0.66	6.22	0.36	1.96e-9	Crohn's disease;
CESC	cis	rs12410462	1.000	rs76233861	chr1:227673909	G/A	cg04117972	chr1:227635322	NA	0.65	6.28	0.36	1.38e-9	Major depressive disorder;
CESC	cis	rs875971	0.830	rs6976714	chr7:65891461	G/A	cg12463550	chr7:65579703	CRCP	0.49	6.17	0.35	2.57e-9	Aortic root size;
CESC	cis	rs10779751	0.734	rs1194820	chr1:11129259	A/C	cg08854313	chr1:11322531	MTOR	0.8	11.54	0.58	3.1e-25	Body mass index;
CESC	cis	rs854765	0.583	rs4925123	chr17:17784374	A/G	cg04398451	chr17:18023971	MYO15A	0.62	8.7	0.47	3.63e-16	Total body bone mineral density;
CESC	cis	rs1707322	0.896	rs785512	chr1:46534543	A/G	cg03146154	chr1:46216737	IPP	-0.7	-9.2	-0.49	1.08e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs3008870	1.000	rs3008874	chr1:67431365	A/T	cg08660285	chr1:67390436	MIER1;WDR78	1.06	15.19	0.68	6.65e-38	Lymphocyte percentage of white cells;
CESC	cis	rs9929218	0.954	rs34530130	chr16:68827620	C/T	cg02972257	chr16:68554789	NA	0.45	5.28	0.31	2.69e-7	Colorectal cancer;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg04275040	chr17:78936628	RPTOR	0.44	6.81	0.39	6.66e-11	Fibrinogen levels;
CESC	cis	rs7647973	0.925	rs6446257	chr3:49253492	A/G	cg07636037	chr3:49044803	WDR6	-0.67	-8.68	-0.47	4.07e-16	Menarche (age at onset);
CESC	trans	rs7618501	0.633	rs55751738	chr3:49972101	A/G	cg21659725	chr3:3221576	CRBN	0.49	6.81	0.39	6.69e-11	Intelligence (multi-trait analysis);
CESC	cis	rs2108622	0.701	rs118144071	chr19:15979194	A/G	cg13772218	chr19:15982569	NA	0.29	5.56	0.32	6.47e-8	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05617973	chr19:49468917	FTL	0.58	6.53	0.37	3.43e-10	Gut microbiome composition (summer);
CESC	cis	rs2836974	0.568	rs442972	chr21:40534757	C/T	cg11644478	chr21:40555479	PSMG1	-0.83	-12.84	-0.62	1.17e-29	Cognitive function;
CESC	cis	rs3015497	0.608	rs3015499	chr14:51112460	T/C	cg26011998	chr14:51135199	SAV1	-0.6	-6.73	-0.38	1.02e-10	Mean platelet volume;
CESC	cis	rs4665809	0.549	rs17527979	chr2:26428132	A/G	cg04944784	chr2:26401820	FAM59B	-0.87	-9.24	-0.49	8.34e-18	Gut microbiome composition (summer);
CESC	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg21315798	chr22:50354594	PIM3	0.47	6.09	0.35	3.96e-9	Myopia (pathological);
CESC	cis	rs3772130	0.564	rs28760466	chr3:121601510	A/G	cg20356878	chr3:121714668	ILDR1	0.42	6.17	0.35	2.54e-9	Cognitive performance;
CESC	trans	rs11039798	0.778	rs7944523	chr11:48911019	G/A	cg15704280	chr7:45808275	SEPT13	0.69	6.44	0.37	5.66e-10	Axial length;
CESC	cis	rs11214589	0.651	rs17600713	chr11:113259947	C/T	cg14159747	chr11:113255604	NA	0.35	6.22	0.36	1.89e-9	Neuroticism;
CESC	cis	rs155076	1.000	rs564685	chr13:21846879	A/G	cg11317459	chr13:21872234	NA	-1.05	-11.58	-0.58	2.37e-25	White matter hyperintensity burden;
CESC	cis	rs7193541	0.684	rs9929496	chr16:74668473	G/A	cg01733217	chr16:74700730	RFWD3	1.06	20.92	0.79	4.64e-58	Multiple myeloma;
CESC	cis	rs796364	1.000	rs71424239	chr2:200725473	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.81	-6.33	-0.36	1.03e-9	Schizophrenia;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg15798279	chr7:6523691	KDELR2	0.47	6.5	0.37	4.08e-10	Systemic lupus erythematosus;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg14212983	chr1:21985742	RAP1GAP	-0.41	-6.59	-0.38	2.43e-10	Gambling;
CESC	cis	rs17783634	0.509	rs11775489	chr8:11036843	T/C	cg21775007	chr8:11205619	TDH	-0.39	-5.03	-0.3	9.07e-7	Subjective well-being;
CESC	cis	rs2404602	0.692	rs34287706	chr15:76942402	A/C	cg22467129	chr15:76604101	ETFA	-0.35	-5.21	-0.3	3.89e-7	Blood metabolite levels;
CESC	cis	rs12136530	0.593	rs2314145	chr1:19736843	C/G	cg01832549	chr1:19774989	CAPZB	-0.44	-6.23	-0.36	1.85e-9	Lead levels in blood;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25467969	chr19:17337038	OCEL1	0.56	6.6	0.38	2.23e-10	Gut microbiome composition (summer);
CESC	cis	rs4423214	1.000	rs4944946	chr11:71159429	G/A	cg05163923	chr11:71159392	DHCR7	0.85	12.11	0.6	3.72e-27	Vitamin D levels;
CESC	cis	rs7833790	0.963	rs72686466	chr8:82758928	G/T	cg17211192	chr8:82754475	SNX16	0.7	8.32	0.46	4.71e-15	Diastolic blood pressure;
CESC	cis	rs7666738	0.830	rs1456208	chr4:98678563	C/T	cg05340658	chr4:99064831	C4orf37	0.75	10.76	0.55	1.19e-22	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4077515	0.504	rs10870164	chr9:139315682	C/T	cg14169450	chr9:139327907	INPP5E	-0.5	-7.49	-0.42	1.06e-12	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs2299587	0.554	rs3739404	chr8:17739843	C/A	cg08627089	chr8:17753878	FGL1	-0.39	-5.56	-0.32	6.63e-8	Economic and political preferences;
CESC	cis	rs7666738	0.791	rs1896156	chr4:99020882	C/G	cg18180107	chr4:99064573	C4orf37	0.41	5.39	0.31	1.57e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.67	9.02	0.48	3.83e-17	Prudent dietary pattern;
CESC	cis	rs3096299	0.658	rs4291902	chr16:89560315	G/C	cg16743903	chr16:89593216	SPG7	-0.47	-6.06	-0.35	4.72e-9	Multiple myeloma (IgH translocation);
CESC	cis	rs3785574	0.927	rs2727313	chr17:61961914	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.57	7.08	0.4	1.32e-11	Height;
CESC	cis	rs4919694	1.000	rs75691516	chr10:104652045	C/T	cg04362960	chr10:104952993	NT5C2	0.74	6.45	0.37	5.32e-10	Arsenic metabolism;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg21581312	chr15:35529473	LOC723972	0.47	6.54	0.37	3.12e-10	Fibrinogen levels;
CESC	cis	rs72627509	0.951	rs17087335	chr4:57838583	G/T	cg26694713	chr4:57773883	REST	0.56	5.36	0.31	1.82e-7	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
CESC	cis	rs4722166	0.604	rs2390715	chr7:22783878	A/C	cg13104385	chr7:22767384	IL6	0.48	6.36	0.36	8.89e-10	Lung cancer;
CESC	cis	rs959260	0.623	rs4542691	chr17:73326965	T/C	cg12999837	chr17:73267436	MIF4GD	-0.41	-5.07	-0.3	7.31e-7	Systemic lupus erythematosus;
CESC	cis	rs8017423	0.647	rs4904679	chr14:90821801	C/T	cg14092571	chr14:90743983	NA	0.45	6.82	0.39	6.23e-11	Mortality in heart failure;
CESC	cis	rs7084402	0.967	rs6481404	chr10:60286071	C/G	cg07615347	chr10:60278583	BICC1	-0.56	-8.61	-0.47	6.75e-16	Refractive error;
CESC	cis	rs6580649	0.783	rs1635526	chr12:48396785	C/T	cg24011408	chr12:48396354	COL2A1	0.4	5.26	0.31	2.98e-7	Lung cancer;
CESC	cis	rs769267	0.965	rs2916068	chr19:19516433	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.5	6.46	0.37	4.93e-10	Tonsillectomy;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg12346351	chr4:152330392	FAM160A1	0.48	6.67	0.38	1.52e-10	Systemic lupus erythematosus;
CESC	cis	rs2404602	0.716	rs66754747	chr15:76828568	G/A	cg26408565	chr15:76604113	ETFA	-0.39	-5.72	-0.33	2.83e-8	Blood metabolite levels;
CESC	cis	rs60733400	0.782	rs4648564	chr1:2562169	C/T	cg20673091	chr1:2541236	MMEL1	-0.47	-7.91	-0.44	7.2e-14	Multiple sclerosis;
CESC	cis	rs2735413	0.837	rs7194946	chr16:78095274	G/A	cg04733911	chr16:78082701	NA	0.46	7.28	0.41	3.75e-12	Systolic blood pressure (alcohol consumption interaction);
CESC	cis	rs2712184	0.756	rs2712182	chr2:217647525	T/C	cg05032264	chr2:217675019	NA	-0.34	-5.22	-0.31	3.65e-7	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg15084499	chr1:227505916	CDC42BPA	-0.42	-6.17	-0.35	2.6e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs7659604	0.502	rs13106764	chr4:122699630	C/G	cg19748678	chr4:122722346	EXOSC9	-0.43	-5.4	-0.31	1.49e-7	Type 2 diabetes;
CESC	cis	rs9815354	0.556	rs116717051	chr3:42027411	G/C	cg03022575	chr3:42003672	ULK4	0.75	6.64	0.38	1.72e-10	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs909002	0.849	rs2280386	chr1:32086912	A/C	cg13919466	chr1:32135498	COL16A1	-0.49	-8.49	-0.46	1.51e-15	Intelligence (multi-trait analysis);
CESC	trans	rs116095464	0.614	rs10061564	chr5:271329	T/C	cg00938859	chr5:1591904	SDHAP3	0.64	6.95	0.39	2.88e-11	Breast cancer;
CESC	cis	rs9388451	0.903	rs7758115	chr6:126061502	C/T	cg10911889	chr6:126070802	HEY2	0.35	5.04	0.3	8.47e-7	Brugada syndrome;
CESC	cis	rs10504229	0.683	rs6980850	chr8:58127204	A/G	cg21724239	chr8:58056113	NA	0.57	5.76	0.33	2.29e-8	Developmental language disorder (linguistic errors);
CESC	cis	rs10883723	0.810	rs3818470	chr10:104263675	T/C	cg22532475	chr10:104410764	TRIM8	-0.34	-5.73	-0.33	2.77e-8	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs9611565	0.659	rs9611610	chr22:41949259	A/G	cg06481639	chr22:41940642	POLR3H	-0.66	-6.81	-0.39	6.5500000000000006e-11	Vitiligo;
CESC	cis	rs514406	0.763	rs6685599	chr1:53213172	G/A	cg08859206	chr1:53392774	SCP2	0.54	7.12	0.4	1.03e-11	Monocyte count;
CESC	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg16132339	chr22:24313637	DDTL;DDT	0.4	6.17	0.35	2.54e-9	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs4803468	1.000	rs1043413	chr19:41939297	C/G	cg14132834	chr19:41945861	ATP5SL	0.6	7.54	0.42	7.59e-13	Height;
CESC	cis	rs2732480	0.523	rs34286639	chr12:48629044	C/T	cg04545296	chr12:48745243	ZNF641	0.41	6.86	0.39	4.97e-11	Hemoglobin concentration;Red blood cell count;Hematocrit;
CESC	cis	rs9325144	0.555	rs7960411	chr12:38703019	A/G	cg26384229	chr12:38710491	ALG10B	-0.6	-8.52	-0.46	1.19e-15	Morning vs. evening chronotype;
CESC	cis	rs4588572	0.643	rs1560197	chr5:77768302	T/C	cg11547950	chr5:77652471	NA	-0.42	-5.31	-0.31	2.36e-7	Triglycerides;
CESC	cis	rs7772486	0.754	rs6570708	chr6:145989428	C/T	cg23711669	chr6:146136114	FBXO30	-0.92	-13.79	-0.65	5.61e-33	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs2795502	1.000	rs2796575	chr10:43374911	A/G	cg20628663	chr10:43360327	NA	0.59	6.84	0.39	5.53e-11	Blood protein levels;
CESC	cis	rs66887589	0.616	rs11732621	chr4:120212883	A/C	cg09307838	chr4:120376055	NA	0.65	9.09	0.49	2.44e-17	Diastolic blood pressure;
CESC	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg07308232	chr7:1071921	C7orf50	-0.42	-5.68	-0.33	3.55e-8	Longevity;Endometriosis;
CESC	cis	rs11098499	1.000	rs13435802	chr4:120177960	A/T	cg09307838	chr4:120376055	NA	-0.87	-11.73	-0.58	7.44e-26	Corneal astigmatism;
CESC	cis	rs7937682	0.961	rs1784784	chr11:111483185	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.91	-14.14	-0.66	3.37e-34	Primary sclerosing cholangitis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21959181	chr7:150755243	CDK5;SLC4A2	0.59	6.82	0.39	6.05e-11	Gut microbiome composition (summer);
CESC	cis	rs6460942	0.908	rs112049544	chr7:12242551	A/G	cg20607287	chr7:12443886	VWDE	-0.58	-5.76	-0.33	2.36e-8	Coronary artery disease;
CESC	cis	rs1707322	0.686	rs2230659	chr1:46078884	C/T	cg03146154	chr1:46216737	IPP	-0.79	-10.71	-0.55	1.73e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs6540559	0.673	rs6540561	chr1:209982255	C/T	cg09509183	chr1:209979624	IRF6	0.56	5.75	0.33	2.4e-8	Cleft lip with or without cleft palate;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg20376421	chr12:56546193	MYL6B	0.45	6.32	0.36	1.13e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.54	7.17	0.4	7.41e-12	Lymphocyte counts;
CESC	cis	rs6674176	0.597	rs9326136	chr1:44390392	A/G	cg12908607	chr1:44402522	ARTN	0.51	8.0	0.44	3.89e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs4713118	0.868	rs10484401	chr6:27746590	A/T	cg17221315	chr6:27791827	HIST1H4J	-0.47	-5.39	-0.31	1.58e-7	Parkinson's disease;
CESC	cis	rs2228479	0.850	rs12597299	chr16:89822364	C/A	cg14709524	chr16:89940631	TCF25	0.93	6.94	0.39	3.03e-11	Skin colour saturation;
CESC	cis	rs1448094	0.533	rs4412812	chr12:86151238	G/A	cg02569458	chr12:86230093	RASSF9	-0.42	-6.37	-0.36	8.4e-10	Major depressive disorder;
CESC	cis	rs3858526	0.584	rs10734559	chr11:5861788	A/C	cg02574844	chr11:5959923	NA	-0.45	-6.47	-0.37	4.62e-10	DNA methylation (variation);
CESC	cis	rs1448094	0.511	rs61930074	chr12:86218759	G/C	cg19622623	chr12:86230825	RASSF9	-0.44	-5.73	-0.33	2.79e-8	Major depressive disorder;
CESC	cis	rs35306767	0.953	rs11253517	chr10:970524	A/G	cg20503657	chr10:835505	NA	-0.7	-7.48	-0.42	1.07e-12	Eosinophil percentage of granulocytes;
CESC	cis	rs713587	0.719	rs4665736	chr2:25187599	C/T	cg01884057	chr2:25150051	NA	-0.39	-7.42	-0.41	1.64e-12	Body mass index in non-asthmatics;
CESC	trans	rs12310956	0.532	rs11052922	chr12:33957476	A/G	cg26384229	chr12:38710491	ALG10B	0.48	6.68	0.38	1.37e-10	Morning vs. evening chronotype;
CESC	trans	rs9388451	0.626	rs1343116	chr6:126069702	C/A	cg05039488	chr6:79577232	IRAK1BP1	-0.66	-9.31	-0.5	4.92e-18	Brugada syndrome;
CESC	cis	rs2243480	1.000	rs35046236	chr7:65408613	T/C	cg25894440	chr7:65020034	NA	-0.59	-5.07	-0.3	7.57e-7	Diabetic kidney disease;
CESC	cis	rs10876993	0.928	rs1678530	chr12:58054076	A/C	cg18357645	chr12:58087776	OS9	0.6	9.29	0.5	6.03e-18	Celiac disease or Rheumatoid arthritis;
CESC	trans	rs7047415	1.000	rs7873723	chr9:98543757	T/C	cg00788170	chr1:227921688	SNAP47;LOC100130093;JMJD4	0.45	6.02	0.35	5.84e-9	Alzheimer disease and age of onset;
CESC	cis	rs7945705	0.967	rs1569408	chr11:8909732	G/A	cg09997546	chr11:8931473	C11orf17;ST5	0.37	5.97	0.34	7.44e-9	Hemoglobin concentration;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg05602567	chr22:32871203	FBXO7	0.45	6.18	0.35	2.45e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs9811920	0.965	rs6767441	chr3:99863183	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.45	7.21	0.41	5.78e-12	Axial length;
CESC	cis	rs1046896	0.561	rs8076476	chr17:80861017	A/C	cg05255149	chr17:80675120	FN3KRP	0.46	5.09	0.3	6.91e-7	Glycated hemoglobin levels;
CESC	cis	rs4234798	0.546	rs4689667	chr4:7249188	A/T	cg02658934	chr4:7637892	SORCS2	0.45	5.7	0.33	3.18e-8	Insulin-like growth factors;
CESC	cis	rs73206853	0.841	rs57726856	chr12:110961123	T/C	cg12870014	chr12:110450643	ANKRD13A	0.62	5.2	0.3	3.98e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
CESC	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	7.68	0.43	3.15e-13	Prudent dietary pattern;
CESC	cis	rs3087591	1.000	rs2854322	chr17:29699416	C/T	cg24425628	chr17:29625626	OMG;NF1	0.46	5.84	0.34	1.51e-8	Hip circumference;
CESC	cis	rs7618915	0.547	rs2878726	chr3:52748271	C/G	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.31	5.43	0.32	1.25e-7	Bipolar disorder;
CESC	cis	rs7927592	0.871	rs11228284	chr11:68322767	A/T	cg20283391	chr11:68216788	NA	-0.61	-7.36	-0.41	2.26e-12	Total body bone mineral density;
CESC	cis	rs6724607	1.000	rs10165399	chr2:191441595	A/G	cg10560079	chr2:191398806	TMEM194B	0.48	6.87	0.39	4.69e-11	Pulse pressure;
CESC	cis	rs4319547	0.956	rs7397990	chr12:123119472	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.57	-6.83	-0.39	5.88e-11	Body mass index;
CESC	cis	rs798554	0.797	rs1182174	chr7:2875420	G/A	cg04166393	chr7:2884313	GNA12	0.57	7.37	0.41	2.16e-12	Height;
CESC	cis	rs2933343	0.729	rs1680794	chr3:128620390	A/G	cg25356066	chr3:128598488	ACAD9	0.58	7.92	0.44	6.4e-14	IgG glycosylation;
CESC	cis	rs2576037	0.583	rs644731	chr18:44426877	C/T	cg19077165	chr18:44547161	KATNAL2	-0.6	-9.21	-0.49	1.02e-17	Personality dimensions;
CESC	cis	rs1552244	0.810	rs7612908	chr3:10089148	A/G	cg00149659	chr3:10157352	C3orf10	0.74	8.69	0.47	3.76e-16	Alzheimer's disease;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg20021244	chr5:139944115	APBB3;SLC35A4	0.41	6.18	0.35	2.34e-9	Gambling;
CESC	cis	rs6860806	0.507	rs272891	chr5:131664394	G/T	cg18758796	chr5:131593413	PDLIM4	0.38	5.24	0.31	3.35e-7	Breast cancer;
CESC	cis	rs7223966	1.000	rs16947042	chr17:61766457	T/G	cg11494091	chr17:61959527	GH2	0.39	5.5	0.32	9.15e-8	Hip circumference adjusted for BMI;Body mass index;
CESC	cis	rs6912958	0.547	rs451089	chr6:88041859	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.45	7.91	0.44	7.05e-14	Monocyte percentage of white cells;
CESC	cis	rs2075371	0.933	rs2544181	chr7:133944934	C/T	cg11752832	chr7:134001865	SLC35B4	0.52	6.72	0.38	1.11e-10	Mean platelet volume;
CESC	cis	rs425277	0.539	rs3128338	chr1:2046786	G/A	cg23803603	chr1:2058230	PRKCZ	-0.34	-5.8	-0.34	1.9e-8	Height;
CESC	trans	rs5769765	0.955	rs9616367	chr22:50303515	A/C	cg09872104	chr7:134855509	C7orf49	-0.54	-6.15	-0.35	2.77e-9	Schizophrenia;
CESC	cis	rs858239	0.539	rs6975852	chr7:23186654	T/C	cg23682824	chr7:23144976	KLHL7	0.46	5.85	0.34	1.45e-8	Cerebrospinal fluid biomarker levels;
CESC	cis	rs9487051	0.872	rs1111866	chr6:109610846	A/C	cg12927641	chr6:109611667	NA	0.43	6.73	0.38	1.06e-10	Reticulocyte fraction of red cells;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10311315	chr2:101889706	SNORD89	-0.56	-6.5	-0.37	3.91e-10	Gut microbiome composition (summer);
CESC	cis	rs9910055	0.762	rs7213436	chr17:42252163	A/G	cg08499158	chr17:42289980	UBTF	0.49	6.34	0.36	9.7e-10	Total body bone mineral density;
CESC	cis	rs6912958	0.559	rs242270	chr6:88062190	C/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.46	-8.17	-0.45	1.28e-14	Monocyte percentage of white cells;
CESC	cis	rs6570726	0.935	rs416987	chr6:145847005	G/C	cg05347473	chr6:146136440	FBXO30	0.49	6.62	0.38	1.96e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs4450131	0.522	rs11245325	chr10:126348061	C/T	cg20435097	chr10:126320824	FAM53B	0.29	5.17	0.3	4.6e-7	White blood cell count (basophil);
CESC	cis	rs67311347	1.000	rs4973997	chr3:40460145	G/A	cg09455208	chr3:40491958	NA	0.45	7.68	0.43	3.1e-13	Renal cell carcinoma;
CESC	cis	rs7103648	0.897	rs2278890	chr11:47399602	G/A	cg03711944	chr11:47377212	SPI1	-0.39	-6.06	-0.35	4.76e-9	Diastolic blood pressure;Systolic blood pressure;
CESC	cis	rs6582630	0.519	rs11495700	chr12:38288240	A/G	cg13010199	chr12:38710504	ALG10B	0.53	6.57	0.37	2.63e-10	Drug-induced liver injury (flucloxacillin);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24333206	chr3:140660642	SLC25A36	-0.56	-6.51	-0.37	3.72e-10	Gut microbiome composition (summer);
CESC	cis	rs1707322	0.826	rs10890349	chr1:46249955	T/C	cg06784218	chr1:46089804	CCDC17	0.37	6.34	0.36	1e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7809950	0.723	rs2237662	chr7:106874065	C/G	cg23024343	chr7:107201750	COG5	-0.51	-6.73	-0.38	1.07e-10	Coronary artery disease;
CESC	cis	rs736408	0.677	rs1042779	chr3:52821011	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	6.45	0.37	5.19e-10	Bipolar disorder;
CESC	cis	rs3820068	0.603	rs72647120	chr1:15956769	G/T	cg17385448	chr1:15911702	AGMAT	0.41	6.63	0.38	1.86e-10	Systolic blood pressure;
CESC	cis	rs28829049	0.597	rs1009806	chr1:19500551	T/C	cg13387374	chr1:19411106	UBR4	0.45	5.8	0.34	1.88e-8	QRS duration in Tripanosoma cruzi seropositivity;
CESC	cis	rs1538970	0.924	rs12046816	chr1:45891543	G/T	cg05343316	chr1:45956843	TESK2	0.89	12.41	0.61	3.59e-28	Platelet count;
CESC	cis	rs1046896	0.514	rs9894705	chr17:80823758	A/C	cg19046167	chr17:80928561	B3GNTL1	-0.47	-5.72	-0.33	2.86e-8	Glycated hemoglobin levels;
CESC	cis	rs2735413	0.846	rs72800943	chr16:78079555	G/A	cg04733911	chr16:78082701	NA	-0.53	-9.01	-0.48	4.08e-17	Systolic blood pressure (alcohol consumption interaction);
CESC	cis	rs6502050	0.835	rs9901076	chr17:80170020	G/A	cg23985595	chr17:80112537	CCDC57	-0.42	-6.63	-0.38	1.9e-10	Life satisfaction;
CESC	cis	rs10883723	0.810	rs7069356	chr10:104254359	G/C	cg22532475	chr10:104410764	TRIM8	-0.34	-5.73	-0.33	2.77e-8	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs5758659	1.000	rs134873	chr22:42657566	T/G	cg15557168	chr22:42548783	NA	-0.5	-7.87	-0.44	8.97e-14	Cognitive function;
CESC	cis	rs9560113	0.556	rs9560128	chr13:112221924	A/G	cg10483660	chr13:112241077	NA	0.43	7.13	0.4	9.81e-12	Menarche (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15540553	chr11:64018643	PLCB3	0.54	6.26	0.36	1.5e-9	Gut microbiome composition (summer);
CESC	cis	rs67311347	1.000	rs4973898	chr3:40459532	A/G	cg09455208	chr3:40491958	NA	-0.47	-8.43	-0.46	2.23e-15	Renal cell carcinoma;
CESC	cis	rs7618915	0.547	rs12496476	chr3:52708737	A/G	cg07507251	chr3:52567010	NT5DC2	0.42	7.32	0.41	2.95e-12	Bipolar disorder;
CESC	cis	rs7618915	0.547	rs11130314	chr3:52697082	T/C	cg18404041	chr3:52824283	ITIH1	-0.39	-6.58	-0.37	2.56e-10	Bipolar disorder;
CESC	cis	rs7945705	0.837	rs2742474	chr11:9002089	A/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.34	-5.76	-0.33	2.35e-8	Hemoglobin concentration;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09658066	chr6:35995354	MAPK14	0.54	6.26	0.36	1.57e-9	Gut microbiome composition (summer);
CESC	cis	rs514406	0.505	rs269287	chr1:53168842	T/C	cg08736216	chr1:53307985	ZYG11A	-0.4	-6.78	-0.38	7.66e-11	Monocyte count;
CESC	cis	rs708547	0.957	rs781667	chr4:57798469	A/G	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.52	-5.4	-0.31	1.49e-7	Response to bleomycin (chromatid breaks);
CESC	cis	rs2204008	0.840	rs7136347	chr12:38453531	G/A	cg13010199	chr12:38710504	ALG10B	0.53	6.74	0.38	9.64e-11	Bladder cancer;
CESC	cis	rs7520050	0.966	rs6675726	chr1:46560643	A/G	cg03146154	chr1:46216737	IPP	-0.43	-5.57	-0.32	6.38e-8	Red blood cell count;Reticulocyte count;
CESC	trans	rs7726839	0.540	rs58599998	chr5:596087	A/G	cg25482853	chr8:67687455	SGK3	1.04	10.08	0.53	1.87e-20	Obesity-related traits;
CESC	cis	rs853679	0.517	rs9468286	chr6:28079428	C/T	cg23281280	chr6:28129359	ZNF389	0.58	7.93	0.44	6.31e-14	Depression;
CESC	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg10819733	chr22:24237672	NA	-0.46	-6.51	-0.37	3.67e-10	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs875971	0.965	rs697968	chr7:65535033	G/A	cg26939375	chr7:64535504	NA	-0.44	-5.44	-0.32	1.24e-7	Aortic root size;
CESC	cis	rs10883723	0.810	rs61873733	chr10:104251458	G/A	ch.10.2196322F	chr10:104248062	ACTR1A	0.42	5.1	0.3	6.38e-7	Allergic disease (asthma, hay fever or eczema);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23888375	chr2:203776317	ALS2CR8;WDR12	0.53	6.61	0.38	2.15e-10	Gut microbiome composition (summer);
CESC	cis	rs7666738	0.830	rs1120708	chr4:98931260	G/C	cg05340658	chr4:99064831	C4orf37	0.82	12.17	0.6	2.24e-27	Colonoscopy-negative controls vs population controls;
CESC	cis	rs2304069	0.913	rs3812009	chr5:149380159	G/C	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.93	11.35	0.57	1.31e-24	HIV-1 control;
CESC	cis	rs9486715	0.867	rs9486181	chr6:96868132	G/A	cg06623918	chr6:96969491	KIAA0776	0.91	14.05	0.65	6.83e-34	Headache;
CESC	cis	rs76878669	0.515	rs12576299	chr11:66132286	T/C	cg18002602	chr11:66138449	SLC29A2	0.4	6.65	0.38	1.71e-10	Educational attainment (years of education);
CESC	cis	rs72945132	0.882	rs7118156	chr11:70142922	T/C	cg14191688	chr11:70257035	CTTN	0.42	5.34	0.31	1.95e-7	Coronary artery disease;
CESC	cis	rs12893668	0.572	rs35011804	chr14:104151400	C/T	cg08213375	chr14:104286397	PPP1R13B	0.33	5.41	0.32	1.42e-7	Reticulocyte count;
CESC	cis	rs2281558	0.583	rs11087526	chr20:25648016	A/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.48	5.35	0.31	1.87e-7	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;
CESC	cis	rs10751667	0.961	rs7396670	chr11:929269	A/G	cg20946044	chr11:1010712	AP2A2	-0.42	-5.56	-0.32	6.59e-8	Alzheimer's disease (late onset);
CESC	cis	rs2295359	0.892	rs12401432	chr1:67656931	C/G	cg17031739	chr1:67600172	NA	0.41	5.48	0.32	9.94e-8	Psoriasis;
CESC	cis	rs28830936	1.000	rs11632424	chr15:42095351	G/A	cg11010575	chr15:42129464	JMJD7-PLA2G4B;JMJD7	-0.41	-5.59	-0.32	5.56e-8	Diastolic blood pressure;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg04370575	chr6:26537479	HMGN4	0.48	6.26	0.36	1.55e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs172166	0.611	rs203883	chr6:28078356	A/G	cg23281280	chr6:28129359	ZNF389	0.43	6.41	0.37	6.55e-10	Cardiac Troponin-T levels;
CESC	cis	rs6582630	0.502	rs4385963	chr12:38295264	G/A	cg26384229	chr12:38710491	ALG10B	0.7	10.34	0.54	2.92e-21	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs1797885	0.934	rs1797889	chr3:12559386	T/G	cg26432171	chr3:12704882	RAF1	-0.47	-5.84	-0.34	1.55e-8	Immature fraction of reticulocytes;
CESC	cis	rs11626933	0.885	rs28517514	chr14:90788709	G/A	cg14092571	chr14:90743983	NA	-0.9	-14.89	-0.67	7.47e-37	Gut microbiota (bacterial taxa);
CESC	cis	rs1008375	0.966	rs11722132	chr4:17697217	T/C	cg04450456	chr4:17643702	FAM184B	0.36	5.15	0.3	5.16e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs9393777	0.582	rs6936561	chr6:26640895	C/T	cg12292205	chr6:26970375	C6orf41	-0.5	-5.72	-0.33	2.9e-8	Intelligence (multi-trait analysis);
CESC	cis	rs10465746	0.967	rs6703382	chr1:84435700	G/A	cg10977910	chr1:84465055	TTLL7	0.46	6.32	0.36	1.08e-9	Obesity-related traits;
CESC	cis	rs2204008	0.614	rs4578492	chr12:38036350	T/C	cg13010199	chr12:38710504	ALG10B	0.54	6.63	0.38	1.87e-10	Bladder cancer;
CESC	cis	rs72829446	0.530	rs56078345	chr17:7394341	T/C	cg02795151	chr17:7402630	POLR2A	0.55	5.83	0.34	1.63e-8	Androgen levels;
CESC	cis	rs5498	0.869	rs2569702	chr19:10403947	A/G	cg21994045	chr19:10403936	ICAM5	0.45	6.39	0.37	7.48e-10	Lymphocyte counts;Soluble ICAM-1;Blood protein levels;
CESC	cis	rs769267	0.965	rs2315025	chr19:19426609	C/T	cg03709012	chr19:19516395	GATAD2A	0.95	13.57	0.64	3.38e-32	Tonsillectomy;
CESC	cis	rs17401966	0.838	rs946503	chr1:10308631	C/G	cg15208524	chr1:10270712	KIF1B	-0.4	-5.3	-0.31	2.4e-7	Hepatocellular carcinoma;
CESC	cis	rs7512552	0.839	rs1260421	chr1:150357780	G/A	cg15654264	chr1:150340011	RPRD2	0.39	5.17	0.3	4.68e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs3105593	0.547	rs3131559	chr15:50780214	C/A	cg08437265	chr15:50716283	USP8	0.49	6.41	0.37	6.65e-10	QT interval;
CESC	cis	rs4308124	0.708	rs6727313	chr2:111971540	G/A	cg04571233	chr2:111982156	NA	-0.62	-6.8	-0.39	6.82e-11	Vitiligo;
CESC	cis	rs801193	1.000	rs1553610	chr7:66197233	T/C	cg11764359	chr7:65958608	NA	0.69	9.1	0.49	2.27e-17	Aortic root size;
CESC	cis	rs3733585	0.673	rs4311316	chr4:9955971	A/C	cg11266682	chr4:10021025	SLC2A9	0.54	9.94	0.52	5.31e-20	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs7618915	0.547	rs6762813	chr3:52726695	C/T	cg18099408	chr3:52552593	STAB1	-0.31	-5.18	-0.3	4.4e-7	Bipolar disorder;
CESC	cis	rs7666738	0.677	rs13120306	chr4:99036099	A/T	cg05340658	chr4:99064831	C4orf37	0.82	12.42	0.61	3.27e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs4144027	0.967	rs10133399	chr14:104361843	A/T	cg08213375	chr14:104286397	PPP1R13B	0.28	5.09	0.3	6.88e-7	Blood metabolite levels;
CESC	cis	rs2243480	1.000	rs383402	chr7:65586653	A/C	cg18252515	chr7:66147081	NA	1.18	12.3	0.6	8.08e-28	Diabetic kidney disease;
CESC	cis	rs2075371	1.000	rs447266	chr7:133989543	A/G	cg11752832	chr7:134001865	SLC35B4	0.57	7.47	0.42	1.2e-12	Mean platelet volume;
CESC	cis	rs514406	0.584	rs12095247	chr1:53193796	A/C	cg08859206	chr1:53392774	SCP2	0.54	6.79	0.38	7.33e-11	Monocyte count;
CESC	cis	rs873946	0.586	rs3793686	chr10:134569559	A/G	cg26818010	chr10:134567672	INPP5A	-0.9	-11.14	-0.56	6.82e-24	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs546131	0.820	rs744841	chr11:34857667	G/A	cg06937548	chr11:34938143	PDHX;APIP	0.49	6.22	0.36	1.97e-9	Lung disease severity in cystic fibrosis;
CESC	cis	rs703842	0.616	rs870392	chr12:58219173	C/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.56	6.46	0.37	5e-10	Multiple sclerosis;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg26526983	chr16:12136938	RUNDC2A	0.42	6.0	0.35	6.45e-9	Fibrinogen levels;
CESC	cis	rs9611565	0.694	rs2142505	chr22:41820541	A/G	cg06634786	chr22:41940651	POLR3H	0.73	7.31	0.41	3.18e-12	Vitiligo;
CESC	cis	rs12325245	0.536	rs12709002	chr16:58614337	A/C	cg02549819	chr16:58548995	SETD6	0.97	6.45	0.37	5.42e-10	Schizophrenia;
CESC	cis	rs7208859	0.562	rs11650923	chr17:29008167	G/A	cg19761014	chr17:28927070	LRRC37B2	0.82	6.69	0.38	1.3100000000000001e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02079880	chr6:157802436	ZDHHC14	0.59	6.21	0.36	2e-9	Gut microbiome composition (summer);
CESC	cis	rs7674212	0.540	rs2720469	chr4:104086484	C/T	cg16532752	chr4:104119610	CENPE	-0.44	-5.96	-0.34	8.1e-9	Type 2 diabetes;
CESC	cis	rs2742417	0.609	rs11709306	chr3:45773732	G/A	cg04837898	chr3:45731254	SACM1L	-0.46	-6.11	-0.35	3.5e-9	Response to anti-depressant treatment in major depressive disorder;
CESC	cis	rs15676	0.812	rs10819447	chr9:131576416	T/G	cg00228799	chr9:131580591	ENDOG	0.44	5.44	0.32	1.21e-7	Blood metabolite levels;
CESC	cis	rs274567	0.501	rs272855	chr5:131687175	C/T	cg18758796	chr5:131593413	PDLIM4	0.38	5.11	0.3	6.09e-7	Blood metabolite levels;
CESC	cis	rs113835537	0.529	rs57207756	chr11:66270360	C/T	cg24851651	chr11:66362959	CCS	0.48	5.7	0.33	3.11e-8	Airway imaging phenotypes;
CESC	cis	rs3747547	0.892	rs11792678	chr9:38020036	A/G	cg13774184	chr9:37916125	SHB	-0.73	-6.25	-0.36	1.61e-9	Metabolite levels (Dihydroxy docosatrienoic acid);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg17766062	chr2:75062663	HK2	0.51	6.47	0.37	4.7e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs1448094	0.512	rs11503595	chr12:86244075	T/A	cg00310523	chr12:86230176	RASSF9	0.35	5.4	0.31	1.47e-7	Major depressive disorder;
CESC	cis	rs853679	0.517	rs9380049	chr6:28048535	A/G	cg22143856	chr6:28129313	ZNF389	0.49	6.3	0.36	1.2e-9	Depression;
CESC	trans	rs877282	0.838	rs11253373	chr10:774857	A/G	cg22713356	chr15:30763199	NA	1.24	12.53	0.61	1.32e-28	Uric acid levels;
CESC	cis	rs10504229	0.953	rs75585481	chr8:58192202	T/C	cg22535103	chr8:58192502	C8orf71	-1.05	-13.08	-0.63	1.71e-30	Developmental language disorder (linguistic errors);
CESC	trans	rs877282	0.891	rs11595385	chr10:800539	A/G	cg22713356	chr15:30763199	NA	1.36	13.59	0.64	2.89e-32	Uric acid levels;
CESC	cis	rs72634258	0.786	rs6682709	chr1:8173796	A/C	cg00042356	chr1:8021962	PARK7	-0.47	-5.21	-0.3	3.76e-7	Inflammatory bowel disease;
CESC	cis	rs1008375	0.966	rs3733576	chr4:17586703	T/C	cg27347728	chr4:17578864	LAP3	0.49	5.58	0.32	6.07e-8	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs3820928	0.874	rs10166736	chr2:227900419	C/T	cg11843606	chr2:227700838	RHBDD1	-0.5	-6.51	-0.37	3.73e-10	Pulmonary function;
CESC	cis	rs9311474	0.713	rs352168	chr3:52237970	C/T	cg05315796	chr3:52349193	DNAH1	0.3	5.24	0.31	3.23e-7	Electroencephalogram traits;
CESC	cis	rs2836974	0.932	rs35571600	chr21:40590624	A/C	cg27266027	chr21:40555129	PSMG1	0.44	5.21	0.3	3.77e-7	Cognitive function;
CESC	cis	rs5750830	0.620	rs1007337	chr22:39781585	C/T	cg05872129	chr22:39784769	NA	-0.77	-11.03	-0.56	1.59e-23	Intelligence (multi-trait analysis);
CESC	cis	rs12348691	0.503	rs7849834	chr9:100606188	T/C	cg13688889	chr9:100608707	NA	-0.89	-13.48	-0.64	7.1e-32	Alopecia areata;
CESC	cis	rs1065852	0.526	rs56234624	chr22:42388826	A/G	cg22189786	chr22:42395067	WBP2NL	0.43	5.42	0.32	1.33e-7	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
CESC	cis	rs6952808	0.689	rs2008263	chr7:2048335	A/G	cg21782813	chr7:2030301	MAD1L1	0.5	7.18	0.4	6.92e-12	Bipolar disorder and schizophrenia;
CESC	cis	rs6433857	0.657	rs2368177	chr2:181501242	T/C	cg23363182	chr2:181467187	NA	-0.45	-6.8	-0.39	6.88e-11	Body mass index;
CESC	cis	rs3105593	1.000	rs3101855	chr15:50859874	A/G	cg08437265	chr15:50716283	USP8	0.4	5.19	0.3	4.28e-7	QT interval;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10334916	chr2:241508098	RNPEPL1	0.54	6.13	0.35	3.18e-9	Gut microbiome composition (summer);
CESC	cis	rs9818941	0.824	rs4511848	chr3:157732021	A/C	cg08654915	chr3:157813417	NA	-0.45	-7.28	-0.41	3.9e-12	Height;
CESC	trans	rs6462411	0.652	rs12701229	chr7:3896634	A/G	cg08023175	chr19:57967606	VN1R1	-0.41	-6.06	-0.35	4.72e-9	Quantitative traits;
CESC	cis	rs7824557	0.583	rs4448232	chr8:11231354	G/T	cg21775007	chr8:11205619	TDH	0.55	8.3	0.45	5.24e-15	Retinal vascular caliber;
CESC	cis	rs769267	0.965	rs4808938	chr19:19401218	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	7.46	0.42	1.24e-12	Tonsillectomy;
CESC	cis	rs9611565	0.512	rs139573	chr22:42214785	G/A	cg06481639	chr22:41940642	POLR3H	-0.57	-5.59	-0.32	5.59e-8	Vitiligo;
CESC	cis	rs7208859	0.673	rs999796	chr17:29159404	G/C	cg19761014	chr17:28927070	LRRC37B2	0.56	5.54	0.32	7.17e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs501120	0.810	rs510785	chr10:44749990	C/A	cg09554077	chr10:44749378	NA	0.51	6.82	0.39	6.06e-11	Coronary artery disease;Coronary heart disease;
CESC	cis	rs950776	0.720	rs11637890	chr15:78935419	C/G	cg06917634	chr15:78832804	PSMA4	-0.54	-6.49	-0.37	4.31e-10	Sudden cardiac arrest;
CESC	cis	rs11155671	0.530	rs9383914	chr6:150207234	T/G	cg09699651	chr6:150184138	LRP11	0.55	7.61	0.42	4.89e-13	Testicular germ cell tumor;
CESC	cis	rs7412746	0.658	rs11589458	chr1:150792616	A/G	cg22823121	chr1:150693482	HORMAD1	0.48	6.65	0.38	1.63e-10	Melanoma;
CESC	cis	rs10744422	1.000	rs2135014	chr12:123333065	C/T	cg25930673	chr12:123319894	HIP1R	-0.72	-5.73	-0.33	2.79e-8	Schizophrenia;
CESC	cis	rs9611565	0.659	rs9611610	chr22:41949259	A/G	cg17376030	chr22:41985996	PMM1	0.68	7.17	0.4	7.37e-12	Vitiligo;
CESC	cis	rs965469	1.000	rs6051792	chr20:3343519	T/C	cg25506879	chr20:3388711	C20orf194	-0.55	-5.85	-0.34	1.43e-8	IFN-related cytopenia;
CESC	cis	rs7666738	0.606	rs10006454	chr4:99080361	G/A	cg24818145	chr4:99064322	C4orf37	0.4	5.14	0.3	5.32e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg11494091	chr17:61959527	GH2	0.72	12.33	0.6	6.37e-28	Prudent dietary pattern;
CESC	cis	rs12118280	0.512	rs116395849	chr1:108750548	G/A	cg11967332	chr1:108735228	SLC25A24	0.64	6.79	0.38	7.34e-11	Myeloid white cell count;
CESC	cis	rs1448094	0.511	rs10506923	chr12:86152595	C/T	cg02569458	chr12:86230093	RASSF9	-0.46	-7.15	-0.4	8.28e-12	Major depressive disorder;
CESC	cis	rs7267979	1.000	rs7020	chr20:25278600	G/A	cg08601574	chr20:25228251	PYGB	0.38	5.51	0.32	8.32e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs1983170	0.673	rs11164934	chr1:92015267	C/T	cg02896835	chr1:92012615	NA	0.55	5.38	0.31	1.61e-7	Eosinophil percentage of white cells;
CESC	cis	rs7818688	0.546	rs13250762	chr8:95987570	A/G	cg16049864	chr8:95962084	TP53INP1	0.55	5.82	0.34	1.67e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs7917772	0.636	rs4919676	chr10:104524352	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.44	-5.18	-0.3	4.3e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs2204008	0.744	rs67889662	chr12:38327042	T/A	cg26384229	chr12:38710491	ALG10B	0.74	10.63	0.55	3.17e-22	Bladder cancer;
CESC	cis	rs9322193	0.884	rs2095375	chr6:150128173	C/A	cg13206674	chr6:150067644	NUP43	0.42	5.83	0.34	1.64e-8	Lung cancer;
CESC	cis	rs7584330	0.737	rs61212490	chr2:238365230	T/C	cg14458575	chr2:238380390	NA	0.62	8.39	0.46	3.03e-15	Prostate cancer;
CESC	cis	rs6121246	0.529	rs6060174	chr20:30183538	G/A	cg13852791	chr20:30311386	BCL2L1	0.58	5.51	0.32	8.44e-8	Mean corpuscular hemoglobin;
CESC	cis	rs6754311	0.731	rs4954490	chr2:136608231	G/A	cg15123519	chr2:136567270	LCT	0.31	5.16	0.3	4.81e-7	Mosquito bite size;
CESC	cis	rs11792861	0.541	rs838824	chr9:111670707	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	-0.42	-5.6	-0.33	5.3e-8	Menarche (age at onset);
CESC	cis	rs7697216	0.668	rs4072805	chr4:175839285	C/G	cg14561282	chr4:175839468	ADAM29	0.5	5.52	0.32	8.07e-8	Breast cancer;
CESC	cis	rs875971	0.862	rs6460306	chr7:66060793	T/C	cg18252515	chr7:66147081	NA	0.46	6.0	0.35	6.54e-9	Aortic root size;
CESC	cis	rs5750830	0.649	rs5750820	chr22:39825322	T/G	cg24399712	chr22:39784796	NA	-0.83	-11.13	-0.56	7.06e-24	Intelligence (multi-trait analysis);
CESC	cis	rs9486719	0.948	rs2499813	chr6:96875338	T/C	cg06623918	chr6:96969491	KIAA0776	0.81	8.23	0.45	8.62e-15	Migraine;Coronary artery disease;
CESC	cis	rs11112613	0.713	rs12296355	chr12:105953321	C/A	cg03607813	chr12:105948248	NA	0.59	7.23	0.41	5.26e-12	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
CESC	cis	rs7264396	0.563	rs6060570	chr20:34291166	A/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.64	6.86	0.39	4.8e-11	Total cholesterol levels;
CESC	cis	rs8114671	0.836	rs6058154	chr20:33585834	C/T	cg08999081	chr20:33150536	PIGU	-0.36	-5.08	-0.3	7.13e-7	Height;
CESC	cis	rs714031	0.900	rs5757762	chr22:40064581	C/T	cg21377881	chr22:40064566	CACNA1I	-0.41	-6.67	-0.38	1.5e-10	Schizophrenia;
CESC	trans	rs7395662	0.517	rs10454483	chr11:48754997	A/G	cg15704280	chr7:45808275	SEPT13	-0.58	-7.01	-0.4	1.94e-11	HDL cholesterol;
CESC	cis	rs8020095	0.571	rs1918483	chr14:67607623	G/T	cg19548862	chr14:67692701	FAM71D	-0.47	-5.58	-0.32	5.87e-8	Depression (quantitative trait);
CESC	cis	rs858239	0.665	rs6964665	chr7:23211352	G/A	cg23682824	chr7:23144976	KLHL7	0.46	6.03	0.35	5.5e-9	Cerebrospinal fluid biomarker levels;
CESC	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg11905131	chr22:24372483	LOC391322	-0.64	-9.33	-0.5	4.35e-18	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs10885582	0.754	rs10885576	chr10:116298843	G/A	cg17056676	chr10:116301354	ABLIM1	-0.29	-5.3	-0.31	2.38e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs477692	0.905	rs555545	chr10:131411586	G/A	cg05714579	chr10:131428358	MGMT	0.52	7.3	0.41	3.29e-12	Response to temozolomide;
CESC	cis	rs7680126	0.597	rs78917351	chr4:10208063	A/C	cg00071950	chr4:10020882	SLC2A9	-0.53	-5.88	-0.34	1.2e-8	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
CESC	cis	rs6740322	0.948	rs6715072	chr2:43562230	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.57	-6.37	-0.36	8.27e-10	Coronary artery disease;
CESC	trans	rs1373453	0.764	rs710729	chr12:70061392	A/G	cg19702771	chr4:82058885	PRKG2	0.65	6.02	0.35	5.66e-9	Orofacial clefts;
CESC	cis	rs763121	1.000	rs138457	chr22:38898051	T/C	cg06544989	chr22:39130855	UNC84B	-0.43	-7.71	-0.43	2.5e-13	Menopause (age at onset);
CESC	cis	rs3820928	0.648	rs1997484	chr2:227898962	T/A	cg11843606	chr2:227700838	RHBDD1	-0.48	-6.44	-0.37	5.72e-10	Pulmonary function;
CESC	cis	rs73195822	0.667	rs7967408	chr12:111164408	A/C	cg12870014	chr12:110450643	ANKRD13A	0.64	5.66	0.33	3.91e-8	Itch intensity from mosquito bite;
CESC	cis	rs875971	0.798	rs7789615	chr7:65878661	A/G	cg18252515	chr7:66147081	NA	-0.46	-6.05	-0.35	5e-9	Aortic root size;
CESC	cis	rs7605827	0.930	rs7571679	chr2:15596603	C/T	cg19274914	chr2:15703543	NA	0.32	5.69	0.33	3.38e-8	Educational attainment (years of education);
CESC	cis	rs9309473	0.607	rs7567343	chr2:73596605	C/A	cg20560298	chr2:73613845	ALMS1	-0.49	-6.79	-0.39	7.27e-11	Metabolite levels;
CESC	cis	rs992157	0.798	rs10193383	chr2:219157692	C/T	cg00012203	chr2:219082015	ARPC2	0.75	9.7	0.51	3.1e-19	Colorectal cancer;
CESC	cis	rs1707322	0.717	rs2991989	chr1:46082965	C/T	cg03146154	chr1:46216737	IPP	-0.8	-11.01	-0.56	1.87e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs72781680	0.611	rs4149373	chr2:24300023	C/T	cg08917208	chr2:24149416	ATAD2B	0.54	5.15	0.3	5.09e-7	Lymphocyte counts;
CESC	cis	rs7208859	0.623	rs9899268	chr17:29150255	T/C	cg14008862	chr17:28927542	LRRC37B2	0.66	5.22	0.31	3.64e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs8180040	0.729	rs11720439	chr3:47347003	T/G	cg27129171	chr3:47204927	SETD2	-0.63	-9.12	-0.49	1.97e-17	Colorectal cancer;
CESC	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg16405210	chr4:1374714	KIAA1530	0.94	12.7	0.62	3.5e-29	Longevity;
CESC	cis	rs7923609	0.967	rs10509189	chr10:65264126	T/C	cg01631684	chr10:65280961	REEP3	-0.43	-5.4	-0.31	1.47e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7188697	0.845	rs1981960	chr16:58597289	C/G	cg02549819	chr16:58548995	SETD6	0.43	5.4	0.31	1.51e-7	QT interval;
CESC	cis	rs6570726	0.526	rs4895674	chr6:145735860	T/G	cg23711669	chr6:146136114	FBXO30	-0.55	-7.1	-0.4	1.13e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7520050	0.966	rs11579634	chr1:46466391	A/G	cg03146154	chr1:46216737	IPP	0.41	5.13	0.3	5.73e-7	Red blood cell count;Reticulocyte count;
CESC	cis	rs9926296	0.632	rs72807526	chr16:89775946	A/G	cg03605463	chr16:89740564	NA	0.55	6.57	0.37	2.73e-10	Vitiligo;
CESC	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg26304593	chr6:42947056	PEX6	-0.43	-5.55	-0.32	6.8e-8	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs950169	0.919	rs17300292	chr15:84762568	G/C	cg17507749	chr15:85114479	UBE2QP1	0.61	6.73	0.38	1.05e-10	Schizophrenia;
CESC	cis	rs34375054	0.660	rs57031290	chr12:125593053	A/G	cg25124228	chr12:125621409	AACS	-0.56	-6.63	-0.38	1.84e-10	Post bronchodilator FEV1/FVC ratio;
CESC	trans	rs60380162	0.963	rs4655942	chr1:87722759	G/T	cg20163645	chr8:1900353	ARHGEF10	-0.43	-6.05	-0.35	4.95e-9	Loneliness (linear analysis);
CESC	cis	rs9910055	0.593	rs2905983	chr17:42212429	T/G	cg08499158	chr17:42289980	UBTF	0.52	6.51	0.37	3.65e-10	Total body bone mineral density;
CESC	cis	rs6912958	1.000	rs6933587	chr6:88175577	T/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.53	-7.42	-0.41	1.56e-12	Monocyte percentage of white cells;
CESC	cis	rs2204008	0.744	rs11514073	chr12:38399553	A/C	cg26384229	chr12:38710491	ALG10B	0.73	10.39	0.54	1.89e-21	Bladder cancer;
CESC	cis	rs2228479	0.850	rs11649162	chr16:89807131	C/A	cg14709524	chr16:89940631	TCF25	0.92	6.91	0.39	3.59e-11	Skin colour saturation;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21518056	chr19:33183187	NUDT19	0.62	6.81	0.39	6.7e-11	Gut microbiome composition (summer);
CESC	cis	rs67311347	1.000	rs73080137	chr3:40516412	A/G	cg24209194	chr3:40518798	ZNF619	0.53	6.99	0.39	2.23e-11	Renal cell carcinoma;
CESC	cis	rs9303401	0.573	rs62081879	chr17:57181524	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.0	12.81	0.62	1.44e-29	Cognitive test performance;
CESC	cis	rs9549260	0.567	rs7332730	chr13:41265979	C/A	cg21288729	chr13:41239152	FOXO1	0.61	7.72	0.43	2.43e-13	Red blood cell count;
CESC	cis	rs1552244	0.882	rs9312044	chr3:10037481	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.75	-9.64	-0.51	4.83e-19	Alzheimer's disease;
CESC	cis	rs11077998	0.967	rs11657886	chr17:80516173	T/C	cg10255544	chr17:80519551	FOXK2	0.54	8.71	0.47	3.3e-16	Reticulocyte fraction of red cells;
CESC	cis	rs4523957	0.614	rs7220685	chr17:2059385	A/G	cg16513277	chr17:2031491	SMG6	-0.72	-10.2	-0.53	8.12e-21	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs11252926	0.574	rs4881313	chr10:487973	C/T	cg03684893	chr10:554711	DIP2C	0.39	5.94	0.34	9.14e-9	Psychosis in Alzheimer's disease;
CESC	cis	rs4713118	0.513	rs1225591	chr6:28148752	G/A	cg23281280	chr6:28129359	ZNF389	0.42	6.22	0.36	1.92e-9	Parkinson's disease;
CESC	trans	rs61931739	0.500	rs7306435	chr12:34482933	A/G	cg13010199	chr12:38710504	ALG10B	-0.5	-6.41	-0.37	6.7e-10	Morning vs. evening chronotype;
CESC	cis	rs8014204	0.935	rs2853779	chr14:75368508	G/A	cg26191576	chr14:75389716	RPS6KL1	0.36	5.25	0.31	3.06e-7	Caffeine consumption;
CESC	cis	rs6942756	1.000	rs9640854	chr7:128884057	A/T	cg02491457	chr7:128862824	NA	-0.67	-9.4	-0.5	2.77e-18	White matter hyperintensity burden;
CESC	cis	rs7607369	0.559	rs4674343	chr2:219660346	C/T	cg02176678	chr2:219576539	TTLL4	0.39	6.96	0.39	2.68e-11	Red blood cell count;Amyotrophic lateral sclerosis;
CESC	cis	rs79976124	0.879	rs10944856	chr6:66636960	G/C	cg07460842	chr6:66804631	NA	0.72	8.31	0.45	5.13e-15	Type 2 diabetes;
CESC	cis	rs7834588	0.523	rs4134468	chr8:63841096	T/C	cg20602954	chr8:63776762	NKAIN3	0.32	5.31	0.31	2.27e-7	Response to Vitamin E supplementation;
CESC	cis	rs1949733	1.000	rs1880023	chr4:8480831	C/T	cg11789530	chr4:8429930	ACOX3	-0.78	-11.27	-0.57	2.5e-24	Response to antineoplastic agents;
CESC	cis	rs798554	1.000	rs798554	chr7:2759795	C/T	cg19346786	chr7:2764209	NA	-0.47	-6.8	-0.39	6.74e-11	Height;
CESC	cis	rs9911578	1.000	rs3744109	chr17:56594197	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.41	-5.53	-0.32	7.63e-8	Intelligence (multi-trait analysis);
CESC	cis	rs11785400	1.000	rs9720653	chr8:143731939	T/G	cg24634471	chr8:143751801	JRK	0.46	6.03	0.35	5.46e-9	Schizophrenia;
CESC	cis	rs2302190	0.882	rs11658998	chr17:56655786	T/G	cg25885038	chr17:56607967	SEPT4	-0.4	-5.43	-0.32	1.27e-7	Vitamin D levels;
CESC	cis	rs7618915	0.501	rs9917834	chr3:52634619	A/C	cg05564831	chr3:52568323	NT5DC2	0.48	7.64	0.42	4.06e-13	Bipolar disorder;
CESC	cis	rs7312933	0.618	rs6582390	chr12:42634586	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.46	5.96	0.34	8e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
CESC	cis	rs2735413	0.514	rs7192129	chr16:78136414	A/G	cg04733911	chr16:78082701	NA	0.38	6.09	0.35	3.99e-9	Systolic blood pressure (alcohol consumption interaction);
CESC	cis	rs4523957	0.893	rs11078019	chr17:2162121	G/A	cg16513277	chr17:2031491	SMG6	-0.6	-8.18	-0.45	1.22e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs4819052	0.788	rs13049700	chr21:46701909	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.88	12.16	0.6	2.4e-27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
CESC	cis	rs8017423	0.935	rs4904661	chr14:90729332	T/C	cg14092571	chr14:90743983	NA	-0.56	-8.38	-0.46	3.07e-15	Mortality in heart failure;
CESC	cis	rs2479106	0.553	rs3739827	chr9:126690157	A/G	cg16191174	chr9:126692580	DENND1A	-0.52	-6.45	-0.37	5.37e-10	Polycystic ovary syndrome;
CESC	cis	rs7259376	0.936	rs10454118	chr19:22559605	C/G	cg02657401	chr19:22469223	NA	0.25	5.07	0.3	7.45e-7	Menopause (age at onset);
CESC	cis	rs2742234	0.955	rs2503865	chr10:43659536	C/T	cg07801480	chr10:43725741	RASGEF1A	0.42	5.99	0.35	6.69e-9	Hirschsprung disease;
CESC	cis	rs4835473	0.932	rs6847869	chr4:144904034	C/A	cg25736465	chr4:144833511	NA	0.4	6.13	0.35	3.25e-9	Immature fraction of reticulocytes;
CESC	cis	rs9291683	0.588	rs3796829	chr4:10019138	C/G	cg11266682	chr4:10021025	SLC2A9	0.72	14.87	0.67	8.73e-37	Bone mineral density;
CESC	cis	rs7512552	0.839	rs832622	chr1:150392830	A/G	cg15654264	chr1:150340011	RPRD2	0.4	5.3	0.31	2.4e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs2415984	0.538	rs4595715	chr14:46967541	C/T	cg14871534	chr14:47121158	RPL10L	-0.34	-5.07	-0.3	7.31e-7	Number of children ever born;
CESC	cis	rs7772486	0.875	rs11755334	chr6:146399297	T/C	cg23711669	chr6:146136114	FBXO30	0.82	12.45	0.61	2.54e-28	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs672059	1.000	rs638781	chr1:183157358	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.54	6.99	0.39	2.28e-11	Hypertriglyceridemia;
CESC	cis	rs7799006	0.606	rs878534	chr7:2314652	G/A	cg12745145	chr7:2261452	MAD1L1	-0.33	-5.19	-0.3	4.18e-7	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs9611565	0.694	rs79011	chr22:41866938	A/G	cg17376030	chr22:41985996	PMM1	-0.55	-6.21	-0.36	1.98e-9	Vitiligo;
CESC	cis	rs1707322	0.752	rs11211168	chr1:46163647	C/T	cg03146154	chr1:46216737	IPP	0.82	11.55	0.58	2.81e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11239016	chr16:90085722	DBNDD1	0.58	6.46	0.37	5.05e-10	Gut microbiome composition (summer);
CESC	cis	rs7945705	0.875	rs2653616	chr11:8885892	A/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.38	-6.41	-0.37	6.46e-10	Hemoglobin concentration;
CESC	cis	rs561341	1.000	rs548957	chr17:30302411	G/A	cg23018236	chr17:30244563	NA	-0.52	-5.1	-0.3	6.39e-7	Hip circumference adjusted for BMI;
CESC	cis	rs7927771	0.832	rs7940536	chr11:47395240	G/A	cg20307385	chr11:47447363	PSMC3	0.59	7.03	0.4	1.73e-11	Subjective well-being;
CESC	cis	rs11677416	1.000	rs4848300	chr2:113527906	T/C	cg27083787	chr2:113543245	IL1A	0.41	5.16	0.3	4.75e-7	Response to antipsychotic treatment in schizophrenia (working memory);
CESC	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg17541715	chr7:1216824	NA	-0.4	-5.59	-0.32	5.68e-8	Longevity;Endometriosis;
CESC	cis	rs6502050	0.835	rs66932937	chr17:80116803	G/A	cg23985595	chr17:80112537	CCDC57	-0.41	-6.46	-0.37	4.88e-10	Life satisfaction;
CESC	cis	rs9733	0.596	rs72702523	chr1:150650425	G/T	cg04414720	chr1:150670196	GOLPH3L	0.63	9.01	0.48	4.11e-17	Tonsillectomy;
CESC	cis	rs2549003	1.000	rs2070731	chr5:131819798	T/C	cg00255919	chr5:131827918	IRF1	0.53	8.28	0.45	6.28e-15	Asthma (sex interaction);
CESC	cis	rs793571	0.544	rs383902	chr15:59034174	C/T	cg05156742	chr15:59063176	FAM63B	0.65	8.83	0.48	1.44e-16	Schizophrenia;
CESC	cis	rs7692995	1.000	rs1380293	chr4:18027235	T/C	cg08925142	chr4:18023851	LCORL	-0.44	-5.14	-0.3	5.22e-7	Height;
CESC	cis	rs754466	0.580	rs10762765	chr10:79566407	T/C	cg17075019	chr10:79541650	NA	-0.82	-12.76	-0.62	2.19e-29	Liver enzyme levels (gamma-glutamyl transferase);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg03425468	chr1:155164676	MIR92B	-0.44	-6.35	-0.36	9.48e-10	Fibrinogen levels;
CESC	cis	rs12545109	0.879	rs893234	chr8:57363885	G/A	cg09654669	chr8:57350985	NA	-0.57	-6.65	-0.38	1.66e-10	Obesity-related traits;
CESC	cis	rs34779708	0.931	rs72789687	chr10:35372489	G/A	cg03585969	chr10:35415529	CREM	0.77	10.07	0.53	2.06e-20	Inflammatory bowel disease;Crohn's disease;
CESC	cis	rs7618915	0.547	rs11709448	chr3:52647449	T/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.3	5.18	0.3	4.37e-7	Bipolar disorder;
CESC	cis	rs1862618	0.671	rs173763	chr5:56225418	G/A	cg20203395	chr5:56204925	C5orf35	-0.39	-5.24	-0.31	3.23e-7	Initial pursuit acceleration;
CESC	cis	rs12134245	0.776	rs12122066	chr1:92005140	C/T	cg07090678	chr1:91966139	CDC7	0.42	5.67	0.33	3.66e-8	Breast cancer;
CESC	cis	rs1801251	0.778	rs2250654	chr2:233752376	A/T	cg25237894	chr2:233734115	C2orf82	-0.5	-8.87	-0.48	1.14e-16	Coronary artery disease;
CESC	cis	rs7666738	0.830	rs4699574	chr4:98725544	C/T	cg17366294	chr4:99064904	C4orf37	0.57	7.94	0.44	5.7e-14	Colonoscopy-negative controls vs population controls;
CESC	cis	rs795484	0.610	rs2936839	chr12:118580315	T/C	cg16572268	chr12:118583242	PEBP1	-0.35	-5.06	-0.3	8.02e-7	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09551160	chr10:80828924	ZMIZ1	0.53	6.2	0.36	2.18e-9	Gut microbiome composition (summer);
CESC	cis	rs2742417	0.603	rs2064063	chr3:45759924	T/A	cg04837898	chr3:45731254	SACM1L	-0.47	-6.25	-0.36	1.61e-9	Response to anti-depressant treatment in major depressive disorder;
CESC	cis	rs55823223	0.648	rs936394	chr17:73852008	C/A	cg10935138	chr17:73851978	WBP2	0.84	9.68	0.51	3.62e-19	Psoriasis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12277888	chr11:35723985	TRIM44	-0.65	-7.82	-0.43	1.29e-13	Gut microbiome composition (summer);
CESC	cis	rs9640161	0.789	rs2098053	chr7:150043205	G/A	cg17279839	chr7:150038598	RARRES2	0.51	6.03	0.35	5.62e-9	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs7552404	1.000	rs1498315	chr1:76159225	G/A	cg22875332	chr1:76189707	ACADM	0.66	7.81	0.43	1.31e-13	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs11249608	0.636	rs62393070	chr5:178447943	A/G	cg21905437	chr5:178450457	ZNF879	0.58	8.09	0.45	2.14e-14	Pubertal anthropometrics;
CESC	trans	rs3780486	0.813	rs3780488	chr9:33133812	T/C	cg04842962	chr6:43655489	MRPS18A	1.0	18.73	0.75	1.91e-50	IgG glycosylation;
CESC	cis	rs7264396	1.000	rs224429	chr20:34152018	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.54	-7.01	-0.4	2.04e-11	Total cholesterol levels;
CESC	cis	rs17666538	0.792	rs7820788	chr8:601846	C/T	cg23958373	chr8:599963	NA	0.78	6.22	0.36	1.93e-9	IgG glycosylation;
CESC	cis	rs7666738	0.830	rs13147768	chr4:98833675	A/T	cg05340658	chr4:99064831	C4orf37	0.72	10.37	0.54	2.25e-21	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6547741	0.967	rs4665996	chr2:27814343	T/C	cg21248554	chr2:27665150	KRTCAP3	0.25	5.08	0.3	7.23e-7	Oral cavity cancer;
CESC	cis	rs2635047	0.615	rs2684819	chr18:44710691	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.41	5.59	0.32	5.7e-8	Educational attainment;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg16579101	chr12:6677158	NOP2	0.48	6.55	0.37	2.94e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs2295359	1.000	rs11465753	chr1:67631423	T/C	cg03340356	chr1:67600835	NA	0.33	5.34	0.31	2e-7	Psoriasis;
CESC	cis	rs8053891	0.615	rs2000999	chr16:72108093	G/A	cg01557791	chr16:72042693	DHODH	-0.49	-5.05	-0.3	8.32e-7	Coronary artery disease;
CESC	cis	rs9926296	0.585	rs6500441	chr16:89828669	C/G	cg27121462	chr16:89883253	FANCA	0.77	11.41	0.57	8.45e-25	Vitiligo;
CESC	cis	rs1881797	1.000	rs7527856	chr1:247688139	C/T	cg05639522	chr1:247681581	NA	0.45	6.05	0.35	4.97e-9	Acute lymphoblastic leukemia (childhood);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08030545	chr16:22308466	POLR3E	-0.66	-8.08	-0.44	2.37e-14	Gut microbiome composition (summer);
CESC	cis	rs1577917	1.000	rs10498958	chr6:86649705	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.51	6.65	0.38	1.62e-10	Response to antipsychotic treatment;
CESC	cis	rs9512730	0.553	rs1007701	chr13:28049143	C/G	cg04070771	chr13:27998621	GTF3A	-0.49	-5.41	-0.32	1.4e-7	Schizophrenia;
CESC	cis	rs11997175	0.646	rs10954936	chr8:33686165	C/T	ch.8.33884649F	chr8:33765107	NA	0.57	7.37	0.41	2.15e-12	Body mass index;
CESC	cis	rs3096299	0.719	rs2965945	chr16:89514017	T/C	cg16743903	chr16:89593216	SPG7	-0.39	-5.07	-0.3	7.45e-7	Multiple myeloma (IgH translocation);
CESC	cis	rs2742234	0.911	rs3004214	chr10:43631698	C/T	cg15436174	chr10:43711423	RASGEF1A	-0.43	-5.16	-0.3	4.88e-7	Hirschsprung disease;
CESC	trans	rs208520	0.909	rs60604603	chr6:67022955	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.81	7.68	0.43	3.1400000000000003e-13	Exhaled nitric oxide output;
CESC	cis	rs11677416	1.000	rs72825514	chr2:113527706	G/T	cg27083787	chr2:113543245	IL1A	0.58	7.33	0.41	2.81e-12	Response to antipsychotic treatment in schizophrenia (working memory);
CESC	cis	rs9788682	1.000	rs9788682	chr15:78802586	A/G	cg06917634	chr15:78832804	PSMA4	0.48	5.58	0.32	6.07e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs7512552	0.839	rs7523428	chr1:150430472	G/A	cg15654264	chr1:150340011	RPRD2	0.39	5.19	0.3	4.1e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
CESC	trans	rs208515	0.560	rs207084	chr6:66776966	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.01	-19.26	-0.76	2.71e-52	Exhaled nitric oxide levels;
CESC	cis	rs7923609	0.846	rs10761739	chr10:65062008	C/G	cg01631684	chr10:65280961	REEP3	0.44	5.53	0.32	7.61e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs3820068	0.608	rs12740492	chr1:16048951	A/T	cg13390004	chr1:15929781	NA	0.33	5.05	0.3	8.14e-7	Systolic blood pressure;
CESC	cis	rs59072704	0.920	rs74373761	chr1:244496553	G/C	cg16908123	chr1:244486252	NA	-0.47	-5.42	-0.32	1.32e-7	Monocyte count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19585003	chr12:112280177	C12orf47;MAPKAPK5	0.58	6.34	0.36	9.73e-10	Gut microbiome composition (summer);
CESC	cis	rs2479106	0.656	rs1857393	chr9:126497262	T/C	cg16191174	chr9:126692580	DENND1A	0.42	5.17	0.3	4.59e-7	Polycystic ovary syndrome;
CESC	cis	rs8018808	0.967	rs12889722	chr14:77850267	T/C	cg20045696	chr14:77926864	AHSA1	-0.37	-5.06	-0.3	7.85e-7	Myeloid white cell count;
CESC	cis	rs7772486	0.840	rs2777478	chr6:146309117	T/C	cg23711669	chr6:146136114	FBXO30	0.9	13.1	0.63	1.45e-30	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6933660	0.646	rs6915598	chr6:151778664	T/C	cg02564969	chr6:151773285	C6orf211;RMND1	0.57	5.74	0.33	2.53e-8	Menarche (age at onset);
CESC	cis	rs8111998	0.826	rs10421335	chr19:22768105	G/A	cg19914732	chr19:22715077	NA	-0.37	-5.18	-0.3	4.45e-7	Corneal structure;
CESC	cis	rs17253792	0.822	rs79807559	chr14:56108117	G/A	cg01858014	chr14:56050164	KTN1	-0.96	-7.52	-0.42	8.3e-13	Putamen volume;
CESC	trans	rs4756846	1.000	rs72871370	chr11:16440171	T/A	cg05579622	chr5:10618622	ANKRD33B	0.75	6.83	0.39	5.71e-11	Obesity and osteoporosis;
CESC	cis	rs7605827	0.930	rs2277915	chr2:15493881	A/G	cg19274914	chr2:15703543	NA	0.31	5.62	0.33	4.89e-8	Educational attainment (years of education);
CESC	cis	rs9858542	1.000	rs9882740	chr3:49702484	T/C	cg07274523	chr3:49395745	GPX1	0.65	8.36	0.46	3.6e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	trans	rs11148252	0.595	rs4885117	chr13:53153027	T/C	cg18335740	chr13:41363409	SLC25A15	0.57	7.98	0.44	4.48e-14	Lewy body disease;
CESC	cis	rs977987	0.872	rs4887816	chr16:75319716	T/C	cg03315344	chr16:75512273	CHST6	0.4	5.59	0.32	5.76e-8	Dupuytren's disease;
CESC	cis	rs35110281	0.693	rs3819161	chr21:45092653	A/G	cg04455712	chr21:45112962	RRP1B	0.49	7.14	0.4	9.24e-12	Mean corpuscular volume;
CESC	cis	rs1448094	0.512	rs7308229	chr12:86239849	A/T	cg19622623	chr12:86230825	RASSF9	0.48	6.4	0.37	6.89e-10	Major depressive disorder;
CESC	cis	rs3026101	0.671	rs1806265	chr17:5320044	T/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.44	5.8	0.34	1.87e-8	Body mass index;
CESC	cis	rs2011503	0.941	rs2010506	chr19:19387356	C/T	cg11584989	chr19:19387371	SF4	0.62	7.43	0.42	1.48e-12	Bipolar disorder;
CESC	trans	rs916888	0.773	rs169201	chr17:44790203	A/G	cg07870213	chr5:140052090	DND1	0.65	6.78	0.38	7.75e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs5769765	1.000	rs34774661	chr22:50267508	C/G	cg26441486	chr22:50317300	CRELD2	-0.39	-5.5	-0.32	8.72e-8	Schizophrenia;
CESC	cis	rs514406	0.861	rs7513052	chr1:53241360	C/T	cg27535305	chr1:53392650	SCP2	0.31	5.51	0.32	8.35e-8	Monocyte count;
CESC	cis	rs9303280	0.743	rs12946510	chr17:37912377	C/T	cg19468946	chr17:37922297	IKZF3	-0.42	-5.73	-0.33	2.73e-8	Self-reported allergy;
CESC	cis	rs1448094	0.845	rs7132262	chr12:86346304	C/T	cg02569458	chr12:86230093	RASSF9	0.39	5.64	0.33	4.25e-8	Major depressive disorder;
CESC	cis	rs796364	0.806	rs56216998	chr2:200944333	G/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.77	-6.8	-0.39	6.95e-11	Schizophrenia;
CESC	cis	rs1799949	0.929	rs799906	chr17:41278116	T/C	cg23758822	chr17:41437982	NA	0.99	16.77	0.72	1.6700000000000001e-43	Menopause (age at onset);
CESC	cis	rs9902453	0.817	rs7217961	chr17:28403112	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.69	-9.08	-0.49	2.59e-17	Coffee consumption (cups per day);
CESC	cis	rs5760092	0.572	rs738806	chr22:24234172	A/G	cg04234412	chr22:24373322	LOC391322	-0.56	-7.02	-0.4	1.84e-11	Urinary 1,3-butadiene metabolite levels in smokers;
CESC	cis	rs12618769	0.597	rs961242	chr2:99138979	G/A	cg10123293	chr2:99228465	UNC50	0.4	5.38	0.31	1.64e-7	Bipolar disorder;
CESC	trans	rs1116547	0.602	rs4705551	chr5:112843077	C/G	cg10115368	chr14:100435663	NA	0.51	6.05	0.35	4.85e-9	Cerebral amyloid angiopathy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26310643	chr1:87019145	CLCA4	-0.53	-6.0	-0.35	6.6e-9	Gut microbiome composition (summer);
CESC	cis	rs6952808	0.594	rs3778964	chr7:2138109	C/T	cg04267008	chr7:1944627	MAD1L1	-0.61	-7.4	-0.41	1.77e-12	Bipolar disorder and schizophrenia;
CESC	cis	rs1801251	0.896	rs921054	chr2:233694673	G/A	cg25237894	chr2:233734115	C2orf82	-0.36	-6.47	-0.37	4.65e-10	Coronary artery disease;
CESC	cis	rs7666738	0.830	rs11944855	chr4:99068258	G/A	cg03467027	chr4:99064603	C4orf37	0.48	5.96	0.34	7.81e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9916302	0.904	rs2061338	chr17:37421767	T/C	cg07936489	chr17:37558343	FBXL20	-0.8	-11.48	-0.58	5.11e-25	Glomerular filtration rate (creatinine);
CESC	cis	rs10097731	0.901	rs10464891	chr8:82042900	C/A	cg25230327	chr8:82042993	NA	-0.56	-6.33	-0.36	1.06e-9	Serum total protein level;
CESC	cis	rs9660180	0.934	rs12729990	chr1:1812035	T/A	cg23982607	chr1:1823379	GNB1	-0.79	-12.85	-0.62	1.04e-29	Body mass index;
CESC	cis	rs8114671	0.805	rs4616	chr20:33590358	C/T	cg07148914	chr20:33460835	GGT7	-0.43	-5.53	-0.32	7.53e-8	Height;
CESC	cis	rs6430585	0.583	rs2322813	chr2:136582809	A/G	cg07169764	chr2:136633963	MCM6	1.35	20.2	0.78	1.47e-55	Corneal structure;
CESC	cis	rs17023223	0.537	rs4508058	chr1:119684250	T/C	cg05756136	chr1:119680316	WARS2	-0.46	-5.54	-0.32	7.2e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
CESC	cis	rs6089584	0.888	rs2146853	chr20:60617908	A/T	cg24733560	chr20:60626293	TAF4	0.45	6.44	0.37	5.45e-10	Body mass index;
CESC	cis	rs7811142	1.000	rs68116612	chr7:100006493	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.99	11.37	0.57	1.18e-24	Platelet count;
CESC	cis	rs780094	0.544	rs780110	chr2:27685388	G/A	cg21248554	chr2:27665150	KRTCAP3	-0.29	-6.2	-0.36	2.17e-9	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
CESC	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg24503407	chr1:205819492	PM20D1	0.84	13.9	0.65	2.34e-33	Menarche (age at onset);
CESC	cis	rs473651	0.716	rs548179	chr2:239320505	G/A	cg21699342	chr2:239360505	ASB1	0.5	8.24	0.45	8.13e-15	Multiple system atrophy;
CESC	trans	rs11039798	0.660	rs28435129	chr11:48629795	A/T	cg15704280	chr7:45808275	SEPT13	0.6	6.24	0.36	1.73e-9	Axial length;
CESC	cis	rs10465746	0.780	rs7551787	chr1:84419297	A/G	cg10977910	chr1:84465055	TTLL7	0.51	7.22	0.41	5.54e-12	Obesity-related traits;
CESC	cis	rs11825685	0.887	rs76377465	chr11:134569562	T/G	cg06603561	chr11:134479413	NA	-0.58	-5.09	-0.3	6.9e-7	IgG glycosylation;
CESC	cis	rs798554	0.679	rs1639066	chr7:2892972	A/G	cg04166393	chr7:2884313	GNA12	0.61	8.12	0.45	1.79e-14	Height;
CESC	cis	rs4720575	1.000	rs4720574	chr7:47085597	A/C	cg00036614	chr7:47093842	NA	-0.41	-6.4	-0.37	7.1e-10	Angiotensin-converting enzyme inhibitor intolerance;
CESC	cis	rs4689592	0.503	rs10516184	chr4:7060959	C/T	cg26116260	chr4:7069785	GRPEL1	0.84	9.22	0.49	9.86e-18	Monocyte percentage of white cells;
CESC	cis	rs12500824	0.564	rs61183568	chr4:77253029	C/T	cg20311846	chr4:77356250	SHROOM3	0.41	8.0	0.44	3.99e-14	Coronary artery disease;
CESC	cis	rs11676348	0.772	rs12694427	chr2:218945045	C/T	cg00012203	chr2:219082015	ARPC2	-0.44	-5.47	-0.32	1.02e-7	Ulcerative colitis;
CESC	cis	rs2635047	0.967	rs2576030	chr18:44659166	G/A	cg19077165	chr18:44547161	KATNAL2	-0.5	-6.86	-0.39	4.87e-11	Educational attainment;
CESC	cis	rs3845702	0.668	rs12693215	chr2:180826007	A/C	cg01881094	chr2:180872142	CWC22	-0.97	-8.87	-0.48	1.12e-16	Schizophrenia;
CESC	cis	rs3747547	0.792	rs72726049	chr9:38049744	C/T	cg13774184	chr9:37916125	SHB	-0.71	-5.6	-0.33	5.44e-8	Metabolite levels (Dihydroxy docosatrienoic acid);
CESC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg12196473	chr3:99536614	MIR548G;C3orf26	-0.47	-6.01	-0.35	5.97e-9	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs3015497	0.624	rs2934700	chr14:51135177	C/A	cg26011998	chr14:51135199	SAV1	-0.62	-7.02	-0.4	1.82e-11	Mean platelet volume;
CESC	cis	rs10911363	0.550	rs10911353	chr1:183489203	G/A	cg09173681	chr1:183549694	NCF2	0.52	7.59	0.42	5.6e-13	Systemic lupus erythematosus;
CESC	cis	rs7772486	0.790	rs2265919	chr6:146221753	A/G	cg05347473	chr6:146136440	FBXO30	0.55	7.05	0.4	1.57e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs12200560	0.524	rs1413525	chr6:97073096	C/T	cg06623918	chr6:96969491	KIAA0776	0.47	5.9	0.34	1.13e-8	Coronary heart disease;
CESC	cis	rs9611565	0.512	rs2050031	chr22:42152266	A/G	cg06481639	chr22:41940642	POLR3H	0.6	5.97	0.34	7.49e-9	Vitiligo;
CESC	cis	rs3806843	0.966	rs3756341	chr5:140171194	C/T	cg26395211	chr5:140044315	WDR55	-0.41	-5.25	-0.31	3.15e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs12451471	0.637	rs12950757	chr17:78096800	T/G	cg06718696	chr17:78121285	EIF4A3	0.84	10.38	0.54	2.13e-21	Plateletcrit;Mean corpuscular hemoglobin concentration;
CESC	cis	rs854765	0.583	rs7213225	chr17:17869111	T/C	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.55	7.06	0.4	1.45e-11	Total body bone mineral density;
CESC	cis	rs7249921	0.802	rs1046345	chr19:35660752	C/T	cg15419183	chr19:35660584	FXYD5	0.56	8.36	0.46	3.57e-15	Platelet count;
CESC	cis	rs7020830	0.830	rs17487601	chr9:37213641	G/A	cg14294708	chr9:37120828	ZCCHC7	1.19	21.64	0.8	1.68e-60	Schizophrenia;
CESC	cis	rs9322193	0.923	rs35967444	chr6:149996724	G/A	cg04369109	chr6:150039330	LATS1	-0.4	-5.51	-0.32	8.53e-8	Lung cancer;
CESC	cis	rs12410462	0.901	rs2814090	chr1:227658444	C/G	cg04117972	chr1:227635322	NA	-0.62	-6.2	-0.36	2.11e-9	Major depressive disorder;
CESC	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg24642844	chr7:1081250	C7orf50	-0.76	-9.35	-0.5	3.75e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	trans	rs11039798	1.000	rs3902928	chr11:48581458	A/T	cg15704280	chr7:45808275	SEPT13	0.66	6.21	0.36	2.01e-9	Axial length;
CESC	cis	rs72945132	0.882	rs7116191	chr11:70159781	G/A	cg00319359	chr11:70116639	PPFIA1	0.78	7.71	0.43	2.52e-13	Coronary artery disease;
CESC	cis	rs933688	1.000	rs2059208	chr5:90732065	A/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.09	14.27	0.66	1.2e-34	Smoking behavior;
CESC	cis	rs7264396	0.943	rs224421	chr20:34145461	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.56	-7.06	-0.4	1.46e-11	Total cholesterol levels;
CESC	cis	rs3087591	0.919	rs2285892	chr17:29553485	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.43	-5.31	-0.31	2.31e-7	Hip circumference;
CESC	cis	rs7618501	0.633	rs4688755	chr3:50064424	G/A	cg24308560	chr3:49941425	MST1R	0.62	9.05	0.49	3.27e-17	Intelligence (multi-trait analysis);
CESC	cis	rs6942756	1.000	rs13235749	chr7:128879678	C/G	cg02491457	chr7:128862824	NA	-0.7	-10.17	-0.53	9.75e-21	White matter hyperintensity burden;
CESC	trans	rs916888	0.610	rs199438	chr17:44791643	G/A	cg10053473	chr17:62856997	LRRC37A3	-0.66	-8.92	-0.48	7.58e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs2797160	1.000	rs1739357	chr6:126019655	T/G	cg05901451	chr6:126070800	HEY2	0.47	6.75	0.38	9.44e-11	Endometrial cancer;
CESC	cis	rs1862618	0.573	rs1550821	chr5:56242323	C/T	cg18230493	chr5:56204884	C5orf35	0.8	9.54	0.51	9.74e-19	Initial pursuit acceleration;
CESC	cis	rs7072216	0.763	rs8181292	chr10:100175477	A/G	cg26618903	chr10:100175079	PYROXD2	-0.37	-5.75	-0.33	2.45e-8	Metabolite levels;
CESC	cis	rs9733	0.596	rs1136808	chr1:150702717	G/C	cg18016565	chr1:150552671	MCL1	0.34	5.28	0.31	2.67e-7	Tonsillectomy;
CESC	cis	rs67311347	1.000	rs4974017	chr3:40473519	C/T	cg01475735	chr3:40494733	NA	-0.41	-5.36	-0.31	1.81e-7	Renal cell carcinoma;
CESC	cis	rs2073300	0.609	rs8183135	chr20:23384284	C/T	cg16736954	chr20:23401023	NAPB	0.8	6.25	0.36	1.67e-9	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs561341	0.941	rs736678	chr17:30347423	G/T	cg12193833	chr17:30244370	NA	-0.73	-6.51	-0.37	3.83e-10	Hip circumference adjusted for BMI;
CESC	cis	rs6912958	0.781	rs7750207	chr6:88303967	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-6.59	-0.38	2.31e-10	Monocyte percentage of white cells;
CESC	cis	rs6502050	0.634	rs11077973	chr17:80095191	C/T	cg23985595	chr17:80112537	CCDC57	-0.42	-6.6	-0.38	2.18e-10	Life satisfaction;
CESC	cis	rs6582630	0.548	rs8189608	chr12:38327775	T/G	cg26384229	chr12:38710491	ALG10B	-0.42	-5.52	-0.32	8e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs12042938	0.905	rs823160	chr1:231776636	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.44	6.02	0.35	5.76e-9	Neuranatomic and neurocognitive phenotypes;
CESC	cis	rs9811920	0.638	rs793440	chr3:99643176	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.61	9.74	0.51	2.34e-19	Axial length;
CESC	cis	rs12142240	0.698	rs1475389	chr1:46816429	T/C	cg10495392	chr1:46806563	NSUN4	0.57	6.28	0.36	1.39e-9	Menopause (age at onset);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg17784606	chr1:1190558	UBE2J2	0.5	6.97	0.39	2.55e-11	Fibrinogen levels;
CESC	cis	rs7085104	0.700	rs10883785	chr10:104603588	A/G	cg04362960	chr10:104952993	NT5C2	0.51	6.61	0.38	2.17e-10	Immature fraction of reticulocytes;Schizophrenia;
CESC	cis	rs8044995	0.563	rs73615919	chr16:68398862	C/T	cg26727032	chr16:67993705	SLC12A4	-0.51	-5.23	-0.31	3.36e-7	Schizophrenia;
CESC	cis	rs6570726	0.846	rs1935616	chr6:145943512	C/T	cg23711669	chr6:146136114	FBXO30	0.87	12.7	0.61	3.59e-29	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs763121	0.925	rs5750654	chr22:39051428	T/C	cg06544989	chr22:39130855	UNC84B	0.51	9.42	0.5	2.24e-18	Menopause (age at onset);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23615016	chr1:87794216	LMO4	0.58	7.08	0.4	1.29e-11	Gut microbiome composition (summer);
CESC	cis	rs6831352	0.918	rs17218108	chr4:100055755	T/C	cg12011299	chr4:100065546	ADH4	-0.6	-6.62	-0.38	2.04e-10	Alcohol dependence;
CESC	cis	rs7937682	0.632	rs12785809	chr11:111776055	T/A	cg09085632	chr11:111637200	PPP2R1B	0.88	11.26	0.57	2.77e-24	Primary sclerosing cholangitis;
CESC	cis	rs798554	0.836	rs798500	chr7:2790685	C/T	cg04166393	chr7:2884313	GNA12	-0.57	-7.3	-0.41	3.42e-12	Height;
CESC	cis	rs7216064	1.000	rs7212293	chr17:65847325	A/G	cg07042672	chr17:66097459	LOC651250	-0.61	-7.61	-0.42	4.76e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs4665809	0.590	rs2289019	chr2:26420809	G/C	cg26314531	chr2:26401878	FAM59B	-0.83	-9.29	-0.5	5.94e-18	Gut microbiome composition (summer);
CESC	trans	rs673604	0.505	rs676614	chr1:36107510	G/T	cg04761648	chr13:26829199	CDK8	0.54	6.18	0.35	2.4e-9	Endometrial cancer;
CESC	cis	rs727563	0.635	rs5758444	chr22:42133921	T/A	cg06481639	chr22:41940642	POLR3H	0.55	5.53	0.32	7.53e-8	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs2072499	0.966	rs2253677	chr1:156171296	C/G	cg25208724	chr1:156163844	SLC25A44	-1.02	-19.58	-0.77	2.13e-53	Testicular germ cell tumor;
CESC	cis	rs6570726	0.935	rs368848	chr6:145855281	A/T	cg23711669	chr6:146136114	FBXO30	0.8	11.75	0.59	6.33e-26	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs12188164	0.525	rs2561665	chr5:460135	A/G	cg16584290	chr5:462447	EXOC3	0.47	7.09	0.4	1.19e-11	Cystic fibrosis severity;
CESC	cis	rs2303759	0.918	rs9749416	chr19:49885005	G/A	cg22307029	chr19:49891270	CCDC155	0.65	7.68	0.43	3.04e-13	Multiple sclerosis;
CESC	cis	rs4595586	0.679	rs1156706	chr12:39372641	G/A	cg26384229	chr12:38710491	ALG10B	0.44	6.31	0.36	1.15e-9	Morning vs. evening chronotype;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg23019286	chr1:227728774	NA	-0.41	-6.1	-0.35	3.69e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg08721840	chr1:155293541	RUSC1;C1orf104	-0.43	-6.13	-0.35	3.1e-9	Gambling;
CESC	trans	rs11098499	0.865	rs9996417	chr4:120295862	T/C	cg25214090	chr10:38739885	LOC399744	0.68	9.23	0.49	8.9e-18	Corneal astigmatism;
CESC	cis	rs6540559	0.673	rs7511996	chr1:210018473	C/A	cg21951975	chr1:209979733	IRF6	0.55	6.64	0.38	1.75e-10	Cleft lip with or without cleft palate;
CESC	cis	rs17539620	0.624	rs62432746	chr6:154838986	A/G	cg20019720	chr6:154832845	CNKSR3	0.46	6.06	0.35	4.57e-9	Lipoprotein (a) levels;
CESC	trans	rs1814175	0.645	rs10839448	chr11:49938930	G/A	cg03929089	chr4:120376271	NA	-0.89	-14.83	-0.67	1.17e-36	Height;
CESC	cis	rs7246657	0.943	rs4802766	chr19:37981933	T/C	cg23950597	chr19:37808831	NA	-0.64	-6.69	-0.38	1.3e-10	Coronary artery calcification;
CESC	cis	rs920590	0.758	rs7010174	chr8:19661930	G/C	cg01411142	chr8:19674711	INTS10	0.52	5.86	0.34	1.39e-8	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs6076065	0.894	rs2243448	chr20:23378345	G/A	cg11657817	chr20:23433608	CST11	0.4	6.02	0.35	5.68e-9	Facial morphology (factor 15, philtrum width);
CESC	cis	rs959260	1.000	rs9909076	chr17:73384809	G/T	cg12999837	chr17:73267436	MIF4GD	-0.48	-5.67	-0.33	3.72e-8	Systemic lupus erythematosus;
CESC	cis	rs863345	0.935	rs10797025	chr1:158519525	T/C	cg12129480	chr1:158549410	OR10X1	-0.33	-6.56	-0.37	2.84e-10	Pneumococcal bacteremia;
CESC	cis	rs57221529	0.709	rs72703034	chr5:577101	C/T	cg16447950	chr5:562315	NA	-0.64	-6.81	-0.39	6.59e-11	Lung disease severity in cystic fibrosis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17483139	chr1:1822401	GNB1	0.58	6.43	0.37	5.89e-10	Gut microbiome composition (summer);
CESC	cis	rs2836974	0.545	rs8128901	chr21:40710419	G/A	cg11890956	chr21:40555474	PSMG1	0.69	9.49	0.5	1.38e-18	Cognitive function;
CESC	cis	rs780094	0.544	rs2303370	chr2:27651375	C/T	cg02592271	chr2:27665507	KRTCAP3	-0.26	-5.68	-0.33	3.46e-8	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
CESC	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg18402987	chr7:1209562	NA	0.76	7.79	0.43	1.5e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs1005277	0.579	rs176880	chr10:38401417	C/G	cg00409905	chr10:38381863	ZNF37A	0.45	5.99	0.35	6.64e-9	Extrinsic epigenetic age acceleration;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21487261	chr17:79368981	NA	-0.57	-6.56	-0.37	2.85e-10	Gut microbiome composition (summer);
CESC	cis	rs6540559	1.000	rs4844895	chr1:209958580	T/C	cg23283495	chr1:209979779	IRF6	0.5	7.05	0.4	1.51e-11	Cleft lip with or without cleft palate;
CESC	cis	rs3026101	0.671	rs56019636	chr17:5297551	A/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.43	5.68	0.33	3.57e-8	Body mass index;
CESC	cis	rs11098499	0.697	rs28655325	chr4:120372999	A/G	cg09307838	chr4:120376055	NA	0.94	13.54	0.64	4.29e-32	Corneal astigmatism;
CESC	cis	rs992157	0.735	rs10932765	chr2:219099484	T/C	cg20019365	chr2:219134978	PNKD;AAMP	0.69	9.72	0.51	2.63e-19	Colorectal cancer;
CESC	cis	rs4563143	0.647	rs117946634	chr19:29256822	G/T	cg12756686	chr19:29218302	NA	0.59	7.62	0.42	4.52e-13	Methadone dose in opioid dependence;
CESC	cis	rs6714710	0.603	rs55776387	chr2:98405034	T/C	cg26665480	chr2:98280029	ACTR1B	0.6	8.26	0.45	6.99e-15	Posterior cortical atrophy and Alzheimer's disease;
CESC	cis	rs6499255	1.000	rs73579458	chr16:69804764	G/C	cg15192750	chr16:69999425	NA	0.48	5.95	0.34	8.45e-9	IgE levels;
CESC	cis	rs6563842	0.563	rs9603786	chr13:41316364	G/A	cg21288729	chr13:41239152	FOXO1	0.6	7.78	0.43	1.66e-13	Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;
CESC	cis	rs8177253	0.530	rs8177177	chr3:133463195	A/G	cg24879335	chr3:133465180	TF	0.34	6.26	0.36	1.53e-9	Iron status biomarkers;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg17059624	chr11:85358760	TMEM126A	-0.43	-6.21	-0.36	2.03e-9	Gambling;
CESC	cis	rs769267	0.965	rs2315024	chr19:19423817	T/A	cg03709012	chr19:19516395	GATAD2A	0.97	14.12	0.66	3.77e-34	Tonsillectomy;
CESC	cis	rs12188164	0.515	rs17562461	chr5:411361	C/T	cg26850624	chr5:429559	AHRR	-0.43	-5.64	-0.33	4.34e-8	Cystic fibrosis severity;
CESC	cis	rs854765	0.583	rs62064156	chr17:17822480	C/T	cg16928487	chr17:17741425	SREBF1	-0.59	-10.25	-0.53	5.56e-21	Total body bone mineral density;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20693608	chr4:113152836	AP1AR	0.56	6.25	0.36	1.59e-9	Gut microbiome composition (summer);
CESC	cis	rs7520050	0.931	rs11211198	chr1:46282673	G/A	cg03146154	chr1:46216737	IPP	-0.47	-6.19	-0.36	2.34e-9	Red blood cell count;Reticulocyte count;
CESC	trans	rs7098100	0.596	rs2666781	chr10:22205676	C/A	cg20133923	chr20:3027467	MRPS26	0.41	6.04	0.35	5.2e-9	Breast cancer;
CESC	cis	rs642803	1.000	rs642803	chr11:65560620	C/T	cg10518572	chr11:65560635	OVOL1	0.31	6.65	0.38	1.71e-10	Urate levels;
CESC	trans	rs7615952	0.543	rs4645102	chr3:125424441	A/G	cg07211511	chr3:129823064	LOC729375	-0.58	-7.33	-0.41	2.74e-12	Blood pressure (smoking interaction);
CESC	cis	rs9640161	0.750	rs11765644	chr7:150026339	C/G	cg13722127	chr7:150037890	RARRES2	0.36	5.08	0.3	7.12e-7	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs2191566	0.664	rs55958002	chr19:44543788	A/T	cg20607764	chr19:44506953	ZNF230	-0.43	-5.52	-0.32	8.25e-8	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs17253792	0.822	rs76557162	chr14:56064701	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.85	6.13	0.35	3.15e-9	Putamen volume;
CESC	cis	rs2645694	0.533	rs2703125	chr4:77819900	T/C	cg18351406	chr4:77819688	ANKRD56	0.54	6.79	0.38	7.56e-11	Emphysema distribution in smoking;
CESC	cis	rs798554	0.757	rs960273	chr7:2857876	T/C	cg18446336	chr7:2847575	GNA12	-0.38	-5.58	-0.32	5.92e-8	Height;
CESC	cis	rs9790314	1.000	rs336585	chr3:161081670	A/G	cg04691961	chr3:161091175	C3orf57	-0.43	-5.47	-0.32	1.07e-7	Morning vs. evening chronotype;
CESC	cis	rs933688	1.000	rs11948075	chr5:90680579	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.11	12.36	0.6	5.17e-28	Smoking behavior;
CESC	cis	rs1215050	0.740	rs783916	chr4:99026264	A/C	cg05340658	chr4:99064831	C4orf37	-0.65	-9.09	-0.49	2.37e-17	Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs7072216	0.763	rs942805	chr10:100168372	G/A	cg26618903	chr10:100175079	PYROXD2	-0.37	-5.55	-0.32	7.01e-8	Metabolite levels;
CESC	cis	rs9611565	0.512	rs139562	chr22:42196684	G/C	cg03806693	chr22:41940476	POLR3H	-1.14	-13.32	-0.63	2.55e-31	Vitiligo;
CESC	cis	rs425277	0.606	rs3128339	chr1:2046938	G/T	cg23803603	chr1:2058230	PRKCZ	-0.34	-5.8	-0.34	1.9e-8	Height;
CESC	cis	rs7219021	0.885	rs3848457	chr17:46866026	C/T	cg16584676	chr17:46985605	UBE2Z	-0.55	-6.19	-0.36	2.22e-9	Schizophrenia or bipolar disorder;
CESC	cis	rs9818941	0.793	rs9874758	chr3:157735625	A/G	cg08654915	chr3:157813417	NA	-0.46	-7.48	-0.42	1.07e-12	Height;
CESC	trans	rs6981523	0.566	rs34162231	chr8:11003088	A/T	cg15556689	chr8:8085844	FLJ10661	-0.53	-6.22	-0.36	1.98e-9	Neuroticism;
CESC	cis	rs7666738	0.830	rs13149346	chr4:99009933	C/T	cg18180107	chr4:99064573	C4orf37	0.4	5.3	0.31	2.48e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7666738	0.830	rs9992391	chr4:98916052	G/A	cg03676636	chr4:99064102	C4orf37	0.34	5.15	0.3	5.1e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08209163	chr13:28024472	MTIF3	0.66	8.14	0.45	1.6e-14	Gut microbiome composition (summer);
CESC	cis	rs7208859	0.623	rs7219361	chr17:29080393	G/A	cg19761014	chr17:28927070	LRRC37B2	0.78	6.42	0.37	6.22e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs4665809	0.567	rs6546848	chr2:26444414	G/C	cg26314531	chr2:26401878	FAM59B	-0.85	-9.23	-0.49	8.65e-18	Gut microbiome composition (summer);
CESC	cis	rs4237845	0.537	rs4237844	chr12:58267987	A/G	cg02175503	chr12:58329896	NA	-0.49	-5.84	-0.34	1.52e-8	Intelligence (multi-trait analysis);
CESC	cis	rs1577917	1.000	rs10455456	chr6:86670322	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.45	-5.92	-0.34	9.76e-9	Response to antipsychotic treatment;
CESC	cis	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg24209723	chr18:12913133	NA	-0.4	-5.43	-0.32	1.28e-7	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	trans	rs8073060	0.586	rs225296	chr17:33924847	C/G	cg19694781	chr19:47549865	TMEM160	-0.7	-6.88	-0.39	4.3e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
CESC	cis	rs11098499	0.615	rs28850368	chr4:120554313	G/A	cg09307838	chr4:120376055	NA	0.78	10.46	0.54	1.13e-21	Corneal astigmatism;
CESC	cis	rs3857536	0.741	rs9363558	chr6:66937260	C/T	cg07460842	chr6:66804631	NA	-0.42	-5.34	-0.31	1.96e-7	Blood trace element (Cu levels);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24048372	chr5:93954560	C5orf36;ANKRD32	0.58	6.71	0.38	1.16e-10	Gut microbiome composition (summer);
CESC	cis	rs854765	0.647	rs8066764	chr17:17974668	C/T	cg16928487	chr17:17741425	SREBF1	-0.51	-8.37	-0.46	3.39e-15	Total body bone mineral density;
CESC	cis	rs1005277	0.579	rs2472181	chr10:38386764	T/C	cg25517755	chr10:38738941	LOC399744	-0.47	-6.05	-0.35	4.86e-9	Extrinsic epigenetic age acceleration;
CESC	cis	rs9322193	0.962	rs10872656	chr6:150120580	A/C	cg05861140	chr6:150128134	PCMT1	-0.37	-5.36	-0.31	1.82e-7	Lung cancer;
CESC	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.71	9.86	0.52	9.4e-20	Prudent dietary pattern;
CESC	cis	rs763014	0.833	rs3743904	chr16:632767	A/G	cg00908189	chr16:619842	PIGQ	0.67	9.42	0.5	2.33e-18	Height;
CESC	cis	rs2290159	0.800	rs56363132	chr3:12680403	T/C	cg23032965	chr3:12705835	RAF1	0.54	5.72	0.33	2.81e-8	Cholesterol, total;
CESC	cis	rs7124681	0.584	rs11039448	chr11:47918416	G/T	cg18512352	chr11:47633146	NA	-0.38	-5.92	-0.34	9.8e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
CESC	cis	rs11690935	0.550	rs6746701	chr2:172869255	G/A	cg13550731	chr2:172543902	DYNC1I2	0.48	6.51	0.37	3.84e-10	Schizophrenia;
CESC	cis	rs2180341	0.814	rs6569488	chr6:127726256	C/T	cg24812749	chr6:127587940	RNF146	0.84	12.05	0.59	5.93e-27	Breast cancer;
CESC	cis	rs593982	0.920	rs76925283	chr11:65548108	C/T	cg08755490	chr11:65554678	OVOL1	-1.26	-10.54	-0.54	6.22e-22	Atopic dermatitis;
CESC	cis	rs1808579	0.904	rs1631685	chr18:21134239	C/T	cg14672496	chr18:21087552	C18orf8	0.41	5.92	0.34	1e-8	Hip circumference;Body mass index;BMI (adjusted for smoking behaviour);
CESC	trans	rs1814175	0.588	rs1794144	chr11:49918233	A/G	cg15704280	chr7:45808275	SEPT13	-1.01	-18.94	-0.76	3.64e-51	Height;
CESC	cis	rs863345	0.564	rs10908667	chr1:158500121	G/A	cg12129480	chr1:158549410	OR10X1	-0.34	-6.84	-0.39	5.49e-11	Pneumococcal bacteremia;
CESC	cis	rs7666738	0.830	rs11941961	chr4:99065654	G/T	cg03467027	chr4:99064603	C4orf37	0.48	5.94	0.34	9.13e-9	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3096299	0.869	rs748941	chr16:89440754	T/A	cg02187348	chr16:89574699	SPG7	0.55	7.32	0.41	2.92e-12	Multiple myeloma (IgH translocation);
CESC	cis	rs7552404	1.000	rs4559448	chr1:76203456	A/G	cg22875332	chr1:76189707	ACADM	0.66	7.95	0.44	5.33e-14	Blood metabolite levels;Acylcarnitine levels;
CESC	trans	rs877282	0.891	rs11253355	chr10:768367	C/G	cg22713356	chr15:30763199	NA	1.17	11.73	0.58	7.23e-26	Uric acid levels;
CESC	cis	rs2425143	1.000	rs12479473	chr20:34398628	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.79	-7.2	-0.4	6.33e-12	Blood protein levels;
CESC	cis	rs6580649	0.941	rs72644842	chr12:48448274	A/G	cg24011408	chr12:48396354	COL2A1	-0.42	-5.28	-0.31	2.67e-7	Lung cancer;
CESC	cis	rs3008870	1.000	rs2815357	chr1:67491854	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.98	13.07	0.63	1.83e-30	Lymphocyte percentage of white cells;
CESC	cis	rs7811142	1.000	rs4463351	chr7:100078226	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.13	13.06	0.63	1.98e-30	Platelet count;
CESC	cis	rs939658	0.805	rs1915726	chr15:79420620	C/G	cg17916960	chr15:79447300	NA	-0.37	-6.13	-0.35	3.21e-9	Refractive error;
CESC	cis	rs11785400	0.793	rs4430071	chr8:143737680	T/C	cg24634471	chr8:143751801	JRK	0.46	5.91	0.34	1.06e-8	Schizophrenia;
CESC	cis	rs951366	0.576	rs1832775	chr1:205734032	C/T	cg17178900	chr1:205818956	PM20D1	-0.42	-5.3	-0.31	2.48e-7	Menarche (age at onset);
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg14796370	chr20:61273660	SLCO4A1	-0.44	-6.11	-0.35	3.58e-9	Prostate cancer (SNP x SNP interaction);
CESC	trans	rs731565	1.000	rs1525254	chr7:147406140	C/T	cg13413955	chr9:842914	DMRT1	-0.69	-6.43	-0.37	6.09e-10	Diabetic kidney disease;
CESC	cis	rs9815354	0.812	rs4577439	chr3:41952540	T/A	cg03022575	chr3:42003672	ULK4	0.68	5.92	0.34	9.9e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs12188164	0.580	rs2672755	chr5:457249	G/T	cg16584290	chr5:462447	EXOC3	0.45	6.75	0.38	9.17e-11	Cystic fibrosis severity;
CESC	cis	rs5750830	0.649	rs5750808	chr22:39790987	G/A	cg11247378	chr22:39784982	NA	-0.64	-9.61	-0.51	5.94e-19	Intelligence (multi-trait analysis);
CESC	cis	rs10911251	0.528	rs2333622	chr1:183075456	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.88	14.2	0.66	2.05e-34	Colorectal cancer;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg10341310	chr8:66582206	MTFR1	-0.46	-6.36	-0.36	8.76e-10	Gut microbiota (bacterial taxa);
CESC	trans	rs916888	0.773	rs199535	chr17:44822662	A/G	cg01341218	chr17:43662625	NA	0.91	11.23	0.57	3.32e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs10791097	0.609	rs3751039	chr11:130773076	A/G	cg12179176	chr11:130786555	SNX19	-0.78	-13.75	-0.65	7.93e-33	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs71277158	0.688	rs73879163	chr3:169770802	T/C	cg04067573	chr3:169899625	PHC3	0.52	5.4	0.31	1.5e-7	Prostate cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16349277	chr4:83323642	NA	-0.6	-7.11	-0.4	1.05e-11	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09910967	chr6:139456200	HECA	0.58	6.87	0.39	4.59e-11	Gut microbiome composition (summer);
CESC	cis	rs9399135	1.000	rs1014021	chr6:135334600	C/T	cg24558204	chr6:135376177	HBS1L	-0.49	-6.73	-0.38	1.07e-10	Red blood cell count;
CESC	cis	rs1862618	0.853	rs6450409	chr5:56101399	A/G	cg12311346	chr5:56204834	C5orf35	-0.64	-7.96	-0.44	4.98e-14	Initial pursuit acceleration;
CESC	cis	rs897984	0.806	rs12928852	chr16:30943988	C/T	cg02466173	chr16:30829666	NA	0.49	8.33	0.46	4.26e-15	Dementia with Lewy bodies;
CESC	cis	rs3008870	1.000	rs2755240	chr1:67477339	T/G	cg08660285	chr1:67390436	MIER1;WDR78	1.01	13.78	0.65	5.96e-33	Lymphocyte percentage of white cells;
CESC	cis	rs7649275	0.541	rs898419	chr3:53783785	A/C	cg21503701	chr3:53781065	CACNA1D	-0.39	-5.2	-0.3	3.9e-7	Trans fatty acid levels;
CESC	cis	rs2625529	0.652	rs2415128	chr15:72191073	T/C	cg16672083	chr15:72433130	SENP8	0.42	6.19	0.36	2.34e-9	Red blood cell count;
CESC	cis	rs7555523	0.830	rs6660601	chr1:165695855	C/T	cg24409356	chr1:165738333	TMCO1	0.89	8.13	0.45	1.7e-14	Intraocular pressure;Glaucoma (high intraocular pressure);
CESC	cis	rs798766	1.000	rs798754	chr4:1720757	A/G	cg05874882	chr4:1763078	NA	-0.58	-8.39	-0.46	2.84e-15	Bladder cancer;Urinary bladder cancer;
CESC	cis	rs2455799	0.573	rs2470539	chr3:15717844	C/T	cg16303742	chr3:15540471	COLQ	-0.39	-6.04	-0.35	5.19e-9	Mean platelet volume;
CESC	cis	rs853679	0.542	rs6934769	chr6:28090931	A/G	cg20151795	chr6:28129481	ZNF389	0.44	5.74	0.33	2.6e-8	Depression;
CESC	cis	rs597539	0.654	rs619727	chr11:68627535	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.78	9.46	0.5	1.68e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs10838687	1.000	rs753993	chr11:47349969	C/A	cg25783544	chr11:47291846	MADD	0.57	6.82	0.39	6.3e-11	Proinsulin levels;
CESC	cis	rs453301	0.624	rs330058	chr8:9089809	G/A	cg17143192	chr8:8559678	CLDN23	-0.45	-5.41	-0.32	1.42e-7	Joint mobility (Beighton score);
CESC	cis	rs35306767	0.951	rs12777021	chr10:967270	T/C	cg25019033	chr10:957182	NA	-0.6	-6.55	-0.37	3.04e-10	Eosinophil percentage of granulocytes;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg09379601	chr19:12992224	DNASE2	0.48	6.42	0.37	6.12e-10	Systemic lupus erythematosus;
CESC	cis	rs1451375	0.617	rs2876829	chr7:50566762	A/G	cg14593290	chr7:50529359	DDC	0.52	6.62	0.38	1.96e-10	Malaria;
CESC	cis	rs7666738	0.830	rs6818045	chr4:99049374	G/A	cg24818145	chr4:99064322	C4orf37	0.39	5.13	0.3	5.74e-7	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19451033	chr5:141276143	LOC729080	-0.68	-7.91	-0.44	6.82e-14	Gut microbiome composition (summer);
CESC	cis	rs3733585	0.781	rs13103690	chr4:9972778	T/G	cg02734326	chr4:10020555	SLC2A9	-0.46	-6.74	-0.38	9.94e-11	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs6582630	0.537	rs10785436	chr12:38461040	G/C	cg13010199	chr12:38710504	ALG10B	0.44	5.79	0.33	2.02e-8	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs6460942	0.915	rs6968695	chr7:12443878	G/C	cg20607287	chr7:12443886	VWDE	-0.7	-8.49	-0.46	1.46e-15	Coronary artery disease;
CESC	cis	rs6500602	0.727	rs55939215	chr16:4541390	C/G	cg08645402	chr16:4508243	NA	0.57	9.16	0.49	1.5e-17	Schizophrenia;
CESC	cis	rs6502050	0.835	rs6502077	chr17:80122966	G/C	cg23985595	chr17:80112537	CCDC57	-0.41	-6.57	-0.37	2.6200000000000003e-10	Life satisfaction;
CESC	cis	rs5758659	0.652	rs133300	chr22:42389839	A/G	cg19513890	chr22:42538836	CYP2D7P1	-0.4	-5.62	-0.33	4.9e-8	Cognitive function;
CESC	cis	rs10254118	0.757	rs7788086	chr7:133135206	C/T	cg10665199	chr7:133106180	EXOC4	0.58	7.98	0.44	4.39e-14	Intelligence (multi-trait analysis);
CESC	cis	rs6738485	0.507	rs66569888	chr2:106886967	G/A	cg16099169	chr2:106886729	NA	-0.74	-7.47	-0.42	1.15e-12	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
CESC	cis	rs8067354	0.681	rs76856339	chr17:57800966	G/A	cg02344993	chr17:57696989	CLTC	0.58	6.14	0.35	3.08e-9	Hemoglobin concentration;
CESC	cis	rs2073300	0.609	rs12625164	chr20:23354269	T/C	cg12062639	chr20:23401060	NAPB	1.03	7.98	0.44	4.32e-14	Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs1862618	0.573	rs2591962	chr5:56237155	G/A	cg24549020	chr5:56110836	MAP3K1	-0.59	-6.42	-0.37	6.32e-10	Initial pursuit acceleration;
CESC	cis	rs4722166	0.564	rs1800797	chr7:22766221	A/G	cg26061582	chr7:22766209	IL6	0.52	5.79	0.34	2.01e-8	Lung cancer;
CESC	cis	rs7618915	0.547	rs6976	chr3:52728804	C/T	cg07507251	chr3:52567010	NT5DC2	0.4	7.01	0.4	1.94e-11	Bipolar disorder;
CESC	cis	rs1862618	0.853	rs832584	chr5:56179212	A/G	cg18230493	chr5:56204884	C5orf35	0.71	8.41	0.46	2.5e-15	Initial pursuit acceleration;
CESC	cis	rs4713118	0.587	rs61471148	chr6:28037032	T/A	cg23281280	chr6:28129359	ZNF389	0.55	6.99	0.39	2.28e-11	Parkinson's disease;
CESC	cis	rs1008375	1.000	rs3815413	chr4:17654648	T/C	cg04450456	chr4:17643702	FAM184B	0.36	5.06	0.3	7.87e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs10097731	0.901	rs10464932	chr8:82042901	T/G	cg25230327	chr8:82042993	NA	-0.56	-6.33	-0.36	1.06e-9	Serum total protein level;
CESC	cis	rs4973397	0.810	rs12999051	chr2:232276992	T/A	cg09339159	chr2:232260559	B3GNT7	0.59	6.03	0.35	5.62e-9	Anti-saccade response;
CESC	trans	rs9329221	0.621	rs522483	chr8:9812969	C/G	cg15556689	chr8:8085844	FLJ10661	-0.49	-6.38	-0.36	7.81e-10	Neuroticism;
CESC	cis	rs6933660	0.720	rs6913515	chr6:151753470	G/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.48	-6.3	-0.36	1.22e-9	Menarche (age at onset);
CESC	cis	rs6570726	0.935	rs385134	chr6:145851005	C/T	cg05347473	chr6:146136440	FBXO30	0.49	6.62	0.38	1.96e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7000551	0.715	rs2469745	chr8:22343464	C/T	cg12081754	chr8:22256438	SLC39A14	0.42	5.65	0.33	4.03e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
CESC	cis	rs7618915	0.547	rs62253700	chr3:52625019	T/A	cg05564831	chr3:52568323	NT5DC2	0.45	6.96	0.39	2.68e-11	Bipolar disorder;
CESC	cis	rs637571	0.522	rs556643	chr11:65733289	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.44	6.43	0.37	5.96e-10	Eosinophil percentage of white cells;
CESC	cis	rs1610096	0.538	rs2279796	chr19:1059004	A/G	cg18950617	chr19:1066959	HMHA1	-0.43	-5.21	-0.3	3.77e-7	Neutrophil percentage of granulocytes;
CESC	cis	rs6860806	0.661	rs2136187	chr5:131577894	T/C	cg04518342	chr5:131593106	PDLIM4	0.4	6.15	0.35	2.9e-9	Breast cancer;
CESC	cis	rs11690935	0.550	rs6718013	chr2:172869185	A/G	cg13550731	chr2:172543902	DYNC1I2	0.49	6.75	0.38	9.18e-11	Schizophrenia;
CESC	trans	rs11098499	0.754	rs4107728	chr4:120253910	G/A	cg25214090	chr10:38739885	LOC399744	0.65	9.0	0.48	4.51e-17	Corneal astigmatism;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg07355551	chr20:2489285	ZNF343	0.49	6.37	0.36	8.11e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs4595586	0.545	rs11611625	chr12:39387207	T/C	cg26384229	chr12:38710491	ALG10B	0.54	7.53	0.42	7.85e-13	Morning vs. evening chronotype;
CESC	cis	rs875971	0.545	rs4441996	chr7:65588220	T/C	cg11764359	chr7:65958608	NA	-0.79	-9.62	-0.51	5.56e-19	Aortic root size;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02400751	chr11:74459640	RNF169	-0.62	-7.4	-0.41	1.79e-12	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20725035	chr3:148709344	GYG1	0.63	7.29	0.41	3.64e-12	Gut microbiome composition (summer);
CESC	cis	rs4409675	0.576	rs6565	chr1:28213157	T/C	cg23691781	chr1:28212827	C1orf38	0.29	5.67	0.33	3.73e-8	Corneal astigmatism;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24397552	chr15:40226086	EIF2AK4	-0.63	-7.45	-0.42	1.29e-12	Gut microbiome composition (summer);
CESC	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg23034840	chr1:205782522	SLC41A1	-0.69	-9.24	-0.49	8.23e-18	Monocyte percentage of white cells;
CESC	cis	rs875971	0.660	rs79009421	chr7:66068509	G/C	cg11764359	chr7:65958608	NA	-0.72	-9.5	-0.5	1.33e-18	Aortic root size;
CESC	cis	rs644799	1.000	rs525404	chr11:95566520	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.68	8.58	0.47	8.14e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs514406	0.661	rs562641	chr1:53374666	C/T	cg24675658	chr1:53192096	ZYG11B	-0.66	-9.13	-0.49	1.78e-17	Monocyte count;
CESC	cis	rs736408	0.522	rs11716747	chr3:52748857	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	7.96	0.44	5.13e-14	Bipolar disorder;
CESC	cis	rs2228479	0.850	rs17226512	chr16:89839976	T/C	cg00800038	chr16:89945340	TCF25	-0.92	-7.64	-0.42	4.02e-13	Skin colour saturation;
CESC	cis	rs7949030	0.591	rs12049914	chr11:62369436	C/G	cg11742103	chr11:62369870	EML3;MTA2	0.64	9.58	0.51	7.23e-19	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs6460942	0.915	rs62448600	chr7:12454944	T/G	cg10578991	chr7:12443926	VWDE	-0.5	-5.52	-0.32	7.93e-8	Coronary artery disease;
CESC	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	22.27	0.81	1.17e-62	Prudent dietary pattern;
CESC	cis	rs514406	0.621	rs2003250	chr1:53196666	T/C	cg24675658	chr1:53192096	ZYG11B	0.64	7.96	0.44	5.13e-14	Monocyte count;
CESC	cis	rs7259376	0.875	rs1991830	chr19:22514730	G/A	cg02657401	chr19:22469223	NA	-0.26	-5.25	-0.31	3.14e-7	Menopause (age at onset);
CESC	cis	rs2576037	0.583	rs2164104	chr18:44567743	G/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.76	-12.18	-0.6	2.08e-27	Personality dimensions;
CESC	cis	rs6570726	0.846	rs6914304	chr6:145921017	T/C	cg23711669	chr6:146136114	FBXO30	0.83	12.25	0.6	1.19e-27	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6669008	1.000	rs55912359	chr1:114167099	C/T	cg26035817	chr1:114414802	PTPN22	0.43	6.23	0.36	1.85e-9	Bacteremia;
CESC	cis	rs780096	0.565	rs780104	chr2:27677691	G/A	cg24768116	chr2:27665128	KRTCAP3	-0.3	-5.57	-0.32	6.2e-8	Total body bone mineral density;
CESC	cis	rs9457247	1.000	rs430097	chr6:167405073	A/G	cg07741184	chr6:167504864	NA	0.28	5.1	0.3	6.54e-7	Crohn's disease;
CESC	cis	rs7301826	1.000	rs2001483	chr12:131318645	A/G	cg11011512	chr12:131303247	STX2	0.4	5.09	0.3	6.86e-7	Plasma plasminogen activator levels;
CESC	cis	rs7246657	0.943	rs13345116	chr19:37847098	A/T	cg23950597	chr19:37808831	NA	-0.55	-6.09	-0.35	3.96e-9	Coronary artery calcification;
CESC	cis	rs9875589	0.794	rs2117039	chr3:13963330	T/C	cg19554555	chr3:13937349	NA	0.39	5.08	0.3	7.24e-7	Ovarian reserve;
CESC	cis	rs6752107	0.967	rs56227616	chr2:234157741	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.43	5.91	0.34	1.02e-8	Crohn's disease;Inflammatory bowel disease;
CESC	cis	rs11997175	0.583	rs12680811	chr8:33778426	A/C	ch.8.33884649F	chr8:33765107	NA	0.53	6.81	0.39	6.5e-11	Body mass index;
CESC	cis	rs853679	0.517	rs3757185	chr6:28107776	T/A	cg23281280	chr6:28129359	ZNF389	0.59	8.21	0.45	9.45e-15	Depression;
CESC	trans	rs629535	0.773	rs630235	chr8:70033529	T/G	cg21567404	chr3:27674614	NA	0.93	11.25	0.57	2.83e-24	Dupuytren's disease;
CESC	cis	rs1949733	0.958	rs3103069	chr4:8509451	T/G	cg11789530	chr4:8429930	ACOX3	-0.74	-10.08	-0.53	1.94e-20	Response to antineoplastic agents;
CESC	cis	rs17826219	0.636	rs4055314	chr17:29079769	T/C	cg19761014	chr17:28927070	LRRC37B2	0.78	6.41	0.37	6.61e-10	Body mass index;
CESC	trans	rs7656342	0.808	rs10003216	chr4:9766749	A/G	cg09262369	chr15:66648794	TIPIN	-0.48	-6.0	-0.35	6.61e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs2346177	0.554	rs36006825	chr2:46708945	G/T	cg02822958	chr2:46747628	ATP6V1E2	0.44	5.47	0.32	1.03e-7	HDL cholesterol;
CESC	cis	rs1642645	0.915	rs6696291	chr1:42500421	C/T	cg16685388	chr1:42384056	HIVEP3	-0.35	-5.08	-0.3	7.05e-7	Left ventricular obstructive tract defect (maternal effect);
CESC	cis	rs6062302	0.522	rs2297427	chr20:62221364	G/A	cg09650180	chr20:62225654	GMEB2	-0.8	-9.13	-0.49	1.75e-17	Glioblastoma;
CESC	cis	rs10857712	0.703	rs12253520	chr10:135235321	C/A	cg01444801	chr10:135216882	MTG1	-0.46	-5.26	-0.31	3.03e-7	Systemic lupus erythematosus;
CESC	cis	rs9488822	0.676	rs6918059	chr6:116349041	C/T	cg26893134	chr6:116381904	FRK	0.25	6.16	0.35	2.74e-9	Cholesterol, total;LDL cholesterol;
CESC	cis	rs611744	0.550	rs57045491	chr8:109279120	A/C	cg21045802	chr8:109455806	TTC35	0.45	5.56	0.32	6.42e-8	Dupuytren's disease;
CESC	cis	rs1869839	0.527	rs673535	chr7:114364104	C/G	cg05338976	chr7:114561850	MDFIC	0.36	5.06	0.3	7.75e-7	Crohn's disease;
CESC	cis	rs873946	0.557	rs34854637	chr10:134582962	A/G	cg26818010	chr10:134567672	INPP5A	-0.91	-11.33	-0.57	1.63e-24	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs3126085	0.935	rs1390487	chr1:152194601	G/A	cg26876637	chr1:152193138	HRNR	0.46	5.23	0.31	3.49e-7	Atopic dermatitis;
CESC	cis	rs9640161	0.742	rs2108851	chr7:150019634	T/C	cg21361702	chr7:150065534	REPIN1	0.56	6.54	0.37	3.2e-10	Blood protein levels;Circulating chemerin levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07393419	chr7:72741883	FKBP6;TRIM50	-0.47	-6.0	-0.35	6.55e-9	Gut microbiome composition (summer);
CESC	cis	rs4555082	0.789	rs2816649	chr14:105708326	A/G	cg06808227	chr14:105710500	BRF1	-0.52	-6.44	-0.37	5.58e-10	Mean platelet volume;Platelet distribution width;
CESC	cis	rs7666738	0.830	rs13140676	chr4:98804978	C/T	cg03467027	chr4:99064603	C4orf37	0.43	5.47	0.32	1.02e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs60154123	0.730	rs652256	chr1:210465017	T/C	cg21951975	chr1:209979733	IRF6	0.45	6.15	0.35	2.92e-9	Coronary artery disease;
CESC	cis	rs1005277	0.579	rs1780121	chr10:38529437	C/A	cg25517755	chr10:38738941	LOC399744	-0.49	-6.39	-0.37	7.49e-10	Extrinsic epigenetic age acceleration;
CESC	cis	rs7552404	0.960	rs12085123	chr1:76149749	G/A	cg10523679	chr1:76189770	ACADM	0.72	8.31	0.45	5.07e-15	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs3858526	0.834	rs10839169	chr11:6003190	C/G	cg13902645	chr11:5959945	NA	-0.48	-5.76	-0.33	2.36e-8	DNA methylation (variation);
CESC	cis	rs1552244	0.882	rs36006511	chr3:10054191	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.76	-9.76	-0.51	2.03e-19	Alzheimer's disease;
CESC	cis	rs933688	1.000	rs1035477	chr5:90743325	T/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.1	12.13	0.6	3.17e-27	Smoking behavior;
CESC	cis	rs8040855	0.627	rs12913859	chr15:85638418	A/G	cg08123816	chr15:85640762	PDE8A	-0.41	-6.09	-0.35	4.03e-9	Bulimia nervosa;
CESC	cis	rs11191270	0.554	rs10444022	chr10:104084889	A/G	cg15320455	chr10:103880129	LDB1	0.6	5.74	0.33	2.56e-8	Intelligence (multi-trait analysis);
CESC	cis	rs9443645	0.901	rs9361466	chr6:79618352	T/C	cg05283184	chr6:79620031	NA	-0.42	-6.42	-0.37	6.18e-10	Intelligence (multi-trait analysis);
CESC	cis	rs1971256	0.500	rs3912291	chr6:151818210	G/A	cg10883421	chr6:151773342	RMND1;C6orf211	0.59	5.16	0.3	4.83e-7	Endometriosis;
CESC	cis	rs710216	0.843	rs710220	chr1:43415346	G/T	cg07803811	chr1:43423981	SLC2A1	0.49	5.51	0.32	8.47e-8	Red cell distribution width;
CESC	cis	rs2836974	0.568	rs452377	chr21:40537183	T/C	cg17971929	chr21:40555470	PSMG1	0.87	12.83	0.62	1.2e-29	Cognitive function;
CESC	cis	rs916888	0.773	rs199445	chr17:44817408	C/T	cg01570182	chr17:44337453	NA	0.87	10.01	0.52	3.3e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs2204008	0.811	rs11525004	chr12:38333807	T/A	cg26384229	chr12:38710491	ALG10B	0.73	10.9	0.56	4.29e-23	Bladder cancer;
CESC	cis	rs7312774	0.618	rs11612483	chr12:107346884	A/G	cg16260113	chr12:107380972	MTERFD3	0.82	7.48	0.42	1.11e-12	Severe influenza A (H1N1) infection;
CESC	cis	rs7772486	0.806	rs4243478	chr6:146284560	A/G	cg23711669	chr6:146136114	FBXO30	-0.77	-10.76	-0.55	1.22e-22	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs425277	0.585	rs364677	chr1:2071765	A/G	cg12718519	chr1:2058417	PRKCZ	-0.25	-5.31	-0.31	2.36e-7	Height;
CESC	cis	rs10751667	0.666	rs12295141	chr11:947065	G/A	cg06064525	chr11:970664	AP2A2	-0.48	-9.44	-0.5	1.95e-18	Alzheimer's disease (late onset);
CESC	cis	rs11651000	0.625	rs58067360	chr17:45819587	G/C	cg00777063	chr17:45855553	NA	-0.37	-5.39	-0.31	1.53e-7	IgG glycosylation;
CESC	cis	rs9486719	0.857	rs13208321	chr6:96860354	C/T	cg06623918	chr6:96969491	KIAA0776	-0.63	-7.1	-0.4	1.17e-11	Migraine;Coronary artery disease;
CESC	cis	rs3096299	0.900	rs4785666	chr16:89462771	C/G	cg02187348	chr16:89574699	SPG7	0.5	6.57	0.37	2.63e-10	Multiple myeloma (IgH translocation);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg21119375	chr2:44393385	NA	0.46	6.03	0.35	5.62e-9	Fibrinogen levels;
CESC	cis	rs11252926	0.589	rs12359901	chr10:475068	A/G	cg18196295	chr10:418757	DIP2C	-0.53	-7.16	-0.4	7.94e-12	Psychosis in Alzheimer's disease;
CESC	cis	rs35110281	0.782	rs2838329	chr21:45023329	T/C	cg21573476	chr21:45109991	RRP1B	-0.49	-6.79	-0.38	7.38e-11	Mean corpuscular volume;
CESC	cis	rs959260	1.000	rs2053158	chr17:73393459	A/T	cg20590849	chr17:73267439	MIF4GD	0.54	6.32	0.36	1.11e-9	Systemic lupus erythematosus;
CESC	cis	rs9287719	0.967	rs4519489	chr2:10739087	A/T	cg00105475	chr2:10696890	NA	0.39	5.61	0.33	4.96e-8	Prostate cancer;
CESC	cis	rs56399783	0.808	rs73049331	chr7:2799911	C/T	cg19731401	chr7:2775893	GNA12	0.63	5.9	0.34	1.09e-8	Childhood ear infection;
CESC	cis	rs9815354	0.812	rs73071315	chr3:41805887	T/C	cg03022575	chr3:42003672	ULK4	0.7	6.18	0.35	2.42e-9	Pulse pressure;Diastolic blood pressure;
CESC	cis	rs7267979	1.000	rs2387881	chr20:25378172	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.87	-17.82	-0.74	3.14e-47	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs11583043	0.874	rs6577222	chr1:101420502	C/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.55	6.12	0.35	3.39e-9	Ulcerative colitis;Inflammatory bowel disease;
CESC	cis	rs6460942	0.915	rs79232243	chr7:12459494	G/A	cg17427002	chr7:12443146	VWDE	-0.52	-5.04	-0.3	8.67e-7	Coronary artery disease;
CESC	cis	rs2011503	1.000	rs1989867	chr19:19447470	A/G	cg11584989	chr19:19387371	SF4	-0.64	-7.79	-0.43	1.51e-13	Bipolar disorder;
CESC	cis	rs9300255	0.506	rs61388686	chr12:123810873	G/A	cg05973401	chr12:123451056	ABCB9	0.42	5.35	0.31	1.91e-7	Neutrophil percentage of white cells;
CESC	cis	rs4822044	0.561	rs132781	chr22:42046122	T/G	cg06481639	chr22:41940642	POLR3H	0.6	6.16	0.35	2.74e-9	Cannabis dependence symptom count;
CESC	cis	rs11785693	0.862	rs6990234	chr8:4996812	A/G	cg26367366	chr8:4980734	NA	0.77	7.52	0.42	8.43e-13	Neuroticism (multi-trait analysis);Neuroticism;
CESC	cis	rs239198	0.578	rs11155708	chr6:101292189	G/A	cg09795085	chr6:101329169	ASCC3	0.43	5.26	0.31	2.92e-7	Menarche (age at onset);
CESC	cis	rs6732160	0.774	rs7606271	chr2:73367698	T/G	cg01422370	chr2:73384389	NA	0.41	6.84	0.39	5.58e-11	Intelligence (multi-trait analysis);
CESC	cis	rs3733346	0.553	rs6813110	chr4:942660	C/T	cg08222618	chr4:941054	TMEM175	0.45	6.91	0.39	3.5e-11	Sjögren's syndrome;
CESC	cis	rs13191362	1.000	rs34177053	chr6:163007772	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.78	8.21	0.45	9.97e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs7267979	0.565	rs13040726	chr20:25559881	T/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.7	-11.11	-0.56	8.86e-24	Liver enzyme levels (alkaline phosphatase);
CESC	trans	rs11818084	0.664	rs2885316	chr10:126003317	T/C	cg19462022	chr13:114810756	RASA3	0.39	6.17	0.35	2.48e-9	Clozapine-induced cytotoxicity;
CESC	cis	rs763014	0.931	rs710925	chr16:633354	G/A	cg07256732	chr16:621771	PIGQ	-0.3	-5.14	-0.3	5.22e-7	Height;
CESC	cis	rs11203032	0.831	rs4417181	chr10:90967093	T/C	cg16672925	chr10:90967113	CH25H	0.73	7.12	0.4	1.01e-11	Heart failure;
CESC	cis	rs7829975	0.511	rs2976902	chr8:8341105	T/G	cg15556689	chr8:8085844	FLJ10661	0.53	6.51	0.37	3.71e-10	Mood instability;
CESC	cis	rs1059312	0.808	rs900982	chr12:129304369	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.86	-12.58	-0.61	9.34e-29	Systemic lupus erythematosus;
CESC	cis	rs2228479	0.850	rs62054599	chr16:89808850	C/G	cg00800038	chr16:89945340	TCF25	-0.88	-7.36	-0.41	2.3e-12	Skin colour saturation;
CESC	cis	rs12145833	0.538	rs9803701	chr1:243391634	T/C	cg02356786	chr1:243265016	LOC731275	-0.79	-6.57	-0.37	2.71e-10	Obesity (early onset extreme);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10727759	chr12:50017361	PRPF40B	0.6	7.29	0.41	3.59e-12	Gut microbiome composition (summer);
CESC	cis	rs2119480	0.762	rs376602	chr13:111304944	T/C	cg16216153	chr13:111290848	CARKD	-0.37	-5.58	-0.32	5.86e-8	Diastolic blood pressure;
CESC	cis	rs6460942	0.915	rs6945067	chr7:12444731	A/C	cg13733410	chr7:12443478	VWDE	-0.53	-5.45	-0.32	1.17e-7	Coronary artery disease;
CESC	cis	rs12500824	0.536	rs4241593	chr4:77386032	G/C	cg20311846	chr4:77356250	SHROOM3	-0.31	-5.62	-0.33	4.83e-8	Coronary artery disease;
CESC	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg18402987	chr7:1209562	NA	0.76	7.61	0.42	4.74e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs4713118	0.662	rs9380045	chr6:28025279	A/G	cg23281280	chr6:28129359	ZNF389	0.5	6.56	0.37	2.75e-10	Parkinson's disease;
CESC	trans	rs6479874	0.598	rs2660220	chr10:52736099	G/T	cg02905881	chr2:48009730	MSH6	0.78	6.0	0.35	6.46e-9	Migraine;
CESC	cis	rs149026780	1	rs149026780	chr2:97881612	A/C	cg26665480	chr2:98280029	ACTR1B	-0.94	-6.87	-0.39	4.45e-11	Monocyte chemoattractant protein-3 levels;
CESC	cis	rs10129255	0.500	rs12101190	chr14:107192386	C/T	cg23076370	chr14:107095027	NA	-0.65	-9.53	-0.51	1.09e-18	Kawasaki disease;
CESC	cis	rs2274273	0.686	rs66842809	chr14:55630571	T/C	cg04306507	chr14:55594613	LGALS3	0.32	5.64	0.33	4.26e-8	Protein biomarker;
CESC	cis	rs12681366	0.537	rs10095298	chr8:95484581	G/A	cg13257157	chr8:95487014	RAD54B	0.46	5.63	0.33	4.65e-8	Nonsyndromic cleft lip with cleft palate;
CESC	cis	rs2929278	0.617	rs4617832	chr15:44030579	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	-0.53	-6.96	-0.39	2.68e-11	Schizophrenia;
CESC	cis	rs4268898	0.608	rs72793980	chr2:24428859	T/C	cg06627628	chr2:24431161	ITSN2	-0.84	-9.72	-0.51	2.74e-19	Asthma;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg00810945	chr16:21964237	UQCRC2	0.49	6.47	0.37	4.67e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs9487051	0.837	rs4403290	chr6:109611583	A/T	cg01475377	chr6:109611718	NA	-0.49	-8.21	-0.45	9.56e-15	Reticulocyte fraction of red cells;
CESC	cis	rs9902453	0.817	rs4294865	chr17:28205736	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.48	5.61	0.33	5.07e-8	Coffee consumption (cups per day);
CESC	cis	rs1355223	0.583	rs2116085	chr11:34884001	C/A	cg11058730	chr11:34937778	PDHX;APIP	0.86	13.16	0.63	9.16e-31	Systemic lupus erythematosus and Systemic sclerosis;
CESC	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg26338869	chr17:61819248	STRADA	0.68	8.87	0.48	1.08e-16	Prudent dietary pattern;
CESC	cis	rs11098499	0.863	rs3822195	chr4:120471660	C/T	cg09307838	chr4:120376055	NA	0.91	12.56	0.61	1.08e-28	Corneal astigmatism;
CESC	cis	rs17376456	0.825	rs67328989	chr5:93243133	T/A	cg25358565	chr5:93447407	FAM172A	1.12	10.28	0.53	4.4e-21	Diabetic retinopathy;
CESC	cis	rs7542091	0.704	rs12022221	chr1:210046178	A/C	cg09509183	chr1:209979624	IRF6	0.39	5.71	0.33	2.97e-8	Monobrow;
CESC	cis	rs10242455	0.702	rs73401510	chr7:99065812	A/C	cg18809830	chr7:99032528	PTCD1	-0.64	-5.43	-0.32	1.27e-7	Blood metabolite levels;
CESC	cis	rs1008375	1.000	rs6846238	chr4:17629939	A/G	cg15017067	chr4:17643749	FAM184B	0.41	5.94	0.34	8.84e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs7845219	0.544	rs4570121	chr8:95917088	C/T	cg23172400	chr8:95962367	TP53INP1	-0.39	-7.15	-0.4	8.42e-12	Type 2 diabetes;
CESC	cis	rs9325144	0.560	rs13377717	chr12:38639474	T/A	cg26384229	chr12:38710491	ALG10B	-0.61	-9.62	-0.51	5.53e-19	Morning vs. evening chronotype;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10776926	chr13:21750229	SKA3;MRP63	-0.6	-6.74	-0.38	9.69e-11	Gut microbiome composition (summer);
CESC	cis	rs1062177	0.950	rs892005	chr5:151180621	A/G	cg00977110	chr5:151150581	G3BP1	0.66	7.11	0.4	1.06e-11	Preschool internalizing problems;
CESC	cis	rs7520050	0.966	rs12411269	chr1:46271052	C/T	cg24296786	chr1:45957014	TESK2	0.43	5.41	0.32	1.38e-7	Red blood cell count;Reticulocyte count;
CESC	cis	rs13108904	0.557	rs1250095	chr4:1239312	C/T	cg02018176	chr4:1364513	KIAA1530	-0.38	-5.04	-0.3	8.61e-7	Obesity-related traits;
CESC	cis	rs1577917	0.771	rs2842601	chr6:86330133	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.54	-7.38	-0.41	1.99e-12	Response to antipsychotic treatment;
CESC	cis	rs8114671	0.935	rs945960	chr20:33762854	A/G	cg24642439	chr20:33292090	TP53INP2	0.44	5.37	0.31	1.73e-7	Height;
CESC	cis	rs5769765	0.671	rs138833	chr22:50178917	A/G	cg26441486	chr22:50317300	CRELD2	0.37	5.04	0.3	8.56e-7	Schizophrenia;
CESC	cis	rs1144333	1.000	rs5745354	chr1:76275178	G/A	cg10523679	chr1:76189770	ACADM	-0.59	-5.97	-0.34	7.55e-9	Attention function in attention deficit hyperactive disorder;
CESC	cis	rs6496667	0.542	rs58182460	chr15:90897309	A/T	cg22089800	chr15:90895588	ZNF774	0.57	5.76	0.33	2.27e-8	Rheumatoid arthritis;
CESC	cis	rs7107174	1.000	rs10501426	chr11:78057122	C/T	cg02023728	chr11:77925099	USP35	0.39	5.55	0.32	7.03e-8	Testicular germ cell tumor;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg16265557	chr4:8443089	ACOX3	-0.5	-6.57	-0.37	2.66e-10	Asthma;
CESC	cis	rs7666738	0.830	rs6833312	chr4:98951356	A/T	cg17366294	chr4:99064904	C4orf37	0.59	8.52	0.46	1.24e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs454510	0.826	rs347903	chr1:120192431	C/T	cg16322792	chr1:120165303	ZNF697	0.38	5.99	0.35	6.77e-9	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
CESC	cis	rs5167	0.645	rs1130742	chr19:45452812	C/T	cg13119609	chr19:45449297	APOC2	0.38	5.22	0.31	3.56e-7	Blood protein levels;
CESC	cis	rs3768617	0.510	rs10752902	chr1:183090265	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.89	14.36	0.66	5.44e-35	Fuchs's corneal dystrophy;
CESC	cis	rs916888	0.610	rs199436	chr17:44789285	C/T	cg01570182	chr17:44337453	NA	-0.66	-8.95	-0.48	6.54e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs265548	0.538	rs36688	chr19:17911212	A/C	cg00024989	chr19:17902242	NA	0.47	8.16	0.45	1.39e-14	Tumor biomarkers;
CESC	cis	rs7833790	0.724	rs1054078	chr8:82712153	A/G	cg07697082	chr8:82753677	SNX16	0.41	6.22	0.36	1.92e-9	Diastolic blood pressure;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01591470	chr14:39736043	CTAGE5	0.61	7.35	0.41	2.42e-12	Gut microbiome composition (summer);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.48	6.66	0.38	1.54e-10	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs12410462	0.681	rs78978081	chr1:227571619	G/A	cg04117972	chr1:227635322	NA	0.74	6.17	0.35	2.52e-9	Major depressive disorder;
CESC	cis	rs644799	1.000	rs693597	chr11:95589629	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.69	8.47	0.46	1.73e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	trans	rs11098499	0.909	rs1546502	chr4:120235898	A/G	cg25214090	chr10:38739885	LOC399744	0.7	9.63	0.51	5.2e-19	Corneal astigmatism;
CESC	cis	rs5750830	0.621	rs743838	chr22:39824707	T/G	cg24399712	chr22:39784796	NA	-0.81	-10.53	-0.54	6.85e-22	Intelligence (multi-trait analysis);
CESC	cis	rs722599	0.748	rs17102884	chr14:75374899	C/T	cg11812906	chr14:75593930	NEK9	-0.46	-5.65	-0.33	4.2e-8	IgG glycosylation;
CESC	trans	rs7656342	0.808	rs10003216	chr4:9766749	A/G	cg19546875	chr21:45432889	TRAPPC10	-0.51	-6.2	-0.36	2.16e-9	Gut microbiota (bacterial taxa);
CESC	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg13867718	chr16:29973267	TMEM219	-0.48	-6.44	-0.37	5.5e-10	Height;
CESC	cis	rs6570726	0.935	rs430561	chr6:145813140	C/T	cg05347473	chr6:146136440	FBXO30	0.49	6.77	0.38	8.09e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7666738	0.715	rs61114099	chr4:98931270	C/T	cg05340658	chr4:99064831	C4orf37	0.82	12.17	0.6	2.24e-27	Colonoscopy-negative controls vs population controls;
CESC	cis	rs734999	0.505	rs4073286	chr1:2539901	A/C	cg20673091	chr1:2541236	MMEL1	0.45	7.57	0.42	6.17e-13	Ulcerative colitis;
CESC	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg07677032	chr17:61819896	STRADA	0.47	6.3	0.36	1.21e-9	Prudent dietary pattern;
CESC	cis	rs7666738	0.830	rs6831925	chr4:98947401	T/C	cg03467027	chr4:99064603	C4orf37	0.46	5.82	0.34	1.74e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs7264396	0.676	rs1341603	chr20:34556216	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.77	-10.17	-0.53	1e-20	Total cholesterol levels;
CESC	cis	rs6570726	0.791	rs4896820	chr6:145894957	T/C	cg05347473	chr6:146136440	FBXO30	0.48	6.44	0.37	5.62e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6430585	0.528	rs721765	chr2:136748779	C/A	cg07169764	chr2:136633963	MCM6	1.28	17.38	0.73	1.11e-45	Corneal structure;
CESC	cis	rs8067354	0.527	rs1292039	chr17:57974913	A/T	cg02344993	chr17:57696989	CLTC	0.54	5.57	0.32	6.18e-8	Hemoglobin concentration;
CESC	cis	rs1707322	0.964	rs785509	chr1:46527300	G/A	cg06784218	chr1:46089804	CCDC17	-0.35	-5.9	-0.34	1.11e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs727563	0.635	rs5751141	chr22:42107745	A/G	cg06481639	chr22:41940642	POLR3H	0.61	6.24	0.36	1.72e-9	Crohn's disease;Inflammatory bowel disease;
CESC	trans	rs17125944	0.615	rs7151643	chr14:53313661	G/C	cg01134794	chr4:78529898	CXCL13	0.54	6.09	0.35	3.9e-9	Alzheimer's disease (late onset);
CESC	cis	rs12142240	0.698	rs72886907	chr1:46814265	C/T	cg10495392	chr1:46806563	NSUN4	0.57	6.21	0.36	2.02e-9	Menopause (age at onset);
CESC	cis	rs42648	0.869	rs12704518	chr7:89914388	G/T	cg23697855	chr7:89950296	NA	0.27	5.05	0.3	8.24e-7	Homocysteine levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22221222	chr6:3751199	C6orf145	0.58	7.16	0.4	8.1e-12	Gut microbiome composition (summer);
CESC	cis	rs873946	0.648	rs1548281	chr10:134552982	C/T	cg18305652	chr10:134549665	INPP5A	0.46	6.53	0.37	3.37e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs35306767	0.903	rs12769431	chr10:922633	T/C	cg25019033	chr10:957182	NA	-0.59	-6.38	-0.36	7.8e-10	Eosinophil percentage of granulocytes;
CESC	cis	rs1448094	0.512	rs57278040	chr12:86237886	A/G	cg00310523	chr12:86230176	RASSF9	0.34	5.26	0.31	2.9e-7	Major depressive disorder;
CESC	cis	rs977987	0.902	rs4888430	chr16:75494424	T/C	cg03315344	chr16:75512273	CHST6	0.53	7.74	0.43	2.12e-13	Dupuytren's disease;
CESC	cis	rs9790314	1.000	rs6775627	chr3:160953609	A/G	cg03342759	chr3:160939853	NMD3	-0.46	-6.01	-0.35	5.98e-9	Morning vs. evening chronotype;
CESC	cis	rs1862618	0.853	rs1423621	chr5:56101035	G/T	cg24531977	chr5:56204891	C5orf35	-0.83	-10.98	-0.56	2.32e-23	Initial pursuit acceleration;
CESC	cis	rs72781680	0.898	rs72782137	chr2:24047805	C/T	cg08917208	chr2:24149416	ATAD2B	0.95	8.71	0.47	3.45e-16	Lymphocyte counts;
CESC	cis	rs875971	0.800	rs427557	chr7:65519250	A/G	cg12463550	chr7:65579703	CRCP	0.57	7.22	0.41	5.6e-12	Aortic root size;
CESC	cis	rs765787	0.530	rs12917187	chr15:45538297	A/G	cg24006582	chr15:45444508	DUOX1	-0.59	-7.32	-0.41	3.04e-12	Uric acid levels;
CESC	cis	rs3126085	0.935	rs12401851	chr1:152259022	T/C	cg03465714	chr1:152285911	FLG	0.5	5.98	0.34	7.27e-9	Atopic dermatitis;
CESC	cis	rs1506636	0.962	rs2896335	chr7:123376855	A/T	cg03229431	chr7:123269106	ASB15	-0.52	-6.91	-0.39	3.58e-11	Plateletcrit;Platelet count;
CESC	cis	rs2836974	0.897	rs2836927	chr21:40543216	T/C	cg17971929	chr21:40555470	PSMG1	1.05	16.26	0.71	1.05e-41	Cognitive function;
CESC	cis	rs61931739	0.500	rs9919726	chr12:34510783	A/G	cg06521331	chr12:34319734	NA	-0.37	-5.09	-0.3	6.85e-7	Morning vs. evening chronotype;
CESC	cis	rs17826219	0.706	rs73271850	chr17:29142140	A/G	cg14008862	chr17:28927542	LRRC37B2	0.65	5.14	0.3	5.34e-7	Body mass index;
CESC	cis	rs13118159	0.836	rs12647145	chr4:1338618	C/A	cg20887711	chr4:1340912	KIAA1530	0.44	5.93	0.34	9.23e-9	Longevity;
CESC	cis	rs660498	0.581	rs616550	chr10:27740796	T/C	cg25705717	chr10:27608719	NA	0.43	5.53	0.32	7.67e-8	Asthma (childhood onset);
CESC	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg24503407	chr1:205819492	PM20D1	0.75	11.73	0.58	7.32e-26	Menarche (age at onset);
CESC	cis	rs601339	1.000	rs645491	chr12:123181661	T/C	cg11919336	chr12:123188078	GPR109A	0.47	6.27	0.36	1.49e-9	Adiponectin levels;
CESC	cis	rs2074585	0.806	rs2657949	chr15:90950790	G/A	cg22089800	chr15:90895588	ZNF774	0.6	8.01	0.44	3.68e-14	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
CESC	cis	rs769267	0.930	rs4808965	chr19:19631655	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.59	7.37	0.41	2.15e-12	Tonsillectomy;
CESC	cis	rs6963495	0.818	rs6956234	chr7:105149707	A/G	cg13798780	chr7:105162888	PUS7	0.76	7.8	0.43	1.47e-13	Bipolar disorder (body mass index interaction);
CESC	cis	rs7044106	0.762	rs1547268	chr9:123408688	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.64	8.63	0.47	5.83e-16	Hip circumference adjusted for BMI;
CESC	cis	rs10256972	0.524	rs6945202	chr7:1116558	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.52	-6.84	-0.39	5.38e-11	Longevity;Endometriosis;
CESC	cis	rs7481584	0.517	rs80872	chr11:3049984	G/T	cg08508325	chr11:3079039	CARS	0.29	5.16	0.3	4.96e-7	Calcium levels;
CESC	cis	rs896854	0.625	rs4735336	chr8:95973410	A/C	cg26343298	chr8:95960752	TP53INP1	-0.36	-6.05	-0.35	5.04e-9	Type 2 diabetes;
CESC	cis	rs873946	0.564	rs2803992	chr10:134550882	T/C	cg06453172	chr10:134556979	INPP5A	-0.38	-5.21	-0.3	3.74e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
CESC	cis	rs12142240	0.698	rs17361887	chr1:46834775	A/G	cg10495392	chr1:46806563	NSUN4	0.57	6.01	0.35	6.05e-9	Menopause (age at onset);
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg13870041	chr1:227015885	NA	-0.41	-6.16	-0.35	2.67e-9	Gambling;
CESC	cis	rs17826219	0.636	rs12946563	chr17:29103166	C/G	cg19761014	chr17:28927070	LRRC37B2	0.75	6.17	0.35	2.49e-9	Body mass index;
CESC	cis	rs10791097	0.694	rs10791103	chr11:130757161	G/A	cg12179176	chr11:130786555	SNX19	0.65	10.14	0.53	1.29e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs7714584	1.000	rs11747270	chr5:150258867	C/T	cg22134413	chr5:150180641	NA	-0.48	-5.42	-0.32	1.34e-7	Crohn's disease;
CESC	cis	rs6502050	0.835	rs4789722	chr17:80151881	G/A	cg23985595	chr17:80112537	CCDC57	-0.4	-6.33	-0.36	1.05e-9	Life satisfaction;
CESC	cis	rs7818688	0.654	rs11783262	chr8:95979816	A/G	cg16049864	chr8:95962084	TP53INP1	0.55	5.55	0.32	6.92e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
CESC	cis	rs6582630	0.537	rs1949610	chr12:38387838	C/T	cg26384229	chr12:38710491	ALG10B	0.72	10.91	0.56	3.86e-23	Drug-induced liver injury (flucloxacillin);
CESC	cis	rs1707322	1.000	rs11211248	chr1:46476844	A/G	cg03146154	chr1:46216737	IPP	0.71	9.51	0.5	1.21e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs7412746	0.646	rs1972060	chr1:150937594	T/C	cg22823121	chr1:150693482	HORMAD1	0.37	5.16	0.3	4.89e-7	Melanoma;
CESC	cis	rs2479106	0.892	rs2768819	chr9:126593370	A/G	cg16191174	chr9:126692580	DENND1A	0.47	6.47	0.37	4.79e-10	Polycystic ovary syndrome;
CESC	cis	rs7100689	0.784	rs4934139	chr10:82177023	C/A	cg00277334	chr10:82204260	NA	-0.57	-7.01	-0.4	1.94e-11	Post bronchodilator FEV1;
CESC	cis	rs75804782	0.641	rs72987309	chr2:239348025	A/G	cg18131467	chr2:239335373	ASB1	-0.67	-5.9	-0.34	1.13e-8	Morning vs. evening chronotype;Chronotype;
CESC	cis	rs12681366	0.708	rs1011249	chr8:95438061	G/A	cg13257157	chr8:95487014	RAD54B	0.38	5.19	0.3	4.26e-7	Nonsyndromic cleft lip with cleft palate;
CESC	cis	rs17431357	0.867	rs73230314	chr12:120995953	A/G	cg25045489	chr12:120971538	RNF10	-0.93	-5.46	-0.32	1.1e-7	Insulin resistance/response;
CESC	cis	rs6691722	0.506	rs1016209	chr1:24745615	A/G	cg02336364	chr1:24764700	NIPAL3	-0.31	-6.3	-0.36	1.25e-9	Response to interferon beta in multiple sclerosis;
CESC	trans	rs561341	1.000	rs564714	chr17:30318404	C/T	cg27661571	chr11:113659931	NA	-0.87	-8.07	-0.44	2.48e-14	Hip circumference adjusted for BMI;
CESC	cis	rs35110281	0.627	rs7282704	chr21:44966253	A/G	cg01579765	chr21:45077557	HSF2BP	-0.5	-8.22	-0.45	9.04e-15	Mean corpuscular volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08945467	chr1:58522070	DAB1	-0.66	-7.91	-0.44	7.23e-14	Gut microbiome composition (summer);
CESC	cis	rs3784262	1.000	rs4369598	chr15:58318603	G/T	cg12031962	chr15:58353849	ALDH1A2	-0.32	-5.12	-0.3	5.89e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
CESC	cis	rs3785574	0.927	rs2854183	chr17:61968002	C/T	cg11494091	chr17:61959527	GH2	0.37	5.12	0.3	5.97e-7	Height;
CESC	cis	rs929596	0.606	rs10178992	chr2:234657877	T/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.59	-7.32	-0.41	2.95e-12	Total bilirubin levels in HIV-1 infection;
CESC	cis	rs6456156	0.586	rs12213683	chr6:167460718	G/A	cg07741184	chr6:167504864	NA	0.35	6.0	0.35	6.57e-9	Primary biliary cholangitis;
CESC	cis	rs708547	0.836	rs1718882	chr4:57859533	C/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.78	11.09	0.56	9.72e-24	Response to bleomycin (chromatid breaks);
CESC	cis	rs9916302	0.706	rs9890198	chr17:37457480	A/C	cg07936489	chr17:37558343	FBXL20	0.96	10.55	0.54	5.78e-22	Glomerular filtration rate (creatinine);
CESC	trans	rs10743315	0.557	rs80051304	chr12:19286086	G/A	cg09562322	chr12:119419143	SRRM4	-0.48	-6.27	-0.36	1.48e-9	Gut microbiota (bacterial taxa);
CESC	cis	rs10782582	0.593	rs6675212	chr1:76230829	C/A	cg22875332	chr1:76189707	ACADM	-0.44	-5.23	-0.31	3.45e-7	Daytime sleep phenotypes;
CESC	cis	rs2282802	0.685	rs7717563	chr5:139689968	A/G	cg26211634	chr5:139558579	C5orf32	-0.46	-6.56	-0.37	2.73e-10	Intelligence (multi-trait analysis);
CESC	cis	rs10838687	0.736	rs3824866	chr11:47258853	C/T	cg25783544	chr11:47291846	MADD	0.56	6.49	0.37	4.09e-10	Proinsulin levels;
CESC	cis	rs909674	0.662	rs2899318	chr22:39837625	A/G	cg11247378	chr22:39784982	NA	-0.61	-8.63	-0.47	5.8e-16	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
CESC	cis	rs9488822	0.676	rs11153593	chr6:116335131	C/A	cg15226275	chr6:116381976	FRK	0.24	6.18	0.36	2.38e-9	Cholesterol, total;LDL cholesterol;
CESC	cis	rs72781680	0.821	rs72790304	chr2:24108557	G/A	cg08917208	chr2:24149416	ATAD2B	0.67	6.69	0.38	1.29e-10	Lymphocyte counts;
CESC	cis	rs7833986	0.501	rs72653953	chr8:56970795	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.61	7.49	0.42	1.02e-12	Height;
CESC	cis	rs2425143	0.908	rs74784474	chr20:34422464	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.68	5.87	0.34	1.27e-8	Blood protein levels;
CESC	cis	rs9649213	0.537	rs6971825	chr7:97979548	C/T	cg08684580	chr7:98029266	BAIAP2L1	-0.35	-5.8	-0.34	1.85e-8	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs10464366	0.517	rs13231075	chr7:39174806	G/T	cg18850127	chr7:39170497	POU6F2	0.37	5.18	0.3	4.43e-7	IgG glycosylation;
CESC	cis	rs6499255	0.951	rs10163235	chr16:69739867	G/T	cg15192750	chr16:69999425	NA	0.51	6.07	0.35	4.38e-9	IgE levels;
CESC	cis	rs1005277	0.579	rs2504140	chr10:38387579	T/G	cg25517755	chr10:38738941	LOC399744	-0.47	-6.05	-0.35	4.86e-9	Extrinsic epigenetic age acceleration;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03258011	chr17:54857409	NA	0.48	6.13	0.35	3.24e-9	Gut microbiota (bacterial taxa);
CESC	trans	rs61931739	0.500	rs10844734	chr12:34043083	G/A	cg26384229	chr12:38710491	ALG10B	0.53	7.22	0.41	5.44e-12	Morning vs. evening chronotype;
CESC	cis	rs6460942	0.915	rs80345607	chr7:12442249	T/C	cg10578991	chr7:12443926	VWDE	-0.51	-5.67	-0.33	3.75e-8	Coronary artery disease;
CESC	cis	rs2777491	0.574	rs72739644	chr15:41719706	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.07	-17.08	-0.72	1.34e-44	Ulcerative colitis;
CESC	cis	rs17711722	0.653	rs2460421	chr7:65491123	A/T	cg14393609	chr7:65229607	NA	-0.49	-6.8	-0.39	6.73e-11	Calcium levels;
CESC	cis	rs7100689	0.646	rs10749573	chr10:82136839	T/A	cg00277334	chr10:82204260	NA	-0.57	-7.51	-0.42	9.08e-13	Post bronchodilator FEV1;
CESC	cis	rs5758659	0.714	rs5758574	chr22:42481400	G/C	cg19513890	chr22:42538836	CYP2D7P1	0.36	5.28	0.31	2.71e-7	Cognitive function;
CESC	cis	rs6570726	0.818	rs437147	chr6:145875423	A/T	cg05347473	chr6:146136440	FBXO30	0.57	7.21	0.4	5.99e-12	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06013127	chr17:27903940	GIT1	-0.57	-6.0	-0.35	6.6e-9	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14450605	chr10:51572496	NCOA4	-0.67	-8.17	-0.45	1.24e-14	Gut microbiome composition (summer);
CESC	cis	rs11792861	0.619	rs2289480	chr9:111705501	A/C	cg05043794	chr9:111880884	C9orf5	-0.31	-5.65	-0.33	4.21e-8	Menarche (age at onset);
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg24367984	chr17:1945160	OVCA2;DPH1	-0.44	-6.24	-0.36	1.73e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs116095464	0.558	rs7731089	chr5:290422	A/C	cg22496380	chr5:211416	CCDC127	-0.74	-8.46	-0.46	1.77e-15	Breast cancer;
CESC	cis	rs6691722	0.503	rs6692646	chr1:24707629	C/T	cg18323236	chr1:24743029	NIPAL3	0.37	5.47	0.32	1.02e-7	Response to interferon beta in multiple sclerosis;
CESC	cis	rs7412746	0.658	rs11204750	chr1:150939744	C/A	cg22823121	chr1:150693482	HORMAD1	0.39	5.35	0.31	1.93e-7	Melanoma;
CESC	cis	rs644799	1.000	rs596277	chr11:95566886	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	13.72	0.64	9.86e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs4642101	0.640	rs3901666	chr3:12824363	G/T	cg24848339	chr3:12840334	CAND2	-0.38	-5.99	-0.35	6.66e-9	QRS complex (12-leadsum);
CESC	cis	rs7662987	0.938	rs28730592	chr4:100003743	C/T	cg13256891	chr4:100009986	ADH5	-0.72	-5.39	-0.31	1.52e-7	Smoking initiation;
CESC	cis	rs939658	0.805	rs35318825	chr15:79447098	C/A	cg17916960	chr15:79447300	NA	-0.36	-5.72	-0.33	2.86e-8	Refractive error;
CESC	cis	rs7937682	0.737	rs518294	chr11:111424716	A/T	cg09085632	chr11:111637200	PPP2R1B	-0.76	-10.13	-0.53	1.34e-20	Primary sclerosing cholangitis;
CESC	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg14893161	chr1:205819251	PM20D1	0.86	15.15	0.68	8.92e-38	Menarche (age at onset);
CESC	cis	rs2952156	0.883	rs907089	chr17:37833600	C/T	cg07936489	chr17:37558343	FBXL20	-0.63	-8.36	-0.46	3.48e-15	Asthma;
CESC	cis	rs4835473	0.897	rs1545437	chr4:144617842	G/T	cg25736465	chr4:144833511	NA	-0.37	-5.49	-0.32	9.48e-8	Immature fraction of reticulocytes;
CESC	cis	rs17711722	1.000	rs17711722	chr7:65271197	C/T	cg18876405	chr7:65276391	NA	-0.7	-9.84	-0.52	1.15e-19	Calcium levels;
CESC	cis	rs875971	0.895	rs3857684	chr7:65938158	G/C	cg12463550	chr7:65579703	CRCP	0.57	7.32	0.41	2.95e-12	Aortic root size;
CESC	cis	rs11792861	0.816	rs113624314	chr9:111689953	G/A	cg05043794	chr9:111880884	C9orf5	-0.38	-6.4	-0.37	6.93e-10	Menarche (age at onset);
CESC	cis	rs9611565	0.625	rs73178625	chr22:41928320	G/C	cg06481639	chr22:41940642	POLR3H	-0.58	-6.15	-0.35	2.77e-9	Vitiligo;
CESC	cis	rs11030122	0.702	rs7128762	chr11:3943277	C/G	cg18678763	chr11:4115507	RRM1	-0.44	-5.89	-0.34	1.17e-8	Mean platelet volume;Platelet distribution width;
CESC	cis	rs3859192	0.577	rs25645	chr17:38173143	G/A	cg17344932	chr17:38183730	MED24;SNORD124	0.62	9.25	0.49	7.49e-18	White blood cell count;
CESC	cis	rs1008375	1.000	rs10939740	chr4:17617490	T/C	cg15017067	chr4:17643749	FAM184B	0.43	6.11	0.35	3.45e-9	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs6460942	0.778	rs76030612	chr7:12462937	C/A	cg20607287	chr7:12443886	VWDE	-0.71	-10.03	-0.52	2.84e-20	Coronary artery disease;
CESC	cis	rs4911259	0.552	rs13037833	chr20:31459562	C/T	cg13636640	chr20:31349939	DNMT3B	-0.56	-7.85	-0.43	1e-13	Inflammatory bowel disease;
CESC	cis	rs7923609	0.967	rs7095571	chr10:65150959	T/G	cg01631684	chr10:65280961	REEP3	-0.41	-5.16	-0.3	4.89e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs9910055	0.531	rs6503490	chr17:42246656	A/G	cg13607699	chr17:42295918	UBTF	0.57	7.4	0.41	1.78e-12	Total body bone mineral density;
CESC	cis	rs7666738	0.581	rs34205844	chr4:98887494	C/A	cg17366294	chr4:99064904	C4orf37	0.52	7.1	0.4	1.13e-11	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6842047	0.706	rs4862667	chr4:187136416	A/G	cg09526685	chr4:187126073	CYP4V2	0.63	5.36	0.31	1.78e-7	Blood protein levels;
CESC	cis	rs617791	0.508	rs2276132	chr11:65770545	G/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.46	-5.28	-0.31	2.65e-7	Breast cancer;
CESC	cis	rs4843747	0.749	rs13333619	chr16:88072076	C/T	cg06915872	chr16:87998081	BANP	0.55	6.69	0.38	1.32e-10	Menopause (age at onset);
CESC	cis	rs6964587	0.839	rs12536702	chr7:91471576	G/C	cg17063962	chr7:91808500	NA	0.53	6.88	0.39	4.34e-11	Breast cancer;
CESC	cis	rs1707322	0.963	rs4459051	chr1:46451203	A/G	cg05343316	chr1:45956843	TESK2	0.44	5.42	0.32	1.36e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs1552244	0.572	rs17032426	chr3:10167112	G/A	cg00149659	chr3:10157352	C3orf10	1.01	12.53	0.61	1.33e-28	Alzheimer's disease;
CESC	cis	rs9457247	0.871	rs1811121	chr6:167403539	T/C	cg23791538	chr6:167370224	RNASET2	-0.58	-8.28	-0.45	6.16e-15	Crohn's disease;
CESC	cis	rs7520050	0.807	rs4274104	chr1:46217941	T/C	cg24296786	chr1:45957014	TESK2	-0.46	-5.98	-0.34	7.23e-9	Red blood cell count;Reticulocyte count;
CESC	cis	rs4665809	0.531	rs34081866	chr2:26475940	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.06	12.34	0.6	5.85e-28	Gut microbiome composition (summer);
CESC	cis	rs910316	1.000	rs2098297	chr14:75619118	G/T	cg11812906	chr14:75593930	NEK9	-0.92	-16.16	-0.7	2.35e-41	Height;
CESC	cis	rs2637266	0.655	rs846628	chr10:78538392	G/A	cg18941641	chr10:78392320	NA	0.41	7.71	0.43	2.61e-13	Pulmonary function;
CESC	cis	rs939574	1.000	rs908196	chr2:220088248	A/G	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-0.6	-6.08	-0.35	4.14e-9	Platelet distribution width;
CESC	cis	rs10754283	0.967	rs4658307	chr1:90117586	G/T	cg21401794	chr1:90099060	LRRC8C	0.68	9.1	0.49	2.28e-17	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs6938	0.618	rs11638130	chr15:75183935	G/A	cg13906792	chr15:75199810	C15orf17	-0.34	-5.05	-0.3	8.42e-7	Breast cancer;
CESC	cis	rs68170813	0.641	rs79434636	chr7:107105656	A/C	cg02696742	chr7:106810147	HBP1	-0.56	-5.26	-0.31	3.03e-7	Coronary artery disease;
CESC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg04170460	chr16:29985301	TAOK2	-0.5	-6.8	-0.39	6.92e-11	Age-related hearing impairment (SNP x SNP interaction);
CESC	cis	rs2050392	0.590	rs2065723	chr10:30720462	A/T	cg25182066	chr10:30743637	MAP3K8	-0.46	-6.02	-0.35	5.85e-9	Inflammatory bowel disease;
CESC	cis	rs11625487	0.609	rs17824567	chr14:77976450	G/T	cg20045696	chr14:77926864	AHSA1	0.59	5.19	0.3	4.29e-7	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
CESC	cis	rs2115536	1.000	rs2115536	chr15:80194247	C/T	cg00225070	chr15:80189496	MTHFS	0.56	8.0	0.44	4e-14	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg07578976	chr6:5086036	PPP1R3G	0.45	6.51	0.37	3.65e-10	Systemic lupus erythematosus;
CESC	cis	rs722599	0.748	rs1059326	chr14:75369385	C/T	cg11812906	chr14:75593930	NEK9	-0.47	-5.69	-0.33	3.32e-8	IgG glycosylation;
CESC	cis	rs8112211	0.911	rs2286476	chr19:38850759	G/A	cg14299480	chr19:38876666	GGN	-0.44	-6.02	-0.35	5.74e-9	Blood protein levels;
CESC	cis	rs514406	0.755	rs11206015	chr1:53242187	T/C	cg16325326	chr1:53192061	ZYG11B	-0.71	-11.84	-0.59	3e-26	Monocyte count;
CESC	cis	rs6570726	0.791	rs1935612	chr6:145906090	T/A	cg05347473	chr6:146136440	FBXO30	0.53	6.97	0.39	2.48e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs757110	0.866	rs5213	chr11:17408404	C/T	cg15432903	chr11:17409602	KCNJ11	0.69	10.05	0.53	2.49e-20	Type 2 diabetes;
CESC	cis	rs2997447	0.761	rs17257093	chr1:26436231	C/A	cg24596570	chr1:26146463	FAM54B;LOC646471	0.62	5.33	0.31	2.07e-7	QRS complex (12-leadsum);
CESC	cis	rs4713118	0.662	rs149901	chr6:27965503	C/T	cg17221315	chr6:27791827	HIST1H4J	0.44	5.31	0.31	2.27e-7	Parkinson's disease;
CESC	cis	rs9287719	0.935	rs1309	chr2:10743546	A/G	cg00105475	chr2:10696890	NA	0.39	5.64	0.33	4.44e-8	Prostate cancer;
CESC	cis	rs1034435	0.547	rs5767174	chr22:48898857	A/G	cg05992904	chr22:48892994	FAM19A5	-0.45	-6.67	-0.38	1.48e-10	Late-onset Alzheimer's disease;
CESC	cis	rs11792861	0.926	rs72607174	chr9:111899132	A/T	cg13535736	chr9:111863775	C9orf5	-0.5	-6.61	-0.38	2.12e-10	Menarche (age at onset);
CESC	cis	rs780096	0.546	rs715325	chr2:27725572	C/A	cg24768116	chr2:27665128	KRTCAP3	-0.33	-5.99	-0.35	6.64e-9	Total body bone mineral density;
CESC	cis	rs59698941	0.943	rs56927472	chr5:132226038	T/A	cg02081065	chr5:132209139	LEAP2	-0.52	-5.11	-0.3	6.08e-7	Apolipoprotein A-IV levels;
CESC	cis	rs3857536	0.674	rs9345798	chr6:66951331	A/G	cg07460842	chr6:66804631	NA	-0.42	-5.25	-0.31	3.11e-7	Blood trace element (Cu levels);
CESC	cis	rs4970988	0.556	rs6681426	chr1:150586971	G/A	cg13175981	chr1:150552382	MCL1	0.44	5.3	0.31	2.38e-7	Urate levels;
CESC	cis	rs796364	1.000	rs769950	chr2:200730028	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.89	8.76	0.47	2.4e-16	Schizophrenia;
CESC	cis	rs2836974	0.605	rs2836988	chr21:40707975	A/G	cg22974920	chr21:40686053	BRWD1	-0.42	-5.23	-0.31	3.53e-7	Cognitive function;
CESC	cis	rs4595586	0.545	rs7980848	chr12:39375166	G/C	cg26384229	chr12:38710491	ALG10B	0.54	7.53	0.42	7.85e-13	Morning vs. evening chronotype;
CESC	cis	rs4727027	0.716	rs4727020	chr7:148837317	C/T	cg23583168	chr7:148888333	NA	-0.69	-9.45	-0.5	1.82e-18	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs6840360	0.533	rs13139327	chr4:152728590	A/C	cg22705602	chr4:152727874	NA	-0.37	-5.07	-0.3	7.38e-7	Intelligence (multi-trait analysis);
CESC	trans	rs1888221	0.580	rs1537017	chr9:117811315	G/C	cg11017500	chr13:111290755	CARKD	-0.46	-6.1	-0.35	3.69e-9	Glucose homeostasis traits;
CESC	cis	rs9487051	0.799	rs351725	chr6:109547939	G/A	cg01475377	chr6:109611718	NA	-0.38	-5.7	-0.33	3.11e-8	Reticulocyte fraction of red cells;
CESC	cis	rs7208859	0.623	rs11652631	chr17:29060766	A/G	cg14008862	chr17:28927542	LRRC37B2	0.65	5.12	0.3	5.86e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	cis	rs1506636	1.000	rs2402671	chr7:123355483	T/C	cg03229431	chr7:123269106	ASB15	-0.52	-6.91	-0.39	3.58e-11	Plateletcrit;Platelet count;
CESC	cis	rs2180341	1.000	rs6569486	chr6:127708424	A/C	cg27446573	chr6:127587934	RNF146	1.03	14.81	0.67	1.41e-36	Breast cancer;
CESC	cis	rs514406	0.893	rs1242315	chr1:53417181	A/G	cg16325326	chr1:53192061	ZYG11B	0.91	14.92	0.68	5.92e-37	Monocyte count;
CESC	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg03188948	chr7:1209495	NA	0.42	5.25	0.31	3.08e-7	Longevity;Endometriosis;
CESC	cis	rs66686620	1.000	rs6546473	chr2:69260357	C/T	cg12800200	chr2:69260302	ANTXR1	0.39	5.74	0.33	2.57e-8	Breast cancer;
CESC	cis	rs7552404	1.000	rs11161521	chr1:76216330	T/C	cg22875332	chr1:76189707	ACADM	0.59	6.89	0.39	4.15e-11	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg04234412	chr22:24373322	LOC391322	-0.51	-7.24	-0.41	4.98e-12	Liver enzyme levels (gamma-glutamyl transferase);
CESC	trans	rs9467711	0.659	rs66757203	chr6:26454956	C/T	cg06606381	chr12:133084897	FBRSL1	-0.94	-6.86	-0.39	4.96e-11	Autism spectrum disorder or schizophrenia;
CESC	cis	rs7927771	0.524	rs10742820	chr11:47781057	C/T	cg20307385	chr11:47447363	PSMC3	-0.58	-8.01	-0.44	3.54e-14	Subjective well-being;
CESC	cis	rs11969893	0.649	rs9390699	chr6:101306502	C/G	cg12253828	chr6:101329408	ASCC3	0.93	8.37	0.46	3.4e-15	Economic and political preferences (immigration/crime);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00518698	chr21:35015074	ITSN1;CRYZL1	0.56	6.2	0.36	2.1e-9	Gut microbiome composition (summer);
CESC	cis	rs7243790	1.000	rs17558111	chr18:51963953	G/A	cg04730925	chr18:51795821	POLI	-0.42	-5.52	-0.32	8.02e-8	Diastolic blood pressure;
CESC	cis	rs9486719	1.000	rs12530462	chr6:97053514	C/T	cg18709589	chr6:96969512	KIAA0776	-0.52	-5.73	-0.33	2.73e-8	Migraine;Coronary artery disease;
CESC	cis	rs2629540	0.847	rs12763093	chr10:126395688	C/G	cg08799069	chr10:126477246	METTL10	-0.55	-6.92	-0.39	3.35e-11	Cocaine dependence;
CESC	cis	rs12586317	0.547	rs2038254	chr14:35462134	C/T	cg05294307	chr14:35346193	BAZ1A	-0.51	-5.45	-0.32	1.16e-7	Psoriasis;
CESC	cis	rs11785400	1.000	rs6995314	chr8:143749718	A/G	cg24634471	chr8:143751801	JRK	-0.46	-6.07	-0.35	4.36e-9	Schizophrenia;
CESC	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg12419862	chr22:24373484	LOC391322	-0.98	-16.46	-0.71	2e-42	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs3091242	0.933	rs61775174	chr1:25787313	G/A	cg12412775	chr1:25698385	RHCE	0.3	5.25	0.31	3.2e-7	Erythrocyte sedimentation rate;
CESC	cis	rs6696846	0.765	rs4394715	chr1:205108393	T/G	cg00857998	chr1:205179979	DSTYK	0.56	7.37	0.41	2.21e-12	Red blood cell count;
CESC	cis	rs1506636	1.000	rs2299984	chr7:123356921	G/T	cg03229431	chr7:123269106	ASB15	0.47	6.39	0.37	7.43e-10	Plateletcrit;Platelet count;
CESC	cis	rs57502260	0.834	rs3736228	chr11:68201295	A/G	cg20283391	chr11:68216788	NA	0.61	5.27	0.31	2.77e-7	Total body bone mineral density (age 45-60);
CESC	cis	rs2440129	0.611	rs1126667	chr17:6902760	C/T	cg22741997	chr17:6900356	ALOX12	-0.37	-5.77	-0.33	2.25e-8	Tonsillectomy;
CESC	trans	rs9833726	0.799	rs71318645	chr3:86137405	G/T	cg10416071	chr15:75628863	COMMD4	0.59	6.12	0.35	3.37e-9	Breast cancer;
CESC	cis	rs1372520	0.627	rs2583964	chr4:90727218	A/G	cg15133208	chr4:90757351	SNCA	-0.43	-5.79	-0.33	2.02e-8	Neuroticism;
CESC	cis	rs7552404	1.000	rs6672180	chr1:76123973	C/G	cg03433033	chr1:76189801	ACADM	0.69	8.27	0.45	6.34e-15	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs8020095	0.571	rs17248252	chr14:67562929	T/G	cg19548862	chr14:67692701	FAM71D	-0.47	-5.63	-0.33	4.6e-8	Depression (quantitative trait);
CESC	cis	rs6460942	0.591	rs62448733	chr7:12350526	C/T	cg02935154	chr7:12443704	VWDE	-0.49	-5.06	-0.3	7.74e-7	Coronary artery disease;
CESC	cis	rs12476592	0.602	rs2028887	chr2:63716223	A/G	cg17519650	chr2:63277830	OTX1	-0.46	-5.64	-0.33	4.33e-8	Childhood ear infection;
CESC	cis	rs1538970	0.781	rs713358	chr1:45988267	C/G	cg06784218	chr1:46089804	CCDC17	0.34	5.52	0.32	7.91e-8	Platelet count;
CESC	cis	rs7666738	0.830	rs7687315	chr4:98900613	A/G	cg17366294	chr4:99064904	C4orf37	0.58	7.97	0.44	4.76e-14	Colonoscopy-negative controls vs population controls;
CESC	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	7.65	0.43	3.76e-13	Prudent dietary pattern;
CESC	cis	rs11828289	0.660	rs76458473	chr11:23237355	T/G	cg20040320	chr11:23191996	NA	-0.67	-5.77	-0.33	2.23e-8	Cancer;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22335246	chr12:120763591	PLA2G1B	-0.58	-6.74	-0.38	9.6e-11	Gut microbiome composition (summer);
CESC	cis	rs16854884	0.586	rs6782789	chr3:143746691	G/A	cg01302019	chr3:143689584	C3orf58	-0.32	-5.07	-0.3	7.32e-7	Economic and political preferences (feminism/equality);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03072483	chr17:78327711	RNF213;LOC100294362	-0.63	-7.12	-0.4	1.01e-11	Gut microbiome composition (summer);
CESC	cis	rs854765	0.655	rs4470201	chr17:17844870	G/A	cg16928487	chr17:17741425	SREBF1	-0.56	-9.73	-0.51	2.53e-19	Total body bone mineral density;
CESC	cis	rs7618501	0.633	rs3774733	chr3:50037123	C/G	cg24308560	chr3:49941425	MST1R	-0.63	-9.16	-0.49	1.5e-17	Intelligence (multi-trait analysis);
CESC	cis	rs7605378	0.528	rs1704190	chr2:200760629	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.49	5.41	0.32	1.43e-7	Osteoporosis;
CESC	cis	rs7605827	0.897	rs2890488	chr2:15635439	T/A	cg19274914	chr2:15703543	NA	0.37	6.64	0.38	1.76e-10	Educational attainment (years of education);
CESC	cis	rs4595586	0.545	rs17546375	chr12:39407248	C/A	cg13010199	chr12:38710504	ALG10B	0.43	5.44	0.32	1.19e-7	Morning vs. evening chronotype;
CESC	cis	rs8092503	1.000	rs12457718	chr18:52499626	T/C	cg12377874	chr18:52495404	RAB27B	0.37	6.11	0.35	3.62e-9	Childhood body mass index;
CESC	cis	rs8031584	0.958	rs7176569	chr15:31244495	G/T	cg14298792	chr15:30685198	CHRFAM7A	0.46	5.49	0.32	9.17e-8	Huntington's disease progression;
CESC	cis	rs4975709	0.610	rs4975704	chr5:1859807	C/A	cg17650747	chr5:1873721	NA	0.43	5.93	0.34	9.39e-9	Cardiovascular disease risk factors;
CESC	cis	rs778371	0.676	rs2293780	chr2:233635213	T/C	cg08000102	chr2:233561755	GIGYF2	0.84	14.64	0.67	5.94e-36	Schizophrenia;
CESC	cis	rs7727544	0.684	rs2516788	chr5:131715565	G/C	cg24060327	chr5:131705240	SLC22A5	0.64	8.51	0.46	1.29e-15	Blood metabolite levels;
CESC	cis	rs875971	1.000	rs778722	chr7:65844828	T/C	cg11764359	chr7:65958608	NA	0.98	15.79	0.7	4.82e-40	Aortic root size;
CESC	cis	rs28386778	0.863	rs3760252	chr17:61852186	G/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	9.97	0.52	4.41e-20	Prudent dietary pattern;
CESC	cis	rs6032067	0.777	rs62208416	chr20:43803226	G/A	cg10761708	chr20:43804764	PI3	0.56	6.61	0.38	2.15e-10	Blood protein levels;
CESC	cis	rs597539	0.690	rs497149	chr11:68626639	A/T	cg01988459	chr11:68622903	NA	-0.4	-5.23	-0.31	3.48e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg05313129	chr8:58192883	C8orf71	-0.48	-5.27	-0.31	2.89e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs11642862	1.000	rs112691371	chr16:30868216	C/T	cg02466173	chr16:30829666	NA	-0.6	-5.57	-0.32	6.36e-8	Tonsillectomy;
CESC	cis	rs7264396	0.887	rs224419	chr20:34143092	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.5	-6.31	-0.36	1.15e-9	Total cholesterol levels;
CESC	cis	rs2180341	0.618	rs4502958	chr6:127593113	G/A	cg27446573	chr6:127587934	RNF146	0.62	8.48	0.46	1.62e-15	Breast cancer;
CESC	cis	rs2303745	0.589	rs11882562	chr19:17395055	C/G	cg02221750	chr19:17393354	ANKLE1	0.51	6.09	0.35	3.9e-9	Systemic lupus erythematosus;
CESC	cis	rs9311474	0.508	rs11720159	chr3:52617802	T/G	cg17372223	chr3:52568218	NT5DC2	0.41	6.34	0.36	9.81e-10	Electroencephalogram traits;
CESC	cis	rs6062302	0.522	rs6090476	chr20:62248001	G/A	cg09650180	chr20:62225654	GMEB2	-0.82	-9.32	-0.5	4.63e-18	Glioblastoma;
CESC	cis	rs644799	1.000	rs651445	chr11:95539122	T/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.53	6.41	0.37	6.77e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs72781680	0.898	rs10490752	chr2:24025132	C/T	cg08917208	chr2:24149416	ATAD2B	0.95	8.71	0.47	3.45e-16	Lymphocyte counts;
CESC	cis	rs76878669	0.561	rs12416747	chr11:66135614	A/G	cg18002602	chr11:66138449	SLC29A2	0.4	6.68	0.38	1.42e-10	Educational attainment (years of education);
CESC	cis	rs597539	0.690	rs635529	chr11:68626294	C/T	cg01988459	chr11:68622903	NA	-0.4	-5.05	-0.3	8.4e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs13082711	0.522	rs6551192	chr3:27343376	C/T	cg02860705	chr3:27208620	NA	0.39	5.21	0.3	3.83e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
CESC	cis	rs9649213	0.555	rs34695842	chr7:97931062	G/T	cg00277769	chr7:97922759	BAIAP2L1	-0.33	-5.42	-0.32	1.31e-7	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs61931739	0.817	rs11053071	chr12:34201400	A/G	cg19457237	chr12:34500585	NA	-0.38	-5.47	-0.32	1.02e-7	Morning vs. evening chronotype;
CESC	cis	rs35110281	0.774	rs2838327	chr21:45018566	A/C	cg01579765	chr21:45077557	HSF2BP	-0.57	-9.91	-0.52	6.75e-20	Mean corpuscular volume;
CESC	cis	rs698833	0.886	rs6721675	chr2:44566027	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.54	6.73	0.38	1.04e-10	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06397424	chr16:15737279	NDE1;KIAA0430	-0.55	-6.32	-0.36	1.12e-9	Gut microbiome composition (summer);
CESC	cis	rs11997175	0.574	rs4520125	chr8:33648628	C/T	ch.8.33884649F	chr8:33765107	NA	0.65	8.33	0.46	4.44e-15	Body mass index;
CESC	cis	rs7216064	1.000	rs34872586	chr17:65863466	T/C	cg07042672	chr17:66097459	LOC651250	-0.54	-5.59	-0.32	5.61e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	cis	rs3106136	0.609	rs1876917	chr4:95099737	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.46	-6.23	-0.36	1.8e-9	Capecitabine sensitivity;
CESC	cis	rs3026101	0.671	rs3026144	chr17:5316680	G/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.41	5.27	0.31	2.84e-7	Body mass index;
CESC	cis	rs7084402	0.967	rs1593674	chr10:60291908	A/C	cg07615347	chr10:60278583	BICC1	0.6	9.41	0.5	2.54e-18	Refractive error;
CESC	cis	rs400736	0.729	rs1546846	chr1:8004259	C/T	cg25007680	chr1:8021821	PARK7	-0.56	-7.72	-0.43	2.44e-13	Response to antidepressants and depression;
CESC	cis	rs6674176	0.561	rs7161	chr1:44438974	A/G	cg12908607	chr1:44402522	ARTN	0.53	8.16	0.45	1.32e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	trans	rs1814175	0.817	rs4084376	chr11:49831160	T/C	cg03929089	chr4:120376271	NA	-0.91	-15.47	-0.69	6.65e-39	Height;
CESC	cis	rs6952808	1.000	rs6952808	chr7:1886535	C/G	cg05863683	chr7:1912471	MAD1L1	0.39	5.8	0.34	1.85e-8	Bipolar disorder and schizophrenia;
CESC	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg02071572	chr4:1403502	NA	0.37	5.48	0.32	1e-7	Longevity;
CESC	cis	rs10461617	0.617	rs1423623	chr5:56065575	A/G	cg12311346	chr5:56204834	C5orf35	0.56	7.21	0.41	5.79e-12	Type 2 diabetes;
CESC	cis	rs7923609	0.778	rs7075195	chr10:65050659	A/G	cg01631684	chr10:65280961	REEP3	-0.45	-5.64	-0.33	4.38e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs9611565	0.918	rs6002351	chr22:41757223	C/T	cg06481639	chr22:41940642	POLR3H	-0.45	-5.2	-0.3	3.93e-7	Vitiligo;
CESC	cis	rs5753037	0.543	rs140128	chr22:30150140	T/C	cg01021169	chr22:30184971	ASCC2	-0.55	-7.74	-0.43	2.14e-13	Type 1 diabetes;
CESC	cis	rs6540559	1.000	rs742215	chr1:209961023	A/T	cg22029157	chr1:209979665	IRF6	0.7	9.86	0.52	9.47e-20	Cleft lip with or without cleft palate;
CESC	cis	rs9910055	0.659	rs7216294	chr17:42251095	T/C	cg13607699	chr17:42295918	UBTF	0.56	7.21	0.4	5.91e-12	Total body bone mineral density;
CESC	cis	rs116988415	0.584	rs78707026	chr14:65249283	A/G	cg25083366	chr14:65239357	SPTB	0.66	5.14	0.3	5.23e-7	Daytime sleep phenotypes;
CESC	cis	rs7666738	0.791	rs11097601	chr4:98960103	C/T	cg17366294	chr4:99064904	C4orf37	0.6	8.52	0.46	1.2e-15	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg03188948	chr7:1209495	NA	0.42	5.28	0.31	2.67e-7	Longevity;Endometriosis;
CESC	trans	rs11098499	0.820	rs13122709	chr4:120555356	T/A	cg25214090	chr10:38739885	LOC399744	0.67	9.43	0.5	2.22e-18	Corneal astigmatism;
CESC	cis	rs7824557	0.675	rs2736265	chr8:11186674	A/G	cg21775007	chr8:11205619	TDH	0.52	7.71	0.43	2.52e-13	Retinal vascular caliber;
CESC	cis	rs7561273	0.586	rs9309225	chr2:24292863	T/C	cg20701182	chr2:24300061	SF3B14	0.45	6.03	0.35	5.41e-9	Quantitative traits;
CESC	cis	rs6141600	0.540	rs964786	chr20:34688491	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.43	-6.06	-0.35	4.74e-9	Height;Hip circumference;
CESC	cis	rs17818399	0.749	rs4142759	chr2:46783890	A/G	cg06386533	chr2:46925753	SOCS5	0.48	5.25	0.31	3.06e-7	Height;
CESC	trans	rs3780486	0.718	rs10971418	chr9:33122024	A/C	cg04842962	chr6:43655489	MRPS18A	-0.74	-9.19	-0.49	1.15e-17	IgG glycosylation;
CESC	cis	rs2034088	0.833	rs7219151	chr17:440497	G/A	cg13332499	chr17:408570	NA	0.5	8.84	0.48	1.38e-16	Hip circumference adjusted for BMI;
CESC	cis	rs7726839	0.540	rs72703092	chr5:599269	G/A	cg16447950	chr5:562315	NA	-0.6	-6.05	-0.35	4.91e-9	Obesity-related traits;
CESC	cis	rs7656342	0.686	rs10031303	chr4:9841690	A/T	cg00071950	chr4:10020882	SLC2A9	0.41	5.68	0.33	3.62e-8	Gut microbiota (bacterial taxa);
CESC	cis	rs11958404	0.860	rs6868830	chr5:157442187	T/C	cg05962755	chr5:157440814	NA	0.62	6.66	0.38	1.57e-10	IgG glycosylation;
CESC	cis	rs6967414	0.685	rs6944332	chr7:6758018	G/A	cg09896999	chr7:6746977	ZNF12	-0.52	-6.19	-0.36	2.31e-9	Hematocrit;Hemoglobin concentration;
CESC	trans	rs163030	0.870	rs335607	chr5:76746523	A/G	cg26150533	chr8:82396069	FABP4	-0.39	-6.0	-0.35	6.54e-9	Caudate nucleus volume;
CESC	cis	rs959260	0.920	rs4789187	chr17:73394784	A/G	cg12999837	chr17:73267436	MIF4GD	-0.52	-5.79	-0.34	1.98e-8	Systemic lupus erythematosus;
CESC	cis	rs2836974	0.666	rs1888487	chr21:40683259	A/G	cg11890956	chr21:40555474	PSMG1	-0.95	-14.89	-0.67	7.8e-37	Cognitive function;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21123656	chr7:99775134	STAG3;GPC2	0.55	6.02	0.35	5.92e-9	Gut microbiome composition (summer);
CESC	cis	rs6952808	0.630	rs10239050	chr7:2158390	A/G	cg04267008	chr7:1944627	MAD1L1	-0.52	-6.17	-0.35	2.48e-9	Bipolar disorder and schizophrenia;
CESC	cis	rs6460942	0.731	rs75994414	chr7:12307992	C/A	cg02935154	chr7:12443704	VWDE	-0.59	-5.9	-0.34	1.11e-8	Coronary artery disease;
CESC	cis	rs10504229	0.679	rs11783963	chr8:58130496	T/A	cg22535103	chr8:58192502	C8orf71	-0.8	-9.04	-0.49	3.38e-17	Developmental language disorder (linguistic errors);
CESC	cis	rs7666738	0.830	rs13139078	chr4:99020774	C/T	cg18180107	chr4:99064573	C4orf37	0.41	5.39	0.31	1.57e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs6723226	0.698	rs13409142	chr2:32666137	C/T	cg02381751	chr2:32503542	YIPF4	0.81	11.89	0.59	2.06e-26	Intelligence (multi-trait analysis);
CESC	cis	rs3125734	0.633	rs3765002	chr10:64006124	G/T	cg09941381	chr10:64027924	RTKN2	-0.31	-5.23	-0.31	3.39e-7	Rheumatoid arthritis;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27517717	chr19:2977389	TLE6	0.6	6.89	0.39	4.04e-11	Gut microbiome composition (summer);
CESC	cis	rs734999	0.545	rs6684865	chr1:2546229	A/G	cg18854424	chr1:2615690	NA	-0.35	-7.07	-0.4	1.38e-11	Ulcerative colitis;
CESC	cis	rs10170846	0.731	rs10180632	chr2:223526384	G/A	cg25565276	chr2:223520875	FARSB	0.5	6.98	0.39	2.39e-11	Schizophrenia (inflammation and infection response interaction);
CESC	cis	rs2290405	0.527	rs4690329	chr4:931385	T/A	cg04824913	chr4:887549	GAK	0.65	8.43	0.46	2.26e-15	Systemic sclerosis;
CESC	cis	rs7786808	0.552	rs896762	chr7:158182029	A/G	cg01191920	chr7:158217561	PTPRN2	0.31	5.09	0.3	6.67e-7	Obesity-related traits;
CESC	cis	rs6439153	0.967	rs12695512	chr3:128722082	T/G	cg25356066	chr3:128598488	ACAD9	0.53	6.92	0.39	3.33e-11	Pneumococcal bacteremia;
CESC	cis	rs698833	0.638	rs698785	chr2:44744389	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.41	5.05	0.3	8.09e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs4718428	0.672	rs36038499	chr7:66289615	A/G	cg18252515	chr7:66147081	NA	-0.47	-5.21	-0.3	3.85e-7	Corneal structure;
CESC	cis	rs6545883	0.860	rs6749226	chr2:61509783	G/A	cg15711740	chr2:61764176	XPO1	0.39	5.05	0.3	8.27e-7	Tuberculosis;
CESC	cis	rs7552404	1.000	rs4646961	chr1:76217169	G/A	cg10523679	chr1:76189770	ACADM	0.71	8.42	0.46	2.39e-15	Blood metabolite levels;Acylcarnitine levels;
CESC	trans	rs7618501	1.000	rs4855862	chr3:49748833	C/T	cg21659725	chr3:3221576	CRBN	-0.82	-13.57	-0.64	3.35e-32	Intelligence (multi-trait analysis);
CESC	cis	rs12410462	0.581	rs4329477	chr1:227552494	A/G	cg23173402	chr1:227635558	NA	-0.53	-5.12	-0.3	5.97e-7	Major depressive disorder;
CESC	cis	rs7666738	0.830	rs13145011	chr4:98993410	G/A	cg18180107	chr4:99064573	C4orf37	0.4	5.23	0.31	3.41e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs10781543	0.776	rs4378078	chr9:139375962	A/G	cg14169450	chr9:139327907	INPP5E	0.52	8.0	0.44	4e-14	Monocyte percentage of white cells;
CESC	cis	rs1707322	0.963	rs9787412	chr1:46371596	C/T	cg03146154	chr1:46216737	IPP	0.71	9.86	0.52	9.69e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs11677416	0.677	rs2856840	chr2:113538604	T/A	cg27083787	chr2:113543245	IL1A	0.41	5.17	0.3	4.65e-7	Response to antipsychotic treatment in schizophrenia (working memory);
CESC	cis	rs2070433	0.539	rs56157650	chr21:47957959	T/C	cg12379764	chr21:47803548	PCNT	0.65	8.45	0.46	1.9e-15	Lymphocyte counts;
CESC	cis	rs2576037	0.583	rs11659693	chr18:44458733	C/T	cg19077165	chr18:44547161	KATNAL2	-0.61	-9.33	-0.5	4.26e-18	Personality dimensions;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg10341310	chr8:66582206	MTFR1	0.51	7.29	0.41	3.51e-12	Fibrinogen levels;
CESC	cis	rs1185460	0.967	rs3825061	chr11:118944675	C/T	cg23280166	chr11:118938394	VPS11	0.5	6.37	0.36	8.42e-10	Coronary artery disease;
CESC	cis	rs10911232	0.507	rs4652769	chr1:183009196	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.87	13.67	0.64	1.52e-32	Hypertriglyceridemia;
CESC	cis	rs561341	1.000	rs7214017	chr17:30332220	T/C	cg19193384	chr17:30244184	NA	-0.61	-6.47	-0.37	4.74e-10	Hip circumference adjusted for BMI;
CESC	cis	rs11098499	1.000	rs10029750	chr4:120172543	A/G	cg09307838	chr4:120376055	NA	0.86	11.44	0.58	6.63e-25	Corneal astigmatism;
CESC	cis	rs35306767	0.903	rs13377166	chr10:886259	G/A	cg20503657	chr10:835505	NA	0.79	7.96	0.44	4.97e-14	Eosinophil percentage of granulocytes;
CESC	cis	rs5758659	0.652	rs133321	chr22:42405322	A/G	cg15557168	chr22:42548783	NA	-0.42	-6.27	-0.36	1.48e-9	Cognitive function;
CESC	trans	rs2727020	0.521	rs7107178	chr11:49526668	G/A	cg15704280	chr7:45808275	SEPT13	0.81	9.79	0.52	1.63e-19	Coronary artery disease;
CESC	cis	rs7188697	0.848	rs40187	chr16:58556566	T/C	cg21335942	chr16:58549945	SETD6	0.47	5.49	0.32	9.38e-8	QT interval;
CESC	cis	rs798554	1.000	rs798544	chr7:2763102	A/G	cg18446336	chr7:2847575	GNA12	0.4	6.2	0.36	2.17e-9	Height;
CESC	cis	rs7662987	0.517	rs1377689	chr4:100021787	A/G	cg12011299	chr4:100065546	ADH4	0.6	6.6	0.38	2.23e-10	Smoking initiation;
CESC	cis	rs875971	1.000	rs6958277	chr7:65979349	A/G	cg11764359	chr7:65958608	NA	0.94	14.51	0.67	1.69e-35	Aortic root size;
CESC	cis	rs7264396	0.676	rs6058380	chr20:34552900	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.77	-10.23	-0.53	6.44e-21	Total cholesterol levels;
CESC	cis	rs36051895	0.664	rs10117501	chr9:5094246	G/A	cg02405213	chr9:5042618	JAK2	-0.49	-6.02	-0.35	5.79e-9	Pediatric autoimmune diseases;
CESC	cis	rs7605827	0.930	rs10929373	chr2:15663317	T/C	cg19274914	chr2:15703543	NA	0.32	5.72	0.33	2.84e-8	Educational attainment (years of education);
CESC	cis	rs2204008	0.837	rs11183232	chr12:37941053	A/G	cg26384229	chr12:38710491	ALG10B	0.67	9.77	0.51	1.9e-19	Bladder cancer;
CESC	cis	rs11683229	0.704	rs35589581	chr2:63107944	T/C	cg17519650	chr2:63277830	OTX1	-0.68	-5.55	-0.32	6.94e-8	Protein quantitative trait loci;
CESC	cis	rs1348850	0.554	rs11679519	chr2:178432110	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.6	6.33	0.36	1.07e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg11965913	chr1:205819406	PM20D1	0.87	15.78	0.7	5.31e-40	Menarche (age at onset);
CESC	cis	rs3091242	0.933	rs12402120	chr1:25751632	C/T	cg02931644	chr1:25747376	RHCE	0.42	6.91	0.39	3.7e-11	Erythrocyte sedimentation rate;
CESC	cis	rs1008375	0.932	rs9884565	chr4:17655096	A/G	cg16339924	chr4:17578868	LAP3	0.63	8.03	0.44	3.2e-14	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs61931739	0.817	rs1705754	chr12:34145569	A/G	cg19457237	chr12:34500585	NA	-0.37	-5.15	-0.3	5.06e-7	Morning vs. evening chronotype;
CESC	cis	rs6951245	0.872	rs57068908	chr7:1060084	A/C	cg00431813	chr7:1051703	C7orf50	0.43	5.34	0.31	1.98e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs78132593	0.718	rs72702521	chr1:150650194	C/T	cg04414720	chr1:150670196	GOLPH3L	-0.52	-5.24	-0.31	3.31e-7	High light scatter reticulocyte count;
CESC	cis	rs1799949	1.000	rs8176077	chr17:41276348	T/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.45	6.3	0.36	1.21e-9	Menopause (age at onset);
CESC	cis	rs1799949	1.000	rs3092988	chr17:41201702	C/T	cg23758822	chr17:41437982	NA	1.01	14.72	0.67	2.92e-36	Menopause (age at onset);
CESC	cis	rs6502050	0.835	rs7219138	chr17:80079896	C/T	cg11859384	chr17:80120422	CCDC57	0.38	5.15	0.3	5.1e-7	Life satisfaction;
CESC	cis	rs9399401	0.667	rs6903424	chr6:142699948	A/C	cg03128060	chr6:142623767	GPR126	0.33	5.9	0.34	1.08e-8	Chronic obstructive pulmonary disease;
CESC	trans	rs9929218	0.954	rs57688464	chr16:68826109	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.63	-8.27	-0.45	6.69e-15	Colorectal cancer;
CESC	cis	rs3931020	0.548	rs17618340	chr1:75247617	G/A	cg10128416	chr1:75198403	TYW3;CRYZ	0.48	6.3	0.36	1.23e-9	Resistin levels;
CESC	cis	rs3858526	0.523	rs10838749	chr11:5884246	A/G	cg13902645	chr11:5959945	NA	-0.64	-9.15	-0.49	1.61e-17	DNA methylation (variation);
CESC	cis	rs1799949	0.965	rs8176310	chr17:41199913	T/C	cg23758822	chr17:41437982	NA	0.95	16.4	0.71	3.22e-42	Menopause (age at onset);
CESC	cis	rs7772486	0.817	rs9322047	chr6:146400394	G/A	cg23711669	chr6:146136114	FBXO30	0.82	12.42	0.61	3.29e-28	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7827545	1.000	rs6578238	chr8:135569490	A/C	cg17885191	chr8:135476712	NA	0.45	5.83	0.34	1.62e-8	Hypertension (SNP x SNP interaction);
CESC	trans	rs6981523	0.553	rs11783045	chr8:11056175	A/G	cg06636001	chr8:8085503	FLJ10661	-0.52	-6.14	-0.35	3.02e-9	Neuroticism;
CESC	trans	rs1814175	0.645	rs10839456	chr11:49964093	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.41	-6.15	-0.35	2.82e-9	Height;
CESC	cis	rs920590	0.527	rs79929516	chr8:19650050	G/C	cg01411142	chr8:19674711	INTS10	0.59	5.93	0.34	9.53e-9	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs11247915	0.561	rs11583258	chr1:26624270	C/T	cg04990556	chr1:26633338	UBXN11	-0.62	-6.83	-0.39	5.7e-11	Obesity-related traits;
CESC	cis	rs2228479	0.850	rs17226428	chr16:89842884	T/A	cg00800038	chr16:89945340	TCF25	-0.91	-7.57	-0.42	6.35e-13	Skin colour saturation;
CESC	trans	rs330048	0.561	rs1825100	chr8:9146270	C/T	cg15556689	chr8:8085844	FLJ10661	-0.61	-7.16	-0.4	7.77e-12	Systemic lupus erythematosus;
CESC	cis	rs9309473	0.500	rs4852308	chr2:73834035	T/G	cg20560298	chr2:73613845	ALMS1	0.48	6.83	0.39	5.88e-11	Metabolite levels;
CESC	cis	rs780096	0.526	rs780106	chr2:27681598	A/C	cg12648201	chr2:27665141	KRTCAP3	-0.35	-6.56	-0.37	2.79e-10	Total body bone mineral density;
CESC	cis	rs8008758	0.517	rs1620117	chr14:101696931	C/A	cg26224664	chr14:101693935	NA	-0.47	-8.69	-0.47	3.95e-16	Body mass index (alcohol intake interaction);
CESC	cis	rs4919694	1.000	rs78214351	chr10:104822688	A/G	cg04362960	chr10:104952993	NT5C2	0.79	7.08	0.4	1.27e-11	Arsenic metabolism;
CESC	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg07677032	chr17:61819896	STRADA	0.49	6.27	0.36	1.49e-9	Prudent dietary pattern;
CESC	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg24846343	chr22:24311635	DDTL	0.74	13.62	0.64	2.18e-32	Liver enzyme levels (gamma-glutamyl transferase);
CESC	cis	rs9916302	0.706	rs6503521	chr17:37715551	A/C	cg07936489	chr17:37558343	FBXL20	0.87	9.23	0.49	8.8e-18	Glomerular filtration rate (creatinine);
CESC	cis	rs8070740	0.898	rs4605225	chr17:5324136	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.51	6.35	0.36	9.3e-10	Menopause (age at onset);
CESC	cis	rs9359856	0.564	rs36040566	chr6:90372574	A/C	cg13799429	chr6:90582589	CASP8AP2	-0.62	-5.7	-0.33	3.12e-8	Bipolar disorder;
CESC	cis	rs6500602	0.609	rs7202910	chr16:4518948	T/A	cg08645402	chr16:4508243	NA	0.42	5.95	0.34	8.46e-9	Schizophrenia;
CESC	cis	rs1847202	0.563	rs13095184	chr3:72951008	A/G	cg10804678	chr3:72788309	NA	-0.41	-5.38	-0.31	1.63e-7	Motion sickness;
CESC	cis	rs7940866	0.838	rs1991898	chr11:130801786	C/G	cg12179176	chr11:130786555	SNX19	-0.62	-9.67	-0.51	3.89e-19	Schizophrenia;
CESC	cis	rs28386778	0.669	rs12603821	chr17:62006432	G/A	cg11494091	chr17:61959527	GH2	-0.79	-13.94	-0.65	1.7e-33	Prudent dietary pattern;
CESC	cis	rs7618915	0.621	rs6788993	chr3:52605136	T/C	cg07507251	chr3:52567010	NT5DC2	0.33	5.67	0.33	3.7e-8	Bipolar disorder;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19250764	chr7:66461952	TYW1;SBDS	0.55	6.42	0.37	6.25e-10	Gut microbiome composition (summer);
CESC	cis	rs769267	0.965	rs12460764	chr19:19431963	G/T	cg17414380	chr19:19431394	KIAA0892;SF4	-0.46	-5.69	-0.33	3.45e-8	Tonsillectomy;
CESC	cis	rs12458462	0.509	rs3786241	chr18:77494328	A/C	cg23301140	chr18:77439876	CTDP1	0.39	5.12	0.3	5.77e-7	Monocyte count;
CESC	trans	rs35883536	1.000	rs4907921	chr1:101128249	C/T	cg16931499	chr17:42786676	DBF4B	0.41	6.01	0.35	6.07e-9	Monocyte count;
CESC	cis	rs561341	0.941	rs112569713	chr17:30271738	C/T	cg19193384	chr17:30244184	NA	-0.64	-6.73	-0.38	1.07e-10	Hip circumference adjusted for BMI;
CESC	cis	rs1832871	0.683	rs9457224	chr6:158666139	C/T	cg07165851	chr6:158734300	TULP4	0.6	6.41	0.37	6.66e-10	Height;
CESC	cis	rs4727027	0.833	rs2107846	chr7:148832774	G/A	cg23158103	chr7:148848205	ZNF398	-0.43	-7.01	-0.4	1.95e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
CESC	cis	rs875971	1.000	rs1144895	chr7:65541307	C/G	cg10691866	chr7:65817282	TPST1	0.33	5.27	0.31	2.85e-7	Aortic root size;
CESC	cis	rs35110281	0.774	rs1003280	chr21:44997322	A/G	cg21573476	chr21:45109991	RRP1B	-0.41	-5.72	-0.33	2.85e-8	Mean corpuscular volume;
CESC	cis	rs28374715	0.532	rs316604	chr15:41775221	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.06	-17.26	-0.73	2.96e-45	Ulcerative colitis;
CESC	cis	rs11864453	0.647	rs3852781	chr16:72123556	T/A	cg16558253	chr16:72132732	DHX38	-0.55	-8.54	-0.46	1.08e-15	Fibrinogen levels;
CESC	cis	rs6089829	0.855	rs6062781	chr20:61667128	G/A	cg08564027	chr20:61660810	NA	0.9	15.37	0.69	1.54e-38	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs2228479	0.557	rs12933317	chr16:89828220	A/G	cg00800038	chr16:89945340	TCF25	-0.89	-7.33	-0.41	2.79e-12	Skin colour saturation;
CESC	cis	rs4713118	0.621	rs4713133	chr6:28034041	T/C	cg17949981	chr6:28129498	ZNF389	0.42	5.2	0.3	3.96e-7	Parkinson's disease;
CESC	cis	rs9614461	0.702	rs2294202	chr22:45738327	A/T	cg15911859	chr22:45810043	RIBC2;SMC1B	0.64	6.93	0.39	3.2e-11	Tonsillectomy;
CESC	cis	rs11690935	0.527	rs7586556	chr2:172901887	G/C	cg13550731	chr2:172543902	DYNC1I2	0.47	6.24	0.36	1.75e-9	Schizophrenia;
CESC	cis	rs17253792	0.822	rs10483643	chr14:56089931	G/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.79	5.91	0.34	1.06e-8	Putamen volume;
CESC	cis	rs6460942	0.841	rs17444203	chr7:12461864	C/G	cg17427002	chr7:12443146	VWDE	0.5	5.71	0.33	2.98e-8	Coronary artery disease;
CESC	cis	rs5758511	0.680	rs739147	chr22:42671066	T/G	cg00645731	chr22:42541494	CYP2D7P1	0.58	8.7	0.47	3.59e-16	Birth weight;
CESC	cis	rs9581857	0.547	rs9581869	chr13:28082498	G/A	cg01674679	chr13:27998804	GTF3A	-0.63	-5.1	-0.3	6.52e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
CESC	cis	rs7208859	0.573	rs11656121	chr17:29214043	A/G	cg19761014	chr17:28927070	LRRC37B2	0.63	5.31	0.31	2.38e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23162967	chr3:105587981	CBLB	0.58	6.57	0.37	2.6200000000000003e-10	Gut microbiome composition (summer);
CESC	cis	rs7551222	0.752	rs885012	chr1:204544001	C/A	cg20240347	chr1:204465584	NA	-0.28	-5.67	-0.33	3.82e-8	Schizophrenia;
CESC	cis	rs2304069	0.954	rs10045945	chr5:149419297	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.93	12.0	0.59	8.6e-27	HIV-1 control;
CESC	cis	rs916888	0.773	rs199448	chr17:44809001	A/G	cg15921436	chr17:44337874	NA	0.74	8.11	0.45	1.84e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs9914988	0.943	rs9303621	chr17:27161138	A/G	cg20469991	chr17:27169893	C17orf63	-0.48	-5.21	-0.3	3.82e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CESC	cis	rs875971	0.862	rs4718377	chr7:66049678	C/T	cg19163074	chr7:65112434	INTS4L2	0.42	5.25	0.31	3.16e-7	Aortic root size;
CESC	cis	rs9611565	0.694	rs202664	chr22:41813886	C/T	cg03806693	chr22:41940476	POLR3H	1.15	14.69	0.67	3.71e-36	Vitiligo;
CESC	cis	rs2228479	0.850	rs2302162	chr16:89845287	A/G	cg14709524	chr16:89940631	TCF25	0.91	6.76	0.38	8.75e-11	Skin colour saturation;
CESC	cis	rs9925964	0.591	rs11649653	chr16:30918487	C/G	cg02466173	chr16:30829666	NA	0.36	5.5	0.32	8.78e-8	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs397969	0.646	rs1638527	chr17:19845393	A/G	cg12073167	chr17:19770448	ULK2	0.46	5.46	0.32	1.12e-7	Platelet count;
CESC	cis	rs60012524	1	rs60012524	chr2:99559117	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.65	-7.67	-0.43	3.25e-13	Chronic sinus infection;
CESC	cis	rs2479724	0.846	rs2251084	chr6:41838119	T/C	cg17623882	chr6:41773611	USP49	-0.41	-5.83	-0.34	1.58e-8	Menarche (age at onset);
CESC	cis	rs780096	0.546	rs2911712	chr2:27626945	A/T	cg12648201	chr2:27665141	KRTCAP3	-0.34	-6.29	-0.36	1.34e-9	Total body bone mineral density;
CESC	cis	rs7692995	1.000	rs7695840	chr4:17962379	A/G	cg08925142	chr4:18023851	LCORL	-0.45	-5.13	-0.3	5.66e-7	Height;
CESC	cis	rs1707322	0.964	rs785508	chr1:46527159	G/A	cg06784218	chr1:46089804	CCDC17	-0.35	-5.9	-0.34	1.11e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs910316	0.763	rs175016	chr14:75459633	C/T	cg16144293	chr14:75469539	EIF2B2	0.41	5.44	0.32	1.2e-7	Height;
CESC	cis	rs9611565	0.506	rs1883825	chr22:41703408	A/G	cg03806693	chr22:41940476	POLR3H	-0.73	-8.54	-0.46	1.06e-15	Vitiligo;
CESC	cis	rs17209837	1.000	rs45526438	chr7:87089927	G/A	cg00919237	chr7:87102261	ABCB4	-0.53	-6.03	-0.35	5.36e-9	Gallbladder cancer;
CESC	cis	rs3096299	0.719	rs2965817	chr16:89513234	C/T	cg02034447	chr16:89574710	SPG7	0.47	6.06	0.35	4.56e-9	Multiple myeloma (IgH translocation);
CESC	trans	rs4674842	0.637	rs4674862	chr2:224923426	A/T	cg05748497	chr7:156804268	MNX1	-0.5	-6.49	-0.37	4.28e-10	Cerebrospinal T-tau levels;
CESC	cis	rs1062177	1.000	rs12515762	chr5:151209922	G/T	cg00977110	chr5:151150581	G3BP1	0.63	6.72	0.38	1.12e-10	Preschool internalizing problems;
CESC	cis	rs12477438	0.684	rs6756880	chr2:99676991	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.64	-8.73	-0.47	2.94e-16	Chronic sinus infection;
CESC	cis	rs6540556	0.723	rs1999826	chr1:209919275	C/T	cg23920097	chr1:209922102	NA	-0.38	-5.33	-0.31	2.06e-7	Red blood cell count;
CESC	cis	rs1799949	1.000	rs33926631	chr17:41304463	T/C	cg05368731	chr17:41323189	NBR1	0.79	11.2	0.57	4.42e-24	Menopause (age at onset);
CESC	cis	rs2072499	0.695	rs112223391	chr1:156156094	G/A	cg24450063	chr1:156163899	SLC25A44	0.98	12.06	0.6	5.65e-27	Testicular germ cell tumor;
CESC	cis	rs8114671	0.562	rs2076667	chr20:33506964	G/A	cg24642439	chr20:33292090	TP53INP2	0.43	5.19	0.3	4.19e-7	Height;
CESC	cis	rs3768617	0.811	rs10911232	chr1:183052533	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.63	8.88	0.48	1.02e-16	Fuchs's corneal dystrophy;
CESC	cis	rs4969178	0.965	rs12450528	chr17:76395753	G/A	cg20026190	chr17:76395443	PGS1	0.49	7.81	0.43	1.34e-13	HDL cholesterol levels;
CESC	cis	rs929596	0.517	rs3806592	chr2:234625936	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.55	-7.09	-0.4	1.24e-11	Total bilirubin levels in HIV-1 infection;
CESC	cis	rs10883723	0.810	rs10748824	chr10:104274466	T/C	ch.10.2196322F	chr10:104248062	ACTR1A	0.42	5.16	0.3	4.76e-7	Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs4780401	0.632	rs8055462	chr16:11834821	T/C	cg01061890	chr16:11836724	TXNDC11	-0.58	-7.71	-0.43	2.6e-13	Rheumatoid arthritis;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg20546810	chr20:2489835	ZNF343	-0.52	-6.76	-0.38	8.98e-11	Fibrinogen levels;
CESC	cis	rs7103648	0.864	rs12801188	chr11:47388214	G/A	cg03711944	chr11:47377212	SPI1	-0.39	-6.09	-0.35	3.9e-9	Diastolic blood pressure;Systolic blood pressure;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02798621	chr6:82462430	FAM46A	-0.53	-6.14	-0.35	3.03e-9	Gut microbiome composition (summer);
CESC	cis	rs6570726	0.935	rs12663204	chr6:145818373	G/A	cg05347473	chr6:146136440	FBXO30	0.49	6.71	0.38	1.2e-10	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs7264396	0.563	rs6058302	chr20:34290037	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.89	-10.78	-0.55	1.03e-22	Total cholesterol levels;
CESC	cis	rs7811142	1.000	rs1000215	chr7:100004543	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.07	13.64	0.64	1.95e-32	Platelet count;
CESC	cis	rs2108622	0.727	rs77780918	chr19:15982707	T/C	cg13772218	chr19:15982569	NA	0.29	5.8	0.34	1.85e-8	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
CESC	cis	rs10504229	0.636	rs72649133	chr8:58054681	G/A	cg02725872	chr8:58115012	NA	-0.42	-5.64	-0.33	4.38e-8	Developmental language disorder (linguistic errors);
CESC	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg09747230	chr5:43613142	NNT	-0.51	-6.81	-0.39	6.44e-11	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs9611519	0.780	rs1535048	chr22:41684093	C/T	cg03806693	chr22:41940476	POLR3H	-0.72	-8.24	-0.45	8.26e-15	Neuroticism;
CESC	cis	rs854765	0.583	rs8080823	chr17:17864048	T/C	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.49	6.22	0.36	1.97e-9	Total body bone mineral density;
CESC	cis	rs7914558	1.000	rs1890184	chr10:104748459	A/C	cg04362960	chr10:104952993	NT5C2	0.47	6.24	0.36	1.77e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
CESC	cis	rs9916302	0.904	rs9898170	chr17:37510092	T/C	cg20243544	chr17:37824526	PNMT	-0.47	-5.74	-0.33	2.54e-8	Glomerular filtration rate (creatinine);
CESC	cis	rs4971059	0.654	rs12028043	chr1:155132836	A/G	cg22049894	chr1:155113146	DPM3	0.48	6.07	0.35	4.32e-9	Breast cancer;
CESC	cis	rs28386778	0.700	rs12449555	chr17:62003982	T/A	cg22520471	chr17:61851767	DDX42;CCDC47	-0.83	-11.64	-0.58	1.48e-25	Prudent dietary pattern;
CESC	cis	rs9902453	0.904	rs7212292	chr17:28409264	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.68	-8.81	-0.48	1.72e-16	Coffee consumption (cups per day);
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg14950044	chr20:49457327	BCAS4	-0.51	-6.9	-0.39	3.85e-11	Gut microbiota (bacterial taxa);
CESC	cis	rs7943191	0.810	rs7942991	chr11:62337203	A/G	cg13298116	chr11:62369859	EML3;MTA2	-0.52	-7.55	-0.42	7.15e-13	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
CESC	cis	rs684232	0.623	rs417171	chr17:576941	A/G	cg12384639	chr17:618140	VPS53	0.41	5.27	0.31	2.81e-7	Prostate cancer;
CESC	cis	rs9914988	0.943	rs7211502	chr17:27163295	C/A	cg20469991	chr17:27169893	C17orf63	-0.48	-5.21	-0.3	3.82e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
CESC	cis	rs780096	0.526	rs1647266	chr2:27693485	T/C	cg21248554	chr2:27665150	KRTCAP3	-0.36	-7.38	-0.41	2.02e-12	Total body bone mineral density;
CESC	cis	rs514406	0.861	rs554760	chr1:53266749	G/A	cg24675658	chr1:53192096	ZYG11B	0.56	6.99	0.39	2.2e-11	Monocyte count;
CESC	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.7	9.72	0.51	2.66e-19	Prudent dietary pattern;
CESC	cis	rs2836950	0.565	rs3171465	chr21:40552307	A/G	cg17971929	chr21:40555470	PSMG1	-0.53	-6.94	-0.39	3.08e-11	Menarche (age at onset);
CESC	cis	rs7843479	0.930	rs2054713	chr8:21840534	A/G	cg17168535	chr8:21777572	XPO7	0.52	7.25	0.41	4.55e-12	Mean corpuscular volume;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06391762	chr17:46908391	CALCOCO2	0.57	6.57	0.37	2.71e-10	Gut microbiome composition (summer);
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg05947499	chr12:113704091	TPCN1	0.49	6.4	0.37	7.11e-10	Fibrinogen levels;
CESC	trans	rs17039065	0.920	rs11737760	chr4:109441230	A/G	cg27151770	chr16:49620536	ZNF423	-0.51	-6.21	-0.36	2.09e-9	Gut microbiome composition (summer);
CESC	cis	rs8062405	1.000	rs62037367	chr16:28874547	C/G	cg08761264	chr16:28874980	SH2B1	-0.47	-5.85	-0.34	1.42e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
CESC	cis	rs4148883	0.628	rs34195655	chr4:100073795	C/T	cg12011299	chr4:100065546	ADH4	0.67	9.97	0.52	4.3e-20	Alcohol dependence;
CESC	trans	rs3942852	0.568	rs10838800	chr11:48094879	C/T	cg15704280	chr7:45808275	SEPT13	-0.73	-9.55	-0.51	9.45e-19	Acute lymphoblastic leukemia (childhood);
CESC	cis	rs10504229	0.689	rs17801390	chr8:58054768	T/C	cg24829409	chr8:58192753	C8orf71	-0.64	-7.2	-0.4	6.25e-12	Developmental language disorder (linguistic errors);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17928916	chr17:80041824	FASN	-0.55	-6.23	-0.36	1.87e-9	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00871979	chr18:11982063	IMPA2	-0.58	-6.38	-0.36	7.65e-10	Gut microbiome composition (summer);
CESC	cis	rs7552404	1.000	rs72686191	chr1:76218319	G/T	cg03433033	chr1:76189801	ACADM	0.64	7.42	0.41	1.54e-12	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs1475911	0.708	rs66994219	chr21:43521647	G/A	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.45	-6.85	-0.39	5.27e-11	IgG glycosylation;
CESC	cis	rs7615952	0.599	rs6803160	chr3:125709554	G/T	cg04553112	chr3:125709451	NA	-0.51	-5.59	-0.33	5.51e-8	Blood pressure (smoking interaction);
CESC	cis	rs644799	0.544	rs525087	chr11:95632266	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.51	6.73	0.38	1.03e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs7809950	0.678	rs17153981	chr7:106922106	A/G	cg23024343	chr7:107201750	COG5	-0.53	-6.69	-0.38	1.3e-10	Coronary artery disease;
CESC	cis	rs3820068	0.581	rs6692461	chr1:15928449	A/G	cg16988262	chr1:15930761	NA	0.33	5.35	0.31	1.89e-7	Systolic blood pressure;
CESC	cis	rs3747547	0.685	rs72726067	chr9:38099153	G/A	cg13774184	chr9:37916125	SHB	-0.61	-5.05	-0.3	8.06e-7	Metabolite levels (Dihydroxy docosatrienoic acid);
CESC	cis	rs2299587	0.554	rs3853531	chr8:17748920	C/T	cg08627089	chr8:17753878	FGL1	0.41	5.78	0.33	2.07e-8	Economic and political preferences;
CESC	cis	rs4253772	0.872	rs45576734	chr22:46638365	A/G	cg00784671	chr22:46762841	CELSR1	-0.51	-5.27	-0.31	2.87e-7	LDL cholesterol;Cholesterol, total;
CESC	cis	rs8067545	0.532	rs56371654	chr17:19960362	G/T	cg12073167	chr17:19770448	ULK2	-0.43	-5.11	-0.3	6.19e-7	Schizophrenia;
CESC	cis	rs17826219	0.568	rs9903854	chr17:29153998	C/T	cg13385521	chr17:29058706	SUZ12P	0.75	5.95	0.34	8.3e-9	Body mass index;
CESC	cis	rs9287719	0.649	rs7589694	chr2:10700874	T/C	cg00105475	chr2:10696890	NA	0.39	5.37	0.31	1.74e-7	Prostate cancer;
CESC	cis	rs9611565	0.512	rs139571	chr22:42214238	G/A	cg17376030	chr22:41985996	PMM1	0.79	8.24	0.45	7.8e-15	Vitiligo;
CESC	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg11288833	chr15:55489084	RSL24D1	0.45	6.33	0.36	1.03e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
CESC	cis	rs6088580	0.634	rs4277599	chr20:33008905	A/G	cg06115741	chr20:33292138	TP53INP2	-0.51	-6.98	-0.39	2.43e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs1003719	0.788	rs2835592	chr21:38464387	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.63	8.77	0.47	2.14e-16	Eye color traits;
CESC	cis	rs344364	0.511	rs12596510	chr16:1949480	G/A	cg26617929	chr16:1858877	NA	-0.49	-5.15	-0.3	5.09e-7	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs6835098	0.816	rs13111572	chr4:174159788	G/A	cg08422745	chr4:174089978	GALNT7	0.77	10.33	0.54	2.99e-21	Dementia and core Alzheimer's disease neuropathologic changes;
CESC	cis	rs4555082	0.874	rs2816612	chr14:105723103	C/T	cg27165867	chr14:105738592	BRF1	-0.52	-5.66	-0.33	3.92e-8	Mean platelet volume;Platelet distribution width;
CESC	cis	rs11864453	0.647	rs3852781	chr16:72123556	T/A	cg01557791	chr16:72042693	DHODH	-0.43	-5.57	-0.32	6.39e-8	Fibrinogen levels;
CESC	cis	rs2549003	0.966	rs10065633	chr5:131816716	T/C	cg21138405	chr5:131827807	IRF1	0.54	9.24	0.49	8.12e-18	Asthma (sex interaction);
CESC	cis	rs2204008	0.774	rs11495721	chr12:38337224	A/C	cg13010199	chr12:38710504	ALG10B	0.45	5.79	0.34	1.95e-8	Bladder cancer;
CESC	cis	rs11098499	0.863	rs1480939	chr4:120456927	T/C	cg24375607	chr4:120327624	NA	0.43	5.21	0.3	3.82e-7	Corneal astigmatism;
CESC	cis	rs34421088	0.678	rs35726503	chr8:11591916	A/T	cg12395012	chr8:11607386	GATA4	0.39	5.78	0.33	2.05e-8	Neuroticism;
CESC	cis	rs514406	0.667	rs10788942	chr1:53210521	A/T	cg25767906	chr1:53392781	SCP2	0.42	5.73	0.33	2.66e-8	Monocyte count;
CESC	cis	rs826838	1.000	rs826891	chr12:39100824	A/G	cg26384229	chr12:38710491	ALG10B	-0.62	-9.93	-0.52	5.65e-20	Heart rate;
CESC	cis	rs8044868	0.530	rs12446480	chr16:72056757	A/G	cg16558253	chr16:72132732	DHX38	-0.36	-5.48	-0.32	1.01e-7	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
CESC	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg03647317	chr4:187891568	NA	-0.38	-5.33	-0.31	2.09e-7	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6598163	0.700	rs12813179	chr12:132302228	C/G	cg02426739	chr12:132285352	NA	0.39	5.16	0.3	4.94e-7	Migraine;
CESC	cis	rs3892630	0.588	rs7245709	chr19:33242755	C/T	cg13157960	chr19:33183277	NUDT19	0.53	5.33	0.31	2.09e-7	Red blood cell traits;
CESC	cis	rs1862618	0.853	rs252904	chr5:56118733	A/T	cg22800045	chr5:56110881	MAP3K1	0.81	9.86	0.52	9.81e-20	Initial pursuit acceleration;
CESC	cis	rs4460629	0.742	rs4625273	chr1:155076043	C/T	cg01019262	chr1:155095195	NA	-0.3	-5.05	-0.3	8.42e-7	Serum magnesium levels;
CESC	cis	rs13102973	0.965	rs28799927	chr4:135867094	A/G	cg14419869	chr4:135874104	NA	-0.4	-6.29	-0.36	1.32e-9	Subjective well-being;
CESC	cis	rs9649465	1.000	rs7776792	chr7:123335350	C/T	cg04330084	chr7:123175371	IQUB	0.38	5.2	0.3	4.04e-7	Migraine;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg13180005	chr1:182360683	GLUL	-0.52	-6.47	-0.37	4.7e-10	Ulcerative colitis;
CESC	trans	rs7246760	0.618	rs73008109	chr19:9734056	C/T	cg02900749	chr2:68251473	NA	-0.8	-6.18	-0.35	2.43e-9	Pursuit maintenance gain;
CESC	cis	rs3733585	0.648	rs7376155	chr4:9952588	C/T	cg00071950	chr4:10020882	SLC2A9	-0.69	-11.34	-0.57	1.42e-24	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs7589728	0.514	rs12465706	chr2:88467459	C/A	cg18490616	chr2:88469792	THNSL2	0.56	5.38	0.31	1.64e-7	Plasma clusterin levels;
CESC	cis	rs3008870	0.755	rs2815368	chr1:67500778	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.6	7.97	0.44	4.75e-14	Lymphocyte percentage of white cells;
CESC	cis	rs11958404	0.546	rs6556332	chr5:157433684	A/G	cg05962755	chr5:157440814	NA	0.39	5.69	0.33	3.39e-8	IgG glycosylation;
CESC	cis	rs5760092	0.755	rs915589	chr22:24261004	C/T	cg23131131	chr22:24373011	LOC391322	0.66	7.56	0.42	6.72e-13	Urinary 1,3-butadiene metabolite levels in smokers;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13009927	chr2:242254519	SEPT2;HDLBP	0.58	7.12	0.4	1.03e-11	Gut microbiome composition (summer);
CESC	cis	rs3820928	0.605	rs7560867	chr2:227780945	C/A	cg05526886	chr2:227700861	RHBDD1	-0.55	-7.59	-0.42	5.42e-13	Pulmonary function;
CESC	cis	rs10078	1.000	rs10078	chr5:438102	G/T	cg08916839	chr5:415575	AHRR	0.41	5.42	0.32	1.34e-7	Fat distribution (HIV);
CESC	cis	rs2742234	0.868	rs2505512	chr10:43633596	G/A	cg15436174	chr10:43711423	RASGEF1A	-0.41	-5.25	-0.31	3.18e-7	Hirschsprung disease;
CESC	cis	rs7264396	0.563	rs61191623	chr20:34219987	A/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.58	5.65	0.33	4.22e-8	Total cholesterol levels;
CESC	cis	rs7772486	0.686	rs9403741	chr6:146030548	G/A	cg05347473	chr6:146136440	FBXO30	-0.53	-6.99	-0.39	2.21e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs6867032	1.000	rs4975802	chr5:2019750	T/C	cg26168224	chr5:2018326	NA	0.98	19.59	0.77	1.89e-53	Gut microbiome composition (winter);
CESC	cis	rs992157	0.560	rs7605980	chr2:219100869	C/G	cg20019365	chr2:219134978	PNKD;AAMP	0.54	7.05	0.4	1.53e-11	Colorectal cancer;
CESC	cis	rs6502050	0.799	rs4789681	chr17:80100546	G/A	cg11859384	chr17:80120422	CCDC57	-0.38	-5.11	-0.3	6.21e-7	Life satisfaction;
CESC	cis	rs4713118	0.662	rs9380046	chr6:28030499	T/C	cg19592336	chr6:28129416	ZNF389	0.53	6.87	0.39	4.51e-11	Parkinson's disease;
CESC	cis	rs2836974	0.897	rs11911112	chr21:40528346	A/C	cg27266027	chr21:40555129	PSMG1	0.48	5.86	0.34	1.37e-8	Cognitive function;
CESC	cis	rs7833790	0.685	rs13255262	chr8:82728024	T/G	cg02079420	chr8:82753780	SNX16	0.55	8.25	0.45	7.73e-15	Diastolic blood pressure;
CESC	cis	rs6502050	0.835	rs6502059	chr17:80082886	T/C	cg11859384	chr17:80120422	CCDC57	0.38	5.12	0.3	6.01e-7	Life satisfaction;
CESC	cis	rs4665809	0.531	rs12987980	chr2:26462093	A/T	cg26314531	chr2:26401878	FAM59B	0.85	9.04	0.49	3.46e-17	Gut microbiome composition (summer);
CESC	cis	rs6951245	1.000	rs884977	chr7:1066410	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.51	6.47	0.37	4.8e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs172166	0.637	rs1233708	chr6:28173219	C/T	cg12963246	chr6:28129442	ZNF389	0.35	5.04	0.3	8.58e-7	Cardiac Troponin-T levels;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12064626	chr21:40817896	SH3BGR	-0.62	-7.42	-0.41	1.62e-12	Gut microbiome composition (summer);
CESC	cis	rs3092073	0.624	rs7275164	chr20:44604822	G/A	cg17986701	chr20:44574422	PCIF1	0.35	5.06	0.3	7.82e-7	Intelligence (multi-trait analysis);
CESC	cis	rs863345	0.933	rs2051068	chr1:158507184	A/G	cg12129480	chr1:158549410	OR10X1	-0.32	-6.48	-0.37	4.43e-10	Pneumococcal bacteremia;
CESC	cis	rs796364	0.806	rs4673634	chr2:200863349	A/C	cg23649088	chr2:200775458	C2orf69	0.6	5.37	0.31	1.74e-7	Schizophrenia;
CESC	cis	rs3780486	0.522	rs7029897	chr9:33124042	T/C	cg13443165	chr9:33130375	B4GALT1	0.47	7.15	0.4	8.69e-12	IgG glycosylation;
CESC	trans	rs61931739	0.500	rs34167298	chr12:34534338	G/A	cg26384229	chr12:38710491	ALG10B	0.72	10.84	0.55	6.43e-23	Morning vs. evening chronotype;
CESC	cis	rs9611565	0.729	rs2413647	chr22:41907148	G/A	cg03806693	chr22:41940476	POLR3H	-1.2	-14.88	-0.67	7.9e-37	Vitiligo;
CESC	trans	rs9858542	0.953	rs35261698	chr3:49537839	C/G	cg21659725	chr3:3221576	CRBN	-0.54	-6.37	-0.36	8.2e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs3750965	0.734	rs11604251	chr11:68820429	A/G	cg01403660	chr11:68851641	TPCN2	-0.39	-5.05	-0.3	8.21e-7	Hair color;
CESC	cis	rs3008870	0.755	rs2815355	chr1:67485034	A/G	cg02640540	chr1:67518911	SLC35D1	0.44	5.36	0.31	1.84e-7	Lymphocyte percentage of white cells;
CESC	cis	rs1552244	1.000	rs57631744	chr3:10118962	T/C	cg00166722	chr3:10149974	C3orf24	0.55	7.09	0.4	1.21e-11	Alzheimer's disease;
CESC	cis	rs9916302	0.904	rs7216086	chr17:37709422	G/A	cg15445000	chr17:37608096	MED1	0.4	6.49	0.37	4.18e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs6912958	0.781	rs13193380	chr6:88297057	G/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-6.58	-0.37	2.55e-10	Monocyte percentage of white cells;
CESC	cis	rs9911578	0.967	rs8075786	chr17:56819216	T/C	cg12560992	chr17:57184187	TRIM37	0.92	15.09	0.68	1.43e-37	Intelligence (multi-trait analysis);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24450312	chr1:206681158	RASSF5	0.59	6.77	0.38	8.48e-11	Gut microbiome composition (summer);
CESC	cis	rs27434	0.583	rs28129	chr5:96155518	G/A	cg16492584	chr5:96139282	ERAP1	-0.36	-5.09	-0.3	6.81e-7	Ankylosing spondylitis;
CESC	cis	rs3096299	0.606	rs4785573	chr16:89565403	A/G	cg02034447	chr16:89574710	SPG7	0.5	6.03	0.35	5.36e-9	Multiple myeloma (IgH translocation);
CESC	cis	rs1153858	1.000	rs66939267	chr15:45676902	T/A	cg21132104	chr15:45694354	SPATA5L1	0.86	11.62	0.58	1.67e-25	Homoarginine levels;
CESC	cis	rs477692	0.571	rs10764890	chr10:131347163	G/A	cg24747557	chr10:131355152	MGMT	-0.4	-5.76	-0.33	2.28e-8	Response to temozolomide;
CESC	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg23708337	chr7:1209742	NA	0.52	5.16	0.3	4.88e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs9311474	0.508	rs12629701	chr3:52619836	T/C	cg18404041	chr3:52824283	ITIH1	-0.38	-6.4	-0.37	7.12e-10	Electroencephalogram traits;
CESC	cis	rs7219021	0.705	rs9904288	chr17:47031973	T/C	cg16584676	chr17:46985605	UBE2Z	-0.62	-7.12	-0.4	1.04e-11	Schizophrenia or bipolar disorder;
CESC	cis	rs6088580	0.524	rs11167241	chr20:33250835	C/T	cg08999081	chr20:33150536	PIGU	-0.46	-6.42	-0.37	6.23e-10	Glomerular filtration rate (creatinine);
CESC	cis	rs67311347	0.956	rs6771527	chr3:40506548	T/C	cg01475735	chr3:40494733	NA	0.43	5.32	0.31	2.18e-7	Renal cell carcinoma;
CESC	trans	rs4332037	1.000	rs6947019	chr7:1950337	G/A	cg11693508	chr17:37793320	STARD3	0.68	6.53	0.37	3.39e-10	Bipolar disorder;
CESC	cis	rs2235544	0.565	rs635045	chr1:54469109	A/G	cg25741118	chr1:54482237	LDLRAD1	0.23	5.64	0.33	4.44e-8	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
CESC	cis	rs4704187	0.687	rs28376290	chr5:74454706	C/T	cg03227963	chr5:74354835	NA	0.3	5.46	0.32	1.08e-7	Response to amphetamines;
CESC	cis	rs7584330	0.518	rs6715245	chr2:238445803	C/T	cg14458575	chr2:238380390	NA	0.66	6.56	0.37	2.78e-10	Prostate cancer;
CESC	cis	rs60871478	1.000	rs34761279	chr7:794471	A/G	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.61	5.99	0.35	6.71e-9	Cerebrospinal P-tau181p levels;
CESC	cis	rs8031584	0.541	rs1983459	chr15:31208749	C/T	cg19680485	chr15:31195859	MTMR15	-0.43	-5.26	-0.31	3.02e-7	Huntington's disease progression;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14802876	chr6:34217098	C6orf1	0.63	7.8	0.43	1.42e-13	Gut microbiome composition (summer);
CESC	cis	rs4555082	0.957	rs2816609	chr14:105720803	A/C	cg06808227	chr14:105710500	BRF1	-0.5	-6.3	-0.36	1.24e-9	Mean platelet volume;Platelet distribution width;
CESC	cis	rs1008375	0.897	rs6820164	chr4:17630115	G/A	cg15017067	chr4:17643749	FAM184B	0.37	5.18	0.3	4.38e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs7945705	0.967	rs56316046	chr11:8876598	G/T	cg21881798	chr11:8931708	C11orf17;ST5	0.48	7.65	0.43	3.67e-13	Hemoglobin concentration;
CESC	cis	rs4713118	0.662	rs9468276	chr6:28027688	A/C	cg26335602	chr6:28129616	ZNF389	0.44	5.61	0.33	5.19e-8	Parkinson's disease;
CESC	cis	rs12995491	0.731	rs56188884	chr2:88508657	G/A	cg14558114	chr2:88469736	THNSL2	-0.52	-7.56	-0.42	6.77e-13	Response to metformin (IC50);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03477043	chr16:2812423	SRRM2	-0.63	-7.14	-0.4	8.78e-12	Gut microbiome composition (summer);
CESC	cis	rs3015497	0.789	rs1389652	chr14:51125240	T/C	cg09863266	chr14:51125203	SAV1	-0.36	-5.66	-0.33	3.95e-8	Mean platelet volume;
CESC	cis	rs10504229	1.000	rs67237174	chr8:58175776	T/C	cg24829409	chr8:58192753	C8orf71	-0.76	-10.08	-0.53	2e-20	Developmental language disorder (linguistic errors);
CESC	trans	rs7937682	0.889	rs1784787	chr11:111486125	T/A	cg18187862	chr3:45730750	SACM1L	0.48	6.01	0.35	6.26e-9	Primary sclerosing cholangitis;
CESC	cis	rs34375054	0.660	rs900411	chr12:125612839	C/T	cg25124228	chr12:125621409	AACS	-0.53	-6.5	-0.37	4.05e-10	Post bronchodilator FEV1/FVC ratio;
CESC	cis	rs9908102	0.740	rs4792310	chr17:12908734	T/A	cg26162695	chr17:12921313	ELAC2	0.51	5.44	0.32	1.19e-7	Schizophrenia;
CESC	cis	rs1799949	1.000	rs16940	chr17:41245237	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	8.6	0.47	6.88e-16	Menopause (age at onset);
CESC	cis	rs11098499	0.739	rs10013032	chr4:120149419	C/T	cg09307838	chr4:120376055	NA	-0.68	-8.42	-0.46	2.43e-15	Corneal astigmatism;
CESC	cis	rs1552244	1.000	rs6442146	chr3:10073544	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.88	12.07	0.6	5.12e-27	Alzheimer's disease;
CESC	cis	rs7385804	0.796	rs221801	chr7:100290031	C/A	cg16850897	chr7:100343110	ZAN	0.51	7.07	0.4	1.39e-11	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
CESC	cis	rs10479542	0.549	rs4376229	chr5:179042971	A/G	cg14820908	chr5:178986412	RUFY1	0.39	5.59	0.32	5.52e-8	Lung cancer;
CESC	cis	rs7666738	0.687	rs6839454	chr4:99073914	T/C	cg05340658	chr4:99064831	C4orf37	0.81	11.84	0.59	2.93e-26	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24323328	chr12:1099998	ERC1	0.62	7.28	0.41	3.78e-12	Gut microbiome composition (summer);
CESC	trans	rs757081	0.643	rs665311	chr11:17206740	A/T	cg00391031	chr10:72237473	KIAA1274	0.31	6.01	0.35	6.14e-9	Systolic blood pressure;
CESC	cis	rs6500395	1.000	rs9939103	chr16:48592376	G/C	cg04672837	chr16:48644449	N4BP1	0.5	6.23	0.36	1.78e-9	Response to tocilizumab in rheumatoid arthritis;
CESC	trans	rs2727020	0.675	rs7929401	chr11:49350832	C/A	cg15704280	chr7:45808275	SEPT13	-0.75	-8.67	-0.47	4.35e-16	Coronary artery disease;
CESC	cis	rs12711979	0.740	rs6715434	chr2:3820862	T/G	cg17052675	chr2:3827356	NA	-0.41	-6.47	-0.37	4.74e-10	Itch intensity from mosquito bite adjusted by bite size;
CESC	cis	rs9902453	0.845	rs58575982	chr17:28221776	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.65	8.14	0.45	1.59e-14	Coffee consumption (cups per day);
CESC	cis	rs11997175	0.713	rs6997661	chr8:33638554	A/G	ch.8.33884649F	chr8:33765107	NA	-0.56	-7.45	-0.42	1.31e-12	Body mass index;
CESC	cis	rs9399135	0.636	rs7749106	chr6:135268142	G/A	cg22676075	chr6:135203613	NA	0.46	6.39	0.37	7.62e-10	Red blood cell count;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03517376	chr16:30389231	MYLPF	0.53	6.63	0.38	1.91e-10	Gut microbiome composition (summer);
CESC	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg21280719	chr6:42927975	GNMT	-0.29	-6.71	-0.38	1.18e-10	Alzheimer's disease in APOE e4+ carriers;
CESC	cis	rs1538970	0.781	rs10890330	chr1:45920406	G/A	cg05343316	chr1:45956843	TESK2	0.91	12.32	0.6	7.03e-28	Platelet count;
CESC	cis	rs644799	1.000	rs473148	chr11:95628606	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.81	11.46	0.58	5.95e-25	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs6142102	0.625	rs7263727	chr20:32540939	T/C	cg08999081	chr20:33150536	PIGU	0.34	5.12	0.3	5.84e-7	Skin pigmentation;
CESC	cis	rs9733	0.566	rs72702554	chr1:150678234	A/G	cg22823121	chr1:150693482	HORMAD1	0.48	7.14	0.4	9.03e-12	Tonsillectomy;
CESC	cis	rs10540	1.000	rs61876341	chr11:495892	C/G	cg03576123	chr11:487126	PTDSS2	-1.12	-11.22	-0.57	3.61e-24	Body mass index;
CESC	cis	rs9291683	0.530	rs11723591	chr4:9985398	T/A	cg02734326	chr4:10020555	SLC2A9	0.48	7.09	0.4	1.18e-11	Bone mineral density;
CESC	cis	rs1784581	0.588	rs1789986	chr6:162409978	C/T	cg17173639	chr6:162384350	PARK2	-0.56	-8.48	-0.46	1.58e-15	Itch intensity from mosquito bite;
CESC	cis	rs6963495	0.818	rs73192149	chr7:105210910	A/G	cg19920283	chr7:105172520	RINT1	0.68	6.26	0.36	1.56e-9	Bipolar disorder (body mass index interaction);
CESC	cis	rs8017423	0.791	rs7146250	chr14:90711703	A/G	cg14092571	chr14:90743983	NA	-0.57	-8.51	-0.46	1.28e-15	Mortality in heart failure;
CESC	cis	rs4242434	0.857	rs11777808	chr8:22462755	A/C	cg03733263	chr8:22462867	KIAA1967	0.95	16.03	0.7	6.97e-41	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
CESC	cis	rs9322193	0.962	rs6903998	chr6:150152493	T/C	cg13206674	chr6:150067644	NUP43	0.42	5.93	0.34	9.66e-9	Lung cancer;
CESC	cis	rs6456156	0.792	rs10946215	chr6:167516181	A/G	cg07741184	chr6:167504864	NA	-0.36	-6.23	-0.36	1.84e-9	Primary biliary cholangitis;
CESC	cis	rs9303280	0.651	rs59716545	chr17:38031857	T/G	cg19468946	chr17:37922297	IKZF3	-0.42	-5.54	-0.32	7.32e-8	Self-reported allergy;
CESC	cis	rs858239	0.601	rs28673077	chr7:23250854	C/T	cg23682824	chr7:23144976	KLHL7	0.45	5.79	0.34	2e-8	Cerebrospinal fluid biomarker levels;
CESC	cis	rs7666738	0.830	rs17484966	chr4:99014432	T/C	cg05340658	chr4:99064831	C4orf37	0.8	12.51	0.61	1.52e-28	Colonoscopy-negative controls vs population controls;
CESC	cis	rs3749237	0.537	rs4459909	chr3:49469217	T/C	cg06212747	chr3:49208901	KLHDC8B	0.52	6.99	0.39	2.26e-11	Resting heart rate;
CESC	cis	rs7647973	1.000	rs10865956	chr3:49581559	C/A	cg02487422	chr3:49467188	NICN1	0.39	5.13	0.3	5.59e-7	Menarche (age at onset);
CESC	cis	rs9488822	0.676	rs10456902	chr6:116333742	C/G	cg15226275	chr6:116381976	FRK	-0.25	-6.22	-0.36	1.9e-9	Cholesterol, total;LDL cholesterol;
CESC	cis	rs597539	0.652	rs544370	chr11:68653232	C/T	cg01988459	chr11:68622903	NA	-0.39	-5.61	-0.33	5.05e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs875971	0.516	rs6945322	chr7:65336056	T/C	cg11764359	chr7:65958608	NA	0.67	8.6	0.47	7.27e-16	Aortic root size;
CESC	trans	rs11098499	0.863	rs12498539	chr4:120468370	C/T	cg25214090	chr10:38739885	LOC399744	0.67	9.27	0.49	6.8e-18	Corneal astigmatism;
CESC	cis	rs568617	0.953	rs583887	chr11:65644027	T/C	cg04055107	chr11:65626734	MUS81;CFL1	-0.69	-7.4	-0.41	1.81e-12	Crohn's disease;
CESC	cis	rs68170813	0.559	rs17427158	chr7:106824259	G/T	cg02696742	chr7:106810147	HBP1	-0.53	-5.07	-0.3	7.37e-7	Coronary artery disease;
CESC	cis	rs9325144	0.555	rs1843867	chr12:38703855	A/G	cg26384229	chr12:38710491	ALG10B	-0.59	-8.79	-0.48	1.96e-16	Morning vs. evening chronotype;
CESC	cis	rs644799	1.000	rs586498	chr11:95537828	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.71	9.2	0.49	1.11e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
CESC	cis	rs9487051	1.000	rs9487052	chr6:109617086	C/T	cg01475377	chr6:109611718	NA	-0.42	-6.4	-0.37	6.83e-10	Reticulocyte fraction of red cells;
CESC	cis	rs4523957	0.890	rs432200	chr17:2191960	A/G	cg16513277	chr17:2031491	SMG6	0.59	8.01	0.44	3.66e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
CESC	cis	rs2274273	0.662	rs2147970	chr14:55660217	C/T	cg04306507	chr14:55594613	LGALS3	0.31	5.27	0.31	2.78e-7	Protein biomarker;
CESC	cis	rs9837602	0.507	rs1718244	chr3:99512608	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.6	-9.52	-0.5	1.15e-18	Breast cancer;
CESC	cis	rs8077577	0.895	rs1563371	chr17:18111793	C/T	cg16794390	chr17:18148240	FLII	0.41	5.64	0.33	4.37e-8	Obesity-related traits;
CESC	cis	rs933688	1.000	rs7715402	chr5:90679504	T/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.15	15.47	0.69	6.41e-39	Smoking behavior;
CESC	cis	rs2204008	0.543	rs2387018	chr12:38065638	C/T	cg13010199	chr12:38710504	ALG10B	0.5	6.35	0.36	9.45e-10	Bladder cancer;
CESC	cis	rs7571561	0.625	rs6712295	chr2:213275113	A/G	cg20637307	chr2:213403960	ERBB4	0.48	5.34	0.31	1.96e-7	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);
CESC	cis	rs17095355	0.901	rs12569425	chr10:111758177	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.52	-5.99	-0.35	6.73e-9	Biliary atresia;
CESC	cis	rs4975709	0.569	rs4975743	chr5:1859941	G/T	cg12288994	chr5:1860383	NA	0.4	6.65	0.38	1.68e-10	Cardiovascular disease risk factors;
CESC	cis	rs832540	0.603	rs6870175	chr5:56093371	A/G	cg12311346	chr5:56204834	C5orf35	-0.47	-5.69	-0.33	3.35e-8	Coronary artery disease;
CESC	cis	rs10857712	0.754	rs2297033	chr10:135234848	C/T	cg01444801	chr10:135216882	MTG1	-0.46	-5.24	-0.31	3.29e-7	Systemic lupus erythematosus;
CESC	cis	rs2425143	1.000	rs78421482	chr20:34376486	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.79	-7.16	-0.4	8.09e-12	Blood protein levels;
CESC	cis	rs2235642	0.821	rs8051895	chr16:1602811	A/G	cg03715980	chr16:1756201	MAPK8IP3	0.38	5.05	0.3	8.33e-7	Coronary artery disease;
CESC	cis	rs6496667	0.533	rs7173201	chr15:90991195	A/T	cg22089800	chr15:90895588	ZNF774	0.45	5.81	0.34	1.75e-8	Rheumatoid arthritis;
CESC	cis	rs1050631	0.592	rs1785909	chr18:33731173	G/A	cg25426722	chr18:33708991	SLC39A6;ELP2	0.53	7.16	0.4	7.87e-12	Esophageal squamous cell cancer (length of survival);
CESC	cis	rs6542838	0.641	rs4850890	chr2:99535426	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.42	-5.47	-0.32	1.02e-7	Fear of minor pain;
CESC	cis	rs735396	1.000	rs735396	chr12:121438844	T/C	cg02403541	chr12:121454288	C12orf43	0.63	9.18	0.49	1.25e-17	N-glycan levels;
CESC	cis	rs3096299	0.935	rs3102387	chr16:89432276	A/C	cg02187348	chr16:89574699	SPG7	0.54	7.09	0.4	1.21e-11	Multiple myeloma (IgH translocation);
CESC	cis	rs916888	0.697	rs199516	chr17:44856485	C/T	cg01570182	chr17:44337453	NA	-0.87	-10.54	-0.54	6.18e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	cis	rs2576037	0.583	rs8098948	chr18:44512332	C/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.34	5.42	0.32	1.37e-7	Personality dimensions;
CESC	cis	rs9291683	0.632	rs11734786	chr4:10041499	A/C	cg00071950	chr4:10020882	SLC2A9	0.83	14.41	0.66	3.63e-35	Bone mineral density;
CESC	cis	rs11203032	0.831	rs10887922	chr10:90930236	G/A	cg16672925	chr10:90967113	CH25H	0.7	6.65	0.38	1.62e-10	Heart failure;
CESC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg03731171	chr3:149530375	RNF13	-0.45	-6.32	-0.36	1.13e-9	Gambling;
CESC	cis	rs8103278	1.000	rs9676288	chr19:46292060	G/T	cg11657440	chr19:46296263	DMWD	-0.61	-7.65	-0.43	3.62e-13	Coronary artery disease;
CESC	cis	rs2635047	0.967	rs12960444	chr18:44607314	T/C	cg19077165	chr18:44547161	KATNAL2	-0.5	-6.84	-0.39	5.53e-11	Educational attainment;
CESC	cis	rs9926296	0.632	rs7184315	chr16:89799373	C/G	cg04287289	chr16:89883240	FANCA	-0.64	-8.65	-0.47	4.89e-16	Vitiligo;
CESC	trans	rs2733310	0.739	rs1012321	chr15:57146502	G/A	cg13494055	chr3:59115467	NA	-0.43	-6.04	-0.35	5.22e-9	Mean platelet volume;
CESC	cis	rs72781680	1.000	rs115861480	chr2:24129464	T/A	cg20701182	chr2:24300061	SF3B14	0.78	6.73	0.38	1.07e-10	Lymphocyte counts;
CESC	cis	rs4642101	0.686	rs9822382	chr3:12828828	T/G	cg05775895	chr3:12838266	CAND2	0.35	5.24	0.31	3.32e-7	QRS complex (12-leadsum);
CESC	trans	rs17685	0.816	rs11763076	chr7:75765963	C/T	cg19862616	chr7:65841803	NCRNA00174	0.85	12.37	0.61	4.87e-28	Coffee consumption;Coffee consumption (cups per day);
CESC	cis	rs7666738	0.830	rs4699584	chr4:98952019	A/G	cg03467027	chr4:99064603	C4orf37	0.45	5.6	0.33	5.22e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs172166	0.694	rs1770131	chr6:28086413	C/T	cg17221315	chr6:27791827	HIST1H4J	0.45	5.81	0.34	1.75e-8	Cardiac Troponin-T levels;
CESC	cis	rs863345	0.967	rs11265023	chr1:158513048	C/T	cg12129480	chr1:158549410	OR10X1	-0.33	-6.64	-0.38	1.73e-10	Pneumococcal bacteremia;
CESC	cis	rs6496667	0.609	rs7183707	chr15:90883733	G/T	cg22089800	chr15:90895588	ZNF774	0.5	6.09	0.35	4.05e-9	Rheumatoid arthritis;
CESC	cis	rs67311347	0.868	rs10865895	chr3:40378677	C/T	cg09455208	chr3:40491958	NA	0.47	8.03	0.44	3.16e-14	Renal cell carcinoma;
CESC	cis	rs896854	0.738	rs1713669	chr8:95958637	C/G	cg09323728	chr8:95962352	TP53INP1	-0.37	-7.49	-0.42	1.01e-12	Type 2 diabetes;
CESC	cis	rs7267979	1.000	rs7268053	chr20:25328286	A/T	cg08601574	chr20:25228251	PYGB	-0.38	-5.51	-0.32	8.54e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs7100689	0.516	rs3862532	chr10:82015725	A/C	cg09936400	chr10:82049201	MAT1A	0.35	5.2	0.3	4.01e-7	Post bronchodilator FEV1;
CESC	cis	rs1218582	0.741	rs7544528	chr1:154844585	C/T	cg24250549	chr1:154909240	PMVK	0.62	8.54	0.46	1.05e-15	Prostate cancer;
CESC	cis	rs703842	1.000	rs11172344	chr12:58193448	T/C	cg00677455	chr12:58241039	CTDSP2	0.53	6.97	0.39	2.45e-11	Multiple sclerosis;
CESC	cis	rs7811142	1.000	rs73161759	chr7:100009994	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.78	6.78	0.38	7.85e-11	Platelet count;
CESC	cis	rs6060717	0.536	rs3829829	chr20:34537160	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.7	-6.39	-0.37	7.58e-10	Hip circumference adjusted for BMI;
CESC	cis	rs3733585	0.664	rs17245436	chr4:9958169	A/G	cg11266682	chr4:10021025	SLC2A9	-0.6	-11.09	-0.56	1.01e-23	Cleft plate (environmental tobacco smoke interaction);
CESC	cis	rs660498	0.526	rs610451	chr10:27705152	A/G	cg08398567	chr10:27609333	NA	-0.4	-5.73	-0.33	2.76e-8	Asthma (childhood onset);
CESC	cis	rs651907	0.513	rs34963630	chr3:101504817	C/T	cg12386194	chr3:101231763	SENP7	0.41	5.15	0.3	5e-7	Colorectal cancer;
CESC	cis	rs7927592	0.913	rs10896330	chr11:68254998	A/G	cg20283391	chr11:68216788	NA	-0.51	-6.13	-0.35	3.15e-9	Total body bone mineral density;
CESC	cis	rs7618915	0.571	rs12632381	chr3:52607685	G/A	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	5.67	0.33	3.7e-8	Bipolar disorder;
CESC	cis	rs1707322	1.000	rs34694458	chr1:46332696	G/A	cg03146154	chr1:46216737	IPP	0.74	10.2	0.53	7.96e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs66731853	0.771	rs541244	chr1:20889380	G/A	cg04087271	chr1:20915334	CDA	-0.53	-7.64	-0.42	4.01e-13	Mean corpuscular volume;
CESC	cis	rs722599	0.683	rs8014695	chr14:75301617	C/G	cg08847533	chr14:75593920	NEK9	0.49	6.07	0.35	4.49e-9	IgG glycosylation;
CESC	cis	rs6695640	0.854	rs2526830	chr1:17728119	A/G	cg01904812	chr1:17746340	RCC2	0.35	5.18	0.3	4.4e-7	Mean platelet volume;
CESC	cis	rs9300255	0.510	rs1790133	chr12:123698518	T/G	cg19016782	chr12:123741754	C12orf65	-0.45	-6.5	-0.37	3.9e-10	Neutrophil percentage of white cells;
CESC	cis	rs4253772	0.591	rs6519994	chr22:46656805	A/G	cg09491104	chr22:46646882	C22orf40	0.59	8.96	0.48	5.79e-17	LDL cholesterol;Cholesterol, total;
CESC	cis	rs9733	0.791	rs11204693	chr1:150647987	C/T	cg13175981	chr1:150552382	MCL1	0.62	9.37	0.5	3.23e-18	Tonsillectomy;
CESC	cis	rs4664308	0.618	rs62175487	chr2:160892521	C/T	cg03641300	chr2:160917029	PLA2R1	-0.59	-8.54	-0.46	1.04e-15	Idiopathic membranous nephropathy;
CESC	cis	rs4555082	0.681	rs28588570	chr14:105709606	A/T	cg27165867	chr14:105738592	BRF1	-0.53	-6.07	-0.35	4.39e-9	Mean platelet volume;Platelet distribution width;
CESC	cis	rs4555082	0.834	rs2816623	chr14:105733295	G/A	cg13114125	chr14:105738426	BRF1	-0.89	-11.05	-0.56	1.31e-23	Mean platelet volume;Platelet distribution width;
CESC	cis	rs2479724	0.870	rs3747753	chr6:41753380	G/T	cg08135965	chr6:41755394	TOMM6	-0.42	-5.58	-0.32	5.93e-8	Menarche (age at onset);
CESC	cis	rs501120	0.657	rs114070077	chr10:44742911	A/G	cg09554077	chr10:44749378	NA	0.43	5.19	0.3	4.27e-7	Coronary artery disease;Coronary heart disease;
CESC	cis	rs6499129	0.558	rs7203742	chr16:67605794	A/G	cg26727032	chr16:67993705	SLC12A4	0.58	7.19	0.4	6.45e-12	Waist-to-hip ratio adjusted for body mass index;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13204435	chr8:95731830	DPY19L4	0.57	6.74	0.38	9.77e-11	Gut microbiome composition (summer);
CESC	trans	rs1519277	1.000	rs35190664	chr2:123981189	C/T	cg14726583	chr6:40310514	NA	0.62	6.04	0.35	5.08e-9	Breast cancer in childhood cancer survivors treated with less than 10 gray radiotherapy;
CESC	trans	rs561341	0.556	rs542244	chr17:30307242	T/C	cg27661571	chr11:113659931	NA	-0.83	-7.73	-0.43	2.26e-13	Hip circumference adjusted for BMI;
CESC	cis	rs80282103	0.867	rs12241632	chr10:1069070	A/T	cg08668510	chr10:1095578	IDI1	0.73	6.25	0.36	1.61e-9	Glomerular filtration rate (creatinine);
CESC	cis	rs597539	0.652	rs496616	chr11:68672800	G/C	cg21963583	chr11:68658836	MRPL21	0.37	5.25	0.31	3.15e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
CESC	cis	rs9612	1.000	rs346544	chr19:44256205	A/G	cg08581076	chr19:44259116	C19orf61	0.5	6.09	0.35	3.89e-9	Exhaled nitric oxide output;
CESC	cis	rs10504229	1.000	rs59549824	chr8:58186205	A/C	cg22535103	chr8:58192502	C8orf71	-1.05	-13.08	-0.63	1.68e-30	Developmental language disorder (linguistic errors);
CESC	cis	rs2742234	0.590	rs2435377	chr10:43683600	A/G	cg07801480	chr10:43725741	RASGEF1A	-0.4	-5.19	-0.3	4.25e-7	Hirschsprung disease;
CESC	cis	rs7927771	0.929	rs12787646	chr11:47669665	T/C	cg18512352	chr11:47633146	NA	-0.56	-8.67	-0.47	4.37e-16	Subjective well-being;
CESC	cis	rs6591182	0.504	rs7116712	chr11:65372518	A/G	cg27068330	chr11:65405492	SIPA1	-0.6	-7.49	-0.42	1.03e-12	Non-alcoholic fatty liver disease histology (lobular);
CESC	cis	rs7264396	0.563	rs2225950	chr20:34333015	C/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.63	6.72	0.38	1.08e-10	Total cholesterol levels;
CESC	cis	rs12142240	0.698	rs67276232	chr1:46825484	T/G	cg00530320	chr1:46809349	NSUN4	0.6	8.01	0.44	3.73e-14	Menopause (age at onset);
CESC	cis	rs875971	1.000	rs35149210	chr7:65929925	T/C	cg18876405	chr7:65276391	NA	0.51	6.82	0.39	6.05e-11	Aortic root size;
CESC	cis	rs798554	1.000	rs798560	chr7:2758309	A/G	cg13628971	chr7:2884303	GNA12	0.57	7.33	0.41	2.71e-12	Height;
CESC	cis	rs9916302	0.904	rs612194	chr17:37442707	T/A	cg00129232	chr17:37814104	STARD3	0.53	6.84	0.39	5.58e-11	Glomerular filtration rate (creatinine);
CESC	cis	rs7264396	0.563	rs2425100	chr20:34310115	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.89	-10.65	-0.55	2.79e-22	Total cholesterol levels;
CESC	cis	rs72781680	0.665	rs72788298	chr2:24104293	T/C	cg08917208	chr2:24149416	ATAD2B	0.6	6.04	0.35	5.06e-9	Lymphocyte counts;
CESC	cis	rs3820928	0.967	rs4675114	chr2:227768362	C/T	cg11843606	chr2:227700838	RHBDD1	-0.42	-5.62	-0.33	4.8e-8	Pulmonary function;
CESC	cis	rs9640161	0.789	rs36035506	chr7:150057843	C/T	cg21361702	chr7:150065534	REPIN1	0.61	6.72	0.38	1.13e-10	Blood protein levels;Circulating chemerin levels;
CESC	cis	rs1878931	0.507	rs8054222	chr16:3413477	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.66	-7.9	-0.44	7.4e-14	Body mass index (adult);
CESC	cis	rs12946454	0.696	rs4792819	chr17:43247957	A/C	cg10701640	chr17:43249399	NA	0.48	8.92	0.48	7.87e-17	Systolic blood pressure;
CESC	cis	rs9487051	0.802	rs9487039	chr6:109610163	A/T	cg01475377	chr6:109611718	NA	-0.51	-8.36	-0.46	3.66e-15	Reticulocyte fraction of red cells;
CESC	cis	rs1670533	1.000	rs3816474	chr4:1050653	G/A	cg04106633	chr4:1044584	NA	0.46	5.11	0.3	6.21e-7	Recombination rate (females);
CESC	cis	rs7833790	1.000	rs28696138	chr8:82770794	G/A	cg17211192	chr8:82754475	SNX16	0.7	8.32	0.46	4.71e-15	Diastolic blood pressure;
CESC	cis	rs8028182	0.636	rs4886707	chr15:75755467	C/T	cg20655648	chr15:75932815	IMP3	0.54	6.93	0.39	3.22e-11	Sudden cardiac arrest;
CESC	cis	rs3806843	0.832	rs2531360	chr5:140116664	G/A	cg16179182	chr5:140090404	VTRNA1-1	0.38	5.11	0.3	6.26e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs6860806	0.661	rs4705927	chr5:131578608	C/G	cg12564285	chr5:131593104	PDLIM4	0.39	5.8	0.34	1.84e-8	Breast cancer;
CESC	trans	rs5758511	0.773	rs73165164	chr22:42355549	T/C	cg15080870	chr19:47770746	CCDC9	0.5	6.19	0.36	2.24e-9	Birth weight;
CESC	cis	rs2180341	0.960	rs7753913	chr6:127671296	A/G	cg27446573	chr6:127587934	RNF146	1.06	15.51	0.69	4.62e-39	Breast cancer;
CESC	cis	rs1552244	0.935	rs66493421	chr3:10092569	G/A	cg00166722	chr3:10149974	C3orf24	0.55	6.25	0.36	1.65e-9	Alzheimer's disease;
CESC	cis	rs6430585	0.583	rs59243420	chr2:136584538	A/T	cg07169764	chr2:136633963	MCM6	1.34	19.43	0.77	6.67e-53	Corneal structure;
CESC	cis	rs12893668	0.572	rs11540512	chr14:104147377	C/T	cg08213375	chr14:104286397	PPP1R13B	0.33	5.41	0.32	1.42e-7	Reticulocyte count;
CESC	cis	rs7666738	0.830	rs1405767	chr4:98965295	T/C	cg03676636	chr4:99064102	C4orf37	0.33	5.14	0.3	5.39e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1448094	0.512	rs61930861	chr12:86245023	G/T	cg00310523	chr12:86230176	RASSF9	0.35	5.46	0.32	1.1e-7	Major depressive disorder;
CESC	cis	rs910316	0.763	rs175036	chr14:75464295	C/T	cg11812906	chr14:75593930	NEK9	-0.81	-13.34	-0.63	2.05e-31	Height;
CESC	cis	rs8020095	0.571	rs28539317	chr14:67480832	G/A	cg19548862	chr14:67692701	FAM71D	-0.48	-5.77	-0.33	2.17e-8	Depression (quantitative trait);
CESC	cis	rs1799949	1.000	rs11649954	chr17:41420035	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.4	5.42	0.32	1.32e-7	Menopause (age at onset);
CESC	cis	rs4665809	1.000	rs7599132	chr2:26279810	A/T	cg26119090	chr2:26468346	HADHA;HADHB	0.77	8.7	0.47	3.66e-16	Gut microbiome composition (summer);
CESC	cis	rs10911232	0.507	rs4369195	chr1:182996291	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.84	13.19	0.63	6.74e-31	Hypertriglyceridemia;
CESC	trans	rs4927850	0.958	rs1975582	chr3:195751439	G/T	cg16724585	chr3:197361211	NA	-0.55	-6.94	-0.39	3.04e-11	Pancreatic cancer;
CESC	cis	rs11252926	0.604	rs2050970	chr10:515870	C/T	cg03684893	chr10:554711	DIP2C	-0.43	-6.58	-0.37	2.49e-10	Psychosis in Alzheimer's disease;
CESC	cis	rs6460942	0.915	rs7803002	chr7:12306738	C/T	cg06484146	chr7:12443880	VWDE	-0.4	-5.63	-0.33	4.6e-8	Coronary artery disease;
CESC	cis	rs4975709	0.589	rs1466607	chr5:1864856	A/G	cg11168104	chr5:1857477	NA	-0.38	-5.54	-0.32	7.31e-8	Cardiovascular disease risk factors;
CESC	cis	rs1153858	0.943	rs67045941	chr15:45677011	A/G	cg14582100	chr15:45693742	SPATA5L1	0.42	5.95	0.34	8.38e-9	Homoarginine levels;
CESC	trans	rs7628583	0.877	rs12494731	chr3:64082003	G/T	cg18266620	chr1:110882148	RBM15	-0.59	-6.05	-0.35	5.03e-9	Parental extreme longevity (95 years and older);
CESC	cis	rs10504229	0.906	rs7842482	chr8:58167720	A/T	cg02725872	chr8:58115012	NA	-0.34	-5.32	-0.31	2.18e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs910316	0.737	rs175072	chr14:75502827	T/C	cg15467112	chr14:75489610	MLH3	-0.33	-5.11	-0.3	6.23e-7	Height;
CESC	cis	rs2295359	1.000	rs2295359	chr1:67635950	G/A	cg03340356	chr1:67600835	NA	0.35	5.76	0.33	2.27e-8	Psoriasis;
CESC	cis	rs1005277	0.579	rs2474586	chr10:38418882	T/C	cg00409905	chr10:38381863	ZNF37A	-0.48	-6.39	-0.37	7.35e-10	Extrinsic epigenetic age acceleration;
CESC	cis	rs854765	0.822	rs1889014	chr17:17767165	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.42	-5.6	-0.33	5.26e-8	Total body bone mineral density;
CESC	cis	rs11098499	0.954	rs6849171	chr4:120409549	G/A	cg24375607	chr4:120327624	NA	0.46	5.75	0.33	2.39e-8	Corneal astigmatism;
CESC	cis	rs2652822	0.571	rs11858666	chr15:63526239	G/C	cg02713581	chr15:63449717	RPS27L	0.49	6.18	0.36	2.38e-9	Metabolic traits;
CESC	cis	rs4654899	0.680	rs11805006	chr1:21249603	C/T	cg05370193	chr1:21551575	ECE1	0.35	5.4	0.31	1.48e-7	Superior frontal gyrus grey matter volume;
CESC	cis	rs2455799	0.573	rs2455830	chr3:15749213	C/T	cg09340198	chr3:15902540	ANKRD28	-0.32	-5.11	-0.3	6.11e-7	Mean platelet volume;
CESC	cis	rs10504229	0.683	rs58438731	chr8:58134790	C/T	cg24829409	chr8:58192753	C8orf71	-0.58	-7.2	-0.4	6.31e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs1448094	0.511	rs17279464	chr12:86164473	C/T	cg02569458	chr12:86230093	RASSF9	0.5	7.74	0.43	2.17e-13	Major depressive disorder;
CESC	cis	rs6429082	0.518	rs1812350	chr1:235659920	C/A	cg26050004	chr1:235667680	B3GALNT2	0.82	12.98	0.62	3.75e-30	Adiposity;
CESC	trans	rs7615952	0.604	rs9837847	chr3:125623919	G/A	cg07211511	chr3:129823064	LOC729375	-0.88	-8.15	-0.45	1.47e-14	Blood pressure (smoking interaction);
CESC	cis	rs17293817	0.589	rs2387656	chr10:1420571	C/T	cg04271617	chr10:1416546	ADARB2	0.36	5.73	0.33	2.68e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
CESC	cis	rs561341	1.000	rs554078	chr17:30330109	A/C	cg19193384	chr17:30244184	NA	-0.71	-6.64	-0.38	1.73e-10	Hip circumference adjusted for BMI;
CESC	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg26338869	chr17:61819248	STRADA	0.7	9.28	0.5	6.1e-18	Prudent dietary pattern;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg11208313	chr17:27276484	PHF12	-0.47	-6.47	-0.37	4.83e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs11997175	1.000	rs6468200	chr8:33745191	A/T	ch.8.33884649F	chr8:33765107	NA	0.66	8.48	0.46	1.63e-15	Body mass index;
CESC	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg00983485	chr15:31284262	MTMR10	0.5	6.42	0.37	6.3e-10	Gut microbiota (bacterial taxa);
CESC	cis	rs4481887	1.000	rs4481887	chr1:248496863	A/G	cg00666640	chr1:248458726	OR2T12	0.41	6.57	0.37	2.64e-10	Common traits (Other);
CESC	cis	rs3008870	0.959	rs2985816	chr1:67387750	G/T	cg02640540	chr1:67518911	SLC35D1	0.48	5.19	0.3	4.09e-7	Lymphocyte percentage of white cells;
CESC	cis	rs56346965	0.506	rs2159818	chr2:191532789	A/G	cg10560079	chr2:191398806	TMEM194B	-0.48	-5.96	-0.34	8.17e-9	Bone mineral density (Ward's triangle area);
CESC	cis	rs9660992	0.710	rs1172136	chr1:205247097	T/G	cg21643547	chr1:205240462	TMCC2	-0.46	-6.16	-0.35	2.67e-9	Mean corpuscular volume;Mean platelet volume;
CESC	cis	rs12220238	1.000	rs10824106	chr10:75958408	C/T	cg19889307	chr10:75911429	ADK;AP3M1	-0.61	-5.18	-0.3	4.48e-7	Soluble interleukin-2 receptor subunit alpha;
CESC	cis	rs74181299	0.750	rs13421845	chr2:65336033	G/A	cg05010058	chr2:65284262	CEP68	-0.31	-5.15	-0.3	5.18e-7	Pulse pressure;
CESC	cis	rs7605827	0.930	rs6431706	chr2:15600019	C/T	cg19274914	chr2:15703543	NA	0.32	5.65	0.33	4.03e-8	Educational attainment (years of education);
CESC	cis	rs7666738	0.830	rs7657497	chr4:99044028	A/G	cg24818145	chr4:99064322	C4orf37	0.38	5.04	0.3	8.49e-7	Colonoscopy-negative controls vs population controls;
CESC	cis	rs1568889	1.000	rs61889054	chr11:28333000	A/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.76	9.64	0.51	4.9e-19	Bipolar disorder;
CESC	cis	rs4319547	0.737	rs10846920	chr12:122943231	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.49	-6.15	-0.35	2.82e-9	Body mass index;
CESC	cis	rs698833	0.926	rs786419	chr2:44685153	G/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.46	5.8	0.34	1.89e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
CESC	cis	rs12188164	1.000	rs55842567	chr5:437586	G/A	cg21144161	chr5:423903	AHRR	0.37	6.09	0.35	3.9e-9	Cystic fibrosis severity;
CESC	cis	rs6433857	0.594	rs1950029	chr2:181520566	G/C	cg23363182	chr2:181467187	NA	-0.46	-6.35	-0.36	9.29e-10	Body mass index;
CESC	cis	rs7044106	0.708	rs1324472	chr9:123375110	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.63	8.53	0.46	1.16e-15	Hip circumference adjusted for BMI;
CESC	cis	rs916888	0.647	rs199523	chr17:44848517	C/A	cg15921436	chr17:44337874	NA	-0.48	-6.0	-0.35	6.6e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg08548086	chr5:73980929	HEXB	-0.5	-6.17	-0.35	2.54e-9	Asthma;
CESC	cis	rs4568518	0.530	rs6970593	chr7:17989359	A/G	cg03009463	chr7:17980271	SNX13	-0.39	-5.19	-0.3	4.23e-7	Measles;
CESC	cis	rs6460942	0.915	rs1595802	chr7:12439672	C/T	cg16278512	chr7:12443529	VWDE	-0.56	-5.96	-0.34	8.1e-9	Coronary artery disease;
CESC	cis	rs7618915	0.571	rs34954168	chr3:52612159	C/T	cg18099408	chr3:52552593	STAB1	-0.32	-5.2	-0.3	4.02e-7	Bipolar disorder;
CESC	cis	rs7635838	0.892	rs9310383	chr3:11491305	A/G	cg00170343	chr3:11313890	ATG7	-0.46	-6.32	-0.36	1.07e-9	HDL cholesterol;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04712435	chr14:90863145	CALM1	0.66	7.87	0.44	9.2e-14	Gut microbiome composition (summer);
CESC	cis	rs2797160	0.967	rs984041	chr6:126021328	A/T	cg05901451	chr6:126070800	HEY2	0.44	6.41	0.37	6.53e-10	Endometrial cancer;
CESC	cis	rs1499614	1.000	rs2707828	chr7:66171377	G/A	cg18252515	chr7:66147081	NA	-1.42	-14.62	-0.67	6.69e-36	Gout;
CESC	cis	rs34172651	0.517	rs189919	chr16:24737741	G/A	cg00339695	chr16:24857497	SLC5A11	-0.53	-6.58	-0.37	2.56e-10	Intelligence (multi-trait analysis);
CESC	cis	rs9875589	0.957	rs4407395	chr3:13951673	A/G	cg19554555	chr3:13937349	NA	0.52	6.52	0.37	3.48e-10	Ovarian reserve;
CESC	cis	rs9322193	0.923	rs9371207	chr6:150179223	A/G	cg04369109	chr6:150039330	LATS1	-0.41	-5.35	-0.31	1.9e-7	Lung cancer;
CESC	cis	rs425277	0.561	rs11584491	chr1:2042543	A/G	cg19257562	chr1:2043853	PRKCZ	0.35	5.82	0.34	1.73e-8	Height;
CESC	cis	rs2235544	0.565	rs676562	chr1:54468638	C/G	cg25741118	chr1:54482237	LDLRAD1	0.24	5.77	0.33	2.2e-8	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
CESC	cis	rs933688	0.938	rs1477348	chr5:90707823	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.11	12.45	0.61	2.47e-28	Smoking behavior;
CESC	cis	rs780096	0.526	rs1406295	chr2:27689700	A/G	cg22903471	chr2:27725779	GCKR	-0.52	-7.39	-0.41	1.88e-12	Total body bone mineral density;
CESC	cis	rs9322193	0.923	rs1112729	chr6:150087627	C/A	cg05861140	chr6:150128134	PCMT1	-0.38	-5.43	-0.32	1.29e-7	Lung cancer;
CESC	cis	rs4901869	0.966	rs4901870	chr14:59334221	A/T	cg02291164	chr14:59296302	NA	-0.44	-7.36	-0.41	2.32e-12	Panic disorder;
CESC	cis	rs10504229	0.569	rs75466737	chr8:58055034	A/G	cg14926445	chr8:58193284	C8orf71	-0.54	-5.1	-0.3	6.45e-7	Developmental language disorder (linguistic errors);
CESC	cis	rs9899728	0.539	rs57813751	chr17:73053512	C/T	cg27626185	chr17:73056755	KCTD2	-0.95	-8.43	-0.46	2.23e-15	Alzheimer's disease or small vessel stroke;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg18797053	chr2:220143977	DNAJB2	0.46	6.19	0.36	2.29e-9	Systemic lupus erythematosus;
CESC	cis	rs826838	0.967	rs826876	chr12:39123843	T/C	cg13010199	chr12:38710504	ALG10B	-0.46	-6.44	-0.37	5.5e-10	Heart rate;
CESC	cis	rs9354308	0.899	rs2802056	chr6:66546219	C/A	cg07460842	chr6:66804631	NA	0.58	6.53	0.37	3.29e-10	Metabolite levels;
CESC	trans	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg17548406	chr8:17104535	VPS37A;CNOT7	-0.51	-6.23	-0.36	1.8e-9	Ulcerative colitis;
CESC	cis	rs589448	0.933	rs523398	chr12:69752775	C/T	cg20891283	chr12:69753455	YEATS4	0.99	17.16	0.73	6.54e-45	Cerebrospinal fluid biomarker levels;
CESC	cis	rs9457247	0.534	rs4710154	chr6:167394634	A/T	cg25258033	chr6:167368657	RNASET2	-0.36	-5.2	-0.3	3.89e-7	Crohn's disease;
CESC	cis	rs10463316	0.894	rs3846711	chr5:150740749	A/G	cg03212797	chr5:150827313	SLC36A1	-0.48	-6.07	-0.35	4.52e-9	Metabolite levels (Pyroglutamine);
CESC	cis	rs7777484	0.534	rs2533886	chr7:2834869	C/T	cg18446336	chr7:2847575	GNA12	-0.39	-6.5	-0.37	3.87e-10	Height;
CESC	cis	rs7666738	0.830	rs6846229	chr4:99016546	C/T	cg03467027	chr4:99064603	C4orf37	0.46	5.83	0.34	1.62e-8	Colonoscopy-negative controls vs population controls;
CESC	cis	rs9309473	0.607	rs7573719	chr2:73582986	G/A	cg20560298	chr2:73613845	ALMS1	-0.46	-6.22	-0.36	1.92e-9	Metabolite levels;
CESC	cis	rs751728	0.638	rs4713686	chr6:33787506	C/T	cg25922239	chr6:33757077	LEMD2	0.39	5.15	0.3	5.13e-7	Crohn's disease;
CESC	cis	rs3749237	0.576	rs3877784	chr3:49539417	C/T	cg02487422	chr3:49467188	NICN1	0.56	8.19	0.45	1.09e-14	Resting heart rate;
CESC	cis	rs4713118	0.597	rs172166	chr6:28020820	C/G	cg23161317	chr6:28129485	ZNF389	0.5	6.24	0.36	1.75e-9	Parkinson's disease;
CESC	cis	rs6502050	0.865	rs74480314	chr17:80117716	C/T	cg11859384	chr17:80120422	CCDC57	-0.38	-5.18	-0.3	4.42e-7	Life satisfaction;
CESC	cis	rs9858542	1.000	rs11709525	chr3:49690496	C/T	cg07274523	chr3:49395745	GPX1	0.67	8.51	0.46	1.29e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
CESC	cis	rs6088590	0.965	rs6087619	chr20:33288511	C/G	cg24642439	chr20:33292090	TP53INP2	0.84	12.0	0.59	8.84e-27	Coronary artery disease;
CESC	cis	rs10463316	0.894	rs6579866	chr5:150762524	A/G	cg03212797	chr5:150827313	SLC36A1	-0.46	-6.02	-0.35	5.83e-9	Metabolite levels (Pyroglutamine);
CESC	cis	rs7809950	0.911	rs7778250	chr7:107224565	C/A	cg23024343	chr7:107201750	COG5	0.44	5.89	0.34	1.19e-8	Coronary artery disease;
CESC	cis	rs2549003	1.000	rs6873426	chr5:131818631	G/T	cg00255919	chr5:131827918	IRF1	0.51	8.62	0.47	6.06e-16	Asthma (sex interaction);
CESC	cis	rs7618915	0.547	rs11177	chr3:52721305	G/A	cg18404041	chr3:52824283	ITIH1	-0.4	-6.78	-0.38	7.82e-11	Bipolar disorder;
CESC	cis	rs736408	0.660	rs2019065	chr3:52809525	C/T	cg17372223	chr3:52568218	NT5DC2	-0.41	-6.12	-0.35	3.42e-9	Bipolar disorder;
CESC	cis	rs501120	0.929	rs528668	chr10:44762584	G/A	cg09554077	chr10:44749378	NA	0.52	6.89	0.39	4.1e-11	Coronary artery disease;Coronary heart disease;
CESC	cis	rs3820068	0.705	rs1800616	chr1:15832229	G/A	cg17385448	chr1:15911702	AGMAT	0.38	5.9	0.34	1.1e-8	Systolic blood pressure;
CESC	cis	rs7552404	0.727	rs2172508	chr1:76320215	A/G	cg03433033	chr1:76189801	ACADM	0.63	6.16	0.35	2.73e-9	Blood metabolite levels;Acylcarnitine levels;
CESC	cis	rs7412746	0.658	rs72704685	chr1:150897687	C/G	cg04414720	chr1:150670196	GOLPH3L	0.51	6.76	0.38	8.61e-11	Melanoma;
CESC	cis	rs1153858	1.000	rs12594857	chr15:45667178	A/G	cg21132104	chr15:45694354	SPATA5L1	0.86	11.62	0.58	1.67e-25	Homoarginine levels;
CESC	cis	rs7666738	0.830	rs6819177	chr4:99040907	T/C	cg05340658	chr4:99064831	C4orf37	0.82	12.88	0.62	8.44e-30	Colonoscopy-negative controls vs population controls;
CESC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg23839556	chr1:53905233	FLJ40434	-0.39	-6.04	-0.35	5.21e-9	Asthma;
CESC	cis	rs9393777	0.513	rs7740197	chr6:26663478	C/T	cg11502198	chr6:26597334	ABT1	-0.51	-5.16	-0.3	4.89e-7	Intelligence (multi-trait analysis);
CESC	cis	rs3806843	0.933	rs2337987	chr5:140188383	T/G	cg16179182	chr5:140090404	VTRNA1-1	-0.4	-5.11	-0.3	6.12e-7	Depressive symptoms (multi-trait analysis);
CESC	cis	rs2592394	0.675	rs711827	chr2:176999120	G/A	cg13092806	chr2:177043255	NA	0.52	5.85	0.34	1.43e-8	Magnesium levels;Peripheral arterial disease (traffic-related air pollution interaction);
CESC	cis	rs4144743	0.941	rs7222617	chr17:45324080	G/T	cg18085866	chr17:45331354	ITGB3	-0.66	-7.64	-0.43	3.87e-13	Body mass index;
CESC	cis	rs2836974	0.931	rs12151994	chr21:40690397	A/C	cg11890956	chr21:40555474	PSMG1	1.13	19.25	0.76	2.85e-52	Cognitive function;
CESC	cis	rs10751667	0.666	rs6597960	chr11:977036	C/T	cg20946044	chr11:1010712	AP2A2	-0.39	-5.4	-0.31	1.48e-7	Alzheimer's disease (late onset);
CESC	cis	rs10504229	0.834	rs7015674	chr8:58153166	C/T	cg02725872	chr8:58115012	NA	-0.37	-5.83	-0.34	1.6e-8	Developmental language disorder (linguistic errors);
CESC	trans	rs35110281	0.693	rs4819290	chr21:45122713	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.47	6.06	0.35	4.66e-9	Mean corpuscular volume;
CESC	trans	rs1814175	0.935	rs11040463	chr11:49685574	C/T	cg15704280	chr7:45808275	SEPT13	-1.0	-17.76	-0.74	4.96e-47	Height;
CESC	cis	rs2952156	0.876	rs2313171	chr17:37833842	T/C	cg20243544	chr17:37824526	PNMT	0.63	8.34	0.46	3.98e-15	Asthma;
CESC	cis	rs12410462	0.681	rs58496521	chr1:227582375	T/C	cg04117972	chr1:227635322	NA	0.71	6.16	0.35	2.66e-9	Major depressive disorder;
CESC	cis	rs1668873	0.562	rs10157145	chr1:205261963	T/C	cg21643547	chr1:205240462	TMCC2	0.35	5.16	0.3	4.94e-7	Mean platelet volume;
CESC	cis	rs4919694	1.000	rs12253284	chr10:104665145	G/C	cg04362960	chr10:104952993	NT5C2	0.74	6.43	0.37	5.8e-10	Arsenic metabolism;
CESC	cis	rs2730245	0.528	rs1188954	chr7:158691417	G/A	cg01943577	chr7:158741284	NA	-0.45	-5.96	-0.34	8.09e-9	Height;
CESC	cis	rs11252926	0.574	rs4881313	chr10:487973	C/T	cg16386425	chr10:429943	DIP2C	0.5	6.44	0.37	5.46e-10	Psychosis in Alzheimer's disease;
CESC	cis	rs2072499	0.966	rs6427307	chr1:156190083	A/G	cg24450063	chr1:156163899	SLC25A44	1.06	20.29	0.78	7.01e-56	Testicular germ cell tumor;
CESC	cis	rs9612	1.000	rs9612	chr19:44235517	A/G	cg08581076	chr19:44259116	C19orf61	0.52	5.88	0.34	1.25e-8	Exhaled nitric oxide output;
CESC	cis	rs7474896	0.537	rs2505255	chr10:38359642	C/A	cg25427524	chr10:38739819	LOC399744	-0.46	-5.32	-0.31	2.16e-7	Obesity (extreme);
CESC	cis	rs1728785	0.818	rs1728769	chr16:68564186	C/T	cg02972257	chr16:68554789	NA	-0.55	-6.37	-0.36	8.21e-10	Ulcerative colitis;
CESC	cis	rs76878669	0.561	rs7107191	chr11:66140397	G/A	cg18002602	chr11:66138449	SLC29A2	0.4	6.66	0.38	1.58e-10	Educational attainment (years of education);
CESC	cis	rs6952808	0.929	rs11761270	chr7:1923695	C/T	cg05863683	chr7:1912471	MAD1L1	0.5	7.62	0.42	4.53e-13	Bipolar disorder and schizophrenia;
CESC	cis	rs9389248	0.708	rs7750574	chr6:135350932	G/C	cg24558204	chr6:135376177	HBS1L	0.7	10.0	0.52	3.43e-20	High light scatter reticulocyte percentage of red cells;
CESC	cis	rs2832191	0.740	rs2853830	chr21:30416824	A/G	cg08807101	chr21:30365312	RNF160	0.97	15.17	0.68	7.53e-38	Dental caries;
CESC	cis	rs6728642	1.000	rs57035274	chr2:97608124	C/A	cg26665480	chr2:98280029	ACTR1B	-0.64	-6.4	-0.37	7.17e-10	Bipolar disorder lithium response (continuous) or schizophrenia;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15531788	chr10:38146671	ZNF248	0.59	6.66	0.38	1.55e-10	Gut microbiome composition (summer);
CESC	cis	rs13191362	0.935	rs67084568	chr6:162988548	C/A	cg06582575	chr6:163149167	PACRG;PARK2	0.82	8.34	0.46	4.2e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
CESC	cis	rs6493487	0.512	rs71471587	chr15:51281623	G/T	cg02338191	chr15:51200825	AP4E1	0.61	5.58	0.32	6.04e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
CESC	cis	rs10754283	0.934	rs6684676	chr1:90102173	C/T	cg21401794	chr1:90099060	LRRC8C	0.7	9.41	0.5	2.54e-18	Amyotrophic lateral sclerosis (sporadic);
CESC	cis	rs2933343	0.700	rs2624910	chr3:128650275	G/C	cg25356066	chr3:128598488	ACAD9	0.61	8.58	0.47	8.13e-16	IgG glycosylation;
CESC	cis	rs2290720	0.896	rs6538983	chr12:101721860	T/C	cg22051763	chr12:101673672	UTP20	-0.49	-6.02	-0.35	5.86e-9	Brain structure (hippocampal volume);
CESC	cis	rs7412746	0.658	rs2272214	chr1:150931462	C/T	cg17724175	chr1:150552817	MCL1	0.38	5.93	0.34	9.31e-9	Melanoma;
CESC	cis	rs10178094	1.000	rs10208158	chr2:161331081	C/T	cg03641300	chr2:160917029	PLA2R1	0.38	5.39	0.31	1.55e-7	White blood cell count;
CESC	cis	rs6696846	0.791	rs10158848	chr1:205061192	C/T	cg00857998	chr1:205179979	DSTYK	0.57	7.5	0.42	9.67e-13	Red blood cell count;
CESC	cis	rs10504229	0.596	rs7004566	chr8:58115602	G/C	cg24829409	chr8:58192753	C8orf71	-0.58	-7.2	-0.4	6.31e-12	Developmental language disorder (linguistic errors);
CESC	cis	rs6580649	0.941	rs72644844	chr12:48465425	A/C	cg24011408	chr12:48396354	COL2A1	-0.41	-5.27	-0.31	2.86e-7	Lung cancer;
CESC	cis	rs1190552	0.841	rs56144019	chr14:102949731	G/A	cg18135206	chr14:102964638	TECPR2	0.42	5.26	0.31	3e-7	Blood protein levels;
CESC	cis	rs2836974	0.899	rs2836938	chr21:40574191	C/T	cg11644478	chr21:40555479	PSMG1	1.01	16.05	0.7	5.64e-41	Cognitive function;
CESC	cis	rs7927771	0.832	rs935914	chr11:47387599	C/T	cg05585544	chr11:47624801	NA	0.48	7.09	0.4	1.24e-11	Subjective well-being;
CESC	cis	rs1552244	0.882	rs13100734	chr3:10022878	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.76	-9.6	-0.51	6.32e-19	Alzheimer's disease;
CESC	trans	rs561341	1.000	rs510264	chr17:30323414	A/G	cg27661571	chr11:113659931	NA	-0.87	-8.07	-0.44	2.48e-14	Hip circumference adjusted for BMI;
CESC	cis	rs2742234	0.541	rs10793426	chr10:43745280	G/A	cg07801480	chr10:43725741	RASGEF1A	-0.41	-5.22	-0.31	3.61e-7	Hirschsprung disease;
CESC	cis	rs4253772	0.591	rs6008362	chr22:46652737	G/A	cg09491104	chr22:46646882	C22orf40	-0.6	-9.19	-0.49	1.18e-17	LDL cholesterol;Cholesterol, total;
CESC	cis	rs9910055	0.639	rs11656871	chr17:42269141	G/C	cg10896456	chr17:42255109	ASB16;C17orf65	0.47	6.96	0.39	2.68e-11	Total body bone mineral density;
CESC	cis	rs1559088	0.545	rs7257431	chr19:33566924	A/G	cg03563238	chr19:33554763	RHPN2	-0.32	-5.84	-0.34	1.5e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
CESC	trans	rs9929218	0.954	rs34097984	chr16:68824148	T/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.62	-8.14	-0.45	1.51e-14	Colorectal cancer;
CESC	cis	rs4664308	0.618	rs66484345	chr2:160894930	C/T	cg03641300	chr2:160917029	PLA2R1	-0.59	-8.49	-0.46	1.46e-15	Idiopathic membranous nephropathy;
CESC	cis	rs7917772	0.503	rs11191347	chr10:104351617	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.53	7.51	0.42	8.92e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
CESC	cis	rs2456568	0.570	rs1827932	chr11:93663319	A/T	cg26875233	chr11:93583750	C11orf90	-0.32	-5.82	-0.34	1.69e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
CESC	cis	rs4862750	0.872	rs13101380	chr4:187894744	G/A	cg27532560	chr4:187881888	NA	-0.4	-6.08	-0.35	4.21e-9	Lobe attachment (rater-scored or self-reported);
CESC	trans	rs1814175	0.585	rs4881661	chr11:50000117	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.42	-6.12	-0.35	3.32e-9	Height;
CESC	cis	rs1707322	0.896	rs785512	chr1:46534543	A/G	cg06784218	chr1:46089804	CCDC17	-0.33	-5.55	-0.32	7e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
CESC	cis	rs1008375	0.933	rs6847966	chr4:17634255	G/A	cg15017067	chr4:17643749	FAM184B	0.38	5.45	0.32	1.16e-7	Parasitemia in Tripanosoma cruzi seropositivity;
CESC	cis	rs7727544	0.709	rs272852	chr5:131688767	G/A	cg24060327	chr5:131705240	SLC22A5	-0.65	-8.62	-0.47	6.27e-16	Blood metabolite levels;
CESC	cis	rs10504229	0.906	rs112793785	chr8:58190537	T/C	cg05313129	chr8:58192883	C8orf71	-0.55	-6.49	-0.37	4.09e-10	Developmental language disorder (linguistic errors);
CESC	cis	rs858239	1.000	rs199351	chr7:23300049	A/C	cg23682824	chr7:23144976	KLHL7	0.46	6.33	0.36	1.02e-9	Cerebrospinal fluid biomarker levels;
CESC	cis	rs4563143	0.663	rs2218396	chr19:29236392	C/T	cg12667521	chr19:29218732	NA	0.41	6.17	0.35	2.53e-9	Methadone dose in opioid dependence;
CESC	cis	rs6754311	0.638	rs2322659	chr2:136555659	A/G	cg07169764	chr2:136633963	MCM6	-0.7	-8.87	-0.48	1.13e-16	Mosquito bite size;
CESC	cis	rs10744422	1.000	rs4759355	chr12:123316566	A/G	cg22842854	chr12:123319900	HIP1R	-0.61	-5.17	-0.3	4.53e-7	Schizophrenia;
CESC	cis	rs1144333	0.655	rs114383686	chr1:76325327	C/T	cg22875332	chr1:76189707	ACADM	0.52	5.08	0.3	7.1e-7	Attention function in attention deficit hyperactive disorder;
CESC	trans	rs916888	0.821	rs199525	chr17:44847834	T/G	cg22968622	chr17:43663579	NA	1.32	17.92	0.74	1.34e-47	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13436879	chr15:41136556	SPINT1	0.53	6.15	0.35	2.78e-9	Gut microbiome composition (summer);
CESC	cis	rs2228479	0.850	rs11076623	chr16:89844120	G/T	cg06558623	chr16:89946397	TCF25	1.16	9.27	0.49	6.64e-18	Skin colour saturation;
CESC	cis	rs1799949	1.000	rs8176289	chr17:41206056	T/C	cg23758822	chr17:41437982	NA	1.0	14.95	0.68	4.7e-37	Menopause (age at onset);
CESC	cis	rs79349575	0.783	rs4793991	chr17:47001801	A/G	cg16584676	chr17:46985605	UBE2Z	0.54	6.7	0.38	1.24e-10	Type 2 diabetes;
CESC	cis	rs60843830	1.000	rs3791223	chr2:222336	T/C	cg00108164	chr2:264199	ACP1;SH3YL1	0.77	9.68	0.51	3.6e-19	Spherical equivalent (joint analysis main effects and education interaction);
CESC	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg18402987	chr7:1209562	NA	0.75	7.49	0.42	1.04e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
CESC	cis	rs2120019	0.938	rs8036573	chr15:75308690	C/T	cg17294928	chr15:75287854	SCAMP5	-0.74	-8.61	-0.47	6.72e-16	Blood trace element (Zn levels);
CESC	cis	rs9611565	0.559	rs132768	chr22:42013523	C/A	cg06481639	chr22:41940642	POLR3H	0.6	6.14	0.35	2.95e-9	Vitiligo;
CESC	cis	rs7618501	0.633	rs12485600	chr3:50025530	A/G	cg24110177	chr3:50126178	RBM5	-0.52	-7.06	-0.4	1.42e-11	Intelligence (multi-trait analysis);
CESC	cis	rs7216064	1.000	rs62084214	chr17:65843325	C/G	cg12091567	chr17:66097778	LOC651250	-0.86	-8.83	-0.48	1.49e-16	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
CESC	trans	rs9467711	0.606	rs9348709	chr6:26360311	G/A	cg06606381	chr12:133084897	FBRSL1	-0.76	-6.87	-0.39	4.66e-11	Autism spectrum disorder or schizophrenia;
CESC	cis	rs3760982	0.585	rs68073292	chr19:44291401	T/C	cg11993925	chr19:44307056	LYPD5	0.33	5.68	0.33	3.62e-8	Breast cancer (estrogen-receptor negative);Breast cancer;
CESC	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg23134520	chr20:44485949	ACOT8;ZSWIM3	-0.49	-6.44	-0.37	5.52e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
CESC	cis	rs2963155	0.518	rs852978	chr5:142690596	T/C	cg17617527	chr5:142782415	NR3C1	0.82	7.82	0.43	1.28e-13	Breast cancer;
CESC	cis	rs17433780	0.808	rs1074541	chr1:89509499	A/G	cg09516651	chr1:89888402	LOC400759	0.7	10.7	0.55	1.94e-22	Carotid intima media thickness;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00966591	chr1:20126388	TMCO4	0.63	6.74	0.38	9.59e-11	Gut microbiome composition (summer);
CESC	cis	rs3096299	0.719	rs2911262	chr16:89515041	C/T	cg02034447	chr16:89574710	SPG7	0.44	5.61	0.33	5.06e-8	Multiple myeloma (IgH translocation);
CESC	cis	rs9902453	1.000	rs7223786	chr17:28332107	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.62	-7.83	-0.43	1.15e-13	Coffee consumption (cups per day);
CESC	cis	rs651907	0.535	rs4342086	chr3:101503765	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.43	5.69	0.33	3.42e-8	Colorectal cancer;
CESC	cis	rs3815700	1.000	rs10407204	chr19:33097353	C/T	cg02997394	chr19:33096574	ANKRD27	0.71	7.25	0.41	4.59e-12	Eosinophilic esophagitis;
CESC	cis	rs736408	0.634	rs11717836	chr3:52807736	A/G	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.3	5.11	0.3	6.11e-7	Bipolar disorder;
CESC	trans	rs6089829	0.889	rs6062773	chr20:61663262	G/C	cg23505145	chr19:12996616	KLF1	0.52	6.74	0.38	1e-10	Prostate cancer (SNP x SNP interaction);
CESC	cis	rs317689	0.876	rs547332	chr12:69743639	C/G	cg14784868	chr12:69753453	YEATS4	0.64	8.07	0.44	2.49e-14	Response to diuretic therapy;
CESC	cis	rs7078219	0.523	rs10883366	chr10:101287785	G/A	cg09788492	chr10:101292477	NKX2-3	0.34	6.46	0.37	5e-10	Dental caries;
CESC	cis	rs478304	0.651	rs10896037	chr11:65503424	A/G	cg10518572	chr11:65560635	OVOL1	-0.33	-6.6	-0.38	2.18e-10	Acne (severe);
CESC	cis	rs1348850	0.519	rs1527406	chr2:178525655	C/T	cg22681709	chr2:178499509	PDE11A	-0.49	-7.04	-0.4	1.63e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
CESC	cis	rs7527798	0.592	rs6684643	chr1:207846242	A/T	cg21110645	chr1:207815933	NA	-0.33	-5.65	-0.33	4.1e-8	Erythrocyte sedimentation rate;
CESC	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg07308232	chr7:1071921	C7orf50	-0.39	-5.17	-0.3	4.69e-7	Longevity;Endometriosis;
CESC	cis	rs853679	0.517	rs9393886	chr6:28050039	T/G	cg19592336	chr6:28129416	ZNF389	0.6	7.97	0.44	4.69e-14	Depression;
CESC	cis	rs6963495	0.932	rs55700120	chr7:105148460	G/T	cg13798780	chr7:105162888	PUS7	0.76	7.8	0.43	1.47e-13	Bipolar disorder (body mass index interaction);
CESC	trans	rs12681287	0.547	rs7837569	chr8:87507366	C/T	cg27317242	chr8:23145699	R3HCC1	-0.53	-6.35	-0.36	9.05e-10	Caudate activity during reward;
CESC	cis	rs752010	0.841	rs11210498	chr1:42077958	T/G	cg06885757	chr1:42089581	HIVEP3	0.47	7.63	0.42	4.21e-13	Lupus nephritis in systemic lupus erythematosus;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04742047	chr19:14544036	PKN1	0.64	7.22	0.41	5.39e-12	Gut microbiome composition (summer);
CESC	cis	rs863345	0.604	rs1112915	chr1:158444447	T/C	cg12129480	chr1:158549410	OR10X1	-0.35	-7.05	-0.4	1.59e-11	Pneumococcal bacteremia;
CESC	cis	rs7772486	0.790	rs10223507	chr6:146285204	C/A	cg05347473	chr6:146136440	FBXO30	-0.54	-7.05	-0.4	1.6e-11	Lobe attachment (rater-scored or self-reported);
CESC	cis	rs763121	0.925	rs5757165	chr22:38994577	C/T	cg06544989	chr22:39130855	UNC84B	0.52	9.63	0.51	5.28e-19	Menopause (age at onset);
CESC	cis	rs8016982	0.855	rs10149681	chr14:81686319	G/A	cg01989461	chr14:81687754	GTF2A1	0.57	7.4	0.41	1.83e-12	Schizophrenia;
CESC	cis	rs2303745	0.589	rs6512179	chr19:17399105	T/C	cg22549504	chr19:17448937	GTPBP3	0.52	5.88	0.34	1.24e-8	Systemic lupus erythematosus;
CESC	cis	rs1799949	1.000	rs35668327	chr17:41273095	G/A	cg25072359	chr17:41440525	NA	0.43	5.74	0.33	2.6e-8	Menopause (age at onset);
CESC	cis	rs5743618	0.537	rs6837838	chr4:38770576	T/A	cg02016764	chr4:38805732	TLR1	-0.33	-5.16	-0.3	4.84e-7	Asthma;Allergic disease (asthma, hay fever or eczema);
CESC	cis	rs4664308	0.870	rs1870104	chr2:161032285	A/G	cg03641300	chr2:160917029	PLA2R1	-0.61	-8.95	-0.48	6.4e-17	Idiopathic membranous nephropathy;
CESC	cis	rs7551222	0.752	rs10900599	chr1:204541943	T/C	cg20240347	chr1:204465584	NA	-0.27	-5.52	-0.32	8.01e-8	Schizophrenia;
CESC	trans	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg07035315	chr22:18483421	MICAL3	0.44	6.08	0.35	4.11e-9	Systemic lupus erythematosus;
CESC	cis	rs9287719	0.901	rs4555317	chr2:10744247	A/G	cg02196655	chr2:10830764	NOL10	-0.38	-5.83	-0.34	1.61e-8	Prostate cancer;
CESC	cis	rs7267979	0.816	rs6115094	chr20:25210827	A/G	cg08601574	chr20:25228251	PYGB	0.39	5.6	0.33	5.47e-8	Liver enzyme levels (alkaline phosphatase);
CESC	cis	rs2439831	1.000	rs101094	chr15:43787322	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.89	10.58	0.54	4.72e-22	Lung cancer in ever smokers;
CESC	cis	rs6815814	0.950	rs66819621	chr4:38819403	A/G	cg02016764	chr4:38805732	TLR1	-0.56	-6.31	-0.36	1.15e-9	Breast cancer;
CESC	cis	rs8078723	1.000	rs4795418	chr17:38164851	T/C	cg17467752	chr17:38218738	THRA	0.69	10.54	0.54	6.17e-22	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
CESC	cis	rs344364	0.511	rs1742463	chr16:1946110	A/G	cg26617929	chr16:1858877	NA	-0.49	-5.15	-0.3	5.09e-7	Glomerular filtration rate in chronic kidney disease;
CESC	cis	rs2235642	0.821	rs2281234	chr16:1602938	A/G	cg03715980	chr16:1756201	MAPK8IP3	0.38	5.05	0.3	8.33e-7	Coronary artery disease;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17100696	chr17:71088862	SLC39A11	0.58	6.26	0.36	1.51e-9	Gut microbiome composition (summer);
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05168842	chr11:61584319	FADS1	0.59	7.01	0.4	1.97e-11	Gut microbiome composition (summer);
CESC	cis	rs709400	0.663	rs11624367	chr14:103892818	T/A	cg12935359	chr14:103987150	CKB	-0.56	-8.21	-0.45	9.64e-15	Body mass index;
CESC	cis	rs1595825	0.891	rs7595819	chr2:198543156	A/C	cg10820045	chr2:198174542	NA	-0.42	-5.2	-0.3	3.89e-7	Ulcerative colitis;
CESC	trans	rs9937837	0.918	rs41477949	chr16:31287427	A/T	cg04903759	chr3:167238645	WDR49	0.52	6.29	0.36	1.28e-9	Systemic lupus erythematosus;
CESC	cis	rs5769765	0.862	rs9616384	chr22:50313082	C/T	cg02269571	chr22:50332266	NA	-0.56	-6.99	-0.39	2.26e-11	Schizophrenia;
CESC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg17340796	chr11:85339599	TMEM126B;DLG2	-0.44	-6.04	-0.35	5.21e-9	Fibrinogen levels;
CESC	trans	rs360798	0.532	rs1906201	chr2:62806373	C/T	cg07814414	chr15:31774773	NA	-0.41	-6.09	-0.35	3.88e-9	Coronary artery disease;
CESC	cis	rs7193541	0.684	rs7191665	chr16:74688948	T/G	cg05580060	chr16:74700937	RFWD3	-0.49	-6.3	-0.36	1.27e-9	Multiple myeloma;
CESC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00910521	chr17:75484950	SEPT9	-0.63	-7.05	-0.4	1.59e-11	Gut microbiome composition (summer);
CESC	cis	rs12142240	0.698	rs1475388	chr1:46816465	G/A	cg10495392	chr1:46806563	NSUN4	0.57	6.28	0.36	1.39e-9	Menopause (age at onset);
CESC	cis	rs11148252	0.574	rs7139495	chr13:53283318	A/G	cg00495681	chr13:53174319	NA	0.59	8.24	0.45	8.2e-15	Lewy body disease;
CESC	cis	rs870825	0.616	rs4615214	chr4:185624129	G/C	cg04058563	chr4:185651563	MLF1IP	0.64	7.05	0.4	1.59e-11	Blood protein levels;
CESC	cis	rs4906332	1.000	rs34347076	chr14:103955069	G/A	cg09975044	chr14:104007538	NA	0.47	6.39	0.37	7.49e-10	Coronary artery disease;